NATIONAL INSTITUTES OF HEALTH

CUMULATED INDEX MEDICUS

1999

VOLUME 40 BOOK 6

SUBJECT INDEX
Gi–Inr

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, MD 20894
NIH Publication Number: 00-259

ISSN: 0090-1423

Cumulated Index Medicus

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated index medicus.
Vol. 1 (Jan.-Dec. 1960)-
-- Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1960-
v. -- (1971-1979: DHEW publication ; no. (NIH) 72-259, etc.)

Annual.
As of Feb. 1998, citations published 1964-1965 also available online as: OLDMEDLINE, accessible through Internet Grateful Med.
Cumulation of the monthly publication: Index medicus.
Issues for 1967- include Bibliography of medical reviews.
HTTP- Citations published 1964-1965 also available online: http://igm.nlm.nih.gov/.
Continues: Quarterly cumulative index medicus.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.) III. Index medicus IV. Bibliography of medical reviews V. Title: OLDMEDLINE VI. Series: DHEW publication ; no. (NIH) 72-259, etc. VII. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated index medicus.
SUPT. OF DOCS. NO: HE 20.3612/3:

ZW 1 I384

This book is printed on acid-free paper for permanence.

The Secretary of Health and Human Services has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 2000.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328

CUMULATED INDEX MEDICUS 1999

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Headings viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xvi

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1519
Full Title Listing 1625

BOOK 2 Subject Index **A-At** 1709

BOOK 3 Subject Index **Au-Cg** 3556

BOOK 4 Subject Index **Ch-Do** 5371

BOOK 5 Subject Index **Dp-Gh** 7197

BOOK 6 Subject Index **Gi-Inr** 9029

BOOK 7 Subject Index **Ins-Mem** 10790

BOOK 8 Subject Index **Men-Os** 12631

BOOK 9 Subject Index **Ot-Pt** 14473

BOOK 10 Subject Index **Pu-Ss** 16294

BOOK 11 Subject Index **St-Z** 18087

Book 12 Author Index **A-De** 19943

BOOK 13 Author Index **Df-I** 21742

BOOK 14 Author Index **J-Mn** 23500

BOOK 15 Author Index **Mo-Se** 25314

BOOK 16 Author Index **Sf-Z** 27180

BOOK 17 Bibliography of Medical Reviews **A-Im** 29047

Book 18 Bibliography of Medical Reviews **In-Z** 30144

DRUG THERAPY

[The duration of the action of a single dose of aspirin, kurantil and nicotinic acid during pregnancy complicated by EPH gestosis] Udut VV, et al. **Eksp Klin Farmakol** 1999 May-Jun;62(3):37-9 (Eng. Abstr.) **(Rus)**

[Ozone hemotherapy and the basal metabolic pathways of body adaptation in gestoses] Ivanchenko SA. **Lik Sprava** 1998 Jun;(4):149-50 (Eng. Abstr.) **(Rus)**

[The antepartum preparation of women with late gestoses] Kaminskii VV, et al. **Lik Sprava** 1999 Mar;(2):109-10 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

[The pathomorphology of the kidneys in the fetuses of mothers suffering from late gestosis, type-1 diabetes mellitus and chronic glomerulonephritis] Iakovtsova AF, et al. **Arkh Patol** 1998 Nov-Dec;60(6):33-6 (Eng. Abstr.) **(Rus)**

METABOLISM

Elastin of the umbilical cord arteries and its alterations in EPH gestosis (preeclampsia). Pawlicka E, et al. **Biol Neonate** 1999;75(2):91-6

The activities of some glycosaminoglycan-degrading enzymes in the wall of the umbilical cord artery and their alteration in edema, proteinuria, hypertension (EPH)-gestosis. Romanowicz L, et al. **Clin Chem Lab Med** 1999 Apr;37(4):417-21

An immunohistochemical study of cadherin 5 (VE-cadherin) in vascular endothelial cells in placentas with gestosis. Kawashima M, et al. **J Obstet Gynaecol Res** 1998 Dec; 24(6):375-84

PHYSIOPATHOLOGY

Temporal organization of fetal behavior from 24-weeks gestation onwards in normal and complicated pregnancies. Nijhuis IJ, et al. **Dev Psychobiol** 1999 May;34(4):257-68

[Pathogenesis of systemic hemodynamic disorders and choice of optimal obstetrical strategy in pregnant patients with gestosis] Strizhakov AN, et al. **Vestn Ross Akad Med Nauk** 1999;(1):51-7 (Eng. Abstr.) **(Rus)**

THERAPY

[Ozone hemotherapy and endogenous intoxication in gestoses] Chuev PN, et al. **Lik Sprava** 1999 Mar;(2):107-8 (Eng. Abstr.) **(Rus)**

[Ozone hemotherapy in the combined treatment of gestoses] Chuev PN, et al. **Lik Sprava** 1998 Oct-Nov;(7):36-8 (24 ref.) **(Rus)**

[Ozone hemotherapy and disorders of the functional energy competence of the cell membranes in gestoses] Ivanchenko SA. **Lik Sprava** 1998 Jul-Aug;(5):96-8 (Eng. Abstr.) **(Rus)**

GESTRINONE

THERAPEUTIC USE

Non-surgical treatment of meningioma: a case report and review. Sharif S, et al. **Br J Neurosurg** 1998 Aug; 12(4):369-72

Clinical effects of gestrinone for the treatment of pelvic endometriosis in infertile patients. Pruksananonda K, et al. **J Med Assoc Thai** 1999 Jan;82(1):9-14

GESTURES

An experimental investigation of the role of iconic gestures in lexical access using the tip-of-the-tongue phenomenon. Beattie G, et al. **Br J Psychol** 1999 Feb;90 (Pt 1):35-56

Ideomotor apraxia in early Alzheimer's disease: time and accuracy measures. Willis L, et al. **Brain Cogn** 1998 Nov; 38(2):220-33

How to get to the cafeteria: gesture and speech in blind and sighted children's spatial descriptions. Iverson JM. **Dev Psychol** 1999 Jul;35(4):1132-42

Intentional communication by chimpanzees: a cross-sectional study of the use of referential gestures. Leavens DA, et al. **Dev Psychol** 1998 Sep;34(5):813-22

Gesture and early bilingual development. Nicoladis E, et al. **Dev Psychol** 1999 Mar;35(2):514-26

Role of somatosensory feedback from tools in realizing movements by patients with ideomotor apraxia. Wada Y, et al. **Eur Neurol** 1999;41(2):73-8

Development of adaptive phonetic gestures in children: evidence from vowel devoicing in two different dialects of Japanese. Imaizumi S, et al. **J Acoust Soc Am** 1999 Aug; 106(2):1033-44

Procedures for teaching appropriate gestural communication skills to children with autism. Buffington DM, et al. **J Autism Dev Disord** 1998 Dec;28(6):535-45

Introducing infants to referential events: a development study of maternal ostensive marking in French. Colas A. **J Child Lang** 1999 Feb;26(1):113-31

Gestural communication in Alzheimer's disease. Glosser G, et al. **J Clin Exp Neuropsychol** 1998 Feb;20(1):1-13

Analyses of deficits in gestural pantomime. Roy EA, et al. **J Clin Exp Neuropsychol** 1998 Oct;20(5):628-43

Gestures and words in early development of children with Down syndrome. Caselli MC, et al. **J Speech Lang Hear Res** 1998 Oct;41(5):1125-35

Dysarthric sentence intelligibility: contribution of iconic gestures and message predictiveness. Garcia JM, et al. **J Speech Lang Hear Res** 1998 Dec;41(6):1282-93

Why people gesture when they speak [letter] Iverson JM, et al. **Nature** 1998 Nov 19;396(6708):228

Simultaneous and delayed matching to sample in gesture users and speakers with mental retardation. Brady NC, et al. **Res Dev Disabil** 1998 Sep-Oct;19(5):409-21

[Effects of advance information given by sensory cues on the duration and precision of a pointing movement in Parkinson's disease] Gueye L, et al. **Dakar Med** 1998; 43(1):49-53 (Eng. Abstr.) **(Fre)**

GETAH VIRUS see **ALPHAVIRUS**

GGTP see **GAMMA-GLUTAMYLTRANSFERASE**

GHETTOS see **POVERTY AREAS**

GHOST TEETH see **ODONTODYSPLASIA**

GI, INHIBITORY G-PROTEIN see **G-PROTEIN, INHIBITORY GI**

GIANOTTI-CROSTI SYNDROME see **ACRODERMATITIS**

GIANT BOTTLE-NOSED WHALES see **WHALES**

GIANT CELL ARTERITIS see **TEMPORAL ARTERITIS**

GIANT CELL GRANULOMA see **GRANULOMA, GIANT CELL**

GIANT CELL TUMOR OF BONE

Giant cell tumors of the jugular foramen. Rosenbloom JS, et al. **Am J Otolaryngol** 1999 May-Jun;20(3):176-9 (20 ref.)

Update on giant cell tumor of bone. Schwartz HS. **Compr Ther** 1998 Oct;24(10):488-93 (52 ref.)

CHEMISTRY

Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents. James IE, et al. **J Bone Miner Res** 1999 Sep;14(9):1562-9

DIAGNOSIS

Osteoclastomalike anaplastic carcinoma of the thyroid gland diagnosed by fine needle aspiration cytology. Report of two cases. Kumar PV, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1345-8

Mammary carcinoma with osteoclastlike giant cells cytologically mimicking benign breast disease. A case report. Shabb NS, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1284-8

Recurrent giant-cell tumor presenting as a soft-tissue mass. A report of four cases. Lee FY, et al. **J Bone Joint Surg Am** 1999 May;81(5):703-7

Giant cell tumor of the foot phalanges in children: a case report. Alvarez Ramos A, et al. **J Pediatr Orthop B** 1999 Apr;8(2):132-5 (19 ref.)

Giant cell tumor of the skull. Lee JA, et al. **Radiographics** 1998 Sep-Oct;18(5):1295-302 (11 ref.)

[Multiple brown tumors of the paranasal sinuses in tertiary hyperparathyroidism] Pöckler-Schöniger C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):72-5 (10 ref.) **(Ger)**

[Primary hyperparathyroidism diagnosed as a multicentric giant cell tumor of bone--case report] Filarska D, et al. **Przegl Lek** 1998;55(10):549-51 (Eng. Abstr.) **(Pol)**

[Giant-cell tumor of bone] Calçada CP, et al. **Acta Med Port** 1998 Jun;11(6):563-8 (15 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Chronic renal failure causing brown tumors and myelopathy. Case report and review of pathophysiology and treatment. Fineman I, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):242-6 (18 ref.)

GENETICS

Cytofluorometric DNA ploidy analysis in giant cell tumor of bone: histologic and prognostic value. Murata H, et al. **Cancer Lett** 1999 Mar 1;136(2):223-9

Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Rao VH, et al. **Int J Oncol** 1999 Feb; 14(2):291-300

Giant cell tumor of the sternum. Report of a case with a 17q isochromosome. Bay JO, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):49-52

METABOLISM

Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Gouin F, et al. **Cytokine** 1999 Apr;11(4):282-9

Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Masui F, et al. **Pathol Int** 1998 Sep; 48(9):723-9

Giant cell tumor of bone: an immunohistochemical comparative study. Masui F, et al. **Pathol Int** 1998 May; 48(5):355-61

[Bone tumors and androgen metabolism] Kushlinskii NE, et al. **Usp Fiziol Nauk** 1999 Jul-Sep;30(3):14-22 (57 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Mammary carcinoma with osteoclastlike giant cells cytologically mimicking benign breast disease. A case report. Shabb NS, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1284-8

Bone giant cell tumour in neuropathological practice. A fifty year overview. Kujas M, et al. **Arch Anat Cytol Pathol** 1999;47(1):7-12 (10 ref.)

Pseudoanaplastic giant cell tumor of bone. Layfield LJ, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):163-6

Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Rao VH, et al. **Int J Oncol** 1999 Feb; 14(2):291-300

Multifocal, metachronous giant-cell tumor of the ulna. A case report. Park YK, et al. **J Bone Joint Surg Am** 1999 Mar;81(3):409-13

Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. de Souza PE, et al. **J Oral Pathol Med** 1999 Feb;28(2):54-8

Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Masui F, et al. **Pathol Int** 1998 Sep; 48(9):723-9

Giant cell tumor of the sternum. Report of a case with a 17q isochromosome. Bay JO, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):49-52

Giant cell tumor of bone in an aged Fischer 344 rat. Imai T, et al. **Toxicol Pathol** 1998 Nov-Dec;26(6):802-5

[Promotive effect of TNF-alpha and M-CSF on osteolysis induced by giant cell tumor of bone] Wen J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct;26(5):273-6 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Giant-cell tumor of the skull base. Lee HJ, et al. **Neuroradiology** 1999 Apr;41(4):305-7

[A case of a aggressive giant-cell tumor with multiple bone metastases] De Smedt M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):293-6 (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Radiation therapy in the treatment of giant cell tumor of bone. Nair MK, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1065-9

SECONDARY

Giant cell tumour of bone with pulmonary metastases. A report of three cases. Sanjay BK, et al. **Int Orthop** 1998; 22(3):200-4

SURGERY

Immune responses to osteoarticular allografts of the knee--cytokine studies. Nordström DC, et al. **Arch Orthop Trauma Surg** 1999;119(3-4):195-8

Vascularized fibular graft after excision of giant cell tumor of the distal radius. A case report. Ihara K, et al. **Clin Orthop** 1999 Feb;(359):189-96

Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Malawer MM, et al. **Clin Orthop** 1999 Feb;(359):176-88 (71 ref.)

Treatment of giant-cell tumors of long bones with curettage and bone-grafting. Blackley HR, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):811-20

Use of polymethylmethacrylate in large osseous defects in the foot and ankle following tumor excision. Thomas JL, et al. **J Foot Ankle Surg** 1999 May-Jun;38(3):208-13

Assessment of vascularized fibular graft one year after reconstruction of the wrist after excision of a giant-cell tumour. Ferracini R, et al. **J Hand Surg [Br]** 1999 Aug; 24(4):497-500

Prevention of recurrent giant-cell tumors of long bones--a new surgical technique. Salai M, et al. **J Surg Oncol** 1999 Sep;72(1):37-8

[Repair of bone defect of distal end of radius and its functional restoration] Zhang M, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):229-30 (Eng. Abstr.) **(Chi)**

[Application of artificial humeral head in the treatment of tumor of upper end of humerus] Zhang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 May;11(3):139-41 (Eng. Abstr.) **(Chi)**

[A case of a aggressive giant-cell tumor with multiple bone metastases] De Smedt M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):293-6 (Eng. Abstr.) **(Fre)**

[Acute symptom transverse laminectomy for a benign osteoclastoma of thethoracic spine--case report and review of the literature] Gruber AW, et al. **Zentralbl Neurochir** 1999;60(2):93-9 (18 ref.) (Eng. Abstr.) **(Ger)**

GIANT CELL TUMOR OF BONE

ULTRASTRUCTURE

Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Gouin F, et al. **Cytokine** 1999 Apr;11(4):282-9

GIANT CELL TUMORS

Long-term survival of a patient with a giant-cell tumor of the sphenoid body: a case report. Pau A, et al. **Tumori** 1999 Mar-Apr;85(2):137-9 (28 ref.)

CHEMISTRY

Loss of the TSC2 product tuberin in subependymal giant-cell tumors. Arai Y, et al. **Acta Neuropathol (Berl)** 1999 Sep; 98(3):233-9

COMPLICATIONS

Pathologic causes of the superior oblique click syndrome. White VA, et al. **Ophthalmology** 1999 Jul;106(7):1292-5

DIAGNOSIS

Destruction of the glenoid joint fossa by a tenosynovial giant-cell tumour of the skull base: a case report. Stojadinovic S, et al. **Int J Oral Maxillofac Surg** 1999 Apr; 28(2):132-4 (11 ref.)

Giant cell tumor of the tendon sheath of the knee. van Es HW, et al. **J Belge Radiol** 1998 Oct;81(5):251

[A tumor can hide another one] Chatelain D, et al. **Ann Pathol** 1998 Dec;18(6):503-4 **(Fre)**

DRUG THERAPY

Interferon and giant cell tumors [comment] Dickerman JD. **Pediatrics** 1999 Jun;103(6 Pt 1):1282-3. Comment on: Pediatrics 1999 Jun;103(6 Pt 1):1145-9.

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a [see comments] Kaban LB, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1145-9. Comment in: Pediatrics 1999 Jun;103(6 Pt 1):1282-3.

ETIOLOGY

Multiple giant cell tumors complicating Paget's disease. Pathak HJ, et al. **AJR Am J Roentgenol** 1999 Jun; 172(6):1696-7

GENETICS

K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Westra WH, et al. **Am J Surg Pathol** 1998 Oct;22(10):1247-54 (33 ref.)

Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. O'Brien KP, et al. **Genes Chromosomes Cancer** 1998 Oct;23(2):187-93

[Giant cell tumor of bone. Morphological, immunohistochemical, morphometric and DNA flow cytometric findings] Kröber SM, et al. **Verh Dtsch Ges Pathol** 1998;82:279-83 (Eng. Abstr.) **(Ger)**

METABOLISM

Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Fukuda T, et al. **Pathol Int** 1998 Oct;48(10):757-62

PATHOLOGY

Loss of the TSC2 product tuberin in subependymal giant-cell tumors. Arai Y, et al. **Acta Neuropathol (Berl)** 1999 Sep; 98(3):233-9

Giant cell tumor and temporal bone. Magliulo G, et al. **An Otorrinolaringol Ibero Am** 1998;25(5):481-90

Extraorbital giant cell angiofibroma. Wiebe BM, et al. **APMIS** 1999 Jul;107(7):695-8

Bone tumors in the pelvis presenting growth during pregnancy. Komiya S, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):22-9

Giant-cell tumor in soft parts in a patient with osseous Paget's disease: diagnosis by fine-needle aspiration. Galed-Placed I, et al. **Diagn Cytopathol** 1998 Nov;19(5):352-4

Giant cell tumour of the retropharynx. Paulino AF, et al. **Histopathology** 1998 Oct;33(4):344-8

Pedal giant cell tumor of tendon sheath. Paez H, et al. **J Am Podiatr Med Assoc** 1999 Jul;89(7):368-72

Measurement of invasive potential provides an accurate prognostic marker for giant cell tumour of tendon sheath. Grover R, et al. **J Hand Surg [Br]** 1998 Dec;23(6):728-31

Giant cell angiofibroma of the orbit and eyelid. Hayashi N, et al. **Ophthalmology** 1999 Jun;106(6):1223-9

Giant cell fibroblastoma: an entity or a reactive phenomenon? Karabela-Bouropoulou V, et al. **Pathol Res Pract** 1999; 195(6):413-9

Osteoclast-like giant cell tumor of the pancreas with metastases to gallbladder and lymph nodes. A case report. Sun AP, et al. **Pathol Res Pract** 1998;194(8):587-94; discussion 595

[Giant cell tumor of bone. Morphological, immunohistochemical, morphometric and DNA flow cytometric findings] Kröber SM, et al. **Verh Dtsch Ges Pathol** 1998;82:279-83 (Eng. Abstr.) **(Ger)**

[Differential diagnosis of giant cell tumor of bone] Salzer-Kuntschik M. **Verh Dtsch Ges Pathol** 1998;82:154-9 (19 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radiotherapy for the treatment of giant cell tumor of the spine: a report of six cases and review of the literature. Khan DC, et al. **Cancer Invest** 1999;17(2):110-3 (24 ref.)

SURGERY

Giant-cell tumor of the patella: report of two cases. Wang IC, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Sep; 21(3):338-42

[Giant cell tumor of the patella] Obrębski M, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(6):607-9 (Eng. Abstr.) **(Pol)**

GIANT CELLS

Formation of multinucleated giant cells in the mouse lung is promoted in the absence of interleukin-12. Anderson S, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):371-8

Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy. Mor-Vaknin N, et al. **Cell Biol Int** 1998;22(2):95-103

Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Ward BJ, et al. **Diagn Microbiol Infect Dis** 1999 Mar; 33(3):147-52

Acute exacerbation of overlapping autoimmune liver disease with development of giant cell hepatitis after 14 years' disease duration [letter] Stoffel MP, et al. **J Intern Med** 1998 Oct;244(4):355-60

Molecular markers and cell cycle inhibitors show the importance of cell cycle progression in nematode-induced galls and syncytia. de Almeida Engler J, et al. **Plant Cell** 1999 May;11(5):793-808

[A giant-cell tumor-like formation in the parietal bone] Shchepeshkin IA, et al. **Vopr Onkol** 1998;44(6):734-7 **(Rus)**

CYTOLOGY

IL-13 as well as IL-4 induces monocytes/macrophages and a monoblastic cell line (UG3) to differentiate into multinucleated giant cells in the presence of M-CSF. Ikeda T, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):265-72

Chondroclasts and osteoclasts in bones of young rats: comparison of ultrastructural and functional features. Nordahl J, et al. **Calcif Tissue Int** 1998 Nov;63(5):401-8

Suppression of FRP-1/CD98-mediated multinucleated giant cell and osteoclast formation by an anti-FRP-1/CD98 mAb, HBJ 127, that inhibits c-src expression. Tajima M, et al. **Cell Immunol** 1999 May 1;193(2):162-9

Are human placental bed giant cells merely aggregates of small mononuclear trophoblast cells? An ultrastructural and immunocytochemical study. al-Lamki RS, et al. **Hum Reprod** 1999 Feb;14(2):496-504

Generation of multinucleated giant cells in vitro by culture of human monocytes with Mycobacterium bovis BCG in combination with cytokine-containing supernatants. Gasser A, et al. **Infect Immun** 1999 Jan;67(1):395-402

CD44 occupancy prevents macrophage multinucleation. Sterling H, et al. **J Cell Biol** 1998 Nov 2;143(3):837-47

DNA content and ploidy level of bovine placentomal trophoblast giant cells. Klisch K, et al. **Placenta** 1999 Jul-Aug;20(5-6):451-8

DRUG EFFECTS

Effects of aluminum on plasma membrane as revealed by analysis of alkaline band formation in internodal cells of Chara corallina. Takano M, et al. **Cell Struct Funct** 1999 Jun;24(3):131-7

ENZYMOLOGY

Expression of rat DNA (cytosine-5) methyltransferase (DNA MTase) in rodent trophoblast giant cells: molecular cloning and characterization of rat DNA MTase. Kimura H, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):495-501

Meltrin-alpha, a fusion protein involved in multinucleated giant cell and osteoclast formation. Abe E, et al. **Calcif Tissue Int** 1999 Jun;64(6):508-15

METABOLISM

Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Kaiser M, et al. **Am J Pathol** 1999 Sep;155(3):765-74

Trophoblast giant cells express NF-kappa B2 during early mouse development. Muggia A, et al. **Dev Genet** 1999; 25(1):23-30

MICROBIOLOGY

Generation of multinucleated giant cells in vitro by culture of human monocytes with Mycobacterium bovis BCG in combination with cytokine-containing supernatants. Gasser A, et al. **Infect Immun** 1999 Jan;67(1):395-402

PATHOLOGY

Giant cell atypical fibroxanthoma: does it really exist? [letter; comment] Zelger BG, et al. **Am J Dermatopathol** 1999 Feb; 21(1):108-10. Comment on: Am J Dermatopathol 1997 Apr;19(2):174-9.

Gastric carcinoma with osteoclast-like giant cells. Baschinsky DY, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1678-81

Peripheral T-cell lymphoma with Toutonlike tumor giant cells associated with HIV infection: report of two cases. Arber DA, et al. **Am J Surg Pathol** 1999 May;23(5):519-22

What is the role of giant cells in AL-amyloidosis? Olsen KE, et al. **Amyloid** 1999 Jun;6(2):89-97

Primary lung tumors infiltrated by osteoclast-like giant cells. Bocklage TJ, et al. **Ann Diagn Pathol** 1998 Aug;2(4):229-40

Tumors of the pancreas with osteoclast-like and pleomorphic giant cells: an immunohistochemical and ploidy study. Deckard-Janatpour K, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):266-72 (47 ref.)

Giant syncytia and virus-like particles in ovarian carcinoma cells isolated from ascites fluid. Rakowicz-Szulczynska EM, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):115-26

Tumor remnants within giant cells following irradiation of cutaneous squamous cell carcinoma. Moore T, et al. **Dermatol Surg** 1998 Oct;24(10):1094-6

Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Torres Y, et al. **Eur J Clin Invest** 1998 Nov;28(11):930-6

Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Kuratani T, et al. **Histol Histopathol** 1998 Jul;13(3):751-9

Immunohistochemical characterization of pleomorphic giant cells in basal cell carcinoma. Cutlan RT, et al. **J Cutan Pathol** 1999 Aug;26(7):353-6

Dysgerminoma with syncytiotrophoblastic giant cells arising from 46,XX pure gonadal dysgenesis. Morimura Y, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):654-6

Origin of histiocyte-like cells and multinucleated giant cells in malignant fibrous histiocytoma: neoplastic or reactive? Hatano H, et al. **Pathol Int** 1999 Jan;49(1):14-22

Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Michal M. **Pathol Res Pract** 1998;194(8):529-33

Infantile liver giant cells: immunohistological study of their proliferative state and possible mechanisms of formation. Koukoulis G, et al. **Pediatr Dev Pathol** 1999 Jul-Aug; 2(4):353-9

[Adult multi-nuclear cell hepatitis. A study in 17 patients] Tordjmann T, et al. **Gastroenterol Clin Biol** 1998 Mar; 22(3):305-10 (Eng. Abstr.) **(Fre)**

[Epithelioid angiomyolipoma of the kidney--a new tumor entity. Case report on a tumor with many multinucleated giant cells] Moch H, et al. **Pathologe** 1998 Nov;19(6):436-41 (30 ref.) (Eng. Abstr.) **(Ger)**

[A case of giant cell hepatitis complicated with insulin dependent diabetes mellitus] Otani Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1037-41 **(Jpn)**

[Post-infantile giant-cell hepatitis of probable autoimmune origin (letter)] Elizalde IR, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):457-9 (6 ref.) **(Spa)**

PHYSIOLOGY

HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A, et al. **AIDS** 1999 Jul 30; 13(11):1305-11

Distinct regulatory regions from the prolactin-like protein C variant promoter direct trophoblast giant cell versus spongiotrophoblast cell-specific expression. Dai G, et al. **Endocrinology** 1999 Oct;140(10):4691-8

Aggregation of mononucleated precursors triggers cell surface expression of alphavbeta3 integrin, essential to formation of osteoclast-like multinucleated cells. Boissy P, et al. **J Cell Sci** 1998 Sep;111 (Pt 17):2563-74

Human T-cell leukaemia/lymphoma virus type I syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7. Daenke S, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1429-36

RADIATION EFFECTS

Tumor remnants within giant cells following irradiation of cutaneous squamous cell carcinoma. Moore T, et al. **Dermatol Surg** 1998 Oct;24(10):1094-6

ULTRASTRUCTURE

Electron microscopic observations and X-ray microanalysis of a multinucleated giant cell. Bay BH, et al. **J Electron Microsc (Tokyo)** 1998;47(4):359-61

Human immunodeficiency virus-rich multinucleated giant cells in the colon: a case report with transmission electron microscopy, immunohistochemistry, and in situ

hybridization. Lewin-Smith M, et al. **Mod Pathol** 1999 Jan; 12(1):75-81

VIROLOGY

HIV-1 (p24)-positive multinucleated giant cells in HIV-associated lymphoepithelial lesion of the parotid gland. A report of two cases. Vicandi B, et al. **Acta Cytol** 1999 Mar-Apr;43(2):247-51

Giant syncytia and virus-like particles in ovarian carcinoma cells isolated from ascites fluid. Rakowicz-Szulczynska EM, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):115-26

Restricted replication of non-syncytium-inducing HIV in Th1 and Th2 lymphocytes. Poli G, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):95-6 (10 ref.)

Human immunodeficiency virus-rich multinucleated giant cells in the colon: a case report with transmission electron microscopy, immunohistochemistry, and in situ hybridization. Lewin-Smith M, et al. **Mod Pathol** 1999 Jan; 12(1):75-81

The Warthin-Finkeldey-type giant cell in HIV infection, what is it? Orenstein JM. **Ultrastruct Pathol** 1998 Jul-Aug; 22(4):293-303

The macrophage origin of the HIV-expressing multinucleated giant cells in hyperplastic tonsils and adenoids. Orenstein JM, et al. **Ultrastruct Pathol** 1999 Mar-Apr;23(2):79-91

Role of the leukocyte function antigen-1 conformational state in the process of human immunodeficiency virus type 1-mediated syncytium formation and virus infection. Fortin JF, et al. **Virology** 1999 Apr 25;257(1):228-38

GIANT CELLS, FOREIGN-BODY

Phagocytosis of new cementum-like islets formed inside the gingival connective tissue in cyclosporin-A treated rats. Ayanoglou CM. **J Periodontal Res** 1999 Feb;34(2):65-9

DRUG EFFECTS

Alkylsilane-modified surfaces: inhibition of human macrophage adhesion and foreign body giant cell formation. Jenney CR, et al. **J Biomed Mater Res** 1999 Jul;46(1):11-21

GIANT CELLS, MULTINUCLEATED see **GIANT CELLS**

GIANT LYMPH NODE HYPERPLASIA

Paediatric Castleman disease: report of seven cases and review of the literature. Parez N, et al. **Eur J Pediatr** 1999 Aug;158(8):631-7 (73 ref.)

[Multicentric Castleman's disease] Horie R, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):330-2 (15 ref.) **(Jpn)**

BLOOD

Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Nishi J, et al. **Br J Haematol** 1999 Mar;104(3):482-5

COMPLICATIONS

Castleman's disease with Kaposi's sarcoma and glomerulonephritis [letter] Chim CS, et al. **Am J Med** 1999 Aug;107(2):186-8

Multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Hattori K, et al. **Ann Hematol** 1998 Oct;77(4):179-81 (15 ref.)

Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune hemolytic anemia. Lerza R, et al. **Ann Hematol** 1999 Apr; 78(4):193-6

Hodgkin's and Castleman's disease in a patient with systemic mastocytosis. Saletti P, et al. **Ann Hematol** 1999 Feb; 78(2):97-100

Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Bélec L, et al. **Blood** 1999 Jun 1;93(11):3643-53

Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease. Bélec L, et al. **Clin Infect Dis** 1999 Mar;28(3):678-9

Kaposi's sarcoma associated with Castleman's disease [letter] Zeidman A, et al. **Eur J Haematol** 1999 Jul;63(1):67-70

Castleman's disease: a rare cause of hematemesis. Zamir A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):112-5

Systemic lupus erythematosus and Castleman's disease. Suwannaroj S, et al. **J Rheumatol** 1999 Jun;26(6):1400-3

The dialysed patient with both Castleman disease and Kaposi sarcoma. Nampoory MR, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2373-6

[Castleman's disease and chromophobe carcinoma of the kidney. An incidental association?] Tissier F, et al. **Ann Pathol** 1998 Nov;18(5):429-31 (Eng. Abstr.) **(Fre)**

[Castleman disease and solitary plasmacytoma of the acromion (letter)] Dupuy O, et al. **Rev Med Interne** 1999 Jan;20(1):83-4 **(Fre)**

[Multicentric Castleman's disease with lymphoid interstitial pneumonia and polyneuropathy] Mizuno I, et al. **Rinsho Ketsueki** 1998 Aug;39(8):593-9 (Eng. Abstr.) **(Jpn)**

[Crow-Fukase syndrome associated with Castleman disease showing hypertrophic cranial pachymeningitis and bilateral internal carotid artery occlusion] Hori T, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):456-60 (Eng. Abstr.) **(Jpn)**

[Angiofollicular lymphoid hyperplasia with ossification in abdominal surgery] Shapochnik MB, et al. **Khirurgiia (Mosk)** 1999;(2):61-2 **(Rus)**

[Localized Castleman's disease associated with high-grade lymphoma] Sanz Garcia RM, et al. **An Med Interna** 1999 Jun;16(6):305-7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

CT and MR appearance of Castleman's disease of the neck. Davis BT, et al. **AJR Am J Roentgenol** 1999 Sep; 173(3):861-2

Castleman disease presenting with ophthalmic signs and symptoms. Kurokawa T, et al. **Am J Ophthalmol** 1999 Jul; 128(1):114-6

A transitional variant of Castleman's disease presenting as a chylous pleural effusion. Ten Hoor T, et al. **Chest** 1999 Jan;115(1):285-8

Castleman disease: CT and MR imaging features of a retroperitoneal location in association with paraneoplastic pemphigus. Irsutti M, et al. **Eur Radiol** 1999;9(6):1219-21

Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. Chorzelski T, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):393-400 (42 ref.)

Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman's tumor. Lee IJ, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):294-7

Intracranial Castleman's disease of solitary form. Case report. Hashimoto H, et al. **J Neurosurg** 1999 Mar;90(3):563-6

Castleman's disease restricted to the parapharyngeal space. Ottaviani F, et al. **J Otolaryngol** 1999 Apr;28(2):95-8

Mesenteric Castleman's disease masquerading as inflammatory bowel disease. Rodefeld MD, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):589-92

Castleman's disease of the erector spinae muscle. Williams HR, et al. **Skeletal Radiol** 1998 Nov;27(11):637-40 (21 ref.)

Castleman disease of the pararenal retroperitoneum: report of a case. Okada S, et al. **Surg Today** 1999;29(2):178-81

[Pancreatic localization of Castleman's tumor (letter)] Le Borgne J, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):536-8 **(Fre)**

[Nodular lymphoid hyperplasia of the colon and terminal ileum. Case report] Peršić M, et al. **Lijec Vjesn** 1998 Mar-Apr;120(3-4):62-4 (Eng. Abstr.) **(Scr)**

[A new case of localized Castleman's disease (letter)] Marcos Sánchez F, et al. **An Med Interna** 1998 Dec;15(12):673-4 **(Spa)**

[Castleman's disease in the retroperitoneal region] Pérez Garcia FJ, et al. **Arch Esp Urol** 1999 May;52(4):388-92 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS [letter] Zietz C, et al. **N Engl J Med** 1999 Jun 17;340(24):1923-4

IMMUNOLOGY

Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease [letter] Foussat A, et al. **AIDS** 1999 Jan 14;13(1):150-2

Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma [published erratum appears in Lab Invest 1999 Jul;79(7):835] Teruya-Feldstein J, et al. **Lab Invest** 1998 Dec;78(12):1637-42

[A little known cause of antiphospholipid antibodies: Castleman's disease (letter)] Granel B, et al. **Rev Med Interne** 1999 Jun;20(6):542-4 **(Fre)**

PATHOLOGY

Proliferative lesions in Castleman's disease [letter; comment] Desai S. **Am J Surg Pathol** 1999 Jan;23(1):134. Comment on: Am J Surg Pathol 1997 Nov;21(11):1295-306.

The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Bowne WB, et al. **Cancer** 1999 Feb 1;85(3):706-17 (61 ref.)

Fine-needle aspiration findings in Castleman's disease. Meyer L, et al. **Diagn Cytopathol** 1999 Jul;21(1):57-60

Retroperitoneal Castleman's disease of the hyaline vascular type presenting arborizing calcification. Sadamoto Y, et al. **Intern Med** 1998 Aug;37(8):691-3

[Castleman's disease of the abdomen] Collet T, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):297-9 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Castleman's disease associated with chronic inflammatory demyelinating polyradiculoneuropathy: a clinical and electrophysiological follow-up study. Fernández-Torre JL, et al. **Clin Neurophysiol** 1999 Jun;110(6):1133-8

RADIOGRAPHY

Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Johkoh T, et al. **Radiology** 1998 Nov; 209(2):477-81

Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation. McAdams HP, et al. **Radiology** 1998 Oct;209(1):221-8

SURGERY

Hyaline vascular Castleman's disease of the mediastinum. Cioffi U, et al. **Int Surg** 1999 Apr-Jun;84(2):115-7

Intracranial Castleman's disease of solitary form. Case report. Hashimoto H, et al. **J Neurosurg** 1999 Mar;90(3):563-6

THERAPY

Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen. Strohal R, et al. **Br J Haematol** 1998 Dec;103(3):788-90

The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Bowne WB, et al. **Cancer** 1999 Feb 1;85(3):706-17 (61 ref.)

[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition] Nishimoto N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1745-50 (20 ref.) **(Jpn)**

ULTRASONOGRAPHY

Color Doppler findings in Castleman's disease of the mesentery. Konno K, et al. **J Clin Ultrasound** 1998 Nov-Dec;26(9):474-8

VIROLOGY

Isolated leptomeningeal Castleman's disease with viral particles in the follicular dendritic cells. Gulati P, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1026-9 (18 ref.)

Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Bélec L, et al. **Blood** 1999 Jun 1;93(11):3643-53

Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome [letter] Papo T, et al. **Br J Haematol** 1999 Mar;104(4):932-3

Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease [see comments] Hayashi M, et al. **Intern Med** 1999 Mar;38(3):279-82. Comment in: Intern Med 1999 Mar;38(3):221-2.

An attractive relation of human herpesvirus-8 with multicentric Castleman's disease [editorial; comment] Katano H, et al. **Intern Med** 1999 Mar;38(3):221-2 (10 ref.) Comment on: Intern Med 1999 Mar;38(3):279-82.

Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Staskus KA, et al. **J Virol** 1999 May;73(5):4181-7

Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma [published erratum appears in Lab Invest 1999 Jul;79(7):835] Teruya-Feldstein J, et al. **Lab Invest** 1998 Dec;78(12):1637-42

Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions. Gaidano G, et al. **Med Oncol** 1999 Apr;16(1):8-12

Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Dupin N, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4546-51

The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Cesarman E, et al. **Semin Cancer Biol** 1999 Jun;9(3):165-74 (92 ref.)

GIANT OTTERS see **OTTERS**

GIANT PANDAS see **BEARS**

GIANT PLATELET SYNDROME see **BERNARD-SOULIER SYNDROME**

GIANT SILKMOTHS see **MOTHS**

GIANT SILKWORMS see **MOTHS**

GIARDIA

CHEMISTRY

Giardia muris: evidence for a beta-giardin homologue. Heyworth MF, et al. **Exp Parasitol** 1999 Mar;91(3):284-7

DRUG EFFECTS

Antigiardial isoflavones from Machaerium aristulatum. elSohly HN, et al. **Planta Med** 1999 Jun;65(5):490

ENZYMOLOGY

Purification and characterization of UDP-N-acetylglucosamine pyrophosphorylase from encysting Giardia. Bulik DA, et al. **Mol Biochem Parasitol** 1998 Sep 1;95(1):135-9

GIARDIA

GENETICS

Comparison of the levels of intra-specific genetic variation within Giardia muris and Giardia intestinalis. Andrews RH, et al. **Int J Parasitol** 1998 Aug;28(8):1179-85

Rapid DNA extraction methods and new primers for randomly amplified polymorphic DNA analysis of Giardia duodenalis. Deng MQ, et al. **J Microbiol Methods** 1999 Aug;37(2):193-200

Characterization of Giardia duodenalis by polymerase-chain-reaction fingerprinting. Homan WL, et al. **Parasitol Res** 1998 Sep;84(9):707-14

PCR-based DNA fingerprinting of Giardia duodenalis isolates using the intergenic rDNA spacer. Hopkins RM, et al. **Parasitology** 1999 Jun;118 (Pt 6):531-9

GROWTH & DEVELOPMENT

Semi-quantitative characterization of electroporation-assisted disinfection processes for inactivation of Giardia and Cryptosporidium. Haas CN, et al. **J Appl Microbiol** 1999 Jun;86(6):899-905

IMMUNOLOGY

Epidemic and endemic seroprevalence of antibodies to Cryptosporidium and Giardia in residents of three communities with different drinking water supplies. Isaac-Renton J, et al. **Am J Trop Med Hyg** 1999 Apr; 60(4):578-83

ISOLATION & PURIFICATION

Fate of Cryptosporidium oocysts, Giardia cysts, and microbial indicators during wastewater treatment and anaerobic sludge digestion. Chauret C, et al. **Can J Microbiol** 1999 Mar;45(3):257-62

The effect of waste water reuse in irrigation on the contamination level of food crops by Giardia cysts and Ascaris eggs. Amahmid O, et al. **Int J Food Microbiol** 1999 Aug 1;49(1-2):19-26

An evaluation of the Gelman Envirochek capsule for the simultaneous concentration of Cryptosporidium and Giardia from water. Matheson Z, et al. **J Appl Microbiol** 1998 Oct;85(4):755-61

Evaluation of a portable differential continuous flow centrifuge for concentration of Cryptosporidium oocysts and Giardia cysts from water. Zuckerman U, et al. **J Appl Microbiol** 1999 Jun;86(6):955-61

TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. Boone JH, et al. **J Clin Microbiol** 1999 Mar;37(3):611-4

Detection of Cryptosporidium oocysts and Giardia cysts in the tissues of eastern oysters (Crassostrea virginica) carrying principal oyster infectious diseases. Graczyk TK, et al. **J Parasitol** 1998 Oct;84(5):1039-42

The prevalence of Giardia and Cryptosporidium in Taiwan water supplies. Hsu BM, et al. **J Toxicol Environ Health** 1999 Jun 11;57(3):149-60

The prevalence of Cryptosporidium and Giardia spp. in fecal samples from free-ranging white-tailed deer (Odocoileus virginianus) in the southeastern United States. Rickard LG, et al. **J Vet Diagn Invest** 1999 Jan;11(1):65-72

Endoscopic aspiration of intestinal contents in dogs and cats: 394 cases. Leib MS, et al. **J Vet Intern Med** 1999 May-Jun; 13(3):191-3

Evaluation of the recovery of waterborne Giardia cysts by freshwater clams and cyst detection in clam tissue. Graczyk TK, et al. **Parasitol Res** 1999 Jan;85(1):30-4

Characterization of Giardia duodenalis by polymerase-chain-reaction fingerprinting. Homan WL, et al. **Parasitol Res** 1998 Sep;84(9):707-14

Occurrence of Cryptosporidium oocysts and Giardia cysts in water supplies of San Pedro Sula, Honduras. Solo-Gabriele HM, et al. **Rev Panam Salud Publica** 1998 Dec;4(6):398-400

[Giardia, a potential cause of diarrhea] Koene MG, et al. **Tijdschr Diergeneeskd** 1999 May 15;124(10):310-2 (29 ref.) (Eng. Abstr.) **(Dut)**

GIARDIA INTESTINALIS see **GIARDIA LAMBLIA**

GIARDIA LAMBLIA

Giardia intestinalis is unlikely to be a major cause of the poor growth of rural Gambian infants. Lunn PG, et al. **J Nutr** 1999 Apr;129(4):872-7

Helicobacter pylori and Giardia lamblia infections in hemodialysis patients [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1803-4

CHEMISTRY

Giardia intestinalis: conservation of the variant-specific surface protein VSP417-1 (TSA417) and identification of a divergent homologue encoded at a duplicated locus in genetic group II isolates. Ey PL, et al. **Exp Parasitol** 1998 Nov;90(3):250-61

Functional identification of alpha 1-giardin as an annexin of Giardia lamblia. Bauer B, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):147-53

CLASSIFICATION

Molecular comparison of Giardia lamblia isolates. Lu SQ, et al. **Int J Parasitol** 1998 Sep;28(9):1341-5

Characterization of Giardia lamblia groups A and B from North India by isoenzyme and random amplified polymorphic DNA analysis. Paintlia AS, et al. **Parasitol Res** 1999 Jun;85(6):510-2

DRUG EFFECTS

Cysticidal effect of chlorine dioxide on Giardia intestinalis cysts. Winiecka-Krusnell J, et al. **Acta Trop** 1998 Jul 30; 70(3):369-72

Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Upcroft JA, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):73-6

Giardia lamblia: in-vitro sensitivity to some chemotherapeutic agents. Baveja UK, et al. **J Commun Dis** 1998 Jun;30(2):79-84

Antiprotozoal properties of Helianthemum glomeratum. Meckes M, et al. **Phytother Res** 1999 Mar;13(2):102-5

Antiamoebic and antigiardial activity of plant flavonoids [letter] Calzada F, et al. **Planta Med** 1999 Feb;65(1):78-80

ENZYMOLOGY

Point mutations in the guanine phosphoribosyltransferase from Giardia lamblia modulate pyrophosphate binding and enzyme catalysis. Page JP, et al. **Eur J Biochem** 1999 Feb; 259(3):565-71

Sequence and phylogenetic position of a class II aldolase gene in the amitochondriate protist, Giardia lamblia. Henze K, et al. **Gene** 1998 Nov 19;222(2):163-8

Cloning of two putative Giardia lamblia glucosamine 6-phosphate isomerase genes only one of which is transcriptionally activated during encystment. Van Keulen H, et al. **J Eukaryot Microbiol** 1998 Nov-Dec;45(6):637-42

Isolation and subunit composition of the 20S proteasome of Giardia lamblia. Emmerlich V, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):131-4

GENETICS

A DNA-based probe for differentiation of Giardia lamblia group A and B isolates from northern India. Paintlia AS, et al. **Clin Infect Dis** 1999 May;28(5):1178-80

Sequence and phylogenetic position of a class II aldolase gene in the amitochondriate protist, Giardia lamblia. Henze K, et al. **Gene** 1998 Nov 19;222(2):163-8

Cloning and sequencing of an acetyl-CoA synthetase (ADP-forming) gene from the amitochondriate protist, Giardia lamblia. Sánchez LB, et al. **Gene** 1999 Jun 11; 233(1-2):225-31

Molecular comparison of Giardia lamblia isolates. Lu SQ, et al. **Int J Parasitol** 1998 Sep;28(9):1341-5

Identification and characterization of a ran gene promoter in the protozoan pathogen Giardia lamblia. Sun CH, et al. **J Biol Chem** 1999 Jul 9;274(28):19699-706

Primary structure and phylogenetic relationships of a malate dehydrogenase gene from Giardia lamblia. Roger AJ, et al. **J Mol Evol** 1999 Jun;48(6):750-5

Axenic cultivation and characterization of Giardia lamblia isolated from humans in Korea. Park SJ, et al. **Korean J Parasitol** 1999 Jun;37(2):121-5

A new locus (vsp417-4) belonging to the tsa417-like subfamily of variant-specific surface protein genes in Giardia intestinalis. Ey PL, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):55-68

Characterisation of the gene encoding phosphoribosylpyrophosphate synthetase (PRS) of Giardia intestinalis. Kyradji S, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1-2):225-8

Structural basis of karyotype heterogeneity in Giardia lamblia. Le Blancq SM, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1-2):199-208

Characterisation and expression of the carbamate kinase gene from Giardia intestinalis. Minotto L, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):43-51

Sequence survey of the Giardia lamblia genome. Smith MW, et al. **Mol Biochem Parasitol** 1998 Sep 15;95(2):267-80

A signal recognition particle receptor gene from the early-diverging eukaryote, Giardia lamblia. Svärd SG, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):253-64

Molecular systematics of the parasitic protozoan Giardia intestinalis. Monis PT, et al. **Mol Biol Evol** 1999 Sep; 16(9):1135-44

Differentiation-associated surface antigen variation in the ancient eukaryote Giardia lamblia. Svärd SG, et al. **Mol Microbiol** 1998 Dec;30(5):979-89

Comparison of tsa417-like variant-specific surface protein (VSP) genes in Giardia intestinalis and identification of a novel locus in genetic group II isolates. Ey PL, et al. **Parasitology** 1998 Nov;117 (Pt 5):445-55

GROWTH & DEVELOPMENT

A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro. Kang EW, et al. **Parasitology** 1998 Sep;117 (Pt 3):229-34

IMMUNOLOGY

Immune effector responses to an excretory-secretory product of Giardia lamblia. Kaur H, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):93-105

Antigenic variation and the murine immune response to Giardia lamblia. Müller N, et al. **Int J Parasitol** 1998 Dec; 28(12):1829-39 (56 ref.)

Antiparasite activity of sea-anemone cytolysins on Giardia duodenalis and specific targeting with anti-Giardia antibodies. Tejuca M, et al. **Int J Parasitol** 1999 Mar; 29(3):489-98

Differentiation-associated surface antigen variation in the ancient eukaryote Giardia lamblia. Svärd SG, et al. **Mol Microbiol** 1998 Dec;30(5):979-89

[The detection of antibodies to the trophozoite antigens of Lamblia by an immunoenzyme method] Dedkova LM, et al. **Med Parazitol (Mosk)** 1999 Jan-Mar;(1):46-8 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Sedimentation of free and attached Cryptosporidium oocysts and Giardia cysts in water. Medema GJ, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4460-6

Infectious diarrhea in tourists staying in a resort hotel. Hardie RM, et al. **Emerg Infect Dis** 1999 Jan-Feb;5(1):168-71

Immunochromatographic strip-based detection of Entamoeba histolytica-E. dispar and Giardia lamblia coproantigen. Pillai DR, et al. **J Clin Microbiol** 1999 Sep; 37(9):3017-9

Giardia lamblia associated arthritis in a 19-month-old child [letter] LeBlanc CM, et al. **J Rheumatol** 1999 Sep; 26(9):2066-7 (14 ref.)

Improved immunofluorescence assay for detection of Giardia and Cryptosporidium from asymptomatic adult cervine animals. Deng MQ, et al. **Parasitol Res** 1999 Aug; 85(8-9):733-6

[A case of imported paratyphoid fever associated with Giardia lamblia and Isospora belli infection] Sakamoto M, et al. **Kansenshogaku Zasshi** 1998 Dec;72(12):1317-20 (Eng. Abstr.) **(Jpn)**

[Henoch-Schoenlein purpura and toxocarosis] Pawłowska-Kamieniak A, et al. **Pol Merkuriusz Lek** 1998 Apr;4(22):217-8 (Eng. Abstr.) **(Pol)**

[Frequency of giardiasis in children with chronic abdominal pain coming from North-East Poland] Skorochodzki J, et al. **Przegl Epidemiol** 1998;52(3):309-15 (Eng. Abstr.) **(Pol)**

METABOLISM

Giardia lamblia: incorporation of free and conjugated fatty acids into glycerol-based phospholipids. Gibson GR, et al. **Exp Parasitol** 1999 May;92(1):1-11

Protein synthesis in Giardia lamblia may involve interaction between a downstream box (DB) in mRNA and an anti-DB in the 16S-like ribosomal RNA. Yu DC, et al. **Mol Biochem Parasitol** 1998 Oct 30;96(1-2):151-65

PHYSIOLOGY

Possible role of calmodulin in excystation of Giardia lamblia. Bernal RM, et al. **Parasitol Res** 1998 Sep;84(9):687-93

ULTRASTRUCTURE

The peripheral vesicles of trophozoites of the primitive protozoan Giardia lamblia may correspond to early and late endosomes and to lysosomes. Lanfredi-Rangel A, et al. **J Struct Biol** 1998 Nov;123(3):225-35

GIARDIASIS

[Giardiasis] Takeuchi T. **Ryoikibetsu Shokogun Shirizu** 1999; (24 Pt 2):427-9 (7 ref.) **(Jpn)**

COMPLICATIONS

Giardia intestinalis is unlikely to be a major cause of the poor growth of rural Gambian infants. Lunn PG, et al. **J Nutr** 1999 Apr;129(4):872-7

Giardia lamblia associated arthritis in a 19-month-old child [letter] LeBlanc CM, et al. **J Rheumatol** 1999 Sep; 26(9):2066-7 (14 ref.)

Intestinal amoebiasis, giardiasis and geohelminthiases: their association with other intestinal parasites and reported intestinal symptoms. Utzinger J, et al. **Trans R Soc Trop Med Hyg** 1999 Mar-Apr;93(2):137-41

[Hepato-biliary involvement in lambliasis (letter)] Dominguez S, et al. **Gastroenterol Clin Biol** 1998 Jun-Jul; 22(6-7):647-8 **(Fre)**

[Massive duodenal lambliasis and Helicobacter heilmannii gastritis in a diabetic patient (letter)] Grouls V, et al. **Dtsch Med Wochenschr** 1999 May 14;124(19):611 **(Ger)**

[A case of imported paratyphoid fever associated with Giardia lamblia and Isospora belli infection] Sakamoto M, et al. **Kansenshogaku Zasshi** 1998 Dec;72(12):1317-20 (Eng. Abstr.) **(Jpn)**

[Frequency of giardiasis in children with chronic abdominal pain coming from North-East Poland] Skorochodzki J, et al. **Przegl Epidemiol** 1998;52(3):309-15 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Review article: the management of Giardiasis. Vesy CJ, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):843-50 (44 ref.)

TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. Boone JH, et al. **J Clin Microbiol** 1999 Mar;37(3):611-4

75-year-old man with fever, weight loss, and diarrhea. Denktas AE, et al. **Mayo Clin Proc** 1998 Oct;73(10):983-6

Recent advances in the diagnosis in livestock of Cryptosporidium, Toxoplasma, Giardia and other protozoa of veterinary importance. Taylor MA, et al. **Res Vet Sci** 1998 Nov-Dec;65(3):183-93 (140 ref.)
[Giardiasis in clinical data] Ondrušková M, et al. **Epidemiol Mikrobiol Imunol** 1998 Aug;47(3):97-9 (Eng. Abstr.) **(Slo)**

DRUG THERAPY

Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. Reynoldson JA, et al. **Acta Trop** 1998 Aug 15; 71(1):27-44
Review article: the management of Giardiasis. Vesy CJ, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):843-50 (44 ref.)
Quinacrine for treatment of giardiasis [letter] Wolfe MS, et al. **J Travel Med** 1998 Dec;5(4):228
A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro. Kang EW, et al. **Parasitology** 1998 Sep;117 (Pt 3):229-34

EPIDEMIOLOGY

Epidemic and endemic seroprevalence of antibodies to Cryptosporidium and Giardia in residents of three communities with different drinking water supplies. Isaac-Renton J, et al. **Am J Trop Med Hyg** 1999 Apr; 60(4):578-83
Epidemiology of giardiasis and cryptosporidiosis in Jamaica. Lindo JF, et al. **Am J Trop Med Hyg** 1998 Nov; 59(5):717-21
Epidemiology of giardiasis in Tasmania: a potential risk to residents and visitors. Kettlewell JS, et al. **J Travel Med** 1998 Sep;5(3):127-30
Helicobacter pylori and Giardia lamblia infections in hemodialysis patients [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1803-4
[The effect of the technogenic pollution of the natural environment on the prevalence of parasitic diseases in the Republic of Byelarus] Skripova LV. **Med Parazitol (Mosk)** 1999 Jan-Mar;(1):6-8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Immune effector responses to an excretory-secretory product of Giardia lamblia. Kaur H, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):93-105
Antigenic variation and the murine immune response to Giardia lamblia. Müller N, et al. **Int J Parasitol** 1998 Dec; 28(12):1829-39 (56 ref.)

PARASITOLOGY

Infectious diarrhea in tourists staying in a resort hotel. Hardie RM, et al. **Emerg Infect Dis** 1999 Jan-Feb;5(1):168-71
Characterization of Giardia lamblia groups A and B from North India by isoenzyme and random amplified polymorphic DNA analysis. Paintlia AS, et al. **Parasitol Res** 1999 Jun;85(6):510-2
[Frequency of giardiasis in children with chronic abdominal pain coming from North-East Poland] Skorochodzki J, et al. **Przegl Epidemiol** 1998;52(3):309-15 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Cysticidal effect of chlorine dioxide on Giardia intestinalis cysts. Winiecka-Krusnell J, et al. **Acta Trop** 1998 Jul 30; 70(3):369-72

VETERINARY

Efficacy of a drug combination of praziquantel, pyrantel pamoate, and febantel against giardiasis in dogs. Barr SC, et al. **Am J Vet Res** 1998 Sep;59(9):1134-6
Calves as a potential reservoir of Cryptosporidium parvum and Giardia sp. Bednarska M, et al. **Ann Agric Environ Med** 1998;5(2):135-8
Prevalence and geographical distribution of Giardia spp. and Cryptosporidium spp. in dairy farms in Québec. Ruest N, et al. **Can Vet J** 1998 Nov;39(11):697-700
Duration of naturally acquired giardiosis and cryptosporidiosis in dairy calves and their association with diarrhea. O'Handley RM, et al. **J Am Vet Med Assoc** 1999 Feb 1;214(3):391-6
The prevalence of Cryptosporidium and Giardia spp. in fecal samples from free-ranging white-tailed deer (Odocoileus virginianus) in the southeastern United States. Rickard LG, et al. **J Vet Diagn Invest** 1999 Jan;11(1):65-72
Endoscopic aspiration of intestinal contents in dogs and cats: 394 cases. Leib MS, et al. **J Vet Intern Med** 1999 May-Jun; 13(3):191-3
Improved immunofluorescence assay for detection of Giardia and Cryptosporidium from asymptomatic adult cervine animals. Deng MQ, et al. **Parasitol Res** 1999 Aug; 85(8-9):733-6
Recent advances in the diagnosis in livestock of Cryptosporidium, Toxoplasma, Giardia and other protozoa of veterinary importance. Taylor MA, et al. **Res Vet Sci** 1998 Nov-Dec;65(3):183-93 (140 ref.)
[Giardia, a potential cause of diarrhea] Koene MG, et al. **Tijdschr Diergeneeskd** 1999 May 15;124(10):310-2 (29 ref.) (Eng. Abstr.) **(Dut)**

GIBBERELLA

see related
FUSARIUM

DRUG EFFECTS

Induction of a polyubiquitin gene (ubi1) by potato phytoalexins and heat shock in Gibberella pulicaris. Loser K, et al. **Curr Genet** 1998 Dec;34(5):404-9

ENZYMOLOGY

Gibberellin biosynthesis in Gibberella fujikuroi: cloning and characterization of the copalyl diphosphate synthase gene. Tudzynski B, et al. **Curr Genet** 1998 Sep;34(3):234-40
Gibberellin biosynthetic pathway in Gibberella fujikuroi: evidence for a gene cluster. Tudzynski B, et al. **Fungal Genet Biol** 1998 Dec;25(3):157-70

GENETICS

Deletions in the gibberellin biosynthesis gene cluster of Gibberella fujikuroi by restriction enzyme-mediated integration and conventional transformation-mediated mutagenesis. Linnemannstöns P, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2558-64
A polyketide synthase gene required for biosynthesis of fumonisin mycotoxins in Gibberella fujikuroi mating population A. Proctor RH, et al. **Fungal Genet Biol** 1999 Jun;27(1):100-12
Gibberellin biosynthetic pathway in Gibberella fujikuroi: evidence for a gene cluster. Tudzynski B, et al. **Fungal Genet Biol** 1998 Dec;25(3):157-70
Isolation, characterization and disruption of the areA nitrogen regulatory gene of Gibberella fujikuroi. Tudzynski B, et al. **Mol Gen Genet** 1999 Feb;261(1):106-14

METABOLISM

Nitrogen repression of fumonisin B1 biosynthesis in Gibberella fujikuroi. Shim WB, et al. **FEMS Microbiol Lett** 1999 Aug 1;177(1):109-16

GIBBERELLINS

ANALYSIS

GA3 content in antheridia of Chara vulgaris at the proliferative stage and in spermiogenesis estimated by capillary electrophoresis. Kazmierczak A, et al. **Folia Histochem Cytobiol** 1999;37(1):49-52

BIOSYNTHESIS

Deletions in the gibberellin biosynthesis gene cluster of Gibberella fujikuroi by restriction enzyme-mediated integration and conventional transformation-mediated mutagenesis. Linnemannstöns P, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2558-64
Gibberellin biosynthesis in Gibberella fujikuroi: cloning and characterization of the copalyl diphosphate synthase gene. Tudzynski B, et al. **Curr Genet** 1998 Sep;34(3):234-40
Gibberellin biosynthetic pathway in Gibberella fujikuroi: evidence for a gene cluster. Tudzynski B, et al. **Fungal Genet Biol** 1998 Dec;25(3):157-70
Modification of gibberellin production and plant development in Arabidopsis by sense and antisense expression of gibberellin 20-oxidase genes. Coles JP, et al. **Plant J** 1999 Mar;17(5):547-56
Regulation of gibberellin biosynthesis genes during flower and early fruit development of tomato. Rebers M, et al. **Plant J** 1999 Feb;17(3):241-50
Over-expression of a tobacco homeobox gene, NTH15, decreases the expression of a gibberellin biosynthetic gene encoding GA 20-oxidase. Tanaka-Ueguchi M, et al. **Plant J** 1998 Aug;15(3):391-400
Genetic analysis of gibberellin biosynthesis. Hedden P, et al. **Plant Physiol** 1999 Feb;119(2):365-70 (46 ref.)
Arabidopsis ent-kaurene oxidase catalyzes three steps of gibberellin biosynthesis. Helliwell CA, et al. **Plant Physiol** 1999 Feb;119(2):507-10
The first step of gibberellin biosynthesis in pumpkin is catalyzed by at least two copalyl diphosphate synthases encoded by differentially regulated genes. Smith MW, et al. **Plant Physiol** 1998 Dec;118(4):1411-9
Phytochrome regulates gibberellin biosynthesis during germination of photoblastic lettuce seeds. Toyomasu T, et al. **Plant Physiol** 1998 Dec;118(4):1517-23

GENETICS

Deletions in the gibberellin biosynthesis gene cluster of Gibberella fujikuroi by restriction enzyme-mediated integration and conventional transformation-mediated mutagenesis. Linnemannstöns P, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2558-64
Gibberellin: inhibitor of an inhibitor of...? Harberd NP, et al. **Bioessays** 1998 Dec;20(12):1001-8 (35 ref.)
The Arabidopsis dwarf mutant shi exhibits reduced gibberellin responses conferred by overexpression of a new putative zinc finger protein. Fridborg I, et al. **Plant Cell** 1999 Jun;11(6):1019-32
Regulation of gibberellin biosynthesis genes during flower and early fruit development of tomato. Rebers M, et al. **Plant J** 1999 Feb;17(3):241-50
Genetic analysis of gibberellin biosynthesis. Hedden P, et al. **Plant Physiol** 1999 Feb;119(2):365-70 (46 ref.)

IMMUNOLOGY

Expression of a functional single-chain antibody against GA24/19 in transgenic tobacco. Shimada N, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):779-83
Preparation and application of anti-idiotypic antibody against anti-gibberellin A4 antibody. Suzuki Y, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):648-54

METABOLISM

Gibberellin: inhibitor of an inhibitor of...? Harberd NP, et al. **Bioessays** 1998 Dec;20(12):1001-8 (35 ref.)
Gibberellin signaling. Bethke PC, et al. **Curr Opin Plant Biol** 1998 Oct;1(5):440-6 (66 ref.)
Feedback regulation of GA5 expression and metabolic engineering of gibberellin levels in Arabidopsis. Xu YL, et al. **Plant Cell** 1999 May;11(5):927-36
Gibberellin-photoaffinity labelling of two polypeptides in plant plasma membranes. Lovegrove A, et al. **Plant J** 1998 Aug;15(3):311-20
Molecular characterization of catalytic-subunit cDNA sequences encoding protein phosphatases 1 and 2A and study of their roles in the gibberellin-dependent Osamy-c expression in rice. Chang M, et al. **Plant Mol Biol** 1999 Jan;39(1):105-15
Independent regulation of flowering by phytochrome B and gibberellins in Arabidopsis. Blázquez MA, et al. **Plant Physiol** 1999 Aug;120(4):1025-32
Overexpression of 20-oxidase confers a gibberellin-overproduction phenotype in Arabidopsis. Huang S, et al. **Plant Physiol** 1998 Nov;118(3):773-81
Molecular cloning and functional expression of gibberellin 2- oxidases, multifunctional enzymes involved in gibberellin deactivation. Thomas SG, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4698-703

PHARMACOLOGY

Gibberellic acid stabilises microtubules in maize suspension cells to cold and stimulates acetylation of alpha-tubulin. Huang RF, et al. **FEBS Lett** 1999 Jan 29;443(3):317-20
Molecular cloning and analysis of a pea cDNA that is expressed in darkness and very rapidly induced by gibberellic acid. Li HY, et al. **Mol Gen Genet** 1998 Sep; 259(4):393-7
'Green revolution' genes encode mutant gibberellin response modulators. Peng J, et al. **Nature** 1999 Jul 15; 400(6741):256-61
Characterization of a protein kinase gene responsive to auxin and gibberellin in cucumber hypocotyls. Chono M, et al. **Plant Cell Physiol** 1998 Sep;39(9):958-67
Transcript level for a gene encoding a putative type Ia plasma membrane receptor is induced by gibberellin in deepwater rice. van der Knaap E, et al. **Plant Cell Physiol** 1998 Nov; 39(11):1127-32
Gibberellin-responsive genes: high level of transcript accumulation in leaf sheath meristematic tissue from Zea mays L. Ogawa M, et al. **Plant Mol Biol** 1999 Jul; 40(4):645-57
Gibberellin and abscisic acid regulate GAST1 expression at the level of transcription. Shi L, et al. **Plant Mol Biol** 1998 Dec;38(6):1053-60
Isolation and molecular characterization of gibberellin-regulated H1 and H2B histone cDNAs in the leaf of the gibberellin-deficient tomato. van den Heuvel KJ, et al. **Plant Mol Biol** 1999 Mar;39(5):883-90
DNaseI footprints suggest the involvement of at least three types of transcription factors in the regulation of alpha-Amy2/A by gibberellin. Willmott RL, et al. **Plant Mol Biol** 1998 Nov;38(5):817-25
Extragenic suppressors of the Arabidopsis gai mutation alter the dose-response relationship of diverse gibberellin responses. Peng J, et al. **Plant Physiol** 1999 Apr; 119(4):1199-208
Cloning and characterization of a gibberellin-induced RNase expressed in barley aleurone cells. Rogers SW, et al. **Plant Physiol** 1999 Apr;119(4):1457-64

GIBBON APE LEUKEMIA VIRUS see **LEUKEMIA VIRUS, GIBBON APE**

GIBBONS see **HYLOBATES**

GIEDION-LANGER SYNDROME see **LANGER-GIEDION SYNDROME**

GIEMSA STAIN see **AZURE STAINS**

GIFT see **GAMETE INTRAFALLOPIAN TRANSFER**

GIFTED CHILD see **CHILD, GIFTED**

GIFTS, FINANCIAL see **FUND RAISING**

GIGANTISM

see related
BECKWITH-WIEDEMANN SYNDROME
Images in clinical medicine. Pituitary gigantism. Gagel RF, et al. **N Engl J Med** 1999 Feb 18;340(7):524

GIGANTISM

BLOOD

Growth hormone isoforms in a girl with gigantism. Ng LL, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb; 12(1):99-106

COMPLICATIONS

Cancer in Sotos syndrome [letter] Yule SM. **Arch Dis Child** 1999 May;80(5):493

Myocardial infarction with Moyamoya disease and pituitary gigantism in a young female patient. Ahn YK, et al. **Jpn Circ J** 1999 Aug;63(8):644-8

Sotos syndrome associated with West syndrome and a visual disorder. Suzuki N, et al. **Pediatr Int** 1999 Aug;41(4):395-8

[Acute shock encephalopathy syndrome in a girl with Sotos syndrome--with special reference to differentiation from Reye syndrome] Kimura S, et al. **No To Hattatsu** 1999 Jul;31(4):355-8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Suppression of growth hormone by oral glucose in the evaluation of tall stature. Holl RW, et al. **Horm Res** 1999; 51(1):20-4

DRUG THERAPY

Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy. Näntö-Salonen K, et al. **Acta Paediatr** 1999 Jan; 88(1):29-33

ETIOLOGY

Digital enlargement in tuberous sclerosis. Lustberg H, et al. **Skeletal Radiol** 1999 Feb;28(2):116-8

GENETICS

McCune-Albright syndrome: clinical and molecular evidence of mosaicism in an unusual giant patient. Tinschert S, et al. **Am J Med Genet** 1999 Mar 12;83(2):100-8 (8 ref.)

Gastric carcinoma in Sotos syndrome (cerebral gigantism). Le Marec B, et al. **Ann Genet** 1999;42(2):113-6 (23 ref.)

Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. Gadelha MR, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):249-56

Breakpoint mapping by FISH in a Sotos patient with a constitutional translocation t(3;6) [letter] Kok K, et al. **J Med Genet** 1999 Apr;36(4):346-7

PATHOLOGY

Testicular yolk sac tumour in a patient with Sotos syndrome. Muraishi O, et al. **BJU Int** 1999 Feb;83(3):357-8

PHYSIOPATHOLOGY

Growth in Sotos syndrome. Agwu JC, et al. **Arch Dis Child** 1999 Apr;80(4):339-42

PREVENTION & CONTROL

Oestrogen treatment of tall stature [letter; comment] Brook CG, et al. **Arch Dis Child** 1998 Aug;79(2):199. Comment on: Arch Dis Child 1998 Feb;78(2):148-51.

GILBERT'S DISEASE

[The benign hyperbilirubinemia syndrome] Vítek L. **Vnitr Lek** 1998 Oct;44(10):624 **(Cze)**

COMPLICATIONS

Epirubicin in a breast cancer patient with Gilbert's syndrome: apparent lack of major pharmacokinetic alterations [letter] Riggi M, et al. **Ann Oncol** 1999 Mar;10(3):360-1

[alpha-thalassemia accompanied with Gilbert's syndrome] Koiso H, et al. **Rinsho Ketsueki** 1998 Sep;39(9):703-8 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Doxorubicin dosage guidelines in a patient with hyperbilirubinemia of Gilbert's syndrome. Cupp MJ, et al. **Ann Pharmacother** 1998 Oct;32(10):1026-9

ENZYMOLOGY

Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. Akaba K, et al. **J Hum Genet** 1999;44(1):22-5

GENETICS

The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels [letter] Cappellini MD, et al. **Br J Haematol** 1999 Mar;104(4):928-9

Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Biondi ML, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):897-8

Bilirubin levels in the acute hemolytic crisis of G6PD deficiency are related to Gilbert's syndrome. Iolascon A, et al. **Eur J Haematol** 1999 May;62(5):307-10

A case of anorexia nervosa with hyperbilirubinaemia in a patient homozygous for a mutation in the bilirubin UDP-glucuronosyltransferase gene. Maruo Y, et al. **Eur J Pediatr** 1999 Jul;158(7):547-9

Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous beta-thalassemia. Galanello R, et al. **Haematologica** 1999 Feb;84(2):103-5

(TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Iolascon A, et al. **Haematologica** 1999 Feb;84(2):106-9

Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes. Sampietro M, et al. **Haematologica** 1999 Feb;84(2):150-7 (51 ref.)

Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. Akaba K, et al. **J Hum Genet** 1999;44(1):22-5

Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. Monaghan G, et al. **J Pediatr** 1999 Apr;134(4):441-6

METABOLISM

[Hepatobiliary clearance of glycocholic acid in Gilbert's disease] Serna Miquel I, et al. **An Med Interna** 1998 Nov; 15(11):580-3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Gilbert's syndrome and jaundice in glucose-6-phosphate dehydrogenase deficient neonates. Iolascon A, et al. **Haematologica** 1999 Feb;84(2):99-102

URINE

[The heterogeneity of paracetamol metabolism in Gilbert's disease] Esteban Rodriguez A, et al. **Gastroenterol Hepatol** 1999 Jun-Jul;22(6):265-9 (Eng. Abstr.) **(Spa)**

GILLES DE LA TOURETTE'S DISEASE see **TOURETTE SYNDROME**

GILLS

CHEMISTRY

Increase of metallothionein-immunopositive chloride cells in the gills of brown trout and rainbow trout after exposure to sewage treatment plant effluents. Burkhardt-Holm P, et al. **Histochem J** 1999 Jun;31(6):339-46

A mechanism for branchial acid excretion in marine fish: identification of multiple Na+/H+ antiporter (NHE) isoforms in gills of two seawater teleosts. Claiborne JB, et al. **J Exp Biol** 1999 Feb;202 (Pt 3):315-24

CYTOLOGY

Isolation of viable cell types from the gill epithelium of Japanese eel Anguilla japonica. Wong CK, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R363-72

Toxicity of 4-chloroaniline in early life stages of zebrafish (Danio rerio): II. Cytopathology and regeneration of liver and gills after prolonged exposure to waterborne 4-chloroaniline. Burkhardt-Holm P, et al. **Arch Environ Contam Toxicol** 1999 Jul;37(1):85-102

Studies on the eosinophilic granule cells in the gills of the rainbow trout, Oncorhynchus mykiss. Holland JW, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):321-8

DRUG EFFECTS

Effects of cadmium on gill Na,K-ATPase of the estuarine crab Chasmagnathus granulata (Decapoda, Grapsidae) during postmolt: in vivo and in vitro studies. Rodriguez Moreno PA, et al. **Bull Environ Contam Toxicol** 1998 Nov; 61(5):629-36

Toxicity of fatty acid 18:5n3 from Gymnodinium cf. mikimotoi: I. Morphological and biochemical aspects on Dicentrarchus labrax gills and intestine. Sola F, et al. **J Appl Toxicol** 1999 Jul-Aug;19(4):279-84

Growth suppression and branchitis in trout exposed to hydrogen peroxide. Speare DJ, et al. **J Comp Pathol** 1999 May;120(4):391-402

Modulation of cholinergic transmission in the neuronal network of the gill and siphon withdrawal reflex in Aplysia. Storozhuk M, et al. **Neuroscience** 1999 Apr;90(1):291-301

Potential mechanisms of the enhancement of aldicarb toxicity to Japanese medaka, Oryzias latipes, at high salinity. El-Alfy A, et al. **Toxicol Appl Pharmacol** 1998 Sep; 152(1):175-83

EMBRYOLOGY

In situ detection of apoptotic cells by TUNEL in the gill epithelium of the developing brown trout (Salmo trutta). Rojo MC, et al. **J Anat** 1998 Oct;193 (Pt 3):391-8

ENZYMOLOGY

Does gill boundary layer carbonic anhydrase contribute to carbon dioxide excretion: a comparison between dogfish (Squalus acanthias) and rainbow trout (Oncorhynchus mykiss). Perry SF, et al. **J Exp Biol** 1999 Mar;202 (Pt 6):749-56

Enzymatic capacities for beta-oxidation of fatty fuels are low in the gill of teleost fishes despite presence of fatty acid-binding protein. Crockett EL, et al. **J Exp Zool** 1999 Aug 1;284(3):276-85

Osmoregulation and salinity effects on the expression and activity of Na+,K(+)-ATPase in the gills of European sea bass, Dicentrarchus labrax (L.). Jensen MK, et al. **J Exp Zool** 1998 Oct 15;282(3):290-300

Carbonic anhydrase in the gills of seawater- and freshwater-acclimated flounders Platichthys flesus: purification, characterization, and immunohistochemical localization. Sender S, et al. **J Histochem Cytochem** 1999 Jan;47(1):43-50

INNERVATION

Neurorespiratory pattern of gill and lung ventilation in the decerebrate spontaneously breathing tadpole. Gdovin MJ, et al. **Respir Physiol** 1998 Aug;113(2):135-46

METABOLISM

Metallothionein response in gills of Oreochromis mossambicus exposed to copper in fresh water. Dang Z, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R320-31

Na+-K+-ATPase and Na+/Ca2+ exchange activities in gills of hyperregulating Carcinus maenas. Lucu C, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R490-9

Chloride cell subtypes in the gill epithelium of Japanese eel Anguilla japonica. Wong CK, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):R517-22

Uptake of particulate lead via the gills of fish (Carassius auratus). Tao S, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):352-7

Technical evaluation of oxygen transfer rates of fish gills and artificial gills. Matsuda N, et al. **ASAIO J** 1999 Jul-Aug;45(4):293-8

PACAP (pituitary adenylate cyclase-activating peptide)-like immunoreactivity in the gill arch of the goldfish, Carassius auratus: distribution and comparison with VIP. de Girolamo P, et al. **Cell Tissue Res** 1998 Sep;293(3):567-71

The effects of elevated summer temperature and sublethal pollutants (ammonia, low pH) on protein turnover in the gill and liver of rainbow trout (Oncorhynchus mykiss) on a limited food ration. Morgan IJ, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 May; 123(1):43-53

Cu uptake, metabolism and elimination in fed and starved European eels (Anguilla anguilla) during adaptation to water-borne Cu exposure. Grosell M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):295-305

The eicosanoid generating capacity of isolated cell populations from the gills of the rainbow trout, Oncorhynchus mykiss. Holland JW, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Mar;122(3):297-306

Developmental expression of Pax1/9 genes in urochordate and hemichordate gills: insight into function and evolution of the pharyngeal epithelium. Ogasawara M, et al. **Development** 1999 Jun;126(11):2539-50

Regulation of Cl- secretion in seawater fish (Dicentrarchus labrax) gill respiratory cells in primary culture. Avella M, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):353-63

Characterization of binding sites for calcitonin gene related peptide in abalone gill. Duvail L, et al. **Peptides** 1999; 20(3):361-6

ATP-dependent silver transport across the basolateral membrane of rainbow trout gills. Bury NR, et al. **Toxicol Appl Pharmacol** 1999 Aug 15;159(1):1-8

MICROBIOLOGY

Atypical bacterial gill disease in Atlantic salmon hatcheries in British Columbia. Brocklebank JR. **Can Vet J** 1999 Jan; 40(1):54

The association of Flavobacterium columnare strains of high and low virulence with gill tissue of black mollies (Poecilia sphenops). Decostere A, et al. **Vet Microbiol** 1999 Jul 1; 67(4):287-98

PARASITOLOGY

Egg development, hatching and early life-history of Dissonus manteri (Copepoda), parasitic on the gills of coral trout, Plectropomus leopardus. Bennett SM. **Int J Parasitol** 1999 Feb;29(2):267-74

Morphology and ultrastructure of the anterior adhesive areas of the capsalid monogenean parasites Benedenia rohdei from the gills and B. lutjani from the pelvic fins of Lutjanus carponotatus (Pisces: Lutjanidae). Whittington ID, et al. **Parasitol Res** 1999 May;85(5):399-408

Development of monogenean communities on the gills of roach fry (Rutilus rutilus). Bagge AM, et al. **Parasitology** 1999 May;118 (Pt 5):479-87

Larval survival characteristics and behaviour of the gill monogenean Discocotyle sagittata. Gannicott AM, et al. **Parasitology** 1998 Nov;117 (Pt 5):491-8

PATHOLOGY

Gill lamellar pillar cell necrosis, a new birnavirus disease in Japanese eels. Lee NS, et al. **Dis Aquat Organ** 1999 Jun 23;37(1):13-21

Extent of gill pathology in the toadfish Tetractenos hamiltoni caused by Naobranchia variabilis (Copepoda: Naobranchiidae). Roubal FR. **Dis Aquat Organ** 1999 Feb 26;35(3):203-11

Histochemical study of skin and gills of Senegal sole, Solea senegalensis larvae and adults. Sarasquete C, et al.

Histol Histopathol 1998 Jul;13(3):727–35

Growth suppression and branchitis in trout exposed to hydrogen peroxide. Speare DJ, et al. **J Comp Pathol** 1999 May;120(4):391–402

PHYSIOLOGY

Energy cost of NaCl transport in isolated gills of cutthroat trout. Morgan JD, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R631–9

Characterization of the heat shock response in the gills of sea lampreys and a brook lamprey at different intervals of their life cycles. Wood LA, et al.
Comp Biochem Physiol A Mol Integr Physiol 1998 Jul; 120(3):509–18

Regulation of gill cytosolic corticosteroid receptors in juvenile Atlantic salmon: interaction effects of growth hormone with prolactin and triiodothyronine. Shrimpton JM, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):262–74

Urea and water permeability in the ureotelic gulf toadfish (Opsanus beta). Pärt P, et al. **J Exp Zool** 1999 Jan 1; 283(1):1–12

Fictive gill and lung ventilation in the pre- and postmetamorphic tadpole brain stem. Torgerson CS, et al. **J Neurophysiol** 1998 Oct;80(4):2015–22

Neurorespiratory pattern of gill and lung ventilation in the decerebrate spontaneously breathing tadpole. Gdovin MJ, et al. **Respir Physiol** 1998 Aug;113(2):135–46

ULTRASTRUCTURE

Ultrastructural changes in fish gills as biomarker to assess small stream pollution. Pawert M, et al. **Tissue Cell** 1998 Dec;30(6):617–26

GINGER see **ZINGIBERALES**

GINGIVA

see related
GINGIVECTOMY
GINGIVOPLASTY

Dental and gingival pain as side effects of niacin therapy. Leighton RF, et al. **Chest** 1998 Nov;114(5):1472–4

Clinical trial of gingival retraction cords. Jokstad A.
J Prosthet Dent 1999 Mar;81(3):258–61

A new gingival retraction impression system for a one-stage root-form implant. Jones JD, et al. **J Prosthet Dent** 1998 Sep;80(3):371–3

Orthodontics and orthognathic surgery in the combined treatment of an excessively "gummy smile". Fowler P.
N Z Dent J 1999 Jun;95(420):53–4

ANATOMY & HISTOLOGY

Achieving optimal gingival esthetics around restored natural teeth and implants. Rationale, concepts, and techniques. Bichacho N. **Dent Clin North Am** 1998 Oct;42(4):763–80

Soft tissue transfer models: the patient-dentist-laboratory connection. Saba S. **J Can Dent Assoc** 1998 Sep;64(8):584–5

Lymphatic vessel system in gingival peri-implant tissues in humans. Marchetti C, et al. **J Periodontal Res** 1999 May; 34(4):229–31

Retained free gingival graft rugae: a 9-year case report. Breault LG, et al. **J Periodontol** 1999 Apr;70(4):438–40

Blockout technique for impressions of teeth with increased open gingival embrasures. Hummert TW, et al.
J Prosthet Dent 1999 Jul;82(1):100–2

BLOOD SUPPLY

Ultrastructural identification of Weibel-Palade bodies in human gingival blood vessels. Giarratana M, et al.
Bull Group Int Rech Sci Stomatol Odontol 1998 Apr–Sep; 40(2–3):76–9

Smoking and vascular density of healthy marginal gingiva. Persson L, et al. **Eur J Oral Sci** 1998 Oct;106(5):953–7

Vascular endothelial growth factors and progression of periodontal diseases. Johnson RB, et al. **J Periodontol** 1999 Aug;70(8):848–52

[Changes in the gingival microcirculatory bed in health and experimental periodontitis] Shuntikova EV, et al.
Patol Fiziol Eksp Ter 1998 Jul–Sep;(3):18–20 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Immunocytochemical localization of substance P neurokinin-1 receptors in rat gingival tissue. Kido MA, et al. **Cell Tissue Res** 1999 Aug;297(2):213–22

Relationship between hydroxy fatty acids and prostaglandin E2 in gingival tissue. Nichols F, et al. **Infect Immun** 1998 Dec;66(12):5805–11

The relationship between concentrations of proinflammatory cytokines within gingiva and the adjacent sulcular depth. McGee JM, et al. **J Periodontol** 1998 Aug;69(8):865–71

CYTOLOGY

Normalization of keratinocyte-type integrins during the establishment of the oral mucosa phenotype in vitro. Tomakidi P, et al. **Anat Anz** 1999 Jan;181(1):127–32

Morphologic characteristics of initial lymphatics of the healthy and diseased human gingiva. Marchetti C, et al. **Anat Rec** 1999 Jun 1;255(2):175–9

Three-dimensional appearance of Langerhans cells in human gingival epithelium as revealed by confocal laser scanning microscopy. Ito H, et al. **Arch Oral Biol** 1998 Sep; 43(9):741–4

CD40 engagement modulates the production of matrix metalloproteinases by gingival fibroblasts. Wassenaar A, et al. **Clin Exp Immunol** 1999 Jan;115(1):161–7

Transplantation of human pulpal and gingival fibroblasts attached to synthetic scaffolds. Buurma B, et al.
Eur J Oral Sci 1999 Aug;107(4):282–9

Adherence of Porphyromonas gingivalis to epithelial cells: analysis by flow cytometry [published erratum appears in Eur J Oral Sci 1998 Dec;106(6):1051] Huard-Delcourt A, et al. **Eur J Oral Sci** 1998 Oct;106(5):938–44

Estimation of early G1 phase keratinocyte frequencies in gingival epithelium as a tool for studies of gingival epithelium proliferation. Godlewski A, et al.
Folia Histochem Cytobiol 1999;37(2):155–6

Evaluation of initial attachment of human gingival fibroblast cells to biodegradable membranes in vitro by light and scanning electron microscopy. Unsal B, et al.
J Oral Sci 1999 Jun;41(2):57–60

Calcitonin gene-related peptide acts as a mitogen for human Gin-1 gingival fibroblasts by activating the MAP kinase signalling pathway. Kawase T, et al. **J Periodontal Res** 1999 Apr;34(3):160–8

Transepithelial electrical resistance and tight junctions of human gingival keratinocytes. Meyle J, et al.
J Periodontal Res 1999 May;34(4):214–22

Monoclonal antibodies against integrin subunits alpha6 and beta1 inhibit migration of gingival epithelium in organ culture. Gräber HG, et al. **J Periodontol** 1999 Apr; 70(4):388–93

Possible role of monkey gingival fibroblasts in external basement membrane maintenance. Onizawa T, et al.
Tissue Cell 1998 Oct;30(5):502–9

DRUG EFFECTS

In vitro cytotoxicity of orthodontic bonding resins on human oral fibroblasts. Tang AT, et al.
Am J Orthod Dentofacial Orthop 1999 Aug;116(2):132–8

Induction of apoptosis in human gingival fibroblasts by a Porphyromonas gingivalis protease preparation. Wang PL, et al. **Arch Oral Biol** 1999 Apr;44(4):337–42

The effects of extracellular citric acid acidosis on the viability, cellular adhesion capacity and protein synthesis of cultured human gingival fibroblasts. Lan WC, et al.
Aust Dent J 1999 Jun;44(2):123–30

Induction of mitogen-inducible nuclear orphan receptor by interleukin 1 in human synovial and gingival fibroblasts. Borghaei RC, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):334–8

Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1beta and epidermal growth factor. Yucel-Lindberg T, et al.
Biochem Biophys Res Commun 1999 Apr 13;257(2):528–32

Alterations of gingival morphology in nifedipine-fed rats. Hsiao CT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul;62(7):443–9

Influence of resin-based restoration materials on cytotoxicity in gingival fibroblasts. Willershausen B, et al.
Eur J Med Res 1999 Apr 27;4(4):149–55

Enhancement of lipopolysaccharide-stimulated PGE2 and IL-1beta production in gingival fibroblast cells from old rats. Okamura H, et al. **Exp Gerontol** 1999 Jun;34(3):379–92

Effects of extracellular matrix constituents on the attachment of human oral epithelial cells at the titanium surface. Park JC, et al. **Int J Oral Maxillofac Implants** 1998 Nov–Dec; 13(6):826–36

The effect of PDGF, TGF-beta and IGF in combination on androgen metabolism by fibroblasts. Kasasa SC, et al.
J Clin Periodontol 1998 Aug;25(8):640–6

Effects of areca nut, inflorescence piper betle extracts and arecoline on cytotoxicity, total and unscheduled DNA synthesis in cultured gingival keratinocytes. Jeng JH, et al. **J Oral Pathol Med** 1999 Feb;28(2):64–71

Phagocytosis of new cementum-like islets formed inside the gingival connective tissue in cyclosporin-A treated rats. Ayanoglou CM. **J Periodontal Res** 1999 Feb;34(2):65–9

The influence of prostaglandins on steroid conversions by human gingival fibroblasts. Soory M, et al.
J Periodontal Res 1998 Nov;33(8):439–47

In vitro modulation of human gingival epithelial cell attachment and migration by minocycline-HCL. Vanheusden A, et al. **J Periodontal Res** 1998 Aug; 33(6):377–85

Areca nut extract inhibits the growth, attachment, and matrix protein synthesis of cultured human gingival fibroblasts. Chang MC, et al. **J Periodontol** 1998 Oct;69(10):1092–7

Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. Myrillas TT, et al. **J Periodontol** 1999 Mar;70(3):294–300

In vitro cytotoxicity of the nitric oxide donor, S-nitroso-N-acetyl-penicillamine, towards cells from human oral tissue. Babich H, et al. **Pharmacol Toxicol** 1999 May;84(5):218–25

Scanning electron microscopy of cyclosporine-induced gingival overgrowth. Ashrafi SH, et al.
Scanning Microsc 1996;10(1):219–24; 224–5

[In vitro comparison of marginal adaptation of different filling materials. II. Effect of the site and method of preparation on the marginal adaptation] Köhalmi T, et al.
Fogorv Sz 1999 Apr;92(4):111–21 (Eng. Abstr.) **(Hun)**

ENZYMOLOGY

A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Golub LM, et al.
Ann N Y Acad Sci 1999 Jun 30;878:290–310

Heparin and fragments modulate the expression of collagen-degrading enzymes (matrix metalloproteinases 1 and 2) by human gingival fibroblasts. Hornebeck W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:625–8

Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Sorsa T, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:130–40 (28 ref.)

The uptake of two androgen substrates by cultured human gingival fibroblasts in response to minocycline and metabolic studies using a cell-free system. Soory M, et al.
Arch Oral Biol 1999 Mar;44(3):215–22

Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. Sugano N, et al. **J Periodontal Res** 1998 Nov;33(8):448–52

Increase of urokinase-type plasminogen activator receptor expression in human gingival fibroblasts by Porphyromonas gingivalis lipopolysaccharide. Ogura N, et al.
J Periodontol 1999 Apr;70(4):402–8

IMMUNOLOGY

The gingival plasma cell infiltrate in renal transplant patients on an immunosuppressive regimen. Saether K, et al.
Acta Odontol Scand 1998 Oct;56(5):281–7

Involvement of CD14 on human gingival fibroblasts in Porphyromonas gingivalis lipopolysaccharide-mediated interleukin-6 secretion. Wang PL, et al. **Arch Oral Biol** 1998 Sep;43(9):687–94

IL-10 inhibits Porphyromonas gingivalis LPS-stimulated human gingival fibroblasts production of IL-6. Wang PL, et al. **Biochem Biophys Res Commun** 1999 Sep 24; 263(2):372–7

Epithelial antimicrobial peptides: review and significance for oral applications. Weinberg A, et al.
Crit Rev Oral Biol Med 1998;9(4):399–414 (94 ref.)

Interleukin 1beta-secreting cells in inflamed gingival tissue of adult periodontitis patients. Lo YJ, et al. **Cytokine** 1999 Aug;11(8):626–33

Increase of crevicular interleukin 1beta under academic stress at experimental gingivitis sites and at sites of perfect oral hygiene. Deinzer R, et al. **J Clin Periodontol** 1999 Jan; 26(1):1–8

Tobacco smoking and gingival neutrophil activity in young adults. Persson L, et al. **J Clin Periodontol** 1999 Jan; 26(1):9–13

Gingival epithelial cells increase interleukin-8 secretion in response to Actinobacillus actinomycetemcomitans challenge. Huang GT, et al. **J Periodontol** 1998 Oct; 69(10):1105–10

Soluble CD14-dependent intercellular adhesion molecular-1 induction by Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts. Masaka T, et al.
J Periodontol 1999 Jul;70(7):772–8

Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. Tonetti MS, et al. **J Periodontol** 1998 Oct;69(10):1139–47

INJURIES

Evaluation of the incidence of gingival abrasion as a result of toothbrushing. Danser MM, et al. **J Clin Periodontol** 1998 Sep;25(9):701–6

Evaluation of the incidence of gingival abrasion as a result of toothbrushing [letter] Saxer UP. **J Clin Periodontol** 1999 Jul;26(7):480

INNERVATION

[Adrenergic gum innervation during experimental periodontitis] Urbanovich VI, et al.
Biull Eksp Biol Med 1999 May;127(5):564–8 **(Rus)**

[Somatosensory trigeminal evoked potentials after gingival stimulation of the mental nerve. Normal values] Villanueva JA, et al. **Rev Neurol** 1998 Nov;27(159):817–23 (Eng. Abstr.) **(Spa)**

METABOLISM

Benzydamine reduces prostaglandin production in human gingival fibroblasts challenged with interleukin-1 beta or tumor necrosis factor alpha. Modéer T, et al.
Acta Odontol Scand 1999 Feb;57(1):40–5

The effect of centrifugal force on the transcription levels of collagen type I and collagenase in cultured canine gingival fibroblasts. Redlich M, et al. **Arch Oral Biol** 1998 Apr;43(4):313–6

Influence of heparin(s) on the interleukin-1-beta-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Gogly B, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1447–54

Cytokeratin expression in human oral gingival epithelial cells in vitro regulation by titanium-based implant materials. Lagneau C, et al. **Biomaterials** 1998 Jun;19(11–12):1109–15

Localization of the interleukin-1 beta (Il-1 beta) by immunohistochemistry in healthy and inflamed human gingiva. Bons-Sicard C, et al.
Bull Group Int Rech Sci Stomatol Odontol 1998 Apr-Sep; 40(2-3):83-91

IL-6 expression by oral fibroblasts is regulated by androgen. Parkar M, et al. **Cytokine** 1998 Aug;10(8):613-9

Enhancement of lipopolysaccharide-stimulated PGE2 and IL-1beta production in gingival fibroblast cells from old rats. Okamura H, et al. **Exp Gerontol** 1999 Jun;34(3):379-92

Treponema denticola outer membrane enhances the phagocytosis of collagen-coated beads by gingival fibroblasts. Battikhi T, et al. **Infect Immun** 1999 Mar; 67(3):1220-6

Transcriptional activation of mRNA of intercellular adhesion molecule 1 and induction of its cell surface expression in normal human gingival fibroblasts by Mycoplasma salivarium and Mycoplasma fermentans. Dong L, et al.
Infect Immun 1999 Jun;67(6):3061-5

Expression of VLA-integrins and their related basement membrane ligands in gingiva from patients of various periodontitis categories. Gürses N, et al.
J Clin Periodontol 1999 Apr;26(4):217-24

Abnormally high levels of cystatin S in submandibular glands, saliva, and gingiva of plaque-resistant rats. Abe K, et al.
J Dent Res 1998 Nov;77(11):1913-9

Intracellular interleukin-1 alpha production in human gingival fibroblasts is differentially regulated by various cytokines. Kobayashi M, et al. **J Dent Res** 1999 Apr; 78(4):840-9

Direct interaction between gingival fibroblasts and lymphoid cells induces inflammatory cytokine mRNA expression in gingival fibroblasts. Murakami S, et al. **J Dent Res** 1999 Jan;78(1):69-76

Signal transduction pathways involved in the synergistic stimulation of prostaglandin production by interleukin-1beta and tumor necrosis factor alpha in human gingival fibroblasts. Yucel-Lindberg T, et al.
J Dent Res 1999 Jan;78(1):61-8

Dissolution of type I collagen fibrils by gingival fibroblasts isolated from patients of various periodontitis categories. Havemose-Poulsen A, et al. **J Periodontal Res** 1998 Jul; 33(5):280-91

Prostaglandin E2 and I2 regulate intercellular adhesion molecule-1 expression in interleukin-1 beta-stimulated human gingival fibroblasts [published erratum appears in J Periodontal Res 1999 May;34(4):232] Iwasaki K, et al.
J Periodontal Res 1999 Feb;34(2):97-104

The influence of prostaglandins on steroid conversions by human gingival fibroblasts. Soory M, et al.
J Periodontal Res 1998 Nov;33(8):439-47

The influence of interleukin gene polymorphism on expression of interleukin-1beta and tumor necrosis factor-alpha in periodontal tissue and gingival crevicular fluid. Engebretson SP, et al. **J Periodontol** 1999 Jun; 70(6):567-73

Androgens modulate interleukin-6 production by gingival fibroblasts in vitro. Gornstein RA, et al. **J Periodontol** 1999 Jun;70(6):604-9

Vascular endothelial growth factors and progression of periodontal diseases. Johnson RB, et al. **J Periodontol** 1999 Aug;70(8):848-52

Interleukin (IL)-1 and Porphyromonas gingivalis lipopolysaccharide stimulation of IL-6 production by fibroblasts derived from healthy or periodontally diseased human gingival tissue. Kent LW, et al. **J Periodontol** 1999 Mar;70(3):274-82

Involvement of prostaglandins in histamine H1 receptor-operated Ca2+ entry in human gingival fibroblasts. Ogata Y, et al. **Life Sci** 1999;64(4):PL71-7

Morphometric analysis of human gingival elastic fibres degradation by human leukocyte elastase protective effect of avocado and soybean unsaponifiables (ASU). Kut C, et al. **Pathol Biol (Paris)** 1998 Sep;46(7):571-6

Possible role of monkey gingival fibroblasts in external basement membrane maintenance. Onizawa T, et al.
Tissue Cell 1998 Oct;30(5):502-9

MICROBIOLOGY

Contact-dependent protein secretion in Porphyromonas gingivalis. Park Y, et al. **Infect Immun** 1998 Oct; 66(10):4777-82

Subgingival microflora and treatment in prepubertal periodontitis associated with chronic idiopathic neutropenia. Kamma JJ, et al. **J Clin Periodontol** 1998 Sep; 25(9):759-65

Subgingival microbial profile of Papillon-Lefèvre patients assessed by DNA-probes. Lundgren T, et al.
J Clin Periodontol 1998 Aug;25(8):624-9

Semi-automated measurement of motility of human subgingival microflora by image analysis. Ojima M, et al.
J Clin Periodontol 1998 Aug;25(8):612-6

A murine model of accelerated periodontal disease in diabetes. Lalla E, et al. **J Periodontal Res** 1998 Oct; 33(7):387-99

Effect of cysteine protease of Porphyromonas gingivalis on adhesion molecules in gingival epithelial cells. Wang PL, et al. **Jpn J Pharmacol** 1999 May;80(1):75-9

Microbiotica associated with refractory periodontis. Prevalence and antibiotic susceptibility. Barone A, et al.
Minerva Stomatol 1999 May;48(5):191-201 **(Eng, Ita)**

Associations amongst three feline Porphyromonas species from the gingival margin of cats during periodontal health and disease. Norris JM, et al. **Vet Microbiol** 1999 Mar 12; 65(3):195-207

PATHOLOGY

Interleukin 1beta-secreting cells in inflamed gingival tissue of adult periodontitis patients. Lo YJ, et al. **Cytokine** 1999 Aug;11(8):626-33

Castration prevents calcium channel blocker-induced gingival hyperplasia in beagle dogs. Dayan D, et al.
Hum Exp Toxicol 1998 Jul;17(7):396-402

The gingival plasma cell infiltrate in HIV-positive patients with periodontitis is disorganized. Myint M, et al.
J Clin Periodontol 1999 Jun;26(6):358-65

Extensive expression of TGF-beta1 in chronically-inflamed periodontal tissue. Steinsvoll S, et al. **J Clin Periodontol** 1999 Jun;26(6):366-73

Failure of macrophage activation in destructive periodontal disease. Chapple CC, et al. **J Pathol** 1998 Nov;186(3):281-6

Distribution of macrophage lineage cells in rat gingival tissue after topical application of lipopolysaccharide: an immunohistochemical study using monoclonal antibodies: OX6, ED1 and ED2. Miyauchi M, et al.
J Periodontal Res 1998 Aug;33(6):345-51

A classification system for loss of papillary height. Nordland WP, et al. **J Periodontol** 1998 Oct;69(10):1124-6

Density of CD1a-labeled Langerhans' cells in normal human gingiva and in nifedipine- and immunosuppressive medication-induced gingival overgrowth. Nurmenniemi PK, et al. **J Periodontol** 1999 Jul;70(7):752-6

Tissue sculpturing: an alternative method for improving esthetics of anterior fixed prosthodontics. Jacques LB, et al. **J Prosthet Dent** 1999 May;81(5):630-3

Tacrolimus can resolve cyclosporin-induced gingival hyperplasia [letter] Harikrishnan P, et al.
Nephrol Dial Transplant 1999 Jul;14(7):1805-6

PHYSIOLOGY

Gingival response to orthodontic force. Redlich M, et al.
Am J Orthod Dentofacial Orthop 1999 Aug;116(2):152-8 (54 ref.)

Tissue management needs for adhesive dentistry now and in the future. Fischer DE. **Dent Clin North Am** 1998 Oct; 42(4):595-606, vii

Long-term stability of the mucogingival complex following guided tissue regeneration in gingival recession defects. Scabbia A, et al. **J Clin Periodontol** 1998 Dec;25(12):1041-6

TGF-beta1 influences early gingival wound healing in rats: an immunohistochemical evaluation of stromal remodelling by extracellular matrix molecules and PCNA. Okuda K, et al. **J Oral Pathol Med** 1998 Nov;27(10):463-9

Fluid dynamics of gingival tissues. Del Fabbro M, et al.
J Periodontal Res 1998 Aug;33(6):328-34

SURGERY

The effect of cleaning on blood contamination in the dental surgery following periodontal procedures. Edmunds LM, et al. **Aust Dent J** 1998 Oct;43(5):349-53

Root coverage with a connective tissue with partial thickness double pedicle graft and an acellular dermal matrix graft: a clinical and histological evaluation of a case report. Harris RJ. **J Periodontol** 1998 Nov;69(11):1305-11

TRANSPLANTATION

Comparative clinical study of a bioabsorbable membrane and subepithelial connective tissue graft in the treatment of human gingival recession. Borghetti A, et al.
J Periodontol 1999 Feb;70(2):123-30

Retained free gingival graft rugae: a 9-year case report. Breault LG, et al. **J Periodontol** 1999 Apr;70(4):438-40

A comparison of 2 root coverage techniques: guided tissue regeneration with a bioabsorbable matrix style membrane versus a connective tissue graft combined with a coronally positioned pedicle graft without vertical incisions. results of a series of consecutive cases. Harris RJ.
J Periodontol 1998 Dec;69(12):1426-34

Human histologic evaluation of root coverage obtained with a connective tissue with partial thickness double pedicle graft. A case report. Harris RJ. **J Periodontol** 1999 Jul; 70(7):813-21

Subpedicle connective tissue graft versus guided tissue regeneration with bioabsorbable membrane in the treatment of human gingival recession defects. Trombelli L, et al.
J Periodontol 1998 Nov;69(11):1271-7

The use of a stent-resin-bonded splint combination to stabilize a free gingival autograft. Arikan A, et al.
J Prosthet Dent 1999 Feb;81(2):215-7

ULTRASONOGRAPHY

Ultrasonic determination of thickness of masticatory mucosa: a methodologic study. Müller HP, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Aug;88(2):248-53

ULTRASTRUCTURE

The structure of the interstitial surfaces of the epithelial basement membranes of mouse oral mucosa, gingiva and tongue. Abe M, et al. **Arch Oral Biol** 1999 Jul;44(7):587-94

Ultrastructural identification of Weibel-Palade bodies in human gingival blood vessels. Giarratana M, et al.
Bull Group Int Rech Sci Stomatol Odontol 1998 Apr-Sep; 40(2-3):76-9

GINGIVAL BLEEDING ON PROBING see **PERIODONTAL INDEX**

GINGIVAL CREVICULAR FLUID

Calibration of the Periotron 8000 and 6000 by polynomial regression. Chapple IL, et al. **J Periodontal Res** 1999 Feb; 34(2):79-86

CHEMISTRY

Interleukin-1beta and beta-glucuronidase in gingival crevicular fluid from molars during rapid palatal expansion. Tzannetou S, et al. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):686-96

Interleukin 1 beta, interleukin 6, beta 2-microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human periodontal disease. Mogi M, et al.
Arch Oral Biol 1999 Jun;44(6):535-9

Detection of prostaglandin E2 and matrix metalloproteinases in implant crevicular fluid. Aboyoussef H, et al.
Int J Oral Maxillofac Implants 1998 Sep-Oct;13(5):689-96

Presence of cortisol in gingival crevicular fluid. A pilot study. Axtelius B, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):929-32

Crevicular fluid prostaglandin E2 levels in periodontitis-resistant and periodontitis-susceptible adults. Heasman PA, et al. **J Clin Periodontol** 1998 Dec; 25(12):1003-7

Gingival crevicular fluid osteocalcin in adult periodontitis. Lee AJ, et al. **J Clin Periodontol** 1999 Apr;26(4):252-6

Calcitonin gene-related peptide in gingival crevicular fluid in periodontal health and disease. Lundy FT, et al.
J Clin Periodontol 1999 Apr;26(4):212-6

High levels of soluble intercellular adhesion molecule-1 (ICAM-1) in crevicular fluid of periodontitis patients with plaque. Molé N, et al. **J Clin Periodontol** 1998 Sep; 25(9):754-8

Phylloquinone in gingival crevicular fluid in adult periodontitis. Rawlinson A, et al. **J Clin Periodontol** 1998 Aug;25(8):662-5

Gingival fluid IL-1beta in postmenopausal females on supportive periodontal therapy. A longitudinal 2-year study. Reinhardt RA, et al. **J Clin Periodontol** 1998 Dec; 25(12):1029-35

Vascular endothelial growth factor in human periodontal disease. Booth V, et al. **J Periodontal Res** 1998 Nov; 33(8):491-9

Periotron 8000: calibration characteristics and reliability. Ciantar M, et al. **J Periodontal Res** 1998 Jul;33(5):259-64

Calprotectin, a leukocyte protein related to inflammation, in gingival crevicular fluid. Kido J, et al.
J Periodontal Res 1998 Oct;33(7):434-7

Calprotectin and lactoferrin levels in the gingival crevicular fluid of children. Miyasaki KT, et al. **J Periodontol** 1998 Aug;69(8):879-83

The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum [published erratum appears in J Periodontol 1999 Feb;70(2):238] Stoller NH, et al. **J Periodontol** 1998 Oct;69(10):1085-91

DRUG EFFECTS

The effect of ammonium glycopyrrolate (Robinul)-induced xerostomia on oral mucosal wetness and flow of gingival crevicular fluid in humans. Wolff MS, et al.
Arch Oral Biol 1999 Feb;44(2):97-102

ENZYMOLOGY

Longitudinal evaluation of aspartate aminotransferase in the crevicular fluid of implants with bone loss and signs of progressive disease. Rühling A, et al.
Int J Oral Maxillofac Implants 1999 May-Jun;14(3):428-35

Crevicular fluid level of beta-glucuronidase in relation to clinical periodontal parameters and putative periodontal pathogens in early-onset periodontitis. Albandar JM, et al.
J Clin Periodontol 1998 Aug;25(8):630-9

Long-term monitoring of adult periodontitis patients in supportive periodontal therapy: correlation of gingival crevicular fluid proteases with probing attachment loss. Bader HI, et al. **J Clin Periodontol** 1999 Feb;26(2):99-105

Prediction and diagnosis of attachment loss by enhanced chemiluminescent assay of crevicular fluid alkaline phosphatase levels. Chapple IL, et al.
J Clin Periodontol 1999 Mar;26(3):190-8

Microbiological features and crevicular fluid aspartate aminotransferase enzyme activity in early onset periodontitis patients. Kuru B, et al. **J Clin Periodontol** 1999 Jan;26(1):19-25

Relationship between levels of aspartate aminotransferase in gingival crevicular fluid and conventional measures of periodontal status assessed using PocketWatch: a cross-sectional study. Shimada K, et al. **J Oral Sci** 1999 Mar;41(1):35-40

Analysis of gingival crevicular fluid intracytoplasmic enzyme activity in patients with adult periodontitis and rapidly progressive periodontitis. A longitudinal study model with

periodontal treatment. Atici K, et al. **J Periodontol** 1998 Oct;69(10):1155–63

Relationship of the subgingival microbiota to a chairside test for aspartate aminotransferase in gingival crevicular fluid. Wong MY, et al. **J Periodontol** 1999 Jan;70(1):57–62

IMMUNOLOGY

Smoking and cervicular fluid levels of IL-6 and TNF-alpha in periodontal disease. Boström L, et al. **J Clin Periodontol** 1999 Jun;26(6):352–7

Increase of crevicular interleukin 1beta under academic stress at experimental gingivitis sites and at sites of perfect oral hygiene. Deinzer R, et al. **J Clin Periodontol** 1999 Jan; 26(1):1–8

The correlation of gingival crevicular fluid interleukin-8 levels and periodontal status in localized juvenile periodontitis. Ozmeriç N, et al. **J Periodontol** 1998 Nov; 69(11):1299–304

METABOLISM

Effect of an antibacterial dental varnish on the levels of prostanoids, leukotriene B4, and interleukin-1 beta in gingival crevicular fluid. Yucel-Lindberg T, et al. **Acta Odontol Scand** 1999 Feb;57(1):23–7

Immunochemical detection of the proteoglycans decorin and biglycan in human gingival crevicular fluid from sites of advanced periodontitis. Waddington RJ, et al. **Arch Oral Biol** 1998 Apr;43(4):287–95

The influence of interleukin gene polymorphism on expression of interleukin-1beta and tumor necrosis factor-alpha in periodontal tissue and gingival crevicular fluid. Engebretson SP, et al. **J Periodontol** 1999 Jun; 70(6):567–73

[Relationship between the activity of leukocyte chemokines in gingival crevicular fluid and periodontitis] Zou S, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Dec;19(6):442–6 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Gingival crevicular pH in experimental gingivitis and occlusal trauma in man. Kobayashi K, et al. **J Periodontol** 1998 Sep;69(9):1036–43

GINGIVAL CURETTAGE see **SUBGINGIVAL CURETTAGE**

GINGIVAL DISEASES

Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity. Scully C, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):56–68 (122 ref.)

CLASSIFICATION

A classification system for loss of papillary height. Nordland WP, et al. **J Periodontol** 1998 Oct;69(10):1124–6

DIAGNOSIS

Nephroquiz for the Beginner. Look at the face and you have the diagnosis. This patient suffered from epulis [published erratum appears in Nephrol Dial Transplant 1998 Oct;13(10):2716] Hardt S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1879–81

Linear IgA disease histopathologically and clinically masquerading as lichen planus. Cohen DM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):196–201

DRUG THERAPY

[In situ penicillin therapy in the treatment of epulis] el Wady W, et al. **Med Trop (Mars)** 1998;58(2):149–54 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Periodontal status and oral hygiene practices of pregnant and non-pregnant women. Nuamah I, et al. **East Afr Med J** 1998 Dec;75(12):712–4

Spontaneous early exposure of submerged implants: I. Classification and clinical observations. Tal H. **J Periodontol** 1999 Feb;70(2):213–9

PATHOLOGY

Inflammatory pseudotumor in the mandibular retromolar region. Ide F, et al. **J Oral Pathol Med** 1998 Nov; 27(10):508–10

Pericoronal hamartomatous lesions in the opercula of teeth delayed in eruption: an immunohistochemical study of the extracellular matrix. Yonemochi H, et al. **J Oral Pathol Med** 1998 Oct;27(9):441–52

Gingival salivary gland choristoma. A case report. Ledesma-Montes C, et al. **J Periodontol** 1998 Oct; 69(10):1164–6 (12 ref.)

RADIOTHERAPY

A clinical study on the removal of gingival melanin pigmentation with the CO(2) laser. Nakamura Y, et al. **Lasers Surg Med** 1999;25(2):140–7

SURGERY

Cryosurgical treatment of melanin-pigmented gingiva. Yeh CJ. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):660–3

VETERINARY

Histoplasmosis in the skin and gingiva in a dog. Kagawa Y, et al. **J Vet Med Sci** 1998 Jul;60(7):863–5

Proliferative potential of canine oral epulides and malignant neoplasms assessed by bromodeoxyuridine labeling. Yoshida K, et al. **Vet Pathol** 1999 Jan;36(1):35–41

Fibrous epulides in a horse [letter] King M, et al. **Vet Rec** 1999 Jul 10;145(2):56

GINGIVAL EXUDATE see **GINGIVAL CREVICULAR FLUID**

GINGIVAL FIBROMATOSIS see **FIBROMATOSIS, GINGIVAL**

GINGIVAL FISTULA see **DENTAL FISTULA**

GINGIVAL HEMORRHAGE

CHEMICALLY INDUCED

Is inhibition of nitric oxide synthase a mechanism for SSRI-induced bleeding? [letter] Shen WW, et al. **Psychosomatics** 1999 May-Jun;40(3):268–9

DIAGNOSIS

Evaluation of 2 methods to assess gingival bleeding in smokers and non-smokers in natural and experimental gingivitis. Lie MA, et al. **J Clin Periodontol** 1998 Sep; 25(9):695–700

DRUG THERAPY

A controlled multicenter study of adjunctive use of tetracycline periodontal fibers in mandibular class II furcations with persistent bleeding. Tonetti MS, et al. **J Clin Periodontol** 1998 Sep;25(9):728–36

EPIDEMIOLOGY

Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988–1994. Albandar JM, et al. **J Periodontol** 1999 Jan; 70(1):30–43

GINGIVAL HYPERPLASIA

CHEMICALLY INDUCED

Telangiectasis and gingival hyperplasia as side-effects of amlodipine (Norvasc) in a 3-year-old girl [letter] van der Vleuten CJ, et al. **Acta Derm Venereol** 1999 Jul;79(4):323–4

Analysis of peripheral blood leukocytes in patients with cyclosporine A-induced gingival hyperplasia. Cebeci I, et al. **J Periodontol** 1998 Dec;69(12):1435–9

Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. Ellis JS, et al. **J Periodontol** 1999 Jan;70(1):63–7

Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. Kantarci A, et al. **J Periodontol** 1999 Jun;70(6):587–93

Expression of p53 protein and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin. Saito K, et al. **J Periodontol** 1999 Jun;70(6):581–6

Medically induced gingival hyperplasia [letter; comment] Härkönen M. **Mayo Clin Proc** 1999 Jul;74(7):742–3. Comment on: Mayo Clin Proc 1998 Dec;73(12):1196–9.

Medically induced gingival hyperplasia [see comments] Meraw SJ, et al. **Mayo Clin Proc** 1998 Dec;73(12):1196–9 (42 ref.). Comment in: Mayo Clin Proc 1999 Jul;74(7):742–3.

Tacrolimus and gingival hyperplasia [letter] Basile C, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2980–1

Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman [letter; comment] Wirnsberger GH, et al. **Transplantation** 1999 May 15;67(9):1289–91. Comment on: Transplantation 1998 Jun 27;65(12):1611–5.

[Drug-induced gingival hyperplasia] Nohl F, et al. **Ther Umsch** 1998 Sep;55(9):573–5 (Eng. Abstr.) **(Ger)**

[Gingival hyperplasia during treatment with nifedipine] Bokor-Bratić M, et al. **Med Pregl** 1998 Sep-Oct; 51(9-10):445–8 (Eng. Abstr.) **(Ser)**

COMPLICATIONS

Expression of p53 protein and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin. Saito K, et al. **J Periodontol** 1999 Jun;70(6):581–6

DRUG THERAPY

Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman [letter; comment] Wirnsberger GH, et al. **Transplantation** 1999 May 15;67(9):1289–91. Comment on: Transplantation 1998 Jun 27;65(12):1611–5.

EPIDEMIOLOGY

Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. Ellis JS, et al. **J Periodontol** 1999 Jan;70(1):63–7

ETIOLOGY

Partial regression of advanced cyclosporin-induced gingival hyperplasia after treatment with azithromycin. A case report. Nowicki M, et al. **Ann Transplant** 1998;3(3):25–7

Chronic bacterial inflammation of the gum: the main risk factor for posttransplant gingival hyperplasia? [letter] Wirnsberger GH, et al. **Clin Nephrol** 1999 Jan;51(1):63–4

MICROBIOLOGY

Re: Periodontal management of gingival overgrowth in the heart transplant patient: a case report (1997;68:1140–1146) [letter; comment] Payne VM. **J Periodontol** 1998 Nov; 69(11):1314–5. Comment on: J Periodontol 1997 Nov;68(11):1140–6.

PATHOLOGY

Destructive membranous periodontal disease (Ligneous periodontitis). Günhan O, et al. **J Periodontol** 1999 Aug; 70(8):919–25 (15 ref.)

THERAPY

Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. Kantarci A, et al. **J Periodontol** 1999 Jun;70(6):587–93

GINGIVAL HYPERTROPHY

ETIOLOGY

[Vulvar and gingival ulcers and skull tumors] Morand JJ, et al. **Rev Med Interne** 1998 Dec;19(12):931–4 **(Fre)**

GINGIVAL INDEX see **PERIODONTAL INDEX**

GINGIVAL NEOPLASMS

COMPLICATIONS

Peripheral ossifying fibroma associated with a neonatal tooth: case report. Kohli K, et al. **Pediatr Dent** 1998 Nov-Dec; 20(7):428–9

CONGENITAL

Congenital granular-cell tumor of the gingiva. Tokar B, et al. **Pediatr Surg Int** 1998 Oct;13(8):594–6

DIAGNOSIS

Primary malignant melanoma of the oral cavity. Report of an unusual case. Dimitrakopoulos I, et al. **Aust Dent J** 1998 Dec;43(6):379–81

[Case for diagnosis. Blue nevus] Lombardi T, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):277–8 **(Fre)**

[Chronic cough in AIDS] Bassetti S. **Schweiz Rundsch Med Prax** 1998 Sep 23;87(39):1265–7 **(Ger)**

DRUG THERAPY

Topical application of vitamin A to oral leukoplakia: A clinical case series. Epstein JB, et al. **Cancer** 1999 Sep 15; 86(6):921–7

ENZYMOLOGY

Inhibition of Na+,K+-ATPase by cisplatin and its recovery by 2-mercaptoethanol in human squamous cell carcinoma cells. Sakakibara N, et al. **Anticancer Drugs** 1999 Feb; 10(2):203–11

METABOLISM

Inhibition of the synthesis of eicosanoid-like substances in a human oral cancer cell line by interferon-gamma and eicosapentaenoic acid. Meng CL, et al. **Arch Oral Biol** 1998 Dec;43(12):979–86

PATHOLOGY

Lateral retropharyngeal node metastasis from carcinoma of the upper gingiva and maxillary sinus. Kimura Y, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1221–4

Hobnail hemangioma: a pseudomalignant vascular lesion with a reappraisal of targetoid hemosiderotic hemangioma. Guillou L, et al. **Am J Surg Pathol** 1999 Jan;23(1):97–105

Endodermal sinus (yolk sac) tumor of oral cavity originating from gingiva. Kutluhan A, et al. **Auris Nasus Larynx** 1998 Dec;25(4):459–62

Tumour thickness and relationship to locoregional failure in cancer of the buccal mucosa. Mishra RC, et al. **Eur J Surg Oncol** 1999 Apr;25(2):186–9

The enhancing effect of excess retinol palmitate on induction of odontogenic tumors and inhibitory effect on squamous cell carcinoma of the gingiva in hamsters treated with N-methylnitrosourea. Kohgo T, et al.

GINGIVAL NEOPLASMS

Histol Histopathol 1999 Jan;14(1):157–63

Clarification of diagnostic criteria for ameloblastic fibroma [letter; comment] Shimoyama T, et al.
J Oral Maxillofac Surg 1999 Feb;57(2):219. Comment on: J Oral Maxillofac Surg 1998 Mar;56(3):399–401.

Gastric and gingival localization of mucosa-associated lymphoid tissue (MALT) lymphoma. An immunohistochemical, virological and clinical case report. Margiotta V, et al. **J Periodontol** 1999 Aug;70(8):914–8

Myoepithelioma of the gingiva. Report of a case. Piattelli A, et al. **J Periodontol** 1999 Jun;70(6):683–7

Polypoid mass of the gingiva [clinical conference] Izumi K, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Aug;88(2):117–21

Pleural metastasis of a squamous cell carcinoma of the gingiva [letter] Ishikawa H, et al. **Respiration** 1999;66(2):195

[Granular cell tumor and congenital epulis. Histochemical and immunohistochemical of 58 cases] Billeret-Lebranchu V, et al. **Arch Anat Cytol Pathol** 1999;47(1):31–7 (Eng. Abstr.) **(Fre)**

[Epithelioma cuniculatum. Apropos of a case in the anterior gingiva with involvement of the mandibular symphyseal bone and reconstruction using a fibular osteocutaneous flap and integrated implants] Huault M, et al.
Rev Stomatol Chir Maxillofac 1998 Oct;99(3):143–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Leiomyosarcoma of the gingiva. Apropos of a case. Review of the literature] Moussaoui O, et al.
Rev Stomatol Chir Maxillofac 1998 Oct;99(3):132–7 (29 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Metastatic osteosarcoma to the mandibular gingiva: a case report. Suzuki K, et al. **J Oral Maxillofac Surg** 1999 Jul; 57(7):864–8

Gingival metastasis from a prostate adenocarcinoma: report of a case. Piattelli A, et al. **J Periodontol** 1999 Apr; 70(4):441–4

SURGERY

Congenital granular-cell tumor of the gingiva. Tokar B, et al. **Pediatr Surg Int** 1998 Oct;13(8):594–6

VETERINARY

The effect of intralesional bleomycin on canine acanthomatous epulis. Yoshida K, et al.
J Am Anim Hosp Assoc 1998 Nov-Dec;34(6):457–61

Oral malignant melanoma with osteoid formation in a dog. Chénier S, et al. **Vet Pathol** 1999 Jan;36(1):74–6

Proliferative potential of canine oral epulides and malignant neoplasms assessed by bromodeoxyuridine labeling. Yoshida K, et al. **Vet Pathol** 1999 Jan;36(1):35–41

GINGIVAL OVERGROWTH

CHEMICALLY INDUCED

Role of medullasin in nifedipine-induced gingival overgrowth in rats. Ozaki Y, et al. **Arch Oral Biol** 1998 Oct;43(10):801–10

Cyclosporin A-induced gingival overgrowth in the rat: a histological, ultrastructural and histomorphometric evaluation. Ayanoglou CM, et al. **J Periodontal Res** 1999 Jan;34(1):7–15

Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth. Kamali F, et al.
J Periodontal Res 1999 Apr;34(3):145–53

Signal recognition particle receptor (SRPR) is downregulated in a rat model of cyclosporin A-induced gingival overgrowth. Marley JJ, et al.
J Periodontal Res 1999 May;34(4):188–96

Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. Sugano N, et al. **J Periodontal Res** 1998 Nov;33(8):448–52

Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. Myrillas TT, et al. **J Periodontol** 1999 Mar;70(3):294–300

[An increase in gingival volume induced by drugs (phenytoin, cyclosporine and calcium antagonists). A review of the literature] Garzino-Demo P, et al. **Minerva Stomatol** 1998 Sep;47(9):387–98 (115 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Role of medullasin in nifedipine-induced gingival overgrowth in rats. Ozaki Y, et al. **Arch Oral Biol** 1998 Oct;43(10):801–10

PATHOLOGY

Density of CD1a-labeled Langerhans' cells in normal human gingiva and in nifedipine- and immunosuppressive medication-induced gingival overgrowth. Nurmenniemi PK, et al. **J Periodontol** 1999 Jul;70(7):752–6

SURGERY

Gingival lesions in a patient with dermochondrocorneal dystrophy (François syndrome). A case report. Sardella A, et al. **J Clin Periodontol** 1998 Dec;25(12):1047–9 (9 ref.)

GINGIVAL POCKET

see related
PERIODONTAL POCKET

GINGIVAL RECESSION

EPIDEMIOLOGY

Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988–1994. Albandar JM, et al. **J Periodontol** 1999 Jan; 70(1):30–43

ETIOLOGY

Occlusal disharmony [letter; comment] Schlott WJ.
J Am Dent Assoc 1998 Oct;129(10):1372. Comment on: J Am Dent Assoc 1998 Jun;129(6):765–6.

Gingival recession and toothbrushing in an Italian School of Dentistry: a pilot study. Checchi L, et al.
J Clin Periodontol 1999 May;26(5):276–80

SURGERY

Long-term stability of the mucogingival complex following guided tissue regeneration in gingival recession defects. Scabbia A, et al. **J Clin Periodontol** 1998 Dec;25(12):1041–6

Comparative clinical study of a bioabsorbable membrane and subepithelial connective tissue graft in the treatment of human gingival recession. Borghetti A, et al.
J Periodontol 1999 Feb;70(2):123–30

Human histologic evaluation of root coverage obtained with a connective tissue with partial thickness double pedicle graft. A case report. Harris RJ. **J Periodontol** 1999 Jul; 70(7):813–21

Root coverage with a connective tissue with partial thickness double pedicle graft and an acellular dermal matrix graft: a clinical and histological evaluation of a case report. Harris RJ. **J Periodontol** 1998 Nov;69(11):1305–11

A comparison of 2 root coverage techniques: guided tissue regeneration with a bioabsorbable matrix style membrane versus a connective tissue graft combined with a coronally positioned pedicle graft without vertical incisions. results of a series of consecutive cases. Harris RJ.
J Periodontol 1998 Dec;69(12):1426–34

Root coverage employing an envelope technique or guided tissue regeneration with a bioabsorbable membrane. Müller HP, et al. **J Periodontol** 1999 Jul;70(7):743–51

CREST syndrome and periodontal surgery: a case report. Stanford TW Jr, et al. **J Periodontol** 1999 May;70(5):536–41

Adverse effects associated with a bioabsorbable guided tissue regeneration device in the treatment of human gingival recession defects. A clinicopathologic case report. Tatakis DN, et al. **J Periodontol** 1999 May;70(5):542–7

Subpedicle connective tissue graft versus guided tissue regeneration with bioabsorbable membrane in the treatment of human gingival recession defects. Trombelli L, et al.
J Periodontol 1998 Nov;69(11):1271–7

A 2-year clinical evaluation of a diphenylphosphorylazide-cross-linked collagen membrane for the treatment of buccal gingival recession. Zahedi S, et al. **J Periodontol** 1998 Sep;69(9):975–81

THERAPY

Improvement of multiple facial gingival recession by non-surgical and supportive periodontal therapy: a case report. Ando K, et al. **J Periodontol** 1999 Aug;70(8):909–13

GINGIVECTOMY

An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery. A double-blind, split-mouth, cross-over study. Thomason JM, et al. **J Clin Periodontol** 1999 Sep;26(9):577–82

GINGIVITIS

CHEMICALLY INDUCED

Desquamative gingivitis, sole manifestation of tosylamide/formaldehyde resin allergy. Staines KS, et al.
Contact Dermatitis 1998 Aug;39(2):90

COMPLICATIONS

Evaluation of 2 methods to assess gingival bleeding in smokers and non-smokers in natural and experimental gingivitis. Lie MA, et al. **J Clin Periodontol** 1998 Sep; 25(9):695–700

Bell's palsy associated with herpes simplex gingivostomatitis. A case report. Nasatzky E, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998 Sep;86(3):293–6

The natural history of primary herpes simplex type 1 gingivostomatitis in children. Amir J, et al.
Pediatr Dermatol 1999 Jul-Aug;16(4):259–63

DIAGNOSIS

Clinical and microbiological findings in elderly subjects with gingivitis or periodontitis. Schlegel-Bregenzer B, et al.
J Clin Periodontol 1998 Nov;25(11 Pt 1):897–907

Gingival lesions diagnosed as pemphigus vulgaris in an adolescent. Case report. Navarro CM, et al.
J Periodontol 1999 Jul;70(7):808–12

DRUG THERAPY

Effect of an antibacterial dental varnish on the levels of prostanoids, leukotriene B4, and interleukin-1 beta in gingival crevicular fluid. Yucel-Lindberg T, et al.
Acta Odontol Scand 1999 Feb;57(1):23–7

Antibacterial agents in the control of supragingival plaque--a review. Eley BM. **Br Dent J** 1999 Mar 27;186(6):286–96 (128 ref.)

New medicinal treatment for severe gingivostomatitis. Katayama S, et al. **Int J Mol Med** 1998 Dec;2(6):675–9

Physicochemical characterization and preliminary in vivo efficacy of bioadhesive, semisolid formulations containing flurbiprofen for the treatment of gingivitis. Jones DS, et al. **J Pharm Sci** 1999 Jun;88(6):592–8

[Laboratory and clinical investigation of multifunctional dentifrices. Clinical study of a new triclosan-containing toothpaste] Dóri F, et al. **Fogorv Sz** 1999 Mar;92(3):67–78 (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Some periodontological parameters in patients with oesophagogastric passage insufficiency. Katunarić M, et al.
Coll Antropol 1998 Dec;22 Suppl:199–203

Oral hygiene and gingivitis in a Swedish adult population 1973, 1983 and 1993. Hugoson A, et al.
J Clin Periodontol 1998 Oct;25(10):807–12

Gingival recession, gingival bleeding, and dental calculus in adults 30 years of age and older in the United States, 1988–1994. Albandar JM, et al. **J Periodontol** 1999 Jan; 70(1):30–43

The relationship of dental calculus to caries, gingivitis, and selected salivary factors in 11- to 13-year-old children in Chiang Mai, Thailand. Pattanaporn K, et al.
J Periodontol 1998 Sep;69(9):955–61

[Dental care for the handicapped: general problems] Martens LC. **Rev Belge Med Dent** 1997;52(2):9–26 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Gingivitis artefacta--a case report of a patient undergoing orthodontic treatment. Spencer RJ, et al. **Br J Orthod** 1999 Jun;26(2):93–6

Cigarette smoking and oral lesions other than cancer. Meraw SJ, et al. **Clin Dermatol** 1998 Sep-Oct;16(5):625–31 (52 ref.)

Desquamative gingivitis and balanitis--linear IgA disease or cicatricial pemphigoid? Kirtschig G, et al.
Clin Exp Dermatol 1998 Jul;23(4):173–7

The relationship between oral malodor, gingivitis, and periodontitis. A review. Ratcliff PA, et al.
J Periodontol 1999 May;70(5):485–9 (32 ref.)

GENETICS

Cytokine mRNA expression in lesions in cats with chronic gingivostomatitis. Harley R, et al.
Clin Diagn Lab Immunol 1999 Jul;6(4):471–8

Longitudinal changes in TCRB variable gene expression and markers of gingival inflammation in experimental gingivitis. Preshaw PM, et al. **J Clin Periodontol** 1998 Oct; 25(10):774–80

IMMUNOLOGY

T-cell interactions with extracellular matrix proteins in periodontal disease. Słotwińska SM, et al. **Immunol Lett** 1998 Oct;63(3):131–4

In situ detection of apoptosis at sites of chronic bacterially induced inflammation in human gingiva. Tonetti MS, et al. **Infect Immun** 1998 Nov;66(11):5190–5

Presence of activated B-1 cells in chronic inflamed gingival tissue. Aramaki M, et al. **J Clin Immunol** 1998 Nov; 18(6):421–9

Increase of crevicular interleukin 1beta under academic stress at experimental gingivitis sites and at sites of perfect oral hygiene. Deinzer R, et al. **J Clin Periodontol** 1999 Jan; 26(1):1–8

Differences in the inflammatory response in young and old human subjects during the course of experimental gingivitis. Fransson C, et al. **J Clin Periodontol** 1999 Jul; 26(7):453–60

Longitudinal changes in TCRB variable gene expression and markers of gingival inflammation in experimental gingivitis. Preshaw PM, et al. **J Clin Periodontol** 1998 Oct; 25(10):774–80

Topical distribution of Fc gammaRI, Fc gammaRII and Fc gammaRIII in inflamed human gingiva. Yuan ZN, et al.
J Clin Periodontol 1999 Jul;26(7):441–7

The relationship between concentrations of proinflammatory cytokines within gingiva and the adjacent sulcular depth. McGee JM, et al. **J Periodontol** 1998 Aug;69(8):865–71

METABOLISM

Localization of the interleukin-1 beta (Il-1 beta) by immunohistochemistry in healthy and inflamed human gingiva. Bons-Sicard C, et al.
Bull Group Int Rech Sci Stomatol Odontol 1998 Apr-Sep; 40(2-3):83–91

Calcitonin gene-related peptide in gingival crevicular fluid

in periodontal health and disease. Lundy FT, et al. **J Clin Periodontol** 1999 Apr;26(4):212–6

The influence of prostaglandins on steroid conversions by human gingival fibroblasts. Soory M, et al. **J Periodontal Res** 1998 Nov;33(8):439–47

Vascular endothelial growth factors and progression of periodontal diseases. Johnson RB, et al. **J Periodontol** 1999 Aug;70(8):848–52

Association of oxygen tension in human periodontal pockets with gingival inflammation. Tanaka M, et al. **J Periodontol** 1998 Oct;69(10):1127–30

Levels of human defensin-1, an antimicrobial peptide, in saliva of patients with oral inflammation. Mizukawa N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):539–43

MICROBIOLOGY

Oral microbiota in smokers and non-smokers in natural and experimentally-induced gingivitis. Lie MA, et al. **J Clin Periodontol** 1998 Aug;25(8):677–86

Paediatric AIDS--related linear gingival erythema: a form of erythematous candidiasis? Velegraki A, et al. **J Oral Pathol Med** 1999 Apr;28(4):178–82

Persistence of oral colonization by the same Actinobacillus actinomycetemcomitans strain(s). Saarela MH, et al. **J Periodontol** 1999 May;70(5):504–9

PATHOLOGY

Morphologic characteristics of initial lymphatics of the healthy and diseased human gingiva. Marchetti C, et al. **Anat Rec** 1999 Jun 1;255(2):175–9

In situ detection of apoptosis at sites of chronic bacterially induced inflammation in human gingiva. Tonetti MS, et al. **Infect Immun** 1998 Nov;66(11):5190–5

PHYSIOPATHOLOGY

Gingival crevicular pH in experimental gingivitis and occlusal trauma in man. Kobayashi K, et al. **J Periodontol** 1998 Sep;69(9):1036–43

Growth and development considerations in the diagnosis of gingivitis and periodontitis in children. Bimstein E, et al. **Pediatr Dent** 1999 May-Jun;21(3):186–91 (80 ref.)

PREVENTION & CONTROL

6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo. (I). Effect on plaque formation and gingivitis. Hase JC, et al. **J Clin Periodontol** 1998 Sep;25(9):746–53

The effect of xylitol and chlorhexidine acetate/xylitol chewing gums on plaque accumulation and gingival inflammation. Simons D, et al. **J Clin Periodontol** 1999 Jun; 26(6):388–91

A practice-based randomised controlled trial of the efficacy of an electric and a manual toothbrush on gingival health in patients with fixed orthodontic appliances. Clerehugh V, et al. **J Dent** 1998 Nov;26(8):633–9

A comparison of the efficacy of 2 powered toothbrushes in affecting plaque accumulation, gingivitis, and gingival bleeding. Barnes CM, et al. **J Periodontol** 1999 Aug; 70(8):840–7

SURGERY

Gingival lesions in a patient with dermochondrocorneal dystrophy (François syndrome). A case report. Sardella A, et al. **J Clin Periodontol** 1998 Dec;25(12):1047–9 (9 ref.)

[A 3-year experience with guided tissue regeneration procedures] Windisch P, et al. **Fogorv Sz** 1998 Oct; 91(10):295–304 (Eng. Abstr.) **(Hun)**

VIROLOGY

Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. Contreras A, et al. **J Periodontol** 1999 May;70(5):478–84

The natural history of primary herpes simplex type 1 gingivostomatitis in children. Amir J, et al. **Pediatr Dermatol** 1999 Jul-Aug;16(4):259–63

GINGIVITIS, NECROTIZING ULCERATIVE

[Necrotizing stomatitis] Michiwaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):369–71 (3 ref.) **(Jpn)**

BLOOD

Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. Lee LA, et al. **J Invest Dermatol** 1999 Aug;113(2):146–51

COMPLICATIONS

[Recurrent episodes of ulcerative gingivostomatitis associated with cyclic neutropenia] Sucker C, et al. **Hautarzt** 1999 Jul;50(7):503–6 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Is chronic ulcerative stomatitis an entity? Clinical and immunological findings in 18 cases. Chorzelski TP, et al. **Eur J Dermatol** 1998 Jun;8(4):261–5

IMMUNOLOGY

Necrotizing ulcerative periodontitis associated with severe congenital immunodeficiency in a prepubescent subject: clinical findings and response to intravenous immunoglobulin treatment. Batista EL Jr, et al. **J Clin Periodontol** 1999 Aug;26(8):499–504

Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. Lee LA, et al. **J Invest Dermatol** 1999 Aug;113(2):146–51

THERAPY

Necrotizing ulcerative periodontitis associated with severe congenital immunodeficiency in a prepubescent subject: clinical findings and response to intravenous immunoglobulin treatment. Batista EL Jr, et al. **J Clin Periodontol** 1999 Aug;26(8):499–504

VETERINARY

Necrotising stomatitis associated with Fusobacterium necrophorum in three sows. Ramos-Vara JA, et al. **Vet Rec** 1998 Sep 5;143(10):282–3

GINGIVOPLASTY

Cleft lip and palate treated by presurgical orthopedics, gingivoperiosteoplasty, and lip adhesion (POPLA) compared with previous lip adhesion method: a preliminary study of serial dental casts. Millard DR, et al. **Plast Reconstr Surg** 1999 May;103(6):1630–44

ADVERSE EFFECTS

Root coverage with a connective tissue with partial thickness double pedicle graft and an acellular dermal matrix graft: a clinical and histological evaluation of a case report. Harris RJ. **J Periodontol** 1998 Nov;69(11):1305–11

METHODS

Palatal sliding strip flap: soft tissue management to restore maxillary anterior esthetics at stage 2 surgery: a clinical report. Adriaenssens P, et al. **Int J Oral Maxillofac Implants** 1999 Jan-Feb;14(1):30–6

Retained free gingival graft rugae: a 9-year case report. Breault LG, et al. **J Periodontol** 1999 Apr;70(4):438–40

Root coverage with a connective tissue with partial thickness double pedicle graft and an acellular dermal matrix graft: a clinical and histological evaluation of a case report. Harris RJ. **J Periodontol** 1998 Nov;69(11):1305–11

GINGIVOSIS see **GINGIVAL DISEASES**

GINGIVOSTOMATITIS, HERPETIC see **STOMATITIS, HERPETIC**

GINKGO BILOBA

The protective effect of Ginkgo biloba extract on CCl4-induced hepatic damage. Ozenirler S, et al. **Acta Physiol Hung** 1997-98;85(3):277–85

Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation. Akiba S, et al. **Biochem Mol Biol Int** 1998 Dec;46(6):1243–8

Ginkgo biloba extract EGb761 reduces the development of amphetamine-induced behavioral sensitization: effects on hippocampal type II corticosteroid receptors. Trovero F, et al. **Brain Res** 1999 Feb 6;818(1):135–9

Antagonistic effects of extract from leaves of ginkgo biloba on glutamate neurotoxicity. Zhu L, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jul;18(4):344–7

Effects of EGb761 and superoxide dismutase in an experimental model of retinopathy generated by intravitreal production of superoxide anion radical. Baudouin C, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):58–66

Solid-phase extraction and gas chromatography-mass spectrometry determination of kaempferol and quercetin in human urine after consumption of Ginkgo biloba tablets. Watson DG, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19;723(1-2):203–10

Evidence that the ginkgo biloba extract, EGb 761, neither accelerates nor enhances the rapid compensation of the static symptoms of unilateral vestibular deafferentation in guinea pig. Schlatter M, et al. **J Vestib Res** 1999;9(2):111–8

Subarachnoid haemorrhage associated with Ginkgo biloba [letter] [see comments] Vale S. **Lancet** 1998 Jul 4; 352(9121):36. Comment in: Lancet 1998 Oct 3;352(9134):1145–6.

Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice. Pierre S, et al. **Neuroreport** 1999 Jan 18;10(1):47–51

Inhibition of rat adjuvant-induced arthritis by ginkgetin, a biflavone from ginkgo biloba leaves [letter] Kim HK, et al. **Planta Med** 1999 Jun;65(5):465–7

Ginkgo biloba and memory for a maze. Gajewski A, et al. **Psychol Rep** 1999 Apr;84(2):481–4

The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Itil TM, et al. **Psychopharmacol Bull** 1998; 34(3):391–7

[Effects of ginkgo leave concentrated oral liquor in treating asthma] Li MH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr; 17(4):216–8 (Eng. Abstr.) **(Chi)**

[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000] Clostre F. **Ann Pharm Fr** 1999 Jul;57 Suppl 1:1S8–88 (295 ref.) (Eng. Abstr.) **(Fre)**

[Study on the efficacy of ginkgo biloba extract, magnesium and levo-arginine in the treatment of patients with 2d stage arteriopathies. A preliminary study] Michelini S, et al. **Minerva Cardioangiol** 1998 Sep;46(9):319–20 **(Ita)**

[The efficacy of treating cerebral ischemia due to changes in the major cerebral arteries by using the preparation Tanakan (EGB 761)] Dziak LA, et al. **Lik Sprava** 1998 Aug;(6):125–7 (Eng. Abstr.) **(Rus)**

[Effects of tanakan on blood lipid peroxidation and platelet aggregation properties in patients with insulin-dependent diabetes mellitus] Balashova TS, et al. **Ter Arkh** 1998; 70(12):49–54 (Eng. Abstr.) **(Rus)**

[Neurasthenia as a variant of the asthenic syndrome: a pharmacotherapeutic analysis modelled on tanakan therapy] Krasnov VN, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(7):37–40 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Commonly used medicinal herbs [letter] Eliason BC. **Arch Fam Med** 1999 Sep-Oct;8(5):376

Botanical briefs. The Ginkgo tree--Ginkgo biloba L. McGovern TW, et al. **Cutis** 1999 Sep;64(3):154–6

Extracts of Ginkgo biloba and bleeding or haemorrhage [letter; comment] Skogh M. **Lancet** 1998 Oct 3; 352(9134):1145–6. Comment on: Lancet 1998 Jul 4;352(9121):36.

CHEMISTRY

Purification and some chemical properties of 30 kDa Ginkgo biloba glycoprotein, which reacts with antiserum against beta 1-->2 xylose-containing N-glycans. Kimura Y, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):463–7

Protective effects of Ginkgo biloba extract against lysophosphatidylcholine-induced vascular endothelial cell damage. Chen JX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):359–63

Hemorheology and walking of peripheral arterial occlusive diseases patients during treatment with Ginkgo biloba extract. Li AL, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep;19(5):417–21

Inhibition of serum deprivation- and staurosporine-induced neuronal apoptosis by Ginkgo biloba extract and some of its constituents. Ahlemeyer B, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):423–30

Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. Saponara R, et al. **J Nat Prod** 1998 Nov;61(11):1386–7

Effects of EGb 761 on fatty acid reincorporation during reperfusion following ischemia in the brain of the awake gerbil. Rabin O, et al. **Mol Chem Neuropathol** 1998 May; 34(1):79–101

The discriminative stimulus properties of EGb 761, an extract of Ginkgo biloba. Winter JC, et al. **Pharmacol Biochem Behav** 1999 Mar;62(3):543–7

Additional information to the in vitro antioxidant activity of Ginkgo biloba L. Lugasi A, et al. **Phytother Res** 1999 Mar;13(2):160–2

The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Rigney U, et al. **Phytother Res** 1999 Aug; 13(5):408–15

Bioavailability of ginkgolides and bilobalide from extracts of ginkgo biloba using GC/MS [letter] Biber A, et al. **Planta Med** 1999 Mar;65(2):192–3

PHYSIOLOGY

Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice. Wu WR, et al. **Life Sci** 1999;65(2):157–64

THERAPEUTIC USE

Effects on skeletal muscle fibres of diabetes and Ginkgo biloba extract treatment. Punkt K, et al. **Acta Histochem** 1999 Feb;101(1):53–69

Effects of ginkgo biloba extract on impairment of learning induced by cerebral ischemia in mice. Tadano T, et al. **Am J Chin Med** 1998;26(2):127–32

The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Oken BS, et al. **Arch Neurol** 1998 Nov; 55(11):1409–15 (94 ref.)

"Active hypoallergenicity" [letter; comment] Perrenoud D, et al. **Contact Dermatitis** 1998 Nov;39(5):274. Comment on: Contact Dermatitis 1998 Mar;38(3):123–6.

The effects of prostaglandin E2 indomethacin & Ginkgo biloba extract on resistance to experimental sepsis. Cantürk NZ, et al. **Indian J Med Res** 1998 Sep;108:88–92

Ginkgo biloba for dementia: a reasonable alternative? Wincor MZ. **J Am Pharm Assoc (Wash)** 1999 May-Jun;39(3):415–6

Effects of Ginkgo biloba extract on the cochlear damage induced by local gentamicin installation in guinea pigs. Jung

GINKGO BILOBA

HW, et al. **J Korean Med Sci** 1998 Oct;13(5):525–8

Ginkgo biloba extract increases ocular blood flow velocity. Chung HS, et al. **J Ocul Pharmacol Ther** 1999 Jun; 15(3):233–40

Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. Curtis-Prior P, et al. **J Pharm Pharmacol** 1999 May;51(5):535–41

Ginkgo biloba for antidepressant-induced sexual dysfunction? [letter; comment] Balon R. **J Sex Marital Ther** 1999 Jan-Mar;25(1):1–2. Comment on: J Sex Marital Ther 1998 Apr-Jun;24(2):139–43.

Caution recommended [letter; comment] Levine SB. **J Sex Marital Ther** 1999 Jan-Mar;25(1):2–5. Comment on: J Sex Marital Ther 1998 Apr-Jun;24(2):139–43.

The clinical applications of Ginkgo biloba, St. John's wort, saw palmetto, and soy. Glisson J, et al. **Nurse Pract** 1999 Jun;24(6):28, 31, 35–6 passim; quiz 47–9 (65 ref.)

The effects of free oxygen radical scavenger and platelet-activating factor antagonist agents in experimental acute pancreatitis. Soybir G, et al. **Pancreas** 1999 Aug; 19(2):143–9

[The results of using different forms of a Ginkgo biloba extract (EGb 761) in the combined treatment of patients with circulatory encephalopathy] Ivaniv OP. **Lik Sprava** 1998 Dec;(8):123–8 (Eng. Abstr.) **(Ukr)**

GINKGOPHYTA see **GINKGO BILOBA**

GINSENG

The effects of ginseng radix rubra on human vascular endothelial cells. Nakajima S, et al. **Am J Chin Med** 1998; 26(3–4):365–73

Inhibitory effects of ginseng total saponin on nicotine-induced hyperactivity, reverse tolerance and dopamine receptor supersensitivity. Kim HS, et al. **Behav Brain Res** 1999 Aug;103(1):55–61

In vitro antioxidant activity of Vietnamese ginseng saponin and its components. Huong NT, et al. **Biol Pharm Bull** 1998 Sep;21(9):978–81

Role of transforming growth factor-beta pathway in the mechanism of wound healing by saponin from Ginseng Radix rubra. Kanzaki T, et al. **Br J Pharmacol** 1998 Sep; 125(2):255–62

The relaxation effects of ginseng saponin in rabbit corporal smooth muscle: is it a nitric oxide donor? Kim HJ, et al. **Br J Urol** 1998 Nov;82(5):744–8

Effect of saponins of Panax notoginseng on synaptosomal 45Ca uptake. Ma LY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):213–5

Panax ginseng blocks morphine-induced thymic apoptosis by lowering plasma corticosterone level. Kim YR, et al. **Gen Pharmacol** 1999 Jun;32(6):647–52

Subacute toxicity study of the combination of ginseng (Panax ginseng) and ashwagandha (Withania somnifera) in rats: a safety assessment. Aphale AA, et al. **Indian J Physiol Pharmacol** 1998 Apr;42(2):299–302

Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Yun TK, et al. **Int J Epidemiol** 1998 Jun;27(3):359–64

Ginseng supplementation does not enhance healthy young adults' peak aerobic exercise performance. Allen JD, et al. **J Am Coll Nutr** 1998 Oct;17(5):462–6

Orally administered ginseng extract reduces serum total cholesterol and triglycerides that induce fatty liver in 66% hepatectomized rats. Cui X, et al. **J Int Med Res** 1998 Aug-Sep;26(4):181–7

Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. Akao T, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1155–60

Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. Zhu M, et al. **J Pharm Pharmacol** 1999 Feb;51(2):175–80

In vitro and in vivo experimental effect of Korean red ginseng on erection. Choi YD, et al. **J Urol** 1999 Oct; 162(4):1508–11

Effects of ginseng on ethanol induced sedation in mice. Koo MW. **Life Sci** 1999;64(2):153–60

Effect of American ginseng (Panax quinquefolium) on male copulatory behavior in the rat. Murphy LL, et al. **Physiol Behav** 1998 Jun 15;64(4):445–50

Beneficial effects of ginsenosides of stems and leaves on cardiac and coronary vascular functions after 12-hour rat heart preservation. Zhang JM, et al. **Transplant Proc** 1999 Aug;31(5):2175–8

ADVERSE EFFECTS

Probable false authentication of herbal plants: ginseng [letter; comment] Wong HC. **Arch Intern Med** 1999 May 24; 159(10):1142–3. Comment on: Arch Intern Med 1998 Nov 9;158(20):2200–11.

[Gynecomastia in a male and ginseng (letter)] Palop V, et al. **Med Clin (Barc)** 1999 May 29;112(19):758 **(Spa)**

CHEMISTRY

Determination of ginsenosides in plant extracts from Panax ginseng and Panax quinquefolius L. by LC/MS/MS. Wang X, et al. **Anal Chem** 1999 Apr 15;71(8):1579–84

Characterization of a PACAP-like immunoreactive component in red ginseng root. Takashima N, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:561–5

Effect of Panax ginseng extract on passive avoidance retention in old rats. Jaenicke B, et al. **Arch Pharm Res** 1991 Mar;14(1):25–9

Effect of ginseng total saponin on bovine adrenal tyrosine hydroxylase. Kim HS, et al. **Arch Pharm Res** 1998 Dec; 21(6):782–4

Ginsenoside Rf2, a new dammarane glycoside from Korean red ginseng (Panax ginseng). Park JD, et al. **Arch Pharm Res** 1998 Oct;21(5):615–7

Western blotting for ginseng saponins, ginsenosides using anti-ginsenoside Rb1 monoclonal antibody. Fukuda N, et al. **Biol Pharm Bull** 1999 Feb;22(2):219–20

Acyl-CoA: cholesterol acyltransferase inhibitory activity of ginseng sapogenins, produced from the ginseng saponins. Kwon BM, et al. **Bioorg Med Chem Lett** 1999 May 17; 9(10):1375–8

Effects of administration of the standardized Panax ginseng extract G115 on hepatic antioxidant function after exhaustive exercise. Voces J, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jun;123(2):175–84

Capillary electrophoretic analysis of ginseng polypeptide. Kajiwara H, et al. **Electrophoresis** 1998 Jun;19(8–9):1270–4

Gynostemma pentaphyllum: identification of major sapogenins and differentiation from Panax species. Cui J, et al. **Eur J Pharm Sci** 1999 Jul;8(3):187–91

Effects of ginseng saponins on responses induced by various receptor stimuli. Tachikawa E, et al. **Eur J Pharmacol** 1999 Mar 12;369(1):23–32

Korean red ginseng saponins with low ratios of protopanaxadiol and protopanaxatriol saponin improve scopolamine-induced learning disability and spatial working memory in mice. Jin SH, et al. **J Ethnopharmacol** 1999 Aug;66(2):123–9

Ginseng total saponin inhibits nicotine-induced hyperactivity and conditioned place preference in mice. Kim HS, et al. **J Ethnopharmacol** 1999 Jul;66(1):83–90

Modulation of American ginseng on brainstem GABAergic effects in rats. Yuan CS, et al. **J Ethnopharmacol** 1998 Oct; 62(3):215–22

Isolation and characterization of a group of oligopeptides related to oxidized glutathione from the root of Panax ginseng. Chen ZK, et al. **J Pept Res** 1998 Aug;52(2):137–42

Protopanaxatriol ginsenosides inhibit glucose uptake in primary cultured rabbit renal proximal tubular cells by arachidonic acid release. Han HJ, et al. **Kidney Blood Press Res** 1999;22(3):114–20

Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent pathway. Kim HE, et al. **Life Sci** 1999;65(3):PL33–40

Inhibition by ginsenosides Rb1 and Rg1 of cocaine-induced hyperactivity, conditioned place preference, and postsynaptic dopamine receptor supersensitivity in mice. Kim HS, et al. **Pharmacol Biochem Behav** 1999 Jul; 63(3):407–12

Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits. Ismail MF, et al. **Pharmacol Res** 1999 Feb;39(2):157–66

Non-ginsenoside nicotinic activity in ginseng species. Lewis R, et al. **Phytother Res** 1999 Feb;13(1):59–64

Tyrosinase inhibitory p-coumaric acid from ginseng leaves. Lim JY, et al. **Phytother Res** 1999 Aug;13(5):371–5

Cytotoxicity of natural ginseng glycosides and semisynthetic analogues. Atopkina LN, et al. **Planta Med** 1999 Feb; 65(1):30–4

Effects of a standardized Panax ginseng extract on the skeletal muscle of the rat: a comparative study in animals at rest and under exercise. Ferrando A, et al. **Planta Med** 1999 Apr;65(3):239–44

Effects of ginseng extract on various haematological parameters during aerobic exercise in the rat [letter] Ferrando A, et al. **Planta Med** 1999 Apr;65(3):288–90

Acute and chronic effects of ginseng total saponin and amphetamine on fixed-interval performance in rats [letter] Halladay AK, et al. **Planta Med** 1999 Mar;65(2):162–4

CLASSIFICATION

Molecular authentication of Panax species. Ngan F, et al. **Phytochemistry** 1999 Mar;50(5):787–91

CYTOLOGY

[Interferon-inducing action of polysaccharide-containing biopolymers from ginseng root and cell culture] Smolina TP, et al. **Antibiot Khimioter** 1998;43(11):21–3 (Eng. Abstr.) **(Rus)**

GENETICS

Molecular authentication of Panax species. Ngan F, et al. **Phytochemistry** 1999 Mar;50(5):787–91

A MADS box gene homologous to AG is expressed in seedlings as well as in flowers of ginseng. Kim YS, et al. **Plant Cell Physiol** 1998 Aug;39(8):836–45

GROWTH & DEVELOPMENT

Production of ginseng and its bioactive components in plant cell culture: current technological and applied aspects. Wu J, et al. **J Biotechnol** 1999 Feb 19;68(2–3):89–99 (56 ref.)

THERAPEUTIC USE

Effect of panax notoginseng extracts on inferior sperm motility in vitro. Chen JC, et al. **Am J Chin Med** 1999; 27(1):123–8

Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension. Han KH, et al. **Am J Chin Med** 1998;26(2):199–209

Synthesis of ginseng diyne analogues and their antiproliferative activity against L1210 cells. Kim SI, et al. **Arch Pharm (Weinheim)** 1999 Apr;332(4):133–6

Panax ginseng protects the testis against 2,3,7,8-tetrachlorodibenzo-p-dioxin induced testicular damage in guinea pigs. Kim W, et al. **BJU Int** 1999 May;83(7):842–9

Improvement of early postburn cardiac function by use of Panax notoginseng and immediate total eschar excision in one operation. Huang YS, et al. **Burns** 1999 Feb;25(1):35–41

Saponin contents and anticarcinogenic effects of ginseng depending on types and ages in mice. Yun TK, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):293–8

Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Song Z, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):882–7

Effect of petroleum ether extract of Panax ginseng roots on proliferation and cell cycle progression of human renal cell carcinoma cells. Sohn J, et al. **Exp Mol Med** 1998 Mar 31;30(1):47–51

116 cases of coronary angina pectoris treated with powder composed of radix ginseng, radix notoginseng and succinum. Yuan J, et al. **J Tradit Chin Med** 1997 Mar; 17(1):14–7

A delivery circuit for normothermic reperfusion model. Yuan SM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jan;15(1):8–11

[Effect of xinmaitong capsule on damage of lipid peroxidation in coronary heart disease patients with myocardial ischemia] Qiu RX, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):342–4 (Eng. Abstr.) **(Chi)**

[Observation of therapeutic effect by combined administration of Salvia miltiorrhiza, ligustrazine and Panax notoginseng on late hemorrhagic shock of rabbits] Wang ZW, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 May;17(5):292–4 (Eng. Abstr.) **(Chi)**

GIZZARD

ENZYMOLOGY

Immunological detection of ecto-ATPase in chicken and rat tissues: characterization, distribution, and a cautionary note. Smith TM, et al. **Biochem Mol Biol Int** 1998 Aug; 45(5):1057–66

Rho-associated kinase of chicken gizzard smooth muscle. Feng J, et al. **J Biol Chem** 1999 Feb 5;274(6):3744–52

METABOLISM

Expression of chicken gizzard RLC complements the cytokinesis and developmental defects of Dictyostelium RLC null cells. Chen P, et al. **J Muscle Res Cell Motil** 1999 Feb;20(2):177–86

Ca2+-independent phosphorylation of myosin in rat caudal artery and chicken gizzard myofilaments. Weber LP, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):805–24

PATHOLOGY

Effects of cimetidine on broiler fattening and on stress-induced gizzard erosion in chicken. Grabarević Z, et al. **Acta Vet Hung** 1999;47(2):233–41

GLA PROTEIN, BONE see **OSTEOCALCIN**

GLACIAL ACETIC ACID see **ACETIC ACID**

GLANDERS

DIAGNOSIS

Serodiagnosis of equine piroplasmosis, dourine, and glanders using an arrayed immunoblotting method. Katz JB, et al. **J Vet Diagn Invest** 1999 May;11(3):292–4

IMMUNOLOGY

[Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines] Manzeniuk IN, et al. **Antibiot Khimioter** 1999;44(6):21–6 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Equine glanders in Turkey. Arun S, et al. **Vet Rec** 1999 Mar 6;144(10):255–8

PATHOLOGY

The hamster model of intraperitoneal Burkholderia mallei (glanders). Fritz DL, et al. **Vet Pathol** 1999 Jul;36(4):276–91

GLANDULAR FEVER see **INFECTIOUS MONONUCLEOSIS**

GLANZMANN THROMBASTHENIA see

THROMBASTHENIA

GLARE

Cataract in traffic. Mäntyjärvi M, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr;237(4):278–82

Comparison between anti-reflection-coated and uncoated spectacle lenses for presbyopic highway patrol troopers. Bachman WG, et al. **J Am Optom Assoc** 1999 Feb; 70(2):103–9

Consultation section. Cataract surgical problem [see comments] **J Cataract Refract Surg** 1998 Dec; 24(12):1554–61. Comment in: J Cataract Refract Surg 1999 May;25(5):604–5.

Functional vision and corneal changes after laser in situ keratomileusis determined by contrast sensitivity, glare testing, and corneal topography. Holladay JT, et al. **J Cataract Refract Surg** 1999 May;25(5):663–9

Analysis of edge glare phenomena in intraocular lens edge designs. Holladay JT, et al. **J Cataract Refract Surg** 1999 Jun;25(6):748–52

Computerized method to measure glare and contrast sensitivity in cataract patients. Martin L. **J Cataract Refract Surg** 1999 Mar;25(3):411–5

Glare and light streaks: a complication of IOL implantation [letter; comment] Shipper I. **J Cataract Refract Surg** 1999 May;25(5):604–5. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1554–61.

Functional complaints, visual acuity, spatial contrast sensitivity, and glare disability in preoperative and postoperative cataract patients. Superstein R, et al. **J Cataract Refract Surg** 1999 Apr;25(4):575–81

Comparison of methods to assess visual impairment from glare and light scattering with posterior capsule opacification. Tan JC, et al. **J Cataract Refract Surg** 1998 Dec;24(12):1626–31

Prospective bilateral study of night glare after laser in situ keratomileusis with single zone and transition zone ablation. el Danasoury MA. **J Refract Surg** 1998 Sep–Oct; 14(5):512–6

Objective and subjective evaluation of photic phenomena after monofocal and multifocal intraocular lens implantation. Dick HB, et al. **Ophthalmology** 1999 Oct; 106(10):1878–86

[Effect of luminance on contrast sensitivity and glare in the mesopic range] Rassow B. **Klin Monatsbl Augenheilkd** 1999 Jun;214(6):401–6 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Image quality degradation by light scattering in display devices. Flynn MJ, et al. **J Digit Imaging** 1999 May; 12(2):50–9

GLASGOW COMA SCALE

Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. McKeating EG, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:117–9

Efficiency of the Glasgow Outcome Scale (GOS)–Score for the long-term follow-up after severe brain injuries. Woischneck D, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:138–41

Predictors of long-term outcome in severe head injury. Lai YC, et al. **Ann Acad Med Singapore** 1998 May;27(3):326–31

Assessment of the grimace component of a coma scale [letter; comment] Newton CR. **Arch Dis Child** 1998 Dec;79(6):532 . Comment on: Arch Dis Child 1997 Dec;77(6):519–21.

The Glasgow Coma Score: reliable evidence? Crossman J, et al. **Injury** 1998 Jul;29(6):435–7

Depression after traumatic brain injury as a function of Glasgow Outcome Score. McCleary C, et al. **J Clin Exp Neuropsychol** 1998 Apr;20(2):270–9

A prospective study of Glasgow Coma Scale (GCS), age, CSF-neutrophil count, and CSF-protein and glucose levels as prognostic indicators in 100 adult patients with meningitis [see comments] Schutte CM, et al. **J Infect** 1998 Sep;37(2):112–5. Comment in: J Infect 1998 Sep;37(2):104–5.

Assessing disability after head injury: improved use of the Glasgow Outcome Scale. Pettigrew LE, et al. **J Neurosurg** 1998 Dec;89(6):939–43

How should a subarachnoid hemorrhage grading scale be determined? A combinatorial approach based solely on the Glasgow Coma Scale. Takagi K, et al. **J Neurosurg** 1999 Apr;90(4):680–7

Primary end points in phase III clinical trials of severe head trauma: DRS versus GOS. The American Brain Injury Consortium Study Group. Choi SC, et al. **J Neurotrauma** 1998 Oct;15(10):771–6

Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Teasdale GM, et al. **J Neurotrauma** 1998 Aug;15(8):587–97 (23 ref.)

Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. Wilson JT, et al. **J Neurotrauma** 1998 Aug;15(8):573–85

Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial. Morris GF, et al. **Neurosurgery** 1998 Dec;43(6):1369–72; discussion 1372–4

[Validation of the prognostic accuracy of neurosurgical admission scales after rupture of cerebral aneurysms] Aulmann C, et al. **Zentralbl Neurochir** 1998;59(3):171–80 (Eng. Abstr.) **(Ger)**

GLASGOW OUTCOME SCALE see **GLASGOW COMA SCALE**

GLASS

Retained glass foreign bodies in wounds: predictive value of wound characteristics, patient perception, and wound exploration. Steele MT, et al. **Am J Emerg Med** 1998 Nov; 16(7):627–30

Critical role of glass fiber length in TNF-alpha production and transcription factor activation in macrophages. Ye J, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L426–34

Adaptation of capillary isoelectric focusing to microchannels on a glass chip. Hofmann O, et al. **Anal Chem** 1999 Feb 1;71(3):678–86

Influence of fibre length, dissolution and biopersistence on the production of mesothelioma in the rat peritoneal cavity. Miller BG, et al. **Ann Occup Hyg** 1999 Apr;43(3):155–66

Hierarchical cluster analysis applied to workers' exposures in fiberglass insulation manufacturing. Wu JD, et al. **Ann Occup Hyg** 1999 Jan;43(1):43–55

Deposition and retention of vital and dead Streptococcus sanguinis cells on glass surfaces in a flow-chamber system. Weiger R, et al. **Arch Oral Biol** 1999 Aug;44(8):621–8

Changes in surface hardness of conventional restorative glass ionomer cements. De Moor RJ, et al. **Biomaterials** 1998 Dec;19(24):2269–75

Behaviour of human osteoblasts cultured on bioactive glass coatings. Oliva A, et al. **Biomaterials** 1998 Jun; 19(11–12):1019–25

Glass fiber contamination of cigarette filters: an additional health risk to the smoker? [see comments] Pauly JL, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov; 7(11):967–79. Comment in: Cancer Epidemiol Biomarkers Prev 1998 Nov;7(11):965–6.

Quantifying the cleanliness of glass capillaries. Bowman CL. **Cell Biochem Biophys** 1998;29(3):203–23

Adsorption of calcitonin to glass. Law SL, et al. **Drug Dev Ind Pharm** 1999 Feb;25(2):253–6

On the suitability of fiberglass reinforced polyester as building material for mesocosms. Berghahn R, et al. **Ecotoxicol Environ Saf** 1999 Jul;43(3):267–73

In situ microscopic analysis of asbestos and synthetic vitreous fibers retained in hamster lungs following inhalation. Rogers RA, et al. **Environ Health Perspect** 1999 May; 107(5):367–75

Comparison of cytoskeletal structures in glass-adherent and polyethylene terephthalate (PET) membrane-adherent human pulmonary fibroblasts. Aufderheide M, et al. **Exp Toxicol Pathol** 1999 Jan;51(1):3–7

Delay in the application of the cover glass is a potential source of error with the Makler Counting Chamber. Matson P, et al. **Fertil Steril** 1999 Sep;72(3):559–61

Investigation of early bone formation using resorbable bioactive glass in the rat mandible. Furusawa T, et al. **Int J Oral Maxillofac Implants** 1998 Sep–Oct;13(5):672–6

Hybrid casts: a comparison of different casting materials. Philbin TM, et al. **J Am Osteopath Assoc** 1999 Jun; 99(6):311–2

Effect of bioactive glass particle size on osseous regeneration [letter] Ducheyne P. **J Biomed Mater Res** 1999 Aug; 46(2):301–4

Glass-based coatings for titanium implant alloys. Gomez-Vega JM, et al. **J Biomed Mater Res** 1999 Sep 15;46(4):549–59

In vitro calcium phosphate layer formation on sol-gel glasses of the CaO-SiO(2) system. Izquierdo-Barba I, et al. **J Biomed Mater Res** 1999 Nov;47(2):243–50

Behavior of bone marrow cells cultured on three different coatings of gel-derived bioactive glass-ceramics at early stages of cell differentiation. Łączka-Osyczka A, et al. **J Biomed Mater Res** 1998 Dec 5;42(3):433–42

Bioactive glasses induce chemiluminescence by human polymorphonuclear leukocytes. Lindfors NC, et al. **J Biomed Mater Res** 1999 Oct;47(1):91–4

Transmission electron microscopic study of interface between bioactive bone cement and bone: comparison of apatite and wollastonite containing glass-ceramic filler with hydroxyapatite and beta-tricalcium phosphate fillers. Okada Y, et al. **J Biomed Mater Res** 1999 Jun 15; 45(4):277–84

Influence of composition and surface characteristics on the in vitro bioactivity of SiO(2)-CaO-P(2)O(5)-MgO sol-gel glasses. Pérez-Pariente J, et al. **J Biomed Mater Res** 1999 Nov;47(2):170–5

Patterned glass surfaces direct cell adhesion and process outgrowth of primary neurons of the central nervous system. Saneinejad S, et al. **J Biomed Mater Res** 1998 Oct; 42(1):13–9

Effect of bioactive glass particle size on osseous regeneration of cancellous defects. Wheeler DL, et al. **J Biomed Mater Res** 1998 Sep 15;41(4):527–33

Is glass visible on plain radiographs? A cadaver study. Arbona N, et al. **J Foot Ankle Surg** 1999 Jul–Aug; 38(4):264–70

Biodegradable controlled release glass in the repair of peripheral nerve injuries. Lenihan DV, et al. **J Hand Surg [Br]** 1998 Oct;23(5):588–93

Adsorption of small hydroxy acids on glass: a pitfall in quantitative urinary organic acid analysis by GC-MS. van Landeghem AA, et al. **J Inherit Metab Dis** 1999 May; 22(3):293–6

Analysis of bacterial communities on historical glass by denaturing gradient gel electrophoresis of PCR-amplified gene fragments coding for 16S rRNA. Rölleke S, et al. **J Microbiol Methods** 1999 May;36(1–2):107–14

A novel and rapid method for culturing pure rat spinal cord astrocytes on untreated glass. Silva GA, et al. **J Neurosci Methods** 1998 Mar 13;80(1):75–9

Effect of serum proteins on osteoblast adhesion to surface-modified bioactive glass and hydroxyapatite. El-Ghannam A, et al. **J Orthop Res** 1999 May;17(3):340–5

A bioactive glass particulate in the treatment of molar furcation invasions. Anderegg CR, et al. **J Periodontol** 1999 Apr;70(4):384–7

Survival of Dicor glass-ceramic dental restorations over 14 years. Part II: effect of thickness of Dicor material and design of tooth preparation. Malament KA, et al. **J Prosthet Dent** 1999 Jun;81(6):662–7

Repair of acrylic resin denture base reinforced with glass fiber. Stipho HD. **J Prosthet Dent** 1998 Nov;80(5):546–50

Prosthodontic treatment with a glass fiber-reinforced resin-bonded fixed partial denture: A clinical report. Vallittu PK. **J Prosthet Dent** 1999 Aug;82(2):132–5

Genetic alterations of cancer-related genes in glass fiber-induced transformed cells. Whong WZ, et al. **J Toxicol Environ Health** 1999 Mar 26;56(6):397–404

Diffusion and relaxation in interface layers of crystals in nanoporous glass. Zavada T, et al. **Magn Reson Imaging** 1998 Jun–Jul;16(5–6):695–7

Field-cycling NMR relaxometry of molecules undergoing Lévy walks at the surface of fine particles and porous glass. Zavada T, et al. **Magn Reson Imaging** 1998 Jun–Jul; 16(5–6):711–3

Mortality from nephritis and nephrosis in the fibreglass manufacturing industry. Chiazze L, et al. **Occup Environ Med** 1999 Mar;56(3):164–6

On the relevant spectral parts for glassblowers' cataract [letter; comment] Vos JJ, et al. **Ophthalmic Physiol Opt** 1998 May;18(3):311–3. Comment on: Ophthalmic Physiol Opt 1997 May;17(3):216–24.

Ultraviolet radiation penetrating vehicle glass: a field based comparative study. Kimlin MG, et al. **Phys Med Biol** 1999 Apr;44(4):917–26

Adsorption of EGF receptor ligands to test tubes--a factor with implications for studies on the potency of these peptides. Jørgensen PE, et al. **Scand J Clin Lab Invest** 1999 May;59(3):191–7

Cancer mortality of art glass workers in Tuscany, Italy. Pirastu R, et al. **Scand J Work Environ Health** 1998 Oct; 24(5):386–91

Efficiency of leukocyte removal by filters made of superfine glass fiber membranes. Zou Y, et al. **Vox Sang** 1999; 76(1):22–6

[The microwave oven for drying thick blood smears. Benefits and limits for microscopic observation of Plasmodium falciparum trophozoites and gametocytes] Le Goff G, et al. **Bull Soc Pathol Exot** 1998;91(3):214–6 (Eng. Abstr.) **(Fre)**

[Biocompatibility of glass and silicon] Uhlemann J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:438–40 **(Ger)**

[An unusual eye injury] Reiss M. **Schweiz Med Wochenschr** 1999 Jan 30;129(4):138 **(Ger)**

[Resin-bonded inlay bridges made of glass-fiber-reinforced composites. A step-by-step description of their clinical use] Göhring TN, et al. **Schweiz Monatsschr Zahnmed** 1999; 109(4):368–84 **(Ger, Fre)**

[Failure conditions of glass filament yarns: a contribution to the valuation of carcinogenic potentials of fiber fragments] Oser M, et al. **Zentralbl Hyg Umweltmed** 1998 Sep; 201(3):251–67 (Eng. Abstr.) **(Ger)**

[A cohort study of art glass workers in the Empoli area] Bartoli D, et al. **Med Lav** 1998 Sep–Oct;89(5):424–36 (Eng. Abstr.) **(Ita)**

[Man-made vitreous fibers: current state of knowledge] Chiappino G. **Med Lav** 1999 Jan–Feb;90(1):5–9 (Eng. Abstr.) **(Ita)**

[The use of biological monitoring in the assessment of occupational exposure to styrene in fiberglass-reinforced plastics industry] Brygiert H, et al. **Med Pr** 1998; 49(5):439–48 (Eng. Abstr.) **(Pol)**

[Use of the BIOGRAN preparation in surgical treatment of periodontal disease] Ziętek M, et al. **Polim Med** 1998; 28(3–4):63–9 (Eng. Abstr.) **(Pol)**

[Bronchoscopic study of broncho-pulmonary system among workers of fiberglass production industry] Gadzhiev AS, et al. **Med Tr Prom Ekol** 1999;(5):39–41 **(Rus)**

CHEMISTRY

Immobilization of oligonucleotides onto a glass support via disulfide bonds: A method for preparation of DNA microarrays. Rogers YH, et al. **Anal Biochem** 1999 Jan 1; 266(1):23–30

Kinetics and thermodynamics of free flavins and the flavin-based redox active site within glucose oxidase dissolved in solution or sequestered within a sol-gel-derived glass. Hartnett AM, et al. **Anal Chem** 1999

GLASS

Mar 15;71(6):1215-24

Apatite formation on PDMS-modified CaO-SiO2-TiO2 hybrids prepared by sol-gel process. Chen Q, et al. **Biomaterials** 1999 Jun;20(12):1127-32

Adsorption from plasma and buffer of single- and two-chain high molecular weight kininogen to glass and sulfonated polyurethane surfaces. Cornelius RM, et al. **Biomaterials** 1999 Feb;20(4):341-50

Protein-resistant coatings for glass and metal oxide surfaces derived from oligo(ethylene glycol)-terminated alkytrichlorosilanes. Lee SW, et al. **Biomaterials** 1998 Sep; 19(18):1669-75

Water sorption, solubility and effect of post-curing of glass fibre reinforced polymers. Miettinen VM, et al. **Biomaterials** 1999 Jul;20(13):1187-94

A quantitative study of the sintering and mechanical properties of hydroxyapatite/phosphate glass composites. Tancred DC, et al. **Biomaterials** 1998 Oct;19(19):1735-43

Properties and cytotoxicity of water soluble Na2O-CaO-P2O5 glasses. Uo M, et al. **Biomaterials** 1998 Dec;19(24):2277-84

Crystallization, fluoridation and some properties of apatite thin films prepared through rf-sputtering from CaO-P2O5 glasses. Yamashita K, et al. **Biomaterials** 1998 Jul; 19(14):1239-44

An innovative pre-impregnated glass fiber for reinforcing composites. Goldberg AJ, et al. **Dent Clin North Am** 1999 Jan;43(1):127-33, vi-vii

Characterisation of the glass transition of HPMC using modulated temperature differential scanning calorimetry. McPhillips H, et al. **Int J Pharm** 1999 Mar 25;180(1):83-90

Hydrophobicity, surface tension, and zeta potential measurements of glass-reinforced hydroxyapatite composites. Lopes MA, et al. **J Biomed Mater Res** 1999 Jun 15;45(4):370-5

In-vitro study of fracture strength and marginal adaptation of fibre-reinforced adhesive fixed partial inlay dentures. Behr M, et al. **J Dent** 1999 Feb;27(2):163-8

Stoichiometry of the leaching process of fluoride-containing aluminosilicate glass-ionomer glasses. De Maeyer EA, et al. **J Dent Res** 1999 Jul;78(7):1312-8

Reactivity of fluoride-containing calcium aluminosilicate glasses used in dental glass-ionomer cements. De Maeyer EA, et al. **J Dent Res** 1998 Dec;77(12):2005-11

Chemical bonding of lead in glasses through isotropic vs anisotropic correlation: PASS shifted echo. Fayon F, et al. **J Magn Reson** 1999 Mar;137(1):116-21

Effect of initiator concentration, exposure time and particle size of the filler upon the mechanical properties of a light-curing radiopaque dental composite. Kalliyana Krishnan V, et al. **J Oral Rehabil** 1998 Oct;25(10):747-51

Nucleation and crystallization kinetics of hydrated amorphous lactose above the glass transition temperature. Schmitt EA, et al. **J Pharm Sci** 1999 Mar;88(3):291-6

Flexural properties of acrylic resin polymers reinforced with unidirectional and woven glass fibers. Vallittu PK. **J Prosthet Dent** 1999 Mar;81(3):318-26

Perfluorocarbon liquid manipulation of high-density intraocular foreign bodies. Sudhalkar HA, et al. **Retina** 1998;18(5):460-5

Structural study of a lead-barium-aluminum phosphate glass by MAS-NMR spectroscopy. Gongyi G. **Solid State Nucl Magn Reson** 1998 Nov;13(1-2):119-22

Distribution of principal values of the 31P NMR chemical shift tensor in phosphate glasses. Losso P, et al. **Solid State Nucl Magn Reson** 1998 Nov;13(1-2):113-8

[The evaluation of mean indoor concentration of radon based on the measurement of 210Pb concentration in glass] Skubalski J, et al. **Med Pr** 1998;49(5):483-8 (Eng. Abstr.) **(Pol)**

GLASS IONOMER CEMENTS

Shear bond strength of a resin-reinforced glass ionomer cement: an in vitro comparative study. Chung CH, et al. **Am J Orthod Dentofacial Orthop** 1999 Jan;115(1):52-4

Enamel demineralization adjacent to orthodontic brackets bonded with hybrid glass ionomer cements: an in vitro study [see comments] Vorhies AB, et al. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):668-74 . Comment in: Am J Orthod Dentofacial Orthop 1999 May;115(5):13A.

Conservative interproximal box-only polyacid modified composite restorations in primary molars, twelve-month clinical results. Marks LA, et al. **ASDC J Dent Child** 1999 Jan-Feb;66(1):23-9, 12

Assessment of compomer proximal restorations in primary molars: a retrospective study in children. Mass E, et al. **ASDC J Dent Child** 1999 Mar-Apr;66(2):93-7, 84

Amalgam bonding [letter; comment] Budden JC. **Br Dent J** 1999 Jun 12;186(11):544. Comment on: Br Dent J 1999 Apr 10;186(7):328-32.

ART restorations and glass ionomer sealants in Zimbabwe: survival after 3 years. Frencken JE, et al. **Community Dent Oral Epidemiol** 1998 Dec;26(6):372-81

A 2-year clinical study of two glass ionomer cements used in the atraumatic restorative treatment (ART) technique. Ho TF, et al. **Community Dent Oral Epidemiol** 1999 Jun; 27(3):195-201

Multifunctional bases and liners. Elledge DA. **Dent Clin North Am** 1998 Oct;42(4):739-54, x

Ionomeric cement implants in the middle ear of the baboon (Papio ursinus) as a primate model. Geyer G, et al. **Eur Arch Otorhinolaryngol** 1998;255(8):402-9

Glass-ionomer cement: evaluation as an orbital implant. Hintschich C, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Feb;237(2):169-74

Clinical behaviour of glass ionomer restorations in primary teeth. Espelid I, et al. **J Dent** 1999 Aug;27(6):437-42

Fluoride release, microbial inhibition and microleakage pattern of two orthodontic band cements. Gillgrass TJ, et al. **J Dent** 1999 Aug;27(6):455-61

Retention of posts with resin, glass ionomer and hybrid cements. Love RM, et al. **J Dent** 1998 Sep;26(7):599-602

Glass-ionomer restoratives: a systematic review of a secondary caries treatment effect. Randall RC, et al. **J Dent Res** 1999 Feb;78(2):628-37 (76 ref.)

Longevity of extensive class II open-sandwich restorations with a resin-modified glass-ionomer cement. van Dijken JW, et al. **J Dent Res** 1999 Jul;78(7):1319-25

The treatment of class III maxillary furcations using a resin-ionomer. A case report. Anderegg CR. **J Periodontol** 1998 Aug;69(8):948-50

Diametral and compressive strength of dental core materials. Cho GC, et al. **J Prosthet Dent** 1999 Sep;82(3):272-6

Titanium and glass-ionomer cement as ossicular replacement materials: biocompatibility results after implantation in the rabbit. Schwager K, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):322-8

Bonded compomer slope for anterior tooth crossbite correction. Croll TP, et al. **Pediatr Dent** 1999 Jul-Aug; 21(4):293-4

Resin-modified glass ionomer cement restorations in primary molars. Folkesson UH, et al. **Swed Dent J** 1999;23(1):1-9

Transient reduction of mutans streptococci on tooth surfaces using a chlorhexidine-containing glass ionomer cement varnish. Hoszek A, et al. **Swed Dent J** 1999;23(2-3):97-105

[Long-term outcome after reconstruction of the cranial base with ionomer cement] Baier G, et al. **Laryngorhinootologie** 1998 Aug;77(8):467-73 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Decalcification in relation to brackets bonded with glass ionomer cement or a resin adhesive. Millett DT, et al. **Angle Orthod** 1999 Feb;69(1):65-70

CHEMISTRY

Shear bond strength of composite, glass ionomer, and acidic primer adhesive systems. Bishara SE, et al. **Am J Orthod Dentofacial Orthop** 1999 Jan;115(1):24-8

Shear bond strengths of two resin-modified glass ionomer cements to porcelain. Chung CH, et al. **Am J Orthod Dentofacial Orthop** 1999 May;115(5):533-5

A comparison of the shear bond strengths of two glass ionomer cements. Meehan MP, et al. **Am J Orthod Dentofacial Orthop** 1999 Feb;115(2):125-32

Bonding of hybrid ionomers and resin cements to modified orthodontic band materials. Mennemeyer VA, et al. **Am J Orthod Dentofacial Orthop** 1999 Feb;115(2):143-7

Product clarification [letter; comment] Mertz C. **Am J Orthod Dentofacial Orthop** 1999 Jul;116(1):15A-16A . Comment on: Am J Orthod Dentofacial Orthop 1999 Jan;115(1):24-8.

Laboratory evaluation of a compomer and a resin-modified glass ionomer cement for orthodontic bonding. Millet DT, et al. **Angle Orthod** 1999 Feb;69(1):58-63; discussion 64

Solubility of a resin-modified glass ionomer cement. Quackenbush BM, et al. **ASDC J Dent Child** 1998 Sep-Oct; 65(5):310-2, 354

Comparative in vitro microradiographic effects of resin-modified and autopolymerizing glass ionomers on demineralization of primary and permanent enamel. Wandera A, et al. **ASDC J Dent Child** 1998 Jul-Aug; 65(4):239-43, 229

Resin-ionomer restorative materials for children: a review [see comments] Hse KM, et al. **Aust Dent J** 1999 Mar; 44(1):1-11 (106 ref.). Comment in: Aust Dent J 1999 Jun;44(2):138.

Restorative materials [letter; comment] Mount GJ. **Aust Dent J** 1999 Jun;44(2):138. Comment on: Aust Dent J 1999 Mar;44(1):1-11.

Effect of monovalent ions in glass ionomer on their uptake and re-release. Hadley PC, et al. **Biomaterials** 1999 May; 20(9):891-7

Long-term flexural strengths of resin-modified glass-ionomer cements. Kanchanavasita W, et al. **Biomaterials** 1998 Sep;19(18):1703-13

A preliminary study of the effect of glass-ionomer and related dental cements on the pH of lactic acid storage solutions. Nicholson JW, et al. **Biomaterials** 1999 Jan;20(2):155-8

The influence of sample dimensions on fluoride ion release from a glass ionomer restorative cement. Williams JA, et al. **Biomaterials** 1999 Jul;20(14):1327-37

Comparison of ion release from a glass ionomer cement as a function of the method of incorporation of added ions. Williams JA, et al. **Biomaterials** 1999 Mar;20(6):589-94

In vitro fluoride uptake by intra-orally aged and contaminated glass ionomer cement. Damen JJ, et al. **Caries Res** 1999;33(1):88-90

Evaluating the effects of fluoride-releasing dental materials on adjacent interproximal caries. Donly KJ, et al. **J Am Dent Assoc** 1999 Jun;130(6):817-25

Fluoride release from tooth-colored restorative materials: a 12-month report. Aboush YE, et al. **J Can Dent Assoc** 1998 Sep;64(8):561-4, 568

Glass polyalkenoate cements [letter] Davidson CL, et al. **J Dent** 1999 Sep;27(7):539

Long-term surface micro-hardness of resin-modified glass ionomers. Kanchanavasita W, et al. **J Dent** 1998 Nov; 26(8):707-12

Fluoride release from orthodontic bonding agents: a comparison of three in vitro models. Monteith VL, et al. **J Dent** 1999 Jan;27(1):53-61

The effect of curing regime on the release of hydroxyethyl methacrylate (HEMA) from resin-modified glass-ionomer cements. Palmer G, et al. **J Dent** 1999 May;27(4):303-11

The uptake and release of fluoride by ion-leaching cements after exposure to toothpaste. Rothwell M, et al. **J Dent** 1998 Sep;26(7):591-7

Failure of resin-modified glass-ionomers subjected to shear loading. Sidhu SK, et al. **J Dent** 1999 Jul;27(5):373-81

Crack formation of all-ceramic crowns dependent on different core build-up and luting materials. Sindel J, et al. **J Dent** 1999 Mar;27(3):175-81

Reactivity of fluoride-containing calcium aluminosilicate glasses used in dental glass-ionomer cements. De Maeyer EA, et al. **J Dent Res** 1998 Dec;77(12):2005-11

Stoichiometry of the leaching process of fluoride-containing aluminosilicate glass-ionomer glasses. De Maeyer EA, et al. **J Dent Res** 1999 Jul;78(7):1312-8

Residual monomer/additive release and variability in cytotoxicity of light-curing glass-ionomer cements and compomers [letter; comment] Demke RS. **J Dent Res** 1999 Mar;78(3):724. Comment on: J Dent Res 1998 Dec;77(12):2012-9.

Ion distribution in matrix parts of glass-polyalkenoate cement by SIMS. Maeda T, et al. **J Dent Res** 1999 Jan;78(1):86-90

Fluoride release/uptake of polyacid-modified resin composites (compomers) in neutral and acidic buffer solutions. Attin T, et al. **J Oral Rehabil** 1999 May; 26(5):388-93

Finishing and polishing of the ceromer material Targis. Lab-side and chair-side methods. Behr M, et al. **J Oral Rehabil** 1999 Jan;26(1):1-6

The effect of saliva on fluoride release by a glass-ionomer filling material. Bell A, et al. **J Oral Rehabil** 1999 May; 26(5):407-12

The influence of finishing time on the marginal seal of a resin-modified glass-ionomer and polyacid-modified resin composite. Lim CC, et al. **J Oral Rehabil** 1999 Jan; 26(1):48-52

Changes on storage of polyacid-modified composite resins. Nicholson JW, et al. **J Oral Rehabil** 1998 Aug;25(8):616-20

Comparison of marginal sealing ability of new generation bonding systems. Yap AU, et al. **J Oral Rehabil** 1998 Sep; 25(9):666-71

Effect of fluorosis on shear bond strength of glass ionomer-based restorative materials to dentin. Awliya WY, et al. **J Prosthet Dent** 1999 Mar;81(3):290-4

Effect of early water contact on solubility of glass ionomer luting cements. Gemalmaz D, et al. **J Prosthet Dent** 1998 Oct;80(4):474-8

In vitro study of fracture incidence and compressive fracture load of all-ceramic crowns cemented with resin-modified glass ionomer and other luting agents. Leevailoj C, et al. **J Prosthet Dent** 1998 Dec;80(6):699-707

Fluoride release of glass ionomer-based luting cements in vitro. Robertello FJ, et al. **J Prosthet Dent** 1999 Aug; 82(2):172-6

Microleakage of Class V resin-modified glass ionomer and compomer restorations. Toledano M, et al. **J Prosthet Dent** 1999 May;81(5):610-5

Adaptation of Class II Vitremer restorations with and without primer: a morphometric study. Gleicher H, et al. **Pediatr Dent** 1998 Jul-Aug;20(4):263-6

Fissure penetration and antibacterial effect in vitro of a glass ionomer cement containing chlorhexidine gluconate. Hoszek A, et al. **Swed Dent J** 1998;22(4):133-41

PHARMACOLOGY

Cariostatic effect of a light-cured, resin-reinforced glass-ionomer for banding orthodontic brackets in vivo. A combined study using microradiography and confocal laser scanning microscopy. Czochrowska E, et al. **J Orofac Orthop** 1998;59(5):265-73 **(Eng, Ger)**

In vitro enamel effects of a resin-modified glass ionomer: fluoride uptake and resistance to demineralization. Wandera A. **Pediatr Dent** 1998 Nov-Dec;20(7):411-7

[Tests on ionic release from glass-ionomer cements] Eramo S, et al. **Minerva Stomatol** 1998 Jul-Aug;47(7-8):299-302 (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Influence of light irradiation on the volumetric change of polyacid-modified resin composites. Miyazaki M, et al. **J Dent** 1999 Feb;27(2):149-53

Light-hardened luting cement for orthodontic bands and appliances. Croll TP. **Pediatr Dent** 1999 Mar-Apr; 21(2):121-3

THERAPEUTIC USE

Tympanoplasty type II with ionomeric cement and

titanium-gold-angle prostheses. Maassen MM, et al. **Am J Otol** 1998 Nov;19(6):693-9

Preventing sensitivity in Class II composite resin restorations [see comments] Christensen GJ. **J Am Dent Assoc** 1998 Oct;129(10):1469-70. Comment in: J Am Dent Assoc 1998 Dec;129(12):1668.

Reconstruction of the ossicular chain in the middle ear with glass ionomer cement. Brask T. **Laryngoscope** 1999 Apr; 109(4):573-6

Barodontalgia: a review, and the influence of simulated diving on microleakage and on the retention of full cast crowns. Lyons KM, et al. **Mil Med** 1999 Mar;164(3):221-7

TOXICITY

Residual monomer/additive release and variability in cytotoxicity of light-curing glass-ionomer cements and compomers [see comments] Geurtsen W, et al. **J Dent Res** 1998 Dec;77(12):2012-9. Comment in: J Dent Res 1999 Mar;78(3):724.

GLASSES see **EYEGLASSES**

GLAUCARUBIN

ANALOGS & DERIVATIVES

Studies on the anxiolytic activity of Eurycoma longifolia Jack roots in mice. Ang HH, et al. **Jpn J Pharmacol** 1999 Apr; 79(4):497-500

Anticancer activity of glaucarubinone analogues. Valeriote FA, et al. **Oncol Res** 1998;10(4):201-8

Quassinoids from the twigs and thorns of Castela polyandra. Grieco PA, et al. **Phytochemistry** 1999 Feb;50(4):637-45

In vitro anti-trichomonic activity of Castela texana. Calzado-Flores C, et al. **Proc West Pharmacol Soc** 1998; 41:173-4

PHARMACOLOGY

Anti-malarial activities of acylated bruceolide derivatives. Murakami N, et al. **Bioorg Med Chem Lett** 1998 Mar 3; 8(5):459-62

GLAUCOMA

see related
FILTERING SURGERY
SCLEROSTOMY
TRABECULECTOMY

Proceedings of the 13th Annual General Meeting of the Italian Association for the Study of Glaucoma. Rapallo, Italy, 13-14 March 1998. **Acta Ophthalmol Scand Suppl** 1998;(227):8-54

Normal tension glaucoma--a practical approach. Kamal D, et al. **Br J Ophthalmol** 1998 Jul;82(7):835-40 (86 ref.)

Monograph series on aging-related diseases: XI. Glaucoma. Elolia R, et al. **Chronic Dis Can** 1998;19(4):157-69 (121 ref.)

Gradual painless visual loss: glaucoma. Kendrick R. **Clin Geriatr Med** 1999 Feb;15(1):95-101, vi-vii

Defining glaucoma, defining disease: the 1998 Dohlman Lecture. Spaeth GL. **Int Ophthalmol Clin** 1999 Winter; 39(1):1-14

Abstracts from the 1999 annual meeting of the American Glaucoma Society. **J Glaucoma** 1999 Feb;8(1 Suppl):1-22

New perspectives on glaucoma [see comments] Dreyer EB, et al. **JAMA** 1999 Jan 27;281(4):306-8 (27 ref.). Comment in: JAMA 1999 Jun 16;281(23):2186-7.

New perspectives in glaucoma [letter; comment] Harris A, et al. **JAMA** 1999 Jun 16;281(23):2186-7. Comment on: JAMA 1999 Jan 27;281(4):306-8.

[Glaucoma] Hørven I. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2008 **(Nor)**

[An orthogonal model of operative adjustment control of intraocular pressure parameters] Turakhanov KhV, et al. **Med Tekh** 1998 Nov-Dec;(6):30-2 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Acute glaucoma, chronic glaucoma, and serotoninergic drugs [letter; comment] Eke T, et al. **Br J Ophthalmol** 1998 Aug; 82(8):976-8. Comment on: Br J Ophthalmol 1997 Mar;81(3):252.

Case report: visual loss caused by facial steroids. Michaeli-Cohen A, et al. **Can Fam Physician** 1998 Nov; 44:2462-3

Glaucoma secondary to topical use of steroid cream. thoe Schwartzenberg GW, et al. **Can J Ophthalmol** 1999 Jun; 34(4):222-5

Steroid-induced glaucoma in a young woman. Wax M. **J Glaucoma** 1998 Oct;7(5):353-8

Indiscriminate use of corticosteroid-containing eyedrops. Baratz KH, et al. **Mayo Clin Proc** 1999 Apr;74(4):362-6 (35 ref.)

CLASSIFICATION

Comparative glaucomatology. II: The experimental glaucomas. Gelatt KN, et al. **J Glaucoma** 1998 Aug; 7(4):282-94 (116 ref.)

Peripheral paraphrasing the glaucoma lexicon [editorial] Van Buskirk EM. **J Glaucoma** 1999 Jun;8(3):157-8

[A decisive rule in classifying diseases of the visual system] Nishanov AKh, et al. **Med Tekh** 1999 Jul-Aug;(4):16-8 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Trabeculectomy and phacoemulsification: one-way and two-way approach compared after one year. Bellucci R, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):50-1

Hyphema associated with pupillary dilation in a patient with exfoliation glaucoma and warfarin therapy. Greenfield DS, et al. **Am J Ophthalmol** 1999 Jul;128(1):98-100

Visual limitations assessment in patients with glaucoma [letter] Lu DW, et al. **Br J Ophthalmol** 1998 Nov; 82(11):1347

Follow up of focal narrowing of retinal arterioles in glaucoma. Papastathopoulos KI, et al. **Br J Ophthalmol** 1999 Mar;83(3):285-9

Elastosis of the lamina cribrosa in glaucomatous optic neuropathy. Pena JD, et al. **Exp Eye Res** 1998 Nov; 67(5):517-24

Risk factors for late presentation in chronic glaucoma. Fraser S, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2251-7

Ganglion cell losses underlying visual field defects from experimental glaucoma. Harwerth RS, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2242-50

Glaucoma in Sturge-Weber syndrome. Awad AH, et al. **J Aapos** 1999 Feb;3(1):40-5

Sub-Tenon's anesthesia for combined cataract and glaucoma surgery [letter] Bellucci R, et al. **J Cataract Refract Surg** 1999 May;25(5):606-7

One-site versus 2-site phacotrabeculectomy: a randomized study. el Sayyad F, et al. **J Cataract Refract Surg** 1999 Jan;25(1):77-82

Long-term changes in intraocular pressure after clear corneal phacoemulsification: normal patients versus glaucoma suspect and glaucoma patients [see comments] Shingleton BJ, et al. **J Cataract Refract Surg** 1999 Jul;25(7):885-90. Comment in: J Cataract Refract Surg 1999 Jul;25(7):877.

A frequency-doubling perimetric study in normal-tension glaucoma with hemifield defect. Kondo Y, et al. **J Glaucoma** 1998 Aug;7(4):261-5

Phacotrabeculectomy versus two-stage operation: a matched study. El-Sayyad FF, et al. **Ophthalmic Surg Lasers** 1999 Apr;30(4):260-5

Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Osborne NN, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S102-28 (235 ref.)

[Glaucoma and cataract--surgery at two times] Collignon-Brach J. **Bull Soc Belge Ophtalmol** 1998; 268:61-8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Combined interventions: cataract and glaucoma review of the literature] Detry-Morel M. **Bull Soc Belge Ophtalmol** 1998;268:45-60 (77 ref.) (Eng. Abstr.) **(Fre)**

[A case of congenital uveal ectropion with glaucoma] Bąk A, et al. **Klin Oczna** 1998;100(5):319-21 (Eng. Abstr.) **(Pol)**

[Glaucomatous optic neuropathy. Its etiopathogenetic aspects; the therapeutic consequences] Apostol S. **Oftalmologia** 1998;44(3):13-6 (10 ref.) (Eng. Abstr.) **(Rum)**

CONGENITAL

Combined trabeculotomy and trabeculectomy as an initial procedure in uncomplicated congenital glaucoma. Mullaney PB, et al. **Arch Ophthalmol** 1999 Apr; 117(4):457-60

Hereditary motor and sensory neuropathy with congenital glaucoma. Report on a family. Arruda WO, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2A):190-4

Prognosis of primary ab externo surgery for primary congenital glaucoma. Dietlein TS, et al. **Br J Ophthalmol** 1999 Mar;83(3):317-22

Corneal opacity and congenital glaucoma associated with massive heparan sulfaturia: report of one case. Lin SC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Jan-Feb;40(1):46-9

Management of congenital glaucoma [clinical conference] Khaw PT, et al. **J Glaucoma** 1999 Feb;8(1):81-5

Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma. Plásilová M, et al. **J Med Genet** 1999 Apr; 36(4):290-4

Long-term results of trabeculectomy for congenital glaucoma [see comments] Dureau P, et al. **J Pediatr Ophthalmol Strabismus** 1998 Jul-Aug; 35(4):198-202. Comment in: J Pediatr Ophthalmol Strabismus 1998 Jul-Aug;35(4):192.

Glaucoma and other "headaches" [editorial; comment] Wagner RS, et al. **J Pediatr Ophthalmol Strabismus** 1998 Jul-Aug;35(4):192. Comment on: J Pediatr Ophthalmol Strabismus 1998 Jul-Aug;35(4):198-202. Comment on: J Pediatr Ophthalmol Strabismus 1998 Jul-Aug;35(4):203-8; quiz 227-8.

Surgical results and complications of mitomycin C-augmented trabeculectomy in refractory developmental glaucoma. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 Jun;30(6):473-80

PHACE: a neurocutaneous syndrome with important ophthalmologic implications: case report and literature review. Coats DK, et al. **Ophthalmology** 1999 Sep; 106(9):1739-41 (10 ref.)

Unusual vascular dysplasia presenting as an intra-abdominal catastrophe. Menon P, et al. **Pediatr Surg Int** 1999 Jul; 15(5-6):440-1

[Treatment of congenital glaucoma with trabeculotomy] Kong L, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May; 33(3):169-72 (Eng. Abstr.) **(Chi)**

[Is the functional prognosis of congenital glaucoma so unfavorable? (letter)] Rouland JF. **J Fr Ophtalmol** 1999 May;22(5):591-2 **(Fre)**

[Deep sclerectomy in congenital glaucoma. Preliminary results] Tixier J, et al. **J Fr Ophtalmol** 1999 May;22(5):545-8 (Eng. Abstr.) **(Fre)**

[Eyeball growth after successful glaucoma surgery in the 1st year of life--follow-up values for primary congenital glaucoma] Dietlein TS, et al. **Klin Monatsbl Augenheilkd** 1998 Aug;213(2):67-70 (Eng. Abstr.) **(Ger)**

[Revision of iris incarceration after trabeculectomy in congenital glaucoma. A case report] Dietlein TS, et al. **Ophthalmologe** 1999 Jun;96(6):410-2 (Eng. Abstr.) **(Ger)**

[A case of congenital uveal ectropion with glaucoma] Bąk A, et al. **Klin Oczna** 1998;100(5):319-21 (Eng. Abstr.) **(Pol)**

[2 clinico-genetic types of primary congenital glaucomas in Slovakia] Gerinec A, et al. **Cesk Slov Oftalmol** 1998; 54(5):289-93 (Eng. Abstr.) **(Slo)**

[Molecular diagnosis of mutations responsible for recurrent and severe forms of primary congenital glaucoma] Plásilová M, et al. **Cesk Slov Oftalmol** 1998;54(5):281-8 (Eng. Abstr.) **(Slo)**

DIAGNOSIS

Comparing significance and magnitude of glaucomatous visual field defects using the SITA and Full Threshold strategies. Bengtsson B, et al. **Acta Ophthalmol Scand** 1999 Apr;77(2):143-6

Blue-on-yellow perimetry in the diagnosis of glaucoma. Teesalu P. **Acta Ophthalmol Scand** 1999 Jun;77(3):364-5

Common causes of vision loss in elderly patients. Quillen DA. **Am Fam Physician** 1999 Jul;60(1):99-108 (28 ref.)

Lens holder artifact simulating glaucomatous defect in automated perimetry [letter] Donahue SP. **Arch Ophthalmol** 1998 Dec;116(12):1681-3

Severity and stability of glaucoma: patient perception compared with objective measurement. Viswanathan AC, et al. **Arch Ophthalmol** 1999 Apr;117(4):450-4

Detection of glaucoma with scanning laser polarimetry. Weinreb RN, et al. **Arch Ophthalmol** 1998 Dec; 116(12):1583-9

Testing for glaucoma with the frequency-doubling illusion in the whole, macular and eccentric visual fields. Maddess T, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug; 27(3-4):194-6

Comparison between laser scanning tomography and computerised image analysis of the optic disc. Azuara-Blanco A, et al. **Br J Ophthalmol** 1999 Mar; 83(3):295-8

Automated perimetry by optometrists in patients at low risk of glaucoma [letter] Dayan MR, et al. **Br J Ophthalmol** 1998 Oct;82(10):1221

Mid-peripheral pattern electrical retinal responses in normals, glaucoma suspects, and glaucoma patients. Shorstein NH, et al. **Br J Ophthalmol** 1999 Jan;83(1):15-23

Temporal contrast sensitivity with peripheral and central stimulation in glaucoma diagnosis. Velten IM, et al. **Br J Ophthalmol** 1999 Feb;83(2):199-205

Optic nerve assessment: a clinical endpoint of optic neuropathy. Antón López A. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S37-9 (11 ref.)

Psychophysical endpoints. Johnson CA. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S48-51 (10 ref.)

Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Weinreb RN, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S40-3 (29 ref.)

Glaucoma screening by optometrists: positive predictive value of visual field testing. Newman DK, et al. **Eye** 1998; 12 (Pt 6):921-4

The changing pattern of glaucoma referrals by optometrists. Vernon SA. **Eye** 1998;12 (Pt 5):854-7

Learning effect in automatic static perimetry with Dicon TKS 4000 computed perimeter. Konareva-Kostianeva M, et al. **Folia Med (Plovdiv)** 1998;40(3B Suppl 3):34-7

The Liverpool Delphi evaluation [letter; comment] González de la Rosa M. **Graefes Arch Clin Exp Ophthalmol** 1999 Mar;237(3):259-61. Comment on: Graefes Arch Clin Exp Ophthalmol 1998 Jul;236(7):493-500.

Software for 3-D visualization/analysis of optic-disc images. Yogesan K, et al. **IEEE Eng Med Biol Mag** 1999 Jan-Feb; 18(1):43-9

Gonioscopy. Thomas R, et al. **Indian J Ophthalmol** 1998 Dec; 46(4):255-61 (1 ref.)

A comparison of the Synemed Glaucoma and the Humphrey 30-2 threshold perimetry tests. Harwood LW, et al. **J Am Optom Assoc** 1999 Apr;70(4):240-4

Increasing sampling density improves reproducibility of optical coherence tomography measurements. Gurses-Ozden R, et al. **J Glaucoma** 1999 Aug;8(4):238-41

Agreement in assessing glaucomatous discs in a clinical teaching setting with stereoscopic disc photographs, planimetry, and laser scanning tomography. Hatch WV, et al. **J Glaucoma** 1999 Apr;8(2):99-104

GLAUCOMA

Glaucoma imaging: technology in progress [editorial] Mills RP. **J Glaucoma** 1999 Apr;8(2):87–9

Correlation of functional and structural measurements in eyes suspected of having glaucoma. Polo V, et al. **J Glaucoma** 1999 Jun;8(3):172–6

Quantitative nerve fiber layer measurement using scanning laser polarimetry and modulation parameters in the detection of glaucoma. Xu L, et al. **J Glaucoma** 1998 Aug; 7(4):270–7

Do non contact tonometers read high? Henson DB, et al. **Ophthalmic Physiol Opt** 1998 May;18(3):308–10

Glaucoma detection rate: a useful concept, to be distinguished from accuracy of referral (positive predictive value) [letter] Tuck MW, et al. **Ophthalmic Physiol Opt** 1998 Nov; 18(6):545–6

Optic nerve head and retinal nerve fiber layer analysis. American Academy of Ophthalmology. **Ophthalmology** 1999 Jul;106(7):1414–24

Heidelberg retina tomography and optical coherence tomography in normal, ocular-hypertensive, and glaucomatous eyes. Mistlberger A, et al. **Ophthalmology** 1999 Oct;106(10):2027–32

Evaluation of focal defects of the nerve fiber layer using optical coherence tomography. Pieroth L, et al. **Ophthalmology** 1999 Mar;106(3):570–9

The changing nature of glaucoma [editorial] Fingeret M, et al. **Optom Vis Sci** 1999 Aug;76(8):515

Glaucoma screening: the importance of combining test data. Harper RA, et al. **Optom Vis Sci** 1999 Aug;76(8):537–43

Glaucoma: diagnosis and management. Infeld DA, et al. **Postgrad Med J** 1998 Dec;74(878):709–15 (41 ref.)

Can the Tono-Pen replace the Schiøtz tonometer in general practice? Christoffersen T, et al. **Scand J Prim Health Care** 1998 Dec;16(4):238–41

Glaucoma update--what physicians and the public need to know. Sim DH. **Singapore Med J** 1999 Apr;40(4):317–20 (26 ref.)

[Modification of color perception during the course if glaucoma] Malbrel C. **J Fr Ophtalmol** 1999 Feb;22(1):57–60 (Eng. Abstr.) **(Fre)**

[Pitfalls in automatic perimetry] Nordmann JP, et al. **J Fr Ophtalmol** 1999 Feb;22(1):84–9 **(Fre)**

[Evaluation of the Humphrey perimetry programs SITA Standard and SITA Fast in normal probands and patients with glaucoma] Nordmann JP, et al. **J Fr Ophtalmol** 1998 Oct;21(8):549–54 (Eng. Abstr.) **(Fre)**

[Measuring intraocular pressure. Pitfalls and limits] Renard JP. **J Fr Ophtalmol** 1999 Feb;22(1):90–3 **(Fre)**

[Comparative study of 2 classifications of glaucomatous perimetric deficits] Risse JF, et al. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):738–42 (Eng. Abstr.) **(Fre)**

[Pitfalls of examining the optic papilla (our determining a papillary excavation] Rouland JF. **J Fr Ophtalmol** 1999 Feb;22(1):94–8 **(Fre)**

[Micro-optic tonometer] Drescher J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:566–7 **(Ger)**

[An eye phantom for calibrating and evaluating tonometers] Lemke K, et al. **Biomed Tech (Berl)** 1998;43 Suppl:112–3 **(Ger)**

[Technical measurement problems in a new procedure for noncontact intraocular pressure measurement] Rothe R, et al. **Biomed Tech (Berl)** 1998;43 Suppl:110–1 **(Ger)**

[2nd Aachen Glaucoma Symposium 1998. Organization and reporting: O. Aarend, M. D.] **Klin Monatsbl Augenheilkd** 1999;215 Suppl 1:1–3 **(Ger)**

[Glaucoma and pregnancy--review of the literature with a case report] Cursiefen C, et al. **Klin Monatsbl Augenheilkd** 1998 Sep;213(3):126–31 (58 ref.) (Eng. Abstr.) **(Ger)**

[Study of the optic papilla and nerve fiber layer in glaucoma] Mojon DS, et al. **Klin Monatsbl Augenheilkd** 1999 May; 214(5):295–9 (Eng. Abstr.) **(Ger)**

[Imaging nerve fiber bundle defects with laser polarimetry in glaucoma. A clinical study with the Nerve Fiber Analyzer I] Serguhn S, et al. **Ophthalmologe** 1999 Jun; 96(6):364–9 (Eng. Abstr.) **(Ger)**

[Evaluation of the Swedish interactive thresholding algorithm, a new thresholding algorithm, of the Humphrey Field Analyzer in glaucoma patients] Inazumi K, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct;102(10):667–72 (Eng. Abstr.) **(Jpn)**

[The effectiveness of glaucomatous visual field test using a size I stimulus] Osako M, et al. **Nippon Ganka Gakkai Zasshi** 1999 Mar;103(3):201–7 (Eng. Abstr.) **(Jpn)**

[The significance and interpretation of the electrophysiological and psychophysiological analyses in the diagnosis of glaucoma] Palacz O, et al. **Klin Oczna** 1998;100(6):407–12 (23 ref.) (Eng. Abstr.) **(Pol)**

[Flash electroretinography and pattern-type visual evoked potentials in early glaucoma] Turno-Kręcicka A, et al. **Klin Oczna** 1998;100(5):285–8 (Eng. Abstr.) **(Pol)**

[Vascular risk factors in glaucoma] Stefan C, et al. **Oftalmologia** 1998;45(4):37–44 (Eng. Abstr.) **(Rum)**

[Contrast and color sensitivity in the diagnosis of glaucoma: neurophysiological aspects] Aref'eva IuA. **Vestn Oftalmol** 1998 Jul-Aug;114(4):49–51 (77 ref.) **(Rus)**

[New concept of glaucoma. Primarily an optic neuropathy, not a disease of the anterior chamber angle] Heijl A. **Lakartidningen** 1999 Apr 7;96(14):1688–91 (22 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

Topical therapies for glaucoma: what family physicians need to know. Lewis PR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1871–9, 1882 (30 ref.)

The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group [see comments] **Am J Ophthalmol** 1998 Oct;126(4):498–505. Comment in: Am J Ophthalmol 1998 Oct;126(4):578–81. Comment in: Am J Ophthalmol 1999 May;127(5):623–5. Comment in: Am J Ophthalmol 1999 May;127(5):625–6.

Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Beck AD, et al. **Am J Ophthalmol** 1998 Nov; 126(5):648–57

The treatment of normal-tension glaucoma [editorial; comment] Caprioli J. **Am J Ophthalmol** 1998 Oct; 126(4):578–81 (21 ref.). Comment on: Am J Ophthalmol 1998 Oct;126(4):487–97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498–505.

Mitomycin C trabeculectomy in eyes with cicatricial conjunctiva. Honjo M, et al. **Am J Ophthalmol** 1998 Dec; 126(6):823–4

Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Yang CB, et al. **Am J Ophthalmol** 1998 Oct;126(4):600–2

Pressure or progression? [letter; comment] Burnstein Y, et al. **Arch Ophthalmol** 1999 Mar;117(3):417–9. Comment on: Arch Ophthalmol 1997 Jul;115(7):847–52.

Marijuana smoking vs cannabinoids for glaucoma therapy [see comments] Green K. **Arch Ophthalmol** 1998 Nov; 116(11):1433–7 (82 ref.). Comment in: Arch Ophthalmol 1998 Nov;116(11):1512–3.

Marijuana and glaucoma [editorial; comment] Kaufman PL. **Arch Ophthalmol** 1998 Nov;116(11):1512–3. Comment on: Arch Ophthalmol 1998 Nov;116(11):1433–7.

A randomized phase II trial of interferon-alpha2b versus 5-fluorouracil after trabeculectomy. Gillies MC, et al. **Aust N Z J Ophthalmol** 1999 Feb;27(1):37–44

Factors associated with use of glaucoma medications in a population of older people: The Blue Mountains Eye Study. Hourihan F, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug; 27(3–4):176–9

Update in glaucoma: the new pharmacotherapies. Latanoprost. Buys YM. **Can J Ophthalmol** 1998 Aug; 33(5):255–7; discussion 257–8

Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine. Crichton AC. **Can J Ophthalmol** 1998 Aug;33(5):254–5; discussion 257–8

Update in glaucoma: the new pharmacotherapies. Dorzolamide hydrochloride. Gould LF. **Can J Ophthalmol** 1998 Aug;33(5):253–4; discussion 257–8

Ocular medications in children. Wallace DK, et al. **Clin Pediatr (Phila)** 1998 Nov;37(11):645–52 (46 ref.)

Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension. Walters TR, et al. **Clin Ther** 1998 Nov-Dec;20(6):1170–8

Prostaglandin analogues in the treatment of glaucoma. Linden C, et al. **Drugs Aging** 1999 May;14(5):387–98 (108 ref.)

Mechanisms of neuroprotection and applications in ocular disease. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S52–81; quiz S82–4 (0 ref.)

Optic nerve degeneration and potential neuroprotection: implications for glaucoma. Schwartz M, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S9–11

Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma [letter] Korsch E, et al. **Eur J Pediatr** 1999 Aug;158(8):685

The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. McKibbin M, et al. **Eye** 1999;13 (Pt 1):31–4

Adjunctive mitomycin C in primary trabeculectomy in young adults: a long-term study of case-matched young patients. Jacobi PC, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):652–7

Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Kobelt G, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):207–19

Adverse events associated with commonly used glaucoma drugs. Vogel R, et al. **Int Ophthalmol Clin** 1999 Spring; 39(2):107–24 (82 ref.)

The effect of mitomycin C on Molteno implant surgery: a 1-year randomized, masked, prospective study. Cantor L, et al. **J Glaucoma** 1998 Aug;7(4):240–6

Trabeculectomy with mitomycin C: intermediate-term results. Perkins TW, et al. **J Glaucoma** 1998 Aug;7(4):230–6

Ginkgo biloba extract increases ocular blood flow velocity. Chung HS, et al. **J Ocul Pharmacol Ther** 1999 Jun; 15(3):233–40

Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. Harris A, et al. **J Ocul Pharmacol Ther** 1999 Jun;15(3):189–97

Relationship between acetazolamide blood concentration and its side effects in glaucomatous patients. Inatani M, et al. **J Ocul Pharmacol Ther** 1999 Apr;15(2):97–105

The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications. Le HH, et al. **J Ocul Pharmacol Ther** 1999 Aug;15(4):305–12

A novel method for controlling the quantity of mitomycin-C applied during filtering surgery for glaucoma. Mehel E, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):491–6

Treatment of ocular hypertension and glaucoma with modified xiaoyao san (ease powder). Li B. **J Tradit Chin Med** 1997 Mar;17(1):44–6

New perspectives in glaucoma. Murphy SD. **Med Health R I** 1999 Feb;82(2):58–61 (7 ref.)

Medical management of glaucoma. Alward WL. **N Engl J Med** 1998 Oct 29;339(18):1298–307 (118 ref.)

A trial of dorzolamide for glaucoma. Gillies WE, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):728–32

Episcleral versus combined episcleral and intrascleral application of mitomycin-C in trabeculectomy. Vass C, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):714–21

Trabeculectomy with long-term-stored mitomycin C in West Indian population. Chen PP, et al. **Ophthalmologica** 1998; 212(6):404–6

The results of trabeculectomy with and without mitomycin C in young patients. Yalvac IS, et al. **Ophthalmologica** 1998; 212(6):399–403

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Shin DH, et al. **Ophthalmology** 1999 Feb; 106(2):386–90

Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. thoe Schwartzenberg GW, et al. **Ophthalmology** 1999 Aug;106(8):1616–20

Augmentation of filtering blebs with perfluoropropane gas bubble: an experimental and pilot clinical study [published erratum appears in Ophthalmology 1999 Aug;106(8):1458] Wong HT, et al. **Ophthalmology** 1999 Mar;106(3):545–9

Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Ponticello GS, et al. **Pharm Biotechnol** 1998;11:555–74 (45 ref.)

Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy. Sponsel WE, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S210–3

Topical timolol therapy in pregnancy: is it safe for the fetus? Wagenvoort AM, et al. **Teratology** 1998 Dec;58(6):258–62

[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost (letter; comment)] Gebhardt DO. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):275. Comment on: Ned Tijdschr Geneeskd 1998 Sep 26;142(39):2138–41. **(Dut)**

[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost (see comments)] Hoyng PF, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2138–41 (27 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):275. **(Dut)**

[Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection] Detry-Morel M. **J Fr Ophtalmol** 1999 Feb;22(1):122–34 (45 ref.) **(Fre)**

[Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe] Levrat F, et al. **J Fr Ophtalmol** 1999 Mar; 22(2):186–91 (Eng. Abstr.) **(Fre)**

[Modern anti-glaucoma drugs and their secondary effects] Mermoud A. **Rev Med Suisse Romande** 1998 Nov; 118(11):937–40 **(Fre)**

[Effect of naftidrofuryl (praxilene) on optic nerve head blood flow in the patient with glaucoma] Achache F, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):260–2 (Eng. Abstr.) **(Ger)**

[Glaucoma therapy with a prostaglandin analogue. Latanoprost--sure indications, safe monotherapy] **Ophthalmologe** 1999 May;96(5 Suppl):1–4 **(Ger)**

[Squamous metaplasia of bulbar conjunctiva in the course of long-term topical antiglaucoma therapy] Wróblewska E. **Klin Oczna** 1999;101(1):41–3 (Eng. Abstr.) **(Pol)**

[Goblet cells density of bulbar conjunctiva after long-term topical antiglaucoma agents] Wróblewska E. **Klin Oczna** 1999;101(1):45–7 (Eng. Abstr.) **(Pol)**

[Schirmer test I and BUT (break-up-time) in patients treated with topical antiglaucoma drugs for a long time] Wróblewska E. **Klin Oczna** 1999;101(1):49–50 (Eng. Abstr.) **(Pol)**

[Efficacy of oral adrenergic beta blockers in the treatment of glaucoma] Bonet S, et al. **Med Clin (Barc)** 1998 Oct 10;111(11):419 **(Spa)**

ECONOMICS

Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom. Kobelt G, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):207–19

ENZYMOLOGY

A novel truncating mutation of cytochrome P4501B1 (CYP1B1) gene in primary infantile glaucoma. Kakiuchi T, et al. **Am J Ophthalmol** 1999 Sep;128(3):370–2

Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Neufeld AH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9944–8

Retinal vulnerability to glutamate excitotoxicity in canine glaucoma: induction of neuronal nitric oxide synthase in retinal ganglion cells. Franco-Bourland RE, et al. **Proc West Pharmacol Soc** 1998;41:201–4

EPIDEMIOLOGY

Glaucoma pattern amongst the elderly Chinese in Singapore. Sim DH, et al. **Ann Acad Med Singapore** 1998 Nov; 27(6):819–23

ETHNOLOGY

Glaucoma drainage implants in Asian eyes. Aung T, et al. **Ophthalmology** 1998 Nov;105(11):2117–22

ETIOLOGY

Malignant glaucoma after diode laser cyclophotocoagulation. Azuara-Blanco A, et al. **Am J Ophthalmol** 1999 Apr; 127(4):467–9

Venous collateral remodeling in a patient with posttraumatic glaucoma. Piltz-Seymour JR, et al. **Am J Ophthalmol** 1999 Jul;128(1):101–3

Developing laser-induced glaucoma in rabbits. Johnson B, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):180–3

Post-penetrating keratoplasty glaucoma: risk factors, management and visual outcome. Sihota R, et al. **Aust N Z J Ophthalmol** 1998 Nov;26(4):305–9

Retrospective analysis of risk factors for late presentation of chronic glaucoma. Fraser S, et al. **Br J Ophthalmol** 1999 Jan;83(1):24–8

Pulsatile ocular blood flow [editorial; comment] James CB. **Br J Ophthalmol** 1998 Jul;82(7):720–1. Comment on: Br J Ophthalmol 1998 Jul;82(7):731–6.

Vasospasm and glaucoma [editorial; comment] O'Brien C. **Br J Ophthalmol** 1998 Aug;82(8):855–6. Comment on: Br J Ophthalmol 1998 Aug;82(8):862–70.

The effect of chronic ischemia on the primate optic nerve. Cioffi GA, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9 Suppl 1:S34–6

Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma. Zhou L, et al. **Int J Mol Med** 1998 Feb; 1(2):339–46

Vascular dysregulation: a principal risk factor for glaucomatous damage? Flammer J, et al. **J Glaucoma** 1999 Jun;8(3):212–9 (112 ref.)

Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. Dkhissi O, et al. **J Neuroendocrinol** 1998 Nov;10(11):863–9

Experimental glaucoma model in the rat induced by laser trabecular photocoagulation after an intracameral injection of India ink. Ueda J, et al. **Jpn J Ophthalmol** 1998 Sep-Oct; 42(5):337–44

Ahmed valve implant for uncontrolled uveitic glaucoma. Gil-Carrasco F, et al. **Ocul Immunol Inflamm** 1998 Mar; 6(1):27–37

Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Honavar SG, et al. **Ophthalmology** 1999 Jan;106(1):169–76; discussion 177

Ocular amyloidosis and secondary glaucoma. Nelson GA, et al. **Ophthalmology** 1999 Jul;106(7):1363–6

[Vascular risk factors associated with glaucoma—a survey of ophthalmologists] Erb C, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):A8–12 **(Ger)**

[Diode laser cyclophotocoagulation of secondary glaucoma caused by anterior, necrotizing scleritis] Schlote T, et al. **Klin Monatsbl Augenheilkd** 1998 Nov;213(5):306–8 (Eng. Abstr.) **(Ger)**

[The excitotoxicity theory of glaucoma] Vorwerk CK, et al. **Klin Monatsbl Augenheilkd** 1999 Jan;214(1):2–11 (102 ref.) (Eng. Abstr.) **(Ger)**

[Periorbital pressure and papilledema.Papilledema, episcleral glaucoma and tinnitus in multiple dura fistulas and sinus thrombosis] Schütt F, et al. **Ophthalmologe** 1998 Dec; 95(12):844–5 **(Ger)**

[Secondary glaucoma in Paraguay. Etiology and incidence] Strohl A, et al. **Ophthalmologe** 1999 Jun;96(6):359–63 (20 ref.) (Eng. Abstr.) **(Ger)**

[Endothelins and nitric oxide: their significance in the regulation of ocular blood flow and intraocular pressure and their role in the pathogenesis of primary glaucoma] Bakshinskii PP. **Vestn Oftalmol** 1999 May-Jun;115(3):33–7 (73 ref.) **(Rus)**

GENETICS

Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Mears AJ, et al. **Am J Hum Genet** 1998 Nov;63(5):1316–28

A novel truncating mutation of cytochrome P4501B1 (CYP1B1) gene in primary infantile glaucoma. Kakiuchi T, et al. **Am J Ophthalmol** 1999 Sep;128(3):370–2

Discordance of primary infantile glaucoma in monozygotic twins. Zhang K, et al. **Am J Ophthalmol** 1999 Jul; 128(1):97–8

Familial occurrence of pseudoexfoliation in Canada. Damji KF, et al. **Can J Ophthalmol** 1999 Aug;34(5):257–65

Glaucoma genetics, present and future. Friedman JS, et al. **Clin Genet** 1999 Feb;55(2):71–9 (62 ref.)

Familial deafness associated with iris degeneration and glaucoma [letter; comment] Booth A. **Eye** 1998;12 (Pt 3a):490–1. Comment on: Eye 1997;11 (Pt 4):476–8.

Histopathological changes in iridocorneal angle of inherited glaucoma in rabbits. Ueno A, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Aug;237(8):654–60

Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Fingert JH, et al. **Hum Mol Genet** 1999 May;8(5):899–905

Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma. Plásilová M, et al. **J Med Genet** 1999 Apr; 36(4):290–4

An orthopaedic scoring system for nail-patella syndrome and application to a kindred with variable expressivity and glaucoma. Farley FA, et al. **J Pediatr Orthop** 1999 Sep-Oct;19(5):624–31

A trabecular meshwork glucocorticoid response (TIGR) gene mutation affects translocational processing. Zimmerman CC, et al. **Mol Vis** 1999 Aug 23;5:19

Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Chang B, et al. **Nat Genet** 1999 Apr; 21(4):405–9

Histopathology and molecular basis of iridogoniodysgenesis syndrome. Pearce WG, et al. **Ophthalmic Genet** 1999 Jun; 20(2):83–8

[Penetrating keratoplasty in primary congenital glaucoma] Marrakchi S, et al. **J Fr Ophtalmol** 1998 Jan;21(1):28–33 (Eng. Abstr.) **(Fre)**

[Systemic side-effects of latanoprost in a child with aniridia and glaucoma] Schmidtborn F. **Ophthalmologe** 1998 Sep; 95(9):633–4 (Eng. Abstr.) **(Ger)**

[Discovering phenomena leading to the death of retinal ganglion cells in glaucoma: the aim of ophthalmology at the end of the 20th century. (The report introducing the 1st Glaucoma Symposium organized by Glaucoma Section of POS -- Wroclaw, April 17-18, 1998)] Niżankowska MH. **Klin Oczna** 1998;100(6):413–5 **(Pol)**

[Molecular diagnosis of mutations responsible for recurrent and severe forms of primary congenital glaucoma] Plášilová M, et al. **Cesk Slov Oftalmol** 1998;54(5):281–8 (Eng. Abstr.) **(Slo)**

HISTORY

What is glaucoma? Ramanathan S, et al. **Perspect Biol Med** 1998 Autumn;42(1):8–13 (17 ref.)

[Wolfgang Stock, his ophthalmopathologic collection and progress in glaucoma treatment in the 2nd half of the 20th century] Rohrbach JM, et al. **Klin Monatsbl Augenheilkd** 1998 Aug;213(2):87–92 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Epitope mapping of anti-rhodopsin antibodies from patients with normal pressure glaucoma. Romano C, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1275–80

METABOLISM

Effect of ticrynafen on aqueous humor dynamics in monkeys. Croft MA, et al. **Arch Ophthalmol** 1998 Nov;116(11):1481–8

Sialyl Lewis X, Lewis X, and N-acetyllactosamine expression on normal and glaucomatous eyes. Terraciano AJ, et al. **Curr Eye Res** 1999 Feb;18(2):73–8

Glutamate receptor subunit GluR2 and NMDAR1 immunoreactivity in the retina of macaque monkeys with experimental glaucoma does not identify vulnerable neurons. Hof PR, et al. **Exp Neurol** 1998 Oct;153(2):234–41

Immunohistochemical distribution of type VI collagen in normal and glaucomatous human trabecular meshwork. Dietlein TS, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Aug;236(8):597–601

Quantification of intraoperative administration of mitomycin-C in filtering surgery with surgical sponge material. Larrosa JM, et al. **J Glaucoma** 1999 Feb;8(1):46–50

A trabecular meshwork glucocorticoid response (TIGR) gene mutation affects translocational processing. Zimmerman CC, et al. **Mol Vis** 1999 Aug 23;5:19

Laminin heterogeneity around Schlemm's canal in normal humans and glaucoma patients. Dietlein TS, et al. **Ophthalmic Res** 1998;30(6):380–7

Non-destructive analysis of the conformational changes in human lens lipid and protein structures of the immature cataracts associated with glaucoma [letter] Lin SY, et al. **Spectrochim Acta A Mol Biomol Spectrosc** 1998 Sep; 54A(10):1509–17

Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Neufeld AH. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S129–35 (54 ref.)

An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Vorwerk CK, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S142–50 (98 ref.)

[Mitomycin C concentrations in rabbit ocular tissues after topical administration during glaucoma filtration surgery] Xia X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(4):307–9 (Eng. Abstr.) **(Chi)**

[Changes in transforming growth factor-beta and platelet-derived growth factor in the optic nerve head in monkey experimental glaucoma] Fukuchi T, et al. **Nippon Ganka Gakkai Zasshi** 1999 Mar;103(3):193–200 (Eng. Abstr.) **(Jpn)**

NURSING

Working with glaucoma patients - prospects for "shared care". Martin LM. **Acta Ophthalmol Scand** 1999 Feb; 77(1):103–6

PATHOLOGY

Glaucoma, apoptosis, death, and life. Spaeth GL. **Acta Ophthalmol Scand Suppl** 1998;(227):9–15 (79 ref.)

Deviant axons and glaucomatous damage [editorial; comment] Caprioli J. **Br J Ophthalmol** 1998 Jun;82(6):595–6 Comment on: Br J Ophthalmol 1998 Jun;82(6):680–3.

Measurement of optic disc size: equivalence of methods to correct for ocular magnification [see comments] Garway-Heath DF, et al. **Br J Ophthalmol** 1998 Jun; 82(6):643–9. Comment in: Br J Ophthalmol 1999 Feb;83(2):252.

Vertical cup/disc ratio in relation to optic disc size: its value in the assessment of the glaucoma suspect. Garway-Heath DF, et al. **Br J Ophthalmol** 1998 Oct;82(10):1118–24

Sources of bias in studies of optic disc and retinal nerve fibre layer morphology. Garway-Heath DF, et al. **Br J Ophthalmol** 1998 Sep;82(9):986

RA/DA cumulative curve analysis of local and diffuse neuroretinal rim area damage in glaucoma patients. Rolando M, et al. **Br J Ophthalmol** 1998 Jul;82(7):769–72

Measurement of retinal nerve fibre layer by scanning laser polarimetry and high pass resolution perimetry in normal tension glaucoma with relatively high or low intraocular pressure. Shirakashi M, et al. **Br J Ophthalmol** 1999 Mar; 83(3):353–7

Collagen fibrillar network in the optic nerve head of normal monkey eyes and monkey eyes with laser-induced glaucoma--a scanning electron microscopic study. Sawaguchi S, et al. **Curr Eye Res** 1999 Feb;18(2):143–9

Histopathological changes in iridocorneal angle of inherited glaucoma in rabbits. Ueno A, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Aug;237(8):654–60

Morphologic changes in chronic high-pressure experimental glaucoma in rhesus monkeys. Hayreh SS, et al. **J Glaucoma** 1999 Feb;8(1):56–71

Reversal of optic disc topography in patients with glaucomatocyclitic crisis after remission of attack. Park KH, et al. **J Glaucoma** 1998 Aug;7(4):225–9

Histomorphometric analysis of optic nerve changes in experimental glaucoma. Yücel YH, et al. **J Glaucoma** 1999 Feb;8(1):38–45

Diode laser cyclophotocoagulation: histopathology in two cases of clinical failure. Walland MJ, et al. **Ophthalmic Surg Lasers** 1998 Oct;29(10):852–6

New technologies for diagnosing and monitoring glaucomatous optic neuropathy. Zangwill LM, et al. **Optom Vis Sci** 1999 Aug;76(8):526–36

Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Nickells RW. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S151–61 (94 ref.)

[Pachymetry in patients with glaucoma] Hornová J, et al. **Cesk Slov Oftalmol** 1999 Jul;55(4):212–5 (Eng. Abstr.) **(Cze)**

[Morphometry of the optic disc in Togolese patients with glaucoma or suspected glaucoma. Preliminary study] Balo KP, et al. **J Fr Ophtalmol** 1998 May;21(5):328–32 (Eng. Abstr.) **(Fre)**

[Localization by immunogold of collagen VI, laminin and fibrillin in the trabecular meshwork of patients with glaucoma] Delaigue O, et al. **J Fr Ophtalmol** 1999 Feb; 22(1):61–6 (Eng. Abstr.) **(Fre)**

[The excitotoxicity theory of glaucoma] Vorwerk CK, et al. **Klin Monatsbl Augenheilkd** 1999 Jan;214(1):2–11 (102 ref.) (Eng. Abstr.) **(Ger)**

[Morphometric features in the lamina cribrosa observed by a scanning laser ophthalmoscope] Maeda H, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jan;103(1):48–55 (Eng. Abstr.) **(Jpn)**

[Neuronal cell death mechanism in glaucomatous optic neuropathy] Murakami A, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct;102(10):645–53 (85 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group [see comments] [published erratum appears in Am J Ophthalmol 1999 Jan;127(1):120] **Am J Ophthalmol** 1998 Oct;126(4):487–97. Comment in: Am J Ophthalmol 1998 Oct;126(4):578–81. Comment in: Am J Ophthalmol 1999 May;127(5):623–5. Comment in: Am J Ophthalmol 1999 May;127(5):625–6.

Severity and stability of glaucoma: patient perception compared with objective measurement. Viswanathan AC, et al. **Arch Ophthalmol** 1999 Apr;117(4):450–4

Effects of short term increase of intraocular pressure on optic disc cupping. Azuara-Blanco A, et al. **Br J Ophthalmol** 1998 Aug;82(8):880–3

Peripapillary retinal blood flow in normal tension glaucoma. Chung HS, et al. **Br J Ophthalmol** 1999 Apr;83(4):466–9

Simulating binocular visual field status in glaucoma. Crabb DP, et al. **Br J Ophthalmol** 1998 Nov;82(11):1236–41

Pulsatile ocular blood flow investigation in asymmetric normal tension glaucoma and normal subjects [see comments] Fontana L, et al. **Br J Ophthalmol** 1998 Jul; 82(7):731–6. Comment in: Br J Ophthalmol 1998 Jul;82(7):720–1.

Visual field progression in glaucoma [letter; comment] Heijl

A, et al. **Br J Ophthalmol** 1998 Sep;82(9):1097–8. Comment on: Br J Ophthalmol 1997 Dec;81(12):1037–42.

Apoptotic mechanisms in neurodegeneration: possible relevance to glaucoma. Tatton WG. **Eur J Ophthalmol** 1999 Jan–Mar;9 Suppl 1:S22–9 (52 ref.)

Central and peripheral arteriovenous passage times of the retina in glaucoma. Duijm HF, et al. **Exp Eye Res** 1999 Aug;69(2):145–53

The correlation of the visual field with scanning laser ophthalmoscope measurements in glaucoma. Tole DM, et al. **Eye** 1998;12 (Pt 4):686–90

Psychological characteristics of patients with normal–tension glaucoma. Erb C, et al.
Graefes Arch Clin Exp Ophthalmol 1999 Sep;237(9):753–7

Epitope mapping of anti–rhodopsin antibodies from patients with normal pressure glaucoma. Romano C, et al.
Invest Ophthalmol Vis Sci 1999 May;40(6):1275–80

Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects. Tomita K, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1144–51

The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Viswanathan S, et al. **Invest Ophthalmol Vis Sci** 1999 May; 40(6):1124–36

A frequency–doubling perimetric study in normal–tension glaucoma with hemifield defect. Kondo Y, et al.
J Glaucoma 1998 Aug;7(4):261–5

Comparison of 24–2 and 30–2 perimetry in glaucomatous and nonglaucomatous optic neuropathies. Khoury JM, et al. **J Neuroophthalmol** 1999 Jun;19(2):100–8

Trabeculectomy function after cataract extraction. Chen PP, et al. **Ophthalmology** 1998 Oct;105(10):1928–35

Progressive visual field defects from experimental glaucoma: measurements with white and colored stimuli. Harwerth RS, et al. **Optom Vis Sci** 1999 Aug;76(8):558–70

Frequency doubling technology perimetry using a 24–-2 stimulus presentation pattern. Johnson CA, et al.
Optom Vis Sci 1999 Aug;76(8):571–81

Normal–tension glaucoma and central corneal thickness. Peplinski L, et al. **Optom Vis Sci** 1999 Aug;76(8):596–8

Neuronal death in glaucoma. Quigley HA.
Prog Retin Eye Res 1999 Jan;18(1):39–57 (87 ref.)

Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. Anderson DR. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S5–9 (27 ref.)

Systemic and ocular vascular roles of the antiglaucoma agents beta–adrenergic antagonists and Ca2+ entry blockers. Yu DY, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S214–22 (82 ref.)

Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Mills RP.
Trans Am Ophthalmol Soc 1998;96:753–812

[Color Doppler imaging analysis of ocular hemodynamics in low–tension glaucoma] Fu J, et al.
Chung Hua Yen Ko Tsa Chih 1997 Mar;33(2):96–9 (Eng. Abstr.) **(Chi)**

[Contrast sensitivity in glaucoma and ocular hypertension] Liška V, et al. **Cesk Slov Oftalmol** 1998 Nov;54(6):373–82 (Eng. Abstr.) **(Cze)**

[Vascular risk factors associated with glaucoma–-a survey of ophthalmologists] Erb C, et al.
Klin Monatsbl Augenheilkd 1999 Mar;214(3):A8–12 **(Ger)**

[Twenty–year follow–up of visual field defects in primary glaucoma eyes] Kozaki J, et al.
Nippon Ganka Gakkai Zasshi 1999 Jan;103(1):18–25 (Eng. Abstr.) **(Jpn)**

[Association between watershed zone and visual field defect in normal tension glaucoma] Sato Y, et al.
Nippon Ganka Gakkai Zasshi 1998 Aug;102(8):502–8 (Eng. Abstr.) **(Jpn)**

[Intraocular circulation in glaucoma] Krasnov MM.
Vestn Oftalmol 1998 Sep–Oct;114(5):5–7 **(Rus)**

PREVENTION & CONTROL

Goniosurgery for prevention of aniridic glaucoma. Chen TC, et al. **Arch Ophthalmol** 1999 Sep;117(9):1144–8

A traumatic "peripheral iridotomy" protects against pigment dispersion and glaucoma [letter] Shuttleworth GN.
Br J Ophthalmol 1999 Mar;83(3):376

Goniosurgery for prevention of aniridic glaucoma. Chen TC, et al. **Trans Am Ophthalmol Soc** 1998;96:155–65; discussion 165–9

PSYCHOLOGY

Glaucoma and quality of the life. Perfetti S, et al.
Acta Ophthalmol Scand Suppl 1998;(227):52

Psychological characteristics of patients with normal–tension glaucoma. Erb C, et al.
Graefes Arch Clin Exp Ophthalmol 1999 Sep;237(9):753–7

Glaucoma and quality–of–life [letter; comment] Bunce C, et al. **Ophthalmology** 1999 Mar;106(3):440. Comment on: Ophthalmology 1998 Mar;105(3):561–6.

[The patient with glaucoma and his treatment: is there real perception?] Naacke H, et al. **J Fr Ophtalmol** 1999 Feb; 22(1):99–101 (16 ref.) **(Fre)**

REHABILITATION

A new device for ocular massage after trabeculectomy [letter] Quaranta L. **Acta Ophthalmol Scand** 1999 Jun;77(3):355–6

[Intraocular pressure self–monitoring in glaucoma patients (news)] Draeger J. **Klin Monatsbl Augenheilkd** 1998 Jul; 213(1):aA9 **(Ger)**

[The glaucoma work group–-an initiative of the Tübingen University Eye Clinic] Erb C, et al.
Klin Monatsbl Augenheilkd 1998 Jul;213(1):aA6–8 **(Ger)**

SURGERY

Postoperative systemic corticosteroid treatment and Molteno implant surgery: a randomized clinical trial. Välimäki J, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):50–6

Viscocanalostomy: a pilot study. Carassa RG, et al.
Acta Ophthalmol Scand Suppl 1998;(227):51–2

Cyclosporine C: a study of wound–healing modulation after trabeculectomy in rabbit. Nuzzi R, et al.
Acta Ophthalmol Scand Suppl 1998;(227):48–9

Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Beck AD, et al. **Am J Ophthalmol** 1998 Nov; 126(5):648–57

The Ahmed valve in refractory pediatric glaucoma. Englert JA, et al. **Am J Ophthalmol** 1999 Jan;127(1):34–42

Mitomycin C trabeculectomy in eyes with cicatricial conjunctiva. Honjo M, et al. **Am J Ophthalmol** 1998 Dec; 126(6):823–4

Intermediate–term clinical experience with the Ahmed Glaucoma Valve implant. Huang MC, et al.
Am J Ophthalmol 1999 Jan;127(1):27–33

Mini–trabeculectomy without radial incisions. Ophir A.
Am J Ophthalmol 1999 Feb;127(2):212–3

Ciliary body endophotocoagulation during pars plana vitrectomy for pediatric patients with vitreoretinal disorders and glaucoma. Sears JE, et al.
Am J Ophthalmol 1998 Nov;126(5):723–5

Follow–up of the original cohort with the Ahmed glaucoma valve implant. Topouzis F, et al. **Am J Ophthalmol** 1999 Aug;128(2):198–204

A clinical comparison of transscleral cyclophotocoagulation with neodymium: YAG and semiconductor diode lasers. Youn J, et al. **Am J Ophthalmol** 1998 Nov;126(5):640–7

Conjunctival advancement for late–onset filtering bleb leaks: indications and outcomes. Budenz DL, et al.
Arch Ophthalmol 1999 Aug;117(8):1014–9

Reaffirming the role of the laser in glaucoma management [editorial] Higginbotham EJ. **Arch Ophthalmol** 1999 Aug; 117(8):1075–6 (13 ref.)

Combined trabeculotomy and trabeculectomy as an initial procedure in uncomplicated congenital glaucoma. Mullaney PB, et al. **Arch Ophthalmol** 1999 Apr; 117(4):457–60

A randomized phase II trial of interferon–alpha2b versus 5–fluorouracil after trabeculectomy. Gillies MC, et al.
Aust N Z J Ophthalmol 1999 Feb;27(1):37–44

Trabeculectomy survival with and without intra–operative 5–fluorouracil application in an Asian population. Wong JS, et al. **Aust N Z J Ophthalmol** 1998 Nov;26(4):283–8

Filtration procedures supplemented with mitomycin C in the management of childhood glaucoma. Azuara–Blanco A, et al. **Br J Ophthalmol** 1999 Feb;83(2):151–6

Prognosis of primary ab externo surgery for primary congenital glaucoma. Dietlein TS, et al.
Br J Ophthalmol 1999 Mar;83(3):317–22

Pars plana vitrectomy with pars plana tube implantation in eyes with intractable glaucoma. Kaynak S, et al.
Br J Ophthalmol 1998 Dec;82(12):1377–82

"New" surgical treatments for glaucoma [editorial; comment] Khaw PT, et al. **Br J Ophthalmol** 1999 Jan;83(1):1–2. Comment on: Br J Ophthalmol 1999 Jan;83(1):6–11.

Suramin inhibits wound healing following filtering procedures for glaucoma. Mietz H, et al.
Br J Ophthalmol 1998 Jul;82(7):816–20

"Cyclodiode": results of a standard protocol. Spencer AF, et al. **Br J Ophthalmol** 1999 Mar;83(3):311–6

Diode laser cyclophotocoagulation in refractory glaucoma. Linsen MC, et al. **Bull Soc Belge Ophtalmol** 1998;270:69–73

The long–term effect of Yag laser posterior capsulotomy on intraocular pressure after combined glaucoma and cataract surgery. Zeyen P, et al. **Bull Soc Belge Ophtalmol** 1999; 271:99–103

Short–term clinical study on a new aqueous humor drainage implant for refractory glaucoma. Duan X, et al.
Chin Med J (Engl) 1997 Nov;110(11):879–82

Results of trabeculotomy and guarded filtration procedure for glaucoma associated with Sturge–Weber syndrome. Irkeç M, et al. **Eur J Ophthalmol** 1999 Apr–Jun;9(2):99–102

Long–term follow–up of Molteno drains used in the treatment of glaucoma presenting in childhood. Cunliffe IA, et al. **Eye** 1998;12 (Pt 3a):379–85

Adjunctive mitomycin C in primary trabeculectomy in young adults: a long–term study of case–matched young patients. Jacobi PC, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):652–7

Effect of mitomycin C on aqueous humor flow, flare and intraocular pressure in eyes with glaucoma 2 years after trabeculectomy. Ustundag C, et al.
Graefes Arch Clin Exp Ophthalmol 1998 Oct;236(10):734–8

Diode laser transscleral cyclophotocoagulation. Chen TC, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):169–76 (32 ref.)

Advances in aqueous shunting procedures. Leuenberger EU, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):139–53 (79 ref.)

Long–term evaluation of initial filtration surgery. Wang WQ, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):133–8

Human anti–transforming growth factor–beta2 antibody: a new glaucoma anti–scarring agent. Cordeiro MF, et al.
Invest Ophthalmol Vis Sci 1999 Sep;40(10):2225–34

Intermediate–term results of endoscopic diode laser cyclophotocoagulation for pediatric glaucoma. Plager DA, et al. **J Aapos** 1999 Jun;3(3):131–7

Novel synthetic meshwork for glaucoma treatment. I. Design and preliminary in vitro and in vivo evaluation of various expanded poly(tetrafluoroethylene) materials. Jallet V, et al. **J Biomed Mater Res** 1999 Nov;47(2):260–9

Combined cataract and glaucoma surgery: trabeculectomy versus endoscopic laser cycloablation. Gayton JL, et al.
J Cataract Refract Surg 1999 Sep;25(9):1214–9

Combined surgery for severe eye trauma with extensive iridodialysis, posterior lens dislocation, and intractable glaucoma. Lam DS, et al. **J Cataract Refract Surg** 1999 Feb;25(2):285–8

One–site versus 2–site phacotrabeculectomy: a randomized study. el Sayyad F, et al. **J Cataract Refract Surg** 1999 Jan;25(1):77–82

Reticulated hyaluronic acid implant in nonperforating trabecular surgery [see comments] Sourdille P, et al.
J Cataract Refract Surg 1999 Mar;25(3):332–9. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.

The effect of mitomycin C on Molteno implant surgery: a 1–year randomized, masked, prospective study. Cantor L, et al. **J Glaucoma** 1998 Aug;7(4):240–6

Mitomycin–C in combined or two–stage procedure trabeculectomy followed by penetrating keratoplasty. Chowers I, et al. **J Glaucoma** 1999 Jun;8(3):184–7

Glaucoma surgery in the patient undergoing anticoagulation [clinical conference] Jampel H. **J Glaucoma** 1998 Aug; 7(4):278–81

The imposter of Seidel [editorial] Katz SE, et al.
J Glaucoma 1998 Aug;7(4):223–4

Trabeculectomy with mitomycin C: intermediate–term results. Perkins TW, et al. **J Glaucoma** 1998 Aug;7(4):230–6

Audible pops during cyclodiode procedures. Rebolleda G, et al. **J Glaucoma** 1999 Jun;8(3):177–83

Contact transscleral diode cyclophotocoagulation for refractory glaucoma. Threlkeld AB, et al. **J Glaucoma** 1999 Feb;8(1):3–7

Intraocular pressure control after contact transscleral diode cyclophotocoagulation in eyes with intractable glaucoma. Yap–Veloso MI, et al. **J Glaucoma** 1998 Oct;7(5):319–28

Late–onset, bleb–associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. Solomon A, et al. **J Ocul Pharmacol Ther** 1999 Aug;15(4):283–93

Long–term results of trabeculectomy for congenital glaucoma [see comments] Dureau P, et al.
J Pediatr Ophthalmol Strabismus 1998 Jul–Aug; 35(4):198–202. Comment in: J Pediatr Ophthalmol Strabismus 1998 Jul–Aug;35(4):192.

Glaucoma and other "headaches" [editorial; comment] Wagner RS, et al. **J Pediatr Ophthalmol Strabismus** 1998 Jul–Aug;35(4):192. Comment on: J Pediatr Ophthalmol Strabismus 1998 Jul–Aug;35(4):198–202. Comment on: J Pediatr Ophthalmol Strabismus 1998 Jul–Aug;35(4):203–8; quiz 227–8.

Subconjunctival silicone oil drainage through the Molteno implant. Hyung SM, et al. **Korean J Ophthalmol** 1998 Jun; 12(1):73–5

New perspectives in glaucoma. Murphy SD.
Med Health R I 1999 Feb;82(2):58–61 (7 ref.)

Understanding and controlling the scarring response: the contribution of histology and microscopy. Daniels JT, et al. **Microsc Res Tech** 1998 Sep 1;42(5):317–33 (60 ref.)

Ahmed valve implant for uncontrolled uveitic glaucoma. Gil–Carrasco F, et al. **Ocul Immunol Inflamm** 1998 Mar; 6(1):27–37

Circumferential perilimbal anesthesia for combined cataract glaucoma surgery. Anderson CJ.
Ophthalmic Surg Lasers 1999 Mar;30(3):205–7

Oral prednisone in guarded filtration procedures supplemented with antimetabolites. Azuara–Blanco A, et al. **Ophthalmic Surg Lasers** 1999 Feb;30(2):126–32

Acquired Pseudo–Brown's syndrome immediately following Ahmed valve glaucoma implant. Coats DK, et al.
Ophthalmic Surg Lasers 1999 May;30(5):396–7

Combined phacoemulsification and trabeculectomy versus trabeculectomy alone: a comparison study using mitomycin–C. Derick RJ, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):707–13

Rapid preparation of small–volume autologous fibrinogen concentrate and its same day use in bleb leaks after glaucoma filtration surgery. Gammon RR, et al.
Ophthalmic Surg Lasers 1998 Dec;29(12):1010–2

Surgical results and complications of mitomycin C–augmented trabeculectomy in refractory developmental glaucoma. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 Jun;30(6):473–80

Nd:Yag goniopuncture after deep sclerectomy with collagen implant. Mermoud A, et al. **Ophthalmic Surg Lasers** 1999 Feb;30(2):120–5

A slit–lamp needling filtration procedure for uncontrolled glaucoma in pseudophakic and aphakic eyes. Mistlberger A, et al. **Ophthalmic Surg Lasers** 1999 Mar;30(3):237–40

Combined cyclodialysis and cataract surgery. Rowan PJ.
Ophthalmic Surg Lasers 1998 Dec;29(12):962–8

Use of viscoelastics post–trabeculectomy: a survey of

members of the American Glaucoma Society. Salvo EC Jr, et al. **Ophthalmic Surg Lasers** 1999 Apr;30(4):271–5
Surgical revision of glaucoma shunt implants. Tsai JC, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):41–6
Episcleral versus combined episcleral and intrascleral application of mitomycin-C in trabeculectomy. Vass C, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):714–21
Trabeculectomy with long-term-stored mitomycin C in West Indian population. Chen PP, et al. **Ophthalmologica** 1998; 212(6):404–6
A major review of antimetabolites in glaucoma therapy. Loon SC, et al. **Ophthalmologica** 1999;213(4):234–45 (117 ref.)
The results of trabeculectomy with and without mitomycin C in young patients. Yalvac IS, et al. **Ophthalmologica** 1998; 212(6):399–403
Glaucoma drainage implants in Asian eyes. Aung T, et al. **Ophthalmology** 1998 Nov;105(11):2117–22
A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ayyala RS, et al. **Ophthalmology** 1998 Oct;105(10):1968–76
Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery. al-Hazmi A, et al. **Ophthalmology** 1998 Oct;105(10):1915–20
Long-term outcome of aqueous shunt surgery in ten patients with iridocorneal endothelial syndrome. Kim DK, et al. **Ophthalmology** 1999 May;106(5):1030–4
The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. Lewis R, et al. **Ophthalmology** 1998 Dec;105(12):2256–9
Primary combined trabeculotomy-trabeculectomy for early-onset glaucoma in Sturge-Weber syndrome. Mandal AK. **Ophthalmology** 1999 Aug;106(8):1621–7
Cyclophotocoagulation for glaucoma after penetrating keratoplasty [letter; comment] Muñoz FJ, et al. **Ophthalmology** 1999 Apr;106(4):644–5. Comment on: Ophthalmology 1998 Aug;105(8):1550–6.
The comparative benefits of glaucoma filtering surgery with an electric-pulse targeted drug delivery system demonstrated in an animal model. Oshima Y, et al. **Ophthalmology** 1999 Jun;106(6):1140–6
Location of glaucoma drainage devices (addendum to previous report) [letter; comment] Read RW, et al. **Ophthalmology** 1998 Nov;105(11):1977. Comment on: Ophthalmology 1996 Feb;103(2):299–305.
Modified aqueous drainage implants in the treatment of complicated glaucomas in eyes with pre-existing episcleral bands. Smith MF, et al. **Ophthalmology** 1998 Dec; 105(12):2237–42
Factors associated with elevated rates of adverse outcomes after cyclodestructive procedures versus drainage device procedures. Topouzis F, et al. **Ophthalmology** 1998 Dec; 105(12):2276–81
Longitudinal changes in optic disc topography of adult patients after trabeculectomy. Topouzis F, et al. **Ophthalmology** 1999 Jun;106(6):1147–51
Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Trible JR, et al. **Ophthalmology** 1998 Dec;105(12):2243–50
Long-term outcome of cyclocryotherapy for refractory pediatric glaucoma. Wagle NS, et al. **Ophthalmology** 1998 Oct;105(10):1921–6; discussion 1926–7
Neodymium: YAG transconjunctival laser revision of late-failing filtering blebs. Weber PA, et al. **Ophthalmology** 1999 Oct;106(10):2023–6
Augmentation of filtering blebs with perfluoropropane gas bubble: an experimental and pilot clinical study [published erratum appears in Ophthalmology 1999 Aug;106(8):1458] Wong HT, et al. **Ophthalmology** 1999 Mar;106(3):545–9
Combined penetrating keratoplasty and trabeculectomy with mitomycin C. WuDunn D, et al. **Ophthalmology** 1999 Feb; 106(2):396–400
Clinical study of combined penetrating keratoplasty, pars plana vitrectomy with temporary keratoprosthesis, and pars plana seton implant. Johnston RH, et al. **Retina** 1999; 19(2):116–21
Dysfunctional filtering blebs. Azuara-Blanco A, et al. **Surv Ophthalmol** 1998 Sep-Oct;43(2):93–126 (291 ref.)
Control of intraocular pressure after trabeculectomy. Haynes WL, et al. **Surv Ophthalmol** 1999 Jan-Feb;43(4):345–55 (82 ref.)
[A short-term clinical study on a new aqueous humor drainage implant for refractory glaucoma] Duan X, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Mar;33(2):121–4 (Eng. Abstr.) **(Chi)**
[Treatment of congenital glaucoma with trabeculotomy] Kong L, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May; 33(3):169–72 (Eng. Abstr.) **(Chi)**
[Initial clinical experience with deep sclerectomy in ambulatory surgery in glaucoma] Pitrová S, et al. **Cesk Slov Oftalmol** 1999 Jan;55(1):3–9 (Eng. Abstr.) **(Cze)**
[Glaucoma and cataract--surgery at two times] Collignon-Brach J. **Bull Soc Belge Ophtalmol** 1998; 268:61–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Combined interventions: cataract and glaucoma review of the literature] Detry-Morel M. **Bull Soc Belge Ophtalmol** 1998;268:45–60 (77 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of refractory glaucoma with trans-scleral cyclo-photocoagulation using a Diode laser] Detry-Morel M, et al. **Bull Soc Belge Ophtalmol** 1999;272:45–52 (Eng. Abstr.) **(Fre)**
[Deep non-perforating sclerectomy: a bad name for good surgery] Baudouin C. **J Fr Ophtalmol** 1999 Aug-Sep; 22(7):780 **(Fre)**
[External trabeculectomy with aspiration: surgical technique] Béchetoille A. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):787–90 **(Fre)**
[Non-perforating external sclero-trabeculectomy] Demailly P, et al. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):791–3 **(Fre)**
[Deep sclerectomy: surgical technique] Mermoud A. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):781–6 **(Fre)**
[Non-perforating surgery of the trabeculum with reticulated hyaluronic acid implant: why, how, what results?] Sourdille P, et al. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):794–7 **(Fre)**
[Value of tenonectomy at the time of trabeculectomy in Africa] Schemann JF, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1996;73:89–99 **(Fre)**
[Prognostic value of anterior chamber hemorrhage following glaucoma filtering surgery] Denk PO, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):156–9 (Eng. Abstr.) **(Ger)**
[Cyclocryotherapy in neovascular glaucoma and non-neovascular glaucoma] Heuring AH, et al. **Klin Monatsbl Augenheilkd** 1998 Oct;213(4):213–9 (Eng. Abstr.) **(Ger)**
[Wound healing after glaucoma filtering surgery--a review] Knorr M, et al. **Klin Monatsbl Augenheilkd** 1999 Mar; 214(3):147–55 (79 ref.) (Eng. Abstr.) **(Ger)**
[Risk factors for trabeculectomy failure] Koller TL, et al. **Klin Monatsbl Augenheilkd** 1998 Jul;213(1):1–8 (Eng. Abstr.) **(Ger)**
[Cyclocryocoagulation in treatment of therapy refractory glaucoma: a retrospective analysis of 185 cryocoagulation procedures] Nicaeus T, et al. **Klin Monatsbl Augenheilkd** 1999 Apr;214(4):224–30 (Eng. Abstr.) **(Ger)**
[Combined cataract and glaucoma surgery] Diestelhorst M. **Ophthalmologe** 1999 Jan;96(1):54–69 (36 ref.) **(Ger)**
[Intraocular pressure regulation after combined glaucoma and cataract operation] Dittmer K, et al. **Ophthalmologe** 1998 Jul;95(7):499–503 (Eng. Abstr.) **(Ger)**
[Posterior synechiae after Nd:YAG laser iridotomy. A clinical study] Kraemer C, et al. **Ophthalmologe** 1998 Sep; 95(9):625–32 (Eng. Abstr.) **(Ger)**
[Controlled cyclophotocoagulation] Preussner PR. **Ophthalmologe** 1998 Sep;95(9):645–50 (Eng. Abstr.) **(Ger)**
[Trabeculotomy, deep sclerectomy and viscocanalostomy. Non-fistulating microsurgical glaucoma operation ab externo] Schwenn O, et al. **Ophthalmologe** 1998 Dec; 95(12):835–43 (30 ref.) (Eng. Abstr.) **(Ger)**
[Diode laser trans-scleral cyclo-photo-coagulation] Mańkowska A, et al. **Klin Oczna** 1999;101(2):103–4 (Eng. Abstr.) **(Pol)**
[Surgical stimulation of uveoscleral discharge in primary glaucoma] Kornilaeva GG. **Vestn Oftalmol** 1999 Jan-Feb; 115(1):34–5 (30 ref.) **(Rus)**
[The surgical treatment of normotensive glaucoma] Shmyreva VF, et al. **Vestn Oftalmol** 1998 Sep-Oct; 114(5):7–10 (Eng. Abstr.) **(Rus)**

THERAPY

Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Liesegang TJ. **Cornea** 1998 Nov; 17(6):574–83 (88 ref.)
Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow. Relevance for potential gene therapy of glaucoma. Borrás T, et al. **Gene Ther** 1999 Apr;6(4):515–24
Managing the steroid responder [letter; comment] Seiler T, et al. **J Cataract Refract Surg** 1998 Nov;24(11):1420–1. Comment on: J Cataract Refract Surg 1998 May;24(5):715–8.
A comparative study of the chemical stability of various mitomycin C solutions used in glaucoma filtering surgery. Francoeur AM, et al. **J Glaucoma** 1999 Aug;8(4):242–6
Management of congenital glaucoma [clinical conference] Khaw PT, et al. **J Glaucoma** 1999 Feb;8(1):81–5
Steroid-induced glaucoma in a young woman. Wax M. **J Glaucoma** 1998 Oct;7(5):353–8
First, do no harm? [editorial] Spaeth GL. **Ophthalmic Surg Lasers** 1999 Mar;30(3):173–5
Diode laser cyclophotocoagulation: histopathology in two cases of clinical failure. Walland MJ, et al. **Ophthalmic Surg Lasers** 1998 Oct;29(10):852–6
Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Katz J. **Ophthalmology** 1999 Feb;106(2):391–5
Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. Kosoko O, et al. **Ophthalmology** 1998 Nov;105(11):2105–11
The changing nature of glaucoma [editorial] Fingeret M, et al. **Optom Vis Sci** 1999 Aug;76(8):515
GP management of glaucoma. Fraser S, et al. **Practitioner** 1998 Dec;242(1593):855–8 (3 ref.)
A perspective of gene therapy in the glaucomas. Kaufman PL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S91–7
Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Levin LA. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S98–101 (26 ref.)
[Clinical and basic study on glaucoma (editorial)] Zhao J. **Chung Hua Yen Ko Tsa Chih** 1997 May;33(3):163–4 **(Chi)**
[Times change, does glaucoma also change over time? (editorial)] Mehrle G. **Klin Monatsbl Augenheilkd** 1998 Jul; 213(1):aA5 **(Ger)**
[Diode laser cyclophotocoagulation of secondary glaucoma caused by anterior, necrotizing scleritis] Schlote T, et al. **Klin Monatsbl Augenheilkd** 1998 Nov;213(5):306–8 (Eng. Abstr.) **(Ger)**
["The Umeå case" and the significance of scientific evidence. Uncertain effect of reduced ocular pressure in glaucoma] Orn P. **Lakartidningen** 1998 Oct 14;95(42):4566–7 **(Swe)**

ULTRASONOGRAPHY

Evaluation of ocular arterial changes in glaucoma with color Doppler ultrasonography. Chiou HJ, et al. **J Ultrasound Med** 1999 Apr;18(4):295–302
Normal-tension glaucoma and central corneal thickness. Peplinski L, et al. **Optom Vis Sci** 1999 Aug;76(8):596–8
[Color Doppler ultrasonography of short para-optic ciliary arteries in vascular glaucoma] Bresson-Dumont H, et al. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):743–8 (Eng. Abstr.) **(Fre)**

VETERINARY

Signs of glaucoma in rhesus monkeys from a restricted gene pool. Dawson WW, et al. **J Glaucoma** 1998 Oct;7(5):343–8

GLAUCOMA, ANGLE-CLOSURE

CHEMICALLY INDUCED

Suspected ciliary block associated with Viscoat use. Berger RR, et al. **J Cataract Refract Surg** 1999 Apr;25(4):594–6
Acute angle closure glaucoma precipitated by intranasal application of cocaine. Hari CK, et al. **J Laryngol Otol** 1999 Mar;113(3):250–1
[Acute glaucoma in the course of treatment with aerosols of ipratropium bromide and salbutamol (letter)] Lellouche N, et al. **Presse Med** 1999 May 22-29;28(19):1017 **(Fre)**

COMPLICATIONS

Peripapillary atrophy in primary angle-closure glaucoma: a comparative study with primary open-angle glaucoma. Uchida H, et al. **Am J Ophthalmol** 1999 Feb;127(2):121–8
Consultation section. Cataract surgical problem. **J Cataract Refract Surg** 1998 Aug;24(8):1018–26
A tooth for an eye: dental procedures in unrecognized glaucoma. Joseph A. **J R Soc Med** 1999 May;92(5):249
Spontaneous suprachoroidal hemorrhage in age-related macular degeneration presenting as angle-closure glaucoma. Alexandrakis G, et al. **Retina** 1998;18(5):485–6

DIAGNOSIS

Malignant glaucoma. Fellman R, et al. **J Glaucoma** 1999 Apr; 8(2):149–53
Optic disc topographic measurements after pupil dilation. Zangwill LM, et al. **Ophthalmology** 1999 Sep;106(9):1751–5
Visual field responses to a hand vibration stimulus. Chai E, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S79–86
The Hettinger hand vibration test, vasospasm, and glaucoma. Goldberg I, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S66–78
[Glaucoma with microcornea; morphometry and differential diagnosis] Fukuchi T, et al. **Nippon Ganka Gakkai Zasshi** 1998 Nov;102(11):746–51 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Shin DH, et al. **Am J Ophthalmol** 1999 May;127(5):511–5
Clinical diorama. Myers K. **J Am Optom Assoc** 1998 Nov; 69(11):744–5

ENZYMOLOGY

The relationship between gelatinase A activity in aqueous humor and glaucoma. Kee C, et al. **J Glaucoma** 1999 Feb; 8(1):51–5

EPIDEMIOLOGY

Prevalence of primary glaucoma in an urban south Indian population. Jacob A, et al. **Indian J Ophthalmol** 1998 Jun; 46(2):81–6

ETIOLOGY

Angle-closure glaucoma secondary to ciliochoroidal detachment. Stockl FA, et al. **Can J Ophthalmol** 1998 Aug; 33(5):280–2
Pupillary block after pupillary capture of an AcrySof intraocular lens [see comments] Nagamoto S, et al. **J Cataract Refract Surg** 1998 Sep;24(9):1271–4. Comment in: J Cataract Refract Surg 1999 Mar;25(3):305.
Recurrent angle-closure glaucoma. Palmberg P. **J Glaucoma** 1999 Jun;8(3):208–11
A malignant glaucoma-like syndrome following pars plana

vitrectomy. Massicotte EC, et al. **Ophthalmology** 1999 Jul; 106(7):1375–9

Predisposing factors for chronic angle-closure glaucoma. Salmon JF. **Prog Retin Eye Res** 1999 Jan;18(1):121–32 (60 ref.)

GENETICS

Autosomal dominant nanophthalmos (NNO1) with high hyperopia and angle-closure glaucoma maps to chromosome 11. Othman MI, et al. **Am J Hum Genet** 1998 Nov;63(5):1411–8

PHYSIOPATHOLOGY

The use of the G1 and Octosmart programs in detecting temporal changes in the visual field. Fankhauser F 2nd, et al. **Int Ophthalmol** 1997–98;21(6):311–7

SURGERY

Treatment of malignant glaucoma with contact transscleral cyclophotocoagulation. Carassa RG, et al. **Arch Ophthalmol** 1999 May;117(5):688–90

Prospective evaluation of extraocular motility following double-plate molteno implantation. Dobler-Dixon AA, et al. **Arch Ophthalmol** 1999 Sep;117(9):1155–60

Trabeculectomy with releasable sutures: a prospective, randomized pilot study. Raina UK, et al. **Arch Ophthalmol** 1998 Oct;116(10):1288–93

Limited argon laser peripheral iridoplasty as immediate treatment for an acute attack of primary angle closure glaucoma: a preliminary study. Lai JS, et al. **Eye** 1999;13 (Pt 1):26–30

Ahmed valve and uveitic glaucoma. Da Mata AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):155–67

Consultation section. Cataract surgical problem. **J Cataract Refract Surg** 1998 Aug;24(8):1018–26

Lens extraction for uncontrolled angle-closure glaucoma: long-term follow-up. Gunning FP, et al. **J Cataract Refract Surg** 1998 Oct;24(10):1347–56

Changes in optic disc parameters after intraocular pressure reduction in adult glaucoma patients. Yoshikawa K, et al. **Jpn J Ophthalmol** 1999 May-Jun;43(3):225–31

Comparative study of three phacotrabeculectomy procedures through a single incision. Kim JW, et al. **Korean J Ophthalmol** 1998 Jun;12(1):30–6

Initial trabeculectomy with intraoperative mitomycin-C application in primary glaucomas. Rasheed el-S. **Ophthalmic Surg Lasers** 1999 May;30(5):360–6

Aqueous misdirection after glaucoma drainage device implantation. Greenfield DS, et al. **Ophthalmology** 1999 May;106(5):1035–40

Immediate argon laser peripheral iridoplasty as treatment for acute attack of primary angle-closure glaucoma: a preliminary study. Lam DS, et al. **Ophthalmology** 1998 Dec; 105(12):2231–6

Reversal of optic disc cupping after glaucoma surgery analyzed with a scanning laser tomograph. Lesk MR, et al. **Ophthalmology** 1999 May;106(5):1013–8

Otago glaucoma surgery outcome study: long-term results of trabeculectomy--1976 to 1995. Molteno AC, et al. **Ophthalmology** 1999 Sep;106(9):1742–50

Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma. Teekhasaenee C, et al. **Ophthalmology** 1999 Apr;106(4):669–74; discussion 674–5

Immediate argon laser peripheral iridoplasty for acute attack of PACG (addendum to previous report) [letter] Tham CC, et al. **Ophthalmology** 1999 Jun;106(6):1042–3

[Clinical observation of trabeculectomy without conjunctival incision] Jiang M, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May;33(3):178–80 (Eng. Abstr.) **(Chi)**

[Argon laser peripheral iridoplasty and laser iridectomy for plateau iris glaucoma] Peng D, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May;33(3):165–8 (Eng. Abstr.) **(Chi)**

[The clinical effect after locally using mitomycin C during trabeculectomy in glaucoma] Xia X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):249–52 (Eng. Abstr.) **(Chi)**

[Results of a survey of current therapy of primary angle block glaucoma] Motschmann M, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):aA11–9 **(Ger)**

[The efficacy of Charleux's peripheral iridectomy] Radian AB, et al. **Oftalmologia** 1998;45(4):63–6 (Eng. Abstr.) **(Rum)**

ULTRASONOGRAPHY

Ultrasound biomicroscopy as decisive examination in resolving special glaucoma cases. Marchini G, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):30–1

Ultrasound biomicroscopic and conventional ultrasonographic study of ocular dimensions in primary angle-closure glaucoma. Marchini G, et al. **Ophthalmology** 1998 Nov;105(11):2091–8

[Ultrasound biomicroscopy and therapy of malignant glaucoma] Schroeder W, et al. **Klin Monatsbl Augenheilkd** 1999 Jul;215(1):19–27 (Eng. Abstr.) **(Ger)**

VETERINARY

Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Dkhissi O, et al. **Invest Ophthalmol Vis Sci** 1999 Apr;40(5):990–5

GLAUCOMA CAPSULARE see **EXFOLIATION SYNDROME**

GLAUCOMA, CLOSED-ANGLE see **GLAUCOMA, ANGLE-CLOSURE**

GLAUCOMA DRAINAGE IMPLANTS

The Ahmed valve in refractory pediatric glaucoma. Englert JA, et al. **Am J Ophthalmol** 1999 Jan;127(1):34–42

Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant. Huang MC, et al. **Am J Ophthalmol** 1999 Jan;127(1):27–33

Follow-up of the original cohort with the Ahmed glaucoma valve implant. Topouzis F, et al. **Am J Ophthalmol** 1999 Aug;128(2):198–204

Comparison of different biomaterials for glaucoma drainage devices. Ayyala RS, et al. **Arch Ophthalmol** 1999 Feb; 117(2):233–6

Pars plana vitrectomy with pars plana tube implantation in eyes with intractable glaucoma. Kaynak S, et al. **Br J Ophthalmol** 1998 Dec;82(12):1377–82

Glaucoma drainage devices; past, present, and future. Lim KS, et al. **Br J Ophthalmol** 1998 Sep;82(9):1083–9 (85 ref.)

Ahmed valve and uveitic glaucoma. Da Mata AP, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):155–67

Advances in aqueous shunting procedures. Leuenberger EU, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):139–53 (79 ref.)

Novel synthetic meshwork for glaucoma treatment. I. Design and preliminary in vitro and in vivo evaluation of various expanded poly(tetrafluoroethylene) materials. Jallet V, et al. **J Biomed Mater Res** 1999 Nov;47(2):260–9

Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma [see comments] Mermoud A, et al. **J Cataract Refract Surg** 1999 Mar; 25(3):323–31. Comment in: J Cataract Refract Surg 1999 Mar;25(3):297. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.

Reticulated hyaluronic acid implant in nonperforating trabecular surgery [see comments] Sourdille P, et al. **J Cataract Refract Surg** 1999 Mar;25(3):332–9. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.

Nd:Yag goniopuncture after deep sclerectomy with collagen implant. Mermoud A, et al. **Ophthalmic Surg Lasers** 1999 Feb;30(2):120–5

Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG? Spiegel D, et al. **Ophthalmic Surg Lasers** 1999 Jun;30(6):492–4

Surgical revision of glaucoma shunt implants. Tsai JC, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):41–6

Glaucoma drainage implants in Asian eyes. Aung T, et al. **Ophthalmology** 1998 Nov;105(11):2117–22

A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. Ayyala RS, et al. **Ophthalmology** 1998 Oct;105(10):1968–76

Long-term outcome of aqueous shunt surgery in ten patients with iridocorneal endothelial syndrome. Kim DK, et al. **Ophthalmology** 1999 May;106(5):1030–4

Modified aqueous drainage implants in the treatment of complicated glaucomas in eyes with pre-existing episcleral bands. Smith MF, et al. **Ophthalmology** 1998 Dec; 105(12):2237–42

Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Trible JR, et al. **Ophthalmology** 1998 Dec;105(12):2243–50

Clinical study of combined penetrating keratoplasty, pars plana vitrectomy with temporary keratoprosthesis, and pars plana seton implant. Johnston RH, et al. **Retina** 1999; 19(2):116–21

[A short-term clinical study on a new aqueous humor drainage implant for refractory glaucoma] Duan X, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Mar;33(2):121–4 (Eng. Abstr.) **(Chi)**

[Artificial trabeculum (MESH). Clinical and histological study in the rabbit] Helies P, et al. **J Fr Ophtalmol** 1998 May;21(5):351–60 (Eng. Abstr.) **(Fre)**

[Non-perforating surgery of the trabeculum with reticulated hyaluronic acid implant: why, how, what results?] Sourdille P, et al. **J Fr Ophtalmol** 1999 Aug-Sep;22(7):794–7 **(Fre)**

[Prognostic value of anterior chamber hemorrhage following glaucoma filtering surgery] Denk PO, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):156–9 (Eng. Abstr.) **(Ger)**

[Wound healing after glaucoma filtering surgery--a review] Knorr M, et al. **Klin Monatsbl Augenheilkd** 1999 Mar; 214(3):147–55 (79 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Myositis associated with a Baerveldt glaucoma implant. Oh KT, et al. **Am J Ophthalmol** 1999 Sep;128(3):375–6

Tube erosion following insertion of a glaucoma drainage device with a pericardial patch graft. Lama PJ, et al. **Arch Ophthalmol** 1999 Sep;117(9):1243–4

Acquired Pseudo-Brown's syndrome immediately following Ahmed valve glaucoma implant. Coats DK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):396–7

A false-positive Seidel test after Ahmed valve insertion. Piccone MR, et al. **Ophthalmic Surg Lasers** 1999 Apr; 30(4):313–4

Aqueous misdirection after glaucoma drainage device implantation. Greenfield DS, et al. **Ophthalmology** 1999 May;106(5):1035–40

Factors associated with elevated rates of adverse outcomes after cyclodestructive procedures versus drainage device procedures. Topouzis F, et al. **Ophthalmology** 1998 Dec; 105(12):2276–81

GLAUCOMA FILTRATION IMPLANTS see **GLAUCOMA DRAINAGE IMPLANTS**

GLAUCOMA, NEOVASCULAR

ETIOLOGY

[Secondary glaucoma caused by iris tumor. Iris metastasis of adenocarcinoma of the breast] Höche A, et al. **Ophthalmologe** 1999 May;96(5):342–3 **(Ger)**

METABOLISM

Increased interleukin-6 in aqueous humor of neovascular glaucoma. Chen KH, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2627–32

[Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma] Kozawa T, et al. **Nippon Ganka Gakkai Zasshi** 1998 Nov;102(11):731–8 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Increased nitric oxide levels in aqueous humor of diabetic patients with neovascular glaucoma [letter] Chiou SH, et al. **Diabetes Care** 1999 May;22(5):861–2

SURGERY

Short-term clinical study on a new aqueous humor drainage implant for refractory glaucoma. Duan X, et al. **Chin Med J (Engl)** 1997 Nov;110(11):879–82

Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma. Oguri A, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):722–7

[Cyclocryotherapy in neovascular glaucoma and non-neovascular glaucoma] Heuring AH, et al. **Klin Monatsbl Augenheilkd** 1998 Oct;213(4):213–9 (Eng. Abstr.) **(Ger)**

[Intraocular interventions in eyes with rubeosis iridis and neovascular glaucoma] Lucke K, et al. **Ophthalmologe** 1998 Jul;95(7):514–28 (10 ref.) **(Ger)**

THERAPY

[Vitreoretinal surgery in the treatment of neovascular glaucoma] Psichias A, et al. **Klin Monatsbl Augenheilkd** 1999 Feb;214(2):61–70 (Eng. Abstr.) **(Ger)**

GLAUCOMA, OPEN-ANGLE

Bilateral open-angle glaucoma. Ringvold A. **Acta Ophthalmol Scand** 1999 Feb;77(1):114–6

BLOOD

Red blood cell membrane integrity in primary open angle glaucoma: ex vivo and in vitro studies. Zabala L, et al. **Eye** 1999;13 (Pt 1):101–3

Erythrocyte deformability in high-tension and normal tension glaucoma. Ates H, et al. **Int Ophthalmol** 1998; 22(1):7–12

[Correlations between retinal fluorescein angiography and blood viscosity and other factors in patients with primary open angle glaucoma] Liu X, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Jan;33(1):22–5 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Wordinger RJ, et al. **Prog Retin Eye Res** 1999 Sep;18(5):629–67 (224 ref.)

CLASSIFICATION

The definition of normal-tension glaucoma [see comments] Lee BL, et al. **J Glaucoma** 1998 Dec;7(6):366–71. Comment in: J Glaucoma 1998 Dec;7(6):363–5.

The tale of normal-tension glaucoma [editorial; comment] Van Buskirk EM. **J Glaucoma** 1998 Dec;7(6):363–5 (13 ref.) Comment on: J Glaucoma 1998 Dec;7(6):366–71.

COMPLICATIONS

Results of a combined procedure for cataract and glaucoma, using Crozafon-De Laage punch. Sandvig KU. **Acta Ophthalmol Scand** 1999 Feb;77(1):88–90

A prospective study of combined phacoemulsification-trabeculectomy versus conventional

phacoemulsification in cataract patients with coexisting open angle glaucoma. Storr-Paulsen A, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):696-9

Relationship between parapapillary atrophy and visual field abnormality in primary open-angle glaucoma. Kono Y, et al. **Am J Ophthalmol** 1999 Jun;127(6):674-80

Peripapillary atrophy in primary angle-closure glaucoma: a comparative study with primary open-angle glaucoma. Uchida H, et al. **Am J Ophthalmol** 1999 Feb;127(2):121-8

Unilateral capsular glaucoma after long-standing bilateral pigmentary glaucoma. Tarkkanen A, et al. **Eye** 1999 Apr; 13 (Pt 2):212-4

Falsely elevated intraocular pressure due to increased central corneal thickness. Bron AM, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Mar;237(3):220-4

Risk factors for visual field damage progression in normal-tension glaucoma eyes. Daugeliene L, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Feb;237(2):105-8

Clinical evaluation of SITA: a new family of perimetric testing strategies. Shirato S, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):29-34

Slope of the peripapillary nerve fiber layer surface in glaucoma. Caprioli J, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2321-8

Parapapillary chorioretinal atrophy in chronic high-pressure experimental glaucoma in rhesus monkeys. Hayreh SS, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2296-303

Morphology of single ganglion cells in the glaucomatous primate retina. Weber AJ, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2304-20

Body mass index in glaucoma. Gasser P, et al. **J Glaucoma** 1999 Feb;8(1):8-11

Optic cup deepening spatially correlated with optic nerve damage in focal normal-pressure glaucoma. Jonas JB, et al. **J Glaucoma** 1999 Aug;8(4):227-31

New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Neufeld AH. **J Glaucoma** 1998 Dec;7(6):434-8 (44 ref.)

Intraocular pressure reduction following phacoemulsification cataract extraction with posterior chamber lens implantation in glaucoma patients. Kim DD, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):37-40

Unilateral glaucomatous damage in a patient with hemifacial spasm. Killer HE, et al. **Ophthalmologica** 1999;213(4):273-5

The probability of blindness from open-angle glaucoma. Hattenhauer MG, et al. **Ophthalmology** 1998 Nov; 105(11):2099-104

The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Mitchell P, et al. **Ophthalmology** 1999 Oct;106(10):2010-5

High prevalence of glaucoma in patients with sleep apnea syndrome. Mojon DS, et al. **Ophthalmology** 1999 May; 106(5):1009-12

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Moroi SE, et al. **Ophthalmology** 1999 May; 106(5):1024-9

Localized wedge-shaped defects of retinal nerve fiber layer and disc hemorrhage in glaucoma. Sugiyama K, et al. **Ophthalmology** 1999 Sep;106(9):1762-7

Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma. Teus MA, et al. **Ophthalmology** 1998 Dec;105(12):2225-9; discussion 2229-30

[The procedure of the ophthalmologist surgeon in hypertension after antiglaucoma operations in patients with open-angle glaucoma] Ignat'ev AN, et al. **Voen Med Zh** 1999 Jul;320(7):46-9 **(Rus)**

DIAGNOSIS

An amplitude ratio of pattern visually evoked cortical potentials. Fujimoto N, et al. **Acta Ophthalmol Scand** 1999 Apr;77(2):157-9

Optic nerve head sector analysis recognizes glaucoma most effectively around disc poles. Gundersen KG, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):13-8

The Draeger autotonometer: its advantages and limits. Bolla N, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):21-2

Frequency doubling perimetry in glaucoma early diagnosis. Brusini P, et al. **Acta Ophthalmol Scand Suppl** 1998; (227):23-4

Blue-yellow perimetry in patients with ocular hypertone. Serra A, et al. **Acta Ophthalmol Scand Suppl** 1998; (227):24-7

Glaucomatocyclitic crisis in a child [letter; comment] Teekhasaenee C, et al. **Am J Ophthalmol** 1999 May; 127(5):626-7. Comment on: Am J Ophthalmol 1998 Jul;126(1):136-7.

Tonometry and corneal thickness [editorial; comment] Brubaker RF. **Arch Ophthalmol** 1999 Jan;117(1):104-5 (12 ref.). Comment on: Arch Ophthalmol 1999 Jan;117(1):14-6.

Comparison of conventional and high-pass resolution perimetry in a prospective study of patients with glaucoma and healthy controls. Chauhan BC, et al. **Arch Ophthalmol** 1999 Jan;117(1):24-33

Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma [see comments] Copt RP, et al. **Arch Ophthalmol** 1999 Jan; 117(1):14-6. Comment in: Arch Ophthalmol 1999 Jan;117(1):104-5.

Optic nerve head morphologic characteristics in high-tension and normal-tension glaucoma. Iester M, et al. **Arch Ophthalmol** 1999 Aug;117(8):1010-3

Extrafoveal photostress recovery test in glaucoma and idiopathic central serous chorioretinopathy. Horiguchi M, et al. **Br J Ophthalmol** 1998 Sep;82(9):1007-12

Preperimetric glaucoma diagnosis by confocal scanning laser tomography of the optic disc. Mardin CY, et al. **Br J Ophthalmol** 1999 Mar;83(3):299-304

A new parameter for assessing the thickness of the retinal nerve fiber layer for glaucoma diagnosis. Kogure S, et al. **Eur J Ophthalmol** 1999 Apr-Jun;9(2):93-8

The full-field flicker test in glaucomas: influence of intraocular pressure and pattern of visual field losses. Horn FK, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Aug; 237(8):621-8

Influence of optic disc size on the sensitivity of the Heidelberg Retina Tomograph. Mardin CY, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):641-5

Optic disc surface smoothness and visual field indices. Rolando M, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 May;237(5):372-6

Risk factors for the progression of treated primary open-angle glaucoma: a multivariate life-table analysis. Suzuki Y, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun;237(6):463-7

Test-retest variability of frequency-doubling perimetry and conventional perimetry in glaucoma patients and normal subjects. Chauhan BC, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):648-56

Asymmetry in optic disc parameters: the Blue Mountains Eye Study. Ong LS, et al. **Invest Ophthalmol Vis Sci** 1999 Apr; 40(5):849-57

The SITA perimetric threshold algorithms in glaucoma. Wild JM, et al. **Invest Ophthalmol Vis Sci** 1999 Aug; 40(9):1998-2009

Interobserver agreement of Heidelberg retina tomograph parameters. Hatch WV, et al. **J Glaucoma** 1999 Aug; 8(4):232-7

Detection of optic disc changes with Glaucoma-Scope probability maps. Yamada N, et al. **J Glaucoma** 1998 Dec; 7(6):378-87

Blue-on-yellow perimetry using an Armaly glaucoma screening program. Maeda H, et al. **Ophthalmologica** 1999; 213(2):71-5

Differentiating patients with glaucoma from glaucoma suspects and normal subjects by nerve fiber layer assessment with scanning laser polarimetry. Choplin NT, et al. **Ophthalmology** 1998 Nov;105(11):2068-76

Intraocular pressure difference in Goldmann applanation tonometry versus Perkins hand-held applanation tonometry in overweight patients [see comments] dos Santos MG, et al. **Ophthalmology** 1998 Dec;105(12):2260-3. Comment in: Ophthalmology 1999 Jun;106(6):1041.

The cupped disc. Who needs neuroimaging? [see comments] Greenfield DS, et al. **Ophthalmology** 1998 Oct; 105(10):1866-74. Comment in: Ophthalmology 1999 May;106(5):855.

Differentiating glaucomatous from nonglaucomatous optic atrophy [letter; comment] Lee AG. **Ophthalmology** 1999 May;106(5):855. Comment on: Ophthalmology 1998 Oct;105(10):1866-74.

Retinal nerve fiber layer measurement by nerve fiber analyzer in normal subjects and patients with glaucoma. Lee VW, et al. **Ophthalmology** 1999 May;106(5):1006-8

Blue-on-yellow visual field and retinal nerve fiber layer in ocular hypertension and glaucoma. Teesalu P, et al. **Ophthalmology** 1998 Nov;105(11):2077-81

Cup-to-disc ratio: ophthalmoscopy versus automated measurement in a general population: The Rotterdam Study. Wolfs RC, et al. **Ophthalmology** 1999 Aug; 106(8):1597-601

Optic disc topographic measurements after pupil dilation. Zangwill LM, et al. **Ophthalmology** 1999 Sep;106(9):1751-5

Visual field responses to a hand vibration stimulus. Chai E, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S79-86

The Hettinger hand vibration test, vasospasm, and glaucoma. Goldberg I, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S66-78

Objective perimetry in glaucoma: recent advances with multifocal stimuli. Graham SL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S199-209

[Juvenile glaucoma. Seven case reports] Alliot E, et al. **J Fr Ophtalmol** 1998 Mar;21(3):176-9 (Eng. Abstr.) **(Fre)**

[Asymmetrical forms of primary open angle glaucoma] Balo KP, et al. **J Fr Ophtalmol** 1998 Aug-Sep;21(7):479-83 (Eng. Abstr.) **(Fre)**

[Is corneal thickness measurement reliable and useful?] Bron A, et al. **J Fr Ophtalmol** 1999 Mar;22(2):160-8 (Eng. Abstr.) **(Fre)**

[Rapid Tendency Oriented Perimeter (TOP) with the Octopus visual field analyzer] Lachkar Y, et al. **J Fr Ophtalmol** 1998 Mar;21(3):180-4 (Eng. Abstr.) **(Fre)**

[Exit of the retinal central vascular trunk and extent of para-papillary atrophy] Budde WM, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):300-1 (Eng. Abstr.) **(Ger)**

[Influence of myopic disc shape in a classification program of the Heidelberg retina tomograph] Yamazaki Y, et al. **Nippon Ganka Gakkai Zasshi** 1999 May;103(5):392-8 (Eng. Abstr.) **(Jpn)**

[New concept of glaucoma. Primarily an optic neuropathy, not a disease of the anterior chamber angle] Heijl A. **Lakartidningen** 1999 Apr 7;96(14):1688-91 (22 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group. Hutzelmann JE, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):717-22

Clinical experience with latanoprost: a retrospective study of 153 patients. Martin L. **Acta Ophthalmol Scand** 1999 Jun;77(3):336-9

The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Smith SL, et al. **Acta Ophthalmol Scand** 1999 Apr;77(2):189-92

Fatty acid use in glaucomatous optic neuropathy treatment. Cellini M, et al. **Acta Ophthalmol Scand Suppl** 1998; (227):41-2

Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma. D'Andrea A, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):36-8

Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients. Mastropasqua L, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):36

Sympathetic use of latanoprost 0.005% in 30 eyes. Montrone F, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):38-9

Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow. Vetrugno M, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):40-1

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma [letter; comment] Danias J, et al. **Am J Ophthalmol** 1999 May;127(5):623-5 . Comment on: Am J Ophthalmol 1998 Oct;126(4):487-97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498-505.

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Katz LJ. **Am J Ophthalmol** 1999 Jan; 127(1):20-6

Effect of topical anti-inflammatory treatment on the long-term outcome of laser trabeculoplasty. Fluorometholone-Laser Trabeculoplasty Study Group. Kim YY, et al. **Am J Ophthalmol** 1998 Nov;126(5):721-3

Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. Kim YY, et al. **Am J Ophthalmol** 1998 Dec; 126(6):755-62

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Konstas AG, et al. **Am J Ophthalmol** 1999 Jul;128(1):15-20

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma [letter; comment] Leske MC, et al. **Am J Ophthalmol** 1999 May;127(5):625-6 . Comment on: Am J Ophthalmol 1998 Oct;126(4):487-97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498-505.

Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Shin DH, et al. **Am J Ophthalmol** 1999 May;127(5):511-5

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Stewart WC, et al. **Am J Ophthalmol** 1999 Feb;127(2):142-7

Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Wayman LL, et al. **Arch Ophthalmol** 1998 Nov; 116(11):1438-40

Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma. Schmidt KG, et al. **Br J Ophthalmol** 1998 Jul;82(7):758-62

Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Schenker H, et al. **Clin Ther** 1999 Jan;21(1):138-47

A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Eisenberg DL, et al. **Drug Saf** 1999 Jun; 20(6):505-14 (58 ref.)

Darkening of eyelashes in a patient treated with latanoprost [letter] Reynolds A, et al. **Eye** 1998;12 (Pt 4):741-3

Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Diestelhorst M, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Aug;236(8):577-81

The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Vainio-Jylhä E, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Feb;237(2):100-4

Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Kimal Arici M, et al. **Int Ophthalmol** 1998;22(1):37-42

Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response. Nuzzi R, et al. **Int Ophthalmol** 1998;22(1):31-5

The effectiveness of latanoprost for the treatment of pediatric glaucoma. Enyedi LB, et al. **J Aapos** 1999 Feb;3(1):33-9

Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. Nishimoto JH, et al. **J Am Optom Assoc** 1999 Apr;70(4):233–9

Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. Adamsons IA, et al. **J Glaucoma** 1998 Dec; 7(6):395–401

Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. Altuna JC, et al. **J Glaucoma** 1999 Jun;8(3):199–203

Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. Bucci MG. **J Glaucoma** 1999 Feb;8(1):24–30

Three assumptions: ocular blood flow and glaucoma [editorial; comment] Cioffi GA. **J Glaucoma** 1998 Oct; 7(5):299–300. Comment on: J Glaucoma 1998 Oct;7(5):301–5. Comment on: J Glaucoma 1998 Oct;7(5):336–42.

A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. Drance SM. **J Glaucoma** 1998 Aug;7(4):247–52

Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. Kent AR, et al. **J Glaucoma** 1999 Aug;8(4):257–62

The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects [see comments] Piltz JR, et al. **J Glaucoma** 1998 Oct; 7(5):336–42. Comment in: J Glaucoma 1998 Oct;7(5):299–300.

Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. Stewart WC, et al. **J Glaucoma** 1998 Dec;7(6):402–7

The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma [see comments] Yamamoto T, et al. **J Glaucoma** 1998 Oct;7(5):301–5. Comment in: J Glaucoma 1998 Oct;7(5):299–300.

The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy. Smith SL, et al. **J Ocul Pharmacol Ther** 1999 Feb; 15(1):29–39

A new system to supply carbon dioxide safely to glaucoma patients. Niwa Y, et al. **Jpn J Ophthalmol** 1999 Jan-Feb; 43(1):16–9

Prognostic factors for hypotensive effects of isopropyl unoprostone in eyes with primary open-angle glaucoma. Yoshida K, et al. **Jpn J Ophthalmol** 1998 Sep-Oct; 42(5):417–23

The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Yüksel N, et al. **Ophthalmologica** 1999;213(4):228–33

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Boyle JE, et al. **Ophthalmology** 1998 Oct;105(10):1945–51

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Clineschmidt CM, et al. **Ophthalmology** 1998 Oct; 105(10):1952–9

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP. **Ophthalmology** 1998 Oct;105(10):1960–7

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Mastropasqua L, et al. **Ophthalmology** 1999 Mar; 106(3):550–5

Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Parisi V, et al. **Ophthalmology** 1999 Jun;106(6):1126–34

Ab-interno goniotrabeculotomy versus mitomycin C trabeculectomy for adult open-angle glaucoma: a 2-year randomized clinical trial. Quaranta L, et al. **Ophthalmology** 1999 Jul;106(7):1357–62

The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group [see comments] Strohmaier K, et al. **Ophthalmology** 1998 Oct; 105(10):1936–44. Comment in: Ophthalmology 1999 Jun;106(6):1044–5.

Introductory comments on potential differences between beta-blockers in the treatment of open-angle glaucoma. Drance SM. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S173–5 (22 ref.)

Serum lipid physiology and the influence of glaucoma medications. Stewart WC, et al. **Surv Ophthalmol** 1998 Nov-Dec;43(3):233–44 (134 ref.)

[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid] Hazouard E, et al. **J Fr Ophtalmol** 1999 Feb;22(1):73–5 (Eng. Abstr.) **(Fre)**

[Effect of naftidrofuryl (praxilene) on optic nerve head blood flow in the patient with glaucoma] Achache F, et al. **Klin Monatsbl Augenheilkd** 1999 May;214(5):260–2 (Eng. Abstr.) **(Ger)**

[New drugs in glaucoma therapy (news)] Gramer E. **Klin Monatsbl Augenheilkd** 1998 Jul;213(1):aA10–2 **(Ger)**

[Latanoprost (Xalatan)-induced macular edema] Reis A, et al. **Klin Monatsbl Augenheilkd** 1998 Jul;213(1):63–4 (Eng. Abstr.) **(Ger)**

[Peak pulse blood volume and topical antiglaucoma drugs in rhesus monkeys with experimental open angle glaucoma] Schmidt KG, et al. **Klin Monatsbl Augenheilkd** 1998 Dec; 213(6):341–6 (Eng. Abstr.) **(Ger)**

[Case from general practice. Bradycardic atrial flutter] Osterwalder P, et al. **Schweiz Rundsch Med Prax** 1998 Aug 12;87(33):1034–6 **(Ger)**

[The effect of chronic beta-blocker treatment on the evolution of primary open-angle glaucoma] Chiselita D, et al. **Oftalmologia** 1998;42(2):47–52 (Eng. Abstr.) **(Rum)**

[Effect of local hypotensive therapy on ocular hemodynamics in patients with primary open-angle glaucoma] Bakshinskii PP. **Vestn Oftalmol** 1999 Jan-Feb;115(1):8–10 (Eng. Abstr.) **(Rus)**

[Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma] Egorov EA, et al. **Vestn Oftalmol** 1998 Jul-Aug;114(4):19–20 (Eng. Abstr.) **(Rus)**

[Xalathane: comparative assessment of efficacy and safety in hypotensive therapy of glaucoma] Erichev VP, et al. **Vestn Oftalmol** 1998 Jul-Aug;114(4):20–1 (Eng. Abstr.) **(Rus)**

[Therapy of patients with primary open-angle glaucoma with proxofelin, a combined form of proxodolol] Ermakova VN, et al. **Vestn Oftalmol** 1999 Jan-Feb;115(1):3–5 (Eng. Abstr.) **(Rus)**

ECONOMICS

Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Kobelt G, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Nov;236(11):811–21

EMBRYOLOGY

Does raised intraocular pressure begin in utero? Foss AJ, et al. **Br J Ophthalmol** 1998 Oct;82(10):1125–30

ENZYMOLOGY

The relationship between gelatinase A activity in aqueous humor and glaucoma. Kee C, et al. **J Glaucoma** 1999 Feb; 8(1):51–5

EPIDEMIOLOGY

Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Wolfs RC, et al. **Arch Ophthalmol** 1998 Dec;116(12):1640–5

Prevalence of primary glaucoma in an urban south Indian population. Jacob A, et al. **Indian J Ophthalmol** 1998 Jun; 46(2):81–6

The age distribution of primary open angle glaucoma [published erratum appears in Ophthalmic Epidemiol 1999 Mar;6(1):84] Tuck MW, et al. **Ophthalmic Epidemiol** 1998 Dec;5(4):173–83

High prevalence of glaucoma in patients with sleep apnea syndrome. Mojon DS, et al. **Ophthalmology** 1999 May; 106(5):1009–12

[Prevalence of primary chronic open-angle glaucoma in Ivory Coast] Ahnoux-Zabsonre A, et al. **J Fr Ophtalmol** 1998 Nov;21(9):643–7 (Eng. Abstr.) **(Fre)**

ETHNOLOGY

HLA-DRB and HLA-DQB loci in the genetic susceptibility to develop glaucoma in Mexicans. Gil-Carrasco F, et al. **Am J Ophthalmol** 1999 Sep;128(3):297–300

Cataract, glaucoma and season of birth amongst patients born on the Indian subcontinent. Weale RA. **Indian J Ophthalmol** 1998 Dec;46(4):211–5

ETIOLOGY

Corticosteroid-induced glaucoma attributable to an adrenocorticotropin-secreting malignant carcinoid tumor of the thymus. Blumenthal EZ, et al. **Am J Ophthalmol** 1999 Jul;128(1):100–1

Glaucoma and vasospasm [see comments] Broadway DC, et al. **Br J Ophthalmol** 1998 Aug;82(8):862–70. Comment in: Br J Ophthalmol 1998 Aug;82(8):855–6.

Juvenile onset primary open-angle glaucoma: three case studies and review. Bachman JA. **J Am Optom Assoc** 1998 Dec;69(12):785–95 (42 ref.)

Semiconductor diode laser transscleral cyclophotocoagulation in a patient with glaucoma secondary to metastatic tumor to the iris. El-Harazi SM, et al. **J Glaucoma** 1998 Oct;7(5):317–8

Clinical factors associated with progression of normal-tension glaucoma. Ishida K, et al. **J Glaucoma** 1998 Dec;7(6):372–7

Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma. Haefliger IO, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S51–8

[Acute open-angle glaucoma in a woman with AS hemoglobinopathy] Grunewald F, et al. **J Fr Ophtalmol** 1998 Feb;21(2):142–5 (Eng. Abstr.) **(Fre)**

[Pathogenesis and treatment of low (normal) pressure glaucoma] Shmyreva VF, et al. **Vestn Oftalmol** 1998 Jul-Aug;114(4):47–8 (35 ref.) **(Rus)**

GENETICS

Glaucoma simplex congenitum in the Veli Brgud village, the Opatija County, Republic of Croatia--a genealogical nine-generation study. Tomašić V, et al. **Acta Med Croatica** 1998;52(4–5):235–7

Ultrasound biomicroscopical study of the irido-corneal angle in dominant juvenile open-angle glaucoma, in POAG, and in normal eyes. Urbak SF. **Acta Ophthalmol Scand** 1999 Apr;77(2):160–4

Molecular basis of open-angle glaucoma in Italy. Angius A, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):16–7

The role of class I and class II HLA antigens in primary open angle glaucoma (POAG). Ferreri G, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):17–9

Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma [letter] Wiggs JL, et al. **Am J Hum Genet** 1998 Nov;63(5):1549–52

Mutations of the TIGR/MYOC gene in primary open-angle glaucoma in Korea [letter] Yoon SJ, et al. **Am J Hum Genet** 1999 Jun;64(6):1775–8

HLA-DRB and HLA-DQB loci in the genetic susceptibility to develop glaucoma in Mexicans. Gil-Carrasco F, et al. **Am J Ophthalmol** 1999 Sep;128(3):297–300

GLC1F, a new primary open-angle glaucoma locus, maps to 7q35–q36. Wirtz MK, et al. **Arch Ophthalmol** 1999 Feb; 117(2):237–41

Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Wolfs RC, et al. **Arch Ophthalmol** 1998 Dec;116(12):1640–5

Expression pattern and in situ localization of the mouse homologue of the human MYOC (GLC1A) gene in adult brain. Swiderski RE, et al. **Brain Res Mol Brain Res** 1999 May 7;68(1–2):64–72

Family history and some other factors in primary open angle glaucoma. Konareva-Kostianeva M. **Folia Med (Plovdiv)** 1998;40(4):78–81

Family history of glaucoma in the primary and secondary open-angle glaucomas. Budde WM, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jul;237(7):554–7

Adult-onset primary open angle glaucoma does not localize to chromosome 2cen-q13 in North American families. Allingham RR, et al. **Hum Hered** 1998 Sep-Oct;48(5):251–5

Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Allingham RR, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2288–95

Chronic open-angle glaucoma and associated ophthalmic findings in monozygotic twins and their spouses in Iceland. Gottfredsdottir MS, et al. **J Glaucoma** 1999 Apr;8(2):134–9

A GLC1A gene Gln368Stop mutation in a patient with normal-tension open-angle glaucoma. Mardin CY, et al. **J Glaucoma** 1999 Apr;8(2):154–6

A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma. Kennan AM, et al. **J Med Genet** 1998 Nov; 35(11):957–60

Novel TIGR/MYOC mutations in families with juvenile onset primary open angle glaucoma. Stoilova D, et al. **J Med Genet** 1998 Dec;35(12):989–92

Clinical phenotype of a Japanese family with primary open angle glaucoma caused by a Pro370Leu mutation in the MYOC/TIGR gene. Taniguchi F, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):80–4

Detection of a new TIGR gene mutation in a Japanese family with primary open angle glaucoma. Yokoyama A, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):85–8

GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. Rozsa FW, et al. **Mol Vis** 1998 Oct 6;4:20

[An example of dominant inheritance in the transmission of chronic open-angle glaucoma. Apropos of an Algerian family] Ouhadj O, et al. **J Fr Ophtalmol** 1999 May; 22(5):571–6 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Tezel G, et al. **Arch Ophthalmol** 1999 Jul;117(7):917–24

Autoantibodies to small heat shock proteins in glaucoma. Tezel G, et al. **Invest Ophthalmol Vis Sci** 1998 Nov; 39(12):2277–87

METABOLISM

Effects of methotrexate treatment on serum immunoreactivity of a patient with normal-pressure glaucoma. Fellman RL, et al. **Am J Ophthalmol** 1999 Jun;127(6):724–5

The healing optic nerve in glaucoma: transforming growth factor beta and optic nerve head remodelling [editorial; comment] Cordeiro MF, et al. **Br J Ophthalmol** 1999 Feb; 83(2):132–3. Comment on: Br J Ophthalmol 1999 Feb;83(2):209–18.

Transforming growth factor beta isoforms in human optic nerve heads [see comments] Pena JD, et al. **Br J Ophthalmol** 1999 Feb;83(2):209–18. Comment in: Br J Ophthalmol 1999 Feb;83(2):132–3.

Reduced plasma cortisol binding to albumin in ocular hypertension and primary open-angle glaucoma. McCarty

GR, et al. **Curr Eye Res** 1999 Jun;18(6):467-76

Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. Pena JD, et al. **Exp Eye Res** 1999 Jan; 68(1):29-40

Cellular and plasma fibronectin in the aqueous humour of primary open-angle glaucoma, exfoliative glaucoma and cataract patients. Vesaluoma M, et al. **Eye** 1998;12 (Pt 5):886-90

Na-K-Cl cotransport in normal and glaucomatous human trabecular meshwork cells. Putney LK, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):425-34

Primary open-angle glaucoma may be a hyaluronic acid deficiency disease: potential for glucosamine in prevention and therapy. McCarty MF. **Med Hypotheses** 1998 Dec; 51(6):483-4 (13 ref.)

[Permeability of blood-eye barrier in patients with primary glaucoma combined with lens opacity] Kurysheva NI, et al. **Vestn Oftalmol** 1998 Nov-Dec;114(6):3-6 (Eng. Abstr.) **(Rus)**

MORTALITY

Survival of glaucoma patients. Egge K, et al. **Acta Ophthalmol Scand** 1999 Aug;77(4):397-401

PATHOLOGY

Patterns of optic disk damage in patients with early focal visual field loss. Emdadi A, et al. **Am J Ophthalmol** 1998 Dec;126(6):763-71

Optic neuropathy resembling normal-pressure glaucoma in a teenager with congenital macrodiscs [letter] Jonas JB, et al. **Arch Ophthalmol** 1998 Oct;116(10):1384-6

Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Neufeld AH. **Arch Ophthalmol** 1999 Aug;117(8):1050-6

Optic disc morphology in pigmentary glaucoma. Jonas JB, et al. **Br J Ophthalmol** 1998 Aug;82(8):875-9

Neuroretinal rim width ratios in morphological glaucoma diagnosis. Jonas JB, et al. **Br J Ophthalmol** 1998 Dec; 82(12):1366-71

Correlation between the orbital and intraocular portions of the optic nerve in glaucomatous and ocular hypertensive eyes. Beatty S, et al. **Eye** 1998;12 (Pt 4):707-13

Correlation of peripapillary nerve fiber layer thickness by scanning laser polarimetry with visual field defects in patients with glaucoma. Chen YY, et al. **J Glaucoma** 1998 Oct;7(5):312-6

Early magnocellular loss in glaucoma demonstrated using the pseudorandomly stimulated flash visual evoked potential. Klistorner AI, et al. **J Glaucoma** 1999 Apr; 8(2):140-8

Situation with glaucoma and the state of mind in the glaucoma community [letter; comment] Kotik J. **J Glaucoma** 1998 Dec;7(6):446-7. Comment on: J Glaucoma 1998 Apr;7(2):73-4.

Change in optic disc topography associated with diurnal variation in intraocular pressure. Lee BL, et al. **J Glaucoma** 1999 Jun;8(3):221-3

Retinal nerve fiber layer thickness within the area of apparently normal visual field in normal-tension glaucoma with hemifield defect. Reyes RD, et al. **J Glaucoma** 1998 Oct;7(5):329-35

Retinal vessel diameter in normal and primary open-angle glaucoma. Lee SB, et al. **Korean J Ophthalmol** 1998 Jun; 12(1):51-9

Peripapillary atrophy in normal and primary open-angle glaucoma. Uhm KB, et al. **Korean J Ophthalmol** 1998 Jun; 12(1):37-50

Asymmetry in intraocular pressure and retinal nerve fiber layer thickness in normal-tension glaucoma. Gugleta K, et al. **Ophthalmologica** 1999;213(4):219-23

Optic disk appearances in primary open-angle glaucoma. Broadway DC, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S223-43 (246 ref.)

[Relationship between visual field loss and retinal nerve fiber layer thickness in open-angle glaucoma] Ono J, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct;102(10):685-91 (Eng. Abstr.) **(Jpn)**

[Stereometry of temporal peripapillary atrophy in early-stage open-angle glaucoma] Yoshikawa K, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jul;103(7):538-43 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Intraocular pressure and visual field defects. Bojić L, et al. **Acta Med Croatica** 1998;52(4-5):219-20

Vascular resistance in primary open angle glaucoma. Aldoori MI, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):668-70

Evaluation of the efficacy of nicergoline on blood flow and ocular function in patients affected by chronic simple glaucoma. Protti R, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):42-5

Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow. Vetrugno M, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):40-1

Relationship between cefalo-ophthalmic haemodynamics and visual function in patients affected by carotid stenosis. Possible links with critical low tension glaucoma pictures. Vitale Brovarone F, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):45-6

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma [letter; comment] Danias J, et al. **Am J Ophthalmol** 1999 May;127(5):623-5 . Comment on: Am J Ophthalmol 1998 Oct;126(4):487-97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498-505.

Optic nerve blood flow in glaucoma: effect of systemic hypertension. Grunwald JE, et al. **Am J Ophthalmol** 1999 May;127(5):516-22

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma [letter; comment] Leske MC, et al. **Am J Ophthalmol** 1999 May;127(5):625-6 . Comment on: Am J Ophthalmol 1998 Oct;126(4):487-97. Comment on: Am J Ophthalmol 1998 Oct;126(4):498-505.

The Collaborative Normal-Tension Glaucoma Study and some of its lessons [editorial] Drance SM. **Can J Ophthalmol** 1999 Feb;34(1):1-6 (19 ref.) **(Eng, Fre)**

A comparative study of computerised visual field testing and optic disc morphometric parameters in the follow-up of primary open angle glaucoma. Macri A, et al. **Eye** 1998; 12 (Pt 6):916-20

Ambulatory blood pressure monitoring in glaucoma patients. The nocturnal systolic dip and its relationship with disease progression. Collignon N, et al. **Int Ophthalmol** 1998; 22(1):19-25

The use of the G1 and Octosmart programs in detecting temporal changes in the visual field. Fankhauser F 2nd, et al. **Int Ophthalmol** 1997-98;21(6):311-7

Optic nerve and choroidal circulation in glaucoma. Grunwald JE, et al. **Invest Ophthalmol Vis Sci** 1998 Nov; 39(12):2329-36

Peripheral endothelial dysfunction in normal pressure glaucoma. Henry E, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1710-4

Effects of long-term hypotensive therapy with nonselective beta-blockers on ocular hemodynamics in primary open-angle glaucoma. Evans DW, et al. **J Glaucoma** 1999 Feb;8(1):12-7

Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. Koseki N, et al. **J Glaucoma** 1999 Apr; 8(2):117-23

Reproducibility of color Doppler imaging for orbital arteries in Japanese patients with normal-tension glaucoma. Niwa Y, et al. **Jpn J Ophthalmol** 1998 Sep-Oct;42(5):389-92

Relationship between blood flow velocities in retrobulbar vessels and laser Doppler flowmetry at the optic disk in glaucoma patients. Bohdanecka Z, et al. **Ophthalmologica** 1999;213(3):145-9

Blood flow velocity in the peripheral circulation of glaucoma patients. O'Brien C, et al. **Ophthalmologica** 1999; 213(3):150-3

Progression of peripapillary atrophy [letter; comment] Heltzer JM. **Ophthalmology** 1999 May;106(5):857. Comment on: Ophthalmology 1998 Aug;105(8):1541-5.

Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Wilson MR, et al. **Ophthalmology** 1998 Nov;105(11):2112-6

Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Harris A, et al. **Prog Retin Eye Res** 1999 Sep;18(5):669-87 (122 ref.)

Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Chung HS, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S43-50 (64 ref.)

Nocturnal hypotension: role in glaucoma progression. Graham SL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S10-6 (64 ref.)

The role of age and cardiovascular disease in glaucomatous optic neuropathy. Hayreh SS. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S27-42 (132 ref.)

Laser Doppler flowmetry of the optic nerve head in glaucoma. Piltz-Seymour JR. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S191-8 (56 ref.)

Color Doppler imaging of the retrobulbar circulation in glaucoma. Rankin SJ. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S176-82 (28 ref.)

Visual evoked potential assessment of the effects of glaucoma on visual subsystems. Greenstein VC, et al. **Vision Res** 1998 Jun;38(12):1901-11

Abnormal motion displacement thresholds are associated with fine scale luminance sensitivity loss in glaucoma. Westcott MC, et al. **Vision Res** 1998 Oct;38(20):3171-80

Characteristics of frequency-of-seeing curves for a motion stimulus in glaucoma eyes, glaucoma suspect eyes, and normal eyes. Westcott MC, et al. **Vision Res** 1999 Feb; 39(3):631-9

[A comparative study of visual field defects between primary open-angle and low tension glaucoma] Yu M, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May;33(3):173-7 (Eng. Abstr.) **(Chi)**

[Interest in the Heidelberg Retinal Flowmeter for measuring the retinal and papillary blood flow] Collignon-Brach J. **Bull Soc Belge Ophtalmol** 1998;270:51-5 (Eng. Abstr.) **(Fre)**

[Peak pulse blood volume in controlled modification of local perfusion parameters] Schmidt KG, et al. **Klin Monatsbl Augenheilkd** 1998 Dec;213(6):347-50 (Eng. Abstr.) **(Ger)**

[Relationship between visual field loss and retinal nerve fiber layer thickness in open-angle glaucoma] Ono J, et al. **Nippon Ganka Gakkai Zasshi** 1998 Oct;102(10):685-91 (Eng. Abstr.) **(Jpn)**

[Impact of disorders in blood rheology on progress of glaucoma in patients with stable normalized intraocular pressure] Egorov VV, et al. **Vestn Oftalmol** 1999 Jan-Feb; 115(1):5-7 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Loss of iridolenticular contact in eyes with exfoliation syndrome may protect against glaucoma. Konstas AG, et al. **Acta Ophthalmol Scand** 1999 Aug;77(4):467-70

Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration. Ellis JD, et al. **Br J Ophthalmol** 1999 Mar;83(3):369-72 (46 ref.)

Primary open-angle glaucoma may be a hyaluronic acid deficiency disease: potential for glucosamine in prevention and therapy. McCarty MF. **Med Hypotheses** 1998 Dec; 51(6):483-4 (13 ref.)

PSYCHOLOGY

The "personality" of the glaucomatous patient: preliminary results. Spinelli D, et al. **Acta Ophthalmol Scand Suppl** 1998; (227):53-4

Spatial and temporal visual filtering in patients with glaucoma and ocular hypertension. Vogt U, et al. **Eye** 1998;12 (Pt 4):691-6

SURGERY

The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Odberg T, et al. **Acta Ophthalmol Scand** 1999 Apr;77(2):176-81

Goniocurettage for removing trabecular meshwork: clinical results of a new surgical technique in advanced chronic open-angle glaucoma. Jacobi PC, et al. **Am J Ophthalmol** 1999 May;127(5):505-10

Outcomes of primary phakic trabeculectomies without versus with 0.5- to 1-minute versus 3- to 5-minute mitomycin C. Kim YY, et al. **Am J Ophthalmol** 1998 Dec; 126(6):755-62

Effect of topical anti-inflammatory treatment on the long-term outcome of laser trabeculoplasty. Fluorometholone-Laser Trabeculoplasty Study Group. Kim YY, et al. **Am J Ophthalmol** 1998 Nov;126(5):721-3

The Advanced Glaucoma Intervention Study (AGIS): 5. Encapsulated bleb after initial trabeculectomy. Schwartz AL, et al. **Am J Ophthalmol** 1999 Jan;127(1):8-19

Iridolenticular contact decreases following laser iridotomy for pigment dispersion syndrome. Breingan PJ, et al. **Arch Ophthalmol** 1999 Mar;117(3):325-8

Prospective evaluation of extraocular motility following double-plate molteno implantation. Dobler-Dixon AA, et al. **Arch Ophthalmol** 1999 Sep;117(9):1155-60

Glaucoma care in Olmsted County, Minnesota, 1965-1980: filtering surgery and vision outcomes [editorial; comment] Gaasterland DE. **Arch Ophthalmol** 1999 Sep;117(9):1236-7 (17 ref.). Comment on: Arch Ophthalmol 1999 Sep;117(9):1211-5.

Probability of filtration surgery in patients with open-angle glaucoma [see comments] Hattenhauer MG, et al. **Arch Ophthalmol** 1999 Sep;117(9):1211-5. Comment in: Arch Ophthalmol 1999 Sep;117(9):1236-7.

Tube erosion following insertion of a glaucoma drainage device with a pericardial patch graft. Lama PJ, et al. **Arch Ophthalmol** 1999 Sep;117(9):1243-4

Trabeculectomy with releasable sutures: a prospective, randomized pilot study. Raina UK, et al. **Arch Ophthalmol** 1998 Oct;116(10):1288-93

Age over 46 years does not affect the pressure lowering effect of trabeculectomy in primary open angle glaucoma. Briggs MC, et al. **Br J Ophthalmol** 1999 Mar;83(3):280-4

Deep sclerectomy with collagen implant: medium term results [see comments] Karlen ME, et al. **Br J Ophthalmol** 1999 Jan;83(1):6-11. Comment in: Br J Ophthalmol 1999 Jan;83(1):1-2.

Immediate intraocular pressure response to selective laser trabeculoplasty. Lanzetta P, et al. **Br J Ophthalmol** 1999 Jan;83(1):29-32

Course of exfoliation and simplex glaucoma after primary trabeculectomy. Popovic V, et al. **Br J Ophthalmol** 1999 Mar;83(3):305-10

Medium to long-term intraocular pressure control following small flap trabeculectomy (microtrabeculectomy) in relatively low risk eyes. Vernon SA, et al. **Br J Ophthalmol** 1998 Dec;82(12):1383-6

Non-penetrating deep sclerectomy preliminary results. Bas JM, et al. **Bull Soc Belge Ophtalmol** 1999;272:55-9

Is combined phacoemulsification and trabeculectomy as effective as trabeculectomy alone? Noben KJ, et al. **Bull Soc Belge Ophtalmol** 1998;270:85-90

Assessment of corneal decompensation in eyes having undergone molteno shunt procedures compared to eyes having undergone trabeculectomy. Zalloum JN, et al. **CLAO J** 1999 Jan;25(1):57-60

Delayed post-operative use of 5-fluorouracil as an adjunct in medically uncontrolled open angle glaucoma.

Mastropasqua L, et al. **Eye** 1998;12 (Pt 4):701–6
Post-operative inflammation following deep sclerectomy with collagen implant versus standard trabeculectomy. Chiou AG, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Aug;236(8):593–6
Management of phacolytic glaucoma: experience of 135 cases. Braganza A, et al. **Indian J Ophthalmol** 1998 Sep; 46(3):139–43
Evaluation of laser sclerostomy fistulas using ultrasound biomicroscopy. Häring G, et al. **Int Ophthalmol** 1997–98; 21(5):261–4
Understanding the new primary open-angle glaucoma preferred practice pattern. Lee PP. **Int Ophthalmol Clin** 1998 Summer;38(3):93–9
Mitomycin C-augumented trabeculectomy with postoperative wound modulation in pediatric glaucoma. Freedman SF, et al. **J Aapos** 1999 Apr;3(2):117–24
Consultation section. Cataract surgical problem. **J Cataract Refract Surg** 1999 Apr;25(4):467–73
Combined surgery for cataract and glaucoma: phacoemulsification and deep sclerectomy compared with phacoemulsification and trabeculectomy [see comments] Gianoli F, et al. **J Cataract Refract Surg** 1999 Mar; 25(3):340–6. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.
Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma [see comments] Mermoud A, et al. **J Cataract Refract Surg** 1999 Mar; 25(3):323–31. Comment in: J Cataract Refract Surg 1999 Mar;25(3):297. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.
New approaches to trabecular surgery [editorial; comment] Obstbaum SA. **J Cataract Refract Surg** 1999 Mar;25(3):297 Comment on: J Cataract Refract Surg 1999 Mar;25(3):316–22. Comment on: J Cataract Refract Surg 1999 Mar;25(3):323–31.
Nonpenetrating trabecular surgery: it's worth the change [editorial; comment] Sourdille P. **J Cataract Refract Surg** 1999 Mar;25(3):298–300 (8 ref.). Comment on: J Cataract Refract Surg 1999 Mar;25(3):316–22. Comment on: J Cataract Refract Surg 1999 Mar;25(3):323–31. Comment on: J Cataract Refract Surg 1999 Mar;25(3):332–9. Comment on: J Cataract Refract Surg 1999 Mar;25(3):340–6.
Viscocanalostomy for open-angle glaucoma in black African patients [see comments] Stegmann R, et al. **J Cataract Refract Surg** 1999 Mar;25(3):316–22. Comment in: J Cataract Refract Surg 1999 Mar;25(3):297. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.
Semiconductor diode laser transscleral cyclophotocoagulation in a patient with glaucoma secondary to metastatic tumor to the iris. El-Harazi SM, et al. **J Glaucoma** 1998 Oct;7(5):317–8
Trabeculectomy using a sutureless scleral tunnel technique: a preliminary study. Lai JS, et al. **J Glaucoma** 1999 Jun; 8(3):188–92
Quantification of blood--aqueous barrier breakdown after trabeculectomy: pseudoexfoliation versus primary open-angle glaucoma. Nguyen NX, et al. **J Glaucoma** 1999 Feb;8(1):18–23
Mitomycin C in higher risk trabeculectomy: a prospective comparison of 0.2- to 0.4-mg/cc doses. Sanders SP, et al. **J Glaucoma** 1999 Jun;8(3):193–8
Fornix-based versus limbal-based conjunctival flaps in initial trabeculectomy with postoperative 5-fluorouracil: four-year follow-up findings. el Sayyad F, et al. **J Glaucoma** 1999 Apr;8(2):124–8
Effect of trabeculectomy on visual field in progressive normal-tension glaucoma. Daugeliene L, et al. **Jpn J Ophthalmol** 1998 Jul–Aug;42(4):286–92
Changes in optic disc parameters after intraocular pressure reduction in adult glaucoma patients. Yoshikawa K, et al. **Jpn J Ophthalmol** 1999 May–Jun;43(3):225–31
Comparative study of three phacotrabeculectomy procedures through a single incision. Kim JW, et al. **Korean J Ophthalmol** 1998 Jun;12(1):30–6
Erbium: YAG laser trabecular ablation (LTA) in the surgical treatment of glaucoma. Dietlein TS, et al. **Lasers Surg Med** 1998;23(2):104–10
Endocapsular hematoma: report of a case following glaucoma surgery in a pseudophakic eye. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):389–93 (22 ref.)
Intraocular pressure control and visual outcome in patients with phacolytic glaucoma managed by extracapsular cataract extraction with or without posterior chamber intraocular lens implantation. Mandal AK, et al. **Ophthalmic Surg Lasers** 1998 Nov;29(11):880–9
Initial trabeculectomy with intraoperative mitomycin-C application in primary glaucomas. Rasheed el-S. **Ophthalmic Surg Lasers** 1999 May;30(5):360–6
Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG? Spiegel D, et al. **Ophthalmic Surg Lasers** 1999 Jun;30(6):492–4
Effects of frequency-doubled Nd:YAG laser trabeculoplasty on diurnal intraocular pressure variations in primary open-angle glaucoma. Guzey M, et al. **Ophthalmologica** 1999;213(4):214–8
Aqueous misdirection after glaucoma drainage device implantation. Greenfield DS, et al. **Ophthalmology** 1999 May;106(5):1035–40
Microendoscopic trabecular surgery in glaucoma management. Jacobi PC, et al. **Ophthalmology** 1999 Mar; 106(3):538–44
Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Latina MA, et al. **Ophthalmology** 1998 Nov;105(11):2082–8; discussion 2089–90
Reversal of optic disc cupping after glaucoma surgery analyzed with a scanning laser tomograph. Lesk MR, et al. **Ophthalmology** 1999 May;106(5):1013–8
Otago glaucoma surgery outcome study: long-term results of trabeculectomy--1976 to 1995. Molteno AC, et al. **Ophthalmology** 1999 Sep;106(9):1742–50
Ab-interno goniotrabeculotomy versus mitomycin C trabeculectomy for adult open-angle glaucoma: a 2-year randomized clinical trial. Quaranta L, et al. **Ophthalmology** 1999 Jul;106(7):1357–62
Efficacy of apraclonidine 1% versus pilocarpine 4% for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. Ren J, et al. **Ophthalmology** 1999 Jun; 106(6):1135–9
[Clinical observation of trabeculectomy without conjunctival incision] Jiang M, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May;33(3):178–80 (Eng. Abstr.) **(Chi)**
[The clinical effect after locally using mitomycin C during trabeculectomy in glaucoma] Xia X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):249–52 (Eng. Abstr.) **(Chi)**
[Deep nonpenetrating sclerectomy and open angle glaucoma. Intermediate results from the first operated patients] Hamard P, et al. **J Fr Ophtalmol** 1999 Feb;22(1):25–31 (Eng. Abstr.) **(Fre)**
[Artificial trabeculum (MESH). Clinical and histological study in the rabbit] Helies P, et al. **J Fr Ophtalmol** 1998 May;21(5):351–60 (Eng. Abstr.) **(Fre)**
[Non-penetrating deep sclerectomy in the surgical treatment of chronic open-angle glaucoma. Mid-term results] Massy J, et al. **J Fr Ophtalmol** 1999 Apr;22(3):292–8 (Eng. Abstr.) **(Fre)**
[External trabecular excision--alternative to filtering glaucoma operation in patients with open angle glaucoma] Schmidt J, et al. **Klin Monatsbl Augenheilkd** 1998 Dec; 213(6):320–5 (Eng. Abstr.) **(Ger)**
[Combined phacoemulsification and goniotrepanation in primary chronic open angle glaucoma and classical pseudoexfoliation glaucoma] Heuring AH, et al. **Ophthalmologe** 1999 May;96(5):312–8 (Eng. Abstr.) **(Ger)**
[Ab externo erbium YAG laser sclerostomy versus conventional trabeculectomy. Treatment of glaucoma patients] Spiegel D, et al. **Ophthalmologe** 1998 Aug; 95(8):537–41 (Eng. Abstr.) **(Ger)**
[The outlook for the use of diode laser radiation for trabeculoplasty in treating primary open-angle glaucoma] Litvinova GG, et al. **Vestn Oftalmol** 1998 Sep–Oct; 114(5):10–3 (Eng. Abstr.) **(Rus)**

THERAPY

Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment. Katz J, et al. **Arch Ophthalmol** 1999 Sep;117(9):1137–42
Risk factors for early filtration failure requiring suture release after primary glaucoma triple procedure with adjunctive mitomycin. Morris DA, et al. **Arch Ophthalmol** 1999 Sep; 117(9):1149–54
Prospects for genetic intervention in primary open-angle glaucoma. Wirtz MK, et al. **Drugs Aging** 1998 Nov; 13(5):333–40 (42 ref.)
Medical treatment patterns of ASCRS members for primary open-angle glaucoma--1998 survey. Shingleton BJ, et al. **J Cataract Refract Surg** 1999 Jan;25(1):118–27
Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Bergeá B, et al. **Ophthalmology** 1999 May;106(5):997–1004; discussion 1004–5
Decisions, decisions. Brubaker RF. **Ophthalmology** 1999 Jan; 106(1):165–8
The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Musch DC, et al. **Ophthalmology** 1999 Apr; 106(4):653–62
[Heparin inhalations and laser exposure of blood in treatment of patients with open-angle glaucoma] Balashova LM, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):6–9 (Eng. Abstr.) **(Rus)**
[Pathogenesis and treatment of low (normal) pressure glaucoma] Shmyreva VF, et al. **Vestn Oftalmol** 1998 Jul–Aug;114(4):47–8 (35 ref.) **(Rus)**

ULTRASONOGRAPHY

Ultrasound biomicroscopical study of the irido-corneal angle in dominant juvenile open-angle glaucoma, in POAG, and in normal eyes. Urbak SF. **Acta Ophthalmol Scand** 1999 Apr;77(2):160–4
Evaluation of laser sclerostomy fistulas using ultrasound biomicroscopy. Häring G, et al. **Int Ophthalmol** 1997–98; 21(5):261–4
[Doppler ultrasonographic examination in glaucoma] Borisova SA. **Vestn Oftalmol** 1998 Jul–Aug;114(4):52–5 (76 ref.) **(Rus)**

GLAUCOMA, PIGMENTARY see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA, SIMPLE see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA SIMPLEX see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA, SUSPECT see **OCULAR HYPERTENSION**

GLIA see **NEUROGLIA**

GLIADIN

ADMINISTRATION & DOSAGE

Brush border enzyme activities in the small intestine after long-term gliadin feeding in animal models of human coeliac disease. Kozáková H, et al. **Folia Microbiol (Praha)** 1998;43(5):497–500

ADVERSE EFFECTS

A novel wheat gliadin as a cause of exercise-induced anaphylaxis. Palosuo K, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):912–7
In vitro screening of food peptides toxic for coeliac and other gluten-sensitive patients: a review. Silano M, et al. **Toxicology** 1999 Feb 15;132(2–3):99–110 (98 ref.)

ANALYSIS

Comparative studies of the relative mobility of gliadin at low pH by capillary electrophoresis and conventional electrophoretic techniques. Rumbo M, et al. **J Capillary Electrophor** 1998 Jan–Apr;5(1–2):39–44
Presence of high levels of non-degraded gliadin in breast milk from healthy mothers. Chirdo FG, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1186–92

CHEMISTRY

Partial amino acid sequence of gamma-46 gliadin. Egorov TA, et al. **Biochemistry (Mosc)** 1998 Sep;63(9):1061–7
Determination of disulfide bonds in gamma-46 gliadin. Egorov TA, et al. **Biochemistry (Mosc)** 1999 Mar; 64(3):294–7
Small angle X-ray scattering of wheat seed-storage proteins: alpha-, gamma- and omega-gliadins and the high molecular weight (HMW) subunits of glutenin. Thomson NH, et al. **Biochim Biophys Acta** 1999 Mar 19; 1430(2):359–66
Fractionation of gliadin hydrolysates in water-ethanol by ultrafiltration with modified or unmodified membranes. Bérot S, et al. **Biotechnol Bioeng** 1999 Mar 20;62(6):649–58
Disulfide mapping of gamma-46 gliadin. Egorov TA, et al. **J Protein Chem** 1998 Aug;17(6):531

DIAGNOSTIC USE

Studies in vivo of omega-gliadins in gluten sensitivity (coeliac sprue disease). Ensari A, et al. **Clin Sci (Colch)** 1998 Oct;95(4):419–24

IMMUNOLOGY

Celiac disease in Turkish short-statured children and the value of antigliadin antibody in diagnosis. Altuntaş B, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):457–60
A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation? Biagi F, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):945–50
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice [see comments] Rostami K, et al. **Am J Gastroenterol** 1999 Apr;94(4):888–94. Comment in: Am J Gastroenterol 1999 Apr;94(4):869–71.
IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Ots M, et al. **Am J Nephrol** 1999;19(4):453–8
Antibodies to endomysium and gliadin in coeliac disease [letter; comment] Hill PG, et al. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):783–4. Comment on: Ann Clin Biochem 1998 May;35 (Pt 3):436–8.
Intestinal antibodies against gliadin, tissue-transglutaminase, beta-lactoglobulin, and ovalbumin in patients with irritable bowel syndrome. Wahnschaffe U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:280–4
Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies. Uhlig H, et al. **Autoimmunity** 1998; 28(4):185–95
T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC). O'Keeffe J, et al. **Clin Exp Immunol** 1999 Aug;117(2):269–76
Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin. ten Dam M, et al. **Clin Exp Immunol** 1998 Nov;114(2):189–95
In vitro model of the pathogenesis of celiac disease. Oberhuber G, et al. **Dig Dis** 1998 Nov–Dec;16(6):341–4 (48 ref.)
Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Volta U, et al. **Dig Dis Sci** 1998 Oct;43(10):2190–5
HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. Quarsten H, et al. **Eur J Immunol** 1999 Aug;29(8):2506–14
Measurement of gluten using a monoclonal antibody to a coeliac toxic peptide of A-gliadin. Ellis HJ, et al. **Gut** 1998

Aug;43(2):190–5
Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease [see comments] Krupicková S, et al. **Gut** 1999 Feb;44(2):168–73. Comment in: Gut 1999 Feb;44(2):151–2.
Dietary modifications: food dependent autoimmunity in coeliac disease. Mowat AM. **Gut** 1998 Nov;43(5):599–600
Gliadin activates mucosal cell mediated immunity in cultured rectal mucosa from coeliac patients and a subset of their siblings. Troncone R, et al. **Gut** 1998 Oct;43(4):484–9
Lack of cross-reactivity between casein and gliadin in sera from coeliac disease patients. Paranos S, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):152–4
Quantitative antigliadin antibody measurement in clinical practice: an Italian multicentre study. SIGEP Working Group on Quantitative AGA Standardization. Catassi C, et al. **Ital J Gastroenterol Hepatol** 1999 Jun–Jul; 31(5):366–70
Endomysium and antigliadin antibodies in dermatitis herpetiformis and other bullous diseases [letter] Economidou J, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):184–5
High frequency of antigliadin antibodies and absence of antireticulin and antiendomysium antibodies in patients with ulcerative colitis. Kull K, et al. **J Gastroenterol** 1999 Feb;34(1):61–5
Analysis of anti-gliadin antibodies by immunoblot analysis and enzyme-linked immunosorbent assay using gliadin fractions as antigens. Chirdo FG, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):171–7
Further studies of anti-endomysium and anti-gliadin antibodies in patients with suspected celiac disease. Del Rosario MA, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug; 27(2):191–5
IgA-gliadin antibodies, IgA-containing circulating immune complexes, and IgA glomerular deposits in wasting marmoset syndrome. Schroeder C, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1875–80
Prevalence of IgA-antiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Carlsson AK, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1248–52
Comparative analysis of serologic screening tests for the initial diagnosis of celiac disease. Russo PA, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):75–8
Is gliadin mispresented to the immune system in coeliac disease? A hypothesis. Biagi F, et al. **QJM** 1999 Feb; 92(2):119–22 (34 ref.)
Small-bowel mucosal inflammation in reticulin or gliadin antibody-positive patients without villous atrophy. Kaukinen K, et al. **Scand J Gastroenterol** 1998 Sep; 33(9):944–9
Intravenous or intranasal administration of gliadin is able to down-regulate the specific immune response in mice. Rossi M, et al. **Scand J Immunol** 1999 Aug;50(2):177–82
HLA restriction patterns of gliadin- and astrovirus-specific CD4+ T cells isolated in parallel from the small intestine of celiac disease patients. Molberg O, et al. **Tissue Antigens** 1998 Nov;52(5):407–15
[Milestones in the immunopathogenesis of endemic sprue] Dreier G, et al. **Z Gastroenterol** 1999 Jan;37(1):117–9 **(Ger)**
[Dosage of the antibody antigliadin in first degree relatives of celiac patients] Nunes CR, et al. **Arq Gastroenterol** 1998 Jan–Mar;35(1):69–73 (Eng. Abstr.) **(Por)**

METABOLISM

Targeting of gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR to Golgi complexes and vacuoles within celiac disease enterocytes. Zimmer KP, et al. **FASEB J** 1998 Oct;12(13):1349–57
HLA-DR53 molecules are associated with susceptibility to celiac disease and selectively bind gliadin-derived peptides. Clot F, et al. **Immunogenetics** 1999 Aug;49(9):800–7
Partial in vitro digestion of active gliadin-related peptides in celiac disease. Cornell HJ. **J Protein Chem** 1998 Nov; 17(8):739–44

PHARMACOLOGY

alpha-Gliadin-induced T cell activation from the peripheral blood measured by CD69 expression. Perticarari S, et al. **Eur J Histochem** 1997;41 Suppl 2:203–4

TOXICITY

In vitro cytotoxic effect of wheat gliadin-derived peptides on the Caco-2 intestinal cell line is associated with intracellular oxidative imbalance: implications for coeliac disease. Rivabene R, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):152–60

GLIAL FIBRILLARY ACIDIC PROTEIN

Cell differentiation increases astrocyte phagocytic activity. A quantitative analysis of both GFAP labeling and PAS-stained yeast cells. Iacono RF, et al. **Medicina (B Aires)** 1999;59(2):171–5

ANALYSIS

Glial fibrillary acidic protein-like immunoreactive ependymal elements in the third ventricle of the rat. A study at different stages of development. Juanes JA, et al. **Acta Anat (Basel)** 1992;145(4):364–9
Astroglial architecture of the carp (Cyprinus carpio) brain as revealed by immunohistochemical staining against glial fibrillary acidic protein (GFAP). Kálmán M. **Anat Embryol (Berl)** 1998 Nov;198(5):409–33
Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma. Luider TM, et al. **Electrophoresis** 1999 Apr–May;20(4–5):1087–91
GFAP, S-100 and vimentin proteins in rat after cerebral post-ischemic reperfusion. Martinez G, et al. **Int J Dev Neurosci** 1998 Oct;16(6):519–26
An enzyme-linked immunosorbent assay for glial fibrillary acidic protein as an indicator of the presence of brain or spinal cord in meat. Schmidt GR, et al. **J Food Prot** 1999 Apr;62(4):394–7
Pre- or postembedding immunocytochemistry: which to choose for the localization of glial fibrillary acidic protein (GFAP)? Hajós F, et al. **J Neurosci Methods** 1998 Nov 1;85(1):99–105
A method to quantify glial fibrillary acidic protein immunoreactivity on the suprachiasmatic nucleus. Vilaplana J, et al. **J Neurosci Methods** 1999 May 1; 88(2):181–7
Alterations in temporal/spatial distribution of GFAP- and vimentin-positive astrocytes after spinal cord contusion with the New York University spinal cord injury device. Baldwin SA, et al. **J Neurotrauma** 1998 Dec;15(12):1015–26
Immunocytochemical evidence for a distinct GFAP-negative subpopulation of astrocytes in the adult rat hippocampus. Walz W, et al. **Neurosci Lett** 1998 Dec 4;257(3):127–30
[Observation on oligodendroglioma with light, electron microscopy and immunohistochemistry] Hang Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Dec;26(6):346–8 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Glial fibrillary acidic protein (GFAP) immunoreactivity in enteric ganglia of the chick embryo. Balaskas C, et al. **Brain Res** 1998 Sep 7;804(2):275–83
The developmentally regulated avian protein IFAPa-400 is transitin. Ma X, et al. **Brain Res Dev Brain Res** 1998 Jul 1;109(1):59–66
Differential role of specific PKC isoforms in the proliferation of glial cells and the expression of the astrocytic markers GFAP and glutamine synthetase. Brodie C, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):108–17
Thyroid hormone regulates protein expression in C6 glioma cells. Trentin AG, et al. **Braz J Med Biol Res** 1998 Oct; 31(10):1281–4 (20 ref.)
Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. Pena JD, et al. **Exp Eye Res** 1999 Jan; 68(1):29–40
Cortical spreading depression increases protein synthesis and upregulates basic fibroblast growth factor. Kawahara N, et al. **Exp Neurol** 1999 Jul;158(1):27–36
Adenovirus-mediated over-expression of p21Waf-1 differentially affects the proliferation, telomerase activity, and expression of glial fibrillary acidic protein in human glioma cells. Terasaki M, et al. **Int J Oncol** 1999 Jan; 14(1):63–9
Effects of pulsed magnetic stimulation of GFAP levels in cultured astrocytes. Chan P, et al. **J Neurosci Res** 1999 Jan 15;55(2):238–44
Role of glial fibrillary acidic protein expression in the biology of human glioblastoma U-373MG cells. Murphy KG, et al. **J Neurosurg** 1998 Dec;89(6):997–1006
Sequential changes in glial fibrillary acidic protein and gene expression following parasagittal fluid-percussion brain injury in rats. Dietrich WD, et al. **J Neurotrauma** 1999 Jul;16(7):567–81
GFAP gene expression is altered in young rats following developmental low level lead exposure. Partl S, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):547–51
Fibroblast growth factor-9 (glia-activating factor) stimulates proliferation and production of glial fibrillary acidic protein in human gliomas either in the presence or in the absence of the endogenous growth factor expression. Miyagi N, et al. **Oncol Rep** 1999 Jan–Feb;6(1):87–92
[Astrogliosis and basic fibrobl..st growth factor] Li L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Feb;26(1):8–10 (Eng. Abstr.) **(Chi)**

BLOOD

Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Missler U, et al. **Clin Chem** 1999 Jan;45(1):138–41

CEREBROSPINAL FLUID

Detection of light subunit neurofilament and glial fibrillary acidic protein in cerebrospinal fluid of Trypanosoma brucei gambiense-infected patients. Lejon V, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):94–8
Markers of nerve tissue injury in the cerebrospinal fluid in patients with lumbar disc herniation and sciatica. Brisby H, et al. **Spine** 1999 Apr 15;24(8):742–6

CHEMISTRY

Role of the C-terminal extension in the interaction of S100A1 with GFAP, tubulin, the S100A1- and S100B-inhibitory peptide, TRTK-12, and a peptide derived from p53, and the S100A1 inhibitory effect on GFAP polymerization. Garbuglia M, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):36–41

DEFICIENCY

Altered taurine release following hypotonic stress in astrocytes from mice deficient for GFAP and vimentin. Ding M, et al. **Brain Res Mol Brain Res** 1998 Nov 12; 62(1):77–81

GENETICS

Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Theurillat JP, et al. **Am J Pathol** 1999 Feb;154(2):581–90
Neurons induce GFAP gene promoter of cultured astrocytes from transgenic mice. Gomes FC, et al. **Glia** 1999 Apr; 26(2):97–108
Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. Pekny M, et al. **J Cell Biol** 1999 May 3;145(3):503–14
Glial fibrillary acidic protein transcription responses to transforming growth factor-beta1 and interleukin-1beta are mediated by a nuclear factor-1-like site in the near-upstream promoter. Krohn K, et al. **J Neurochem** 1999 Apr;72(4):1353–61
Structural features of the rat GFAP gene and identification of a novel alternative transcript. Condorelli DF, et al. **J Neurosci Res** 1999 May 1;56(3):219–28
Sequential changes in glial fibrillary acidic protein and gene expression following parasagittal fluid-percussion brain injury in rats. Dietrich WD, et al. **J Neurotrauma** 1999 Jul;16(7):567–81
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Trejo F, et al. **Life Sci** 1999; 65(5):483–91
GFAPbeta mRNA expression in the normal rat brain and after neuronal injury. Condorelli DF, et al. **Neurochem Res** 1999 May;24(5):709–14
Tubulin and glial fibrillary acidic protein gene expression in developing fetal human brain at midgestation. Pal U, et al. **Neurochem Res** 1999 May;24(5):637–41
Suppression of glial tumor growth by expression of glial fibrillary acidic protein. Toda M, et al. **Neurochem Res** 1999 Feb;24(2):339–43
Stochastic determination of the chromosomal region responsible for expression of human glial fibrillary acidic protein in astrocytic tumors. Yoshimine T, et al. **Neurosci Lett** 1998 May 8;247(1):29–32
Altered physiology of Purkinje neurons in cerebellar slices from transgenic mice with chronic central nervous system expression of interleukin-6. Nelson TE, et al. **Neuroscience** 1999 Mar;89(1):127–36
GFAP gene expression is altered in young rats following developmental low level lead exposure. Partl S, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):547–51

IMMUNOLOGY

Cerebral calcification in a patient with systemic lupus erythematosus and a monoclonal IgG reactive with glial fibrillary acidic protein [letter] Stuart BM, et al. **Br J Rheumatol** 1998 Dec;37(12):1355–7
[Clinical and immunochemical characteristics of remittent multiple sclerosis] Gusev EI, et al. **Vestn Ross Akad Med Nauk** 1999;(7):40–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Formation of GFAP cytoplasmic inclusions in astrocytes and their disaggregation by alphaB-crystallin. Koyama Y, et al. **Am J Pathol** 1999 May;154(5):1563–72
Distribution of glial fibrillary acidic protein and vimentin-immunopositive elements in the developing chicken brain from hatch to adulthood. Kálmán M, et al. **Anat Embryol (Berl)** 1998 Sep;198(3):213–35
Astrocyte reaction in the rat vestibular nuclei after unilateral removal of Scarpa's ganglion. Li H, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):181–8
beta-Amyloid toxicity in rat brain reaggregate cultures. Davenport Jones J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):S240
Glial fibrillary acidic protein expression but no glial demarcation follows the lesion in the molecular layer of cerebellum. Ajtai BM, et al. **Brain Res** 1998 Aug 17; 802(1–2):285–8
A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Fukumura M, et al. **Brain Res** 1998 Sep 21;806(1):1–7
Regulation of protein phosphorylation in astrocyte cultures by external calcium ions: specific effects on the phosphorylation of glial fibrillary acidic protein (GFAP), vimentin and heat shock protein 27 (HSP27). Gottfried C, et al. **Brain Res** 1999 Jul 3;833(2):142–9
Pregnenolone reverses the age-dependent accumulation of glial fibrillary acidic protein within astrocytes of specific

regions of the rat brain. Legrand A, et al. **Brain Res** 1998 Aug 17;802(1-2):125-33

Ciliary neurotrophic factor stimulates nuclear hypertrophy and increases the GFAP content of cultured astrocytes. Levison SW, et al. **Brain Res** 1998 Aug 24;803(1-2):189-93

Temporally structured impulse activity in spontaneously discharging somatosensory cortical neurons in the awake cat: recognition and quantitative description of four different patterns of bursts, post-recording GFAP immunohistology and computer reconstruction of the studied cortical surface. Miasnikov AA, et al. **Brain Res Brain Res Protoc** 1999 Apr;4(1):49-68

Annexin VI binds S100A1 and S100B and blocks the ability of S100A1 and S100B to inhibit desmin and GFAP assemblies into intermediate filaments. Garbuglia M, et al. **Cell Calcium** 1998 Sep;24(3):177-91

Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Greber S, et al. **Electrophoresis** 1999 Apr-May; 20(4-5):928-34

Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Von Lubitz DK, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):157-63

Different distribution of S-100 protein and glial fibrillary acidic protein (GFAP) immunoreactive cells and their relations with nitrergic neurons in the human fetal small intestine. Fekete E, et al. **Histol Histopathol** 1999 Jul; 14(3):785-90

Unilateral injury to the adult rat optic nerve causes multiple cellular responses in the contralateral site. Bodeutsch N, et al. **J Neurobiol** 1999 Jan;38(1):116-28

Decrease of glial fibrillary acidic protein in rat frontal cortex following aluminum treatment. Guo-Ross SX, et al. **J Neurochem** 1999 Oct;73(4):1609-14

Age-related changes of glial fibrillary acidic protein immunoreactive astrocytes in the rat cerebellar cortex. Sabbatini M, et al. **Mech Ageing Dev** 1999 May 3; 108(2):165-72

Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Karson CN, et al. **Mol Psychiatry** 1999 Jan;4(1):39-45

The S100B protein inhibits phosphorylation of GFAP and vimentin in a cytoskeletal fraction from immature rat hippocampus. Ziegler DR, et al. **Neurochem Res** 1998 Oct; 23(10):1259-63

Glial fibrillary acidic protein (GFAP)-immunoreactivity is reduced by castration in the interpeduncular nucleus of male rats. Hajós F, et al. **Neuroreport** 1999 Aug 2; 10(11):2229-33

The mGluR stimulating GFAP phosphorylation in immature hippocampal slices has some properties of a group II receptor. Kommers T, et al. **Neuroreport** 1999 Jul 13; 10(10):2119-23

NMDA-induced increases in rat brain glutamine synthetase but not glial fibrillary acidic protein are mediated by free radicals. Davenport Jones JE, et al. **Neurosci Lett** 1998 May 8;247(1):37-40

Heat-shock proteins expression in fish central nervous system and its possible relation with water acidosis resistance. Martin M, et al. **Neurosci Res** 1998 Jun;31(2):97-106

Effects of transient cerebral ischemia on glial fibrillary acidic protein phosphorylation and immunocontent in rat hippocampus. Valentim LM, et al. **Neuroscience** 1999; 91(4):1291-7

Enhancement of cocaine-induced hyperthermia fails to elicit neurotoxicity. Cappon GD, et al. **Neurotoxicol Teratol** 1998 Sep-Oct;20(5):531-5

Decreases in brain glial fibrillary acidic protein (GFAP) are associated with increased serum corticosterone following inhalation exposure to toluene. Little AR Jr, et al. **Neurotoxicology** 1998 Aug-Oct;19(4-5):739-47

Human glioblastoma differentiation is modulated by growth environment. Gascón A, et al. **Pathol Res Pract** 1999; 195(2):71-5

The expression of B-50/GAP-43 and GFAP after bilateral olfactory bulbectomy in rats. Cízková D, et al. **Physiol Res** 1997;46(6):487-95

Methimazole toxicity in rodents: covalent binding in the olfactory mucosa and detection of glial fibrillary acidic protein in the olfactory bulb. Bergman U, et al. **Toxicol Appl Pharmacol** 1999 Mar 1;155(2):190-200

PHYSIOLOGY

Glial fibrillary acidic protein is necessary for mature astrocytes to react to beta-amyloid. Xu K, et al. **Glia** 1999 Feb 15;25(4):390-403

Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma. Ylikoski J, et al. **Hear Res** 1998 Oct;124(1-2):17-26

GLIAL INTERMEDIATE FILAMENT PROTEIN see **GLIAL FIBRILLARY ACIDIC PROTEIN**

GLIBENCLAMIDE see **GLYBURIDE**

GLICLAZIDE

CHEMISTRY

Gliclazide. Parvez M, et al. **Acta Crystallogr C** 1999 Jan 15; 55 (Pt 1):74-5

Study of the inclusion of gliclazide in alpha-cyclodextrin. Arias-Blanco MJ, et al. **J Pharm Biomed Anal** 1998 Oct; 18(1-2):275-9

PHARMACOKINETICS

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. Courtois P, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):211-22

PHARMACOLOGY

Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Fukuzawa M, et al. **Diabetes Res Clin Pract** 1999 Mar;43(3):147-54

Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Gribble FM, et al. **Diabetologia** 1999 Jul;42(7):845-8

Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats. Dachicourt N, et al. **Eur J Pharmacol** 1998 Nov 20;361(2-3):243-51

The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. Tanira MO, et al. **Pharmacol Res** 1999 May;39(5):349-56

THERAPEUTIC USE

The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus. Ammari F, et al. **Diabet Med** 1999 Feb; 16(2):142-6

Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia [letter] Bardini G, et al. **Diabet Med** 1998 Aug;15(8):706

Medium-term hypoglycaemic effects of two different oral formulations of gliclazide [letter] Galeone F, et al. **Diabet Med** 1999 Jul;16(7):618-9

Antioxidant effects of gliclazide and soluble adhesion molecules in type 2 diabetes [letter; comment] Elhadd TA, et al. **Diabetes Care** 1999 Mar;22(3):528-30. Comment on: Diabetes Care 1998 Apr;21(4):487-93.

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Tessier D, et al. **Metabolism** 1999 Jul;48(7):897-903

[Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data] Galeone F, et al. **Minerva Endocrinol** 1998 Sep;23(3):71-5 (Eng. Abstr.) **(Ita)**

GLIDIAZINAMIDE see **GLIPIZIDE**

GLIDING BACTERIA

CLASSIFICATION

Description of Cellulophaga baltica gen. nov., sp. nov. and Cellulophaga fucicola gen. nov., sp. nov. and reclassification of [Cytophaga] lytica to Cellulophaga lytica gen. nov., comb. nov. Johansen JE, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1231-40

GENETICS

Phylogenetic affinity of a wide, vacuolate, nitrate-accumulating Beggiatoa sp. from Monterey Canyon, California, with Thioploca spp. Ahmad A, et al. **Appl Environ Microbiol** 1999 Jan;65(1):270-7

GLIOBLASTOMA

Oscillating growth patterns of multicellular tumour spheroids. Chignola R, et al. **Cell Prolif** 1999 Feb; 32(1):39-48

In vitro and in vivo radiation sensitivity of glioblastoma multiforme: correction [letter] Taghian A. **Int J Radiat Oncol Biol Phys** 1998 Sep 1;42(2):464

Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. Deininger MH, et al. **J Neuroimmunol** 1999 Mar 1; 95(1-2):202-8

A 54-year-old woman with recurrent headaches and seizures. Kavanagh BD, et al. **Oncology (Huntingt)** 1998 Nov;12(11):1669-73

[A survey of malignant gliomas accompanied with visceral malignancies] Hayashi T, et al. **No Shinkei Geka** 1998 Oct; 26(10):909-15 (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Effect of hyperosmotic solutions on human brain tumour vasculature. Sato S, et al. **Acta Neurochir (Wien)** 1998; 140(11):1135-41; disc 1141-2

Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? [comment] Laurén J, et al. **Am J Pathol** 1998 Nov;153(5):1333-9 (79 ref.). Comment on: Am J Pathol 1998 Nov;153(5):1459-66.

Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Roberts WG, et al. **Am J Pathol** 1998 Oct;153(4):1239-48

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis [see comments] Stratmann A, et al. **Am J Pathol** 1998 Nov; 153(5):1459-66. Comment in: Am J Pathol 1998 Nov;153(5):1333-9.

CEREBROSPINAL FLUID

Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. Sato Y, et al. **J Neurooncol** 1998 Oct; 40(1):47-50

Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy? Streffer JR, et al. **J Neurooncol** 1998 Dec;40(3):233-5

[The permeability of the hemato-encephalic barrier in neurological cancer patients in the postoperative period] Kislitsyn IuV. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan-Mar;(1):25-7; discussion 27-8 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Carnemolla B, et al. **Am J Pathol** 1999 May;154(5):1345-52

Tissue factor and cell morphology variations in cell lines subcloned from U87-MG. Carson SD, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):539-47

Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Hiura T, et al. **Cancer** 1998 Dec 1;83(11):2361-9

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Debinski W, et al. **Clin Cancer Res** 1999 May;5(5):985-90

An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Debinski W. **Crit Rev Oncog** 1998;9(3-4):255-68 (81 ref.)

Comparison of in vivo 1H MRS of human brain tumours with 1H HR-MAS spectroscopy of intact biopsy samples in vitro. Barton SJ, et al. **MAGMA** 1999 May;8(2):121-8

Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Bouvier-Labit C, et al. **Neuropathol Appl Neurobiol** 1998 Oct;24(5):381-8

c-myc oncogene family expression in glioblastoma and survival. Herms JW, et al. **Surg Neurol** 1999 May; 51(5):536-42

Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Nagashima G, et al. **Surg Neurol** 1999 Mar;51(3):292-9

COMPLICATIONS

Chiasmal apoplexy, an unusual complication of cerebral glioblastoma [letter] Wright M, et al. **Eye** 1999 Apr;13 (Pt 2):268-9

Chiasmal apoplexy, an unusual complication of cerebral glioblastoma [letter] Wright M, et al. **Eye** 1999;13 (Pt 1):120-1

Drug-responsive mania in a man with a brain tumor [letter] Mazure CM, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter;11(1):114-5

Temporal glioblastoma causing trigemiral neuralgia. Case illustration. Deshpande S, et al. **J Neurosurg** 1999 Sep; 91(3):515

Association of cerebral venous malformation with glioblastoma--case report. Kanai H, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):738-42 (16 ref.)

CONGENITAL

Prenatal sonographic findings associated with malignant astrocytoma following normal early third-trimester ultrasonography. Sylvestre G, et al. **Am J Perinatol** 1998; 15(10):581-4

Congenital glioblastoma diagnosed by fetal sonography. Lee DY, et al. **Childs Nerv Syst** 1999 Apr;15(4):197-201 (27 ref.)

DIAGNOSIS

Bone metastasis of glioblastoma multiforme confirmed by fine needle biopsy. Frappaz D, et al. **Acta Neurochir (Wien)** 1999;141(5):551-2

Intracranial tumor masquerading as cervical radiculopathy: a case study. Clar SA, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1301-2

Gliomatosis cerebri with secondary glioblastoma formation: report of two cases. Kannuki S, et al. **Brain Tumor Pathol** 1998;15(2):111-6

Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Lee SW, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1;43(1):79-88

Glioblastoma presenting as carbon monoxide poisoning. Turner M, et al. **J Accid Emerg Med** 1999 Mar;16(2):155-6

Improved diagnosis of contrast-enhancing brain lesions with multifunctional MRI assessment: a case report. Flacke S, et al. **J Magn Reson Imaging** 1999 May;9(5):741-4

Isolated oculomotor nerve palsy: an unusual presentation of glioblastoma multiforme. Case report and review of the literature. al-Yamany M, et al. **J Neurooncol** 1999 Jan; 41(1):77-80

[Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas?] Egelhof T, et al. **Radiologe** 1998 Nov;38(11):943-7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A phase I–II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Larner J, et al. **Am J Clin Oncol** 1998 Dec;21(6):579–83

Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Sankar A, et al. **Anticancer Drugs** 1999 Feb;10(2):179–85

Polyoxoanions are cytotoxic to malignant glioma cells. Wolff JE, et al. **Anticancer Drugs** 1998 Oct;9(9):803–7

Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Fukushima T, et al. **Anticancer Res** 1998 Sep–Oct; 18(5D):3965–70

Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Chamberlain MC, et al. **Arch Neurol** 1999 Jun;56(6):703–8

Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Sanders MM, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1157–66

The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers [editorial; comment] Brem H, et al. **Cancer** 1999 Jul 15;86(2):197–9. Comment on: Cancer 1999 Jul 15;86(2):325–30.

Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study [see comments] Menei P, et al. **Cancer** 1999 Jul 15;86(2):325–30. Comment in: Cancer 1999 Jul 15;86(2):197–9.

The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Baumgartner G, et al. **Cancer Lett** 1998 Sep 11;131(1):85–99

Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Rubsam LZ, et al. **Cancer Res** 1999 Feb 1;59(3):669–75

(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Sun LQ, et al. **Cancer Res** 1998 Dec 1;58(23):5411–7

Chemotherapy for spinal cord astrocytoma: can natural history be modified? Lowis SP, et al. **Childs Nerv Syst** 1998 Jul;14(7):317–21

Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Begemann M, et al. **Clin Cancer Res** 1996 Jun;2(6):1017–30

Inhibition of human glioblastoma cell adhesion and invasion by
4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and
4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Narla RK, et al. **Clin Cancer Res** 1998 Oct;4(10):2463–71

Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Ruan S, et al. **Clin Cancer Res** 1999 Jan;5(1):197–202

MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Kirches E, et al. **Clin Neuropathol** 1999 Jan–Feb;18(1):1–8

Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. da Rocha AB, et al. **Eur J Cancer** 1999 May;35(5):833–9

A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Gundersen S, et al. **Eur J Cancer** 1998 Sep; 34(10):1565–9

Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Fulda S, et al. **Int J Cancer** 1999 Jul 30;82(3):435–41

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Groves MD, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):127–35

The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Kleinberg L, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):535–43

Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Williams JA, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):631–9

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. Paulsen F, et al. **J Cancer Res Clin Oncol** 1999 Jul;125(7):411–8

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. Brandes AA, et al. **J Clin Oncol** 1999 Feb;17(2):645–50

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Friedman HS, et al. **J Clin Oncol** 1998 Dec;16(12):3851–7

Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. Boiardi A, et al. **J Neurooncol** 1999 Jan;41(2):151–7

Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. Chamberlain MC, et al. **J Neurooncol** 1999 May;43(1):71–8

Tamoxifen radiosensitization in human glioblastoma cell lines. Donson AM, et al. **J Neurosurg** 1999 Mar;90(3):533–6

Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. Khalid MH, et al. **J Neurosurg** 1999 May;90(5):918–27

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma [see comments] Buckner JC, et al. **Mayo Clin Proc** 1999 Feb; 74(2):137–45. Comment in: Mayo Clin Proc 1999 Jun;74(6):641–2.

Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group. Grovas AC, et al. **Med Pediatr Oncol** 1999 Aug;33(2):83–7

Studies on the mechanism of resistance to rapamycin in human cancer cells. Hosoi H, et al. **Mol Pharmacol** 1998 Nov;54(5):815–24

Secondary glioblastoma remarkably reduced by steroid administration after anaplastic transformation from gliomatosis cerebri--case report. Hirose Y, et al. **Neurol Med Chir (Tokyo)** 1998 Dec;38(12):865–70

Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study. Behrens PF, et al. **Neurosurgery** 1998 Aug;43(2):235–40; discussion 240–1

Morbidity and survival after
1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Subach BR, et al. **Neurosurgery** 1999 Jul; 45(1):17–22; discussion 22–3

Time until initiation of tumor growth is an effective measure of the anti-angiogenic effect of TNP-470 on human glioblastoma in nude mice. Kragh M, et al. **Oncol Rep** 1999 Jul-Aug;6(4):759–62

Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Arab S, et al. **Oncol Res** 1999;11(1):33–9

Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol. Lederman G, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):162–74

[Dependence of the antineoplastic effect of hormonal cytostatic cortifen on expression of glucocorticoid receptors in brain tumor cells] Smirnova ZS, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):331–3 **(Rus)**

ENZYMOLOGY

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Nakada M, et al. **Am J Pathol** 1999 Feb; 154(2):417–28

Endonuclease activity and hydrogen peroxide-induced cytotoxicity in human glioblastoma and glioma cell lines. Iida M, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1235–40

Expression of CD 73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Ludwig HC, et al. **Anticancer Res** 1999 May-Jun;19(3A):1747–52

Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Sawaya R, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):632–6

Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Leirdal M, et al. **Br J Cancer** 1999 Jul;80(10):1558–64

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Haas-Kogan D, et al. **Curr Biol** 1998 Oct 22;8(21):1195–8

FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. Sonoda Y, et al. **J Biol Chem** 1999 Apr 9;274(15):10566–70

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Friedman HS, et al. **J Clin Oncol** 1998 Dec;16(12):3851–7

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. Jaeckle KA, et al. **J Clin Oncol** 1998 Oct; 16(10):3310–5

Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells. Takahashi K, et al. **J Neurochem** 1999 Jun;72(6):2356–61

Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to beta-amyloid peptide. Deb S, et al. **J Neurosci Res** 1999 Jan 1;55(1):44–53

Mutation of the uracil DNA glycosylase gene detected in glioblastoma. Moon YW, et al. **Mutat Res** 1998 Nov 3; 421(2):191–6

Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Kiaris H, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):226–31

EPIDEMIOLOGY

Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Scott JN, et al. **Ann Neurol** 1999 Aug;46(2):183–8

Long-term glioblastoma multiforme survivors: a population-based study. Scott JN, et al. **Can J Neurol Sci** 1998 Aug;25(3):197–201

ETIOLOGY

Transmission of glioblastoma multiforme through liver transplantation [letter] [see comments] [published erratum appears in Lancet 1998 Oct 17;352(9136):1316] Frank S, et al. **Lancet** 1998 Jul 4;352(9121):31. Comment in: Lancet 1998 Jul 4;352(9121):2–3. Comment in: Lancet 1998 Sep 5;352(9130):822.

Glioblastoma multiforme following prophylactic cranial irradiation and intrathecal methotrexate in a child with acute lymphoblastic leukaemia : a case report. Muzumdar DP, et al. **Neurol India** 1999 Jun;47(2):142–4

[A case of glioblastoma manifesting 49 years after lobotomy] Fukushima H, et al. **No To Shinkei** 1998 Aug;50(8):755–60 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Fujisawa H, et al. **Am J Pathol** 1999 Aug;155(2):387–94

Identification of genetic markers of the glial tumor by means of differential display technique. Comincini S, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):277–80

Association of EGFR gene fragments with nuclear matrices in glioblastoma cell lines. Wang ZH, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4329–32

Genetic aberrations in glioblastoma multiforme: translocation of chromosome 10 in an O-2A-like cell line. Mao X, et al. **Br J Cancer** 1999 Feb;79(5–6):724–31

Subsets of glioblastoma: clinical and histological vs. genetic typing [editorial; comment] Kleihues P. **Brain Pathol** 1998 Oct;8(4):667–8. Comment on: Brain Pathol 1998 Oct;8(4):655–87.

Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes [see comment] Newcomb EW, et al. **Brain Pathol** 1998 Oct;8(4):655–67. Comment on: Brain Pathol 1998 Oct;8(4):667–8.

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Perry A, et al. **Cancer** 1999 Aug 15;86(4):672–83

Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients. Frigerio S, et al. **Cancer Genet Cytogenet** 1999 Mar;109(2):172–4

A recurrent 19q11-12 breakpoint suggested by cytogenetic and fluorescence in situ hybridization analysis of three glioblastoma cell lines. Magnani I, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):82–6

Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Ehemann V, et al. **Cancer Lett** 1999 Apr 26;138(1-2):101–6

Chromosomal aberrations detected by comparative genomic hybridization (CGH) in human astrocytic tumors. Maruno M, et al. **Cancer Lett** 1999 Jan 8;135(1):61–6

Glioblastoma cell-specific expression of fibroblast growth factor receptor-1beta requires an intronic repressor of RNA splicing. Jin W, et al. **Cancer Res** 1999 Jan 15; 59(2):316–9

Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Huhn SL, et al. **Clin Cancer Res** 1999 Jun;5(6):1435–43

Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. Scheck AC, et al. **Clin Cancer Res** 1996 Jan;2(1):187–99

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Haas-Kogan D, et al. **Curr Biol** 1998 Oct 22;8(21):1195–8

Assignment of the GOV (Glioblastoma overexpressed) gene to human chromosome band 19p13.2 by fluorescence in situ hybridization. Chen XN, et al. **Cytogenet Cell Genet** 1998;83(3–4):230–1

3' end structure and rearrangements of EGFR in glioblastomas. Eley G, et al. **Genes Chromosomes Cancer** 1998 Nov;23(3):248–54

Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2–7 gene deletion in human glioblastomas. Worm K, et al. **Hum Pathol** 1999 Feb;30(2):222–7

Differential polymerase chain reaction: a technical comparison of three methods for the detection of CDK4 gene amplification in glioblastomas. Fan X, et al. **Int J Oncol** 1998 Nov;13(5):963–6

p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Haas-Kogan DA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):399–403

Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. Abounader R, et al. **J Natl Cancer Inst** 1999 Sep 15; 91(18):1548–56

Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. Abe T, et al.

J Neurooncol 1998 Oct;40(1):11-8

Alleletyping of an oligodendrocyte-type-2 astrocyte lineage derive from a human glioblastoma multiforme. Mao X, et al. **J Neurooncol** 1998 Dec;40(3):243-50

Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. Cheng Y, et al. **J Neuropathol Exp Neurol** 1999 Feb;58(2):120-8

Acquired rearrangement of an amplified epidermal growth factor receptor (EGFR) gene in a human glioblastoma xenograft. Goike HM, et al. **J Neuropathol Exp Neurol** 1999 Jul;58(7):697-701

Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. Jung V, et al. **J Neuropathol Exp Neurol** 1999 Sep; 58(9):993-9

Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. Liu L, et al. **J Neuropathol Exp Neurol** 1998 Dec;57(12):1138-45

The hPMS2 exon 5 mutation and malignant glioma. Case report. Taylor MD, et al. **J Neurosurg** 1999 May; 90(5):946-50

Genetic profile of the giant cell glioblastoma. Peraud A, et al. **Lab Invest** 1999 Feb;79(2):123-9

Mutation of the uracil DNA glycosylase gene detected in glioblastoma. Moon YW, et al. **Mutat Res** 1998 Nov 3; 421(2):191-6

Clinical importance of c-Met protein expression in high grade astrocytic tumors. Hirose Y, et al. **Neurol Med Chir (Tokyo)** 1998 Dec;38(12):851-8; discussion 858-9

Stochastic determination of the chromosomal region responsible for expression of human glial fibrillary acidic protein in astrocytic tumors. Yoshimine T, et al. **Neurosci Lett** 1998 May 8;247(1):29-32

Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Li Q, et al. **Oncogene** 1999 May 27;18(21):3284-9

cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines. Rhee CH, et al. **Oncogene** 1999 Apr 29;18(17):2711-7

Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences. Saxena A, et al. **Oncogene** 1999 Feb 11;18(6):1385-90

Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Somerville RP, et al. **Oncogene** 1998 Oct 1;17(13):1755-7

Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling. Rhee CH, et al. **Oncol Rep** 1999 Mar-Apr;6(2):393-401

Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. Rathore A, et al. **Pathol Oncol Res** 1999;5(1):21-7

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas. Biernat W, et al. **Pol J Pathol** 1998; 49(4):267-71

A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Rieske P, et al. **Pol J Pathol** 1998;49(3):145-9

First gene involved in glioblastoma progression identified. Kolchinsky A. **Surg Neurol** 1999 Jul;52(1):19-20

[Clinical and pathological significance of p53 gene mutation in human cerebral glioblastoma multiforme] Matsumoto R. **Hokkaido Igaku Zasshi** 1998 Jul;73(4):407-17 (Eng. Abstr.) **(Jpn)**

[Expression of p53 protein and proliferative activity in multiform glioblastoma] Zimnoch L, et al. **Neurol Neurochir Pol** 1998 Jul-Sep;32(4):877-83 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Enhancing effect of tumor necrosis factor (TNF)-alpha, but not IFN-gamma, on the tumor-specific cytotoxicity of gammadeltaT cells from glioblastoma patients. Suzuki Y, et al. **Cancer Lett** 1999 Jun 1;140(1-2):161-7

In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Fujimiya Y, et al. **Clin Cancer Res** 1997 Apr;3(4):633-43

Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients. Fujimiya Y, et al. **J Hematother** 1999 Feb; 8(1):29-37

Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy? Streffer JR, et al. **J Neurooncol** 1998 Dec;40(3):233-5

Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Tran CT, et al. **Neuropathol Appl Neurobiol** 1998 Aug;24(4):293-301

METABOLISM

Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Deininger MH, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):240-4

Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins. Sultana S, et al. **Am J Pathol** 1998 Oct; 153(4):1157-68

Malignant human gliomas express an amiloride-sensitive Na+ conductance. Bubien JK, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1405-10

Supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas are characterized by a differential expression of S100 proteins. Camby I, et al. **Brain Pathol** 1999 Jan;9(1):1-19

Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Khalid MH, et al. **Brain Tumor Pathol** 1998; 15(2):89-94

Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas. Miyagami M, et al. **Brain Tumor Pathol** 1998;15(2):95-100

Expression and cellular localization of low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in human glioblastoma in vivo. Yamamoto M, et al. **Brain Tumor Pathol** 1998;15(1):23-30

Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis [published erratum appears in Cancer Res 1999 Mar 1;59(5):1167] Davies MA, et al. **Cancer Res** 1998 Dec 1; 58(23):5285-90

Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Fuller GN, et al. **Cancer Res** 1999 Sep 1;59(17):4228-32

Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Huang RP, et al. **Cancer Res** 1998 Nov 15;58(22):5089-96

Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Rubsam LZ, et al. **Cancer Res** 1999 Feb 1;59(3):669-75

Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Sano T, et al. **Cancer Res** 1999 Apr 15;59(8):1820-4

Microglial/macrophage expression of interleukin 10 in human glioblastomas. Wagner S, et al. **Int J Cancer** 1999 Jul 2; 82(1):12-6

Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Moriyama T, et al. **Int J Mol Med** 1999 May;3(5):531-6 (66 ref.)

Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Debinski W, et al. **Int J Oncol** 1999 Sep;15(3):481-6

Suppression of heat-induced p53 accumulation and activation by CDDP or x-rays in human glioblastoma cells. Matsumoto H, et al. **Int J Oncol** 1998 Oct;13(4):741-7

Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in vivo. Mohanam S, et al. **Int J Oncol** 1999 Jan;14(1):169-74

Increased uptake of 99mTc-HMPAO in necrotic brain tumors. Lee SH, et al. **J Korean Med Sci** 1998 Oct; 13(5):529-32

Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression. Donson AM, et al. **J Neurooncol** 1998 Dec;40(3):205-14

Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1. Osmak M, et al. **J Neurooncol** 1999 Apr;42(2):95-102

Presurgical serum albumin levels predict survival time from glioblastoma multiforme. Schwartzbaum JA, et al. **J Neurooncol** 1999 May;43(1):35-41

Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. Kato S, et al. **J Neuropathol Exp Neurol** 1999 May;58(5):430-41

Ets-1 positively regulates expression of urokinase-type plasminogen activator (uPA) and invasiveness of astrocytic tumors. Nakada M, et al. **J Neuropathol Exp Neurol** 1999 Apr;58(4):329-34

Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. Verity AN, et al. **J Neurosci Res** 1999 Jan 15;55(2):187-97

Role of glial fibrillary acidic protein expression in the biology of human glioblastoma U-373MG cells. Murphy KG, et al. **J Neurosurg** 1998 Dec;89(6):997-1006

Relations between intracellular Ca2+ stores and store-operated Ca2+ entry in primary cultured human glioblastoma cells. Hartmann J, et al. **J Physiol (Lond)** 1998 Dec 1;513 (Pt 2):411-24

CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. Sehgal A, et al. **J Surg Oncol** 1998 Oct;69(2):99-104

Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. Endo M, et al. **Microvasc Res** 1999 Sep;58(2):89-98

Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors. Kitange G, et al. **Mod Pathol** 1999 Jun;12(6):618-26

Immunohistochemical analysis of cyclin A in astrocytic tumours. Chakrabarty A, et al. **Neuropathol Appl Neurobiol** 1998 Jun;24(3):239-45

Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Khoshyomn S, et al. **Neurosurgery** 1999 Mar; 44(3):568-77; discussion 577-8

Intercellular signaling initiated by nitric oxide produced in heat-shocked human glioblastoma cells. Matsumoto H, et al. **Nitric Oxide** 1999;3(2):180-9

Human glioblastoma differentiation is modulated by growth environment. Gascón A, et al. **Pathol Res Pract** 1999; 195(2):71-5

Occurrence of ganglioside GD3 in neoplastic astrocytes. An immunocytochemical study in humans. Kawai K, et al. **Virchows Arch** 1999 Mar;434(3):201-5

[Relationship between p16 and Rb protein expression in astrocytomas] Lin Y, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Dec;26(6):340-2 (Eng. Abstr.) **(Chi)**

[The prognostic importance of cancer-associated proteins and apoptosis in glioblastomas of the cerebral hemispheres] Korshunov AG, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan-Mar;(1):3-7 (Eng. Abstr.) **(Rus)**

MORTALITY

Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes [see comment] Newcomb EW, et al. **Brain Pathol** 1998 Oct;8(4):655-67. Comment on: Brain Pathol 1998 Oct;8(4):667-8.

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. Jaeckle KA, et al. **J Clin Oncol** 1998 Oct; 16(10):3310-5

[Prognosis of brain tumors: epidemiology, survival time and clinical course] Steiner HH, et al. **Versicherungsmedizin** 1998 Oct 1;50(5):173-9 (32 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Lovely MP, et al. **Oncol Nurs Forum** 1999 Jun;26(5):921-5

PATHOLOGY

Squash cytology of pleomorphic xanthoastrocytoma mimicking glioblastoma. A case report. Kobayashi S, et al. **Acta Cytol** 1999 Jul-Aug;43(4):652-8

Vitamin D metabolites activate the sphingomyelin pathway and induce death of glioblastoma cells. Magrassi L, et al. **Acta Neurochir (Wien)** 1998;140(7):707-13; discussion 713-4

Apoptosis in astrocytomas with different grades of malignancy. Yew DT, et al. **Acta Neurochir (Wien)** 1998; 140(4):341-7

Extracellular matrix-induced cell migration from glioblastoma biopsy specimens in vitro Mahesparan R, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):231-9

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Fujisawa H, et al. **Am J Pathol** 1999 Aug;155(2):387-94

Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Scott JN, et al. **Ann Neurol** 1999 Aug;46(2):183-8

Association of EGFR gene fragments with nuclear matrices in glioblastoma cell lines. Wang ZH, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4329-32

Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. Dash RC, et al. **Arch Pathol Lab Med** 1999 Apr; 123(4):342-5

Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo. Sawaya R, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):632-6

Tissue factor and cell morphology variations in cell lines subcloned from U87-MG. Carson SD, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):539-47

Subsets of glioblastoma: clinical and histological vs. genetic typing [editorial; comment] Kleihues P. **Brain Pathol** 1998 Oct;8(4):667-8. Comment on: Brain Pathol 1998 Oct;8(4):655-87.

Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Khalid MH, et al. **Brain Tumor Pathol** 1998; 15(2):89-94

Cell death induced by high-linear-energy transfer carbon beams in human glioblastoma cell lines. Tsuchida Y, et al. **Brain Tumor Pathol** 1998;15(2):71-6

Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Al-Saleem T, et al. **Cancer** 1998 Nov 15; 83(10):2208-16

Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cheney IW, et al. **Cancer Res** 1999 May 15;59(10):2318-23

Malignant cerebellar astrocytomas in childhood. Experience with four cases. Bristot R, et al. **Childs Nerv Syst** 1998 Oct;14(10):532-6

Glioblastoma multiforme in a dermoid cyst of the ovary. A

case report. den Boon J, et al. **Eur J Gynaecol Oncol** 1999; 20(3):187–8

Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1. Pijuan-Thompson V, et al. **Exp Cell Res** 1999 May 25;249(1):86–101

Fetal glioblastoma: rapid growth during the third trimester. Kamitomo M, et al. **Fetal Diagn Ther** 1998 Nov–Dec; 13(6):339–42

MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults. Matsumoto T, et al. **Histopathology** 1998 Nov; 33(5):446–52

Glioblastoma multiforme in a mature ovarian teratoma with recurring brain tumours. Yadav A, et al. **Histopathology** 1999 Aug;35(2):170–3 (10 ref.)

Characterization of human glioblastoma xenograft growth in athymic mice. Ozawa T, et al. **In Vivo** 1998 Jul–Aug; 12(4):369–74

Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Kraus A, et al. **Int J Cancer** 1999 Mar 15;80(6):930–4

Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. Hayen W, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2241–51

Endobronchial metastasis of glioblastoma multiforme diagnosed by fiberoptic bronchoscopic biopsy. Chung YH, et al. **J Formos Med Assoc** 1999 Feb;98(2):133–5

Intraoperative dynamic MRI: localization of sites of brain tumor recurrence after high-dose radiotherapy. Schwartz RB, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1085–9

Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. Sugahara T, et al. **J Magn Reson Imaging** 1999 Jan; 9(1):53–60

Gastrin inhibits motility, decreases cell death levels and increases proliferation in human glioblastoma cell lines. De Hauwer C, et al. **J Neurobiol** 1998 Nov 15;37(3):373–82

Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. Goswami S, et al. **J Neurochem** 1998 Nov;71(5):1837–45

Expression of granulocyte colony-stimulating factor in recurrent glial tumors is inversely correlated with tumor progression. Stan AC, et al. **J Neuroimmunol** 1999 Feb 1; 94(1–2):66–73

Alleletyping of an oligodendrocyte-type-2 astrocyte lineage derive from a human glioblastoma multiforme. Mao X, et al. **J Neurooncol** 1998 Dec;40(3):243–50

Prognostic limitations of the Daumas-Duport grading scheme in childhood supratentorial astroglial tumors. Brown WD, et al. **J Neuropathol Exp Neurol** 1998 Nov; 57(11):1035–40

Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. Cheng Y, et al. **J Neuropathol Exp Neurol** 1999 Feb;58(2):120–8

Pleuropulmonary metastasis from an intracranial glioblastoma. Greif J, et al. **Lung Cancer** 1998 May; 20(2):135–7

In vivo establishment of T98G human glioblastoma. Rubenstein M, et al. **Methods Find Exp Clin Pharmacol** 1999 Jul–Aug;21(6):391–3

Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Harland SP, et al. **Neurosurgery** 1998 Oct; 43(4):890–8; discussion 898–9

Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors. Iwata S, et al. **Neurosurgery** 1999 Jul;45(1):24–8; discussion 29

Pleomorphic xanthoastrocytoma with malignant progression [letter; comment] Charbel FT. **Surg Neurol** 1998 Oct; 50(4):385–6. Comment on: Surg Neurol 1997 Feb;47(2):162–9.

Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Nagashima G, et al. **Surg Neurol** 1999 Mar;51(3):292–9

[Effects of nordihydroguaiaretic acid on the growth and differentiation of SHG-44 glioma cell line] Bian X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct;26(5):285–8 (Eng. Abstr.) **(Chi)**

[Study on p53 protein expression, cell proliferation and apoptosis in benign and malignant brain tumors] Yu S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct; 26(5):293–6 (Eng. Abstr.) **(Chi)**

[Grading of astrocytomas and oligodendrogliomas] Kolles H, et al. **Pathologe** 1998 Jul;19(4):259–68 (49 ref.) (Eng. Abstr.) **(Ger)**

[Appearance of the resection area of brain tumors in intraoperative MRI imaging] Dietrich J, et al. **Radiologe** 1998 Nov;38(11):935–42 (Eng. Abstr.) **(Ger)**

[201T1C1 accumulation dynamics in glioma with different grades of malignancy: an investigation using dynamic SPECT] Sugo N, et al. **No Shinkei Geka** 1998 Oct; 26(10):881–7 (Eng. Abstr.) **(Jpn)**

[Inhibition of fibroblast growth factor receptor 1 expression in human glioblastoma cell contributes to the cell growth suppression] Yamada SM, et al. **No To Shinkei** 1998 Dec; 50(12):1101–5 (Eng. Abstr.) **(Jpn)**

[Proliferative activity of glial neoplasms of the brain] Zimnoch L, et al. **Neurol Neurochir Pol** 1999 Jan–Feb; 33(1):87–96 (Eng. Abstr.) **(Pol)**

[Cerebral gliomatosis with development of multifocal glioblastoma] Martinez-Mata AM, et al. **Rev Neurol** 1999 Apr 16–30;28(8):781–3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Functional activation of EphA5 receptor does not promote cell proliferation in the aberrant EphA5 expressing human glioblastoma U-118 MG cell line. Bruce V, et al. **Brain Res** 1999 Mar 6;821(1):169–76

Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. Hayen W, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2241–51

Nitric oxide-mediated modulation of interleukin-8 production by a human glioblastoma cell line, T98G, cocultured with myeloid and monocytic cell lines. Oda T, et al. **J Interferon Cytokine Res** 1998 Oct;18(10):905–12

Hormonal effects on glioblastoma multiforme in the nude rat model. Plunkett RJ, et al. **J Neurosurg** 1999 Jun; 90(6):1072–7

PREVENTION & CONTROL

Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences. Saxena A, et al. **Oncogene** 1999 Feb 11;18(6):1385–90

PSYCHOLOGY

Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Lovely MP, et al. **Oncol Nurs Forum** 1999 Jun;26(5):921–5

RADIOGRAPHY

[Glioblastoma fed by meningeal branches of the external carotid artery: a case report] Okuyama T, et al. **No Shinkei Geka** 1999 May;27(5):447–52 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Cerebral gliomatosis with development of multifocal glioblastoma] Martinez-Mata AM, et al. **Rev Neurol** 1999 Apr 16–30;28(8):781–3 (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Sasaki M, et al. **Eur J Nucl Med** 1998 Sep;25(9):1261–9

RADIOTHERAPY

Intracavity fractionated balloon brachytherapy in glioblastoma. Johannesen TB, et al. **Acta Neurochir (Wien)** 1999;141(2):127–33

Cell death induced by high-linear-energy transfer carbon beams in human glioblastoma cell lines. Tsuchida Y, et al. **Brain Tumor Pathol** 1998;15(2):71–6

(E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Sun LQ, et al. **Cancer Res** 1998 Dec 1;58(23):5411–7

Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Huhn SL, et al. **Clin Cancer Res** 1999 Jun;5(6):1435–43

A comparison of two planning techniques for radiotherapy of high grade astrocytomas. Crosby TD, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):392–8

Low dose hypersensitivity in the T98G human glioblastoma cell line. Short S, et al. **Int J Radiat Biol** 1999 Jul; 75(7):847–55

A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Groves MD, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):127–35

p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Haas-Kogan DA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):399–403

The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Kleinberg L, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):535–43

Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Mohan DS, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):981–7

Beam collimation and bolusing material optimizations for 10boron neutron capture enhancement of fast neutron (BNCEFN): definition of the optimum irradiation technique. Pignol JP, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1151–9

Postirradiation primary Kaposi's sarcoma of the head and neck. De Pasquale R, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):312–4

Re: impact of stromal sensitivity on radiation response of tumors [letter; comment] Budach W. **J Natl Cancer Inst** 1998 Dec 2;90(23):1842. Comment on: J Natl Cancer Inst 1993 Jun 16;85(12):988–93.

Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. Joel DD, et al. **J Neurooncol** 1999 Feb;41(3):213–21

Boron neutron capture enhancement (BNCE) of fast neutron irradiation for glioblastoma: increase of thermal neutron flux with heavy material collimation, a theoretical evaluation. Paquis P, et al. **J Neurooncol** 1999 Jan; 41(1):21–30

Tamoxifen radiosensitization in human glioblastoma cell lines. Donson AM, et al. **J Neurosurg** 1999 Mar;90(3):533–6

Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. Fitzek MM, et al. **J Neurosurg** 1999 Aug;91(2):251–60

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. Akabani G, et al. **J Nucl Med** 1999 Apr;40(4):631–8

Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Nieder C, et al. **Radiat Oncol Investig** 1999;7(1):36–41

Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. Hulshof MC, et al. **Radiother Oncol** 1998 Aug;48(2):135–42

The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Stüben G, et al. **Radiother Oncol** 1998 Aug;48(2):143–8

Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961). Hideghéty K, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:111–4

Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Lang O, et al. **Strahlenther Onkol** 1998 Dec;174(12):629–32

Organisation and management of the first clinical trial of BNCT in Europe (EORTC protocol 11961).EORTC BNCT study group. Sauerwein W, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:108–11

[Spinal metastases of malignant gliomas] Materlik B, et al. **Strahlenther Onkol** 1998 Sep;174(9):478–81 (Eng. Abstr.) **(Ger)**

SECONDARY

Spinal drop metastases in recurrent glioblastoma multiforme. Buhl R, et al. **Acta Neurochir (Wien)** 1998;140(10):1001–5

Bone metastasis of glioblastoma multiforme confirmed by fine needle biopsy. Frappaz D, et al. **Acta Neurochir (Wien)** 1999;141(5):551–2

Systemic metastases of glioblastoma multiforme. Waite KJ, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):205–7

Endobronchial metastasis of glioblastoma multiforme diagnosed by fiberoptic bronchoscopic biopsy. Chung YH, et al. **J Formos Med Assoc** 1999 Feb;98(2):133–5

A case of cervical lymph node metastasis resulting from glioblastoma multiforme. Datta CK, et al. **W V Med J** 1998 Sep–Oct;94(5):276–8

SURGERY

Intraoperative microdialysis and tissue-pO2 measurement in human glioma. Baunach S, et al. **Acta Neurochir Suppl (Wien)** 1998;71:241–3

Decreased BOLD functional MR activation of the motor and sensory cortices adjacent to a glioblastoma multiforme: implications for image-guided neurosurgery [see comments] Holodny AI, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):609–12. Comment in: AJNR Am J Neuroradiol 1999 Apr;20(4):536.

Dose-related increases in cerebrospinal fluid concentrations of methotrexate in a postoperative patient with glioblastoma. Morikawa N, et al. **Ann Pharmacother** 1999 Sep;33(9):952–6

Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Klein R, et al. **Childs Nerv Syst** 1998 Jun;14(6):288–91 (23 ref.)

Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Mohan DS, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):981–7

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Friedman HS, et al. **J Clin Oncol** 1998 Nov;16(11):3570–5

Primary cerebellar glioblastomas multiforme in children. Report of four cases. Kulkarni AV, et al. **J Neurosurg** 1999 Mar;90(3):546–50

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. Shrieve DC, et al. **J Neurosurg** 1999 Jan;90(1):72–7

Two-staged resection of a left frontal astrocytoma involving the operculum and insula using intraoperative neurophysiological monitoring--case report. Kumabe T, et al. **Neurol Med Chir (Tokyo)** 1998 Aug;38(8):503–7

Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Quan D, et al. **Neurology** 1999 Jul 13;53(1):211–3

Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas [letter; comment] De Witte O, et al. **Neurosurgery** 1998 Aug;43(2):398–9. Comment on: Neurosurgery 1997 Nov;41(5):1028–36; discussion 1036–8.

Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol.

GLIOBLASTOMA

Lederman G, et al. **Stereotact Funct Neurosurg** 1997;69(1-4 Pt 2):162-74

Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961). Hideghéty K, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:111-4

THERAPY

A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Rainov NG, et al. **Adv Exp Med Biol** 1998;451:393-403

A new treatment for high grade gliomas of the brain. Brady LW. **Bull Mem Acad R Med Belg** 1998;153(5-6):255-61; discussion 261-2

Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells. Berenstein M, et al. **Cancer Gene Ther** 1999 Jul-Aug;6(4):358-66

Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase. Haselsberger K, et al. **Cancer Lett** 1998 Sep 11; 131(1):109-11

Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Mohan PM, et al. **Cancer Res** 1999 Jul 15;59(14):3369-73

Successful use of a plant gene in the treatment of cancer in vivo. Cortés ML, et al. **Gene Ther** 1998 Nov; 5(11):1499-507

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Palù G, et al. **Gene Ther** 1999 Mar;6(3):330-7

Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Beutler AS, et al. **Hum Gene Ther** 1999 Jan 1;10(1):95-101

A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Klatzmann D, et al. **Hum Gene Ther** 1998 Nov 20; 9(17):2595-604

Adenovirus mediated gene therapy in a glioblastoma vaccine model; specific antitumor immunity and abrogation of immunosuppression. Donson AM, et al. **J Neurooncol** 1998 Dec;40(3):205-14

A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive CxT24-neo3 glioblastoma cell. Kaetzel DM, et al. **J Neurooncol** 1998 Aug;39(1):33-46

A syngeneic mouse glioma model for study of glioblastoma therapy. Weiner NE, et al. **J Neuropathol Exp Neurol** 1999 Jan;58(1):54-60

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. Wallenfriedman MA, et al. **J Neurosurg** 1999 Jun; 90(6):1064-71

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma [letter] Csatary LK, et al. **JAMA** 1999 May 5;281(17):1588-9

Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Tsurushima H, et al. **Jpn J Cancer Res** 1999 May;90(5):536-45

Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation. Tian XX, et al. **Neuropathol Appl Neurobiol** 1998 Oct; 24(5):389-96

Parameters influencing the efficiency of the thymidine kinase/ganciclovir strategy in human glioblastoma cell lines. Sturtz FG, et al. **Stereotact Funct Neurosurg** 1997; 68(1-4 Pt 1):252-7

Pleomorphic xanthoastrocytoma with malignant progression [letter; comment] Charbel FT. **Surg Neurol** 1998 Oct; 50(4):385-6. Comment on: Surg Neurol 1997 Feb;47(2):162-9.

Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Puri RK. **Toxicol Pathol** 1999 Jan-Feb;27(1):53-7 (28 ref.)

[Gene therapy of cerebral glioblastoma by adenovirus vector. Experimental model in the rat] Dufour T, et al. **Chirurgie** 1998 Apr;123(2):168-74 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Prenatal sonographic findings associated with malignant astrocytoma following normal early third-trimester ultrasonography. Sylvestre G, et al. **Am J Perinatol** 1998; 15(10):581-4

Congenital glioblastoma diagnosed by fetal sonography. Lee DY, et al. **Childs Nerv Syst** 1999 Apr;15(4):197-201 (27 ref.)

ULTRASTRUCTURE

The ultrastructure of glial tumors of astrocytic lineage: a review. Liberski PP. **Folia Neuropathol** 1998;36(3):161-77 (83 ref.)

GLIOBLASTOMA-DERIVED T-CELL SUPPRESSOR FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

GLIOBLASTOMA MULTIFORME see **GLIOBLASTOMA**

GLIOBLASTOMA, RETINAL see **RETINOBLASTOMA**

GLIOMA

Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells. Held-Feindt J, et al. **Brain Res Mol Brain Res** 1999 Jan 22;64(1):101-7

Differentially expressed genes in C6.9 glioma cells during vitamin D-induced cell death program. Baudet C, et al. **Cell Death Differ** 1998 Jan;5(1):116-25

Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Wagenknecht B, et al. **Cell Death Differ** 1999 Apr; 6(4):370-6

Bibliography. Current world literature. Brain and nervous system. **Curr Opin Oncol** 1999 May;11(3):B103-10

Gliomas. Cokgor I, et al. **Eur J Cancer** 1998 Nov; 34(12):1910-5; discussion 1916-8 (84 ref.)

An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. Grobben B, et al. **J Neurochem** 1999 Feb; 72(2):826-34

CP-10, a chemotactic peptide, is expressed in lesions of experimental autoimmune encephalomyelitis, neuritis, uveitis and in C6 gliomas. Deininger MH, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):156-63

Development of a new mouse brain tumor model using implantable micro-cannulas. Griffitt W, et al. **J Neurooncol** 1999 Jan;41(2):117-20

Restoration of wild-type PTEN expression leads to apoptosis, induces differentiation, and reduces telomerase activity in human glioma cells. Tian XX, et al. **J Neuropathol Exp Neurol** 1999 May;58(5):472-9

Pontine gliomas: a lesson to learn [editorial; comment] Constantini S, et al. **Neuropediatrics** 1998 Dec;29(6):282-3 . Comment on: Neuropediatrics 1998 Dec;29(6):328-30.

Complete remission of a diffuse pontine glioma [see comments] Lenard HG, et al. **Neuropediatrics** 1998 Dec; 29(6):328-30. Comment in: Neuropediatrics 1998 Dec;29(6):282-3.

Enhanced expression of neurotrophic factors by C6 rat glioma cells after transfection with glia maturation factor. Zaheer A, et al. **Neurosci Lett** 1999 Apr 23;265(3):203-6

Postoperative neuroimaging of high-grade gliomas: comparison of transcranial sonography, magnetic resonance imaging, and computed tomography. Becker G, et al. **Neurosurgery** 1999 Mar;44(3):469-77; discussion 477-8

Choroid plexus papilloma: a clinicopathological study of 23 cases. Sarkar C, et al. **Surg Neurol** 1999 Jul;52(1):37-9

BLOOD

Serum cholesterol in cerebral malignancies. Grieb P, et al. **J Neurooncol** 1999 Jan;41(2):175-80

Hypotheses concerning roles of dietary energy, cured meat, and serum tocopherols in adult glioma development. Schwartzbaum JA, et al. **Neuroepidemiology** 1999; 18(3):156-66

Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of alpha-fetoprotein. Hany MA, et al. **Pediatr Hematol Oncol** 1998 Sep-Oct;15(5):437-41

BLOOD SUPPLY

Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Sugahara T, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1479-86

Blood-brain barrier and blood volume imaging of cerebral glioma using functional CT: a pictorial review. Leggett DA, et al. **Australas Radiol** 1998 Nov;42(4):335-40

Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Johansson M, et al. **Br J Cancer** 1999 Apr;80(1-2):142-8

Scatter factor/hepatocyte growth factor gene transfer increases rat blood-glioma barrier permeability. Book AA, et al. **Brain Res** 1999 Jul 3;833(2):173-80

X-ray-induced P-selectin localization to the lumen of tumor blood vessels. Hallahan DE, et al. **Cancer Res** 1998 Nov 15;58(22):5216-20

Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Nishie A, et al. **Clin Cancer Res** 1999 May;5(5):1107-13

Absence of host-site influence on angiogenesis, blood flow, and permeability in transplanted RG-2 gliomas. Molnar P, et al. **Drug Metab Dispos** 1999 Sep;27(9):1085-91

Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma. Kazuno M, et al. **Eur J Cancer** 1999 Mar;35(3):502-6

Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. Weissleder R, et al. **Eur J Cancer** 1998 Aug;34(9):1448-54

MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Tynninen O, et al. **Invest Radiol** 1999 Jun;34(6):427-34

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [see comments] Benjamin LE, et al. **J Clin Invest** 1999 Jan;103(2):159-65. Comment in: J Clin Invest 1999 Jan;103(2):157-8.

NMR imaging of changes in vascular morphology due to tumor angiogenesis. Dennie J, et al. **Magn Reson Med** 1998 Dec;40(6):793-9

Global HDO uptake in human glioma xenografts is related to the perfused capillary distribution. van der Sanden BP, et al. **Magn Reson Med** 1999 Sep;42(3):479-89

A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Bernsen HJ, et al. **Microvasc Res** 1999 May;57(3):244-57

Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin. Sugita M, et al. **Neurol Res** 1998 Sep;20(6):559-63

Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Swaroop GR, et al. **Neuroreport** 1998 Aug 3;9(11):2577-81

Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Bernsen HJ, et al. **Neurosurgery** 1998 Sep;43(3):570-5; discussion 575-6

CHEMICALLY INDUCED

Glial tumors in the MNU rat model: induction of pure and mixed gliomas that do not require typical missense mutations of p53. Rushing EJ, et al. **J Neuropathol Exp Neurol** 1998 Nov;57(11):1053-60

Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Thulborn KR, et al. **Magn Reson Med** 1999 Feb;41(2):351-9

CHEMISTRY

Isolation of plasma membranes from rat C6 glioma cells cultivated on microcarriers. Wang Q, et al. **Acta Histochem** 1999 Jul;101(3):327-39

Chemical, metabolic and immunological characterization of gangliosides of human glioma cells. Maeda Y, et al. **Cancer Biochem Biophys** 1998 Nov;16(4):313-32

Mouse cytochrome b561: cDNA cloning and expression in rat brain, mouse embryos, and human glioma cell lines. Srivastava M, et al. **DNA Cell Biol** 1998 Sep;17(9):771-7

Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. Zou JP, et al. **J Immunol** 1999 Apr 15; 162(8):4882-92

Expression of PECAM-1/CD31 isoforms in human brain gliomas. Aroca F, et al. **J Neurooncol** 1999 May;43(1):19-25

Coexpression of genes involved in apoptosis in central nervous system neoplasms. Bruggers CS, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):19-25

Expression of oncoprotein Bcl-2 and bax protein in the infiltration zone and in the parenchyma of primary glia-derived supratentorial neoplasms. Kałuża J, et al. **Pol J Pathol** 1998;49(4):273-7

CLASSIFICATION

[Classification and grading of gliomas and meningiomas] Niedermayer I, et al. **Radiologe** 1998 Nov;38(11):888-97 (63 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Gliomatosis cerebri: clinical features, treatment, and prognosis. Kim DG, et al. **Acta Neurochir (Wien)** 1998; 140(8):755-62

Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema. Takahashi H, et al. **Acta Neurochir (Wien)** 1999;141(7):771-8

Diffuse brain stem tumor in an adolescent with multiple enchondromatosis (Ollier's disease). Frappaz D, et al. **Childs Nerv Syst** 1999 May;15(5):222-5 (24 ref.)

Choroid plexus papilloma of the temporal horn associated with transtentorial herniation. Sener RN. **Comput Med Imaging Graph** 1998 May-Jun;22(3):263-4

Color Doppler image of central retinal artery of eyes with an intraconal mass. Mendivil A, et al. **Curr Eye Res** 1999 Feb;18(2):104-9

Dermatofibrosarcoma protuberans in an infant with a history of choroid plexus papilloma. Libow LF, et al. **Cutis** 1999 Feb;63(2):95-7

Epilepsy and gliomas: incidence and treatment in 119 patients. Pace A, et al. **J Exp Clin Cancer Res** 1998 Dec;17(4):479-82

So-called posterior internuclear ophthalmoplegia due to a pontine glioma: a clinicopathological study [letter] Wiest G, et al. **J Neurol** 1999 May;246(5):412-5

Simultaneous occurrence of a supra- and an infratentorial glioma in a patient with Ollier's disease: more evidence for non-mesodermal tumor predisposition in multiple enchondromatosis. Hofman S, et al. **Skeletal Radiol** 1998 Dec;27(12):688-91

[Unilateral congenital nystagmus revealing a glioma of the optic pathways] Feki J, et al. **Tunis Med** 1998 Nov; 76(11):417-20 **(Fre)**

[Optic glioma in children with type 1 neurofibromatosis] Ben-Arush M, et al. **Harefuah** 1998 Oct;135(7-8):264-7, 336 (Eng. Abstr.) **(Heb)**

[Subarachnoid hemorrhage due to conus medullaris ependymoma] Janda R, et al. **Neurol Neurochir Pol** 1998 Mar-Apr;32(2):409-15 (Eng. Abstr.) **(Pol)**

[A skull base tumor complicated by rhinorrhea]

Hermanowski M, et al. **Otolaryngol Pol** 1997;51 Suppl 25:86–9 (Eng. Abstr.) **(Pol)**

CONGENITAL

Endoscopic approach to nasal glioma. Burckhardt W, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):747–8

DIAGNOSIS

Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Selvapandian S, et al. **Acta Neurochir (Wien)** 1999; 141(7):721–6; discussion 726–7

Prognostic relevance of cell proliferation markers and DNA-ploidy in gliomas. Struikmans H, et al. **Acta Neurochir (Wien)** 1998;140(2):140–7

Subcutaneous sacrococcygeal myxopapillary ependymoma. Chung JY, et al. **AJNR Am J Neuroradiol** 1999 Feb; 20(2):344–6

MR spectroscopy of bilateral thalamic gliomas. Estève F, et al. **AJNR Am J Neuroradiol** 1999 May;20(5):876–81

Diffuse malignant leptomeningeal gliomatosis in a child: a case report and review of the literature. Paulino AC, et al. **Am J Clin Oncol** 1999 Jun;22(3):243–6

Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas. Kishima H, et al. **Br J Cancer** 1999 Jan;79(2):333–9

MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Rosenbaum T, et al. **Brain Dev** 1999 Jun;21(4):268–73

Gliomatosis cerebri with secondary glioblastoma formation: report of two cases. Kannuki S, et al. **Brain Tumor Pathol** 1998;15(2):111–6

Answer to case of the month #60. Postoperative dissemination of fat particles in the subarachnoid spaces and intraventricular system from spinal dermoid tumour. Belley G, et al. **Can Assoc Radiol J** 1999 Apr;50(2):131–4

An enhancing optic nerve lesion: malignant glioma of adulthood [letter; comment] Jordan DR. **Can J Ophthalmol** 1998 Oct;33(6):306–7. Comment on: Can J Ophthalmol 1997 Oct;32(6):409–13.

Immunocytochemical detection of insulin-like growth factor II (IGF-II) in choroid plexus papilloma: a possible marker for differential diagnosis. Kubo S, et al. **Clin Neuropathol** 1999 Mar–Apr;18(2):74–9

Gliomatosis cerebri: findings with computed tomography and magnetic resonance imaging. Ponce P, et al. **Eur J Radiol** 1998 Oct;28(3):226–9

Pathways from symptoms to medical care: a descriptive study of symptom development and obstacles to early diagnosis in brain tumour patients. Salander P, et al. **Fam Pract** 1999 Apr;16(2):143–8

Comparison of the diagnostic information in relative cerebral blood volume, maximum concentration, and subtraction signal intensity maps based on magnetic resonance imaging of gliomas. Berchtenbreiter C, et al. **Invest Radiol** 1999 Jan;34(1):75–81

Choroid plexus papilloma. Boelhouwers HJ, et al. **J Belge Radiol** 1998 Oct;81(5):234

Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. Poptani H, et al. **J Cancer Res Clin Oncol** 1999;125(6):343–9

Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. Perilongo G, et al. **J Child Neurol** 1999 Jun;14(6):352–6 (13 ref.)

Sequential imaging and volumetric analysis of an intracerebral C6 glioma by means of a clinical MRI system. Raila FA, et al. **J Neurooncol** 1999 May;43(1):11–7

Monitoring tumor activity in low grade glioma of childhood. Mölenkamp G, et al. **Klin Padiatr** 1998 Jul–Aug; 210(4):239–42

3D spin-lock imaging of human gliomas. Aronen HJ, et al. **Magn Reson Imaging** 1999 Sep;17(7):1001–10

Brainstem tuberculoma mimicking glioma: the role of antituberculous drugs as a diagnostic tool. Del Brutto OH, et al. **Neurology** 1999 Jan 1;52(1):210–1

Adult brainstem gliomas. Landolfi JC, et al. **Neurology** 1998 Oct;51(4):1136–9

Stump the professor [editorial] **Obstet Gynecol Surv** 1999 Jul; 54(7):417–20

A correlative study of gliomas using in vivo bromodeoxyuridine labeling index and computer-aided malignancy grading. Sharma S, et al. **Pathol Oncol Res** 1999;5(2):134–41

Neuropathological biopsy diagnoses in clinical practice: how thorough and reproducible are they? [letter] Ojeda VJ, et al. **Pathology** 1998 Aug;30(3):328–9 (14 ref.)

Test and teach. Number ninety one: Part 1. Subependymal giant cell astrocytoma. Singh M, et al. **Pathology** 1999 Feb; 31(1):23–4, 51

Globular glioma of the tectum. Antunes NL, et al. **Pediatr Neurol** 1999 Jul;21(1):492–5

MRI diagnosis of gliomatosis cerebri. Keene DL, et al. **Pediatr Neurol** 1999 Feb;20(2):148–51

Primary multifocal leptomeningeal gliomatosis. Verslegers I, et al. **Pediatr Radiol** 1998 Aug;28(8):580–2

Optic gliomas. Hollander MD, et al. **Radiol Clin North Am** 1999 Jan;37(1):59–71, ix

Brain tumor volume measurement: comparison of manual and semiautomated methods. Joe BN, et al. **Radiology** 1999 Sep; 212(3):811–6

[Retina where the neurons become tangled] Fabre M, et al. **Rev Med Interne** 1999;20 Suppl 2:322s–324s **(Fre)**

[Neuronavigation. Computer-assisted neurosurgery] Ostertag CB, et al. **Nervenarzt** 1999 Jun;70(6):517–21 (38 ref.) (Eng. Abstr.) **(Ger)**

[Fluid-attenuated-inversion-recovery (FLAIR) imaging in the diagnosis of cerebral gliomas and metastases] Essig M, et al. **Radiologe** 1999 Feb;39(2):151–60 (32 ref.) (Eng. Abstr.) **(Ger)**

[Effect of brain edema on the recurrence pattern of malignant gliomas] Hartmann M, et al. **Radiologe** 1998 Nov; 38(11):948–53 (Eng. Abstr.) **(Ger)**

[Brain stem glioma] Wietelmann D, et al. **Radiologe** 1998 Nov;38(11):904–12 (Eng. Abstr.) **(Ger)**

[Practical aspects in the diagnosis and treatment of cerebral gliomas] Rosenfeld MR, et al. **Neurologia** 1999 Mar; 14(3):111–21 (124 ref.) **(Spa)**

DRUG THERAPY

Phase II North Central Cancer Treatment Group study of 2-chlorodeoxyadenosine in patients with recurrent glioma. Rajkumar SV, et al. **Am J Clin Oncol** 1999 Apr; 22(2):168–71

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Shalinsky DR, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:236–70

Malignant glioma: who benefits from adjuvant chemotherapy? [see comments] DeAngelis LM, et al. **Ann Neurol** 1998 Oct;44(4):691–5. Comment in: Ann Neurol 1999 Jun;45(6):824.

Malignant glioma: who benefits from adjuvant chemotherapy? [letter; comment] Schlegel U. **Ann Neurol** 1999 Jun;45(6):824. Comment on: Ann Neurol 1998 Oct;44(4):691–5.

Tamoxifen as a potential treatment of glioma. Mastronardi L, et al. **Anticancer Drugs** 1998 Aug;9(7):581–6 (65 ref.)

Falsification of tetrazolium dye (MTT) based cytotoxicity assay results due to mycoplasma contamination of cell cultures. Denecke J, et al. **Anticancer Res** 1999 Mar–Apr; 19(2A):1245–8

Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro. Haugland HK, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):149–56

Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Knüpfer MM, et al. **Anticancer Res** 1998 Sep–Oct; 18(5A):3585–9

Topotecan-based combination chemotherapy for human malignant glioma. Schmidt F, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):1217–21

Doxorubicin-induced cell death in highly invasive human gliomas. Stan AC, et al. **Anticancer Res** 1999 Mar–Apr; 19(2A):941–50

Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Emerich DF, et al. **Br J Cancer** 1999 Jun;80(7):964–70

Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Glaser T, et al. **Br J Cancer** 1999 May;80(5–6):756–65

Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. Ray SK, et al. **Brain Res** 1999 May 22;829(1–2):18–27

Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line. Hamada Y, et al. **Brain Tumor Pathol** 1998;15(2):77–82

A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Allen J, et al. **Cancer** 1999 Sep 15;86(6):1064–9

Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Friedman HS, et al. **Cancer** 1999 Mar 1;85(5):1160–5

Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Witham TF, et al. **Cancer** 1999 Oct 1;86(7):1347–53

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Hanley ML, et al. **Cancer Chemother Pharmacol** 1998;42(6):479–82

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration [published erratum appears in Cancer Chemother Pharmacol 1999;43(5):439–40] Marzolini C, et al. **Cancer Chemother Pharmacol** 1998; 42(6):433–40

Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Zucchetti M, et al. **Cancer Chemother Pharmacol** 1999;44(2):173–6

Chemotherapy for adults with malignant glioma. Cokgor I, et al. **Cancer Invest** 1999;17(4):264–72 (92 ref.)

Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. Eitel K, et al. **Cancer Lett** 1999 Jul 19;142(1):11–6

Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Kikuchi T, et al. **Cancer Lett** 1999 Jan 8;135(1):47–51

Phase I trial of temozolomide using an extended continuous oral schedule. Brock CS, et al. **Cancer Res** 1998 Oct 1; 58(19):4363–7

Angiostatin suppresses malignant glioma growth in vivo. Kirsch M, et al. **Cancer Res** 1998 Oct 15;58(20):4654–9

Use of chlorotoxin for targeting of primary brain tumors. Soroceanu L, et al. **Cancer Res** 1998 Nov 1;58(21):4871–9

Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Perez JM, et al. **Chem Biol Interact** 1999 Jan 29;117(2):99–115

Diffuse brain stem gliomas. Are we improving outcome? Shuper A, et al. **Childs Nerv Syst** 1998 Oct;14(10):578–81

Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Chenevert TL, et al. **Clin Cancer Res** 1997 Sep;3(9):1457–66

Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Couldwell WT, et al. **Clin Cancer Res** 1996 Apr;2(4):619–22

Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Kim B, et al. **Clin Cancer Res** 1995 Jun;1(6):643–50

Combination interferon-alpha2a and 13-cis-retinoic acid enhances radiosensitization of human malignant glioma cells in vitro. Malone C, et al. **Clin Cancer Res** 1999 Feb; 5(2):417–23

Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Minami H, et al. **Clin Cancer Res** 1999 Jun; 5(6):1325–30

A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Pollack IF, et al. **Clin Cancer Res** 1997 Jul;3(7):1109–15

Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Price A, et al. **Clin Cancer Res** 1999 Apr;5(4):845–54

Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Ross BD, et al. **Clin Cancer Res** 1995 Jun;1(6):651–7

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Silber JR, et al. **Clin Cancer Res** 1999 Apr;5(4):807–14

Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Yung WK, et al. **Clin Cancer Res** 1996 Dec;2(12):1931–5

New chemotherapy options for the treatment of malignant gliomas. Burton E, et al. **Curr Opin Oncol** 1999 May; 11(3):157–61 (24 ref.)

Protamine inhibits angiogenesis and growth of C6 rat glioma: a synergistic effect when combined with carmustine. Arrieta O, et al. **Eur J Cancer** 1998 Dec;34(13):2101–6

A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Ford J, et al. **Eur J Cancer** 1998 Oct;34(11):1807–11

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. van den Bent MJ, et al. **Eur J Cancer** 1998 Sep;34(10):1570–4

Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Rieger J, et al. **Eur J Pharmacol** 1999 Jan 22;365(2–3):301–8

Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. Sánchez C, et al. **FEBS Lett** 1998 Sep 25;436(1):6–10

Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Weller M, et al. **Int J Cancer** 1998 Dec 18;79(6):640–4

Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials. Zhao Q, et al. **Int J Mol Med** 1998 Apr; 1(4):693–702

Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. Saitoh Y, et al. **Int J Oncol** 1999 Sep; 15(3):499–504

Reirradiation and lomustine in patients with relapsed high-grade gliomas. Arcicasa M, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):789–93

Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. Rajkumar SV, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):969–75

Chemosensitivity of glioma cells in vitro: a meta analysis. Wolff JE, et al. **J Cancer Res Clin Oncol** 1999 Aug-Sep; 125(8–9):481–6

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Chang SM, et al. **J Clin Oncol** 1999 Mar;17(3):984–90

Irinotecan therapy in adults with recurrent or progressive malignant glioma. Friedman HS, et al. **J Clin Oncol** 1999 May;17(5):1516–25

Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. Aquino VM, et al. **J Neurooncol** 1999 Feb;41(3):255–9

Gossypol treatment of recurrent adult malignant gliomas. Bushunow P, et al. **J Neurooncol** 1999 May;43(1):79–86

Use of different outcome measures in randomised studies of malignant glioma can significantly alter the interpretation

of time to progression: reanalysis of the MRC BR2 study. Chataway J, et al. **J Neurooncol** 1999 May;43(1):87–92
A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma. Kuratsu J, et al. **J Neurooncol** 1999 Apr; 42(2):177–81
Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs. Naganuma H, et al. **J Neurooncol** 1998 Sep;39(3):227–36
Acute-leukemia following treatment of malignant glioma. Perry JR, et al. **J Neurooncol** 1998 Oct;40(1):39–46 (56 ref.)
Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model. Pollina J, et al. **J Neurooncol** 1998 Sep;39(3):217–25
Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. Roesdi MF, et al. **J Neurooncol** 1998 Dec;40(3):251–5
Effect of dietary vitamin A or N-acetylcysteine on ethylnitrosourea-induced rat gliomas. Ross DA, et al. **J Neurooncol** 1998 Oct;40(1):29–38
An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. Sugawa N, et al. **J Neurooncol** 1998 Sep; 39(3):237–44
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model. Takeda N, et al. **J Neurooncol** 1999 Feb;41(3):235–46
Postoperative radiotherapy for supratentorial malignant gliomas. Yeh SA, et al. **J Neurooncol** 1999 Apr;42(2):183–7
Tetrazepinones are equally cytotoxic to Mer+ and Mer- human tumor cell lines. Jean-Claude BJ, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):484–9
Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center. Stein ME, et al. **J Surg Oncol** 1999 Jul;71(3):167–70
Efficacy of antineoplastons A10 and AS2-1 [letter; comment] Burzynski SR. **Mayo Clin Proc** 1999 Jun;74(6):641–2. Comment on: Mayo Clin Proc 1999 Feb;74(2):137–45.
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. Jakacki RI, et al. **Med Pediatr Oncol** 1998 Dec;31(6):483–90
Growth inhibition of experimental glioma by human interferon-beta superinduced by cationic liposomes entrapping polyinosilic:polycytidilic acid. Bucur N, et al. **Neurol Med Chir (Tokyo)** 1998 Aug;38(8):469–73; discussion 473–4
Secondary glioblastoma remarkably reduced by steroid administration after anaplastic transformation from gliomatosis cerebri--case report. Hirose Y, et al. **Neurol Med Chir (Tokyo)** 1998 Dec;38(12):865–70
Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study. Behrens PF, et al. **Neurosurgery** 1998 Aug;43(2):235–40; discussion 240–1
Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Bernsen HJ, et al. **Neurosurgery** 1998 Sep;43(3):570–5; discussion 575–6
Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Cloughesy TF, et al. **Neurosurgery** 1999 Feb;44(2):270–8; discussion 278–9
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. Rajkumar SV, et al. **Neurosurgery** 1999 Jan;44(1):67–73
PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Soffietti R, et al. **Neurosurgery** 1998 Nov;43(5):1066–73
Anti-telomerase therapy suppressed glioma proliferation. Yamaguchi F, et al. **Oncol Rep** 1999 Jul-Aug;6(4):773–6
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. McPake CR, et al. **Oncol Res** 1998; 10(5):235–44
Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas. Kaplan RS, et al. **Oncology (Huntingt)** 1999 Apr;13(4):532–3, 537
Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors. Pollack IF, et al. **Pediatr Neurosurg** 1998 Nov;29(5):228–44 (213 ref.)
Treatment of malignant gliomas: a new approach. Paccapelo A, et al. **Tumori** 1998 Sep-Oct;84(5):529–33
[Sensitivity to etoposide of human malignant glioma cell lines. Mechanisms of action] Beauchesne P, et al. **Cancer Radiother** 1999 Jan-Feb;3(1):57–64 (Eng. Abstr.) **(Fre)**
[A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas] Mizumatsu S, et al. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2055–60 (Eng. Abstr.) **(Jpn)**
[The use of cycloferon in experimental radiotherapy of tumors] Ivanov SD, et al. **Vopr Onkol** 1999;45(3):292–7 (Eng. Abstr.) **(Rus)**

ECONOMICS

[Modified cost-benefit analysis takes equity into consideration. Treatment of brain tumors is more cost-effective than hip replacement] Lindholm L, et al. **Lakartidningen** 1999 Jun 2;96(22):2749–54 (Eng. Abstr.) **(Swe)**

ENZYMOLOGY

Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. Dygas A, et al. **Acta Biochim Pol** 1999;46(1):99–106
In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Mandell JW, et al. **Am J Pathol** 1998 Nov;153(5):1411–23
Influence of putative antiinvasive agents on matrix metalloproteinase secretion by human neoplastic glia in vitro. Rooprai HK, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:654–7
Endonuclease activity and hydrogen peroxide-induced cytotoxicity in human glioblastoma and glioma cell lines. Iida M, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1235–40
A metalloprotease activity from C6 glioma cells inactivates the myelin-associated neurite growth inhibitors and can be neutralized by antibodies. Hensel T, et al. **Br J Cancer** 1998 Dec;78(12):1564–72
Distribution and activity of transglutaminase in rat brain carcinogenesis and in gliomas. Tunici P, et al. **Cancer Lett** 1999 Jun 1;140(1-2):47–51
Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Wagenknecht B, et al. **Cell Death Differ** 1998 Oct;5(10):894–900
Heat shock induction of a 65 kDa ATP-binding proteinase in rat C6 glioma cells. Xu CS, et al. **Cell Res** 1999 Jun; 9(2):135–44
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Ali-Osman F, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2253–61
O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Silber JR, et al. **Clin Cancer Res** 1999 Apr;5(4):807–14
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Rolhion C, et al. **Int J Cancer** 1999 Aug 20;84(4):416–20
Adenovirus-mediated expression of an olfactory cyclic nucleotide-gated channel regulates the endogenous Ca2+-inhibitable adenylyl cyclase in C6-2B glioma cells. Fagan KA, et al. **J Biol Chem** 1999 Apr 30; 274(18):12445–53
Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB. Chin LS, et al. **J Biomed Sci** 1999 May-Jun;6(3):213–8
Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas. Falchetti ML, et al. **J Clin Pathol** 1999 Mar;52(3):234–6
Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. Wagner S, et al. **J Neurooncol** 1998 Nov;40(2):113–22
Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas. Taniguchi K, et al. **J Neurosurg** 1999 Sep;91(3):477–82
Tyrosinase transfection produces melanin synthesis and growth retardation in glioma cells. Singh MV, et al. **Melanoma Res** 1998 Dec;8(6):493–8
Telomerase activity in microdissected human gliomas. Weil RJ, et al. **Mod Pathol** 1999 Jan;12(1):41–6
Over-expression of acetylcholinesterase stimulates the expression of agrin in NG108-15 cells. Choi RC, et al. **Neurosci Lett** 1998 May 22;248(1):17–20

EPIDEMIOLOGY

Drinking water source and chlorination byproducts in Iowa. III. Risk of brain cancer. Cantor KP, et al. **Am J Epidemiol** 1999 Sep 15;150(6):552–60
Occupational exposure to magnetic fields and brain tumours in central Sweden. Rodvall Y, et al. **Eur J Epidemiol** 1998 Sep;14(6):563–9
Use of cellular telephones and the risk for brain tumours: A case-control study. Hardell L, et al. **Int J Oncol** 1999 Jul;15(1):113–6

ETIOLOGY

Diet and brain cancer in adults: a case-control study in northeast China. Hu J, et al. **Int J Cancer** 1999 Mar 31; 81(1):20–3
Role of medical history in brain tumour development. Results from the international adult brain tumour study. Schlehofer B, et al. **Int J Cancer** 1999 Jul 19;82(2):155–60
An international case-control study of adult glioma and meningioma: the role of head trauma. Preston-Martin S, et al. **Int J Epidemiol** 1998 Aug;27(4):579–86
Hypotheses concerning roles of dietary energy, cured meat, and serum tocopherols in adult glioma development. Schwartzbaum JA, et al. **Neuroepidemiology** 1999; 18(3):156–66
Dental radiography after age 25 years, amalgam fillings and tumours of the central nervous system. Rodvall Y, et al. **Oral Oncol** 1998 Jul;34(4):265–9

GENETICS

Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Leung SY, et al. **Am J Pathol** 1998 Oct;153(4):1181–8
Hensin, the polarity reversal protein, is encoded by DMBT1, a gene frequently deleted in malignant gliomas. Takito J, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):F277–89
Targeting in gene therapy for gliomas. Fueyo J, et al. **Arch Neurol** 1999 Apr;56(4):445–8 (8 ref.)
Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Büschges R, et al. **Brain Pathol** 1999 Jul;9(3):435–42; discussion 432–3
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Ishii N, et al. **Brain Pathol** 1999 Jul;9(3):469–79
Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line. Hamada Y, et al. **Brain Tumor Pathol** 1998;15(2):77–82
Cytogenetic changes in two cases of subependymal giant-cell astrocytoma. Dębiec-Rychter M, et al. **Cancer Genet Cytogenet** 1999 Feb;109(1):29–33
Identification of PTEN-related sequences in glioma cells and in non-neoplastic cell lines. Chiariello E, et al. **Cancer Lett** 1999 Apr 26;138(1-2):1–4
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Aghi M, et al. **Cancer Res** 1999 Aug 15;59(16):3861–5
Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Harada K, et al. **Cancer Res** 1998 Oct 15;58(20):4694–700
Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Miller CR, et al. **Cancer Res** 1998 Dec 15;58(24):5738–48
Expression level of Bcl-2 determines anti- or proapoptotic function. Shinoura N, et al. **Cancer Res** 1999 Aug 15; 59(16):4119–28
Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. El-Zein R, et al. **Carcinogenesis** 1999 May;20(5):811–5
Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Bredel M, et al. **Clin Cancer Res** 1999 Jul; 5(7):1786–92
Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma. Gao L, et al. **Clin Cancer Res** 1997 Jun;3(6):977–81
Expression of the genes encoding myelin basic protein and proteolipid protein in human malignant gliomas. Golfinos JG, et al. **Clin Cancer Res** 1997 May;3(5):799–804
Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Lin H, et al. **Clin Cancer Res** 1998 Oct;4(10):2447–54
Molecular pathogenesis of malignant gliomas. Rasheed BK, et al. **Curr Opin Oncol** 1999 May;11(3):162–7 (37 ref.)
Comparative genomic in situ hybridization discloses recurrent gain of chromosome 4 in experimental gliomas of the rat. Kappler R, et al. **Cytogenet Cell Genet** 1999; 84(3-4):194–8
Growth hormone-mediated regulation of insulin-like growth factor I promoter activity in C6 glioma cells. Benbassat C, et al. **Endocrinology** 1999 Jul;140(7):3073–81
Molecular genetic characterisation of intracerebrally transplanted brain tumours. Schlegel J, et al. **Exp Toxicol Pathol** 1999 Jan;51(1):41–5
Germline hMSH2 and differential somatic mutations in patients with Turcot's syndrome. Chan TL, et al. **Genes Chromosomes Cancer** 1999 Jun;25(2):75–81
Dynamics of genetic alterations associated with glioma recurrence. Hulsebos TJ, et al. **Genes Chromosomes Cancer** 1998 Oct;23(2):153–8
Consistent aneuploidies in choroid plexus papillomas [letter] Punnett HH, et al. **Genes Chromosomes Cancer** 1999 Mar; 24(3):293
Functional and molecular analyses of 10q deletions in human gliomas. Steck PA, et al. **Genes Chromosomes Cancer** 1999 Feb;24(2):135–43
Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Holland EC, et al. **Genes Dev** 1998 Dec 1; 12(23):3644–9
A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Holland EC, et al. **Genes Dev** 1998 Dec 1;12(23):3675–85
Genomic difference analysis by two-dimensional DNA fingerprinting reveals typical changes in human low-grade gliomas. Marczinek K, et al. **Glia** 1998 Jun;23(2):130–8
Molecular genetic analysis of non-astrocytic gliomas [comment] Al-Sarraj ST. **Histopathology** 1999 Apr; 34(4):370–1. Comment on: Histopathology 1999 Apr;34(4):331–41.
Molecular genetic analysis of non-astrocytic gliomas [see comments] Tong CY, et al. **Histopathology** 1999 Apr; 34(4):331–41. Comment in: Histopathology 1999 Apr;34(4):370–1.

Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line. Craperi D, et al. **Hum Gene Ther** 1999 Mar 1;10(4):679–88

Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Shinoura N, et al. **Hum Gene Ther** 1998 Sep 20; 9(14):1983–93

Molecular analysis of glioma and skin-tumour alterations in a xeroderma-pigmentosum child. Giglia G, et al. **Int J Cancer** 1999 May 5;81(3):345–50

O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Rolhion C, et al. **Int J Cancer** 1999 Aug 20;84(4):416–20

Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Weller M, et al. **Int J Cancer** 1998 Dec 18;79(6):640–4

Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Zhou XP, et al. **Int J Cancer** 1999 Apr 20;84(2):150–4

Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Gomez-Manzano C, et al. **Int J Mol Med** 1999 Jan;3(1):81–5 (55 ref.)

Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Galanis E, et al. **Int J Oncol** 1998 Oct;13(4):717–24

Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. James CD, et al. **Int J Oncol** 1999 Sep;15(3):547–53

IL-10 gene transfer to intracranial 9L glioma: tumor inhibition and cooperation with IL-2. Book AA, et al. **J Neuroimmunol** 1998 Dec 1;92(1–2):50–9

Analysis of the p21 gene in gliomas. Li YJ, et al. **J Neurooncol** 1998 Nov;40(2):107–11

The significance of the expression of tumor suppressor gene DCC in human gliomas. Nakatani K, et al. **J Neurooncol** 1998 Dec;40(3):237–42

Establishment of two glioma cell lines from two surgical specimens obtained at different times from the same individual. Onda K, et al. **J Neurooncol** 1999 Feb; 41(3):247–54

Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. Husemann K, et al. **J Neuropathol Exp Neurol** 1999 Oct;58(10):1041–50

Glial tumors in the MNU rat model: induction of pure and mixed gliomas that do not require typical missense mutations of p53. Rushing EJ, et al. **J Neuropathol Exp Neurol** 1998 Nov;57(11):1053–60

Overexpression of bax in human glioma cell lines. Vogelbaum MA, et al. **J Neurosurg** 1999 Sep;91(3):483–9

Molecular characterization of CXCR-4: a potential brain tumor-associated gene. Sehgal A, et al. **J Surg Oncol** 1998 Dec;69(4):239–48

Activation of recombinant h 5-HT1B and h 5-HT1D receptors stably expressed in C6 glioma cells produces increases in Ca2+-dependent K+ current. Le Grand B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):608–15

The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Fueyo J, et al. **Neurology** 1998 Nov;51(5):1250–5 (49 ref.)

A novel gene, LG11, from 10q24 is rearranged and downregulated in malignant brain tumors. Chernova OB, et al. **Oncogene** 1998 Dec 3;17(22):2873–81

Differential stability of the DNA-activated protein kinase catalytic subunit mRNA in human glioma cells. Galloway AM, et al. **Oncogene** 1999 Feb 11;18(6):1361–8

Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase. Morimoto AM, et al. **Oncogene** 1999 Feb 11;18(6):1261–6

Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Smith JS, et al. **Oncogene** 1999 Jul 15; 18(28):4144–52

PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Wick W, et al. **Oncogene** 1999 Jul 8;18(27):3936–43

Patient survival and microsatellite instability in gliomas by high-resolution fluorescent analysis. Mizoguchi M, et al. **Oncol Rep** 1999 Jul–Aug;6(4):791–5

Microsatellite instability is infrequent in sporadic adult gliomas. Lundin DA, et al. **Oncol Res** 1998;10(8):421–8

Growth factor receptors as targets for therapy in pediatric brain tumors. Meuillet EJ, et al. **Pediatr Neurosurg** 1998 Jul;29(1):1–13 (116 ref.)

The renin-angiotensin system in hybrid NG108-15 cells. Renin gene is from mouse neuroblastoma, angiotensinogen and angiotensin-converting enzyme genes are of rat glioma origin. Laflamme L, et al. **Regul Pept** 1998 Oct 16; 77(1–3):9–15

[The molecular genetics of gliomas and the outlook for molecular neurosurgery] Zozulia IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct–Dec; (4):45–51 (132 ref.) **(Rus)**

HISTORY

Hans-Joachim Scherer (1906–1945), pioneer in glioma research. Peiffer J, et al. **Brain Pathol** 1999 Apr;9(2):241–5

Historical development of surgery for glial tumors. Salcman M. **J Neurooncol** 1999 May;42(3):195–204 (63 ref.)

IMMUNOLOGY

Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Mizuno M, et al. **Cancer Immunol Immunother** 1998 Dec;47(4):227–32

Absence of p53 autoantibodies in sera from glioma patients. Rainov NG, et al. **Clin Cancer Res** 1995 Jul;1(7):775–81

CD44 expression and hyaluronic acid binding of malignant glioma cells. Knüpfer MM, et al. **Clin Exp Metastasis** 1999 Feb;17(1):71–6

Laminin receptor alpha6beta4 integrin is highly expressed in ENU-induced glioma in rat. Previtali SC, et al. **Glia** 1999 Mar;26(1):55–63

Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. Zou JP, et al. **J Immunol** 1999 Apr 15; 162(8):4882–92

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Ikeda K, et al. **Nat Med** 1999 Aug;5(8):881–7

Cervical lymph nodes play the role of regional lymph nodes in brain tumour immunity in rats. Okamoto Y, et al. **Neuropathol Appl Neurobiol** 1999 Apr;25(2):113–22

Expression and regulation of HLA-G in human glioma cell lines. Maier S, et al. **Transplant Proc** 1999 Jun;31(4):1849–53

METABOLISM

Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. Wójcik M, et al. **Acta Biochim Pol** 1999; 46(1):125–31

Effect of intracarotid infusion of etoposide: modification of the permeability of the blood-brain barrier and the blood-tumor barrier in rat brain tumor model. Maeda Y, et al. **Acta Med Okayama** 1999 Feb;53(1):5–11

5-Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 brain tumours and in the normal rat brain [published erratum appears in Acta Neurochir (Wien) 1998;140(8):881] Hebeda KM, et al. **Acta Neurochir (Wien)** 1998;140(5):503–12; discussion 512–3

Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells. Hinek A, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):399–407

Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Mishima K, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):322–8

Human astrocytic brain tumors express APO2L/TRAIL. Rieger J, et al. **Acta Neuropathol (Berl)** 1999 Jan;97(1):1–4

The in vivo metabolic investigation of brain gliomas with positron emission tomography. Derlon JM. **Adv Tech Stand Neurosurg** 1998;24:41–76 (184 ref.)

Analysis of inhibitory effects of scutellariae radix and baicalein on prostaglandin E2 production in rat C6 glioma cells. Nakahata N, et al. **Am J Chin Med** 1998; 26(3–4):311–23

Densities of I2-imidazoline receptors, imidazoline receptor proteins, and MAO-B sites in human gliomas and pituitary adenomas. Barturen F, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:203–7

Sphingosine and phorbol ester modulate protein kinase C activity and modify ATP-evoked calcium mobilization in glioma C6 cells. Czajkowski R, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):614–8

Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Roller A, et al. **Biochem Biophys Res Commun** 1999 Jun 16; 259(3):600–5

Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Soda Y, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):313–21

Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Kurihara A, et al. **Bioconjug Chem** 1999 May-Jun;10(3):502–11

Effects of Sho-saiko-to, San'o-shashin-to and Scutellariae Radix on intracellular Ca2+ mobilization in C6 rat glioma cells. Kyo R, et al. **Biol Pharm Bull** 1998 Oct; 21(10):1067–71

Pharmacokinetics of etoposide and carboplatin in cerebrospinal fluid and plasma during hyperosmotic disruption of the blood brain barrier and intraarterial combination chemotherapy. Morikawa N, et al. **Biol Pharm Bull** 1999 Apr;22(4):428–31

Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia. Allalunis-Turner MJ, et al. **Br J Cancer** 1999 Apr;80(1–2):104–9

Maitotoxin-induced nerve growth factor production accompanied by the activation of a voltage-insensitive Ca2+ channel in C6-BU-1 glioma cells. Obara Y, et al. **Br J Pharmacol** 1999 Aug;127(7):1577–82

Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Büschges R, et al. **Brain Pathol** 1999 Jul;9(3):435–42; discussion 432–3

Influence of serum-free culture conditions on steroid 5alpha-reductase mRNA expression in rat C6 glioma cells. Morita K, et al. **Brain Res** 1999 May 29;830(1):179–82

Cyclosporin A inhibits activation of inducible nitric oxide synthase in C6 glioma cell line. Trajković V, et al. **Brain Res** 1999 Jan 16;816(1):92–8

Modulation of TNF-alpha mRNA production in rat C6 glioma cells by TNF-alpha, IL-1beta, IL-6, and IFN-alpha: in vitro analysis of cytokine-cytokine interactions. Gayle D, et al. **Brain Res Bull** 1998 Oct; 47(3):231–5

Brain tumor development in rats is associated with changes in central nervous system cytokine and neuropeptide systems. Ilyin SE, et al. **Brain Res Bull** 1999 Mar 1; 48(4):363–73

Specific vanilloid responses in C6 rat glioma cells. Biró T, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):89–98

TrkA receptors delay C6-2B glioma cell growth in rat striatum. Rabin SJ, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):273–6

Expression of vascular endothelial growth factor and p53 protein in association with neovascularization in human malignant gliomas. Miyagami M, et al. **Brain Tumor Pathol** 1998;15(2):95–100

Function of aberrant EGFR in malignant gliomas. Sugawa N, et al. **Brain Tumor Pathol** 1998;15(1):53–7

Thyroid hormone regulates protein expression in C6 glioma cells. Trentin AG, et al. **Braz J Med Biol Res** 1998 Oct; 31(10):1281–4 (20 ref.)

Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Chen ZP, et al. **Can J Neurol Sci** 1999 May;26(2):104–9

Chemical, metabolic and immunological characterization of gangliosides of human glioma cells. Maeda Y, et al. **Cancer Biochem Biophys** 1998 Nov;16(4):313–32

Synergism between mild hyperthermia and interferon-beta gene expression. Bouhon IA, et al. **Cancer Lett** 1999 May 24;139(2):153–8

An in vivo rat model for visualizing glioma tumor cell invasion using stable persistent expression of the green fluorescent protein. Fillmore HL, et al. **Cancer Lett** 1999 Jul 1;141(1–2):9–19

A new boronated porphyrin (STA-BX909) for neutron capture therapy: an in vitro survival assay and in vivo tissue uptake study. Matsumura A, et al. **Cancer Lett** 1999 Jul 1;141(1–2):203–9

Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Miccoli L, et al. **Cancer Res** 1998 Dec 15;58(24):5777–86

Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Terpstra M, et al. **Cancer Res** 1998 Nov 15;58(22):5083–8

Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. Yount GL, et al. **Cancer Res** 1999 Mar 15;59(6):1362–5

Expression of IGF-I and IGF-II receptors in rat C6 glioma cells as a function of the growth phase. Wang Q, et al. **Cell Physiol Biochem** 1998;8(6):304–13

Prognostic significance of p53 immunoreactivity in patients with glioma. Kyritsis AP, et al. **Clin Cancer Res** 1995 Dec; 1(12):1617–22

Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Ma J, et al. **Clin Exp Metastasis** 1998 Aug; 16(6):559–68

Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Ohnishi T, et al. **Clin Exp Metastasis** 1998 Nov; 16(8):729–41

BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Gary SC, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):576–81 (31 ref.)

Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Bouzier AK, et al. **Dev Neurosci** 1998; 20(4–5):331–8

Multinuclear NMR spectroscopy studies on NH4Cl-induced metabolic alterations and detoxification processes in primary astrocytes and glioma cells. Zwingmann C, et al. **Dev Neurosci** 1998;20(4–5):417–26

Overexpression of insulin-like growth factor-binding protein-2 in C6 glioma cells results in conditional alteration of cellular growth. Bradshaw SL, et al. **Endocrinology** 1999 Feb;140(2):575–84

Interleukin-1beta and catecholamines synergistically stimulate interleukin-6 release from rat C6 glioma cells in vitro: a potential role for lysophosphatidylcholine. Zumwalt JW, et al. **Endocrinology** 1999 Feb;140(2):888–96

Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma. Kazuno M, et al. **Eur J Cancer** 1999 Mar;35(3):502–6

Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects [see comments] Leaver HA, et al. **Eur J Clin Invest** 1999 Mar; 29(3):220–31. Comment in: Eur J Clin Invest 1999 Mar;29(3):185–8.

Commentary: Free radicals in gliomas: friend or foes?[comments] Ricevuti G. **Eur J Clin Invest** 1999 Mar; 29(3):185–8

CD44 protein in glioma rat cell culture. Serenelli G, et al. **Eur J Histochem** 1997;41 Suppl 2:55–6

Glutamate receptor activation can trigger electrical activity in human glioma cells. Labrakakis C, et al. **Eur J Neurosci** 1998 Jun;10(6):2153–62

Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. Palma C, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):435–43

Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Mohanam S, et al. **Front Biosci** 1999 Feb 15;4:D178–87 (113 ref.)

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Schmidt NO, et al. **Int J Cancer** 1999 Feb 19;84(1):10–8

Hyperthermic sensitization by hematoporphyrin on glioma cells. Saito A, et al. **Int J Hyperthermia** 1998 Sep–Oct; 14(5):503–11

Expression of p120 nucleolar proliferating antigen in human gliomas and growth suppression of glioma cells by p120 ribozyme vector. Sato K, et al. **Int J Oncol** 1999 Mar; 14(3):417–24

MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Biaglow JE, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):871–6

Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Sabatier J, et al. **Invest Radiol** 1999 Mar;34(3):230–5

Energetic and morphological plasticity of C6 glioma cells grown on 3-D support; effect of transient glutamine deprivation. Martin M, et al. **J Bioenerg Biomembr** 1998 Dec;30(6):565–78

Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13c and 1H NMR study. Bouzier AK, et al. **J Biol Chem** 1998 Oct 16;273(42):27162–9

Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. Pulfer SK, et al. **J Drug Target** 1998;6(3):215–27

Immunoelectronmicroscopic analysis of the ligand-induced internalization of the somatostatin receptor subtype 2 in cultured human glioma cells. Krisch B, et al. **J Histochem Cytochem** 1998 Nov;46(11):1233–42

Synthesis and biological evaluation of boron-containing polyamines as potential agents for neutron capture therapy of brain tumors. Zhuo JC, et al. **J Med Chem** 1999 Apr 8;42(7):1282–92

[1-(13)C]glucose metabolism in the tumoral and nontumoral cerebral tissue of a glioma-bearing rat. Bouzier AK, et al. **J Neurochem** 1999 Jun;72(6):2445–55

Expression of mouse sialic acid on gangliosides of a human glioma grown as a xenograft in SCID mice. Ecsedy JA, et al. **J Neurochem** 1999 Jul;73(1):254–9

Paucity of retinoic acid receptor alpha (RAR alpha) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression. Kleinschmidt-DeMasters BK, et al. **J Neurooncol** 1999 Jan;41(1):31–42

Distribution of small magnetic particles in brain tumor-bearing rats. Pulfer SK, et al. **J Neurooncol** 1999 Jan;41(2):99–105

The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. Straathof CS, et al. **J Neurooncol** 1999 Apr; 42(2):117–22

Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. Watanabe T, et al. **J Neurooncol** 1999 Jan;41(2):121–8

Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. Yamanaka R, et al. **J Neurooncol** 1999 May;43(1):27–34

The extracellular matrix of gliomas: modulation of cell function. Gladson CL. **J Neuropathol Exp Neurol** 1999 Oct; 58(10):1029–40 (95 ref.)

Proteasome-dependent degradation of p27/kip1 in gliomas. Piva R, et al. **J Neuropathol Exp Neurol** 1999 Jul; 58(7):691–6

In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. Stummer W, et al. **J Photochem Photobiol B** 1998 Sep;45(2–3):160–9

Reduced connexin43 expression in high-grade human brain glioma cells. Huang RP, et al. **J Surg Oncol** 1999 Jan; 70(1):21–4

Capacitative Ca2+ entry involves Ca2+ influx factor in rat glioma C6 cells. Takemura H, et al. **Life Sci** 1999; 64(17):1493–500

In vivo observation of lactate methyl proton magnetization transfer in rat C6 glioma. Luo Y, et al. **Magn Reson Med** 1999 Apr;41(4):676–85

Global HDO uptake in human glioma xenografts is related to the perfused capillary distribution. van der Sanden BP, et al. **Magn Reson Med** 1999 Sep;42(3):479–89

Effect of carbogen breathing on the physiological profile of human glioma xenografts. van der Sanden BP, et al. **Magn Reson Med** 1999 Sep;42(3):490–9

The effect of hydrogen peroxide upon beta-adrenoceptor density and function in C6 rat glioma cells. Bergström D, et al. **Neurochem Int** 1999 Jan;34(1):63–70

Expression of the GM1-species, [NeuN]-GM1, in a case of human glioma. Fredman P, et al. **Neurochem Res** 1999 Feb; 24(2):275–9

Different constitutive heat shock protein 70 expression during proliferation and differentiation of rat C6 glioma cells. Helmbrecht K, et al. **Neurochem Res** 1999 Oct; 24(10):1293–9

Overexpression of glia maturation factor in C6 cells promotes differentiation and activates superoxide dismutase. Lim R, et al. **Neurochem Res** 1998 Nov;23(11):1445–51

Immunohistochemical study of insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein-2 (IGFBP-2) in choroid plexus papilloma. Kubo S, et al. **Neurol Res** 1999 Jun;21(4):339–44

Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Machein MR, et al. **Neuropathol Appl Neurobiol** 1999 Apr;25(2):104–12

Cell death and oxidative stress in gliomas. Tews DS. **Neuropathol Appl Neurobiol** 1999 Aug;25(4):272–84

Ethanol inhibits G-protein-mediated glucose uptake by C6 glioma cells. Singh SP, et al. **Neuroreport** 1999 Feb 25; 10(3):595–9

Co-existence of two types of [Ca2+]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells [published erratum appears in Neuroscience 1999 Jan;88(1):337] Ubl JJ, et al. **Neuroscience** 1998 Sep;86(2):597–609

Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. Rieger J, et al. **Oncogene** 1998 Nov 5;17(18):2323–32

Role of microtubules in glucose uptake by C6 glioma cells. Singh SP, et al. **Pharmacol Toxicol** 1998 Aug;83(2):83–9

Effect of lead exposure and accumulation on copper homeostasis in cultured C6 rat glioma cells. Qian Y, et al. **Toxicol Appl Pharmacol** 1999 Jul 1;158(1):41–9

The volatile anesthetic enflurane activates capacitative Ca2+ channels in rat glioma C6 cells. Tas PW, et al. **Toxicol Lett** 1998 Nov 23;100–101:265–9

[Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect] Bian X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):248–50 (15 ref.) **(Chi)**

MORTALITY

Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Etienne MC, et al. **Clin Cancer Res** 1998 Oct;4(10):2383–90

Survival rates of malignant gliomas in Burgundy from 1990 to 1995. Billiar T, et al. **Neurol Res** 1999 Mar;21(2):171–4

Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy [letter; comment] Mastronardi L, et al. **Neurosurgery** 1998 Dec;43(6):1496. Comment on: Neurosurgery 1998 Apr;42(4):724–9.

PATHOLOGY

Cell–extracellular matrix interaction in glioma invasion. Goldbrunner RH, et al. **Acta Neurochir (Wien)** 1999; 141(3):295–305; discussion 304–5 (105 ref.)

Estimation of volume doubling time and cell loss in an experimental rat glioma model in vivo. Nakajima M, et al. **Acta Neurochir (Wien)** 1998;140(6):607–12; discussion 612–3

Ependymoma of the cauda equina. Rickert CH, et al. **Acta Neurochir (Wien)** 1999;141(7):781–2

Apoptotic cell death induced by local brain hyperthermia in a rat glioma model. Uesugi S, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):351–6

Another mechanism causing the bystander effect besides the gap junction's role during the glioma gene therapy with HSV-TK/GCV system. Du L, et al. **Adv Exp Med Biol** 1998;451:133–8

Diffusion tensor MR imaging and comparative histology of glioma engrafted in the rat spinal cord. Inglis BA, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):713–6

A distinctive glioneuronal tumor of the adult cerebrum with neuropil-like (including "rosetted") islands: report of 4 cases. Teo JG, et al. **Am J Surg Pathol** 1999 May; 23(5):502–10

p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. Naumann U, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):890–6

Isolation and properties of lead-resistant variants of rat glioma cells. Dolzhanskaya N, et al. **Biol Trace Elem Res** 1998 Oct;65(1):31–43

Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Glaser T, et al. **Br J Cancer** 1999 May;80(5–6):756–65

Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Palma C, et al. **Br J Cancer** 1999 Jan; 79(2):236–43

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Bredel M, et al. **Brain Res Brain Res Rev** 1999 Apr;29(2–3):232–49 (257 ref.)

Video-enhanced microscopic visualization of apoptotic cell death caused by anti-Fas antibody in living human glioma cells. Ohta S, et al. **Brain Tumor Pathol** 1998;15(1):19–21

Final report on the University of California–San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients. Lamborn KR, et al. **Cancer** 1999 Feb 15;85(4):925–35

Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Borbé R, et al. **Cancer Chemother Pharmacol** 1999;44(3):217–27

An in vivo rat model for visualizing glioma tumor cell invasion using stable persistent expression of the green fluorescent protein. Fillmore HL, et al. **Cancer Lett** 1999 Jul 1;141(1–2):9–19

The relationship between nuclear magnetic resonance–visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Barba I, et al. **Cancer Res** 1999 Apr 15;59(8):1861–8

The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Furnari FB, et al. **Cancer Res** 1998 Nov 15;58(22):5002–8

Glioma migration can be blocked by nontoxic inhibitors of myosin II. Gillespie GY, et al. **Cancer Res** 1999 May 1; 59(9):2076–82

Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Harada H, et al. **Cancer Res** 1999 Aug 1;59(15):3783–9

Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Otsuka G, et al. **Cancer Res** 1999 Sep 1;59(17):4446–52

Expression level of Bcl-2 determines anti- or proapoptotic function. Shinoura N, et al. **Cancer Res** 1999 Aug 15; 59(16):4119–28

Direct gap junction communication between malignant glioma cells and astrocytes. Zhang W, et al. **Cancer Res** 1999 Apr 15;59(8):1994–2003

Gliomas. Collins VP. **Cancer Surv** 1998;32:37–51 (81 ref.)

Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Wagenknecht B, et al. **Cell Death Differ** 1998 Oct;5(10):894–900

Diffuse brain stem glioma. A review of stereotactic biopsies. Cartmill M, et al. **Childs Nerv Syst** 1999 May;15(5):235–7; discussion 238

Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Ali-Osman F, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2253–61

Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Bredel M, et al. **Clin Cancer Res** 1997 Nov;3(11):2157–64

Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Kim B, et al. **Clin Cancer Res** 1995 Jun;1(6):643–50

Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Ross BD, et al. **Clin Cancer Res** 1995 Jun;1(6):651–7

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Shawver LK, et al. **Clin Cancer Res** 1997 Jul;3(7):1167–77

Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Uhm JH, et al. **Clin Cancer Res** 1999 Jun;5(6):1587–94

Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Ohnishi T, et al. **Clin Exp Metastasis** 1998 Nov; 16(8):729–41

Pathology of choroid plexus papillomas: a review. Gaudio RM, et al. **Clin Neurol Neurosurg** 1998 Sep;100(3):165–86 (134 ref.)

Imaging the pyramidal tract in patients with brain tumors. Inoue T, et al. **Clin Neurol Neurosurg** 1999 Mar;101(1):4–10

Tamoxifen modulation of carboplatin cytotoxicity in a human U-138 glioma cell line. Mastronardi L, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):89–93

Gliofibroma: mixed glial and mesenchymal tumour. Report of three cases. Sharma MC, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):153–9 (24 ref.)

Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Cummings TJ, et al. **Clin Neuropathol** 1999 Jul–Aug;18(4):190–7

Evaluation of malignant features in oligodendroglial tumors. Saito A, et al. **Clin Neuropathol** 1999 Mar–Apr;18(2):61–73

Fine needle aspiration (FNA) cytology of primary subcutaneous sacrococcygeal myxopapillary ependymoma. Pohar-Marinšek Z, et al. **Cytopathology** 1998 Dec; 9(6):415–20

Overexpression of insulin-like growth factor-binding protein-2 in C6 glioma cells results in conditional alteration of cellular growth. Bradshaw SL, et al. **Endocrinology** 1999 Feb;140(2):575–84

Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. Behnam-Motlagh P, et al. **Eur J Cancer** 1999 Jan;35(1):145–53

Apoptosis induced in glioma rat cells cultivated in the presence of a medicinal infusion of green tea. Serenelli G, et al. **Eur J Histochem** 1997;41 Suppl 2:85–6

Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation.

Hueber A, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):111-5

Methadone-induced desensitization of the delta-opioid receptor is mediated by uncoupling of receptor from G protein. Liu JG, et al. **Eur J Pharmacol** 1999 Jun 18; 374(2):301-8

Neural cell surface differentiation antigen gp130(RB13-6) induces fibroblasts and glioma cells to express astroglial proteins and invasive properties. Deissler H, et al. **FASEB J** 1999 Apr;13(6):657-66

Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. Kitagawa H, et al. **FEBS Lett** 1999 Jan 25;443(2):181-6

BCL-2 promotes migration and invasiveness of human glioma cells. Wick W, et al. **FEBS Lett** 1998 Dec 4; 440(3):419-24

Disorganization of cortical structure and the brain tumors. Kroh H, et al. **Folia Neuropathol** 1999;37(1):20-6

The role of integrins in the malignant phenotype of gliomas. Uhm JH, et al. **Front Biosci** 1999 Feb 15;4:D188-99 (101 ref.)

Enzymatic modulation of cell volume in C6 glioma cells. Bowman CL, et al. **Glia** 1999 Jul;27(1):22-31

Migration arrest in glioma cells is dependent on the alphav integrin subunit. Treasurywala S, et al. **Glia** 1998 Oct; 24(2):236-43

Chordoid glioma of the third ventricle: confirmatory report of a new entity. Vajtai I, et al. **Hum Pathol** 1999 Jun; 30(6):723-6

Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Arato-Ohshima T, et al. **Int J Cancer** 1999 Oct 29;83(3):387-92

Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Hamasuna R, et al. **Int J Cancer** 1999 Jul 19;82(2):274-81

Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Joe YA, et al. **Int J Cancer** 1999 Aug 27;82(5):694-9

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Tonn JC, et al. **Int J Cancer** 1999 Mar 1;80(5):764-72

Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA. Mohanam S, et al. **Int J Oncol** 1998 Dec;13(6):1285-90

Adenovirus-mediated over-expression of p21Waf-1 differentially affects the proliferation, telomerase activity, and expression of glial fibrillary acidic protein in human glioma cells. Terasaki M, et al. **Int J Oncol** 1999 Jan; 14(1):63-9

Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Timiryasova TM, et al. **Int J Oncol** 1999 May;14(5):845-54

Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Tysnes BB, et al. **Invasion Metastasis** 1997;17(5):270-80

MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Tynninen O, et al. **Invest Radiol** 1999 Jun;34(6):427-34

Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB. Chin LS, et al. **J Biomed Sci** 1999 May-Jun;6(3):213-8

Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. Belien AT, et al. **J Cell Biol** 1999 Jan 25;144(2):373-84

Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. Engel S, et al. **J Neuroimmunol** 1999 Sep 1;99(1):13-8

Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. Nabbout R, et al. **J Neurol Neurosurg Psychiatry** 1999 Mar;66(3):370-5

The role of image-guided technology in the surgical planning and resection of gliomas. Barnett GH. **J Neurooncol** 1999 May;42(3):247-58 (62 ref.)

Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Bergström P, et al. **J Neurooncol** 1999 Mar; 42(1):13-21

Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. Bredel M, et al. **J Neurooncol** 1999 Jan;41(1):9-20

Clusters of histologic characteristics in children with infratentorial neuroglial tumors. The Childhood Brain Tumor Consortium. Gilles FH, et al. **J Neurooncol** 1998 Aug;39(1):51-63

Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. Halfter H, et al. **J Neurooncol** 1998 Aug;39(1):1-18

Differentiation and growth inhibition of glioma cells induced by transfer of trk A proto-oncogene. Kokunai T, et al. **J Neurooncol** 1999 Mar;42(1):23-34

The role of stereotactic biopsy in the management of gliomas. Kondziolka D, et al. **J Neurooncol** 1999 May;42(3):205-13 (25 ref.)

Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. Kurimoto M, et al. **J Neurooncol** 1999 Mar;42(1):35-44

Variation of post-treatment H-MRSI choline intensity in pediatric gliomas. Lazareff JA, et al. **J Neurooncol** 1999 Feb;41(3):291-8

Intraoperative cortical mapping as a guide to the surgical resection of gliomas. Matz PG, et al. **J Neurooncol** 1999 May;42(3):233-45 (27 ref.)

Establishment of two glioma cell lines from two surgical specimens obtained at different times from the same individual. Onda K, et al. **J Neurooncol** 1999 Feb; 41(3):247-54

Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats. Saini M, et al. **J Neurooncol** 1999 Mar;42(1):59-67

Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. Trepel M, et al. **J Neurooncol** 1998 Aug; 39(1):19-32

Control of proliferation and survival of C6 glioma cells with modification of the nerve growth factor autocrine system. Watanabe T, et al. **J Neurooncol** 1999 Jan;41(2):121-8

Copper/zinc superoxide dismutase, nuclear DNA content, and progression in human gliomas. Yoshii Y, et al. **J Neurooncol** 1999 Apr;42(2):103-8

Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. Müller MB, et al. **J Neuropathol Exp Neurol** 1999 Jan;58(1):40-5

SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Rempel SA, et al. **J Neuropathol Exp Neurol** 1998 Dec; 57(12):1112-21

CD24 promotes invasion of glioma cells in vivo. Senner V, et al. **J Neuropathol Exp Neurol** 1999 Aug;58(8):795-802

In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha. Wang ZH, et al. **J Neuropathol Exp Neurol** 1999 Aug; 58(8):847-58

Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. Soroceanu L, et al. **J Neurosci** 1999 Jul 15;19(14):5942-54

Growth of precultured human glioma specimens in nude rat brain. Engebraaten O, et al. **J Neurosurg** 1999 Jan; 90(1):125-32

Assessment of the malignant potential of mitogen stimulated human Schwann cells. Emery E, et al. **J Peripher Nerv Syst** 1999;4(2):107-16

Pelvic gliomatosis within foci of endometriosis. Killeen VB, et al. **J Soc Laparoendosc Surg** 1997 Jul-Sep;1(3):267-8

ECM-mediated glioma cell invasion. Goldbrunner RH, et al. **Microsc Res Tech** 1998 Nov 1;43(3):250-7 (80 ref.)

Frameless stereotactic-directed tissue sampling during surgery of suspected low-grade gliomas to avoid histological undergrading. Roessler K, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):183-6

Attachment device for side-biting cannula in stereotactic biopsy--technical note. Koyama T, et al. **Neurol Med Chir (Tokyo)** 1999 Aug;39(8):625-7; discussion 627-8

Proliferative potential of malignant glioma cells before and after interstitial brachytherapy. Kunishio K, et al. **Neurol Med Chir (Tokyo)** 1999 May;39(5):341-9

Inhibition of topoisomerase II alpha subunit de novo synthesis by specific antisense oligonucleotides suppresses human glioma T98G cell growth. Shin M, et al. **Neurol Med Chir (Tokyo)** 1999 Mar;39(3):199-204; discussion 204-5

Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Tanaka S, et al. **Neurol Res** 1999 Jun;21(4):409-14

Adult brainstem gliomas [letter] Chamberlain MC. **Neurology** 1999 Jul 22;53(2):437-8

Cell death and oxidative stress in gliomas. Tews DS. **Neuropathol Appl Neurobiol** 1999 Aug;25(4):272-84

Fibroblast growth factor-9 (glia-activating factor) stimulates proliferation and production of glial fibrillary acidic protein in human gliomas either in the presence or in the absence of the endogenous growth factor expression. Miyagi N, et al. **Oncol Rep** 1999 Jan-Feb;6(1):87-92

Apoptosis and p53 expression in human gliomas. Sipos L, et al. **Pathol Oncol Res** 1998;4(4):267-70

Diffuse leptomeningeal gliomatosis with oligodendroglioma. Ng HK, et al. **Pathology** 1999 Feb;31(1):59-63 (33 ref.)

Test and teach. Number ninety one: Part 1. Subependymal giant cell astrocytoma. Singh M, et al. **Pathology** 1999 Feb; 31(1):23-4, 51

Malignant glial tumor arising from the site of a previous hamartoma/ganglioglioma: coincidence or malignant transformation? Mittler MA, et al. **Pediatr Neurosurg** 1999 Mar;30(3):132-4

Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Reardon DA, et al. **Pediatr Neurosurg** 1998 Jul;29(1):29-35

Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Shoshan Y, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10361-6

Presurgical evaluation of the motor hand area with functional MR imaging in patients with tumors and dysplastic lesions. Achten E, et al. **Radiology** 1999 Feb;210(2):529-38

Two-step spreading mode of human glioma cells on fibrin monomer: interaction of alpha(v)beta3 with the substratum followed by interaction of alpha5beta1 with endogenous cellular fibronectin secreted in the extracellular matrix. Yang W, et al. **Thromb Res** 1999 Mar 15;93(6):279-90

[Proliferative activities, oncoprotein expression and their significance in human gliomas] Bian X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Apr;26(2):89-92 (Eng. Abstr.) **(Chi)**

[Voltage-dependent potassium currents in rat C6 glioma cells] He SF, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):31-8 (Eng. Abstr.) **(Chi)**

[Inhibition of voltage-dependent K+ currents in rat C6 glioma cells by haloperidol and R(-)-NPA] Xie Z, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):45-53 (Eng. Abstr.) **(Chi)**

[Experimental treatment of brain tumor cells using CD suicide gene] Xu LF, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Dec;29(4):385-93 (Eng. Abstr.) **(Chi)**

[Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas?] Egelhof T, et al. **Radiologe** 1998 Nov;38(11):943-7 (Eng. Abstr.) **(Ger)**

[Combination effect of hyperthermia and MX2 on cultured glioma cell lines] Mizumatsu S, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):789-95 (Eng. Abstr.) **(Jpn)**

[Subependymal giant cell astrocytoma associated with tuberous sclerosis exhibiting rapid regrowth after 17 years: a case report] Kawasaki S, et al. **No Shinkei Geka** 1999 Jun;27(6):550-6 (Eng. Abstr.) **(Jpn)**

[In vitro study on intrathecal application of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant tumor] Nakagawa H, et al. **No Shinkei Geka** 1998 Sep;26(9):787-94 (Eng. Abstr.) **(Jpn)**

[Proliferation inhibition of glioma cells by vitamin K2] Sun L, et al. **No Shinkei Geka** 1999 Feb;27(2):119-25 (Eng. Abstr.) **(Jpn)**

[Cerebral gliomatosis with development of multifocal glioblastoma] Martinez-Mata AM, et al. **Rev Neurol** 1999 Apr 16-30;28(8):781-3 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Intracranial gliomas in neurofibromatosis type 1. Listernick R, et al. **Am J Med Genet** 1999 Mar 26;89(1):38-44 (26 ref.)

Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Forsyth PA, et al. **Br J Cancer** 1999 Apr;79(11-12):1828-35

Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines. Franko AJ, et al. **Br J Cancer** 1998 Nov; 78(10):1261-8

Apoptosis in human primary brain tumours. Leaver HA, et al. **Br J Neurosurg** 1998 Dec;12(6):539-46 (58 ref.)

Gamma-ray mutagen sensitivity and survival in patients with glioma. Sigurdson AJ, et al. **Clin Cancer Res** 1998 Dec; 4(12):3031-5

Glutamate receptor activation can trigger electrical activity in human glioma cells. Labrakakis C, et al. **Eur J Neurosci** 1998 Jun;10(6):2153-62

Disorganization of cortical structure and the brain tumors. Kroh H, et al. **Folia Neuropathol** 1999;37(1):20-6

Characterization and validation of noninvasive oxygen tension measurements in human glioma xenografts by 19F-MR relaxometry. van der Sanden BP, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):649-58

Copper/zinc superoxide dismutase, nuclear DNA content, and progression in human gliomas. Yoshii Y, et al. **J Neurooncol** 1999 Apr;42(2):103-8

Transformation of rat glioma cells with the M-CSF gene inhibits tumorigenesis in vivo. Yoshioka H, et al. **J Neurooncol** 1998 Dec;40(3):197-204

Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. Soroceanu L, et al. **J Neurosci** 1999 Jul 15;19(14):5942-54

In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Badie B, et al. **Neurosurgery** 1999 May;44(5):1077-82; discussion 1082-3

Action-potential-like depolarizations relieve opioid inhibition of N-type Ca2+ channels in NG108-15 cells. Tosetti P, et al. **Pflugers Arch** 1999 Feb;437(3):441-8

PSYCHOLOGY

Do research interviews cause distress or interfere in management? Experience from a study of cancer patients. Davies EA, et al. **J R Coll Physicians Lond** 1998 Sep-Oct; 32(5):406-11

RADIOGRAPHY

Blood-brain barrier and blood volume imaging of cerebral glioma using functional CT: a pictorial review. Leggett DA, et al. **Australas Radiol** 1998 Nov;42(4):335-40

Low grade glioma: a measuring radiographic response to radiotherapy. Bauman G, et al. **Can J Neurol Sci** 1999 Feb; 26(1):18-22

Blood-brain barrier and blood volume imaging of cerebral glioma using functional CT: a pictorial review. Leggett DA, et al. **Eur J Radiol** 1999 Jun;30(3):185-90

Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. Lote K, et

al. **J Neurooncol** 1998 Nov;40(2):161–70

Choroid plexus papillomas of the posterior fossa: extraventricular extension, intraventricular and primary extraventricular location. Report of four cases. Beskonakli E, et al. **J Neurosurg Sci** 1998 Mar;42(1):37–40

[Neuroradiologic diagnosis of tumor in the inner nasal canthus] Reiche W, et al. **Radiologe** 1998 Nov; 38(11):968–71 **(Ger)**

RADIONUCLIDE IMAGING

Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Bader JB, et al. **Eur J Nucl Med** 1999 Feb;26(2):144–51

Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Soler C, et al. **Eur J Nucl Med** 1998 Dec;25(12):1649–57

111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Korppi-Tommola T, et al. **Nucl Med Commun** 1999 Feb;20(2):145–52

201Tl SPET in the differential diagnosis of brain tumours. Taki S, et al. **Nucl Med Commun** 1999 Jul;20(7):637–45

The value of 201thallium-SPECT imaging in childhood brainstem gliomas. Nadvi SS, et al. **Pediatr Radiol** 1998 Aug;28(8):575–9

Intracranial mass lesions: sequential thallium and gallium scintigraphy in patients with AIDS. Lee VW, et al. **Radiology** 1999 May;211(2):507–12

11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Voges J, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):129–35

[Importance of cerebral tomoscintigraphy using technetium-labeled sestamibi in the differential diagnosis of current tumor vs. radiation necrosis in subtentorial glial tumors in the adult] Lamy-Lhullier C, et al. **Neurochirurgie** 1999 May;45(2):110–7 (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Gliomatosis cerebri: clinical features, treatment, and prognosis. Kim DG, et al. **Acta Neurochir (Wien)** 1998; 140(8):755–62

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study. Riva P, et al. **Acta Oncol** 1999;38(3):351–9

Prognostic factors and survival in patients with spinal cord gliomas after radiation therapy. Abdel-Wahab M, et al. **Am J Clin Oncol** 1999 Aug;22(4):344–51

Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Grill J, et al. **Ann Neurol** 1999 Mar;45(3):393–6

Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Kohshi K, et al. **Br J Cancer** 1999 Apr; 80(1–2):236–41

The importance of choice of anaesthetics in studying radiation effects in the 9L rat glioma. Pavlovic M, et al. **Br J Cancer Suppl** 1996 Jul;27:S222–5

Enhanced normal tissue doses caused by tumour shrinkage during brachytherapy. Dale RG, et al. **Br J Radiol** 1999 May;72(857):499–501

Low grade glioma: a measuring radiographic response to radiotherapy. Bauman G, et al. **Can J Neurol Sci** 1999 Feb; 26(1):18–22

Combined radiation and p53 gene therapy of malignant glioma cells. Badie B, et al. **Cancer Gene Ther** 1999 Mar-Apr;6(2):155–62

Permanent I-125 brain stem implants in children. Chuba PJ, et al. **Childs Nerv Syst** 1998 Oct;14(10):570–7

Diffuse brain stem gliomas. Are we improving outcome? Shuper A, et al. **Childs Nerv Syst** 1998 Oct;14(10):578–81

Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Merlo A, et al. **Clin Cancer Res** 1999 May;5(5):1025–33

Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Zhang W, et al. **Clin Cancer Res** 1996 May;2(5):843–6

Novel radiation technologies for malignant gliomas. Shafman TD, et al. **Curr Opin Oncol** 1999 May;11(3):147–51 (39 ref.)

Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Kiebert GM, et al. **Eur J Cancer** 1998 Nov;34(12):1902–9

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Paganelli G, et al. **Eur J Nucl Med** 1999 Apr;26(4):348–57

Modern aspects of radiation therapy for glial tumours of the brain. Rampling R. **Forum (Genova)** 1998 Jul-Sep; 8(3):289–301 (107 ref.)

Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Gridley DS, et al. **Int J Oncol** 1998 Nov;13(5):1093–8

Radiation-induced DNA double-strand breaks and rejoining in malignant glioma cells. Ozawa T, et al. **Int J Radiat Biol** 1999 May;75(5):563–70

Reirradiation and lomustine in patients with relapsed high-grade gliomas. Arcicasa M, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):789–93

Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Brada M, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15; 43(2):287–92

Hyperfractionated radiotherapy in the management of diffuse intrinsic brainstem tumors: when is enough enough? [editorial; comment] Fisher PG, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):947–9. Comment on: Int J Radiat Oncol Biol Phys 1999 Mar 15;43(5):959–64.

Permanent 125iodine implants for recurrent malignant gliomas. Gaspar LE, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):977–82

There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy [see comments] Mandell LR, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15; 43(5):959–64. Comment in: Int J Radiat Oncol Biol Phys 1999 Mar 15;43(5):947–9.

Comparison of radiosensitization by 41 degrees C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells. Raaphorst GP, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):185–8

Efficacy of radiotherapy for malignant gliomas in elderly patients. Villà S, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):977–80

The results of radiotherapy for brainstem tumors. Schild SE, et al. **J Neurooncol** 1998 Nov;40(2):171–7

Postoperative radiotherapy for supratentorial malignant gliomas. Yeh SA, et al. **J Neurooncol** 1999 Apr;42(2):183–7

Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Kokunai T, et al. **Jpn J Cancer Res** 1999 Jun;90(6):638–46

Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics. Wheeler FJ, et al. **Med Phys** 1999 Jul;26(7):1237–44

Proliferative potential of malignant glioma cells before and after interstitial brachytherapy. Kunishio K, et al. **Neurol Med Chir (Tokyo)** 1999 May;39(5):341–9

Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. Cardinale RM, et al. **Radiat Oncol Investig** 1998;6(4):175–81

Protracted exposure radiosensitization of experimental human malignant glioma. Williams JA, et al. **Radiat Oncol Investig** 1998;6(6):255–63

Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II study. Jeremic B, et al. **Radiother Oncol** 1998 Oct;49(1):49–54

11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Voges J, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):129–35

[Concomitant chemoradiotherapy and malignant glial tumors in the adult] Honnorat J. **Cancer Radiother** 1998 Dec; 2(6):672–8 (46 ref.) (Eng. Abstr.) **(Fre)**

[A clinical evaluation of combination therapy with radiation, MCNU, carboplatin and IFN-beta or with radiation, MCNU, carboplatin, etoposide and IFN-beta for malignant gliomas] Mizumatsu S, et al. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2055–60 (Eng. Abstr.) **(Jpn)**

[The use of cycloferon in experimental radiotherapy of tumors] Ivanov SD, et al. **Vopr Onkol** 1999;45(3):292–7 (Eng. Abstr.) **(Rus)**

SECONDARY

Cerebral gliomas and metastases: assessment with contrast-enhanced fast fluid-attenuated inversion-recovery MR imaging. Essig M, et al. **Radiology** 1999 Feb; 210(2):551–7

SECRETION

Glioma cells release excitotoxic concentrations of glutamate. Ye ZC, et al. **Cancer Res** 1999 Sep 1;59(17):4383–91

SURGERY

Radiation-induced brain tumours: potential late complications of radiation therapy for brain tumours. Nishio S, et al. **Acta Neurochir (Wien)** 1998;140(8):763–70

Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Stummer W, et al. **Acta Neurochir (Wien)** 1998; 140(10):995–1000

Hypothalamic gliomas. Dolenc VV. **Adv Tech Stand Neurosurg** 1999;25:161–94 (57 ref.)

Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Brandes AA, et al. **Am J Clin Oncol** 1999 Aug;22(4):387–90 (26 ref.)

Transnasal endoscopic repair of congenital defects of the skull base in children. Van Den Abbeele T, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):580–4

Surgery of low-grade gliomas--technical aspects. Berger MS. **Clin Neurosurg** 1997;44:161–80 (14 ref.)

Low-grade gliomas: in search of evidence-based treatment. Bernstein M. **Clin Neurosurg** 1997;44:315–30 (45 ref.)

Gliomas--past, present, and future. Black KL, et al. **Clin Neurosurg** 1999;45:160–3 (20 ref.)

Brainstem gliomas. Hoffman HJ. **Clin Neurosurg** 1997; 44:549–58 (17 ref.)

Criteria for patient selection: low-grade gliomas. Piepmeier JM. **Clin Neurosurg** 1997;44:51–62 (28 ref.)

Operative approach due to results of functional magnetic resonance imaging in central brain tumors. Wildförster U, et al. **Comput Aided Surg** 1998;3(4):162–5

Novel radiation technologies for malignant gliomas. Shafman TD, et al. **Curr Opin Oncol** 1999 May;11(3):147–51 (39 ref.)

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Hudes RS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):293–8

Fractionated stereotactic radiotherapy of small intracranial malignancies. Tokuuye K, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):989–94

Immediate side effects of stereotactic radiotherapy and radiosurgery. Werner-Wasik M, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):299–304

The role of surgery in low grade gliomas. Bampoe J, et al. **J Neurooncol** 1999 May;42(3):259–69 (72 ref.)

The role of image-guided technology in the surgical planning and resection of gliomas. Barnett GH. **J Neurooncol** 1999 May;42(3):247–58 (62 ref.)

Extent of resection as a prognostic variable in the treatment of gliomas. Hess KR. **J Neurooncol** 1999 May;42(3):227–31 (23 ref.)

The role of surgery in pediatric gliomas. Pollack IF. **J Neurooncol** 1999 May;42(3):271–88 (75 ref.)

Historical development of surgery for glial tumors. Salcman M. **J Neurooncol** 1999 May;42(3):195–204 (63 ref.)

Extent of resection in malignant gliomas: a critical summary. Sawaya R. **J Neurooncol** 1999 May;42(3):303–5

Basic surgical techniques in the resection of malignant gliomas. Toms SA, et al. **J Neurooncol** 1999 May; 42(3):215–26 (40 ref.)

Complications and expected outcome of glioma surgery. Vives KP, et al. **J Neurooncol** 1999 May;42(3):289–302 (42 ref.)

Resection of malignant gliomas of childhood [letter; comment] Kreth FW, et al. **J Neurosurg** 1999 Jun; 90(6):1147–8. Comment on: J Neurosurg 1998 Jul;89(1):52–9.

Brain tumour surgery: triumphs and tragedies. Whittle IR. **J R Coll Surg Edinb** 1999 Apr;44(2):72–7

Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism. Keegan MT, et al. **Mayo Clin Proc** 1999 Mar;74(3):264–8

Radical surgery and reoperation in supratentorial malignant glial tumors. Daneyemez M, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):209–13

Comparison between operative findings on malignant glioma by a fluorescein surgical microscopy and histological findings. Kuroiwa T, et al. **Neurol Res** 1999 Jan;21(1):130–4

The role of radiosurgery for glial neoplasms. Alexander E 3rd, et al. **Neurosurg Clin N Am** 1999 Apr;10(2):351–8 (66 ref.)

Endoscopic approach to nasal glioma. Burckhardt W, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):747–8

Chronic intractable epilepsy associated with a tumor located in the central region: functional mapping data and postoperative outcome. Devaux B, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):229–38

Choroid plexus papilloma of the cerebellopontine angle: a twelve patient series. Talacchi A, et al. **Surg Neurol** 1999 Jun;51(6):621–9

[Therapy for intracranial lesions by gamma knife] Hou Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):347–50 (Eng. Abstr.) **(Chi)**

[Neuronavigation. Computer-assisted neurosurgery] Ostertag CB, et al. **Nervenarzt** 1999 Jun;70(6):517–21 (38 ref.) (Eng. Abstr.) **(Ger)**

[Subependymal giant cell astrocytoma associated with tuberous sclerosis exhibiting rapid regrowth after 17 years: a case report] Kawasaki S, et al. **No Shinkei Geka** 1999 Jun;27(6):550–6 (Eng. Abstr.) **(Jpn)**

[The molecular genetics of gliomas and the outlook for molecular neurosurgery] Zozulia IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct-Dec; (4):45–51 (132 ref.) **(Rus)**

THERAPY

IL-4 gene transfer for the treatment of experimental gliomas. Benedetti S, et al. **Adv Exp Med Biol** 1998;451:315–21

Another mechanism causing the bystander effect besides the gap junction's role during the glioma gene therapy with HSV-TK/GCV system. Du L, et al. **Adv Exp Med Biol** 1998;451:133–8

Gene therapy for malignant glioma patients. Puumalainen AM, et al. **Adv Exp Med Biol** 1998;451:505–9

Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Sasaki M, et al. **Ann Oncol** 1998 Nov;9(11):1155–66 (101 ref.)

Gene therapy of gliomas: receptor and transcriptional targeting. Spear MA. **Anticancer Res** 1998 Sep-Oct; 18(5A):3223–31 (123 ref.)

Clinical management of brain stem glioma. Walker DA, et al. **Arch Dis Child** 1999 Jun;80(6):558–64 (77 ref.)

Targeting in gene therapy for gliomas. Fueyo J, et al. **Arch Neurol** 1999 Apr;56(4):445–8 (8 ref.)

Brain tumors in children. Packer RJ. **Arch Neurol** 1999 Apr; 56(4):421–5 (16 ref.)
Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Beauchesne P, et al. **Cancer Chemother Pharmacol** 1999;44(3):210–6
Combined radiation and p53 gene therapy of malignant glioma cells. Badie B, et al. **Cancer Gene Ther** 1999 Mar–Apr;6(2):155–62
Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus–defective vector expressing interferon–gamma. Kanno H, et al. **Cancer Gene Ther** 1999 Mar–Apr;6(2):147–54
Regression of orthotopic brain tumors by cytokine–assisted tumor vaccines primed in the brain. Tseng SH, et al. **Cancer Gene Ther** 1999 Jul–Aug;6(4):302–12
Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon–gamma, interleukin–7, or B7–1–transfected tumor cells. Visse E, et al. **Cancer Gene Ther** 1999 Jan–Feb;6(1):37–44
Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene [see comments] Kim JH, et al. **Cancer J Sci Am** 1998 Nov–Dec;4(6):364–9 . Comment in: Cancer J Sci Am 1998 Nov–Dec;4(6):349–50.
Synergism between mild hyperthermia and interferon–beta gene expression. Bouhon IA, et al. **Cancer Lett** 1999 May 24;139(2):153–8
Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM–1) transfection in mouse glioma cells. Kikuchi T, et al. **Cancer Lett** 1999 Aug 3;142(2):201–6
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Aghi M, et al. **Cancer Res** 1999 Aug 15;59(16):3861–5
Eradication of rat malignant gliomas by retroviral–mediated, in vivo delivery of the interleukin 4 gene. Benedetti S, et al. **Cancer Res** 1999 Feb 1;59(3):645–52
Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Galipeau J, et al. **Cancer Res** 1999 May 15;59(10):2384–94
Antiangiogenesis treatment for gliomas: transfer of antisense–vascular endothelial growth factor inhibits tumor growth in vivo. Im SA, et al. **Cancer Res** 1999 Feb 15; 59(4):895–900
Highly augmented cytopathic effect of a fiber–mutant E1B–defective adenovirus for gene therapy of gliomas. Shinoura N, et al. **Cancer Res** 1999 Jul 15;59(14):3411–6
Selective killing of glioma cell lines using an astrocyte–specific expression of the herpes simplex virus–thymidine kinase gene. Vandier D, et al. **Cancer Res** 1998 Oct 15;58(20):4577–80
Ionizing radiation improves survival in mice bearing intracranial high–grade gliomas injected with genetically modified herpes simplex virus. Bradley JD, et al. **Clin Cancer Res** 1999 Jun;5(6):1517–22
Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high–grade gliomas. Bredel M, et al. **Clin Cancer Res** 1997 Nov;3(11):2157–64
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Debinski W, et al. **Clin Cancer Res** 1995 Nov;1(11):1253–8
A phase I trial of a new recombinant human beta–interferon (BG9015) for the treatment of patients with recurrent gliomas. Fine HA, et al. **Clin Cancer Res** 1997 Mar; 3(3):381–7
125I–labeled anti–epidermal growth factor receptor–vIII single–chain Fv exhibits specific and high–level targeting of glioma xenografts. Kuan CT, et al. **Clin Cancer Res** 1999 Jun;5(6):1539–49
Intracerebral adenovirus–mediated p53 tumor suppressor gene therapy for experimental human glioma. Li H, et al. **Clin Cancer Res** 1999 Mar;5(3):637–42
Neoplasms [editorial] Thomas DG. **Curr Opin Neurol** 1998 Dec;11(6):617–8
Gene transfer technologies for malignant gliomas. Weyerbrock A, et al. **Curr Opin Oncol** 1999 May; 11(3):168–73 (54 ref.)
New frontiers in therapy of malignant gliomas. Puduvalli VK, et al. **Forum (Genova)** 1998 Jul–Sep;8(3):261–9 (89 ref.)
In vitro and in vivo effects of retrovirus–mediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy. Cirenei N, et al. **Gene Ther** 1998 Sep;5(9):1221–6
Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL–4 plus HSVtk tumor vaccine. Okada H, et al. **Gene Ther** 1999 Feb; 6(2):219–26
Decorin gene transfer–mediated suppression of TGF–beta synthesis abrogates experimental malignant glioma growth in vivo. Ständer M, et al. **Gene Ther** 1998 Sep;5(9):1187–94
Transduction of glioma cells using a high–titer retroviral vector system and their subsequent migration in brain tumors. Tamura M, et al. **Gene Ther** 1998 Dec; 5(12):1698–704
Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Ambar BB, et al. **Hum Gene Ther** 1999 Jul 1;10(10):1641–8
FADD gene therapy for malignant gliomas in vitro and in vivo [see comments] Kondo S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1599–608. Comment in: Hum Gene Ther 1998 Jul 20;9(11):1527–8.
Antiangiogenic gene therapy in a rat glioma model using a dominant–negative vascular endothelial growth factor receptor 2. Machein MR, et al. **Hum Gene Ther** 1999 May 1;10(7):1117–28
Beta–galactosidase gene transfer to human malignant glioma in vivo using replication–deficient retroviruses and adenoviruses. Puumalainen AM, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1769–74
Generation of fiber–mutant recombinant adenoviruses for gene therapy of malignant glioma. Yoshida Y, et al. **Hum Gene Ther** 1998 Nov 20;9(17):2503–15
Anti–tumor activity of interleukin–2–producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Kikuchi T, et al. **Int J Cancer** 1999 Jan 29;80(3):425–30
Evaluation of radiation effects against C6 glioma in combination with vaccinia virus–p53 gene therapy. Gridley DS, et al. **Int J Oncol** 1998 Nov;13(5):1093–8
Antitumor activity of killer cells stimulated with both interleukin–2 and interleukin–12 on mouse glioma cells. Kikuchi T, et al. **J Immunother** 1999 May;22(3):245–50
Effect of in situ retroviral interleukin–4 transfer on established intracranial tumors. Saleh M, et al. **J Natl Cancer Inst** 1999 Mar 3;91(5):438–45
Opportunities for improving the quality of care in malignant cerebral glioma [letter] Davies E, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):693
Sensitization to hyperthermia by intracellular acidification of C6 glioma cells. Kitai R, et al. **J Neurooncol** 1998 Sep; 39(3):197–203
Variation of post–treatment H–MRSI choline intensity in pediatric gliomas. Lazareff JA, et al. **J Neurooncol** 1999 Feb;41(3):291–8
Treatment of intracranial gliomas with bone marrow–derived dendritic cells pulsed with tumor antigens. Liau LM, et al. **J Neurosurg** 1999 Jun;90(6):1115–24
Comparative study on the ALA photodynamic effects of human glioma and meningioma cells. Tsai JC, et al. **Lasers Surg Med** 1999;24(4):296–305
Gene therapy of central nervous system tumors. Wakabayashi T, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):763–71 (48 ref.)
Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF–beta antisense gene. Liau LM, et al. **Neurol Res** 1998 Dec;20(8):742–7
The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Fueyo J, et al. **Neurology** 1998 Nov;51(5):1250–5 (49 ref.)
Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor–Mediated Permeabilizer–7). Barth RF, et al. **Neurosurgery** 1999 Feb;44(2):351–9; discussion 359–60
Evaluation of pGL1–TNF–alpha therapy in combination with radiation. Li J, et al. **Oncol Res** 1998;10(7):379–87
New treatment strategies for malignant gliomas. Avgeropoulos NG, et al. **Oncologist** 1999;4(3):209–24 (126 ref.)
Potential prognostic factors of relapse–free survival in childhood optic pathway glioma: a multivariate analysis. Chan MY, et al. **Pediatr Neurosurg** 1998 Jul;29(1):23–8
Growth factor receptors as targets for therapy in pediatric brain tumors. Meuillet EJ, et al. **Pediatr Neurosurg** 1998 Jul;29(1):1–13 (116 ref.)
A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Horton HM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1553–8
Evaluation of cross–resistance between responses to cisplatin, hyperthermia, and radiation in human glioma cells and eight clones selected for cisplatin resistance. Raaphorst GP, et al. **Radiat Oncol Investig** 1999;7(3):153–7
Gene stereotactic neurosurgery for recurrent malignant gliomas. Colombo F, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):245–51
[Gene transduction for experimental brain tumors using recombinant adenovirus vector] Ichikawa T, et al. **No To Shinkei** 1998 Aug;50(8):731–8 (Eng. Abstr.) **(Jpn)**
[Antitumor gene therapy using suicide genes] Berenstein M, et al. **Medicina (B Aires)** 1998;58(2):185–8 (Eng. Abstr.) **(Spa)**
[Molecular control of the cellular cycle and apoptosis: new treatments for gliomas] Fueyo J, et al. **Neurologia** 1998 Aug–Sep;13(7):349–55 (67 ref.) (Eng. Abstr.) **(Spa)**
[Practical aspects in the diagnosis and treatment of cerebral gliomas] Rosenfeld MR, et al. **Neurologia** 1999 Mar; 14(3):111–21 (124 ref.) **(Spa)**

ULTRASTRUCTURE

Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. Remmers AE, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):827–33

VETERINARY

Ultrasonographic confirmation of a space–occupying lesion in the brain of a horse: choroid plexus papilloma. Pirie RS, et al. **Equine Vet J** 1998 Sep;30(5):445–8
What is your neurologic diagnosis? Space–occupying mass in the right side of the cortical region of the forebrain such as neoplasia or granuloma more likely than generalized inflammatory disease. Evans J, et al. **J Am Vet Med Assoc** 1999 Feb 1;214(3):337–9
Evidence of neoplastic nature and viral aetiology of so–called fowl glioma. Ochiai K, et al. **Vet Rec** 1999 Jul 17; 145(3):79–81

VIROLOGY

Encephalomyocarditis (EMC) virus infection in PC12 and C6 cells. Su W, et al. **Int J Exp Pathol** 1998 Dec;79(6):411–6
Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. Arbour N, et al. **J Virol** 1999 Apr;73(4):?326–37

GLIOMA, RETINAL see **RETINOBLASTOMA**

GLIOMA, SUBEPENDYMAL

DIAGNOSIS

Intracranial subependymoma. Neumann DP, et al. **Conn Med** 1998 Oct;62(10):583–5

GENETICS

Cytogenetic investigation in subependymoma [letter] Dal Cin P, et al. **Cancer Genet Cytogenet** 1999 Jan 1;108(1):84

PATHOLOGY

Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB–1 immunohistochemical analysis with other ependymal neoplasms. Prayson RA, et al. **Arch Pathol Lab Med** 1999 Apr;123(4):306–9

GLIOSARCOMA

Novel gliosarcoma cell line expressing green fluorescent protein: A model for quantitative assessment of angiogenesis. Moore A, et al. **Microvasc Res** 1998 Nov; 56(3):145–53

BLOOD SUPPLY

Deuterium NMR tissue perfusion measurements using the tracer uptake approach: II. Comparison with microspheres in tumors. Simpson NE, et al. **Magn Reson Med** 1999 Aug; 42(2):240–7

DIAGNOSIS

[Gliosarcomas] Sousa O, et al. **Acta Med Port** 1998 Jun; 11(6):573–6 (19 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Damage to tumour and brain by interstitial photodynamic therapy in the 9L rat tumour model comparing intravenous and intratumoral administration of the photosensitiser. Hebeda KM, et al. **Acta Neurochir (Wien)** 1998; 140(5):495–501
Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine–based cancer gene therapy. Jounaidi Y, et al. **Cancer Res** 1998 Oct 1;58(19):4391–401
CD44s–targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma. Gunia S, et al. **Clin Exp Metastasis** 1999 May;17(3):221–30
Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. Kong Q, et al. **J Surg Oncol** 1998 Oct;69(2):76–82
Photodynamic therapy using Photofrin in combination with buthionine sulfoximine (BSO) to treat 9L gliosarcoma in rat brain. Jiang F, et al. **Lasers Surg Med** 1998;23(3):161–6

IMMUNOLOGY

Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type–1. Song GY, et al. **J Neuroimmunol** 1999 Jan 1;93(1–2):1–7

METABOLISM

Increased uptake of 99mTc–HMPAO in necrotic brain tumors. Lee SH, et al. **J Korean Med Sci** 1998 Oct; 13(5):529–32
Enhanced uptake of [3H] spermidine by 9L rat brain tumors after direct intratumoral infusion of inhibitors of enzymes of the polyamine biosynthetic pathway. Redgate ES, et al. **J Neurooncol** 1999 Apr;42(2):123–30

PATHOLOGY

Pathologic quiz case. Gliosarcoma containing malignant fibrohistiocytic, osseous, and chondroid elements. Malone JC, et al. **Arch Pathol Lab Med** 1999 Apr;123(4):358–60
October 1998--61 year old male with brain tumor and oral, lung, and palpebral masses. Gjerdrum LM, et al. **Brain Pathol** 1999 Apr;9(2):421–2
Gliosarcoma with angiosarcomatous features: a case report. Shintaku M, et al. **Brain Tumor Pathol** 1998;15(2):101–5
Gliosarcoma: a case with unusual epithelial feature. Kim DS, et al. **J Korean Med Sci** 1999 Jun;14(3):345–50
Functional magnetic resonance (fMR) imaging of a rat brain tumor model: implications for evaluation of tumor microvasculature and therapeutic response. Mazurchuk R, et al. **Magn Reson Imaging** 1999 May;17(4):537–48

GLIOSARCOMA

RADIONUCLIDE IMAGING

Enhanced uptake of [11C]TPMP in canine brain tumor: a PET study. Madar I, et al. **J Nucl Med** 1999 Jul; 40(7):1180–5

RADIOTHERAPY

Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Rogulski KR, et al. **Clin Cancer Res** 1997 Nov;3(11):2081–8

Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron-wiggler-generated X rays. Laissue JA, et al. **Int J Cancer** 1998 Nov 23;78(5):654–60

Neutron capture therapy with a new boron-porphyrin compound in the rat 9L glioma model. Shibata Y, et al. **J Exp Clin Cancer Res** 1998 Sep;17(3):285–9

Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. Joel DD, et al. **J Neurooncol** 1999 Feb;41(3):213–21

SECONDARY

October 1998--61 year old male with brain tumor and oral, lung, and palpebral masses. Gjerdrum LM, et al. **Brain Pathol** 1999 Apr;9(2):421–2

THERAPY

A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Rainov NG, et al. **Adv Exp Med Biol** 1998;451:393–403

Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Rogulski KR, et al. **Clin Cancer Res** 1997 Nov;3(11):2081–8

Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Rainov NG, et al. **Hum Gene Ther** 1999 Jan 20;10(2):311–8

Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies [letter; comment] Liao WC, et al. **J Natl Cancer Inst** 1999 Feb 3;91(3):285–6. Comment on: J Natl Cancer Inst 1998 Mar 4;90(5):370–80.

ULTRASTRUCTURE

Gliosarcoma: an immunohistochemical, ultrastructural and fluorescence in situ hybridization study. Horiguchi H, et al. **Pathol Int** 1998 Aug;48(8):595–602

GLIOSIS

The amount of brainstem gliosis in sudden infant death syndrome (SIDS) victims correlates with maternal cigarette smoking during pregnancy. Storm H, et al. **Acta Paediatr** 1999 Jan;88(1):13–8

[Progressive subcortical gliosis (PSG)] Yoshii Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):406–7 (12 ref.) **(Jpn)**

CHEMICALLY INDUCED

Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Escubedo E, et al. **Brain Res** 1998 Dec 14;814(1-2):120–6

Degeneration and gliosis in rat retina and central nervous system following 3,3'-iminodipropionitrile exposure. Seoane A, et al. **Brain Res** 1999 Jul 3;833(2):258–71

Lithium treatment causes gliosis and modifies the morphology of hippocampal astrocytes in rats. Rocha E, et al. **Neuroreport** 1998 Dec 1;9(17):3971–4

DIAGNOSIS

Late-onset sporadic progressive subcortical gliosis. Lanska DJ, et al. **J Neurol Sci** 1998 May 7;157(2):143–7

Radiation change versus recurrent astrocytoma: diagnostic utility of the proliferation index? Bigio EH, et al. **J Neurooncol** 1999 Jan;41(1):55–63

Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Dousset V, et al. **Neurology** 1998 Oct;51(4):1150–5

DRUG THERAPY

Magnetisation transfer magnetic resonance imaging demonstration of perilesional gliosis--relation with epilepsy in treated or healed neurocysticercosis [letter] Gupta RK, et al. **Lancet** 1999 Jul 3;354(9172):44–5

ETIOLOGY

Calcium influx and activation of calpain I mediate acute reactive gliosis in injured spinal cord. Du S, et al. **Exp Neurol** 1999 May;157(1):96–105

Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Renkawek K, et al. **Neuroreport** 1999 Aug 2; 10(11):2273–6

GENETICS

Morphologic and genetic analysis of retinal angioma associated with massive gliosis in a patient with von Hippel-Lindau disease. Vortmeyer AO, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun;237(6):513–7

Tau gene mutation in familial progressive subcortical gliosis. Goedert M, et al. **Nat Med** 1999 Apr;5(4):454–7

Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Dawson GR, et al. **Neuroscience** 1999 Apr;90(1):1–13

Doxycycline control of prion protein transgene expression modulates prion disease in mice. Tremblay P, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12580–5

IMMUNOLOGY

CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue. Hagel C, et al. **Neuropathol Appl Neurobiol** 1999 Aug; 25(4):313–8

METABOLISM

A role for transforming growth factor alpha as an inducer of astrogliosis. Rabchevsky AG, et al. **J Neurosci** 1998 Dec 15;18(24):10541–52

PATHOLOGY

Reactive gliosis of immature Bergmann glia and microglial cell activation in response to cell death of granule cell precursors induced by methylazoxymethanol treatment in developing rat cerebellum. Lafarga M, et al. **Anat Embryol (Berl)** 1998 Aug;198(2):111–22

Cyclo-oxygenase-2 mediates P2Y receptor-induced reactive astrogliosis. Brambilla R, et al. **Br J Pharmacol** 1999 Feb; 126(3):563–7

Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor. Rizvi TA, et al. **Brain Res** 1999 Jan 16; 816(1):111–23

Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue. Overmyer M, et al. **Dement Geriatr Cogn Disord** 1999 Jul-Aug;10(4):252–7

A unique autosomal dominant disorder with indifference to pain: clinicopathologic correlation of indifference to pain and thalamic gliosis. Davis BJ, et al. **Eur Neurol** 1998 Oct; 40(3):141–5

Late-onset sporadic progressive subcortical gliosis. Lanska DJ, et al. **J Neurol Sci** 1998 May 7;157(2):143–7

The microglial response to progressive hydrocephalus in a model of inherited aqueductal stenosis. Mangano FT, et al. **Neurol Res** 1998 Dec;20(8):697–704

No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Falkai P, et al. **Neuropathol Appl Neurobiol** 1999 Feb;25(1):48–53

Reactive microgliosis. Streit WJ, et al. **Prog Neurobiol** 1999 Apr;57(6):563–81 (158 ref.)

PHYSIOPATHOLOGY

Time course for kindling-induced changes in the hilar area of the dentate gyrus: reactive gliosis as a potential mechanism. Adams B, et al. **Brain Res** 1998 Sep 7; 804(2):331–6

N-cadherin at the glial scar in the rat. Vázquez-Chona F, et al. **Brain Res** 1999 Aug 14;838(1-2):45–50

Independent mechanisms of potassium clearance by astrocytes in gliotic tissue. Walz W, et al. **J Neurosci Res** 1999 Jun 15;56(6):595–603

PREVENTION & CONTROL

Dehydroepiandrosterone, pregnenolone and sex steroids down-regulate reactive astroglia in the male rat brain after a penetrating brain injury. García-Estrada J, et al. **Int J Dev Neurosci** 1999 Apr;17(2):145–51

The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Morgan TE, et al. **Neuroscience** 1999 Mar;89(3):687–99

THERAPY

Adenovirus-mediated suicide gene therapy in an in vitro model of reactive gliosis. Audouy S, et al. **Glia** 1999 Feb 1;25(3):293–303

VETERINARY

Oligodendroglial vacuolar degeneration in the bilateral motor cortices and astrocytosis in epileptic beagle dogs. Morita T, et al. **J Vet Med Sci** 1999 Feb;61(2):107–11

GLIOTOXIN

ANALYSIS

[MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis?] Perron H. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):427–38 (52 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Determination of optimum growth conditions for gliotoxin production by Aspergillus fumigatus and development of a novel method for gliotoxin detection. Belkacemi L, et al. **Med Mycol** 1999 Aug;37(4):227–33

PHARMACOLOGY

Effect of gliotoxin on human polymorphonuclear neutrophils. Shah DT, et al. **Infect Dis Obstet Gynecol** 1998;6(4):168–75

Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization. Sonoda K, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2245–51

t-Butylhydroperoxide and gliotoxin stimulate Ca2+ release from rat skeletal muscle mitochondria. Silva JP, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):331–41

GLIPIZIDE

ADMINISTRATION & DOSAGE

Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets. Leaf E, et al. **Am J Health Syst Pharm** 1999 Mar 1; 56(5):454–6

ADVERSE EFFECTS

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Mullins ME, et al. **Ann Emerg Med** 1999 Jan;33(1):129–30. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Robertson WO. **Ann Emerg Med** 1999 Jan;33(1):130–1. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.

ECONOMICS

Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets. Leaf E, et al. **Am J Health Syst Pharm** 1999 Mar 1; 56(5):454–6

PHARMACOKINETICS

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Kidd RS, et al. **Pharmacogenetics** 1999 Feb;9(1):71–80

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. Courtois P, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):211–22

PHARMACOLOGY

Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Sagedal S, et al. **Clin Transplant** 1998 Dec;12(6):553–6

Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues. Tüzün S, et al. **Exp Toxicol Pathol** 1999 Jul;51(4-5):436–41

THERAPEUTIC USE

Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Testa MA, et al. **Diabetes Care** 1998 Dec;21 Suppl 3:C44–52

Triple oral antidiabetic therapy. Kaye TB. **J Diabetes Complications** 1998 Nov-Dec;12(6):311–3

Transient clinical diabetes mellitus in cats: 10 cases (1989-1991). Nelson RW, et al. **J Vet Intern Med** 1999 Jan-Feb;13(1):28–35

Effect of immediate-release glipizide on hypoglycemic vulnerability in fasted, elderly patients with type 2 diabetes [letter] Burge MR, et al. **JAMA** 1999 Mar 24–31; 281(12):1084–5

Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial [see comments] Testa MA, et al. **JAMA** 1998 Nov 4;280(17):1490–6. Comment in: JAMA 1999 Jun 2;281(21):1985; discussion 1986. Comment in: JAMA 1999 Jun 2;281(21):1985–6. Comment in: JAMA 1999 Jun 2;281(21):1987–8.

GLNH see **GIANT LYMPH NODE HYPERPLASIA**

GLOBAL WARMING see **GREENHOUSE EFFECT**

GLOBICEPHALA see **DOLPHINS**

GLOBIN

ANALYSIS

Quantitation of human globin chain synthesis by cellulose acetate electrophoresis. Salmon JE, et al. **Anal Biochem** 1978 Nov;91(1):146–57

Evaluation of glycated globins by matrix-assisted laser desorption/ionization mass spectrometry. Lapolla A, et al. **Clin Chem** 1999 Feb;45(2):288–90

Human globin chain separation by capillary electrophoresis in acidic isoelectric buffers. Righetti PG, et al. **Electrophoresis** 1998 Jul;19(10):1733–7

Two-colour immunocytochemical staining of gamma (gamma) and epsilon (epsilon) type haemoglobin in fetal red cells. Mesker WE, et al. **Prenat Diagn** 1998 Nov; 18(11):1131–7

Direct evaluation of glycated and glyco-oxidized globins by

matrix-assisted laser desorption/ionization mass spectrometry. Lapolla A, et al. **Rapid Commun Mass Spectrom** 1999;13(1):8–14

BIOSYNTHESIS

Quantitation of human globin chain synthesis by cellulose acetate electrophoresis. Salmon JE, et al. **Anal Biochem** 1978 Nov;91(1):146–57

Transcription factor CP2 is crucial in hemoglobin synthesis during erythroid terminal differentiation in vitro. Chae JH, et al. **Biochem Biophys Res Commun** 1999 Sep 24; 263(2):580–3

Unusually severe heterozygous beta-thalassemia: evidence for an interacting gene affecting globin translation. Ho PJ, et al. **Blood** 1998 Nov 1;92(9):3428–35

Globin chain synthesis analysis by high performance liquid chromatography in the screening of thalassemia syndromes. Galanello R, et al. **Hemoglobin** 1998 Sep–Nov; 22(5–6):501–8

Position-independent human beta-globin gene expression mediated by a recombinant adeno-associated virus vector carrying the chicken beta-globin insulator [published erratum appears in J Hum Genet 1999;44(4):273] Inoue T, et al. **J Hum Genet** 1999;44(3):152–62

Identification of Id2 as a globin regulatory protein by representational difference analysis of K562 cells induced to express gamma-globin with a fungal compound. Holmes ML, et al. **Mol Cell Biol** 1999 Jun;19(6):4182–90

CHEMISTRY

Peroxynitrite reacts with methemoglobin to generate globin-bound free radical species. Implications for vascular injury. Cooper CE, et al. **Adv Exp Med Biol** 1998; 454:195–202

Quaternary structure sensitive tyrosine residues in human hemoglobin: UV resonance raman studies of mutants at alpha140, beta35, and beta145 tyrosine. Nagai M, et al. **Biochemistry** 1999 Jan 26;38(4):1243–51

The artificial alpha1beta1-contact mutant hemoglobin, Hb Phe-35beta, shows only small functional abnormalities. Nakatsukasa T, et al. **FEBS Lett** 1998 Dec 11;441(1):93–6

Probing the reactivity of nucleophile residues in human 2,3-diphosphoglycerate/deoxy-hemoglobin complex by aspecific chemical modifications. Scaloni A, et al. **FEBS Lett** 1999 Jun 11;452(3):190–4

Thermal stabilization of multimeric proteins: a case study with alpha-globulin. Radha C, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):76–85

Structural and functional roles of heme binding module in globin proteins: identification of the segment regulating the heme binding structure. Inaba K, et al. **J Mol Biol** 1998; 283(1):311–27

Non-functional conserved residues in globins and their possible role as a folding nucleus. Ptitsyn OB, et al. **J Mol Biol** 1999 Aug 20;291(3):671–82

Crystal structure of a protein with an artificial exon-shuffling, module M4-substituted chimera hemoglobin beta alpha, at 2.5 A resolution. Shirai T, et al. **J Mol Biol** 1999 Mar 26; 287(2):369–82

Three-dimensional reconstruction of Lumbricus terrestris hemoglobin at 22 A resolution: intramolecular localization of the globin and linker chains. Taveau JC, et al. **J Mol Biol** 1999 Jun 25;289(5):1343–59

Characterization of a hemoglobin-like protein from adult Haemonchus contortus. Fetterer RH, et al. **J Parasitol** 1999 Apr;85(2):295–300

Modeling and superposition of multiple protein structures using affine transformations: analysis of the globins. Wu TD, et al. **Pac Symp Biocomput** 1998;:509–20

[Hemoglobin alpha chain isoelectric point modification under the action of urea, sodium cyanate, succinic anhydride or diethylene triamine pentaacetic acid anhydride] Legendre JM, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):605–12 (Eng. Abstr.) **(Fre)**

GENETICS

Comparison of repair activity in different genomic regions. Chakalova L, et al. **Acta Biochim Pol** 1998;45(1):173–81

Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene. Chase MB, et al. **Am J Hematol** 1999 Jan;60(1):27–35

Hb Iraq-Halabja beta10 (A7) Ala-->Val (GCC-->GTC): a new beta-chain silent variant in a family with multiple Hb disorders. Deutsch S, et al. **Am J Hematol** 1999 Jul; 61(3):187–93

Alpha-thalassemia carrier identification by DNA analysis in the screening for thalassemia. Galanello R, et al. **Am J Hematol** 1998 Dec;59(4):273–8

Hemoglobins in Togolese newborns: Hb S, Hb C, Hb Bart's, and alpha-globin gene status. Segbena AY, et al. **Am J Hematol** 1998 Nov;59(3):208–13

Phenotypic variability of Filipino beta(o)-thalassemia/HbE patients in Indonesia. Setianingsih I, et al. **Am J Hematol** 1999 Sep;62(1):7–12

Hematological effects of atypical and Cameroon beta-globin gene haplotypes in adult sickle cell anemia. Steinberg MH, et al. **Am J Hematol** 1998 Oct;59(2):121–6

Double heterozygosity for the codon beta 39 C-to-T nonsense mutation and a triplicate alpha-globin gene locus can cause "dominantly" inherited beta-thalassemia intermedia. Rhodes SL, et al. **Am J Med Sci** 1999 May; 317(5):341–5

Sequences from the 5' flanking region of the epsilon-globin gene support the relationship of Callicebus with the pitheciins. Porter CA, et al. **Am J Primatol** 1999;48(1):69–75

Beta-globin haplotypes analysis in Afro-Brazilians from the Amazon region: evidence for a significant gene flow from Atlantic West Africa. Pante-De-Sousa G, et al. **Ann Hum Biol** 1999 Jul–Aug;26(4):365–73

Stem cell gene therapy for the beta-chain hemoglobinopathies. Problems and progress. Emery DW, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:94–107; discussion 107–8 (64 ref.)

Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes. Ofori-Acquah SF, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):181–7

Protein-DNA footprinting of the human epsilon-globin promoter in human intact cells using nitrogen mustard analogues and other DNA-damaging agents. Temple MD, et al. **Biochim Biophys Acta** 1999 Jun 9;1445(3):245–56

Description and targeted deletion of 5' hypersensitive site 5 and 6 of the mouse beta-globin locus control region. Bender MA, et al. **Blood** 1998 Dec 1;92(11):4394–403

Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Ikuta T, et al. **Blood** 1998 Oct 15;92(8):2924–33

Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. Ishiguro K, et al. **Blood** 1998 Dec 1;92(11):4383–93

Development of viral vectors for gene therapy of beta-chain hemoglobinopathies: optimization of a gamma-globin gene expression cassette. Li Q, et al. **Blood** 1999 Apr 1; 93(7):2208–16

Comparison of expression of human globin genes transferred into mouse erythroleukemia cells and in transgenic mice. Skarpidi E, et al. **Blood** 1998 Nov 1;92(9):3416–21

Recombination breakpoints in the human beta-globin gene cluster. Smith RA, et al. **Blood** 1998 Dec 1;92(11):4415–21

Correct function of the locus control region may require passage through a nonerythroid cellular environment. Vassilopoulos G, et al. **Blood** 1999 Jan 15;93(2):703–12

Analysis of linked human epsilon and gamma transgenes: effect of locus control region hypersensitive sites 2 and 3 or a distal YY1 mutation on stage-specific expression patterns. Zhu W, et al. **Blood** 1999 May 15;93(10):3540–9

Identification of upstream regulatory elements that repress expression of adult beta-like globin genes in a primitive erythroid environment. Ebb D, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):356–69

Development of a condensed locus control region cassette and testing in retrovirus vectors for A gamma-globin. Emery DW, et al. **Blood Cells Mol Dis** 1998 Sep; 24(3):322–39

Targeted remodeling of human beta-globin promoter chromatin structure produces increased expression and decreased silencing. Iler N, et al. **Blood Cells Mol Dis** 1999 Feb;25(1):47–60

DNA-protein interactions in the proximal zeta-globin promoter: identification of novel CCACCC- and CCAAT-binding proteins. Sabath DE, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):183–98

Unexpected pattern of beta-globin mutations in beta-thalassaemia patients from northern Portugal. Cabeda JM, et al. **Br J Haematol** 1999 Apr;105(1):68–74

A new sickle cell disease phenotype associating Hb S trait, severe pyruvate kinase deficiency (PK Conakry), and an alpha2 globin gene variant (Hb Conakry). Cohen-Solal M, et al. **Br J Haematol** 1998 Dec;103(4):950–6

A case of non-beta-globin gene linked beta thalassaemia in a Dutch family with two additional alpha-gene defects: the common -alpha3.7 deletion and the rare IVS1-116 (A-->G) acceptor splice site mutation. Giordano PC, et al. **Br J Haematol** 1998 Nov;103(2):370–6

Molecular, haematological and clinical studies of a silent beta-gene C-->G mutation at 6 bp 3' to the termination codon (+1480 C-->G) in twelve Greek families. Maragoudaki E, et al. **Br J Haematol** 1998 Oct;103(1):45–51

Activation of the human delta-globin gene promoter in primary adult erythroid cells. Tang DC, et al. **Br J Haematol** 1998 Dec;103(3):835–8

Do LCRs open chromatin domains? Higgs DR. **Cell** 1998 Oct 30;95(3):299–302 (18 ref.)

Role of chromatin structure and distal enhancers in tissue-specific transcriptional regulation in vitro. Bagga R, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:569–76 (48 ref.)

Gene therapy: repairing haemoglobin disorders with ribozymes. Weatherall DJ. **Curr Biol** 1998 Sep 24; 8(19):R696–8 (13 ref.)

Activation by locus control regions? Grosveld F. **Curr Opin Genet Dev** 1999 Apr;9(2):152–7 (45 ref.)

Physical mapping of ADCY2, FSHB and HBB to bovine chromosome 15 by FISH of bovine bacterial artificial chromosome clones. Amarante MR, et al. **Cytogenet Cell Genet** 1999;85(3–4):271–2

A new beta-globin gene from the zebrafish, betaE1, and its pattern of transcription during embryogenesis. Quinkertz A, et al. **Dev Genes Evol** 1999 Feb;209(2):126–31

The gamma-globin promoter has a major role in competitive inhibition of beta-globin gene expression in early erythroid development. Sargent TG, et al. **DNA Cell Biol** 1999 Apr; 18(4):293–303

Deletion of a region that is a candidate for the difference between the deletion forms of hereditary persistence of fetal hemoglobin and deltabeta-thalassemia affects beta- but not gamma-globin gene expression. Calzolari R, et al. **EMBO J** 1999 Feb 15;18(4):949–58

Inefficient processing impairs release of RNA from the site of transcription. Custódio N, et al. **EMBO J** 1999 May 17;18(10):2855–66

Regulation of embryonic/fetal globin genes by nuclear hormone receptors: a novel perspective on hemoglobin switching. Filipe A, et al. **EMBO J** 1999 Feb 1;18(3):687–97

Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing. Huang Y, et al. **EMBO J** 1999 Mar 15;18(6):1642–52

An insulator element and condensed chromatin region separate the chicken beta-globin locus from an independently regulated erythroid-specific folate receptor gene. Prioleau MN, et al. **EMBO J** 1999 Jul 15; 18(14):4035–48

A 3'-flanking NF-kappaB site mediates developmental silencing of the human zeta-globin gene. Wang Z, et al. **EMBO J** 1999 Apr 15;18(8):2218–28

Transcriptionally active and inactive mouse beta-globin gene loci are repaired at similar rates after ultraviolet irradiation. Chakalova L, et al. **Eur J Biochem** 1999 May;261(3):667–73

Haemoglobin F (HbF) levels in sickle-cell anaemia patients homozygous for the Bantu haplotype [letter] Mouélé R, et al. **Eur J Haematol** 1999 Aug;63(2):136–7

Nucleotide changes in the gamma-globin promoter and the (AT)xNy(AT)z polymorphic sequence of beta LCRHS-2 region associated with altered levels of HbF. Samakoglu S, et al. **Eur J Hum Genet** 1999 Apr;7(3):345–56

In the nucleus and cytoplasm of chicken erythroleukemic cells, prosomes containing the p23K subunit are found in centers of globin (pre-)mRNA processing and accumulation. De Conto F, et al. **Exp Cell Res** 1999 Aug 1;250(2):569–75

Maturation and developmental stage-related changes in fetal globin gene expression are reproduced in transiently transfected primary adult human erythroblasts. Ni H, et al. **Exp Hematol** 1999 Jan;27(1):46–53

Oxygen tension modulates beta-globin switching in embryoid bodies. Bichet S, et al. **FASEB J** 1999 Feb;13(2):285–95

DNA polymorphisms in the gamma-straight phibeta1-beta-globin gene region of the long-tailed macaque in comparison with those of the rhesus and the Japanese macaques. Shimizu K, et al. **Folia Primatol (Basel)** 1998;69(6):397–9

Molecular cloning and characterization of two sets of alpha-theta genes inthe rat alpha-like globin gene cluster. Satoh H, et al. **Gene** 1999 Apr 1;230(1):91–9

A sequence with homology to human HPFH-linked enhancer elements and to a family of G-protein linked membrane receptor genes is located downstream of the chicken beta-globin locus. Staines DM, et al. **Gene** 1999 Jul 8;234(2):345–52

Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system. Narayanan K, et al. **Gene Ther** 1999 Mar;6(3):442–7

Individual LCR hypersensitive sites cooperate to generate an open chromatin domain spanning the human beta-globin locus. Li G, et al. **Genes Cells** 1998 Jul;3(7):415–29

Mechanisms of developmental control of transcription in the murine alpha- and beta-globin loci. Trimborn T, et al. **Genes Dev** 1999 Jan 1;13(1):112–24

A long terminal repeat of the human endogenous retrovirus ERV-9 is located in the 5' boundary area of the human beta-globin locus control region. Long Q, et al. **Genomics** 1998 Dec 15;54(3):542–55

A database of experimental results on globin gene expression. Riemer C, et al. **Genomics** 1998 Nov 1;53(3):325–37

C-->T mutation at -158 G gamma HPFH associated with 4 bp deletion (-225–222) in the promoter region of the A gamma gene in homozygous beta 0 39 nonsense thalassemia [letter] Ataulfo Gonzalez F, et al. **Haematologica** 1999 Jan; 84(1):90–2

A novel polymorphism 3' to the beta-globin gene. Badens C, et al. **Hemoglobin** 1998 Jul;22(4):387–90

Characterization and locus assignment of two alpha-globin variants present in the Maltese population: Hb St. Luke's [alpha95(G2)Pro-->Arg] and Hb Setif [alpha94(G1)Asp-->Tyr]. Bezzina Wettinger S, et al. **Hemoglobin** 1999 May;23(2):145–57

Hb Siriraj: a G-->A substitution at codon 7 of the beta-globin chain creates an MboII cutting site. Chang JG, et al. **Hemoglobin** 1999 May;23(2):197–9

Hb Schlierbach or beta108(G10)Asn-->Ile: a new variant with low oxygen affinity detected in a Swiss family. Frischknecht H, et al. **Hemoglobin** 1999 Feb;23(1):83–7

Two new beta-thalassemia mutations: codon 88 (CTG-->C--) and codons 83–86 (GGC/ACC/TTT/GCC-->GGCC). Hattori Y, et al. **Hemoglobin** 1999 May;23(2):187–92

Detection of alpha2- and alpha1-globin gene variants by a modified cycle sequencing method. Hitchen J, et al. **Hemoglobin** 1998 Jul;22(4):373–6

A new beta chain variant, Hb Vienna or beta77(EF1)His-->Gln. Hopmeier P, et al. **Hemoglobin** 1998 Jul;22(4):391–5

The beta+-thalassemia mutation [IVS-II-5 (G-->C]

creates an alternative splicing site in the second intervening sequence. Jiang NH, et al. **Hemoglobin** 1999 May; 23(2):171–6

Molecular characterization of beta-thalassemia in Pakistan. Khan SN, et al. **Hemoglobin** 1998 Jul;22(4):333–45

Another example of the beta-thalassemia mutation, IVS-I (-2) or codon 30 (A-->G), found in a Chinese family. Li W, et al. **Hemoglobin** 1998 Jul;22(4):377–81

Hb Nijkerk: a new mutation at codons 138/139 of the beta-globin gene inducing severe hemolytic anemia in a Dutch girl. van den Berg HM, et al. **Hemoglobin** 1999 May; 23(2):135–44

A novel C-->A transversion within the distal CCAAT motif of the Ggamma-globin gene in the Algerian Ggammabeta+-hereditary persistence of fetal hemoglobin. Zertal-Zidani S, et al. **Hemoglobin** 1999 May;23(2):159–69

Analysis of gamma-globin expression cassettes in retrovirus vectors. Emery DW, et al. **Hum Gene Ther** 1999 Apr 10; 10(6):877–88

Long-term genetic modification of rhesus monkey hematopoietic cells following transplantation of adenoassociated virus vector-transduced CD34+ cells. Schimmenti S, et al. **Hum Gene Ther** 1998 Dec 10; 9(18):2727–34

A system for shuttling 200-kb BAC/PAC clones into human cells: stable extrachromosomal persistence and long-term ectopic gene activation. Westphal EM, et al. **Hum Gene Ther** 1998 Sep 1;9(13):1863–73

Genetic variations in human fetal globin gene microsatellites and their functional relevance. Lapoumeroulie C, et al. **Hum Genet** 1999 Apr;104(4):307–14

Contribution of gene conversion in the evolution of the human beta-like globin gene family. Papadakis MN, et al. **Hum Genet** 1999 Feb;104(2):117–25 (89 ref.)

Major beta-globin gene mutations in eastern India and their associated haplotypes. Bandyopadhyay A, et al. **Hum Hered** 1999 Jul;49(4):232–5

LCR-dependent gene expression in beta-globin YAC transgenics: detailed structural studies validate functional analysis even in the presence of fragmented YACs. Peterson KR, et al. **Hum Mol Genet** 1998 Dec; 7(13):2079–88

alpha-Thalassaemia due to a single codon deletion in the alpha1-globin gene. Computational structural analysis of the new alpha-chain variant. Mutations in brief no. 132. Online. Ayala S, et al. **Hum Mutat** 1998;11(5):412

A single, large deletion accounts for all the beta-globin gene mutations in twenty families from Sabah (North Borneo), Malaysia. Mutation in brief no. 240. Online. Thong MK, et al. **Hum Mutat** 1999;13(5):413

Identification of the new polymorphism IVS1-91 C-->T in the beta globin gene. Primignani P, et al. **Hum Mutat (Online)** 1999 Sep 19;14(3):272

Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. Guasch A, et al. **J Am Soc Nephrol** 1999 May; 10(5):1014–9

Repairing the sickle cell mutation. I. Specific covalent binding of a photoreactive third strand to the mutated base pair. Broitman S, et al. **J Biol Chem** 1999 Jul 30; 274(31):21763–8

Requirement of an E1A-sensitive coactivator for long-range transactivation by the beta-globin locus control region. Forsberg EC, et al. **J Biol Chem** 1999 Sep 17; 274(38):26850–9

The roles of 5'-HS2, 5'-HS3, and the gamma-globin TATA, CACCC, and stage selector elements in suppression of beta-globin expression in early development. Sargent TG, et al. **J Biol Chem** 1999 Apr 16;274(16):11229–36

Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. Schmajuk G, et al. **J Biol Chem** 1999 Jul 30;274(31):21783–9

Functional analysis of DNA sequences located within a cluster of DNase I hypersensitive sites colocalizing with a MAR element at the upstream border of the chicken alpha-globin gene domain. Razin SV, et al. **J Cell Biochem** 1999 Jul 1;74(1):38–49

The identification of ferritin in the nucleus of K562 cells, and investigation of a possible role in the transcriptional regulation of adult beta-globin gene expression. Pountney D, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):825–31

Detection of neutral and charged mutations in alpha- and beta-human globin chains by capillary zone electrophoresis in isoelectric, acidic buffers. Saccomani A, et al. **J Chromatogr A** 1999 Feb 5;832(1-2):225–38

Model for the fetal recruitment of simian gamma-globin genes based on findings from two New World monkeys Cebus apella and Callithrix jacchus (Platyrrhini, Primates). Chiu CH, et al. **J Exp Zool** 1999 Apr 15;285(1):27–40

Feline adult beta-globin polymorphism reflected in restriction fragment length patterns. Kohn B, et al. **J Hered** 1999 Jan-Feb;90(1):177–81

Position-independent human beta-globin gene expression mediated by a recombinant adeno-associated virus vector carrying the chicken beta-globin insulator [published erratum appears in J Hum Genet 1999;44(4):273] Inoue T, et al. **J Hum Genet** 1999;44(3):152–62

Expression-dependent perturbation of nucleosomal phases at HS2 of the human beta-LCR: possible correlation with periodic bent DNA. Onishi Y, et al. **J Mol Biol** 1998 Dec 11;284(4):989–1004

Phylogenetic relationships within the genus Equus and the evolution of alpha and theta globin genes. Oakenfull EA, et al. **J Mol Evol** 1998 Dec;47(6):772–83

Organization, structure, and evolution of the nonadult rat beta-globin gene cluster. Satoh H, et al. **J Mol Evol** 1999 Jul;49(1):122–9

The effect of bu shen sheng xue fang on beta-thalassemia at gene level. Wu Z, et al. **J Tradit Chin Med** 1998 Dec; 18(4):300–3

Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. Osborne CS, et al. **J Virol** 1999 Jul; 73(7):5490–6

Nucleotide sequences of the mouse globin beta gene cDNAs in a wild derived new haplotype Hbb(w1). Ueda Y, et al. **Mamm Genome** 1999 Sep;10(9):879–82

Purification and RNA binding properties of the polycytidylate-binding proteins alphaCP1 and alphaCP2. Kiledjian M, et al. **Methods** 1999 Jan;17(1):84–91

DNA bend sites in the human beta-globin locus: evidence for a basic and universal structural component of genomic DNA. Wada-Kiyama Y, et al. **Mol Biol Evol** 1999 Jul; 16(7):922–30

The beta-globin LCR is not necessary for an open chromatin structure or developmentally regulated transcription of the native mouse beta-globin locus. Epner E, et al. **Mol Cell** 1998 Oct;2(4):447–55

FKLF, a novel Krüppel-like factor that activates human embryonic and fetal beta-like globin genes. Asano H, et al. **Mol Cell Biol** 1999 May;19(5):3571–9

Hypersensitive site 2 specifies a unique function within the human beta-globin locus control region to stimulate globin gene transcription. Bungert J, et al. **Mol Cell Biol** 1999 Apr;19(4):3062–72

Assembly of the alpha-globin mRNA stability complex reflects binary interaction between the pyrimidine-rich 3' untranslated region determinant and poly(C) binding protein alphaCP. Chkheidze AN, et al. **Mol Cell Biol** 1999 Jul;19(7):4572–81

Enhancer-dependent transcriptional oscillations in mouse erythroleukemia cells. Feng YQ, et al. **Mol Cell Biol** 1999 Jul;19(7):4907–17

Enhancement of beta-globin locus control region-mediated transactivation by mitogen-activated protein kinases through stochastic and graded mechanisms. Forsberg EC, et al. **Mol Cell Biol** 1999 Aug;19(8):5565–75

Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements. Mayeda A, et al. **Mol Cell Biol** 1999 Mar;19(3):1853–63

The locus control region is necessary for gene expression in the human beta-globin locus but not the maintenance of an open chromatin structure in erythroid cells. Reik A, et al. **Mol Cell Biol** 1998 Oct;18(10):5992–6000

Substitution of the human beta-spectrin promoter for the human agamma-globin promoter prevents silencing of a linked human beta-globin gene in transgenic mice. Sabatino DE, et al. **Mol Cell Biol** 1998 Nov;18(11):6634–40

Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Schaal TD, et al. **Mol Cell Biol** 1999 Jan;19(1):261–73

The chicken beta-globin 5'HS4 boundary element blocks enhancer-mediated suppression of silencing. Walters MC, et al. **Mol Cell Biol** 1999 May;19(5):3714–26

An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro. Wang Z, et al. **Mol Cell Biol** 1999 Jul;19(7):4552–60

Topoisomerase II-mediated DNA cleavage on the cruciform structure formed within the 5'upstream region of the human beta-globin gene. Lee GE, et al. **Mol Cells** 1998 Aug 31; 8(4):424–30

Evolution and molecular characterization of a beta-globin gene from the Australian Echidna Tachyglossus aculeatus (Monotremata). Lee MH, et al. **Mol Phylogenet Evol** 1999 Jul;12(2):205–14

Molecular phylogeny of ateline new world monkeys (Platyrrhini, atelinae) based on gamma-globin gene sequences: evidence that brachyteles is the sister group of lagothrix. Meireles CM, et al. **Mol Phylogenet Evol** 1999 Jun;12(1):10–30

DNA methylation represses transcription in vivo. Siegfried Z, et al. **Nat Genet** 1999 Jun;22(2):203–6

Isochores result from mutation not selection [letter] Francino MP, et al. **Nature** 1999 Jul 1;400(6739):30–1

Effects of altered gene order or orientation of the locus control region on human beta-globin gene expression in mice. Tanimoto K, et al. **Nature** 1999 Mar 25; 398(6725):344–8

Conserved elements containing NF-E2 and tandem GATA binding sites are required for erythroid-specific chromatin structure reorganization within the human beta-globin locus control region. Pomerantz O, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5684–91

The polyoma virus enhancer cannot substitute for DNase I core hypersensitive sites 2-4 in the human beta-globin LCR. Tanimoto K, et al. **Nucleic Acids Res** 1999 Aug 1; 27(15):3130–7

Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Wang G, et al. **Nucleic Acids Res** 1999 Jul 1;27(13):2806–13

HbF synthesis during stress erythropoiesis as determined by gamma-mRNA/non-alpha-mRNA quantification. Bard H, et al. **Pediatr Res** 1999 May;45(5 Pt 1):684–6

Thalassemia and malaria: new insights into an old problem. Clegg JB, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug; 111(4):278–82 (35 ref.)

Conservation of sequence and structure flanking the mouse and human beta-globin loci: the beta-globin genes are embedded within an array of odorant receptor genes [published erratum appears in Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8307] Bulger M, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5129–34

Derepression of human embryonic zeta-globin promoter by a locus-control region sequence. Huang BL, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14669–74

A normal beta-globin allele as a modifier gene ameliorating the severity of alpha-thalassemia in mice. Leder A, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6291–5

The beta-globin promoter is important for recruitment of erythroid Krüppel-like factor to the locus control region in erythroid cells. Lee JS, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10051–5

Tissue-specific and developmental stage-specific DNA binding by a mammalian SWI/SNF complex associated with human fetal-to-adult globin gene switching. O'Neill D, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):349–54

Studies on fetal hemoglobin and gamma globin gene triplication in newborns in Jordan. Sadiq MF. **Proc Natl Sci Counc Repub China B** 1998 Jul;22(3):108–13

Association of the 5'HS4 sequence of the chicken beta-globin locus control region with human EF1 alpha gene promoter induces ubiquitous and high expression of human CD55 and CD59 cDNAs in transgenic rabbits. Taboit-Dameron F, et al. **Transgenic Res** 1999 Jun;8(3):223–35

Microchimerism analysis using polymerase chain reaction assays that selectively amplify donor DNA. Sahota A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):800–1

[Molecular diagnosis of beta-thalassemia intermedia] Chen J, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):575–8 (Eng. Abstr.) **(Chi)**

[Interaction of cis-regulatory element in the 5' flanking sequence of human beta-globin gene with trans-acting factors at different developmental stages] Chen SY, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Dec;29(4):379–84 (Eng. Abstr.) **(Chi)**

[Haplotypes of the beta-globulin locus in Czechs and Slovaks with beta-thalassemia and structurally variant hemoglobins (published erratum appears in Vnitr Lek 1999 Jan;45(1):45)] Kynčlová E, et al. **Vnitr Lek** 1998 Sep;44(9):518–23 (Eng. Abstr.) **(Cze)**

[Globin gene mutation is a model of genetic abnormalities] Hattori Y. **Rinsho Byori** 1999 Mar;47(3):244–51 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular genetics of the thalassemias in Argentina] Varela V, et al. **Sangre (Barc)** 1999 Jun;44(3):210–5 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunization with a synthetic peptide conjugate derived from the N-terminal sequence of either the beta-chain of haemoglobin or the immunosuppressive protein (reOLT 4) reduces the litter size of pregnant rats. Lord R, et al. **Scand J Immunol** 1999 Feb;49(2):162–8

ISOLATION & PURIFICATION

Separation of human globin chains by micellar electrokinetic capillary chromatography. Lin C, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20; 719(1-2):47–54

METABOLISM

Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene. Chase MB, et al. **Am J Hematol** 1999 Jan;60(1):27–35

Evidence for continuous basel generation of GC-MAF: absence in infantile osteopetrosis and restoration after bone marrow transplant [letter; comment] Datta HK, et al. **Blood** 1999 Jun 1;93(11):4026–7. Comment on: Blood 1996 Aug 15;88(4):1473–8. Comment on: Blood 1996 Oct 15;88(8):2898–905.

The 5'-flanking cis-acting elements of the human epsilon-globin gene associates with the nuclear matrix and binds to the nuclear matrix proteins. Yan ZJ, et al. **Cell Res** 1998 Sep;8(3):209–18

Characterization of a valine-lysine thiourea cross-link on rat globin produced by carbon disulfide or N,N-diethyldithiocarbamate in vivo. Erve JCL, et al. **Chem Res Toxicol** 1998 Oct;11(10):1128–36

THERAPEUTIC USE

Reversal of lethal alpha- and beta-thalassemias in mice by expression of human embryonic globins. Russell JE, et al. **Blood** 1998 Nov 1;92(9):3057–63

GLOBOSIDES

ANALYSIS

Globoside expression within the human placenta. Jordan JA, et al. **Placenta** 1999 Jan;20(1):103–8

CHEMISTRY

Isolation and characterization of a novel Forssman active

acidic glycosphingolipid with branched isoglobo-, ganglio-, and neolacto-series hybrid sugar chains. Yamamoto H, et al. **J Biochem (Tokyo)** 1999 May; 125(5):923-30

IMMUNOLOGY

Cytomegalovirus is not associated with IgM anti-myelin-associated glycoprotein/sulphate-3-glucuronyl paragloboside antibody-associated neuropathy. Lunn MP, et al. **Ann Neurol** 1999 Aug;46(2):267-70

Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. Weiss MD, et al. **J Neuroimmunol** 1999 Mar 1;95(1-2):174-84

[A case of mononeuropathy multiplex associated with anti-GM1 and -SGLPG antibodies in a patient with ongoing Hashimoto disease] Nishihara T, et al. **Rinsho Shinkeigaku** 1998 Oct-Nov;38(10-11):926-30 (Eng. Abstr.) **(Jpn)**

GLOBULINS

ANALYSIS

[Serum globulin levels and activities of daily living in centenarians] Nozaki H, et al. **Nippon Ronen Igakkai Zasshi** 1998 Sep;35(9):680-5 (Eng. Abstr.) **(Jpn)**

BLOOD see SERUM GLOBULINS

CHEMISTRY

Models for the multisubunit conformation of oil-seed globulins. Carrasco B, et al. **Biochem Soc Trans** 1998 Nov; 26(4):721-5

Analysis of thermal stability of soya globulins using monoclonal antibodies. Huang L, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):215-26

The roles of the N-linked glycans and extension regions of soybean beta-conglycinin in folding, assembly and structural features. Maruyama N, et al. **Eur J Biochem** 1998 Dec 1;258(2):854-62

Molecular basis of film formation from a soybean protein: comparison between the conformation of glycinin in aqueous solution and in films. Subirade M, et al. **Int J Biol Macromol** 1998 Nov;23(4):241-9

[The application of the endotoxin test for globulin and other blood products] Fujiwara H, et al. **Yakugaku Zasshi** 1999 Jun;119(6):451-5 (Eng. Abstr.) **(Jpn)**

GENETICS

Quality and safety evaluation of genetically engineered rice with soybean glycinin: analyses of the grain composition and digestibility of glycinin in transgenic rice. Momma K, et al. **Biosci Biotechnol Biochem** 1999 Feb;63(2):314-8

Speciation and domestication in maize and its wild relatives: evidence from the globulin-1 gene. Hilton H, et al. **Genetics** 1998 Oct;150(2):863-72

IMMUNOLOGY

Comparison of ELISA QuikScreen and PRA-STAT with CDC-AHG for PRA determination. Bishara A, et al. **Transplant Proc** 1999 Jun;31(4):1878

METABOLISM

Evidence for continuous basel generation of GC-MAF: absence in infantile osteopetrosis and restoration after bone marrow transplant [letter; comment] Datta HK, et al. **Blood** 1999 Jun 1;93(11):4026-7. Comment on: Blood 1996 Aug 15;88(4):1473-8. Comment on: Blood 1996 Oct 15;88(8):2898-905.

Neurological manifestations of malignant and non-malignant dysglobulinaemias. Steck AJ. **J Neurol** 1998 Oct; 245(10):634-9 (26 ref.)

Soybean beta-conglycinin alpha subunit is phosphorylated on two distinct serines by protein kinase CK2 in vitro. Ralet MC, et al. **J Protein Chem** 1999 Apr;18(3):315-23

GLOBULINS, IMMUNE see IMMUNOGLOBULINS

GLOBUS HYSTERICUS see CONVERSION DISORDER

GLOBUS PALLIDUS

Changes in quality of life following unilateral pallidal stimulation in Parkinson's disease. Vingerhoets G, et al. **J Psychosom Res** 1999 Mar;46(3):247-55

[Treatment of early-onset generalized dystonia by chronic bilateral stimulation of the internal globus pallidus. Apropos of a case] Coubes P, et al. **Neurochirurgie** 1999 May; 45(2):139-44 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Pallidal and cerebellar inputs to thalamocortical neurons projecting to the supplementary motor area in Macaca fuscata: a triple-labeling light microscopic study. Sakai ST, et al. **Anat Embryol (Berl)** 1999 Jan;199(1):9-19

The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al. **J Chem Neuroanat** 1999 May;16(3):153-65 (36 ref.)

Morphological organization of the globus pallidus-subthalamic nucleus system studied in organotypic cultures. Plenz D, et al. **J Comp Neurol** 1998 Aug 10; 397(4):437-57

CHEMISTRY

Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone. Grimm JW, et al. **Brain Res** 1998 Aug 10;801(1-2):182-9

Dopaminergic modulation of pallidal preproenkephalin mRNA. Schuller JJ, et al. **Brain Res Mol Brain Res** 1999 May 21;69(1):149-53

Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Bernard V, et al. **Eur J Neurosci** 1998 Dec;10(12):3721-36

Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Goodchild RE, et al. **Eur J Neurosci** 1999 Feb;11(2):449-56

CYTOLOGY

GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Vitek JL, et al. **Adv Neurol** 1998;78:211-9 (32 ref.)

Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. Hedreen JC. **J Comp Neurol** 1999 Jul 5;409(3):400-10

Selective innervation of neostriatal interneurons by a subclass of neuron in the globus pallidus of the rat. Bevan MD, et al. **J Neurosci** 1998 Nov 15;18(22):9438-52

Population characteristics of preproenkephalin mRNA-containing neurons in the globus pallidus of the rat. Hoover BR, et al. **Neurosci Lett** 1999 Apr 23; 265(3):199-202

Extrastriatal dopaminergic innervation of human basal ganglia. Cossette M, et al. **Neurosci Res** 1999 May; 34(1):51-4

DRUG EFFECTS

Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone. Grimm JW, et al. **Brain Res** 1998 Aug 10;801(1-2):182-9

Kir6.2 oligoantisense administered into the globus pallidus reduces apomorphine-induced turning in 6-OHDA hemiparkinsonian rats. Lamensdorf I, et al. **Brain Res** 1999 Feb 13;818(2):275-84

Haloperidol induces Fos expression in the globus pallidus and substantia nigra of cynomolgus monkeys. Wirtshafter D, et al. **Brain Res** 1999 Jul 24;835(2):154-61

Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. Miller AS, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):199-205

Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. Lieberman DM, et al. **J Neurosurg** 1999 May;90(5):928-34

Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. Lonser RR, et al. **J Neurosurg** 1999 Aug;91(2):294-302

Inhibition of levodopa effects by internal pallidal stimulation [see comments] Krack P, et al. **Mov Disord** 1998 Jul; 13(4):648-52. Comment in: Mov Disord 1999 May;14(3):536-40.

GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine. Merello M, et al. **Mov Disord** 1999 May; 14(3):481-3

Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Merello M, et al. **Mov Disord** 1999 Jan;14(1):45-9

Dizocilpine maleate, MK-801, but not 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline, NBQX, prevents transneuronal degeneration of nigral neurons after neurotoxic striatal-pallidal lesion. DeGiorgio LA, et al. **Neuroscience** 1999 Apr;90(1):79-85

Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons. Svenningsson P, et al. **Neuroscience** 1999 Mar;89(3):827-37

Manganese neurotoxicity: a review of clinical features, imaging and pathology. Pal PK, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):227-38 (139 ref.)

Repeated heroin administration increases extracellular opioid peptide-like immunoreactivity in the globus pallidus/ventral pallidum of freely moving rats. Olive MF, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):251-4

[Disturbances of the rat motor activity during multiple microinjections of picrotoxin into the globus pallidus and caudal neostriatum] Iakimovskii AF. **Biull Eksp Biol Med** 1998 Oct;126(10):381-3 **(Rus)**

[Simultaneous transplantation of fetal mesencephalic cells to the striatum and globus pallidus of rats with lesions induced by 6-hydroxydopamine] Alvarez-Fonseca P, et al. **Rev Neurol** 1998 Apr;26(152):537-40 (Eng. Abstr.) **(Spa)**

INJURIES

Globus pallidus lesions inhibit the induction of c-Fos by haloperidol in the basal ganglia output nuclei in rats. Miwa H, et al. **Neurosci Lett** 1998 Jun 26;250(1):29-32

METABOLISM

Expression of enkephalin in pallido-striatal neurons. Voorn P, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:671-5

Role of NMDA glutamate receptors in regulating D2 dopamine-dependent Fos induction in the rat striatopallidal pathway. Pollack AE, et al. **Brain Res** 1999 Feb 13; 818(2):543-7

Comparison of the rat dorsal and ventral striatopallidal system. A study using the GABA(A)-receptor alpha1-subunit and parvalbumin immunolabeling. Riedel A, et al. **Exp Brain Res** 1998 Jul;121(2):215-21

Group I metabotropic glutamate receptors at GABAergic synapses in monkeys. Hanson JE, et al. **J Neurosci** 1999 Aug 1;19(15):6488-96

Presynaptic mu and delta opioid receptor modulation of GABAA IPSCs in the rat globus pallidus in vitro. Stanford IM, et al. **J Neurosci** 1999 Jun 15;19(12):4796-803

High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. Burrows KB, et al. **Neuroscience** 1999 Mar;90(3):833-50

Manganese neurotoxicity: a mechanistic hypothesis. Verity MA. **Neurotoxicology** 1999 Apr-Jun;20(2-3):489-97 (41 ref.)

PATHOLOGY

Direct stereotactic MRI location in the globus pallidus for chronic stimulation in Parkinson's disease. Lemaire JJ, et al. **Acta Neurochir (Wien)** 1999;141(7):759-65; discussion 766

Hereditary dentatorubral-pallidoluysian atrophy: detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain. Hayashi Y, et al. **Acta Neuropathol (Berl)** 1998 Dec;96(6):547-52

Dentatorubropallidoluysian atrophy: clinicopathological study of dementia and involvement of the nucleus basalis of Meynert in seven autopsy cases. Tsuchiya K, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):502-8

Abnormal dentatorubral-pallidoluysian atrophy (DRPLA) protein complex is pathologically ubiquitinated in DRPLA brains. Yazawa I, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):133-8

Different complex formations of dentatorubral-pallidoluysian atrophy (DRPLA) protein in human and rat neurons. Yazawa I, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):209-13

Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. O'Kusky JR, et al. **Brain Res** 1999 Feb 13;818(2):468-79

The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease. Hardman CD, et al. **Exp Neurol** 1999 Jul;158(1):135-42

MPTP-Induced pallidal lesions in rhesus monkeys. Zhang Z, et al. **Exp Neurol** 1999 Jan;155(1):140-9

Single sperm analysis of the CAG repeats in the gene for dentatorubral-pallidoluysian atrophy (DRPLA): the instability of the CAG repeats in the DRPLA gene is prominent among the CAG repeat diseases. Takiyama Y, et al. **Hum Mol Genet** 1999 Mar;8(3):453-7

Molecular base of "de novo" DRPLA [editorial; comment] Abe K. **Intern Med** 1999 Mar;38(3):223 (7 ref.). Comment on: Intern Med 1999 Mar;38(3):287-9.

Genetic analysis of a dentatorubral-pallidoluysian atrophy family: relevance to apparent sporadic cases [see comments] Hattori M, et al. **Intern Med** 1999 Mar;38(3):287-9. Comment in: Intern Med 1999 Mar;38(3):223.

Methylmalonic acidaemia with bilateral globus pallidus involvement: a neuropathological study. Larnaout A, et al. **J Inherit Metab Dis** 1998 Aug;21(6):639-44

Dystonia after striatopallidal and thalamic stroke: clinicoradiological correlations and pathophysiological mechanisms. Krystkowiak P, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):703-8

Slowly progressive L-DOPA nonresponsive pure akinesia due to nigropallidal degeneration: a clinicopathological case study. Katayama S, et al. **J Neurol Sci** 1998 Dec 11; 161(2):169-72

Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. Yoshii F, et al. **J Neurol Sci** 1998 Sep 18;160(1):87-91

Intranuclear neuronal inclusions in DRPLA [letter; comment] Becher MW, et al. **Mov Disord** 1998 Sep; 13(5):852-3. Comment on: Mov Disord 1997 Jul;12(4):519-30.

Severe akinetic syndrome resulting from a bilateral basal ganglia lesion following bone marrow transplantation. Pirker W, et al. **Mov Disord** 1999 May;14(3):525-8

New MRI findings in Creutzfeldt-Jakob disease: high signal in the globus pallidus on T1-weighted images. de Priester JA, et al. **Neuroradiology** 1999 Apr;41(4):265-8

Transient globus pallidus T1 shortening associated with polycythaemia and dystonia. Gruber Gikovate C, et al. **Neuroradiology** 1999 Apr;41(4):288-91

High-intensity basal ganglia lesions on T1-weighted images in two toddlers with elevated blood manganese with portosystemic shunts. Ihara K, et al. **Neuroradiology** 1999 Mar;41(3):195-8

Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. Kataoka K, et al. **Neurosci Lett** 1999 May 14;266(3):220-2

Stereotactic targeting of the globus pallidus internus in Parkinson's disease: imaging versus electrophysiological mapping. Guridi J, et al. **Neurosurgery** 1999 Aug; 45(2):278-87; discussion 287-9

Magnetic resonance imaging-based stereotactic localization of the globus pallidus and subthalamic nucleus. Starr PA, et al. **Neurosurgery** 1999 Feb;44(2):303-13; discussion 313-4

Reversibility of hyperintense globus pallidus on T 1-weighted MRI follow- ing surgery for a portosystemic shunt in an 8-year-old girl. Ikeda S, et al. **Pediatr Radiol** 1999 Jun;29(6):449-50

Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Clark LN, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):13103-7

An MRI study of the basal ganglia in autism. Sears LL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 May; 23(4):613-24

Sequential postoperative appearance of radiofrequency pallidotomy lesions on MRI. Lim JY, et al. **Stereotact Funct Neurosurg** 1997;69(1-4 Pt 2):46-53

Comparison of actual pallidotomy lesion location with expected stereotactic location. Tsao K, et al. **Stereotact Funct Neurosurg** 1998;71(1):1-19

[High signal intensity of globus pallidus on T1-weighted MRI in liver cirrhosis patients: clinical and pathological study] Ihara H. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Aug; 58(9):479-88 (Eng. Abstr.) **(Jpn)**

[Genetic analysis including predictive DNA testing in a Japanese family with dentatorubral-pallidoluysian atrophy] Nishio H, et al. **No To Hattatsu** 1998 Nov;30(6):512-6 (Eng. Abstr.) **(Jpn)**

[A case of juvenile type dentatorubral-pallidoluysian atrophy (DRPLA) with psychomotor retardation since infancy] Wada Y, et al. **No To Hattatsu** 1998 Nov;30(6):543-8 (Eng. Abstr.) **(Jpn)**

[A case of late adult-onset dentatorubral-pallidoluysian atrophy (DRPLA) successfully treated with V-P shunt operation] Fujita N, et al. **Rinsho Shinkeigaku** 1998 Jun; 38(6):516-9 (Eng. Abstr.) **(Jpn)**

[Disappearance of globus pallidus hyperintensity in a patient with portal-systemic encephalopathy after occlusion of the shunt vessel] Taguchi Y, et al. **Rinsho Shinkeigaku** 1999 May;39(5):565-9 (Eng. Abstr.) **(Jpn)**

[Pallido-nigro-luysial atrophy] Hasegawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):78-81 (6 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: differential diagnosis of progressive myoclonus epilepsy] Naito H. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):163-5 (13 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: differential diagnosis of chorea)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):101-3 (10 ref.) **(Jpn)**

[Dentatorubral-pallidoluysian atrophy (DRPLA: Naito-Oyanagi disease)] Tsuji S. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):275-9 (17 ref.) **(Jpn)**

PHYSIOLOGY

GABA-mediated inhibition of raphe pallidus neurons regulates sympathetic outflow to brown adipose tissue. Morrison SF, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R290-7

Electrophysiological properties of anatomically identified ventral pallidal neurons in rat brain slices. Bengtson CP, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:691-4

The concepts of the ventral striatopallidal system and extended amygdala. de Olmos JS, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:1-32 (100 ref.)

Involvement of the ventral pallidum in working memory tasks with or without a delay. Floresco SB, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:711-6

Involvement of the pallidal-thalamocortical circuit in adaptive behavior. Kalivas PW, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:64-70 (23 ref.)

Opioid modulation of ventral pallidal inputs. Napier TC, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:176-201 (89 ref.)

Effects of electrolytic lesions of the lateral pallidum on motor coordination, spatial learning, and regional brain variations of cytochrome oxidase activity in rats. Jeljeli M, et al. **Behav Brain Res** 1999 Jul;102(1-2):61-71

Response properties of neurons in the caudate-putamen and globus pallidus to noxious and non-noxious thermal stimulation in anesthetized rats. Chudler EH. **Brain Res** 1998 Nov 23;812(1-2):283-8

Injections of D-amphetamine into the ventral pallidum increase locomotor activity and responding for conditioned reward: a comparison with injections into the nucleus accumbens. Fletcher PJ, et al. **Brain Res** 1998 Sep 14; 805(1-2):29-40

Effects of bilateral electrical stimulation of the ventral pallidum on acoustic startle. Li L, et al. **Brain Res** 1999 Jul 31;836(1-2):164-72

Globus pallidus lesions depress the excitatory responses to apomorphine but not amphetamine in the subthalamic nucleus of the behaving rat with a 6-OHDA nigra lesion. Olds ME, et al. **Brain Res** 1998 Nov 23;812(1-2):50-64

Blockade of GABAA receptors in the medial ventral pallidum elicits feeding in satiated rats. Stratford TR, et al. **Brain Res** 1999 Apr 17;825(1-2):199-203

Dopaminergic modulation of pallidal preproenkephalin mRNA. Schuller JJ, et al. **Brain Res Mol Brain Res** 1999 May 21;69(1):149-53

Microstimulation of movements from cerebellar-receiving, but not pallidal-receiving areas of the macaque thalamus under ketamine anaesthesia. Miall RC, et al. **Exp Brain Res** 1998 Dec;123(4):387-96

Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Wichmann T, et al. **Exp Brain Res** 1999 Apr;125(4):397-409

The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. Parent M, et al. **J Chem Neuroanat** 1999 May;16(3):153-65 (36 ref.)

Morphological organization of the globus pallidus-subthalamic nucleus system studied in organotypic cultures. Plenz D, et al. **J Comp Neurol** 1998 Aug 10; 397(4):437-57

Delayed rectifier currents in rat globus pallidus neurons are attributable to Kv2.1 and Kv3.1/3.2 K(+) channels. Baranauskas G, et al. **J Neurosci** 1999 Aug 1; 19(15):6394-404

In vivo extracellular electrophysiology of pallidal neurons in dystonic and nondystonic hamsters. Gernert M, et al. **J Neurosci Res** 1999 Sep 15;57(6):894-905

Multisecond oscillations in firing rate in the globus pallidus: synergistic modulation by D1 and D2 dopamine receptors. Ruskin DN, et al. **J Pharmacol Exp Ther** 1999 Sep; 290(3):1493-501

Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia [letter] Krauss JK, et al. **Lancet** 1999 Sep 4;354(9181):837-8

Decrease in akinesia seems to result from chronic electrical stimulation in the external (GPe) rather than internal (Gpi) pallidum [letter; comment] Hariz MI. **Mov Disord** 1999 May;14(3):536-40. Comment on: Mov Disord 1998 Jul;13(4):648-52.

A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus [see comments] Plenz D, et al. **Nature** 1999 Aug 12;400(6745):677-82. Comment in: Nature 1999 Aug 12;400(6745):621-2.

Monkey globus pallidus external segment neurons projecting to the neostriatum. Kita H, et al. **Neuroreport** 1999 May 14;10(7):1467-72

The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. Nikolaus S, et al. **Neuroreport** 1999 Aug 2; 10(11):2293-6

Features of the spike activity of globus pallidus neurons and pallido-thalamic functional interactions during targeted verbally cued movements in humans. Raeva SN. **Neurosci Behav Physiol** 1998 Sep-Oct;28(5):493-9

GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata. Celada P, et al. **Neuroscience** 1999 Mar; 89(3):813-25

Synergistic influences of the striatum and the globus pallidus on postural and locomotor control. Hebb MO, et al. **Neuroscience** 1999 May;90(2):413-21

Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Lindskog M, et al. **Neuroscience** 1999;88(4):1005-8

Dopamine-opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression. Mavridis M, et al. **Neuroscience** 1999; 92(3):945-66

Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Nakao N, et al. **Neuroscience** 1999 Jan;88(2):469-77

Striatal, pallidal, and pars reticulata evoked inhibition of nigrostriatal dopaminergic neurons is mediated by GABA(A) receptors in vivo. Paladini CA, et al. **Neuroscience** 1999 Mar;89(3):799-812

Characterization of cardiorespiratory responses to electrical stimulation of the globus pallidus in cat. Angyán L, et al. **Physiol Behav** 1999 Mar;66(1):53-8

Involvement of the ventral tegmental area opiate receptors in self-stimulation elicited from the ventral pallidum. Panagis G, et al. **Psychopharmacology (Berl)** 1998 Oct; 139(3):222-9

Is the medial globus pallidus a site for stimulation or lesioning in the treatment of Parkinson's disease? Tronnier VM, et al. **Stereotact Funct Neurosurg** 1997;69(1-4 Pt 2):62-8

Group I mGluRs modulate calcium currents in rat GP: functional implications. Stefani A, et al. **Synapse** 1998 Dec; 30(4):424-32

PHYSIOPATHOLOGY

Image-guided electrophysiologically controlled posteroventral pallidotomy for the treatment of Parkinson's disease: a 28-case analysis. Hirai T, et al. **Adv Neurol** 1999; 80:585-91

Long-term electrostimulation of the ventroposterolateral pallidum in the treatment of Parkinson's disease. Siegfried J, et al. **Adv Neurol** 1999;80:623-6

D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Joyce JN, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:595-613 (61 ref.)

The role of the striatopallidal and extended amygdala systems in drug addiction. Koob GF. **Ann N Y Acad Sci** 1999 Jun 29;877:445-60 (85 ref.)

Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ardouin C, et al. **Ann Neurol** 1999 Aug;46(2):217-23

Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Volkmann J, et al. **Ann Neurol** 1998 Dec;44(6):953-61

Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. Gálvez-Jiménez N, et al. **Can J Neurol Sci** 1998 Nov;25(4):300-5

Clinical neurophysiologic findings in patients with rapidly progressive familial parkinsonism and dementia with pallido-ponto-nigral degeneration. Wszolek ZK, et al. **Electroencephalogr Clin Neurophysiol** 1998 Sep; 107(3):213-22

Basal ganglia and gait control: apomorphine administration and internal pallidum stimulation in Parkinson's disease. Grasso R, et al. **Exp Brain Res** 1999 May;126(2):139-48

Cognitive outcome after unilateral pallidal stimulation in Parkinson's disease. Vingerhoets G, et al. **J Neurol Neurosurg Psychiatry** 1999 Mar;66(3):297-304

Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. Schneider JS, et al. **J Neurosci** 1999 Aug 1;19(15):6643-9

Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review. Ghika J, et al. **J Neurosurg** 1998 Nov;89(5):713-8

Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum. Bejjani BP, et al. **Mov Disord** 1998 Nov;13(6):969-70

Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD [letter; comment] Stanzione P, et al. **Neurology** 1998 Dec;51(6):1776-7. Comment on: Neurology 1997 Dec;49(6):1564-9.

Evidence for the involvement of the pallidum in the modulation of seizures in a genetic model of absence epilepsy in the rat. Deransart C, et al. **Neurosci Lett** 1999 Apr 16;265(2):131-4

Microelectrode recording during posteroventral pallidotomy: impact on target selection and complications. Alterman RL, et al. **Neurosurgery** 1999 Feb;44(2):315-21; discussion 321-3

Effects of lesions of the Substantia Innominata/Ventral Pallidum, globus pallidus and medial septum on rat's performance in object-recognition and radial-maze tasks: physostigmine and amphetamine treatments. Ennaceur A. **Pharmacol Res** 1998 Oct;38(4):251-63

Dynamics of tremor-related oscillations in the human globus pallidus: a single case study. Hurtado JM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1674-9

Neuronal activity in GP and Vim of parkinsonian patients and clinical changes of tremor through surgical interventions. Hayase N, et al. **Stereotact Funct Neurosurg** 1998;71(1):20-8

Infrequent types of pallidal discharges during pallidotomy. Taha JM, et al. **Stereotact Funct Neurosurg** 1997;68(1-4 Pt 1):231-5

Computer analysis of the tonic, phasic, and kinesthetic activity of pallidal discharges in Parkinson patients. Favre J, et al. **Surg Neurol** 1999 Jun;51(6):665-72; discussion 672-3

RADIOGRAPHY

Localization accuracy of AC-PC line and functional pallidal target using BRW stereotactic implementation system and axial CT scanning. An experimental study. Rampini P, et al. **J Neurosurg Sci** 1998 Dec;42(4):195-201

SURGERY

Current controversies in pallidal surgery. Hariz MI. **Adv Neurol** 1999;80:593-602 (87 ref.)

Image-guided electrophysiologically controlled posteroventral pallidotomy for the treatment of Parkinson's disease: a 28-case analysis. Hirai T, et al. **Adv Neurol** 1999; 80:585-91

Reversal of levodopa failure syndrome by posteroventral-ansa pallidotomy. Iacono RP, et al. **Adv Neurol** 1999;80:619-22

Posteroventral medial pallidotomy in advanced Parkinson's disease. Lang AE, et al. **Adv Neurol** 1999;80:575-83

GPi pallidotomy for dystonia: clinical outcome and neuronal activity. Vitek JL, et al. **Adv Neurol** 1998;78:211-9 (32 ref.)

Stereotactic microelectrode-guided posteroventral pallidotomy and pallidal deep brain stimulation for Parkinson's disease. Tan AK, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):767-71

Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Bronstein JM, et al. **Arch Neurol** 1999 Sep;56(9):1064-9 (41 ref.)

New and emerging therapies for Parkinson disease. Jankovic J. **Arch Neurol** 1999 Jul;56(7):785-90 (56 ref.)

Preliminary results in surgery of Parkinson's disease. Nasser

JA, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):533–9

"The pallidotomy debate": are micro-electrode-guided pallidotomies always located in the pallidum? [letter] Hariz MI, et al. **Br J Neurosurg** 1998 Dec;12(6):595–7

Unilateral pallidotomy for advanced Parkinson's disease [editorial; comment] Gregory R. **Brain** 1999 Mar;122 (Pt 3):381–2. Comment on: Brain 1999 Mar;122 (Pt 3):405–16. Comment on: Brain 1999 Mar;122 (Pt 3):417–25.

Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease [see comments] Gross RE, et al. **Brain** 1999 Mar;122 (Pt 3):405–16. Comment in: Brain 1999 Mar;122 (Pt 3):381–2.

Voluntary movement after pallidotomy in severe Parkinson's disease. Kimber TE, et al. **Brain** 1999 May;122 (Pt 5):895–906

The effects of posteroventral pallidotomy on the preparation and execution of voluntary hand and arm movements in Parkinson's disease. Limousin P, et al. **Brain** 1999 Feb;122 (Pt 2):315–27

Reassessment of unilateral pallidotomy in Parkinson's disease. A 2-year follow-up study [see comments] Samii A, et al. **Brain** 1999 Mar;122 (Pt 3):417–25. Comment in: Brain 1999 Mar;122 (Pt 3):381–2.

Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. Gálvez-Jiménez N, et al. **Can J Neurol Sci** 1998 Nov;25(4):300–5

Posterior ventral pallidotomy: techniques and theoretical considerations. Bakay RA, et al. **Clin Neurosurg** 1997; 44:197–210 (10 ref.)

Outcomes assessment for pallidotomy. Cosgrove GR, et al. **Clin Neurosurg** 1997;44:385–99 (18 ref.)

Selection of patients for surgery for Parkinson's disease. Tasker RR. **Clin Neurosurg** 1997;44:63–7 (18 ref.)

Automated atlas integration and interactive three-dimensional visualization tools for planning and guidance in functional neurosurgery. St-Jean P, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):672–80

The effect of unilateral posteroventral pallidotomy on the kinematics of the reach to grasp movement. Bennett KM, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):479–87

Posteroventral pallidotomy can ameliorate attacks of paroxysmal dystonia induced by exercise [letter] Bhatia KP, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):604–5

Transient hiccups after posteroventral pallidotomy for Parkinson's disease [letter] de Bie RM, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):124–5

Pallidal activity during dystonia: somatosensory reorganisation and changes with severity. Lenz FA, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):767–70

Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. Ghika J, et al. **J Neurosurg** 1999 Aug;91(2):313–21 (114 ref.)

Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. Gross RE, et al. **J Neurosurg** 1999 Mar; 90(3):468–77

Crusade for microelectrode guidance in pallidotomy [letter; comment] Hariz MI, et al. **J Neurosurg** 1999 Jan; 90(1):175–9. Comment on: J Neurosurg 1998 Jun;88(6):1027–43.

Unilateral pallidotomy for reduction of parkinsonian pain. Honey CR, et al. **J Neurosurg** 1999 Aug;91(2):198–201

Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. Case report. Justesen CR, et al. **J Neurosurg** 1999 Mar;90(3):551–4

Outcomes after stereotactically guided pallidotomy for advanced Parkinson's disease. Kondziolka D, et al. **J Neurosurg** 1999 Feb;90(2):197–202

Benefit of bilateral pallidotomy in the treatment of generalized dystonia. Case report. Lin JJ, et al. **J Neurosurg** 1999 May;90(5):974–6

Prefrontal dysfunction following unilateral posteroventral pallidotomy in Parkinson's disease. Yokoyama T, et al. **J Neurosurg** 1999 Jun;90(6):1005–10

Localization accuracy of AC-PC line and functional pallidal target using BRW stereotactic implementation system and axial CT scanning. An experimental study. Rampini P, et al. **J Neurosurg Sci** 1998 Dec;42(4):195–201

Reversible Huntington's disease--lesion to the globus pallidus? [letter; comment] Altschuler EL. **Lancet** 1999 Jan 16;353(9148):240–1. Comment on: Lancet 1998 Nov 7;352(9139):1520–1.

Stereotactic posteroventral pallidotomy: clinical methods and results at 1-year follow up. Dalvi A, et al. **Mov Disord** 1999 Mar;14(2):256–61

Movement and reaction times and fine coordination tasks following pallidotomy. Jankovic J, et al. **Mov Disord** 1999 Jan;14(1):57–62

Pallidotomy for tremor. Lozano AM, et al. **Mov Disord** 1998; 13 Suppl 3:107–10 (11 ref.)

Unilateral radiofrequency lesion versus electrostimulation of posteroventral pallidum: a prospective randomized comparison. Merello M, et al. **Mov Disord** 1999 Jan; 14(1):50–6

Pallidotomy for generalized dystonia. Ondo WG, et al. **Mov Disord** 1998 Jul;13(4):693–8

Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease. Skalabrin EJ, et al. **Mov Disord** 1998 Sep;13(5):775–81

Transient acute depression induced by high-frequency deep-brain stimulation [letter] Bezerra ML, et al. **N Engl J Med** 1999 Sep 23;341(13):1003; discussion 1004

Square-wave jerks induced by pallidotomy in parkinsonian patients. Averbuch-Heller L, et al. **Neurology** 1999 Jan 1; 52(1):185–8

Efficacy of levodopa therapy on motor function after posteroventral pallidotomy for Parkinson's disease. Uitti RJ, et al. **Neurology** 1998 Dec;51(6):1755–7

Neuropsychological and motor functioning after unilateral anatomically guided posterior ventral pallidotomy. Preoperative performance and three-month follow-up. Cahn DA, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Jul; 11(3):136–45

Microelectrode recording during posteroventral pallidotomy: impact on target selection and complications. Alterman RL, et al. **Neurosurgery** 1999 Feb;44(2):315–21; discussion 321–3

Stereotactic targeting of the globus pallidus internus in Parkinson's disease: imaging versus electrophysiological mapping. Guridi J, et al. **Neurosurgery** 1999 Aug; 45(2):278–87; discussion 287–9

Comparison of 1-year follow-up evaluations of patients with indication for pallidotomy who did not undergo surgery versus patients with Parkinson's disease who did undergo pallidotomy: a case control study. Merello M, et al. **Neurosurgery** 1999 Mar;44(3):461–7; discussion 467–8

Pallidotomy lesion locations: significance of microelectrode refinement. Tsao K, et al. **Neurosurgery** 1998 Sep; 43(3):506–12; discussion 512–3

Visual evoked potentials during posteroventral pallidotomy for Parkinson's disease. Yokoyama T, et al. **Neurosurgery** 1999 Apr;44(4):815–22; discussion 822–4

Stereotactic radiosurgical pallidotomy and thalamotomy with the gamma knife: MR imaging findings with clinical correlation--preliminary experience. Friedman DP, et al. **Radiology** 1999 Jul;212(1):143–50

Pallidal targeting with the COMPASS system. Alterman RL, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):69–72

Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist? Amano K, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):5–18

Is there a relationship between size and site of the stereotactic lesion and symptomatic results of pallidotomy and thalamotomy? Hariz MI, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):28–45

Optimal target localization for ventroposterolateral pallidotomy: the role of imaging, impedance measurement, macrostimulation and microelectrode recording. Heilbrun MP, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):19–27

Comparison between stereotactic CT and MRI coordinates of pallidal and thalamic targets using the Laitinen noninvasive stereoadapter. Hirabayashi H, et al. **Stereotact Funct Neurosurg** 1998;71(3):117–30

Study on the function of the basal ganglia and frontal cortex using depth microrecording and PET scan in relation to the outcome of pallidotomy for the treatment of rigid-akinesia-type Parkinson's disease. Hirato M, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):86–92

Sequential postoperative appearance of radiofrequency pallidotomy lesions on MRI. Lim JY, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):46–53

Pallidotomy revisited. Analysis of posteroventral pallidotomy. Narabayashi H. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):54–61

Infrequent types of pallidal discharges during pallidotomy. Taha JM, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):231–5

Comparative magnetic resonance image-based evaluation of thalamotomy and pallidotomy lesion volumes. Tollefson TT, et al. **Stereotact Funct Neurosurg** 1998;71(3):131–44

Is the medial globus pallidus a site for stimulation or lesioning in the treatment of Parkinson's disease? Tronnier VM, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):62–8

Comparison of actual pallidotomy lesion location with expected stereotactic location. Tsao K, et al. **Stereotact Funct Neurosurg** 1998;71(1):1–19

Pallidotomy with the gamma knife: a positive experience. Young RF, et al. **Stereotact Funct Neurosurg** 1998 Oct;70 Suppl 1:218–28

Computer analysis of the tonic, phasic, and kinesthetic activity of pallidal discharges in Parkinson patients. Favre J, et al. **Surg Neurol** 1999 Jun;51(6):665–72; discussion 672–3

[Stereotaxic thalamotomy and pallidotomy in the treatment of Parkinson disease (letter; comment)] Chapman AH, et al. **Arq Neuropsiquiatr** 1999 Mar;57(1):151–2. Comment on: Arq Neuropsiquiatr 1998 Dec;56(4):789–97. **(Por)**

[Stereotaxic thalamotomy and pallidotomy with computerized planning in Parkinson's disease: short-term evaluation of motor function in 50 patients (see comments)] Ferraz FP, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):789–97 (Eng. Abstr.). Comment in: Arq Neuropsiquiatr 1999 Mar;57(1):151–2. **(Por)**

[Posteroventral pallidotomy in Parkinson's disease (editorial)] Giménez Roldán S. **Neurologia** 1999 Feb;14(2):49–52 (16 ref.) **(Spa)**

[Pallidotomy in the treatment of complicated Parkinson's disease: clinical results at two years and analysis of prognostic factors] Linazasoro G, et al. **Neurologia** 1999 Feb;14(2):53–61 (Eng. Abstr.) **(Spa)**

[Pathophysiological bases, clinical results and indications for surgical treatment in Parkinson disease] Obeso JA, et al. **Neurologia** 1999 May;14 Suppl 1:54–71 (106 ref.) (Eng. Abstr.) **(Spa)**

[Simultaneous transplantation of fetal mesencephalic cells to the striatum and globus pallidus of rats with lesions induced by 6-hydroxydopamine] Alvarez-Fonseca P, et al. **Rev Neurol** 1998 Apr;26(152):537–40 (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans. Reiner A, et al. **Neuroscience** 1999;88(3):775–93

GLOMANGIOMA see **GLOMUS TUMOR**

GLOMERELLA see **PHYLLACHORALES**

GLOMERULAR FILTRATION RATE

Microalbuminuria, glomerular filtration rate, and dietary fat and protein intakes in type 1 diabetes [letter; comment] Bouhanick B, et al. **Am J Clin Nutr** 1999 Jan;69(1):153. Comment on: Am J Clin Nutr 1998 Jan;67(1):50–7.

Excretion of progastrin products in human urine. Hansen CP, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G985–92

Serum chromogranin A and its relationship to endogenous markers of glomerular filtration rate. Mojiminiyi OA, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):247–9

Prediction equation for glomerular filtration rate [letter] Ando Y, et al. **Ann Intern Med** 1999 Oct 19;131(8):629–30; discussion 630

Prediction equation for glomerular filtration rate [letter] Goldwasser P. **Ann Intern Med** 1999 Oct 19;131(8):629; discussion 630

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, et al. **Ann Intern Med** 1999 Mar 16;130(6):461–70

Prediction equation for glomerular filtration rate [letter] Matz R. **Ann Intern Med** 1999 Oct 19;131(8):629; discussion 630

Cystatin C serum concentrations underestimate glomerular filtration rate in renal transplant recipients. Bökenkamp A, et al. **Clin Chem** 1999 Oct;45(10):1866–8

Glomerular filtration rate determination in diabetic patients using iohexol clearance--comparison of single and multiple plasma sampling methods. Chowdhury TA, et al. **Clin Chim Acta** 1998 Oct;277(2):153–8

Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. Orlando R, et al. **Clin Nephrol** 1999 Jun; 51(6):341–7

Glomerular filtration rate and serum creatinine: a reply to Fujita et al [letter; comment] Pedersen RS. **Clin Nephrol** 1999 Jun;51(6):388–9. Comment on: Clin Nephrol 1998 Nov;50(5):284–8.

Glomerular filtration rate measurement in cirrhotic patients with renal failure. Roy L, et al. **Clin Nephrol** 1998 Dec; 50(6):342–6

Simulation of renal function by tumor and its effect on the calculated glomerular filtration rate. Boxen I. **Clin Nucl Med** 1999 May;24(5):338–42

Intra- and interoperator variations in region-of-interest drawing and their effect on the measurement of glomerular filtration rates. White DR, et al. **Clin Nucl Med** 1999 Mar; 24(3):177–81

Application of newer clearance techniques for the determination of glomerular filtration rate. Gaspari F, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):675–80

Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. Christensen PK, et al. **Diabet Med** 1999 May;16(5):388–94

Long-term glycaemic control directly correlates with glomerular filtration rate in early Type 1 diabetes mellitus before the onset of microalbuminuria. Soper CP, et al. **Diabet Med** 1998 Dec;15(12):1010–4

Relationship between glomerular hyperfiltration and ACE insertion/deletion polymorphism in type 1 diabetic children and adolescents. Bouhanick B, et al. **Diabetes Care** 1999 Apr;22(4):618–22

Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Chaiken RL, et al. **Diabetes Care** 1998 Dec;21(12):2129–34

Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Taniwaki H, et al. **Diabetes Care** 1998 Nov;21(11):1848–55

Changing glomerular filtration with progression from impaired glucose tolerance to Type II diabetes mellitus. Nelson RG, et al. **Diabetologia** 1999 Jan;42(1):90–3

Evaluation and validation of ureteric jet index by glomerular filtration rate. Chiu NT, et al. **Invest Radiol** 1999 Aug; 34(8):499–502

Transcutaneous renal function monitor: precision during unsteady hemodynamics. Bauman LA, et al. **J Clin Monit Comput** 1998 May;14(4):275–82

Evaluation of glomerular filtration rate by camera-based method in both children and adults. Inoue Y, et al. **J Nucl Med** 1998 Oct;39(10):1784–8

Chromium-51-EDTA clearance in adults with a single-plasma sample. Mårtensson J, et al. **J Nucl Med** 1998 Dec;39(12):2131–7

GLOMERULAR FILTRATION RATE

Renal depth estimates to improve the accuracy of glomerular filtration rate. Steinmetz AP, et al. **J Nucl Med** 1998 Oct; 39(10):1822–5

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Wollesen F, et al. **Kidney Int** 1999 Mar;55(3):1028–35

Cystatin C in paediatric nephrology. Present situation and prospects. Fanos V, et al. **Minerva Pediatr** 1999 May; 51(5):167–77 (41 ref.) **(Eng, Ita)**

Glomerulotubular neck stenosis: the link between interstitial scarring and reduced GFR? Cohen EP. **Nephrol Dial Transplant** 1998 Nov;13(11):2961–2

Glomerular filtration rate estimation from plasma creatinine after inhibition of tubular secretion: relevance of the creatinine assay. Kemperman FA, et al. **Nephrol Dial Transplant** 1999 May;14(5):1247–51

Validity of rapid estimation of glomerular filtration rate in type 2 diabetic patients with normal renal function. Nielsen S, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):615–9

Glomerular filtration rate estimated from the uptake phase of 99mTc-DTPA renography in chronic renal failure. Petersen LJ, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1673–8

Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C. Risch L, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):1991–6

Renal haemodynamic responses to a chicken or beef meal in normal individuals [letter; comment] Zitta S, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):794–5. Comment on: Nephrol Dial Transplant 1998 Sep;13(9):2261–4.

Body surface area correction in single-sample methods of glomerular filtration rate estimation. Hamilton D, et al. **Nucl Med Commun** 1999 Mar;20(3):273–8

Evolution of single kidney glomerular filtration rate in urinary tract infection. Arnello F, et al. **Pediatr Nephrol** 1999 Feb;13(2):121–4

Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Bardoux P, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10397–402

Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. Hansen HP, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):405–13

Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: results of an observational study. Morris-Stiff GJ, et al. **Transpl Int** 1999;12(4):288–92

Renal function reserve in stable grafts and its relationship to renal morphologic parameters. Fulladosa X, et al. **Transplant Proc** 1999 Sep;31(6):2302–3

[Evaluation of long-term monitoring of glomerular filtration in individuals with kidney transplantation] Schück O, et al. **Cas Lek Cesk** 1998 Nov 2;137(21):647–50 (Eng. Abstr.) **(Cze)**

[Determination of cystatin C in serum and its use in prediction of glomerular filtration] Stejskal D, et al. **Vnitr Lek** 1998 Sep;44(9):555–7 **(Cze)**

[Estimation of glomerular filtration rate by the formula GFR = K x T/Pcr] Haenggi MH, et al. **Arch Pediatr** 1999 Feb; 6(2):165–72 (Eng. Abstr.) **(Fre)**

[Measurement of glomerular filtration rate (GFR) after administration of iodine contrast medium with the Renalyzer PRX90 in healthy cats and cats with kidney diseases] Meyer-Lindenberg A, et al. **Berl Munch Tierarztl Wochenschr** 1998 Sep;111(9):344–51 (Eng. Abstr.) **(Ger)**

[Measurement of glomerular filtration rate in connection with 99Tc-DTPA renography] Cappelen T, et al. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):521–5 (Eng. Abstr.) **(Nor)**

[Practical considerations respecting the clinical use of serum cystatin C as a marker of glomerular filtration] Riveiro Cruz A, et al. **Rev Clin Esp** 1999 Apr;199(4):193–7 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Fassi A, et al. **Am J Kidney Dis** 1999 Feb; 33(2):267–75

Lovastatin preserves renal function in experimental diabetes. Inman SR, et al. **Am J Med Sci** 1999 Apr;317(4):215–21

Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Zhong Z, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F595–604

Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Park JH, et al. **Biopharm Drug Dispos** 1998 Sep;19(6):357–64

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects [see comments] Mathur VS, et al. **Crit Care Med** 1999 Sep;27(9):1832–7. Comment in: Crit Care Med 1999 Sep;27(9):2044–5.

Haemodynamic and renal effects of felodipine in young and elderly subjects. Lernfelt B, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):595–601

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Angeli P, et al. **Hepatology** 1999 Jun;29(6):1690–7

Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. Wilcox CS, et al. **J Am Soc Nephrol** 1999 Apr;10(4):714–20

A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? Andreev E, et al. **J Intern Med** 1999 Sep;246(3):247–52 (61 ref.)

Superoxide-mediated glomerulopathy in the endotoxin-treated pregnant rat. Faas MM, et al. **Kidney Blood Press Res** 1998;21(6):432–7

REIN follow-up trial. Ramipril Efficacy in Nephropathy [letter; comment] Locatelli F, et al. **Lancet** 1998 Dec 19–26; 352(9145):2020–1; discussion 2021–2. Comment on: Lancet 1998 Jul 25;352(9124):296. Comment on: Lancet 1998 Oct 17;352(9136):1252–6.

REIN follow-up trial. Ramipril Efficacy in Nephropathy [letter; comment] Montagnino G. **Lancet** 1998 Dec 19–26; 352(9145):2021–2. Comment on: Lancet 1998 Oct 17;352(9136):1252–6.

[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency] Hottelart C, et al. **Nephrologie** 1999; 20(1):41–4 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

A simple, nonradioactive method for evaluating single-nephron filtration rate using FITC-inulin. Lorenz JN, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):F172–7

Hyperfiltration in patients with type I diabetes mellitus: a prevalence study. Cotroneo P, et al. **Clin Nephrol** 1998 Oct; 50(4):214–7

Measurement of changes in glomerular filtration rate induced by atrial natriuretic peptide in the rat kidney. Caron N, et al. **Exp Physiol** 1999 Jul;84(4):689–96

Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Osei SY, et al. **Hypertension** 1999 Jan;33(1 Pt 2):559–64

The dynamics of glomerular filtration after Caesarean section. Lafayette RA, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1561–5

Measurement of glomerular filtration rate and effective renal plasma flow in the conscious beagle dog by single intravenous bolus of iohexol and p-aminohippuric acid. Laroute V, et al. **J Pharmacol Toxicol Methods** 1999 Feb; 41(1):17–25

Effects of SWL on glomerular filtration rate and renal plasma flow in uninephrectomized minipigs. Clayman RV. **J Urol** 1998 Nov;160(5):1950–1

Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Reichert LJ, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):91–7

Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate. Filler G, et al. **Pediatr Nephrol** 1999 Aug;13(6):501–5

Influence of hyperfiltration on the measurement of urinary N-acetyl-beta-D-glucosaminidase. Müller D, et al. **Pediatr Nephrol** 1999 Aug;13(6):519–23

Cystatin C as a marker for glomerular filtration rate in pediatric patients. Ylinen EA, et al. **Pediatr Nephrol** 1999 Aug;13(6):506–9

Appropriate corrections to glomerular filtration rate and volume of distribution based on the bolus injection and single-compartment technique. Peters AM, et al. **Physiol Meas** 1999 Aug;20(3):313–27

Glomerular filtration rate in normal and abnormal pregnancies. Baylis C. **Semin Nephrol** 1999 Mar;19(2):133–9 (55 ref.)

[How I examine...diabetic nephropathy. Second part: assessment of glomerular filtration] Weekers L, et al. **Rev Med Liege** 1998 Sep;53(9):571–5 (11 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Pharmacokinetic aspects of measurement of glomerular filtration rate in the dog: a review. Heiene R, et al. **J Vet Intern Med** 1998 Nov-Dec;12(6):401–14 (86 ref.)

Comparison between the scintigraphic uptake and plasma clearance of 99mTc-diethylenetriaminepentacetic acid (DTPA) for the evaluation of the glomerular filtration rate in dogs. Barthez PY, et al. **Vet Radiol Ultrasound** 1998 Sep-Oct;39(5):470–4

GLOMERULAR MESANGIUM

CHEMISTRY

Presence of the beta1I isotype of tubulin in the nuclei of cultured mesangial cells from rat kidney. Walss C, et al. **Cell Motil Cytoskeleton** 1999;42(4):274–84

Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). Westerhuis R, et al. **J Am Soc Nephrol** 1999 Apr;10(4):770–8

Cultured human glomerular mesangial cells express the C5a receptor. Braun M, et al. **Kidney Int** 1998 Nov;54(5):1542–9

TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Riser BL, et al. **Kidney Int** 1999 Aug;56(2):428–39

Human mesangial cells express inducible macrophage scavenger receptor. Ruan XZ, et al. **Kidney Int** 1999 Aug; 56(2):440–51

[Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP] Nguyen G, et al. **Nephrologie** 1998;19(7):411–6 (8 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Enrichment of transiently transfected mesangial cells by cell sorting after cotransfection with GFP. Chen R, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F777–85

Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Horney MJ, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):F1045–53

Involvement of PDGF in pressure-induced mesangial cell proliferation through PKC and tyrosine kinase pathways. Kato H, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F105–12

ROS stimulate reorganization of mesangial cell-collagen gels by tyrosine kinase signaling. Zent R, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F278–87

Collagen type I modulates the platelet-derived growth factor (PDGF) regulation of the growth and expression of beta1 integrins by rat mesangial cells. Kagami S, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):728–32

A multifunctional transcription factor (A1p145) regulates the smooth muscle phenotype in mesangial cells. Takeoka H, et al. **Biochem Biophys Res Commun** 1998 Nov 18; 252(2):290–5

Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Grandaliano G, et al. **Exp Nephrol** 1999 May-Jun;7(3):229–35

Pressure oscillation regulates human mesangial cell growth and collagen synthesis. Mertens PR, et al. **Hypertension** 1998 Nov;32(5):945–52

Matrix-mesangial cell interaction modulates migration of macrophages. Singhal PC, et al. **J Investig Med** 1998 Dec; 46(9):453–9

Fibronectin augments monocyte adhesion to low-density lipoprotein-stimulated mesangial cells. Chana RS, et al. **Kidney Int** 1999 Jan;55(1):179–88

Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo. Hugo CP, et al. **Kidney Int** 1999 Jun;55(6):2236–49

Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate. Nishimura M, et al. **Kidney Int** 1999 Feb;55(2):520–8

Human mesangial cells express inducible macrophage scavenger receptor. Ruan XZ, et al. **Kidney Int** 1999 Aug; 56(2):440–51

Regulation of survival and death of mesangial cells by extracellular matrix. Sugiyama H, et al. **Kidney Int** 1998 Oct;54(4):1188–96

Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Ruiz-Ortega M, et al. **Kidney Int Suppl** 1998 Dec;68:S41–5

Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Wang ZQ, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3052–7

Effect of the platelet-derived growth factor antagonist trapidil on mesangial cell proliferation in rats. Futamura A, et al. **Nephron** 1999;81(4):428–33

Detection of cell death of cultured mouse mesangial cells induced by oxidized low-density lipoprotein. Tashiro K, et al. **Nephron** 1999;82(1):51–8

[Effects of glycated protein on the expression of plasminogen activator inhibitor-1 of cultured human mesangial cells] Deng Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep; 77(9):672–5 (Eng. Abstr.) **(Chi)**

[The effects of endothelin and bFGF on proliferation of MC and synergetic effect of insulin] Liu J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):159–62 (Eng. Abstr.) **(Chi)**

DRUG EFFECTS

Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change. Bussolati B, et al. **Am J Pathol** 1999 Feb;154(2):623–32

Tumor necrosis factor-alpha and ceramide induce cell death through different mechanisms in rat mesangial cells. Guo YL, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F390–7

Resistance to TNF-alpha cytotoxicity can be achieved through different signaling pathways in rat mesangial cells. Guo YL, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C435–41

Estradiol reverses TGF-beta1-stimulated type IV collagen gene transcription in murine mesangial cells. Silbiger S, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):F1113–8

Effect of Perilla frutescens extract on nitric oxide production by cultured murine mesangial cells. Makino T, et al. **Biol Pharm Bull** 1999 May;22(5):476–80

Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. Di Paolo S, et al. **Clin Exp Immunol** 1999 Aug;117(2):355–60

LDL receptor gene expression in human mesangial cells under the influence of calcium channel blockers. Ruan XZ, et al. **Clin Nephrol** 1999 May;51(5):263–71

Ca2+ response of rat mesangial cells to ATP analogues. Gutierrez AM, et al. **Eur J Pharmacol** 1999 Mar 12; 369(1):107–12

Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. Inoue T, et al. **Eur J Pharmacol** 1998 Nov 20;361(2-3):285–91

Mechanism of adrenomedullin-stimulated hyaluronic acid release in rat mesangial cells. Parameswaran N, et al.

Eur J Pharmacol 1999 Apr 16;370(3):313–8

Regulation of glomerular mesangial cell proliferation in culture by adrenomedullin. Parameswaran N, et al. **Eur J Pharmacol** 1999 May 7;372(1):85–95

SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells. Parameswaran N, et al. **Eur J Pharmacol** 1999 Apr 23;371(1):75–82

Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Grandaliano G, et al. **Exp Nephrol** 1999 May-Jun;7(3):229–35

Lipoprotein (a) stimulates mitogen activated protein kinase in human mesangial cells. Mondorf UF, et al. **FEBS Lett** 1998 Dec 18;441(2):205–8

Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Yagi M, et al. **Gen Pharmacol** 1998 Nov;31(5):765–73

Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells. Elliot SJ, et al. **J Am Soc Nephrol** 1999 Jan;10(1):62–8

Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells. Kaizuka M, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1516–23

The antioxidant N-acetylcysteine induces mesangial cells to create three-dimensional cytoarchitecture that underlies cellular differentiation. Kitamura M. **J Am Soc Nephrol** 1999 Apr;10(4):746–51

Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. Mene P, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1478–86

Lovastatin inhibits mesangial cell proliferation via p27Kip1. Terada Y, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2235–43

Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. Guan Z, et al. **J Biol Chem** 1998 Oct 30;273(44):28670–6

Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells. Huwiler A, et al. **J Biol Chem** 1999 Mar 12;274(11):7190–5

Selective sensitization to tumor necrosis factor-alpha-induced apoptosis by blockade of NF-kappaB in primary glomerular mesangial cells. Sugiyama H, et al. **J Biol Chem** 1999 Jul 9;274(28):19532–7

The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. Yavuz DG, et al. **J Hypertens** 1999 Aug;17(8):1217–23

Circulating factor in patients with recurrent focal segmental glomerulosclerosis postrenal transplantation inhibits expression of inducible nitric oxide synthase and nitric oxide production by cultured rat mesangial cells. Trachtman H, et al. **J Investig Med** 1999 Mar;47(3):114–20

Glucocorticoid effect on human mesangial cell cytoskeletal proteins. Koukouritaki SB, et al. **J Lab Clin Med** 1999 Apr; 133(4):378–83

Inhibition of activated human mesangial cell proliferation by the natural product of Cordyceps sinensis (H1-A): an implication for treatment of IgA mesangial nephropathy. Lin CY, et al. **J Lab Clin Med** 1999 Jan;133(1):55–63

Tretinoin prevents age-related renal changes and stimulates antioxidant defenses in cultured renal mesangial cells. Manzano VM, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):123–32

Fibronectin augments monocyte adhesion to low-density lipoprotein-stimulated mesangial cells. Chana RS, et al. **Kidney Int** 1999 Jan;55(1):179–88

Hydrogen peroxide activates ion currents in rat mesangial cells. Gloy J, et al. **Kidney Int** 1999 Jul;56(1):181–9

Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Hoffman BB, et al. **Kidney Int** 1998 Oct; 54(4):1107–16

Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo. Hugo CP, et al. **Kidney Int** 1999 Jun;55(6):2236–49

Angiotensin II induces superoxide anion production by mesangial cells. Jaimes EA, et al. **Kidney Int** 1998 Sep; 54(3):775–84

Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kang MJ, et al. **Kidney Int** 1999 Jun;55(6):2203–14

Serotonin enhances the production of type IV collagen by human mesangial cells. Kasho M, et al. **Kidney Int** 1998 Oct;54(4):1083–92

Angiotensin II inhibits interleukin-1 beta-induced nitric oxide production in cultured rat mesangial cells. Kihara M, et al. **Kidney Int** 1999 Apr;55(4):1277–83

Lipoprotein(a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins. Mondorf UF, et al. **Kidney Int** 1999 Apr;55(4):1359–66

L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Peters H, et al. **Kidney Int** 1999 Jun; 55(6):2264–73

Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1 [see comments] Silbiger S, et al. **Kidney Int** 1999 Apr;55(4):1268–76. Comment in: Kidney Int 1999 Apr;55(4):1577–9.

Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Simon M, et al. **Kidney Int** 1998 Oct;54(4):1117–27

c-Rel and p65 trans-activate the monocyte chemoattractant protein-1 gene in interleukin-1 stimulated mesangial cells. Stylianou E, et al. **Kidney Int** 1999 Sep;56(3):873–82

Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kamanna VS, et al. **Kidney Int Suppl** 1999 Jul;71:S70–5 (23 ref.)

Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. Massy ZA, et al. **Kidney Int Suppl** 1999 Jul;71:S80–3

Effect of lipoproteins on mesangial cell proliferation. Nishida Y, et al. **Kidney Int Suppl** 1999 Jul;71:S51–3

Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Nishimura M, et al. **Kidney Int Suppl** 1999 Jul;71:S97–100

Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Nogaki F, et al. **Kidney Int Suppl** 1999 Jul;71:S198–201

Phospholipase A2 activity in ox-LDL-stimulated mesangial cells and modulation by alpha-tocopherol. Ozaki M, et al. **Kidney Int Suppl** 1999 Jul;71:S171–3

Probucol suppresses ICAM-1 expression in rat mesangial cells: possible role of IL-1. Sugiura T, et al. **Kidney Int Suppl** 1999 Jul;71:S167–70 (10 ref.)

Lysophosphatidylcholine up-regulates IL-1 beta-induced iNOS expression in rat mesangial cells. Taniuchi M, et al. **Kidney Int Suppl** 1999 Jul;71:S156–8

Lysophosphatidylcholine induces platelet-derived growth factor gene expression in a human mesangial cell line. Tone Y, et al. **Kidney Int Suppl** 1999 Jul;71:S182–5

Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Yoshimura A, et al. **Kidney Int Suppl** 1999 Jul;71:S84–7 (7 ref.)

Blocking of cell proliferation, cytokines production and genes expression following administration of Chinese herbs in the human mesangial cells. Kuo YC, et al. **Life Sci** 1999; 64(23):2089–99

Glycosaminoglycan prevents hyperglycemia-induced renal TGF-beta 1 gene expression. Gambaro G, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:20–1

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Hauser IA, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):58–63

TGF-beta- and angiotensin-II-induced mesangial matrix protein secretion is mediated by protein kinase C. Weiss RH, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2804–13

Angiotensin II-induced modulation of rat mesangial cell phenotype. Zhang X, et al. **Radiat Res** 1999 Jun; 151(6):725–35

Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Herrera GA, et al. **Ultrastruct Pathol** 1999 Mar-Apr; 23(2):107–26

EMBRYOLOGY

Regulation of tissue plasminogen activator production in cultured human fetal mesangial cells. Yoshiko B, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):508–13

Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. Nelson PJ, et al. **J Cell Sci** 1999 Feb;112 (Pt 3):361–70

ENZYMOLOGY

Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells. Cohen MP, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F684–90

Neuronal NOS contributes to biphasic autoregulatory response during enhanced TGF activity. Ichihara A, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F113–20

Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Wang JL, et al. **Am J Physiol** 1998 Oct; 275(4 Pt 2):F613–22

Protein kinase C phosphorylates and activates GTP cyclohydrolase I in rat renal mesangial cells. Lapize C, et al. **Biochem Biophys Res Commun** 1998 Oct 29; 251(3):802–5

Integrins mediate the inhibitory effect of focal adhesion on angiotensin II-induced p44/42 mitogen-activated protein (MAP) kinase activity in human mesangial cells. Shikata Y, et al. **Biochem Biophys Res Commun** 1999 Aug 11; 261(3):820–3

Selective ceramide binding to protein kinase C-alpha and -delta isoenzymes in renal mesangial cells. Huwiler A, et al. **Biochemistry** 1998 Oct 13;37(41):14556–62

Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Bassa BV, et al. **Biochim Biophys Acta** 1999 Mar 8;1449(2):137–49

Competitive RT-PCR for measuring metalloproteinase gene expression in human mesangial cells exposed to a hyperglycemic environment. Death AK, et al. **Biotechniques** 1999 Sep;27(3):512–8, 520

Cross-talk between group IIA-phospholipase A2 and inducible NO-synthase in rat renal mesangial cells. Rupprecht G, et al. **Br J Pharmacol** 1999 May;127(1):51–6

Regulation of cyclooxygenase-2 expression in human mesangial cells--transcriptional inhibition by IL-13. Diaz-Cazorla M, et al. **Eur J Biochem** 1999 Feb; 260(1):268–74

Glucosamine induces translocation of protein kinase C isoenzymes in mesangial cells. Kolm-Litty V, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):377–83

Inhibition of Ca2+-independent phospholipase A2 by bromoenol lactone attenuates prostaglandin generation induced by interleukin-1 beta and dibutyryl cAMP in rat mesangial cells. Akiba S, et al. **FEBS Lett** 1998 Oct 23; 437(3):225–8

Negative regulation of interleukin-1beta-activated neutral sphingomyelinase by protein kinase C in rat mesangial cells. Kaszkin M, et al. **FEBS Lett** 1998 Nov 27;440(1-2):163–6

Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. Awazu M, et al. **J Am Soc Nephrol** 1999 Apr;10(4):738–45

Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells. Diaz-Cazorla M, et al. **J Am Soc Nephrol** 1999 May;10(5):943–52

Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. Kapor-Drezgic J, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1193–203

Inducible nitric oxide synthase can be induced in the absence of active nuclear factor-kappaB in rat mesangial cells: involvement of the Janus kinase 2 signaling pathway. Nakashima O, et al. **J Am Soc Nephrol** 1999 Apr; 10(4):721–9

Increases in ceramide levels in normal human mesangial cells subjected to different cellular stresses result from changes in distinct enzyme activities and can influence cellular responses to other stimuli. Sweeney EA, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):737–45

Nitric oxide stimulates the stress-activated protein kinase p38 in rat renal mesangial cells. Huwiler A, et al. **J Exp Biol** 1999 Mar;202 (Pt 6):655–60

Purification and characterization of angiotensin I-converting enzymes from mesangial cells in culture. Andrade MC, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2063–74

Nitric oxide induces heme oxygenase-1 gene expression in mesangial cells. Datta PK, et al. **Kidney Int** 1999 May; 55(5):1734–9

Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Datta PK, et al. **Kidney Int** 1999 Aug;56(2):486–93

High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Glogowski EA, et al. **Kidney Int** 1999 Feb;55(2):486–99

Interleukin-1 stimulates Jun N-terminal/stress-activated protein kinase by an arachidonate-dependent mechanism in mesangial cells [see comments] Huang S, et al. **Kidney Int** 1999 May;55(5):1740–9. Comment in: Kidney Int 1999 May;55(5):2070–1.

Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kang MJ, et al. **Kidney Int** 1999 Jun;55(6):2203–14

IMMUNOLOGY

Anti-dsDNA autoantibody cross-reacts with the C-terminal hydrophobic cluster region containing phenylalanines in the acidic ribosomal phosphoprotein P1 to exert a cytostatic effect on the cells. Sun KH, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):334–9

Transcriptional regulation of the interleukin-6 gene in mesangial cells. Grassl C, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1466–77

The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. Sato T, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1242–52

A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Yoshikawa N, et al. **J Am Soc Nephrol** 1999 Jan;10(1):101–9

Expression and physical association of Fc alpha receptor and Fc receptor gamma chain in human mesangial cells. Suzuki Y, et al. **Nephrol Dial Transplant** 1999 May;14(5):1117–23

[Case of glomerular nephritis with C1q uniquely deposited in the mesangial region] Sato K, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1518–20 **(Jpn)**

METABOLISM

Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change. Bussolati B, et al. **Am J Pathol** 1999 Feb;154(2):623–32

Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals. Mooney A, et al. **Am J Pathol** 1999 Aug; 155(2):599–606

Shrinkage-induced activation of Na+/H+ exchange in rat renal mesangial cells. Bevensee MO, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):C674–83

Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells. Chansel D, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F535–42

Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Grewal JS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F922–30

Glucose transporters control gene expression of aldose reductase, PKCalpha, and GLUT1 in mesangial cells in vitro. Henry DN, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F97–104

LDL stimulates collagen mRNA synthesis in mesangial cells through induction of PKC and TGF-beta expression. Lee

HS, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):F369–76
Altered protein kinase C activation of Na+/Ca2+ exchange in mesangial cells from salt-sensitive rats. Mashburn NA, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):F574–80
Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose. Mogyorosi A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F827–32
AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Umino T, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F433–41
In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Isaac J, et al. **Amyloid** 1998 Dec;5(4):238–46
Signaling transduction pathway of angiotensin II in human mesangial cells: mediation of focal adhesion and GTPase activating proteins. Shikata Y, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):234–8
A multifunctional transcription factor (A1p145) regulates the smooth muscle phenotype in mesangial cells. Takeoka H, et al. **Biochem Biophys Res Commun** 1998 Nov 18; 252(2):290–5
Regulation of gene expression by alternative polyadenylation and mRNA instability in hyperglycaemic mesangial cells. Abdel Wahab N, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):405–11
Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. Frank S, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):367–74
Interleukin 1beta decreases prostacyclin synthase activity in rat mesangial cells via endogenous peroxynitrite formation. Zou MH, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):507–12
Association of TGF-beta signaling in angiotensin II-induced PAI-1 mRNA upregulation in mesangial cells: role of PKC. Motojima M, et al. **Biochim Biophys Acta** 1999 Apr 1;1449(3):217–26
The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. McLennan SV, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Feb;45(1):123–35 (87 ref.)
Low-density lipoproteins enhance transforming growth factor-beta 1 (TGF-beta 1) and monocyte chemotactic protein-1 (MCP-1) expression induced by cyclosporin in human mesangial cells. Di Paolo S, et al. **Clin Exp Immunol** 1999 Aug;117(2):355–60
Lysophosphatidic acid and mesangial cells: implications for renal diseases. Inoue CN, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):431–6 (40 ref.)
The mitogen-activated protein kinase p38 is necesssary for interleukin 1beta-induced monocyte chemoattractant protein 1 expression by human mesangial cells. Rovin BH, et al. **Cytokine** 1999 Feb;11(2):118–26
IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Lupia E, et al. **Diabetes** 1999 Aug;48(8):1638–44
Regulation of the laminin C1 promoter in cultured mesangial cells. Phillips SL, et al. **Diabetes** 1999 Oct;48(10):2083–9
Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Singh R, et al. **Diabetes** 1999 Oct;48(10):2066–73
Potentiating effects of hyper-osmolality and epidermal growth factor on the release of arachidonic acid in human glomerular mesangial cells. Sansom SC, et al. **Diabetes Res Clin Pract** 1999 Jan;43(1):21–31
Metabolic rates of 4-hydroxynonenal in tubular and mesangial cells of the kidney. Petras T, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):59–62
Identification of copper/zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats. Frank S, et al. **FASEB J** 1999 May;13(8):869–82
Binding affinity of sarpogrelate to 5-HT(2A) receptor ligand recognition sites in rat renal cortical and mesangial cells in culture. Nishio H, et al. **Gen Pharmacol** 1999 Jul; 33(1):51–7
Pressure oscillation regulates human mesangial cell growth and collagen synthesis. Mertens PR, et al. **Hypertension** 1998 Nov;32(5):945–52
Mesangial AT1 receptors: expression, signaling, and regulation. Ardaillou R, et al. **J Am Soc Nephrol** 1999 Jan; 10 Suppl 11:S40–6 (63 ref.)
Regulation of nuclear factor kappaB by corticosteroids in rat mesangial cells. Auwardt RB, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1620–8
Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. Baricos WH, et al. **J Am Soc Nephrol** 1999 Apr;10(4):790–5
Thrombin stimulates synthesis of type IV collagen and tissue inhibitor of metalloproteinases-1 by cultured human mesangial cells. Kaizuka M, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1516–23
Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. Mene P, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1478–86
Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. Noguchi K, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1815–25
Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. Pupilli C, et al. **J Am Soc Nephrol** 1999 Feb;10(2):245–55
Regulation of RANTES and ICAM-1 expression in murine mesangial cells. Satriano JA, et al. **J Am Soc Nephrol** 1997 Apr;8(4):596–603
Increases in ceramide levels in normal human mesangial cells subjected to different cellular stresses result from changes in distinct enzyme activities and can influence cellular responses to other stimuli. Sweeney EA, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):737–45
Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. Murphy M, et al. **J Biol Chem** 1999 Feb 26;274(9):5830–4
Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. Nelson PJ, et al. **J Cell Sci** 1999 Feb;112 (Pt 3):361–70
Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). Hiromura K, et al. **J Clin Invest** 1999 Mar;103(5):597–604
Expression of cysteine proteinases and their inhibitor, cystatin beta, in cultured rat mesangial cells. Makita Y, et al. **J Diabetes Complications** 1998 Nov-Dec;12(6):328–36
Gene expression and synthesis of natriuretic peptides by cultured human glomerular cells. Lai KN, et al. **J Hypertens** 1999 Apr;17(4):575–83
Chemokine amplification in mesangial cells. Luo Y, et al. **J Immunol** 1999 Oct 1;163(7):3985–92
Glucocorticoid effect on human mesangial cell cytoskeletal proteins. Koukouritaki SB, et al. **J Lab Clin Med** 1999 Apr; 133(4):378–83
Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy? Leung JC, et al. **J Lab Clin Med** 1999 Feb;133(2):152–60
Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. Shaykh M, et al. **J Lab Clin Med** 1999 Mar;133(3):302–8
Activation of STAT1 alpha by phosphatase inhibitor vanadate in glomerular mesangial cells: involvement of tyrosine and serine phosphorylation. Bardgette J, et al. **J Recept Signal Transduct Res** 1999 Sep;19(5):865–84
Mesangial cells from diabetic NOD mice constitutively express increased density of atrial natriuretic peptide C receptors. Ardaillou N, et al. **Kidney Int** 1999 Apr; 55(4):1293–302
Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Asano K, et al. **Kidney Int** 1999 Jun;55(6):2289–98
Ca2+ signaling induced by sphingosylphosphorylcholine and sphingosine 1-phosphate via distinct mechanisms in rat glomerular mesangial cells. Chen PF, et al. **Kidney Int** 1998 Nov;54(5):1470–83
Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Cortes P, et al. **Kidney Int** 1998 Dec;54(6):1985–98
IgA induced activation of human mesangial cells: independent of FcalphaR1 (CD 89). Diven SC, et al. **Kidney Int** 1998 Sep;54(3):837–47
Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Hoffman BB, et al. **Kidney Int** 1998 Oct; 54(4):1107–16
TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Inoki K, et al. **Kidney Int** 1999 May;55(5):1704–12
Serotonin enhances the production of type IV collagen by human mesangial cells. Kasho M, et al. **Kidney Int** 1998 Oct;54(4):1083–92
Role of intron 1 in smooth muscle alpha-actin transcriptional regulation in activated mesangial cells in vivo. Kawada N, et al. **Kidney Int** 1999 Jun;55(6):2338–48
Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kazes I, et al. **Kidney Int** 1998 Dec;54(6):1976–84
Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate. Nishimura M, et al. **Kidney Int** 1999 Feb;55(2):520–8
Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Oh JH, et al. **Kidney Int** 1998 Dec;54(6):1872–8
TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Riser BL, et al. **Kidney Int** 1999 Aug;56(2):428–39
Estradiol suppresses type I collagen synthesis in mesangial cells via activation of activator protein-1 [see comments] Silbiger S, et al. **Kidney Int** 1999 Apr;55(4):1268–76. Comment in: Kidney Int 1999 Apr;55(4):1577–9.
Shiga toxin 1 elicits diverse biologic responses in mesangial cells. Simon M, et al. **Kidney Int** 1998 Oct;54(4):1117–27
Regulation of smooth muscle alpha-actin expression and hypertrophy in cultured mesangial cells. Stephenson LA, et al. **Kidney Int** 1998 Oct;54(4):1175–87
c-Rel and p65 trans-activate the monocyte chemoattractant protein-1 gene in interleukin-1 stimulated mesangial cells. Stylianou E, et al. **Kidney Int** 1999 Sep;56(3):873–82
Identification of ceramide targets in interleukin-1 and tumor necrosis factor-alpha signaling in mesangial cells. Pfeilschifter J, et al. **Kidney Int Suppl** 1998 Sep;67:S34–9 (34 ref.)
Human mesangial cells express inducible macrophage scavenger receptor: an Ap-1 and ets mediated response. Ruan XZ, et al. **Kidney Int Suppl** 1999 Jul;71:S163–6
Rat mesangial cells express two unique isoforms of laminin which modulate mesangial cell phenotype. Hansen KM, et al. **Matrix Biol** 1998 Jun;17(2):117–30
Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells--possible role of osteopontin. Nagasaki T, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1861–6
Abnormal distribution of mesangium-specific laminin in glomeruli of patients with idiopathic membranous nephropathy. Horikoshi S, et al. **Nephron** 1999;81(3):284–8
Expression of the molecule detectable by anti-propolypeptide of von Willebrand factor antibody in rat mesangial cells in anti-Thy 1.1 mAb 1-22-3 induced glomerulonephritis: A marker of injured mesangial cells. Wakasugi M, et al. **Nephron** 1999;82(4):338–47
Evidence for a functional hepatocyte growth factor receptor in human mesangial cells. Kallincos NC, et al. **Regul Pept** 1998 Jun 30;74(2-3):137–42
Mycophenolic acid inhibits PDGF-induced osteopontin expression in rat mesangial cells. Wang W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1176–7
Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Herrera GA, et al. **Ultrastruct Pathol** 1999 Mar-Apr; 23(2):107–26
[Effect of platelet derived growth factor on the growth of human glomerular mesangial cells in vitro] Chen G, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):200–2 (Eng. Abstr.) **(Chi)**
[The effect of cationic ferritin to the permeability of renal glomerular basement membrane and the mesangial area] Li L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct; 26(5):301–2 (Eng. Abstr.) **(Chi)**
[The relationship between tumor necrosis factor and glomerular mesangial cells] Liu Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):203–6 (Eng. Abstr.) **(Chi)**
[Informative value of immunomembrane indicator of glomerulonephritis activity and effectiveness of membranostabiliser dimephosphon] Sigitova ON, et al. **Ter Arkh** 1999;71(6):39–42 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Fibrillary glomerulonephritis in a renal allograft. Palanichamy V, et al. **Am J Kidney Dis** 1998 Nov;32(5):E4
Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Gambaro G, et al. **Am J Nephrol** 1999;19(4):530–4
Nephrotic mice (ICGN strain): a model of diffuse mesangial sclerosis in infantile nephrotic syndrome. Mizuno S, et al. **Am J Nephrol** 1999;19(1):73–82
Lifelong prevention of mesangial enlargement by whole pancreas transplantation in rats with diabetes mellitus. Orloff LA, et al. **Arch Surg** 1999 Aug;134(8):889–97
Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. Yoshimura A, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2027–39
Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. Ziswiler R, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2055–66
Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). Hiromura K, et al. **J Clin Invest** 1999 Mar;103(5):597–604
Carbamylated proteins activate glomerular mesangial cells and stimulate collagen deposition. Shaykh M, et al. **J Lab Clin Med** 1999 Mar;133(3):302–8
Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. Sasaki S, et al. **J Pathol** 1999 Mar;187(4):481–9
A rare case of patent ductus arteriosus in a dog with glomerular mesangiolysis. Katayama K, et al. **J Vet Med Sci** 1998 Nov;60(11):1263–4
Role of mesangial cell damage in progressive renal disease. Shimizu F, et al. **Kidney Blood Press Res** 1999;22(1-2):5–12 (34 ref.)
Dissociation of mesangial cell migration and proliferation in experimental glomerulonephritis. Haseley LA, et al. **Kidney Int** 1999 Sep;56(3):964–72
L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Peters H, et al. **Kidney Int** 1999 Jun; 55(6):2264–73
Regulation of smooth muscle alpha-actin expression and hypertrophy in cultured mesangial cells. Stephenson LA, et al. **Kidney Int** 1998 Oct;54(4):1175–87
Changes in the pattern of fibronectin mRNA alternative splicing in acute experimental mesangioproliferative nephritis. Alonso J, et al. **Lab Invest** 1999 Feb;79(2):185–94
Protection against nitric oxide-induced apoptosis in rat mesangial cells demands mitogen-activated protein kinases and reduced glutathione. Sandau KB, et al. **Mol Pharmacol** 1999 Oct;56(4):744–51
Mesangial hyperplasia in a patient with renovascular hypertension and proteinuria [letter; comment] Schiller A, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2704–5. Comment on: Nephrol Dial Transplant 1998 Jun;13(6):1562–4.

Thin glomerular basement membranes in patients with hematuria and minimal change disease. Marquez B, et al. **Ultrastruct Pathol** 1999 May-Jun;23(3):149-56
[Thin membrane nephropathy: 27 cases] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):736-9 (Eng. Abstr.) **(Chi)**
[Effect of Astragalus Angelica mixture on serum lipids and glomerulosclerosis in rats with nephrotic syndrome] Lu Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Aug;17(8):478-80 (Eng. Abstr.) **(Chi)**
[Severity of glomerular damage with IgA nephropathy and renal prognosis: a comparison between pattern classification and calculated classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):329-35 (Eng. Abstr.) **(Jpn)**
[Evaluation of the severity of glomerular damage in IgA nephropathy: significance of hyaline glomeruli in pattern classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):336-43 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways. Bassa BV, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):F328-37
Resistance to TNF-alpha cytotoxicity can be achieved through different signaling pathways in rat mesangial cells. Guo YL, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C435-41
Tumor necrosis factor-alpha and ceramide induce cell death through different mechanisms in rat mesangial cells. Guo YL, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F390-7
Inactivation of kinase cascades in mesangial cells grown on collagen type I. Miralem T, et al. **Am J Physiol** 1998 Oct; 275(4 Pt 2):F585-94
Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Schulze-Lohoff E, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F962-71
Effects of cytosolic Ca2+ on membrane voltage and conductance of cultured mesangial cells from stroke-prone spontaneously hypertensive rats and WKY rats. Nakagawa K, et al. **Biochem Biophys Res Commun** 1999 Mar 16; 256(2):273-7
Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Ishida T, et al. **Diabetes** 1999 Mar; 48(3):595-602
Mesangial matrix modulation and glomerulosclerosis. Fogo AB. **Exp Nephrol** 1999 Mar-Apr;7(2):147-59 (107 ref.)
Mesangial cells and their adhesive properties. Pröls F, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):137-46 (77 ref.)
Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. Gruden G, et al. **J Am Soc Nephrol** 1999 Apr;10(4):730-7
A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner. Abe H, et al. **J Biol Chem** 1999 Jul 23;274(30):20874-8
Effect of trace levels of nigericin on intracellular pH and acid-base transport in rat renal mesangial cells. Bevensee MO, et al. **J Membr Biol** 1999 May 15;169(2):131-9
Role of glomerular endothelial damage in progressive renal disease. Yamanaka N, et al. **Kidney Blood Press Res** 1999; 22(1-2):13-20 (60 ref.)
Hydrogen peroxide activates ion currents in rat mesangial cells. Gloy J, et al. **Kidney Int** 1999 Jul;56(1):181-9
Activation of mesangial cell signaling cascades in response to mechanical strain. Ingram AJ, et al. **Kidney Int** 1999 Feb;55(2):476-85
Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Ishibashi R, et al. **Kidney Int** 1999 Aug;56(2):589-600
The central role of nuclear factor-kappa B in mesangial cell activation. Massy ZA, et al. **Kidney Int Suppl** 1999 Jul; 71:S76-9 (23 ref.)
Influence of osmotic stress on heat shock proteins 25 and 72 in mouse mesangial cells. Müller E, et al. **Kidney Int Suppl** 1998 Sep;67:S162-4
Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Ruiz-Ortega M, et al. **Kidney Int Suppl** 1998 Dec;68:S41-5
Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications [editorial] Cortes P, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1351-4
Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Wang ZQ, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3052-7
Angiotensin II maintains the structure and function of glomerular mesangium via type 1a receptor. What we have learned from null mutant mice minus the angiotensin II type 1a receptor gene. Inokuchi S, et al. **Virchows Arch** 1998 Oct;433(4):349-57

RADIATION EFFECTS

Irradiation of rat mesangial cells alters the expression of gene products associated with the development of renal fibrosis. Zhao W, et al. **Radiat Res** 1999 Aug;152(2):160-9

ULTRASTRUCTURE

Familial lobular glomerulopathy: first case report in Asia. Sato H, et al. **Am J Kidney Dis** 1998 Jun;31(6):E3
The antioxidant N-acetylcysteine induces mesangial cells to create three-dimensional cytoarchitecture that underlies cellular differentiation. Kitamura M. **J Am Soc Nephrol** 1999 Apr;10(4):746-51
The terminal sequence of complement plays an essential role in antibody-mediated renal cell apoptosis. Sato T, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1242-52

GLOMERULONEPHRITIS

see related
KIDNEY FAILURE, CHRONIC

A syndrome of immune complex glomerulonephritis and ophthalmic abnormalities. Amirlak I, et al. **J Med Genet** 1999 Aug;36(8):641-4
Glomerulonephritis. Couser WG. **Lancet** 1999 May 1; 353(9163):1509-15 (39 ref.)
[Progresses in the study of nephrology in China, 1997] Zhang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):887-8 (0 ref.) **(Chi)**
[Acute post-streptococcal glomerulonephritis] Nishiyama J, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):541-4 (15 ref.) **(Jpn)**

BLOOD

The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis. Fujita T, et al. **Clin Immunol** 1999 Jul; 92(1):97-102
Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis. Nitta K, et al. **Clin Nephrol** 1999 Aug;52(2):76-82
Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Templar J, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):946-51
The serum cystatin C concentration measured by particle-enhanced immunonephelometry is well correlated with inulin clearance in patients with various types of glomerulonephritis [letter] Hayashi T, et al. **Nephron** 1999; 82(1):90-2
Hemostasis, platelet functions, serotonin and serum lipids during omega-3 fatty acid treatment in patients with glomerulonephritis [letter] Malyszko JS, et al. **Nephron** 1998 Sep;80(1):94-6
Serum vascular endothelial growth factor concentration in rapidly progressive glomerulonephritis [letter] Nitta K, et al. **Nephron** 1998 Nov;80(3):357-8
The role of blood platelets in glomerulonephritis. Myśliwiec M. **Przegl Lek** 1998;55 Suppl 1:24-7 (10 ref.) **(Eng, Pol)**
Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Chrzanowska M, et al. **Ther Drug Monit** 1999 Apr;21(2):231-7
[Platelet dysfunction and pregnancy in gestational exacerbation of chronic glomerulonephritis] Kozlovskaia NL, et al. **Ter Arkh** 1999;71(6):43-5 (Eng. Abstr.) **(Rus)**
[Spectrofluorometric analysis of protein fractions of blood serum of health donors and patients with kidney diseases] Parkhomenko TV, et al. **Tsitologiia** 1998;40(8-9):786-91 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test. Brik R, et al. **Am J Nephrol** 1998;18(5):430-2
Role of free radicals in the pathogenesis of lipid-induced glomerulosclerosis in rats [published erratum appears in Kidney Int 1999 Aug;56(2):780] Ishiyama A, et al. **Kidney Int** 1999 Apr;55(4):1348-58
Antiglomerular basement membrane antibody-mediated glomerulonephritis after intranasal cocaine use. Peces R, et al. **Nephron** 1999;81(4):434-8
Exposure to hydrocarbons and renal disease: an experimental animal model. Mutti A, et al. **Ren Fail** 1999 May-Jul; 21(3-4):369-85
The hemolytic uremic syndrome as a complication of adriamycin nephropathy. Viero RM, et al. **Ren Fail** 1998 Jul;20(4):565-71
Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. Zanetta G, et al. **Transplantation** 1999 May 27;67(10):1376-8
[Extra-capillary glomerulonephritis induced by D-penicillamine therapy (letter)] Marlier S, et al. **Presse Med** 1999 Apr 3;28(13):689-90 **(Fre)**
[A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves' disease] Kawasaki Y, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):612-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Novel classification of glomerulonephritis in the monograph of Franz Volhard and Theodor Fahr. Fogazzi GB, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2965-7
[The importance of a new classification of chronic glomerulonephritis for determining the prognosis of the disease] Ratner MIa, et al. **Arkh Patol** 1998 Nov-Dec; 60(6):30-2 (Eng. Abstr.) **(Rus)**
[Implication of clinical and morphological types of chronic glomerulonephritis, tubulointerstitial changes in prognosis of disease progression Ratner MIa, et al. **Klin Med (Mosk)** 1999;77(1):30-3 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Anders HJ, et al. **Am J Kidney Dis** 1999 Apr;33(4):e3
Interferon therapy: a double-edged sword? [editorial; comment] Cattran DC. **Am J Kidney Dis** 1999 Jun; 33(6):1174-6. Comment on: Am J Kidney Dis 1999 Jun;33(6):1040-8. Comment on: Am J Kidney Dis 1999 Jun;33(6):1142-6.
Intraglomerular monocyte infiltration and immune deposits in diffuse lupus glomerulonephritis. Ichiryu MS, et al. **Am J Kidney Dis** 1999 May;33(5):866-71
Fibrillary glomerulonephritis and Charcot-Marie-Tooth disease. Nadal MA, et al. **Am J Kidney Dis** 1998 Nov; 32(5):E3
Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy [see comments] Ohta S, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1040-8. Comment in: Am J Kidney Dis 1999 Jun;33(6):1174-6.
Sequential development of anti-GBM nephritis and ANCA-associated Pauci-immune glomerulonephritis. Verburgh CA, et al. **Am J Kidney Dis** 1999 Aug;34(2):344-8
Castleman's disease with Kaposi's sarcoma and glomerulonephritis [letter] Chim CS, et al. **Am J Med** 1999 Aug;107(2):186-8
Chronic rheumatoid arthritis complicated by myeloperoxidase antineutrophil cytoplasmic antibody-associated nephritis. Yorioka N, et al. **Am J Nephrol** 1999;19(4):527-9
Psoriasis and glomerulonephritis [letter] Kim M, et al. **Clin Exp Dermatol** 1998 Nov;23(6):295-6
Acute rheumatic pancarditis associated with poststreptococcal acute glomerulonephritis: a patient report. Kakkera DR, et al. **Clin Pediatr (Phila)** 1998 Sep; 37(9):569-72 (11 ref.)
Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43-55; discussion 55-63 (92 ref.)
Pregnancy aggravates proteinuria in subclinical glomerulonephritis in the rat. Faas MM, et al. **J Lab Clin Med** 1999 Sep;134(3):267-74
The patient with two renal diseases: crescentic glomerulonephritis and renal AA amyloid. Bernheim J, et al. **Nephrol Dial Transplant** 1999 May;14(5):1315-6
Glomerulonephritis in mixed cryoglobulinaemia: what treatment? [editorial] Campise M, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):281-3 (13 ref.)
Simultaneous occurrence of fibrillary glomerulopathy and AL amyloid. Dussol B, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2630-2
Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Fabrizi F, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1991-7
Microscopic polyangiitis associated with non-Hodgkin's lymphoma [letter] Garcia Parés D, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1038-40
Proteinase-3-antineutrophil cytoplasmic antibody (PR3-ANCA) positive crescentic glomerulonephritis in a patient with Down's syndrome and infectious endocarditis. Haseyama T, et al. **Nephrol Dial Transplant** 1998 Aug; 13(8):2142-6
Sjögren's syndrome complicated by MPO-ANCA positive crescentic glomerulonephritis [letter] Kamachi M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1033-4
Rapidly progressive glomerulonephritis in a patient with advanced renal cell carcinoma. Sommer M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2107-9
Coincidence of haemolytic uraemic syndrome and c-ANCA-associated rapidly progressive glomerulonephritis. Stefanidis I, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1818-21
Crescentic glomerulonephritis associated with membranous nephropathy in a case with primary Sjögren's syndrome. Tatsumi H, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2624-7
Fibrillary glomerulonephritis occurring in association with hereditary angioneurotic oedema, pernicious anaemia and hypothyroidism. Whitaker G, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1822-4
Takayasu's arteritis coexisting with Wegener's granulomatosis in a teenager with renal insufficiency: case report. Mejia-Hernandez C, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):385-8
Frequency of microscopic hematuria in acute poststreptococcal glomerulonephritis [letter] Bircan Z, et al. **Pediatr Nephrol** 1999 Apr;13(3):269-70
Crescentic glomerulonephritis in hyper IgD syndrome. Tsimaratos M, et al. **Pediatr Nephrol** 1999 Feb;13(2):132-4
[Clinical thinking and decision-making in practice. A patient with arthritis, skin lesions and a perforated nasal septum] Braam B, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7; 143(32):1653-8 (Eng. Abstr.) **(Dut)**
[Association of acute pericarditis and acute renal insufficiency: causes and prognosis] Klisnick A, et al.

Presse Med 1998 Oct 31;27(33):1668–73 (41 ref.) (Eng. Abstr.) **(Fre)**

[Rapid clinical course of glomerulonephritis accompanying postinfectious reactive arthritis] Gindzienska-Sieskiewicz E, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):147–8 (Eng. Abstr.) **(Pol)**

[Values of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part I. Establishing individual norms for glomerular hematuria] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):277–9 (16 ref.) (Eng. Abstr.) **(Pol)**

[Value of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part II: Analysis of factors modifying morphology of erythrocytes in urine sediment] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):280–4 (Eng. Abstr.) **(Pol)**

[Glomerulonephritis associated with hepatitis c virus infection] Lopes LM, et al. **Rev Soc Bras Med Trop** 1999 Jan-Feb;32(1):1–6 (Eng. Abstr.) **(Por)**

[A case of chronic glomerulonephritis nephrotic form remission complicated by nephrotic crisis and sepsis] Trigulova VS, et al. **Ter Arkh** 1999;71(6):72–3 **(Rus)**

[The characteristics of the lesions of the esophagogastroduodenal area in patients with chronic glomerulonephritis who have experienced the effect of ionizing radiation] Moiseienko VO. **Lik Sprava** 1998 Jun; (4):12–5 (Eng. Abstr.) **(Ukr)**

DIAGNOSIS

Fibrillary glomerulonephritis in siblings. Chan TM, et al. **Am J Kidney Dis** 1998 May;31(5):E4

Fibrillary glomerulonephritis and Charcot-Marie-Tooth disease. Nadal MA, et al. **Am J Kidney Dis** 1998 Nov; 32(5):E3

Fibrillary glomerulonephritis in a renal allograft. Palanichamy V, et al. **Am J Kidney Dis** 1998 Nov;32(5):E4

A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paucksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Splenic lymphoma presenting as necrotizing glomerulonephritis. Messiaen T, et al. **Clin Nephrol** 1998 Dec;50(6):387–9

Determination of glomerular permselectivity: is it useful for diagnosis and clinical management of patients with glomerular disease? Mayer G. **Kidney Blood Press Res** 1998; 21(2–4):267–8 (11 ref.)

Hypercholesterolemia and glomerular diseases in urinary screening of school children. Asami T, et al. **Pediatr Nephrol** 1999 Feb;13(2):125–8

[Etiology and therapy of acute progressive glomerulonephritis] Yamaguchi N, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1254–62 (9 ref.) **(Jpn)**

[Value of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part II: Analysis of factors modifying morphology of erythrocytes in urine sediment] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):280–4 (Eng. Abstr.) **(Pol)**

[Values of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part I. Establishing individual norms for glomerular hematuria] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):277–9 (16 ref.) (Eng. Abstr.) **(Pol)**

[Implication of clinical and morphological types of chronic glomerulonephritis, tubulointerstitial changes in prognosis of disease progression Ratner MIa, et al. **Klin Med (Mosk)** 1999;77(1):30–3 (Eng. Abstr.) **(Rus)**

DIET THERAPY

Hemostasis, platelet functions, serotonin and serum lipids during omega-3 fatty acid treatment in patients with glomerulonephritis [letter] Malyszko JS, et al. **Nephron** 1998 Sep;80(1):94–6

DRUG THERAPY

Cyclosporine treatment of glomerular diseases. Klein M, et al. **Annu Rev Med** 1999;50:1–15 (69 ref.)

Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review. Le Moing V, et al. **Clin Infect Dis** 1999 May;28(5):1057–61 (32 ref.)

Delayed pubertal growth spurt and normal adult height attainment in boys receiving long-term alternate-day prednisone therapy. Polito C, et al. **Clin Pediatr (Phila)** 1999 May;38(5):279–85

Macrophage depletion by albumin microencapsulated clodronate: attenuation of cytokine release in macrophage-dependent glomerulonephritis. D'Souza MJ, et al. **Drug Dev Ind Pharm** 1999 May;25(5):591–6

Angiotensin II type I receptor antagonist suppresses proteinuria and glomerular lesions in experimental nephritis. Nagamatsu T, et al. **Eur J Pharmacol** 1999 Jun 11;374(1):93–101

Corticosteroid therapy in glomerulonephritis [editorial; comment] Shigematsu H. **Intern Med** 1998 Aug;37(8):651 . Comment on: Intern Med 1998 Jul;37(7):585–91.

Sensitized cells come of age: a new era in renal immunology with important therapeutic implications [editorial; comment] Couser WG. **J Am Soc Nephrol** 1999 Mar; 10(3):664–5 (21 ref.). Comment on: J Am Soc Nephrol 1999 Mar;10(3):499–506.

Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. Seto M, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1367–76

Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. Ziswiler R, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2055–66

Effects of candesartan on the proteinuria of chronic glomerulonephritis. Kurokawa K. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S57–60; discussion S61

New approaches to modify glomerular inflammation. Kluth DC, et al. **J Nephrol** 1999 Mar-Apr;12(2):66–75 (101 ref.)

Superoxide-mediated glomerulopathy in the endotoxin-treated pregnant rat. Faas MM, et al. **Kidney Blood Press Res** 1998;21(6):432–7

Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Cook HT, et al. **Kidney Int** 1999 Apr; 55(4):1319–26

MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Guasch A, et al. **Kidney Int** 1999 Jul;56(1):261–7

Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis. Peters H, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:22–3

Marked bradycardia due to pulsed and oral methylprednisolone therapy in a patient with rapidly progressive glomerulonephritis [letter] Küçükosmanoğlu O, et al. **Nephron** 1998 Dec;80(4):484

Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. Nakahama H, et al. **Nephron** 1999;81(4):421–7

Effect of a novel immunosuppressant, FK 506, on autoimmune glomerulonephritis in Brown Norway rats. Nakahama H, et al. **Nephron** 1999 Feb;81(2):215–20

Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. Uhlenius N, et al. **Nephron** 1999 Feb;81(2):221–9

Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis. De La Torre M, et al. **Transplant Proc** 1998 Dec;30(8):3952–4

[Factors analysis of pregnancy success in chronic glomerulus diseases] Zhang J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):75–7 (Eng. Abstr.) **(Chi)**

[Treatment of nephrosis in the child] Loirat C, et al. **Arch Pediatr** 1998;5 Suppl 2:142s–149s (72 ref.) **(Fre)**

[Effects of deoxyspergualin on proliferative glomerulonephritis] Hotta O, et al. **Nippon Jinzo Gakkai Shi** 1999 Jan;41(1):21–8 (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

[The pathomorphology of the kidneys in the fetuses of mothers suffering from late gestosis, type-1 diabetes mellitus and chronic glomerulonephritis] Iakovtsova AF, et al. **Arkh Patol** 1998 Nov-Dec;60(6):33–6 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. Franssen CF, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1506–15

Role of xanthine oxidase in passive Heymann nephritis in rats. Gwinner W, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):538–44

[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis] Kutyrina IM, et al. **Ter Arkh** 1999;71(6):30–4 (Eng. Abstr.) **(Rus)**

[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis] Andreenko GV, et al. **Vestn Ross Akad Med Nauk** 1999;(2):58–61 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

The changing pattern of glomerulonephritis in Singapore over the past two decades. Woo KT, et al. **Clin Nephrol** 1999 Aug;52(2):96–102

Renal disease in the elderly. Davison AM. **Contrib Nephrol** 1998;124:126–37; discussion 137–45 (42 ref.)

The epidemiology and prognosis of glomerulonephritis in Denmark 1985–1997. Heaf J, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1889–97

Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Research Group on Progressive Chronic Renal Disease. **Nephron** 1999;82(3):205–13

[Glomerulonephritis in the general medical statistical reporting of Ukraine] Pyrih LA, et al. **Lik Sprava** 1998 Jun;(4):165–8 **(Ukr)**

ETIOLOGY

Pauci-immune rapidly progressive glomerulonephritis after nephrectomy in a renal donor. Gulati MS, et al. **Am J Kidney Dis** 1999 Feb;33(2):E9

MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. Messiaen T, et al. **Am J Kidney Dis** 1998 Nov;32(5):E6

Glomerulonephritis in a patient with complement factor I deficiency. Sadallah S, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1153–7

Crescentic glomerulonephritis developing 3 months after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Takeuchi M, et al. **Bone Marrow Transplant** 1998 Oct;22(7):725–7

Infectious endocarditis, vasculitis, and glomerulonephritis [letter; comment] Collazos J, et al. **Clin Infect Dis** 1999 Jun;28(6):1342–3. Comment on: Clin Infect Dis 1998 Jul;27(1):224–5.

Immunopathogenesis of crescentic glomerulonephritis. Tipping PG, et al. **Curr Opin Nephrol Hypertens** 1999 May; 8(3):281–6 (50 ref.)

IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Kitching AR, et al. **Eur J Immunol** 1999 Jan;29(1):1–10

Granulomatous glomerulonephritis in intravenous drug users: a report of three cases in oxycodone addicts. Segal A, et al. **Hum Pathol** 1998 Nov;29(11):1246–9

Glomerulonephritis in autopsy cases with hepatitis C virus infection [see comments] Arase Y, et al. **Intern Med** 1998 Oct;37(10):836–40. Comment in: Intern Med 1998 Oct;37(10):800–1.

Effect of renovascular hypertension on experimental glomerulonephritis in rats. Wenzel UO, et al. **J Lab Clin Med** 1999 Sep;134(3):292–303

Growth hormone and somatostatin in glomerular injury. Baud L, et al. **J Nephrol** 1999 Jan-Feb;12(1):18–23 (65 ref.)

Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis [see comments] Cockwell P, et al. **Kidney Int** 1999 Mar; 55(3):852–63. Comment in: Kidney Int 1999 Mar;55(3):1125–7.

Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. Cu GA, et al. **Kidney Int** 1998 Sep; 54(3):819–26

Evidence of lectin complement pathway activation in poststreptococcal glomerulonephritis [letter] Ohsawa I, et al. **Kidney Int** 1999 Sep;56(3):1158–9

ANCA: fuel for the fire or the spark that ignites the flame? [editorial; comment] Salant DJ. **Kidney Int** 1999 Mar; 55(3):1125–7 (15 ref.). Comment on: Kidney Int 1999 Mar;55(3):852–63.

Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Suzuki Y, et al. **Kidney Int** 1998 Oct;54(4):1166–74

MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Wada T, et al. **Kidney Int** 1999 Sep;56(3):995–1003

Glomerulonephritis [letter] Durand JM, et al. **Lancet** 1999 Jul 31;354(9176):428–9

Henoch-Schönlein purpura associated with segmental and focal proliferative glomerulonephritis in a patient with Hodgkin's disease. Blanco P, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):179–80

Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Briggs JD, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):564–5

Myofibroblasts and the progression of crescentic glomerulonephritis. Goumenos D, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1652–61

Acute nephrotoxic serum nephritis in complement knockout mice: relative roles of the classical and alternate pathways in neutrophil recruitment and proteinuria. Hébert MJ, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2799–803

Pathophysiology of ANCA-associated glomerulonephritis. Muller Kobold AC, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1366–75 (105 ref.)

The heterogeneity of glomerulonephritis associated with HIV [letter] Rivera M, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):244–5

Seizures as the presenting feature of post-streptococcal glomerulonephritis [letter] Roussos L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1034–5

Fulminant ulcerative colitis associated with both masseter muscle myositis and immunoglobulin M nephropathy. Ishiwada N, et al. **Pediatr Int** 1999 Aug;41(4):385–8

Nitric oxide and glomerulonephritis. Cattell V. **Semin Nephrol** 1999 May;19(3):277–87 (68 ref.)

[An experience of treatment of double positive myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) and anti-glomerular basement membrane antibodies in Goodpasture's syndrome onset of crescentic glomerulonephritis] Takeda T, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):591–6 (Eng. Abstr.) **(Jpn)**

[Immune complex-mediated glomerulonephritis associated with infective endocarditis with aortic valve vegetation] Yoshida K, et al. **Nippon Jinzo Gakkai Shi** 1998 Jul; 40(5):359–63 (Eng. Abstr.) **(Jpn)**

[Etiology and therapy of secondary chronic glomerulonephritis] Sugisaki T. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1277–86 (17 ref.) **(Jpn)**

[The characteristics of the pathogenesis and clinical forms of the course of glomerulonephritis in adolescent patients] Dudar IO. **Lik Sprava** 1999 Apr-May;(3):115–8 (Eng. Abstr.) **(Ukr)**

GENETICS

Familial fibrillary glomerulopathies: what is the role of fibronectin? Hildebrandt F, et al.
Adv Nephrol Necker Hosp 1998;28:429–37 (16 ref.)

Fibrillary glomerulonephritis in siblings. Chan TM, et al.
Am J Kidney Dis 1998 May;31(5):E4

Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Nowack R, et al.
Am J Kidney Dis 1999 Aug;34(2):364–73 (99 ref.)

Familial lobular glomerulopathy: first case report in Asia. Sato H, et al. **Am J Kidney Dis** 1998 Jun;31(6):E3

Deletion polymorphism of the angiotensin converting enzyme gene predicts persistent proteinuria in Henoch-Schönlein purpura nephritis. Yoshioka T, et al. **Arch Dis Child** 1998 Nov;79(5):394–9

Glomerular inflammation: use of genetically deficient mice to elucidate the roles of leukocyte adhesion molecules and Fc-gamma receptors in vivo. Mayadas TN, et al.
Curr Opin Nephrol Hypertens 1999 May;8(3):293–8 (26 ref.)

Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. Wagner J, et al. **J Am Soc Nephrol** 1999 Mar;10(3):545–51

Apolipoprotein E epsilon 4 allele and nephrotic glomerular diseases in children. Asami T, et al. **Pediatr Nephrol** 1999 Apr;13(3):233–6

HISTORY

The concept of 'glomerulonephritis': the fascinating history of evolution and emergence of a specialist's nosology focus on Italy and Torino. Stratta P, et al. **Am J Nephrol** 1999; 19(1):83–91

The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis [classical article] Lerner RA, et al., **J Am Soc Nephrol** 1999 Jun; 10(6):1389–404

The description of renal 'arterio-capillary fibrosis' by William W. Gull. Fogazzi GB. **Nephrol Dial Transplant** 1999 May; 14(5):1327–9

Bright's disease and albuminuria as seen by the famous neurologist Jean-Martin Charcot. Fogazzi GB.
Nephrol Dial Transplant 1998 Sep;13(9):2407–8

IMMUNOLOGY

SIV-associated nephropathy in rhesus macaques infected with lymphocyte-tropic SIVmac239. Gattone VH 2nd, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1163–80

Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft. Adams PL, et al.
Am J Kidney Dis 1999 Mar;33(3):552–4

A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Effect of estradiol and progesterone on the low-dose endotoxin-induced glomerular inflammatory response of the female rat. Faas MM, et al. **Am J Reprod Immunol** 1999 Mar;41(3):224–31

The role of sialidase in the development of hypocomplementemia in postinfectious acute glomerulonephritis. Fujita T, et al. **Clin Immunol** 1999 Jul; 92(1):97–102

Long-term follow-up of patients with isolated C3 nephritis [letter] Grcevska L, et al. **Clin Nephrol** 1998 Oct; 50(4):269–70

Glomerular inflammation: use of genetically deficient mice to elucidate the roles of leukocyte adhesion molecules and Fc-gamma receptors in vivo. Mayadas TN, et al.
Curr Opin Nephrol Hypertens 1999 May;8(3):293–8 (26 ref.)

Immunopathogenesis of crescentic glomerulonephritis. Tipping PG, et al. **Curr Opin Nephrol Hypertens** 1999 May; 8(3):281–6 (50 ref.)

Inducible nitric oxide synthase induction in Thy 1 glomerulonephritis is complement and reactive oxygen species dependent. Mosley K, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):26–34

Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice. Ryffel B, et al. **Int J Exp Pathol** 1998 Dec;79(6):453–60

Sensitized cells come of age: a new era in renal immunology with important therapeutic implications [editorial; comment] Couser WG. **J Am Soc Nephrol** 1999 Mar; 10(3):664–5 (21 ref.). Comment on: J Am Soc Nephrol 1999 Mar;10(3):499–506.

Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis [see comments] Cunningham MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):499–506. Comment in: J Am Soc Nephrol 1999 Mar;10(3):664–5.

In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. Franssen CF, et al.
J Am Soc Nephrol 1999 Jul;10(7):1506–15

Improved survival and amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1 knockout mice. Janssen U, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1805–14

IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. Kitching AR, et al. **J Am Soc Nephrol** 1999 Apr;10(4):752–9

The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats. Suzuki S, et al.
J Am Soc Nephrol 1999 Feb;10(2):264–70

All four putative ligand-binding domains in megalin contain pathogenic epitopes capable of inducing passive Heymann nephritis. Yamazaki H, et al. **J Am Soc Nephrol** 1998 Sep; 9(9):1638–44

Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis. Penny MJ, et al. **J Exp Med** 1998 Nov 16;188(10):1775–84

Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. Schiller B, et al. **J Exp Med** 1998 Oct 5;188(7):1353–8

Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. Allen AR, et al. **J Immunol** 1999 May 1;162(9):5519–27

CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. Kuroiwa T, et al.
J Immunol 1999 Aug 15;163(4):2168–75

The nephritogenic T cell response in murine chronic graft-versus-host disease. Meyers CM, et al. **J Immunol** 1998 Nov 15;161(10):5321–30

Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. Mitchell DA, et al. **J Immunol** 1999 May 15;162(10):5676–9

Autoantibodies to myeloperoxidase: clinical and pathophysiological significance. Kallenberg CG.
J Mol Med 1998 Sep;76(10):682–7 (38 ref.)

Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis [see comments] Cockwell P, et al. **Kidney Int** 1999 Mar; 55(3):852–63. Comment in: Kidney Int 1999 Mar;55(3):1125–7.

Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Feng L, et al. **Kidney Int** 1999 Aug; 56(2):612–20

Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Holdsworth SR, et al. **Kidney Int** 1999 Apr;55(4):1198–216

The concept of glomerular self-defense. Kitamura M, et al.
Kidney Int 1999 May;55(5):1639–71 (413 ref.)

Immunomodulatory effects of interferon-gamma on autoreactive nephritogenic T-cell clones. Meyers CM, et al. **Kidney Int** 1999 Apr;55(4):1395–406

Complement regulatory proteins in glomerular diseases. Nangaku M. **Kidney Int** 1998 Nov;54(5):1419–28 (112 ref.)

Evidence of lectin complement pathway activation in poststreptococcal glomerulonephritis [letter] Ohsawa I, et al. **Kidney Int** 1999 Sep;56(3):1158–9

ANCA: fuel for the fire or the spark that ignites the flame? [editorial; comment] Salant DJ. **Kidney Int** 1999 Mar; 55(3):1125–7 (15 ref.). Comment on: Kidney Int 1999 Mar;55(3):852–63.

Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Topham PS, et al. **Kidney Int** 1999 May;55(5):1763–75

MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Wada T, et al. **Kidney Int** 1999 Sep;56(3):995–1003

Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Le Hir M, et al. **Lab Invest** 1998 Dec;78(12):1625–31

Proteinase-3-antineutrophil cytoplasmic antibody (PR3-ANCA) positive crescentic glomerulonephritis in a patient with Down's syndrome and infectious endocarditis. Haseyama T, et al. **Nephrol Dial Transplant** 1998 Aug; 13(8):2142–6

Sjögren's syndrome complicated by MPO-ANCA positive crescentic glomerulonephritis [letter] Kamachi M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1033–4

Coincidence of haemolytic uraemic syndrome and c-ANCA-associated rapidly progressive glomerulonephritis. Stefanidis I, et al.
Nephrol Dial Transplant 1998 Jul;13(7):1818–21

Effect of a novel immunosuppressant, FK 506, on autoimmune glomerulonephritis in Brown Norway rats. Nakahama H, et al. **Nephron** 1999 Feb;81(2):215–20

Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Sano H, et al. **Nephron** 1998 Oct; 80(2):153–61

Immune complex disease associated with Epstein-Barr virus infectious mononucleosis. Lande MB, et al.
Pediatr Nephrol 1998 Oct;12(8):651–3

Immunopathogenesis of glomerulonephritis; the importance of new concepts for clinical practice. Klinger M.
Przegl Lek 1998;55 Suppl 1:17–8 **(Eng, Pol)**

A new immunoelectron microscopy approach for the detection of immunoglobulin and complement deposits in epoxy-embedded renal biopsies. Brorson SH, et al.
Ultrastruct Pathol 1998 Nov-Dec;22(6):449–57

[Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D] Kyndt X, et al.
Presse Med 1999 Jan 16;28(2):67–70 (Eng. Abstr.) **(Fre)**

[Fc receptor redux: the role of immunoglobulin receptor (FcR) in glomerulonephritis] Ra C, et al.
Nippon Naika Gakkai Zasshi 1998 Aug 10;87(8):1568–76 (19 ref.) **(Jpn)**

[Case of glomerular nephritis with C1q uniquely deposited in the mesangial region] Sato K, et al.
Nippon Naika Gakkai Zasshi 1999 Aug 10;88(8):1518–20 **(Jpn)**

[Anti-neutrophil cytoplasmic antibodies ANCA in glomerulonephritis and systemic vasculitis with renal involvement--the frequency of occurrence and ability for granulocyte activation in vitro] Mazanowska O, et al.
Pol Arch Med Wewn 1998 May;99(5):390–7 (Eng. Abstr.) **(Pol)**

METABOLISM

Plasma and urine levels of adrenomedullin and proadrenomedullin N-terminal 20 peptide in chronic glomerulonephritis. Kinoshita H, et al.
Am J Kidney Dis 1999 Jul;34(1):114–9

T lymphocyte adhesion mechanisms within inflamed human kidney: studies with a Stamper-Woodruff assay. Chakravorty SJ, et al. **Am J Pathol** 1999 Feb;154(2):503–14

Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Floege J, et al.
Am J Pathol 1999 Jan;154(1):169–79

Down-regulation of PTH/PTHrP receptor in the kidney of patients with renal impairment. Chen J, et al.
Chin Med J (Engl) 1998 Jan;111(1):24–7

Analysis of nitric oxide in the exhaled air of patients with chronic glomerulonephritis. Kakoki M, et al.
Clin Nephrol 1999 Aug;52(2):83–90

Inducible nitric oxide synthase induction in Thy 1 glomerulonephritis is complement and reactive oxygen species dependent. Mosley K, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):26–34

Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. Raats CJ, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1689–99

Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis. Yamamoto T, et al.
J Am Soc Nephrol 1998 Dec;9(12):2253–61

Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. Allen AR, et al. **J Immunol** 1999 May 1;162(9):5519–27

Are there new activity markers of glomerular inflammation? A renal pathologist's view. Kashgarian M.
Kidney Blood Press Res 1998;21(2-4):215–6 (11 ref.)

Changes in glomerular thromboxane A2 receptor expression and ligand binding following immune injury. Bresnahan BA, et al. **Kidney Int** 1999 Jan;55(1):139–47

In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Cockwell P, et al. **Kidney Int** 1998 Sep; 54(3):827–36

Tissue factor pathway inhibitor expression in human crescentic glomerulonephritis. Cunningham MA, et al.
Kidney Int 1999 Apr;55(4):1311–8

MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Guasch A, et al. **Kidney Int** 1999 Jul;56(1):261–7

High expression of erythropoietin receptor in human chronic progressive glomerulonephritis [letter] Ikegaya N, et al.
Kidney Int 1999 Sep;56(3):1159–60

Role of free radicals in the pathogenesis of lipid-induced glomerulosclerosis in rats [published erratum appears in Kidney Int 1999 Aug;56(2):780] Ishiyama A, et al.
Kidney Int 1999 Apr;55(4):1348–58

Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Schneider A, et al.
Kidney Int 1999 Jul;56(1):135–44

Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis [see comments] Schneider A, et al. **Kidney Int** 1999 Feb; 55(2):430–41. Comment in: Kidney Int 1999 Feb;55(2):738–9.

Glomerular lipids in non-hereditary forms of glomerulopathy/glomerulonephritis. Gröne HJ.
Nephrol Dial Transplant 1999 Jun;14(6):1595–8

Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Lhotta K, et al.
Nephrol Dial Transplant 1999 Apr;14(4):881–6

Urine IgG2/IgG4-ratio indicates the significance of the charge selective properties of the glomerular capillary wall for the macromolecular transport in glomerular diseases. Tencer J, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1425–9

Glomerulonephritis and sodium retention: enhancement of Na+/K+-ATPase activity in the collecting duct is shared by rats with puromycin induced nephrotic syndrome and mice with spontaneous lupus-like glomerulonephritis. Zolty E, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2192–5

Plasma and urinary levels of adrenomedullin in chronic glomerulonephritis patients with proteinuria. Kubo A, et al. **Nephron** 1998 Oct;80(2):227–30

Expression of the molecule detectable by anti-propolypeptide of von Willebrand factor antibody in rat mesangial cells in anti-Thy 1.1 mAb 1-22-3 induced glomerulonephritis: A marker of injured mesangial cells. Wakasugi M, et al.
Nephron 1999;82(4):338–47

Glomerular deposits and hypoalbuminemia in acute post-streptococcal glomerulonephritis. West CD, et al.
Pediatr Nephrol 1998 Aug;12(6):471–4

Variable expression of heparan sulfate epitopes in crescents

of human glomerulonephritis. Morita H, et al. **Virchows Arch** 1999 Feb;434(2):145–51

[Effects of immunosuppressor and cytostatic agents on the extracellular matrix production during experimental neuropathies] Krivoshchapov LG, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):584–7 **(Rus)**

[Relation between metabolism of trace elements and the antioxidant defense system in chronic nephropathies] Podracká L, et al. **Cas Lek Cesk** 1999 May 24;138(11):337–9 (Eng. Abstr.) **(Slo)**

MICROBIOLOGY

Post-infectious glomerulonephritis in a patient with Gemella haemolysans endocarditis [letter] Zingaro L, et al. **Am J Med** 1999 Jan;106(1):125–6

Streptococcus pyogenes strains containing emm12 and emm55 possess a novel gene coding for distantly related SIC protein. Hartas J, et al. **Microb Pathog** 1999 Jan; 26(1):25–33

Henoch-Schönlein purpura nephritis associated with methicillin-resistant Staphylococcus aureus infection [letter] Hirayama K, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2703–4

Methycillin-resistant Staphylococcus aureus-related glomerulonephritis. Kobayashi M, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:17–8

Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis--a novel hazard emerging on the horizon [editorial] Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):2999–3001 (14 ref.)

Frequency of microscopic hematuria in acute poststreptococcal glomerulonephritis [letter] Bircan Z, et al. **Pediatr Nephrol** 1999 Apr;13(3):269–70

MORTALITY

Has the prognosis for patients with pauci-immune necrotizing glomerulonephritis improved? McLaughlin K, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1696–701

PATHOLOGY

Hematuria, proteinuria, hypertension, and renal failure in a 10-year-old boy. Phillips CL, et al. **Am J Kidney Dis** 1999 Apr;33(4):814–9

Familial lobular glomerulopathy: first case report in Asia. Sato H, et al. **Am J Kidney Dis** 1998 Jun;31(6):E3

When noncongophilic glomerular fibrils do not represent fibrillary glomerulonephritis: nonspecific mesangial fibrils in sclerosing glomeruli. Kronz JD, et al. **Clin Nephrol** 1998 Oct;50(4):218–23

Role of tubule epithelial cells in the pathogenesis of tubulointerstitial fibrosis induced by glomerular disease [editorial] Healy E, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):525–30 (57 ref.)

Glomerulosclerosis: the role of interstitial myofibroblasts in its progression. el Nahas M, et al. **Curr Top Pathol** 1999; 93:167–71 (31 ref.)

Granulomatous glomerulonephritis in intravenous drug users: a report of three cases in oxycodone addicts. Segal A, et al. **Hum Pathol** 1998 Nov;29(11):1246–9

Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis [see comments] Cunningham MA, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):499–506. Comment in: J Am Soc Nephrol 1999 Mar;10(3):664–5.

IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. Kitching AR, et al. **J Am Soc Nephrol** 1999 Apr;10(4):752–9

Mast cells in rapidly progressive glomerulonephritis. Tóth T, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1498–505

Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. Yoshimura A, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2027–39

Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. Ziswiler R, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2055–66

CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-to-cell contact-dependent mechanisms. Kuroiwa T, et al. **J Immunol** 1999 Aug 15;163(4):2168–75

Crescentic glomerulonephritis: a clinicopathologic analysis of 17 cases with emphasis on glomerular and interstitial neutrophil infiltration. Suh KS, et al. **J Korean Med Sci** 1999 Jun;14(3):293–8

Are there new activity markers of glomerular inflammation? A renal pathologist's view. Kashgarian M. **Kidney Blood Press Res** 1998;21(2–4):215–6 (11 ref.)

Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Holdsworth SR, et al. **Kidney Int** 1999 Apr;55(4):1198–216

The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kim YG, et al. **Kidney Int** 1999 Jun; 55(6):2349–61

L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Peters H, et al. **Kidney Int** 1999 Jun; 55(6):2264–73

Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Hattori M, et al. **Kidney Int Suppl** 1999 Jul;71:S47–50

Control of monocyte influx in glomerulonephritis in transplanted kidneys in the rat. De Heer E, et al. **Lab Invest** 1998 Oct;78(10):1327–37

The patient with two renal diseases: crescentic glomerulonephritis and renal AA amyloid. Bernheim J, et al. **Nephrol Dial Transplant** 1999 May;14(5):1315–6

Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Ferrario F, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1627–31 (37 ref.)

Myofibroblasts and the progression of crescentic glomerulonephritis. Goumenos D, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1652–61

Antiglomerular basement membrane antibody-mediated glomerulonephritis after intranasal cocaine use. Peces R, et al. **Nephron** 1999;81(4):434–8

Fibrillary and immunotactoid glomerulopathies. Ferrario F, et al. **Ren Fail** 1998 Nov;20(6):801–8 (24 ref.)

The double or single renal graft depending on the percentage of glomerulosclerosis in the preimplant biopsy reduces the number of discarded kidneys from donors older than 60 years. Andrés A, et al. **Transplant Proc** 1999 Sep; 31(6):2285–6

[Clinical and pathological characteristics in Chinese patients with pauci-immune crescentic glomerulonephritis] Tang Z, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov; 36(11):740–3 (Eng. Abstr.) **(Chi)**

[Fibrillary glomerulopathy and immunotactoid glomerulopathy] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):782–4 (10 ref.) **(Chi)**

[Current topics in the renal pathology researches (editorial)] Guo M. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug; 26(4):196–9 **(Chi)**

[Case of immunotactoid glomerulopathy (ITG) associated with acute active glomerular lesion] Abe F, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1527–9 **(Jpn)**

[Prediction of accelerated progression of chronic glomerulonephritis basing on clinical and histomorphological data] Ratner MIa, et al. **Ter Arkh** 1999; 71(6):27–30 (Eng. Abstr.) **(Rus)**

[Informative value of immunomembrane indicator of glomerulonephritis activity and effectiveness of membranostabiliser dimephosphon] Sigitova ON, et al. **Ter Arkh** 1999;71(6):39–42 (Eng. Abstr.) **(Rus)**

[Histopathologic changes in the kidneys in patients with asymtomatic pathologic findings in urine] Hrvačević R, et al. **Vojnosanit Pregl** 1998 Sep-Oct;55(5):477–82 (Eng. Abstr.) **(Scc)**

PHYSIOPATHOLOGY

Crescentic glomerulonephritis developing 3 months after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Takeuchi M, et al. **Bone Marrow Transplant** 1998 Oct;22(7):725–7

Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Shu KH, et al. **Clin Nephrol** 1999 Jul;52(1):5–9

Glomerular podocytes and adhesive interaction with glomerular basement membrane. Mundel P, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):160–6 (44 ref.)

Mesangial cells and their adhesive properties. Pröls F, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):137–46 (77 ref.)

Leukocyte-endothelial cell interactions – lessons from knockout mice. Rosenkranz AR, et al. **Exp Nephrol** 1999 Mar-Apr;7(2):125–36 (122 ref.)

Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonephritis. Seto M, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1367–76

Macrophage activation and programming and its role for macrophage function in glomerular inflammation. Erwig LP, et al. **Kidney Blood Press Res** 1999;22(1-2):21–5 (46 ref.)

The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kim YG, et al. **Kidney Int** 1999 Jun; 55(6):2349–61

Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis [see comments] Schneider A, et al. **Kidney Int** 1999 Feb; 55(2):430–41. Comment in: Kidney Int 1999 Feb;55(2):738–9.

Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Suzuki Y, et al. **Kidney Int** 1998 Oct;54(4):1166–74

Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis. Clarkson MR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3043–51 (92 ref.)

Seizures as the presenting feature of post-streptococcal glomerulonephritis [letter] Roussos L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1034–5

Cytokine network and resident renal cells in glomerular diseases. Schena FP. **Nephrol Dial Transplant** 1999;14 Suppl 1:22–6 (46 ref.)

Rapidly progressive glomerulonephritis in a patient with advanced renal cell carcinoma. Sommer M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2107–9

Crescentic glomerulonephritis with normal renal function after 28 years of follow-up. Villa M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2671–3

The serum cystatin C concentration measured by particle-enhanced immunonephelometry is well correlated with inulin clearance in patients with various types of glomerulonephritis [letter] Hayashi T, et al. **Nephron** 1999; 82(1):90–2

The pathogenesis of progressive renal failure. Vleming LJ, et al. **Neth J Med** 1999 Mar;54(3):114–28 (200 ref.)

Progression of renal damage in chronic glomerulonephritis and the therapeutical implications. Schena FP. **Przegl Lek** 1998;55 Suppl 1:28

De novo and recurrent diseases: recurrent glomerulopathies. Charpentier B, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):264–6

The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Andresdottir MB, et al. **Transplantation** 1999 Sep 15;68(5):623–7

[Inflammatory mechanisms of renal fibrosis: glomerulonephritis] Baud L, et al. **Bull Acad Natl Med** 1999;183(1):23–31 (27 ref.) (Eng. Abstr.) **(Fre)**

[The restoration of cardiovascular system function in patients with chronic glomerulonephritis after the use in staged medical rehabilitation of measured therapeutic physical exercise] Hryshko VH. **Lik Sprava** 1998 Jul-Aug;(5):106–9 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. Penny MJ, et al. **J Am Soc Nephrol** 1998 Dec; 9(12):2272–82

The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats. Suzuki S, et al. **J Am Soc Nephrol** 1999 Feb;10(2):264–70

Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Feng L, et al. **Kidney Int** 1999 Aug; 56(2):612–20

Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Le Hir M, et al. **Lab Invest** 1998 Dec;78(12):1625–31

Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Johnston F, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):327–32

Vitamin E suppresses oxidative stress and glomerulosclerosis in rat remnant kidney. Hahn S, et al. **Pediatr Nephrol** 1999 Apr;13(3):195–8

[The prevention of autoimmune kidney lesions developing in long-term exposure to epoxy compounds] Li IaB. **Lik Sprava** 1998 Jul-Aug;(5):62–5 (Eng. Abstr.) **(Rus)**

REHABILITATION

[An efficacy study of the treatment of patients with chronic pyelonephritis and urolithiasis using sulfate-bicarbonate calcium-magnesium mineral water] Telina EN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jul-Aug;(4):26–8 (Eng. Abstr.) **(Rus)**

[The restoration of cardiovascular system function in patients with chronic glomerulonephritis after the use in staged medical rehabilitation of measured therapeutic physical exercise] Hryshko VH. **Lik Sprava** 1998 Jul-Aug;(5):106–9 (Eng. Abstr.) **(Ukr)**

SURGERY

Kidney transplantation in patients with vasculitis and predominant renal involvement. Bayés B, et al. **Transplant Proc** 1999 Sep;31(6):2324–5

De novo and recurrent diseases: recurrent glomerulopathies. Charpentier B, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):264–6

THERAPY

Interferon therapy: a double-edged sword? [editorial; comment] Cattran DC. **Am J Kidney Dis** 1999 Jun; 33(6):1174–6. Comment on: Am J Kidney Dis 1999 Jun;33(6):1040–8. Comment on: Am J Kidney Dis 1999 Jun;33(6):1142–6.

Role of interferon-alpha in the treatment of primary glomerulonephritis [see comments] Al-Wakeel J, et al. **Am J Kidney Dis** 1999 Jun;33(6):1142–6. Comment in: Am J Kidney Dis 1999 Jun;33(6):1174–6.

Plasmapheresis in treatment of acute oligoanuria in crescentic glomerulonephritis. Grcevska L, et al. **Artif Organs** 1998 Oct;22(10):827–30

Inflamed site-specific gene delivery using bone marrow-derived CD11b+CD18+ vehicle cells in mice. Yokoo T, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1731–8

Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Stegmayr BG, et al. **Int J Artif Organs** 1999 Feb;22(2):81–7

Determination of glomerular permselectivity: is it useful for diagnosis and clinical management of patients with glomerular disease? Mayer G. **Kidney Blood Press Res** 1998; 21(2-4):267–8 (11 ref.)

Gene therapy by transforming growth factor-beta

receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis [see comments] Isaka Y, et al. **Kidney Int** 1999 Feb;55(2):465-75 Comment in: Kidney Int 1999 Feb;55(2):740-1.

Evidence-based recommendations for the management of glomerulonephritis. Introduction. Cattran DC. **Kidney Int Suppl** 1999 Jun;70:S1-2 (8 ref.)

Glomerulonephritis [letter] Wardle EN. **Lancet** 1999 Jul 31; 354(9176):429

Macrophage migration inhibitory factor (MIF)--potential perspectives for immune-intervention in renal disease [editorial] Atkins RC, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2719-20

Glomerulonephritis in mixed cryoglobulinaemia: what treatment? [editorial] Campise M, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):281-3 (13 ref.)

Lupus profundus (panniculitis) in a chronic haemodialysis patient. Chen MT, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):966-8

Progression of renal damage in chronic glomerulonephritis and the therapeutical implications. Schena FP. **Przegl Lek** 1998;55 Suppl 1:28

Plasmapheresis in the treatment of rapidly progressive glomerulonephritis. Harada T, et al. **Ther Apher** 1997 Nov; 1(4):366-9

Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis. Kaplan AA. **Ther Apher** 1997 Aug;1(3):255-9 (47 ref.)

Plasmapheresis for removal of myeloperoxidase antineutrophil cytoplasmic antibodies: a case report. Yorioka N, et al. **Ther Apher** 1998 Nov;2(4):314-6

[Effects of danshen on solute transport by peritoneal dialysis] Liu F, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(3):237-9 (Eng. Abstr.) **(Chi)**

[Etiology and therapy of chronic primary glomerulonephritis] Dohi K, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1271-6 (6 ref.) **(Jpn)**

[Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov; 5(29):304-6 (14 ref.) (Eng. Abstr.) **(Pol)**

[The effect of reflexotherapy on the hemostatic system of patients with glomerulonephritis] Holub TI. **Lik Sprava** 1999 Apr-May;(3):157-61 (Eng. Abstr.) **(Ukr)**

URINE

Level of red blood cells in the urinary sediment reflects the degree of renal activity in Wegener's granulomatosis [see comments] Fujita T, et al. **Clin Nephrol** 1998 Nov; 50(5):284-8. Comment in: Clin Nephrol 1999 Jun;51(6):388-9.

Composition of the sugar moiety of Tamm-Horsfall protein in patients with urinary diseases. Olczak T, et al. **Int J Clin Lab Res** 1999;29(2):68-74

High serum IgE levels are associated with selective proteinuria in glomerulonephritis [letter] Pall AA, et al. **Kidney Int** 1999 Jul;56(1):351-3

The young lady with massive proteinuria, biopsy-confirmed steroid-resistant minimal change glomerulonephritis and episodes of turbid urine. Klemm A, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):231-2

[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis] Podorol'skaia LV, et al. **Vopr Med Khim** 1999 Mar-Apr;45(2):158-64 (Eng. Abstr.) **(Rus)**

VETERINARY

Immune reactivity following CD40L blockade: role in autoimmune glomerulonephritis in susceptible recipients. Banu N, et al. **Autoimmunity** 1999;30(1):21-33

Determination of bovine beta2-microglobulin and albumin in urine by a reversed-phase high-performance liquid chromatography. Nakajima Y, et al. **J Vet Med Sci** 1999 Jul;61(7):725-9

Glomerulosclerosis in captive cheetahs (Acinonyx jubatus). Bolton LA, et al. **Vet Pathol** 1999 Jan;36(1):14-22

VIROLOGY

SIV-associated nephropathy in rhesus macaques infected with lymphocyte-tropic SIVmac239. Gattone VH 2nd, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1163-80

Cytomegalovirus-induced necrotizing and crescentic glomerulonephritis in a renal transplant patient. Detwiler RK, et al. **Am J Kidney Dis** 1998 Nov;32(5):820-4

Epstein-Barr virus detection in kidney biopsy specimens correlates with glomerular mesangial injury. Iwama H, et al. **Am J Kidney Dis** 1998 Nov;32(5):785-93

Renal manifestations of hepatitis C infection. Daghestani L, et al. **Am J Med** 1999 Mar;106(3):347-54 (103 ref.)

Prevalence of hepatitis C virus antibodies in primary glomerulonephritis in Brazil. Lopes LM, et al. **Am J Nephrol** 1998;18(6):495-7

Parvovirus glomerulonephritis in a patient with sickle cell disease. Tolaymat A, et al. **Pediatr Nephrol** 1999 May; 13(4):340-2

GLOMERULONEPHRITIS, FOCAL SCLEROSING see **GLOMERULOSCLEROSIS, FOCAL**

GLOMERULONEPHRITIS, IGA

IgA nephropathy. From molecules to men. Tomino Y. **Contrib Nephrol** 1999;126:III-IX, 1-115

IgA nephropathy. Hunley TE, et al. **Curr Opin Pediatr** 1999 Apr;11(2):152-7 (56 ref.)

Berger disease: thirty years later. Davin JC, et al. **Eur J Pediatr** 1999 Jun;158(6):437-43 (87 ref.)

IgA nephropathy and pregnancy. Koido S, et al. **Tokai J Exp Clin Med** 1998 Mar;23(1):31-7

[HIV-associated nephropathy in children] Cachat F, et al. **Arch Pediatr** 1998 Dec;5(12):1353-8 (39 ref.) (Eng. Abstr.) **(Fre)**

[Results of a survey of the relationship between palatine tonsil and IgA nephropathy] Akagi H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Mar;102(3):305-10 (Eng. Abstr.) **(Jpn)**

BLOOD

Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy? Rostoker G, et al. **Clin Exp Immunol** 1998 Dec;114(3):468-76

IgA interaction with carboxy-terminal 43-kD fragment of fibronectin in IgA nephropathy. Waga S, et al. **J Am Soc Nephrol** 1999 Feb;10(2):256-63

Evaluation of serum lipid abnormalities in chronic nephritis. Hirano H, et al. **Kidney Int Suppl** 1999 Jul;71:S147-9

Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Roodnat JI, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):353-9

Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. van Zandbergen G, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3058-64

Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Matsumoto K, et al. **Nephron** 1999;82(1):32-8

Serum levels of soluble Fas and disease activity in patients with IgA nephropathy. Shou I, et al. **Nephron** 1999; 81(4):387-92

CLASSIFICATION

[Evaluation of the severity of glomerular damage in IgA nephropathy: significance of hyaline glomeruli in pattern classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):336-43 (Eng. Abstr.) **(Jpn)**

[Severity of glomerular damage with IgA nephropathy and renal prognosis: a comparison between pattern classification and calculated classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):329-35 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

IgA nephropathy in psoriasis. Ahuja TS, et al. **Am J Nephrol** 1998;18(5):425-9 (26 ref.)

Clinical features of Henoch-Schönlein purpura. Italian Group of Renal Immunopathology. Coppo R, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):143-50

Henoch-Schönlein nephritis in children and adults. Morphological features and clinicopathological correlations. Rieu P, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):151-9 (48 ref.)

Clinical features and natural history of IgA nephropathy [published erratum appears in Ann Med Interne (Paris) 1999 Apr;150(3):272] Rychlik I, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):117-26

Recurrence of IgA nephropathy after renal transplantation. van der Boog PJ, et al. **Ann Med Interne (Paris)** 1999 Feb; 150(2):137-42 (62 ref.)

Pernicious anemia and IgA nephropathy: a reply to Nunes et al. [letter] Campbell P. **Clin Nephrol** 1999 Jun;51(6):391-2

IgA glomerulonephritis associated with microscopic polyangiitis or Churg-Strauss syndrome. Richer C, et al. **Clin Nephrol** 1999 Jul;52(1):47-50

Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of hemolytic uremic syndrome with glomerular disease. Morita S, et al. **Intern Med** 1999 Jun;38(6):495-9 (27 ref.)

Acquired reactive perforating collagenosis with IgA nephropathy. Iwamoto I, et al. **J Dermatol** 1998 Sep; 25(9):597-600 (13 ref.)

IgA nephropathy in cystic fibrosis. Stirati G, et al. **J Nephrol** 1999 Jan-Feb;12(1):30-1

17-year-old female with IgA and abdominal pain: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Olay S, et al. **J Okla State Med Assoc** 1999 Feb;92(2):77-82

IgA nephropathy in a patient with systemic lupus erythematosus [letter] Basile C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1891-2

A case of Whipple's disease associated with acute Ebstein Barr virus hepatitis and Berger's disease [letter] Evrenkaya R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):241-2

Relapsing nephrotic syndrome in a patient with Kimura's disease and IgA glomerulonephritis. Natov SN, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2358-63

Simultaneous IgA nephropathy and Wegener's granulomatosis--overlap or coincidence (the role of renal biopsy). Vrtovsnik F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1266-7

Diffuse panbronchiolitis and IgA nephropathy: relation to bronchus-associated lymphoid tissue [letter] Kurihara I, et al. **Nephron** 1999;81(4):450-1

Increased urinary excretion of macrophage-colony-stimulating factor (M-CSF) in patients with IgA nephropathy: tonsil stimulation enhances urinary M-CSF excretion. Matsuda M, et al. **Nephron** 1999; 81(3):264-70

Renal failure due to IgA (Berger) nephropathy with inflammatory demyelinating polyradiculoneuropathy [letter] Nishida Y, et al. **Nephron** 1998 Sep;80(1):123-4

IgA nephropathy complicating diabetic glomerulosclerosis [letter; comment] Sessa A, et al. **Nephron** 1998 Dec; 80(4):488-9. Comment on: Nephron 1998;79(3):279-87.

[A case of relapsing polychondritis with IgA nephropathy] Satoh F, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Feb;21(1):41-7 (Eng. Abstr.) **(Jpn)**

[A case of myelodysplastic syndrome associated with IgA nephropathy] Hayashi S, et al. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):373-6 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The emerging spectrum of IgA-mediated renal diseases: is there an IgA variant of Goodpasture's syndrome? [editorial; comment] Lee SM, et al. **Am J Kidney Dis** 1999 Sep; 34(3):565-8. Comment on: Am J Kidney Dis 1999 Sep;34(3):549-55.

Correlations among expression of glomerular intercellular adhesion molecule 1 (ICAM-1), levels of serum soluble ICAM-1, and renal histopathology in patients with IgA nephropathy. Nguyen TT, et al. **Am J Nephrol** 1999; 19(4):495-9

Clinical features and natural history of IgA nephropathy [published erratum appears in Ann Med Interne (Paris) 1999 Apr;150(3):272] Rychlik I, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):117-26

Quantitative analysis of interleukin 6 (IL-6) in patients with IgA nephropathy after tonsillectomy. Baba Y, et al. **Auris Nasus Larynx** 1999 Apr;26(2):177-82

A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN). Auwardt R, et al. **Clin Nephrol** 1999 Jul;52(1):1-4

Neuropeptide Y Y1 receptor polymorphism as a prognostic predictor in Japanese patients with IgA nephropathy. Ito H, et al. **Clin Nephrol** 1999 May;51(5):272-9

New diagnostic and therapeutic aspects in IgA nephropathy. Floege J. **Kidney Blood Press Res** 1998;21(2-4):283-5 (14 ref.)

Simultaneous IgA nephropathy and Wegener's granulomatosis--overlap or coincidence (the role of renal biopsy). Vrtovsnik F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1266-7

Drunken driving and renal failure--do you see a link? Wagner J, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):1019-20

IgA glomerulonephritis with irregular intramembranous dense deposits. Katz A, et al. **Nephron** 1998 Nov; 80(3):340-3

[Diagnostic value of serum IGA-fibronectin aggregates to IGA nephropathy] Wei L, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):83-6 (Eng. Abstr.) **(Chi)**

[Primary IgA nephropathy in the child: natural history, epidemiology and prognostic factors] Boudailliez B, et al. **Arch Pediatr** 1998;5 Suppl 2:150s-152s (14 ref.) **(Fre)**

["Nothing in the lungs, all in the kidneys!"] Andres E, et al. **Rev Med Interne** 1999;20 Suppl 2:315s-316s **(Fre)**

[A case of subclinical IgA nephropathy and cyclosporin associated arteriolopathy diagnosed by non-episode biopsy of graft kidney after renal transplantation] Namba Y, et al. **Hinyokika Kiyo** 1999 May;45(5):349-53 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Russo D, et al. **Am J Kidney Dis** 1999 May; 33(5):851-6

ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Remuzzi A, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F457-66

Treatment of immunoglobulin A nephropathy. Schiele J, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):127-36 (71 ref.)

Is cyclosporine A safe in IgA nephropathy and nephrotic syndrome? [letter] Révai T, et al. **Clin Nephrol** 1999 Jul; 52(1):66

Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Buemi M, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):649-52

The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. Donadio JV Jr, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1772-7

The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. Perico N, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2308-17

A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Yoshikawa N, et al. **J Am Soc Nephrol** 1999 Jan;10(1):101-9

Inhibition of activated human mesangial cell proliferation by the natural product of Cordyceps sinensis (H1-A): an implication for treatment of IgA mesangial nephropathy. Lin CY, et al. **J Lab Clin Med** 1999 Jan;133(1):55-63

TCM differential treatment of 30 cases of IgA nephropathy. Xie T, et al. **J Tradit Chin Med** 1997 Dec;17(4):243-6

Management of IgA nephropathy: evidence-based recommendations. Nolin L, et al. **Kidney Int Suppl** 1999 Jun;70:S56-62 (56 ref.)

Corticosteroids in IgA nephropathy [letter; comment] Ashman N, et al. **Lancet** 1999 Jun 19;353(9170):2159-60. Comment on: Lancet 1999 Mar 13;353(9156):883-7.

Treatment of IgA nephropathy [comment] Harper L, et al. **Lancet** 1999 Mar 13;353(9156):860-2. Comment on: Lancet 1999 Mar 13;353(9156):883-7.

Corticosteroids in IgA nephropathy: a randomised controlled trial [see comments] Pozzi C, et al. **Lancet** 1999 Mar 13; 353(9156):883-7. Comment in: Lancet 1999 Mar 13;353(9156):860-2. Comment in: Lancet 1999 Jun 19;353(9170):2159-60.

The patient with IgA glomerulonephritis--what is the role of steroid treatment? [editorial] Locatelli F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1057-60 (12 ref.)

Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients? Yoshikawa N, et al. **Nephrol Dial Transplant** 1999 May;14(5):1097-9

Influence of alpha-tocopherol over the time course of experimental IgA nephropathy. Kuemmerle NB, et al. **Pediatr Nephrol** 1999 Feb;13(2):108-12

[Comparative study of the reno-protective effect of short- and long-acting antihypertensive agents in IgA nephropathy] Vas T, et al. **Orv Hetil** 1999 Sep 5; 140(36):1991-5 (Eng. Abstr.) **(Hun)**

[Small cell lung cancer associated with nephrotic syndrome: remission after chemotherapy] Tomoda K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jun;36(6):541-4 (20 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Prognosis of tonsillectomy in patients with IgA nephropathy. Akagi H, et al. **Acta Otolaryngol Suppl** 1999;540:64-6

ETIOLOGY

Association of IgA nephropathy with Clostridium difficile colitis. Gaughan WJ, et al. **Am J Kidney Dis** 1999 Oct; 34(4):e16

Risk factors for IgA nephropathy: a case-control study in Japan. Wakai K, et al. **Am J Kidney Dis** 1999 Apr; 33(4):738-45

The relevance of experimental models in the pathogenetic investigation of primary IgA nephropathy. Montinaro V, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):99-107 (94 ref.)

Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Montenegro V, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):265-72 (103 ref.)

Structural features of IgA molecules which contribute to IgA nephropathy. Feehally J, et al. **J Nephrol** 1999 Mar-Apr; 12(2):59-65 (30 ref.)

Combined administration of IgA and IgG anti-Thy-1 antibodies enhances renal inflammation in rats. Van Dixhoorn MG, et al. **Kidney Int** 1999 Jun;55(6):2299-309

Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients. Italian Group of Renal Immunopathology. Amoroso A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3184-8

Expression and physical association of Fc alpha receptor and Fc receptor gamma chain in human mesangial cells. Suzuki Y, et al. **Nephrol Dial Transplant** 1999 May;14(5):1117-23

IgA nephropathy in mice following repeated administration of conjugated Haemophilus influenzae type B vaccine (PRP-T). Kavukçu S, et al. **Tokai J Exp Clin Med** 1997 Oct;22(4):167-74

GENETICS

Association of a T-cell receptor constant alpha chain gene polymorphism with progression of IgA nephropathy in Japanese patients. Deenitchina SS, et al. **Am J Kidney Dis** 1999 Aug;34(2):279-88

Familial clustering of IgA nephropathy: further evidence in an Italian population. Scolari F, et al. **Am J Kidney Dis** 1999 May;33(5):857-65

Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population. Stratta P, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1071-9

Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Tanaka R, et al. **Am J Kidney Dis** 1999 Aug;34(2):289-95

A case of IgA nephropathy in three sisters with thin basement membrane disease. Yoshida K, et al. **Am J Nephrol** 1998; 18(5):422-4

Genetic factors in IgA nephropathy. Schmidt S, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):86-90 (47 ref.)

Association of angiotensin-converting enzyme gene polymorphism and renal pathology in Japanese children with IgA nephropathy. Asano T, et al. **Clin Nephrol** 1999 Jun;51(6):335-40

Effects of lisinopril administration on blood bcl-2 concentrations in patients with immunoglobulin A nephropathy. Buemi M, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):649-52

Familial IgA nephropathy. Scolari F. **J Nephrol** 1999 Jul-Aug;12(4):213-9 (79 ref.)

Conserved T-cell receptor beta chain CDR3 sequences in IgA nephropathy biopsies. Wu H, et al. **Kidney Int** 1999 Jan;55(1):109-19

The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Greer MR, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1980-3

[Pathogenesis of IgA nephropathies] Davin JC. **Rev Med Liege** 1998 Jul;53(7):437-40 (48 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Barratt J, et al. **Am J Kidney Dis** 1999 Jun;33(6):1049-57

Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody [see comments] Fervenza FC, et al. **Am J Kidney Dis** 1999 Sep;34(3):549-55. Comment in: Am J Kidney Dis 1999 Sep;34(3):565-8.

IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Ots M, et al. **Am J Nephrol** 1999;19(4):453-8

Pathogenesis of IgA nephropathy. Feehally J, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):91-8 (39 ref.)

Enhanced expression of L-selectin on peripheral blood lymphocytes from patients with IgA nephropathy. Kennel-de March A, et al. **Clin Exp Immunol** 1999 Mar; 115(3):542-6

Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Montenegro V, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):265-72 (103 ref.)

Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies. Yan D, et al. **Food Chem Toxicol** 1998 Dec; 36(12):1095-106

A case of aortitis syndrome and IgA nephropathy: possible role of human leukocyte antigens in both diseases. Kanahara K, et al. **Hiroshima J Med Sci** 1999 Mar; 48(1):25-9

Late expression of tumor necrosis factor-alpha is markedly depressed in patients with IgA nephropathy. Bull RL, et al. **Immunol Invest** 1998 Jul-Sep;27(4-5):243-55

Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. Franssen CF, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1915-23

Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. Hiki Y, et al. **J Am Soc Nephrol** 1999 Apr;10(4):760-9

Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). Westerhuis R, et al. **J Am Soc Nephrol** 1999 Apr;10(4):770-8

Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. Tomana M, et al. **J Clin Invest** 1999 Jul;104(1):73-81

Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Rantala I, et al. **Kidney Int** 1999 Jun;55(6):2274-80

Conserved T-cell receptor beta chain CDR3 sequences in IgA nephropathy biopsies. Wu H, et al. **Kidney Int** 1999 Jan;55(1):109-19

Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: effects against deterioration of renal function. A Biomedicine and Health Research Concerted Action. Coppo R. **Nephrol Dial Transplant** 1999 Apr; 14(4):840-1 (17 ref.)

Exposed peptide core of IgA1 hinge region in IgA nephropathy. Kokubo T, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):81-5

Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Roodnat JI, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):353-9

Expression and physical association of Fc alpha receptor and Fc receptor gamma chain in human mesangial cells. Suzuki Y, et al. **Nephrol Dial Transplant** 1999 May;14(5):1117-23

Expression of Fas antigen on CD4 subsets in peripheral blood from patients with IgA nephropathy [letter; comment] Sato M, et al. **Nephron** 1999;81(3):349-50. Comment on: Nephron 1992;60(4):397-403.

The immunopathogenesis of IgA-nephropathy. Floege J. **Przegl Lek** 1998;55 Suppl 1:19-21

[Pathogenesis of IgA nephropathies] Davin JC. **Rev Med Liege** 1998 Jul;53(7):437-40 (48 ref.) (Eng. Abstr.) **(Fre)**

[Isolation of glomerular IgA deposits from biopsied kidney tissues of patients with IgA nephritis and analysis of the antibody specificity of IgA] Ogawa Y. **Hokkaido Igaku Zasshi** 1999 May;74(3):217-30 (Eng. Abstr.) **(Jpn)**

[Anti-myeloperoxidase and anti-lactoferrin antibodies in patients with IgA nephropathy and Henoch-Schönlein purpura] Nishiya K, et al. **Rinsho Byori** 1999 Feb; 47(2):185-7 (Eng. Abstr.) **(Jpn)**

METABOLISM

Expression of interferon-inducible Mx-proteins in patients with IgA nephropathy or Henoch-Schönlein purpura. Floege J, et al. **Am J Kidney Dis** 1999 Mar;33(3):434-40

ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Remuzzi A, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F457-66

Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. Allen AC, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1763-71

Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy? Leung JC, et al. **J Lab Clin Med** 1999 Feb;133(2):152-60

Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy. Allen AC. **J Nephrol** 1999 Mar-Apr;12(2):76-84 (46 ref.)

Enhanced interstitial expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Ando Y, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1408-17

Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Endo M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1984-90

Transforming growth factor-beta, endothelin-1, and c-fos expression in necrotizing/crescentic IgA glomerulonephritis. Rastaldi MP, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1668-74

A case of IgA nephropathy with split reduction of alpha5(V) chain of type IV collagen in glomerular basement membrane [letter] Horita S, et al. **Nephron** 1998 Dec; 80(4):482-3

Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Matsuda M, et al. **Nephron** 1998 Dec;80(4):408-13

VCAM-1, ICAM-1, and E-selectin in IgA nephropathy and Schönlein-Henoch syndrome: differences between tissue expression and serum concentration. Mrowka C, et al. **Nephron** 1999;81(3):256-63

Coexpression of collagens and collagen-binding heat shock protein 47 in human diabetic nephropathy and IgA nephropathy. Razzaque MS, et al. **Nephron** 1998 Dec; 80(4):434-43

Interleukin-6 localization and the prognosis of IgA nephropathy. Taniguchi Y, et al. **Nephron** 1999 Jan; 81(1):94-8

[Distribution of fibronectin in kidney of IgA nephropathy and its clinicopathological correlation] Shi Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun;36(6):390-3 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

Role of chlamydia pneumoniae (TWAR) in IgA nephropathy [letter] Chen M, et al. **Nephron** 1998 Sep;80(1):92

PATHOLOGY

Clinical features of Henoch-Schönlein purpura. Italian Group of Renal Immunopathology. Coppo R, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):143-50

Morphological features in IgA nephropathy. Ferrario F, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):108-16 (65 ref.)

The relevance of experimental models in the pathogenetic investigation of primary IgA nephropathy. Montinaro V, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):99-107 (94 ref.)

Association of angiotensin-converting enzyme gene polymorphism and renal pathology in Japanese children with IgA nephropathy. Asano T, et al. **Clin Nephrol** 1999 Jun;51(6):335-40

Tenascin expression may reflect the activity and chronicity of human IgA nephropathy. Masaki T, et al. **Clin Nephrol** 1998 Oct;50(4):205-13

Significance of medial hypertrophy of blood vessels in IgA nephritis [letter] Woo KT, et al. **Clin Nephrol** 1999 Feb; 51(2):132

Glomerular basement membrane thickness in primary diffuse IgA nephropathy: ultrastructural morphometric analysis. Danilewicz M, et al. **Int Urol Nephrol** 1998;30(4):513-9

Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. Suzuki D, et al. **J Am Soc Nephrol** 1999 Apr;10(4):822-32

A quantitative study of mesangial deposits and glomerular monocytes/macrophages in IgA-nephropathy and proliferative mesangial (non-IgA) glomerulonephritis. Danilewicz M, et al. **J Nephrol** 1998 Sep-Oct;11(5):255-60

Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Ehara T, et al. **Kidney Int** 1998 Nov; 54(5):1675-83

Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Rantala I, et al. **Kidney Int** 1999 Jun;55(6):2274-80

Uteroglobin is essential in preventing immunoglobulin A

nephropathy in mice. Zheng F, et al. **Nat Med** 1999 Sep; 5(9):1018–25

Does circulating erythropoietin reflect progression of IgA nephropathy? Comparison with urinary N-acetyl-beta-D-glucosaminidase. Machiguchi T, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):635–40

cANCA positivity in a case of IgA glomerulonephritis (IgAGN) with necrotizing lesions [letter] Rollino C, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):797–8

IgM/IgA nephropathy in callitrichids: antigen studies. Brack M, et al. **Nephron** 1999;82(3):221–31

IgA glomerulonephritis with irregular intramembranous dense deposits. Katz A, et al. **Nephron** 1998 Nov; 80(3):340–3

Glomerular hypertrophy as a prognostic marker in childhood IgA nephropathy. Tóth T, et al. **Nephron** 1998 Nov; 80(3):285–91

Glomerular membranopathy in children with IgA nephropathy and Henoch Schönlein purpura. Vogler C, et al. **Pediatr Dev Pathol** 1999 May–Jun;2(3):227–35

Morphometric analysis of glomerular and interstitial lesions in idiopathic IgA nephropathy and Schoenlein–Henoch nephritis. Danilewicz M, et al. **Pol J Pathol** 1998; 49(4):303–7

Age-related histologic alterations after prednisolone therapy in children with IgA nephropathy. Tanaka H, et al. **Tohoku J Exp Med** 1998 Aug;185(4):247–52

[Importance of the duration from the onset of a urinary abnormality until a biopsy is performed: a multivariate analysis on the application of renal biopsy for patients with IgA nephropathy] Kiyoshi Y, et al. **Nippon Jinzo Gakkai Shi** 1998 Sep;40(7):547–54 (Eng. Abstr.) **(Jpn)**

[Evaluation of the severity of glomerular damage in IgA nephropathy: significance of hyaline glomeruli in pattern classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):336–43 (Eng. Abstr.) **(Jpn)**

[Severity of glomerular damage with IgA nephropathy and renal prognosis: a comparison between pattern classification and calculated classification] Kiyoshi Y. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):329–35 (Eng. Abstr.) **(Jpn)**

[A clinicopathological study of recurrent IgA nephropathy following renal transplantation] Matsugami K, et al. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):322–8 (Eng. Abstr.) **(Jpn)**

[Relationship between glomerular epithelial cell injury and proteinuria in IgA nephropathy] Wakai S, et al. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):315–21 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. Ritz E, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1798–804

Macrophage migration inhibitory factor in IgA nephropathy [letter] Taniguchi Y, et al. **Kidney Int** 1998 Dec; 54(6):2245–6

Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch–Schoenlein patients. Italian Group of Renal Immunopathology. Amoroso A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3184–8

Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Csiky B, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):86–90

Role of T cells in murine IgA nephropathy. Nagasawa R, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:12–3 (3 ref.)

Current concepts and controversies in IgA nephropathy. Waldo FB, et al. **Pediatr Nephrol** 1998 Aug;12(6):498–504 (69 ref.)

Is IgA nephropathy in renal transplants a risk leading to graft failure? Sakurai T, et al. **Transplant Proc** 1999 Sep; 31(6):2651–4

PREVENTION & CONTROL

Tonsillectomy does not prevent a progressive course in IgA nephropathy. Rasche FM, et al. **Clin Nephrol** 1999 Mar; 51(3):147–52

SURGERY

Recurrence of IgA nephropathy after renal transplantation. van der Boog PJ, et al. **Ann Med Interne (Paris)** 1999 Feb; 150(2):137–42 (62 ref.)

Clinical risk factors for recurrence of IgA nephropathy. Freese P, et al. **Clin Transplant** 1999 Aug;13(4):313–7

The use of mycophenolate mofetil (Cellcept) in renal transplantation. Vanrenterghem Y. **Contrib Nephrol** 1998; 124:64–9; discussion 69–75 (31 ref.)

Recurrent IgA nephropathy after kidney transplantation: not a benign condition [editorial] Floege J, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1933–5 (14 ref.)

Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension. Di Paolo S, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1357–8

[Therapeutic effects and prognostic factors of tonsillectomy for IgA nephropathy in long-term follow-up] Hattori K. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Dec;101(12):1412–22 (Eng. Abstr.) **(Jpn)**

[Long-term prognosis for tonsillectomy patients with IgA nephropathy] Kosaka M. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Jul;101(7):916–23 (Eng. Abstr.) **(Jpn)**

THERAPY

New diagnostic and therapeutic aspects in IgA nephropathy. Floege J. **Kidney Blood Press Res** 1998;21(2–4):283–5 (14 ref.)

The immunopathogenesis of IgA-nephropathy. Floege J. **Przegl Lek** 1998;55 Suppl 1:19–21

Treatment of mesangial immunoglobulin A glomerulonephritis. Kincaid-Smith P. **Semin Nephrol** 1999 Mar;19(2):166–72 (52 ref.)

URINE

Increased urinary excretion of macrophage-colony-stimulating factor (M-CSF) in patients with IgA nephropathy: tonsil stimulation enhances urinary M-CSF excretion. Matsuda M, et al. **Nephron** 1999; 81(3):264–70

GLOMERULONEPHRITIS, LUPUS see **LUPUS NEPHRITIS**

GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE

Prolonged asymptomatic dense deposit disease in Chinese. Report of 2 cases in Taiwan. Mao T, et al. **Am J Nephrol** 1998;18(5):464–8

BLOOD

High prevalence of hepatitis C virus antibodies in older patients with membranoproliferative glomerulonephritis [letter] Ohsawa I, et al. **Nephron** 1999;82(4):366–7

CHEMICALLY INDUCED

Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin [letter] Kistler A, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):243–4

COMPLICATIONS

Membranoproliferative glomerulonephritis with subendothelial deposits (type 1) associated with hepatitis G virus infection in a renal transplant recipient. Berthoux P, et al. **Am J Nephrol** 1999;19(4):513–8

Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus-related mixed cryoglobulinemia. Gómez-Tello V, et al. **Intensive Care Med** 1999 Mar; 25(3):319–22

Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. Cheng JT, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1566–74

The pregnant patient with partial lipodystrophy developing acute renal failure—onset of de novo membranoproliferative glomerulonephritis. Demetriou K, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2121–4

Membranoproliferative glomerulonephritis and gastric adenocarcinoma [letter] Enriquez R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):242–3

Mesangiocapillary glomerulonephritis in a patient with Nocardia pneumonia. Jose MD, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2628–9

Nephrotic syndrome secondary to primary immunoglobulin-G mesangioproliferative glomerulonephritis [letter] Sepandj F, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1889–90

Cutaneous telangiectasias, sparse hair, and type I membranoproliferative glomerulonephritis. Gupta IR, et al. **Pediatr Nephrol** 1999 Feb;13(2):129–31

Glomerulonephritis without IgA deposits in a case of Henoch-Schönlein purpura. Tanaka H, et al. **Pediatr Nephrol** 1999 Sep;13(7):597–9

[Subretinal neovascular membranes in membranoproliferative glomerulonephritis type II] Framme C, et al. **Klin Monatsbl Augenheilkd** 1998 Oct;213(4):252–3 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Prediction in idiopathic membranous nephropathy. Marx BE, et al. **Kidney Int** 1999 Aug;56(2):666–73

DRUG THERAPY

Successful treatment with steroid pulse therapy in a case of immunotactoid glomerulopathy with hypocomplementemia. Kurihara I, et al. **Am J Kidney Dis** 1998 Jul;32(1):E4

Interferon toxicity in hepatitis C virus-associated type II cryoglobulinemia [letter] Di Lullo L, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):506

Failure of cyclosporin therapy in type II mixed cryoglobulinemia associated with hepatitis C virus infection [letter] Horsmans Y, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):514–5

Cyclophosphamide therapy in a patient with membranoproliferative glomerulonephritis and essential mixed cryoglobulinaemia. Abu-Shakra M, et al. **Clin Rheumatol** 1998;17(5):395–6

Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Chen YM, et al. **Kidney Int** 1999 Sep; 56(3):932–43

Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Nakamura T, et al. **Kidney Int** 1999 Mar;55(3):877–89

Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Peters H, et al. **Kidney Int** 1998 Nov; 54(5):1570–80

Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Misiani R, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1558–60

[Experimental treatment of rhubarb on mesangio-proliferative glomerulonephritis in rats] Wei J, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):87–9 (Eng. Abstr.) **(Chi)**

[Effects of low-molecular-weight heparin on proliferative glomerulonephritis] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):731–5 (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

Enhanced expression of membrane type-1 matrix metalloproteinase in mesangial proliferative glomerulonephritis. Hayashi K, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2262–71

Different activation of mitogen-activated protein kinases in experimental proliferative glomerulonephritis. Bokemeyer D, et al. **Kidney Int Suppl** 1998 Sep;67:S189–91

The alternative pathway C3 convertase and glomerular deposits. West CD, et al. **Pediatr Nephrol** 1999 Jun; 13(5):448–53 (41 ref.)

ETIOLOGY

Nephrotic syndrome with mesangial proliferative glomerulonephritis induced by multiple wasp stings. Tauk B, et al. **Am J Nephrol** 1999;19(1):70–2

Hepatitis virus and glomerulonephritis [editorial; comment] Yamabe H. **Intern Med** 1998 Oct;37(10):800–1. Comment on: Intern Med 1998 Oct;37(10):836–40.

Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. Markowitz GS, et al. **J Am Soc Nephrol** 1998 Dec; 9(12):2244–52

Role of thrombin in mesangial proliferative glomerulonephritis [letter] Kitamoto Y, et al. **Kidney Int** 1998 Nov;54(5):1767–8

Glomerulonephritis [letter] Durand JM, et al. **Lancet** 1999 Jul 31;354(9176):428–9

Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Abbas NA, et al. **Nephrol Dial Transplant** 1999 May;14(5):1272–5

Reversal of c-ANCA positive mesangiocapillary glomerulonephritis after removal of an infected cysto-atrial shunt. Bonarek H, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1771–3

Remission of HBV-related mesangioproliferative glomerulonephritis after interferon therapy. Dhiman RK, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):176–8

Cryoglobulinaemia, membranoproliferative glomerulonephritis and pANCA in a patient treated with carbamazepine [letter] Lhotta K, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1890–1

Glomerulonephritis without IgA deposits in a case of Henoch-Schönlein purpura. Tanaka H, et al. **Pediatr Nephrol** 1999 Sep;13(7):597–9

Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Jha V, et al. **Ren Fail** 1998 Nov;20(6):845–50

[Extrahepatic manifestations of hepatitis C virus] Tohme A, et al. **J Med Liban** 1998 Mar–Apr;46(2):84–8 (58 ref.) **(Fre)**

GENETICS

A Th1 response is essential for induction of crescentic glomerulonephritis in mice. Schatzmann U, et al. **Kidney Blood Press Res** 1999;22(3):135–9

[Familial membranoproliferative glomerulonephritis] Bogdanović RM, et al. **Srp Arh Celok Lek** 1999 May–Jun; 127(5–6):163–71 (Eng. Abstr.) **(Scc)**

IMMUNOLOGY

Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Levy Y, et al. **Immunol Res** 1998 Aug; 18(1):55–60 (45 ref.)

Detection of urinary macrophages expressing the CD16 (Fc gamma RIII) molecule: a novel marker of acute inflammatory glomerular injury. Hotta O, et al. **Kidney Int** 1999 May;55(5):1927–34

Nephrotic syndrome secondary to primary immunoglobulin-G mesangioproliferative glomerulonephritis [letter] Sepandj F, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1889–90

METABOLISM

Immunohistochemical study of tenascin in mesangial

proliferative (IgA-negative) glomerulonephritis. Wagrowska-Danilewicz M, et al. **Acta Histochem** 1999 Jul; 101(3):351-9

Lysophosphatidic acid and mesangial cells: implications for renal diseases. Inoue CN, et al. **Clin Sci (Colch)** 1999 Apr; 96(4):431-6 (40 ref.)

Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Yagi M, et al. **Gen Pharmacol** 1998 Nov;31(5):765-73

Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. Noguchi K, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1815-25

Differential expression of thrombospondin and cellular fibronectin during remodeling in proliferative glomerulonephritis. Barnes JL, et al. **J Histochem Cytochem** 1999 Apr;47(4):533-44

Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. Sasaki S, et al. **J Pathol** 1999 Mar;187(4):481-9

Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Yoshimura A, et al. **Kidney Int Suppl** 1999 Jul;71:S84-7 (7 ref.)

MORTALITY

Prediction in idiopathic membranous nephropathy. Marx BE, et al. **Kidney Int** 1999 Aug;56(2):666-73

PATHOLOGY

Proteinuria and renal insufficiency three years after treatment of gastric lymphoma. Markowitz GS, et al. **Am J Kidney Dis** 1999 Sep;34(3):588-93

Renal involvement in essential monoclonal (type 1) IgG cryoglobulinemia [letter] Grcevska L, et al. **Clin Nephrol** 1998 Sep;50(3):200-2

An unusual case of dense deposit disease with nodular sclerotic lesions of the glomeruli [letter] Razzaque MS, et al. **Clin Nephrol** 1999 May;51(5):326-8

Localization in situ of type VI collagen protein and its mRNA in mesangial proliferative glomerulonephritis using renal biopsy sections. Razzaque MS, et al. **Histochem Cell Biol** 1999 Jan;111(1):1-6

A rare complication of renal biopsy in a child with membranoproliferative glomerulonephritis. Ozdemir S, et al. **Int Urol Nephrol** 1998;30(6):689-92

Mesangial proliferative glomerulonephritis in chronic obstructive pulmonary disease. Dasgupta DJ, et al. **J Indian Med Assoc** 1998 Nov;96(11):338-40

Membranoproliferative glomerulonephritis associated with HCV infection in native kidneys and renal allograft. Jeong HJ, et al. **J Korean Med Sci** 1998 Dec;13(6):670-5

A quantitative study of mesangial deposits and glomerular monocytes/macrophages in IgA-nephropathy and proliferative mesangial (non-IgA) glomerulonephritis. Danilewicz M, et al. **J Nephrol** 1998 Sep-Oct;11(5):255-60

Dissociation of mesangial cell migration and proliferation in experimental glomerulonephritis. Haseley LA, et al. **Kidney Int** 1999 Sep;56(3):964-72

Human glomerular structure under normal conditions and in isolated glomerular disease. Bohle A, et al. **Kidney Int Suppl** 1998 Sep;67:S186-8

Membranoproliferative glomerulonephritis type III [clinical conference] Meyers KE, et al. **Pediatr Nephrol** 1998 Aug; 12(6):512-22 (109 ref.)

Recurrence of membranoproliferative glomerulonephritis in renal allografts. Shimizu T, et al. **Transplant Proc** 1998 Nov; 30(7):3910-3

SURGERY

Recurrence of membranoproliferative glomerulonephritis in renal allografts. Shimizu T, et al. **Transplant Proc** 1998 Nov; 30(7):3910-3

THERAPY

Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Jindal KK. **Kidney Int Suppl** 1999 Jun;70:S33-40 (27 ref.)

Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Levin A. **Kidney Int Suppl** 1999 Jun;70:S41-6 (34 ref.)

Management of idiopathic membranous nephropathy: evidence-based recommendations. Muirhead N. **Kidney Int Suppl** 1999 Jun;70:S47-55 (54 ref.)

Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Abbas NA, et al. **Nephrol Dial Transplant** 1999 May;14(5):1272-5

Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. Andresdottir MB, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1723-31

Remission of HBV-related mesangioproliferative glomerulonephritis after interferon therapy. Dhiman RK, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):176-8

Henoch-Schönlein nephritis. Adverse effect of treatment with intravenous immunoglobulin [letter] Villarreal IR, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):795-7

VIROLOGY

Diabetic nephropathy with concurrent hepatitis C virus infection related membranoproliferative glomerulonephritis. Ramesh Prasad GV, et al. **Clin Nephrol** 1999 Jan;51(1):50-3

HCV infection, cryoglobulinaemia, membranoproliferative glomerulonephritis and low grade non-Hodgkin lymphoma [comment] Lunel F, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):54-5 (18 ref.). Comment on: Ital J Gastroenterol Hepatol 1999 Jan-Feb;31(1):45-53.

Cryoglobulinaemic membranoproliferative glomerulonephritis and hepatits C virus infection [see comments] Mazzaro C, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):45-53. Comment in: Ital J Gastroenterol Hepatol 1999 Jan-Feb;31(1):54-5.

High prevalence of hepatitis C virus antibodies in older patients with membranoproliferative glomerulonephritis [letter] Ohsawa I, et al. **Nephron** 1999;82(4):366-7

GLOMERULONEPHRITIS, MEMBRANOUS

Membranous glomerulonephritis. Wasserstein AG. **J Am Soc Nephrol** 1997 Apr;8(4):664-74 (45 ref.)

COMPLICATIONS

Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607-12 (27 ref.)

Primary biliary cirrhosis associated with membranous glomerulonephritis. Goto T, et al. **Intern Med** 1999 Jan; 38(1):22-6

Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. Cheng JT, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1566-74

Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Praga M, et al. **Kidney Int** 1998 Sep;54(3):915-20

Treatment of progressive renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone [letter; comment] Baker LR, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2704. Comment on: Nephrol Dial Transplant 1998 Feb;13(2):443-8.

Pulmonary haemorrhage in a patient with idiopathic membranous nephropathy. Dienstl A, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1815-7

Retroperitoneal fibrosis and membranous nephropathy. Improvement of both diseases after treatment with steroids and immunosuppressive agents. Moroni G, et al. **Nephrol Dial Transplant** 1999 May;14(5):1303-5

MPO antibody-positive vasculitis in a patient with psoriatic arthritis and gold-induced membranous glomerulonephritis. Quarenghi MI, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2104-6

Disseminated cutaneous plasmacellular granuloma associated with membranous glomerulonephritis. Querfeld U, et al. **Nephrol Dial Transplant** 1999 May;14(5):1268-71

Enlarged cervical lymph nodes two years after diagnosis of membranous glomerulonephritis. Wolf G, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2679-81

Nephrotic syndrome due to membranous glomerulonephritis in a patient with idiopathic thrombocytopenic purpura [letter] Tamura K, et al. **Nephron** 1999;82(1):87-9

Hemophagocytic syndrome in a patient with Hashimoto's thyroiditis and membranous nephritis [letter] Taniguchi Y, et al. **Nephron** 1999 Feb;81(2):246-7

A case of membranous nephropathy associated with psoriasis vulgaris [letter] Yamaji H, et al. **Nephron** 1998 Sep; 80(1):111-2

alpha-Interferon therapy for HBV-related glomerulonephritis. Lopes Neto EP, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1823-5

[Hyperinfection by S. stercoralis: membranous glomerulonephritis, double bacteremia and petechiae exanthema (letter)] Tornero C, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):495-6 **(Spa)**

[Membranous glomerulonephritis, necrotizing arteritis and pulmonary interstitial disease] **Medicina (B Aires)** 1999; 59(2):181-6 **(Spa)**

DIAGNOSIS

Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Laluck BJ Jr, et al. **Am J Kidney Dis** 1999 Jun;33(6):1026-32

Forty-six-year-old man with unexplained hematuria, proteinuria, and pulmonary infiltrates: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Lee S, et al. **J Okla State Med Assoc** 1998 Oct;91(7):399-405

[Membranous glomerulonephritis] Hengstler P. **Schweiz Rundsch Med Prax** 1999 Jun 3;88(23):1052-4 **(Ger)**

DRUG THERAPY

Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Ahuja M, et al. **Am J Kidney Dis** 1999 Sep; 34(3):521-9

Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine. Butty H, et al. **Am J Kidney Dis** 1999 Feb;33(2):E8

Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. Suki WN, et al. **Am J Nephrol** 1999;19(4):474-9

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Boumpas DT, et al. **Clin Nephrol** 1999 Aug;52(2):67-75

Lipid-lowering therapy in membranous nephropathy. Haas M, et al. **Kidney Int Suppl** 1999 Jul;71:S110-2 (22 ref.)

Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? [letter] Fritsche L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1036-8

Retroperitoneal fibrosis and membranous nephropathy. Improvement of both diseases after treatment with steroids and immunosuppressive agents. Moroni G, et al. **Nephrol Dial Transplant** 1999 May;14(5):1303-5

Does cyclosporin have a role in the treatment of membranous nephropathy? [editorial] Ponticelli C, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):23-5 (15 ref.)

Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Heise G, et al. **Nephron** 1998 Oct;80(2):220-6

alpha-Interferon therapy for HBV-related glomerulonephritis. Lopes Neto EP, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1823-5

ETIOLOGY

Membranous glomerulonephritis associated with Graves' disease. Becker BA, et al. **Am J Kidney Dis** 1999 Feb; 33(2):369-73 (14 ref.)

Appearance of nephrotic syndrome following interferon-alpha therapy in a patient with hepatitis B virus and hepatitis C virus coinfection. Endo M, et al. **Am J Nephrol** 1998;18(5):439-43

Diffuse glomerular basement membrane lamellation in renal allografts from pediatric donors to adult recipients. Nadasdy T, et al. **Am J Surg Pathol** 1999 Apr;23(4):437-42

Mechanisms of progressive glomerular injury in membranous nephropathy. Squarer A, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1389-98

HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy. Bhimma R, et al. **Kidney Int** 1999 Jun; 55(6):2440-9

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Dharnidharka VR, et al. **Pediatr Nephrol** 1998 Oct;12(8):654-7

Membranous nephropathy associated with childhood sarcoidosis. Dimitriades C, et al. **Pediatr Nephrol** 1999 Jun; 13(5):444-7 (16 ref.)

[A case of malignant rheumatoid arthritis complicated by secondary amyloidosis and membranous nephropathy] Nakanishi K, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov; 40(8):607-11 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Childhood membranous nephropathy, circulating antibodies to the 58-kD TIN antigen, and anti-tubular basement membrane nephritis: an 11-year follow-up. Iványi B, et al. **Am J Kidney Dis** 1998 Dec;32(6):1068-74 (38 ref.)

The subepithelial formation of immune complexes in membranous glomerulonephritis may be harmless and secondary to toxic or allergic factors. Ravnskov U. **Scand J Immunol** 1998 Nov;48(5):469-74 (58 ref.)

HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy. Vaughan RW, et al. **Tissue Antigens** 1998 Aug;52(2):130-4

[A child case of idiopathic membranous glomerulonephritis associated with isolated anti-nuclear antibody detected by urine mass-screening of school children] Tanaka H, et al. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):349-53 (Eng. Abstr.) **(Jpn)**

METABOLISM

Excessive expression of the tumor necrosis factor-alpha gene in the kidneys of patients with membranous glomerulonephritis. Wu TH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Sep; 61(9):524-30

Visceral glomerular epithelial cell DNA synthesis in experimental and human membranous disease. Bailey E, et al. **Exp Nephrol** 1998 Jul-Aug;6(4):352-8

Redistribution of glomerular epithelial cell adhesion molecules in membranous glomerulonephritis [letter] Gibbons RM, et al. **Histopathology** 1999 Jun;34(6):553-5

Abnormal distribution of mesangium-specific laminin in glomeruli of patients with idiopathic membranous nephropathy. Horikoshi S, et al. **Nephron** 1999;81(3):284-8

PATHOLOGY

Spatial arrangement of subepithelial deposits in lupus and nonlupus membranous nephropathy. Muda AO, et al. **Am J Kidney Dis** 1999 Jul;34(1):85-91

Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Cosyns JP, et al. **Clin Nephrol** 1998 Sep;50(3):144-53 (36 ref.)

Diffuse thin glomerular basement membrane in association

with idiopathic membranous glomerulonephritis. Tóth T, et al. **Clin Nephrol** 1998 Sep;50(3):137-43
Mechanisms of progressive glomerular injury in membranous nephropathy. Squarer A, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1389-98
Clinicopathological characteristics of interstitial foam cells in membranous nephropathy. Kurihara I, et al. **Kidney Int Suppl** 1999 Jul;71:S144-6
Unusual case of membranous nephropathy exhibiting type III collagen microfibrils [letter] Matsumura N, et al. **Nephron** 1998 Sep;80(1):104-5
Preexisting membranous nephropathy in allograft kidney. Nakazawa K, et al. **Nephron** 1999 Jan;81(1):76-80
Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis. Saito T, et al. **Nephron** 1998 Dec;80(4):414-20
A case of membranous nephropathy associated with psoriasis vulgaris [letter] Yamaji H, et al. **Nephron** 1998 Sep; 80(1):111-2
Membranous nephropathy with chronic graft-versus-host disease in a bone marrow transplant recipient [letter] Yorioka N, et al. **Nephron** 1998 Nov;80(3):371-2
[Thin membrane nephropathy: 27 cases] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):736-9 **(Eng. Abstr.) (Chi)**
[Extramembranous glomerulonephritis: clinicopathologic finding in a group of 45 Cameroonians] Youmbissi TJ, et al. **Arch Anat Cytol Pathol** 1999;47(1):48-52 (Eng. Abstr.) **(Fre)**
[Physiopathology and treatment of membranous nephropathy] Ideura T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1856-62 (22 ref.) **(Jpn)**
[Membranous glomerulonephritis, necrotizing arteritis and pulmonary interstitial disease] **Medicina (B Aires)** 1999; 59(2):181-6 **(Spa)**

PREVENTION & CONTROL

Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2501-8

URINE

Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Senatorski G, et al. **Res Exp Med (Berl)** 1998 Dec;198(4):199-206

VIROLOGY

Membranous nephropathy associated with hepatitis B virus infection: long-term clinical and histological outcome. Gonzalo A, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):416-8
HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy. Vaughan RW, et al. **Tissue Antigens** 1998 Aug;52(2):130-4

GLOMERULONEPHRITIS, MESANGIOCAPILLARY see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

GLOMERULONEPHRITIS, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

GLOMERULOSCLEROSIS, DIABETIC see **DIABETIC NEPHROPATHIES**

GLOMERULOSCLEROSIS, FOCAL

[HIV-associated nephropathy in children] Cachat F, et al. **Arch Pediatr** 1998 Dec;5(12):1353-8 (39 ref.) (Eng. Abstr.) **(Fre)**
[Clinical features of focal-segmental glomerular sclerosis (review of literature and personal findings)] Krasnova TN, et al. **Ter Arkh** 1999;71(6):77-80 (35 ref.) **(Rus)**

BLOOD

Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Praga M, et al. **Am J Kidney Dis** 1999 Jan; 33(1):52-8
"The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. Sharma M, et al. **J Am Soc Nephrol** 1999 Mar;10(3):552-61
Circulating factor in patients with recurrent focal segmental glomerulosclerosis postrenal transplantation inhibits expression of inducible nitric oxide synthase and nitric oxide production by cultured rat mesangial cells. Trachtman H, et al. **J Investig Med** 1999 Mar;47(3):114-20
Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Zheng F, et al. **Kidney Int** 1998 Dec;54(6):1999-2007

CHEMICALLY INDUCED

High fructose-fed rats: a model of glomerulosclerosis involving the renin-angiotensin system and renal gelatinases. Zaoui P, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:716-9
Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat. Sato J, et al. **Br J Pharmacol** 1998 Oct;125(3):469-76
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy [see comments] Shah M, et al. **Cancer** 1998 Nov 1;83(9):1938-46 (53 ref.). Comment in: Cancer 1999 Jun 15;85(12):2669-70.
Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Andrews PA, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):187-9
Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy [letter] Dressler D, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):2049-50

COMPLICATIONS

Periodic discharge of adrenocorticotropin and vasopressin associated with focal glomerulosclerosis. Yokoyama W, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):600-3
Unilateral focal segmental glomerulosclerosis with contralateral sparing on the side of renal artery stenosis. Johnston RJ, et al. **AJR Am J Roentgenol** 1999 Jan; 172(1):35-7
A case of mitochondrial cytopathy with a typical point mutation for MELAS, presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Kurogouchi F, et al. **Am J Nephrol** 1998; 18(6):551-6
Living-related-donor kidney transplantation outcome in recipients with primary focal-segmental glomerulosclerosis. Refaie A, et al. **Am J Nephrol** 1999; 19(1):55-9
Nesidioblastosis, myelodysplastic syndrome and nodular diabetic glomerulosclerosis in an elderly nondiabetic woman: an autopsy report. Yeh SP, et al. **Diabet Med** 1999 May;16(5):437-41
Focal segmental glomerulosclerosis and Turner syndrome [letter] Wattad A, et al. **Nephron** 1998 Sep;80(1):106
Impact of recurrent nephrotic syndrome after renal transplantation in young patients. Wühl E, et al. **Pediatr Nephrol** 1998 Sep;12(7):529-33
Focal segmental glomerulosclerosis complicating unilateral nephrectomy for Wilms' tumor [letter] Munden MM, et al. **Pediatr Radiol** 1999 Jul;29(7):562
[Primary Sjögren's syndrome and glomerulonephritis] Tholl U, et al. **Dtsch Med Wochenschr** 1998 Dec 18; 123(51-52):1541-6 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

The diagnostic trash bin of focal and segmental glomerulosclerosis--an effort to provide rational clinical guidelines [editorial] Schmidt A, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):550-2

DIET THERAPY

Short- and long-term effects of fish oil on proteinuria, morphology and renal hemodynamics in the Milan normotensive rat model of spontaneous glomerulosclerosis. Eberhard OK, et al. **Kidney Blood Press Res** 1999; 22(3):128-34

DRUG THERAPY

Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. Hahn S, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2089-95
Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney. Hamar P, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S234-8
Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Griffin KA, et al. **Kidney Int** 1999 May;55(5):1849-60
Management of minimal lesion glomerulonephritis: evidence-based recommendations. Bargman JM. **Kidney Int Suppl** 1999 Jun;70:S3-16 (78 ref.)
Management of focal segmental glomerulosclerosis: evidence-based recommendations. Burgess E. **Kidney Int Suppl** 1999 Jun;70:S26-32 (36 ref.)
Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Hirawa N, et al. **Nephron** 1999 Feb;81(2):183-93
Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Aviles DH, et al. **Pediatr Nephrol** 1999 May;13(4):298-300
IgG subclass/IgM ratio and response to therapy in focal segmental glomerulonecrosis. Fu LW, et al. **Pediatr Nephrol** 1998 Nov;12(9):761-3
Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Rennert WP, et al. **Pediatr Nephrol** 1999 Feb;13(2):113-6
Treatment practices of FSGS among North American pediatric nephrologists. Vehaskari VM. **Pediatr Nephrol** 1999 May;13(4):301-3
Effects of eprosartan on glomerular injury in rats with reduced renal mass. Gandhi M, et al. **Pharmacology** 1999 Aug;59(2):89-94
Multiple joint pain following steroid therapy. McClelland D, et al. **Postgrad Med J** 1998 Oct;74(876):629-30
[Effects of low-molecular-weight heparin on proliferative glomerulonephritis] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):731-5 (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

Lymphocyte ectoenzymes in childhood idiopathic nephrotic syndrome. Stefanović V, et al. **Pediatr Nephrol** 1998 Nov; 12(9):755-60

EPIDEMIOLOGY

HIV-associated nephropathy: outcome and prognosis factors. Groupe d'Etudes Néphrologiques d'Ile de France. Laradi A, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2327-35 (34 ref.)
High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Srivastava T, et al. **Pediatr Nephrol** 1999 Jan;13(1):13-8
Long-term outcome of focal segmental glomerulosclerosis after renal transplantation. Holgado R, et al. **Transplant Proc** 1999 Sep;31(6):2304-5

ETHNOLOGY

Age and ethnicity affect the risk and outcome of focal segmental glomerulosclerosis. Sorof JM, et al. **Pediatr Nephrol** 1998 Nov;12(9):764-8

ETIOLOGY

Glomerulosclerosis, tubulointerstitial fibrosis, and obstructive uropathy in PEPCK-TGF-beta1 transgenic mice. Kopp JB. **Am J Kidney Dis** 1999 Jul;34(1):177-83
Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. Yoshida H, et al. **Am J Kidney Dis** 1999 Jun;33(6):1158-63
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy [letter; comment] Jadoul M. **Cancer** 1999 Jun 15;85(12):2669-70. Comment on: Cancer 1998 Nov 1;83(9):1938-46.
The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. Barisoni L, et al. **J Am Soc Nephrol** 1999 Jan;10(1):51-61
Focal segmental glomerulosclerosis in children with acute lymphocytic leukemia: case reports and review of literature. Sathiapalan RK, et al. **J Pediatr Hematol Oncol** 1998 Sep-Oct;20(5):482-5
A role for leptin in glomerulosclerosis? [editorial; comment] Ballermann BJ. **Kidney Int** 1999 Sep;56(3):1154-5 (9 ref.) . Comment on: Kidney Int 1999 Sep;56(3):860-72.
Do oxidized lipoproteins contribute to glomerulosclerosis? [editorial; comment] Gröne HJ. **Kidney Int** 1998 Sep; 54(3):995-6. Comment on: Kidney Int 1998 Sep;54(3):848-56.
Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments] Wolf G, et al. **Kidney Int** 1999 Sep;56(3):860-72
Nodular glomerulosclerosis in a renal allograft of a non-diabetic recipient. Abdi R, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):493-6
Secondary focal and segmental glomerulosclerosis. Ferrario F, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:58-67 (18 ref.)
Non-diabetic glomerulosclerosis in renal transplantation [letter] Rivera M, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):2053
Molecular basis of injury and progression in focal glomerulosclerosis [editorial] Harris RC. **Nephron** 1999; 82(4):289-99 (155 ref.)
Posttransplant recurrent FSGS: molecular insights and future directions. Schachter AD, et al. **Nephron** 1999;82(4):300-5 (42 ref.)
A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus [letter] Kessler M, et al. **Transplantation** 1999 Feb 27;67(4):641-3

GENETICS

Focal segmental glomerulosclerosis: a need for caution in live-related renal transplantation. Winn MP, et al. **Am J Kidney Dis** 1999 May;33(5):970-4
Identification of DNA polymorphisms associated with the V type alpha1-antitrypsin gene. Gaillard MC, et al. **Biochim Biophys Acta** 1999 Feb 16;1444(2):166-70
Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Winn MP, et al. **Genomics** 1999 Jun 1;58(2):113-20
Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Frishberg Y, et al. **Kidney Int** 1998 Dec; 54(6):1843-9
Clinical and genetic heterogeneity in familial focal segmental glomerulosclerosis. International Collaborative Group for the Study of Familial Focal Segmental Glomerulosclerosis. Winn MP, et al. **Kidney Int** 1999 Apr;55(4):1241-6
Screening for genes up-regulated in 5/6 nephrectomized mouse kidney. Zhang H, et al. **Kidney Int** 1999 Aug; 56(2):549-58

Expression of the recessive glomerulosclerosis gene Mpv17 regulates MMP-2 expression in fibroblasts, the kidney, and the inner ear of mice. Reuter A, et al. **Mol Biol Cell** 1998 Jul;9(7):1675–82

Molecular biology of diabetic glomerulosclerosis. Del Prete D, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:20–5 (52 ref.)

The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. Lenz O, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3074–8

IMMUNOLOGY

T lymphocyte subsets and cytokine production by graft-infiltrating cells in FSGS recurrence post-transplantation. de Oliveira JG, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):713–6

Focal segmental glomerulosclerosis in a 32-year-old kidney allograft after 7 years without immunosuppression. Trimarchi HM, et al. **Nephron** 1999;82(3):270–3

IgG subclass/IgM ratio and response to therapy in focal segmental glomerulonecrosis. Fu LW, et al. **Pediatr Nephrol** 1998 Nov;12(9):761–3

METABOLISM

WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Yang Y, et al. **Am J Pathol** 1999 Jan;154(1):181–92

Identification of oxidized low density lipoprotein in human renal biopsies [see comments] Lee HS, et al. **Kidney Int** 1998 Sep;54(3):848–56. Comment in: Kidney Int 1998 Sep;54(3):995–6.

Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Paizis K, et al. **Kidney Int** 1999 Jun; 55(6):2310–21

Differential CR1 expression in idiopathic focal segmental glomerulosclerosis [letter] Arora M, et al. **Nephron** 1999 Jan;81(1):115–6

Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Hirawa N, et al. **Nephron** 1999 Feb;81(2):183–93

PATHOLOGY

Diversity and unity of focal and segmental glomerular sclerosis. Bariéty J, et al. **Adv Nephrol Necker Hosp** 1998; 28:1–42 (268 ref.)

Focal-segmental glomerulosclerosis. The relationship between tubular atrophy and segmental sclerosis. Bonsib SM. **Am J Clin Pathol** 1999 Mar;111(3):343–8

Evolution of experimentally induced papillary necrosis to focal segmental glomerulosclerosis and nephrotic proteinuria. Garber SL, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1033–9

Collapsing glomerulopathy: clinical characteristics and follow-up [see comments] Grcevska L, et al. **Am J Kidney Dis** 1999 Apr;33(4):652–7. Comment in: Am J Kidney Dis 1999 Apr;33(4):801–3.

Idiopathic nodular glomerulosclerosis. Herzenberg AM, et al. **Am J Kidney Dis** 1999 Sep;34(3):560–4

Development of focal segmental glomerulosclerosis in the renal allograft of a patient with lupus. Kim JS, et al. **Am J Kidney Dis** 1999 Sep;34(3):e13

Long-term furosemide treatment in the normal rat: dissociation of glomerular hypertrophy and glomerulosclerosis. Lane PH. **Am J Kidney Dis** 1999 Jun; 33(6):1058–63

Collapsing glomerulopathy: expanding interest in a shrinking tuft [editorial; comment] Meyrier AY. **Am J Kidney Dis** 1999 Apr;33(4):801–3. Comment on: Am J Kidney Dis 1999 Apr;33(4):652–7. Comment on: Am J Kidney Dis 1999 Apr;33(4):658–66.

Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy. Nagata M, et al. **Am J Kidney Dis** 1998 Dec;32(6):962–9

Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations [see comments] Stokes MB, et al. **Am J Kidney Dis** 1999 Apr;33(4):658–66. Comment in: Am J Kidney Dis 1999 Apr;33(4):801–3.

Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Binder CJ, et al. **Am J Pathol** 1999 Apr;154(4):1067–75

Glomerular hypertrophy in preeclamptic patients with focal segmental glomerulosclerosis. A morphometric analysis. Nishimoto K, et al. **Clin Nephrol** 1999 Apr;51(4):209–19

Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Kitamura H, et al. **Exp Nephrol** 1998 Jul–Aug; 6(4):328–36

Origin of hyperplastic epithelial cells in idiopathic collapsing glomerulopathy. Kihara I, et al. **Histopathology** 1999 Jun; 34(6):537–47

Renal lesions in AIDS: a biopsy and autopsy study. Madiwale C, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):45–54

Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. Hahn S, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2089–95

Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. Moulin B, et al. **J Am Soc Nephrol** 1999 Mar;10(3):519–28

More questions than answers [editorial; comment] Conley SB. **Kidney Int** 1999 May;55(5):2072–3. Comment on: Kidney Int 1999 May;55(5):1885–90.

Predictive value of race in post-transplantation recurrence of focal segmental glomerulosclerosis in children. Butani L, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):166–8

Secondary focal and segmental glomerulosclerosis. Ferrario F, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:58–67 (18 ref.)

Oligonephronia, not exuberant apoptosis, accounts for the development of glomerulosclerosis in the bcl-2 knockout mouse. Gassler N, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2509–18

Definition of 'focal segmental glomerulosclerosis' [letter; comment] Howie AJ. **Nephrol Dial Transplant** 1999 Feb; 14(2):514. Comment on: Nephrol Dial Transplant 1998 May;13(5):1107–9.

From segmental glomerulosclerosis to total nephron degeneration and interstitial fibrosis: a histopathological study in rat models and human glomerulopathies. Kriz W, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2781–98

Morphological features of primary focal and segmental glomerulosclerosis. Noël LH. **Nephrol Dial Transplant** 1999;14 Suppl 3:53–7 (51 ref.)

Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis. Saito T, et al. **Nephron** 1998 Dec;80(4):414–20

Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Stehman-Breen C, et al. **Nephron** 1999 Jan;81(1):37–40

The long-term prognosis of benign nephrosclerosis accompanied by focal glomerulosclerosis and renal cortical interstitial fibrosis, designated so-called decompensated benign nephrosclerosis by Fahr, Bohle and Ratscheck. Wehrmann M, et al. **Pathol Res Pract** 1998;194(8):571–6

Is vacuolization of podocytes and glomerular endothelial cells of prognostic value with respect to FSGS? Salwa-Zurawska W, et al. **Pol J Pathol** 1998;49(3):165–74

T cell hypofunctions and glomerular sclerotic and angiogenic changes found both in rats received unilateral nephrectomy plus transplantation of syngeneic mesenteric lymph nodes and in rats received unilateral nephrectomy plus splenectomy. Nakatsuji T. **Tohoku J Exp Med** 1998 Sep; 186(1):1–11

[Relationship between glomerular epithelial cell injury and proteinuria in IgA nephropathy] Wakai S, et al. **Nippon Jinzo Gakkai Shi** 1998 Jul;40(5):315–21 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Mesangial matrix modulation and glomerulosclerosis. Fogo AB. **Exp Nephrol** 1999 Mar–Apr;7(2):147–59 (107 ref.)

Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Frishberg Y, et al. **Kidney Int** 1998 Dec; 54(6):1843–9

Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Zheng F, et al. **Kidney Int** 1998 Dec;54(6):1999–2007

Cytokines and glomerulosclerosis. Isaka Y, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:30–2

Clinical picture and outcome of primary focal segmental glomerulosclerosis. Korbet SM. **Nephrol Dial Transplant** 1999;14 Suppl 3:68–73 (35 ref.)

Cell proliferation and apoptosis of the glomerular epithelial cells in rats with puromycin aminonucleoside nephrosis. Shiiki H, et al. **Pathobiology** 1998;66(5):221–9

Focal segmental glomerulosclerosis progression to end-stage renal disease within 48 months is a risk factor for recurrence after pediatric renal transplantation. Kim SJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1393–4

PREVENTION & CONTROL

Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats. Reckelhoff JF, et al. **Am J Hypertens** 1999 May;12(5):492–8

ACE-I vs angiotensin II receptor antagonists: prevention of renal injury in chronic rat models. Taal MW, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S51–6; discussion S61 (41 ref.)

Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. Kobayashi S, et al. **J Lab Clin Med** 1999 Feb;133(2):134–43

Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable. de Boer E, et al. **Kidney Int Suppl** 1999 Jul;71:S42–6

Effects of polyunsaturated fatty acids on rat glomerulosclerosis induced by hypercholesterolaemic diet. Romero R, et al. **Res Exp Med (Berl)** 1998 Jul;198(1):1–10

Plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis of kidney allograft in adult recipients. Iguchi Y, et al. **Ther Apher** 1997 May;1(2):191–4

[Lipid-lowering effect of pravastatin on glomerulosclerosis protection and treatment] Lu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):242–5 (Eng. Abstr.) **(Chi)**

SURGERY

Recurrence of focal segmental glomerulosclerosis associated with Kimura's disease after kidney transplantation. Romão JE, et al. **Am J Kidney Dis** 1998 Mar;31(3):E3

Predictive value of race in post-transplantation recurrence of focal segmental glomerulosclerosis in children. Butani L, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):166–8

Focal segmental glomerulosclerosis progression to end-stage renal disease within 48 months is a risk factor for recurrence after pediatric renal transplantation. Kim SJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1393–4

THERAPY

Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Haas M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2013–6

Treatment of primary focal segmental glomerulosclerosis. Meyrier A. **Nephrol Dial Transplant** 1999;14 Suppl 3:74–8 (41 ref.)

Low-density lipoprotein apheresis for focal glomerular sclerosis. Yorioka N, et al. **Ther Apher** 1997 Nov;1(4):370–1

[Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy] Ezaki Y, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):83–8 (Eng. Abstr.) **(Jpn)**

VETERINARY

Rhesus macaques infected with macrophage-tropic simian immunodeficiency virus (SIVmacR71/17E) exhibit extensive focal segmental and global glomerulosclerosis. Stephens EB, et al. **J Virol** 1998 Nov;72(11):8820–32

GLOMUS AORTICUM see **AORTIC BODIES**

GLOMUS CAROTICUM see **CAROTID BODY**

GLOMUS JUGULARE

ANATOMY & HISTOLOGY

[Relation between jugular bulb variation and middle and inner ear diseases] Chen J, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Oct; 11(10):484–5 (10 ref.) **(Chi)**

GLOMUS JUGULARE TUMOR

GENETICS

Image cytometric nuclear DNA quantitation of paragangliomas in tissue sections. Prognostic significance. Held EL, et al. **Anal Quant Cytol Histol** 1997 Dec; 19(6):501–6

p53 and p16INK4A mutations during the progression of glomus tumor. Güran S, et al. **Pathol Oncol Res** 1999; 5(1):41–5

PATHOLOGY

[Biology and growth velocity of tumors of the globus jugulotympanicum and glomus caroticum] Gosepath J, et al. **Laryngorhinootologie** 1998 Aug;77(8):429–33 (Eng. Abstr.) **(Ger)**

SECRETION

[Octreotide and a serotonin-secreting glomus tumor] García Galán F, et al. **Rev Esp Anestesiol Reanim** 1999 May; 46(5):219–22 (Eng. Abstr.) **(Spa)**

SURGERY

Leksell gamma knife radiosurgery of the tumor glomus jugulare and tympanicum. Liščák R, et al. **Stereotact Funct Neurosurg** 1998 Oct;70 Suppl 1:152–60

[Interruption of the lateral sinus in surgery of paraganglioma and acoustic neurinoma. Apropos of 2 complications] Stramandinoli E, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec;115(6):362–6 (Eng. Abstr.) **(Fre)**

[Jugulotympanic paraganglioma: therapy concepts under development] Schick B, et al. **Laryngorhinootologie** 1998 Aug;77(8):434–43 (Eng. Abstr.) **(Ger)**

THERAPY

Facial palsy after glomus jugulare tumour embolization. Marangos N, et al. **J Laryngol Otol** 1999 Mar;113(3):268–70

GLOMUS TUMOR

COMPLICATIONS

A case of multiple subungual glomus tumors associated with neurofibromatosis type 1. Okada O, et al. **J Dermatol** 1999 Aug;26(8):535–7 (7 ref.)

CONGENITAL

Giant congenital multiple patch-like glomus tumors. Yoon TY, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):826–8

DIAGNOSIS

MR imaging of a subungual glomus tumor. Opdenakker G,

et al. **AJR Am J Roentgenol** 1999 Jan;172(1):250–1

A case of invisible glomus tumor in an unusual site [letter] Yoshimoto S, et al. **Ann Plast Surg** 1999 Sep;43(3):336–8

Glomus vagale presenting as a supraclavicular mass: magnetic resonance imaging findings. Puvaneswary M, et al. **Australas Radiol** 1998 Nov;42(4):367–9

Familial multiple glomus tumours: differential diagnosis and relation to carotid body/glomus jugulare tumours [letter; comment] Theodoropoulos DS. **Br J Plast Surg** 1998 Oct; 51(7):571. Comment on: Br J Plast Surg 1998 Jan;51(1):32–7.

Subungual glomus tumor: combined use of MR1 and three-dimensional contrast MR angiography. Boudghene FP, et al. **J Magn Reson Imaging** 1998 Nov–Dec; 8(6):1326–8

Enormous glomus tumor of the shoulder. Roberts SN, et al. **J Shoulder Elbow Surg** 1999 Jul–Aug;8(4):365–6

[Glomus tumor of the nose] Matschiner F, et al. **HNO** 1999 Feb;47(2):122–5 (Eng. Abstr.) **(Ger)**

GENETICS

A gene for inherited cutaneous venous anomalies ("glomangiomas") localizes to chromosome 1p21–22. Boon LM, et al. **Am J Hum Genet** 1999 Jul;65(1):125–33

PATHOLOGY

Solitary plaque-like telangiectatic glomangioma. Requena L, et al. **Br J Dermatol** 1998 Nov;139(5):902–5

Glomangiosarcoma of the hip: report of a highly aggressive tumour with widespread distant metastases. Watanabe K, et al. **Br J Dermatol** 1998 Dec;139(6):1097–101

Type 2 segmental manifestation of multiple glomus tumors: A review and reclassification of 5 case reports. Happle R, et al. **Dermatology** 1999;198(3):270–2 (11 ref.)

Unusual presentation of multiple subcutaneous glomus tumours of the lower limb with extensive glomus cell hyperplasia [letter] Graadt Van Roggen JF, et al. **Histopathology** 1999 May;34(5):474–5

Glomus tumor of the uterine cervix. Albores-Saavedra J, et al. **Int J Gynecol Pathol** 1999 Jan;18(1):69–72

Histochemical investigation into the molecular mechanisms of malignant transformation in a benign glomus tumour. Hegyi L, et al. **J Clin Pathol** 1998 Nov;51(11):872–4

Multiple glomus tumors [letter] Alli N, et al. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):262–3

The problem of the persistently purple nail. Glomus tumor of the nail bed. Mishriki YY. **Postgrad Med** 1998 Oct; 104(4):193–4

RADIOGRAPHY

Case report: glomus tumour of the nasal cavity and paranasal sinuses. Shimono T, et al. **Neuroradiology** 1998 Aug; 40(8):527–9

SURGERY

Treatment of multiple glomangioma with tuneable dye laser. Sharma JK, et al. **J Cutan Med Surg** 1999 Jan;3(3):167–8

A glomus tumour with four recurrences. Dailiana ZH, et al. **J Hand Surg [Br]** 1999 Feb;24(1):131–2

An unusual case of multiple recurrence of a glomangioma. Looi KP, et al. **J Hand Surg [Br]** 1999 Jun;24(3):387–9

Malignant glomus tumors. Manolidis S, et al. **Laryngoscope** 1999 Jan;109(1):30–4

[Glomus tumor of the nail area. Apropos of a series of 55 patients] Foucher G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jul; 85(4):362–6 (Eng. Abstr.) **(Fre)**

[Atypical course of Barre-Masson disease] Deviatov VA. **Khirurgiia (Mosk)** 1999;(4):62 **(Rus)**

THERAPY

[Sclerosing in multiple familial glomangiomas] Vente C, et al. **Hautarzt** 1998 Aug;49(8):657–61 (Eng. Abstr.) **(Ger)**

GLOMUS TYMPANICUM see **PARAGANGLIA, NONCHROMAFFIN**

GLOMUS VAGALE see **AORTIC BODIES**

GLOSSALGIA

Medically unexplained chronic orofacial pain. Temporomandibular pain and dysfunction syndrome, orofacial phantom pain, burning mouth syndrome, and trigeminal neuralgia. Marbach JJ. **Med Clin North Am** 1999 May;83(3):691–710, vi–vii (36 ref.)

DRUG THERAPY

Effectiveness of kampo medicine (sai-boku-to) in treatment of patients with glossodynia [see comments] Bersho K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):682–6. Comment in: Oral Surg Oral Med Oral Pathol Oral Radio 1998 Dec;86(6):678–81.

GLOSSECTOMY

Free flap reconstruction after near-total glossectomy in the child. Sajjadian A, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):614–6

ADVERSE EFFECTS

The difference between delayed extubation and tracheostomy in post-operative sleep apnea after glossectomy or laryngectomy. Saito T, et al. **Jpn J Clin Oncol** 1999 Mar; 29(3):127–31

HISTORY

The treatment of macroglossia before the 20th century. Ring ME. **Am J Otolaryngol** 1999 Jan–Feb;20(1):28–36

REHABILITATION

Speech articulation after subtotal glossectomy and reconstruction with a myocutaneous flap. Knuuttila H, et al. **Acta Otolaryngol** 1999;119(5):621–6

Mastication, deglutition and speech considerations in prosthodontic rehabilitation of a total glossectomy patient. Cötert HS, et al. **J Oral Rehabil** 1999 Jan;26(1):75–9

GLOSSINA see **TSETSE FLIES**

GLOSSITIS

DRUG THERAPY

Effect of pyridoxine or riboflavin supplementation on plasma homocysteine levels in women with oral lesions. Lakshmi AV, et al. **Natl Med J India** 1998 Jul–Aug;11(4):171–2

PATHOLOGY

A painless mass on the tongue of a young man. Gauchia Moreno R, et al. **Arch Dermatol** 1999 May;135(5):593, 596

GLOSSITIS AREATA EXFOLIATIVA see **GLOSSITIS, BENIGN MIGRATORY**

GLOSSITIS, BENIGN MIGRATORY

CHEMICALLY INDUCED

Lithium and geographic tongue [letter] Gracious BL, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep; 38(9):1069–70

DIAGNOSIS

Clinical Images: geographic tongue. Murphy FT, et al. **Arthritis Rheum** 1999 May;42(5):1061

[Exfoliatio areata linguae et mucosae oris: a mucous membrane manifestation of psoriasis pustulosa?] Casper U, et al. **Hautarzt** 1998 Nov;49(11):850–4 (Eng. Abstr.) **(Ger)**

GLOSSODYNIA see **GLOSSALGIA**

GLOSSOPHARYNGEAL NERVE

Glossopharyngeal neuralgia associated with a vascular loop demonstrated by magnetic resonance imaging. Boch AL, et al. **Acta Neurochir (Wien)** 1998;140(8):813–8

Relief of chronic refractory hiccups with glossopharyngeal nerve block [letter; comment] Babacan A, et al. **Anesth Analg** 1998 Oct;87(4):980. Comment on: Anesth Analg 1997 Jan;84(1):229.

Giant cell arteritis and Vernet's syndrome [letter; comment] Jeret JS. **Neurology** 1999 Feb;52(3):677. Comment on: Neurology 1998 Jun;50(6):1862–4.

Computed tomography-guided trigeminal tractotomy-nucleotomy in the management of vagoglossopharyngeal and geniculate neuralgias. Kanpolat Y, et al. **Neurosurgery** 1998 Sep;43(3):484–9; discussion 490

Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Kobata H, et al. **Neurosurgery** 1998 Dec; 43(6):1351–61; discussion 1361–2 (109 ref.)

[Parapharyngeal tumors. Apropos of 6 cases] Guichard C, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec; 115(6):355–61 (Eng. Abstr.) **(Fre)**

[Collet-Sicard syndrome disclosing periarteritis nodosa] Krystkowiak P, et al. **Rev Neurol (Paris)** 1998 Nov; 154(11):777–9 (Eng. Abstr.) **(Fre)**

[A case of Foix-Chavany-Marie syndrome and crossed aphasia after right corona radiata infarction with history of left hemispheric infarction] Kobayashi S, et al. **Rinsho Shinkeigaku** 1998 Oct–Nov;38(10–11):910–4 (Eng. Abstr.) **(Jpn)**

[Use of gabapentin in glossopharyngeal neuralgia] García Callejo FJ, et al. **Acta Otorrinolaringol Esp** 1999 Mar; 50(2):175–7 (Eng. Abstr.) **(Spa)**

[Lower cranial nerve involvement as the initial manifestation of Lyme borreliosis] Velázquez JM, et al. **Neurologia** 1999 Jan;14(1):36–7 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Dopamine modulates carotid nerve responses induced by acetylcholine on the cat petrosal ganglion in vitro. Alcayaga J, et al. **Brain Res** 1999 Jun 12;831(1–2):97–103

PHYSIOLOGY

Role of taste in the microstructure of quinine ingestion by rats. Spector AC, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1687–703

Responses of single taste fibers and whole chorda tympani and glossopharyngeal nerve in the domestic pig, Sus scrofa. Danilova V, et al. **Chem Senses** 1999 Jun;24(3):301–16

Cellular expression of alpha-gustducin and the A blood group antigen in rat fungiform taste buds cross-reinnervated by the IXth nerve. Smith DV, et al. **J Comp Neurol** 1999 Jun 21;409(1):118–30

Developmental changes in membrane properties of chemoreceptor afferent neurons of the rat petrosal ganglia. Donnelly DF. **J Neurophysiol** 1999 Jul;82(1):209–15

Glossopharyngeal nerve transection eliminates quinine-stimulated fos-like immunoreactivity in the nucleus of the solitary tract: implications for a functional topography of gustatory nerve input in rats. King CT, et al. **J Neurosci** 1999 Apr 15;19(8):3107–21

Directing gene expression to gustducin-positive taste receptor cells. Wong GT, et al. **J Neurosci** 1999 Jul 15; 19(14):5802–9

Glossopharyngeal nerve transection reduces quinine avoidance in rats not given presurgical stimulus exposure. Markison S, et al. **Physiol Behav** 1999 Jan 1–15; 65(4–5):773–8

PHYSIOPATHOLOGY

Glossopharyngeal neuralgia referred from a pontine lesion. McCarron MO, et al. **Cephalalgia** 1999 Mar;19(2):115–7

Acquired and isolated asymmetrical palatal palsy. Cuvellier JC, et al. **Neuropediatrics** 1998 Dec;29(6):324–5

[Unilateral tonsillectomy complicated by glossopharyngeal nerve neuralgia and late hemorrhage from the tonsillar segment] Izvin AI, et al. **Vestn Otorinolaringol** 1999;(1):53 **(Rus)**

SURGERY

[Via the submandible: cervical glossopharyngeal neurectomy and histomorphology findings] Lu W, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Aug; 11(8):346–8 (Eng. Abstr.) **(Chi)**

GLOSSOPYROSIS see **GLOSSALGIA**

GLOTTIS

The results of radiotherapy for T1 glottic cancers; influence of radiation beam energy. Yamamoto M, et al. **Acta Med Okayama** 1999 Apr;53(2):91–4

Glottis simulator [letter] de Menezes Lyra R. **Anesth Analg** 1999 Jun;88(6):1422–3

A multimodal strategy for the treatment of patients with T2 invasive squamous cell carcinoma of the glottis. Laccourreye O, et al. **Cancer** 1999 Jan 1;85(1):40–6

Quantitation of nucleolar organizer regions by image analysis in glottic squamous cell carcinoma. Barnes P, et al. **Clin Invest Med** 1999 Apr;22(2):36–43

The impact of preoperative tracheotomy on T3 transglottic carcinomas of the larynx. Carrillo JF, et al. **Eur Arch Otorhinolaryngol** 1999;256(2):78–82

Neo-adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3–T4: 5-year oncologic results. Laccourreye O, et al. **Head Neck** 1998 Oct;20(7):595–9

Partial laryngectomy as salvage surgery for radiation failures in T1–T2 laryngeal cancer. Rodriguez-Cuevas S, et al. **Head Neck** 1998 Oct;20(7):630–3

Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Marshak G, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1009–13

The impact of treatment time and smoking on local control and complications in T1 glottic cancer [see comments] van der Voet JC, et al. **Int J Radiat Oncol Biol Phys** 1998 Sep 1;42(2):247–55. Comment in: Int J Radiat Oncol Biol Phys 1999 Jul 1;44(4):967–8.

Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. Mancuso AA, et al. **J Clin Oncol** 1999 Feb;17(2):631–7

Use of injectable autologous collagen for correcting glottic gaps: initial results. Remacle M, et al. **J Voice** 1999 Jun; 13(2):280–8

Second malignant neoplasia in patients with T1 glottic cancer treated with radiation. Fujita M, et al. **Laryngoscope** 1998 Dec;108(12):1853–5

Botulinum toxin: adjunctive treatment for posterior glottic synechiae. Nathan CO, et al. **Laryngoscope** 1999 Jun; 109(6):855–7

Comparative estimation of cure rates for supraglottic and glottic cancer in radiotherapy. Golen M, et al. **Neoplasma** 1999;46(1):66–71

Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis. Halstead LA. **Otolaryngol Head Neck Surg** 1999 May;120(5):683–8

Submucosal squamous cell carcinoma of the subglottis. Porter GC, et al. **Otolaryngol Head Neck Surg** 1999 May; 120(5):745–6

Minimally invasive surgery for posterior glottic stenosis. Rovó L, et al. **Otolaryngol Head Neck Surg** 1999 Jul; 121(1):153–6

Significance of pretreatment hemoglobin level in patients

with T1 glottic cancer. Canaday DJ, et al. **Radiat Oncol Investig** 1999;7(1):42–8

Surgery or radiotherapy for early stages carcinomas of the glottic larynx. Magnano M, et al. **Tumori** 1999 May–Jun; 85(3):188–93

Subglottic stenosis in a child: a complication of prolonged endotracheal intubation. Akpan SG. **West Afr J Med** 1998 Oct–Dec;17(4):290–1

ANATOMY & HISTOLOGY

Three-dimensional changes in the upper airway during neuromuscular stimulation of laryngeal muscles. Ludlow CL, et al. **Artif Organs** 1999 May;23(5):463–5

Anatomical bases of glottic widening surgery related to arytenoidectomy. Reidenbach MM. **Clin Anat** 1999; 12(2):94–102

Unilateral cricothyroid contraction and glottic configuration. Woodson GE, et al. **J Voice** 1998 Sep;12(3):335–9

DRUG EFFECTS

Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C. Spector JE, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1125–9

EMBRYOLOGY

TNM glottic: role of the vocal muscle, arytenoid cartilage, and inferior paraglottic space in impaired vocal cord mobility (T2). An embryological and clinical study. Rucci L, et al. **Ann Otol Rhinol Laryngol** 1998 Dec; 107(12):1038–45

INJURIES

Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C. Spector JE, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1125–9

INNERVATION

Neurochemical markers in the nervous plexus of the canine glottis. Yamamoto Y, et al. **J Auton Nerv Syst** 1998 Jul 15;71(2–3):111–9

Correspondence of electroglottographic closed quotient to vocal fold impact stress in excised canine larynges. Verdolini K, et al. **J Voice** 1998 Dec;12(4):415–23

PATHOLOGY

Subglottic carcinoma: review of a series and characterization of its patterns of spread. Strome SE, et al. **Ear Nose Throat J** 1999 Aug;78(8):622–4, 626, 628, passim

Transnasal endoscopic examination of the subglottis and trachea using topical anesthesia in the otolaryngology clinic. Hogikyan ND. **Laryngoscope** 1999 Jul;109(7 Pt 1):1170–3

Impact of laryngeal paralysis and its treatment on the glottic aperture and upper airway flow characteristics during exercise. Beaty MM, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):819–23

Subglottic stenosis: a complication of percutaneous tracheotomy. McQueen CT, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):543–5

PHYSIOLOGY

Effect of the signal measured from the glottis on determination of the vocal tract shape. Gülmezoğlu MB, et al. **Ann Biomed Eng** 1998 Nov–Dec;26(6):1082–90

Laryngeal movements during the respiratory cycle measured with an endoscopic imaging technique in the conscious horse at rest. Lafortuna CL, et al. **Exp Physiol** 1999 Jul; 84(4):739–46

Glottal characteristics of male speakers: acoustic correlates and comparison with female data. Hanson HM, et al. **J Acoust Soc Am** 1999 Aug;106(2):1064–77

Characteristics of glottis-induced turbulence in oscillatory flow: an empirical investigation. Choi Y, et al. **J Biomech Eng** 1998 Apr;120(2):217–26

Parameterization of the voice source by combining spectral decay and amplitude features of the glottal flow. Alku P, et al. **J Speech Lang Hear Res** 1998 Oct;41(5):990–1002

Effects of lung volume on the glottal voice source. Iwarsson J, et al. **J Voice** 1998 Dec;12(4):424–33

Effects of prolonged oral reading on F0, SPL, subglottal pressure and amplitude characteristics of glottal flow waveforms. Vilkman E, et al. **J Voice** 1999 Jun;13(2):303–12

PHYSIOPATHOLOGY

Posterior glottic stenosis: a canine model. Courey MS, et al. **Ann Otol Rhinol Laryngol** 1998 Oct;107(10 Pt 1):839–46

Dynamics of subneoglottic lumen in tracheoesophageal phonation. Mohri M, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):974–6

TNM glottic: role of the vocal muscle, arytenoid cartilage, and inferior paraglottic space in impaired vocal cord mobility (T2). An embryological and clinical study. Rucci L, et al. **Ann Otol Rhinol Laryngol** 1998 Dec; 107(12):1038–45

Complete glottic closure during central apnea in lambs. Lemaire D, et al. **J Otolaryngol** 1999 Feb;28(1):13–9

Direct measurement of subglottic pressure and laryngeal resistance in normal subjects and in spasmodic dysphonia. Plant RL, et al. **J Voice** 1998 Sep;12(3):300–14

Glottographic measures before and after levodopa treatment in Parkinson's disease. Jiang J, et al. **Laryngoscope** 1999 Aug;109(8):1287–94

RADIATION EFFECTS

Consequences of voice impairment in daily life for patients following radiotherapy for early glottic cancer: voice quality, vocal function, and vocal performance. Verdonck-de Leeuw IM, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 15;44(5):1071–8

Enhanced regeneration response of laryngeal and hypopharyngeal mucosa with accelerated hyperfractionated radiation therapy for glottic cancers. Mariya Y, et al. **Radiat Med** 1998 Nov–Dec;16(6):469–72

Predicting the local outcome of glottic squamous cell carcinoma after definitive radiation therapy: value of computed tomography-determined tumour parameters. Hermans R, et al. **Radiother Oncol** 1999 Jan;50(1):39–46

Comparison of external radiotherapy, laser microsurgery and partial laryngectomy for the treatment of T1N0M0 glottic carcinomas: a retrospective evaluation. Rosier JF, et al. **Radiother Oncol** 1998 Aug;48(2):175–83

[Oncologic surgery of the larynx after failure of radiotherapy] Pinilla M, et al. **Acta Otorrinolaringol Esp** 1998 Nov–Dec; 49(8):633–6 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Differential features of transglottic carcinoma] León X, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):569–75 (Eng. Abstr.) **(Spa)**

SURGERY

Transverse infrahyoid approach to bilateral glottic tumors. Reino AJ, et al. **Ann Otol Rhinol Laryngol** 1999 Jan; 108(1):24–30

Local recurrence after vertical partial laryngectomy, a conservative modality of treatment for patients with Stage I–II squamous cell carcinoma of the glottis. Laccourreye O, et al. **Cancer** 1999 Jun 15;85(12):2549–56

Modified subtotal laryngectomy with cricohyoidoepiglottopexy--long term results in 81 patients. Crampette L, et al. **Head Neck** 1999 Mar;21(2):95–103

Outpatient transoral laser vaporization of anterior glottic webs and keel placement: risks of airway compromise. Casiano RR, et al. **J Voice** 1998 Dec;12(4):536–9

Vocal function after vertical partial laryngectomy with glottic reconstruction by false vocal fold flap: durational and frequency measures. Biacabe B, et al. **Laryngoscope** 1999 May;109(5):698–704

Combined endolaryngeal and external approaches for iatrogenic glottic web. Hsiao TY. **Laryngoscope** 1999 Aug; 109(8):1347–50

Autologous transplantation of fascia into the vocal fold: a new phonosurgical technique for glottal incompetence. Tsunoda K, et al. **Laryngoscope** 1999 Mar;109(3):504–8

Phonatory results after laser surgery for glottic carcinoma. Sittel C, et al. **Otolaryngol Head Neck Surg** 1998 Oct; 119(4):418–24

[Oncologic surgery of the larynx after failure of radiotherapy] Pinilla M, et al. **Acta Otorrinolaringol Esp** 1998 Nov–Dec; 49(8):633–6 (Eng. Abstr.) **(Spa)**

GLOVES, PROTECTIVE

The combined use of moisturizers and occlusive gloves: an experimental study. Held E, et al. **Am J Contact Dermat** 1999 Sep;10(3):146–52

A simple hand hygiene exercise. Aspöck C, et al. **Am J Infect Control** 1999 Aug;27(4):370–2

Glove resistance to permeation by a 7.5% hydrogen peroxide sterilizing and disinfecting solution. Monticello MV, et al. **Am J Infect Control** 1999 Aug;27(4):364–6

Protecting the latex sensitive from chemotherapy [letter; comment] Claussen K. **Am J Nurs** 1999 May;99(5):14. Comment on: Am J Nurs 1998 Nov;98(11):59–65.

Does art imitate life? [letter] Leibowitz R. **Am J Nurs** 1998 Nov;98(11):18

Male torque strength in simulated oil rig tasks: the effects of grease-smeared gloves and handle length, diameter and orientation. Imrhan SN, et al. **Appl Ergon** 1999 Oct; 30(5):455–62

Glove permeation tests using novel microchemical techniques for 2, 4-dichlorophenoxyacetic acid (2,4-D) derivatives. Lin YW, et al. **Arch Environ Contam Toxicol** 1999 May; 36(4):485–9

Characterization of a three-phase response in gloved cold-stressed fingers. Shitzer A, et al. **Eur J Appl Physiol** 1998 Jul;78(2):155–62

Modular glovebox connector and associated good practices for control of radioactive and chemically toxic materials. Hoover MD, et al. **Health Phys** 1999 Jan;76(1):66–72

Cow's milk casein, a hidden allergen in natural rubber latex gloves. Ylitalo L, et al. **J Allergy Clin Immunol** 1999 Jul; 104(1):177–80

Ease of donning commercially available latex examination gloves. Côté SJ, et al. **J Biomed Mater Res** 1998 Fall; 43(3):331–7

Failure of glove hole detection device for synthetic gloves. Neal JG, et al. **J Biomed Mater Res** 1999 Spring;48(1):24–6

Glove powder: implications for infection control. Dave J, et al. **J Hosp Infect** 1999 Aug;42(4):283–5 (22 ref.)

Butyl & Viton hand protection. Groce DF. **Occup Health Saf** 1999 Jul;68(7):42–5

[The efficacy of repeated disinfection of disposable gloves during usage] Pitten FA, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):555–62 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Glove-related hand urticaria in the absence of Type I latex allergy. Armstrong DK, et al. **Contact Dermatitis** 1999 Jul; 41(1):42

Glove powder affects skin roughness, one parameter of skin irritation. Brehler R, et al. **Contact Dermatitis** 1998 Nov; 39(5):227–30

Latex hypersensitivity/glove component reaction as a contributing factor to osteomyelitis of the hand: a case report and review of the literature. Duplechain MT, et al. **J La State Med Soc** 1998 Nov;150(11):527–32 (22 ref.)

Latex allergy. Miller D. **Occup Health Saf** 1999 Apr; 68(4):62–5

STANDARDS

Laboratory simulation of splashes and spills of organophosphate insecticides on chemically protective gloves used in agriculture. Canning KM, et al. **Ann Agric Environ Med** 1998;5(2):155–67

Thermoregulatory responses to cold: effects of handwear with multi-layered clothing. Gonzalez RR, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1076–82

A new test for cut resistance. Parrish E. **Occup Health Saf** 1999 Jan;68(1):72–3

SUPPLY & DISTRIBUTION

Latex allergy. Miller D. **Occup Health Saf** 1999 Apr; 68(4):62–5

UTILIZATION

Understanding physicians' intention to use a simple infection control measure: wearing gloves. Godin G, et al. **Am J Infect Control** 1998 Aug;26(4):413–7

Hand washing and use of gloves while managing patients receiving mechanical ventilation in the ICU. Khatib M, et al. **Chest** 1999 Jul;116(1):172–5

Test of the Fishbein and Ajzen models as predictors of health care workers' glove use. Levin PF. **Res Nurs Health** 1999 Aug;22(4):295–307

GLOVES, SURGICAL

Gloves. Caelleigh AS. **Acad Med** 1998 Nov;73(11):1132

Leaking gloves [letter] Mori H, et al. **Aust Dent J** 1998 Dec; 43(6):436

Double gloving and a glove perforation indication system during the dental treatment of HIV-positive patients: are they necessary? Avery CM, et al. **Br Dent J** 1999 Jan 9; 186(1):27–9

Blood splashes to the masks and goggles during caesarean section [letter; comment] Foley E, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):932. Comment on: Br J Obstet Gynaecol 1997 Dec;104(12):1405–6.

Double gloving and a system for identifying glove perforations in maxillofacial trauma surgery. Avery CM, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):316–9

The hazards of vinyl glove ingestion in the mentally retarded patient with pica: new implications for surgical management. Kamal I, et al. **Can J Surg** 1999 Jun; 42(3):201–4

Glove perforation rate in open lung surgery. Hollaus PH, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):461–4

Postoperative exposure to glove powders modulates production of peritoneal eicosanoids during peritoneal wound healing. Chegini N, et al. **Eur J Surg** 1999 Jul; 165(7):698–704

Biomechanical performance of examination gloves. Jackson EM, et al. **J Biomed Mater Res** 1999;48(4):572–7

Biomechanical performance of orthopedic gloves. Jackson EM, et al. **J Biomed Mater Res** 1999;48(2):193–8

The scientific basis of surgical glove selection in an in vitro fertilization laboratory. Reddy VR, et al. **J Biomed Mater Res** 1999;48(4):569–71

The selection of proper gloves for intraoral surgery [editorial] Laskin DM. **J Oral Maxillofac Surg** 1999 Aug;57(8):887

Powder-free protein-poor natural rubber latex gloves and latex sensitization [letter] Levy D, et al. **JAMA** 1999 Mar 17;281(11):988

Allergy to natural rubber latex. Yunginger JW. **Minn Med** 1998 Sep;81(9):27–30 (33 ref.)

Latex gloves [letter] Packham C. **Occup Med (Lond)** 1999 May;49(4):267

Evaluation of hand sensibility with single and double latex gloves. Novak CB, et al. **Plast Reconstr Surg** 1999 Jan; 103(1):128–31

Glove powder complications. Shymko M. **Radiol Technol** 1999 Jul–Aug;70(6):576–8

An inexpensive laparoscopic gallbladder retrieval bag [letter; comment] Imrie CW. **Surg Endosc** 1999 Mar;13(3):313. Comment on: Surg Endosc 1998 Jan;12(1):83.

Water-glove balloon system: a useful option to salvage liver grafts with postreperfusion suprahepatic vena caval kinking. Boggi U, et al. **Transplantation** 1998 Nov 27;

66(10):1317–9
Surgical gloves: current problems. Osman MO, et al. **World J Surg** 1999 Jul;23(7):630–7; discussion 637 (84 ref.)
[Removal of surgical specimens during laparoscopic surgery using a glove] Vons C. **J Chir (Paris)** 1998 Oct;135(4):176 **(Fre)**
[Electron microscopic analysis of particles from surgical gloves and their possible introduction into the epidural space during epidural anesthesia] Reina MA, et al. **Rev Esp Anestesiol Reanim** 1999 Feb;46(2):60–6 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

An evaluation of the prevalence of latex sensitivity among atopic and non-atopic intensive care workers. Watts DN, et al. **Am J Ind Med** 1998 Oct;34(4):359–63
Banning of powdered latex gloves [letter] Perrin L. **Br Dent J** 1998 Aug 22;185(4):158–9
Latex allergy in an orthognathic patient and implications for clinical management. Nattrass C, et al. **Br J Oral Maxillofac Surg** 1999 Feb;37(1):11–3
The dental team and latex hypersensitivity. ADA Council on Scientific Affairs. **J Am Dent Assoc** 1999 Feb; 130(2):257–64 (50 ref.)
Dental surgeons with natural rubber latex allergy: a report of 20 cases. Field EA. **Occup Med (Lond)** 1999 Feb; 49(2):103–7
A review of current literature on epidemiology of immediate glove irritation and latex allergy. Kujala V. **Occup Med (Lond)** 1999 Jan;49(1):3–9 (73 ref.)
[Latex gloves in surgery and examinations] Korn M. **Dtsch Med Wochenschr** 1998 Nov 13;123(46):1395–6 **(Ger)**
[High price for cheap powdered gloves] Edelstam G. **Lakartidningen** 1999 Feb 17;96(7):774, 778–9 **(Swe)**

ECONOMICS

Health care worker disability due to latex allergy and asthma: a cost analysis. Phillips VL, et al. **Am J Public Health** 1999 Jul;89(7):1024–8

HISTORY

The use of surgical gloves in the operating room. Cooper M, et al. **Am Surg** 1999 Jan;65(1):90–1
The surgeon's glove. Rutkow IM. **Arch Surg** 1999 Feb; 134(2):223

STANDARDS

Evaluation of the quality of surgical gloves among four different manufactures. Hwang KL, et al. **Ann Occup Hyg** 1999 May;43(4):275–81
Improving glove barrier effectiveness. Rabussay DP, et al. **AORN J** 1997 Dec;66(6):1043–6, 1049–54, 1057–60 passim (55 ref.)
Failure of a new double glove hole detection system in the Emergency Department. Fisher MD, et al. **J Biomed Mater Res** 1999;48(2):199–201

UTILIZATION

Glove usage and reporting of needlestick injuries by junior hospital medical staff. Hettiaratchy S, et al. **Ann R Coll Surg Engl** 1998 Nov;80(6):439–41
The use of gloves in Australian dermatological practice. Ong CS, et al. **Australas J Dermatol** 1999 May;40(2):83–8
The global ethics of latex gloves: reflections on natural resource use in healthcare. Pierce J, et al. **Camb Q Healthc Ethics** 1999 Winter;8(1):98–107

GLQ223 see **TRICHOSANTHIN**

GLUCAGON

see related
RECEPTORS, GLUCAGON

[GLP-1 (7–36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM] Gutniak M. **Journ Annu Diabetol Hotel Dieu** 1998;:157–71 (59 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

The usefulness of glucagon hydrochloride for colonic distention in CT colonography. Yee J, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):169–72
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Gutzwiller JP, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1541–4
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Todd JF, et al. **Clin Sci (Colch)** 1998 Sep;95(3):325–9
Metabolic responses of dairy cows and heifers to various intravenous dosages of glucagon. Hippen AR, et al. **J Dairy Sci** 1999 Jun;82(6):1128–38
Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. Hippen AR, et al. **J Dairy Sci** 1999 Jun;82(6):1139–52
Metabolic responses of lactating dairy cows to 14-day intravenous infusions of glucagon. She P, et al. **J Dairy Sci** 1999 Jun;82(6):1118–27
Regulation of messenger ribonucleic acid expression for gluconeogenic enzymes during glucagon infusions into lactating cows. She P, et al. **J Dairy Sci** 1999 Jun; 82(6):1153–63
Effect of amino acids on the plasma concentration and urinary excretion of uric acid and uridine. Yamamoto T, et al. **Metabolism** 1999 Aug;48(8):1023–7
[Case of pancreatic diabetes with improvement in carbohydrate and lipid metabolism brought about by injections of a small quantity of glucagon] Kawashima J, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):336–8 **(Jpn)**

ADVERSE EFFECTS

Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. Mochiki E, et al. **J Gastroenterol** 1998 Dec; 33(6):835–41

ANALYSIS

Cellular composition and anatomic distribution in nonfunctioning pancreatic endocrine tumors: immunohistochemical study of 30 cases. Zheng X, et al. **Chin Med J (Engl)** 1998 Apr;111(4):373–6
Glucagonoma syndrome: survival 24 years following diagnosis. Nightingale KJ, et al. **Dig Surg** 1999;16(1):68–71
Ultraimmunocytochemical analysis of pancreatic islet hormones. Tomasz P, et al. **Folia Histochem Cytobiol** 1999; 37(2):71–2
Glucagon- and NPY-related peptide-immunoreactive cells in the gut of sea bass (Dicentrarchus labrax L.): a light and electron microscopic study. Gómez-visus I, et al. **Gen Comp Endocrinol** 1998 Oct;112(1):26–37
A non-receptor-type protein phosphotyrosine phosphatase is enriched in secretory vesicles of glucagon - and pancreatic polypeptide - secreting cells of the endocrine pancreas. Wimmer M, et al. **Histochem Cell Biol** 1999 Feb; 111(2):135–42

ANTAGONISTS & INHIBITORS

Effect of GIP and GLP-1 antagonists on insulin release in the rat. Tseng CC, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1049–54
Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9–39). Meurer JA, et al. **Metabolism** 1999 Jun;48(6):716–24

BIOSYNTHESIS

Ultrastructural pattern of glucagon producing-cells in the gastric mucosa of the developing opossum Didelphis albiventris (Marsupialia). Fonseca CC, et al. **Anat Anz** 1998 Oct;180(5):477–80
Insulin, but not glucose lowering corrects the hyperglucagonemia and increased proglucagon messenger ribonucleic acid levels observed in insulinopenic diabetes. Dumonteil E, et al. **Endocrinology** 1998 Nov;139(11):4540–6
Integral rein control in physiology. Saunders PT, et al. **J Theor Biol** 1998 Sep 21;194(2):163–73
Removal of N-terminal polyhistidine tags from recombinant proteins using engineered aminopeptidases. Pedersen J, et al. **Protein Expr Purif** 1999 Apr;15(3):389–400

BLOOD

Inappropriately high plasma insulin levels in suspected perinatal asphyxia. Davis DJ, et al. **Acta Paediatr** 1999 Jan; 88(1):76–81
Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. MacIntosh CG, et al. **Am J Clin Nutr** 1999 May;69(5):999–1006
Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes. Hiroyoshi M, et al. **Am J Gastroenterol** 1999 Apr; 94(4):976–81
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Näslund E, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R910–6
Impact of lack of suppression of glucagon on glucose tolerance in humans. Shah P, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E283–90
Pattern of plasma cyclic nucleotides and related hormones in liver cirrhosis and hepatocellular carcinoma. Bamonti-Catena F, et al. **Clin Chem Lab Med** 1998 Sep; 36(9):709–14
Increased splanchnic blood flow after hypoglycaemia in diabetic and normal man: evidence against glucagon as a mediator. Parker DR, et al. **Clin Sci (Colch)** 1999 Feb; 96(2):179–84
Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Charlton MR, et al. **Diabetes** 1998 Nov;47(11):1748–56
Acute metabolic response to high-carbohydrate, high-starch meals compared with moderate-carbohydrate, low-starch meals in subjects with type 2 diabetes. Gannon MC, et al. **Diabetes Care** 1998 Oct;21(10):1619–26
Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Sàbat M, et al. **Dig Dis Sci** 1998 Oct;43(10):2184–9
Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Schiedermaier P, et al. **Digestion** 1999 Mar-Apr; 60(2):132–40
Effects of low feed intake and hot environment on plasma profiles of glucose, nonesterified fatty acids, insulin, glucagon, and IGF-I in lactating sows. de Bragança MM, et al. **Domest Anim Endocrinol** 1999 Feb;16(2):89–101
Heat influences on plasma insulin and glucagon in response to secretogogues in non-lactating dairy cows. Itoh F, et al. **Domest Anim Endocrinol** 1998 Nov;15(6):499–510
Insulin, but not glucose lowering corrects the hyperglucagonemia and increased proglucagon messenger ribonucleic acid levels observed in insulinopenic diabetes. Dumonteil E, et al. **Endocrinology** 1998 Nov;139(11):4540–6
Fasting increases the plasma glucagon response in the migratory garden warbler (Sylvia borin). Totzke U, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):116–21
Indices of carbohydrate and lipid metabolism in vasopressin-replete and -deficient New Zealand genetically hypertensive rats. Al-Barazanji KA, et al. **Horm Metab Res** 1998 Dec;30(12):717–20
Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Ranganath LR, et al. **Horm Metab Res** 1999 Apr;31(4):262–6
Leptin increases circulating glucose, insulin and glucagon via sympathetic neural activation in fasted mice. Ahrén B, et al. **Int J Obes Relat Metab Disord** 1999 Jun; 23(6):660–5
Splanchnic glucagon kinetics in exercising alloxan-diabetic dogs. Coker RH, et al. **J Appl Physiol** 1999 May; 86(5):1626–31
Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Acerini CL, et al. **Metabolism** 1998 Dec; 47(12):1481–9
The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Nyholm B, et al. **Metabolism** 1999 Jul;48(7):935–41
Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Wishart JM, et al. **Peptides** 1998;19(6):1049–53
Plasma glucagon, glucose, insulin, and motilin in rats anticipating daily meals. Davidson AJ, et al. **Physiol Behav** 1999 Apr;66(2):309–15
Plasma glicentin in diabetic and gastrectomized patients. Naito H, et al. **Regul Pept** 1999 Jan 1;79(1):55–61
Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Wettergren A, et al. **Regul Pept** 1998 Oct 16;77(1–3):83–7

CHEMISTRY

The interaction of bioactive peptides with an immobilized phosphatidylcholine monolayer. Mozsolits H, et al. **Biophys J** 1999 Sep;77(3):1428–44
Purification and characterization of insulin and peptides derived from proglucagon and prosomatostatin from the fruit-eating fish, the pacu Piaractus mesopotamicus. de Lima JA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):127–35
Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones. Holz GG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):177–84
Freeze tolerance in the wood frog Rana sylvatica is associated with unusual structural features in insulin but not in glucagon. Conlon JM, et al. **J Mol Endocrinol** 1998 Oct;21(2):153–9
Structure-function analysis of a series of glucagon-like peptide-1 analogs. Parker JC, et al. **J Pept Res** 1998 Nov; 52(5):398–409
Reformulated glucagon diluent phenol-free [letter] Burda AM, et al. **J Toxicol Clin Toxicol** 1999;37(1):127

CLASSIFICATION

The incretins--outdated terminology in man? [letter] Edwads CM, et al. **Diabetologia** 1999 Sep;42(9):1148–9

DIAGNOSTIC USE

Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST). Orme SM, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):773–8

GENETICS

Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones. Holz GG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):177–84
Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Kaneko K, et al.

Diabetes Res Clin Pract 1999 May;44(2):83–92

Chronic exposure to high glucose concentrations increases proglucagon messenger ribonucleic acid levels and glucagon release from InR1G9 cells. Dumonteil E, et al. **Endocrinology** 1999 Oct;140(10):4644–50

Pax6 and Cdx2/3 form a functional complex on the rat glucagon gene promoter G1-element. Andersen FG, et al. **FEBS Lett** 1999 Feb 26;445(2–3):306–10

Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. Kaestner KH, et al. **Genes Dev** 1999 Feb 15;13(4):495–504

Intestinal nutrient-gene interaction: the effect of feed deprivation and refeeding on cholecystokinin and proglucagon gene expression. Suominen AH, et al. **J Anim Sci** 1998 Dec;76(12):3104–13

Characterization of a novel calcium response element in the glucagon gene. Fürstenau U, et al. **J Biol Chem** 1999 Feb 26;274(9):5851–60

Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G1 control element. Ritz-Laser B, et al. **J Biol Chem** 1999 Feb 12;274(7):4124–32

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. Merchenthaler I, et al. **J Comp Neurol** 1999 Jan 11;403(2):261–80

Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7–36)amide on vasopressin and oxytocin release. Zueco JA, et al. **J Neurochem** 1999 Jan;72(1):10–6

Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Hill ME, et al. **Mol Endocrinol** 1999 Sep;13(9):1474–86

Association of leptin receptor (OB-Rb), NPY and GLP-1 gene expression in the ovine and murine brainstem. Mercer JG, et al. **Regul Pept** 1998 Sep 25;75–76:271–8

[Post-translational maturation of proglucagon: variations in tissues and regulation pathways] Bataille D, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:127–40 (45 ref.) **(Fre)**

[Expression and regulation of the glucagon gene] Ritz-Laser B, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:113–26 (85 ref.) **(Fre)**

IMMUNOLOGY

Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. Litvak DA, et al. **J Gastrointest Surg** 1998 Mar-Apr;2(2):146–50

ISOLATION & PURIFICATION

Experimental model for optimization of hydrophobic interaction: chromatographic purification of glucagon. Dimov N, et al. **Biomed Chromatogr** 1999 Jun;13(4):304–8

Purification and characterization of insulin and peptides derived from proglucagon and prosomatostatin from the fruit-eating fish, the pacu Piaractus mesopotamicus. de Lima JA, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):127–35

Multiple forms of glucagon and somatostatin isolated from the intestine of the southern-hemisphere lamprey Geotria australis. Wang Y, et al. **Gen Comp Endocrinol** 1999 Feb; 113(2):274–82

Insulin and proglucagon-derived peptides from the horned frog, Ceratophrys ornata (Anura:Leptodactylidae). White AM, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):143–54

METABOLISM

Involvement of a local fenton reaction in the reciprocal modulation by O2 of the glucagon-dependent activation of the phosphoenolpyruvate carboxykinase gene and the insulin-dependent activation of the glucokinase gene in rat hepatocytes. Kietzmann T, et al. **Biochem J** 1998 Oct 15; 335 (Pt 2):425–32

Tachykinins stimulate release of peptide hormones (glucagon-like peptide-1) and paracrine (somatostatin) and neurotransmitter (vasoactive intestinal polypeptide) from porcine ileum through NK-1 receptors. Schmidt PT, et al. **Dig Dis Sci** 1999 Jul;44(7):1273–81

Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2. Damholt AB, et al. **Endocrinology** 1999 Oct; 140(10):4800–8

Chronic exposure to high glucose concentrations increases proglucagon messenger ribonucleic acid levels and glucagon release from InR1G9 cells. Dumonteil E, et al. **Endocrinology** 1999 Oct;140(10):4644–50

Quantification of gluconeogenesis in cirrhosis: response to glucagon. Bugianesi E, et al. **Gastroenterology** 1998 Dec; 115(6):1530–40

Inhibitory effect of enterostatin on the beta cell response to digestive insulinotropic peptides. Rodriguez-Gallardo J, et al. **Int J Obes Relat Metab Disord** 1999 Aug;23(8):787–92

Intestinal nutrient-gene interaction: the effect of feed deprivation and refeeding on cholecystokinin and proglucagon gene expression. Suominen AH, et al. **J Anim Sci** 1998 Dec;76(12):3104–13

The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. Chen X, et al. **J Clin Invest** 1999 Feb;103(3):365–72

A synthetic glucagon-like peptide-1 analog with improved plasma stability. Ritzel U, et al. **J Endocrinol** 1998 Oct; 159(1):93–102

Human insulin induces a higher glucagon response to induced hypoglycemia in short normal children, compared to porcine insulin. Kanaka-Gantenbein C, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb;12(1):39–46

Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors. Yibchok-anun S, et al. **Life Sci** 1998; 63(21):1871–8

Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Mason EE. **Obes Surg** 1999 Jun; 9(3):223–8 (35 ref.)

Biological activity of GLP-1-analogues with N-terminal modifications. Siegel EG, et al. **Regul Pept** 1999 Feb 5; 79(2–3):93–102

Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin. Wøjdemann M, et al. **Regul Pept** 1999 Apr 30;80(3):101–6

[Quantitative change of glucagon and insulin immunoreactivities in the pancreas of fasting rats] Chen L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):359–60 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Effects of intravenous infusion of glucose and pancreatic glucagon on abomasal function in dairy cows. Holtenius K, et al. **Acta Vet Scand** 1998;39(2):291–300

Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):89–94

Apparent thermogenic effect of injected glucagon is not due to a direct effect on brown fat cells. Dicker A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1674–82

GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Näslund E, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R910–6

Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Wettergren A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G984–92

Miniglucagon: a local regulator of islet physiology. Dalle S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:132–40

Effect of rat glicentin on intestinal adaptation in small intestine-resected rats. Hirotani Y, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:601–5

A target cell to oxyntomodulin and glicentin: the antral smooth muscle cell. Rodier G, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:458–62

PACAP and GLP-1 protect islet beta-cells against Ca2+ toxicity induced by high K+. Yaekura K, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:445–50

Role of GLP-1 in meal-taking. Hellström PM, et al. **Appetite** 1999 Apr;32(2):276

Hormonal regulation of stearoyl coenzyme-A desaturase 1 activity and gene expression in primary cultures of chicken hepatocytes. Lefevre P, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):329–37

Identification of an oxygen-responsive element in the 5'-flanking sequence of the rat cytosolic phosphoenolpyruvate carboxykinase-1 gene, modulating its glucagon-dependent activation. Bratke J, et al. **Biochem J** 1999 May 1;339 (Pt 3):563–9

Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule. Aarab L, et al. **Br J Pharmacol** 1999 Feb;126(4):1041–9

Glucagon-like peptide-1 activates the adenylyl cyclase system in rockfish enterocytes and brain membranes. Mommsen TP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Sep; 121(1):49–56

Glucagon decreases cytokine induction of nitric oxide synthase and action on insulin secretion in RIN5F cells and rat and human islets of Langerhans. Belin VD, et al. **Cytokine** 1999 Aug;11(8):585–92

Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Sandhu H, et al. **Diabetes** 1999 May; 48(5):1045–53

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Buteau J, et al. **Diabetologia** 1999 Jul;42(7):856–64

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Greig NH, et al. **Diabetologia** 1999 Jan; 42(1):45–50

Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Tolessa T, et al. **Dig Dis Sci** 1998 Oct;43(10):2284–90

Glucagon ameliorates pancreatic subcellular redistribution of lysosomal enzyme in rats with acute pancreatitis of closed duodenal loop. Hirano T, et al. **Dig Surg** 1999;16(1):16–21

Effect of doses of glucagon used to treat food impaction on esophageal motor function of normal subjects. Colon V, et al. **Dysphagia** 1999 Winter;14(1):27–30

Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic beta-cells independently of protein kinase A. Bode HP, et al. **Endocrinology** 1999 Sep;140(9):3919–27

Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes [published erratum appears in Endocrinology 1999 Mar;140(3):1384] Rodier G, et al. **Endocrinology** 1999 Jan;140(1):22–8

Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Siegel EG, et al. **Eur J Clin Invest** 1999 Jul;29(7):610–4

Glucagon amplifies tetrodotoxin-resistant Na+ oscillations in glucose-stimulated pancreatic beta-cells. Grapengiesser E. **Exp Clin Endocrinol Diabetes** 1998;106(4):303–9

Somatostatin binding to hepatocytes isolated from rainbow trout, Oncorhynchus mykiss, is modulated by insulin and glucagon. Pesek MJ, et al. **Gen Comp Endocrinol** 1998 Nov; 112(2):183–90

Glucagon-like peptide-1: a potent regulator of food intake in humans. Gutzwiller JP, et al. **Gut** 1999 Jan;44(1):81–6

Inhibition of rat hepatocyte proliferation by transforming growth factor beta and glucagon is associated with inhibition of ERK2 and p70 S6 kinase. Dixon M, et al. **Hepatology** 1999 May;29(5):1418–24

Connexin 32 gap junctions enhance stimulation of glucose output by glucagon and noradrenaline in mouse liver. Stümpel F, et al. **Hepatology** 1998 Dec;28(6):1616–20

Miniglucagon (glucagon 19–29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. Dalle S, et al. **J Biol Chem** 1999 Apr 16;274(16):10869–76

A review of potential cardiovascular uses of intravenous glucagon administration. White CM. **J Clin Pharmacol** 1999 May;39(5):442–7 (41 ref.)

Effects of glucagon on glycogenolysis and gluconeogenesis are region-specific in periportal and perivenous hepatocytes. Ikezawa Y, et al. **J Lab Clin Med** 1998 Dec; 132(6):547–55

Glucagon induces suppression of ATP-sensitive K+ channel activity through a Ca2+/calmodulin-dependent pathway in mouse pancreatic beta-cells. He LP, et al. **J Membr Biol** 1998 Dec 1;166(3):237–44

Steroid hormones block amyloid fibril-induced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) formazan exocytosis: relationship to neurotoxicity. Liu Y, et al. **J Neurochem** 1998 Dec; 71(6):2322–9

Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells. Andreis PG, et al. **Life Sci** 1999;64(24):2187–97

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Burcelin R, et al. **Metabolism** 1999 Feb;48(2):252–8

Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Stumvoll M, et al. **Metabolism** 1998 Oct;47(10):1227–32

Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Salapatek AM, et al. **Mol Endocrinol** 1999 Aug; 13(8):1305–17

Effects of glucagon on axoplasmic transport in mouse superior cervical ganglion cells. Tao Y, et al. **Neuroreport** 1999 Aug 2;10(11):2401–4

Effects of glucagon in the control of endogenous glucose production in man. Surmely JF, et al. **Nutrition** 1999 Apr; 15(4):267–73

Central action of glucagon. Morawska D, et al. **Pol J Pharmacol** 1998 Mar-Apr;50(2):125–33

Preservation of livers from non-heart-beating donors: modulation of cAMP signal and organ viability by glucagon. Minor T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1068

Insulin and intracellular calcium responsiveness to glucagon-like peptide-1 and pituitary adenylate cyclase-activating peptide by dispersed adult porcine islet cells. Davalli AM, et al. **Transplantation** 1999 Jan 15; 67(1):174–6

[A new look at the mechanism of action of glucagon] Pecker F, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:141–55 (51 ref.) **(Fre)**

PHYSIOLOGY

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)

Is there appetite after GLP-1 and PACAP? Christophe J. **Ann N Y Acad Sci** 1998 Dec 11;865:323–35 (88 ref.)

Effect of rat glicentin on intestinal adaptation in small intestine-resected rats. Hirotani Y, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:601–5

Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)

Insulin, insulin-like growth factor-I (IGF-I) and glucagon: the evolution of their receptors. Navarro I, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):137–53 (153 ref.)

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Edwards CM, et al. **Diabetes** 1999 Jan;48(1):86–93

Effect of continuous subcutaneous insulin infusion with lispro

on hepatic responsiveness to glucagon in type 1 diabetes. Launay B, et al. **Diabetes Care** 1998 Oct;21(10):1627–31
The incretins--outdated terminology in man? [letter] Edwads CM, et al. **Diabetologia** 1999 Sep;42(9):1148–9
Is glucagon-like peptide 1 an incretin hormone? Nauck MA. **Diabetologia** 1999 Mar;42(3):373–9 (67 ref.)
Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Giralt M, et al. **Dig Dis Sci** 1999 Feb;44(2):322–9
Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Wang X, et al. **Endocrinology** 1999 Oct;140(10):4904–7
cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). Holz GG, et al. **J Biol Chem** 1999 May 14;274(20):14147–56
Insulin- and glucagon-independent effects of calcitonin gene-related peptide in the conscious dog. Moore MC, et al. **Metabolism** 1999 May;48(5):603–10
Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. van Delft J, et al. **Metabolism** 1999 Jan;48(1):41–6

SECRETION

Stimulation by 2-deoxy-D-glucose tetraacetates of hormonal secretion from the perfused rat pancreas. Leclercq-Meyer V, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E689–96
Dual mode of action of glucose pentaacetates on hormonal secretion from the isolated perfused rat pancreas. Leclercq-Meyer V, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E610–7
Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas. Yibchok-Anun S, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E56–62
Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Burcelin R, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:277–85 (42 ref.)
Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. Efanova IB, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):162–5
Evidence for nitric oxide mediated effects on islet hormone secretory phospholipase C signal transduction mechanisms. Akesson B, et al. **Biosci Rep** 1998 Aug;18(4):199–213
Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Kaneko K, et al. **Diabetes Res Clin Pract** 1999 May;44(2):83–92
Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Toft-Nielsen M, et al. **Diabetologia** 1998 Oct;41(10):1180–6
GLP-1 release in man after lower large bowel resection or intrarectal glucose administration. Printz H, et al. **Digestion** 1998 Nov-Dec;59(6):689–95
Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Rocca AS, et al. **Endocrinology** 1999 Apr;140(4):1687–94
Isolation of functional glucagon islets of Langerhans from the chicken pancreas. Ruffier L, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):153–62
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Landstedt-Hallin L, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3140–5
Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. Massimino SP, et al. **J Nutr** 1998 Oct;128(10):1786–93
Influence of nitric oxide modulators on cholinergically stimulated hormone release from mouse islets. Aring;kesson B, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):463–73
Gastrectomy induces impaired insulin and glucagon secretion: evidence for a gastro-insular axis in mice. Salehi A, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):579–91
Failure of human and mouse leptin to affect insulin, glucagon and somatostatin secretion by the perfused rat pancreas at physiological glucose concentration. Leclercq-Meyer V, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):111–8
Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Anini Y, et al. **Pflugers Arch** 1999 Aug;438(3):299–306
A nutrient-regulated cytosolic calcium oscillator in endocrine pancreatic glucagon-secreting cells. Bode HP, et al. **Pflugers Arch** 1999 Feb;437(3):324–34
Effects of branched-chain-enriched amino acid solution on insulin and glucagon secretion and blood glucose level in liver cirrhosis. Tabaru A, et al. **Scand J Gastroenterol** 1998 Aug;33(8):853–9

THERAPEUTIC USE

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Nauck MA. **Acta Diabetol** 1998 Oct;35(3):117–29 (166 ref.)
On the treatment of diabetes mellitus with glucagon-like peptide-1. Holst JJ, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:336–43 (37 ref.)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Ahrén B. **Bioessays** 1998 Aug;20(8):642–51 (74 ref.)
Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Nauck MA, et al. **Diabetes Care** 1998 Nov;21(11):1925–31
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Toft-Nielsen MB, et al. **Diabetes Care** 1999 Jul;22(7):1137–43
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Näslund E, et al. **Int J Obes Relat Metab Disord** 1999 Mar;23(3):304–11
Peduncular hallucinosis related to propranolol self-poisoning: efficacy of intravenous glucagon [letter] Hazouard E, et al. **Intensive Care Med** 1999 Mar;25(3):336–7
The effect of nutritional and hormonal supplementation on protein synthesis immediately after liver transplantation. Geevarghese SK, et al. **J Surg Res** 1999 Feb;81(2):196–200
Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Freyse EJ, et al. **Metabolism** 1999 Jan;48(1):134–7
[Severe intoxication probably from olanzapine (Zyprexa) Beneficial effect of glucagon] Joye F, et al. **Ann Fr Anesth Reanim** 1999 Jun;18(6):686–90 (Eng. Abstr.) **(Fre)**

GLUCAGON RECEPTORS see **RECEPTORS, GLUCAGON**

GLUCAGONOMA

COMPLICATIONS

A rare combination consisting of primary hyperaldosteronism and glucagonoma. Abe H, et al. **Am J Gastroenterol** 1999 May;94(5):1397–401 (31 ref.)
Differentiating non-paraneoplastic from glucagonoma associated necrolytic migratory erythema [letter] Rohna R, et al. **Singapore Med J** 1998 Aug;39(8):385
[Skin of lizard, skin of chagrin] Dolmazon C, et al. **Rev Med Interne** 1998;19 Suppl 2:264s–266s **(Fre)**
[Necrolytic migratory erythema] Dandrifosse JF, et al. **Rev Med Liege** 1998 Dec;53(12):778–83 (Eng. Abstr.) **(Fre)**
[Glucagonoma--somatostatinoma] Schusdziarra V. **Z Gastroenterol** 1999 Jun;Suppl 1:33–5 (20 ref.) **(Eng. Abstr.)** **(Ger)**
[Pancreatic glucagonoma and deep vein thrombosis] Guilarte López-Mañas J, et al. **Gastroenterol Hepatol** 1998 Dec; 21(10):483–5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Apoptosis with positive direct immunofluorescence findings in a patient with necrolytic migratory erythema. Perniciaro C, et al. **Cutis** 1998 Sep;62(3):129–32
Glucagonoma syndrome: survival 24 years following diagnosis. Nightingale KJ, et al. **Dig Surg** 1999;16(1):68–71
Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)
Image of the month. Glucagonoma syndrome. Halkic N, et al. **Gastroenterology** 1999 Jun;116(6):1286, 1510
Diabetes but not psoriasis. Uwaifo GI, et al. **Lancet** 1999 Aug 7;354(9177):480
[Glucogonoma syndrome] De Haas ER, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1336–7 **(Dut)**
[Coexistence of two different neuroendocrine tumors of the upper gastrointestinal tract and of the pancreas] Pfeiffer A. **Dtsch Med Wochenschr** 1999 Jun 4;124(22):712–3 **(Ger)**

EPIDEMIOLOGY

Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. Soga J, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):312–9 (23 ref.)

METABOLISM

Protein metabolism in glucagonoma. Barazzoni R, et al. **Diabetologia** 1999 Mar;42(3):326–9

PATHOLOGY

Glucagonoma syndrome: a case report. Shyr YM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep; 62(9):639–43 (12 ref.)
Asymptomatic glucagonoma presenting with an isolated hepatic nodule. De Giorgio R, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):1093–6
Cystic glucagonoma: A rare variant of an uncommon neuroendocrine pancreas tumor. Brown K, et al. **J Gastrointest Surg** 1998 Nov-Dec;2(6):533–6
[Mallison's tumor (glucagonoma)] Lakreeva MG, et al. **Khirurgiia (Mosk)** 1999;(2):63–6 (61 ref.) **(Rus)**

PHYSIOPATHOLOGY

A nutrient-regulated cytosolic calcium oscillator in endocrine pancreatic glucagon-secreting cells. Bode HP, et al. **Pflugers Arch** 1999 Feb;437(3):324–34

RADIONUCLIDE IMAGING

F-18 fluorodeoxyglucose positron emission tomography imaging in ectopic nonfunctioning glucagonoma. Yasuda S, et al. **Clin Nucl Med** 1998 Jul;23(7):474–5

SECONDARY

Treatment of metastatic glucagonoma to the liver: case report and literature review. Casadei R, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):308–12 (34 ref.)
[Status epilepticus: first manifestation of a metastatic glucagonoma (letter)] Alvarez de Arcaya A, et al. **Rev Clin Esp** 1998 Oct;198(10):713–4 **(Spa)**

SECRETION

The entero-insular axis in glucagonoma. A report of 2 cases [letter] Ranganath L, et al. **Clin Endocrinol (Oxf)** 1999 Jun; 50(6):817–8

THERAPY

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)
Treatment of metastatic glucagonoma to the liver: case report and literature review. Casadei R, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):308–12 (34 ref.)

GLUCAN 1,4-ALPHA-GLUCOSIDASE

see related **GLYCOGEN STORAGE DISEASE TYPE II**

ADVERSE EFFECTS

Occupational protein contact dermatitis from glucoamylase. Kanerva L, et al. **Contact Dermatitis** 1999 Sep;41(3):171–3

ANALYSIS

Simultaneous measurement of alpha-amylase and glucoamylase activities in sake rice koji by capillary electrophoresis of sodium dodecyl sulfate-protein complexes and activity measurement of glucoamylase by in-capillary enzyme reaction method. Watanabe T, et al. **Electrophoresis** 1998 Oct;19(13):2331–7

ANTAGONISTS & INHIBITORS

Baicalein, an alpha-glucosidase inhibitor from Scutellaria baicalensis. Nishioka T, et al. **J Nat Prod** 1998 Nov; 61(11):1413–5

BIOSYNTHESIS

pH regulation of recombinant glucoamylase production in Fusarium venenatum JeRS 325, a transformant with a Fusarium oxysporum alkaline (trypsin-like) protease promoter [letter] Wiebe MG, et al. **Biotechnol Bioeng** 1999 Aug 5;64(3):368–72
Optimization and stability of glucoamylase production by recombinant strains of Aspergillus niger in chemostat culture. Withers JM, et al. **Biotechnol Bioeng** 1998 Aug 20;59(4):407–18
Recombinant glucoamylase production by Aspergillus niger B1 in chemostat and pH auxostat cultures. Swift RJ, et al. **Fungal Genet Biol** 1998 Nov;25(2):100–9

CHEMISTRY

Structure of glucoamylase from Saccharomycopsis fibuligera at 1.7 A resolution. Sevčík J, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):854–66
Thermodynamics of reversible and irreversible unfolding and domain interactions of glucoamylase from Aspergillus niger studied by differential scanning and isothermal titration calorimetry. Christensen T, et al. **Biochemistry** 1999 May 11;38(19):6300–10
Thermal unfolding of the starch binding domain of Aspergillus niger glucoamylase. Tanaka A, et al. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2127–32
Crosslinking of glucoamylases via carbohydrates hardly affects catalysis but impairs stability. Sasvári Z, et al. **Biotechnol Bioeng** 1999 May 20;63(4):459–63
Structure-function relationships in glucoamylases encoded by variant Saccharomycopsis fibuligera genes. Solovicová A, et al. **Eur J Biochem** 1999 Sep;264(3):756–64
X-ray analysis of yeast glucoamylases prepared by gene engineering techniques. Solovicová A, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:16–8
Coimmobilization of glucoamylase and glucose isomerase by molecular deposition technique for one-step conversion of dextrin to fructose. Ge Y, et al. **J Biotechnol** 1999 Jan 8; 67(1):33–40
Stabilization of Aspergillus awamori glucoamylase by proline substitution and combining stabilizing mutations. Allen MJ, et al. **Protein Eng** 1998 Sep;11(9):783–8

DEFICIENCY

Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of

Japanese quail with acid maltase deficiency. Tsujino S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1609-16

A 60-year-old woman with weakness, fatigue, and acute respiratory failure: case report and discussion of the differential diagnosis. Sander HW, et al. **Mil Med** 1998 Oct; 163(10):715-8

Decompensated cor pulmonaleas the first manifestation of adult-onset myopathy. Kurz D, et al. **Respiration** 1998; 65(4):317-9

GENETICS

Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation. Ponce E, et al. **Am J Pathol** 1999 Apr;154(4):1089-96

Development of an arming yeast strain for efficient utilization of starch by co-display of sequential amylolytic enzymes on the cell surface. Murai T, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):65-70

pH regulation of recombinant glucoamylase production in Fusarium venenatum JeRS 325, a transformant with a Fusarium oxysporum alkaline (trypsin-like) protease promoter [letter] Wiebe MG, et al. **Biotechnol Bioeng** 1999 Aug 5;64(3):368-72

Improving operating performance of glucoamylase by mutagenesis. Ford C. **Curr Opin Biotechnol** 1999 Aug; 10(4):353-7 (53 ref.)

Structure-function relationships in glucoamylases encoded by variant Saccharomycopsis fibuligera genes. Solovicová A, et al. **Eur J Biochem** 1999 Sep;264(3):756-64

Genetic and enzymatic characterisation of glucoamylases from yeast. Hostinová E. **Gen Physiol Biophys** 1998 Jun; 17 Suppl 1:19-21

X-ray analysis of yeast glucoamylases prepared by gene engineering techniques. Solovicová A, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:16-8

Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Tsujino S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1609-16

Study of the glucoamylase promoter in Aspergillus niger using green fluorescent protein. Santerre Henriksen AL, et al. **Microbiology** 1999 Mar;145 (Pt 3):729-34

Functional analysis of multiple AUG codons in the transcripts of the STA2 glucoamylase gene from Saccharomyces cerevisiae. Vivier MA, et al. **Mol Gen Genet** 1999 Feb;261(1):11-20

Effect on thermostability and catalytic activity of introducing disulfide bonds into Aspergillus awamori glucoamylase. Li Y, et al. **Protein Eng** 1998 Aug;11(8):661-7

ISOLATION & PURIFICATION

Purification and properties of the raw-starch-digesting glucoamylases from Corticium rolfsii. Nagasaka Y, et al. **Appl Microbiol Biotechnol** 1998 Sep;50(3):323-30

METABOLISM

Molecular breeding of polysaccharide-utilizing yeast cells by cell surface engineering. Ueda M, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:528-37

Purification and properties of the raw-starch-digesting glucoamylases from Corticium rolfsii. Nagasaka Y, et al. **Appl Microbiol Biotechnol** 1998 Sep;50(3):323-30

Kinetics and performance of a co-immobilised system of amyloglucosidase and Zymomonas mobilis. Hellendoorn L, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):694-704

Crosslinking of glucoamylases via carbohydrates hardly affects catalysis but impairs stability. Sasvári Z, et al. **Biotechnol Bioeng** 1999 May 20;63(4):459-63

Improving operating performance of glucoamylase by mutagenesis. Ford C. **Curr Opin Biotechnol** 1999 Aug; 10(4):353-7 (53 ref.)

Separation and direct detection of raw and gelatinized starch hydrolyzing activities of glucoamylase on isoelectric focusing gels. Suresh C, et al. **Electrophoresis** 1999 Mar; 20(3):483-5

Functional analysis of O-linked oligosaccharides in threonine/serine-rich region of Aspergillus glucoamylase by expression in mannosyltransferase-disruptants of yeast. Goto M, et al. **Eur J Biochem** 1999 Mar;260(3):596-602

Determinants of the fidelity of processing glucoamylase-lysozyme fusions by Aspergillus niger. Spencer JA, et al. **Eur J Biochem** 1998 Nov 15; 258(1):107-12

The starch-binding domain from glucoamylase disrupts the structure of starch. Southall SM, et al. **FEBS Lett** 1999 Mar 19;447(1):58-60

Genetic and enzymatic characterisation of glucoamylases from yeast. Hostinová E. **Gen Physiol Biophys** 1998 Jun; 17 Suppl 1:19-21

The degradation of glycogen in the lysosomes of newborn rat hepatocytes: glycogen-, maltose- and isomaltose-hydrolyzing acid alpha glucosidase activities in liver. Kalamidas SA, et al. **Histol Histopathol** 1999 Jan; 14(1):23-30

Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome. Morisawa Y, et al. **J Neurol Sci** 1998 Oct 8;160(2):175-9

Effect on thermostability and catalytic activity of introducing disulfide bonds into Aspergillus awamori glucoamylase. Li Y, et al. **Protein Eng** 1998 Aug;11(8):661-7

Mutations to alter Aspergillus awamori glucoamylase selectivity. IV. Combinations of Asn20-->Cys/Ala27-->Cys, Ser30-->Pro, Gly137-->Ala, 311-4 loop, Ser411-->Ala and Ser436-->Pro. Liu HL, et al. **Protein Eng** 1999 Feb; 12(2):163-72

THERAPEUTIC USE

Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. Fridh G, et al. **Swed Dent J** 1999; 23(2-3):49-57

[Treatment of Pompe's disease with recombinant enzymes] Van Hove JL. **Verh K Acad Geneeskd Belg** 1998; 60(4):347-57 (Eng. Abstr.) **(Dut)**

GLUCAN ENDO-1,3-BETA-D-GLUCOSIDASE

News & notes: production, purification, and properties of an endo-1, 3-beta-glucanase from the basidiomycete Agaricus bisporus. Galán B, et al. **Curr Microbiol** 1999 Mar; 38(3):190-3

Identification of contaminating fungal DNA sequences in Zymolyase. Rimek D, et al. **J Clin Microbiol** 1999 Mar; 37(3):830-1

CHEMISTRY

The laminarinase from thermophilic eubacterium Rhodothermus marinus--conformation, stability, and identification of active site carboxylic residues by site-directed mutagenesis. Krah M, et al. **Eur J Biochem** 1998 Oct 1;257(1):101-11

GENETICS

Purification and characterization of P33 protein of Candida utilis homologous to bgl2p of Saccharomyces cerevisiae; comparative analysis of the role of these proteins in molecular organization of the yeast cell walls. Kalebina TS, et al. **Biochemistry (Mosc)** 1998 Dec;63(12):1419-23

ISOLATION & PURIFICATION

Purification and determination of the action pattern of Haliotis tuberculata laminarinase. Lépagnol-Descamps V, et al. **Carbohydr Res** 1998 Aug;310(4):283-9

METABOLISM

A 1,3-beta-glucanosyltransferase isolated from the cell wall of Aspergillus fumigatus is a homologue of the yeast Bgl2p. Mouyna I, et al. **Microbiology** 1998 Nov;144 (Pt 11):3171-80

GLUCAN PHOSPHORYLASE see **PHOSPHORYLASE**

GLUCAN 1,4-ALPHA-GLUCOSIDASE

GENETICS

The identification of five novel mutations in the lysosomal acid a-(1-4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online. Beesley CE, et al. **Hum Mutat** 1998;11(5):413

GLUCANS

Maillard reaction and AGE formation in glucose and polyglucose dialysis solutions. Tomo T, et al. **Perit Dial Int** 1999 May-Jun;19(3):274-7

ADMINISTRATION & DOSAGE

The taste of polycose in hamsters. Formaker BK, et al. **Chem Senses** 1998 Dec;23(6):675-82

An airbone mold-derived product, beta-1,3-D-glucan, potentiates airway allergic responses. Wan GH, et al. **Eur J Immunol** 1999 Aug;29(8):2491-7

Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Soltys J, et al. **Infect Immun** 1999 Jan; 67(1):244-52

Quantitation of dextran 70 in peritoneal dialysate from patients administered 7.5% polyglucose. Burke RA, et al. **J Chromatogr B Biomed Sci Appl** 1998 Oct 23;718(1):115-20

[Glucose polymer (icodextrin) as a component of fluid for peritoneal dialysis] Czyżewska K, et al. **Pol Arch Med Wewn** 1998 May;99(5):417-22 (44 ref.) **(Pol)**

ADVERSE EFFECTS

Severe cutaneous hypersensitivity requiring permanent icodextrin withdrawal in a CAPD patient. Queffeulou G, et al. **Clin Nephrol** 1999 Mar;51(3):184-6

A review of the studies of the safety of polydextrose in food. Burdock GA, et al. **Food Chem Toxicol** 1999 Feb-Mar; 37(2-3):233-64 (21 ref.)

Reversibility of the curdlan feeding effects on the morphological structure of intestinal mucosa in rats. Tetsuguchi M, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Oct;44(5):601-12

Icodextrin allergy in a peritoneal dialysis patient. Fletcher S, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2656-8

A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Wens R, et al. **Perit Dial Int** 1998 Nov-Dec;18(6):603-9

ANALYSIS

Airways inflammation, atopy, and (1-->3)-beta-D-glucan exposures in two schools. Rylander R, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1685-7

Composition of the cell walls of several yeast species. Nguyen TH, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):206-12

Indoor endotoxin and glucan in association with airway inflammation and systemic symptoms. Wan GH, et al. **Arch Environ Health** 1999 May-Jun;54(3):172-9

Analysis of the oligosaccharide units of xyloglucans by digestion with isoprimeverose-producing oligoxyloglucan hydrolase followed by anion-exchange chromatography. Konishi T, et al. **Biosci Biotechnol Biochem** 1998 Dec; 62(12):2421-4

Structural analysis of xyloglucan oligosaccharides by the post-source decay fragmentation method of MALDI-TOF mass spectrometry: influence of the degree of substitution by branched galactose, xylose, and fucose on the fragment ion intensities. Yamagaki T, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2470-5

Positive interference of icodextrin metabolites in some enzymatic glucose methods [letter] Janssen W, et al. **Clin Chem** 1998 Nov;44(11):2379-80

Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. Uchiyama M, et al. **FEMS Immunol Med Microbiol** 1999 Jul 15; 24(4):411-20

Beta-glucan reflects liver injury after preservation and transplantation in dogs. Katsuramaki T, et al. **J Invest Surg** 1999 Jan-Feb;12(1):39-43

Corpus amylaceum (polyglucosan body) in the peripheral olfactory system. Leel-Ossy L, et al. **Pathol Oncol Res** 1998;4(3):212-6

BIOSYNTHESIS

Higher intracellular levels of uridinemonophosphate under nitrogen-limited conditions enhance metabolic flux of curdlan synthesis in Agrobacterium species. Kim MK, et al. **Biotechnol Bioeng** 1999 Feb 5;62(3):317-23

Detection of two loci involved in (1-->3)-beta-glucan (curdlan) biosynthesis by Agrobacterium sp. ATCC31749, and comparative sequence analysis of the putative curdlan synthase gene. Stasinopoulos SJ, et al. **Glycobiology** 1999 Jan;9(1):31-41

Cloning, sequencing, and characterization of the cgmB gene of Sinorhizobium meliloti involved in cyclic beta-glucan biosynthesis. Wang P, et al. **J Bacteriol** 1999 Aug; 181(15):4576-83

The role of glucosidase I (Cwh41p) in the biosynthesis of cell wall beta-1,6-glucan is indirect. Abeijon C, et al. **Mol Biol Cell** 1998 Oct;9(10):2729-38

Further studies of the role of cyclic beta-glucans in symbiosis. An NdvC mutant of Bradyrhizobium japonicum synthesizes cyclodecakis-(1-->3)-beta-glucosyl. Bhagwat AA, et al. **Plant Physiol** 1999 Mar;119(3):1057-64

BLOOD

Comparison of PCR, (1-->3)-beta-D-glucan and galactomannan assays in sera of rats with experimental invasive aspergillosis. Hashimoto A, et al. **J Clin Lab Anal** 1998;12(5):257-62

Evaluation of a new laboratory test measuring plasma (1-->3)-beta-D-glucan in the diagnosis of Candida deep mycosis: comparison with a serologic test. Hiyoshi M, et al. **Kansenshogaku Zasshi** 1999 Jan;73(1):1-6

[Clinical features of deep mycosis in critical care center--comparison of serological tests and cultures for mycosis] Kawayama T, et al. **Kansenshogaku Zasshi** 1999 Aug;73(8):743-8 (Eng. Abstr.) **(Jpn)**

[Non-culture based laboratory diagnosis of sepsis] Obayashi T. **Rinsho Byori** 1999 Jun;47(6):487-93 (6 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Isolation of a French bean (Phaseolus vulgaris L.) homolog to the beta-glucan elicitor-binding protein of soybean (Glycine max L.). Mithöfer A, et al. **Biochim Biophys Acta** 1999 Apr 14;1418(1):127-32

Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Akiyoshi K, et al. **Bioconjug Chem** 1999 May-Jun;10(3):321-4

Structural studies of the extracellular beta-D-glucans from Phytophthora parasitica Dastur. Gandon C, et al. **Carbohydr Res** 1998 Dec 15;313(3-4):259-63

Self-assembling nanospheres of hydrophobized pullulans in water. Jeong YI, et al. **Drug Dev Ind Pharm** 1999 Aug; 25(8):917-27

Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. Akiyoshi K, et al. **J Controlled Release** 1998 Aug 14;54(3):313-20

Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. Tabata Y, et al. **J Interferon Cytokine Res** 1999 Mar;19(3):287-92

Comparative measurement of the molecular weight of an

antineoplastic glucan from BCG vaccine. Farrugia IV, et al. **J Pharm Pharmacol** 1998 Nov;50(11):1205-11

IMMUNOLOGY

(1-->3)-beta-D-glucan may contribute to pollen sensitivity. Rylander R, et al. **Clin Exp Immunol** 1999 Mar;115(3):383-4

An airbone mold-derived product, beta-1,3-D-glucan, potentiates airway allergic responses. Wan GH, et al. **Eur J Immunol** 1999 Aug;29(8):2491-7

(1-->3)-beta-D-glucan and endotoxin modulate immune response to inhaled allergen. Rylander R, et al. **Mediators Inflamm** 1998;7(2):105-10

ISOLATION & PURIFICATION

Purification of a growth-suppressing factor for bovine artery endothelial cells from mouse lymphoma P388D1 cells. Usui S, et al. **Biol Pharm Bull** 1999 Jan;22(1):16-20

Solubilization of yeast cell-wall beta-(1-->3)-D-glucan by sodium hypochlorite oxidation and dimethyl sulfoxide extraction. Ohno N, et al. **Carbohydr Res** 1999 Mar 31; 316(1-4):161-72

Isolation and characterization of cyclic alpha-(1-->4)-glucans having degrees of polymerization 9-31 and their quantitative analysis by high-performance anion-exchange chromatography with pulsed amperometric detection. Koizumi K, et al. **J Chromatogr A** 1999 Aug 13;852(2):407-16

METABOLISM

Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Lossos A, et al. **Ann Neurol** 1998 Dec;44(6):867-72

Production of sophorolipids from whey: development of a two-stage process with Cryptococcus curvatus ATCC 20509 and Candida bombicola ATCC 22214 using deproteinized whey concentrates as substrates. Daniel HJ, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):40-5

Structure of the glucan-binding sugar chain of Tip1p, a cell wall protein of Saccharomyces cerevisiae. Fujii T, et al. **Biochim Biophys Acta** 1999 Apr 19;1427(2):133-44

Identification, purification and properties of a beta-1,3-glucan-specific lectin from the serum of the cockroach, Blaberus discoidalis which is implicated in immune defence reactions. Chen C, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Mar; 122(3):309-19

Detection of enzymes active on various beta-1,3-glucans after denaturing polyacrylamide gel electrophoresis. Trudel J, et al. **Electrophoresis** 1998 Jul;19(10):1788-92

Functional reconstitution of beta-glucan elicitor-binding activity upon incorporation into lipid vesicles. Mithöfer A, et al. **FEBS Lett** 1999 Sep 17;458(2):129-32

Evidence for substrate binding of a recombinant thermostable xylanase originating from Rhodothermus marinus. Karlsson EN, et al. **FEMS Microbiol Lett** 1998 Nov 1;168(1):1-7

Structural and antigenic characteristics of Streptococcus sobrinus glucan binding proteins. Smith DJ, et al. **Infect Immun** 1998 Nov;66(11):5565-9

Two major proteins from locust plasma are involved in coagulation and are specifically precipitated by laminarin, a beta-1,3-glucan. Duvic B, et al. **Insect Biochem Mol Biol** 1998 Dec;28(12):959-67

The mdoC gene of Escherichia coli encodes a membrane protein that is required for succinylation of osmoregulated periplasmic glucans. Lacroix JM, et al. **J Bacteriol** 1999 Jun;181(12):3626-31

The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Xia Y, et al. **J Immunol** 1999 Feb 15;162(4):2281-90

Crystal structure of Thermoactinomyces vulgaris R-47 alpha-amylase II (TVAII) hydrolyzing cyclodextrins and pullulan at 2.6 A resolution. Kamitori S, et al. **J Mol Biol** 1999 Apr 16;287(5):907-21

Adult polyglucosan body disease associated with an extrapyramidal syndrome. Robertson NP, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):788-90 (22 ref.)

The contribution of the O-glycosylated protein Pir2p/Hsp150 to the construction of the yeast cell wall in wild-type cells and beta 1,6-glucan-deficient mutants. Kapteyn JC, et al. **Mol Microbiol** 1999 Mar;31(6):1835-44

A cytokinesis-defective mutant of Arabidopsis (cyt1) characterized by embryonic lethality, incomplete cell walls, and excessive callose accumulation. Nickle TC, et al. **Plant J** 1998 Aug;15(3):321-32

Several thaumatin-like proteins bind to beta-1,3-glucans. Trudel J, et al. **Plant Physiol** 1998 Dec;118(4):1431-8

Reaggregation and binding of cell wall proteins from Candida albicans to structural polysaccharides. Aguado C, et al. **Res Microbiol** 1998 May;149(5):327-38

Growth dependence of alpha-glucan phosphorylase activity in Thermus thermophilus. Boeck B, et al. **Res Microbiol** 1998 Mar;149(3):171-6

Three-dimensional structure of a barley beta-D-glucan exohydrolase, a family 3 glycosyl hydrolase. Varghese JN, et al. **Structure Fold Des** 1999 Feb 15;7(2):179-90

PHARMACOKINETICS

Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Liang J, et al. **Int J Immunopharmacol** 1998 Nov;20(11):595-614

Enhanced accumulation of sialyl Lewis X-carboxymethylpullulan conjugate in acute inflammatory lesion. Horie K, et al. **Pharm Res** 1999 Feb;16(2):314-20

PHARMACOLOGY

Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with beta-glucan. Bourdon I, et al. **Am J Clin Nutr** 1999 Jan; 69(1):55-63

Effect of intramammary infusion of beta-1,3-glucan or interleukin-2 on leukocyte subpopulations in mammary glands of sheep. Waller KP, et al. **Am J Vet Res** 1999 Jun; 60(6):703-7

Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill. Fujimiya Y, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):113-8

Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Dellinger EP, et al. **Arch Surg** 1999 Sep;134(9):977-83

Increase of hematopoietic responses by triple or single helical conformer of an antitumor (1-->3)-beta-D-glucan preparation, Sonifilan, in cyclophosphamide-induced leukopenic mice. Tsuzuki A, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):104-10

Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Ebina T, et al. **Biotherapy** 1998;11(4):259-65

Effect of beta-glucan from oats and yeast on serum lipids. Bell S, et al. **Crit Rev Food Sci Nutr** 1999 Mar;39(2):189-202 (33 ref.)

Molecular cloning of cDNA for pro-phenol-oxidase-activating factor I, a serine protease is induced by lipopolysaccharide or 1,3-beta-glucan in coleopteran insect, Holotrichia diomphalia larvae. Lee SY, et al. **Eur J Biochem** 1998 Nov 1;257(3):615-21

In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Patchen ML, et al. **Exp Hematol** 1998 Dec; 26(13):1247-54

Babesia bigemina: in vitro and in vivo effects of curdlan sulfate on growth of parasites. Igarashi I, et al. **Exp Parasitol** 1998 Nov;90(3):290-3

Inhibition of lymphoproliferative response and its restoration with a glucan immunomodulator in mice with experimental larval toxocarosis. Borošková Z, et al. **Folia Microbiol (Praha)** 1998;43(5):475-6

Effects of in vivo administration of adamantylamide dipeptide on bone marrow granulocyte-macrophage hemopoietic progenitor cells (GM-CFC) and on ability of serum of the treated mice to stimulate GM-CFC colony formation in vitro: comparison with muramyl dipeptide and glucan. Vacek A, et al. **Immunopharmacol Immunotoxicol** 1999 Feb; 21(1):1-14

Effects of particulate and soluble (1-3)-beta-glucans on Ca2+ influx in NR8383 alveolar macrophages. Mörk AC, et al. **Immunopharmacology** 1998 Jul;40(1):77-89

PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Wakshull E, et al. **Immunopharmacology** 1999 Feb;41(2):89-107

Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Liang J, et al. **Int J Immunopharmacol** 1998 Nov;20(11):595-614

Role of curdlan sulfate in the production of beta-chemokines and interleukin-16. Naito T, et al. **Med Microbiol Immunol (Berl)** 1998 Jun;187(1):43-8

Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Woodrow G, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1530-5

Tolerance to morphine-induced antinociception is decreased by chronic sucrose or polycose intake. D'Anci KE. **Pharmacol Biochem Behav** 1999 May;63(1):1-11

Immunologically active (1-->3)-(1-->4)-alpha-D-glucan from Cetraria islandica. Olafsdottir ES, et al. **Phytomedicine** 1999 Mar;6(1):33-9

The effect of nonspecific immunostimulation of pregnant mares with 1,3/1,6 glucan and levamisole on the immunoglobulins levels in colostrum, selected indices of nonspecific cellular and humoral immunity in foals in neonatal and postnatal period. Krakowski L, et al. **Vet Immunol Immunopathol** 1999 Mar 29;68(1):1-11

THERAPEUTIC USE

Plasma lipid changes after supplementation with beta-glucan fiber from yeast. Nicolosi R, et al. **Am J Clin Nutr** 1999 Aug;70(2):208-12

"Active hypoallergenicity" [letter; comment] Perrenoud D, et al. **Contact Dermatitis** 1998 Nov;39(5):274. Comment on: Contact Dermatitis 1998 Mar;38(3):123-6.

Therapeutic intervention with complement and beta-glucan in cancer. Ross GD, et al. **Immunopharmacology** 1999 May; 42(1-3):61-74 (116 ref.)

Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). Yan J, et al. **J Immunol** 1999 Sep 15;163(6):3045-52

Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Posthuma N, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2341-4

Inhibiting early activation of tissue nuclear factor-kappa B and nuclear factor interleukin 6 with (1-->3)-beta-D-glucan increases long-term survival in polymicrobial sepsis. Williams DL, et al. **Surgery** 1999 Jul; 126(1):54-65

TOXICITY

A toxicological assessment of curdlan. Spicer EJ, et al. **Food Chem Toxicol** 1999 Apr;37(4):455-79

GLUCARIC ACID

ANALOGS & DERIVATIVES

ND-2001 suppresses lung metastasis of human renal cancer cells in athymic mice. Kuramitsu Y, et al. **Anticancer Drugs** 1998 Sep;9(8):739-41

Inhibitory effect of ND2001 on spontaneous multiple metastasis of NC 65 tumors derived from human renal cancer cells intradermally transplanted into nude mice. Nakatsugawa S, et al. **Anticancer Drugs** 1999 Feb; 10(2):229-33

CHEMISTRY

Evolution of enzymatic activities in the enolase superfamily: characterization of the (D)-glucarate/galactarate catabolic pathway in Escherichia coli. Hubbard BK, et al. **Biochemistry** 1998 Oct 13;37(41):14369-75

GLUCITOL see **SORBITOL**

GLUCOAMYLASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

GLUCOCEREBROSIDASE see **GLUCOSYLCERAMIDASE**

GLUCOCEREBROSIDES see **GLUCOSYLCERAMIDES**

GLUCOCHLORAL see **CHLORALOSE**

GLUCOCORTICOID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

GLUCOCORTICOID RECEPTORS see **RECEPTORS, GLUCOCORTICOID**

GLUCOCORTICOIDS

see related
RECEPTORS, GLUCOCORTICOID

Multiplicity of glucocorticoid action in inhibiting allograft rejection. Almawi WY, et al. **Cell Transplant** 1998 Nov-Dec;7(6):511-23 (199 ref.)

Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia. Ortoft G, et al. **J Bone Miner Res** 1999 May; 14(5):710-21

Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. Reynolds PD, et al. **J Clin Endocrinol Metab** 1999 Feb; 84(2):663-9

ADMINISTRATION & DOSAGE

Can growth hormone counteract the effects of glucocorticoids on protein metabolism? Beaufrère B. **Acta Paediatr Suppl** 1999 Feb;88(428):97-9 (24 ref.)

Mechanisms of rhinitis. Baraniuk JN. **Allergy Asthma Proc** 1998 Nov-Dec;19(6):343-7 (37 ref.)

Comparison of clinical efficacy of inhaled glucocorticoids. Rohdewald PJ. **Arzneimittelforschung** 1998 Aug; 48(8):789-96 (36 ref.)

Age-dependent effect of oral glucocorticoids on markers of bone resorption in patients with acute asthma. Bornefalk E, et al. **Calcif Tissue Int** 1998 Jul;63(1):9-13

Administration of a glucocorticoid with depot effect counteracts the stimulating effect of growth hormone on cancellous and cortical bone of the vertebral body in rats. Ortoft G, et al. **Calcif Tissue Int** 1998 Jul;63(1):14-21

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Steroid delivery in croup. Maurice S. **J Accid Emerg Med** 1998 Jul;15(4):229

Pressurized metered-dose inhalers and holding chambers for inhaled glucocorticoid therapy in childhood asthma [letter; comment] Rubin BK. **J Allergy Clin Immunol** 1999 Jun; 103(6):1224-5. Comment on: J Allergy Clin Immunol 1998 Nov;102(5):719-21.

Benefits and risks of inhaled glucocorticoids in children with persistent asthma. Simons FE. **J Allergy Clin Immunol** 1998 Nov;102(5):S77-84 (75 ref.)

Mechanisms of glucocorticoid reduction in asthmatic subjects

treated with intravenous immunoglobulin. Spahn JD, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):421–6

Early steroid withdrawal in liver transplantation is safe and beneficial. Everson GT, et al. **Liver Transpl Surg** 1999 Jul; 5(4 Suppl 1):S48–57 (23 ref.)

Treatment of glucocorticoid-dependent Takayasu's arteritis with cyclosporin [letter] Horigome H, et al. **Med J Aust** 1999 Jun 7;170(11):566

Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies [see comments] Braithwaite SS, et al. **Postgrad Med** 1998 Nov;104(5):163–6, 171, 175–6 . Comment in: Postgrad Med 1999 May 1;105(5):36.

Corticosteroid treatment of asthma: now at the crossroads. Reply to Drs Seale and Donnelly [letter] Szefler SJ. **Respir Med** 1999 Feb;93(2):142–4

How should rheumatologists prescribe low-dose glucocorticoids? [editorial] Palazzo E. **Rev Rhum Engl Ed** 1999 Mar;66(3):127–30

[Increased cataract risk with increased inhalation of steroids?] Ritzmann P. **Schweiz Rundsch Med Prax** 1999 Jun 24; 88(25–26):1144 **(Ger)**

[Stress steroids] Inada E. **Masui** 1998 Dec;47 Suppl:S70–6 (31 ref.) **(Jpn)**

ADVERSE EFFECTS

Do inhaled corticosteroids significantly increase cataract surgery in elderly patients? Franfelder FT. **Arch Ophthalmol** 1998 Oct;116(10):1369

Diagnosis and treatment of glucocorticoid-induced osteoporosis. Zaqqa D, et al. **Cleve Clin J Med** 1999 Apr; 66(4):221–30 (60 ref.)

The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. Oelkers W. **Eur J Endocrinol** 1998 Dec;139(6):567–70 (22 ref.)

Steroid safety: the endocrinologist's view. Grossman A. **Int J Clin Pract Suppl** 1998 Sep;96:33–8 (14 ref.)

Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications. Wolthers OD, et al. **J Asthma** 1999 Sep;36(6):477–86 (119 ref.)

Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. Ishida Y, et al. **J Bone Miner Res** 1998 Dec;13(12):1822–6 (81 ref.)

New developments in the pathogenesis and treatment of steroid-induced osteoporosis[Editorial] Manolagas SC, et al. **J Bone Miner Res** 1999 Jul;14(7):1061–6 (38 ref.)

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. Eastell R, et al. **J Intern Med** 1998 Oct;244(4):271–92 (129 ref.)

Glucocorticoid-induced secondary osteopenia in female rats: a time course study as compared with ovariectomy-induced osteopenia and response to salmon calcitonin. Nitta T, et al. **Jpn J Pharmacol** 1999 Mar; 79(3):379–86

Prevention and treatment of glucocorticoid-induced osteoporosis. Eggelmeijer F. **Pharm World Sci** 1998 Oct; 20(5):193–7 (50 ref.)

Do long-term glucocorticoid treatments induce behavioral rhythm disturbances in rats? Endo Y. **Physiol Behav** 1999 Jul;66(5):751–5

Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Cortet B, et al. **Rev Rhum Engl Ed** 1999 Apr;66(4):214–9

Drug selection and the management of corticosteroid-related diabetes mellitus. Hoogwerf B, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):489–505 (69 ref.)

Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? Robinzon B, et al. **Rheumatology (Oxford)** 1999 Jun;38(6):488–95 (111 ref.)

[Severe osteoporosis during glucocorticoid therapy] Aitio ML, et al. **Duodecim** 1995;111(20):1949–53 **(Fin)**

[Corticosteroid osteoporosis in the adult] Weryha G, et al. **Presse Med** 1998 Oct 24;27(32):1641–6 (44 ref.) (Eng. Abstr.) **(Fre)**

[Increased cataract risk with increased inhalation of steroids?] Ritzmann P. **Schweiz Rundsch Med Prax** 1999 Jun 24; 88(25–26):1144 **(Ger)**

[Neurological side-effects of antiallergic drug, colchicine and glucocorticoids] Tanaka C, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):606–9 (12 ref.) **(Jpn)**

ANALOGS & DERIVATIVES see GLUCOCORTICOIDS, SYNTHETIC

ANALYSIS

Noninvasive fecal monitoring of glucocorticoids in spotted hyenas, Crocuta crocuta. Goymann W, et al. **Gen Comp Endocrinol** 1999 Jun;114(3):340–8

Fecal glucocorticoids document stress in female Barbary macaques (Macaca sylvanus). Wallner B, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):80–6

Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. Ghoshal K, et al. **J Biol Chem** 1998 Oct 23;273(43):27904–10

ANTAGONISTS & INHIBITORS

Release of endogenous dopamine in cultured mesencephalic neurons: influence of dopaminergic agonists and glucocorticoid antagonists. Rougé-Pont F, et al. **Eur J Neurosci** 1999 Jul;11(7):2343–50

Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids. Cheng W, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):265–71

Insulin inhibition of glucocorticoid-stimulated gene transcription: requirement for an insulin response element? Pierreux CE, et al. **Mol Cell Endocrinol** 1999 Jan 25; 147(1–2):1–5 (33 ref.)

Antisense oligomers of cfos and cjun block glucocorticoid stimulation of thyrotropin-releasing hormone (TRH) gene expression in cultured anterior pituitary cells. Luo LG, et al. **Peptides** 1998;19(8):1295–302

BIOSYNTHESIS

Paracrine glucocorticoid activity produced by mouse thymic epithelial cells. Pazirandeh A, et al. **FASEB J** 1999 May; 13(8):893–901

Phytoestrogens alter adrenocortical function: genistein and daidzein suppress glucocorticoid and stimulate androgen production by cultured adrenal cortical cells. Mesiano S, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2443–8

BLOOD

How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy? [letter] Koch CA, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):818–9

Relation of glucocorticosteroids and testosterone to the annual cycle of free-living degus in semiarid central Chile. Kenagy GJ, et al. **Gen Comp Endocrinol** 1999 Aug; 115(2):236–43

Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. Komesaroff PA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):606–10

Sclerosing pancreatocholangitis [letter] Kasperlik-Załuska AA, et al. **Lancet** 1999 Aug 28;354(9180):776

Correlation between plasma glucocorticoids and clinical outcomes in living-related renal transplant recipients. Shibata N, et al. **Transplant Proc** 1998 Nov;30(7):3053–6

[Protective role of the free glucocorticoid pool in development of autoimmune hemolytic anemia] Kariagina AIu, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):572–5 **(Rus)**

DEFICIENCY

Profound postanesthetic hypoglycemia attributable to glucocorticoid deficiency in 2 dogs. Lane IF, et al. **Can Vet J** 1999 Jul;40(7):497–500

Overlap of chronic fatigue syndrome with primary adrenocortical insufficiency [letter; comment] Baschetti R. **Horm Metab Res** 1999 Jul;31(7):439. Comment on: Horm Metab Res 1999 Jan;31(1):18–21.

Triple-A syndrome. Shivananda, et al. **Indian Pediatr** 1998 Nov;35(11):1131–5

Exclusion of the adrenocorticotropin (ACTH) receptor (MC2R) locus in some families with ACTH resistance but no mutations of the MC2R coding sequence (familial glucocorticoid deficiency type 2). Naville D, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3592–6

Gender-dependent characteristics of the hypothalamo-corticotrope axis function in glucocorticoid-replete and glucocorticoid-depleted rats. Chisari AN, et al. **J Endocrinol Invest** 1998 Dec; 21(11):737–43

Genetic heterogeneity of adrenocorticotropin (ACTH) resistance syndromes: identification of a novel mutation of the ACTH receptor gene in hereditary glucocorticoid deficiency. Wu SM, et al. **Mol Genet Metab** 1998 Aug; 64(4):256–65

[Myocardiopathy and isolated glucocorticoid deficit with ACTH resistance: a fortuitous association?] Vigneron P, et al. **Arch Pediatr** 1999 Mar;6(3):283–5 (Eng. Abstr.) **(Fre)**

[ACTH receptor, ACTH receptor anomaly, and familial glucocorticoid deficiency] Fukata J, et al. **Nippon Rinsho** 1998 Jul;56(7):1836–42 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Glucocorticoid control of glial gene expression. Vardimon L, et al. **J Neurobiol** 1999 Sep 15;40(4):513–27 (132 ref.)

Identification of a glucocorticoid response element in the rat beta2-adrenergic receptor gene. Cornett LE, et al. **Mol Pharmacol** 1998 Dec;54(6):1016–23

HISTORY

Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis [editorial] Kirwan JR, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):100–2

IMMUNOLOGY

The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids. Pekarski O, et al. **Autoimmunity** 1998;28(4):235–41

METABOLISM

Endogenous glucocorticoids released during acute toxic liver injury enhance hepatic IL-10 synthesis and release. Swain MG, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G199–205

Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Burton PJ, et al. **Biol Reprod** 1999 Feb;60(2):234–40 (98 ref.)

How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy? [letter] **Clin Endocrinol (Oxf)** 1999 Mar;50(3):406

Selective dependence of intracerebroventricular neuropeptide Y-elicited effects on central glucocorticoids. Zakrzewska KE, et al. **Endocrinology** 1999 Jul; 140(7):3183–7

Development of the cerebral cortex: XIII. Stress and brain development: II. McEwen B. **J Am Acad Child Adolesc Psychiatry** 1999 Jan;38(1):101–3

Renal Na/H exchanger NHE-3 and Na-PO4 cotransporter NaPi-2 protein expression in glucocorticoid excess and deficient states. Loffing J, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1560–7

The glucocorticoid receptor is tethered to DNA-bound Oct-1 at the mouse gonadotropin-releasing hormone distal negative glucocorticoid response element. Chandran UR, et al. **J Biol Chem** 1999 Jan 22;274(4):2372–8

Valine 571 functions as a regional organizer in programming the glucocorticoid receptor for differential binding of glucocorticoids and mineralocorticoids. Lind U, et al. **J Biol Chem** 1999 Jun 25;274(26):18515–23

CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. Yamada K, et al. **J Biol Chem** 1999 Feb 26;274(9):5880–7

Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. Takeda T, et al. **J Endocrinol** 1998 Nov; 159(2):323–30

Enigmas of adrenal androgen and glucocorticoid dissociation in premenopausal onset rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1999 Feb; 26(2):247–50. Comment on: J Rheumatol 1999 Feb;26(2):282–8.

Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Rogatsky I, et al. **Mol Cell Biol** 1999 Jul; 19(7):5036–49

p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Pfitzner E, et al. **Mol Endocrinol** 1998 Oct;12(10):1582–93

Cyclic adenosine-3',5'-monophosphate-mediated activation of a glutamine synthetase composite glucocorticoid response element. Richardson J, et al. **Mol Endocrinol** 1999 Apr;13(4):546–54

Structural requirements of the glucocorticoid and retinoic acid response units in the phosphoenolpyruvate carboxykinase gene promoter. Sugiyama T, et al. **Mol Endocrinol** 1998 Oct;12(10):1487–98

The phosphoenolpyruvate carboxykinase gene glucocorticoid response unit: identification of the functional domains of accessory factors HNF3 beta (hepatic nuclear factor-3 beta) and HNF4 and the necessity of proper alignment of their cognate binding sites. Wang JC, et al. **Mol Endocrinol** 1999 Apr;13(4):604–18

Long-term lack of endogenous glucocorticoids down-regulates glucocorticoid receptor levels in the rat forebrain. Hu Z, et al. **Neuroscience** 1999;90(4):1185–95

Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Rook GA, et al. **Novartis Found Symp** 1998;217:73–87; discussion 87–98 (36 ref.)

Glucocorticoid metabolism in proximal tubules modulates angiotensin II-induced electrolyte transport. Brem AS, et al. **Proc Soc Exp Biol Med** 1999 Jun;221(2):111–7

Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoid feedback. Kovács KJ. **Prog Brain Res** 1998;119:31–43 (70 ref.)

Stimulation of liver RNA and protein breakdown in endotoxemic rats: role of glucocorticoids. Saadane A, et al. **Shock** 1999 Jun;11(6):429–35

[11 beta-hydroxysteroid dehydrogenases: key enzymes in the action of mineralocorticoids and glucocorticoids] Diederich S, et al. **Dtsch Med Wochenschr** 1999 Jan 22; 124(3):51–5 (43 ref.) **(Ger)**

[The regulation of steroidogenesis by 17 alpha-hydroxylase/17,20-lyase (P450c17)] Katagiri M, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):43–50 (43 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Comparison of clinical efficacy of inhaled glucocorticoids. Rohdewald PJ. **Arzneimittelforschung** 1998 Aug; 48(8):789–96 (36 ref.)

Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids. Rohatagi S, et al. **J Clin Pharmacol** 1999 Jul;39(7):661–3

Controlled iontophoretic release of glucocorticoids through epithelial cell monolayers. Schaffnit R, et al. **J Controlled Release** 1998 Jun;54(1):9–14

The ideal steroid. Brattsand R. **Pulm Pharmacol Ther** 1999; 12(2):119–22 (19 ref.)

PHARMACOLOGY

Differential effects of natural and synthetic glucocorticoids on cytochrome 17alpha-hydroxylase (P-45017alpha) and cytochrome P-450 side-chain cleavage (P-450scc) messenger ribonucleic acid in the sheep placenta. Ma XH, et al. **Am J Obstet Gynecol** 1999 May;180(5):1215–21

SP-A 3'-UTR is involved in the glucocorticoid inhibition of human SP-A gene expression. Hoover RR, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):L917–24

Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Atsuta J, et al. **Am J Respir Cell Mol Biol** 1999 Apr;20(4):643–50

Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle. Fernandes D, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):77–88

Control of expression of the gene for the arginine transporter Cat-1 in rat liver cells by glucocorticoids and insulin. Liu J, et al. **Amino Acids** 1998;15(4):321–37

Corticosteroid resistance in mild asthma: markers of persistent inflammation. Matsuse H, et al. **Ann Allergy Asthma Immunol** 1999 May;82(5):457–62

Inhibition of skin 11beta-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids. Hennebold JD, et al. **Arch Dermatol Res** 1998 Aug;290(8):413–9

Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression. Sakai H, et al. **Arch Dermatol Res** 1999 Apr;291(4):224–31

Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Vande Berg BC, et al. **Arthritis Rheum** 1999 Jul;42(7):1405–11

Transcription of the human thyrotropin-releasing hormone receptor gene-analysis of basal promoter elements and glucocorticoid response elements. Høvring PI, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):829–34

Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Buttgereit F, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):363–8

Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Korn SH, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1561–9

Role of CBP in glucocorticoid-induced gene repression. Adcock IM, et al. **Biochem Soc Trans** 1998 Aug;26(3):S255

Effect of glucocorticoids on the mouse methionine adenosyltransferase A1 gene expression, which is regulated by two promoters. Sakata SF, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2–3):127–36

Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Burton PJ, et al. **Biol Reprod** 1999 Feb;60(2):234–40 (98 ref.)

Glucocorticoids stimulate the accumulation of lipids in the rat corpus luteum. Towns R, et al. **Biol Reprod** 1999 Aug; 61(2):416–21

Effects of glucocorticoids on maturation of pig oocytes and their subsequent fertilizing capacity in vitro. Yang JG, et al. **Biol Reprod** 1999 Apr;60(4):929–36

Significance of enhanced cytokine receptor expression by glucocorticoids [letter] Almawi WY, et al. **Blood** 1998 Nov 15;92(10):3979–80

Depolarization counteracts glucocorticoid inhibition of adenohypophysical corticotroph cells. Lim MC, et al. **Br J Pharmacol** 1998 Aug;124(8):1735–43

Glucocorticoids potently block tumour necrosis factor-alpha- and lipopolysaccharide-induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation. Messmer UK, et al. **Br J Pharmacol** 1999 Aug;127(7):1633–40

Corticotropin-releasing hormone expression is the major target for glucocorticoid feedback-control at the hypothalamic level. Kretz O, et al. **Brain Res** 1999 Feb 13;818(2):488–91

Preproenkephalin mRNA and enkephalin levels in the adult Syrian hamster: the influence from glucocorticoids. Jimenez R, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1-2):179–83

An electron probe x-ray microanalytical study of dentine minerals in sucrose-fed or glucocorticoid-medicated rats. Huumonen S, et al. **Calcif Tissue Int** 1999 Sep;65(3):223–5

Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Ramdas J, et al. **Cancer Res** 1999 Mar 15; 59(6):1378–85

Administration of glucocorticoids markedly increases the numbers of granulocytes and extrathymic T cells in the bone marrow. Maruyama S, et al. **Cell Immunol** 1999 May 25;194(1):28–35

Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Krett NL, et al. **Clin Cancer Res** 1997 Oct;3(10):1781–7

Glucocorticoids and muscle catabolism. Hasselgren PO. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):201–5 (35 ref.)

Leukaemia inhibitory factor expression is inhibited by glucocorticoids through post-transcriptional mechanisms. Grosset C, et al. **Cytokine** 1999 Jan;11(1):29–36

Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Morange PE, et al. **Diabetes** 1999 Apr;48(4):890–5

Glucocorticoids modulate the biosynthesis and processing of prothyrotropin releasing-hormone (proTRH). Bruhn TO, et al. **Endocrine** 1998 Oct;9(2):143–52

Glucocorticoid replacement, but not corticotropin-releasing hormone deficiency, prevents adrenalectomy-induced anorexia in mice. Jacobson L. **Endocrinology** 1999 Jan; 140(1):310–7

Insulin-like growth factor (IGF) binding proteins modulate the glucocorticoid-dependent biological effects of IGF-II in cultured fetal rat hepatocytes. Menuelle P, et al. **Endocrinology** 1999 May;140(5):2232–40

Glucocorticoid-stimulated gene expression knocked out by knock-in mutation. Berg JP. **Eur J Endocrinol** 1998 Nov; 139(5):479–80 (13 ref.)

Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats. Venero C, et al. **Eur J Neurosci** 1999 Jul;11(7):2465–73

Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease. Behl C. **Exp Gerontol** 1998 Nov-Dec;33(7–8):689–96 (51 ref.)

Glucocorticoid modulation of gp120-induced effects on calcium-dependent degenerative events in primary hippocampal and cortical cultures. Howard SA, et al. **Exp Neurol** 1999 Jul;158(1):164–70

Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. Huang ST, et al. **FASEB J** 1999 Mar;13(3):467–76

Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. Hofmann TG, et al. **FEBS Lett** 1998 Dec 28;441(3):441–6

Gap junctional communication and regulation of the glycogenic response to insulin by cell density and glucocorticoids in cultured fetal rat hepatocytes. Siddiqui MU, et al. **Hepatology** 1999 Apr;29(4):1147–55

Glucocorticoids inhibit superoxide anion production and p22 phox mRNA expression in human aortic smooth muscle cells. Marumo T, et al. **Hypertension** 1998 Dec;32(6):1083–8

Protective effects of glucocorticoids on taxol-induced cytotoxicity in human leukemia HL-60 cells. Pae HO, et al. **Immunopharmacol Immunotoxicol** 1999 Aug; 21(3):439–53

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Goulding NJ, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S158–65 (68 ref.)

A comparison of the inhibitory effects of budesonide, beclomethasone dipropionate, dexamethasone, hydrocortisone and tixocortol pivalate on cytokine release from leukocytes recovered from human bronchoalveolar lavage. Whelan CJ, et al. **Inflamm Res** 1999 Apr;48(4):224–8

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma [see comments] Shapiro G, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):789–96. Comment in: J Allergy Clin Immunol 1998 Nov;102(5):719–21.

Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by glucocorticoids. Miyazawa K, et al. **J Biochem (Tokyo)** 1998 Dec 1;124(6):1130–7

A silencer element in the regulatory region of glutamine synthetase controls cell type-specific repression of gene induction by glucocorticoids. Avisar N, et al. **J Biol Chem** 1999 Apr 16;274(16):11399–407

The interleukin-1 type 2 receptor gene displays immediate early gene responsiveness in glucocorticoid-stimulated human epidermal keratinocytes. Lukiw WJ, et al. **J Biol Chem** 1999 Mar 26;274(13):8630–8

The glucocorticoid response element II is functionally homologous in rat and human insulin-like growth factor-binding protein-1 promoters. Schweizer-Groyer G, et al. **J Biol Chem** 1999 Apr 23;274(17):11679–86

Receptor interacting protein RIP140 inhibits both positive and negative gene regulation by glucocorticoids. Subramaniam N, et al. **J Biol Chem** 1999 Jun 18; 274(25):18121–7

Effect of polyelectrolyte complex (PEC) on human periodontal ligament fibroblast (HPLF) functions in the presence of glucocorticoids. Hamano T, et al. **J Biomater Sci Polym Ed** 1998;9(9):985–1000

Placental glucose transporter expression is regulated by glucocorticoids. Hahn T, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1445–52

Local modulation by 11beta-hydroxysteroid dehydrogenase of glucocorticoid effects on the activity of 15-hydroxyprostaglandin dehydrogenase in human chorion and placental trophoblast cells [see comments] Patel FA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):395–400. Comment in: J Clin Endocrinol Metab 1999 Feb;84(2):393–4.

Glucocorticoids enhance acid activation of the Na+/H+ exchanger 3 (NHE3). Ambühl PM, et al. **J Clin Invest** 1999 Feb;103(3):429–35

Regulation of vascular endothelial growth factor secretion in human meningioma cells. Tsai JC, et al. **J Formos Med Assoc** 1999 Feb;98(2):111–7

Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. Liu Y, et al. **J Immunol** 1999 Mar 15;162(6):3639–46

Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. Schmidt M, et al. **J Immunol** 1999 Sep 15;163(6):3484–90

Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. Vieira PL, et al. **J Immunol** 1998 Nov 15;161(10):5245–51

Selective activation of the probasin androgen-responsive region by steroid hormones. Kasper S, et al. **J Mol Endocrinol** 1999 Jun;22(3):313–25

Glucocorticoid modulation of Ca2+ homeostasis in human B lymphoblasts. Gardner JP, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):385–96

Glucocorticoid block of protein kinase C signalling in mouse pituitary corticotroph AtT20 D16:16 cells. Tian L, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):757–68

Tissue- and temporal-specific regulation of 11beta-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo. Jamieson PM, et al. **J Steroid Biochem Mol Biol** 1999 Mar;68(5–6):245–50

Quantity of partial agonist activity for antiglucocorticoids complexed with mutant glucocorticoid receptors is constant in two different transactivation assays but not predictable from steroid structure. Sarlis NJ, et al. **J Steroid Biochem Mol Biol** 1999 Feb;68(3–4):89–102

Glucocorticoids, oxysterols, and cAMP with glucocorticoids each cause apoptosis of CEM cells and suppress c-myc. Thompson EB, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):453–61 (32 ref.)

Glucocorticoid-resistant B-lymphoblast cell line derived from the Bolivian squirrel monkey (Saimiri boliviensis boliviensis). Reynolds PD, et al. **Lab Anim Sci** 1998 Aug; 48(4):364–70

Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia. McConkey DJ, et al. **Leuk Lymphoma** 1999 May;33(5–6):421–31 (60 ref.)

Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Watanabe M, et al. **Life Sci** 1998;63(19):1685–92

Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. van der Velden VH. **Mediators Inflamm** 1998;7(4):229–37 (173 ref.)

Inhibition by insulin of glucocorticoid-induced gene transcription: involvement of the ligand-binding domain of the glucocorticoid receptor and independence from the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Pierreux CE, et al. **Mol Endocrinol** 1998 Sep;12(9):1343–54

Glucocorticoids inhibit the expression of calcium-dependent potassium channels in vascular smooth muscle. Brem AS, et al. **Mol Genet Metab** 1999 May;67(1):53–7

Up- and down-regulation by glucocorticoids of the constitutive expression of the mast cell growth factor stem cell factor by human lung fibroblasts in culture. Kassel O, et al. **Mol Pharmacol** 1998 Dec;54(6):1073–9

Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Vanden Berghe W, et al. **Mol Pharmacol** 1999 Oct;56(4):797–806

Enhanced interstitial expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Ando Y, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1408–17

Acute effects of glucocorticoids: behavioral and pharmacological perspectives. Haller J, et al. **Neurosci Biobehav Rev** 1998;23(2):337–44 (82 ref.)

Calcitonin gene-related peptide gene expression in collagen-induced arthritis is differentially regulated in primary afferents and motoneurons: influence of glucocorticoids. Nohr D, et al. **Neuroscience** 1999; 93(2):759–73

Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Hartmann BL, et al. **Oncogene** 1999 Jan 21;18(3):713–9

c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts. Löffler M, et al. **Oncogene** 1999 Aug 12;18(32):4626–31

Differential effects of glucocorticoids on colony stimulating factors produced by neonatal mononuclear cells. Witek-Janusek L, et al. **Pediatr Res** 1999 Feb;45(2):224–9

Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Perlman JM. **Semin Pediatr Neurol** 1998 Sep;5(3):202–10 (89 ref.)

Effect of inhaled corticosteroid therapy on bone markers and bone density [letter] Beauchesne MF. **Thorax** 1999 Sep;

54(9):861-2

A possible correlation between the blood leukocyte formula and the use of glucocorticoids as growth promoters in beef cattle. Brambilla G, et al. **Vet Res Commun** 1998 Nov; 22(7):457-65

Perspective article: transforming growth factor-beta: crossroad of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts. Shukla A, et al. **Wound Repair Regen** 1999 May-Jun;7(3):133-40 (73 ref.)

[Ionic mechanism of hyperpolarization induced by glucocorticoid in mammalian neurons] Wang W, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):537-44 (Eng. Abstr.) **(Chi)**

[Induction of apoptosis in lymphocytes by glucocorticoids: between physiology and pharmacology] Pallardy M, et al. **C R Seances Soc Biol Fil** 1998;192(6):1051-63 (37 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of the enhaled glucocorticosteroid effect on non-specific and specific bronchial reactivity with particular reference to the late inflammatory phase in atopic asthma patients. I. The effect of a single dose of budesonide R on specific and non-specific bronchial reactivity] Chyrek-Borowska S, et al. **Pol Merkuriusz Lek** 1998 May; 4(23):247-9 (Eng. Abstr.) **(Pol)**

[The effect of o-aminoazotoluene on glucocorticoid induction of tyrosine aminotransferase in mice sensitive to its hepatocarcinogenic activity is mediated by transcription factor HNF3gamma] Merkulova TI, et al. **Dokl Akad Nauk** 1998 Aug;361(5):700-3 **(Rus)**

PHYSIOLOGY

Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Miller AH, et al. **Adv Exp Med Biol** 1999; 461:107-16 (33 ref.)

Upper airway epithelial cells support eosinophil survival in vitro through production of GM-CSF and prostaglandin E2: regulation by glucocorticoids and TNF-alpha. Daffern PJ, et al. **Allergy Asthma Proc** 1999 Jul-Aug;20(4):243-53

Identification of glucocorticoid-responsive elements that control transcription of rat glutamine synthetase. Chandrasekhar S, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L319-31

Transcriptional control of the murine polymeric IgA receptor promoter by glucocorticoids. Li TW, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1425-34

Defective ACTH response to stress in previously stressed rats: dependence on glucocorticoid status. Marti O, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R869-77

Role of glucocorticoids in the maturation of renal cortical Na+-K+-ATPase during fetal life in sheep. Petershack JA, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1825-32

Multiple epithelial cell-derived factors enhance neutrophil survival. Regulation by glucocorticoids and tumor necrosis factor-alpha. Daffern PJ, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):259-67

Modulation by cytokines of glucocorticoid action. Angeli A, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:210-20 (44 ref.)

Sex hormones and glucocorticoids: interactions with the immune system. Da Silva JA. **Ann N Y Acad Sci** 1999 Jun 22;876:102-17; discussion 117-8 (78 ref.)

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1-11; discussion 11-3 (59 ref.)

Further thoughts on the immunomodulatory role of glucocorticoids: comment on the article by Buttgereit et al [letter; comment] Wilckens T. **Arthritis Rheum** 1999 Feb; 42(2):393-6. Comment on: Arthritis Rheum 1998 May;41(5):761-7.

Glucocorticoids and fetal programming. Seckl JR, et al. **Biochem Soc Trans** 1999 Feb;27(2):74-8 (51 ref.)

Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Linder MW, et al. **Drug Metab Rev** 1999 Feb;31(1):247-71 (41 ref.)

Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Bujalska IJ, et al. **Endocrinology** 1999 Jul;140(7):3188-96

Pharmacological characterization of central and peripheral type I and type II adrenal steroid receptors in the prairie vole, a glucocorticoid-resistant rodent. Hastings NB, et al. **Endocrinology** 1999 Oct;140(10):4459-69

Hormonal effects on epilepsy in women. Klein P, et al. **Epilepsia** 1998;39 Suppl 8:S9-16 (92 ref.)

Complex regulation of the expression of the polysialylated form of the neuronal cell adhesion molecule by glucocorticoids in the rat hippocampus. Rodriguez JJ, et al. **Eur J Neurosci** 1998 Sep;10(9):2994-3006

Effects of glucocorticoids on apoptosis of infiltrated eosinophils and neutrophils in rats. Nittoh T, et al. **Eur J Pharmacol** 1998 Jul 31;354(1):73-81

In vitro and in vivo effects of glucocorticoids on gene transfer to skeletal muscle. Braun S, et al. **FEBS Lett** 1999 Jul 9;454(3):277-82

Glucocorticoids, stress, and behavior: shifting the timeframe. Orchinik M. **Horm Behav** 1998 Dec;34(3):320-7 (47 ref.)

Prenatal stress: consequences of glucocorticoids on hippocampal development and function. Takahashi LK. **Int J Dev Neurosci** 1998 Jun-Jul;16(3-4):199-207 (80 ref.)

Glucocorticoids downregulate the vasopressin-regulated urea transporter in rat terminal inner medullary collecting ducts. Naruse M, et al. **J Am Soc Nephrol** 1997 Apr; 8(4):517-23

Comment--do glucocorticoids mediate the hypoglycemia-induced rise in insulin-like growth factor binding protein-1? [letter; comment] Baxter RC, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2259-61. Comment on: J Clin Endocrinol Metab 1998 Dec;83(12):4426-30.

Corticotropin-releasing hormone signals adversity in both the placenta and the brain: regulation by glucocorticoids and allostatic overload. Schulkin J. **J Endocrinol** 1999 Jun; 161(3):349-56 (108 ref.)

Protective role of adrenal glucocorticoids for gastric mucosa in spontaneously hypertensive rats. Suzuki H, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):376-83

Glucocorticoids upregulate intestinal nutrient transport in a time-dependent and substrate-specific fashion. Iannoli P, et al. **J Gastrointest Surg** 1998 Sep-Oct;2(5):449-57

Endogenous glucocorticoids protect against cytokine-mediated lethality during viral infection. Ruzek MC, et al. **J Immunol** 1999 Mar 15;162(6):3527-33

Thymus-derived glucocorticoids set the thresholds for thymocyte selection by inhibiting TCR-mediated thymocyte activation. Vacchio MS, et al. **J Immunol** 1999 Aug 1;163(3):1327-33

Glucocorticoid control of glial gene expression. Vardimon L, et al. **J Neurobiol** 1999 Sep 15;40(4):513-27 (132 ref.)

Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. Birt DF, et al. **J Nutr** 1999 Feb;129(2S Suppl):571S-574S (15 ref.)

Glucocorticoids mediate the enhanced expression of intestinal type II arginase and argininosuccinate lyase in postweaning pigs. Flynn NE, et al. **J Nutr** 1999 Apr;129(4):799-803

An anti-inflammatory role for glucocorticoids in the ovaries? Hillier SG, et al. **J Reprod Immunol** 1998 Aug;39(1-2):21-7 (36 ref.)

Prenatal stress and glucocorticoid effects on the developing gender-related brain. Reznikov AG, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):109-15 (40 ref.)

Glucocorticoid signalling--multiple variations of a common theme. Reichardt HM, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):1-6 (38 ref.)

Stress hormones and brain aging: adding injury to insult? [news; comment] Porter NM, et al. **Nat Neurosci** 1998 May; 1(1):3-4. Comment on: Nat Neurosci 1998 May;1(1):69-73.

The role and mechanisms of action of glucocorticoid involvement in memory storage. Sandi C. **Neural Plast** 1998 Jul-Sep;6(3):41-52 (58 ref.)

Accelerated maturation of the thymic stroma in the progeny of adrenalectomized pregnant rats. Sacedón R, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):23-30

Stress, glucocorticoids and structural plasticity of the hippocampus. Fuchs E, et al. **Neurosci Biobehav Rev** 1998; 23(2):295-300 (77 ref.)

Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone. Antonawich FJ, et al. **Neuroscience** 1999 Jan;88(1):319-25

Regulation of nitric oxide synthase messenger RNA expression in the rat hippocampus by glucocorticoids. López-Figueroa MO, et al. **Neuroscience** 1998 Nov; 87(2):439-46

Steroid hormone regulation of vasopressinergic neurotransmission in the central nervous system. Watters JJ, et al. **Prog Brain Res** 1998;119:247-61 (60 ref.)

Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Schulkin J, et al. **Psychoneuroendocrinology** 1998 Apr; 23(3):219-43 (150 ref.)

Glucocorticoid activity in the fetal spontaneously hypertensive rat. Lewis RM, et al. **Reprod Fertil Dev** 1998; 10(4):341-6

Severe kyphosis secondary to glucocorticoid-induced osteoporosis in a young adult with Cushing's disease. A case report and literature review. Freehill AK, et al. **Spine** 1999 Jan 15;24(2):189-93 (14 ref.)

Thioredoxin in the endocrine response to stress. Tanaka H, et al. **Vitam Horm** 1999;57:153-75 (93 ref.)

[Age related changes in cellular signal transduction of glucocorticoid hormones in rat brain] Martin R, et al. **Z Gerontol Geriatr** 1999 Apr;32(2):76-82 (Eng. Abstr.) **(Ger)**

[Glucocorticoid resistance syndrome and hypothalamo-pituitary-adrenal axis] Arai K. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):396-401 (36 ref.) **(Jpn)**

RADIATION EFFECTS

[The behavioral effects of a single adverse exposure in a number of rat generations: the role of maternal glucocorticoids] Dygalo NN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 May-Jun; 49(3):489-94 (Eng. Abstr.) **(Rus)**

SECRETION

Long-term effects of prenatal stress and postnatal handling on age-related glucocorticoid secretion and cognitive performance: a longitudinal study in the rat. Vallée M, et al. **Eur J Neurosci** 1999 Aug;11(8):2906-16

Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells. Andreis PG, et al. **Life Sci** 1999;64(24):2187-97

Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Raber J. **Mol Neurobiol** 1998 Aug;18(1):1-22 (246 ref.)

THERAPEUTIC USE

Comparing inhaled glucocorticosteroids. Pedersen S. **Allergy** 1999;54 Suppl 49:42-50

Immunologic basis and management of steroid-resistant asthma. Leung DY, et al. **Allergy Asthma Proc** 1999 Jan-Feb;20(1):9-14 (32 ref.)

Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Hamid QA, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1600-4

Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticoids in children. Lanz MJ, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):161-4

Treatment of croup with glucocorticoids. Sitzman SJ, et al. **Ann Pharmacother** 1998 Sep;32(9):973-4 (14 ref.)

Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid. Werth VP, et al. **Arch Dermatol Res** 1998 Jul;290(7):388-93

Glucocorticoids in central nervous system bacterial infection. Coyle PK. **Arch Neurol** 1999 Jul;56(7):796-801

Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al [letter; comment] Kirwan JR. **Arthritis Rheum** 1999 May;42(5):1066-7. Comment on: Arthritis Rheum 1998 Jul;41(7):1190-5.

The effectiveness of glucocorticoids in treating croup: meta-analysis. Ausejo M, et al. **BMJ** 1999 Sep 4; 319(7210):595-600

Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. van der Windt DA, et al. **BMJ** 1998 Nov 7;317(7168):1292-6

Inhaled glucocorticoids in children: A favourable therapeutic index. Simons FE. **Can Respir J** 1999 Mar-Apr;6(2):175-8 (40 ref.)

New concepts in treatment protocols for severe systemic vasculitis. Gross WL. **Curr Opin Rheumatol** 1999 Jan; 11(1):41-6 (63 ref.)

Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Lindgren SC, et al. **Eur J Gastroenterol Hepatol** 1998 Oct; 10(10):831-5

A case of idiopathic deep vein thrombosis improved with glucocorticoid therapy. Otsuka F, et al. **Haematologia (Budap)** 1999;29(4):305-12

Induced sputum and response to glucocorticoids. Hargreave FE. **J Allergy Clin Immunol** 1998 Nov;102(5):S102-5 (36 ref.)

Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. MacConnachie AA, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4328-31

Glucocorticosteroid therapy for multiple sclerosis: a critical review. Andersson PB, et al. **J Neurol Sci** 1998 Sep 18; 160(1):16-25 (89 ref.)

Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids [see comments] Cutolo M, et al. **J Rheumatol** 1999 Feb;26(2):282-8. Comment in: J Rheumatol 1999 Feb;26(2):247-50.

Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. Ishii T, et al. **Jpn J Pharmacol** 1998 Dec;78(4):505-9

Idiopathic thrombocytopenic purpura in adults [editorial; comment] Wiley JS. **Med J Aust** 1999 Mar 1;170(5):196-7 . Comment on: Med J Aust 1999 Mar 1;170(5):216-7.

Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Shulman RJ, et al. **Pediatr Res** 1998 Oct;44(4):519-23

The ideal steroid. Brattsand R. **Pulm Pharmacol Ther** 1999; 12(2):119-22 (19 ref.)

Systemic glucocorticoid-dependent manifestations in a patient with tuberculosis revealed by methotrexate [letter] Valls I, et al. **Rev Rhum Engl Ed** 1999 Mar;66(3):184-5

Use of steroids in renal transplantation. Ponticelli C, et al. **Transplant Proc** 1999 Sep;31(6):2210-1 (18 ref.)

[Glucocorticoids and multiple myeloma. Mechanism of action, resistance and clinical use] Paule B, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):502-7 (54 ref.) (Eng. Abstr.) **(Fre)**

[Corticoids and allergy] Delacourt C. **Arch Pediatr** 1999;6 Suppl 1:105S-107S (Eng. Abstr.) **(Fre)**

[Corticosteroids] Löfdahl CG. **Rev Mal Respir** 1998 Sep;15 Suppl 2:S42-4 **(Fre)**

[Corticotherapy and infectious broncho-pulmonary diseases. Workshop proceedings. 13-14 September 1997] **Rev Pneumol Clin** 1998 Sep;54 Suppl 2:S1-31 **(Fre)**

[Glucocorticoids in the therapy of rheumatism. 2: Systemic corticoid therapy] Kaiser H. **Fortschr Med** 1998 Dec 10; 116(34):41-3 **(Ger)**

[Single gene forms of hypertension. Glucocorticoid suppressible aldosteronism, Liddle syndrome et al.] Rettig R. **Fortschr Med** 1998 Aug 20;116(22-23):38 **(Ger)**

[Specific aspects of the course of bronchial asthma therapy in perimenopausal period] Paleev NP, et al. **Klin Med (Mosk)** 1999;77(5):17-20 (Eng. Abstr.) **(Rus)**

TOXICITY

Comparison of the cytotoxic effects of corticoids on the neoplastic B cells. Genty V, et al. **Hematol Cell Ther** 1998 Dec;40(6):251-8

URINE

Influence of veterinary care on the urinary corticoid:creatinine ratio in dogs. van Vonderen IK, et al. **J Vet Intern Med** 1998 Nov-Dec;12(6):431-5

GLUCOCORTICOIDS, SYNTHETIC

see related
ANTI-INFLAMMATORY AGENTS, STEROIDAL
ANTI-INFLAMMATORY AGENTS, TOPICAL

Efficacy of the selective prostaglandin synthase type 2 inhibitor nimesulide in blocking basal prostaglandin production and delaying glucocorticoid-induced premature labor in sheep. Poore KR, et al. **Am J Obstet Gynecol** 1999 May;180(5):1244-53

Five-year follow-up of a bipolar steroid-eluting ventricular pacing lead. Schwaab B, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1226-8

[Synthetic glucocorticoid in the treatment of connective tissue diseases] Ichikawa Y, et al. **Nippon Rinsho** 1999 Feb; 57(2):425-31 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Antenatal steroids to prevent respiratory distress syndrome: multiple gestation as an effect modifier. Quist-Therson EC, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):388-92

Systemic effects of a short course of betamethasone compared with high-dose inhaled budesonide in early childhood asthma. Hedlin G, et al. **Acta Paediatr** 1999 Jan;88(1):48-51

Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Kovács L, et al. **Acta Paediatr** 1998 Jul;87(7):792-8

Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Shinn C, et al. **Am J Kidney Dis** 1999 Aug;34(2):304-7

A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. Egerman RS, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1120-3

Comparison between oral and intramuscular dexamethasone in suppressing unconjugated estriol levels during the third trimester. Egerman RS, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1234-6

Serial betamethasone administration: effect on maternal salivary estriol levels. Hendershott CM, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S219-22

Placebo-controlled comparison between a single dose and a multidose of betamethasone in accelerating lung maturation of mice offspring. Stewart JD, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1241-7

Successful infiltration of the flexor tendon sheath. Vanderhooft E, et al. **Am J Orthop** 1999 May;28(5):298-300

Exhaled nitric oxide concentrations during treatment of wheezing exacerbation in infants and young children. Baraldi E, et al. **Am J Respir Crit Care Med** 1999 Apr; 159(4 Pt 1):1284-8

Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss? Boulet LP, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):838-44

Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Crompton GK, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):824-8

Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Pullerits T, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1814-8

Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season. Rosenthal R, et al. **Am J Rhinol** 1998 Nov-Dec; 12(6):427-33

Peri-operative steroid supplementation [letter] Law RC, et al. **Anaesthesia** 1999 Apr;54(4):393-5

Peri-operative steroid supplementation. Nicholson G, et al. **Anaesthesia** 1998 Nov;53(11):1091-104 (125 ref.)

Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study [see comments] Lin RY, et al. **Ann Emerg Med** 1999 May;33(5):487-94. Comment in: Ann Emerg Med 1999 May;33(5):561-4.

Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Martínez-Cáceres EM, et al. **Ann Neurol** 1998 Oct; 44(4):682-5

Ultrasound guided injection of plantar fasciitis [letter; comment] Quinn M, et al. **Ann Rheum Dis** 1998 Dec; 57(12):749-50. Comment on: Ann Rheum Dis 1998 Jun;57(6):383-4.

Staphylococcal septic arthritis in rabbits [letter] Rothschild BM. **Ann Rheum Dis** 1999 Jun;58(6):386

High-dose trimethoprim-sulfamethoxazole therapy with corticosteroids in previously intolerant patients with AIDS-associated Pneumocystis carinii pneumonia [letter] Iborra C, et al. **Arch Dermatol** 1999 Mar;135(3):350-1

Fluoroscopic transforaminal lumbar epidural steroids: an outcome study. Lutz GE, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1362-6

Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Ravaud P, et al. **Arthritis Rheum** 1999 Mar;42(3):475-82

Comparison of inhaled beclomethasone and budesonide. Patients do not take prescribed doses [letter] Cates C. **BMJ** 1999 Jul 10;319(7202):124-5; discussion 126

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Löfdahl CG, et al. **BMJ** 1999 Jul 10;319(7202):87-90

Vesiculobullous Darier's disease responsive to oral prednisolone steroids [letter] Speight EL. **Br J Dermatol** 1998 Nov;139(5):934-5

Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Alpdogan O, et al. **Br J Haematol** 1998 Dec; 103(4):1061-3

Randomized prospective study of the influence of steroids on postoperative eye-opening after exploration of the orbital floor. Flood TR, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):312-5

Acute retinal necrosis--early manifestation and successful treatment with steroid and acyclovir: case report. Lin YC, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):493-7

A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. Aziz I, et al. **Chest** 1999 Mar;115(3):623-8

A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers. Cox G, et al. **Chest** 1999 May;115(5):1271-7

Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma [see comments] Gross G, et al. **Chest** 1999 Feb;115(2):343-51. Comment in: Chest 1999 Feb;115(2):316-8.

Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma [see comments] Landwehr LP, et al. **Chest** 1998 Nov;114(5):1349-56. Comment in: Chest 1999 Jun;116(1):267-8.

Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages [editorial; comment] Tashkin DP. **Chest** 1999 Feb;115(2):316-8. Comment on: Chest 1999 Feb;115(2):343-51.

Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Wales D, et al. **Chest** 1999 May;115(5):1278-84

The efficacy of perioperative steroid therapy in pediatric primary palatoplasty. Senders CW, et al. **Cleft Palate Craniofac J** 1999 Jul;36(4):340-4

New technique for artificial lung maturation. Direct intramuscular fetal corticosteroid therapy. Ljubić A, et al. **Clin Exp Obstet Gynecol** 1999;26(1):16-9

Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Nzeusseu A, et al. **Clin Exp Rheumatol** 1999 Jul-Aug; 17(4):441-6

Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. Zakrzewska KE, et al. **Diabetes** 1999 Feb;48(2):365-70

Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice. Rousseau D, et al. **Eur Cytokine Netw** 1998 Dec;9(4):655-61

Risk of overtreatment with current peak flow criteria in self-management plans. Dutch CNSLD Study Group. Chronic Non-Specific Lung Disease. Douma WR, et al. **Eur Respir J** 1998 Oct;12(4):848-52

A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Egan JJ, et al. **Eur Respir J** 1999 Jun;13(6):1267-75

Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Leach CL, et al. **Eur Respir J** 1998 Dec;12(6):1346-53

Intralesional steroids augment the effects of endoscopic dilation in corrosive esophageal strictures. Kochhar R, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):509-13

The effect of dexamethasone administration at different stages of gestation on maternal plasma steroid concentrations in the baboon (Papio cynocephalus). Castracane VD. **Hum Reprod** 1998 Aug;13(8):2282-5

Response to steroid therapy in patients of idiopathic pulmonary fibrosis: a retrospective analysis. Behera D, et al. **Indian J Chest Dis Allied Sci** 1998 Jul-Sep;40(3):163-9

Formulation of triamcinolone acetonide pellets suitable for coating and colon targeting. Villar-López ME, et al. **Int J Pharm** 1999 Mar 15;179(2):229-35

Long-term results of corticosteroid administration via appendicostomy in patients with ulcerative colitis involving the entire colon. Tateishi M, et al. **Int Surg** 1998 Jul-Sep; 83(3):235-40

Dexamethasone supplementation to gonadotropin stimulation for in vitro fertilization in polycystic ovarian disease. Bider D, et al. **J Assist Reprod Genet** 1999 May;16(5):233-5

Liposomes promote pulmonary glucocorticoid delivery. Suntres ZE, et al. **J Drug Target** 1998;6(3):175-82

Uptake of research findings into clinical practice: a controlled study of the impact of a brief external intervention on the use of corticosteroids in preterm delivery [letter] Mant J, et al. **J Eval Clin Pract** 1999 Feb;5(1):73-9

Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B [see comments] Liaw YF, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):804-6. Comment in: J Gastroenterol Hepatol 1999 Aug;14(8):741-4.

CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. Tornatore KM, et al. **J Med** 1998;29(3-4):159-83

High dose intramuscular methylprednisolone in experimental Staphylococcus aureus endophthalmitis. Yoshizumi MO, et al. **J Ocul Pharmacol Ther** 1999 Feb;15(1):91-6

Palatability and cost comparison of five liquid corticosteroid formulations. Hutto CJ, et al. **J Pediatr Oncol Nurs** 1999 Apr;16(2):74-7

The effect of dose on the characterization of aerodynamic particle-size distributions of beclomethasone dipropionate metered-dose inhalers. el-Araud KA, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1081-5

Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. Rowe BH, et al. **JAMA** 1999 Jun 9;281(22):2119-26

Chronic lung disease of prematurity--prevention by inhaled corticosteroids? Greenough A. **Lancet** 1999 Jul 24; 354(9175):266-7

Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis [letter; comment] Haworth CS, et al. **Lancet** 1999 May 29;353(9167):1886. Comment on: Lancet 1999 Feb 27;353(9154):750.

Corticosteroids in IgA nephropathy: a randomised controlled trial [see comments] Pozzi C, et al. **Lancet** 1999 Mar 13; 353(9156):883-7. Comment in: Lancet 1999 Mar 13;353(9156):860-2. Comment in: Lancet 1999 Jun 19;353(9170):2159-60.

Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia [see comments] Cole CH, et al. **N Engl J Med** 1999 Apr 1;340(13):1005-10. Comment in: N Engl J Med 1999 Apr 1;340(13):1036-8.

Bronchopulmonary dysplasia--no simple solution [editorial; comment] Martin RJ, et al. **N Engl J Med** 1999 Apr 1; 340(13):1036-8. Comment on: N Engl J Med 1999 Apr 1;340(13):1005-10.

Secondary glioblastoma remarkably reduced by steroid administration after anaplastic transformation from gliomatosis cerebri--case report. Hirose Y, et al. **Neurol Med Chir (Tokyo)** 1998 Dec;38(12):865-70

Effect of corticosteroids on brain growth in fetal sheep. Huang WL, et al. **Obstet Gynecol** 1999 Aug;94(2):213-8

Phase II results of an intraocular steroid delivery system for cataract surgery. Chang DF, et al. **Ophthalmology** 1999 Jun;106(6):1172-7

Administration of inhaled medication via a tracheostomy in infants with chronic lung disease of prematurity. Subhedar NV, et al. **Pediatr Rehabil** 1999 Apr-Jun;3(2):41-2

Antenatal glucocorticoids modulate the amplitude of pulsatile cortisol secretion in premature neonates. Arnold JD, et al. **Pediatr Res** 1998 Dec;44(6):876-81

Altered immune function in human newborns after prenatal administration of betamethasone: enhanced natural killer cell activity and decreased T cell proliferation in cord blood. Kavelaars A, et al. **Pediatr Res** 1999 Mar; 45(3):306-12

A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Garland JS, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):91-9

Taking the itch out of poison ivy. Are you prescribing the right medication? Brodell RT, et al. **Postgrad Med** 1999 Jul;106(1):69-70

Systemic activity of inhaled and swallowed beclomethasone dipropionate and the effect of different inhaler devices. Trescoli C, et al. **Postgrad Med J** 1998 Nov;74(877):675-7

Symptomatic lumbar facet joint synovial cysts: clinical assessment of facet joint steroid injection after 1 and 6 months and long-term follow-up in 30 patients. Parlier-Cuau C, et al. **Radiology** 1999 Feb;210(2):509-13

Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia [see comments] Kikuchi A, et al. **Reg Anesth Pain Med** 1999 Jul-Aug;24(4):287-93. Comment in: Reg Anesth Pain Med 1999 Jul-Aug;24(4):283-5.

Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Aaron SD, et al. **Respir Med** 1998 Aug;92(8):1059-65

Asthma-related prescribing patterns with four different corticosteroid inhaler devices. Frost GD, et al. **Respir Med** 1998 Dec;92(12):1352-8

Efficacy of epidural steroids in low back pain and sciatica.

A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rozenberg S, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):79–85 (23 ref.)

Oral and inhaled corticosteroids in the treatment of pulmonary sarcoidosis--a critical reappraisal. Milman N. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):150–7 (46 ref.)

Pain-free intralesional injection of triamcinolone for the treatment of keloid. Ono N. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):89–91

Cervical epidural steroid injection with intrinsic spinal cord damage [letter; comment] Manchikanti L. **Spine** 1999 Jun 1;24(11):1170–2. Comment on: Spine 1998 Oct 1;23(19):2137–42; discussion 2141–2.

Accuracy of blind versus fluoroscopically guided caudal epidural injection. Stitz MY, et al. **Spine** 1999 Jul 1; 24(13):1371–6

EUROSCOP, ISOLDE and the Copenhagen city lung study [editorial] Burge PS. **Thorax** 1999 Apr;54(4):287–8

Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease [see comments] Confalonieri M, et al. **Thorax** 1998 Jul;53(7):583–5. Comment in: Thorax 1999 Feb;54(2):186. Comment in: Thorax 1999 Feb;54(2):186–7.

Vascularity in asthmatic airways: relation to inhaled steroid dose [editorial; comment] Hogg JC. **Thorax** 1999 Apr; 54(4):283. Comment on: Thorax 1999 Apr;54(4):289–95.

Vascularity in asthmatic airways: relation to inhaled steroid dose [see comments] Orsida BE, et al. **Thorax** 1999 Apr; 54(4):289–95. Comment in: Thorax 1999 Apr;54(4):283.

Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis. van Grunsven PM, et al. **Thorax** 1999 Apr; 54(4):316–22

Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. van Rensen EL, et al. **Thorax** 1999 May;54(5):403–8

A randomised, prospective study on the conversion from cyclosporine-prednisone to cyclosporine-azathioprine at 6 months after renal transplantation. de Sévaux RG, et al. **Transpl Int** 1998;11 Suppl 1:S322–4

Cluster of postinjection abscesses related to corticosteroid injections and use of benzalkonium chloride. Olson RK, et al. **West J Med** 1999 Mar;170(3):143–7

[Personal experience with long-term peroral corticosteroid therapy in patients with bronchial asthma] Susa Z, et al. **Vnitr Lek** 1998 Nov;44(11):679–81 **(Cze)**

[Intra-articular glucocorticoid injections in joint diseases] Ostergaard M, et al. **Ugeskr Laeger** 1999 Feb 1;161(5):582–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[A case of noninflammatory corneal edema following anterior-posterior radial keratotomy successfully treated by topical steroids] Fukuda K, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jan;103(1):61–5 (Eng. Abstr.) **(Jpn)**

[A case report of steroid-responsive progressive encephalomyelitis with rigidity showing muscle stiffness limited to the upper body] Matsuno S, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):680–2 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy] Itoh M, et al. **Yakugaku Zasshi** 1999 Mar;119(3):229–35 (Eng. Abstr.) **(Jpn)**

[Acute renal failure induced by antitubercular antibiotics reversible after steroid pulse therapy] Nikolaev AIu, et al. **Ter Arkh** 1999;71(6):74 **(Rus)**

[Lymphotherapy of early postoperative period in intraocular cataract correction] Bocharov VE, et al. **Vestn Oftalmol** 1999 Jan-Feb;115(1):22–4 (Eng. Abstr.) **(Rus)**

[The use of low doses of prednisolone for the treatment of patients with Duchenne-Becker myodystrophy] Shakhovskaia NI, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(6):23–6 (Eng. Abstr.) **(Rus)**

[Is therapy with local filtration at primary care clinics feasible? (letter)] Fernández-Hita A, et al. **Aten Primaria** 1999 Jun 30;24(2):117–8 **(Spa)**

[Infiltration of soft parts: indications and risks (letter; comment)] Sanz Rodrigo C, et al. **Aten Primaria** 1999 Jun 30;24(2):118–9. Comment on: Aten Primaria 1999 Jan;23(1):4–7. **(Spa)**

[Comparison of the efficacy of intraarticular and intraarterial injections of two betamethasone preparations in patients with osteoarthritis or epicondilytis] Oksenberg D, et al. **Rev Med Chil** 1998 Jun;126(6):623–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Adverse effects of prenatal glucocorticoid treatment in the preterm infant. Rubaltelli FF, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:35–8 (25 ref.)

Photo quiz. Back rash. Shekarappa RJ, et al. **Am Fam Physician** 1999 Sep 1;60(3):927–8

Fatal myocardial infarction in an elderly woman with severe ulcerative colitis: what is the role of steroids? [letter; comment] Baty V, et al. **Am J Gastroenterol** 1998 Oct; 93(10):2000–1. Comment on: Am J Gastroenterol 1997 Mar;92(3):461–4.

Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Vermillion ST, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):320–7

Transient hypertrophic cardiomyopathy in the newborn following multiple doses of antenatal corticosteroids. Yunis KA, et al. **Am J Perinatol** 1999;16(1):17–21

Gastric hemorrhage in dogs given high doses of methylprednisolone sodium succinate. Rohrer CR, et al. **Am J Vet Res** 1999 Aug;60(8):977–81

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Geusens P, et al. **Ann Rheum Dis** 1998 Dec;57(12):724–7

Pulse methylprednisolone therapy for arthritis causing muscle weakness. Shanahan EM, et al. **Ann Rheum Dis** 1999 Sep; 58(9):521–2

Neurological adverse effects of early postnatal dexamethasone in very preterm infants [letter; comment] Baud O, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar; 80(2):F159. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Jul;79(1):F26–33.

Pharmacological validation of a feline model of steroid-induced ocular hypertension. Bhattacherjee P, et al. **Arch Ophthalmol** 1999 Mar;117(3):361–4

Allergic reactions after systemic administration of glucocorticosteroid therapy. Alexiou C, et al. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1260–4

Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia. Amin SB, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):795–800

Haematological effects of betamethasone treatment in late pregnancy. Wallace EM, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):396–8

Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions [see comments] Findlay CA, et al. **BMJ** 1998 Sep 12;317(7160):739–40. Comment in: BMJ 1999 May 15;318(7194):1355. Comment in: BMJ 1999 May 15;318(7194):1356.

Myopathy following mechanical ventilation for acute severe asthma: the role of muscle relaxants and corticosteroids [see comments] Behbehani NA, et al. **Chest** 1999 Jun; 115(6):1627–31. Comment in: Chest 1999 Jun;115(6):1490–2.

The influence of inhaled corticosteroids on bone mineral density in asthmatic children [editorial; comment] König P, et al. **Clin Exp Allergy** 1998 Sep;28(9):1039–42 (19 ref.) . Comment on: Clin Exp Allergy 1998 Sep;28(9):1066–71.

Bone mineral density and body composition in patients with airflow obstruction--the role of inhaled steroid therapy, disease and lifestyle [see comments] Lau EM, et al. **Clin Exp Allergy** 1998 Sep;28(9):1066–71. Comment in: Clin Exp Allergy 1998 Sep;28(9):1039–42.

Diffuse peritonitis in steroid-treated patients. Menegaux F, et al. **Dig Surg** 1998;15(3):247–51

GH and zinc treatments for short stature caused by steroid treatments in a young patient with autoimmune hepatitis (type 1). Mori Y, et al. **Endocr J** 1998 Apr;45 Suppl:S163–5

Ulcerative colitis following introduction of zafirlukast and corticosteroid withdrawal in severe atopic asthma [letter] Kroegel C, et al. **Eur Respir J** 1999 Jul;14(1):243

Central serous chorioretinopathy complicating solar retinopathy treated with glucocorticoids. Bouzas EA, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Feb; 237(2):166–8

Fibrotic scar formation in central serous chorioretinopathy developed during systemic treatment with corticosteroids. Hooymans JM. **Graefes Arch Clin Exp Ophthalmol** 1998 Nov;236(11):876–9

Management of bone disease in patients on long term glucocorticoid therapy. Compston JE. **Gut** 1999 Jun; 44(6):770–2

Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis. Compston JE. **Gut** 1999 Jun;44(6):780–1

Iatrogenic Cushing's syndrome. Ganguly S, et al. **Indian Pediatr** 1998 Dec;35(12):1236–7

Metabolic bone disease in adults with inflammatory bowel disease. Adachi JD, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):200–11 (137 ref.)

Simultaneous rupture of both peroneal tendons after corticosteroid injection: operative treatment. Madsen BL, et al. **Injury** 1999 May;30(4):299–300

The importance of obesity and hyperlipidaemia in patients with renal transplants. Locsey L, et al. **Int Urol Nephrol** 1998;30(6):767–75

Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids. Yawalkar N, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):790–3

Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. Ebeling PR, et al. **J Bone Miner Res** 1998 Aug;13(8):1283–9

Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. Lippuner K, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3795–802

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. Sartori TM, et al. **J Heart Lung Transplant** 1999 Jul;18(7):693–700

Are bisphosphonates useful in the management of corticosteroid induced osteoporosis in transplant patients? [editorial] Arlen DJ, et al. **J Nephrol** 1999 Jan-Feb; 12(1):5–8 (29 ref.)

Inhaled corticosteroids and likelihood of cataract extraction [letter; comment] Frantz EA, et al. **JAMA** 1999 Mar 3; 281(9):791; discussion 792–3. Comment on: JAMA 1998 Aug 12;280(6):539–43.

Inhaled corticosteroids and likelihood of cataract extraction [letter; comment] Hassaballa H. **JAMA** 1999 Mar 3; 281(9):792–3. Comment on: JAMA 1998 Aug 12;280(6):539–43.

Proximal myopathy associated with inhaled steroids [letter] Herzog AG. **JAMA** 1999 Jan 6;281(1):37

Inhaled corticosteroids and likelihood of cataract extraction [letter; comment] Kao NL. **JAMA** 1999 Mar 3;281(9):791; discussion 792–3. Comment on: JAMA 1998 Aug 12;280(6):539–43.

Glucocorticoid-induced adrenal insufficiency [clinical conference] Krasner AS. **JAMA** 1999 Aug 18;282(7):671–6

Inhaled corticosteroids and likelihood of cataract extraction [letter; comment] Wasserman SI, et al. **JAMA** 1999 Mar 3;281(9):791–2; discussion 792–3. Comment on: JAMA 1998 Aug12;280(6):539–43.

Inhaled corticosteroids and likelihood of cataract extraction [letter; comment] Whitmore SE. **JAMA** 1999 Mar 3; 281(9):791; discussion 792–3. Comment on: JAMA 1998 Aug 12;280(6):539–43.

A case of non-Hodgkin's lymphoma following long-term corticosteroid therapy for Addison's disease. Kakiuchi T, et al. **Jpn J Ophthalmol** 1998 Sep-Oct;42(5):393–7

Churg-Strauss syndrome and antiasthma therapy [letter; comment] Frosi A, et al. **Lancet** 1999 Mar 27; 353(9158):1102. Comment on: Lancet 1999 Jan 2;353(9146):57–62.

Budesonide substitution in Crohn's disease relieves CNS toxicity of systemic steroids [letter] Thomas MC, et al. **Med J Aust** 1998 Nov 16;169(10):560

Marked bradycardia due to pulsed and oral methylprednisolone therapy in a patient with rapidly progressive glomerulonephritis [letter] Küçükosmanoğlu O, et al. **Nephron** 1998 Dec;80(4):484

Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Satoh N, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):185–8

Conjunctival necrosis following the administration of subconjunctival corticosteroid [letter; comment] Allen QB, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):779–80. Comment on: Ophthalmic Surg Lasers 1998 Jan;29(1):79–80.

Accidental subretinal injection of triamcinolone acetonide. Modarres M, et al. **Ophthalmic Surg Lasers** 1998 Nov; 29(11):935–8

Clinical observations on catch-up growth in asthmatic children following withdrawal of inhaled glucocorticosteroids [letter] Saha MT, et al. **Pediatr Pulmonol** 1998 Oct;26(4):292–4

Behavioral effects of corticosteroids in steroid-sensitive nephrotic syndrome. Soliday E, et al. **Pediatrics** 1999 Oct; 104(4):e51

Painful hips in a patient on long-term steroid treatment. Lay JP, et al. **Postgrad Med J** 1998 Nov;74(877):693–4

Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Wordinger RJ, et al. **Prog Retin Eye Res** 1999 Sep;18(5):629–67 (224 ref.)

Bilateral serous retinal detachment resembling central serous chorioretinopathy following epidural steroid injection. Kao LY. **Retina** 1998;18(5):479–81

Two new cases of glucocorticoid-induced pancreatitis [letter] Di Fazano CS, et al. **Rev Rhum Engl Ed** 1999 Apr;66(4):235

Sarcoidosis and central serous retinopathy: a dangerous combination. Sharma OP, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):189–91

Bone loss and glucocorticoid therapy in patients with respiratory disease. Fairney A. **Thorax** 1999 Aug;54 Suppl 2:S52–7 (65 ref.)

Persistent hiccups induced by dexamethasone. Ross J, et al. **West J Med** 1999 Jan;170(1):51–2

[Prevention of glucocorticoid induced osteoporosis] Hachulla E, et al. **Rev Med Interne** 1998 Jul;19(7):492–500 (Eng. Abstr.) **(Fre)**

[Rifampicin-glucocorticoid combinations (editorial)] Lévesque H, et al. **Rev Med Interne** 1998 May;19(5):303–4 **(Fre)**

[Glucocorticoid-induced diabetes mellitus in gastrointestinal diseases] Kern W, et al. **Z Gastroenterol** 1999 Jun;Suppl 1:36–42 (43 ref.) (Eng. Abstr.) **(Ger)**

[Frequent occurrence of diabetes mellitus after corticosteroid treatment in mixed cryoglobulinemia. An HCV-related complication?] Marson P, et al. **Minerva Med** 1998 Jul-Aug;89(7-8):277–81 (42 ref.) (Eng. Abstr.) **(Ita)**

[Multifocal osteonecrosis caused by corticosteroid treatment in low dosage: a case] Serrao A, et al. **Radiol Med (Torino)** 1999 May;97(5):414–6 **(Ita)**

[A case of cutaneous tuberculosis associated with steroid therapy for mixed connective tissue disease] Yagi T, et al. **Kekkaku** 1998 Sep;73(9):557–62 (Eng. Abstr.) **(Jpn)**

[Corticosteroid purpura] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):403–4 (7 ref.) **(Jpn)**

[The assessment of the effect of glucocorticosteroid and

nonsteroidal anti-inflammatory preparations on the development of an erosive-ulcerative lesion of the gastrointestinal tract in patients with rheumatic diseases] Karateev AE, et al. **Ter Arkh** 1999;71(2):26-30 (Eng. Abstr.) **(Rus)**

[Hallucinations after infusion of large doses of corticosteroids. A well-known and unusually well-reported side effect] Askmark H. **Lakartidningen** 1999 Mar 17;96(11):1336 **(Swe)**

[Glucocorticoid-induced osteoporosis] Povorozniuk VV, et al. **Lik Sprava** 1998 Jul-Aug;(5):34-41 (52 ref.) **(Ukr)**

ANALYSIS

Determination of betamethasone and triamcinolone acetonide by GC-NCI-MS in excreta of treated animals and development of a fast oxidation procedure for derivatisation of corticosteroids. Courtheyn D, et al. **Analyst** 1998 Dec; 123(12):2409-14

Detection of corticosteroids in injection sites and cocktails by MSn. De Wasch K, et al. **Analyst** 1998 Dec; 123(12):2415-22

First identification of prednisone in human hair by liquid chromatography-ionspray mass spectrometry [letter] Cirimele V, et al. **J Anal Toxicol** 1999 May-Jun;23(3):225-6

ANTAGONISTS & INHIBITORS

Antidepressants inhibit the glucocorticoid stimulation of thyrotropin releasing hormone expression in cultured hypothalamic neurons. Jackson IM, et al.
J Investig Med 1998 Dec;46(9):470-4

[RU486 reverses dexamethasone-mediated suppression of IL-2 receptor expressions in lymphocytes of rat spleen] Liang F, et al.
Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih 1997 Feb; 13(1):50-2 (Eng. Abstr.) **(Chi)**

BLOOD

Relation of plasma dexamethasone to clinical response. Wenting-Van Wijk MJ, et al. **Clin Exp Rheumatol** 1999 May-Jun;17(3):305-12

Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Varis T, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):363-8

Variations in glucocorticoid levels within the physiological range affect plasma leptin levels. Elimam A, et al.
Eur J Endocrinol 1998 Dec;139(6):615-20

CONTRAINDICATIONS

Cyclosporin A mono-therapy in nephrotic syndrome with contra-indication of steroid therapy. Hayashi T, et al.
Intern Med 1999 Mar;38(3):272-5

DIAGNOSTIC USE

Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Stratakis CA, et al. **Ann Intern Med** 1999 Oct 19; 131(8):585-91

Patterns of DST positivity in remitted affective disorders. Deshauer D, et al. **Biol Psychiatry** 1999 Apr 15; 45(8):1023-9

The lower limits of dexamethasone window in Chinese depressives. Shiah IS, et al. **Biol Psychiatry** 1998 Oct 1; 44(7):648-55

Adrenal incidentalomas and glucocorticoid autonomy. Aron DC. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):157-8

Reproducibility of the low dose dexamethasone suppression test: comparison between direct plasma and salivary cortisol assays. Reynolds RM, et al.
Clin Endocrinol (Oxf) 1998 Sep;49(3):307-10

Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. Castro M, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):878-82

ECONOMICS

Palatability and cost comparison of five liquid corticosteroid formulations. Hutto CJ, et al. **J Pediatr Oncol Nurs** 1999 Apr;16(2):74-7

HISTORY

[Glucocorticoids: 50 years of their use in rheumatology (editorial)] Nasonov EL. **Ter Arkh** 1999;71(5):5-9 **(Rus)**

IMMUNOLOGY

Effects of cytokines, butyrate and dexamethasone on serum amyloid A and apolipoprotein A-I synthesis in human HUH-7 hepatoma cells. Malle E, et al.
Scand J Immunol 1999 Aug;50(2):183-7

METABOLISM

Negative regulation of rat hepatic aldehyde dehydrogenase 3 by glucocorticoids. Lindahl R, et al.
Adv Exp Med Biol 1999;463:159-64

Involvement of p27Kip1 in the G1- and S/G2-phase lengthening mediated by glucocorticoids in normal human lymphocytes. Baghdassarian N, et al.
Cell Growth Differ 1999 Jun;10(6):405-12

The glucocorticoid properties of the synthetic steroid pregna-1,4-diene-11beta-ol-3,20-dione (deltaHOP) are not entirely correlated with the steroid binding to the glucocorticoid receptor. Vicent GP, et al.
Mol Cell Endocrinol 1999 Mar 25;149(1-2):207-19

PHARMACOKINETICS

High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Weijtens O, et al.
Am J Ophthalmol 1999 Aug;128(2):192-7

In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Smith CL, et al. **Arzneimittelforschung** 1998 Sep;48(9):956-60

Detection of prednisolone in vitreous following systemic administration [letter] Flaxel CJ, et al. **Eye** 1998;12 (Pt 6):1013-4

Detection of dexamethasone in the cornea and lens by NMR spectroscopy. Midelfart A, et al.
Graefes Arch Clin Exp Ophthalmol 1999 May;237(5):415-23

A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. Argenti D, et al.
J Clin Pharmacol 1999 Jul;39(7):695-702

Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Parnes LS, et al. **Laryngoscope** 1999 Jul;109(7 Pt 2):1-17

PHARMACOLOGY

Effect of transforming growth factor-beta on insulin-like growth factor 1- and dexamethasone-induced proliferation and differentiation in primary cultures of pig preadipocytes. Richardson RL, et al. **Acta Anat (Basel)** 1992;145(4):321-6

The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Rotmensch S, et al.
Acta Obstet Gynecol Scand 1999 Jul;78(6):493-500

Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Lin YJ, et al.
Acta Paediatr 1998 Oct;87(10):1061-5

The effect of prednisolone on canine neutrophil function: in vivo and in vitro studies. Trowald-Wigh G, et al.
Acta Vet Scand 1998;39(2):201-13

Corticosteroid effects on cytokines and chemokines. Frieri M. **Allergy Asthma Proc** 1999 May-Jun;20(3):147-59 (98 ref.)

Effects of methylprednisolone on human myeloid leukemic cells in vitro. Ozbek N, et al. **Am J Hematol** 1999 Apr; 60(4):255-9

Differential effects of natural and synthetic glucocorticoids on cytochrome 17alpha-hydroxylase (P-45017alpha) and cytochrome P-450 side-chain cleavage (P-450scc) messenger ribonucleic acid in the sheep placenta. Ma XH, et al. **Am J Obstet Gynecol** 1999 May;180(5):1215-21

Betamethasone-mediated vascular dysfunction and changes in hematological profile in the ovine fetus. Anwar MA, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1137-43

Dexamethasone increases eNOS gene expression and prevents renal vasoconstriction induced by cyclosporin. Bobadilla NA, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):F464-71

Dexamethasone inhibits small intestinal growth via increased protein catabolism in neonatal pigs. Burrin DG, et al.
Am J Physiol 1999 Feb;276(2 Pt 1):E269-77

Na(+)-K(+)-ATPase gene regulation by glucocorticoids in a fetal lung epithelial cell line. Chalaka S, et al.
Am J Physiol 1999 Jul;277(1 Pt 1):L197-203

Electrogenic Na+ transport in rat late distal colon by natural and synthetic glucocorticosteroids. Grotjohann I, et al.
Am J Physiol 1999 Feb;276(2 Pt 1):G491-8

Kinetic impairment of nitrogen and muscle glutamine metabolisms in old glucocorticoid-treated rats. Minet-Quinard R, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E558-64

Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Underwood JL, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):C330-42

Dexamethasone regulation of lung epithelial cell and fibroblast interleukin-11 production. Wang J, et al.
Am J Physiol 1999 Jan;276(1 Pt 1):L175-85

Glucocorticoid-induced apoptosis of dendritic cells in the rat tracheal mucosa. Brokaw JJ, et al.
Am J Respir Cell Mol Biol 1998 Oct;19(4):598-605

Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo. Narumi K, et al. **Am J Respir Cell Mol Biol** 1998 Dec;19(6):936-41

Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Gayan-Ramirez G, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):283-9

Renal handling of amino acids in 5/6-nephrectomized rats: stimulation of renal amino acid reabsorption after treatment with triiodothyronine or dexamethasone under amino acid load. Fleck C, et al. **Amino Acids** 1999;16(2):149-64

Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. Lanza L, et al.
Ann N Y Acad Sci 1999 Jun 22;876:193-7

Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. Scudeletti M, et al.
Ann N Y Acad Sci 1999 Jun 22;876:164-79

Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Chaney MA, et al. **Ann Thorac Surg** 1999 Apr;67(4):1006-11

Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Brus R.
Arch Intern Med 1999 Sep 13;159(16):1903-8

Intravitreal dexamethasone effect on intravitreal vancomycin elimination in endophthalmitis. Park SS, et al.
Arch Ophthalmol 1999 Aug;117(8):1058-62

Effect of prednisone on response to influenza virus vaccine in asthmatic children. Fairchok MP, et al.
Arch Pediatr Adolesc Med 1998 Dec;152(12):1191-5

Dexamethasone enhances In vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Mori K, et al.
Arterioscler Thromb Vasc Biol 1999 Sep;19(9):2112-8

The role of phosphatidylinositol 3-kinase in the regulation of cell response to steroid hormones. Krasil'nikov MA, et al. **Biochim Biophys Acta** 1999 Jul 8;1450(3):434-43

Effects of dexamethasone on IL-1beta, IL-6, and TNF-alpha production by mononuclear cells of newborns and adults. Bessler H, et al. **Biol Neonate** 1999;75(4):225-33

Effect of dexamethasone pretreatment on the dexamethasone-dependent induction of tyrosine aminotransferase activity in primary cultured rat hepatocytes. Nimi S, et al. **Biol Pharm Bull** 1998 Oct; 21(10):1009-12

Alteration of acetaminophen metabolism by sulfate and steroids in primary monolayer hepatocyte cultures of rats and mice. Seo KW, et al. **Biol Pharm Bull** 1999 Mar; 22(3):261-4

Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Feinman R, et al. **Blood** 1999 May 1;93(9):3044-52

The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Nakagawa M, et al.
Blood 1999 Apr 15;93(8):2730-7

Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Treon SP, et al.
Blood 1999 Feb 15;93(4):1287-98

Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Gram J, et al. **Bone** 1998 Sep;23(3):297-302

Prednisolone prevents decreases in trabecular bone mass and strength by reducing bone resorption and bone formation defect in adjuvant-induced arthritic rats. Okazaki Y, et al.
Bone 1998 Oct;23(4):353-60

Basic fibroblast growth factor enhances the growth and expression of the osteogenic phenotype of dexamethasone-treated human bone marrow-derived bone-like cells in culture. Pri-Chen S, et al. **Bone** 1998 Aug;23(2):111-7

Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice. Honma Y, et al. **Br J Cancer** 1999 Apr;80(1-2):96-103

Temporal changes in fetal cardiovascular, behavioural, metabolic and endocrine responses to maternally administered dexamethasone in the late gestation fetal sheep. Bennet L, et al. **Br J Obstet Gynaecol** 1999 Apr; 106(4):331-9

Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model. El-Hashim AZ, et al. **Br J Pharmacol** 1999 Mar;126(6):1513-21

Glucocorticoid receptor antagonists in the hippocampus modify the negative feedback following neural stimuli. Feldman S, et al. **Brain Res** 1999 Mar 6;821(1):33-7

Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors. Morita K, et al. **Brain Res** 1999 Jan 23;816(2):309-16

Dexamethasone effects on cerebral protein synthesis prior to and following hypoxia-ischemia in immature rat. Tuor UI, et al. **Brain Res Bull** 1999 Jan 1;48(1):61-4

Glucocorticoid administration alters nuclear transcription factors in fetal rat brain: implications for the use of antenatal steroids. Slotkin TA, et al. **Brain Res Dev Brain Res** 1998 Nov 1;111(1):11-24

Hormonal regulation of the osteoblastic phenotype expression in neonatal murine calvarial cells. Chen TL, et al.
Calcif Tissue Int 1999 Apr;64(4):304-9

Basic fibroblast growth factor in the presence of dexamethasone stimulates colony formation, expansion, and osteoblastic differentiation by rat bone marrow stromal cells. Scutt A, et al. **Calcif Tissue Int** 1999 Jan;64(1):69-77

Superoxide dismutase, catalase and glutathione peroxidase activities in the lymphoid organs and skeletal muscles of rats treated with dexamethasone. Pereira B, et al.
Cell Biochem Funct 1999 Mar;17(1):15-9

Effect of dexamethasone on the assembly of the matrix of fibronectin and on its receptors organization in Ehlers-Danlos syndrome skin fibroblasts. Zoppi N, et al.
Cell Biol Int 1998;22(7-8):499-508

Investigation of glucocorticoid-induced apoptotic pathway: processing of caspase-6 but not caspase-3. Miyashita T, et al. **Cell Death Differ** 1998 Dec;5(12):1034-41

Dexamethasone has a biphasic effect on the c-Jun mRNA expression in the fetal and adult rat lung, in vivo. Kouretas D, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Mar; 45(2):219-23

Glucocorticoid regulation of motoneuronal parameters in rats with spinal cord injury. Gonzalez SL, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):597–611

Combined effects of glucocorticoids and electromechanical activity on the acetylcholinesterase expression in the fast rat muscle. Vodiskar J, et al. **Chem Biol Interact** 1999 May 14;119–120:333–9

Glucocorticoids differentially control synthesis of acetylcholinesterase and butyrylcholinesterase in rat liver and brain. Weber U, et al. **Chem Biol Interact** 1999 May 14;119–120:341–7

Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge. Giannini D, et al. **Chest** 1999 Mar;115(3):629–34

Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium. Jun SS, et al. **Circ Res** 1999 Feb 5; 84(2):193–200

Glucocorticoid regulation of cardiac K+ currents and L-type Ca2+ current in neonatal mice. Wang L, et al. **Circ Res** 1999 Jul 23;85(2):168–73

Betamethasone prevents virus-induced airway inflammation but not airway hyperresponsiveness in guinea pigs. Leusink-Muis A, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:82–5

Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. Torsteinsdóttir I, et al. **Clin Exp Immunol** 1999 Mar;115(3):554–60

Glucocorticoids modulate the development of dendritic cells from blood precursors. van den Heuvel MM, et al. **Clin Exp Immunol** 1999 Mar;115(3):577–83

Transcriptional control by corticosteroids of CHIF gene expression in the rat distal colon. Brennan FE, et al. **Clin Exp Pharmacol Physiol** 1999 May–Jun;26(5–6):489–91

Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Varis T, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):363–8

Effects of methylprednisolone and cyclosporine A on fungal growth in vitro. Bell NP, et al. **Cornea** 1999 May; 18(3):306–13

Influence of methylprednisolone on cytokine balance during cardiac surgery [see comments] [published erratum appears in Crit Care Med 1999 Jul;27(7):1404] Kawamura T, et al. **Crit Care Med** 1999 Mar;27(3):545–8. Comment in: Crit Care Med 1999 Mar;27(3):463–4.

Glucocorticoids induce a Th2 response in vitro. Ramirez F. **Dev Immunol** 1998;6(3–4):233–43

Regulation of ob gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes. Bradley RL, et al. **Diabetes** 1999 Feb;48(2):272–8

Decreased corticosensitivity in quiescent Crohn's disease: an ex vivo study using whole blood cell cultures. Franchimont D, et al. **Dig Dis Sci** 1999 Jun;44(6):1208–15

Glucocorticoids increase preproendothelin-1 expression in rat aorta. Provencher PH, et al. **Endocr Res** 1998 Aug–Nov; 24(3–4):737–41

Consequences of treatment with dexamethasone in rats on the susceptibility of total plasma and isolated lipoprotein fractions to copper oxidation. Belkebir-Mesbah D, et al. **Endocrine** 1999 Jun;10(3):233–42

Leptin modulates the glucocorticoid-induced ovarian steroidogenesis. Barkan D, et al. **Endocrinology** 1999 Apr; 140(4):1731–8

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis [see comments] Hofbauer LC, et al. **Endocrinology** 1999 Oct;140(10):4382–9 . Comment in: Endocrinology 1999 Oct;140(10):4377–81.

Progesterone- and dexamethasone-dependent osteoprogenitors in bone cell populations derived from rat vertebrae are different and distinct. Ishida Y, et al. **Endocrinology** 1999 Jul;140(7):3210–8

Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. Katsuyama K, et al. **Endocrinology** 1999 May;140(5):2183–90

Steroid regulation of human placental integrins: suppression of alpha2 integrin expression in cytotrophoblasts by glucocorticoids. Ryu JS, et al. **Endocrinology** 1999 Sep; 140(9):3904–8

Prenatal dexamethasone treatment does not prevent alterations of the hypothalamic pituitary adrenal axis in steroid 21-hydroxylase deficient mice. Tajima T, et al. **Endocrinology** 1999 Jul;140(7):3354–62

Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions. Yip RG, et al. **Endocrinology** 1999 Mar;140(3):1219–27

Enzyme activity of rat tibialis anterior muscle differs between treatment with triamcinolone and prednisolone and nutritional deprivation. Koerts-de Lang E, et al. **Eur J Appl Physiol** 1999 Feb;79(3):274–9

An open comparison of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg. Sáez Barcelona JA, et al. **Eur J Clin Pharmacol** 1999 Apr; 55(2):105–9

Effect of glucocorticoids on renal dopamine production. Aguirre JA, et al. **Eur J Pharmacol** 1999 Apr 16; 370(3):271–8

Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. Yoneda H, et al. **Eur J Pharmacol** 1998 Dec 4;362(2–3):213–9

Effects of anabolic steroids on diaphragm impairment induced by methylprednisolone in emphysematous hamsters. van Balkom RH, et al. **Eur Respir J** 1999 May; 13(5):1062–9

Prevention of both T2- and diffusion-weighted increases in image intensity during cerebral hypoxia-ischemia in infant rats pretreated with dexamethasone. Tuor UI, et al. **Exp Brain Res** 1999 Mar;125(2):217–20

Beta-methasone increases sweat gland formation and suppresses fibre formation in fetal sheep. Edwards JE, et al. **Exp Dermatol** 1999 Aug;8(4):349–50

Effect of povidone-iodine on wound healing in control, diabetic and steroid depressed rats. Margaret I, et al. **Fundam Clin Pharmacol** 1999;13(4):490–3

Effect of neonatal glucocorticoid treatment on bone mineralization of adult nontreated, dexamethasone-treated or vitamin D3-treated rats. Karabélyos C, et al. **Gen Pharmacol** 1998 Nov;31(5):789–91

Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes [see comments] Hearing SD, et al. **Gut** 1999 Sep;45(3):382–8. Comment in: Gut 1999 Sep;45(3):324–5.

Elevated serum progesterone concentrations during the early follicular phase of the menstrual cycle: clinical significance and therapeutic implications. Keck C, et al. **Gynecol Endocrinol** 1999 Jun;13(3):161–5

Antenatal dexamethasone therapy does not affect circulating concentrations of insulin-like growth factor binding protein-1. Oguch O, et al. **Hum Reprod** 1998 Jun; 13(6):1714–6

Effect of 6 beta-methylprednisolone on mouse pregnancy rate. Velilla E, et al. **Hum Reprod** 1999 Jan;14(1):207–10

Glucocorticoidal regulation of pituitary vasopressin content in rats. Shoji M, et al. **Hypertens Res** 1999 Mar;22(1):39–42

Induction of apoptosis by dexamethasone in the B cell lineage. Andreau K, et al. **Immunopharmacology** 1998 Jul; 40(1):67–76

The effect of dexamethasone on tissue fibrinolytic system in male and female rats. Tsantarliotou M, et al. **In Vivo** 1999 Mar–Apr;13(2):119–24

Glucocorticoid-mediated regulation of thymic dendritic cell function. Sacedón R, et al. **Int Immunol** 1999 Aug; 11(8):1217–24

Glucocorticoid hormone suppression of human neutrophil-mediated tumor cell cytostasis. Yazawa H, et al. **Int J Cancer** 1999 Mar 31;81(1):74–80

Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma. Zhou L, et al. **Int J Mol Med** 1998 Feb; 1(2):339–46

In vitro effects of dexamethasone on human corneal keratocytes. Bourcier T, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1061–70

Glucocorticoids induce glutamine synthetase in folliculostellate cells of rat pituitary glands in vivo and in vitro. Shirasawa N, et al. **J Anat** 1999 May;194 (Pt 4):567–77

Dexamethasone in resting and exercising men. II. Effects on adrenocortical hormones. Lac G, et al. **J Appl Physiol** 1999 Jul;87(1):183–8

Dexamethasone in resting and exercising men. I. Effects on bioenergetics, minerals, and related hormones. Marquet P, et al. **J Appl Physiol** 1999 Jul;87(1):175–82

Down-regulation of human granzyme B expression by glucocorticoids. Dexamethasone inhibits binding to the Ikaros and AP-1 regulatory elements of the granzyme B promoter. Wargnier A, et al. **J Biol Chem** 1998 Dec 25; 273(52):35326–31

Glucocorticoids decrease interleukin-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia. Stanton RP, et al. **J Bone Miner Res** 1999 Jul;14(7):1104–14

Dexamethasone modulates the expression of endothelin-1 and -A receptors in A7r5 vascular smooth muscle cells. Koshino Y, et al. **J Cardiovasc Pharmacol** 1998 Oct; 32(4):665–72

Enhanced proliferation of human fibroblasts, in the presence of dexamethasone, is accompanied by changes in p21Waf1/Cip1/Sdi1 and the insulin-like growth factor type 1 receptor. Li S, et al. **J Cell Physiol** 1998 Dec; 177(3):396–401

Synergistic effects of feeding and dexamethasone on serum leptin levels. Laferrère B, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3742–5

Effect of somatotropin, insulin, and glucocorticoid on lipolysis in chronic cultures of adipose tissue from lactating cows. Lanna DP, et al. **J Dairy Sci** 1999 Jan;82(1):60–8

Glucocorticoid-induced insulin resistance of protein synthesis is independent of the rapamycin-sensitive pathways in rat skeletal muscle. Dardevet D, et al. **J Endocrinol** 1999 Jul;162(1):77–85

A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover. Heuck C, et al. **J Endocrinol** 1998 Oct; 159(1):127–31

The role of growth hormone and glucocorticoid in glucose handling in vivo. Johansen T, et al. **J Endocrinol** 1999 Jul; 162(1):87–93

Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture. Soret B, et al. **J Endocrinol** 1999 Jun;161(3):517–24

Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. Börcsök I, et al. **J Exp Med** 1998 Nov 2;188(9):1563–73

Glucocorticoid suppresses autocrine survival of mast cells by inhibiting IL-4 production and ICAM-1 expression. Yoshikawa H, et al. **J Immunol** 1999 May 15; 162(10):6162–70

Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. Agarwal SK, et al. **J Interferon Cytokine Res** 1998 Dec; 18(12):1059–68

Glucocorticoid effect on human mesangial cell cytoskeletal proteins. Koukouritaki SB, et al. **J Lab Clin Med** 1999 Apr; 133(4):378–83

Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. de Jong EC, et al. **J Leukoc Biol** 1999 Aug;66(2):201–4

Dexamethasone-induced hypertrophy in rat neonatal cardiac myocytes involves an elevated L-type Ca(2+)current. Whitehurst RM Jr, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1551–8

Administration of dexamethasone up-regulates protein kinase C activity and the expression of gamma and epsilon protein kinase C isozymes in the rat brain. Dwivedi Y, et al. **J Neurochem** 1999 Jan;72(1):380–7

Repeated administration of dexamethasone increases phosphoinositide-specific phospholipase C activity and mRNA and protein expression of the phospholipase C beta 1 isozyme in rat brain. Dwivedi Y, et al. **J Neurochem** 1999 Aug;73(2):780–90

Activation of nuclear factor kappaB by nitric oxide in rat striatal neurones: differential inhibition of the p50 and p65 subunits by dexamethasone. Simpson CS, et al. **J Neurochem** 1999 Jul;73(1):353–61

Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. Uz T, et al. **J Neurochem** 1999 Aug;73(2):693–9

Region-specific regulation of RGS4 (Regulator of G-protein-signaling protein type 4) in brain by stress and glucocorticoids: in vivo and in vitro studies. Ni YG, et al. **J Neurosci** 1999 May 15;19(10):3674–80

Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor. Shi B, et al. **J Neurosci** 1998 Nov 15;18(22):9326–34

Adrenal function in premature infants during inhaled beclomethasone therapy. Cole CH, et al. **J Pediatr** 1999 Jul;135(1):65–70

Growth hormone and insulin-like growth factor-I therapy promote protein deposition and growth in dexamethasone-treated piglets. Ward WE, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):404–10

Lung physiological and metabolic changes in lambs with congenital diaphragmatic hernia after administration of prenatal maternal corticosteroids. Kapur P, et al. **J Pediatr Surg** 1999 Feb;34(2):354–6

Effects of dexamethasone, growth factors, and tracheal ligation on the development of nitrofen-exposed hypoplastic murine fetal lungs in organ culture. Zgleszewski SE, et al. **J Pediatr Surg** 1999 Aug; 34(8):1187–95

Glucocorticoid enhances interleukin-1-induced pressor response in freely moving rats through its effect on nitric oxide release. Watanabe T, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):24–30

Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. Zareie M, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1245–9

The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. Rahman P, et al. **J Rheumatol** 1999 Feb;26(2):325–30

Dexamethasone suppresses vascular smooth muscle cell proliferation. Reil TD, et al. **J Surg Res** 1999 Jul; 85(1):109–14

Antenatal betamethasone and fetoplacental blood flow [letter; comment] Adamson SL, et al. **Lancet** 1999 Jul 17; 354(9174):255–6. Comment on: Lancet 1999 Apr 24;363(9162):1404–7.

Corticosteroids in IgA nephropathy [letter; comment] Ashman N, et al. **Lancet** 1999 Jun 19;353(9170):2159–60. Comment on: Lancet 1999 Mar 13;353(9156):883–7.

Antenatal betamethasone and fetoplacental blood flow [letter; comment] Wijnberger LD, et al. **Lancet** 1999 Jul 17; 354(9174):256. Comment on: Lancet 1999 Apr 24;353(9162):1404–7.

Age-associated decline in responses of naïve T cells to in vitro immunization reflects shift in glucocorticoid sensitivity. Dozmorov IM, et al. **Life Sci** 1999; 64(20):1849–59

Short-term glucocorticoid administration decreases both hypothalamic and pituitary galanin synthesis in the adult male rat. Brogan RS, et al. **Metabolism** 1999 Jun; 48(6):792–6

Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. de Lange P, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1–2):163–8

The negative regulation of the rat aldehyde dehydrogenase 3 gene by glucocorticoids: involvement of a single imperfect palindromic glucocorticoid responsive element.

Falkner KC, et al. **Mol Pharmacol** 1999 Apr;55(4):649–57

Dexamethasone stimulates human A1 adenosine receptor (A1AR) gene expression through multiple regulatory sites in promoter B. Ren H, et al. **Mol Pharmacol** 1999 Feb; 55(2):309–16

Glucocorticoids increase bradykinin B2 receptor gene transcription in cultured guinea-pig tracheal smooth muscle cells. Scherrer D, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):153–9

The antiproliferative effect of glucocorticoids: is it related to induction of TGF-beta? [editorial] Almawi WY, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2450–2 (12 ref.)

Dexamethasone rapidly regulates TRH mRNA levels in hypothalamic cell cultures: interaction with the cAMP pathway. Pérez-Martínez L, et al. **Neuroendocrinology** 1998 Nov;68(5):345–54

Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Kawamura A, et al. **Neurol Med Chir (Tokyo)** 1998 Oct;38(10):633–8; discussion 638–40

Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Machein MR, et al. **Neuropathol Appl Neurobiol** 1999 Apr;25(2):104–12

Dexamethasone prevents the induction of COX-2 mRNA and prostaglandins in the lumbar spinal cord following intraplantar FCA in parallel with inhibition of oedema. Hay CH, et al. **Neuropharmacology** 1998 Jun;37(6):739–44

Dexamethasone selectively suppresses microglial trophic responses to hippocampal deafferentation. Woods AG, et al. **Neuroscience** 1999;91(4):1277–89

Effect of in utero exposure to betamethasone on motivation/anxiety testing in mice offspring. Rayburn WF, et al. **Neurotoxicol Teratol** 1998 Jul-Aug;20(4):475–81

PGE2 synthesis by corneal endothelial cells: effect of glucocorticoids and NSAIDs. García-Cabanes C, et al. **Ophthalmic Res** 1999;31(1):42–6

Effect of diclofenac sodium and dexamethasone on cultured human Tenon's capsule fibroblasts. Sun R, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):382–8

The human insulin gene contains multiple transcriptional elements that respond to glucocorticoids. Fernandez-Mejia C, et al. **Pancreas** 1999 May;18(4):336–41

The expulsion of Echinostoma trivolvis caused by goblet cell hyperplasia in severe combined immunodeficient (SCID) mice. Fujino T, et al. **Parasite** 1998 Sep;5(3):219–22

Early effects of inhaled steroids on airway hyperreactivity and pulmonary function in asthma [see comments] Sherrington CA, et al. **Pediatr Pulmonol** 1999 Jun; 27(6):376–82. Comment in: Pediatr Pulmonol 1999 Jun;27(6):365–8.

Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? [see comments] Van Bever HP, et al. **Pediatr Pulmonol** 1999 Jun; 27(6):369–75. Comment in: Pediatr Pulmonol 1999 Jun;27(6):365–8.

Hyperoxia and glucocorticoid modify retinal vessel growth and interleukin-1 receptor antagonist in newborn rabbits. Lawas-Alejo PA, et al. **Pediatr Res** 1999 Mar;45(3):313–7

Neonatal catecholamine content of adrenal and extra-adrenal chromaffin tissue after prenatal exposure to dexamethasone. Moftaquir-Handaj A, et al. **Pediatr Res** 1999 Jan;45(1):60–5

Gene expression of cellular retinoid-binding proteins: modulation by retinoic acid and dexamethasone in postnatal rat lung. Whitney D, et al. **Pediatr Res** 1999 Jan;45(1):2–7

Interactions between glucocorticoids and the growth hormone-insulin-like growth factor axis. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):183–9 (62 ref.)

Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Jobe AH, et al. **Pediatrics** 1998 Nov;102(5):1116–25

Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. O'Shea TM, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):15–21

Treatment with dexamethasone alters yawning behavior induced by cholinergic but not dopaminergic agonist. Hipólide DC, et al. **Physiol Behav** 1999 Jan 1–15; 65(4–5):829–32

Glucocorticoids augment fibroblast-mediated contraction of collagen gels by inhibition of endogenous PGE production. Sköld CM, et al. **Proc Assoc Am Physicians** 1999 May–Jun; 111(3):249–58

Antiglucocorticoid activity of hepatocyte nuclear factor-6. Pierreux CE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8961–6

Dexamethasone on inducible nitric oxide synthase and nitrite/nitrate production in myocardial infarction. Kimura A, et al. **Proc Soc Exp Biol Med** 1998 Nov;219(2):138–43

High-dose naloxone (1.0 mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone. Martín-Del-Campo AF, et al. **Psychoneuroendocrinology** 1998 May;23(4):413–24

Dexamethasone blocks sleep induced improvement of declarative memory. Plihal W, et al. **Psychoneuroendocrinology** 1999 Apr;24(3):313–31

Effects of acute prednisone administration on memory, attention and emotion in healthy human adults. Schmidt LA, et al. **Psychoneuroendocrinology** 1999 May; 24(4):461–83

Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. Porter RJ, et al. **Psychopharmacology (Berl)** 1999 Mar;143(1):64–71

Comparative effects of betamethasone, cyclosporin and nedocromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharide. Corbel M, et al. **Pulm Pharmacol Ther** 1999;12(3):165–71

Selenium, glutathione peroxidase and superoxide dismutase in maltese asthmatic patients: effect of glucocorticoid administration. Fenech AG, et al. **Pulm Pharmacol Ther** 1998;11(4):301–8

Effects of inhaled corticosteroid on bone turnover in children with bronchial asthma. Chay OM, et al. **Respirology** 1999 Mar;4(1):63–7

Methyl-prednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. Hodge S, et al. **Scand J Immunol** 1999 May;49(5):548–53

Expression of cyclooxygenase-2 mRNA after global ischemia is regulated by AMPA receptors and glucocorticoids. Koistinaho J, et al. **Stroke** 1999 Sep;30(9):1900–5; discussion 1905–6

A possible correlation between the blood leukocyte formula and the use of glucocorticoids as growth promoters in beef cattle. Brambilla G, et al. **Vet Res Commun** 1998 Nov; 22(7):457–65

Sequence-specific transcription factors during glucocorticoid-induced apoptosis in acute lymphoblastic leukemia cells. Hartmann BL, et al. **Wien Klin Wochenschr** 1999 May 7;111(9):360–7

Flumethasone-induced insulin resistance in calves. Sternbauer K, et al. **Zentralbl Veterinarmed A** 1998 Sep; 45(6–7):441–3

[Effects of dexamethasone on cAMP production induced by prostaglandin E2 in aortic smooth muscle cells] Zhao Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Apr; 26(2):96–9 (Eng. Abstr.) **(Chi)**

[Glucocorticoid (prednisolone) effects on various blood, urine and liver parameters in cows in the second post partum week] Fürll M, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Sep; 26(5):262–8 (Eng. Abstr.) **(Ger)**

[Dexamethasone-induced apoptosis in peripheral T lymphocytes from patients with asthma] Oneda K. **Arerugi** 1999 Jan;48(1):13–22 (Eng. Abstr.) **(Jpn)**

[Effects of exogenous glucocorticoids on the bone marrow colony-forming activity during cytostatic exposure] Khlusov IA, et al. **Biull Eksp Biol Med** 1999 Apr; 127(4):412–4 **(Rus)**

[Amine-containing lymph node structures during chronic glucocorticoid administration] Smorodchenko AT. **Biull Eksp Biol Med** 1999 Mar;127(3):270–2 **(Rus)**

[Effects of glucocorticoids on alkaline phosphomonoesterase isoforms] Voronina NP, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):416–9 **(Rus)**

[The effect of dexamethasone and thyroxine on the ratio of membrane and soluble forms of intestinal disaccharidases in ontogenesis of rats] Gordova LA, et al. **Dokl Akad Nauk** 1999 Mar;365(1):135–7 **(Rus)**

[Changes in the transmembrane potential of thymocytes during dexamethasone- and Ca2(+)-induced apoptosis] Dukhanin AS, et al. **Eksp Klin Farmakol** 1999 May–Jun; 62(3):40–3 (Eng. Abstr.) **(Rus)**

[The effect of glucocorticoid preparations on liver metabolism] Vengerovskii AI, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):75–80 (90 ref.) (Eng. Abstr.) **(Rus)**

[Effect of prednisolone on the gastric juice basal secretion during blockade of M-cholinoreceptors by gastrozepin in rats] Trefilov AB. **Ross Fiziol Zh Im I M Sechenova** 1999 Feb;85(2):323–7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Postoperative systemic corticosteroid treatment and Molteno implant surgery: a randomized clinical trial. Välimäki J, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):50–6

Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Svedmyr J, et al. **Acta Paediatr** 1999 Jan;88(1):42–7

Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Carcao MD, et al. **Acta Paediatr Suppl** 1998 Jun;424:71–4

Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. Fickert P, et al. **Am J Gastroenterol** 1998 Oct;93(10):1985–6

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Gertz MA, et al. **Am J Hematol** 1999 Jun;61(2):115–9

Renal failure resulting from infiltration by inflammatory myofibroblastic tumor responsive to corticosteroid therapy. Williams ME, et al. **Am J Kidney Dis** 1998 Jun;31(6):E5

Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Amorim MM, et al. **Am J Obstet Gynecol** 1999 May;180(5):1283–8

Control of visual symptoms in two men with birdshot retinochoroidopathy using low-dose oral corticosteroid therapy. Ladas JG, et al. **Am J Ophthalmol** 1999 Jul; 128(1):116–8

Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Hansen EF, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1267–71

Airway smooth muscle as a target of glucocorticoid action in the treatment of asthma. Hirst SJ, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S201–6 (63 ref.)

A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Lin JL, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):357–60

Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Meduri GU, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1432–41

Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Pizzichini E, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1511–7

Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. Baronci C, et al. **Ann Ist Super Sanita** 1998;34(4):457–61

Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren's syndrome. Izumi M, et al. **Ann Rheum Dis** 1998 Aug;57(8):464–9

Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. Stratta RJ, et al. **Ann Surg** 1999 May;229(5):701–8; discussion 709–12

Serological response to Leishmania infantum in a patient treated with prednisone. Punda-Polić V, et al. **Ann Trop Med Parasitol** 1998 Sep;92(6):731–3

Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Pronk LC, et al. **Anticancer Drugs** 1998 Oct;9(9):759–64

Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid [letter] Lebrun-Vignes B, et al. **Arch Dermatol** 1999 Jan; 135(1):89–90

Difficult asthma: beyond the guidelines. Balfour-Lynn I. **Arch Dis Child** 1999 Feb;80(2):201–6 (47 ref.)

Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease [see comments] Bhuta T, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F26–33. Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F159.

Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis. Croasdale CR, et al. **Arch Ophthalmol** 1999 Jul;117(7):966–8

Effects of glucocorticoids on bone mineral density in rheumatoid arthritis patients. A longitudinal study. Miyamoto S, et al. **Arch Orthop Trauma Surg** 1999; 119(1–2):18–21

Idiopathic steroid responsive chronic lymphocytic meningitis--clinical features and long-term outcome in 17 patients. Charleston AJ, et al. **Aust N Z J Med** 1998 Dec; 28(6):784–9

Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Challa JK, et al. **Aust N Z J Ophthalmol** 1998 Nov;26(4):277–81

Acute obstructive hydrocephalus complicating bacterial meningitis. Use of dexamethasone remains contentious [letter; comment] Rashid A. **BMJ** 1999 Jan 9; 318(7176):123–4. Comment on: BMJ 1998 Jun 20;316(7148):1887–9.

Antenatal corticosteroid prescribing: setting standards of care [letter; comment] Chaudhry R, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):932. Comment on: Br J Obstet Gynaecol 1997 Nov;104(11):1262–6.

Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Bosch-Driessen EH, et al. **Br J Ophthalmol** 1998 Aug;82(8):858–60 (36 ref.)

Topical steroids and alkali burns [letter; comment] Dutton GN. **Br J Ophthalmol** 1998 Sep;82(9):1098–9. Comment on: Br J Ophthalmol 1997 Sep;81(9):732–4.

Dexamethasone treatment prior to reperfusion improves the survival of skin flaps subjected to secondary venous ischaemia. Willemart G, et al. **Br J Plast Surg** 1998 Dec; 51(8):624–8

Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Hickling P, et al. **Br J Rheumatol** 1998 Sep;37(9):930–6

Re: Management of idiopathic carpal tunnel syndrome [letter; comment] Sheehan NJ. **Br J Rheumatol** 1998 Oct; 37(10):1139–40. Comment on: Br J Rheumatol 1997 Dec;36(12):1328–30.

Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications. Slotkin TA, et al. **Brain Res Bull** 1998 Nov 1;47(4):345–8

Use of topical steroid therapy in the management of nonnecrotizing anterior scleritis. McMullen M, et al. **Can J Ophthalmol** 1999 Jun;34(4):217–21

Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Fujimoto K, et al. **Chest** 1999 Mar; 115(3):697–702

Steroids in acute exacerbation of asthma: how do we grade the evidence? [editorial; comment] Marik PE, et al. **Chest** 1999 Aug;116(2):273–5. Comment on: Chest 1999

Aug;116(2):285–95.
Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS. Meduri GU. **Chest** 1999 Jul;116(1 Suppl):116S–118S
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Pietinalho A, et al. **Chest** 1999 Aug;116(2):424–31
Corticosteroids in the emergency department therapy of acute adult asthma: an evidence-based evaluation [see comments] Rodrigo G, et al. **Chest** 1999 Aug;116(2):285–95 . Comment in: Chest 1999 Aug;116(2):273–5.
Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Van Andel AE, et al. **Chest** 1999 Mar;115(3):703–7
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Vander Els NJ, et al. **Chest** 1998 Dec;114(6):1779–81
Nonoperative treatment of cerebellar abscesses. A case report and review of the literature. Spinnato S, et al. **Childs Nerv Syst** 1998 Oct;14(10):606–9 (47 ref.)
Current management of thyroid-associated ophthalmopathy [comment] Kendall-Taylor P. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):11–2. Comment on: Clin Endocrinol (Oxf) 1998 Jul;49(1):21–8.
Glucocorticoid therapy for nonislet cell tumour hypoglycaemia (NICTH) [letter] McNulty SJ, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):546
Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Teale JD, et al. **Clin Endocrinol (Oxf)** 1998 Oct; 49(4):491–8
Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey [see comments] Weetman AP, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):21–8. Comment in: Clin Endocrinol (Oxf) 1998 Jul;49(1):11–2.
A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Weir DC, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:125–8
Successful treatment of pemphigus vegetans by addition of etretinate to systemic steroids. Ichimiya M, et al. **Clin Exp Dermatol** 1998 Jul;23(4):178–80
Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Hernández-Cruz B, et al. **Clin Exp Rheumatol** 1999 Jan–Feb;17(1):81–7
Effects of glucocorticoids on bone mass in patients with polymyalgia rheumatica. A longitudinal study [letter] Mur E, et al. **Clin Exp Rheumatol** 1998 Sep–Oct;16(5):623
Relation of plasma dexamethasone to clinical response. Wenting-Van Wijk MJ, et al. **Clin Exp Rheumatol** 1999 May–Jun;17(3):305–12
Successful treatment of catastrophic antiphospholipid syndrome in a pregnant woman [letter] Wislowska M. **Clin Exp Rheumatol** 1999 Mar–Apr;17(2):261
Use of corticosteroids in glomerulonephritis related to infective endocarditis: three cases and review. Le Moing V, et al. **Clin Infect Dis** 1999 May;28(5):1057–61 (32 ref.)
Anti-inflammatory actions of glucocorticoids: molecular mechanisms [editorial] Barnes PJ. **Clin Sci (Colch)** 1998 Jun;94(6):557–72 (178 ref.)
Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Sorkness CA, et al. **Clin Ther** 1999 Feb;21(2):353–67
Glucocorticoids in the treatment of croup: barking up the right tree [editorial] Klassen TP. **CMAJ** 1998 Nov 3; 159(9):1121–2
Steroid therapy for late septic shock [letter; comment] Ellison RT 3rd. **Crit Care Med** 1999 Jul;27(7):1402. Comment on: Crit Care Med 1998 Apr;26(4):645–50.
No steroids or STITCH for CPB? [editorial; comment] Kan H, et al. **Crit Care Med** 1999 Mar;27(3):463–4 (16 ref.). Comment on: Crit Care Med 1999 Mar;27(3):545–8.
Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. ter Borg F, et al. **Dig Dis Sci** 1998 Oct;43(10):2267–70
Drug therapy in the management of type 1 autoimmune hepatitis. Czaja AJ. **Drugs** 1999 Jan;57(1):49–68 (152 ref.)
Long term follow-up of a 46,XY phenotypic girl with 17alpha-hydroxylase deficiency treated with alternate-day dexamethasone. Satoh M, et al. **Endocr J** 1998 Jun; 45(3):285–90
Lack of effectiveness of dexamethasone in neonatal bacterial meningitis. Daoud AS, et al. **Eur J Pediatr** 1999 Mar; 158(3):230–3
Inhaled salbutamol and beclomethasone for preventing broncho-pulmonary dysplasia: a randomised double-blind study. Denjean A, et al. **Eur J Pediatr** 1998 Nov; 157(11):926–31
MR imaging of muscular sarcoidosis after steroid therapy. Otake S, et al. **Eur Radiol** 1998;8(9):1651–3
Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Montón C, et al. **Eur Respir J** 1999 Jul;14(1):218–20
Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate. Pennings HJ, et al. **Eur Respir J** 1999 Jun; 13(6):1260–6
Exhaled carbon monoxide levels during treatment of acute asthma. Yamara M, et al. **Eur Respir J** 1999 Apr; 13(4):757–60
The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: a preliminary study [see comments] Lam DS, et al. **Eye** 1998;12 (Pt 4):615–8. Comment in: Eye 1998 ;12 (Pt 4):609–10.
Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Lafranco Dafflon M, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr;237(4):289–95
Glucocorticoid unresponsiveness in severe ulcerative colitis [comment] Corrigan CJ. **Gut** 1999 Sep;45(3):324–5. Comment on: Gut 1999 Sep;45(3):382–8.
Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Philip J, et al. **Gynecol Oncol** 1999 Jul;74(1):68–73
Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations: long term palliation or bridge to cardiac transplantation? Therrien J, et al. **Heart** 1999 Aug;82(2):241–3
Effect of adrenalectomy and glucocorticoid therapy on lipid metabolism of lactating rats. Couto RC, et al. **Horm Metab Res** 1998 Oct;30(10):614–8
Effect of prednisolone on serum and follicular fluid androgen concentrations in women with polycystic ovary syndrome undergoing in-vitro fertilization. Fridström M, et al. **Hum Reprod** 1999 Jun;14(6):1440–4
Treatment of autoimmune premature ovarian failure. Kalantaridou SN, et al. **Hum Reprod** 1999 Jul;14(7):1777–82
Effect of antenatal dexamethasone therapy on maternal plasma human chorionic gonadotrophin, oestradiol and progesterone. Ogueh O, et al. **Hum Reprod** 1999 Feb; 14(2):303–6
Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids. Hirano T, et al. **Immunopharmacology** 1998 Jul;40(1):57–66
Severe alopecia areata treated with systemic corticosteroids. Alabdulkareem AS, et al. **Int J Dermatol** 1998 Aug; 37(8):622–4
ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. Number 210, October 1998 (Replaces Number 147, December 1994). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Mar;64(3):334–5
Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Bilaçeroğlu S, et al. **Int J Tuberc Lung Dis** 1999 Jan;3(1):47–54
Treatment of traumatic optic neuropathy. Pomeranz HD, et al. **Int Ophthalmol Clin** 1999 Winter;39(1):185–94 (49 ref.)
Comparing the anti-inflammatory effects of corticotherapy and non-steroid anti-inflammatory drugs in infertile patients with infectious aetiology. Altay B, et al. **Int Urol Nephrol** 1999;31(1):101–6
Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. Thomas R, et al. **Intensive Care Med** 1999 May; 25(5):475–80
Nodular fasciitis: response to intralesional corticosteroids. Graham BS, et al. **J Am Acad Dermatol** 1999 Mar; 40(3):490–2
Beneficial effects of treatment of early subclinical rejection: a randomized study. Rush D, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2129–34
Use of human recombinant erythropoietin and prednisone for treatment of myelodysplastic syndrome with erythroid predominance in a dog. Boone LI, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):999–1001
Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? Tassani P, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):165–72
Combined use of steroid, antibiotics and early bougienage against stricture formation following caustic esophageal burns. Karnak I, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):307–10
Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. Abe T, et al. **J Cataract Refract Surg** 1999 Sep;25(9):1286–8
Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. Azziz R, et al. **J Clin Endocrinol Metab** 1999 Mar; 84(3):946–50
Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. Cerame BI, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3129–34
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3790–4
Treatment of hemangiopericytoma-induced hypoglycemia with growth hormone and corticosteroids [letter] Gullo D, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1758–9
Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. Lajic S, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3872–80
Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. Leonard N, et al. **J Clin Pathol** 1998 Oct;51(10):750–3
Nonmucosal eosinophilic gastroenteritis: sonographic appearance at presentation and during follow-up of response to prednisone therapy. Maroy B. **J Clin Ultrasound** 1998 Nov–Dec;26(9):483–6
Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. Balfour IC, et al. **J Heart Lung Transplant** 1999 May;18(5):492–5
Clinical stable systemic mastocytosis with interferon alpha-2b therapy. Hübner C, et al. **J Intern Med** 1997 Jun; 241(6):529–33
The steroid resistance of Crohn's disease. Mingrone G, et al. **J Investig Med** 1999 Jul;47(6):319–25
Inhale deeply ... it's safe [editorial] Garcia DP. **J Ky Med Assoc** 1999 Jan;97(1):27–8
Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. Shetlar MR, et al. **J Lab Clin Med** 1998 Dec;132(6):491–6
Effect of pulsed dexamethasone therapy on tolerance of intravenously administered lipids in extremely low birth weight infants. Sentipal-Walerius J, et al. **J Pediatr** 1999 Feb;134(2):229–32
The effects of Betamethasone on white blood cells during pregnancy with PPROM. Diebel ND, et al. **J Perinat Med** 1998;26(3):204–7
Glucocorticoid attenuates a decrease of antithrombin III following major surgery. Matsutani T, et al. **J Surg Res** 1998 Oct;79(2):158–63
Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? Wan S, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1004–8
Dexamethasone treatment of congenital adrenal hyperplasia in utero: an experimental therapy of unproven safety. Miller WL. **J Urol** 1999 Aug;162(2):537–40
Adjunctive oral corticosteroids reduce renal scarring: the piglet model of reflux and acute experimental pyelonephritis. Pohl HG, et al. **J Urol** 1999 Sep;162(3 Pt 1):815–20
Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. Leviton LC, et al. **JAMA** 1999 Jan 6;281(1):46–52
Methylprednisolone for unresolving ARDS [letter; comment] Wheeler A, et al. **JAMA** 1998 Dec 23–30;280(24):2074. Comment on: JAMA 1998 Jul 8;280(2):159–65. Comment on: JAMA 1998 Jul 8;280(2):182–3.
Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Wakakura M, et al. **Jpn J Ophthalmol** 1999 Mar–Apr;43(2):133–8
Treatment of IgA nephropathy [comment] Harper L, et al. **Lancet** 1999 Mar 13;353(9156):860–2. Comment on: Lancet 1999 Mar 13;353(9156):883–7.
Myocarditis and primary Sjögren's syndrome [letter] Levin MD, et al. **Lancet** 1999 Jul 10;354(9173):128–9
Betamethasone and placental vascular resistance [letter] Montenegro N. **Lancet** 1999 Jun 12;353(9169):2073–4
High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Thornton PD, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):167–70
The immunoreactive propensity of autoimmune hepatitis: is It corticosteroid-dependent after liver transplantation? [editorial; comment] Czaja AJ. **Liver Transpl Surg** 1999 Sep;5(5):460–3 (29 ref.). Comment on: Liver Transpl Surg 1999 Sep;5(5):375–80.
Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis [see comments] Trouillot TE, et al. **Liver Transpl Surg** 1999 Sep;5(5):375–80 . Comment in: Liver Transpl Surg 1999 Sep;5(5):460–3.
Scleromyxedema: a complete response to prednisone. Rayson D, et al. **Mayo Clin Proc** 1999 May;74(5):481–4
A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Hussain I, et al. **Med Mycol** 1999 Apr;37(2):97–9
Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Melani AS, et al. **Monaldi Arch Chest Dis** 1999 Jun;54(3):224–7
Steroid-responsive multifocal demyelinating neuropathy with central involvement. Liguori R, et al. **Muscle Nerve** 1999 Feb;22(2):262–5
Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants [see comments] Baud O, et al. **N Engl J Med** 1999 Oct 14;341(16):1190–6 . Comment in: N Engl J Med 1999 Oct 14;341(16):1229–31.
Glucocorticoid therapy for chronic obstructive pulmonary disease [editorial; comment] Boushey HA. **N Engl J Med** 1999 Jun 24;340(25):1990–1. Comment on: N Engl J Med 1999 Jun 24;340(25):1941–7. Comment on: N Engl J Med 1999 Jun 24;340(25):1948–53.
Periventricular leukomalacia--prospects for prevention [editorial; comment] Fanaroff AA, et al. **N Engl J Med** 1999 Oct 14;341(16):1229–31. Comment on: N Engl J Med 1999 Oct 14;341(16):1190–6.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group [see comments] Niewoehner DE, et al. **N Engl J Med** 1999 Jun 24;

340(25):1941-7. Comment in: **N Engl J Med** 1999 Jun 24;340(25):1990-1.

Steroid-sensitive nephrotic syndrome, sarcoidosis and thyroiditis--a new syndrome? Nishiki M, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2008-10

Wilms' tumour-associated late nephrotic syndrome responsive to treatment. Topaloglu R, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):954-6

Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy. Wright RA, et al. **Neurology** 1999 Jan 15;52(2):386-8

The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells. Vandebrouck C, et al. **Neurosci Lett** 1999 Jul 9;269(2):110-4

Somatosensory spinal cord evoked potentials in the evaluation of the effect of dexamethasone in experimental spinal cord injury. Güney O, et al. **Neurosurg Rev** 1998; 21(4):265-9

Effectiveness of antenatal steroids in obstetric subgroups. Elimian A, et al. **Obstet Gynecol** 1999 Feb;93(2):174-9

The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Levin LA, et al. **Ophthalmology** 1999 Jul;106(7):1268-77

Effects of systemic steroid treatment in chronic polypoid rhinosinusitis evaluated with magnetic resonance imaging. Damm M, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):517-23

Efficacy of corticosteroids in acute bronchiolitis: short-term and long-term follow-up. Berger I, et al. **Pediatr Pulmonol** 1998 Sep;26(3):162-6

Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy. Kiper N, et al. **Pediatr Pulmonol** 1999 Mar;27(3):180-4

Inhaled corticosteroids in childhood asthma [editorial; comment] Landau LI. **Pediatr Pulmonol** 1999 Jun; 27(6):365-8. Comment on: Pediatr Pulmonol 1999 Jun;27(6):369-75. Comment on: Pediatr Pulmonol 1999 Jun;27(6):376-82.

Prophylaxis in asthmatic patients prior to intravenous contrast [letter] McHugh K, et al. **Pediatr Radiol** 1999 Jan; 29(1):78

Pulmonary neuroendocrine cells in nitrofen-induced diaphragmatic hernia and the effect of prenatal glucocorticoids. Gosney JR, et al. **Pediatr Surg Int** 1999; 15(3-4):180-3

Effect of antenatal glucocorticoid administration on insulin-like growth factor I and II levels in hypoplastic lung in nitrofen-induced congenital diaphragmatic hernia in rats. Oue T, et al. **Pediatr Surg Int** 1999;15(3-4):175-9

Pathological evaluation of steroid withdrawal in pediatric renal transplant recipients. Aikawa A, et al. **Pediatr Transplant** 1999 May;3(2):131-8

Corticosteroid elimination in pediatric solid organ transplantation [editorial; comment] Fine RN, et al. **Pediatr Transplant** 1998 Feb;2(1):3-5 (23 ref.). Comment on: Pediatr Transplant 1998 Feb;2(1):30-4. Comment on: Pediatr Transplant 1998 Feb;2(1):64-9. Comment on: Pediatr Transplant 1998 Feb;2(1):70-5.

Factors affecting growth and strategies for treatment in children after renal transplantation. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):176-82 (37 ref.)

Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Kothadia JM, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):22-7

Effects of prenatal steroids on water and sodium homeostasis in extremely low birth weight neonates. Omar SA, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):482-8

Early dexamethasone therapy and blood cell count in preterm infants. Peng CT, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):476-81

Medications used in the treatment of multiple sclerosis. Schapiro RT. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):437-46, ix (48 ref.)

The use of perioperative corticosteroids in craniomaxillofacial surgery. Assimes TL, et al. **Plast Reconstr Surg** 1999 Jan;103(1):313-21; quiz 322

Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level. Dichter JR, et al. **Respir Med** 1999 Jun;93(6):373-8

Glucocorticoid receptor mRNA levels in bronchial epithelial cells of patients with COPD: influence of glucocorticoids. Korn SH, et al. **Respir Med** 1998 Sep;92(9):1102-9

Rhodococcus equi lung abscess complicating Evan's syndrome treated with corticosteroid. Tsang KW, et al. **Respiration** 1998;65(4):327-30

Corticosteroid rescue in late paediatric acute respiratory distress syndrome. Goh AY, et al. **Respirology** 1999 Sep; 4(3):295-7

Increased use of inhaled corticosteroids and reduced hospitalizations in adult asthmatics: 11 years' experience in a Japanese hospital. Ishihara K, et al. **Respirology** 1998 Sep;3(3):193-7

A case of group II non-specific interstitial pneumonia developed during corticosteroid therapy after acute respiratory distress syndrome. Ishioka S, et al. **Respirology** 1999 Sep;4(3):283-5

Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma. Norhaya MR, et al. **Respirology** 1999 Mar;4(1):77-81

Diagnostic and therapeutic challenges. Schatz H, et al. **Retina** 1998;18(6):551-3 (2 ref.)

Glucocorticosteroids in the management of rheumatoid arthritis. Laan RF, et al. **Rheumatology (Oxford)** 1999 Jan; 38(1):6-12 (49 ref.)

Recommendations of the Optic Neuritis Study Group [letter; comment] Blondeau P. **Surv Ophthalmol** 1998 Nov-Dec; 43(3):291. Comment on: Surv Ophthalmol 1998 Jan-Feb;42(4):373-7.

Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Harig F, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):111-8

Corticosteroids and ibuprofen in cystic fibrosis [letter] Balfour-Lynn IM, et al. **Thorax** 1999 Jul;54(7):657

Glucocorticoids decrease c-fos expression in human nasal polyps in vivo. Baraniuk JN, et al. **Thorax** 1998 Jul; 53(7):577-82

Glucocorticoid insensitive asthma: a one year clinical follow up pilot study. Demoly P, et al. **Thorax** 1998 Dec; 53(12):1063-5

Inhaled corticosteroids in COPD [letter; comment] Sherwood Burge P. **Thorax** 1999 Jul;54(7):655-6. Comment on: Thorax 1999 Jan;54(1):7-14.

Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Stirling RG, et al. **Thorax** 1998 Dec;53(12):1030-4

Pseudo-steroid resistant asthma. Thomas PS, et al. **Thorax** 1999 Apr;54(4):352-6

Morbidity from asthma in relation to regular treatment: a community based study. Walsh LJ, et al. **Thorax** 1999 Apr; 54(4):296-300

Steroid hormone-responsive secondary factor X deficiency [letter] Hamasaki A, et al. **Thromb Haemost** 1998 Dec; 80(6):1032-3

Effects of dexamethasone on functional and pathological changes in rat bronchi caused by high acute exposure to chlorine. Demnati R, et al. **Toxicol Sci** 1998 Oct;45(2):242-6

Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study. Tisone G, et al. **Transpl Int** 1998;11 Suppl 1:S267-9

Recombinant interferon-alpha-2A with or without steroid pretreatment in children with chronic hepatitis B. Ozen H, et al. **Turk J Pediatr** 1998 Oct-Dec;40(4):503-14

[The effect of antenatal corticosteroid prophylaxis in premature newborns with the use of surfactant therapy] Iarúkova N, et al. **Akush Ginekol (Sofiia)** 1998;37(2):20-3 (Eng. Abstr.) **(Bul)**

[Do corticoids have a preventive effect on laryngeal edema after tracheal extubation?] Demeure D. **Ann Fr Anesth Reanim** 1997;16(7):fi19-20 **(Fre)**

[Prenatal dexamethasone by the oral maternal route: perhaps soon (news)] Jacqz-Aigrain E. **Arch Pediatr** 1998 Jan; 5(1):95-6 **(Fre)**

[Autoimmune cholangitis successfully treated with corticotherapy. One case] Mitry E, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):94-7 (Eng. Abstr.) **(Fre)**

[Cervical epidural injection technic under computed tomography guidance in the treatment of cervicobrachial neuralgia] Morcet N, et al. **J Radiol** 1999 Feb;80(2):161-2 (Eng. Abstr.) **(Fre)**

[A case of cerebral giant-cell angiitis associated with cerebral amyloid angiopathy. Favorable evolution with corticosteroid therapy] Masson C, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):695-8 (Eng. Abstr.) **(Fre)**

[Corticotherapy and infectious broncho-pulmonary diseases. Workshop proceedings. 13-14 September 1997] **Rev Pneumol Clin** 1998 Sep;54 Suppl 2:S1-31 **(Fre)**

[Use of glucocorticoids in therapy of rheumatic disease. 1: Value--precautions--choice of drug preparation] Kaiser H. **Fortschr Med** 1998 Nov 20;116(32):44-5 **(Ger)**

[Allergic rhinitis. Topical steroids without systemic effect] Maegele M. **Med Monatsschr Pharm** 1999 Mar;22(3):89-90 **(Ger)**

[Betamethasone versus placebo in Peyronie's disease] Cipollone G, et al. **Arch Ital Urol Androl** 1998 Sep; 70(4):165-8 (Eng. Abstr.) **(Ita)**

[A case of fulminant Mycoplasma pneumoniae pneumonia successfully treated by steroid therapy] Fujishiro M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):476-80 (Eng. Abstr.) **(Jpn)**

[The joint use of prednisolone and phospholipid-containing hepatoprotectors in experimental chronic hepatitis] Vengerovskii AI, et al. **Eksp Klin Farmakol** 1999 Mar-Apr; 62(2):28-30 (Eng. Abstr.) **(Rus)**

[Treatment of thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999;77(7):56-9 (0 ref.) **(Rus)**

[Myopericarditis: clinical picture, diagnosis and treatment] Gurevich MA, et al. **Klin Med (Mosk)** 1999;77(7):33-6 (12 ref.) (Eng. Abstr.) **(Rus)**

[Treatment of rheumatic arthritis: role of glucocorticoids] Nasonov EL, et al. **Klin Med (Mosk)** 1999;77(4):4-8 (58 ref.) **(Rus)**

[Clinical presentation, course and treatment of recurrent sarcoidosis: followup data] Ozerova LV, et al. **Probl Tuberk** 1999;(1):47-51 (Eng. Abstr.) **(Rus)**

[Combined therapy of thrombocytopenia in SLE patient with antiphospholipid syndrome] Reshetniak TM, et al. **Ter Arkh** 1998;70(11):67-8 **(Rus)**

[Effects of corticosteroid and nonsteroid antiinflammatory drugs on corneal transparency after photorefraction keratectomy] Makarov IA, et al. **Vestn Oftalmol** 1998 Nov-Dec;114(6):19-22 (Eng. Abstr.) **(Rus)**

[Intravenous immunoglobulin in combined therapy for children with juvenile rheumatoid arthritis (evaluation of therapeutical efficiency and factors that influence them)] Shaikov AV, et al. **Vestn Ross Akad Med Nauk** 1998; (12):36-9 (Eng. Abstr.) **(Rus)**

[Glucocorticoid treatment improves glucose tolerance in patients with temporal arteritis or polymyalgia rheumatica] Sáez Barcelona JA, et al. **Rev Clin Esp** 1999 May; 199(5):270-4 (Eng. Abstr.) **(Spa)**

TOXICITY

Repeated use of betamethasone in rabbits: effects of treatment variation on adrenal suppression, pulmonary maturation, and pregnancy outcome. Pratt L, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):995-1005

Effect of steroid hormones on blood pressure. Dodic M, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):550-2

Dexamethasone-induced abnormalities in growth and bone metabolism in piglets are partially attenuated by growth hormone with no synergistic effect of insulin-like growth factor-I. Ward WE, et al. **Pediatr Res** 1998 Aug; 44(2):215-21

URINE

Development of a coupled-column liquid chromatographic-tandem mass spectrometric method for the direct determination of betamethasone in urine. Polettini A, et al. **J Chromatogr B Biomed Sci Appl** 1998 Aug 25;713(2):339-52

GLUCOCORTICOIDS, TOPICAL

ADMINISTRATION & DOSAGE

Update on inhaled corticosteroids: safety, compliance, and new delivery systems. Simon RA. **Allergy Asthma Proc** 1999 May-Jun;20(3):161-5 (33 ref.)

A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Nocker RE, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1499-505

An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. Wood LJ, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1457-63

Treatment of staphylococcal septic arthritis in rabbits by systemic antibiotics and intra-articular corticosteroids. Wysenbeek AJ, et al. **Ann Rheum Dis** 1998 Nov; 57(11):687-90

Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. van der Vleuten CJ, et al. **Arch Dermatol Res** 1999 Jul-Aug;291(7-8):390-5

Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. Fox GF, et al. **Arch Dis Child** 1999 Apr;80(4):343-7

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth BJ. **Arch Intern Med** 1999 May 10;159(9):941-55

Keloids and hypertrophic scars: results with intraoperative and serial postoperative corticosteroid injection therapy. Chowdri NA, et al. **Aust N Z J Surg** 1999 Sep;69(9):655-9

Comparison of inhaled beclometasone and budesonide. Back titration of inhaled steroids is uncommon in New Zealand [letter; comment] Black P. **BMJ** 1999 Jul 10;319(7202):125; discussion 126. Comment on: BMJ 1998 Oct 10;317(7164):986-90.

Comparison of inhaled beclomethasone and budesonide. Study was inadequate [letter; comment] Edsbäcker S, et al. **BMJ** 1999 Jul 10;319(7202):125-6; discussion 126. Comment on: BMJ 1998 Oct 10;317(7164):986-90.

Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Thorsson L, et al. **Br J Clin Pharmacol** 1999 Jun;47(6):619-24

Frequency of application of topical corticosteroids: an overview. Lagos BR, et al. **Br J Dermatol** 1998 Nov; 139(5):763-6 (21 ref.)

Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of seasonal allergic rhinitis. Rhinocort Study Group. Yang WH, et al. **Can Respir J** 1998 Nov-Dec;5(6):455-60

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Baraniuk J, et al. **Chest** 1999 Sep; 116(3):625-32

Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Poulin YP. **Cutis** 1999 Jan;63(1):41-8

Effects of local budesonide treatment on the cell-mediated immune response in acute and relapsing colitis in rats. Palmen MJ, et al. **Dig Dis Sci** 1998 Nov;43(11):2518-25

Sucralfate and methylprednisolone enemas in active ulcerative colitis: a prospective, single-blind study. Wright JP, et al. **Dig Dis Sci** 1999 Sep;44(9):1899-901

Mometasone furoate decreases adhesion molecule expression

in psoriasis. Berti E, et al. **Eur J Dermatol** 1998 Sep; 8(6):421–6

Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. du Bois RM, et al. **Eur Respir J** 1999 Jun;13(6):1345–50

NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Mattes J, et al. **Eur Respir J** 1999 Jun; 13(6):1391–5

Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis. Tanner V, et al. **Eye** 1998;12 (Pt 4):679–85

A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. Meltzer EO, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):107–14

Modulation of irritation-induced increase of E-selectin mRNA in vivo by topically applied corticosteroids. Kukutsch NA, et al. **J Invest Dermatol** 1999 Aug; 113(2):170–4

Transtympanic dexamethasone application in Ménière's disease: an alternative treatment for intractable vertigo. Sennaroğlu L, et al. **J Laryngol Otol** 1999 Mar; 113(3):217–21

Medical management of phimosis in children: our experience with topical steroids. Monsour MA, et al. **J Urol** 1999 Sep; 162(3 Pt 2):1162–4 (13 ref.)

Pressure measurements during injection of corticosteroids. Paul S, et al. **Med Biol Eng Comput** 1998 Nov;36(6):729–33

Clinical surveillance of a tined, bipolar, J-shaped, steroid-eluting, silicone-insulated atrial pacing lead. Glikson M, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1079–81

Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Williams RO 3rd, et al. **Pharm Dev Technol** 1999 May;4(2):167–79

Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients. Ayres JG, et al. **Respir Med** 1999 Jan;93(1):27–32

Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma. Herjavecz I, et al. **Respir Med** 1999 Apr;93(4):230–5

The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema. Goh CL, et al. **Singapore Med J** 1999 May;40(5):341–4

First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma [see comments] Blais L, et al. **Thorax** 1998 Dec;53(12):1025–9 . Comment in: Thorax 1998 Dec;53(12):1005–6.

Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Brand PL, et al. **Thorax** 1999 Feb;54(2):103–7

Societal and health care benefits of early use of inhaled steroids [editorial; comment] Haahtela T, et al. **Thorax** 1998 Dec;53(12):1005–6. Comment on: Thorax 1998 Dec;53(12):1025–9.

Inhaled corticosteroids in COPD [letter; comment] Tsang KW. **Thorax** 1999 Feb;54(2):186. Comment on: Thorax 1998 Jul;53(7):583–5.

Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis [see comments] van Grunsven PM, et al. **Thorax** 1999 Jan; 54(1):7–14. Comment in: Thorax 1999 Jan;54(1):3–4. Comment in: Thorax 1999 Jul;54(7):655–6.

[Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid (see comments)] Zimmermann R, et al. **Ann Dermatol Venereol** 1999 Jan; 126(1):13–6 (Eng. Abstr.). Comment in: Ann Dermatol Venereol 1999 Jan;126(1):11–2. **(Fre)**

[A case of noninflammatory corneal edema following anterior-posterior radial keratotomy successfully treated by topical steroids] Fukuda K, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jan;103(1):61–5 (Eng. Abstr.) **(Jpn)**

[Inhaled corticosteroids and asthma education] Gómez Tejada RA, et al. **Medicina (B Aires)** 1998;58(6):692–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Contact puzzle: Worsening of a recurrent facial eruption despite treatment. Diagnosis: allergic contact dermatitis caused by desonide. Garner LA, et al. **Am J Contact Dermat** 1999 Jun;10(2):81–2

Disturbance of the menstrual pattern after local injection with triamcinolone acetonide [letter] Mens JM, et al. **Ann Rheum Dis** 1998 Nov;57(11):700

Anaphylaxis to intradermal triamcinolone acetonide [letter] Downs AM, et al. **Arch Dermatol** 1998 Sep;134(9):1163–4

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth BJ. **Arch Intern Med** 1999 May 10;159(9):941–55

Cushing's syndrome induced by betamethasone nose drops. In rhinological disease betamethasone should be regarded as systemic corticosteroid [letter] Homer JJ, et al. **BMJ** 1999 May 15;318(7194):1355

Cushing's syndrome induced by betamethasone nose drops. Children taking intranasal corticosteroids should be monitored for growth retardation [letter; comment] Malozowski S, et al. **BMJ** 1999 May 15;318(7194):1355. Comment on: BMJ 1998 Sep 12;317(7160):739–40.

Cushing's syndrome induced by betamethasone nose drops. Learning difficulties may complicate the issue [letter; comment] Scorrer T, et al. **BMJ** 1999 May 15; 318(7194):1356. Comment on: BMJ 1998 Sep 12;317(7160):739–40.

The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Oikarinen A, et al. **Br J Dermatol** 1998 Dec;139(6):1106–10

Case report: visual loss caused by facial steroids. Michaeli-Cohen A, et al. **Can Fam Physician** 1998 Nov; 44:2462–3

Glaucoma secondary to topical use of steroid cream. thoe Schwartzenberg GW, et al. **Can J Ophthalmol** 1999 Jun; 34(4):222–5

Active sensitization to sodium metabisulfite in hydrocortisone cream. Heshmati S, et al. **Contact Dermatitis** 1999 Sep; 41(3):166–7

Patch testing with budesonide in serial dilutions: the significance of dose, occlusion time and reading time. Isaksson M, et al. **Contact Dermatitis** 1999 Jan;40(1):24–31

Active sensitization to budesonide and para-phenylenediamine from patch testing. Le Coz CJ, et al. **Contact Dermatitis** 1998 Sep;39(3):153–5

Contact allergy to prednicarbate: frequency of positive reactions in consecutively-patch-tested patients. Stingeni L, et al. **Contact Dermatitis** 1999 May;40(5):286–7

Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Malo JL, et al. **Eur Respir J** 1999 May; 13(5):993–8

Managing the steroid responder [letter; comment] Seiler T, et al. **J Cataract Refract Surg** 1998 Nov;24(11):1420–1. Comment on: J Cataract Refract Surg 1998 May;24(5):715–8.

Steroid-induced glaucoma in a young woman. Wax M. **J Glaucoma** 1998 Oct;7(5):353–8

Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin. Marlière V, et al. **J Pediatr** 1999 Jul;135(1):122–4

Persistent hiccups associated with intraarticular corticosteroid injection [letter] Gutierrez-Ureña S, et al. **J Rheumatol** 1999 Mar;26(3):760

Indiscriminate use of corticosteroid-containing eyedrops. Baratz KH, et al. **Mayo Clin Proc** 1999 Apr;74(4):362–6 (35 ref.)

On observational studies on growth effects of inhaled corticosteroids in asthma [letter] Russell G. **Pediatr Pulmonol** 1999 Apr;27(4):294–6

Intranasal steroids and septum perforation--an overlooked complication? A description of the course of events and a discussion of the causes. Cervin A, et al. **Rhinology** 1998 Sep;36(3):128–32

Laryngeal aspergillosis following high dose inhaled fluticasone therapy for asthma. Fairfax AJ, et al. **Thorax** 1999 Sep;54(9):860–1

[Cutaneous complications of inhaled corticoids] Guillot B, et al. **Ann Dermatol Venereol** 1998 Dec;125(12):927–30 (30 ref.) **(Fre)**

[Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops] Fuchs M, et al. **HNO** 1999 Jul;47(7):647–50 (Eng. Abstr.) **(Ger)**

ANALYSIS

Skin Cap and corticosteroids [letter; comment] Boyce D. **Dermatol Online J** 1997 Dec;3(2):11e–11f. Comment on: Dermatol Online J 1997 Mar;3(1):3.

Immediacy is both a liability and an asset of the Internet [editorial; comment] Huntley A. **Dermatol Online J** 1997 Dec;3(2):11b. Comment on: Dermatol Online J 1997 Mar;3(1):3.

Skin Cap analysis in Spain [letter] Sanmartin O. **Dermatol Online J** 1997 Dec;3(2):11g

Skin Cap: what have we learned, and when did we learn it? [editorial] Smith K. **Dermatol Online J** 1997 Dec; 3(2):11c

Determination of betamethasone dipropionate and salicylic acid in pharmaceutical preparations by high-performance liquid chromatography. Kedor-Hackmann ER, et al. **Drug Dev Ind Pharm** 1998 Jun;24(6):553–5

BLOOD

Automated sample preparation for the determination of budesonide in plasma samples by liquid chromatography and tandem mass spectrometry. Kronkvist K, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):401–9

PHARMACOKINETICS

Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Thorsson L, et al. **Br J Clin Pharmacol** 1999 Jun;47(6):619–24

Evaluation of topical application of clobetasol 17-propionate from various cream bases. Fang JY, et al. **Drug Dev Ind Pharm** 1999 Jan;25(1):7–14

Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Thorsson L, et al. **Eur Respir J** 1998 Dec;12(6):1340–5

Development in release testing of topical dosage forms: use of the Enhancer Cell with automated sampling. Rege PR, et al. **J Pharm Biomed Anal** 1998 Sep;17(8):1226–33

Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Schwarb FP, et al. **Pharm Res** 1999 Jun;16(6):909–15

Videoendoscopic analysis of nasal steroid distribution. Weber R, et al. **Rhinology** 1999 Jun;37(2):69–73

Bioavailability of clobetasol propionate-quantification of drug concentrations in the stratum corneum by dermatopharmacokinetics using tape stripping. Weigmann H, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Jan–Apr; 12(1–2):46–53

Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Dempsey OJ, et al. **Thorax** 1999 Jul;54(7):614–7

PHARMACOLOGY

Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps. Tingsgaard PK, et al. **Acta Otolaryngol** 1999; 119(3):362–8

Lung type II cell and macrophage annexin I release: differential effects of two glucocorticoids. Hall SE, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L114–21

Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Sano A, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1903–9

Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Brus R. **Arch Intern Med** 1999 Sep 13;159(16):1903–8

Acetone has anti-inflammatory effects on experimental contact reactions. Sjögren F, et al. **Contact Dermatitis** 1999 Jul;41(1):22–9

Effects of a corticosteroid, budesonide, on production of bioactive IL-12 by human monocytes. Larsson S, et al. **Cytokine** 1998 Oct;10(10):786–9

Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Schwarb FP, et al. **Eur J Pharm Biopharm** 1999 May;47(3):261–7

Effects of beta2-agonists and budesonide on interleukin-1beta and leukotriene B4 secretion: studies of human monocytes and alveolar macrophages. Zetterlund A, et al. **J Asthma** 1998;35(7):565–73

Expression of vitamin D receptor in cultured human keratinocytes and fibroblasts is not altered by corticosteroids. Midorikawa K, et al. **J Dermatol Sci** 1999 Sep;21(1):8–12

Inhaled corticosteroids and growth velocity in children with asthma [letter] Purucker M, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):264–6

Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? In vivo and in vitro studies. Saunders MW, et al. **Laryngoscope** 1999 May;109(5):785–90

Budesonide down-regulates eosinophil locomotion but has no effects on ECP release or on H2O2 production. Lantero S, et al. **Lung** 1999;177(4):219–28

Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva. Lenander-Lumikari M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):695–9

Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Gregson RK, et al. **Osteoporos Int** 1998;8(5):418–22

Effect of inhaled beclomethasone dipropionate and budesonide on growth in children with asthma. Allen DB. **Respir Med** 1998 Jul;92 Suppl B:37–45 (42 ref.)

A qualitative estimate of the influence of halcinonide concentration and urea on the reservoir formation in the stratum corneum. Clarys P, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Jan–Apr; 12(1–2):85–9

THERAPEUTIC USE

Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment [letter] Braun R, et al. **Acta Derm Venereol** 1998 Sep; 78(5):385

Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Scarpa C. **Acta Derm Venereol Suppl (Stockh)** 1994;186:47

Topical budesonide treatment reduces endothelial expression of intercellular adhesion molecules (vascular cell adhesion molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps. Tingsgaard PK, et al. **Acta Otolaryngol** 1999; 119(3):362–8

Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Berkowitz RB, et al. **Allergy Asthma Proc** 1999 May–Jun;20(3):167–72

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Murray JJ, et al. **Allergy Asthma Proc** 1999 May–Jun; 20(3):173–80

Ultrapotent topical corticosteroid treatment of childhood

genital lichen sclerosus. Garzon MC, et al. **Arch Dermatol** 1999 May;135(5):525–8

Side to side comparison of topical treatment in atopic dermatitis. Ainley-Walker PF, et al. **Arch Dis Child** 1998 Aug;79(2):149–52

Persistent nocturnal cough: randomised controlled trial of high dose inhaled corticosteroid. Davies MJ, et al. **Arch Dis Child** 1999 Jul;81(1):38–44

Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. Klimuk SK, et al. **Biochim Biophys Acta** 1999 Mar 4; 1417(2):191–201

Comparison of inhaled beclomethasone and budesonide. Studies of potencies of asthma drugs have methodological limitations [letter; comment] Suissa S, et al. **BMJ** 1999 Jul 10;319(7202):126. Comment on: BMJ 1998 Oct 10;317(7164):986–90.

Inhaled corticosteroid improves bronchial reactivity and decreases symptoms in patients with mitral stenosis. Cieslewicz G, et al. **Chest** 1998 Oct;114(4):1070–4

Nonsteroidal anti-inflammatories (NSAIDS), oral hypoglycemics, and topical steroids. An overview. Guadara J, et al. **Clin Podiatr Med Surg** 1998 Oct; 15(4):687–703, vi (36 ref.)

Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Wilson AM, et al. **Clin Sci (Colch)** 1998 Oct;95(4):513–7

Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. Nissen JB, et al. **Dermatology** 1999;198(1):11–7

Mucosal inflammation in severe glucocorticoid-dependent asthma. Vrugt B, et al. **Eur Respir J** 1999 Jun;13(6):1245–52

Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease [letter] Rutgeerts P. **Gut** 1999 Jul;45(1):13–4

Response of segmental vitiligo to 0.05% clobetasol propionate cream. Khalid M, et al. **Int J Dermatol** 1998 Sep;37(9):705–8

Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone [see comments] D'Arienzo A, et al. **Ital J Gastroenterol Hepatol** 1998 Jun; 30(3):254–7. Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):258–9.

Optimizing strategies in refractory ulcerative colitis [comment] Mulder CJ. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):258–9. Comment on: Ital J Gastroenterol Hepatol 1998 Jun;30(3):254–7.

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. Masuyama K, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):610–7

Time to onset of effect of fluticasone propionate in patients with asthma. Szefler SJ, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):780–8

Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. Dahlman-Ghozlan K, et al. **J Am Acad Dermatol** 1999 Mar;40(3):451–7

Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. Miller JJ, et al. **J Am Acad Dermatol** 1999 Oct;41(4):546–9

Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Austad J, et al. **J Eur Acad Dermatol Venereol** 1998 Jul; 11(1):19–24

Mometasone furoate versus betamethasone vale-rate in the treatment of allergic contact dermatitis [letter] Grandolfo M, et al. **J Eur Acad Dermatol Venereol** 1999 Mar; 12(2):178–80

Treatments for atopic eczema. Lord RW Jr. **J Fam Pract** 1999 Sep;48(9):663–4

Intranasal budesonide or fluticasone for allergic rhinitis. Yedavally-Yellayi SK, et al. **J Fam Pract** 1999 Apr; 48(4):248–9

Topical inhalant steroid (budesonide, Pulmicort nasal) therapy in intubation granuloma. Roh HJ, et al. **J Laryngol Otol** 1999 May;113(5):427–32

A superpotent topical steroid for constricting breast cancer symptoms [letter] Cheville A, et al. **J Pain Symptom Manage** 1999 Mar;17(3):149–52

Lichen sclerosus. Therapy with clobetasol propionate. Lorenz B, et al. **J Reprod Med** 1998 Sep;43(9):790–4

Lichen sclerosus of the vulva. Long-term steroid maintenance therapy. Sinha P, et al. **J Reprod Med** 1999 Jul;44(7):621–4

Topical steroid treatment of phimosis in boys. Chu CC, et al. **J Urol** 1999 Sep;162(3 Pt 1):861–3

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Vestbo J, et al. **Lancet** 1999 May 29; 353(9167):1819–23

Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Arriaga MA, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1682–5

Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. Wright ED, et al. **Laryngoscope** 1998 Oct;108(10):1528–33

Effect of inhaled glucocorticoid on the cellular profile and cytokine levels in induced sputum from asthmatic patients. Inoue H, et al. **Lung** 1999;177(1):53–62

Mometasone furoate nasal spray for allergic rhinitis. **Med Lett Drugs Ther** 1999 Feb 12;41(1046):16–7

Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Marsh P, et al. **Ophthalmology** 1999 Apr;106(4):811–6

Zinc aspartate, biotin, and clobetasol propionate in the treatment of alopecia areata in childhood [letter] Camacho FM, et al. **Pediatr Dermatol** 1999 Jul-Aug;16(4):336–8

Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. Mancini AJ, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):337–41

Serum leptin in children with asthma treated with inhaled budesonide. Heuck C, et al. **Respir Med** 1999 Apr; 93(4):268–71

Sub-tenon's corticosteroids for the treatment of macular edema in bone marrow transplant retinopathy. Walton RC, et al. **Retina** 1999;19(2):171–3

What you need to know--medications for rhinitis--uses and abuses. Soh KB. **Singapore Med J** 1999 Feb;40(2):120–2

Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time. Faul JL, et al. **Thorax** 1998 Sep;53(9):753–61

[The application of corticosteroid following photorefractive keratectomy] Li W, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Jan;33(1):16–8 (Eng. Abstr.) **(Chi)**

[Question of the Month. How do you prescribe the quantity of topical corticoids to be used?] Crickx B. **Ann Dermatol Venereol** 1999 Jun-Jul;126(6-7):547–52 **(Fre)**

[Allergic rhinitis. Topical steroids without systemic effect] Maegele M. **Med Monatsschr Pharm** 1999 Mar;22(3):89–90 **(Ger)**

[Triderm in the treatment of atopic dermatitis] Kaliuzhnaia DD. **Voen Med Zh** 1999 Feb;320(2):53–5 **(Rus)**

[Adrenal function and lipid metabolism in asthmatic children treated with budesonide] Paoli-de Valeri M, et al. **Salud Publica Mex** 1999 Mar-Apr;41(2):119–23 (Eng. Abstr.) **(Spa)**

[Corticosteroid is efficient against abuse of nasal decongestants] Graf P, et al. **Lakartidningen** 1998 Sep 30; 95(40):4344–6 **(Swe)**

GLUCOKINASE

ANALYSIS

Glucokinase is concentrated in insulin-secretory granules of pancreatic B-cells. Toyoda Y, et al. **Histochem Cell Biol** 1999 Jul;112(1):35–40

Nutrient-dependent distribution of insulin and glucokinase immunoreactivities in rat pancreatic beta cells. Jörns A, et al. **Virchows Arch** 1999 Jan;434(1):75–82

BIOSYNTHESIS

High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. McCarty MF. **Med Hypotheses** 1999 May;52(5):401–6 (75 ref.)

BLOOD

Comparison of glucokinase activities in the peripheral leukocytes between dogs and cats. Arai T, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):53–6

CHEMISTRY

Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Mahalingam B, et al. **Diabetes** 1999 Sep;48(9):1698–705

High-resolution electrospray ionization Fourier transform mass spectrometry with infrared multiphoton dissociation of glucokinase from Bacillus Stearothermophilus. Dufresne CP, et al. **J Am Soc Mass Spectrom** 1998 Nov;9(11):1222–5

DEFICIENCY

Specific insulin and proinsulin secretion in glucokinase-deficient individuals. Pardini VC, et al. **Braz J Med Biol Res** 1999 Apr;32(4):427–30

GENETICS

A missense mutation, Val62Ala, in the glucokinase gene in a Norwegian family with maturity-onset diabetes of the young. Njølstad PR, et al. **Acta Paediatr** 1998 Aug; 87(8):853–6

Involvement of a local fenton reaction in the reciprocal modulation by O2 of the glucagon-dependent activation of the phosphoenolpyruvate carboxykinase gene and the insulin-dependent activation of the glucokinase gene in rat hepatocytes. Kietzmann T, et al. **Biochem J** 1998 Oct 15; 335 (Pt 2):425–32

Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype. Miller SP, et al. **Diabetes** 1999 Aug;48(8):1645–51

Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice. Sreenan SK, et al. **Diabetes** 1998 Dec;47(12):1881–8

High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Lehto M, et al. **Diabetologia** 1999 Sep; 42(9):1131–7

D-glucose transport and utilization in pituitary adenoma cells transfected with glucokinase gene [letter; comment] Malaisse WJ. **Diabetologia** 1999 Apr;42(4):498. Comment on: Diabetologia 1998 Dec;41(12):1492–501.

Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose [published erratum appears in Diabetologia 1999 Apr;42(4):498] [see comments] Motoyoshi S, et al. **Diabetologia** 1998 Dec;41(12):1492–501. Comment in: Diabetologia 1999 Apr;42(4):498.

Effect of retinoic acid on glucokinase activity and gene expression and on insulin secretion in primary cultures of pancreatic islets. Cabrera-Valladares G, et al. **Endocrinology** 1999 Jul;140(7):3091–6

Expression and regulation of glucokinase in rat islet beta- and alpha-cells during development. Tu J, et al. **Endocrinology** 1999 Aug;140(8):3762–6

Adenovirus-mediated knockout of a conditional glucokinase gene in isolated pancreatic islets reveals an essential role for proximal metabolic coupling events in glucose-stimulated insulin secretion. Piston DW, et al. **J Biol Chem** 1999 Jan 8;274(2):1000–4

Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. Baroni MG, et al. **J Endocrinol** 1999 Apr;161(1):59–68

Effect of a beta3-adrenergic agonist on liver glucokinase gene expression in alloxan-diabetic rats. Milagro FI, et al. **J Physiol Biochem** 1999 Mar;55(1):25–31

GLUT2 and glucokinase expression is coordinately regulated by sulfonylurea. Porzio O, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1-2):155–61

METABOLISM

The physiological role of glucokinase binding and translocation in hepatocytes. Agius L. **Adv Enzyme Regul** 1998;38:303–31

Inhibitory effects of streptozotocin, tumor necrosis factor-alpha, and interleukin-1beta on glucokinase activity in pancreatic islets and gene expression of GLUT2 and glucokinase. Park C, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):217–24

Effects of acute or prolonged exposure to human leptin on isolated human islet function. Lupi R, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):637–41

Selective fermentation of xylose by a mutant of Tetragenococcus halophila defective in phosphoenolpyruvate:mannose phosphotransferase, phosphofructokinase, and glucokinase. Abe K, et al. **Biosci Biotechnol Biochem** 1998 Oct;62(10):2062–4

Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. O'Doherty RM, et al. **Diabetes** 1999 Oct; 48(10):2022–7

Metabolic regulation, activity state, and intracellular binding of glucokinase in insulin-secreting cells. Tiedge M, et al. **Diabetes** 1999 Mar;48(3):514–23

D-glucose transport and utilization in pituitary adenoma cells transfected with glucokinase gene [letter; comment] Malaisse WJ. **Diabetologia** 1999 Apr;42(4):498. Comment on: Diabetologia 1998 Dec;41(12):1492–501.

Mannitol 1-phosphate mediates an inhibitory effect of mannitol on the activity and the translocation of glucokinase in isolated rat hepatocytes. Niculescu L, et al. **Diabetologia** 1998 Aug;41(8):947–54

Effect of retinoic acid on glucokinase activity and gene expression and on insulin secretion in primary cultures of pancreatic islets. Cabrera-Valladares G, et al. **Endocrinology** 1999 Jul;140(7):3091–6

Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Romero-Navarro G, et al. **Endocrinology** 1999 Oct; 140(10):4595–600

Glucokinase regulatory protein is essential for the proper subcellular localisation of liver glucokinase. de la Iglesia N, et al. **FEBS Lett** 1999 Aug 6;456(2):332–8

Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii. Qian-Cutrone J, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):245–55

Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. Aiston S, et al. **J Biol Chem** 1999 Aug 27;274(35):24559–66

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. Postic C, et al. **J Biol Chem** 1999 Jan 1;274(1):305–15

Glycolysis, turbo design and the endocrine pancreatic beta cell [letter; comment] Iynedjian PB. **Trends Biochem Sci** 1998 Dec;23(12):467–8. Comment on: Trends Biochem Sci 1998 May;23(5):162–9.

GLUCONATES

Identification of a gluconic acid derivative attached to the N-terminus of histidine-tagged proteins expressed in bacteria. Yan Z, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):793–800

GLUCONATES

BLOOD

Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Seligman PA, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):898–901

CHEMISTRY

Oxidative decarboxylation of 6-phosphogluconate by 6-phosphogluconate dehydrogenase proceeds by a stepwise mechanism with NADP and APADP as oxidants. Hwang CC, et al. **Biochemistry** 1998 Sep 8;37(36):12596–602

METABOLISM

Simultaneous production of catalase, glucose oxidase and gluconic acid by Aspergillus niger mutant. Fiedurek J, et al. **Acta Microbiol Pol** 1998;47(4):355–64

Production of medium-chain-length poly(3-hydroxyalkanoates) from gluconate by recombinant Escherichia coli. Klinke S, et al. **Appl Environ Microbiol** 1999 Feb;65(2):540–8

Retention and regeneration of native NAD(H) in noncharged ultrafiltration membrane reactors: application to L-lactate and gluconate production. Obón JM, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):510–7

A new rapid method to detect inhibition of Amadori product generated by delta-gluconolactone. Rahbar S, et al. **Clin Chim Acta** 1999 Sep;287(1–2):123–30

The gluconate high affinity transport of GntI in Escherichia coli involves a multicomponent complex system. Porco A, et al. **J Basic Microbiol** 1998;38(5–6):395–404

PHARMACOLOGY

Inhibition of P-glycoprotein-mediated transport by a hydrophobic contaminant in commercial gluconate salts. Vanoye CG, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1439–42

Protection of excitotoxic neuronal death by gluconate through blockade of N-methyl-D-aspartate receptors. Sakaguchi T, et al. **Neuroscience** 1999;92(2):677–84

THERAPEUTIC USE

Zinc gluconate lozenges for treating the common cold. Evans MF, et al. **Can Fam Physician** 1997 Mar;43:453

GLUCONEOGENESIS

Alterations in hepatic gluconeogenesis, prostanoid, and intracellular calcium during sepsis. Maitra SR, et al. **Acad Emerg Med** 1999 Jun;6(6):588–95

13C NMR measurements of human gluconeogenic fluxes after ingestion of [U-13C]propionate, phenylacetate, and acetaminophen. Jones JG, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):E843–52

Measurement of gluconeogenesis and mass isotopomer analysis based on [U-(13)C]glucose. Radziuk J, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E199–207

Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Large V, et al. **Diabetes** 1999 Jun; 48(6):1251–7

Acn9 is a novel protein of gluconeogenesis that is located in the mitochondrial intermembrane space. Dennis RA, et al. **Eur J Biochem** 1999 Apr;261(1):236–43

Quantification of gluconeogenesis in cirrhosis: response to glucagon. Bugianesi E, et al. **Gastroenterology** 1998 Dec; 115(6):1530–40

Substrate utilization for hepatic gluconeogenesis is altered by increased glucose demand in ruminants. Overton TR, et al. **J Anim Sci** 1999 Jul;77(7):1940–51

Effects of a high-fat diet and voluntary wheel running on gluconeogenesis and lipolysis in rats. Podolin DA, et al. **J Appl Physiol** 1999 Apr;86(4):1374–80

Effect of fatty liver on hepatic gluconeogenesis in periparturient dairy cows. Rukkwamsuk T, et al. **J Dairy Sci** 1999 Mar;82(3):500–5

Changes in glycemia induced by exercise in rats: contribution of hepatic glycogenolysis and gluconeogenesis. Borba-Murad GR, et al. **Res Commun Mol Pathol Pharmacol** 1998 Nov; 102(2):113–23

DRUG EFFECTS

Fatty acids and glycerol or lactate are required to induce gluconeogenesis from alanine in isolated rabbit renal cortical tubules. Lietz T, et al. **Amino Acids** 1999; 16(1):41–58

Acute effect of leptin on hepatic glycogenolysis and gluconeogenesis in perfused rat liver. Nemecz M, et al. **Hepatology** 1999 Jan;29(1):166–72

Effects of glucagon on glycogenolysis and gluconeogenesis are region-specific in periportal and perivenous hepatocytes. Ikezawa Y, et al. **J Lab Clin Med** 1998 Dec; 132(6):547–55

Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Stumvoll M, et al. **Metabolism** 1998 Oct;47(10):1227–32

Effect of theophylline on glucose production and lipolysis in preterm infants (< or = 32 weeks). Diderholm B, et al. **Pediatr Res** 1999 May;45(5 Pt 1):674–9

GENETICS

Enhanced gluconeogenesis and hepatic insulin resistance in insulin-like growth factor binding protein-1 transgenic mice. Rajkumar K, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):491–7

Regulation of messenger ribonucleic acid expression for gluconeogenic enzymes during glucagon infusions into lactating cows. She P, et al. **J Dairy Sci** 1999 Jun; 82(6):1153–63

PHYSIOLOGY

Calories and aging alter gene expression for gluconeogenic, glycolytic, and nitrogen-metabolizing enzymes. Dhahbi JM, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E352–60

Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Petersen KF, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E529–35

A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo. Previs SF, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E154–60

The inhibition of gluconeogenesis following alcohol in humans. Siler SQ, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E897–907

Effect of a selective rise in hepatic artery insulin on hepatic glucose production in the conscious dog. Sindelar DK, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E806–13

Resistance to insulin's acute direct hepatic effect in suppressing steady-state glucose production in individuals with type 2 diabetes. Lewis GF, et al. **Diabetes** 1999 Mar; 48(3):570–6

Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition. Sunehag AL, et al. **Diabetes** 1999 Apr;48(4):791–800

Comments on metabolic needs for glucose and the role of gluconeogenesis. Brosnan JT. **Eur J Clin Nutr** 1999 Apr; 53 Suppl 1:S107–11 (25 ref.)

The transcription factor CCAAT/enhancer-binding protein beta regulates gluconeogenesis and phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. Arizmendi C, et al. **J Biol Chem** 1999 May 7; 274(19):13033–40

Postnatal profiles of glycogenolysis and gluconeogenesis are modified in rat pups by maternal dietary glucose restriction. Lanoue L, et al. **J Nutr** 1999 Apr;129(4):820–7

GLUCOSACCHARIC ACID see **GLUCARIC ACID**

GLUCOSAMINE

ADMINISTRATION & DOSAGE

Hype about glucosamine. Adams ME. **Lancet** 1999 Jul 31; 354(9176):353–4

ADVERSE EFFECTS

Immediate-hypersensitivity reaction to glucosamine sulfate. Matheu V, et al. **Allergy** 1999 Jun;54(6):643

ANALOGS & DERIVATIVES

Simultaneous determination of glucosamine and glucosamine 4-phosphate in Lipid A with high-performance anion-exchange chromatography (HPAEC). Kiang J, et al. **Carbohydr Res** 1998 Nov;312(1–2):73–6

Access to tetrachlorophthalimide-protected ethyl 2-amino-2-deoxy-1-thio-beta-D-glucopyranosides. Olsson L, et al. **Carbohydr Res** 1998 Dec 31;314(3–4):273–6

Synthesis and biological evaluation of ureido and thioureido derivatives of 2-amino-2-deoxy-D-glucose and related aminoalcohols as N-acetyl-beta-D-hexosaminidase inhibitors. Tournaire-Arellano C, et al. **Carbohydr Res** 1998 Dec 21;314(1–2):47–63

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Mitrakou A, et al. **Diabet Med** 1998 Aug; 15(8):657–60

Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Virkamäki A, et al. **Diabetes** 1999 May;48(5):1101–7

Enhancement in the lysozyme activity of the hen egg white foam matrix by cross-linking in the presence of N-acetyl glucosamine. Marolia KZ, et al. **J Biochem Biophys Methods** 1999 Feb 25;39(1–2):115–7

Glycoscience moves from the laboratory to the clinic [news] Rowe PM. **Lancet** 1999 Jul 31;354(9176):402

Miglitol for type 2 diabetes mellitus. **Med Lett Drugs Ther** 1999 May 21;41(1053):49–50

Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Russell JC, et al. **Metabolism** 1999 Jun;48(6):701–6

Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose [published erratum appears in Obes Res 1999 Mar;7(2):232] Axen KV, et al. **Obes Res** 1999 Jan;7(1):83–9

Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Bassleer C, et al. **Osteoarthritis Cartilage** 1998 Nov;6(6):427–34

ANALYSIS

Simultaneous determination of glucosamine and glucosamine 4-phosphate in Lipid A with high-performance anion-exchange chromatography (HPAEC). Kiang J, et al. **Carbohydr Res** 1998 Nov;312(1–2):73–6

Mass spectrometric profiling of glucosamine, glucosamine polymers and their catecholamine adducts. Model reactions and cuticular hydrolysates of Toxorhynchites amboinensis (Culicidae) pupae. Kerwin JL, et al. **Insect Biochem Mol Biol** 1999 Jul;29(7):599–607

Glucosamine content of tempe mould, Rhizopus oligosporus. Sparringa RA, et al. **Int J Food Microbiol** 1999 Mar 1; 47(1–2):153–7

BLOOD

Glucosamine levels in people with ischaemic heart disease with and without type II diabetes. Nowak A, et al. **Pol Arch Med Wewn** 1998 Nov;100(5):419–25

CHEMISTRY

13C CP MAS NMR study of ureido sugars, derivatives of 2-amino-2-deoxy-beta-D-glucopyranose and dipeptides. Wawer I, et al. **Solid State Nucl Magn Reson** 1998 Aug; 12(1):45–50

METABOLISM

Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. Gawlitzek M, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):518–28

Differences in metabolism of 5-fluorouracil and 5-fluorouridine and regulation by glucosamine in human colon cancer multicell tumor spheroids. Chen TB, et al. **NMR Biomed** 1999 May;12(3):157–67

PHARMACOLOGY

Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Sandy JD, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):59–66

Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Holmäng A, et al. **Diabetes** 1999 Jan;48(1):106–11

Glucosamine infusion in rats rapidly impairs insulin stimulation of phosphoinositide 3-kinase but does not alter activation of Akt/protein kinase B in skeletal muscle. Kim YB, et al. **Diabetes** 1999 Feb;48(2):310–20

Glucosamine induces translocation of protein kinase C isoenzymes in mesangial cells. Kolm-Litty V, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):377–83

Enhancement in the lysozyme activity of the hen egg white foam matrix by cross-linking in the presence of N-acetyl glucosamine. Marolia KZ, et al. **J Biochem Biophys Methods** 1999 Feb 25;39(1–2):115–7

The inhibition of capacitative calcium entry due to ATP depletion but not due to glucosamine is reversed by staurosporine. Vemuri S, et al. **J Biol Chem** 1999 Jul 16; 274(29):20165–70

Primary open-angle glaucoma may be a hyaluronic acid deficiency disease: potential for glucosamine in prevention and therapy. McCarty MF. **Med Hypotheses** 1998 Dec; 51(6):483–4 (13 ref.)

PHYSIOLOGY

Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Patti ME, et al. **Diabetes** 1999 Aug;48(8):1562–71

Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Ciaraldi TP, et al. **Endocrinology** 1999 Sep;140(9):3971–80

A case for glucosamine. Hussain MA. **Eur J Endocrinol** 1998 Nov;139(5):472–5 (45 ref.)

THERAPEUTIC USE

Glucosamine sulfate use in osteoarthritis. Runkel DR, et al. **Am J Health Syst Pharm** 1999 Feb 1;56(3):267–9 (20 ref.)

Comment: glucosamine: selecting appropriate study exclusion criteria [letter; comment] Barclay TS, et al. **Ann Pharmacother** 1998 Dec;32(12):1371–2. Comment on: Ann Pharmacother 1998 May;32(5):602–3.

Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF. **Med Hypotheses** 1998 Jul;51(1):11–5 (63 ref.)

Glucosamine in osteoarthritis and gastrointestinal disorders: an exemplar of the need for a paradigm shift. Russell AL. **Med Hypotheses** 1998 Oct;51(4):347–9

Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Leffler CT, et al. **Mil Med** 1999 Feb;164(2):85–91

Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Deal CL, et al. **Rheum Dis Clin North Am** 1999 May;25(2):379–95 (38 ref.)

GLUCOSAMINE SYNTHETASE see
GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING)

GLUCOSAMINEPHOSPHATE ISOMERASE (GLUTAMINE-FORMING) see
GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING)

GLUCOSE

see related
BLOOD GLUCOSE
GLYCOSURIA
HYPERGLYCEMIA
HYPOGLYCEMIA

Evaluation of two dextrose-based directly compressible excipients. Olmo IG, et al. **Drug Dev Ind Pharm** 1998 Aug; 24(8):771–8

Purification of a mannose/glucose-specific hemagglutinin/lectin from a Vibrio cholerae O1 strain. Sasmal D, et al. **FEMS Immunol Med Microbiol** 1999 Mar; 23(3):221–7

Glucose and culture of human embryos [comment] Bavister BD. **Fertil Steril** 1999 Aug;72(2):233–4. Comment on: Fertil Steril 1999 Aug;72(2):229–32.

Glucose-free medium in human in vitro fertilization and embryo transfer: a large-scale, prospective, randomized clinical trial [see comments] Coates A, et al. **Fertil Steril** 1999 Aug;72(2):229–32. Comment in: Fertil Steril 1999 Aug;72(2):233–4.

Characterization of three related glucose repressors and genes they regulate in Saccharomyces cerevisiae. Lutfiyya LL, et al. **Genetics** 1998 Dec;150(4):1377–91

Semen preparation by standard swim-up versus swim-up with test yolk buffer incubation in intrauterine insemination: a randomized study. Ragni G, et al. **Hum Reprod** 1998 Jul; 13(7):1859–63

Genes involved in cell wall localization and side chain formation of rhamnose-glucose polysaccharide in Streptococcus mutans. Yamashita Y, et al. **J Bacteriol** 1998 Nov;180(21):5803–7

Glucose loading precipitates acute encephalopathy in thiamin-deficient rats. Zimitat C, et al. **Metab Brain Dis** 1999 Mar;14(1):1–20

Transformation of monomorphic Trypanosoma brucei bloodstream form trypomastigotes into procyclic forms at 37 degrees C by removing glucose from the culture medium. Milne KG, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):99–112

Treatment of hypokalemia [letter; comment] [published erratum appears in N Engl J Med 1999 Feb 25;340(8):663] Agarwal A, et al. **N Engl J Med** 1999 Jan 14;340(2):154–5; discussion 155. Comment on: N Engl J Med 1998 Aug 13;339(7):451–8.

Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Qamar IU, et al. **Perit Dial Int** 1999 May-Jun;19(3):237–47

Maillard reaction and AGE formation in glucose and polyglucose dialysis solutions. Tomo T, et al. **Perit Dial Int** 1999 May-Jun;19(3):274–7

Evaluation of techniques for the cryopreservation of washed spermatozoa: comparisons between Ham's F-10 and TEST-yolk media. Zavos PM, et al. **Tohoku J Exp Med** 1998 Apr;184(4):277–84

ADMINISTRATION & DOSAGE

Intraoperative glucose administration influences respiratory quotient during paediatric anaesthesia. Sandström K, et al. **Acta Anaesthesiol Scand** 1999 Mar;43(3):302–7

Hyponatremia: evaluating the correction factor for hyperglycemia. Hillier TA, et al. **Am J Med** 1999 Apr; 106(4):399–403

Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Nath CE, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1417–23

Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Nucci M, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1445–8

Effects of food, glucose, and water ingestion on feeding activity in the toad (Bufo bufo). Laming PR, et al. **Behav Neurosci** 1998 Oct;112(5):1266–72

Dose-dependent action of glucose on memory processes in women: effect on serial position and recall priority. Messier C, et al. **Brain Res Cogn Brain Res** 1998 Oct;7(2):221–33

Simulation studies on neural predictive control of glucose using the subcutaneous route. Trajanoski Z, et al. **Comput Methods Programs Biomed** 1998 May;56(2):133–9

Biphasic insulin secretion during intravenous glucose tolerance test promotes optimal interstitial insulin profile. Getty L, et al. **Diabetes** 1998 Dec;47(12):1941–7

Plasma and interstitial glucose dynamics after intravenous glucose injection: evaluation of the single-compartment glucose distribution assumption in the minimal models. Regittnig W, et al. **Diabetes** 1999 May;48(5):1070–81

GLP-1 release in man after lower large bowel resection or intrarectal glucose administration. Printz H, et al. **Digestion** 1998 Nov-Dec;59(6):689–95

Microvascular skin blood flow following the ingestion of 75 g glucose in healthy individuals. Forst T, et al. **Exp Clin Endocrinol Diabetes** 1998;106(6):454–9

Neogenesis vs. apoptosis As main components of pancreatic beta cell ass changes in glucose-infused normal and mildly diabetic adult rats. Bernard C, et al. **FASEB J** 1999 Jul; 13(10):1195–205

Noninvasive treatment of heterotopic pregnancy? [letter; comment] Hönigl W, et al. **Fertil Steril** 1999 Mar; 71(3):586–7. Comment on: Fertil Steril 1998 Jan;69(1):149–51.

Carbohydrate-deficient glycoprotein syndrome type 1: correction of the glycosylation defect by deprivation of glucose or supplementation of mannose. Körner C, et al. **Glycoconj J** 1998 May;15(5):499–505

Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus. Ciampelli M, et al. **Horm Res** 1998;49(6):263–8

Further optimization of culture method for rat keratinocytes: titration of glucose and sodium chloride. Oku H, et al. **In Vitro Cell Dev Biol Anim** 1999 Feb;35(2):67–74

Effects of medium-chain triacylglycerol ingested with carbohydrate on metabolism and exercise performance. Goedecke JH, et al. **Int J Sport Nutr** 1999 Mar;9(1):35–47

Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Riddell MC, et al. **Int J Sport Nutr** 1999 Mar;9(1):24–34

Glucose ingestion and whole blood ionized calcium and magnesium in the third trimester of pregnancy. Bracero LA, et al. **J Am Coll Nutr** 1998 Aug;17(4):385–7

Quantitation of dextran 70 in peritoneal dialysate from patients administered 7.5% polyglucose. Burke RA, et al. **J Chromatogr B Biomed Sci Appl** 1998 Oct 23;718(1):115–20

Effects of graded duodenal infusions of glucose on yield and composition of milk from dairy cows. 1. Diets based on corn silage. Hurtaud C, et al. **J Dairy Sci** 1998 Dec; 81(12):3239–47

Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. Ciprandi G, et al. **J Investig Allergol Clin Immunol** 1999 Jan-Feb; 9(1):35–8

Potentiated glucose deprivation-induced death of astrocytes after induction of iNOS. Choi JJ, et al. **J Neurosci Res** 1998 Dec 15;54(6):870–5

Postnatal profiles of glycogenolysis and gluconeogenesis are modified in rat pups by maternal dietary glucose restriction. Lanoue L, et al. **J Nutr** 1999 Apr;129(4):820–7

Low intensity exercise and varying proportions of dietary glucose and fat modify milk and mammary gland compositions and pup growth. Matsuno AY, et al. **J Nutr** 1999 Jun;129(6):1167–75

Modulation of bone mass and turnover in growing rats by voluntary weight-bearing exercise and glucose supplementation. Omi N, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Jun;44(3):409–421

The "two bag system" for variable intravenous dextrose and fluid administration: benefits in diabetic ketoacidosis management. Grimberg A, et al. **J Pediatr** 1999 Mar; 134(3):376–8

The effect of nutritional and hormonal supplementation on protein synthesis immediately after liver transplantation. Geevarghese SK, et al. **J Surg Res** 1999 Feb;81(2):196–200

The influence of intravenous infusions of glucose and amino acids of pancreatic enzyme and mucosal protein synthesis in human subjects. O'Keefe SJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep-Oct;22(5):253–8

Preservation of the incretin effect after orthotopic pancreas transplantation in inbred rats. Kissler HJ, et al. **Metabolism** 1999 May;48(5):645–50

The influence of frequent and excessive intake of glucose on microvascular aging in healthy mice. Yamada S, et al. **Microcirculation** 1999 Mar;6(1):55–62

Infant feeding practices in a deprived environment: a concern for early introduction of water and glucose D water to neonates. Ojofeitimi EO, et al. **Nutr Health** 1999; 13(1):11–21

Chronic effects of somatotropin treatment in vivo and in vitro on lipogenic activity of goat adipose tissue in a glucose-free buffer during acute incubation. Skarda J. **Physiol Res** 1999; 48(1):43–9

Glucose-induced increase in memory performance in patients with schizophrenia. Newcomer JW, et al. **Schizophr Bull** 1999;25(2):321–35

Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Scott JF, et al. **Stroke** 1999 Apr;30(4):793–9

Renal failure in surgical patients. Treatment with intravenous essential amino acids and hypertonic glucose. Dudrick SJ, et al. **Surgery** 1970 Jul;68(1):180–5; discussion 185–6

[Changes in intraoperative blood glucose and ketone body concentrations during the repair of lipomyelomeningocele in children] Nonogaki M, et al. **Masui** 1998 Oct; 47(10):1226–8 (Eng. Abstr.) **(Jpn)**

[The effect of polarizing mixture KIG (potassium + insulin + glucose) on some metabolites of glucose transformation in patients with ischemic stroke during the earliest period of illness] Adach B. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:15–22 (Eng. Abstr.) **(Pol)**

[Glucose polymer (icodextrin) as a component of fluid for peritoneal dialysis] Czyżewska K, et al. **Pol Arch Med Wewn** 1998 May;99(5):417–22 (44 ref.) **(Pol)**

ADVERSE EFFECTS

Severe cutaneous hypersensitivity requiring permanent icodextrin withdrawal in a CAPD patient. Queffeulou G, et al. **Clin Nephrol** 1999 Mar;51(3):184–6

Peritoneal dialysis: diabetes of the peritoneal cavity [editorial; comment] Rosenberg ME. **J Lab Clin Med** 1999 Aug; 134(2):103–4. Comment on: J Lab Clin Med 1999 Aug;134(2):124–32.

Enterobacter cloacae and Pseudomonas aeruginosa polymicrobial bloodstream infections traced to extrinsic contamination of a dextrose multidose vial. Archibald LK, et al. **J Pediatr** 1998 Nov;133(5):640–4

Icodextrin allergy in a peritoneal dialysis patient. Fletcher S, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2656–8

Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit. Garosi G, et al. **Perit Dial Int** 1998 Nov-Dec;18(6):610–9

The effect of octreotide on peritoneal alterations induced by high concentration of glucose. Günal AI, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):532–4

A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Wens R, et al. **Perit Dial Int** 1998 Nov-Dec;18(6):603–9

ANALOGS & DERIVATIVES

Dual mode of action of glucose pentaacetates on hormonal secretion from the isolated perfused rat pancreas. Leclercq-Meyer V, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E610–7

Insulinotropic action of beta-L-glucose pentaacetate. Malaisse WJ, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E993–E1006

Enzymatic conversion of glucose to UDP-4-keto-6-deoxyglucose in Streptomyces spp. Liu SY, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3972–6

Determination of the structure for polysubstituted flavonoid and 6-C-glucosyl flavonoids using 13C-1H long range couplings. Lee MW. **Arch Pharm Res** 1994 Dec;17(6):487–9

Differences in the time course of the metabolic response of B and non-B pancreatic islet cells to D-glucose and metabolized or non-metabolized hexose esters. Mercan D, et al. **Biochem Biophys Res Commun** 1999 Aug 27; 262(2):346–9

Regioselective hydrolysis of peracetylated alpha-D-glycopyranose catalyzed by immobilized lipases in aqueous medium. A facile preparation of useful intermediates for oligosaccharide synthesis. Bastida A, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):633–6

Formation of glucoraphanin by chemoselective oxidation of natural glucoerucin: a chemoenzymatic route to sulforaphane. Iori R, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1047–8

Synthesis of an N-glucoasparagine analog as a building block for a V3-loop glycopeptide from gp120 of HIV-I. Schäfer A, et al. **Carbohydr Res** 1998 Dec;313(2):107–16

The use of fluoro- and deoxy-substrate analogs to examine binding specificity and catalysis in the enzymes of the sorbitol pathway. Scott ME, et al. **Carbohydr Res** 1998 Dec 15;313(3-4):247–53

Failure of streptozotocin tetraacetate to undergo extensive hydrolysis and to inhibit D-glucose metabolism and insulinotropic action in rat pancreatic islets. Olivares E, et al. **Cell Biochem Funct** 1998 Dec;16(4):233–7

Insulinotropic action of monosaccharide esters: therapeutic perspectives. Malaisse WJ. **Diabetologia** 1999 Mar; 42(3):286–91 (81 ref.)

Effect of D-mannoheptulose upon the cationic and secretory responses to alpha-D-glucose pentaacetate in perifused rat pancreatic islets. Jijakli H, et al. **Endocrine** 1999 Jun; 10(3):219–24

From beta-glucanase to beta-glucansynthase: glycosyl transfer to alpha-glycosyl fluorides catalyzed by a mutant endoglucanase lacking its catalytic nucleophile. Malet C, et al. **FEBS Lett** 1998 Nov 27;440(1-2):208–12

Isomeric and anomeric specificity of the metabolic and secretory response of rat pancreatic islets to glucose pentaacetate. Kadiata MM, et al. **Int J Mol Med** 1999 Jun; 3(6):573–5

Insulinotropic action of the polyacetate esters of two non-nutrient monosaccharides in normal and diabetic rats. Malaisse WJ, et al. **Int J Mol Med** 1998 Jul;2(1):95–8

Effects of hexose pentaacetates on electrical activity and cytosolic Ca2+ in mouse pancreatic islets. Pomares R, et al. **Int J Mol Med** 1999 Jan;3(1):15–20

Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives. Moreau P, et al. **J Med Chem** 1999 May 20;42(10):1816–22

Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. Venkatarangan P, et al. **J Med Chem** 1999 Jun 17; 42(12):2169–79

Isolation and structure elucidation of new PKCalpha inhibitors from Pinus flexilis. Lee KK, et al. **J Nat Prod** 1998 Nov;61(11):1407–9

Opposite effects of D-glucose pentaacetate and D-galactose pentaacetate anomers on insulin release evoked by succinic acid dimethyl ester in rat pancreatic islets. Kadiata MM, et al. **Life Sci** 1999;64(9):751-4

Conversion of dTDP-4-keto-6-deoxyglucose to free dTDP-4-keto-rhamnose by the rmlC gene products of Escherichia coli and Mycobacterium tuberculosis. Stern RJ, et al. **Microbiology** 1999 Mar;145 (Pt 3):663-71

Unexpected electrophysiological effects of D-19575, a new cytostatic drug. Kleta R, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:18-20

Biological evaluation of two iodine-123-labeled D-glucose acetals prepared as glucose transporter radioligands. Brunet-Desruet MD, et al. **Nucl Med Biol** 1998 Jul; 25(5):473-80

The effects of NPY and 5-TG on responding to cues for fats and carbohydrates. Altizer AM, et al. **Physiol Behav** 1999 Jan 1-15;65(4-5):685-90

Shamimin: a new flavonol C-glycoside from leaves of Bombax ceiba [letter] Faizi S, et al. **Planta Med** 1999 May; 65(4):383-5

Inhibitory effects of tetragalloylglucose and digalloylhamamelose on adhesion and in vitro invasion of mouse lung carcinoma cells. Saeki K, et al. **Planta Med** 1999 Apr;65(3):227-9

Hypotensive, hypoglycaemic and toxicological studies on the flavonol C-glycoside shamimin from Bombax ceiba. Saleem R, et al. **Planta Med** 1999 May;65(4):331-4

Effects of extracellular pH upon the insulinotropic action of alpha-D-glucose pentaacetate. Ayvaz G, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan;103(1):83-90

ANALYSIS

Can routinely combined analysis of glucose and lactate in vitreous humour be useful in current forensic practice? De Letter EA, et al. **Am J Forensic Med Pathol** 1998 Dec; 19(4):335-42

Simultaneous quantitation from infrared spectra of glucose concentrations, lactate concentrations, and lecithin/sphingomyelin ratios in amniotic fluid. Liu KZ, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):696-702

Glucose sensor for low-cost lifetime-based sensing using a genetically engineered protein. Tolosa L, et al. **Anal Biochem** 1999 Feb 1;267(1):114-20

Continuous ultraslow microdialysis and ultrafiltration for subcutaneous sampling as demonstrated by glucose and lactate measurements in rats. Kaptein WA, et al. **Anal Chem** 1998 Nov 15;70(22):4696-700

A fluorescence-based glucose biosensor using concanavalin A and dextran encapsulated in a poly(ethylene glycol) hydrogel. Russell RJ, et al. **Anal Chem** 1999 Aug 1; 71(15):3126-32

Non-aqueous enzymology approach for improvement of reagentless mediator-based glucose biosensor. Lukachova LV, et al. **Analyst** 1998 Oct;123(10):1981-5

Analysis of glycolysis relevant compounds in saliva by microbiosensors. Yoda K, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:600-4

Improved biosensor for glucose based on glucose oxidase-immobilized silk fibroin membrane. Zhang YQ, et al. **Appl Biochem Biotechnol** 1998 Nov-Dec;75(2-3):215-33

The fluorescence emission of the apo-glucose oxidase from Aspergillus niger as probe to estimate glucose concentrations. D'Auria S, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):550-3

Evaluation of genotoxic and immunotoxic activities of potential glucose biosensor components: ferrocenes. Gąsiorowski K, et al. **Biometals** 1999 Mar;12(1):19-26

Multielectrode array for simultaneous recording of glucose, oxygen and electrocorticography from cerebral cortex in experimental focal epilepsy. Dalbasti T, et al. **Biosens Bioelectron** 1998 Oct 1;13(7-8):881-8

Improved operational stability of biosensors based on enzyme-polyelectrolyte complex adsorbed into a porous carbon electrode. Gavalas VG, et al. **Biosens Bioelectron** 1998 Nov 15;13(11):1205-11

The carbon paste electrode encrusted with a microreactor as glucose biosensor. Kulys J. **Biosens Bioelectron** 1999 May 31;14(5):473-9

Improvement of the performance of H2O2 oxidation at low working potential by incorporating TTF-TCNQ into a platinum wire electrode for glucose determination. Li QS, et al. **Biosens Bioelectron** 1999 Mar 15;14(3):327-34

High-throughput flow-injection analysis of glucose and glutamate in food and biological samples by using enzyme/polyion complex-bilayer membrane-based electrodes as the detectors. Mizutani F, et al. **Biosens Bioelectron** 1998 Oct 1;13(7-8):809-15

Containment sensors for the determination of L-lactate and glucose. Perdomo J, et al. **Biosens Bioelectron** 1999 Jan 1;14(1):27-32

Calibration of glucose biosensors by using pre-steady state kinetic data. Rinken T, et al. **Biosens Bioelectron** 1998 Oct 1;13(7-8):801-7

Modeling the response time of an in vivo glucose affinity sensor. Clark HR, et al. **Biotechnol Prog** 1999 Mar-Apr; 15(2):259-66

Positive interference of icodextrin metabolites in some enzymatic glucose methods [letter] Janssen W, et al. **Clin Chem** 1998 Nov;44(11):2379-80

Interstitial lactate levels in human skin at rest and during an oral glucose load: a microdialysis study. Petersen LJ. **Clin Physiol** 1999 May;19(3):246-50

Microdialysis of glucose in subcutaneous adipose tissue up to 3 weeks in healthy volunteers. Wientjes KJ, et al. **Diabetes Care** 1998 Sep;21(9):1481-8

Glucose concentration in parotid saliva after glucose/food intake in individuals with glucose intolerance and diabetes mellitus. Borg Andersson A, et al. **Eur J Oral Sci** 1998 Oct;106(5):931-7

Glucose concentration in human subcutaneous adipose tissue: comparison between forearm and abdomen. Thomas K, et al. **Exp Clin Endocrinol Diabetes** 1998;106(6):465-9

Chemical analysis of adnexal cyst fluid. Parker MF, et al. **Gynecol Oncol** 1999 Apr;73(1):16-20

Measurement of glucose in tracheobronchial secretions to detect aspiration of enteral feedings. Metheny NA, et al. **Heart Lung** 1998 Sep-Oct;27(5):285-92

Evaluation of peritoneal fluid pH, glucose concentration, and lactate dehydrogenase activity for detection of septic peritonitis in horses. Van Hoogmoed L, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1032-6

Rapid identification of Candida glabrata by using a dipstick to detect trehalase-generated glucose. Peltroche-Llacsahuanga H, et al. **J Clin Microbiol** 1999 Jan;37(1):202-5

Accuracy of portable glucose meters for rapid determination of amniotic fluid glucose levels. Alamia V Jr, et al. **J Matern Fetal Med** 1998 Jul-Aug;7(4):183-9

Amniotic fluid glucose and cytokines values in the early diagnosis of amniotic infection in patients with preterm labor and intact membranes. Gonzalez-Bosquet E, et al. **J Matern Fetal Med** 1999 Jul-Aug;8(4):155-8

Complexities underlying the quantitative determination of myocardial glucose uptake with 2-deoxyglucose. Doenst T, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1595-604

Effects of proteins, blood cells and glucose on the viscosity of cerebrospinal fluid. Bloomfield IG, et al. **Pediatr Neurosurg** 1998 May;28(5):246-51

[Content of certain sugars and polyols in cataractous nucleus in non-diabetics and diabetic patients with type II diabetes] Sabasiński K, et al. **Klin Oczna** 1999;101(2):89-92 (Eng. Abstr.) **(Pol)**

[Noninvasive method for glycemia detection] Lopukhin IuM, et al. **Klin Lab Diagn** 1998 Oct;(10):13-6 **(Rus)**

[A sensitive method for quantitative analysis of hydrogen peroxide and oxidase substrates in biological samples] Honchar MV. **Ukr Biokhim Zh** 1998 Sep-Oct;70(5):157-63 (Eng. Abstr.) **(Ukr)**

[Delayed assessment of glucose level bioassays using a chemical stabilizer] Iarmol'chuk GM. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):147-51 (Eng. Abstr.) **(Ukr)**

ANTAGONISTS & INHIBITORS

Effects of antimetabolites to glucose and fatty acids on galanin-1 receptor mRNA levels in the hypothalamic paraventricular and supraoptic nuclei. Gorbatyuk O, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:430-1

Flavonoids are potential inhibitors of glucose uptake in U937 cells. Park JB. **Biochem Biophys Res Commun** 1999 Jul 5; 260(2):568-74

Inhibition of glucose-induced insulin release by 3-O-methyl-D-glucose: enzymatic, metabolic and cationic determinants. Sener A, et al. **Mol Cell Biochem** 1999 Apr; 194(1-2):133-45

Ethanol inhibits G-protein-mediated glucose uptake by C6 glioma cells. Singh SP, et al. **Neuroreport** 1999 Feb 25; 10(3):595-9

BIOSYNTHESIS

Importance of glutamate dehydrogenase stimulation for glucose and glutamine synthesis in rabbit renal tubules incubated with various amino acids. Winiarska K, et al. **Acta Biochim Pol** 1998;45(3):825-31

Hepatic glucose production during exercise. Kjaer M. **Adv Exp Med Biol** 1998;441:117-27 (67 ref.)

Effects of beta-adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. Cersosimo E, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E792-7

Glucose production during strenuous exercise in humans: role of epinephrine. Howlett K, et al. **Am J Physiol** 1999 Jun; 276(6 Pt 1):E1130-5

Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Petersen KF, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E529-35

Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. Vicini P, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E285-94

Regulation of glucose production by the liver. Nordlie RC, et al. **Annu Rev Nutr** 1999;19:379-406 (117 ref.)

Commodity scale production of sugars from starches. Crabb WD, et al. **Curr Opin Microbiol** 1999 Jun;2(3):252-6 (30 ref.)

Renal glucose production during insulin-induced hypoglycemia in humans. Cersosimo E, et al. **Diabetes** 1999 Feb;48(2):261-6

Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting. Ekberg K, et al. **Diabetes** 1999 Feb;48(2):292-8

Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia. Giacca A, et al. **Diabetes** 1998 Nov;47(11):1763-70

Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stable-labeled minimal model approach. Nagasaka S, et al. **Diabetes** 1999 May;48(5):1054-60

Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Nielsen MF, et al. **Diabetes** 1998 Nov; 47(11):1735-47

The direct and indirect effects of insulin on hepatic glucose production in vivo. Cherrington AD, et al. **Diabetologia** 1998 Sep;41(9):987-96 (24 ref.)

Enzymes from Sulfolobus shibatae for the production of trehalose and glucose from starch. Di Lernia I, et al. **Extremophiles** 1998 Nov;2(4):409-16

Glucose production during exercise in humans: a-hv balance and isotopic-tracer measurements compared. Bergeron R, et al. **J Appl Physiol** 1999 Jul;87(1):111-5

Counterregulatory response to hypoglycemia differs according to the insulin delivery route, but does not affect glucose production in normal humans. Lewis GF, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1037-46

Effects of glucagon on glycogenolysis and gluconeogenesis are region-specific in periportal and perivenous hepatocytes. Ikezawa Y, et al. **J Lab Clin Med** 1998 Dec; 132(6):547-55

Postnatal profiles of glycogenolysis and gluconeogenesis are modified in rat pups by maternal dietary glucose restriction. Lanoue L, et al. **J Nutr** 1999 Apr;129(4):820-7

Glucose production by the human kidney--its importance has been underestimated [editorial] Stumvoll M. **Nephrol Dial Transplant** 1998 Dec;13(12):2996-9 (18 ref.)

Effects of glucagon in the control of endogenous glucose production in man. Surmely JF, et al. **Nutrition** 1999 Apr; 15(4):267-73

Glucose production by the human placenta in vivo. Prendergast CH, et al. **Placenta** 1999 Sep;20(7):591-8

Normal hepatic glucose production in the absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes. Guillam MT, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12317-21

BLOOD see BLOOD GLUCOSE

CEREBROSPINAL FLUID

Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. Leib SL, et al. **Clin Infect Dis** 1999 Jul;29(1):69-74

Biochemical analysis of serum and cerebrospinal fluid in clinically normal adult camels (Camelus dromedarius). Nazifi S, et al. **Res Vet Sci** 1998 Jul-Aug;65(1):83-4

[Spinal subarachnoid hemorrhage presenting as disturbance of consciousness with severe hypoglycorrhachia] Nakamura T, et al. **Nippon Ronen Igakkai Zasshi** 1998 Dec; 35(12):924-8 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Hongu M, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1545-55

CHEMISTRY

Chemical modification studies on the glucose/mannose specific lectins from field and lablab beans. Nadimpalli SK. **Biochem Mol Biol Int** 1999 May;47(5):825-34

Immunochemical detection of N2-[1-(1-carboxy)ethyl]guanosine, an advanced glycation end product formed by the reaction of DNA and reducing sugars or L-ascorbic acid in vitro. Seidel W, et al. **Biochim Biophys Acta** 1998 Nov 27;1425(3):478-84

Effect of sugar-modified beta-cyclodextrins on dissolution and absorption characteristics of phenytoin. Tanino T, et al. **Biol Pharm Bull** 1999 Mar;22(3):298-304

Cross-linking of proteins by Maillard processes--characterization and detection of a lysine-arginine cross-link derived from D-glucose. Lederer MO, et al. **Bioorg Med Chem** 1999 Jun;7(6):1081-8

Cross-linking of proteins by Maillard processes--model reactions of D-glucose or methylglyoxal with butylamine and guanidine derivatives. Lederer MO, et al. **Bioorg Med Chem** 1998 Jul;6(7):993-1002

Syntheses and cytotoxicities of four stereoisomers of muricatacin from D-glucose. Yoon SH, et al. **Bioorg Med Chem** 1998 Jul;6(7):1043-9

On the analogy between forskolin and D-glucose. Abbadi M, et al. **Bioorg Med Chem Lett** 1999 Jul 5;9(13):1779-82

Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. al-Abed Y, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2109-10

Synthesis of a high-mannose-type glycopeptide analog containing a glucose-asparagine linkage. Deras IL, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1763-6

Reaction of guanosine with glucose under oxidative conditions. Seidel W, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2017-22

Detection of ethanol in a two-component glucose/ethanol

mixture using a nonselective microbial sensor and a glucose enzyme electrode. Reshetilov AN, et al. **Biosens Bioelectron** 1998 Oct 1;13(7-8):787-93

Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Mahalingam B, et al. **Diabetes** 1999 Sep;48(9):1698-705

Effect of pH, phosphate and copper on the interaction of glucose with albumin. Tessier F, et al. **Glycoconj J** 1998 Jun;15(6):571-4

Influence of glycation on cis/trans isomerization and tautomerization in novel morphiceptin-related Amadori compounds. Zigrović I, et al. **Glycoconj J** 1998 Jun; 15(6):563-70

Compatibility of paclitaxel in 5% glucose solution with ECOFLAC low-density polyethylene containers-stability under different storage conditions. Sautou-Miranda V, et al. **Int J Pharm** 1999 Feb 1;178(1):77-82

Strobilurin M, tetrachloropyrocatechol and tetrachloropyrocatechol methyl ether: new antibiotics from a Mycena species. Daferner M, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):816-22

Exploiting glycation to stiffen and strengthen tissue equivalents for tissue engineering. Girton TS, et al. **J Biomed Mater Res** 1999 Jul;46(1):87-92

Stability of captopril in invert sugar solution. Sam WJ, et al. **J Clin Pharm Ther** 1998 Dec;23(6):451-6

Gradient BIRDR: a method to select uncoupled magnetization. Heikkinen S, et al. **J Magn Reson** 1999 Mar; 137(1):93-9

Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. Venkatarangan P, et al. **J Med Chem** 1999 Jun 17; 42(12):2169-79

Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Rashduni DL, et al. **Metabolism** 1999 Feb; 48(2):139-43

Polysaccharide elasticity governed by chair-boat transitions of the glucopyranose ring. Marszalek PE, et al. **Nature** 1998 Dec 17;396(6712):661-4

DEFICIENCY

Extracellular reduced glutathione increases neuronal vulnerability to combined chemical hypoxia and glucose deprivation. Regan RF, et al. **Brain Res** 1999 Jan 30; 817(1-2):145-50

Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. Brana C, et al. **Eur J Neurosci** 1999 Jul;11(7):2375-84

Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection? Chaudieu I, et al. **Eur J Neurosci** 1999 Jul;11(7):2413-21

Spreading depression determines acute cellular damage in the hippocampal slice during oxygen/glucose deprivation. Obeidat AS, et al. **Eur J Neurosci** 1998 Nov;10(11):3451-61

Early sodium elevations induced by combined oxygen and glucose deprivation in pyramidal cortical neurons. Pisani A, et al. **Eur J Neurosci** 1998 Nov;10(11):3572-4

Effects of transient oxygen-glucose deprivation on G-proteins and G-protein-coupled receptors in rat CA3 pyramidal cells in vitro. Tanabe M, et al. **Eur J Neurosci** 1998 Jun;10(6):2037-45

Effect of acute glucose depletion following glucose excess on surfactant phospholipid synthesis in developing fetal lung. Marwah GS, et al. **Exp Lung Res** 1999 Jun; 25(4):291-302

Down-regulation of epidermal growth factor receptor-signaling pathway by binding of GRP78/BiP to the receptor under glucose-starved stress conditions. Cai B, et al. **J Cell Physiol** 1998 Nov;177(2):282-8

Brain-derived neurotrophic factor (BDNF) protects cultured rat cerebellar granule neurons against glucose deprivation-induced apoptosis. Tong L, et al. **J Neural Transm** 1998;105(8-9):905-14

Electrophysiological recordings and calcium measurements in striatal large aspiny interneurons in response to combined O2/glucose deprivation. Pisani A, et al. **J Neurophysiol** 1999 May;81(5):2508-16

Oxygen/glucose deprivation in hippocampal slices: altered intraneuronal elemental composition predicts structural and functional damage. Taylor CP, et al. **J Neurosci** 1999 Jan 15;19(2):619-29

Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. Abbruscato TJ, et al. **J Pharmacol Exp Ther** 1999 May;289(2):668-75

Effect of induced tolerance on biochemical disturbances in hippocampal slices from the gerbil during and after oxygen/glucose deprivation. Paschen W, et al. **Neuroreport** 1999 May 14;10(7):1417-21

Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. Lynch JJ 3rd, et al. **Neurosci Lett** 1998 Aug 21;252(3):207-10

Induction of hypoxia inducible factor 1 by oxygen glucose deprivation is attenuated by hypoxic preconditioning in rat cultured neurons. Ruscher K, et al. **Neurosci Lett** 1998 Sep 25;254(2):117-20

Metabotropic glutamate receptor agonists protect from oxygen-glucose deprivation- and colchicine-induced apoptosis in primary cultures of cerebellar granule cells. Kalda A, et al. **Neuroscience** 1999;92(1):7-14

Pharmacological inhibition of the Na(+)/Ca(2+) exchanger enhances depolarizations induced by oxygen/glucose deprivation but not responses to excitatory amino acids in rat striatal neurons. Calabresi P, et al. **Stroke** 1999 Aug; 30(8):1687-94

DIAGNOSTIC USE

Effect of carbohydrate intake on serum 3,5,3'-triiodothyronine-response to glucose ingestion and its relation to glucose tolerance in lean non-insulin-dependent diabetic patients. Koh H, et al. **Arzneimittelforschung** 1999 Jan;49(1):30-4

Detection of capillary protein leakage by glucose and indocyanine green dilutions during the early post-burn period. Ishihara H, et al. **Burns** 1998 Sep;24(6):525-31

Suppression of post-glucose hyperinsulinaemia does not affect blood pressure in either normotensive or hypertensive subjects. Savage MW, et al. **Clin Sci (Colch)** 1998 Jun;94(6):609-14

Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Daniel S, et al. **Diabetes** 1999 Sep;48(9):1686-90

Disruption of the pulsatile and entropic modes of insulin release during an unvarying glucose stimulus in elderly individuals. Meneilly GS, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1938-43

1-[Carbon-11]-glucose radiation dosimetry and distribution in human imaging studies. Graham MM, et al. **J Nucl Med** 1998 Oct;39(10):1805-10

HISTORY

Effects of postprandial administration of glucose on the acquisition of appetites (first published in French in 1959) [classical article] Le Magnen J. **Appetite** 1999 Aug; 33(1):14-6

METABOLISM

The effect of euglucaemic hyperinsulinaemia on forearm blood flow and glucose uptake in the human forearm. Fugmann A, et al. **Acta Diabetol** 1998 Dec;35(4):203-6

Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Hansen BF, et al. **Acta Diabetol** 1998 Jul;35(2):101-3

Metabolic changes of the human donor cornea during organ-culture. Redbrake C, et al. **Acta Ophthalmol Scand** 1999 Jun;77(3):266-72

The effect of hyperglycaemia on regional cerebral glucose oxidation in humans studied with [1-11C]-D-glucose. Blomqvist G, et al. **Acta Physiol Scand** 1998 Aug; 163(4):403-15

The Kety-Schmidt technique for repeated measurements of global cerebral blood flow and metabolism in the conscious rat. Linde R, et al. **Acta Physiol Scand** 1999 Apr; 165(4):395-401

Glucose consumption by various tissues in pregnant rats: effects of a 6-day euglycaemic hyperinsulinaemic clamp. Nieuwenhuizen AG, et al. **Acta Physiol Scand** 1998 Nov; 164(3):325-34

Role of nitric oxide in contraction induced glucose transport. Balon TW. **Adv Exp Med Biol** 1998;441:87-95 (40 ref.)

Compartmental models: theory and practice using the SAAM II software system. Cobelli C, et al. **Adv Exp Med Biol** 1998;445:79-101

Role of transverse tubules (T-tubules) in muscle glucose transport. Dohm GL, et al. **Adv Exp Med Biol** 1998; 441:27-34 (17 ref.)

Insulin signaling and glucose transport in insulin resistant skeletal muscle. Special reference to GLUT4 transgenic and GLUT4 knockout mice. Galuska D, et al. **Adv Exp Med Biol** 1998;441:73-85 (67 ref.)

Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Hespel P, et al. **Adv Exp Med Biol** 1998;441:97-106 (53 ref.)

Training effects on muscle glucose transport during exercise. Richter EA, et al. **Adv Exp Med Biol** 1998;441:107-16 (56 ref.)

An overview of muscle glucose uptake during exercise. Sites of regulation. Wasserman DH, et al. **Adv Exp Med Biol** 1998;441:1-16 (122 ref.)

Regional cerebral glucose metabolism and blood flow in a patient with Marchiafava-Bignami disease. Ishii K, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1249-51

Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Capristo E, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):209-17

Cellular mechanisms of insulin resistance in humans. Shulman GI. **Am J Cardiol** 1999 Jul 8;84(1A):3J-10J (28 ref.)

Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. Englyst KN, et al. **Am J Clin Nutr** 1999 Mar;69(3):448-54

Euglycemic hyperinsulinemic clamp to assess posthepatic glucose appearance after carbohydrate loading. 2. Evaluation of corn and mung bean starches in healthy men. Lang V, et al. **Am J Clin Nutr** 1999 Jun;69(6):1183-8

Euglycemic hyperinsulinemic clamp to assess posthepatic glucose appearance after carbohydrate loading. 1. Validation in pigs. Lang V, et al. **Am J Clin Nutr** 1999 Jun;69(6):1174-82

Effect of the glycemic index and content of indigestible carbohydrates of cereal-based breakfast meals on glucose tolerance at lunch in healthy subjects. Liljeberg HG, et al. **Am J Clin Nutr** 1999 Apr;69(4):647-55

Physical activity in elderly subjects with impaired glucose tolerance and newly diagnosed diabetes mellitus. Baan CA, et al. **Am J Epidemiol** 1999 Feb 1;149(3):219-27

Effects of aging on the insulin actions for the glucose metabolism and renal function in normotensives and essential hypertensives. Miyazaki Y, et al. **Am J Hypertens** 1998 Sep;11(9):1056-64

Regulation of glucose transport by hypoxia. Zhang JZ, et al. **Am J Kidney Dis** 1999 Jul;34(1):189-202 (108 ref.)

Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3-14 (100 ref.)

Placental glucose transport and GLUT 1 expression in insulin-dependent diabetes. Jansson T, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):163-8

Muscle net glucose uptake and glucose kinetics after endurance training in men. Bergman BC, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E81-92

Effects of hyper- and hypoosmolality on whole body protein and glucose kinetics in humans. Berneis K, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E188-95

Glucose metabolism and beta-cell mass in adult offspring of rats protein and/or energy restricted during the last week of pregnancy. Bertin E, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E11-7

Undermodeling affects minimal model indexes: insights from a two-compartment model. Caumo A, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1171-93

Insulin regulation of renal glucose metabolism in humans. Cersosimo E, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E78-84

Reduced glucose availability attenuates circadian responses to light in mice. Challet E, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 2):R1063-70

Skeletal muscle phosphatidylcholine fatty acids and insulin sensitivity in normal humans. Clore JN, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E665-70

TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. del Aguila LF, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E849-55

Insulin does not change the intracellular distribution of hexokinase in rat heart. Doenst T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E558-67

SNAP23 promotes insulin-dependent glucose uptake in 3T3-L1 adipocytes: possible interaction with cytoskeleton. Foster LJ, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1108-14

A negative arterial-portal venous glucose gradient increases net hepatic glucose uptake in euglycemic dogs. Galassetti P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E126-34

Overexpression of hexokinase II increases insulinand exercise-stimulated muscle glucose uptake in vivo. Halseth AE, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E70-7

Lumped constant for deoxyglucose is decreased when myocardial glucose uptake is enhanced. Hashimoto K, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H129-33

ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. Henriksen EJ, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R332-6

Glucose transporters control gene expression of aldose reductase, PKCalpha, and GLUT1 in mesangial cells in vitro. Henry DN, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F97-104

Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs. Hsieh PS, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E987-92

Effect of tension on contraction-induced glucose transport in rat skeletal muscle. Ihlemann J, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E208-14

DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase. Ishizuka T, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E196-204

Carbohydrate ingestion can completely suppress endogenous glucose production during exercise. Jeukendrup AE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E672-83

Insulin regulation of glucose transport and phosphorylation in skeletal muscle assessed by PET. Kelley DE, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E361-9

Developmental regulation of genes mediating murine brain glucose uptake. Khan JY, et al. **Am J Physiol** 1999 Mar; 276(3 Pt 2):R892-900

Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC. Khayat ZA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1487-97

Insulin resistance of muscle glucose transport in male and female rats fed a high-sucrose diet. Kim JY, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R665-72

Paracellular glucose transport plays a minor role in the unanesthetized dog. Lane JS, et al. **Am J Physiol** 1999 Mar; 276(3 Pt 1):G789-94

Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Levin BE, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1223-31 (114 ref.)

Splanchnic retention of intraduodenal and intrajejunal glucose in healthy adults. Livesey G, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E709-16

Simultaneous time-varying systemic appearance of oral and hepatic glucose in adults monitored with stable isotopes. Livesey G, et al. **Am J Physiol** 1998 Oct;275(4 Pt

1):E717-28
Hyperlactatemia reduces muscle glucose uptake and GLUT-4 mRNA while increasing (E1alpha)PDH gene expression in rat. Lombardi AM, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E922-9
Glucose effectiveness is the major determinant of intravenous glucose tolerance in the rat. McArthur MD, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E739-46
Hepatic and muscle glucose metabolism during total parenteral nutrition: impact of infection. McGuinness OP, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E763-9
Increased decorin mRNA in diabetic mouse kidney and in mesangial and tubular cells cultured in high glucose. Mogyorosi A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F827-32
Differential effect of amino acid infusion route on net hepatic glucose uptake in the dog. Moore MC, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E295-302
Interactions between gastric volume and duodenal nutrients in the control of liquid gastric emptying. Moran TH, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R997-R1002
Mitochondrial protein and HSP70 signaling after ischemia in hypothermic-adapted hearts augmented with glucose. Ning XH, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R11-7
Mechanisms of glucose intolerance during triglyceride infusion. Rigalleau V, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E641-8
Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Russell RR 3rd, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H643-9
Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Schneiter P, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E806-13
Effect of fentanyl on morphine levels in the brain in rats receiving intracerebroventricular injection of TNF-alpha. Shirouzu Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E635-40
Substrate oxidation by the portal drained viscera of fed piglets. Stoll B, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E168-75
Insulin action on heart and skeletal muscle glucose uptake in weight lifters and endurance athletes. Takala TO, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E706-11
Surgery-induced insulin resistance in human patients: relation to glucose transport and utilization. Thorell A, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E754-61
Effect of calorie restriction on in vivo glucose metabolism by individual tissues in rats. Wetter TJ, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E728-38
I. Glucose galactose malabsorption. Wright EM. **Am J Physiol** 1998 Nov;275(5 Pt 1):G879-82 (24 ref.)
Whole body glucose metabolism. Zierler K. **Am J Physiol** 1999 Mar;276(3 Pt 1):E409-26 (137 ref.)
Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. Pietrini P, et al. **Am J Psychiatry** 1999 Mar; 156(3):470-3
Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Smith GS, et al. **Am J Psychiatry** 1999 May; 156(5):683-9
Influence of fermentable fiber on small intestinal dimensions and transport of glucose and proline in dogs. Buddington RK, et al. **Am J Vet Res** 1999 Mar;60(3):354-8
Measurement of hepatic glucose output, krebs cycle, and gluconeogenic fluxes by NMR analysis of a single plasma glucose sample. Jones JG, et al. **Anal Biochem** 1998 Oct 1;263(1):39-45
Automated sampling device for monitoring intracellular metabolite dynamics. Schaefer U, et al. **Anal Biochem** 1999 May 15;270(1):88-96
Functional brain imaging during anesthesia in humans: effects of halothane on global and regional cerebral glucose metabolism. Alkire MT, et al. **Anesthesiology** 1999 Mar; 90(3):701-9
Coupling of local cerebral blood flow to local cerebral glucose utilization during isoflurane and sevoflurane anesthesia [letter; comment] Archer DP, et al. **Anesthesiology** 1999 Sep;91(3):889-91. Comment on: Anesthesiology 1998 Dec;89(6):1480-8.
Local cerebral blood flow, local cerebral glucose utilization, and flow-metabolism coupling during sevoflurane versus isoflurane anesthesia in rats [see comments] Lenz C, et al. **Anesthesiology** 1998 Dec;89(6):1480-8. Comment in: Anesthesiology 1999 Sep;91(3):889-91.
Effect of glucose availability on pulsatile luteinizing hormone release in rams before and after castration. Kittok RJ. **Anim Reprod Sci** 1999 Feb 12;55(1):35-45
Glucose tolerance and myocardial F-18 fluorodeoxyglucose uptake in normal regions in coronary heart disease patients. Hasegawa S, et al. **Ann Nucl Med** 1998 Dec;12(6):363-8
Effect of major hepatectomy on glucose and lactate metabolism. Chioléro R, et al. **Ann Surg** 1999 Apr; 229(4):505-13
Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Eigenbrodt E, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3267-74
Metabolic characteristics of different malignant cancer cell lines. Mazurek S, et al. **Anticancer Res** 1998 Sep-Oct; 18(5A):3275-82
Effects of Salmonella typhimurium infection and ofloxacin treatment on glucose and glutamine metabolism in Caco-2/TC-7 cells. Posho L, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2950-5
Physiological characterisation of a pyruvate-carboxylase-negative Saccharomyces cerevisiae mutant in batch and chemostat cultures. de Jong-Gubbels P, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):253-63
Heterofermentative metabolism of glucose and ribose and utilisation of citrate by the smooth biotype of Lactobacillus amylovorus NCFB 2745. Whitley K, et al. **Antonie Van Leeuwenhoek** 1999 Apr;75(3):217-23
Alteration of glucose consumption kinetics with progression of baculovirus infection in Spodoptera frugiperda cells. Raghunand N, et al. **Appl Biochem Biotechnol** 1999 Jun; 80(3):231-42
Expression of the Escherichia coli pntA and pntB genes, encoding nicotinamide nucleotide transhydrogenase, in Saccharomyces cerevisiae and its effect on product formation during anaerobic glucose fermentation. Anderlund M, et al. **Appl Environ Microbiol** 1999 Jun; 65(6):2333-40
Lethality of a heat- and phosphate-catalyzed glucose by-product to Escherichia coli O157:H7 and partial protection conferred by the rpoS regulon. Byrd JJ, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2396-401
Enzymatic conversion of glucose to UDP-4-keto-6-deoxyglucose in Streptomyces spp. Liu SY, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3972-6
Training in swimming reduces blood pressure and increases muscle glucose transport activity as well as GLUT4 contents in stroke-prone spontaneously hypertensive rats. Song YJ, et al. **Appl Human Sci** 1998 Nov;17(6):275-80
Metabolic responses to different glucose and glutamine levels in baby hamster kidney cell culture. Cruz HJ, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):579-85
Carbon catabolite repression of invertase during batch cultivations of Saccharomyces cerevisiae: the role of glucose, fructose, and mannose. Dynesen J, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):579-82
Oxygen starvation induces cell death in Candida shehatae fermentations of D-xylose, but not D-glucose. Kastner JR, et al. **Appl Microbiol Biotechnol** 1999 Jun;51(6):780-5
The influence of carbon source on the level and composition of ceramides of the Candida lipolytica yeast. Rupčić J, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):583-8
Glucose overflow metabolism and mixed-acid fermentation in aerobic large-scale fed-batch processes with Escherichia coli. Xu B, et al. **Appl Microbiol Biotechnol** 1999 May; 51(5):564-71
Heterogeneity of glucose transport in rat liver microsomal vesicles. Banhegyi G, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):133-8
Yeast mutants of glucose metabolism with defects in the coordinate regulation of carbon assimilation. Dennis RA, et al. **Arch Biochem Biophys** 1999 May 15;365(2):279-88
Activation of Glut1 glucose transporter in response to inhibition of oxidative phosphorylation. Hamrahian AH, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):375-9
Effects of endoglycoceramidase or D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol on glucose uptake, glycolysis, and mitochondrial respiration in HL60 cells. Ji L, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):107-14
Self-glucosylation of glycogenin, the initiator of glycogen biosynthesis, involves an inter-subunit reaction. Lin A, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):163-70
Glycolytic metabolites and intracellular signaling in the pancreatic beta cell. Lubell A, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):178-84
Mechanism of stimulation of glucose transport by H2O2: role of phospholipase C. Prasad RK, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):113-22
Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo. Westergaard N, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):55-60
Insulin induced hypoglycaemia: comparison of glucose and glycerol concentrations in plasma and microdialysate from subcutaneous adipose tissue. Kamel A, et al. **Arch Dis Child** 1999 Jan;80(1):42-5
Renal processing of glucose in well and sick neonates. Coulthard MG, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F92-8
System of 14C-glucose incorporation in axenic cultures of Entamoeba invadens: IP-1 strain. Calzado-Flores C, et al. **Arch Med Res** 1998 Autumn;29(3):225-30
Changes in insulin sensitivity, secretion and glucose effectiveness during menstrual cycle. Escalante Pulido JM, et al. **Arch Med Res** 1999 Jan-Feb;30(1):19-22
Metabolic state of Zymomonas mobilis in glucose-, fructose-, and xylose-fed continuous cultures as analysed by 13C- and 31P-NMR spectroscopy. De Graaf AA, et al. **Arch Microbiol** 1999 May-Jun;171(6):371-85
When do strokes cause dementia? Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function [editorial; comment] Foster NL, et al. **Arch Neurol** 1999 Jul;56(7):778-9. Comment on: Arch Neurol 1999 Jul;56(7):809-14.
Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function [see comments] Kwan LT, et al. **Arch Neurol** 1999 Jul;56(7):809-14. Comment in: Arch Neurol 1999 Jul;56(7):778-9.
Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. Teipel SJ, et al. **Arch Neurol** 1999 Apr; 56(4):467-73
The effect of the new oral hypoglycemic agent A-4166 on glucose turnover in the high fat diet-induced and/or in the hereditary insulin resistance of rats. Klimeš I, et al. **Arch Physiol Biochem** 1998 Oct;106(4):325-32
Effect of sucrose feeding on glucose tolerance and their relationship with lipid metabolism in maternal and fetal livers in rat. Oliveros L, et al. **Arch Physiol Biochem** 1997 Dec;105(7):640-4
Similar effects of cis-diamminedichloroplatinum(II) and cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) on sodium-coupled glucose uptake in renal brush-border membrane vesicles. Potdevin S, et al. **Arch Toxicol** 1998 Oct;72(10):663-70
Glucose phosphorylation is essential for the turnover of neutral lipid and the second stage assembly of triacylglycerol-rich ApoB-containing lipoproteins in primary hepatocyte cultures. Brown AM, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):321-9
Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Karjalainen L, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct;18(10):1548-53
17 beta-estradiol reduces glycoxidative damage in the artery wall. Walsh BA, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):840-6
Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Kao CH, et al. **Arthritis Rheum** 1999 Jan;42(1):61-8
Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. Trenkwalder P. **Basic Res Cardiol** 1998;93 Suppl 2:140-4
A factor from pancreatic and colonic cancer cells stimulates glucose uptake and lactate production in myoblasts. Li J, et al. **Biochem Biophys Res Commun** 1999 Jul 14; 260(3):626-33
Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Ogiso Y, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):448-52
A mutation Ser213/Asn in the hexokinase 1 from Schizosaccharomyces pombe increases its affinity for glucose. Petit T, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):714-9
Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Takemoto M, et al. **Biochem Biophys Res Commun** 1999 May 19; 258(3):722-6
Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Valerio A, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):622-8
Effects of transiently expressed atypical (zeta, lambda), conventional (alpha, beta) and novel (delta, epsilon) protein kinase C isoforms on insulin-stimulated translocation of epitope-tagged GLUT4 glucose transporters in rat adipocytes: specific interchangeable effects of protein kinases C-zeta and C-lambda. Bandyopadhyay G, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):461-70
1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle. Brozinick JT Jr, et al. **Biochem J** 1999 May 1;339 (Pt 3):533-40
Insulin-sensitive regulation of glucose transport and GLUT4 translocation in skeletal muscle of GLUT1 transgenic mice. Etgen GJ Jr, et al. **Biochem J** 1999 Jan 1;337 (Pt 1):51-7
Thyroid hormone regulation of the Na+/glucose cotransporter SGLT1 in Caco-2 cells. Matosin-Matekalo M, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):633-40
Long-term maintenance of low concentrations of fructose for the study of hepatic glucose phosphorylation. Phillips JW, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):497-501
Different sources of acidity in glucose-elicited extracellular acidification in the yeast Saccharomyces cerevisiae. Lapathitis G, et al. **Biochem Mol Biol Int** 1998 Dec; 46(5):973-8
Arachidonic acid and protein synthesis inhibitor act synergistically to suppress insulin-stimulated glucose transport in 3T3-L1 adipocytes. Liu D, et al. **Biochem Mol Biol Int** 1998 Nov;46(4):681-8
A proposed estimate of the tumor aggressiveness of human breast cancer using radiorespirometry. Mayaudon J, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1073-9
Distinct regulation of glucose transport by interleukin-3 and oncogenes in a murine bone marrow-derived cell line. Ahmed N, et al. **Biochem Pharmacol** 1999 Feb 15; 57(4):387-96
Growth hormone regulation of mammary glucose. Faulkner A. **Biochem Soc Trans** 1998 Aug;26(3):S206
Use of an antisense strategy to dissect the role of MAP kinases in cellular signalling. Sale EM, et al. **Biochem Soc Trans** 1998 Aug;26(3):S254
Calnexin and BiP interact with acid phosphatase independently of glucose trimming and reglucosylation in

Schizosaccharomyces pombe. Jannatipour M, et al. **Biochemistry** 1998 Dec 8;37(49):17253–61

Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. Lam JT, et al. **Biochim Biophys Acta** 1999 Feb 24;1453(2):297–303

Interactions of sodium pentobarbital with D-glucose and L-sorbose transport in human red cells. Naftalin RJ, et al. **Biochim Biophys Acta** 1999 Jun 9;1419(1):78–88

Glucose metabolism in Neurospora is altered by heat shock and by disruption of HSP30. Plesofsky N, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):73–82

Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucose-induced morphological and functional changes of cultured bovine retinal pericytes. Wakisaka M, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):83–91

Characterization of glucose transport activity reconstituted from heart and other tissues. Wheeler TJ, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1–2):217–30

In vivo 13C NMR study of glucose and cellobiose metabolism by four cellulolytic strains of the genus Fibrobacter. Matheron C, et al. **Biodegradation** 1998;9(6):451–61

How do yeast cells sense glucose? Kruckeberg AL, et al. **Bioessays** 1998 Dec;20(12):972–6 (36 ref.)

Sugars as signal molecules in plant seed development. Wobus U, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):937–44 (40 ref.)

Metabolism of radiolabeled glucose by mouse oocytes and oocyte–cumulus cell complexes. Downs SM, et al. **Biol Reprod** 1999 Jun;60(6):1446–52

Activities of glucose metabolic enzymes in human preantral follicles: in vitro modulation by follicle-stimulating hormone, luteinizing hormone, epidermal growth factor, insulin-like growth factor I, and transforming growth factor beta1. Roy SK, et al. **Biol Reprod** 1999 Mar; 60(3):763–8

Lack of acute zinc effects in glucose metabolism in healthy and insulin-dependent diabetes mellitus patients. Brandão-Neto J, et al. **Biometals** 1999 Jun;12(2):161–5

Mode of action of escins Ia and IIa and E,Z-senegin II on glucose absorption in gastrointestinal tract. Matsuda H, et al. **Bioorg Med Chem** 1998 Jul;6(7):1019–23

Production of rhamnolipid biosurfactant by fed-batch culture of Pseudomonas aeruginosa using glucose as a sole carbon source. Lee Y, et al. **Biosci Biotechnol Biochem** 1999 May; 63(5):946–7

Effects of glucose and glycerol on gamma-poly(glutamic acid) formation by Bacillus licheniformis ATCC 9945a. Ko YH, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):430–7

Elevated glutamate dehydrogenase flux in glucose-deprived hybridoma and myeloma cells: evidence from 1H/15N NMR. Martinelle K, et al. **Biotechnol Bioeng** 1998 Nov 20;60(4):508–17

Generalized linearization of kinetics of glucose isomerization to fructose by immobilized glucose isomerase. Palazzi E, et al. **Biotechnol Bioeng** 1999 May 5;63(3):273–84

Stimulation of glucose catabolism through the pentose pathway by the absence of the two pyruvate kinase isoenzymes in Escherichia coli. Ponce E, et al. **Biotechnol Bioeng** 1998 Apr 20–May 5;58(2–3):292–5

Modeling the response time of an in vivo glucose affinity sensor. Clark HR, et al. **Biotechnol Prog** 1999 Mar–Apr; 15(2):259–66

Adaptive control at low glucose concentration of HEK-293 cell serum-free cultures. Siegwart P, et al. **Biotechnol Prog** 1999 Jul–Aug;15(4):608–16

Modeling of overflow metabolism in batch and fed-batch cultures of Escherichia coli. Xu B, et al. **Biotechnol Prog** 1999 Jan–Feb;15(1):81–90

Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Trenkwalder P, et al. **Blood Press** 1998 May;7(3):170–5

Effects of diazepam and ketamine administered individually or in combination on regional rates of glucose utilization in rat brain. Eintrei C, et al. **Br J Anaesth** 1999 Apr; 82(4):596–602

Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Hussey HJ, et al. **Br J Cancer** 1999 Jun;80(8):1231–5

Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study. Nuutinen J, et al. **Br J Cancer** 1999 May;80(3–4):513–8

Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Reul BA, et al. **Br J Pharmacol** 1999 Jan;126(2):467–77

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Yada T, et al. **Br J Pharmacol** 1999 Mar;126(5):1205–13

Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Meguro K, et al. **Brain** 1999 Aug;122 (Pt 8):1519–31

Perisylvian dysgenesis. Clinical, EEG, MRI and glucose metabolism features in 10 patients. Van Bogaert P, et al. **Brain** 1998 Dec;121 (Pt 12):2229–38

Evolution of brain glucose metabolism with age in epileptic infants, children and adolescents. Bentourkia M, et al. **Brain Dev** 1998 Oct;20(7):524–9

Acetyl-L-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Aureli T, et al. **Brain Res** 1998 Jun 15;796(1–2):75–81

Increase in glucose transporter densities of Glut3 and decrease of glucose utilization in rat brain after one week of hypoglycemia. Duelli R, et al. **Brain Res** 1999 Jun 12; 831(1–2):254–62

The effect of sequential lesioning in the basal forebrain on cerebral cortical glucose metabolism in rats. An animal positron emission tomography study. Katsumi Y, et al. **Brain Res** 1999 Aug 7;837(1–2):75–82

Cerebral glucose metabolism during opioid withdrawal following methylnaloxonium injection into the locus coeruleus. Kimes AS, et al. **Brain Res** 1998 Dec 14; 814(1–2):1–12

Alterations in local cerebral glucose utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride. Levant B, et al. **Brain Res** 1998 Nov 23; 812(1–2):193–9

Altered brain glucose metabolism in transgenic-PFKL mice with elevated L-phosphofructokinase: in vivo NMR studies. Peled-Kamar M, et al. **Brain Res** 1998 Nov 9; 810(1–2):138–45

Cryopreservation of rat cortical synaptosomes and analysis of glucose and glutamate transporter activities, and mitochondrial function. Begley JG, et al. **Brain Res Brain Res Protoc** 1998 Sep;3(1):76–82

Effect of chronic vitamin D infusion upon in vivo glucose disposal. Saxe AW, et al. **Calcif Tissue Int** 1999 Mar; 64(3):248–51

Time of peritoneal cavity exposure influences postoperative glucose production. Schricker T, et al. **Can J Anaesth** 1999 Apr;46(4):352–8

Glucose tolerance is improved after low- and high-intensity exercise in middle-age men and women. Bonen A, et al. **Can J Appl Physiol** 1998 Dec;23(6):583–93

Fuel metabolism during exercise: the role of the glucose-fatty acid cycle in mediating carbohydrate and fat metabolism. Rodgers CD. **Can J Appl Physiol** 1998 Dec;23(6):528–33 (29 ref.)

Mediation of glucoregulation at rest and during exercise by the glucose-fatty acid cycle: in vivo and in vitro studies. Rodgers CD, et al. **Can J Appl Physiol** 1998 Dec; 23(6):534–57 (91 ref.)

The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Schiepers C, et al. **Cancer** 1999 Feb 15; 85(4):803–11

Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Yamada M, et al. **Cancer Chemother Pharmacol** 1999;44(1):59–64

Glucose uptake in the human gastric cancer cell line, MKN28, is increased by insulin stimulation. Noguchi Y, et al. **Cancer Lett** 1999 Jun 1;140(1–2):69–74

Insulin resistance was connected with the alterations of substrate utilization in patients with cancer. Yoshikawa T, et al. **Cancer Lett** 1999 Jul 1;141(1–2):93–8

Synthesis of glucosylated 1,2,3-triazole derivatives. Chen XM, et al. **Carbohydr Res** 1999 Feb 28;315(3–4):262–7

The use of fluoro- and deoxy-substrate analogs to examine binding specificity and catalysis in the enzymes of the sorbitol pathway. Scott ME, et al. **Carbohydr Res** 1998 Dec 15;313(3–4):247–53

Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. King LM, et al. **Cardiovasc Res** 1998 Aug;39(2):381–92

Analysis of pH-driven disruption of oral microbial communities in vitro. Bradshaw DJ, et al. **Caries Res** 1998; 32(6):456–62

Environmental modulation of the inhibitory action of D-mannoheptulose upon D-glucose metabolism in isolated rat pancreatic islets. Picton S, et al. **Cell Biochem Funct** 1999 Mar;17(1):65–71

Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. Chibber R, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Feb;45(1):47–57

Role of voltage-dependent Na+ channels for rhythmic Ca2+ signalling in glucose-stimulated mouse pancreatic beta-cells. Eberhardson M, et al. **Cell Signal** 1999 May; 11(5):343–8

Synergistic effect of arachidonic acid and cyclic AMP on glucose transport in 3T3-L1 adipocytes. Fong JC, et al. **Cell Signal** 1999 Jan;11(1):53–8

Excitability changes and glucose metabolism in experimentally induced focal cortical dysplasias. Redecker C, et al. **Cereb Cortex** 1998 Oct–Nov;8(7):623–34

Antidiabetic principles of natural medicines. III. Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Matsuda H, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1399–403

The effect of environmental conditions and glucose feeding in shaking flask on glutathione (GSH) production. Li Y, et al. **Chin J Biotechnol** 1998;14(2):85–91

Effect of artemether on glucose uptake and glycogen content in Schistosoma japonicum. Xiao SH, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jul;18(4):363–7

alpha-adrenergic stimulation mediates glucose uptake through phosphatidylinositol 3-kinase in rat heart. Doenst T, et al. **Circ Res** 1999 Mar 5;84(4):467–74

Glucose for the heart. Depre C, et al. **Circulation** 1999 Feb 2;99(4):578–88 (152 ref.)

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Malmberg K, et al. **Circulation** 1999 May 25;99(20):2626–32

Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Yasunari K, et al. **Circulation** 1999 Mar 16; 99(10):1370–8

Effect of tumor necrosis factor alpha on vascular resistance, nitric oxide production, and glucose and oxygen consumption in perfused tissue-isolated human melanoma xenografts. Kristensen CA, et al. **Clin Cancer Res** 1997 Mar; 3(3):319–24

Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Fogar P, et al. **Clin Chim Acta** 1998 Oct;277(2):181–9

Trypsin digestion of histones inhibited by glucose [letter] Jobst K, et al. **Clin Chim Acta** 1998 Aug 28;276(2):187–9

Lack of associations between serum leptin, a polymorphism in the gene for the beta 3-adrenergic receptor and glucose tolerance in the Dutch population. Janssen JA, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):229–34

Pathophysiology of type 2 diabetes in the elderly. Meneilly GS. **Clin Geriatr Med** 1999 May;15(2):239–53 (59 ref.)

Glucotoxicity: potential mechanisms. Mooradian AD, et al. **Clin Geriatr Med** 1999 May;15(2):255 (59 ref.)

EEG power changes are related to regional cerebral glucose metabolism in vascular dementia. Szelies B, et al. **Clin Neurophysiol** 1999 Apr;110(4):615–20

Effects of a sympathetic activation by a lower body negative pressure on glucose and lipid metabolism. Henry S, et al. **Clin Physiol** 1998 Nov;18(6):562–9

Altered skeletal muscle glucose transport and blood lipid levels in habitual cigarette smokers. Rincón J, et al. **Clin Physiol** 1999 Mar;19(2):135–42

Glucose metabolism in chronic diabetic foot ulcers measured in vivo using microdialysis. Simonsen L, et al. **Clin Physiol** 1998 Jul;18(4):355–9

Effects of adrenaline on glucose and glutamine metabolism and superoxide production by rat neutrophils. Garcia C, et al. **Clin Sci (Colch)** 1999 Jun;96(6):549–55

Glucose metabolism in vivo in crossbred Holstein cattle feeding on different types of roughage during late pregnancy and early lactation. Chaiyabutr N, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Apr; 119(4):905–13

Mixed graphical models for simultaneous model identification and control applied to the glucose-insulin metabolism. Bleckert G, et al. **Comput Methods Programs Biomed** 1998 May;56(2):141–55

Extracellular lactate and glucose alterations in the brain after head injury measured by microdialysis [see comments] Goodman JC, et al. **Crit Care Med** 1999 Sep;27(9):1965–73 . Comment in: Crit Care Med 1999 Sep;27(9):2063–4.

Intracellular glucose switches between cyclic ADP-ribose and inositol trisphosphate triggering of cytosolic Ca2+ spiking. Cancela JM, et al. **Curr Biol** 1998 Jul 16;8(15):865–8

Leu343Phe substitution in the Malx3 protein of Saccharomyces cerevisiae increases the constitutivity and glucose insensitivity of MAL gene expression. Higgins VJ, et al. **Curr Genet** 1999 Jun;35(5):491–8

Regulation of glucose utilization in yeast. Carlson M. **Curr Opin Genet Dev** 1998 Oct;8(5):560–4

Glucose repression in yeast. Carlson M. **Curr Opin Microbiol** 1999 Apr;2(2):202–7 (55 ref.)

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13–34 (293 ref.)

Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Ishii K, et al. **Dement Geriatr Cogn Disord** 1998 Nov–Dec;9(6):317–22

Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Bouzier AK, et al. **Dev Neurosci** 1998; 20(4–5):331–8

Studies of the source of glucose in the extracellular compartment of the rat brain. Fillenz M, et al. **Dev Neurosci** 1998;20(4–5):365–8

Functional energy metabolism: in vivo 13C-NMR spectroscopy evidence for coupling of cerebral glucose consumption and glutamatergic neuronalactivity. Sibson NR, et al. **Dev Neurosci** 1998;20(4–5):321–30 (56 ref.)

Glucose transporter expression in brain: relationship to cerebral glucose utilization. Vannucci SJ, et al. **Dev Neurosci** 1998;20(4–5):369–79

Comparison of lactate and glucose metabolism in cultured neocortical neurons and astrocytes using 13C-NMR spectroscopy. Waagepetersen HS, et al. **Dev Neurosci** 1998; 20(4–5):310–20

Reduced adipocyte insulin sensitivity in Caucasian and Asian subjects with coronary heart disease. Frost GS, et al. **Diabet Med** 1998 Dec;15(12):1003–9

Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy. Lafrance L, et al. **Diabet Med**

1998 Nov;15(11):972–8
A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Menzel R, et al. **Diabet Med** 1998 Oct; 15(10):816–20
Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insulin complexes. Shojaee-Moradie F, et al. **Diabet Med** 1998 Nov; 15(11):928–36
Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. Björklund A, et al. **Diabetes** 1999 Jul;48(7):1409–14
Tyrosine phosphorylation of specific protein kinase C isoenzymes participates in insulin stimulation of glucose transport in primary cultures of rat skeletal muscle. Braiman L, et al. **Diabetes** 1999 Oct;48(10):1922–9
Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice. Burcelin R, et al. **Diabetes** 1999 Jun;48(6):1264–9
Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Cherrington AD. **Diabetes** 1999 May; 48(5):1198–214 (57 ref.)
Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Chinookoswong N, et al. **Diabetes** 1999 Jul;48(7):1487–92
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. Edwards CM, et al. **Diabetes** 1999 Jan;48(1):86–93
Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Eriksson JW, et al. **Diabetes** 1999 Aug; 48(8):1572–8
Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Friedman JE, et al. **Diabetes** 1999 Sep; 48(9):1807–14
Removal of adenosine decreases the responsiveness of muscle glucose transport to insulin and contractions. Han DH, et al. **Diabetes** 1998 Nov;47(11):1671–5
Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Haque MS, et al. **Diabetes** 1999 Sep;48(9):1706–12
Hepatic glucose cycling does not contribute to the development of hyperglycemia in Zucker diabetic fatty rats. Henly DC, et al. **Diabetes** 1999 Feb;48(2):342–6
Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Holmäng A, et al. **Diabetes** 1999 Jan;48(1):106–11
Insulin-regulated mitochondrial gene expression is associated with glucose flux in human skeletal muscle. Huang X, et al. **Diabetes** 1999 Aug;48(8):1508–14
Differential effects of safflower oil versus fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and pyruvate dehydrogenase flux in skeletal muscle: a 13C nuclear magnetic resonance study. Jucker BM, et al. **Diabetes** 1999 Jan;48(1):134–40
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Kishi Y, et al. **Diabetes** 1999 Oct; 48(10):2045–51
Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation: usefulness of leptin for the treatment of obesity-associated diabetes. Masuzaki H, et al. **Diabetes** 1999 Aug; 48(8):1615–22
Opposite effects of acute hypoglycemia and acute hyperglycemia on glucose transport and glucose transporters in perfused rat skeletal muscle. Mathoo JM, et al. **Diabetes** 1999 Jun;48(6):1281–8
Role of the human kidney in glucose counterregulation. Meyer C, et al. **Diabetes** 1999 May;48(5):943–8
Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Minokoshi Y, et al. **Diabetes** 1999 Feb;48(2):287–91
Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Ogawa Y, et al. **Diabetes** 1999 Sep;48(9):1822–9
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Oku A, et al. **Diabetes** 1999 Sep;48(9):1794–800
Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Roden M, et al. **Diabetes** 1999 Feb;48(2):358–64
Muscle fiber type-specific defects in insulin signal transduction to glucose transport in diabetic GK rats. Song XM, et al. **Diabetes** 1999 Mar;48(3):664–70
Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Tsiani E, et al. **Diabetes** 1998 Nov;47(11):1676–86
Glucose metabolism in vitro of cultured and transplanted mouse pancreatic islets microencapsulated by means of a high-voltage electrostatic field. King A, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B121–6
Vitamin D3 deficiency and alterations of glucose metabolism in rat endocrine pancreas. Billaudel B, et al. **Diabetes Metab** 1998 Sep;24(4):344–50
Non oxidative fructose disposal is not inhibited by lipids in humans. Surmely JF, et al. **Diabetes Metab** 1999 Sep; 25(3):233–40
Glucose transport in brain and retina: implications in the management and complications of diabetes. Kumagai AK. **Diabetes Metab Res Rev** 1999 Jul-Aug;15(4):261–73 (163 ref.)
Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Randle PJ. **Diabetes Metab Rev** 1998 Dec;14(4):263–83 (174 ref.)
Evaluation of a real-time blood glucose monitor in children with diabetic ketoacidosis. Coss-Bu JA, et al. **Diabetes Res Clin Pract** 1999 Jun;44(3):175–81
Long-term follow-up of insulin-dependent diabetes mellitus patients with recurrent episodes of severe hypoglycaemia. Oskarsson P, et al. **Diabetes Res Clin Pract** 1999 Jun; 44(3):165–74
Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Ahrén B, et al. **Diabetologia** 1998 Nov;41(11):1374–80
Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Fujita Y, et al. **Diabetologia** 1998 Dec;41(12):1459–66
In late pregnancy insulin-dependent glucose transport/phosphorylation is selectively impaired and activation of glycogen synthase by insulin facilitated in skeletal muscles of 24-h starved rats. Holness MJ, et al. **Diabetologia** 1999 Jul;42(7):802–11
Changes in glucose transport and protein kinase Cbeta(2) in rat skeletal muscle induced by hyperglycaemia. Kawano Y, et al. **Diabetologia** 1999 Sep;42(9):1071–9
A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Maegawa H, et al. **Diabetologia** 1999 Feb;42(2):151–9
D-glucose transport and utilization in pituitary adenoma cells transfected with glucokinase gene [letter; comment] Malaisse WJ. **Diabetologia** 1999 Apr;42(4):498. Comment on: Diabetologia 1998 Dec;41(12):1492–501.
Induction of rat muscle insulin resistance by epinephrine is accompanied by increased interstitial glucose and lactate concentrations. Niklasson M, et al. **Diabetologia** 1998 Dec; 41(12):1467–73
Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-alpha-lipoic acid. Obrosova I, et al. **Diabetologia** 1998 Dec;41(12):1442–50
Impaired glucose transport and protein kinase B activation by insulin, but not okadaic acid, in adipocytes from subjects with Type II diabetes mellitus. Rondinone CM, et al. **Diabetologia** 1999 Jul;42(7):819–25
Comparison of the effects of D-mannoheptulose and its hexaacetate ester on D-glucose metabolism and insulinotropic action in rat pancreatic islets. Sener A, et al. **Diabetologia** 1998 Sep;41(9):1109–13
Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats. Vettor R, et al. **Diabetologia** 1998 Nov;41(11):1361–7
Insulin-dependent whole-body glucose utilization and insulin-responses to glucose in week 9 and week 19 of lactation in dairy cows fed rumen-protected crystalline fat or free fatty acids. Blum JW, et al. **Domest Anim Endocrinol** 1999 Feb;16(2):123–34
Glucose and maltodextrin in enteral diets have different effects on jejunal absorption of nutrients, sodium and water and on flow rate in mini pigs. Weber E, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):446–9
Efficient transition to growth on fermentable carbon sources in Saccharomyces cerevisiae requires signaling through the Ras pathway. Jiang Y, et al. **EMBO J** 1998 Dec 1; 17(23):6942–51
Effects of tumor necrosis factor-alpha on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects. Ciaraldi TP, et al. **Endocrinology** 1998 Dec;139(12):4793–800
Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Ciaraldi TP, et al. **Endocrinology** 1999 Sep;140(9):3971–80
Hormone-regulated and glucose-sensitive transport of dehydroascorbic acid in immature rat granulosa cells. Kodaman PH, et al. **Endocrinology** 1999 Aug; 140(8):3659–65
Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Rouru J, et al. **Endocrinology** 1999 Aug; 140(8):3688–92
Exendin-(9–39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence. Serre V, et al. **Endocrinology** 1998 Nov;139(11):4448–54
Effects of knockout of the protein kinase C beta gene on glucose transport and glucose homeostasis. Standaert ML, et al. **Endocrinology** 1999 Oct;140(10):4470–7
Differential effects of leptin in regulation of tissue glucose utilization in vivo. Wang JL, et al. **Endocrinology** 1999 May; 140(5):2117–24
Interictal spikes increase cerebral glucose metabolism and blood flow: a PET study. Bittar RG, et al. **Epilepsia** 1999 Feb;40(2):170–8
Hippocampal cell density and subcortical metabolism in temporal lobe epilepsy. Dlugos DJ, et al. **Epilepsia** 1999 Apr;40(4):408–13
Thalamocortical circuits causing remote hypometabolism during focal interictal epilepsy. Bruehl C, et al. **Epilepsy Res** 1998 Nov;32(3):379–87
Local cerebral glucose utilization in adult and immature GAERS. Nehlig A, et al. **Epilepsy Res** 1998 Sep; 32(1-2):206–12
Decreased glucose metabolism causes separation of hoof lamellae in vitro: a trigger for laminitis? Pass MA, et al. **Equine Vet J Suppl** 1998 Sep;(26):133–8
The strict molybdate-dependence of glucose-degradation by the thermoacidophile Sulfolobus acidocaldarius reveals the first crenarchaeotic molybdenum containing enzyme--an aldehyde oxidoreductase. Kardinahl S, et al. **Eur J Biochem** 1999 Mar;260(2):540–8
31P and 13C nuclear magnetic resonance studies of metabolic pathways in Pasteurella multocida characterization of a new mannitol-producing metabolic pathway. Rager MN, et al. **Eur J Biochem** 1999 Aug;263(3):695–701
Acute and chronic exposure of rat intestinal mucosa to dextran promotes SGLTI-mediated glucose transport. Debnam ES, et al. **Eur J Clin Invest** 1998 Aug;28(8):651–8
High dose insulin does not increase glucose transfer across the blood-brain barrier in humans: a re-evaluation. Knudsen GM, et al. **Eur J Clin Invest** 1999 Aug; 29(8):687–91
Prandial glucose regulation and cardiovascular disease in type 2 diabetes. Kuusisto J, et al. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:7–11 (42 ref.)
Glucose metabolism and the postprandial state. Lefebvre PJ, et al. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:1–6 (38 ref.)
Comments on metabolic needs for glucose and the role of gluconeogenesis. Brosnan JT. **Eur J Clin Nutr** 1999 Apr; 53 Suppl 1:S107–11 (25 ref.)
Rye bread decreases postprandial insulin response but does not alter glucose response in healthy Finnish subjects. Leinonen K, et al. **Eur J Clin Nutr** 1999 Apr;53(4):262–7
The glycaemic index of potatoes: the effect of variety, cooking method and maturity. Soh NL, et al. **Eur J Clin Nutr** 1999 Apr;53(4):249–54
Insulin-like growth factor binding protein-1 as a predictor of glucose-stimulated hyperinsulinemia in prepubertal obese children. Saitoh H, et al. **Eur J Endocrinol** 1999 Mar; 140(3):231–4
Local cerebral glucose utilization in the AS/AGU rat: a mutant with movement disorders. Lam AG, et al. **Eur J Neurosci** 1998 Jun;10(6):1963–7
Longitudinal versus radial effects of hydroxypropylmethylcellulose on gastrointestinal glucose absorption in dogs. Reppas C, et al. **Eur J Pharm Sci** 1999 Jul;8(3):211–9
Cardiovascular effects of captopril and enalapril in obese Zucker rats. Duarte J, et al. **Eur J Pharmacol** 1999 Jan 22;365(2-3):225–32
Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound. Furukawa N, et al. **Eur J Pharmacol** 1999 Apr 23;371(1):51–8
Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Pelé-Tounian A, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):81–7
Effect of subchronic metrifonate treatment on cerebral glucose metabolism in young and aged rats. Poindessous-Jazat F, et al. **Eur J Pharmacol** 1998 Dec 11; 363(1):17–28
Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Komatsu N, et al. **Eur Neurol** 1999 Jul; 42(1):41–8
Role of platelet-activating factor in glucose uptake and utilization of different tissues. Ottlakán A. **Eur Surg Res** 1998;30(6):393–402
Hypothermia attenuates hyperglycolysis in the periphery of ischemic core in rat brain. Tohyama Y, et al. **Exp Brain Res** 1998 Oct;122(3):333–8
H-ras induces glucose uptake in brown adipocytes in an insulin- and phosphatidylinositol 3-kinase-independent manner. Valverde AM, et al. **Exp Cell Res** 1998 Sep 15; 243(2):274–81
Characterization of regulatory elements on the promoter region of human ATP-citrate lyase. Moon YA, et al. **Exp Mol Med** 1999 Jun 30;31(2):108–14
The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Pedersen WA, et al. **Exp Neurol** 1999 Jan;155(1):1–10
Cryptosporidium parvum infection in suckling rats: impairment of mucosal permeability and Na(+)-glucose cotransport. Capet C, et al. **Exp Parasitol** 1999 Feb; 91(2):119–25
Hymenolepis diminuta: glucose and glycogen gradients in the adult tapeworm. Pappas PW, et al. **Exp Parasitol** 1999 Apr;91(4):315–26
Basolateral D-glucose transport activity along the crypt–villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2. Cheeseman CI, et al. **Exp Physiol** 1998 Sep;83(5):605–16
Effect of glucose-dependent insulinotropic polypeptide on

whole-body glucose utilization in sheep. Rose MT, et al. **Exp Physiol** 1998 Nov;83(6):783-92
Effect of hypocalcaemia on glucose metabolism in hyperketonaemic piglets. Schlumbohm C, et al. **Exp Physiol** 1999 Jul;84(4):707-23
Glucose and free radicals impair the antioxidant properties of serum albumin. Bourdon E, et al. **FASEB J** 1999 Feb; 13(2):233-44
Tissue-specific effects of in vivo adenosine receptor blockade on glucose uptake in Zucker rats. Crist GH, et al. **FASEB J** 1998 Oct;12(13):1301-8
Exercise-induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis. Hjeltnes N, et al. **FASEB J** 1998 Dec; 12(15):1701-12
Acute hyperglycemia regulates transcription and posttranscriptional stability of PKCbetaII mRNA in vascular smooth muscle cells. Patel NA, et al. **FASEB J** 1999 Jan;13(1):103-13
Insulin-independent glucose transport regulates insulin sensitivity. Ebeling P, et al. **FEBS Lett** 1998 Oct 9; 436(3):301-3 (46 ref.)
Caffeine releases a glucose-primed endoplasmic reticulum Ca2+ pool in the insulin secreting cell line INS-1. Gamberucci A, et al. **FEBS Lett** 1999 Mar 12; 446(2-3):309-12
Essential arginine residues in maize starch synthase IIa are involved in both ADP-glucose and primer binding. Imparl-Radosevich JM, et al. **FEBS Lett** 1999 Sep 3; 457(3):357-62
Specific detections of the early process of the glycation reaction by fructose and glucose in diabetic rat lens. Kawasaki Y, et al. **FEBS Lett** 1998 Dec 11;441(1):116-20
Repression of enzymes of the pentose phosphate pathway by glucose in fission yeast. Mehta S, et al. **FEBS Lett** 1998 Dec 4;440(3):430-3
In vivo operation of the pentose phosphate pathway in frog oocytes is limited by NADP+ availability. Preller A, et al. **FEBS Lett** 1999 Mar 5;446(1):149-52
Impaired glucose sensing by intrahepatic, muscarinic nerves for an insulin-stimulated hepatic glucose uptake in streptozotocin-diabetic rats. Stümpel F, et al. **FEBS Lett** 1998 Oct 2;436(2):185-8
Growth requirements of pyruvate-decarboxylase-negative Saccharomyces cerevisiae. Flikweert MT, et al. **FEMS Microbiol Lett** 1999 May 1;174(1):73-9
Glucose transport in a methylotrophic yeast Hansenula polymorpha. Karp H, et al. **FEMS Microbiol Lett** 1998 Sep 15;166(2):267-73
Impaired growth on glucose of a pyruvate dehydrogenase-negative mutant of Kluyveromyces lactis is due to a limitation in mitochondrial acetyl-coenzyme A uptake. Zeeman AM, et al. **FEMS Microbiol Lett** 1999 Aug 1;177(1):23-8
Glucose repression of maltase and methanol-oxidizing enzymes in the methylotrophic yeast Hansenula polymorpha: isolation and study of regulatory mutants. Alamäe T, et al. **Folia Microbiol (Praha)** 1998;43(5):443-52
Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. Blackburn RV, et al. **Free Radic Biol Med** 1999 Feb; 26(3-4):419-30
The effect of oxygen radicals on rat thymocyte glucose transport is independent of the site of their generation. Fiorentini D, et al. **Free Radic Biol Med** 1999 Mar; 26(5-6):661-8
Quercetin glucosides interact with the intestinal glucose transport pathway. Gee JM, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):19-25
Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Millican SA, et al. **Free Radic Res** 1998 May;28(5):533-42
Carbon catabolite repression of gene expression and conidiation in Neurospora crassa. Ebbole DJ. **Fungal Genet Biol** 1998 Oct;25(1):15-21 (50 ref.)
Quantification of gluconeogenesis in cirrhosis: response to glucagon. Bugianesi E, et al. **Gastroenterology** 1998 Dec; 115(6):1530-40
Enteric glucagon 37 rather than pancreatic glucagon 29 stimulates glucose absorption in rat intestine. Stümpel F, et al. **Gastroenterology** 1998 Nov;115(5):1163-71
Leptin increases glucose transport and utilization in skeletal muscle in vitro. Ceddia RB, et al. **Gen Pharmacol** 1998 Nov;31(5):799-801
Searching for ways to upregulate GLUT4 glucose transporter expression in muscle. Zorzano A, et al. **Gen Pharmacol** 1998 Nov;31(5):705-13 (119 ref.)
Negative regulation of the pts operon by Mlc: mechanism underlying glucose induction in Escherichia coli. Tanaka Y, et al. **Genes Cells** 1999 Jul;4(7):391-9
Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. Kaestner KH, et al. **Genes Dev** 1999 Feb 15;13(4):495-504
Transbilayer movement of Glc-P-dolichol and its function as a glucosyl donor: protein-mediated transport of a water-soluble analog into sealed ER vesicles from pig brain. Rush JS, et al. **Glycobiology** 1998 Dec;8(12):1195-205
Connexin 32 gap junctions enhance stimulation of glucose output by glucagon and noradrenaline in mouse liver. Stümpel F, et al. **Hepatology** 1998 Dec;28(6):1616-20
Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Cagnacci A, et al. **Hum Reprod** 1999 Apr;14(4):893-7
Effects of glutathione on red blood cell intracellular magnesium: relation to glucose metabolism. Barbagallo M, et al. **Hypertension** 1999 Jul;34(1):76-82
Vasodilator response to systemic but not to local hyperinsulinemia in the human forearm. Cardillo C, et al. **Hypertension** 1998 Oct;32(4):740-5
Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET. Bertoldo A, et al. **IEEE Trans Biomed Eng** 1998 Dec; 45(12):1429-48
The direct effect of dopamine on glucose release from primary cultured rat hepatocytes. Shiroyama K, et al. **In Vivo** 1998 Sep-Oct;12(5):527-9
Islet amyloid polypeptide decreases the effects of insulin-like growth factor-I on glucose transport and glycogen synthesis in skeletal muscle [published erratum appears in Int J Biochem Cell Biol 1999 Jun;31(6):733] Dimitriadis G, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1039-46
Control of mRNA turnover as a mechanism of glucose repression in Saccharomyces cerevisiae. Scheffler IE, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1175-93 (113 ref.)
A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells which overproduce PKC-betaII. Yamamoto M, et al. **Int J Cancer** 1999 Sep 24;83(1):98-106
Effects of vascular or luminal administration and of simultaneous glucose availability on glutamine utilization by isolated rat small intestine. Plauth M, et al. **Int J Colorectal Dis** 1999 Apr;14(2):95-100
Glucose metabolism in cholinoceptive cortical rat brain regions after basal forebrain cholinergic lesion. Mehlhorn G, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):675-90
Brain glucose metabolism in eating disorders assessed by positron emission tomography. Delvenne V, et al. **Int J Eat Disord** 1999 Jan;25(1):29-37
IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion (review). Karlsson E. **Int J Mol Med** 1999 Jun;3(6):577-84 (142 ref.)
Leptin concentrations during oral glucose tolerance test (OGTT) in obese and normal weight women. Bougoulia M, et al. **Int J Obes Relat Metab Disord** 1999 Jun; 23(6):625-8
The impact of increased dietary lipid on the regulation of glucose uptake and oxidation by insulin in brown- and a range of white-adipose-tissue depots in vivo. Holness MJ, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):629-38
Effects of tumor necrosis factor alpha on leptin secretion and gene expression: relationship to changes of glucose metabolism in isolated rat adipocytes. Medina EA, et al. **Int J Obes Relat Metab Disord** 1999 Aug;23(8):896-903
Glycemic index--a new tool in sport nutrition? Burke LM, et al. **Int J Sport Nutr** 1998 Dec;8(4):401-15 (52 ref.)
Detection of histamine-induced capillary protein leakage and hypovolaemia by determination of indocyanine green and glucose dilution method in dogs. Suzuki A, et al. **Intensive Care Med** 1999 Mar;25(3):304-10
L-carnitine improves glucose disposal in type 2 diabetic patients. Mingrone G, et al. **J Am Coll Nutr** 1999 Feb; 18(1):77-82
Effects of insulin and amino acids on glucose and leucine metabolism in CAPD patients. Castellino P, et al. **J Am Soc Nephrol** 1999 May;10(5):1050-8
Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. Kapor-Drezgic J, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1193-203
An improved mouse sperm-oocyte plasmalemma binding assay: studies on characteristics of sperm binding in medium with or without glucose. Redkar AA, et al. **J Androl** 1999 Jul-Aug;20(4):500-8
Metabolic adaptation to experimentally increased glucose demand in ruminants. Overton TR, et al. **J Anim Sci** 1998 Nov;76(11):2938-46
Effects of laidlomycin propionate and monensin on glucose utilization and nutrient transport by Streptococcus bovis and Selenomonas ruminantium. Wampler JL, et al. **J Anim Sci** 1998 Oct;76(10):2730-6
Strobilurin M, tetrachloropyrocatechol and tetrachloropyrocatechol methyl ether: new antibiotics from a Mycena species. Daferner M, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):816-22
Oxidation of an oral [13C]glucose load at rest and prolonged exercise in trained and sedentary subjects. Burelle Y, et al. **J Appl Physiol** 1999 Jan;86(1):52-60
Short-term exercise enhances insulin-stimulated GLUT-4 translocation and glucose transport in adipose cells. Ferrara CM, et al. **J Appl Physiol** 1998 Dec;85(6):2106-11
Limitations to exercise- and maximal insulin-stimulated muscle glucose uptake. Halseth AE, et al. **J Appl Physiol** 1998 Dec;85(6):2305-13
Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade. Lekas MC, et al. **J Appl Physiol** 1999 Aug;87(2):722-31
Autoradiographic determination of local cerebral blood flow and local cerebral glucose utilization during chemical stimulation of the nucleus tractus solitarii of anesthetized rats. Maeda M, et al. **J Auton Nerv Syst** 1998 Apr 30; 69(2-3):132-40
Glucose transport in the extremely thermoacidophilic Sulfolobus solfataricus involves a high-affinity membrane-integrated binding protein. Albers SV, et al. **J Bacteriol** 1999 Jul;181(14):4285-91
Regulation of the Bacillus subtilis GlcT antiterminator protein by components of the phosphotransferase system. Bachem S, et al. **J Bacteriol** 1998 Oct;180(20):5319-26
The EIIGlc protein is involved in glucose-mediated activation of Escherichia coli gapA and gapB-pgk transcription. Charpentier B, et al. **J Bacteriol** 1998 Dec; 180(24):6476-83
A Zymomonas mobilis mutant with delayed growth on high glucose concentrations. Douka E, et al. **J Bacteriol** 1999 Aug;181(15):4598-604
The general stress sigma factor sigmaS of Escherichia coli is induced during diauxic shift from glucose to lactose. Fischer D, et al. **J Bacteriol** 1998 Dec;180(23):6203-6
Regulation and adaptation of glucose metabolism of the parasitic protist Leishmania donovani at the enzyme and mRNA levels. ter Kuile BH. **J Bacteriol** 1999 Aug; 181(16):4863-72
Glucose metabolism in ger mutants of Saccharomyces cerevisiae. Uemura H, et al. **J Bacteriol** 1999 Aug; 181(15):4719-23
Growth and glucose repression are controlled by glucose transport in Saccharomyces cerevisiae cells containing only one glucose transporter. Ye L, et al. **J Bacteriol** 1999 Aug; 181(15):4673-5
Functioning of DcuC as the C4-dicarboxylate carrier during glucose fermentation by Escherichia coli. Zientz E, et al. **J Bacteriol** 1999 Jun;181(12):3716-20
Quantitative determination of the main glucose metabolic fluxes in human erythrocytes by 13C- and 1H-MR spectroscopy. Messana I, et al. **J Biochem Biophys Methods** 1999 Feb 25;39(1-2):63-84
Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13c and 1H NMR study. Bouzier AK, et al. **J Biol Chem** 1998 Oct 16;273(42):27162-9
Trimming and readdition of glucose to N-linked oligosaccharides determines calnexin association of a substrate glycoprotein in living cells. Cannon KS, et al. **J Biol Chem** 1999 Mar 12;274(11):7537-44
Mutation of tyrosine 960 within the insulin receptor juxtamembrane domain impairs glucose transport but does not inhibit ligand-mediated phosphorylation of insulin receptor substrate-2 in 3T3-L1 adipocytes. Chaika OV, et al. **J Biol Chem** 1999 Apr 23;274(17):12075-80
Signaling mechanisms that regulate glucose transport. Czech MP, et al. **J Biol Chem** 1999 Jan 22;274(4):1865-8 (78 ref.)
Glucose uptake kinetics and transcription of HXT genes in chemostat cultures of Saccharomyces cerevisiae. Diderich JA, et al. **J Biol Chem** 1999 May 28;274(22):15350-9
In vivo adenoviral delivery of recombinant human protein kinase C-zeta stimulates glucose transport activity in rat skeletal muscle. Etgen GJ, et al. **J Biol Chem** 1999 Aug 6;274(32):22139-42
Purinergic inhibition of glucose transport in cardiomyocytes. Fischer Y, et al. **J Biol Chem** 1999 Jan 8;274(2):755-61
L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. Goldwaser I, et al. **J Biol Chem** 1999 Sep 10; 274(37):26617-24
Stimulation of IRS-1-associated phosphatidylinositol 3-kinase and Akt/protein kinase B but not glucose transport by beta1-integrin signaling in rat adipocytes. Guilherme A, et al. **J Biol Chem** 1998 Dec 11; 273(50):33119-22
Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. Hajduch E, et al. **J Biol Chem** 1999 May 7;274(19):13563-8
A novel factor binding to the glucose response elements of liver pyruvate kinase and fatty acid synthase genes. Hasegawa J, et al. **J Biol Chem** 1999 Jan 8;274(2):1100-7
Identification of wortmannin-sensitive targets in 3T3-L1 adipocytes. DissociationoOf insulin-stimulated glucose uptake and glut4 translocation. Hausdorff SF, et al. **J Biol Chem** 1999 Aug 27;274(35):24677-84
Hexokinase II-deficient mice. Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes. Heikkinen S, et al. **J Biol Chem** 1999 Aug 6; 274(32):22517-23
Insulin receptor substrate-2 is not necessary for insulin- and exercise-stimulated glucose transport in skeletal muscle. Higaki Y, et al. **J Biol Chem** 1999 Jul 23;274(30):20791-5
Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. El-Jack AK, et al. **J Biol Chem** 1999 Mar 19;274(12):7946-51
Tryptophan 388 in putative transmembrane segment 10 of the rat glucose transporter Glut1 is essential for glucose transport. Kasahara T, et al. **J Biol Chem** 1998 Oct 30; 273(44):29113-7
CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion. Kato I, et al. **J Biol Chem** 1999 Jan 22;274(4):1869-72
Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. Liu L, et al. **J Biol Chem** 1998 Nov 20;273(47):31160-7
Cysteine scanning mutagenesis of the segment between putative transmembrane helices IV and V of the high

affinity Na+/Glucose cotransporter SGLT1. Evidence that this region participates in the Na+ and voltage dependence of the transporter. Lo B, et al. **J Biol Chem** 1998 Nov 6;273(45):29341–51

Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. Malhotra R, et al. **J Biol Chem** 1999 Apr 30; 274(18):12567–75

Insulin-stimulated glucose transport minireview series. Olefsky JM. **J Biol Chem** 1999 Jan 22;274(4):1863

Identification of a glucose response element in the promoter of the rat glucagon receptor gene. Portois L, et al. **J Biol Chem** 1999 Mar 19;274(12):8181–90

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. Postic C, et al. **J Biol Chem** 1999 Jan 1;274(1):305–15

The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism. Summers SA, et al. **J Biol Chem** 1999 Jun 18;274(25):17934–40

An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. Sweeney G, et al. **J Biol Chem** 1999 Apr 9;274(15):10071–8

Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. Trinh KY, et al. **J Biol Chem** 1998 Nov 20; 273(47):31615–20

Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes. Wu-Wong JR, et al. **J Biol Chem** 1999 Mar 19;274(12):8103–10

Spectrophotometric kinetic study and analytical implications of the glucose oxidase-catalyzed reduction of [MIII(LL)2Cl2]+ complexes by D-glucose (M = Os and Ru, LL = 2,2'-bipyridine and 1,10-phenanthroline type ligands). Ryabov AD, et al. **J Biol Inorg Chem** 1999 Apr; 4(2):175–82

Manipulation of carbon assimilation with respect to expression of the pac gene for improving production of penicillin acylase in Escherichia coli. Chou CP, et al. **J Biotechnol** 1999 Mar 26;69(1):27–38

Dynamics and modeling on fermentative production of poly (beta-hydroxybutyric acid) from sugars via lactate by a mixed culture of Lactobacillus delbrueckii and Alcaligenes eutrophus. Katoh T, et al. **J Biotechnol** 1999 Jan 22; 67(2–3):113–34

An ethanol-sensitive variant of the PC12 neuronal cell line: sensitivity to alcohol is associated with increased cell adhesion and decreased glucose accumulation. Dwyer DS, et al. **J Cell Physiol** 1999 Jan;178(1):93–101

Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. Blandini F, et al. **J Cereb Blood Flow Metab** 1999 Feb;19(2):149–54

The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice. Browne SE, et al. **J Cereb Blood Flow Metab** 1999 Feb;19(2):144–8

In vivo injection of [1-13C]glucose and [1,2-13C]acetate combined with ex vivo 13C nuclear magnetic resonance spectroscopy: a novel approach to the study of middle cerebral artery occlusion in the rat. Håberg A, et al. **J Cereb Blood Flow Metab** 1998 Nov;18(11):1223–32

Separate neuronal and glial Na+,K+-ATPase isoforms regulate glucose utilization in response to membrane depolarization and elevated extracellular potassium. Honegger P, et al. **J Cereb Blood Flow Metab** 1999 Sep; 19(9):1051–9

High prevalence of bihemispheric structural and functional defects in Sturge-Weber syndrome. Maria BL, et al. **J Child Neurol** 1998 Dec;13(12):595–605

Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression. Maria BL, et al. **J Child Neurol** 1998 Dec;13(12):606–18

Effect of chronic treatment with lacidipine or lisinopril on intracellular partitioning of glucose metabolism in type 2 diabetes mellitus. Bonora E, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1544–50

Intrinsic site-specific differences in the expression of leptin in human adipocytes and its autocrine effects on glucose uptake. Zhang HH, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2550–6

The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. Chen X, et al. **J Clin Invest** 1999 Feb;103(3):365–72

Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Dresner A, et al. **J Clin Invest** 1999 Jan;103(2):253–9

Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. Liu S, et al. **J Clin Invest** 1999 Jan;103(2):207–13

The molecular basis of disorders of red cell enzymes. McMullin MF. **J Clin Pathol** 1999 Apr;52(4):241–4 (19 ref.)

Changes in plasma and milk concentrations of glucose and IGF-1 in response to exogenous growth hormone in lactating goats. Faulkner A. **J Dairy Res** 1999 May; 66(2):207–14

Glucose metabolism and milk yield of cows infused abomasally or ruminally with starch. Knowlton KF, et al. **J Dairy Sci** 1998 Dec;81(12):3248–58

In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues. Iannello S, et al. **J Diabetes Complications** 1999 Mar-Apr;13(2):68–73

Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. Ceddia RB, et al. **J Endocrinol** 1998 Sep;158(3):R7–9

Insulin action in growth hormone-deficient and age-matched control rats: effect of growth hormone treatment. Daugaard JR, et al. **J Endocrinol** 1999 Jan;160(1):127–35

Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates. Derman SG, et al. **J Endocrinol** 1999 Mar;160(3):415–23

Fanconi-Bickel syndrome--a congenital defect of the liver-type facilitative glucose transporter. SSIEM Award. Society for the Study of Inborn Errors of Metabolism. Santer R, et al. **J Inherit Metab Dis** 1998 Jun;21(3):191–4

Genetically engineered mice in drug development. Livingston JN. **J Intern Med** 1999 Jun;245(6):627–35 (37 ref.)

Tumor necrosis factor-alpha alters glucose metabolism in suckling rats. Battelino T, et al. **J Lab Clin Med** 1999 Jun; 133(6):583–9

Structure of D-allose binding protein from Escherichia coli bound to D-allose at 1.8 A resolution. Chaudhuri BN, et al. **J Mol Biol** 1999 Mar 12;286(5):1519–31

Ischemia-stimulated glucose uptake does not require catecholamines in rat heart. Doenst T, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):435–43

Complexities underlying the quantitative determination of myocardial glucose uptake with 2-deoxyglucose. Doenst T, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1595–604

Enhancement of post-ischemic myocardial function by chronic 17 beta -estradiol treatment: role of alterations in glucose metabolism. Fraser H, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1539–49

Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. Wambolt RB, et al. **J Mol Cell Cardiol** 1999 Mar; 31(3):493–502

Continuing: Biology of cachexia [letter; comment] Bozzetti F. **J Natl Cancer Inst** 1999 Jun 16;91(12):1077; discussion 1077–8. Comment on: J Natl Cancer Inst 1997 Dec 3;89(23):1763–73. Comment on: J Natl Cancer Inst 1998 Apr 15;90(8):628.

Local transport kinetics of glucose during acute and chronic nicotine infusion in rat brains. Duelli R, et al. **J Neural Transm** 1998;105(8–9):1017–28

Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Münch G, et al. **J Neural Transm** 1998;105(4–5):439–61 (125 ref.)

The effects of (+)-UH232 and (-)-DS121 on local cerebral glucose utilization in rats. Walker EL, et al. **J Neural Transm** 1999;106(1):59–74

Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors. Boado RJ. **J Neural Transm Suppl** 1998;53:323–31

Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. Hoyer S. **J Neural Transm Suppl** 1998;54:187–94 (43 ref.)

[1-(13)C]glucose metabolism in the tumoral and nontumoral cerebral tissue of a glioma-bearing rat. Bouzier AK, et al. **J Neurochem** 1999 Jun;72(6):2445–55

Extracellular glucose concentrations in the rat hippocampus measured by zero-net-flux: effects of microdialysis flow rate, strain, and age. McNay EC, et al. **J Neurochem** 1999 Feb;72(2):785–90

Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. Mattson MP, et al. **J Neurochem** 1999 Aug;73(2):532–7

Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. Simpson IA, et al. **J Neurochem** 1999 Jan;72(1):238–47

Effect of corticotropin-releasing hormone antagonist on oestrogen-dependent glucoprivic suppression of luteinizing hormone secretion in female rats. Tsukahara S, et al. **J Neuroendocrinol** 1999 Feb;11(2):101–5

Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. Szakáll S, et al. **J Neuroimaging** 1998 Oct;8(4):197–204

Regional metabolism: associations with dyscalculia in Alzheimer's disease. Hirono N, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):913–6

Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure. Arahata Y, et al. **J Neurol Sci** 1999 Mar 1;163(2):119–26

Dynamic changes in glucose metabolism induced by thiamine deficiency and its replenishment as revealed by a positron autoradiography technique using rat living brain slices. Murata T, et al. **J Neurol Sci** 1999 Mar 15;164(1):29–36

The effect of aniracetam on cerebral glucose metabolism in rats after lesioning of the basal forebrain measured by PET. Ouchi Y, et al. **J Neurol Sci** 1999 Mar 15;164(1):7–12

Heterogeneity of glucose metabolism in corticobasal degeneration. Taniwaki T, et al. **J Neurol Sci** 1998 Nov 26;161(1):70–6

Alteration of regional cerebral glucose utilization with delusions in Alzheimer's disease. Hirono N, et al. **J Neuropsychiatry Clin Neurosci** 1998 Fall;10(4):433–9

Application of positron emission tomography to determine cerebral glucose utilization in conscious infant monkeys. Moore AH, et al. **J Neurosci Methods** 1999 May 1; 88(2):123–33

Direct administration and utilization of [1-13C]glucose by fetal brain and liver tissues under normal and ischemic conditions: 1H, 31P, and 13C NMR studies. Brand A, et al. **J Neurosci Res** 1998 Oct 1;54(1):97–108

Increased inspired oxygen concentration as a factor in improved brain tissue oxygenation and tissue lactate levels after severe human head injury. Menzel M, et al. **J Neurosurg** 1999 Jul;91(1):1–10

Influence of early posttraumatic hypothermia therapy on local cerebral blood flow and glucose metabolism after fluid-percussion brain injury. Zhao W, et al. **J Neurosurg** 1999 Mar;90(3):510–9

Cerebral glucose metabolism in acute and persistent vegetative state. Rudolf J, et al. **J Neurosurg Anesthesiol** 1999 Jan;11(1):17–24

Regional changes in cerebral extracellular glucose and lactate concentrations following severe cortical impact injury and secondary ischemia in rats. Krishnappa IK, et al. **J Neurotrauma** 1999 Mar;16(3):213–24

Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency). Fukuchi K, et al. **J Nucl Med** 1999 Feb; 40(2):239–43

Cerebral glucose metabolism in patients with frontotemporal dementia. Ishii K, et al. **J Nucl Med** 1998 Nov; 39(11):1875–8

Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. Maruyama I, et al. **J Nucl Med** 1999 Jul;40(7):1085–90

Quantification of glucose transport and phosphorylation in human skeletal muscle using FDG PET. Reinhardt M, et al. **J Nucl Med** 1999 Jun;40(6):977–85

Increased brain glucose utilization in Salla disease (free sialic acid storage disorder). Suhonen-Polvi H, et al. **J Nucl Med** 1999 Jan;40(1):12–8

Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. Tsuchida T, et al. **J Nucl Med** 1999 Sep;40(9):1441–5

Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. Gray AM, et al. **J Nutr** 1998 Dec;128(12):2319–23

Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. Massimino SP, et al. **J Nutr** 1998 Oct;128(10):1786–93

Glucose uptake in dilated small intestine. Kawaguchi AL, et al. **J Pediatr Surg** 1998 Nov;33(11):1670–3

Lymphatic absorption of glucose and fatty acids as determined by direct measurement. Sigalet DL, et al. **J Pediatr Surg** 1999 Jan;34(1):39–43

Recent progress in insulin signal transduction. Hei YJ. **J Pharmacol Toxicol Methods** 1998 Oct;40(3):123–35 (95 ref.)

Effect of feeding extruded kidney bean diets on in vivo intestinal absorption of D-glucose. Alonso R, et al. **J Physiol Biochem** 1998 Dec;54(4):241–2

alpha-MeGlc and D-glucose transport by hepatopancreatic brush border membrane vesicles from prawn. Blaya JA, et al. **J Physiol Biochem** 1998 Mar;54(1):1–7

Effect of muscle glycogen on glucose, lactate and amino acid metabolism during exercise and recovery in human subjects. Blomstrand E, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):293–302

Role of adenosine in regulating glucose uptake during contractions and hypoxia in rat skeletal muscle. Derave W, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):255–63

Glucose kinetics during prolonged exercise in highly trained human subjects: effect of glucose ingestion. Jeukendrup AE, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):579–89

Metabolism and inflammatory mediators in the peritendinous space measured by microdialysis during intermittent isometric exercise in humans. Langberg H, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):919–27

Glucose-receptive neurones in the rat ventromedial hypothalamus express KATP channels composed of Kir6.1 and SUR1 subunits. Lee K, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):439–52

Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Berent S, et al. **J Psychiatr Res** 1999 Jan-Feb;33(1):7–16

Physiological characterization of mBSA antigen induced arthritis in the rat. II. Joint blood flow, glucose metabolism, and cell proliferation. Andersson SE, et al. **J Rheumatol** 1998 Sep;25(9):1778–84

1997 Sir William Refshauge Lecture. Skeletal muscle glucose metabolism during exercise: implications for health and performance. Hargreaves M. **J Sci Med Sport** 1998 Dec; 1(4):195–202 (59 ref.)

The Kidney's role in glucose balance following partial hepatectomy. Jones CE, et al. **J Surg Res** 1998 Oct; 79(2):136–40

Epidermal growth factor stimulates the recovery of glucose absorption after small bowel transplantation. Kato Y, et al. **J Surg Res** 1998 Dec;80(2):315–9

Regional cerebral blood flow and regional glucose use during

rewarding after hypothermic cardiopulmonary bypass [letter; comment] Miyamoto TA, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1228–9. Comment on: J Thorac Cardiovasc Surg 1998 Sep;116(3):503–10.

Hepatic and peripheral glucose metabolism in intensive care patients receiving continuous high- or low-carbohydrate enteral nutrition. Tappy L, et al. **JPEN J Parenter Enteral Nutr** 1999 Sep–Oct;23(5):260–7; discussion 267–8

Protopanaxatriol ginsenosides inhibit glucose uptake in primary cultured rabbit renal proximal tubular cells by arachidonic acid release. Han HJ, et al. **Kidney Blood Press Res** 1999;22(3):114–20

The Nobel Chronicles. 1947: Carl Ferdinand Cori (1896–1984); Gerty Theresa Radnitz Cori (1896–1957); and Bernardo Alberto Houssay (1887–1971). Raju TN. **Lancet** 1999 Mar 27;353(9158):1108

N-glycosylation of glucose transporter-1 (Glut-1) is associated with increased transporter affinity for glucose in human leukemic cells. Ahmed N, et al. **Leuk Res** 1999 Apr;23(4):395–401

Alpha-adrenoceptor-mediated glucose release from perifused catfish hepatocytes. Fabbri E, et al. **Life Sci** 1999; 65(1):27–35

Glycogen turnover in skeletal muscle is stimulated along with glucose uptake in vivo during contraction. Huang MT. **Life Sci** 1998;63(22):2023–30

Enhanced cytotoxicity and suppression of glucose transport rate by combined treatment of recombinant human tumour necrosis factor-alpha and hyperthermia on L929 cells. Liong E, et al. **Life Sci** 1999;65(8):PL81–6

Enhancement of glucose transport in small intestinal brush border membrane of retinol administered rat. Tanii H, et al. **Life Sci** 1999;64(15):1259–64

Insulin sensitivity, glucose effectiveness, and insulin secretion in nondiabetic offspring of patients with non-insulin-dependent diabetes mellitus: a cross-sectional study. Araújo-Vilar D, et al. **Metabolism** 1999 Aug; 48(8):978–83

Glucose contribution to in vivo synthesis of glyceride-glycerol and fatty acids in rats adapted to a high-protein, carbohydrate-free diet. Botion LM, et al. **Metabolism** 1998 Oct;47(10):1217–21

The contribution of glucose to neonatal glucose homeostasis in the lamb. Cowett RM, et al. **Metabolism** 1998 Oct; 47(10):1239–44

Increased dependence of glucose production on peripheral insulin in diabetic depancreatized dogs. Giacca A, et al. **Metabolism** 1999 Feb;48(2):153–60

Effect of masoprocol on glucose transport and lipolysis by isolated rat adipocytes. Gowri MS, et al. **Metabolism** 1999 Apr;48(4):411–4

Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Henriksen JE, et al. **Metabolism** 1999 Sep;48(9):1128–35

Both positive and negative portal venous and hepatic arterial glucose gradients stimulate hepatic glucose uptake after the same amount of glucose is infused into the splanchnic bed in conscious dogs. Horikawa S, et al. **Metabolism** 1998 Nov;47(11):1295–302

Effect of resistance training with or without chromium picolinate supplementation on glucose metabolism in older men and women. Joseph LJ, et al. **Metabolism** 1999 May; 48(5):546–53

Impact of acute epinephrine removal on hepatic glucose metabolism during stress hormone infusion. McGuinness OP, et al. **Metabolism** 1999 Jul;48(7):910–4

Leptin does not affect adipocyte glucose metabolism: studies in fresh and cultured adipocytes. Mick G, et al. **Metabolism** 1998 Nov;47(11):1360–5

Zinc supplementation improves glucose disposal in patients with cirrhosis [letter; comment] Samman S. **Metabolism** 1999 Aug;48(8):1069–70. Comment on: Metabolism 1998 Jul;47(7):792–8.

Dose-response relationship of insulin to glucose fluxes in the awake and unrestrained mouse. Shen HQ, et al. **Metabolism** 1999 Aug;48(8):965–70

Intracerebroventricular administration of leptin markedly enhances insulin sensitivity and systemic glucose utilization in conscious rats. Shi ZQ, et al. **Metabolism** 1998 Oct; 47(10):1274–80

Substrate interactions in the short- and long-term regulation of renal glucose oxidation. Sugden MC, et al. **Metabolism** 1999 Jun;48(6):707–15

Peripheral tissue glucose uptake is not reduced after an oral glucose load in Southern Italian subjects at risk of developing non-insulin-dependent diabetes mellitus. Thorburn AW, et al. **Metabolism** 1999 Jan;48(1):80–5

Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Velasquez MT, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):7–11 (64 ref.)

Adenosine triphosphate-sensitive potassium channels are involved in insulin-mediated glucose transport in humans. Wasada T, et al. **Metabolism** 1999 Apr;48(4):432–6

Chronic leptin administration increases insulin-stimulated skeletal muscle glucose uptake and transport. Yaspelkis BB 3rd, et al. **Metabolism** 1999 May;48(5):671–6

Transcription of the pcbAB, pcbC and penDE genes of Penicillium chrysogenum AS-P-78 is repressed by glucose and the repression is not reversed by alkaline pHs. Gutiérrez S, et al. **Microbiology** 1999 Feb;145 (Pt 2):317–24

Inactivation of the Kluyveromyces lactis KlPDA1 gene leads to loss of pyruvate dehydrogenase activity, impairs growth on glucose and triggers aerobic alcoholic fermentation. Zeeman AM, et al. **Microbiology** 1998 Dec;144 (Pt 12):3437–46

Mechanism of stimulation of glucose transport in response to inhibition of oxidative phosphorylation: analysis with myc-tagged Glut1. Koseoglu MH, et al. **Mol Cell Biochem** 1999 Apr;194(1–2):109–16

An in vitro study on the role of metal catalyzed oxidation in glycation and crosslinking of collagen. Sajithlal GB, et al. **Mol Cell Biochem** 1999 Apr;194(1–2):257–63

Interference of D-mannoheptulose with D-glucose phosphorylation, metabolism and functional effects: comparison between liver, parotid cells and pancreatic islets. Scruel O, et al. **Mol Cell Biochem** 1998 Oct; 187(1–2):113–20

Std1 and Mth1 proteins interact with the glucose sensors to control glucose-regulated gene expression in Saccharomyces cerevisiae. Schmidt MC, et al. **Mol Cell Biol** 1999 Jul;19(7):4561–71

Dbf2 is implicated in a Cbt1-dependent pathway following a shift from glucose to galactose or non-fermentable carbon sources in Saccharomyces cerevisiae. Grandin N, et al. **Mol Gen Genet** 1999 Mar;261(2):402–7

Mechanical function and substrate oxidation in the neonatal pig heart subjected to pacing-induced tachycardia. Ascuitto RJ, et al. **Mol Genet Metab** 1999 Mar;66(3):212–23

Glucose utilization in muscle fiber types: use of the partial pancreatectomized rat model to distinguish effects of glucose and insulin on insulin resistance. Rizk NM, et al. **Mol Genet Metab** 1998 Sep;65(1):44–50

Glucose metabolism in Chlamydia trachomatis: the 'energy parasite' hypothesis revisited. Iliffe-Lee ER, et al. **Mol Microbiol** 1999 Jul;33(1):177–87

A Saccharomyces cerevisiae G-protein coupled receptor, Gpr1, is specifically required for glucose activation of the cAMP pathway during the transition to growth on glucose. Kraakman L, et al. **Mol Microbiol** 1999 Jun;32(5):1002–12

Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Sánchez C, et al. **Mol Pharmacol** 1998 Nov;54(5):834–43

Metabolism of glucose, pyruvate, and glutamine during the maturation of oocytes derived from pre-pubertal and adult cows. Steeves TE, et al. **Mol Reprod Dev** 1999 Sep; 54(1):92–101

Participation of the pyrazine cation radical in the formation of mutagens in the reaction of glucose/glycine/creatinine. Kikugawa K, et al. **Mutat Res** 1999 Jul 21;444(1):133–44

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes [see comments] Cline GW, et al. **N Engl J Med** 1999 Jul 22;341(4):240–6. Comment in: N Engl J Med 1999 Jul 22;341(4):248–57.

Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus [comment] Shepherd PR, et al. **N Engl J Med** 1999 Jul 22;341(4):248–57 (103 ref.). Comment on: N Engl J Med 1999 Jul 22;341(4):240–6.

Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats [see comments] Aitman TJ, et al. **Nat Genet** 1999 Jan;21(1):76–83. Comment in: Nat Genet 1999 Jan;21(1):61–2.

Risk of developing diabetic nephropathy is not associated with synergism between the angiotensin II (type 1) receptor C1166 allele and poor glycaemic control. Savage DA, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):891–4

Age-related shift in brain region activity during successful memory performance. Hazlett EA, et al. **Neurobiol Aging** 1998 Sep–Oct;19(5):437–45

Post-training glucose administration attenuates forgetting of passive-avoidance conditioning in 18-day-old rats. Flint RW Jr, et al. **Neurobiol Learn Mem** 1999 Jul;72(1):62–7

AF-DX 116, a presynaptic muscarinic receptor antagonist, potentiates the effects of glucose and reverses the effects of insulin on memory. Kopf SR, et al. **Neurobiol Learn Mem** 1998 Nov;70(3):305–13

Does the 'mystery of the extra glucose' during CNS activation reflect glutamate synthesis? Hertz L, et al. **Neurochem Int** 1999 Jan;34(1):71–5 (35 ref.)

Attachment of PC12 cells to adhesion substratum induces the accumulation of glucose transporters (GLUTs) and stimulates glucose metabolism. Dwyer DS, et al. **Neurochem Res** 1998 Aug;23(8):1107–16

Defective glucose transport across brain tissue barriers: a newly recognized neurological syndrome. Klepper J, et al. **Neurochem Res** 1999 Apr;24(4):587–94

Impaired effective cortical connectivity in vegetative state: preliminary investigation using PET. Laureys S, et al. **Neuroimage** 1999 Apr;9(4):377–82

Cerebral metabolism of the remote area after epilepsy surgery. Akimura T, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):16–25; discussion 25–7

Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Bohnen NI, et al. **Neurology** 1999 Feb;52(3):541–6

Effects of repeated high-dose methamphetamine on local cerebral glucose utilization in rats. Huang YH, et al. **Neuropsychopharmacology** 1999 Sep;21(3):427–34

Effect of inhibition of glucose and fat metabolism on galanin-R1 receptor mRNA levels in the rat hypothalamic paraventricular and supraoptic nuclei. Gorbatyuk O, et al. **Neuroreport** 1998 Nov 16;9(16):3565–9

Cerebral glucose metabolism in unilateral entorhinal cortex-lesioned rats: an animal PET study. Hayashi T, et al. **Neuroreport** 1999 Jul 13;10(10):2113–8

Decreased glucose transporter densities, rate constants and glucose utilization in visual structures of rat brain during chronic visual deprivation. Duelli R, et al. **Neurosci Lett** 1998 Jun 26;250(1):49–52

Brain water content, glucose transporter densities and glucose utilization after 3 days of water deprivation in the rat. Duelli R, et al. **Neurosci Lett** 1999 Aug 13;271(1):13–6

Issues in measuring glucose metabolism of rat brain using PET: the effect of harderian glands on the frontal lobe. Fukuyama H, et al. **Neurosci Lett** 1998 Oct 16; 255(2):99–102

Labeling of N-acetylaspartate and N-acetylaspartylglutamate in rat neocortex, hippocampus and cerebellum from [1-13C]glucose. Tyson RL, et al. **Neurosci Lett** 1998 Jul 31;251(3):181–4

Tc(V)-DMS tumor localization mechanism: a pH-sensitive Tc(V)-DMS-enhanced target/nontarget ratio by glucose-mediated acidosis. Horiuchi K, et al. **Nucl Med Biol** 1998 Aug;25(6):549–55

The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Waki A, et al. **Nucl Med Biol** 1998 Oct;25(7):593–7

Regional glucose utilization in infarcted and remote myocardium: its relation to coronary anatomy and perfusion. Fragasso G, et al. **Nucl Med Commun** 1998 Jul; 19(7):625–32

Binding of the glucose-dependent Mig1p repressor to the GAL1 and GAL4 promoters in vivo:-regulationby glucose and chromatin structure. Frolova E, et al. **Nucleic Acids Res** 1999 Mar 1;27(5):1350–8

Metabolic complications of HIV disease. Swindells S. **Nurse Pract** 1999 Feb;24(2):125–6, 129 (13 ref.)

Glycemic index, nutrient density, and promotion of aberrant crypt foci in rat colon. Corpet DE, et al. **Nutr Cancer** 1998; 32(1):29–36

Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose [published erratum appears in Obes Res 1999 Mar;7(2):232] Axen KV, et al. **Obes Res** 1999 Jan;7(1):83–9

Adrenalectomy reduces adiposity by decreasing food efficiency, not direct effects on white adipose tissue. Edens NK, et al. **Obes Res** 1999 Jul;7(4):395–401

Liver function tests and glucose and lipid metabolism in growth-restricted fetuses. Roberts A, et al. **Obstet Gynecol** 1999 Aug;94(2):290–4

Activity of key enzymes in glucose catabolism during the growth and metacyclogenesis of Leishmania infantum. Louassini M, et al. **Parasitol Res** 1999 Apr;85(4):300–6

Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Wishart JM, et al. **Peptides** 1998;19(6):1049–53

Multiphasic consequences of the acute administration of ethanol on cerebral glucose metabolism in the rat. Lyons D, et al. **Pharmacol Biochem Behav** 1998 Oct;61(2):201–6

Effects of two aldose reductase inhibitors upon sorbitol output, D-glucose metabolism and insulin release in islets from normal and hereditarily diabetic rats. Flores LE, et al. **Pharmacol Res** 1998 Jun;37(6):493–6

The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. Tanira MO, et al. **Pharmacol Res** 1999 May;39(5):349–56

Purification and characterization of a mannose/glucose-specific lectin from Castanea crenata. Nomura K, et al. **Phytochemistry** 1998 Oct;49(3):667–73

Diffusive transfer of water and glucose across the chorionic plate of the isolated human term placenta. Schröder HJ, et al. **Placenta** 1999 Jan;20(1):59–63

Electrical properties of the intestinal mucosa of the chicken and the effects of luminal glucose. Amat C, et al. **Poult Sci** 1999 Aug;78(8):1126–31

Contribution of glucose transport to the control of the glycolytic flux in Trypanosoma brucei. Bakker BM, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10098–103

Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Shen J, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8235–40

Efficient export of the glucose transporter Hxt1p from the endoplasmic reticulum requires Gsf2p. Sherwood PW, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7415–20

Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3alpha-deficient mice. Shih DQ, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10152–7

Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats. Park SC, et al. **Proc Soc Exp Biol Med** 1999 Jul; 221(3):224–33

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Turner NC, et al. **Prog Drug Res** 1998;51:33–94 (370 ref.)

Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Dwyer DS, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Jan; 23(1):69–80

A mathematical model for the analysis of cross-sectional

brain glucose metabolism data in children. Muzik O, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 May; 23(4):589–600

Effect of a restricted diet on the metabolism of glucose in uteri isolated from immature rats: influence of indomethacin and nordihydroguaiaretic acid. Finkelberg AB, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Sep; 59(3):175–9

Effects of gliquidone on D-glucose metabolism in rat pancreatic islets depend on hexose concentration. Picton S, et al. **Res Commun Mol Pathol Pharmacol** 1998 Nov; 102(2):99–112

Transport of glucose by a phosphoenolpyruvate:mannose phosphotransferase system in Pasteurella multocida. Binet MR, et al. **Res Microbiol** 1998 Feb;149(2):83–94

Assessing insulin sensitivity in the cat: evaluation of the hyperinsulinemic euglycemic clamp and the minimal model analysis. Petrus DJ, et al. **Res Vet Sci** 1998 Sep–Oct; 65(2):179–81

Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Buchsbaum MS, et al. **Schizophr Bull** 1998;24(3):343–64 (165 ref.)

Brain glucose metabolism with [18F]-fluorodeoxyglucose and positron emission tomography before and after surgical resection of epileptogenic cavernous angiomas. Gogoleva SM, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):225–8

Uncoupling of oxygen and glucose metabolism in persistent crossed cerebellar diaschisis. Yamauchi H, et al. **Stroke** 1999 Jul;30(7):1424–8

Putative roles of melatonin in glucose regulation. Van Cauter E. **Therapie** 1998 Sep–Oct;53(5):467–72 (36 ref.)

Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Boerner AR, et al. **Thyroid** 1998 Sep; 8(9):765–72

Non-radioisotopic glucose turnover in children with falciparum malaria and enteric fever. Singh B, et al. **Trans R Soc Trop Med Hyg** 1998 Sep–Oct;92(5):532–7

Effect of cyclosporine on glucose tolerance in streptozotocin-diabetic rats: cyclosporine may deteriorate insulin sensitivity. Kang JS, et al. **Transplant Proc** 1999 Aug;31(5):2150–3

Feasting, fasting and fermenting. Glucose sensing in yeast and other cells. Johnston M. **Trends Genet** 1999 Jan; 15(1):29–33 (82 ref.)

Glucose uptake in Oesophagostomum dentatum and the effect of oxfendazole. Petersen MB, et al. **Vet Parasitol** 1998 Dec 31;80(2):159–66

Dynamic responses of reserve carbohydrate metabolism under carbon and nitrogen limitations in Saccharomyces cerevisiae. Parrou JL, et al. **Yeast** 1999 Feb;15(3):191–203

Transcription of the HXT4 gene is regulated by Gcr1p and Gcr2p in the yeast S. cerevisiae. Türkel S, et al. **Yeast** 1999 Aug;15(11):1045–57

Multiple regulatory proteins mediate repression and activation by interaction with the yeast Mig1 binding site. Wu J, et al. **Yeast** 1998 Aug;14(11):985–1000

Glucose metabolism during the final stage of human oocyte maturation: genetic expression of hexokinase, glucose phosphate isomerase and phosphofructokinase. el Mouatassim S, et al. **Zygote** 1999 Feb;7(1):45–50

[Glucose-galactose malabsorption. The first reported case in Denmark] Boisen KA, et al. **Ugeskr Laeger** 1999 Jun 28;161(26):4008–9 (Eng. Abstr.) **(Dan)**

[From the glycogenic function of the liver to gene regulation by glucose] Kahn A. **C R Seances Soc Biol Fil** 1998; 192(5):813–27 (39 ref.) (Eng. Abstr.) **(Fre)**

[Hexose transporters in humans: their role in insulin sensitivity of peripheral tissues] Bastard JP, et al. **Rev Med Interne** 1998 Feb;19(2):108–18 (67 ref.) (Eng. Abstr.) **(Fre)**

[Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes] Scheen AJ, et al. **Rev Med Liege** 1999 Jun;54(6):535–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Functional imaging in idiopathic generalized epilepsy] Ryvlin P, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):691–3 (13 ref.) (Eng. Abstr.) **(Fre)**

[Skin aging--a problem of nutritional care?] Boschmann M, et al. **Forsch Komplementarmed** 1999 Feb;6(1):54–5 **(Ger)**

[Investigations on the effect of "ecstasy" on cerebral glucose metabolism: an 18-FDG PET study] Schreckenberger M, et al. **Nuklearmedizin** 1998;37(8):262–7 (Eng. Abstr.) **(Ger)**

[PET evaluation of glucose metabolism in cancer] Yasuda S, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):756–61 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes] Kato M. **Hokkaido Igaku Zasshi** 1998 Nov;73(6):613–25 (Eng. Abstr.) **(Jpn)**

[Studies on aging through analysis of the glucose metabolism related to the ATP--production of the senescence accelerated mouse (SAM)] Shimano Y. **Hokkaido Igaku Zasshi** 1998 Nov;73(6):557–69 (Eng. Abstr.) **(Jpn)**

[Transepithelial transport of glucose] Takata K. **Kaibogaku Zasshi** 1998 Oct;73(5):485–95 (62 ref.) (Eng. Abstr.) **(Jpn)**

[The relationship between discrepant areas on 201TlCl/123I-BMIPP myocardial scintigraphy, local wall motion, and glucose metabolism in patients with myocardial infarction] Tanaka A. **Kaku Igaku** 1998 Nov;35(9):857–69 (Eng. Abstr.) **(Jpn)**

[Ibudilast prevents oxygen-glucose deprivation-induced oligodendroglial injury] Yoshioka A, et al. **No To Shinkei** 1999 Jan;51(1):49–54 (Eng. Abstr.) **(Jpn)**

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16–34 (49 ref.) (Eng. Abstr.) **(Jpn)**

[A new method of evaluating the utilization of nutrients (carbohydrates, amino acids and fatty acids) on the plastic and energy goals in the animal body] Virovets OA, et al. **Vopr Pitan** 1998;(3):14–7 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Approaches to population kinetic analysis with application to metabolic studies. Vicini P, et al. **Adv Exp Med Biol** 1998;445:103–13

Modeling intermittent digesta flow to calculate glucose uptake capacity of the bovine small intestine. Cant JP, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1442–51

Prior exercise increases net hepatic glucose uptake during a glucose load. Galassetti P, et al. **Am J Physiol** 1999 Jun; 276(6 Pt 1):E1022–9

Effect of fast duration on disposition of an intraduodenal glucose load in the conscious dog. Galassetti P, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E543–52

Cytokine-induced glucose uptake in skeletal muscle: redox regulation and the role of alpha-lipoic acid. Khanna S, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1327–33

Magnitude of functional adaptation after intestinal resection. O'Connor TP, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1265–75

Impaired stimulation of intestinal glucose absorption via hepatoenteral nerves in streptozotocin-diabetic rats. Stümpel F, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G285–91

Glucose uptake in horses with polysaccharide storage myopathy. De La Corte FD, et al. **Am J Vet Res** 1999 Apr;60(4):458–62

Safe pre-operative fasting times after milk or clear fluid in children. A preliminary study using real-time ultrasound. Sethi AK, et al. **Anaesthesia** 1999 Jan;54(1):51–9

Influence of betaine and salinomycin on intestinal absorption of methionine and glucose and on the ultrastructure of intestinal cells and parasite developmental stages in chicks infected with Eimeria acervulina. Augustine PC, et al. **Avian Dis** 1999 Jan–Mar;43(1):89–97

Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Wang Q, et al. **Biochem J** 1998 May 1;331 (Pt 3):917–28

In vivo measurements of glucose absorption in preterm infants. Shulman RJ. **Biol Neonate** 1999 Jul;76(1):10–8

Estimation of the initial distribution volume of glucose by an incremental plasma glucose level at 3 min after i.v. glucose in humans. Hirota K, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):361–4

Effect of Walker 256 tumor growth on intestinal absorption of leucine, methionine and glucose in newly weaned and mature rats. Gomes-Marcondes MC, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1345–8

The glucose transport in retinal pigment epithelium is via passive facilitated diffusion. To CH, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Dec; 121(4):441–4

High glucose uptake by adipocytes in a type 1 diabetic patient with a partial 'honeymoon' period. Arrieta-Blanco FJ, et al. **Diabet Med** 1998 Sep;15(9):788–90

Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes. Forbes A, et al. **Diabetes** 1998 Dec;47(12):1915–9

Influence of obstructive jaundice on jejunal absorption of glucose, electrolytes, and vitamin A in rats. Borges EL, et al. **Dig Dis Sci** 1998 Oct;43(10):2196–200

Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. van Dokkum W, et al. **Eur J Clin Nutr** 1999 Jan;53(1):1–7

Metformin interaction with insulin-regulated glucose uptake, using the Xenopus laevis oocyte model expressing the mammalian transporter GLUT4. Detaille D, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):127–36

LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Prasad RK, et al. **Eur J Pharmacol** 1999 Jan 29;366(1):101–9

Age-related changes on glucose transport and utilization of human erythrocytes: effect of oxidative stress. Güven M, et al. **Gerontology** 1999;45(2):79–82

Acute increase, stimulated by prostaglandin E2, in glucose absorption via the sodium dependent glucose transporter-1 in rat intestine. Scholtka B, et al. **Gut** 1999 Apr;44(4):490–6

YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Shimaya A, et al. **Horm Metab Res** 1998 Sep; 30(9):543–8

Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Ceddia RB, et al. **Int J Obes Relat Metab Disord** 1999 Jan;23(1):75–82

Activation of beta3-adrenoceptors by exogenous dopamine to lower glucose uptake into rat adipocytes. Lee TL, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):86–90

Identification of a gene in Staphylococcus xylosus encoding a novel glucose uptake protein. Fiegler H, et al. **J Bacteriol** 1999 Aug;181(16):4929–36

Measurement of myocardial glucose uptake in patients with ischemic cardiomyopathy: application of a new quantitative method using regional tracer kinetic information. Wiggers H, et al. **J Nucl Med** 1999 Aug;40(8):1292–300

Reduced glucose consumption in the curly tail mouse does not initiate the pathogenesis leading to spinal neural tube defects. Peeters MC, et al. **J Nutr** 1998 Oct;128(10):1819–28

A new insulin-mimetic vanadyl complex, (N-pyridylmethylaspartate)oxovanadium(IV) with VO(N2O2) coordination mode, and evaluation of its effect on uptake of D-glucose by Ehrlich ascites tumour cells. Tawa R, et al. **J Pharm Pharmacol** 1999 Feb;51(2):119–24

Carrier-mediated transport systems for glucose in mucosal cells of the human oral cavity. Oyama Y, et al. **J Pharm Sci** 1999 Aug;88(8):830–4

Hexose transport in the apical and basolateral membranes of enterocytes in chickens adapted to high and low NaCl intakes. Garriga C, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):189–99

TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Inoki K, et al. **Kidney Int** 1999 May;55(5):1704–12

Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. Lee YC, et al. **Metabolism** 1998 Dec;47(12):1468–71

Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Kotani K, et al. **Mol Cell Biol** 1998 Dec;18(12):6971–82

Enhanced release of norepinephrine in rat hippocampus during spontaneous alternation tests. Men D, et al. **Neurobiol Learn Mem** 1999 May;71(3):289–300

Ethanol inhibits G-protein-mediated glucose uptake by C6 glioma cells. Singh SP, et al. **Neuroreport** 1999 Feb 25; 10(3):595–9

PHARMACOLOGY

Sodium at high concentrations increases glucose-induced insulin secretion in the perfused rat pancreas. Mokuda O, et al. **Acta Diabetol** 1998 Oct;35(3):154–7

Effects of magnesium and glucose, insulin, potassium (GIK) solution on the action potential parameters of guinea-pig atrial muscle. Ingemansson MP, et al. **Acta Physiol Scand** 1998 Oct;164(2):173–9

Effects of intravenous infusion of glucose and pancreatic glucagon on abomasal function in dairy cows. Holtenius K, et al. **Acta Vet Scand** 1998;39(2):291–300

Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):89–94

Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. Ahrén B, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E93–102

Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Amiri F, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F691–9

Voltage-dependent entry and generation of slow Ca2+ oscillations in glucose-stimulated pancreatic beta-cells. Dryselius S, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E512–8

Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Horney MJ, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):F1045–53

Stimulation by 2-deoxy-D-glucose tetraacetates of hormonal secretion from the perfused rat pancreas. Leclercq-Meyer V, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E689–96

Glucose induces an acute increase of superoxide dismutase activity in incubated rat pancreatic islets. Oliveira HR, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C507–10

Glucose-stimulated insulin secretion is not obligatorily linked to an increase in O2 consumption in betaHC9 cells. Papas KK, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1100–6

Measurement of gluconeogenesis and mass isotopomer analysis based on [U-(13)C]glucose. Radziuk J, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E199–207

Glucose-induced desensitization of the pancreatic beta-cell is species dependent. Zawalich WS, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E917–24

Insulin-like growth factor-1 receptors mediate infragenicular vascular smooth muscle cell proliferation in response to glucose and insulin not by insulin receptors. Avena R, et al. **Am J Surg** 1999 Aug;178(2):156–61

Effect of increasing glucose concentrations on Sertoli cell viability in the nonobese diabetic mouse. Gondos B, et al. **Ann Clin Lab Sci** 1998 Jul–Aug;28(4):236–41

Autocrine action of PACAP in islets augments glucose-induced insulin secretion. Yada T, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:451–7

The absence of effect of glucose on memory is associated with low susceptibility to the amnestic effects of scopolamine in a strain of mice. Messier C.
Behav Brain Res 1998 Nov;96(1-2):47-57

Effect of glucose, glucose regulation, and word imagery value on human memory. Messier C, et al.
Behav Neurosci 1999 Jun;113(3):431-8

Glucose protection from MPP+-induced apoptosis depends on mitochondrial membrane potential and ATP synthase. Chalmers-Redman RM, et al.
Biochem Biophys Res Commun 1999 Apr 13;257(2):440-7

Nitric oxide does not initiate but potentiates glucose-induced insulin secretion in pancreatic beta-cells. Ding Y, et al.
Biochem Biophys Res Commun 1998 Oct 29;251(3):699-703

PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion. Filipsson K, et al.
Biochem Biophys Res Commun 1999 Mar 24;256(3):664-7

Synchronization of glucose-induced Ca2+ transients in pancreatic beta-cells by a diffusible factor. Grapengiesser E, et al. **Biochem Biophys Res Commun** 1999 Jan 19; 254(2):436-9

An aldose reductase inhibitor prevents the glucose-induced increase in PDGF-beta receptor in cultured rat aortic smooth muscle cells. Kasuya Y, et al.
Biochem Biophys Res Commun 1999 Aug 11;261(3):853-8

Gpr1p, a putative G-protein coupled receptor, regulates glucose-dependent cellular cAMP level in yeast Saccharomyces cerevisiae. Yun CW, et al.
Biochem Biophys Res Commun 1998 Nov 9;252(1):29-33

Transcriptional regulation of the human asparagine synthetase gene by carbohydrate availability.
Barbosa-Tessmann IP, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):151-8

Mode of regulation of the extracellular signal-regulated kinases in the pancreatic beta-cell line MIN6 and their implication in the regulation of insulin gene transcription. Benes C, et al. **Biochem J** 1999 May 15;340 (Pt 1):219-25

Glucose induces expression of stearoyl-CoA desaturase in 3T3-L1 adipocytes. Jones BH, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):405-8

Glucose and thyroid hormone co-regulate the expression of the intestinal fructose transporter GLUT5.
Matosin-Matekalo M, et al. **Biochem J** 1999 Apr 15;339 (Pt 2):233-9

Two HNF-1 binding sites govern the glucose repression of the human sucrase-isomaltase promoter. Rodolosse A, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):115-23

Regulation of mammalian pyruvate dehydrogenase alpha subunit gene expression by glucose in HepG2 cells. Tan J, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):49-56

Glucose- and phorbol ester-induced insulin secretion in human insulinoma cells--association with protein kinase C activation. Miura A, et al. **Biochem Mol Biol Int** 1998 Nov;46(4):739-45

Glucose regulation of growth hormone secretion in lactating sheep. Faulkner A. **Biochem Soc Trans** 1998 Nov;26(4):S387

The PLC1 encoded phospholipase C in the yeast Saccharomyces cerevisiae is essential for glucose-induced phosphatidylinositol turnover and activation of plasma membrane H+-ATPase. Coccetti P, et al.
Biochim Biophys Acta 1998 Oct 21;1405(1-3):147-54

Effects of high glucose on the hypoxic isolated guinea pig heart: interactions with ATP-dependent K+ channels? Gillessen S, et al. **Biochim Biophys Acta** 1999 Apr 19; 1427(2):256-64

Obese mice have higher insulin receptor levels in the hepatocyte cell nucleus following insulin stimulation in vivo with an oral glucose meal. Gletsu NA, et al.
Biochim Biophys Acta 1999 Aug 30;1454(3):251-60

Delayed labelling of brain glutamate after an intra-arterial [13C]glucose bolus: evidence for aerobic metabolism of guinea pig brain glycogen store. Griffin JL, et al.
Biochim Biophys Acta 1999 Jul 8;1450(3):297-307

Glucose and non-glucidic nutrients exert permissive effects on 2-keto acid regulation of pancreatic beta-cell function. McClenaghan NH, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):110-8

High glucose concentrations inhibit glucose phosphorylation, but not glucose transport, in human endothelial cells. Viñals F, et al. **Biochim Biophys Acta** 1999 Jun 8;1450(2):119-29

Competitive RT-PCR for measuring metalloproteinase gene expression in human mesangial cells exposed to a hyperglycemic environment. Death AK, et al.
Biotechniques 1999 Sep;27(3):512-8, 520

Effects of pulse addition of carbon sources on continuous cultivation of Escherichia coli containing a recombinant E. coli gapA gene. Gschaedler A, et al.
Biotechnol Bioeng 1999 Jun 20;63(6):712-20

Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. Anello M, et al.
Br J Pharmacol 1999 Aug;127(8):1883-91

Effects of glucose and related substrates on the recovery of the electrical activity of gonadotropin-releasing hormone pulse generator which is decreased by insulin-induced hypoglycemia in the estrogen-primed ovariectomized rat. He D, et al. **Brain Res** 1999 Feb 27;820(1-2):71-6

Effects of changes in glucose concentration on synaptic plasticity in hippocampal slices. Kamal A, et al.
Brain Res 1999 Apr 10;824(2):238-42

Reduced glucose-induced neuronal activation in the hypothalamus of diet-induced obese rats. Levin BE, et al.
Brain Res 1998 Oct 19;808(2):317-9

Intra-septal injections of glucose and glibenclamide attenuate galanin-induced spontaneous alternation performance deficits in the rat. Stefani MR, et al. **Brain Res** 1998 Nov 30;813(1):50-6

Higher sensitivity of CA1 synapses to aglycemia in streptozotocin-diabetic rats is age-dependent. Tekkök S, et al. **Brain Res** 1998 Dec 7;813(2):268-73

Glucose and tolbutamide trigger transients of Ca2+ in single pancreatic beta-cells exposed to tetraethylammonium. Eberhardson M, et al. **Cell Calcium** 1999 May;25(5):355-60

In vivo evaluation of glucose permeability of an immunoisolation device intended for islet transplantation: a novel application of the microdialysis technique. Rafael E, et al. **Cell Transplant** 1999 May-Jun;8(3):317-26

The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Bialik S, et al. **Circ Res** 1999 Sep 3;85(5):403-14

Liver freezing response of the freeze-tolerant wood frog, Rana sylvatica, in the presence and absence of glucose. I. Experimental measures. Devireddy RV, et al.
Cryobiology 1999 Jun;38(4):310-26

Liver freezing response of the freeze-tolerant wood frog, Rana sylvatica, in the presence and absence of glucose. II. Mathematical modeling. Devireddy RV, et al.
Cryobiology 1999 Jun;38(4):327-38

Modulation of VEGF production by pH and glucose in retinal Müller cells. Brooks SE, et al. **Curr Eye Res** 1998 Sep;17(9):875-82

The effect of elevated extracellular glucose on migration, adhesion and proliferation of SV40 transformed human corneal epithelial cells. McDermott AM, et al.
Curr Eye Res 1998 Sep;17(9):924-32

Glucose-mediated regulation of transforming growth factor-beta (TGF-beta) and TGF-beta receptors in human retinal endothelial cells. Pascal MM, et al.
Curr Eye Res 1999 Aug;19(2):162-70

Glucose repression on RIM1, a gene encoding a mitochondrial single-stranded DNA-binding protein, in Saccharomyces cerevisiae: a possible regulation at pre-mRNA splicing. Li Z, et al. **Curr Genet** 1998 Dec; 34(5):351-9

Interleukin 1beta mediates the effect of high D-glucose on the secretion of TNF-alpha by mouse uterine epithelial cells. Pampfer S, et al. **Cytokine** 1999 Jul;11(7):500-9

Long-term regulation of lipolysis and hormone-sensitive lipase by insulin and glucose. Botion LM, et al.
Diabetes 1999 Sep;48(9):1691-7

Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Chan CB, et al. **Diabetes** 1999 Jul;48(7):1482-6

Beta-cell hypertrophy in fa/fa rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. Chan CB, et al. **Diabetes** 1999 May; 48(5):997-1005

Intermediate expansions of a GAA repeat in the frataxin gene are not associated with type 2 diabetes or altered glucose-induced beta-cell function in Danish Caucasians. Dalgaard LT, et al. **Diabetes** 1999 Apr;48(4):914-7

Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic beta-cells recorded in vivo. Fernandez J, et al.
Diabetes 1999 Apr;48(4):754-7

Glucose regulation of glutaminolysis and its role in insulin secretion. Gao ZY, et al. **Diabetes** 1999 Aug;48(8):1535-42

Augmentation of Ca2+-stimulated insulin release by glucose and long-chain fatty acids in rat pancreatic islets: free fatty acids mimic ATP-sensitive K+ channel-independent insulinotropic action of glucose. Komatsu M, et al.
Diabetes 1999 Aug;48(8):1543-9

Shared biochemical properties of glucotoxicity and lipotoxicity in islets decrease citrate synthase activity and increase phosphofructokinase activity. Liu YQ, et al.
Diabetes 1998 Dec;47(12):1889-93

Glucose entrainment of high-frequency plasma insulin oscillations in control and type 2 diabetic subjects. Mao CS, et al. **Diabetes** 1999 Apr;48(4):714-21

Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Marshak S, et al. **Diabetes** 1999 Jun;48(6):1230-6

Altered hypothalamic function in response to glucose ingestion in obese humans. Matsuda M, et al. **Diabetes** 1999 Sep;48(9):1801-6

Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stable-labeled minimal model approach. Nagasaka S, et al. **Diabetes** 1999 May;48(5):1054-60

The K+-ATP channel-independent pathway of regulation of insulin secretion by glucose: in search of the underlying mechanism. Sato Y, et al. **Diabetes** 1998 Nov; 47(11):1713-21

Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Singh R, et al. **Diabetes** 1999 Oct;48(10):2066-73

Role for heparin-binding growth factors in glucose-induced vascular dysfunction. Stephan CC, et al. **Diabetes** 1998 Nov;47(11):1771-8

cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets. Yajima H, et al.
Diabetes 1999 May;48(5):1006-12

Hypothalamic glucose sensor: similarities to and differences from pancreatic beta-cell mechanisms. Yang XJ, et al.
Diabetes 1999 Sep;48(9):1763-72

Long-term culture of free or encapsulated islets isolated from specific pathogen-free (SPF) pigs. Duvivier V, et al.
Diabetes Metab 1998 Dec;24(6):517-22

Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus. Paquot N, et al. **Diabetes Metab** 1998 Dec;24(6):523-8

Effects of parathyroid hormone infusion on glucose tolerance and glucose-stimulated insulin secretion in normal and uremic rats. Chen SM, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):85-94

Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Hou X, et al.
Diabetologia 1999 Feb;42(2):188-94

Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Jones SC, et al. **Diabetologia** 1999 Sep;42(9):1113-9

Glucose induces early growth response gene (Egr-1) expression in pancreatic beta cells. Josefsen K, et al.
Diabetologia 1999 Feb;42(2):195-203

The effects of glucose-induced oxidative stress on growth and extracellular matrix gene expression of vascular smooth muscle cells. Sharpe PC, et al. **Diabetologia** 1998 Oct; 41(10):1210-9

The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain. Todor IN, et al.
Drugs Exp Clin Res 1998;24(5-6):247-52

Glucose and maltodextrin in enteral diets have different effects on jejunal absorption of nutrients, sodium and water and on flow rate in mini pigs. Weber E, et al.
DTW Dtsch Tierarztl Wochenschr 1998 Dec;105(12):446-9

Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of the human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and Gö 6976-insensitive pathway. Furukawa N, et al. **Endocr J** 1999 Feb; 46(1):43-58

Rapid transient increase of biliary triiodothyronine excretion during short-term infusion of glucose and arginine in rats. Langer P, et al. **Endocr Regul** 1999 Jun;33(2):83-9

Glucose rapidly decreases plasma membrane GLUT4 content in rat skeletal muscle. Marette A, et al. **Endocrine** 1999 Feb;10(1):13-8

Chronic exposure to high glucose concentrations increases proglucagon messenger ribonucleic acid levels and glucagon release from InR1G9 cells. Dumonteil E, et al.
Endocrinology 1999 Oct;140(10):4644-50

Glucose regulates expression of inositol 1,4,5-trisphosphate receptor isoforms in isolated rat pancreatic islets. Lee B, et al. **Endocrinology** 1999 May;140(5):2173-82

Identification of an adipocyte-specific negative glucose response region in the cytosolic aspartate aminotransferase gene. Plee-Gautier E, et al. **Endocrinology** 1998 Dec; 139(12):4936-44

Glucose-induced preproinsulin gene expression is inhibited by the free fatty acid palmitate. Ritz-Laser B, et al.
Endocrinology 1999 Sep;140(9):4005-14

Dysfunction of the islet lysosomal system conveys impairment of glucose-induced insulin release in the diabetic GK rat. Salehi A, et al. **Endocrinology** 1999 Jul; 140(7):3045-53

Glucose regulation of insulin secretion independent of the opening or closure of adenosine triphosphate-sensitive K+ channels in beta cells. Sato Y, et al. **Endocrinology** 1999 May;140(5):2252-7

High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Manduteanu I, et al.
Endothelium 1999;6(4):315-24

Transcriptional regulation of fatty acid synthase gene by insulin/glucose, polyunsaturated fatty acid and leptin in hepatocytes and adipocytes in normal and genetically obese rats. Fukuda H, et al. **Eur J Biochem** 1999 Mar; 260(2):505-11

Effect of glucose and deoxyglucose on the redistribution of calcium in ehrlich ascites tumour and Zajdela hepatoma cells and its consequences for mitochondrial energetics. Further arguments for the role of Ca(2+) in the mechanism of the crabtree effect. Wojtczak L, et al.
Eur J Biochem 1999 Jul;263(2):495-501

Effect of glucose, sucrose and fructose on plasma glucose and insulin responses in normal humans: comparison with white bread. Lee BM, et al. **Eur J Clin Nutr** 1998 Dec; 52(12):924-8

L-arginine stimulation of glucose-induced insulin secretion through membrane depolarization and independent of nitric oxide. Thams P, et al. **Eur J Endocrinol** 1999 Jan; 140(1):87-93

Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Greene DA, et al.
Eur J Pharmacol 1999 Jun 30;375(1-3):217-23 (85 ref.)

Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide. Laghmich A, et al.
Eur J Pharmacol 1998 May 8;348(2-3):265-70

The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Lupi

R, et al. **Eur J Pharmacol** 1999 Jan 8;364(2-3):205-9

JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Ohta T, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):91-9

Glucagon amplifies tetrodotoxin-resistant Na+ oscillations in glucose-stimulated pancreatic beta-cells. Grapengiesser E. **Exp Clin Endocrinol Diabetes** 1998;106(4):303-9

Effect of high-glucose concentrations on the expression of collagens and fibronectin by fibroblasts in culture. Benazzoug Y, et al. **Exp Gerontol** 1998 Aug;33(5):445-55

Effect of acute glucose depletion following glucose excess on surfactant phospholipid synthesis in developing fetal lung. Marwah GS, et al. **Exp Lung Res** 1999 Jun; 25(4):291-302

Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation. Burkhart KK, et al. **Exp Neurol** 1998 Dec; 154(2):464-72

Volumetric change of the lateral ventricles in the human brain following glucose loading. Puri BK, et al. **Exp Physiol** 1999 Jan;84(1):223-6

Glucose induces glucose 6-phosphatase hydrolytic subunit gene transcription in an insulinoma cell line (INS-1). Schmoll D, et al. **FEBS Lett** 1999 Jan 22;443(1):53-6

NADH reoxidation does not control glycolytic flux during exposure of respiring Saccharomyces cerevisiae cultures to glucose excess. Brambilla L, et al. **FEMS Microbiol Lett** 1999 Feb 15;171(2):133-40

Glucose and phosphate--important or unimportant in culture media for embryos? [letter; comment] Quinn P. **Fertil Steril** 1998 Oct;70(4):782-3. Comment on: Fertil Steril 1998 May;69(5):970-1.

Calcium vs. iron-mediated processes in hydrogen peroxide toxicity to L929 cells: effects of glucose. Lomonosova EE, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):493-503

Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Paget C, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):121-9

Hormone coexpression in the adult toad endocrine pancreas: double-label immunofluorescence under basal conditions and after glucose injection. Luna G, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):29-36

Induction of Fos immunoreactivity by acute glucose deprivation in the rat caudal brainstem: relation to NADPH diaphorase localization. Briski KP. **Histochem Cell Biol** 1999 Mar;111(3):229-33

Insulin-like growth factor-I prevents apoptosis in sympathetic neurons exposed to high glucose. Russell JW, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):90-6

Potentiation of glucose-induced insulin secretion by fagomine, a pseudo-sugar isolated from mulberry leaves. Taniguchi S, et al. **Horm Metab Res** 1998 Nov; 30(11):679-83

Does glucose affect fertilization, development and pregnancy rates of human in-vitro fertilized oocytes? Barak Y, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:203-11

Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells. Hishikawa K, et al. **Hypertension** 1998 Dec;32(6):1011-5

Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Natarajan R, et al. **Hypertension** 1999 Jan;33(1 Pt 2):378-84

Glycated serum stimulation of macrophages in GK- and streptozotocin-rats for the proliferation of primary cultured smooth muscle cells of the aorta. Kimura I, et al. **Immunopharmacology** 1998 Aug;40(2):105-18

Effect of elevated glucose on contractile and relaxant response of aortic strips in Indian bonnet monkey (Macaca radiata radiata). Savithiri S, et al. **Indian J Exp Biol** 1998 Aug;36(8):780-5

Suppression of DNA synthesis of cultured mesothelial cells by supplemented albumin. Horiuchi T, et al. **Int J Artif Organs** 1998 Aug;21(8):451-6

Sweetener augmentation of serum triacylglycerol during a fat challenge test in humans. Singleton MJ, et al. **J Am Coll Nutr** 1999 Apr;18(2):179-85

High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: role of hyperosmolarity. Sitter T, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2005-12

Fattiviracin A1, a novel antiviral agent produced by Streptomyces microflavus strain No. 2445. II. Biological properties. Yokomizo K, et al. **J Antibiot (Tokyo)** 1998 Nov;51(11):1035-9

Glucose-induced acid tolerance appearing at neutral pH in log-phase Escherichia coli and its reversal by cyclic AMP. Rowbury RJ, et al. **J Appl Microbiol** 1998 Sep;85(3):615-20

Effect of tryptophan and of glucose on exercise capacity of horses. Farris JW, et al. **J Appl Physiol** 1998 Sep; 85(3):807-16

Low oxygen inhibits but complex high-glucose medium facilitates in vitro maturation of squirrel monkey oocyte-granulosa cell complexes. Yeoman RR, et al. **J Assist Reprod Genet** 1999 Feb;16(2):102-7

Superior mesenteric artery dilatation alone does not account for glucose-induced hypotension in human sympathetic denervation. Puvi-Rajasingham S, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):184-91

Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. Efanova IB, et al. **J Biol Chem** 1998 Dec 11;273(50):33501-7

Regulation of insulin-like growth factor-I and -II by glucose in primary cultures of fetal rat hepatocytes. Goya L, et al. **J Biol Chem** 1999 Aug 27;274(35):24633-40

The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. Han P, et al. **J Biol Chem** 1999 Aug 6;274(32):22337-44

Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. Potential role for strategically located mitochondria. Kennedy HJ, et al. **J Biol Chem** 1999 May 7;274(19):13281-91

Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells. Macfarlane WM, et al. **J Biol Chem** 1999 Jan 8;274(2):1011-6

Effect of glucose on endothelin-1-induced calcium transients in cultured bovine retinal pericytes. McGinty A, et al. **J Biol Chem** 1999 Sep 3;274(36):25250-3

The role of ubiquitin conjugation in glucose-induced proteolysis of Saccharomyces maltose permease. Medintz I, et al. **J Biol Chem** 1998 Dec 18;273(51):34454-62

Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. Murphy M, et al. **J Biol Chem** 1999 Feb 26;274(9):5830-4

Glucose decreases Na+,K+-ATPase activity in pancreatic beta-cells. An effect mediated via Ca2+-independent phospholipase A2 and protein kinase C-dependent phosphorylation of the alpha-subunit. Owada S, et al. **J Biol Chem** 1999 Jan 22;274(4):2000-8

Adenovirus-mediated knockout of a conditional glucokinase gene in isolated pancreatic islets reveals an essential role for proximal metabolic coupling events in glucose-stimulated insulin secretion. Piston DW, et al. **J Biol Chem** 1999 Jan 8;274(2):1000-4

Antiproliferative effect of elevated glucose in human microvascular endothelial cells. Kamal K, et al. **J Cell Biochem** 1998 Dec 15;71(4):491-501

Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. Kim HD, et al. **J Cell Physiol** 1999 Jul;180(1):97-104

Cerebral oxygen/glucose ratio is low during sensory stimulation and rises above normal during recovery: excess glucose consumption during stimulation is not accounted for by lactate efflux from or accumulation in brain tissue. Madsen PL, et al. **J Cereb Blood Flow Metab** 1999 Apr; 19(4):393-400

Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus. Basu R, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2314-9

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Freda PU, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3808-16

Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. Hostens K, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1386-90

Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. Igarashi M, et al. **J Clin Invest** 1999 Jan;103(2):185-95

Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. Nguyen MH, et al. **J Clin Microbiol** 1999 Jan;37(1):141-5

Glucose does not stimulate apoprotein B secretion from HepG2 cells because of insufficient stimulation of triglyceride synthesis. Jiang H, et al. **J Lipid Res** 1998 Nov; 39(11):2277-85

Glucose-induced period-doubling cascade in the electrical activity of pancreatic beta-cells. Deng B. **J Math Biol** 1999 Jan;38(1):21-78

Tyrosine kinases play a permissive role in glucose-induced insulin secretion from adult rat islets. Persaud SJ, et al. **J Mol Endocrinol** 1999 Feb;22(1):19-28

Glucose sensitivity of porcine and human islets in vitro. Brandhorst H, et al. **J Mol Med** 1999 Jan;77(1):90-2

Glucose minimally attenuates scopolamine-but not morphine-induced deficits on a water maze alternation task. Means LW, et al. **J Neural Transm** 1998; 105(10-12):1171-85

Down-regulation of neuronal nitric oxide synthase by nitric oxide after oxygen-glucose deprivation in rat forebrain slices. De Alba J, et al. **J Neurochem** 1999 Jan;72(1):248-54

Inhibition of high glucose-induced protein mono-ADP-ribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells. Di Giulio AM, et al. **J Neurosci Res** 1999 Sep 1;57(5):663-9

Effect of glucose administration on contusion volume after moderate cortical impact injury in rats. Cherian L, et al. **J Neurotrauma** 1998 Dec;15(12):1059-66

Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers. De Geeter F, et al. **J Nucl Med** 1998 Nov;39(11):1850-6

Glucose and amino acids interact with hormones to control expression of insulin-like growth factor-I and growth hormone receptor mRNA in cultured pig hepatocytes. Brameld JM, et al. **J Nutr** 1999 Jul;129(7):1298-306

Fetal vascular responses to maternal glucose administration in streptozocin-induced ovine diabetes mellitus. Dickinson JE, et al. **J Obstet Gynaecol Res** 1998 Oct;24(5):325-33

Glucose and glutamine gavage increase portal vein nitric oxide metabolite levels via adenosine A2b activation. Matheson PJ, et al. **J Surg Res** 1999 Jun 1;84(1):57-63

Superior protection in orthotopic rat lung transplantation with cyclic adenosine monophosphate and nitroglycerin-containing preservation solution. Kayano K, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):135-44

The additive effects of glucose and insulin on the proliferation of infragenicular vascular smooth muscle cells. Avena R, et al. **J Vasc Surg** 1998 Dec;28(6):1033-8; discussion 1038-9

A novel mutant from apoptosis-resistant colon cancer HT-29 cells showing hyper-apoptotic response to hypoxia, low glucose and cisplatin. Suzuki H, et al. **Jpn J Cancer Res** 1998 Nov;89(11):1169-78

Contribution of Na+/Ca2+ exchanger to glucose-induced [Ca2+]i increase in rat pancreatic islets. Yoshihashi K, et al. **Jpn J Physiol** 1999 Feb;49(1):71-80

High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Glogowski EA, et al. **Kidney Int** 1999 Feb;55(2):486-99

Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Hoffman BB, et al. **Kidney Int** 1998 Oct; 54(4):1107-16

Roles of prostaglandin E receptors in mesangial cells under high-glucose conditions. Ishibashi R, et al. **Kidney Int** 1999 Aug;56(2):589-600

Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kang MJ, et al. **Kidney Int** 1999 Jun;55(6):2203-14

Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Morrisey K, et al. **Kidney Int** 1999 Jan;55(1):160-7

Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Oh JH, et al. **Kidney Int** 1998 Dec;54(6):1872-8

TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Riser BL, et al. **Kidney Int** 1999 Aug;56(2):428-39

Mechanisms through which high glucose concentration raises [Ca2+]i in renal proximal tubular cells. Symonian M, et al. **Kidney Int** 1998 Oct;54(4):1206-13

Regulation of the Na+/H+ antiporter in patients with mild chronic renal failure: effect of glucose. Tepel M, et al. **Kidney Int** 1999 Jul;56(1):172-80

Glucose consumption by rats decreases cytochrome P450 enzyme activity by altering hepatic lipids. Stewart CC, et al. **Life Sci** 1999;64(23):2163-72

Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Teixeira AS, et al. **Life Sci** 1999;64(8):655-62

Interleukin-1beta-induced nitric oxide production in rat aortic endothelial cells: inhibition by estradiol in normal and high glucose cultures. Xu R, et al. **Life Sci** 1999; 64(26):2451-62

Glucose regulation of GRP78 gene expression. Mote PL, et al. **Mech Ageing Dev** 1998 Aug 14;104(2):149-58

Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Cleare W, et al. **Med Mycol** 1999 Aug;37(4):235-43

Effect of branched-chain amino acids (BCAA), glucose, and glucose plus BCAA on endurance performance in rats. Calders P, et al. **Med Sci Sports Exerc** 1999 Apr;31(4):583-7

Effect of carbohydrate ingestion on sprint performance following continuous and intermittent exercise. Sugiura K, et al. **Med Sci Sports Exerc** 1998 Nov;30(11):1624-30

Troglitazone and vascular reactivity: role of glucose and calcium. Ali SS, et al. **Metabolism** 1999 Jan;48(1):125-30

Long-term exposure of isolated rat islets of Langerhans to supraphysiologic glucose concentrations decreases insulin mRNA levels. Briaud I, et al. **Metabolism** 1999 Mar; 48(3):319-23

Effect of amino acids and glucose on exercise-induced gut and skeletal muscle proteolysis in dogs. Hamada K, et al. **Metabolism** 1999 Feb;48(2):161-6

Effect of glucose on ureagenesis during exercise in amino acid-infused dogs. Hamada K, et al. **Metabolism** 1998 Nov; 47(11):1303-7

Effect of vitamin E and N-acetylcysteine on phosphatidylserine externalization and induction of coagulation by high-glucose-treated human erythrocytes. Jain SK, et al. **Metabolism** 1999 Aug;48(8):957-9

Immunoblockade of endogenous glucagon-like peptide-1 by monoclonal antibodies in conscious rats: effect on the insulin response to intragastric glucose. van Delft J, et al. **Metabolism** 1999 Jan;48(1):41-6

Effect of glucose on the plasma concentration and urinary excretion of uridine and purine bases. Yamamoto T, et al. **Metabolism** 1999 Mar;48(3):338-41

The influence of frequent and excessive intake of glucose on microvascular aging in healthy mice. Yamada S, et al. **Microcirculation** 1999 Mar;6(1):55-62

Effects of L-carnitine on mechanical recovery of isolated rat hearts in relation to the perfusion with glucose and palmitate. Löster H, et al. **Mol Cell Biochem** 1998 Aug; 185(1-2):65-75

Hexose metabolism in pancreatic islets: effect of D-glucose upon D-fructose metabolism. Scruel O, et al. **Mol Cell Biochem** 1999 Jul;197(1-2):209-16

ADD1/SREBP-1c is required in the activation of hepatic

lipogenic gene expression by glucose. Foretz M, et al. **Mol Cell Biol** 1999 May;19(5):3760–8

Nrg1 is a transcriptional repressor for glucose repression of STA1 gene expression in Saccharomyces cerevisiae. Park SH, et al. **Mol Cell Biol** 1999 Mar;19(3):2044–50

Reversible association between the V1 and V0 domains of yeast vacuolar H+–ATPase is an unconventional glucose–induced effect. Parra KJ, et al. **Mol Cell Biol** 1998 Dec;18(12):7064–74

Failure of human and mouse leptin to affect insulin, glucagon and somatostatin secretion by the perfused rat pancreas at physiological glucose concentration. Leclercq–Meyer V, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):111–8

Two different gene elements are required for glucose regulation of S14 transcription. Liu B, et al. **Mol Cell Endocrinol** 1999 Feb 25;148(1–2):11–9

Impaired glucose–stimulated insulin release in islets from adult rats malnourished during foetal–neonatal life. Wilson MR, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1–2):41–8

A mutation in Saccharomyces cerevisiae adenylate cyclase, Cyr1K1876M, specifically affects glucose– and acidification–induced cAMP signalling and not the basal cAMP level. Vanhalewyn M, et al. **Mol Microbiol** 1999 Jul;33(2):363–76

Glucose and related catabolite repressors are powerful inhibitors of pKM101–enhanced UV mutagenesis in Escherichia coli. Ambrose M, et al. **Mutat Res** 1998 Nov 9;422(1):107–12

Heterogeneous characteristics of imidazoline–induced insulin secretion. Rustenbeck I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):235–42

Increased reabsorptive capacity after ureteral obstruction reduces the ability of glucose to inhibit phosphate reabsorption in rat kidney. Westenfelder C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1675–81

Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis. Woodrow G, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1530–5

Attenuation of morphine–induced behavioral changes in rodents by D– and L–glucose. Talley CP, et al. **Neurobiol Learn Mem** 1999 Jan;71(1):62–79

Stimulation of immunoreactive insulin release by glucose in rat brain synaptosomes. Santos MS, et al. **Neurochem Res** 1999 Jan;24(1):33–6

Glucose effects on cognition in adults with Down's syndrome. Manning CA, et al. **Neuropsychology** 1998 Jul; 12(3):479–84

Glucose plus insulin infusion improves cerebral outcome after asphyxial cardiac arrest. Katz LM, et al. **Neuroreport** 1998 Oct 26;9(15):3363–7

Influence of gamma–aminobutyric acid on retinal cells excitotoxicity upon glucose deprivation. Rego AC, et al. **Neurosci Res** 1999 May;34(1):31–6

ATP–sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose–mediated memory enhancement. Stefani MR, et al. **Neuroscience** 1999;93(2):557–63

Enhancement of antitumor effect of hyperthermia with glucose administration in murine mammary carcinoma. Akagi K, et al. **Oncol Rep** 1999 May–Jun;6(3):593–6

Interactions between vitamin E and glucose on B–cell functions in the rat: an in vivo and in vitro study. Tajiri Y, et al. **Pancreas** 1999 Apr;18(3):274–81

Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Delarue J, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):505–11

Effects of commercial glucose–based peritoneal dialysates on peripheral blood phagocytes apoptosis. Jin HM, et al. **Perit Dial Int** 1999;19 Suppl 2:S388–93

High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor–beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Kang DH, et al. **Perit Dial Int** 1999 May–Jun;19(3):221–30

Increased flavor acceptance and preference conditioned by the postingestive actions of glucose. Pérez C, et al. **Physiol Behav** 1998 Jun 15;64(4):483–92

Soybean– and olive–oils–enriched diets increase insulin secretion to glucose stimulus in isolated pancreatic rat islets. Picinato MC, et al. **Physiol Behav** 1998 Nov 15;65(2):289–94

Glucose, but not fat, phase shifts the feeding–entrained circadian clock. Stephan FK, et al. **Physiol Behav** 1998 Nov 15;65(2):277–88

Effect of glucose on the conformation of ADPMg(II) bound at the active site of yeast hexokinase PI. Maity H, et al. **Physiol Chem Phys Med NMR** 1998;30(1):49–62

Glycaemic regulation of glucose transporter expression and activity in the human placenta. Illsley NP, et al. **Placenta** 1998 Sep;19(7):517–24

Sugars modulate an unusual mode of control of the cell–wall invertase gene (Incw1) through its 3' untranslated region in a cell suspension culture of maize. Cheng WH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10512–7

Glycogen concentration in human skeletal muscle: effect of prolonged insulin and glucose infusion. Hansen BF, et al. **Scand J Med Sci Sports** 1999 Aug;9(4):209–13

Role of NADH shuttle system in glucose–induced activation of mitochondrial metabolism and insulin secretion. Eto K, et al. **Science** 1999 Feb 12;283(5404):981–5

Effects of glucose and PaO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra. Anderson RE, et al. **Stroke** 1999 Jan;30(1):160–70

Sodium influx plays a major role in the membrane depolarization induced by oxygen and glucose deprivation in rat striatal spiny neurons. Calabresi P, et al. **Stroke** 1999 Jan;30(1):171–9

Evaluation of in vivo and in vitro quality of apheresis–collected RBC stored for 42 days. Holme S, et al. **Vox Sang** 1998;75(3):212–7

Impact of storage at 22 degrees C and citrate anticoagulation on the cytokine secretion of mononuclear leukocytes. Müller–Steinhardt M, et al. **Vox Sang** 1998;75(1):12–7

Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l–lactate. Hehenberger K, et al. **Wound Repair Regen** 1998 Mar–Apr;6(2):135–41

[Gluco–lipotoxicity and gene expression in the pancreatic beta cell] Prentki M, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:17–27 (50 ref.) **(Fre)**

[Role of the NADH shuttle system in glucose–induced insulin secretion] Eto K, et al. **Nippon Rinsho** 1999 Mar; 57(3):503–14 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of reactive oxygen–related enzymes in human umbilical vein endothelial cells (HUVEC) cultured with high concentrations of glucose] Nakano A, et al. **Rinsho Byori** 1999 Jul;47(7):676–81 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Cobelli C, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1031–6

Adenylyl cyclase activity and glucose release from the liver of the European eel, Anguilla anguilla. Fabbri E, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1563–70

Glucose regulation of the IGF response system in chondrocytes: induction of an IGF–I–resistant state. Kelley KM, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1164–71

GLUT–1 or GLUT–4 transgenes in obese mice improve glucose tolerance but do not prevent insulin resistance. Marshall BA, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E390–400

Impact of lack of suppression of glucagon on glucose tolerance in humans. Shah P, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E283–90

Duodenal loading with glucose induces fos expression in rat brain: selective blockade by devazepide. Wang L, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R667–74

Pituitary adenylate cyclase activating polypeptide stimulates insulin secretion in a glucose–dependent manner in vivo. Ahrén B, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:466–70

Glucose controls cathepsin expression in Ras–transformed fibroblasts. Tournu C, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):15–24

A region of the cellobiohydrolase I promoter from the filamentous fungus Trichoderma reesei mediates glucose repression in Saccharomyces cerevisiae, dependent on mitochondrial activity. Carraro DM, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):407–14

Endogenous nitric oxide inhibits glucose–induced insulin secretion by suppression of phosphofructokinase activity in pancreatic islets. Tsuura Y, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):34–8

AMP–activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Salt IP, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):533–9

Glucose–dependent decreased DNA synthesis in bovine retinal endothelial cells is mediated by protein kinase C iota. Knott RM, et al. **Biochem Soc Trans** 1998 Aug; 26(3):S260

Glucose–induced thermal stabilization of the native conformation of GLUT 1. Epand RF, et al. **Biochemistry** 1999 Jan 5;38(1):454–8

Endogenous substrates of sphingosine–dependent kinases (SDKs) are chaperone proteins: heat shock proteins, glucose–regulated proteins, protein disulfide isomerase, and calreticulin. Megidish T, et al. **Biochemistry** 1999 Mar 16; 38(11):3369–78

Lesions of glucose–responsive neurons impair synchronizing effects of calorie restriction in mice. Challet E, et al. **Brain Res** 1998 Aug 10;801(1–2):244–50

Effects of mu and kappa opioid receptor antagonists on glucoprivic induction of Fos immunoreactivity in the rat preoptic area and hypothalamus. Briski KP, et al. **Brain Res Bull** 1999 Jun;49(3):181–7

The role of glucose in the regulation of substrate interaction during exercise. Sidossis LS. **Can J Appl Physiol** 1998 Dec; 23(6):558–69 (46 ref.)

ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Waterworth DM, et al. **Circulation** 1999 Apr 13;99(14):1872–7

The role of glucose, long–chain triglycerides and amino acids for promotion of amino acid balance across peripheral tissues in man. Svanberg E, et al. **Clin Physiol** 1999 Jul; 19(4):311–20

Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Bruttomesso D, et al. **Diabetes** 1999 Jan;48(1):99–105

Mechanisms of glucose hypersensitivity in beta–cells from normoglycemic, partially pancreatectomized mice. Martin F, et al. **Diabetes** 1999 Oct;48(10):1954–61

Regulation of the insulin gene by glucose: stimulation of trans–activation potency of human PDX–1 N–terminal domain. Shushan EB, et al. **DNA Cell Biol** 1999 Jun; 18(6):471–9

Insulin, but not glucose lowering corrects the hyperglucagonemia and increased proglucagon messenger ribonucleic acid levels observed in insulinopenic diabetes. Dumonteil E, et al. **Endocrinology** 1998 Nov;139(11):4540–6

Arrest of pulsatile luteinizing hormone (LH) secretion during insulin–induced hypoglycemia (IIH): improvement by intrahypothalamic perfusion with glucose. Rodriguez M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(4):257–61

Suboptimal energy balance selectively up–regulates muscle GLUT gene expression but reduces insulin–dependent glucose uptake during postnatal development. Katsumata M, et al. **FASEB J** 1999 Aug;13(11):1405–13

Pleiotropic control of glucose and hormone responses by PRL1, a nuclear WD protein, in Arabidopsis. Németh K, et al. **Genes Dev** 1998 Oct 1;12(19):3059–73

Glucose stimulates phagocytosis of unopsonized Pseudomonas aeruginosa by cultivated human alveolar macrophages. Wong SY, et al. **Infect Immun** 1999 Jan; 67(1):16–21

The role of glutamine, serum and energy factors in growth of enterocyte–like cell lines. Wirén M, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1331–6

The changes in adenine nucleotides measured in glucose–stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. Detimary P, et al. **J Biol Chem** 1998 Dec 18; 273(51):33905–8

Regulation of prostate cancer cell division by glucose. Singh G, et al. **J Cell Physiol** 1999 Sep;180(3):431–8

Can changes in plasma insulin concentration explain the variability in leptin response to weight loss in obese women with normal glucose tolerance? Carantoni M, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):869–72

Role of endogenous opiates in glucoprivic inhibition of the luteinizing hormone surge and fos expression by preoptic gonadotropin–releasing hormone neurones in ovariectomized steroid–primed female rats. Briski KP, et al. **J Neuroendocrinol** 1998 Oct;10(10):769–76

Glucose availability modulates the timing of the luteinizing hormone surge in the ewe. Medina CL, et al. **J Neuroendocrinol** 1998 Oct;10(10):785–92

Immunostimulated glial cells potentiate glucose deprivation–induced death of cultured rat cerebellar granule cells. Kim WK, et al. **J Neurotrauma** 1999 May; 16(5):415–24

Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Zhang SL, et al. **Kidney Int** 1999 Feb;55(2):454–64

Elevated glucose potentiates contraction of isolated rat resistance arteries and augments protein kinase C–induced intracellular calcium release. Cipolla MJ. **Metabolism** 1999 Aug;48(8):1015–22

Relationships between the pituitary–adrenal hormones, insulin, and glucose in middle–aged men: moderating influence of psychosocial stress. Keltikangas–Järvinen L, et al. **Metabolism** 1998 Dec;47(12):1440–9

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile–thiazolidide. Pauly RP, et al. **Metabolism** 1999 Mar;48(3):385–9

Proliferation–dependent vulnerability of glucose–deprived astrocytes to nitric oxide–induced cytotoxicity. Choi JJ, et al. **Neurosci Lett** 1998 Nov 6;256(2):109–12

Glucose–sensitive neurons in the rat arcuate nucleus contain neuropeptide Y. Muroya S, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):113–6

Nitric oxide–enhanced excitotoxicity–independent apoptosis of glucose–deprived neurons. Kim WK, et al. **Neurosci Res** 1999 Apr;33(4):281–9

Effects of food restriction on glucose tolerance, insulin secretion, and islet–cell proliferation in pregnant rats. Nieuwenhuizen AG, et al. **Physiol Behav** 1999 Jan 1–15; 65(4–5):671–7

Stimulated changes in localized cerebral energy consumption under anesthesia. Shulman RG, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3245–50

Toxicity of low levels of methylglyoxal: depletion of blood glutathione and adverse effect on glucose tolerance in mice. Ankrah NA, et al. **Toxicol Lett** 1999 Sep 20;109(1–2):61–7

Glucose action 'beyond ionic events' in the pancreatic beta cell [published erratum appears in Trends Pharmacol Sci 1999 Mar;20(3):124] Aizawa T, et al. **Trends Pharmacol Sci** 1998 Dec;19(12):496–9 (48 ref.)

RADIATION EFFECTS

Suppression of radiation damping in high–resolution NMR. Barjat H, et al. **J Magn Reson** 1999 Jan;136(1):114–7

SECRETION

Increase by anaphylatoxin C5a of glucose output in perfused rat liver via prostanoids derived from nonparenchymal cells: direct action of prostaglandins and indirect action of thromboxane A(2) on hepatocytes. Schieferdecker HL, et al. **Hepatology** 1999 Aug;30(2):454–61

GLUCOSE

THERAPEUTIC USE

Differences in respiratory metabolism during treatment of hypoglycemia in infants of diabetic mothers and small-for-gestational-age infants. Kinnala A, et al. **Am J Perinatol** 1998 Jun;15(6):363-7

Effect of glucose-water ingestion on exercise thermoregulation in men dehydrated after water immersion. Dearborn AS, et al. **Aviat Space Environ Med** 1999 Jan;70(1):35-41

Oral glucose and venepuncture reduce blood sampling pain in newborns. Eriksson M, et al. **Early Hum Dev** 1999 Jul; 55(3):211-8

Hemiplegia hypoglycaemia syndrome. Vanpee D, et al. **Eur J Emerg Med** 1999 Jun;6(2):157-9

Effects of glucose on chemically induced acute hepatic failure in rats. Birraux J, et al. **Eur J Pediatr Surg** 1998 Oct; 8(5):282-7

Comparative study of rice-based oral rehydration salt solution versus glucose-based oral rehydration salt solution (WHO) in children with acute dehydrating diarrhoea. Sharma A, et al. **J Indian Med Assoc** 1998 Dec;96(12):367-8

Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. Wolfsdorf JI, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):136-43

Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. Yuan TH, et al. **J Toxicol Clin Toxicol** 1999;37(4):463-74

Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Posthuma N, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2341-4

Effects of glucose infusion on the endocrine, metabolic and cardiorespiratory responses to halothane anaesthesia of ponies. Luna SP, et al. **Vet Rec** 1999 Jul 24;145(4):100-3

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307-9 (30 ref.) (Eng. Abstr.) **(Pol)**

[A combined treatment method for alcoholic patients using medikhronal, microwave resonance therapy and holotropic breathing] Zaritskii MG. **Lik Sprava** 1998 Oct-Nov; (7):126-32 (Eng. Abstr.) **(Rus)**

[The effect of medikhronal on the biogenic amine level in the brain structures and blood of animals with alcohol dependence] Kharchenko NK. **Fiziol Zh** 1999;45(4):111-9 (Eng. Abstr.) **(Ukr)**

TOXICITY

In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Harmon JS, et al. **Diabetes** 1999 Oct;48(10):1995-2000

Glucose decreases steady state mRNA content of hydrophobic surfactant proteins B and C in fetal rat lung explants. Rayani HH, et al. **Exp Lung Res** 1999 Jan-Feb; 25(1):69-79

Cytotoxic action of 2-deoxy-D-glucose tetraacetate upon human lymphocytes, fibroblasts and melanoma cells. Reinhold U, et al. **Int J Mol Med** 1998 Feb;1(2):427-30

Potentiation by 2-deoxy-D-glucose tetraacetate of the cytostatic action of alpha-difluoromethylornithine in tumoral insulin-producing cells. Olivares E, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1395-7

Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Tanaka Y, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10857-62

Comparative toxicity of glucose and lidocaine administered intrathecally in the rat. Hashimoto K, et al. **Reg Anesth Pain Med** 1998 Sep-Oct;23(5):444-50

URINE see GLYCOSURIA

GLUCOSE, BLOOD see BLOOD GLUCOSE

GLUCOSE CLAMP TECHNIQUE

Clenbuterol-induced insulin resistance in calves measured by hyperinsulinemic, euglycemic clamp technique. Sternbauer K, et al. **Acta Vet Scand** 1998;39(2):281-9

Euglycemic hyperinsulinemic clamp to assess posthepatic glucose appearance after carbohydrate loading. 1. Validation in pigs. Lang V, et al. **Am J Clin Nutr** 1999 Jun;69(6):1174-82

Experience with the Biostator for diagnosis and assisted surgery of 21 insulinomas. Gin H, et al. **Eur J Endocrinol** 1998 Oct;139(4):371-7

Measurement of insulin sensitivity: influence of potassium supply during euglycaemic glucose clamps in healthy volunteers. Rave K, et al. **Exp Clin Endocrinol Diabetes** 1999;107(5):313-7

Reduced insulin-mediated glucose uptake by euglycemic clamp in offspring of patients with type 2 diabetes. Strojek K, et al. **Exp Clin Endocrinol Diabetes** 1998;106(6):470-4

How to measure insulin sensitivity. Ferrannini E, et al. **J Hypertens** 1998 Jul;16(7):895-906 (61 ref.)

VETERINARY

Assessing insulin sensitivity in the cat: evaluation of the hyperinsulinemic euglycemic clamp and the minimal model analysis. Petrus DJ, et al. **Res Vet Sci** 1998 Sep-Oct; 65(2):179-81

GLUCOSE CLAMPING see GLUCOSE CLAMP TECHNIQUE

GLUCOSE DEHYDROGENASES

CHEMISTRY

Site-directed mutagenesis study on the thermal stability of a chimeric PQQ glucose dehydrogenase and its structural interpretation. Witarto AB, et al. **Appl Biochem Biotechnol** 1999 Spring;77-79:159-68

On the mechanism and specificity of soluble, quinoprotein glucose dehydrogenase in the oxidation of aldose sugars. Olsthoorn AJ, et al. **Biochemistry** 1998 Sep 29; 37(39):13854-61

Topographical characterization of the ubiquinone reduction site of glucose dehydrogenase in Escherichia coli using depth-dependent fluorescent inhibitors. Miyoshi H, et al. **Biochim Biophys Acta** 1999 May 26;1412(1):29-36

The 1.7 A crystal structure of the apo form of the soluble quinoprotein glucose dehydrogenase from Acinetobacter calcoaceticus reveals a novel internal conserved sequence repeat. Oubrie A, et al. **J Mol Biol** 1999 Jun 4;289(2):319-33

Engineering a chimeric pyrroloquinoline quinone glucose dehydrogenase: improvement of EDTA tolerance, thermal stability and substrate specificity. Yoshida H, et al. **Protein Eng** 1999 Jan;12(1):63-70

GENETICS

Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Mason PJ, et al. **Blood Cells Mol Dis** 1999 Feb; 25(1):30-7

gdhB, a gene encoding a second quinoprotein glucose dehydrogenase in Pantoea citrea, is required for pink disease of pineapple. Pujol CJ, et al. **Microbiology** 1999 May;145 (Pt 5):1217-26

METABOLISM

Stereoselective reduction of ethyl 4-chloro-3-oxobutanoate by Escherichia coli transformant cells coexpressing the aldehyde reductase and glucose dehydrogenase genes. Kataoka M, et al. **Appl Microbiol Biotechnol** 1999 Apr; 51(4):486-90

Characterization of the membrane quinoprotein glucose dehydrogenase from Escherichia coli and characterization of a site-directed mutant in which histidine-262 has been changed to tyrosine. Cozier GE, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):639-47

Site-directed mutagenesis of the quinoprotein glucose dehydrogenase of Escherichia coli; the role of His262 in PQQ binding and determination of substrate specificity. Cozier GE, et al. **Biochem Soc Trans** 1998 Aug;26(3):S270

PQQ as redox shuttle for quinoprotein glucose dehydrogenase. Jin W, et al. **Biol Chem** 1998 Aug-Sep; 379(8-9):1207-11

GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE see GASTRIC INHIBITORY POLYPEPTIDE

GLUCOSE INTOLERANCE

see related
DIABETES MELLITUS
GLUCOSE TOLERANCE TEST

Impaired fasting glucose is not a risk factor for atherosclerosis. Hanefeld M, et al. **Diabet Med** 1999 Mar; 16(3):212-8

Effects of glucose intolerance on myocardial function and collagen-linked glycation. Avendano GF, et al. **Diabetes** 1999 Jul;48(7):1443-7

Impaired glucose tolerance--not a diagnosis. Keen H. **Diabetes Metab Rev** 1998 Sep;14 Suppl 1:S5-12 (47 ref.)

The association of dietary fibres with glucose tolerance is partly explained by concomitant intake of thiamine: the Hoorn Study. Bakker SJ, et al. **Diabetologia** 1998 Oct; 41(10):1168-75

Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Fujita Y, et al. **Diabetologia** 1998 Dec;41(12):1459-66

Glucose tolerance and resistance to insulin-stimulated glucose uptake in men aged 70 years in relation to size at birth. McKeigue PM, et al. **Diabetologia** 1998 Oct; 41(10):1133-8

Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Ruige JB, et al. **Diabetologia** 1999 Feb;42(2):177-80

Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. Ahrén B, et al. **Eur J Endocrinol** 1998 Oct;139(4):461-7

Chromimum, glucose intolerance and diabetes. Anderson RA. **J Am Coll Nutr** 1998 Dec;17(6):548-55 (75 ref.)

Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Luo S, et al. **Neuroendocrinology** 1998 Jul;68(1):1-10

[Impaired glucose tolerance: progress in research and challenge (editorial)] Pan C. **Chung Hua Nei Ko Tsa Chih** 1997 Mar;36(3):147-8 **(Chi)**

BLOOD

Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Ford ES, et al. **Am J Epidemiol** 1999 Jan 15;149(2):168-76

Effects of new criteria for type 2 diabetes on the rate of postpartum glucose intolerance in women with gestational diabetes. Conway DL, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):610-4

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Morel Y, et al. **Diabet Med** 1999 Aug;16(8):650-5

In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Pietzsch J, et al. **Diabetes** 1998 Dec;47(12):1928-34

Is there a glycemic threshold for mortality risk? [see comments] Balkau B, et al. **Diabetes Care** 1999 May; 22(5):696-9. Comment in: Diabetes Care 1999 May;22(5):659-60.

Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Watanabe N, et al. **Diabetes Care** 1999 Jan;22(1):152-6

Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Avignon A, et al. **Int J Obes Relat Metab Disord** 1999 May;23(5):512-7

Economic evaluation of alternative indicators for screening for diabetes mellitus. Shirasaya K, et al. **Prev Med** 1999 Aug;29(2):79-86

[The usefulness of basal blood glucose and glycosylated hemoglobin for the detection of abnormal glucose tolerance in the relatives of patients with type-2 diabetes mellitus] Costa A, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):241-4 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Behrens G, et al. **AIDS** 1999 Jul 9;13(10):F63-70

Impaired glucose tolerance and protease inhibitors [letter] Walli R, et al. **Ann Intern Med** 1998 Nov 15;129(10):837-8

Mechanism of the diabetogenic action of cyclosporin A. Menegazzo LA, et al. **Horm Metab Res** 1998 Nov; 30(11):663-7

CLASSIFICATION

Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes. Kousta E, et al. **Diabetes Care** 1999 Jun;22(6):933-7

Impaired glucose tolerance. Why is it not a disease? [editorial; comment] Perry RC, et al. **Diabetes Care** 1999 Jun; 22(6):883-5 (33 ref.). Comment on: Diabetes Care 1999 Jun;22(6):920-4.

Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Puavilai G, et al. **Diabetes Res Clin Pract** 1999 Apr;44(1):21-6

COMPLICATIONS

Rehydration of moderately dehydrated children with transient glucose intolerance using rice oral rehydration solution. Yurdakök K, et al. **Acta Paediatr** 1999 Jan; 88(1):34-7

Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study [see comments] Brand FN, et al. **Am Heart J** 1998 Nov;136(5):919-27. Comment in: Am Heart J 1998 Nov;136(5):762-4

Cardiovascular disease in cirrhosis--a point-prevalence study in relation to glucose tolerance. Marchesini G, et al. **Am J Gastroenterol** 1999 Mar;94(3):655-62

Impaired glucose tolerance. Why is it not a disease? [editorial; comment] Perry RC, et al. **Diabetes Care** 1999 Jun; 22(6):883-5 (33 ref.). Comment on: Diabetes Care 1999 Jun;22(6):920-4.

Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Rajala U, et al. **Diabetes Care** 1998 Oct;21(10):1664-9

Impaired glucose tolerance: a risk factor for type 2 diabetes and cardiovascular disease. Chiasson JL. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S1-2

Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance. Rabasa-Lhoret R, et al. **Drugs Aging** 1998 Aug; 13(2):131-43 (91 ref.)

The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects. Niemi M, et al. **Gut** 1999 Apr;44(4):557-62

Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events [letter] [see comments] Byington RP, et al. **Lancet** 1997 Oct 11;350(9084):1075-6. Comment in: Lancet 1998 Jan 17;351(9097):216-7.

[Major nutrition-related risk factors of ischemic heart disease: dyslipoproteinemia, obesity, hypertension, glucose intolerance] Pados G. **Orv Hetil** 1999 Jul 11; 140(28):1563-72 (50 ref.) (Eng. Abstr.) **(Hun)**

[Role of impaired glucose tolerance in the progression of hypertension] Takagi Y, et al.

Nippon Ronen Igakkai Zasshi 1998 Nov;35(11):830–8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Potential impact of a change in the diagnostic criteria for diabetes mellitus on the prevalence of abnormal glucose tolerance in a local community at risk of diabetes: impact of new diagnostic criteria for diabetes mellitus. Davies MJ, et al. **Diabet Med** 1999 Apr;16(4):343–6

The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. de Vegt F, et al. **Diabetes Care** 1998 Oct; 21(10):1686–90

Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Ko GT, et al. **Diabetes Care** 1998 Dec;21(12):2094–7

Glycosylated hemoglobin levels and new diagnostic criteria [letter] Raj D, et al. **Diabetes Care** 1998 Dec;21(12):2198–9

Fasting plasma glucose is a useful test for the detection of gestational diabetes. Brazilian Study of Gestational Diabetes (EBDG) Working Group. Reichelt AJ, et al. **Diabetes Care** 1998 Aug;21(8):1246–9

Fasting proinsulin concentrations predict the development of type 2 diabetes. Wareham NJ, et al. **Diabetes Care** 1999 Feb;22(2):262–70

Diagnosis and follow-up of subjects with impaired glucose tolerance: how reliable is OGTT? Report from a Nigerian survey. Olatunbosun ST. **Diabetes Res Clin Pract** 1998 Aug; 41(2):147–8

Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Puavilai G, et al. **Diabetes Res Clin Pract** 1999 Apr;44(1):21–6

Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance [letter] Larsson H, et al. **Diabetologia** 1998 Sep;41(9):1124–5

Stress coping and social support in glucose tolerance abnormality. Fukunishi I, et al. **J Psychosom Res** 1998 Oct; 45(4):361–9

Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria [see comments] Barzilay JI, et al. **Lancet** 1999 Aug 21;354(9179):622–5. Comment in: Lancet 1999 Aug 21;354(9179):610–1.

Economic evaluation of alternative indicators for screening for diabetes mellitus. Shirasaya K, et al. **Prev Med** 1999 Aug;29(2):79–86

DRUG THERAPY

Effects of benazepril on insulin resistance and glucose tolerance in uremia. Wu Z, et al. **Clin Nephrol** 1998 Aug; 50(2):108–12

Effect of metformin on patients with impaired glucose tolerance. Li CL, et al. **Diabet Med** 1999 Jun;16(6):477–81

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Morel Y, et al. **Diabet Med** 1999 Aug;16(8):650–5

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Chiasson JL, et al. **Diabetes Care** 1998 Oct;21(10):1720–5

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Laube H, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):231–3

EPIDEMIOLOGY

Glucose intolerance and adenomas of the sigmoid colon in Japanese men (Japan). Kono S, et al. **Cancer Causes Control** 1998 Aug;9(4):441–6

Glucose intolerance and associated factors in the Fergana Valley, Uzbekistan. King H, et al. **Diabet Med** 1998 Dec; 15(12):1052–62

Fetal growth and hyperinsulinaemia in adult life. Martyn CN, et al. **Diabet Med** 1998 Aug;15(8):688–94

Low birth weight, family history of diabetes, and glucose intolerance in Swedish middle-aged men. Carlsson S, et al. **Diabetes Care** 1999 Jul;22(7):1043–7

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years [see comments] Coutinho M, et al. **Diabetes Care** 1999 Feb; 22(2):233–40. Comment in: ACP J Club 1999 Jul-Aug;131(1):23.

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Ehrmann DA, et al. **Diabetes Care** 1999 Jan;22(1):141–6

Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. King H. **Diabetes Care** 1998 Aug;21 Suppl 2:B9–13

Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects [see comments] Ko GT, et al. **Diabetes Care** 1998 Aug;21(8):1221–5. Comment in: Diabetes Care 1998 Aug;21(8):1215–6.

Standardized comparison of glucose intolerance in west African-origin populations of rural and urban Cameroon, Jamaica, and Caribbean migrants to Britain. Mbanya JC, et al. **Diabetes Care** 1999 Mar;22(3):434–40

Birth weight and the future development of diabetes. A review of the evidence. Phillips DI. **Diabetes Care** 1998 Aug;21 Suppl 2:B150–5 (41 ref.)

Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Silverman BL, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B142–9

Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Suematsu C, et al. **Diabetes Care** 1999 Feb; 22(2):228–32

Ultrasonographic manifestations of carotid atherosclerosis and glucose intolerance in elderly eastern Finnish men. Tuomilehto J, et al. **Diabetes Care** 1998 Aug;21(8):1349–52

High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic? Chen KT, et al. **Diabetes Res Clin Pract** 1999 Apr;44(1):59–69

High prevalence of abnormal glucose tolerance and metabolic disturbances in first degree relatives of NIDDM patients. A study in Catalonia, a mediterranean community. Costa A, et al. **Diabetes Res Clin Pract** 1998 Sep;41(3):191–6

Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Ramachandran A, et al. **Diabetes Res Clin Pract** 1999 Jun; 44(3):207–13

Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. Shera AS, et al. **Diabetes Res Clin Pract** 1999 Apr; 44(1):49–58

Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. Gamberini MR, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:867–9

[A survey on diabetes mellitus in the staff of electric power system in Baotou city] Jia G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Aug; 19(4):205–7 (Eng. Abstr.) **(Chi)**

[Study on the epidemiological characteristics of diabetes mellitus and IGT in China] Wang K, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):282–5 (Eng. Abstr.) **(Chi)**

[The prevalence of hypertension, diabetes mellitus and hyperlipemia among 1369 subjects for physical examination in Changsha] Duan Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):407–10 (Eng. Abstr.) **(Chi)**

[Prevalence of glucose intolerance in Japan--from the National Circulatory Disorders Basic Survey, 1990] Nakano M, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov; 35(11):839–44 (Eng. Abstr.) **(Jpn)**

ETHNOLOGY

Standardized comparison of glucose intolerance in west African-origin populations of rural and urban Cameroon, Jamaica, and Caribbean migrants to Britain. Mbanya JC, et al. **Diabetes Care** 1999 Mar;22(3):434–40

Prevalence of diabetes and impaired glucose tolerance in Nigerians, Jamaicans and US blacks. Rotimi CN, et al. **Ethn Dis** 1999 Spring-Summer;9(2):190–200

Age, body mass index and 2-hour plasma glucose are the major determinants of blood pressure in Chinese women newly diagnosed to have glucose intolerance. Ko GT, et al. **Int J Cardiol** 1999 Apr 30;69(1):33–9

ETIOLOGY

Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Lima FB, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E934–41

Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors [letter] Mauss S, et al. **Ann Intern Med** 1999 Jan 19;130(2):162–3

High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease. Yawata N, et al. **Br J Ophthalmol** 1999 Jan;83(1):39–42

Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Fernández-Real JM, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):53–61

GH-binding protein in obese men with varying glucose tolerance: relationship to body fat distribution, insulin secretion and the GH-IGF-I axis. Nam SY, et al. **Eur J Endocrinol** 1999 Feb;140(2):159–63

Glucose intolerance in patients with thalassemia major: insulin resistance and hyperproinsulinemia. Cario H, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:953–5

The protective effect of good physical fitness when young on the risk of impaired glucose tolerance when old. Takemura Y, et al. **Prev Med** 1999 Jan;28(1):14–9

GENETICS

Exclusion of insulin receptor substrate 2 (IRS-2) as a major locus for early-onset autosomal dominant type 2 diabetes. Bektas A, et al. **Diabetes** 1999 Mar;48(3):640–2

Altered beta-cell characteristics in impaired glucose tolerant carriers of a GAA trinucleotide repeat polymorphism in the frataxin gene [published erratum appears in Diabetes 1999 Jul;48(7):1493] t Hart LM, et al. **Diabetes** 1999 Apr; 48(4):924–6

Effects of genetic predisposition on proinsulin responses in Asian Indians. Ramachandran A, et al. **Diabetes Res Clin Pract** 1998 Jul;41(1):71–7

Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats. Mathews CE, et al. **Diabetologia** 1999 Jan;42(1):35–40

Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study [see comments] Poulsen P, et al. **Diabetologia** 1999 Feb;42(2):139–45. Comment in: Diabetologia 1999 Feb;42(2):125–7.

Localization of tub and uncoupling proteins (Ucp) 2 and 3 to a region of rat chromosome 1 linked to glucose intolerance and adiposity in the Goto-Kakizaki (GK) type 2 diabetic rat. Kaisaki PJ, et al. **Mamm Genome** 1998 Nov; 9(11):910–2

Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue [see comments] Lauro D, et al. **Nat Genet** 1998 Nov; 20(3):294–8. Comment in: Nat Genet 1998 Nov;20(3):223–5.

[The usefulness of basal blood glucose and glycosylated hemoglobin for the detection of abnormal glucose tolerance in the relatives of patients with type-2 diabetes mellitus] Costa A, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):241–4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

GAD antibodies in elderly men in different categories of glucose tolerance [letter] Ylihärsilä H, et al. **Diabetes Care** 1999 Jun;22(6):996–7

Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Rolandsson O, et al. **Diabetologia** 1999 May;42(5):555–9

METABOLISM

Reduced glucose effectiveness as a feature of glucose intolerance: evidence in elderly type-2 diabetic subjects. Viviani GL, et al. **Aging (Milano)** 1999 Jun;11(3):169–75

Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. Ahrén B, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E93–102

A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome [see comments] Wareham NJ, et al. **Br J Nutr** 1998 Sep;80(3):235–41. Comment in: Br J Nutr 1998 Sep;80(3):215–6.

Glucose concentration in parotid saliva after glucose/food intake in individuals with glucose intolerance and diabetes mellitus. Borg Andersson A, et al. **Eur J Oral Sci** 1998 Oct;106(5):931–7

Insulin secretion and sensitivity in children on cyclic total parenteral nutrition. Lienhardt A, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov-Dec;22(6):382–6

Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue [see comments] Lauro D, et al. **Nat Genet** 1998 Nov; 20(3):294–8. Comment in: Nat Genet 1998 Nov;20(3):223–5.

Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Luo S, et al. **Neuroreport** 1999 Jul 13;10(10):2073–7

MORTALITY

No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Eriksson KF, et al. **Diabetologia** 1998 Sep;41(9):1010–6

PHYSIOPATHOLOGY

Birthweight in women with potential gestational diabetes mellitus--an effect of obesity rather than glucose intolerance? Lauszus FF, et al. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):520–5

The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Wei M, et al. **Ann Intern Med** 1999 Jan 19; 130(2):89–96

Insulin secretion and action in different stages of glucose tolerance in Asian Indians. Snehalatha C, et al. **Diabet Med** 1999 May;16(5):408–14

In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Pietzsch J, et al. **Diabetes** 1998 Dec;47(12):1928–34

Fasting glucose and progression of impaired glucose tolerance [letter; comment] Cockram CS. **Diabetes Care** 1999 Feb;22(2):369–70. Comment on: Diabetes Care 1998 Jul;21(7):1183–7.

Association between central adiposity and multimetabolic syndrome in a special cohort of women with prior gestational diabetes [letter; comment] Kerényi Z, et al. **Diabetes Care** 1999 May;22(5):876–7. Comment on: Diabetes Care 1998 Nov;21(11):1836–42.

Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Shaw JE, et al. **Diabetes Care** 1999 Mar;22(3):399–402

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study [see comments] Tominaga M, et al.

GLUCOSE INTOLERANCE

Diabetes Care 1999 Jun;22(6):920–4. Comment in: Diabetes Care 1999 Jun;22(6):883–5.

Impaired glucose tolerance: what are the clinical implications? Alberti KG. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S3–8 (29 ref.)

Effects of parathyroid hormone infusion on glucose tolerance and glucose-stimulated insulin secretion in normal and uremic rats. Chen SM, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):85–94

Implications of blood glucose, insulin resistance and beta-cell function in impaired glucose tolerance. Göke B. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S15–20 (43 ref.)

Evidence for direct action of alloxan to induce insulin resistance at the cellular level. Ader M, et al. **Diabetologia** 1998 Nov;41(11):1327–36

Changing glomerular filtration with progression from impaired glucose tolerance to Type II diabetes mellitus. Nelson RG, et al. **Diabetologia** 1999 Jan;42(1):90–3

Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT). Leonhardt W, et al. **Exp Clin Endocrinol Diabetes** 1999; 107(1):46–52

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. Avena R, et al. **J Vasc Surg** 1998 Dec; 28(6):1024–31; discussion 1031–2

THERAPY

Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Eriksson J, et al. **Diabetologia** 1999 Jul;42(7):793–801

No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Eriksson KF, et al. **Diabetologia** 1998 Sep;41(9):1010–6

Comparison of short-term diet and exercise on insulin action in individuals with abnormal glucose tolerance. Arciero PJ, et al. **J Appl Physiol** 1999 Jun;86(6):1930–5

URINE

Abnormality in urinary protein excretion in Japanese men with impaired glucose tolerance. Fujita H, et al. **Diabetes Care** 1999 May;22(5):823–6

Analysis of urinary albumin, transferrin, N-acetyl-beta-D-glucosaminidase and beta2-microglobulin in patients with impaired glucose tolerance. Hiratsuka N, et al. **J Clin Lab Anal** 1998; 12(6):351–5

GLUCOSE OXIDASE

Study of the thermal stability and enzymatic activity of an immobilised enzymatic system for the bilirubin oxidation. Vidal MM, et al. **Biomaterials** 1999 Apr;20(8):757–63

ANTAGONISTS & INHIBITORS

Inactivation of glucose oxidase by diperoxovanadate-derived oxidants. Rao AV, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):163–73

BIOSYNTHESIS

Simultaneous production of catalase, glucose oxidase and gluconic acid by Aspergillus niger mutant. Fiedurek J, et al. **Acta Microbiol Pol** 1998;47(4):355–64

CHEMISTRY

1.8 and 1.9 A resolution structures of the Penicillium amagasakiense and Aspergillus niger glucose oxidases as a basis for modelling substrate complexes. Wohlfahrt G, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May; 55(5):969–77

Electrostatic immobilization of glucose oxidase in a weak acid, polyelectrolyte hyperbranched ultrathin film on gold: fabrication, characterization, and enzymatic activity. Franchina JG, et al. **Anal Chem** 1999 Aug 1;71(15):3133–9

Kinetics and thermodynamics of free flavins and the flavin-based redox active site within glucose oxidase dissolved in solution or sequestered within a sol-gel-derived glass. Hartnett AM, et al. **Anal Chem** 1999 Mar 15;71(6):1215–24

An immunosensor based on the glucose oxidase label and optical oxygen detection. Papkovsky DB, et al. **Anal Chem** 1999 Apr 15;71(8):1568–73

Nature of oxygen activation in glucose oxidase from Aspergillus niger: the importance of electrostatic stabilization in superoxide formation. Su Q, et al. **Biochemistry** 1999 Jun 29;38(26):8572–81

Hydrogen peroxide production from reactive liposomes encapsulating enzymes. Kaszuba M, et al. **Biochim Biophys Acta** 1999 Jul 15;1419(2):221–8

Effects of sucrose, citric buffer and glucose oxidase on the stability of captopril in liquid formulations. Liu J, et al. **J Clin Pharm Ther** 1999 Apr;24(2):145–50

DIAGNOSTIC USE

A survey of bedside methods used to detect pulmonary aspiration of enteral formula in intubated tube-fed patients. Metheny NA, et al. **Am J Crit Care** 1999 May;8(3):160–7; quiz 168–9

IMMUNOLOGY

Glucose 1- and 2-oxidases from fungal strains: isolation and production of monoclonal antibodies. Karmali A, et al. **J Biotechnol** 1999 Apr 15;69(2–3):151–62

METABOLISM

Electrostatic immobilization of glucose oxidase in a weak acid, polyelectrolyte hyperbranched ultrathin film on gold: fabrication, characterization, and enzymatic activity. Franchina JG, et al. **Anal Chem** 1999 Aug 1;71(15):3133–9

The fluorescence emission of the apo-glucose oxidase from Aspergillus niger as probe to estimate glucose concentrations. D'Auria S, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):550–3

Nature of oxygen activation in glucose oxidase from Aspergillus niger: the importance of electrostatic stabilization in superoxide formation. Su Q, et al. **Biochemistry** 1999 Jun 29;38(26):8572–81

Glucose oxidase-produced H2O2 induces Ca2+-dependent DNA damage in human peripheral blood lymphocytes. Panayiotidis M, et al. **Free Radic Biol Med** 1999 Mar; 26(5–6):548–56

Spectrophotometric kinetic study and analytical implications of the glucose oxidase-catalyzed reduction of [MIII(LL)2Cl2]+ complexes by D-glucose (M = Os and Ru, LL = 2,2'-bipyridine and 1,10-phenanthroline type ligands). Ryabov AD, et al. **J Biol Inorg Chem** 1999 Apr; 4(2):175–82

Aspects of the mechanism of catalysis of glucose oxidase: a docking, molecular mechanics and quantum chemical study. Meyer M, et al. **J Comput Aided Mol Des** 1998 Sep; 12(5):425–40

[Study on optimal conditions for the determination of glucose by measurement of oxygen consumption rate] Liu F, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Feb;19(1):75–7 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Effect of a mouth rinse containing amyloglucosidase and glucose oxidase on recurrent aphthous ulcers in children and adolescents. Fridh G, et al. **Swed Dent J** 1999; 23(2–3):49–57

GLUCOSE OXIDOREDUCTASES see **GLUCOSE DEHYDROGENASES**

GLUCOSE-6-PHOSPHATASE

ANALYSIS

Glucose-6-phosphatase is present in normal and pre-eclamptic placental trophoblasts: ultrastructural enzyme-histochemical evidence. Matsubara S, et al. **Placenta** 1999 Jan;20(1):81–5

ANTAGONISTS & INHIBITORS

Peroxyvanadium compounds inhibit glucose-6-phosphatase activity and glucagon-stimulated hepatic glucose output in the rat in vivo. Westergaard N, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):55–60

Phosphatidylinositol 3-kinase translocates onto liver endoplasmic reticulum and may account for the inhibition of glucose-6-phosphatase during refeeding. Daniele N, et al. **J Biol Chem** 1999 Feb 5;274(6):3597–601

BIOSYNTHESIS

Glucose induces glucose 6-phosphatase hydrolytic subunit gene transcription in an insulinoma cell line (INS-1). Schmoll D, et al. **FEBS Lett** 1999 Jan 22;443(1):53–6

BLOOD

Failure to detect preterm infants at risk of hypoglycemia before discharge. Hume R, et al. **J Pediatr** 1999 Apr; 134(4):499–502

GENETICS

Hepatocellular expression of glucose-6-phosphatase is unaltered during hepatic regeneration. Zakko WF, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G717–22

Identification of a cAMP response element within the glucose- 6-phosphatase hydrolytic subunit gene promoter which is involved in the transcriptional regulation by cAMP and glucocorticoids in H4IIE hepatoma cells. Schmoll D, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):457–63

Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Davies GF, et al. **Biochim Biophys Acta** 1999 Aug 12; 1451(1):122–31

A novel DraI polymorphism in the 3' untranslated region of human glucose-6-phosphatase gene: useful for carrier detection and prenatal diagnosis of glycogen storage disease type Ia. Lam CW, et al. **Clin Genet** 1998 Jun;53(6):502–3

Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Ayala JE, et al. **Diabetes** 1999 Sep; 48(9):1885–9

Structure and promoter activity of an islet-specific glucose-6-phosphatase catalytic subunit-related gene. Ebert DH, et al. **Diabetes** 1999 Mar;48(3):543–51

Heteroduplex analysis: a useful screening method for glycogen storage disease type Ia. Narita T, et al. **Diagn Mol Pathol** 1998 Apr;7(2):111–3

Hepatocyte nuclear factor 1alpha is an accessory factor required for activation of glucose-6-phosphatase gene transcription by glucocorticoids. Lin B, et al. **DNA Cell Biol** 1998 Nov;17(11):967–74

The glucose-6 phosphatase gene is expressed in human and rat small intestine: regulation of expression in fasted and diabetic rats. Rajas F, et al. **Gastroenterology** 1999 Jul; 117(1):132–9

Linkage disequilibrium and linkage analysis of the glucose-6-phosphatase gene [see comments] Wong LJ, et al. **Hum Genet** 1998 Aug;103(2):199–203. Comment in: Hum Genet 1999 Feb;104(2):193.

Identification of three novel mutations (Q54P, W70X and T108I) in the glucose-6-phosphatase gene of patients with glycogen storage disease type Ia. Mutation in brief no. 256. Online. Trioche P, et al. **Hum Mutat** 1999;14(1):91

Cloning and characterization of cDNAs encoding a candidate glycogen storage disease type Ib protein in rodents. Lin B, et al. **J Biol Chem** 1998 Nov 27;273(48):31656–60

Case report: Hepatocellular carcinoma in type Ia glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family. Nakamura T, et al. **J Gastroenterol Hepatol** 1999 Jun; 14(6):553–8

Molecular aspects of glycogen storage disease type Ia in Turkish patients: a novel mutation in the glucose-6-phosphatase gene. Hüner G, et al. **J Inherit Metab Dis** 1998 Jun;21(4):445–6

Glycogen storage disease type Ia in three siblings with the G270V mutation. Parvari R, et al. **J Inherit Metab Dis** 1999 Apr;22(2):149–54

A novel mutation in a Brazilian patient with glycogen storage disease type Ia. Sartorato EL, et al. **J Inherit Metab Dis** 1998 Jun;21(4):447

Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia. Stroppiano M, et al. **J Inherit Metab Dis** 1999 Feb;22(1):43–9

Endotoxin-induced alterations in hepatic glucose-6-phosphatase activity and gene expression. Maitra SR, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):79–83

Origin of the Japanese population [letter; comment] Lam CW. **Science** 1999 May 14;284(5417):1125. Comment on: Science 1999 Mar 5;283(5407):1426–7.

METABOLISM

Ontogeny of the murine glucose-6-phosphatase system. Pan CJ, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):17–24

Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone. Aoki K, et al. **Diabetes** 1999 Aug; 48(8):1579–85

Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. Aiston S, et al. **J Biol Chem** 1999 Aug 27;274(35):24559–66

Conformational change of the catalytic subunit of glucose-6-phosphatase in rat liver during the fetal-to-neonatal transition. Puskás F, et al. **J Biol Chem** 1999 Jan 1;274(1):117–22

Ultracytochemical localization of glucose-6-phosphatase in the rat anterior pituitary cells. Yashiro T, et al. **J Electron Microsc (Tokyo)** 1998;47(3):243–9

Localization of glucose-6-phosphatase activity and carbohydrates in boar caput epididymal principal cells. Geissbühler DM, et al. **J Reprod Fertil** 1998 Sep; 114(1):103–10

Glucose-6-phosphatase mRNA levels in kidney isolated tubule suspensions are increased by dexamethasone and decreased by insulin. Simonnet H. **Metabolism** 1999 Aug; 48(8):1052–6

Endotoxin-induced alterations in hepatic glucose-6-phosphatase activity and gene expression. Maitra SR, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):79–83

PHYSIOLOGY

Ontogeny of the murine glucose-6-phosphatase system. Pan CJ, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):17–24

GLUCOSE-6-PHOSPHATASE DEFICIENCY see **GLYCOGEN STORAGE DISEASE TYPE I**

GLUCOSE-6-PHOSPHATE

ANALOGS & DERIVATIVES

Substrate specificity of 2-deoxy-scyllo-inosose synthase, the starter enzyme for 2-deoxystreptamine biosynthesis, toward deoxyglucose-6-phosphates and proposed mechanism. Iwase N, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2396–407

Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Virkamäki

A, et al. **Diabetes** 1999 May;48(5):1101–7
Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Glass-Marmor L, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):195–9
In vivo microdialysis of 2-deoxyglucose 6-phosphate into brain: a novel method for the measurement of interstitial pH using 31P-NMR. Kintner DB, et al. **J Neurochem** 1999 Jan;72(1):405–12

ANALYSIS

Mediated, amperometric biosensor for glucose-6-phosphate monitoring based on entrapped glucose-6-phosphate dehydrogenase, Mg2+ ions, tetracyanoquinodimethane, and nicotinamide adenine dinucleotide phosphate in carbon paste. Bassi AS, et al. **Anal Biochem** 1999 Mar 15; 268(2):223–8

CHEMISTRY

The mechanism of sugar phosphate isomerization by glucosamine 6-phosphate synthase. Teplyakov A, et al. **Protein Sci** 1999 Mar;8(3):596–602

METABOLISM

Glycogen depletion rather than glucose 6-P increments controls early glycogen recovery in human cultured muscle. Montell E, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1489–95
Allosteric regulation of type I hexokinase: A site-directed mutational study indicating location of the functional glucose 6-phosphate binding site in the N-terminal half of the enzyme. Sebastian S, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):203–10
Insulin unexpectedly increases the glucose 6-phosphate Ka of skeletal muscle glycogen synthase in calorie-restricted monkeys. Ortmeyer HK, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):309–23
Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. Aiston S, et al. **J Biol Chem** 1999 Aug 27;274(35):24559–66
Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. Trinh KY, et al. **J Biol Chem** 1998 Nov 20; 273(47):31615–20
Glucose 6-phosphate and fructose 1,6-bisphosphate can be used as ATP-regenerating systems by cerebellum Ca2+-transport ATPase. Ramos RC, et al. **J Neurochem** 1999 Jan;72(1):81–6

PHARMACOLOGY

Glucose 6-phosphate alters rat skeletal muscle contractile apparatus and sarcoplasmic reticulum function. Williams JH, et al. **Exp Physiol** 1998 Jul;83(4):489–502
Amelioration by glucose-6-phosphate and NADP of potato glycoalkaloid inhibition in cell, enzyme and liposome assays. Roddick JG, et al. **Phytochemistry** 1999 May; 51(1):23–7

PHYSIOLOGY

The role of glucose 6-phosphate in yeast glycolysis [letter; comment] Boles E. **Trends Microbiol** 1998 Dec;6(12):472–3 . Comment on: Trends Microbiol 1998 Aug;6(8):314–9.

GLUCOSE-6-PHOSPHATE DEHYDROGENASE see **GLUCOSEPHOSPHATE DEHYDROGENASE**

GLUCOSE-6-PHOSPHATE ISOMERASE

ANALYSIS

Analytical micro-preparative electrophoresis: quantitation of phosphoglucose isomerase isoenzymes. Marshall MJ, et al. **Anal Biochem** 1978 Nov;91(1):283–92

ANTAGONISTS & INHIBITORS

Synthesis and evaluation of a new inhibitor of phosphoglucose isomerases: the enediolate analogue 5-phospho-D-arabinohydroxamate. Hardré R, et al. **Bioorg Med Chem Lett** 1998 Dec 1;8(23):3435–8

CHEMISTRY

Characterization of Aspergillus niger phosphoglucose isomerase. Use for quantitative determination of erythrose 4-phosphate. Ruijter GJ, et al. **Biochimie** 1999 Mar; 81(3):267–72
The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin. Sun YJ, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5412–7

DEFICIENCY

Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Kugler W, et al. **Hum Genet** 1998 Oct;103(4):450–4

GENETICS

The effect of mating system differences on nucleotide diversity at the phosphoglucose isomerase locus in the plant genus Leavenworthia. Liu F, et al. **Genetics** 1999 Jan; 151(1):343–57
The protozoan parasite Toxoplasma gondii expresses two functional plant-like glycolytic enzymes. Implications for evolutionary origin of apicomplexans. Dzierszinski F, et al. **J Biol Chem** 1999 Aug 27;274(35):24888–95
Glucose metabolism during the final stage of human oocyte maturation: genetic expression of hexokinase, glucose phosphate isomerase and phosphofructokinase. el Mouatassim S, et al. **Zygote** 1999 Feb;7(1):45–50

ISOLATION & PURIFICATION

Purification and properties of phosphoglucose isomerases of Trypanosoma cruzi. Concepcion JL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):211–22

METABOLISM

Effect of mebendazole and praziquantel on glucosephosphate isomerase and glyceraldehydephosphate dehydrogenase in Echinococcus granulosus cyst wall harbored in mice. You JQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):75–7
Purification and properties of phosphoglucose isomerases of Trypanosoma cruzi. Concepcion JL, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):211–22
Mutational analysis of the conserved cationic residues of Bacillus stearothermophilus 6-phosphoglucose isomerase. Meng M, et al. **Eur J Biochem** 1998 Oct 15;257(2):500–5

GLUCOSE PHOSPHOMUTASE see **PHOSPHOGLUCOMUTASE**

GLUCOSE-SODIUM TRANSPORT SYSTEM see **MONOSACCHARIDE TRANSPORT PROTEINS**

GLUCOSE SOLUTION, HYPERTONIC

METABOLISM

Effect of a dietary nonionic surfactant on small intestinal nutrient transport. Donegan L, et al. **Dig Dis Sci** 1999 Jul; 44(7):1423–7

PHARMACOLOGY

Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose. Louchami K, et al. **Endocrine** 1998 Jun; 8(3):247–50
The influence of a glucose drink on a demanding working memory task. Martin PY, et al. **Physiol Behav** 1999 Aug 1;67(1):69–74
Glucose and memory: fractionation of enhancement effects? Foster JK, et al. **Psychopharmacology (Berl)** 1998 Jun; 137(3):259–70
Determination of glycocalicin in platelet concentrate supernatants stored in a synthetic medium (Seto solution) [letter] Kunishima S, et al. **Vox Sang** 1998;75(1):74–5

GLUCOSE TOLERANCE TEST

The determination of basal glycemia and glucose tolerance curve: the manners of blood sampling. Golda V. **Acta Medica (Hradec Kralove)** 1998;41(3):121–3
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. Walli R, et al. **AIDS** 1998 Oct 22;12(15):F167–73
The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Joffe GM, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):1032–7
Overestimation of minimal model glucose effectiveness in presence of insulin response is due to undermodeling. Cobelli C, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1031–6
Glucose effectiveness is the major determinant of intravenous glucose tolerance in the rat. McArthur MD, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E739–46
Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. Vicini P, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E285–94
Impaired glucose tolerance and abnormal movements in patients with schizophrenia. Schultz SK, et al. **Am J Psychiatry** 1999 Apr;156(4):640–2
Quantitative immunohistochemical analysis of islet amyloid polypeptide (IAPP) in normal, impaired glucose tolerant, and diabetic cats. Ma Z, et al. **Amyloid** 1998 Dec; 5(4):255–61
Treadmill training enhances glucose tolerance more in pregnant than in virgin rats. Muñoz C, et al. **Biol Neonate** 1999 May;75(5):337–42
Effect of breakfast fat content on glucose tolerance and risk factors of atherosclerosis and thrombosis. Frape DL, et al. **Br J Nutr** 1998 Oct;80(4):323–31
The effect of occult diabetic status and oral glucose intake on brachial artery vasoactivity in patients with peripheral vascular disease. Avena R, et al. **Cardiovasc Surg** 1998 Dec; 6(6):584–9
Human oral mucosa studies with varying blood glucose concentration by non-invasive ATR-FT-IR-spectroscopy. Heise HM, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Sep;44(6):899–912
Controlled oral glucose tolerance test: evaluation of insulin resistance with an insulin infusion algorithm that forces the OGTT glycaemic curve within the normal range. A feasibility study. Volpicelli G, et al. **Clin Physiol** 1999 Jan; 19(1):32–44
Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Kilpatrick ES, et al. **Diabet Med** 1999 Jun;16(6):496–9
Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. American Diabetes Association. Mannucci E, et al. **Diabet Med** 1999 Jul; 16(7):579–85
Fetal growth and hyperinsulinaemia in adult life. Martyn CN, et al. **Diabet Med** 1998 Aug;15(8):688–94
No deterioration in insulin sensitivity, but impairment of both pancreatic beta-cell function and glucose sensitivity, in Japanese women with former gestational diabetes mellitus. Sakamaki H, et al. **Diabet Med** 1998 Dec;15(12):1039–44
Insulin secretion and action in different stages of glucose tolerance in Asian Indians. Snehalatha C, et al. **Diabet Med** 1999 May;16(5):408–14
Reversion from type 2 diabetes to nondiabetic status. Influence of the 1997 American Diabetes Association criteria. Burke JP, et al. **Diabetes Care** 1998 Aug; 21(8):1266–70
Screening for gestational diabetes mellitus. A perspective in 1998. Carr SR. **Diabetes Care** 1998 Aug;21 Suppl 2:B14–8
Differential glucose tolerance in dipper and nondipper essential hypertension: the implications of circadian blood pressure regulation on glucose tolerance in hypertension. Chen JW, et al. **Diabetes Care** 1998 Oct;21(10):1743–8
Effect of phlebotomy on plasma glucose and insulin concentrations [letter] Facchini FS. **Diabetes Care** 1998 Dec;21(12):2190
Isn't it time to retire the oral glucose tolerance test for diabetes screening and diagnosis? [editorial; comment] Goldstein DE. **Diabetes Care** 1998 Aug;21(8):1215–6. Comment on: Diabetes Care 1998 Aug;21(8):1221–5.
Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Ko GT, et al. **Diabetes Care** 1998 Dec;21(12):2094–7
Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes. Kousta E, et al. **Diabetes Care** 1999 Jun;22(6):933–7
Early postpartum metabolic assessment in women with prior gestational diabetes. Pallardo F, et al. **Diabetes Care** 1999 Jul;22(7):1053–8
Revised concept for the estimation of insulin sensitivity from a single sample [letter] Raynaud E, et al. **Diabetes Care** 1999 Jun;22(6):1003–4
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study [see comments] Tominaga M, et al. **Diabetes Care** 1999 Jun;22(6):920–4. Comment in: Diabetes Care 1999 Jun;22(6):883–5.
Fasting proinsulin concentrations predict the development of type 2 diabetes. Wareham NJ, et al. **Diabetes Care** 1999 Feb;22(2):262–70
Impact of the new ADA diagnostic criteria for diabetes on an obese population: comparison with OGTT-based who criteria. Preliminary results [letter] Richard JL, et al. **Diabetes Metab** 1998 Sep;24(4):365–7
Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Castell C, et al. **Diabetes Res Clin Pract** 1999 Jan;43(1):33–40
Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Puavilai G, et al. **Diabetes Res Clin Pract** 1999 Apr;44(1):21–6
Epidemiological considerations related to the new diagnostic criteria for diabetes mellitus. The European Diabetes Epidemiology Group (EDEG) [news] **Diabetologia** 1998 Nov;41(11):51–2
Association between poor glucose tolerance and rapid post natal weight gain in seven-year-old children. Crowther NJ, et al. **Diabetologia** 1998 Oct;41(10):1163–7
Reduction of plasma leptin during a short-term fast, an oral glucose tolerance or a meal test can be a misleading bias in clinical studies [letter] Panarotto D, et al. **Diabetologia** 1999 May;42(5):634
Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Ruige JB, et al. **Diabetologia** 1999 Feb;42(2):177–80
Relationship between impaired glucose tolerance, non-insulin-dependent diabetes mellitus and obesity. Ferrannini E, et al. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:3–6; discussion 6–7
Effects of caffeine on glucose tolerance: a placebo-controlled study. Pizziol A, et al. **Eur J Clin Nutr** 1998 Nov; 52(11):846–9
Postpartum oral glucose tolerance tests in mothers of macarosomic infants: inadequacy of current antenatal test

criteria in detecting prediabetic state. Bukulmez O, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):29–34

Changes in sex hormones during an oral glucose tolerance test in healthy premenopausal women. Ivandic A, et al. **Fertil Steril** 1999 Feb;71(2):268–73

Changes in uterine artery doppler velocimetry in pregnant patients undergoing glucose tolerance test may predict adverse outcome in later pregnancy: a preliminary study. Jaffe R, et al. **Fetal Diagn Ther** 1998 Jul–Aug;13(4):241–3

Calcium homeostasis during oral glucose load in healthy women. D'Erasmo E, et al. **Horm Metab Res** 1999 Apr; 31(4):271–3

Suppression of growth hormone by oral glucose in the evaluation of tall stature. Holl RW, et al. **Horm Res** 1999; 51(1):20–4

Low vitamin K intake effects on glucose tolerance in rats. Sakamoto N, et al. **Int J Vitam Nutr Res** 1999 Jan; 69(1):27–31

The Ala/Val98 polymorphism of the hepatocyte nuclear factor–1alpha gene contributes to the interindividual variation in serum C-peptide response during an oral glucose tolerance test: evidence from studies of 231 glucose-tolerant first degree relatives of type 2 diabetic probands. Urhammer SA, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4506–9

Influence of feed intake and source of dietary carbohydrate on the metabolic response to propionate and glucose challenges in lactating goats. Schmidely P, et al. **J Dairy Sci** 1999 Apr;82(4):738–46

Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. Arrigo T, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:863–6

Glucose tolerance and beta-cell secretion in patients with thalassaemia major. Mangiagli A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:985–6

When is diabetes diabetes? [editorial; comment] Vinicor F. **JAMA** 1999 Apr 7;281(13):1222–4. Comment on: JAMA 1998 Apr 7;281(13):1203–10.

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe [see comments] **Lancet** 1999 Aug 21;354(9179):617–21. Comment in: Lancet 1999 Aug 21;354(9179):610–1.

Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Curb JD, et al. **Neurology** 1999 Mar 23;52(5):971–5

Inhibitory action of oral thyrotropin-releasing hormone on the glucoregulatory response of the oral glucose tolerance test. Duntas LH, et al. **Thyroid** 1998 Oct;8(10):929–33

[Measurement of glucose and diagnosis of diabetes mellitus] Odum L. **Ugeskr Laeger** 1999 Feb 15;161(7):928–31 (20 ref.) (Eng. Abstr.) **(Dan)**

[Glucose tolerance test for tracing of mitochondrial toxicity from nucleoside analogs] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2231–2 **(Dut)**

[Changes in insulin-glucose quotients in a glucose tolerance test in the third trimester] Günter HH, et al. **Zentralbl Gynakol** 1999;121(8):357–66 (Eng. Abstr.) **(Ger)**

[Study on blood glucose control of subjects with borderline type abnormality in 75 G oral glucose tolerance test values. The establishment of a high risk group on the basis of yearly observations] Goto A, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul;45(7):645–52 (Eng. Abstr.) **(Jpn)**

[Oral glucose load in gestational diabetes--a test that should be used reasonably] Daae LN. **Tidsskr Nor Laegeforen** 1999 Aug 10;119(18):2686 **(Nor)**

METHODS

Right lateral position reduces intra-individual variation during oral glucose tolerance tests [letter] Sanaka M, et al. **Diabet Med** 1998 Aug;15(8):706–7

Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Hermans MP, et al. **Diabetologia** 1999 Jun;42(6):678–87

Assessment of insulin sensitivity and secretion with the labelled intravenous glucose tolerance test: improved modelling analysis. Mari A. **Diabetologia** 1998 Sep; 41(9):1029–39

Beta-cell function during insulin-modified intravenous glucose tolerance test successfully assessed by the C-peptide minimal model. Toffolo G, et al. **Metabolism** 1999 Sep;48(9):1162–6

[The values of selected lipid parameters and atrial pressure in persons with hyperinsulinemia and normal glucose tolerance] Klin MJ, et al. **Pol Merkuriusz Lek** 1998 Jun; 4(24):312–4 (Eng. Abstr.) **(Pol)**

[The functional interrelationships of blood glucose and immunoreactive insulin in the intravenous glucose tolerance test in coronary atherosclerosis patients] Denisova TP, et al. **Klin Lab Diagn** 1999 Jul;(7):9–11 (Eng. Abstr.) **(Rus)**

[The metabolic syndrome: its detection with the 50-gram glucose test] Velázquez Alonso L, et al. **Aten Primaria** 1998 Nov 30;22(9):557–61 (Eng. Abstr.) **(Spa)**

STANDARDS

Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance. Levy J, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E365–75

Fasting plasma glucose in screening for diabetes in the Taiwanese population. Chang CJ, et al. **Diabetes Care** 1998 Nov;21(11):1856–60

Comparison of glucose tolerance categories according to World Health Organization and American Diabetes Association diagnostic criteria in a population-based study in Brazil. The Japanese-Brazilian Diabetes Study Group. Gimeno SG, et al. **Diabetes Care** 1998 Nov;21(11):1889–92

Lack of agreement between the World Health Organization Category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Gómez-Pérez FJ, et al. **Diabetes Care** 1998 Nov; 21(11):1886–8

The 75-g glucose tolerance test in pregnancy: a reference range determined on a low-risk population and related to selected pregnancy outcomes [see comments] Moses RG, et al. **Diabetes Care** 1998 Nov;21(11):1807–11. Comment in: Diabetes Care 1998 Nov;21(11):1789. Comment in: Diabetes Care 1999 Apr;22(4):653–4.

Gestational diabetes mellitus: who to test. How to test [editorial; comment] [see comments] Pettitt DJ. **Diabetes Care** 1998 Nov;21(11):1789. Comment on: Diabetes Care 1998 Nov;21(11):1803–6. Comment on: Diabetes Care 1998 Nov;21(11):1807–11. Comment in: Diabetes Care 1999 Apr;22(4):653–4.

Evaluation of the new fasting plasma glucose cutpoint of 7.0 mmol/l in detection of diabetes mellitus in the Thai population. Nitiyanant W, et al. **Diabetes Res Clin Pract** 1998 Sep;41(3):171–6

Diagnosis and follow-up of subjects with impaired glucose tolerance: how reliable is OGTT? Report from a Nigerian survey. Olatunbosun ST. **Diabetes Res Clin Pract** 1998 Aug; 41(2):147–8

Low carbohydrate intake and oral glucose-tolerance tests [letter; comment] Baschetti R. **Lancet** 1998 Oct 10; 352(9135):1223–4. Comment on: Lancet 1998 Jul 25;352(9124):289.

Low carbohydrate intake and oral glucose-tolerance tests [letter; comment] Yoshioka K, et al. **Lancet** 1998 Oct 10; 352(9135):1223; discussion 1224. Comment on: Lancet 1998 Jul 25;352(9124):289.

UTILIZATION

Influence of the laboratory upon requests for oral glucose tolerance tests for the diagnosis of diabetes mellitus [letter] Greenhalgh H, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):260–1

GLUCOSE TRANSPORT PROTEIN see **MONOSACCHARIDE TRANSPORT PROTEINS**

GLUCOSEPHOSPHATASE see **GLUCOSE-6-PHOSPHATASE**

GLUCOSEPHOSPHATASE DEFICIENCY see **GLYCOGEN STORAGE DISEASE TYPE I**

GLUCOSEPHOSPHATE DEHYDROGENASE

ANALYSIS

Prognostic estimation of survival of colorectal cancer patients with the quantitative histochemical assay of G6PDH activity and the multiparameter classification program CLASSIF1. Van Driel BE, et al. **Cytometry** 1999 Aug 15; 38(4):176–83

The correlation of cytologic degree of differentiation of infiltrative ductal breast carcinoma and cytochemical activity of glucose-6-phosphate dehydrogenase. Bokun R, et al. **Vojnosanit Pregl** 1998 Jul–Aug;55(4):369–72

ANTAGONISTS & INHIBITORS

Fructose induced deactivation of glucose-6-phosphate dehydrogenase activity and its prevention by pyruvate: implications in cataract prevention. Zhao W, et al. **Free Radic Res** 1998 Oct;29(4):315–20

Inhibition of cytoplasmic antigen, glucose- 6-phosphate dehydrogenase, by VH-CH1, an intracellular Fd fragment antibody derived from a semisynthetic Fd fragment phage display library. Mulligan-Kehoe MJ, et al. **J Mol Biol** 1999 May 28;289(1):41–55

BIOSYNTHESIS

Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Tsukamoto N, et al. **Blood Cells Mol Dis** 1998 Jun; 24(2):231–8

Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. Salvemini F, et al. **J Biol Chem** 1999 Jan 29; 274(5):2750–7

BLOOD

Hexokinase, glucose-6-phosphate dehydrogenase and antioxidant enzymes in diabetic reticulocytes: effects of insulin and vanadate. Gupta BL, et al. **Biochem Mol Biol Int** 1998 Dec;46(6):1145–52

Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Mordmüller B, et al. **Eur Cytokine Netw** 1998 Sep;9(3):239–45

Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. Tsai KJ, et al. **FEBS Lett** 1998 Oct 9;436(3):411–4

CHEMISTRY

Solution of the structure of tetrameric human glucose 6-phosphate dehydrogenase by molecular replacement. Au SW, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr; 55 (Pt 4):826–34

Stabilization against thermal inactivation promoted by sugars on enzyme structure and function: why is trehalose more effective than other sugars? Sola-Penna M, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):10–4

Regulation of D-glucose-6-phosphate dehydrogenase from Schizosaccharomyces pombe. Tsai CS, et al. **Biochem Cell Biol** 1998;76(4):645–8

DEFICIENCY see GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY

DRUG EFFECTS

Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. Van Driel BE, et al. **J Histochem Cytochem** 1999 May; 47(5):575–82 (50 ref.)

GENETICS

Analysis of common mutations and associated haplotypes in Chinese patients with glucose-6-phosphate dehydrogenase deficiency. Li P, et al. **Biochem Mol Biol Int** 1998 Dec; 46(6):1135–43

The interaction between Gilbert's syndrome and G6PD deficiency influences bilirubin levels [letter] Cappellini MD, et al. **Br J Haematol** 1999 Mar;104(4):928–9

Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Mordmüller B, et al. **Eur Cytokine Netw** 1998 Sep;9(3):239–45

Molecular anatomy of the human glucose 6-phosphate dehydrogenase core promoter. Franzè A, et al. **FEBS Lett** 1998 Oct 23;437(3):313–8

Detection of the most common G6PD gene mutations in Chinese using amplification refractory mutation system. Du CS, et al. **Hum Hered** 1999 Jun;49(3):133–8

Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait. Samilchuk E, et al. **Hum Hered** 1999 Jan;49(1):41–4

G6PD Mount Sinai: a new severe hemolytic variant characterized by dual mutations at nucleotides 376G and 1159T (N126D). Vlachos A, et al. **Hum Mutat** 1998;Suppl 1:S154–5

Glucose-6-phosphate dehydrogenase (G6PD) variants in Malaysian Chinese. Ainoon O, et al. **Hum Mutat (Online)** 1999 Oct;14(4):352

Amino acid conservation and clinical severity of human glucose-6-phosphate dehydrogenase mutations. Cheng YS, et al. **J Biomed Sci** 1999 Mar–Apr;6(2):106–14

Polyunsaturated fatty acids inhibit the expression of the glucose-6-phosphate dehydrogenase gene in primary rat hepatocytes by a nuclear posttranscriptional mechanism. Stabile LP, et al. **J Lipid Res** 1998 Oct;39(10):1951–63

Inhibition of cytoplasmic antigen, glucose- 6-phosphate dehydrogenase, by VH-CH1, an intracellular Fd fragment antibody derived from a semisynthetic Fd fragment phage display library. Mulligan-Kehoe MJ, et al. **J Mol Biol** 1999 May 28;289(1):41–55

Induction of glucose-6-phosphate dehydrogenase by lipopolysaccharide contributes to preventing nitric oxide-mediated glutathione depletion in cultured rat astrocytes. Garcia-Nogales P, et al. **J Neurochem** 1999 Apr; 72(4):1750–8

Genetic relationships of populations and the origins of new infestations of the Mediterranean fruit fly. He M, et al. **Mol Ecol** 1999 Aug;8(8):1247–57

Phylogenetic relationships of the New World monkeys (Primates, platyrrhini) based on nuclear G6PD DNA sequences. von Dornum M, et al. **Mol Phylogenet Evol** 1999 Apr;11(3):459–76

Postnatal expression of glucose-6-phosphate dehydrogenase in different brain areas. Ninfali P, et al. **Neurochem Res** 1998 Sep;23(9):1197–204

Molecular basis of glucose-6-phosphate dehydrogenase deficiency among Filipinos. Silao CL, et al. **Pediatr Int** 1999 Apr;41(2):138–41

Evidence for functional convergence of redox regulation in G6PDH isoforms of cyanobacteria and higher plants. Wendt UK, et al. **Plant Mol Biol** 1999 Jun;40(3):487–94

[Molecular characterization of glucose-6-phosphate dehydrogenase variants in four ethnic groups in Yunnan province of China] Jiang W, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Jun; 16(3):149–52 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

A rapid method for the purification of glucose-6-phosphate dehydrogenase from bovine lens. Ulusu NN, et al. **Int J Biochem Cell Biol** 1999 Jul;31(7):787-96

Purification, localisation and characterisation of glucose-6-phosphate dehydrogenase of Trypanosoma brucei. Heise N, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):21-32

METABOLISM

Importance of glucose-6-phosphate dehydrogenase activity in cell death. Tian WN, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1121-31

Dietary fats alter the activity and expression of glucose-6-phosphate dehydrogenase in rat lymphoid cells and tissues. Otton R, et al. **Biochem Mol Biol Int** 1998 Oct; 46(3):529-36

High glucose-6-phosphate dehydrogenase activity contributes to the structural plasticity of periglomerular cells in the olfactory bulb of adult rats. Ninfali P, et al. **Brain Res** 1999 Feb 20;819(1-2):150-4

Erythrocyte glucose-6-phosphate dehydrogenase activity assay and affinity for its substrate under "physiological" conditions. Leite AA, et al. **Braz J Med Biol Res** 1998 Dec;31(12):1533-5

G6PD activity and gene expression in leukemic cells from G6PD-deficient subjects. Batetta B, et al. **Cancer Lett** 1999 Jun 1;140(1-2):53-8

Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Préville X, et al. **Exp Cell Res** 1999 Feb 25;247(1):61-78

Degradation of hypochlorite-damaged glucose-6-phosphate dehydrogenase by the 20S proteasome. Ullrich O, et al. **Free Radic Biol Med** 1999 Sep;27(5-6):487-92

Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. Van Driel BE, et al. **J Histochem Cytochem** 1999 May; 47(5):575-82 (50 ref.)

A carbohydrate-rich diet stimulates glucose-6-phosphate dehydrogenase expression in rat hepatic sinusoidal endothelial cells. Spolarics Z. **J Nutr** 1999 Jan;129(1):105-8

The age-related changes in lipogenic enzymes: the role of dietary factors and thyroid hormone responsiveness. Mooradian AD, et al. **Mech Ageing Dev** 1999 May 3; 108(2):139-49

Purification, localisation and characterisation of glucose-6-phosphate dehydrogenase of Trypanosoma brucei. Heise N, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):21-32

Evidence for functional convergence of redox regulation in G6PDH isoforms of cyanobacteria and higher plants. Wendt UK, et al. **Plant Mol Biol** 1999 Jun;40(3):487-94

[Effect of hypoxia on activity of glucose-6-phosphate dehydrogenase in red mullet and sea scorpion tissues] Rusinova OS. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):63-8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Glucose 6-phosphate dehydrogenase is required for Salmonella typhimurium virulence and resistance to reactive oxygen and nitrogen intermediates. Lundberg BE, et al. **Infect Immun** 1999 Jan;67(1):436-8

[Expression and biochemical characterization of human G6PD gene 1376 and 1388 mutation in G6PD-deficient Escherichia coli] Jiang WY, et al. **I Chuan Hsueh Pao** 1998; 25(4):301-7 (Eng. Abstr.) **(Chi)**

GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY

BLOOD

Haemoglobin A2 concentration in glucose-6-phosphate-dehydrogenase-deficient patients. Al-Jawadi O, et al. **Acta Haematol** 1998;100(2):99-100

Limits to the use of the glucose 6-phosphate dehydrogenase/6-phosphogluconate dehydrogenase index for the detection of glucose 6-phosphate dehydrogenase deficiency [letter] Mosca A, et al. **Clin Chem Lab Med** 1998 Sep;36(9):737-8

Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Mordmüller B, et al. **Eur Cytokine Netw** 1998 Sep;9(3):239-45

Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. Tsai KJ, et al. **FEBS Lett** 1998 Oct 9;436(3):411-4

Increased erythrocyte deformability in fetal erythropoiesis and in erythrocytes deficient in glucose-6-phosphate dehydrogenase and other glycolytic enzymes. Johnson RM, et al. **Pediatr Res** 1999 Jan;45(1):106-13

COMPLICATIONS

Primaquine prophylaxis against malaria [letter; comment] Heppner DG Jr, et al. **Ann Intern Med** 1999 Mar 16; 130(6):536; discussion 536-7. Comment on: Ann Intern Med 1998 Aug 1;129(3):241-4.

Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Kaplan M, et al. **Clin Perinatol** 1998 Sep;25(3):575-90, viii (65 ref.)

Hemolysis due to G-6-PD deficiency induced by endoscopic sphincterotomy [letter] Katsinelos P, et al. **Endoscopy** 1998 Aug;30(6):581

Efficacy of WHO regimens in the management of leprosy patients with G6PD deficiency. Mysore V, et al. **Int J Lepr Other Mycobact Dis** 1999 Jun;67(2):159-61

Severe jaundice in a gunshot casualty due to the coexistence of Dubin-Johnson and glucose-6-phosphate dehydrogenase deficiency. Zamir D, et al. **J Clin Gastroenterol** 1999 Jun;28(4):383-5

Therapeutic modalities for G6PD-related jaundice [letter] Manzar S. **J Trop Pediatr** 1999 Feb;45(1):57

Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. Kaplan M, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):68-74

Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase- deficient newborns [letter] Kaplan M, et al. **Pediatrics** 1999 Feb;103(2):536-7

Field trials of a rapid test for G6PD deficiency in combination with a rapid diagnosis of malaria. Tantular IS, et al. **Trop Med Int Health** 1999 Apr;4(4):245-50

DIAGNOSIS

Evaluation of the blue formazan spot test for screening glucose 6 phosphate dehydrogenase deficiency. Pujades A, et al. **Int J Hematol** 1999 Jun;69(4):234-6

Field trials of a rapid test for G6PD deficiency in combination with a rapid diagnosis of malaria. Tantular IS, et al. **Trop Med Int Health** 1999 Apr;4(4):245-50

[Determination of glucose-6-phosphate dehydrogenase deficiency to prevent possible drug-induced hemolysis] Hadad Meléndez P, et al. **Rev Cubana Med Trop** 1991; 43(3):205 **(Spa)**

DRUG THERAPY

Effect of desferrioxamine in acute haemolytic anaemia of glucose-6-phosphate dehydrogenase deficiency. al-Rimawi HS, et al. **Acta Haematol** 1999;101(3):145-8

ENZYMOLOGY

G6PD activity and gene expression in leukemic cells from G6PD-deficient subjects. Batetta B, et al. **Cancer Lett** 1999 Jun 1;140(1-2):53-8

Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Mordmüller B, et al. **Eur Cytokine Netw** 1998 Sep;9(3):239-45

[Expression and biochemical characterization of human G6PD gene 1376 and 1388 mutation in G6PD-deficient Escherichia coli] Jiang WY, et al. **I Chuan Hsueh Pao** 1998; 25(4):301-7 (Eng. Abstr.) **(Chi)**

EPIDEMIOLOGY

Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Kaneko A, et al. **Acta Trop** 1998 Jul 30; 70(3):285-302

Primary lactase deficiency and past malarial endemicity in Sardinia [see comments] Meloni T, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):490-3. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):494-5.

Glucose-6-phosphate dehydrogenase deficiency and osteoarthritis in men of Northern Sardinia [letter] Fioravanti A, et al. **J Rheumatol** 1999 Jun;26(6):1425

GENETICS

Epidemiology of clinical hyperbilirubinaemia in Al Ain, United Arab Emirates. Dawodu A, et al. **Ann Trop Paediatr** 1998 Jun;18(2):93-9

Analysis of common mutations and associated haplotypes in Chinese patients with glucose-6-phosphate dehydrogenase deficiency. Li P, et al. **Biochem Mol Biol Int** 1998 Dec; 46(6):1135-43

Diversity in expression of glucose-6-phosphate dehydrogenase deficiency in females. Abdulrazzaq YM, et al. **Clin Genet** 1999 Jan;55(1):13-9

Genetic analysis of the glucose-6-phosphate dehydrogenase deficiency in a southern Croatia. Terzić J, et al. **Coll Antropol** 1998 Dec;22(2):485-9

Bilirubin levels in the acute hemolytic crisis of G6PD deficiency are related to Gilbert's syndrome. Iolascon A, et al. **Eur J Haematol** 1999 May;62(5):307-10

Detection of the most common G6PD gene mutations in Chinese using amplification refractory mutation system. Du CS, et al. **Hum Hered** 1999 Jun;49(3):133-8

Glucose-6-phosphate dehydrogenase (G6PD) variants in Malaysian Chinese. Ainoon O, et al. **Hum Mutat (Online)** 1999 Oct;14(4):352

Why G-6-PD deficiency is common in females [letter] Goraya JS. **Indian Pediatr** 1998 Sep;35(9):933

Glucose-6-phosphate dehydrogenase deficiency: why girls are affected? [letter; comment] Goyal R. **Indian Pediatr** 1998 Jul;35(7):688-9. Comment on: Indian Pediatr 1998 Jan;35(1):52-5.

Molecular basis of glucose-6-phosphate dehydrogenase deficiency among Filipinos. Silao CL, et al. **Pediatr Int** 1999 Apr;41(2):138-41

[Common mutation analysis for patients found in Tianjin area with glucose-6-phosphate dehydrogenase deficiency] Song L, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Aug;16(4):224-7 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Neutrophil function in glucose-6-phosphate dehydrogenase deficient neonates [letter] Yeung CY, et al. **J Paediatr Child Health** 1999 Jun;35(3):324-5

METABOLISM

Effect of vitamin K1 on glucose-6-phosphate dehydrogenase deficient neonatal erythrocytes in vitro. Kaplan M, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F218-20

PHYSIOPATHOLOGY

Gilbert's syndrome and jaundice in glucose-6-phosphate dehydrogenase deficient neonates. Iolascon A, et al. **Haematologica** 1999 Feb;84(2):99-102

Hemolytic crisis in G6PD-deficient individuals in the occupational setting. Djerassi L. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S26-8

Neutrophil function in glucose-6-phosphate dehydrogenase deficient neonates [letter] Yeung CY, et al. **J Paediatr Child Health** 1999 Jun;35(3):324-5

GLUCOSEPHOSPHATE ISOMERASE see **GLUCOSE-6-PHOSPHATE ISOMERASE**

GLUCOSEPHOSPHATE URIDYLYLTRANSFERASE see **UTP-GLUCOSE-1-PHOSPHATE URIDYLYLTRANSFERASE**

GLUCOSEPHOSPHATES

ANALYSIS

Simultaneous determination of glucosamine and glucosamine 4-phosphate in Lipid A with high-performance anion-exchange chromatography (HPAEC). Kiang J, et al. **Carbohydr Res** 1998 Nov;312(1-2):73-6

Growth dependence of alpha-glucan phosphorylase activity in Thermus thermophilus. Boeck B, et al. **Res Microbiol** 1998 Mar;149(3):171-6

CHEMISTRY

Simplification of adenophostin A defines a minimal structure for potent glucopyranoside-based mimics of D-myo-inositol 1,4,5-trisphosphate. Marwood RD, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):453-8

GLUCOSIDASES

ANALYSIS

Single cell studies of enzymatic hydrolysis of a tetramethylrhodamine labeled triglucoside in yeast. Le XC, et al. **Glycobiology** 1999 Mar;9(3):219-25

ANTAGONISTS & INHIBITORS

A facile synthesis of D-glucose-type gem-diamine 1-N-iminosugars: a new family of glucosidase inhibitors. Shitara E, et al. **Bioorg Med Chem** 1999 Jun;7(6):1241-6

Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Baron AD. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S51-5 (8 ref.)

Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Holman RR. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S21-5 (18 ref.)

CHEMICAL SYNTHESIS

Enzymatic transformations in supersaturated substrate solutions: I. A general study with glycosidases. Millqvist-Fureby A, et al. **Biotechnol Bioeng** 1998 Oct 20; 60(2):190-6

CHEMISTRY

Development of an ultra-high-temperature process for the enzymatic hydrolysis of lactose. I. The properties of two thermostable beta-glycosidases. Petzelbauer I, et al. **Biotechnol Bioeng** 1999 Aug 5;64(3):322-32

GENETICS

The transcriptional activator XlnR regulates both xylanolytic and endoglucanase gene expression in Aspergillus niger. van Peij NN, et al. **Appl Environ Microbiol** 1998 Oct; 64(10):3615-9

Restoration of the activity of active-site mutants of the hyperthermophilic beta-glycosidase from Sulfolobus solfataricus: dependence of the mechanism on the action of external nucleophiles. Moracci M, et al. **Biochemistry** 1998 Dec 8;37(49):17262-70

GLUCOSIDASES

METABOLISM

Restoration of the activity of active-site mutants of the hyperthermophilic beta-glycosidase from Sulfolobus solfataricus: dependence of the mechanism on the action of external nucleophiles. Moracci M, et al. **Biochemistry** 1998 Dec 8;37(49):17262-70

The gene bglH present in the bgl operon of Escherichia coli, responsible for uptake and fermentation of beta-glucosides encodes for a carbohydrate-specific outer membrane porin. Andersen C, et al. **Mol Microbiol** 1999 Jan;31(2):499-510

A diagnostic protocol for adult-onset glycogen storage disease type II. Ausems MG, et al. **Neurology** 1999 Mar 10;52(4):851-3

GLUCOSIDES

ADMINISTRATION & DOSAGE

Protective effects of dietary cyanidin 3-O-beta-D-glucoside on liver ischemia-reperfusion injury in rats. Tsuda T, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):361-6

Association of liposomes containing a soybean-derived sterylglucoside mixture with rat primary cultured hepatocytes. Shimizu K, et al. **Biol Pharm Bull** 1998 Aug; 21(8):818-22

High absorbency and subchronic morphologic effects on the nasal epithelium of a nasal insulin powder dosage form with a soybean-derived sterylglucoside mixture in rabbits. Yamamoto T, et al. **Biol Pharm Bull** 1998 Aug;21(8):866-70

Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Li D, et al. **Cancer Lett** 1999 Jul 19;142(1):91-6

Renal drug targeting using a vector "alkylglycoside". Suzuki K, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):57-64

ANALYSIS

PhastSystem electrophoresis in beta-octylglucoside containing gels with immunodetection of a nondenatured vesicle-associated membrane protein. Buzás Z, et al. **Electrophoresis** 1999 Jun;20(7):1390-7

High-performance liquid chromatography coupled with fluorescence detection for the determination of trans-astringin in wine. Carando S, et al. **J Chromatogr A** 1999 Jul 23;849(2):617-20

The modified DNA base beta-D-glucosyl-hydroxymethyluracil is not found in the tsetse fly stages of Trypanosoma brucei. van Leeuwen F, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):127-30

[Leiocarposid--lead structure for the quality assurance of Solidaginis virgaureae herba] Bader G, et al. **Pharmazie** 1998 Nov;53(11):805-6 **(Ger)**

[On the constituents of the root of fukuchiyama-jio, the hybrid of Rehmannia glutinosa var. purpurea and R. glutinosa forma hueichingensis] Kitagawa I, et al. **Yakugaku Zasshi** 1998 Oct;118(10):464-75 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Ability of the exopolymer excreted by Pseudoalteromonas antarctica NF3, to coat liposomes and to protect these structures against octyl glucoside. de la Maza A, et al. **J Biomater Sci Polym Ed** 1999;10(5):557-72

BIOSYNTHESIS

Biosynthesis of cyanogenic glucosides in Triglochin maritima and the involvement of cytochrome P450 enzymes. Nielsen JS, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):121-30

Biosynthesis and function of the modified DNA base beta-D-glucosyl-hydroxymethyluracil in Trypanosoma brucei. van Leeuwen F, et al. **Mol Cell Biol** 1998 Oct; 18(10):5643-51

The presence of CYP79 homologues in glucosinolate-producing plants shows evolutionary conservation of the enzymes in the conversion of amino acid to aldoxime in the biosynthesis of cyanogenic glucosides and glucosinolates. Bak S, et al. **Plant Mol Biol** 1998 Nov;38(5):725-34

BLOOD

Determination of aloesin in plasma by high-performance liquid chromatography as fluorescent 9-anthroyl derivative. Kim KH, et al. **Arch Pharm Res** 1998 Dec; 21(6):651-6

CHEMICAL SYNTHESIS

Syntheses of 1-deoxy-3-s-(1-thio-alpha-D-glucopyranosyl)-mannojirimycin and 1-deoxy-3-O-(5-thio-alpha-D-glucopyranosyl)-mannojirimycin as potential inhibitors of endo-alpha-D-mannosidase. Ding Y, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1215-20

Enzymatic synthesis of unsaturated fatty acid glucoside esters for dermo-cosmetic applications. Bousquet MP, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):730-6

A novel approach to biotransformations in aqueous-organic two-phase systems: enzymatic synthesis of alkyl beta-[D]-glucosides using microencapsulated beta-glucosidase. Yi Q, et al. **Biotechnol Bioeng** 1998 Nov 5;60(3):385-90

Synthesis of aryl 3-O-beta-cellobiosyl-beta-D-glucopyranosides for reactivity studies of 1,3-1,4-beta-glucanases. Planas A, et al. **Carbohydr Res** 1998 Aug;310(1-2):53-64

Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C, et al. **J Med Chem** 1999 Jul 29;42(15):2927-35

CHEMISTRY

PAF antagonistic activity of 2-hydroxy-3-methoxybenzoic acid glucose ester from Gentiana scabra. Huh H, et al. **Arch Pharm Res** 1998 Aug;21(4):436-9

Antibacterial phenylpropanoid glycosides from Paulownia tomentosa Steud. Kang KH, et al. **Arch Pharm Res** 1994 Dec;17(6):470-5

Galloylpaeoniflorin, a new acylated monoterpene glucoside from paeony root. Kang SS, et al. **Arch Pharm Res** 1991 Mar;14(1):52-4

Determination of the structure for polysubstituted flavonoid and 6-C-glucosyl flavonoids using 13C-1H long range couplings. Lee MW. **Arch Pharm Res** 1994 Dec;17(6):487-9

Characterization of a heat modifiable protein, Escherichia coli outer membrane protein OmpA in binary surfactant system of sodium dodecyl sulfate and octylglucoside. Ohnishi S, et al. **Biochim Biophys Acta** 1998 Oct 15; 1375(1-2):101-9

Ptaquiloside Z, a new toxic unstable sesquiterpene glucoside from the neotropical bracken fern Pteridium aquilinum var. caudatum. Castillo UF, et al. **Bioorg Med Chem** 1998 Nov; 6(11):2229-33

Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Ohkubo M, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1219-24

Potent anticonvulsant paeonimetabolin-I derivatives obtained by incubation of paeoniflorin and thiol compounds with Lactobacillus brevis. Abdel-Hafez AA, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep;46(9):1486-7

PhastSystem electrophoresis in beta-octylglucoside containing gels with immunodetection of a nondenatured vesicle-associated membrane protein. Buzás Z, et al. **Electrophoresis** 1999 Jun;20(7):1390-7

Spectroscopic studies of the interaction of Ca2+-ATPase-peptides with dodecyl maltoside and its brominated analog. Soulié S, et al. **Eur J Biochem** 1998 Oct 1;257(1):216-27

GENETICS

Characterization of Mycobacterium smegmatis mutants defective in 1-d-myo-inosityl-2-amino-2-deoxy-alpha-d-glucopyranoside and mycothiol biosynthesis. Newton GL, et al. **Biochem Biophys Res Commun** 1999 Feb 16; 255(2):239-44

ISOLATION & PURIFICATION

Isolation and identification of succinic semialdehyde dehydrogenase inhibitory compound from the rhizome of Gastrodia elata Blume. Baek NI, et al. **Arch Pharm Res** 1999 Apr;22(2):219-24

PAF antagonistic activity of 2-hydroxy-3-methoxybenzoic acid glucose ester from Gentiana scabra. Huh H, et al. **Arch Pharm Res** 1998 Aug;21(4):436-9

Iridoid compounds from Boschniakia rossica. Yin ZZ, et al. **Arch Pharm Res** 1999 Feb;22(1):78-80

A new sinapoyl derivative of isovitexin 6''-O-beta-D-glucopyranoside from Alliaria petiolata. Haribal M, et al. **J Nat Prod** 1999 Jan;62(1):179-80

Patulosides A and B, novel xanthone glycosides from cell suspension cultures of Hypericum patulum. Ishiguro K, et al. **J Nat Prod** 1999 Jun;62(6):906-8

Pikuroside: a novel iridoid from Picrorhiza kurroa. Jia Q, et al. **J Nat Prod** 1999 Jun;62(6):901-3

Isolation and absolute structures of enantiomeric 1,2-bis(4-hydroxy-3-methoxyphenyl)-1,3-propanediol 1-O-glucosides from the bark of Hovenia trichocarpa. Yoshikawa K, et al. **J Nat Prod** 1998 Sep;61(9):1137-9

Iridoid and seco-iridoid glucosides from Chioccoca alba (Rubiaceae). Carbonezi CA, et al. **Phytochemistry** 1999 Jul; 51(6):781-5

Trans-fused iridoid glycosides from Penstemon mucronatus. Krull RE, et al. **Phytochemistry** 1998 Dec;49(8):2413-5

[Flavonoids in the rhizome of Sparganum stoloniferum Buch.-Ham.] Zhang W, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Sep;21(9):550-1, 576 (Eng. Abstr.) **(Chi)**

[Studies on the constituents of Ligustrum species. XIX. Structures of iridoid glucosides from the leaves of Ligustrum lucidum AIT] Kikuchi M, et al. **Yakugaku Zasshi** 1999 Jun;119(6):444-50 (Eng. Abstr.) **(Jpn)**

METABOLISM

Metabolism of liriodendrin and syringin by human intestinal bacteria and their relation to in vitro cytotoxicity. Kim DH, et al. **Arch Pharm Res** 1999 Feb;22(1):30-4

The different functions of BglF, the E. coli beta-glucoside permease and sensor of the bgl system, have different structural requirements. Chen Q, et al. **Biochemistry** 1998 Dec 1;37(48):17040-7

Interaction of a novel GDP exchange inhibitor with the Ras protein. Ganguly AK, et al. **Biochemistry** 1998 Nov 10; 37(45):15631-7

Spectroscopic studies on the interaction of aristololactam-beta-D-glucoside with DNA and RNA double and triple helices: A comparative study. Ray A, et al. **Biochemistry** 1999 May 11;38(19):6239-47

Anticonvulsant activity of paeonimetabolin-I adducts obtained by incubation of paeoniflorin and thiol compounds with Lactobacillus brevis. Abdel-Hafez AA, et al. **Biol Pharm Bull** 1999 May;22(5):491-7

Enzymatic synthesis of alpha-butylglucoside lactate: a new alpha-hydroxy acid derivative. Bousquet MP, et al. **Biotechnol Bioeng** 1999 Jan 20;62(2):225-34

In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil) 5H-indolo+ +[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans. Takenaga N, et al. **Drug Metab Dispos** 1999 Feb;27(2):213-20

Absorption and metabolism of cyanidin 3-O-beta-D-glucoside in rats. Tsuda T, et al. **FEBS Lett** 1999 Apr 23;449(2-3):179-82

Active alpha-glucoside transport in Saccharomyces cerevisiae. Stambuk BU, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):105-10

Single cell studies of enzymatic hydrolysis of a tetramethylrhodamine labeled triglucoside in yeast. Le XC, et al. **Glycobiology** 1999 Mar;9(3):219-25

Growth of Azospirillum irakense KBC1 on the aryl beta-glucoside salicin requires either salA or salB. Faure D, et al. **J Bacteriol** 1999 May;181(10):3003-9

A novel Sinorhizobium meliloti operon encodes an alpha-glucosidase and a periplasmic-binding-protein-dependent transport system for alpha-glucosides. Willis LB, et al. **J Bacteriol** 1999 Jul; 181(14):4176-84

Identification of glutathionyl-3-hydroxykynurenine glucoside as a novel fluorophore associated with aging of the human lens. Garner B, et al. **J Biol Chem** 1999 Jul 23;274(30):20847-54

Biotransformation of resveratrol to piceid by Bacillus cereus. Cichewicz RH, et al. **J Nat Prod** 1998 Oct;61(10):1313-4

Elucidation of a PTS-carbohydrate chemotactic signal pathway in Escherichia coli using a time-resolved behavioral assay. Lux R, et al. **Mol Biol Cell** 1999 Apr; 10(4):1133-46

Biosynthesis and function of the modified DNA base beta-D-glucosyl-hydroxymethyluracil in Trypanosoma brucei. van Leeuwen F, et al. **Mol Cell Biol** 1998 Oct; 18(10):5643-51

A putative sigma factor from Streptomyces sp. strain A21 can activate the expression of the cryptic operon bgl in Escherichia coli K-12. Marri L, et al. **Mol Gen Genet** 1999 Feb;261(1):201-7

The gene bglH present in the bgl operon of Escherichia coli, responsible for uptake and fermentation of beta-glucosides encodes for a carbohydrate-specific outer membrane porin. Andersen C, et al. **Mol Microbiol** 1999 Jan;31(2):499-510

The photochemical attachment of the O-glucoside of 3-hydroxykynurenine to alpha-crystallin: a model for lenticular aging. Dillon J, et al. **Photochem Photobiol** 1999 Feb;69(2):248-53

Iridoid glycoside biosynthesis in Penstemon secundiflorus. Another H-5, H-9 trans-iridoid glycoside. Krull RE, et al. **Phytochemistry** 1998 Nov;49(6):1605-8

PHARMACOKINETICS

In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil) 5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites. Takenaga N, et al. **Drug Metab Dispos** 1999 Feb;27(2):205-12

Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. Shimoi K, et al. **FEBS Lett** 1998 Nov 6;438(3):220-4

Intestinal absorption of acyclovir beta-glucoside: comparative study with acyclovir, guanosine, and kinetin beta-glucoside. Mizuma T, et al. **Pharm Res** 1999 Jan; 16(1):69-73

PHARMACOLOGY

Alaternin, cassiaside and rubrofusarin gentiobioside, radical scavenging principles from the seeds of Cassia tora on 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical. Choi JS, et al. **Arch Pharm Res** 1994 Dec;17(6):462-6

Metabolism of liriodendrin and syringin by human intestinal bacteria and their relation to in vitro cytotoxicity. Kim DH, et al. **Arch Pharm Res** 1999 Feb;22(1):30-4

Inhibitory effect of tetrahydroswertianolin on tumor necrosis factor-alpha-dependent hepatic apoptosis in mice. Hase K, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1431-7

Restoration of the activity of active-site mutants of the hyperthermophilic beta-glycosidase from Sulfolobus solfataricus: dependence of the mechanism on the action of external nucleophiles. Moracci M, et al. **Biochemistry** 1998 Dec 8;37(49):17262-70

Nasal insulin delivery in rabbits using soybean-derived sterylglucoside and sterol mixtures as novel enhancers in

suspension dosage forms. Ando T, et al. **Biol Pharm Bull** 1998 Aug;21(8):862–5
Induction of cytokines by a phenylpropanoid glycoside acteoside. Inoue M, et al. **Biol Pharm Bull** 1998 Dec; 21(12):1394–5
The promoting effects of geniposidic acid and aucubin in Eucommia ulmoides Oliver leaves on collagen synthesis. Li Y, et al. **Biol Pharm Bull** 1998 Dec;21(12):1306–10
Improvement in the turnover rate of the stratum corneum in false aged model rats by the administration of geniposidic acid in Eucommia ulmoides Oliver Leaf. Li Y, et al. **Biol Pharm Bull** 1999 Jun;22(6):582–5
Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED–110. Zembower DE, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):145–50
Effects of simmondsin on food intake, growth, and metabolic variables in lean (+/?) and obese (fa/fa) Zucker rats. Flo G, et al. **Br J Nutr** 1999 Feb;81(2):159–67
Inhibitory effects of monoacylated 2-O-beta-galactosylglycerols on Epstein–Barr virus activation: the significant role of the hexanoyl chain. Colombo D, et al. **Cancer Lett** 1999 Aug 23;143(1):1–4
Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Bailly C, et al. **Cancer Res** 1999 Jun 15;59(12):2853–60
A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Komatani H, et al. **Cancer Res** 1999 Jun 1;59(11):2701–8
Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Yoshinari T, et al. **Cancer Res** 1999 Sep 1;59(17):4271–5
Inhibition of some hepatic lysosomal glycosidases by ethanolamines and phenyl 6-deoxy-6-(morpholin-4-yl)-beta-D-glucopyranoside. Balbaa M, et al. **Carbohydr Res** 1999 Apr 30;317(1–4):100–9
Antioxidative and chelating activities of phenylpropanoid glycosides from Pedicularis striata. Li J, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):77–80
Two different modes of inhibition of the rat brain Na+, K(+)-ATPase by triterpene glycosides, psolusosides A and B from the holothurian Psolus fabricii. Gorshkova IA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):101–8
Quercetin glucosides interact with the intestinal glucose transport pathway. Gee JM, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):19–25
Comparison of the effects of simmondsin and cholecystokinin on metabolism, brown adipose tissue and the pancreas in food-restricted rats. Flo G, et al. **Horm Metab Res** 1998 Aug;30(8):504–8
The bvr locus of Listeria monocytogenes mediates virulence gene repression by beta-glucosides. Brehm K, et al. **J Bacteriol** 1999 Aug;181(16):5024–32
A pH-dependent conformational change of NhaA Na(+)/H(+) antiporter of Escherichia coli involves loop VIII–IX, plays a role in the pH response of the protein, and is maintained by the pure protein in dodecyl maltoside. Gerchman Y, et al. **J Biol Chem** 1999 Aug 27; 274(35):24617–24
Anticoagulant and antiprotease activities of a heparinoid sulfated glucoside-bearing polymer. Onishi M, et al. **J Biomater Sci Polym Ed** 1998;9(9):973–84
Mode of action of Buddleja cordata verbascoside against Staphylococcus aureus. Avila JG, et al. **J Ethnopharmacol** 1999 Jul;66(1):75–8
The satiating effect of a diet containing jojoba meal (Simmondsia chinensis) in dogs. Hawthorne AJ, et al. **J Nutr** 1998 Dec;128(12 Suppl):2669S–2670S
Disaccharide esters screened for inhibition of tumor necrosis factor-alpha release are new anti-cancer agents. Okabe S, et al. **Jpn J Cancer Res** 1999 Jun;90(6):669–76
The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. Chan P, et al. **Life Sci** 1998;63(19):1679–84
Acteoside inhibits apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury. Xiong Q, et al. **Life Sci** 1999;65(4):421–30
Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Bailly C, et al. **Mol Pharmacol** 1999 Feb;55(2):377–85
The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor. Pollack S, et al. **Mol Pharmacol** 1999 Jul;56(1):185–95
Different changes in concentrations of monoamines and their metabolites and amino acids in various brain regions by the herbal medicine/Toki-Shakuyaku-San between female and male senescence-accelerated mice (SAMP8). Komatsu M, et al. **Neurochem Res** 1999 Jul;24(7):825–31
Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from multimer dissociation. Pillion DJ, et al. **Pharm Res** 1998 Oct;15(10):1637–9
Mechanism of action of verbascoside on the isolated rat heart: increases in level of prostacyclin. Pennacchio M, et al. **Phytother Res** 1999 May;13(3):254–5
Yariv reagent treatment induces programmed cell death in Arabidopsis cell cultures and implicates arabinogalactan protein involvement. Gao M, et al. **Plant J** 1999 Aug; 19(3):321–31
Colony stimulating factor-inducing activity of isoflavone C-glucosides from the bark of Dalbergia monetaria [letter] Kawaguchi K, et al. **Planta Med** 1998 Oct;64(7):653–5
Hypoglycaemic activity of an HMG-containing flavonoid glucoside, chamaemeloside, from Chamaemelum nobile. König GM, et al. **Planta Med** 1998 Oct;64(7):612–4
Inhibitory effect of luteolin 4'-O-glucoside from Kummerowia striata and other flavonoids on interleukin-5 bioactivity [letter] Park KY, et al. **Planta Med** 1999 Jun; 65(5):457–9
Liver-protective activities of aucubin derived from traditional oriental medicine. Chang IM. **Res Commun Mol Pathol Pharmacol** 1998 Nov; 102(2):189–204
[Effect of glucosidorum Tripterygii tororum on interleukin-6 and interleukin-8 on human peripheral mononuclear cells of healthy subjects] Wang ZG. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):348–50 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Effects of paeoniflorin derivatives on scopolamine-induced amnesia using a passive avoidance task in mice; structure-activity relationship. Abdel-Hafez AA, et al. **Biol Pharm Bull** 1998 Nov;21(11):1174–9
Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Prasad K. **Circulation** 1999 Mar 16; 99(10):1355–62
Papillary hypertrophy of the upper tarsal conjunctiva during contact lens wear: a 4-month study with ethyl-6-O-decanoyl-glucoside. Vaahtoranta-Lehtonen HH, et al. **CLAO J** 1999 Apr;25(2):105–8
T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Oku A, et al. **Diabetes** 1999 Sep;48(9):1794–800
Antidotal effect of glucoside extracted from Astragalus membranaceus on dimethoate intoxication in guinea pigs. Li Y, et al. **Med Lav** 1998;89 Suppl 2:S136–41
In vivo radioprotection by ocimum flavonoids: survival of mice. Uma Devi P, et al. **Radiat Res** 1999 Jan;151(1):74–8

GLUCOSIDURONATES see **GLUCURONATES**

GLUCOSINOLATES

ADMINISTRATION & DOSAGE

Effects of the bacterial status of rats on the changes in some liver cytochrome P450 (EC 1.14.14.1) apoproteins consequent to a glucosinolate-rich diet. Nugon-Baudon L, et al. **Br J Nutr** 1998 Sep;80(3):231–4

ANALYSIS

High-performance liquid-phase separation of glycosides. III. Determination of total glucosinolates in cabbage and rapeseed by capillary electrophoresis via the enzymatically released glucose. Karcher A, et al. **Anal Biochem** 1999 Feb 1;267(1):92–9

BIOSYNTHESIS

The presence of CYP79 homologues in glucosinolate-producing plants shows evolutionary conservation of the enzymes in the conversion of amino acid to aldoxime in the biosynthesis of cyanogenic glucosides and glucosinolates. Bak S, et al. **Plant Mol Biol** 1998 Nov;38(5):725–34

CHEMICAL SYNTHESIS

Thio sugars: biological relevance as potential new therapeutics. Witczak ZJ. **Curr Med Chem** 1999 Feb; 6(2):165–78 (100 ref.)

CHEMISTRY

Thio sugars: biological relevance as potential new therapeutics. Witczak ZJ. **Curr Med Chem** 1999 Feb; 6(2):165–78 (100 ref.)

METABOLISM

Conversion of glucosinolates to isothiocyanates in humans after ingestion of cooked watercress. Getahun SM, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):447–51

PHARMACOLOGY

Modulation of cytochrome P-450 and glutathione S-transferase isoform expression in vivo by intact and degraded indolyl glucosinolates. Bonnesen C, et al. **Nutr Cancer** 1999;33(2):178–87

URINE

Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Shapiro TA, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec; 7(12):1091–100

GLUCOSYL CERAMIDES see **GLUCOSYLCERAMIDES**

GLUCOSYLCERAMIDASE

ADMINISTRATION & DOSAGE

Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Zirzow GC, et al. **Neurochem Res** 1999 Feb; 24(2):301–5
Cerebroside-beta-glucosidase encapsulation in liposomes for Gaucher's disease treatment revisited. Korablyov V, et al. **Pharm Res** 1999 Mar;16(3):466–9
Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. Elstein D, et al. **QJM** 1998 Jul;91(7):483–8
[Uveitis masquerade syndrome in Gaucher disease. Causal treatment by alglucerase substitution therapy] Dann K, et al. **Klin Monatsbl Augenheilkd** 1998 Dec;213(6):358–61 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy [letter] Erjavec Z, et al. **Ann Oncol** 1999 Feb;10(2):243
Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. Aviner S, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):92–4

ANALYSIS

Cerezyme: a case study. Edmunds T. **Dev Biol Stand** 1998; 96:131–40
Beta-glucocerebrosidase activity in mammalian stratum corneum. Takagi Y, et al. **J Lipid Res** 1999 May;40(5):861–9

ANTAGONISTS & INHIBITORS

Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Ogawa S, et al. **Bioorg Med Chem** 1998 Oct;6(10):1955–62
Synthesis and evaluation of glucocerebrosidase inhibitory activity of anhydro deoxyinositols from (+)-epi- and (-)-vibo-quercitols. Ogawa S, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1493–8
Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. Overkleeft HS, et al. **J Biol Chem** 1998 Oct 9;273(41):26522–7

CHEMISTRY

A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Friedman B, et al. **Blood** 1999 May 1;93(9):2807–16

DEFICIENCY

Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice. Doering T, et al. **FEBS Lett** 1999 Mar 26;447(2-3):167–70

GENETICS

Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease. Germain DP, et al. **Am J Hum Genet** 1998 Aug;63(2):415–27
Glucocerebrosidase mutations among Chinese neuronopathic and non-neuronopathic Gaucher disease patients [letter] Choy FY, et al. **Am J Med Genet** 1999 Jun 11;84(5):484–6
Mutation analysis of Gaucher disease patients from Argentina: high prevalence of the RecNciI mutation. Cormand B, et al. **Am J Med Genet** 1998 Dec 4; 80(4):343–51 (43 ref.)
A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Sinclair G, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):420–7
Dolphin beta-glucocerebrosidase, map position 1q22. Bielec P, et al. **Chromosome Res** 1998 Aug;6(5):425
Homozygosity for two mild glucocerebrosidase mutations of probable Iberian origin [letter] Amaral O, et al. **Clin Genet** 1999 Jul;56(1):100–2
Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease? Stone DL, et al. **Eur J Hum Genet** 1999 May-Jun;7(4):505–9
Murine MHC class II locus control region drives expression of human beta-glucocerebrosidase in antigen presenting cells of transgenic mice. Guy J, et al. **Gene Ther** 1999 Apr; 6(4):498–507
Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Dunbar CE, et al. **Hum Gene Ther** 1998 Nov 20; 9(17):2629–40
Long-term expression, systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primary myoblasts. Liu C, et al. **Hum Gene Ther** 1998 Nov 1;9(16):2375–84
Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Ida H, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):120–6
Two novel polymorphic sequences in the glucocerebrosidase gene region enhance mutational screening and founder

effect studies of patients with Gaucher disease. Lau EK, et al. **Hum Genet** 1999 Apr;104(4):293–300

Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population [published erratum appears in Hum Mutat 1999;13(3):255] Horowitz M, et al. **Hum Mutat** 1998;12(4):240–4

Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher disease patients. Mutation in brief no. 251. Online. Sarria AJ, et al. **Hum Mutat** 1999;14(1):88

Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. Grace ME, et al. **J Clin Invest** 1999 Mar; 103(6):817–23

Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes [see comments] Liu C, et al. **J Mol Med** 1998 Oct;76(11):773–81. Comment in: J Mol Med 1998 Oct;76(11):723–4.

Lessons from glucosylceramide and Gaucher's disease [comment] Luft FC. **J Mol Med** 1998 Oct;76(11):723–4. Comment on: J Mol Med 1998 Oct;76(11):773–81.

IMMUNOLOGY

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Rosenberg M, et al. **Blood** 1999 Mar 15;93(6):2081–8

METABOLISM

A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Friedman B, et al. **Blood** 1999 May 1;93(9):2807–16

Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators. Madar-Shapiro L, et al. **J Inherit Metab Dis** 1999 Jun;22(5):623–37

Beta-glucocerebrosidase activity in mammalian stratum corneum. Takagi Y, et al. **J Lipid Res** 1999 May;40(5):861–9

PHARMACOKINETICS

Long-term expression, systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primary myoblasts. Liu C, et al. **Hum Gene Ther** 1998 Nov 1;9(16):2375–84

THERAPEUTIC USE

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Rosenberg M, et al. **Blood** 1999 Mar 15;93(6):2081–8

Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. Aviner S, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):92–4

Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease [see comments] Cohen IJ, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):296–302. Comment in: Blood Cells Mol Dis 1998 Sep;24(3):303–5; discussion 306–8.

Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease [comment] Elstein D, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):303–5; discussion 306–8 . Comment on: Blood Cells Mol Dis 1998 Sep;24(3):296–302.

Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Czartoryska B, et al. **Clin Biochem** 1998 Jul;31(5):417–20

Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. Elstein D, et al. **Clin Genet** 1998 Sep;54(3):179–84

Enzyme replacement therapy for Gaucher's disease: the early Canadian experience. MacKenzie JJ, et al. **CMAJ** 1998 Nov 17;159(10):1273–8

Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient [letter] Aporta Rodriguez R, et al. **Haematologica** 1998 Sep;83(9):852–3

Hematologic response in type I Gaucher's disease after enzyme replacement therapy [letter] Parco S, et al. **Haematologica** 1999 Apr;84(4):376–7

Enzyme replacement therapy in type III Gaucher disease. Tylki-Szymańska A, et al. **J Inherit Metab Dis** 1999 Apr; 22(2):203–4

Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease [letter] Cenarro A, et al. **Lancet** 1999 Feb 20;353(9153):642–3

Quality of life assessment in adults with type 1 Gaucher disease. Masek BJ, et al. **Qual Life Res** 1999 May;8(3):263–8

Alglucerase treatment of type 1 Gaucher disease with pulmonary involvement. Martinez Odrizola P, et al. **Respir Med** 1998 Dec;92(12):1370–2

Enzyme therapy in Gaucher disease type 2: an autopsy case. Takahashi T, et al. **Tohoku J Exp Med** 1998 Oct; 186(2):143–9

[Gaucher's disease and enzyme replacement therapy] Cornu F. **Ann Pharm Fr** 1998;56(3):102–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months] Versteegh C, et al. **Arch Pediatr** 1998 Dec;5(12):1341–3 (Eng. Abstr.) **(Fre)**

GLUCOSYLCERAMIDES

BIOSYNTHESIS

Apoptosis induced by N-hexanoylsphingosine in CHP-100 cells associates with accumulation of endogenous ceramide and is potentiated by inhibition of glucocerebroside synthesis. Spinedi A, et al. **Cell Death Differ** 1998 Sep; 5(9):785–91

Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. Liu YY, et al. **J Biol Chem** 1999 Jan 8;274(2):1140–6

CHEMISTRY

Structure-activity relationship and conformational analysis of monoglycosylceramides on the syngeneic mixed leukocyte reaction. Iijima H, et al. **Bioorg Med Chem** 1998 Oct;6(10):1905–10

Structure and properties of totally synthetic galacto- and gluco-cerebrosides. Saxena K, et al. **J Lipid Res** 1999 May; 40(5):839–49

Isolation and structure of glucosylceramides from the starfish Cosmasterias lurida. Maier MS, et al. **Lipids** 1998 Aug; 33(8):825–7

ISOLATION & PURIFICATION

Isolation and structure of glucosylceramides from the starfish Cosmasterias lurida. Maier MS, et al. **Lipids** 1998 Aug; 33(8):825–7

METABOLISM

Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Pämpols T, et al. **Acta Neuropathol (Berl)** 1999 Jan;97(1):91–7

Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Nicholson KM, et al. **Br J Cancer** 1999 Oct;81(3):423–30

Apoptosis induced by N-hexanoylsphingosine in CHP-100 cells associates with accumulation of endogenous ceramide and is potentiated by inhibition of glucocerebroside synthesis. Spinedi A, et al. **Cell Death Differ** 1998 Sep; 5(9):785–91

Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice. Doering T, et al. **FEBS Lett** 1999 Mar 26;447(2–3):167–70

Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. Korkotian E, et al. **J Biol Chem** 1999 Jul 30;274(31):21673–8

Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. Wilkening G, et al. **J Biol Chem** 1998 Nov 13;273(46):30271–8

Intracellular degradation of fluorescent glycolipids by lysosomal enzymes and their activators. Madar-Shapiro L, et al. **J Inherit Metab Dis** 1999 Jun;22(5):623–37

Lessons from glucosylceramide and Gaucher's disease [comment] Luft FC. **J Mol Med** 1998 Oct;76(11):723–4. Comment on: J Mol Med 1998 Oct;76(11):773–81.

Drastically abnormal gluco- and galactosylceramide composition does not affect ganglioside metabolism in the brain of mice deficient in galactosylceramide synthase. Suzuki K, et al. **Neurochem Res** 1999 Apr;24(4):471–4

PHARMACOLOGY

Structure-activity relationship and conformational analysis of monoglycosylceramides on the syngeneic mixed leukocyte reaction. Iijima H, et al. **Bioorg Med Chem** 1998 Oct;6(10):1905–10

PHYSIOLOGY

Modulation of carcinoembryonic antigen release by glucosylceramide--implications for HT29 cell differentiation. Babia T, et al. **Eur J Biochem** 1998 Nov 15;258(1):233–42

GLUCOSYLTRANSFERASES

ANALYSIS

Characterization of trehalose phosphorylase from Schizophyllum commune. Eis C, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):385–93

ANTAGONISTS & INHIBITORS

Action of agents on glucosyltransferases from Streptococcus mutans in solution and adsorbed to experimental pellicle. Wunder D, et al. **Arch Oral Biol** 1999 Mar;44(3):203–14

Chemotherapy by slowing glucosphingolipid synthesis. Radin NS. **Biochem Pharmacol** 1999 Mar 15;57(6):589–95 (33 ref.)

Reassessment of acarbose as a transition state analogue inhibitor of cyclodextrin glycosyltransferase. Mosi R, et al. **Biochemistry** 1998 Dec 8;37(49):17192–8

Synthesis and evaluation of morpholino- and pyrrolidinosphingolipids as inhibitors of glucosylceramide synthase. Miura T, et al. **Bioorg Med Chem** 1998 Sep; 6(9):1481–9

Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Nicholson KM, et al. **Br J Cancer** 1999 Oct;81(3):423–30

Improved inhibitors of glucosylceramide synthase. Lee L, et al. **J Biol Chem** 1999 May 21;274(21):14662–9

[Modulators of glycosphingolipid biosynthesis (PDMP): application to cell biology] Inokuchi J. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2495–502 (38 ref.) **(Jpn)**

BIOSYNTHESIS

Production of trehalose synthase from a basidiomycete, Grifola frondosa, in Escherichia coli. Saito K, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):193–8

Application of factorial designs for optimization of cyclodextrin glycosyltransferase production from Klebsiella pneumoniae pneumoniae AS-22. Gawande BN, et al. **Biotechnol Bioeng** 1999 Jul 20;64(2):168–73

An early salicylic acid-, pathogen- and elicitor-inducible tobacco glucosyltransferase: role in compartmentalization of phenolics and H2O2 metabolism. Chong J, et al. **FEBS Lett** 1999 Sep 17;458(2):204–8

CHEMISTRY

Crystallization and improvement of crystal quality for x-ray diffraction of maltooligosyl trehalose synthase by reductive methylation of lysine residues. Kobayashi M, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):931–3

Effect of chemical modification of cyclodextrin glycosyltransferase (CGTase) from Thermoanaerobacter sp. on its activity and product selectivity. Alcalde M, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:183–7

Analysis of purified maize starch synthases IIa and IIb: SS isoforms can be distinguished based on their kinetic properties. Imparl-Radosevich JM, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):131–8

Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study. Wu K, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):395–400

The crystal structure of the Escherichia coli maltodextrin phosphorylase-acarbose complex. O'Reilly M, et al. **Biochemistry** 1999 Apr 27;38(17):5337–45

Key role of the diglucosyldiacylglycerol synthase for the nonbilayer-bilayer lipid balance of Acholeplasma laidlawii membranes. Vikström S, et al. **Biochemistry** 1999 Apr 27; 38(17):5511–20

Essential histidyl residues at the active site(s) of sucrose-phosphate synthase from Prosopis juliflora. Sinha AK, et al. **Biochim Biophys Acta** 1998 Nov 10; 1388(2):397–404

Conversion of cyclodextrin into high-amylose starch of low molecular mass by means of cyclodextrin glucanotransferase. Rendleman JAJr, et al. **Biotechnol Appl Biochem** 1998 Dec;28 (Pt 3):219–28

Proton relay system in the active site of maltodextrinphosphorylase via hydrogen bonds with large proton polarizability: an FT-IR difference spectroscopy study. Bartl F, et al. **Eur Biophys J** 1999;28(3):200–7

Chemical modification of lysine side chains of cyclodextrin glycosyltransferase from Thermoanaerobacter causes a shift from cyclodextrin glycosyltransferase to alpha-amylase specificity. Alcalde M, et al. **FEBS Lett** 1999 Feb 26; 445(2–3):333–7

Secondary structure of Streptococcus downei GTF-I glucansucrase. Monchois V, et al. **FEMS Microbiol Lett** 1999 Aug 15;177(2):243–8

Sequence analysis of the gene encoding amylosucrase from Neisseria polysaccharea and characterization of the recombinant enzyme. De Montalk GP, et al. **J Bacteriol** 1999 Jan;181(2):375–81

Trapped in the act of catalysis [news; comment] Davies GJ, et al. **Nat Struct Biol** 1999 May;6(5):406–8. Comment on: Nat Struct Biol 1999 May;6(5):432–6.

X-ray structures along the reaction pathway of cyclodextrin glycosyltransferase elucidate catalysis in the alpha-amylase family [see comments] Uitdehaag JC, et al. **Nat Struct Biol** 1999 May;6(5):432–6. Comment in: Nat Struct Biol 1999 May;6(5):406–8.

DEFICIENCY

Nonglucosylated oligosaccharides are transferred to protein in MI8-5 Chinese hamster ovary cells. Quellhorst GJ Jr, et al. **Glycobiology** 1999 Jan;9(1):65–72

Carbohydrate-deficient glycoprotein syndrome type V: deficiency of dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase. Körner C, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13200–5

[Solving riddles of glycosphingolipids: analyses of sphingolipid functions by a glucosylceramide synthase-deficient mutant] Ichikawa S, et al.

Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2281-7 (35 ref.) **(Jpn)**

DRUG EFFECTS

Effects of surfactants on glucosyltransferase production and in vitro sucrose-dependent colonization by Streptococcus mutans. Tomita Y, et al. **Arch Oral Biol** 1998 Sep; 43(9):735-40

GENETICS

Identification of Tn10 insertions in the rfaG, rfaP, and galU genes involved in lipopolysaccharide core biosynthesis that affect Escherichia coli adhesion. Genevaux P, et al. **Arch Microbiol** 1999 Jul;172(1):1-8

Molecular cloning and characterization of the mouse ceramide glucosyltransferase gene. Ichikawa S, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):707-11

Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study. Wu K, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):395-400

Assignment1 of a UDP-glucose:ceramide glucosyltransferase gene (Ugcg) to mouse chromosome band 4B3 by in situ hybridization. Ichikawa S, et al. **Cytogenet Cell Genet** 1998; 83(1-2):14-5

Cloning of cellulose synthase genes from Acetobacter xylinum JCM 7664: implication of a novel set of cellulose synthase genes. Umeda Y, et al. **DNA Res** 1999 Apr 30; 6(2):109-15

Two tobacco genes induced by infection, elicitor and salicylic acid encode glucosyltransferases acting on phenylpropanoids and benzoic acid derivatives, including salicylic acid. Fraissinet-Tachet L, et al. **FEBS Lett** 1998 Oct 23;437(3):319-23

Maltose metabolism of Lactobacillus sanfranciscensis: cloning and heterologous expression of the key enzymes, maltose phosphorylase and phosphoglucomutase. Ehrmann MA, et al. **FEMS Microbiol Lett** 1998 Dec 1;169(1):81-6

Detection of two loci involved in (1-->3)-beta-glucan (curdlan) biosynthesis by Agrobacterium sp. ATCC31749, and comparative sequence analysis of the putative curdlan synthase gene. Stasinopoulos SJ, et al. **Glycobiology** 1999 Jan;9(1):31-41

Inactivation of the gbpA gene of Streptococcus mutans alters structural and functional aspects of plaque biofilm which are compensated by recombination of the gtfB and gtfC genes. Hazlett KR, et al. **Infect Immun** 1999 Aug; 67(8):3909-14

Recombination between gtfB and gtfC is required for survival of a dTDP-rhamnose synthesis-deficient mutant of Streptococcus mutans in the presence of sucrose. Yamashita Y, et al. **Infect Immun** 1999 Jul;67(7):3693-7

Sucrose-phosphate synthase from Synechocystis sp. strain PCC 6803: identification of the spsA gene and characterization of the enzyme expressed in Escherichia coli. Curatti L, et al. **J Bacteriol** 1998 Dec;180(24):6776-9

Sequence analysis of the gene encoding amylosucrase from Neisseria polysaccharea and characterization of the recombinant enzyme. De Montalk GP, et al. **J Bacteriol** 1999 Jan;181(2):375-81

Isolation of an active catalytic core of Streptococcus downei MFe28 GTF-I glucosyltransferase. Monchois V, et al. **J Bacteriol** 1999 Apr;181(7):2290-2

A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. Thompson JR, et al. **J Bacteriol** 1999 Jan;181(2):444-53

Cloning and functional expression of UGT genes encoding sterol glucosyltransferases from Saccharomyces cerevisiae, Candida albicans, Pichia pastoris, and Dictyostelium discoideum. Warnecke D, et al. **J Biol Chem** 1999 May 7;274(19):13048-59

Molecular cloning and biochemical characterization of a novel anthocyanin 5-O-glucosyltransferase by mRNA differential display for plant forms regarding anthocyanin. Yamazaki M, et al. **J Biol Chem** 1999 Mar 12; 274(11):7405-11

Effects of mutations in the starch-binding domain of Bacillus macerans cyclodextrin glycosyltransferase. Chang HY, et al. **J Biotechnol** 1998 Oct 27;65(2-3):191-202

Expression and structural characterization of a baculovirus ecdysteroid UDP-glucosyltransferase. Evans OP, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):485-92

Functional analysis of the O antigen glucosylation gene cluster of Shigella flexneri bacteriophage SfX. Guan S, et al. **Microbiology** 1999 May;145 (Pt 5):1263-73

Genomic organization and expression properties of the MtSucS1 gene, which encodes a nodule-enhanced sucrose synthase in the model legume Medicago truncatula. Hohnjec N, et al. **Mol Gen Genet** 1999 Apr;261(3):514-22

Analysis of the cps1 gene provides evidence for a septation checkpoint in Schizosaccharomyces pombe. Le Goff X, et al. **Mol Gen Genet** 1999 Aug;262(1):163-72

Cloning and expression of a prokaryotic sucrose-phosphate synthase gene from the cyanobacterium Synechocystis sp. PCC 6803. Lunn JE, et al. **Plant Mol Biol** 1999 May; 40(2):297-305

Tissue-specific expression of two genes for sucrose synthase in carrot (Daucus carota L.). Sturm A, et al. **Plant Mol Biol** 1999 Jan;39(2):349-60

The localization and expression of the class II starch synthases of wheat. Li Z, et al. **Plant Physiol** 1999 Aug; 120(4):1147-56

A Selaginella lepidophylla trehalose-6-phosphate synthase complements growth and stress-tolerance defects in a yeast tps1 mutant. Zentella R, et al. **Plant Physiol** 1999 Apr; 119(4):1473-82

A mutation in the human ortholog of the Saccharomyces cerevisiae ALG6 gene causes carbohydrate-deficient glycoprotein syndrome type-Ic. Imbach T, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6982-7

Isolation of a cytokinin gene, ZOG1, encoding zeatin O-glucosyltransferase from Phaseolus lunatus. Martin RC, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):284-9

ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Yahr TL, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13899-904

IMMUNOLOGY

A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Childers NK, et al. **Infect Immun** 1999 Feb;67(2):618-23

Antibody to glucosyltransferase induced by synthetic peptides associated with catalytic regions of alpha-amylases. Smith DJ, et al. **Infect Immun** 1999 May; 67(5):2638-42

ISOLATION & PURIFICATION

Purification and characterization of an extremely thermostable cyclomaltodextrin glucanotransferase from a newly isolated hyperthermophilic archaeon, a Thermococcus sp. Tachibana Y, et al. **Appl Environ Microbiol** 1999 May;65(5):1991-7

Purification and properties of a novel raw starch degrading cyclomaltodextrin glucanotransferase from Bacillus firmus. Gawande BN, et al. **Appl Microbiol Biotechnol** 1999 Apr; 51(4):504-9

Purification of tomato sucrose synthase phosphorylated isoforms by Fe(III)-immobilized metal affinity chromatography. Anguenot R, et al. **Arch Biochem Biophys** 1999 May 1;365(1):163-9

Purification and characterization of sucrose synthase isozymes from etiolated rice seedlings. Huang DY, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):107-13

Purification and characterization of trehalose phosphorylase from the commercial mushroom Agaricus bisporus. Wannet WJ, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):177-88

Purification of glucosyltransferases (GtfB/C and GtfD) from mutant strains of Streptococcus mutans. Chia JS, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Feb;28(1):1-12

Purification and characterization of Streptococcus mutans glucosyltransferase (GtfC) expressed in Escherichia coli. Chia JS, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Nov;28(4):242-55

A single step purification process for cyclodextrin glucanotransferase from a Bacillus sp. isolated from soil. Thatai A, et al. **Prep Biochem Biotechnol** 1999 Feb; 29(1):35-47

Characterization of the Bacillus macerans cyclodextrin glucanotransferase overexpressed in Escherichia coli. Jeang CL, et al. **Proc Natl Sci Counc Repub China B** 1999 Apr; 23(2):62-8

METABOLISM

Effect of chemical modification of cyclodextrin glycosyltransferase (CGTase) from Thermoanaerobacter sp. on its activity and product selectivity. Alcalde M, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:183-7

Glucosylation by dextransucrase. Modeling of reaction kinetics and unconventional products. Heincke K, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:203-6

Biosynthesis of glycoproteins in Candida albicans: biochemical characterization of dolichol phosphate glucose synthase. Rodriguez-Bonilla J, et al. **Antonie Van Leeuwenhoek** 1998 May;73(4):373-80

Purification and properties of a novel raw starch degrading cyclomaltodextrin glucanotransferase from Bacillus firmus. Gawande BN, et al. **Appl Microbiol Biotechnol** 1999 Apr; 51(4):504-9

Production of cyclomaltononaose (delta-cyclodextrin) by cyclodextrin glycosyltransferases from Bacillus spp. and bacterial isolates. Larsen KL, et al. **Appl Microbiol Biotechnol** 1998 Sep;50(3):314-7

Identification of two uridine binding domain peptides of the UDP-glucose-binding site of rabbit muscle glycogenin. Carrizo ME, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):786-9

Glucuronidation of the environmental oestrogen bisphenol A by an isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Yokota H, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):405-9

Purification and characterization of sucrose synthase isozymes from etiolated rice seedlings. Huang DY, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):107-13

Identification of a gene, SOO1, which complements osmo-sensitivity and defect in in vitro beta1,3-glucan synthase activity in Saccharomyces cerevisiae. Lee DW, et al. **Biochim Biophys Acta** 1999 Jun 8;1450(2):145-54

Multi-enzymatic glucosylation using Eucalyptus UDP-glucosyltransferase coupled UDPglucose-fermentation by bakers' yeast. Nakajima N, et al. **Biosci Biotechnol Biochem** 1999 May;63(5):934-6

Modelling of oligosaccharide synthesis by dextransucrase. Demuth B, et al. **Biotechnol Bioeng** 1999 Mar 5; 62(5):583-92

Acceptor specificity of cellobiose phosphorylase from Cellvibrio gilvus: synthesis of three branched trisaccharides. Percy A, et al. **Carbohydr Res** 1998 Jun; 308(3-4):423-9

A misfolded protein conformation is not a sufficient condition for in vivo glucosylation by the UDP-Glc:glycoprotein glucosyltransferase. Fernández F, et al. **EMBO J** 1998 Oct 15;17(20):5877-86

Chemical modification of lysine side chains of cyclodextrin glycosyltransferase from Thermoanaerobacter causes a shift from cyclodextrin glycosyltransferase to alpha-amylase specificity. Alcalde M, et al. **FEBS Lett** 1999 Feb 26; 445(2-3):333-7

The stereochemical course of the reaction mechanism of trehalose phosphorylase from Schizophyllum commune. Eis C, et al. **FEBS Lett** 1998 Dec 4;440(3):440-3

Two tobacco genes induced by infection, elicitor and salicylic acid encode glucosyltransferases acting on phenylpropanoids and benzoic acid derivatives, including salicylic acid. Fraissinet-Tachet L, et al. **FEBS Lett** 1998 Oct 23;437(3):319-23

Essential arginine residues in maize starch synthase IIa are involved in both ADP-glucose and primer binding. Imparl-Radosevich JM, et al. **FEBS Lett** 1999 Sep 3; 457(3):357-62

Proposition for the biochemical mechanism occurring in the sucrose isomerase active site. Veronese T, et al. **FEBS Lett** 1998 Dec 28;441(3):348-52

Bacterial alpha-glucan phosphorylases. Schinzel R, et al. **FEMS Microbiol Lett** 1999 Feb 15;171(2):73-9 (34 ref.)

Four critical aspartic acid residues potentially involved in the catalytic mechanism of Escherichia coli K-12 WaaR. Shibayama K, et al. **FEMS Microbiol Lett** 1999 May 1; 174(1):105-9

The O-linked fucose glycosylation pathway: identification and characterization of a uridine diphosphoglucose: fucose-beta1,3-glucosyltransferase activity from Chinese hamster ovary cells. Moloney DJ, et al. **Glycobiology** 1999 Jul;9(7):679-87

Functional analyses of a conserved region in glucosyltransferases of Streptococcus mutans. Chia JS, et al. **Infect Immun** 1998 Oct;66(10):4797-803

Expression and study of recombinant ExoM, a beta1-4 glucosyltransferase involved in succinoglycan biosynthesis in Sinorhizobium meliloti. Lellouch AC, et al. **J Bacteriol** 1999 Feb;181(4):1141-8

The thermophilic yeast Hansenula polymorpha does not require trehalose synthesis for growth at high temperatures but does for normal acquisition of thermotolerance. Reinders A, et al. **J Bacteriol** 1999 Aug;181(15):4665-8

Conserved structural regions involved in the catalytic mechanism of Escherichia coli K-12 WaaO (RfaI). Shibayama K, et al. **J Bacteriol** 1998 Oct;180(20):5313-8

Maltose metabolism in the hyperthermophilic archaeon Thermococcus litoralis: purification and characterization of key enzymes. Xavier KB, et al. **J Bacteriol** 1999 Jun; 181(11):3358-67

Composition and functional analysis of the Saccharomyces cerevisiae trehalose synthase complex. Bell W, et al. **J Biol Chem** 1998 Dec 11;273(50):33311-9

Modification of the T cell antigen receptor (TCR) complex by UDP-glucose:glycoprotein glucosyltransferase. TCR folding is finalized convergent with formation of alpha beta delta epsilon gamma epsilon complexes. Gardner TG, et al. **J Biol Chem** 1999 May 14;274(20):14094-9

G-protein-stimulated phospholipase D activity is inhibited by lethal toxin from Clostridium sordellii in HL-60 cells. El Hadj NB, et al. **J Biol Chem** 1999 May 14; 274(20):14021-31

The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides. Heinrichs DE, et al. **J Biol Chem** 1998 Nov 6;273(45):29497-505

Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. Liu YY, et al. **J Biol Chem** 1999 Jan 8;274(2):1140-6

Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. Marks DL, et al. **J Biol Chem** 1999 Jan 1;274(1):451-6

Glucosylceramide synthase inhibitor inhibits the action of nerve growth factor in PC12 cells. Mutoh T, et al. **J Biol Chem** 1998 Oct 2;273(40):26001-7

Effects of mutations in the starch-binding domain of Bacillus macerans cyclodextrin glycosyltransferase. Chang HY, et al. **J Biotechnol** 1998 Oct 27;65(2-3):191-202

The UDP-Glc:Glycoprotein glucosyltransferase is essential for Schizosaccharomyces pombe viability under conditions of extreme endoplasmic reticulum stress. Fanchiotti S, et al. **J Cell Biol** 1998 Nov 2;143(3):625-35

Fission yeast alpha-glucan synthase Mok1 requires the actin cytoskeleton to localize the sites of growth and plays an essential role in cell morphogenesis downstream of protein kinase C function. Katayama S, et al. **J Cell Biol** 1999 Mar

GLUCOSYLTRANSFERASES

22;144(6):1173–86

Expression and structural characterization of a baculovirus ecdysteroid UDP-glucosyltransferase. Evans OP, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):485–92

Uridine diphosphate-glucose transport into the endoplasmic reticulum of Saccharomyces cerevisiae: in vivo and in vitro evidence. Castro O, et al. **Mol Biol Cell** 1999 Apr; 10(4):1019–30

A UDP glucosyltransferase from Bacillus subtilis successively transfers up to four glucose residues to 1,2-diacylglycerol: expression of ypfP in Escherichia coli and structural analysis of its reaction products. Jorasch P, et al. **Mol Microbiol** 1998 Jul;29(2):419–30

X-ray structures along the reaction pathway of cyclodextrin glycosyltransferase elucidate catalysis in the alpha-amylase family [see comments] Uitdehaag JC, et al. **Nat Struct Biol** 1999 May;6(5):432–6. Comment in: Nat Struct Biol 1999 May;6(5):406–8.

An increase in apparent affinity for sucrose of mung bean sucrose synthase is caused by in vitro phosphorylation or directed mutagenesis of Ser11. Nakai T, et al. **Plant Cell Physiol** 1998 Dec;39(12):1337–41

Site-directed mutagenesis of serine 158 demonstrates its role in spinach leaf sucrose-phosphate synthase modulation. Toroser D, et al. **Plant J** 1999 Feb;17(4):407–13

Transgenic tomato plants with decreased sucrose synthase are unaltered in starch and sugar accumulation in the fruit. Chengappa S, et al. **Plant Mol Biol** 1999 May;40(2):213–21

A Selaginella lepidophylla trehalose-6-phosphate synthase complements growth and stress-tolerance defects in a yeast tps1 mutant. Zentella R, et al. **Plant Physiol** 1999 Apr; 119(4):1473–82

A vital role for glycosphingolipid synthesis during development and differentiation. Yamashita T, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9142–7

Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Schnecke V, et al. **Proteins** 1998 Oct 1;33(1):74–87

Glycolysis, turbo design and the endocrine pancreatic beta cell [letter; comment] Iynedjian PB. **Trends Biochem Sci** 1998 Dec;23(12):467–8. Comment on: Trends Biochem Sci 1998 May;23(5):162–9.

[Recent advances in the analysis of ganglioside synthesis] Furukawa K. **Seikagaku** 1998 Jul;70(7):532–6 (28 ref.) **(Jpn)**

PHYSIOLOGY

Lamellar granule biogenesis: a role for ceramide glucosyltransferase, lysosomal enzyme transport, and the Golgi. Madison KC, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(2):80–6

GLUCURONATES

ANALYSIS

Can ethyl glucuronide be determined in post-mortem body fluids and tissues? [letter] Wurst FM, et al. **Alcohol Alcohol** 1999 Mar-Apr;34(2):262–3

Western blotting method for the immunostaining detection of glucuronides of glycyrrhetic acid using anti-glycyrrhizin monoclonal antibody. Shan S, et al. **Biol Pharm Bull** 1999 Feb;22(2):221–3

The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Korecka M, et al. **Clin Chem** 1999 Jul; 45(7):1047–50

A simple HPLC method for monitoring mycophenolic acid and its glucuronidated metabolite in transplant recipients. Seebacher G, et al. **Clin Chem Lab Med** 1999 Apr; 37(4):409–15

A fluorescent assay amenable to measuring production of beta-D-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Trubetskoy OV, et al. **Drug Metab Dispos** 1999 May;27(5):555–7

Structural elucidation of a novel exopolysaccharide produced by a mucoid clinical isolate of Burkholderia cepacia. Characterization of a trisubstituted glucuronic acid residue in a heptasaccharide repeating unit. Cérantola S, et al. **Eur J Biochem** 1999 Mar;260(2):373–83

Mass spectrometric and tandem mass spectrometric behavior of nitrocatechol glucuronides: a comparison of atmospheric pressure chemical ionization and electrospray ionization. Keski-Hynnilä H, et al. **J Am Soc Mass Spectrom** 1999 Jun;10(6):537–45

Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. Vree TB, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22; 721(2):217–28

Variations in urinary 1-hydroxypyrene glucuronide in relation to smoking and the modification effects of GSTM1 and GSTT1. Hong YC, et al. **Toxicol Lett** 1999 Sep 5; 108(2–3):217–23

Comparison of three analytical methods for 1-hydroxypyrene glucuronide in urine after non-occupational exposure to polycyclic aromatic hydrocarbons. Lee CK, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):209–15

BLOOD

Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Shipkova M, et al. **Clin Chem** 1999 Jan;45(1):127–9

High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. Kurita A, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 19; 724(2):335–44

Determination of ethyl glucuronide, a minor metabolite of ethanol, in human serum by liquid chromatography-electrospray ionization mass spectrometry. Nishikawa M, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 16; 726(1–2):105–10

A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Svensson JO, et al. **Ther Drug Monit** 1999 Jun; 21(3):322–4

CHEMICAL SYNTHESIS

Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard. Lougerstay-Madec R, et al. **Anticancer Drug Des** 1998 Dec;13(8):995–1007

Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides. Luukkanen L, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):150–4

Synthesis of delta4-beta-D-glucopyranosiduronic acids as mimetics of 2,3-unsaturated sialic acids for sialidase inhibition. Florio P, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2065–8

Synthesis of glucuronides of multidrug resistance reversing drug MS-209. Suzuki T, et al. **Bioorg Med Chem Lett** 1999 Mar 8;9(5):659–62

Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). Leu YL, et al. **J Med Chem** 1999 Sep 9;42(18):3623–8

CHEMISTRY

A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs. Papot S, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2545–8

Determination of Kow values for a series of aryl glucuronides. Kuehl DW, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):109–16

Stereochemistry of metabolites of a tobacco-specific lung carcinogen in smokers' urine. Carmella SG, et al. **Cancer Res** 1999 Aug 1;59(15):3602–5

Glucuronic acid conjugates. Bedford CT. **J Chromatogr B Biomed Sci Appl** 1998 Oct 9; 717(1–2):313–26 (78 ref.)

IMMUNOLOGY

Heterogeneity of antibody specificity in Taiwanese patients with polyneuropathy and IgM paraproteinemia. Lin KP, et al. **J Biomed Sci** 1998 Nov-Dec;5(6):441–5

ISOLATION & PURIFICATION

Separation of the glucuronides of entacapone and its (Z)-isomer in urine by micellar electrokinetic capillary chromatography. Lehtonen P, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 8;721(1):127–34

METABOLISM

Ethyl glucuronide--a marker of alcohol consumption and a relapse marker with clinical and forensic implications. Wurst FM, et al. **Alcohol Alcohol** 1999 Jan-Feb;34(1):71–7

Glucuronidation of the environmental oestrogen bisphenol A by an isoform of UDP-glucuronosyltransferase, UGT2B1, in the rat liver. Yokota H, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):405–9

Mono- and Diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7. Bock KW, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):653–6

Characterization of an antineoplastic glucuronide prodrug. Cheng TL, et al. **Biochem Pharmacol** 1999 Jul 15; 58(2):325–8

Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy. Yoshida H, et al. **Biol Pharm Bull** 1999 Jul;22(7):716–20

Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Sakamoto H, et al. **Cancer Lett** 1999 Jan 8;135(1):113–9

Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Nowell SA, et al. **Carcinogenesis** 1999 Jun;20(6):1107–14

Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Upadhyaya P, et al. **Carcinogenesis** 1999 Aug;20(8):1577–82

Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chiou YJ, et al. **Chem Biol Interact** 1999 Jul 1;121(2):141–59

Glucuronidation in humans. Pharmacogenetic and developmental aspects. de Wildt SN, et al. **Clin Pharmacokinet** 1999 Jun;36(6):439–52 (103 ref.)

Species differences in N-glucuronidation. Chiu SH, et al. **Drug Metab Dispos** 1998 Sep;26(9):838–47 (64 ref.)

Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Green MD, et al. **Drug Metab Dispos** 1998 Sep;26(9):860–7 (64 ref.)

N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Hawes EM. **Drug Metab Dispos** 1998 Sep;26(9):830–7 (75 ref.)

Glucuronidation of R- and S-ketoprofen, acetaminophen, and diflunisal by liver microsomes of adjuvant-induced arthritic rats. Meunier CJ, et al. **Drug Metab Dispos** 1999 Jan;27(1):26–31

Biotransformation of curcumin through reduction and glucuronidation in mice. Pan MH, et al. **Drug Metab Dispos** 1999 Apr;27(4):486–94

A fluorescent assay amenable to measuring production of beta-D-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Trubetskoy OV, et al. **Drug Metab Dispos** 1999 May;27(5):555–7

N-glucuronidation of benzidine and its metabolites. Role in bladder cancer. Zenser TV, et al. **Drug Metab Dispos** 1998 Sep;26(9):856–9 (43 ref.)

The small intestine can both absorb and glucuronidate luminal flavonoids. Spencer JP, et al. **FEBS Lett** 1999 Sep 17;458(2):224–30

Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Kamisako T, et al. **Hepatology** 1999 Aug;30(2):485–90

Regulation of hexuronate utilization in Bacillus subtilis. Mekjian KR, et al. **J Bacteriol** 1999 Jan;181(2):426–33

The glucuronic acid utilization gene cluster from Bacillus stearothermophilus T-6. Shulami S, et al. **J Bacteriol** 1999 Jun;181(12):3695–704

Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. Kobayashi M, et al. **J Biol Chem** 1999 Apr 9;274(15):10474–80

On-line deconjugation of glucuronides using an immobilized enzyme reactor based upon beta-glucuronidase. Di Marco MP, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 18; 715(2):379–86

Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. Furlan V, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1169–75

Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts. Bailey MJ, et al. **J Pharmacol Toxicol Methods** 1999 Feb;41(1):27–32

Glucuronidation of naringenin in rats. Peng HW, et al. **Planta Med** 1998 Dec;64(8):779

The role of glucuronidation in N-(3,5-dichlorophenyl)succinimide (NDPS) nephrotoxicity: nephrotoxic potential of NDPS and NDPS metabolites in Gunn, Wistar, and Fischer 344 rats. Hong SK, et al. **Toxicol Appl Pharmacol** 1999 Jan 15; 154(2):170–80

Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Cheng Z, et al. **Toxicol Sci** 1998 Sep;45(1):52–7

Effect of glucuronidation substrates/inhibitors on N-(3,5-dichlorophenyl)succinimide nephrotoxicity in Fischer 344 rats. Hong SK, et al. **Toxicology** 1999 Jan 1; 132(1):43–55

[Inhibition of the antioxidant protection, microsomal oxidation, and xenobiotic glucuroconjugation in rats with cholestasis and their regulation] Bushma MI, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):194–7 **(Rus)**

PHARMACOKINETICS

Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. Sabordo L, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):414–20

PHARMACOLOGY

Study of structure--hepatoprotective relationships of oleanene-type triterpenoidal glucuronides obtained from several fabaceous plants on rat primary hepatocyte cultures. Kinjo J, et al. **Biol Pharm Bull** 1999 Feb;22(2):203–6

Studies on Kochiae Fructus. V. Antipruritic effects of oleanolic acid glycosides and the structure-requirement. Matsuda H, et al. **Biol Pharm Bull** 1998 Nov;21(11):1231–3

Synthesis of delta4-beta-D-glucopyranosiduronic acids as mimetics of 2,3-unsaturated sialic acids for sialidase inhibition. Florio P, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2065–8

Hepatoprotective and hepatotoxic actions of oleanolic acid-type triterpenoidal glucuronides on rat primary hepatocyte cultures. Kinjo J, et al. **Chem Pharm Bull (Tokyo)** 1999 Feb;47(2):290–2

Antidiabetic principles of natural medicines. III.

Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Matsuda H, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1399-403

Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. Zhang Y, et al. **J Nutr** 1999 Feb;129(2):399-405

N-linked glycoside and glucuronide conjugates of the retinoid, acitretin, are biologically active in cornea and conjunctiva. Ubels JL, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):505-16

Microvascular protective activity of flavonoid glucuronides fraction from Tulipa gesneriana. Budzianowski J, et al. **Phytother Res** 1999 Mar;13(2):166-8

THERAPEUTIC USE

Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth. Abou-Issa HM, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):999-1004

TOXICITY

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Platel D, et al. **Br J Cancer** 1999 Sep;81(1):24-7

Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Upadhyaya P, et al. **Carcinogenesis** 1999 Aug;20(8):1577-82

URINE

O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Rosing H, et al. **Anticancer Drugs** 1998 Aug;9(7):587-92

Separatory determination of diastereomeric ibuprofen glucuronides in human urine by liquid chromatography/electrospray ionization-mass spectrometry. Ikegawa S, et al. **Biomed Chromatogr** 1998 Nov-Dec;12(6):317-21

Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Hecht SS, et al. **Cancer Res** 1999 Feb 1;59(3):590-6

Simultaneous extraction of selected benzodiazepines and benzodiazepine-glucuronides from urine by immunoadsorption. Franzelius C, et al. **J Anal Toxicol** 1998 Sep;22(5):359-62

Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine. Lehtonen P, et al. **J Chromatogr A** 1999 Mar 19;836(1):173-88

A validated method for the determination of paracetamol and its glucuronide and sulphate metabolites in the urine of HIV+/AIDS patients using wavelength-switching UV detection. Di Girolamo A, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1191-7

Usefulness of the hydrogen--deuterium exchange method in the study of drug metabolism using liquid chromatography-tandem mass spectrometry. Ohashi N, et al. **J Pharm Biomed Anal** 1998 Nov;18(3):325-34

Determination of free and glucuronated hexane metabolites without prior hydrolysis by liquid- and gas-chromatography coupled with mass spectrometry. Manini P, et al. **Toxicol Lett** 1999 Sep 5;108(2-3):225-31

GLUCURONIDASE

ANALYSIS

Interleukin-1beta and beta-glucuronidase in gingival crevicular fluid from molars during rapid palatal expansion. Tzannetou S, et al. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):686-96

Crevicular fluid level of beta-glucuronidase in relation to clinical periodontal parameters and putative periodontal pathogens in early-onset periodontitis. Albandar JM, et al. **J Clin Periodontol** 1998 Aug;25(8):630-9

Enhanced in situ detection of beta-glucuronidase activity in murine tissue. Kopen GC, et al. **J Histochem Cytochem** 1999 Jul;47(7):965-8

ANTAGONISTS & INHIBITORS

Inhibitory effect of phloridzin and phloretin on glucuronidation of p-nitrophenol, acetaminophen and 1-naphthol: kinetic demonstration of the influence of glucuronidation metabolism on intestinal absorption in rats. Mizuma T, et al. **Biochim Biophys Acta** 1998 Oct 23; 1425(2):398-404

Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Kim DH, et al. **Biol Pharm Bull** 1999 Feb;22(2):162-4

Inhibition of some hepatic lysosomal glycosidases by ethanolamines and phenyl 6-deoxy-6-(morpholin-4-yl)-beta-D-glucopyranoside. Balbaa M, et al. **Carbohydr Res** 1999 Apr 30;317(1-4):100-9

BIOSYNTHESIS

Processing of transgenic corn seed and its effect on the recovery of recombinant beta-glucuronidase. Kusnadi AR, et al. **Biotechnol Bioeng** 1998 Oct 5;60(1):44-52

Implications of alpha-amylase production and beta-glucuronidase expression in Escherichia coli strains. Caldini G, et al. **Microbios** 1999;99(393):123-30

CHEMISTRY

Characterization and immunolocalization of beta-D-glucuronidase in mouse testicular germ cells and spermatozoa. Abou-Haila A, et al. **Exp Cell Res** 1999 Feb 25;247(1):48-60

Identification of Glu-540 as the catalytic nucleophile of human beta-glucuronidase using electrospray mass spectrometry. Wong AW, et al. **J Biol Chem** 1998 Dec 18;273(51):34057-62

beta-Glucuronidase activity following complex coacervation and spray drying microencapsulation. Burgess DJ, et al. **J Microencapsul** 1998 Sep-Oct;15(5):569-79

Directed evolution of the surface chemistry of the reporter enzyme beta-glucuronidase. Matsumura I, et al. **Nat Biotechnol** 1999 Jul;17(7):696-701

DEFICIENCY

Effects of beta-glucuronidase-deficient and lycopene-producing Escherichia coli strains on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Arimochi H, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):322-7

Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Fyfe JC, et al. **Genomics** 1999 Jun 1;58(2):121-8

Intracisternal A-particle element transposition into the murine beta-glucuronidase gene correlates with loss of enzyme activity: a new model for beta-glucuronidase deficiency in the C3H mouse. Gwynn B, et al. **Mol Cell Biol** 1998 Nov;18(11):6474-81

Beta-glucuronidase deficiency as cause of recurrent hydrops fetalis: the first early prenatal diagnosis by chorionic villus sampling. Van Eyndhoven HW, et al. **Prenat Diagn** 1998 Sep;18(9):959-62

GENETICS

Detection of plasmid-encoded gusA gene in GUS-positive Escherichia coli. Singh M, et al. **Biotechniques** 1999 Feb; 26(2):261-4

Efficiency of physical (light) or chemical (ABA, tetracycline, CuSO4 or 2-CBSU)-stimulus-dependent gus gene expression in tobacco cell suspensions. Boetti H, et al. **Biotechnol Bioeng** 1999 Jul 5;64(1):1-13

Efficient and persistent expression of beta-glucuronidase gene in CD34+ cells from human umbilical cord blood by retroviral vector. Ohashi T, et al. **Eur J Haematol** 1998 Oct;61(4):235-9

Green fluorescent protein (GFP) as a reporter gene for the plant pathogenic oomycete Phytophthora palmivora. van West P, et al. **FEMS Microbiol Lett** 1999 Sep 1; 178(1):71-80

Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Watson GL, et al. **Gene Ther** 1998 Dec;5(12):1642-9

Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Daly TM, et al. **Hum Gene Ther** 1999 Jan 1;10(1):85-94

Encapsulation of various recombinant mammalian cell types in different alginate microcapsules. Peirone M, et al. **J Biomed Mater Res** 1998 Dec 15;42(4):587-96

Biochemical basis of the beta-glucuronidase gene defect causing canine mucopolysaccharidosis VII. Ray J, et al. **J Hered** 1999 Jan-Feb;90(1):119-23

Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. Stein CS, et al. **J Virol** 1999 Apr;73(4):3424-9

Variant clinical course of mucopolysaccharidosis type VII in two groups of mice carrying the same mutation. Casal ML, et al. **Lab Invest** 1998 Dec;78(12):1575-81

Growth hormone and insulin-like growth factor-I enhance beta-glucuronidase gene activation by androgen in mouse kidney. Niermann GL, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1-2):47-55

Directed evolution of the surface chemistry of the reporter enzyme beta-glucuronidase. Matsumura I, et al. **Nat Biotechnol** 1999 Jul;17(7):696-701

Fusions between green fluorescent protein and beta-glucuronidase as sensitive and vital bifunctional reporters in plants [corrected and republished article originally printed in Plant Mol Biol 1998 Jul;37(4):715-27] Quaedvlieg NE, et al. **Plant Mol Biol** 1998 Nov; 38(5):861-73

Beta-glucuronidase P408S, P415L allele in a Mexican population: population screening in Guadalajara and prenatal diagnosis. Rafiqui Islam M, et al. **Prenat Diagn** 1998 Aug;18(8):822-5

Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Daly TM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2296-300

Infection of tobacco or Arabidopsis plants by CMV counteracts systemic post-transcriptional silencing of nonviral (trans)genes. Béclin C, et al. **Virology** 1998 Dec 20;252(2):313-7

ISOLATION & PURIFICATION

Purification and characterization of glycyrrhetic acid mono-glucuronide beta-D-glucuronidase in Eubacterium sp. GLH. Akao T. **Biol Pharm Bull** 1999 Jan;22(1):80-2

METABOLISM

Interference by carbohydrate substrates, flavonoids, and monosaccharide derivatives on bacterial beta-D-glucuronidase assays. Mariscal A, et al. **Arch Environ Contam Toxicol** 1998 Nov;35(4):588-93

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Ciotti M, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):199-202

Characterization of an antineoplastic glucuronide prodrug. Cheng TL, et al. **Biochem Pharmacol** 1999 Jul 15; 58(2):325-8

Beta-glucuronidase and hyperbilirubinemia in breast-Fed babies. La Torre A, et al. **Biol Neonate** 1999;75(2):82-4

Distribution of enzymes involved in the metabolism of glycyrrhizin in various organs of rat. Akao T. **Biol Pharm Bull** 1998 Oct;21(10):1036-44

Biotransformation of glycyrrhizin to 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide by Streptococcus LJ-22, a human intestinal bacterium. Kim DH, et al. **Biol Pharm Bull** 1999 Mar;22(3):320-2

Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Freeman BJ, et al. **Blood** 1999 Sep 15;94(6):2142-50

Genistein inhibits lysosomal enzyme release by suppressing Ca2+ influx in HL-60 granulocytes. Foster FM, et al. **Cell Calcium** 1999 Jan;25(1):69-76

Toxicological significance in the cleavage of esterase-beta-glucuronidase complex in liver microsomes by organophosphorus compounds. Satoh T, et al. **Chem Biol Interact** 1999 May 14;119-120:471-8

Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Zenser TV, et al. **Drug Metab Dispos** 1999 Sep;27(9):1064-7

Characterization and immunolocalization of beta-D-glucuronidase in mouse testicular germ cells and spermatozoa. Abou-Haila A, et al. **Exp Cell Res** 1999 Feb 25;247(1):48-60

Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Daly TM, et al. **Hum Gene Ther** 1999 Jan 1;10(1):85-94

Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Ghodsi A, et al. **Hum Gene Ther** 1998 Nov 1; 9(16):2331-40

Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. Islam MR, et al. **J Biol Chem** 1999 Aug 13;274(33):23451-5

Single cell analysis and selection of living retrovirus vector-corrected mucopolysaccharidosis VII cells using a fluorescence-activated cell sorting-based assay for mammalian beta-glucuronidase enzymatic activity. Lorincz MC, et al. **J Biol Chem** 1999 Jan 8;274(2):657-65

The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding. York SJ, et al. **J Biol Chem** 1999 Jan 8;274(2):1164-71

On-line deconjugation of chloramphenicol-beta-D-glucuronide on an immobilized beta-glucuronidase column. Application to the direct analysis of urine samples. Pasternyk M, et al. **J Chromatogr A** 1998 Dec 18;828(1-2):135-40

In vitro cleavage of paracetamol glucuronide by human liver and kidney beta-glucuronidase: determination of paracetamol by capillary electrophoresis. Bohnenstengel F, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22; 721(2):295-9.

On-line deconjugation of glucuronides using an immobilized enzyme reactor based upon beta-glucuronidase. Di Marco MP, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 18; 715(2):379-86

Influence of spices on the bacterial (enzyme) activity in experimental colon cancer. Nalini N, et al. **J Ethnopharmacol** 1998 Aug;62(1):15-24

beta-Glucuronidase activity following complex coacervation and spray drying microencapsulation. Burgess DJ, et al. **J Microencapsul** 1998 Sep-Oct;15(5):569-79

Flaxseed and lignans increase cecal beta-glucuronidase activity in rats. Jenab M, et al. **Nutr Cancer** 1999; 33(2):154-8

PHARMACOKINETICS

Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Cheng TL, et al. **Bioconjug Chem** 1999 May-Jun;10(3):520-8

THERAPEUTIC USE

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Cheng TL, et al. **Br J Cancer** 1999 Mar;79(9-10):1378-85

GLUCURONIDASE

Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Soper BW, et al. **Pediatr Res** 1999 Feb;45(2):180–6

Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Vogler C, et al. **Pediatr Res** 1999 Jun;45(6):838–44

GLUCURONIDES see **GLUCURONATES**

D-GLUCURONOLACTONE DEHYDROGENASE see **ALDEHYDE DEHYDROGENASE**

GLUCURONOSYLTRANSFERASE

[Hyaluronan synthase: functional analysis of hyaluronan by gene modification] Itano N, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2387–93 (50 ref.) **(Jpn)**

ANALYSIS

Promoting effects of kojic acid due to serum TSH elevation resulting from reduced serum thyroid hormone levels on development of thyroid proliferative lesions in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Mitsumori K, et al. **Carcinogenesis** 1999 Jan;20(1):173–6

ANTAGONISTS & INHIBITORS

UDP-glucuronosyltransferase inhibitors. Golovinsky E, et al. **Eur J Drug Metab Pharmacokinet** 1998 Oct–Dec; 23(4):453–6 (29 ref.)

Inhibitory effects of uridine diphosphate on UDP-glucuronosyltransferase. Yokota H, et al. **Life Sci** 1998;63(19):1693–9

Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Terrier N, et al. **Mol Pharmacol** 1999 Jul;56(1):226–34

Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Zucker K, et al. **Ther Drug Monit** 1999 Feb;21(1):35–43

Novobiocin inhibits both UDP-glucuronosyltransferase and cytochrome P450-mediated enzyme activities in pig liver microsomes. Villar D, et al. **Vet Res Commun** 1998 Sep; 22(6):405–14

BIOSYNTHESIS

Molecular basis of bilirubin UDP-glucuronosyltransferase induction in spontaneously diabetic rats, acetone-treated rats and starved rats. Braun L, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):587–92

Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Reinach B, et al. **Chem Biol Interact** 1999 Jun 1; 121(1):37–48

Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Münzel PA, et al. **Drug Metab Dispos** 1999 May; 27(5):569–73

UDP-glucuronosyltransferase UGT1A7 induced in rat small intestinal mucosa by oral administration of 2-naphthoflavone. Kobayashi T, et al. **Eur J Biochem** 1998 Dec 15;258(3):948–55

Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Ritter JK, et al. **Hepatology** 1999 Aug;30(2):476–84

Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. Davila JC, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar; 35(3):120–30

Induction of drug metabolizing enzymes by 1,7-phenanthroline and oltipraz in mice is unrelated to Ah-responsiveness. Carr BA, et al. **J Biochem Mol Toxicol** 1999;13(2):77–82

Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Strassburg CP, et al. **Mol Pharmacol** 1998 Oct;54(4):647–54

The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Li YQ, et al. **Pharm Res** 1999 Feb;16(2):191–7

The UDP-glucuronyltransferase inducers, phenobarbital and pregnenolone-16alpha-carbonitrile, enhance thyroid-follicular cell apoptosis: association with TGF-beta1 expression. Kolaja KL, et al. **Toxicol Lett** 1999 Jun 1;106(2–3):143–50

Dose-response examination of UDP-glucuronosyltransferase inducers and their ability to increase both TGF-beta expression and thyroid follicular cell apoptosis. Kolaja KL, et al. **Toxicol Sci** 1998 Nov;46(1):31–7

BLOOD

Purification and characterization of fetal bovine serum beta-N-acetyl-D-galactosaminyltransferase and beta-D-glucuronyltransferase involved in chondroitin sulfate biosynthesis. Tsuchida K, et al. **Eur J Biochem** 1999 Sep;264(2):461–7

CHEMISTRY

Photoaffinity labeling of the aglycon binding site of the recombinant human liver UDP-glucuronosyltransferase UGT1A6 with 7-azido-4-methylcoumarin. Senay C, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):75–84

Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans. Pless D, et al. **Drug Metab Dispos** 1999 May;27(5):588–95

Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. Itano N, et al. **J Biol Chem** 1999 Aug 27;274(35):25085–92

The active streptococcal hyaluronan synthases (HASs) contain a single HAS monomer and multiple cardiolipin molecules. Tlapak-Simmons VL, et al. **J Biol Chem** 1998 Oct 2;273(40):26100–9

Alteration of human UDP-glucuronosyltransferase UGT2B17 regio-specificity by a single amino acid substitution. Dubois SG, et al. **J Mol Biol** 1999 May 28; 289(1):29–39

DEFICIENCY

Three different hepatocyte transplantation techniques for enzyme deficiency disease and acute hepatic failure. te Velde AA, et al. **Artif Organs** 1992 Oct;16(5):522–6

Supplement of liver enzyme by intestinal and kidney transplants in congenitally enzyme-deficient rat. Kokudo N, et al. **Microsurgery** 1999;19(2):103–7

DRUG EFFECTS

Hepatic UDP-glucuronosyltransferase in rainbow trout (Oncorhynchus mykiss) and preliminary assessment of response to pulp mill cooking liquor. Sturm A, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):608–15

GENETICS

AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms. Bock KW, et al. **Adv Enzyme Regul** 1998; 38:207–22

Mutation of UGT1A1 gene in a case of Crigler-Najjar syndrome type II [letter] Ishihara T, et al. **Am J Gastroenterol** 1999 Jun;94(6):1711–2

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ando Y, et al. **Ann Oncol** 1998 Aug;9(8):845–7

The significance of amino acid residue Asp446 for enzymatic stability of rat UDP-glucuronosyltransferase UGT1A6. Iwano H, et al. **Arch Biochem Biophys** 1999 Mar 1; 363(1):116–20

Small intestinal UDP-glucuronosyltransferase sheUGT1A07: partial purification and cDNA cloning from sheep small intestine. Kobayashi T, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):143–52

A variant TATA box in the bilirubin UDP-glucuronosyltransferase 1 gene promoter does not contribute to neonatal jaundice in the Japanese population [letter] Waku S, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F159

Cloning and characterization of a simian UDP-glucuronosyltransferase enzyme UGT2B20, a novel C19 steroid-conjugating protein. Barbier O, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):567–74

Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. Jedlitschky G, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):837–43

Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Strassburg CP, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):489–98

Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Akaba K, et al. **Biochem Mol Biol Int** 1998 Sep; 46(1):21–6

Induction of UDP-glycosyltransferase family 1 genes in rat liver: different patterns of mRNA expression with two inducers, 3-methylcholanthrene and beta-naphthoflavone. Saarikoski ST, et al. **Biochem Pharmacol** 1998 Sep 1; 56(5):569–75

Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Kosaki R, et al. **Cancer Res** 1999 Mar 1;59(5):1141–5

Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Tada K, et al. **Cell Transplant** 1998 Nov-Dec;7(6):607–16

Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method. Tchernof A, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):637–42

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Iyer L, et al. **Clin Pharmacol Ther** 1999 May;65(5):576–82

Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Bock KW, et al. **Drug Metab Rev** 1999 May;31(2):411–22 (44 ref.)

HMC-1 mast cells activate human orbital fibroblasts in coculture: evidence for up-regulation of prostaglandin E2 and hyaluronan synthesis. Smith TJ, et al. **Endocrinology** 1999 Aug;140(8):3518–25

Molecular cloning, expression and characterization of a monkey steroid UDP-glucuronosyltransferase, UGT2B19, that conjugates testosterone. Belanger G, et al. **Eur J Biochem** 1999 Mar;260(3):701–8

Bilirubin levels in the acute hemolytic crisis of G6PD deficiency are related to Gilbert's syndrome. Iolascon A, et al. **Eur J Haematol** 1999 May;62(5):307–10

A case of anorexia nervosa with hyperbilirubinaemia in a patient homozygous for a mutation in the bilirubin UDP-glucuronosyltransferase gene. Maruo Y, et al. **Eur J Pediatr** 1999 Jul;158(7):547–9

Genetic basis of fasting hyperbilirubinemia [letter; comment] Ishihara T, et al. **Gastroenterology** 1999 May;116(5):1272. Comment on: Gastroenterology 1997 Nov;113(5):1707–13.

(TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Iolascon A, et al. **Haematologica** 1999 Feb;84(2):106–9

Antisense inhibition of hyaluronan synthase-2 in human articular chondrocytes inhibits proteoglycan retention and matrix assembly. Nishida Y, et al. **J Biol Chem** 1999 Jul 30;274(31):21893–9

Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. Akaba K, et al. **J Hum Genet** 1999;44(1):22–5

Intermittent jaundice in patients with acute leukaemia: a common mutation of the bilirubin uridine-diphosphate glucuronosyltransferase gene among Asians. Kimura T, et al. **J Inherit Metab Dis** 1999 Aug;22(6):747–53

Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. Monaghan G, et al. **J Pediatr** 1999 Apr;134(4):441–6

Delayed response to phenobarbital treatment of a Crigler-Najjar type II patient with partially inactivating missense mutations in the bilirubin UDP-glucuronosyltransferase gene. Ciotti M, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):210–3

Morphine regulation of a novel uridine diphosphate glucuronosyl-transferase in guinea pig pups following in utero exposure. Smith SA, et al. **Mol Genet Metab** 1999 Sep;68(1):68–77

Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Bernard P, et al. **Mol Pharmacol** 1999 Sep;56(3):526–36

Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Strassburg CP, et al. **Mol Pharmacol** 1998 Oct;54(4):647–54

Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Maruo Y, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1224–7

The UGT1A1*28 allele is relatively rare in a Japanese population. Ando Y, et al. **Pharmacogenetics** 1998 Aug; 8(4):357–60

UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Lampe JW, et al. **Pharmacogenetics** 1999 Jun;9(3):341–9

Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type I with a chimeric oligonucleotide. Kren BT, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10349–54

[Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes]Ozawa S. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):69–81 (126 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Purification and characterization of a glucuronyltransferase involved in the biosynthesis of the HNK-1 epitope on glycoproteins from rat brain. Terayama K, et al. **J Biol Chem** 1998 Nov 13;273(46):30295–300

Purification and lipid dependence of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis. Tlapak-Simmons VL, et al. **J Biol Chem** 1999 Feb 12;274(7):4239–45

METABOLISM

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ando Y, et al. **Ann Oncol** 1998 Aug;9(8):845–7

Enzymatic glucuronidation of a novel cholesterol absorption inhibitor, Sch 58235. Zaks A, et al. **Appl Biochem Biotechnol** 1998 May-Jun;73(2–3):205–14

The significance of amino acid residue Asp446 for enzymatic stability of rat UDP-glucuronosyltransferase UGT1A6. Iwano H, et al. **Arch Biochem Biophys** 1999 Mar 1; 363(1):116–20

Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. King CD, et al. **Arch Biochem Biophys** 1999 May 1;365(1):156–62

Photoaffinity labeling of the aglycon binding site of the recombinant human liver UDP-glucuronosyltransferase

UGT1A6 with 7-azido-4-methylcoumarin. Senay C, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):75-84

Identification of the uridine diphosphate glucuronosyltransferase isoform UGT1A6 in rat brain and in primary cultures of neurons and astrocytes. Suleman FG, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):63-7

Kinetic studies of hepatocyte UDP-glucuronosyltransferase: evidence of an allosteric enzyme. Bruni S, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jul; 27(4):343-56

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Ciotti M, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):199-202

Mono- and Diglucuronide formation from benzo[a]pyrene and chrysene diphenols by AHH-1 cell-expressed UDP-glucuronosyltransferase UGT1A7. Bock KW, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):653-6

Mammalian hyaluronan synthases: investigation of functional relationships in vivo. Spicer AP, et al. **Biochem Soc Trans** 1999 Feb;27(2):109-15 (25 ref.)

Properties of the hyaluronan synthase from group A Streptococcus pyogenes. Tlapak-Simmons VL, et al. **Biochem Soc Trans** 1999 Feb;27(2):105-9

Chemical modification of rat hepatic microsomes with N-ethylmaleimide results in inactivation of both UDP-N-acetylglucosamine-dependent stimulation of glucuronidation and UDP-glucuronic acid uptake. Ikushiro S, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):388-96

UDP-glucuronosyltransferases in human intestinal mucosa. Radominska-Pandya A, et al. **Biochim Biophys Acta** 1998 Nov 2;1394(2-3):199-208

Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Kosaki R, et al. **Cancer Res** 1999 Mar 1;59(5):1141-5

Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Nowell SA, et al. **Carcinogenesis** 1999 Jun;20(6):1107-14

Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Green MD, et al. **Drug Metab Dispos** 1998 Sep;26(9):860-7 (64 ref.)

Immunohistochemical localization of UDP-glucuronosyltransferases in rat brain during early development. Martinasevic MK, et al. **Drug Metab Dispos** 1998 Oct;26(10):1039-41

Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans. Pless D, et al. **Drug Metab Dispos** 1999 May;27(5):588-95

Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by rat UDP-glucuronosyltransferase 2B1. Ren Q, et al. **Drug Metab Dispos** 1999 Sep;27(9):1010-6

A fluorescent assay amenable to measuring production of beta-D-glucuronides produced from recombinant UDP-glycosyl transferase enzymes. Trubetskoy OV, et al. **Drug Metab Dispos** 1999 May;27(5):555-7

The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Albert C, et al. **Endocrinology** 1999 Jul;140(7):3292-302

Expression of a functionally active human hepatic UDP-glucuronosyltransferase (UGT1A6) lacking the N-terminal signal sequence in the endoplasmic reticulum. Ouzzine M, et al. **FEBS Lett** 1999 Jul 9;454(3):187-91

UDP-glucuronosyltransferase activity in human liver and colon. Strassburg CP, et al. **Gastroenterology** 1999 Jan; 116(1):149-60

Hyaluronan synthase expression in bovine eyes. Usui T, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):563-7

Trianthema portulacastrum restores the antioxidant defense enzyme levels and hepatic biotransformation patterns in experimental rat hepatocarcinogenesis. Bhattacharya S, et al. **Ital J Biochem** 1998 Dec;47(4):225-32

Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. Bai X, et al. **J Biol Chem** 1999 May 7;274(19):13017-24

Molecular directionality of polysaccharide polymerization by the Pasteurella multocida hyaluronan synthase. DeAngelis PL. **J Biol Chem** 1999 Sep 10;274(37):26557-62

Identification of enzymes responsible for the metabolism of heme in human platelets. Nowell SA, et al. **J Biol Chem** 1998 Dec 11;273(50):33342-6

Cloning and expression of a novel galactoside beta1, 3-glucuronyltransferase involved in the biosynthesis of HNK-1 epitope. Shimoda Y, et al. **J Biol Chem** 1999 Jun 11;274(24):17115-22

Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis. Tlapak-Simmons VL, et al. **J Biol Chem** 1999 Feb 12;274(7):4246-53

Formation of HNK-1 determinants and the glycosaminoglycan tetrasaccharide linkage region by UDP-GlcUA:Galactose beta1, 3-glucuronosyltransferases. Wei G, et al. **J Biol Chem** 1999 Mar 19;274(12):7857-64

Treatment of mammalian cells with the endoplasmic reticulum-proliferator compactin strongly induces recombinant and endogenous xenobiotic metabolizing enzymes and 3-hydroxy-3-methylglutaryl-CoA reductase in vitro. McLaughlin L, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):515-23

Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. Strasser SI, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):88-94

Alteration of human UDP-glucuronosyltransferase UGT2B17 regio-specificity by a single amino acid substitution. Dubois SG, et al. **J Mol Biol** 1999 May 28; 289(1):29-39

Characterization of UDP-glucuronosyltransferases active on steroid hormones. Hum DW, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):413-23 (73 ref.)

Xenobiotic-metabolizing enzymes in carp (Cyprinus carpio) liver, spleen, and head kidney following experimental Listeria monocytogenes infection. Chambras C, et al. **J Toxicol Environ Health** 1999 Feb 12;56(3):205-19

UDPGT cDNA expression and UDPGT1 in human liver. Sheen YY, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:136-9

UDP-glucuronosyltransferase in the rat olfactory bulb: identification of the UGT1A6 isoform and age-related changes in 1-naphthol glucuronidation. Gradinaru D, et al. **Neurochem Res** 1999 Aug;24(8):995-1000

Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Lévesque E, et al. **Pharmacogenetics** 1999 Apr; 9(2):207-16

Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Guyonnet D, et al. **Toxicol Appl Pharmacol** 1999 Jan 1;154(1):50-8

Phenobarbital, beta-naphthoflavone, clofibrate, and pregnenolone-16alpha-carbonitrile do not affect hepatic thyroid hormone UDP-glucuronosyl transferase activity, and thyroid gland function in mice. Viollon-Abadie C, et al. **Toxicol Appl Pharmacol** 1999 Feb 15;155(1):1-12

Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Cheng Z, et al. **Toxicol Sci** 1998 Sep;45(1):52-7

[Human drug metabolizing enzymes. II. Conjugation enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):284-8 (21 ref.) (Eng. Abstr.) **(Hun)**

[Effect of dietary selenium on the activity of UDP-glucuronosyltransferases and metabolism of mycotoxin deoxynivalenol in rats] Obol'skiĭ OL, et al. **Vopr Pitan** 1998;(4):18-23 (Eng. Abstr.) **(Rus)**

[Benzodiazepines metabolism in various models of experimental liver diseases] Ghanem C, et al. **Acta Gastroenterol Latinoam** 1999;29(1):3-7 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Itano N, et al. **Cancer Res** 1999 May 15;59(10):2499-504

Glucuronidation: a dual control. Guéraud F, et al. **Gen Pharmacol** 1998 Nov;31(5):683-8 (54 ref.)

[Hyaluronan synthase: a scenario for remodeling the extracellular matrix] Itano N, et al. **Seikagaku** 1998 Sep; 70(9):1171-5 (15 ref.) **(Jpn)**

GLUCURONYLTRANSFERASE see **GLUCURONOSYLTRANSFERASE**

GLUE PROTEINS, DROSOPHILA

GENETICS

SDS-PAGE pattern polymorphism of X-chromosomal glue proteins in natural populations of two Drosophila nasuta subgroup species. Ramesh SR, et al. **Biochem Genet** 1999 Feb;37(1-2):1-21

The helix-loop-helix proteins dAP-4 and daughterless bind both in vitro and in vivo to SEBP3 sites required for transcriptional activation of the Drosophila gene Sgs-4. King-Jones K, et al. **J Mol Biol** 1999 Aug 6;291(1):71-82

The transcriptional switch between the Drosophila genes Pig-1 and Sgs-4 depends on a SEBP1 binding site within a shared enhancer region [published erratum appears in Mol Gen Genet 1999 Mar;261(2):428] Hofmann A, et al. **Mol Gen Genet** 1998 Oct;259(6):656-63

GLUE SNIFFING see **SUBSTANCE-RELATED DISORDERS**

GLUES see **ADHESIVES**

GLUTAMATE see **GLUTAMIC ACID**

GLUTAMATE AGENTS see **EXCITATORY AMINO ACID AGENTS**

GLUTAMATE AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

GLUTAMATE-AMMONIA LIGASE

ANTAGONISTS & INHIBITORS

Preserved hypocapnic pial arteriolar constriction during hyperammonemia by glutamine synthetase inhibition. Hirata T, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H456-63

An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets. Harth G, et al. **J Exp Med** 1999 May 3; 189(9):1425-36

Inhibition of glutamine synthetase decreases proliferation of cultured rat intestinal epithelial cells. DeMarco V, et al. **J Nutr** 1999 Jan;129(1):57-62

Effects of inhibiting glutamine synthetase and blocking glutamate uptake on b-wave generation in the isolated rat retina. Winkler BS, et al. **Vis Neurosci** 1999 Mar-Apr; 16(2):345-53

BIOSYNTHESIS

Differential role of specific PKC isoforms in the proliferation of glial cells and the expression of the astrocytic markers GFAP and glutamine synthetase. Brodie C, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):108-17

Glutamine synthetase expression in perinatal spiny mouse liver. Lamers WH, et al. **Eur J Biochem** 1999 Jun; 262(3):803-9

Dehydroepiandrosterone increases the zone [correction of in zone] of glutamine synthetase-positive hepatocytes in female rat liver: a putative androgenic effect [published erratum appears in Histochem Cell Biol 1999 Jun;111(6):489] Mayer D, et al. **Histochem Cell Biol** 1999 May;111(5):375-80

Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. Sun YN, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):720-8

CHEMISTRY

Preliminary crystallographic studies on glutamine synthetase from Mycobacterium tuberculosis. Gill HS, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):865-8

Glutamine synthetase expression in rat lung is regulated by protein stability. Labow BI, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):L877-86

Strategies for protein-based nanofabrication: Ni2+-NTA as a chemical mask to control biologically imposed symmetry. Dabrowski MJ, et al. **Chem Biol** 1998 Dec;5(12):689-97

Functional importance of Asp56 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase. An essential residue for transferase but not for biosynthetic enzyme activity. Clemente MT, et al. **Eur J Biochem** 1999 Sep; 264(2):453-60

Site-directed mutagenesis of Glu-297 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase alters kinetic and structural properties and confers resistance to L-methionine sulfoximine. Clemente MT, et al. **Plant Mol Biol** 1999 Jul;40(5):835-45

Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation. Tien M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7809-14

DRUG EFFECTS

Oxidative modification of glutamine synthetase by 2,2'-azobis(2- amidinopropane) dihydrochloride. Ma YS, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):129-34

Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Fraser CM, et al. **Br J Pharmacol** 1999 Apr;126(7):1634-8

GENETICS

Identification of glucocorticoid-responsive elements that control transcription of rat glutamine synthetase. Chandrasekhar S, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L319-31

Glutamine synthetase expression in rat lung is regulated by protein stability. Labow BI, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):L877-86

Diel rhythms in ribulose-1,5-bisphosphate carboxylase/oxygenase and glutamine synthetase gene expression in a natural population of marine picoplanktonic cyanobacteria (Synechococcus spp.). Wyman M. **Appl Environ Microbiol** 1999 Aug;65(8):3651-9

De novo expression of glutamine synthetase during transformation of hepatic stellate cells into myofibroblast-like cells. Bode JG, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):697-700

Analysis of Frankia evolutionary radiation using glnII sequences. Cournoyer B, et al. **FEMS Microbiol Lett** 1999 Aug 1;177(1):29-34

Biochemical analysis of a blood meal-induced Aedes aegypti glutamine synthetase gene. Smartt CT, et al. **Insect Biochem Mol Biol** 1998 Dec;28(12):935-45

Function and regulation of glnA in the methanogenic archaeon Methanococcus maripaludis. Cohen-Kupiec R, et al. **J Bacteriol** 1999 Jan;181(1):256-61

Sensing of nitrogen limitation by Bacillus subtilis: comparison to enteric bacteria. Hu P, et al. **J Bacteriol** 1999 Aug; 181(16):5042-50

A silencer element in the regulatory region of glutamine

synthetase controls cell type-specific repression of gene induction by glucocorticoids. Avisar N, et al. **J Biol Chem** 1999 Apr 16;274(16):11399-407

Protein kinase C delta (PKCdelta) inhibits the expression of glutamine synthetase in glial cells via the PKCdelta regulatory domain and its tyrosine phosphorylation. Brodie C, et al. **J Biol Chem** 1998 Nov 13;273(46):30713-8

Cyclic adenosine-3',5'-monophosphate-mediated activation of a glutamine synthetase composite glucocorticoid response element. Richardson J, et al. **Mol Endocrinol** 1999 Apr;13(4):546-54

Nitrogen control of the glnN gene that codes for GS type III, the only glutamine synthetase in the cyanobacterium Pseudanabaena sp. PCC 6903. Crespo JL, et al. **Mol Microbiol** 1998 Dec;30(5):1101-12

Chloroplast-expressed glutamine synthetase (ncpGS): potential utility for phylogenetic studies with an example from Oxalis (Oxalidaceae). Emshwiller E, et al. **Mol Phylogenet Evol** 1999 Aug;12(3):310-9

Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells express glutamine synthetase: developmental and cell type-specific regulation. Baas D, et al. **Mol Psychiatry** 1998 Jul;3(4):356-61

Expression analysis of a cytosolic glutamine synthetase gene in cotyledons of Scots pine seedlings: developmental, light regulation and spatial distribution of specific transcripts. Cantón FR, et al. **Plant Mol Biol** 1999 Jul;40(4):623-34

Complexity and expression of the glutamine synthetase multigene family in the amphidiploid crop Brassica napus. Ochs G, et al. **Plant Mol Biol** 1999 Feb;39(3):395-405

A strong constitutive positive element is essential for the ammonium-regulated expression of a soybean gene encoding cytosolic glutamine synthetase. Tercé-Laforgue T, et al. **Plant Mol Biol** 1999 Feb;39(3):551-64

Regulation of the spatiotemporal pattern of expression of the glutamine synthetase gene. Lie-Venema H, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:243-308 (499 ref.)

ISOLATION & PURIFICATION

The glutamine synthetase from the hyperthermoacidophilic crenarcheon Sulfolobus acidocaldarius: isolation, characterization and sequencing of the gene. Yin Z, et al. **Biol Chem** 1998 Nov;379(11):1349-54

Isolation and characterization of a protein with high affinity for DNA: the glutamine synthetase of Thermus thermophilus 111. Mary J, et al. **J Mol Biol** 1999 Feb 12; 286(1):121-34

METABOLISM

Glutamine synthetase expression in muscle is regulated by transcriptional and posttranscriptional mechanisms. Labow BI, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1136-45

Regulation of glutamine synthetase from the white button mushroom Agaricus bisporus. Kersten MA, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):228-34

Oxidative modification of glutamine synthetase by 2,2'-azobis(2- amidinopropane) dihydrochloride. Ma YS, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):129-34

beta-Amyloid toxicity in rat brain reaggregate cultures. Davenport Jones J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):S240

Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Osada T, et al. **Cancer** 1999 Feb 15;85(4):819-31

Ability of retinal Müller glial cells to protect neurons against excitotoxicity in vitro depends upon maturation and neuron-glial interactions. Heidinger V, et al. **Glia** 1999 Feb 1;25(3):229-39

Changes in the activity levels of glutamine synthetase, glutaminase and glycogen synthetase in rats subjected to hypoxic stress. Vats P, et al. **Int J Biometeorol** 1999 Apr; 42(4):205-9

Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro. Stanimirovic DB, et al. **Int J Dev Neurosci** 1999 Jun;17(3):173-84

Glucocorticoids induce glutamine synthetase in folliculostellate cells of rat pituitary glands in vivo and in vitro. Shirasawa N, et al. **J Anat** 1999 May;194 (Pt 4):567-77

Function and regulation of glnA in the methanogenic archaeon Methanococcus maripaludis. Cohen-Kupiec R, et al. **J Bacteriol** 1999 Jan;181(1):256-61

Glutamine synthetase: a key enzyme for intestinal epithelial differentiation? Weiss MD, et al. **JPEN J Parenter Enteral Nutr** 1999 May-Jun;23(3):140-6

Rapid establishment of high-producing cell lines using dicistronic vectors with glutamine synthetase as the selection marker. Pu H, et al. **Mol Biotechnol** 1998 Aug; 10(1):17-25

Cyclic adenosine-3',5'-monophosphate-mediated activation of a glutamine synthetase composite glucocorticoid response element. Richardson J, et al. **Mol Endocrinol** 1999 Apr;13(4):546-54

NMDA-induced increases in rat brain glutamine synthetase but not glial fibrillary acidic protein are mediated by free radicals. Davenport Jones JE, et al. **Neurosci Lett** 1998 May 8;247(1):37-40

Site-directed mutagenesis of Glu-297 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase alters kinetic and structural properties and confers resistance to L-methionine sulfoximine. Clemente MT, et al. **Plant Mol Biol** 1999 Jul;40(5):835-45

Glutamine synthetase inactivation by protein-protein interaction. Garcia-Dominguez M, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7161-6

Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation. Tien M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7809-14

[Key enzymes of biosynthesis of amino acids of the glutamic series in the virus-cell system Anabaena variabilis + A-1] Mendzhul MI, et al. **Ukr Biokhim Zh** 1998 Jan-Feb; 70(1):16-22 (Eng. Abstr.) **(Rus)**

GLUTAMATE ANTAGONISTS see **EXCITATORY AMINO ACID ANTAGONISTS**

GLUTAMATE CARBOXY-LYASE see **GLUTAMATE DECARBOXYLASE**

GLUTAMATE-CYSTEINE LIGASE

ANTAGONISTS & INHIBITORS

Design, synthesis and evaluation of transition-state analogue inhibitors of Escherichia coli gamma-glutamylcysteine synthetase. Tokutake N, et al. **Bioorg Med Chem** 1998 Oct; 6(10):1935-53

BIOSYNTHESIS

Inducible expression of the gamma-glutamylcysteine synthetase light subunit by t-butylhydroquinone in HepG2 cells is not dependent on an antioxidant-responsive element. Galloway DC, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):535-9

Cysteine control over glutathione homeostasis in Chinese hamster fibroblasts overexpressing a gamma-glutamylcysteine synthetase activity. Vincent BR, et al. **Eur J Biochem** 1999 Jun;262(3):873-8

Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Iida T, et al. **Int J Cancer** 1999 Jul 30; 82(3):405-11

Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. Yamane Y, et al. **J Biol Chem** 1998 Nov 20;273(47):31075-85

Effect of thioacetamide on the hepatic expression of gamma-glutamylcysteine synthetase subunits in the Rat. Lu SC, et al. **Toxicol Appl Pharmacol** 1999 Sep 15; 159(3):161-8

CHEMISTRY

Identification of an important cysteine residue in human glutamate-cysteine ligase catalytic subunit by site-directed mutagenesis. Tu Z, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):675-80

DEFICIENCY

The glutathione-deficient, cadmium-sensitive mutant, cad2-1, of Arabidopsis thaliana is deficient in gamma-glutamylcysteine synthetase. Cobbett CS, et al. **Plant J** 1998 Oct;16(1):73-8

DRUG EFFECTS

Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients. Oguri T, et al. **Ann Oncol** 1999 Apr;10(4):455-60

GENETICS

The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Griffith OW, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:209-67, xii (188 ref.)

gamma-glutamylcysteine synthetase: mRNA stabilization and independent subunit transcription by 4-hydroxy-2-nonenal. Liu RM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L861-9

Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Moinova HR, et al. **Biochem Biophys Res Commun** 1999 Aug 11; 261(3):661-8

Pyrrolidine dithiocarbamate up-regulates the expression of the genes encoding the catalytic and regulatory subunits of gamma-glutamylcysteine synthetase and increases intracellular glutathione levels. Wild AC, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):659-65

Regulation of gamma-glutamylcysteine synthetase regulatory subunit (GLCLR) gene expression: identification of the major transcriptional start site in HT29 cells. Galloway DC, et al. **Biochim Biophys Acta** 1999 Jul 7;1446(1-2):47-56

Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison. Tanaka T, et al. **Biochim Biophys Acta** 1999 May 24;1427(3):367-77

Lack of correlation of MRP and gamma-glutamylcysteine synthetase overexpression with doxorubicin resistance due to increased apoptosis in SV40 large T-antigen-transformed human mesothelial cells. Ogretmen B, et al. **Cancer Chemother Pharmacol** 1998;42(6):441-6

Structure and refinement of the physical mapping of the gamma- glutamylcysteine ligase regulatory subunit (GLCLR) gene to chromosome 1p22.1 within the critically deleted region of human malignant mesothelioma. Rozet JM, et al. **Cytogenet Cell Genet** 1998;82(1-2):91-4

Effect of ethanol and high-fat feeding on hepatic gamma-glutamylcysteine synthetase subunit expression in the rat. Lu SC, et al. **Hepatology** 1999 Jul;30(1):209-14

Regulation of gamma-glutamylcysteine synthetase subunit gene expression in retinal Müller cells by oxidative stress. Lu SC, et al. **Invest Ophthalmol Vis Sci** 1999 Jul; 40(8):1776-82

Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. Iwata-Ichikawa E, et al. **J Neurochem** 1999 Jun; 72(6):2334-44

The putative gene for the first enzyme of glutathione biosynthesis in Plasmodium berghei and Plasmodium falciparum. Birago C, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):33-40

The putative gamma-glutamylcysteine synthetase from Plasmodium falciparum contains large insertions and a variable tandem repeat. Lüersen K, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):131-42

The glutathione-deficient, cadmium-sensitive mutant, cad2-1, of Arabidopsis thaliana is deficient in gamma-glutamylcysteine synthetase. Cobbett CS, et al. **Plant J** 1998 Oct;16(1):73-8

METABOLISM

The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Griffith OW, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:209-67, xii (188 ref.)

Overexpression of the regulatory subunit of gamma-glutamylcysteine synthetase in HeLa cells increases gamma-glutamylcysteine synthetase activity and confers drug resistance. Tipnis SR, et al. **Biochem J** 1999 Feb 1; 337 (Pt 3):559-66

Identification of glutathione S-transferase isozymes and gamma-glutamylcysteine synthetase as negative acute-phase proteins in rat liver. Buetler TM. **Hepatology** 1998 Dec;28(6):1551-60

Trypanosoma brucei gamma-glutamylcysteine synthetase. Characterization of the kinetic mechanism and the role of Cys-319 in cystamine inactivation. Brekken DL, et al. **J Biol Chem** 1998 Oct 9;273(41):26317-22

Determination of cellular thiols and glutathione-related enzyme activities: versatility of high-performance liquid chromatography-spectrofluorimetric detection. Parmentier C, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20; 719(1-2):37-46

Autophosphorylation inhibits the activity of gamma-glutamylcysteine synthetase. Sekhar KR, et al. **J Enzyme Inhib** 1999;14(4):323-30

Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1. Manna SK, et al. **Oncogene** 1999 Jul 29;18(30):4371-82

PHYSIOLOGY

The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for gamma-glutamylcysteine synthetase and gamma-glutamyl transpeptidase. Moellering D, et al. **FEBS Lett** 1999 Apr 9;448(2-3):292-6

GLUTAMATE DECARBOXYLASE

ANALYSIS

Co-localization of corticotropin-releasing hormone with glutamate decarboxylase and calcium-binding proteins in infant rat neocortical interneurons. Yan XX, et al. **Exp Brain Res** 1998 Dec;123(3):334-40

GABAergic system in the developing mammalian retina: dual sources of GABA at early stages of postnatal development. Yamasaki EN, et al. **Int J Dev Neurosci** 1999 Jun; 17(3):201-13

Distribution of bulbospinal gamma-aminobutyric acid-synthesizing neurons of the ventral respiratory group of the rat. Ellenberger HH. **J Comp Neurol** 1999 Aug 16; 411(1):130-44

Pre-embedding staining for GAD67 versus postembedding staining for GABA as markers for central GABAergic terminals. Murphy SM, et al. **J Histochem Cytochem** 1998 Nov;46(11):1261-8

Cholinergic neurons of the nucleus basalis of Meynert receive cholinergic, catecholaminergic and GABAergic synapses: an electron microscopic investigation in the monkey. Smiley JF, et al. **Neuroscience** 1999 Jan;88(1):241-55

ANTAGONISTS & INHIBITORS

Nitric oxide mediates IL-1beta stimulation of heat shock protein but not IL-1beta inhibition of glutamic acid

decarboxylase. Hao W, et al. **Autoimmunity** 1999; 29(2):93–101

Partial deafferentation of the developing rat spinal cord delays the spontaneous repression of GAD67 mRNAs in spinal cells. Feldblum S, et al. **Perspect Dev Neurobiol** 1998; 5(2–3):131–43

[Effects of L-malate, an inhibitor of glutamate decarboxylase, on learning and memory in mice] Zhou HY, et al. **Yao Hsueh Hsueh Pao** 1996;31(12):897–900 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. New KC, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1–2):121–35

Expression of two forms of glutamic acid decarboxylase (GAD67 and GAD65) during postnatal development of rat somatosensory barrel cortex. Kiser PJ, et al. **J Comp Neurol** 1998 Dec 7;402(1):62–74

Spiny calretinin-immunoreactive neurons in the hilus and CA3 region of the rat hippocampus: local axon circuits, synaptic connections, and glutamic acid decarboxylase 65/67 mRNA expression. Martinez A, et al. **J Comp Neurol** 1999 Feb 22;404(4):438–48

Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. Tisch R, et al. **J Immunol** 1999 Aug 1;163(3):1178–87

Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines. Mi J, et al. **J Neurosci Res** 1999 Jul 1; 57(1):137–48

Partial deafferentation of the developing rat spinal cord delays the spontaneous repression of GAD67 mRNAs in spinal cells. Feldblum S, et al. **Perspect Dev Neurobiol** 1998; 5(2–3):131–43

CHEMISTRY

Crystallization and preliminary X-ray analysis of the beta-isoform of glutamate decarboxylase from Escherichia coli. Malashkevich VN, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1020–2

Conformational alteration in serum albumin as a carrier for pyridoxal phosphate: a distinction from pyridoxal phosphate-dependent glutamate decarboxylase. Zhang F, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):195–202

High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. Schwartz HL, et al. **J Mol Biol** 1999 Apr 16;287(5):983–99

Two isoforms of glutamate decarboxylase: why? Soghomonian JJ, et al. **Trends Pharmacol Sci** 1998 Dec; 19(12):500–5 (72 ref.)

DEFICIENCY

Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Kash SF, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1698–703

GENETICS

Expression of the Corynebacterium glutamicum panD gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in Escherichia coli. Dusch N, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1530–9

Inhibition of mitochondrial oxidative phosphorylation induces hyper-expression of glutamic acid decarboxylase in pancreatic islet cells. Myers MA, et al. **Autoimmunity** 1999;30(1):43–51

Simultaneous detection of glutamic acid decarboxylase and reelin mRNA in adult rat neurons using in situ hybridization and immunofluorescence. Pesold C, et al. **Brain Res Brain Res Protoc** 1998 Nov;3(2):155–60

Intra-accumbens infusions of antisense oligodeoxynucleotides to one isoform of glutamic acid decarboxylase mRNA, GAD65, but not to GAD67 mRNA, impairs sustained attention performance in the rat. Miner LA, et al. **Brain Res Cogn Brain Res** 1999 Jan;7(3):269–83

Ontogeny of the GNRH-, glutaminase- and glutamate decarboxylase-gene expression in the hypothalamus of female rats. Roth C, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):105–14

Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. New KC, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1–2):121–35

Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Eaton MJ, et al. **Cell Transplant** 1999 Jan–Feb;8(1):87–101

L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Cenci MA, et al. **Eur J Neurosci** 1998 Aug;10(8):2694–706

GABAergic inhibition in the rat pontine nuclei is exclusively extrinsic: evidence from an in situ hybridization study for GAD67 mRNA. Möck M, et al. **Exp Brain Res** 1999 Feb; 124(4):529–32

The TATA-less rat GAD65 promoter can be activated by Sp1 through non-consensus elements. Skak K, et al. **Gene** 1999 Aug 20;236(2):231–41

DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes-prone NOD mice. Wiest-Ladenburger U, et al. **Horm Metab Res** 1998 Oct; 30(10):605–9

Distribution of glutamic acid decarboxylase mRNA in the forebrain of the rainbow trout as studied by in situ hybridization. Anglade I, et al. **J Comp Neurol** 1999 Jul 26;410(2):277–89

Up-regulation of GAD65 and GAD67 in remaining hippocampal GABA neurons in a model of temporal lobe epilepsy. Esclapez M, et al. **J Comp Neurol** 1999 Sep 27; 412(3):488–505

GABA, GABA transporters, GABA(A) receptor subunits, and GAD mRNAs in the rat parabrachial and Kölliker-Fuse nuclei. Guthmann A, et al. **J Comp Neurol** 1998 Oct 19;400(2):229–43

Distribution of GABAergic cells and fibers in the hippocampal formation of the macaque monkey: an immunohistochemical and in situ hybridization study. Jongen-Rêlo AL, et al. **J Comp Neurol** 1999 May 31; 408(2):237–71

Distribution of glutamic acid decarboxylase mRNA-containing neurons in rat medulla projecting to thoracic spinal cord in relation to monoaminergic brainstem neurons. Stornetta RL, et al. **J Comp Neurol** 1999 May 10;407(3):367–80

Coordinated transcriptional regulation of the unc-25 glutamic acid decarboxylase and the unc-47 GABA vesicular transporter by the Caenorhabditis elegans UNC-30 homeodomain protein. Eastman C, et al. **J Neurosci** 1999 Aug 1;19(15):6225–34

The Caenorhabditis elegans gene unc-25 encodes glutamic acid decarboxylase and is required for synaptic transmission but not synaptic development. Jin Y, et al. **J Neurosci** 1999 Jan 15;19(2):539–48

Lactococcus lactis contains only one glutamate decarboxylase gene. Nomura M, et al. **Microbiology** 1999 Jun;145 (Pt 6):1375–80

Multiplicity of glutamic acid decarboxylases (GAD) in vertebrates: molecular phylogeny and evidence for a new GAD paralog. Bosma PT, et al. **Mol Biol Evol** 1999 Mar; 16(3):397–404

The response to stationary-phase stress conditions in Escherichia coli: role and regulation of the glutamic acid decarboxylase system. De Biase D, et al. **Mol Microbiol** 1999 Jun;32(6):1198–211

GABA and histogenesis in fetal and neonatal mouse brain lacking both the isoforms of glutamic acid decarboxylase. Ji F, et al. **Neurosci Res** 1999 Mar;33(3):187–94

Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats. Consolo S, et al. **Neuroscience** 1999;89(4):1183–7

Gene expression of the GAD67 and GAD65 isoforms of glutamate decarboxylase is differentially altered in subpopulations of striatal neurons in adult rats lesioned with 6-OHDA as neonates. Laprade N, et al. **Synapse** 1999 Jul; 33(1):36–48

IMMUNOLOGY

Peptide from glutamic acid decarboxylase similar to coxsackie B virus stimulates IFN-gamma mRNA expression in Th1-like lymphocytes from children with recent-onset insulin-dependent diabetes mellitus. Karlsson MG, et al. **Acta Diabetol** 1998 Oct;35(3):137–44

Antibodies to glutamic acid decarboxylase in young Chinese diabetic patients. Ko GT, et al. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):761–7

Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ishida K, et al. **Ann Neurol** 1999 Aug;46(2):263–7

Appearance of islet cell autoantibodies after clinical diagnosis of diabetes mellitus. Landin-Olsson M, et al. **Autoimmunity** 1999;29(1):57–63

Autoantigenic reactivity of diabetes sera with a hybrid glutamic acid decarboxylase GAD67-65 molecule GAD67(1–101)/GAD65(96–585). Teoh KL, et al. **Autoimmunity** 1998;28(4):259–66

A monoclonal antibody-based characterization of autoantibodies against glutamic acid decarboxylase in adults with latent autoimmune diabetes. Ziegler B, et al. **Autoimmunity** 1998;28(2):61–8

T cell response pattern to glutamic acid decarboxylase 65 (GAD65) peptides of newly diagnosed type 1 diabetic patients sharing susceptible HLA haplotypes. Rharbaoui F, et al. **Clin Exp Immunol** 1999 Jul;117(1):30–7

Progression to type 1 diabetes is associated with a change in the immunoglobulin isotype profile of autoantibodies to glutamic acid decarboxylase (GAD65). Childhood Diabetes in Finland Study Group. Petersen JS, et al. **Clin Immunol** 1999 Feb;90(2):276–81

Antibodies to GAD in diabetic patients with chronic hepatitis C [letter] Ando H, et al. **Diabet Med** 1998 Sep;15(9):797

Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Tuomi T, et al. **Diabetes** 1999 Jan;48(1):150–7

GAD antibodies in classification of Asian type 2 diabetes [letter; comment] Fukui M, et al. **Diabetes Care** 1999 Jun; 22(6):1011–2. Comment on: Diabetes Care 1999 Jan;22(1):175–6.

Islet cell autoimmunity in white and black children and adolescents with IDDM. Libman IM, et al. **Diabetes Care** 1998 Nov;21(11):1824–7

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Littorin B, et al. **Diabetes Care** 1999 Mar;22(3):409–12

Three cases of GAD65 antibody-positive diabetes with ketosis and abrupt onset resulting in non-insulin-dependent state [letter] Morimoto J, et al. **Diabetes Care** 1998 Nov; 21(11):2037–9

GAD65 antibodies in classification of Asian Indian diabetic subjects with onset between 20 and 40 years [letter] [see comments] Ramachandran A, et al. **Diabetes Care** 1999 Jan; 22(1):175–6. Comment in: Diabetes Care 1999 Jun;22(6):1011–2.

T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report [see comments] Shimada A, et al. **Diabetes Care** 1999 Apr;22(4):615–7. Comment in: Diabetes Care 1999 Apr;22(4):541–2.

GAD antibodies in elderly men in different categories of glucose tolerance [letter] Ylihärsilä H, et al. **Diabetes Care** 1999 Jun;22(6):996–7

Vesicular autoantigens of type 1 diabetes. Solimena M. **Diabetes Metab Rev** 1998 Sep;14(3):227–40 (91 ref.)

The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan. Takino H, et al. **Diabetes Metab Rev** 1998 Dec; 14(4):334–5

Inverse relationship between GAD65 antibody levels and severe retinopathy in younger type 1 diabetic patients. Agardh D, et al. **Diabetes Res Clin Pract** 1998 Apr; 40(1):9–14

Antibodies to glutamic acid decarboxylase (GAD) in non-obese Japanese diabetics without insulin therapy: a comparison of two commercial RIA kits based on recombinant and pig brain GAD. Bando Y, et al. **Diabetes Res Clin Pract** 1998 Jul;41(1):25–33

Systemic levels of cytokines and GAD-specific autoantibodies isotypes in Chinese IDDM patients. Ng WY, et al. **Diabetes Res Clin Pract** 1999 Feb;43(2):127–35

Prevalence of glutamic acid decarboxylase antibodies amongst young Malaysian diabetics. Wan Nazaimoon WM, et al. **Diabetes Res Clin Pract** 1999 Jan;43(1):59–66

Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Yoshioka K, et al. **Diabetes Res Clin Pract** 1998 Nov; 42(2):85–9

Towards a World Health Organization (WHO) approved standard sample for islet cell antibodies, GAD65 and IA-2 autoantibodies [letter] Lernmark A, et al. **Diabetologia** 1999 Mar;42(3):381–2

Autoantigens IA-2 and GAD in Type 1 (insulin-dependent) diabetes. Leslie RD, et al. **Diabetologia** 1999 Jan;42(1):3–14 (105 ref.)

Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Rolandsson O, et al. **Diabetologia** 1999 May;42(5):555–9

Immune-mediated retinopathy in a patient with stiff-man syndrome. Steffen H, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Mar;237(3):212–9

Clinical characteristics, and time course of pancreatic beta-cell function and glutamic acid decarboxylase antibodies in Thai patients with adult-onset Type 1 diabetes: distinction between patients of rapid- and slow-onset. Rattarasarn C, et al. **Horm Metab Res** 1999 May;31(5):311–6

DNA vaccination with glutamic acid decarboxylase (GAD) generates a strong humoral immune response in BALB/c, C57BL/6, and in diabetes-prone NOD mice. Wiest-Ladenburger U, et al. **Horm Metab Res** 1998 Oct; 30(10):605–9

NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice. Abraham RS, et al. **Hum Immunol** 1999 Jul;60(7):583–90

CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Ou D, et al. **Hum Immunol** 1999 Aug;60(8):652–64

Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus. Tabata H, et al. **Hum Immunol** 1998 Sep;59(9):549–60

Peptide specificity of high-titer anti-glutamic acid decarboxylase (GAD)65 autoantibodies. Rharbaoui F, et al. **Immunol Lett** 1998 Jul;62(3):123–30

Epitope dominance: evidence for reciprocal determinant spreading to glutamic acid decarboxylase in non-obese diabetic mice. Zechel MA, et al. **Immunol Rev** 1998 Aug; 164:111–8 (33 ref.)

Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Boyton RJ, et al. **Int Immunol** 1998 Dec;10(12):1765–76

T cell responses to enterovirus antigens and to beta-cell

autoantigens in unaffected children positive for IDDM-associated autoantibodies. Juhela S, et al. **J Autoimmun** 1999 Jun;12(4):269-78

High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. Kasuga A, et al. **J Autoimmun** 1999 Mar;12(2):131-5

Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. Maclaren N, et al. **J Autoimmun** 1999 Jun;12(4):279-87

Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. Maron R, et al. **J Autoimmun** 1999 Jun;12(4):251-8

Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. Plesner A, et al. **J Autoimmun** 1998 Aug; 11(4):335-41

GAD65-Reactive T cells in a non-diabetic stiff-man syndrome patient. Schloot NC, et al. **J Autoimmun** 1999 Jun;12(4):289-96

Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals. Reijonen H, et al. **J Immunol** 1999 Aug 1;163(3):1674-81

Production of glutathione-coated microtitre plates for capturing recombinant glutathione S-transferase fusion proteins as antigens in immunoassays. Murray AM, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):133-9

Analysis of antibody responses against coxsackie virus B4 protein 2C and the diabetes autoantigen GAD(65). Vreugdenhil GR, et al. **J Med Virol** 1999 Oct;59(2):256-61

High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. Schwartz HL, et al. **J Mol Biol** 1999 Apr 16;287(5):983-99

Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. Jaeger C, et al. **J Mol Med** 1999 Jan;77(1):45-8

Paraneoplastic stiff limb syndrome [letter] Silverman IE. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):126-7

Test for diabetic tendency may aid risk factor studies [news] Marwick C. **JAMA** 1999 Feb 17;281(7):599

Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Walikonis JE, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1161-6

Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Abele M, et al. **Neurology** 1999 Mar 10; 52(4):857-9

Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Menard V, et al. **Pharm Res** 1999 Jul;16(7):1059-66

The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Chao CC, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9299-304

GAD, a single autoantigen for diabetes [comment] von Boehmer H, et al. **Science** 1999 May 14;284(5417):1135, 1137. Comment on: Science 1999 May 14;284(5417):1183-7.

Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells [see comments] Yoon JW, et al. **Science** 1999 May 14;284(5417):1183-7. Comment in: Science 1999 May 14;284(5417):1135, 1137.

[Clinical characteristics and main diagnostic points of latent autoimmune diabetes mellitus in adults] Pan X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Mar;36(3):159-64 (Eng. Abstr.) **(Chi)**

[When and why should anti-GAD antibodies by looked for in the non-insulin-dependent diabetic patient?] Atlan-Gepner C, et al. **Diabetes Metab** 1999 Jun; 25(2):177-9 (18 ref.) **(Fre)**

[Antibodies to glutamic acid decarboxylase (GADA) as markers of risk for development of insulin-dependent diabetes mellitus] Kretowski A, et al. **Przegl Lek** 1998; 55(6):315-9 (Eng. Abstr.) **(Pol)**

[Glutamate decarboxylase (GAD)--an autoantigen in insulin-dependent diabetes mellitus (IDDM)] Tursky T, et al. **Bratisl Lek Listy** 1999 Feb;100(2):85-8 (34 ref.) (Eng. Abstr.) **(Slo)**

[Spinal myoclonus with antibodies against glutamic decarboxylase (letter)] Uterga JM, et al. **Neurologia** 1998 Aug-Sep;13(7):367-8 **(Spa)**

METABOLISM

Large motor neuron involvement in Stiff-man syndrome: a qualitative and quantitative study. Ishizawa K, et al. **Acta Neuropathol (Berl)** 1999 Jan;97(1):63-70

Expression of the Corynebacterium glutamicum panD gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in Escherichia coli. Dusch N, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1530-9

Enzymes that exploit imines--one way or the other. Abell C. **Biochem Soc Trans** 1998 Aug;26(3):310-5 (15 ref.)

Role of nitric oxide on GABA, glutamic acid, activities of GABA-T and GAD in rat brain cerebral cortex. Jayakumar AR, et al. **Brain Res** 1999 Aug 7; 837(1-2):229-35

Simultaneous detection of glutamic acid decarboxylase and reelin mRNA in adult rat neurons using in situ hybridization and immunofluorescence. Pesold C, et al. **Brain Res Brain Res Protoc** 1998 Nov;3(2):155-60

Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells. Bridgett M, et al. **Diabetes** 1998 Dec; 47(12):1848-56

Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Harfouch-Hammoud E, et al. **Diabetes** 1999 Oct;48(10):1937-47

Heterogeneity in glutamic acid decarboxylase expression among single rat pancreatic beta cells. Sánchez-Soto MC, et al. **Diabetologia** 1999 Sep;42(9):1086-92

An endogenous activator of renal glutamic acid decarboxylase effects of adenosine triphosphate, phosphate and chloride on the activity of this enzyme. Turský T, et al. **Eur J Biochem** 1999 Jun;262(3):696-703

Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Sasaki K, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):165-73

Role of synaptic vesicle proton gradient and protein phosphorylation on ATP-mediated activation of membrane-associated brain glutamate decarboxylase. Hsu CC, et al. **J Biol Chem** 1999 Aug 20;274(34):24366-71

Calcium-calmodulin-induced dimerization of the carboxyl-terminal domain from petunia glutamate decarboxylase. A novel calmodulin-peptide interaction motif. Yuan T, et al. **J Biol Chem** 1998 Nov 13; 273(46):30328-35

Changes in GAD- and GABA- immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors. Eaton MJ, et al. **J Chem Neuroanat** 1998 Dec;16(1):57-72

Distribution of glutamic acid decarboxylase mRNA in the forebrain of the rainbow trout as studied by in situ hybridization. Anglade I, et al. **J Comp Neurol** 1999 Jul 26;410(2):277-89

GABA level and GAD activity in human and mouse normal and neoplastic mammary gland. Mazurkiewicz M, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):247-53

Decrease in glutamic acid decarboxylase level in the hypothalamus of spontaneously hypertensive rats. Horn EM, et al. **J Hypertens** 1998 May;16(5):625-33

GABA synthesis in astrocytes after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase 65 or 67. New KC, et al. **J Neurochem** 1998 Dec;71(6):2304-12

Alteration of the GABAergic neuronal system of the retina and superior colliculus in streptozotocin-induced diabetic rat. Honda M, et al. **Kobe J Med Sci** 1998 Feb;44(1):1-8

Regional distribution and relative amounts of glutamate decarboxylase isoforms in rat and mouse brain. Sheikh SN, et al. **Neurochem Int** 1999 Jul;35(1):73-80

Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Abele M, et al. **Neurology** 1999 Mar 10; 52(4):857-9

Differential localization of GABA(A) receptor alpha and beta subunits in the hamster retina and relationship with glutamic acid decarboxylase immunoreactivity. Lee YL, et al. **Neurosci Lett** 1998 May 22;248(1):29-32

GABA and histogenesis in fetal and neonatal mouse brain lacking both the isoforms of glutamic acid decarboxylase. Ji F, et al. **Neurosci Res** 1999 Mar;33(3):187-94

Development of the GABA system in organotypic culture of hippocampal and cerebellar slices from a 67-kDa isoform of glutamic acid decarboxylase (GAD67)-deficient mice. Ji F, et al. **Neurosci Res** 1999 Mar;33(3):233-7

Are GAD65 and GAD67 associated with specific pools of GABA in brain? Martin DL, et al. **Perspect Dev Neurobiol** 1998;5(2-3):119-29 (56 ref.)

Influence of intracerebroventricular administration of tetanus toxin on experimental seizures and protection afforded by some antiepileptic drugs in mice. Korolkiewicz R, et al. **Pharmacol Res** 1998 Jun;37(6):477-83

Local GABA circuit control of experience-dependent plasticity in developing visual cortex. Hensch TK, et al. **Science** 1998 Nov 20;282(5393):1504-8

Synaptic connectivity of two types of recoverin-labeled cone bipolar cells and glutamic acid decarboxylase immunoreactive amacrine cells in the inner plexiform layer of the rat retina. Chun MH, et al. **Vis Neurosci** 1999 Jul-Aug;16(4):791-800

PHYSIOLOGY

Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Kash SF, et al. **Horm Metab Res** 1999 May;31(5):340-4

THERAPEUTIC USE

Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy. Qin HY, et al. **J Autoimmun** 1998 Dec; 11(6):591-601

GLUTAMATE DEHYDROGENASE

BIOSYNTHESIS

High protein diet induces pericentral glutamate dehydrogenase and ornithine aminotransferase to provide sufficient glutamate for pericentral detoxification of ammonia in rat liver lobules. Boon L, et al. **Histochem Cell Biol** 1999 Jun;111(6):445-52

BLOOD

Characterization of Plasmodium falciparum glutamate dehydrogenase-soluble antigen. Rodriguez-Acosta A, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1149-55

Detection of glutamate dehydrogenase enzyme activity in Plasmodium falciparum infection. Rodriguez-Acosta A, et al. **Indian J Med Res** 1999 Apr;109:152-6

CHEMISTRY

Identification and characterization of kinetically competent carbinolamine and alpha-iminoglutarate complexes in the glutamate dehydrogenase-catalyzed oxidation of L-glutamate using a multiwavelength transient state approach. Maniscalco SJ, et al. **Biochemistry** 1998 Oct 13; 37(41):14585-90

Amino acid residues involved in the catalytic mechanism of NAD-dependent glutamate dehydrogenase from Halobacterium salinarum [published erratum appears in Biochim Biophys Acta 1999 May 24;1427(3):417] Pérez-Pomares F, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):513-25

Enzyme activity below the dynamical transition at 220 K. Daniel RM, et al. **Biophys J** 1998 Nov;75(5):2504-7

Engineering activity and stability of Thermotoga maritima glutamate dehydrogenase. II: construction of a 16-residue ion-pair network at the subunit interface. Lebbink JH, et al. **J Mol Biol** 1999 Jun 4;289(2):357-69

Insights into the mechanism of domain closure and substrate specificity of glutamate dehydrogenase from Clostridium symbiosum. Stillman TJ, et al. **J Mol Biol** 1999 Jan 15; 285(2):875-85

Reactive cysteine residue of bovine brain glutamate dehydrogenase isoproteins. Cho SW, et al. **Mol Cells** 1999 Feb 28;9(1):91-8

NAD+-dependent glutamate dehydrogenase of the edible mushroom Agaricus bisporus: biochemical and molecular characterization. Kersten MA, et al. **Mol Gen Genet** 1999 Apr;261(3):452-62

Protein thermostability above 100 degreesC: a key role for ionic interactions. Vetriani C, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12300-5

Use of protein engineering to explore subunit interactions in an allosteric enzyme: construction of inter-subunit hybrids in Clostridium symbiosum glutamate dehydrogenase. Aghajanian S, et al. **Protein Eng** 1998 Jul; 11(7):569-75

Specificity of coenzyme analogues and fragments in promoting or impeding the refolding of clostridial glutamate dehydrogenase. Aghajanian S, et al. **Protein Sci** 1999 Apr;8(4):866-72

Pressure-induced thermostabilization of glutamate dehydrogenase from the hyperthermophile Pyrococcus furiosus. Sun MM, et al. **Protein Sci** 1999 May;8(5):1056-63

The structure of bovine glutamate dehydrogenase provides insights into the mechanism of allostery. Peterson PE, et al. **Structure Fold Des** 1999 Jul 15;7(7):769-82

GENETICS

Glutamate dehydrogenase, the marker protein of Plasmodium falciparum--cloning, expression and characterization of the malarial enzyme. Wagner JT, et al. **Eur J Biochem** 1998 Dec 1;258(2):813-9

Transcriptional repression of gdhA in Escherichia coli is mediated by the Nac protein. Camarena L, et al. **FEMS Microbiol Lett** 1998 Oct 1;167(1):51-6

Hyperinsulinism-hyperammonemia syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics. Yorifuji T, et al. **Hum Genet** 1999 Jun; 104(6):476-9

Role and regulation of Bacillus subtilis glutamate dehydrogenase genes. Belitsky BR, et al. **J Bacteriol** 1998 Dec;180(23):6298-305

The amino-terminal 100 residues of the nitrogen assimilation control protein (NAC) encode all known properties of NAC from Klebsiella aerogenes and Escherichia coli. Muse WB, et al. **J Bacteriol** 1999 Feb;181(3):934-40

Identification of a novel single base-pair polymorphism in the glutamate dehydrogenase (GLUD1) gene. Muroi J, et al. **J Hum Genet** 1999;44(4):268-9

Knockout of the glutamate dehydrogenase gene in bloodstream Trypanosoma brucei in culture has no effect on editing of mitochondrial mRNAs. Estévez AM, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):5-17

NAD+-dependent glutamate dehydrogenase of the edible mushroom Agaricus bisporus: biochemical and molecular characterization. Kersten MA, et al. **Mol Gen Genet** 1999 Apr;261(3):452-62

Cloning and characterization of glutamate dehydrogenase (GDH) from the gut of Haemonchus contortus. Skuce PJ, et al. **Parasitology** 1999 Mar;118 (Pt 3):297-304

Isolation and characterization of two cDNA clones encoding for glutamate dehydrogenase in Nicotiana plumbaginifolia. Ficarelli A, et al. **Plant Cell Physiol** 1999 Mar;40(3):339-42

An enhancer element located downstream of the major glutamate dehydrogenase gene of Bacillus subtilis. Belitsky BR, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;

96(18):10290–5

IMMUNOLOGY

Different antigenic reactivities of bovine brain glutamate dehydrogenase isoproteins. Choi SY, et al. **J Neurochem** 1999 May;72(5):2162–9

ISOLATION & PURIFICATION

Purification and characterization of cold-active L-glutamate dehydrogenase independent of NAD(P) and oxygen. Yamamura A, et al. **J Biochem (Tokyo)** 1999 Apr; 125(4):760–9

The kinetic locking-on strategy for bioaffinity purification: further studies with bovine liver glutamate dehydrogenase. O'Flaherty M, et al. **Protein Expr Purif** 1999 Jul; 16(2):276–97

METABOLISM

Importance of glutamate dehydrogenase stimulation for glucose and glutamine synthesis in rabbit renal tubules incubated with various amino acids. Winiarska K, et al. **Acta Biochim Pol** 1998;45(3):825–31

Chemical rescue of the catalytically disabled clostridial glutamate dehydrogenase mutant D165S by fluoride ion. Hayden BM, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):555–60

Changes in the activities of three diagnostic enzymes in the heart of rats following the consumption of diets deficient in zinc and essential fatty acids. Adisa AO, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):571–6

Patterns of activation of the norleucine activity of a quadruple mutant derived from clostridial glutamate dehydrogenase. Goyal A, et al. **Biochem Soc Trans** 1998 Nov;26(4):S380

The location of active site opening and closing events in the prehydride transfer phase of the oxidative deamination reaction catalyzed by bovine liver glutamate dehydrogenase using a novel pH jump approach. Saha SK, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):261–5

Activity of glutamate dehydrogenase is increased in ammonia-stressed hybridoma cells. Bonarius HP, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):447–53

Elevated glutamate dehydrogenase flux in glucose-deprived hybridoma and myeloma cells: evidence from 1H/15N NMR. Martinelle K, et al. **Biotechnol Bioeng** 1998 Nov 20;60(4):508–17

The presence of glutamate dehydrogenase is a selective advantage for the Cyanobacterium synechocystis sp. strain PCC 6803 under nonexponential growth conditions. Chávez S, et al. **J Bacteriol** 1999 Feb;181(3):808–13

Purification and characterization of cold-active L-glutamate dehydrogenase independent of NAD(P) and oxygen. Yamamura A, et al. **J Biochem (Tokyo)** 1999 Apr; 125(4):760–9

Photoaffinity labeling of brain glutamate dehydrogenase isoproteins with an azido-ADP. Cho SW, et al. **J Biol Chem** 1999 May 14;274(20):13948–53

Identification of an NAD+ binding site of brain glutamate dehydrogenase isoproteins by photoaffinity labeling. Cho SW, et al. **J Biol Chem** 1998 Nov 20;273(47):31125–30

Insights into the mechanism of domain closure and substrate specificity of glutamate dehydrogenase from Clostridium symbiosum. Stillman TJ, et al. **J Mol Biol** 1999 Jan 15; 285(2):875–85

Electrostatic contributions to the stability of hyperthermophilic proteins. Xiao L, et al. **J Mol Biol** 1999 Jun 25;289(5):1435–44

Isoergonic cooperativity: a novel form of allostery. Fisher HF, et al. **Methods Enzymol** 1998;295:331–49

Cellular and regional expression of glutamate dehydrogenase in the rat nervous system: non-radioactive in situ hybridization and comparative immunocytochemistry. Schmitt A, et al. **Neuroscience** 1999;92(1):293–308

Cloning and characterization of glutamate dehydrogenase (GDH) from the gut of Haemonchus contortus. Skuce PJ, et al. **Parasitology** 1999 Mar;118 (Pt 3):297–304

[Key enzymes of biosynthesis of amino acids of the glutamic series in the virus-cell system Anabaena variabilis + A-1] Mendzhul MI, et al. **Ukr Biokhim Zh** 1998 Jan–Feb; 70(1):16–22 (Eng. Abstr.) **(Rus)**

GLUTAMATE DEHYDROGENASE (NADP+)

ANALYSIS

Fluorescence and quenching comparative studies of halophilic and bovine glutamate dehydrogenase. Ferrer J, et al. **J Photochem Photobiol B** 1998 Dec;47(2-3):148–54

GLUTAMATE RECEPTORS see **RECEPTORS, GLUTAMATE**

GLUTAMATE RECEPTORS, METABOTROPIC see **RECEPTORS, METABOTROPIC GLUTAMATE**

GLUTAMATE SYNTHASE

BIOSYNTHESIS

Glutamine synthetase expression and activity are regulated by 3,5,3'-triodo-L-thyronine and hydrocortisone in rat oligodendrocyte cultures. Baas D, et al. **Int J Dev Neurosci** 1998 Aug;16(5):333–40

CHEMISTRY

Organization and structure of NADH-dependent glutamate synthase gene from rice plants. Goto S, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):298–308

GENETICS

The Aspergillus nidulans gltA gene encoding glutamate synthase is required for ammonium assimilation in the absence of NADP-glutamate dehydrogenase. Macheda ML, et al. **Curr Genet** 1999 Jan;34(6):467–71

[Nucleotide sequence of gltB gene encoding the large subunit of Rhodobacter sphaeroides glutamate synthase] Lu T, et al. **Wei Sheng Wu Hsueh Pao** 1997 Apr;37(2):87–94 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Glutamate synthase: a complex iron-sulfur flavoprotein. Vanoni MA, et al. **Cell Mol Life Sci** 1999 Apr;55(4):617–38 (67 ref.)

GLUTAMATE-TRNA LIGASE

GENETICS

Co-transcription of Rhizobium meliloti lysyl-tRNA synthetase and glutamyl-tRNA synthetase genes. Pelchat M, et al. **FEBS Lett** 1999 Apr 16;449(1):23–7

Cloning of the glutamyl-tRNA synthetase (gltX) gene from Pseudomonas aeruginosa. Franklund CV, et al. **J Bacteriol** 1999 Jun;181(11):3582–6

In vivo and in vitro processing of the Bacillus subtilis transcript coding for glutamyl-tRNA synthetase, serine acetyltransferase, and cysteinyl-tRNA synthetase. Pelchat M, et al. **RNA** 1999 Feb;5(2):281–9

METABOLISM

Immunoelectron microscopic localization of glutamyl-/prolyl-tRNA synthetase within the eukaryotic multisynthetase complex. Norcum MT, et al. **J Biol Chem** 1999 Apr 30;274(18):12205–8

Aminoacylation of hypomodified tRNAGlu in vivo. Krüger MK, et al. **J Mol Biol** 1998 Dec 4;284(3):609–20

Major identity element of glutamine tRNAs from Bacillus subtilis and Escherichia coli in the reaction with B. subtilis glutamyl-tRNA synthetase. Kim SI, et al. **Mol Cells** 1998 Aug 31;8(4):459–65

GLUTAMATES

see related
EXCITATORY AMINO ACID AGONISTS
POLYGLUTAMIC ACID
RECEPTORS, GLUTAMATE

ADMINISTRATION & DOSAGE

Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley RB, et al. **Cancer Res** 1999 Aug 15;59(16):3998–4003

AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

ANTAGONISTS & INHIBITORS

Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. Fredriksson A, et al. **J Neural Transm** 1999;106(3-4):283–300

Prolonged inhibition of glutamate reuptake down-regulates NMDA receptor functions in cultured cerebellar granule cells. Cebers G, et al. **J Neurochem** 1999 May;72(5):2181–90

Effects of glutamate uptake blockers on stimulus-induced field potentials in rat entorhinal cortex in vitro. Iserhot C, et al. **Neurosci Lett** 1999 Jan 8;259(2):103–6

BIOSYNTHESIS

Role of ornithine in the N-acetylglutamate turnover in the liver of rats. Hayase K, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):506–9

CHEMICAL SYNTHESIS

(2S,4S)-amino-4-(2,2-diphenylethyl)pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist. Escribano A, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):765–70

Brominated 7-hydroxycoumarin-4-ylmethyls: photolabile protecting groups with biologically useful cross-sections for two photon photolysis. Furuta T, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1193–200

CHEMISTRY

Agonist selectivity of mGluR1 and mGluR2 metabotropic receptors: a different environment but similar recognition of an extended glutamate conformation. Jullian N, et al. **J Med Chem** 1999 May 6;42(9):1546–55

Crystal structure of phosphoserine aminotransferase from Escherichia coli at 2.3 A resolution: comparison of the unligated enzyme and a complex with alpha-methyl-l-glutamate. Hester G, et al. **J Mol Biol** 1999 Feb 26;286(3):829–50

DRUG EFFECTS

The effect of intravenous or subarachnoid lidocaine on glutamate accumulation during transient forebrain ischemia in rats. Terada H, et al. **Anesth Analg** 1999 Oct;89(4):957–61

GENETICS

Splicing of the glutamate transporter EAAT2: a candidate gene of amyotrophic lateral sclerosis [letter] Meyer T, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):954

METABOLISM

A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Payton M, et al. **Biochem Pharmacol** 1999 Sep 1; 58(5):779–85

Barbiturates impair astrocyte glutamate uptake. Swanson RA, et al. **Glia** 1998 Dec;24(4):365–71

High protein diet induces pericentral glutamate dehydrogenase and ornithine aminotransferase to provide sufficient glutamate for pericentral detoxification of ammonia in rat liver lobules. Boon L, et al. **Histochem Cell Biol** 1999 Jun;111(6):445–52

Characterization of mutations that allow p-aminobenzoyl-glutamate utilization by Escherichia coli. Hussein MJ, et al. **J Bacteriol** 1998 Dec;180(23):6260–8

Comparison of the D-glutamate-adding enzymes from selected gram-positive and gram-negative bacteria. Walsh AW, et al. **J Bacteriol** 1999 Sep;181(17):5395–401

L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. Goldwaser I, et al. **J Biol Chem** 1999 Sep 10; 274(37):26617–24

Metabolic regulation of protein-bound glutamyl phosphates: insights into the function of prothymosin alpha. Tao L, et al. **J Cell Physiol** 1999 Feb;178(2):154–63

An increase in glutamate release follows a decrease in gamma aminobutyric acid and the pubertal increase in luteinizing hormone releasing hormone release in the female rhesus monkeys. Terasawa E, et al. **J Neuroendocrinol** 1999 Apr; 11(4):275–82

Influence of the oestrous cycle on L-glutamate and L-aspartate transport in rat brain synaptosomes. Mitrovic AD, et al. **Neurochem Int** 1999 Feb;34(2):101–8

Regional distribution of low affinity kainate receptors in brain of Macaca fascicularis determined by autoradiography using [3H](2S,4R)-4-methylglutamate. Carroll FY, et al. **Neurosci Lett** 1998 Oct 16;255(2):71–4

[Effects of excitatory sulfur amino acids on glutamate transport in synaptosomes isolated from the rat cerebral cortex] Kuroda K. **Rinsho Shinkeigaku** 1998 Dec; 38(12):1019–23 (Eng. Abstr.) **(Jpn)**

[The enhancement of glutamate release in the nucleus accumbens of rats with a destroyed hippocampal formation during an emotional conditioned response] Saul'skaia NB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar–Apr; 49(2):245–53 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

[The bioavailability of tableted drug forms of the new Russian nootropic preparation nooglutil in rabbits] Chesnokova EA, et al. **Eksp Klin Farmakol** 1998 Jul–Aug;61(4):48–50 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Shih C, et al. **Adv Enzyme Regul** 1998;38:135–52

Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Schultz RM, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):437–43

Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Worzalla JF, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3235–9

Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Terashima T, et al. **Biosci Biotechnol Biochem** 1999 Apr; 63(4):615–8

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Britten CD, et al. **Cancer Chemother Pharmacol** 1999;44(2):105–10

"Atypical" neuromodulatory profile of glutapyrone, a representative of a novel 'class' of amino acid-containing dipeptide-mimicking 1,4-dihydropyridine (DHP) compounds: in vitro and in vivo studies. Misane I, et al. **Eur Neuropsychopharmacol** 1998 Dec;8(4):329–47

Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. Sugiyama T, et al. **Jpn J Cancer Res** 1999 Jul;90(7):775–80

Na+, K+ and Ca2+ antagonize the glutamate- and glycine-induced decrease of [3H]MK-801 binding observed in the presence of Mg2+ at low pH. Liu Y, et al. **Neurochem Int** 1999 Apr;34(4):291–301

Priming of group 2 metabotropic glutamate receptors facilitates induction of long-term depression in the dentate

gyrus of freely moving rats. Manahan-Vaughan D.
Neuropharmacology 1998 Dec;37(12):1459-64

LY339434, a GluR5 kainate receptor agonist. Small B, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1261-7

The kainate receptor antagonist 2S,4R-4-methylglutamate attenuates mechanical allodynia and thermal hyperalgesia in a rat model of nerve injury. Sutton JL, et al.
Neuroscience 1999;91(1):283-92

Glutamate-induced swelling of cultured astrocytes is mediated by metabotropic glutamate receptor. Yuan F, et al. **Sci China C Life Sci** 1996 Oct;39(5):517-22

[Influence of locus coeruleus stimulation on the vagal-cardiovascular reflex] Chen Y, et al.
Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih 1997 Aug; 13(3):242-5 (Eng. Abstr.) **(Chi)**

[Mechanisms of neuronal calcium homeostasis destabilization caused by hyperstimulation of glutamate receptors] Khodorov BI, et al. **Vestn Ross Akad Med Nauk** 1998; (8):41-6 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acid. Lima TT, et al. **Brain Res** 1998 Aug 17; 802(1-2):55-60

Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Walker BR, et al. **Epilepsia** 1999 Aug;40(8):1051-7

Systemic administration of lipopolysaccharide induces release of nitric oxide and glutamate and c-fos expression in the nucleus tractus solitarii of rats. Lin HC, et al.
Hypertension 1999 May;33(5):1218-24

Effects of guanine nucleotides on adenosine and glutamate modulation of cAMP levels in optic tectum slices from chicks. Tasca CI, et al. **Neurochem Int** 1999 Mar; 34(3):213-20

Effects of the P2-purinoceptor antagonists suramin and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid on glutamatergic synaptic transmission in rat dorsal horn neurons of the spinal cord. Gu JG, et al. **Neurosci Lett** 1998 Sep 11;253(3):167-70

[Glutamate neurotoxicity during spinal cord ischemia--neuroprotective effects of glutamate receptor antagonists] Nakamichi T.
Jpn J Thorac Cardiovasc Surg 1998 Sep;46(9):854-9 (Eng. Abstr.) **(Jpn)**

RADIATION EFFECTS

Focal photolysis of caged glutamate produces long-term depression of hippocampal glutamate receptors [see comments] Kandler K, et al. **Nat Neurosci** 1998 Jun; 1(2):119-23. Comment in: Nat Neurosci 1998 Jun;1(2):89-90.

THERAPEUTIC USE

Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Sugiyama T, et al. **Cancer Lett** 1998 Nov 13;133(1):19-26

Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Sugiyama T, et al. **Clin Cancer Res** 1999 Feb;5(2):413-6

Partial N-acetylglutamate synthetase deficiency in a 13-year-old girl: diagnosis and response to treatment with N-carbamylglutamate. Plecko B, et al. **Eur J Pediatr** 1998 Dec;157(12):996-8

5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid. Clerici C, et al.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):385-90

N-acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate. Morris AA, et al.
J Inherit Metab Dis 1998 Dec;21(8):867-8

Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer. Johnson D, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):1-2

Overview of MTA in the treatment of non-small cell lung cancer. Postmus PE, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):31-6 (35 ref.)

TOXICITY

Development of inflammation after application of mustard oil or glutamate to the rat temporomandibular joint. Fiorentino PM, et al. **Arch Oral Biol** 1999 Jan;44(1):27-32

Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines. Faessel HM, et al. **Biochem Pharmacol** 1999 Mar 1;57(5):567-77

Chronic administration of aluminium L-glutamate in young mature rats: effects on iron levels and lipid peroxidation in selected brain areas. Deloncle R, et al. **Toxicol Lett** 1999 Jan 11;104(1-2):65-73

URINE

Kinetic model of folate metabolism in nonpregnant women consuming [2H2]folic acid: isotopic labeling of urinary folate and the catabolite para-acetamidobenzoylglutamate indicates slow, intake-dependent, turnover of folate pools. Gregory JF 3rd, et al. **J Nutr** 1998 Nov;128(11):1896-906

GLUTAMIC ACID

see related

RECEPTORS, GLUTAMATE

Clinical evaluation of efficacy and safety of a new method for chemo-mechanical removal of caries. A multi-centre study. Ericson D, et al. **Caries Res** 1999 May-Jun; 33(3):171-7

The negative charge of Glu-127 in protein kinase A and its biorecognition. Batkin M, et al. **FEBS Lett** 1999 Jun 11;452(3):395-9

Probing the function of the invariant glutamyl residue 312 in spinach ferredoxin-NADP+ reductase. Aliverti A, et al. **J Biol Chem** 1998 Dec 18;273(51):34008-15

Identification of Glu-540 as the catalytic nucleophile of human beta-glucuronidase using electrospray mass spectrometry. Wong AW, et al. **J Biol Chem** 1998 Dec 18;273(51):34057-62

Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. Bilak MM, et al.
J Neuropathol Exp Neurol 1999 Jul;58(7):719-28

Site-directed mutagenesis of Glu-297 from the alpha-polypeptide of Phaseolus vulgaris glutamine synthetase alters kinetic and structural properties and confers resistance to L-methionine sulfoximine. Clemente MT, et al. **Plant Mol Biol** 1999 Jul;40(5):835-45

ADMINISTRATION & DOSAGE

Cardiovascular responses to microinjections of glutamate into the nucleus tractus solitarii of unanesthetized supracollicular decerebrate rats. Dhruva A, et al.
Brain Res 1998 Aug 10;801(1-2):88-100

Biochemical and immunological changes on oral glutamate feeding in male albino rats. Kumar D, et al.
Int J Biometeorol 1999 Apr;42(4):201-4

Cardiorespiratory responses to glutamate microinjected into the medullary raphé. Bernard DG. **Respir Physiol** 1998 Jul; 113(1):11-21

ADVERSE EFFECTS

Nerve growth factor, ganglioside and vitamin E reverse glutamate cytotoxicity in hippocampal cells. Cunha GM, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):107-12

Age-related toxicity to lactate, glutamate, and beta-amyloid in cultured adult neurons. Brewer GJ. **Neurobiol Aging** 1998 Nov-Dec;19(6):561-8

ANALOGS & DERIVATIVES

Structural determinants of substrates and inhibitors: probing glutamate transporters with 2,4-methanopyrrolidine-2,4-dicarboxylate. Esslinger CS, et al. **Bioorg Med Chem Lett** 1998 Nov 3;8(21):3101-6

Synthesis and proteinase inhibitory properties of diphenyl phosphonate analogues of aspartic and glutamic acids. Hamilton R, et al. **Bioorg Med Chem Lett** 1998 Jul 7; 8(13):1655-60

Synthesis and biological activity of glutamic acid derivatives. Receveur JM, et al. **Bioorg Med Chem Lett** 1998 Jan 20; 8(2):127-32

A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system. Bridges RJ, et al. **Curr Pharm Des** 1999 May;5(5):363-79 (127 ref.)

Effects of N-methacryloyl amino acid applications on hybrid layer formation at the interface of intertubular dentin. Suzuki K, et al. **J Dent Res** 1998 Nov;77(11):1881-8

A multisubstrate adduct inhibitor of AICAR transformylase. Wall M, et al. **J Med Chem** 1999 Sep 9;42(18):3421-4

Design and synthesis of conformationally constrained inhibitors of high-affinity, sodium-dependent glutamate transporters. Chamberlin AR, et al. **Methods Enzymol** 1998; 296:175-89

ANALYSIS

An increase in extracellular glutamate is a sensitive method of detecting ischaemic neuronal damage during cranial base and cerebrovascular surgery. An in vivo microdialysis study. Mendelowitsch A, et al. **Acta Neurochir (Wien)** 1998; 140(4):349-55; discussion 356

Determination of glutamate by high-performance liquid chromatography with fluorescence detection in superfusates of rat brain preparations. Ioannou N, et al.
Anal Biochem 1998 Nov 1;264(1):82-6

Enzyme-based flow injection analysis system for glutamine and glutamate in mammalian cell culture media. Mayer C, et al. **Anal Biochem** 1999 Mar 1;268(1):110-6

Subcellular compartmentation of glutathione and glutathione precursors. A high resolution immunogold analysis of the outer retina of guinea pig. Huster D, et al.
Anat Embryol (Berl) 1998 Oct;198(4):277-87

Application of thick film technology in mass production of biosensors. Hu JJ. **Ann N Y Acad Sci** 1998 Dec 13; 864:305-8

High-throughput flow-injection analysis of glucose and glutamate in food and biological samples by using enzyme/polyion complex-bilayer membrane-based electrodes as the detectors. Mizutani F, et al.
Biosens Bioelectron 1998 Oct 1;13(7-8):809-15

Characterisation of a thermophilic L-glutamate dehydrogenase biosensor for amperometric determination of L-glutamate by flow injection analysis. Pasco N, et al.
Biosens Bioelectron 1999 Feb;14(2):171-8

A subpopulation of neurons in the rat rostral nucleus of the solitary tract that project to the parabrachial nucleus express glutamate-like immunoreactivity. Gill CF, et al.
Brain Res 1999 Mar 13;821(2):251-62

Glutamate/aspartate and leu-enkephalin immunoreactivity in mammillothalamic projection neurons of the rat. Gonzalo-Ruiz A, et al. **Brain Res Bull** 1998 Dec; 47(6):565-74

Coexistence of glutamate and acetylcholine in the developing motoneurons. Fu WM, et al. **Chin J Physiol** 1998 Sep 30; 41(3):127-32

Hippocampal synaptic density and glutamate immunoreactivity following transient cerebral ischaemia in the chick. Horner CH, et al. **Eur J Neurosci** 1998 Dec; 10(12):3913-7

C isotopomer analysis of glutamate by heteronuclear multiple quantum coherence-total correlation spectroscopy (HMQC-TOCSY). Carvalho RA, et al. **FEBS Lett** 1998 Dec 4;440(3):382-6

The concentration of glutamate in cerebral tissue as a factor for the assessment of the emotional state before death. A preliminary report. Hauser R, et al. **Int J Legal Med** 1999; 112(3):184-7

GABA- and glutamate-immunoreactive synapses on sympathetic preganglionic neurons projecting to the superior cervical ganglion. Llewellyn-Smith IJ, et al.
J Auton Nerv Syst 1998 Jul 15;71(2-3):96-110

Simultaneous determination of basal and evoked output levels of aspartate, glutamate, taurine and 4-aminobutyric acid during microdialysis and from superfused brain slices. Bianchi L, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19;723(1-2):47-59

Distribution of input and output synapses on the central branches of bushcricket and cricket auditory afferent neurones: immunocytochemical evidence for GABA and glutamate in different populations of presynaptic boutons. Hardt M, et al. **J Comp Neurol** 1999 Jan 18;403(3):281-94

Immunocytochemical localization of glutamate and gamma-aminobutyric acid in the accessory olfactory bulb of the rat. Quaglino E, et al. **J Comp Neurol** 1999 May 24;408(1):61-72

Chemical anatomy of excitatory endings in the dorsal cochlear nucleus of the rat: differential synaptic distribution of aspartate aminotransferase, glutamate, and vesicular zinc. Rubio ME, et al. **J Comp Neurol** 1998 Sep 28;399(3):341-58

Monte carlo simulation of vesicular release, spatiotemporal distribution of glutamate in synaptic cleft and generation of postsynaptic currents. Glavinovic MI. **Pflugers Arch** 1999 Feb;437(3):462-70

Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Dahchour A, et al. **Psychiatry Res** 1998 May 20;82(2):107-14

Changes in the amygdala amino acid microdialysate after conditioning with a cue associated with ethanol. Quertemont E, et al. **Psychopharmacology (Berl)** 1998 Sep; 139(1-2):71-8

Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Schroeder H, et al.
Psychopharmacology (Berl) 1999 Jul;145(1):61-6

BIOSYNTHESIS

A neural network for the optimization of fed-batch glutamic acid production. Miao Z, et al. **Chin J Biotechnol** 1998; 14(2):125-31

Excitatory amino acid synthesis in hypoxic brain slices: does alanine act as a substrate for glutamate production in hypoxia? Griffin JL, et al. **J Neurochem** 1998 Dec; 71(6):2477-86

Does the 'mystery of the extra glucose' during CNS activation reflect glutamate synthesis? Hertz L, et al.
Neurochem Int 1999 Jan;34(1):71-5 (35 ref.)

Similarities and interactions between GABAergic and glutaminergic systems [editorial] Car H, et al.
Rocz Akad Med Bialymst 1998;43:5-26 (123 ref.)

BLOOD

Lysine and glutamate transport in the erythrocytes of common brushtail possum, Tammar Wallaby and eastern grey, kangaroo. Ogawa E, et al.
Comp Biochem Physiol A Mol Integr Physiol 1998 Apr; 119(4):951-6

Portal hyperglutamatemia after dietary supplementation with monosodium glutamate in pigs. Blachier F, et al.
Digestion 1999 Jul-Aug;60(4):349-57

Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice. Mennini T, et al. **J Neurol Sci** 1998 Apr 15;157(1):31-6

Apoptosis of cerebellar granule cells induced by serum withdrawal, glutamate or beta-amyloid, is independent of Jun kinase or p38 mitogen activated protein kinase activation. Gunn-Moore FJ, et al. **Neurosci Lett** 1998 Jun 26;250(1):53-6

Assessment of myocardial glutamate requirements early after coronary artery bypass surgery. Vanhanen I, et al. **Scand Cardiovasc J** 1998;32(3):145–52

CEREBROSPINAL FLUID

Involvement of microglia in cerebrospinal fluid glutamate increase in SIV-infected rhesus monkeys (Macaca mulatta). Koutsilieri E, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):471–7

The effects of moderate hypothermia and intrathecal tetracaine on glutamate concentrations of intrathecal dialysate and neurologic and histopathologic outcome in transient spinal cord ischemia in rabbits. Wakamatsu H, et al. **Anesth Analg** 1999 Jan;88(1):56–62

Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Faustman WO, et al. **Biol Psychiatry** 1999 Jan 1;45(1):68–75

Thiopental attenuates energetic impairment but fails to normalize cerebrospinal fluid glutamate in brain-injured patients. Stover JF, et al. **Crit Care Med** 1999 Jul; 27(7):1351–7

Peroxynitrite generation might explain elevated glutamate and aspartate levels in multiple sclerosis cerebrospinal fluid [letter; comment] Gurwitz D, et al. **Eur J Clin Invest** 1998 Sep;28(9):760–1. Comment on: Eur J Clin Invest 1997 Dec;27(12):1038–43.

Rett syndrome: 1H spectroscopic imaging at 4.1 Tesla. Pan JW, et al. **J Child Neurol** 1999 Aug;14(8):524–8

A subtype of pyridoxine-dependent epilepsy with normal CSF glutamate concentration. Kure S, et al. **J Inherit Metab Dis** 1998 Jun;21(4):431–2

Regional cerebral blood flow and cerebrospinal fluid glutamate in leukoaraiosis. Oishi M, et al. **J Neurol** 1998 Dec;245(12):777–80

Glutamate and taurine are increased in ventricular cerebrospinal fluid of severely brain-injured patients. Stover JF, et al. **J Neurotrauma** 1999 Feb;16(2):135–42

Thiopental and midazolam do not seem to impede metabolism of glutamate in brain-injured patients. Stover JF, et al. **Psychopharmacology (Berl)** 1999 Jan;141(1):66–70

CHEMISTRY

Glycerol affects the quantification of aspartate and glutamate in acid-hydrolyzed proteins. Juranville JF, et al. **Amino Acids** 1998;15(3):253–62

The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. He W, et al. **Biochemistry** 1999 Aug 17;38(33):10871–7

Role of glutamate 144 and glutamate 164 in the catalytic mechanism of enoyl-CoA hydratase. Hofstein HA, et al. **Biochemistry** 1999 Jul 20;38(29):9508–16

Glutamate 190 is a general acid catalyst in the 6-phosphogluconate-dehydrogenase-catalyzed reaction. Karsten WE, et al. **Biochemistry** 1998 Nov 10; 37(45):15691–7

Role of glutamate 91 in information transfer during substrate activation of yeast pyruvate decarboxylase. Li H, et al. **Biochemistry** 1999 Aug 3;38(31):9992–10003

Electron transfer induces side-chain conformational changes of glutamate-286 from cytochrome bo3. Lübben M, et al. **Biochemistry** 1999 Feb 16;38(7):2048–56

Identification and characterization of kinetically competent carbinolamine and alpha-iminoglutarate complexes in the glutamate dehydrogenase-catalyzed oxidation of L-glutamate using a multiwavelength transient state approach. Maniscalco SJ, et al. **Biochemistry** 1998 Oct 13; 37(41):14585–90

The hydrogen-bonding network of water molecules and the peptide backbone in the region connecting Asp83, Gly120, and Glu113 in bovine rhodopsin. Nagata T, et al. **Biochemistry** 1998 Dec 8;37(49):17216–22

The roles of Glu-327 and His-446 in the bisphosphatase reaction of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase probed by NMR spectroscopic and mutational analyses of the enzyme in the transient phosphohistidine intermediate complex. Okar DA, et al. **Biochemistry** 1999 Apr 6; 38(14):4471–9

Characterization of Glu126 and Arg144, two residues that are indispensable for substrate binding in the lactose permease of Escherichia coli. Sahin-Tóth M, et al. **Biochemistry** 1999 Jan 12;38(2):813–9

Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site. Shobe J, et al. **Biochemistry** 1999 Mar 2;38(9):2745–51

Proximity between Glu126 and Arg144 in the lactose permease of Escherichia coli. Zhao M, et al. **Biochemistry** 1999 Jun 8;38(23):7407–12

Mutagenesis of glutamate 820 of the gastric H+,K+-ATPase alpha-subunit to aspartate decreases the apparent ATP affinity. Hermsen HP, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1–2):251–7

L-Glutamic acid and L-lysine as useful building blocks for the preparation of bifunctional DTPA-like ligands. Anelli PL, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):137–40

The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase. Kass IJ, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2663–8

Synthesis and metabotropic glutamate receptor activity of a 2-aminobicyclo[3.2.0]heptane-2,5-dicarboxylic acid, a molecule possessing an extended glutamate conformation. Kozikowski AP, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):925–30

Ion permeation and glutamate residues linked by Poisson-Nernst-Planck theory in L-type calcium channels. Nonner W, et al. **Biophys J** 1998 Sep;75(3):1287–305

Indispensable glutamic acid residue-139 of NtpK proteolipid in the reaction of vacuolar Na(+)-translocating ATPase in Enterococcus hirae. Takase K, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):1125–9

Characterization of the Asp94 and Glu242 mutants in myeloperoxidase, the residues linking the heme group via ester bonds. Kooter IM, et al. **Eur J Biochem** 1999 Aug; 264(1):211–7

The enhancing of a cysteine proteinase activity at acidic pH by protein engineering, the role of glutamic 50 in the enzyme mechanism of caricain [published erratum appears in FEBS Lett 1998 Nov 27;440(1–2):250] Ikeuchi Y, et al. **FEBS Lett** 1998 Oct 16;437(1–2):91–6

Crystal structure of deoxy-human hemoglobin beta6 Glu --> Trp. Implications for the structure and formation of the sickle cell fiber. Harrington DJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32690–6

Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. Evidence that Glu19 of G-CSF interacts with Arg288 of the receptor. Layton JE, et al. **J Biol Chem** 1999 Jun 18;274(25):17445–51

Biochemical evidence for heme linkage through esters with Asp-93 and Glu-241 in human eosinophil peroxidase. The ester with Asp-93 is only partially formed in vivo. Oxvig C, et al. **J Biol Chem** 1999 Jun 11;274(24):16953–8

Requirements of protein kinase cdelta for catalytic function. Role of glutamic acid 500 and autophosphorylation on serine 643. Stempka L, et al. **J Biol Chem** 1999 Mar 26; 274(13):8886–92

Design and synthesis of conformationally constrained inhibitors of high-affinity, sodium-dependent glutamate transporters. Chamberlin AR, et al. **Methods Enzymol** 1998; 296:175–89

Structure of a glutamate-receptor ligand-binding core in complex with kainate. Armstrong N, et al. **Nature** 1998 Oct 29;395(6705):913–7

[Precursor of a molten globule in a statistical copolymer, comprised of hydrophobic and hydrophilic amino acids. Karnup AS, et al. **Mol Biol (Mosk)** 1998 Jul-Aug; 32(4):657–63 **(Rus)**

DEFICIENCY

A glutamatergic deficiency model of schizophrenia. Carlsson A, et al. **Br J Psychiatry Suppl** 1999;(37):2–6 (21 ref.)

DRUG EFFECTS

Nerve growth factor inducer, 4-methyl catechol, potentiates central sensitization associated with acceleration of spinal glutamate release after mustard oil paw injection in rats. Ishikawa T, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):587–96

Nicotine enhances presynaptic and postsynaptic glutamatergic neurotransmission to activate cardiac parasympathetic neurons. Neff RA, et al. **Circ Res** 1998 Dec 14–28;83(12):1241–7

Riluzole, a glutamate release inhibitor, and motor behavior. Kretschmer BD, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Aug; 358(2):181–90

Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Pérez de la Mora M, et al. **Neurosci Lett** 1999 Jan 15;259(3):181–5

Intra-striatal phencyclidine inhibits N-methyl-D-aspartic acid-stimulated increase in glutamate levels of freely moving rats. Yamamoto Y, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Jan; 23(1):161–74

GENETICS

A glutamate to lysine mutation at the end of 2B rod domain of keratin 2e gene in ichthyosis bullosa of Siemens. Yang JM, et al. **Acta Derm Venereol** 1998 Nov;78(6):417–9

A novel variant of transthyretin (Glu42Asp) associated with sporadic late-onset cardiac amyloidosis. Dupuy O, et al. **Amyloid** 1998 Dec;5(4):285–7

Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Radcliffe KA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:591–610

The roles of threonine-136 and glutamate-137 of human medium chain acyl-CoA dehydrogenase in FAD binding and peptide folding using site-directed mutagenesis: creation of an FAD-dependent mutant, T136D. Saijo T, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):49–57

The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Mori Y, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):138–40

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Watson DJ, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):703–9

Effects of mutation of the conserved glutamic acid-286 in subunit I of cytochrome c oxidase from Rhodobacter sphaeroides. Jünemann S, et al. **Biochemistry** 1999 Apr 20; 38(16):5248–55

Proton uptake by carboxylic acid groups upon photoreduction of the secondary quinone (QB) in bacterial reaction centers from Rhodobacter sphaeroides: FTIR studies on the effects of replacing Glu H173. Nabedryk E, et al. **Biochemistry** 1998 Oct 13;37(41):14457–62

The influence of mutation at Glu44 and Glu56 of cytochrome b5 on the protein's stabilization and interaction between cytochrome c and cytochrome b5. Qian W, et al. **Biochemistry** 1998 Oct 6;37(40):14137–50

Coronary artery disease is not associated with the E298-->D variant of the constitutive, endothelial nitric oxide synthase gene [letter] Liyou N, et al. **Clin Genet** 1998 Dec; 54(6):528–9

Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. Maas A, et al. **J Immunol** 1999 Jun 1;162(11):6526–33

Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. Wang Z, et al. **J Immunol** 1999 Aug 1; 163(3):1647–53

Prenatal molecular diagnosis of severe ornithine carbamoyltransferase deficiency due to a novel mutation, E181G. Topaloglu AK, et al. **J Inherit Metab Dis** 1999 Feb;22(1):82–3

The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females. Hellström L, et al. **J Intern Med** 1999 Mar;245(3):253–9

A novel glutamic acid to aspartic acid mutation near the end of the 2B rod domain in the keratin 1 chain in epidermolytic hyperkeratosis. Yang JM, et al. **J Invest Dermatol** 1999 Mar;112(3):376–9

The modification of the wobble base of tRNAGlu modulates the translation rate of glutamic acid codons in vivo. Krüger MK, et al. **J Mol Biol** 1998 Dec 4;284(3):621–31

METABOLISM

Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats. Zhang X, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):1004–9

The effect of glutamate uptake inhibitors on hippocampal evoked potentials in vitro. el-Sherif Y, et al. **Acta Neurobiol Exp (Warsz)** 1999;59(2):89–97

Intraoperative microdialysis and tissue-pO2 measurement in human glioma. Baunach S, et al. **Acta Neurochir Suppl (Wien)** 1998;71:241–3

Effects of mild and moderate hypothermia on cerebral metabolism and glutamate in an experimental head injury. Mori K, et al. **Acta Neurochir Suppl (Wien)** 1998;71:222–4

Changes of perilymphatic glutamate and cochlear blood flow following ischemia. Haruta A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:44–7

Quantitative immunogold cytochemistry reveals sources of glutamate release in inner ear ischemia. Matsubara A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:48–51

Synaptic and extrasynaptic roles of glutamate in the mammalian hippocampus. Kullmann DM. **Acta Physiol Scand** 1999 Jun;166(2):79–83 (25 ref.)

Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1. Kort JJ. **AIDS Res Hum Retroviruses** 1998 Oct 10; 14(15):1329–39

Glutamate receptors in the cingulate cortex, hippocampus, and cerebellar vermis of alcoholics. Freund G, et al. **Alcohol Clin Exp Res** 1999 Jan;23(1):1–6

Pattern of substrate utilization in vascular smooth muscle using 13C isotopomer analysis of glutamate. Allen TM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2227–35

Brain O2 consumption and glutamate release during hypoglycemic coma in piglets are temperature sensitive. Ichord RN, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2053–62

Effects of pH changes on systems ASC and B in rabbit ileum. Munck BG, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G173–84

Substrate oxidation by the portal drained viscera of fed piglets. Stoll B, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E168–75

Release of endogenous excitatory amino acids in the neostriatum of the rat under physiological and pharmacologically-induced conditions. Herrera-Marschitz M, et al. **Amino Acids** 1998;14(1–3):197–203 (22 ref.)

Glutamate release inhibitors: a critical assessment of their action mechanism. Obrenovitch TP, et al. **Amino Acids** 1998;14(1–3):143–50 (43 ref.)

Dopamine-glutamate interactions in the basal ganglia. Schmidt WJ. **Amino Acids** 1998;14(1–3):5–10 (17 ref.)

Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Sonsalla PK, et al. **Amino Acids** 1998;14(1–3):69–74 (13 ref.)

Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Verhagen Metman L, et al. **Amino Acids** 1998;14(1–3):75–82

Clonidine inhibits and phorbol acetate activates glutamate release from rat spinal synaptoneurosomes. Shinomura T, et al. **Anesth Analg** 1999 Jun;88(6):1401–5

Lamotrigine attenuates cortical glutamate release during global cerebral ischemia in pigs on cardiopulmonary bypass. Conroy BP, et al. **Anesthesiology** 1999 Mar; 90(3):844–54

Propofol prevents peroxide-induced inhibition of glutamate transport in cultured astrocytes. Sitar SM, et al. **Anesthesiology** 1999 May;90(5):1446–53

Galanin controls excitability of the brain. Chepurnov SA, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:547–50

Nitric oxide synthase inhibitor decreases NMDA-induced elevations of extracellular glutamate and intracellular Ca2+ levels via a cGMP-independent mechanism in cerebellar granule neurons. Oh S, et al. **Arch Pharm Res** 1999 Feb;22(1):48–54

Effects of chronic lead exposure on glutamate release and uptake in cerebellar cells of rat pups. Yi EY, et al. **Arch Pharm Res** 1998 Apr;21(2):113–9

Cloning, sequencing, and developmental expression levels of a novel glutamate-gated chloride channel homologue in the parasitic nematode Haemonchus contortus. Forrester SG, et al. **Biochem Biophys Res Commun** 1999 Jan 27; 254(3):529–34

Arachidonic acid as a messenger for the expression of long-term potentiation. Nishizaki T, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):446–9

Catalytic triad of microsomal epoxide hydrolase: replacement of Glu404 with Asp leads to a strongly increased turnover rate. Arand M, et al. **Biochem J** 1999 Jan 1;337 (Pt 1):37–43

Aspartate-27 and glutamate-473 are involved in catalysis by Zymomonas mobilis pyruvate decarboxylase. Chang AK, et al. **Biochem J** 1999 Apr 15;339 (Pt 2):255–60

Identification of Glu-120 as the catalytic nucleophile in Streptomyces lividans endoglucanase celB. Zechel DL, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):139–45

Glutamate release is involved in PAF-increased cyclic GMP levels in hippocampus. Calcerrada MC, et al. **Biochem Mol Biol Int** 1999 Mar;47(3):529–35

Decreased glutamate metabolism in cultured astrocytes in the presence of thiopental. Qu H, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):1075–80

Uptake of L-glutamate into synaptic vesicles: competitive inhibition by dyes with biphenyl and amino- and sulphonic acid-substituted naphthyl groups. Roseth S, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1243–9

Glutamyl substrate-induced exposure of a free cysteine residue in the vitamin K-dependent gamma-glutamyl carboxylase is critical for vitamin K epoxidation. Bouchard BA, et al. **Biochemistry** 1999 Jul 20;38(29):9517–23

Receptor activation by human C5a des Arg74 but not intact C5a is dependent on an interaction between Glu199 of the receptor and Lys68 of the ligand. Crass T, et al. **Biochemistry** 1999 Jul 27;38(30):9712–7

N-tosyl-L-phenylalanine chloromethyl ketone, a serine protease inhibitor, identifies glutamate 398 at the coenzyme-binding site of human aldehyde dehydrogenase. Evidence for a second "naked anion" at the active site. Dryjanski M, et al. **Biochemistry** 1998 Oct 6;37(40):14151–6

Acidic residues involved in cation and substrate interactions in the Na+/dicarboxylate cotransporter, NaDC-1. Griffith DA, et al. **Biochemistry** 1999 Jun 8;38(23):7524–31

Role of glutamate 144 and glutamate 164 in the catalytic mechanism of enoyl-CoA hydratase. Hofstein HA, et al. **Biochemistry** 1999 Jul 20;38(29):9508–16

Redox properties of human medium-chain acyl-CoA dehydrogenase, modulation by charged active-site amino acid residues. Mancini-Samuelson GJ, et al. **Biochemistry** 1998 Oct 13;37(41):14605–12

Posttranslational modifications of the C-terminus of alpha-tubulin in adult rat brain: alpha 4 is glutamylated at two residues. Redeker V, et al. **Biochemistry** 1998 Oct 20;37(42):14838–44

Modulation by L- and D-isoforms of amino acids of the L-glutamate response of N-methyl-D-aspartate receptors. Sakata K, et al. **Biochemistry** 1999 Aug 3;38(31):10099–106

Glutamic acid 472 and lysine 480 of the sodium pump alpha 1 subunit are essential for activity. Their conservation in pyrophosphatases suggests their involvement in recognition of ATP phosphates. Scheiner-Bobis G, et al. **Biochemistry** 1999 Jul 20;38(29):9198–208

Delayed labelling of brain glutamate after an intra-arterial [13C]glucose bolus: evidence for aerobic metabolism of guinea pig brain glycogen store. Griffin JL, et al. **Biochim Biophys Acta** 1999 Jul 8;1450(3):297–307

The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase. Kass IJ, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2663–8

Nicotine administration stimulates the in vivo N-methyl-D-aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. Fedele E, et al. **Br J Pharmacol** 1998 Nov;125(5):1042–8

Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum. Hill MP, et al. **Br J Pharmacol** 1999 May;127(1):275–83

Concentration-dependent isoflurane effects on depolarization-evoked glutamate and GABA outflows from mouse brain slices. Liachenko S, et al. **Br J Pharmacol** 1999 May;127(1):131–8

Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Okada M, et al. **Br J Pharmacol** 1998 Jul;124(6):1277–85

Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Aghajanian GK, et al. **Brain Res** 1999 Apr 17;825(1-2):161–71

Nicotinic acetylcholine receptor mediated modulation of evoked excitatory amino acid release in the nucleus tractus solitarius of the rat: evidence from in vivo microdialysis. Ashworth-Preece MA, et al. **Brain Res** 1998 Sep 28; 806(2):287–91

Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV). Attwell PJ, et al. **Brain Res** 1998 Sep 14;805(1-2):138–43

Lead increases tetrodotoxin-insensitive spontaneous release of glutamate and GABA from hippocampal neurons. Braga MF, et al. **Brain Res** 1999 Apr 24;826(1):10–21

Nanomolar concentrations of lead inhibit glutamatergic and GABAergic transmission in hippocampal neurons. Braga MF, et al. **Brain Res** 1999 Apr 24;826(1):22–34

Real-time measurement of ischemia-evoked glutamate release in the cerebral cortex of four and eleven vessel rat occlusion models. Caragine LP, et al. **Brain Res** 1998 May 18;793(1-2):255–64

Postmortem elevation in extracellular glutamate in the rat hippocampus when brain temperature is maintained at physiological levels: implications for the use of human brain autopsy tissues. Geddes JW, et al. **Brain Res** 1999 Jun 12; 831(1-2):104–12

Involvement of glutamate release in substance P-induced phase delays of suprachiasmatic neuron activity rhythm in vitro. Hamada T, et al. **Brain Res** 1999 Jul 31; 836(1-2):190–3

Generation of reactive oxygen species, release of L-glutamate and activation of caspases are required for oxygen-induced apoptosis of embryonic hippocampal neurons in culture. Ishikawa Y, et al. **Brain Res** 1999 Apr 3;824(1):71–80

Role of nitric oxide on GABA, glutamic acid, activities of GABA-T and GAD in rat brain cerebral cortex. Jayakumar AR, et al. **Brain Res** 1999 Aug 7; 837(1-2):229–35

Reverse transport of glutamate during depolarization in immature hippocampal slices. Katsumori H, et al. **Brain Res** 1999 Feb 20;819(1-2):160–4

Blockade of glutamate reuptake in the rat nucleus accumbens increases locomotor activity. Kim JH, et al. **Brain Res** 1999 Feb 20;819(1-2):165–9

Transient in vivo membrane depolarization and glutamate release before anoxic depolarization in rat striatum. Kunimatsu T, et al. **Brain Res** 1999 Jun 12;831(1-2):273–82

PhTx4, a new class of toxins from Phoneutria nigriventer spider venom, inhibits the glutamate uptake in rat brain synaptosomes. Mafra RA, et al. **Brain Res** 1999 Jun 12; 831(1-2):297–300

Effects of hyperosmolarity and ion substitutions on amino acid efflux from the ischemic rat cerebral cortex. Phillis JW, et al. **Brain Res** 1999 May 15;828(1-2):1–11

Nitric oxide (NO) release by glutamate and NMDA in the dorsal horn of the spinal cord: an in vivo electrochemical approach in the rat. Rivot JP, et al. **Brain Res** 1999 Mar 6;821(1):101–10

Real-time monitoring of glutamate transmitter release with anoxic depolarization during anoxic insult in rat striatum. Satoh M, et al. **Brain Res** 1999 Mar 20;822(1-2):142–8

Effects of handling on extracellular levels of glutamate and other amino acids in various areas of the brain measured by microdialysis. Timmerman W, et al. **Brain Res** 1999 Jul 3;833(2):150–60

Ultrastructure of glutamate and GABA immunoreactive axon terminals of the rat nucleus tractus solitarius, with a note on infralimbic cortex afferents. Torrealba F, et al. **Brain Res** 1999 Feb 27;820(1-2):20–30

Neuropeptide Y inhibits glutamate release and long-term potentiation in rat dentate gyrus. Whittaker E, et al. **Brain Res** 1999 May 8;827(1-2):229–33

Autoradiography of [3H]glutamate binding during pentobarbital tolerance and withdrawal in the rat. Jang CG, et al. **Brain Res Bull** 1999 Jan 1;48(1):99–102

Expression of glutamate transporters in the adult bovine corpus callosum. Domercq M, et al. **Brain Res Mol Brain Res** 1999 Apr 20;67(2):296–302

Hypothermia prevents biphasic glutamate release and corresponding neuronal degeneration after transient spinal cord ischemia in the rat. Ishikawa T, et al. **Cell Mol Neurobiol** 1999 Apr;19(2):199–208

Changing patterns of spatial buffering of glutamate in developing rat retinae are mediated by the Müller cell glutamate transporter GLAST. Pow DV, et al. **Cell Tissue Res** 1999 Jul;297(1):57–66

[3H]CNQX and NMDA-sensitive [3H]glutamate binding sites and AMPA receptor subunit RNA transcripts in the striatum of normal and weaver mutant mice and effects of ventral mesencephalic grafts. Mitsacos A, et al. **Cell Transplant** 1999 Jan-Feb;8(1):11–23

Glutamate metabolism of the heart during coronary artery bypass grafting. Pietersen HG, et al. **Clin Nutr** 1998 Apr; 17(2):73–5

Clearance of glutamate inside the synapse and beyond. Bergles DE, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):293–8 (64 ref.)

Ketone bodies and brain glutamate and GABA metabolism. Daikhin Y, et al. **Dev Neurosci** 1998;20(4-5):358–64

Localized in vivo 13C-NMR of glutamate metabolism in the human brain: initial results at 4 tesla. Gruetter R, et al. **Dev Neurosci** 1998;20(4-5):380–8

Functional energy metabolism: in vivo 13C-NMR spectroscopy evidence for coupling of cerebral glucose consumption and glutamatergic neuronalactivity. Sibson NR, et al. **Dev Neurosci** 1998;20(4-5):321–30 (56 ref.)

In vivo investigation of glutamate-glutamine metabolism in hyperammonemic monkey brain using 13C-magnetic resonance spectroscopy. Tsukada Y, et al. **Dev Neurosci** 1998;20(4-5):427–33

The effect of Glu75 of staphylococcal nuclease on enzyme activity, protein stability and protein unfolding. Chen HM, et al. **Eur J Biochem** 1999 May;261(3):599–609

C-fos and c-jun in the paraventricular nucleus play a role in regulating peptide gene expression, oxytocin and glutamate release, and maternal behaviour. Da Costa AP, et al. **Eur J Neurosci** 1999 Jul;11(7):2199–210

Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Gioanni Y, et al. **Eur J Neurosci** 1999 Jan;11(1):18–30

Chronic hyperammonemia impairs the glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo. Hermenegildo C, et al. **Eur J Neurosci** 1998 Oct;10(10):3201–9

Astrocytes regulate the developmental appearance of GABAergic and glutamatergic postsynaptic currents in cultured embryonic rat spinal neurons. Li YX, et al. **Eur J Neurosci** 1999 Jul;11(7):2537–51

Rapid desensitization converts prolonged glutamate release into a transient EPSC at ribbon synapses between retinal bipolar and amacrine cells. Maguire G. **Eur J Neurosci** 1999 Jan;11(1):353–62

Evidence for functional native NMDA receptors activated by glycine or D-serine alone in the absence of glutamatergic coagonist. Paudice P, et al. **Eur J Neurosci** 1998 Sep;10(9):2934–44

GABA(B) receptors as potential targets for drugs able to prevent excessive excitatory amino acid transmission in the spinal cord. Bonanno G, et al. **Eur J Pharmacol** 1998 Dec 4;362(2-3):143–8

The pharmacological profile of L-glutamate transport in human NT2 neurones is consistent with excitatory amino acid transporter 2. Dunlop J, et al. **Eur J Pharmacol** 1998 Nov 6;360(2-3):249–56

Anti-B-50 (GAP-43) antibodies decrease exocytosis of glutamate in permeated synaptosomes. Hens JJ, et al. **Eur J Pharmacol** 1998 Dec 18;363(2-3):229–40

Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Kobayashi T, et al. **Eur J Pharmacol** 1998 Dec 11;363(1):1–15 (110 ref.)

Nocistatin reverses nociceptin inhibition of glutamate release from rat brain slices. Nicol B, et al. **Eur J Pharmacol** 1998 Sep 4;356(2-3):R1–3

Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Sasaki K, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):165–73

Redox mechanisms at the glutamate synapse and their significance: a review. Smythies J. **Eur J Pharmacol** 1999 Apr 1;370(1):1–7 (87 ref.)

Changes in the extracellular levels of glutamate and aspartate during ischemia and hypoglycemia. Effects of hypothermia. Boris-Möller F, et al. **Exp Brain Res** 1998 Aug; 121(3):277–84

Hippocampal neurochemical and electrophysiological measures from freely moving rats. Bronzino JD, et al. **Exp Neurol** 1999 Jan;155(1):150–5

Hypothermia ameliorates ischemic brain damage and suppresses the release of extracellular amino acids in both normo- and hyperglycemic subjects. Li PA, et al. **Exp Neurol** 1999 Jul;158(1):242–53

The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Pedersen WA, et al. **Exp Neurol** 1999 Jan;155(1):1–10

Haemonchus contortus: characterization of a glutamate binding site in unselected and ivermectin-selected larvae and adults. Paiement J, et al. **Exp Parasitol** 1999 May; 92(1):32–9

Identification of the catalytic glutamate in the E1 component of human pyruvate dehydrogenase. Fang R, et al. **FEBS Lett** 1998 Oct 23;437(3):273–7

Short-term block of Na+/K+-ATPase in neuro-glial cell cultures of cerebellum induces glutamate dependent damage of granule cells. Stelmashook EV, et al. **FEBS Lett** 1999 Jul 30;456(1):41–4

Astrocytic glutamate uptake and prion protein expression. Brown DR, et al. **Glia** 1999 Feb 1;25(3):282–92

Metabotropic glutamate receptor agonists reduce glutamate release from cultured astrocytes. Ye ZC, et al. **Glia** 1999 Feb 1;25(3):270–81

Glutamate-like immunoreactivity in axon terminals from the olfactory bulb to the piriform cortex. Hennequet L, et al. **Histol Histopathol** 1998 Jul;13(3):683–7

Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP-ribosyltransferase. Radke J, et al. **Infect Immun** 1999 Mar;67(3):1508–10

Effects of prolonged exercise on brain ammonia and amino acids. Guezennec CY, et al. **Int J Sports Med** 1998 Jul; 19(5):323–7

Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Dkhissi O, et al. **Invest Ophthalmol Vis Sci** 1999 Apr;40(5):990–5

Ethambutol is toxic to retinal ganglion cells via an excitotoxic

pathway. Heng JE, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):190–6

Sodium-dependent glutamate uptake by an alkaliphilic, thermophilic Bacillus strain, TA2.A1. Peddie CJ, et al. **J Bacteriol** 1999 May;181(10):3172–7

Two amino acids within the alpha4 helix of Galphai1 mediate coupling with 5-hydroxytryptamine1B receptors. Bae H, et al. **J Biol Chem** 1999 May 21;274(21):14963–71

Zinc coordination and substrate catalysis within the neuropeptide processing enzyme endopeptidase EC 3.4.24.15. Identification of active site histidine and glutamate residues. Cummins PM, et al. **J Biol Chem** 1999 Jun 4;274(23):16003–9

Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. Islam MR, et al. **J Biol Chem** 1999 Aug 13;274(33):23451–5

Glutamate residues required for substrate binding and cleavage activity in mitochondrial processing peptidase. Kitada S, et al. **J Biol Chem** 1998 Dec 4;273(49):32547–53

Glu300 of rat carboxypeptidase E is essential for enzymatic activity but not substrate binding or routing to the regulated secretory pathway. Qian Y, et al. **J Biol Chem** 1999 Apr 23;274(17):11582–6

A single amino acid change (substitution of glutamate 3 with alanine) in the N-terminal region of rat liver carnitine palmitoyltransferase I abolishes malonyl-CoA inhibition and high affinity binding. Shi J, et al. **J Biol Chem** 1999 Apr 2;274(14):9421–6

Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. Tanner KG, et al. **J Biol Chem** 1999 Jun 25;274(26):18157–60

Mutagenesis of the conserved residue Glu259 of Gsalpha demonstrates the importance of interactions between switches 2 and 3 for activation. Warner DR, et al. **J Biol Chem** 1999 Feb 19;274(8):4977–84

Simultaneous glutamate and perfusion fMRI responses to regional brain stimulation. Forman SD, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1064–70

Simultaneous determination of gamma-aminobutyric acid and glutamic acid in the brain of 3-mercaptopropionic acid-treated rats using liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Ma D, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 16; 726(1-2):285–90

Selective loss of phorbol-12,13-dibutyrate-facilitated L-glutamate transport in forebrain neurons of aged rats. Daniels KK, et al. **J Gerontol A Biol Sci Med Sci** 1998 Nov;53(6):B449–51

In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. Blüml S. **J Magn Reson** 1999 Feb;136(2):219–25

Structure, interaction and electron transfer between cytochrome b5, its E44A and/or E56A mutants and cytochrome c. Sun YL, et al. **J Mol Biol** 1999 Jan 8; 285(1):347–59

Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy. Carlsson ML. **J Neural Transm** 1998; 105(4–5):525–35 (72 ref.)

Extracellular glutamate levels are chronically elevated in the brains of LP-BM5-infected mice: a mechanism of retrovirus-induced encephalopathy. Espey MG, et al. **J Neurochem** 1998 Nov;71(5):2079–87

Formation of N-pyroglutamyl peptides from N-Glu and N-Gln precursors in Aplysia neurons. Garden RW, et al. **J Neurochem** 1999 Feb;72(2):676–81

The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. Gray AM, et al. **J Neurochem** 1999 Sep; 73(3):1066–74

Prenatal exposure to aluminum reduces expression of neuronal nitric oxide synthase and of soluble guanylate cyclase and impairs glutamatergic neurotransmission in rat cerebellum. Llansola M, et al. **J Neurochem** 1999 Aug; 73(2):712–8

Increase in external glutamate and NMDA receptor activation contribute to H2O2-induced neuronal apoptosis. Mailly F, et al. **J Neurochem** 1999 Sep;73(3):1181–8

Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. Mattson MP, et al. **J Neurochem** 1999 Aug;73(2):532–7

A calcium/calmodulin-dependent nitric oxide synthase, NMDAR2/3 receptor subunits, and glutamate in the CNS of the cuttlefish Sepia officinalis: localization in specific neural pathways controlling the inking system. Palumbo A, et al. **J Neurochem** 1999 Sep;73(3):1254–63

Presynaptic kappa-opioid and muscarinic receptors inhibit the calcium-dependent component of evoked glutamate release from striatal synaptosomes. Rawls SM, et al. **J Neurochem** 1999 Sep;73(3):1058–65

The amino terminus with a conserved glutamic acid of G protein-coupled receptor kinases is indispensable for their ability to phosphorylate photoactivated rhodopsin. Yu QM, et al. **J Neurochem** 1999 Sep;73(3):1222–7

Origins of the extracellular glutamate released during total metabolic blockade in the immature retina. Zeevalk GD, et al. **J Neurochem** 1998 Dec;71(6):2373–81

Long-term potentiation in the dentate gyrus is not linked to increased extracellular glutamate concentration. Jay TM, et al. **J Neurophysiol** 1999 Apr;81(4):1741–8

Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. Quintero JE, et al. **J Neurophysiol** 1999 Aug;82(2):533–9

Glutamate release through volume-activated channels during spreading depression. Basarsky TA, et al. **J Neurosci** 1999 Aug 1;19(15):6439–45

Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors. Carvalho AL, et al. **J Neurosci** 1999 Jun 15;19(12):4748–54

Lysophosphatidic acid stimulates neurotransmitter-like conductance changes that precede GABA and L-glutamate in early, presumptive cortical neuroblasts. Dubin AE, et al. **J Neurosci** 1999 Feb 15;19(4):1371–81

The concentration of synaptically released glutamate outside of the climbing fiber-Purkinje cell synaptic cleft. Dzubay JA, et al. **J Neurosci** 1999 Jul 1;19(13):5265–74

Glutamate uptake limits synaptic excitation of retinal ganglion cells. Higgs MH, et al. **J Neurosci** 1999 May 15; 19(10):3691–700

EAT-4, a homolog of a mammalian sodium-dependent inorganic phosphate cotransporter, is necessary for glutamatergic neurotransmission in caenorhabditis elegans. Lee RY, et al. **J Neurosci** 1999 Jan 1;19(1):159–67

The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. Lehre KP, et al. **J Neurosci** 1998 Nov 1;18(21):8751–7

Presynaptic regulation of glutamate release in the ventral tegmental area during morphine withdrawal. Manzoni OJ, et al. **J Neurosci** 1999 Aug 1;19(15):6629–36

Active role of glutamate uptake in the synaptic transmission from retinal nonspiking neurons. Matsui K, et al. **J Neurosci** 1999 Aug 15;19(16):6755–66

Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: major roles for glutamate and Na+-dependent Ca2+ release from mitochondria. Zhang Y, et al. **J Neurosci** 1999 May 1;19(9):3307–15

An improved method for the detection of changes in brain extracellular glutamate levels. Kohno T, et al. **J Neurosci Methods** 1998 Jun 1;81(1-2):199–205

Distribution of functional glutamate receptors in cultured embryonic Drosophila myotubes revealed using focal release of L-glutamate from caged compound by laser. Saitoe M, et al. **J Neurosci Methods** 1998 Apr 30; 80(2):163–70

Astrocytes: glutamate producers for neurons. Hertz L, et al. **J Neurosci Res** 1999 Aug 15;57(4):417–28 (133 ref.)

Glutamate transport in cultures from developing avian cerebellum: presence of GLT-1 immunoreactivity in Purkinje neurons. Meaney JA, et al. **J Neurosci Res** 1998 Dec 1;54(5):595–603

Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study. Vespa P, et al. **J Neurosurg** 1998 Dec;89(6):971–82

Mechanisms of excitatory amino acid release in contused brain tissue: effects of hypothermia and in situ administration of Co2+ on extracellular levels of glutamate. Maeda T, et al. **J Neurotrauma** 1998 Sep; 15(9):655–64

Brevetoxins cause acute excitotoxicity in primary cultures of rat cerebellar granule neurons. Berman FW, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):439–44

Expression of the GLT-1 subtype of Na+-dependent glutamate transporter: pharmacological characterization and lack of regulation by protein kinase C. Tan J, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1600–10

Dithiocarbamate pesticides affect glutamate transport in brain synaptic vesicles. Vaccari A, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):1–5

On the mechanism of histaminergic inhibition of glutamate release in the rat dentate gyrus. Brown RE, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):777–86

Microdialysis update: optimizing the advantages [comment] Connelly CA. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):303 . Comment on: J Physiol (Lond) 1999 Jan 15;514 (Pt 2):567–78.

Potentiation of transmitter release by protein kinase C in goldfish retinal bipolar cells. Minami N, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):219–25

Neurotransmitters and neuromodulators controlling the hypoxic respiratory response in anaesthetized cats [see comments] Richter DW, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):567–78. Comment in: J Physiol (Lond) 1999 Jan 15;514 (Pt 2):303.

Modulation of extracellular glutamate concentration in rat brain slices by cystine-glutamate exchange. Warr O, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):783–93

The acetylcholine, GABA, glutamate triangle in the rat forebrain. Pepeu G, et al. **J Physiol Paris** 1998 Oct-Dec; 92(5–6):351–5 (51 ref.)

Glutamate-like immunoreactivity during hair cell recovery after gentamicin exposure in the chinchilla vestibular sensory periphery. Chin KW, et al. **Laryngoscope** 1999 Jul; 109(7 Pt 1):1037–44

Training in the Morris water maze occludes the synergism between ACPD and arachidonic acid on glutamate release in synaptosomes prepared from rat hippocampus. McGahon B, et al. **Learn Mem** 1996 Nov-Dec;3(4):296–304

Multiple bond 13C-13C spin-spin coupling provides complementary information in a 13C NMR isotopomer analysis of glutamate. Carvalho RA, et al. **Magn Reson Med** 1999 Jul;42(1):197–200

Age-related changes in septal serotonergic, GABAergic and glutamatergic facilitation of retention in SAMP8 mice. Flood JF, et al. **Mech Ageing Dev** 1998 Sep 15; 105(1-2):173–88

Patch-clamp, ion-sensing, and glutamate-sensing techniques to study glutamate transport in isolated retinal glial cells. Billups B, et al. **Methods Enzymol** 1998;296:617–32

Use of antisense oligodeoxynucleotides to inhibit expression of glutamate transporter subtypes. Bristol LA, et al. **Methods Enzymol** 1998;296:514–29

Examination of glutamate transporter heterogeneity using synaptosomal preparations. Robinson MB. **Methods Enzymol** 1998;296:189–202

Glutamate uptake in Purkinje cells in rat cerebellar slices. Takahashi M, et al. **Methods Enzymol** 1998;296:608–17

Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. Vanhoutte P, et al. **Mol Cell Biol** 1999 Jan;19(1):136–46

The effect of 4 beta-phorbol-12,13-dibutyrate and staurosporine on the extracellular glutamate levels during ischemia in the rat striatum. Boris-Möller F, et al. **Mol Chem Neuropathol** 1998 Aug-Dec;35(1-3):133–47

A single amino acid, glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Dajani R, et al. **Mol Pharmacol** 1998 Dec;54(6):942–8

Nontransportable inhibitors attenuate reversal of glutamate uptake in synaptosomes following a metabolic insult. Koch HP, et al. **Mol Pharmacol** 1999 Jun;55(6):1044–8

CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Litschig S, et al. **Mol Pharmacol** 1999 Mar;55(3):453–61

Interaction of glutamic-acid-rich proteins with the cGMP signalling pathway in rod photoreceptors. Körschen HG, et al. **Nature** 1999 Aug 19;400(6746):761–6

Passive avoidance training and recall are associated with increased glutamate levels in the intermediate medial hyperstriatum ventrale of the day-old chick. Daisley JN, et al. **Neural Plast** 1998 Jul-Sep;6(3):53–61

Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway. Abarca J, et al. **Neurochem Int** 1999 Jul;35(1):19–33

Chronic exposure to aluminium impairs the glutamate-nitric oxide-cyclic GMP pathway in the rat in vivo. Hermenegildo C, et al. **Neurochem Int** 1999 Mar; 34(3):245–53

Mechanism by which GABA, through its GABA(A) receptor, modulates glutamate release from rat cortical neurons in culture. Herrero MT, et al. **Neurochem Int** 1999 Feb;34(2):141–8

Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Morari M, et al. **Neurochem Int** 1998 Nov; 33(5):383–97 (119 ref.)

On the relationship between extracellular glutamate, hyperexcitation and neurodegeneration, in vivo. Tapia R, et al. **Neurochem Int** 1999 Jan;34(1):23–31 (111 ref.)

Reversible activation of glutamate transport in rat brain glia by protein kinase C and an okadaic acid-sensitive phosphoprotein phosphatase. Daniels KK, et al. **Neurochem Res** 1999 Aug;24(8):1017–25

Amphetamine increases extracellular concentrations of glutamate in the prefrontal cortex of the awake rat: a microdialysis study. Del Arco A, et al. **Neurochem Res** 1998 Sep;23(9):1153–8

Endogenous dopamine increases extracellular concentrations of glutamate and GABA in striatum of the freely moving rat: involvement of D1 and D2 dopamine receptors. Expósito I, et al. **Neurochem Res** 1999 Jul;24(7):849–56

Receptor interactions of beta-N-oxalyl-L-alpha,beta-diaminopropionic acid, the Lathyrus sativus putative excitotoxin, with synaptic membranes. Jain RK, et al. **Neurochem Res** 1998 Sep; 23(9):1191–6

Self-stimulation of lateral hypothalamus and ventral tegmentum increases the levels of noradrenaline, dopamine, glutamate, and AChE activity, but not 5-hydroxytryptamine and GABA levels in hippocampus and motor cortex. Shankaranarayana Rao BS, et al. **Neurochem Res** 1998 Aug;23(8):1053–9

Neurotransmitter release from the medial hyperstriatum ventrale of the chick forebrain accompanying filial imprinting behavior, measured by in vivo microdialysis. Tsukada Y, et al. **Neurochem Res** 1999 Feb;24(2):315–20

Effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia on cerebral blood flow and metabolism, lactate, and extracellular glutamate in experimental head injury. Mori K, et al. **Neurol Res** 1998 Dec;20(8):719–26

1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Pioro EP, et al. **Neurology** 1999 Jul 13;53(1):71–9

A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Stern-Bach Y, et al. **Neuron** 1998 Oct;21(4):907–18

Submillisecond kinetics of glutamate release from a sensory synapse [see comments] von Gersdorff H, et al. **Neuron**

1998 Nov;21(5):1177–88. Comment in: Neuron 1998 Nov;21(5):940–1.

Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Bartlett RD, et al. **Neuropharmacology** 1998 Jul;37(7):839–46

Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms. Del Arco A, et al. **Neuropharmacology** 1999 Jul;38(7):943–54

Effects of PKA and PKC modulators on high affinity glutamate uptake in primary neuronal cell cultures from rat cerebral cortex. Lortet S, et al. **Neuropharmacology** 1999 Mar;38(3):395–402

Group I mGlu receptors potentiate synaptosomal [3H]glutamate release independently of exogenously applied arachidonic acid. Reid ME, et al. **Neuropharmacology** 1999 Apr;38(4):477–85

Simultaneous effects of local dexfenfluramine application on extracellular glutamate and serotonin levels in rat frontal cortex: a reverse microdialysis study. Rocher C, et al. **Neuropharmacology** 1999 Apr;38(4):513–23

The metabotropic glutamate receptor 1 is not involved in the facilitation of glutamate release in cerebrocortical nerve terminals. Sistiaga A, et al. **Neuropharmacology** 1998 Dec; 37(12):1485–92

The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Ferraro L, et al. **Neuropsychopharmacology** 1999 Apr;20(4):346–56

Minimal effect of brain temperature changes on glutamate release in rat following severe global brain ischemia: a dialysis electrode study. Asai S, et al. **Neuroreport** 1998 Dec 1;9(17):3863–8

Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Corsi C, et al. **Neuroreport** 1999 Mar 17;10(4):687–91

Periaqueductal gray matter glutamate and GABA decrease following subcutaneous formalin injection in rat. Maione S, et al. **Neuroreport** 1999 May 14;10(7):1403–7

Synaptosomal glutamate release induced by the fraction Bc2 from the venom of the sea anemone Bunodosoma caissarum. Migues PV, et al. **Neuroreport** 1999 Jan 18; 10(1):67–70

Region-specific increase in glutamate release from dorsal horn of rats with adjuvant inflammation. Sasaki M, et al. **Neuroreport** 1998 Oct 5;9(14):3219–22

Striatal dopamine-glutamate interactions reflected in substantia nigra reticulata firing. Timmerman W, et al. **Neuroreport** 1998 Dec 1;9(17):3829–36

Effects of brain temperature on CBF thresholds for extracellular glutamate release and reuptake in the striatum in a rat model of graded global ischemia. Zhao H, et al. **Neuroreport** 1998 Oct 5;9(14):3183–8

Neither L-NAME nor L-arginine changes extracellular glutamate elevation and anoxic depolarization during global ischemia and reperfusion in rat. Zhao H, et al. **Neuroreport** 1999 Feb 5;10(2):313–8

Glutamate and the UMAMI taste: sensory, metabolic, nutritional and behavioural considerations. A review of the literature published in the last 10 years. Bellisle F. **Neurosci Biobehav Rev** 1999;23(3):423–38 (152 ref.)

The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Ferraro L, et al. **Neurosci Lett** 1998 Sep 4; 253(2):135–8

NMDA induced glutamate release from the suprachiasmatic nucleus: an in vitro study in the rat. Hamada T, et al. **Neurosci Lett** 1998 Nov 6;256(2):93–6

Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Kaehler ST, et al. **Neurosci Lett** 1999 Mar 12; 262(3):199–202

Dorsal facial area of cat medulla; 5-HT2 action on glutamate release in regulating common carotid blood flow. Kuo JS, et al. **Neurosci Lett** 1999 May 7;266(2):137–40

Both protein kinase G dependent and independent mechanisms are involved in the modulation of glutamate release by nitric oxide in rat hippocampal nerve terminals. Sequeira SM, et al. **Neurosci Lett** 1999 Feb 12; 261(1-2):29–32

Evidence for a neurotransmitter role of glutamate in guinea pig myenteric plexus neurons. Sinsky M, et al. **Neurosci Lett** 1998 Dec 18;258(2):109–12

Increased calcium/calmodulin protein kinase activity in astrocytes chronically exposed to ethanol: influences on glutamate transport. Smith TL, et al. **Neurosci Lett** 1999 Jul 16;269(3):145–8

Effect of systemic ethanol on basal and stimulated glutamate releases in the nucleus accumbens of freely moving Sprague-Dawley rats: a microdialysis study. Yan QS, et al. **Neurosci Lett** 1998 Dec 11;258(1):29–32

The release of amino acids from rat neostriatum and substantia nigra in vivo: a dual microdialysis probe analysis. Bianchi L, et al. **Neuroscience** 1998 Nov;87(1):171–80

Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Bouron A, et al. **Neuroscience** 1999 Mar; 90(3):729–36

High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. Burrows KB, et al. **Neuroscience** 1999 Mar;90(3):833–50

Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Casamenti F, et al. **Neuroscience** 1999;91(3):831–42

Effects of nitric oxide synthase gene knockout on neurotransmitter release in vivo. Kano T, et al. **Neuroscience** 1998 Oct;86(3):695–9

K(+)-induced reversal of astrocyte glutamate uptake is limited by compensatory changes in intracellular Na+. Longuemare MC, et al. **Neuroscience** 1999;93(1):285–92

Enhancement of glutamate release uncovers spillover-mediated transmission by N-methyl-D-aspartate receptors in the rat hippocampus. Lozovaya NA, et al. **Neuroscience** 1999;91(4):1321–30

Glutamate release in the nucleus tractus solitarius induced by peripheral lipopolysaccharide and interleukin-1 beta. Mascarucci P, et al. **Neuroscience** 1998 Oct;86(4):1285–90

Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Meshul CK, et al. **Neuroscience** 1999 Jan;88(1):1–16

Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Noda M, et al. **Neuroscience** 1999;92(4):1465–74

A high-affinity presynaptic kainate-type glutamate receptor facilitates glutamate exocytosis from cerebral cortex nerve terminals (synaptosomes). Perkinton MS, et al. **Neuroscience** 1999;90(4):1281–92

Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Romanides AJ, et al. **Neuroscience** 1999;92(1):97–106

Interaction between dopamine and glutamate in the sensorimotor cortex during conditioned placing reaction. Storozhuk VM, et al. **Neuroscience** 1998 Jul;85(2):347–59

Neuroprotective effect of mild hypothermia cannot be explained in terms of a reduction of glutamate release during ischemia. Yamamoto H, et al. **Neuroscience** 1999; 91(2):501–9

Bolus maternal cocaine administration does not produce a large increase in fetal sheep cerebral cortical glutamate concentration. Penning DH, et al. **Neurotoxicol Teratol** 1999 Mar-Apr;21(2):177–80

Does formate reduce alpha-ketoglutarate and ammonia to glutamate? Maughan Q, et al. **Orig Life Evol Biosph** 1999 Aug;29(4):355–60

3H-L-glutamate binding and 3H-D-aspartate release from hippocampal tissue during the development of pentylenetetrazole kindling in rats. Schröeder H, et al. **Pharmacol Biochem Behav** 1999 Feb;62(2):349–52

Extracellular glutamate diffusion determines the occupancy of glutamate receptors at CA1 synapses in the hippocampus. Kullmann DM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):395–402 (57 ref.)

In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Rothman DL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1165–77 (65 ref.)

Hepatic export of glutathione and uptake of constituent amino acids, glutamate and cysteine, in broilers in vivo. Wang S, et al. **Poult Sci** 1998 Oct;77(10):1556–64

Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Jabaudon D, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8733–8

Synaptically released glutamate reduces gamma-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. Min MY, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9932–7

Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Shen J, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8235–40

Two serine residues of the glutamate transporter GLT-1 are crucial for coupling the fluxes of sodium and the neurotransmitter. Zhang Y, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1710–5

Retinal vulnerability to glutamate excitotoxicity in canine glaucoma: induction of neuronal nitric oxide synthase in retinal ganglion cells. Franco-Bourland RE, et al. **Proc West Pharmacol Soc** 1998;41:201–4

Uptake of glutamate into synaptic vesicles. Fonnum F, et al. **Prog Brain Res** 1998;116:87–101 (83 ref.)

Presynaptic modulation of glutamate release. Nicholls DG. **Prog Brain Res** 1998;116:15–22 (52 ref.)

Calcium channels coupled to glutamate release. Turner TJ. **Prog Brain Res** 1998;116:3–14 (56 ref.)

Glial glutamate transport as target for nitric oxide: consequences for neurotoxicity. Ye ZC, et al. **Prog Brain Res** 1998;118:241–51 (42 ref.)

Acetylcholine and glutamate release during sleep-wakefulness in the pedunculopontine tegmental nucleus and norepinephrine changes regulated by nitric oxide. Kodama T, et al. **Psychiatry Clin Neurosci** 1999 Apr; 53(2):109–11

Glutamate uptake in mice bred for ethanol withdrawal severity. Buckman JF, et al. **Psychopharmacology (Berl)** 1999 Apr;143(2):174–82

Neuroprotective strategies: voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition. Obrenovitch TP. **Rev Neurosci** 1998 Jul-Dec; 9(3):203–11 (74 ref.)

Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Petroff OA, et al. **Seizure** 1999 Apr;8(2):120–7

Neurochemical monitoring of fatal middle cerebral artery infarction. Berger C, et al. **Stroke** 1999 Feb;30(2):460–3

Effects of S-nitrosoglutathione on acute vasoconstriction and glutamate release after subarachnoid hemorrhage. Sehba FA, et al. **Stroke** 1999 Sep;30(9):1955–61

Inhibition of ischemia-induced glutamate release in rat striatum by dihydrokinate and an anion channel blocker. Seki Y, et al. **Stroke** 1999 Feb;30(2):433–40

An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Vorwerk CK, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S142–50 (98 ref.)

Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Keys AS, et al. **Synapse** 1998 Dec;30(4):393–401

Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Meshul CK, et al. **Synapse** 1998 Oct; 30(2):211–20

Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures. Di Monte DA, et al. **Toxicol Appl Pharmacol** 1999 Aug 1; 158(3):296–302

The effect of volatile anaesthetics on synaptic release and uptake of glutamate. Larsen M, et al. **Toxicol Lett** 1998 Nov 23;100-101:59–64 (29 ref.)

Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Kullmann DM, et al. **Trends Neurosci** 1998 Jan;21(1):8–14 (57 ref.)

Reduced glutamate uptake by retinal glial cells under ischemic/hypoxic conditions. Napper GA, et al. **Vis Neurosci** 1999 Jan-Feb;16(1):149–58

[Effects of lead on the release of glutamate neurotransmitter in rat hippocampal slices] Zhang H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):285–7 (Eng. Abstr.) **(Chi)**

[Activation of glutamate uptake in rat hippocampal synaptosome by lead] Zhang H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):16–8 (Eng. Abstr.) **(Chi)**

[Acidosis and neuroprotection in two types of acidosis model rats under isoflurane anesthesia: evaluation of blood flow, pH and amino acid levels in the cortex] Shimizu A, et al. **Masui** 1998 Oct;47(10):1173–82 (Eng. Abstr.) **(Jpn)**

[Effect of food conditioned operant reflex acquisition on the glutamate receptor binding in the rat brain] Karpova IV. **Ross Fiziol Zh Im I M Sechenova** 1998 Sep;84(9):913–9 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Wolfe LA, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):38–48

Modulation of striatal neuronal activity by glutamate and GABA: iontophoresis in awake, unrestrained rats. Kiyatkin EA, et al. **Brain Res** 1999 Mar 20;822(1-2):88–106

Effect of calcium on the uptake of glutamate by synaptosomes: possible involvement of two different mechanisms. Zhu BG, et al. **J Neural Transm** 1999; 106(3-4):257–64

Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired. Sánchez-Carbente MR, et al. **J Neurochem** 1999 Jan; 72(1):129–38

Voltage-dependent uptake is a major determinant of glutamate concentration at the cone synapse: an analytical study. Roska B, et al. **J Neurophysiol** 1998 Oct; 80(4):1951–60

Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. Levy LM, et al. **J Neurosci** 1998 Dec 1; 18(23):9620–8

Selected pyrethroid insecticides stimulate glutamate uptake in brain synaptic vesicles. Vaccari A, et al. **Neuroreport** 1998 Oct 26;9(15):3519–23

PHARMACOLOGY

Taurine, glutamate and GABA modulate the outgrowth from goldfish retinal explants and its concentrations are affected by the crush of the optic nerve. Lima L, et al. **Amino Acids** 1998;15(3):195–209

Effect of glutamate and angiotensin II on whole cell currents and release of nitric oxide in the rat subfornical organ. Schmid HA. **Amino Acids** 1998;14(1-3):113–9 (25 ref.)

Prevention of glutamate neurotoxicity in cultured neurons by 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran (CR-6), a scavenger of nitric oxide. Montoliu C, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):255–61

Competitive inhibition of a glutamate carboxypeptidase by phosphonamidothionate derivatives of glutamic acid. Rodriguez CE, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1415–8

Effects of vitamin D3, 17beta-estradiol, vasoactive intestinal peptide, and glutamate on electric coupling between rat osteoblast-like cells in vitro. Schirrmacher K, et al. **Bone** 1998 Dec;23(6):521-6

Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Olmos G, et al. **Br J Pharmacol** 1999 Jul;127(6):1317-26

Phrenic nerve responses to chemical stimulation of the subregions of ventral medullary respiratory neuronal group in the rat. Chitravanshi VC, et al. **Brain Res** 1999 Mar 13;821(2):443-60

Cardiovascular responses to microinjections of glutamate into the nucleus tractus solitarii of unanesthetized supracollicular decerebrate rats. Dhruva A, et al. **Brain Res** 1998 Aug 10;801(1-2):88-100

The glutamate induced phase shift in the SCN slice: a two pulse study. Franken P, et al. **Brain Res** 1999 Feb 6; 818(1):34-40

Ascorbate modulates glutamate-induced excitations of striatal neurons. Kiyatkin EA, et al. **Brain Res** 1998 Nov 23;812(1-2):14-22

A microdialysis study investigating the mechanisms of hydroxyl radical formation in rat striatum exposed to glutamate. Lancelot E, et al. **Brain Res** 1998 Nov 2; 809(2):294-6

Substance P post-synaptically potentiates glutamate-induced currents in dorsal vagal neurons. Liu X, et al. **Brain Res** 1998 Aug 31;804(1):95-104

The increase in angiotensin type-2 receptor mRNA level by glutamate stimulation in cultured rat cortical cells. Makino I, et al. **Brain Res** 1998 Sep 7;804(2):296-305

Effect of noradrenergic inputs on the cardiovascular depressor responses to stimulation of central nucleus of the amygdala. Roder S, et al. **Brain Res** 1999 Feb 13; 818(2):531-5

Role of carbon monoxide in L-glutamate-induced cardiovascular responses in nucleus tractus solitarius of conscious rats. Silva CC, et al. **Brain Res** 1999 Apr 10; 824(2):147-52

Resistance of gonadotropin-releasing hormone neurons to glutamatergic neurotoxicity. Ebling FJ, et al. **Brain Res Bull** 1998 Dec;47(6):575-84

Effects of gonadal steroids on the GABA and glutamate contents of the early developing tilapia brain. Wang LH, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):273-6

Isoform-specific translocation of protein kinase C following glutamate administration in primary hippocampal neurons. Buchner K, et al. **Brain Res Mol Brain Res** 1999 Feb 5; 64(2):222-35

Possible role of NF-kappaB and p53 in the glutamate-induced pro-apoptotic neuronal pathway. Grilli M, et al. **Cell Death Differ** 1999 Jan;6(1):22-7 (77 ref.)

Glutamatergic control of the expression of the proenkephalin gene in rat frontoparietal cortical slice cultures. Just L, et al. **Cereb Cortex** 1998 Dec;8(8):702-9

Stimulation of locus coeruleus increases arterial pressure in rabbits. Chen YY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):437-40

8-(N,N-diethylamino)-n-octyl-3,4,5-trimethoxybenzoate reduced [Ca2+]i elevation induced by histamine, serotonin, and glutamate in cultured calf basilar artery smooth muscle cells. Wang B, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May;19(3):251-3

Potential cardiovascular applications of glutamate, aspartate, and other amino acids. Arsenian M. **Clin Cardiol** 1998 Sep; 21(9):620-4 (44 ref.)

Can experimental conditions explain the discrepancy over glutamate stimulation of aerobic glycolysis? Hertz L, et al. **Dev Neurosci** 1998;20(4-5):339-47

Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Araque A, et al. **Eur J Neurosci** 1998 Jun;10(6):2129-42

Reversal of glutamate excitotoxicity by activation of PKC-associated metabotropic glutamate receptors in cerebellar granule cells relies on NR2C subunit expression. Pizzi M, et al. **Eur J Neurosci** 1999 Jul;11(7):2489-96

The influence of Carisolv on enamel and dentine surface topography. Wennerberg A, et al. **Eur J Oral Sci** 1999 Aug;107(4):297-306

Glutamate and antimitotic agents induce differentiation, p53 activation, and apoptosis in rodent neostriatal cell lines immortalized with the tsA58 allele of SV40 large T antigen. Conejero C, et al. **Exp Neurol** 1999 Jul;158(1):109-20

Electrophysiological properties of mitogen-expanded adult rat spinal cord and subventricular zone neural precursor cells. Liu RH, et al. **Exp Neurol** 1999 Jul;158(1):143-54

Haemonchus contortus: effects of glutamate, ivermectin, and moxidectin on inulin uptake activity in unselected and ivermectin-selected adults. Paiement JP, et al. **Exp Parasitol** 1999 Jul;92(3):193-8

Blockade of mitochondrial Ca2+ uptake by mitochondrial inhibitors amplifies the glutamate-induced calcium response in cultured cerebellar granule cells. Khodorov B, et al. **FEBS Lett** 1999 Sep 17;458(2):162-6

Excitotoxic damage of retinal glial cells depends upon normal neuron-glial interactions. Heidinger V, et al. **Glia** 1998 Jun; 23(2):146-55

Müller cell swelling, glutamate uptake, and excitotoxic neurodegeneration in the isolated rat retina. Izumi Y, et al. **Glia** 1999 Feb 15;25(4):379-89

Mature hippocampal astrocytes exhibit functional metabotropic and ionotropic glutamate receptors in situ. Shelton MK, et al. **Glia** 1999 Mar;26(1):1-11

Age-dependent differences in glutamate-induced phosphorylation systems in rat hippocampal slices. Angenstein F, et al. **Hippocampus** 1999;9(2):173-85

Properties of an L-glutamate-induced acid tolerance response which involves the functioning of extracellular induction components. Rowbury RJ, et al. **J Appl Microbiol** 1999 Feb;86(2):325-30

Involvement of the ipsilateral rostral ventrolateral medulla in the pressor response to L-glutamate microinjection into the nucleus tractus solitarii of awake rats. Mauad H, et al. **J Auton Nerv Syst** 1998 Nov 25;74(1):43-8

Physiological characterization of Pseudomonas aeruginosa during exotoxin A synthesis: glutamate, iron limitation, and aconitase activity. Somerville G, et al. **J Bacteriol** 1999 Feb;181(4):1072-8

Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca2+/calmodulin-dependent protein kinases in cultured rat hippocampal neurons. Kasahara J, et al. **J Biol Chem** 1999 Mar 26;274(13):9061-7

Conformational changes of the smooth endoplasmic reticulum are facilitated by L-glutamate and its receptors in rat Purkinje cells. Banno T, et al. **J Comp Neurol** 1998 Dec 14;402(2):252-63

Mapping glutamatergic drive in the vertebrate retina with a channel-permeant organic cation. Marc RE. **J Comp Neurol** 1999 Apr 28;407(1):47-64

Picrotoxin blockade of invertebrate glutamate-gated chloride channels: subunit dependence and evidence for binding within the pore. Etter A, et al. **J Neurochem** 1999 Jan; 72(1):318-26

L-Glutamate and insulin enhance glycogen synthesis in cultured astrocytes from the rat brain through different intracellular mechanisms. Hamai M, et al. **J Neurochem** 1999 Jul;73(1):400-7

Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors. Kretschmer BD. **J Neurochem** 1999 Aug;73(2):839-48

Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons. Schwarzschild MA, et al. **J Neurochem** 1999 Jun; 72(6):2248-55

Magnetic resonance spectroscopy studies on changes in cerebral calcium and zinc and the energy state caused by excitotoxic amino acids. Thatcher NM, et al. **J Neurochem** 1999 Jun;72(6):2471-8

Role of non-NMDA receptors in osmotic and glutamate stimulation of vasopressin release: effect of rapid receptor desensitization. Sladek CD, et al. **J Neuroendocrinol** 1998 Dec;10(12):897-903

Glutamate regulates IP3-type and CICR stores in the avian cochlear nucleus. Kato BM, et al. **J Neurophysiol** 1999 Apr; 81(4):1587-96

GABAB receptor-mediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development. Obrietan K, et al. **J Neurophysiol** 1999 Jul;82(1):94-102

Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. Akiyama M, et al. **J Neurosci** 1999 Feb 1;19(3):1115-21

Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. Behar TN, et al. **J Neurosci** 1999 Jun 1;19(11):4449-61

Glutamate inhibits thalamic reticular neurons. Cox CL, et al. **J Neurosci** 1999 Aug 1;19(15):6694-9

Striatal neuronal activity and responsiveness to dopamine and glutamate after selective blockade of D1 and D2 dopamine receptors in freely moving rats. Kiyatkin EA, et al. **J Neurosci** 1999 May 1;19(9):3594-609

Active motor neurons potentiate their own sensory inputs via glutamate-induced long-term potentiation. Le Ray D, et al. **J Neurosci** 1999 Feb 15;19(4):1473-83

Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. Roy J, et al. **J Neurosci** 1998 Dec 1;18(23):9673-84

An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. Schurr A, et al. **J Neurosci** 1999 Jan 1;19(1):34-9

Glutamate inhibits GABA excitatory activity in developing neurons. van den Pol AN, et al. **J Neurosci** 1998 Dec 15; 18(24):10749-61

Expression of glutamate receptors on cultured cerebral endothelial cells. Krizbai IA, et al. **J Neurosci Res** 1998 Dec 15;54(6):814-9

Energy metabolism and NAD-NADH redox state in brain slices in response to glutamate exposure and ischemia. Kannurpatti SS, et al. **Metab Brain Dis** 1999 Mar; 14(1):33-43

Non-synaptic effects of glutamic acid and GABA in cultures of developing neural cells. Jelitai M, et al. **Neurobiology (Bp)** 1998;6(4):471-2

The difference in the effect of glutamate and NO synthase inhibitor on free calcium concentration and Na+, K+-ATPase activity in synaptosomes from various brain regions. Avrova NF, et al. **Neurochem Res** 1999 Sep; 24(9):1101-6

Orphanin FQ/nociceptin modulates glutamate- and kainic acid-induced currents in acutely isolated rat spinal dorsal horn neurons. Shu YS, et al. **Neuropeptides** 1998 Dec; 32(6):567-71

The role of systemic, spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Ferreira J, et al. **Neuropharmacology** 1999 Jun;38(6):835-42

Functional coupling of human metabotropic glutamate receptor hmGlu1d: comparison to splice variants hmGlu1a and -1b. Hiltscher R, et al. **Neuropharmacology** 1998 Jul; 37(7):827-37

Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Miñana MD, et al. **Neuropharmacology** 1998 Jul; 37(7):847-57

Glutamate but not interleukin-6 influences the phosphorylation of tau in primary rat hippocampal neurons. Hüll M, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):33-6

Zinc modulation of AMPA receptors may be relevant to splice variants in carp retina. Shen Y, et al. **Neurosci Lett** 1999 Jan 15;259(3):177-80

Taurine antagonizes calcium overload induced by glutamate or chemical hypoxia in cultured rat hippocampal neurons. Zhao P, et al. **Neurosci Lett** 1999 Jun 11;268(1):25-8

Ca2+ regulation by the Na(+)-Ca2+ exchanger in retinal horizontal cells depolarized by L-glutamate. Hayashida Y, et al. **Neurosci Res** 1998 Jul;31(3):189-99

Desensitization of AMPA receptors on horizontal cells isolated from crucian carp retina. Lu T, et al. **Neurosci Res** 1998 Jun;31(2):123-35

The glutamate and carbachol effects on the early post-denervation depolarization in rat diaphragm are directed towards furosemide-sensitive chloride transport. Urazaev AK, et al. **Neurosci Res** 1999 Feb;33(2):81-6

5-Hydroxytryptamine and glutamate modulate velocity and extent of intercellular calcium signalling in hippocampal astroglial cells in primary cultures. Blomstrand F, et al. **Neuroscience** 1999;88(4):1241-53

Glutamate-triggered calcium signalling in mouse bergmann glial cells in situ: role of inositol-1,4,5-trisphosphate-mediated intracellular calcium release. Kirischuk S, et al. **Neuroscience** 1999;92(3):1051-9

High-affinity calcium indicators underestimate increases in intracellular calcium concentrations associated with excitotoxic glutamate stimulations. Stout AK, et al. **Neuroscience** 1999 Mar;89(1):91-100

Cortistatin affects glutamate sensitivity in mouse hypothalamic neurons through activation of sst2 somatostatin receptor subtype. Vasilaki A, et al. **Neuroscience** 1999 Jan;88(2):359-64

Nitrergic stimulation of the locus coeruleus modulates blood pressure and heart rate in the anaesthetized rat. Yao ST, et al. **Neuroscience** 1999;91(2):621-9

Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen KM, et al. **Neurotoxicology** 1998 Aug-Oct; 19(4-5):669-74 (51 ref.)

Right hemisphere involvement in imprinting memory revealed by glutamate treatment. Johnston AN, et al. **Pharmacol Biochem Behav** 1998 Aug;60(4):863-71

N-methyl-D-aspartate antagonists, glutamate release inhibitors, 4-aminopyridine at neuromuscular transmission. Koyuncuoğlu H, et al. **Pharmacol Res** 1998 Jun; 37(6):485-91

The modulatory effect of spermine on the glutamate-NMDA receptor is regionally variable in normal human adult cerebral cortex. Mortensen M, et al. **Pharmacol Toxicol** 1999 Mar;84(3):135-42

Taste dimensions of monosodium glutamate (MSG) in a food system: role of glutamate in young American subjects. Okiyama A, et al. **Physiol Behav** 1998 Aug;65(1):177-81

Glutamate-, kainate- and NMDA-evoked membrane currents in identified glial cells in rat spinal cord slice. Ziak D, et al. **Physiol Res** 1998;47(5):365-75

Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Chalecka-Franaszek E, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8745-50

Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of beta-blockers. Gross RL, et al. **Surv Ophthalmol** 1999 Jun; 43 Suppl 1:S162-70

[Influences of acetylcholine, glutamic acid and GABA on the neuronal firings in ventromedial thalamic nucleus] Gao D, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):60-3 (Eng. Abstr.) **(Chi)**

[Role of substance P in pressor response of lateral hypothamus-perifornical region to glutamate] Wang Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov;13(4):337-41 (Eng. Abstr.) **(Chi)**

[Respiratory effects of microinjection of 2 types of amino acid neurotransmitters in medial areas of nucleus retrofacialis] Wu Z, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):241, 245 **(Chi)**

[Effects of glutamate and ATP on interleukin 6 production by cultured neonatal rat astrocyte] Wu L, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):116-8 (Eng. Abstr.) **(Chi)**

[Role of substance P in pressor response of central amygdaloid nucleus to glutamate] Lu YC, et al.

Sheng Li Hsueh Pao 1997 Aug;49(4):419-26 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Phrenic nerve response to glutamate antagonist microinjection in the ventral medulla. Beagle JL, et al. **Adv Exp Med Biol** 1998;450:61-5

Local glutamatergic and GABAergic synaptic circuits and metabotropic glutamate receptors in the hypothalamic paraventricular and supraoptic nuclei. Tasker JG, et al. **Adv Exp Med Biol** 1998;449:117-21

Glutamate in the nucleus of the solitary tract activates both ionotropic and metabotropic glutamate receptors. Foley CM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1858-66

Glutamatergic projection to RVLM mediates suppression of reflex bradycardia by parabrachial nucleus. Len WB, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1482-92

Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Yokoyama O, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R935-42

Molecular and physiological evidence for glutamate (umami) taste transduction via a G protein-coupled receptor. Chaudhari N, et al. **Ann N Y Acad Sci** 1998 Nov 30; 855:398-406 (32 ref.)

Glutamate and synaptic plasticity at mammalian primary olfactory synapses. Ennis M, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:457-66

Glutamatergic modulation of subcortical motor and limbic circuits. Healy DJ, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:684-7

Introductory remarks on umami taste. Kurihara K, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:393-7

VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. Magistretti PJ, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:213-25 (38 ref.)

The neurophysiology of taste and olfaction in primates, and umami flavor. Rolls ET, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:426-37 (30 ref.)

Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection. Urushitani M, et al. **Ann Neurol** 1998 Nov;44(5):796-807

Role of the buried glutamate in the alpha-helical coiled coil domain of the macrophage scavenger receptor. Suzuki K, et al. **Biochemistry** 1999 Feb 9;38(6):1751-6

Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Tsai G, et al. **Biol Psychiatry** 1998 Oct 15;44(8):667-74

Presynaptic and postsynaptic actions of halothane at glutamatergic synapses in the mouse hippocampus. Kirson ED, et al. **Br J Pharmacol** 1998 Aug;124(8):1607-14

Glutamatergic aspects of schizophrenia. Tamminga C. **Br J Psychiatry Suppl** 1999;(37):12-5 (15 ref.)

Synaptic effects of nitric oxide on enkephalinergic, GABAergic, and glutamatergic networks of the rat periaqueductal gray. Hall CW, et al. **Brain Res** 1998 Sep 14;805(1-2):69-87

The pattern of neurotransmitter alterations in LP-BM5 infected mice is consistent with glutamatergic hyperactivation. Kustova Y, et al. **Brain Res** 1998 May 18;793(1-2):119-26

Interactions of cholinergic and glutamatergic neuronal systems in the functional activation of cerebral blood flow response: a PET study in unanesthetized monkeys. Tsukada H, et al. **Brain Res** 1998 Jun 15;796(1-2):82-90

Role of glutamate in the amygdala and lateral hypothalamus in conditioned taste aversion. Tucci S, et al. **Brain Res** 1998 Nov 30;813(1):44-9

Reversible attenuation of glutamatergic transmission in hippocampal CA1 neurons of rat brain slices following transient cerebral ischemia. Zhang L, et al. **Brain Res** 1999 Jun 19;832(1-2):31-9

Differential effects of glutamatergic blockade on circadian and photic regulation of gene expression in the hamster suprachiasmatic nucleus. Guido ME, et al. **Brain Res Mol Brain Res** 1999 Apr 20;67(2):247-57

Locomotor-activity-induced changes in striatal levels of preprotachykinin and preproenkephalin mRNA. Regulation by the dopaminergic and glutamatergic systems. Liste I, et al. **Brain Res Mol Brain Res** 1999 Jun 18; 70(1):74-83

A role of gamma-amino butyric acid (GABA) and glutamate in control of puberty in female rhesus monkeys: effect of an antisense oligodeoxynucleotide for GAD67 messenger ribonucleic acid and MK801 on luteinizing hormone-releasing hormone release. Kasuya E, et al. **Endocrinology** 1999 Feb;140(2):705-12

Nitric oxide and glutamate interaction in the control of cortical and hippocampal excitability. Ferraro G, et al. **Epilepsia** 1999 Jul;40(7):830-6

Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Bezard E, et al. **Eur J Neurosci** 1999 Jun;11(6):2167-70

Direct glutamate-mediated presynaptic inhibition of sensory afferents by the postsynaptic motor neurons. Cattaert D, et al. **Eur J Neurosci** 1998 Dec;10(12):3737-46

Electrophysiological and neurochemical study of the rat geniculo-cortical pathway. Evidence for glutamatergic neurotransmission. Sáez JA, et al. **Eur J Neurosci** 1998 Sep; 10(9):2790-801

Dihydrokainate-sensitive neuronal glutamate transport is required for protection of rat cortical neurons in culture against synaptically released glutamate. Wang GJ, et al. **Eur J Neurosci** 1998 Aug;10(8):2523-31

Sound-evoked efflux of excitatory amino acids in the guinea-pig cochlea in vitro. Jäger W, et al. **Exp Brain Res** 1998 Aug;121(4):425-32

Use-dependent exaggeration of brain injury: is glutamate involved? Humm JL, et al. **Exp Neurol** 1999 Jun; 157(2):349-58

Local disinhibition of neocortical neuronal circuits causes augmentation of glutamatergic and GABAergic synaptic transmission in the rat neostriatum in vitro. Schlösser B, et al. **Exp Neurol** 1999 May;157(1):180-93

Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Lessmann V. **Gen Pharmacol** 1998 Nov;31(5):667-74 (79 ref.)

Mechanism of the pathogenesis of glutamate neurotoxicity in retinal ischemia. Adachi K, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Oct;236(10):766-74

Neuromuscular glutamatergic and GABAergic channels. Dudel J, et al. **Invert Neurosci** 1997 Sep-Dec;3(2-3):89-92 (26 ref.)

A highly conserved glutamate residue (Glu-270) is essential for plant alternative oxidase activity. Albury MS, et al. **J Biol Chem** 1998 Nov 13;273(46):30301-5

Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading: the role of glutamate as a paracrine signaling agent in the skeleton. Skerry TM. **J Bone Miner Metab** 1999;17(1):66-70 (20 ref.)

Newly formed excitatory pathways provide a substrate for hyperexcitability in experimental temporal lobe epilepsy. Esclapez M, et al. **J Comp Neurol** 1999 Jun 14; 408(4):449-60

Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain. Ishimaru MJ, et al. **J Comp Neurol** 1999 Jun 14;408(4):461-76

Assessing the roles of glutamatergic and cholinergic synaptic drive in the control of fictive swimming frequency in young Xenopus tadpoles. Zhao FY, et al. **J Comp Physiol [A]** 1998 Dec;183(6):753-8

Glutamate augments retrovirus-induced immunodeficiency through chronic stimulation of the hypothalamic-pituitary-adrenal axis. Espey MG, et al. **J Immunol** 1999 Apr 15; 162(8):4998-5002

Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. Genever PG, et al. **J Invest Dermatol** 1999 Mar;112(3):337-42

The role of glutamate in dementia [published erratum appears in J Neural Transm 1999;106(2):213] Kornhuber J, et al. **J Neural Transm Suppl** 1998;53:277-87 (49 ref.)

Dependence of neurones on astrocytes in a coculture system renders neurones sensitive to transforming growth factor beta1-induced glutamate toxicity. Brown DR. **J Neurochem** 1999 Mar;72(3):943-53

Glutamatergic induction of CREB phosphorylation and Fos expression in primary cultures of the suprachiasmatic hypothalamus in vitro is mediated by co-ordinate activity of NMDA and non-NMDA receptors. Schurov IL, et al. **J Neuroendocrinol** 1999 Jan;11(1):43-51

Glutamate controls the induction of GABA-mediated giant depolarizing potentials through AMPA receptors in neonatal rat hippocampal slices. Bolea S, et al. **J Neurophysiol** 1999 May;81(5):2095-102

Metabotropic glutamate receptor modulation of glutamate responses in the suprachiasmatic nucleus. Haak LL. **J Neurophysiol** 1999 Mar;81(3):1308-17

Glutamate-triggered events inducing corticostriatal long-term depression. Calabresi P, et al. **J Neurosci** 1999 Jul 15;19(14):6102-10

Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. Castilho RF, et al. **J Neurosci** 1998 Dec 15;18(24):10277-86

Noradrenergic excitation of magnocellular neurons in the rat hypothalamic paraventricular nucleus via intranuclear glutamatergic circuits. Daftary SS, et al. **J Neurosci** 1998 Dec 15;18(24):10619-28

L-Type Ca(2+) channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons. Rajadhyaksha A, et al. **J Neurosci** 1999 Aug 1;19(15):6348-59

GABA- and glutamate-activated channels in green fluorescent protein-tagged gonadotropin-releasing hormone neurons in transgenic mice. Spergel DJ, et al. **J Neurosci** 1999 Mar 15;19(6):2037-50

Ammonium and glutamate released by neurons are signals regulating the nutritive function of a glial cell. Tsacopoulos M, et al. **J Neurosci** 1997 Apr 1;17(7):2383-90

CREB in the mouse SCN: a molecular interface coding the phase-adjusting stimuli light, glutamate, PACAP, and melatonin for clockwork access. von Gall C, et al. **J Neurosci** 1998 Dec 15;18(24):10389-97

Citron binds to PSD-95 at glutamatergic synapses on inhibitory neurons in the hippocampus. Zhang W, et al. **J Neurosci** 1999 Jan 1;19(1):96-108

Developmental changes in EPSC quantal size and quantal content at a central glutamatergic synapse in rat. Bellingham MC, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):861-9

Blockade of NR2B-containing NMDA receptors prevents BDNF enhancement of glutamatergic transmission in hippocampal neurons. Crozier RA, et al. **Learn Mem** 1999 May-Jun;6(3):257-66

Glutamate and cyclic AMP regulate the expression of galactokinase in Mycobacterium smegmatis. Raychaudhuri S, et al. **Microbiology** 1998 Aug;144 (Pt 8):2131-40

Excitatory synapses. Neither too loud nor too quiet [news; comment] Kullmann DM. **Nature** 1999 May 13; 399(6732):111-2. Comment on: Nature 1999 May 13;399(6732):151-5.

Glutamic acid and Alzheimer's disease. Arias C, et al. **Neurobiology (Bp)** 1998;6(1):33-43 (90 ref.)

Effects of endogenous glutamate on extracellular concentrations of GABA, dopamine, and dopamine metabolites in the prefrontal cortex of the freely moving rat: involvement of NMDA and AMPA/KA receptors. Del Arco A, et al. **Neurochem Res** 1999 Aug;24(8):1027-35

Role of glutamate receptors and glutamate transporters in the regulation of the glutamate-glutamine cycle in the awake rat. Segovia G, et al. **Neurochem Res** 1999 Jun; 24(6):779-83

Activation of AMPA, kainate, and metabotropic receptors at hippocampal mossy fiber synapses: role of glutamate diffusion. Min MY, et al. **Neuron** 1998 Sep;21(3):561-70

Morphofunctional studies of the interactions of the glutamatergic, cholinergic, and dopaminergic systems in the neostriatum. Oleshko NN. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):397-401

Adverse psychological impact, glutamatergic dysfunction, and risk factors for Alzheimer's disease. Myhrer T. **Neurosci Biobehav Rev** 1998;23(1):131-9 (100 ref.)

Apoptosis of cerebellar granule cells induced by serum withdrawal, glutamate or beta-amyloid, is independent of Jun kinase or p38 mitogen activated protein kinase activation. Gunn-Moore FJ, et al. **Neurosci Lett** 1998 Jun 26;250(1):53-6

Glutamergic transmission of neuronal responses to carbachol in rat dorsal cochlear nucleus slices. Chen K, et al. **Neuroscience** 1999 Mar;90(3):1043-9

Dopamine depresses glutamatergic synaptic transmission in the rat parabrachial nucleus in vitro. Chen X, et al. **Neuroscience** 1999 May;90(2):457-68

Synaptic depression induced by pharmacological activation of metabotropic glutamate receptors in the perirhinal cortex in vitro. McCaffery B, et al. **Neuroscience** 1999;93(3):977-84

Mediation and modulation by eicosanoids of responses of spinal dorsal horn neurons to glutamate and substance P receptor agonists: results with indomethacin in the rat in vivo. Pitcher GM, et al. **Neuroscience** 1999;93(3):1109-21

Glutamate-induced increase of extracellular glutamate through N-methyl-D-aspartate receptors in ethanol withdrawal. Rossetti ZL, et al. **Neuroscience** 1999; 93(3):1135-40

Effects of lesions to the glutamatergic afferents to the nucleus accumbens in the modulation of reactivity to spatial and non-spatial novelty in mice. Sargolini F, et al. **Neuroscience** 1999;93(3):855-67

Bilirubin inhibits transport of neurotransmitters in synaptic vesicles. Roseth S, et al. **Pediatr Res** 1998 Sep;44(3):312-6

Nitric oxide and the anticonvulsant action of antiepileptic drugs. Czuczwar SJ. **Pol J Pharmacol** 1999 Jan-Feb; 51(1):101-2 (18 ref.)

Ca2+/calmodulin-dependent kinase II mediates simultaneous enhancement of gap-junctional conductance and glutamatergic transmission. Pereda AE, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13272-7

Glutamate and gamma-aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. Vogt KE, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1118-22

Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. Alessandri B, et al. **Prog Brain Res** 1998;116:303-30 (180 ref.)

Glutamate induced cell death: apoptosis or necrosis? Ankarcrona M. **Prog Brain Res** 1998;116:265-72 (66 ref.)

Glutamate in the human brain: possible roles in synaptic transmission and ischemia. Berg-Johnsen J, et al. **Prog Brain Res** 1998;116:287-302 (126 ref.)

The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Farber NB, et al. **Prog Brain Res** 1998;116:421-37 (60 ref.)

Synthesis of glutamate and its regulation. Kvamme E. **Prog Brain Res** 1998;116:73-85 (109 ref.)

Glutamate toxicity in chronic neurodegenerative disease. Lancelot E, et al. **Prog Brain Res** 1998;116:331-47 (190 ref.)

The glutamate synapse as a therapeutical target: perspectives for the future. Meldrum BS. **Prog Brain Res** 1998; 116:441-58 (132 ref.)

Neurodegeneration and glutamate induced oxidative stress. Nakao N, et al. **Prog Brain Res** 1998;116:245-63 (116 ref.)

Involvement of glutamate in human epileptic activities. Scheyer RD. **Prog Brain Res** 1998;116:359-69 (93 ref.)

Control of time course of glutamatergic synaptic currents. Trussell L. **Prog Brain Res** 1998;116:59-69 (74 ref.)

The glutamate synapse: a target in the pharmacological management of hyperalgesic pain states. Urban MO, et al. **Prog Brain Res** 1998;116:407-20 (81 ref.)

The synaptic pharmacology underlying sensory processing in the superior colliculus. Binns KE. **Prog Neurobiol** 1999 Oct;59(2):129-59 (172 ref.)

New clues to how neurons strengthen their connections [news; comment] Barinaga M. **Science** 1999 Jun 11; 284(5421):1755-7. Comment on: Science 1999 Jun

11;284(5421):1805–11. Comment on: Science 1999 Jun 11;284(5421):1811–6.
Characteristics of neurons with high-frequency discharge in the central nervous system and their relationship to chronic pain. Experimental and clinical investigations. Yamashiro K, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):149–54
Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. McBain CJ, et al. **Trends Neurosci** 1999 May;22(5):228–35 (61 ref.)
[NO donors transform neuronal response to glutamate] D'iakonova TL. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1152–9 (Eng. Abstr.) **(Rus)**
[Inhibition of Na, K-adenosine triphosphatase by glutamate in cerebral cortex synaptosomes. Protective effect of alpha-tocopherol and superoxide dismutase] Tiurina IuIu, et al. **Zh Evol Biokhim Fiziol** 1998 May–Jun;34(3):325–32 **(Rus)**

POISONING

Glutamate-induced neuron death requires mitochondrial calcium uptake. Stout AK, et al. **Nat Neurosci** 1998 Sep; 1(5):366–73
Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Antonelli T, et al. **Neuroreport** 1998 Dec 21; 9(18):4209–13

SECRETION

Different effects of volatile anesthetics and polyhalogenated alkanes on depolarization-evoked glutamate release in rat cortical brain slices. Eilers H, et al. **Anesth Analg** 1999 May; 88(5):1168–74
Glioma cells release excitotoxic concentrations of glutamate. Ye ZC, et al. **Cancer Res** 1999 Sep 1;59(17):4383–91
Excessive release of [3H]noradrenaline and glutamate in response to simulation of ischemic conditions in rat spinal cord slice preparation: effect of NMDA and AMPA receptor antagonists. Nakai T, et al. **Eur J Pharmacol** 1999 Feb 5;366(2–3):143–50
Hypothermia ameliorates ischemic brain damage and suppresses the release of extracellular amino acids in both normo- and hyperglycemic subjects. Li PA, et al. **Exp Neurol** 1999 Jul;158(1):242–53
Brain-derived neurotrophic factor induces rapid and transient release of glutamate through the non-exocytotic pathway from cortical neurons. Takei N, et al. **J Biol Chem** 1998 Oct 16;273(42):27620–4
The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. Bellocchio EE, et al. **J Neurosci** 1998 Nov 1;18(21):8648–59
Noradrenaline inhibits glutamate release in the rat bed nucleus of the stria terminalis: in vivo microdialysis studies. Forray MI, et al. **J Neurosci Res** 1999 Feb 1;55(3):311–20
Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Shen M, et al. **Mol Pharmacol** 1999 Jan;55(1):8–13
Relationships between glutamate release, blood flow and spreading depression: real-time monitoring using an electroenzymatic dialysis electrode. Iijima T, et al. **Neurosci Res** 1998 Nov;32(3):201–7
Monte carlo simulation of vesicular release, spatiotemporal distribution of glutamate in synaptic cleft and generation of postsynaptic currents. Glavinovic MI. **Pflugers Arch** 1999 Feb;437(3):462–70
Roles of Na(+)-Ca2+ exchange and of mitochondria in the regulation of presynaptic Ca2+ and spontaneous glutamate release. Scotti AL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):357–64
Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Golembiowska K, et al. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):63–70
Imaging of glutamate release from the goldfish retinal slice. Ayoub GS, et al. **Vision Res** 1998 Oct;38(19):2909–12
[Is endogenously released DOPA itself an upstream factor for increase in glutamate release and delayed neuronal cell death induced by transient ischemia in rats?] Misu Y, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:93P–97P (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Improved high altitude hypoxic tolerance and amelioration of anorexia and hypophagia in rats on oral glutamate supplementation. Kumar D, et al. **Aviat Space Environ Med** 1999 May;70(5):475–9
Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. Boyle FM, et al. **J Neurooncol** 1999 Jan;41(2):107–16
Effect of dietary glutamate on chemotherapy-induced immunosuppression. Lin CM, et al. **Nutrition** 1999 Sep; 15(9):687–96
[An amino acid metabolic complex in optimizing the cardiac hemodynamic characteristics of patients with ischemic heart disease] Berezin AE, et al. **Lik Sprava** 1998 Dec; (8):94–6 (Eng. Abstr.) **(Rus)**

TOXICITY

Role of amino acids in cochlear degeneration: morphological changes in cochlear outer hair cells following glutamate application. Sunami K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:22–5
Protection by imidazol(ine) compounds of L-glutamate neurotoxicity through NMDA receptor blockade. DeGregorio-Rocasolano N, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:452
Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP. Said SI, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:226–37
Nitric oxide in mechanisms of brain damage induced by neurotoxic effect of glutamate. Bashkatova VG, et al. **Biochemistry (Mosc)** 1998 Jul;63(7):866–73
Neuronal excitotoxicity: the role of mitochondria. Nicholls DG, et al. **Biofactors** 1998;8(3–4):287–99 (64 ref.)
Nitric oxide mediates glutamate-induced mitochondrial depolarization in rat cortical neurons. Almeida A, et al. **Brain Res** 1999 Jan 23;816(2):580–6
Reduced mitochondrial manganese-superoxide dismutase activity exacerbates glutamate toxicity in cultured mouse cortical neurons. Li Y, et al. **Brain Res** 1998 Dec 14; 814(1–2):164–70
Activation of NMDA receptors protects against glutamate neurotoxicity in the retina: evidence for the involvement of neurotrophins. Rocha M, et al. **Brain Res** 1999 May 8;827(1–2):79–92
Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Shinpo K, et al. **Brain Res** 1999 Feb 20; 819(1–2):170–3
Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. Shoge K, et al. **Brain Res** 1999 Aug 21;839(1):66–73
Protective effects of vasoactive intestinal peptide against delayed glutamate neurotoxicity in cultured retina. Shoge K, et al. **Brain Res** 1998 Oct 26;809(1):127–36
Glutamate-induced cytotoxicity in PC12 pheochromocytoma cells: role of oxidation of phospholipids, glutathione and protein sulfhydryls revealed by bcl-2 transfection. Tyurin VA, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):270–81
Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in Vitro model for assessment of the neuroprotective effects of estrogens. Zaulyanov LL, et al. **Cell Mol Neurobiol** 1999 Dec;19(6):705–18
Neurotoxic mechanisms of degeneration in motor neuron diseases. Ludolph AC, et al. **Drug Metab Rev** 1999 Aug; 31(3):619–34 (75 ref.)
Ability of retinal Müller glial cells to protect neurons against excitotoxicity in vitro depends upon maturation and neuron-glial interactions. Heidinger V, et al. **Glia** 1999 Feb 1;25(3):229–39
Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. Osaka H, et al. **J Cell Biochem** 1999 Jun 1;73(3):303–11
Glutamate neurotoxicity in rat cerebellar granule cells involves cytochrome c release from mitochondria and mitochondrial shuttle impairment. Atlante A, et al. **J Neurochem** 1999 Jul;73(1):237–46
Oxidative stress, mitochondrial function, and acute glutamate excitotoxicity in cultured cerebellar granule cells. Castilho RF, et al. **J Neurochem** 1999 Apr;72(4):1394–401
Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line. Xiao N, et al. **J Neurochem** 1999 Jan;72(1):95–101
The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. Singer CA, et al. **J Neurosci** 1999 Apr 1;19(7):2455–63
In vivo glutamate neurotoxicity is associated with reductions in calcium/calmodulin-dependent protein kinase II immunoreactivity. Babcock AM, et al. **J Neurosci Res** 1999 Apr 1;56(1):36–43
Neuroprotection by pigment epithelial-derived factor against glutamate toxicity in developing primary hippocampal neurons. DeCoster MA, et al. **J Neurosci Res** 1999 Jun 15;56(6):604–10
In vitro neuroprotection against glutamate toxicity provided by novel non-competitive N-methyl-D-aspartate antagonists. Drian MJ, et al. **J Neurosci Res** 1999 Sep 15; 57(6):927–34
Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration [published erratum appears in J Neurosci Res 1998 Oct 1;54(1):123] Kim YC, et al. **J Neurosci Res** 1998 Aug 15;53(4):426–32
Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. Sawada H, et al. **J Neurosci Res** 1998 Dec 1;54(5):707–19
Fluid percussion brain injury exacerbates glutamate-induced focal damage in the rat. Di X, et al. **J Neurotrauma** 1999 Mar;16(3):195–201
Brain temperature modifies glutamate neurotoxicity in vivo. Suehiro E, et al. **J Neurotrauma** 1999 Apr;16(4):285–97
Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. Shimada Y, et al. **J Pharm Pharmacol** 1999 Jun;51(6):715–22
Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Hansen HS, et al. **Lipids** 1999;34 Suppl:S327–30 (37 ref.)
Neurons depend on astrocytes in a coculture system for protection from glutamate toxicity. Brown DR. **Mol Cell Neurosci** 1999 May;13(5):379–89
Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: effects of NMDA antagonists, antioxidants and MAO inhibitors. Jacobsson SO, et al. **Neurochem Int** 1999 Jan;34(1):49–62
Ciliary neurotrophic factor protects hippocampal neurons from excitotoxic damage. Semkova I, et al. **Neurochem Int** 1999 Jul;35(1):1–10
Distinct glycolysis inhibitors determine retinal cell sensitivity to glutamate-mediated injury. Rego AC, et al. **Neurochem Res** 1999 Mar;24(3):351–8
Micromolar L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurones. Cheung NS, et al. **Neuropharmacology** 1998 Oct–Nov; 37(10–11):1419–29
Sex-specific expression of N-methyl D-aspartate receptor (NMDAR) in the preoptic area of neonatal rats. Hsu C, et al. **Neurosci Lett** 1999 Mar 5;262(2):85–8
Neurotoxicity of ammonia and glutamate: molecular mechanisms and prevention. Felipo V, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):675–81
The role of excitotoxicity in neurodegenerative disease: implications for therapy. Doble A. **Pharmacol Ther** 1999 Mar;81(3):163–221 (694 ref.)
Anticonvulsant properties of linalool in glutamate-related seizure models. Elisabetsky E, et al. **Phytomedicine** 1999 May;6(2):107–13
Electrically evoked [3H]GABA release from cerebral cortical cultures: an in vitro approach for studying glutamate-induced neurotoxicity. Tomasini MC, et al. **Synapse** 1998 Nov;30(3):247–54
Effects of U-83836E on glutamate-induced neurotoxicity in dissociated rat cerebellar granule cells. Sureda FX, et al. **Toxicol Appl Pharmacol** 1999 Apr 1;156(1):1–5
Interactions of excitatory neurotransmitters and xenobiotics in excitotoxicity and oxidative stress: glutamate and lead. Savolainen KM, et al. **Toxicol Lett** 1998 Dec 28; 102–103:363–7 (25 ref.)
[Protective effect of neurotrophin against glutamate neurotoxicity in cortical cultures] Kume T, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:98P–102P (Eng. Abstr.) **(Jpn)**

GLUTAMIC ACID-SPECIFIC TRNA see **RNA, TRANSFER, GLU**

GLUTAMIC-OXALOACETIC TRANSAMINASE see **ASPARTATE TRANSAMINASE**

GLUTAMIC-PYRUVIC TRANSAMINASE see **ALANINE TRANSAMINASE**

GLUTAMINASE

ANALYSIS

Characterization of mitochondrial glutaminase and amino acids at prolonged times after experimental focal cerebral ischemia. Newcomb R, et al. **Brain Res** 1998 Nov 30; 813(1):103–11

BIOSYNTHESIS

Overexpression of salt-tolerant glutaminase from Micrococcus luteus K-3 in Escherichia coli and its purification. Nandakumar R, et al. **Protein Expr Purif** 1999 Mar;15(2):155–61

CHEMISTRY

Formation and isolation of a covalent intermediate during the glutaminase reaction of a class II amidotransferase. Schnizer HG, et al. **Biochemistry** 1999 Mar 23; 38(12):3677–82
The function of Glu338 in the catalytic triad of the carbamoyl phosphate synthetase amidotransferase domain. Hewagama A, et al. **Biochim Biophys Acta** 1998 Nov 10;1388(2):489–99

GENETICS

Sequence and molecular analysis of the Rhizobium etli glsA gene, encoding a thermolabile glutaminase. Calderón J, et al. **Biochim Biophys Acta** 1999 Mar 19;1444(3):451–6
Ontogeny of the GNRH-, glutaminase- and glutamate decarboxylase-gene expression in the hypothalamus of female rats. Roth C, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):105–14
Early differential expression of two glutaminase mRNAs in mouse spleen after tumor implantation. Aledo JC, et al. **Cancer Lett** 1998 Nov 13;133(1):95–9
Physical and genetic linkage of glutaminase (Gls), signal transducer and activator of transcription 1 (Stat1), and xeroderma pigmentosum complementation group G (Xpg) on mouse proximal chromosome 1. Lévy N, et al. **Genomics** 1998 Dec 1;54(2):355–6
Quantitation of glutaminase mRNA in enterocytes using competitive RT-PCR. Kong SE, et al. **Mol Cell Probes** 1998 Oct;12(5):339–41

GLUTAMINASE

METABOLISM

Rat liver endothelial cell glutamine transporter and glutaminase expression contrast with parenchymal cells. Lohmann R, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G743–50

Involvement of essential cysteine and histidine residues in the activity of isolated glutaminase from tumour cells. Campos JA, et al. **Biochim Biophys Acta** 1998 Dec 8; 1429(1):275–83

Distribution of phosphate-activated glutaminase isozymes in the chicken: absence from liver but presence of high activity in pectoralis muscle. Wu G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jun; 120(2):285–90

Changes in the activity levels of glutamine synthetase, glutaminase and glycogen synthetase in rats subjected to hypoxic stress. Vats P, et al. **Int J Biometeorol** 1999 Apr; 42(4):205–9

Effect of NMDA antagonists on the activity of glutaminase and aspartate aminotransferase in the developing rat cerebellum. Moran J, et al. **Int J Dev Neurosci** 1999 Feb; 17(1):57–65

Postembedding immunogold labelling reveals subcellular localization and pathway-specific enrichment of phosphate activated glutaminase in rat cerebellum. Laake JH, et al. **Neuroscience** 1999;88(4):1137–51

Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Krivošíková Z, et al. **Physiol Res** 1998;47(3):177–83

Administration of nerve growth factor, brain-derived neurotrophic factor and insulin-like growth factor-II protects phosphate-activated glutaminase in the ischemic and reperfused rat retinas. Tomita H, et al. **Tohoku J Exp Med** 1999 Mar;187(3):227–36

PHYSIOLOGY

The role of glutaminase in the small intestine. McCauley R, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):405–13 (68 ref.)

GLUTAMINE

Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Pfohl M, et al. **Diabetes** 1999 Mar;48(3):623–7

A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. Gomes I, et al. **J Neurochem** 1999 Aug; 73(2):612–22

ADMINISTRATION & DOSAGE

Glutamine supplementation in catabolic patients. Sacks GS. **Ann Pharmacother** 1999 Mar;33(3):348–54 (59 ref.)

Glutamine. Heys SD, et al. **Br J Surg** 1999 Mar;86(3):289–90

Dietary glutamine supplementation reduces plasma nitrate levels in rats [see comments] Houdijk AP, et al. **Clin Nutr** 1998 Feb;17(1):11–4. Comment in: Clin Nutr 1998 Feb;17(1):1–2.

Glutamine-containing TPN: a question of life and death for intensive care unit-patients? Wernerman J. **Clin Nutr** 1998 Feb;17(1):3–6 (31 ref.)

Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix? Santoso JT, et al. **Gynecol Oncol** 1998 Dec;71(3):359–63

Effects of vascular or luminal administration and of simultaneous glucose availability on glutamine utilization by isolated rat small intestine. Plauth M, et al. **Int J Colorectal Dis** 1999 Apr;14(2):95–100

Intravenous glutamine or limited enteral feedings in piglets: amelioration of small intestinal disuse atrophy. Remillard RL, et al. **J Nutr** 1998 Dec;128(12 Suppl):2723S–2726S

Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome. Alavi K, et al. **J Pediatr Surg** 1998 Nov;33(11):1666–9

Glutamine-enriched total parenteral nutrition preserves respiratory immunity and improves survival to a Pseudomonas Pneumonia. DeWitt RC, et al. **J Surg Res** 1999 Jun 1;84(1):13–8

A comparison of parenteral and enteral feeding in neonatal piglets, including an assessment of the utilization of a glutamine-rich, pediatric elemental diet. Bertolo RF, et al. **JPEN J Parenter Enteral Nutr** 1999 Mar–Apr;23(2):47–55

Parenteral glutamine infusion alters insulin-mediated glucose metabolism. Borel MJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep–Oct;22(5):280–5

Enteral glutamine supplementation for very-low-birth-weight infants decreases hospital costs. Dallas MJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov–Dec;22(6):352–6

Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Hammarqvist F. **JPEN J Parenter Enteral Nutr** 1999 Jan–Feb;23(1):43–4

Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. Schloerb PR, et al. **JPEN J Parenter Enteral Nutr** 1999 May–Jun;23(3):117–22

Glutamine-enriched enteral nutrition in patients with multiple trauma [letter; comment] Mitchell I, et al. **Lancet** 1998 Nov 7;352(9139):1553. Comment on: Lancet 1998 Sep 5;352(9130):772–6.

Small bowel adaptation with growth hormone and glutamine after massive resection of rat's small bowel. Waitzberg DL, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):81–90 (66 ref.)

Randomized clinical outcome study of critically ill patients given glutamine-supplemented enteral nutrition [see comments] Jones C, et al. **Nutrition** 1999 Feb;15(2):108–15 . Comment in: Nutrition 1999 Feb;15(2):158–9.

[Pancreatitis and translocation--approaches for nutritional strategies] Foitzik T. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:596–8 (Eng. Abstr.) **(Ger)**

[Effect of alanyl-glutamine in postoperative total parenteral nutrition on postoperative immunosuppression and morbidity. Preliminary results of a prospective randomized study] Jacobi CA, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:605–11 (Eng. Abstr.) **(Ger)**

[Glutamine--its metabolic role and possibilities for clinical use] Turczynowski W, et al. **Przegl Lek** 1998;55(12):659–62 (14 ref.) (Eng. Abstr.) **(Pol)**

ANALOGS & DERIVATIVES

The mechanical properties of fluoride-treated bone in the ovariectomized rat. Giavaresi G, et al. **Calcif Tissue Int** 1999 Sep;65(3):237–41

Is alpha-ketoisocaproyl-glutamine a suitable glutamine precursor to sustain fibroblast growth? Coudray-Lucas C, et al. **Clin Nutr** 1999 Feb;18(1):29–33

Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma [see comments] Buckner JC, et al. **Mayo Clin Proc** 1999 Feb; 74(2):137–45. Comment in: Mayo Clin Proc 1999 Jun;74(6):641–2.

Efficacy of antineoplastons A10 and AS2-1 [letter; comment] Burzynski SR. **Mayo Clin Proc** 1999 Jun;74(6):641–2. Comment on: Mayo Clin Proc 1999 Feb;74(2):137–45.

ANALYSIS

Determination of glutamine in muscle protein facilitates accurate assessment of proteolysis and de novo synthesis-derived endogenous glutamine production. Kuhn KS, et al. **Am J Clin Nutr** 1999 Oct;70(4):484–9

Enzyme-based flow injection analysis system for glutamine and glutamate in mammalian cell culture media. Mayer C, et al. **Anal Biochem** 1999 Mar 1;268(1):110–6

Quantification of glutamine in proteins and peptides using enzymatic hydrolysis and reverse-phase high-performance liquid chromatography. Tsao M, et al. **Anal Biochem** 1999 Apr 10;269(1):143–8

Differentiation of lysine/glutamine in peptide sequence analysis by electrospray ionization sequential mass spectrometry coupled with a quadrupole ion trap. Bahr U, et al. **Rapid Commun Mass Spectrom** 1998;12(19):1382–8

ANTAGONISTS & INHIBITORS

A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Hidalgo M, et al. **Clin Cancer Res** 1998 Nov;4(11):2763–70

BIOSYNTHESIS

Importance of glutamate dehydrogenase stimulation for glucose and glutamine synthesis in rabbit renal tubules incubated with various amino acids. Winiarska K, et al. **Acta Biochim Pol** 1998;45(3):825–31

Glutamine synthesis is heterogeneous and differentially regulated along the rabbit renal proximal tubule. Ferrier B, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):543–50

15N-NMR spectroscopy studies of ammonia transport and glutamine synthesis in the hyperammonemic rat brain. Shen J, et al. **Dev Neurosci** 1998;20(4–5):434–43

Accelerated glutamine synthesis in critically ill patients cannot maintain normal intramuscular free glutamine concentration. Mittendorfer B, et al. **JPEN J Parenter Enteral Nutr** 1999 Sep–Oct;23(5):243–50; discussion 250–2

Glutamine biosynthesis and the utilization of succinate and glutamine by Rhizobium etli and Sinorhizobium meliloti. Encarnación S, et al. **Microbiology** 1998 Sep;144 (Pt 9):2629–38

BLOOD

HSP70 expression in granulocytes and lymphocytes of patients with polytrauma: comparison with plasma glutamine. Weingartmann G, et al. **Clin Nutr** 1999 Apr; 18(2):121–4

Competitive sustained exercise in humans, lymphokine activated killer cell activity, and glutamine--an intervention study. Rohde T, et al. **Eur J Appl Physiol** 1998 Oct;78(5):448–53

Blood leukocyte and glutamine fluctuations after eccentric exercise. Miles MP, et al. **Int J Sports Med** 1999 Jul; 20(5):322–7

A comparison of plasma glutamine concentration in athletes from different sports. Hiscock N, et al. **Med Sci Sports Exerc** 1998 Dec;30(12):1693–6

CHEMISTRY

Formation and isolation of a covalent intermediate during the glutaminase reaction of a class II amidotransferase. Schnizer HG, et al. **Biochemistry** 1999 Mar 23; 38(12):3677–82

Synthesis and testing of azaglutamine derivatives as inhibitors of hepatitis A virus (HAV) 3C proteinase. Huang Y, et al. **Bioorg Med Chem** 1999 Apr;7(4):607–19

Increased HLA-DQ2-affinity of a synthetic gliadin peptide by acid-induced deamidation of glutamine residues. Terreaux C, et al. **Bioorg Med Chem Lett** 1998 Aug 4; 8(15):2039–44

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Dragovich PS, et al. **J Med Chem** 1999 Apr 8;42(7):1213–24

Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges. Koerber SC, et al. **J Med Chem** 1998 Dec 3;41(25):5002–11

Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. Word JM, et al. **J Mol Biol** 1999 Jan 29;285(4):1735–47

Localization of a single transglutaminase-reactive glutamine in the third domain of RAP, the alpha2-macroglobulin receptor-associated protein. Rasmussen LK, et al. **J Protein Chem** 1999 Jan;18(1):69–73

Asparagine and glutamine rotamers: B-factor cutoff and correction of amide flips yield distinct clustering. Lovell SC, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):400–5

[Analysis of the immunologic heterogeneity of HIV-1: I. "Arginine-glutamine trigger" in the fourth position of the central tetrapeptide of the V3 loop of gp120] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Jul–Aug;32(4):717–28 **(Rus)**

GENETICS

Factor V Arg506Gln mutation is not associated with cardiovascular mortality in older women. Roest M, et al. **Am J Epidemiol** 1999 Apr 1;149(7):665–70

A novel and de novo spontaneous point mutation (Glu271STOP) of the antithrombin gene results in a type I deficiency and thrombophilia. Tarantino MD, et al. **Am J Hematol** 1999 Feb;60(2):126–9

The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Ombres D, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct;18(10):1611–6

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Watson DJ, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):703–9

Engineered recombinant factor VII Q217 variants with altered inhibitor specificities. Chang YJ, et al. **Biochemistry** 1999 Aug 24;38(34):10940–8

Transient kinetics of formation and reaction of the uridylyl-enzyme form of galactose-1-P uridylyltransferase and its Q168R-variant: insight into the molecular basis of galactosemia. Geeganage S, et al. **Biochemistry** 1998 Oct 13;37(41):14500–7

Two stable unfolding intermediates of the disease-causing L68Q variant of human cystatin C. Gerhartz B, et al. **Biochemistry** 1998 Dec 8;37(49):17309–17

Role of the S1' subsite glutamine 215 in activity and specificity of stromelysin-3 by site-directed mutagenesis. Holtz B, et al. **Biochemistry** 1999 Sep 14;38(37):12174–9

Substitution at residue 214 of human thymidylate synthase alters nucleotide binding and isomerization of ligand-protein complexes. Steadman DJ, et al. **Biochemistry** 1999 Apr 27;38(17):5582–7

The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Kantoff P, et al. **Biochim Biophys Acta** 1998 Nov 26;1378(3):C1–5 (25 ref.)

Polymorphism of homopolymeric glutamines in coactivators for nuclear hormone receptors. Hayashi Y, et al. **Endocr J** 1999 Apr;46(2):279–84

Circulating activated protein C in subjects with heterozygous Gln506-factor V. Petäjä J, et al. **Haemostasis** 1998 Jan–Feb; 28(1):31–6

Gln --> Arg 191 polymorphism of paraoxonase and Parkinson's disease. Akhmedova S, et al. **Hum Hered** 1999 Jun;49(3):178–80

A Gln/Arg polymorphism at codon 349 of the hBUBR1 gene. Katagiri T, et al. **J Hum Genet** 1999;44(2):131–2

Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis. Kim TW, et al. **J Korean Med Sci** 1998 Dec;13(6):587–90

Naturally occurring scrapie in Southdown sheep. Tyler JW, et al. **J Vet Intern Med** 1999 May–Jun;13(3):213–6

SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Sittler A, et al. **Mol Cell** 1998 Oct;2(4):427–36

tRNA(2Gln) mutants that translate the CGA arginine codon as glutamine in Escherichia coli. Tsai F, et al. **RNA** 1998 Dec;4(12):1514–22

Glutamine repeats and neurodegenerative diseases: molecular aspects. Perutz MF. **Trends Biochem Sci** 1999 Feb; 24(2):58–63 (40 ref.)

IMMUNOLOGY

Glutamine and the effects of exhaustive exercise upon the immune response. Castell LM, et al.

Can J Physiol Pharmacol 1998 May;76(5):524–32 (77 ref.)
Dietary glutamine enhances murine T-lymphocyte responsiveness. Kew S, et al. **J Nutr** 1999 Aug; 129(8):1524–31

METABOLISM

Regulation of hepatic glutamine metabolism during exercise in the dog. Halseth AE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E655–64
The metabolic consequences of critical illness: acute effects on glutamine and protein metabolism. Jackson NC, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E163–70
Glutamine synthetase expression in rat lung is regulated by protein stability. Labow BI, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):L877–86
Kinetic impairment of nitrogen and muscle glutamine metabolisms in old glucocorticoid-treated rats. Minet-Quinard R, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E558–64
Rate at which glutamine enters TCA cycle influences carbon atom fate in intestinal epithelial cells. Quan J, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1299–308
Substrate oxidation by the portal drained viscera of fed piglets. Stoll B, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E168–75
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Yarasheski KE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E577–83
Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Eigenbrodt E, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3267–74
Effects of Salmonella typhimurium infection and ofloxacin treatment on glucose and glutamine metabolism in Caco-2/TC-7 cells. Posho L, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2950–5
Metabolic responses to different glucose and glutamine levels in baby hamster kidney cell culture. Cruz HJ, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):579–85
Stability of the Escherichia coli ATP synthase F0F1 complex is dependent on interactions between gamma Gln-269 and the beta subunit loop beta Asp-301–beta Asp-305. Omote H, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):277–82
Expression, purification, and in vitro characterization of the human outer mitochondrial membrane receptor human translocase of the outer mitochondrial membrane 20. Schleiff E, et al. **Arch Biochem Biophys** 1999 Jul 1; 367(1):95–103
Effects on substrate reduction of substitution of histidine-195 by glutamine in the alpha-subunit of the MoFe protein of Azotobacter vinelandii nitrogenase. Dilworth MJ, et al. **Biochemistry** 1998 Dec 15;37(50):17495–505
Deamidation of specific glutamine residues from alpha-A crystallin during aging of the human lens. Takemoto L, et al. **Biochemistry** 1998 Sep 29;37(39):13681–5
Conversion of a beta-ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine. Witkowski A, et al. **Biochemistry** 1999 Sep 7;38(36):11643–50
Activities of enzymes involved in glutamine metabolism in connection with energy production in the gastrointestinal tract epithelium of newborn, suckling and weaned piglets. Madej M, et al. **Biol Neonate** 1999;75(4):250–8
Effect of extracellular glutamine concentration on primary and secondary metabolism of a murine hybridoma: an in vivo 13C nuclear magnetic resonance study. Mancuso A, et al. **Biotechnol Bioeng** 1998 Jan 20;57(2):172–86
Effect of glutamine limitation on the death of attached Chinese hamster ovary cells. Sanfeliu A, et al. **Biotechnol Bioeng** 1999 Jul 5;64(1):46–53
Immunoelectron microscopy of AMPA receptor subunits reveals three types of putative glutamatergic synapse in the rat vestibular end organs. Matsubara A, et al. **Brain Res** 1999 Feb 20;819(1–2):58–64
Metabolic fate of glutamine in lymphocytes, macrophages and neutrophils. Curi R, et al. **Braz J Med Biol Res** 1999 Jan;32(1):15–21
Glutamine: a potentially useful supplement for athletes. Antonio J, et al. **Can J Appl Physiol** 1999 Feb;24(1):1–14 (64 ref.)
Extracellular glutamine level reduction enhances 5-fluorouracil cytotoxicity. Sukemori S, et al. **Cancer Biochem Biophys** 1998 Jun;16(1–2):53–61
Lymphocyte proliferation modulated by glutamine: involved in the endogenous redox reaction. Chang WK, et al. **Clin Exp Immunol** 1999 Sep;117(3):482–8
Glutamine, a regulator of acute phase protein synthesis. Meisse D, et al. **Clin Nutr** 1999 Apr;18(2):111–2
Effects of adrenaline on glucose and glutamine metabolism and superoxide production by rat neutrophils. Garcia C, et al. **Clin Sci (Colch)** 1999 Jun;96(6):549–55
Macrophage-mediated lysis of a beta-cell line, tumour necrosis factor-alpha release from bacillus Calmette-Guérin (BCG)-activated murine macrophages and interleukin-8 release from human monocytes are dependent on extracellular glutamine concentration and glutamine metabolism. Murphy C, et al. **Clin Sci (Colch)** 1999 Jan;96(1):89–97
Importance of glutamine metabolism in murine macrophages and human monocytes to L-arginine biosynthesis and rates of nitrite or urea production. Murphy C, et al. **Clin Sci (Colch)** 1998 Oct;95(4):397–407
Effects in vivo of decreased plasma and intracellular muscle glutamine concentration on whole-body and hindquarter protein kinetics in rats. Olde Damink SW, et al. **Clin Sci (Colch)** 1999 Jun;96(6):639–46
Glutamine: establishing clinical indications. Griffiths RD. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):177–82 (58 ref.)
In vivo investigation of glutamate-glutamine metabolism in hyperammonemic monkey brain using 13C-magnetic resonance spectroscopy. Tsukada Y, et al. **Dev Neurosci** 1998;20(4–5):427–33
Glucose regulation of glutaminolysis and its role in insulin secretion. Gao ZY, et al. **Diabetes** 1999 Aug;48(8):1535–42
Addressing substrate glutamine requirements for tissue transglutaminase using substance P analogues. Pastor MT, et al. **FEBS Lett** 1999 May 28;451(3):231–4
Glutamine-230 influences enzyme solubility but not catalysis in Streptomyces clavuligerus isopenicillin N synthase. Loke P, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):439–43
Effects of vascular or luminal administration and of simultaneous glucose availability on glutamine utilization by isolated rat small intestine. Plauth M, et al. **Int J Colorectal Dis** 1999 Apr;14(2):95–100
Effects of prolonged exercise on brain ammonia and amino acids. Guezennec CY, et al. **Int J Sports Med** 1998 Jul; 19(5):323–7
Energetic and morphological plasticity of C6 glioma cells grown on 3-D support; effect of transient glutamine deprivation. Martin M, et al. **J Bioenerg Biomembr** 1998 Dec;30(6):565–78
Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg1152 --> Gln insulin receptor. Miele C, et al. **J Biol Chem** 1999 Jan 29;274(5):3094–102
Glu-857 moderates K+-dependent stimulation and SCH 28080-dependent inhibition of the gastric H,K-ATPase. Rulli SJ, et al. **J Biol Chem** 1999 May 21;274(21):15245–50
Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. Mazurek S, et al. **J Cell Physiol** 1999 Oct;181(1):136–46
Blood-brain barrier glutamine transport during normoglycemic and hyperglycemic focal cerebral ischemia. Kawai N, et al. **J Cereb Blood Flow Metab** 1999 Jan; 19(1):79–86
In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. Blüml S. **J Magn Reson** 1999 Feb;136(2):219–25
DNA distortion and multimerization: novel functions of the glutamine-rich domain of GAGA factor. Wilkins RC, et al. **J Mol Biol** 1999 Jan 15;285(2):515–25
Formation of N-pyroglutamyl peptides from N-Glu and N-Gln precursors in Aplysia neurons. Garden RW, et al. **J Neurochem** 1999 Feb;72(2):676–81
Synthesis of vesicular GABA from glutamine involves TCA cycle metabolism in neocortical neurons. Waagepetersen HS, et al. **J Neurosci Res** 1999 Aug 1;57(3):342–9
Food deprivation and refeeding influence growth, nutrient retention and functional recovery of rats. Boza JJ, et al. **J Nutr** 1999 Jul;129(7):1340–6
Short bowel syndrome, intestinal permeability and glutamine [letter; comment] Brewster D, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):614–6. Comment on: J Pediatr Gastroenterol Nutr 1998 Feb;26(2):123–8.
Integrin and cytoskeletal involvement in signalling cell volume changes to glutamine transport in rat skeletal muscle. Low SY, et al. **J Physiol (Lond)** 1998 Oct 15;512 (Pt 2):481–5
Reactivating tammar wallaby blastocysts oxidize fatty acids and amino acids. Spindler RE, et al. **J Reprod Fertil** 1999 Jan;115(1):79–86
Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Stumvoll M, et al. **Kidney Int** 1999 Mar;55(3):778–92 (218 ref.)
Localized 15N NMR spectroscopy of rat brain by ISIS. Kanamori K, et al. **Magn Reson Med** 1999 Mar;41(3):456–63
Whole-body protein metabolism assessed by leucine and glutamine kinetics in adult patients with active celiac disease. Messing B, et al. **Metabolism** 1998 Dec; 47(12):1429–33
Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Stumvoll M, et al. **Metabolism** 1998 Oct;47(10):1227–32
Glutamine biosynthesis and the utilization of succinate and glutamine by Rhizobium etli and Sinorhizobium meliloti. Encarnación S, et al. **Microbiology** 1998 Sep;144 (Pt 9):2629–38
Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Saluja D, et al. **Mol Cell Biol** 1998 Oct;18(10):5734–43
Glutamine, as a precursor of glutathione, and oxidative stress. Amores-Sánchez MI, et al. **Mol Genet Metab** 1999 Jun; 67(2):100–5 (47 ref.)
Metabolism of glucose, pyruvate, and glutamine during the maturation of oocytes derived from pre-pubertal and adult cows. Steeves TE, et al. **Mol Reprod Dev** 1999 Sep; 54(1):92–101
Inhibition of glutamine transport in rat brain mitochondria by some amino acids and tricarboxylic acid cycle intermediates. Roberg B, et al. **Neurochem Res** 1999 Jul; 24(7):809–14
Glutamine transport in rat brain synaptic and non-synaptic mitochondria. Roberg B, et al. **Neurochem Res** 1999 Mar; 24(3):383–90
1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Pioro EP, et al. **Neurology** 1999 Jul 13;53(1):71–9
Re: Glutamine homologues and derivatives: a limiting factor in current artificial nutrition by F.H.R. Pesty, PharmD and F. Sultan, PhD [letter; comment] Fürst P, et al. **Nutrition** 1999 Jan;15(1):75–7. Comment on: Nutrition 1997 Jun;13(6):575–7.
In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics. Rothman DL, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jul 29; 354(1387):1165–77 (65 ref.)
Regulation of nitrate reductase transcript levels by glutamine accumulating in the leaves of a ferredoxin-dependent glutamate synthase-deficient gluS mutant of Arabidopsis thaliana, and by glutamine provided via the roots. Dzuibany C, et al. **Planta** 1998 Nov;206(4):515–22
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Shen J, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8235–40
A comparison of the effects of clonidine and CNQX infusion into the locus coeruleus and the amygdala on naloxone-precipitated opiate withdrawal in the rat. Taylor JR, et al. **Psychopharmacology (Berl)** 1998 Jul;138(2):133–42
Swimming-exercise increases the capacity of perfused rat liver to produce urea from ammonia and L-glutamine. Ferreira EB, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec;102(3):289–303
Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. Petroff OA, et al. **Seizure** 1999 Apr;8(2):120–7
Glutamine and transforming growth factor-alpha stimulate extracellular regulated kinases and enhance recovery of villous surface area in porcine ischemic-injured intestine. Blikslager AT, et al. **Surgery** 1999 Feb;125(2):186–94
[Cachexia in cancer: disturbances in the protein and aminoacid metabolism] de Blaauw I, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3;143(27):1408–13 (60 ref.) (Eng. Abstr.) **(Dut)**
[Glutamine and the liver cell: metabolism, properties and the concept of metabolic regulation by cell swelling] Lavoinne A, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):557–62 (31 ref.) (Eng. Abstr.) **(Fre)**
[Glutamine--its metabolic role and possibilities for clinical use] Turczynowski W, et al. **Przegl Lek** 1998;55(12):659–62 (14 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Examination of metabolism of viscera drained by the portal vein in neonatal calves, using short-term intravenous infusions of glutamine and other nutrients. Nappert G, et al. **Am J Vet Res** 1999 Apr;60(4):437–45
Nutrient uptake by viscera drained by the portal vein in neonatal calves during intravenous infusion of glutamine. Nappert G, et al. **Am J Vet Res** 1999 Apr;60(4):446–51
Absence of glutamine isotopic steady state: implications for the assessment of whole-body glutamine production rate. Van Acker BA, et al. **Clin Sci (Colch)** 1998 Sep; 95(3):339–46
Kinetic analysis of L-glutamine transport into porcine jejunal enterocyte brush-border membrane vesicles. Fan MZ, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Dec; 121(4):411–22
Glutamine uptake at the blood-brain barrier is mediated by N-system transport. Ennis SR, et al. **J Neurochem** 1998 Dec;71(6):2565–73

PHARMACOLOGY

Effect of glutamine on the intestinal permeability changes induced by indomethacin in humans. Hond ED, et al. **Aliment Pharmacol Ther** 1999 May;13(5):679–85
Effect of intravenous glutamine on duodenal mucosa protein synthesis in healthy growing dogs. Marchini JS, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E747–53
Effects of glutamine supplementation of an amino acid-based purified diet on intestinal mucosal integrity in cats with methotrexate-induced enteritis. Marks SL, et al. **Am J Vet Res** 1999 Jun;60(6):755–63
Induction of gadd153 mRNA by nutrient deprivation is overcome by glutamine. Huang Q, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):225–31
Glutamine: a potentially useful supplement for athletes. Antonio J, et al. **Can J Appl Physiol** 1999 Feb;24(1):1–14 (64 ref.)
Is alpha-ketoisocaproyl-glutamine a suitable glutamine precursor to sustain fibroblast growth? Coudray-Lucas C, et al. **Clin Nutr** 1999 Feb;18(1):29–33
L-argine-nitric oxide metabolism. Glutamine: a new player in this metabolic game? [editorial; comment] Roth E. **Clin Nutr** 1998 Feb;17(1):1–2 (15 ref.). Comment on: Clin Nutr 1998 Feb;17(1):11–4.
Cytokine production by human peripheral blood mononuclear cells: differential senstivity to glutamine availability. Yaqoob P, et al. **Cytokine** 1998 Oct; 10(10):790–4
The effects of glutamine on intestinal epithelial cell proliferation in parenterally fed rats. Mandir N, et al.

Gut 1999 May;44(5):608–14

Is glutamine essential for the maintenance of intestinal function? A study in the isolated perfused rat small intestine. Plauth M, et al. **Int J Colorectal Dis** 1999 Apr; 14(2):86–94

Effect of oral glutamine on whole body carbohydrate storage during recovery from exhaustive exercise. Bowtell JL, et al. **J Appl Physiol** 1999 Jun;86(6):1770–7

Intravenous glutamine or short-chain fatty acids reduce central venous catheter infection in a model of total parenteral nutrition. McAndrew HF, et al. **J Pediatr Surg** 1999 Feb;34(2):281–5

Acute L-glutamine ingestion does not improve maximal effort exercise. Haub MD, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):240–4

Glutamine protects against doxorubicin-induced cardiotoxicity. Cao Y, et al. **J Surg Res** 1999 Jul; 85(1):178–82

Glucose and glutamine gavage increase portal vein nitric oxide metabolite levels via adenosine A2b activation. Matheson PJ, et al. **J Surg Res** 1999 Jun 1;84(1):57–63

Glutamine attenuates leukocyte-endothelial cell adhesion in indomethacin-induced intestinal inflammation in the rat. Arndt H, et al. **JPEN J Parenter Enteral Nutr** 1999 Jan-Feb;23(1):12–8

Glutamine reduces phorbol-12,13-dibutyrate-induced macromolecular hyperpermeability in HT-29Cl.19A intestinal cells. Kouznetsova L, et al. **JPEN J Parenter Enteral Nutr** 1999 May-Jun;23(3):136–9

Effects of glutamine administration on liver regeneration following hepatectomy. Ito A, et al. **Nutrition** 1999 Jan; 15(1):23–8

An increase in mucosal insulin-like growth factor II content in postresectional rat intestine suggests autocrine or paracrine growth stimulation. Wirén M, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1080–6

Protective effects of the amino acid glutamine and of ascorbic acid against chromosomal damage induced by doxorubicin in mammalian cells. Tavares DC, et al. **Teratog Carcinog Mutagen** 1998;18(4):153–61

Expression of heat shock proteins induced by L(+)-glutamine injection and survival of hypothermically stored heart grafts. Kojima R, et al. **Transplant Proc** 1998 Nov;30(7):3746–7

Glutamine-induced heme oxygenase-1 protects intestines and hearts from warm ischemic injury. Tamaki T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1018–9

PHYSIOLOGY

The Glu residue in the conserved Asn-Glu-Pro sequence of endoglycoceramidase is essential for enzymatic activity. Sakaguchi K, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):89–93

Glutamine and regulation of gene expression in rat hepatocytes: the role of cell swelling. Lavoinne A, et al. **Biochimie** 1998 Oct;80(10):807–11 (31 ref.)

The role of glutamine, serum and energy factors in growth of enterocyte-like cell lines. Wirén M, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1331–6

The glutamine-rich domain of the Drosophila GAGA factor is necessary for amyloid fibre formation in vitro, but not for chromatin remodelling. Agianian B, et al. **J Mol Biol** 1999 Jan 15;285(2):527–44

Presynaptic long-term depression at a central glutamatergic synapse: a role for CaMKII. Margrie TW, et al. **Nat Neurosci** 1998 Sep;1(5):378–83

Role of glutamate receptors and glutamate transporters in the regulation of the glutamate-glutamine cycle in the awake rat. Segovia G, et al. **Neurochem Res** 1999 Jun; 24(6):779–83

Re: Glutamine homologues and derivatives: a limiting factor in current artificial nutrition by F.H.R. Pesty, PharmD and F. Sultan, PhD [letter; comment] Fürst P, et al. **Nutrition** 1999 Jan;15(1):75–7. Comment on: Nutrition 1997 Jun;13(6):575–7.

The Sixth John M. Kinney International Awards for Nutrition and Metabolism . "Glutamine-enhanced bacterial killing by neutrophils from postoperative patients": background [see comments] Furukawa S. **Nutrition** 1999 Jun;15(6):439–42 (37 ref.). Comment in: Nutrition 1999 Jun;15(6):443.

The role of glutamine in modulating the body's immune function [comment] Sriram K. **Nutrition** 1999 Jun;15(6):443 . Comment on: Nutrition 1999 Jun;15(6):439–42.

Glutamine, exercise and immune function. Links and possible mechanisms. Walsh NP, et al. **Sports Med** 1998 Sep; 26(3):177–91 (96 ref.)

[Nutritional importance of glutamine] de Vasconcelos MI, et al. **Arq Gastroenterol** 1998 Jul-Sep;35(3):207–15 (41 ref.) (Eng. Abstr.) **(Por)**

THERAPEUTIC USE

Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Okuno SH, et al. **Am J Clin Oncol** 1999 Jun;22(3):258–61

The role of glutamine in skeletal muscle ischemia/reperfusion injury in the rat hind limb model. Prem JT, et al. **Am J Surg** 1999 Aug;178(2):147–50

Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Anderson PM, et al. **Bone Marrow Transplant** 1998 Aug;22(4):339–44

Glutamine in the support of patients following bone marrow transplantation [see comments] Wilmore DW, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):323–7 (34 ref.). Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313–4.

L-glutamine enemas attenuate mucosal injury in experimental colitis. Kaya E, et al. **Dis Colon Rectum** 1999 Sep; 42(9):1209–15

Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Decker-Baumann C, et al. **Eur J Cancer** 1999 Feb;35(2):202–7

Glutamine in parenteral nutrition: more food for thought [comment] Elia M. **Gut** 1999 Jul;45(1):6–7. Comment on: Gut 1999 Jul;45(1):82–8.

A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition [see comments] Powell-Tuck J, et al. **Gut** 1999 Jul;45(1):82–8. Comment in: Gut 1999 Jul;45(1):6–7.

Total parenteral nutrition with glutamine dipeptide shortened hospital stays and improved immune status and nitrogen economy after major abdominal surgery. Powell-Tuck J. **Gut** 1999 Feb;44(2):155

Glutamine treatment of paclitaxel-induced myalgias and arthralgias [letter; comment] Savarese D, et al. **J Clin Oncol** 1998 Dec;16(12):3918–9. Comment on: J Clin Oncol 1997 Jun;15(6):2385–93.

Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. Den Hond E, et al. **JPEN J Parenter Enteral Nutr** 1999 Jan-Feb; 23(1):7–11

Treating patients with severe sepsis [letter; comment] Felbinger TW, et al. **N Engl J Med** 1999 Jul 1;341(1):56–7 . Comment on: N Engl J Med 1999 Jan 21;340(3):207–14.

Is glutamine a pretender to the throne? [editorial] Abcouwer SF, et al. **Nutrition** 1999 Jan;15(1):71–2

Enteral administration of glutamine in purulent peritonitis. Furukawa S, et al. **Nutrition** 1999 Jan;15(1):29–31

[Comparative study of the evolution of inflammatory colitis treated with an elemental diet, glutamine and 5-ASA. An experimental study in rats] Biondo-Simões M de L, et al. **Arq Gastroenterol** 1998 Apr-Jun;35(2):116–25 (Eng. Abstr.) **(Por)**

TOXICITY

Gamma-glutamyl transpeptidase-dependent mutagenicity and cytotoxicity of gamma-glutamyl derivatives: a model for biochemical targeting of chemotherapeutic agents. Keren R, et al. **Environ Mol Mutagen** 1998;32(4):377–86

GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING)

BIOSYNTHESIS

Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Cooksey RC, et al. **Endocrinology** 1999 Mar;140(3):1151–7

Overexpression of L-glutamine:D-fructose-6-phosphate amidotransferase provides resistance to methylmercury in Saccharomyces cerevisiae. Miura N, et al. **FEBS Lett** 1999 Sep 17;458(2):215–8

CHEMISTRY

Oligomeric structure and regulation of Candida albicans glucosamine-6-phosphate synthase. Milewski S, et al. **J Biol Chem** 1999 Feb 12;274(7):4000–8

The mechanism of sugar phosphate isomerization by glucosamine 6-phosphate synthase. Teplyakov A, et al. **Protein Sci** 1999 Mar;8(3):596–602

Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: evidence from a 1.6 A crystal structure of the isomerase domain. Teplyakov A, et al. **Structure** 1998 Aug 15;6(8):1047–55

GENETICS

Overexpression of L-glutamine:D-fructose-6-phosphate amidotransferase provides resistance to methylmercury in Saccharomyces cerevisiae. Miura N, et al. **FEBS Lett** 1999 Sep 17;458(2):215–8

cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse. Oki T, et al. **Genomics** 1999 Apr 15;57(2):227–34

Cloning and sequence analysis of Histoplasma capsulatum glucosamine-6-phosphate synthase gene fragment. Sachadyn P, et al. **Mycopathologia** 1998;142(2):67–70

Chlorella virus PBCV-1 encodes functional glutamine: fructose-6-phosphate amidotransferase and UDP-glucose dehydrogenase enzymes. Landstein D, et al. **Virology** 1998 Oct 25;250(2):388–96

ISOLATION & PURIFICATION

Oligomeric structure and regulation of Candida albicans glucosamine-6-phosphate synthase. Milewski S, et al. **J Biol Chem** 1999 Feb 12;274(7):4000–8

METABOLISM

Effects of eicosapentaenoic acid and its 15-hydroperoxy and 15-hydroxy derivatives on glucosamine synthetase activity in rabbit gastric mucosa. Fujita T, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):157–63

Regulation of glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase. Zhou J, et al. **Diabetes** 1998 Dec;47(12):1836–40

GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING)

GENETICS

Glutamine: fructose-6-phosphate amidotransferase activity and gene expression are regulated in a tissue-specific fashion in pregnant rats. Yki-Järvinen H, et al. **Life Sci** 1999;65(2):215–23

METABOLISM

Glutamine: fructose-6-phosphate amidotransferase activity and gene expression are regulated in a tissue-specific fashion in pregnant rats. Yki-Järvinen H, et al. **Life Sci** 1999;65(2):215–23

GLUTAMINE KETOGLUTARATE AMIDOTRANSFERASE see **GLUTAMATE SYNTHASE**

GLUTAMINE PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE see **AMIDOPHOSPHORIBOSYLTRANSFERASE**

GLUTAMINE-SPECIFIC TRNA see **RNA, TRANSFER, GLN**

GLUTAMINE SYNTHETASE see **GLUTAMATE-AMMONIA LIGASE**

GLUTAMINYL-PEPTIDE GAMMA-GLUTAMYLTRANSFERASE see **PROTEIN-GLUTAMINE GAMMA-GLUTAMYLTRANSFERASE**

GLUTAMYL T RNA SYNTHETASE see **GLUTAMATE-TRNA LIGASE**

GLUTAMYL TRANSPEPTIDASE see **GAMMA-GLUTAMYLTRANSFERASE**

GLUTARAL

Morphology of human neutrophils: a comparison of cryofixation, routine gluteraldehyde fixation, and the effects of dimethyl sulfoxide. Gilbert CS, et al. **Anat Rec** 1998 Oct;252(2):254–63

Quantitation of adsorption and conjugation of plasma proteins by residual glutaraldehyde in fixed collagenous tissue with radioiodinated plasma proteins. Setiawan T, et al. **ASAIO J** 1998 Sep-Oct;44(5):M445–8

Biocompatibility studies of anionic collagen membranes with different degree of glutaraldehyde cross-linking. Goissis G, et al. **Biomaterials** 1999 Jan;20(1):27–34

Biaxial mechanical/structural effects of equibiaxial strain during crosslinking of bovine pericardial xenograft materials. Langdon SE, et al. **Biomaterials** 1999 Jan; 20(2):137–53

Biocompatibility study of a biological tissue fixed with a naturally occurring crosslinking reagent. Huang LL, et al. **J Biomed Mater Res** 1998 Dec 15;42(4):568–76

High-level disinfection with 2% alkalinized glutaraldehyde solution for reuse of laparoscopic disposable plastic trocars [letter; comment] Zayyan KS, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):117–8. Comment on: J Laparoendosc Adv Surg Tech A 1998 Feb;8(1):47–52.

ADVERSE EFFECTS

Does glutaraldehyde induce calcification of bioprosthetic tissues? Vincentelli A, et al. **Ann Thorac Surg** 1998 Dec; 66(6 Suppl):S255–8

Glutaraldehyde as a possible cause of diarrhoea after sigmoidoscopy. Hanson JM, et al. **Br J Surg** 1998 Oct; 85(10):1385–7

CT findings of glutaraldehyde colitis: a report of two cases. Zissin R, et al. **Clin Radiol** 1999 Feb;54(2):123–5

[Glutaraldehyde-induced colitis. A case studied with contrast media enema and computerized tomography] Catalano O, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):126–7 **(Ita)**

ANALYSIS

Chiral separation of DL-tryptophan using porous membranes containing multilayered bovine serum albumin crosslinked with glutaraldehyde. Nakamura M, et al. **J Chromatogr A** 1998 Sep 25;822(1):53–8

CHEMISTRY

Assessment of glutaraldehyde crosslinking efficiency with an amine-specific fluorescent probe. Ricks J, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S240-4

Optimization of protease immobilization by covalent binding using glutaraldehyde. Chae HJ, et al. **Appl Biochem Biotechnol** 1998 May-Jun;73(2-3):195-204

Biological effects and cytotoxicity of the composite composed by tricalcium phosphate and glutaraldehyde cross-linked gelatin. Lin FH, et al. **Biomaterials** 1998 May; 19(10):905-17

Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. Doyle MP, et al. **J Biol Chem** 1999 Jan 22;274(4):2583-91

Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. Adami RC, et al. **J Pharm Sci** 1999 Aug;88(8):739-46

[Adsorption on synthetic membranes and immunogenic properties of aprotinin cross-linked by glutaraldehyde] Timofeeva TA, et al. **Bioorg Khim** 1999 Apr;25(4):264-9 (Eng. Abstr.) **(Rus)**

METABOLISM

Role of glutaraldehyde in calcification of porcine aortic valve fibroblasts [see comments] Kim KM, et al. **Am J Pathol** 1999 Mar;154(3):843-52. Comment in: Am J Pathol 1999 Mar;154(3):671-5.

PHARMACOLOGY

Efficacy of peroxygen compounds against glutaraldehyde-resistant mycobacteria. Stanley PM. **Am J Infect Control** 1999 Aug;27(4):339-43

Comparison of cytokine secretion profiles provoked in mice by glutaraldehyde and formaldehyde. Dearman RJ, et al. **Clin Exp Allergy** 1999 Jan;29(1):124-32

The effect of daunorubicin and glutaraldehyde treatment on the structure of erythrocyte membrane. Szwarocka A, et al. **Int J Pharm** 1999 Apr 20;181(1):117-23

Reduced glutaraldehyde susceptibility in Mycobacterium chelonae associated with altered cell wall polysaccharides. Manzoor SE, et al. **J Antimicrob Chemother** 1999 Jun; 43(6):759-65

Ortho-phthalaldehyde: a possible alternative to glutaraldehyde for high level disinfection. Walsh SE, et al. **J Appl Microbiol** 1999 Jun;86(6):1039-46

The efficacy of three common hospital liquid germicides to inactivate Cryptosporidium parvum oocysts. Wilson JA, et al. **J Hosp Infect** 1999 Jul;42(3):231-7

Evaluation of the efficacy of glutaraldehyde and peroxygen for disinfection of dental instruments. Angelillo IF, et al. **Lett Appl Microbiol** 1998 Nov;27(5):292-6

Fluorescence spectroscopy monitoring of the conformational restraint of formaldehyde- and glutaraldehyde-treated infectious bursal disease virus proteins. Cepica A, et al. **Vaccine** 1998 Dec;16(20):1957-61

POISONING

In-vivo glutaraldehyde fixation of the brain stem and spinal cord after inadvertent intrathecal injection. Davis JH, et al. **J Forensic Sci** 1998 Nov;43(6):1232-6

THERAPEUTIC USE

Gelatin-resorcinol-formaldehyde-glutaraldehyde glue for sealing pulmonary air leaks during thoracoscopic operation. Nomori H, et al. **Ann Thorac Surg** 1999 Jan;67(1):212-6

No-React anticalcification tissue treatment results with stentless heart valves in two adolescents. Milo S, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1222-3

[An effective case of a new biological adhesive agent, gelatin-resorcinol formaldehyde-glutaralhyde glue (GRFG-glue) in treating refractory pulmonary fistula following lobectomy for pulmonary aspergilloma] Umemori Y, et al. **Kyobu Geka** 1999 Sep;52(10):872-4 (Eng. Abstr.) **(Jpn)**

TOXICITY

Glutaraldehyde-induced esophageal injury. Histologic study of laboratory rats. Isserow JA, et al. **Invest Radiol** 1998 Oct;33(10):730-3

GLUTARALDEHYDE see **GLUTARAL**

GLUTARALDEHYDE-STABILIZED GRAFTS see **BIOPROSTHESIS**

GLUTARATES

BLOOD

Quantification of glutaric acid by isotope dilution mass spectrometry for patients with glutaric acidemia type I: selected ion monitoring vs. selected ion storage. Hagen T, et al. **Clin Chim Acta** 1999 Apr;282(1-2):185-95

CHEMICAL SYNTHESIS

Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis. Shah JH, et al. **J Med Chem** 1999 Aug 12;42(16):3014-7

Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents. Sun IC, et al. **J Med Chem** 1998 Nov 5;41(23):4648-57

CHEMISTRY

Identification and characterization of kinetically competent carbinolamine and alpha-iminoglutarate complexes in the glutamate dehydrogenase-catalyzed oxidation of L-glutamate using a multiwavelength transient state approach. Maniscalco SJ, et al. **Biochemistry** 1998 Oct 13; 37(41):14585-90

METABOLISM

Hypoketotic hypoglycemic coma in a 21-month-old child. Hostetler MA, et al. **Ann Emerg Med** 1999 Sep;34(3):394-8

3-Hydroxyglutaric and glutaric acids are neurotoxic through NMDA receptors in vitro. Kölker S, et al. **J Inherit Metab Dis** 1999 May;22(3):259-62

Glutaric aciduria type I: pathomechanisms of neurodegeneration. Ullrich K, et al. **J Inherit Metab Dis** 1999 Jun;22(4):392-403

PHARMACOLOGY

Pharmacology of G-1-64, a new nondepolarizing neuromuscular blocking agent with rapid onset and short duration of action. Gyermek L, et al. **Acta Anaesthesiol Scand** 1999 Jul;43(6):651-7

Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acid. Lima TT, et al. **Brain Res** 1998 Aug 17; 802(1-2):55-60

Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Perez JM, et al. **Chem Biol Interact** 1999 Jan 29;117(2):99-115

LY339434, a GluR5 kainate receptor agonist. Small B, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1261-7

URINE

Facial anomalies in D-2-hydroxyglutaric aciduria. Amiel J, et al. **Am J Med Genet** 1999 Sep 10;86(2):124-9 (12 ref.)

Novel mutations of the glutaryl-CoA dehydrogenase gene in two Japanese patients with glutaric aciduria type I. Ikeda H, et al. **Am J Med Genet** 1998 Dec 4;80(4):327-9

D-2-Hydroxyglutaric aciduria: biochemical marker or clinical disease entity? van der Knaap MS, et al. **Ann Neurol** 1999 Jan;45(1):111-9

Recurrent fetal polycystic kidneys associated with glutaric aciduria type II. Kjaergaard S, et al. **APMIS** 1998 Dec; 106(12):1188-93

Abuse or metabolic disorder [letter; comment] Champion MP, et al. **Arch Dis Child** 1999 Jan;80(1):100. Comment on: Arch Dis Child 1998 Apr;78(4):399.

Glutaric aciduria and suspected child abuse. Morris AA, et al. **Arch Dis Child** 1999 May;80(5):404-5

Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in glutaric aciduria type 1: clinical and MRI correlations. Al-Essa M, et al. **Brain Dev** 1998 Aug;20(5):295-301

18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in type IV 3-methylglutaconic aciduria: clinical and MRI correlations. Al-Essa M, et al. **Brain Dev** 1999 Jan; 21(1):24-9

Glutaric aciduria type I with high residual glutaryl-CoA dehydrogenase activity. Pineda M, et al. **Dev Med Child Neurol** 1998 Dec;40(12):840-2

L-2-hydroxyglutaric aciduria and lactic acidosis. Barth PG, et al. **J Inherit Metab Dis** 1998 Jun;21(3):251-4

Feasibility of molecular prenatal diagnosis of glutaric aciduria type I in chorionic villi. Busquets C, et al. **J Inherit Metab Dis** 1998 Jun;21(3):243-6

3-Methylglutaconic aciduria and hypermethioninaemia in a child with clinical and neuroradiological findings of Leigh disease. Di Rocco M, et al. **J Inherit Metab Dis** 1999 Jun; 22(5):593-8

Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. Hoffmann GF, et al. **J Inherit Metab Dis** 1999 Jun;22(4):381-91 (30 ref.)

3-Methylglutaconic aciduria associated with hepatosplenomegaly, macrocytic anaemia, fever episodes, recurrent infections, cervical lymphadenopathy and progressive decrease of physical performance. Holtmann MH, et al. **J Inherit Metab Dis** 1998 Aug;21(6):683-5

Biochemistry of glutaric aciduria type I: activities of in vitro expressed wild-type and mutant cDNA encoding human glutaryl-CoA dehydrogenase. Liesert M, et al. **J Inherit Metab Dis** 1999 May;22(3):256-8

Normal acylcarnitines in maternal urine during a pregnancy affected by glutaric aciduria type II. Manning NJ, et al. **J Inherit Metab Dis** 1999 Feb;22(1):88-9

3-Methylglutaconic aciduria type I: clinical heterogeneity as a neurometabolic disease. Shoji Y, et al. **J Inherit Metab Dis** 1999 Feb;22(1):1-8

D-2-hydroxyglutaric aciduria: further clinical delineation. van der Knaap MS, et al. **J Inherit Metab Dis** 1999 Jun; 22(4):404-13

D-2-hydroxyglutaric aciduria: evidence of clinical and biochemical heterogeneity. Wagner L, et al. **J Inherit Metab Dis** 1998 Jun;21(3):247-50

What is the origin of 3-methylglutaconic acid? Walsh R, et al. **J Inherit Metab Dis** 1999 May;22(3):251-5

Recurrent rhabdomyolysis in a child with glutaric aciduria type I. Wilson CJ, et al. **J Inherit Metab Dis** 1999 Jun; 22(5):663-4

L-2-hydroxyglutaric aciduria: two Japanese adult cases in one family. Fujitake J, et al. **J Neurol** 1999 May; 246(5):378-82

X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)-MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273-6 (19 ref.). Comment on: J Pediatr 1999 Sep;135(3):311-5.

Genetic analysis of the G4.5 gene in families with suspected Barth syndrome [see comments] Cantlay AM, et al. **J Pediatr** 1999 Sep;135(3):311-5. Comment in: J Pediatr 1999 Sep;135(3):273-6.

Glutaryl-CoA dehydrogenase deficiency presenting as 3-hydroxyglutaric aciduria. Nyhan WL, et al. **Mol Genet Metab** 1999 Mar;66(3):199-204

Severe clinical course with recurrent hyperpyrexia in a patient with glutaric aciduria type I [letter] Hauser SE, et al. **Neuropediatries** 1999 Feb;30(1):51-2

L-2-Hydroxyglutaric aciduria: MRI in seven cases. D'Incerti L, et al. **Neuroradiology** 1998 Nov;40(11):727-33

Glutaric aciduria type I: ultrasonographic demonstration of early signs. Forstner R, et al. **Pediatr Radiol** 1999 Feb; 29(2):138-43

Subdural haematoma in a child with glutaric aciduria type I. Köhler M, et al. **Pediatr Radiol** 1998 Aug;28(8):582

[Glutaric aciduria type 1: phenotypic variability. Report of 6 patients] Casella EB, et al. **Arq Neuropsiquiatr** 1998 Sep; 56(3B):545-52 (Eng. Abstr.) **(Por)**

GLUTATHIONE

ADMINISTRATION & DOSAGE

Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. Roum JH, et al. **J Appl Physiol** 1999 Jul;87(1):438-43

Influence of buthionine sulfoximine and reduced glutathione on arecoline-induced chromosomal damage and sister chromatid exchange in mouse bone marrow cells in vivo. Deb S, et al. **Mutagenesis** 1998 May;13(3):243-8

ANALOGS & DERIVATIVES

Formation of gamma-glutamylpropargylglycylglycine from propargylglycine in human blood and erythrocytes. Nagamine N, et al. **Acta Med Okayama** 1999 Feb; 53(1):19-25

S-nitrosoglutathione enhances neutrophil DNA fragmentation and cell death. Fortenberry JD, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L435-42

Analysis of DNA adduct, S-[2-(N7-guanyl)ethyl]glutathione, by liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry. Huang H, et al. **Anal Biochem** 1998 Dec 1;265(1):139-50

Determination of S-nitrosoglutathione in human and rat plasma by high-performance liquid chromatography with fluorescence and ultraviolet absorbance detection after precolumn derivatization with o-phthalaldehyde. Tsikas D, et al. **Anal Biochem** 1999 Aug 15;273(1):32-40

Gas chromatographic-mass spectrometric detection of S-nitroso-cysteine and S-nitroso-glutathione. Tsikas D, et al. **Anal Biochem** 1999 Aug 1;272(2):117-22

Electrocatalytic reduction of S-nitrosoglutathione at electrodes modified with an electropolymerized film of a pyrrole-derived viologen system and their application to cellular S-nitrosoglutathione determinations. Wu Q, et al. **Anal Biochem** 1998 Oct 1;263(1):102-12

S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione. Ji Y, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):67-78

Fates and vascular action of S-nitrosoglutathione and related compounds in the circulation. Kashiba M, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):213-8

The role of glutathione and cysteine conjugates in the nephrotoxicity of o-xylene in rats. Morel G, et al. **Arch Toxicol** 1998 Sep;72(9):553-8

Induction of apoptosis by selenite and selenodiglutathione in HL-60 cells: correlation with cytotoxicity. Cho DY, et al. **Biochem Mol Biol Int** 1999 May;47(5):781-93

Role of mitogen-activated protein kinases in S-nitrosoglutathione-induced macrophage apoptosis. Callsen D, et al. **Biochemistry** 1999 Feb 23;38(8):2279-86

Inhibitory effects in vitro of S-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-glutathione, a proposed metabolite of L-histidine, on gamma-glutamyltransferase activity. Shimizu H, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):112-8

The Achilles' heel of trypanosomatids: trypanothione-mediated hydroperoxide metabolism. Flohé L. **Biofactors** 1998;8(1-2):87-91 (20 ref.)

S-(1,2-Dicarboxyethyl)glutathione in yeast: partial purification of its synthesizing enzyme. Tsuboi S, et al. **Biol Pharm Bull** 1999 Jan;22(1):21-5

Electrochemical studies of S-nitrosothiols. Hou Y, et al. **Bioorg Med Chem Lett** 1998 Nov 3;8(21):3065-70

Synthesis and activity of gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycine: a metabolically stable inhibitor of glyoxalase I. Vince R, et al. **Bioorg Med Chem Lett** 1999 Mar 22;9(6):853-6

Entamoeba histolytica: a eukaryote with trypanothione metabolism instead of glutathione metabolism. Ondarza RN, et al. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):47–52

Adaptive response to glutathione S-transferase inhibitors. Ciaccio PJ, et al. **Br J Cancer Suppl** 1996 Jul;27:S93–8 (47 ref.)

Radiation sensitisation by nitric oxide releasing agents. Mitchell JB, et al. **Br J Cancer Suppl** 1996 Jul;27:S181–4

Quinol-glutathione conjugate-induced mutation spectra in the supF gene replicated in human AD293 cells and bacterial MBL50 cells. Jeong JK, et al. **Cancer Res** 1999 Aug 1;59(15):3641–5

Inhibition effects of 5-S-glutathionyl-N-beta-alanyl-L-dopa analogues against Src protein tyrosine kinase. Zheng ZB, et al. **Chem Pharm Bull (Tokyo)** 1999 Jun;47(6):777–82

Selective inhibition of Src protein tyrosine kinase by analogues of 5-S-glutathionyl-beta-alanyl-L-dopa. Zheng ZB, et al. **Chem Pharm Bull (Tokyo)** 1998 Dec; 46(12):1950–1

Different inhibitory effects of 5-S-glutathionyl-beta-alanyl-L-dopa (5-S-GA-L-D) analogues on autophosphorylation and substrate phosphorylation of Src protein tyrosine kinase [letter] Zheng ZB, et al. **Chem Pharm Bull (Tokyo)** 1999 Jan; 47(1):136–7

Immunochemical analysis of quinol-thioether-derived covalent protein adducts in rodent species sensitive and resistant to quinol-thioether-mediated nephrotoxicity. Kleiner HE, et al. **Chem Res Toxicol** 1998 Nov; 11(11):1291–300

S-nitrosoglutathione reduces the rate of embolization in humans. Molloy J, et al. **Circulation** 1998 Oct 6; 98(14):1372–5

Diminished CYP2E1 expression and formation of 2-S-glutathionyl acetate, a glutathione conjugate derived from 1,1-dichloroethylene epoxide, in murine lung tumors. Forkert PG, et al. **Drug Metab Dispos** 1999 Jan;27(1):68–73

Protection of cultured gastric cells against tert-butyl hydroperoxide by glutathione isopropyl ester. Yamaguchi N, et al. **Eur J Pharmacol** 1998 Jun 26;351(3):363–9

Design and synthesis of glutathione analogues. Lucente G, et al. **Farmaco** 1998 Dec 30;53(12):721–35 (103 ref.)

The spawning pheromone cysteine-glutathione disulfide ('hereithione') arouses a multicomponent nuptial behavior and electrophysiological activity in Nereis succinea males. Ram JL, et al. **FASEB J** 1999 May;13(8):945–52

Induction of apoptosis of monocyte-macrophage lineage cells by 5-S-GAD. Hijikata M, et al. **FEBS Lett** 1999 Sep 3; 457(3):405–8

Evidence for peroxynitrite formation during S-nitrosoglutathione photolysis in air saturated solutions. Mutus B, et al. **FEBS Lett** 1999 Apr 16;449(1):79–82

Gender related differences in ATP-dependent transport of dinitrophenyl-glutathione conjugate across murine canalicular liver plasma membrane. Srivastava SK, et al. **FEBS Lett** 1999 Feb 26;445(2-3):291–4

S-nitrosoglutathione inhibits platelet activation and deposition in coronary artery saphenous vein grafts in vitro and in vivo. Salas E, et al. **Heart** 1998 Aug;80(2):146–50

Nitric oxide inactivates rat hepatic methionine adenosyltransferase In vivo by S-nitrosylation. Ruiz F, et al. **Hepatology** 1998 Oct;28(4):1051–7

S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. Balazy M, et al. **J Biol Chem** 1998 Nov 27;273(48):32009–15

Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. Chiche JD, et al. **J Biol Chem** 1998 Dec 18;273(51):34263–71

The vacuolar H+-ATPase of clathrin-coated vesicles is reversibly inhibited by S-nitrosoglutathione. Forgac M. **J Biol Chem** 1999 Jan 15;274(3):1301–5

Identification of glutathionyl-3-hydroxykynurenine glucoside as a novel fluorophore associated with aging of the human lens. Garner B, et al. **J Biol Chem** 1999 Jul 23;274(30):20847–54

Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. Pérez-Mato I, et al. **J Biol Chem** 1999 Jun 11; 274(24):17075–9

Degradation of S-nitrosocysteine in vascular tissue homogenates: role of divalent ions. Kostka P, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):665–70

The ectoenzyme gamma-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B lymphocytes. Henson SE, et al. **J Immunol** 1999 Aug 15;163(4):1845–52

A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides. Hamilton DS, et al. **J Med Chem** 1999 May 20; 42(10):1823–7

Intracellular redox state determines whether nitric oxide is toxic or protective to rat oligodendrocytes in culture. Rosenberg PA, et al. **J Neurochem** 1999 Aug;73(2):476–84

Glutathione monoethyl ester and inhibition of the oxyhemoglobin-induced increase in cytosolic calcium in cultured smooth-muscle cells. Arai T, et al. **J Neurosurg** 1999 Mar;90(3):527–32

Glutathone and glutathione ethyl ester supplementation of mice alter glutathione homeostasis during exercise. Leeuwenburgh C, et al. **J Nutr** 1998 Dec;128(12):2420–6

In vivo formation and localization of 1,1-dichloroethylene epoxide in murine liver: identification of its glutathione conjugate 2-S-glutathionyl acetate. Forkert PG. **J Pharmacol Exp Ther** 1999 Sep;290(3):1299–306

Glutathione conjugate interactions with DNA-dependent protein kinase. Shen H, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1101–6

Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester. Grattagliano I, et al. **J Surg Res** 1999 Sep;86(1):2–8

Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione. Mayers I, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1009–16

Identification of S-(1,2-dichlorovinyl)glutathione in the blood of human volunteers exposed to trichloroethylene. Lash LH, et al. **J Toxicol Environ Health** 1999 Jan 8; 56(1):1–21

Interference of S-alkyl derivatives of glutathione with brain ionotropic glutamate receptors. Jenei Z, et al. **Neurochem Res** 1998 Aug;23(8):1085–91

S-nitrosothiols are stored by platelets and released during platelet-neutrophil interactions. Hirayama A, et al. **Nitric Oxide** 1999;3(2):95–104

A new assay for the determination of low-molecular-weight nitrosothiols (nitrosoglutathione), NO, and nitrites by using a specific and sensitive solid-state amperometric gas sensor. Palmerini CA, et al. **Nitric Oxide** 1998;2(5):375–80

Endogenous glutathione conjugates: occurrence and biological functions. Wang W, et al. **Pharmacol Rev** 1998 Sep;50(3):335–56 (204 ref.)

Effects of S-nitrosoglutathione on acute vasoconstriction and glutamate release after subarachnoid hemorrhage. Sehba FA, et al. **Stroke** 1999 Sep;30(9):1955–61

Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Bond CS, et al. **Structure Fold Des** 1999 Jan 15;7(1):81–9

S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets. Howard CM, et al. **Thromb Res** 1998 Aug 1;91(3):113–20

Nitric oxide upregulates HLA-DR in human vascular endothelial cells. Simonson MS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):737–8

ANALYSIS

An improved monobromobimane assay for glutathione utilizing tris- (2-carboxyethyl)phosphine as the reductant. Anderson MT, et al. **Anal Biochem** 1999 Jul 15;272(1):107–9

5-(Pentafluorobenzoylamino)fluorescein: A selective substrate for the determination of glutathione concentration and glutathione S-transferase activity. Arttamangkul S, et al. **Anal Biochem** 1999 May 1;269(2):410–7

13C-Isotopic enrichment of glutathione in cell extracts determined by nuclear magnetic resonance spectroscopy. Gamcsik MP. **Anal Biochem** 1999 Jan 1;266(1):58–65

Simultaneous measurement of foliar glutathione, gamma-glutamylcysteine, and amino acids by high-performance liquid chromatography: comparison with two other assay methods for glutathione. Noctor G, et al. **Anal Biochem** 1998 Nov 1;264(1):98–110

Subcellular compartmentation of glutathione and glutathione precursors. A high resolution immunogold analysis of the outer retina of guinea pig. Huster D, et al. **Anat Embryol (Berl)** 1998 Oct;198(4):277–87

Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison. Tanaka T, et al. **Biochim Biophys Acta** 1999 May 24;1427(3):367–77

Localization of glutathione and induction of glutathione synthesis-related proteins in mouse brain by low doses of gamma-rays. Kojima S, et al. **Brain Res** 1998 Oct 19; 808(2):262–9

Immunocytochemical demonstration of reduced glutathione in neurons of rat forebrain. Maybodi L, et al. **Brain Res** 1999 Jan 30;817(1-2):199–205

DL-methionine supplementation of rice-and-bean diets affects gamma-glutamyltranspeptidase activity and glutathione content in livers of growing rats. De-Oliveira IM, et al. **Braz J Med Biol Res** 1999 Apr;32(4):483–8

Lipid peroxidation, antioxidant enzymes and glutathione levels in human erythrocytes exposed to colloidal iron hydroxide in vitro. Ferreira AL, et al. **Braz J Med Biol Res** 1999 Jun;32(6):689–94

Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery. Vahrmeijer AL, et al. **Cancer Chemother Pharmacol** 1999;44(2):111–6

Glutathione and ascorbate are negatively correlated with oxidative DNA damage in human lymphocytes. Lenton KJ, et al. **Carcinogenesis** 1999 Apr;20(4):607–13

Semiquantitative bioluminescent assay of glutathione. Romero FJ, et al. **J Biolumin Chemilumin** 1998 Sep-Oct; 13(5):263–6

17-Beta estradiol regulation of myocardial glutathione and its role in protection against myocardial stunning in dogs. Kim YD, et al. **J Cardiovasc Pharmacol** 1998 Sep; 32(3):457–65

Liver glutathione content and glutathione-dependent enzymes of two species of freshwater fish as bioindicators of chemical pollution. Almar M, et al. **J Environ Sci Health B** 1998 Nov;33(6):769–83

Reduced glutathione, gamma-glutamylcysteine, cysteine and gamma-glutamylglutamine in gamma-glutamyltransferase deficiency. Hammond JW, et al. **J Inherit Metab Dis** 1999 May;22(3):235–9

Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Asensi M, et al. **Methods Enzymol** 1999;299:267–76

Nonenzymatic colorimetric assay of glutathione in the presence of other mercaptans. Chaudiere J, et al. **Methods Enzymol** 1999;299:276–86

Measurement of glutathione, glutathione disulfide, and other thiols in mammalian cell and tissue homogenates using high-performance liquid chromatography separation of N-(1-pyrenyl)maleimide derivatives. Ridnour LA, et al. **Methods Enzymol** 1999;299:258–67

Reduced glutathione and glutathione disulfide. Browne RW, et al. **Methods Mol Biol** 1998;108:347–52

Alterations in superoxide dismutase activities, lipid peroxidation and glutathione levels in thinner inhaled rat lungs: relationship between histopathological properties. Ulakoğlu EZ, et al. **Pharmacol Res** 1998 Sep;38(3):209–14

Glutathione depletion and oxidative damage in mitochondria following exposure to cadmium in rat liver and kidney. Nigam D, et al. **Toxicol Lett** 1999 Jun 1;106(2-3):151–7

ANTAGONISTS & INHIBITORS

Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Ginsburg H, et al. **Biochem Pharmacol** 1998 Nov 15;56(10):1305–13

Induction of apoptosis in the CNS during development by the combination of hyperoxia and inhibition of glutathione synthesis. Taglialatela G, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):936–42

Chloroacetonitrile (CAN) induces glutathione depletion and 8-hydroxylation of guanine bases in rat gastric mucosa. Ahmed AE, et al. **J Biochem Mol Toxicol** 1999; 13(3-4):119–26

Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. Li H, et al. **J Neurochem** 1998 Nov;71(5):2049–62

Inhibition of glutathione synthesis with propargylglycine enhances N-acetylmethionine protection and methylation in bromobenzene-treated Syrian hamsters. Lertratanangkoon K, et al. **J Nutr** 1999 Mar;129(3):649–56

The expression of heme oxygenase-1 gene responded to oxidative stress produced by phorone, a glutathione depletor, in the rat liver: the relevance to activation of c-jun n-terminal kinase. Oguro T, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):773–8

Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Seyfried J, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):1–4

BIOSYNTHESIS

The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Griffith OW, et al. **Adv Enzymol Relat Areas Mol Biol** 1999;73:209–67, xii (188 ref.)

Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Jahoor F, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E205–11

Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase. Moellering D, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):74–82

The effect of prostaglandin E2 on cystine uptake and glutathione synthesis by human lung fibroblasts. Rishikof DC, et al. **Biochim Biophys Acta** 1998 Oct 21; 1405(1-3):155–60

Localization of glutathione and induction of glutathione synthesis-related proteins in mouse brain by low doses of gamma-rays. Kojima S, et al. **Brain Res** 1998 Oct 19; 808(2):262–9

Influence of intense sound exposure on glutathione synthesis in the cochlea. Yamasoba T, et al. **Brain Res** 1998 Aug 31;804(1):72–8

The effect of environmental conditions and glucose feeding in shaking flask on glutathione (GSH) production. Li Y, et al. **Chin J Biotechnol** 1998;14(2):85–91

Regulation of hepatic glutathione synthesis: current concepts and controversies. Lu SC. **FASEB J** 1999 Jul; 13(10):1169–83 (124 ref.)

Apocynin increases glutathione synthesis and activates AP-1 in alveolar epithelial cells. Lapperre TS, et al. **FEBS Lett** 1999 Jan 25;443(2):235–9

The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for gamma-glutamylcysteine synthetase and gamma-glutamyl

transpeptidase. Moellering D, et al. **FEBS Lett** 1999 Apr 9;448(2-3):292-6
Protective role of glutathione synthesis in response to oxidized low density lipoprotein in human vascular endothelial cells. Cho S, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):589-602
Development of glutathione synthesis and gamma-glutamyltranspeptidase activities in tissues from newborn infants. Lavoie JC, et al. **Free Radic Biol Med** 1998 Apr;24(6):994-1001
Molecular mechanism of the regulation of glutathione synthesis by tumor necrosis factor-alpha and dexamethasone in human alveolar epithelial cells. Rahman I, et al. **J Biol Chem** 1999 Feb 19;274(8):5088-96
Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. Iwata-Ichikawa E, et al. **J Neurochem** 1999 Jun; 72(6):2334-44
Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. Dringen R, et al. **J Neurosci** 1999 Jan 15; 19(2):562-9
Inhibition of glutathione synthesis with propargylglycine enhances N-acetylmethionine protection and methylation in bromobenzene-treated Syrian hamsters. Lertratanangkoon K, et al. **J Nutr** 1999 Mar;129(3):649-56
Glutathione synthetic activity in the lungs in newborn guinea pigs. Lavoie JC, et al. **Lung** 1999;177(1):1-7
The putative gene for the first enzyme of glutathione biosynthesis in Plasmodium berghei and Plasmodium falciparum. Birago C, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):33-40
N-acetylcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain. Dringen R, et al. **Neurosci Lett** 1999 Jan 8;259(2):79-82
Regulation of hepatic glutathione synthesis. Lu SC. **Semin Liver Dis** 1998;18(4):331-43 (127 ref.)

BLOOD

The impact of propylthiouracil therapy on lipid peroxidation and antioxidant status parameters in hyperthyroid patients. Seven A, et al. **Acta Med Okayama** 1999 Feb;53(1):27-30
Determination of plasma alpha-glutathione-S-transferases in chronic alcohol abusers: relationship with alcohol intake and liver involvement. Loguercio C, et al. **Alcohol Alcohol** 1998 Jul-Aug;33(4):366-72
Effects of dietary cysteine on blood sulfur amino acid, glutathione, and malondialdehyde concentrations in cats. Fettman MJ, et al. **Am J Vet Res** 1999 Mar;60(3):328-33
HPLC determination of glutathione and other thiols in human mononuclear blood cells. Raggi MA, et al. **Biomed Chromatogr** 1998 Sep-Oct;12(5):262-6
Lymphocyte glutathione levels in children with cystic fibrosis. Lands LC, et al. **Chest** 1999 Jul;116(1):201-5
Lymphocyte glutathione levels in acute leukemia. Singh Ghalaut V, et al. **Clin Chim Acta** 1999 Jul;285(1-2):85-9
Cysteine and glutathione in catabolic conditions and immunological dysfunction. Dröge W. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):227-33 (89 ref.)
'Erythrocyte glutathione system and children with Down syndrome' [letter] Mine IE, et al. **Dev Med Child Neurol** 1999 Feb;41(2):141-2
Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type I diabetic patients. Jain SK, et al. **Diabetes** 1999 Sep; 48(9):1850-5
Age-associated alteration of blood thiol-group-related antioxidants in smokers. Liu CS, et al. **Environ Res** 1999 Jan;80(1):18-24
Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate. Pennings HJ, et al. **Eur Respir J** 1999 Jun; 13(6):1260-6
Plasma levels of glutathione, alpha-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF alpha on glutathione synthesis. Kretzschmar M, et al. **Exp Toxicol Pathol** 1998 Sep; 50(4-6):477-83
Erythrocyte glutathione balance and membrane stability during preeclampsia. Spickett CM, et al. **Free Radic Biol Med** 1998 Apr;24(6):1049-55
Influence of cigarette smoking on Vitamin C, glutathione and lipid peroxidation status. Banerjee KK, et al. **Indian J Public Health** 1998 Jan-Mar;42(1):20-3
Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Schettler V, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2588-93
Plasma alpha-lipoic acid and total glutathione levels in patients on maintenance hemodialysis [letter] Reddi AS, et al. **Nephron** 1999;82(4):357
Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Knapen MF, et al. **Obstet Gynecol** 1998 Dec;92(6):1012-5
Age-related changes of plasma glutathione and cysteine in broilers: effect of dithiothreitol reduction vitro on free and bound pools. Wang S, et al. **Poult Sci** 1998 Aug; 77(8):1234-40
Oxidative stress in chronic renal failure. Martin-Mateo MC, et al. **Ren Fail** 1999 Mar;21(2):155-67
Glutathione status in liver and plasma during development of biliary cirrhosis after bile duct ligation. Purucker E, et al. **Res Exp Med (Berl)** 1998 Dec;198(4):167-74
Effect of alcohol and/or cocaine on blood glutathione and the ultrastructure of the liver of pregnant CF-1 mice. Afifi NM, et al. **Toxicol Lett** 1998 Sep 1;98(1-2):1-12
Toxicity of low levels of methylglyoxal: depletion of blood glutathione and adverse effect on glucose tolerance in mice. Ankrah NA, et al. **Toxicol Lett** 1999 Sep 20;109(1-2):61-7
Lowered antioxidant status of red blood cells in post-parturient haemoglobinuria of buffaloes. Chugh SK, et al. **Vet Res Commun** 1998 Sep;22(6):385-8
[Blood and leukocyte glutathione and glutathione S-transferase: relationship to cholesterolemia in healthy volunteers] Gannagé-Yared MH, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):321-7 (Eng. Abstr.) **(Fre)**

CEREBROSPINAL FLUID

Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Tohgi H, et al. **Neurosci Lett** 1999 Feb 5;260(3):204-6

CHEMICAL SYNTHESIS

Stereoselective formation of glutathione S-conjugates from halovinylmercapturate sulphoxides. Rosner E, et al. **Xenobiotica** 1999 Apr;29(4):327-40

CHEMISTRY

Is the glutathione conjugate of trans-4-hydroxy-2-nonenal transported by the multispecific organic anion transporting-ATPase of human erythrocytes? Dygas A, et al. **Acta Biochim Pol** 1998;45(1):59-65
Differential enantioselectivity of murine glutathione S-transferase isoenzymes in the glutathione conjugation of trans-3,4-dihydroxy-1, 2-oxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene stereoisomers. Hu X, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):40-8
Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties. Chakrabarti S, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1471-9
Crystal structure of a murine glutathione S-transferase in complex with a glutathione conjugate of 4-hydroxynon-2-enal in one subunit and glutathione in the other: evidence of signaling across the dimer interface. Xiao B, et al. **Biochemistry** 1999 Sep 14;38(37):11887-94
Identification of an enzymatically formed glutathione conjugate of the cyanobacterial hepatotoxin microcystin-LR: the first step of detoxication. Pflugmacher S, et al. **Biochim Biophys Acta** 1998 Nov 27;1425(3):527-33
Thiol/disulfide exchange between small heat shock protein 25 and glutathione. Zavialov AV, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):123-32
Naphthazarin derivatives (II): formation of glutathione conjugate, inhibition of DNA topoisomerase-I and cytotoxicity. Song GY, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2407-12
Additional pathways of S-conjugate formation during interaction of 4-nitrosophenetole with glutathione. Gallemann D, et al. **Chem Res Toxicol** 1998 Dec; 11(12):1411-22
Cysteine control over glutathione homeostasis in Chinese hamster fibroblasts overexpressing a gamma-glutamylcysteine synthetase activity. Vincent BR, et al. **Eur J Biochem** 1999 Jun;262(3):873-8
Membrane dipeptidase and glutathione are major components of pig pancreatic zymogen granules. Höfken T, et al. **Exp Cell Res** 1998 Nov 1;244(2):481-90
S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. Balazy M, et al. **J Biol Chem** 1998 Nov 27;273(48):32009-15
Surface characterization, protein adsorption, and initial cell-surface reactions on glutathione and 3-mercapto-1,2,-propanediol immobilized to gold. Kanagaraja S, et al. **J Biomed Mater Res** 1999 Sep 15; 46(4):582-91
On-column formation of arsenic-glutathione species detected by size-exclusion chromatography in conjunction with arsenic-specific detectors. Gailer J, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1-2):83-93
Production of glutathione-coated microtitre plates for capturing recombinant glutathione S-transferase fusion proteins as antigens in immunoassays. Murray AM, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):133-9
1H NMR studies of the reactions of copper(I) and copper(II) with D-penicillamine and glutathione. Kato N, et al. **J Inorg Biochem** 1999 Jun 15;75(2):117-21
Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: a proposed mechanism of brain retention. Nock BA, et al. **J Med Chem** 1999 Mar 25;42(6):1066-75
Stereoisomers of glutathione: preparation and enzymatic reactivities. Oikawa T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Apr;45(2):223-9

DEFICIENCY

alpha-Tocopherol and reduced glutathione deficiency and decreased deformability of erythrocytes after thermal skin injury. Bekyarova G, et al. **Acta Physiol Pharmacol Bulg** 1998;23(2):55-9
Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Jahoor F, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E205-11
Glutathione depletion induces giant DNA and high-molecular-weight DNA fragmentation associated with apoptosis through lipid peroxidation and protein kinase C activation in C6 glioma cells. Higuchi Y, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):33-42
Reduced glutathione accelerates the oxidative damage produced by sodium n-propylthiosulfate, one of the causative agents of onion-induced hemolytic anemia in dogs. Yamato O, et al. **Biochim Biophys Acta** 1999 Apr 19;1427(2):175-82
The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease. Marshall KA, et al. **Free Radic Biol Med** 1999 Sep; 27(5-6):515-20
(E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Selley ML. **Free Radic Biol Med** 1998 Jul 15;25(2):169-74
Exacerbation of copper toxicity in primary neuronal cultures depleted of cellular glutathione. White AR, et al. **J Neurochem** 1999 May;72(5):2092-8
Effects of glutathione depletion on oxidant-induced endothelial cell injury. Gilmont RR, et al. **J Surg Res** 1998 Nov;80(1):62-8
Changes in cardiac electrophysiology, morphology, tissue biochemistry and vascular reactions in glutathione depleted animals. Pacher P, et al. **Mol Cell Biochem** 1998 Aug; 185(1-2):183-90
Glutathione depletion causes an uncoupling effect on retinal horizontal cells through oxidative stress. Zhou ZY, et al. **Neuroscience** 1999;90(4):1493-9
Glutathione depletion increases brain susceptibility to m-dinitrobenzene neurotoxicity. Hu HL, et al. **Neurotoxicology** 1999 Feb;20(1):83-90
The glutathione-deficient, cadmium-sensitive mutant, cad2-1, of Arabidopsis thaliana is deficient in gamma-glutamylcysteine synthetase. Cobbett CS, et al. **Plant J** 1998 Oct;16(1):73-8
Glutathione therapy: from prodrugs to genes. Anderson ME, et al. **Semin Liver Dis** 1998;18(4):415-24 (84 ref.)
Disposition of inorganic mercury following biliary obstruction and chemically induced glutathione depletion: dispositional changes one hour after the intravenous administration of mercuric chloride. Zalups RK, et al. **Toxicol Appl Pharmacol** 1999 Jan 15;154(2):135-44
Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Shimizu M, et al. **Toxicol Sci** 1998 Oct; 45(2):204-11

DIAGNOSTIC USE

The heparin-glutathione test: an alternative to the hypo-osmotic swelling test to select viable sperm for intracytoplasmic sperm injection. Vendrell FJ, et al. **Fertil Steril** 1998 Dec;70(6):1156-61

DRUG EFFECTS

Beneficial effects of S-adenosyl-L-methionine on aminolevulinic acid dehydratase, glutathione, and lipid peroxidation during acute lead-ethanol administration in mice. Flora GJ, et al. **Alcohol** 1999 Jun-Jul;18(2-3):103-8
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Mulders TM, et al. **Clin Cancer Res** 1995 Dec;1(12):1525-36
Haloperidol-induced changes in glutathione and energy metabolism: effect of nicergoline. Vairetti M, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):67-72
Anethole dithiolethione, a putative neuroprotectant, increases intracellular and extracellular glutathione levels during starvation of cultured astroglial cells. Dringen R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):616-22
Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Böhm S, et al. **Oncology** 1999; 57(2):115-20
[A comparative evaluation of the action of kvamatel and omez on the glutathione system in different sections of the digestive system in experimental duodenal ulcer] Daminov ShN, et al. **Eksp Klin Farmakol** 1998 Jul-Aug;61(4):26-8 (Eng. Abstr.) **(Rus)**
[The effect of melatonin on photoperiod changes in the glutathione system of the brain under acute hypoxia] Zamors'kyi II, et al. **Fiziol Zh** 1999;45(4):69-76 (Eng. Abstr.) **(Ukr)**

METABOLISM

The influence of propolis ethanol extract on liver microsomal enzymes and glutathione after chronic alcohol administration. Lin SC, et al. **Am J Chin Med** 1999; 27(1):83-93
Effect of garlic active principle, diallyl disulfide, on cell viability, lipid peroxidation, glutathione concentration and

its related enzyme activities in primary rat hepatocytes. Sheen LY, et al. **Am J Chin Med** 1999;27(1):95–105

Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Celli A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G749–57

Abnormal glutathione transport in cystic fibrosis airway epithelia. Gao L, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):L113–8

Stimulation of cystine uptake by nitric oxide: regulation of endothelial cell glutathione levels. Li H, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C803–11

Peroxide-induced membrane blebbing in endothelial cells associated with glutathione oxidation but not apoptosis. van Gorp RM, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):C20–8

Ascorbate and glutathione homeostasis in vascular smooth muscle cells: cooperation with endothelial cells. Voskoboinik I, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1031–9

Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Comhair SA, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1824–9

Acrolein cytotoxicity and glutathione depletion in n-3 fatty acid sensitive- and resistant human tumor cells. Rudra PK, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):461–9

Purification, characterization, and glutathione binding to selenoprotein W from monkey muscle. Gu QP, et al. **Arch Biochem Biophys** 1999 Jan 1;361(1):25–33

Cellular responses to nitric oxide: role of protein S-thiolation/dethiolation. Padgett CM, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):232–42

Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Srivastava SK, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):89–94

Formation and export of the glutathione conjugate of 4-hydroxy-2, 3-E-nonenal (4-HNE) in hepatoma cells. Tjalkens RB, et al. **Arch Biochem Biophys** 1999 Jan 1; 361(1):113–9

Effect of betaine administration on metabolism of hepatic glutathione in rats. Kim SK, et al. **Arch Pharm Res** 1998 Dec;21(6):790–2

Effects of N-nitrosodimethylamine (NDMA) on the oxidative status of rat liver. Taniguchi M, et al. **Arch Toxicol** 1999 Apr-May;73(3):141–6

Determination of glutathione transferase (GSTT1-1) activities in different tissues based on formation of radioactive metabolites using 35S-glutathione. Thier R, et al. **Arch Toxicol** 1998 Dec;72(12):811–5

Vitamin C protects human arterial smooth muscle cells against atherogenic lipoproteins: effects of antioxidant vitamins C and E on oxidized LDL-induced adaptive increases in cystine transport and glutathione. Siow RC, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct; 18(10):1662–70

Glutathione and catalase provide overlapping defenses for protection against hydrogen peroxide in the yeast Saccharomyces cerevisiae. Grant CM, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):893–8

Glutathione-dependent oxidative modification of protoporphyrin and other dicarboxylic porphyrins by mammalian and plant peroxidases. Jacobs NJ, et al. **Biochem Biophys Res Commun** 1999 May 27;259(1):195–200

Regulation of 2-carboxy-D-arabinitol 1-phosphate phosphatase: activation by glutathione and interaction with thiol reagents. Heo J, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):409–16

Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Paulusma CC, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):393–401

ATP-dependent transport of reduced glutathione in yeast secretory vesicles. Rebbeor JF, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):723–9

Protection against hydrogen peroxide cytotoxicity in rat-1 fibroblasts provided by the oncoprotein Bcl-2: maintenance of calcium homoeostasis is secondary to the effect of Bcl-2 on cellular glutathione. Rimpler MM, et al. **Biochem J** 1999 May 15;340 (Pt 1):291–7

Pyrrolidine dithiocarbamate up-regulates the expression of the genes encoding the catalytic and regulatory subunits of gamma-glutamylcysteine synthetase and increases intracellular glutathione levels. Wild AC, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):659–65

Effects of the antiproliferative cyclopentenone prostaglandin A1 on glutathione metabolism in human cancer cells in culture. de Bittencourt PI Jr, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1255–64

Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. I. Differential expression in human cancer cell lines. de Bittencourt Júnior PI, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1227–41

Glutathione metabolism and glutathione S-conjugate export ATPase (MRP1/GS-X pump) activity in cancer. II. Cell-to-cell variability, relation with cellular activation state and functional absence of GS-X pump in lymphocytes. de Bittencourt Júnior PI, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1243–54

Modelling cortical cataractogenesis XX. In vitro effect of alpha-lipoic acid on glutathione concentrations in lens in model diabetic cataractogenesis. Kilic F, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):585–95

5-Azacytidine modulates gamma-glutamyltransferase and glutathione levels in two human prostatic adenocarcinoma cell lines. el Yaagoubi M, et al. **Biochem Mol Biol Int** 1998 Oct;46(2):321–31

Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Famin O, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):59–68

Role of glutathione and methylation in the biliary excretion of selenium. The paradoxical effect of sulfobromophthalein. Gyurasics A, et al. **Biochem Pharmacol** 1998 Nov 15; 56(10):1381–9

Renal cellular transport of exogenous glutathione: heterogeneity at physiological and pharmacological concentrations. Lash LH, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):897–907

Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Merad-Boudia M, et al. **Biochem Pharmacol** 1998 Sep 1;56(5):645–55

Interactions of prostaglandin A2 with the glutathione-mediated biotransformation system. van Iersel ML, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1383–90

An immortalized in vitro model of the blood-brain barrier: glutathione levels and sensitivity to oxidative stress. Dobbie MS, et al. **Biochem Soc Trans** 1998 Nov;26(4):S354

Astrocytic mitochondrial respiratory chain complex I activity and cellular GSH status. Stewart VC, et al. **Biochem Soc Trans** 1998 Nov;26(4):S345

Regulation of PTP1B via glutathionylation of the active site cysteine 215. Barrett WC, et al. **Biochemistry** 1999 May 18;38(20):6699–705

Ceruloplasmin has a distinct active site for the catalyzing glutathione-dependent reduction of alkyl hydroperoxide. Cha MK, et al. **Biochemistry** 1999 Sep 14;38(37):12104–10

Nicotinic acetylcholine receptor probed with a photoactivatable agonist: improved labeling specificity by addition of CeIV/glutathione. Extension to laser flash photolabeling. Grutter T, et al. **Biochemistry** 1999 Jun 8; 38(23):7476–84

The catalytic mechanism of the glutathione-dependent dehydroascorbate reductase activity of thioltransferase (glutaredoxin). Washburn MP, et al. **Biochemistry** 1999 Jan 5;38(1):268–74

Evidence for the proenkephalin processing enzyme prohormone thiol protease (PTP) as a multicatalytic cysteine protease complex: activation by glutathione localized to secretory vesicles. Yasothornsrikul S, et al. **Biochemistry** 1999 Jun 8;38(23):7421–30

The role of mitochondrial glutathione in DNA base oxidation. Giulivi C, et al. **Biochim Biophys Acta** 1998 Sep 7;1366(3):265–74

In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Koppal T, et al. **Biochim Biophys Acta** 1999 Mar 30;1453(3):407–11

Induction of cystine transport via system x-c and maintenance of intracellular glutathione levels in pancreatic acinar and islet cell lines. Sato H, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1-2):85–94

Specific interaction of methionine adenosyltransferase with free radicals. Avila MA, et al. **Biofactors** 1998;8(1-2):27–32

Oxidative stress: role of mitochondria and protection by glutathione. Fernández-Checa JC, et al. **Biofactors** 1998; 8(1-2):7–11 (21 ref.)

Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: role of glutathione. Obrador E, et al. **Biofactors** 1998;8(1-2):23–6 (20 ref.)

Influence of glutathione on zinc-mediated cellular toxicity. Walther UI, et al. **Biol Trace Elem Res** 1999 Feb; 67(2):97–107

Glutathione transport systems of the budding yeast Saccharomyces cerevisiae. Miyake T, et al. **Biosci Biotechnol Biochem** 1998 Oct;62(10):1858–64

Entamoeba histolytica: a eukaryote with trypanothione metabolism instead of glutathione metabolism. Ondarza RN, et al. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):47–52

Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Dai J, et al. **Blood** 1999 Jan 1;93(1):268–77

Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Tsukamoto N, et al. **Blood Cells Mol Dis** 1998 Jun; 24(2):231–8

Glutathione-linked enzymes in benign and malignant oesophageal tissue. Levy RD, et al. **Br J Cancer** 1999 Apr; 80(1-2):32–7

2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Sood C, et al. **Br J Cancer Suppl** 1996 Jul;27:S287–93

Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in vitro blood-brain barrier model system. Hurst RD, et al. **Brain Res** 1998 Aug 17;802(1-2):232–40

Net efflux of cysteine, glutathione and related metabolites from rat hippocampal slices during oxygen/glucose deprivation: dependence on gamma-glutamyl transpeptidase. Li X, et al. **Brain Res** 1999 Jan 2;815(1):81–8

Sodium cyanate alters glutathione homeostasis in rodent brain: relationship to neurodegenerative diseases in protein-deficient malnourished populations in Africa. Tor-Agbidye J, et al. **Brain Res** 1999 Feb 27;820(1-2):12–9

Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Wüllner U, et al. **Brain Res** 1999 Apr 24;826(1):53–62

Glutamate-induced cytotoxicity in PC12 pheochromocytoma cells: role of oxidation of phospholipids, glutathione and protein sulfhydryls revealed by bcl-2 transfection. Tyurin VA, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):270–81

Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Loe DW, et al. **Cancer Res** 1998 Nov 15;58(22):5130–6

Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Hanigan MH, et al. **Carcinogenesis** 1999 Apr;20(4):553–9

Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes. van Lieshout EM, et al. **Carcinogenesis** 1998 Oct;19(10):1873–5

Influence of glutathione levels and heat-shock on the steady-state levels of oxidative DNA base modifications in mammalian cells. Will O, et al. **Carcinogenesis** 1999 Feb; 20(2):333–7

Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and the loss of glutathione. Bojes HK, et al. **Cell Death Differ** 1999 Jan;6(1):61–70

Conjugation of isoprene monoepoxides with glutathione, catalyzed by alpha, mu, pi and theta-class glutathione S-transferases of rat and man. Bogaards JJ, et al. **Chem Biol Interact** 1999 Jan 1;117(1):1–14

Glutathione conjugation of perchloroethene in subcellular fractions from rodent and human liver and kidney. Dekant W, et al. **Chem Biol Interact** 1998 Nov 6;116(1-2):31–43

Ring addition of the alpha-amino group of glutathione increases the reactivity of benzoquinone thioethers. Alt C, et al. **Chem Res Toxicol** 1998 Oct;11(10):1223–33

Glutathione-dependent generation of reactive oxygen species by the peroxidase-catalyzed redox cycling of flavonoids. Galati G, et al. **Chem Res Toxicol** 1999 Jun;12(6):521–5

Theoretical study of the SNV reaction of trichloroethylene (TCE) and CH3S- as a model for glutathione conjugation of TCE. Shim JY, et al. **Chem Res Toxicol** 1999 Apr; 12(4):308–16

Ethanol ingestion impairs alveolar epithelial glutathione homeostasis and function, and predisposes to endotoxin-mediated acute lung injury. Guidot D, et al. **Chest** 1999 Jul;116(1 Suppl):82S

Structure-activity relationship of schisandrins in enhancing liver mitochondrial glutathione status in CCl4-poisoned mice. Ip SP, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):313–6

Effect of alpha-hederin on hepatic detoxifying systems in mice. Liu YP, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):33–6

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Gupta E, et al. **Clin Cancer Res** 1995 Oct;1(10):1133–6

Translational studies of glutathione in bladder cancer cell lines and human specimens. Pendyala L, et al. **Clin Cancer Res** 1997 May;3(5):793–8

Thiol and redox reactive agents exert different effects on glutathione metabolism in HeLa cell cultures. Hultberg B, et al. **Clin Chim Acta** 1999 May;283(1-2):21–32

Lymphocyte proliferation modulated by glutamine: involved in the endogenous redox reaction. Chang WK, et al. **Clin Exp Immunol** 1999 Sep;117(3):482–8

In vitro and in vivo effects of heavy metals on mussel digestive gland hexokinase activity: the role of glutathione. Canesi L, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):261–8

Corneal transport of circulating glutathione in normal and galactosemic guinea pigs. Kannan R, et al. **Cornea** 1999 May;18(3):321–7

Rhizobacterial glutathione levels as affected by starvation and cadmium exposure. Hultberg M. **Curr Microbiol** 1998 Nov;37(5):301–5

Mechanistic imperatives for the evolution of glutathione transferases. Armstrong RN. **Curr Opin Chem Biol** 1998 Oct;2(5):618–23 (54 ref.)

Glutathione-mediated detoxification systems in plants. Dixon DP, et al. **Curr Opin Plant Biol** 1998 Jun;1(3):258–66 (51 ref.)

Glutathione restoration as indicator for cellular metabolism of astroglial cells. Dringen R, et al. **Dev Neurosci** 1998; 20(4-5):401–7

Xenobiotic metabolism, oxidant stress and chronic pancreatitis. Focus on glutathione. Wallig MA. **Digestion** 1998;59 Suppl 4:13–24 (100 ref.)

Diminished CYP2E1 expression and formation of 2-S-glutathionyl acetate, a glutathione conjugate derived from 1,1-dichloroethylene epoxide, in murine lung tumors. Forkert PG, et al. **Drug Metab Dispos** 1999 Jan;27(1):68–73

Glutathione conjugation of trichloroethylene in human liver and kidney: kinetics and individual variation. Lash LH, et al. **Drug Metab Dispos** 1999 Mar;27(3):351–9

Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Tang W, et al. **Drug Metab Dispos** 1999 Mar;27(3):365–72

The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups. D'Incalci M, et al. **Eur J Cancer** 1998 Oct;34(11):1749-55

Increased glutathione levels in neurochemically identified fibre systems in the aged rat lumbar motor nuclei. Ramirez-León V, et al. **Eur J Neurosci** 1999 Aug; 11(8):2935-48

Glutathione and glutathione-related enzymes in reproduction. A review. Knapen MF, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):171-84 (136 ref.)

5-Oxoprolinuria in patients with and without defects in the gamma-glutamyl cycle. Mayatepek E. **Eur J Pediatr** 1999 Mar;158(3):221-5

Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Anderson CP, et al. **Exp Cell Res** 1999 Jan 10;246(1):183-92

An impediment to glutathione diffusion in older normal human lenses: a possible precondition for nuclear cataract. Sweeney MH, et al. **Exp Eye Res** 1998 Nov;67(5):587-95

Overproduction of Cu/Zn-superoxide dismutase or Bcl-2 prevents the brain mitochondrial respiratory dysfunction induced by glutathione depletion. Mérad-Saidoune M, et al. **Exp Neurol** 1999 Aug;158(2):428-36

Influence of hypoxia and hypoxia/hypercapnia upon brain and blood peroxidative and glutathione status in normal weight and growth-restricted newborn piglets. Barth A, et al. **Exp Toxicol Pathol** 1998 Sep;50(4-6):402-10

Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. Esteve JM, et al. **FASEB J** 1999 Jun;13(9):1055-64

Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. Klatt P, et al. **FASEB J** 1999 Sep; 13(12):1481-90

Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. Lizard G, et al. **FASEB J** 1998 Dec;12(15):1651-63

Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. Clément MV, et al. **FEBS Lett** 1998 Nov 27;440(1-2):13-8

N-acetylcysteine protects epithelial cells against the oxidative imbalance due to Clostridium difficile toxins. Fiorentini C, et al. **FEBS Lett** 1999 Jun 18;453(1-2):124-8

Requirement of intact human ceruloplasmin for the glutathione-linked peroxidase activity. Kim IG, et al. **FEBS Lett** 1998 Oct 23;437(3):293-6

Detoxication of carcinogenic fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase P1-1 variants and glutathione. Sundberg K, et al. **FEBS Lett** 1998 Nov 6;438(3):206-10

GSTP1-1 stereospecifically catalyzes glutathione conjugation of ethacrynic acid. van Iersel ML, et al. **FEBS Lett** 1998 Dec 11;441(1):153-7

Depression of glutathione content, elevation of CYP2E1-dependent activation, and the principal determinant of the fasting-mediated enhancement of 1,3-dichloro-2-propanol hepatotoxicity in the rat. Fry JR, et al. **Food Chem Toxicol** 1999 Apr;37(4):351-5

Apoptotic process in the monkey small intestinal epithelium: I. Association with glutathione level and its efflux. Benard O, et al. **Free Radic Biol Med** 1999 Feb;26(3-4):245-52

gamma-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Drozdz R, et al. **Free Radic Biol Med** 1998 Nov 1;25(7):786-92

Oxidative insult specifically decreases levels of a mitochondrial transcript. Elliott RM, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):646-55

Involvement of oxidative stress in paraquat-induced metallothionein synthesis under glutathione depletion. Nakagawa I, et al. **Free Radic Biol Med** 1998 Jun; 24(9):1390-5

Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Navarro J, et al. **Free Radic Biol Med** 1999 Feb; 26(3-4):410-8

Quercetin inhibits hydrogen peroxide-induced oxidation of the rat lens. Sanderson J, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):639-45

Determinants of intestinal detoxication of lipid hydroperoxides. Aw TY. **Free Radic Res** 1998 Jun; 28(6):637-46 (52 ref.)

Investigation of the transport of intact glutathione in human and rat type II pneumocytes. van Klaveren RJ, et al. **Free Radic Res** 1999 May;30(5):371-81

Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Colell A, et al. **Gastroenterology** 1998 Dec;115(6):1541-51

Effects of progesterone and estradiol benzoate on glutathione dependent antioxidant enzyme activities in the brain of female rats. Pajović SB, et al. **Gen Physiol Biophys** 1999 Mar;18(1):35-44

Differential effects of pharmacological doses of melatonin on malondialdehyde and glutathione levels in young and old rats. Gonca Akbulut K, et al. **Gerontology** 1999; 45(2):67-71

Rapid clearance of tertiary butyl hydroperoxide by cultured astroglial cells via oxidation of glutathione. Dringen R, et al. **Glia** 1998 Jun;23(2):139-45

CD95-Mediated murine hepatic apoptosis requires an intact glutathione status. Hentze H, et al. **Hepatology** 1999 Jul; 30(1):177-85

Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. Vos TA, et al. **Hepatology** 1999 Feb;29(2):421-6

Protection by extracellular glutathione against sulfur mustard induced toxicity in vitro. Amir A, et al. **Hum Exp Toxicol** 1998 Dec;17(12):652-60

Impact of dietary supplement of Crassostrea gigas extract (JCOE) on glutathione levels and glutathione S-transferase activity in rat tissues. Gaté L, et al. **In Vivo** 1998 May-Jun; 12(3):299-303

GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Zhang K, et al. **Int J Oncol** 1999 May; 14(5):861-7

Trypsinogen activation and glutathione content are linked to pancreatic injury in models of biliary acute pancreatitis. Lüthen R, et al. **Int J Pancreatol** 1998 Dec;24(3):193-202

The measurement of bioreductive capacity of tumor cells using methylene blue. Biaglow JE, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):769-73

Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-L-cysteine or L-buthionine-S,R-sulfoximine. Tuttle S, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):833-8

Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Nelson KC, et al. **Invest Ophthalmol Vis Sci** 1999 Aug; 40(9):1927-35

Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Obrosova IG, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):680-8

Trianthema portulacastrum restores the antioxidant defense enzyme levels and hepatic biotransformation patterns in experimental rat hepatocarcinogenesis. Bhattacharya S, et al. **Ital J Biochem** 1998 Dec;47(4):225-32

The role of glutathione in the gastrointestinal tract: a review. Loguercio C, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):401-7 (105 ref.)

In vivo formation of codeinone-glutathione adduct: isolation and identification of a new metabolite in the bile of codeine-treated guinea pig. Ishida T, et al. **J Anal Toxicol** 1998 Nov-Dec;22(7):567-72

Free radical activity, antioxidant enzyme, and glutathione changes with muscle stretch injury in rabbits. Best TM, et al. **J Appl Physiol** 1999 Jul;87(1):74-82

Alpha-lipoic acid supplementation: tissue glutathione homeostasis at rest and after exercise. Khanna S, et al. **J Appl Physiol** 1999 Apr;86(4):1191-6

Is thallium-induced nephrotoxicity in rats connected with riboflavin and/or GSH?--reconsideration of hypotheses on the mechanism of thallium toxicity. Appenroth D, et al. **J Appl Toxicol** 1999 Jan-Feb;19(1):61-6

Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione. Mizutani T, et al. **J Appl Toxicol** 1999 May-Jun;19(3):193-8

Effect of intracellular glutathione on the production of prostaglandin D2 in RBL-2H3 cells oxidized by tert-butyl hydroperoxide. Sakamoto H, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):90-5

Preferential transport of glutathione versus glutathione disulfide in rat liver microsomal vesicles. Bánhegyi G, et al. **J Biol Chem** 1999 Apr 30;274(18):12213-6

Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation. Klatt P, et al. **J Biol Chem** 1999 May 28;274(22):15857-64

Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. Mohr S, et al. **J Biol Chem** 1999 Apr 2;274(14):9427-30

ATP-dependent transport of reduced glutathione on YCF1, the yeast orthologue of mammalian multidrug resistance associated proteins. Rebbeor JF, et al. **J Biol Chem** 1998 Dec 11;273(50):33449-54

Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. Salvemini F, et al. **J Biol Chem** 1999 Jan 29; 274(5):2750-7

The fate of the oxidizing tyrosyl radical in the presence of glutathione and ascorbate. Implications for the radical sink hypothesis. Sturgeon BE, et al. **J Biol Chem** 1998 Nov 13;273(46):30116-21

Disulfiram augments oxidative stress in rat brain following bilateral carotid artery occlusion. Ningaraj NS, et al. **J Biomed Sci** 1998;5(3):226-30

Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. Dekant W, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):174-81 (93 ref.)

Determination of cellular thiols and glutathione-related enzyme activities: versatility of high-performance liquid chromatography-spectrofluorimetric detection. Parmentier C, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20; 719(1-2):37-46

The effects of cadmium on the hepatic and renal levels of reduced glutathione, the activity of glutathione S-transferase and gamma glutamyl transpeptidase. Karmakar R, et al. **J Environ Pathol Toxicol Oncol** 1999; 18(1):29-35

Glutathione depletion inhibits oxidant-induced activation of nuclear factor-kappa B, AP-1, and c-Jun/ATF-2 in cultured guinea-pig gastric epithelial cells [see comments] Rokutan K, et al. **J Gastroenterol** 1998 Oct;33(5):646-55. Comment in: J Gastroenterol 1998 Oct;33(5):775-6.

Oxidative stress, glutathione and transcription factors. How are they related to gastric mucosal injuries? [editorial; comment] Terano A. **J Gastroenterol** 1998 Oct;33(5):775-6 . Comment on: J Gastroenterol 1998 Oct;33(5):646-55.

Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. Barbaro G, et al. **J Hepatol** 1999 May; 30(5):774-82

Mutations of Gly to Ala in human glutathione transferase P1-1 affect helix 2 (G-site) and induce positive cooperativity in the binding of glutathione. Lo Bello M, et al. **J Mol Biol** 1998 Dec 18;284(5):1717-25

The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. Dringen R, et al. **J Neurochem** 1999 Jun;72(6):2523-30

Induction of glucose-6-phosphate dehydrogenase by lipopolysaccharide contributes to preventing nitric oxide-mediated glutathione depletion in cultured rat astrocytes. Garcia-Nogales P, et al. **J Neurochem** 1999 Apr; 72(4):1750-8

1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. Garcion E, et al. **J Neurochem** 1999 Aug;73(2):859-66

Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. Han J, et al. **J Neurochem** 1999 Oct;73(4):1683-95

Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. Ibi M, et al. **J Neurochem** 1999 Oct;73(4):1696-703

GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. Kannan R, et al. **J Neurochem** 1999 Jul; 73(1):390-9

The detoxification of cumene hydroperoxide by the glutathione system of cultured astroglial cells hinges on hexose availability for the regeneration of NADPH. Kussmaul L, et al. **J Neurochem** 1999 Sep;73(3):1246-53

Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. Spencer JP, et al. **J Neurochem** 1998 Nov;71(5):2112-22

Glutathione efflux induced by NMDA and kainate: implications in neurotoxicity? Wallin C, et al. **J Neurochem** 1999 Oct;73(4):1566-72

Inhibition of neutral sphingomyelinase activation and ceramide formation by glutathione in hypoxic PC12 cell death. Yoshimura S, et al. **J Neurochem** 1999 Aug; 73(2):675-83

The endogenous antioxidant glutathione as a factor in the survival of physically injured mammalian spinal cord neurons. Lucas JH, et al. **J Neuropathol Exp Neurol** 1998 Oct;57(10):937-54

Evaluation of glutathione localization in brain using 99mTc meso-HMPAO. Sasaki T, et al. **J Nucl Med** 1999 Jun; 40(6):1056-60

Distribution of glutathione and technetium-99m-meso-HMPAO in normal and diethyl maleate-treated mouse brain mitochondria. Sasaki T, et al. **J Nucl Med** 1998 Dec;39(12):2178-83

Keratinocyte growth factor enhances glutathione redox state in rat intestinal mucosa during nutritional repletion. Jonas CR, et al. **J Nutr** 1999 Jul;129(7):1278-84

Decreasing ascorbate intake does not affect the levels of glutathione, tocopherol or retinol in the ascorbate-requiring osteogenic disorder shionogi rats. Smith D, et al. **J Nutr** 1999 Jun;129(6):1229-32

Isolation and characterization of a group of oligopeptides related to oxidized glutathione from the root of Panax ginseng. Chen ZK, et al. **J Pept Res** 1998 Aug;52(2):137-42

Resistance to glutathione depletion in diabetic and non-diabetic human erythrocytes in-vitro. Coleman MD, et al. **J Pharm Pharmacol** 1999 Jan;51(1):21-5

Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats. Gunnarsdottir S, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):950-7

High-affinity efflux transport system for glutathione conjugates on the luminal membrane of a mouse brain capillary endothelial cell line (MBEC4). Homma M, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):198-203

Glutathione conjugate interactions with DNA-dependent protein kinase. Shen H, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1101-6

Bimolecular glutathione conjugation kinetics of ethacrynic acid in rat liver: in vitro and perfusion studies. Tirona RG, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1230-41

Low glutathione and glutathione S-transferase levels in Barrett's esophagus as compared to normal esophageal epithelium. van Lieshout EM, et al. **Jpn J Cancer Res** 1999 Jan;90(1):81-5

Intracellular glutathione redox status modulates MCP-1 expression in pulmonary granulomatous vasculitis. Desai A, et al. **Lab Invest** 1999 Jul;79(7):837-47

Antioxidant potential of evening primrose oil administration in hyperlipemic rabbits. De La Cruz JP, et al. **Life Sci** 1999;65(5):543–55

Decreased susceptibility to lipid peroxidation of Goto-Kakizaki rats: relationship to mitochondrial antioxidant capacity. Ferreira FM, et al. **Life Sci** 1999; 65(10):1013–25

Detection of glutathione in the human brain in vivo by means of double quantum coherence filtering. Trabesinger AH, et al. **Magn Reson Med** 1999 Aug;42(2):283–9

An ataxia telangiectasia model: inefficient cell differentiation and possible reversal by serine protease inhibitors, tumor necrosis factor inhibitors, dexamethasone, and glutathione enhancers. Knittweis J. **Med Hypotheses** 1998 Jul; 51(1):53–7 (88 ref.)

Role of glutathione in the detoxification of ferriprotoporphyrin IX in chloroquine resistant Plasmodium berghei. Platel DF, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):215–23

Schisandrin B protects against myocardial ischemia-reperfusion injury by enhancing myocardial glutathione antioxidant status. Yim TK, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):151–6

Differential protein S-thiolation of glyceraldehyde-3-phosphate dehydrogenase isoenzymes influences sensitivity to oxidative stress. Grant CM, et al. **Mol Cell Biol** 1999 Apr;19(4):2650–6

Glutamine, as a precursor of glutathione, and oxidative stress. Amores-Sánchez MI, et al. **Mol Genet Metab** 1999 Jun; 67(2):100–5 (47 ref.)

Protection against nitric oxide-induced apoptosis in rat mesangial cells demands mitogen-activated protein kinases and reduced glutathione. Sandau KB, et al. **Mol Pharmacol** 1999 Oct;56(4):744–51

Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Van Aubel RA, et al. **Mol Pharmacol** 1999 Oct;56(4):714–9

Cumulus expansion during in vitro maturation of bovine oocytes: relationship with intracellular glutathione level and its role on subsequent embryo development. Furnus CC, et al. **Mol Reprod Dev** 1998 Sep;51(1):76–83

Bleomycin genotoxicity alteration by glutathione and cytochrome P-450 cellular content in respiratory proficient and deficient strains of Saccharomyces cerevisiae. Poli P, et al. **Mutagenesis** 1999 Mar;14(2):233–8

Role of glutathione on acrolein-induced cytotoxicity and mutagenicity in Escherichia coli. Nunoshiba T, et al. **Mutat Res** 1999 Jun 7;442(1):1–8

Reconsideration of some hypotheses on the mechanism of thallium toxicity in rats with special respect to riboflavin and glutathione. Appenroth D, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:16–8

Evidence of glutathione transporter in rat brain synaptosomal membrane vesicles. Iantomasi T, et al. **Neurochem Int** 1999 Jun;34(6):509–16

Sleep deprivation induces brain region-specific decreases in glutathione levels. D'Almeida V, et al. **Neuroreport** 1998 Aug 24;9(12):2853–6

Sensitization by prolonged glutathione depletion of kainic acid to potentiate DNA binding of the nuclear transcription factor activator protein-1 in murine hippocampus. Kitayama T, et al. **Neurosci Lett** 1999 Jul 16;269(3):157–60

Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine. Moszczynska A, et al. **Neurosci Lett** 1998 Oct 9; 255(1):49–52

Cooperation between glutathione depletion and protein synthesis inhibition against naturally occurring neuronal death. Castagné V, et al. **Neuroscience** 1998 Oct; 86(3):895–902

Glutathione redox disturbances in human immunodeficiency virus infection: immunologic and therapeutic consequences [editorial] Aukrust P, et al. **Nutrition** 1999 Feb;15(2):165–7 (32 ref.)

The glutathione content of retinal Müller (glial) cells: the effects of aging and of application of free-radical scavengers. Paasche G, et al. **Ophthalmic Res** 1998; 30(6):351–60

Wallerian degeneration and hyperalgesia after peripheral nerve injury are glutathione-dependent. Wagner R, et al. **Pain** 1998 Aug;77(2):173–9

Unexpected increased thiabendazole tolerance in Haemonchus contortus resistant to anthelmintics by modulation of glutathione activity. Kerboeuf D, et al. **Parasitol Res** 1999 Aug;85(8–9):713–8

Glutathione protects macrophages and Leishmania major against nitric oxide-mediated cytotoxicity. Romão PR, et al. **Parasitology** 1999 Jun;118 (Pt 6):559–66

Regulation of cytochrome P4501A metabolism by glutathione. Otto DM, et al. **Pharmacol Toxicol** 1999 May; 84(5):201–10

Glutathione-dependent antioxidant enzyme activities and glutathione content in the rat brain at different stages of oestrous cycle. Saicic ZS, et al. **Physiol Res** 1998;47(1):61–7

Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with pre-eclampsia. Knapen MF, et al. **Placenta** 1999 Sep;20(7):541–6

Glutathione metabolic genes coordinately respond to heavy metals and jasmonic acid in Arabidopsis. Xiang C, et al. **Plant Cell** 1998 Sep;10(9):1539–50

Maize glutathione-dependent formaldehyde dehydrogenase: protein sequence and catalytic properties. Wippermann U, et al. **Planta** 1999 Mar;208(1):12–8

Effect of several sesquiterpene lactones on lipid peroxidation and glutathione level. Jodynis-Liebert J, et al. **Planta Med** 1999 May;65(4):320–4

Hepatic export of glutathione and uptake of constituent amino acids, glutamate and cysteine, in broilers in vivo. Wang S, et al. **Poult Sci** 1998 Oct;77(10):1556–64

Regulation of the OxyR transcription factor by hydrogen peroxide and the cellular thiol-disulfide status. Aslund F, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6161–5

Common structural features of MAPEG — a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Jakobsson PJ, et al. **Protein Sci** 1999 Mar; 8(3):689–92

Molecular dynamics simulations of human glutathione transferase P1-1: analysis of the induced-fit mechanism by GSH binding. Stella L, et al. **Proteins** 1999 Oct 1;37(1):1–9

Molecular dynamics simulations of human glutathione transferase P1-1: conformational fluctuations of the apo-structure. Stella L, et al. **Proteins** 1999 Oct 1;37(1):10–9

Possible role of plasma GSH in modulating smoking related radiation pneumonitis [letter] Bhattathiri VN. **Radiother Oncol** 1999 Jun;51(3):291–2

Phospholipid fatty acid composition affects enzymatic antioxidant defenses in cultured Swiss 3T3 fibroblasts. Benito S, et al. **Redox Rep** 1997 Oct-Dec;3(5–6):281–6

Pyridine nucleotide flux and glutathione oxidation in the cultured rat conceptus. Akella SS, et al. **Reprod Toxicol** 1999 May-Jun;13(3):203–13

Effect of streptozotocin on glutathione and lipid peroxide levels in various tissues of rats. Baştar I, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):265–72

Metabolism of glutathione in isolated non filtering rat kidneys. Sampaio HA, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):305–12

Glutathione status in liver and plasma during development of biliary cirrhosis after bile duct ligation. Purucker E, et al. **Res Exp Med (Berl)** 1998 Dec;198(4):167–74

Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Ballatori N, et al. **Semin Liver Dis** 1998; 18(4):377–87 (125 ref.)

Glutathione defense in non-parenchymal cells. DeLeve LD. **Semin Liver Dis** 1998;18(4):403–13 (95 ref.)

Mitochondrial glutathione: importance and transport. Fernández-Checa JC, et al. **Semin Liver Dis** 1998; 18(4):389–401 (99 ref.)

Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Ookhtens M, et al. **Semin Liver Dis** 1998; 18(4):313–29 (125 ref.)

Effects of glutathione depletion on selenite- and selenate-induced embryotoxicity in cultured rat embryos. Usami M, et al. **Teratog Carcinog Mutagen** 1999; 19(4):257–66

Effects of mild chronic heat exposure on the concentrations of thiobarbituric acid reactive substances, glutathione, and selenium, and glutathione peroxidase activity in the mouse liver. Kasanuma Y, et al. **Tohoku J Exp Med** 1998 Jun; 185(2):79–87

The effect of prenatal methylmercury exposure on the GSH level and lipid peroxidation in the fetal brain and placenta of mice. Watanabe C, et al. **Tohoku J Exp Med** 1999 Feb; 187(2):121–6

Glutathione conjugation of 4-hydroxy-trans-2,3-nonenal in the rat in vivo, the isolated perfused liver and erythrocytes. Boon PJ, et al. **Toxicol Appl Pharmacol** 1999 Sep 15; 159(3):214–23

Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91–7

Chrysotile-mediated imbalance in the glutathione redox system in the development of pulmonary injury. Abidi P, et al. **Toxicol Lett** 1999 May 20;106(1):31–9

Effect of lycopene on lipid peroxidation and glutathione-dependent enzymes induced by T-2 toxin in vivo. Leal M, et al. **Toxicol Lett** 1999 Sep 20;109(1–2):1–10

The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. Singhal SS, et al. **Toxicol Lett** 1999 Sep 20;109(1–2):87–95

Metallothionein induction attenuates the effects of glutathione depletors in rat hepatocytes. Haïdara K, et al. **Toxicol Sci** 1999 Jun;49(2):297–305

ANIT-induced disruption of biliary function in rat hepatocyte couplets. Orsler DJ, et al. **Toxicol Sci** 1999 Feb; 47(2):203–10

Cellular and subcellular heterogeneity of glutathione metabolism and transport in rat kidney cells. Lash LH, et al. **Toxicology** 1998 Sep 1;130(1):1–15

Haloalcohols deplete glutathione when incubated with fortified liver fractions. Garle MJ, et al. **Xenobiotica** 1999 May;29(5):533–45

[Glutathione metabolism in the tissues of the cerebral hemispheres in trauma] Hornets VI, et al. **Patol Fiziol Eksp Ter** 1998 Jul-Sep;(3):22–4 (Eng. Abstr.) **(Rus)**

[Protective role of the glutathione system in rat organs after administration of embiquine] Boitsova LV. **Ukr Biokhim Zh** 1998 Jan-Feb;70(1):113–7 (Eng. Abstr.) **(Rus)**

[Photoperiodic changes of the glutathione system of the brain under acute hypoxia] Zamors'kyi II, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):69–75 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Serafino A, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1909–18

Glutathione-independent prostaglandin D2 synthase in ram and stallion epididymal fluids: origin and regulation. Fouchécourt S, et al. **Biol Reprod** 1999 Mar;60(3):558–66

Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate. Asakura T, et al. **Br J Cancer** 1999 May;80(5–6):711–5

ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Renes J, et al. **Br J Pharmacol** 1999 Feb; 126(3):681–8

Extracellular reduced glutathione increases neuronal vulnerability to combined chemical hypoxia and glucose deprivation. Regan RF, et al. **Brain Res** 1999 Jan 30; 817(1–2):145–50

Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Sakamoto H, et al. **Cancer Lett** 1999 Jan 8;135(1):113–9

Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation. Wright SC, et al. **Cancer Res** 1998 Dec 1;58(23):5570–6

In vivo effects of ascorbate and glutathione on the uptake of chromium, formation of chromium(V), chromium-DNA binding and 8-hydroxy-2'-deoxyguanosine in liver and kidney of osteogenic disorder shionogi rats following treatment with chromium(VI). Yuann JM, et al. **Carcinogenesis** 1999 Jul;20(7):1267–75

Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Janiszewski M, et al. **Cardiovasc Res** 1998 Aug;39(2):327–38

Different inhibitory effects of 5-S-glutathionyl-beta-alanyl-L-dopa (5-S-GA-L-D) analogues on autophosphorylation and substrate phosphorylation of Src protein tyrosine kinase [letter] Zheng ZB, et al. **Chem Pharm Bull (Tokyo)** 1999 Jan; 47(1):136–7

Significance of glutathione-dependent antioxidant system in diabetes-induced embryonic malformations. Sakamaki H, et al. **Diabetes** 1999 May;48(5):1138–44

Glutathione protects PC12 cells from ascorbate- and dopamine-induced apoptosis. Si F, et al. **Exp Brain Res** 1998 Dec;123(3):263–8

Protection from oxidant injury by sodium-dependent GSH uptake in retinal Müller cells. Kannan R, et al. **Exp Eye Res** 1999 May;68(5):609–16

Design and synthesis of glutathione ana'ogues. Lucente G, et al. **Farmaco** 1998 Dec 30;53(12):721–35 (103 ref.)

4-Hydroxynonenal inhibits glutathione peroxidase: protection by glutathione. Bosch-Morell F, et al. **Free Radic Biol Med** 1999 Jun;26(11–12):1383–7

Glutathione (GSH) and the toxicity of oxidised low-density lipoprotein to human monocyte-macrophages. Hardwick SJ, et al. **Free Radic Res** 1999 Jan;30(1):11–9

Glutathione protects the rat liver against reperfusion injury after hypothermic preservation. Bilzer M, et al. **Gastroenterology** 1999 Jul;117(1):200–10

Protection by extracellular glutathione against sulfur mustard induced toxicity in vitro. Amir A, et al. **Hum Exp Toxicol** 1998 Dec;17(12):652–60

Protection of human upper respiratory tract cell lines against sulphur mustard toxicity by glutathione esters. Andrew DJ, et al. **Hum Exp Toxicol** 1998 Jul;17(7):387–95

Diisopropylglutathione ester protects A549 cells from the cytotoxic effects of sulphur mustard. Lindsay CD, et al. **Hum Exp Toxicol** 1998 Nov;17(11):606–12

Effects of glutathione on red blood cell intracellular magnesium: relation to glucose metabolism. Barbagallo M, et al. **Hypertension** 1999 Jul;34(1):76–82

Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. Prasad A, et al. **J Am Coll Cardiol** 1999 Aug;34(2):507–14

The antioxidant N-acetylcysteine induces mesangial cells to create three-dimensional cytoarchitecture that underlies cellular differentiation. Kitamura M. **J Am Soc Nephrol** 1999 Apr;10(4):746–51

Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. Tsumoto K, et al. **J Immunol Methods** 1998 Oct 1; 219(1–2):119–29

Endogenous glutathione protects cerebral endothelial cells from traumatic injury. Gidday JM, et al. **J Neurotrauma** 1999 Jan;16(1):27–36

Glutathone and glutathione ethyl ester supplementation of mice alter glutathione homeostasis during exercise. Leeuwenburgh C, et al. **J Nutr** 1998 Dec;128(12):2420–6

Reduced glutathione inhibits beta-NAD+-activated non-selective cation currents in the CRI-G1 rat insulin-secreting cell line. Herson PS, et al.

J Physiol (Lond) 1999 Jan 1;514 (Pt 1):47-57
Dependence of cadmium-metallothionein nephrotoxicity on glutathione. Shaikh ZA, et al. **J Toxicol Environ Health** 1999 Jun 11;57(3):211-22
Effect of intraocular irrigating solution on flicker electroretinogram during cataract surgery in human eye. Kitamura K, et al. **Jpn J Ophthalmol** 1998 Jul-Aug; 42(4):275-80
Cysteine, glutathione (GSH) and zinc and copper ions together are effective, natural, intracellular inhibitors of (AIDS) viruses. Sprietsma JE. **Med Hypotheses** 1999 Jun; 52(6):529-38 (100 ref.)
A novel, synergistic interaction between 17 beta-estradiol and glutathione in the protection of neurons against beta-amyloid 25-35-induced toxicity in vitro. Gridley KE, et al. **Mol Pharmacol** 1998 Nov;54(5):874-80
Glutathione activation of chloropicrin in the Salmonella mutagenicity test. Schneider M, et al. **Mutat Res** 1999 Feb 19;439(2):233-8
Interference of S-alkyl derivatives of glutathione with brain ionotropic glutamate receptors. Jenei Z, et al. **Neurochem Res** 1998 Aug;23(8):1085-91
Potentiation of excitotoxic injury by high concentrations of extracellular reduced glutathione. Regan RF, et al. **Neuroscience** 1999;91(2):463-70
Differential non-redox inhibitory effects of glutathione against protein kinase C isozyme family members. Ward NE, et al. **Oncol Rep** 1999 Mar-Apr;6(2):307-10
Glutathione (GSH) reduces the open probability of mechanosensitive channels in Escherichia coli protoplasts. Koprowski P, et al. **Pflugers Arch** 1999 Aug;438(3):361-4
Rehabilitating role of glutathione ester on cisplatin induced nephrotoxicity. Babu E, et al. **Ren Fail** 1999 Mar; 21(2):209-17
Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme. Zakharyan RA, et al. **Toxicol Appl Pharmacol** 1999 Feb 1;154(3):287-91

PHYSIOLOGY

Regulation of nitric oxide synthase induction by iron and glutathione in asbestos-treated human lung epithelial cells. Park SH, et al. **Arch Biochem Biophys** 1998 Dec 1; 360(1):47-52
Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells. Cho S, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):104-8
Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. Abe T, et al. **Biochem Pharmacol** 1999 Jul 1; 58(1):69-76
Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells. Vahrmeijer AL, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):655-64
Glutathione and duodenal reduction and absorption of iron. Simpson RJ, et al. **Biochem Soc Trans** 1998 Nov;26(4):S352
Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. Dröge W, et al. **Biofactors** 1998;8(1-2):97-102 (23 ref.)
Direct evidence for glutathione as mediator of apoptosis in neuronal cells. Nicole A, et al. **Biomed Pharmacother** 1998; 52(9):349-55
The role of glutathione in p-aminophenol-induced nephrotoxicity in the mouse. Song H, et al. **Drug Chem Toxicol** 1999 Aug;22(3):529-44
Review: The role of glutathione in the regulation of apoptosis. Hall AG. **Eur J Clin Invest** 1999 Mar; 29(3):238-45 (61 ref.)
Glutathione depletion enhances germ cell toxicity of butadiene metabolites: a flow cytometric study. Cordelli E, et al. **Eur J Histochem** 1997;41 Suppl 2:173-4
The protective role of endogenous glutathione in carrageenan-induced pleurisy in the rat. Cuzzocrea S, et al. **Eur J Pharmacol** 1999 May 14;372(2):187-97
Glutathione-dependent ascorbate recycling activity of rat serum albumin. Vethanayagam JG, et al. **Free Radic Biol Med** 1999 Jun;26(11-12):1591-8
Glutathione modulates rat and mouse hepatocyte sensitivity to tumor necrosis factor toxicity. Xu Y, et al. **Gastroenterology** 1998 Nov;115(5):1229-37
Changes in sensitivity of a human myeloid cell line (U937) to metal toxicity after glutathione depletion. Danfour M, et al. **Immunopharmacol Immunotoxicol** 1999 May; 21(2):277-93
Response of preimplantation murine embryos to heat shock as modified by developmental stage and glutathione status. Aréchiga CF, et al. **In Vitro Cell Dev Biol Anim** 1998 Sep; 34(8):655-9
Glutathione modulates lipid composition of human colon derived HT-29 cells. Madesh M, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1345-52
Increased replication of Sendai virus in morphine-treated epithelial cells: evidence for the involvement of the intracellular levels of glutathione. Macchia I, et al. **Int J Immunopharmacol** 1999 Mar;21(3):185-93
Different foci for the regulation of the activity of the KefB and KefC glutathione-gated K+ efflux systems. Ness LS, et al. **J Biol Chem** 1999 Apr 2;274(14):9524-30
Glutathione and signal transduction in the mammalian CNS. Janáky R, et al. **J Neurochem** 1999 Sep;73(3):889-902 (99 ref.)
Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. Mytilineou C, et al. **J Neurochem** 1999 Jul;73(1):112-9
Role of endogenous glutathione in the oxidation of dopamine. Rabinovic AD, et al. **J Neurochem** 1998 Nov;71(5):2071-8
Role of glutathione in the antiulcer effect of hot water extract of black tea (Camellia sinensis). Maity S, et al. **Jpn J Pharmacol** 1998 Nov;78(3):285-92
Role of antioxidant defenses in the tolerance of severe dehydration by anurans. The case of the leopard frog Rana pipiens. Hermes-Lima M, et al. **Mol Cell Biochem** 1998 Dec;189(1-2):79-89
Role of glutathione on renal mitochondrial status in hyperoxaluria. Muthukumar A, et al. **Mol Cell Biochem** 1998 Aug;185(1-2):77-84
Glutathione homeostasis in response to exercise training and nutritional supplements. Sen CK. **Mol Cell Biochem** 1999 Jun;196(1-2):31-42 (99 ref.)
Buthionine sulfoximine prevents the reduction of the genotoxic activity of maleic hydrazide by soil humic substances in Vicia faba seedlings. De Marco A, et al. **Mutat Res** 1999 Jan 13;438(2):89-95
Protection of reoxygenated cardiomyocytes against sarcolemmal fragility: the role of glutathione. Obermayr RP, et al. **Pflugers Arch** 1999 Aug;438(3):365-70
Glutathione-dependent antioxidant enzyme activities and glutathione content in the rat brain at different stages of oestrous cycle. Saicic ZS, et al. **Physiol Res** 1998;47(1):61-7
Glutathione in the cellular defense of human lung cells exposed to hyperoxia and high pressure. Djurhuus R, et al. **Undersea Hyperb Med** 1999 Summer;26(2):75-85
[Glutathione and cisplatin resistance in head and neck cancer] Nishimura T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Feb;102(2):236-42 (Eng. Abstr.) **(Jpn)**

SECRETION

Induction of the multispecific organic anion transporter (cMoat/mrp2) gene and biliary glutathione secretion by the herbicide 2,4,5-trichlorophenoxyacetic acid in the mouse liver. Wielandt AM, et al. **Biochem J** 1999 Jul 1; 341 (Pt 1):105-11

THERAPEUTIC USE

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Hospers GA, et al. **Br J Cancer** 1999 May;80(5-6):629-38 (81 ref.)
A rationale for glutathione therapy. Lenzi A, et al. **Hum Reprod** 1998 Jun;13(6):1419-22
Effect of orally administered reduced- and oxidized-glutathione against acetaminophen-induced liver injury in rats. Sugimura Y, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Oct;44(5):613-24
Glutathione therapy: from prodrugs to genes. Anderson ME, et al. **Semin Liver Dis** 1998;18(4):415-24 (84 ref.)
Glutathione reduces the toxicity associated with antitumor therapy of ascites fluid adsorbed over Staphylococcus aureus Cowan I in tumor bearing mice. Verma AS, et al. **Toxicol Lett** 1999 Jun 1;106(2-3):119-27

GLUTATHIONE S-ALKYLTRANSFERASE see **GLUTATHIONE TRANSFERASE**

GLUTATHIONE S-ARYLTRANSFERASE see **GLUTATHIONE TRANSFERASE**

GLUTATHIONE DISULFIDE

ANALYSIS

Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Asensi M, et al. **Methods Enzymol** 1999;299:267-76
Measurement of glutathione, glutathione disulfide, and other thiols in mammalian cell and tissue homogenates using high-performance liquid chromatography separation of N-(1-pyrenyl)maleimide derivatives. Ridnour LA, et al. **Methods Enzymol** 1999;299:258-67
Reduced glutathione and glutathione disulfide. Browne RW, et al. **Methods Mol Biol** 1998;108:347-52

BLOOD

Rise in plasma oxidized glutathione by experimental hypoglycemia. Jiang ZL, et al. **Tohoku J Exp Med** 1999 Jan;187(1):59-64

CHEMISTRY

Reactivity of the human thioltransferase (glutaredoxin) C7S, C25S, C78S, C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity. Yang Y, et al. **Biochemistry** 1998 Dec 8;37(49):17145-56
Stereoisomers of glutathione: preparation and enzymatic reactivities. Oikawa T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Apr;45(2):223-9

METABOLISM

Preferential transport of glutathione versus glutathione disulfide in rat liver microsomal vesicles. Bánhegyi G, et al. **J Biol Chem** 1999 Apr 30;274(18):12213-6
Keratinocyte growth factor enhances glutathione redox state in rat intestinal mucosa during nutritional repletion. Jonas CR, et al. **J Nutr** 1999 Jul;129(7):1278-84
Regulation of the OxyR transcription factor by hydrogen peroxide and the cellular thiol-disulfide status. Aslund F, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6161-5
Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Suzuki H, et al. **Semin Liver Dis** 1998;18(4):359-76 (155 ref.)

PHARMACOLOGY

Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Janiszewski M, et al. **Cardiovasc Res** 1998 Aug;39(2):327-38
S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets. Howard CM, et al. **Thromb Res** 1998 Aug 1;91(3):113-20
Purification and some properties of an oxydative inhibitor in rabbit reticulocyte lysates. Erdogdu G, et al. **Z Naturforsch [C]** 1998 Sep-Oct;53(9-10):897-901

GLUTATHIONE S-EPOXIDETRANSFERASE see **GLUTATHIONE TRANSFERASE**

GLUTATHIONE INSULIN TRANSHYDROGENASE see **PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE)**

GLUTATHIONE PEROXIDASE

ANALYSIS

Immunohistochemical localization and characterization of a rat Clara cell 26-kDa protein (CC26) with similarities to glutathione peroxidase and phospholipase A2. Power JH, et al. **Exp Lung Res** 1999 Jul-Aug;25(5):379-92
Effect of selenium deficiency on cellular and extracellular glutathione peroxidases: immunochemical detection and mRNA analysis in rat kidney and serum. Nakane T, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):504-11
The localization of glutathione peroxidase in the photoreceptor cells and the retinal pigment epithelial cells of Wistar and Royal College of Surgeons dystrophic rats. Akeo K, et al. **Pigment Cell Res** 1999 Apr;12(2):107-17

ANTAGONISTS & INHIBITORS

4-Hydroxynonenal inhibits glutathione peroxidase: protection by glutathione. Bosch-Morell F, et al. **Free Radic Biol Med** 1999 Jun;26(11-12):1383-7
Only the glutathione dependent antioxidant enzymes are inhibited by haematotoxic hydroxylamines. Spooren AA, et al. **Hum Exp Toxicol** 1998 Oct;17(10):554-9

BIOSYNTHESIS

Antioxidant enzyme defence responses of human MCF-7 and SW480 cancer cells to conjugated linoleic acid. O'Shea M, et al. **Anticancer Res** 1999 May-Jun;19(3A):1953-9
Comparative effects of phenylenebis(methylene)selenocyanate isomers on xenobiotic metabolizing enzymes in organs of female CD rats. Sohn OS, et al. **Carcinogenesis** 1999 Apr;20(4):615-21
Testosterone mediates expression of the selenoprotein PHGPx by induction of spermatogenesis and not by direct transcriptional gene activation. Maiorino M, et al. **FASEB J** 1998 Oct;12(13):1359-70
Enhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegeneration. Lindenau J, et al. **Glia** 1998 Oct;24(2):252-6
GPx3: the plasma-type glutathione peroxidase is expressed under androgenic control in the mouse epididymis and vas deferens. Schwaab V, et al. **Mol Reprod Dev** 1998 Dec; 51(4):362-72

BLOOD

Determination of glutathione peroxidase activity and its contribution to hydrogen peroxide removal in erythrocytes. Wakimoto M, et al. **Acta Med Okayama** 1998 Oct; 52(5):233-7
Sulphydryl groups and their relation to the antioxidant enzymes of chelonian red blood cells. Torsoni MA, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):147-56
Human plasma glutathione peroxidase and symptom severity in schizophrenia. Yao JK, et al. **Biol Psychiatry** 1999 Jun 1;45(11):1512-5
Antioxidative metabolism in Down syndrome. Tekşen F, et al. **Biol Trace Elem Res** 1998 Aug;63(2):123-7
Whole blood glutathione peroxidase activity in melanoma patients. Ros-Bullón MR, et al. **Cancer Lett** 1999 Sep 20; 144(1):25-30
Blood plasma levels of lipoperoxides, glutathione peroxidase, beta carotene, vitamin A and E in women with habitual abortion. Simşek M, et al. **Cell Biochem Funct** 1998 Dec; 16(4):227-31
Elevated lipid peroxidation and disturbed antioxidant enzyme activities in plasma and erythrocytes of patients with uterine cervicitis and myoma. Chiou JF, et al.

Clin Biochem 1999 Apr;32(3):189–92

Plasma levels of selenium, selenoprotein P and glutathione peroxidase and their correlations to fish intake and serum levels of thyrotropin and thyroid hormones: a study on Latvian fish consumers. Hagmar L, et al. **Eur J Clin Nutr** 1998 Nov;52(11):796–800

Maternal and fetal plasma concentrations of endothelin, lipidhydroperoxides, glutathione peroxidase and fibronectin in relation to abnormal umbilical artery velocimetry. Karsdorp VH, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):39–44

Antioxidant status in patients with acute respiratory distress syndrome [editorial; comment] Koch T. **Intensive Care Med** 1999 Feb;25(2):134–6 (18 ref.). Comment on: Intensive Care Med 1999 Feb;25(2):180–5.

Effects of dietary levels of selenium-enriched yeast and sodium selenite as selenium sources fed to growing-finishing pigs on performance, tissue selenium, serum glutathione peroxidase activity, carcass characteristics, and loin quality. Mahan DC, et al. **J Anim Sci** 1999 Aug;77(8):2172–9

Antioxidant enzyme activities and lipid peroxides in the plasma of patients with benign prostatic hyperplasia or prostate cancer are not predictive. Doğru-Abbasoğlu S, et al. **J Cancer Res Clin Oncol** 1999 Jul;125(7):402–4

Effects of smoking on plasma and erythrocyte antioxidant defense systems. Durak I, et al. **J Toxicol Environ Health** 1999 Mar 26;56(6):373–8

Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Whitin JC, et al. **Mol Genet Metab** 1998 Nov;65(3):238–45

Effects of heparin and enoxaparin on lipids and oxidant system during a single hemodialysis session [letter] Cavdar C, et al. **Nephron** 1999;82(1):81–3

Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Roxborough HE, et al. **Nephron** 1999;81(3):278–83

Associations of antioxidant enzymes with cataract and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées à l'Age. Delcourt C, et al. **Ophthalmology** 1999 Feb;106(2):215–22

Selenium, glutathione peroxidase and superoxide dismutase in maltese asthmatic patients: effect of glucocorticoid administration. Fenech AG, et al. **Pulm Pharmacol Ther** 1998;11(4):301–8

Lipid peroxidation and antioxidant enzyme activities in patients with type 1 diabetes mellitus. Ruiz C, et al. **Scand J Clin Lab Invest** 1999 Apr;59(2):99–105

Temporal variations in blood glutathione peroxidase (GSHPx) activity in sheep at pasture in a Mediterranean area. Andres S, et al. **Vet J** 1999 Mar;157(2):186–8

The effect of buparvaquone treatment on the levels of some antioxidant vitamins, lipid peroxidation and glutathione peroxidase in cattle with theileriosis. Naziroğlu M, et al. **Zentralbl Veterinarmed [B]** 1999 May;46(4):233–9

[The comparison of selenium status between the children suffered from pneumonia and the normal children from kindergarten] Cui H, et al. **Wei Sheng Yen Chiu** 1997 Jul; 26(4):242–4 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Kinetic study of the reaction of glutathione peroxidase with peroxynitrite. Briviba K, et al. **Chem Res Toxicol** 1998 Dec; 11(12):1398–401

A novel glutathione peroxidase in bovine eye. Sequence analysis, mRNA level, and translation. Singh AK, et al. **J Biol Chem** 1998 Oct 2;273(40):26171–8

Schizosaccharomyces pombe homologue of glutathione peroxidase, which does not contain selenocysteine, is induced by several stresses and works as an antioxidant. Yamada K, et al. **Yeast** 1999 Aug;15(11):1125–32

[Structure and function of phospholipid hydroperoxide glutathione peroxidase] Imai H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1236–46 (58 ref.) **(Jpn)**

DEFICIENCY

Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Kenet G, et al. **Arterioscler Thromb Vasc Biol** 1999 Aug; 19(8):2017–23

Glutathione peroxidase-deficient mice are more susceptible to neutrophil-mediated hepatic parenchymal cell injury during endotoxemia: importance of an intracellular oxidant stress. Jaeschke H, et al. **Hepatology** 1999 Feb;29(2):443–50

Increased resistance of GPx-1 transgenic mice to tumor promoter-induced loss of glutathione peroxidase activity in skin. Bilodeau JF, et al. **Int J Cancer** 1999 Mar 15; 80(6):863–7

Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Roxborough HE, et al. **Nephron** 1999;81(3):278–83

DRUG EFFECTS

Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. Winklhofer-Roob BM, et al. **Free Radic Biol Med** 1998 Jul 15;25(2):242–9

Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. Yao JK, et al. **J Psychiatr Res** 1998 Nov-Dec;32(6):385–91

GENETICS

Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Wong HR, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L836–41

Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. Gladyshev VN, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):488–93

mRNA stability and selenocysteine insertion sequence efficiency rank gastrointestinal glutathione peroxidase high in the hierarchy of selenoproteins. Wingler K, et al. **Eur J Biochem** 1999 Jan;259(1–2):149–57

Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Bensadoun JC, et al. **Eur J Neurosci** 1998 Oct;10(10):3231–6

Cloning of the mouse phospholipid hydroperoxide glutathione peroxidase gene. Borchert A, et al. **FEBS Lett** 1999 Mar 12;446(2–3):223–7

The CCAAT-box binding factor NF-Y is required for the expression of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Huang HS, et al. **FEBS Lett** 1999 Jul 16;455(1–2):111–6

Thyroid stimulating hormone and selenium supply interact to regulate selenoenzyme gene expression in thyroid cells (FRTL-5) in culture. Villette S, et al. **FEBS Lett** 1998 Oct 30;438(1–2):81–4

Modulation of antioxidant enzymes p21WAF1 and p53 expression during proliferation and differentiation of human melanoma cell lines. Bravard A, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):1027–33

Knockout of cellular glutathione peroxidase gene renders mice susceptible to diquat-induced oxidative stress. Fu Y, et al. **Free Radic Biol Med** 1999 Sep;27(5–6):605–11

Effect of selenium deficiency on cellular and extracellular glutathione peroxidases: immunochemical detection and mRNA analysis in rat kidney and serum. Nakane T, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):504–11

Testing a biochemical model of human genetic resistance to falciparum malaria by the analysis of variation at protein and microsatellite loci. Destro-Bisol G, et al. **Hum Biol** 1999 Jun;71(3):315–32

Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1. Forsberg L, et al. **Hum Mutat** 1999;13(4):294–300

Genetic analysis of glutathione peroxidase in oxidative stress response of Saccharomyces cerevisiae. Inoue Y, et al. **J Biol Chem** 1999 Sep 17;274(38):27002–9

Transcriptional activation of the human glutathione peroxidase promoter by p53. Tan M, et al. **J Biol Chem** 1999 Apr 23;274(17):12061–6

UGA codon position affects the efficiency of selenocysteine incorporation into glutathione peroxidase-1. Wen W, et al. **J Biol Chem** 1998 Oct 23;273(43):28533–41

Murine phospholipid hydroperoxide glutathione peroxidase: cDNA sequence, tissue expression, and mapping. Knopp EA, et al. **Mamm Genome** 1999 Jun;10(6):601–5

Expression of extracellular glutathione peroxidase type 5 (GPX5) in the rat male reproductive tract. Williams K, et al. **Mol Hum Reprod** 1998 Sep;4(9):841–8

METABOLISM

Expression of extracellular glutathione peroxidase in human and mouse gastrointestinal tract. Tham DM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1463–71

Expression and developmental profile of antioxidant enzymes in human lung and liver. Asikainen TM, et al. **Am J Respir Cell Mol Biol** 1998 Dec;19(6):942–9

Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Comhair SA, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1824–9

Kinetic studies of abzyme with glutathione peroxidase activity. Gao SJ, et al. **Ann N Y Acad Sci** 1998 Dec 13; 864:280–3

A selenium-containing abzyme, the activity of which surpassed the level of native glutathione peroxidase. Luo G, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:136–41

Changes in antioxidant enzyme activities and lipid peroxidation related to bromoethylamine-induced renal cytotoxicity. Thielemann LE, et al. **Arch Med Res** 1999 Jan-Feb;30(1):14–8

Identification of the dehydroascorbic acid reductase and thioltransferase (Glutaredoxin) activities of bovine erythrocyte glutathione peroxidase. Washburn MP, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):567–71

Changes of superoxide dismutase, glutathione perioxidase and lipid peroxides in the brain of mice preconditioned by hypoxia. Duan C, et al. **Biol Signals Recept** 1999 Jul–Oct; 8(4–5):256–60

Cytoprotection against lipid hydroperoxides correlates with increased glutathione peroxidase activities, but not selenium uptake from different selenocompounds. Leist M, et al. **Biol Trace Elem Res** 1999 May;68(2):159–74

Effect of vitamin E and selenium supplementation of cockerel diets on glutathione peroxidase activity and lipid peroxidation susceptibility in sperm, testes, and liver. Surai P, et al. **Biol Trace Elem Res** 1998 Summer;64(1–3):119–32

Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells. Okada F, et al. **Br J Cancer** 1999 Feb;79(3–4):377–85

Endurance training alters antioxidant enzyme gene expression in rat skeletal muscle. Gore M, et al. **Can J Physiol Pharmacol** 1998 Dec;76(12):1139–45

Glutathione-related enzyme activities in human fetal adrenal, liver, and kidney. Peng RX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):167–71

Protection of ebselen against anoxic damage of cultured neurons of cerebral cortex. Tan YX, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):201–3

Variations in erythrocyte antioxidant glutathione peroxidase activity during the menstrual cycle. Massafra C, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):63–7

Antihypertensive drug therapy and antioxidant enzyme mRNA levels in spontaneously hypertensive (SHR) rats. Ma L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):119–26

Fatty acid composition, glutathione peroxidase and superoxide dismutase activity and total antioxidant activity of avian semen. Surai PF, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jul; 120(3):527–33

In utero methylmercury exposure differentially affects the activities of selenoenzymes in the fetal mouse brain. Watanabe C, et al. **Environ Res** 1999 Apr;80(3):208–14

UV-A1 cytotoxicity and antioxidant defence in keratinocytes and fibroblasts. Leccia MT, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):478–82

Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Bensadoun JC, et al. **Eur J Neurosci** 1998 Oct;10(10):3231–6

Glutathione and glutathione-related enzymes in reproduction. A review. Knapen MF, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):171–84 (136 ref.)

Age-related changes in antioxidant enzyme activities in the small intestine and liver from Wistar rats. Jang I, et al. **Exp Anim** 1998 Oct;47(4):247–52

Inverse regulation of lipid-peroxidizing and hydroperoxyl lipid-reducing enzymes by interleukins 4 and 13. Schnurr K, et al. **FASEB J** 1999 Jan;13(1):143–54

Glutathione peroxidase-like activity of caeruloplasmin as an important lung antioxidant. Park YS, et al. **FEBS Lett** 1999 Sep 17;458(2):133–6

Protection of PC12 cells glutathione peroxidase in L-DOPA induced cytotoxicity. Kim-Han JS, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):512–8

Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. Winklhofer-Roob BM, et al. **Free Radic Biol Med** 1998 Jul 15;25(2):242–9

Effects of nerve growth factor on brain glutathione-related enzymes from aged rats. Cruz-Aguado R, et al. **Fundam Clin Pharmacol** 1998;12(5):538–45

Activity of glutathione peroxidase and superoxide dismutase in workers occupationally exposed to mercury. Bulat P, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S37–9

Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase. Garberg P, et al. **Int J Biochem Cell Biol** 1999 Feb; 31(2):291–301

Effects of bromoethylamine on antioxidant capacity, lipid peroxidation, and morphological characteristics of rat liver. Thielemann LE, et al. **J Biochem Mol Toxicol** 1999; 13(1):47–52

Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. Arai M, et al. **J Biol Chem** 1999 Feb 19; 274(8):4924–33

Acetaminophen toxicity. Opposite effects of two forms of glutathione peroxidase. Mirochnitchenko O, et al. **J Biol Chem** 1999 Apr 9;274(15):10349–55

Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein p. Saito Y, et al. **J Biol Chem** 1999 Jan 29; 274(5):2866–71

Accumulation of mercury and its effect on antioxidant enzymes in brain, liver, and kidneys of mice. Hussain S, et al. **J Environ Sci Health B** 1999 Jul;34(4):645–60

Development of eosinophil peroxidase activity and concomitant alteration of the antioxidant defenses in the liver of mice infected with Schistosoma mansoni. Gharib B, et al. **J Hepatol** 1999 Apr;30(4):594–602

Selenium deficiency in tissue culture: implications for oxidative metabolism. Baker RD Jr, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):387–92

A significant relationship between glutathione-peroxidase (GSH-PO) localization and biological action of testosterone in rat ventral prostate. Murakoshi M, et al. **J Toxicol Sci** 1999 Aug;24(3):209–16

Glutathione peroxidase activity modulates fatty acid profiles of plasma and breast milk in Chinese women. Dodge ML, et al. **J Trace Elem Med Biol** 1999 Apr;12(4):221–30

Murine phospholipid hydroperoxide glutathione peroxidase: cDNA sequence, tissue expression, and mapping. Knopp EA, et al. **Mamm Genome** 1999 Jun;10(6):601–5

Premature induction of aging in sublethally H_2O_2-treated young MRC5 fibroblasts correlates with increased glutathione peroxidase levels and resistance to DNA

breakage. Caldini R, et al. **Mech Ageing Dev** 1998 Sep 15; 105(1-2):137-50

Modifications of the antioxidant enzymes in relation to chromosome imbalances in human melanoma cell lines. Bravard A, et al. **Melanoma Res** 1998 Aug;8(4):329-35

Reactive nitrogen and oxygen intermediates in patients with cutaneous leishmaniasis. Erel O, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr;94(2):179-83

Regulation of cardiomyocyte apoptosis in ischemic reperfused mouse heart by glutathione peroxidase. Maulik N, et al. **Mol Cell Biochem** 1999 Jun;196(1-2):13-21

Expression of extracellular glutathione peroxidase type 5 (GPX5) in the rat male reproductive tract. Williams K, et al. **Mol Hum Reprod** 1998 Sep;4(9):841-8

Enalapril increases antioxidant enzyme activity in renal cortical tissue of five-sixths-nephrectomized rats. Verbeelen DL, et al. **Nephron** 1998 Oct;80(2):214-9

NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Cruz-Aguado R, et al. **Neurochem Int** 1999 Feb; 34(2):125-30

Superoxide dismutase, catalase, glutathione peroxidase and xanthine oxidase in diabetic rat lenses. Cekiç O, et al. **Ophthalmic Res** 1999;31(5):346-50

Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with pre-eclampsia. Knapen MF, et al. **Placenta** 1999 Sep;20(7):541-6

A role for glutathione transferases functioning as glutathione peroxidases in resistance to multiple herbicides in black-grass. Cummins I, et al. **Plant J** 1999 May; 18(3):285-92

Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase. Gladyshev VN, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):835-9

Phospholipid fatty acid composition affects enzymatic antioxidant defenses in cultured Swiss 3T3 fibroblasts. Benito S, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):281-6

Effects of mild chronic heat exposure on the concentrations of thiobarbituric acid reactive substances, glutathione, and selenium, and glutathione peroxidase activity in the mouse liver. Kasanuma Y, et al. **Tohoku J Exp Med** 1998 Jun; 185(2):79-87

[An experimental study on effects of antimony on anti-oxidase system on liver mitochondria in mice] Wang A, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):229-30 (Eng. Abstr.) **(Chi)**

[Relationship between values of antioxidant enzyme system activity in various tissues of intact rats] Levadnaia OV, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):53-8 (Eng. Abstr.) **(Rus)**

[Peroxide metabolism on respiratory muscles: effect of growth, maturation and aging] Montecinos L, et al. **Rev Med Chil** 1999 Mar;127(3):269-75 (Eng. Abstr.) **(Spa)**

[Short-term effects of septo-hippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain] Cruz R, et al. **Rev Neurol** 1998 Apr;26(152):551-4 (Eng. Abstr.) **(Spa)**

[Activity of antioxidant enzymes and intensity of free radical oxidation processes in swine tissues during postnatal adaptation] Snitynskyi VV, et al. **Ukr Biokhim Zh** 1998 Mar-Apr;70(2):105-10 (Eng. Abstr.) **(Ukr)**

PHARMACOLOGY

Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Konorev EA, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):421-8

ICAM-1 and VCAM-1 expression induced by TNF-alpha are inhibited by a glutathione peroxidase mimic. d'Alessio P, et al. **Free Radic Biol Med** 1998 Apr;24(6):979-87

Failure of glutathione peroxidase to reduce transient ischemic injury in the rat hippocampal CA1 subfield. Yano T, et al. **Resuscitation** 1998 Oct-Nov;39(1-2):91-8

PHYSIOLOGY

Ageing alters aortic antioxidant enzyme activities in Fischer-344 rats. Demaree SR, et al. **Acta Physiol Scand** 1999 Jul;166(3):203-8

Influence of glutathione peroxidase on coronary artery responses to alterations in PO2 and H2O2. Mohazzab-H KM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H235-41

The effect of photochemical stress upon the lenses of normal and glutathione peroxidase-1 knockout mice. Spector A, et al. **Exp Eye Res** 1998 Oct;67(4):457-71

Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein. Cheng W, et al. **FASEB J** 1999 Aug;13(11):1467-75

Contribution of antioxidant enzymes to the adaptive response to ionizing radiation of human lymphoblasts. Bravard A, et al. **Int J Radiat Biol** 1999 May;75(5):639-45

Selenium's role in infertility explained [news; comment] Strauss E. **Science** 1999 Aug 27;285(5432):1339. Comment on: Science 1999 Aug 27;285(5432):1393-6.

Dual function of the selenoprotein PHGPx during sperm maturation [see comments] Ursini F, et al. **Science** 1999 Aug 27;285(5432):1393-6. Comment in: Science 1999 Aug 27;285(5432):1339.

[Structure and function of phospholipid hydroperoxide glutathione peroxidase] Imai H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1236-46 (58 ref.) **(Jpn)**

GLUTATHIONE PROTEIN DISULFIDE OXIDOREDUCTASE see **PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE)**

GLUTATHIONE REDUCTASE

ADMINISTRATION & DOSAGE

Microinjected glutathione reductase crystals as indicators of the redox status in living cells. Keese MA, et al. **FEBS Lett** 1999 Mar 26;447(2-3):135-8

ANALYSIS

Purification of glutathione reductase from bovine brain, generation of an antiserum, and immunocytochemical localization of the enzyme in neural cells. Gutterer JM, et al. **J Neurochem** 1999 Oct;73(4):1422-30

ANTAGONISTS & INHIBITORS

Only the glutathione dependent antioxidant enzymes are inhibited by haematotoxic hydroxylamines. Spooren AA, et al. **Hum Exp Toxicol** 1998 Oct;17(10):554-9

Inhibitors of glutathione reductase as potential antimalarial drugs. Kinetic cooperativity and effect of dimethyl sulphoxide on inhibition kinetics. Lüönd RM, et al. **J Enzyme Inhib** 1998 Aug;13(5):327-45

Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. Gallwitz H, et al. **J Med Chem** 1999 Feb 11;42(3):364-72

BLOOD

Sulphydryl groups and their relation to the antioxidant enzymes of chelonian red blood cells. Torsoni MA, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):147-56

[Antioxidant enzyme activity in the erythrocytes of rats with alloxan diabetes] Terekhina NA, et al. **Patol Fiziol Eksp Ter** 1998 Oct-Dec;(4):25-6 (Eng. Abstr.) **(Rus)**

[Erythrocyte glutathione reductase in pregnant women with hemoglobin AA and AS] López N, et al. **Sangre (Barc)** 1999 Jun;44(3):195-8 (Eng. Abstr.) **(Spa)**

CHEMICAL SYNTHESIS

Probing the kinetic mechanism and coenzyme specificity of glutathione reductase from the cyanobacterium Anabaena PCC 7120 by redesign of the pyridine-nucleotide-binding site. Danielson UH, et al. **Biochemistry** 1999 Jul 20; 38(29):9254-63

CHEMISTRY

Redox potentials for yeast, Escherichia coli and human glutathione reductase relative to the NAD+/NADH redox couple: enzyme forms active in catalysis. Veine DM, et al. **Biochemistry** 1998 Nov 3;37(44):15575-82

Modification of arginine residues at the substrate binding site of yeast glutathione reductase. Pandey A, et al. **Indian J Biochem Biophys** 1998 Jun;35(3):157-60

Stereoisomers of glutathione: preparation and enzymatic reactivities. Oikawa T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Apr;45(2):223-9

DEFICIENCY

Glutathione reductase activity deficiency in homozygous Gr1a1Neu mice does not cause haemolytic anaemia. Pretsch W. **Genet Res** 1999 Feb;73(1):1-5

GENETICS

Gene transfer of mitochondrially targeted glutathione reductase protects H441 cells from t-butyl hydroperoxide-induced oxidant stresses. O'Donovan DJ, et al. **Am J Respir Cell Mol Biol** 1999 Feb;20(2):256-63

Cloning, nucleotide sequence, and disruption of Streptococcus mutans glutathione reductase gene (gor). Yamamoto Y, et al. **Biosci Biotechnol Biochem** 1999 Jun; 63(6):1056-62

Glutathione reductase activity deficiency in homozygous Gr1a1Neu mice does not cause haemolytic anaemia. Pretsch W. **Genet Res** 1999 Feb;73(1):1-5

Gene cloning and expression of cytosolic glutathione reductase in rice (Oryza sativa L.). Kaminaka H, et al. **Plant Cell Physiol** 1998 Dec;39(12):1269-80

ISOLATION & PURIFICATION

Purification of a glutathione S-transferase and a glutathione conjugate-specific dehydrogenase involved in isoprene metabolism in Rhodococcus sp. strain AD45. van Hylckama Vlieg JE, et al. **J Bacteriol** 1999 Apr; 181(7):2094-101

Purification of glutathione reductase from bovine brain, generation of an antiserum, and immunocytochemical localization of the enzyme in neural cells. Gutterer JM, et al. **J Neurochem** 1999 Oct;73(4):1422-30

METABOLISM

Probing the kinetic mechanism and coenzyme specificity of glutathione reductase from the cyanobacterium Anabaena PCC 7120 by redesign of the pyridine-nucleotide-binding site. Danielson UH, et al. **Biochemistry** 1999 Jul 20; 38(29):9254-63

Role of active site tyrosine residues in catalysis by human glutathione reductase. Krauth-Siegel RL, et al. **Biochemistry** 1998 Oct 6;37(40):13968-77

Structure-activity relationship of schisandrins in enhancing liver mitochondrial glutathione status in CCl4-poisoned mice. Ip SP, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):313-6

Glutathione-related enzyme activities in human fetal adrenal, liver, and kidney. Peng RX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):167-71

Glutathione reductase activity and flavin concentration in guinea-pig tissues. Suzuki M, et al. **Exp Anim** 1999 Jul; 48(3):199-202

Activity of glutathione transferase and reductase in tissues of bird cherry-oat aphid during its host-plant alternation. Laskowska I, et al. **Exp Toxicol Pathol** 1999 Jul; 51(4-5):357-9

Increased oxidative stress in the RAW 264.7 macrophage cell line is partially mediated via the S-nitrosothiol-induced inhibition of glutathione reductase. Butzer U, et al. **FEBS Lett** 1999 Feb 26;445(2-3):274-8

Microinjected glutathione reductase crystals as indicators of the redox status in living cells. Keese MA, et al. **FEBS Lett** 1999 Mar 26;447(2-3):135-8

Evidence for the co-existence of glutathione reductase and trypanothione reductase in the non-trypanosomatid Euglenozoa: Euglena gracilis Z. Montrichard F, et al. **FEBS Lett** 1999 Jan 8;442(1):29-33

Effects of nerve growth factor on brain glutathione-related enzymes from aged rats. Cruz-Aguado R, et al. **Fundam Clin Pharmacol** 1998;12(5):538-45

GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Zhang K, et al. **Int J Oncol** 1999 May; 14(5):861-7

Accumulation of mercury and its effect on antioxidant enzymes in brain, liver, and kidneys of mice. Hussain S, et al. **J Environ Sci Health B** 1999 Jul;34(4):645-60

Modifications of the antioxidant enzymes in relation to chromosome imbalances in human melanoma cell lines. Bravard A, et al. **Melanoma Res** 1998 Aug;8(4):329-35

NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Cruz-Aguado R, et al. **Neurochem Int** 1999 Feb; 34(2):125-30

Effect of dietary vitamin E on antioxidant status and antioxidant enzyme activities in Sprague-Dawley rats. Lii CK, et al. **Nutr Cancer** 1998;32(2):95-100

Optimized heterologous expression of glutathione reductase from Cyanobacterium anabaena PCC 7120 and characterization of the recombinant protein. Jiang F, et al. **Protein Expr Purif** 1999 Feb;15(1):92-8

[Short-term effects of septo-hippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain] Cruz R, et al. **Rev Neurol** 1998 Apr;26(152):551-4 (Eng. Abstr.) **(Spa)**

[Activity of antioxidant enzymes and intensity of free radical oxidation processes in swine tissues during postnatal adaptation] Snitynskyi VV, et al. **Ukr Biokhim Zh** 1998 Mar-Apr;70(2):105-10 (Eng. Abstr.) **(Ukr)**

GLUTATHIONE SYNTHASE

CHEMISTRY

Molecular basis of glutathione synthetase deficiency and a rare gene permutation event. Polekhina G, et al. **EMBO J** 1999 Jun 15;18(12):3204-13

Phosphatidylinositol phosphate kinase: a link between protein kinase and glutathione synthase folds. Grishin NV. **J Mol Biol** 1999 Aug 13;291(2):239-47 (31 ref.)

DEFICIENCY

Clinical, biochemical, and molecular characterization of patients with glutathione synthetase deficiency. Al-Jishi E, et al. **Clin Genet** 1999 Jun;55(6):444-9

5-Oxoprolinuria in patients with and without defects in the gamma-glutamyl cycle. Mayatepek E. **Eur J Pediatr** 1999 Mar;158(3):221-5

Generalized glutathione synthetase deficiency and pregnancy. Ristoff E, et al. **J Inherit Metab Dis** 1999 Aug; 22(6):758-9

GENETICS

Molecular basis of glutathione synthetase deficiency and a rare gene permutation event. Polekhina G, et al. **EMBO J** 1999 Jun 15;18(12):3204-13

Biosynthesis of phytochelatins in the fission yeast. Phytochelatin synthesis: a second role for the glutathione synthetase gene of Schizosaccharomyces pombe. Al-Lahham A, et al. **Yeast** 1999 Mar 30;15(5):385-96

ISOLATION & PURIFICATION

S-(1,2-Dicarboxyethyl)glutathione in yeast: partial

purification of its synthesizing enzyme. Tsuboi S, et al. **Biol Pharm Bull** 1999 Jan;22(1):21–5

METABOLISM

Determination of cellular thiols and glutathione-related enzyme activities: versatility of high-performance liquid chromatography-spectrofluorimetric detection. Parmentier C, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20; 719(1–2):37–46

GLUTATHIONE SYNTHETASE see **GLUTATHIONE SYNTHASE**

GLUTATHIONE TRANSFERASE

Human glutathione S-transferases. Whalen R, et al. **Semin Liver Dis** 1998;18(4):345–58 (149 ref.)

ANALYSIS

Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Kase H, et al. **Acta Cytol** 1998 Nov–Dec;42(6):1397–402

5-(Pentafluorobenzoylamino)fluorescein: A selective substrate for the determination of glutathione concentration and glutathione S-transferase activity. Arttamangkul S, et al. **Anal Biochem** 1999 May 1;269(2):410–7

Enhancement of glutathione S-transferase placental-form positive liver cell foci development by microcystin-LR in aflatoxin B1-initiated rats. Sekijima M, et al. **Carcinogenesis** 1999 Jan;20(1):161–5

Effects of dietary anticarcinogens on rat gastrointestinal glutathione S-transferase theta 1-1 levels. van Lieshout EM, et al. **Carcinogenesis** 1998 Nov;19(11):2055–7

Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Ali-Osman F, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2253–61

Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Alpert LC, et al. **Clin Cancer Res** 1997 May;3(5):661–7

Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Nishimura T, et al. **Clin Cancer Res** 1996 Nov;2(11):1859–65

Drug metabolizing enzyme systems in the houbara bustard (Chlamydotis undulata). Bailey TA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Oct;120(3):365–72

Glutathione S-transferases: two-dimensional electrophoretic protein markers of lead exposure. Witzmann FA, et al. **Electrophoresis** 1998 Jun;19(8–9):1332–5

Glutathione S-transferase in human endometrium: quantitation and interindividual variability in isoform content. Barnette KG, et al. **Gynecol Obstet Invest** 1999; 47(2):114–9

Distribution of glutathione S-transferases in the human ovary: an immunohistochemical study. Tiltman AJ, et al. **Gynecol Obstet Invest** 1999;47(4):247–50

Immunohistochemical localization of glutathione S-transferase-T1 in murine kidney, liver, and lung. Quondamatteo F, et al. **Histochem Cell Biol** 1998 Oct; 110(4):417–23

Immunolocalisation of the glutathione S-transferases, GST-26 and GST-28, within adult Schistosoma japonicum. Gobert GN, et al. **Int J Parasitol** 1998 Sep;28(9):1437–43

Liver glutathione content and glutathione-dependent enzymes of two species of freshwater fish as bioindicators of chemical pollution. Almar M, et al. **J Environ Sci Health B** 1998 Nov;33(6):769–83

Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. Flendrig LM, et al. **J Hepatol** 1999 Feb;30(2):311–20

Lack of inhibitory effects of the Ju-myo protein on development of glutathione S-transferase placental form-positive foci in the male F344 rat liver. Ichihara T, et al. **J Toxicol Sci** 1999 Feb;24(1):27–31

Immunohistochemical localization of glutathione S-transferase alpha and pi in human esophageal squamous epithelium, Barrett's epithelium and carcinoma. van Lieshout EM, et al. **Jpn J Cancer Res** 1999 May;90(5):530–5

Characterization of rat pancreatic glutathione S-transferases by chromatofocusing, reverse-phase high-performance liquid chromatography, and immunohistochemistry. March TH, et al. **Pancreas** 1998 Oct;17(3):217–28

Marriage of a medium-term liver model to surrogate markers--a practical approach for risk and benefit assessment. Moore MA, et al. **Toxicol Pathol** 1999 Mar–Apr;27(2):237–42 (37 ref.)

Value of alpha-glutathione sulfotransferase in the assessment of hepatic injury after experimental long-term preservation. Cascales P, et al. **Transplant Proc** 1999 Sep;31(6):2435–6

Quantitative immunohistochemical analysis of the glutathione S-transferase GSTM1: in situ phenotyping in archival material. Fritz P, et al. **Xenobiotica** 1999 Jul;29(7):693–702

[A study on diagnosis of oral squamous cell carcinoma (oral SCC) by glutathione S-transferase-pi (GST-pi)] Kobayashi Y. **Kokubyo Gakkai Zasshi** 1999 Mar;66(1):46–56 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. Cornett R, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):752–6

Adaptive response to glutathione S-transferase inhibitors. Ciaccio PJ, et al. **Br J Cancer Suppl** 1996 Jul;27:S93–8 (47 ref.)

Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid. Caffrey PB, et al. **Cancer Lett** 1999 Feb 8;136(1):47–52

Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Mulders TM, et al. **Clin Cancer Res** 1995 Dec;1(12):1525–36

Only the glutathione dependent antioxidant enzymes are inhibited by haematotoxic hydroxylamines. Spooren AA, et al. **Hum Exp Toxicol** 1998 Oct;17(10):554–9

In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells. Shoieb AM, et al. **In Vivo** 1998 Sep–Oct;12(5):455–62

Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers. Bannenberg G, et al. **J Biol Chem** 1999 Jan 22; 274(4):1994–9

BIOSYNTHESIS

Placental glutathione S-transferase isoenzyme expression during promotion of two-stage hamster cheek-pouch carcinogenesis. Lin CC, et al. **Arch Oral Biol** 1999 Jun; 44(6):525–9

Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against oxidative stress. Fiander H, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):591–5

Disruption of c-Fos leads to increased expression of NAD(P)H:quinone oxidoreductase1 and glutathione S-transferase. Wilkinson J 4th, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):855–8

Altered glutathione transferase levels in rat skin inflamed due to contact hypersensitivity: induction of the alpha-class subunit 1. Kimura J, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):605–10

Increased bioactivation of dihaloalkanes in rat liver due to induction of class theta glutathione S-transferase T1-1. Sherratt PJ, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):619–30

Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. van Lieshout EM, et al. **Cancer Res** 1999 Feb 1;59(3):586–9

Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. Zhang Y, et al. **Cancer Res** 1998 Oct 15;58(20):4632–9

Decreased expression of glutathione S-transferase M1 in HPV16-transfected human cervical keratinocytes in culture. Chen C, et al. **Carcinogenesis** 1999 Apr; 20(4):699–703

Differential induction of rat hepatic microsomal epoxide hydrolase and rGSTA2 by diazines: the role of cytochrome P450 2E1-mediated metabolic activation. Cho MK, et al. **Chem Biol Interact** 1998 Nov 27;116(3):229–45

Thioureas differentially induce rat hepatic microsomal epoxide hydrolase and rGSTA2 irrespective of their oxygen radical scavenging effect: effects on toxicant-induced liver injury. Kim SG, et al. **Chem Biol Interact** 1999 Jan 29;117(2):117–34

Preclinical and clinical evaluation of broccoli supplements as inducers of glutathione S-transferase activity. Clapper ML, et al. **Clin Cancer Res** 1997 Jan;3(1):25–30

Some effects of the fungicide propiconazole on cytochrome P450 and glutathione S-transferase in brown trout (Salmo trutta). Egaas E, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Mar;122(3):337–44

Coordinate regulation of NAD(P)H:quinone oxidoreductase and glutathione-S-transferases in primary cultures of rat neurons and glia: role of the antioxidant/electrophile responsive element. Ahlgren-Beckendorf JA, et al. **Glia** 1999 Jan 15;25(2):131–42

Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. Davila JC, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar; 35(3):120–30

Molecular cloning and heterologous expression of a glutathione S-transferase involved in insecticide resistance from the diamondback moth, Plutella xylostella. Huang HS, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):651–8

Induction of glutathione S-transferase hGST 5.8 is an early response to oxidative stress in RPE cells. Singhal SS, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2652–9

Selective expression of a glutathione S-transferase subclass during spermatogenesis. Rowe JD, et al. **J Androl** 1998 Sep–Oct;19(5):558–67

Expression of two glutathione S-transferase genes in the yeast Issatchenkia orientalis is induced by o-dinitrobenzene during cell growth arrest. Tamaki H, et al. **J Bacteriol** 1999 May;181(9):2958–62

Induction of drug metabolizing enzymes by 1,7-phenanthroline and oltipraz in mice is unrelated to Ah-responsiveness. Carr BA, et al. **J Biochem Mol Toxicol** 1999;13(2):77–82

Preferential expression of biotransformation enzymes in the olfactory organs of Drosophila melanogaster, the antennae. Wang Q, et al. **J Biol Chem** 1999 Apr 9;274(15):10309–15

Exogenous 17beta-estradiol blocks alpha and mu but not pi class glutathione S-transferase immunoreactivity in epithelium of Syrian hamster vas deferens. Hudson CE, et al. **J Histochem Cytochem** 1999 Jan;47(1):91–8

TGF-beta increases leukotriene C4 synthase expression in the monocyte-like cell line, THP-1. Riddick CA, et al. **J Immunol** 1999 Jan 15;162(2):1101–7

Expression of foreign gene in mycobacterium regulated by human Mycobacterium tuberculosis heat shock protein 70 promoter. Cheng J, et al. **J Tongji Med Univ** 1997; 17(4):193–9

Dose-dependent induction of carcinomas and glutathione S-transferase placental form negative eosinophilic foci in the rat liver by di(2-ethylhexyl)phthalate after diethylnitrosamine initiation. Sano M, et al. **J Toxicol Sci** 1999 Aug;24(3):177–86

Glutathione transferase (class pi) and tissue transglutaminase (Tgase C) expression in pterygia. Kim YJ, et al. **Korean J Ophthalmol** 1998 Jun;12(1):6–13

Differential induction of glutathione S-transferase subunits by spironolactone in rat liver, jejunum and colon. Catania VA, et al. **Life Sci** 1998;63(26):2285–93

Induction of glutathione s-transferase-pi in Barrett's metaplasia and Barrett's adenocarcinoma cell lines. Compton KR, et al. **Mol Carcinog** 1999 Feb;24(2):128–36

[Diet and antioxidant--a nutritional intervention study] He L, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Dec;18(6):325–7 (Eng. Abstr.) **(Chi)**

BLOOD

Determination of plasma alpha-glutathione-S-transferases in chronic alcohol abusers: relationship with alcohol intake and liver involvement. Loguercio C, et al. **Alcohol Alcohol** 1998 Jul–Aug;33(4):366–72

Erythrocyte glutathione S transferase as a marker of oxidative stress at birth. Neefjes VM, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F130–3

Glutathione S-transferase Alpha 1-1 and aminotransferases in umbilical cord blood. Knapen MF, et al. **Early Hum Dev** 1999 Mar;54(2):129–35

Administration of prostaglandin E1 reduces post-operative hepatocellular damage and restores hepatic integrity in patients undergoing hepatectomy. Baek Y, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1836–41

Plasma glutathione S-transferase Pi 1-1 measurements in the study of hemolysis in hypertensive disorders of pregnancy. Knapen MF, et al. **Hypertens Pregnancy** 1999;18(2):147–56

Detection and clinical significance of plasma glutathione-S-transferases in dogs with lymphoma. Hahn KA, et al. **In Vivo** 1999 Mar–Apr;13(2):173–5

The use of human glutathione S-transferase A1 in the detection of cystic fibrosis liver disease. Hung JC, et al. **J Paediatr Child Health** 1998 Aug;34(4):335–8

Comparison between serum alpha-glutathione S-transferase and aminotransaminases in detecting cytolysis in hepatitis C-infected children. Namour F, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):534–7

Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Loguercio C, et al. **Liver** 1998 Jun;18(3):166–72

The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Boran M, et al. **Nephron** 1999;82(1):22–6

Indications for determination of alpha-glutathione-s-transferase after liver transplantation. Platz KP, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):462–4

The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. Dickson RC, et al. **Transplantation** 1999 Jul 27;68(2):247–53

[Blood and leukocyte glutathione and glutathione S-transferase: relationship to cholesterolemia in healthy volunteers] Gannagé-Yared MH, et al. **Ann Biol Clin (Paris)** 1998 May–Jun;56(3):321–7 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Crystallization of an intact GST-estrogen receptor hormone binding domain fusion protein. Lally JM, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):423–6

Preliminary X-ray crystallographic studies of a newly defined human theta-class glutathione transferase. McKinstry WJ, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jan 1;54 (Pt 1):148–50

Differential enantioselectivity of murine glutathione S-transferase isoenzymes in the glutathione conjugation of trans-3,4-dihydroxy-1, 2-oxy-1,2,3,4-tetrahydrobenzo[c]phenanthrene stereoisomers. Hu X, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):40–8

Affinity labeling of pig lung glutathione S-transferase pi by 4-(fluorosulfonyl)benzoic acid. Pettigrew NE, et al. **Arch Biochem Biophys** 1999 Apr 1;364(1):107–14

Multiple unfolded states of glutathione transferase bbGSTP1-1 by guanidinium chloride. Sacchetta P, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):100-6

Quantitative differences in the active-site hydrophobicity of five human glutathione S-transferase isoenzymes: water-soluble carcinogen-selective properties of the neoplastic GSTP1-1 species. Satoh K, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):271-6

A topologically conserved aliphatic residue in alpha-helix 6 stabilizes the hydrophobic core in domain II of glutathione transferases and is a structural determinant for the unfolding pathway. Wallace LA, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):413-8

Elucidation of a monovalent cation dependence and characterization of the divalent cation binding site of the fosfomycin resistance protein (FosA). Bernat BA, et al. **Biochemistry** 1999 Jun 8;38(23):7462-9

Thiol ester hydrolysis catalyzed by glutathione S-transferase A1-1. Dietze EC, et al. **Biochemistry** 1998 Oct 20; 37(42):14948-57

Fast product formation and slow product release are important features in a hysteretic reaction mechanism of glutathione transferase T2-2. Jemth P, et al. **Biochemistry** 1999 Aug 3;38(31):9982-91

Structure and function of residue 104 and water molecules in the xenobiotic substrate-binding site in human glutathione S-transferase P1-1. Ji X, et al. **Biochemistry** 1999 Aug 10;38(32):10231-8

Stopped-flow kinetic analysis of the ligand-induced coil-helix transition in glutathione S-transferase A1-1: evidence for a persistent denatured state. Nieslanik BS, et al. **Biochemistry** 1999 May 25;38(21):6971-80

Functions of His107 in the catalytic mechanism of human glutathione S-transferase hGSTM1a-1a. Patskovsky YV, et al. **Biochemistry** 1999 Jan 26;38(4):1193-202

Class sigma glutathione transferase unfolds via a dimeric and a monomeric intermediate: impact of subunit interface on conformational stability in the superfamily. Stevens JM, et al. **Biochemistry** 1998 Nov 3;37(44):15534-41

Crystal structure of a murine glutathione S-transferase in complex with a glutathione conjugate of 4-hydroxynon-2-enal in one subunit and glutathione in the other: evidence of signaling across the dimer interface. Xiao B, et al. **Biochemistry** 1999 Sep 14;38(37):11887-94

Characterization of toad liver glutathione transferase. Bucciarelli T, et al. **Biochim Biophys Acta** 1999 Apr 12; 1431(1):189-98

Homology modeling of cephalopod lens S-crystallin: a natural mutant of sigma-class glutathione transferase with diminished endogenous activity. Chuang CC, et al. **Biophys J** 1999 Feb;76(2):679-90

LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Penrose JF. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):133-52 (90 ref.)

Glutathione S-transferases--a review. Salinas AE, et al. **Curr Med Chem** 1999 Apr;6(4):279-309 (103 ref.)

Mechanistic imperatives for the evolution of glutathione transferases. Armstrong RN. **Curr Opin Chem Biol** 1998 Oct;2(5):618-23 (54 ref.)

Strategies to characterize the mechanisms of action and the active sites of glutathione S-transferases: a review. van der Aar EM, et al. **Drug Metab Rev** 1998 Aug;30(3):569-643 (169 ref.)

Molecular dynamics simulations of a protein-protein dimer: particle-mesh Ewald electrostatic model yields far superior results to standard cutoff model. Norberto de Souza O, et al. **J Biomol Struct Dyn** 1999 Jun;16(6):1205-18

Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. Bruns CM, et al. **J Mol Biol** 1999 May 7;288(3):427-39

Mutations of Gly to Ala in human glutathione transferase P1-1 affect helix 2 (G-site) and induce positive cooperativity in the binding of glutathione. Lo Bello M, et al. **J Mol Biol** 1998 Dec 18;284(5):1717-25

Solution structure of the carboxyl terminus of a human class Mu glutathione S-transferase: NMR assignment strategies in large proteins. McCallum SA, et al. **J Mol Biol** 1999 Feb 5;285(5):2119-32

The ligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). Oakley AJ, et al. **J Mol Biol** 1999 Aug 27; 291(4):913-26

The projection structure of the membrane protein microsomal glutathione transferase at 3 A resolution as determined from two-dimensional hexagonal crystals. Schmidt-Krey I, et al. **J Mol Biol** 1999 Apr 30; 288(2):243-53

Salmonid olfactory system-specific protein (N24) exhibits glutathione S-transferase class pi-like structure. Kudo H, et al. **J Neurochem** 1999 Apr;72(4):1344-52

Stereoisomers of glutathione: preparation and enzymatic reactivities. Oikawa T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Apr;45(2):223-9

Characterization of glutathione S-transferase of Taenia solium. Vibanco-Pérez N, et al. **J Parasitol** 1999 Jun; 85(3):448-53

Parameters for the two-dimensional crystallization of the membrane protein microsomal glutathione transferase. Schmidt-Krey I, et al. **J Struct Biol** 1998 Oct;123(2):87-96

Preliminary crystallographic study of glutathione S-transferase fused with the nuclear matrix targeting signal of the transcription factor AML-1/CBF-alpha2. Tang L, et al. **J Struct Biol** 1998 Sep;123(1):83-5

The locally denatured state of glutathione S-transferase A1-1: transition state analysis of ligand-dependent formation of the C-terminal helix. Nieslanik BS, et al. **Pac Symp Biocomput** 1999;:554-65

A homology model for the human theta-class glutathione transferase T1-1. Flanagan JU, et al. **Proteins** 1998 Nov 15;33(3):444-54

Structures of herbicides in complex with their detoxifying enzyme glutathione S-transferase - explanations for the selectivity of the enzyme in plants. Prade L, et al. **Structure** 1998 Nov 15;6(11):1445-52

CLASSIFICATION

Structure and organization of the human theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex. Coggan M, et al. **Biochem J** 1998 Sep 15; 334 (Pt 3):617-23

DEFICIENCY

Leukotriene C4-synthesis deficiency: a new inborn error of metabolism linked to a fatal developmental syndrome [see comments] Mayatepek E, et al. **Lancet** 1998 Nov 7; 352(9139):1514-7. Comment in: Lancet 1998 Nov 7;352(9139):1487-8.

DRUG EFFECTS

Effect of nodularin on the expression of glutathione S-transferase placental form and proliferating cell nuclear antigen in N-nitrosodiethylamine initiated hepatocarcinogenesis in the male Fischer 344 rat. Song KY, et al. **Carcinogenesis** 1999 Aug;20(8):1541-8

Modulation of drug-metabolizing systems by bacterial endotoxin in carp liver and immune organs. Marionnet D, et al. **Ecotoxicol Environ Saf** 1998 Oct;41(2):189-94

Modulation of cytochrome P-450 and glutathione S-transferase isoform expression in vivo by intact and degraded indolyl glucosinolates. Bonnesen C, et al. **Nutr Cancer** 1999;33(2):178-87

Modulatory potential of Spirulina fusiformis on carcinogen metabolizing enzymes in Swiss albino mice. Mittal A, et al. **Phytother Res** 1999 Mar;13(2):111-4

GENETICS

Expression, crystallization and preliminary X-ray analysis of ligand-free human glutathione S-transferase M2-2. Patskovska LN, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):458-60

Alpha, beta-unsaturated aldehydes mediate inducible expression of glutathione S-transferase in hepatoma cells through activation of the antioxidant response element (ARE). Tjalkens RB, et al. **Adv Exp Med Biol** 1999; 463:123-31

Glutathione S-transferase M1 genotypes and the risk of squamous carcinoma of the cervix: a population-based case-control study. Chen C, et al. **Am J Epidemiol** 1999 Sep 15;150(6):568-72

Glutathione S-transferase M1 genotypes and the risk of vulvar cancer: a population-based case-control study. Chen C, et al. **Am J Epidemiol** 1999 Sep 1;150(5):437-42

Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Yu MW, et al. **Am J Epidemiol** 1999 Apr 1;149(7):621-9

Expression and inducibility of alpha, pi, and Mu glutathione S-transferase protein and mRNA in murine lung. Forkert PG, et al. **Am J Respir Cell Mol Biol** 1999 Jan;20(1):143-52

Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Mattey DL, et al. **Ann Rheum Dis** 1999 Mar;58(3):164-8

Identification of two activating elements in the proximal promoter region of the human glutathione transferase-A1 and -A2 genes. Lörper M, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):122-7

Role of active-site residues 107 and 108 of glutathione S-transferase mGSTA4-4 in determining the catalytic properties of the enzyme for 4-hydroxynonenal. Nanduri B, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):167-74

Distinctive structure of the human GSTM3 gene-inverted orientation relative to the mu class glutathione transferase gene cluster. Patskovsky YV, et al. **Arch Biochem Biophys** 1999 Jan 1;361(1):85-93

Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Srivastava SK, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):89-94

Alpha,beta-unsaturated aldehydes increase glutathione S-transferase mRNA and protein: correlation with activation of the antioxidant response element. Tjalkens RB, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):42-50

Glutathione S-transferase (GST) M1 and GST T1 genotypes and hematopoietic effects of benzene exposure. Hsieh LL, et al. **Arch Toxicol** 1999 Mar;73(2):80-2

Structure and organization of the human theta-class glutathione S-transferase and D-dopachrome tautomerase gene complex. Coggan M, et al. **Biochem J** 1998 Sep 15; 334 (Pt 3):617-23

Genomic organization, 5'-flanking region and chromosomal localization of the human glutathione transferase A4 gene. Desmots F, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):437-42

Molecular cloning, expression and site-directed mutagenesis of glutathione S-transferase from Ochrobactrum anthropi. Favaloro B, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):573-9

Genomic cloning and characterization of the rat glutathione S-transferase-A3-subunit gene. Fotouhi-Ardakani N, et al. **Biochem J** 1999 May 1;339 (Pt 3):685-93

Co-expression of glutathione S-transferase with methionine aminopeptidase: a system of producing enriched N-terminal processed proteins in Escherichia coli. Hwang DD, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):335-42

Identification of an enhancer element of class Pi glutathione S-transferase gene required for expression by a co-planar polychlorinated biphenyl. Matsumoto M, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):599-605

Expression and purification of the first nucleotide-binding domain and linker region of human multidrug resistance gene product: comparison of fusions to glutathione S-transferase, thioredoxin and maltose-binding protein. Wang C, et al. **Biochem J** 1999 Feb 15;338 (Pt 1):77-81

Gene structure, expression and chromosomal localization of murine theta class glutathione transferase mGSTT1-1. Whittington A, et al. **Biochem J** 1999 Jan 1;337 (Pt 1):141-51

Lipopolysaccharide inhibition of rat hepatic microsomal epoxide hydrolase and glutathione S-transferase gene expression irrespective of nuclear factor-kappaB activation. Choi SH, et al. **Biochem Pharmacol** 1998 Dec 1; 56(11):1427-36

Correlation of increased mortality with the suppression of radiation-inducible microsomal epoxide hydrolase and glutathione S-transferase gene expression by dexamethasone: effects on vitamin C and E-induced radioprotection. Nam SY, et al. **Biochem Pharmacol** 1998 Nov 15;56(10):1295-304

Cellular balance of glutathione levels through the expression of gamma-glutamylcysteine synthetase and glutathione thiol transferase genes in human hepatic cells resistant to a glutathione poison. Tanaka T, et al. **Biochim Biophys Acta** 1999 May 24;1427(3):367-77

Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Krajinovic M, et al. **Blood** 1999 Mar 1;93(5):1496-501

Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Charrier J, et al. **Br J Cancer** 1999 Jan;79(2):346-53

Genetic polymorphism of glutathione S-transferase P1 gene and lung cancer risk. To-Figueras J, et al. **Cancer Causes Control** 1999 Feb;10(1):65-70

Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: a prospective study. Gertig DM, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1001-5

Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Jourenkova-Mironova N, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Feb;8(2):185-8

Chromosomal aberrations in humans induced by urban air pollution: influence of DNA repair and polymorphisms of glutathione S-transferase M1 and N-acetyltransferase 2. Knudsen LE, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 1):303-10

Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Lin DX, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1013-8

Glutathione S-transferase M1 and susceptibility to nasopharyngeal carcinoma. Nazar-Stewart V, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jun;8(6):547-51

Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Nyberg F, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):875-83

Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Pastorelli R, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Aug;7(8):703-9

Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype. Ramachandran S, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jan; 8(1):61-7

Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Rebbeck TR, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 1):283-7

Urinary total isothiocyanate (ITC) in a population-based sample of middle-aged and older Chinese in Singapore: relationship with dietary total ITC and glutathione S-transferase M1/T1/P1 genotypes. Seow A, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Sep;7(9):775-81

NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Slattery ML, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec;7(12):1079-84

Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Welfare M, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 1):289-92

Polymorphism of glutathione S-transferase loci GSTM1 and GSTT1 and susceptibility to colorectal cancer in Egypt. Abdel-Rahman SZ, et al. **Cancer Lett** 1999 Jul 19; 142(1):97-104

Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Katoh T, et al. **Cancer Lett** 1998 Oct 23;132(1-2):147-52

Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers. Kihara M, et al. **Cancer Lett** 1999 Mar 22;137(1):53-60

Ethnic susceptibility to lung cancer: differences in CYP2E1, CYP1A1 and GSTM1 genetic polymorphisms between French Caucasian and Chilean populations. Quiñones L, et al. **Cancer Lett** 1999 Jul 1;141(1-2):167-71

A multiplex-PCR/RFLP procedure for simultaneous CYP2E1, mEH and GSTM1 genotyping. Salama SA, et al. **Cancer Lett** 1999 Aug 23;143(1):51-6

Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Esteller M, et al. **Cancer Res** 1998 Oct 15;58(20):4515-8

Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Hu X, et al. **Cancer Res** 1998 Dec 1;58(23):5340-3

Differential protection against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced DNA damage in HepG2 cells stably transfected with allelic variants of pi class human glutathione S-transferase. Hu X, et al. **Cancer Res** 1999 May 15;59(10):2358-62

Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Le Marchand L, et al. **Cancer Res** 1998 Nov 1;58(21):4858-63

Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. van Lieshout EM, et al. **Cancer Res** 1999 Feb 1;59(3):586-9

Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Lemos MC, et al. **Carcinogenesis** 1999 Jul;20(7):1225-9

Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers. Nair UJ, et al. **Carcinogenesis** 1999 May;20(5):743-8

Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Ozawa S, et al. **Carcinogenesis** 1999 Jun;20(6):991-5

Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer. Wang YC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul; 62(7):395-403

Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer. Howells RE, et al. **Clin Cancer Res** 1998 Oct; 4(10):2439-45

Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. O'Dwyer PJ, et al. **Clin Cancer Res** 1997 May;3(5):783-91

Overexpression and amplification of glutathione S-transferase pi gene in head and neck squamous cell carcinomas. Wang X, et al. **Clin Cancer Res** 1997 Jan; 3(1):111-4

Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Arruda VR, et al. **Clin Genet** 1998 Sep;54(3):210-4

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Wormhoudt LW, et al. **Crit Rev Toxicol** 1999 Jan; 29(1):59-124 (545 ref.)

Characterization and chromosome location of the gene GSTZ1 encoding the human Zeta class glutathione transferase and maleylacetoacetate isomerase. Blackburn AC, et al. **Cytogenet Cell Genet** 1998;83(1-2):109-14

Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Ingelman-Sundberg M. **Drug Metab Rev** 1999 May; 31(2):449-59 (27 ref.)

High expression of bovine alpha glutathione S-transferase (GSTA1, GSTA2) subunits is mainly associated with steroidogenically active cells and regulated by gonadotropins in bovine ovarian follicles. Rabahi F, et al. **Endocrinology** 1999 Aug;140(8):3507-17

Risk of recurrent spontaneous abortion, cigarette smoking, and genetic polymorphisms in NAT2 and GSTM1. Mendola P, et al. **Epidemiology** 1998 Nov;9(6):666-8

Distribution of microsomal glutathione transferase 1 in mammalian tissues. Estonius M, et al. **Eur J Biochem** 1999 Mar; 260(2):409-13

GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels. Butkiewicz D, et al. **Eur J Cancer Prev** 1999 Aug; 8(4):315-23

CYP2D6 and GSTM1 genotypes in a Polish population. Gawronska-Szklarz B, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):389-92

Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients. Hong YS, et al. **Exp Mol Med** 1998 Dec 31;30(4):192-8

Polymorphism of GSTM1 gene in patients with colorectal cancer and colonic polyps. Gawrońska-Szklarz B, et al. **Exp Toxicol Pathol** 1999 Jul;51(4-5):321-5

Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis. Piredda L, et al. **FASEB J** 1999 Feb;13(2):355-64

Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. Van Schooten FJ, et al. **FASEB J** 1998 Oct;12(13):1409-17

Detoxication of carcinogenic fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase P1-1 variants and glutathione. Sundberg K, et al. **FEBS Lett** 1998 Nov 6;438(3):206-10

Glutathione S-transferases and prevention of cellular free radical damage. Ketterer B. **Free Radic Res** 1998 Jun; 28(6):647-58 (70 ref.)

Expression and regulation of leukotriene-synthesis enzymes in rat liver cells. Shimada K, et al. **Hepatology** 1998 Nov; 28(5):1275-81

Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Stroombergen MC, et al. **Hum Exp Toxicol** 1999 Mar;18(3):141-5

Molecular cloning and heterologous expression of a glutathione S-transferase involved in insecticide resistance from the diamondback moth, Plutella xylostella. Huang HS, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):651-8

Is the insect glutathione S-transferase I gene family intronless? Lougarre A, et al. **Insect Mol Biol** 1999 Feb; 8(1):141-3

Ethylene oxide-protein adduct formation in humans: influence of glutathione-S-transferase polymorphisms. Müller M, et al. **Int Arch Occup Environ Health** 1998 Oct; 71(7):499-502

Influence of GSTM1 genotypes on anti-BPDE-DNA adduct levels in mononuclear white blood cells of humans exposed to PAH. Pavanello S, et al. **Int Arch Occup Environ Health** 1999 Jul;72(4):238-46

Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Cheng L, et al. **Int J Cancer** 1999 Jun 21;84(3):220-4

Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Jourenkova-Mironova N, et al. **Int J Cancer** 1999 Mar 31;81(1):44-8

Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Morita S, et al. **Int J Cancer** 1999 Mar 1;80(5):685-8

The cloning and characterization of a new stress response protein. A mammalian member of a family of theta class glutathione s-transferase-like proteins. Kodym R, et al. **J Biol Chem** 1999 Feb 19;274(8):5131-7

An olfactory-specific glutathione-S-transferase in the sphinx moth Manduca sexta. Rogers ME, et al. **J Exp Biol** 1999 Jun;202 (Pt 12):1625-37

Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. Reich K, et al. **J Invest Dermatol** 1999 Aug;113(2):214-20

Evolution of differential substrate specificities in Mu class glutathione transferases probed by DNA shuffling. Hansson LO, et al. **J Mol Biol** 1999 Mar 26;287(2):265-76

Mutations of Gly to Ala in human glutathione transferase P1-1 affect helix 2 (G-site) and induce positive cooperativity in the binding of glutathione. Lo Bello M, et al. **J Mol Biol** 1998 Dec 18;284(5):1717-25

Salmonid olfactory system-specific protein (N24) exhibits glutathione S-transferase class pi-like structure. Kudo H, et al. **J Neurochem** 1999 Apr;72(4):1344-52

Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. Ambrosone CB, et al. **J Nutr** 1999 Feb;129(2S Suppl):565S-568S

Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. Lee E, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:140-2

Inhibition of early-phase exogenous and endogenous liver carcinogenesis in transgenic rats harboring a rat glutathione S-transferase placental form gene. Nakae D, et al. **Jpn J Cancer Res** 1998 Nov;89(11):1118-25

Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Murata M, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):657-60

Parkinson's disease, pesticides, and glutathione transferase polymorphisms [see comments] Menegon A, et al. **Lancet** 1998 Oct 24;352(9137):1344-6. Comment in: Lancet 1998 Oct 24;352(9137):1328-9. Comment in: Lancet 1999 Jan 2;353(9146):71-2.

Glutathione transferase polymorphism and Parkinson's disease [letter; comment] Paolini M, et al. **Lancet** 1999 Jan 2;353(9146):71-2. Comment on: Lancet 1998 Oct 24;352(9137):1344-6.

Deleted mutation of GSTT-1 gene in patients with MDS [letter] Maeda Y, et al. **Leukemia** 1998 Dec;12(12):2039

Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis. Baranova H, et al. **Mol Hum Reprod** 1999 Jul;5(7):636-41

Micronuclei in blood lymphocytes and genetic polymorphism for GSTM1, GSTT1 and NAT2 in pesticide-exposed greenhouse workers. Falck GC, et al. **Mutat Res** 1999 May 17;441(2):225-37

Influence of metabolic genotype GSTM1 on levels of urinary mutagens in patients treated topically with coal tar. Gabbani G, et al. **Mutat Res** 1999 Mar 15;440(1):27-33

Evaluation of DNA damage by the Comet assay in shoe workers exposed to toluene and other organic solvents. Pitarque M, et al. **Mutat Res** 1999 Apr 26;441(1):115-27

Glutathione S-transferase M1 genotype influences sister chromatid exchange induction but not adaptive response in human lymphocytes treated with 1,2-epoxy-3-butene. Sąsiadek M, et al. **Mutat Res** 1999 Feb 19;439(2):207-12

Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers. Salagovic J, et al. **Neoplasma** 1998;45(5):312-7

Peripheral biomarkers and exposure to manganese. Smargiassi A, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):401-6 (37 ref.)

Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Millar DS, et al. **Oncogene** 1999 Feb 11;18(6):1313-24

Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Venugopal R, et al. **Oncogene** 1998 Dec 17; 17(24):3145-56

Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Tanimoto K, et al. **Oral Oncol** 1999 Mar; 35(2):191-6

Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression. Smooker PM, et al. **Parasite Immunol** 1999 Jul;21(7):357-64

No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease. De Sousa M, et al. **Pharmacogenetics** 1998 Aug;8(4):353-5

Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Jourenkova-Mironova N, et al. **Pharmacogenetics** 1998 Dec;8(6):495-502

Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Katoh T, et al. **Pharmacogenetics** 1999 Apr;9(2):165-9

Detection of the GSTM1*0 allele by long polymerase chain reaction. Kerb R, et al. **Pharmacogenetics** 1999 Feb; 9(1):89-94

Individual sensitivity to cytogenetic effects of 1,2:3,4-diepoxybutane in cultured human lymphocytes: influence of glutathione S-transferase M1, P1 and T1 genotypes. Landi S, et al. **Pharmacogenetics** 1998 Dec; 8(6):461-71

Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Matthias C, et al. **Pharmacogenetics** 1998 Apr;8(2):91-100

Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients [published erratum appears in Pharmacogenetics 1999 Feb;9(1):following 127] Nedelcheva Kristensen V, et al. **Pharmacogenetics** 1998 Oct;8(5):441-7

p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. Przygodzki RM, et al. **Pharmacogenetics** 1998 Dec;8(6):503-11

High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Rojas M, et al. **Pharmacogenetics** 1998 Apr;8(2):109-18

The hereditary transmission of the glutathione transferase hGSTT1-1 conjugator phenotype in a large family. Wiebel FA, et al. **Pharmacogenetics** 1999 Apr;9(2):251-6

Selection of Arabidopsis mutants overexpressing genes driven by the promoter of an auxin-inducible glutathione S-transferase gene. van der Kop DA, et al. **Plant Mol Biol** 1999 Mar;39(5):979-90

The role of alternative mRNA splicing in generating heterogeneity within the Anopheles gambiae class I glutathione S-transferase family. Ranson H, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14284-9

Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Hengstler JG, et al. **Recent Results Cancer Res** 1998; 154:47-85 (178 ref.)

High-throughput genotyping method for glutathione S-transferase T1 and M1 gene deletions using TaqMan probes. Shi MM, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan;103(1):3-15

The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Layton MA, et al.

Rheumatology (Oxford) 1999 Jan;38(1):43–7
Glutathione S-transferase (GST) M1, T1, P1, N-acetyltransferase (NAT) 1 and 2 genetic polymorphisms and susceptibility to colorectal cancer. Yoshioka M, et al. **Sangyo Ika Daigaku Zasshi** 1999 Jun 1;21(2):133–47
N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study. Rodrigo L, et al. **Scand J Gastroenterol** 1999 Mar;34(3):303–7
Influence of genetic polymorphisms of biotransformation enzymes on gene mutations, strand breaks of deoxyribonucleic acid, and micronuclei in mononuclear blood cells and urinary 8-hydroxydeoxyguanosine in potroom workers exposed to polyaromatic hydrocarbons. Carstensen U, et al. **Scand J Work Environ Health** 1999 Aug;25(4):351–60
Glutathione S-transferase M1 and P1 genotypes and urinary excretion of 1-hydroxypyrene in coke oven workers. Ovrebø S, et al. **Sci Total Environ** 1998 Sep 4;220(1):25–31
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Ishii T, et al. **Thorax** 1999 Aug;54(8):693–6
Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. El-Masri HA, et al. **Toxicol Appl Pharmacol** 1999 Aug 1;158(3):221–30
Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis. Board P, et al. **Toxicol Lett** 1998 Dec 28;102–103:149–54
Polymorphisms in xenobiotic conjugation and disease predisposition. Brockmöller J, et al. **Toxicol Lett** 1998 Dec 28;102–103:173–83 (64 ref.)
A 47-amino-acid fragment of SV40 T antigen represses transcription from human GSTalpha promoters. Sompayrac L, et al. **Virology** 1998 Sep 30;249(2):275–85
[The mutation of deletion for glutathione S-transferase M1 gene in the tissue of hepatocellular carcinoma] Bian J, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Jun; 16(3):171–3 (Eng. Abstr.) **(Chi)**
[Glutathione S-transferase M1, T1 genotypes and the risk of esophageal cancer: a case-control study] Lin D, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Aug; 19(4):195–9 (Eng. Abstr.) **(Chi)**
[Immunohistologic and molecular genetic studies of the effect of glutathione-S-transferases on the development of squamous epithelial carcinomas in the area of the head-neck] Matthias C, et al. **Laryngorhinootologie** 1999 Apr;78(4):182–8 (Eng. Abstr.) **(Ger)**
[Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes] Ozawa S. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):69–81 (126 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Simplified gene-fragment phage display system for epitope mapping. Gupta S, et al. **Biotechniques** 1999 Aug; 27(2):328–30, 332–4
Glutathione S-transferase as a major autoantigen in anti-SLA-positive autoimmune hepatitis [letter; comment] Klein R, et al. **Gastroenterology** 1999 Apr;116(4):1015–6. Comment on: Gastroenterology 1998 Feb;114(2):329–35.
Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium. Kremer L, et al. **Infect Immun** 1998 Dec;66(12):5669–76
Schistosoma bovis: vaccine effects of a recombinant homologous glutathione S-transferase in sheep. Boulanger D, et al. **Int J Parasitol** 1999 Mar;29(3):415–8
Differential expression of PSP94 in rat prostate lobes as demonstrated by an antibody against recombinant GST-PSP94. Kwong J, et al. **J Cell Biochem** 1999 Sep 1;74(3):406–17
Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. Sun JB, et al. **J Immunol** 1999 Jul 15;163(2):1045–52
Production of glutathione-coated microtitre plates for capturing recombinant glutathione S-transferase fusion proteins as antigens in immunoassays. Murray AM, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):133–9
Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment. Dupré, et al. **J Infect Dis** 1999 Aug;180(2):454–63
Glutathione S-transferases of 28kDa as major vaccine candidates against schistosomiasis. Riveau G, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:87–94 (41 ref.)
Egg-hatching inhibition in mice immunized with recombinant Schistosoma bovis 28 kDa glutathione S-transferase. Da Costa AV, et al. **Parasite Immunol** 1999 Jul;21(7):341–50
Definition and mapping of epitopes recognized by specific monoclonal antibodies to Schistosoma bovis 28 kDa glutathione S-transferase: relation with anti-egg viability immunity. da Costa AV, et al. **Parasite Immunol** 1999 Jan; 21(1):9–18
Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression. Smooker PM, et al. **Parasite Immunol** 1999 Jul;21(7):357–64
Generation of native bovine mAbs by phage display. O'Brien PM, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):640–5
Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge. Boulanger D, et al. **Vaccine** 1999 Jan 28;17(4):319–26
Induction of specific cell-mediated immunity in mice by oral immunization with Salmonella expressing Onchocerca volvulus glutathione S-transferase. Catmull J, et al. **Vaccine** 1999 Jan;17(1):31–9
Lack of humoral and cellular responses against glutathione S-transferases in Fasciola hepatica experimentally infected sheep. Moreau E, et al. **Vet Res** 1998 Nov-Dec; 29(6):585–91
Isolation, characterization and comparison of antipeptide and antiprotein rabbit antibodies to the pi-isoform of glutathione S-transferase. Di Modugno F, et al. **Z Naturforsch [C]** 1998 Sep-Oct;53(9–10):902–10

ISOLATION & PURIFICATION

Purification and characterization of a novel alpha-class glutathione transferase from human liver. Pastore A, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1235–43
Purification of a glutathione S-transferase and a glutathione conjugate-specific dehydrogenase involved in isoprene metabolism in Rhodococcus sp. strain AD45. van Hylckama Vlieg JE, et al. **J Bacteriol** 1999 Apr; 181(7):2094–101
[Isolation and purification of recombinant truncated (delta2–27) cytochrome P450 2B4 expressed in E. coli cells as a fusion protein with glutathione-S-transferase] Sokolov NN, et al. **Vopr Med Khim** 1999 Jan-Feb;45(1):24–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Determination of intestinal alpha-glutathione S-transferase after ischemia-reperfusion injury. Braun F, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):229–33
Enzymes metabolizing aldehydes in HL-60 human leukemic cells. Barrera G, et al. **Adv Exp Med Biol** 1999;463:517–22
Formation of lens aldose reductase mixed disulfides with GSH by UV irradiation and its proteolysis by lens calpain. Mizoguchi T, et al. **Adv Exp Med Biol** 1999;463:481–6
Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione S-transferase-pi by treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion. Tominaga K, et al. **Am J Gastroenterol** 1999 Jun;94(6):1664–8
Influence of the amino acid residue downstream of (Asp)4Lys on enterokinase cleavage of a fusion protein. Hosfield T, et al. **Anal Biochem** 1999 Apr 10;269(1):10–6
Role of active-site residues 107 and 108 of glutathione S-transferase mGSTA4-4 in determining the catalytic properties of the enzyme for 4-hydroxynonenal. Nanduri B, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):167–74
Affinity labeling of pig lung glutathione S-transferase pi by 4-(fluorosulfonyl)benzoic acid. Pettigrew NE, et al. **Arch Biochem Biophys** 1999 Apr 1;364(1):107–14
Multiple unfolded states of glutathione transferase bbGSTP1-1 by guanidinium chloride. Sacchetta P, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):100–6
Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Srivastava SK, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):89–94
Alpha,beta-unsaturated aldehydes increase glutathione S-transferase mRNA and protein: correlation with activation of the antioxidant response element. Tjalkens RB, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):42–50
Species differences in the glutathione transferase GSTT1-1 activity towards the model substrates methyl chloride and dichloromethane in liver and kidney. Thier R, et al. **Arch Toxicol** 1998 Oct;72(10):622–9
Determination of glutathione transferase (GSTT1-1) activities in different tissues based on formation of radioactive metabolites using 35S-glutathione. Thier R, et al. **Arch Toxicol** 1998 Dec;72(12):811–5
Marked expression of glutathione S-transferase A4-4 detoxifying 4-hydroxy-2(E)-nonenal in the skin of rats irradiated by ultraviolet B-band light (UVB). Hiratsuka A, et al. **Biochem Biophys Res Commun** 1999 Jul 14; 260(3):740–6
Shifting substrate specificity of human glutathione transferase (from class Pi to class alpha) by a single point mutation. Nuccetelli M, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):184–9
Mutagenic activity and DNA adduct formation by 1, 2-epoxy-3-(p-nitrophenoxy)propane, an HIV-1 protease inhibitor and GST substrate. Said B, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):844–7
Glutathione transferase zeta-catalyzed biotransformation of deuterated dihaloacetic acids. Wempe MF, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):779–83
Recombinant human glutathione S-transferases catalyse enzymic isomerization of 13-cis-retinoic acid to all-trans-retinoic acid in vitro. Chen H, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):223–6
Molecular cloning, expression and site-directed mutagenesis of glutathione S-transferase from Ochrobactrum anthropi. Favaloro B, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):573–9
Determinants of specificity for aflatoxin B1-8,9-epoxide in alpha-class glutathione S-transferases. McDonagh PD, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):95–101
Reversible penetration of alpha-glutathione S-transferase into biological membranes revealed by photosensitized labelling in situ. Merezhinskaya N, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):597–604
Secretion of glutathione S-transferase isoforms in the seminiferous tubular fluid, tissue distribution and sex steroid binding by rat GSTM1. Mukherjee SB, et al. **Biochem J** 1999 May 15;340 (Pt 1):309–20
Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Bruhn C, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1189–93
Characterization of a chlorambucil-resistant human ovarian carcinoma cell line overexpressing glutathione S-transferase mu. Horton JK, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):693–702
Elucidation of a monovalent cation dependence and characterization of the divalent cation binding site of the fosfomycin resistance protein (FosA). Bernat BA, et al. **Biochemistry** 1999 Jun 8;38(23):7462–9
Fast product formation and slow product release are important features in a hysteretic reaction mechanism of glutathione transferase T2-2. Jemth P, et al. **Biochemistry** 1999 Aug 3;38(31):9982–91
Stopped-flow kinetic analysis of the ligand-induced coil-helix transition in glutathione S-transferase A1-1: evidence for a persistent denatured state. Nieslanik BS, et al. **Biochemistry** 1999 May 25;38(21):6971–80
Functions of His107 in the catalytic mechanism of human glutathione S-transferase hGSTM1a-1a. Patskovsky YV, et al. **Biochemistry** 1999 Jan 26;38(4):1193–202
Photoaffinity labeling of rat liver glutathione S-transferase, 4-4, by glutathionyl S-[4-(succinimidyl)-benzophenone]. Wang J, et al. **Biochemistry** 1998 Nov 10;37(45):15671–9
Amino acid substitutions at positions 207 and 221 contribute to catalytic differences between murine glutathione S-transferase A1-1 and A2-2 toward (+)-anti-7,8-dihydroxy-9,10-epoxy-7,8,9, 10-tetrahydrobenzo[a]pyrene. Xia H, et al. **Biochemistry** 1999 Aug 3;38(31):9824–30
Contribution of breakdown in the regulation of mouse liver glutathione S-transferase subunits during protein depletion and re-feeding. Garcia-Mata R, et al. **Biochim Biophys Acta** 1998 Nov 19;1448(1):46–50
Direct observation of nucleocytoplasmic transport by microinjection of GFP-tagged proteins in living cells. Rosorius O, et al. **Biotechniques** 1999 Aug;27(2):350–5
Reduction of MTT by glutathione S-transferase. York JL, et al. **Biotechniques** 1998 Oct;25(4):622–4, 626–8
Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Den Boer ML, et al. **Br J Haematol** 1999 Feb; 104(2):321–7
Inhibition of glutathione S-transferase catalyzed xenobiotic detoxication by organotin compounds in tropical marine fish tissues. Al-Ghais SM, et al. **Bull Environ Contam Toxicol** 1999 Feb;62(2):207–13
Characterization of glutathione S-transferases (GST) activities in Perna perna and Mytilus galloprovincialis used as a biomarker of pollution in the Agadir marine bay (South of Morocco). Kaaya A, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):623–9
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Pool-Zobel BL, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jul;8(7):609–14
Genetic properties for the suppression of development of putative preneoplastic glutathione S-transferase placental form-positive foci in the liver of carcinogen-resistant DRH strain rats. Denda A, et al. **Cancer Lett** 1999 Jun 1; 140(1–2):59–67
Inhibition of liver glutathione S-transferase placental form-positive foci development in the rat hepatocarcinogenesis by Porphyra tenera (Asakusa-nori). Ichihara T, et al. **Cancer Lett** 1999 Jul 1;141(1–2):211–8
Strong expression of glutathione S-transferase placental form in early preneoplastic lesions and decrease with progression in hamster buccal pouch carcinogenesis. Iida K, et al. **Cancer Lett** 1999 Jan 29;135(2):129–36
Maternal or paternal exposure to radiation increases susceptibility to the induction of glutathione S-transferase-positive hepatic foci in offspring rats. Lee YS, et al. **Cancer Lett** 1998 Oct 23;132(1–2):31–6
Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Hu X, et al. **Cancer Res** 1998 Dec 1;58(23):5340–3
Expression of glutathione S-transferase theta class isoenzymes in human colorectal and gastric cancers. de Bruin WC, et al. **Carcinogenesis** 1999 Aug;20(8):1453–7
Expression of stably transfected murine glutathione S-transferase A3-3 protects against nucleic acid alkylation and cytotoxicity by aflatoxin B1 in hamster V79 cells expressing rat cytochrome P450-2B1. Fields WR, et al. **Carcinogenesis** 1999 Jun;20(6):1121–5
Prevention by 1'-acetoxychavicol acetate of the induction but not growth of putative preneoplastic, glutathione S-transferase placental form-positive, focal lesions in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Kobayashi Y, et al. **Carcinogenesis** 1998 Oct; 19(10):1809–14

Detoxification of optically active bay- and fjord-region polycyclic aromatic hydrocarbon dihydrodiol epoxides by human glutathione transferase P1-1 expressed in Chinese hamster V79 cells. Seidel A, et al. **Carcinogenesis** 1998 Nov; 19(11):1975-81

Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes. van Lieshout EM, et al. **Carcinogenesis** 1998 Oct;19(10):1873-5

Resistance to the promotion of glutathione S-transferase 7-7-positive liver lesions in Copenhagen rats. Wood GA, et al. **Carcinogenesis** 1999 Jul;20(7):1169-75

The effect of 1/3 partial hepatectomy on the growth of glutathione S-transferase positive foci. Yusuf A, et al. **Carcinogenesis** 1999 Jun;20(6):1143-5

Conjugation of isoprene monoepoxides with glutathione, catalyzed by alpha, mu, pi and theta-class glutathione S-transferases of rat and man. Bogaards JJ, et al. **Chem Biol Interact** 1999 Jan 1;117(1):1-14

Expression of glutathione transferase isoenzymes in the porcine ovary in relationship to follicular maturation and luteinization. Eliasson M, et al. **Chem Biol Interact** 1999 Jan 1;117(1):35-48

Activation of microsomal glutathione S-transferase and inhibition of cytochrome P450 1A1 activity as a model system for detecting protein alkylation by thiourea-containing compounds in rat liver microsomes. Onderwater RC, et al. **Chem Res Toxicol** 1999 May; 12(5):396-402

Glutathione transferase zeta-catalyzed biotransformation of dichloroacetic acid and other alpha-haloacids. Tong Z, et al. **Chem Res Toxicol** 1998 Nov;11(11):1332-8

Modulation of hepatic and intestinal glutathione S-transferases and other antioxidant enzymes by dietary lipids in streptozotocin diabetic rats. Girón MD, et al. **Chemosphere** 1999 Jun;38(13):3003-13

Glutathione-related enzyme activities in human fetal adrenal, liver, and kidney. Peng RX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):167-71

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent. Gupta E, et al. **Clin Cancer Res** 1995 Oct;1(10):1133-8

Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. O'Dwyer PJ, et al. **Clin Cancer Res** 1997 May;3(5):783-91

Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. Sreerama L, et al. **Clin Cancer Res** 1995 Oct; 1(10):1153-63

Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Galli F, et al. **Clin Chem** 1999 Oct; 45(10):1781-8

Variability of glutathione S-transferase alpha in human liver and plasma. Mulder TP, et al. **Clin Chem** 1999 Mar; 45(3):355-9

LTC4 synthase. Enzymology, biochemistry, and molecular characterization. Penrose JF. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):133-52 (90 ref.)

Glutathione S-transferase of goat lens: evidence for expression of only class mu isoenzymes. Ahmad H, et al. **Curr Eye Res** 1998 Nov;17(11):1097-101

Activated sulfonamides are cleaved by glutathione-S-transferases. Koeplinger KA, et al. **Drug Metab Dispos** 1999 Sep;27(9):986-91

Prolactin increases the hepatic content of mu-class subunits of glutathione S-transferase in the rat. Luquita MG, et al. **Drug Metab Dispos** 1999 Jan;27(1):122-4

Mechanism, structure-activity studies, and potential applications of glutathione S-transferase-catalyzed cleavage of sulfonamides. Zhao Z, et al. **Drug Metab Dispos** 1999 Sep;27(9):992-8

Regulation of JNK signaling by GSTp. Adler V, et al. **EMBO J** 1999 Mar 1;18(5):1321-34

Temporal patterns of DNA adduct formation and glutathione S-transferase activity in the testes of rats fed aflatoxin B1: a comparison with patterns in the liver. Sotomayor RE, et al. **Environ Mol Mutagen** 1999;33(4):293-302

Distribution of microsomal glutathione transferase 1 in mammalian tissues. A predominant alternate first exon in human tissues. Estonius M, et al. **Eur J Biochem** 1999 Mar; 260(2):409-13

Aflatoxin B1 and sulphobromophthalein binding to the dimeric human glutathione S-transferase A1-1: a fluorescence spectroscopic analysis. Sluis-Cremer N, et al. **Eur J Biochem** 1998 Oct 15;257(2):434-42

The carbohydrate crystalean and colonic microflora modulate expression of glutathione S-transferase subunits in colon of rats. Treptow-van Lishaut S, et al. **Eur J Nutr** 1999 Apr;38(2):76-83

Glutathione and glutathione-related enzymes in reproduction. A review. Knapen MF, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):171-84 (136 ref.)

Age-related changes in antioxidant enzyme activities in the small intestine and liver from Wistar rats. Jang I, et al. **Exp Anim** 1998 Oct;47(4):247-52

Enhancement of aflatoxin B1-induced enzyme altered hepatic foci in rats by treatment with carbon tetrachloride. Qin G, et al. **Exp Mol Med** 1998 Dec 31;30(4):186-91

Activity of glutathione transferase and reductase in tissues of bird cherry-oat aphid during its host-plant alternation. Laskowska I, et al. **Exp Toxicol Pathol** 1999 Jul; 51(4-5):357-9

Binding of alpha-tocopherylquinone, an oxidized form of alpha-tocopherol, to glutathione-S-transferase in the liver cytosol. Arita M, et al. **FEBS Lett** 1998 Oct 9;436(3):424-6

Demonstration of cell-specific phosphorylation of LTC4 synthase. Gupta N, et al. **FEBS Lett** 1999 Apr 16; 449(1):66-70

Detoxication of carcinogenic fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferase P1-1 variants and glutathione. Sundberg K, et al. **FEBS Lett** 1998 Nov 6;438(3):206-10

GSTP1-1 stereospecifically catalyzes glutathione conjugation of ethacrynic acid. van Iersel ML, et al. **FEBS Lett** 1998 Dec 11;441(1):153-7

Variable expression of glutathione S-transferase isoenzymes in the fungus, Mucor circinelloides. Dowd CA, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):13-7

Anti-genotoxicity and glutathione S-transferase activity in mice pretreated with caffeinated and decaffeinated coffee. Abraham SK, et al. **Food Chem Toxicol** 1999 Jul; 37(7):733-9

Liver cancer is induced by a subnecrogenic dose of DENA when associated with fasting/refeeding: role of glutathione-transferase and lipid peroxidation. Muzio G, et al. **Free Radic Biol Med** 1999 May;26(9-10):1314-20

Glutathione S-transferases and prevention of cellular free radical damage. Ketterer B. **Free Radic Res** 1998 Jun; 28(6):647-58 (70 ref.)

Oxidative DNA damage in vivo: relationship to age, plasma antioxidants, drug metabolism, glutathione-S-transferase activity and urinary creatinine excretion. Poulsen HE, et al. **Free Radic Res** 1998 Dec;29(6):565-71

Effects of nerve growth factor on brain glutathione-related enzymes from aged rats. Cruz-Aguado R, et al. **Fundam Clin Pharmacol** 1998;12(5):538-45

Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Konishi I, et al. **Gynecol Oncol** 1998 Sep;70(3):365-71

Identification of glutathione S-transferase isozymes and gamma-glutamylcysteine synthetase as negative acute-phase proteins in rat liver. Buetler TM. **Hepatology** 1998 Dec;28(6):1551-60

Endotoxin suppresses the oltipraz-mediated induction of major hepatic glutathione transferases and cytochromes P450 in the rat. Mahéo K, et al. **Hepatology** 1998 Dec; 28(6):1655-62

Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Whalen R, et al. **Hepatology** 1999 Oct;30(4):927-33

Impact of dietary supplement of Crassostrea gigas extract (JCOE) on glutathione levels and glutathione S-transferase activity in rat tissues. Gaté L, et al. **In Vivo** 1998 May-Jun; 12(3):299-303

Mechanism of an insect glutathione S-transferase: kinetic analysis supporting a rapid equilibrium random sequential mechanism with housefly II isoform. Nay B, et al. **Insect Biochem Mol Biol** 1999 Jan;29(1):71-9

Influence of age, hormones and germ cells on glutathione S-transferase activity in cultured Sertoli cells. Castellón EA. **Int J Androl** 1999 Feb;22(1):49-55

Purification and characterization of a novel alpha-class glutathione transferase from human liver. Pastore A, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1235-43

Glutathione S-transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinoma. Zhang H, et al. **Int J Cancer** 1999 Apr 20;84(2):135-8

Characterization of cytochrome P450 and glutathione S-transferase activity and expression in male and female ob/ob mice. Roe AL, et al. **Int J Obes Relat Metab Disord** 1999 Jan;23(1):48-53

Immunocytochemical localization of the Ya, Yb1, Yc, Yf, and Yo subunits of glutathione S-transferases in the cauda epididymidis and vas deferens of adult rats. Andonian S, et al. **J Androl** 1999 Jan-Feb;20(1):145-57

The effects of aging on the expression of glutathione S-transferases in the testis and epididymis of the Brown Norway rat. Mueller A, et al. **J Androl** 1998 Jul-Aug; 19(4):450-65

A novel membrane-bound glutathione S-transferase functions in the stationary phase of the yeast Saccharomyces cerevisiae. Choi JH, et al. **J Biol Chem** 1998 Nov 6;273(45):29915-22

Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. Zabel U, et al. **J Biol Chem** 1999 Jun 25; 274(26):18149-52

Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1-1: use of a highly sensitive gas chromatographic-mass spectrometric method. Ritter CA, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 25; 730(1):25-31

The effects of cadmium on the hepatic and renal levels of reduced glutathione, the activity of glutathione S-transferase and gamma glutamyl transpeptidase. Karmakar R, et al. **J Environ Pathol Toxicol Oncol** 1999; 18(1):29-35

Correlation of changes in natural killer cell activity and glutathione S-transferase placental form positive hepatocytes in diethylnitrosamine-induced rat hepatocarcinogenesis. Lee YS, et al. **J Korean Med Sci** 1999 Apr;14(2):171-4

Benzoic acid derivatives induce recovery of catalytic activity in the partially inactive Met208Lys mutant of human glutathione transferase A1-1. Gustafsson A, et al. **J Mol Biol** 1999 May 14;288(4):787-800

Dynamic interaction between soluble tubulin and C-terminal domains of N-methyl-D-aspartate receptor subunits. van Rossum D, et al. **J Neurochem** 1999 Mar;72(3):962-73

Distribution of 5-chloromethylfluorescein diacetate staining during meiotic maturation and fertilization in vitro of mouse oocytes. Tarin JJ, et al. **J Reprod Fertil** 1998 Nov; 114(2):211-8

Induction of murine hepatic glutathione S-transferase by dietary dehydroepiandrosterone. Milewich L, et al. **J Steroid Biochem Mol Biol** 1993 Sep;46(3):321-9

Xenobiotic-metabolizing enzymes in carp (Cyprinus carpio) liver, spleen, and head kidney following experimental Listeria monocytogenes infection. Chambras C, et al. **J Toxicol Environ Health** 1999 Feb 12;56(3):205-19

Low glutathione and glutathione S-transferase levels in Barrett's esophagus as compared to normal esophageal epithelium. van Lieshout EM, et al. **Jpn J Cancer Res** 1999 Jan;90(1):81-5

Promotional effects of CO2 laser on DMBA-induced hamster buccal pouch carcinogenesis as shown by immunohistochemistry of the placental form of glutathione S-transferase. Iida K, et al. **Lasers Surg Med** 1999; 24(5):360-7

Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Chemin I, et al. **Liver** 1999 Apr;19(2):81-7

NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Cruz-Aguado R, et al. **Neurochem Int** 1999 Feb; 34(2):125-30

Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Lovell MA, et al. **Neurology** 1998 Dec;51(6):1562-6

Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with pre-eclampsia. Knapen MF, et al. **Placenta** 1999 Sep;20(7):541-6

A role for glutathione transferases functioning as glutathione peroxidases in resistance to multiple herbicides in black-grass. Cummins I, et al. **Plant J** 1999 May; 18(3):285-92

Molecular dynamics simulations of human glutathione transferase P1-1: analysis of the induced-fit mechanism by GSH binding. Stella L, et al. **Proteins** 1999 Oct 1;37(1):1-9

Molecular dynamics simulations of human glutathione transferase P1-1: conformational fluctuations of the apo-structure. Stella L, et al. **Proteins** 1999 Oct 1;37(1):10-9

Phospholipid fatty acid composition affects enzymatic antioxidant defenses in cultured Swiss 3T3 fibroblasts. Benito S, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):281-6

Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1. Diah SK, et al. **Toxicol Appl Pharmacol** 1999 Jun 1;157(2):85-93

Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Guyonnet D, et al. **Toxicol Appl Pharmacol** 1999 Jan 1;154(1):50-8

The role of glutathione S-transferases as a defense against reactive electrophiles in the blood vessel wall. He NG, et al. **Toxicol Appl Pharmacol** 1998 Sep;152(1):83-9

Identification of amino acid residues essential for high aflatoxin B1-8,9-epoxide conjugation activity in alpha class glutathione S-transferases through site-directed mutagenesis. Van Ness KP, et al. **Toxicol Appl Pharmacol** 1998 Sep;152(1):166-74

Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Chomarat P, et al. **Toxicol Lett** 1998 Dec 28; 102-103:595-601

Effects of lead on glutathione S-transferase expression in rat kidney: a dose-response study. Wright LS, et al. **Toxicol Sci** 1998 Dec;46(2):254-9

Circadian variation of hepatic glutathione S-transferase activities in the mouse. Inoue N, et al. **Xenobiotica** 1999 Jan;29(1):43-51

Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines. Wang K, et al. **Xenobiotica** 1999 Feb;29(2):155-70

Influence of chemical treatments on glutathione S-transferases of maize with activity towards metolachlor and cinnamic acid. Cottingham CK, et al. **Z Naturforsch [C]** 1998 Nov-Dec;53(11-12):973-9

[Human drug metabolizing enzymes. II. Conjugation enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):284-8 (21 ref.) (Eng. Abstr.) **(Hun)**

[Short-term effects of septo-hippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain] Cruz R, et al. **Rev Neurol** 1998 Apr;26(152):551-4 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against

oxidative stress. Fiander H, et al.
Biochem Biophys Res Commun 1999 Sep 7;262(3):591–5
Does glutathione-S-transferase dethiolate lens protein-thiol mixed disulfides?-A comparative study with thioltransferase. Raghavachari N, et al. **Exp Eye Res** 1999 Jun;68(6):715–24
Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Xie C, et al.
Free Radic Biol Med 1998 Nov 15;25(8):979–88

PHYSIOLOGY

The role of human glutathione S-transferases hGSTA1-1 and hGSTA2-2 in protection against oxidative stress. Zhao T, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):216–24
Enzyme-mediated dichloromethane toxicity and mutagenicity of bacterial and mammalian dichloromethane-active glutathione S-transferases. Gisi D, et al. **Arch Toxicol** 1999 Mar;73(2):71–9
Glutathione S-transferase (GST) M1 and GST T1 genotypes and hematopoietic effects of benzene exposure. Hsieh LL, et al. **Arch Toxicol** 1999 Mar;73(2):80–2
Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells. Cnubben NH, et al. **Cancer Res** 1998 Oct 15; 58(20):4616–23
Glutathione S-transferases--a review. Salinas AE, et al.
Curr Med Chem 1999 Apr;6(4):279–309 (103 ref.)
Modeling the chemoprotective functions of glutathione S-transferases in cultured cell lines by heterologous expression. Townsend AJ, et al. **Drug Metab Rev** 1999 Feb; 31(1):43–69 (106 ref.)
Functional analysis of the evolutionarily conserved proline 53 residue in Proteus mirabilis glutathione transferase B1-1. Allocati N, et al. **FEBS Lett** 1999 Feb 26;445(2-3):347–50
Temperature adaptation of glutathione S-transferase P1-1. A case for homotropic regulation of substrate binding. Caccuri AM, et al. **J Biol Chem** 1999 Jul 2;274(27):19276–80
Role of glutathione S-transferase 8-8 in allylamine resistance of vascular smooth muscle cells in vitro. He N, et al.
Toxicol Appl Pharmacol 1999 Jul 15;158(2):177–85
Concise review of the glutathione S-transferases and their significance to toxicology. Eaton DL, et al. **Toxicol Sci** 1999 Jun;49(2):156–64 (71 ref.)
Glutathione-S-transferase activity in malarial parasites. Srivastava P, et al. **Trop Med Int Health** 1999 Apr; 4(4):251–4

URINE

Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer. Lafuente A, et al.
Anticancer Res 1998 Sep-Oct;18(5B):3771–2
Usefulness of the assessment of urinary enzyme leakage in monitoring acute fluoride nephrotoxicity. Usuda K, et al.
Arch Toxicol 1999 Aug;73(6):346–51
Variations in urinary 1-hydroxypyrene glucuronide in relation to smoking and the modification effects of GSTM1 and GSTT1. Hong YC, et al. **Toxicol Lett** 1999 Sep 5; 108(2-3):217–23

GLUTEAL REGION see **BUTTOCKS**

GLUTEN

Bone recovery after a gluten-free diet: a 5-year follow-up study. Kemppainen T, et al. **Bone** 1999 Sep;25(3):355–60
Microscopic and collagenous colitis in treated celiac disease due to food allergy? [letter; comment] Barbato M, et al. **Gastroenterology** 1999 Mar;116(3):778. Comment on: Gastroenterology 1997 Jun;112(6):1830–8.
Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. Kaukinen K, et al.
Scand J Gastroenterol 1999 Feb;34(2):163–9
[Epidemiological and evolutionary profile of childhood celiac disease (report of 118 cases)] Hachicha M, et al.
Tunis Med 1999 Jan;77(1):6–11 **(Fre)**

ADMINISTRATION & DOSAGE

Characterization of intestinal morphologic, biochemical, and ultrastructural features in gluten-sensitive Irish Setters during controlled oral gluten challenge exposure after weaning. Manners HK, et al. **Am J Vet Res** 1998 Nov; 59(11):1435–40
Antibodies in relation to gluten intake. Mäki M, et al.
Dig Dis 1998 Nov-Dec;16(6):330–2 (24 ref.)
Oral mucosal changes in coeliac patients on a gluten-free diet. Lähteenoja H, et al. **Eur J Oral Sci** 1998 Oct; 106(5):899–906
Effect of wheat bran on serum lipids: influence of particle size and wheat protein. Jenkins DJ, et al.
J Am Coll Nutr 1999 Apr;18(2):159–65
Gluten-free diet decreases urinary peptide levels in children with celiac disease. Ek J, et al.
J Pediatr Gastroenterol Nutr 1999 Sep;29(3):282–5
[Oats can be included in gluten-free diet] Hallert C, et al. **Lakartidningen** 1999 Jul 28;96(30-31):3339–40 (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

The widening spectrum of celiac disease. Murray JA.
Am J Clin Nutr 1999 Mar;69(3):354–65 (121 ref.)
Gluten sensitivity: a many headed hydra [editorial] Hadjivassiliou M, et al. **BMJ** 1999 Jun 26;318(7200):1710–1
Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Ventura A, et al. **Gastroenterology** 1999 Aug; 117(2):297–303
Coeliac disease: how much of what is toxic to whom? Feighery CF. **Gut** 1998 Aug;43(2):164–5
Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Hadjivassiliou M, et al. **Lancet** 1998 Nov 14; 352(9140):1582–5
In vitro screening of food peptides toxic for coeliac and other gluten-sensitive patients: a review. Silano M, et al.
Toxicology 1999 Feb 15;132(2-3):99–110 (98 ref.)

ANALOGS & DERIVATIVES

Small angle X-ray scattering of wheat seed-storage proteins: alpha-, gamma- and omega-gliadins and the high molecular weight (HMW) subunits of glutenin. Thomson NH, et al. **Biochim Biophys Acta** 1999 Mar 19; 1430(2):359–66
Evolution of the high molecular weight glutenin loci of the A, B, D, and G genomes of wheat. Allaby RG, et al.
Genome 1999 Apr;42(2):296–307
Characterization of a low-molecular-weight glutenin subunit gene from bread wheat and the corresponding protein that represents a major subunit of the glutenin polymer. Masci S, et al. **Plant Physiol** 1998 Dec;118(4):1147–58

ANALYSIS

An innovative sandwich ELISA system based on an antibody cocktail for gluten analysis. Sorell L, et al. **FEBS Lett** 1998 Nov 13;439(1-2):46–50
Measurement of gluten using a monoclonal antibody to a coeliac toxic peptide of A-gliadin. Ellis HJ, et al. **Gut** 1998 Aug;43(2):190–5
Selective identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of different types of gluten in foods made with cereal mixtures. Camafeita E, et al. **J Chromatogr A** 1998 Oct 9; 823(1-2):299–306

CHEMISTRY

Thermal properties of corn gluten meal and its proteic components. Di Gioia L, et al. **Int J Biol Macromol** 1999 May;24(4):341–50
Screening of gluten avenins in foods by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Camafeita E, et al. **J Mass Spectrom** 1998 Oct;33(10):1023–8

GENETICS

Genetics of the immune response to gluten in coeliac disease. Sollid LM. **Dig Dis** 1998 Nov-Dec;16(6):345–7 (19 ref.)
Identification of cis-regulatory elements required for endosperm expression of the rice storage protein glutelin gene GluB-1. Washida H, et al. **Plant Mol Biol** 1999 May; 40(1):1–12

IMMUNOLOGY

Gluten: is it also a determinant of islet autoimmunity? Bonifacio E, et al. **Diabetes Metab Rev** 1998 Sep; 14(3):258–9
In vivo gluten ingestion in coeliac disease. Ciclitira PJ, et al. **Dig Dis** 1998 Nov-Dec;16(6):337–40 (20 ref.)
Genetics of the immune response to gluten in coeliac disease. Sollid LM. **Dig Dis** 1998 Nov-Dec;16(6):345–7 (19 ref.)
Tolerance to oats in dermatitis herpetiformis. Reunala T, et al. **Gut** 1998 Oct;43(4):490–3

METABOLISM

Specificity of a wheat gluten aspartic proteinase. Bleukx W, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):317–24

PHARMACOKINETICS

Intestinal permeability of Irish setter puppies challenged with a controlled oral dose of gluten. Garden OA, et al.
Res Vet Sci 1998 Jul-Aug;65(1):23–8

PHARMACOLOGY

Children with celiac disease express inducible nitric oxide synthase in the small intestine during gluten challenge. Holmgren Peterson K, et al. **Scand J Gastroenterol** 1998 Sep;33(9):939–43

GLUTEN ENTEROPATHY see **CELIAC DISEASE**

GLUTETHIMIDE

PHARMACOLOGY

Mechanism of the synergistic induction of CYP2H by isopentanol plus ethanol: comparison to glutethimide and relation to induction of 5-aminolevulinate synthase. Louis CA, et al. **Arch Biochem Biophys** 1998 Dec 15; 360(2):239–47

GLYBURIDE

ADMINISTRATION & DOSAGE

Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Qureshi SA, et al.
Eur J Pharm Sci 1999 Feb;7(3):249–58

ADVERSE EFFECTS

Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Zapęcka-Dubno B, et al. **Arzneimittelforschung** 1999 Apr;49(4):330–4
Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Stahl M, et al. **Diabet Med** 1999 Jul;16(7):586–90
Glibenclamide-induced hypoglycemic coma in 51 older patients with type 2 diabetes mellitus [letter] Ben-Ami H, et al. **J Am Geriatr Soc** 1999 May;47(5):631–3
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Landstedt-Hallin L, et al.
J Clin Endocrinol Metab 1999 Sep;84(9):3140–5
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Landstedt-Hallin L, et al.
J Intern Med 1999 Sep;246(3):299–307

ANALOGS & DERIVATIVES

Synthesis of sulfonylurea conjugated copolymer via PEO spacer and its in vitro short-term bioactivity in insulin secretion from islets of Langerhans: Hwang JS, et al.
Biomaterials 1998 Jul;19(13):1189–95
Insulinotropic effect of new glibenclamide isosteres. Ouedraogo R, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):625–31
P-glycoprotein inhibition by glibenclamide and related compounds. Golstein PE, et al. **Pflugers Arch** 1999 Apr; 437(5):652–60

CHEMICAL SYNTHESIS

ATP-sensitive potassium channels. Schwanstecher M, et al.
Methods Enzymol 1999;294:445–58

CHEMISTRY

Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Qureshi SA, et al.
Eur J Pharm Sci 1999 Feb;7(3):249–58
Insulinotropic effect of new glibenclamide isosteres. Ouedraogo R, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):625–31

METABOLISM

Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel. Gros L, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):766–70

PHARMACOKINETICS

The effect of stress on the pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats. Abd Elaziz MA, et al. **Eur J Drug Metab Pharmacokinet** 1998 Jul-Sep;23(3):371–6
Co-administration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms. Savolainen J, et al. **Pharm Res** 1998 Nov;15(11):1696–701
Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. Courtois P, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):211–22
[Preparation and utility of glibenclamide suppository for hospital use] Takahashi Y, et al. **Yakugaku Zasshi** 1998 Sep; 118(9):401–7 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Renal microvascular actions of calcitonin gene-related peptide. Reslerova M, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):F1078–85
Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels and intracellular Ca(2+) release in HepG2 human hepatoblastoma cells. Kim JA, et al.
Biochem Biophys Res Commun 1999 Aug 11;261(3):682–8
The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Mukai E, et al.
Biochem Biophys Res Commun 1998 Oct 20;251(2):477–81
Intra-septal injections of glucose and glibenclamide attenuate galanin-induced spontaneous alternation performance deficits in the rat. Stefani MR, et al. **Brain Res** 1998 Nov 30;813(1):50–6
Observations on the effect of glibenclamide on noninvasive clinical parameters of myocardial ischemia [letter] Köppel H, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):383–5
Opening of potassium channels: the common

cardioprotective link between preconditioning and natural hibernation? Kevelaitis E, et al. **Circulation** 1999 Jun 15; 99(23):3079–85

Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Kawaki J, et al. **Diabetes** 1999 Oct;48(10):2001–6

Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Ren J, et al. **Diabetes** 1999 Oct;48(10):2059–65

Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Fukuzawa M, et al. **Diabetes Res Clin Pract** 1999 Mar;43(3):147–54

Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide. Kemp BK, et al. **Eur J Pharmacol** 1998 Aug 7;354(2–3):173–8

Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. El-Reyani NE, et al. **Eur J Pharmacol** 1999 Jan 22;365(2–3):187–92

Glibenclamide-sensitive K+ channels underlying levcromakalim-induced relaxation in pig urethra. Teramoto N, et al. **Eur J Pharmacol** 1999 Jan 22; 365(2–3):291–300

Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues. Tüzün S, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):436–41

Sulfonylureas blockade of neural and cardiac HERG channels. Rosati B, et al. **FEBS Lett** 1998 Nov 27; 440(1–2):125–30

Effects of glyburide–cyclosporin A interaction on interleukin-2 production in rats. Sireci G, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):583–98

Relevance of inter- and intraventricular electrical dispersion to arrhythmogenesis in normal and ischaemic rabbit myocardium: a study with cromakalim, 5-hydroxydecanoate and glibenclamide. Wolk R, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):323–34

Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. Williams S, et al. **J Hypertens** 1998 May; 16(5):705–11

Cystic fibrosis transmembrane conductance regulator (CFTR) confers glibenclamide sensitivity to outwardly rectifying chloride channel (ORCC) in Hi-5 insect cells. Julien M, et al. **J Membr Biol** 1999 Apr 1;168(3):229–39

KATP channel modulators and myocardial damages induced by ischemia-reperfusion: membrane lipids injury and arrhythmias. Picard S, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2613–21

Potentiation of quantal catecholamine secretion by glibenclamide: evidence for a novel role of sulphonylurea receptors in regulating the Ca(2+) sensitivity of exocytosis. Taylor SC, et al. **J Neurosci** 1999 Jul 15;19(14):5741–9

Stimulation of epithelial sodium channel activity by the sulfonylurea glibenclamide. Chrabi A, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):341–7

Pharmacological evidence for a KATP channel in renin-secreting cells from rat kidney. Russ U, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):781–90

Glibenclamide, an antagonist of ATP sensitive K+ channels, blocks free radical generation in the rat myocardium. Obata T, et al. **Neurosci Lett** 1998 Nov 20;257(1):57–9

P-glycoprotein inhibition by glibenclamide and related compounds. Golstein PE, et al. **Pflugers Arch** 1999 Apr; 437(5):652–60

Cardioprotective effect of enantiomers of cicletanine (BN50417, BN50418) in ischaemic/reperfused isolated working rat hearts: interaction with glibenclamide. Ferdinandy P, et al. **Pharmacol Res** 1999 Mar;39(3):225–31

The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. Tanira MO, et al. **Pharmacol Res** 1999 May;39(5):349–56

Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. Ueda K, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1268–72

THERAPEUTIC USE

Lung local defense in experimental diabetes mellitus and the effect of 11,20-dihydroxyecdysone in combination with maninil. Najmutdinova DK, et al. **Arch Insect Biochem Physiol** 1999;41(3):144–7

Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Mocanu MM, et al. **Cardiovasc Drugs Ther** 1999 Apr;13(2):115–22

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Damsbo P, et al. **Diabetes Care** 1999 May;22(5):789–94

Effect of troglitazone on body fat distribution in type 2 diabetic patients. Mori Y, et al. **Diabetes Care** 1999 Jun; 22(6):908–12

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Wolffenbuttel BH, et al. **Diabetes Care** 1999 Mar; 22(3):463–7

Repaglinide versus glyburide: a one-year comparison trial. Marbury T, et al. **Diabetes Res Clin Pract** 1999 Mar; 43(3):155–66

The warm-up phenomenon and ischaemic preconditioning: an uncertain relationship [editorial; comment] Cohen MV, et al. **Eur Heart J** 1999 Feb;20(3):167–8 (9 ref.). Comment on: Eur Heart J 1999 Feb;20(3):196–202. Comment on: Eur Heart J 1999 Feb;20(3):203–10.

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide [see comments] Klepzig H, et al. **Eur Heart J** 1999 Mar;20(6):439–46. Comment in: Eur Heart J 1999 Mar;20(6):403–5.

Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon [see comments] Tomai F, et al. **Eur Heart J** 1999 Feb;20(3):196–202. Comment in: Eur Heart J 1999 Feb;20(3):167–8.

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Landgraf R, et al. **Eur J Clin Pharmacol** 1999 May;55(3):165–71

Triple oral antidiabetic therapy. Kaye TB. **J Diabetes Complications** 1998 Nov–Dec;12(6):311–3

Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. Williams S, et al. **J Hypertens** 1998 May; 16(5):705–11

Glucose disturbances and regulation with glibenclamide in thalassemia. Ladis V, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:871–8

Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients. Niazi R, et al. **JPMA J Pak Med Assoc** 1998 Nov;48(11):336–8

[Clinical study of glibenclamide in combination with kelening treatment in non-insulin dependent diabetes mellitus] Zhou P. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):29–31 (Eng. Abstr.) **(Chi)**

GLYCANS see **POLYSACCHARIDES**

GLYCATION END PRODUCTS, ADVANCED see **GLYCOSYLATION END PRODUCTS, ADVANCED**

GLYCERALDEHYDE 3-PHOSPHATE

ANALOGS & DERIVATIVES

Synthesis of phosphono analogues of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. Page P, et al. **Bioorg Med Chem** 1999 Jul;7(7):1403–12

ANTAGONISTS & INHIBITORS

Carnosine prevents glyceraldehyde 3-phosphate-mediated inhibition of aspartate aminotransferase. Swearengin TA, et al. **Arch Toxicol** 1999 Aug;73(6):307–9

CHEMISTRY

Synthesis of phosphono analogues of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate. Page P, et al. **Bioorg Med Chem** 1999 Jul;7(7):1403–12

GENETICS

Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)

METABOLISM

Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Kish SJ, et al. **Arch Neurol** 1998 Oct;55(10):1299–304 (29 ref.)

On the absence of the glyceraldehyde 3-phosphate/pyruvate pathway for isoprenoid biosynthesis in fungi and yeasts. Disch A, et al. **FEMS Microbiol Lett** 1998 Nov 15; 168(2):201–8

The ferredoxin-dependent conversion of glyceraldehyde-3-phosphate in the hyperthermophilic archaeon Pyrococcus furiosus represents a novel site of glycolytic regulation. van der Oost J, et al. **J Biol Chem** 1998 Oct 23;273(43):28149–54

PHARMACOLOGY

Carnosine prevents glyceraldehyde 3-phosphate-mediated inhibition of aspartate aminotransferase. Swearengin TA, et al. **Arch Toxicol** 1999 Aug;73(6):307–9

GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE see **GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES**

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (NADP+) see **GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES**

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (NADP+)(PHOSPHORYLATING) see **GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES**

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING) see **GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES**

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES

ANALYSIS

Reconstitution of membrane fusion between pancreatic islet secretory granules and plasma membranes: catalysis by a protein constituent recognized by monoclonal antibodies directed against glyceraldehyde-3-phosphate dehydrogenase. Han X, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1–2):95–107

ANTAGONISTS & INHIBITORS

Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite. Souza JM, et al. **Arch Biochem Biophys** 1998 Dec 15;360(2):187–94

Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. Ishii T, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):133–43

Cryoinactivation and conformational drift of glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle. Tian S, et al. **Biol Chem** 1998 Nov;379(11):1319–22

Synthesis and structure-activity relationships of adenosine analogs as inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Modifications at positions 5' and 8. Aronov AM, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3505–10

Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. Aronov AM, et al. **J Med Chem** 1998 Nov 19;41(24):4790–9

NO depletes cellular ATP contents via inactivation of glyceraldehyde-3-phosphate dehydrogenase in PC12 cells. Yasuda M, et al. **J Toxicol Sci** 1998 Dec;23(5):389–94

Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase. Sheline CT, et al. **Neurobiol Dis** 1998 Jul;5(1):47–54

Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Aronov AM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4273–8

BIOSYNTHESIS

Circadian synthesis of a nuclear-encoded chloroplast glyceraldehyde-3-phosphate dehydrogenase in the dinoflagellate Gonyaulax polyedra is translationally controlled. Fagan T, et al. **Biochemistry** 1999 Jun 15; 38(24):7689–95

mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. Feldhaus LM, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2475–85

ONO-1603, a potential antidementia drug, delays age-induced apoptosis and suppresses overexpression of glyceraldehyde-3-phosphate dehydrogenase in cultured central nervous system neurons. Katsube N, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):6–13

CHEMISTRY

Crystallization and preliminary X-ray diffraction studies of D-glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic archaeon Methanothermus fervidus. Charron C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jul;55 (Pt 7):1353–5

Characterization, crystallization and preliminary X-ray investigation of glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic archaeon Sulfolobus solfataricus. Fleming TM, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1;54 (Pt 4):671–4

Crystallization and preliminary crystallographic analysis of glyceraldehyde 3-phosphate dehydrogenase from Sacchromyces cerevisiae (baker's yeast). Gilboa R, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(2 (Pt 6)):1467–70

Crystallization and preliminary X-ray study of chloroplast glyceraldehyde-3-phosphate dehydrogenase. Sabatino P, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Feb;55 (Pt 2):566–7

Structure of holo-glyceraldehyde-3-phosphate dehydrogenase from Palinurus versicolor refined at 2 A resolution. Song S, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1;54 (Pt 4):558–69

Protein-induced fusion of phospholipid vesicles of heterogeneous sizes. de Arcuri BF, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):586–90

Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Zhong H, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):523–6

D-Glyceraldehyde-3-phosphate dehydrogenase: structural basis and functional role of the acyl transfer reactions. Nagradova NK, et al. **Biochemistry (Mosc)** 1998 May; 63(5):504–15 (75 ref.)

Conformational structure and binding mode of glyceraldehyde-3-phosphate dehydrogenase to tRNA studied by Raman and CD spectroscopy. Carmona P, et al. **Biochim Biophys Acta** 1999 Jul 13;1432(2):222–33

Thermal unfolding of phosphorylating D-glyceraldehyde-3-phosphate dehydrogenase studied by differential scanning calorimetry. Levashov P, et al. **Biochim Biophys Acta** 1999 Aug 17;1433(1-2):294-306

Cryoinactivation and conformational drift of glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle. Tian S, et al. **Biol Chem** 1998 Nov;379(11):1319-22

A stable cold folding intermediate of rabbit muscle D-glyceraldehyde 3-phosphate dehydrogenase. Zhang NX, et al. **Eur J Biochem** 1999 Sep;264(3):1002-8

Mildly oxidized GAPDH: the coupling of the dehydrogenase and acyl phosphatase activities. Schmalhausen EV, et al. **FEBS Lett** 1999 Jun 11;452(3):219-22

Characterization of the glyceraldehyde-3-phosphate gene and the use of its promoter for heterologous expression in Cryptococcus neoformans, a human pathogen. Varma A, et al. **Gene** 1999 May 31;232(2):155-63

Thiols mediate superoxide-dependent NADH modification of glyceraldehyde-3-phosphate dehydrogenase. Rivera-Nieves J, et al. **J Biol Chem** 1999 Jul 9; 274(28):19525-31

Crystal structure of the glyceraldehyde-3-phosphate dehydrogenase from the hyperthermophilic archaeon Sulfolobus solfataricus. Isupov MN, et al. **J Mol Biol** 1999 Aug 20;291(3):651-60

Structure of active site carboxymethylated D-glyceraldehyde-3-phosphate dehydrogenase from Palinurus versicolor. Song SY, et al. **J Mol Biol** 1999 Apr 9;287(4):719-25

Participation of chaperonin GroEL in the folding of D-glyceraldehyde-3-phosphate dehydrogenase. An approach based on the use of different oligomeric forms of the enzyme immobilized on sepharose. Bulatnikov IG, et al. **J Protein Chem** 1999 Jan;18(1):79-87

Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Aronov AM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4273-8

DRUG EFFECTS

Acyl phosphatase activity of NO-inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH): a potential mechanism for uncoupling glycolysis from ATP generation in NO-producing cells. Albina JE, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):5-9

Regulation of cation transport pathways and glycolytic enzyme activity by alterations in red cell volume. Kaloyianni M, et al. **Cell Biochem Funct** 1999 Jun; 17(2):75-88

GENETICS

Use of the glyceraldehyde-3-phosphate dehydrogenase promoter for production of functional mammalian membrane transport proteins in the yeast Pichia pastoris. Döring F, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):531-5

Circadian synthesis of a nuclear-encoded chloroplast glyceraldehyde-3-phosphate dehydrogenase in the dinoflagellate Gonyaulax polyedra is translationally controlled. Fagan T, et al. **Biochemistry** 1999 Jun 15; 38(24):7689-95

Norepinephrine, tri-iodothyronine and insulin upregulate glyceraldehyde-3-phosphate dehydrogenase mRNA during Brown adipocyte differentiation. Barroso I, et al. **Eur J Endocrinol** 1999 Aug;141(2):169-79

Characterization of the glyceraldehyde-3-phosphate gene and the use of its promoter for heterologous expression in Cryptococcus neoformans, a human pathogen. Varma A, et al. **Gene** 1999 May 31;232(2):155-63

Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human cervical cancers. Kim JW, et al. **Gynecol Oncol** 1998 Nov;71(2):266-9

The EIIGlc protein is involved in glucose-mediated activation of Escherichia coli gapA and gapB-pgk transcription. Charpentier B, et al. **J Bacteriol** 1998 Dec; 180(24):6476-83

The ferredoxin-dependent conversion of glyceraldehyde-3-phosphate in the hyperthermophilic archaeon Pyrococcus furiosus represents a novel site of glycolytic regulation. van der Oost J, et al. **J Biol Chem** 1998 Oct 23;273(43):28149-54

Several novel transcripts of glyceraldehyde-3-phosphate dehydrogenase expressed in adult chicken testis. Mezquita J, et al. **J Cell Biochem** 1998 Oct 1;71(1):127-39

Translational control of viral and host protein synthesis during the course of herpes simplex virus type 1 infection: evidence that initiation of translation is the limiting step. Laurent AM, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2765-75

The phylogeny of glyceraldehyde-3-phosphate dehydrogenase indicates lateral gene transfer from cryptomonads to dinoflagellates. Fagan T, et al. **J Mol Evol** 1998 Dec;47(6):633-9

Comparison and evolutionary analysis of the glycosomal glyceraldehyde-3-phosphate dehydrogenase from different Kinetoplastida. Hannaert V, et al. **J Mol Evol** 1998 Dec; 47(6):728-38

Tamoxifen up-regulates oestrogen receptor-alpha, c-fos and glyceraldehyde 3-phosphate-dehydrogenase mRNAs in ovine endometrium. Robertson JA, et al. **J Steroid Biochem Mol Biol** 1998 Nov;67(4):285-92

Cloning of a trans-spliced glyceraldehyde-3-phosphate-dehydrogenase gene from the potato cyst nematode Globodera rostochiensis and expression of its putative promoter region in Caenorhabditis elegans. Qin L, et al. **Mol Biochem Parasitol** 1998 Oct 30; 96(1-2):59-67

Glyceraldehyde-3-phosphate dehydrogenase gene diversity in eubacteria and eukaryotes: evidence for intra- and inter-kingdom gene transfer. Figge RM, et al. **Mol Biol Evol** 1999 Apr;16(4):429-40

Increased expression of glyceraldehyde-3-phosphate dehydrogenase in cultured astrocytes following exposure to manganese. Hazell AS, et al. **Neurochem Int** 1999 Jul; 35(1):11-7

Over-expression of GAPDH induces apoptosis in COS-7 cells transfected with cloned GAPDH cDNAs. Tajima H, et al. **Neuroreport** 1999 Jul 13;10(10):2029-33

Early changes of gene expression during cerulein supramaximal stimulation. Yuan S, et al. **Pancreas** 1999 Jul; 19(1):45-50

Evidence on the origin of cassava: phylogeography of Manihot esculenta. Olsen KM, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5586-91

Quantitative polymerase chain reaction using an external control mRNA for determination of gene expression in a heterogeneous cell population. Shibata M, et al. **Toxicol Sci** 1999 Jun;49(2):290-6

IMMUNOLOGY

Clinical strains of Candida albicans express the surface antigen glyceraldehyde 3-phosphate dehydrogenase in vitro and in infected tissues. Gil ML, et al. **FEMS Immunol Med Microbiol** 1999 Mar;23(3):229-34

Reactivation of glyceraldehyde-3-phosphate dehydrogenase using conjugates of monoclonal antibodies with polyelectrolyte complexes. An attempt to make an artificial chaperone. Dainiak MB, et al. **J Mol Recognit** 1998 Winter; 11(1-6):25-7

ISOLATION & PURIFICATION

Two glycolytic enzymes from Sulfolobus solfataricus. Crowhurst GS, et al. **Biochem Soc Trans** 1998 Aug; 26(3):S275

METABOLISM

Upregulation of M-creatine kinase and glyceraldehyde3-phosphate dehydrogenase: two markers of muscle disuse. Cros N, et al. **Am J Physiol** 1999 Feb; 276(2 Pt 2):R308-16

The active site of phosphorylating glyceraldehyde-3-phosphate dehydrogenase is not designed to increase the nucleophilicity of a serine residue. Boschi-Muller S, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):259-66

Engineered glycolytic glyceraldehyde-3-phosphate dehydrogenase binds the anti conformation of NAD+ nicotinamide but does not experience A-specific hydride transfer. Eyschen J, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):219-27

Pea chloroplast glyceraldehyde-3-phosphate dehydrogenase has uracil glycosylase activity. Wang X, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):348-53

Protein-induced fusion of phospholipid vesicles of heterogeneous sizes. de Arcuri BF, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):586-90

Demonstration of a RNA-dependent nuclear interaction between the promyelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Carlile GW, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):691-6

Stimulation of glyceraldehyde-3-phosphate dehydrogenase by oxyhemoglobin. Brookes PS, et al. **Biochem Soc Trans** 1998 Aug;26(3):S246

Evidence for the chemical activation of essential cys-302 upon cofactor binding to nonphosphorylating glyceraldehyde 3-phosphate dehydrogenase from Streptococcus mutans. Marchal S, et al. **Biochemistry** 1999 Sep 28;38(39):12950-8

D-Glyceraldehyde-3-phosphate dehydrogenase: structural basis and functional role of the acyl transfer reactions. Nagradova NK, et al. **Biochemistry (Mosc)** 1998 May; 63(5):504-15 (75 ref.)

New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Sirover MA. **Biochim Biophys Acta** 1999 Jul 13;1432(2):159-84 (166 ref.)

Glyceraldehyde-3-phosphate dehydrogenase expression during apoptosis and proliferation of rat ventral prostate. Epner DE, et al. **Biol Reprod** 1999 Sep;61(3):687-91

Cotransport of glyceraldehyde-3-phosphate dehydrogenase and actin in axons of chicken motoneurons. Yuan A, et al. **Cell Mol Neurobiol** 1999 Dec;19(6):733-44

Effect of artemether on glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and pyruvate kinase of Schistosoma japonicum harbored in mice. Xiao SH, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May; 19(3):279-81

Effect of mebendazole and praziquantel on glucosephosphate isomerase and glyceraldehydephosphate dehydrogenase in Echinococcus granulosus cyst wall harbored in mice. You JQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):75-7

Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Cooper AJ, et al. **Dev Neurosci** 1998;20(4-5):462-8

Glyceraldehyde-3-phosphate dehydrogenase from Ehrlich ascites carcinoma cells its possible role in the high glycolysis of malignant cells. Bagui S, et al. **Eur J Biochem** 1999 Jun;262(2):386-95

Immunopurification of a sarcomeric junctional protein complex containing GAPDH. McDonald KA, et al. **Exp Cell Res** 1998 Sep 15;243(2):305-18

Substituting selenocysteine for active site cysteine 149 of phosphorylating glyceraldehyde 3-phosphate dehydrogenase reveals a peroxidase activity. Boschi-Muller S, et al. **FEBS Lett** 1998 Nov 20; 439(3):241-5

Mildly oxidized GAPDH: the coupling of the dehydrogenase and acyl phosphatase activities. Schmalhausen EV, et al. **FEBS Lett** 1999 Jun 11;452(3):219-22

Engineering a central metabolic pathway: glycolysis with no net phosphorylation in an Escherichia coli gap mutant complemented with a plant GapN gene. Valverde F, et al. **FEBS Lett** 1999 Apr 23;449(2-3):153-8

5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells. McKenzie SM, et al. **Gut** 1999 Feb; 44(2):180-5

The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase. Modun B, et al. **Infect Immun** 1999 Mar;67(3):1086-92

Regulation of glyceraldehyde-3-phosphate dehydrogenase in differentiating HD3 cells. Grdiša M. **Int J Biochem Cell Biol** 1998 Nov;30(11):1245-51

"Half of the sites" binding of D-glyceraldehyde-3-phosphate dehydrogenase folding intermediate with GroEL. Li J, et al. **J Biol Chem** 1999 Apr 16;274(16):10790-4

Nitric oxide-induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase. Mohr S, et al. **J Biol Chem** 1999 Apr 2;274(14):9427-30

Several novel transcripts of glyceraldehyde-3-phosphate dehydrogenase expressed in adult chicken testis. Mezquita J, et al. **J Cell Biochem** 1998 Oct 1;71(1):127-39

Electrostatic contributions to the stability of hyperthermophilic proteins. Xiao L, et al. **J Mol Biol** 1999 Jun 25;289(5):1435-44

Reactivation of glyceraldehyde-3-phosphate dehydrogenase using conjugates of monoclonal antibodies with polyelectrolyte complexes. An attempt to make an artificial chaperone. Dainiak MB, et al. **J Mol Recognit** 1998 Winter; 11(1-6):25-7

Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. Saunders PA, et al. **J Neurochem** 1999 Mar;72(3):925-32

Disappearance of glyceraldehyde 3-phosphate dehydrogenase from erythrocyte membrane by hemolysis with thermostable direct hemolysin of Vibrio parahaemolyticus or Vibrio cholerae El Tor hemolysin. Zhang D, et al. **Microbiol Immunol** 1999;43(3):303-5

Differential protein S-thiolation of glyceraldehyde-3-phosphate dehydrogenase isoenzymes influences sensitivity to oxidative stress. Grant CM, et al. **Mol Cell Biol** 1999 Apr;19(4):2650-6

Increased expression of glyceraldehyde-3-phosphate dehydrogenase in cultured astrocytes following exposure to manganese. Hazell AS, et al. **Neurochem Int** 1999 Jul; 35(1):11-7

Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. Lubec G, et al. **Neurosci Lett** 1999 Jan 29;260(2):141-5

Relationship between the physiology of Enterobacter agglomerans CNCM 1210 grown anaerobically on glycerol and the culture conditions. Barbirato F, et al. **Res Microbiol** 1997 Jul-Aug;148(6):475-84

Modification of glyceraldehyde-3-phosphate dehydrogenase in response to nitric oxide in intestinal preconditioning. Sola A, et al. **Transplantation** 1999 Jun 15;67(11):1446-52

PHYSIOLOGY

Memory and imprinting in multienzyme complexes. Evidence for information transfer from glyceraldehyde-3-phosphate dehydrogenase to phosphoribulokinase under reduced state in Chlamydomonas reinhardtii. Lebreton S, et al. **J Biol Chem** 1999 Jul 23;274(30):20879-84

GLYCERATE (3-2)-PHOSPHOMUTASE see **PHOSPHOGLYCERATE MUTASE**

GLYCERIC ACIDS

METABOLISM

Combined effect of the growth temperature and salinity of the medium on the accumulation of compatible solutes by Rhodothermus marinus and Rhodothermus obamensis. Silva Z, et al. **Extremophiles** 1999 May;3(2):163-72

A phosphoglycerate to inorganic phosphate ratio is the major factor in controlling starch levels in chloroplasts via ADP-glucose pyrophosphorylase regulation. Kleczkowski LA. **FEBS Lett** 1999 Apr 1;448(1):153-6

PHARMACOLOGY

Ultrasensitive glycogen synthesis in Cyanobacteria. Gómez Casati, et al. **FEBS Lett** 1999 Mar 5;446(1):117-21

GLYCERIDES

Discovery and characterization of endogenous cannabinoids. Martin BR, et al. **Life Sci** 1999;65(6-7):573-95 (54 ref.)

[2-Arachidonoylglycerol: an endogenous cannabinoid receptor agonist] Sugiura T, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1104-10 (28 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Overfeeding fat as monoglyceride or triglyceride: effect on appetite, nutrient balance and the subsequent day's energy intake. Johnstone AM, et al. **Eur J Clin Nutr** 1998 Aug; 52(8):610-8

ADVERSE EFFECTS

Urticaria due to occupational exposure to glyceryl monothioglycolate permanent wave solution [letter] Shelley WB, et al. **Acta Derm Venereol** 1998 Nov; 78(6):471-2

ANALYSIS

Improvement in the Iatroscan thin-layer chromatographic-flame ionisation detection analysis of marine lipids. Separation and quantitation of monoacylglycerols and diacylglycerols in standards and natural samples. Striby L, et al. **J Chromatogr A** 1999 Jul 23;849(2):371-80

Trick or treat from food endocannabinoids? [letter; comment] Di Marzo V, et al. **Nature** 1998 Dec 17;396(6712):636-7. Comment on: Nature 1996 Aug 22;382(6593):677-8.

BIOSYNTHESIS

Starvation depresses acylglycerol biosynthesis in bovine subcutaneous but not intramuscular adipose tissue homogenates. Smith SB, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):165-74

Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Di Marzo V, et al. **Eur J Biochem** 1999 Aug; 264(1):258-67

Synthesis of 1-monoglycerides having C11-20 branched chain fatty acids and their hemolysis effects. Ping X, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):345-7

Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. Bisogno T, et al. **J Neurochem** 1999 May;72(5):2113-9

CHEMISTRY

Interaction mode specific reorganization of gel phase monoglyceride bilayers by beta-lactoglobulin. Boots JW, et al. **Biochim Biophys Acta** 1999 Aug 20;1420(1-2):241-51

Solubilization of ubiquinone-10 in the lamellar and bicontinuous cubic phases of aqueous monoolein. Barauskas J, et al. **Chem Phys Lipids** 1999 Feb;97(2):167-79

Diversity in the fatty-acid conformation and chain packing of cis-unsaturated lipids. Kaneko F, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):417-25 (45 ref.)

Bioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate. Nielsen LS, et al. **Eur J Pharm Sci** 1998 Jul;6(3):231-9

Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. Barnett-Norris J, et al. **J Med Chem** 1998 Nov 19;41(24):4861-72

Influence of additives on the release profile of nifedipine from poly(DL-lactide-co-glycolide) microspheres. Sansdrap P, et al. **J Microencapsul** 1998 Sep-Oct;15(5):545-53

Drug compatibility with the sponge phases formed in monoolein, water, and propylene glycol or poly(ethylene glycol). Alfons K, et al. **J Pharm Sci** 1998 Dec; 87(12):1527-30

Characterization of the effects of drug addition on the structure of glyceryl monoolein/water gel systems using low frequency dielectric spectroscopy. He R, et al. **J Pharm Sci** 1999 Jun;88(6):635-9

From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Mechoulam R, et al. **Nat Prod Rep** 1999 Apr;16(2):131-43 (120 ref.)

IMMUNOLOGY

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Schröder U, et al. **Vaccine** 1999 Apr 9; 17(15-16):2096-103

METABOLISM

Lipase-catalyzed syntheses of monoglycerides by hydrolysis of soybean oil in AOT/isooctane reversed micelles. Fan HL, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:267-72

Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Bisogno T, et al. **Biochem Biophys Res Commun** 1999 Mar 16; 256(2):377-80

Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Goparaju SK, et al. **Biochem Pharmacol** 1999 Feb 15;57(4):417-23

An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Ben-Shabat S, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):23-31

Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Mechoulam R, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):R1-3

Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Di Marzo V, et al. **Lipids** 1999;34 Suppl:S319-25 (25 ref.)

PHARMACOLOGY

Breakfasts high in monoglyceride or triglyceride: no differential effect on appetite or energy intake. Johnstone AM, et al. **Eur J Clin Nutr** 1998 Aug;52(8):603-9

Endocannabinoids. Mechoulam R, et al. **Eur J Pharmacol** 1998 Oct 16;359(1):1-18 (161 ref.)

Efficacy of neem oil-water emulsion against mosquito immatures. Batra CP, et al. **Indian J Malariol** 1998 Mar; 35(1):15-21

Synthesis of 1-monoglycerides having C11-20 branched chain fatty acids and their hemolysis effects. Ping X, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):345-7

Inhibition of Bacillus licheniformis spore growth in milk by nisin, monolaurin, and pH combinations. Mansour M, et al. **J Appl Microbiol** 1999 Feb;86(2):311-24

Impact of medium-chain monoglycerides on intestinal colonisation by Vibrio cholerae or enterotoxigenic Escherichia coli. Petschow BW, et al. **J Med Microbiol** 1998 May;47(5):383-9

Glyceryl monooleate cubic phase gel as chemical stability enhancer of cefazolin and cefuroxime. Sadhale Y, et al. **Pharm Dev Technol** 1998 Nov;3(4):549-56

THERAPEUTIC USE

Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. Thormar H, et al. **Sex Transm Infect** 1999 Jun; 75(3):181-5

Medical management of common bile duct stones. González-Koch A, et al. **World J Surg** 1998 Nov; 22(11):1145-50 (48 ref.)

GLYCERIN see **GLYCEROL**

GLYCEROKINASE see **GLYCEROL KINASE**

GLYCEROL

Crystallization of ice in aqueous solutions of glycerol and dimethyl sulfoxide 2: ice crystal growth kinetics. Hey JM, et al. **Cryobiology** 1998 Sep;37(2):119-30

Rapid purification of intact minichromosomes over a glycerol cushion. Di Croce L, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):e11

Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications. Robergs RA, et al. **Sports Med** 1998 Sep;26(3):145-67 (57 ref.)

[Effect of cryopreservation on the morphology of blastocysts of the ferret Mustela eversmanni] Kizilova EA, et al. **Ontogenez** 1998 Nov-Dec;29(6):429-36 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Comparison between the intravenous and esophageal-gastric administration of glycerol in changing cochlear blood flow and serum osmolarity in the guinea pig. Noi O, et al. **Eur Arch Otorhinolaryngol** 1999;256(2):61-8

Use of an agent to reduce scattering in skin. Vargas G, et al. **Lasers Surg Med** 1999;24(2):133-41

The endoneurial response to neurolytic agents is highly dependent on the mode of application. Westerlund T, et al. **Reg Anesth Pain Med** 1999 Jul-Aug;24(4):294-302

[Early and late results of treating trigeminal neuralgia by Gasserian ganglioglycerolysis using a personal subjective pain measurement scale] Janik S. **Ann Acad Med Stetin** 1998;44:155-74 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Skin necrosis induced by extravasation of glycerol-containing peripheral parenteral nutrition formulation. Sacks GS, et al. **J Miss State Med Assoc** 1999 Sep;40(9):307-11

Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. Shibata N, et al. **J Pharm Pharmacol** 1999 Apr;51(4):397-404

ANALOGS & DERIVATIVES

Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice. Badary OA, et al. **Anticancer Drugs** 1998 Oct;9(9):809-15

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. van Tellingen O, et al. **Br J Cancer** 1999 Sep;81(2):330-5

Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Ellis AG, et al. **Cancer Chemother Pharmacol** 1999;43(1):13-8

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Sparreboom A, et al. **Cancer Res** 1999 Apr 1;59(7):1454-7

Phase I trial of cremophor EL with bolus doxorubicin. Millward MJ, et al. **Clin Cancer Res** 1998 Oct;4(10):2321-9

Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis. Engblom P, et al. **Eur J Cancer** 1999 Feb;35(2):284-8

Polyglycerol polyricinoleate (PGPR) is a compound used in the baking industry and in the manufacture of chocolate [letter] James WH. **Food Chem Toxicol** 1999 Feb-Mar; 37(2-3):268-9

Does polyglycerol polyricinoleate alter offspring sex ratios? [letter] James WH. **Food Chem Toxicol** 1999 Aug;37(8):919

Surface characterization, protein adsorption, and initial cell-surface reactions on glutathione and 3-mercapto-1,2,-propanediol immobilized to gold. Kanagaraja S, et al. **J Biomed Mater Res** 1999 Sep 15; 46(4):582-91

A cyclitol derivative as a replication inhibitor from the marine sponge Petrosia sp. Kim DK, et al. **J Nat Prod** 1999 May;62(5):773-6

Selective block by glyceryl nonivamide of inwardly rectifying K+ current in rat anterior pituitary GH3 cells. Wu SN, et al. **Life Sci** 1998;63(19):PL281-8

Rapid complexing of oxoacylglycerols with amino acids, peptides and aminophospholipids. Kurvinen JP, et al. **Lipids** 1999 Mar;34(3):299-305

ANALYSIS

Development of a biosensor for monitoring of glycerol during alcoholic fermentation. Compagnone D, et al. **Biosens Bioelectron** 1998 Oct 1;13(7-8):875-80

BLOOD

Regional glycerol and free fatty acid metabolism before and after meal ingestion. Jensen MD. **Am J Physiol** 1999 May; 276(5 Pt 1):E863-9

Blood glycerol is an important precursor for intramuscular triacylglycerol synthesis. Guo Z, et al. **J Biol Chem** 1999 Aug 20;274(34):23702-6

[What about hyperglycerolemia? (letter)] Casamayou H, et al. **Presse Med** 1999 Jan 9;28(1):17 **(Fre)**

CEREBROSPINAL FLUID

Raised cerebrospinal fluid glycerol concentration associated with use of dichloroacetate [letter; comment] Morris AA, et al. **Arch Dis Child** 1998 Sep;79(3):290-1. Comment on: Arch Dis Child 1997 Dec;77(6):535-41.

CHEMICAL SYNTHESIS

Conformationally constrained analogues of diacylglycerol having a perhydrofuro[3,4-c]furan-1,4-dione bis-gamma-butyrolactone skeleton. Lee J, et al. **Arch Pharm Res** 1998 Apr;21(2):164-7

Synthesis of azidophospholipids and labeling of lysophosphatidylcholine acyltransferase from developing soybean cotyledons. Tumaney AW, et al. **Biochim Biophys Acta** 1999 Jul 9;1439(1):47-56

CHEMISTRY

Glycerol affects the quantification of aspartate and glutamate in acid-hydrolyzed proteins. Juranville JF, et al. **Amino Acids** 1998;15(3):253-62

Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Beadle JR, et al. **Antivir Chem Chemother** 1998 Jan;9(1):33-40

A comparative study of the activation of protein kinase C alpha by different diacylglycerol isomers. Sánchez-Piñera P, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):387-95

Glycerol's influence on the oxidized insulin B-chain conformation in relation to the selectivity variation of subtilisin: an nuclear magnetic resonance and simulated annealing study. Dupradeau FY, et al. **Biochim Biophys Acta** 1999 Jan 11;1429(2):446-58

Formation of a molten-globule-like state of cytochrome c induced by high concentrations of glycerol. Santucci R, et al. **Biochimie** 1999 Jul;81(7):745-51

Modification of ceftibuten transport by changes in lipid fluidity caused by fatty acid glycerol esters. Koga K, et al. **Biol Pharm Bull** 1999 Jan;22(1):103-6

Effects of fatty acid glycerol esters on intestinal absorptive and secretory transport of ceftibuten. Koga K, et al. **Biol Pharm Bull** 1999 Apr;22(4):402-6

Effects of various adjuvants (lactic acid, glycerol, and chitosan) on the injectability of a calcium phosphate cement. Leroux L, et al. **Bone** 1999 Aug;25(2 Suppl):31S-34S

Switch from an aquaporin to a glycerol channel by two amino acids substitution. Lagrée V, et al. **J Biol Chem** 1999 Mar 12;274(11):6817-9

Surfactant-spreading and surface-compression disturbance on a thin viscous film. Bull JL, et al. **J Biomech Eng** 1999 Feb;121(1):89-98

Structural studies by 1H NMR and molecular modeling of peptide substrates of thermolysin in relation with its proteasic activity in water and glycerol. Baltora-Rosset

S, et al. **J Biomol Struct Dyn** 1999 Apr;16(5):1061–74

Mobility and free radical concentration effects in proton–electron double–resonance imaging. de Sousa PL, et al. **J Magn Reson** 1998 Nov;135(1):118–25

Relaxation effects in a system of a spin–1/2 nucleus coupled to a quadrupolar spin subjected to RF irradiation: evaluation of broadband decoupling schemes. Smith SA, et al. **J Magn Reson** 1999 Jan;136(1):27–36

Rapid complexing of oxoacylglycerols with amino acids, peptides and aminophospholipids. Kurvinen JP, et al. **Lipids** 1999 Mar;34(3):299–305

Crystal structure of Escherichia coli uracil DNA glycosylase and its complexes with uracil and glycerol: structure and glycosylase mechanism revisited. Xiao G, et al. **Proteins** 1999 Apr 1;35(1):13–24

ISOLATION & PURIFICATION

New acetylenic enol ethers of glycerol from the sponge Petrosia sp. Sco Y, et al. **J Nat Prod** 1999 Jan;62(1):122–6

A new method for monitoring the contamination of glycerol with diethylene glycol. Gomes MT, et al. **J Pharm Pharmacol** 1999 Feb;51(2):233–6

METABOLISM

Lipid second messengers derived from glycerolipids and sphingolipids, and their role in smooth muscle function. Ohanian J, et al. **Acta Physiol Scand** 1998 Dec; 164(4):533–48 (138 ref.)

Glycerol and nonesterified fatty acid metabolism in human muscle and adipose tissue in vivo. Coppack SW, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):E233–40

Bioconversion of fumarate to succinate using glycerol as a carbon source. Ryu HW, et al. **Appl Biochem Biotechnol** 1999 Spring;77–79:511–20

Insulin induced hypoglycaemia: comparison of glucose and glycerol concentrations in plasma and microdialysate from subcutaneous adipose tissue. Kamel A, et al. **Arch Dis Child** 1999 Jan;80(1):42–5

Research note: investigation on the metabolism of glycerol in the rumen of bulls. Kijora C, et al. **Arch Tierernahr** 1998; 51(4):341–8

Chronic ethanol administration alters hepatic rates of glycerol phosphorylation and glycerol 3-phosphate oxidation: a dynamic in vivo 31P magnetic resonance spectroscopy study. Brauer M, et al. **Biochem Cell Biol** 1998;76(2–3):542–52

Purification and functional reconstitution of soybean nodulin 26. An aquaporin with water and glycerol transport properties. Dean RM, et al. **Biochemistry** 1999 Jan 5; 38(1):347–53

Kinetic, dynamic, and pathway studies of glycerol metabolism by Klebsiella pneumoniae in anaerobic continuous culture: III. Enzymes and fluxes of glycerol dissimilation and 1,3-propanediol formation. Ahrens K, et al. **Biotechnol Bioeng** 1998 Sep 5;59(5):544–52

Effects of glucose and glycerol on gamma-poly(glutamic acid) formation by Bacillus licheniformis ATCC 9945a. Ko YH, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):430–7

Kinetic, dynamic, and pathway studies of glycerol metabolism by Klebsiella pneumoniae in anaerobic continuous culture: IV. Enzymes and fluxes of pyruvate metabolism. Menzel K, et al. **Biotechnol Bioeng** 1998 Dec 5;60(5):617–26

Cell electrophoretic mobility and glycerol lysis of human erythrocytes in various diseases. Hashimoto N, et al. **Electrophoresis** 1998 Jun;19(7):1227–30

Isolation and characterization of two glycerol-fermenting clostridial strains from a pilot scale anaerobic digester treating high lipid-content slaughterhouse waste. Jarvis GN, et al. **J Appl Microbiol** 1999 Mar;86(3):412–20

sn-glycerol-1-phosphate-forming activities in Archaea: separation of archaeal phospholipid biosynthesis and glycerol catabolism by glycerophosphate enantiomers. Nishihara M, et al. **J Bacteriol** 1999 Feb;181(4):1330–3

Intracellular glycerol levels modulate the activity of Sln1p, a Saccharomyces cerevisiae two-component regulator. Tao W, et al. **J Biol Chem** 1999 Jan 1;274(1):360–7

Transport of water and glycerol in aquaporin 3 is gated by H(+). Zeuthen T, et al. **J Biol Chem** 1999 Jul 30; 274(31):21631–6

Non-linear optimization of biotechnological processes by stochastic algorithms: application to the maximization of the production rate of ethanol, glycerol and carbohydrates by Saccharomyces cerevisiae. Rodriguez-Acosta F, et al. **J Biotechnol** 1999 Feb 5;68(1):15–28

Lactate and glycerol release from the subcutaneous adipose tissue of obese urban women from South Africa: important metabolic implications. van der Merwe MT, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4084–91

Lactate and glycerol release from subcutaneous adipose tissue in black and white lean men. van der Merwe MT, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2888–95

Freeze tolerance and cryoprotectant mobilization in the gray treefrog (Hyla versicolor). Layne JR Jr. **J Exp Zool** 1999 Feb 15;283(3):221–5

VLDL-triglyceride production after alcohol ingestion, studied using [2-13C1] glycerol. Siler SQ, et al. **J Lipid Res** 1998 Dec;39(12):2319–28

Involvement of reactive oxygen species in membrane phospholipid breakdown and energy perturbation after traumatic brain injury in the rat. Lewen A, et al. **J Neurotrauma** 1998 Jul;15(7):521–30

Metabolism and inflammatory mediators in the peritendinous space measured by microdialysis during intermittent isometric exercise in humans. Langberg H, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):919–27

Fps1p controls the accumulation and release of the compatible solute glycerol in yeast osmoregulation. Tamás MJ, et al. **Mol Microbiol** 1999 Feb;31(4):1087–104

Rational design of Rhizopus oryzae lipase with modified stereoselectivity toward triradylglycerols. Scheib H, et al. **Protein Eng** 1998 Aug;11(8):675–82

Stereoselectivity of Mucorales lipases toward triradylglycerols--a simple solution to a complex problem. Scheib H, et al. **Protein Sci** 1999 Jan;8(1):215–21

Relationship between the physiology of Enterobacter agglomerans CNCM 1210 grown anaerobically on glycerol and the culture conditions. Barbirato F, et al. **Res Microbiol** 1997 Jul–Aug;148(6):475–84

Neurochemical monitoring of fatal middle cerebral artery infarction. Berger C, et al. **Stroke** 1999 Feb;30(2):460–3

[Utilization of glucose, valine, glycerin and palmitic acid by energy and anabolic pathways of metabolism in rats] Virovets OA, et al. **Vopr Pitan** 1999;68(2):44–7 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Pharmacokinetics of serum glycerol and changes of ICP: comparison of gastric and duodenal administration. Takagi H, et al. **Acta Neurochir Suppl (Wien)** 1998;71:34–6

The rebound phenomenon of glycerol-induced changes in the endolymphatic space. Takeda T, et al. **Acta Otolaryngol** 1999;119(3):341–4

A mouse model to test the in vivo efficacy of chemical chaperones. Bai C, et al. **J Pharmacol Toxicol Methods** 1998 Jul;40(1):39–45

The antimalarial drug chloroquine inhibits glycerol uptake into cardiac cells. Hatch GM, et al. **Proc West Pharmacol Soc** 1998;41:21–4

PHARMACOLOGY

Effects of mannitol and glycerol on cerebral energy metabolism in gerbils. Tsuda Y, et al. **Acta Neurol Scand** 1998 Jul;98(1):36–40

Fatty acids and glycerol or lactate are required to induce gluconeogenesis from alanine in isolated rabbit renal cortical tubules. Lietz T, et al. **Amino Acids** 1999; 16(1):41–58

Enzymatic and structural approaches of the thermolysin mechanism in glycerol-containing media. Pauthe E, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:458–62

Effects of glycerol on intracellular ice formation and dehydration of onion epidermis. Tsuruta T, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:217–26

An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol [see comments] Rubin BK. **Chest** 1999 Jul;116(1):195–200 . Comment in: Chest 1999 Jul;116(1):6–8.

Increased positivity of skin test and allergenic stability of glycerinated soybean hull extracts. Morell F, et al. **Clin Exp Allergy** 1999 Mar;29(3):388–93

Intracolonic glycerol induces abdominal contractions in rats: role of 5-HT3 receptors. Botella A, et al. **Fundam Clin Pharmacol** 1998;12(6):619–23

Comparative effects of glycerol and Urografin on cochlear blood flow and serum osmolarity. Noi O, et al. **Hear Res** 1998 Sep;123(1–2):55–60

The effects of coital lubricants on sperm motility in vitro. Anderson L, et al. **Hum Reprod** 1998 Dec;13(12):3351–6

Freezing of testicular tissue as a minced suspension preserves sperm quality better than whole-biopsy freezing when glycerol is used as cryoprotectant. Crabbé E, et al. **Int J Androl** 1999 Feb;22(1):43–8

The 1998 Lindberg Award. Comparison of glycerol preservation with cryopreservation methods on HIV-1 inactivation. van Baare J, et al. **J Burn Care Rehabil** 1998 Nov–Dec;19(6):494–500

Plasticising effect of water and glycerin on human skin in vivo. Pedersen LK, et al. **J Dermatol Sci** 1999 Jan; 19(1):48–52

The matrix effects on kinetic rate constants of antibody-antigen interactions reflect solvent viscosity. Morgan CL, et al. **J Immunol Methods** 1998 Aug 1; 217(1–2):51–60

Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone. Ohnishi T, et al. **Radiat Res** 1999 Apr;151(4):498–500

THERAPEUTIC USE

The effect of peripheral glycerol on trigeminal neuropathic pain examined by quantitative assessment of abnormal pain and sensory perception. Eide PK, et al. **Acta Neurochir (Wien)** 1998;140(12):1271–7

Glycerol gangliotomy of the second dorsal cervical root in rats: an experimental study to evaluate a minimal invasive approach for the treatment of the chronic cervicogenic headache. Ludwig HC, et al. **Cephalalgia** 1998 Nov; 18(9):612–7

Transcranial doppler monitoring of intracranial pressure therapy with mannitol, sorbitol and glycerol in patients with acute stroke. Treib J, et al. **Eur Neurol** 1998 Nov; 40(4):212–9

Prevention of sodium lauryl sulfate irritant contact dermatitis by Pro-Q aerosol foam skin protectant. Patterson SE, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):783–5

Hyperhydrating with glycerol: implications for athletic performance. Wagner DR. **J Am Diet Assoc** 1999 Feb; 99(2):207–12 (19 ref.)

Trigeminal nerve peripheral branch phenol/glycerol injections for tic douloureux. Wilkinson HA. **J Neurosurg** 1999 May;90(5):828–32

The effect of a new tear substitute containing glycerol and hyaluronate on keratoconjunctivitis sicca. Solomon A, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):497–504

Relief of trigeminal neuralgia after percutaneous retrogasserian glycerol rhizolysis is dependent on normalization of abnormal temporal summation of pain, without general impairment of sensory perception. Eide PK, et al. **Neurosurgery** 1998 Sep;43(3):462–72; discussion 472–4

[Experience in the application of iodine-diceryn in the treatment of purulent wounds] Bondarev RV. **Klin Khir** 1999;(1):7–8 (Eng. Abstr.) **(Rus)**

TOXICITY

Mouse spermatozoa in high concentrations of glycerol: chemical toxicity vs osmotic shock at normal and reduced oxygen concentrations. Katkov II, et al. **Cryobiology** 1998 Dec;37(4):325–38

GLYCEROL ETHERS see **GLYCERYL ETHERS**

GLYCEROL KINASE

CHEMISTRY

A flash-annealing technique to improve diffraction limits and lower mosaicity in crystals of glycerol kinase. Yeh JI, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):479–80

X-Ray structure of glycerol kinase complexed with an ATP analog implies a novel mechanism for the ATP-dependent glycerol phosphorylation by glycerol kinase. Mao C, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):640–4

Crystal structures of Escherichia coli glycerol kinase variant S58-->W in complex with nonhydrolyzable ATP analogues reveal a putative active conformation of the enzyme as a result of domain motion. Bystrom CE, et al. **Biochemistry** 1999 Mar 23;38(12):3508–18

Crystal structure of a complex of Escherichia coli glycerol kinase and an allosteric effector fructose 1,6-bisphosphate. Ormö M, et al. **Biochemistry** 1998 Nov 24;37(47):16565–72

Thermostable glycerol kinase from a hyperthermophilic archaeon: gene cloning and characterization of the recombinant enzyme. Koga Y, et al. **Protein Eng** 1998 Dec; 11(12):1219–27

DEFICIENCY

Late-onset atopic dermatitis in complex glycerol kinase deficiency with chromosome Xp21 region deletion: is there a pathogenic relationship?[letter] Sueyoshi F, et al. **Dermatology** 1999;198(1):98–9

GENETICS

Cloning, sequencing, high expression, and crystallization of the thermophile Thermus aquaticus glycerol kinase. Huang HS, et al. **Biosci Biotechnol Biochem** 1998 Dec; 62(12):2375–81

Clinical heterogeneity and novel mutations in the glycerol kinase gene in three families with isolated glycerol kinase deficiency. Sjarif DR, et al. **J Med Genet** 1998 Aug; 35(8):650–6

Thermostable glycerol kinase from a hyperthermophilic archaeon: gene cloning and characterization of the recombinant enzyme. Koga Y, et al. **Protein Eng** 1998 Dec; 11(12):1219–27

ISOLATION & PURIFICATION

A novel glycerol kinase from Flavobacterium meningosepticum: characterization, gene cloning and primary structure. Sakasegawa S, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2388–95

METABOLISM

Limits to inducer exclusion: inhibition of the bacterial phosphotransferase system by glycerol kinase. Rohwer JM, et al. **Mol Microbiol** 1998 Jul;29(2):641–52

Glycerol kinase from Escherichia coli and an Ala65-->Thr mutant: the crystal structures reveal conformational changes with implications for allosteric regulation. Feese MD, et al. **Structure** 1998 Nov 15;6(11):1407–18

PHARMACOLOGY

Limits to inducer exclusion: inhibition of the bacterial phosphotransferase system by glycerol kinase. Rohwer JM, et al. **Mol Microbiol** 1998 Jul;29(2):641–52

GLYCEROL MONOESTER HYDROLASES see **MONOACYLGLYCEROL LIPASES**

GLYCEROL PHOSPHATE ETHERS see **PHOSPHOLIPID ETHERS**

GLYCEROL PHOSPHOGLYCERIDES

GLYCEROL PHOSPHOGLYCERIDES see **PHOSPHATIDYLGLYCEROLS**

GLYCEROLPHOSPHATE ACYLTRANSFERASE see **GLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE**

GLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE

CHEMISTRY

Analysis of amino acid motifs diagnostic for the sn-glycerol-3-phosphate acyltransferase reaction. Lewin TM, et al. **Biochemistry** 1999 May 4;38(18):5764-71

GENETICS

Rat sn-glycerol-3-phosphate acyltransferase: molecular cloning and characterization of the cDNA and expressed protein. Ganesh Bhat B, et al. **Biochim Biophys Acta** 1999 Aug 18;1439(3):415-23

A missense mutation accounts for the defect in the glycerol-3-phosphate acyltransferase expressed in the plsB26 mutant. Heath RJ, et al. **J Bacteriol** 1999 Mar; 181(6):1944-6

METABOLISM

AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Muoio DM, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):783-91

A missense mutation accounts for the defect in the glycerol-3-phosphate acyltransferase expressed in the plsB26 mutant. Heath RJ, et al. **J Bacteriol** 1999 Mar; 181(6):1944-6

GLYCEROLPHOSPHATE DEHYDROGENASE

BIOSYNTHESIS

Different signalling pathways contribute to the control of GPD1 gene expression by osmotic stress in Saccharomyces cerevisiae. Rep M, et al. **Microbiology** 1999 Mar;145 (Pt 3):715-27

CHEMISTRY

Site-directed mutations of the FAD-linked glycerophosphate dehydrogenase gene impairs the mitochondrial anchoring of the enzyme in transfected COS-7 cells. Fabregat ME, et al. **Biochem Biophys Res Commun** 1998 Nov 9; 252(1):173-7

GENETICS

Quantitative aspects of the use of bacterial chloramphenicol acetyltransferase as a reporter system in the yeast Saccharomyces cereviniae. Alipour H, et al. **Anal Biochem** 1999 May 15;270(1):153-8

Improved ethanol production by glycerol-3-phosphate dehydrogenase mutants of Saccharomyces cerevisiae. Valadi H, et al. **Appl Microbiol Biotechnol** 1998 Oct; 50(4):434-9

Detection of a new variant of the mitochondrial glycerol-3-phosphate dehydrogenase gene in Spanish type 2 DM patients. Gudayol M, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):439-45

Regulation of the expression of the sn-glycerol-3-phosphate dehydrogenase gene in Drosophila melanogaster. Bartoszewski S, et al. **Biochem Genet** 1998 Oct; 36(9-10):329-50

Nucleotide sequence and expression of the sn-glycerol-3-phosphate dehydrogenase gene in Locusta migratoria. Wilanowski TM, et al. **Biochim Biophys Acta** 1998 Dec 22;1443(3):414-8

DNA polymorphisms at alpha-Gpdh locus of Drosophila melanogaster in Korean population. Kang SJ, et al. **Genes Genet Syst** 1998 Aug;73(4):227-35

Fitness of wild-caught Drosophila melanogaster females: allozyme variants of GPDH, ADH, PGM, and EST. Ochando MD, et al. **Genetica** 1999;105(1):7-18

Expression of the GPDH-4 isozyme of sn-glycerol-3-phosphate dehydrogenase in three Drosophila species. Wilanowski TM, et al. **Heredity** 1998 Oct;81 (Pt 4):390-5

METABOLISM

Ability of cytosolic malate dehydrogenase and lactate dehydrogenase to increase the ratio of NADPH to NADH oxidation by cytosolic glycerol-3-phosphate dehydrogenase. Fahien LA, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):185-94

Effect of NADH-X on cytosolic glycerol-3-phosphate dehydrogenase. Prabhakar P, et al. **Arch Biochem Biophys** 1998 Dec 15;360(2):195-205

Site-directed mutations of the FAD-linked glycerophosphate dehydrogenase gene impairs the mitochondrial anchoring of the enzyme in transfected COS-7 cells. Fabregat ME, et al. **Biochem Biophys Res Commun** 1998 Nov 9; 252(1):173-7

Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan. Denise H, et al. **Eur J Biochem** 1999 Jan;259(1-2):339-46

Effect of hexachlorobenzene on NADPH-generating lipogenic enzymes and L-glycerol-3-phosphate dehydrogenase in brown adipose tissue. Alvarez L, et al. **J Endocrinol Invest** 1999 Jun;22(6):436-45

PHYSIOLOGY

Regulation of the expression of the sn-glycerol-3-phosphate dehydrogenase gene in Drosophila melanogaster. Bartoszewski S, et al. **Biochem Genet** 1998 Oct; 36(9-10):329-50

GLYCEROPHOSPHATE ETHERS see **PHOSPHOLIPID ETHERS**

GLYCEROPHOSPHATES

CHEMISTRY

[Structure of glycerophosphate-containing O-specific polysaccharide from Pseudoalteromonas sp. KMM 639] Gorshkova RP, et al. **Bioorg Khim** 1998 Nov;24(11):839-41 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

MR colonography: optimized enema composition. Luboldt W, et al. **Radiology** 1999 Jul;212(1):265-9

METABOLISM

Chronic ethanol administration alters hepatic rates of glycerol phosphorylation and glycerol 3-phosphate oxidation: a dynamic in vivo 31P magnetic resonance spectroscopy study. Brauer M, et al. **Biochem Cell Biol** 1998;76(2-3):542-52

Purinogen is not an endogenous substrate used in endothelial cells during substrate deprivation. Culic O, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):523-7

Recognition of binding sites I and II by the TrpI activator protein of pseudomonas aeruginosa: efficient binding to both sites requires InGP even when site II is replaced by site I. Olekhnovich I, et al. **Gene** 1998 Nov 26; 223(1-2):247-55

Redundant systems of phosphatidic acid biosynthesis via acylation of glycerol-3-phosphate or dihydroxyacetone phosphate in the yeast Saccharomyces cerevisiae. Athenstaedt K, et al. **J Bacteriol** 1999 Mar;181(5):1458-63

sn-glycerol-1-phosphate-forming activities in Archaea: separation of archaeal phospholipid biosynthesis and glycerol catabolism by glycerophosphate enantiomers. Nishihara M, et al. **J Bacteriol** 1999 Feb;181(4):1330-3

PHARMACOLOGY

Matrix mineralization in MC3T3-E1 cell cultures initiated by beta-glycerophosphate pulse. Fratzl-Zelman N, et al. **Bone** 1998 Dec;23(6):511-20

Osteoblastic phenotype of rat marrow stromal cells cultured in the presence of dexamethasone, beta-glycerolphosphate, and L-ascorbic acid. Peter SJ, et al. **J Cell Biochem** 1998 Oct 1;71(1):55-62

THERAPEUTIC USE

Randomized trial of calcium glycerophosphate-supplemented infant formula to prevent lead absorption. Sargent JD, et al. **Am J Clin Nutr** 1999 Jun;69(6):1224-30

GLYCEROPHOSPHOLIPIDS

BIOSYNTHESIS

Formation of phosphatidic acid and subclasses of phosphatidylethanol in human neutrophils upon interleukin-8 stimulation. Tou JS, et al. **Cell Signal** 1999 Feb;11(2):137-41

BLOOD

Phosphatidylethanol in blood as a marker of ethanol consumption in healthy volunteers: comparison with other markers. Varga A, et al. **Alcohol Clin Exp Res** 1998 Nov; 22(8):1832-7

Study of mechanisms involved in the collision-induced dissociation of carboxylate anions from glycerophospholipids using negative ion electrospray tandem quadrupole mass spectrometry. Hvattum E, et al. **Rapid Commun Mass Spectrom** 1998;12(19):1405-9

CHEMISTRY

Polymorphism of the 1-palmitoyl-2-arachidonoyl-phosphatidyl-ethanolamine/dimyristoyl-phos phatidylmethanol mixture, a phospholipase A2 substrate. Jacob M, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):879-82

Influence of docosahexaenoic acid and cholesterol on lateral lipid organization in phospholipid mixtures. Huster D, et al. **Biochemistry** 1998 Dec 8;37(49):17299-308

Multiple factors influence the binding of a soluble, Ca2+-independent, diacylglycerol kinase to unilamellar phosphoglyceride vesicles. Thomas WE, et al. **Biochemistry** 1999 Mar 16;38(11):3310-9

METABOLISM

Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia. Yorek MA, et al. **Biochim Biophys Acta** 1999 Mar 25; 1437(3):287-300

Heterogeneous long chain acyl-CoA synthetases control distribution of individual fatty acids in newly-formed glycerolipids of neuronal cells undergoing neurite outgrowth. Li J, et al. **Neurochem Res** 1999 Jun; 24(6):739-50

PHARMACOLOGY

Proinflammatory macrophage-activating properties of the novel phospholipid diacylglycerol pyrophosphate. Balboa MA, et al. **J Biol Chem** 1999 Jan 1;274(1):522-6

Regulation of the p21-activated kinase-related Dictyostelium myosin I heavy chain kinase by autophosphorylation, acidic phospholipids, and Ca2+-calmodulin. Lee SF, et al. **J Biol Chem** 1998 Oct 23;273(43):27911-7

GLYCERYL ETHERS

ANALYSIS

Characterizations of Pneumocystis carinii and rat lung lipids: glyceryl ethers and fatty alcohols. Kaneshiro ES, et al. **J Lipid Res** 1998 Oct;39(10):1907-17

PHARMACOLOGY

Differentiation-promoting effect of 1-O (2 methoxy) hexadecyl glycerol in human colon cancer cells. Wang H, et al. **J Cell Physiol** 1999 Feb;178(2):173-8

GLYCERYL TRINITRATE see **NITROGLYCERIN**

GLYCERYLPHOSPHORYLCHOLINE

ANALOGS & DERIVATIVES

Biosynthesis of 1,2-dieicosapentaenoyl-sn-glycero-3-phosphocholine in Caenorhabditis elegans. Tanaka T, et al. **Eur J Biochem** 1999 Jul;263(1):189-95

Secreted and intracellular phospholipases A2 inhibition by 1-decyl 2-octyl-glycerophosphocholine in rat peritoneal macrophages. Boucrot P, et al. **Fundam Clin Pharmacol** 1998;12(4):433-41

Identification and pharmacological characterization of platelet-activating factor and related 1-palmitoyl species in human inflammatory blistering diseases. Travers JB, et al. **Prostaglandins Other Lipid Mediat** 1998 Aug; 56(5-6):305-24

CHEMISTRY

Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry. Hsu FF, et al. **J Am Soc Mass Spectrom** 1998 May;9(5):516-26

METABOLISM

Cortical and medullary betaine-GPC modulated by osmolality independently of oxygen in the intact kidney. Cowin GJ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):F338-46

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34-49 (78 ref.)

Caffeine causes glycerophosphorylcholine accumulation through ryanodine-inhibitable increase of cellular calcium and activation of phospholipase A2 in cultured MDCK cells. Kim DK, et al. **Exp Mol Med** 1998 Sep 30;30(3):151-8

GLYCINE

see related
RECEPTORS, GLYCINE

Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association. Javadpour MM, et al. **Biophys J** 1999 Sep;77(3):1609-18

Biochemical hemodynamic and hematological changes during transcervical resection of the endometrium using 1.5% glycine as the irrigating solution. Kriplani A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):99-104

Sorbitol-mannitol solution for urological electrosurgical resection-- a safer fluid than glycine 1.5%. Dawkins GP, et al. **Eur Urol** 1999 Aug;36(2):99-102

Identification of a de novo glycine substitution in the type VII collagen gene in a proband with mild dystrophic epidermolysis bullosa [see comments] Cserhalmi-Friedman PB, et al. **Exp Dermatol** 1999 Apr;8(2):143-5. Comment in: Exp Dermatol 1999 Apr;8(2):92-5.

Aromatic rescue of glycine in beta sheets. Merkel JS, et al. **Fold Des** 1998;3(6):449-55

Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. Koh TJ, et al. **J Clin Invest** 1999 Apr;103(8):1119-26

Root-specific expression of genes for novel glycine-rich proteins cloned by use of an antiserum against xylem sap proteins of cucumber. Sakuta C, et al. **Plant Cell Physiol** 1998 Dec;39(12):1330-6

Glycine rinse protects against liver injury during transplantation. Arora AS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):505-6

ADMINISTRATION & DOSAGE

Experience with isotonic 2.2% glycine as distension medium for hysteroscopic endomyometrial resection. Tapper AM, et al. **Gynecol Obstet Invest** 1999;47(4):263-7

Glycine improves survival after hemorrhagic shock in the rat. Zhong Z, et al. **Shock** 1999 Jul;12(1):54-62

ADVERSE EFFECTS

Loss of vision: a manifestation of TURP syndrome. A case report. Khan-Ghori SN, et al. **Middle East J Anesthesiol** 1998 Oct;14(6):441-9

Comparison of urological irrigating fluids containing glycine and mannitol in volunteers. Sandfeldt L, et al. **Prostate** 1999 Oct 1;41(2):89-98

[Bronchial asthma due to Stronger Neo-Minophagen C] Nakatsumi Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):644-6 (Eng. Abstr.) **(Jpn)**

AGONISTS

Glycine agonists: what can they teach us about schizophrenia? [comment] Farber NB, et al. **Arch Gen Psychiatry** 1999 Jan;56(1):13-7 (50 ref.). Comment on: Arch Gen Psychiatry 1999 Jan;56(1):21-7. Comment on: Arch Gen Psychiatry 1999 Jan;56(1):29-36.

A partial agonist at strychnine-insensitive glycine sites facilitates spatial learning in aged rats. Popik P, et al. **J Physiol Pharmacol** 1999 Mar;50(1):139-51

ANALOGS & DERIVATIVES

Chiral recognition between host and guest: a binaphthyl-18-crown-6 host with D-phenylglycinium methyl ester perchlorate guest. A difficult structure solved with CRUNCH. Cram DJ, et al. **Acta Crystallogr B** 1999 Jun 1;55 (Pt 3):432-40

Formation of gamma-glutamylpropargylglycylglycine from propargylglycine in human blood and erythrocytes. Nagamine N, et al. **Acta Med Okayama** 1999 Feb; 53(1):19-25

Glycine derivatives of imidazolones as potential ligands of glycine binding site of NMDA receptors. Part 1. Kieć-Kononowicz K, et al. **Acta Pol Pharm** 1998 Sep-Oct; 55(5):381-8

Bioavailability of iron glycine [letter; comment] Ashmead HD. **Am J Clin Nutr** 1999 Apr;69(4):737-8. Comment on: Am J Clin Nutr 1998 Apr;67(4):664-8.

NHS-MAS3: a bifunctional chelator alternative to NHS-MAG3. Chang F, et al. **Appl Radiat Isot** 1999 Apr; 50(4):723-32

The toxicity of glyphosate and several glyphosate formulations to four species of southwestern Australian frogs. Mann RM, et al. **Arch Environ Contam Toxicol** 1999 Feb;36(2):193-9

Residues critical for formylglycine formation and/or catalytic activity of arylsulfatase A. Knaust A, et al. **Biochemistry** 1998 Oct 6;37(40):13941-6

Effects of a water-soluble prodrug of vitamin E on doxorubicin-induced toxicity in mice. Nagata Y, et al. **Biol Pharm Bull** 1999 Jul;22(7):698-702

Ion exchange chromatography of aluminum using 3-carboxy-2-naphthylamine-N,N-diacetic acid as a fluorescent post-column chelating reagent. Miyahara T, et al. **Biomed Chromatogr** 1999 Feb;13(1):70-4

2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors. Collado I, et al. **Bioorg Med Chem Lett** 1998 Oct 20;8(20):2849-54

Synthesis of DNA analogues with novel carboxamidomethyl phosphonamide and glycinamide internucleoside linkages. Efimov VA, et al. **Bioorg Med Chem Lett** 1998 May 5; 8(9):1013-8

Thrombin inhibitors based on a propargylglycine template. Lee K, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1013-8

High affinity phenylglycinol-based NK1 receptor antagonists. Owens AP, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):51-6

Synthesis and preliminary evaluation of (S)-2-(4'-carboxycubyl)glycine, a new selective mGluR1 antagonist. Pellicciari R, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1569-74

Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Wang Y, et al. **Biopharm Drug Dispos** 1999 Mar; 20(2):69-75

Uptake of the herbicidal glyphosate by Escherichia coli K-12. Cherepenko E, et al. **Biosci Rep** 1999 Feb;19(1):43-9

Production of D-phenylglycine from racemic (D,L)-phenylglycine via isoelectrically-trapped penicillin G acylase. Bossi A, et al. **Biotechnol Bioeng** 1998 Nov 20; 60(4):454-61

Optimization of a heterogeneous reaction system for the production of optically active D-amino acids using thermostable D-hydantoinase. Lee DC, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):729-38

Production of D-p-hydroxyphenylglycine by N-carbamoyl-D-amino acid amidohydrolase-overproducing Escherichia coli strains. Chao YP, et al. **Biotechnol Prog** 1999 Jul-Aug;15(4):603-7

A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Hattori K, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1283-9

A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K, et al. **Br J Haematol** 1999 Apr; 105(1):303-12

Antagonist activity of alpha-substituted 4-carboxyphenylglycine analogues at group I metabotropic glutamate receptors expressed in CHO cells. Doherty AJ, et al. **Br J Pharmacol** 1999 Jan;126(1):205-10

Antagonism of the mGlu5 agonist 2-chloro-5-hydroxyphenylglycine by the novel selective mGlu5 antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) in the thalamus. Salt TE, et al. **Br J Pharmacol** 1999 Jul;127(5):1057-9

Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV). Attwell PJ, et al. **Brain Res** 1998 Sep 14;805(1-2):138-43

A case-control study of non-Hodgkin lymphoma and exposure to pesticides [letter] Acquavella J, et al. **Cancer** 1999 Aug 15;86(4):729-31

Inhibition effect of propargylglycine on human fibrosarcoma HT-1080 cell invasiveness. Haga A, et al. **Cancer Biochem Biophys** 1998 Jun;16(1-2):31-43

Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Lozonschi L, et al. **Cancer Res** 1999 Mar 15;59(6):1252-8

Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts. Wadkins RM, et al. **Cancer Res** 1999 Jul 15;59(14):3424-8

Glioma cells release excitotoxic concentrations of glutamate. Ye ZC, et al. **Cancer Res** 1999 Sep 1;59(17):4383-91

The cytotoxicity of DNA carboxymethylation and methylation by the model carboxymethylating agent azaserine in human cells. O'Driscoll M, et al. **Carcinogenesis** 1999 Sep;20(9):1855-62

Neuronal free calcium measurement using BTC/AM, a low affinity calcium indicator. Hyrc KL, et al. **Cell Calcium** 1998 Sep;24(3):165-75

Herbicide (Roundup) pneumonitis. Pushnoy LA, et al. **Chest** 1998 Dec;114(6):1769-71

Gastrosparing effect of new antiinflammatory drug amtolmetin guacyl in the rat: involvement of nitric oxide. Pisano C, et al. **Dig Dis Sci** 1999 Apr;44(4):713-24

Sequence determinants directing conversion of cysteine to formylglycine in eukaryotic sulfatases. Dierks T, et al. **EMBO J** 1999 Apr 15;18(8):2084-91

Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Spiegelstein O, et al. **Epilepsia** 1999 May;40(5):545-52

The structural requirements for the design of antiepileptic-glycine derivatives. Sussan S, et al. **Epilepsy Res** 1999 Apr;34(2-3):207-20

Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Sussan S, et al. **Epilepsy Res** 1999 Jan;33(1):11-21

The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease [see comments] Linder R, et al. **Eur Heart J** 1999 Apr; 20(7):506-18. Comment in: Eur Heart J 1999 Apr;20(7):479-80.

The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points [see comments] Näslund U, et al. **Eur Heart J** 1999 May;20(10):771-7. Comment in: Eur Heart J 1999 May;20(10):708-9.

Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Chapman AG, et al. **Eur J Pharmacol** 1999 Feb 26;368(1):17-24

Induction of long-lasting depression by (+)-alpha-methyl-4-carboxyphenylglycine and other group II mGlu receptor ligands in the dentate gyrus of the hippocampus in vitro. Huang L, et al. **Eur J Pharmacol** 1999 Feb 5;366(2-3):151-8

Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Kilbride J, et al. **Eur J Pharmacol** 1998 Sep 4; 356(2-3):149-57

ONO-5046 is a potent inhibitor of neutrophil elastase in human pleural effusion after lobectomy. Sakuma T, et al. **Eur J Pharmacol** 1998 Jul 24;353(2-3):273-9

Effect of ONO-5046, a specific neutrophil elastase inhibitor, on the phorbol myristate acetate-induced injury in isolated dog lung. Wang HG, et al. **Exp Lung Res** 1999 Jan-Feb; 25(1):55-67

Safety evaluation of ferrous bisglycinate chelate. Jeppsen RB, et al. **Food Chem Toxicol** 1999 Jul;37(7):723-31

Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Ciccarelli R, et al. **Glia** 1999 Sep;27(3):275-81

Human ocular effects from self-reported exposures to Roundup herbicides. Acquavella JF, et al. **Hum Exp Toxicol** 1999 Aug;18(8):479-86

Clinical impact of upper gastrointestinal tract injuries in glyphosate-surfactant oral intoxication. Chang CY, et al. **Hum Exp Toxicol** 1999 Aug;18(8):475-8

Clinical and gastroscopic evaluation of amtolmetin guacyl versus diclofenac in patients with rheumatoid arthritis [see comments] Bianchi Porro G, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):378-85. Comment in: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):386-7.

Posttranslational formation of formylglycine in prokaryotic sulfatases by modification of either cysteine or serine. Dierks T, et al. **J Biol Chem** 1998 Oct 2;273(40):25560-4

Effects of sample preparation conditions on biomolecular solid-state NMR lineshapes. Jakeman DL, et al. **J Biomol NMR** 1998 Oct;12(3):417-21

Rapid determination of glyphosate in cereal samples by means of pre-column derivatisation with 9-fluorenylmethyl chloroformate and coupled-column liquid chromatography with fluorescence detection. Hogendoorn EA, et al. **J Chromatogr A** 1999 Feb 12;833(1):67-73

Determination of the absolute configuration of alpha-hydroxyglycine derivatives by enzymatic conversion and chiral high-performance liquid chromatography. McIninch JK, et al. **J Chromatogr A** 1998 Dec 18; 828(1-2):191-8

Analysis and degradation study of glyphosate and of aminomethylphosphonic acid in natural waters by means of polymeric and ion-exchange solid-phase extraction columns followed by ion chromatography-post-column derivatization with fluorescence detection. Mallat E, et al. **J Chromatogr A** 1998 Oct 9;823(1-2):129-36

Determination of glyphosate by ion chromatography. Zhu Y, et al. **J Chromatogr A** 1999 Jul 30;850(1-2):297-301

Effects of N-methacryloyl amino acid applications on hybrid layer formation at the interface of intertubular dentin. Suzuki K, et al. **J Dent Res** 1998 Nov;77(11):1881-8

Inhibition of succinic semialdehyde dehydrogenase by N-formylglycine. Kumar S, et al. **J Enzyme Inhib** 1998 Aug;13(5):369-76

The effects of a neutrophil elastase inhibitor (ONO-5046.Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs. Tomizawa N, et al. **J Heart Lung Transplant** 1999 Jul;18(7):637-45

Effect of a specific synthetic inhibitor of neutrophil elastase (ONO-5046) on the course of acute hemorrhagic pancreatitis in dogs. Imamura M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):422-8

Three-dimensional 13C shift/1H-15N coupling/15N shift solid-state NMR correlation spectroscopy. Gu Z, et al. **J Magn Reson** 1999 Jun;138(2):193-8

"BEST" homonuclear adiabatic decoupling for 13C- and 15N-double-labeled proteins. Zhang S, et al. **J Magn Reson** 1999 Jun;138(2):281-7

Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives. Nikam SS, et al. **J Med Chem** 1999 Jun 17;42(12):2266-71

(2R,1'S,2'R,3'S)-2-(2'-Carboxy-3'-phenylcyclopropyl) glycine (PCCG-13), the first potent and selective competitive antagonist of phospholipase D-coupled metabotropic glutamate receptors: asymmetric synthesis and preliminary biological properties. Pellicciari R, et al. **J Med Chem** 1999 Jul 15;42(14):2716-20

Characterization of (2S,2'R,3'R)-2-(2',3'-[3H]-dicarboxycyclopropyl)glycine binding in rat brain. Mutel V, et al. **J Neurochem** 1998 Dec;71(6):2558-64

Differential effects of metabotropic glutamate receptor antagonists on bursting activity in the amygdala. Keele NB, et al. **J Neurophysiol** 1999 May;81(5):2056-65

Inhibition of glutathione synthesis with propargylglycine enhances N-acetylmethionine protection and methylation in bromobenzene-treated Syrian hamsters. Lertratanangkoon K, et al. **J Nutr** 1999 Mar;129(3):649-56

(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. Gasparini F, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1678-87

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. Uriuda Y, et al. **J Pharmacol Toxicol Methods** 1998 Mar;39(2):81-9

Effect of specific neutrophil elastase inhibitor on ischemia/reperfusion injury in rat liver transplantation. Soejima Y, et al. **J Surg Res** 1999 Sep;86(1):150-4

The effect of neutrophil elastase inhibitor in hepatectomy with ischemia in dogs. Tomizawa N, et al. **J Surg Res** 1999 Feb;81(2):230-7

p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Mienie LJ, et al. **Life Sci** 1999;65(5):535-42

Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Nozawa Y, et al. **Life Sci** 1999; 64(22):2061-70

Metabolism of cystathionine, N-monoacetylcystathionine,

perhydro-1,4-thiazepine-3,5-dicarboxylic acid, and cystathionine ketimine in the liver and kidney of D,L-propargylglycine-treated rats. Zhang J, et al. **Metabolism** 1998 Oct;47(10):1233-8

Antagonist pharmacology of metabotropic glutamate receptors coupled to phospholipase D activation in adult rat hippocampus: focus on (2R,1'S,2'R,3'S)-2-(2'-carboxy-3'-phenylcyclopropyl) glycine versus 3, 5-dihydroxyphenylglycine. Albani-Torregrossa S, et al. **Mol Pharmacol** 1999 Apr; 55(4):699-707

In vivo effects of the NMDA receptor agonist tetrazolyl-glycine related to the function of small-diameter primary afferents. Lembeck F, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):38-41

Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Brabet I, et al. **Neuropharmacology** 1998 Aug;37(8):1043-51

Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Bruno V, et al. **Neuropharmacology** 1999 Feb;38(2):199-207

Priming of group 2 metabotropic glutamate receptors facilitates induction of long-term depression in the dentate gyrus of freely moving rats. Manahan-Vaughan D. **Neuropharmacology** 1998 Dec;37(12):1459-64

Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Mannaioni G, et al. **Neuropharmacology** 1999 Jul;38(7):917-26

(S)-4C3HPG reduces infarct size after focal cerebral ischemia [published erratum appears in Neuropharmacology 1999 Feb;38(2):327] Rauca C, et al. **Neuropharmacology** 1998 Dec;37(12):1649-52

Gastric effects of the novel non-steroidal anti-inflammatory drug amtolmetin guacyl [editorial] Coruzzi G, et al. **Nutrition** 1999 Apr;15(4):325-6

Intrathecal administration of the mGluR compound, (S)-4CPG, attenuates hyperalgesia and allodynia associated with sciatic nerve constriction injury in rats. Fisher K, et al. **Pain** 1998 Jul;77(1):59-66

Analogs of thyrotropin-releasing hormone using an aminoglycine-based template. Kirby DA, et al. **Peptides** 1998;19(10):1679-83

Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement. Sjöström M, et al. **Pharm Res** 1999 Jan;16(1):74-9

Comparison of the effects of low and high concentrations of group I metabotropic receptor agonists on field potentials in the hippocampal CA1 region in vitro. Zahorodna A, et al. **Pol J Pharmacol** 1998 Jul-Oct; 50(4-5):291-8

Potentiation of synaptic transmission by (S)-3,5-dihydroxy phenylglycine in the rat dentate gyrus in vitro: a role for voltage dependent calcium channels and protein kinase C. O'Leary DM, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Jan; 23(1):133-47

The effect of potassium diazoacetate on human peripheral lymphocytes, human adenocarcinoma Colon caco-2 cells, and rat primary colon cells in the comet assay. Anderson D, et al. **Teratog Carcinog Mutagen** 1999;19(2):137-46

Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Eriksson H, et al. **Thromb Haemost** 1999 Mar; 81(3):358-63

Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Eriksson M, et al. **Thromb Haemost** 1998 Dec;80(6):1022-6

Glyphosate toxicosis in domestic animals: a survey from the data of the Centre National d'Informations Toxicologiques Veterinaires (CNITV). Burgat V, et al. **Vet Hum Toxicol** 1998 Dec;40(6):363-7

[Reproductive and developmental toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na (1). Fertility study in rats] Chihara N, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:503-14 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (2). Study for effects on pre- and postnatal development in rats, including maternal function] Nishimura T, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:515-29 (Eng. Abstr.) **(Jpn)**

[Reproductive and developmental toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (3). Teratogenicity study in rabbits] Nishimura T, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:531-8 (Eng. Abstr.) **(Jpn)**

[Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (5). 6-month repeated dose intravenous toxicity study in dogs with 1-month recovery test] Okamoto M, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:483-501 (Eng. Abstr.) **(Jpn)**

[Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (4). 6-month repeated dose intravenous toxicity study in rats with 1-month recovery test] Yamaguchi K, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:457-82 (Eng. Abstr.) **(Jpn)**

[Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (3). 4-week repeated dose intravenous toxicity study in dogs with 4-week recovery test] Yamaguchi K, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:435-55 (Eng. Abstr.) **(Jpn)**

[Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (1). Single-dose intravenous toxicity studies in rats and dogs] Yanagi H, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:409-13 (Eng. Abstr.) **(Jpn)**

[Toxicity study of sodium N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino] benzoyl] aminoacetate tetrahydrate (ONO-5046.Na) (2). 4-week repeated dose intravenous toxicity study in rats with 4-week recovery test] Yanagi H, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 3:415-34 (Eng. Abstr.) **(Jpn)**

[Antioxidative effect of N2-mercaptopropionylglycine (N2 MPG) in experimental acute pancreatitis] Abdo EE, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul-Aug; 53(4):169-73 (Eng. Abstr.) **(Por)**

ANALYSIS

Swelling and ketoprofen release characteristics of thermo- and pH-responsive copolymer gels. Negishi M, et al. **Drug Dev Ind Pharm** 1999 Apr;25(4):437-44

Origins of the glycinergic inputs to the rat locus coeruleus and dorsal raphe nuclei: a study combining retrograde tracing with glycine immunohistochemistry. Rampon C, et al. **Eur J Neurosci** 1999 Mar;11(3):1058-66

The DNA puff BhB10-1 gene encodes a glycine-rich protein secreted by the late stage larval salivary glands of Bradysia hygida. Fontes AM, et al. **Gene** 1999 Apr 29;231(1-2):67-75

Presence of the vesicular inhibitory amino acid transporter in GABAergic and glycinergic synaptic terminal boutons. Dumoulin A, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):811-23

Selective correlation of amide groups to glycine alpha protons and of arginine guanidine groups to delta protons in proteins by multiple quantum spectroscopy. Bazzo R, et al. **J Magn Reson** 1999 Jan;136(1):15-21

An experimental design approach to the optimisation of a flow injection analysis method for glycine. Vannecke C, et al. **J Pharm Biomed Anal** 1999 Jan;18(6):963-73

Glycine-immunoreactive synapses in the central nucleus of the inferior colliculus. An electron microscopic study in the cat. Liu Y, et al. **Neurosci Lett** 1999 Jul 16;269(3):183-5

A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Waziri R, et al. **Schizophr Res** 1999 Jun 22;37(3):205-15

ANTAGONISTS & INHIBITORS

GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality. Danysz W, et al. **Amino Acids** 1998;14(1-3):235-9 (13 ref.)

Novel glycineB antagonists show neuroprotective activity in vivo. Wenk GL, et al. **Amino Acids** 1998;14(1-3):223-6

New synthesis of substituted 2-carboxyindole derivatives: versatile introduction of a carbamoylethynyl moiety at the C-3 position. Hewkin CT, et al. **Arch Pharm (Weinheim)** 1999 Feb;332(2):55-8

Substituted indole-2-carboxylates as potent antagonists of the glycine binding site associated with the NMDA receptor. Micheli F, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):271-8 (36 ref.)

Evidence for a possible glycinergic inhibitory neurotransmission in the midbrain and rostral pons of the rat studied by gephyrin. Mineff EM, et al. **Arch Physiol Biochem** 1998 Jul;106(3):210-20

Unusual synthesis of new glycine antagonists via sequential aldol condensation-lactonization-elimination reaction. Giacobbe SA, et al. **Bioorg Med Chem Lett** 1998 Jul 7; 8(13):1689-92

The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Dannhardt G, et al. **Curr Med Chem** 1998 Aug;5(4):253-63 (58 ref.)

Inhibitory effect of ondansetron on glycine response of dissociated rat hippocampal neurons. Ye JH, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):104-11

BLOOD

One-methyl group metabolism in non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid homocysteine levels. Van Hove JL, et al. **J Inherit Metab Dis** 1998 Dec;21(8):799-811

Xeroderma pigmentosum group C splice mutation associated with autism and hypoglycinemia [published erratum appears in J Invest Dermatol 1999 Mar;112(3):402] Khan SG, et al. **J Invest Dermatol** 1998 Nov;111(5):791-6

A case of multiple system atrophy with hyperglycinaemia due to a selective deficiency of glycine transporter mRNA. Lane RJ, et al. **Neuropathol Appl Neurobiol** 1998 Oct; 24(5):353-8

Neonatal type of nonketotic hyperglycinemia. Lu FL, et al. **Pediatr Neurol** 1999 Apr;20(4):295-300

Polyhydramnios as a first prenatal symptom of non-ketotic hyperglycinaemia [letter] Sterniste W, et al. **Prenat Diagn** 1998 Aug;18(8):863-4

[Non-ketotic hyperglycinemia: clinical and therapeutic course in three patients] Rite Gracia S, et al. **An Esp Pediatr** 1999 Apr;50(4):408-10 **(Spa)**

CHEMICAL SYNTHESIS

Structure and activity studies on glycine receptor ligands. Part 5. Diphenyl imidazolin-4-one glycinamides. Kieć-Kononowicz K, et al. **Acta Pol Pharm** 1998 Sep-Oct; 55(5):389-96

CHEMISTRY

Crystallization and preliminary X-ray analysis of a new L-aminopeptidase-D-amidase/D-esterase activated by a Gly-Ser peptide bond hydrolysis. Bompard-Gilles C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):699-701

Rubredoxin from Clostridium pasteurianum. Structures of G10A, G43A and G10VG43A mutant proteins. Mutation of conserved glycine 10 to valine causes the 9-10 peptide link to invert. Maher MJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):962-8

The glycine box: a determinant of specificity for fibroblast growth factor. Luo Y, et al. **Biochemistry** 1998 Nov 24; 37(47):16506-15

The hydrogen-bonding network of water molecules and the peptide backbone in the region connecting Asp83, Gly120, and Glu113 in bovine rhodopsin. Nagata T, et al. **Biochemistry** 1998 Dec 8;37(49):17216-22

The role of proline and glycine in determining the backbone flexibility of a channel-forming peptide. Jacob J, et al. **Biophys J** 1999 Mar;76(3):1367-76

Detection of concomitant formation of O6-carboxymethyl- and O6-methyl-2'-deoxyguanosine in DNA exposed to nitrosated glycine derivatives using a combined immunoaffinity/HPLC method. Harrison KL, et al. **Chem Res Toxicol** 1999 Jan;12(1):106-11

The structural requirements for the design of antiepileptic-glycine derivatives. Sussan S, et al. **Epilepsy Res** 1999 Apr;34(2-3):207-20

Neighboring glycine residues are essential for P2X2 receptor/channel function. Nakazawa K, et al. **Eur J Pharmacol** 1999 Apr 16;370(3):R5-6

Theoretical calculations of glycine and alanine gas-phase acidities. Topol IA, et al. **J Am Soc Mass Spectrom** 1999 Apr;10(4):318-22

Fragmentation of the large subunit of ribulose-1,5-bisphosphate carboxylase by reactive oxygen species occurs near Gly-329. Ishida H, et al. **J Biol Chem** 1999 Feb 19;274(8):5222-6

A computational study of intramolecular proton transfer in gaseous protonated glycine. Zhang K, et al. **J Chem Inf Comput Sci** 1999 Mar-Apr;39(2):382-95

Transport of a series of D-phenylalanine-glycine hexapeptides across rat alveolar epithelia in vitro. Evans JP, et al. **J Drug Target** 1998;6(4):251-9

Analysis of error propagation from NMR-derived internuclear distances into molecular structure of cyclo-pro-gly. Džakula Z, et al. **J Magn Reson** 1998 Dec; 135(2):454-65

Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety. Lebreton L, et al. **J Med Chem** 1999 Jan 28;42(2):277-90

Site-specific prebiotic oligomerization reactions of glycine on the surface of hectorite. Porter TL, et al. **J Mol Evol** 1998 Oct;47(4):373-7

Synthesis, conformational study, and spectroscopic characterization of the cyclic C alpha, alpha-disubstituted glycine 9-amino-9-fluorenecarboxylic acid. Savrda J, et al. **J Pept Sci** 1999 Feb;5(2):61-74

The Theileria annulata sporozoite and macroschizont polypeptide encoded by the spm1 gene shares phenylalanine-glycine motifs with nuclear pore proteins. Knight P, et al. **Mol Biochem Parasitol** 1999 May 15; 100(1):135-40

Solid phase synthesis of azapeptides using an automatic synthesizer. Ahn IA, et al. **Mol Divers** 1998-99;4(1):23-4

Conservation of structure and cold-regulation of RNA-binding proteins in cyanobacteria: probable convergent evolution with eukaryotic glycine-rich RNA-binding proteins. Maruyama K, et al. **Nucleic Acids Res** 1999 May 1;27(9):2029-36

Autocatalytic synthesis of oligoglycine in a simulated submarine hydrothermal system. Imai E, et al. **Orig Life Evol Biosph** 1999 May;29(3):249-59

A study of conserved in-loop and out-of-loop glycine residues in the large subunit of ribulose bisphosphate carboxylase/oxygenase by directed mutagenesis. Cheng ZQ, et al. **Protein Eng** 1998 Jun;11(6):457-65

Effects of the length of a glycine linker connecting the N-and C-termini of a circularly permuted dihydrofolate reductase.

Iwakura M, et al. **Protein Eng** 1998 Aug;11(8):707–13
Elongation of oligopeptides in a simulated submarine hydrothermal system. Imai E, et al. **Science** 1999 Feb 5; 283(5403):831–3
A glycyl radical site in the crystal structure of a class III ribonucleotide reductase. Logan DT, et al. **Science** 1999 Mar 5;283(5407):1499–504
Multiple-quantum relaxation in the magic-angle-spinning NMR of 13C spin pairs. Karlsson T, et al. **Solid State Nucl Magn Reson** 1999 Jun;14(1):43–58

DRUG EFFECTS

Amino acid volume and hydropathy of a transmembrane site determine glycine and anesthetic sensitivity of glycine receptors. Yamakura T, et al. **J Biol Chem** 1999 Aug 13; 274(33):23006–12

GENETICS

Heterozygous glycine substitution in the COL11A2 gene in the original patient with the Weissenbacher-Zweymüller syndrome demonstrates its identity with heterozygous OSMED (nonocular Stickler syndrome). Pihlajamaa T, et al. **Am J Med Genet** 1998 Nov 2;80(2):115–20
Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. Wang G, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):683–5
The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Mori Y, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):138–40
Backbone dynamics of the N-terminal domain of the HIV-1 capsid protein and comparison with the G94D mutant conferring cyclosporin resistance/dependence. Campos-Olivas R, et al. **Biochemistry** 1999 Aug 10; 38(32):10262–71
The midpoint potentials for the oxidized-semiquinone couple for Gly57 mutants of the Clostridium beijerinckii flavodoxin correlate with changes in the hydrogen-bonding interaction with the proton on N(5) of the reduced flavin mononucleotide cofactor as measured by NMR chemical shift temperature dependencies. Chang FC, et al. **Biochemistry** 1999 Jun 1;38(22):7168–76
A recurrent glycine substitution mutation, G2043R, in the type VII collagen gene (COL7A1) in dominant dystrophic epidermolysis bullosa. Mellerio JE, et al. **Br J Dermatol** 1998 Oct;139(4):730–7
Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G, S1255L) and one novel polymorphism (L49L) [letter] Cartault F, et al. **Clin Genet** 1998 Nov;54(5):437–9
The Gly972—>Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. Porzio O, et al. **J Clin Invest** 1999 Aug;104(3):357–64
Context-dependent immunogenicity of an S206G-substituted H-2Db-restricted simian virus 40 large T antigen epitope I variant. Mylin LM. **J Immunol** 1999 Feb 15;162(4):2171–9
Prenatal molecular diagnosis of severe ornithine carbamoyltransferase deficiency due to a novel mutation, E181G. Topaloglu AK, et al. **J Inherit Metab Dis** 1999 Feb;22(1):82–3
Dominant dystrophic epidermolysis bullosa (Pasini) caused by a novel glycine substitution mutation in the type VII collagen gene (COL7A1). Jonkman MF, et al. **J Invest Dermatol** 1999 May;112(5):815–7
Novel and de novo glycine substitution mutations in the type VII collagen gene (COL7A1) in dystrophic epidermolysis bullosa: implications for genetic counseling. Rouan F, et al. **J Invest Dermatol** 1998 Dec;111(6):1210–3
Compound heterozygosity for a recessive glycine substitution and a splice site mutation in the COL7A1 gene causes an unusually mild form of localized recessive dystrophic epidermolysis bullosa. Terracina M, et al. **J Invest Dermatol** 1998 Nov;111(5):744–50
von Willebrand disease with G4022A mutation (vWd Sungnam): a case report. Song KS, et al. **J Korean Med Sci** 1999 Feb;14(1):93–6
An alpha2(I) glycine to aspartate substitution is responsible for the presence of a kink in type I collagen in a lethal case of osteogenesis imperfecta. Forlino A, et al. **Matrix Biol** 1998 Dec;17(8–9):575–84
Random mutagenesis into the conserved Gly154 of subtilisin E: isolation and characterization of the revertant enzymes. Takagi H, et al. **Protein Eng** 1998 Dec;11(12):1205–10

IMMUNOLOGY

Monoclonal antibody monospecific to glycine for brain immunocytochemistry. Fujiwara K, et al. **Brain Res** 1998 Sep 28;806(2):210–8
Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. Blake NW, et al. **J Virol** 1999 Sep;73(9):7381–9

METABOLISM

GlycineB recognition site of NMDA receptors and its antagonists. Danysz W, et al. **Amino Acids** 1998; 14(1–3):205–6
Effects of NMDA receptor antagonists on nociceptive responses in vivo: comparison of antagonists acting at the glycine site with uncompetitive antagonists. McClean M, et al. **Amino Acids** 1998;14(1–3):217–21
Expression and characterization of a glycine-binding fragment of the N-methyl-D-aspartate receptor subunit NR1. Miyazaki J, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):687–92
N-acylglycine amidation: implications for the biosynthesis of fatty acid primary amides. Wilcox BJ, et al. **Biochemistry** 1999 Mar 16;38(11):3235–45
5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists. Acklin P, et al. **Bioorg Med Chem Lett** 1998 Mar 3;8(5):493–8
5-Aminomethylquinoxaline-2,3-diones. Part II: N-aryl derivatives as novel NMDA/glycine and AMPA antagonists. Auberson YP, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):71–4
Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands. Cordi A, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1409–14
The role of sodium in the in vivo absorption of glycine by the intestine of the amphibian discoglossus pictus. Saidane D, et al. **Boll Soc Ital Biol Sper** 1997 Jul-Aug; 73(7–8):115–22
Infants in Trinidad excrete more 5-L-oxoproline (L-pyroglutamic acid) in urine than infants in England: an environmental not ethnic difference. Lenton C, et al. **Br J Nutr** 1998 Jul;80(1):51–5
Electron microscopic analysis of gamma-aminobutyric acid and glycine colocalization in rat trigeminal subnucleus caudalis. Dumba JS, et al. **Brain Res** 1998 Sep 21; 806(1):16–25
Monoclonal antibody monospecific to glycine for brain immunocytochemistry. Fujiwara K, et al. **Brain Res** 1998 Sep 28;806(2):210–8
The adenylate cyclase inhibitor MDL-12330A has a non-specific effect on glycine transport in Müller cells from the retina. Gadea A, et al. **Brain Res** 1999 Aug 14; 838(1–2):200–4
Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats. Lorenc-Koci E, et al. **Brain Res** 1998 May 18;793(1–2):315–20
Expression of glycylated tubulin during the differentiation of spermatozoa in mammals. Kann ML, et al. **Cell Motil Cytoskeleton** 1998;41(4):341–52
Defective cytoplasmic granule formation.II. Differences in patterns of radiolabeling of secretory granules in beige versus normal mouse pancreatic acinar cells after [3H]glycine administration in vivo. Hammel I, et al. **Cell Tissue Res** 1998 Sep;293(3):445–52
Characterization of a renal medium chain acyl-CoA synthetase responsible for glycine conjugation in mouse kidney mitochondria. Kasuya F, et al. **Chem Biol Interact** 1999 Apr 15;118(3):233–46
Effects of fibrates on the glycine conjugation of benzoic acid in rats. Gregus Z, et al. **Drug Metab Dispos** 1998 Nov; 26(11):1082–8
Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. James MO, et al. **Drug Metab Dispos** 1998 Nov;26(11):1134–43
Transmembrane remote conformational suppression of the Gly-332 mutation of the Tn10-encoded metal-tetracycline/H+ antiporter. Kawabe T, et al. **FEBS Lett** 1999 Aug 20;457(1):169–73
Change to alanine of one out of four selectivity filter glycines in KtrB causes a two orders of magnitude decrease in the affinities for both K+ and Na+ of the Na+ dependent K+ uptake system KtrAB from Vibrio alginolyticus. Tholema N, et al. **FEBS Lett** 1999 May 7;450(3):217–20
Characterization of glycine transport in cultured Müller glial cells from the retina. Gadea A, et al. **Glia** 1999 Jun; 26(4):273–9
Rapid uptake and degradation of glycine by astroglial cells in culture: synthesis and release of serine and lactate. Verleysdonk S, et al. **Glia** 1999 Sep;27(3):239–48
Strychnine-insensitive [3H] glycine binding to synaptosomal membranes from the chick retina. Rodriguez-Contreras A, et al. **Int J Dev Neurosci** 1998 Aug;16(5):413–21
Biosynthesis of the pyrimidine moiety of thiamine independent of the PurF enzyme (Phosphoribosylpyrophosphate amidotransferase) in Salmonella typhimurium: incorporation of stable isotope-labeled glycine and formate. Enos-Berlage JL, et al. **J Bacteriol** 1999 Feb;181(3):841–8
Functional similarities between the Listeria monocytogenes virulence regulator PrfA and cyclic AMP receptor protein: the PrfA* (Gly145Ser) mutation increases binding affinity for target DNA. Vega Y, et al. **J Bacteriol** 1998 Dec; 180(24):6655–60
Two amino acids within the alpha4 helix of Galphai1 mediate coupling with 5-hydroxytryptamine1B receptors. Bae H, et al. **J Biol Chem** 1999 May 21;274(21):14963–71
Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure. Borowsky B, et al. **J Biol Chem** 1998 Oct 30; 273(44):29077–85
A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. Siciliano SJ, et al. **J Biol Chem** 1999 Jan 22;274(4):1905–13
Multiple functional proteins are produced by cleaving Asn-Gln bonds of a single precursor by vacuolar processing enzyme. Yamada K, et al. **J Biol Chem** 1999 Jan 22;274(4):2563–70
Developmental expression of the glycine transporter GLYT2 in the auditory system of rats suggests involvement in synapse maturation. Friauf E, et al. **J Comp Neurol** 1999 Sep 13;412(1):17–37
Development of GABA, glycine, and their receptors in the auditory brainstem of gerbil: a light and electron microscopic study. Korada S, et al. **J Comp Neurol** 1999 Jul 12;409(4):664–81
Evidence for glycinergic respiratory neurons: Bötzinger neurons express mRNA for glycinergic transporter 2. Schreihofer AM, et al. **J Comp Neurol** 1999 May 17; 407(4):583–97
Differential iron transport into phagosomes isolated from the RAW264.7 macrophage cell lines transfected with Nramp1Gly169 or Nramp1Asp169. Kuhn DE, et al. **J Leukoc Biol** 1999 Jul;66(1):113–9
Glycyl-tRNA synthetase uses a negatively charged pit for specific recognition and activation of glycine. Arnez JG, et al. **J Mol Biol** 1999 Mar 12;286(5):1449–59
Delineation of the structural determinants of the N-methyl-D-aspartate receptor glycine binding site. Sandhu S, et al. **J Neurochem** 1999 Apr;72(4):1694–8
Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. Berger AJ, et al. **J Neurophysiol** 1998 Dec;80(6):3336–40
Sodium action potentials are not required for light-evoked release of GABA or glycine from retinal amacrine cells. Bieda MC, et al. **J Neurophysiol** 1999 Jun;81(6):3092–5
Divalent cations modulate N-methyl-D-aspartate receptor function at the glycine site. Hashemzadeh-Gargari H, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1356–62
Modulation of the glycine response by Ca2+-permeable AMPA receptors in rat spinal neurones. Xu TL, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):701–11
Purification, hydrodynamic properties, and glycosylation analysis of glycine transporters. Aragón C, et al. **Methods Enzymol** 1998;296:3–17
Role for the leucine-responsive regulatory protein (Lrp) as a structural protein in regulating the Escherichia coli gcvTHP operon. Stauffer LT, et al. **Microbiology** 1999 Mar;145 (Pt 3):569–76
CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Kasper LH, et al. **Mol Cell Biol** 1999 Jan;19(1):764–76
Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site. Nichols AC, et al. **Mol Chem Neuropathol** 1998 Aug-Dec;35(1–3):1–12
Participation of the pyrazine cation radical in the formation of mutagens in the reaction of glucose/glycine/creatinine. Kikugawa K, et al. **Mutat Res** 1999 Jul 21;444(1):133–44
Complex polyamine effects on [3H]MDL 105,519 binding to the NMDA receptor glycine site. Sharma TA, et al. **Neurochem Int** 1998 Aug;33(2):155–9
Spermine inhibits [3H]glycine binding at the NMDA receptors from plexiform layers of chick retina. Calderón F, et al. **Neurochem Res** 1998 Nov;23(11):1363–9
[3H]CGP 61594, the first photoaffinity ligand for the glycine site of NMDA receptors. Benke D, et al. **Neuropharmacology** 1999 Feb;38(2):233–42
Concurrent activation of hippocampal glycine and polyamine sites of the N-methyl-D-aspartate receptor synergistically reverses working memory deficits in rats. Kishi A, et al. **Neurosci Lett** 1998 Dec 4;257(3):131–4
Alpha2-adrenoceptor-mediated enhancement of glycine response in rat sacral dorsal commissural neurons. Nabekura J, et al. **Neuroscience** 1999 Mar;89(1):29–41
An extra tRNAGly(U*CU) found in ascidian mitochondria responsible for decoding non-universal codons AGA/AGG as glycine. Kondow A, et al. **Nucleic Acids Res** 1999 Jun 15;27(12):2554–9
Identification of glycine-extended CCK peptides in endocrine cells and modulation of CCK amide and CCK Gly content and secretion from endocrine tumor cells by an inhibitor of amidation. Beinfeld MC, et al. **Peptides** 1998; 19(8):1393–8
Strychnine-insensitive glycine/NMDA sites are altered in two stress models of depression. Nowak G, et al. **Pol J Pharmacol** 1998 Jul-Oct;50(4–5):365–9
Distribution of the glycine transporter glyt-1 in mammalian and nonmammalian retinae. Pow DV, et al. **Vis Neurosci** 1999 Mar-Apr;16(2):231–9
Effect of chlorophenoxyacetic acid herbicides on glycine conjugation of benzoic acid. Gregus Z, et al. **Xenobiotica** 1999 Jun;29(6):547–59
[Non-ketotic hyperglycinemia: clinical and therapeutic course in three patients] Rite Gracia S, et al. **An Esp Pediatr** 1999 Apr;50(4):408–10 **(Spa)**

PHARMACOKINETICS

Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Wang Y, et al. **Biopharm Drug Dispos** 1999 Mar; 20(2):69–75

GLYCINE

PHARMACOLOGY

Glycine derivatives of imidazolones as potential ligands of glycine binding site of NMDA receptors. Part 1. Kieć-Kononowicz K, et al. **Acta Pol Pharm** 1998 Sep-Oct; 55(5):381-8

Intravenous glycine improves survival in rat liver transplantation. Schemmer P, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G924-32

Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Zhong Z, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F595-604

Modulation of NMDA receptors by glycine--introduction to some basic aspects and recent developments. Parsons CG, et al. **Amino Acids** 1998;14(1-3):207-16 (87 ref.)

Influence of glycinergic inhibition on spinal neuron excitability during amphibian tadpole locomotion. Perrins R, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:472-4

Effects of glycine or (+/-)-3-amino-1-hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats' performance in the elevated plus-maze task. Teixeira KV, et al. **Behav Neurosci** 1999 Feb; 113(1):196-203

Mode of action of ICS 205,930, a novel type of potentiator of responses to glycine in rat spinal neurones. Chesnoy-Marchais D. **Br J Pharmacol** 1999 Feb; 126(3):801-9

Glycine induces a novel form of long-term potentiation in the superficial layers of the superior colliculus. Platt B, et al. **Br J Pharmacol** 1998 Sep;125(2):293-300

Modulation of glycine-induced currents by zinc and other metal cations in neurons acutely dissociated from the dorsal motor nucleus of the vagus of the rat. Doi A, et al. **Brain Res** 1999 Jan 23;816(2):424-30

Glycine-activated chloride currents of neurons freshly isolated from the ventral tegmental area of rats. Ye JH, et al. **Brain Res** 1998 Jun 15;796(1-2):53-62

Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Rose ML, et al. **Carcinogenesis** 1999 May; 20(5):793-8

In vitro modulation of L-arginine transport in trophoblast cells by glucose. Eaton BM, et al. **Eur J Clin Invest** 1998 Dec;28(12):1006-10

Evidence for functional native NMDA receptors activated by glycine or D-serine alone in the absence of glutamatergic coagonist. Paudice P, et al. **Eur J Neurosci** 1998 Sep;10(9):2934-44

Ethanol sensitivity of NMDA receptor function in developing cerebellar granule neurons. Bhave SV, et al. **Eur J Pharmacol** 1999 Mar 19;369(2):247-59

Cocaine decreases the glycine-induced Cl- current of acutely dissociated rat hippocampal neurons. Ren J, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):125-30

Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression. Spittler A, et al. **FASEB J** 1999 Mar;13(3):563-71

Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells. Stachlewitz RF, et al. **Hepatology** 1999 Mar;29(3):737-45

The effect of arginine or glycine supplementation on gastrointestinal function, muscle injury, serum amino acid concentrations and performance during a marathon run. Buchman AL, et al. **Int J Sports Med** 1999 Jul;20(5):315-21

Converting enzyme inhibition and the glomerular hemodynamic response to glycine in diabetic rats. Slomowitz LA, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1447-54

Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine. Langer S, et al. **J Invest Dermatol** 1999 May;112(5):723-8

Contribution of single-channel properties to the time course and amplitude variance of quantal glycine currents recorded in rat motoneurons. Singer JH, et al. **J Neurophysiol** 1999 Apr;81(4):1608-16

Junctional versus extrajunctional glycine and GABA(A) receptor-mediated IPSCs in identified lamina I neurons of the adult rat spinal cord. Chéry N, et al. **J Neurosci** 1999 Sep 1;19(17):7342-55

Synaptic control of glycine and GABA(A) receptors and gephyrin expression in cultured motoneurons. Lévi S, et al. **J Neurosci** 1999 Sep 1;19(17):7434-49

Comparison of glycine and GABA actions on the zebrafish homomeric glycine receptor. Fucile S, et al. **J Physiol (Lond)** 1999 Jun 1;517 (Pt 2):369-83

Modulation of motoneuron N-methyl-D-aspartate receptors by the inhibitory neurotransmitter glycine. Berger AJ, et al. **J Physiol Paris** 1999 Jan-Apr;93(1-2):23-7

Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Zhong Z, et al. **Mol Pharmacol** 1999 Sep;56(3):455-63

The interaction of general anaesthetics and neurosteroids with GABA(A) and glycine receptors. Belelli D, et al. **Neurochem Int** 1999 May;34(5):447-52

Na+, K+ and Ca2+ antagonize the glutamate- and glycine-induced decrease of [3H]MK-801 binding observed in the presence of Mg2+ at low pH. Liu Y, et al. **Neurochem Int** 1999 Apr;34(4):291-301

Noxious thermal stimulation of c-fos activity induced in rat lumbar spinal cord is reduced by AP-5 but not by glycine. Huang W, et al. **Neurosci Lett** 1999 Jan 4;259(1):1-4

Ferrous iron modulates quinolinate-mediated [3H]MK-801 binding to rat brain synaptic membranes in the presence of glycine and spermidine. St'astny F, et al. **Neurosci Lett** 1999 Mar 5;262(2):105-8

Kinetics of sevoflurane action on GABA- and glycine-induced currents in acutely dissociated rat hippocampal neurons. Kira T, et al. **Neuroscience** 1998 Jul; 85(2):383-94

Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat. Khandwala H, et al. **Pain** 1998 Jul;77(1):87-95

Low expression of the ClC-2 chloride channel during postnatal development: a mechanism for the paradoxical depolarizing action of GABA and glycine in the hippocampus. Mladinić M, et al. **Proc R Soc Lond B Biol Sci** 1999 Jun 22;266(1425):1207-13

Protection against chronic cadmium toxicity by glycine. Shaikh ZA, et al. **Toxicology** 1999 Feb 15;132(2-3):139-46

A comparison of the inhibitory actions of glycine and GABA on acetylcholine release from the rabbit retina. Linn DM. **Vis Neurosci** 1998 Nov-Dec;15(6):1057-65

[Effects of microinjection of sodium glutamate and glycine into ventrolateral nucleus of tractus solitarius on the discharges of phrenic nerve in rabbits] Liu SX, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):227-9 (Eng. Abstr.) **(Chi)**

[Effects of dipeptides Gly-Pro, Pro-Gly, glycine, and proline on the cardiotropic effect of acetylcholine] Babskaia NE, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):139-41 **(Rus)**

PHYSIOLOGY

Induction of resting microglia in culture medium devoid of glycine and serine. Tanaka J, et al. **Glia** 1998 Oct; 24(2):198-215

Gamma-aminobutyric acidergic and glycinergic inputs shape coding of amplitude modulation in the chinchilla cochlear nucleus. Backoff PM, et al. **Hear Res** 1999 Aug; 134(1-2):77-88

Control of expression of one-carbon metabolism genes of Saccharomyces cerevisiae is mediated by a tetrahydrofolate-responsive protein binding to a glycine regulatory region including a core 5'-CTTCTT-3' motif. Hong SP, et al. **J Biol Chem** 1999 Apr 9;274(15):10523-32

Localization of components of glycinergic synapses during rat spinal cord development. Colin I, et al. **J Comp Neurol** 1998 Aug 31;398(3):359-72

Glycine immunoreactivity of multipolar neurons in the ventral cochlear nucleus which project to the dorsal cochlear nucleus. Doucet JR, et al. **J Comp Neurol** 1999 Jun 14;408(4):515-31

Glycinergic amacrine cells of the rat retina. Menger N, et al. **J Comp Neurol** 1998 Nov 9;401(1):34-46

Inhibition of primate spinothalamic tract neurons by spinal glycine and GABA is modulated by guanosine 3',5'-cyclic monophosphate. Lin Q, et al. **J Neurophysiol** 1999 Mar; 81(3):1095-103

Glycinergic miniature synaptic currents and receptor cluster sizes differ between spinal cord interneurons. Oleskevich S, et al. **J Neurophysiol** 1999 Jul;82(1):312-9

The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons. Chaudhry FA, et al. **J Neurosci** 1998 Dec 1;18(23):9733-50

Glycine. Hall JC. **JPEN J Parenter Enteral Nutr** 1998 Nov-Dec;22(6):393-8 (84 ref.)

Development of glycinergic transmission in organotypic cultures from auditory brain stem. Ehrlich I, et al. **Neuroreport** 1998 Aug 24;9(12):2785-90

Strychnine-sensitive glycine responses in neurons of the lateral amygdala: an electrophysiological and immunocytochemical characterization. Danober L, et al. **Neuroscience** 1998 Jul;85(2):427-41

Modulation of N-methyl-D-aspartate receptor function by glycine transport. Bergeron R, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15730-4

POISONING

An 87-year-old man with hypotension and confusion after cystoscopy. Yende S, et al. **Chest** 1999 May;115(5):1449-51

SECRETION

Astrocytes modulate nitric oxide production by microglial cells through secretion of serine and glycine. Yang L, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):277-82

THERAPEUTIC USE

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Potkin SG, et al. **Am J Psychiatry** 1999 Jan;156(1):145-7

Glycine agonists: what can they teach us about schizophrenia? [comment] Farber NB, et al. **Arch Gen Psychiatry** 1999 Jan;56(1):13-7 (50 ref.). Comment on: Arch Gen Psychiatry 1999 Jan;56(1):21-7. Comment on: Arch Gen Psychiatry 1999 Jan;56(1):29-36.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia [see comments] Heresco-Levy U, et al. **Arch Gen Psychiatry** 1999 Jan; 56(1):29-36. Comment in: Arch Gen Psychiatry 1999 Jan;56(1):13-7.

D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia [editorial; comment] Krystal JH, et al. **Biol Psychiatry** 1998 Dec 1;44(11):1075-6. Comment on: Biol Psychiatry 1998 Dec 1;44(11):1081-9.

[Glycine therapy of schizophrenia; its rationale and a review of clinical trials] Semba J. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Jun; 18(3):71-80 (63 ref.) (Eng. Abstr.) **(Jpn)**

[A combined treatment method for alcoholic patients using medikhronal, microwave resonance therapy and holotropic breathing] Zaritskii MG. **Lik Sprava** 1998 Oct-Nov; (7):126-32 (Eng. Abstr.) **(Rus)**

[Neuroprotective effects of glycine in the acute period of ischemic stroke] Gusev EI, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(2):12-20 (Eng. Abstr.) **(Rus)**

[The effect of medikhronal on the biogenic amine level in the brain structures and blood of animals with alcohol dependence] Kharchenko NK. **Fiziol Zh** 1999;45(4):111-9 (Eng. Abstr.) **(Ukr)**

TOXICITY

Glycine toxicity after high-dose i.v. infusion of 1.5% glycine in the mouse. Olsson J, et al. **Br J Anaesth** 1999 Feb; 82(2):250-4

URINE

p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Mienie LJ, et al. **Life Sci** 1999;65(5):535-42

GLYCINE AGENTS

ADMINISTRATION & DOSAGE

Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Dyker AG, et al. **Stroke** 1999 May; 30(5):986-92

CHEMICAL SYNTHESIS

3-(2-Carbamoylvinyl)-4,5-dimethylpyrrole-2-carboxylic acids as ligands at the NMDA glycine-binding site: a study on the 2-carbamoylvinyl chain modification. Balsamini C, et al. **Farmaco** 1999 Jan-Feb;54(1-2):101-11

Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. Di Fabio R, et al. **J Med Chem** 1999 Sep 9;42(18):3486-93

METABOLISM

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Javitt DC, et al. **Biol Psychiatry** 1999 Mar 15;45(6):668-79

PHARMACOKINETICS

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Javitt DC, et al. **Biol Psychiatry** 1999 Mar 15;45(6):668-79

First time in human for GV196771: interspecies scaling applied on dose selection. Iavarone L, et al. **J Clin Pharmacol** 1999 Jun;39(6):560-6

PHARMACOLOGY

A possible mechanism underlying corymine inhibition of glycine-induced Cl- current in Xenopus oocytes. Leewanich P, et al. **Eur J Pharmacol** 1998 May 8; 348(2-3):271-7

GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. Karcz-Kubicha M, et al. **Neuropharmacology** 1999 Jan; 38(1):109-19

Resistive loading reduces ventilatory response to strychnine in anesthetized rabbits. Delpierre S, et al. **Neurosci Lett** 1998 Oct 9;255(1):29-32

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Danysz W, et al. **Pharmacol Rev** 1998 Dec;50(4):597-664 (806 ref.)

Strychnine- and bicuculline-induced changes in the firing pattern of motoneurones during in vitro fictive locomotion reveal a possible N-methyl-D-aspartic acid (NMDA)-mediated suppression of motor discharge in wallaby (Macropus eugenii) pouch young. Ho SM. **Somatosens Mot Res** 1998;15(4):325-32

THERAPEUTIC USE

New pharmaceutical approaches to stroke prevention, treatment [news] Phillips P. **JAMA** 1999 Jun 9; 281(22):2075-6

GLYCINE CHENODEOXYCHOLATE see **GLYCOCHENODEOXYCHOLIC ACID**

GLYCINE CHOLATE see **GLYCOCHOLIC ACID**

GLYCINE DEOXYCHOLATE see **GLYCODEOXYCHOLIC ACID**

GLYCINE HYDROXYMETHYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Cobalamin-dependent methionine synthase and serine hydroxymethyltransferase: targets for chemotherapeutic intervention? Matthews RG, et al. **Adv Enzyme Regul** 1998; 38:377-92

CHEMISTRY

Purification, crystallization and preliminary X-ray analysis of human recombinant cytosolic serine hydroxymethyltransferase. Renwick SB, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1030-1

Thermodynamic analysis of the binding of the polyglutamate chain of 5-formyltetrahydropteroylpolyglutamates to serine hydroxymethyltransferase. Huang T, et al. **Biochemistry** 1998 Sep 29;37(39):13536-42

Crystal structure of rabbit cytosolic serine hydroxymethyltransferase at 2.8 A resolution: mechanistic implications. Scarsdale JN, et al. **Biochemistry** 1999 Jun 29;38(26):8347-58

Crystal forms and subunit stoichiometry of serine hydroxymethyltransferase. Kazanina G, et al. **J Struct Biol** 1998 Oct;123(2):169-74

The structure of serine hydroxymethyltransferase as modeled by homology and validated by site-directed mutagenesis. Pascarella S, et al. **Protein Sci** 1998 Sep;7(9):1976-82

The crystal structure of human cytosolic serine hydroxymethyltransferase: a target for cancer chemotherapy. Renwick SB, et al. **Structure** 1998 Sep 15; 6(9):1105-16

GENETICS

Threonine aldolase overexpression plus threonine supplementation enhanced riboflavin production in Ashbya gossypii. Monschau N, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4283-90

Identification and characterization of a serine hydroxymethyltransferase isoform in Caenorhabditis briggsae. Vatcher GP, et al. **Gene** 1999 Apr 16; 230(2):137-44

ISOLATION & PURIFICATION

Purification and partial characterization of three isoforms of serine hydroxymethyltransferase from Crithidia fasciculata. Capelluto DG, et al. **Mol Biochem Parasitol** 1999 Jan 25; 98(2):187-201

METABOLISM

A new route to L-threo-3-[4-(methylthio)phenylserine], a key intermediate for the synthesis of antibiotics: recombinant low-specificity D-threonine aldolase-catalyzed stereospecific resolution. Liu JQ, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):586-91

Investigation of serine hydroxymethyltransferase in methanogens. Lin Z, et al. **Can J Microbiol** 1998 Jul; 44(7):652-6

GLYCINE MAX see **SOYBEANS**

GLYCINE RECEPTORS see **RECEPTORS, GLYCINE**

GLYCINE-SPECIFIC TRNA see **RNA, TRANSFER, GLY**

GLYCINE-TRNA LIGASE

GENETICS

A mutation in GRS1, a glycyl-tRNA synthetase, affects 3'-end formation in Saccharomyces cerevisiae. Magrath C, et al. **Genetics** 1999 May;152(1):129-41

METABOLISM

Glycyl-tRNA synthetase uses a negatively charged pit for specific recognition and activation of glycine. Arnez JG, et al. **J Mol Biol** 1999 Mar 12;286(5):1449-59

GLYCOCALYX

The glycocalyx of the sperm surface. Schröter S, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):302-13 (115 ref.)

CHEMISTRY

Synthesis of the spacer-containing beta-D-GalpNAc-(1-->4)-beta-D-GlcpNAc-(1-->3)-alpha-D-Galp moiety, representing the non-fucosylated backbone trisaccharide of the glycocalyx glycan of the parasite Schistosoma mansoni. Halkes KM, et al. **Carbohydr Res** 1998 Jun;308(3-4):329-38

Macro and microheterogeneity in normal endothelial cells: differential composition of luminal glycocalyx and functional implications. Brouland JP, et al. **Endothelium** 1999;6(3):251-62

IMMUNOLOGY

Cell surface sialic acid and the regulation of immune cell interactions: the neuraminidase effect reconsidered. Bagriaçik E, et al. **Glycobiology** 1999 Mar;9(3):267-75

Characterization of an immunogenic glycocalyx on the surfaces of Cryptosporidium parvum oocysts and sporozoites. Nanduri J, et al. **Infect Immun** 1999 Apr; 67(4):2022-4

METABOLISM

Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Henry CB, et al. **Am J Physiol** 1999 Aug; 277(2 Pt 2):H508-14

Immunolabeling analysis of biosynthetic and degradative pathways of cell surface components (glycocalyx) in Paramecium cells. Flötenmeyer M, et al. **Eur J Cell Biol** 1999 Jan;78(1):67-77

Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat. Frängsmyr L, et al. **Tumour Biol** 1999 Sep-Oct; 20(5):277-92

PHYSIOLOGY

Albumin microbubble persistence during myocardial contrast echocardiography is associated with microvascular endothelial glycocalyx damage. Lindner JR, et al. **Circulation** 1998 Nov 17;98(20):2187-94

ULTRASTRUCTURE

Detection of glycoconjugates by lectin gold labelling, silver enhancement, and scanning electron microscopy. Gebert A, et al. **J Electron Microsc (Tokyo)** 1999;48(1):85-7

Brush cells of the mouse intestine possess a specialized glycocalyx as revealed by quantitative lectin histochemistry. Further evidence for a sensory function. Gebhard A, et al. **J Histochem Cytochem** 1999 Jun; 47(6):799-808

GLYCOCHENODEOXYCHOLATE see **GLYCOCHENODEOXYCHOLIC ACID**

GLYCOCHENODEOXYCHOLIC ACID

PHARMACOLOGY

Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Jones B, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G723-30

GLYCOCHOLATE see **GLYCOCHOLIC ACID**

GLYCOCHOLIC ACID

ANALOGS & DERIVATIVES

DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. Marin JJ, et al. **Int J Cancer** 1998 Oct 29; 78(3):346-52

Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). Macias RI, et al. **J Controlled Release** 1999 Feb 1;57(2):161-9

Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. Macias RI, et al. **J Lipid Res** 1998 Sep;39(9):1792-8

BLOOD

Cörrelation of serum cholylglycine level with hepatic dysfunction in children with sickle cell anemia. Sayad AE, et al. **Clin Pediatr (Phila)** 1999 May;38(5):293-6

[The changes of lipid metabolism and hemorrheology in intrahepatic cholestasis during pregnancy] Dai H, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1997 Dec;32(12):728-31 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

[Hepatobiliary clearance of glycocholic acid in Gilbert's disease] Serna Miquel I, et al. **An Med Interna** 1998 Nov; 15(11):580-3 (Eng. Abstr.) **(Spa)**

GLYCOCONJUGATES

Carbohydrates and glycoconjugates biophysical methods. Lakey JH, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):543-4

ANALYSIS

Applications of lectins and neoglycoconjugates in histology and pathology. Danguy A, et al. **Acta Anat (Basel)** 1998; 161(1-4):206-18 (106 ref.)

Glycobiology of the olfactory system. Plendl J, et al. **Acta Anat (Basel)** 1998;161(1-4):234-53 (188 ref.)

Glycoconjugate expression and cartilage development of the cranial skeleton. Zschäbitz A. **Acta Anat (Basel)** 1998; 161(1-4):254-74 (162 ref.)

Fluorescent-assisted detection of oligosialyl units in glycoconjugates. Sato C, et al. **Anal Biochem** 1999 Jan 1; 266(1):102-9

Structural analysis of glycoconjugates by on-target enzymatic digestion and MALDI-TOF-MS. Geyer H, et al. **Anal Chem** 1999 Jan 15;71(2):476-82

Detection of glycosidic residues in carpal glands of wild and domestic pig revealed by basic and lectin histochemistry. Pedini V, et al. **Anat Anz** 1999 May;181(3):269-74

Maturation-related changes in distribution of lectin receptors in baboon (Papio anubis) spermatozoa during epididymal maturation. Mburu DN. **Arch Androl** 1999 May-Jun; 42(3):199-203

Specific staining of nonpyramidal cell populations of the cerebral cortex by lectin cytochemistry on semithin sections. Beneyto M, et al. **Brain Res Bull** 1999 Jul 1; 49(4):251-62

Utilization of ELISA technology to measure biological activities of carbohydrates relevant in disease status. Gervay J, et al. **Curr Med Chem** 1999 Feb;6(2):129-53 (89 ref.)

Differential distribution of lectin-binding glycoconjugates in the secretory granules of hamster oviductal ampulla during the estrous cycle: a quantitative cytochemical analysis. El-Mestrah M, et al. **Histochem Cell Biol** 1999 Jan; 111(1):23-32

Glycoconjugates of the rat ciliary body epithelium: a lectin histochemical and protein blotting study. Chan FL, et al. **Histochem J** 1999 Feb;31(2):95-107

Identification and localisation of glycoconjugates in the olfactory mucosa of the armadillo Chaetophractus villosus. Ferrari CC, et al. **J Anat** 1999 Apr;194 (Pt 3):395-405

Lectin binding patterns in nonsensory regions of rat cochlea during postnatal development. Khan KM, et al. **J Anat** 1999 May;194 (Pt 4):497-504

Characteristics of lectin staining patterns assessed by a modified sensitive thermo-method in rat livers with heterologous serum-induced fibrosis. Miyamoto M, et al. **J Vet Med Sci** 1998 Aug;60(8):953-60

Cell-surface sialoglycoconjugate structures in wild-type and mutant Crithidia fasciculata. do Valle Matta MA, et al. **Parasitol Res** 1999 Apr;85(4):293-9

Expression patterns of type II pneumocyte apical surface glycoconjugates in lung adenocarcinoma cells. Hachiya T, et al. **Virchows Arch** 1999 Jan;434(1):63-9

BIOSYNTHESIS

Expression patterns of complex glycoconjugates and endogenous lectins during fetal development of the viscerocranium. Zschäbitz A, et al. **Anat Anz** 1999 Jan; 181(1):117-21

Glycoconjugate expression in follicle-associated epithelium (FAE) covering the nasal-associated lymphoid tissue (NALT) in specific pathogen-free and conventional rats. Jeong KI, et al. **Exp Anim** 1999 Jan;48(1):23-9

Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. Khoo KH, et al. **J Biol Chem** 1999 Apr 2; 274(14):9778-85

Altered expression of epithelial cell surface glycoconjugates and intermediate filaments at the margins of mucosal wounds. Dabelsteen E, et al. **J Invest Dermatol** 1998 Oct; 111(4):592-7

Glycoconjugate secretion in human airways in vitro: effects of epithelium removal. Sossé-Alaoui H, et al. **Mediators Inflamm** 1998;7(1):25-30

BLOOD

Isolation and characterization of lectin from Thai marine crab (Scylla serrata) with binding specificity to sialoglycoconjugates and its application. Kongtawelert P. **Mol Mar Biol Biotechnol** 1998 Dec;7(4):280-6

CHEMICAL SYNTHESIS

Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Reuter JD, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):271-8

In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains. Basten JE, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1201-6

Chemical and enzymatic synthesis of glycoconjugates. 5: One-pot regioselective synthesis of bioactive galactobiosides using a CLONEZYME thermophilic glycosidase library. Li J, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):35-8

Stereoselective syntheses of phosphorylated and sulfated glycosyl serines in glycosaminoglycan for biological probes. Tamura J, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):1911-4

A simple synthesis of 8-(methoxycarbonyl)octyl 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside and derivatives and their use in the preparation of neoglycoconjugates. Becker B, et al. **Carbohydr Res** 1999 Jan 31;315(1-2):148-58

Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus. Tsuchida A, et al. **Glycoconj J** 1998 Nov;15(11):1047-54

N alpha- and N epsilon-D-galacturonoyl-L-lysine amides: properties and possible occurrence in plant cell walls. Perrone P, et al. **Phytochemistry** 1998 Dec;49(7):1879-90

CHEMISTRY

Strategies for glycoconjugate analysis. Geyer H, et al. **Acta Anat (Basel)** 1998;161(1-4):18-35

Structural analysis of glycoconjugates by on-target enzymatic digestion and MALDI-TOF-MS. Geyer H, et

al. **Anal Chem** 1999 Jan 15;71(2):476–82

Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Akiyoshi K, et al. **Bioconjug Chem** 1999 May-Jun;10(3):321–4

The synthesis and enzymatic incorporation of sialic acid derivatives for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates. Martin R, et al. **Bioorg Med Chem** 1998 Aug;6(8):1283–92

Synthesis and phototoxic property of tetra- and octa-glycoconjugated tetraphenylchlorins. Mikata Y, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3543–8

A highly efficient preparation of neoglycoconjugate vaccines using subcarriers that bear clustered carbohydrate antigens. Zhang J, et al. **Bioorg Med Chem Lett** 1999 Feb 8; 9(3):487–90

Human milk glycoconjugates that inhibit pathogens. Newburg DS. **Curr Med Chem** 1999 Feb;6(2):117–27 (33 ref.)

Bioanalytic applications of mass spectrometry. Costello CE. **Curr Opin Biotechnol** 1999 Feb;10(1):22–8 (60 ref.)

Polyacrylamide-based glycoconjugates as tools in glycobiology. Bovin NV. **Glycoconj J** 1998 May; 15(5):431–46 (98 ref.)

Identification of major glycoconjugates from Mycobacterium bovis culture filtrate by biotin-hydrazide labeling. Massó F, et al. **Glycoconj J** 1998 Sep;15(9):843–6

[Transportation of cytotoxic liposomes to malignant cells using a carbohydrate determinant] Vodovozova EL, et al. **Bioorg Khim** 1998 Oct;24(10):760–7 (Eng. Abstr.) **(Rus)**

[The molecular biological mechanisms of the functioning of microbial glycopolymers and carbohydrases] Zakharova IIa. **Mikrobiol Z** 1998 Nov-Dec;60(6):3–25 (122 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Detection of glycoconjugates by lectin gold labelling, silver enhancement, and scanning electron microscopy. Gebert A, et al. **J Electron Microsc (Tokyo)** 1999;48(1):85–7

Affinity-purification of concanavalin A-binding ciliary glycoconjugates of starved and feeding Tetrahymena thermophila. Driscoll C, et al. **J Eukaryot Microbiol** 1999 Mar-Apr;46(2):142–6

Recombinant expression of a galectin from the sheep gastrointestinal parasite Teladorsagia circumcincta: its use in isolating galectin-glycoconjugates. Greenhalgh CJ, et al. **Protein Expr Purif** 1999 Jun;16(1):152–9

METABOLISM

Immunofluorescent detection of CD15-fucosylated glycoconjugates in primary cerebellar cultures and their function in glial-neuronal adhesion in the central nervous system. Sajdel-Sulkowska EM. **Acta Biochim Pol** 1998; 45(3):781–90

Glycoconjugates in small antral ovarian follicles of the river buffalo (Bubalus bubalis L.). Parillo F, et al. **Acta Histochem** 1998 Jul;100(3):229–43

Developmental changes of sugar occurrence and distribution in the rat submandibular and sublingual glands. Accili D, et al. **Anat Embryol (Berl)** 1999 Feb;199(2):113–23

Up-regulation of the alpha2,6-sialyltransferase messenger ribonucleic acid increases glycoconjugates containing alpha2, 6-linked sialic acid residues in granulosa cells during follicular atresia of porcine ovaries. Kimura Y, et al. **Biol Reprod** 1999 Jun;60(6):1475–82

Chemical and enzymatic synthesis of glycoconjugates. 5: One-pot regioselective synthesis of bioactive galactobiosides using a CLONEZYME thermophilic glycosidase library. Li J, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):35–8

Stereoselective syntheses of phosphorylated and sulfated glycosyl serines in glycosaminoglycan for biological probes. Tamura J, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):1911–4

Sialyl Lewis X, Lewis X, and N-acetyllactosamine expression on normal and glaucomatous eyes. Terraciano AJ, et al. **Curr Eye Res** 1999 Feb;18(2):73–8

Lectin histochemistry and identification of O-acetylated sialoderivatives in the horse sublingual gland. Scocco P, et al. **Eur J Histochem** 1999;43(1):47–54

Plasmodium falciparum: molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates. Barragan A, et al. **Exp Parasitol** 1999 Feb;91(2):133–43

Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Keppler OT, et al. **Glycobiology** 1999 Jun;9(6):557–69

Lectin histochemistry study in the human vas deferens. Arenas MI, et al. **Glycoconj J** 1998 Nov;15(11):1085–91

Glycoconjugate expression during early mouse oculogenesis. Buse E, et al. **Histochem J** 1998 Nov;30(11):819–27

Characterization of glycoconjugates of guinea pig seminal vesicle by lectin histochemistry. Chan FL, et al. **Histochem J** 1998 Jun;30(6):447–59

Cytoplasmic accumulation of peanut agglutinin-binding glycoconjugates in the cells of primary melanoma correlates with clinical outcome. Cochran AJ, et al. **Hum Pathol** 1999 May;30(5):556–61

Relevance of sialoglycoconjugates in murine thymocytes during maturation and selection in the thymus. Alvarez G, et al. **Immunol Invest** 1999 Jan;28(1):9–18

A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation. Bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions. Mylvaganam M, et al. **J Biol Chem** 1999 Jul 16;274(29):20725–32

Metabolic delivery of ketone groups to sialic acid residues. Application To cell surface glycoform engineering. Yarema KJ, et al. **J Biol Chem** 1998 Nov 20;273(47):31168–79

In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. Remmelink M, et al. **J Cancer Res Clin Oncol** 1999;125(5):275–85

Participation of ABH glycoconjugates in the secretory response to Escherichia coli heat-labile toxin in rabbit intestine. Galván EM, et al. **J Infect Dis** 1999 Aug; 180(2):419–25

Visualization of sulfated glycoconjugates in the chicken embryonic heart by whole-mount alcian blue staining. Wang PR, et al. **J Oral Sci** 1998 Dec;40(4):153–7

Lectin-binding patterns in the olfactory epithelium and vomeronasal organ of the common marmoset. Nakajima T, et al. **J Vet Med Sci** 1998 Sep;60(9):1005–11

Lectin cytochemistry of the lacrimal sac epithelium in experimental dacryocystitis. Maeda S, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):69–74

Lectin cytochemistry of the rabbit conjunctiva and lacrimal sac. Maeda S, et al. **Jpn J Ophthalmol** 1998 Nov-Dec; 42(6):443–9

Lectin cytochemical analysis of lacrimal pleomorphic adenomas. Motegi K, et al. **Jpn J Ophthalmol** 1998 Jul-Aug;42(4):249–55

Expression of glycoconjugates in human eustachian tubes with otitis media. Sone M, et al. **Laryngoscope** 1998 Oct; 108(10):1474–9

Helicobacter pylori attaches to NeuAc alpha 2,3Gal beta 1,4 glycoconjugates produced in the stomach of transgenic mice lacking parietal cells. Syder AJ, et al. **Mol Cell** 1999 Mar;3(3):263–74

Interaction of cholera toxin and Escherichia coli heat-labile enterotoxin with glycoconjugates from rabbit intestinal brush border membranes: relationship with ABH blood group determinants. Balanzino LE, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):53–62

Sialoglycoconjugates in primary and recurrent mixed tumors of lacrimal glands. Hayakawa K, et al. **Ophthalmic Res** 1998;30(6):374–9

UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Keppler OT, et al. **Science** 1999 May 21; 284(5418):1372–6

PHARMACOLOGY

In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains. Basten JE, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1201–6

Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers. Dreef-Tromp CM, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2081–6

Role of lactosyl glycan sequences in inhibiting enteropathogenic Escherichia coli attachment. Vanmaele RP, et al. **Infect Immun** 1999 Jul;67(7):3302–7

PHYSIOLOGY

Specific glycoconjugates are present at the oolemma of the fertilization site in the egg of Discoglossus pictus (Anurans) and bind spermatozoa in an in vitro assay. Maturi G, et al. **Dev Biol** 1998 Dec 1;204(1):210–23

Pseudomonas aeruginosa binds to neoglycoconjugates bearing mucin carbohydrate determinants and predominantly to sialyl-Lewis x conjugates. Scharfman A, et al. **Glycobiology** 1999 Aug;9(8):757–64

Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Karlsson KA. **Mol Microbiol** 1998 Jul;29(1):1–11 (76 ref.)

[Roles of glycoconjugates in the fertilization] Matsumoto M, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2471–8 (54 ref.) **(Jpn)**

SECRETION

Respiratory carcinoma cell lines. MUC genes and glycoconjugates. Berger JT, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):500–10

Comparative study of glycoconjugates of the rat prostatic lobes by lectin histochemistry. Chan FL, et al. **Prostate** 1999 Jan 1;38(1):1–16

GLYCODEOXYCHOLATE see **GLYCODEOXYCHOLIC ACID**

GLYCODEOXYCHOLIC ACID

BLOOD

[Pre- and post-operative changes in serum levels of glycocholic acid and 3,5,3'-triiodothyronine and their clinical significance in patients with cholelithiasis] Hu M, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):162–4 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

[Glycodeoxycholic acid changes the membrane fluidity and superoxides of lipids in hepatocytes] Huang W, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):46–7 (Eng. Abstr.) **(Chi)**

GLYCOGEN

Clear cell (glycogen-rich) rhabdomyosarcoma presenting as cervical lymphadenopathy. Govender D, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan-Feb; 61(1):52–4 (9 ref.)

ANALYSIS

Age- and strain-related differences in dehydrogenase activity and glycogen levels in CBA and C57 mouse cochleas. Ding DL, et al. **Audiol Neurootol** 1999 Mar-Apr;4(2):55–63

Low myometrial glycogen content compared with rectus muscle in term pregnant women before labor. Steingrimsdóttir T, et al. **Gynecol Obstet Invest** 1999; 47(3):166–71

Does the sequence of onset of rigor mortis depend on the proportion of muscle fibre types and on intra-muscular glycogen content? Kobayashi M, et al. **Int J Legal Med** 1999;112(3):167–71

Microfluorometric analyses of glycogen in freshly dissected, single skeletal muscle fibres of the cane toad using a mechanically skinned fibre preparation. Nguyen LT, et al. **J Muscle Res Cell Motil** 1998 Aug;19(6):631–8

Cytochemistry and ultrastructure of canine myocardium undergoing global ischemia and reperfusion injury. Yuan SM. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jan; 15(1):1–7

Effects of genetics and maternal dietary iodide supplementation on glycogen content of organs within embryonic turkeys. Christensen VL, et al. **Poult Sci** 1999 Jun;78(6):890–8

[Further contribution on glycogen in fetal intestinal epithelium] Wille KH, et al. **Anat Histol Embryol** 1999 Mar; 28(1):27–30 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

13C nuclear magnetic resonance study of glycogen resynthesis in muscle after glycogen-depleting exercise in healthy men receiving an infusion of lipid emulsion. Delmas-Beauvieux MC, et al. **Diabetes** 1999 Feb; 48(2):327–33

BIOSYNTHESIS

Glycogen depletion rather than glucose 6-P increments controls early glycogen recovery in human cultured muscle. Montell E, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1489–95

A dramatic accumulation of glycogen in the brown adipose tissue of rats following recovery from cold exposure. Farkas V, et al. **Arch Biochem Biophys** 1999 May 1; 365(1):54–61

Self-glucosylation of glycogenin, the initiator of glycogen biosynthesis, involves an inter-subunit reaction. Lin A, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):163–70

Differential signaling of insulin and IGF-1 receptors to glycogen synthesis in murine hepatocytes. Park BC, et al. **Biochemistry** 1999 Jun 8;38(23):7517–23

Acetyl-L-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Aureli T, et al. **Brain Res** 1998 Jun 15;796(1-2):75–81

13C nuclear magnetic resonance study of glycogen resynthesis in muscle after glycogen-depleting exercise in healthy men receiving an infusion of lipid emulsion. Delmas-Beauvieux MC, et al. **Diabetes** 1999 Feb; 48(2):327–33

Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. Sekar N, et al. **Endocrinology** 1999 Mar;140(3):1125–31

Ultrasensitive glycogen synthesis in Cyanobacteria. Gómez Casati, et al. **FEBS Lett** 1999 Mar 5;446(1):117–21

Islet amyloid polypeptide decreases the effects of insulin-like growth factor-I on glucose transport and glycogen synthesis in skeletal muscle [published erratum appears in Int J Biochem Cell Biol 1999 Jun;31(6):733] Dimitriadis G, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1039–46

Regulated expression of the Streptococcus mutans dlt genes correlates with intracellular polysaccharide accumulation. Spatafora GA, et al. **J Bacteriol** 1999 Apr;181(8):2363–72

Novel aspects of the regulation of glycogen storage. Roach PJ, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):139–51 (50 ref.)

Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. Aiston S, et al. **J Biol Chem** 1999 Aug 27;274(35):24559–66

Control of glycogen synthesis in cultured human muscle cells. Halse R, et al. **J Biol Chem** 1999 Jan 8;274(2):776–80

Mitochondrial respiratory mutants in yeast inhibit glycogen accumulation by blocking activation of glycogen synthase. Yang R, et al. **J Biol Chem** 1998 Nov 20;273(47):31337–44

L-Glutamate and insulin enhance glycogen synthesis in cultured astrocytes from the rat brain through different

intracellular mechanisms. Hamai M, et al. **J Neurochem** 1999 Jul;73(1):400–7

Insulin-stimulated glycogen synthesis in cultured hepatoma cells: differential effects of inhibitors of insulin signaling molecules. Sung CK, et al.
J Recept Signal Transduct Res 1998 Jul–Nov; 18(4–6):243–63

Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Srivastava AK, et al.
Mol Cell Biochem 1998 May;182(1–2):135–41 (65 ref.)

Novel, starch-like polysaccharides are synthesized by an unbound form of granule-bound starch synthase in glycogen-accumulating mutants of Chlamydomonas reinhardtii. Dauvillée D, et al. **Plant Physiol** 1999 Jan; 119(1):321–30

Pride and prejudice: the discovery of the primer for glycogen synthesis. Whelan WJ. **Protein Sci** 1998 Sep;7(9):2038–41

CHEMISTRY

The fractal structure of glycogen: A clever solution to optimize cell metabolism. Meléndez R, et al. **Biophys J** 1999 Sep;77(3):1327–32

Growth dependence of alpha-glucan phosphorylase activity in Thermus thermophilus. Boeck B, et al.
Res Microbiol 1998 Mar;149(3):171–6

METABOLISM

High-intensity exercise and muscle glycogen availability in humans. Balsom PD, et al. **Acta Physiol Scand** 1999 Apr; 165(4):337–45

Regulation of GLUT4 protein expression and glycogen storage after prolonged exercise. Kuo CH, et al.
Acta Physiol Scand 1999 Feb;165(2):193–201

Regulation of glycogen breakdown by glycogen level in contracting rat muscle. Vandenberghe K, et al.
Acta Physiol Scand 1999 Mar;165(3):307–14

Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Hespel P, et al.
Adv Exp Med Biol 1998;441:97–106 (53 ref.)

Myocardial adenine nucleotides, glycogen, and Na, K-ATPase in patients with idiopathic dilated cardiomyopathy requiring mechanical circulatory support. Ishino K, et al. **Am J Cardiol** 1999 Feb 1;83(3):396–9

Regulation of glycogen accumulation in L6 myotubes cultured under optimized differentiation conditions. Elsner P, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E925–33

Assessment of glycogen turnover in aerobic, ischemic, and reperfused working rat hearts. Fraser H, et al.
Am J Physiol 1998 Nov;275(5 Pt 2):H1533–41

Carbohydrate ingestion can completely suppress endogenous glucose production during exercise. Jeukendrup AE, et al.
Am J Physiol 1999 Apr;276(4 Pt 1):E672–83

Decreased insulin-stimulated GLUT-4 translocation in glycogen-supercompensated muscles of exercised rats. Kawanaka K, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E907–12

Glycogen depletion rather than glucose 6-P increments controls early glycogen recovery in human cultured muscle. Montell E, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1489–95

Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Petersen KF, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E529–35

Applications of NMR spectroscopy to study muscle glycogen metabolism in man. Roden M, et al. **Annu Rev Med** 1999; 50:277–90 (56 ref.)

Utilization of reducing power in light-limited cultures of Chromatium vinosum DSM 185. Sánchez O, et al.
Arch Microbiol 1998 Nov;170(6):411–7

Protein targeting to glycogen/PPP1R5: screening of coding and flanking genomic regions for polymorphisms and association analysis with insulin action in Pima Indians. Permana PA, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):184–6

Specific features of glycogen metabolism in the liver. Bollen M, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):19–31 (180 ref.)

Delayed labelling of brain glutamate after an intra-arterial [13C]glucose bolus: evidence for aerobic metabolism of guinea pig brain glycogen store. Griffin JL, et al.
Biochim Biophys Acta 1999 Jul 8;1450(3):297–307

Muscle substrate utilization and lactate production. MacDougall JD, et al. **Can J Appl Physiol** 1999 Jun; 24(3):209–15

Insulin receptor substrate-1 is over-expressed in glycogenotic but not in amphophilic preneoplastic hepatic foci induced in rats by N-nitrosomorpholine and dehydroepiandrosterone. Nehrbass D, et al. **Cancer Lett** 1999 Jun 1;140(1–2):75–9

Loss of protection by hypoxic preconditioning in aging Fischer 344 rat hearts related to myocardial glycogen content and Na+ imbalance. Tani M, et al.
Cardiovasc Res 1999 Mar;41(3):594–602

Combined effects of insulin and dexamethasone on cyclic AMP phosphodiesterase 3 and glycogen metabolism in cultured rat hepatocytes. Hermsdorf T, et al.
Cell Signal 1998 Oct;10(9):629–35

Developmental regulation and ultrastructure of glycogen deposits during murine tooth morphogenesis. Ohshima H, et al. **Cell Tissue Res** 1999 Aug;297(2):271–81

Effect of artemether on glucose uptake and glycogen content in Schistosoma japonicum. Xiao SH, et al.
Chung Kuo Yao Li Hsueh Pao 1997 Jul;18(4):363–7

Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin. Aiston S, et al. **Diabetes** 1999 Jan;48(1):15–20

Relative insensitivity of avian skeletal muscle glycogen to nutritive status. Edwards MR, et al.
Domest Anim Endocrinol 1999 May;16(4):239–47

Insulin-like growth factor (IGF) binding proteins modulate the glucocorticoid-dependent biological effects of IGF-II in cultured fetal rat hepatocytes. Menuelle P, et al.
Endocrinology 1999 May;140(5):2232–40

Training decreases muscle glycogen turnover during exercise. Azevedo JL Jr, et al. **Eur J Appl Physiol** 1998 Nov;78(6):479–86

Hymenolepis diminuta: glucose and glycogen gradients in the adult tapeworm. Pappas PW, et al. **Exp Parasitol** 1999 Apr;91(4):315–26

A tentative mechanism of the ternary complex formation between phosphorylase kinase, glycogen phosphorylase b and glycogen. Andreeva IE, et al. **FEBS Lett** 1999 Feb 19;445(1):173–6

A conserved domain for glycogen binding in protein phosphatase-1 targeting subunits. Wu J, et al.
FEBS Lett 1998 Nov 13;439(1–2):185–91

Acute effect of leptin on hepatic glycogenolysis and gluconeogenesis in perfused rat liver. Nemecz M, et al.
Hepatology 1999 Jan;29(1):166–72

The degradation of glycogen in the lysosomes of newborn rat hepatocytes: glycogen-, maltose- and isomaltose-hydrolyzing acid alpha glucosidase activities in liver. Kalamidas SA, et al. **Histol Histopathol** 1999 Jan; 14(1):23–30

Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Tsujino S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1609–16

Carbohydrate intake and multiple sprint sports: with special reference to football (soccer). Balsom PD, et al.
Int J Sports Med 1999 Jan;20(1):48–52

Glycaemic control, muscle glycogen and exercise performance in IDDM athletes on diets of varying carbohydrate content. McKewen MW, et al.
Int J Sports Med 1999 Aug;20(6):349–53

Glycogen depletion patterns in trained rats adapted to a high-fat or high-carbohydrate diet. Nakamura M, et al.
Int J Sports Med 1998 Aug;19(6):419–24

Muscle glycogen accumulation after a marathon: roles of fiber type and pro- and macroglycogen. Asp S, et al.
J Appl Physiol 1999 Feb;86(2):474–8

Failure of autoresuscitation in weanling mice: significance of cardiac glycogen and heart rate regulation. Deshpande P, et al. **J Appl Physiol** 1999 Jul;87(1):203–10

Effects of endurance exercise training on muscle glycogen accumulation in humans. Greiwe JS, et al.
J Appl Physiol 1999 Jul;87(1):222–6

Role of submaximal exercise in promoting creatine and glycogen accumulation in human skeletal muscle. Robinson TM, et al. **J Appl Physiol** 1999 Aug;87(2):598–604

Function of trehalose and glycogen in cell cycle progression and cell viability in Saccharomyces cerevisiae. Silljé HHW, et al. **J Bacteriol** 1999 Jan;181(2):396–400

Gene organization and transcription analysis of the Agrobacterium tumefaciens glycogen (glg) operon: two transcripts for the single phosphoglucomutase gene. Ugalde JE, et al. **J Bacteriol** 1998 Dec;180(24):6557–64

1,5-Anhydroglucitol promotes glycogenolysis in Escherichia coli. Shiga Y, et al. **J Biochem (Tokyo)** 1999 Jan; 125(1):166–72

Glycogen repletion following burst activity: a carbohydrate-sparing mechanism in animals adapted to arid environments? Bräu L, et al. **J Exp Zool** 1999 Aug 1; 284(3):271–5

Partitioning of glycogen, lipid, and sugar in ovaries and body remnants of female Aedes aegypti (Diptera: Culicidae) fed human blood. Naksathit AT, et al. **J Med Entomol** 1999 Jan;36(1):18–22

Amounts of glycogen, lipid, and sugar in adult female Aedes aegypti (Diptera: Culicidae) fed sucrose. Naksathit AT, et al. **J Med Entomol** 1999 Jan;36(1):8–12

Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. Wambolt RB, et al. **J Mol Cell Cardiol** 1999 Mar; 31(3):493–502

Noninvasive measurements of [1-(13)C]glycogen concentrations and metabolism in rat brain in vivo. Choi IY, et al. **J Neurochem** 1999 Sep;73(3):1300–8

Postnatal profiles of glycogenolysis and gluconeogenesis are modified in rat pups by maternal dietary glucose restriction. Lanoue L, et al. **J Nutr** 1999 Apr;129(4):820–7

Effect of muscle glycogen on glucose, lactate and amino acid metabolism during exercise and recovery in human subjects. Blomstrand E, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):293–302

Glycogen content and excitation-contraction coupling in mechanically skinned muscle fibres of the cane toad. Stephenson DG, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:177–87

Glycogen turnover in skeletal muscle is stimulated along with glucose uptake in vivo during contraction. Huang MT.
Life Sci 1998;63(22):2023–30

Altered purine and glycogen metabolism in skeletal muscle during exercise in patients with heart failure. Kinugawa T, et al. **Metabolism** 1999 Apr;48(4):484–8

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes [see comments] Cline GW, et al.
N Engl J Med 1999 Jul 22;341(4):240–6. Comment in: N Engl J Med 1999 Jul 22;341(4):248–57.

On the inhibition of hepatic glycogenolysis by fructose. A 31P-NMR study in perfused rat liver using the fructose analogue 2,5-anhydro-D-mannitol. Bruynseels K, et al.
NMR Biomed 1999 May;12(3):145–56

Glycogen concentration in human skeletal muscle: effect of prolonged insulin and glucose infusion. Hansen BF, et al.
Scand J Med Sci Sports 1999 Aug;9(4):209–13

Levels of choroidal body carbonic anhydrase activity and glycogen in farmed halibut. Williams DL, et al. **Vet J** 1998 Nov;156(3):223–9

[Effects of exposure to hypoxia on the skin temperature and glycogen content of frostbitten feet in rabbits] Tian J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May;13(2):118–20 (Eng. Abstr.) **(Chi)**

[A new look at the mechanism of action of glucagon] Pecker F, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:141–55 (51 ref.) **(Fre)**

[Cytochemical indices of glycogen content in neutrophil granulocytes in peripheral blood among the patients with prostatitis] Klimenko PM. **Klin Khir** 1999;(1):33–4 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Chromatin binding and polymerization of the endogenous Xenopus egg lamins: the opposing effects of glycogen and ATP. Lourim D, et al. **J Cell Sci** 1998 Dec 18;111 (Pt 24):3675–86

PHYSIOLOGY

Appetite and blood glucose profiles in humans after glycogen-depleting exercise. Melanson KJ, et al.
J Appl Physiol 1999 Sep;87(3):947–54

GLYCOGEN BRANCHING ENZYME see **1,4-ALPHA-GLUCAN BRANCHING ENZYME**

GLYCOGEN DEBRANCHING ENZYME see **GLYCOGEN DEBRANCHING ENZYME SYSTEM**

GLYCOGEN DEBRANCHING ENZYME DEFICIENCY see **GLYCOGEN STORAGE DISEASE TYPE III**

GLYCOGEN DEBRANCHING ENZYME SYSTEM

see related
GLYCOGEN STORAGE DISEASE TYPE III

CHEMISTRY

Monte Carlo simulation of 4-alpha-glucanotransferase reaction. Nakatani H. **Biopolymers** 1999 Aug;50(2):145–51

GENETICS

Thermus aquaticus ATCC 33923 amylomaltase gene cloning and expression and enzyme characterization: production of cycloamylose. Terada Y, et al.
Appl Environ Microbiol 1999 Mar;65(3):910–5

High level expression of Thermococcus litoralis 4-alpha-glucanotransferase in a soluble form in Escherichia coli with a novel expression system involving minor arginine tRNAs and GroELS. Imamura H, et al.
FEBS Lett 1999 Sep 3;457(3):393–6

A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb [letter; comment] Chen YT. **Hum Genet** 1999 Jan;104(1):111–2. Comment on: Hum Genet 1998 Jan;102(1):1–5.

Novel donor splice site mutations of AGL gene in glycogen storage disease type IIIa. Hadjigeorgiou GM, et al.
J Inherit Metab Dis 1999 Aug;22(6):762–3

METABOLISM

Thermus aquaticus ATCC 33923 amylomaltase gene cloning and expression and enzyme characterization: production of cycloamylose. Terada Y, et al.
Appl Environ Microbiol 1999 Mar;65(3):910–5

Monte Carlo simulation of 4-alpha-glucanotransferase reaction. Nakatani H. **Biopolymers** 1999 Aug;50(2):145–51

Thermotoga maritima maltosyltransferase, a novel type of maltodextrin glycosyltransferase acting on starch and malto-oligosaccharides. Meissner H, et al.
Eur J Biochem 1998 Dec 15;258(3):1050–8

Maltose metabolism in the hyperthermophilic archaeon Thermococcus litoralis: purification and characterization of key enzymes. Xavier KB, et al. **J Bacteriol** 1999 Jun; 181(11):3358–67

GLYCOGEN PHOSPHORYLASE see **PHOSPHORYLASE**

GLYCOGEN (STARCH) SYNTHASE see **GLYCOGEN**

GLYCOGEN (STARCH) SYNTHASE

SYNTHASE

GLYCOGEN STORAGE DISEASE

COMPLICATIONS

[Multiple hepatic tumors] Marie I, et al. **Rev Med Interne** 1998 Jul;19(7):516–7 **(Fre)**

DIAGNOSIS

A 5-year-old boy with hepatomegaly and linear growth delay. Adamenko RS, et al. **Curr Opin Pediatr** 1998 Oct; 10(5):523–6

Hypertrophic cardiomyopathy in a newborn infant [clinical conference] Gottesman GS, et al. **J Pediatr** 1999 Jan; 134(1):114–8

Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency. Regalado JJ, et al. **Pediatr Cardiol** 1999 Jul–Aug; 20(4):304–7

[Value of pulmonary gas exchange study during exercise in the diagnosis of a muscular glycogenosis] Laure P, et al. **Arch Pediatr** 1999 Jan;6(1):50–3 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

A novel DraI polymorphism in the 3' untranslated region of human glucose-6-phosphatase gene: useful for carrier detection and prenatal diagnosis of glycogen storage disease type Ia. Lam CW, et al. **Clin Genet** 1998 Jun;53(6):502–3

Glycogen storage diseases of muscle. DiMauro S, et al. **Curr Opin Neurol** 1998 Oct;11(5):477–84 (61 ref.)

GENETICS

Clinical, biochemical and molecular findings in a patient with X-linked liver glycogenosis followed for 40 years. Hendrickx J, et al. **Eur J Pediatr** 1998 Nov;157(11):919–23

Molecular characterization of a novel endonuclease (Xib) and possible involvement in lysosomal glycogen storage disorders. Malferrari G, et al. **Exp Mol Pathol** 1999 Jun; 66(2):123–30

[Molecular bases of glycogenoses (news)] Labrune P. **Arch Pediatr** 1998 Nov;5(11):1199 **(Fre)**

IMMUNOLOGY

Neutropenia and neutrophil dysfunction in glycogen storage disease type Ic. Visser G, et al. **J Inherit Metab Dis** 1998 Jun;21(3):227–31

METABOLISM

Glycogen storage diseases and the liver. Burchell A. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):337–54 (78 ref.)

Fanconi-Bickel syndrome--a congenital defect of the liver-type facilitative glucose transporter. SSIEM Award. Society for the Study of Inborn Errors of Metabolism. Santer R, et al. **J Inherit Metab Dis** 1998 Jun;21(3):191–4

[Value of pulmonary gas exchange study during exercise in the diagnosis of a muscular glycogenosis] Laure P, et al. **Arch Pediatr** 1999 Jan;6(1):50–3 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome. Morisawa Y, et al. **J Neurol Sci** 1998 Oct 8;160(2):175–9

PHYSIOPATHOLOGY

Fanconi-Bickel syndrome--the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Santer R, et al. **Eur J Pediatr** 1998 Oct;157(10):783–97 (80 ref.)

VETERINARY

Glucose uptake in horses with polysaccharide storage myopathy. De La Corte FD, et al. **Am J Vet Res** 1999 Apr;60(4):458–62

GLYCOGEN STORAGE DISEASE TYPE I

[Patient-controlled sedation using propofol for a patient with von Gierke disease] Kakinohana M, et al. **Masui** 1998 Sep; 47(9):1104–8 (Eng. Abstr.) **(Jpn)**

BLOOD

A convenient diagnostic function test of peripheral blood neutrophils in glycogen storage disease type Ib. Verhoeven AJ, et al. **Pediatr Res** 1999 Jun;45(6):881–5

COMPLICATIONS

Case report: Hepatocellular carcinoma in type Ia glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family. Nakamura T, et al. **J Gastroenterol Hepatol** 1999 Jun; 14(6):553–8

Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia. Faivre L, et al. **J Inherit Metab Dis** 1999 Aug;22(6):723–32

Hepatomegaly and multiple liver lesions. Chang HC, et al. **Postgrad Med J** 1998 Jul;74(873):439–40

Association of heterozygote glucose-6-phosphate-dehydrogenase deficiency with more advanced disease in sarcoidosis [letter] Drent M. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):108–9

DIAGNOSIS

Magnetic resonance imaging findings of hepatic adenomas in von Gierke (type I) glycogen storage disease: case report. Debaere C, et al. **Can Assoc Radiol J** 1999 Jun;50(3):161–4

Heteroduplex analysis: a useful screening method for glycogen storage disease type Ia. Narita T, et al. **Diagn Mol Pathol** 1998 Apr;7(2):111–3

A convenient diagnostic function test of peripheral blood neutrophils in glycogen storage disease type Ib. Verhoeven AJ, et al. **Pediatr Res** 1999 Jun;45(6):881–5

DIET THERAPY

Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. Wolfsdorf JI, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):136–43

[Corn starch in the treatment of patients with glycogenosis type I and III] Galiano Segovia MJ, et al. **Nutr Hosp** 1998 Sep–Oct;13(5):228–32 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Linkage disequilibrium and linkage analysis of the glucose-6-phosphatase gene [see comments] Wong LJ, et al. **Hum Genet** 1998 Aug;103(2):199–203. Comment in: Hum Genet 1999 Feb;104(2):193.

Cloning and characterization of cDNAs encoding a candidate glycogen storage disease type 1b protein in rodents. Lin B, et al. **J Biol Chem** 1998 Nov 27;273(48):31656–60

Glycogen storage disease type Ia in three siblings with the G270V mutation. Parvari R, et al. **J Inherit Metab Dis** 1999 Apr;22(2):149–54

Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia. Stroppiano M, et al. **J Inherit Metab Dis** 1999 Feb;22(1):43–9

GENETICS

Complete genomic structure and mutational spectrum of PHKA2 in patients with x-linked liver glycogenosis type I and II. Hendrickx J, et al. **Am J Hum Genet** 1999 Jun; 64(6):1541–9

A gene on chromosome 11q23 coding for a putative glucose-6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. Veiga-da-Cunha M, et al. **Am J Hum Genet** 1998 Oct;63(4):976–83

Three major G6PD-deficient polymorphic variants identified among the Mauritian population. Kotea R, et al. **Br J Haematol** 1999 Mar;104(4):849–54

Structure and mutation analysis of the glycogen storage disease type 1b gene [published erratum appears in FEBS Lett 1999 Feb 26;445(2–3):451] Marcolongo P, et al. **FEBS Lett** 1998 Oct 2;436(2):247–50

Structure of the gene mutated in glycogen storage disease type Ib. Gerin I, et al. **Gene** 1999 Feb 18;227(2):189–95

Genomic structure of the human glucose 6-phosphate translocase gene and novel mutations in the gene of a Japanese patient with glycogen storage disease type Ib. Ihara K, et al. **Hum Genet** 1998 Oct;103(4):493–6

Molecular diagnosis of type Ic glycogen storage disease. Janecke AR, et al. **Hum Genet** 1999 Mar;104(3):275–7

1176C polymorphism in Japanese patients with glycogen storage disease type Ia [letter; comment] Okubo M, et al. **Hum Genet** 1999 Feb;104(2):193. Comment on: Hum Genet 1998 Aug;103(2):199–203.

Glycogen storage disease type Ia: four novel mutations (175delGG, R170X, G266V and V338F) identified. Mutations in brief no. 220. Online. Rake JP, et al. **Hum Mutat** 1999;13(2):173

Identification of three novel mutations (Q54P, W70X and T108I) in the glucose-6-phosphatase gene of patients with glycogen storage disease type Ia. Mutation in brief no. 256. Online. Trioche P, et al. **Hum Mutat** 1999;14(1):91

Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. Hiraiwa H, et al. **J Biol Chem** 1999 Feb 26;274(9):5532–6

Cloning and characterization of cDNAs encoding a candidate glycogen storage disease type 1b protein in rodents. Lin B, et al. **J Biol Chem** 1998 Nov 27;273(48):31656–60

Case report: Hepatocellular carcinoma in type Ia glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family. Nakamura T, et al. **J Gastroenterol Hepatol** 1999 Jun; 14(6):553–8

Molecular aspects of glycogen storage disease type Ia in Turkish patients: a novel mutation in the glucose-6-phosphatase gene. Hüner G, et al. **J Inherit Metab Dis** 1998 Jun;21(4):445–6

Glycogen storage disease type Ia in three siblings with the G270V mutation. Parvari R, et al. **J Inherit Metab Dis** 1999 Apr;22(2):149–54

A novel mutation in a Brazilian patient with glycogen storage disease type Ia. Sartorato EL, et al. **J Inherit Metab Dis** 1998 Jun;21(4):447

Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia. Stroppiano M, et al. **J Inherit Metab Dis** 1999 Feb;22(1):43–9

Origin of the Japanese population [letter; comment] Lam CW. **Science** 1999 May 14;284(5417):1125. Comment on: Science 1999 Mar 5;283(5407):1426–7.

PATHOLOGY

[An autopsy case of adult onset glycogen storage disease type Ia] Akakura N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec;95(12):1367–73 (17 ref.) **(Jpn)**

GLYCOGEN STORAGE DISEASE TYPE II

COMPLICATIONS

Increased occurrence of cleft lip in glycogen storage disease type II (GSDII): exclusion of a contiguous gene syndrome in two patients by presence of intragenic mutations including a novel nonsense mutation Gln58Stop. Huie ML, et al. **Am J Med Genet** 1999 Jul 2;85(1):5–8

An interesting case of infant sudden death: severe hypertrophic cardiomyopathy in Pompe's disease. Metzl JD, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):821–2

DIAGNOSIS

A diagnostic protocol for adult-onset glycogen storage disease type II. Ausems MG, et al. **Neurology** 1999 Mar 10;52(4):851–3

Decompensated cor pulmonaleas the first manifestation of adult-onset myopathy. Kurz D, et al. **Respiration** 1998; 65(4):317–9

[Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease] Willemsen MA, et al. **Ned Tijdschr Geneeskd** 1998 Jun 13;142(24):1388–92 (Eng. Abstr.) **(Dut)**

[Differential diagnosis in anorexia nervosa: glycogenosis II (the Pompe type)] Fischer P, et al. **Dtsch Med Wochenschr** 1999 Aug 6;124(31–32):925–9 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Bijvoet AG, et al. **Hum Mol Genet** 1998 Oct;7(11):1815–24

ETHNOLOGY

Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally "common" in white populations [letter; comment] Hirschhorn R, et al. **J Med Genet** 1999 Jan;36(1):85–6. Comment on: J Med Genet 1995 Oct;32(10):836–7.

GENETICS

Complete genomic structure and mutational spectrum of PHKA2 in patients with x-linked liver glycogenosis type I and II. Hendrickx J, et al. **Am J Hum Genet** 1999 Jun; 64(6):1541–9

Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease [letter] Martiniuk F, et al. **Am J Med Genet** 1998 Aug 27;79(1):69–72

A large Alu-mediated deletion, identified by PCR, as the molecular basis for glycogen storage disease type II (GSDII). Huie ML, et al. **Hum Genet** 1999 Jan;104(1):94–8

The identification of five novel mutations in the lysosomal acid a-(1–4) glucosidase gene from patients with glycogen storage disease type II. Mutations in brief no. 134. Online. Beesley CE, et al. **Hum Mutat** 1998;11(5):413

Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Ko TM, et al. **Hum Mutat** 1999;13(5):380–4

Novel mutations in African American patients with glycogen storage disease Type II. Mutations in brief no. 209. Online. Raben N, et al. **Hum Mutat** 1999;13(1):83–4

Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally "common" in white populations [letter; comment] Hirschhorn R, et al. **J Med Genet** 1999 Jan;36(1):85–6. Comment on: J Med Genet 1995 Oct;32(10):836–7.

METABOLISM

Altered trafficking and turnover of LAMP-1 in Pompe disease-affected cells. Meikle PJ, et al. **Mol Genet Metab** 1999 Mar;66(3):179–88

PATHOLOGY

Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle. Fernández R, et al. **Neuromuscul Disord** 1999 May;9(3):136–43

PHYSIOPATHOLOGY

[Pompe disease or type 2 glycogenosis] Hansoul S, et al. **Rev Med Liege** 1999 Mar;54(3):149–53 (Eng. Abstr.) **(Fre)**

THERAPY

Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. Nicolino MP, et al. **Hum Mol Genet** 1998 Oct; 7(11):1695-702

Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Amalfitano A, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8861-6

[Treatment of Pompe's disease with recombinant enzymes] Van Hove JL. **Verh K Acad Geneeskd Belg** 1998; 60(4):347-57 (Eng. Abstr.) **(Dut)**

GLYCOGEN STORAGE DISEASE TYPE III

COMPLICATIONS

Fatal liver cirrhosis and esophageal variceal hemorrhage in a patient with type IIIa glycogen storage disease. Okuda S, et al. **Intern Med** 1998 Dec;37(12):1055-7

Case report: rupture of a gastric varix in liver cirrhosis associated with glycogen storage disease type III. Hashimoto M, et al. **J Gastroenterol Hepatol** 1998 Feb; 13(2):232-5

Glycogen storage disease type III with diagnosis complicated by gluten-sensitive enteropathy. Artan R, et al. **J Inherit Metab Dis** 1998 Jun;21(4):437-8

DIET THERAPY

[Corn starch in the treatment of patients with glycogenosis type I and III] Galiano Segovia MJ, et al. **Nutr Hosp** 1998 Sep-Oct;13(5):228-32 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements [letter; comment] Lee P. **Br J Obstet Gynaecol** 1999 Feb; 106(2):181-2. Comment on: Br J Obstet Gynaecol 1998 Jun;105(6):677-80.

ENZYMOLOGY

A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb [letter; comment] Chen YT. **Hum Genet** 1999 Jan;104(1):111-2. Comment on: Hum Genet 1998 Jan;102(1):1-5.

Novel donor splice site mutations of AGL gene in glycogen storage disease type IIIa. Hadjigeorgiou GM, et al. **J Inherit Metab Dis** 1999 Aug;22(6):762-3

GENETICS

A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb [letter; comment] Chen YT. **Hum Genet** 1999 Jan;104(1):111-2. Comment on: Hum Genet 1998 Jan;102(1):1-5.

Novel donor splice site mutations of AGL gene in glycogen storage disease type IIIa. Hadjigeorgiou GM, et al. **J Inherit Metab Dis** 1999 Aug;22(6):762-3

GLYCOGEN STORAGE DISEASE TYPE IV

DIAGNOSIS

The exercise test in Andersen syndrome. Katz JS, et al. **Arch Neurol** 1999 Mar;56(3):352-6

GENETICS

Early-onset fetal hydrops and muscle degeneration in siblings due to a novel variant of type IV glycogenosis. Cox PM, et al. **Am J Med Genet** 1999 Sep 10;86(2):187-93

PATHOLOGY

Glycogen storage disease type IV presenting as hydrops fetalis. Alegria A, et al. **J Inherit Metab Dis** 1999 May; 22(3):330-2

VETERINARY

Amylopectinosis in fetal and neonatal Quarter Horses. Render JA, et al. **Vet Pathol** 1999 Mar;36(2):157-60

GLYCOGEN STORAGE DISEASE TYPE V

COMPLICATIONS

Noncardiogenic pulmonary edema and rhabdomyolsis after protamine administration in a patient with unrecognized McArdle's disease. Lobato EB, et al. **Anesthesiology** 1999 Jul;91(1):303-5

[Muscular intolerance of exercise. Current data (editorial)] Serratrice G. **Presse Med** 1998 Oct 31;27(33):1683-6 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Late-onset McArdle's disease mimicking treatment-resistant polymyositis. Report of a case and review of the literature [letter] Pego R, et al. **Rev Rhum Engl Ed** 1999 Apr; 66(4):236-7

[McArdle's disease. Apropos of a case] Yuste JR, et al. **Rev Med Univ Navarra** 1998 Jan-Mar;42(1):29-33 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. MacLean D, et al. **Neurology** 1998 Nov;51(5):1456-9

ENZYMOLOGY

McArdle's disease. The unsolved mystery of the reappearing enzyme. Martinuzzi A, et al. **Am J Pathol** 1999 Jun; 154(6):1893-7

A nonsense mutation in the myophosphorylase gene in a Japanese family with McArdle's disease. Bruno C, et al. **Neuromuscul Disord** 1999 Jan;9(1):34-7

GENETICS

Molecular characterization of McArdle's disease in two large Finnish families. Bruno C, et al. **J Neurol Sci** 1999 Jun 1;165(2):121-5

Asymptomatic McArdle's disease associated with hyper-creatine kinase-emia and absence of myophosphorylase. Gospe SM Jr, et al. **Neurology** 1998 Oct;51(4):1228-9

A new mutation in the myophosphorylase gene (Asn684Tyr) in a Spanish patient with McArdle's disease. Andreu AL, et al. **Neuromuscul Disord** 1999 May;9(3):171-3

A nonsense mutation in the myophosphorylase gene in a Japanese family with McArdle's disease. Bruno C, et al. **Neuromuscul Disord** 1999 Jan;9(1):34-7

McArdle's disease associated with homozygosity for the missense mutation Gly204Ser of the myophosphorylase gene in a Spanish patient. Rubio JC, et al. **Neuromuscul Disord** 1999 May;9(3):174-5

METABOLISM

Asymptomatic McArdle's disease associated with hyper-creatine kinase-emia and absence of myophosphorylase. Gospe SM Jr, et al. **Neurology** 1998 Oct;51(4):1228-9

PHYSIOPATHOLOGY

Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. MacLean D, et al. **Neurology** 1998 Nov;51(5):1456-9

GLYCOGEN STORAGE DISEASE TYPE VII

DIAGNOSIS

Muscle phosphofructokinase deficiency (Tarui's disease): report of a case. Lin HC, et al. **J Formos Med Assoc** 1999 Mar;98(3):205-8

METABOLISM

In vivo determination of altered hemoglobin saturation in dogs with M-type phosphofructokinase deficiency. McCully K, et al. **Muscle Nerve** 1999 May;22(5):621-7

Impaired aerobic glycolysis in muscle phosphofructokinase deficiency results in biphasic post-exercise phosphocreatine recovery in 31P magnetic resonance spectroscopy. Grehl T, et al. **Neuromuscul Disord** 1998 Oct;8(7):480-8

GLYCOGEN SYNTHASE

DRUG EFFECTS

Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. Sekar N, et al. **Endocrinology** 1999 Mar;140(3):1125-31

In vivo insulin signaling in the myocardium of streptozotocin-diabetic rats: opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos. Wang PH, et al. **Endocrinology** 1999 Mar;140(3):1141-50

Insulin unexpectedly increases the glucose 6-phosphate Ka of skeletal muscle glycogen synthase in calorie-restricted monkeys. Ortmeyer HK, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):309-23

GENETICS

Expression of naturally occurring variants in the muscle glycogen synthase gene. Orho-Melander M, et al. **Diabetes** 1999 Apr;48(4):918-20

A paired-sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene. Orho-Melander M, et al. **Diabetologia** 1999 Sep;42(9):1138-45

HISTORY

Pride and prejudice: the discovery of the primer for glycogen synthesis. Whelan WJ. **Protein Sci** 1998 Sep;7(9):2038-41

METABOLISM

Cellular and molecular mechanisms involved in insulin's potentiation of glycogen synthase activity by metformin. Detaille D, et al. **Biochem Pharmacol** 1999 Nov 1; 58(9):1475-86

Manganese sulfate-dependent glycosylation of endogenous glycoproteins in human skeletal muscle is catalyzed by a nonglucose 6-P-dependent glycogen synthase and not glycogenin. Jiao Y, et al. **Biochim Biophys Acta** 1999 Mar 14;1427(1):1-12

Changes of activity of liver glycogen synthase in experimental diabetes mellitus rats. Wang Y, et al. **Chin Med J (Engl)** 1998 Jan;111(1):32-4

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13-34 (293 ref.)

Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Virkamäki A, et al. **Diabetes** 1999 May;48(5):1101-7

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Damsbo P, et al. **Diabetes Care** 1998 Sep;21(9):1489-94

In late pregnancy insulin-dependent glucose transport/phosphorylation is selectively impaired and activation of glycogen synthase by insulin facilitated in skeletal muscles of 24-h starved rats. Holness MJ, et al. **Diabetologia** 1999 Jul;42(7):802-11

Glucosamine regulation of glucose metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in non-diabetic and type 2 diabetic subjects. Ciaraldi TP, et al. **Endocrinology** 1999 Sep;140(9):3971-80

RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin. Standaert ML, et al. **Endocrinology** 1999 May;140(5):2145-51

Changes in the activity levels of glutamine synthetase, glutaminase and glycogen synthetase in rats subjected to hypoxic stress. Vats P, et al. **Int J Biometeorol** 1999 Apr; 42(4):205-9

Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase. Beck-Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):255-79 (39 ref.)

Inhibitor-1 is not required for the activation of glycogen synthase by insulin in skeletal muscle. Scrimgeour AG, et al. **J Biol Chem** 1999 Jul 23;274(30):20949-52

Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1). Takata M, et al. **J Biol Chem** 1999 Jul 16;274(29):20611-8

Mitochondrial respiratory mutants in yeast inhibit glycogen accumulation by blocking activation of glycogen synthase. Yang R, et al. **J Biol Chem** 1998 Nov 20;273(47):31337-44

Effects of exercise and insulin on insulin signaling proteins in human skeletal muscle. Koval JA, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):998-1004

Genetic and biochemical characterization of Saccharomyces cerevisiae mutants resistant to trifluoroleucine. Casalone E, et al. **Res Microbiol** 1997 Sep-Oct;148(7):613-23

GLYCOGEN SYNTHASE KINASES see **CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE**

GLYCOGEN SYNTHETASE see **GLYCOGEN SYNTHASE**

GLYCOGENOSIS see **GLYCOGEN STORAGE DISEASE**

GLYCOGENOSIS 1 see **GLYCOGEN STORAGE DISEASE TYPE I**

GLYCOGENOSIS 2 see **GLYCOGEN STORAGE DISEASE TYPE II**

GLYCOGENOSIS 3 see **GLYCOGEN STORAGE DISEASE TYPE III**

GLYCOGENOSIS 4 see **GLYCOGEN STORAGE DISEASE TYPE IV**

GLYCOGENOSIS 5 see **GLYCOGEN STORAGE DISEASE TYPE V**

GLYCOGENOSIS 7 see **GLYCOGEN STORAGE DISEASE TYPE VII**

GLYCOHEMOGLOBIN A see **HEMOGLOBIN A, GLYCOSYLATED**

GLYCOL METHACRYLATE GEL see **POLYHYDROXYETHYL METHACRYLATE**

GLYCOLATES

see related
POLYGLYCOLIC ACID

Removal by human apurinic/apyrimidinic endonuclease 1 (Ape 1) and Escherichia coli exonuclease III of 3'-phosphoglycolates from DNA treated with neocarzinostatin, calicheamicin, and gamma-radiation. Chaudhry MA, et al. **Biochem Pharmacol** 1999 Mar 1; 57(5):531-8

ADMINISTRATION & DOSAGE

Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Kakita LS, et al. **Clin Ther** 1998 Sep-Oct;20(5):960-70

BLOOD

Glycolate kinetics and hemodialysis clearance in ethylene glycol poisoning. META Study Group. Moreau CL, et al. **J Toxicol Clin Toxicol** 1998;36(7):659-66

CHEMICAL SYNTHESIS

Novel antiallergic and antiinflammatory agents. Part I: Synthesis and pharmacology of glycolic amide derivatives. Ban M, et al. **Bioorg Med Chem** 1998 Jul;6(7):1069-76

CHEMISTRY

A 1H-NMR study of the permeation of glycolic acid through phospholipid membranes. Males RG, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1-2):333-8

Determination of the absolute configuration of alpha-hydroxyglycine derivatives by enzymatic conversion and chiral high-performance liquid chromatography. McIninch JK, et al. **J Chromatogr A** 1998 Dec 18; 828(1-2):191-8

DIAGNOSTIC USE

Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. Kobayashi H, et al. **J Nucl Med** 1999 May;40(5):837-45

METABOLISM

In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT. Cohen VI, et al. **J Mol Neurosci** 1998 Aug;11(1):1-9

Exonuclease IX of Escherichia coli removes 3' phosphoglycolate end groups from DNA. Sandigursky M, et al. **Radiat Res** 1998 Dec;150(6):609-11

Examination on biological activities and fates of new steroids, steroid-17-yl methyl glycolate derivatives. Suzuki T, et al. **Tohoku J Exp Med** 1999 Feb;187(2):127-40

PHARMACOKINETICS

Assessment of in vitro percutaneous absorption of glycolic acid through human skin sections using a flow-through diffusion cell system. Jiang M, et al. **J Dermatol Sci** 1998 Dec;18(3):181-8

Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in F344 rats and B6C3F1 mice. Dill JA, et al. **Toxicol Appl Pharmacol** 1998 Dec; 153(2):227-42

PHARMACOLOGY

Chloride channel blockers inhibit Ca2+ uptake by the smooth muscle sarcoplasmic reticulum. Pollock NS, et al. **Biophys J** 1998 Oct;75(4):1759-66

Increased in vivo collagen synthesis and in vitro cell proliferative effect of glycolic acid. Kim SJ, et al. **Dermatol Surg** 1998 Oct;24(10):1054-8

The effect of glycolic acid on photoaged albino hairless mouse skin. Moon SE, et al. **Dermatol Surg** 1999 Mar; 25(3):179-82

THERAPEUTIC USE

Effects of glycolic acid on psoriasis [letter] Berardesca E, et al. **Clin Exp Dermatol** 1998 Jul;23(4):190-1

Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Spellman MC, et al. **Clin Ther** 1998 Jul-Aug; 20(4):711-21

Glycolic acid peeling in the treatment of acne. Atzori L, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):119-22

TOXICITY

Ethylene glycol developmental toxicity: unraveling the roles of glycolic acid and metabolic acidosis. Carney EW, et al. **Toxicol Sci** 1999 Jul;50(1):117-26

GLYCOLIC-LACTIC ACID POLYESTER see **POLYGLACTIN 910**

GLYCOLIPIDS

IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids--recommendations 1997. Chester MA. **Eur J Biochem** 1998 Oct 15;257(2):293-8

[Basic study on glyco chains] Suzuki A. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2631-9 (4 ref.) **(Jpn)**

ANALYSIS

Molecular identification of the antigens recognized by monoclonal antibody JT95 specific for thyroid carcinomas. Kimura N, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):449-53

Glycolipids from sponges. VII. Simplexides, novel immunosuppressive glycolipids from the Caribbean sponge Plakortis simplex. Costantino V, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):271-6

Establishment of a quantitative assay of abnormal glycolipid expression in endometrial cells, and its diagnostic value for endometrial carcinoma. Kobayashi Y, et al. **Clin Cancer Res** 1996 Apr;2(4):749-54

Is PGL-1 also present in Leishmania donovani promastigotes? Gupta PN, et al. **Indian J Lepr** 1998 Apr-Jun;70(2):161-4

Glycolipid-enriched caveolae and caveolae-like domains in the nervous system. Masserini M, et al. **J Neurochem** 1999 Jul;73(1):1-11 (121 ref.)

High-pressure freezing and freeze-substitution of native rat brain: suitability for preservation and immunoelectron microscopic localization of myelin glycolipids. Kirschning E, et al. **J Neurosci Res** 1998 Aug 15;53(4):465-74

Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk-fed preterm infants. Peterson JA, et al. **Pediatr Res** 1998 Oct;44(4):499-506

Chemical and lectin-gold electron microscopical studies of the expression of the Galalpha1-determinant in the pig aorta. Hallberg EC, et al. **Xenotransplantation** 1998 Nov; 5(4):246-56

[Characterization of phenolic glycolipid-I (PGL-I) like antigen in renal cell carcinoma] Matsuda H. **Nippon Hinyokika Gakkai Zasshi** 1998 Aug;89(8):683-92 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. Bieberich E, et al. **J Neurochem** 1999 Mar;72(3):1040-9

BIOSYNTHESIS

Production of sophorolipids from whey: development of a two-stage process with Cryptococcus curvatus ATCC 20509 and Candida bombicola ATCC 22214 using deproteinized whey concentrates as substrates. Daniel HJ, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):40-5

Rhamnose lipids--biosynthesis, microbial production and application potential. Lang S, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):22-32 (116 ref.)

Multi-enzyme kinetic analysis of glycolipid biosynthesis. Bieberich E, et al. **Biochim Biophys Acta** 1999 Jun 15; 1432(1):113-24

Identification and recombinant expression of a Mycobacterium avium rhamnosyltransferase gene (rtfA) involved in glycopeptidolipid biosynthesis. Eckstein TM, et al. **J Bacteriol** 1998 Nov;180(21):5567-73

Neutral glycolipid and ganglioside composition of type-1 and type-2 astrocytes from rat cerebral hemisphere. Murakami K, et al. **J Neurosci Res** 1999 Feb 1;55(3):382-93

Characterization of antarctic hydrocarbon-degrading bacteria capable of producing bioemulsifiers. Yakimov MM, et al. **New Microbiol** 1999 Jul;22(3):249-56

Arabidopsis galactolipid biosynthesis and lipid trafficking mediated by DGD1. Dörmann P, et al. **Science** 1999 Jun 25;284(5423):2181-4

CHEMICAL SYNTHESIS

Synthesis of beta-D-arabinofuranosyl-1-monophosphoryl polyprenols: examination of their function as mycobacterial arabinosyl transferase donors. Lee RE, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):951-4

Novel disaccharide inhibitors of human glioma cell division. Aguilera B, et al. **J Med Chem** 1998 Nov 5;41(23):4599-606

Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. Sliedregt LA, et al. **J Med Chem** 1999 Feb 25;42(4):609-18

CHEMISTRY

Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. Bush CA, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:269-93 (150 ref.)

Surface-active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):59-70 (70 ref.)

Production and structure elucidation of di- and oligosaccharide lipids (biosurfactants) from Tsukamurella sp. nov. Vollbrecht E, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):530-7

Phase and surface properties of lipid bilayers containing neoglycolipids. Luzardo MC, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):81-90

Key role of the diglucosyldiacylglycerol synthase for the nonbilayer-bilayer lipid balance of Acholeplasma laidlawii membranes. Vikström S, et al. **Biochemistry** 1999 Apr 27; 38(17):5511-20

Synthetic neoglycolipids for biological applications: correlation between their structures and their interactions with membrane proteins. Rico-Lattes I, et al. **Biochimie** 1998 May-Jun;80(5-6):483-7 (18 ref.)

Infrared spectroscopy of glycolipids. Brandenburg K, et al. **Chem Phys Lipids** 1998 Nov;96(1-2):23-40 (75 ref.)

Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. Fukasawa M, et al. **FEBS Lett** 1998 Dec 28;441(3):353-6

Gas-liquid chromatography of the heptafluorobutyrate derivatives of the O-methyl-glycosides on capillary columns: a method for the quantitative determination of the monosaccharide composition of glycoproteins and glycolipids. Zanetta JP, et al. **Glycobiology** 1999 Mar; 9(3):255-66

Structure of a new glycolipid from the Mycobacterium avium-Mycobacterium intracellulare complex. Watanabe M, et al. **J Bacteriol** 1999 Apr;181(7):2293-7

Multiple forms of lactadherin (breast antigen BA46) and butyrophilin are secreted into human milk as major components of milk fat globule membrane. Cavaletto M, et al. **J Dairy Res** 1999 May;66(2):295-301

Glycosyldiacylglycerolipids from the lichen Dictyonema glabratum. Sassaki GL, et al. **J Nat Prod** 1999 Jun; 62(6):844-7

A novel monoacyldiglycosyl-monoacylglycerol from Flavobacterium marinotypicum. Yagi H, et al. **J Nat Prod** 1999 Apr;62(4):631-2

Characterization of glycolipids from Meiothermus spp. Ferreira AM, et al. **Microbiology** 1999 May;145 (Pt 5):1191-9

Distinct structures and functions of related pre- and postsynaptic carbohydrates at the mammalian neuromuscular junction. Martin PT, et al. **Mol Cell Neurosci** 1999 Feb;13(2):105-18

Rubiginoside, a farnesyl glycoside from Lepisanthes rubiginosa. Adesanya SA, et al. **Phytochemistry** 1999 Aug; 51(8):1039-41

alpha-Gal epitopes in animal tissue glycoproteins and glycolipids. Rydberg L, et al. **Subcell Biochem** 1999; 32:107-25 (88 ref.)

Looking at lipid rafts? [see comments] Jacobson K, et al. **Trends Cell Biol** 1999 Mar;9(3):87-91 (34 ref.). Comment in: Trends Cell Biol 1999 Jun;9(6):212-3.

CLASSIFICATION

Nomenclature of glycolipids. **Carbohydr Res** 1998 Nov; 312(4):167-75

GENETICS

Purification and characterization of avian glycolipid: beta-galactosyltransferases (GalT-4 and GalT-3): cloning and expression of truncated betaGalT-4. Basu SS, et al. **Acta Biochim Pol** 1998;45(2):451-67

A mutant deficient in the plastid lipid DGD is defective in protein import into chloroplasts. Chen LJ, et al. **Plant J** 1998 Oct;16(1):33-9

IMMUNOLOGY

Mycoplasma fermentans glycolipid triggers inflammatory response in rat astrocytes. Ben-Menachem G, et al. **Brain Res** 1998 Aug 24;803(1-2):34-8

CD1-mediated immune responses to glycolipids. Burdin N, et al. **Curr Opin Immunol** 1999 Jun;11(3):326-31 (64 ref.)

Self glycolipids as T-cell autoantigens. Shamshiev A, et al. **Eur J Immunol** 1999 May;29(5):1667-75

Costimulatory action of glycoinositolphospholipids from Trypanosoma cruzi: increased interleukin 2 secretion and induction of nuclear translocation of the nuclear factor of activated T cells 1. Bellio M, et al. **FASEB J** 1999 Sep; 13(12):1627-36

Wax D of Mycobacterium tuberculosis induced osteomyelitis accompanied by reactive bone formation in Buffalo rats. Kawabata Y, et al. **FEMS Immunol Med Microbiol** 1998 Dec;22(4):293-302

Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Tripathi PK, et al. **Hybridoma** 1999 Apr; 18(2):193-202

Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Speir JA, et al. **Immunity** 1999 Jan;10(1):51-61

Basidiolipids from Agaricus are novel immune adjuvants. Jennemann R, et al. **Immunobiology** 1999 Jun;200(2):277-89

Antibodies against peripheral myelin glycolipids in people with HIV infection. Petratos S, et al. **Immunol Cell Biol** 1998 Dec;76(6):535-41

Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a beta-mannosylated glycolipid. Riggs MW, et al. **Infect Immun** 1999 Mar;67(3):1317-22

Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Stefani MM, et al. **Int J Lepr Other Mycobact Dis** 1998 Sep;66(3):356-64

Complement activation by bacterial surface glycolipids: a study with planar bilayer membranes. Münstermann M, et

al. **J Membr Biol** 1999 Feb 1;167(3):223-32

Rapid serodiagnosis of Mycobacterium avium-intracellulare complex infection by ELISA with cord factor (trehalose 6, 6'-dimycolate), and serotyping using the glycopeptidolipid antigen. Enomoto K, et al. **Microbiol Immunol** 1998;42(10):689-96

Effect of polar glycopeptidolipids from Mycobacterium chelonae (GPLp-Mc) on phagocytosis and superoxide anion production of macrophages from mice. Influence of physical activity. Garcia Garcia JJ, et al. **Mol Cell Biochem** 1998 Jun;183(1-2):159-63

Anti M. leprae IgM antibody determination by ultramicroimmunoenzymatic (UMELISA HANSEN) for the diagnosis and monitoring leprosy. Torrella A, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun;40(3):177-81

Immunological and ultrastructural disruptions of T lymphocytes following exposure to the glycopeptidolipid isolated from the Mycobacterium avium complex. Pourshafie MR, et al. **Scand J Immunol** 1999 Apr; 49(4):405-10

Presentation of bacterial lipid antigens by CD1 molecules. Prigozy TI, et al. **Trends Microbiol** 1998 Nov;6(11):454-9 (25 ref.)

Serotaxonomic analysis of glycolipids from Mycobacterium chelonae-M. fortuitum complex and bovine farcy strains. Hamid ME, et al. **Zentralbl Bakteriol** 1998 Jul;288(1):23-34

[The development of intestinal dysbacteriosis in newborn infants with a deficiency of antibodies to the Re-glycolipid] Likhoded VG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug;(4):67-8 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Purification and characterization of avian glycolipid: beta-galactosyltransferases (GalT-4 and GalT-3): cloning and expression of truncated betaGalT-4. Basu SS, et al. **Acta Biochim Pol** 1998;45(2):451-67

Isolation and characterization of novel neutral glycolipids from Thermoplasma acidophilum. Uda I, et al. **Biochim Biophys Acta** 1999 Aug 18;1439(3):363-70

Glycolipid antigen for use in diagnostic assays for bovine tuberculosis. Ostyn A, et al. **Res Microbiol** 1997 Jul-Aug; 148(6):491-500

METABOLISM

A fluorescence resonance energy transfer approach for monitoring protein-mediated glycolipid transfer between vesicle membranes. Mattjus P, et al. **Anal Biochem** 1999 Mar 15;268(2):297-304

Production and structure elucidation of di- and oligosaccharide lipids (biosurfactants) from Tsukamurella sp. nov. Vollbrecht E, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):530-7

Adamantyl globotriaosyl ceramide: a monovalent soluble mimic which inhibits verotoxin binding to its glycolipid receptor. Mylvaganam M, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):391-4

Targeting of MAL, a putative element of the apical sorting machinery, to glycolipid-enriched membranes requires a pre-golgi sorting event. Puertollano R, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):689-92

Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters. Jasinska R, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):677-86

Accumulation of glycolipids in mutant Chinese hamster ovary cells (Z65) with defective peroxisomal assembly and comparison of the metabolic rate of glycosphingolipids between Z65 cells and wild-type CHO-K1 cells. Saito M, et al. **Biochim Biophys Acta** 1999 Apr 19;1438(1):55-62

Synthetic neoglycolipids for biological applications: correlation between their structures and their interactions with membrane proteins. Rico-Lattes I, et al. **Biochimie** 1998 May-Jun;80(5-6):483-7 (18 ref.)

Evidence that free GPI glycolipids are essential for growth of Leishmania mexicana. Ilgoutz SC, et al. **EMBO J** 1999 May 17;18(10):2746-55

Correspondence of gradual developmental increases of expression of galectin-reactive glycoconjugates with alterations of the total contents of the two differentially regulated galectins in chicken intestine and liver as indication for overlapping functions. Lips KS, et al. **Histol Histopathol** 1999 Jul;14(3):743-60

BRCA1 and BRCA2 proteins are expressed in milk fat globules [letter] Bernard-Gallon DJ, et al. **Int J Cancer** 1999 May 31;81(5):839-43

The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion. Miura R, et al. **J Biol Chem** 1999 Apr 16;274(16):11431-8

Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. Okajima T, et al. **J Biol Chem** 1999 Apr 23;274(17):11479-86

Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. Arab S, et al. **J Cell Physiol** 1998 Dec;177(4):646-60

CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. Spada FM, et al. **J Exp Med** 1998 Oct 19;188(8):1529-34

Glycolipids as potential binding sites for HIV: topology in the sperm plasma membrane in relation to the regulation of membrane fusion. Gadella BM, et al. **J Reprod Immunol** 1998 Dec;41(1-2):233-53

In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2. Takeda T, et al. **Microbiol Immunol** 1999;43(4):331-7

Inflammatory cytokines inhibit upregulation of glycolipid expression by Schwann cells in vitro. Lisak RP, et al. **Neurology** 1998 Dec;51(6):1661-5

A mutant deficient in the plastid lipid DGD is defective in protein import into chloroplasts. Chen LJ, et al. **Plant J** 1998 Oct;16(1):33-9

[Brain cerebrosides and sulfocerebrosides after treatment with hydrocortisone] Chaeva LS, et al. **Vopr Med Khim** 1998 Sep-Oct;44(5):459-63 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Action of a new mammalian DNA polymerase inhibitor, sulfoquinovosyldiacylglycerol. Ohta K, et al. **Biol Pharm Bull** 1999 Feb;22(2):111-6

Mycoplasma fermentans glycolipid triggers inflammatory response in rat astrocytes. Ben-Menachem G, et al. **Brain Res** 1998 Aug 24;803(1-2):34-8

Mannosylerythritol lipid is a potent inducer of apoptosis and differentiation of mouse melanoma cells in culture. Zhao X, et al. **Cancer Res** 1999 Jan 15;59(2):482-6

Proapoptotic activity of a Trypanosoma cruzi ceramide-containing glycolipid turned on in host macrophages by IFN-gamma. Freire-de-Lima CG, et al. **J Immunol** 1998 Nov 1;161(9):4909-16

Effects of macrophage inhibitory factor-A3 (MIF-A3) on cytokine secretion and phagolysosome fusion in murine macrophages. Hines ME 2nd, et al. **Vet Microbiol** 1999 Feb 23;65(1):47-60

PHYSIOLOGY

Implication of glycolipids in lens fiber development. Ogiso M. **Acta Biochim Pol** 1998;45(2):501-7

Eukaryotic glycosylation: whim of nature or multipurpose tool? Reuter G, et al. **Cell Mol Life Sci** 1999 Mar; 55(3):368-422 (671 ref.)

Myelination in the absence of galactolipids and proteolipid proteins. Coetzee T, et al. **Mol Cell Neurosci** 1999 Jul; 14(1):41-51

High expression of glycosphingolipids involved in procoagulant activity of cancer cells. Suzuki M, et al. **Oncol Rep** 1999 Jan-Feb;6(1):113-5

Granuloma formation and in vitro macrophage activation in mice by mycoloyl glycolipids from Nocardia asteroides and related taxa. Han Y, et al. **Osaka City Med J** 1998 Dec;44(2):201-17

Protective function of human milk: the milk fat globule. Hamosh M, et al. **Semin Perinatol** 1999 Jun;23(3):242-9 (65 ref.)

[Promotion of phagocytosis and prevention of phagosome-lysosome (P-L) fusion in human peripheral blood monocytes by serotype specific glycopeptidolipid (GPL) antigen of Mycobacterium avium complex (MAC)] Minami H. **Kekkaku** 1998 Sep;73(9):545-56 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Hyaluronate, tetrachlorodecaoxide, and galactolipid prevent adhesions after implantation of Gore-Tex and dura mater into the abdominal wall in rats. Schier F, et al. **Pediatr Surg Int** 1999;15(3-4):255-9

GLYCOLS

Adjusting selectivity in micellar electrokinetic capillary chromatography with 1,2-hexanediol. Allen DJ, et al. **Electrophoresis** 1999 Jan;20(1):100-10

ADVERSE EFFECTS

[Adverse effects of glycolic irrigation solutions] Radal M, et al. **Therapie** 1999 Mar-Apr;54(2):233-6 (Eng. Abstr.) **(Fre)**

ANALYSIS

Determination of glycols in air: development of sampling and analytical methodology and application to theatrical smokes. Pendergrass SM. **Am Ind Hyg Assoc J** 1999 Jul-Aug;60(4):452-7

Simultaneous determination of water and enediols or thiols in chemical products and drugs not amenable to direct Karl Fischer titration. Kuselman I, et al. **J AOAC Int** 1999 Jul-Aug;82(4):840-61

CHEMICAL SYNTHESIS

Synthesis, toxicological, pharmacological assessment, and in vitro bronchodilating activity of some 7-theophyllinylacetyloxyglycols. Zlatkov A, et al. **Arch Pharm (Weinheim)** 1998 Oct;331(10):313-8

METABOLISM

Butadiene diolepoxide- and diepoxybutane-derived DNA adducts at N7-guanine: a high occurrence of diolepoxide-derived adducts in mouse lung after 1,3-butadiene exposure. Koivisto P, et al. **Carcinogenesis** 1999 Jul;20(7):1253-9

2'-Deoxycytidine glycols, a missing link in the free radical-mediated oxidation of DNA. Tremblay S, et al. **J Biol Chem** 1999 Jul 23;274(30):20833-8

PHARMACOKINETICS

Metabolism of 3-butene-1,2-diol in B6C3F1 mice. Evidence for involvement of alcohol dehydrogenase and cytochrome p450. Kemper RA, et al. **Drug Metab Dispos** 1998 Sep; 26(9):914-20

URINE

Gas chromatographic determination of 3-butene-1,2-diol in urine samples after 1,3-butadiene exposure. Anttinen-Klemetti T, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jul 9;730(2):257-64

GLYCOLYSIS

Myocardial aerobic metabolism is impaired in a cell culture model of cyanotic heart disease. Merante F, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1673-81

Analysis of glycolysis relevant compounds in saliva by microbiosensors. Yoda K, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:600-4

Prolonged preservation of the blood-perfused canine heart with glycolysis-promoting solution. Takeuchi K, et al. **Ann Thorac Surg** 1999 Sep;68(3):903-7

Effect of specific growth rate on fermentative capacity of baker's yeast. Van Hoek P, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4226-33

Characterization of glycolysis and pentose phosphate pathway activity during sperm entry into the mouse oocyte. Urner F, et al. **Biol Reprod** 1999 Apr;60(4):973-8

In vivo nuclear magnetic resonance studies of glycolytic kinetics in Lactococcus lactis. Neves AR, et al. **Biotechnol Bioeng** 1999 Jul 20;64(2):200-12

Copurification of selected glycolytic enzymes with retinal S-antigen (arrestin) by hydroxyapatite agarose chromatography of bovine retina. Mirshahi M, et al. **Curr Eye Res** 1999 May;18(5):327-34

Top-down control analysis of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. Ainscow EK, et al. **Eur J Biochem** 1999 Aug;263(3):671-85

Mechanisms of control of heart glycolysis. Depré C, et al. **Eur J Biochem** 1998 Dec 1;258(2):277-90 (202 ref.)

Impaired glycolysis and protein catabolism induced by acid in L6 rat muscle cells. Bevington A, et al. **Eur J Clin Invest** 1998 Nov;28(11):908-17

Engineering a central metabolic pathway: glycolysis with no net phosphorylation in an Escherichia coli gap mutant complemented with a plant GapN gene. Valverde F, et al. **FEBS Lett** 1999 Apr 23;449(2-3):153-8

Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. Malhotra R, et al. **J Biol Chem** 1999 Apr 30; 274(18):12567-75

Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease. Bigl M, et al. **J Neural Transm** 1999;106(5-6):499-511

Oxidative metabolism and anaerobic glycolysis during repeated exercise. Rico-Sanz J. **J Physiol Biochem** 1998 Dec;54(4):217-25

To re-emphasize the need for fluoride in blood samples for glucose-level testing. Khan II, et al. **JPMA J Pak Med Assoc** 1998 Apr;48(4):113-4

Leukocyte glycolysis and lactate output in animal sepsis and ex vivo human blood. Haji-Michael PG, et al. **Metabolism** 1999 Jun;48(6):779-85

Transcriptional activation of the glycolytic las operon and catabolite repression of the gal operon in Lactococcus lactis are mediated by the catabolite control protein CcpA. Luesink EJ, et al. **Mol Microbiol** 1998 Nov;30(4):789-98

Two-compartment model for determination of glycolytic rates of solid tumors by in vivo 13C NMR spectroscopy. Artemov D, et al. **NMR Biomed** 1998 Nov;11(8):395-404

Contribution of glucose transport to the control of the glycolytic flux in Trypanosoma brucei. Bakker BM, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10098-103

Evaluation of glycolytic parameters and cytoplasmic redox status as markers of hepatic function in liver transplantation. Igea J, et al. **Transplant Proc** 1999 Sep; 31(6):2443-4

Glycolysis, turbo design and the endocrine pancreatic beta cell [letter; comment] Iynedjian PB. **Trends Biochem Sci** 1998 Dec;23(12):467-8. Comment on: Trends Biochem Sci 1998 May;23(5):162-9.

Starting up yeast glycolysis [see comments] Gonçalves P, et al. **Trends Microbiol** 1998 Aug;6(8):314-9 (31 ref.). Comment in: Trends Microbiol 1998 Dec;6(12):472-3.

Complete sequence of glycolytic enzymes in the mycorrhizal basidiomycete, Suillus bovinus. Kowallik W, et al. **Z Naturforsch [C]** 1998 Sep-Oct;53(9-10):818-27

[Physical activity exhibits differences in the action of fat metabolism in men and women--results of a microdialysis study] Boschmann M, et al. **Forsch Komplementarmed** 1999 Feb;6(1):52-3 **(Ger)**

GLYCOLYSIS

DRUG EFFECTS

Stimulation of both aerobic glycolysis and Na(+)-K(+)-ATPase activity in skeletal muscle by epinephrine or amylin. James JH, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E176-86

Effects of endoglycoceramidase or D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol on glucose uptake, glycolysis, and mitochondrial respiration in HL60 cells. Ji L, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):107-14

Acyl phosphatase activity of NO-inhibited glyceraldehyde-3-phosphate dehydrogenase (GAPDH): a potential mechanism for uncoupling glycolysis from ATP generation in NO-producing cells. Albina JE, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):5-9

Arginine activates glycolysis of goat epididymal spermatozoa: an NMR study. Patel AB, et al. **Biophys J** 1998 Sep;75(3):1522-8

Influence of furfural on anaerobic glycolytic kinetics of Saccharomyces cerevisiae in batch culture. Palmqvist E, et al. **Biotechnol Bioeng** 1999 Feb 20;62(4):447-54

Can experimental conditions explain the discrepancy over glutamate stimulation of aerobic glycolysis? Hertz L, et al. **Dev Neurosci** 1998;20(4-5):339-47

Application of metabolic control analysis to the study of toxic effects of copper in muscle glycolysis. Jannaschk D, et al. **FEBS Lett** 1999 Feb 19;445(1):144-8

Influence of Coccinia indica on certain enzymes in glycolytic and lipolytic pathway in human diabetes. Kamble SM, et al. **Indian J Med Sci** 1998 Apr;52(4):143-6

Mechanisms of insulin resistance in non-oxidative glucose metabolism: the role of glycogen synthase. Beck-Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):255-79 (39 ref.)

An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. Schurr A, et al. **J Neurosci** 1999 Jan 1;19(1):34-9

Feeding a low energy diet and refeeding a control diet affect glycolysis differently in the slow- and fast-twitch muscles of adult male Wistar rats. Bissonnette DJ, et al. **J Nutr** 1998 Oct;128(10):1723-30

Effects of Ca(2+)-ionophore A23187 and calmodulin antagonists on regulatory mechanisms of glycolysis and cell viability of NIH-3T3 fibroblasts. Ashkenazy-Shahar M, et al. **Mol Genet Metab** 1999 Aug;67(4):334-42

Distinct glycolysis inhibitors determine retinal cell sensitivity to glutamate-mediated injury. Rego AC, et al. **Neurochem Res** 1999 Mar;24(3):351-8

Hyper-responsiveness of adrenal sympathetic nerve activity in spontaneously hypertensive rats to ganglionic blockade, mental stress and neuronglucopenia. Zhang W, et al. **Pflugers Arch** 1998 Dec;437(1):56-60

GENETICS

A human gene, hSGT1, can substitute for GCR2, which encodes a general regulatory factor of glycolytic gene expression in Saccharomyces cerevisiae. Sato T, et al. **Mol Gen Genet** 1999 Jan;260(6):535-40

Glucose metabolism in Chlamydia trachomatis: the 'energy parasite' hypothesis revisited. Iliffe-Lee ER, et al. **Mol Microbiol** 1999 Jul;33(1):177-87

PHYSIOLOGY

Calories and aging alter gene expression for gluconeogenic, glycolytic, and nitrogen-metabolizing enzymes. Dhahbi JM, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E352-60

Colocalization of glycolytic enzyme activity and KATP channels in basolateral membrane of Necturus enterocytes. Dubinsky WP, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1653-9

Comparative study of free and bound glycolytic enzymes from sea scorpion brain. Lushchak VI, et al. **Biochem Cell Biol** 1998;76(4):609-14

The structural design of glycolysis: an evolutionary approach. Heinrich R, et al. **Biochem Soc Trans** 1999 Feb; 27(2):294-8 (11 ref.)

Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study. Lodi R, et al. **Brain** 1999 Jan;122 (Pt 1):121-30

Effect of hypoxia on the activity and binding of glycolytic and associated enzymes in sea scorpion tissues. Lushchak VI, et al. **Braz J Med Biol Res** 1998 Aug;31(8):1059-67

Regulation of cation transport pathways and glycolytic enzyme activity by alterations in red cell volume. Kaloyianni M, et al. **Cell Biochem Funct** 1999 Jun; 17(2):75-88

Comments on metabolic needs for glucose and the role of gluconeogenesis. Brosnan JT. **Eur J Clin Nutr** 1999 Apr; 53 Suppl 1:S107-11 (25 ref.)

Hypothermia attenuates hyperglycolysis in the periphery of ischemic core in rat brain. Tohyama Y, et al. **Exp Brain Res** 1998 Oct;122(3):333-8

Identification and characterisation of early reactions of asparagine-linked oligosaccharide assembly in Entamoeba histolytica. Vargas-Rodriguez L, et al. **Int J Parasitol** 1998 Sep;28(9):1333-40

What controls glycolysis in bloodstream form Trypanosoma brucei? Bakker BM, et al. **J Biol Chem** 1999 May 21; 274(21):14551-9

Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. Discher DJ, et al. **J Biol Chem** 1998 Oct 2; 273(40):26087-93

Myogenin induces a shift of enzyme activity from glycolytic to oxidative metabolism in muscles of transgenic mice. Hughes SM, et al. **J Cell Biol** 1999 May 3;145(3):633-42

Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. Mazurek S, et al. **J Cell Physiol** 1999 Oct;181(1):136-46

The role of glycolysis in myocardial calcium control. Aasum E, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1703-12

Astrocytes respond to hypoxia by increasing glycolytic capacity. Marrif H, et al. **J Neurosci Res** 1999 Jul 15; 57(2):255-60

Glycolysis is independent of oxygenation state in stimulated human skeletal muscle in vivo. Conley KE, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):935-45

Preferential regulation of rabbit cardiac L-type Ca2+ current by glycolytic derived ATP via a direct allosteric pathway. Losito VA, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):67-78

Hindlimb ischemia-reperfusion increases complement deposition and glycolysis. Wong MS, et al. **J Surg Res** 1999 Jul;85(1):130-5

Enhanced glycolysis after maturation of bovine oocytes in vitro is associated with increased developmental competence. Krisher RL, et al. **Mol Reprod Dev** 1999 May; 53(1):19-26

Increased erythrocyte deformability in fetal erythropoiesis and in erythrocytes deficient in glucose-6-phosphate dehydrogenase and other glycolytic enzymes. Johnson RM, et al. **Pediatr Res** 1999 Jan;45(1):106-13

Location-location-location. Srere PA, et al. **Trends Biochem Sci** 1998 Sep;23(9):319-20 (24 ref.)

The role of glucose 6-phosphate in yeast glycolysis [letter; comment] Boles E. **Trends Microbiol** 1998 Dec;6(12):472-3
Comment on: Trends Microbiol 1998 Aug;6(8):314-9.

GLYCOPEPTIDES

Novel lipoamino acid- and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. Tóth I, et al. **J Med Chem** 1999 Sep 23;42(19):4010-3

ANALYSIS

Analysis of phospho- and glycopolypeptides with infrared matrix-assisted laser desorption and ionization. Cramer R, et al. **Anal Chem** 1998 Dec 1;70(23):4939-44

Release and analysis of polypeptides and glycopolypeptides from formalin-fixed, paraffin wax-embedded tissue. Brooks SA, et al. **Histochem J** 1998 Aug;30(8):609-15

BIOSYNTHESIS

Molecular mechanism of VanHst, an alpha-ketoacid dehydrogenase required for glycopeptide antibiotic resistance from a glycopeptide producing organism. Marshall CG, et al. **Biochemistry** 1999 Jun 29; 38(26):8485-91

Identification and recombinant expression of a Mycobacterium avium rhamnosyltransferase gene (rtfA) involved in glycopeptidolipid biosynthesis. Eckstein TM, et al. **J Bacteriol** 1998 Nov;180(21):5567-73

CHEMICAL SYNTHESIS

Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Hoffmann R, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):459-67

Structure-binding relationships for the interaction between a vancomycin monoclonal antibody Fab fragment and a library of vancomycin analogues and tracers. Adamczyk M, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):176-85

Diversity of C-linked neoglycopeptides for the exploration of subsite-assisted carbohydrate binding interactions. Arya P, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1127-32

Synthesis of a high-mannose-type glycopeptide analog containing a glucose-asparagine linkage. Deras IL, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1763-6

Synthesis of sialyl Lewis X mimetics using the Ugi four-component reaction. Tsai CY, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2333-8

RGDS glycosylated peptides as inhibitors of cell-attachment and platelet aggregation. Harth-Fritschy E, et al. **J Pept Res** 1998 Jul;52(1):51-9

A concise methodology for the stereoselective synthesis of O-glycosylated amino acid building blocks: complete 1H NMR assignments and their application in solid-phase glycopeptide synthesis. Satyanarayana J, et al. **J Pept Res** 1998 Sep;52(3):165-79

CHEMISTRY

Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. McManus AM, et al. **Biochemistry** 1999 Jan 12;38(2):705-14

Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon. Hanessian S, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2441-6

The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Badcock G, et al. **Cancer Res** 1999 Sep 15;59(18):4715-9

Analysis of specific interactions of synthetic glycopolypeptides carrying N-acetyllactosamine and related compounds with lectins. Zeng X, et al. **Carbohydr Res** 1998 Nov;312(4):209-17

High prevalence of 2-mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain glycopeptides by reductive alkaline hydrolysis. Chai W, et al. **Eur J Biochem** 1999 Aug;263(3):879-88

NMR and molecular modeling studies on two glycopeptides from the carbohydrate-protein linkage region of connective tissue proteoglycans. Agrawal PK, et al. **Glycobiology** 1999 Jul;9(7):669-77

Different O-glycosylation of respiratory mucin glycopeptides from a patient with cystic fibrosis. Thomsson KA, et al. **Glycoconj J** 1998 Aug;15(8):823-33

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Glithero A, et al. **Immunity** 1999 Jan;10(1):63-74

Polypeptide-polysaccharide conjugates produced by spontaneous non-enzymatic glycation. Berry L, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):434-9

'Wave-type' structure of a synthetic hexaglycosylated decapeptide: a part of the extracellular domain of human glycophorin A. Schuster O, et al. **J Biomol NMR** 1999 May;14(1):33-45

Peptide and glycopeptide dendrimers. Part II. Veprek P, et al. **J Pept Sci** 1999 May;5(5):203-20 (154 ref.)

Analysis of peptidogalactomannans from the mycelial surface of Aspergillus fumigatus. Haido RM, et al. **Med Mycol** 1998 Oct;36(5):313-21

Structural characterization of the N-linked oligosaccharides from tomato fruit. Zeleny R, et al. **Phytochemistry** 1999 May;51(2):199-210

GENETICS

Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of a VanB-type Enterococcus faecalis. Baptista M, et al. **Mol Microbiol** 1999 Apr;32(1):17-28

IMMUNOLOGY

Structure-binding relationships for the interaction between a vancomycin monoclonal antibody Fab fragment and a library of vancomycin analogues and tracers. Adamczyk M, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):176-85

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Glithero A, et al. **Immunity** 1999 Jan;10(1):63-74

Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Speir JA, et al. **Immunity** 1999 Jan;10(1):51-61

MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. Deck MB, et al. **J Immunol** 1999 Apr 15;162(8):4740-4

Rapid serodiagnosis of Mycobacterium avium-intracellulare complex infection by ELISA with cord factor (trehalose 6, 6'-dimycolate), and serotyping using the glycopeptidolipid antigen. Enomoto K, et al. **Microbiol Immunol** 1998;42(10):689-96

Effect of polar glycopeptidolipids from Mycobacterium chelonae (GPLp-Mc) on phagocytosis and superoxide anion production of macrophages from mice. Influence of physical activity. Garcia Garcia JJ, et al. **Mol Cell Biochem** 1998 Jun;183(1-2):159-63

Immunological and ultrastructural disruptions of T lymphocytes following exposure to the glycopeptidolipid isolated from the Mycobacterium avium complex. Pourshafie MR, et al. **Scand J Immunol** 1999 Apr; 49(4):405-10

ISOLATION & PURIFICATION

Isolation, partial characterization and biological activity of mannosyl glycopeptides from seminal plasma. Lopes CH, et al. **Glycoconj J** 1998 May;15(5):477-81

Separation of enantiomers on a chiral stationary phase based on ovoglycoprotein. V. Influence of immobilization method on chiral resolution. Haginaka J, et al. **J Chromatogr A** 1999 Apr 30;840(2):171-81

Mutual separation of hinge-glycopeptide isomers bearing five N-acetylgalactosamine residues from normal human serum immunoglobulin A1 by capillary electrophoresis. Iwase H, et al. **J Chromatogr B Biomed Sci Appl** 1999 May 28; 728(2):175-83

METABOLISM

Partial vapor-phase hydrolysis of peptide bonds: A method for mass spectrometric determination of O-glycosylated sites in glycopeptides. Mirgorodskaya E, et al. **Anal Biochem** 1999 Apr 10;269(1):54-65

Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides. Spencer DI, et al. **Biospectroscopy** 1999;5(2):79-91

Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides. Iida S, et al. **J Biol Chem** 1999 Apr 16; 274(16):10697-705

MHC-restricted, glycopeptide-specific T cells show

specificity for both carbohydrate and peptide residues. Deck MB, et al. **J Immunol** 1999 Apr 15;162(8):4740–4
Role for cell adhesion and glycosyl (HNK-1 and oligomannoside) recognition in the sharpening of the regenerating retinotectal projection in goldfish. Schmidt JT, et al. **J Neurobiol** 1998 Dec;37(4):659–71

PHARMACOLOGY

Validity of screening procedures for glycopeptide-resistant enterococci. Wendt C, et al.
Eur J Clin Microbiol Infect Dis 1999 Jun;18(6):422–7
Intrathecal administration of p-hydroxymercuribenzoate or phosphoramidon/bestatin-combined induces antinociceptive effects through different opioid mechanisms. Tan-No K, et al. **Neuropeptides** 1998 Oct; 32(5):411–5
Characterization of tachykinin receptors mediating bronchomotor and vasodepressor responses to neuropeptide gamma and substance P in the anaesthetized rabbit. Yuan L, et al. **Pulm Pharmacol Ther** 1998 Feb; 11(1):31–9
Effects of macrophage inhibitory factor-A3 (MIF-A3) on cytokine secretion and phagolysosome fusion in murine macrophages. Hines ME 2nd, et al. **Vet Microbiol** 1999 Feb 23;65(1):47–60

THERAPEUTIC USE

[Glycopeptides in lung and bone diseases in children] Gendrel D. **Presse Med** 1999 Apr 3;28(13):718–9 **(Fre)**
[Glycopeptides: mechanism of action and of resistance] Leclercq R. **Presse Med** 1999 Apr 3;28(13):720–1 **(Fre)**
[The role of glycopeptides in hematology] Tourniaire B. **Presse Med** 1999 Apr 10;28(14):764–5 **(Fre)**

GLYCOPHORIN

ANALYSIS

Analysis of receptor for Vibrio cholerae El tor hemolysin with a monoclonal antibody that recognizes glycophorin B of human erythrocyte membrane. Zhang D, et al. **Infect Immun** 1999 Oct;67(10):5332–7
NOR polyagglutination and Sta glycophorin in one family: relation of NOR polyagglutination to terminal alpha-galactose residues and abnormal glycolipids. Kuśnierz-Alejska G, et al. **Transfusion** 1999 Jan;39(1):32–8

CHEMICAL SYNTHESIS

Preparation of insoluble transmembrane peptides: glycophorin-A, prion (110–137), and FGFR (368–397). Glover KJ, et al. **Anal Biochem** 1999 Aug 1;272(2):270–4

CHEMISTRY

'Wave-type' structure of a synthetic hexaglycosylated decapeptide: a part of the extracellular domain of human glycophorin A. Schuster O, et al. **J Biomol NMR** 1999 May;14(1):33–45

GENETICS

Expression of the membrane protein glycophorin A as a fusion with the antibiotic resistance protein neomycin phosphotransferase II. Krömer WJ, et al.
Biotechnol Bioeng 1998 Jan 20;57(2):238–44
XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Lunn RM, et al. **Cancer Res** 1999 Jun 1;59(11):2557–61
Substitution of the insulin receptor transmembrane domain with that of glycophorin A inhibits insulin action. Gardin A, et al. **FASEB J** 1999 Aug;13(11):1347–57
Diagnosis of ataxia telangiectasia with the glycophorin A somatic mutation assay. Grant SG, et al. **Genet Test** 1997-98;1(4):261–7
In vivo somatic mutations in Werner's syndrome. Kyoizumi S, et al. **Hum Genet** 1998 Oct;103(4):405–10
Polymarker, HLA-DQA1, and D1S80 allele frequency data in Chamorro and Filipino populations from Guam. Budowle B, et al. **J Forensic Sci** 1998 Nov;43(6):1195–8
Glycophorin A mutation Ala65 —> Pro gives rise to a novel pair of MNS alleles ENEP (MNS39) and HAG (MNS41) and altered Wrb expression: direct evidence for GPA/band 3 interaction necessary for normal Wrb expression. Poole J, et al. **Transfus Med** 1999 Jun;9(2):167–74
[One type of new glycophorin variant found in Hunan] Xia H, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):185–6 **(Chi)**
[Long-term effects of chronic radiation exposure on the level of somatic mutations in peripheral blood cells] Akleev AV, et al. **Radiats Biol Radioecol** 1998 Jul-Aug;38(4):573–85 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Shared epitopes of glycoprotein A and protein 4.1 defined by antibody NaM10-3C10. Rasamoelisolo M, et al.
Hybridoma 1998 Jun;17(3):283–8
Removal of erythroid cells from umbilical cord blood mononuclear cell preparations using magnetic beads and a monoclonal antibody against glycophorin A. Elliott SR, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):121–30
Fine specificities of murine anti-Mg monoclonal antibodies. Jaśkiewicz E, et al. **Transfus Med** 1999 Jun;9(2):161–6
Use of a phycoerythrin-conjugated anti-glycophorin A monoclonal antibody as a double label to improve the accuracy of FMH quantification by flow cytometry. Lloyd-Evans P, et al. **Transfus Med** 1999 Jun;9(2):155–60
The murine monoclonal antibody NaM26-4C6 identifies a common structure on band 3 and glycophorin C. Loirat MJ, et al. **Transfus Med** 1999 Mar;9(1):69–79

METABOLISM

Evidence for age-related deamidation reactions in erythrocyte p55 and glycophorins C and D: implications for signal transduction involving tumour-suppressor proteins in higher eukaryotes. Lofthouse JT.
Med Hypotheses 1998 Oct;51(4):321–4 (14 ref.)

PHYSIOLOGY

Effects of anti-M antiserum on surface charge of red cells. Foresto P, et al. **Clin Hemorheol Microcirc** 1999;20(2):141–3

GLYCOPROTEIN HORMONES, ALPHA SUBUNIT

ANALYSIS

TSH expression in murine hypophyseal pars tuberalis-specific cells. Bockmann J, et al. **Acta Anat (Basel)** 1997; 160(3):189–94
Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. Hayes FJ, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1028–36
[Clinical use of a quadruple biochemical marker in the prediction of obstetric complications] Aranda Gallegos JE, et al. **Ginecol Obstet Mex** 1999 Jan;67:18–22 (Eng. Abstr.) **(Spa)**

BLOOD

Pituitary glycoprotein hormone a-subunit secretion by cirrhotic patients. Oliveira MC, et al.
Braz J Med Biol Res 1999 Jan;32(1):73–7
Biochemical markers for clinically non-functioning pituitary tumours. Harris PE. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):163–4
Response of the free alpha-subunit to GnRH distinguishes individuals with 'functional' from those with permanent hypogonadotropic hypogonadism. Mainieri AS, et al.
Horm Res 1998;50(4):212–6
Free alpha-subunits of human chorionic gonadotropin in preeclampsia. Moodley D, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):283–7
Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas. Vantyghem MC, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):434–40
Alpha subunit of glycoprotein hormones in the sera of acromegalic patients and its mRNA in the tumors. Machiavelli GA, et al. **Neurol Res** 1999 Apr;21(3):247–9
The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors. Popovic V, et al. **Thyroid** 1998 Oct;8(10):935–9

CHEMISTRY

Solution structure of the alpha-subunit of human chorionic gonadotropin. Erbel PJ, et al. **Eur J Biochem** 1999 Mar; 260(2):490–8

GENETICS

Influence of a cap site element on tissue-restricted expression of the glycoprotein hormone alpha-subunit gene. Cox GS, et al. **Biochem Biophys Res Commun** 1999 Jul 14; 260(3):752–9
Effect of site directed mutagenesis in the CMGCC region of the alpha-subunit on immunoreactive human thyrotropin. Miyai K, et al. **Endocr J** 1998 Aug; 45(4):467–73
Thyroid hormone is essential for pituitary somatotropes and lactotropes. Stahl JH, et al. **Endocrinology** 1999 Apr; 140(4):1884–92
Cloning of cDNAs for the pituitary glycoprotein hormone alpha subunit precursor molecules in three amphibian species, Bufo japonicus, Rana catesbeiana, and Cynops pyrrhogaster. Arai Y, et al. **Gen Comp Endocrinol** 1998 Oct;112(1):46–53
Mechanisms that mediate negative regulation of the thyroid-stimulating hormone alpha gene by the thyroid hormone receptor. Tagami T, et al. **J Biol Chem** 1999 Aug 6;274(32):22345–53
An upstream regulator of the glycoprotein hormone alpha-subunit gene mediates pituitary cell type activation and repression by different mechanisms. Wood WM, et al. **J Biol Chem** 1999 May 28;274(22):15526–32
Sodium butyrate-mediated induction of the glycoprotein hormone alpha-subunit gene: requirement for continued protein synthesis, identification of a butyrate-responsive element, and inhibition of promoter activation by 2-deoxyglucose. Haas MJ, et al. **J Cell Biochem** 1999 Aug 1;74(2):242–63
Activation of the glycoprotein hormone alpha-subunit gene promoter in thyrotropes. Sarapura VD, et al.
Mol Cell Endocrinol 1998 Nov 25;146(1-2):77–86
Functional interactions of an upstream enhancer of the mouse glycoprotein hormone alpha-subunit gene with proximal promoter sequences. Wood WM, et al.
Mol Cell Endocrinol 1998 Jul 25;142(1-2):141–52
Cyclic AMP- and differentiation-dependent regulation of the proximal alphaHCG gene promoter in term villous trophoblasts. Knöfler M, et al. **Mol Hum Reprod** 1999 Jun; 5(6):573–80
Alpha subunit of glycoprotein hormones in the sera of acromegalic patients and its mRNA in the tumors. Machiavelli GA, et al. **Neurol Res** 1999 Apr;21(3):247–9

IMMUNOLOGY

Characterization of monoclonal antibodies recognizing alpha and beta subunits of human chorionic gonadotropin hormone. Tayapiwatana C, et al.
Asian Pac J Allergy Immunol 1998 Jun-Sep;16(2-3):127–35

METABOLISM

Zonal variation in the distribution of an alpha 1-acid glycoprotein glycoform receptor in human adrenal cortex. Andersen UO, et al. **Acta Histochem** 1999 Feb;101(1):113–9
The alpha-subunit of human choriogonadotropin interacts with the exodomain of the luteinizing hormone/choriogonadotropin receptor. Hong S, et al.
Endocrinology 1999 Jun;140(6):2486–93
Expression of the alpha- and beta-subunits of human chorionic gonadotropin by subsets of parathyroid cells in states of hyperparathyroidism. Carlinfante G, et al.
J Pathol 1998 Aug;185(4):389–93
The beta-subunit of human choriogonadotropin interacts with the exodomain of the luteinizing hormone/choriogonadotropin receptor and changes its interaction with the alpha-subunit. Hong SH, et al.
Mol Endocrinol 1999 Aug;13(8):1285–94

PHYSIOLOGY

Functional uncoupling between intracellular calcium dynamics and secretion in the alphaT3-1 gonadotropic cell line. Trueta C, et al. **J Cell Physiol** 1999 Jun;179(3):347–57

SECRETION

Free alpha-subunit and intact TSH secretion in vitro are closely associated in human somatotroph adenomas. Aylwin SJ, et al. **Eur J Endocrinol** 1998 Oct;139(4):378–86

GLYCOPROTEIN SIALYLTRANSFERASES see **SIALYLTRANSFERASES**

GLYCOPROTEIN SYNDROME, CARBOHYDRATE-DEFICIENT see **CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME**

GLYCOPROTEINS

New clothes for amyloid enhancing factor (AEF): silk as AEF. Kisilevsky R, et al. **Amyloid** 1999 Jun;6(2):98–106
Structure, function and evolution of antifreeze proteins. Ewart KV, et al. **Cell Mol Life Sci** 1999 Feb;55(2):271–83 (84 ref.)
A thin glycoprotein coating of a synthetic lenticule does not cause nutritional deficiency of the anterior cornea. Xie RZ, et al. **Curr Eye Res** 1999 May;18(5):335–41
Evaluation of materials used for bedding encasement: effect of pore size in blocking cat and dust mite allergen. Vaughan JW, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):227–31
Dust anchoring characteristics of electret fibres with respect to Der p 1 allergen carrying particles. Gaynor PT, et al. **Med Biol Eng Comput** 1998 Sep;36(5):615–20
Partial protection of mice against Trypanosoma cruzi after immunizing with the TcY 72 antigenic preparation. Gomes YM, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr; 94(2):167–72
Pitfalls in evaluating mite exposure from house-dust samples. Hallas TE. **Respir Med** 1998 Sep;92(9):1099–101
[Regulation of prostate gland-specific gene expression] Ueyama H, et al. **Seikagaku** 1999 Mar;71(3):210–4 (17 ref.) **(Jpn)**
[Direct promotion of polypeptide folding by asnglycans] Yamaguchi H. **Seikagaku** 1999 Mar;71(3):201–5 (9 ref.) **(Jpn)**
[Development of streptavidin-based neoglycoprotein as a glycoprobe] Hashimoto Y, et al.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2479–83 (4 ref.) **(Jpn)**
[Basic study on glyco chains] Suzuki A.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2631–9 (4 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Bousquet J, et al. **Allergy** 1999 Mar;54(3):249–60
An in vivo study of antifreeze protein adjuvant cryosurgery. Pham L, et al. **Cryobiology** 1999 Mar;38(2):169–75
Oral tolerance induced to house dust mite extract in naive

and sensitized mice: evaluation of immunoglobulin G anti-immunoglobulin E autoantibodies and IgG-IgE complexes. Sato MN, et al. **Immunology** 1998 Oct; 95(2):193-9

Repeated intratracheal inoculation of house dust mite (Dermatophagoides farinae) induces pulmonary eosinophilic inflammation and IgE antibody production in mice. Yu CK, et al. **J Allergy Clin Immunol** 1999 Jul; 104(1):228-36

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. Haselden BM, et al. **J Exp Med** 1999 Jun 21;189(12):1885-94

Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. Blank M, et al. **J Immunol** 1998 Nov 15; 161(10):5303-12

Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters. Muro MD, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun; 9(3):146-54

Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. Tabar AI, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun; 9(3):155-64

Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Afek A, et al. **Pathobiology** 1999;67(1):19-25

[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin] Matsukawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov; 95(11):1229-34 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Ohashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:113-7

The role of dust mite antigen sensitization and atopic dermatitis [editorial; comment] Friedmann PS. **Clin Exp Allergy** 1999 Jul;29(7):869-72 (34 ref.). Comment on: Clin Exp Allergy 1999 Jul;29(7):920-5.

Inverse correlation of domestic exposure to Dermatophagoides pteronyssinus antigen patch test reactivity in patients with atopic dermatitis [see comments] Gutgesell C, et al. **Clin Exp Allergy** 1999 Jul;29(7):920-5 . Comment in: Clin Exp Allergy 1999 Jul;29(7):869-72.

Association between Der p 1 concentration and peak expiratory flow rate in children with wheeze: a longitudinal analysis. Jalaludin B, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):382-6

ANALYSIS

The effect of dry heat on mite, cat, and dog allergens. Cain G, et al. **Allergy** 1998 Dec;53(12):1213-5

Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Ciprandi G, et al. **Allergy** 1999 Apr; 54(4):358-65

A pilot study of the effect of mechanical ventilation and heat exchange on house-dust mites and Der p 1 in New Zealand homes. Crane J, et al. **Allergy** 1998 Aug;53(8):755-62

Deposition of cat (Fel d 1), dog (Can f 1), and horse allergen over time in public environments--a model of dispersion. Egmar AC, et al. **Allergy** 1998 Oct;53(10):957-61

Mite elimination--clinical effect on eczema. Friedmann PS, et al. **Allergy** 1998;53(48 Suppl):97-100

Mite-allergen levels in Norwegian homes. Gaarder PI. **Allergy** 1998;53(48 Suppl):58-9 (13 ref.)

Indoor environmental factors associated with house-dust-mite allergen (Der p 1) levels in south-eastern Australian houses. Garrett MH, et al. **Allergy** 1998 Nov; 53(11):1060-5

Mite allergens in feather and synthetic pillows. Hallam C, et al. **Allergy** 1999 Apr;54(4):407-8

Identification and quantification of mite allergens. Luczynska CM. **Allergy** 1998;53(48 Suppl):54-7 (26 ref.)

House-dust-mite allergen (Der p 1) levels in university colleges. Mahmic A, et al. **Allergy** 1998 Oct;53(10):976-80

Complete mattress encasing is not superior to partial encasing in the reduction of mite allergen. Vichyanond P, et al. **Allergy** 1999 Jul;54(7):736-41

Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Postle AD, et al. **Am J Respir Cell Mol Biol** 1999 Jan;20(1):90-8

Systematic analysis of N-linked sugar chains from whole tissue employing partial automation. Fujimoto I, et al. **Anal Biochem** 1999 Feb 15;267(2):336-43

Quantitative cleavage of the N-glycosidic bond under the normal conditions of methanolysis used for the analysis of glycoprotein monosaccharides. Maes E, et al. **Anal Biochem** 1999 Feb 15;267(2):300-8

High-performance liquid chromatography in clinical analysis. Anderson DJ. **Anal Chem** 1999 Jun 15; 71(12):314R-327R (379 ref.)

18O-labeling of N-glycosylation sites to improve the identification of gel-separated glycoproteins using peptide mass mapping and database searching. Küster B, et al. **Anal Chem** 1999 Apr 1;71(7):1431-40

Effect of two different types of vacuum cleaners on airborne Fel d 1 levels. Rønborg SM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):307-10

Expression of novel surface antigens on early hematopoietic cells. Bühring HJ, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:25-38; discussion 38-9

Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. al Moustafa AE, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):481-6

Overview of N- and O-linked oligosaccharide structures found in various yeast species. Gemmill TR, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):227-37 (96 ref.)

Identification of naturally occurring follistatin complexes in human biological fluids. Wang EY, et al. **Biol Reprod** 1999 Jan;60(1):8-13

Ruthenium red preserves glycoprotein peplomers of C-type retroviruses for transmission electron microscopy. Fassel TA, et al. **Biotech Histochem** 1998 Jul;73(4):222-7

Immunofluorescence localization of glycoproteins using tissue printing: detection of pistil extensin-like proteins in tobacco. Pierson ES, et al. **Biotechniques** 1999 Mar; 26(3):450-3

The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Badcock G, et al. **Cancer Res** 1999 Sep 15;59(18):4715-9

Localization and identification of galactose/N-acetylgalactosamine and sialic acid-containing proteins in Chinese hamster metaphase chromosomes. Myllyharju J, et al. **Cell Biol Int** 1998; 22(2):85-9

The oligomeric integrity of toposome is essential for its morphogenetic function. Scaturro G, et al. **Cell Biol Int** 1998;22(4):321-6

Immunohistochemical demonstration of inter-alpha-trypsin inhibitor light chain (bikunin) in human mast cells. Ide H, et al. **Cell Tissue Res** 1999 Jul;297(1):149-54

The distribution of sugar chains on the vomeronasal epithelium observed with an atomic force microscope. Osada T, et al. **Chem Senses** 1999 Feb;24(1):1-6

Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. George J, et al. **Circulation** 1999 May 4;99(17):2227-30

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Steinberg J, et al. **Clin Cancer Res** 1997 Oct;3(10):1707-11

On carpets, construction and covers [editorial; comment] Brunekreef B. **Clin Exp Allergy** 1999 Apr;29(4):433-5. Comment on: Clin Exp Allergy 1999 Apr;29(4):461-9.

Do mite avoidance measures affect mite and cat airborne allergens? Carswell F, et al. **Clin Exp Allergy** 1999 Feb; 29(2):193-200

Feather or synthetic? That is the question [editorial; comment] [see comments] Custovic A, et al. **Clin Exp Allergy** 1999 Feb;29(2):144-7 (32 ref.). Comment on: Clin Exp Allergy 1999 Feb;29(2):182-5. Comment in: Clin Exp Allergy 1999 Apr;29(4):429-32.

Residential characteristics influence Der p 1 levels in homes in Melbourne, Australia [see comments] Dharmage S, et al. **Clin Exp Allergy** 1999 Apr;29(4):461-9. Comment in: Clin Exp Allergy 1999 Apr;29(4):433-5.

Indoor factors associated with concentrations of house dust mite allergen, Der p 1, in a random sample of houses in Norwich, UK. Luczynska C, et al. **Clin Exp Allergy** 1998 Oct;28(10):1201-9

House dust mite allergen exposure in infancy. Mahmic A, et al. **Clin Exp Allergy** 1998 Dec;28(12):1487-92

House dust mite allergen (Der p 1) accumulation on new synthetic and feather pillows [see comments] Rains N, et al. **Clin Exp Allergy** 1999 Feb;29(2):182-5. Comment in: Clin Exp Allergy 1999 Feb;29(2):144-7. Comment in: Clin Exp Allergy 1999 Apr;29(4):429-32.

Fel d 1 and Can f 1 in settled dust and airborne Fel d 1 in allergen avoidance day-care centres for atopic children in relation to number of pet-owners, ventilation and general cleaning. Wickman M, et al. **Clin Exp Allergy** 1999 May; 29(5):626-32

Receptors for collapsin/semaphorins. Fujisawa H, et al. **Curr Opin Neurobiol** 1998 Oct;8(5):587-92 (61 ref.)

Accurate detection of both glycoproteins and total proteins on blots: control of side reactions occurring after periodate oxidation of proteins. Bouchez-Mahiout I, et al. **Electrophoresis** 1999 Jun;20(7):1412-7

Profiling glycoprotein n-linked oligosaccharide by capillary electrophoresis. Chen FT, et al. **Electrophoresis** 1998 Nov; 19(15):2639-44

The combination of Indian ink staining with immunochemiluminescence detection allows precise identification of antigens on blots: application to the study of glycosylated barley storage proteins. Eynard L, et al. **Electrophoresis** 1998 Jun;19(8-9):1394-6

Glycobiology and proteomics: is mass spectrometry the Holy Grail? Packer NH, et al. **Electrophoresis** 1998 Aug; 19(11):1872-82 (62 ref.)

Analyzing glycoproteins separated by two-dimensional gel electrophoresis. Packer NH, et al. **Electrophoresis** 1998 May;19(6):981-8

Electrophoretic methods for process monitoring and the quality assessment of recombinant glycoproteins. Taverna M, et al. **Electrophoresis** 1998 Nov;19(15):2572-94 (186 ref.)

Expression and localisation of stanniocalcin 1 in rat bladder, kidney and ovary. Worthington RA, et al. **Electrophoresis** 1999 Jul;20(10):2071-6

Variability of house dust mite allergen exposure in dwellings. Hirsch T, et al. **Environ Health Perspect** 1998 Oct; 106(10):659-64

Re: Procalcitonin: a new parameter for the diagnosis of bacterial infection in the perioperative period. Oczenski et al., Eur J Anaesthesiol 1998; 15: 129-132 [letter; comment] Reinhart K, et al. **Eur J Anaesthesiol** 1998 Sep; 15(5):618-9. Comment on: Eur J Anaesthesiol 1998 Mar;15(2):202-9.

In situ detection of a fungal glycoprotein-elicitor in stem rust-infected susceptible and resistant wheat using immunogold electron microscopy. Particke KH, et al. **Eur J Cell Biol** 1998 Aug;76(4):265-73

Diagnostic value of CA 72-4 and carcinoembryonic antigen determination in the fluid of pancreatic cystic lesions. Hammel P, et al. **Eur J Gastroenterol Hepatol** 1998 Apr; 10(4):345-8

Glycoproteins of trabecular meshwork, cornea and sclera. Chapman SA, et al. **Eye** 1998;12 (Pt 3a):440-8

Carcinoembryonic antigen-related cell-cell adhesion molecule C-CAM is greatly increased in serum and urine of rats with liver diseases. Lucka L, et al. **FEBS Lett** 1998 Oct 30;438(1-2):37-40

Observations of high iron diamine-alcian blue stain in uterine cervical glandular lesions. Kase H, et al. **Gynecol Obstet Invest** 1999;48(1):56-60

Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy. Rawal RM, et al. **Head Neck** 1999 May;21(3):192-7

Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells. Moore EE, et al. **Horm Metab Res** 1999 Jul;31(7):406-14

Endometrial protein PP14 and CA-125 in recurrent miscarriage patients: correlation with pregnancy outcome. Dalton CF, et al. **Hum Reprod** 1998 Nov;13(11):3197-202

Concentrations of placental protein 14 in uterine flushings from infertile women: validation of the collection technique and method of expression of results. Hamilton JA, et al. **Hum Reprod** 1998 Dec;13(12):3357-62

Identification of a glycoprotein produced by enterotoxigenic Escherichia coli. Lindenthal C, et al. **Infect Immun** 1999 Aug;67(8):4084-91

Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. van Hal NL, et al. **Int J Cancer** 1999 Sep 9;82(6):837-45

Molecular heterogeneity of hCGbeta--related glycoproteins and the clinical relevance in trophoblastic and non-trophoblastic tumors. Nishimura R, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S29-32

School as a risk environment for children allergic to cats and a site for transfer of cat allergen to homes [see comments] Almqvist C, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1012-7. Comment in: J Allergy Clin Immunol 1999 Jun;103(6):1002-4.

Evaluation of air and dust sampling schemes for Fel d 1, Der f 1, and Der p 1 allergens in homes in the Detroit area. Peterson EL, et al. **J Allergy Clin Immunol** 1999 Aug; 104(2 Pt 1):348-55

Bikunin, a serine protease inhibitor, is present on the cell boundary of epidermis. Cui CY, et al. **J Invest Dermatol** 1999 Aug;113(2):182-8

SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. Chiu YY, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):239-44

Evaluation of adsorption preconcentration/capillary zone electrophoresis/nanoelectrospray mass spectrometry for peptide and glycoprotein analyses. Bateman KP, et al. **J Mass Spectrom** 1998 Nov;33(11):1109-23

Quantitative analysis of Gly m Bd 28K in soybean products by a sandwich enzyme-linked immunosorbent assay. Bando N, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Oct; 44(5):655-64

Salivary histatins in patients with recurrent oral candidiasis. Bercier JG, et al. **J Oral Pathol Med** 1999 Jan;28(1):26-9

Glycoprotein detection of 2-D separated proteins. Packer NH, et al. **Methods Mol Biol** 1999;112:341-52 (4 ref.)

Stromelysins in placental membranes and amniotic fluid with premature rupture of membranes. Fortunato SJ, et al. **Obstet Gynecol** 1999 Sep;94(3):435-40

Changes in lectin binding patterns in rat esophageal epithelium during development. Fukawa W, et al. **Okajimas Folia Anat Jpn** 1999 Mar;75(6):335-44

Comparison of p53 and CD44 variant 6 expression between paired primary and recurrent ovarian cancer: an immunohistochemical analysis. Kamura T, et al. **Oncol Rep** 1999 Jan-Feb;6(1):97-101

Expression of protective protein in human tissue. Sohma O, et al. **Pediatr Neurol** 1999 Mar;20(3):210-4

Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk-fed preterm infants. Peterson JA, et al. **Pediatr Res** 1998 Oct;44(4):499-506

Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma. Michaels EK, et al. **Urology** 1998 Nov;52(5):920-4

ANTAGONISTS & INHIBITORS

Fluoride inhibition of bovine spleen purple acid phosphatase: characterization of a ternary enzyme-phosphate-fluoride

complex as a model for the active enzyme-substrate-hydroxide complex. Pinkse MW, et al. **Biochemistry** 1999 Aug 3;38(31):9926–36

The design and synthesis of inhibitors of the cysteinyl protease, Der p I. Billson J, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):993–8

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis [see comments] Hofbauer LC, et al. **Endocrinology** 1999 Oct;140(10):4382–9 . Comment in: Endocrinology 1999 Oct;140(10):4377–81.

Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist. Banno H, et al. **Eur J Pharmacol** 1999 Feb 19;367(2–3):275–82

Irreversible inactivation of purple acid phosphatase by hydrogen peroxide and ascorbate. Beck JL, et al. **J Inorg Biochem** 1999 Apr;73(4):245–52

Inhibitory properties of human recombinant Arg24–>Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2). Kamei S, et al. **Thromb Res** 1999 May 1;94(3):147–52

BIOSYNTHESIS

Glycoproteins and their relationship to human disease. Brockhausen I, et al. **Acta Anat (Basel)** 1998;161(1–4):36–78 (455 ref.)

Expression of the Rh-related glycoprotein (Rh50). Suyama K, et al. **Acta Haematol** 1998;100(4):181–6

Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis. Guadagni F, et al. **Am J Pathol** 1999 Apr;154(4):993–9

Free and N-linked oligomannosides as markers of the quality control of newly synthesized glycoproteins. Cacan R, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):1–5

Expression of members of the thrombospondin family by human skeletal tissues and cultured cells. Carron JA, et al. **Biochem Biophys Res Commun** 1999 Sep 24; 263(2):389–91

Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Hofbauer LC, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):776–81

Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Murakami T, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):747–52

The dolichol pathway of N-linked glycosylation. Burda P, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):239–57 (125 ref.)

Asparagine-linked glycosylation in the yeast Golgi. Dean N. **Biochim Biophys Acta** 1999 Jan 6;1426(2):309–22 (98 ref.)

O-glycosylation potential of lepidopteran insect cell lines. Lopez M, et al. **Biochim Biophys Acta** 1999 Mar 14; 1427(1):49–61

Reglucosylation of glycoproteins and quality control of glycoprotein folding in the endoplasmic reticulum of yeast cells. Parodi AJ. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):287–95 (44 ref.)

Yeast glycosylation – foundations and building blocks. Robbins PW. **Biochim Biophys Acta** 1999 Jan 6; 1426(2):225–6

Investigation of the glycosyltransferase enzymes involved in the initial stages of the N-linked protein glycosylation pathway in Aspergillus niger. Wallis GL, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):91–8

Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Sidis Y, et al. **Biol Reprod** 1998 Oct;59(4):807–12

Production of recombinant Der fI (a major mite allergen) by Aspergillus oryzae. Shoji H, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):703–9

Production of recombinant Der fI with the native IgE-binding activity using a baculovirus expression system. Shoji H, et al. **Biosci Biotechnol Biochem** 1997 Oct; 61(10):1668–73

Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells [letter] Horn PA, et al. **Blood** 1999 Feb 15;93(4):1435–7

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Burger AM, et al. **Clin Cancer Res** 1997 Mar;3(3):455–63

Protein N-glycosylation: molecular genetics and functional significance. Kukuruzinska MA, et al. **Crit Rev Oral Biol Med** 1998;9(4):415–48 (332 ref.)

Hyaluronectin secretion by monocytes: downregulation by IL-4 and IL-13, upregulation by IL-10. Girard N, et al. **Cytokine** 1999 Aug;11(8):579–84

Analysis of chicken Wnt-13 expression demonstrates coincidence with cell division in the developing eye and is consistent with a role in induction. Jasoni C, et al. **Dev Dyn** 1999 Jul;215(3):215–24

Novel guidance cues during neuronal pathfinding in the early scaffold of axon tracts in the rostral brain. Anderson RB, et al. **Development** 1999 May;126(9):1859–68

Temperature dependent characteristics of a recombinant infectious hematopoietic necrosis virus glycoprotein produced in insect cells. Cain KD, et al. **Dis Aquat Organ** 1999 Apr 15;36(1):1–10

Expression of activin and follistatin in the rat hypothalamus: anatomical association with gonadotropin-releasing hormone neurons and possible role of central activin in the regulation of luteinizing hormone release. MacConell LA, et al. **Endocrine** 1998 Dec;9(3):233–41

Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Hofbauer LC, et al. **Endocrinology** 1999 Sep;140(9):4367–70

Advance in the study of inhibin, activin and follistatin production in pregnant women. Qu J, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):141–8 (88 ref.)

Transforming growth factor beta-1 up-regulates clusterin synthesis in thyroid epithelial cells. Wegrowski Y, et al. **Exp Cell Res** 1999 Mar 15;247(2):475–83

Post-translational processing of two alpha-amylase inhibitors and an arcelin from the common bean, Phaseolus vulgaris. Young NM, et al. **FEBS Lett** 1999 Mar 5;446(1):203–6

Isolation and cDNA cloning of somatolactin in rabbitfish (Siganus guttatus). Ayson FG, et al. **Gen Comp Endocrinol** 1999 Aug;115(2):292–300

Cloning and phylogenetic relationship of red drum somatolactin cDNA and effects of light on pituitary somatolactin mRNA expression. Zhu Y, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):69–79

Expression of DSD-1-PG in primary neural and glial-derived cell line cultures, upregulation by TGF-beta, and implications for cell-substrate interactions of the glial cell line Oli-neu. Schnädelbach O, et al. **Glia** 1998 Jun; 23(2):99–119

Otoconial agenesis in tilted mutant mice. Ornitz DM, et al. **Hear Res** 1998 Aug;122(1–2):60–70

Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Yokota A, et al. **Hematol Oncol** 1998 Dec;16(4):131–41

Follistatin and activin A production by the male reproductive tract. Anderson RA, et al. **Hum Reprod** 1998 Dec; 13(12):3319–25

Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. De Angelis E, et al. **Int J Oncol** 1999 Mar;14(3):437–40

In vivo specificity of human alpha1,3/4-fucosyltransferases III-VII in the biosynthesis of LewisX and Sialyl LewisX motifs on complex-type N-glycans. Coexpression studies from bhk-21 cells together with human beta-trace protein. Grabenhorst E, et al. **J Biol Chem** 1998 Nov 20; 273(47):30985–94

Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. Lakins J, et al. **J Biol Chem** 1998 Oct 23;273(43):27887–95

Cloning and expression of a novel galactoside beta1, 3-glucuronyltransferase involved in the biosynthesis of HNK-1 epitope. Shimoda Y, et al. **J Biol Chem** 1999 Jun 11;274(24):17115–22

Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. Takai H, et al. **J Biol Chem** 1998 Oct 16;273(42):27091–6

Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells. Sakata M, et al. **J Bone Miner Res** 1999 Sep;14(9):1486–92

Hakata antigen, a new member of the ficolin/opsonin p35 family, is a novel human lectin secreted into bronchus/alveolus and bile. Akaiwa M, et al. **J Histochem Cytochem** 1999 Jun;47(6):777–86

Coelomocytes express SpBf, a homologue of factor B, the second component in the sea urchin complement system. Smith LC, et al. **J Immunol** 1998 Dec 15;161(12):6784–93

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. Yun TJ, et al. **J Immunol** 1998 Dec 1;161(11):6113–21

Pneumococcus activation of the 5-lipoxygenase pathway and production of glycoproteins in the middle ear of rats. Lin J, et al. **J Infect Dis** 1999 May;179(5):1145–51

An autologous self-antigen differentially regulates expression of I-A glycoproteins and B7 costimulatory molecules on CD4- CD8- T helper cells. Walker MR, et al. **J Leukoc Biol** 1999 Jul;66(1):120–6

Expression and characterization of saposin-like proteins. Zaltash S, et al. **J Protein Chem** 1998 Aug;17(6):523–4

Specificity and synergism of polypeptide growth factors in stimulating the synthesis of proteoglycans and a novel high molecular weight anionic glycoprotein by articular chondrocyte cultures. Chopra R, et al. **J Rheumatol** 1998 Aug;25(8):1578–84

Effects of diabetes and insulin treatment of diabetic rats on hyaluronan and hyaluronectin production in injured aorta. Chajara A, et al. **J Vasc Res** 1999 May-Jun;36(3):209–21

Calphostin C induces expression of amphiregulin mRNA via reactive oxygen species in IEC-6 cells. Miyazaki Y, et al. **Life Sci** 1998;63(25):PL361–5

A trabecular meshwork glucocorticoid response (TIGR) gene mutation affects translocational processing. Zimmerman CC, et al. **Mol Vis** 1999 Aug 23;5:19

Mouse semaphorin H inhibits neurite outgrowth from sensory neurons. Miyazaki N, et al. **Neurosci Res** 1999 Apr; 33(4):269–74

Developmental localization of semaphorin H messenger RNA acting as a collapsing factor on sensory axons in the mouse brain. Miyazaki N, et al. **Neuroscience** 1999; 93(1):401–8

Stromelysins in placental membranes and amniotic fluid with premature rupture of membranes. Fortunato SJ, et al. **Obstet Gynecol** 1999 Sep;94(3):435–40

Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. Dodge GR, et al. **Osteoarthritis Cartilage** 1998 Nov;6(6):435–40

The arcelin-5 gene of Phaseolus vulgaris directs high seed-specific expression in transgenic Phaseolus acutifolius and Arabidopsis plants. Goossens A, et al. **Plant Physiol** 1999 Aug;120(4):1095–104

YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Volck B, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug; 110(4):351–60

Beta2-glycoprotein-I mRNA transcripts are expressed by hepatocytes but not by resting or activated human endothelial cells. Alvarado-de la Barrera C, et al. **Thromb Res** 1998 Jun 1;90(5):239–43

Type II fish antifreeze protein accumulation in transgenic tobacco does not confer frost resistance. Kenward KD, et al. **Transgenic Res** 1999 Apr;8(2):105–17

Genetic optimization of recombinant glycoprotein production by mammalian cells. Fussenegger M, et al. **Trends Biotechnol** 1999 Jan;17(1):35–42 (121 ref.)

Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat. Frängsmyr L, et al. **Tumour Biol** 1999 Sep-Oct; 20(5):277–92

[Effect of conditions od Trichosporon pullulans culturing on the synthesis of immunomodulating glycoprotein] Eroshin VK, et al. **Mikrobiologiia** 1999 Mar-Apr; 68(2):160–3 (Eng. Abstr.) **(Rus)**

BLOOD

Long-term ethanol exposure alters the sialylation index of plasma apolipoprotein J (Apo J) in rats. Ghosh P, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4):720–5

IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Cucurull E, et al. **Am J Med Sci** 1999 Jul;318(1):55–60

Clearance of Clara cell secretory protein 16 (CC16) and surfactant proteins A and B from blood in acute respiratory failure. Doyle IR, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1528–35

Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Yokoyama A, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1680–4

Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Conrozier T, et al. **Ann Rheum Dis** 1998 Sep;57(9):527–32

The value of a single skin prick testing for specific IgE Dermatophagoides pteronyssinus to distinguish atopy from non-atopic asthmatic children in the tropics. Santoso H. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2–3):69–74

ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Piñeiro M, et al. **Biochem Biophys Res Commun** 1999 Sep 16; 263(1):224–9

Serum apolipoprotein H and its relationship to lipids and other apolipoproteins in normal human men and women. Crook MA, et al. **Blood Coagul Fibrinolysis** 1999 Jun; 10(4):197–200

Serum YKL-40 and colorectal cancer. Cintin C, et al. **Br J Cancer** 1999 Mar;79(9–10):1494–9

Procalcitonin--a sepsis parameter in severe burn injuries. von Heimburg D, et al. **Burns** 1998 Dec;24(8):745–50

Serum surfactant protein-A levels predict development of ARDS in at-risk patients. Greene KE, et al. **Chest** 1999 Jul;116(1 Suppl):90S–91S

Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. Henry H, et al. **Clin Chem** 1999 Sep;45(9):1408–13

Circulating cat allergen and immune complexes in cat-allergic children. Casas R, et al. **Clin Exp Allergy** 1998 Oct;28(10):1258–63

Procalcitonin in early detection of postoperative complications. Reith HB, et al. **Dig Surg** 1998;15(3):260–5

Lectin-gradient gel affinity electrophoresis of glycoproteins. Taketa K, et al. **Electrophoresis** 1998 Jun;19(8–9):1275–8

Procalcitonin--a new indicator for bacterial infections. Steinbach G, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):164–7 (36 ref.)

A receptor for the lipocalin placental protein 14 on human monocytes. Miller RE, et al. **FEBS Lett** 1998 Oct 9; 436(3):455–60

Placental protein 14 and pregnancy-specific beta 1-glycoprotein in women with suppressed, normal and stimulated follicular maturation. Baumann CK, et al. **Gynecol Endocrinol** 1998 Aug;12(4):231–41

Ex vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy. Vávrová J, et al. **Hematol Cell Ther** 1999 Jun;41(3):105–12

The absence of 150-kDa insulin-like growth factor complexes in fetal rat serum is not due to a lack of

functional acid-labile subunit. Lee CY, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):182-5

Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Mehdi H, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):63-71

A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy. Fowler PA, et al. **Hum Reprod** 1998 Dec; 13(12):3530-6

Is the measurement of placental protein-14 and CA-125 in plasma and uterine flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding? Li TC, et al. **Hum Reprod** 1998 Oct;13(10):2895-901

Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. O'Connor AE, et al. **Hum Reprod** 1999 Mar;14(3):827-32

Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles. Westergaard LG, et al. **Hum Reprod** 1998 Sep;13(9):2612-9

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Yano K, et al. **J Bone Miner Res** 1999 Apr;14(4):518-27

Decreased serum levels of acid-labile subunit in patients with anorexia nervosa. Fukuda I, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2034-6

The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. Juul A, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4408-15

Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. Pelliccia P, et al. **J Clin Immunol** 1999 Mar;19(2):143-7

Anti-cardiolipin antibody and anti-cardiolipin beta-2-glycoprotein I antibody in patients with recurrent fetal miscarriage. Higashino M, et al. **J Perinat Med** 1998; 26(5):384-9

Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. Newkirk MM, et al. **J Rheumatol** 1999 Mar;26(3):597-603

Procalcitonin as a marker of severity in septic shock. Schröder J, et al. **Langenbecks Arch Surg** 1999 Feb; 384(1):33-8

Revealing some oncofetal antigens in peripheral blood mononuclear cells of donors and patients with B-chronic lymphocytic leukemia. Penezina O, et al. **Leuk Res** 1998 Nov;22(11):1009-13

Dietary specific sugars for serum protein enzymatic glycosylation in man. Berger V, et al. **Metabolism** 1998 Dec;47(12):1499-503

Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Yokoyama A, et al. **Respirology** 1998 Sep; 3(3):199-202

Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Johansen JS, et al. **Rheumatology (Oxford)** 1999 Jul;38(7):618-26

Serum KL-6, a novel mucin-like glycoprotein, as an indicator of interstitial pneumonitis following lobectomy. Sakuma T, et al. **Surg Today** 1999;29(2):121-8

Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS, and sepsis. Boeken U, et al. **Thorac Cardiovasc Surg** 1998 Dec; 46(6):348-51

Procalcitonin as a marker of systemic inflammation after conventional or minimally invasive coronary artery bypass grafting. Kilger E, et al. **Thorac Cardiovasc Surg** 1998 Jun; 46(3):130-3

Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Arnout J, et al. **Thromb Haemost** 1999 Jun;81(6):929-34

The prevalence of a non-phospholipid-binding form of beta2-glycoprotein I in human plasma--consequences for the development of anti-beta2-glycoprotein I antibodies. Horbach DA, et al. **Thromb Haemost** 1998 Nov;80(5):791-7

Estimation of plasma beta-2-glycoprotein levels by competitive ELISA. Balasubramanian K, et al. **Thromb Res** 1998 Oct 15;92(2):91-7

Erythroid accelerating factor detected in serum from rats with drug induced hemolysis. Kasai M, et al. **Tohoku J Exp Med** 1998 Dec;186(4):279-89

Elevated serum levels of fetal antigen 1,a member of the epidermal growth factor superfamily, in patients with small cell lung cancer. Harken Jensen C, et al. **Tumour Biol** 1999 Sep-Oct;20(5):256-62

Maternal cardiolipin, beta 2-glycoprotein-I and prothrombin antibody expression in high-risk pregnancies with bilateral abnormal uterine artery Doppler waveforms. Donohoe S, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):317-22

Pregnancy-associated glycoprotein and decreased polymorphonuclear leukocyte function in early post-partum dairy cows. Dosogne H, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):47-54

[Procalcitonin: a new marker of bacterial infection. Importance and prospects (editorial)] Bohuon C, et al. **Arch Pediatr** 1999 Feb;6(2):141-4 (23 ref.) **(Fre)**

[The value of procalcitonin in neonatal infections] Maire F, et al. **Arch Pediatr** 1999 May;6(5):503-9 (Eng. Abstr.) **(Fre)**

[Procalcitonin, a marker of bacterial meningitis in children] Bohuon C, et al. **Bull Acad Natl Med** 1998;182(7):1469-75; discussion 1475-7 (Eng. Abstr.) **(Fre)**

[Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis] Marti C, et al. **Z Rheumatol** 1999 Apr;58(2):79-87 (Eng. Abstr.) **(Ger)**

[Evaluation of procalcitonin levels in patients with systemic inflammatory response syndrome as the diagnosis of infection and the severity of illness] Endo S, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):197-204 (Eng. Abstr.) **(Jpn)**

[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis] Kondo A, et al. **Kekkaku** 1998 Oct;73(10):585-90 (Eng. Abstr.) **(Jpn)**

[Tumor markers and gastric cancer. TAG-72 is the most useful (letter)] Fernández-Llamazares J, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):800 **(Spa)**

CHEMICAL SYNTHESIS

Synthesis of a neoglycoprotein containing the Lewis X analogous trisaccharide beta-D-GalpNAc-(1-->4)[alpha-L-Fucp-(1-->3)]-beta-D-GlcpNAc. Bartek J, et al. **Carbohydr Res** 1998 Jun; 308(3-4):259-73

Chemoenzymatic synthesis of spacer-linked oligosaccharides for the preparation of neoglycoproteins. Gonzalez Lio R, et al. **Carbohydr Res** 1999 Apr 30;317(1-4):180-90

Improved synthesis of an aldobiouronic acid related to hardwood xylans, and preparation of a derivative thereof suitable for linking to proteins. Hirsch J, et al. **Carbohydr Res** 1998 Aug;310(1-2):145-9

CHEMISTRY

Glycoproteins and their relationship to human disease. Brockhausen I, et al. **Acta Anat (Basel)** 1998;161(1-4):36-78 (455 ref.)

Glycoproteins now and then: a personal account. Sharon N. **Acta Anat (Basel)** 1998;161(1-4):7-17

A database analysis of potential glycosylating Asn-X-Ser/Thr consensus sequences. Christlet TH, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Aug;55 (Pt 8):1414-20

Crystallization and preliminary crystallographic analysis of the major horse allergen Equ c 1. Grégoire C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):880-2

Crystallization and preliminary X-ray diffraction studies of mammalian purple acid phosphatase. Guddat LW, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Aug;55 (Pt 8):1462-4

Crystallization and preliminary X-ray crystallographic studies on apolipoprotein H (beta2-glycoprotein-I) from human plasma. Saxena A, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(2 (Pt 6)):1450-2

Structure of type III antifreeze protein at 277 K. Ye Q, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1;54 (Pt 4):700-2

X-ray crystallographic determination of the structure of the influenza C virus haemagglutinin-esterase-fusion glycoprotein. Zhang X, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):945-61

Analysis of carbohydrate heterogeneity in a glycoprotein using liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry. Kawasaki N, et al. **Anal Biochem** 1999 May 1; 269(2):297-303

Electrospray ionization-ion trap mass spectrometry for structural analysis of complex N-linked glycoprotein oligosaccharides. Welskopf AS, et al. **Anal Chem** 1998 Oct 15;70(20):4441-7

Structure and conformation of complex carbohydrates of glycoproteins, glycolipids, and bacterial polysaccharides. Bush CA, et al. **Annu Rev Biophys Biomol Struct** 1999; 28:269-93 (150 ref.)

Modification of beta 2glycoprotein I by glutardialdehyde. Conformational changes and aggregation accompany exposure of the cryptic autoepitope. Galazka M, et al. **Appl Biochem Biotechnol** 1999 Jan;76(1):1-13

Secondary structure of antifreeze proteins from overwintering larvae of the beetle Dendroides canadensis. Li N, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):25-32

The solution structure of heregulin-alpha and a N-terminal mutant with suppressed activity. Adler M, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):156-61

Homologue scanning mutagenesis of heregulin reveals receptor specific binding epitopes. Harris A, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):220-4

Assignment of disulfide linkages in chum salmon stanniocalcin. Hulova I, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):295-9

N-linked oligosaccharides of vomeromodulin, a putative pheromone transporter in rat. Mechref Y, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):451-5

NMR structural studies on antifreeze proteins. Sönnichsen FD, et al. **Biochem Cell Biol** 1998;76(2-3):284-93 (41 ref.)

Cytosolic deglycosylation process of newly synthesized glycoproteins generates oligomannosides possessing one GlcNAc residue at the reducing end. Duvet S, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):389-96

Mucus glycoproteins from pig gastric mucosa: different mucins are produced by the surface epithelium and the glands. Nordman H, et al. **Biochem J** 1998 May 1;331 (Pt 3):687-94

Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. Sleat DE, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):547-51

The insertion of human apolipoprotein H into phospholipid membranes: a monolayer study. Wang SX, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):225-32

Organization of the inter-alpha-inhibitor heavy chains on the chondroitin sulfate originating from Ser(10) of bikunin: posttranslational modification of Ialpha1-derived bikunin. Enghild JJ, et al. **Biochemistry** 1999 Sep 7;38(36):11804-13

Structure analysis of a fusogenic peptide sequence from the sea urchin fertilization protein bindin. Glaser RW, et al. **Biochemistry** 1999 Feb 23;38(8):2560-9

A complex family of highly heterogeneous and internally repetitive hyperactive antifreeze proteins from the beetle Tenebrio molitor. Liou YC, et al. **Biochemistry** 1999 Aug 31;38(35):11415-24

The ice-binding site of sea raven antifreeze protein is distinct from the carbohydrate-binding site of the homologous C-type lectin. Loewen MC, et al. **Biochemistry** 1998 Dec 22;37(51):17745-53

Evidence for nonbridged coordination of p-nitrophenyl phosphate to the dinuclear Fe(III)-M(II) center in bovine spleen purple acid phosphatase during enzymatic turnover. Merkx M, et al. **Biochemistry** 1999 Aug 3;38(31):9914-25

Structural analysis of the heparin-binding site of the NC1 domain of collagen XIV by CD and NMR. Montserret R, et al. **Biochemistry** 1999 May 18;38(20):6479-88

Fluoride inhibition of bovine spleen purple acid phosphatase: characterization of a ternary enzyme-phosphate-fluoride complex as a model for the active enzyme-substrate-hydroxide complex. Pinkse MW, et al. **Biochemistry** 1999 Aug 3;38(31):9926-36

Conformational and amino acid residue requirements for the saposin C neuritogenic effect. Qi X, et al. **Biochemistry** 1999 May 11;38(19):6284-91

Isolation and characterization of an antifreeze protein from the longhorn sculpin, Myoxocephalus octodecimspinosis. Deng G, et al. **Biochim Biophys Acta** 1998 Nov 10; 1388(2):305-14

Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Fernandez AZ, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):291-9

Structure of the glucan-binding sugar chain of Tip1p, a cell wall protein of Saccharomyces cerevisiae. Fujii T, et al. **Biochim Biophys Acta** 1999 Apr 19;1427(2):133-44

Structural properties of human glycodelin A in water and in water-alcohol mixtures: a comparison with bovine beta-lactoglobulin A. Gaudiano MC, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):451-61

A systematic approach to evaluate the modification of lens proteins by glycation-induced crosslinking. Lee KW, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):141-51

Cell adhesion activity for murine carcinoma cells of a wheat germ 55-kDa protein with binding affinity for animal extracellular matrix proteins. Shoji Y, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):498-504

Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19-21 (4 ref.)

Ice-binding surface of fish type III antifreeze. Chen G, et al. **Biophys J** 1999 Sep;77(3):1602-8

A spreading technique for forming film in a captive bubble. Putz G, et al. **Biophys J** 1998 Nov;75(5):2229-39

Purification and some chemical properties of 30 kDa Ginkgo biloba glycoprotein, which reacts with antiserum against beta 1-->2 xylose-containing N-glycans. Kimura Y, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):463-7

Structures of N-linked oligosaccharides of glycoproteins from tobacco BY2 suspension cultured cells. Palacpac NQ, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):35-9

Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. Gawlitzek M, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):518-28

Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. Valley U, et al. **Biotechnol Bioeng** 1999 Aug 20;64(4):401-17

Use of mannosamine for inducing the addition of outer arm N-acetylglucosamine onto N-linked oligosaccharides of recombinant proteins in insect cells. Donaldson M, et al. **Biotechnol Prog** 1999 Mar-Apr;15(2):168-73

Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood. Buscaglia CA, et al. **Blood** 1999 Mar 15;93(6):2025-32

Elevation of alpha2-->6 sialyltransferase and alpha1-->2 fucosyltransferase activities in human choriocarcinoma. Fukushima K, et al. **Cancer Res** 1998 Oct 1;58(19):4301-6

Conformationally altered beta 2-glycoprotein I is the antigen

for anti-cardiolipin autoantibodies. Chamley LW, et al. **Clin Exp Immunol** 1999 Mar;115(3):571-6

Isolation and partial characterization of an opioid-like 88 kDa hibernation-related protein. Horton ND, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):787-805

Lectins as chaperones in glycoprotein folding. Trombetta ES, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):587-92 (48 ref.)

Biological importance of glycosylation. Dwek RA. **Dev Biol Stand** 1998;96:43-7

Evaluation of glycosylation. Reinhold VN. **Dev Biol Stand** 1998;96:49-53

Primary structure of a 120 kDa protein associated with the fucose sulfate glycoconjugate constituting the acrosome reaction-inducing substance of the sea urchin, Hemicentrotus pulcherrimus. Ohbayashi H, et al. **Dev Growth Differ** 1998 Dec;40(6):641-50

Nonspecific interactions alter lipopolysaccharide patterns and protein mobility on sodium dodecyl sulfate polyacrylamide gels. Yuan A, et al. **Electrophoresis** 1999 Jul;20(10):1946-9

All-trans retinol, vitamin D and other hydrophobic compounds bind in the axial pore of the five-stranded coiled-coil domain of cartilage oligomeric matrix protein. Guo Y, et al. **EMBO J** 1998 Sep 15;17(18):5265-72

The active site of purple acid phosphatase from sweet potatoes (Ipomoea batatas) metal content and spectroscopic characterization. Durmus A, et al. **Eur J Biochem** 1999 Mar;260(3):709-16

Disulfide bond mapping and structural characterization of spruce budworm antifreeze protein. Gauthier SY, et al. **Eur J Biochem** 1998 Dec 1;258(2):445-53

Type I 'antifreeze' proteins. Structure-activity studies and mechanisms of ice growth inhibition. Harding MM, et al. **Eur J Biochem** 1999 Sep;264(3):653-65 (81 ref.)

Flavonol 2,4-dioxygenase from Aspergillus niger DSM 821, a type 2 CuII-containing glycoprotein. Hund HK, et al. **Eur J Biochem** 1999 Aug;263(3):871-8

Presence of asparagine-linked N-acetylglucosamine and chitobiose in Pyrus pyrifolia S-RNases associated with gametophytic self-incompatibility. Ishimizu T, et al. **Eur J Biochem** 1999 Aug;263(3):624-34

The structure of a glycosylated protein hormone responsible for sex determination in the isopod, Armadillidium vulgare. Martin G, et al. **Eur J Biochem** 1999 Jun;262(3):727-36

Structural and membrane-binding properties of saposin D. Tatti M, et al. **Eur J Biochem** 1999 Jul;263(2):486-94

A 50-kDa variant form of human surfactant protein D. Mason RJ, et al. **Eur Respir J** 1998 Nov;12(5):1147-55

Contributions of the ionization states of acidic residues to the stability of the coiled coil domain of matrilin-1. Dames SA, et al. **FEBS Lett** 1999 Mar 5;446(1):75-80

Glycodelin and beta-lactoglobulin, lipocalins with a high structural similarity, differ in ligand binding properties. Koistinen H, et al. **FEBS Lett** 1999 Apr 30;450(1-2):158-62

Studies of a putative ice-binding motif in winter flounder skin-type anti-freeze polypeptide. Lin Q, et al. **FEBS Lett** 1999 Jun 25;453(3):331-4

A leucine-rich repeat protein of carrot that exhibits antifreeze activity. Meyer K, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):171-8

Artificial antifreeze polypeptides: alpha-helical peptides with KAAK motifs have antifreeze and ice crystal morphology modifying properties. Zhang W, et al. **FEBS Lett** 1999 Jul 23;455(3):372-6

Pharmacological characterization of arginine vasotocin vascular smooth muscle receptors in the trout (Oncorhynchus mykiss) in vitro. Conklin DJ, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):36-46

Quantitative analysis of sugar constituents of glycoproteins by capillary electrophoresis. Chen FT, et al. **Glycobiology** 1998 Nov;8(11):1045-52

Structural characterization of the N-linked oligosaccharides in bile salt-stimulated lipase originated from human breast milk. Mechref Y, et al. **Glycobiology** 1999 Mar;9(3):227-34

Oligosaccharide analysis and molecular modeling of soluble forms of glycoproteins belonging to the Ly-6, scavenger receptor, and immunoglobulin superfamilies expressed in Chinese hamster ovary cells. Rudd PM, et al. **Glycobiology** 1999 May;9(5):443-58

Complete glycan structure of the S-layer glycoprotein of Aneurinibacillus thermoaerophilus GS4-97. Schäffer C, et al. **Glycobiology** 1999 Apr;9(4):407-14

Gas-liquid chromatography of the heptafluorobutyrate derivatives of the O-methyl-glycosides on capillary columns: a method for the quantitative determination of the monosaccharide composition of glycoproteins and glycolipids. Zanetta JP, et al. **Glycobiology** 1999 Mar; 9(3):255-66

A general approach to desalting oligosaccharides released from glycoproteins. Packer NH, et al. **Glycoconj J** 1998 Aug;15(8):737-47

Glycotargeting: a receptor-mediated delivery using sugar ligands [comment] Paillard F. **Hum Gene Ther** 1999 Feb 10;10(3):337-9. Comment on: Hum Gene Ther 1999 Feb 10;10(3):395-406.

Minimum chemical requirements for adhesin activity of the acid-stable part of Candida albicans cell wall phosphomannoprotein complex. Kanbe T, et al. **Infect Immun** 1998 Dec;66(12):5812-8

Flagellins, but not endoflagellar sheath proteins, of Treponema pallidum and of pathogen-related oral spirochetes are glycosylated. Wyss C. **Infect Immun** 1998 Dec;66(12):5751-4

Matrix-assisted laser desorption/ionization mass spectrometry of acidic glycoconjugates facilitated by the use of spermine as a co-matrix. Mechref Y, et al. **J Am Soc Mass Spectrom** 1998 Dec;9(12):1293-302

Exposure of human, boar, or bull sperm to a synthetic peptide increases binding to an egg-membrane substrate. Amann RP, et al. **J Androl** 1999 Jan-Feb;20(1):34-41

Exposure of thawed frozen bull sperm to a synthetic peptide before artificial insemination increases fertility. Amann RP, et al. **J Androl** 1999 Jan-Feb;20(1):42-6

Quantitative and qualitative analysis of type III antifreeze protein structure and function. Graether SP, et al. **J Biol Chem** 1999 Apr 23;274(17):11842-7

Structure-function relationships in a type I antifreeze polypeptide. The role of threonine methyl and hydroxyl groups in antifreeze activity. Zhang W, et al. **J Biol Chem** 1998 Dec 25;273(52):34806-12

Separation of enantiomers on a chiral stationary phase based on ovoglycoprotein. III. Effect of aggregation of ovoglycoprotein on chiral resolution. Haginaka J, et al. **J Chromatogr A** 1999 Jan 8;830(1):81-9

Multiple forms of lactadherin (breast antigen BA46) and butyrophilin are secreted into human milk as major components of milk fat globule membrane. Cavaletto M, et al. **J Dairy Res** 1999 May;66(2):295-301

Component PP3 from bovine milk is a substrate for transglutaminase. Sequence location of putative crosslinking sites. Sørensen ES, et al. **J Dairy Res** 1999 Feb;66(1):145-50

Conformational studies of a synthetic peptide from the putative lipid-binding domain of bovine milk component PP3. Campagna S, et al. **J Dairy Sci** 1998 Dec; 81(12):3139-48

The primary structure of caprine PP3: amino acid sequence, phosphorylation, and glycosylation of component PP3 from the proteose-peptone fraction of caprine milk. Lister IM, et al. **J Dairy Sci** 1998 Aug;81(8):2111-5

Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein. Gaudin Y, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1647-56

Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. Torresi J, et al. **J Gen Virol** 1999 May;80 (Pt 5):1185-8

Deduced structural model for animal rhabdovirus glycoproteins. Walker PJ, et al. **J Gen Virol** 1999 May;80 (Pt 5):1211-20

Influence of mite growth culture phases on the biological standardization of allergenic extracts. Eraso E, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):201-6

New multidimensional editing experiments for measurement of amide deuterium isotope effects on Cbeta chemical shifts in 13C, 15N-labeled proteins. Meissner A, et al. **J Magn Reson** 1998 Dec;135(2):547-50

Characterization of pathotype-specific epitopes of newcastle disease virus fusion glycoproteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and post-source decay sequencing. Lopaticki S, et al. **J Mass Spectrom** 1998 Oct;33(10):950-60

Three-dimensional structure of a mammalian purple acid phosphatase at 2.2 A resolution with a mu-(hydr)oxo bridged di-iron center. Lindqvist Y, et al. **J Mol Biol** 1999 Aug 6;291(1):135-47

Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. Müller SA, et al. **J Mol Biol** 1999 Aug 27;291(4):801-13

Crystal structure of a mammalian purple acid phosphatase. Uppenberg J, et al. **J Mol Biol** 1999 Jul 2;290(1):201-11

Incomplete trifluoroacetic acid deprotection of asparagine-trityl-protecting group in the vicinity of a reduced peptide bond. Quesnel A, et al. **J Pept Res** 1998 Aug;52(2):107-11

Ligand-binding capabilities, 2.4-A resolution crystal structure, and characterization of oligosaccharides of PSP-I/PSP-II, a porcine heterodimeric lectin of glycosylated spermadhesins. Calvete JJ, et al. **J Protein Chem** 1998 Aug;17(6):538-40

Localization of a single transglutaminase-reactive glutamine in the third domain of RAP, the alpha2-macroglobulin receptor-associated protein. Rasmussen LK, et al. **J Protein Chem** 1999 Jan;18(1):69-73

Crystallization and preliminary X-ray crystallographic analysis of spruce budworm antifreeze protein. Graether SP, et al. **J Struct Biol** 1999 Jun 1;126(1):72-5

Crystallization and preliminary X-ray diffraction analysis of group 5 mite allergen from Dermatophagoides pteronyssinus. Liaw SH, et al. **J Struct Biol** 1998 Nov; 123(3):265-8

The matrilins: a novel family of oligomeric extracellular matrix proteins. Deák F, et al. **Matrix Biol** 1999 Feb; 18(1):55-64 (71 ref.)

Identification and characterization of a heparin binding site within the NC1 domain of chicken collagen XIV. Giry-Lozinguez C, et al. **Matrix Biol** 1998 Jun;17(2):145-9

Molecular cloning and characterization of the polypeptide backbone of Schistosoma mansoni circulating cathodic antigen. Abdeen HH, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1-2):149-59

Structure of the glycosylphosphatidylinositol-anchor of the trans-sialidase from Trypanosoma cruzi metacyclic trypomastigote forms. Agusti R, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1-2):123-31

Distinct structures and functions of related pre- and postsynaptic carbohydrates at the mammalian neuromuscular junction. Martin PT, et al. **Mol Cell Neurosci** 1999 Feb;13(2):105-18

A sensitive fluorescent assay for measuring the cysteine protease activity of Der p 1, a major allergen from the dust mite Dermatophagoides pteronyssinus. Schulz O, et al. **Mol Pathol** 1998 Aug;51(4):222-4

O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins. Gupta R, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):370-2

Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Duke-Cohan JS, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11336-41

Otoconin-90, the mammalian otoconial matrix protein, contains two domains of homology to secretory phospholipase A2. Wang Y, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15345-50

NMR analysis of the N-terminal SRCR domain of human CD5: engineering of a glycoprotein for superior characteristics in NMR experiments. McAlister MS, et al. **Protein Eng** 1998 Oct;11(10):847-53

The NTR module: domains of netrins, secreted frizzled related proteins, and type I procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases. Bányai L, et al. **Protein Sci** 1999 Aug; 8(8):1636-42

Determination of the complete covalent structure of the major glycoform of DQH sperm surface protein, a novel trypsin-resistant boar seminal plasma O-glycoprotein related to pB1 protein. Bezouska K, et al. **Protein Sci** 1999 Jul;8(7):1551-6

The insect immune protein scolexin is a novel serine proteinase homolog. Finnerty CM, et al. **Protein Sci** 1999 Jan;8(1):242-8

Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Sánchez LM, et al. **Science** 1999 Mar 19;283(5409):1914-9

The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases. Parry MA, et al. **Structure** 1998 Sep 15;6(9):1195-206

Crystal structure of mammalian purple acid phosphatase. Guddat LW, et al. **Structure Fold Des** 1999 Jul 15; 7(7):757-67

Crystal structure of the trimeric alpha-helical coiled-coil and the three lectin domains of human lung surfactant protein D. Håkansson K, et al. **Structure Fold Des** 1999 Mar 15; 7(3):255-64

Glycoproteins: glycan presentation and protein-fold stability. Wormald MR, et al. **Structure Fold Des** 1999 Jul 15; 7(7):R155-60 (35 ref.)

alpha-Gal epitopes in animal tissue glycoproteins and glycolipids. Rydberg L, et al. **Subcell Biochem** 1999; 32:107-25 (88 ref.)

Characterization of beta2-glycoprotein I binding to phospholipid membranes. Harper MF, et al. **Thromb Haemost** 1998 Oct;80(4):610-4

Primary structures of hemagglutinin-esterase and spike glycoproteins of murine coronavirus DVIM. Morita E, et al. **Virus Genes** 1998;17(2):123-8

[Synthesis and biological properties of artificial antigens based on 280-289 fragment of beta2-gpI] Pal'keeva ME, et al. **Bioorg Khim** 1998 Jul;24(7):502-8 (Eng. Abstr.) **(Rus)**

[Deglycosylation of glycoproteins] Vinogradov AA, et al. **Bioorg Khim** 1998 Nov;24(11):803-15 (86 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Pämpols T, et al. **Acta Neuropathol (Berl)** 1999 Jan;97(1):91-7

Caveolin-3 deficiency as a cause of limb-girdle muscular dystrophy. Kunkel L. **J Child Neurol** 1999 Jan;14(1):33-4

Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease. Tohyama J, et al. **J Inherit Metab Dis** 1999 Jun;22(5):649-62

Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. Vartanian T, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):731-5

[Sarcoglycanopathies] Colomer J. **Rev Neurol** 1999 Jan 16-31;28(2):150-3 (30 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSTIC USE

Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Brinck U, et al. **Acta Anat (Basel)** 1998;161(1-4):219-33 (90 ref.)

Diagnostic value of nasal provocation challenge with allergens in children. Jean R, et al. **Allergy** 1998 Oct; 53(10):990-4

Fetal fibronectin as a marker for an imminent (preterm) delivery. A new technique using the glycoprotein lectin

immunosorbent assay. Hampel DJ, et al.
J Immunol Methods 1999 Apr 22;224(1-2):31-42
Diagnostic glycoproteins of Taenia solium cysts share homologous 14- and 18-kDa subunits. Greene RM, et al.
Mol Biochem Parasitol 1999 Apr 30;99(2):257-61
[Cysteine-dependent protease in Trypanosoma cruzi useful for the diagnosis of Chagas disease] Alberti Amador E, et al. **Rev Cubana Med Trop** 1998;50(1):75-81 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

The salubrious effect of tamoxifen [correction of Tamaxifen] on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer woman. Thangaraju M, et al. **Mol Cell Biochem** 1998 Aug;185(1-2):85-94

GENETICS

Molecular basis of open-angle glaucoma in Italy. Angius A, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):16-7
Analysis of sequence diversity in the C2-V3 regions of the external glycoproteins of HIV type 1 in Singapore. Se-Thoe SY, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1601-4
Molecular basis for Rh(null) syndrome: identification of three new missense mutations in the Rh50 glycoprotein gene. Huang CH, et al. **Am J Hematol** 1999 Sep;62(1):25-32
Rhmod syndrome: a family study of the translation-initiator mutation in the Rh50 glycoprotein gene. Huang C, et al.
Am J Hum Genet 1999 Jan;64(1):108-17
Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma [letter] Wiggs JL, et al. **Am J Hum Genet** 1998 Nov;63(5):1549-52
Mutations of the TIGR/MYOC gene in primary open-angle glaucoma in Korea [letter] Yoon SJ, et al.
Am J Hum Genet 1999 Jun;64(6):1775-8
Identification of nine novel mutations in cartilage oligomeric matrix protein in patients with pseudoachondroplasia and multiple epiphyseal dysplasia. Deere M, et al.
Am J Med Genet 1999 Aug 27;85(5):486-90
Recombinant SP-D carbohydrate recognition domain is a chemoattractant for human neutrophils. Cai GZ, et al.
Am J Physiol 1999 Jan;276(1 Pt 1):L131-6
Genomic organization of the mouse gene for lung surfactant protein D. Lawson PR, et al.
Am J Respir Cell Mol Biol 1999 May;20(5):953-63
Enhanced retroviral transduction efficiency of pancreatic tumor cell lines using different envelope glycoproteins. Howard BD, et al. **Ann N Y Acad Sci** 1999 Jun 30; 880:366-70
Evolution of olfactomedin. Structural constraints and conservation of primary sequence motifs. Karavanich C, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:294-300
Expression and characterization of an epididymis-specific gene. Fan HY, et al. **Arch Androl** 1999 Mar-Apr;42(2):63-9
Molecular cloning and characterization of a novel testis-specific nucleoporin-related gene. Wang LF, et al.
Arch Androl 1999 Mar-Apr;42(2):71-84
The glycoprotein of the carcinoembryonic antigen (CEA) gene family expressed on epithelial keratinocytes in viral warts. Egawa K, et al. **Arch Dermatol Res** 1998 Aug; 290(8):453-7
Identification, sequence analysis and characterisation of equine herpesvirus 5 glycoprotein B. Holloway SA, et al.
Arch Virol 1999;144(2):287-307
Structure analysis of the rice yellow stunt rhabdovirus glycoprotein gene and its mRNA. Luo ZL, et al.
Arch Virol 1998;143(12):2453-9
Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Boot RG, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):687-94
Polymorphism of beta2-glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Gushiken FC, et al.
Arthritis Rheum 1999 Jun;42(6):1189-93
A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Hirose N, et al.
Arthritis Rheum 1999 Aug;42(8):1655-61
Identification of a novel seven-transmembrane receptor with homology to glycoprotein receptors and its expression in the adult and developing mouse. Hermey G, et al.
Biochem Biophys Res Commun 1999 Jan 8;254(1):273-9
Molecular cloning of a second human stanniocalcin homologue (STC2). Ishibashi K, et al.
Biochem Biophys Res Commun 1998 Sep 18;250(2):252-8
Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Langmann T, et al.
Biochem Biophys Res Commun 1999 Apr 2;257(1):29-33
Stimulation of PC cell-derived growth factor (epithelin/granulin precursor) expression by estradiol in human breast cancer cells. Lu R, et al.
Biochem Biophys Res Commun 1999 Mar 5;256(1):204-7
Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Nagai M, et al.
Biochem Biophys Res Commun 1999 Apr 21;257(3):719-23
cDNA cloning and distribution of the Xenopus follistatin-related protein. Okabayashi K, et al.
Biochem Biophys Res Commun 1999 Jan 8;254(1):42-8
Sequence analysis of the spacer region between the RHD and RHCE genes. Okuda H, et al.
Biochem Biophys Res Commun 1999 Sep 24;263(2):378-83
ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Piñeiro M, et al. **Biochem Biophys Res Commun** 1999 Sep 16; 263(1):224-9
Phage display cDNA cloning of protein with carbohydrate affinity. Yamamoto M, et al.
Biochem Biophys Res Commun 1999 Feb 16;255(2):194-9
Characterization of the human proline/arginine-rich end leucine-rich repeat protein (PRELP) gene promoter and identification of a repressor element. Grover J, et al.
Biochem J 1998 Nov 15;336 (Pt 1):77-82
Nerve growth factor and epidermal growth factor stimulate clusterin gene expression in PC12 cells. Gutacker C, et al. **Biochem J** 1999 May 1;339 (Pt 3):759-66
Importance of splicing for prosaposin sorting. Madar-Shapiro L, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):433-43
Purification, characterization and cDNA cloning of a phospholipase A2 inhibitor from the serum of the non-venomous snake Elaphe quadrivirgata. Okumura K, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):165-71
An array of binding sites for hepatocyte nuclear factor 4 of high and low affinities modulates the liver-specific enhancer for the human alpha1-microglobulin/bikunin precursor. Rouet P, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):577-84
Genetics of the hydrophilic surfactant proteins A and D. Floros J, et al. **Biochim Biophys Acta** 1998 Nov 19; 1408(2-3):312-22 (53 ref.)
Insecticidal activity of an alpha-amylase inhibitor-like protein resembling a putative precursor of alpha-amylase inhibitor in the common bean, Phaseolus vulgaris L. Ishimoto M, et al. **Biochim Biophys Acta** 1999 Jun 15; 1432(1):104-12
Cloning and expression of Der f 6, a serine protease allergen from the house dust mite, Dermatophagoides farinae. Kawamoto S, et al. **Biochim Biophys Acta** 1999 Jul 7; 1454(2):201-7
Expression pattern and in situ localization of the mouse homologue of the human MYOC (GLC1A) gene in adult brain. Swiderski RE, et al. **Brain Res Mol Brain Res** 1999 May 7;68(1-2):64-72
The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Lee SB, et al. **Cell** 1999 Sep 3;98(5):663-73
Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Caronti B, et al.
Clin Exp Immunol 1999 Jan;115(1):214-9
Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. Meroni L, et al. **Clin Immunol** 1999 Sep;92(3):276-84
Guinea pig alpha 1-microglobulin/bikunin: cDNA sequencing, tissue expression and expression during acute phase. Yoshida K, et al.
Comp Biochem Physiol B Biochem Mol Biol 1999 Feb; 122(2):165-72
Evolution of the diverse antifreeze proteins. Cheng CH.
Curr Opin Genet Dev 1998 Dec;8(6):715-20 (34 ref.)
Comparative cytogenetic mapping of COL14A1, the gene for human and mouse collagen XIV. Imhof M, et al.
Cytogenet Cell Genet 1999;84(3-4):217-9
Follistatin and noggin are excluded from the zebrafish organizer. Bauer H, et al. **Dev Biol** 1998 Dec 15; 204(2):488-507
Expression of SC1 is associated with the migration of myotomes along the dermomyotome during somitogenesis in early mouse embryos. Ringuette M, et al.
Dev Genes Evol 1998 Sep;208(7):403-6
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Luetteke NC, et al.
Development 1999 Jun;126(12):2739-50
A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al.
Development 1999 Jan;126(1):37-49
Mutational analysis of the coding regions of the genes encoding protein kinase B-alpha and -beta, phosphoinositide-dependent protein kinase-1, phosphatase targeting to glycogen, protein phosphatase inhibitor-1, and glycogenin: lessons from a search for genetic variability of the insulin-stimulated glycogen synthesis pathway of skeletal muscle in NIDDM patients. Hansen L, et al.
Diabetes 1999 Feb;48(2):403-7
Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Olsson U, et al. **Diabetes** 1999 Mar;48(3):616-22
Cloning and expression of a putative glycoprotein gene of channel catfish virus using baculovirus expression system. Kucuktas H, et al. **Dis Aquat Organ** 1998 Nov 30; 34(3):231-7
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Hofbauer LC, et al. **Endocrinology** 1999 Sep;140(9):4367-70
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Lee SK, et al.
Endocrinology 1999 Aug;140(8):3552-61
Comparative analysis of mammalian stanniocalcin genes. Varghese R, et al. **Endocrinology** 1998 Nov;139(11):4714-25
Evidence for stanniocalcin gene expression in mammalian bone. Yoshiko Y, et al. **Endocrinology** 1999 Apr; 140(4):1869-74
Structure of the human beta2-glycoprotein I (apolipoprotein H) gene. Okkels H, et al. **Eur J Biochem** 1999 Jan; 259(1-2):435-40
Comparison of expression patterns and cell adhesion properties of the mouse biliary glycoproteins Bbgp1 and Bbgp2. Robitaille J, et al. **Eur J Biochem** 1999 Sep; 264(2):534-44
A 42-kDa glycoprotein from chicken egg-envelope, an avian homolog of the ZPC family glycoproteins in mammalian Zona pellucida. Its first identification, cDNA cloning and granulosa cell-specific expression. Takeuchi Y, et al.
Eur J Biochem 1999 Mar;260(3):736-42
An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity. Regis S, et al. **Eur J Hum Genet** 1999 Feb-Mar; 7(2):125-30
Neuregulin is a mitogen and survival factor for olfactory bulb ensheathing cells and an isoform is produced by astrocytes. Pollock GS, et al. **Eur J Neurosci** 1999 Mar; 11(3):769-80
Semaphorin D acts as a repulsive factor for entorhinal and hippocampal neurons. Steup A, et al. **Eur J Neurosci** 1999 Feb;11(2):729-34
Cloning of adriamycin-resistant related (arr) gene in an adriamycin-resistant L1210 variant. Kim JR, et al.
Exp Mol Med 1998 Sep 30;30(3):145-9
Regulation of semaphorin III/collapsin-1 gene expression during peripheral nerve regeneration. Pasterkamp RJ, et al. **Exp Neurol** 1998 Oct;153(2):313-27
Random mutagenesis and screening of complex glycoproteins: expression of human gonadotropins in Dictyostelium discoideum. Linskens MH, et al.
FASEB J 1999 Apr;13(6):639-45
Cloning and expression of interleukin-18 binding protein. Aizawa Y, et al. **FEBS Lett** 1999 Feb 26;445(2-3):338-42
Clusterin (SGP-2) gene expression is cell cycle dependent in normal human dermal fibroblasts. Bettuzzi S, et al.
FEBS Lett 1999 Apr 9;448(2-3):297-300
Co-introduction of an antisense gene for an endogenous seed storage protein can increase expression of a transgene in Arabidopsis thaliana seeds. Goossens A, et al.
FEBS Lett 1999 Jul 30;456(1):160-4
A leucine-rich repeat protein of carrot that exhibits antifreeze activity. Meyer K, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):171-8
Surfactant protein A and D expression in the porcine Eustachian tube. Paananen R, et al. **FEBS Lett** 1999 Jun 11;452(3):141-4
The promoter of human p22/PACAP response gene 1 (PRG1) contains functional binding sites for the p53 tumor suppressor and for NFkappaB. Schäfer H, et al.
FEBS Lett 1998 Oct 2;436(2):139-43
The extensin multigene family responds differentially to superoxide or hydrogen peroxide in tomato cell cultures. Wisniewski JP, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):264-8
Studies on the GH/SL gene family: cloning of African lungfish (Protopterus annectens) growth hormone and somatolactin and toad (Bufo marinus) growth hormone. May D, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):121-35
Structure and polymorphism of the Chironomus thummi gene encoding special lobe-specific silk protein, ssp160. Berezikov E, et al. **Gene** 1998 Nov 26;223(1-2):347-54
Isolation, characterisation and embryonic expression of WNT11, a gene which maps to 11q13.5 and has possible roles in the development of skeleton, kidney and lung. Lako M, et al. **Gene** 1998 Sep 28;219(1-2):101-10
The alpha1-microglobulin/bikunin gene: characterization in mouse and evolution. Lindqvist A, et al. **Gene** 1999 Jul 8;234(2):329-36
Organization and transcriptional regulation of Drosophila Na(+), K(+)-ATPase beta subunit genes: Nrv1 and Nrv2. Xu P, et al. **Gene** 1999 Aug 20;236(2):303-13
Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway. Harrison DA, et al.
Genes Dev 1998 Oct 15;12(20):3252-63
Isolation and functional characterization of the human 90K promoter. Brakebusch C, et al. **Genomics** 1999 Apr 15; 57(2):268-78
Intergenic splicing between a HERV-H endogenous retrovirus and two adjacent human genes. Kowalski PE, et al. **Genomics** 1999 May 1;57(3):371-9
Structural organization and expression patterns of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Scott IC, et al. **Genomics** 1999 Jan 15;55(2):229-34
Mapping the mouse otoconin-90 (Oc90) gene to chromosome 15. Wang Y, et al. **Genomics** 1999 Jun 1;58(2):214-5
Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Yokota A, et al. **Hematol Oncol** 1998 Dec;16(4):131-41
The absence of 150-kDa insulin-like growth factor

complexes in fetal rat serum is not due to a lack of functional acid-labile subunit. Lee CY, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):182-5

Apolipoprotein J polymorphisms and serum HDL cholesterol levels in African blacks. Nestlerode CS, et al. **Hum Biol** 1999 Apr;71(2):197-218

Novel and recurrent COMP (cartilage oligomeric matrix protein) mutations in pseudoachondroplasia and multiple epiphyseal dysplasia. Ikegawa S, et al. **Hum Genet** 1998 Dec;103(6):633-8

A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype. Maxwell MA, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):38-44

Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations. Mehdi H, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):63-71

Genomic organisation of the human chordin gene and mutation screening of candidate Cornelia de Lange syndrome genes. Smith M, et al. **Hum Genet** 1999 Jul-Aug; 105(1-2):104-11

Genetic polymorphisms of apolipoproteins A-IV, E and H in Koreans. Kim HS, et al. **Hum Hered** 1998 Nov-Dec; 48(6):313-7

Trinucleotide expansion mutations in the cartilage oligomeric matrix protein (COMP) gene. Délot E, et al. **Hum Mol Genet** 1999 Jan;8(1):123-8

Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Fingert JH, et al. **Hum Mol Genet** 1999 May;8(5):899-905

Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Tazi Ahnini R, et al. **Hum Mol Genet** 1999 Jun;8(6):1135-40

Identification of five novel mutations in cartilage oligomeric matrix protein gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Loughlin J, et al. **Hum Mutat** 1998; Suppl 1:S10-7

Pseudoachondroplasia due to the substitution of the highly conserved Asp482 by Gly in the seventh calmodulin-like repeat of cartilage oligomeric matrix protein. Susic S, et al. **Hum Mutat** 1998;Suppl 1:S125-7

Gorilla RH-like genes and antigens. Apoil PA, et al. **Immunogenetics** 1999 Feb;49(2):125-33

Molecular cloning, characterization, and expression of the M antigen of Histoplasma capsulatum. Zancopé-Oliveira RM, et al. **Infect Immun** 1999 Apr;67(4):1947-53

Cloning of follistatin-related protein as a novel autoantigen in systemic rheumatic diseases. Tanaka M, et al. **Int Immunol** 1998 Sep;10(9):1305-14

Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Niemeyer CC, et al. **Int J Cancer** 1999 May 17;81(4):588-91

Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. van Hal NL, et al. **Int J Cancer** 1999 Sep 9;82(6):837-45

Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Allingham RR, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2288-95

Evaluation of the APOH gene as a positional candidate for prcd in dogs. Gu W, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1229-37

Modulation of myocilin/TIGR expression in human trabecular meshwork. Tamm ER, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2577-82

Expression of soluble human signaling lymphocytic activation molecule in vivo. Isomäki P, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):114-8

Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. Iida S, et al. **J Am Soc Nephrol** 1999 May;10(5):986-96

Deletion of new covalently linked cell wall glycoproteins alters the electrophoretic mobility of phosphorylated wall components of Saccharomyces cerevisiae. Mrsa V, et al. **J Bacteriol** 1999 May;181(10):3076-86

Expression of trans-sialidase and 85-kDa glycoprotein genes in Trypanosoma cruzi is differentially regulated at the post-transcriptional level by labile protein factors. Abuin G, et al. **J Biol Chem** 1999 May 7;274(19):13041-7

The exon structure of the human MAGP-2 gene. Similarity with the MAGP-1 gene is confined to two exons encoding a cysteine-rich region. Hatzinikolas G, et al. **J Biol Chem** 1998 Nov 6;273(45):29309-14

Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein induces endothelial cell sprouting. Kim I, et al. **J Biol Chem** 1999 Sep 10;274(37):26523-8

Molecular cloning of the oncofetal isoform of the human pancreatic bile salt-dependent lipase. Pasqualini E, et al. **J Biol Chem** 1998 Oct 23;273(43):28208-18

The bovine mimecan gene. Molecular cloning and characterization of two major RNA transcripts generated by alternative use of two splice acceptor sites in the third exon. Tasheva ES, et al. **J Biol Chem** 1999 Jun 25; 274(26):18693-701

Differential display identification of plunc, a novel gene expressed in embryonic palate, nasal epithelium, and adult lung. Weston WM, et al. **J Biol Chem** 1999 May 7; 274(19):13698-703

Expression of transcripts for cysteine-rich secretory proteins (CRISPs) in the murine lacrimal gland. Haendler B, et al. **J Cell Physiol** 1999 Mar;178(3):371-8

Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis. Klock G, et al. **J Cell Physiol** 1998 Dec;177(4):593-605

Caveolin-3 deficiency as a cause of limb-girdle muscular dystrophy. Kunkel L. **J Child Neurol** 1999 Jan;14(1):33-4

Promegestone (R5020) and mifepristone (RU486) both function as progestational agonists of human glycodelin gene expression in isolated human epithelial cells. Taylor RN, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):4006-12

Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis. Brandhorst TT, et al. **J Exp Med** 1999 Apr 19;189(8):1207-16

Sequence analyses of human herpesvirus-8 strains from both African human immunodeficiency virus-negative and -positive childhood endemic Kaposi's sarcoma show a close relationship with strains identified in febrile children and high variation in the K1 glycoprotein. Kasolo FC, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3055-65

Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. Matthews DA, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):345-53

Comparative sequence analysis and predictions for the envelope glycoproteins of foamy viruses. Wang G, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):245-54

A GLC1A gene Gln368Stop mutation in a patient with normal-tension open-angle glaucoma. Mardin CY, et al. **J Glaucoma** 1999 Apr;8(2):154-6

Genomic organization, mapping, and polymorphisms of the gene encoding human cartilage intermediate layer protein (CILP). Nakamura I, et al. **J Hum Genet** 1999;44(3):203-5

Proline-rich vaccine candidate antigen of Coccidioides immitis: conservation among isolates and differential expression with spherule maturation. Peng T, et al. **J Infect Dis** 1999 Feb;179(2):518-21

Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. Viard I, et al. **J Invest Dermatol** 1999 Mar;112(3):290-6

Assessment of the interphotoreceptor matrix proteoglycan-1 (IMPG1) gene localised to 6q13-q15 in autosomal dominant Stargardt-like disease (ADSTGD), progressive bifocal chorioretinal atrophy (PBCRA), and North Carolina macular dystrophy (MCDR1). Gehrig A, et al. **J Med Genet** 1998 Aug;35(8):641-5

A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma. Kennan AM, et al. **J Med Genet** 1998 Nov; 35(11):957-60

Novel TIGR/MYOC mutations in families with juvenile onset primary open angle glaucoma. Stoilova D, et al. **J Med Genet** 1998 Dec;35(12):989-92

Involvement of the C-terminal region of yeast proteinase B inhibitor 2 in its inhibitory action. Kojima S, et al. **J Mol Biol** 1999 Feb 26;286(3):775-85

Glycodelin mRNA is expressed in the genital tract of male and female rats (Rattus norvegicus). Keil C, et al. **J Mol Endocrinol** 1999 Aug;23(1):57-66

Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats. Calcutt NA, et al. **J Neuropathol Exp Neurol** 1999 Jun; 58(6):628-36

Evidence for a role of the chemorepellent semaphorin III and its receptor neuropilin-1 in the regeneration of primary olfactory axons. Pasterkamp RJ, et al. **J Neurosci** 1998 Dec 1;18(23):9962-76

Collapsin-1/semaphorin-III/D is regulated developmentally in Purkinje cells and collapses pontocerebellar mossy fiber neuronal growth cones. Rabacchi SA, et al. **J Neurosci** 1999 Jun 1;19(11):4437-48

Differential mRNA display cloning and characterization of a Cryptosporidium parvum gene expressed during intracellular development. Schroeder AA, et al. **J Parasitol** 1999 Apr;85(2):213-20

Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. Iida S, et al. **J Urol** 1999 Oct; 162(4):1480-6

Analysis of ruminant respiratory syncytial virus isolates by RNAse protection of the G glycoprotein transcripts. Alansari H, et al. **J Vet Diagn Invest** 1999 May;11(3):215-20

Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family. Cai JS, et al. **J Vet Med Sci** 1999 May;61(5):503-11

Molecular cloning of cDNA for equine follistatin and its gene expression in the reproductive tissues of the mare. Sugawara Y, et al. **J Vet Med Sci** 1999 Mar;61(3):201-7

Identification and characterization of Kaposi's sarcoma-associated herpesvirus K8.1 virion glycoprotein. Li M, et al. **J Virol** 1999 Feb;73(2):1341-9

Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. Miletic H, et al. **J Virol** 1999 Jul; 73(7):6114-6

Clinical phenotype of a Japanese family with primary open angle glaucoma caused by a Pro370Leu mutation in the MYOC/TIGR gene. Taniguchi F, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):80-4

Detection of a new TIGR gene mutation in a Japanese family with primary open angle glaucoma. Yokoyama A, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):85-8

Expression of the Wnt gene family during late nephrogenesis and complete ureteral obstruction. Nguyen HT, et al. **Lab Invest** 1999 Jun;79(6):647-58

Gene mutation responsible for fatal EBV complication discovered [news] McCarthy M. **Lancet** 1998 Oct 3; 352(9134):1125

Corneodesmosin (MHC S) gene in guttate psoriasis [letter] Tazi-Ahnini R, et al. **Lancet** 1999 Aug 14;354(9178):597

Detection of bikunin mRNA in limited portions of rat brain. Takano M, et al. **Life Sci** 1999;65(8):757-62

Genetics of apolipoprotein H (beta2-glycoprotein I) and anionic phospholipid binding. Kamboh MI, et al. **Lupus** 1998;7 Suppl 2:S10-3 (24 ref.)

Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. Hecht JT, et al. **Matrix Biol** 1998 Dec; 17(8-9):625-33

Developmental expression analysis of murine autotaxin (ATX). Bächner D, et al. **Mech Dev** 1999 Jun;84(1-2):121-5

Developmental expression patterns of mouse sFRP genes encoding members of the secreted frizzled related protein family. Leimeister C, et al. **Mech Dev** 1998 Jul; 75(1-2):29-42

Genetic variation in the VP4 and NSP4 genes of human rotavirus serotype 3 (G3 type) isolated in China and Japan. Cao XR, et al. **Microbiol Immunol** 1999;43(2):171-5

Molecular cloning and characterization of the polypeptide backbone of Schistosoma mansoni circulating cathodic antigen. Abdeen HH, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1-2):149-59

Transcription of 'inactive' expression sites in African trypanosomes leads to expression of multiple transferrin receptor RNAs in bloodstream forms. Ansorge I, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1-2):81-94

Assembly of a novel cartilage matrix protein filamentous network: molecular basis of differential requirement of von Willebrand factor A domains. Chen Q, et al. **Mol Biol Cell** 1999 Jul;10(7):2149-62

The molecular evolution of sperm bindin in six species of sea urchins (Echinoida: Strongylocentrotidae). Biermann CH. **Mol Biol Evol** 1998 Dec;15(12):1761-71

Molecular cloning and developmental expression of rat glycogenin in cardiac tissue. Pak BJ, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):117-23

Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Chang AC, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):95-9

Molecular cloning and characterization of stanniocalcin-related protein. DiMattia GE, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):137-40

In situ hybridization analysis of stanniocalcin mRNA expressing cells in the mouse kidney. Yoshiko Y, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):37-40

Distribution of neuregulin-1 (nrg1) and erbB4 transcripts in embryonic chick hindbrain. Dixon M, et al. **Mol Cell Neurosci** 1999 Apr;13(4):237-58

Molecular cloning, tissue-specific expression, and chromosomal localization of a novel nerve growth factor-regulated G-protein- coupled receptor, nrg-1. Glickman M, et al. **Mol Cell Neurosci** 1999 Aug; 14(2):141-52

Expression of the gene encoding the chemorepellent semaphorin III is induced in the fibroblast component of neural scar tissue formed following injuries of adult but not neonatal CNS. Pasterkamp RJ, et al. **Mol Cell Neurosci** 1999 Feb;13(2):143-66

Neuregulins and erbB receptors at neuromuscular junctions and at agrin-induced postsynaptic-like apparatus in skeletal muscle. Rimer M, et al. **Mol Cell Neurosci** 1998 Sep; 12(1-2):1-15

Molecular characterization of two light-induced, gamete-specific genes from Chlamydomonas reinhardtii that encode hydroxyproline-rich proteins. Rodriguez H, et al. **Mol Gen Genet** 1999 Mar;261(2):267-74

Peritoneal endometriotic lesions differentially express a haptoglobin-like gene. Piva M, et al. **Mol Hum Reprod** 1999 Jan;5(1):71-8

Cloning of complementary DNA encoding the pB1 component of the 54-kilodalton glycoprotein of boar seminal plasma. Plucienniczak G, et al. **Mol Reprod Dev** 1999 Mar;52(3):303-9

Purification, characterization, and molecular cloning of carp hyosophorin. Tsao CC, et al. **Mol Reprod Dev** 1999 Mar; 52(3):288-96

Early embryonic expression of the growth hormone family protein genes in the developing rainbow trout, Oncorhynchus mykiss. Yang BY, et al. **Mol Reprod Dev** 1999 Jun;53(2):127-34

GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein. Rozsa FW, et al. **Mol Vis** 1998 Oct 6;4:20

A trabecular meshwork glucocorticoid response (TIGR) gene mutation affects translocational processing. Zimmerman CC, et al. **Mol Vis** 1999 Aug 23;5:19

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease [see comments] Bodzioch M, et al. **Nat Genet** 1999 Aug;22(4):347-51. Comment in: Nat Genet 1999 Aug;22(4):316-8.

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency [see comments] Brooks-Wilson A, et al. **Nat Genet** 1999 Aug;22(4):336-45 . Comment in: Nat Genet 1999 Aug;22(4):316-8.

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 [see comments] Rust S, et al. **Nat Genet** 1999 Aug;22(4):352-5. Comment in: Nat Genet 1999 Aug;22(4):316-8.

The mouse mahogany locus encodes a transmembrane form of human attractin. Gunn TM, et al. **Nature** 1999 Mar 11; 398(6723):152-6

C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Grewal RP, et al. **Neurosci Lett** 1999 Aug 13; 271(1):65-7

Expression of mouse semaphorin H mRNA in the inner ear of mouse fetuses. Miyazaki N, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):127-9

The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Weinstein EJ, et al. **Oncogene** 1998 Oct 22;17(16):2107-13

Differential expression of the murine Ly-6A/E antigen homolog of human squamous cell carcinoma antigen E48 during malignant transformation and tumor progression of squamous cell carcinoma line Pam 212. Kato T, et al. **Otolaryngol Head Neck Surg** 1998 Oct;119(4):408-11

The detection of Trichinella with polymerase chain reaction (PCR) primers constructed using sequences of random amplified polymorphic DNA (RAPD) or sequences of complementary DNA encoding excretory-secretory (E-S) glycoproteins. Wu Z, et al. **Parasitology** 1998 Aug;117 (Pt 2):173-83

The S15 self-incompatibility haplotype in Brassica oleracea includes three S gene family members expressed in stigmas. Cabrillac D, et al. **Plant Cell** 1999 May;11(5):971-86

Comparative analysis of S haplotypes with very similar SLG alleles in Brassica rapa and Brassica oleracea. Kusaba M, et al. **Plant J** 1999 Jan;17(1):83-91

Map positions of SFR genes in relation to other freezing-related genes of Arabidopsis thaliana. Thorlby G, et al. **Plant J** 1999 Feb;17(4):445-52

Control of expression of a gene encoding an extensin by phytochrome and a blue light receptor in spores of Adiantum capillus-veneris L. Uchida K, et al. **Plant J** 1998 Sep;15(6):813-9

Regulation by biotic and abiotic stress of a wheat germin gene encoding oxalate oxidase, a H2O2-producing enzyme. Berna A, et al. **Plant Mol Biol** 1999 Feb;39(3):539-49

Arabidopsis thaliana contains a large family of germin-like proteins: characterization of cDNA and genomic sequences encoding 12 unique family members. Carter C, et al. **Plant Mol Biol** 1998 Dec;38(6):929-43

Characterization of a germin-like protein gene expressed in somatic and zygotic embryos of pine (Pinus caribaea Morelet). Neutelings G, et al. **Plant Mol Biol** 1998 Dec; 38(6):1179-90

The Atger3 promoter confers circadian clock-regulated transcription with peak expression at the beginning of the night. Staiger D, et al. **Plant Mol Biol** 1999 Jul;40(5):873-82

Introduction of SLG (S locus glycoprotein) alters the phenotype of endogenous S haplotype, but confers no new S haplotype specificity in Brassica rapa L. Takasaki T, et al. **Plant Mol Biol** 1999 Jul;40(4):659-68

The Arabidopsis extensin gene is developmentally regulated, is induced by wounding, methyl jasmonate, abscisic and salicylic acid, and codes for a protein with unusual motifs. Merkouropoulos G, et al. **Planta** 1999 Apr;208(2):212-9

Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Liu X, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13024-9

A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin [comment] Odunsi K, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20; 96(15):8315-7. Comment on: Proc Natl Acad Sci U S A 1999 Jul 20;96(15):8573-8.

Dynamic visualization of nervous system in live Drosophila. Sun B, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10438-43

Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin [see comments] Urbanek M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8573-8. Comment in: Proc Natl Acad Sci U S A 1999 Jul 20;96(15):8315-7.

Characterization of otoconin-95, the major protein of murine otoconia, provides insights into the formation of these inner ear biominerals. Verpy E, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):529-34

Inhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor). Zhang H, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14202-7

Stable, high-level expression of a type I antifreeze protein in Escherichia coli. Solomon RG, et al. **Protein Expr Purif** 1999 Jun;16(1):53-62

Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Atsumi T, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):721-3

Gene linked to faulty cholesterol transport [news] Gura T. **Science** 1999 Aug 6;285(5429):814-5

Increased gene dosage augments antifreeze protein levels in transgenic Drosophila melanogaster. Duncker BP, et al. **Transgenic Res** 1999 Feb;8(1):45-50

Expression of surfactant protein mRNA in normal and neoplastic lung of B6C3F1 mice as demonstrated by in situ hybridization. Pilling AM, et al. **Vet Pathol** 1999 Jan; 36(1):57-63

Channel catfish virus gene 50 encodes a secreted, mucin-like glycoprotein. Vanderheijden N, et al. **Virology** 1999 Apr 25;257(1):220-7

Identification of human and mouse homologs of the MC51L-53L-54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus. Xiang Y, et al. **Virology** 1999 May 10;257(2):297-302

Structure, expression and phylogenetic analysis of the glycoprotein gene of Cocal virus. Bhella RS, et al. **Virus Res** 1998 Apr;54(2):197-205

Identification and characterization of the glycoprotein E and I genes of canine herpesvirus. Nishikawa Y, et al. **Virus Res** 1998 Jul;56(1):77-92

A single point mutation at a splice site generates a silent RH50 gene in a composite heterozygous RHnull blood donor [letter] Cowley NM, et al. **Vox Sang** 1999;76(4):247-8

IMMUNOLOGY

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Bousquet J, et al. **Allergy** 1999 Mar;54(3):249-60

Biologic activity of Dermatophagoides siboney and Blomia tropicalis allergens in exposed and unexposed mite-allergic individuals. Effect of patient selection on the biologic standardization of mite extracts. Casas R, et al. **Allergy** 1999 Apr;54(4):392-6

Peak expiration flow variations may reflect house-dust-mite exposure and patient reactivity. Hallas TE, et al. **Allergy** 1998;53(48 Suppl):101-3

Sensitization to allergens of house-dust mite in adults with atopic dermatitis in a cold temperature region. Holm L, et al. **Allergy** 1999 Jul;54(7):708-15

Reactivity to recombinant house-dust-mite allergens in asthma and rhinitis in a tropical environment. Lynch NR, et al. **Allergy** 1998 Aug;53(8):808-11

Exposure to an abundance of cat (Fel d 1) and dog (Can f 1) allergens in Swedish farming households. Parvaneh S, et al. **Allergy** 1999 Mar;54(3):229-34

House-dust-mite allergens. Thomas WR, et al. **Allergy** 1998 Sep;53(9):821-32 (126 ref.)

House-dust mite hypersensitivity, eczema, and other nonpulmonary manifestations of allergy. Tupker RA, et al. **Allergy** 1998;53(48 Suppl):92-6 (33 ref.)

Bronchial allergen challenge in subjects with low levels of allergic sensitization to indoor allergens. Witteman AM, et al. **Allergy** 1999 Apr;54(4):366-74

Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Gómez-Pacheco L, et al. **Am J Med** 1999 Apr;106(4):417-23

Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome. Lee RM, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):642-8

Correlation between beta 2-glycoprotein antibodies and antiphospholipid antibodies in patients with reproductive failure. Chong P, et al. **Am J Reprod Immunol** 1998 Dec; 40(6):414-7

Linkage of house dust mite allergy with the HLA region. Torres-Galván MJ, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):198-203

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arnett FC, et al. **Arthritis Rheum** 1999 Feb;42(2):268-74

Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-beta2-glycoprotein I antibodies. Rovere P, et al. **Arthritis Rheum** 1999 Jul;42(7):1412-20

High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease. Farsi A, et al. **Autoimmunity** 1999;30(2):93-8

Glycosylated ectodomain of the human thyrotropin receptor induces antibodies capable of reacting with multiple blocking antibody epitopes. Seetharamaiah GS, et al. **Autoimmunity** 1999;29(1):21-31

Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity. Celli CM, et al. **Biochim Biophys Acta** 1999 Jan 12; 1416(1-2):225-38

Structure, biologic properties, and expression of surfactant protein D (SP-D). Crouch EC. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):278-89 (72 ref.)

Interactions of surfactant protein D with pathogens, allergens and phagocytes. Reid KB. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):290-5 (34 ref.)

Preparation of a monoclonal antibody specific for human stanniocalcin. Koide Y, et al. **Biol Pharm Bull** 1998 Dec; 21(12):1352-5

Purification and some chemical properties of 30 kDa Ginkgo biloba glycoprotein, which reacts with antiserum against beta 1-->2 xylose-containing N-glycans. Kimura Y, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):463-7

Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy. Saleh MN, et al. **Biotech Histochem** 1998 Jul;73(4):186-97

Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test [letter; comment] Mercier E, et al. **Blood** 1998 Oct 15;92(8):2993-4. Comment on: Blood 1998 Mar 15;91(6):1999-2004.

Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Zhu M, et al. **Br J Haematol** 1999 Apr;105(1):102-9

Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Inanç M, et al. **Br J Rheumatol** 1998 Oct;37(10):1089-94

Absence of anti-beta2 glycoprotein I antibodies in giant cell arteritis: a study of 45 biopsy-proven cases. Liozon E, et al. **Br J Rheumatol** 1998 Oct;37(10):1129-31

Pattern of immune response to GP43 from Paracoccidioides brasiliensis in susceptible and resistant mice is influenced by antigen-presenting cells. de Almeida SR, et al. **Cell Immunol** 1998 Nov 25;190(1):68-76

Induction of allergic reactions in guinea pigs with purified house dust mite allergens. Yasue M, et al. **Cell Immunol** 1999 Mar 15;192(2):185-93

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Macey DJ, et al. **Clin Cancer Res** 1997 Sep; 3(9):1547-55

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG, et al. **Clin Cancer Res** 1999 May; 5(5):953-61

Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Russoniello C, et al. **Clin Cancer Res** 1998 Sep;4(9):2237-43

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Xu FJ, et al. **Clin Cancer Res** 1997 Sep;3(9):1629-34

Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Zhang S, et al. **Clin Cancer Res** 1998 Nov;4(11):2669-76

The Cheshire cat's grin--is cat allergy here to stay? [editorial; comment] Bateman BJ, et al. **Clin Exp Allergy** 1999 Jun; 29(6):725-8 (30 ref.). Comment on: Clin Exp Allergy 1999 Jun;29(6):759-61. Comment on: Clin Exp Allergy 1999 Jun;29(6):762-5.

Circulating cat allergen and immune complexes in cat-allergic children. Casas R, et al. **Clin Exp Allergy** 1998 Oct;28(10):1258-63

Allergenic differences between the domestic mites Blomia tropicalis and Dermatophagoides pteronyssinus. Chew FT, et al. **Clin Exp Allergy** 1999 Jul;29(7):982-8

Altered antigenicity of M-177, a 177-kDa allergen from the house dust mite Dermatophagoides farinae, in stored extract. Fujikawa A, et al. **Clin Exp Allergy** 1998 Dec; 28(12):1549-58

Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients [see comments] Gruber W, et al. **Clin Exp Allergy** 1999 Feb;29(2):176-81. Comment in: Clin Exp Allergy 1999 Feb;29(2):143.

High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats [see comments] Ichikawa K, et al. **Clin Exp Allergy** 1999 Jun; 29(6):754-61. Comment in: Clin Exp Allergy 1999 Jun;29(6):725-8.

Primary sequence and molecular model of the variable region of a mouse monoclonal anti-Der p 1 antibody showing a similar epitope specificity as human IgE. McElveen JE, et al. **Clin Exp Allergy** 1998 Nov;28(11):1427-34

House dust mite allergen exposure in infancy. Mahmic A, et al. **Clin Exp Allergy** 1998 Dec;28(12):1487-92

Dermatophagoides sp. and IgE anti-D. pteronyssinus and D. farinae detection in a Venezuelan community at more than 2000 m above the sea level. Rangel A, et al. **Clin Exp Allergy** 1998 Sep;28(9):1100-3

The interaction between the dust mite antigen Der p 1 and cell-signalling molecules in amplifying allergic disease. Schulz O, et al. **Clin Exp Allergy** 1999 Apr;29(4):439-44 (72 ref.)

The late asthmatic response is associated with baseline allergen-specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin-5. van der Veen MJ, et al. **Clin Exp Allergy** 1999 Feb;29(2):217-27

Attenuation of house dust mite Dermatophagoides farinae-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. Yu CK, et al. **Clin Exp Allergy** 1999 Mar;29(3):414-22

Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats [see comments] Carlsén S, et al. **Clin Exp Immunol** 1998 Dec;114(3):477-84. Comment in: Clin Exp Immunol 1998 Dec;114(3):330-2.

Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Chamley LW, et al. **Clin Exp Immunol** 1999 Mar;115(3):571-6

Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Lakos G, et al. **Clin Exp Immunol** 1999 Sep;117(3):574-9

Evidence of idiotypic modulation in the immune response to gp43, the major antigenic component of Paracoccidioides brasiliensis in both mice and humans. Souza AR, et al. **Clin Exp Immunol** 1998 Oct;114(1):40-8

Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Wu R, et al. **Clin Exp Immunol** 1999 Mar;115(3):561-6

HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. Hashimoto H, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):423-7

Anticardiolipin and anti-beta 2glycoprotein I immunoassays in the diagnosis of antiphospholipid syndrome. Tincani A, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):396-402 (103 ref.)

Autoantibodies to leukocyte alphaMbeta2 integrin glycoproteins in HIV infection. Rubinstein DB, et al. **Clin Immunol** 1999 Mar;90(3):352-9

Detecting serum antibodies to a purified recombinant proline-rich antigen of Coccidioides immitis in patients with coccidioidomycosis. Orsborn KI, et al. **Clin Infect Dis** 1998 Dec;27(6):1475-8

Membrane receptors for soluble defense collagens. Tenner AJ. **Curr Opin Immunol** 1999 Feb;11(1):34-41 (79 ref.)

Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Koutroubakis IE, et al. **Dig Dis Sci** 1998 Nov;43(11):2507-12

Mapping of linear antibody epitopes of the glycoprotein of VHSV, a salmonid rhabdovirus. Fernandez-Alonso M, et al. **Dis Aquat Organ** 1998 Nov 30;34(3):167-76

Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Bachmann MF, et al. **Eur J Immunol** 1998 Oct; 28(10):3110-9

The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. McKay PF, et al. **Eur J Immunol** 1998 Dec;28(12):4071-83

Elevation of specific immunoglobulin A antibodies to both allergen and bacterial antigen in induced sputum from asthmatics [see comments] Nahm DH, et al. **Eur Respir J** 1998 Sep;12(3):540-5. Comment in: Eur Respir J 1998 Sep;12(3):517-8.

Trypanosoma cruzi: monoclonal antibodies to the surface glycoprotein superfamily differentiate subsets of the 85-kDa surface glycoproteins and confirm simultaneous expression of variant 85-kDa surface glycoproteins. Kahn SJ, et al. **Exp Parasitol** 1999 May;92(1):48-56

N-linked glycan of a sperm CD52 glycoform associated with human infertility. Diekman AB, et al. **FASEB J** 1999 Aug; 13(11):1303-13

Antibodies to beta2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study. Stern C, et al. **Fertil Steril** 1998 Nov;70(5):938-44

Human reproductive failure is not a clinical feature associated with beta(2) glycoprotein-I antibodies in anticardiolipin and lupus anticoagulant seronegative patients (the antiphospholipid/cofactor syndrome). Balasch J, et al. **Hum Reprod** 1999 Aug;14(8):1956-9

Differential production of monoclonal antibodies to carbohydrate moiety or peptides moiety of glycoproteins by different routes of immunization. Kimura A, et al. **Hybridoma** 1998 Jun;17(3):245-50

Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Tripathi PK, et al. **Hybridoma** 1999 Apr; 18(2):193-202

Intrathymic function of the human cortical epithelial cell surface antigen gp200-MR6: single-chain antibodies to evolutionarily conserved determinants disrupt mouse thymus development. Palmer DB, et al. **Immunology** 1999 Feb;96(2):236-45

Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen. Abuodeh RO, et al. **Infect Immun** 1999 Jun;67(6):2935-40

Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA. Jiang C, et al. **Infect Immun** 1999 Feb;67(2):630-5

Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis. Wüthrich M, et al. **Infect Immun** 1998 Nov;66(11):5443-9

Validation of family sampling for mite allergen (Der p 1) exposure. Carswell F, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):324-5

Seasonal variation in concentrations of mite allergen (Der p 1) in the mattress. Carswell F, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):326-7

Cat-specific IgA antibodies in breast milk from atopic and non-atopic mothers: detection of Fel d 1-IgG immune complexes in cord blood and sera. Casas R, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):317-8

Allergic respiratory responses to Der p 1 in mice. Clarke AH, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2-4):287-8

Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1. Hoyne GF, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):122-4

beta2-Glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients [letter] Fiallo P, et al. **Int J Lepr Other Mycobact Dis** 1998 Sep;66(3):387-8

Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Hombach A, et al. **Int J Mol Med** 1998 Jul;2(1):99-103

Measurement of murine IgE antibody responses to dust mite allergens by in vitro assay. Ma Y, et al. **Int J Mol Med** 1999 Jun;3(6):621-4

Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura [letter; comment] Kaburaki J, et al. **Intern Med** 1998 Sep;37(9):796; discussion 797-8. Comment on: Intern Med 1997 Dec;36(12):882-5.

Neutralization of borna disease virus depends upon terminal carbohydrate residues (alpha-D-man, beta-D-GlcNAc) of glycoproteins gp17 and gp94. Stoyloff R, et al. **Intervirology** 1998;41(2-3):135-40

Genetic regulation of Dermatophagoides pteronyssinus-specific IgE responsiveness: a genome-wide multipoint linkage analysis in families recruited through 2 asthmatic sibs. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):436-42

Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):443-8

Association between Der p 1 concentration and peak expiratory flow rate in children with wheeze: a longitudinal analysis. Jalaludin B, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):382-6

Clinical effects of air cleaners in homes of asthmatic children sensitized to pet allergens. van der Heide S, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):447-51

Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. Caronti B, et al. **J Autoimmun** 1998 Oct;11(5):425-9

Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes [published erratum appears in J Autoimmun 1999 Mar;12(2):143] Levine JS, et al. **J Autoimmun** 1998 Oct; 11(5):413-24

Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies. Rovere P, et al. **J Autoimmun** 1998 Oct;11(5):403-11

Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. Vlachoyiannopoulos PG, et al. **J Clin Immunol** 1998 Nov; 18(6):380-91

A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1). Hansson AS, et al. **J Clin Invest** 1999 Sep;104(5):589-98

Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I. González C, et al. **J Clin Lab Anal** 1999;13(2):59-64

Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome. Lewis S, et al. **J Clin Lab Anal** 1998;12(5):293-7

Location of neutralizing epitopes on the G protein of bovine ephemeral fever rhabdovirus. Kongsuwan K, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2573-81

Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. Blank M, et al. **J Immunol** 1998 Nov 15; 161(10):5303-12

Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. De Palma R, et al. **J Immunol** 1999 Feb 15;162(4):1982-7

Cellular immunity to beta 2-glycoprotein-I in patients with the antiphospholipid syndrome. Visvanathan S, et al. **J Immunol** 1999 Jun 1;162(11):6919-25

Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. Wolvers DA, et al. **J Immunol** 1999 Feb 15;162(4):1994-8

Bikunin, a serine protease inhibitor, is present on the cell boundary of epidermis. Cui CY, et al. **J Invest Dermatol** 1999 Aug;113(2):182-8

Further characterization of IgE-binding antigens in kiwi, with particular emphasis on glycoprotein allergens. Fahlbusch B, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec;8(6):325-32

Anticardiolipin and anti-beta2-glycoprotein I antibodies in Behcet's disease. Kang HJ, et al. **J Korean Med Sci** 1998 Aug;13(4):400-4

Multiple sclerosis with mite antigen-specific IgE. Kira J, et al. **J Neurol Sci** 1998 May 7;157(2):138-42

Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. Pavlinkova G, et al. **J Nucl Med** 1999 Sep;40(9):1536-46

Glycosylation and the immune system. Rudd PM, et al. **J Protein Chem** 1998 Aug;17(6):519

Antiphospholipid antibodies: an update from the eighth international symposium. Silver RM. **J Reprod Immunol** 1999 May;43(1):85-9

IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus [letter; comment] Samarkos M, et al. **J Rheumatol** 1998 Nov;25(11):2283-4. Comment on: J Rheumatol 1998 Jan;25(1):74-8.

Antibodies to beta2-glycoprotein I: a potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. Sanfilippo SS, et al. **J Rheumatol** 1998 Nov;25(11):2131-4

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Cheng-Mayer C, et al. **J Virol** 1999 Jul;73(7):5294-300

Chimeric lyssavirus glycoproteins with increased immunological potential. Jallet C, et al. **J Virol** 1999 Jan; 73(1):225-33

Ebola virus can be effectively neutralized by antibody produced in natural human infection. Maruyama T, et al. **J Virol** 1999 Jul;73(7):6024-30

Mechanism of action of beta2-glycoprotein I-dependent lupus anticoagulants. Arnout J, et al. **Lupus** 1998;7 Suppl 2:S23-8 (64 ref.)

[Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Biasiolo A, et al. **Lupus** 1999; 8(2):121-6

Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Cucurull E, et al. **Lupus** 1999;8(2):134-41

Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Diri E, et al. **Lupus** 1999; 8(4):263-8

Antibodies to cardiolipin and beta2-glycoprotein-1 in HTLV-1-associated myelopathy/tropical spastic paraparesis. Faghiri Z, et al. **Lupus** 1999;8(3):210-4

Beta2 glycoprotein I containing immune-complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels. George J, et al. **Lupus** 1999; 8(2):116-20

Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Gharavi AE, et al. **Lupus** 1998;7 Suppl 2:S52-4 (25 ref.)

Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone. Gharavi AE, et al. **Lupus** 1998;7(5):341-6

A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies. Iverson GM, et al. **Lupus** 1998;7 Suppl 2:S166-9

Anti-beta2-glycoprotein I and anti-prothrombin antibodies in patients with the 'antiphospholipid' syndrome: immunological specificity and clotting profiles. Kandiah DA, et al. **Lupus** 1998;7(5):323-32

Epitopes on beta2-GPI recognized by anticardiolipin antibodies. Koike T, et al. **Lupus** 1998;7 Suppl 2:S14-7 (33 ref.)

Beta2-glycoprotein I: target antigen for 'antiphospholipid' antibodies. Immunological and molecular aspects. Sheng Y, et al. **Lupus** 1998;7 Suppl 2:S5-9 (39 ref.)

Beta2GP-I in the anti phospholipid (Hughes') syndrome--from a cofactor to an autoantigen--from induction to prevention of antiphospholipid syndrome. Shoenfeld Y, et al. **Lupus** 1998;7(8):503-6 (71 ref.)

Anti beta2-glycoprotein I antibodies: clinical significance. Tincani A, et al. **Lupus** 1998;7 Suppl 2:S107-9 (29 ref.)

Anti-beta2-glycoprotein I antibodies. Tsutsumi A, et al. **Lupus** 1998;7 Suppl 2:S98-102 (17 ref.)

Significance of IgA antiphospholipid antibodies. Wilson WA, et al. **Lupus** 1998;7 Suppl 2:S110-3 (34 ref.)

Antigenic relationship between Loboa loboi and Paracoccidioides brasiliensis as shown by serological methods. Camargo ZP, et al. **Med Mycol** 1998 Dec; 36(6):413-7

A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. Focarelli R, et al. **Mol Hum Reprod** 1999 Jan;5(1):46-51

Analysis of human IgE epitope of Der f 2 with anti-Der f 2 mouse monoclonal antibodies. Nishiyama C, et al. **Mol Immunol** 1999 Jan;36(1):53-60

Host organism defense by a peptide-polysaccharide extracted from the fungus Sporothrix schenckii. Carlos IZ, et al. **Mycopathologia** 1998-99;144(1):9-14

Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Lynch A, et al. **Obstet Gynecol** 1999 Feb;93(2):193-8

Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein. Pereira-Chioccola VL, et al. **Parasite Immunol** 1999 Feb;21(2):103-10

Schistosomal granuloma modulation. II. Specific immunogenic carbohydrates can modulate

schistosome-egg-antigen-induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan; 85(1):14-8

Schistosomal granuloma modulation. I. Schistosoma mansoni worm antigens CAA and CCA prime egg-antigen-induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan;85(1):7-13

Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Blank M, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5164-8

Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Iverson GM, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15542-6

Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Trahey M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3006-11

Immunological studies on the settlement-inducing protein complex (SIPC) of the barnacle Balanus amphitrite and its possible involvement in larva-larva interactions. Matsumura K, et al. **Proc R Soc Lond B Biol Sci** 1998 Oct 7;265(1408):1825-30

Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding. Xiang J, et al. **Protein Eng** 1999 May;12(5):417-21

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. Cuadrado MJ, et al. **QJM** 1998 Sep;91(9):619-26

An endogenous human immunostimulant acting on mononuclear phagocytes: a study in laboratory mice. Briend E, et al. **Res Immunol** 1998 Sep-Oct;149(7-8):703-9 (40 ref.)

Catastrophic antiphospholipid syndrome associated with anti-beta-2-glycoprotein I IgA [letter] Abinader A, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):84-5

Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Atsumi T, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):721-3

Administration of interleukin-12 prevents mite Der p 1 allergen-IgE antibody production and airway eosinophil infiltration in an animal model of airway inflammation. Lee YL, et al. **Scand J Immunol** 1999 Mar;49(3):229-36

Nota bene: medicine. Fear of flying! Smith O. **Science** 1999 Apr 2;284(5411):61

Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Limper AH. **Semin Respir Infect** 1998 Dec;13(4):339-47 (77 ref.)

alpha-Gal epitopes on viral glycoproteins. Rother RP, et al. **Subcell Biochem** 1999;32:143-72 (116 ref.)

Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Arnout J, et al. **Thromb Haemost** 1999 Jun;81(6):929-34

Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Arvieux J, et al. **Thromb Haemost** 1998 Sep;80(3):393-8

dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Pengo V, et al. **Thromb Haemost** 1999 Feb; 81(2):256-8

Beta2-glycoprotein I-dependent anticardiolipin antibody is reactive to both beta2-glycoprotein I/oxidized as well as beta2-glycoprotein I/reduced cardiolipin. Matsuda J, et al. **Thromb Res** 1999 Jul 1;95(1):63-7

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Novitzky N, et al. **Transplantation** 1999 Feb 27;67(4):620-6

Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Drings A, et al. **Vaccine** 1999 Mar 17;17(11-12):1549-57

Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells. Sakamoto S, et al. **Vaccine** 1999 Jan 21;17(3):205-18

A chimeric protein comprised of bovine herpesvirus type 1 glycoprotein D and bovine interleukin-6 is secreted by yeast and possesses biological activities of both molecules. Zhu X, et al. **Vaccine** 1999 Jan 21;17(3):269-82

Monoclonal antibodies to the GP5 of porcine reproductive and respiratory syndrome virus are more effective in virus neutralization than monoclonal antibodies to the GP4. Weiland E, et al. **Vet Microbiol** 1999 Apr 19;66(3):171-86

Rotavirus-specific cytotoxic T lymphocytes recognize overlapping epitopes in the amino-terminal region of the VP7 glycoprotein. Buesa J, et al. **Virology** 1999 May 10; 257(2):424-37

Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Zhu L, et al. **Virology** 1999 Apr 10; 256(2):381-92

Location of a linear epitope recognized by monoclonal antibody S16 on the hemagglutinin-esterase glycoprotein of influenza C virus. Muraki Y, et al. **Virus Res** 1999 May; 61(1):53-61

[Ischemic stroke in young patients and/or livedo: is it important to look for anti-beta 2-glycoprotein I antibodies?] Granel F, et al. **Rev Med Interne** 1998 Oct; 19(10):709-12 (Eng. Abstr.) **(Fre)**

[Effects of synthetic peptide fragments of beta2-glycoprotein-I on binding antiphospholipid antibodies with cardiolipin] Kuznetsova TV, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):50-2 **(Rus)**

[Dynamics of the interaction of monoclonal antibodies with antigens immobilized on plates] Bobrovnik SA. **Ukr Biokhim Zh** 1998 May-Jun;70(3):118-28 (Eng. Abstr.) **(Rus)**

[Antiphospholipid-protein antibodies. Effects on the endothelium-platelet interaction] Forastiero RR, et al. **Sangre (Barc)** 1999 Jun;44(3):223-30 (85 ref.) **(Spa)**

ISOLATION & PURIFICATION

Crystallization and preliminary X-ray diffraction studies of mammalian purple acid phosphatase. Guddat LW, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Aug;55 (Pt 8):1462-4

Purification and biochemical characterization of equine pulmonary surfactant protein D. Hobo S, et al. **Am J Vet Res** 1999 Mar;60(3):368-72

Purification and characterization of a histidine-rich glycoprotein that binds cadmium from the blood plasma of the bivalve Mytilus edulis. Nair PS, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):8-14

Purification and characterization of Moran 20K from Morus alba. Kim ES, et al. **Arch Pharm Res** 1999 Feb;22(1):9-12

A 16-kDa fragment of collagen type XIV is a novel neutrophil chemotactic factor purified from rat granulation tissue. Nakagawa H, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):642-5

Isolation and characterization of a novel antifreeze protein from carrot (Daucus carota). Smallwood M, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):385-91

Surfactant proteins A and D: disease markers. Kuroki Y, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2-3):334-45 (47 ref.)

Purification and MALDI-MS characterization of stressin, a stress-associated glycoprotein. Lauc G, et al. **Biol Chem** 1999 Apr;380(4):443-50

Prevalence and determinants of house dust mite allergen in East German homes. Hirsch T, et al. **Clin Exp Allergy** 1998 Aug;28(8):956-64

Somatolactin in the white sturgeon and African lungfish and its evolutionary significance. Amemiya Y, et al. **Gen Comp Endocrinol** 1999 May;114(2):181-90

A novel 26 kilodalton antigen expressed on the surface membrane of activated T cells. Bank I, et al. **Immunobiology** 1999 Feb;200(1):49-61

Mite allergen (Der p 1) is not only carried on mite feces. De Lucca S, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):174-5

Isolation and amino acid sequence of a phospholipase A2 inhibitor from the blood plasma of the sea krait, Laticauda semifasciata. Ohkura N, et al. **J Biochem (Tokyo)** 1999 Feb; 125(2):375-82

Contulakin-G, an O-glycosylated invertebrate neurotensin. Craig AG, et al. **J Biol Chem** 1999 May 14;274(20):13752-9

A novel method of purifying lung surfactant proteins A and D from the lung lavage of alveolar proteinosis patients and from pooled amniotic fluid. Strong P, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):139-49

Expression of an inter-alpha-trypsin inhibitor heavy chain-like protein in the pig endometrium during the oestrous cycle and early pregnancy. Geisert RD, et al. **J Reprod Fertil** 1998 Sep;114(1):35-43

A comparative study on the purification of the Amaranthus leucocarpus syn. hypocondriacus lectin. Hernández P, et al. **Prep Biochem Biotechnol** 1999 Aug;29(3):219-34

Cloning, expression, purification, and immunocharacterization of placental protein-14. Dutta B, et al. **Protein Expr Purif** 1998 Dec;14(3):327-34

Role of inter-alpha-inhibitor and its related proteins in urolithiasis. Purification of an inter-alpha-inhibitor related protein from the bovine kidney. Atmani F, et al. **Urol Res** 1999;27(1):57-61

[Characterization of hepatic bile mucus glycoprotein in hepatolithiasis] Yamazaki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jul;96(7):817-23 (Eng. Abstr.) **(Jpn)**

METABOLISM

Neoglycoprotein-binding sites (endogenous lectins) in the Fallopian tube, uterus and blastocyst of the rabbit during the preimplantation phase and implantation. Biermann L, et al. **Acta Anat (Basel)** 1997;160(3):159-71

Processing of sphingolipid activator proteins and the topology of lysosomal digestion. Sandhoff K, et al. **Acta Biochim Pol** 1998;45(2):373-84 (52 ref.)

Binding specificities of lectins to immobilized glycoproteins and oligosaccharides differ from those of immobilized lectins to oligosaccharides. Tang W, et al. **Acta Med Okayama** 1998 Dec;52(6):311-8

Tear fluid analysis in patients with primary Sjögren's syndrome using lectin probes. A comparative study of patients with primary Sjögren's syndrome, patients with other immune inflammatory connective tissue diseases and controls. Bjerrum KB. **Acta Ophthalmol Scand** 1999 Feb; 77(1):1-8

Receptor homologue scanning functions in the maintenance of MHV-A59 persistence in vitro. Chen W, et al. **Adv Exp Med Biol** 1998;440:743-50

Interactions of enterotropic mouse hepatitis viruses with Bgp2 receptor proteins. Compton SR. **Adv Exp Med Biol** 1998;440:25-31

Virus-receptor interactions and interspecies transfer of a mouse hepatitis virus. Hensley LE, et al. **Adv Exp Med Biol** 1998;440:33-41

Human biliary glycoproteins function as receptors for interspecies transfer of mouse hepatitis virus. Hensley LE, et al. **Adv Exp Med Biol** 1998;440:43-52

Differential receptor-functionality of the two distinct receptor proteins for mouse hepatitis virus. Ohtsuka N, et al. **Adv Exp Med Biol** 1998;440:77-80

Mouse hepatitis virus receptor levels influence virus-induced cytopathology. Rao PV, et al. **Adv Exp Med Biol** 1998; 440:549-55

Isolation and characterization of murine coronavirus mutants resistant to neutralization by soluble receptors. Saeki K, et al. **Adv Exp Med Biol** 1998;440:11-6

Neutralization of MHV-A59 by soluble recombinant receptor glycoproteins. Zelus BD, et al. **Adv Exp Med Biol** 1998;440:3-9

Mite allergens: significance of enzymatic activity. Hewitt CR, et al. **Allergy** 1998;53(48 Suppl):60-3 (15 ref.)

Urinary trypsin inhibitor levels in amniotic fluid of normal human pregnancy: decreased levels observed at parturition. Kobayashi H, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):141-7

Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis. Guadagni F, et al. **Am J Pathol** 1999 Apr;154(4):993-9

Bikunin present in human peritoneal fluid is in part derived from the interaction of serum with peritoneal mesothelial cells. Thomas GJ, et al. **Am J Pathol** 1998 Oct; 153(4):1267-76

Effects of endotoxin on surfactant protein A and D stimulation of NO production by alveolar macrophages. Wright JR, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L650-8

Binding of ovine uterine serpin to lymphocytes. Liu WJ, et al. **Am J Reprod Immunol** 1999 Jun;41(6):428-32

Brief exposure to 95% oxygen alters surfactant protein D and mRNA in adult rat alveolar and bronchiolar epithelium. Aderibigbe AO, et al. **Am J Respir Cell Mol Biol** 1999 Feb;20(2):219-27

Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Fuhrmann M, et al. **Am J Respir Cell Mol Biol** 1999 Feb; 20(2):292-302

Ultrastructure of phospholipid mixtures reconstituted with surfactant proteins B and D. Poulain FR, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):1049-58

Autotaxin expression in non-small-cell lung cancer. Yang Y, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):216-22

Surfactant proteins A and D in premature baboons with chronic lung injury (Bronchopulmonary dysplasia). Evidence for an inhibition of secretion. Awasthi S, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):942-9

Diet, amyloid enhancing factor (AEF) and amyloidogenesis: an hypothesis. Cathcart ES, et al. **Amyloid** 1999 Jun; 6(2):107-13

Involvement of long- and short-range signalling during early tendon development. D'Souza D, et al. **Anat Embryol (Berl)** 1999 Oct;200(4):367-75

Developmental changes of sugar residues and secretory protein in mucous cells of the early postnatal rat parotid gland. Ikeda R, et al. **Anat Rec** 1999 Jun 1;255(2):155-61

Matrix metalloproteinase inhibitor CGS 27023A protects COMP and proteoglycan in the bovine articular cartilage but not the release of their fragments from cartilage after prolonged stimulation in vitro with IL-1 alpha. Ganu V, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:607-11

alpha-actinin-2 is a new component of the dystrophin-glycoprotein complex. Hance JE, et al. **Arch Biochem Biophys** 1999 May 15;365(2):216-22

Self-glucosylation of glycogenin, the initiator of glycogen biosynthesis, involves an inter-subunit reaction. Lin A, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):163-70

Mohs micrographic excision of lentigo maligna using Mel-5 for margin control. Gross EA, et al. **Arch Dermatol** 1999 Jan;135(1):15-7

Perineuronal nets of proteoglycans in the adult mouse brain are digested by collagenase. Murakami T, et al. **Arch Histol Cytol** 1999 May;62(2):199-204

The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Feldmann H, et al. **Arch Virol Suppl** 1999;15:159-69 (53 ref.)

Inhibition of interleukin-1alpha-induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid. Ganu V, et al. **Arthritis Rheum** 1998 Dec; 41(12):2143-51

Influence of N-glycan chain length on chaperone association and intracellular transport of major histocompatibility complex class I proteins. Bennett MJ, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):473-8

Identification of two uridine binding domain peptides of the UDP-glucose-binding site of rabbit muscle glycogenin.

Carrizo ME, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):786–9

Phage display cDNA cloning of protein with carbohydrate affinity. Yamamoto M, et al.
Biochem Biophys Res Commun 1999 Feb 16;255(2):194–9

Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids. Brighton TA, et al.
Biochem J 1999 May 15;340 (Pt 1):59–67

Cytosolic deglycosylation process of newly synthesized glycoproteins generates oligomannosides possessing one GlcNAc residue at the reducing end. Duvet S, et al.
Biochem J 1998 Oct 15;335 (Pt 2):389–96

A novel class of protein from wheat which inhibits xylanases. McLauchlan WR, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):441–6

Identification of human complement Factor H as a ligand for L-selectin. Malhotra R, et al. **Biochem J** 1999 Jul 1; 341 (Pt 1):61–9

39-kDa receptor-associated protein (RAP) facilitates secretion and ligand binding of extracellular region of very-low-density-lipoprotein receptor: implications for a distinct pathway from low-density-lipoprotein receptor. Sato A, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):377–83

Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. Sleat DE, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):547–51

The insertion of human apolipoprotein H into phospholipid membranes: a monolayer study. Wang SX, et al.
Biochem J 1998 Oct 15;335 (Pt 2):225–32

Alternative roles for putative ice-binding residues in type I antifreeze protein. Loewen MC, et al. **Biochemistry** 1999 Apr 13;38(15):4743–9

Structural analysis of the heparin-binding site of the NC1 domain of collagen XIV by CD and NMR. Montserret R,'et al. **Biochemistry** 1999 May 18;38(20):6479–88

Identification of novel peptide binding proteins in the endoplasmic reticulum: ERp72, calnexin, and grp170. Spee P, et al. **Biochemistry** 1999 Aug 10;38(32):10559–66

Intrinsic fluorescence study of the interaction of human apolipoprotein H with phospholipid vesicles. Wang SX, et al. **Biochemistry** 1999 Jul 20;38(29):9477–84

Manganese sulfate-dependent glycosylation of endogenous glycoproteins in human skeletal muscle is catalyzed by a nonglucose 6-P-dependent glycogen synthase and not glycogenin. Jiao Y, et al. **Biochim Biophys Acta** 1999 Mar 14;1427(1):1–12

A porcine homolog of the major secretory protein of human epididymis, HE1, specifically binds cholesterol. Okamura N, et al. **Biochim Biophys Acta** 1999 Jun 10;1438(3):377–87

Interfacial properties of surfactant proteins. Pérez-Gil J, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):203–17 (70 ref.)

Aerosolized endotoxin is immediately bound by pulmonary surfactant protein D in vivo. van Rozendaal BA, et al.
Biochim Biophys Acta 1999 Aug 30;1454(3):261–9

Protein glycosylation in development and disease. Dennis JW, et al. **Bioessays** 1999 May;21(5):412–21 (80 ref.)

Identification of naturally occurring follistatin complexes in human biological fluids. Wang EY, et al. **Biol Reprod** 1999 Jan;60(1):8–13

Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. Gawlitzek M, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):518–28

Use of mannosamine for inducing the addition of outer arm N-acetylglucosamine onto N-linked oligosaccharides of recombinant proteins in insect cells. Donaldson M, et al.
Biotechnol Prog 1999 Mar-Apr;15(2):168–73

AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors [letter] Bühring HJ, et al. **Blood** 1999 Jul 15; 94(2):832–3

Three complement-type repeats of the low-density lipoprotein receptor-related protein define a common binding site for RAP, PAI-1, and lactoferrin. Vash B, et al. **Blood** 1998 Nov 1;92(9):3277–85

CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer. Tempfer C, et al. **Br J Cancer** 1998 Oct;78(8):1091–4

Spermidine-induced glycoprotein fucosylation in immature rat intestine. Gréco S, et al. **C R Acad Sci III** 1999 Jul; 322(7):543–9

Zinc-alpha2-glycoprotein expression as a marker of differentiation in human oral tumors. Brysk MM, et al.
Cancer Lett 1999 Mar 22;137(1):117–20

The oligomeric integrity of toposome is essential for its morphogenetic function. Scaturro G, et al. **Cell Biol Int** 1998;22(4):321–6

Liver glycogenin activity in diabetic and adrenalectomized rats. Gannon MC, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Sep;44(6):941–7

Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. Zhao YY, et al. **Circ Res** 1999 Jun 25;84(12):1380–7

Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Rohrbach S, et al. **Circulation** 1999 Jul 27; 100(4):407–12

Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Brakenhoff RH, et al. **Clin Cancer Res** 1999 Apr;5(4):725–32

Inhibitors of carbohydrate processing: A new class of anticancer agents. Goss PE, et al. **Clin Cancer Res** 1995 Sep;1(9):935–44 (127 ref.)

Guinea pig alpha 1-microglobulin/bikunin: cDNA sequencing, tissue expression and expression during acute phase. Yoshida K, et al.
Comp Biochem Physiol B Biochem Mol Biol 1999 Feb; 122(2):165–72

Lectins as chaperones in glycoprotein folding. Trombetta ES, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):587–92 (48 ref.)

Mammalian BMP-1/Tolloid-related metalloproteinases, including novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of expression relevant to patterning and skeletogenesis. Scott IC, et al. **Dev Biol** 1999 Sep 15;213(2):283–300

Molecular basis for oviductin-mediated processing from gp43 to gp41, the predominant glycoproteins of Xenopus egg envelopes. Kubo H, et al. **Dev Genet** 1999;25(2):123–9

Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Bagnard D, et al. **Development** 1998 Dec;125(24):5043–53

Differential patterning of ventral midline cells by axial mesoderm is regulated by BMP7 and chordin. Dale K, et al. **Development** 1999 Jan;126(2):397–408

Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. Loeb JA, et al. **Development** 1999 Feb; 126(4):781–91

A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al.
Development 1999 Jan;126(1):37–49

Fragmentation pattern of mucins in normal and diseased gastric mucosae: a glycoprotein fractionates with gastric mucins purified from mucosal scrapings of cancer and peptic ulcer patients. Mall AS, et al. **Digestion** 1999; 60(3):216–26

Lectin binding studies of parotid salivary glycoproteins in Sjögren's syndrome. Carpenter GH, et al.
Electrophoresis 1999 Jul;20(10):2124–32

Clinical aspects of altered glycosylation of glycoproteins in cancer. Orntoft TF, et al. **Electrophoresis** 1999 Feb; 20(2):362–71 (117 ref.)

Glycoprotein reglucosylation and nucleotide sugar utilization in the secretory pathway: identification of a nucleoside diphosphatase in the endoplasmic reticulum. Trombetta ES, et al. **EMBO J** 1999 Jun 15;18(12):3282–92

Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. Tuffereau C, et al.
EMBO J 1998 Dec 15;17(24):7250–9

An ATP-driven efflux pump is a novel pathogenicity factor in rice blast disease. Urban M, et al. **EMBO J** 1999 Feb 1;18(3):512–21

Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. McFarlane JR, et al.
Endocrinology 1999 Oct;140(10):4745–52

Modification of the unfolding region in bovine pancreatic ribonuclease and its influence on the thermal stability and proteolytic fragmentation. Arnold U, et al.
Eur J Biochem 1999 Jan;259(1–2):470–5

Type I 'antifreeze' proteins. Structure-activity studies and mechanisms of ice growth inhibition. Harding MM, et al.
Eur J Biochem 1999 Sep;264(3):653–65 (81 ref.)

Flavonol 2,4-dioxygenase from Aspergillus niger DSM 821, a type 2 CuII-containing glycoprotein. Hund HK, et al.
Eur J Biochem 1999 Aug;263(3):871–8

Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Jin G, et al. **Eur J Biochem** 1999 Jul;263(2):534–42

Secretory expression and site-directed mutagenesis studies of the winter flounder skin-type antifreeze polypeptides. Lin Q, et al. **Eur J Biochem** 1999 Aug;264(1):49–54

A Plasmodium chabaudi chabaudi high molecular mass glycoprotein translocated to the host cell membrane by a non-classical secretory pathway. Moura IC, et al.
Eur J Cell Biol 1999 Mar;78(3):186–93

Inhibins, activins and follistatins: a review of complex regulators of the reproductive system. Renier MA, et al.
Eur J Contracept Reprod Health Care 1998 Sep;3(3):129–35 (49 ref.)

Amniotic fluid concentrations of dimeric inhibins, activin A and follistatin in pregnancy. Muttukrishna S, et al.
Eur J Endocrinol 1999 May;140(5):420–4

Increased phosphorylation of eukaryotic initiation factor 2alpha at the G2/M boundary in human osteosarcoma cells correlates with deglycosylation of p67 and a decreased rate of protein synthesis. Datta B, et al. **Exp Cell Res** 1999 Jul 10;250(1):223–30

Subcellular distribution, secretion, and posttranslational modifications of clusterin in thyrocytes. Lemansky P, et al. **Exp Cell Res** 1999 Aug 25;251(1):147–55

Sulfation of intrinsic glycoproteins of the rabbit vitreous. Góes RM, et al. **Exp Eye Res** 1998 Sep;67(3):323–9

Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Lidström AM, et al. **Exp Neurol** 1998 Dec;154(2):511–21

Clusterin upregulation following rubrospinal tract lesion in the adult rat. Liu L, et al. **Exp Neurol** 1999 May; 157(1):69–76

Plasmodium chabaudi chabaudi: a monoclonal antibody raised against soluble antigens present in the plasma of infected mice recognizes a 250-kDa schizont glycoprotein that is secreted during schizogony. Furtado GC, et al.
Exp Parasitol 1999 Jan;91(1):97–100

Binding partners for the myelin-associated glycoprotein of N2A neuroblastoma cells. Strenge K, et al. **FEBS Lett** 1999 Feb 5;444(1):59–64

Structural organization and expression patterns of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Scott IC, et al. **Genomics** 1999 Jan 15;55(2):229–34

Incorporation of 15N from ammonium into the N-linked oligosaccharides of an immunoadhesin glycoprotein expressed in Chinese hamster ovary cells. Gawlitzek M, et al. **Glycobiology** 1999 Feb;9(2):125–31

Bovine mammary gland UDP-GalNAc:GlcNAcbeta-R beta1-->4-N-acetylgalactosaminyltransferase is glycoprotein hormone nonspecific and shows interaction with alpha-lactalbumin. Van den Nieuwenhof IM, et al.
Glycobiology 1999 Feb;9(2):115–23

Comparison of lectin-binding patterns between young adults and older rat glycoproteins in the brain. Sato Y, et al.
Glycoconj J 1998 Dec;15(12):1133–40

Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Grozdanovic Z, et al. **Histol Histopathol** 1999 Jan; 14(1):243–56 (116 ref.)

Correspondence of gradual developmental increases of expression of galectin-reactive glycoconjugates with alterations of the total contents of the two differentially regulated galectins in chicken intestine and liver as indication for overlapping functions. Lips KS, et al.
Histol Histopathol 1999 Jul;14(3):743–60

CD44v6 expression in inflammatory bowel disease is associated with activity detected by endoscopy and pathological features. Camacho FI, et al. **Histopathology** 1999 Aug;35(2):144–9

Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Iczkowski KA, et al. **Histopathology** 1999 Aug; 35(2):150–6

The ovary is not a major source of placental protein 14 (glycodelin). Borri P, et al. **Hum Reprod** 1998 Dec; 13(12):3418–20

Placental protein 14 in endometrium during menstrual cycle and effect of early luteal phase mifepristone administration on its expression in implantation stage endometrium in the rhesus monkey. Lalitkumar PG, et al. **Hum Reprod** 1998 Dec;13(12):3478–86

Is the measurement of placental protein-14 and CA-125 in plasma and uterine flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding? Li TC, et al. **Hum Reprod** 1998 Oct;13(10):2895–901

Follistatin and activin A in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Riley SC, et al. **Hum Reprod** 1998 Sep;13(9):2624–8

Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Kong YY, et al. **Immunol Cell Biol** 1999 Apr; 77(2):188–93 (45 ref.)

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Rowan W, et al. **Immunology** 1998 Nov;95(3):427–36

Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus conidia. Allen MJ, et al.
Infect Immun 1999 Sep;67(9):4563–9

Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes. Gorgani NN, et al. **Int Immunol** 1999 Aug;11(8):1275–82

Increased adhesion of lymphoid cells to glycated proteins. Ivanov GI, et al. **Int J Biochem Cell Biol** 1999 Jul; 31(7):797–804

BRCA1 and BRCA2 proteins are expressed in milk fat globules [letter] Bernard-Gallon DJ, et al. **Int J Cancer** 1999 May 31;81(5):839–43

Lectin characterization of the olfactory system in brachiopterygian fish. Franceschini V, et al.
Int J Dev Neurosci 1999 Feb;17(1):31–6

TIGR and stretch in the trabecular meshwork [letter; comment] Booth A, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1888–9. Comment on: Invest Ophthalmol Vis Sci 1998 Jul;39(8):1361–71.

Cell- and region-specific localization of lysosomal and secretory proteins and endocytic receptors in epithelial cells of the cauda epididymidis and vas deferens of the adult rat. Andonian S, et al. **J Androl** 1999 May-Jun; 20(3):415–29

Structure-specific inhibition of cholesteryl ester transfer protein by azaphilones. Tomoda H, et al.
J Antibiot (Tokyo) 1999 Feb;52(2):160–70

Activin/follistatin and atherosclerosis--a review. Kozaki K, et al. **J Atheroscler Thromb** 1998;5(1):36–40 (41 ref.)

Amino acid residues in the omega-minus region participate in cellular localization of yeast glycosylphosphatidylinositol-attached proteins. Hamada K, et al. **J Bacteriol** 1999 Jul;181(13):3886–9

Deletion of new covalently linked cell wall glycoproteins alters the electrophoretic mobility of phosphorylated wall components of Saccharomyces cerevisiae. Mrsa V, et al.
J Bacteriol 1999 May;181(10):3076–86

Alpha 1,6-linked fucose affects the expression and stability

of polysialic acid-carrying glycoproteins in Chinese hamster ovary cells. Kojima N, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):726-37

Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. Adam L, et al. **J Biol Chem** 1998 Oct 23;273(43):28238-46

Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. Balasubramanian K, et al. **J Biol Chem** 1998 Oct 30; 273(44):29272-7

The nonclassical class I molecule CD1d associates with the novel CD8 ligand gp180 on intestinal epithelial cells. Campbell NA, et al. **J Biol Chem** 1999 Sep 10; 274(37):26259-65

An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. Carraway KL 3rd, et al. **J Biol Chem** 1999 Feb 26;274(9):5263-6

Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. Crovello CS, et al. **J Biol Chem** 1998 Oct 9;273(41):26954-61

Sphingolipid activator proteins are required for epidermal permeability barrier formation. Doering T, et al. **J Biol Chem** 1999 Apr 16;274(16):11038-45

Quantitative and qualitative analysis of type III antifreeze protein structure and function. Graether SP, et al. **J Biol Chem** 1999 Apr 23;274(17):11842-7

The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. Huber M, et al. **J Biol Chem** 1999 Jan 1; 274(1):335-44

Clusterin has chaperone-like activity similar to that of small heat shock proteins. Humphreys DT, et al. **J Biol Chem** 1999 Mar 12;274(11):6875-81

Effect of alternative glycosylation on insulin receptor processing. Hwang JB, et al. **J Biol Chem** 1999 Aug 6; 274(32):22813-20

N-Linked glycosylation and sialylation of the acid-labile subunit. Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs. Janosi JB, et al. **J Biol Chem** 1999 Feb 26;274(9):5292-8

Neuregulin stimulates myogenic differentiation in an autocrine manner. Kim D, et al. **J Biol Chem** 1999 May 28;274(22):15395-400

Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. Korfhagen TR, et al. **J Biol Chem** 1998 Oct 23;273(43):28438-43

The p185(neu)-containing glycoprotein complex of a microfilament-associated signal transduction particle. Purification, reconstitution, and molecular associations with p58(gag) and actin. Li Y, et al. **J Biol Chem** 1999 Sep 3;274(36):25651-8

Release of the neuregulin functional polypeptide requires its cytoplasmic tail. Liu X, et al. **J Biol Chem** 1998 Dec 18; 273(51):34335-40

Domain organization of the 39-kDa receptor-associated protein. Medved LV, et al. **J Biol Chem** 1999 Jan 8; 274(2):717-27

Neurexophilin binding to alpha-neurexins. A single LNS domain functions as an independently folding ligand-binding unit. Missler M, et al. **J Biol Chem** 1998 Dec 25;273(52):34716-23

Characterization of human glycogenin-2, a self-glucosylating initiator of liver glycogen metabolism. Mu J, et al. **J Biol Chem** 1998 Dec 25;273(52):34850-6

Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. Okajima T, et al. **J Biol Chem** 1999 Apr 23;274(17):11479-86

Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks. Piecha D, et al. **J Biol Chem** 1999 May 7;274(19):13353-61

Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein. Rettenberger PM, et al. **J Biol Chem** 1999 Mar 26;274(13):8973-80

Purification and characterization of a glucuronyltransferase involved in the biosynthesis of the HNK-1 epitope on glycoproteins from rat brain. Terayama K, et al. **J Biol Chem** 1998 Nov 13;273(46):30295-300

Intracellular proteolytic processing of the heavy chain of rat pre-alpha-inhibitor. The COOH-terminal propeptide is required for coupling to bikunin. Thuveson M, et al. **J Biol Chem** 1999 Mar 5;274(10):6741-6

Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. Wilkening G, et al. **J Biol Chem** 1998 Nov 13;273(46):30271-8

A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. Wong L, et al. **J Biol Chem** 1999 Mar 26;274(13):8900-9

Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin. Chen MR, et al. **J Biomed Sci** 1998;5(3):173-9

Lysosomal segregation of a mannose-rich glycoprotein imparted by the prosequence of myeloperoxidase. Bening U, et al. **J Cell Biochem** 1998 Nov 1;71(2):158-68

Characterization of zinc-alpha(2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line. Lei G, et al. **J Cell Biochem** 1999 Oct 1; 75(1):160-9

LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Banerji S, et al. **J Cell Biol** 1999 Feb 22;144(4):789-801

Effect of targeted expression of clusterin in photoreceptor cells on retinal development and differentiation. Jomary C, et al. **J Cell Sci** 1999 May;112 (Pt 10):1455-64

Three distinct steps in transport of vesicular stomatitis virus glycoprotein from the ER to the cell surface in vivo with differential sensitivities to GTP gamma S. Pepperkok R, et al. **J Cell Sci** 1998 Jul;111 (Pt 13):1877-88

Memory B lymphocytes from secondary lymphoid organs interact with E-selectin through a novel glycoprotein ligand. Montoya MC, et al. **J Clin Invest** 1999 May; 103(9):1317-27

Clusterin in bovine spongiform encephalopathy (BSE). McHattie S, et al. **J Comp Pathol** 1999 Aug;121(2):159-71

Component PP3 from bovine milk is a substrate for transglutaminase. Sequence location of putative crosslinking sites. Sørensen ES, et al. **J Dairy Res** 1999 Feb;66(1):145-50

Up-regulation of clusterin (sulfated glycoprotein-2) in pancreatic islet cells upon streptozotocin injection to rats. Park IS, et al. **J Endocrinol** 1999 Jul;162(1):57-65

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. Vidal NO, et al. **J Endocrinol** 1998 Oct;159(1):191-5

Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. Naitoh A, et al. **J Gastroenterol Hepatol** 1999 May;14(5):436-45

Antibody-induced endocytosis of viral glycoproteins and major histocompatibility complex class I on pseudorabies virus-infected monocytes. Favoreel HW, et al. **J Gen Virol** 1999 May;80 (Pt 5):1283-91

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. Meunier JC, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):887-96

Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. Torresi J, et al. **J Gen Virol** 1999 May;80 (Pt 5):1185-8

The vaccinia virus A40R gene product is a nonstructural, type II membrane glycoprotein that is expressed at the cell surface. Wilcock D, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2137-48

Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. Ferguson JS, et al. **J Immunol** 1999 Jul 1;163(1):312-21

CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. Mikhalap SV, et al. **J Immunol** 1999 May 15; 162(10):5719-27

Heme-binding by Drosophila retinoid- and fatty acid-binding glycoprotein (RFABG), a member of the proapolipophorin gene family. Duncan T, et al. **J Lipid Res** 1999 Jul;40(7):1222-8

Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. Forte TM, et al. **J Lipid Res** 1999 Jul;40(7):1276-83

Role of sphingolipids in the transport of prosaposin to the lysosomes. Lefrancois S, et al. **J Lipid Res** 1999 Sep; 40(9):1593-603

No pathophysiologic relationship of soluble biliary proteins to cholesterol crystallization in human bile. Wang DQ, et al. **J Lipid Res** 1999 Mar;40(3):415-25

Effects of a metalloproteinase that truncates P-selectin glycoprotein ligand on neutrophil-induced cardiac dysfunction in ischemia/reperfusion. Lefer AM, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2561-6

Growth cone neuropilin-1 mediates collapsin-1/Sema III facilitation of antero- and retrograde axoplasmic transport. Goshima Y, et al. **J Neurobiol** 1999 Jun 15;39(4):579-89

Prominent 85-kDa oligomannosidic glycoproteins of rat brain are signal regulatory proteins and include the SHP substrate-1 for tyrosine phosphatases. Bartoszewicz ZP, et al. **J Neurochem** 1999 Apr;72(4):1688-93

Lack of causal relationship between clusterin expression and photoreceptor apoptosis in light-induced retinal degeneration. Jomary C, et al. **J Neurochem** 1999 May; 72(5):1923-9

Colocalization and complex formation between prosaposin and monosialoganglioside GM3 in neural cells. Misasi R, et al. **J Neurochem** 1998 Dec;71(6):2313-21

A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1. Renzi MJ, et al. **J Neurosci** 1999 Sep 15;19(18):7870-80

Localization and expression of cartilage oligomeric matrix protein by human rheumatoid and osteoarthritic synovium and cartilage. Di Cesare PE, et al. **J Orthop Res** 1999 May; 17(3):437-45

Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. Lipponen P, et al. **J Pathol** 1998 Oct;186(2):157-64

S-fimbriae from Escherichia coli bind to soluble glycoproteins from human milk. Schwertmann A, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):257-63

Apolipoprotein H is not affected by in vitro glycosylation. Gambino R, et al. **J Protein Chem** 1999 Feb;18(2):173-7

Cardiopulmonary bypass reduces pulmonary surfactant activity in infants. Griese M, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):237-44

Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Flint M, et al. **J Virol** 1999 Aug;73(8):6235-44

Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. Klausegger A, et al. **J Virol** 1999 May;73(5):3737-43

The molecular chaperone calnexin interacts with the NSP4 enterotoxin of rotavirus in vivo and in vitro. Mirazimi A, et al. **J Virol** 1998 Nov;72(11):8705-9

Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. Zafrullah M, et al. **J Virol** 1999 May;73(5):4074-82

Increased nonenzymatically glycosylated proteins in the vitreous humor of diabetic animals. Farr AK, et al. **Lab Anim Sci** 1999 Feb;49(1):58-61

beta 2-Glycoprotein I-dependence of anticardiolipin antibodies in multibacillary leprosy patients. Fiallo P, et al. **Lepr Rev** 1998 Dec;69(4):376-81

Characterization of cartilage oligomeric matrix protein (COMP) in human normal and pseudoachondroplasia musculoskeletal tissues. Hecht JT, et al. **Matrix Biol** 1998 Aug;17(4):269-78

Retention of cartilage oligomeric matrix protein (COMP) and cell death in redifferentiated pseudoachondroplasia chondrocytes. Hecht JT, et al. **Matrix Biol** 1998 Dec; 17(8-9):625-33

Metabolic processing of newly synthesized link protein in bovine articular cartilage explant cultures. Tester AM, et al. **Matrix Biol** 1999 Feb;18(1):65-74

A methionine aminopeptidase and putative regulator of translation initiation is required for cell growth and patterning in Drosophila. Cutforth T, et al. **Mech Dev** 1999 Apr;82(1-2):23-8

Comparison of substrate specificities against the fusion glycoprotein of virulent Newcastle disease virus between a chick embryo fibroblast processing protease and mammalian subtilisin-like proteases. Fuji Y, et al. **Microbiol Immunol** 1999;43(2):133-40

Intracellular behavior of rabies virus matrix protein (M) is determined by the viral glycoprotein (G). Nakahara K, et al. **Microbiol Immunol** 1999;43(3):259-70

Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I. Zhang L, et al. **Microbiology** 1999 Jan;145 (Pt 1):177-83

Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Inagaki H, et al. **Mod Pathol** 1999 May; 12(5):546-52

Assembly of a novel cartilage matrix protein filamentous network: molecular basis of differential requirement of von Willebrand factor A domains. Chen Q, et al. **Mol Biol Cell** 1999 Jul;10(7):2149-62

Activation of utrophin promoter by heregulin via the ets-related transcription factor complex GA-binding protein alpha/beta. Khurana TS, et al. **Mol Biol Cell** 1999 Jun;10(6):2075-86

The role of the membrane-spanning domain sequence in glycoprotein-mediated membrane fusion. Taylor GM, et al. **Mol Biol Cell** 1999 Sep;10(9):2803-15

Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor. Alroy I, et al. **Mol Cell Biol** 1999 Mar;19(3):1961-72

The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Howell BW, et al. **Mol Cell Biol** 1999 Jul;19(7):5179-88

ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network [published erratum appears in Mol Cell Biol 1998 Dec;18(12):7602] Pinkas-Kramarski R, et al. **Mol Cell Biol** 1998 Oct; 18(10):6090-101

Changes of nuclear glycoproteins in normal and simian virus 40-transformed WI-38 human lung fibroblasts. Choi SK, et al. **Mol Cells** 1998 Dec 31;8(6):724-30

Cellular distribution and molecular heterogeneity of MAC393 antigen (clusterin, beta-chain) on the surface membrane of bull spermatozoa. Howes EA, et al. **Mol Hum Reprod** 1998 Jul;4(7):673-81

Relaxin stimulates glycodelin mRNA and protein concentrations in human endometrial glandular epithelial cells. Tseng L, et al. **Mol Hum Reprod** 1999 Apr;5(4):372-5

The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Gallimore A, et al. **Mol Immunol** 1998 Jul;35(10):581-91

A 60 kD heat-shock protein-like molecule interacts with the HIV transmembrane glycoprotein gp41. Speth C, et al. **Mol Immunol** 1999 Jun;36(9):619-28

Two glycoprotein populations of band 3 dimers are present in human erythrocytes. Landolt-Marticorena C, et al. **Mol Membr Biol** 1998 Jul-Sep;15(3):153-8

A metalloprotease from Xanthomonas campestris that specifically degrades proline/hydroxyproline-rich glycoproteins of the plant extracellular matrix. Dow JM, et al. **Mol Plant Microbe Interact** 1998 Nov;11(11):1085-93

Role of sialic acid in the endocytosis of prosaposin by the nonciliated cells of the rat efferent ducts. Morales CR. **Mol Reprod Dev** 1998 Oct;51(2):156–66

The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM [see comments] Sayos J, et al. **Nature** 1998 Oct 1; 395(6701):462–9. Comment in: Nature 1998 Oct 1;395(6701):441, 443–4.

Saposins and their interaction with lipids. Vaccaro AM, et al. **Neurochem Res** 1999 Feb;24(2):307–14 (55 ref.)

Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Chen H, et al. **Neuron** 1998 Dec;21(6):1283–90

Isolation and characterisation of the cDNA encoding a glycosylated accessory protein of pea chloroplast DNA polymerase. Gaikwad A, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):3120–9

O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins. Gupta R, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):370–2

Mechanisms underlying the transfer of phosphorylcholine to filarial nematode glycoproteins--a possible role for choline kinase. Houston KM, et al. **Parasitology** 1999 Mar;118 (Pt 3):311–8

Pollen-stigma adhesion in Brassica spp involves SLG and SLR1 glycoproteins. Luu DT, et al. **Plant Cell** 1999 Feb; 11(2):251–62

The glycosylphosphatidylinositol-anchored phosphatase from Spirodela oligorrhiza is a purple acid phosphatase. Nakazato H, et al. **Plant Physiol** 1998 Nov;118(3):1015–20

Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc from intracellular proteins. Roos MD, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct; 110(5):422–32

Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Holmskov U, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10794–9

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Klapper LN, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4995–5000

The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. Gambino R, et al. **Prostaglandins Other Lipid Mediat** 1999 Jul;57(5–6):351–9

Effects of N-butyldeoxynojirimycin and the Lec3.2.8.1 mutant phenotype on N-glycan processing in Chinese hamster ovary cells: application to glycoprotein crystallization. Butters TD, et al. **Protein Sci** 1999 Aug; 8(8):1696–701

Probing the potential glycoprotein binding site of sindbis virus capsid protein with dioxane and model building. Lee S, et al. **Proteins** 1998 Nov 1;33(2):311–7

Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Dent G, et al. **Pulm Pharmacol Ther** 1998 Feb;11(1):47–56

Collagen-bound alpha1-microglobulin in normal and healed tissues and its effect on immunocompetent cells. Santin M, et al. **Scand J Immunol** 1999 Sep;50(3):289–95

Efficient presentation of house dust mite allergen Der p 2 by monocyte-derived dendritic cells and the role of beta 2 integrins. Sung SJ, et al. **Scand J Immunol** 1999 Jan; 49(1):96–105

Gene linked to faulty cholesterol transport [news] Gura T. **Science** 1999 Aug 6;285(5429):814–5

The effect of compressive force applied to the intervertebral disc in vivo. A study of proteoglycans and collagen. Hutton WC, et al. **Spine** 1998 Dec 1;23(23):2524–37

Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Horbach DA, et al. **Thromb Haemost** 1999 Jan;81(1):87–95

Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Merrill JT, et al. **Thromb Haemost** 1999 May;81(5):748–57

Evolving views of protein glycosylation. Drickamer K, et al. **Trends Biochem Sci** 1998 Sep;23(9):321–4 (25 ref.)

Inhibition of cellular glycoprotein incorporation into human immunodeficiency virus-like particles by coexpression of additional cellular interaction partner. Henriksson P, et al. **Virology** 1998 Nov 10;251(1):16–21

Specific binding of recombinant foamy virus envelope protein to host cells correlates with susceptibility to infection. Herchenröder O, et al. **Virology** 1999 Mar 15;255(2):228–36

Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Kahn JS, et al. **Virology** 1999 Feb 1;254(1):81–91

Processing and routage of HIV glycoproteins by furin to the cell surface. Moulard M, et al. **Virus Res** 1999 Mar; 60(1):55–65

[The actions of nucleating proteins in vesicle aggregation and fusion: a preliminary study] Chen Y, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Mar;35(3):181–5 (Eng. Abstr.) **(Chi)**

[Carbohydrate-deficient glycoprotein syndrome and glycosylation of N-glycoproteins] Seta N. **Arch Pediatr** 1999;6 Suppl 2:206s–208s (10 ref.) **(Fre)**

[Apolipoprotein J and Alzheimer's amyloid beta solubility] Matsubara E. **Nippon Ronen Igakkai Zasshi** 1999 Feb; 36(2):110–5 **(Jpn)**

[Calnexin is a molecular chaperone recognizing glycoproteins] Ihara Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2450–4 (21 ref.) **(Jpn)**

[Adhesive glycoproteins of the extracellular matrix] Kwiatkowska D, et al. **Postepy Hig Med Dosw** 1999; 53(1):55–74 (77 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood. Buscaglia CA, et al. **Blood** 1999 Mar 15;93(6):2025–32

Pregnancy and amyloidogenesis: I. Offspring of amyloidotic mice are not predisposed to develop amyloidosis. Shtrasburg S, et al. **J Lab Clin Med** 1999 Aug;134(2):168–72

Specific renal delivery of sugar-modified low-molecular-weight peptides. Suzuki K, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):888–97

The distribution of YKL-40 in osteoarthritic and normal human articular cartilage. Volck B, et al. **Scand J Rheumatol** 1999;28(3):171–9

PHARMACOLOGY

The herbal medicine shoseiryu-to inhibits allergen-induced synthesis of tumour necrosis factor alpha by peripheral blood mononuclear cells in patients with perennial allergic rhinitis. Tanaka A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:118–25

Recombinant SP-D carbohydrate recognition domain is a chemoattractant for human neutrophils. Cai GZ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L131–6

NSP4 elicits age-dependent diarrhea and Ca(2+)mediated I(-) influx into intestinal crypts of CF mice. Morris AP, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G431–44

Surfactant proteins A and D specifically stimulate directed actin-based responses in alveolar macrophages. Tino MJ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L164–74

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Akatsu T, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):229–34

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Hakeda Y, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):796–801

Heregulin regulation of Akt/protein kinase B in breast cancer cells. Liu W, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):897–903

Clusterin prevents aggregation of neuropeptide 106–126 in vitro. McHattie S, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):336–40

Manganese sulfate-dependent glycosylation of endogenous glycoproteins in human skeletal muscle is catalyzed by a nonglucose 6-P-dependent glycogen synthase and not glycogenin. Jiao Y, et al. **Biochim Biophys Acta** 1999 Mar 14;1427(1):1–12

Inhibitory mechanisms of glycoprotein fraction derived from Miscanthus sinensis for the immediate phase response of an IgE-mediated cutaneous reaction. Watanabe C, et al. **Biol Pharm Bull** 1999 Jan;22(1):26–30

Characterization of the pharmacological-sensitivity profile of neoglycoprotein-induced acrosome reaction in mouse spermatozoa. Loeser CR, et al. **Biol Reprod** 1999 Sep; 61(3):629–34

Activin A and follistatin regulate developmental competence of In vitro-produced bovine embryos. Yoshioka K, et al. **Biol Reprod** 1998 Nov;59(5):1017–22

Glycoprotein-inspired materials promote the proteolytic release of cell surface L-selectin. Gordon EJ, et al. **Bioorg Med Chem** 1998 Aug;6(8):1293–9

A high-Mr glycoprotein fraction from cow's milk potent in inhibiting replication of human rotavirus in vitro. Kanamaru Y, et al. **Biosci Biotechnol Biochem** 1999 Jan; 63(1):246–9

Prosaposin prevents programmed cell death of rat cerebellar granule neurons in culture. Tsuboi K, et al. **Brain Res Dev Brain Res** 1998 Oct 1;110(2):249–55

Use of a cysteine proteinase from Carica candamarcensis as a protective agent during DNA extraction. Genelhu MS, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1129–32

Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Yoo JY, et al. **Breast Cancer Res Treat** 1998 Sep;51(1):71–81

Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Tan M, et al. **Cancer Res** 1999 Apr 1;59(7):1620–5

Placental protein 14 functions as a direct T-cell inhibitor. Rachmilewitz J, et al. **Cell Immunol** 1999 Jan 10; 191(1):26–33

Effects of laminin glycopeptides on metastasis-related behaviors of cancer cells. Jiang XN, et al. **Cell Res** 1998 Sep;8(3):231–40

Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections. Fornarini B, et al. **Clin Exp Immunol** 1999 Jan;115(1):91–4

Activin A and follistatin influence expression of somatostatin in the ciliary ganglion in vivo. Darland DC, et al. **Dev Biol** 1998 Oct 15;202(2):293–303

Proliferation of human Schwann cells induced by neu differentiation factor isoforms. Baek SY, et al. **Dev Neurosci** 1998;20(6):512–7

Heregulins or neu differentiation factors and the interactions between peritubular myoid cells and Sertoli cells. Hoeben E, et al. **Endocrinology** 1999 May;140(5):2216–23

Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Horwood NJ, et al. **Endocrinology** 1998 Nov; 139(11):4743–6

Macromolecular antimicrobial glycoprotein, achacin, expressed in a methylotrophic yeast Pichia pastoris. Ogawa M, et al. **FEBS Lett** 1999 Apr 1;448(1):41–4

ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines. Pegues JC, et al. **Int J Oncol** 1999 Jun;14(6):1169–76

Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. Wang M, et al. **Int J Oncol** 1999 Jun;14(6):1185–95

IL-12 affects Dermatophagoides farinae-induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma. Noma T, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):850–8

Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. Rittershaus CW, et al. **J Biol Chem** 1999 Apr 16; 274(16):11237–44

Inhibition of L-selectin-mediated leukocyte rolling by synthetic glycoprotein mimics. Sanders WJ, et al. **J Biol Chem** 1999 Feb 26;274(9):5271–8

Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells. Shinoda E, et al. **J Biol Chem** 1999 Feb 26;274(9):5379–84

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. Morony S, et al. **J Bone Miner Res** 1999 Sep;14(9):1478–85

Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. Shalhoub V, et al. **J Cell Biochem** 1999 Feb 1;72(2):251–61

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. Burgess TL, et al. **J Cell Biol** 1999 May 3;145(3):527–38

Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. Miao HQ, et al. **J Cell Biol** 1999 Jul 12;146(1):233–42

Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions [see comments] Wan H, et al. **J Clin Invest** 1999 Jul;104(1):123–33. Comment in: J Clin Invest 1999 Jul;104(1):3–4.

The effects of histatin-derived basic antimicrobial peptides on oral biofilms. Helmerhorst EJ, et al. **J Dent Res** 1999 Jun;78(6):1245–50

Neu differentiation factor (NDF), a dominant oncogene, causes apoptosis in vitro and in vivo. Grimm S, et al. **J Exp Med** 1998 Oct 19;188(8):1535–9

Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. Borron PJ, et al. **J Immunol** 1998 Nov 1;161(9):4599–603

Myelin and collapsin-1 induce motor neuron growth cone collapse through different pathways: inhibition of collapse by opposing mutants of rac1. Kuhn TB, et al. **J Neurosci** 1999 Mar 15;19(6):1965–75

Essential roles of c-JUN and c-JUN N-terminal kinase (JNK) in neuregulin-increased expression of the acetylcholine receptor epsilon-subunit. Si J, et al. **J Neurosci** 1999 Oct 1;19(19):8498–508

Biological actions of the epidermal growth factors-like domain peptides of mouse schwannoma-derived growth factor and human amphiregulin. Takenouchi T, et al. **J Pept Res** 1999 Feb;53(2):120–5

Transcriptional pathways for synapse-specific, neuregulin-induced and electrical activity-dependent transcription. Fromm L, et al. **J Physiol Paris** 1998 Jun-Aug;92(3–4):173–6

Immunostimulatory effects of pig seminal proteins on pig lymphocytes. Leshin LS, et al. **J Reprod Fertil** 1998 Sep; 114(1):77–84

Enhancement of bovine oocyte fertilization in vitro with a bovine oviductal specific glycoprotein. Martus NS, et al. **J Reprod Fertil** 1998 Jul;113(2):323–9

Protective effects of ulinastatin against ischemia-reperfusion injury. Okuhama Y, et al. **J Surg Res** 1999 Mar;82(1):34–42

Human ileostomy glycoproteins as a model for small intestinal mucus to investigate adhesion of probiotics. Tuomola EM, et al. **Lett Appl Microbiol** 1999 Mar; 28(3):159–63

Involvement of the major glycoprotein (gp43) of Paracoccidioides brasiliensis in attachment to macrophages. Almeida SR, et al. **Med Mycol** 1998 Dec;36(6):405–11

Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Adelsman MA, et al. **Mol Biol Cell** 1999 Sep; 10(9):2861–78

Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Chausovsky A, et al. **Mol Biol Cell** 1998 Nov;9(11):3195–209

Synergistic regulation of Schwann cell proliferation by

heregulin and forskolin. Rahmatullah M, et al. **Mol Cell Biol** 1998 Nov;18(11):6245-52

GGF/neuregulin induces a phenotypic reversion of oligodendrocytes. Canoll PD, et al. **Mol Cell Neurosci** 1999 Feb;13(2):79-94

Urinary trypsin inhibitor down-regulates hyaluronic acid fragment-induced prostanoid release in cultured human amnion cells by inhibiting cyclo-oxygenase-2 expression. Kobayashi H, et al. **Mol Hum Reprod** 1999 Jul;5(7):662-7

Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse [see comments] Nakamura F, et al. **Neuron** 1998 Nov;21(5):1093-100. Comment in: Neuron 1998 Nov;21(5):935-6.

Calpain inhibitor I retards seizure offset in the hippocampus of freely moving rats. Sierra-Paredes G, et al. **Neurosci Lett** 1999 Mar 26;263(2-3):165-8

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Daly JM, et al. **Oncogene** 1999 Jun 10; 18(23):3440-51

The role of the extracellular matrix in skeletal muscle development. Velleman SG. **Poult Sci** 1999 May; 78(5):778-84 (47 ref.)

A comparative study on the purification of the Amaranthus leucocarpus syn. hypocondriacus lectin. Hernández P, et al. **Prep Biochem Biotechnol** 1999 Aug;29(3):219-34

Induction of utrophin gene expression by heregulin in skeletal muscle cells: role of the N-box motif and GA binding protein. Gramolini AO, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3223-7

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Hsu H, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3540-5

Cytoprotective effect of ulinastatin, a Kunitz-type protease inhibitor, on hypoxic injury in L2 cells treated with antimycin A via stabilization of lysosomal fragility. Nakahama H, et al. **Pulm Pharmacol Ther** 1999;12(1):1-6

The influence of beta2-glycoprotein I on tissue factor activity. Ieko M, et al. **Semin Thromb Hemost** 1998; 24(3):211-5

Follistatin possesses trunk and tail organizer activity and lacks head organizer activity. Kablar B. **Tissue Cell** 1999 Feb;31(1):28-33

Ulinastatin, a protease inhibitor, attenuates hepatic ischemia/reperfusion injury by downregulating TNF-alpha in the liver. Aihara T, et al. **Transplant Proc** 1998 Nov; 30(7):3732-4

Evidence of neutrophil involvement in the protective effects of urinary trypsin inhibitor against ischemia reperfusion in vitro. Okuhama Y, et al. **Transplant Proc** 1998 Nov; 30(7):3723-5

Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Médétognon-Benissan J, et al. **Urol Res** 1999;27(1):69-75

PHYSIOLOGY

The role of herpes simplex virus glycoproteins in the virus replication cycle. Rajčáni J, et al. **Acta Virol** 1998 Apr; 42(2):103-18 (195 ref.)

Role of mouse hepatitis virus-A59 receptor Bgp1a expression in virus-induced pathogenesis. Godfraind C, et al. **Adv Exp Med Biol** 1998;440:569-74

Effect of biochemical components on rheologic properties of nasal mucus in chronic sinusitis. Majima Y, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):421-6

The ins and outs of caveolar signaling. m2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Feron O, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:11-9 (39 ref.)

A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Hirose N, et al. **Arthritis Rheum** 1999 Aug;42(8):1655-61

Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Ieko M, et al. **Arthritis Rheum** 1999 Jan;42(1):167-74

ABC1, the mammalian homologue of the engulfment gene ced-7, is required during phagocytosis of both necrotic and apoptotic cells. Moynault A, et al. **Biochem Soc Trans** 1998 Nov;26(4):629-35

Functional roles and structural analysis of lung collectins SP-A and SP-D. Kuroki Y, et al. **Biol Neonate** 1999 Jun; 76 Suppl 1:19-21 (4 ref.)

Investigation into the effects of proteins and lipids on the frictional properties of articular cartilage. Pickard JE, et al. **Biomaterials** 1998 Oct;19(19):1807-12

Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Damstrup L, et al. **Br J Cancer** 1999 Jun;80(7):1012-9

Noncollagenous, nonproteoglycan macromolecules of cartilage. Neame PJ, et al. **Cell Mol Life Sci** 1999 Aug 15;55(10):1327-40 (141 ref.)

Eukaryotic glycosylation: whim of nature or multipurpose tool? Reuter G, et al. **Cell Mol Life Sci** 1999 Mar; 55(3):368-422 (671 ref.)

Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Normanno N, et al. **Clin Cancer Res** 1996 Mar;2(3):601-9

Bone remodelling: a signalling system for osteoclast regulation. Filvaroff E, et al. **Curr Biol** 1998 Sep 24; 8(19):R679-82 (25 ref.)

The Wnts. Loureiro JJ. **Curr Biol** 1999 Jan 14;9(1):R4

Glycodelins: biological activity in reproduction and differentiation. Seppälä M. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):261-3 (15 ref.)

Collapsin-1/semaphorin D is a repellent for chick ganglion of Remak axons. Shepherd IT, et al. **Dev Biol** 1999 Aug 1;212(1):42-53

WNT11 promotes cardiac tissue formation of early mesoderm. Eisenberg CA, et al. **Dev Dyn** 1999 Sep; 216(1):45-58

Semaphorins III and IV repel hippocampal axons via two distinct receptors. Chédotal A, et al. **Development** 1998 Nov;125(21):4313-23

Evidence for collapsin-1 functioning in the control of neural crest migration in both trunk and hindbrain regions. Eickholt BJ, et al. **Development** 1999 May;126(10):2181-9

Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Delbaere A, et al. **Endocrinology** 1999 Jun;140(6):2463-70

C-CAM-mediated adhesion leads to an outside-in dephosphorylation signal. Lucka L, et al. **Eur J Biochem** 1999 Jun;262(2):541-6

Induction of apoptosis due to lowering the level of eukaryotic initiation factor 2-associated protein, p67, from mammalian cells by antisense approach. Datta B, et al. **Exp Cell Res** 1999 Feb 1;246(2):376-83

A reexamination of the role of clusterin as a complement regulator. Hochgrebe TT, et al. **Exp Cell Res** 1999 May 25;249(1):13-21

Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Malinda KM, et al. **Exp Cell Res** 1999 Jul 10;250(1):168-73

Follistatin: a multifunctional regulatory protein. Phillips DJ, et al. **Front Neuroendocrinol** 1998 Oct;19(4):287-322 (236 ref.)

Immunocytochemical study on the localization and distribution of the somatolactin cells in the pituitary gland and the brain of Oreochromis niloticus (Teleostei, cichlidae). Mousa MA, et al. **Gen Comp Endocrinol** 1999 Feb;113(2):197-211

Synapse-specific and neuregulin-induced transcription require an ets site that binds GABPalpha/GABPbeta. Fromm L, et al. **Genes Dev** 1998 Oct 1;12(19):3074-83

Polarity determination in the Drosophila eye: a novel role for unpaired and JAK/STAT signaling. Zeidler MP, et al. **Genes Dev** 1999 May 15;13(10):1342-53

Functional analysis of the fibrinogen-related scabrous gene from Drosophila melanogaster identifies potential effector and stimulatory protein domains. Lee EC, et al. **Genetics** 1998 Oct;150(2):663-73

Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262-9; discussion 270 (39 ref.)

Glycoproteins present in human follicular fluid that inhibit the zona-binding capacity of spermatozoa. Yao YQ, et al. **Hum Reprod** 1998 Sep;13(9):2541-7

Functional roles of the lung surfactant proteins SP-A and SP-D in innate immunity. Reid KB. **Immunobiology** 1998 Aug;199(2):200-7 (44 ref.)

Cryptosporidium parvum apical complex glycoprotein CSL contains a sporozoite ligand for intestinal epithelial cells. Langer RC, et al. **Infect Immun** 1999 Oct;67(10):5282-91

Roles of glycoproteins and oligosaccharides found in human vaginal fluid in bacterial adherence. Rajan N, et al. **Infect Immun** 1999 Oct;67(10):5027-32

Follistatin. Patel K. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1087-93 (17 ref.)

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. De Luca A, et al. **Int J Cancer** 1999 Feb 9;80(4):589-94

Stress proteins and glycoproteins (Review). Henle KJ, et al. **Int J Mol Med** 1998 Jan;1(1):25-32 (112 ref.)

Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement-induced cytolysis. Ibrahim NM, et al. **J Androl** 1999 Mar-Apr;20(2):230-40

Clusterin in the male reproductive tract. Tenniswood M, et al. **J Androl** 1998 Sep-Oct;19(5):508-16 (109 ref.)

Cellular adhesion mediated by factor J, a complement inhibitor. Evidence for nucleolin involvement. Larrucea S, et al. **J Biol Chem** 1998 Nov 27;273(48):31718-25

Multiple involvement of clusterin in chicken ovarian follicle development. Binding to two oocyte-specific members of the low density lipoprotein receptor gene family. Mahon MG, et al. **J Biol Chem** 1999 Feb 12;274(7):4036-44

Enhancement of cell adhesion and spreading by a cartilage-specific noncollagenous protein, cartilage matrix protein (CMP/Matrilin-1), via integrin alpha1beta1. Makihira S, et al. **J Biol Chem** 1999 Apr 16; 274(16):11417-23

Clusterin (Apo J) regulates vascular smooth muscle cell differentiation in vitro. Moulson CL, et al. **J Cell Physiol** 1999 Sep;180(3):355-64

Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195-8 (29 ref.)

Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14. Sano H, et al. **J Immunol** 1999 Jul 1;163(1):387-95

Semaphorins as mediators of neuronal apoptosis. Shirvan A, et al. **J Neurochem** 1999 Sep;73(3):961-71

Mechanisms of protein feedback on gonadotropin secretion. de Kretser DM, et al. **J Reprod Immunol** 1998 Aug; 39(1-2):1-12 (65 ref.)

Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. Wang Q, et al. **J Urol** 1999 Apr;161(4):1378-84

A delayed-implantation-associated protein prevents resumption of DNA synthesis by the trophectoderm of delayed-implanting mouse blastocysts in vitro. Katagiri S, et al. **J Vet Med Sci** 1998 Jul;60(7):791-4

vig-1, a new fish gene induced by the rhabdovirus glycoprotein, has a virus-induced homologue in humans and shares conserved motifs with the MoaA family. Boudinot P, et al. **J Virol** 1999 Mar;73(3):1846-52

Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). Cayabyab M, et al. **J Virol** 1999 Feb; 73(2):976-84

Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. Flint M, et al. **J Virol** 1999 Aug; 73(8):6782-90

Role of rubella virus glycoprotein domains in assembly of virus-like particles. Garbutt M, et al. **J Virol** 1999 May; 73(5):3524-33

An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes. Goepfert PA, et al. **J Virol** 1999 Sep;73(9):7210-7

A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism. Johnston IC, et al. **J Virol** 1999 Aug;73(8):6903-15

Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. Mebatsion T, et al. **J Virol** 1999 Jan;73(1):242-50

Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. Mo C, et al. **J Virol** 1999 May;73(5):4197-207

Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. Morimoto K, et al. **J Virol** 1999 Jan;73(1):510-8

Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells. Meroni PL, et al. **Lupus** 1998;7 Suppl 2:S44-7 (47 ref.)

Mesoderm patterning and somite formation during node regression: differential effects of chordin and noggin. Streit A, et al. **Mech Dev** 1999 Jul;85(1-2):85-96

The role of tenascin-C and related glycoproteins in early chondrogenesis. Mackie EJ, et al. **Microsc Res Tech** 1998 Oct 15;43(2):102-10 (59 ref.)

Clusterin in the male reproductive system: localization and possible function. Bailey R, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):17-23 (60 ref.)

Defective whisker follicles and altered brainstem patterns in activin and follistatin knockout mice. Jhaveri S, et al. **Mol Cell Neurosci** 1998 Nov;12(4-5):206-19

Role of semaphorin III in the developing rodent trigeminal system. Ulupinar E, et al. **Mol Cell Neurosci** 1999 Apr; 13(4):281-92

A cysteine-rich form of Xenopus neuregulin induces the expression of acetylcholine receptors in cultured myotubes. Yang JF, et al. **Mol Cell Neurosci** 1999 Jun;13(6):415-29

The role of glycoproteins in neural development function, and disease. Breen KC, et al. **Mol Neurobiol** 1998 Apr; 16(2):163-220 (512 ref.)

Axon guidance mechanisms: semaphorins as simultaneous repellents and anti-repellents [news; comment] Chen H, et al. **Nat Neurosci** 1998 Oct;1(6):436-9. Comment on: Nat Neurosci 1998 Oct;1(6):487-93.

Dissecting semaphorin signaling [comment] Roskies AL. **Neuron** 1998 Nov;21(5):935-6 (12 ref.). Comment on: Neuron 1998 Nov;21(5):1079-92. Comment on: Neuron 1998 Nov;21(5):1093-100.

A novel role for receptor-associated protein in somatostatin modulation: implications for Alzheimer's disease. Van Uden E, et al. **Neuroscience** 1999;88(3):687-700

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Harari D, et al. **Oncogene** 1999 Apr 29;18(17):2681-9

The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Weinstein EJ, et al. **Oncogene** 1998 Oct 22;17(16):2107-13

Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Liu X, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13024-9

Semaphorin III: role in neuronal development and structural plasticity. Giger RJ, et al. **Prog Brain Res** 1998;117:133-49 (43 ref.)

Role for semaphorin III and its receptor neuropilin-1 in neuronal regeneration and scar formation? Pasterkamp RJ, et al. **Prog Brain Res** 1998;117:151-70 (157 ref.)

Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Sintich SM, et

al. **Prostate** 1999 May;39(2):87–93

Patterning of cortical efferent projections by semaphorin–neuropilin interactions. Polleux F, et al. **Science** 1998 Dec 4;282(5395):1904–6

Protective function of human milk: the milk fat globule. Hamosh M, et al. **Semin Perinatol** 1999 Jun;23(3):242–9 (65 ref.)

CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. de Wynter EA, et al. **Stem Cells** 1998; 16(6):387–96

Role of inter-alpha-inhibitor and its related proteins in experimentally induced calcium oxalate urolithiasis. Localization of proteins and expression of bikunin gene in the rat kidney. Atmani F, et al. **Urol Res** 1999;27(1):63–7

Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Lalani AS, et al. **Virology** 1999 Apr 10;256(2):233–45

[Calcitonin and stanniocalcin. Particular aspects of the endocrine regulation of phospho-calcium metabolism in mammals and fish] Barlet JP, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):281–90 (130 ref.) (Eng. Abstr.) **(Fre)**

[Study on the functions of glycoprotein sugar chains in mammalian development: functions and expression of the beta 1-4 linked galactose residues] Furukawa K. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2309–17 (35 ref.) **(Jpn)**

SECRETION

Secretion of prosaposin, a multifunctional protein, by breast cancer cells. Campana WM, et al. **Biochim Biophys Acta** 1999 May 24;1427(3):392–400

Regulatory mechanisms of surfactant secretion. Mason RJ, et al. **Biochim Biophys Acta** 1998 Nov 19;1408(2–3):226–40 (99 ref.)

High-level expression of secreted glycoproteins in transformed lepidopteran insect cells using a novel expression vector. Farrell PJ, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):656–63

Quantification of the secretory glycoproteins of the subcommissural organ by a sensitive sandwich ELISA with a polyclonal antibody and a set of monoclonal antibodies against the bovine Reissner's fiber. Estivill-Torrús G, et al. **Cell Tissue Res** 1998 Dec;294(3):407–13

N-glycans are not a universal signal for apical sorting of secretory proteins. Su T, et al. **FEBS Lett** 1999 Jun 25; 453(3):391–4

Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Hiraiwa M, et al. **Glia** 1999 Jun;26(4):353–60

Physiological and pathological secretion of cartilage oligomeric matrix protein by cells in culture. Délot E, et al. **J Biol Chem** 1998 Oct 9;273(41):26692–7

The R27080 glycoprotein is abundantly secreted from human cytomegalovirus-infected fibroblasts. Müllberg J, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):437–40

The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Volchkova VA, et al. **Virology** 1998 Oct 25;250(2):408–14

THERAPEUTIC USE

Influence of nasal provocation on FEV1/PEF of asthmatic patients with or without rhinitis. Ferreira MB, et al. **Allerg Immunol (Paris)** 1999 May;31(5):134–8

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Akatsu T, et al. **Bone** 1998 Dec;23(6):495–8

Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. Pène J, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):571–8

Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart. Iwamoto H, et al. **J Cardiovasc Pharmacol** 1999 Apr; 33(4):580–6

An 18-mer peptide fragment of prosaposin ameliorates place navigation disability, cortical infarction, and retrograde thalamic degeneration in rats with focal cerebral ischemia. Igase K, et al. **J Cereb Blood Flow Metab** 1999 Mar; 19(3):298–306

Immediate onset of DNA synthesis in remnant rat liver after 90% hepatectomy by an administration of follistatin. Kogure K, et al. **J Hepatol** 1998 Dec;29(6):977–84

Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters. Muro MD, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun; 9(3):146–54

Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy. Tabar AI, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun; 9(3):155–64

Protection against preterm delivery in mice by urinary trypsin inhibitor. Futamura Y, et al. **Obstet Gynecol** 1999 Jan;93(1):100–8

TOXICITY

Lack of inhibitory effects of the Ju-myo protein on development of glutathione S-transferase placental form-positive foci in the male F344 rat liver. Ichihara T, et al. **J Toxicol Sci** 1999 Feb;24(1):27–31

Diarrhea induction by rotavirus NSP4 in the homologous mouse model system. Horie Y, et al. **Virology** 1999 Sep 30;262(2):398–407

URINE

Eosinophil derived neurotoxin (EDN) levels in commercial human urinary preparations of glycoprotein hormones. Kauffman HF, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):111–3

Schistosoma mansoni: the circulating cathodic antigen forms an abundant product of 41/42 kDa in the urine of infected patients. Abdeen HH, et al. **Exp Parasitol** 1998 Nov; 90(3):286–9

The urinary glycoprotein GP51 as a clinical marker for interstitial cystitis [see comments] Byrne DS, et al. **J Urol** 1999 Jun;161(6):1786–90. Comment in: J Urol 1999 Jun;161(6):1797.

Impairment of the correlation between urinary contents of alpha-1-microglobulin and ulinastatin is induced by intracerebroventricularly administered interleukin-6 in mice. Kaku K, et al. **Neuropsychobiology** 1999;40(1):33–9

Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Médétognon-Benissan J, et al. **Urol Res** 1999;27(1):69–75

GLYCOPYRROLATE

ADMINISTRATION & DOSAGE

Effects of anticholinergics on postoperative vomiting, recovery, and hospital stay in children undergoing tonsillectomy with or without adenoidectomy. Chhibber AK, et al. **Anesthesiology** 1999 Mar;90(3):697–700

Dose effect and benefits of glycopyrrolate in the treatment of bradycardia in anesthetized dogs. Dyson DH, et al. **Can Vet J** 1999 May;40(5):327–31

Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Bachrach SJ, et al. **Clin Pediatr (Phila)** 1998 Aug;37(8):485–90

Pre-emptive glycopyrrolate 0.2 mg and bradycardia during gynaecological laparoscopy with mivacurium. Ambrose C, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):710–3

Pharmacokinetics and oral bioavailability of glycopyrrolate in children. Rautakorpi P, et al. **Pharmacol Toxicol** 1998 Sep;83(3):132–4

ADVERSE EFFECTS

The effect of ammonium glycopyrrolate (Robinul)-induced xerostomia on oral mucosal wetness and flow of gingival crevicular fluid in humans. Wolff MS, et al. **Arch Oral Biol** 1999 Feb;44(2):97–102

Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. Nelskylä K, et al. **Br J Anaesth** 1998 Nov;81(5):757–60

PHARMACOKINETICS

Pharmacokinetics and oral bioavailability of glycopyrrolate in children. Rautakorpi P, et al. **Pharmacol Toxicol** 1998 Sep;83(3):132–4

PHARMACOLOGY

Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Haddad EB, et al. **Br J Pharmacol** 1999 May; 127(2):413–20

Effects of intravenously administered glycopyrrolate in anesthetized horses. Dyson DH, et al. **Can Vet J** 1999 Jan; 40(1):29–32

THERAPEUTIC USE

The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery. Joshi GP, et al. **Anesth Analg** 1999 Sep;89(3):628–31

The use of metoprolol and glycopyrrolate to prevent hypotensive/bradycardic events during shoulder arthroscopy in the sitting position under interscalene block. Liguori GA, et al. **Anesth Analg** 1998 Dec;87(6):1320–5

Diabetic gustatory sweating successfully treated with topical glycopyrrolate: report of a case and review of the literature. Urman JD, et al. **Arch Intern Med** 1999 Apr 26;159(8):877–8

Glycopyrrolate reduces nausea during spinal anaesthesia for caesarean section without affecting neonatal outcome. Ure D, et al. **Br J Anaesth** 1999 Feb;82(2):277–9

The use of topical glycopyrrolate in the treatment of hyperhidrosis. Seukeran DC, et al. **Clin Exp Dermatol** 1998 Sep;23(5):204–5

Use of glycopyrrolate in the treatment of Meniere's disease. Storper IS, et al. **Laryngoscope** 1998 Oct;108(10):1442–5

GLYCOSAMINOGLYCANS

Chondrocyte-seeded collagen matrices implanted in a chondral defect in a canine model. Nehrer S, et al. **Biomaterials** 1998 Dec;19(24):2313–28

Comparison of cultured and uncultured keratinocytes seeded into a collagen-GAG matrix for skin replacements. Butler CE, et al. **Br J Plast Surg** 1999 Mar;52(2):127–32

ADMINISTRATION & DOSAGE

Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Fracasso A, et al. **Am J Kidney Dis** 1999 Jan;33(1):105–10

Imedeen in the treatment of photoaged skin: an efficacy and safety trial over 12 months. Kieffer ME, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):129–36

[Intra-articular administration of galactosaminoglucuronoglycan sulfate in moderate primary gonarthritis. A pilot study] Coaccioli S, et al. **Minerva Med** 1998 Sep;89(9):341–4 (Eng. Abstr.) **(Ita)**

ANALYSIS

Histologic demonstration of glycosaminoglycans in inner ear fluids. Pawlowski KS, et al. **Acta Otolaryngol (Stockh)** 1998 Jul;118(4):505–10

Relations between biochemical markers of osteoarthritis and other disease parameters in a population of dogs with naturally acquired osteoarthritis of the genual joint. Innes JF, et al. **Am J Vet Res** 1998 Dec;59(12):1530–6

An agarose gel electrophoretic method for analysis of sulfated glycosaminoglycans of cultured cells. Funderburgh JL, et al. **Anal Biochem** 1978 Dec; 91(2):464–72

Histochemical studies of glycosaminoglycans in developing periodontal ligaments of ICR mice. Fujii T, et al. **Anat Rec** 1999 Apr 1;254(4):465–73

Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Graham LD, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):542–8

A survey of methodological challenges for glycosaminoglycan/proteoglycan analysis and structural characterization by capillary electrophoresis. Karamanos NK, et al. **Electrophoresis** 1998 Nov;19(15):2561–71 (63 ref.)

Sulphated glycosaminoglycans in guinea pig eosinophils studied by means of cationic colloidal gold. Yang DH, et al. **Histochem J** 1998 Sep;30(9):687–92

Effects of cryopreservation and deconstruction on the dermal glycosaminoglycan content of human skin. Poggi MM, et al. **J Burn Care Rehabil** 1999 May-Jun;20(3):201–6

Sulfated glycosaminoglycans in guinea pig neutrophils studied by use of cationic colloidal gold. Yang DH, et al. **J Histochem Cytochem** 1999 Jul;47(7):881–8

Glycosaminoglycan profile in macrophages exposed to Candida albicans and interleukins. Bodo M, et al. **J Leukoc Biol** 1998 Nov;64(5):650–6

Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Bashir A, et al. **Magn Reson Med** 1999 May;41(5):857–65

Immunohistochemical and histochemical characterization of the mucosubstances of odontogenic myxoma: histogenesis and differential diagnosis. Zhao M, et al. **Pathol Res Pract** 1999;195(6):391–7

BIOSYNTHESIS

Effect of irradiation with a low-intensity diode laser on the metabolism of equine articular cartilage in vitro. Ebert DW, et al. **Am J Vet Res** 1998 Dec;59(12):1613–8

Enhanced channelling of sulphate through a rapidly exchangeable sulphate pool in response to stimulated glycosaminoglycan synthesis in pancreatic epithelial cells. Hill WG, et al. **Biochim Biophys Acta** 1999 Jul 7; 1454(2):174–82

A contribution to the regulation of proteoglycan production: modulation by TGF alpha, TGF beta and IL-1 of glycosaminoglycan biosynthesis on beta-D-xyloside in chick embryo fibroblasts. Evangelisti R, et al. **Connect Tissue Res** 1998;37(1–2):77–85

Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor. Godden JL, et al. **Eur J Cancer** 1999 Mar; 35(3):473–80

Decreased biosynthesis of glycosaminoglycans in the skin of rats with chronic diabetes mellitus. Cechowska-Pasko M, et al. **Exp Toxicol Pathol** 1999 May;51(3):239–43

Neurotrophic growth factors stimulate glycosaminoglycan synthesis in identified retinal cell populations in vitro. Normand G, et al. **Glycobiology** 1998 Dec;8(12):1227–35

Characterization of beta-D-xyloside-initiated glycosaminoglycan synthesized by human skin fibroblasts in the presence of tunicamycin. Takagaki K, et al. **Glycoconj J** 1998 May;15(5):483–9

Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Balazs C, et al. **Horm Metab Res** 1998 Aug;30(8):496–9

Effects of insulin-like growth factor-I, corticosterone, and 3,3', 5-tri-iodo-L-thyronine on glycosaminoglycan synthesis in vertebral cartilage of the clearnose skate, Raja eglanteria. Gelsleichter J, et al. **J Exp Zool** 1999 Oct 1; 284(5):549–56

In vitro suppression of transforming growth factor-beta induced stimulation of glycosaminoglycan synthesis by acetylsalicylic acid and its reversal by misoprostol [see comments] Anastassiades T, et al. **J Rheumatol** 1998 Oct; 25(10):1962–7. Comment in: J Rheumatol 1998 Oct;25(10):1871–3.

Evaluation of clinical agents on articular chondrocyte

metabolism in vitro [editorial; comment] Smith RL.
J Rheumatol 1998 Oct;25(10):1871-3. Comment on: J Rheumatol 1998 Oct;25(10):1962-7.

Role of proteoglycans on testosterone synthesis by purified Leydig cells from immature and mature rats. Grudet N, et al. **J Steroid Biochem Mol Biol** 1999 Feb;68(3-4):153-62

Effect of in vitro aging on the biosynthesis of glycosaminoglycans by human skin fibroblasts. Modulation by the elastin-laminin receptor. Fodil-Bourahla I, et al. **Mech Ageing Dev** 1999 Jan 15;106(3):241-60

Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Lu R, et al. **Thyroid** 1999 Mar;9(3):297-303

[Decreased stimulation of glycosaminoglycan synthesis in cultured human skin fibroblasts within the scope of in vitro aging caused by interleukin 1] Biecker E, et al.
Z Gerontol Geriatr 1999 Apr;32(2):124-30 (Eng. Abstr.) **(Ger)**

[Sulfotransferases involved in the biosynthesis of glycosaminoglycans] Habuchi O, et al.
Tanpakushitsu Kakusan Koso 1998 Dec;43(16 Suppl):2378-86 (64 ref.) **(Jpn)**

[Biosynthesis of sugar chain backbone in glycosaminoglycan] Tsuchida K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec; 43(16 Suppl):2594-601 (47 ref.) **(Jpn)**

CHEMISTRY

Microanalysis of glycosaminoglycan-derived oligosaccharides labeled with a fluorophore 2-aminobenzamide by high-performance liquid chromatography: application to disaccharide composition analysis and exosequencing of oligosaccharides. Kinoshita A, et al. **Anal Biochem** 1999 May 1;269(2):367-78

Distribution and composition of glycosaminoglycans in the left human coronary arterial branches under myocardial bridge. Shinjo SK, et al. **Atherosclerosis** 1999 Apr; 143(2):363-8

Human abdominal aortic aneurysm is closely associated with compositional and specific structural modifications at the glycosaminoglycan level. Theocharis AD, et al.
Atherosclerosis 1999 Aug;145(2):351-8

Enzymatic reconstruction of a hybrid glycosaminoglycan containing 6-sulfated, 4-sulfated, and unsulfated N-acetylgalactosamine. Takagaki K, et al.
Biochem Biophys Res Commun 1999 May 19;258(3):741-4

Adsorption of glycosaminoglycans onto hydroxyapatite using chromatography. Okazaki J, et al. **Biomaterials** 1999 Feb; 20(4):309-14

Stereoselective syntheses of phosphorylated and sulfated glycosyl serines in glycosaminoglycan for biological probes. Tamura J, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):1911-4

Demonstration of the immature glycosaminoglycan tetrasaccharide sequence GlcAbeta1-3Galbeta1-3Galbeta1-4Xyl on recombinant soluble human alpha-thrombomodulin. An oligosaccharide structure on a "part-time" proteoglycan. Nadanaka S, et al. **J Biol Chem** 1998 Dec 11;273(50):33728-34

Generation of artificial proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction between rantes and chondroitin sulfate. Wolff EA, et al. **J Biol Chem** 1999 Jan 22;274(4):2518-24

Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. Deakin JA, et al. **J Cell Sci** 1999 Jun;112 (Pt 12):1999-2009

Effects of a triple enzyme digestion method on a diamine reaction for glycosaminoglycans of the rat aorta in electron microscopy. Ueda H, et al. **J Vet Med Sci** 1998 Nov; 60(11):1169-74

Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Venkataraman G, et al.
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1892-7

Chemical sulfonation and anticoagulant activity of acharan sulfate. Wu SJ, et al. **Thromb Res** 1998 Dec 15;92(6):273-81

IMMUNOLOGY

[The relation between the level of antibodies to the glycosaminoglycans of the cartilage in patients with osteoarthritis and the efficacy of treatment with chondroprotectors] Zavodovskii BV, et al. **Ter Arkh** 1999; 71(5):47-50 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Isolation, characterization and localization of glycosaminoglycans in growing antlers of wapiti (Cervus elaphus). Sunwoo HH, et al.
Comp Biochem Physiol B Biochem Mol Biol 1998 Jun; 120(2):273-83

METABOLISM

Electrophoretic and chromatographic patterns of glycosaminoglycans of the umbilical cord vessels and their alteration in EPH-gestosis. Romanowicz L, et al.
Acta Biochim Pol 1998;45(3):805-9

Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor. Billinghurst RC, et al. **Ann N Y Acad Sci** 1999 Jun 30; 878:594-7

Physical and biological regulation of proteoglycan turnover around chondrocytes in cartilage explants. Implications for tissue degradation and repair. Quinn TM, et al.
Ann N Y Acad Sci 1999 Jun 30;878:420-41

Degradation of acharan sulfate and heparin by Bacteroides stercoris HJ-15, a human intestinal bacterium. Kim DH, et al. **Arch Pharm Res** 1998 Oct;21(5):576-80

Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes. Sartipy P, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec; 18(12):1934-41

Human abdominal aortic aneurysm is closely associated with compositional and specific structural modifications at the glycosaminoglycan level. Theocharis AD, et al.
Atherosclerosis 1999 Aug;145(2):351-8

Oligomeric self-association of basic fibroblast growth factor in the absence of heparin-like glycosaminoglycans. Davis JC, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):613-20

Involvement of the core protein in the first beta-N-acetylgalactosamine transfer to the glycosaminoglycan-protein linkage-region tetrasaccharide and in the subsequent polymerization: the critical determining step for chondroitin sulphate biosynthesis. Nadanaka S, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):353-7

Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products. Tumova S, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):471-81

Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Kuschert GS, et al. **Biochemistry** 1999 Sep 28; 38(39):12959-68

Interleukin-1 induced nitric oxide inhibits sulphation of glycosaminoglycan chains in human articular chondrocytes. Hickery MS, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):282-90

Effects of dietary manganese on arterial glycosaminoglycan metabolism in Sprague-Dawley rats. Yang P, et al.
Biol Trace Elem Res 1998 Summer;64(1-3):275-88

The activities of some glycosaminoglycan-degrading enzymes in the wall of the umbilical cord artery and their alteration in edema, proteinuria, hypertension (EPH)-gestosis. Romanowicz L, et al.
Clin Chem Lab Med 1999 Apr;37(4):417-21

Proteoglycans at the bone-implant interface. Klinger MM, et al. **Crit Rev Oral Biol Med** 1998;9(4):449-63 (107 ref.)

Glycosaminoglycans in components of the rabbit eye: synthesis and characterization. Góes RM, et al.
Curr Eye Res 1999 Aug;19(2):146-53

Binding of interferon gamma by glycosaminoglycans: a strategy for localization and/or inhibition of its activity. Fernandez-Botran R, et al. **Cytokine** 1999 May; 11(5):313-25

Substrate specificity studies of Flavobacterium chondroitinase C and heparitinases towards the glycosaminoglycan--protein linkage region. Use of a sensitive analytical method developed by chromophore-labeling of linkage glycoserines using dimethylaminoazobenzenesulfonyl chloride. Tsuda H, et al.
Eur J Biochem 1999 May;262(1):127-33

Plasmodium falciparum: molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates. Barragan A, et al.
Exp Parasitol 1999 Feb;91(2):133-43

Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Song DU, et al.
Fundam Clin Pharmacol 1998;12(5):546-52

Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Herndon ME, et al. **Glycobiology** 1999 Feb; 9(2):143-55

Glycosaminoglycan and collagen distribution in the developing human vitreous. Azuma N, et al.
Graefes Arch Clin Exp Ophthalmol 1998 Sep;236(9):679-87

The proteoglycans and glycosaminoglycan chains of rabbit synovium. Coleman P, et al. **Histochem J** 1998 Jul; 30(7):519-24

Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi. Leong JM, et al. **Infect Immun** 1998 Dec;66(12):6045-8

Strain variation in glycosaminoglycan recognition influences cell-type-specific binding by lyme disease spirochetes. Parveen N, et al. **Infect Immun** 1999 Apr;67(4):1743-9

Distribution of glycosaminoglycans in rat renal tubular epithelium. Weinstein T, et al. **J Am Soc Nephrol** 1997 Apr; 8(4):586-95

Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. Bai X, et al. **J Biol Chem** 1999 May 7;274(19):13017-24

Intracellular accumulation of secreted proteoglycans inhibits cationic lipid-mediated gene transfer. Co-transfer of glycosaminoglycans to the nucleus. Belting M, et al.
J Biol Chem 1999 Jul 2;274(27):19375-82

Two distinct regions of cyclophilin B are involved in the recognition of a functional receptor and of glycosaminoglycans on T lymphocytes. Carpentier M, et al. **J Biol Chem** 1999 Apr 16;274(16):10990-8

Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. Chakravarty L, et al.
J Biol Chem 1998 Nov 6;273(45):29641-7

The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. Joyce JG, et al. **J Biol Chem** 1999 Feb 26; 274(9):5810-22

Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. Okajima T, et al. **J Biol Chem** 1999 Aug 13;274(33):22915-8

Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4. Petersen F, et al. **J Biol Chem** 1999 Apr 30; 274(18):12376-82

Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. Sartipy P, et al. **J Biol Chem** 1999 Sep 3;274(36):25913-20

Glycosaminoglycans differentially bind HARP and modulate its biological activity. Vacherot F, et al. **J Biol Chem** 1999 Mar 19;274(12):7741-7

Glycosaminoglycans mediate the coacervation of human tropoelastin through dominant charge interactions involving lysine side chains. Wu WJ, et al.
J Biol Chem 1999 Jul 30;274(31):21719-24

Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. Hansen C, et al.
J Clin Endocrinol Metab 1999 Apr;84(4):1409-13

A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. Burns JM, et al.
J Exp Med 1998 Nov 16;188(10):1917-27

Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. Koopmann W, et al. **J Immunol** 1999 Aug 15;163(4):2120-7

Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. Wadström T, et al. **J Med Microbiol** 1999 Mar;48(3):223-33 (90 ref.)

Crystal structure of chondroitin AC lyase, a representative of a family of glycosaminoglycan degrading enzymes. Féthière J, et al. **J Mol Biol** 1999 May 14;288(4):635-47

The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. Castillo GM, et al. **J Neurochem** 1999 Apr;72(4):1681-7

Monitoring glycosaminoglycan replenishment in cartilage explants with gadolinium-enhanced magnetic resonance imaging. Allen RG, et al. **J Orthop Res** 1999 May; 17(3):430-6

Expression of alpha-smooth muscle actin in canine intervertebral disc cells in situ and in collagen-glycosaminoglycan matrices in vitro. Schneider TO, et al. **J Orthop Res** 1999 Mar;17(2):192-9

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. Ishiguro N, et al. **J Rheumatol** 1999 Jan;26(1):34-40

The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. Trkola A, et al.
J Virol 1999 Aug;73(8):6370-9

Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Wolańska M, et al. **Mol Cell Biochem** 1998 Dec;189(1-2):145-52

Entry of OpaA+ gonococci into HEp-2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors. van Putten JP, et al. **Mol Microbiol** 1998 Jul;29(1):369-79

Correlation between [Na+], [glycosaminoglycan] and Na+/K+ pump density in the extracellular matrix of bovine articular cartilage. Mobasheri A. **Physiol Res** 1998; 47(1):47-52

Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. Rhomberg AJ, et al.
Proc Natl Acad Sci U S A 1998 Oct 13;95(21):12232-7

[Histochemical studies of glycosaminoglycans in the developing eyelids of experimental microphthalmic (Cts) mice] Nozaki M, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jun;103(6):425-31 (Eng. Abstr.) **(Jpn)**

[Skin glycosaminoglycans during emotional stress] Abramov IuV, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):134-6 **(Rus)**

PHARMACOLOGY

Oxidative modification of apolipoprotein E in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arai H, et al.
Arch Biochem Biophys 1999 Jul 1;367(1):1-8

Sulphated glycosaminoglycans prevent the neurotoxicity of a human prion protein fragment. Pérez M, et al.
Biochem J 1998 Oct 15;335 (Pt 2):369-74

Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Ruponen M, et al. **Biochim Biophys Acta** 1999 Jan 8;1415(2):331-41

Differential inhibition of retrovirus transduction by

proteoglycans and free glycosaminoglycans. Le Doux JM, et al. **Biotechnol Prog** 1999 May-Jun;15(3):397-406

Impact of various glycosaminoglycans upon cAMP-dependent protein kinase. Dittmann J, et al. **Cell Biochem Funct** 1999 Mar;17(1):21-8

Collagen-GAG substrate enhances the quality of nerve regeneration through collagen tubes up to level of autograft. Chamberlain LJ, et al. **Exp Neurol** 1998 Dec; 154(2):315-29

Adherence and internalization of Streptococcus uberis to bovine mammary epithelial cells are mediated by host cell proteoglycans. Almeida RA, et al. **FEMS Microbiol Lett** 1999 Aug 15;177(2):313-7

Cellular adhesion mediated by factor J, a complement inhibitor. Evidence for nucleolin involvement. Larrucea S, et al. **J Biol Chem** 1998 Nov 27;273(48):31718-25

Modulation of neutral matrix metalloproteinases of involuting rat mammary gland by different cations and glycosaminoglycans. Ambili M, et al. **J Cell Biochem** 1999 May 1;73(2):218-26

Modulation of macrophage and B cell function by glycosaminoglycans. Wrenshall LE, et al. **J Leukoc Biol** 1999 Sep;66(3):391-400

Inhibition of adenylate cyclase of rat hepatic membranes by glycosaminoglycans. Dittmann J, et al. **Life Sci** 1998; 63(24):2199-208

Specificity of glycosaminoglycan suppression of endothelin-1 production by human umbilical vein endothelial cells. Valencia AO, et al. **Life Sci** 1999;65(3):279-84

Glycosaminoglycan prevents hyperglycemia-induced renal TGF-beta 1 gene expression. Gambaro G, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:20-1

Glycosaminoglycans boost insulin-like growth factor-I-promoted neuroprotection: blockade of motor neuron death in the wobbler mouse. Vergani L, et al. **Neuroscience** 1999;93(2):565-72

Chemical sulfonation and anticoagulant activity of acharan sulfate. Wu SJ, et al. **Thromb Res** 1998 Dec 15;92(6):273-81

Sulfation-dependent down-regulation of interferon-gamma-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans. Yard BA, et al. **Transplantation** 1998 Nov 15;66(9):1244-50

PHYSIOLOGY

The contributions of glycosaminoglycans, collagen and other interstitial components to the hydraulic resistivity of porcine aortic wall. Weinberg PD, et al. **Connect Tissue Res** 1997;36(4):297-308

Sperm surface heparin/heparan sulfate is responsible for sperm binding to the uterine envelope in the newt, Cynops pyrrhogaster. Nakai S, et al. **Dev Growth Differ** 1999 Feb; 41(1):101-7

Apoptosis induced by granzyme B-glycosaminoglycan complexes: implications for granule-mediated apoptosis in vivo. Galvin JP, et al. **J Immunol** 1999 May 1; 162(9):5345-50

Effect of depletion of glycosaminoglycans and non-collagenous proteins on interstitial hydraulic permeability in rabbit synovium. Scott D, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):629-43

Silicon and matrix macromolecules: new research opportunities for old diseases from analysis of potential mechanisms of breast implant toxicity. Brawer AE. **Med Hypotheses** 1998 Jul;51(1):27-35 (46 ref.)

Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease interstitial cystitis and possibly Reiter's syndrome. Russell AL. **Med Hypotheses** 1999 Apr; 52(4):297-301

SECRETION

Analysis of constitutive and constitutive-like secretion in semi-intact pituitary cells. Dumermuth E, et al. **Methods** 1998 Oct;16(2):188-97

THERAPEUTIC USE

Oral glycosaminoglycans: a survey of responses. Kavanagh K, et al. **Aust Vet J** 1999 Apr;77(4):220-1

Glycosaminoglycan therapy for long-term diabetic complications? Gambaro G, et al. **Diabetologia** 1998 Aug; 41(8):975-9 (44 ref.)

[Sulodexide in the treatment of right hand necrosis in diabetic patient performing exchanges of continuous ambulatory peritoneal dialysis (CAPD) by himself] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):301-3 (Eng. Abstr.) **(Pol)**

[Sulodexide in the treatment of diabetic nephropathy] Rasovskii BL, et al. **Klin Med (Mosk)** 1998;76(7):40-2 (Eng. Abstr.) **(Rus)**

[The relation between the level of antibodies to the glycosaminoglycans of the cartilage in patients with osteoarthritis and the efficacy of treatment with chondroprotectors] Zavodovskii BV, et al. **Ter Arkh** 1999; 71(5):47-50 (Eng. Abstr.) **(Rus)**

URINE

Urinary glycosaminoglycan excretion in urolithiasis. Akçay T, et al. **Arch Dis Child** 1999 Mar;80(3):271-2

Urinary glycosaminoglycans in recurrent urinary tract infections in kidney transplant patients. Stabellini G, et al. **Biomed Pharmacother** 1999 Jun;53(5-6):274-7

Urinary glycosaminoglycans in renal cell carcinoma [letter] Rodriguez-Cuartero A, et al. **Clin Nephrol** 1998 Dec; 50(6):394

Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Byers S, et al. **Mol Genet Metab** 1998 Dec;65(4):282-90

Urinary glycosaminoglycans and their relationship to microalbuminuria in arterial hypertension [letter] Pérez-Blanco FJ, et al. **Nephron** 1999;81(4):444-5

Conjunctive effects of fibroblast growth factor and glycosaminoglycan on bone metabolism in neonatal bartter syndrome. Williams WJ, et al. **Pediatr Res** 1999 May;45(5 Pt 1):726-32

[Urinary excretion of mucopolysaccharides in pediatric and adolescent patients] de la Cruz Amorós V, et al. **An Esp Pediatr** 1999 Apr;50(4):361-6 (Eng. Abstr.) **(Spa)**

GLYCOSIDASES see **GLYCOSIDE HYDROLASES**

GLYCOSIDE ANTIBIOTICS see **ANTIBIOTICS, AMINOGLYCOSIDE**

GLYCOSIDE HYDROLASES

Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissues. Basu M, et al. **Acta Biochim Pol** 1998;45(2):327-42

The amylopullulanase of Bacillus sp. DSM 405. Brunswick JM, et al. **Appl Microbiol Biotechnol** 1999 Feb;51(2):170-5

Effect of enzyme supplementation of UK-grown lupinus albus on growth performance in broiler chickens. Naveed A, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S36-7

ADMINISTRATION & DOSAGE

Effects of an enzyme feed additive on extent of digestion and milk production of lactating dairy cows. Yang WZ, et al. **J Dairy Sci** 1999 Feb;82(2):391-403

ANALYSIS

Automated assay of glycosidases. Sarber R, et al. **Anal Biochem** 1978 Nov;91(1):361-6

Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Parish CR, et al. **Cancer Res** 1999 Jul 15;59(14):3433-41

Lutzomyia longipalpis: pH in the gut, digestive glycosidases, and some speculations upon Leishmania development. Gontijo NF, et al. **Exp Parasitol** 1998 Nov;90(3):212-9

Determination of N-linked glycosylation of yeast external invertase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Zeng C, et al. **J Mass Spectrom** 1999 Apr;34(4):311-29

ANTAGONISTS & INHIBITORS

Cancer cell heparanase activity associated with invasion and metastasis. Nicolson GL, et al. **Adv Enzyme Regul** 1998; 38:19-32

Isotope edited NMR studies of glycosidases: design and synthesis of a novel glycosidase inhibitor. Hines JV, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1255-60

Polyhydroxylated pyrrolidine and pyrrolizidine alkaloids from Hyancinthoides non-scripta and Scilla campanulata. Kato A, et al. **Carbohydr Res** 1999 Mar 31;316(1-4):95-103

Synthesis and applications for unnatural sugar nucleotides. Elhalabi JM, et al. **Curr Med Chem** 1999 Feb;6(2):93-116 (164 ref.)

Effects of ethanol ingestion on epididymal glycosidases and fertility in the rat. Srikanth V, et al. **Int J Androl** 1998 Dec;21(6):343-51

Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Miao HQ, et al. **Int J Cancer** 1999 Oct 29;83(3):424-31

Ectopic expression of a tobacco invertase inhibitor homolog prevents cold-induced sweetening of potato tubers. Greiner S, et al. **Nat Biotechnol** 1999 Jul;17(7):708-11

Antisense repression of vacuolar and cell wall invertase in transgenic carrot alters early plant development and sucrose partitioning. Tang GQ, et al. **Plant Cell** 1999 Feb; 11(2):177-89

Potential target found for antimetastasis drugs [news] Finkel E. **Science** 1999 Jul 2;285(5424):33-4

[Inhibiting effect of the aqueous extract of Arctostaphylos uva-ursi on myrosinase activity from Brassica napus seeds] Mykytyn MS, et al. **Ukr Biokhim Zh** 1998 Jul-Aug; 70(4):122-6 (Eng. Abstr.) **(Ukr)**

BIOSYNTHESIS

Cloning and sequencing of the beta-fructofuranosidase gene from Bacillus sp. V230. Kurimoto M, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):1107-11

Srb/mediator proteins interact functionally and physically with transcriptional repressor Sfl1. Song W, et al. **EMBO J** 1998 Oct 1;17(19):5757-65

Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Walch ET, et al. **Int J Cancer** 1999 Jul 2;82(1):112-20

Coordinate transcriptional control in the hyperthermophilic archaeon Sulfolobus solfataricus. Haseltine C, et al. **J Bacteriol** 1999 Jul;181(13):3920-7

Phosphorylation of HPr and Crh by HprK, early steps in the catabolite repression signalling pathway for the Bacillus subtilis levanase operon. Martin-Verstraete I, et al. **J Bacteriol** 1999 May;181(9):2966-9

The extracellular xylan degradative system in Clostridium cellulolyticum cultivated on xylan: evidence for cell-free cellulosome production. Mohand-Oussaid O, et al. **J Bacteriol** 1999 Jul;181(13):4035-40

Novel alleles of yeast hexokinase PII with distinct effects on catalytic activity and catabolite repression of SUC2. Hohmann S, et al. **Microbiology** 1999 Mar;145 (Pt 3):703-14

Glucose repression of the Kluyveromyces lactis invertase gene KlINV1 does not require Mig1p. Georis I, et al. **Mol Gen Genet** 1999 Jun;261(4-5):862-70

Expression of a yeast-derived invertase in developing cotyledons of Vicia narbonensis alters the carbohydrate state and affects storage functions. Weber H, et al. **Plant J** 1998 Oct;16(2):163-72

Glycoside hydrolase production by an anaerobic rumen fungus Caecomyces communis. Bata J, et al. **Res Microbiol** 1997 Mar-Apr;148(3):263-9

Immobilization of polymethylgalacturonase producing Aspergillus niger on Luffa sponge material. Slokoska LS, et al. **Z Naturforsch [C]** 1998 Nov-Dec;53(11-12):968-72

BLOOD

Lysosomal enzymes in preterm infants with bronchopulmonary dysplasia: a potential diagnostic marker. Goi G, et al. **Clin Chim Acta** 1998 Nov;278(1):23-34

Alterations in the activity of several glycohydrolases in red blood cell membrane from type 2 diabetes mellitus patients. Goi G, et al. **Metabolism** 1999 Jul;48(7):817-21

CHEMICAL SYNTHESIS

Isotope edited NMR studies of glycosidases: design and synthesis of a novel glycosidase inhibitor. Hines JV, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1255-60

CHEMISTRY

Expression, purification, crystallization and preliminary x-ray analysis of the kappa-carrageenase from Pseudoalteromonas carrageenovora. Michel G, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):918-20

Crystallization and preliminary X-ray analysis of arabinanase A from Pseudomonas fluorescens subspecies cellulosa. Scott M, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Feb;55 (Pt 2):544-6

Crystallization and preliminary X-ray analysis of alpha-D-glucuronidase from Bacillus stearothermophilus T-6. Teplitsky A, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):869-72

On-target exoglycosidase digestions/MALDI-MS for determining the primary structures of carbohydrate chains. Colangelo J, et al. **Anal Chem** 1999 Apr 1;71(7):1479-82

Stability in organic solvent mixtures of beta-glucosidase and beta-fructofuranosidase as dry powder and entrapped in poly-HEMA. Cantarella L, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:219-23

Detection of molecular interactions by using a new peptide-displaying bacteriophage biosensor. Ramirez E, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):801-5

The Glu residue in the conserved Asn-Glu-Pro sequence of endoglycoceramidase is essential for enzymatic activity. Sakaguchi K, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):89-93

Protein heterogeneity of spinach pullulanase results from the coexistence of interconvertible isomeric forms of the monomeric enzyme. Henker A, et al. **Biochem J** 1998 May 1;331 (Pt 3):929-35

cDNA sequence and heterologous expression of monomeric spinach pullulanase: multiple isomeric forms arise from the same polypeptide. Renz A, et al. **Biochem J** 1998 May 1; 331 (Pt 3):937-45

Thermal unfolding of chitosanase from Streptomyces sp. N174: role of tryptophan residues in the protein structure stabilization. Honda Y, et al. **Biochim Biophys Acta** 1999 Jan 11;1429(2):365-76

Structure-function studies on beta-glycosidase from Sulfolobus solfataricus. Molecular bases of thermostability. D'Auria S, et al. **Biochimie** 1998 Nov;80(11):949-57

Isotope edited NMR studies of glycosidases: design and synthesis of a novel glycosidase inhibitor. Hines JV, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1255-60

Formation of glucoraphanin by chemoselective oxidation of natural glucoerucin: a chemoenzymatic route to sulforaphane. Iori R, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1047-8

Hydrostatic pressure rescues native protein from aggregates. Foguel D, et al. **Biotechnol Bioeng** 1999 Jun 5;63(5):552-8

Stability, refolding and Ca2+ binding of pullulanase from the hyperthermophilic archaeon Pyrococcus woesei. Schwerdtfeger RM, et al. **Eur J Biochem** 1999 Sep;

264(2):479–87
Heat-stable pullulanase from Bacillus acidopullulyticus: characterization and refolding after guanidinium chloride-induced unfolding. Stefanova ME, et al. **Extremophiles** 1999 May;3(2):147–52
Crystal structure of the beta-glycosidase from the hyperthermophile Thermosphaera aggregans: insights into its activity and thermostability. Chi YI, et al. **FEBS Lett** 1999 Feb 26;445(2–3):375–83
The evolution of starch-binding domain. Janecek S, et al. **FEBS Lett** 1999 Jul 30;456(1):119–25
Conserved sequence motifs in levansucrases and bifunctional beta-xylosidases and alpha-L-arabinases. Naumoff DG. **FEBS Lett** 1999 Apr 1;448(1):177–9
Secondary structure of Streptococcus downei GTF-I glucansucrase. Monchois V, et al. **FEMS Microbiol Lett** 1999 Aug 15;177(2):243–8
Harmaline interactions with yeast invertase. Gill RK, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):86–90
Crystal structure of a maltogenic amylase provides insights into a catalytic versatility. Kim JS, et al. **J Biol Chem** 1999 Sep 10;274(37):26279–86
Formation of fibrous aggregates from a non-native intermediate: the isolated P22 tailspike beta-helix domain. Schuler B, et al. **J Biol Chem** 1999 Jun 25;274(26):18589–96
Cellulosomes-structure and ultrastructure. Bayer EA, et al. **J Struct Biol** 1998 Dec 15;124(2–3):221–34 (100 ref.)
Structure and evolution of parallel beta-helix proteins. Jenkins J, et al. **J Struct Biol** 1998;122(1–2):236–46 (44 ref.)
Folding and function of repetitive structure in the homotrimeric phage P22 tailspike protein. Seckler R. **J Struct Biol** 1998;122(1–2):216–22
Structural basis of the conversion of T4 lysozyme into a transglycosidase by reengineering the active site. Kuroki R, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3; 96(16):8949–54
Structural comparisons of TIM barrel proteins suggest functional and evolutionary relationships between beta-galactosidase and other glycohydrolases. Juers DH, et al. **Protein Sci** 1999 Jan;8(1):122–36
Phage P22 tailspike protein: removal of head-binding domain unmasks effects of folding mutations on native-state thermal stability. Miller S, et al. **Protein Sci** 1998 Oct; 7(10):2223–32
Structural model for family 32 of glycosyl-hydrolase enzymes. Pons T, et al. **Proteins** 1998 Nov 15;33(3):383–95
There's a right way and a wrong way: in vivo and in vitro folding, misfolding and subunit assembly of the P22 tailspike. Betts S, et al. **Structure Fold Des** 1999 Jun 15; 7(6):R131–9 (44 ref.)
[The molecular biological mechanisms of the functioning of microbial glycopolymers and carbohydrases] Zakharova IIa. **Mikrobiol Z** 1998 Nov–Dec;60(6):3–25 (122 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Sequence, structural, functional, and phylogenetic analyses of three glycosidase families. Mian IS. **Blood Cells Mol Dis** 1998 Jun;24(2):83–100

DRUG EFFECTS

Effects of oxygen on invertase expression in continuous culture of recombinant Saccharomyces cerevisiae containing the SUC2 gene. Pyun YR, et al. **Appl Microbiol Biotechnol** 1999 Mar;51(3):334–9

GENETICS

Pullulanase type I from Fervidobacterium pennavorans Ven5: cloning, sequencing, and expression of the gene and biochemical characterization of the recombinant enzyme. Bertoldo C, et al. **Appl Environ Microbiol** 1999 May; 65(5):2084–91
Med8, a subunit of the mediator CTD complex of RNA polymerase II, directly binds to regulatory elements of SUC2 and HXK2 genes. Chaves RS, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):345–50
Cloning and functional expression of a human heparanase gene. Kussie PH, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):183–7
Genomic DNA sequence of a rice gene coding for a pullulanase-type of starch debranching enzyme. Francisco PB Jr, et al. **Biochim Biophys Acta** 1998 Sep 8; 1387(1–2):469–77
Isolation and characterization of the gene encoding the starch debranching enzyme limit dextrinase from germinating barley. Kristensen M, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):538–46
Insertion analysis of putative functional elements in the promoter region of the Aspergillus oryzae Taka-amylase A gene (amyB) using a heterologous Aspergillus nidulans amdS-lacZ fusion gene system. Kanemori Y, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):180–3
Cloning and sequencing of the beta-fructofuranosidase gene from Bacillus sp. V230. Kurimoto M, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):1107–11
Molecular cloning and sequence analysis of two endoinulinase genes from Aspergillus niger. Ohta K, et al. **Biosci Biotechnol Biochem** 1998 Sep;62(9):1731–8
Expression of the extracellular levansucrase and invertase genes from Zymomonas mobilis in Escherichia coli cells. Yanase H, et al. **Biosci Biotechnol Biochem** 1998 Sep; 62(9):1802–5
Genetic and biochemical characterization of an exopolygalacturonase and a pectate lyase from Yersinia enterocolitica. Liao CH, et al. **Can J Microbiol** 1999 May; 45(5):396–403
Cloning, sequencing, and expression of cscA invertase from Escherichia coli B-62. Sahin-Tóth M, et al. **Can J Microbiol** 1999 May;45(5):418–22
Human HPA endoglycosidase heparanase. Map position 4q21.3. Baker E, et al. **Chromosome Res** 1999;7(4):319
Assignment of the poly(ADP-ribose) glycohydrolase gene (PARG) to human chromosome 10q11.23 and mouse chromosome 14B by in situ hybridization. Amé JC, et al. **Cytogenet Cell Genet** 1999;85(3–4):269–70
Linkage mapping of the rat poly(ADP-ribose) glycohydrolase (Parg) gene to chromosome 16. Shimokawa T, et al. **Exp Anim** 1999 Jul;48(3):217–8
The jasmonate-induced 60 kDa protein of barley exhibits N-glycosidase activity in vivo. Dunaeva M, et al. **FEBS Lett** 1999 Jun 11;452(3):263–6
Expression and secretion of Bacillus polymyxa neopullulanase in Saccharomyces cerevisiae. Yebra MJ, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):41–9
Molecular characterization of a novel beta-1,3-exoglucanase related to mycoparasitism of Trichoderma harzianum. Cohen-Kupiec R, et al. **Gene** 1999 Jan 21;226(2):147–54
A new inducible protein expression system in fission yeast based on the glucose-repressed inv1 promoter. Iacovoni JS, et al. **Gene** 1999 May 17;232(1):53–8
Characterization of rice endo-beta-glucanase genes (Gns2–Gns14) defines a new subgroup within the gene family. Romero GO, et al. **Gene** 1998 Nov 26; 223(1–2):311–20
Cloning of cDNA for a cell wall-bound acid invertase from tomato (Lycopersicon esculentum) and expression of soluble and cell wall-bound invertases in plants and wounded leaves of L. esculentum and L. peruvianum. Ohyama A, et al. **Genes Genet Syst** 1998 Jun;73(3):149–57
Characterization of three related glucose repressors and genes they regulate in Saccharomyces cerevisiae. Lutfiyya LL, et al. **Genetics** 1998 Dec;150(4):1377–91
The human poly(ADP-ribose) glycohydrolase maps to chromosome 10q11.23–21.1 by fluorescence in situ hybridization. Shimokawa T, et al. **Hum Cell** 1998 Dec; 11(4):243–6
The bvr locus of Listeria monocytogenes mediates virulence gene repression by beta-glucosides. Brehm K, et al. **J Bacteriol** 1999 Aug;181(16):5024–32
Regulation of expression of the fructan hydrolase gene of Streptococcus mutans GS-5 by induction and carbon catabolite repression. Burne RA, et al. **J Bacteriol** 1999 May;181(9):2863–71
The type II pullulanase of Thermococcus hydrothermalis: molecular characterization of the gene and expression of the catalytic domain. Erra-Pujada M, et al. **J Bacteriol** 1999 May;181(10):3284–7
A genetic selection for isolating cDNA clones that encode signal peptides. Jacobs KA, et al. **Methods Enzymol** 1999; 303:468–79
The abfB gene encoding the major alpha-L-arabinofuranosidase of Aspergillus nidulans: nucleotide sequence, regulation and construction of a disrupted strain. Gielkens M, et al. **Microbiology** 1999 Mar; 145 (Pt 3):735–41
Horizontal gene transfer in glycosyl hydrolases inferred from codon usage in Escherichia coli and Bacillus subtilis. Garcia-Vallvé S, et al. **Mol Biol Evol** 1999 Sep; 16(9):1125–34
Molecular heterogeneity and regulation of poly(ADP-ribose) glycohydrolase. Amé JC, et al. **Mol Cell Biochem** 1999 Mar;193(1–2):75–81
Glucose repression of the Kluyveromyces lactis invertase gene KlINV1 does not require Mig1p. Georis I, et al. **Mol Gen Genet** 1999 Jun;261(4–5):862–70
The eff-482 locus of Sinorhizobium meliloti CXM1-105 that influences symbiotic effectiveness consists of three genes encoding an endoglycanase, a transcriptional regulator and an adenylate cyclase. Sharypova LA, et al. **Mol Gen Genet** 1999 Jul;261(6):1032–44
Heparanase: breaking down barriers in tumors [news; comment] Eccles SA. **Nat Med** 1999 Jul;5(7):735–6. Comment on: Nat Med 1999 Jul;5(7):793–802. Comment on: Nat Med 1999 Jul;5(7):803–9.
Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis [see comments] Hulett MD, et al. **Nat Med** 1999 Jul;5(7):803–9. Comment in: Nat Med 1999 Jul;5(7):735–6.
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis [see comments] Vlodavsky I, et al. **Nat Med** 1999 Jul; 5(7):793–802. Comment in: Nat Med 1999 Jul;5(7):735–6.
Expression of a yeast-derived invertase in developing cotyledons of Vicia narbonensis alters the carbohydrate state and affects storage functions. Weber H, et al. **Plant J** 1998 Oct;16(2):163–72
Ivr2, a candidate gene for a QTL of vacuolar invertase activity in maize leaves. Gene-specific expression under water stress. Pelleschi S, et al. **Plant Mol Biol** 1999 Jan; 39(2):373–80
Purification and molecular genetic characterization of ZPU1, a pullulanase-type starch-debranching enzyme from maize. Beatty MK, et al. **Plant Physiol** 1999 Jan;119(1):255–66
A single limit dextrinase gene is expressed both in the developing endosperm and in germinated grains of barley. Burton RA, et al. **Plant Physiol** 1999 Mar;119(3):859–71
Expression of the Arabidopsis thaliana invertase gene family. Tymowska-Lalanne Z, et al. **Planta** 1998 Dec; 207(2):259–65
Sugars modulate an unusual mode of control of the cell-wall invertase gene (Incw1) through its 3' untranslated region in a cell suspension culture of maize. Cheng WH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10512–7
Potential target found for antimetastasis drugs [news] Finkel E. **Science** 1999 Jul 2;285(5424):33–4
Cloning and sequence analysis of the gene encoding invertase (INV1) from the yeast Candida utilis. Chávez FP, et al. **Yeast** 1998 Sep 30;14(13):1223–32
[beta-Fructosidases: a new superfamily of glycosyl-hydrolases] Naumov DG, et al. **Mol Biol (Mosk)** 1998 Sep–Oct;32(5):902–7 **(Rus)**
[Homologous locus of genomes of Bacillus subtilis and Bacillus stearothermophilus, containing levansucrase and levanase genes] Naumov DG. **Mol Biol (Mosk)** 1999 Mar–Apr;33(2):207–10 **(Rus)**

ISOLATION & PURIFICATION

Purification and substrate specificities of two alpha-L-arabinofuranosidases from Aspergillus awamori IFO 4033. Kaneko S, et al. **Appl Environ Microbiol** 1998 Oct;64(10):4021–7
Partial purification of heparanase activities in Chinese hamster ovary cells: evidence for multiple intracellular heparanases. Bame KJ, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):191–200
An unusual case of 'uncompetitive activation' by ascorbic acid: purification and kinetic properties of a myrosinase from Raphanus sativus seedlings. Shikita M, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):725–32
A new tool for studying the molecular architecture of the fungal cell wall: one-step purification of recombinant trichoderma beta-(1–6)-glucanase expressed in Pichia pastoris. Bom IJ, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):419–24
Chitosanase activity of the enzyme previously reported as beta-1,3-1,4-glucanase from Bacillus circulans WL-12. Mitsutomi M, et al. **Biosci Biotechnol Biochem** 1998 Nov; 62(11):2107–14
Purification and characterization of Aspergillus ficuum endoinulinase. Uhm TB, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):146–51
Preferential perinuclear localization of poly(ADP-ribose) glycohydrolase. Winstall E, et al. **Exp Cell Res** 1999 Sep 15;251(2):372–8
Human heparanase. Purification, characterization, cloning, and expression. Toyoshima M, et al. **J Biol Chem** 1999 Aug 20;274(34):24153–60
Detection of beta-1,6-glucanase isozymes from Trichoderma strains in sodium dodecyl sulphate-polyacrylamide gel electrophoresis and isoelectrofocusing gels. Soler A, et al. **J Microbiol Methods** 1999 Apr;35(3):245–51
Partial purification and characterisation of sugarcane neutral invertase. Vorster DJ, et al. **Phytochemistry** 1998 Oct; 49(3):651–5
Purification and molecular genetic characterization of ZPU1, a pullulanase-type starch-debranching enzyme from maize. Beatty MK, et al. **Plant Physiol** 1999 Jan;119(1):255–66

METABOLISM

Enzymatic hydrolysis of glycosphingolipids. Li YT, et al. **Anal Biochem** 1999 Aug 15;273(1):1–11 (106 ref.)
Relationship between glycosyl hydrolase inventory and growth physiology of the hyperthermophile Pyrococcus furiosus on carbohydrate-based media. Driskill LE, et al. **Appl Environ Microbiol** 1999 Mar;65(3):893–7
Purification and substrate specificities of two alpha-L-arabinofuranosidases from Aspergillus awamori IFO 4033. Kaneko S, et al. **Appl Environ Microbiol** 1998 Oct;64(10):4021–7
Carbon catabolite repression of invertase during batch cultivations of Saccharomyces cerevisiae: the role of glucose, fructose, and mannose. Dynesen J, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):579–82
Characterization of alpha-L-rhamnosidase of Bacillus sp. GL1 responsible for the complete depolymerization of gellan. Hashimoto W, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):56–60
Unsaturated glucuronyl hydrolase of Bacillus sp. GL1: novel enzyme prerequisite for metabolism of unsaturated oligosaccharides produced by polysaccharide lyases. Hashimoto W, et al. **Arch Biochem Biophys** 1999 Aug 15; 368(2):367–74
Characterization of the interaction of dinitrogenase reductase-activating glycohydrolase from Rhodospirillum rubrum with bacterial membranes. Halbleib CM, et al. **Arch Microbiol** 1999 Jul;172(1):51–8
A cellulose-binding domain-fused recombinant human T cell connective tissue-activating peptide-III manifests heparanase activity. Rechter M, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):657–62
Site-specific characterization of the N-linked glycans of murine prion protein by high-performance liquid chromatography/electrospray mass spectrometry and exoglycosidase digestions. Stimson E, et al.

Biochemistry 1999 Apr 13;38(15):4885–95

Study on. splitting of sucrose glycoside bonds by beta-fructosidase of Aspergillus niger VKM F-801. Korneeva OS, et al. **Biochemistry (Mosc)** 1998 Oct; 63(10):1220–5

Variation in glycosidase activity in soluble fractions in ICR/f rat lenses with the progression of cataract formation. Kamei A. **Biol Pharm Bull** 1999 Feb;22(2):200–2

Partial properties of four glycosidases in normal human lens and variations in their enzyme activities during aging and with the advance of lens coloration. Kamei A. **Biol Pharm Bull** 1998 Sep;21(9):982–6

Chemical and enzymatic synthesis of glycoconjugates. 5: One-pot regioselective synthesis of bioactive galactobiosides using a CLONEZYME thermophilic glycosidase library. Li J, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):35–8

Substrate specificity of the alpha-L-arabinofuranosidase from Trichoderma reesei. Kaneko S, et al. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2205–10

Analysis of the oligosaccharide units of xyloglucans by digestion with isoprimeverose-producing oligoxyloglucan hydrolase followed by anion-exchange chromatography. Konishi T, et al. **Biosci Biotechnol Biochem** 1998 Dec; 62(12):2421–4

Amplification of flow-microcalorimetry signal by means of multiple bioaffinity layering of lectin and glycoenzyme. Gemeiner P, et al. **Biotechnol Appl Biochem** 1998 Oct;28 (Pt 2):155–61

Purification and characterization of a levanbiose-producing levanase from Pseudomonas sp. No. 43. Jung Kang E, et al. **Biotechnol Appl Biochem** 1999 Jun;29 (Pt 3):263–8

The exopolygalacturonase from Aspergillus tubingensis is also active on xylogalacturonan. Kester HC, et al. **Biotechnol Appl Biochem** 1999 Aug;30 (Pt 1):53–7

Advantages in using immobilized thermophilic beta-glycosidase in nonisothermal bioreactors. Febbraio F, et al. **Biotechnol Bioeng** 1998 Jul 5;59(1):108–15

Yeast cell permeabilizing beta-1,3-glucanases: A tool for the integration of downstream processes and metabolic engineering applications to yeast. Ferrer P, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):321–4 (27 ref.)

Kinetic model for the co-action of beta-amylase and debranching enzymes in the production of maltose. Jiahua Z. **Biotechnol Bioeng** 1999 Mar 5;62(5):618–22

Enzymatic transformations in supersaturated substrate solutions: I. A general study with glycosidases. Millqvist-Fureby A, et al. **Biotechnol Bioeng** 1998 Oct 20; 60(2):190–6

Fractionation of sugar beet pulp into pectin, cellulose, and arabinose by arabinases combined with ultrafiltration. Spagnuolo M, et al. **Biotechnol Bioeng** 1999 Sep 20; 64(6):685–91

Enzyme array-amperometric detection in carbohydrate analysis. Sun M, et al. **Biotechnol Bioeng** 1998 Mar 5; 57(5):545–51

Characterization of an endo-1,3-beta-D-glucanase produced during the interaction between the mycoparasite Stachybotrys elegans and its host Rhizoctonia solani. Archambault C, et al. **Can J Microbiol** 1998 Oct; 44(10):989–97

Clues to the origin of high external invertase activity in immobilized growing yeast: prolonged SUC2 transcription and less susceptibility of the enzyme to endogenous proteolysis. de Alteriis E, et al. **Can J Microbiol** 1999 May; 45(5):413–7

Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Shapiro TA, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec; 7(12):1091–100

Mode of action of RG-hydrolase and RG-lyase toward rhamnogalacturonan oligomers. Characterization of degradation products using RG-rhamnohydrolase and RG-galacturonohydrolase. Mutter M, et al. **Carbohydr Res** 1998 Sep;311(3):155–64

Characterization of antigenic epitopes in anti-ulcer pectic polysaccharides from Bupleurum falcatum L. using several carbohydrases. Sakurai MH, et al. **Carbohydr Res** 1998 Oct; 311(4):219–29

In vitro effects of cadmium and DDVP (dichlorvos) on intestinal carbohydrase and protease activities in freshwater teleosts. Golovanova IL, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):21–5

The effect of hypo- and hyperthyroidism on uterine and cervical collagens and glycosidases in albino rats. Gladson M, et al. **Endocr Res** 1999 Feb;25(1):129–37

Hydrolase and transferase activities of the beta-1,3-exoglucanase of Candida albicans. Stubbs HJ, et al. **Eur J Biochem** 1999 Aug;263(3):889–95

In vitro biodegradation study of acetyl and methyl inulins by Bifidobacteria and inulinase. Damian F, et al. **Eur J Pharm Biopharm** 1999 May;47(3):275–82

Poly(ADP-ribose) glycohydrolase is present and active in mammalian cells as a 110-kDa protein. Winstall E, et al. **Exp Cell Res** 1999 Feb 1;246(2):395–8

Polymer hydrolysis in a cold climate. Cummings SP, et al. **Extremophiles** 1999 May;3(2):81–7 (44 ref.)

The evolution of starch-binding domain. Janecek S, et al. **FEBS Lett** 1999 Jul 30;456(1):119–25

From beta-glucanase to beta-glucansynthase: glycosyl transfer to alpha-glycosyl fluorides catalyzed by a mutant endoglucanase lacking its catalytic nucleophile. Malet C, et al. **FEBS Lett** 1998 Nov 27;440(1-2):208–12

Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks N-glycosidase activity. Yamasaki C, et al. **FEBS Lett** 1999 Jan 15;442(2-3):231–4

An unusual pattern of invertase activity development in the thermophilic fungus Thermomyces lanuginosus. Chaudhuri A, et al. **FEMS Microbiol Lett** 1999 Aug 1;177(1):39–45

A new inducible protein expression system in fission yeast based on the glucose-repressed inv1 promoter. Iacovoni JS, et al. **Gene** 1999 May 17;232(1):53–8

Glycosylation of the overlapping sequons in yeast external invertase: effect of amino acid variation on site selectivity in vivo and in vitro. Reddy A, et al. **Glycobiology** 1999 Jun;9(6):547–55

Hydrolase-catalyzed beta-mannosylations. Taubken N, et al. **Glycoconj J** 1998 Aug;15(8):757–67

Harmaline interactions with yeast invertase. Gill RK, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):86–90

Effect of dietary or abomasal supplementation of exogenous polysaccharide-degrading enzymes on rumen fermentation and nutrient digestibility. Hristov AN, et al. **J Anim Sci** 1998 Dec;76(12):3146–56

Influence of sampling site on concentrations and carbohydrate-degrading enzyme activities of protozoa and bacteria in the rumen. Martin C, et al. **J Anim Sci** 1999 Apr;77(4):979–87

Bacteriophage and associated polysaccharide depolymerases--novel tools for study of bacterial biofilms [published erratum appears in J Appl Microbiol 1999 Feb;86(2):359] Hughes KA, et al. **J Appl Microbiol** 1998 Sep;85(3):583–90

Extracellular inulinases from Penicillium janczewskii, a fungus isolated from the rhizosphere of Vernonia herbacea (Asteraceae). Pessoni RA, et al. **J Appl Microbiol** 1999 Jul; 87(1):141–7

Identification of critical, conserved vicinal aspartate residues in mammalian and bacterial ADP-ribosylarginine hydrolases. Konczalik P, et al. **J Biol Chem** 1999 Jun 11; 274(24):16736–40

Activity of an Aspergillus terreus alpha-arabinofuranosidase on phenolic-substituted oligosaccharides. Luonteri E, et al. **J Biotechnol** 1999 Jan 8;67(1):41–8

A glycosyl hydrolase activity of mammalian reovirus sigma1 protein can contribute to viral infection through a mucus layer. Bisaillon M, et al. **J Mol Biol** 1999 Feb 26; 286(3):759–73

Degradation of basement membrane by prostate tumor heparanase. Kosir MA, et al. **J Surg Res** 1999 Jan;81(1):42–7

A simple individual-based model of insoluble polysaccharide hydrolysis: the potential for autosynergism with dual-activity glycosidases [letter] Fenske JJ, et al. **J Theor Biol** 1999 Jul 7;199(1):113–8

In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Rellier N, et al. **Life Sci** 1999;64(17):1571–83

Lysis of Paracoccidioides brasiliensis by Zygosporium geminatum. San-Blas G, et al. **Med Mycol** 1998 Apr; 36(2):75–9

Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Hughes KA, et al. **Microbiology** 1998 Nov;144 (Pt 11):3039–47

Poly(ADP-ribose) turnover in quail myoblast cells: relation between the polymer level and its catabolism by glycohydrolase. Affar EB, et al. **Mol Cell Biochem** 1999 Mar;193(1-2):127–35

Molecular heterogeneity and regulation of poly(ADP-ribose) glycohydrolase. Amé JC, et al. **Mol Cell Biochem** 1999 Mar;193(1-2):75–81

Measurement of poly(ADP-ribose) glycohydrolase activity by high resolution polyacrylamide gel electrophoresis: specific inhibition by histones and nuclear matrix proteins. Pacheco-Rodriguez G, et al. **Mol Cell Biochem** 1999 Mar; 193(1-2):13–8

Heparanase: breaking down barriers in tumors [news; comment] Eccles SA. **Nat Med** 1999 Jul;5(7):735–6. Comment on: Nat Med 1999 Jul;5(7):793–802. Comment on: Nat Med 1999 Jul;5(7):803–9.

Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis [see comments] Hulett MD, et al. **Nat Med** 1999 Jul;5(7):803–9. Comment in: Nat Med 1999 Jul;5(7):735–6.

Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis [see comments] Vlodavsky I, et al. **Nat Med** 1999 Jul; 5(7):793–802. Comment in: Nat Med 1999 Jul;5(7):735–6.

Invertase activity associated with the walls of Solanum tuberosum tubers. Isla MI, et al. **Phytochemistry** 1999 Feb; 50(4):525–34

Delivery of a secreted soluble protein to the vacuole via a membrane anchor. Barrieu F, et al. **Plant Physiol** 1999 Aug;120(4):961–8

Structural basis of the conversion of T4 lysozyme into a transglycosidase by reengineering the active site. Kuroki R, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3; 96(16):8949–54

Role of TYR70 in the N-glycosidase activity of neo-trichosanthin. Yan L, et al. **Toxicon** 1999 Jul; 37(7):961–72

PHARMACOLOGY

Effects of endoglycoceramidase or D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol on glucose uptake, glycolysis, and mitochondrial respiration in HL60 cells. Ji L, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):107–14

Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. Fitzgerald M, et al. **Atherosclerosis** 1999 Jul;145(1):97–106

Effects of grain source and enzyme additive on site and extent of nutrient digestion in dairy cows. Beauchemin KA, et al. **J Dairy Sci** 1999 Feb;82(2):378–90

PHYSIOLOGY

Glucansucrases: mechanism of action and structure-function relationships. Monchois V, et al. **FEMS Microbiol Rev** 1999 Apr;23(2):131–51 (131 ref.)

SECRETION

Inulase-secreting strain of Saccharomyces cerevisiae produces fructose. Brevnova EE, et al. **Biotechnol Bioeng** 1998 Nov 20;60(4):492–7

Androgen regulation of glycosidase secretion in epithelial cell cultures from human epididymis. Castellón EA, et al. **Hum Reprod** 1999 Jun;14(6):1522–7

Membrane association and multimerization of secreton component pulC. Possot OM, et al. **J Bacteriol** 1999 Jul; 181(13):4004–11

Kinetics of the secretion of Bacillus subtilis levanase overproduced during the exponential phase of growth. Leloup L, et al. **Microbiology** 1999 Mar;145 (Pt 3):613–9

ULTRASTRUCTURE

Cellulosomes-structure and ultrastructure. Bayer EA, et al. **J Struct Biol** 1998 Dec 15;124(2-3):221–34 (100 ref.)

GLYCOSIDES

ADMINISTRATION & DOSAGE

Protective effect of Picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus. Mittal N, et al. **Life Sci** 1998;63(20):1823–34

ANALYSIS

Detection of glycosidic residues in carpal glands of wild and domestic pig revealed by basic and lectin histochemistry. Pedini V, et al. **Anat Anz** 1999 May;181(3):269–74

High-performance liquid chromatography with electrospray ionization mass spectrometry and diode array ultraviolet detection in the identification of flavonol aglycones and glycosides in berries. Häkkinen S, et al. **J Chromatogr A** 1998 Dec 31;829(1-2):91–100

Low cyanide exposure from consumption of cassava in Dar es Salaam, Tanzania. Mlingi N, et al. **Nat Toxins** 1998; 6(2):67–72

BIOSYNTHESIS

Seasonal variation of glycyrrhizin and isoliquiritigenin glycosides in the root of Glycyrrhiza glabra L. Hayashi H, et al. **Biol Pharm Bull** 1998 Sep;21(9):987–9

BLOOD

Liquid chromatography/electrospray ionization mass spectrometric characterization of flavonol glycosides in tomato extracts and human plasma. Mauri PL, et al. **Rapid Commun Mass Spectrom** 1999;13(10):924–31

CHEMICAL SYNTHESIS

Synthesis and characterization of a photoactivatable glycoaryldiazirine for surface glycoengineering. Chevolot Y, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):169–75

Syntheses of 1-deoxy-3-s-(1-thio-alpha-D-glucopyranosyl)-mannojirimycin and 1-deoxy-3-O-(5-thio-alpha-D-glucopyranosyl)-mannojirimycin as potential inhibitors of endo-alpha-D-mannosidase. Ding Y, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1215–20

Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-L- and -D-arabinopyranosides possessing antithrombotic activity. Bozó E, et al. **Carbohydr Res** 1998 Oct; 311(4):191–202

Synthesis of sulfated oligosaccharide glycosides having high anti-HIV activity and the relationship between activity and chemical structure. Katsuraya K, et al. **Carbohydr Res** 1999 Feb 28;315(3-4):234–42

Synthesis of the 3-methyl ether and 4-deoxy derivatives of 4-cyanophenyl 1,5-dithio-beta-D-xylopyranoside (Beciparcil). Li Y, et al. **Carbohydr Res** 1999 Mar 31; 316(1-4):104–11

Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611. Daley L, et al. **J Med Chem** 1998 Nov 5;41(23):4475–85

[Synthesis of oligosaccharides related to HNK-1 antigen. 2. Synthesis of $3^{3'}$-O-(3-O-sulfo-beta-D-glucuronopyranosyl)-lacto-N-neotetrao se beta-propylglycoside] Kononov LO, et al.

Bioorg Khim 1998 Aug;24(8):608–22 (Eng. Abstr.) **(Rus)**
[Synthesis of Neu5Ac(alpha2-->6)[Gal(alpha1-->3)]GalNAcalpha and Neu5Ac(alpha2-->6)[Gal(beta1-->3)]GalNAcalpha trisaccharides as protected trifluoroacetamidopropyl glycosides] Simeoni LA, et al. **Biocrg Khim** 1999 Jan; 25(1):62–9 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Structural studies on the binding of 4-methylumbelliferone glycosides of chitin to rainbow trout lysozyme. Vollan VB, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):60–6

Enzymatic modification of natural compounds with pharmacological properties. Riva S, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:70–80 (13 ref.)

Iridoids from Teucrium yemense. Abdel-Sattar E. **Arch Pharm Res** 1998 Dec;21(6):785–6

Characterization of a novel unconjugated pteridine glycoside, cyanopterin, in Synechocystis sp. PCC 6803. Lee HW, et al. **Biochim Biophys Acta** 1999 Jan 27;1410(1):61–70

Introducing a C-interglycosidic bond in a biologically active pentasaccharide hardly affects its biological properties. Petitou M, et al. **Bioorg Med Chem** 1998 Sep;6(9):1509–16

Simplification of adenophostin A defines a minimal structure for potent glucopyranoside-based mimics of D-myo-inositol 1,4,5-trisphosphate. Marwood RD, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):453–8

Radical scavenging activity of phenylpropanoid glycosides in Caryopteris incana. Gao JJ, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):983–8

Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-L- and -D-arabinopyranosides possessing antithrombotic activity. Bozó E, et al. **Carbohydr Res** 1998 Oct; 311(4):191–202

Cyclofructins with six to ten beta-(1-->2)-linked fructofuranose units: geometries, electrostatic profiles, lipophilicity patterns, and potential for inclusion complexation. Immel S, et al. **Carbohydr Res** 1998 Dec; 313(2):91–105

Synthesis of the 3-methyl ether and 4-deoxy derivatives of 4-cyanophenyl 1,5-dithio-beta-D-xylopyranoside (Beciparcil). Li Y, et al. **Carbohydr Res** 1999 Mar 31; 316(1-4):104–11

Isolation and characterization of new limonoid glycosides from Citrus unshiu peels. Sawabe A, et al. **Carbohydr Res** 1999 Jan 31;315(1-2):142–7

Pregnane glycosides, gymnepregosides G-Q from the roots of Gymnema alternifolium. Yoshikawa K, et al. **Chem Pharm Bull (Tokyo)** 1999 Jun;47(6):798–804

Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives. Fernández-Santana V, et al. **Glycoconj J** 1998 Jun; 15(6):549–53

Determining anomericity of the glycosidic bond in Zn(II)-diethylenetriamine-disaccharide complexes using MSn in a quadrupole ion trap. Gaucher SP, et al. **J Am Soc Mass Spectrom** 1999 Mar;10(3):269–72

Roselipins, novel fungal metabolites having a highly methylated fatty acid modified with a mannose and an arabinitol [letter] Omura S, et al. **J Antibiot (Tokyo)** 1999 Jun;52(6):586–9

Components of the ether-insoluble resin glycoside fraction from the seed of Cuscuta australis. Du XM, et al. **J Nat Prod** 1999 May;62(5):722–5

Novel isoflavone, cinnamic acid, and triterpenoid glycosides in soybean molasses. Hosny M, et al. **J Nat Prod** 1999 Jun; 62(6):853–8

Quanolirones I and II, two new human cytomegalovirus protease inhibitors produced by Streptomyces sp. WC76535. Qian-Cutrone J, et al. **J Nat Prod** 1998 Nov; 61(11):1379–82

Two new spirostanol saponins from Allium tuberosum. Sang S, et al. **J Nat Prod** 1999 Jul;62(7):1028–9

New naphthopyranone glycosides from Paepalanthus vellozioides and Paepalanthus latipes. Vilegas W, et al. **J Nat Prod** 1999 May;62(5):746–9

Antioxidative phenolic glycosides from sage (Salvia officinalis). Wang M, et al. **J Nat Prod** 1999 Mar; 62(3):454–6

Two oleanene glycosides from the aerial parts of Caltha polypetala. Baykal T, et al. **Phytochemistry** 1999 Aug; 51(8):1059–63

Cardenolide glycosides from seeds of Corchorus olitorius. Nakamura T, et al. **Phytochemistry** 1998 Dec; 49(7):2097–101

Kaempferol tetraglucosides from cabbage leaves. Nielsen JK, et al. **Phytochemistry** 1998 Dec;49(7):2171–6

Flavonol glycosides from flowers of Crocus speciosus and C. antalyensis. Nørbaek R, et al. **Phytochemistry** 1999 Aug; 51(8):1113–9

Acetylated flavonol triglycosides from Ammi majus L. Singab AN. **Phytochemistry** 1998 Dec;49(7):2177–80

Cytotoxic polyisoprenes and glycosides of long-chain fatty alcohols from Dimocarpus fumatus. Voutquenne L, et al. **Phytochemistry** 1999 Jan;50(1):63–9

Steroidal glycosides of the 14,15-seco-18-nor-pregnane series from Cynanchum ascyrifolium. Yeo H, et al. **Phytochemistry** 1998 Oct;49(4):1129–33

Cycloartane-type glycosides from Aquilegia flabellata. Yoshimitsu H, et al. **Phytochemistry** 1999 Jun;51(3):449–52

Lignan and phenylpropanoid glycosides from Lancea tibetica and their antitumor activity. Su B, et al. **Planta Med** 1999 Aug;65(6):558–61

Solid-state 13C NMR investigations of the glycosidic linkage in alpha-alpha' trehalose. Zhang P, et al. **Solid State Nucl Magn Reson** 1998 Oct;12(4):221–5

ISOLATION & PURIFICATION

Iridoids from Teucrium yemense. Abdel-Sattar E. **Arch Pharm Res** 1998 Dec;21(6):785–6

Isolation and characterization of new limonoid glycosides from Citrus unshiu peels. Sawabe A, et al. **Carbohydr Res** 1999 Jan 31;315(1-2):142–7

Cycloartane triterpene glycosides from the roots of Astragalus brachypterus and Astragalus microcephalus. Bedir E, et al. **J Nat Prod** 1998 Dec;61(12):1469–72

New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus. Chen JL, et al. **J Nat Prod** 1998 Oct;61(10):1295–7

A new iridoid from Scrophularia auriculata ssp. pseudoauriculata. Giner RM, et al. **J Nat Prod** 1998 Sep; 61(9):1162–3

A new pregnane glycoside from Dioscorea collettii var. hypoglauca. Hu K, et al. **J Nat Prod** 1999 Feb; 62(2):299–301

Verbaspinoside, a new iridoid glycoside from Verbascum spinosum. Kalpoutzakis E, et al. **J Nat Prod** 1999 Feb; 62(2):342–4

New steroid glycosides from the deep-water starfish Mediaster murrayi. Kicha AA, et al. **J Nat Prod** 1999 Feb; 62(2):279–82

Norpregnane glycosides from a Thai soft coral, Scleronephthya pallida. Kittakoop P, et al. **J Nat Prod** 1999 Feb;62(2):318–20

Acylated flavonol glycosides from leaves of Stenochlaena palustris. Liu H, et al. **J Nat Prod** 1999 Jan;62(1):70–5

Steroidal glycosides from the bulbs of Allium jesdianum. Mimaki Y, et al. **J Nat Prod** 1999 Jan;62(1):194–7

Aurantosides D, E, and F: new antifungal tetramic acid glycosides from the marine sponge Siliquariaspongia japonica. Sata NU, et al. **J Nat Prod** 1999 Jul;62(7):969–71

Phenylpropanoid glycosides from Penstemon serrulatus. Skrzypek Z, et al. **J Nat Prod** 1999 Jan;62(1):127–9

Iridoid glycosides of Leonurus persicus. Tasdemir D, et al. **J Nat Prod** 1999 Jun;62(6):811–6

Aurantoside C, a new tetramic acid glycoside from the sponge Homophymia conferta. Wolf D, et al. **J Nat Prod** 1999 Jan;62(1):170–2

Five new flavone 5-O-glycosides from Lethedon tannaensis: lethedosides and lethediosides. Zahir A, et al. **J Nat Prod** 1999 Feb;62(2):241–3

Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. Zhou BN, et al. **J Nat Prod** 1998 Nov;61(11):1410–2

Flavonol glycosides from Eschscholtzia californica. Beck MA, et al. **Phytochemistry** 1999 Jan;50(2):329–32

Steroidal alkaloid glycosides from Solanum orbignianum. Coelho RM, et al. **Phytochemistry** 1998 Oct;49(3):893–7

Sesquiterpene lactone glycosides from Lapsana communis L. subsp. communis. Fontanel D, et al. **Phytochemistry** 1999 Aug;51(8):999–1004

Non-quassinoid constituents from the twigs and thorns of Castela polyandra. Grieco PA, et al. **Phytochemistry** 1999 Jun;51(4):575–8

Cholestane rhamnosides from the bulbs of Ornithogalum saundersiae. Kuroda M, et al. **Phytochemistry** 1999 Oct; 52(3):445–52

Cardenolide glycosides from seeds of Corchorus olitorius. Nakamura T, et al. **Phytochemistry** 1998 Dec; 49(7):2097–101

Kaempferol tetraglucosides from cabbage leaves. Nielsen JK, et al. **Phytochemistry** 1998 Dec;49(7):2171–6

Phenethyl alcohol glycosides and isopentenol glycoside from fruit of Bupleurum falcatum. Ono M, et al. **Phytochemistry** 1999 Jul;51(6):819–23

Partially acetylated tri- and tetrarhamnoside dodecanyl ether derivatives from Cleistopholis patens. Seidel V, et al. **Phytochemistry** 1999 Oct;52(3):465–72

Acetylated flavonol triglycosides from Ammi majus L. Singab AN. **Phytochemistry** 1998 Dec;49(7):2177–80

Flavanone glycosides from Alhagi pseudalhagi. Singh VP, et al. **Phytochemistry** 1999 Jun;51(4):587–90

[Studies on the chemical constituents of seed from Nigella glandulifera] Hao HF, et al. **Yao Hsueh Hsueh Pao** 1996; 31(9):689–94 (Eng. Abstr.) **(Chi)**

[Separation and identification of the flavonoids from Buddleia officinalis Maxim] Li JS, et al. **Yao Hsueh Hsueh Pao** 1996; 31(11):849–54 (Eng. Abstr.) **(Chi)**

[Studies on the chemical constituents of Rhodiola fastigita] Peng JN, et al. **Yao Hsueh Hsueh Pao** 1996;31(10):798–800 (Eng. Abstr.) **(Chi)**

[Structure determination of korepimedoside A and korepimedoside B from Epimedium koreanum Nakai] Sun PY, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):602–6 (Eng. Abstr.) **(Chi)**

METABOLISM

The effect of inorganic pyrophosphate on the transport of oleanolic acid monoglycosides into vacuoles isolated from Calendula officinalis leaves. Szakiel A, et al. **Acta Biochim Pol** 1998;45(3):819–23

Structural studies on the binding of 4-methylumbelliferone glycosides of chitin to rainbow trout lysozyme. Vollan VB, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):60–6

Catalysis and specificity in enzymatic glycoside hydrolysis: a 2,5B conformation for the glycosyl-enzyme intermediate revealed by the structure of the Bacillus agaradhaerens family 11 xylanase. Sabini E, et al. **Chem Biol** 1999 Jul; 6(7):483–92

A contribution to the regulation of proteoglycan production: modulation by TGF alpha, TGF beta and IL-1 of glycosaminoglycan biosynthesis on beta-D-xyloside in chick embryo fibroblasts. Evangelisti R, et al. **Connect Tissue Res** 1998;37(1-2):77–85

Initiation of galactosaminoglycan biosynthesis. Separate galactosylation and dephosphorylation pathways for phosphoxylosylated decorin protein and exogenous xyloside. Moses J, et al. **Eur J Biochem** 1999 Mar; 260(3):879–84

Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. Day AJ, et al. **FEBS Lett** 1998 Sep 25;436(1):71–5

Complementation of the Saccharomyces cerevisiae plasma membrane H+-ATPase by a plant H+-ATPase generates a highly abundant fusicoccin binding site. Piotrowski M, et al. **J Biol Chem** 1998 Nov 6;273(45):30018–23

Trapped in the act of catalysis [news; comment] Davies GJ, et al. **Nat Struct Biol** 1999 May;6(5):406–8. Comment on: Nat Struct Biol 1999 May;6(5):432–6.

[Cyanogenesis in plants] Siegien I. **Postepy Biochem** 1998; 44(4):325–33 (90 ref.) **(Pol)**

PHARMACOKINETICS

Characterization of the UDP-glucuronosyltransferases involved in the glucuronidation of an antithrombotic thioxyloside in rat and humans. Pless D, et al. **Drug Metab Dispos** 1999 May;27(5):588–95

Intestinal transport of gentamicin with a novel, glycosteroid drug transport agent. Axelrod HR, et al. **Pharm Res** 1998 Dec;15(12):1876–81

Structural requirements for alkylglycoside-type renal targeting vector. Suzuki K, et al. **Pharm Res** 1999 Jul; 16(7):1026–34

PHARMACOLOGY

Enzymatic modification of natural compounds with pharmacological properties. Riva S, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:70–80 (13 ref.)

Effects of oleanolic acid glycosides on gastrointestinal transit and ileus in mice. Li Y, et al. **Bioorg Med Chem** 1999 Jun; 7(6):1201–5

Aryl C-glycosides: physiologically stable glycomimetics of sialyl Lewis X. Kuribayashi T, et al. **Bioorg Med Chem Lett** 1998 Dec 1;8(23):3307–10

Two different modes of inhibition of the rat brain Na+, K(+)-ATPase by triterpene glycosides, psolusosides A and B from the holothurian Psolus fabricii. Gorshkova IA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):101–8

Characterization of beta-D-xyloside-initiated glycosaminoglycan synthesized by human skin fibroblasts in the presence of tunicamycin. Takagaki K, et al. **Glycoconj J** 1998 May;15(5):483–9

Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, selectively augments human T cell response to mycobacterial protein antigens. Sinha S, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):579–88

Role of Ca2+ on uterine force stimulated by a glycoside from the root of Dalbergia saxatilis. Uchendu CN. **Indian J Physiol Pharmacol** 1999 Apr;43(2):171–8

Influence of OAS-1000 on mediators of inflammation. Scherl DS, et al. **J Clin Periodontol** 1999 Apr;26(4):246–51

Glycoside primers of Psittacanthus cucullaris. Sinha A, et al. **J Nat Prod** 1999 Jul;62(7):1036–8

N-linked glycoside and glucuronide conjugates of the retinoid, acitretin, are biologically active in cornea and conjunctiva. Ubels JL, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):505–16

Curative effect of picroliv on primary cultured rat hepatocytes against different hepatotoxins: an in vitro study. Visen PK, et al. **J Pharmacol Toxicol Methods** 1998 Oct;40(3):173–9

Role of proteoglycans on testosterone synthesis by purified Leydig cells from immature and mature rats. Grudet N, et al. **J Steroid Biochem Mol Biol** 1999 Feb;68(3-4):153–62

Protective effects of oleanolic acid oligoglycosides on ethanol- or indomethacin-induced gastric mucosal lesions in rats. Matsuda H, et al. **Life Sci** 1998;63(17):PL245–50

Picroliv -- a natural product protects cells and regulates the gene expression during hypoxia/reoxygenation. Gaddipati JP, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):271–81

An antitumor promoter from Moringa oleifera Lam. Guevara AP, et al. **Mutat Res** 1999 Apr 6;440(2):181–8

Anti-allergic and anti-anaphylactic activity of picroliv--a standardised iridoid glycoside fraction of Picrorhiza kurroa. Baruah CC, et al. **Pharmacol Res** 1998 Dec;38(6):487–92

Effect of xanthorrhizol, xanthorrhizol glycoside and trachylobanoic acid isolated from Cachani complex plants upon the contractile activity of uterine smooth muscle. Ponce-Monter H, et al. **Phytother Res** 1999 May; 13(3):202–5

A phosphothreonine residue at the C-terminal end of the plasma membrane H+-ATPase is protected by fusicoccin-induced 14-3-3 binding. Olsson A, et al. **Plant Physiol** 1998 Oct;118(2):551-5

Fusicoccin, 14-3-3 proteins, and defense responses in tomato plants. Roberts MR, et al. **Plant Physiol** 1999 Apr; 119(4):1243-50

Cytotoxicity of natural ginseng glycosides and semisynthetic analogues. Atopkina LN, et al. **Planta Med** 1999 Feb; 65(1):30-4

Antineoplastic agents. III: Steroidal glycosides from Solanum nigrum. Hu K, et al. **Planta Med** 1999 Feb;65(1):35-8

[Anabolic properties of furostanol glycosides from Dioscorea deltoidea wall] Dubinskaia VA, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):178-81 **(Rus)**

THERAPEUTIC USE

Effects of oleanolic acid glycosides on gastrointestinal transit and ileus in mice. Li Y, et al. **Bioorg Med Chem** 1999 Jun; 7(6):1201-5

The effects of ArginMax, a natural dietary supplement for enhancement of male sexual function. Ito T, et al. **Hawaii Med J** 1998 Dec;57(12):741-4

TOXICITY

Disruption of proteoglycans in neural tube fluid by beta-D-xyloside alters brain enlargement in chick embryos. Alonso MI, et al. **Anat Rec** 1998 Dec;252(4):499-508

In vitro and in vivo study of the clastogenicity of the flavone cirsitakaoside extracted from Scoparia dulcis L. (Scrophulariaceae). Pereira-Martins SR, et al. **Teratog Carcinog Mutagen** 1998;18(6):293-302

GLYCOSPHINGOLIPIDS

ANALYSIS

Matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis of glycosphingolipids including gangliosides. Taketomi T, et al. **Acta Biochim Pol** 1998; 45(4):987-99

Analysis of glycosphingolipids of human head and neck carcinomas with comparison to normal tissue. Bolot G, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):125-35

Acidic glycosphingolipids of cock testis elucidated by mass spectrometry and NMR spectroscopy. Iga DP, et al. **Glycoconj J** 1998 Dec;15(12):1111-4

Sex- and age-related differences in ceramide dihexosides of primary human brain tumors. Yates AJ, et al. **Lipids** 1999 Jan;34(1):1-4

Detection of Leishmania lipophosphoglycan binding proteins in the gut of the sandfly vector. Dillon RJ, et al. **Parasitology** 1999 Jan;118 (Pt 1):27-32

Chemical and lectin-gold electron microscopical studies of the expression of the Galalpha1-determinant in the pig aorta. Hallberg EC, et al. **Xenotransplantation** 1998 Nov; 5(4):246-56

ANTAGONISTS & INHIBITORS

Chemotherapy by slowing glucosphingolipid synthesis. Radin NS. **Biochem Pharmacol** 1999 Mar 15;57(6):589-95 (33 ref.)

BIOSYNTHESIS

Biosynthesis of inositol phosphoceramides and remodeling of glycosylphosphatidylinositol anchors in Saccharomyces cerevisiae are mediated by different enzymes. Reggiori F, et al. **J Biol Chem** 1998 Nov 13;273(46):30550-9

Cloning of a novel member of the UDP-galactose:beta-N-acetylglucosamine beta1,4-galactosyltransferase family, beta4Gal-T4, involved in glycosphingolipid biosynthesis. Schwientek T, et al. **J Biol Chem** 1998 Nov 6;273(45):29331-40

A vital role for glycosphingolipid synthesis during development and differentiation. Yamashita T, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9142-7

[Regulation of glycosphingolipid synthesis by ceramide revealed by an endoglycoceramidase application] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2488-94 (25 ref.) **(Jpn)**

BLOOD

Fingerprinting of large oligosaccharides linked to ceramide by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: highly heterogeneous polyglycosylceramides of human erythrocytes with receptor activity for Helicobacter pylori. Karlsson H, et al. **Glycobiology** 1999 Aug;9(8):765-78

CHEMICAL SYNTHESIS

Synthetic studies on glycosphingolipids from the parasite Echinococcus multilocularis. Hada N, et al. **Carbohydr Res** 1999 Mar 31;316(1-4):58-70

Synthesis and NMR assignments of galactosylgloboside and its beta-D-GalNAc-(1-->4)-alpha-D-Gal-linked positional isomer in a conjugatable form. Zou W, et al. **Carbohydr Res** 1999 Feb 28;315(3-4):251-61

CHEMISTRY

Intra-species and stage-specific polymorphisms in lipophosphoglycan structure control Leishmania donovani-sand fly interactions. Mahoney AB, et al. **Biochemistry** 1999 Aug 3;38(31):9813-23

Characterization of sphingolipids from mycopathogens: factors correlating with expression of 2-hydroxy fatty acyl (E)-Delta 3-unsaturation in cerebrosides of Paracoccidioides brasiliensis and Aspergillus fumigatus. Toledo MS, et al. **Biochemistry** 1999 Jun 1;38(22):7294-306

Ectoplasmic insertion of a glycosylphosphatidylinositol-anchored protein in glycosphingolipid- and cholesterol-containing phosphatidylcholine vesicles. Nosjean O, et al. **Eur J Biochem** 1999 Aug;263(3):865-70

Relationship of membrane sidedness to the effects of the lipophosphoglycan of Leishmania donovani on the fusion of influenza virus. Razinkov V, et al. **Eur J Biochem** 1999 Jun;262(3):890-9

Fingerprinting of large oligosaccharides linked to ceramide by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: highly heterogeneous polyglycosylceramides of human erythrocytes with receptor activity for Helicobacter pylori. Karlsson H, et al. **Glycobiology** 1999 Aug;9(8):765-78

CLASSIFICATION

Typing of Leishmania lipophosphoglycans by electrospray mass spectrometry. Wilson IB, et al. **Mol Biochem Parasitol** 1999 May 25;100(2):207-15

IMMUNOLOGY

Cancer-associated glycosphingolipid antigens: their structure, organization, and function. Hakomori S. **Acta Anat (Basel)** 1998;161(1-4):79-90 (115 ref.)

Clusters of glycolipid and glycosylphosphatidylinositol-anchored proteins in lymphoid cells: accumulation of actin regulated by local tyrosine phosphorylation. Harder T, et al. **Eur J Immunol** 1999 Feb;29(2):556-62

[Anti-sulfatide antibody associated neuropathy] Kaida K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):500-2 (11 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Control of glial number: purification from mammalian brain extracts of an inhibitor of astrocyte division. Abad-Rodriguez J, et al. **Glia** 1998 Jun;23(2):156-68

Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Müthing J, et al. **Glycobiology** 1999 May;9(5):459-68

Glycosphingolipid binding specificities of Neisseria meningitidis and Haemophilus influenzae: detection, isolation, and characterization of a binding-active glycosphingolipid from human oropharyngeal epithelium. Hugosson S, et al. **J Biochem (Tokyo)** 1998 Dec 1; 124(6):1138-52

METABOLISM

Processing of sphingolipid activator proteins and the topology of lysosomal digestion. Sandhoff K, et al. **Acta Biochim Pol** 1998;45(2):373-84 (52 ref.)

Enzymatic hydrolysis of glycosphingolipids. Li YT, et al. **Anal Biochem** 1999 Aug 15;273(1):1-11 (106 ref.)

Src family kinase activation in glycosphingolipid-rich membrane domains of endothelial cells treated with oxidised low density lipoprotein. Myers SJ, et al. **Atherosclerosis** 1999 Apr;143(2):389-97

Receptor mediated apoptosis of CD8+ T cells by the B subunits of cholera-like enterotoxins. Pitman RS, et al. **Biochem Soc Trans** 1998 Nov;26(4):S338

Oxidation of glycosphingolipids under basic conditions: synthesis of glycosyl "serine acids" as opposed to "ceramide acids". Precursors for neoglycoconjugates with increased ligand binding affinity. Mylvaganam M, et al. **Biochemistry** 1999 Aug 17;38(33):10885-97

Accumulation of glycolipids in mutant Chinese hamster ovary cells (Z65) with defective peroxisomal assembly and comparison of the metabolic rate of glycosphingolipids between Z65 cells and wild-type CHO-K1 cells. Saito M, et al. **Biochim Biophys Acta** 1999 Apr 19;1438(1):55-62

The glycosphingolipidoses-from disease to basic principles of metabolism. Schuette CG, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):759-66 (28 ref.)

Lipophosphoglycan of Leishmania donovani inhibits lipid vesicle fusion induced by the N-terminal extremity of viral fusogenic simian immunodeficiency virus protein. Martin I, et al. **Eur J Biochem** 1998 Nov 15;258(1):150-6

Neutral and acidic glycosphingolipids in glucocorticoid-induced cataract in chick lens. Ogiso M, et al. **Exp Eye Res** 1999 Feb;68(2):229-36

New insights in glycosphingolipid function: "glycosignaling domain," a cell surface assembly of glycosphingolipids with signal transducer molecules,involved in cell adhesion coupled with signaling [letter] Hakomori S, et al. **Glycobiology** 1998 Oct;8(10):xi-xix (66 ref.)

Binding of N-trifluoroacetyl-derivatized natural glycosphingolipids by uropathogenic Escherichia coli and Neisseria subflava. Lanne B, et al. **Glycoconj J** 1998 Oct; 15(10):1017-31

PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Wakshull E, et al. **Immunopharmacology** 1999 Feb;41(2):89-107

Binding of Actinobacillus pleuropneumoniae lipopolysaccharides to glycosphingolipids evaluated by thin-layer chromatography. Abul-Milh M, et al. **Infect Immun** 1999 Oct;67(10):4983-7

Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Ardila-Osorio H, et al. **Int J Cancer** 1999 May 17;81(4):645-9

HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection. Fantini J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):221-9

Characterization of the interaction of hemolytic lectin CEL-III from the marine invertebrate, Cucumaria echinata, with artificial lipid membranes: involvement of neutral sphingoglycolipids in the pore-forming process. Hatakeyama T, et al. **J Biochem (Tokyo)** 1999 Feb; 125(2):277-84

Glycosphingolipid binding specificities of Neisseria meningitidis and Haemophilus influenzae: detection, isolation, and characterization of a binding-active glycosphingolipid from human oropharyngeal epithelium. Hugosson S, et al. **J Biochem (Tokyo)** 1998 Dec 1; 124(6):1138-52

L-selectin interactions with novel mono- and multisulfated Lewisx sequences in comparison with the potent ligand 3'-sulfated Lewisa. Galustian C, et al. **J Biol Chem** 1999 Jun 25;274(26):18213-7

Separation of "glycosphingolipid signaling domain" from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. Iwabuchi K, et al. **J Biol Chem** 1998 Dec 11;273(50):33766-73

Regulation of glycosphingolipid metabolism in liver during the acute phase response. Memon RA, et al. **J Biol Chem** 1999 Jul 9;274(28):19707-13

A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation. Bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions. Mylvaganam M, et al. **J Biol Chem** 1999 Jul 16;274(29):20725-32

Glycosphingolipid-enriched signaling domain in mouse neuroblastoma Neuro2a cells. Mechanism of ganglioside-dependent neuritogenesis. Prinetti A, et al. **J Biol Chem** 1999 Jul 23;274(30):20916-24

Supply-side and trickle-down therapy [comment] Grabowski GA. **J Clin Invest** 1999 Feb;103(4):439-40. Comment on: J Clin Invest 1999 Feb;103(4):497-505.

A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder [see comments] Liu Y, et al. **J Clin Invest** 1999 Feb;103(4):497-505. Comment in: J Clin Invest 1999 Feb;103(4):439-40.

Glycosphingolipid degradation and animal models of GM2-gangliosidoses. Kolter T, et al. **J Inherit Metab Dis** 1998 Aug;21(5):548-63 (54 ref.)

Degradation of blood group A glycolipid A-6-2 by normal and mutant human skin fibroblasts. Asfaw B, et al. **J Lipid Res** 1998 Sep;39(9):1768-80

Tumor-infiltrating macrophages influence the glycosphingolipid composition of murine brain tumors. Ecsedy JA, et al. **J Lipid Res** 1998 Nov;39(11):2218-27

Modulation of phospholipase A2 by electrostatic fields and dipole potential of glycosphingolipids in monolayers. Maggio B. **J Lipid Res** 1999 May;40(5):930-9

Leishmania donovani has distinct mannosylphosphoryltransferases for the initiation and elongation phases of lipophosphoglycan repeating unit biosynthesis. Descoteaux A, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):27-40

Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Hooper NM. **Mol Membr Biol** 1999 Apr-Jun;16(2):145-56 (115 ref.)

Sphingomyelin, glycosphingolipids and ceramide signalling in cells exposed to P-fimbriated Escherichia coli. Hedlund M, et al. **Mol Microbiol** 1998 Sep;29(5):1297-306

Recombinant GM2-activator protein stimulates in vivo degradation of GA2 in GM2 gangliosidosis AB variant fibroblasts but exhibits no detectable binding of GA2 in an in vitro assay. Bierfreund U, et al. **Neurochem Res** 1999 Feb;24(2):295-300

PHARMACOLOGY

Fusion of Sendai virus and individual host cells and inhibition of fusion by lipophosphoglycan measured with image correlation spectroscopy. Rasmusson BJ, et al. **Biochim Biophys Acta** 1998 Sep 16;1404(3):338-52

Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Wolday D, et al. **Infect Immun** 1999 Oct;67(10):5258-64

PHYSIOLOGY

Distinct roles for sphingolipids and glycosphingolipids at

GLYCOSPHINGOLIPIDS

different stages of neuronal development. Futerman AH. **Acta Biochim Pol** 1998;45(2):469–78 (33 ref.)

Intra-species and stage-specific polymorphisms in lipophosphoglycan structure control Leishmania donovani-sand fly interactions. Mahoney AB, et al. **Biochemistry** 1999 Aug 3;38(31):9813–23

Binding of human cytomegalovirus to sulfated glucuronyl glycosphingolipids and their inhibitory effects on the infection. Ogawa-Goto K, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2533–41

Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). Hammache D, et al. **J Virol** 1999 Jun;73(6):5244–8

[Solving riddles of glycosphingolipids: analyses of sphingolipid functions by a glucosylceramide synthase-deficient mutant] Ichikawa S, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2281–7 (35 ref.) **(Jpn)**

[Modulators of glycosphingolipid biosynthesis (PDMP): application to cell biology] Inokuchi J. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2495–502 (38 ref.) **(Jpn)**

[Bioactive glyco-chains and cis-type signalling--introduction] Saito M. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2484–7 (5 ref.) **(Jpn)**

GLYCOSURIA

Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Kilpatrick ES, et al. **Diabet Med** 1999 Jun;16(6):496–9

Renal tubular function affects glycosuria-related urinary excretion of 1,5-anhydroglucitol [letter] Fujisawa T, et al. **Diabetes Care** 1999 May;22(5):863–4

CHEMICALLY INDUCED

High dose inhaled corticosteroids and dose dependent loss of diabetic control. Faul JL, et al. **BMJ** 1998 Nov 28; 317(7171):1491

Deteriorating diabetic control associated with high-dose inhaled budesonide [letter] Faul JL, et al. **Eur Respir J** 1999 Jul;14(1):242–3

Relations between exposure to arsenic, skin lesions, and glucosuria. Rahman M, et al. **Occup Environ Med** 1999 Apr;56(4):277–81

DIAGNOSIS

Is there a role for glycosuria testing in sub-Saharan Africa? van der Sande MA, et al. **Trop Med Int Health** 1999 Jul; 4(7):506–13

GENETICS

A new mouse model of spontaneous diabetes derived from ddY strain. Suzuki W, et al. **Exp Anim** 1999 Jul;48(3):181–9

MICROBIOLOGY

Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. Geerlings SE, et al. **J Med Microbiol** 1999 Jun;48(6):535–9

URINE

Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable. Feleke Y, et al. **Ethiop Med J** 1998 Apr;36(2):93–9

Induction of transient proteinuria, hematuria, and glucosuria by ethanol consumption in Japanese alcoholics. Ito S, et al. **Nephron** 1999;82(3):246–53

[External quality control of the laboratory determination of glucose in the urine and material for its realization] Iarmol'chuk SG. **Klin Lab Diagn** 1998 Nov;(11):39–41 (Eng. Abstr.) **(Rus)**

VETERINARY

Metabolic adaptation to experimentally increased glucose demand in ruminants. Overton TR, et al. **J Anim Sci** 1998 Nov;76(11):2938–46

GLYCOSURIA, RENAL

DIAGNOSIS

Transient renal glucosuria in patients with tetanus. Rezaian GR, et al. **Nephron** 1998 Nov;80(3):292–5

GLYCOSYLATED HEMOGLOBIN A see **HEMOGLOBIN A, GLYCOSYLATED**

GLYCOSYLATION

see related
GLYCOSYLATION END PRODUCTS, ADVANCED
PROTEIN PROCESSING, POST-TRANSLATIONAL

Eukaryotic glycosylation: whim of nature or multipurpose tool? Reuter G, et al. **Cell Mol Life Sci** 1999 Mar; 55(3):368–422 (671 ref.)

Novel forms of protein glycosylation. Vliegenthart JF, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):565–71 (38 ref.)

Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells [see comments] Fajac I, et al. **Hum Gene Ther** 1999 Feb 10;10(3):395–406. Comment in: Hum Gene Ther 1999 Feb 10;10(3):337–9.

GLYCOSYLATION END PRODUCTS, ADVANCED

Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Ando K, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):123–7

Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Saxena AK, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):332–8

Advanced glycation endproducts accelerate calcification in microvascular pericytes. Yamagishi S, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):353–7

A new rapid method to detect inhibition of Amadori product generated by delta-gluconolactone. Rahbar S, et al. **Clin Chim Acta** 1999 Sep;287(1-2):123–30

Plasma protein glycation in Alzheimer's disease. Riviere S, et al. **Glycoconj J** 1998 Oct;15(10):1039–42

Maillard reaction and AGE formation in glucose and polyglucose dialysis solutions. Tomo T, et al. **Perit Dial Int** 1999 May-Jun;19(3):274–7

[Advanced glycation end products or Maillard products] Wautier JL. **Rev Prat** 1998 Nov 1;48(17):1865–7 **(Fre)**

ANALYSIS

N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Nerlich AG, et al. **Atherosclerosis** 1999 May;144(1):41–7

Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Sakata N, et al. **Atherosclerosis** 1998 Nov; 141(1):61–75

Immunochemical detection of N2-[1-(1-carboxy)ethyl]guanosine, an advanced glycation end product formed by the reaction of DNA and reducing sugars or L-ascorbic acid in vitro. Seidel W, et al. **Biochim Biophys Acta** 1998 Nov 27;1425(3):478–84

A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Ligier S, et al. **Br J Rheumatol** 1998 Dec;37(12):1307–14

Relationship between autofluorescence and advanced glycation end products in diabetic lenses. Abiko T, et al. **Exp Eye Res** 1999 Mar;68(3):361–6

Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. Suzuki D, et al. **J Am Soc Nephrol** 1999 Apr;10(4):822–32

Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. Matsuse T, et al. **J Clin Pathol** 1998 Jul;51(7):515–9

Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Ling X, et al. **Lab Invest** 1998 Dec;78(12):1591–606

ANTAGONISTS & INHIBITORS

Novel inhibitors of advanced glycation endproducts. Rahbar S, et al. **Biochem Biophys Res Commun** 1999 Sep 7; 262(3):651–6

Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Tsuchida K, et al. **Diabetologia** 1999 May; 42(5):579–88

Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. Piercy V, et al. **Metabolism** 1998 Dec;47(12):1477–80

[Role of advanced glycation end products (AGE) in the development of diabetic microangiopathies and the beneficial effects of AGE inhibitors] Kawakami M, et al. **Nippon Rinsho** 1999 Mar;57(3):567–72 (18 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Lens proteins block the copper-mediated formation of reactive oxygen species during glycation reactions in vitro. Ortwerth BJ, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):706–10

Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Liu BF, et al. **Diabetes** 1999 Oct; 48(10):2074–82

Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Tanaka Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):17–22

Immunochemical detection of oxalate monoalkylamide, an ascorbate-derived Maillard reaction product in the human lens. Nagaraj RH, et al. **FEBS Lett** 1999 Jun 25; 453(3):327–30

BLOOD

Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Odani H, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):89–93

Factors in human serum interfere with the measurement of advanced glycation endproducts. Dorrian CA, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1069–79

Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control. Turk Z, et al. **Clin Chim Acta** 1998 Oct;277(2):159–70

Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Berg TJ, et al. **Diabetes Care** 1999 Jul;22(7):1186–90

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Berg TJ, et al. **Diabetes Care** 1998 Nov;21(11):1997–2002

Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy [letter] Daimon M, et al. **Diabetes Care** 1999 May;22(5):877–8

Increased serum levels of advanced glycation end-products and diabetic complications. Ono Y, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):131–7

Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography. Floridi A, et al. **J Chromatogr A** 1999 Jun 18;846(1-2):65–71

Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. Chiarelli F, et al. **J Pediatr** 1999 Apr;134(4):486–91

Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress". Jadoul M, et al. **Kidney Int** 1999 Jun;55(6):2487–92

N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Motomiya Y, et al. **Kidney Int** 1998 Oct; 54(4):1357–66

Advanced glycation in D-galactose induced mouse aging model. Song X, et al. **Mech Ageing Dev** 1999 May 17; 108(3):239–51

Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Henle T, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1968–75

A sensitive and specific ELISA for plasma pentosidine. Izuhara Y, et al. **Nephrol Dial Transplant** 1999 Mar; 14(3):576–80

Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. Al-Abed Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2385–90

Diabetes, advanced glycation endproducts and vascular disease. Wautier JL, et al. **Vasc Med** 1998;3(2):131–7 (71 ref.)

CHEMISTRY

Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. al-Abed Y, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2109–10

Towards a new "AGE" of the chemistry and pathophysiology of the Maillard reaction [editorial] Münch G, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):ix–x

DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Seidel W, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1165–70

The effect of an insulin releasing agent, BTS 67582, on advanced glycation end product formation in vitro. Simpson AE, et al. **Life Sci** 1999;64(16):1427–34

CLASSIFICATION

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Thornalley PJ. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1013–23 (70 ref.)

GENETICS

RAGE Gly82Ser polymorphism in diabetic microangiopathy [letter] Liu L, et al. **Diabetes Care** 1999 Apr;22(4):646

IMMUNOLOGY

Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. Shibayama R, et al. **Diabetes** 1999 Sep;48(9):1842–9

Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Farboud B, et al. **Mol Vis** 1999 Jul 14;5:11

ISOLATION & PURIFICATION

Characterisation of a novel AGE-compound derived from lysine and 3-deoxyglucosone. Skovsted IC, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1159–63

METABOLISM

Astrocytic hyaline inclusions contain advanced glycation endproducts in familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation: immunohistochemical and immunoelectron microscopical analyses. Kato S, et al. **Acta Neuropathol (Berl)** 1999 Mar; 97(3):260–6

Advanced glycation endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Shibata N, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):240–6

Carbonyl stress and long-term uremic complications. Miyata T, et al. **Adv Nephrol Necker Hosp** 1998;28:311–9 (41 ref.)

Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Sasaki N, et al. **Am J Pathol** 1998 Oct;153(4):1149–55

Advanced glycation end products in age-related macular degeneration. Ishibashi T, et al. **Arch Ophthalmol** 1998 Dec; 116(12):1629–32

Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Sakata N, et al. **Atherosclerosis** 1999 Jan;142(1):67–77

Sequencing of two alternatively spliced mRNAs corresponding to the extracellular domain of the rat receptor for advanced glycosylation end products (RAGE). Girón MD, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):230–4

Experimental induction of AGEs in fetal L132 lung cells changes the level of intracellular cathepsin D. Kasper M, et al. **Biochem Biophys Res Commun** 1999 Jul 22; 261(1):175–82

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Khalifah RG, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):251–8 (65 ref.)

Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Stitt AW, et al. **Biochem Biophys Res Commun** 1999 Mar 24; 256(3):549–56

Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Sajithlal GB, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1607–14

Generation of active oxygen species from advanced glycation end-products (AGEs) during ultraviolet light A (UVA) irradiation and a possible mechanism for cell damaging. Masaki H, et al. **Biochim Biophys Acta** 1999 Jun 28; 1428(1):45–56

An immunochemical study on tau glycation in paired helical filaments. Ko LW, et al. **Brain Res** 1999 Jun 5;830(2):301–13

Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Münch G, et al. **Brain Res** 1998 Jun 15;796(1–2):307–10

The pathogenesis and consequences of AGE formation in uraemia and its treatment. Dawnay A, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1081–94 (110 ref.)

Chemical modification of proteins by methylglyoxal. Degenhardt TP, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1139–45

Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Fehrenbach H, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1147–57

Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Newkirk MM, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1129–38

Advanced glycation endproducts and cigarette smoking. Nicholl ID, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov; 44(7):1025–33 (55 ref.)

Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum. Shaw S, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1061–8

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Thornalley PJ. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1013–23 (70 ref.)

Hepatic advanced glycation endproduct binding is increased in experimental diabetes. Youssef S, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1095–100

Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chiou YJ, et al. **Chem Biol Interact** 1999 Jul 1;121(2):141–59

Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Schmidt AM, et al. **Circ Res** 1999 Mar 19;84(5):489–97 (89 ref.)

Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Bonnardel-Phu E, et al. **Diabetes** 1999 Oct;48(10):2052–8

Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. He C, et al. **Diabetes** 1999 Jun; 48(6):1308–15

Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Friedman EA. **Diabetes Care** 1999 Mar;22 Suppl 2:B65–71 (62 ref.)

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Degenhardt TP, et al. **Diabetes Res Clin Pract** 1999 Feb;43(2):81–9

Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Hammes HP, et al. **Diabetologia** 1999 Jun;42(6):728–36

A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Soulis T, et al. **Diabetologia** 1999 Apr;42(4):472–9

Reduction of advanced glycation end-product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of poor metabolic control. Sensi M, et al. **Eur J Neurosci** 1998 Sep; 10(9):2768–75

Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. Miyata T, et al. **FEBS Lett** 1998 Oct 16;437(1–2):24–8

Interaction of glycated albumin-gold complexes with mouse brain microvascular endothelium. Vorbrodt AW, et al. **Folia Histochem Cytobiol** 1999;37(1):3–10

Carbonyl stress: increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia [editorial] Miyata T, et al. **Int J Artif Organs** 1999; 22(4):195–8

The effect of advanced glycation end-product formation upon cell-matrix interactions. Paul RG, et al. **Int J Biochem Cell Biol** 1999 Jun;31(6):653–60

Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Sun M, et al. **Int J Exp Pathol** 1998 Aug;79(4):207–22

Carbonyl stress in the pathogenesis of diabetic nephropathy. Suzuki D, et al. **Intern Med** 1999 Apr;38(4):309–14 (60 ref.)

N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Hammes HP, et al. **Invest Ophthalmol Vis Sci** 1999 Jul; 40(8):1855–9

Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Handa JT, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):775–9

Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Stitt AW, et al. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2517–23

Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. Menè P, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1478–86

Protein glycosylation and advanced glycosylated endproducts (AGEs) accumulation: an avian solution? Iqbal M, et al. **J Gerontol A Biol Sci Med Sci** 1999 Apr; 54(4):B171–6; discussion B177–8

Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Münch G, et al. **J Neural Transm** 1998;105(4–5):439–61 (125 ref.)

The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats. Renard C, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1458–66

Simple and fast method to test the receptor for advanced glycosylated endproducts (RAGE) for its tumor suppressive potential using the Tet-On system. Bendik I, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul; 19(1–4):717–28

Binding of long-term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells. Sobal G, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):267–81

Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway. Tsukushi S, et al. **Kidney Int** 1999 May;55(5):1970–6

Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Youssef S, et al. **Kidney Int** 1999 Mar;55(3):907–16

Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Miyata T, et al. **Kidney Int Suppl** 1999 Jul;71:S54–6

Receptors for proteins modified by advanced glycation endproducts (AGE)--their functional role in atherosclerosis. Sano H, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):333–46 (58 ref.)

Cell-associated pentosidine as a marker of aging in human diploid cells in vitro and in vivo. Sell DR, et al. **Mech Ageing Dev** 1998 Nov 16;105(3):221–40

Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Yanagisawa K, et al. **Metabolism** 1998 Nov;47(11):1348–53

Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Nicholl ID, et al. **Mol Med** 1998 Sep;4(9):594–601

Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Farboud B, et al. **Mol Vis** 1999 Jul 14;5:11

Advanced glycation end-products in diabetic nephropathy. Friedman EA. **Nephrol Dial Transplant** 1999;14 Suppl 3:1–9 (82 ref.)

Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Honda K, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1541–9

Implication of carbonyl stress in long-term uraemic complications. Wada T, et al. **Nephrol Dial Transplant** 1999; 14 Suppl 1:79–81 (16 ref.)

Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Witko-Sarsat V, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:76–8 (23 ref.)

Ultrastructural changes and immunohistochemical localization of nitric oxide synthase, advanced glycation end products and NF-kappa B in aorta of streptozotocin treated Mongolian gerbils. Nishigaki R, et al. **Nippon Ika Daigaku Zasshi** 1999 Jun;66(3):166–75

Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains. Kimura T, et al. **Pathol Int** 1998 Aug;48(8):575–9

Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions. Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1999;19 Suppl 2:S68–74

Carbonyl stress: increased carbonyl modification of tissue and cellular proteins in uremia. Miyata T, et al. **Perit Dial Int** 1999;19 Suppl 2:S58–61

Suppression of N(epsilon)-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine. Nakayama M, et al. **Perit Dial Int** 1999 May–Jun;19(3):207–10

AGE accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function. Park MS, et al. **Perit Dial Int** 1999; 19 Suppl 2:S53–7

Pharmacological modulation of AGEs: a unique role for redox-active metal ions. Weiss MF, et al. **Perit Dial Int** 1999;19 Suppl 2:S62–7

Inhibition of advanced glycated end-products [letter] Gandhi JS, et al. **Postgrad Med J** 1999 Jul;75(885):446–7

Advanced glycation endproducts and the kidney. Heidland A, et al. **Przegl Lek** 1998;55 Suppl 1:29–31 (27 ref.)

The use of optical sensors to understand cellular interactions with renal cells. Newman DJ, et al. **Ren Fail** 1999 May–Jul; 21(3–4):349–57

Meeting. American Chemical Society. Raising a glass to health and nanotubes [news] Service RF. **Science** 1999 Sep 24;285(5436):2053; 2055

[Internal diseases and carbonyl stress] Miyata T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):347–54 (21 ref.) **(Jpn)**

[Protein glycosylation end products] Kropiewnicka EH, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):350–8 (34 ref.) **(Pol)**

PHARMACOLOGY

Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Huang JS, et al. **Biochem J** 1999 Aug 15; 342 (Pt 1):231–8

Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1. Sebeková K, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov; 44(7):1051–60

Effects of advanced glycosylation end products on proliferation and cytosolic free calcium in cultured rat aortic smooth muscle cells. Jin H, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):422–5

Expression of receptor for advanced glycosylation end products (AGEP) and inhibition of AGEP-induced cytosolic calcium elevation by diltiazem in cultured rat aortic smooth muscle cells. Zhou QG, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):425–30

Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Kunt T, et al. **Clin Sci (Colch)** 1999 Jan; 96(1):75–82

Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Yamagishi S, et al. **Diabetologia** 1998 Dec;41(12):1435–41

The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Kunt T, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):183–8

High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. Neumann A, et al. **FEBS Lett** 1999 Jun 25;453(3):283–7

Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. Paget C, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):121–9

Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. Menè P, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1478–86

Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. Loske C, et al. **J Neural Transm** 1998; 105(8–9):1005–15

Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Sengoelge G, et al. **Kidney Int** 1998 Nov;54(5):1637–51

[Effects of glycated protein on the expression of plasminogen activator inhibitor-1 of cultured human mesangial cells] Deng Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep; 77(9):672–5 (Eng. Abstr.) **(Chi)**

GLYCOSYLATION END PRODUCTS, ADVANCED

PHYSIOLOGY

Towards a new "AGE" of the chemistry and pathophysiology of the Maillard reaction [editorial] Münch G, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):ix-x

International Diabetes Federation meeting, 1997: nephropathy, retinopathy, and glycation. Bloomgarden ZT. **Diabetes Care** 1998 Sep;21(9):1560-6 (14 ref.)

Advanced glycation end-products reduce the viability of human peritoneal mesothelial cells [letter] Nishida Y, et al. **Nephron** 1998 Dec;80(4):477-8

Pathogenic role of advanced glycation end-products (AGEs): an overview. Weiss MF. **Perit Dial Int** 1999;19 Suppl 2:S47-52 (60 ref.)

[Role of Maillard products in the chronic complications of diabetes mellitus. Bioclinical applications] Trivin F. **Ann Pharm Fr** 1998;56(5):193-6 (Eng. Abstr.) **(Fre)**

[Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus] Nawroth PP, et al. **Med Klin** 1999 Jan 15;94(1):29-38 (156 ref.) (Eng. Abstr.) **(Ger)**

[Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous] Hashimoto H, et al. **Nippon Ganka Gakkai Zasshi** 1998 Jul;102(7):442-6 (Eng. Abstr.) **(Jpn)**

[Role of advanced glycation end products (AGE) in the development of diabetic microangiopathies and the beneficial effects of AGE inhibitors] Kawakami M, et al. **Nippon Rinsho** 1999 Mar;57(3):567-72 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Importance of advanced glycation end products--AGE products] Jakuš V, et al. **Bratisl Lek Listy** 1998 Jul; 99(7):368-75 (82 ref.) (Eng. Abstr.) **(Slo)**

URINE

Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Smulders RA, et al. **Thromb Haemost** 1998 Jul;80(1):52-7

[Detection of glycation end products in the urine of diabetic patients] Wittmann I, et al. **Orv Hetil** 1999 Sep 5; 140(36):1997-2001 (Eng. Abstr.) **(Hun)**

GLYCOSYLCERAMIDASE

GENETICS

Defective intracellular processing of lactase-phlorizin hydrolase protein in rats prenatally exposed to ethanol. Estrada G, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5):1177-83

Transcriptional regulation of pig lactase-phlorizin hydrolase: involvement of HNF-1 and FREACs. Spodsberg N, et al. **Gastroenterology** 1999 Apr;116(4):842-54

Hierarchy of sorting signals in chimeras of intestinal lactase-phlorizin hydrolase and the influenza virus hemagglutinin. Jacob R, et al. **J Biol Chem** 1999 Mar 19; 274(12):8061-7

Lactase-phlorizin hydrolase and sucrase-isomaltase genes are expressed differently along the villus-crypt axis of rat jejunum. Goda T, et al. **J Nutr** 1999 Jun;129(6):1107-13

METABOLISM

Processing of human intestinal prolactase to an intermediate form by furin or by a furin-like proprotein convertase. Mesonero JE, et al. **J Biol Chem** 1998 Nov 6; 273(45):29430-6

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS see **GLYCOSYLPHOSPHATIDYLINOSITOLS**

GLYCOSYLPHOSPHATIDYLINOSITOLS

Characterization of the human leukocyte GPI-anchored glycoprotein CDw108 and its relation to other similar molecules. Angelisová P, et al. **Immunobiology** 1999 Jun; 200(2):234-45

The biosynthesis and post-translational modification of Pbs21 an ookinete-surface protein of Plasmodium berghei. Blanco AR, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):163-73

[GPI-anchored proteins] Ikezawa H. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(8 Suppl):1321-8 (30 ref.) **(Jpn)**

[Development from actions of bacterial phospholipases C on eucaryotic plasma membranes to molecular biology of GPI-anchored proteins] Ikezawa H. **Yakugaku Zasshi** 1999 Jul;119(7):472-94 (86 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Glycosylphosphatidylinositol-anchored proteins in human and pig's milk. Kunz C, et al. **Ann Nutr Metab** 1998; 42(4):189-94

Glycosylphosphatidylinositol-anchored cell-surface proteins from Arabidopsis. Sherrier DJ, et al. **Electrophoresis** 1999 Jul;20(10):2027-35

MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Millán J, et al. **Eur J Immunol** 1998 Nov;28(11):3675-84

Presence of a glycosylphosphatidylinositol lipid anchor on rose arabinogalactan proteins. Svetek J, et al. **J Biol Chem** 1999 May 21;274(21):14724-33

Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin. Salzer JL, et al. **J Neurosci Res** 1998 Oct 15;54(2):147-57

Analysis of the carbohydrate components of glycosylphosphatidylinositol structures using fluorescent labeling. Zitzmann N, et al. **Methods Mol Biol** 1999; 116:73-89 (49 ref.)

CD4 segregates into specific detergent-resistant T-cell membrane microdomains. Millán J, et al. **Tissue Antigens** 1999 Jan;53(1):33-40

BIOSYNTHESIS

Stimulation of glycosylphosphatidylinositol biosynthesis in mammalian cell-free systems by GTP hydrolysis: evidence for the involvement of membrane fusion. Stevens VL, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):577-84

Human and mouse Gpi1p homologues restore glycosylphosphatidylinositol membrane anchor biosynthesis in yeast mutants. Tiede A, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):609-16

Mammalian PIG-L and its yeast homologue Gpi12p are N-acetylglucosaminylphosphatidylinositol de-N-acetylases essential in glycosylphosphatidylinositol biosynthesis. Watanabe R, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):185-92

Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. Tiede A, et al. **Biol Chem** 1999 May;380(5):503-23 (169 ref.)

Glycosylphosphatidylinositol biosynthetic enzymes are localized to a stable tubular subcompartment of the endoplasmic reticulum in Leishmania mexicana. Ilgoutz SC, et al. **EMBO J** 1999 Jul 1;18(13):3643-54

Differences between the trypanosomal and human GlcNAc-PI de-N-acetylases of glycosylphosphatidylinositol membrane anchor biosynthesis. Sharma DK, et al. **Glycobiology** 1999 Apr; 9(4):415-22

GPI1 stabilizes an enzyme essential in the first step of glycosylphosphatidylinositol biosynthesis. Hong Y, et al. **J Biol Chem** 1999 Jun 25;274(26):18582-8

In vitro analysis of GPI biosynthesis in mammalian cells. Stevens VL. **Methods Mol Biol** 1999;116:1-12 (23 ref.)

Selection of mammalian cell mutants in GPI biosynthesis. Stevens VL. **Methods Mol Biol** 1999;116:13-22 (23 ref.)

MCD4 encodes a conserved endoplasmic reticulum membrane protein essential for glycosylphosphatidylinositol anchor synthesis in yeast. Gaynor EC, et al. **Mol Biol Cell** 1999 Mar;10(3):627-48

[Genes involved in GPI-anchor biosynthesis] Maeda Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2410-7 (36 ref.) **(Jpn)**

[Biosynthesis of GPI-anchored proteins and its deficiency] Watanabe R, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun; 44(8 Suppl):1329-36 (48 ref.) **(Jpn)**

BLOOD

A novel glycosylphosphatidyl inositol-anchored protein on human leukocytes: a possible role for regulation of neutrophil adherence and migration. Suzuki K, et al. **J Immunol** 1999 Apr 1;162(7):4277-84

[Case of paroxysmal nocturnal hemoglobinuria diagnosed by the analysis of leukocyte glycosylphosphatidylinositol protein] Hanabusa N, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1557-9 **(Jpn)**

CHEMICAL SYNTHESIS

[Synthesis of inositol-containing glycophospholipids] Stepanov AE, et al. **Bioorg Khim** 1998 Oct;24(10):731-46 (77 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Identification of a new glycosylphosphatidylinositol-anchored 42-kDa protein and its C-terminal peptides from bovine erythrocytes by gas chromatography-, time-of-flight-, and electrospray-ionization-mass spectrometry. Taguchi R, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):60-7

Reconstitution of the glycosylphosphatidylinositol-anchored protein Thy-1: interaction with membrane phospholipids and galactosylceramide. Reid-Taylor KL, et al. **Biochem Cell Biol** 1999;77(3):189-200

Optimising the signal peptide for glycosyl phosphatidylinositol modification of human acetylcholinesterase using mutational analysis and peptide-quantitative structure-activity relationships. Bucht G, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):471-82

Ectoplasmic insertion of a glycosylphosphatidylinositol-anchored protein in glycosphingolipid- and cholesterol-containing phosphatidylcholine vesicles. Nosjean O, et al. **Eur J Biochem** 1999 Aug;263(3):865-70

The carboxyl terminus of Pneumocystis carinii glycoprotein A encodes a functional glycosylphosphatidylinositol signal sequence. Guadiz G, et al. **J Biol Chem** 1998 Oct 2; 273(40):26202-9

Structure of the glycosylphosphatidylinositol-anchor of the trans-sialidase from Trypanosoma cruzi metacyclic trypomastigote forms. Agusti R, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1-2):123-31

Sequence properties of GPI-anchored proteins near the omega-site: constraints for the polypeptide binding site of the putative transamidase. Eisenhaber B, et al. **Protein Eng** 1998 Dec;11(12):1155-61

DEFICIENCY

Paroxysmal nocturnal hemoglobinuria: analysis of the effects of mutant PIG-A on gene expression. Kanai N, et al. **Am J Hematol** 1999 Aug;61(4):221-31 (40 ref.)

Detection of GPI-anchored protein-deficient cells in patients with aplastic anaemia and evidence for clonal expansion during the clinical course. Kawaguchi K, et al. **Br J Haematol** 1999 Apr;105(1):80-4

Developmental abnormalities of glycosylphosphatidylinositol-anchor-deficient embryos revealed by Cre/loxP system. Nozaki M, et al. **Lab Invest** 1999 Mar;79(3):293-9

GENETICS

Assignment of the human GPAA1 gene, which encodes a product required for the attachment of glycosylphosphatidylinositols to proteins, at 8q24. Hiroi Y, et al. **Genomics** 1998 Dec 1;54(2):354-5

Isolation and characterization of a new member of the human Ly6 gene family (LY6H). Horie M, et al. **Genomics** 1998 Nov 1;53(3):365-8

Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice. Shinkel TA, et al. **Transplantation** 1998 Dec 15;66(11):1401-6

[Genes involved in GPI-anchor biosynthesis] Maeda Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2410-7 (36 ref.) **(Jpn)**

IMMUNOLOGY

GPI-microdomains: a role in signalling via immunoreceptors. Horejsi V, et al. **Immunol Today** 1999 Aug;20(8):356-61 (51 ref.)

Cleavage of the glycosylphosphatidylinositol anchor affects the reactivity of thy-1 with antibodies. Kukulansky T, et al. **J Immunol** 1999 May 15;162(10):5993-7

CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Schofield L, et al. **Science** 1999 Jan 8;283(5399):225-9

Prevention of hyperacute rejection by phosphatidylinositol-anchored mini-complement receptor type 1. Mikata S, et al. **Transpl Immunol** 1998 Jun; 6(2):107-10

METABOLISM

Characterization of glycosylphosphatidylinositiol-anchored, secreted, and intracellular vertebrate mono-ADP-ribosyltransferases. Okazaki IJ, et al. **Annu Rev Nutr** 1999;19:485-509 (110 ref.)

Sodium-dependent uptake of [3H]scyllo-inositol by Tetrahymena: incorporation into phosphatidylinositol, phosphatidylinositol-linked glycans, and polyphosphoinositols. Ryals PE, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):261-6

Chondrocyte-mediated catabolism of aggrecan: evidence for a glycosylphosphatidylinositol-linked protein in the aggrecanase response to interleukin-1 or retinoic acid. Sandy JD, et al. **Arch Biochem Biophys** 1999 Jul 15; 367(2):258-64

Release of glycosylphosphatidylinositol-anchored carboxypeptidase M by phosphatidylinositol-specific phospholipase C upregulates enzyme synthesis. Li XY, et al. **Biochem Biophys Res Commun** 1999 Apr 29; 258(1):204-10

Posttranslational modification of glycosylphosphatidylinositol (GPI)-specific phospholipase D and its activity in cleavage of GPI anchors [published erratum appears in Biochem Biophys Res Commun 1998 Dec 9;253(1):193] Tsujioka H, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):737-43

Inositol acylation of glycosylphosphatidylinositols in the pathogenic fungus Cryptococcus neoformans and the model yeast Saccharomyces cerevisiae. Franzot SP, et al. **Biochem J** 1999 May 15;340 (Pt 1):25-32

Insulin-mimetic signalling of synthetic phosphoinositolglycans in isolated rat adipocytes. Frick W, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):163-81

Glycosylphosphatidylinositol-dependent secretory transport in Trypanosoma brucei. McDowell MA, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):681-9

Carboxy-terminal processing of the urokinase receptor: implications for substrate recognition and glycosylphosphatidylinositol anchor addition. Aceto J, et al. **Biochemistry** 1999 Jan 19;38(3):992-1001

Prion proteins carrying pathogenic mutations are resistant to phospholipase cleavage of their glycolipid anchors. Narwa R, et al. **Biochemistry** 1999 Jul 6;38(27):8770-7

Glucosylation of glycosylphosphatidylinositol membrane anchors: identification of uridine diphosphate-glucose as the direct donor for side chain modification in Toxoplasma gondii using carbohydrate analogues. Striepen B, et al.

Biochemistry 1999 Feb 2;38(5):1478–87

Role of the glycosyl-phosphatidylinositol anchor in the intracellular transport of a transmembrane protein in Madin-Darby canine kidney cells. Cailler F, et al. **Biochim Biophys Acta** 1998 Dec 9;1415(1):1–9

Glycosyl phosphatidylinositol (GPI)/inositolphosphate glycan (IPG): an intracellular signalling system involved in the control of thyroid cell proliferation. Petitfrere E, et al. **Biochimie** 1998 Dec;80(12):1063–7

Signalling properties of glycosylphosphatidylinositols and their regulated release from membranes in the turnover of glycosylphosphatidylinositol-anchored proteins. Brodbeck U. **Biol Chem** 1998 Aug-Sep;379(8–9):1041–4 (31 ref.)

A synthetic acceptor substrate for Trypanosoma brucei UDP-Gal: GPI anchor side-chain alpha-galactosyltransferases. Brown JR, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2051–4

Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. McHugh RS, et al. **Cancer Res** 1999 May 15;59(10):2433–7

Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes. O'Brien KD, et al. **Circulation** 1999 Jun 8;99(22):2876–82

Microbial glycoconjugates. Mengeling BJ, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):572–7 (45 ref.)

Glycosylphosphatidylinositol-anchored cell surface proteins regulate position-specific cell affinity in the limb bud. Wada N, et al. **Dev Biol** 1998 Oct 15;202(2):244–52

Evidence that free GPI glycolipids are essential for growth of Leishmania mexicana. Ilgoutz SC, et al. **EMBO J** 1999 May 17;18(10):2746–55

Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. Costagliola S, et al. **FEBS Lett** 1998 Oct 9;436(3):427–33

Towards the in vitro reconstitution of caveolae. Asymmetric incorporation of glycosylphosphatidylinositol (GPI) and gangliosides into liposomal membranes. Villar AV, et al. **FEBS Lett** 1999 Aug 20;457(1):71–4

Assignment of the human GPAA1 gene, which encodes a product required for the attachment of glycosylphosphatidylinositols to proteins, at 8q24. Hiroi Y, et al. **Genomics** 1998 Dec 1;54(2):354–5

Engagement of GPI-linked CD48 contributes to TCR signals and cytoskeletal reorganization: a role for lipid rafts in T cell activation. Moran M, et al. **Immunity** 1998 Dec; 9(6):787–96

Amino acid residues in the omega-minus region participate in cellular localization of yeast glycosylphosphatidylinositol-attached proteins. Hamada K, et al. **J Bacteriol** 1999 Jul;181(13):3886–9

Deletion of GPI7, a yeast gene required for addition of a side chain to the glycosylphosphatidylinositol (GPI) core structure, affects GPI protein transport, remodeling, and cell wall integrity. Benachour A, et al. **J Biol Chem** 1999 May 21;274(21):15251–61

Clostridium septicum alpha toxin uses glycosylphosphatidylinositol-anchored protein receptors. Gordon VM, et al. **J Biol Chem** 1999 Sep 17; 274(38):27274–80

Amino acid sequence requirement for efficient incorporation of glycosylphosphatidylinositol-associated proteins into the cell wall of Saccharomyces cerevisiae. Hamada K, et al. **J Biol Chem** 1998 Oct 9;273(41):26946–53

Biosynthesis of inositol phosphoceramides and remodeling of glycosylphosphatidylinositol anchors in Saccharomyces cerevisiae are mediated by different enzymes. Reggiori F, et al. **J Biol Chem** 1998 Nov 13;273(46):30550–9

Association of sterol- and glycosylphosphatidylinositol-linked proteins with Drosophila raft lipid microdomains. Rietveld A, et al. **J Biol Chem** 1999 Apr 23;274(17):12049–54

Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. Sambamurti K, et al. **J Biol Chem** 1999 Sep 17;274(38):26810–4

A cell-free assay for glycosylphosphatidylinositol anchoring in African trypanosomes. Demonstration of a transamidation reaction mechanism. Sharma DK, et al. **J Biol Chem** 1999 Jun 4;274(23):16479–86

Segregation of glycosylphosphatidylinositol biosynthetic reactions in a subcompartment of the endoplasmic reticulum. Vidugiriene J, et al. **J Biol Chem** 1999 May 21; 274(21):15203–12

Molecular requirements for attachment of the glycosylphosphatidylinositol anchor to the human alpha folate receptor. Tomassetti A, et al. **J Cell Biochem** 1999 Jan 1;72(1):111–8

N-Glycans mediate the apical sorting of a GPI-anchored, raft-associated protein in Madin-Darby canine kidney cells. Benting JH, et al. **J Cell Biol** 1999 Jul 26;146(2):313–20

Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. Wilhelm OG, et al. **J Cell Physiol** 1999 Aug; 180(2):225–35

Phosphorylation of a major GPI-anchored surface protein of Trypanosoma brucei during transport to the plasma membrane. Bütikofer P, et al. **J Cell Sci** 1999 Jun;112 (Pt 11):1785–95

Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108. Yamada A, et al. **J Immunol** 1999 Apr 1;162(7):4094–100

Recognition of the carboxyl-terminal signal for GPI modification requires translocation of its hydrophobic domain across the ER membrane. Wang J, et al. **J Mol Biol** 1999 Mar 12;286(5):1303–10

GPI-anchored human placental alkaline phosphatase has a nonpolarized distribution on the cell surface of mouse cerebellar granule neurons in vitro. Kollins KM, et al. **J Neurobiol** 1999 Apr;39(1):119–41

Identification of reggie-1 and reggie-2 as plasmamembrane-associated proteins which cocluster with activated GPI-anchored cell adhesion molecules in non-caveolar micropatches in neurons. Lang DM, et al. **J Neurobiol** 1998 Dec;37(4):502–23

Imaging fluorescence resonance energy transfer as probe of membrane organization and molecular associations of GPI-anchored proteins. Kenworthy AK, et al. **Methods Mol Biol** 1999;116:37–49 (23 ref.)

Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src-family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma-subunits. Lisanti MP, et al. **Methods Mol Biol** 1999; 116:51–60 (40 ref.)

Analysis of the cell-surface distribution of GPI-anchored proteins. Mayor S. **Methods Mol Biol** 1999;116:23–36 (22 ref.)

Analysis of the lipid moiety of GPI anchor in the yeast Saccharomyces cerevisiae. Reggiori F, et al. **Methods Mol Biol** 1999;116:91–105 (22 ref.)

Roles of free GPIs in amastigotes of Leishmania. Mensa-Wilmot K, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):103–16

Two endoplasmic reticulum (ER) membrane proteins that facilitate ER-to-Golgi transport of glycosylphosphatidylinositol-anchored proteins. Barz WP, et al. **Mol Biol Cell** 1999 Apr;10(4):1043–59

Cell surface GPI-anchoring of CD45 isoforms. ten Dam GB, et al. **Mol Biol Rep** 1998 Nov;25(4):197–204

Interactions between a decapacitation factor and mouse spermatozoa appear to involve fucose residues and a GPI-anchored receptor. Fraser LR. **Mol Reprod Dev** 1998 Oct;51(2):193–202

No prokaryotic GPI anchoring [letter; comment] Nosjean O. **Nat Biotechnol** 1998 Sep;16(9):799. Comment on: Nat Biotechnol 1998 Jun;16(6):576–80.

Release of GPI-anchored Zn2+-glycerophosphocholine cholinephosphodiesterase as an amphiphilic form from bovine brain membranes by bee venom phospholipase A2. Lee JY, et al. **Neurochem Res** 1999 Aug;24(8):1043–50

The glycosylphosphatidylinositol-anchored phosphatase from Spirodela oligorrhiza is a purple acid phosphatase. Nakazato H, et al. **Plant Physiol** 1998 Nov;118(3):1015–20

The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Malaviya R, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8110–5

Endo-N-acetyl-beta-D-glucosaminidases and their potential substrates: structure/function relationships. Karamanos Y **Res Microbiol** 1997 Nov;148(8):661–71 (68 ref.)

PHYSIOLOGY

Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function? Horejsi V, et al. **Immunol Lett** 1998 Sep; 63(2):63–73 (185 ref.)

Modulation of leukocyte transendothelial migration by integrin-associated glycosyl phosphatidyl inositol (GPI)-anchored proteins. Sendo F, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S133–6 (30 ref.)

Purification and characterization of the yeast glycosylphosphatidylinositol-anchored, monobasic-specific aspartyl protease yapsin 2 (Mkc7p). Komano H, et al. **J Biol Chem** 1999 Aug 20;274(34):24431–7

Regulation of leukocyte adherence and migration by glycosylphosphatidyl-inositol-anchored proteins. Sendo F, et al. **J Leukoc Biol** 1999 Sep;66(3):369–74 (58 ref.)

Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice. Shinkel TA, et al. **Transplantation** 1998 Dec 15;66(11):1401–6

GLYCOSYLTRANSFERASES

ANTAGONISTS & INHIBITORS

Synthesis and applications for unnatural sugar nucleotides. Elhalabi JM, et al. **Curr Med Chem** 1999 Feb;6(2):93–116 (164 ref.)

BIOSYNTHESIS

Preferential expression of biotransformation enzymes in the olfactory organs of Drosophila melanogaster, the antennae. Wang Q, et al. **J Biol Chem** 1999 Apr 9;274(15):10309–15

CHEMISTRY

Cloning, crystallization and preliminary X-ray analysis of a nucleotide-diphospho-sugar transferase spsA from Bacillus subtilis. Charnock SJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):677–8

Structure of the nucleotide-diphospho-sugar transferase, SpsA from Bacillus subtilis, in native and nucleotide-complexed forms. Charnock SJ, et al. **Biochemistry** 1999 May 18;38(20):6380–5

Kinetic evidence of the existence of a stable enzyme-glycosyl intermediary complex in the reaction catalyzed by endotransglycosylase. Sulová Z, et al. **Gen Physiol Biophys** 1998 Jun;17(2):133–42

Glycosyltransferases in SWISS-PROT. O'Donovan C, et al. **Glycoconj J** 1998 May;15(5):507–9

Identification, purification, and characterization of transpeptidase and glycosyltransferase domains of Streptococcus pneumoniae penicillin-binding protein 1a. Di Guilmi AM, et al. **J Bacteriol** 1998 Nov;180(21):5652–9

High resolution crystal structures of the Escherichia coli lytic transglycosylase Slt70 and its complex with a peptidoglycan fragment. van Asselt EJ, et al. **J Mol Biol** 1999 Aug 27;291(4):877–98

DEFICIENCY

[Disturbances in aminoglycan synthesis] Jaeken J. **Arch Pediatr** 1999;6 Suppl 2:203s–205s **(Fre)**

GENETICS

Altered mRNA expression of glycosyltransferases in human gastric carcinomas. Petretti T, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2–3):209–18

Cloning, sequencing, and characterization of the lipopolysaccharide biosynthetic enzyme heptosyltransferase I gene (waaC) from Campylobacter jejuni and Campylobacter coli. Klena JD, et al. **Gene** 1998 Nov 19;222(2):177–85

Characterization of a WaaF (RfaF) homolog expressed by Haemophilus ducreyi. Bauer BA, et al. **Infect Immun** 1999 Feb;67(2):899–907

Genetic characterization of a Tn5-disrupted glycosyltransferase gene homolog in Brucella abortus and its effect on lipopolysaccharide composition and virulence. McQuiston JR, et al. **Infect Immun** 1999 Aug;67(8):3830–5

Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C. Mao Y, et al. **J Bacteriol** 1999 Apr;181(7):2199–208

Exopolysaccharide biosynthesis in Lactococcus lactis NIZO B40: functional analysis of the glycosyltransferase genes involved in synthesis of the polysaccharide backbone. van Kranenburg R, et al. **J Bacteriol** 1999 Jan;181(1):338–40

Cloning and overexpression of glycosyltransferases that generate the lipopolysaccharide core of Rhizobium leguminosarum. Kadrmas JL, et al. **J Biol Chem** 1998 Oct 9;273(41):26432–40

Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. Okajima T, et al. **J Biol Chem** 1999 Aug 13;274(33):22915–8

Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. Ruan S, et al. **J Neurochem** 1999 Feb;72(2):514–21

Generation of a novel polysaccharide by inactivation of the aceP gene from the acetan biosynthetic pathway in Acetobacter xylinum. Edwards KJ, et al. **Microbiology** 1999 Jun;145 (Pt 6):1499–506

Endoxyloglucan transferase cDNA isolated from pea roots and its fluctuating expression in hydrotropically responding roots. Takano M, et al. **Plant Cell Physiol** 1999 Feb; 40(2):135–42

Three proteins involved in Caenorhabditis elegans vulval invagination are similar to components of a glycosylation pathway. Herman T, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):974–9

ISOLATION & PURIFICATION

Purification of xyloglucan endotransglycosylases (XETs): a generally applicable and simple method based on reversible formation of an enzyme-substrate complex. Steele NM, et al. **Biochem J** 1999 May 15;340 (Pt 1):207–11

Glycosyltransferase domain of penicillin-binding protein 2a from Streptococcus pneumoniae is membrane associated. di Guilmi AM, et al. **J Bacteriol** 1999 May;181(9):2773–81

Purification of xyloglucan endotransglycosylase based on affinity sorption of the active glycosyl-enzyme intermediate complex to cellulose. Sulová Z, et al. **Protein Expr Purif** 1999 Jul;16(2):231–5

METABOLISM

Converting T4 phage lysozyme into a transglycosidase. Kuroki R, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:362–5

Enzymatic modification of natural compounds with pharmacological properties. Riva S, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:70–80 (13 ref.)

Characterization of a glycosyl transferase inactivating macrolides, encoded by gimA from Streptomyces ambofaciens. Gourmelen A, et al. **Antimicrob Agents Chemother** 1998 Oct;42(10):2612–9

Glycosyltransferase and sulfotransferase activities in chick corneal stromal cells before and after in vitro culture. Nakazawa K, et al. **Arch Biochem Biophys** 1998 Nov 15;

359(2):269–82
Multi-enzyme kinetic analysis of glycolipid biosynthesis. Bieberich E, et al. **Biochim Biophys Acta** 1999 Jun 15; 1432(1):113–24
Mannosylphosphate transfer to yeast mannan. Jigami Y, et al. **Biochim Biophys Acta** 1999 Jan 6;1426(2):335–45 (52 ref.)
Organization of ganglioside synthesis in the Golgi apparatus. Maccioni HJ, et al. **Biochim Biophys Acta** 1999 Feb 25; 1437(2):101–18 (142 ref.)
Investigation of the glycosyltransferase enzymes involved in the initial stages of the N-linked protein glycosylation pathway in Aspergillus niger. Wallis GL, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):91–8
Protein glycosylation in development and disease. Dennis JW, et al. **Bioessays** 1999 May;21(5):412–21 (80 ref.)
A fluorometric assay for glycosyltransferase activities using sugars aminated and tagged with 7-hydroxycoumarin-3-carboxylic acid as substrates and high performance liquid chromatography. Higai K, et al. **Biol Pharm Bull** 1999 Apr;22(4):333–8
Glycosyltransferase catalyzed assemblage of sialyl-Lewis(a)-saccharopeptides. Baisch G, et al. **Carbohydr Res** 1998 Nov;312(1–2):61–72
Mechanisms and pathways from recent deoxysugar biosynthesis research. Johnson DA, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):642–9 (42 ref.)
Introducing transglycosylation activity in a liquefying alpha-amylase. Saab-Rincón G, et al. **FEBS Lett** 1999 Jun 18;453(1–2):100–6
Kinetic evidence of the existence of a stable enzyme-glycosyl intermediary complex in the reaction catalyzed by endotransglycosylase. Sulová Z, et al. **Gen Physiol Biophys** 1998 Jun;17(2):133–42
Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Brockhausen I, et al. **Glycoconj J** 1998 Jun; 15(6):595–603
Exopolysaccharide biosynthesis in Lactococcus lactis NIZO B40: functional analysis of the glycosyltransferase genes involved in synthesis of the polysaccharide backbone. van Kranenburg R, et al. **J Bacteriol** 1999 Jan;181(1):338–40
The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. Lind T, et al. **J Biol Chem** 1998 Oct 9; 273(41):26265–8
Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli. Vollmer W, et al. **J Biol Chem** 1999 Mar 5;274(10):6726–34
The high osmolarity glycerol response (HOG) MAP kinase pathway controls localization of a yeast golgi glycosyltransferase. Reynolds TB, et al. **J Cell Biol** 1998 Nov 16;143(4):935–46
Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering. Storrie B, et al. **J Cell Biol** 1998 Dec 14;143(6):1505–21
Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. Ruan S, et al. **J Neurochem** 1999 Feb;72(2):514–21
In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Rellier N, et al. **Life Sci** 1999;64(17):1571–83
Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica. Heinrichs DE, et al. **Mol Microbiol** 1998 Oct;30(2):221–32 (33 ref.)
In vitro activities of four xyloglucan endotransglycosylases from Arabidopsis. Campbell P, et al. **Plant J** 1999 May; 18(4):371–82
Co- and/or post-translational modifications are critical for TCH4 XET activity. Campbell P, et al. **Plant J** 1998 Aug; 15(4):553–61

PHYSIOLOGY

Penetration of the bacterial cell wall: a family of lytic transglycosylases in bacteriophages and conjugative plasmids [letter] Lehnherr H, et al. **Mol Microbiol** 1998 Oct;30(2):454–7

GLYCYL T RNA SYNTHETASE see **GLYCINE-TRNA LIGASE**

GLYCYLGLYCINE

RADIATION EFFECTS

Product yields from irradiated glycylglycine in oxygen-free solutions: Monte Carlo simulations and comparison with experiments. Bolch WE, et al. **Radiat Environ Biophys** 1998 Oct;37(3):157–66

GLYCYRRHETIC ACID see **GLYCYRRHETINIC ACID**

GLYCYRRHETINIC ACID

ANALOGS & DERIVATIVES

Inhibition of gap junction communication in alveolar epithelial cells by 18alpha-glycyrrhetinic acid. Guo Y, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):L1018–26
Purification and characterization of glycyrrhetic acid mono-glucuronide beta-D-glucuronidase in Eubacterium sp. GLH. Akao T. **Biol Pharm Bull** 1999 Jan;22(1):80–2
Biotransformation of glycyrrhizin to 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide by Streptococcus LJ-22, a human intestinal bacterium. Kim DH, et al. **Biol Pharm Bull** 1999 Mar;22(3):320–2
[Bronchial asthma due to Stronger Neo-Minophagen C] Nakatsumi Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):644–6 (Eng. Abstr.) **(Jpn)**
[The cardioprotective action of 18-dehydroglycyrrhetic acid in experimental myocardial damage] Zakirov NU, et al. **Eksp Klin Farmakol** 1999 Mar-Apr;62(2):19–21 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Western blotting method for the immunostaining detection of glucuronides of glycyrrhetic acid using anti-glycyrrhizin monoclonal antibody. Shan S, et al. **Biol Pharm Bull** 1999 Feb;22(2):221–3

METABOLISM

Biochemical characterization of recombinant HIV-1 reverse transcriptase (rRT) as a glycyrrhizin-binding protein and the CK-II-mediated stimulation of rRT activity potently inhibited by glycyrrhetinic acid derivative. Harada S, et al. **Biol Pharm Bull** 1998 Dec;21(12):1282–5

PHARMACOLOGY

The induction of liver microsomal cytochrome P450 by Glycyrrhiza uralensis and glycyrrhetinic acid in mice. Hu WY, et al. **Biomed Environ Sci** 1999 Mar;12(1):10–4
Inhibition of the gap junctional component of endothelium-dependent relaxations in rabbit iliac artery by 18-alpha glycyrrhetinic acid. Taylor HJ, et al. **Br J Pharmacol** 1998 Sep;125(1):1–3
Effect of sodium glycyrrhetinate on chemical peritonitis in rats. Bao JF, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):277–80
Blockade by 18beta-glycyrrhetinic acid of intercellular electrical coupling in guinea-pig arterioles. Yamamoto Y, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):501–8
The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats. Lin G, et al. **Toxicon** 1999 Sep; 37(9):1259–70
[Effect of beta-glycyrrhizinate on eye mucosa absorption of drugs] Odaka A, et al. **Yakugaku Zasshi** 1999 Jul; 119(7):502–9 (Eng. Abstr.) **(Jpn)**
[The blood-simulating properties of a recombinant colony-stimulating factor and glycyram during cytostatic myelosuppression] Dygai AM, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):34–7 (Eng. Abstr.) **(Rus)**

GLYCYRRHIZA

Historical perspectives on health. The history of liquorice: the plant, its extract, cultivation, commercialisation and etymology. Olukoga A, et al. **J R Soc Health** 1998 Oct; 118(5):300–4
[State of pulmonary metabolism during radiotherapy of thoracic neoformations and possibilities of its correction] Palagina MV, et al. **Ter Arkh** 1999;71(3):45–8 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism [letter] Hasegawa J, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):599–600
Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa. Ishikawa S, et al. **Int J Eat Disord** 1999 Jul;26(1):111–4
Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. Eriksson JW, et al. **J Intern Med** 1999 Mar;245(3):307–10
Reduction of serum testosterone in men by licorice [letter] Armanini D, et al. **N Engl J Med** 1999 Oct 7;341(15):1158
Pontefract cakes can be bad for you: refractory hypertension and liquorice excess. Dellow EL, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):218–20
[Generalized edema] Peghini PE, et al. **Schweiz Rundsch Med Prax** 1998 Dec 10;87(50):1766–8 **(Ger)**
[A case of drug-induced liver injury by Chinese digestive medicine] Nakai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec;95(12):1374–7 **(Jpn)**

CHEMISTRY

Activation of macrophages by crude polysaccharide fractions obtained from shoots of Glycyrrhiza glabra and hairy roots of Glycyrrhiza uralensis in vitro. Nose M, et al. **Biol Pharm Bull** 1998 Oct;21(10):1110–2
Antimicrobial flavonoids from Glycyrrhiza glabra hairy root cultures [letter] Li W, et al. **Planta Med** 1998 Dec; 64(8):746–7
[Polysaccharides of Glycyrrhiza glabra L. and Glycyrrhiza echinata L. Medicinal plants II] Kiss T, et al. **Acta Pharm Hung** 1998 Sep;68(5):263–8 (Eng. Abstr.) **(Hun)**
[Quantitative determination of constituents in various licorice roots by means of high performance liquid chromatography] Kitagawa I, et al. **Yakugaku Zasshi** 1998 Nov;118(11):519–28 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

CYP81E1, a cytochrome P450 cDNA of licorice (Glycyrrhiza echinata L.), encodes isoflavone 2'-hydroxylase. Akashi T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):67–70

GENETICS

CYP81E1, a cytochrome P450 cDNA of licorice (Glycyrrhiza echinata L.), encodes isoflavone 2'-hydroxylase. Akashi T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):67–70

METABOLISM

Establishment of reference values for endocrine tests. II: Hyperprolactinemia. Le Moli R, et al. **Neth J Med** 1999 Aug;55(2):71–5

PHYSIOLOGY

Seasonal variation of glycyrrhizin and isoliquiritigenin glycosides in the root of Glycyrrhiza glabra L. Hayashi H, et al. **Biol Pharm Bull** 1998 Sep;21(9):987–9

GLYCYRRHIZIC ACID

ADMINISTRATION & DOSAGE

Enhanced rectal absorption of amphotericin B lyophilized with glycyrrhizinate in rabbits. Tanaka M, et al. **Biol Pharm Bull** 1998 Aug;21(8):853–7

ADVERSE EFFECTS

[Neurological side-effects of antiallergic drug, colchicine and glucocorticoids] Tanaka C, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):606–9 (12 ref.) **(Jpn)**

ANALYSIS

[Content of progesterone, glucocorticoid and glycyrrhizic acid receptors in normal and tumoral human breast tissue] Il'icheva TN, et al. **Vopr Onkol** 1998;44(4):390–4 (Eng. Abstr.) **(Rus)**

CONTRAINDICATIONS

A cautionary note regarding glycyrrhiza (licorice root) [letter] Stolpman D, et al. **Am J Gastroenterol** 1999 Feb; 94(2):540–1

IMMUNOLOGY

Western blotting method for the immunostaining detection of glucuronides of glycyrrhetic acid using anti-glycyrrhizin monoclonal antibody. Shan S, et al. **Biol Pharm Bull** 1999 Feb;22(2):221–3
Formation of a monoclonal antibody against glycyrrhizin and development of an ELISA. Tanaka H, et al. **Biol Pharm Bull** 1998 Dec;21(12):1391–3

METABOLISM

Characterization of an apoptosis-inducing factor in Habu snake venom as a glycyrrhizin (GL)-binding protein potently inhibited by GL in vitro. Abe Y, et al. **Biol Pharm Bull** 1998 Sep;21(9):924–7
Distribution of enzymes involved in the metabolism of glycyrrhizin in various organs of rat. Akao T. **Biol Pharm Bull** 1998 Oct;21(10):1036–44
Seasonal variation of glycyrrhizin and isoliquiritigenin glycosides in the root of Glycyrrhiza glabra L. Hayashi H, et al. **Biol Pharm Bull** 1998 Sep;21(9):987–9

PHARMACOKINETICS

Biotransformation of glycyrrhizin to 18beta-glycyrrhetinic acid-3-O-beta-D-glucuronide by Streptococcus LJ-22, a human intestinal bacterium. Kim DH, et al. **Biol Pharm Bull** 1999 Mar;22(3):320–2

PHARMACOLOGY

Pharmacological properties of traditional medicines. XXV. Effects of ephedrine, amygdalin, glycyrrhizin, gypsum and their combinations on body temperature and body fluid. Yuan D, et al. **Biol Pharm Bull** 1999 Feb;22(2):165–71
Effect of sodium glycyrrhetinate on neonatal rat myocardial cells. Zhu XW, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):331–3
Effects of glycyrrhizin, an active component of licorice roots, on Candida albicans infection in thermally injured mice. Utsunomiya T, et al. **Clin Exp Immunol** 1999 May; 116(2):291–8
Effects of naloxone, glycyrrhizic acid, dexamethasone and deoxycorticosterone in repetitive stress. Ainsah O, et al. **Clin Exp Pharmacol Physiol** 1999 May-Jun;26(5–6):433–7
Short- and long-term effects of glycyrrhizic acid in repetitive stress. Ainsah O, et al. **Clin Exp Pharmacol Physiol** 1999 May-Jun;26(5–6):444–8

Effects of glycyrrhizin on production of vascular aldosterone and corticosterone. Wu P, et al. **Horm Res** 1999; 51(4):189–92

Glycyrrhizin protects mice from concanavalin A–induced hepatitis without affecting cytokine expression. Okamoto T, et al. **Int J Mol Med** 1999 Aug;4(2):149–52

Simultaneous use of sodium deoxycholate and dipotassium glycyrrhizinate enhances the cellular transport of poorly absorbed compounds across Caco–2 cell monolayers. Sakai M, et al. **J Pharm Pharmacol** 1999 Jan;51(1):27–33

Inhibitory effect of glycyrrhizin on NF–kappaB binding activity in CCl4– plus ethanol–induced liver cirrhosis in rats. Wang JY, et al. **Liver** 1998 Jun;18(3):180–5

In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Imai T, et al. **Pharm Res** 1999 Jan;16(1):80–6

The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine–induced hepatotoxicity in rats. Lin G, et al. **Toxicon** 1999 Sep; 37(9):1259–70

[Inhibitory effect of glycyrrhizin on NF–kappa B binding activity in CCl4 plus ethanol induced liver cirrhosis in rats] Wang J, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):42–3 (Eng. Abstr.) **(Chi)**

[Effects of glycyrrhisin on myocardial ischemia/reperfusion injury of rabbits] Zhang J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):69–71 (Eng. Abstr.) **(Chi)**

[The structure activity relationship of saikosaponins and glycyrrhizin derivatives for Na+, K(+)–ATPase inhibiting action] Zhou QL, et al. **Yao Hsueh Hsueh Pao** 1996; 31(7):496–501 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine–treated mice. Shiota G, et al. **Carcinogenesis** 1999 Jan;20(1):59–63

Inhibitory effect of glycyrrhizin on NF–kappaB binding activity in CCl4– plus ethanol–induced liver cirrhosis in rats. Wang JY, et al. **Liver** 1998 Jun;18(3):180–5

TOXICITY

Cytotoxicity of absorption enhancers in Caco–2 cell monolayers. Sakai M, et al. **J Pharm Pharmacol** 1998 Oct; 50(10):1101–8

GLYCYRRHIZIN see **GLYCYRRHIZIC ACID**

GLYDIAZINAMIDE see **GLIPIZIDE**

GLYOXAL

ANALOGS & DERIVATIVES

Immunochemical detection of glyoxal DNA damage. Mistry N, et al. **Free Radic Biol Med** 1999 May;26(9–10):1267–73

[Studies on the triterpenoid saponins of the root bark of Aralia taibaiensis] Tang HF, et al. **Yao Hsueh Hsueh Pao** 1996;31(7):517–23 (Eng. Abstr.) **(Chi)**

BLOOD

Increase in three alpha,beta–dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Odani H, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):89–93

CHEMISTRY

Chemical cross–linking of ethidium to DNA by glyoxal. Leng F, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):71–81

METABOLISM

Accumulation of alpha–oxoaldehydes during oxidative stress: a role in cytotoxicity. Abordo EA, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):641–8

Carbonyl compounds cross–link cellular proteins and activate protein–tyrosine kinase p60c–Src. Akhand AA, et al. **J Cell Biochem** 1999 Jan 1;72(1):1–7

PHARMACOLOGY

Inhibitors of the chymotrypsin–like activity of proteasome based on di– and tri–peptidyl alpha–keto aldehydes (glyoxals). Lynas JF, et al. **Bioorg Med Chem Lett** 1998 Feb 17;8(4):373–8

GLYOXALASE I see **LACTOYLGLUTATHIONE LYASE**

GLYOXALINYLACRYLIC ACID see **UROCANIC ACID**

GLYOXYLATE TRANSACETYLASE see **MALATE SYNTHASE**

GLYOXYLATES

Asymmetric imine–ene reactions: diastereofacial selective reactions with chiral glyoxylate–derived alpha–imino esters and asymmetric catalysis of enantiofacial selective reactions with prochiral alpha–imino esters. Mikami K, et al. **Amino Acids** 1998;14(4):311–8

CHEMISTRY

Site–specific modification of a single–chain antibody using a novel glyoxylyl–based labeling reagent. Zhao ZG, et al. **Bioconjug Chem** 1999 May–Jun;10(3):424–30

METABOLISM

Glyoxylate cycle enzymes are present in liver peroxisomes of alloxan–treated rats. Popov VN, et al. **FEBS Lett** 1998 Nov 27;440(1–2):55–8

Biosynthesis of polyketomycin produced by Streptomyces diastatochromogenes Tü 6028. Paululat T, et al. **J Antibiot (Tokyo)** 1999 Feb;52(2):96–101

Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. Holmes RP, et al. **J Urol** 1998 Nov; 160(5):1617–24 (68 ref.)

TOXICITY

Toxicity of the styrene metabolite, phenylglyoxylic acid, in rats after three months' oral dosing. Ladefoged O, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):721–37

URINE

[The simultaneous determination of hippuric acid, o–, m–, p–methylhippuric acids, mandelic acid and phenylglyoxylic acid in urine by HPLC] Burrini C. **Med Lav** 1998 Sep–Oct; 89(5):404–11 (Eng. Abstr.) **(Ita)**

GLYPICAN see **HEPARAN SULFATE PROTEOGLYCAN**

GLYPIDIZINE see **GLIPIZIDE**

GM ALLOTYPES see **IMMUNOGLOBULIN GM ALLOTYPES**

GM–CSF see **GRANULOCYTE–MACROPHAGE COLONY–STIMULATING FACTOR**

GM–CSF RECEPTORS see **RECEPTORS, GRANULOCYTE–MACROPHAGE COLONY–STIMULATING FACTOR**

GM–CSF, RECOMBINANT see **GRANULOCYTE MACROPHAGE COLONY–STIMULATING FACTORS, RECOMBINANT**

G(M1) GANGLIOSIDE

see related
GANGLIOSIDOSIS G(M1)

Cholera toxin and GM1: a model membrane study with IAsys. Athanassopoulou N, et al. **Biochem Soc Trans** 1999 Feb;27(2):340–3

ANALOGS & DERIVATIVES

Occurrence of monosialosyl pentahexaosylceramide GalNAc–GM1 as specific tumor–associated ganglioside of human head and neck squamous cell carcinomas. Bolot G, et al. **Cancer Lett** 1999 Jan 29;135(2):159–64

Ganglioside GD1 alpha analogues as high–affinity ligands for myelin–associated glycoprotein (MAG). Sawada N, et al. **Carbohydr Res** 1999 Mar 31;316(1–4):1–5

GD1alpha–replica peptides functionally mimic GD1alpha, an adhesion molecule of metastatic tumor cells, and suppress the tumor metastasis [published erratum appears in FEBS Lett 1999 Feb 12;444(2–3):296] Ishikawa D, et al. **FEBS Lett** 1998 Dec 11;441(1):20–4

Antibodies to GD1alpha and to GQ1beta in Guillain–Barré syndrome and the related disorders. Odaka M, et al. **J Neurol Sci** 1999 Jun 1;165(2):126–32

Role of sialylglycoconjugate(s) in the initial phase of metastasis of liver–metastatic RAW117 lymphoma cells. Kikkawa H, et al. **Jpn J Cancer Res** 1998 Dec; 89(12):1296–305

ANALYSIS

Analysis of receptor for Vibrio cholerae El tor hemolysin with a monoclonal antibody that recognizes glycophorin B of human erythrocyte membrane. Zhang D, et al. **Infect Immun** 1999 Oct;67(10):5332–7

Distribution of gangliosides, GM1 and GM3, in the rat oviduct. Choo YK. **Mol Cells** 1999 Feb 28;9(1):56–60

ANTAGONISTS & INHIBITORS

Structure–based exploration of the ganglioside GM1 binding sites of Escherichia coli heat–labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Minke WE, et al. **Biochemistry** 1999 May 4;38(18):5684–92

BIOSYNTHESIS

Developmental appearance of nuclear GM1 in neurons of the central and peripheral nervous systems. Kozireski–Chuback D, et al. **Brain Res Dev Brain Res** 1999 Jun 2;115(2):201–8

BLOOD

Acute motor axonal neuropathy associated with IgM anti–GM1 following Mycoplasma pneumoniae infection. Heckmann JG, et al. **Eur Neurol** 1999;41(3):175–6

[Brown–Vialetto–Van Laere syndrome: a case with anti–ganglioside GM1 antibodies and literature review] Sztajzel R, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):51–4 (10 ref.) (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

A simple, nonenzymatic method for desialylating polysialylated ganglio–N–tetraose series gangliosides to produce GM1. Schengrund CL, et al. **J Lipid Res** 1999 Jan;40(1):160–3

CHEMISTRY

Structure–based exploration of the ganglioside GM1 binding sites of Escherichia coli heat–labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Minke WE, et al. **Biochemistry** 1999 May 4;38(18):5684–92

IMMUNOLOGY

Anti–GalNAc–GD1a antibody–associated Guillain–Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Hao Q, et al. **Ann Neurol** 1999 Jun;45(6):758–68

Facts and fallacies on anti–GM1 antibodies: physiology of motor neuropathies [editorial; comment] Kaji R, et al. **Brain** 1999 May;122 (Pt 5):797–8. Comment on: Brain 1999 May;122 (Pt 5):807–16.

Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross–reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain–Barré syndrome. Prendergast MM, et al. **Infect Immun** 1999 Jul;67(7):3698–701

Peripheral neuropathies in lupus patients with anti–GM1 antibodies [editorial; comment] Hashimoto H. **Intern Med** 1999 Sep;38(9):689–90 (8 ref.). Comment on: Intern Med 1999 Sep;38(9):729–32.

Systemic lupus erythematosus demonstrating serum anti–GM1 antibody, with sudden onset of drop foot as the initial presentation [see comments] Matsuki Y, et al. **Intern Med** 1999 Sep;38(9):729–32 (25 ref.). Comment in: Intern Med 1999 Sep;38(9):689–90.

Anti–GM1, anti–central myelin proteins, and anti–cardiolipin autoantibodies during plasma–exchange in Guillain–Barré syndrome (GBS). Matà S, et al. **J Clin Apheresis** 1998; 13(4):155–62

Ganglioside GM1 mimicry in Campylobacter strains from sporadic infections in the United States [published erratum appears in J Infect Dis 1999 Jun;179(6):1593] Nachamkin I, et al. **J Infect Dis** 1999 May;179(5):1183–9

Regulation of transmembrane signaling by ganglioside GM1: interaction of anti–GM1 with Neuro2a cells. Ravichandra B, et al. **J Neurochem** 1999 Aug;73(2):557–67

Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain–derived rabies vaccine. Laouini D, et al. **J Neuroimmunol** 1998 Nov 2;91(1–2):63–72

Structure–function studies of an anti–asialo GM1 antibody obtained from a phage display library. Qiu JX, et al. **J Neuroimmunol** 1999 Jun 1;97(1–2):172–81

Hyperreflexia in Guillain–Barré syndrome: relation with acute motor axonal neuropathy and anti–GM1 antibody. Kuwabara S, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):180–4

Autoantibodies to GM1b and GalNAc–GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. Yuki N, et al. **J Neurol Sci** 1999 Apr 1;164(2):134–8

Axonal involvement at the common entrapment sites in Guillain–Barré syndrome with IgG anti–GM1 antibody. Kuwabara S, et al. **Muscle Nerve** 1999 Jul;22(7):840–5

Diaphragmatic paralysis with monoclonal gammopathy and antiganglioside GM1 antibodies. Dozier CE, et al **Neurology** 1999 May 12;52(8):1715–6

Two patterns of clinical recovery in Guillain–Barré syndrome with IgG anti–GM1 antibody. Kuwabara S, et al. **Neurology** 1998 Dec;51(6):1656–60

Haemophilus influenzae has a GM1 ganglioside–like structure and elicits Guillain–Barré syndrome. Mori M, et al. **Neurology** 1999 Apr 12;52(6):1282–4

Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Weiss MD, et al. **Neurology** 1998 Dec;51(6):1738–41

[Clinical utility of measurement for anti–GM1 and anti–GQ1b antibodies] Tagawa Y, et al. **No To Shinkei** 1998 Sep; 50(9):849–53 (Eng. Abstr.) **(Jpn)**

[Anti–GM1 antibodies did not induce conduction block in vivo] Hirota N. **Rinsho Shinkeigaku** 1999 Jan;39(1):96 **(Jpn)**

[A case of mononeuropathy multiplex associated with anti–GM1 and –SGLPG antibodies in a patient with ongoing Hashimoto disease] Nishihara T, et al. **Rinsho Shinkeigaku** 1998 Oct–Nov;38(10–11):926–30 (Eng. Abstr.) **(Jpn)**

[Lower motor neuron disease (syndrome) associated with anti GM1 antibodies] Mezaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):350–3 (12 ref.) **(Jpn)**

METABOLISM

Glycolipid–protein interaction in the mechanism of signal transduction: studies with a photoactivable ganglioside

analogue. Masserini M, et al. **Acta Biochim Pol** 1998; 45(2):393–401

Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers. Thompson JP, et al. **Biochem Pharmacol** 1998 Sep 1; 56(5):591–7

Interactions of amyloid beta-peptide (1–40) with ganglioside-containing membranes. Matsuzaki K, et al. **Biochemistry** 1999 Mar 30;38(13):4137–42

Selection of ganglioside GM1-binding peptides by using a phage library. Matsubara T, et al. **FEBS Lett** 1999 Aug 6;456(2):253–6

Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons. Pitto M, et al. **FEBS Lett** 1998 Nov 13;439(1-2):93–6

Gangliosides GM1 and GD1b are not polarized in mature hippocampal neurons. Shogomori H, et al. **FEBS Lett** 1999 Sep 17;458(2):107–11

Antagonistic effect of ganglioside GM1 and GM3 on the activity and conformation of sarcoplasmic reticulum Ca(2+)-ATPase. Wang Y, et al. **FEBS Lett** 1999 Aug 20; 457(1):144–8

The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. de Haan L, et al. **Immunol Cell Biol** 1998 Jun;76(3):270–9 (95 ref.)

Purification and characterization of a novel protein produced by Bifidobacterium longum SBT2928 that inhibits the binding of enterotoxigenic Escherichia coli Pb176 (CFA/II) to gangliotetraosylceramide. Fujiwara S, et al. **J Appl Microbiol** 1999 Apr;86(4):615–21

High levels of GM1-ganglioside beta-galactosidase in the salivary glands and GM1-like-ganglioside storage in parotids of deficient mice. Nowroozi N, et al. **J Craniofac Genet Dev Biol** 1999 Jan-Mar;19(1):41–7

Intracellular distribution of a biotin-labeled ganglioside, GM1, by immunoelectron microscopy after endocytosis in fibroblasts. Möbius W, et al. **J Histochem Cytochem** 1999 Aug;47(8):1005–14

The 1.25 A resolution refinement of the cholera toxin B-pentamer: evidence of peptide backbone strain at the receptor-binding site. Merritt EA, et al. **J Mol Biol** 1998 Oct 9;282(5):1043–59

Upregulation of nuclear GM1 accompanies axon-like, but not dendrite-like, outgrowth in NG108-15 cells. Kozireski-Chuback D, et al. **J Neurosci Res** 1999 Jan 1; 55(1):107–18

Binding of cholera toxin B subunit: a surface marker for murine microglia but not oligodendrocytes or astrocytes. Nedelkoska L, et al. **J Neurosci Res** 1998 Sep 1; 53(5):605–12

AsGM1+ NK cells prevent metastasis of invading LD-MCA-38 tumor cells in the nude mouse. Volpe CM, et al. **J Surg Res** 1999 Jun 15;84(2):157–61

Expression of the GM1-species, [NeuN]-GM1, in a case of human glioma. Fredman P, et al. **Neurochem Res** 1999 Feb; 24(2):275–9

PHARMACOLOGY

Ganglioside GM1 potentiates NGF action on axotomised medial septal cholinergic neurons. Panni MK, et al. **Brain Res** 1998 Nov 23;812(1-2):76–80

Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation. Schneider JS, et al. **Brain Res** 1998 Nov 30;813(1):82–7

Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition. Davies J, et al. **Eur Respir J** 1999 Mar;13(3):565–70

Effect of the mono- and tetra-sialogangliosides, GM1 and GQ1b, on long-term potentiation in the CA1 hippocampal neurons of the guinea pig. Furuse H, et al. **Exp Brain Res** 1998 Dec;123(3):307–14

Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity. Palermo-Neto J, et al. **Gen Pharmacol** 1999 Feb;32(2):265–70

Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium. Tong HH, et al. **Microb Pathog** 1999 Feb;26(2):111–9

GM1 monosialoganglioside pretreatment protects against soman-induced seizure-related brain damage. Ballough GP, et al. **Mol Chem Neuropathol** 1998 May;34(1):1–23

Decreased neuropeptide content in the spinal cord of aged rats: the effect of GM1 ganglioside. Goettl VM, et al. **Neuroreport** 1999 Feb 25;10(3):513–6

GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats. Goettl VM, et al. **Neuroscience** 1999;92(3):991–1000

GM1 produces attenuation of short-term memory deficits in Hebb-Williams maze performance after unilateral entorhinal cortex lesions. Glasier MM, et al. **Physiol Behav** 1999 May;66(3):441–6

Ganglioside GM1 attenuates scopolamine-induced amnesia in rats and mice. Silva RH, et al. **Psychopharmacology (Berl)** 1999 Jan;141(2):111–7

Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Crain SM, et al. **Trends Pharmacol Sci** 1998 Sep;19(9):358–65

PHYSIOLOGY

The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. de Haan L, et al. **Immunol Cell Biol** 1998 Jun;76(3):270–9 (95 ref.)

Pili binding to asialo-GM1 on epithelial cells can mediate cytotoxicity or bacterial internalization by Pseudomonas aeruginosa. Comolli JC, et al. **Infect Immun** 1999 Jul; 67(7):3207–14

Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. Slevin M, et al. **Int J Cancer** 1999 Jul 30;82(3):412–23

Axonogenesis in neuro-2a cells correlates with GM1 upregulation in the nuclear and plasma membranes. Kozireski-Chuback D, et al. **J Neurosci Res** 1999 Aug 15; 57(4):541–50

GM1 inhibits amyloid beta-protein-induced cytokine release. Ariga T, et al. **Neurochem Res** 1999 Feb;24(2):219–26

Myelin basic protein and myelin basic protein peptides induce the proliferation of Schwann cells via ganglioside GM1 and the FGF receptor. Tzeng SF, et al. **Neurochem Res** 1999 Feb;24(2):255–60

Evaluation of GM1 ganglioside-mediated apoptosis in feline thymocytes. Zhou J, et al. **Vet Immunol Immunopathol** 1998 Nov 6;66(1):25–42

THERAPEUTIC USE

[Gangliosides prevent reduction in exploratory activity and delayed neuronal death in gerbils subjected to transitory cerebral ischemia] Garcia-Salman JD, et al. **Rev Neurol** 1998 Oct;27(158):585–8 (Eng. Abstr.) **(Spa)**

G(M2) GANGLIOSIDE

see related
SANDHOFF DISEASE
TAY-SACHS DISEASE

BIOSYNTHESIS

Reevaluating the effect of Brefeldin A (BFA) on ganglioside synthesis: the location of GM2 synthase cannot be deduced from the inhibition of GM2 synthesis by BFA. Young WW Jr, et al. **Glycobiology** 1999 Jul;9(7):689–95

IMMUNOLOGY

Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo. Fukumoto H, et al. **Int J Cancer** 1999 Aug 27;82(5):759–64

Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Hanibuchi M, et al. **Int J Cancer** 1998 Nov 9;78(4):480–5

Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2. Wu X, et al. **J Immunol** 1999 Jan 1;162(1):533–9

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. Takahashi T, et al. **J Invest Dermatol** 1999 Feb;112(2):205–9

Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. Cavanna B, et al. **J Neuroimmunol** 1999 Feb 1;94(1-2):157–64

Ganglioside vaccines with emphasis on GM2. Livingston P. **Semin Oncol** 1998 Dec;25(6):636–45 (63 ref.)

METABOLISM

Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells. Igdoura SA, et al. **Hum Mol Genet** 1999 Jun;8(6):1111–6

Ganglioside GM2-activator protein and vesicular transport in collecting duct intercalated cells. Mundel TM, et al. **J Am Soc Nephrol** 1999 Mar;10(3):435–43

Structural basis for the resistance of Tay-Sachs ganglioside GM2 to enzymatic degradation. Li YT, et al. **J Biol Chem** 1999 Apr 9;274(15):10014–8

G(M2)-ganglioside metabolism in situ in mucolipidosis IV fibroblasts. Raghavan S, et al. **Neurochem Res** 1999 Apr; 24(4):475–9

GM2 gangliosidosis AB variant: clinical and biochemical studies of a Japanese patient. Sakuraba H, et al. **Neurology** 1999 Jan 15;52(2):372–7

PHARMACOLOGY

GM2 promotes ciliary neurotrophic factor-dependent rescue of immortalized motor neuron-like cell (NSC-34). Usuki S, et al. **Neurochem Res** 1999 Feb;24(2):281–6

Enhancement of TNF-alpha production by ganglioside GM2 in human mononuclear cell culture. Mizutani K, et al. **Neuroreport** 1999 Mar 17;10(4):703–6

PHYSIOLOGY

Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. Slevin M, et al. **Int J Cancer** 1999 Jul 30;82(3):412–23

G(M3) GANGLIOSIDE

ANALOGS & DERIVATIVES

Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Vázquez AM, et al. **Hybridoma** 1998 Dec;17(6):527–34

ANALYSIS

Distribution of gangliosides, GM1 and GM3, in the rat oviduct. Choo YK. **Mol Cells** 1999 Feb 28;9(1):56–60

CHEMICAL SYNTHESIS

Enzymic glycosphingolipid synthesis on polymer supports. III. Synthesis of GM3, its analog [NeuNAcalpha(2-3)Galbeta(1-4)Glcbeta(1-3)Cer] and their lyso-derivatives. Zehavi U, et al. **Glycoconj J** 1998 Jul;15(7):657–62

CHEMISTRY

Studies of the chemical structure of gangliosides in deer antler, Cervus nippon. Jhon GJ, et al. **Chem Pharm Bull (Tokyo)** 1999 Jan;47(1):123–7

Residual dipolar couplings as new conformational restraints in isotropically 13C-enriched oligosaccharides. Kiddle GR, et al. **FEBS Lett** 1998 Sep 25;436(1):128–30

IMMUNOLOGY

Anti-GM3 antibodies activate calcium inflow and inhibit platelet-derived growth factor beta receptors (PDGFbetar) in T51B rat liver epithelial cells. Golard A. **Glycobiology** 1998 Dec;8(12):1221–5

A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Alonso DF, et al. **Int J Oncol** 1999 Jul;15(1):59–66

Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Nam SM, et al. **Oncol Res** 1999;11(1):9–16

Lack of the induction of anti-ganglioside GM3 antibody in the patients with malignant melanoma in Japanese. Nakano J, et al. **Pigment Cell Res** 1998 Aug;11(4):213–5

METABOLISM

Human fibroblasts in culture metabolize differently exogenous G(M3) ganglioside species containing C18 and C20 sphingosine. Chigorno V, et al. **Acta Biochim Pol** 1998; 45(2):385–92

Atherosclerotic aortic gangliosides enhance integrin-mediated platelet adhesion to collagen. Wen FQ, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):519–24

Antagonistic effect of ganglioside GM1 and GM3 on the activity and conformation of sarcoplasmic reticulum Ca(2+)-ATPase. Wang Y, et al. **FEBS Lett** 1999 Aug 20; 457(1):144–8

Colocalization and complex formation between prosaposin and monosialoganglioside GM3 in neural cells. Misasi R, et al. **J Neurochem** 1998 Dec;71(6):2313–21

Repair of BHK cell surface ganglioside GM3 after its degradation by extracellular sialidase. Sillence DJ, et al. **Mol Membr Biol** 1998 Oct-Dec;15(4):229–35

PHARMACOLOGY

Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Kanda N. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):41–4

Induction of nitric oxide production by ganglioside GM3 in murine peritoneal macrophages activated for tumor cytotoxicity. Ding Y, et al. **In Vivo** 1998 May-Jun; 12(3):357–61

A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase c delta translocation. Garofalo T, et al. **J Biol Chem** 1998 Dec 25; 273(52):35153–60

PHYSIOLOGY

Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Ono M, et al. **Cancer Res** 1999 May 15;59(10):2335–9

Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. Slevin M, et al. **Int J Cancer** 1999 Jul 30;82(3):412–23

Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). Hammache D, et al. **J Virol** 1999 Jun;73(6):5244–8

G(M1) GANGLIOSIDOSIS see **GANGLIOSIDOSIS G(M1)**

G(M2) GANGLIOSIDOSIS, TYPE I see **TAY-SACHS DISEASE**

G(M2) GANGLIOSIDOSIS, TYPE II see **SANDHOFF DISEASE**

GMP see **5'-GUANYLIC ACID**

GMP-PNP see **GUANYLYL IMIDODIPHOSPHATE**

GMP-140 see **P-SELECTIN**

GNATHOSTOMA

Clinical manifestations and immunodiagnosis of gnathostomiasis in Culiacan, Mexico. Diaz Camacho SP, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):908–15

Human gnathostomiasis (nodular migratory eosonophilic panniculitis). Ruiz-Maldonado R, et al. **Int J Dermatol** 1999 Jan;38(1):56–7

Spontaneous larval Gnathostoma nipponicum infection in frogs. Oyamada T, et al. **J Vet Med Sci** 1998 Sep; 60(9):1029–31

[Gnathostomiasis] Fujita K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):458–60 (7 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Three cases of human gnathostomiasis caused by Gnathostoma hispidum, with particular reference to the identification of parasitic larvae. Akahane H, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):611–4

Morphological variation and abnormality of cephalic hooklets of Gnathostoma spinigerum hepatic stage larvae from laboratory infected mice. Rojekittikhun W, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):118–22

ISOLATION & PURIFICATION

Human gnathostomiasis caused by Gnathostoma doloresi, with particular reference to the parasitological investigation of the causative agent. Akahane H, et al. **Ann Trop Med Parasitol** 1998 Sep;92(6):721–6

Gnathostomosis, an emerging foodborne zoonotic disease in Acapulco, Mexico. Rojas-Molina N, et al. **Emerg Infect Dis** 1999 Mar-Apr;5(2):264–6

PHYSIOLOGY

Gnathostome infection in swamp eels, Fluta alba, in central Thailand. Nuamtanong S, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):144–7

Seasonal variation in the intensity of Gnathostoma larvae in swamp eels (Fluta alba) sold in a local market in Bangkok. Rojekittikhun W, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):148–53

GNETOPHYTA see **GYMNOSPERMS**

GNOTOBIOTICS see **GERM-FREE LIFE**

GNRH see **GONADORELIN**

GNRH RECEPTORS see **RECEPTORS, LHRH**

GOALS

Goal neglect and inhibitory limitations: dissociable causes of interference effects in conflict situations. De Jong R, et al. **Acta Psychol (Amst)** 1999 Apr;101(2-3):379–94

Goal attainment scaling as a measure of clinically important change in nursing-home patients. Gordon JE, et al. **Age Ageing** 1999 May;28(3):275–81

The relationship between health and human services and the personal goal-directed activities of persons living with AIDS. DuMont KA, et al. **Am J Community Psychol** 1999 Feb;27(1):55–73

Clinical interpretation of "effect of rehabilitation tasks on organization of movement after stroke" [comment] Flinn NA. **Am J Occup Ther** 1999 Jul-Aug;53(4):345–7. Comment on: Am J Occup Ther 1999 Jul-Aug;53(4):333–44.

Effect of rehabilitation tasks on organization of movement after stroke [see comments] Trombly CA, et al. **Am J Occup Ther** 1999 Jul-Aug;53(4):333–44. Comment in: Am J Occup Ther 1999 Jul-Aug;53(4):345–7.

Goals and goal setting in rehabilitation research [editorial; comment] Basford JR. **Arch Phys Med Rehabil** 1999 May; 80(5):479–80. Comment on: Arch Phys Med Rehabil 1999 May;80(5):481–4.

Speed/accuracy trade-offs in target-directed movements. Plamondon R, et al. **Behav Brain Sci** 1997 Jun; 20(2):279–303; discussion 303–49

A developmental study of the relation between combined learning and performance goals and students' self-regulated learning. Bouffard T, et al. **Br J Educ Psychol** 1998 Sep; 68 (Pt 3):309–19

Manual asymmetries in goal-directed movement: examination of the motor output hypothesis. Binsted G, et al. **Brain Cogn** 1998 Oct;38(1):102–10

Evidence relating to goal planning in rehabilitation [editorial] Wade DT. **Clin Rehabil** 1998 Aug;12(4):273–5

Goals as reference points. Heath C, et al. **Cognit Psychol** 1999 Feb;38(1):79–109

How children change their minds: strategy change can be gradual or abrupt. Alibali MW. **Dev Psychol** 1999 Jan; 35(1):127–45

Children's goals and strategies in response to conflicts within a friendship. Rose AJ, et al. **Dev Psychol** 1999 Jan; 35(1):69–79

The rehabilitation process for the geriatric stroke patient--an exploratory study of goal setting and interventions. Wressle E, et al. **Disabil Rehabil** 1999 Feb;21(2):80–7

Movement-related skin strain associated with goal-oriented lip actions. Connor NP, et al. **Exp Brain Res** 1998 Dec; 123(3):235–41

Adolescents' ideas of normative life span development and personal future goals. Malmberg LE, et al. **J Adolesc** 1999 Feb;22(1):33–47

Recovering from stroke: a qualitative investigation of the role of goal setting in late stroke recovery. Lawler J, et al. **J Adv Nurs** 1999 Aug;30(2):401–9

The participants' views of childbirth education: is there congruency with an enablement framework for patient education? Leeseberg Stamler L. **J Adv Nurs** 1998 Nov; 28(5):939–47

Futility and the goals of medicine. Rhodes R. **J Clin Ethics** 1998 Summer;9(2):194–205

Assessing social validity in clinical treatment research: issues and procedures. Foster SL, et al. **J Consult Clin Psychol** 1999 Jun;67(3):308–19

Are smaller weight losses or more achievable weight loss goals better in the long term for obese patients? Jeffery RW, et al. **J Consult Clin Psychol** 1998 Aug;66(4):641–5

A taxonomy for goal setting in the care of persons with dementia. Bogardus ST Jr, et al. **J Gen Intern Med** 1998 Oct;13(10):675–80

The relationship between the effect of setting a goal on standing broad jump performance and behaviour regulation ability in children with intellectual disability. Kokubun M. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):13–8

Are goals and topics influenced by gender and modality in the initial marriage and family therapy session? Werner-Wilson RJ, et al. **J Marital Fam Ther** 1999 Apr; 25(2):253–62

Daily goals, life goals, and worst fears: means, ends, and subjective well-being. King LA, et al. **J Pers** 1998 Oct; 66(5):713–44

Avoidance personal goals and the personality-illness relationship. Elliot AJ, et al. **J Pers Soc Psychol** 1998 Nov; 75(5):1282–99

Approach and avoidance strength during goal attainment: regulatory focus and the "goal looms larger" effect. Förster J, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1115–31

Goal striving, need satisfaction, and longitudinal well-being: the self-concordance model. Sheldon KM, et al. **J Pers Soc Psychol** 1999 Mar;76(3):482–97

Dispositional and situational goal orientations as discriminators among recreational and competitive league athletes. Ryska TA, et al. **J Soc Psychol** 1999 Jun; 139(3):335–42

Achievement goals, beliefs about the causes of success and reported emotion in post-16 physical education. Spray CM, et al. **J Sports Sci** 1999 Mar;17(3):213–9

Goal-specific influences on the representation of spatial perspective. Taylor HA, et al. **Mem Cognit** 1999 Mar; 27(2):309–19

The control of sequential goal-directed movement: learning to use feedback or central planning? Elliott D, et al. **Motor Control** 1998 Jan;2(1):61–80

Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Balleine BW, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):407–19 (50 ref.)

Outcomes of a nonaversive behavior intervention in intellectually impaired individuals using goal attainment scaling. Mate-Kole CC, et al. **Nurs Res** 1999 Jul-Aug; 48(4):220–5

October 1998 Pew report: supportive of NP goals [news] Sharp N. **Nurse Pract** 1998 Dec;23(12):72, 77

In search of perfection [editorial] **Pediatr Dent** 1998 Nov-Dec;20(7):379

Effects of goal setting on physiological response and performance: comment on Theodorakis, Laparidis, Kioumourtzoglou, and Goudas. Gellatly IR. **Percept Mot Skills** 1999 Feb;88(1):251–2

Realistic expectations on the putting green: within and between days trueness of roll. Koslow R, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1441–2

The goals and limitations of Israel's psychiatric case register. Lichtenberg P, et al. **Psychiatr Serv** 1999 Aug;50(8):1043–8

The role of client choice and target selection in self-management therapy for depression in older adults. Rokke PD, et al. **Psychol Aging** 1999 Mar;14(1):155–69

Hope, goal-blocking thoughts, and test-related anxieties. Snyder CR. **Psychol Rep** 1999 Feb;84(1):206–8

The development of self-perceptions of ability and achievement goals and their relations in physical education. Xiang P, et al. **Res Q Exerc Sport** 1998 Sep;69(3):231–41

Goal-setting in clinical medicine. Bradley EH, et al. **Soc Sci Med** 1999 Jul;49(2):267–78

The needs assessment checklist: a clinical approach to measuring outcome. Kennedy P, et al. **Spinal Cord** 1999 Feb;37(2):136–9

[The motivational dominant and goal-directed behavior] Pavlygina RA. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug;48(4):581–90 (Eng. Abstr.) **(Rus)**

GOALS, ORGANIZATIONAL see **ORGANIZATIONAL OBJECTIVES**

GOAT DISEASES

Prevalence of traumatic myiasis in Hungary: a questionnaire survey of veterinarians. Farkas R, et al. **Vet Rec** 1998 Oct 17;143(16):440–3

BLOOD

Persistence of Anaplasma ovis infection and conservation of the msp-2 and msp-3 multigene families within the genus Anaplasma. Palmer GH, et al. **Infect Immun** 1998 Dec; 66(12):6035–9

Haematological changes and antibody response in trypanotolerant sheep and goats following experimental Trypanosoma congolense infection. Goossens B, et al. **Vet Parasitol** 1998 Nov 27;79(4):283–97

Differential haematological effects of tick-borne fever in sheep and goats. Gokce HI, et al. **Zentralbl Veterinarmed [B]** 1999 Mar;46(2):105–15

The effects of Ehrlichia (Cytoecetes) phagocytophila on the clinical chemistry of sheep and goats. Gokce HI, et al. **Zentralbl Veterinarmed [B]** 1999 Mar;46(2):93–103

CHEMICALLY INDUCED

Optic neuropathy and retinopathy in closantel toxicosis of sheep and goats. Gill PA, et al. **Aust Vet J** 1999 Apr; 77(4):259–61

CLASSIFICATION

[Helminth species of goats in Germany] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):427–31 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Diagnostic evaluation of PCR on dried blood samples from goats experimentally infected with Trypanosoma brucei brucei. de Almeida PP, et al. **Acta Trop** 1998 Jul 30; 70(3):269–76

Use of a recombinant maedi-visna virus protein ELISA for the serologic diagnosis of lentivirus infections in small ruminants. Pasick J. **Can J Vet Res** 1998 Oct;62(4):307–10

Fasciola hepatica: partial characterization of circulating antigens. Rodriguez-Osorio M, et al. **J Parasitol** 1998 Oct; 84(5):1053–5

PCR detection of Clostridium perfringens type D in formalin-fixed, paraffin-embedded tissues of goats and sheep. Warren AL, et al. **Lett Appl Microbiol** 1999 Jul; 29(1):15–9

Pitfalls in the application of enzyme-linked immunoassays for the detection of circulating trypanosomal antigens in serum samples. Rebeski DE, et al. **Parasitol Res** 1999 Jul; 85(7):550–6

Evaluation of cellular and serological diagnostic tests for the detection of Mycobacterium bovis-infected goats. Gutiérrez M, et al. **Vet Microbiol** 1998 Aug 15;62(4):281–90

PCR primer evaluation for the detection of trypanosome DNA in naturally infected goats. Pereira de Almeida PJ, et al. **Vet Parasitol** 1998 Dec 31;80(2):111–6

A sensitive polymerase chain reaction based assay for the detection of Setaria digitata: the causative organism of cerebrospinal nematodiasis in goats, sheep and horses. Wijesundera WS, et al. **Vet Parasitol** 1999 Mar 1; 81(3):225–33

Serodiagnosis of goat warble fly infestation by Przhevalskiana silenus with a commercial ELISA kit. Otranto D, et al. **Vet Rec** 1999 Jun 26;144(26):726–9

Detection and identification of Mycoplasma conjunctivae in infectious keratoconjunctivitis by PCR based on the 16S rRNA gene. Giacometti M, et al. **Zentralbl Veterinarmed [B]** 1999 Apr;46(3):173–80

[Detection of caprine arthritis encephalitis virus in sperm of experimentally infected bucks] Travassos C, et al. **Vet Res** 1998 Nov-Dec;29(6):579–84 (Eng. Abstr.) **(Fre)**

[Investigations on manifestations of vitamin E and selenium deficiency in sheep and goats] Bickhardt K, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Jun;106(6):242–7 (Eng. Abstr.) **(Ger)**

[Evaluation of the California mastitis test (CMT) reaction in goat milk and its interpretation] Winter P, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Jan;106(1):30–4 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Anthelmintic resistance in sheep and goat farms on Peninsular Malaysia. Chandrawathani P, et al. **Vet Parasitol** 1999 May; 82(4):305–10

The relationship between faecal egg count reduction and the lethal dose 50% in the egg hatch assay and larval development assay. Maingi N, et al. **Vet Parasitol** 1998 Jun 15;77(2-3):133–45

Anthelmintic resistance in Pashmina (Cashmere) producing goats in India. Laha R, et al. **Vet Res Commun** 1999 May; 23(3):187–9

[Investigations on the treatment of cerebrospinal nematode infections in goats] Pusterla N, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Jan;106(1):22–4 (Eng. Abstr.) **(Ger)**

ECONOMICS

The control of heartwater on large-scale commercial and smallholder farms in Zimbabwe. Chamboko T, et al. **Prev Vet Med** 1999 Apr 9;39(3):191–210

An assessment of the economic impact of heartwater (Cowdria ruminantium infection) and its control in Zimbabwe. Mukhebi AW, et al. **Prev Vet Med** 1999 Apr 9;39(3):173–89

ENZYMOLOGY

Inducible nitric oxide synthase is expressed in joints of goats in the late stage of infection with caprine arthritis encephalitis virus. Lechner F, et al. **Clin Exp Immunol** 1999 Jul;117(1):70–5

EPIDEMIOLOGY

Tick-borne rickettiosis in Guadeloupe, the French West Indies: isolation of Rickettsia africae from Amblyomma variegatum ticks and serosurvey in humans, cattle, and goats. Parola P, et al. **Am J Trop Med Hyg** 1999 Jun; 60(6):888–93

Evidence for freedom from Johne's disease in cattle and goats in Western Australia. Ellis TM, et al. **Aust Vet J** 1998 Sep; 76(9):630–3

PCR-RFLP of outer membrane proteins gene of Dichelobacter nodosus: a new tool in the epidemiology of footrot. Ghimire SC, et al. **Epidemiol Infect** 1999 Jun; 122(3):521–8

Screwworm returns to vex Texas [news] **J Am Vet Med Assoc** 1999 Jan 15;214(2):179

Molecular investigation of a listeriosis outbreak in goats caused by an unusual strain of Listeria monocytogenes. Wiedmann M, et al. **J Am Vet Med Assoc** 1999 Aug 1; 215(3):369–71, 340

Study of Akabane infection in Saudi Arabia by the use of sentinel ruminants. Abu Elzein EM, et al. **J Comp Pathol** 1998 Nov;119(4):473–8

Epidemic of transmissible spongiform encephalopathy in sheep and goats in Italy [letter] Agrimi U, et al. **Lancet** 1999 Feb 13;353(9152):560–1

A study on bluetongue virus infection in Saudi Arabia using sentinel ruminants. Abu Elzein EM, et al. **Onderstepoort J Vet Res** 1998 Dec;65(4):243–51

Mapping goat warble fly distribution and related problems. Giangaspero A, et al. **Parassitologia** 1997 Dec;39(4):423–6

The prevalence of goat hypodermosis in Greece. Papadopoulos E, et al. **Parassitologia** 1997 Dec;39(4):427–9

Associations of veterinary services and farmer characteristics with the prevalences of brucellosis and border disease in small ruminants in Spain. Mainar-Jaime RC, et al. **Prev Vet Med** 1999 Jun 11;40(3–4):193–205

Risk factors for brucellosis seropositivity of goat herds in the Mexicali Valley of Baja California, Mexico. Mikolon AB, et al. **Prev Vet Med** 1998 Dec 1;37(1–4):185–95

Prevalence and distribution of animal trypanosomosis on Buvuma islands in Lake Victoria, Uganda. Magona JW, et al. **Trop Anim Health Prod** 1999 Apr;31(2):83–7

Rinderpest antibody detected in sheep and goats before an outbreak of rinderpest reported in cattle in northern Tanzania. Wambura PN, et al. **Trop Anim Health Prod** 1999 Feb;31(1):9–14

Rift valley fever surveillance in the lower Senegal river basin: update 10 years after the epidemic. Thonnon J, et al. **Trop Med Int Health** 1999 Aug;4(8):580–5

The role of small ruminants in the epidemiology and transmission of foot-and-mouth disease. Barnett PV, et al. **Vet J** 1999 Jul;158(1):6–13 (60 ref.)

Occurrence and diversity of coccidia in indigenous, Saanen and crossbred goats in South Africa. Harper CK, et al. **Vet Parasitol** 1999 Mar 22;82(1):1–9

Prevalence of Sarcocystis spp. in meat-producing animals in Iraq. Latif BM, et al. **Vet Parasitol** 1999 Jul;84(1–2):85–90

Prevalence of Echinococcus granulosus infection in stray dogs and herbivores in Shiraz, Iran. Mehrabani D, et al. **Vet Parasitol** 1999 Oct 1;86(3):217–20

Protostrongylid nematode infection of chamois (Rupicapra rupicapra) at the Bauges massif (French Alps). Nocture M, et al. **Vet Parasitol** 1998 Jun 15;77(2–3):153–61

Toxoplasmosis and iodine deficiency in Angora goats. Slosárková S, et al. **Vet Parasitol** 1999 Feb 25;81(2):89–97

Modelling the prevalence of Echinococcus and Taenia species in small ruminants of different ages in northern Jordan. Torgerson PR, et al. **Vet Parasitol** 1998 Sep; 79(1):35–51

Natural occurrence of scrapie in goats in Italy [see comments] Capucchio MT, et al. **Vet Rec** 1998 Oct 17;143(16):452–3 . Comment in: Vet Rec 1998 Oct 31;143(18):512.

Seroprevalence of Babesia ovis in goats in Catalonia, Spain. Ferrer D, et al. **Vet Rec** 1998 Nov 7;143(19):536–7

Outbreak of coenurosis (Taenia species) in anglonubian goats in the Sultanate of Oman. el Sinnary KA, et al. **Vet Rec** 1999 Mar 13;144(11):296–7

Incidence of Oestrus ovis infestation in Borno-white Sahel goats in the semi-arid zone of Nigeria. Biu AA, et al. **Vet Res** 1999 Jan-Feb;30(1):109–12

[Toxoplasmosis in goats in the Netherlands: a pilot study] Antonis AF, et al. **Tijdschr Diergeneeskd** 1998 Oct 1; 123(19):561–5 (Eng. Abstr.) **(Dut)**

ETIOLOGY

Hepatic encephalopathy associated with paratuberculosis in a goat. Rubin JL, et al. **J Am Vet Med Assoc** 1999 Jul 15;215(2):236–8, 211

Development of goitre and enterohepatonephropathy in Nubian Goats fed with pearl millet (Pennisetum typhoides). Abel Gadir WS, et al. **Vet J** 1999 Mar;157(2):178–85

IMMUNOLOGY

Immunohistochemical study of the local immune response to Fasciola hepatica in primarily and secondarily infected goats. Pérez J, et al. **Vet Immunol Immunopathol** 1998 Aug 31;64(4):337–48

Cellular and humoral responses in the respiratory tract of goats following intranasal stimulation using formalin-killed Pasteurella haemolytica A2. Zamri-Saad M, et al. **Vet Microbiol** 1999 Mar 12;65(3):233–40

Resistance of Galla and Small East African goats in the sub-humid tropics to gastrointestinal nematode infections and the peri-parturient rise in faecal egg counts. Baker RL, et al. **Vet Parasitol** 1998 Sep;79(1):53–64

Liver pathology and immune response in experimental Fasciola hepatica infections of goats. Martínez-Moreno A, et al. **Vet Parasitol** 1999 Mar 22;82(1):19–33

Antibody response in goats experimentally infected with Toxoplasma gondii. Vitor RW, et al. **Vet Parasitol** 1999 Mar 1;81(3):259–63

Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Uzal FA, et al. **Vet Rec** 1998 Oct 24;143(17):472–4

Cross-reactive antigens of Haemonchus contortus adult worms in Teladorsagia circumcincta infected goats. Molina JM, et al. **Vet Res** 1999 Jul-Aug;30(4):393–9

Antibody response in goats vaccinated with liposome-adjuvanted Clostridium perfringens type D epsilon toxoid. Uzal FA, et al. **Vet Res Commun** 1999 May; 23(3):143–50

MICROBIOLOGY

Mycobacterium tuberculosis subsp. caprae subsp. nov.: a taxonomic study of a new member of the Mycobacterium tuberculosis complex isolated from goats in Spain. Aranaz A, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1263–73

Identification and characterisation of serogroup M among Nepalese isolates of Dichelobacter nodosus, the transmitting agent of footrot in small ruminants. Ghimire SC, et al. **Vet Microbiol** 1998 Jul;62(3):217–33

Aetiology of caprine contagious agalactia syndrome in Extremadura, Spain. Gil MC, et al. **Vet Rec** 1999 Jan 2; 144(1):24–5

Rhodococcus equi infections in goats. Tkachuk-Saad O, et al. **Vet Rec** 1998 Sep 12;143(11):311–2

Resistance of ovine, caprine and bovine endothelial cells to Clostridium perfringens type D epsilon toxin in vitro. Uzal FA, et al. **Vet Res Commun** 1999 Aug;23(5):275–84

Serotypes of Pasteurella haemolytica and Pasteurella trehalosi isolated from farm animals in Hungary. Fodor L, et al. **Zentralbl Veterinarmed [B]** 1999 May;46(4):241–7

PARASITOLOGY

Pathological and immunohistochemical study of the liver and hepatic lymph nodes in goats infected with one or more doses of Fasciola hepatica. Pérez J, et al. **J Comp Pathol** 1999 Feb;120(2):199–210

Seasonal occurrence of coccidia in a mixed herd of sheep and goats at Nebo, northern province, South Africa. Harper CK, et al. **J S Afr Vet Assoc** 1998 Sep;69(3):93–4

Eimeria minasensis n. sp. (Apicomplexa: Eimeriidae) in the domestic goat Capra hircus, from Brazil. Silva AC, et al. **Mem Inst Oswaldo Cruz** 1998 Nov-Dec;93(6):741–4

Periparturient rise in fecal egg counts associated with prolactin concentration increase in French Alpine dairy goats. Chartier C, et al. **Parasitol Res** 1998 Oct; 84(10):806–10

Stable and unstable environments influence the genetic diversity of the nematode Teladorsagia circumcincta, a parasite of small ruminants. Gasnier N, et al. **Parasitol Res** 1998 Aug;84(8):676–81

Hypoderma lineatum antigen and anti-Przhevalskiana silenus antibodies: cross-reactivity and antibody kinetics in naturally infested goats. Otranto D, et al. **Parassitologia** 1998 Sep;40(3):325–31

Patent infection with Setaria digitata in goats in Saudi Arabia. El-Azazy OM, et al. **Vet Parasitol** 1999 Mar 31;82(2):161–6

Studies on coccidiosis in goats in Poland. Balicka-Ramisz A. **Vet Parasitol** 1999 Mar 15;81(4):347–9

Estimation of the growth patterns of Oestrus ovis L. larvae hosted by goats in Baja California Sur, Mexico. Cepeda-Palacios R, et al. **Vet Parasitol** 1999 Sep 30; 86(2):119–26

Isoenzyme activities of different strains of Cryptosporidium parvum. El-Ghaysh A, et al. **Vet Parasitol** 1999 Mar 1; 81(3):195–200

Comparative evaluation of two emigration/sedimentation techniques for the recovery of dictyocaulid and protostrongylid larvae from faeces. McKenna PB. **Vet Parasitol** 1999 Jan 28;80(4):345–51

Health and productivity of traditionally managed Djallonke sheep and West African dwarf goats under high and moderate trypanosomosis risk. Osaer S, et al. **Vet Parasitol** 1999 Mar 31;82(2):101–19

Serological survey of antibodies to Toxoplasma gondii in goats, sheep, cattle and water buffaloes in Bahia State, Brazil. Pita Gondim LF, et al. **Vet Parasitol** 1999 May; 82(4):273–6

Natural evolution of gastrointestinal nematodes in goats (Capra hircus) in the semi-arid ecosystem of the Paraíba backwoods, northeastern Brazil. Silva WW, et al. **Vet Parasitol** 1998 Dec 15;80(1):47–52

Arthropod parasites of Nubian ibexes (Capra ibex nubiana) and gazelles (Gazella gazella) in Israel. Yeruham I, et al. **Vet Parasitol** 1999 Jun 15;83(2):167–73

Duration of activity of oral moxidectin against Haemonchus contortus, Teladorsagia circumcincta and Trichostrongylus colubriformis in goats. Torres-Acosta JF, et al. **Vet Rec** 1999 Jun 5;144(23):648–9

Cross-reactive antigens of Haemonchus contortus adult worms in Teladorsagia circumcincta infected goats. Molina JM, et al. **Vet Res** 1999 Jul-Aug;30(4):393–9

PATHOLOGY

Coccidiosis of Brunner's glands in feral goats. Main DC, et al. **Aust Vet J** 1999 Jan;77(1):49

Adenocarcinoma of the small intestine in a goat. Pérez V, et al. **J Comp Pathol** 1998 Oct;119(3):311–6

Comparison of the effects of Clostridium perfringens type D culture supernates in ligated intestinal loops of goats and sheep. Uzal FA, et al. **J Comp Pathol** 1999 Aug; 121(2):127–38

Primary cilium expression in cells from normal and pathological caprine skin [letter] Roperto F, et al. **J Submicrosc Cytol Pathol** 1999 Jan;31(1):169–71

A lysosomal storage disease induced by Ipomoea carnea in goats in Mozambique. de Balogh KK, et al. **J Vet Diagn Invest** 1999 May;11(3):266–73

Disseminated Rhodococcus equi infection in two goats. Davis WP, et al. **Vet Pathol** 1999 Jul;36(4):336–9

Progressive hindlimb paraparesis in a goat associated with a vascular hamartoma. Middleton JR, et al. **Vet Rec** 1999 Mar 6;144(10):264–5

Hepatic lipidosis associated with cobalt deficiency in Omani goats. Johnson EH, et al. **Vet Res Commun** 1999 Jun; 23(4):215–21

PHYSIOPATHOLOGY

Stress-related hormonal and metabolic responses to restraint, with and without butorphanol administration, in pre-conditioned goats. Carroll GL, et al. **Lab Anim Sci** 1998 Aug;48(4):387–90

The response of Nigerian West African Dwarf goats to experimental infections with Haemonchus contortus. Fakae BB, et al. **Res Vet Sci** 1999 Apr;66(2):147–58

Changing reactivity of caprine and ovine mononuclear phagocytes throughout part of the life cycle of Oestrus ovis: assessment through spontaneous and inductible NO production. Duranton C, et al. **Vet Res** 1999 Jul-Aug; 30(4):371–6

[Reactions of cells of nasal and sinusoidal mucosa of goats and sheep naturally infected by Oestrus ovis Linné 1758 (Diptera: Oestridae)] Nguyen VK, et al. **Parasite** 1999 Jun; 6(2):141–9 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Workshop on irradiated larval vaccines. Le Jambre LF, et al. **Int J Parasitol** 1999 Jan;29(1):193–8

Efficacy of flumethrin pour-on against Damalinia caprae of goats (Capra hircus). Garg SK, et al. **Trop Anim Health Prod** 1998 Oct;30(5):273–8

Use of mass vaccination with a reduced dose of REV 1 vaccine for Brucella melitensis control in a population of small ruminants. Scharp DW, et al. **Trop Anim Health Prod** 1999 Jun;31(3):135–41

Protection of kids against Cryptosporidium parvum infection after immunization of dams with CP15-DNA. Sagodira S, et al. **Vaccine** 1999 May 14;17(19):2346–55

Biological control of nematode parasites of livestock in Fiji: screening of fresh dung of small ruminants for the presence of nematophagous fungi. Manueli PR, et al. **Vet Parasitol** 1999 Feb 1;81(1):39–45

Faecal egg counts in Angora goats following natural or experimental challenge with nematode parasites: within-flock variability and repeatabilities. Vlassoff A, et al. **Vet Parasitol** 1999 Jul;84(1–2):113–23

The pharmacokinetics and efficacy of long-term low-level and split-dose administration of albendazole through in-feed formulations against ovine and caprine parasitic gastroenteritis. Sanyal PK. **Vet Res Commun** 1998 Nov; 22(7):467–77

SURGERY

Urinary bladder marsupialization for treatment of obstructive urolithiasis in male goats. May KA, et al. **Vet Surg** 1998 Nov-Dec;27(6):583–8

TRANSMISSION

Transmission of virulent footrot between sheep and goats. Ghimire SC, et al. **Aust Vet J** 1999 Jul;77(7):450–3

Experimentally induced bovine spongiform encephalopathy did not transmit via goat embryos. Foster J, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):517-24

The oral route as a potential way of transmission of Schistosoma bovis in goats. Boulanger D, et al. **J Parasitol** 1999 Jun;85(3):464-7

Natural occurrence of scrapie in goats in Italy [letter; comment] Andrews AH. **Vet Rec** 1998 Oct 31;143(18):512 Comment on: Vet Rec 1998 Oct 17;143(16):452-3.

ULTRASONOGRAPHY

Theriogenology question of the month. The goat is pseudopregnant (hydrometra). Waldow D. **J Am Vet Med Assoc** 1999 Jan 15;214(2):195-6

URINE

Calcium oxalate crystalluria in a goat. Clark P, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):77-8

VIROLOGY

Isolation of caprine arthritis encephalitis virus from goats in Mexico. Daltabuit Test M, et al. **Can J Vet Res** 1999 Jul;63(3):212-5

A preliminary study on the pathogenicity of a strain of caprine herpesvirus-1. Tempesta M, et al. **Comp Immunol Microbiol Infect Dis** 1999 Apr;22(2):137-43

Analysis of ruminant respiratory syncytial virus isolates by RNAse protection of the G glycoprotein transcripts. Alansari H, et al. **J Vet Diagn Invest** 1999 May;11(3):215-20

Immunohistochemical detection of peste des petits ruminants viral antigen in formalin-fixed, paraffin-embedded tissues from cases of naturally occurring infection. Eligulashvili R, et al. **J Vet Diagn Invest** 1999 May;11(3):286-8

Improved detection of capripoxvirus in biopsy samples by PCR. Ireland DC, et al. **J Virol Methods** 1998 Sep;74(1):1-7

Natural reactivation of caprine herpesvirus 1 in latently infected goats. Tempesta M, et al. **Vet Rec** 1998 Aug 15; 143(7):200

PCR detection of lentiviral GAG segment DNA in the white blood cells of sheep and goats. Wagter LH, et al. **Vet Res Commun** 1998 Jul;22(5):355-62

Concealed locations of lentiviruses in caprine arthritis encephalitis system. Perk K. **Virology** 1999 Jan 5;253(1):8-9

GOATPOX VIRUS see **CAPRIPOXVIRUS**

GOATS

A method for differential delivery of intravenous drugs to the head and torso of the goat. Antognini JF, et al. **Anesth Analg** 1998 Dec;87(6):1450-2

Anesthetic potency and cardiopulmonary effects of sevoflurane in goats: comparison with isoflurane and halothane. Hikasa Y, et al. **Can J Vet Res** 1998 Oct; 62(4):299-306

Effects of high pressure and heat treatment on the mineral balance of goats' milk. de la Fuente MA, et al. **J Dairy Res** 1999 Feb;66(1):65-72

15N enrichment of casein amino acids in the milk from goats given a single intravenous dose of L-[15N]leucine. Rubert-Alemán J, et al. **J Dairy Res** 1999 May;66(2):283-8

Fatty acid composition of caprine milk: major, branched-chain, and trans fatty acids. Alonso L, et al. **J Dairy Sci** 1999 May;82(5):878-84

Seasonal changes in protein composition of whey from commercial manufacture of caprine and ovine specialty cheeses. Casper JL, et al. **J Dairy Sci** 1998 Dec; 81(12):3117-22

Effect of high pressure homogenization on microbial and chemico-physical characteristics of goat cheeses. Guerzoni ME, et al. **J Dairy Sci** 1999 May;82(5):851-62

The primary structure of caprine PP3: amino acid sequence, phosphorylation, and glycosylation of component PP3 from the proteose-peptone fraction of caprine milk. Lister IM, et al. **J Dairy Sci** 1998 Aug;81(8):2111-5

Type of milk consumed can influence plasma concentrations of fatty acids and minerals and body composition in infant and weanling pigs. Murry AC Jr, et al. **J Nutr** 1999 Jan; 129(1):132-8

Immunoglobulin G concentration and neonatal survival of goat kids delivered in a pen or on open range. Mellado M, et al. **Prev Vet Med** 1998 Dec 1;37(1-4):33-9

Evaluation of cervical laminectomy and laminoplasty. A longitudinal study in the goat model. Baisden J, et al. **Spine** 1999 Jul 1;24(13):1283-8; discussion 1288-9

Radiographic diagnosis: pulmonary lymphosarcoma in a goat. Rozear L, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec; 39(6):528-31

Fibroblastic osteosarcoma in a chamois (Rupicapra pyrenaica parva). Pérez-Martínez C, et al. **Vet Rec** 1999 Feb 6; 144(6):154

Effects of subarachnoid xylazine and medetomidine on haemodynamics and ECG in goats. Kinjavdekar P, et al. **Zentralbl Veterinarmed A** 1999 Jul;46(5):271-5

ANATOMY & HISTOLOGY

Tongue papillae in goat: a scanning electron-microscopic study. Kumar P, et al. **Anat Histol Embryol** 1998 Dec; 27(6):355-7

Characterization and distribution of B cells in the lymphoid organs of goats. Pallarés FJ, et al. **Anat Histol Embryol** 1999 Jul;28(3):171-6

The comparative anatomical study of the parietal region of the skull of the Korean native goat (Capra hircus). Yi SJ, et al. **Anat Histol Embryol** 1998 Oct;27(5):323-5

Histomorphological study on pattern of fluid movement in cortical bone in goats. Qin L, et al. **Anat Rec** 1999 Aug 1;255(4):380-7

The ultrastructure of the pineal gland in the goat. Lewczuk B, et al. **Folia Histochem Cytobiol** 1999;37(2):77-8

Identification of cell types in the developing goat mammary gland. Li P, et al. **Histochem J** 1999 Jun;31(6):379-93

An anatomic atlas of the medulla oblongata of the adult goat. Dean C, et al. **J Appl Physiol** 1999 Sep;87(3):1220-9

[Comparative tomography of the lymph nodes of the Peulh Peulh sheep and the Sahel goat. II. Lymph nodes of the caudal vascular net. (Pelvic limbs, pelvis, abdomen and thorax)] Agba KC, et al. **Dakar Med** 1996;41(1):11-20 (Eng. Abstr.) **(Fre)**

[Comparative tomography of the lymph nodes of the Peulh Peulh sheep and the Sahel goat. I: Lymph nodes of the cranial vascular net (head, neck and thoracic limb)] Agba KC, et al. **Dakar Med** 1996;41(1):41-6 (Eng. Abstr.) **(Fre)**

[Pulmonary blood vessels in goats] Roos H, et al. **Anat Histol Embryol** 1999 May;28(2):131-7 (Eng. Abstr.) **(Ger)**

BLOOD

Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-linked immunosorbent assay results. Willman JH, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):615-6

Purification and properties of proline-rich antimicrobial peptides from sheep and goat leukocytes. Shamova O, et al. **Infect Immun** 1999 Aug;67(8):4106-11

Vascular sources of phenylalanine, tyrosine, lysine, and methionine for casein synthesis in lactating goats. Bequette BJ, et al. **J Dairy Sci** 1999 Feb;82(2):362-77

Nitroblue tetrazolium reduction of neutrophils in heat stressed goats is not influenced by selenium and vitamin E injection. Katamoto H, et al. **J Vet Med Sci** 1998 Nov; 60(11):1243-9

EMBRYOLOGY

Endocrinological and biophysical responses to further reduction in oxygenation following sustained hypoxemia in fetal goats. Endo C, et al. **J Matern Fetal Med** 1999 Jul-Aug;8(4):184-9

GENETICS

Detection of the goat as2-casein genetic variants by ASA-PCR. Parma P, et al. **Anim Genet** 1999 Jun;30(3):231

A PstI PCR-RFLP at the goat CSN1S2 gene. Ramunno L, et al. **Anim Genet** 1999 Jun;30(3):242

Genetic diversity in Swiss goat breeds based on microsatellite analysis. Saitbekova N, et al. **Anim Genet** 1999 Feb; 30(1):36-41

Caprine testicular hypoplasia associated with sexual reversion decreases the expression of insulin-like growth factor II (IGF-II) mRNA in testes. Flores JM, et al. **Anim Reprod Sci** 1998 Oct 9;52(4):279-88

Chromatin structures of goat and sheep beta-lactoglobulin gene differ. Pena RN, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):649-53

Isolation and characterization of a genomic region upstream from the ovine Na+/d-glucose cotransporter (SGLT1) cDNA. Wood IS, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):533-7

High resolution RBA-banding comparison between early prometaphase chromosomes of cattle (Bos taurus L.) and goat (Capra hircus L.) at 700 band level. Di Berardino D, et al. **Cytogenet Cell Genet** 1998;83(1-2):130-8

Assignment of the bovine aromatase encoding gene CYP19 to 10q26 in goat and 7q24-->q31 in sheep. Goldammer T, et al. **Cytogenet Cell Genet** 1999;85(3-4):258-9

Cytogenetic study of some tissues and age-related changes in cell proportions in a goat-sheep chimera. Jaszczak K, et al. **Cytogenet Cell Genet** 1999;84(1-2):55-7

Physical mapping of the bovine, caprine and ovine homologues of the paired box gene PAX8. López-Corrales NL, et al. **Cytogenet Cell Genet** 1999;84(3-4):179-81

Comparative gene mapping: a fine-scale survey of chromosome rearrangements between ruminants and humans. Schibler L, et al. **Genome Res** 1998 Sep;8(9):901-15

High-resolution human/goat comparative map of the goat polled/intersex syndrome (PIS): the human homologue is contained in a human YAC from HSA3q23. Vaiman D, et al. **Genomics** 1999 Feb 15;56(1):31-9

Studies of synaptonemal complexes in farm mammals--a review. Switoński M, et al. **J Hered** 1998 Nov-Dec; 89(6):473-80 (71 ref.)

Duplicate growth hormone genes in sheep and goat. Wallis M, et al. **J Mol Endocrinol** 1998 Aug;21(1):1-5 (28 ref.)

Cloned genes, goats, and the future of the biopharm [editorial] **Nat Biotechnol** 1999 May;17(5):405

Production of goats by somatic cell nuclear transfer. Baguisi A, et al. **Nat Biotechnol** 1999 May;17(5):456-61

GROWTH & DEVELOPMENT

The effect of bovine somatotropin treatment on production of lactating angora does with kids. Davis JJ, et al. **J Anim Sci** 1999 Jan;77(1):17-24

Heat energy for growing goats and sheep grazing different pastures in the summer. Herselman MJ, et al. **J Anim Sci** 1999 May;77(5):1258-65

IMMUNOLOGY

Postnatal development of lymphocyte subpopulations in the intestinal lymph nodes in goats. Seva J, et al. **Anat Histol Embryol** 1998 Oct;27(5):345-9

The negative effect of repeated equine chorionic gonadotropin treatment on subsequent fertility in Alpine goats is due to a humoral immune response involving the major histocompatibility complex. Roy F, et al. **Biol Reprod** 1999 Apr;60(4):805-13

Postnatal evolution of lymphocyte subpopulations in peripheral blood and lymphoid organs in the goat. Caro MR, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):145-8

METABOLISM

Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. Carroll GL, et al. **Am J Vet Res** 1999 Aug;60(8):986-91

Metabolic effects of amylin in lactating goats. Min SH, et al. **J Anim Sci** 1999 May;77(5):1241-8

Changes in plasma and milk concentrations of glucose and IGF-1 in response to exogenous growth hormone in lactating goats. Faulkner A. **J Dairy Res** 1999 May; 66(2):207-14

Energy expenditure by dry and lactating Alpine does estimated by entry rate of carbon dioxide. Herselman MJ, et al. **J Dairy Sci** 1998 Sep;81(9):2469-74

Influence of feed intake and source of dietary carbohydrate on the metabolic response to propionate and glucose challenges in lactating goats. Schmidely P, et al. **J Dairy Sci** 1999 Apr;82(4):738-46

Hormonal changes during parturition in heifers and goats are related to the phases and severity of labour. Hydbring E, et al. **J Endocrinol** 1999 Jan;160(1):75-85

Maturation-dependent modification of the protein phosphorylation profile of isolated goat sperm plasma membrane. Nath D, et al. **J Reprod Fertil** 1999 Jan; 115(1):29-37

Chronic effects of somatotropin treatment in vivo and in vitro on lipogenic activity of goat adipose tissue in a glucose-free buffer during acute incubation. Skarda J. **Physiol Res** 1999; 48(1):43-9

Pharmacokinetics of ampicillin trihydrate following intravenous administration to water deprived Nubian goats. Elsheikh HA, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):111-4

Pharmacokinetics of amikacin in lactating goats. Abo el-Sooud K. **Zentralbl Veterinarmed A** 1999 May; 46(4):239-46

Effects of catecholamines in vitro on lipogenesis in cultured adipose tissue from young goats. Skarda J. **Zentralbl Veterinarmed A** 1999 Aug;46(6):379-87

MICROBIOLOGY

Isolation and characterization of proteolytic ruminal bacteria from sheep and goats fed the tannin-containing shrub legume Calliandra calothyrsus. McSweeney CS, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3075-83

Characterization of nonenterotoxigenic Escherichia coli strains producing F17 fimbriae isolated from diarrheic lambs and goat kids. Cid D, et al. **J Clin Microbiol** 1999 May;37(5):1370-5

Effect of the addition of fumarate on methane production by ruminal microorganisms in vitro. Asanuma N, et al. **J Dairy Sci** 1999 Apr;82(4):780-7

PARASITOLOGY

Infection kinetics and developmental biology of Cryptosporidium muris (strain MCR) in Korean native kids and Corriedale lambs. Rhee JK, et al. **Korean J Parasitol** 1998 Sep;36(3):171-81

[Helminth species of goats in Germany] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):427-31 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Telemetric registration of heart rate and blood pressure in the same unrestrained goats during pregnancy, lactation and the non-pregnant, non-lactating period. Hydbring E, et al. **Acta Physiol Scand** 1999 Feb;165(2):135-41

Diurnal rhythm of melatonin in bovine milk: pharmacokinetics of exogenous melatonin in lactating cows and goats. Eriksson L, et al. **Acta Vet Scand** 1998; 39(3):301-10

Histomorphological study on pattern of fluid movement in cortical bone in goats. Qin L, et al. **Anat Rec** 1999 Aug 1;255(4):380-7

Foetal loss in dairy goats: function of the adrenal glands, corpus luteum and the foetal-placental unit. Engeland IV, et al. **Anim Reprod Sci** 1999 Apr 31;55(3-4):205-22

Effect of the interval of serial sections of ovarian tissue in the tissue chopper on the number of isolated caprine preantral follicles. Lucci CM, et al. **Anim Reprod Sci** 1999

GOATS

May 17;56(1):39–49

Peritoneal fluid from rabbits or goats as media for in vitro maturation, fertilization and initial culture of caprine oocytes. Malik RK, et al. **Anim Reprod Sci** 1999 Jan 8; 54(3):195–201

Effect of fungal alkaloids on the development of pregnancy and endocrine foetal–placental function in the goat. Vogt Engeland I, et al. **Anim Reprod Sci** 1998 Oct 9; 52(4):289–302

Cerebrovascular effects of dotarizine, a piperazine derivative, in the goat. An in vivo and in vitro complementary study. Torregrosa G, et al. **Arzneimittelforschung** 1999 Aug; 49(8):668–72

Goat fetuses disconnected from the placenta, but reconnected to an artificial placenta, display intermittent breathing movements. Kozuma S, et al. **Biol Neonate** 1999; 75(6):388–97

Oral administration of peptidergic growth hormone (GH) secretagogue KP102 stimulates GH release in goats. Hashizume T, et al. **Domest Anim Endocrinol** 1999 Jan; 16(1):31–9

Cardiovascular changes associated with dehydration and drinking in unrestrained, lactating goats. Olsson K, et al. **Exp Physiol** 1999 May;84(3):571–8

Biochemical and hormonal characterization of follicles from follicular and luteal phase ovaries of goat and sheep. Singh D, et al. **Indian J Exp Biol** 1999 May;37(5):434–8

Is histamine involved in milk ejection in goats? Eriksson L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S90–1

Facilitation of sexual behavior in French–Alpine goats treated with intravaginal progesterone–releasing devices and estradiol during the breeding and nonbreeding seasons. Billings HJ, et al. **J Anim Sci** 1999 Aug;77(8):2073–8

Effects of fumonisin B1–contaminated feeds on weanling angora goats. Gurung NK, et al. **J Anim Sci** 1998 Nov; 76(11):2863–70

Effects of mimosine and 2,3–dihydroxypyridine on fiber shedding in Angora goats. Reis PJ, et al. **J Anim Sci** 1999 May;77(5):1224–9

Adrenocortical response to ACTH in Angora and Spanish goat wethers. Toerien CA, et al. **J Anim Sci** 1999 Jun; 77(6):1558–64

Effect of carotid body denervation on breathing in neonatal goats. Lowry TF, et al. **J Appl Physiol** 1999 Sep; 87(3):1026–34

Effects of histamine H1 receptors on the feeding and drinking patterns in pygmy goats. Rossi R, et al. **J Dairy Sci** 1998 Sep;81(9):2369–75

Use of different dietary protein sources for lactating goats: milk production and composition as functions of protein degradability and amino acid composition. Sanz Sampelayo MR, et al. **J Dairy Sci** 1999 Mar;82(3):555–65

Influence of feed intake and source of dietary carbohydrate on milk yield and composition, nitrogen balance, and plasma constituents of lactating goats. Schmidely P, et al. **J Dairy Sci** 1999 Apr;82(4):747–55

Alteration of the sodium to potassium ratio in milk and the effect on milk secretion in goats. Stelwagen K, et al. **J Dairy Sci** 1999 Jan;82(1):52–9

Effects of maintaining solstice light and temperature on reproductive activity, coat growth, plasma prolactin and melatonin in goats. Gebbie FE, et al. **J Reprod Fertil** 1999 May;116(1):25–33

Pharmacokinetic parameters and milk concentrations of ketoprofen after administration as a single intravenous bolus dose to lactating goats. Musser JM, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):358–63

Tear production in three captive wild herbivores in Israel. Ofri R, et al. **J Wildl Dis** 1999 Jan;35(1):134–6

Stress–related hormonal and metabolic responses to restraint, with and without butorphanol administration, in pre–conditioned goats. Carroll GL, et al. **Lab Anim Sci** 1998 Aug;48(4):387–90

Effect of the H1–histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats. Rossi R, et al. **Physiol Behav** 1999 May;66(3):517–21

Changes in extracellular matrix components and cytokeratins in the endometrium during goat implantation. Guillomot M. **Placenta** 1999 May;20(4):339–45

Biochemical parameters regulating forward motility initiation in vitro in goat immature epididymal spermatozoa. Jaiswal BS, et al. **Reprod Fertil Dev** 1998;10(4):299–307

Diurnal fluctuations in rectal temperature of the Red Sokoto goat during the harmattan season. Ayo JO, et al. **Res Vet Sci** 1999 Feb;66(1):7–9

Respiratory–related pharyngeal constrictor muscle activity in awake goats. O'Halloran KD, et al. **Respir Physiol** 1999 Jun 1;116(1):9–23

The length of the cycle of seminiferous epithelium in goats (Capra hircus). França LR, et al. **Tissue Cell** 1999 Jun; 31(3):274–80

Effect of treatment with buffalo follicular fluid on ovarian function in goats. Kumar H, et al. **Vet Rec** 1998 Aug 29; 143(9):252–4

SURGERY

Observations on the use of midazolam for sedation, and induction of anaesthesia with midazolam in combination with ketamine in the goat. Stegmann GF. **J S Afr Vet Assoc** 1998 Sep;69(3):89–92

VIROLOGY

A new goat adenovirus isolate proposed as the prototype strain for goat adenovirus serotype 1. Lehmkuhl HD, et al. **Arch Virol** 1999;144(8):1611–8

Studies of genetic relationships between bovine, caprine, cervine, and rangiferine alphaherpesviruses and improved molecular methods for virus detection and identification. Ros C, et al. **J Clin Microbiol** 1999 May;37(5):1247–53

Detection of caprine herpesvirus 1 in sacral ganglia of latently infected goats by PCR. Tempesta M, et al. **J Clin Microbiol** 1999 May;37(5):1598–9

GOBLET CELLS

CHEMISTRY

Lectin histochemistry of goblet cell sugar residues in the gut of the chick embryo and of the newborn. Bryk SG, et al. **Tissue Cell** 1999 Apr;31(2):170–5

CYTOLOGY

Proliferation of goblet cells and vacuolated cells in the rabbit distal colon. Grant TD, et al. **Anat Rec** 1998 Sep; 252(1):41–8

Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF–beta receptor type III. Deng X, et al. **Cell Growth Differ** 1999 Jan;10(1):11–8

The influence of gender on the ocular surface. Connor CG, et al. **J Am Optom Assoc** 1999 Mar;70(3):182–6

DRUG EFFECTS

Inflammatory and epithelial responses during the development of ozone–induced mucous cell metaplasia in the nasal epithelium of rats. Cho HY, et al. **Toxicol Sci** 1999 Sep;51(1):135–45

[Goblet cells density of bulbar conjunctiva after long–term topical antiglaucoma agents] Wróblewska E. **Klin Oczna** 1999;101(1):45–7 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Autoimmune enteropathy with goblet–cell antibodies. Rogahn D, et al. **J R Soc Med** 1999 Jun;92(6):311–2

METABOLISM

Cloning and identification of the gene gob–5, which is expressed in intestinal goblet cells in mice. Komiya T, et al. **Biochem Biophys Res Commun** 1999 Feb 16; 255(2):347–51

Goblet–cell–specific transcription of mouse intestinal trefoil factor gene results from collaboration of complex series of positive and negative regulatory elements. Itoh H, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):461–72

Cloning of the gene gob–4, which is expressed in intestinal goblet cells in mice. Komiya T, et al. **Biochim Biophys Acta** 1999 Mar 19;1444(3):434–8

Localization of TFF3 peptide to porcine conjunctival goblet cells. Jagla W, et al. **Cell Tissue Res** 1999 Jun;296(3):525–30

MUC5AC mucin is a component of the human precorneal tear film. Jumblatt MM, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):43–9

Secretory peptides TFF1 and TFF3 synthesized in human conjunctival goblet cells. Langer G, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2220–4

Compensatory response of colon tissue to dextran sulfate sodium–induced colitis. Nakano S, et al. **J Gastroenterol** 1999 Apr;34(2):207–14

Epidermal growth factor system regulates mucin production in airways. Takeyama K, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3081–6

PATHOLOGY

K–ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. Ramnani DM, et al. **Cancer** 1999 Jul 1;86(1):14–21

Goblet–cell mucinous epithelium lining the endometrium and endocervix: evidence of metastasis from an appendiceal primary tumor through the use of cytokeratin–7 and –20 immunostains. Moore WF, et al. **Int J Gynecol Pathol** 1998 Oct;17(4):363–7

Relationship of impression cytology and tear ferning to reports of dry eye. Jackson JA, et al. **J Am Optom Assoc** 1999 Mar;70(3):187–92

IL–4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. Dabbagh K, et al. **J Immunol** 1999 May 15;162(10):6233–7

Immunohistochemical, ultrastructural and molecular study of well differentiated adenocarcinomas of the lung predominantly composed of goblet cells. Shrestha B, et al. **Lung Cancer** 1998 Nov;22(2):103–17

The expulsion of Echinostoma trivolvis caused by goblet cell hyperplasia in severe combined immunodeficient (SCID) mice. Fujino T, et al. **Parasite** 1998 Sep;5(3):219–22

[Goblet cells density of bulbar conjunctiva after long–term topical antiglaucoma agents] Wróblewska E. **Klin Oczna** 1999;101(1):45–7 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Goblet cell–specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice. Gum JR Jr, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G666–76

Goblet cell degranulation after antigen challenge in sensitized guinea pigs. Role of neutrophils. Agusti C, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1253–8

SECRETION

Selective secretion and replenishment of discrete mucin glycoforms from intestinal goblet cells. Stanley CM, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):G191–200

Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Jumblatt JE, et al. **Exp Eye Res** 1998 Sep;67(3):341–6

Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. Rios JD, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1102–11

[Effect of heparin on airway goblet cell secretion in sensitized guinea pigs] Nakata J, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):845–50 (Eng. Abstr.) **(Jpn)**

GOGGLES see **EYE PROTECTIVE DEVICES**

GOITER

Prevalence, age of onset, and natural history of thyroid disease in Pendred syndrome. Reardon W, et al. **J Med Genet** 1999 Aug;36(8):595–8

BLOOD

Proliferative activity of thyroid follicular cells in non–neoplastic goitre and the level of selected thyroid hormones in blood serum. Dzięcioł J, et al. **Folia Histochem Cytobiol** 1999;37(2):67–8

CHEMICALLY INDUCED

Is thyroxine during lithium therapy necessary? [comment] Bartalena L, et al. **J Endocrinol Invest** 1999 Mar;22(3):220–2 (12 ref.). Comment on: J Endocrinol Invest 1998 Dec;21(11):784–6.

Thyroid abnormalities related to iodine excess from water purification units. Peace Corps Thyroid Investigation Group [letter] [see comments] Khan LK, et al. **Lancet** 1998 Nov 7;352(9139):1519. Comment in: Lancet 1998 Dec 19–26;352(9145):2024.

[The role of nitrates in the genesis of goiter morbidity] Gatseva P, et al. **Probl Khig** 1997;22:92–8 (Eng. Abstr.) **(Bul)**

COMPLICATIONS

Goitre presenting as an oropharyngeal mass: an unusual finding in the elderly. Berenholz LP, et al. **J Laryngol Otol** 1999 Feb;113(2):170–1 (6 ref.)

Intrathoracic retroesophageal goiter causing tracheal stenosis. Tsukada H, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Apr;47(4):174–7 (10 ref.)

Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Kasagi K, et al. **Thyroid** 1999 Aug;9(8):791–6

[Pre–neck fixation treatment of severe cervical trachea stenosis (report of 5 cases)] Jin F. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Aug; 11(8):349–51 (Eng. Abstr.) **(Chi)**

[Amyloid goiter] Hrivó A, et al. **Orv Hetil** 1999 Mar 21; 140(12):653–7 (Eng. Abstr.) **(Hun)**

[Acute respiratory failure in the course of thyroid disease] Lukieńczuk T, et al. **Przegl Lek** 1999;56(2):134–8 (Eng. Abstr.) **(Pol)**

[Acute superior vena cava syndrome caused by benign goiter] Podwińska E, et al. **Wiad Lek** 1998;51(9–10):447–9 (Eng. Abstr.) **(Pol)**

CONGENITAL

Missense mutation (C1263R) in the thyroglobulin gene causes congenital goiter with mild hypothyroidism by impaired intracellular transport. Hishinuma A, et al. **Endocr J** 1998 Jun;45(3):315–27

DIAGNOSIS

Osteoclastomalike anaplastic carcinoma of the thyroid gland diagnosed by fine needle aspiration cytology. Report of two cases. Kumar PV, et al. **Acta Cytol** 1997 Jul–Aug;41(4 Suppl):1345–8

Ossifying fibromyxoid tumor misdiagnosed as follicular neoplasia. A case report. Lax S, et al. **Acta Cytol** 1997 Jul–Aug;41(4 Suppl):1261–4

Amyloid goiter presented as a subacute thyroiditis–like symptom in a patient with hypersensitivity vasculitis. Nagai Y, et al. **Endocr J** 1998 Jun;45(3):421–5

Diagnostic imaging of euthyroid goiter. Rufini V, et al. **Rays** 1999 Apr–Jun;24(2):243–62 (53 ref.) **(Eng, Ita)**

The yield of adequate and conclusive fine–needle aspiration results in thyroid nodules is uniform across functional and goiter types. Liel Y. **Thyroid** 1999 Jan;9(1):25–8

[What examinations should be performed in the case of retrosternal or compressive goiter?] Carnaille B. **Ann Chir** 1999;53(1):75–7 **(Fre)**

[Diffused goiter and thyroid nodule. Diagnostic indications] Nunez S, et al. **Rev Prat** 1998 Mar 15;48(6):653–6 (00 ref.)

(Fre)
[Acute respiratory failure in the course of thyroid disease] Lukieńczuk T, et al. **Przegl Lek** 1999;56(2):134–8 (Eng. Abstr.) (Pol)
[Amyloid goiter as the beginning symptom of amyloidosis in a patient with sex-linked agammaglobulinemia (letter)] López J, et al. **Rev Clin Esp** 1999 Jul;199(7):481 (4 ref.) (Spa)

DRUG THERAPY

Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Güllü S, et al. **Endocr J** 1999 Feb; 46(1):221–6
Effects of octreotide on propylotiouracil-induced goiter in rats: a quantitative evaluation. Pawlikowski M, et al. **Histol Histopathol** 1998 Jul;13(3):679–82
Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? Hegedüs L, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):756–60

EPIDEMIOLOGY

The prevalence of goitre and cretinism in a population of the west Ivory Coast. Kouamé P, et al. **Coll Antropol** 1998 Jun;22(1):31–41
What do we call a goiter? [comment] Delange F. **Eur J Endocrinol** 1999 Jun;140(6):486–8. Comment on: Eur J Endocrinol 1999 Jun;140(6):491–7.
Iodine deficiency in Turkey. Yordam N, et al. **Eur J Pediatr** 1999 Jun;158(6):501–5
Assessment of iodine deficiency in Pondicherry. Kapil U, et al. **Indian Pediatr** 1998 Apr;35(4):357–9
Current status of iodine deficiency disorders control program [editorial] Kapil U. **Indian Pediatr** 1998 Sep;35(9):831–6
Iodine-rich drinking water of natural origin in China [letter; comment] Zhao J, et al. **Lancet** 1998 Dec 19–26; 352(9145):2024. Comment on: Lancet 1998 Nov 7;352(9139):1519.
[The analysis of iodine among children in the capital of Zhejiang province] Wang Y, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):157–8 (Eng. Abstr.) (Chi)
[Goiter prevalence and urinary excretion of iodine in a sample of school age children in the city of Rome] Panunzi C, et al. **Ann Ist Super Sanita** 1998;34(3):409–12 (Eng. Abstr.) (Ita)
[Prevalence of simple sporadic goiter in relation to other non-neoplastic thyroid pathologies in an internal medicine department] Russo F, et al. **Minerva Endocrinol** 1998 Dec; 23(4):111–9 (Eng. Abstr.) (Ita)
[The iodine allowance and the prevalence of goiter among the children in organized collectives in the city of Kemerovo] Zinchuk SF, et al. **Vopr Pitan** 1999;68(3):28–30 (Eng. Abstr.) (Rus)

ETIOLOGY

A case of amyloid goiter secondary to Crohn's disease. Habu S, et al. **Endocr J** 1999 Feb;46(1):179–82
Fetal goiter in a iodine-deficient area [letter] Salerno M, et al. **J Endocrinol Invest** 1998 Nov;21(10):721–2
Amyloid goiter due to primary systemic amyloidosis: a diagnostic challenge. Sinha RN, et al. **Thyroid** 1998 Nov; 8(11):1051–4
Thyroid autoimmunity is associated with higher urinary iodine concentrations in an iodine-deficient area of Northwestern Greece. Tsatsoulis A, et al. **Thyroid** 1999 Mar;9(3):279–83
[Mastopathy and simple goiter--mutual relationships] Mizia-Stec K, et al. **Przegl Lek** 1998;55(5):250–8 (Eng. Abstr.) (Pol)

GENETICS

Prader-Willi syndrome associated with fetal goiter: a case report. Insoft RM, et al. **Am J Perinatol** 1999;16(1):29–31
Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes. Viglietto G, et al. **Eur J Endocrinol** 1999 Jun; 140(6):597–607
Molecular analysis of the PDS gene in Pendred syndrome. Coyle B, et al. **Hum Mol Genet** 1998 Jul;7(7):1105–12
Two frequent missense mutations in Pendred syndrome. Van Hauwe P, et al. **Hum Mol Genet** 1998 Jul;7(7):1099–104
Major role of genes in the etiology of simple goiter in females: a population-based twin study. Brix TH, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3071–5
Two novel cysteine substitutions (C1263R and C1995S) of thyroglobulin cause a defect in intracellular transport of thyroglobulin in patients with congenital goiter and the variant type of adenomatous goiter. Hishinuma A, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1438–44
Phenocopies for deafness and goiter development in a large inbred Brazilian kindred with Pendred's syndrome associated with a novel mutation in the PDS gene. Kopp P, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):336–41
Metastatic thyroid carcinoma arising from congenital goiter due to mutation in the thyroperoxidase gene. Medeiros-Neto G, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4162–6
Concurrence of Pendred syndrome, autoimmune thyroiditis, and simple goiter in one family. Vaidya B, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2736–8
A premature stopcodon in thyroglobulin messenger RNA results in familial goiter and moderate hypothyroidism. van de Graaf SA, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2537–42
Significance of trisomy 7 and 12 in thyroid lesions with follicular differentiation: a cytogenetic and in situ hybridization study [published erratum appears in Lab Invest 1999 Sep;79(9):1111] Roque L, et al. **Lab Invest** 1999 Apr;79(4):369–78
The Pendred syndrome gene encodes a chloride-iodide transport protein. Scott DA, et al. **Nat Genet** 1999 Apr; 21(4):440–3
Expression pattern of the mouse ortholog of the Pendred's syndrome gene (Pds) suggests a key role for pendrin in the inner ear. Everett LA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9727–32
Variable phenotype associated with Ser505Asn-activating thyrotropin-receptor germline mutation. Führer D, et al. **Thyroid** 1999 Aug;9(8):757–61
Pendred's syndrome: identification of the genetic defect a century after its recognition. Kopp P. **Thyroid** 1999 Jan; 9(1):65–9 (47 ref.)

HISTORY

Goiter in an eighteenth-century Sicilian mummy. Ciranni R, et al. **Am J Phys Anthropol** 1999 Apr;108(4):427–32
Fable on the superior laryngeal nerve. Gulec SA, et al. **Am Surg** 1999 May;65(5):490–2
Endocrinology and art. Martino E. **J Endocrinol Invest** 1998 Dec;21(11):794
Endocrinology and art. "Christ at the Column". Velazquez: Sevilia 1599--Madrid (Spain) 1660. Martino E. **J Endocrinol Invest** 1999 Jun;22(6):496

METABOLISM

Sulfate transport is not impaired in pendred syndrome thyrocytes. Kraiem Z, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2574–6

PATHOLOGY

Cell proliferation and apoptosis of thyroid follicular cells are involved in the involution of experimental non-tumoral hyperplastic goiter. Riesco JM, et al. **Anat Embryol (Berl)** 1998 Dec;198(6):439–50
Minireview: discussion about the limit between normal thyroid goiter. Langer P. **Endocr Regul** 1999 Mar; 33(1):39–45 (44 ref.)
Proliferative activity of thyroid follicular cells in non-neoplastic goitre and the level of selected thyroid hormones in blood serum. Dzięciol J, et al. **Folia Histochem Cytobiol** 1999;37(2):67–8
Dyshormonogenetic goitre with clear cell change resembling parathyroid adenoma--a case report. Kavishwar VS, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):469–71
Hyperthyroidism of Graves' disease: evidence for only unilateral involvement of the thyroid gland in a 31-year-old female patient. Dimai HP, et al. **J Endocrinol Invest** 1999 Mar;22(3):215–9
Problems in the management of solitary nodules and diffuse goitres. Webb AJ. **J R Soc Med** 1998;91 Suppl 33:17–20 (21 ref.)
The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphil cell change [letter; comment] Máximo V, et al. **Ultrastruct Pathol** 1998 May-Jun;22(3):271–3. Comment on: Ultrastruct Pathol 1998 Jan-Feb;22(1):91–100.
[Immunohistochemical identification of biochemical defect of dyshormonogenetic goiter] de Lima MA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Mar-Apr; 53(2):86–90 (Eng. Abstr.) (Por)

PHYSIOPATHOLOGY

Postural changes of the cervical spine in patients with nontoxic goiter. Gökpinar E, et al. **J Manipulative Physiol Ther** 1998 Nov-Dec;21(9):600–3
What happens to the normal thyroid during pregnancy? Glinoer D. **Thyroid** 1999 Jul;9(7):631–5 (15 ref.)
[Physiopathology of iodine deficiency] Pinchera A, et al. **Ann Ist Super Sanita** 1998;34(3):301–5 (26 ref.) (Eng. Abstr.) (Ita)
[Pathogenesis, surgical treatment and prophylaxis of goiter recurrence] Cheren'ko MP, et al. **Klin Khir** 1999;(3):31–3 (Eng. Abstr.) (Ukr)

PREVENTION & CONTROL

Iodine deficiency. Maberly G. **Bull World Health Organ** 1998; 76 Suppl 2:118–20

RADIONUCLIDE IMAGING

Reverse discordant scintigraphy in diffuse goiter. Huiskes AW, et al. **Clin Nucl Med** 1998 Sep;23(9):588–90
[Change of 99m technetium-pertechnetate uptake by the thyroid under suppression (TcTus) induced by optimization of iodine supply in Germany] Reinhardt MJ, et al. **Nuklearmedizin** 1998;37(6):202–7 (Eng. Abstr.) (Ger)

RADIOTHERAPY

Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Le Moli R, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):783–9
[Can radioactive iodine be used in the treatment of diffuse nontoxic goiter? (letter)] Harboe H. **Ugeskr Laeger** 1998 Dec 14;160(51):7454–5 (Dan)

SURGERY

Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Mirzaei S, et al. **Acta Med Austriaca** 1999;26(1):29–31
Nonrecurrent laryngeal nerves: anatomic considerations during thyroid and parathyroid surgery. Mra Z, et al. **Am J Otolaryngol** 1999 Mar-Apr;20(2):91–5
Management of a pregnant patient with airway obstruction secondary to goitre. Reid AW, et al. **Anaesth Intensive Care** 1999 Aug;27(4):415–7
Large goitre causing difficult intubation and failure to intubate using the intubating laryngeal mask airway: lessons for next time. Wakeling HG, et al. **Br J Anaesth** 1998 Dec; 81(6):979–81
Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a large goitre [see comments] Abdel Rahim AA, et al. **Br J Surg** 1999 Jan; 86(1):88–90. Comment in: Br J Surg 1999 Jul;86(7):967; discussion 968. Comment in: Br J Surg 1999 Jul;86(7):967–8.
Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a large goitre [letter; comment] Lansdown M. **Br J Surg** 1999 Jul;86(7):967; discussion 968. Comment on: Br J Surg 1999 Jan;86(1):88–90.
Respiratory complication after thyroidectomy and the need for tracheostomy in patients with a large goitre [letter; comment] Palazzo FF, et al. **Br J Surg** 1999 Jul;86(7):967–8 . Comment on: Br J Surg 1999 Jan;86(1):88–90.
Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? Hegedüs L, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):756–60
Cervical epidural anesthesia for sub-total thyroidectomy in a patient with aortic incompetence. Ahsan SN, et al. **JPMA J Pak Med Assoc** 1998 Sep;48(9):281–3
Surgical training and vocal-cord paralysis in benign thyroid disease. Runkel N, et al. **Langenbecks Arch Surg** 1998 Aug; 383(3-4):240–2
Usefulness of microsurgery to isolation of recurrent laryngeal nerve and parathyroid during thyroidectomy operations. Cavallaro G, et al. **Microsurgery** 1998;18(8):460–1
Body mass and body composition after total thyroidectomy for benign goiters. Kormas N, et al. **Thyroid** 1998 Sep; 8(9):773–6
Active prophylactic management of respiratory obstruction after standard thyroidectomy for giant goitre in the middle belt region of Nigeria. Obekpa PO, et al. **Trop Doct** 1999 Apr;29(2):75–8
[Serum thyroglobulin compared with ultrasonically detected recurrent goiter] Hartoft-Nielsen ML, et al. **Ugeskr Laeger** 1999 Apr 19;161(16):2352–7 (Eng. Abstr.) (Dan)
[A 7-year experience with goiter surgery in an otorhinolaryngologic department. A retrospective study of the the period 1990-1996] Nielsen TR, et al. **Ugeskr Laeger** 1999 Apr 26;161(17):2537–41 (Eng. Abstr.) (Dan)
[Recurrences after thyroid lobectomy for benign thyroid diseases: analysis of a clinical-instrumental follow up] Marchesi M, et al. **Ann Ital Chir** 1998 Sep-Oct;69(5):581–6 (Eng. Abstr.) (Ita)
[Surgical treatment of thyroid disease in adolescents] Dadan J, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):308–10 (Eng. Abstr.) (Pol)
[Treatment approach for substernal and intrathoracic goiter. Personal experience] Barczyński M, et al. **Przegl Lek** 1999; 56(2):129–33 (Eng. Abstr.) (Pol)
[Pathogenesis, surgical treatment and prophylaxis of goiter recurrence] Cheren'ko MP, et al. **Klin Khir** 1999;(3):31–3 (Eng. Abstr.) (Ukr)

THERAPY

Thyroid swelling--a protocol for management. Thomas WE. **J R Soc Med** 1998;91 Suppl 33:21–7 (36 ref.)

ULTRASONOGRAPHY

Prader-Willi syndrome associated with fetal goiter: a case report. Insoft RM, et al. **Am J Perinatol** 1999;16(1):29–31
Evaluation of goiter endemia by ultrasound in schoolchildren in Val Sarmento (Italy). Lupoli G, et al. **J Endocrinol Invest** 1999 Jul-Aug;22(7):503–7
[Prenatal diagnosis of fetal goiter revealing iodine utilization defect] Gire C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27(8):811–3 (8 ref.) (Eng. Abstr.) (Fre)

VETERINARY

Massive goitre (struma parenchymatosa) in geese. Ivanics E, et al. **Acta Vet Hung** 1999;47(2):217–31
Development of goitre and enterohepatonephropathy in Nubian Goats fed with pearl millet (Pennisetum typhoides). Abel Gadir WS, et al. **Vet J** 1999 Mar;157(2):178–85
[Occurrence of struma in cattle in the Czech Republic] Kursa J, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov;26(6):326–31 (Eng. Abstr.) (Ger)

GOITER, ENDEMIC

[Endemic goiter: clinical picture and evolution] Macchia PE, et al. **Ann Ist Super Sanita** 1998;34(3):307–10 (19 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Maternal and neonatal thyroid status in Saki, Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):57–61

Elevated anti-galactosyl antibody titers in endemic goiter. Knobel M, et al. **Thyroid** 1999 May;9(5):493–8

CHEMICALLY INDUCED

Traditional fermentation increases goitrogenic activity in pearl millet. Elnour A, et al. **Ann Nutr Metab** 1998; 42(6):341–9

COMPLICATIONS

The value of DNA content in predicting the prognosis of thyroid carcinoma in an endemic iodine deficiency region. Onaran Y, et al. **Acta Chir Belg** 1999 Feb;99(1):30–5

The influence of iodine deficiency on the cognitive performance of school children in Saki, south-west Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun; 27(1–2):95–9

The risk of infective thyroiditis in nodular goitres. Ameh EA, et al. **East Afr Med J** 1998 Jul;75(7):425–7

CONGENITAL

Maternal and neonatal thyroid status in Saki, Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):57–61

DIAGNOSIS

Assessment of iodine deficiency disorders in district Hamirpur, Himachal Pradesh. Sohal KS, et al. **Indian Pediatr** 1998 Oct;35(10):1008–11

Urinary iodine excretion as a predictor of the iodine content of breast milk. Pongpaew P, et al. **J Med Assoc Thai** 1999 Mar;82(3):284–9

DRUG THERAPY

Brassiodol, a new iodised oil for goitrous patients. Ingenbleek Y, et al. **Coll Antropol** 1998 Jun;22(1):51–62

EPIDEMIOLOGY

Endemic goitre prevalence in Ifedapo Local Government Area of Oyo State, Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):77–80

Iodine and zinc, but not selenium and copper, deficiency exists in a male Turkish population with endemic goiter. Ozata M, et al. **Biol Trace Elem Res** 1999 Sep;69(3):211–6

Thyroid function in neonates from goitre prevalent areas in Zimbabwe. Chinyanga E, et al. **Cent Afr J Med** 1998 May; 44(5):127–30

Registers and follow-up methods of populations in a public health survey: the example of the village Glanlé in Ivory Coast. Gaimard M, et al. **Coll Antropol** 1998 Jun; 22(1):63–75

Epidemiology and prophylaxis of endemic goitre in the Bwa village of Sirao (Mali). Roux F, et al. **Coll Antropol** 1998 Jun;22(1):43–9

Endemic goitre and urinary iodine levels in rural communities in the Bolgatanga and Builsa districts of the upper east region of Ghana. Asibey-Berko E, et al. **East Afr Med J** 1998 Sep;75(9):501–3

Dr. P. C. Sen Memorial Award Paper. Status of salt iodisation and iodine deficiency in selected districts of different states of India. Kapil U, et al. **Indian J Public Health** 1998 Jul–Sep;42(3):75–80

Persistence of iodine deficiency 25 years after initial correction efforts in the Khumbu region of Nepal. Murdoch DR, et al. **N Z Med J** 1999 Jul 23;112(1092):266–8

[Verification and epidemiological study on endemic iodide-induced goiter in Jiangsu Old Yellow River flooded plain] Zhao J, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Apr; 19(2):100–2 (Eng. Abstr.) **(Chi)**

[The consumption of cassava is not responsible for the etiology of endemic goiter in rural areas in Senegal] Dillon JC, et al. **Sante** 1999 Mar–Apr;9(2):93–9 (Eng. Abstr.) **(Fre)**

[Prevalence of endemic goiter in the health sector of Zitenga (Burkina Faso)] Thiebaut R, et al. **Sante** 1998 Jul–Aug; 8(4):269–74 (Eng. Abstr.) **(Fre)**

[Geographical differences of thyroid carcinoma and basic molecular principles] Goretzki PE, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:200–2 (Eng. Abstr.) **(Ger)**

[Epidemiology of endemic goiter in Italy] Aghini-Lombardi F, et al. **Ann Ist Super Sanita** 1998;34(3):311–4 (Eng. Abstr.) **(Ita)**

[Project for the prevention of thyroid pathology and iodine prophylaxis education in the province of Campobasso] Aiello A, et al. **Ann Ist Super Sanita** 1998;34(3):423–4 (Eng. Abstr.) **(Ita)**

[Goiter and iodine deficiency in Veneto: study on 6285 elementary and media school children] Busnardo B, et al. **Ann Ist Super Sanita** 1998;34(3):437–41 (Eng. Abstr.) **(Ita)**

[Prevalence of goiter and urine iodine in a school population in an area of the Bolognese Apennines] Cassio A, et al. **Ann Ist Super Sanita** 1998;34(3):389–91 (Eng. Abstr.) **(Ita)**

[Epidemiology of endemic goiter in Tuscany] Maccherini D, et al. **Ann Ist Super Sanita** 1998;34(3):395–7 (Eng. Abstr.) **(Ita)**

[Endemic goiter in Latium: environmental and genetic factors] Paggi A. **Ann Ist Super Sanita** 1998;34(3):403–8 (Eng. Abstr.) **(Ita)**

[Widespread endemic goiter and iodine deficiency in the province of Avellino] Pagliara S, et al. **Ann Ist Super Sanita** 1998;34(3):417–21 (Eng. Abstr.) **(Ita)**

[Iodine deficiency and iodine prophylaxis experience in Sicily] Regalbuto C, et al. **Ann Ist Super Sanita** 1998; 34(3):429–36 (Eng. Abstr.) **(Ita)**

[Epidemiologic investigation on the prevalence of goiter and urinary excretion of iodine in the school population of the province of Reggio Emilia] Zini M, et al. **Ann Ist Super Sanita** 1998;34(3):383–7 (Eng. Abstr.) **(Ita)**

[Health status of children and adolescents and risk factors in a geographic endemic area] Sakharev AG, et al. **Gig Sanit** 1999 Jul–Aug;(4):33–5 (Eng. Abstr.) **(Rus)**

[Epidemiology of iodine deficiency in the middle Ob regions] Nekrasova MR, et al. **Ter Arkh** 1998;70(10):26–8 (Eng. Abstr.) **(Rus)**

[An endemic goiter study of a population in the Pyrenees (Cerdanya-Girona)] Vila Ballester LL, et al. **An Med Interna** 1999 Jul;16(7):338–44 (Eng. Abstr.) **(Spa)**

[Current situation of goiter endemic and iodine intake in the population of the Pyrenees and the Segrià region of Lleida] Serna Arnaiz MC, et al. **Aten Primaria** 1998 Dec; 22(10):642–8 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Parameters of thyroid function in the endemic goitre of Akungba and Oke-Agbe villages of Akoko area of southwestern Nigeria. Akindahunsi AA, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):239–42

Endemic goitre in the absence of iodine deficiency in schoolchildren of the Northern Cape Province of South Africa. Jooste PL, et al. **Eur J Clin Nutr** 1999 Jan; 53(1):8–12

GENETICS

Genetic factors in iodine deficiency disorders: a general review. De Braekeleer M, et al. **Coll Antropol** 1998 Jun; 22(1):9–15 (83 ref.)

HISTORY

[National Institute of Hygiene in Warsaw: an initiator of iodine prophylaxis] Lutyński R. **Rocz Panstw Zakl Hig** 1998;49(4):409–13 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Elevated anti-galactosyl antibody titers in endemic goiter. Knobel M, et al. **Thyroid** 1999 May;9(5):493–8

METABOLISM

Parameters of thyroid function in the endemic goitre of Akungba and Oke-Agbe villages of Akoko area of southwestern Nigeria. Akindahunsi AA, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):239–42

Relationship between intrathyroid calcifications and thyroglobulin in endemic goiter. Zaccheroni V, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):213–7

PREVENTION & CONTROL

Thyroid function in neonates from goitre prevalent areas in Zimbabwe. Chinyanga E, et al. **Cent Afr J Med** 1998 May; 44(5):127–30

Endemic goitre: a research protocol elaboration for eradication. Chaventré A, et al. **Coll Antropol** 1998 Jun; 22(1):1–8

Epidemiology and prophylaxis of endemic goitre in the Bwa village of Sirao (Mali). Roux F, et al. **Coll Antropol** 1998 Jun;22(1):43–9

Impact after 1 year of compulsory iodisation on the iodine content of table salt at retailer level in South Africa. Jooste PL, et al. **Int J Food Sci Nutr** 1999 Jan;50(1):7–12

Iodized salt--a constant concern of society [editorial] Sinadinović J. **Med Pregl** 1998 Sep–Oct;51(9–10):389–94 **(Eng, Scr)**

[Development of preventive iodine administration in Austria] Eber O. **Wien Klin Wochenschr** 1998 Nov 13;110(21):733–7 (25 ref.) **(Ger)**

[Preventive iodine administration and iodine excretion in the Vienna area and in the forest quarter] Wagner B, et al. **Wien Klin Wochenschr** 1998 Nov 13;110(21):751–4 (Eng. Abstr.) **(Ger)**

[European project of structural funds: eradication of endemic goiter and iodine deficiency disorders in Southern Italy] Consiglio E. **Ann Ist Super Sanita** 1998;34(3):371–5 (Eng. Abstr.) **(Ita)**

[Experience with iodine prophylaxis in the province of Bolzano] Franzellin F. **Ann Ist Super Sanita** 1998; 34(3):377–81 (Eng. Abstr.) **(Ita)**

[Efficacy and safety of iodine prophylaxis] Vitti P, et al. **Ann Ist Super Sanita** 1998;34(3):357–61 (28 ref.) (Eng. Abstr.) **(Ita)**

[Iodine deficiency and children's rights] Morreale de Escobar G, et al. **An R Acad Nac Med (Madr)** 1998;115(3):683–701; discussion 701–2 **(Spa)**

SURGERY

[Surgery of the goiter] Seiler CA, et al. **Ther Umsch** 1999 Jul;56(7):380–4 (Eng. Abstr.) **(Ger)**

URINE

Endemic goitre and urinary iodine levels in rural communities in the Bolgatanga and Builsa districts of the upper east region of Ghana. Asibey-Berko E, et al. **East Afr Med J** 1998 Sep;75(9):501–3

GOITER, EXOPHTHALMIC see **GRAVES' DISEASE**

GOITER, INTRATHORACIC see **GOITER, SUBSTERNAL**

GOITER, NODULAR

[Multinodular goiter: natural history] Orgiazzi J. **Ann Chir** 1999;53(3):233–6 (4 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Serum selenium levels in multinodular goitre. Samir M, et al. **Clin Otolaryngol** 1998 Dec;23(6):512–4

Hypercalcitoninemia, nodular goiter, and pancreatic tumor. Ghnassia JP, et al. **Thyroid** 1999 Jun;9(6):599–600

Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Ozgen AG, et al. **Thyroid** 1999 Jun;9(6):579–82

COMPLICATIONS

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456–9 (10 ref.)

The risk of infective thyroiditis in nodular goitres. Ameh EA, et al. **East Afr Med J** 1998 Jul;75(7):425–7

Recognizing thyrotoxicosis. Mazzaferri EL. **Hosp Pract (Off Ed)** 1999 May 15;34(5):43–6, 49–51, 55–6 passim

Benign disease of the thyroid gland and vocal fold paralysis. Abboud B, et al. **J Laryngol Otol** 1999 May;113(5):473–4

Unmasking of thyrotoxicosis after initiation of regular haemodialysis treatment? [letter] Utas C, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2423

Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Ozgen AG, et al. **Thyroid** 1999 Jun;9(6):579–82

DIAGNOSIS

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456–9 (10 ref.)

Nodular thyroid disease diagnosed during pregnancy: how and when to treat. Hay ID. **Thyroid** 1999 Jul;9(7):667–70 (30 ref.)

[Hyperthyroidism induced by iodinated roentgen contrast media (see comments)] van Guldener C, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1641–4 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Aug 29;142(35):1969–70. **(Dut)**

[Goiter and nodular thyroid disease: clinical guidelines for diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?)] Cattaneo F, et al. **Ther Umsch** 1999 Jul;56(7):356–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Preoperative and intraoperative diagnosis of surgical thyroid diseases: morphological aspects] Avetis'ian IL, et al. **Klin Khir** 1999;(5):25–7 (Eng. Abstr.) **(Rus)**

[Multinodular euthyroid goiter in twin sisters] Deĭkalo IM. **Klin Khir** 1998;(9–10):98–9 **(Ukr)**

DRUG THERAPY

Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Güllü S, et al. **Endocr J** 1999 Feb; 46(1):221–6

Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy. Paggi A, et al. **Endocr Res** 1999 May;25(2):229–38

The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Takáts KI, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):70–4

ENZYMOLOGY

Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters. Shuja S, et al. **Thyroid** 1999 Jun;9(6):569–77

EPIDEMIOLOGY

Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Lin CC, et al.

Perit Dial Int 1998 Sep-Oct;18(5):516-21

ETIOLOGY

Growth factors and goitrogenesis. Bidey SP, et al. **J Endocrinol** 1999 Mar;160(3):321-32 (123 ref.)

GENETICS

Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. Gabriel EM, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3328-35

Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves' disease-1 (GD-1) close to multinodular goiter-1 (MNG-1). International Consortium for the Genetics of Autoimmune Thyroid Disease. Tomer Y, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4321-7

The clonality of nodules in recurrent goiters at second surgery. Harrer P, et al. **Langenbecks Arch Surg** 1998 Dec; 383(6):453-5

Screening of thyrotropin receptor mutations by fine-needle aspiration biopsy in autonomous functioning thyroid nodules in multinodular goiters. Tassi V, et al. **Thyroid** 1999 Apr;9(4):353-7

Activating thyrotropin receptor mutations in histologically heterogeneous hyperfunctioning nodules of multinodular goiter. Tonacchera M, et al. **Thyroid** 1998 Jul;8(7):559-64

[Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism] Derwahl M. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:25-8 (35 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Endocrinology and art. Martino E. **J Endocrinol Invest** 1999 Jan;22(1):89

METABOLISM

Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Kimura ET, et al. **Thyroid** 1999 Feb;9(2):119-25

PATHOLOGY

Solitary nodular goiter. Review of cytomorphologic features in 441 cases. Das DK, et al. **Acta Cytol** 1999 Jul-Aug; 43(4):563-74

Multinodular goitre presenting as a clinical single nodule: how effective is hemithyroidectomy? Wadström C, et al. **Aust N Z J Surg** 1999 Jan;69(1):34-6

Colloidal aggregates of insoluble inclusions in human goiters. Gerber H, et al. **Biochimie** 1999 May;81(5):441-5

PHYSIOPATHOLOGY

Regulation of breathing in hyperthyroidism: relationship to hormonal and metabolic changes. Pino-Garcia JM, et al. **Eur Respir J** 1998 Aug;12(2):400-7

RADIONUCLIDE IMAGING

Multi-tracer imaging of thyroid nodules: is there a role in the preoperative assessment of nodular goiter? [editorial; comment] Lind P. **Eur J Nucl Med** 1999 Aug;26(8):795-7 . Comment on: Eur J Nucl Med 1999 Aug;26(8):798-803.

The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules [see comments] Mezosi E, et al. **Eur J Nucl Med** 1999 Aug;26(8):798-803. Comment in: Eur J Nucl Med 1999 Aug;26(8):795-7.

Appearance of Graves'-like disease following regression of autonomously functioning thyroid nodules. Two case reports. Orsolon P, et al. **Minerva Endocrinol** 1998 Jun; 23(2):53-6

[F-18-FDG PET in autonomous goiter] Börner AR, et al. **Nuklearmedizin** 1999;38(1):1-6 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radioiodine therapy for multinodular toxic goiter. Nygaard B, et al. **Arch Intern Med** 1999 Jun 28;159(12):1364-8

Fractionated radioiodine treatment of patients with large multinodular toxic goitre [letter; comment] Grabowski Z. **Eur J Nucl Med** 1998 Sep;25(9):1353. Comment on: Eur J Nucl Med 1997 Dec;24(12):1465-9.

Treatment of toxic nodular goitres: Comparative costing of radioiodine therapy and surgery. Dietlein M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S66-70

The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. Takáts KI, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):70-4

Radioiodine treatment for nontoxic multinodular goiter. Maurer AH, et al. **J Nucl Med** 1999 Aug;40(8):1313-6 (64 ref.)

Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Nygaard B, et al. **Thyroid** 1999 May;9(5):477-81

SURGERY

Treatment of toxic nodular goitres: Comparative costing of radioiodine therapy and surgery. Dietlein M, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S66-70

Cost analysis of surgical procedures for toxic nodular goiter. Thomusch O, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S71-4

Differentiated operative therapy of thyroid autonomy (Plummer's disease). Wahl RA, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S78-84 (35 ref.)

Total versus subtotal thyroidectomy in the management of multinodular goiter. Marchesi M, et al. **Int Surg** 1998 Jul-Sep;83(3):202-4

Total thyroidectomy for multinodular goiter [letter; comment] Shiffman MA. **Int Surg** 1998 Apr-Jun;83(2):182 . Comment on: Int Surg 1997 Oct-Dec;82(4):417-9.

The clonality of nodules in recurrent goiters at second surgery. Harrer P, et al. **Langenbecks Arch Surg** 1998 Dec; 383(6):453-5

[Thyroid gland surgery at the 1st Surgical Clinic of the 1st Medical School of Charles University and General Medical School Hospital in Prague--review of problems] Klofanda J, et al. **Rozhl Chir** 1998 Oct;77(10):435-40 (Eng. Abstr.) **(Cze)**

[Surgery of nodular goiter: postoperative hypocalcemia in relation to extent of resection and manipulation of the parathyroid glands] Rimpl I, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1063-6 (Eng. Abstr.) **(Ger)**

[Selective (= morphology and function dependent) surgery of nodular struma: relationship to risk of recurrent laryngeal nerve paralysis by dissection and manipulation of the nerve] Wahl RA, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1051-4 (Eng. Abstr.) **(Ger)**

[Preoperative and intraoperative diagnosis of surgical thyroid diseases: morphological aspects] Avetis'ian IL, et al. **Klin Khir** 1999;(5):25-7 (Eng. Abstr.) **(Rus)**

[Minimally invasive therapy of the cystic-transformed thyroidal nodes] Zubov AD. **Klin Khir** 1999;(3):33-5 (Eng. Abstr.) **(Rus)**

THERAPY

Nodular thyroid disease diagnosed during pregnancy: how and when to treat. Hay ID. **Thyroid** 1999 Jul;9(7):667-70 (30 ref.)

[Goiter and nodular thyroid disease: clinical guidelines for diagnosis and treatment. (Waiting? Hormone therapy? Surgery? radioiodine?)] Cattaneo F, et al. **Ther Umsch** 1999 Jul;56(7):356-63 (42 ref.) (Eng. Abstr.) **(Ger)**

GOITER, SUBSTERNAL

Substernal goiter: clinical experience of 72 cases. Rodriguez JM, et al. **Ann Otol Rhinol Laryngol** 1999 May;108(5):501-4

COMPLICATIONS

Lymphatic compromise associated with substernal goiter. Jonklaas J. **Am J Med** 1998 Oct;105(4):349-52

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456-9 (10 ref.)

Compression syndromes caused by substernal goitres [see comments] Anders HJ. **Postgrad Med J** 1998 Jun; 74(872):327-9 (31 ref.). Comment in: Postgrad Med J 1998 Nov;74(877):701-2.

Compression syndromes caused by substernal goitres [letter; comment] Michel LA, et al. **Postgrad Med J** 1998 Nov; 74(877):701-2. Comment on: Postgrad Med J 1998 Jun;74(872):327-9.

[Intrathoracic goiter as a cause of superior vena cava syndrome] Cichoń S, et al. **Przegl Lek** 1998;55(11):626-8 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Bilateral recurrent nerve paralysis associated with multinodular substernal goiter: a case report. Souza JW, et al. **Am Surg** 1999 May;65(5):456-9 (10 ref.)

Endothoracic goiter with retro-tracheal and pre-esophageal migration. Halkic N, et al. **Schweiz Med Wochenschr** 1999 Mar 6;129(9):386

[Two new cases of autonomous ectopic goiter] Caronia F, et al. **Rev Pneumol Clin** 1998 Feb;54(1):34-7 (Eng. Abstr.) **(Fre)**

[Substernal goiter: a diagnostic and therapeutic problem. (Report of 39 surgically treated cases)] Pozzetto B, et al. **Ann Ital Chir** 1999 Jan-Feb;70(1):29-35; discussion 35-6 (41 ref.) (Eng. Abstr.) **(Ita)**

[Cervico-mediastinal goiter. Our experience] Siragusa G, et al. **Minerva Chir** 1999 Apr;54(4):225-9 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Thyroid carcinoma in intrathoracic goiter. Nervi M, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):337-9

RADIOGRAPHY

Intrathoracic mediastinal thyroid goiter: imaging manifestations. Buckley JA, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):471-5

RADIONUCLIDE IMAGING

Intrathoracic goiter. Steiner D, et al. **Clin Nucl Med** 1999 Jun;24(6):461-3

SURGERY

Cervico-thoracic goiter. A case report. Minet A, et al. **Acta Otorhinolaryngol Belg** 1998;52(4):329-33

Use of a Foley catheter in the removal of a substernal goiter [letter; comment] Lo CY. **Am J Surg** 1998 Oct;176(4):392 . Comment on: Am J Surg 1998 Feb;175(2):155-7.

Surgical aspects of 175 mediastinal goiters. Vadasz P, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):393-7

Thyroid carcinoma in intrathoracic goiter. Nervi M, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):337-9

Management of substernal goiter. Netterville JL, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1611-7

Endothoracic goiter with retro-tracheal and pre-esophageal migration. Halkic N, et al. **Schweiz Med Wochenschr** 1999 Mar 6;129(9):386

[Intrathoracic retrotracheal goiter: excision through a cervical approach] Salame N, et al. **J Chir (Paris)** 1997 Dec;134(7-8):311-3 (Eng. Abstr.) **(Fre)**

GOITROGENS see **ANTITHYROID AGENTS**

GOLD

see related
ANTIRHEUMATIC AGENTS, GOLD
GOLD RADIOISOTOPES

Prevalence of occupational lung disease in a random sample of former mineworkers, Libode District, Eastern Cape Province, South Africa. Trapido AS, et al. **Am J Ind Med** 1998 Oct;34(4):305-13

Comparison of stapes prostheses: a retrospective analysis of individual audiometric results obtained after stapedotomy by implantation of a gold and a teflon piston. de Bruijn AJ, et al. **Am J Otol** 1999 Sep;20(5):573-80

Tympanoplasty type II with ionomeric cement and titanium-gold-angle prostheses. Maassen MM, et al. **Am J Otol** 1998 Nov;19(6):693-9

The impact of HIV infection on Mycobacterium kansasii disease in South African gold miners. Corbett EL, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):10-4

Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Corbett EL, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):15-21

Experience with a new pure gold piston in stapedotomy for cases of otosclerosis. Tange RA, et al. **Auris Nasus Larynx** 1998 Sep;25(3):249-53

SPR analysis of the total reduction of protein adsorption to surfaces coated with mixtures of long- and short-chain polyethylene oxide block copolymers. Pavey KD, et al. **Biomaterials** 1999 May;20(9):885-90

A study on the adsorption structure of an adhesive monomer for precious metals by surface-enhanced Raman scattering spectroscopy. Suzuki M, et al. **Biomaterials** 1999 May; 20(9):839-45

Some considerations on the impact on ecological chemical principles in practice with emphasis on gold mining and cyanide. Korte F, et al. **Ecotoxicol Environ Saf** 1998 Oct; 41(2):119-29 (74 ref.)

Methylmercury neurotoxicity in Amazonian children downstream from gold mining. Grandjean P, et al. **Environ Health Perspect** 1999 Jul;107(7):587-91

Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology. Corbett EL, et al. **Int J Tuberc Lung Dis** 1999 Jun;3(6):501-7

Inflammatory cell recruitment, distribution, and chemiluminescence response at IgG precoated- and thiol functionalized gold surfaces. Källtorp M, et al. **J Biomed Mater Res** 1999 Nov;47(2):251-9

The application of LR gold resin for immunogold labeling. Thorpe JR. **Methods Mol Biol** 1999;117:99-110 (15 ref.)

A petrous bone artefact on MRI: technical note. Arunkumar MJ, et al. **Neuroradiology** 1998 Jun;40(6):385-6

Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners [published erratum appears in Occup Environ Med 1999 Mar;56(3):215-6] Hnizdo E, et al. **Occup Environ Med** 1998 Jul;55(7):496-502

Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Tager RE, et al. **Rheumatology (Oxford)** 1999 May;38(5):397-400

Mercury contamination associated with artisanal gold mining on the island of Mindanao, the Philippines. Appleton JD, et al. **Sci Total Environ** 1999 Apr 5;228(2-3):95-109

Efficacy of gold weight implants in facial nerve palsy: quantitative alterations in blinking. Abell KM, et al. **Vision Res** 1998 Oct;38(19):3019-23

[Risks of upper eyelid gold implantation in peripheral facial paralysis] Schrom T, et al. **HNO** 1999 Apr;47(4):262-8 (Eng. Abstr.) **(Ger)**

[In vivo and in vitro study of the marginal sealing in ceramic-covered gold inlays] Kaán B, et al. **Fogorv Sz** 1998 Dec;91(12):363-73 (Eng. Abstr.) **(Hun)**

[Rehabilitation of facial paralysis by temporal muscle flap and implantation of gold weights] Fernández-Alba J, et al. **Acta Otorrinolaringol Esp** 1999 Jan-Feb;50(1):20-8 (Eng. Abstr.) **(Spa)**

GOLD

[Gold weights for the treatment of lagophthalmos caused by facial paralysis. Our experience and review of the literature] Serrat Soto A, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):518–24 (32 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Gold--a controversial sensitizer. European Environmental and Contact Dermatitis Research Group. Bruze M, et al. **Contact Dermatitis** 1999 Jun;40(6):295–9 (63 ref.)

Laser Doppler perfusion imaging for the documentation of flare-up in contact allergy to gold. Möller H, et al. **Contact Dermatitis** 1999 Sep;41(3):131–5

Lymphomatoid eosinophilic reaction to gold earrings. Park YM, et al. **Contact Dermatitis** 1999 Apr;40(4):216–7

Tissue injury of Injection Gold Probe. Chan LY, et al. **Gastrointest Endosc** 1998 Sep;48(3):291–5

MPO antibody-positive vasculitis in a patient with psoriatic arthritis and gold-induced membranous glomerulonephritis. Quarenghi MI, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2104–6

Goldschlager allergy in a gold allergic patient. Guenthner T, et al. **Vet Hum Toxicol** 1999 Aug;41(4):246

[Thrombocytopenia caused by gold fillings?] Kaboth U, et al. **Internist (Berl)** 1999 Feb;40(2):223–4 **(Ger)**

[Gold induced cystitis] Casella R, et al. **Schweiz Med Wochenschr** 1999 Apr 24;129(16):639 **(Ger)**

ANALYSIS

Computer quantification of intracellular gold particles. Bisland SK, et al. **Biotechniques** 1999 Mar;26(3):494–500

CHEMISTRY

Electrostatic immobilization of glucose oxidase in a weak acid, polyelectrolyte hyperbranched ultrathin film on gold: fabrication, characterization, and enzymatic activity. Franchina JG, et al. **Anal Chem** 1999 Aug 1;71(15):3133–9

Electrochemical quantitation of DNA immobilized on gold. Steel AB, et al. **Anal Chem** 1998 Nov 15;70(22):4670–7

Electron transfer between ferrocene-modified Au/octadecanethiol/lipid BLM electrode and redox couples in solution. Cui X, et al. **Bioelectrochem Bioenerg** 1999 Feb;48(1):243–7

Platelet and cell interactions on gold sputter-deposited polymeric surfaces. Khang G, et al. **Biomed Mater Eng** 1998;8(5–6):299–309

Construction of biosensors using a gold-binding polypeptide and a miniature integrated surface plasmon resonance sensor. Woodbury RG, et al. **Biosens Bioelectron** 1998 Nov 1;13(10):1117–26

Metal release from gold-containing jewelry materials: no gold release detected. Lidén C, et al. **Contact Dermatitis** 1998 Dec;39(6):281–5

Gold(I) complexes as antimicrobial agents. Novelli F, et al. **Farmaco** 1999 Apr 30;54(4):232–6

Surface characterization, protein adsorption, and initial cell-surface reactions on glutathione and 3-mercapto-1,2,-propanediol immobilized to gold. Kanagaraja S, et al. **J Biomed Mater Res** 1999 Sep 15; 46(4):582–91

IMMUNOLOGY

Immunomodulatory activity of a Unani gold preparation used in Indian system of medicine. Bajaj S, et al. **Immunopharmacol Immunotoxicol** 1999 Feb;21(1):151–61

PHARMACOLOGY

Gold(I) complexes as antimicrobial agents. Novelli F, et al. **Farmaco** 1999 Apr 30;54(4):232–6

Analgesic activity of gold preparations used in Ayurveda & Unani-Tibb. Bajaj S, et al. **Indian J Med Res** 1998 Sep; 108:104–11

THERAPEUTIC USE

Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. Rau R, et al. **J Rheumatol** 1998 Aug;25(8):1485–92

GOLD ALLOYS

The gold standard [letter; comment] Colquitt T. **J Am Dent Assoc** 1999 Sep;130(9):1264, 1266, 1268. Comment on: J Am Dent Assoc 1999 Mar;130(3):409–11.

Six-year follow-up of titanium and high-gold porcelain-fused-to-metal fixed partial dentures. Walter M, et al. **J Oral Rehabil** 1999 Feb;26(2):91–6

Effect of washers on reverse torque displacement of dental implant gold retaining screws. Korioth TW, et al. **J Prosthet Dent** 1999 Sep;82(3):312–6

ADVERSE EFFECTS

The tarnished history of a posterior restoration. Rose MD, et al. **Br Dent J** 1998 Nov 14;185(9):436

CHEMISTRY

Determination of gold alloy loss during the production of cast dental restorations. Fitzpatrick BJ, et al. **Aust Dent J** 1998 Dec;43(6):417–21

Metal release from gold-containing jewelry materials: no gold release detected. Lidén C, et al. **Contact Dermatitis** 1998 Dec;39(6):281–5

Age-hardening associated with grain boundary precipitation in a commercial dental gold alloy. Kim HI, et al. **J Oral Rehabil** 1999 Mar;26(3):215–22

Shock absorbability of various restorative materials used on implants. Soumeire J, et al. **J Oral Rehabil** 1999 May; 26(5):394–401

Effect of noble metal conditioners on bonding between prosthetic composite material and silver-palladium-copper-gold alloy. Matsumura H, et al. **J Prosthet Dent** 1999 Jun;81(6):710–4

A simple method of increasing the adhesion between resinous cements and tinplated gold alloys: a pilot study. Ogunyinka A. **J Prosthet Dent** 1998 Sep;80(3):302–6

GOLD ANTIARTHRITIC AGENTS see **ANTIRHEUMATIC AGENTS, GOLD**

GOLD ANTI-INFLAMMATORY AGENTS see **ANTIRHEUMATIC AGENTS, GOLD**

GOLD COLLOID

Use of colloidal gold surface plasmon resonance peak shift to infer affinity constants from the interactions between protein antigens and antibodies specific for single or multiple epitopes. Englebienne P. **Analyst** 1998 Jul; 123(7):1599–603

Ribonuclease-gold labels proteoglycan-containing cytoplasmic granules and ribonucleic acid-containing organelles--a survey. Dvorak AM, et al. **Histol Histopathol** 1999 Apr;14(2):597–626 (166 ref.)

Computer-assisted enhancement permits the use of five nanometer gold probes in low magnification transmission electron microscopy. Broomall K. **J Electron Microsc (Tokyo)** 1998;47(4):355–7

Binding of gold-protein ligand complexes to neurokinin receptors. visualization with the electron microscope on pig coronary artery and rat portal vein. Cathieni MM, et al. **J Vasc Res** 1999 Jan–Feb;36(1):59–67

Preparation of colloidal gold. Oliver C. **Methods Mol Biol** 1999;115:327–30 (10 ref.)

Conjugation of colloidal gold to proteins. Oliver C. **Methods Mol Biol** 1999;115:331–4 (8 ref.)

Colloidal gold/streptavidin methods. Oliver C. **Methods Mol Biol** 1999;115:335–9 (6 ref.)

Pre-embedding labeling methods. Oliver C. **Methods Mol Biol** 1999;115:341–5 (3 ref.)

ANALYSIS

Quantification of protein A-gold staining for peroxisomal enzymes by confocal laser scanning microscopy. Ogiwara N, et al. **J Histochem Cytochem** 1999 Oct;47(10):1343–9

CHEMISTRY

Light-scattering submicroscopic particles as highly fluorescent analogs and their use as tracer labels in clinical and biological applications. Yguerabide J, et al. **Anal Biochem** 1998 Sep 10;262(2):137–56

Colloidal gold filtrates as metal substrates for surface-enhanced infrared absorption spectroscopy. Seelenbinder JA, et al. **Anal Chem** 1999 May 15; 71(10):1963–6

Surface interactions of a homologous series of alpha,omega-amino acids on colloidal silver and gold. Ooka AA, et al. **Biospectroscopy** 1999;5(1):9–17

IMMUNOLOGY

[Use of specific antibodies, labeled with colloidal gold particles, for the detection of Brucella antigens using dot-immunoassay] Zagoskina TIu, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov–Dec; (6):64–8 (Eng. Abstr.) **(Rus)**

GOLD COMPOUNDS

Gold chloride technique to study articular innervation. A protocol validated through computer-assisted colorimetry. Gómez-Barrena E, et al. **Histol Histopathol** 1999 Jan; 14(1):69–79

ADMINISTRATION & DOSAGE

Safety of self-injection of gold and methotrexate. Arthur AB, et al. **J Rheumatol** 1999 Feb;26(2):302–5

ADVERSE EFFECTS

Nickel and gold in skin lesions of pierced earlobes with contact dermatitis. A study using scanning electron microscopy and x-ray microanalysis. Suzuki H. **Arch Dermatol Res** 1998 Oct;290(10):523–7

Reversible pancreatitis, hepatitis, and peripheral polyneuropathy associated with parenteral gold therapy. Ben-Ami H, et al. **J Rheumatol** 1999 Sep;26(9):2049–50

IMMUNOLOGY

In vitro lymphocyte reactivity to gold compounds in the diagnosis of contact hypersensitivity. Vamnes JS, et al. **Contact Dermatitis** 1999 Sep;41(3):156–60

PHARMACOLOGY

Different effects of two gold compounds on muscle contraction, membrane potential and ryanodine receptor. Oba T, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):477–87

THERAPEUTIC USE

Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Cagnoli M, et al. **Anticancer Drugs** 1998 Aug;9(7):603–10

Clinical remission in rheumatoid arthritis: efficacy of a second course of intra-muscular gold [letter] Fernández-Prada M, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):512

GOLD RADIOISOTOPES

CHEMISTRY

198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals. Berning DE, et al. **Nucl Med Biol** 1998 Aug;25(6):577–83

GOLD SALTS, ANTI-RHEUMATIC see **ANTIRHEUMATIC AGENTS, GOLD**

GOLD SODIUM THIOMALATE

ADMINISTRATION & DOSAGE

No significant effects of sodium aurothiomalate on haem metabolism and mixed function oxygenase activity in patients with rheumatoid arthritis. Herrick AL, et al. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):461–2

ADVERSE EFFECTS

Unusual and memorable. Langan SM, et al. **Ann Rheum Dis** 1999 Jan;58(1):68

N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney damage in rheumatoid arthritis patients starting on parenteral gold and Depo-Medrone/placebo injections. Wiland P, et al. **Clin Rheumatol** 1999;18(2):106–13

The flare-up reactions after systemic provocation in contact allergy to nickel and gold. Möller H, et al. **Contact Dermatitis** 1999 Apr;40(4):200–4

PHARMACOLOGY

Effects of antirheumatic drugs on adhesiveness of endothelial cells and neutrophils. Heimbürger M, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1661–9

Synergistic inhibition of human B cell activation by gold sodium thiomalate and auranofin. Hirohata S, et al. **Clin Immunol** 1999 May;91(2):226–33

Different effects of two gold compounds on muscle contraction, membrane potential and ryanodine receptor. Oba T, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):477–87

Aurothiolates enhance the replication of Semliki Forest virus in the CNS and the exocrine pancreas. Scallan MF, et al. **J Neurovirol** 1999 Aug;5(4):392–400

Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. Takahashi K, et al. **Mol Immunol** 1998 Dec;35(17):1081–7

THERAPEUTIC USE

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate. Sander O, et al. **Ann Rheum Dis** 1999 May; 58(5):281–7

Treatment of pemphigus with gold. Pandya AG, et al. **Arch Dermatol** 1998 Sep;134(9):1104–7

A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Menninger H, et al. **Br J Rheumatol** 1998 Oct;37(10):1060–8

Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Rau R, et al. **Br J Rheumatol** 1998 Nov;37(11):1220–6

[Comparative study of the effects of auranofin and aurothiomalate on laboratory and clinical indicators in patients with rheumatoid arthritis] Vlak T, et al. **Reumatizam** 1998;46(1):7–19 (Eng. Abstr.) **(Scr)**

GOLD SODIUM THIOSULFATE

ADVERSE EFFECTS

Gold allergy and artificial sweat [letter] Möller H, et al. **Contact Dermatitis** 1999 Jul;41(1):57–60 (16 ref.)

GOLD THIOGLUCOSE see **AUROTHIOGLUCOSE**

GOLD THIOMALATE see **GOLD SODIUM THIOMALATE**

GOLDENHAR SYNDROME

COMPLICATIONS

Goldenhar syndrome with situs inversus totalis [letter] Görgü M, et al. **Int J Oral Maxillofac Surg** 1998 Oct;27(5):404

DIAGNOSIS

Goldenhar anomaly in one of triplets derived from in vitro fertilization [letter] Ferraris S, et al. **Am J Med Genet** 1999 May 21;84(2):167–8

Auditory and facial nerve dysfunction in patients with hemifacial microsomia. Carvalho GJ, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb;125(2):209–12

[Anomalies of the efferent lacrimal ducts in Goldenhar syndrome (news)] Lüchtenberg M, et al. **Klin Monatsbl Augenheilkd** 1998 Dec;213(6):aA8–9 **(Ger)**

[Goldenhar's syndrome: a case report] Altamar-Rios J. **An Otorrinolaringol Ibero Am** 1998;25(5):491–7 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Mesenchymal chondrosarcoma associated with Goldenhar's syndrome. Ostlere SJ, et al. **Arch Orthop Trauma Surg** 1999; 119(5–6):347–8

PHYSIOPATHOLOGY

Goldenhar syndrome associated with various cardiovascular malformations. Nakajima H, et al. **Jpn Circ J** 1998 Aug; 62(8):617–20

GOLDFISH

Expression of three distinct somatostatin messenger ribonucleic acids (mRNAs) in goldfish brain: characterization of the complementary deoxyribonucleic acids, distribution and seasonal variation of the mRNAs, and action of a somatostatin-14 variant. Lin X, et al. **Endocrinology** 1999 May;140(5):2089–99

Identification and characterization of a receptor from goldfish specific for a teleost growth hormone-releasing hormone-like peptide. Chan KW, et al. **Neuroendocrinology** 1998 Jul;68(1):44–56

ANATOMY & HISTOLOGY

Tectotectal connectivity in goldfish. Herrero L, et al. **J Comp Neurol** 1999 Aug 30;411(3):455–71

Influence of the tectal zone on the distribution of synaptic boutons in the brainstem of goldfish. Herrero L, et al. **J Comp Neurol** 1998 Nov 23;401(3):411–28

Ultrastructure of the olfactory epithelium in intact, axotomized, and bulbectomized goldfish, Carassius auratus. Hansen A, et al. **Microsc Res Tech** 1999 May 15–Jun 1; 45(4–5):325–38

Analysis of dendritic arbors of native and regenerated ganglion cells in the goldfish retina. Cameron DA, et al. **Vis Neurosci** 1999 Mar–Apr;16(2):253–61

GENETICS

Cloning and characterization of GETS-1, a goldfish Ets family member that functions as a transcriptional repressor in muscle. Goldman D, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):267–75

Goldfish brain GluR2: multiple forms, RNA editing, and alternative splicing. Li Z, et al. **Brain Res Mol Brain Res** 1999 Apr 20;67(2):211–20

Production of a biologically active novel goldfish growth hormone in Escherichia coli. Mahmoud SS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Aug; 120(4):657–63

Cloning of a fragment of the osteonectin gene from goldfish, Carassius auratus: its expression and potential regulation by estrogen. Lehane DB, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):80–7

Structural and expression analyses of gonadotropin Ibeta subunit genes in goldfish (Carassius auratus). Sohn YC, et al. **Gene** 1998 Nov 19;222(2):257–67

Functional identification of a goldfish odorant receptor. Speca DJ, et al. **Neuron** 1999 Jul;23(3):487–98

IMMUNOLOGY

The safety and longevity of DNA vaccines for fish. Kanellos T, et al. **Immunology** 1999 Feb;96(2):307–13

DNA is as effective as protein at inducing antibody in fish. Kanellos T, et al. **Vaccine** 1999 Feb 26;17(7–8):965–72

METABOLISM

Uptake of particulate lead via the gills of fish (Carassius auratus). Tao S, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):352–7

Cytological and biochemical alterations in Carassius auratus hepatocytes from exposure to sediment containing dioxins and related compounds. Wu WZ, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):358–63

Fish macrophages express a cyclo-oxygenase-2 homologue after activation. Zou J, et al. **Biochem J** 1999 May 15;340 (Pt 1):153–9

Predominant expression of group-II metabotropic glutamate receptors in the goldfish brain. Poli A, et al. **Brain Res** 1999 Jul 10;834(1–2):142–5

PACAP (pituitary adenylate cyclase-activating peptide)-like immunoreactivity in the gill arch of the goldfish, Carassius auratus: distribution and comparison with VIP. de Girolamo P, et al. **Cell Tissue Res** 1998 Sep;293(3):567–71

NMDA and non-NMDA receptors mediate responses in the primary gustatory nucleus in goldfish. Smeraski CA, et al. **Chem Senses** 1999 Feb;24(1):37–46

Production of a biologically active novel goldfish growth hormone in Escherichia coli. Mahmoud SS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Aug; 120(4):657–63

Gamma-aminobutyric acid up-regulates the expression of a novel secretogranin-II messenger ribonucleic acid in the goldfish pituitary. Blázquez M, et al. **Endocrinology** 1998 Dec;139(12):4870–80

Seasonal changes in mRNA levels of gonadotropin and thyrotropin subunits in the goldfish, Carassius auratus. Sohn YC, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):436–44

Molecular cloning of an estrogen receptor beta subtype from the goldfish, Carassius auratus. Tchoudakova A, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):388–400

mRNA expression of gonadotropin-releasing hormones (GnRHs) and GnRH receptor in goldfish. Yu KL, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):303–11

Dopamine D1-receptor immunolocalization in goldfish retina. Mora-Ferrer C, et al. **J Comp Neurol** 1999 Sep 6; 411(4):705–14

Identification of serum GH-binding proteins in the goldfish (Carassius auratus) and comparison with mammalian GH-binding proteins. Zhang Y, et al. **J Endocrinol** 1999 May;161(2):255–62

Modulation of desensitization at glutamate receptors in isolated crucian carp horizontal cells by concanavalin A, cyclothiazide, aniracetam and PEPA. Shen Y, et al. **Neuroscience** 1999 Mar;89(3):979–90

PHYSIOLOGY

Otolith ocular reflex function of the tangential nucleus in teleost fish. Suwa H, et al. **Ann N Y Acad Sci** 1999 May 28;871:1–14

Behavioral responses to atrazine and diuron in goldfish. Saglio P, et al. **Arch Environ Contam Toxicol** 1998 Oct; 35(3):484–91

Ascending spinal projections to the optic tectum, facial and vagal lobes in the goldfish, Carassius auratus. Prasada Rao PD, et al. **Brain Res** 1999 Jan 30;817(1–2):209–14

Isolation of a 65-kDa protein from white muscle of warm temperature-acclimated goldfish (Carassius auratus). Kikuchi K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jun; 120(2):385–91

Testosterone regulation of gonadotropin production in goldfish. Habibi HR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):339–44 (59 ref.)

Calcitonin cells in the intestine of goldfish and a comparison of the number of cells among saline-fed, soup-fed, or high Ca soup-fed fishes. Okuda R, et al. **Gen Comp Endocrinol** 1999 Feb;113(2):267–73

Activity-dependent refinement in the goldfish retinotectal system is mediated by the dynamic regulation of processes withdrawal: an in vivo imaging study. Johnson FA, et al. **J Comp Neurol** 1999 Apr 19;406(4):548–62

Large-scale synaptic errors during map formation by regeneration optic axons in the goldfish. Meyer RL, et al. **J Comp Neurol** 1999 Jun 28;409(2):299–312

Decrease in occurrence of fast startle responses after selective Mauthner cell ablation in goldfish (Carassius auratus). Zottoli SJ, et al. **J Comp Physiol [A]** 1999 Feb; 184(2):207–18

Induction of alpha1-tubulin gene expression during development and regeneration of the fish central nervous system. Hieber V, et al. **J Neurobiol** 1998 Nov 15; 37(3):429–40

Up-regulation of protein kinase C in regenerating optic nerve fibers of goldfish: immunohistochemistry and kinase activity assay. Schmidt JT. **J Neurobiol** 1998 Sep 5; 36(3):315–24

The kinetics of exocytosis and endocytosis in the synaptic terminal of goldfish retinal bipolar cells. Neves G, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):181–202

Ultrastructural changes in afferent mixed synapses in conditions of long-term potentiation of electrotonic responses on Mauthner neurons in incubated fragments of the goldfish medulla oblongata. Moshkov DA, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):237–41

Central Asian black scorpion venom protects Mauthner neurons from damage due to prolonged stimulation. Tiras NR, et al. **Neurosci Behav Physiol** 1999 May-Jun; 29(3):251–5

Fast and slow recovery phases of goldfish behavior after transection of the optic nerve revealed by a computer image processing system. Kato S, et al. **Neuroscience** 1999; 93(3):907–14

Diffusional anisotropy is induced by subcellular barriers in skeletal muscle. Kinsey ST, et al. **NMR Biomed** 1999 Feb; 12(1):1–7

Selection of macronutrients by goldfish operating self-feeders. Sánchez-Vázquez FJ, et al. **Physiol Behav** 1998 Nov 15;65(2):211–8

Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus). Illing N, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2526–31

Spectral sensitivity of the goldfish Torus longitudinalis. Gibbs MA, et al. **Vis Neurosci** 1998 Sep–Oct;15(5):859–65

Spectral sensitivity of the feedback signal from horizontal cells to cones in goldfish retina. Kraaij DA, et al. **Vis Neurosci** 1998 Sep–Oct;15(5):799–808

Rapid calcium-current kinetics in synaptic terminals of goldfish retinal bipolar neurons. Mennerick S, et al. **Vis Neurosci** 1998 Nov–Dec;15(6):1051–6

Visual function in regenerating teleost retina following cytotoxic lesioning. Mensinger AF, et al. **Vis Neurosci** 1999 Mar–Apr;16(2):241–51

Functional properties of retinal ganglion cells during optic nerve regeneration in the goldfish. Oh DJ, et al. **Vis Neurosci** 1998 Nov–Dec;15(6):1145–55

Imaging of glutamate release from the goldfish retinal slice. Ayoub GS, et al. **Vision Res** 1998 Oct;38(19):2909–12

Spectral sensitivity of cones in the goldfish, Carassius auratus. Palacios AG, et al. **Vision Res** 1998 Jul;38(14):2135–46

[Effect of cytochalasin D on the structure of mixed synapses and their electrotonic conductivity] Pavlik LL, et al. **Tsitologiia** 1999;41(7):590–7 (Eng. Abstr.) **(Rus)**

VIROLOGY

A viral epizootic in cultured populations of juvenile goldfish due to a putative herpesvirus etiology. Groff JM, et al. **J Vet Diagn Invest** 1998 Oct;10(4):375–8

GOLDFISH VIRUS 1-LIKE VIRUSES see **IRIDOVIRIDAE**

GOLF

Realistic expectations on the putting green: within and between days trueness of roll. Koslow R, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1441–2

Golf-related head injuries [letter; comment] Parkinson D. **Surg Neurol** 1999 May;51(5):580–1. Comment on: Surg Neurol 1998 Dec;50(6):608.

Pediatric cranial golf injuries--an emerging contemporary phenomenon? [letter] [see comments] Rosenow JM, et al. **Surg Neurol** 1998 Dec;50(6):608. Comment in: Surg Neurol 1999 May;51(5):580–1.

INJURIES

Wrist pain with triangular fibrocartilage thickening. Abe Y, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):98–9

Shock-wave therapy for tennis and golfer's elbow--1 year follow-up. Krischek O, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):62–6

Golfer's heel. Baquie P. **Aust Fam Physician** 1998 Aug; 27(8):727–8

Golf is a dangerous game [letter] McGuffie AC, et al. **J Accid Emerg Med** 1998 Nov;15(6):437

Shoulder arthroplasty in recreational golfers. Jensen KL, et al. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):362–7

Golf related head injuries in children: the little tigers. McGuffie AC, et al. **Scott Med J** 1998 Oct;43(5):139–40

Golf injuries. An overview. Thériault G, et al. **Sports Med** 1998 Jul;26(1):43–57 (41 ref.)

GOLGI APPARATUS

1898–1998: Camillo Golgi and "the Golgi": one hundred years of terminological clones [editorial] Fabene PF, et al. **Brain Res Bull** 1998 Oct;47(3):195–8 (8 ref.)

The Golgi apparatus and the centrosome are localized to the sites of newly emerging axons in cerebellar granule neurons in vitro. Zmuda JF, et al. **Cell Motil Cytoskeleton** 1998;41(1):18–38

1998: the centenary of the discovery of the Golgi apparatus. Dröscher A. **Glycoconj J** 1998 Aug;15(8):733–6

Isolation of plasma membranes and Golgi apparatus from a single chicken liver homogenate. Vleurick L, et al. **J Cell Biochem** 1999 Mar 1;72(3):349–55

From the "apparato reticolare interno" to "the Golgi": 100 years of Golgi apparatus research. Dröscher A. **Virchows Arch** 1999 Feb;434(2):103–7 (45 ref.)

CHEMISTRY

Preparation of Golgi subfractions with free-solution isotachophoresis: analysis of sphingomyelin synthesis in Golgi subfractions from rat liver. Hofmeister R, et al. **Electrophoresis** 1998 Jun;19(7):1185–94

Identification, purification, and characterization of the rat liver golgi membrane ATP transporter. Puglielli L, et al. **J Biol Chem** 1999 Apr 30;274(18):12665–9

The recycling pathway of protein ERGIC-53 and dynamics of the ER-Golgi intermediate compartment. Klumperman J, et al. **J Cell Sci** 1998 Nov;111 (Pt 22):3411–25

Gene organization of rab6, a marker for the novel Golgi of Plasmodium. Ming M, et al. **Mol Biochem Parasitol** 1999 May 25;100(2):217–22

DRUG EFFECTS

Molecular cloning and functional characterization of brefeldin A-ADP-ribosylated substrate. A novel protein involved in the maintenance of the Golgi structure. Spanfo

S, et al. **J Biol Chem** 1999 Jun 18;274(25):17705-10

Stimulation of Golgi membrane tubulation and retrograde trafficking to the ER by phospholipase A(2) activating protein (PLAP) peptide. Polizotto RS, et al. **J Cell Biochem** 1999 Sep 15;74(4):670-83

Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Palokangas H, et al. **Mol Biol Cell** 1998 Dec;9(12):3561-78

Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes. Dąbroś W, et al. **Pol J Pathol** 1998;49(2):67-76

ENZYMOLOGY

Purification, crystallization and preliminary X-ray crystallographic analysis of recombinant murine Golgi mannosidase IA, a class I alpha-mannosidase involved in Asn-linked oligosaccharide maturation. Vallée F, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Feb;55 (Pt 2):571-3

Enzyme distributions in subcellular fractions of BHK cells infected with Semliki forest virus: evidence for a major fraction of sphingomyelin synthase in the trans-golgi network. Allan D, et al. **Biochim Biophys Acta** 1999 Jul 8;1450(3):277-87

Interactions of (-)-ilimaquinone with methylation enzymes: implications for vesicular-mediated secretion. Radeke HS, et al. **Chem Biol** 1999 Sep;6(9):639-47

Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction. Geoffroy V, et al. **Eur J Biochem** 1999 Feb;259(3):892-900

Alpha-mannosidases involved in N-glycan processing show cell specificity and distinct subcompartmentalization within the Golgi apparatus of cells in the testis and epididymis. Igdoura SA, et al. **Eur J Cell Biol** 1999 Jul;78(7):441-52

Differential localization of protein kinase A type II isozymes in the Golgi-centrosomal area. Keryer G, et al. **Exp Cell Res** 1999 May 25;249(1):131-46

Substrate specificities of recombinant murine Golgi alpha1, 2-mannosidases IA and IB and comparison with endoplasmic reticulum and Golgi processing alpha1,2-mannosidases. Lal A, et al. **Glycobiology** 1998 Oct; 8(10):981-95

A C-terminal di-leucine is required for localization of the Menkes protein in the trans-Golgi network. Petris MJ, et al. **Hum Mol Genet** 1998 Dec;7(13):2063-71

Dynamin II is involved in endocytosis but not in the formation of transport vesicles from the trans-Golgi network. Kasai K, et al. **J Biochem (Tokyo)** 1999 Apr; 125(4):780-9

Receptor-mediated targeting of fluorescent probes in living cells. Farinas J, et al. **J Biol Chem** 1999 Mar 19; 274(12):7603-6

Molecular cloning, characterization, and dynamics of rat formiminotransferase cyclodeaminase, a Golgi-associated 58-kDa protein. Gao YS, et al. **J Biol Chem** 1998 Dec 11;273(50):33825-34

Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. Marks DL, et al. **J Biol Chem** 1999 Jan 1;274(1):451-6

Characterization of a novel giant scaffolding protein, CG-NAP, that anchors multiple signaling enzymes to centrosome and the golgi apparatus. Takahashi M, et al. **J Biol Chem** 1999 Jun 11;274(24):17267-74

Biosynthesis and packaging of carboxypeptidase D into nascent secretory vesicles in pituitary cell lines. Varlamov O, et al. **J Biol Chem** 1999 May 14;274(20):14040-5

The high osmolarity glycerol response (HOG) MAP kinase pathway controls localization of a yeast golgi glycosyltransferase. Reynolds TB, et al. **J Cell Biol** 1998 Nov 16;143(4):935-46

Recycling of golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides an explanation for nocodazole-induced Golgi scattering. Storrie B, et al. **J Cell Biol** 1998 Dec 14;143(6):1505-21

Overexpression of the ARF1 exchange factor ARNO inhibits the early secretory pathway and causes the disassembly of the Golgi complex. Monier S, et al. **J Cell Sci** 1998 Nov;111 (Pt 22):3427-36

Targeting of active sialyltransferase to the plant Golgi apparatus. Wee EG, et al. **Plant Cell** 1998 Oct; 10(10):1759-68

GENETICS

The genes for the Golgi apparatus N-acetylglucosaminyltransferase and the UDP-N-acetylglucosamine transporter are contiguous in Kluyveromyces lactis. Guillen E, et al. **J Biol Chem** 1999 Mar 5;274(10):6641-6

N-Ras induces alterations in Golgi complex architecture and in constitutive protein transport. Babia T, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):477-89

An amino terminal intron indicates that transcripts for the Plasmodium falciparum Golgi network marker Rab6 do not encode alternative amino termini. Templeton TJ, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):149-53

IMMUNOLOGY

High anti-golgi autoantibody levels: an early sign of autoimmune disease? Bizzaro N, et al. **Clin Rheumatol** 1999; 18(4):346-8

METABOLISM

Golgi and electron-microscopic golgi-GABA immunostaining study of the avian optic tectum. Tömböl T. **Acta Anat (Basel)** 1998;162(4):209-25

From the ER to the golgi: insights from the study of combined factors V and VIII deficiency. Nichols WC, et al. **Am J Hum Genet** 1999 Jun;64(6):1493-8 (38 ref.)

Enzymatic synthesis and purification of [(3)H]uridine diphosphate galacturonic acid for use in studying Golgi-localized transporters. Orellana A, et al. **Anal Biochem** 1999 Aug 1;272(2):224-31

Transporters of nucleotide sugars, ATP, and nucleotide sulfate in the endoplasmic reticulum and Golgi apparatus. Hirschberg CB, et al. **Annu Rev Biochem** 1998;67:49-69 (121 ref.)

Antiparasitic effects of the intra-Golgi transport inhibitor megalomicin. Bonay P, et al. **Antimicrob Agents Chemother** 1998 Oct;42(10):2668-73

Cell-free transfer of the vesicular stomatitis virus G protein from an endoplasmic reticulum compartment of baby hamster kidney cells to a rat liver Golgi apparatus compartment for Man8-9 to Man5 processing. Paulik MA, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):265-73

Dynamic recycling of ERGIC53 between the endoplasmic reticulum and the Golgi complex is disrupted by nordihydroguaiaretic acid. Fujiwara T, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):869-76

Protein-protein interactions of the yeast Golgi t-SNARE Sed5 protein distinct from its neural plasma membrane cognate syntaxin 1. Kosodo Y, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):212-6

Targeting of MAL, a putative element of the apical sorting machinery, to glycolipid-enriched membranes requires a pre-golgi sorting event. Puertollano R, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):689-92

Cholesterol regulates oxysterol binding protein (OSBP) phosphorylation and Golgi localization in Chinese hamster ovary cells: correlation with stimulation of sphingomyelin synthesis by 25-hydroxycholesterol. Storey MK, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):247-56

Furin and proprotein convertase 7 (PC7)/lymphoma PC endogenously expressed in rat liver can be resolved into distinct post-Golgi compartments. Wouters S, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):311-6

Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Xia W, et al. **Biochemistry** 1998 Nov 24; 37(47):16465-71

Multiple sorting pathways between the late Golgi and the vacuole in yeast. Conibear E, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):211-30 (135 ref.)

Evidence for protein splicing in the endoplasmic reticulum-Golgi intermediate compartment. Demirov D, et al. **Biochim Biophys Acta** 1999 Jan 11;1448(3):507-11

Protein sorting in the Golgi complex. Füllekrug J, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):77-84 (59 ref.)

Protein transport from the secretory to the endocytic pathway in mammalian cells. Le Borgne R, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):195-209 (136 ref.)

Organization of ganglioside synthesis in the Golgi apparatus. Maccioni HJ, et al. **Biochim Biophys Acta** 1999 Feb 25; 1437(2):101-18 (142 ref.)

Palmitoylation of GAP-43 by the ER-Golgi intermediate compartment and Golgi apparatus. McLaughlin RE, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):82-92

Vesicle budding on Golgi membranes: regulation by G proteins and myosin motors. Stow JL, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):161-71 (98 ref.)

Protein retention and localization in the endoplasmic reticulum and the golgi apparatus. Gomord V, et al. **Biochimie** 1999 Jun;81(6):607-18 (109 ref.)

Procollagen traverses the Golgi stack without leaving the lumen of cisternae: evidence for cisternal maturation [see comments] Bonfanti L, et al. **Cell** 1998 Dec 23; 95(7):993-1003. Comment in: Cell 1998 Dec 23;95(7):883-9.

Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi [see comments] Choy E, et al. **Cell** 1999 Jul 9;98(1):69-80. Comment in: Cell 1999 Jul 9;98(1):9-12.

The curious status of the Golgi apparatus [comment] Gljck BS, et al. **Cell** 1998 Dec 23;95(7):883-9. Comment on: Cell 1998 Dec 23;95(7):993-1003.

Vesicular tubular clusters between the ER and Golgi mediate concentration of soluble secretory proteins by exclusion from COPI-coated vesicles. Martinez-Menárguez JA, et al. **Cell** 1999 Jul 9;98(1):81-90

Proteins involved in membrane transport between the ER and the Golgi apparatus: 21 putative plant homologues revealed by dbEST searching. Andreeva AV, et al. **Cell Biol Int** 1998;22(2):145-60

A novel Rab6-interacting domain defines a family of Golgi-targeted coiled-coil proteins. Barr FA. **Curr Biol** 1999 Apr 8;9(7):381-4

A novel Golgi-localisation domain shared by a class of coiled-coil peripheral membrane proteins. Kjer-Nielsen L, et al. **Curr Biol** 1999 Apr 8;9(7):385-8

The GRIP domain - a novel Golgi-targeting domain found in several coiled-coil proteins. Munro S, et al. **Curr Biol** 1999 Apr 8;9(7):377-80

Transport from the endoplasmic reticulum to the Golgi. Kaiser C, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):477-82 (57 ref.)

Got1p and Sft2p: membrane proteins involved in traffic to the Golgi complex. Conchon S, et al. **EMBO J** 1999 Jul 15;18(14):3934-46

The disulfide-bonded loop of chromogranin B mediates membrane binding and directs sorting from the trans-Golgi network to secretory granules. Glombik MM, et al. **EMBO J** 1999 Feb 15;18(4):1059-70

Sac1p plays a crucial role in microsomal ATP transport, which is distinct from its function in Golgi phospholipid metabolism. Kochendörfer KU, et al. **EMBO J** 1999 Mar 15;18(6):1506-15

The Golgi apparatus is an inositol 1,4,5-trisphosphate-sensitive Ca2+ store, with functional properties distinct from those of the endoplasmic reticulum. Pinton P, et al. **EMBO J** 1998 Sep 15;17(18):5298-308

Retrograde transport from the yeast Golgi is mediated by two ARF GAP proteins with overlapping function. Poon PP, et al. **EMBO J** 1999 Feb 1;18(3):555-64

Specific binding to a novel and essential Golgi membrane protein (Yip1p) functionally links the transport GTPases Ypt1p and Ypt31p. Yang X, et al. **EMBO J** 1998 Sep 1; 17(17):4954-63

Mapping of structural determinants for the oligomerization of p58, a lectin-like protein of the intermediate compartment and cis-Golgi. Lahtinen U, et al. **Eur J Biochem** 1999 Mar;260(2):392-7

Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Menon RP, et al. **Eur J Biochem** 1999 Sep;264(2):569-76

TCRzeta is transported to and retained in the Golgi apparatus independently of other TCR chains: implications for TCR assembly. Dietrich J, et al. **Eur J Immunol** 1999 May; 29(5):1719-28

Trafficking of liposomal antigen to the trans-Golgi of murine macrophages requires both liposomal lipid and liposomal protein. Rao M, et al. **Exp Cell Res** 1999 Jan 10; 246(1):203-11

Post-Golgi trafficking of rhodopsin in retinal photoreceptors. Deretic D. **Eye** 1998;12 (Pt 3b):526-30 (40 ref.)

Targeting of gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR to Golgi complexes and vacuoles within celiac disease enterocytes. Zimmer KP, et al. **FASEB J** 1998 Oct;12(13):1349-57

The N-terminal 77 amino acids from tobacco N-acetylglucosaminyltransferase I are sufficient to retain a reporter protein in the Golgi apparatus of Nicotiana benthamiana cells. Essl D, et al. **FEBS Lett** 1999 Jun 18; 453(1-2):169-73

Constitutive transport between the trans-Golgi network and the plasma membrane according to the maturation model. A hypothesis. Mironov AA, et al. **FEBS Lett** 1998 Nov 27;440(1-2):99-102

Arfaptin 1, an ARF-binding protein, inhibits phospholipase D and endoplasmic reticulum/Golgi protein transport. Williger BT, et al. **FEBS Lett** 1999 Jan 25;443(2):197-200

Chitinase secretion by encysting Entamoeba invadens and transfected Entamoeba histolytica trophozoites: localization of secretory vesicles, endoplasmic reticulum, and Golgi apparatus. Ghosh SK, et al. **Infect Immun** 1999 Jun;67(6):3073-81

Activities of mutant Sar1 proteins in guanine nucleotide binding, GTP hydrolysis, and cell-free transport from the endoplasmic reticulum to the Golgi apparatus. Saito Y, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):816-23

ADP-ribosylation factor-1 is sensitive to N-ethylmaleimide. Yamaguchi T, et al. **J Biochem (Tokyo)** 1998 Dec 1; 124(6):1229-36

Involvement of PITPnm, a mammalian homologue of Drosophila rdgB, in phosphoinositide synthesis on Golgi membranes. Aikawa Y, et al. **J Biol Chem** 1999 Jul 16; 274(29):20569-77

Direct transport of newly synthesized HLA-DR from the trans-Golgi network to major histocompatibility complex class II containing compartments (MIICS) demonstrated using a novel tyrosine-sulfated chimera. Davidson HW. **J Biol Chem** 1999 Sep 17;274(38):27315-22

Specific isoforms of actin-binding proteins on distinct populations of Golgi-derived vesicles. Heimann K, et al. **J Biol Chem** 1999 Apr 16;274(16):10743-50

Selective perturbation of early endosome and/or trans-Golgi network pH but not lysosome pH by dose-dependent expression of influenza M2 protein. Henkel JR, et al. **J Biol Chem** 1999 Apr 2;274(14):9854-60

A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the golgi. Lübke T, et al. **J Biol Chem** 1999 Sep 10; 274(37):25986-9

Sialyltransferase isoforms are phosphorylated in the cis-medial Golgi on serine and threonine residues in their luminal sequences. Ma J, et al. **J Biol Chem** 1999 Mar 19; 274(12):8046-52

The Golgi apparatus plays a significant role in the maintenance of Ca2+ homeostasis in the vps33Delta vacuolar biogenesis mutant of Saccharomyces cerevisiae.

Miseta A, et al. **J Biol Chem** 1999 Feb 26;274(9):5939–47

Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. Parolini I, et al. **J Biol Chem** 1999 Sep 3;274(36):25718–25

Identification and purification of the rat liver Golgi membrane UDP-N-acetylgalactosamine transporter. Puglielli L, et al. **J Biol Chem** 1999 Feb 12;274(7):4474–9

Differential effects of sphingomyelin hydrolysis and cholesterol transport on oxysterol-binding protein phosphorylation and Golgi localization. Ridgway ND, et al. **J Biol Chem** 1998 Nov 20;273(47):31621–8

Topology of Euglena chloroplast protein precursors within endoplasmic reticulum to Golgi to chloroplast transport vesicles. Sulli C, et al. **J Biol Chem** 1999 Jan 1;274(1):457–63

Sorting of furin at the trans-Golgi network. Interaction of the cytoplasmic tail sorting signals with AP-1 Golgi-specific assembly proteins. Teuchert M, et al. **J Biol Chem** 1999 Mar 19;274(12):8199–207

Purification and characterization of a novel 13 S hetero-oligomeric protein complex that stimulates in vitro Golgi transport. Walter DM, et al. **J Biol Chem** 1998 Nov 6;273(45):29565–76

Molecular role for the Rab binding platform of guanine nucleotide dissociation inhibitor in endoplasmic reticulum to Golgi transport. Wu SK, et al. **J Biol Chem** 1998 Oct 9;273(41):26931–8

The localization of myosin VI at the golgi complex and leading edge of fibroblasts and its phosphorylation and recruitment into membrane ruffles of A431 cells after growth factor stimulation. Buss F, et al. **J Cell Biol** 1998 Dec 14;143(6):1535–45

GBF1: A novel Golgi-associated BFA-resistant guanine nucleotide exchange factor that displays specificity for ADP-ribosylation factor 5. Claude A, et al. **J Cell Biol** 1999 Jul 12;146(1):71–84

Fusogenic domains of golgi membranes are sequestered into specialized regions of the stack that can be released by mechanical fragmentation. Dominguez M, et al. **J Cell Biol** 1999 May 17;145(4):673–88

Genetic evidence for ATP-dependent endoplasmic reticulum-to-Golgi apparatus trafficking of ceramide for sphingomyelin synthesis in Chinese hamster ovary cells. Fukasawa M, et al. **J Cell Biol** 1999 Feb 22;144(4):673–85

Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells. Hirschberg K, et al. **J Cell Biol** 1998 Dec 14;143(6):1485–503

GMAP-210, A cis-Golgi network-associated protein, is a minus end microtubule-binding protein. Infante C, et al. **J Cell Biol** 1999 Apr 5;145(1):83–98

Overexpression of CALNUC (nucleobindin) increases agonist and thapsigargin releasable Ca2+ storage in the Golgi. Lin P, et al. **J Cell Biol** 1999 Apr 19;145(2):279–89

Molecular characterization of caveolin association with the Golgi complex: identification of a cis-Golgi targeting domain in the caveolin molecule. Luetterforst R, et al. **J Cell Biol** 1999 Jun 28;145(7):1443–59

KDEL receptor (Erd2p)-mediated retrograde transport of the cholera toxin A subunit from the Golgi involves COPI, p23, and the COOH terminus of Erd2p. Majoul I, et al. **J Cell Biol** 1998 Nov 2;143(3):601–12

Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of shiga toxin B-fragment transport. Mallard F, et al. **J Cell Biol** 1998 Nov 16;143(4):973–90

Chimeric forms of furin and TGN38 are transported with the plasma membrane in the trans-Golgi network via distinct endosomal pathways. Mallet WG, et al. **J Cell Biol** 1999 Jul 26;146(2):345–59

The membrane transport factor TAP/p115 cycles between the Golgi and earlier secretory compartments and contains distinct domains required for its localization and function. Nelson DS, et al. **J Cell Biol** 1998 Oct 19;143(2):319–31

A role for the vesicle tethering protein, p115, in the post-mitotic stacking of reassembling Golgi cisternae in a cell-free system. Shorter J, et al. **J Cell Biol** 1999 Jul 12;146(1):57–70

Reconstitution of retrograde transport from the Golgi to the ER in vitro. Spang A, et al. **J Cell Biol** 1998 Nov 2; 143(3):589–99

N-Ras induces alterations in Golgi complex architecture and in constitutive protein transport. Babiá T, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):477–89

Forward and retrograde trafficking in mitotic animal cells. ER-Golgi transport arrest restricts protein export from the ER into COPII-coated structures. Farmaki T, et al. **J Cell Sci** 1999 Mar;112 (Pt 5):589–600

TbRab2p, a marker for the endoplasmic reticulum of Trypanosoma brucei, localises to the ERGIC in mammalian cells. Field H, et al. **J Cell Sci** 1999 Jan;112 (Pt 2):147–56

The Sec61 complex is located in both the ER and the ER-Golgi intermediate compartment. Greenfield JJ, et al. **J Cell Sci** 1999 May;112 (Pt 10):1477–86

Protein transport from the endoplasmic reticulum to the Golgi apparatus. Hong W. **J Cell Sci** 1998 Oct;111 (Pt 19):2831–9 (123 ref.)

The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Jackson ME, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):467–75

The Golgi-targeting sequence of the peripheral membrane protein p230. Kjer-Nielsen L, et al. **J Cell Sci** 1999 Jun; 112 (Pt 11):1645–54

The recycling pathway of protein ERGIC-53 and dynamics of the ER-Golgi intermediate compartment. Klumperman J, et al. **J Cell Sci** 1998 Nov;111 (Pt 22):3411–25

Uptake by COPI-coated vesicles of both anterograde and retrograde cargo is inhibited by GTPgammaS in vitro. Nickel W, et al. **J Cell Sci** 1998 Oct;111 (Pt 20):3081–90

Alpha-SNAP but not gamma-SNAP is required for ER-Golgi transport after vesicle budding and the Rab1-requiring step but before the EGTA-sensitive step. Peter F, et al. **J Cell Sci** 1998 Sep;111 (Pt 17):2625–33

Blockade of membrane transport and disassembly of the Golgi complex by expression of syntaxin 1A in neurosecretion-incompetent cells: prevention by rbSEC1. Rowe J, et al. **J Cell Sci** 1999 Jun;112 (Pt 12):1865–77

Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells. Toomre D, et al. **J Cell Sci** 1999 Jan;112 (Pt 1):21–33

Transport of bacterial lipopolysaccharide to the golgi apparatus. Thieblemont N, et al. **J Exp Med** 1999 Aug 16;190(4):523–34

Localization of the mixed-lineage kinase DLK/MUK/ZPK to the Golgi apparatus in NIH 3T3 cells. Douziech M, et al. **J Histochem Cytochem** 1999 Oct;47(10):1287–96

TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. Jones SJ, et al. **J Immunol** 1999 Jan 15; 162(2):1042–8

Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. Diano S, et al. **J Neuroendocrinol** 1998 Sep;10(9):647–50

The use of permeabilized cells to investigate secretory granule biogenesis. Ling WL, et al. **Methods** 1998 Oct; 16(2):141–9

Two endoplasmic reticulum (ER) membrane proteins that facilitate ER-to-Golgi transport of glycosylphosphatidylinositol-anchored proteins. Barz WP, et al. **Mol Biol Cell** 1999 Apr;10(4):1043–59

Rab11 is required for trans-golgi network-to-plasma membrane transport and a preferential target for GDP dissociation inhibitor. Chen W, et al. **Mol Biol Cell** 1998 Nov;9(11):3241–57

A modulatory role for clathrin light chain phosphorylation in Golgi membrane protein localization during vegetative growth and during the mating response of Saccharomyces cerevisiae. Chu DS, et al. **Mol Biol Cell** 1999 Mar; 10(3):713–26

A role for Tlg1p in the transport of proteins within the Golgi apparatus of Saccharomyces cerevisiae. Coe JG, et al. **Mol Biol Cell** 1999 Jul;10(7):2407–23

Membrane tubule-mediated reassembly and maintenance of the Golgi complex is disrupted by phospholipase A2 antagonists. de Figueiredo P, et al. **Mol Biol Cell** 1999 Jun; 10(6):1763–82

Localization and recycling of gp27 (hp24gamma3): complex formation with other p24 family members. Füllekrug J, et al. **Mol Biol Cell** 1999 Jun;10(6):1939–55

Chicken erythroid AE1 anion exchangers associate with the cytoskeleton during recycling to the Golgi. Ghosh S, et al. **Mol Biol Cell** 1999 Feb;10(2):455–69

Inhibition of secretion by 1,3-Cyclohexanebis(methylamine), a dibasic compound that interferes with coatomer function. Hu T, et al. **Mol Biol Cell** 1999 Apr;10(4):921–33

Osmotically induced cell volume changes alter anterograde and retrograde transport, Golgi structure, and COPI dissociation. Lee TH, et al. **Mol Biol Cell** 1999 May; 10(5):1445–62

Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Palokangas H, et al. **Mol Biol Cell** 1998 Dec;9(12):3561–78

Vesicle-associated membrane protein 4 is implicated in trans-Golgi network vesicle trafficking. Steegmaier M, et al. **Mol Biol Cell** 1999 Jun;10(6):1957–72

A Rab2 mutant with impaired GTPase activity stimulates vesicle formation from pre-Golgi intermediates. Tisdale EJ. **Mol Biol Cell** 1999 Jun;10(6):1837–49

GS32, a novel Golgi SNARE of 32 kDa, interacts preferentially with syntaxin 6. Wong SH, et al. **Mol Biol Cell** 1999 Jan;10(1):119–34

The dynamics of golgi protein traffic visualized in living yeast cells. Wooding S, et al. **Mol Biol Cell** 1998 Sep;9(9):2667–80

Morphological and functional association of Sec22b/ERS-24 with the pre-Golgi intermediate compartment. Zhang T, et al. **Mol Biol Cell** 1999 Feb;10(2):435–53

The plant vesicle-associated SNARE AtVTI1a likely mediates vesicle transport from the trans-Golgi network to the prevacuolar compartment. Zheng H, et al. **Mol Biol Cell** 1999 Jul;10(7):2251–64

High-affinity binding of the AP-1 adaptor complex to trans-golgi network membranes devoid of mannose 6-phosphate receptors. Zhu Y, et al. **Mol Biol Cell** 1999 Mar;10(3):537–49

Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network. Higgins ME, et al. **Mol Genet Metab** 1999 Sep; 68(1):1–13

Thyroid hormone, T3-dependent phosphorylation and translocation of Trip230 from the Golgi complex to the nucleus. Chen Y, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4443–8

Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Greenfield JP, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):742–7

Evectins: vesicular proteins that carry a pleckstrin homology domain and localize to post-Golgi membranes. Krappa R, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4633–8

p200 ARF-GEP1: a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is targeted by the drug brefeldin A. Mansour SJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7968–73

Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Nohturfft A, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11235–40

An essential role for the phosphatidylinositol transfer protein in the scission of coatomer-coated vesicles from the trans-Golgi network. Simon JP, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11181–6

ADP-ribosylation factor and phosphatidic acid levels in Golgi membranes during budding of coatomer-coated vesicles [published erratum appears in Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2569] Stamnes M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13676–80

A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Stankewich MC, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14158–63

ADP-ribosylation factor 1 dependent clathrin-coat assembly on synthetic liposomes. Zhu Y, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5013–8

Protein sorting by directed maturation of Golgi compartments. Allan BB, et al. **Science** 1999 Jul 2; 285(5424):63–6 (68 ref.)

100 years of Golgi complexities. Jamora C. **Trends Cell Biol** 1999 Jan;9(1):37–8

Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Molloy SS, et al. **Trends Cell Biol** 1999 Jan;9(1):28–35 (64 ref.)

Lipid regulators of membrane traffic through the Golgi complex. Roth MG. **Trends Cell Biol** 1999 May;9(5):174–9 (64 ref.)

PATHOLOGY

Morphological and biochemical analysis of the secretory pathway in melanoma cells with distinct metastatic potential. Ayala I, et al. **FEBS Lett** 1999 May 28; 451(3):315–20

Fragmentation of the Golgi apparatus of Betz cells in patients with amyotrophic lateral sclerosis. Fujita Y, et al. **J Neurol Sci** 1999 Feb 1;163(1):81–5

PHYSIOLOGY

GAIP, a Galphai-3-binding protein, is associated with Golgi-derived vesicles and protein trafficking. Wylie F, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C497–506

A spectrin membrane skeleton of the Golgi complex. Beck KA, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1-2):153–60 (43 ref.)

The role of microtubule-based motor proteins in maintaining the structure and function of the Golgi complex. Burkhardt JK. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):113–26 (89 ref.)

Inheritance of the mammalian Golgi apparatus during the cell cycle. Cabrera-Poch N, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):139–51 (100 ref.)

The plant Golgi apparatus. Dupree P, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):259–70 (84 ref.)

The contribution of lipids and lipid metabolism to cellular functions of the Golgi complex. Fang M, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):85–100 (97 ref.)

COPI in ER/Golgi and intra-Golgi transport: do yeast COPI mutants point the way? Gaynor EC, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):33–51 (124 ref.)

The Golgi complex: perspectives and prospectives. Jamieson JD. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):3–7 (30 ref.)

Rab proteins. Martinez O, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):101–12 (106 ref.)

SNAREs and membrane fusion in the Golgi apparatus. Nichols BJ, et al. **Biochim Biophys Acta** 1998 Aug 14; 1404(1-2):9–31 (149 ref.)

Dynamics of the interphase mammalian Golgi complex as revealed through drugs producing reversible Golgi disassembly. Storrie B, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):127–37 (44 ref.)

Biogenesis of secretory granules in the trans-Golgi network of neuroendocrine and endocrine cells. Tooze SA. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):231–44 (110 ref.)

Gbetagamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D. Jamora C, et al. **Cell** 1999 Jul 9;98(1):59–68

Bulk flow redux? Warren G, et al. **Cell** 1999 Jul 23; 98(2):125–7 (14 ref.)

Golgi's apparatus. **Curr Biol** 1998 Sep 10;8(18):R632–3

The organisation of the Golgi apparatus. Warren G, et al.

Curr Opin Cell Biol 1998 Aug;10(4):493–8 (67 ref.)
Coalescence of Golgi fragments in microtubule-deprived living cells. Polishchuk RS, et al. **Eur J Cell Biol** 1999 Mar;78(3):170–85
Role of microtubules in the organization of the Golgi complex. Thyberg J, et al. **Exp Cell Res** 1999 Feb 1; 246(2):263–79 (234 ref.)
Role of xklp3, a subunit of the Xenopus kinesin II heterotrimeric complex, in membrane transport between the endoplasmic reticulum and the Golgi apparatus. Le Bot N, et al. **J Cell Biol** 1998 Dec 14;143(6):1559–73
Lamellar granule biogenesis: a role for ceramide glucosyltransferase, lysosomal enzyme transport, and the Golgi. Madison KC, et al.
J Investig Dermatol Symp Proc 1998 Aug;3(2):80–6
In vitro reconstitution of microtubule plus end-directed, GTPgammaS-sensitive motility of Golgi membranes. Fullerton AT, et al. **Mol Biol Cell** 1998 Oct;9(10):2699–714
Golgi membrane dynamics. Presley JF, et al.
Mol Biol Cell 1998 Jul;9(7):1617–26
Stacks on tracks: the plant Golgi apparatus traffics on an actin/ER network. Boevink P, et al. **Plant J** 1998 Aug; 15(3):441–7
Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. Chatterton JE, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):915–20
Coming to grips with the Golgi [news] Featherstone C.
Science 1998 Dec 18;282(5397):2172–4
Protein and lipid sorting between the endoplasmic reticulum and the Golgi complex. Nickel W, et al.
Semin Cell Dev Biol 1998 Oct;9(5):493–501 (76 ref.)
Protein and lipid sorting from the trans-Golgi network to secretory granules-recent developments. Thiele C, et al.
Semin Cell Dev Biol 1998 Oct;9(5):511–6 (57 ref.)
Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Kent C, et al. **Trends Biochem Sci** 1999 Apr; 24(4):146–50 (45 ref.)
Glycans in post-Golgi apical targeting: sorting signals or structural props? Rodriguez-Boulan E, et al.
Trends Cell Biol 1999 Aug;9(8):291–4 (45 ref.)
[Current concept of structure and function of the Golgi apparatus. On the 100-anniversary of the discovery by Camillo Golgi] Mironov AA, et al. **Tsitologiia** 1998; 40(6):483–96 (83 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Cytochemical images of secretion in Saccharomyces cerevisiae and animal cells are different. Vořišek J.
Acta Histochem 1998 Nov;100(4):419–38 (99 ref.)

ULTRASTRUCTURE

The history of the Golgi apparatus in neurones from its discovery in 1898 to electron microscopy. Dröscher A.
Brain Res Bull 1998 Oct;47(3):199–203 (62 ref.)
Environmental factors modulate the size and the secretory activity of the notochord. A study of the Golgi apparatus in avian embryos. Monsoro-Burq AH, et al.
C R Acad Sci III 1998 Aug;321(8):621–31
Morphological changes in the Golgi complex correlate with actin cytoskeleton rearrangements. di Campli A, et al.
Cell Motil Cytoskeleton 1999;43(4):334–48
Golgi's apparatus. **Curr Biol** 1998 Sep 10;8(18):R632–3
Low cytoplasmic pH causes fragmentation and dispersal of the Golgi apparatus in human hepatoma cells. Yoshida T, et al. **Int J Exp Pathol** 1999 Feb;80(1):51–7
Stimulation of Golgi membrane tubulation and retrograde trafficking to the ER by phospholipase A(2) activating protein (PLAP) peptide. Polizotto RS, et al.
J Cell Biochem 1999 Sep 15;74(4):670–83
The localization of myosin VI at the golgi complex and leading edge of fibroblasts and its phosphorylation and recruitment into membrane ruffles of A431 cells after growth factor stimulation. Buss F, et al. **J Cell Biol** 1998 Dec 14;143(6):1535–45
Golgi structure in three dimensions: functional insights from the normal rat kidney cell. Ladinsky MS, et al.
J Cell Biol 1999 Mar 22;144(6):1135–49
Golgi structure correlates with transitional endoplasmic reticulum organization in Pichia pastoris and Saccharomyces cerevisiae. Rossanese OW, et al.
J Cell Biol 1999 Apr 5;145(1):69–81
Syntaxin 11 is associated with SNAP-23 on late endosomes and the trans-Golgi network. Valdez AC, et al.
J Cell Sci 1999 Mar;112 (Pt 6):845–54
Novel membranous structures in apical and basal compartments of inner hair cells. Spicer SS, et al.
J Comp Neurol 1999 Jul 5;409(3):424–37
Ultrastructural pathology of Golgi apparatus of nerve cells in human brain edema associated to brain congenital malformations, tumours and trauma. Castejón OJ.
J Submicrosc Cytol Pathol 1999 Apr;31(2):203–13
Osmotically induced cell volume changes alter anterograde and retrograde transport, Golgi structure, and COPI dissociation. Lee TH, et al. **Mol Biol Cell** 1999 May; 10(5):1445–62
Biochemical characterization of the Golgi-complex proteins of Tritrichomonas foetus. Diaz JA, et al. **Parasitol Res** 1998 Sep;84(9):760–2
ADP-ribosylation factor 1 dependent clathrin-coat assembly on synthetic liposomes. Zhu Y, et al.
Proc Natl Acad Sci U S A 1999 Apr 27;96(9):5013–8
Coming to grips with the Golgi [news] Featherstone C.
Science 1998 Dec 18;282(5397):2172–4
[Where does the "Golgi pathway" lead? (on the 100th anniversary of the discovery of the Golgi complex)] Banin VV. **Morfologiia** 1999;115(3):90–7 (27 ref.) **(Rus)**
[Current concept of structure and function of the Golgi apparatus. On the 100-anniversary of the discovery by Camillo Golgi] Mironov AA, et al. **Tsitologiia** 1998; 40(6):483–96 (83 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Intracellular traffic of herpes simplex virus glycoprotein gE: characterization of the sorting signals required for its trans-Golgi network localization. Alconada A, et al.
J Virol 1999 Jan;73(1):377–87
Targeting of a short peptide derived from the cytoplasmic tail of the G1 membrane glycoprotein of Uukuniemi virus (Bunyaviridae) to the Golgi complex. Andersson AM, et al. **J Virol** 1998 Dec;72(12):9585–96

GOLGI TENDON ORGANS see **MECHANORECEPTORS**

GOLTZ SYNDROME see **FOCAL DERMAL HYPOPLASIA**

GONADAL DISORDERS

COMPLICATIONS

Primary amenorrhoea: analysis of 48 cases. Kumar A, et al.
J Indian Med Assoc 1998 Apr;96(4):119–20

ETIOLOGY

Proceedings of the XIth International Workshop on Development, and Function of the Reproductive Organs--Genetic and Endocrine Basis of Gonadal Failure. Amsterdam, the Netherlands, April 16–17, 1998.
Mol Cell Endocrinol 1998 Oct 25;145(1–2):1–174

GENETICS

Single-gene mutations resulting in reproductive dysfunction in women. Adashi EY, et al. **N Engl J Med** 1999 Mar 4; 340(9):709–18 (75 ref.)

GONADAL DYSGENESIS

FISH and PCR analysis of the presence of Y-chromosome sequences in a patient with Xq-isochromosome and testicular tissue. Alvarez-Nava F, et al. **Clin Genet** 1999 May;55(5):356–61
Evolutionary flux of P element regulation in a Drosophila melanogaster hybrid dysgenesis cline. French DJ, et al.
Genet Res 1999 Jun;73(3):205–16

COMPLICATIONS

Severe mixed connective tissue disease in a woman with pure gonadal dysgenesis: estrogens do not influence disease expression. Grodzicky T, et al. **J Rheumatol** 1999 Apr; 26(4):923–6
Dysgerminoma with syncytiotrophoblastic giant cells arising from 46,XX pure gonadal dysgenesis. Morimura Y, et al.
Obstet Gynecol 1998 Oct;92(4 Pt 2):654–6

GENETICS

FMR1 repeat analysis in patients with ovarian dysfunction or failure [letter] Patsalis PC. **Am J Med Genet** 1999 Apr 2;83(4):329–30
Abnormalities of gonadal differentiation. Berkovitz GD, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):133–42 (42 ref.)
A frame shift mutation in the DNA-binding domain of the androgen receptor gene associated with complete androgen insensitivity, persistent müllerian structures, and germ cell tumors in dysgenetic gonads. Chen CP, et al.
Fertil Steril 1999 Jul;72(1):170–3
The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor. Barbosa AS, et al. **Hum Mutat** 1999; 13(2):146–53
Investigation of a unique male and female sibship with Kallmann's syndrome and 46,XX gonadal dysgenesis with short stature. Persson JW, et al. **Hum Reprod** 1999 May; 14(5):1207–12
Risk of gonadoblastoma in female patients with Y chromosome abnormalities and dysgenetic gonads. Gibbons B, et al. **J Paediatr Child Health** 1999 Apr;35(2):210–3
Candidate genes in complete and partial XY sex reversal: mutation analysis of SRY, SRY-related genes and FTZ-F1. Lim HN, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):51–8 (60 ref.)
Characterization of permissivity for hobo-mediated gonadal dysgenesis in Drosophila melanogaster. Bazin C, et al.
Mol Gen Genet 1999 Apr;261(3):480–6
[Gonadal dysgenesis in own material] Gasińska-Drozdowska I, et al. **Ginekol Pol** 1999 May;70(5):363–6 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Prenatal diagnosis of 46,XX male fetuses. Ginsberg NA, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):1006–7

GONADAL DYSGENESIS, 45,X see **TURNER'S SYNDROME**

GONADAL DYSGENESIS, XO see **TURNER'S SYNDROME**

GONADAL DYSGENESIS, 46,XY

COMPLICATIONS

Defective sexual development in an infant with 46, XY, der(9)t(8;9)(q23.1;p23)mat. Pfeiffer RA, et al.
Eur J Pediatr 1999 Mar;158(3):213–6

GENETICS

SRY mutation and tumor formation on the gonads of XP pure gonadal dysgenesis patients. Uehara S, et al.
Cancer Genet Cytogenet 1999 Aug;113(1):78–84
Novel mutation in the SRY gene results in 46,XY gonadal dysgenesis. Cameron FJ, et al. **Hum Mutat** 1998;Suppl 1:S110–1
Mutation in the 5' noncoding region of the SRY gene in an XY sex-reversed patient. Poulat F, et al.
Hum Mutat 1998;Suppl 1:S192–4
Long arm deletion of chromosome 10 in a boy with monorchidism. Mutoh A, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):77–8 (9 ref.)
Infertility and multiple urogenital abnormalities in a male with mosaic 46,XY/45,XO/47,XXY karyotype and mixed phenotype. Filiadis IF, et al. **Urol Int** 1998;61(2):111–4
[XY gonadal dysgenesis (Swyer syndrome) with gonadoblastoma] Lange A, et al. **Zentralbl Gynakol** 1998; 120(11):555–8 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Morphology of gonads in pure XY gonadal dysgenesis. Radaković B, et al. **Coll Antropol** 1999 Jun;23(1):203–11
Gonadal histology with testicular carcinoma in situ in a 15-year-old 46,XY female patient with a premature termination in the steroidogenic acute regulatory protein causing congenital lipoid adrenal hyperplasia. Korsch E, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1628–32
[Dysgerminoma into gonadoblastoma--a clinico-morphological interpretation of 2 cases in female patients with gonadal dysgenesis] Raicheva S, et al.
Akush Ginekol (Sofiia) 1998;37(4):53–4 **(Bul)**

GONADAL DYSGENESIS, MIXED

COMPLICATIONS

Management quandary. Primary amenorrhea due to mixed gonadal dysgenesis. Breech L, et al.
J Pediatr Adolesc Gynecol 1998 Nov;11(4):195–7

DIAGNOSIS

Management quandary. Primary amenorrhea due to mixed gonadal dysgenesis. Breech L, et al.
J Pediatr Adolesc Gynecol 1998 Nov;11(4):195–7

GENETICS

Discordant phenotypes and 45,X/46,X,idic(Y). Kelly TE, et al. **J Med Genet** 1998 Oct;35(10):862–4
45,X/46,XY mosaicism: report of 27 cases. Telvi L, et al.
Pediatrics 1999 Aug;104(2 Pt 1):304–8

PATHOLOGY

Polyneuropathy with minifascicle formation in a patient with 46XY mixed gonadal dysgenesis. Umehara F, et al.
Acta Neuropathol (Berl) 1999 Sep;98(3):309–12

GONADOBLASTOMA

COMPLICATIONS

Morphology of gonads in pure XY gonadal dysgenesis. Radaković B, et al. **Coll Antropol** 1999 Jun;23(1):203–11

DIAGNOSIS

Case of gonadoblastoma in a 9-year-old boy without physical abnormalities. Hatano T, et al. **Int J Urol** 1999 Mar; 6(3):164–6 (9 ref.)

DRUG THERAPY

Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumour. Mathur RV, et al.
Nephrol Dial Transplant 1999 Jul;14(7):1786–8

GENETICS

Gonadoblastoma, mixed germ cell tumor, and Y chromosomal genotype: molecular analysis in four patients. Muroya K, et al. **Genes Chromosomes Cancer** 1999 May; 25(1):40–5
Risk of gonadoblastoma in female patients with Y chromosome abnormalities and dysgenetic gonads. Gibbons

B, et al. **J Paediatr Child Health** 1999 Apr;35(2):210-3

[XY gonadal dysgenesis (Swyer syndrome) with gonadoblastoma] Lange A, et al. **Zentralbl Gynakol** 1998; 120(11):555-8 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Gonadoblastoma with proliferation resembling Sertoli cell tumor. Nomura K, et al. **Int J Gynecol Pathol** 1999 Jan; 18(1):91-3

[Dysgerminoma into gonadoblastoma--a clinico-morphological interpretation of 2 cases in female patients with gonadal dysgenesis] Raicheva S, et al. **Akush Ginekol (Sofiia)** 1998;37(4):53-4 **(Bul)**

VIROLOGY

Human endogenous retrovirus (HERV)-K transcripts in gonadoblastomas and gonadoblastoma-derived germ cell tumours. Herbst H, et al. **Virchows Arch** 1999 Jan; 434(1):11-5

GONADOLIBERIN see **GONADORELIN**

GONADOLIBERIN RECEPTORS see **RECEPTORS, LHRH**

GONADORELIN

see related
RECEPTORS, LHRH

ADMINISTRATION & DOSAGE

When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue. Tanaka T, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):85-8

Influence of dose, frequency, and duration of infused gonadotropin-releasing hormone on secretion of luteinizing hormone and follicle-stimulating hormone in nutritionally anestrous beef cows. Vizcarra JA, et al. **Domest Anim Endocrinol** 1999 Apr;16(3):171-81

Simplifying ovulation induction for surrogacy in women with Mayer-Rokitansky-Kuster-Hauser syndrome. Ben-Rafael Z, et al. **Hum Reprod** 1998 Jun;13(6):1470-1

Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome. Elgendy M, et al. **Hum Reprod** 1998 Sep;13(9):2382-5

Efficacy of preoperative medical treatment in facilitating hysteroscopic endometrial resection, myomectomy and metroplasty: literature review. Parazzini F, et al. **Hum Reprod** 1998 Sep;13(9):2592-7 (22 ref.)

Reproductive performance of dairy cows in various programmed breeding systems including OvSynch and combinations of gonadotropin-releasing hormone and prostaglandin F2 alpha. Stevenson JS, et al. **J Dairy Sci** 1999 Mar;82(3):506-15

Serum leptin levels in males with delayed puberty during short-term pulsatile GnRH administration. Giusti M, et al. **J Endocrinol Invest** 1999 Jan;22(1):6-11

Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate. Yamamoto A, et al. **J Med Invest** 1999 Feb;46(1-2):55-8

Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes. Arunothayanun P, et al. **J Pharm Sci** 1999 Jan;88(1):34-8

Testosterone, LH and FSH episodic secretory patterns in GnRH-immunized bulls. Finnerty M, et al. **J Reprod Fertil** 1998 Sep;114(1):85-94

[A study on androgen deprivation therapy prior to radical prostatectomy with special reference to the tumor volume] Hachiya T, et al. **Nippon Rinsho** 1998 Aug;56(8):2157-61 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Total androgen blockade--concept, theory, method and clinical application] Ozono S, et al. **Nippon Rinsho** 1998 Aug;56(8):2129-34 (27 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

Decreasing estrogen in nonpregnant women lowers uterine myometrial type I nitric oxide synthase protein expression. Weeks AD, et al. **Am J Obstet Gynecol** 1999 Jul; 181(1):25-30

Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Weeks AD, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):8-13

Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas [letter; comment] Cramer SF. **Arch Pathol Lab Med** 1998 Dec;122(12):1045-6. Comment on: Arch Pathol Lab Med 1998 May;122(5):442-6.

Effects of gonadotropin-releasing hormone agonists on leiomyomas [letter; comment] Mesia AF, et al. **Arch Pathol Lab Med** 1999 Apr;123(4):282-3. Comment on: Arch Pathol Lab Med 1998 May;122(5):442-6.

Mitochondrial peripheral-type benzodiazepine receptor expression. Correlation with gonadotropin-releasing hormone (GnRH) agonist-induced apoptosis in the corpus luteum. Papadopoulos V, et al. **Biochem Pharmacol** 1999 Nov 1;58(9):1389-93

Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomised controlled trial [letter] Davies A. **Br J Obstet Gynaecol** 1999 Jul;106(7):751-2

A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Vercellini P, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):672-7

Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Cohen I, et al. **Breast Cancer Res Treat** 1999 May;55(2):119-25

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Matsushima H, et al. **Cancer** 1999 Apr 15;85(8):1822-7

Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide). Kakar SS. **Cancer Res** 1998 Oct 15; 58(20):4558-60

Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Meistrich ML, et al. **Cancer Res** 1999 Aug 1;59(15):3557-60

Depressive symptoms associated with gonadotropin-releasing hormone agonists. Warnock JK, et al. **Depress Anxiety** 1998;7(4):171-7 (45 ref.)

Effect of exogenous FSH on ovulation rate in homozygous carriers or noncarriers of the Booroola FecB gene after hypothalamic-pituitary disconnection or after treatment with a GnRH agonist. Hudson NL, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):69-80

Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Marelli MM, et al. **Endocrinology** 1999 Jan;140(1):329-34

Gn-RH agonists and ovarian endometriosis [editorial; comment] Descamps P, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):143-4 . Comment on: Eur J Obstet Gynecol Reprod Biol 1998 Aug;79(2):145-8.

Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Cramer DW, et al. **Fertil Steril** 1999 Jul;72(1):83-9

Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome. Gonzalez F, et al. **Fertil Steril** 1999 Mar;71(3):439-44

Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Surrey ES. **Fertil Steril** 1999 Mar;71(3):420-4 (17 ref.)

Use of a GnRH agonist to suppress testosterone in wild male Hawaiian monk seals (Monachus schauinslandi). Atkinson S, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):178-82

Gonadotrophin-releasing hormone agonist stimulates milt fluidity and plasma concentrations of 17,20beta-dihydroxylated and 5beta-reduced, 3alpha-hydroxylated C21 steroids in male plaice (Pleuronectes platessa). Vermeirssen EL, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):163-77

Effect of treatment with GnRH agonists on new markers of bone metabolism. Kukuvitis A, et al. **Gynecol Obstet Invest** 1999;47(3):194-6

New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1-13; discussion 14-7 (43 ref.)

Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Friedler S, et al. **Hum Reprod** 1999 Aug;14(8):1944-8

Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF. Janssens RM, et al. **Hum Reprod** 1998 Sep;13(9):2386-91

Effects of agonist dose on in-vitro fertilization [letter; comment] Lashen H, et al. **Hum Reprod** 1998 Oct; 13(10):2973-4. Comment on: Hum Reprod 1997 Nov;12(11):2366-9.

Histological evaluation of endometrium on the day of oocyte retrieval after gonadotrophin-releasing hormone agonist-follicle stimulating hormone ovulation induction for in-vitro fertilization. Lass A, et al. **Hum Reprod** 1998 Nov;13(11):3203-5

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Peñarrubia J, et al. **Hum Reprod** 1998 Dec;13(12):3315-8

Transfer of frozen-thawed embryos in artificially prepared cycles with and without prior gonadotrophin-releasing hormone agonist suppression: a prospective randomized study. Simon A, et al. **Hum Reprod** 1998 Oct;13(10):2712-7

Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone. Weissman A, et al. **Hum Reprod** 1998 Dec;13(12):3421-4

Gonadotropin-releasing hormone-agonist as a neoadjuvant therapy for Sertoli-Leydig cell tumors of the ovary. Chao HT, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):189-90

Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist. Al-Omari WR, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):191-2

The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer. Koibuchi Y, et al. **Int J Mol Med** 1999 Aug; 4(2):145-8

Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Marumo K, et al. **Int J Urol** 1999 Jan;6(1):19-23

A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Matsumiya K, et al. **Int J Urol** 1998 Jul;5(4):361-3

Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. Biljan MM, et al. **J Assist Reprod Genet** 1998 Nov;15(10):599-604

Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment. Antoniazzi F, et al. **J Clin Endocrinol Metab** 1999 Jun; 84(6):1992-6

Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats. Goto T, et al. **J Endocrinol** 1999 Jun;161(3):393-402

The feasibility of long-term treatment of polycystic ovary syndrome with GnRH-agonists. Berga SL. **J Endocrinol Invest** 1998 Oct;21(9):630-1 (7 ref.)

GnRH agonist treatment decreases progesterone synthesis, luteal peripheral benzodiazepine receptor mRNA, ligand binding and steroidogenic acute regulatory protein expression during pregnancy. Sridaran R, et al. **J Mol Endocrinol** 1999 Feb;22(1):45-54

Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. van der Kwast TH, et al. **J Pathol** 1998 Dec;186(4):406-9

Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration [see comments] Oefelein MG. **J Urol** 1998 Nov;160(5):1685-8 . Comment in: J Urol 1999 Jul;162(1):170. Comment in: J Urol 1999 Jul;162(1):170-1.

Changes in body composition in women treated with gonadotropin-releasing hormone agonists. Revilla R, et al. **Maturitas** 1998 Nov 30;31(1):63-8

Regulation of follicular luteinization by a gonadotropin-releasing hormone agonist: relationship between steroidogenesis and apoptosis. Andreu C, et al. **Mol Reprod Dev** 1998 Nov;51(3):287-94

Hormonal treatment of prostate cancer [letter; comment] [see comments] Garnick MB. **N Engl J Med** 1999 Mar 11; 340(10):812-3. Comment on: N Engl J Med 1998 Oct 8;339(15):1036-42. Comment in: N Engl J Med 1999 May 27;340(21):1689.

LHRH agonists. Funk KW, et al. **Pharm Biotechnol** 1998; 11:151-82 (72 ref.)

Effects of short-term suppression of ovarian hormones on cardiovascular and neuroendocrine reactivity to stress in women. Matthews KA, et al. **Psychoneuroendocrinology** 1998 May;23(4):307-22

The effect of a GnRH agonist on follicular dynamics and response to FSH stimulation in prepubertal calves. Dufour JJ, et al. **Reprod Nutr Dev** 1999 Jan-Feb;39(1):133-44

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Hall MC, et al. **Urology** 1999 May;53(5):898-902; discussion 902-3

[The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)] Ivanov S, et al. **Akush Ginekol (Sofiia)** 1998;37(4):25-6 (Eng. Abstr.) **(Bul)**

[The possibility for treating certain forms of endometrial and ovarian carcinomas with GnRH agonists] Nikolov A. **Akush Ginekol (Sofiia)** 1998;37(1):60-3 (24 ref.) **(Bul)**

[Is there a role for GnRH analogs in ovulation stimulation for in vitro fertilization?] Belaisch-Allart J, et al. **Contracept Fertil Sex** 1998 Nov;26(11):761-3 (17 ref.) **(Fre)**

[Endometriosis: clinical, histological and morphometric findings before and after Gn-RH agonist therapy] Ruwe M, et al. **Zentralbl Gynakol** 1998;120(8):391-8 (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Miyazaki M, et al. **Am J Obstet Gynecol** 1999 May;180(5):1095-103

Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Paterson WF, et al. **Arch Dis Child** 1998 Oct;79(4):323-7

Gonadotrophin hormone-releasing hormone analogue treatment of fibroids. Shaw RW.

Baillieres Clin Obstet Gynaecol 1998 Jun;12(2):245–68 (67 ref.)

Mitochondrial peripheral-type benzodiazepine receptor expression. Correlation with gonadotropin-releasing hormone (GnRH) agonist-induced apoptosis in the corpus luteum. Papadopoulos V, et al. **Biochem Pharmacol** 1999 Nov 1;58(9):1389–93

Effects of long-term testosterone, gonadotropin-releasing hormone agonist, and pimozide treatments on gonadotropin II levels and ovarian development in juvenile female striped bass (Morone saxatilis). Holland MC, et al. **Biol Reprod** 1998 Nov;59(5):1153–62

Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. Dupont A, et al. **Br J Urol** 1993 Nov; 72(5 Pt 1):629–34

Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Kahán Z, et al. **Cancer** 1999 Jun 15;85(12):2608–15

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Halmos G, et al. **Cancer Lett** 1999 Mar 1;136(2):129–36

Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide). Kakar SS. **Cancer Res** 1998 Oct 15; 58(20):4558–60

Differential distribution of gonadotropin-releasing hormone variants in the brain of Hydrochaeris hydrochaeris (Mammalia, Rodentia). Montaner AD, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):635–51

Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Lanes R, et al. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):197–202

Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. Barbieri RL, et al. **Endocr Rev** 1999 Jun;20(3):249–52 (27 ref.)

Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G alpha(q/11). Jacobson JD, et al. **Endocrinology** 1999 Aug; 140(8):3429–37

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Raga F, et al. **Endocrinology** 1999 Aug;140(8):3705–12

Regional expression of mRNA encoding a second form of gonadotropin-releasing hormone in the macaque brain. Urbanski HF, et al. **Endocrinology** 1999 Apr;140(4):1945–8

Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Jungwirth et al., Eur J Cancer 1997, 33(7), 1141–1148 [letter; comment] Limonta P, et al. **Eur J Cancer** 1998 Jun; 34(7):1134–6. Comment on: Eur J Cancer 1997 Jun;33(7):1141–8.

Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Rolf C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):63–9

Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Biljan MM, et al. **Fertil Steril** 1998 Dec;70(6):1063–9

The effect of food intake from 2 to 24 weeks of age on LHRH-I content in the median eminence and gonadotrophin levels in pituitary and plasma in female broiler breeder chickens. Bruggeman V, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):200–9

Gonadotrophin-releasing hormone agonist stimulates milt fluidity and plasma concentrations of 17,20beta-dihydroxylated and 5beta-reduced, 3alpha-hydroxylated C21 steroids in male plaice (Pleuronectes platessa). Vermeirssen EL, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):163–77

Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog. Kim JW, et al. **Gynecol Oncol** 1999 Jun;73(3):368–71

Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Pérez-Medina T, et al. **Gynecol Oncol** 1999 May;73(2):299–304

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. **Hum Reprod** 1998 Nov;13(11):3023–31

Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Campo S, et al. **Hum Reprod** 1999 Jan;14(1):44–8

Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Duijkers IJ, et al. **Hum Reprod** 1998 Sep; 13(9):2392–8

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Felberbaum RE, et al. **Hum Reprod** 1998 Jun; 13(6):1660–8

Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Grimbizis G, et al. **Hum Reprod** 1999 Feb;14(2):479–84

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Kol S, et al. **Hum Reprod** 1999 Sep;14(9):2242–4

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Lin Y, et al. **Hum Reprod** 1999 Apr;14(4):885–8

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Olivennes F, et al. **Hum Reprod** 1998 Sep; 13(9):2411–4

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Rongières-Bertrand C, et al. **Hum Reprod** 1999 Mar;14(3):683–8

Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization. Zeyneloglu HB, et al. **Int J Fertil Womens Med** 1998 Nov-Dec;43(6):300–5

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. Szepesházi K, et al. **J Cancer Res Clin Oncol** 1999 Aug-Sep; 125(8-9):444–52

Measurement of the novel decapeptide cetrorelix in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. Niwa M, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11; 729(1-2):245–53

Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. Comaru-Schally AM, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):3826–31

Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. Englund K, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4092–6

Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. Feuillan PP, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):44–9

Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. Leschek EW, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):175–8

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone [published erratum appears in J Clin Endocrinol Metab 1999 Jun;84(6):1978] Pasquino AM, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):449–52

Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. Welt CK, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2163–9

GnRH agonist treatment decreases progesterone synthesis, luteal peripheral benzodiazepine receptor mRNA, ligand binding and steroidogenic acute regulatory protein expression during pregnancy. Sridaran R, et al. **J Mol Endocrinol** 1999 Feb;22(1):45–54

Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotrophin-releasing hormone agonist in the rat hypothalamus. Han YG, et al. **J Neuroendocrinol** 1999 Mar; 11(3):195–201

Interaction of gonadotropin-releasing hormone and its agonist analogs with Ca2+ in a nonpolar milieu. Correlation with biopotencies. Ananthanarayanan VS, et al. **J Pept Res** 1998 Sep;52(3):185–94

Effect of long-term food restriction on pituitary sensitivity to cLHRH-I in broiler breeder females. Bruggeman V, et al. **J Reprod Fertil** 1998 Nov;114(2):267–76

Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer. Lombardi P, et al. **J Vet Pharmacol Ther** 1999 Feb;22(1):56–61

Functional analysis of GnRH receptor ligand binding using biotinylated GnRH derivatives. Byrne B, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1-2):11–9

Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer [letter] Spitz IM, et al. **N Engl J Med** 1999 May 6;340(18):1439

In vitro secretion of gonadotropin-releasing hormone (GnRH) and [hydroxyproline9]GnRH from the rat hypothalamus exhibits a differential sensitivity to castration and second messengers. Rochdi L, et al. **Neuroendocrinology** 1998 Oct;68(4):281–92

Combined use of growth hormone and gonadotropin-releasing hormone analogues: the national cooperative growth study experience. Kohn B, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1014–8

Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty: theoretic and practical considerations. Walvoord EC, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1010–4 (38 ref.)

Degradation kinetics of three gonadorelin analogues: developing a method for calculating epimerization parameters. Hoitink MA, et al. **Pharm Res** 1998 Sep; 15(9):1449–55

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Pályi I, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2361–6

A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Wang X, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11081–4

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Koppán M, et al. **Prostate** 1999 Feb 1;38(2):151–8

GnRH analogues and ovarian ablation: their integration in the adjuvant strategy. Pritchard KI. **Recent Results Cancer Res** 1998;152:285–97 (33 ref.)

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Lamharzi N, et al. **Regul Pept** 1998 Oct 16; 77(1-3):185–92

Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. Ahlgren G, et al. **Urology** 1999 Aug;54(2):329–34

[Effect of the administration of PGF2 alpha synchronously with insemination on the pregnancy rate in mares in an insemination program] Bader H, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):54–60 (Eng. Abstr.) **(Ger)**

[Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue] Yamamoto A, et al. **Hinyokika Kiyo** 1998 Aug;44(8):557–63 (Eng. Abstr.) **(Jpn)**

[A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate] Suzuki Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec; 89(12):961–6 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Prenatal testosterone masculinizes synaptic input to gonadotropin-releasing hormone neurons in sheep. Kim SJ, et al. **Biol Reprod** 1999 Sep;61(3):599–605

Evidence for gonadotropin-releasing hormone peptides in the ovary and testis of rainbow trout. von Schalburg KR, et al. **Biol Reprod** 1999 Jun;60(6):1338–44

Unilateral absence of the terminal nerve and distribution of gonadotropin-releasing hormone immunoreactive neurons in the brain of the common mole-rat (Cryptomys, Rodentia). Jastrow H, et al. **Brain Res** 1998 Dec 7; 813(2):229–40

Gonadotropin-releasing hormone immunoreactivity in the adult and fetal human olfactory system. Kim KH, et al. **Brain Res** 1999 May 1;826(2):220–9

Fos expression in gonadotropin-releasing hormone neurons by naloxone or bicuculline in intact male rats. Mitsushima D, et al. **Brain Res** 1999 Aug 21;839(1):209–12

Sex differentiation of growth hormone-releasing hormone and somatostatin neurons in the mouse hypothalamus: an immunohistochemical and morphological study. Nurhidayat, et al. **Brain Res** 1999 Mar 13;821(2):309–21

Regional changes in GnRH immunoreactivity with puberty in the male Syrian hamster. Richardson HN, et al. **Brain Res** 1999 Jan 30;817(1-2):232–5

Differential distribution of gonadotropin-releasing hormone variants in the brain of Hydrochaeris hydrochaeris (Mammalia, Rodentia). Montaner AD, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):635–51

Corticotropin-releasing hormone-immunopositive nerve elements in apposition to chicken gonadotropin-releasing hormone I-containing perikarya in Japanese quail (Coturnix coturnix japonica) brain. Wang R, et al. **Cell Tissue Res** 1999 Aug;297(2):223–8

Luteinizing hormone-releasing hormone quantified in tissues and slice explant cultures of postnatal rat hypothalami. Maurer JA, et al. **Endocrinology** 1999 Feb;140(2):791–9

Phenotypic differences in the GnRH neuronal system of deer mice Peromyscus maniculatus under a natural short photoperiod. Korytko AI, et al. **J Reprod Fertil** 1998 Nov; 114(2):231–5

Detection of gonadotrophin releasing hormone and its receptor mRNA in human placental trophoblasts using in-situ reverse transcription-polymerase chain reaction. Wolfahrt S, et al. **Mol Hum Reprod** 1998 Oct; 4(10):999–1006

ANTAGONISTS & INHIBITORS

Treatment of gonadotropin dependent precocious puberty

due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. de Brito VN, et al. **Arch Dis Child** 1999 Mar;80(3):231-4

Stimulation of spermatogonial differentiation in juvenile spermatogonial depletion (jsd) mutant mice by gonadotropin-releasing hormone antagonist treatment. Matsumiya K, et al. **Endocrinology** 1999 Oct;140(10):4912-5

Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Rolf C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):63-9

Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin [letter] McCluggage WG, et al. **Histopathology** 1999 Feb; 34(2):184-6

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. **Hum Reprod** 1998 Nov;13(11):3023-31

Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Albano C, et al. **Hum Reprod** 1999 Jun;14(6):1426-30

Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Duijkers IJ, et al. **Hum Reprod** 1998 Sep; 13(9):2392-8

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Kol S, et al. **Hum Reprod** 1999 Sep;14(9):2242-4

Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida. Morales P, et al. **Hum Reprod** 1999 Aug;14(8):2069-74

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Rongières-Bertrand C, et al. **Hum Reprod** 1999 Mar;14(3):683-8

Effect of acute androgen withdrawal by GnRH antagonist on epididymal sperm motility and morphology in the cynomolgus monkey. Yeung CH, et al. **J Androl** 1999 Jan-Feb;20(1):72-9

Titrating luteinizing hormone replacement to sustain the structure and function of the corpus luteum after gonadotropin-releasing hormone antagonist treatment in rhesus monkeys. Duffy DM, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):342-9

Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. Swerdloff RS, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3527-33

The cycle duration of the seminiferous epithelium remains unaltered during GnRH antagonist-induced testicular involution in rats and monkeys. Aslam H, et al. **J Endocrinol** 1999 May;161(2):281-8

Hormonal ablation therapy for metastatic prostatic carcinoma: a review. Leewansangtong S, et al. **J Med Assoc Thai** 1999 Feb;82(2):192-205 (116 ref.)

LHRH antagonists. Haviv F, et al. **Pharm Biotechnol** 1998; 11:131-49 (56 ref.)

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. McLeod DG, et al. **Prostate** 1999 Sep 1;40(4):218-24

Intravenous injections of nicotine decrease the pulsatile secretion of LH by inhibiting the gonadotropin-releasing hormone (GnRH) pulse generator activity in female rats. Sano A, et al. **Psychoneuroendocrinology** 1999 May; 24(4):397-407

Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Lamharzi N, et al. **Regul Pept** 1998 Oct 16; 77(1-3):185-92

Leuprolide, a gonadotropin-releasing hormone agonist, enhances colonization after spermatogonial transplantation into mouse testes. Ogawa T, et al. **Tissue Cell** 1998 Oct; 30(5):583-8

Blockade of the hypothalamic-pituitary-testicular axis with a GnRH antagonist in the neonatal marmoset monkey: changes in Leydig cell ultrastructure. Prince FP, et al. **Tissue Cell** 1998 Dec;30(6):651-61

BIOSYNTHESIS

The olfactory origin of luteinizing hormone-releasing hormone (LHRH) neurons. A new era in reproduction physiology. Daikoku S. **Arch Histol Cytol** 1999 May; 62(2):107-17 (65 ref.)

Effects of gonadotropin-releasing hormone pulse frequency modulation on the reproductive axis of photoinhibited male Siberian hamsters. Meredith JM, et al. **Biol Reprod** 1998 Oct;59(4):813-9

Development and differentiation of gonadotropin hormone-releasing hormone neuronal systems and testes in the Japanese eel (Anguilla japonica). Chiba H, et al. **Gen Comp Endocrinol** 1999 Jun;114(3):449-59

Quantitative in situ hybridization of three gonadotropin-releasing hormone-encoding mRNAs in castrated and progesterone-treated male tilapia. Parhar IS, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):406-14

Ontogeny of gonadotropin-releasing hormone (GnRH) gene expression reveals a distinct origin for GnRH-containing neurons in the midbrain [see comments] White RB, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):322-9. Comment in: Gen Comp Endocrinol 1998 Dec;112(3):276-82.

mRNA expression of gonadotropin-releasing hormones (GnRHs) and GnRH receptor in goldfish. Yu KL, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):303-11

BLOOD

Evaluation of the relationship between semen parameters, pregnancy rate of wives of infertile men with varicocele, and gonadotropin-releasing hormone test before and after varicocelectomy. Segenreich E, et al. **Urology** 1998 Nov; 52(5):853-7

CEREBROSPINAL FLUID

Increase in gonadotropin-releasing hormone (GnRH) levels in CSF after stimulation of the nervus terminalis in Atlantic stingray, Dasyatis sabina. Moeller JF, et al. **Brain Res** 1998 Sep 21;806(1):104-7

CHEMICAL SYNTHESIS

Reaction medium engineering in enzymatic peptide fragment condensation: synthesis of eledoisin and LH-RH. Björup P, et al. **Bioorg Med Chem** 1998 Jul;6(7):891-901

CHEMISTRY

Hydrolysis by somatic angiotensin-I converting enzyme of basic dipeptides from a cholecystokinin/gastrin and a LH-RH peptide extended at the C-terminus with gly-Arg/Lys-arg, but not from diarginyl insulin. Isaac RE, et al. **Eur J Biochem** 1999 Jun;262(2):569-74

Solution conformation on bovine growth hormone releasing factor by 1H NMR and molecular modeling. Kweon J, et al. **FEBS Lett** 1999 Aug 6;456(2):343-8

Computer simulation studies of the fully solvated wild-type and mutated GnRH in extended and beta-turn conformations. Mezei M, et al. **J Biomol Struct Dyn** 1998 Dec;16(3):723-32

DEFICIENCY

Physiologic and genetic insights into the pathophysiology and management of hypogonadotropic hypogonadism. Hall JE. **Ann Endocrinol (Paris)** 1999 Jul;60(2):93-101 (45 ref.)

Androgen receptor immunoreactivity in specific neural regions in normal and hypogonadal male mice: effect of androgens. Apostolinas S, et al. **Brain Res** 1999 Jan 30; 817(1-2):19-24

Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Seminara SB, et al. **Endocr Rev** 1998 Oct; 19(5):521-39 (215 ref.)

Hypogonadotropic hypogonadism. Hayes FJ, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):739-63, vii (94 ref.)

Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea. Kadva A, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3653-62

DIAGNOSTIC USE

Is opioidergic activity responsible for the circadian variation observed in the gonadotrophin responsiveness of early follicular phase women? Rossmanith WG, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):499-503

Gonadotropin-releasing hormone-induced elevation of serum hCG in choriocarcinoma: a case report. Furuhashi M, et al. **Endocr J** 1998 Aug;45(4):585-90

Response of the free alpha-subunit to GnRH distinguishes individuals with 'functional' from those with permanent hypogonadotropic hypogonadism. Mainieri AS, et al. **Horm Res** 1998;50(4):212-6

The predictive value of double Gn-RH provocation test in unprimed Gn-RH-primed and steroid-primed female patients with Kallmann's syndrome. Chryssikopoulos A, et al. **Int J Fertil Womens Med** 1998 Nov-Dec;43(6):291-9

[Gonadotropin response to GnRH and seminal parameters in low grade varicocele] Foppiani L, et al. **Arch Ital Urol Androl** 1999 Feb;71(1):7-12 (Eng. Abstr.) **(Ita)**

GENETICS

Ontogeny of the GNRH-, glutaminase- and glutamate decarboxylase-gene expression in the hypothalamus of female rats. Roth C, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):105-14

Gonadotropin-releasing hormone (GnRH) gene regulation by N-methyl-D-aspartic acid in GT1-1 neuronal cells: differential involvement of c-fos and c-jun protooncogenes. Jung N, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):162-9

Testosterone differentially regulates expression of GnRH messenger RNAs in the terminal nerve, preoptic and midbrain of male tilapia. Soga T, et al. **Brain Res Mol Brain Res** 1998 Sep 18;60(1):13-20

Changes in mediobasal hypothalamic gonadotropin-releasing hormone messenger ribonucleic acid levels induced by mating or ovariectomy in a reflex ovulator, the ferret. Bakker J, et al. **Endocrinology** 1999 Feb;140(2):595-602

Mechanisms for the regulation of gonadotropin-releasing hormone gene expression in the developing mouse. Gore AC, et al. **Endocrinology** 1999 May;140(5):2280-7

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Raga F, et al. **Endocrinology** 1999 Aug;140(8):3705-12

Regulation and expression of gonadotropin-releasing hormone gene differs in brain and gonads in rainbow trout. Von Schalburg KR, et al. **Endocrinology** 1999 Jul; 140(7):3012-24

Gonadotropin-releasing hormone genes: phylogeny, structure, and functions. Fernald RD, et al. **Front Neuroendocrinol** 1999 Jul;20(3):224-40 (74 ref.)

Effects of photoperiod on salmon GnRH mRNA levels in brain of castrated underyearling precocious male masu salmon. Amano M, et al. **Gen Comp Endocrinol** 1999 Jul; 115(1):70-5

Genomic structure and expression sites of three gonadotropin-releasing hormone genes in one species. White RB, et al. **Gen Comp Endocrinol** 1998 Oct; 112(1):17-25

Ontogeny of gonadotropin-releasing hormone (GnRH) gene expression reveals a distinct origin for GnRH-containing neurons in the midbrain [see comments] White RB, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):322-9. Comment in: Gen Comp Endocrinol 1998 Dec;112(3):276-82.

Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. Chen HF, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):743-50

Neurons synthesizing gonadotropin-releasing hormone mRNA subtypes have multiple developmental origins in the medaka. Parhar IS, et al. **J Comp Neurol** 1998 Nov 16;401(2):217-26

Fetal expression of GnRH and GnRH receptor genes in rat testis and ovary. Botté MC, et al. **J Endocrinol** 1998 Oct; 159(1):179-89

A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of the antisense transcript. Millar R, et al. **J Endocrinol** 1999 Jul;162(1):117-26

Multiple GnRHs present in a teleost species are encoded by separate genes: analysis of the sbGnRH and cGnRH-II genes from the striped bass, Morone saxatilis. Chow MM, et al. **J Mol Endocrinol** 1998 Dec;21(3):277-89

Photo-induction of hypothalamic gonadotrophin releasing hormone-I mRNA in the domestic chicken: a role for oestrogen? Dunn IC, et al. **J Neuroendocrinol** 1999 May; 11(5):371-5

Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotrophin-releasing hormone agonist in the rat hypothalamus. Han YG, et al. **J Neuroendocrinol** 1999 Mar; 11(3):195-201

Photoperiod affects the ability of testosterone to alter proopiomelanocortin mRNA, but not luteinizing hormone-releasing hormone mRNA, levels in male sheep. Hileman SM, et al. **J Neuroendocrinol** 1998 Aug; 10(8):587-92

Noradrenergic neurotoxin suppresses gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in ovariectomized and steroid-treated rats. Kang SS, et al. **J Neuroendocrinol** 1998 Dec;10(12):911-8

Reduction of luteinzing hormone secretion induced by long-term feed restriction in male rats is associated with increased expression of GABA-synthesizing enzymes without alterations of GnRH gene expression. Leonhardt S, et al. **J Neuroendocrinol** 1999 Aug;11(8):613-9

GnRH mRNA increases with puberty in the male Syrian hamster brain. Parfitt DB, et al. **J Neuroendocrinol** 1999 Aug;11(8):621-7

Promoter transgenics reveal multiple gonadotropin-releasing hormone-I-expressing cell populations of different embryological origin in mouse brain. Skynner MJ, et al. **J Neurosci** 1999 Jul 15;19(14):5955-66

Expression of GATA-4 in migrating gonadotropin-releasing neurons of the developing mouse. Lawson MA, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):157-61

The GnRH promoter: target of transcription factors, hormones, and signaling pathways. Nelson SB, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):151-5 (22 ref.)

GnRH mRNA and protein expression in human preimplantation embryos. Casañ EM, et al. **Mol Hum Reprod** 1999 Mar;5(3):234-9

Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue. Dong KW, et al. **Mol Hum Reprod** 1998 Sep;4(9):893-8

Detection of gonadotrophin releasing hormone and its receptor mRNA in human placental trophoblasts using in-situ reverse transcription-polymerase chain reaction. Wolfahrt S, et al. **Mol Hum Reprod** 1998 Oct; 4(10):999-1006

Diurnal rhythmicity of gonadotropin-releasing hormone gene expression in the rat. Gore AC.
Neuroendocrinology 1998 Oct;68(4):257–63

Direct regulation of GnRH transcription by CRF-like peptides in an immortalized neuronal cell line. Tellam DJ, et al. **Neuroreport** 1998 Oct 5;9(14):3135–40

Transforming growth factor beta2 is able to modify mRNA levels and release of luteinizing hormone-releasing hormone in a immortalized hypothalamic cell line (GT1-1). Messi E, et al. **Neurosci Lett** 1999 Aug 6;270(3):165–8

Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Bahk JY, et al. **Urol Res** 1998;26(4):259–64

Development of recombinant ovalbumin-luteinizing hormone releasing hormone as a potential sterilization vaccine. Zhang Y, et al. **Vaccine** 1999 Apr 23; 17(17):2185–91

[Expression of hypothalamic hormone and hypothalamic hormone receptor genes in human pituitary and pituitary adenomas using in situ reverse transcription-polymerase chain reaction] Sanno N. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):405–8 **(Jpn)**

IMMUNOLOGY

Antiidiotypic antibody to gonadotropin releasing hormone as probe for cell surface receptors. Karande AA, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):449–59

Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Jacobs E, et al. **Br J Cancer** 1999 May;80(3–4):352–9

Expression of galanin immunoreactivity in gonadotropin-releasing hormone neurons in mice: a confocal microscopic study. Rajendren G, et al. **Brain Res** 1999 Mar 13;821(2):270–6

Molecular mimicry by antiidiotypic monoclonal antibody to gonadotropin releasing hormone. Rajeshwari K, et al. **Immunol Invest** 1999 Mar-May;28(2–3):103–14

Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Ghosh S, et al. **Int Immunol** 1999 Jul;11(7):1103–10

Highly immunogenic and fully synthetic peptide-carrier constructs targetting GnRH. Beekman NJ, et al. **Vaccine** 1999 Apr 9;17(15–16):2043–50

METABOLISM

Photoperiodic effects on gonadotropin-releasing hormone (GnRH) content and the GnRH-immunoreactive neuronal system of male Siberian hamsters. Bernard DJ, et al. **Biol Reprod** 1999 Feb;60(2):272–6

Effects of glucose and related substrates on the recovery of the electrical activity of gonadotropin-releasing hormone pulse generator which is decreased by insulin-induced hypoglycemia in the estrogen-primed ovariectomized rat. He D, et al. **Brain Res** 1999 Feb 27;820(1–2):71–6

Concentration-dependent effects of muscimol to enhance pulsatile GnRH release from GT1-7 neurons in vitro. King TS, et al. **Brain Res** 1999 Apr 3;824(1):56–62

Identification and neuroanatomical distribution of immunoreactivity for mammalian gonadotropin-releasing hormone (mGnRH) in the brain and neural hypophyseal lobe of the toad Bufo arenarum. Miranda LA, et al. **Cell Tissue Res** 1998 Sep;293(3):419–25

Expression of activin and follistatin in the rat hypothalamus: anatomical association with gonadotropin-releasing hormone neurons and possible role of central activin in the regulation of luteinizing hormone release. MacConell LA, et al. **Endocrine** 1998 Dec;9(3):233–41

Perinatal changes in hypothalamic N-methyl-D-aspartate receptors and their relationship to gonadotropin-releasing hormone neurons. Adams MM, et al. **Endocrinology** 1999 May;140(5):2288–96

Estradiol coupling to endothelial nitric oxide stimulates gonadotropin-releasing hormone release from rat median eminence via a membrane receptor. Prevot V, et al. **Endocrinology** 1999 Feb;140(2):652–9

GnRH-systems in the forebrain of cichlid fish. Münz H. **Eur J Morphol** 1999 Apr;37(2–3):100–2

Second form of gonadotropin-releasing hormone in mouse: immunocytochemistry reveals hippocampal and periventricular distribution. Gestrin ED, et al. **FEBS Lett** 1999 Apr 9;448(2–3):289–91

Gonadotropin-releasing hormone genes: phylogeny, structure, and functions. Fernald RD, et al. **Front Neuroendocrinol** 1999 Jul;20(3):224–40 (74 ref.)

Gonadotropin-releasing hormone in mulberry cells of Saccoglossus and Ptychodera (Hemichordata: Enteropneusta). Cameron CB, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):2–10

Aspects of GnRH neurobiology conserved across vertebrate forms [comment] Dellovade T, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):276–82 (33 ref.). Comment on: Gen Comp Endocrinol 1998 Dec;112(3):322–9.

Levels of the native forms of GnRH in the pituitary of the gilthead seabream, Sparus aurata, at several characteristic stages of the gonadal cycle. Holland MCH, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):394–405

Excitatory amino acids act on the median eminence nerve terminals to induce gonadotropin-releasing hormone release in female rats. Kawakami S, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):372–82

Gonadotropin-releasing hormone (GnRH) in ancient teleosts, the bonytongue fishes: putative origin of salmon GnRH [see comments] O'neill DF, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):415–25. Comment in: Gen Comp Endocrinol 1998 Dec;112(3):296–302.

Sex differences in mammalian and chicken-II gonadotropin-releasing hormone immunoreactivity in musk shrew brain. Rissman EF, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):346–55

Cellular mechanism of pulsatile LHRH release. Terasawa E. **Gen Comp Endocrinol** 1998 Dec;112(3):283–95 (135 ref.)

GnRH-immunoreactive neuronal system in the presumptive ancestral chordate, Ciona intestinalis (Ascidian). Tsutsui H, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):426–32

Estrogen regulates gonadotropin-releasing hormone in the nervus terminalis of Xenopus laevis. Wirsig-Wiechmann CR, et al. **Gen Comp Endocrinol** 1999 Aug;115(2):301–8

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone. Messinis IE, et al. **Hum Reprod** 1998 Sep;13(9):2415–20

Hormonal regulation and germ cell-specific expression of heat shock protein 60 (hsp60) in the testis of macaque monkeys (Macaca mulatta and M. fascicularis). Meinhardt A, et al. **Int J Androl** 1998 Oct;21(5):301–7

The glucocorticoid receptor is tethered to DNA-bound Oct-1 at the mouse gonadotropin-releasing hormone distal negative glucocorticoid response element. Chandran UR, et al. **J Biol Chem** 1999 Jan 22;274(4):2372–8

Identification and characterization of the gonadotropin-releasing hormone response elements in the mouse gonadotropin-releasing hormone receptor gene. Norwitz ER, et al. **J Biol Chem** 1999 Jan 8;274(2):867–80

Relationships between sex and the size and number of forebrain gonadotropin-releasing hormone-immunoreactive neurones in the ballan wrasse (Labrus berggylta), a protogynous hermaphrodite. Elofsson UO, et al. **J Comp Neurol** 1999 Jul 19;410(1):158–70

Changes in extracellular LHRH and beta-endorphin-like immunoreactivity in the nucleus infundibularis-median eminence of anestrous ewes under stress condition. Tomaszewska D, et al. **J Neural Transm** 1999; 106(3–4):265–74

Evidence for oestrogen receptor alpha-immunoreactivity in gonadotrophin-releasing hormone-expressing neurones [see comments] Butler JA, et al. **J Neuroendocrinol** 1999 May;11(5):331–5. Comment in: J Neuroendocrinol 1999 May;11(5):323–4.

Identification of alpha1B adrenergic receptor protein in gonadotropin releasing hormone neurones of the female rat. Hosny S, et al. **J Neuroendocrinol** 1998 Sep; 10(9):687–92

Might oestrogen act directly on GnRH neurones? [editorial; comment] Leng G. **J Neuroendocrinol** 1999 May; 11(5):323–4. Comment on: J Neuroendocrinol 1999 May;11(5):325–9. Comment on: J Neuroendocrinol 1999 May;11(5):331–5.

Distribution and seasonal variations in levels of three native GnRHs in the brain and pituitary of perciform fish [published erratum appears in J Neuroendocrinol 1999 Jul;11(7):577] Senthilkumaran B, et al. **J Neuroendocrinol** 1999 Mar;11(3):181–6

An increase in glutamate release follows a decrease in gamma aminobutyric acid and the pubertal increase in luteinizing hormone releasing hormone release in the female rhesus monkeys. Terasawa E, et al. **J Neuroendocrinol** 1999 Apr; 11(4):275–82

Characterization of K+ currents underlying pacemaker potentials of fish gonadotropin-releasing hormone cells. Abe H, et al. **J Neurophysiol** 1999 Feb;81(2):643–53

GABA- and glutamate-activated channels in green fluorescent protein-tagged gonadotropin-releasing hormone neurons in transgenic mice. Spergel DJ, et al. **J Neurosci** 1999 Mar 15;19(6):2037–50

Polysialic acid facilitates migration of luteinizing hormone-releasing hormone neurons on vomeronasal axons. Yoshida K, et al. **J Neurosci** 1999 Jan 15; 19(2):794–801

Interaction of gonadotropin-releasing hormone and its agonist analogs with Ca2+ in a nonpolar milieu. Correlation with biopotencies. Ananthanarayanan VS, et al. **J Pept Res** 1998 Sep;52(3):185–94

Origin and migration of luteinizing hormone-releasing hormone neurons in mammals. Schwanzel-Fukuda M. **Microsc Res Tech** 1999 Jan 1;44(1):2–10 (70 ref.)

Synchronized neuronal networks: the GnRH system. Witkin JW. **Microsc Res Tech** 1999 Jan 1;44(1):11–8 (60 ref.)

Functional analysis of GnRH receptor ligand binding using biotinylated GnRH derivatives. Byrne B, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1-2):11–9

Mechanisms mediating multiple physiological responses to gonadotropin-releasing hormone. Stanislaus D, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1-2):1–10 (73 ref.)

Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Allen MP, et al. **Mol Endocrinol** 1999 Feb;13(2):191–201

Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropin-releasing hormone receptor. Arora KK, et al. **Mol Endocrinol** 1999 Jun;13(6):890–6

Early growth response protein 1 binds to the luteinizing hormone-beta promoter and mediates gonadotropin-releasing hormone-stimulated gene expression. Wolfe MW, et al. **Mol Endocrinol** 1999 May; 13(5):752–63

GnRH mRNA and protein expression in human preimplantation embryos. Casañ EM, et al. **Mol Hum Reprod** 1999 Mar;5(3):234–9

Role of phosphodiesterases in the regulation of gonadotropin- releasing hormone secretion in GT1 cells. Sakakibara H, et al. **Neuroendocrinology** 1998 Dec; 68(6):365–73

Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. McCann SM, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3–4):193–202 (55 ref.)

Preoptic gonadotropin-releasing hormone (GnRH) neurons innervate the pituitary in teleosts. Yamamoto N, et al. **Neurosci Res** 1998 May;31(1):31–8

Caffeine and carbonyl cyanide m-chlorophenylhydrazone increased evoked and spontaneous release of luteinizing hormone-releasing hormone from intact presynaptic terminals. Cao YJ, et al. **Neuroscience** 1999;92(4):1511–21

Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies. Bhatia KS, et al. **Pharm Res** 1998 Dec;15(12):1857–62

Carbomer inhibits tryptic proteolysis of luteinizing hormone-releasing hormone and N-alpha-benzoyl-L-arginine ethyl ester by binding the enzyme. Walker GF, et al. **Pharm Res** 1999 Jul; 16(7):1074–80

Enzymatic degradation of luteinizing hormone releasing hormone (LHRH)/[D-Ala6]-LHRH in lung pneumocytes. Yang X, et al. **Pharm Res** 1998 Sep;15(9):1480–4

[Effects of the fruit of Rubus chingii Hu on hypothalamus-pituitary-sex gland axis in rats] Chen K, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Sep;21(9):560–2 inside back cover (Eng. Abstr.) **(Chi)**

[Hypothalamic LHRH pulse generator] Jiang ZY. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):347–9 (10 ref.) **(Chi)**

PHARMACOKINETICS

Effect of linolenic acid/ethanol or limonene/ethanol and iontophoresis on the in vitro percutaneous absorption of LHRH and ultrastructure of human epidermis. Bhatia KS, et al. **Int J Pharm** 1999 Apr 15;180(2):235–50

Synthesis and bioactivity of fatty acid–conjugated GnRH derivatives. Yahalom D, et al. **Life Sci** 1999;64(17):1543–52

PHARMACOLOGY

Inhibition of salmon calcitonin on secretion of progesterone and GnRH-stimulated pituitary luteinizing hormone. Tsai SC, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):E49–55

Photoperiodic effects on pubertal maturation of spermatogenesis, pituitary responsiveness to exogenous GnRH, and expression of boar taint in crossbred boars. Andersson H, et al. **Anim Reprod Sci** 1998 Dec 31; 54(2):121–37

Correlation between LH response to challenges with GNRH and naloxone during lactation, and LH secretion and follicular development after weaning in the sows. De Rensis F, et al. **Anim Reprod Sci** 1999 Jun 28;56(2):143–52

Effect of adrenocorticotrophic hormone (ACTH1–24) on ovine pituitary gland responsiveness to exogenous pulsatile GnRH and oestradiol-induced LH release in vivo. Phogat JB, et al. **Anim Reprod Sci** 1999 Apr 31;55(3–4):193–203

Induction of ovulation with gonadotropin-releasing hormone during proestrus in cattle: influence on subsequent follicular growth and luteal function. Taponen J, et al. **Anim Reprod Sci** 1999 Mar 19;55(2):91–105

Gonadotropin-releasing hormone activates the equine luteinizing hormone beta promoter through a protein kinase C/mitogen-activated protein kinase pathway. Call GB, et al. **Biol Reprod** 1999 Sep;61(3):715–23

Effect of cycloheximide and tunicamycin on the gonadotrophin-releasing hormone stimulated distal glycosylation of luteinizing hormone by rat pituitary cells. Pérez GT, et al. **Can J Physiol Pharmacol** 1998 Oct-Nov; 76(10–11):1033–40

Ovarian follicular responses in dairy cows treated with GnRH and cloprostenol. Kastelic JP, et al. **Can Vet J** 1998 Feb;39(2):107–9

Effects of intraventricular norepinephrine on LH release in short- and long-term ovariectomized steroids-primed rats [published erratum appears in Chin J Physiol 1999 Mar 31;42(1):52] Pi WP, et al. **Chin J Physiol** 1998 Dec 31; 41(4):235–40

The effect of ACTH on the GnRH-induced release of LH and testosterone in male white-tailed deer. Bubenik GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Feb;122(2):173–9

Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine. Kesler DJ, et al. **Drug Dev Ind Pharm** 1999 Mar; 25(3):315–21

Alterations in intracellular messengers mobilized by gonadotropin-releasing hormone in an experimental

ovarian tumor. Chamson-Reig A, et al. **Endocrinology** 1999 Aug;140(8):3573-80

Absence of gonadotropin surges and gonadotropin-releasing hormone self-priming in ovariectomized (OVX), estrogen (E2)-treated, progesterone receptor knockout (PRKO) mice. Chappell PE, et al. **Endocrinology** 1999 Aug; 140(8):3653-8

Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G alpha(q/11). Jacobson JD, et al. **Endocrinology** 1999 Aug; 140(8):3429-37

Regulation of lutenizing hormone secretion and subunit messenger ribonucleic acid expression by gonadal steroids in perifused pituitary cells from male monkeys and rats. Kawakami S, et al. **Endocrinology** 1999 Aug;140(8):3587-93

Role of protein kinase C in facilitation of luteinizing hormone (LH)-releasing hormone-induced LH surges by neuropeptide Y. Leupen SM, et al. **Endocrinology** 1999 Aug;140(8):3682-7

Transcriptional activation of gonadotropin-releasing hormone (GnRH) receptor gene by GnRH: involvement of multiple signal transduction pathways. Lin X, et al. **Endocrinology** 1999 Jan;140(1):358-64

Activation of the p38 mitogen-activated protein kinase pathway by gonadotropin-releasing hormone. Roberson MS, et al. **Endocrinology** 1999 Mar;140(3):1310-8

Transcriptional activation of the ovine follicle-stimulating hormone beta-subunit gene by gonadotropin-releasing hormone: involvement of two activating protein-1-binding sites and protein kinase C. Strahl BD, et al. **Endocrinology** 1998 Nov;139(11):4455-65

Regulation of gonadotropin-releasing hormone (GnRH) receptor gene expression in sheep: interaction of GnRH and estradiol. Turzillo AM, et al. **Endocrinology** 1998 Dec; 139(12):4890-4

Effects of five natural gonadotropin-releasing hormones on cell suspensions of marine bivalve gonad: stimulation of gonial DNA synthesis. Pazos AJ, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):112-20

Acute N-methyl-D,L-aspartate administration stimulates the luteinizing hormone releasing hormone pulse generator in the ovine fetus. Bettendorf M, et al. **Horm Res** 1999; 51(1):25-30

Effects of dexamethasone and dexamethasone plus naltrexone on pituitary response to GnRH and TRH in normal women. la Marca A, et al. **Horm Res** 1999;51(2):85-90

FSH inhibits the augmentation by oestradiol of the pituitary responsiveness to GnRH in the female rat. Schuiling GA, et al. **Hum Reprod** 1999 Jan;14(1):21-6

Gonadotropin-releasing hormone improves reproductive performance of dairy cows with slow involution of the reproductive tract. Foote RH, et al. **J Anim Sci** 1999 Jan; 77(1):12-6

Reproductive, metabolic, and endocrine responses to feed restriction and GnRH treatment in primiparous, lactating sows. Mao J, et al. **J Anim Sci** 1999 Mar;77(3):724-35

Follicular, hormonal, and pregnancy responses of early postpartum suckled beef cows to GnRH, norgestomet, and prostaglandin F2alpha. Thompson KE, et al. **J Anim Sci** 1999 Jul;77(7):1823-32

Functional uncoupling between intracellular calcium dynamics and secretion in the alphaT3-1 gonadotropic cell line. Trueta C, et al. **J Cell Physiol** 1999 Jun;179(3):347-57

Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. Chen HF, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):743-50

Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. Hayes FJ, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1028-36

Regulation of gonadotrophin secretion by inhibin, testosterone and gonadotrophin-releasing hormone in pituitary cell cultures of male monkeys. Fingscheidt U, et al. **J Endocrinol** 1998 Oct;159(1):103-10

Non-steroidal factors in bovine follicular fluid inhibit or facilitate the action of pulsatile administration of GnRH on LH release in the female rat. van Dieten JA, et al. **J Endocrinol** 1999 May;161(2):237-43

The role of nitric oxide in the control of basal and LHRH-stimulated LH secretion. Pinilla L, et al. **J Endocrinol Invest** 1999 May;22(5):340-8

Direct anticancer activity of gonadotropin-releasing hormone-III. Lovas S, et al. **J Pept Res** 1998 Nov; 52(5):384-9

Effects of luteinizing hormone-releasing hormone on plasma cocaine levels in rhesus monkeys. Mendelson JH, et al. **J Pharmacol Exp Ther** 1999 May;289(2):791-9

Effects of HCG or gonadoreline on seminal parameters and plasma testosterone levels in young male rabbits. Rebollar PG, et al. **J Physiol Biochem** 1998 Sep;54(3):161-6

Annual cycle in LH and testosterone release in response to GnRH challenge in male woodchucks (Marmota monax). Concannon PW, et al. **J Reprod Fertil** 1998 Nov; 114(2):299-305

Effect of transport on pituitary responsiveness to exogenous pulsatile GnRH and oestradiol-induced LH release in intact ewes. Phogat JB, et al. **J Reprod Fertil** 1999 May; 116(1):9-18

Effect of progesterone on the GnRH-induced secretion of oestradiol and androstenedione from the autotransplanted ovary of the anoestrous ewe. Scaramuzzi RJ, et al. **J Reprod Fertil** 1999 May;116(1):127-32

Compensation by pulsatile GnRH infusions for incompetence for oestradiol-induced LH surges in long-term ovariectomized gilts and castrated male pigs. Stickan F, et al. **J Reprod Fertil** 1999 Mar;115(2):333-9

Assessment of hypothalamic-pituitary function by hormonal pulsatility, gonadotropin-releasing hormone and thyrotropin-releasing hormone testing in women with euprolactinemic secondary amenorrhea. Lin KC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):698-705

Dual intracellular pathways in gonadotropin releasing hormone (GNRH) induced desensitization of luteinizing hormone (LH) secretion. Cassina MP, et al. **Life Sci** 1999; 64(24):2215-23

Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Ben-Yehudah A, et al. **Med Oncol** 1999 Apr;16(1):38-45

Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription. Tremblay JJ, et al. **Mol Cell Biol** 1999 Apr;19(4):2567-76

GnRH signalling pathways and GnRH-induced homologous desensitization in a gonadotrope cell line (alphaT3-1). Poulin B, et al. **Mol Cell Endocrinol** 1998 Jul 25; 142(1-2):99-117

Chronic hypersecretion of luteinizing hormone in transgenic mice selectively alters responsiveness of the alpha-subunit gene to gonadotropin-releasing hormone and estrogens. Abbud RA, et al. **Mol Endocrinol** 1999 Sep;13(9):1449-59

Estradiol suppresses phosphorylation of cyclic adenosine 3',5'-monophosphate response element binding protein (CREB) in the pituitary: evidence for indirect action via gonadotropin-releasing hormone. Duan WR, et al. **Mol Endocrinol** 1999 Aug;13(8):1338-52

Functions of the hypophysis-gonad and hypophysis-adrenal cortex systems during repeated administration of gonadotropin-releasing hormone in the postnatal period. Goncharov NP, et al. **Neurosci Behav Physiol** 1998 Sep-Oct;28(5):589-93

Effects of LHRH on avoidance conditioning in normally cycling and ovariectomized female rats. Mora S, et al. **Pharmacol Biochem Behav** 1998 Nov;61(3):221-8

The effect of gonadotrophin releasing hormone and follicle stimulating hormone in conjunction with pregnant mare serum gonadotrophin on the superovulatory response in crossbred sheep in India. Naqvi SM, et al. **Trop Anim Health Prod** 1998 Dec;30(6):369-76

Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Bahk JY, et al. **Urol Res** 1998;26(4):259-64

[An image analysis of the morphological changes of LH cells during LH release peak induced by LHRH in male rats] Zhou SK, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):88-94 (Eng. Abstr.) **(Chi)**

[Reaction of the pituitary gland to a single GnRH administration in the dependence of energy balance in cattle in the puerperium] Bergmann J, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 May; 27(3):154-60 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Galanin: analysis of its coexpression in gonadotropin-releasing hormone and growth hormone-releasing hormone neurons. Hohmann JG, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:221-35 (62 ref.)

LHRH and sexual dimorphism. Merchenthaler I. **Ann N Y Acad Sci** 1998 Dec 21;863:175-87 (44 ref.)

Vomeronasal, olfactory, hormonal convergence in the brain. Cooperation or coincidence? Meredith M. **Ann N Y Acad Sci** 1998 Nov 30;855:349-61 (43 ref.)

Differential regulation of the gonadotropin storage pattern by gonadotropin-releasing hormone pulse frequency in the ewe. Molter-Gérard C, et al. **Biol Reprod** 1999 May; 60(5):1224-30

Lactation inhibits the potentiating effect of galanin upon the GnRH-induced LH release observed in diestrous-1 rat. Cardenas H, et al. **Biol Res** 1998;31(4):351-8

Resistance of gonadotropin-releasing hormone neurons to glutamatergic neurotoxicity. Ebling FJ, et al. **Brain Res Bull** 1998 Dec;47(6):575-84

Ontogenic development of salmon GnRH and chicken GnRH-II systems in the brain of masu salmon (Oncorhynchus masou). Amano M, et al. **Cell Tissue Res** 1998 Sep;293(3):427-34

Evolution of neuroendocrine peptide systems: gonadotropin-releasing hormone and somatostatin. Lin XW, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):375-88 (105 ref.)

Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. McCann SM, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):333-44 (53 ref.)

Estradiol and gonadotropin-releasing hormone (GnRH) interact to increase GnRH receptor expression in ovariectomized ewes after hypothalamic-pituitary disconnection. Kirkpatrick BL, et al. **Endocrine** 1998 Jun; 8(3):225-9

Gonadotropin-releasing hormone regulation of gonadotropin subunit gene expression in female rats: actions on follicle-stimulating hormone beta messenger ribonucleic acid (mRNA) involve differential expression of pituitary activin (beta-B) and follistatin mRNAs. Dalkin AC, et al. **Endocrinology** 1999 Feb;140(2):903-8

Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropin-releasing hormone surge-generating system. Harris TG, et al. **Endocrinology** 1999 Feb;140(2):827-34

Periventricular preoptic area neurons coactivated with luteinizing hormone (LH)-releasing hormone (LHRH) neurons at the time of the LH surge are LHRH afferents. Le WW, et al. **Endocrinology** 1999 Jan;140(1):510-9

Embryonic development of the gonadotropin-releasing hormone (GnRH) system in the chick: a spatio-temporal analysis of GnRH neuronal generation, site of origin, and migration. Mulrenin EM, et al. **Endocrinology** 1999 Jan; 140(1):422-33

Interactions of ovarian steroids with pituitary adenylate cyclase-activating polypeptide and GnRH in anterior pituitary cells. Ortmann O, et al. **Eur J Endocrinol** 1999 Mar;140(3):207-14

Testosterone accelerates the development of the catfish GnRH system in the brain of immature African catfish (Clarias gariepinus). Dubois EA, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):383-93

The effects of estradiol on gonadotropin-releasing hormone neurons in the developing mouse brain. Grober MS, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):356-63

LHRH neurons migrate into the trigeminal nerve when the developing olfactory nerve fibers are physically interrupted in chick embryos. Murakami S, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):312-21

Comparative analysis of GnRH neuronal systems in the amphibian brain. Rastogi RK, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):330-45

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Lin Y, et al. **Hum Reprod** 1999 Apr;14(4):885-8

Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. Dorn C, et al. **J Biol Chem** 1999 May 14;274(20):13870-6

Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. Raga F, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):636-42

Identification and characterization of estrogen receptor alpha-containing neurons projecting to the vicinity of the gonadotropin-releasing hormone perikarya in the rostral preoptic area of the rat. Simonian SX, et al. **J Comp Neurol** 1999 Aug 23;411(2):346-58

Gonadotropin-releasing hormone neuronal system of the freshwater snails Helisoma trivolvis and Lymnaea stagnalis: possible involvement in reproduction. Young KG, et al. **J Comp Neurol** 1999 Feb 22;404(4):427-37

Role of GnRH drive in the pathophysiology of polycystic ovary syndrome. Leondires MP, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):476-85 (78 ref.)

Role of endogenous opiates in glucoprivic inhibition of the luteinizing hormone surge and fos expression by preoptic gonadotropin-releasing hormone neurones in ovariectomized steroid-primed female rats. Briski KP, et al. **J Neuroendocrinol** 1998 Oct;10(10):769-76

Intracellular Ca(2+) oscillations in luteinizing hormone-releasing hormone neurons derived from the embryonic olfactory placode of the rhesus monkey. Terasawa E, et al. **J Neurosci** 1999 Jul 15;19(14):5898-909

GnRH-dependent up-regulation of nitric oxide synthase I level in pituitary gonadotrophs mediates cGMP elevation during rat proestrus. Lozach A, et al. **Mol Cell Endocrinol** 1998 Aug 25;143(1-2):43-51

The tail of the gonadotrophin-releasing hormone receptor: desensitization at, and distal to, G protein-coupled receptors. McArdle CA, et al. **Mol Cell Endocrinol** 1999 May 25;151(1-2):129-36 (63 ref.)

Molecular mechanisms of the regulation of gonadotropin gene expression by gonadotropin-releasing hormone. Kaiser UB. **Mol Cells** 1998 Dec 31;8(6):647-56 (58 ref.)

Diurnal rhythmicity of gonadotropin-releasing hormone gene expression in the rat. Gore AC. **Neuroendocrinology** 1998 Oct;68(4):257-63

Morphological characterization of relationship between gap junctions and gonadotropin releasing hormone nerve terminals in the rat median eminence. Tsukahara S, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):105-8

Activation of nicotinic receptor-induced postsynaptic responses to luteinizing hormone-releasing hormone in bullfrog sympathetic ganglia via a Na+-dependent mechanism. Cao YJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12689-94

Coordinate regulation of gonadotropin-releasing hormone neuronal firing patterns by cytosolic calcium and store depletion. Van Goor F, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4101-6

Electrophysiological correlates of pulsatile and surge gonadotrophin secretion. Nishihara M, et al.

Rev Reprod 1999 May;4(2):110–6 (52 ref.)
Inhibitory effect of melatonin on GnRH-induced LH release. Vanecek J. **Rev Reprod** 1999 May;4(2):67–72 (53 ref.)
[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318–21 (16 ref.) **(Fre)**
[Polycystic ovarian syndrome. GnRH pulse generator defect? (editorial)] Garcia Rudaz MC, et al. **Medicina (B Aires)** 1999;59(1):115–7 **(Spa)**

SECRETION

Dynamics of steroid regulation of GnRH secretion during the oestrus cycle of the ewe. Caraty A, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):68–78 (45 ref.)
Development and organization of the hypophysiotropic hypothalamus driving the pituitary-gonadal axis in the rhesus monkey. Plant TM, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):60–6 (43 ref.)
Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. de Brito VN, et al. **Arch Dis Child** 1999 Mar;80(3):231–4
In vitro nitric oxide effects on basal and gonadotropin-releasing hormone-induced gonadotropin secretion by pituitary gland of male crested newt (Triturus carnifex) during the annual reproductive cycle. Gobbetti A, et al. **Biol Reprod** 1999 May;60(5):1217–23
Gonadotrophin-releasing hormone and oxytocin secretion from the hypothalamus in vitro during pro-oestrus: the effects of time of day and melatonin. Evans JJ, et al. **Brain Res Bull** 1999 Jan 1;48(1):93–7
Walker 256/S carcinosarcoma causes osteoporosis-like changes through ectopical secretion of luteinizing hormone-releasing hormone. Waki Y, et al. **Cancer Res** 1999 Mar 15;59(6):1219–24
Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Couzinet B, et al. **Clin Endocrinol (Oxf)** 1999 Feb; 50(2):229–35
Temporal effects of estradiol (E) on luteinizing hormone-releasing hormone (LHRH) and LH release in castrated male sheep. Lubbers LS, et al. **Domest Anim Endocrinol** 1998 Nov;15(6):511–24
Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. Krsmanovic LZ, et al. **Endocrinology** 1999 Mar;140(3):1423–31
Pulsatility in primates--a perspective from the placode [editorial; comment] Levine JE. **Endocrinology** 1999 Mar; 140(3):1033–5. Comment on: Endocrinology 1993 Nov;133(5):2379–90. Comment on: Endocrinology 1999 Mar;140(3):1432–41.
Expression of a leptin receptor in immortalized gonadotropin-releasing hormone-secreting neurons. Magni P, et al. **Endocrinology** 1999 Apr;140(4):1581–5
Expression of prostacyclin receptors in luteinizing hormone-releasing hormone immortalized neurons: role in the control of hormone secretion. Pimpinelli F, et al. **Endocrinology** 1999 Jan;140(1):171–7
Bradykinin receptor localization and cell signaling pathways used by bradykinin in the regulation of gonadotropin-releasing hormone secretion. Shi B, et al. **Endocrinology** 1999 Oct;140(10):4669–76
Pulsatile release of luteinizing hormone-releasing hormone (LHRH) in cultured LHRH neurons derived from the embryonic olfactory placode of the rhesus monkey [see comments] Terasawa E, et al. **Endocrinology** 1999 Mar; 140(3):1432–41. Comment in: Endocrinology 1999 Mar;140(3):1033–5.
Early prepubertal ontogeny of pulsatile gonadotropin-releasing hormone (GnRH) secretion: I. Inhibitory autofeedback control through prolyl endopeptidase degradation of GnRH. Yamanaka C, et al. **Endocrinology** 1999 Oct;140(10):4609–15
Effects of the GABA-A receptor agonist and antagonist on the in vitro release of hypothalamic catecholamines: apparent parallelism between these effects and the LHRH secretion in adult male rats. Feleder C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):80–4
Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. Hayes FJ, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1028–36
Indirect assessment of pulsatile gonadotropin-releasing hormone release in agonadal prepubertal rhesus monkeys (Macaca mulatta). Suter KJ, et al. **J Endocrinol** 1999 Jan; 160(1):35–41
Serotonergic 5-HT2A receptors important for the oestradiol-induced surge of luteinising hormone-releasing hormone in the rat. Fink G, et al. **J Neuroendocrinol** 1999 Jan;11(1):63–9
Effect of alcohol on the proestrous surge of luteinizing hormone (LH) and the activation of LH-releasing hormone (LHRH) neurons in the female rat. Ogilvie KM, et al. **J Neurosci** 1997 Apr 1;17(7):2595–604
Effect of RU486 injected on proestrous morning on LHRH, LH and 17beta-estradiol secretion during the estrous cycle in rat. Tébar M, et al. **J Physiol Biochem** 1998 Jun; 54(2):91–7
Long-term exposure of hypothalamic explants to melatonin alters the release of gonadotrophin releasing hormone and the density of melatonin binding sites in the pars tuberalis of the male mink (Mustela vison). Messager S, et al. **J Pineal Res** 1999 Jan;26(1):17–27
In vitro secretion of gonadotropin-releasing hormone (GnRH) and [hydroxyproline9]GnRH from the rat hypothalamus exhibits a differential sensitivity to castration and second messengers. Rochdi L, et al. **Neuroendocrinology** 1998 Oct;68(4):281–92
Transforming growth factor beta2 is able to modify mRNA levels and release of luteinizing hormone-releasing hormone in a immortalized hypothalamic cell line (GT1-1). Messi E, et al. **Neurosci Lett** 1999 Aug 6;270(3):165–8
beta-Endorphin blocks luteinizing hormone-releasing hormone release by inhibiting the nitricoxidergic pathway controlling its release. Faletti AG, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1722–6
Evidence for attenuation of gonadotropin pulse frequency in hypergonadotropic women with estradiol secretion in the menopausal transition. Ushiroyama T, et al. **Psychoneuroendocrinology** 1999 Jan;24(1):85–97
Effects of an antisense oligodeoxynucleotide for neuropeptide Y mRNA on in vivo luteinizing hormone-releasing hormone release in ovariectomized female rhesus monkeys. Kasuya E, et al. **Regul Pept** 1998 Sep 25;75–76:319–25
Melatonin and the seasonal control of reproduction. Malpaux B, et al. **Reprod Nutr Dev** 1999 May-Jun;39(3):355–66 (75 ref.)
[Control of catecholaminergic neurotransmitters on the secretion of gonadotropin-releasing hormone] Shen WB. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):368–70 (10 ref.) **(Chi)**
[Development of luteinizing hormone-releasing hormone (LHRH) neurons] Daikoku S. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):388–91 (34 ref.) **(Jpn)**
[Olfactory origin of luteinizing hormone-releasing hormone (LHRH) neurons] Daikoku S. **Nippon Ika Daigaku Zasshi** 1999 Apr;66(2):94–106 (101 ref.) **(Jpn)**

THERAPEUTIC USE

Ovarian hyperstimulation syndrome caused by GnRH-analogue treatment without gonadotropin therapy in a patient with polycystic ovarian syndrome. Jirecek S, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):940–1
L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency. Lado-Abeal J, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):203–7
Clinical course of long term treatment with intermittent subcutaneous injection of LHRH in combination with GH replacement in a male patient with hypothalamic hypogonadism due to disruption of the pituitary stalk. Mori T, et al. **Endocr J** 1998 Apr;45 Suppl:S155–8
Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. Caron P, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):990–6
Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration [see comments] Oefelein MG. **J Urol** 1998 Nov;160(5):1685–8 . Comment in: J Urol 1999 Jul;162(1):170. Comment in: J Urol 1999 Jul;162(1):170–1.
Cryptorchidism: medical and surgical treatment in the 1st year of life. Canavese F, et al. **Pediatr Surg Int** 1998 Nov; 14(1-2):2–5
Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Pályi I, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2361–6
Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. Ahlgren G, et al. **Urology** 1999 Aug;54(2):329–34
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Hall MC, et al. **Urology** 1999 May;53(5):898–902; discussion 902–3
Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Ornstein DK, et al. **Urology** 1998 Dec;52(6):1094–7
Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study. Hooijer GA, et al. **Vet Q** 1999 Jan;21(1):33–7
[Surgical or medical castration with LH-RH analogue for prostatic cancer] Kameyama S, et al. **Nippon Rinsho** 1998 Aug;56(8):2114–8 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer] Kawai K, et al. **Nippon Rinsho** 1998 Aug;56(8):2108–13 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment] Ueda S, et al. **Nippon Rinsho** 1998 Aug;56(8):2119–23 (Eng. Abstr.) **(Jpn)**

GONADORELIN RECEPTORS see **RECEPTORS, LHRH**

GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

GONADOTROPIN-RELEASING HORMONE see **GONADORELIN**

GONADOTROPIN RELEASING-HORMONE RECEPTORS see **RECEPTORS, LHRH**

GONADOTROPIN-RESISTANT OVARY SYNDROME see **OVARIAN FAILURE, PREMATURE**

GONADOTROPINS

see related
RECEPTORS, GONADOTROPIN

ADMINISTRATION & DOSAGE

A randomized controlled trial of three low-dose gonadotrophin protocols for unexplained infertility. Hughes EG, et al. **Hum Reprod** 1998 Jun;13(6):1527–31
The need to step up the gonadotropin dosage in the stimulation phase of IVF treatment predicts a poor outcome. Hock DL, et al. **J Assist Reprod Genet** 1998 Aug; 15(7):427–30
Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective? Lashen H, et al. **J Assist Reprod Genet** 1998 Aug;15(7):438–43

ADVERSE EFFECTS

Effects of urinary gonadotrophin preparations on human in-vitro immune function. Biffoni M, et al. **Hum Reprod** 1998 Sep;13(9):2430–4
Re: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone [letter; comment] Hamilton TC. **J Natl Cancer Inst** 1999 Apr 7;91(7):650–1. Comment on: J Natl Cancer Inst 1998 Dec 2;90(23):1774–86.

ANTAGONISTS & INHIBITORS

Follicle-stimulating hormone is required for the initial phase of spermatogenic restoration in adult rats following gonadotropin suppression. Meachem SJ, et al. **J Androl** 1998 Nov-Dec;19(6):725–35

BIOSYNTHESIS

Testosterone regulation of gonadotropin production in goldfish. Habibi HR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):339–44 (59 ref.)
Growth hormone (GH) and gonadotropin subunit gene expression and pituitary and plasma changes during spermatogenesis and oogenesis in rainbow trout (Oncorhynchus mykiss). Gomez JM, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):413–28
Seasonal changes in mRNA levels of gonadotropin and thyrotropin subunits in the goldfish, Carassius auratus. Sohn YC, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):436–44

BLOOD

Sex hormone status and bone metabolism in men with Crohn's disease. Robinson RJ, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):21–5
Hypokalemia alters sex hormone and gonadotropin levels: evidence that FSH may be required for luteinization. Tejada F, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1037–45
Hypergonadotropic hypogonadism in a 3-year-old girl with blepharophimosis, ptosis, and epicanthus inversus syndrome [see comments] Ogata T, et al. **Horm Res** 1998 Sep; 50(3):190–2. Comment in: Horm Res 1998;50(6):341.
Diurnal rhythm in serum levels of inhibin B in normal men: relation to testicular steroids and gonadotropins. Carlsen E, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1664–9
Does exercise affect female hamster gonadotropins by reducing estradiol negative feedback? Borer KT, et al. **Physiol Behav** 1999 Jan 1-15;65(4-5):855–61

CHEMISTRY

[The functional role of carbohydrate moiety of sturgeon gonadotropin beta-subunit] Zenkevich GA, et al. **Dokl Akad Nauk** 1999 Feb;364(6):828–31 **(Rus)**

DEFICIENCY

Testing the gonadal regression-cytoprotection hypothesis. Crawford BA, et al. **Cancer Res** 1998 Nov 15;58(22):5105–9
Predictive value of serum follicle-stimulating hormone levels in the differentiation between hypogonadotropic hypogonadism and constitutional delay of puberty. Odink RJ, et al. **Horm Res** 1998;49(6):279–87
Antimüllerian hormone in patients with hypogonadotropic hypogonadism. Young J, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2696–9
[Nutritional hypogonadism] Bringer J, et al. **Rev Prat** 1999 Jun 15;49(12):1291–6 (Eng. Abstr.) **(Fre)**
[Premature ovarian insufficiency] Christin-Maitre S. **Rev Prat** 1999 Jun 15;49(12):1297–302 (Eng. Abstr.) **(Fre)**
[Diagnosis and treatment of hypogonadotropism in males and females] Young J, et al. **Rev Prat** 1999 Jun 15;49(12):1283–9 (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

Serum inhibin B levels and the response to gonadotropin stimulation test in pubertal boys with varicocele. Carrillo

A, et al. **J Urol** 1999 Sep;162(3 Pt 1):875–7

GENETICS

Gonadotropin-releasing hormone regulation of gonadotropin subunit gene expression in female rats: actions on follicle-stimulating hormone beta messenger ribonucleic acid (mRNA) involve differential expression of pituitary activin (beta-B) and follistatin mRNAs. Dalkin AC, et al. **Endocrinology** 1999 Feb;140(2):903–8

Mutations in human gonadotropin genes and their physiologic significance in puberty and reproduction. Layman LC. **Fertil Steril** 1999 Feb;71(2):201–18 (77 ref.)

Mutations and polymorphisms in gonadotropin genes. Huhtaniemi I, et al. **Mol Cell Endocrinol** 1999 May 25; 151(1–2):89–94 (39 ref.)

Chronic hypersecretion of luteinizing hormone in transgenic mice selectively alters responsiveness of the alpha-subunit gene to gonadotropin-releasing hormone and estrogens. Abbud RA, et al. **Mol Endocrinol** 1999 Sep;13(9):1449–59

IMMUNOLOGY

Effects of urinary gonadotrophin preparations on human in-vitro immune function. Biffoni M, et al. **Hum Reprod** 1998 Sep;13(9):2430–4

METABOLISM

Differential regulation of the gonadotropin storage pattern by gonadotropin-releasing hormone pulse frequency in the ewe. Molter-Gérard C, et al. **Biol Reprod** 1999 May; 60(5):1224–30

Effect of calf isolation on follicular wave dynamics, gonadotropin and metabolic hormone changes, and interval to first ovulation in beef cows fed either of two energy levels postpartum. Stagg K, et al. **Biol Reprod** 1998 Oct; 59(4):777–83

The effect of food intake from 2 to 24 weeks of age on LHRH-I content in the median eminence and gonadotrophin levels in pituitary and plasma in female broiler breeder chickens. Bruggeman V, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):200–9

11-ketotestosterone induces male-type sexual behavior and gonadotropin secretion in gynogenetic crucian carp, Carassius auratus langsdorfii. Kobayashi M, et al. **Gen Comp Endocrinol** 1999 Aug;115(2):178–87

Possible gonadotropin cells in the lamprey pituitary: colocalization of mammalian LH-like immunoreactivity and glycoconjugate in adult sea lampreys (Petromyzon marinus). Nozaki M, et al. **Gen Comp Endocrinol** 1999 Jan; 113(1):23–31

Role of chloride and inhibitory action of inorganic nitrate on gonadotropin-stimulated steroidogenesis in mouse Leydig tumor cells. Panesar NS. **Metabolism** 1999 Jun; 48(6):693–700

Molecular mechanisms of the regulation of gonadotropin gene expression by gonadotropin-releasing hormone. Kaiser UB. **Mol Cells** 1998 Dec 31;8(6):647–56 (58 ref.)

PHARMACOLOGY

Gonadotropins do not induce antiphospholipid antibodies. Franklin RD, et al. **Am J Reprod Immunol** 1998 Nov; 40(5):359–63

The modulation of gonadotrophic hormone action on the ovary by paracrine and autocrine factors. Campbell BK. **Anat Histol Embryol** 1999 Aug;28(4):247–51

Hormonal regulation of natriuretic peptide system during induced ovarian follicular development in the rat. Gutkowska J, et al. **Biol Reprod** 1999 Jul;61(1):162–70

Regulation and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse ovary during gonadotropin-induced ovulation. Hägglund AC, et al. **Endocrinology** 1999 Sep;140(9):4351–8

Gonadotropin stimulation of pituitary adenylate cyclase-activating polypeptide (PACAP) messenger ribonucleic acid in the rat ovary and the role of PACAP as a follicle survival factor. Lee J, et al. **Endocrinology** 1999 Feb;140(2):818–26

Regulation of 3beta-hydroxysteroid dehydrogenase in gonadotropin-induced steroidogenic desensitization of Leydig cells. Tang PZ, et al. **Endocrinology** 1998 Nov; 139(11):4496–505

Production of steroids from human cumulus cells treated with different concentrations of gonadotropins during culture in vitro. Chian RC, et al. **Fertil Steril** 1999 Jan;71(1):61–6

Effect of exogenous gonadotropins on endometrial maturation in oocyte donors. Meyer WR, et al. **Fertil Steril** 1999 Jan;71(1):109–14

Predictive value of serum estradiol levels for IVF pregnancy outcome after gonadotropin stimulation? [letter; comment] Ravhon A, et al. **Fertil Steril** 1999 Jan;71(1):183–4. Comment on: Fertil Steril 1998 Jun;69(6):1015–9.

Corticosteroids do not influence ovarian responsiveness to gonadotropins in patients with premature ovarian failure: a randomized, placebo-controlled trial. van Kasteren YM, et al. **Fertil Steril** 1999 Jan;71(1):90–5

In-vitro maturation of human germinal vesicle stage oocytes: role of cumulus cells and epidermal growth factor in the culture medium. Goud PT, et al. **Hum Reprod** 1998 Jun; 13(6):1638–44

Steroidogenesis in luteinized granulosa cell cultures varies with follicular priming regimen. Lobb DK, et al. **Hum Reprod** 1998 Aug;13(8):2064–7

Influence of norgestomet in combination with gonadotropins on induction of estrus and ovulation in prepubertal gilts. Knox RV, et al. **J Anim Sci** 1999 Jun;77(6):1348–52

Production and lambing rate of blastocysts derived from in vitro matured oocytes after gonadotropin treatment of prepubertal ewes. Ledda S, et al. **J Anim Sci** 1999 Aug; 77(8):2234–9

The hind paw edema produced by staphylococcal enterotoxin B in female mice is modulated by sex hormones. Desouza IA, et al. **J Nat Toxins** 1999 Jun;8(2):179–88

Involvement of cytosolic phospholipase A2 in the ovulatory process in gonadotropin-primed immature rats. Kurusu S, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Jun; 58(6):405–11

PHYSIOLOGY

Gonadotropin-induced resumption of oocyte meiosis and meiosis-activating sterols. Andersen CY, et al. **Curr Top Dev Biol** 1999;41:163–85 (120 ref.)

Germ cell-specific cyclic adenosine 3',5'-monophosphate response element modulator expression in rodent and primate testis is maintained despite gonadotropin deficiency. Behr R, et al. **Endocrinology** 1999 Jun; 140(6):2746–54

Gonadotropin and steroid regulation of steroid receptor and aryl hydrocarbon receptor messenger ribonucleic acid in macaque granulosa cells during the periovulatory interval. Chaffin CL, et al. **Endocrinology** 1999 Oct;140(10):4753–60

Spermatogenesis without gonadotropins: maintenance has a lower testosterone threshold than initiation. Handelsman DJ, et al. **Endocrinology** 1999 Sep;140(9):3938–46

The impact of sleep on gonadotropin secretion. Rossmanith WG. **Gynecol Endocrinol** 1998 Dec;12(6):381–9 (67 ref.)

Plasma substance-P and substance-K and gonadal steroids in relation to the gonadotropin surge in normal human reproductive cycles. Mohyi DL, et al. **J Assist Reprod Genet** 1998 Oct;15(9):547–51

Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. Welt CK, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2163–9

Gonadotropin independent precocious puberty. Low LC, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug;11(4):497–507 (75 ref.)

Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Lambert A, et al. **Mol Hum Reprod** 1998 Jul;4(7):619–29 (116 ref.)

SECRETION

Role of PACAP in the regulation of gonadotroph hormone secretion during ontogenesis: a single neonatal injection of PACAP delays puberty and its intracerebroventricular administration before the critical period of proestrous stage blocks ovulation in adulthood. Köves K, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:590–4

Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. de Miguel R, et al. **Biochem Pharmacol** 1998 Nov 15;56(10):1331–8

Prolactin replacement fails to inhibit reactivation of gonadotropin secretion in rams treated with melatonin under long days. Lincoln GA, et al. **Biol Reprod** 1999 Mar; 60(3):602–10

Improvement in gonadotropin secretion after corticosteroid therapy in a case of POEMS syndrome. Sasano T, et al. **Endocr J** 1998 Jun;45(3):413–9

Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Seminara SB, et al. **Endocr Rev** 1998 Oct; 19(5):521–39 (215 ref.)

Why is the retention of gonadotrophin secretion common in children with panhypopituitarism due to septo-optic dysplasia? Nanduri VR, et al. **Eur J Endocrinol** 1999 Jan; 140(1):48–50

A brain-Hatschek's pit connection in amphioxus. Gorbman A, et al. **Gen Comp Endocrinol** 1999 Feb;113(2):251–4

The impact of sleep on gonadotropin secretion. Rossmanith WG. **Gynecol Endocrinol** 1998 Dec;12(6):381–9 (67 ref.)

Nitric oxide regulation of gonadotrophin secretion in prepubertal heifers1. Honaramooz A, et al. **J Neuroendocrinol** 1999 Sep;11(9):667–76

Differential effects of estrogen–androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Simon J, et al. **Menopause** 1999 Summer;6(2):138–46

Neural pathway from the olfactory bulbs regulating tonic gonadotropin secretion. Pieper DR, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):555–62 (80 ref.)

Electrophysiological correlates of pulsatile and surge gonadotrophin secretion. Nishihara M, et al. **Rev Reprod** 1999 May;4(2):110–6 (52 ref.)

Regulation of the preovulatory gonadotropin surge by endogenous steroids. Mahesh VB, et al. **Steroids** 1998 Dec; 63(12):616–29 (248 ref.)

THERAPEUTIC USE

Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. Barbieri RL, et al. **Endocr Rev** 1999 Jun;20(3):249–52 (27 ref.)

"Poor responders" to gonadotropins and levels of antibodies to Chlamydia trachomatis? [letter; comment] Sharara FI. **Fertil Steril** 1999 Feb;71(2):388–9. Comment on: Fertil Steril 1998 Aug;70(2):214–8.

Aromatase activity of human granulosa cells in vitro: effects of gonadotrophins and follicular fluid. Guet P, et al. **Hum Reprod** 1999 May;14(5):1182–9

Clomiphene citrate or gonadotrophins for induction of ovulation? Out HJ, et al. **Hum Reprod** 1998 Sep; 13(9):2358–61

Ovarian response to gonadotrophins, optimal method for oocyte retrieval and pregnancy outcome in patients with vaginal agenesis. Wood EG, et al. **Hum Reprod** 1999 May; 14(5):1178–81

Fertility in anovulatory patients after primary cesarean section. Bider D, et al. **J Reprod Med** 1998 Oct; 43(10):869–71

GONADOTROPINS, CHORIONIC

see related
RECEPTORS, GONADOTROPIN

ADMINISTRATION & DOSAGE

Seminal plasma does not advance ovulation in hCG-treated sows. Soede NM, et al. **Anim Reprod Sci** 1998 Dec 1; 54(1):23–9

The negative effect of repeated equine chorionic gonadotropin treatment on subsequent fertility in Alpine goats is due to a humoral immune response involving the major histocompatibility complex. Roy F, et al. **Biol Reprod** 1999 Apr;60(4):805–13

Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma. Tavio M, et al. **Eur J Cancer** 1998 Sep;34(10):1634–7

Value of estradiol response after human chorionic gonadotropin administration in predicting in vitro fertilization success. Meyer WR, et al. **Fertil Steril** 1999 Sep;72(3):542–5

Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles. Zreik TG, et al. **Fertil Steril** 1999 Jun;71(6):1070–4

Is waiting for an endogenous luteinizing hormone surge and/or administration of human chorionic gonadotrophin of benefit in intrauterine insemination? Awonuga A, et al. **Hum Reprod** 1999 Jul;14(7):1765–70

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Doldi N, et al. **Hum Reprod** 1999 Mar;14(3):601–5

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Mannaerts BM, et al. **Hum Reprod** 1998 Jun;13(6):1461–4

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Peñarrubia J, et al. **Hum Reprod** 1998 Dec;13(12):3315–8

Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome. van der Meer M, et al. **Hum Reprod** 1998 Jun; 13(6):1465–9

Secondary treatment failure without anti-human chorionic gonadotropin antibody in a patient with Kallmann syndrome. Kitahara S, et al. **Int J Urol** 1998 Jul; 5(4):398–400

A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Matsumiya K, et al. **Int J Urol** 1998 Jul;5(4):361–3

Dexamethasone supplementation to gonadotropin stimulation for in vitro fertilization in polycystic ovarian disease. Bider D, et al. **J Assist Reprod Genet** 1999 May;16(5):233–5

Serum progesterone before and after human chorionic gonadotropin injection depends on the estradiol response to ovarian hyperstimulation during in vitro fertilization–embryo transfer cycles. Lindheim SR, et al. **J Assist Reprod Genet** 1999 May;16(5):242–6

[Follicular dynamics after treatment with hCG for ovulation induction in mares] Bollwein H, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):47–51 (Eng. Abstr.) **(Ger)**

[Hypogonadotropic hypogonadism treated with HCG monotherapy: report of 3 cases] Mukouyama H, et al. **Hinyokika Kiyo** 1999 Mar;45(3):195–8 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy [letter] Erjavec Z, et al. **Ann Oncol** 1999 Feb;10(2):243

Multiple cerebral infarctions associated with ovarian hyperstimulation syndrome. Yoshii F, et al. **Neurology** 1999 Jul 13;53(1):225–7

[Prevention of multiple pregnancies after ovulation induction with gonadotropins (editorial)] De Geyter C.
Schweiz Rundsch Med Prax 1998 Aug 26;87(35):1087–8 **(Ger)**

ANALYSIS

Correlation between fetal sex and human chorionic gonadotropin in peripheral maternal blood and amniotic fluid in second and third trimester normal pregnancies. Steier JA, et al. **Acta Obstet Gynecol Scand** 1999 May; 78(5):367–71

Analysis of hCG: clinical applications and assay requirements [letter] Mitchell H. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):259–60

Value of human chorionic gonadotropin compared to CEA in discriminating benign from malignant effusions. Lamerz R, et al. **Anticancer Res** 1999 Jul–Aug;19(4A):2421–5

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. de Wit R, et al. **Br J Cancer** 1998 Nov;78(10):1350–5

Expression, characterisation and immunoassay of recombinant marmoset chorionic gonadotrophin dimer and beta-subunit. Amato F, et al. **J Endocrinol** 1998 Oct; 159(1):141–51

Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. Kovalevskaya, et al. **J Endocrinol** 1999 Apr;161(1):99–106

[Human chorionic gonadotropin, its degradation products and possibilities of their use] Hrehorčák M, et al. **Ceska Gynekol** 1999 Apr;64(2):108–13 (62 ref.) **(Cze)**

BIOSYNTHESIS

The relationship between trophoblast differentiation and the production of bioactive hCG. Ho HH, et al. **Early Pregnancy** 1997 Dec;3(4):291–300

BLOOD

MULTISCAN--a Scandinavian multicenter second trimester obstetric ultrasound and serum screening study. Jørgensen FS, et al. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):501–10

Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors. Inanç SE, et al. **Acta Oncol** 1999;38(4):505–9

Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. Liu DF, et al. **Am J Clin Pathol** 1999 Feb;111(2):209–15

New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age. Bahado-Singh RO, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1627–31

Choroid plexus cysts: Is biochemical testing a valuable adjunct to targeted ultrasonography? Sullivan A, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):260–5

Evaluation of different weight correction methods for antenatal serum screening using data from two multi-centre programmes. Kennedy DM, et al. **Ann Clin Biochem** 1999 May;36 (Pt 3):359–64

LIAISON hCG--an automated chemiluminescent immunoassay for the determination of human chorionic gonadotropin (hCG). Oed M, et al. **Anticancer Res** 1999 Jul–Aug;19(4A):2735–7

125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Christensen TB, et al. **Br J Cancer** 1999 Jul;80(10):1577–81

Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans. Christensen TB, et al. **Br J Cancer** 1999 Jul;80(10):1582–7

First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. Biagiotti R, et al. **Br J Obstet Gynaecol** 1998 Aug; 105(8):917–20

False-positive hCG assay results leading to unnecessary surgery and chemotherapy and needless occurrences of diabetes and coma [letter] Cole LA, et al. **Clin Chem** 1999 Feb;45(2):313–4

Evaluation of nicked human chorionic gonadotropin content in clinical specimens by a specific immunometric assay. Kovalevskaya G, et al. **Clin Chem** 1999 Jan;45(1):68–77

Evaluation of the Abbott system in maternal serum screening for Down syndrome: the AxSym analyzer, AFP and hCG reagents and Maciel Prenatal Interpretive Software. Muller F, et al. **Clin Chim Acta** 1998 Sep 14;277(1):65–75

Pregnancy detection by ultrasound and chorionic gonadotropin during the peri-implantation period in the macaque (Macaca fascicularis). Tarantal AF, et al. **Early Pregnancy** 1997 Dec;3(4):281–90

Gonadotropin-releasing hormone-induced elevation of serum hCG in choriocarcinoma: a case report. Furuhashi M, et al. **Endocr J** 1998 Aug;45(4):585–90

TSH receptor gene mutations and familial gestational hyperthyroidism. Asteria C. **Eur J Endocrinol** 1999 Aug; 141(2):93–4

Serum human chorionic gonadotropin measurement in the diagnosis of ectopic pregnancy when transvaginal sonography is inconclusive. Mol BW, et al. **Fertil Steril** 1998 Nov;70(5):972–81

High levels of maternal serum human chorionic gonadotropin in Down syndrome pregnancies: the possible role of a transcription factor on chromosome 21. Goshen R, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):106–11

Phantom hCG and phantom choriocarcinoma. Cole LA. **Gynecol Oncol** 1998 Nov;71(2):325–9

Identification of persistent trophoblastic diseases based on a human chorionic gonadotropin regression curve by means of a stepwise piecewise linear regression analysis after the evacuation of uneventful moles. Shigematsu T, et al. **Gynecol Oncol** 1998 Dec;71(3):376–80

Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor [see comments] Tuncer ZS, et al. **Gynecol Oncol** 1999 Jun;73(3):345–7. Comment in: Gynecol Oncol 1999 Jun;73(3):343–4.

Maternal thyroid function in multiple pregnancy: the variable thyrotropic activity of human chorionic gonadotropin. Sakaguchi N, et al. **Horm Metab Res** 1998 Nov; 30(11):689–93

Human chorionic gonadotrophin concentrations in early pregnancy after in-vitro fertilization. Bjercke S, et al. **Hum Reprod** 1999 Jun;14(6):1642–6

Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional in-vitro fertilization. Lam YH, et al. **Hum Reprod** 1999 Aug; 14(8):2120–3

Modulation of human chorionic gonadotrophin bioactivity during the first trimester of pregnancy. Mock P, et al. **Hum Reprod** 1998 Sep;13(9):2629–32

Effect of antenatal dexamethasone therapy on maternal plasma human chorionic gonadotrophin, oestradiol and progesterone. Ogueh O, et al. **Hum Reprod** 1999 Feb; 14(2):303–6

Serum CA 125 and first trimester abortion. Scarpellini F, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):259–64

High hCG level is a risk factor for predicting the occurrence of brain and/or liver metastases from gestational choriocarcinoma. Yuan CC, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):67–9

Analysis of implantation in assisted reproduction through the use of serial human chorionic gonadotropin measurements. Hsu MI, et al. **J Assist Reprod Genet** 1998 Sep; 15(8):496–503

Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. Rotmensch S, et al. **J Assist Reprod Genet** 1999 Jan;16(1):8–12

Gonadotrophin secretion patterns in testicular cancer patients with greatly increased human chorionic gonadotrophin serum concentrations. Madersbacher S, et al. **J Endocrinol** 1998 Dec;159(3):451–8

Preoperative serum hCG level and intraoperative failure of laparoscopic linear salpingostomy for ectopic pregnancy [letter; comment] Mol BW, et al. **Obstet Gynecol** 1999 Feb; 93(2):319–20. Comment on: Obstet Gynecol 1998 Sep;92(3):373–6.

Resolution of hormonal markers of ectopic gestation: a randomized trial comparing single-dose intramuscular methotrexate with salpingostomy. Saraj AJ, et al. **Obstet Gynecol** 1998 Dec;92(6):989–94

Time length of negativization of hCG serum values after either surgical or medical treatment of ectopic pregnancy. Colacurci N, et al. **Panminerva Med** 1998 Sep;40(3):223–5

Clinical follow-up of high mid-trimester maternal serum intact human chorionic gonadotrophin concentrations in singleton pregnancies. Blundell G, et al. **Prenat Diagn** 1999 Mar;19(3):219–23

Cri-du-chat syndrome diagnosed by amniocentesis performed due to abnormal maternal serum test [letter] Fankhauser L, et al. **Prenat Diagn** 1998 Oct;18(10):1099–100

Low second-trimester maternal serum human chorionic gonadotrophin in a trisomy 9 pregnancy [letter] Lam YH, et al. **Prenat Diagn** 1998 Nov;18(11):1212

Serum hyperglycosylated hCG: a potential screening test for fetal Down syndrome [letter] Shahabi S, et al. **Prenat Diagn** 1999 May;19(5):488–9

Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses. Spong CY, et al. **Prenat Diagn** 1999 Apr;19(4):337–9

[Early diagnosis of ectopic pregnancy by uterine curettage with serum hCG assay] Liu Z, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):415–7 (Eng. Abstr.) **(Chi)**

[Unusual behavior of serum markers in risk evaluation for trisomy 21] Guibaud S, et al. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):439–44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of the association of a serum marker and second trimester ultrasonography for the screening of trisomy 21 in women of less than 38 years. Prospective study of 5,163 patients] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct; 27(6):599–604 (Eng. Abstr.) **(Fre)**

[All rules have exceptions. Ectopic pregnancy in spite of negative HCG] Flam F, et al. **Lakartidningen** 1999 Mar 10;96(10):1195 **(Swe)**

CEREBROSPINAL FLUID

Human chorionic gonadotrophin in CSF, not serum, predicts outcome in germinoma. Inamura T, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):654–7

CHEMISTRY

Dissociation of human chorionic gonadotropin into its free subunits is dependent on naturally occurring molecular structural variation, sample matrix and storage conditions. Butler SA, et al. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):754–60

Beta-hairpin stabilization in a 28-residue peptide derived from the beta-subunit sequence of human chorionic gonadotropin hormone. Silva RA, et al. **Biopolymers** 1999 Oct 5;50(4):413–23

Characterization of human chorionic gonadotropin peptide variants with a radio-receptor assay using recombinant human luteinizing hormone/chorionic gonadotropin receptors. Ho HH, et al. **Early Pregnancy** 1997 Sep; 3(3):204–12

Characterization of human chorionic gonadotropin in normal and abnormal pregnancies. Ho HH, et al. **Early Pregnancy** 1997 Sep;3(3):213–24

Towards minimized gonadotropins with full bioactivity. Heikoop JC, et al. **Eur J Biochem** 1999 Apr;261(1):81–4

Crystal structure of a ternary complex between human chorionic gonadotropin (hCG) and two Fv fragments specific for the alpha and beta-subunits. Tegoni M, et al. **J Mol Biol** 1999 Jun 25;289(5):1375–85

The beta-subunit of human chorionic gonadotrophin exists as a homodimer. Butler SA, et al. **J Mol Endocrinol** 1999 Apr;22(2):185–92

Addition of an N-terminal dimerization domain promotes assembly of hCG analogs: implications for subunit combination and structure-function analysis. Lin W, et al. **Mol Cell Endocrinol** 1999 Jun 25;152(1–2):91–8

Role of amino acid residues at the interface of alpha52asparginyl-N-glycosyl chain of human choriogonadotropin. Shao K, et al. **Mol Cell Endocrinol** 1999 Apr 25;150(1–2):47–56

Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Lee-Huang S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):2678–81

Structural and molecular studies of human chorionic gonadotropin and its receptor. Lustbader JW, et al. **Recent Prog Horm Res** 1998;53:395–424; discussion 424–5 (61 ref.)

GENETICS

Epitopes of human chorionic gonadotropin and their relationship to immunogenicity and cross-reactivity of beta-chain mutants. Porakishvili N, et al. **Am J Reprod Immunol** 1998 Sep;40(3):210–4

Expression of a bioactive, single-chain choriogonadotropin in Dictyostelium discoideum. Heikoop JC, et al. **Eur J Biochem** 1998 Sep 1;256(2):359–63

Random mutagenesis and screening of complex glycoproteins: expression of human gonadotropins in Dictyostelium discoideum. Linskens MH, et al. **FASEB J** 1999 Apr;13(6):639–45

Hyperexpression of biologically active human chorionic gonadotropin using the methylotropic yeast, Pichia pastoris. Sen Gupta C, et al. **J Mol Endocrinol** 1999 Jun; 22(3):273–83

[Up-regulation of human chorionic gonadotropin alpha subunit gene and human mitochondrial cytochrome c oxidase subunit II gene in cis-Diamminedichloroplatinum(II)-resistant human head and neck squamous carcinoma cells] Higuchi E. **Hokkaido Igaku Zasshi** 1999 May;74(3):231–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Crystallization of two hCG-specific monoclonal antibody fragments. Fotinou C, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):405–6

Epitopes of human chorionic gonadotropin and their relationship to immunogenicity and cross-reactivity of beta-chain mutants. Porakishvili N, et al. **Am J Reprod Immunol** 1998 Sep;40(3):210–4

The influence of epitope availability on atomic-force microscope studies of antigen–antibody interactions. Allen S, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):173–8

Humoral immune response to equine chorionic gonadotropin in ewes: association with major histocompatibility complex and interference with subsequent fertility. Roy F, et al. **Biol Reprod** 1999 Jul;61(1):209–18

Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG. Birken S, et al. **Endocrine** 1999 Apr;10(2):137–44

Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition. de Haard H, et al. **Immunotechnology** 1999 Mar;4(3–4):203–15

Secondary treatment failure without anti-human chorionic gonadotropin antibody in a patient with Kallmann syndrome. Kitahara S, et al. **Int J Urol** 1998 Jul; 5(4):398–400

Human chorionic gonadotropin as a target for cancer vaccines. Triozzi PL, et al. **Oncol Rep** 1999 Jan–Feb; 6(1):7–17 (98 ref.)

ISOLATION & PURIFICATION

Purification of human chorionic gonadotrophin from urine by membrane filtration affinity chromatography with a positively charged membrane. Xu B, et al. **Protein Expr Purif** 1999 Jul;16(2):221-3

METABOLISM

hCG: its pancreatic and duodenal receptors and in vivo electrolyte secretion in female rats. Panesar NS, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1430-6

Lutropins appear to contact two independent sites in the extracellular domain of their receptors. Bernard MP, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):611-7

Acidic isoforms of chorionic gonadotrophin in European and Samoan women are associated with hyperemesis gravidarum and may be thyrotrophic. Jordan V, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):619-27

Endocrine analytes in multiple-marker screening. Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963-81, vii (95 ref.)

Regulation of prostaglandin F2alpha-receptor mRNA in human granulosa-luteal cells by human chorionic gonadotrophin and prostaglandin F2alpha. Väänänen JE, et al. **Endocrine** 1998 Jun;8(3):261-7

The same luteinized granulosa-luteal cells from normal and superovulated human chorionic gonadotropin (hCG)-stimulated cycles contain hCG and insulin-like growth factor binding protein-1. Gersak K, et al. **Fertil Steril** 1999 May;71(5):902-6

Renal handling of endogenous human chorionic gonadotrophin in preeclampsia. Ezimokhai M, et al. **Hypertens Pregnancy** 1999;18(2):129-37

Hormonal regulation and germ cell-specific expression of heat shock protein 60 (hsp60) in the testis of macaque monkeys (Macaca mulatta and M. fascicularis). Meinhardt A, et al. **Int J Androl** 1998 Oct;21(5):301-7

Mutations that induce constitutive activation and mutations that impair signal transduction modulate the basal and/or agonist-stimulated internalization of the Lutropin/Choriogonadotropin receptor. Min KS, et al. **J Biol Chem** 1998 Dec 25;273(52):34911-9

In vitro reactivation of latent equid herpesvirus-1 from CD5+/CD8+ leukocytes indirectly by IL-2 or chorionic gonadotrophin. Smith DJ, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2997-3004

Surface retention of an inactivating lutropin receptor mutant in exoloop 3. Bhowmick N, et al. **Mol Cell Biochem** 1998 Oct;187(1-2):221-7

Role of the rate of internalization of the agonist-receptor complex on the agonist-induced down-regulation of the lutropin/choriogonadotropin receptor. Nakamura K, et al. **Mol Endocrinol** 1999 Aug;13(8):1295-304

Steroidogenic enzyme expression in human corpora lutea in the presence and absence of exogenous human chorionic gonadotrophin (HCG). Duncan WC, et al. **Mol Hum Reprod** 1999 Apr;5(4):291-8

PHARMACOKINETICS

Pharmacokinetics of exogenous gonadotropin and ovarian response in in vitro fertilization. Nagata Y, et al. **Fertil Steril** 1999 Aug;72(2):235-9

A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Mannaerts BM, et al. **Hum Reprod** 1998 Jun;13(6):1461-4

Peri-ovarian adhesions interfere with the diffusion of gonadotrophin into the follicular fluid. Nagata Y, et al. **Hum Reprod** 1998 Aug;13(8):2072-6

Low plasma levels of hCG after 10,000-IU hCG injection do not reduce the number or maturation of oocytes recovered in patients undergoing assisted reproduction. al-Hassan S, et al. **J Assist Reprod Genet** 1998 Nov; 15(10):583-6

PHARMACOLOGY

Effect on neonatal oestrogen and hCG treatment on the genital organs of adult female rats. Nikolić Z, et al. **Acta Vet Hung** 1999;47(1):109-15

Alcohol rapidly lowers plasma testosterone levels in the rat: evidence that a neural brain-gonadal pathway may be important for decreased testicular responsiveness to gonadotropin. Rivier C. **Alcohol Clin Exp Res** 1999 Jan; 23(1):38-45

Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro. Uzumcu M, et al. **Am J Reprod Immunol** 1998 Aug;40(2):83-8

Changes in follicular populations following treatment of buffaloes with PMSG (eCG) and Neutra-PMSG for superovulation. Manik RS, et al. **Anim Reprod Sci** 1999 May 17;56(1):31-8

Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells. Srivastava P, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4003-10

Estrogen mediates the protective effects of pregnancy and chorionic gonadotropin in a mouse model of vascular injury. Zhang L, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2059-65

Effect of sinusoidal 50 Hz magnetic field on the testosterone production of mouse primary Leydig cell culture. Forgács Z, et al. **Bioelectromagnetics** 1998;19(7):429-31

Equine chorionic gonadotropin regulates luteal steroidogenesis in pregnant mares. Daels PF, et al. **Biol Reprod** 1998 Nov;59(5):1062-8

Ovarian hormone secretory response to gonadotropins and nitric oxide following chronic nitric oxide deficiency in the rat. Dunnam RC, et al. **Biol Reprod** 1999 Apr; 60(4):959-63

Paradoxical pro-Kaposi's sarcoma activity of preparations of human chorionic gonadotropin [letter; comment] Simonart T, et al. **Blood** 1999 Jul 1;94(1):376-7. Comment on: Blood 1999 Feb 1;93(3):1038-44.

cDNA cloning of a stage-specific gene expressed during HCG-induced spermatogenesis in the Japanese eel. Miura C, et al. **Dev Growth Differ** 1999 Aug;41(4):463-71

Dual regulation of promoter II- and promoter If-derived cytochrome P450 aromatase transcripts in equine granulosa cells during human chorionic gonadotropin-induced ovulation: a novel model for the study of aromatase promoter switching. Boerboom D, et al. **Endocrinology** 1999 Sep;140(9):4133-41

Antioxidants mimic the ability of chorionic gonadotropin to suppress apoptosis in the rabbit corpus luteum in vitro: a novel role for superoxide dismutase in regulating bax expression. Dharmarajan AM, et al. **Endocrinology** 1999 Jun;140(6):2555-61

Human chorionic gonadotropin induces an inverse regulation of steroidogenic acute regulatory protein messenger ribonucleic acid in theca interna and granulosa cells of equine preovulatory follicles. Kerban A, et al. **Endocrinology** 1999 Feb;140(2):667-74

Functional assessment of the calcium messenger system in cultured mouse Leydig tumor cells: regulation of human chorionic gonadotropin-induced expression of the steroidogenic acute regulatory protein. Manna PR, et al. **Endocrinology** 1999 Apr;140(4):1739-51

High expression of bovine alpha glutathione S-transferase (GSTA1, GSTA2) subunits is mainly associated with steroidogenically active cells and regulated by gonadotropins in bovine ovarian follicles. Rabahi F, et al. **Endocrinology** 1999 Aug;140(8):3507-17

The rat 17beta-hydroxysteroid dehydrogenase type III: molecular cloning and gonadotropin regulation. Tsai-Morris CH, et al. **Endocrinology** 1999 Aug; 140(8):3534-42

Towards minimized gonadotropins with full bioactivity. Heikoop JC, et al. **Eur J Biochem** 1999 Apr;261(1):81-4

Gonadotropins induce higher active renin levels in the follicular fluid of normal and hyperstimulated cycles. Loret de Mola JR, et al. **Gynecol Endocrinol** 1999 Jun; 13(3):155-60

Endothelin-1 inhibits basal and human chorionic gonadotrophin-stimulated progesterone production. Apa R, et al. **Hum Reprod** 1998 Sep;13(9):2425-9

Leptin inhibits gonadotrophin-stimulated granulosa cell progesterone production by antagonizing insulin action. Brannian JD, et al. **Hum Reprod** 1999 Jun;14(6):1445-8

Differential effect of exogenous human chorionic gonadotrophin on progesterone production from normal or malfunctioning corpus luteum. Momoeda M, et al. **Hum Reprod** 1998 Jul;13(7):1907-11

Induction of macrophage migration inhibitory factor in human ovary by human chorionic gonadotrophin. Wada S, et al. **Hum Reprod** 1999 Feb;14(2):395-9

Control of the weaning-to-estrus interval in sows using gonadotropins and prostaglandins during lactation. Armstrong TA, et al. **J Anim Sci** 1999 Sep;77(9):2533-9

Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene. Zhou XL, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3364-77

Reduction of hamster egg abnormalities in repeatedly induced ovulation by using the minimum effective dose of human chorionic gonadotrophin. Kanayama K, et al. **J Int Med Res** 1999 Jan-Feb;27(1):22-6

Spatial and temporal modulation of perfusion in the rat ovary measured by arterial spin labeling MRI. Tempel C, et al. **J Magn Reson Imaging** 1999 Jun;9(6):794-803

The butler did it: search for killer(s) of Kaposi's sarcoma cells in preparations of human chorionic gonadotropin [editorial; comment] Darzynkiewicz Z. **J Natl Cancer Inst** 1999 Jan 20;91(2):104-6. Comment on: J Natl Cancer Inst 1999 Jan 20;91(2):135-43.

Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin [see comments] Samaniego F, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):135-43. Comment in: J Natl Cancer Inst 1999 Jan 20;91(2):104-6.

Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin. Gries JM, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):371-7

Effects of HCG or gonadoreline on seminal parameters and plasma testosterone levels in young male rabbits. Rebollar PG, et al. **J Physiol Biochem** 1998 Sep;54(3):161-6

Luteinization and proteolysis in ovarian follicles of Meishan and Large White gilts during the preovulatory period. Driancourt MA, et al. **J Reprod Fertil** 1998 Nov; 114(2):287-97

Spatio-temporal changes of prolyl 4-hydroxylase in granulosa cells during ovulation in eCG-hCG-treated immature rat ovaries. Nagai R, et al. **J Reprod Fertil** 1998 Jul;113(2):349-54

Changes in circulating and ovarian concentrations of bioactive tumour necrosis factor alpha during the first ovulation at puberty in rats and in gonadotrophin-treated immature rats. Rice VM, et al. **J Reprod Fertil** 1998 Jul; 113(2):337-41

Precocious estrus and reproductive ability induced by PG 600 in prepuberal gilts. Iwamura S, et al. **J Vet Med Sci** 1999 Jan;61(1):7-11

Superovulatory responses in Japanese black beef cows following largest follicle aspiration or human chorionic gonadotrophin (hCG) treatment. Otoi T, et al. **J Vet Med Sci** 1998 Aug;60(8):961-3

Mechanism of induction of follicular atresia after equine chorionic gonadotrophin (eCG) antisera treatment in hypophysectomized eCG-injected hamster model: possible involvement of c-myc and cdc25. Kole AR. **Med Hypotheses** 1999 Mar;52(3):265-7

Insulin has a biphasic effect on the ability of human chorionic gonadotropin to induce ovarian cysts in the rat. Bogovich K, et al. **Metabolism** 1999 Aug;48(8):995-1002

Inhibition of rat mammary tumorigenesis by human chorionic gonadotropin associated with increased expression of inhibin. Srivastava P, et al. **Mol Carcinog** 1999 Sep; 26(1):10-9

Regulation of low density lipoprotein receptor mRNA levels by estradiol 17beta and chorionic gonadotropin in human placenta. Shanker YG, et al. **Mol Cell Biochem** 1998 Oct; 187(1-2):133-9

Treatment of human endometrial stromal cells with chorionic gonadotropin promotes their morphological and functional differentiation into decidua. Han SW, et al. **Mol Cell Endocrinol** 1999 Jan 25;147(1-2):7-16

Role of the rate of internalization of the agonist-receptor complex on the agonist-induced down-regulation of the lutropin/choriogonadotropin receptor. Nakamura K, et al. **Mol Endocrinol** 1999 Aug;13(8):1295-304

Two testicular cDNA clones suppressed by gonadotropin stimulation exhibit ZP2- and ZP3-like structures in Japanese eel. Miura T, et al. **Mol Reprod Dev** 1998 Nov; 51(3):235-42

31P NMR studies of phosphate metabolism in the ovulatory process induced by gonadotropins in perfused rabbit ovary. Tanaka K, et al. **NMR Biomed** 1999 Jun;12(4):249-55

Invasion of cytotrophoblastic JEG-3 cells is stimulated by hCG in vitro. Zygmunt M, et al. **Placenta** 1998 Nov; 19(8):587-93

Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Fazleabas AT, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2543-8

Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Hizaki H, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10501-6

Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Lee-Huang S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):2678-81

The alterations of vascular smooth muscle reactivity in vitro by human chorionic gonadotrophin. Ezimokhai M. **Res Exp Med (Berl)** 1998 Dec;198(4):187-98

Inhibition of hCG-stimulated steroidogenesis in cultured mouse Leydig tumor cells by bisphenol A and octylphenols. Nikula H, et al. **Toxicol Appl Pharmacol** 1999 Jun 15;157(3):166-73

Growth-stimulating influence of human chorionic gonadotropin (hCG) on Plasmodium falciparum in vitro. Röhrig G, et al. **Zentralbl Bakteriol** 1999 Feb;289(1):89-99

[Effect of chorionic gonadotropin on the radiation exposed animals] Solopaeva IM. **Biull Eksp Biol Med** 1999 May; 127(5):536-8 **(Rus)**

[The effect of different doses of gonadotropins on the quantitative, morphological and cytogenetic characteristics of oocytes from CBA mice] Kovalenko TA, et al. **Tsitol Genet** 1999 Jan-Feb;33(1):49-53 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Stepwise activation of the gonadotropic signal transduction pathway, and the ability of prostaglandin F2alpha to inhibit this activated pathway. Väänänen JE, et al. **Endocrine** 1998 Jun;8(3):301-7

Preliminary results on the role of embryonic human chorionic gonadotrophin in corpus luteum rescue during early pregnancy and the relationship to abortion and ectopic pregnancy. Alam V, et al. **Hum Reprod** 1999 Sep; 14(9):2375-8

Utero-ovarian interaction in the regulation of reproductive function. Alexander H, et al. **Hum Reprod Update** 1998 Sep-Oct;4(5):550-9 (35 ref.)

Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation. Andersen CY, et al. **J Assist Reprod Genet** 1999 Sep;16(8):425-30

Ceasing of movement-disorder attacks immediately after the onset of pregnancy: possible effect of human chorionic gonadotropin [letter] Madeja M, et al. **Lancet** 1999 Aug 28;354(9180):745

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM.

GONADOTROPINS, CHORIONIC

Thyroid 1999 Jul;9(7):653-7 (42 ref.)

SECRETION

HCG secretion by peripheral mononuclear cells during pregnancy. Alexander H, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):377-87

Identification of L-type calcium channels associated with kappa opioid receptors in human placenta. Cemerikic B, et al. **J Mol Neurosci** 1998 Jun;10(3):261-72

THERAPEUTIC USE

Absence of effect of recombinant growth hormone to classic gonadotropin treatment on spermatogenesis of patients with severe hypogonadotropic hypogonadism. Giagulli VA. **Arch Androl** 1999 Jul-Aug;43(1):47-53

Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Barrio R, et al. **Fertil Steril** 1999 Feb;71(2):244-8

Pharmacokinetics of exogenous gonadotropin and ovarian response in in vitro fertilization. Nagata Y, et al. **Fertil Steril** 1999 Aug;72(2):235-9

Immature oocyte retrieval: lessons from unstimulated IVF cycles. Thornton MH, et al. **Fertil Steril** 1998 Oct; 70(4):647-50

Outcome of in-vitro fertilization through natural cycles in poor responders. Bassil S, et al. **Hum Reprod** 1999 May; 14(5):1262-5

Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Liu PY, et al. **Hum Reprod** 1999 Jun;14(6):1540-5

Recurrent empty follicle syndrome successfully treated with recombinant human chorionic gonadotrophin. Peñarrubia J, et al. **Hum Reprod** 1999 Jul;14(7):1703-6

Ovarian response to gonadotrophins, optimal method for oocyte retrieval and pregnancy outcome in patients with vaginal agenesis. Wood EG, et al. **Hum Reprod** 1999 May; 14(5):1178-81

AIDS-related cutaneous Kaposi's sarcoma: failure of treatment with human chorionic gonadotropin [letter] Sipsas NV, et al. **J Chemother** 1999 Feb;11(1):78-9

AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. Hermans P, et al. **J Hum Virol** 1998 Jan-Feb; 1(2):82-9

Hormonal replacement therapy with HCG and HU-FSH in thalassaemic patients affected by hypogonadotropic hypogonadism. Cisternino M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:885-90

Serum inhibin levels before and after gonadotropin stimulation in cryptorchid boys under age 4 years. Longui CA, et al. **J Pediatr Endocrinol Metab** 1998 Nov-Dec; 11(6):687-92

Human chorionic gonadotrophin therapy in hypogonadal thalassaemic patients with osteopenia: increase in bone mineral density. Perniola R, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:995-6

Microphallic hypospadias--the use of human chorionic gonadotropin and testosterone before surgical repair [editorial; comment] Husmann DA. **J Urol** 1999 Oct; 162(4):1440-1. Comment on: J Urol 1999 Oct;162(4):1435-9.

Preoperative treatment with human chorionic gonadotropin in infancy decreases the severity of proximal hypospadias and chordee [see comments] Koff SA, et al. **J Urol** 1999 Oct;162(4):1435-9. Comment in: J Urol 1999 Oct;162(4):1440-1.

In vitro effects and clinical evaluation of a human chorionic gonadotrophin preparation in acute leukemia. Feldman EJ, et al. **Leukemia** 1998 Nov;12(11):1749-55

Cryptorchidism: medical and surgical treatment in the 1st year of life. Canavese F, et al. **Pediatr Surg Int** 1998 Nov; 14(1-2):2-5

URINE

Evaluation of nicked human chorionic gonadotropin content in clinical specimens by a specific immunometric assay. Kovalevskaya G, et al. **Clin Chem** 1999 Jan;45(1):68-77

Following metastatic placental site trophoblastic tumor with urine beta-core fragment. Rinne K, et al. **Gynecol Oncol** 1999 Aug;74(2):302-3

Effect of low urine specific gravity on pregnancy testing. Neinstein L, et al. **J Am Coll Health** 1998 Nov;47(3):138-9

Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG. Cole LA, et al. **Prenat Diagn** 1999 Apr;19(4):351-9

Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. Cole LA, et al. **Prenat Diagn** 1998 Sep;18(9):926-33

Differential urinary gonadotrophin profiles in early pregnancy and early pregnancy loss. O'Connor JF, et al. **Prenat Diagn** 1998 Dec;18(12):1232-40

GONADOTROPINS, CHORIONIC, HUMAN see **GONADOTROPINS, CHORIONIC**

GONADOTROPINS, CHORIONIC, HUMAN BETA SUBUNIT see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

GONADOTROPINS, EQUINE

ADMINISTRATION & DOSAGE

Improved method of superovulation in monovulatory brushtail possums (Trichosurus vulpecula) using pregnant mares' serum gonadotrophin-luteinizing hormone. Glazier AM, et al. **J Reprod Fertil** 1998 Jul;113(2):191-5

BLOOD

Extraction of equine chorionic gonadotrophin from pregnant mare plasma by direct adsorption on chromatographic media. González G, et al. **Biotechnol Bioeng** 1998 Jan 5; 57(1):22-5

ISOLATION & PURIFICATION

Extraction of equine chorionic gonadotrophin from pregnant mare plasma by direct adsorption on chromatographic media. González G, et al. **Biotechnol Bioeng** 1998 Jan 5; 57(1):22-5

METABOLISM

Oxidation of gonadotrophin (PMSG) by oxygen free radicals alters its structure and hormonal activity. Ortega-Camarillo C, et al. **Mol Reprod Dev** 1999 Mar;52(3):264-8

PHARMACOLOGY

Suppression of ovarian activity in the gilt and reversal by exogenous gonadotrophin administration. Miller AT, et al. **Anim Reprod Sci** 1999 Jan 8;54(3):179-93

Synchronization of estrus in beef cattle with norgestomet and estradiol valerate. Kastelic JP, et al. **Can Vet J** 1999 Mar;40(3):173-8

Ultrasonic evaluation for the time of ovulation in ewes treated with norgestomet and norgestomet followed by pregnant mare's serum gonadotropin. Cardwell BE, et al. **J Anim Sci** 1998 Sep;76(9):2235-8

Time of ovulation in the brushtail possum (Trichosurus vulpecula) following PMSG/LH induced ovulation. Glazier AM. **J Exp Zool** 1999 May 1;283(6):608-11

Spatio-temporal changes of prolyl 4-hydroxylase in granulosa cells during ovulation in eCG-hCG-treated immature rat ovaries. Nagai R, et al. **J Reprod Fertil** 1998 Jul;113(2):349-54

Changes in circulating and ovarian concentrations of bioactive tumour necrosis factor alpha during the first ovulation at puberty in rats and in gonadotrophin-treated immature rats. Rice VM, et al. **J Reprod Fertil** 1998 Jul; 113(2):337-41

Precocious estrus and reproductive ability induced by PG 600 in prepuberal gilts. Iwamura S, et al. **J Vet Med Sci** 1999 Jan;61(1):7-11

Mechanism of induction of follicular atresia after equine chorionic gonadotrophin (eCG) antisera treatment in hypophysectomized eCG-injected hamster model: possible involvement of c-myc and cdc25. Kole AR. **Med Hypotheses** 1999 Mar;52(3):265-7

31P NMR studies of phosphate metabolism in the ovulatory process induced by gonadotropins in perfused rabbit ovary. Tanaka K, et al. **NMR Biomed** 1999 Jun;12(4):249-55

The influence of superovulation preparations on the levels of catecholamines in eminentia mediana, the pituitary and pineal gland of the sheep. Pástorová B. **Physiol Res** 1998; 47(6):471-5

The effect of gonadotrophin releasing hormone and follicle stimulating hormone in conjunction with pregnant mare serum gonadotrophin on the superovulatory response in crossbred sheep in India. Naqvi SM, et al. **Trop Anim Health Prod** 1998 Dec;30(6):369-76

[The effect of different doses of gonadotropins on the quantitative, morphological and cytogenetic characteristics of oocytes from CBA mice] Kovalenko TA, et al. **Tsitol Genet** 1999 Jan-Feb;33(1):49-53 (Eng. Abstr.) **(Ukr)**

GONADOTROPINS, HUMAN MENOPAUSAL see **MENOTROPINS**

GONADOTROPINS, PITUITARY

see related
RECEPTORS, GONADOTROPIN

Comment on gonadotroph adenoma causing ovarian hyperstimulation [letter; comment] Catargi B, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3404. Comment on: J Clin Endocrinol Metab 1998 Oct;83(10):3450-3.

ANALYSIS

Steroid regulation of progesterone receptor expression in cultured rat gonadotropes. Turgeon JL, et al. **Endocrinology** 1999 May;140(5):2318-25

Semen analysis in the Usher syndrome type 2A. van Aarem A, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May-Jun; 61(3):126-30

ANTAGONISTS & INHIBITORS

The anti-gonadotropic effects of cytokines: the role of neuropeptides. Kalra PS, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):321-32 (55 ref.)

BIOSYNTHESIS

Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome. Ahmed SF, et al. **Arch Dis Child** 1999 Apr;80(4):324-9

Insulin-like growth factor-I stimulates gonadotrophin production from eel pituitary cells: a possible metabolic signal for induction of puberty. Huang YS, et al. **J Endocrinol** 1998 Oct;159(1):43-52

BLOOD

Concentrations of gonadotropins, estradiol and progesterone in sows selected on an index of ovulation rate and embryo survival. Mariscal DV, et al. **Anim Reprod Sci** 1998 Dec 1;54(1):31-43

Levels of gonadotropins and adrenocortical hormones in newborns. Wang YM, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov-Dec;39(6):389-92

Effect of long-term alcohol abuse on male sexual function and serum gonadal hormone levels. Gümüş B, et al. **Int Urol Nephrol** 1998;30(6):755-9

Reduction of plasma gonadotropin levels and pituitary tumor size by treatment with bromocriptine in a patient with gonadotropinoma. Yamakita N, et al. **Intern Med** 1999 Mar; 38(3):266-71

A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. Anawalt BD, et al. **J Androl** 1999 May-Jun;20(3):407-14

Hormonal milieu in the maintenance of melasma in fertile women. Hassan I, et al. **J Dermatol** 1998 Aug;25(8):510-2

Ovarian follicular dynamics during anoestrus in ewes. Bartlewski PM, et al. **J Reprod Fertil** 1998 Jul; 113(2):275-85

Effect of long-term food restriction on pituitary sensitivity to cLHRH-I in broiler breeder females. Bruggeman V, et al. **J Reprod Fertil** 1998 Nov;114(2):267-76

Assessment of hypothalamic-pituitary function by hormonal pulsatility, gonadotropin-releasing hormone and thyrotropin-releasing hormone testing in women with euprolactinemic secondary amenorrhea. Lin KC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):698-705

Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Carmi D, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1257-62

The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors. Popovic V, et al. **Thyroid** 1998 Oct;8(10):935-9

Toxic equivalency factors of polychlorinated dibenzo-p-dioxins in an ovulation model: validation of the toxic equivalency concept for one aspect of endocrine disruption. Gao X, et al. **Toxicol Appl Pharmacol** 1999 Jun 1;157(2):107-16

Effects of transurethral prostate resection and transurethral laser prostatectomy on plasma hormone levels. Türkölmez K, et al. **Urol Int** 1998;61(3):162-7

CHEMISTRY

Cortisol selectively stimulates pituitary gonadotropin beta-subunit in a primitive teleost, Anguilla anguilla. Huang YS, et al. **Endocrinology** 1999 Mar;140(3):1228-35

DEFICIENCY

Evaluation of the pituitary gland in idiopathic hypogonadotropic hypogonadism. Jayasundar R, et al. **Acta Radiol** 1999 Jan;40(1):88-94

Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Liu PY, et al. **Hum Reprod** 1999 Jun;14(6):1540-5

Isolated hypogonadotropic hypogonadism in Rathke's cleft cyst: case report. Trincado P, et al. **J Child Neurol** 1998 Aug;13(8):402-5

Growth hormone (GH) substitution in hypogonadotropic, GH-deficient women decreases the follicle-stimulating hormone threshold for monofollicular growth. de Boer JA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):590-5

GENETICS

Structural and expression analyses of gonadotropin Ibeta subunit genes in goldfish (Carassius auratus). Sohn YC, et al. **Gene** 1998 Nov 19;222(2):257-67

METABOLISM

Effects of long-term testosterone, gonadotropin-releasing hormone agonist, and pimozide treatments on gonadotropin II levels and ovarian development in juvenile female striped bass (Morone saxatilis). Holland MC, et al. **Biol Reprod** 1998 Nov;59(5):1153-62

Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. Evans JJ. **Endocr Rev** 1999 Feb; 20(1):46-67 (322 ref.)

Detection of prolactin receptor gene expression in the sheep pituitary gland and visualization of the specific translation

of the signal in gonadotrophs. Tortonese DJ, et al. **Endocrinology** 1998 Dec;139(12):5215–23

Simultaneous localization of Pit-1 protein and gonadotropins on the same cell type in the anterior pituitary glands of the rat. Vidal S, et al. **Histochem Cell Biol** 1998 Aug; 110(2):183–8

Effects of testosterone on gonadotropins, testes, and plasma 17alpha,20beta-dihydroxy-4-pregnene-3-one levels in postbreeding mature Atlantic salmon, Salmo salar, male parr. Antonopoulou E, et al. **J Exp Zool** 1999 Sep 1; 284(4):425–36

The endocrinology of dizygotic twinning in the human. Lambalk CB, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):97–102 (26 ref.)

Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. McCann SM, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):193–202 (55 ref.)

PHARMACOLOGY

Activities of glucose metabolic enzymes in human preantral follicles: in vitro modulation by follicle-stimulating hormone, luteinizing hormone, epidermal growth factor, insulin-like growth factor I, and transforming growth factor beta1. Roy SK, et al. **Biol Reprod** 1999 Mar; 60(3):763–8

GTH II but not GTH I induces final maturation and the development of maturational competence of oocytes of red seabream in vitro. Kagawa H, et al. **Gen Comp Endocrinol** 1998 Oct;112(1):80–8

Developmental competence of immature pig oocytes under the influence of EGF, IGF-I, follicular fluid and gonadotropins during IVM-IVF processes. Illera MJ, et al. **Int J Dev Biol** 1998 Nov;42(8):1169–72

Alterations in rat vaginal histology by exogenous gonadotrophins. Daly TJ, et al. **J Anat** 1998 Oct;193 (Pt 3):469–72

Rabbit ovarian production of interleukin-6 and its potential effects on gonadotropin-induced progesterone secretion in granulosa and theca cells. Bréard E, et al. **J Endocrinol** 1998 Dec;159(3):479–87

Isolated porcine ovarian follicles as a model for the study of hormone and growth factor action on ovarian secretory activity. Sirotkin AV, et al. **J Endocrinol** 1998 Nov; 159(2):313–21

Differential effects of amount of feeding on cell proliferation and progesterone production in response to gonadotrophins and insulin-like growth factor I by ovarian granulosa cells of broiler breeder chickens selected for fatness or leanness. Onagbesan OM, et al. **J Reprod Fertil** 1999 May; 116(1):73–85

PHYSIOLOGY

Effect of stress-like concentrations of cortisol on gonadotroph function in orchidectomized sheep. Daley CA, et al. **Biol Reprod** 1999 Jan;60(1):158–63

Feedback control of gonadotropins in Atlantic salmon, Salmo salar, male parr.I. Castration effects in rematuring and nonrematuring fish. Antonopoulou E, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):132–41

Feedback control of gonadotropins in Atlantic salmon, Salmo salar, male parr.II. Aromatase inhibitor and androgen effects. Antonopoulou E, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):142–50

Duality of gonadotropin in a primitive teleost, Japanese eel (Anguilla japonica). Yoshiura Y, et al. **Gen Comp Endocrinol** 1999 Apr;114(1):121–31

RADIATION EFFECTS

Endocrine and reproductive health status of men who had experienced short-term radiation exposure at Chernobyl. Goncharov NP, et al. **Int J Androl** 1998 Oct;21(5):271–6

SECRETION

Gonadotropin response to naloxone in the mare: effect of time of year and reproductive status. Davison LA, et al. **Biol Reprod** 1998 Nov;59(5):1195–9

Gonadal stage-dependent effects of gonadal steroids on gonadotropin II secretion in the Atlantic croaker (Micropogonias undulatus). Khan IA, et al. **Biol Reprod** 1999 Sep;61(3):834–41

The GnRH receptor gene is preferentially expressed in functioning gonadotroph adenomas and displays a Mae III polymorphism site. Kottler ML, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):115–23

Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids. Nathwani NC, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):107–13

Kallmann's syndrome: is it always for life? Quinton R, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):481–5

Is opioidergic activity responsible for the circadian variation observed in the gonadotrophin responsiveness of early follicular phase women? Rossmanith WG, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):499–503

Gonadotrophin and prolactin secretory dynamics in girls with normal puberty, idiopathic precocious puberty and precocious puberty due to hypothalamic hamartoma. Uriarte MM, et al. **Clin Endocrinol (Oxf)** 1998 Sep; 49(3):363–8

Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. McCann SM, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):333–44 (53 ref.)

Alpha-latrotoxin stimulates inward current, rise in cytosolic calcium concentration, and exocytosis in at pituitary gonadotropes. Tse FW, et al. **Endocrinology** 1999 Jul; 140(7):3025–33

Differential effect of insulin-like growth factor I on in vitro gonadotropin (I and II) and growth hormone secretions in rainbow trout (Oncorhynchus mykiss) at different stages of the reproductive cycle. Weil C, et al. **Endocrinology** 1999 May;140(5):2054–62

Regulation of gonadotrophin secretion by inhibin, testosterone and gonadotrophin-releasing hormone in pituitary cell cultures of male monkeys. Fingscheidt U, et al. **J Endocrinol** 1998 Oct;159(1):103–10

Gonadotrophin secretion patterns in testicular cancer patients with greatly increased human chorionic gonadotrophin serum concentrations. Madersbacher S, et al. **J Endocrinol** 1998 Dec;159(3):451–8

Effects of activin on hormone secretion by single female rat pituitary cells: analysis by cell immunoblot assay. Miyamoto S, et al. **J Endocrinol** 1999 Jun;161(3):375–82

The antiprogestin RU486 dissociates LH and FSH secretion in male rats: evidence for direct action at the pituitary level. Sánchez-Criado JE, et al. **J Endocrinol** 1999 Feb; 160(2):197–203

Seasonal changes in the negative feedback regulation of the secretion of the gonadotrophins by testosterone and inhibin in rams. Tilbrook AJ, et al. **J Endocrinol** 1999 Jan; 160(1):155–67

Testosterone, LH and FSH episodic secretory patterns in GnRH-immunized bulls. Finnerty M, et al. **J Reprod Fertil** 1998 Sep;114(1):85–94

Gonadotrophin profiles and dioestrous pulsatile release patterns in mares as determined by collection of jugular blood at 4 h intervals throughout an oestrous cycle. Irvine CH, et al. **J Reprod Fertil** 1998 Jul;113(2):315–22

Sexual differences in the role of kainate receptors in controlling gonadotrophin secretion in prepubertal rats. Pinilla L, et al. **J Reprod Fertil** 1998 Jul;113(2):269–73

GnRH signalling pathways and GnRH-induced homologous desensitization in a gonadotrope cell line (alphaT3-1). Poulin B, et al. **Mol Cell Endocrinol** 1998 Jul 25; 142(1–2):99–117

Nitric oxide (NO) stimulates gonadotropin secretion in vitro through a calcium-dependent, cGMP-independent mechanism. Pinilla L, et al. **Neuroendocrinology** 1998 Sep; 68(3):180–6

Blockade of the hypothalamic-pituitary-testicular axis with a GnRH antagonist in the neonatal marmoset monkey: changes in Leydig cell ultrastructure. Prince FP, et al. **Tissue Cell** 1998 Dec;30(6):651–61

THERAPEUTIC USE

Recombinant gonadotrophins. Hayden CJ, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):188–96 (51 ref.)

What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins. Balen AH, et al. **Hum Reprod** 1999 Jun; 14(6):1411–7 (59 ref.)

URINE

Measuring endocrine profiles of women in field studies. Kesner JS, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:17–9

GONADS

see related
CASTRATION
SEX REVERSAL, GONADAL

Longitudinal gonadal function after bone marrow transplantation for acute lymphoblastic leukemia during childhood [see comments] Mayer EI, et al. **Pediatr Transplant** 1999 Feb;3(1):38–44. Comment in: Pediatr Transplant 1999 Feb;3(1):1–4.

ABNORMALITIES

Defects in the germ line and gonads of mice lacking connexin43. Juneja SC, et al. **Biol Reprod** 1999 May; 60(5):1263–70

Aberrant South African mosquitoes (Diptera: Culicidae): gynandromorphs and morphologic variants. Jupp PG. **J Am Mosq Control Assoc** 1998 Dec;14(4):470–1

A new lethal syndrome of exomphalos, short limbs, and macrogonadism. Faivre L, et al. **J Med Genet** 1999 Feb; 36(2):131–6

The functional and structural observations of the neonatal reproductive system of alligators exposed in ovo to atrazine, 2,4-D, or estradiol. Crain DA, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):180–5

ANATOMY & HISTOLOGY

Sperm storage in females of the smooth newt (Triturus v. vulgaris L.): I. Ultrastructure of the spermathecae during the breeding season. Sever DM, et al. **J Exp Zool** 1999 Jan 1;283(1):51–70

BLOOD SUPPLY

Angiogenesis in the gonadal capillary network of the chick embryo. Pérez-Aparicio FJ, et al. **Scanning Microsc** 1996; 10(3):859–71; discussion 871–4

CHEMISTRY

Polychlorinated biphenyls and chlordane in the gonads of paddlefish, Polyodon spathula, from the Ohio River. Gundersen DT, et al. **Bull Environ Contam Toxicol** 1998 Nov;61(5):650–7

CYTOLOGY

Effects of five natural gonadotropin-releasing hormones on cell suspensions of marine bivalve gonad: stimulation of gonial DNA synthesis. Pazos AJ, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):112–20

DRUG EFFECTS

Study of alterations produced by cadmium and cadmium/lead administration during gestational and early lactation periods in the reproductive organs of the rat. Corpas I, et al. **Ecotoxicol Environ Saf** 1998 Oct;41(2):180–8

Effects of waterborne exposure to 4-nonylphenol and nonylphenol ethoxylate on secondary sex characteristics and gonads of fathead minnows (Pimephales promelas). Miles-Richardson SR, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S122–S137

Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285–99 (139 ref.)

Effects of relatively low levels of mono-(2-ethylhexyl) phthalate on cocultured Sertoli cells and gonocytes from neonatal rats. Li LH, et al. **Toxicol Appl Pharmacol** 1998 Dec;153(2):258–65

EMBRYOLOGY

Development of tumors from bovine primordial germ cells transplanted to athymic mice. Choi SJ, et al. **Anim Reprod Sci** 1998 Jun 30;52(1):17–25

Gene interactions in gonadal development. Parker KL, et al. **Annu Rev Physiol** 1999;61:417–33 (95 ref.)

Genetic control of gonadal differentiation. Lim HN, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):1–16 (61 ref.)

Reverse transcription-polymerase chain reaction analysis of genes involved in gonadal differentiation in pigs. Parma P, et al. **Biol Reprod** 1999 Sep;61(3):741–8

Genes essential for early events in gonadal development. Parker KL, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):831–8 (55 ref.)

The Caenorhabditis elegans mel-11 myosin phosphatase regulatory subunit affects tissue contraction in the somatic gonad and the embryonic epidermis and genetically interacts with the Rac signaling pathway. Wissmann A, et al. **Dev Biol** 1999 May 1;209(1):111–27

Detailed characterization of the human aorta-gonad-mesonephros region reveals morphological polarity resembling a hematopoietic stromal layer. Marshall CJ, et al. **Dev Dyn** 1999 Jun;215(2):139–47

Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Oreal E, et al. **Dev Dyn** 1998 Aug;212(4):522–32

Vulva formation in Pristionchus pacificus relies on continuous gonadal induction. Sigrist CB, et al. **Dev Genes Evol** 1999 Aug;209(8):451–9

Origin of the gonad in the juvenile of a solitary ascidian, Ciona intestinalis. Yamamoto M, et al. **Dev Growth Differ** 1999 Feb;41(1):73–9

Gene expression during gonadogenesis in the chicken embryo. Smith CA, et al. **Gene** 1999 Jul 8;234(2):395–402

Mammalian sex determination: a molecular drama. Swain A, et al. **Genes Dev** 1999 Apr 1;13(7):755–67 (87 ref.)

Acetylcholinesterase-positive innervation is present at undifferentiated stages of the sea turtle Lepidochelis olivacea embryo gonads: implications for temperature-dependent sex determination. Gutiérrez-Ospina G, et al. **J Comp Neurol** 1999 Jul 19; 410(1):90–8

Stem cell emergence and hemopoietic activity are incompatible in mouse intraembryonic sites. Godin I, et al. **J Exp Med** 1999 Jul 5;190(1):43–52

The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Kim J, et al. **Mol Cell Biol** 1999 Mar;19(3):2289–99

The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 May 25;140(1–2):59–63 (25 ref.)

Role of Ahch in gonadal development and gametogenesis [see comments] Yu RN, et al. **Nat Genet** 1998 Dec; 20(4):353–7. Comment in: Nat Genet 1998 Dec;20(4):318–9.

[Function and expression of transcription factors implicated in gonadal differentiation] Morohashi K. **Nippon Rinsho** 1998 Jul;56(7):1739–44 (19 ref.) (Eng. Abstr.) **(Jpn)**

[The molecular mechanism of hematopoietic stem cell development in the AGM region] Takakura N. **Rinsho Ketsueki** 1999 Apr;40(4):262–7 (15 ref.) **(Jpn)**

[Hematopoietic stem cells and stromal cells in AGM region of mouse embryo] Tuji K. **Rinsho Ketsueki** 1999 Apr; 40(4):268–71 (7 ref.) **(Jpn)**

GONADS

ENZYMOLOGY

P450scc-like immunoreactivity throughout gonadal restructuring in the protogynous hermaphrodite Thalassoma duperrey. Morrey CE, et al. **Int J Dev Biol** 1998 Sep;42(6):811-6

GROWTH & DEVELOPMENT

Ultrastructural features of the adult hermaphrodite gonad of Caenorhabditis elegans: relations between the germ line and soma. Hall DH, et al. **Dev Biol** 1999 Aug 1; 212(1):101-23

Effects of Polydispyrenia simulii (Microspora; Duboscqiidae) on development of the gonads of Simulium pertinax (Diptera; Simuliidae). Castello Branco Junior A. **Mem Inst Oswaldo Cruz** 1999 May-Jun;94(3):421-4

Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. De Santa Barbara P, et al. **Mol Cell Biol** 1998 Nov;18(11):6653-65

Changes in the pituitary metabolism of monoamines (dopamine, norepinephrine, and serotonin) in female and male rainbow trout (Oncorhynchus mykiss) during gonadal recrudescence. Hernandez-Rauda R, et al. **Physiol Biochem Zool** 1999 May-Jun;72(3):352-9

METABOLISM

Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Oreal E, et al. **Dev Dyn** 1998 Aug;212(4):522-32

Patterns of keratins 8, 18 and 19 during gonadal differentiation in the mouse: sex- and time-dependent expression of keratin 19. Appert A, et al. **Differentiation** 1998 Sep;63(5):273-84

Gene expression during gonadogenesis in the chicken embryo. Smith CA, et al. **Gene** 1999 Jul 8;234(2):395-402

Long-term restoration of gonadal activity with xenografts of preoptic area tissue in hypogonadal (hpg) mice. Wood MJ, et al. **Genet Res** 1998 Dec;72(3):229-36

The sexually dimorphic expression of androgen receptors in the song nucleus hyperstriatalis ventrale pars caudale of the zebra finch develops independently of gonadal steroids. Gahr M, et al. **J Neurosci** 1999 Apr 1;19(7):2628-36

Steroid contents of and steroidogenesis in vitro by the developing gonad and mesonephros around sexual differentiation in fetal sheep. Lun S, et al. **J Reprod Fertil** 1998 Sep;114(1):131-9

Alterations in gonadal steroidogenesis in individuals expressing a common genetic variant of luteinizing hormone. Huhtaniemi IT, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1-6):281-5 (26 ref.)

Migration of mesonephric cells into the mammalian gonad depends on Sry. Capel B, et al. **Mech Dev** 1999 Jun; 84(1-2):127-31

Methyl donor for 1-methyladenine biosynthesis in starfish ovarian follicle cells. Mita M, et al. **Mol Reprod Dev** 1999 Sep;54(1):63-8

Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Shughrue PJ, et al. **Steroids** 1998 Oct;63(10):498-504

PHYSIOLOGY

Development and organization of the hypophysiotropic hypothalamus driving the pituitary-gonadal axis in the rhesus monkey. Plant TM, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):60-6 (43 ref.)

Gonadal stage-dependent effects of gonadal steroids on gonadotropin II secretion in the Atlantic croaker (Micropogonias undulatus). Khan IA, et al. **Biol Reprod** 1999 Sep;61(3):834-41

Annual changes in serum calcium and inorganic phosphate levels and correlation with gonadal status of a freshwater murrel, Channa punctatus (Bloch). Srivastav SK, et al. **Braz J Med Biol Res** 1998 Aug;31(8):1069-73

Thyroid and fertility. Mayer G, et al. **Coll Antropol** 1998 Jun;22(1):17-21 (38 ref.)

Regulation of serum leptin levels by gonadal function in rats. Pinilla L, et al. **Eur J Endocrinol** 1999 May;140(5):468-73

Levels of the native forms of GnRH in the pituitary of the gilthead seabream, Sparus aurata, at several characteristic stages of the gonadal cycle. Holland MCH, et al. **Gen Comp Endocrinol** 1998 Dec;112(3):394-405

Proceedings of the XIth International Workshop on Development and Function of the Reproductive Organs--Genetic and Endocrine Basis of Gonadal Failure. Amsterdam, the Netherlands, April 16-17, 1998. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):1-174

The roles of steroidogenic factor 1 in endocrine development and function. Parker KL. **Mol Cell Endocrinol** 1998 Oct 25;145(1-2):15-20 (36 ref.)

Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812-8 (19 ref.)

Signals from the reproductive system regulate the lifespan of C. elegans [see comments] Hsin H, et al. **Nature** 1999 May 27;399(6734):362-6. Comment in: Nature 1999 May 27;399(6734):308-9.

Ageing. A message from the gonads [news; comment] Riddle DL. **Nature** 1999 May 27;399(6734):308-9. Comment on: Nature 1999 May 27;399(6734):362-6.

Hypothalamic-pituitary-gonadal axis in the mutant weaver mouse. Schwartz NB, et al. **Neuroendocrinology** 1998 Dec; 68(6):374-85

Functions of the hypophysis-gonad and hypophysis-adrenal cortex systems during repeated administration of gonadotropin-releasing hormone in the postnatal period. Goncharov NP, et al. **Neurosci Behav Physiol** 1998 Sep-Oct;28(5):589-93

[Physiology and exploration of the gonadotropic axis] Chabbert-Buffet N, et al. **Rev Prat** 1999 Jun 15; 49(12):1270-6 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Gender differences in adrenal and gonadal responses to inflammatory aggression. Da Silva JA, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:148-51

Perturbations of hypothalamic-pituitary-gonadal axis and adrenal androgen functions in rheumatoid arthritis: an odyssey of hormonal relationships to the disease. Masi AT, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:53-62; discussion 62-3 (27 ref.)

Differences between men and women as regards the effects of protein-energy malnutrition on the hypothalamic-pituitary-gonadal axis. Lado-Abeal J, et al. **Nutrition** 1999 May;15(5):351-8

RADIATION EFFECTS

RCR 1997 scientific meeting: audit poster prize winners. **Clin Radiol** 1998 Dec;53(12):911-2

Evaluations of gonad and fetal doses for diagnostic radiology. Tung CJ, et al. **Proc Natl Sci Counc Repub China B** 1999 Jul;23(3):107-13

SURGERY

Laparoscopic gonadectomy in male pseudohermaphrodites. Kriplani A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;81(1):37-41

[Two cases of true hermaphrodite: the usefulness of laparoscopic gonadectomy in childhood. A case report] Sugimoto S, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec;89(12):971-4 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Ultrastructural features of the adult hermaphrodite gonad of Caenorhabditis elegans: relations between the germ line and soma. Hall DH, et al. **Dev Biol** 1999 Aug 1; 212(1):101-23

VIROLOGY

Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Ye X, et al. **Hum Gene Ther** 1998 Sep 20;9(14):2135-42

GONANES

PHARMACOLOGY

Onapristone suppresses prolactin production in explant cultures of leiomyoma. Austin DJ, et al. **Gynecol Obstet Invest** 1999;47(4):268-71

[Effects of progesterone antagonists on the eosinophilic granulocytes in the rat uterus] Schubert AK. **Anat Anz** 1998 Oct;180(5):401-8 (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. El Etreby MF, et al. **Breast Cancer Res Treat** 1998 May; 49(2):109-17

Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Robertson JF, et al. **Eur J Cancer** 1999 Feb;35(2):214-8

GONGFU see **MARTIAL ARTS**

GONGYLONEMA see **SPIRUROIDEA**

GONIOSCOPY

Gonioscopy. Thomas R, et al. **Indian J Ophthalmol** 1998 Dec; 46(4):255-61 (1 ref.)

Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma. Teekhasaenee C, et al. **Ophthalmology** 1999 Apr;106(4):669-74; discussion 674-5

INSTRUMENTATION

Sterilisation of tonometers and gonioscopes. Sood D, et al. **Indian J Ophthalmol** 1998 Jun;46(2):113-6 (15 ref.)

METHODS

[Postoperative ultrasound biomicroscopic evaluation of the tangible position of black diaphragm posterior chamber lenses in congenital and traumatic aniridia in comparison with gonioscopy] Schweykart N, et al. **Klin Monatsbl Augenheilkd** 1999 Jun;214(6):386-90 (Eng. Abstr.) **(Ger)**

GONIOTOMY see **TRABECULECTOMY**

GONOCOCCUS see **NEISSERIA GONORRHOEAE**

GONORRHEA

Gonorrhea. Darville T. **Pediatr Rev** 1999 Apr;20(4):125-8 (4 ref.)

[Gonorrhea] Kubota T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):7-9 (5 ref.) **(Jpn)**

COMPLICATIONS

Hospital-acquired adult gonococcal conjunctivitis [letter] Malhotra R, et al. **J Infect** 1998 Nov;37(3):305

Factors predicting upper genital tract inflammation among women with lower genital tract infection. Nelson DB, et al. **J Womens Health** 1998 Oct;7(8):1033-40

Contact dermatitis from a gonococcal discharge: a case report. Fiumara NJ, et al. **Sex Transm Dis** 1982 Jan-Mar; 9(1):41-2

Specificity of dysuria and discharge complaints and presence of urethritis in male patients attending an STD clinic in Malawi. Dallabetta G, et al. **Sex Transm Infect** 1998 Jun; 74 Suppl 1:S34-7

Periurethral gland abscess: aetiology and treatment Sanders CJ, et al. **Sex Transm Infect** 1998 Aug;74(4):276-8

[Rhabdomyolysis associated with disseminated gonococcal infection in an elderly woman] Attorri S, et al. **Medicina (B Aires)** 1998;58(6):739-40 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: a performance review with clinical and public health considerations [see comments] Koumans EH, et al. **Clin Infect Dis** 1998 Nov;27(5):1171-80 . Comment in: Clin Infect Dis 1998 Nov;27(5):1181-5. Comment in: Clin Infect Dis 1998 Nov;27(5):1186-93.

Can we do better than discrepant analysis for new diagnostic test evaluation? [editorial; comment] Miller WC. **Clin Infect Dis** 1998 Nov;27(5):1186-93. Comment on: Clin Infect Dis 1998 Nov;27(5):1171-80.

Gonococcal arthritis. Angulo JM, et al. **Compr Ther** 1999 Mar;25(3):155-62 (30 ref.)

Diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae. Genitourinary infections in males by the Amplicor PCR assay of urine. Palladino S, et al. **Diagn Microbiol Infect Dis** 1999 Mar;33(3):141-6

Correct samples for diagnostic tests in sexually transmitted diseases: which sample for which test? Stary A. **FEMS Immunol Med Microbiol** 1999 Jul 15;24(4):455-9 (30 ref.)

Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB nested PCR and 16S rRNA PCR. Farrell DJ. **J Clin Microbiol** 1999 Feb;37(2):386-90

Gonococcal endocarditis after a threatened abortion. A case report. Pantanowitz L, et al. **J Reprod Med** 1998 Dec; 43(12):1043-5

Evaluation of the Gen-Probe PACE 2 assay for the detection of asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in male arrestees. Beltrami JF, et al. **Sex Transm Dis** 1998 Nov;25(10):501-4

Evaluation of modified Stuart's medium in Culturettes for transport of Neisseria gonorrhoeae. Ebright JR, et al. **Sex Transm Dis** 1982 Jan-Mar;9(1):45-7

Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in swab specimens by the Hybrid Capture II and PACE 2 nucleic acid probe tests. Modarress KJ, et al. **Sex Transm Dis** 1999 May;26(5):303-8

Evaluation of modified New York City carbohydrate medium for the speciation of Neisseria. Simms DH, et al. **Sex Transm Dis** 1982 Jan-Mar;9(1):34-6

Detection of Neisseria gonorrhoeae infection by ligase chain reaction testing of urine among adolescent women with and without Chlamydia trachomatis infection. Xu K, et al. **Sex Transm Dis** 1998 Nov;25(10):533-8

Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin [published erratum appears in Sex Transm Infect 1998 Dec;74(6):459] Alary M, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S44-9

Validation of the WHO diagnostic algorithm and development of an alternative scoring system for the management of women presenting with vaginal discharge in Malawi. Costello Daly C, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S50-8

Evaluation of simple diagnostic algorithms for Neisseria gonorrhoeae and Chlamydia trachomatis cervical infections in female sex workers in Abidjan, Côte d'Ivoire. Diallo MO, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S106-11

Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. Mayaud P, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S139-46

Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Mayaud P, et al. **Sex Transm Infect** 1998 Jun; 74 Suppl 1:S77-84

Rapid and inexpensive approaches to managing abnormal vaginal discharge or lower abdominal pain: an evaluation

in women attending gynaecology and family planning clinics in Peru. Sánchez SE, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S85–94

Syndromic approach to detection of gonococcal and chlamydial infections among female sex workers in two Philippine cities. Wi T, et al. **Sex Transm Infect** 1998 Jun; 74 Suppl 1:S118–22

[DNA demonstration of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens of medical students (letter)] Rath PM, et al. **Dtsch Med Wochenschr** 1999 May 7; 124(18):577 **(Ger)**

DRUG THERAPY

Efficacy of pefloxacin in acute gonococcal urethritis. Bakare RA, et al. **Afr J Med Med Sci** 1997 Sep–Dec;26(3–4):185–6

Correlation between in vitro quinolone susceptibility of Neisseria gonorrhoeae and outcome of treatment of gonococcal urethritis with single-dose ofloxacin. Kam KM, et al. **Clin Infect Dis** 1999 May;28(5):1165–6

Epidemiology and treatment outcome of infection with antibiotic resistant strains of Neisseria gonorrhoeae in Scotland. Young H. **Commun Dis Public Health** 1999 Sep; 2(3):198–202

Correlates of gonococcal infection and of antimicrobial-resistant Neisseria gonorrhoeae among female sex workers, Republic of the Philippines, 1996–1997. Klausner JD, et al. **J Infect Dis** 1999 Mar;179(3):729–33

Sonographically guided intralesional antibiotic injection for treatment of a recalcitrant pelvic abscess: a case report. Ou MC, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):205–7

Issues in the management of sexually transmitted diseases in Papua New Guinea. Passey M. **P N G Med J** 1996 Sep; 39(3):252–60 (14 ref.)

Treatment of uncomplicated gonococcal infection with trimethoprim-sulfamethoxazole. Brown ST, et al. **Sex Transm Dis** 1982 Jan–Mar;9(1):9–14

Clinical evaluation of ceftibuten in gonorrhea. A pilot study in Hong Kong. Chong LY, et al. **Sex Transm Dis** 1998 Oct;25(9):464–7

A single large dose of trimethoprim–sulfamethoxazole fails to cure gonococcal urethritis in men. Prior RB, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):62–4

Optimal treatment of gonorrhea [letter] Rajan VS. **Sex Transm Dis** 1982 Jan–Mar;9(1):56

Analysis of quinolone resistance mechanisms in a sparfloxacin-resistant clinical isolate of Neisseria gonorrhoeae. Tanaka M, et al. **Sex Transm Dis** 1998 Oct; 25(9):489–93

Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Tapsall JW, et al. **Sex Transm Dis** 1998 Nov;25(10):505–8

Antimicrobial susceptibility and plasmid profile of Neisseria gonorrhoeae in India (New Delhi). Bhalla P, et al. **Sex Transm Infect** 1998 Jun;74(3):210–2

Auxotypes, serovars, and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985–93). Bogaerts J, et al. **Sex Transm Infect** 1998 Jun;74(3):205–9

Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from men with urethritis in Kenya. Claeys G, et al. **Sex Transm Infect** 1998 Aug;74(4):294–5

Prepackaged therapy for urethritis: the "MSTOP" experience in Cameroon. Crabbé F, et al. **Sex Transm Infect** 1998 Aug; 74(4):249–52

Ciprofloxacin resistance in Neisseria gonorrhoeae isolated in Mumbai (formerly Bombay), India. Divekar A, et al. **Sex Transm Infect** 1999 Apr;75(2):122

Evaluation of syndromic patient management algorithm for urethral discharge. Djajakusumah T, et al. **Sex Transm Infect** 1998 Jun;74 Suppl 1:S29–33

Predicting penicillin resistance in patients with gonorrhoea. Goodfellow A, et al. **Sex Transm Infect** 1999 Jun;75(3):190

Managing STIs identified after testing outside genitourinary medicine departments: one model of care. Haddon L, et al. **Sex Transm Infect** 1998 Aug;74(4):256–7

Susceptibility of gonococci isolated in London to therapeutic antibiotics: establishment of a London surveillance programme. London Gonococcal Working Group. Ison CA, et al. **Sex Transm Infect** 1999 Apr;75(2):107–11

In vitro activity of several antimicrobial agents against Neisseria gonorrhoeae in the western region of the Kingdom of Saudi Arabia. Raddadi AA, et al. **Sex Transm Infect** 1998 Aug;74(4):294

Emergence of fluoroquinolone resistant Neisseria gonorrhoeae in New Delhi, India [letter] Rattan A, et al. **Sex Transm Infect** 1998 Jun;74(3):229

Antimicrobial resistance of Neisseria gonorrhoeae in Liberia. Guyot A, et al. **Trans R Soc Trop Med Hyg** 1998 Nov–Dec; 92(6):670–4

Genotypic evolution in a quinolone-resistant Neisseria gonorrhoeae isolate from a patient with clinical failure of levofloxacin treatment. Tanaka M, et al. **Urol Int** 1999; 62(1):64–8

[Gonorrhea occurs even in young people--treat it correctly (letter)] Fredlund H, et al. **Lakartidningen** 1999 Jan 27; 96(4):304 **(Swe)**

EPIDEMIOLOGY

Prevalence and horizontal propagation of gonococcal infections among Nigerian children [see comments] Emele FE, et al. **Acta Paediatr** 1998 Dec;87(12):1295–6. Comment in: Acta Paediatr 1998 Dec;87(12):1214–7.

Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases. Chamot E, et al. **AIDS** 1999 May 28; 13(8):971–9

The evolving epidemiology of chlamydial and gonococcal infections in response to control programs in Winnipeg, Canada. Blanchard JF, et al. **Am J Public Health** 1998 Oct; 88(10):1496–502

Factors associated with gonorrhoea in men aware of being positive for HIV infection: case-control study. Sadiq ST, et al. **BMJ** 1998 Oct 17;317(7165):1052–3

Cyclic patterns of variations in incidence rates of syphilis and gonorrhoea in Slovakia [letter] Dimitrov BD. **Bratisl Lek Listy** 1999 Mar;100(3):183–4

Annual report of the Australian Gonococcal Surveillance Programme, 1998. **Commun Dis Intell** 1999 Jul 8; 23(7):193–7

Annual report of the Australian Gonococcal Surveillance Programme, 1997. **Commun Dis Intell** 1998 Oct 1; 22(10):212–6

Epidemiology and treatment outcome of infection with antibiotic resistant strains of Neisseria gonorrhoeae in Scotland. Young H. **Commun Dis Public Health** 1999 Sep; 2(3):198–202

Assessing the sensitivity of STD surveillance in the Netherlands: an application of the capture--recapture method. Reintjes R, et al. **Epidemiol Infect** 1999 Feb; 122(1):97–102

Characterization of an outbreak of tetM–containing Neisseria gonorrhoeae in Argentina. Fernandez Cobo M, et al. **Int J STD AIDS** 1999 Mar;10(3):169–73

The outcome of contact tracing for gonorrhoea in the United Kingdom. FitzGerald MR, et al. **Int J STD AIDS** 1998 Nov;9(11):657–60

An epidemiological evaluation of the use of microbiological tools for identifying gonorrhoea infection networks. Pierce RL, et al. **Int J STD AIDS** 1999 May;10(5):316–23

Contact tracing for gonorrhoea in homosexual and heterosexual men. Rogstad KE, et al. **Int J STD AIDS** 1999 Aug;10(8):536–8

Neisseria gonorrhoeae in Newcastle upon Tyne 1995–1997: increase in ciprofloxacin resistance. Tayal SC, et al. **Int J STD AIDS** 1999 May;10(5):290–3

Reduced chlamydial infection and gonorrhea among commercial sex workers in Fukuoka City, Japan. Tanaka M, et al. **Int J Urol** 1998 Sep;5(5):471–5

Incidence of gonorrhea in Belgrade, 1988–1994. Bjekić M, et al. **J Infect** 1998 Jul;37(1):44–7

Asymptomatic sexually transmitted disease prevalence in four military populations: application of DNA amplification assays for Chlamydia and gonorrhea screening. Brodine SK, et al. **J Infect Dis** 1998 Oct;178(4):1202–4

Resurgence in gonorrhoea and syphilis in UK might be due to cyclic patterns of variations [letter; comment] Dimitrov BD. **J Public Health Med** 1999 Mar;21(1):117–9. Comment on: J Public Health Med 1992 Jun;14(2):206–14.

From the Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men--San Francisco, California, 1994–1997. **JAMA** 1999 Feb 24;281(8):696–7

Epidemic gonococcal conjunctivitis in Central Australia--a manifestation of cyclical weather patterns? [letter] McKeown DJ, et al. **Med J Aust** 1998 Oct 5;169(7):397

Impact of improved diagnosis and treatment on prevalence of gonorrhoea and chlamydial infection in remote aboriginal communities on Anangu Pitjantjatjara Lands. Miller PJ, et al. **Med J Aust** 1999 May 3;170(9):429–32

Increases in unsafe sex and rectal gonorrhea among men who have sex with men--San Francisco, California, 1994–1997. **MMWR Morb Mortal Wkly Rep** 1999 Jan 29;48(3):45–8

High prevalence of chlamydial and gonococcal infection in women entering jails and juvenile detention centers--Chicago, Birmingham, and San Francisco, 1998. **MMWR Morb Mortal Wkly Rep** 1999 Sep 17;48(36):793–6

Reemergence of gonorrhea in Sweden [editorial] Berglund T, et al. **Sex Transm Dis** 1999 Aug;26(7):390–1

Screening for gonorrhea and chlamydia by DNA amplification in adolescents attending middle school health centers. Opportunity for early intervention. Burstein GR, et al. **Sex Transm Dis** 1998 Sep;25(8):395–402

Quinolone-resistant Neisseria gonorrhoeae: the beginning of the end? Report of quinolone-resistant isolates and surveillance in the southwestern United States, 1989 to 1997. Ehret JM, et al. **Sex Transm Dis** 1998 Nov; 25(10):522–6

Epidemiologic aspects of male gonococcal infection in Greece. Kyriakis KP, et al. **Sex Transm Dis** 1999 Jan; 26(1):43–8

Prevalence of gonococcal and chlamydial infections in commercial sex workers in a Peruvian Amazon city. Paris M, et al. **Sex Transm Dis** 1999 Feb;26(2):103–7

Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and HIV infection among drug users attending an STD/HIV prevention and needle-exchange program in Quebec City, Canada. Poulin C, et al. **Sex Transm Dis** 1999 Aug;26(7):410–20

Epidemiology of gonorrhea [editorial] St John RK, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):81–2

A geographic relation between alcohol availability and gonorrhea rates. Scribner RA, et al. **Sex Transm Dis** 1998 Nov;25(10):544–8

The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Zenilman JM, et al. **Sex Transm Dis** 1999 Feb;26(2):75–81

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in Chilean asymptomatic adolescent males determined by urine sample. Gaete MV, et al. **Sex Transm Infect** 1999 Feb;75(1):67–8

Actual trends of the incidence of syphilis and gonorrhoea in the Slovak Republic in the years 1990–6. Hegyi V, et al. **Sex Transm Infect** 1998 Oct;74(5):376–7

Rapid assessment of sexually transmitted diseases in a sentinel population in Thailand: prevalence of chlamydial infection, gonorrhoea, and syphilis among pregnant women--1996. Kilmarx PH, et al. **Sex Transm Infect** 1998 Jun;74(3):189–93

Do the factors associated with successful contact tracing of patients with gonorrhoea and Chlamydia differ? Ross JD, et al. **Sex Transm Infect** 1999 Apr;75(2):112–5

[Using polymerase chain reaction for the detection of gonorrhoea in women and children in Taiyuan] Li LQ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr;18(2):98–101 (Eng. Abstr.) **(Chi)**

ETHNOLOGY

Contact tracing for gonorrhoea in homosexual and heterosexual men. Rogstad KE, et al. **Int J STD AIDS** 1999 Aug;10(8):536–8

Study on genital tract Chlamydia trachomatis and gonococcal infection in Han and minority (Naxi and Dai) women in China's two provinces. Luo L, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):221–30

ETIOLOGY

Genital infections among antenatal care attendees in Cape Verde. Wessel HF, et al. **Afr J Reprod Health** 1998 Apr; 2(1):32–40

Human experimentation with Neisseria gonorrhoeae: progress and goals. Cohen MS, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S375–9 (30 ref.)

Gonococcal scalp abscess in a neonate delivered by caesarean section. Varady E, et al. **Sex Transm Infect** 1998 Dec; 74(6):451

GENETICS

Molecular epidemiology of tetM genes in Neisseria gonorrhoeae. Turner A, et al. **Sex Transm Infect** 1999 Feb; 75(1):60–6

HISTORY

Identification of the gonococcus by Albert Neisser. 1879 [classical article] Kampmeier RH. **Sex Transm Dis** 1978 Apr–Jun;5(2):71–2

IMMUNOLOGY

Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Fox KK, et al. **Am J Epidemiol** 1999 Feb 15;149(4):353–8

Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review. Russell MW, et al. **Am J Reprod Immunol** 1999 Jul;42(1):58–63 (42 ref.)

Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Hedges SR, et al. **Infect Immun** 1999 Aug;67(8):3937–46

T lymphocyte response to Neisseria gonorrhoeae porin in individuals with mucosal gonococcal infections. Simpson SD, et al. **J Infect Dis** 1999 Sep;180(3):762–73

METABOLISM

Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae. Hedges SR, et al. **Infect Immun** 1998 Dec;66(12):5826–32

MICROBIOLOGY

Disappearance of vancomycin-sensitive strains of Neisseria gonorrhoeae in Djibouti [letter] Massenet D, et al. **Acta Trop** 1999 Apr 30;72(3):317–8

Update on emerging infections: news from the Centers for Disease Control and Prevention. Seligson RA, et al. **Ann Emerg Med** 1998 Dec;32(6):748–50

Isolation of Neisseria gonorrhoeae using urine as a holding medium. Ihunwo OA, et al. **East Afr Med J** 1998 Oct; 75(10):572–5

High prevalence of ciprofloxacin resistance amongst strains of Neisseria gonorrhoeae isolated from commercial sex workers in Bangladesh [letter] Bhuiyan BU, et al. **J Antimicrob Chemother** 1998 Nov;42(5):675–6

Evaluation of the discriminatory power of typing methods for Neisseria gonorrhoeae. Van Looveren M, et al. **J Clin Microbiol** 1999 Jul;37(7):2183–8

Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. Hobbs MM, et al. **J Infect Dis** 1999 Feb; 179(2):371–81

Response of gonococcal clinical isolates to acidic conditions. Pettit RK, et al. **J Med Microbiol** 1999 Feb;48(2):149–56

Association between auxotypes, serogroups, and antibiotic susceptibilities of Neisseria gonorrhoeae isolated from women in Mumbai (formerly Bombay), India. Divekar AA,

et al. **Sex Transm Dis** 1999 Jul;26(6):358–63

Quinolone-resistant Neisseria gonorrhoeae: the beginning of the end? Report of quinolone-resistant isolates and surveillance in the southwestern United States, 1989 to 1997. Ehret JM, et al. **Sex Transm Dis** 1998 Nov; 25(10):522–6

Sexual networks: the integration of social and genetic data. Day S, et al. **Soc Sci Med** 1998 Dec;47(12):1981–92

PATHOLOGY

Gonococcal infection of human fallopian tube mucosa in organ culture: relationship of mucosal tissue TNF-alpha concentration to sloughing of ciliated cells. McGee ZA, et al. **Sex Transm Dis** 1999 Mar;26(3):160–5

PREVENTION & CONTROL

What is the gonococcus telling us? [editorial] Donovan B. **Commun Dis Intell** 1998 Oct 1;22(10):216–7

Success and failure in gonorrhea control. Low N, et al. **Dermatol Clin** 1998 Oct;16(4):713–22

A sustainable behavioral intervention to increase condom use and reduce gonorrhea among sex workers in Singapore: 2-year follow-up. Wong ML, et al. **Prev Med** 1998 Nov–Dec;27(6):891–900

Subsequent sexually transmitted infections among adolescent women with genital infection due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Trichomonas vaginalis. Fortenberry JD, et al. **Sex Transm Dis** 1999 Jan; 26(1):26–32

Assessment of a geographically targeted field intervention on gonorrhea incidence in two New York State counties. Han Y, et al. **Sex Transm Dis** 1999 May;26(5):296–302

Prospective study of barrier contraception for the prevention of sexually transmitted diseases: study design and general characteristics of the study group. Macaluso M, et al. **Sex Transm Dis** 1999 Mar;26(3):127–36

Epidemiology of gonorrhea [editorial] St John RK, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):81–2

Dynamics and control of the transmission of gonorrhea. Yorke JA, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):51–6

Partner notification for gonorrhoea: a comparative study with a provincial and a metropolitan UK clinic. Bell G, et al. **Sex Transm Infect** 1998 Dec;74(6):409–14

Success of partner notification in heterosexuals with gonorrhoea: effects of sex and ethnicity [letter] Rogstad KE, et al. **Sex Transm Infect** 1998 Oct;74(5):379

[Some aspects of the study of gonorrhea vaccine] He F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):248–50 (20 ref.) **(Chi)**

THERAPY

Septic arthritis. Perry CR. **Am J Orthop** 1999 Mar; 28(3):168–78 (93 ref.)

Patient referral outcome in gonorrhoea and chlamydial infections. van Duynhoven YT, et al. **Sex Transm Infect** 1998 Oct;74(5):323–30

TRANSMISSION

Sexual mixing patterns in the spread of gonococcal and chlamydial infections. Aral SO, et al. **Am J Public Health** 1999 Jun;89(6):825–33

Experimental transmission of Neisseria gonorrhoeae from pregnant rat to fetus. Nowicki S, et al. **Infect Immun** 1999 Sep;67(9):4974–6

Sexual histories, partnerships and networks associated with the transmission of gonorrhoea. Day S, et al. **Int J STD AIDS** 1998 Nov;9(11):666–71

An epidemiological evaluation of the use of microbiological tools for identifying gonorrhoea infection networks. Pierce RL, et al. **Int J STD AIDS** 1999 May;10(5):316–23

Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. Lin JS, et al. **J Infect Dis** 1998 Dec; 178(6):1707–12

The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Garnett GP, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):787–97

Assessment of a geographically targeted field intervention on gonorrhea incidence in two New York State counties. Han Y, et al. **Sex Transm Dis** 1999 May;26(5):296–302

Dynamics and control of the transmission of gonorrhea. Yorke JA, et al. **Sex Transm Dis** 1978 Apr–Jun;5(2):51–6

Sexual networks: the integration of social and genetic data. Day S, et al. **Soc Sci Med** 1998 Dec;47(12):1981–92

[Bacterial sexually transmitted diseases (STD). I. Gonorrhea, syphilis, ulcus molle] Hofstetter AG. **Fortschr Med** 1999 Apr 20;117(11):30–2 **(Ger)**

[Gonorrhea and syphilis from Russia to Norway] Aavitsland P. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1487–9 (Eng. Abstr.) **(Nor)**

URINE

Isolation of Neisseria gonorrhoeae using urine as a holding medium. Ihunwo OA, et al. **East Afr Med J** 1998 Oct; 75(10):572–5

GONOSOMES see **SEX CHROMOSOMES**

GONYAULAX see **DINOFLAGELLIDA**

GONYAULAX TOXIN see **SAXITOXIN**

GOODPASTURE SYNDROME

Pulmonary manifestations of Goodpasture's syndrome. Antiglomerular basement membrane disease and related disorders. Ball JA, et al. **Clin Chest Med** 1998 Dec; 19(4):777–91, ix (71 ref.)

COMPLICATIONS

Goodpasture's syndrome associated with multiple sclerosis. Henderson RD, et al. **Acta Neurol Scand** 1998 Aug; 98(2):134–5

Simultaneous presentation of Goodpasture's disease and insulin-dependent diabetes mellitus. Thomas MC, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1997–8

DIAGNOSIS

The emerging spectrum of IgA-mediated renal diseases: is there an IgA variant of Goodpasture's syndrome? [editorial; comment] Lee SM, et al. **Am J Kidney Dis** 1999 Sep; 34(3):565–8. Comment on: Am J Kidney Dis 1999 Sep;34(3):549–55.

Seventy-year-old man with pulmonary problems and renal failure: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Kinasewitz G, et al. **J Okla State Med Assoc** 1997 Nov–Dec; 90(8):431–41

[Apropos of a single bout of renal insufficiency, severe but regressing] Andres E, et al. **Rev Med Interne** 1998;19 Suppl 2:306s–307s **(Fre)**

ETIOLOGY

Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. Abbate M, et al. **Kidney Int** 1998 Nov;54(5):1550–61

[Alveolar hemorrhage in mixed cryoglobulinemia associated with hepatitis C virus infection] Rodriguez-Vidigal FF, et al. **An Med Interna** 1998 Dec;15(12):661–3 (Eng. Abstr.) **(Spa)**

GENETICS

Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease [see comments] Hellmark T, et al. **Kidney Int** 1999 Mar;55(3):936–44. Comment in: Kidney Int 1999 Mar;55(3):1120–2.

Goodpasture syndrome [editorial; comment] Kalluri R. **Kidney Int** 1999 Mar;55(3):1120–2 (22 ref.). Comment on: Kidney Int 1999 Mar;55(3):926–35. Comment on: Kidney Int 1999 Mar;55(3):936–44.

IMMUNOLOGY

Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody [see comments] Fervenza FC, et al. **Am J Kidney Dis** 1999 Sep;34(3):549–55. Comment in: Am J Kidney Dis 1999 Sep;34(3):565–8.

Goodpasture disease. Characterization of a single conformational epitope as the target of pathogenic autoantibodies. Hellmark T, et al. **J Biol Chem** 1999 Sep 3;274(36):25862–8

Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease [see comments] Hellmark T, et al. **Kidney Int** 1999 Mar;55(3):936–44. Comment in: Kidney Int 1999 Mar;55(3):1120–2.

Goodpasture syndrome [editorial; comment] Kalluri R. **Kidney Int** 1999 Mar;55(3):1120–2 (22 ref.). Comment on: Kidney Int 1999 Mar;55(3):926–35. Comment on: Kidney Int 1999 Mar;55(3):936–44.

Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain [see comments] Leinonen A, et al. **Kidney Int** 1999 Mar;55(3):926–35. Comment in: Kidney Int 1999 Mar;55(3):1120–2.

The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Bosch X, et al. **Lupus** 1999; 8(4):258–62 (28 ref.)

[An autopsy case of Goodpasture's syndrome with P-ANCA and systemic vasculitis] Endo Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):55–60 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Goodpasture's syndrome with normal renal function [letter] Kuzmanic D, et al. **Clin Nephrol** 1999 May;51(5):319–20

The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Bosch X, et al. **Lupus** 1999; 8(4):258–62 (28 ref.)

THERAPY

[An experience of treatment of double positive myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) and anti-glomerular basement membrane antibodies in Goodpasture's syndrome onset of crescentic glomerulonephritis] Takeda T, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):591–6 (Eng. Abstr.) **(Jpn)**

GOOSE-BEAKED WHALE see **WHALES**

GOOSEFOOT see **CHENOPODIACEAE**

GOPHERS see **RODENTIA**

GORDIUS see **HELMINTHS**

GORHAM DISEASE see **OSTEOLYSIS, ESSENTIAL**

GORILLA GORILLA

Population structure and group composition of western lowland gorillas in north-western Republic of Congo. Magliocca F, et al. **Am J Primatol** 1999;48(1):1–14

Protein deficiency in a colony of western lowland gorillas (Gorilla g. gorilla). Mundy NI, et al. **J Zoo Wildl Med** 1998 Sep;29(3):261–8

ABNORMALITIES

Spontaneous cleft palate in a newborn gorilla (Gorilla gorilla gorilla). Siebert JR, et al. **Cleft Palate Craniofac J** 1998 Sep;35(5):436–41

ANATOMY & HISTOLOGY

Growth changes in measurements of upper facial positioning. May R, et al. **Am J Phys Anthropol** 1999 Mar;108(3):269–80

Shape of the orbital opening: individual characterization and analysis of variability in modern humans, Gorilla gorilla, and Pan troglodytes. Schmittbuhl M, et al. **Anat Anz** 1999 May;181(3):299–307

Laminar organization of the lateral geniculate nucleus of the gorilla. Nakagawa S, et al. **Folia Primatol (Basel)** 1998; 69(6):377–80

The influence of alveolar structures on the torsional strain field in a gorilla corporeal cross-section. Chen X, et al. **J Hum Evol** 1998 Dec;35(6):611–33

Pneumatic processes in the temporal bone of chimpanzee (Pan troglodytes) and gorilla (Gorilla gorilla). Sherwood RJ. **J Morphol** 1999 Aug;241(2):127–37

BLOOD

Corticotropin-releasing hormone in chimpanzee and gorilla pregnancies. Smith R, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2820–5

GENETICS

Interspecies comparative genome hybridization and interspecies representational difference analysis reveal gross DNA differences between humans and great apes. Toder R, et al. **Chromosome Res** 1998 Sep;6(6):487–94

Gorilla RH-like genes and antigens. Apoil PA, et al. **Immunogenetics** 1999 Feb;49(2):125–33

Full-length L1 elements have arisen recently in the same 1-kb region of the gorilla and human genomes. DeBerardinis RJ, et al. **J Mol Evol** 1998 Sep;47(3):292–301

METABOLISM

Evidence from urinary cortisol that maternal behavior is related to stress in gorillas. Bahr NI, et al. **Physiol Behav** 1998 Jun 15;64(4):429–37

PHYSIOLOGY

Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Pregenzer JF, et al. **Br J Pharmacol** 1999 May;127(2):468–72

PSYCHOLOGY

Evidence from urinary cortisol that maternal behavior is related to stress in gorillas. Bahr NI, et al. **Physiol Behav** 1998 Jun 15;64(4):429–37

GORLIN-PSAUME SYNDROME see **OROFACIODIGITAL SYNDROMES**

GORLIN SYNDROME see **BASAL CELL NEVUS SYNDROME**

GOSERELIN

ADMINISTRATION & DOSAGE

Expensive lesson in administration of goserelin implant [letter] Aamot SM. **Am J Health Syst Pharm** 1999 Feb 1;56(3):277

Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. Sarosdy MF, et al. **BJU Int** 1999 May;83(7):801–6

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration [letter; comment] Dearnaley DP, et al. **J Urol** 1999 Jul; 162(1):170. Comment on: J Urol 1998 Nov;160(5):1685–8.

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for

dosing schedule and neoadjuvant study consideration [letter; comment] Meinhardt W, et al. **J Urol** 1999 Jul; 162(1):170–1. Comment on: J Urol 1998 Nov;160(5):1685–8.

Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Kirby R, et al. **Prostate** 1999 Jul 1;40(2):105–14

[Effectiveness and tolerance of a gonadotropin releasing hormone (goserelin) in treatment of symptomatic endometriosis] Wenzl R, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):283–8 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)] Ivanov S, et al. **Akush Ginekol (Sofiia)** 1998;37(4):25–6 (Eng. Abstr.) **(Bul)**

[A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate] Suzuki Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec; 89(12):961–6 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration [letter; comment] Dearnaley DP, et al. **J Urol** 1999 Jul; 162(1):170. Comment on: J Urol 1998 Nov;160(5):1685–8.

Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration [letter; comment] Meinhardt W, et al. **J Urol** 1999 Jul; 162(1):170–1. Comment on: J Urol 1998 Nov;160(5):1685–8.

ANTAGONISTS & INHIBITORS

Uterine leiomyomas with T-cell infiltration associated with GnRH agonist goserelin [letter; comment] Laforga JB, et al. **Histopathology** 1999 May;34(5):471–2. Comment on: Histopathology 1998 Jul;33(1):80–2.

CHEMISTRY

Degradation kinetics of three gonadorelin analogues: developing a method for calculating epimerization parameters. Hoitink MA, et al. **Pharm Res** 1998 Sep; 15(9):1449–55

THERAPEUTIC USE

GnRH analogue in everyday gynecology: is it possible to rationalize its use? Lyall H, et al. **Acta Obstet Gynecol Scand** 1999 Apr;78(4):340–5

Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Paterson WF, et al. **Arch Dis Child** 1998 Oct;79(4):323–7

A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Vercellini P, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):672–7

Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa. Wang PH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 May;62(5):294–9

Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings. Wang PH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Nov;61(11):625–9

The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Leather AT, et al. **Gynecol Endocrinol** 1999 Feb;13(1):48–55

Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin [letter] McCluggage WG, et al. **Histopathology** 1999 Feb; 34(2):184–6

Extending the treatment boundaries: Zoladex and add-back. Schlaff WD. **Int J Gynaecol Obstet** 1999 Feb;64 Suppl 1:S25–31 (10 ref.)

Does preoperative treatment with a gonadotropin-releasing hormone agonist improve the outcome of endometrial resection? Vercellin P, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):357–60

Pseudomyxoma ovariilike posttherapeutic alteration in prostate adenocarcinoma [letter] Beer TW, et al. **J Clin Pathol** 1998 Nov;51(11):878

Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer. Lombardi P, et al. **J Vet Pharmacol Ther** 1999 Feb;22(1):56–61

Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Sugihara A, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1389–94

Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer. Rosendahl I, et al. **Prostate** 1999 Feb 1;38(2):100–9

Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. Corn BW, et al. **Urology** 1999 Sep;54(3):495–502

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Hall MC, et al. **Urology** 1999 May;53(5):898–902; discussion 902–3

[Myomectomy performed after Zoladex preparation with subsequent repair of the uterine wall via a balloon catheter in the uterine cavity] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(1):55–7 (20 ref.) **(Bul)**

GOSSYPIUM see **COTTON**

GOSSYPOL

see related
COTTONSEED OIL

11 beta HSD and the mechanism of gossypol-induced hypokalemia [letter; comment] Michael AE. **Int J Androl** 1998 Oct;21(5):313. Comment on: Int J Androl 1998 Feb;21(1):2–7. Comment on: Int J Androl 1998 Feb;21(1):8–12.

ADMINISTRATION & DOSAGE

Potential daily sperm production, Sertoli cell number, and seminiferous tubule characteristics in beef bulls fed conventional or gossypol-enriched diets. Cerelli JS, et al. **J Androl** 1999 Jul-Aug;20(4):519–28

Digestion and absorption rates of [3H]-oleic acid and [14C]-triolein do not differ in rats fed heated (-) and (+) gossypol cottonseed and soybean flours. Prost J, et al. **J Nutr** 1998 Nov;128(11):2001–8

ADVERSE EFFECTS

Effects on performance, tissue integrity, and metabolism of vitamin E supplementation for beef heifers fed a diet that contains gossypol. Velasquez-Pereira J, et al. **J Anim Sci** 1998 Nov;76(11):2871–84

Reproductive effects of feeding gossypol and vitamin E to bulls. Velasquez-Pereira J, et al. **J Anim Sci** 1998 Nov; 76(11):2894–904

Long-term effects of feeding gossypol and vitamin E to dairy calves. Velasquez-Pereira J, et al. **J Dairy Sci** 1999 Jun; 82(6):1240–51

ANALOGS & DERIVATIVES

Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Shelley MD, et al. **Cancer Lett** 1999 Jan 29;135(2):171–80

Induction of c-fos, and cytochrome c oxidase subunits I and II by gossypol acetic acid in rat liver cells. Hutchinson RW, et al. **Cell Biol Toxicol** 1998 Dec;14(6):391–9

NAD- and NADP-dependent 11 beta-hydroxysteroid dehydrogenase isoforms in guinea pig kidney with gossypol inhibition. Wang MS, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):481–5

Effect of amino acids on inhibition of lactate dehydrogenase-X by gossypol. Javed MH, et al. **Exp Mol Med** 1999 Mar 31;31(1):25–9

BLOOD

Milk production and plasma gossypol of cows fed cottonseed and oilseed meals with or without rumen-undegradable protein. Blackwelder JT, et al. **J Dairy Sci** 1998 Nov; 81(11):2934–41

METABOLISM

Coordinated accumulation of (+)-delta-cadinene synthase mRNAs and gossypol in developing seeds of Gossypium hirsutum and a new member of the cad1 family from G. arboreum. Meng YL, et al. **J Nat Prod** 1999 Feb; 62(2):248–52

PHARMACOLOGY

Inhibition of aldose reductase by gossypol and gossypol-related compounds. Deck LM, et al. **Adv Exp Med Biol** 1999;463:487–92

Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Shelley MD, et al. **Cancer Lett** 1999 Jan 29;135(2):171–80

Experimental analysis of gossypol and chloroquine interaction in serum and in liver of rat. Achudume AC, et al. **Indian J Exp Biol** 1998 Oct;36(10):1020–2

The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor beta1 production. Zhang Y, et al. **Int J Oncol** 1998 Dec;13(6):1291–7

Long-term effects of gossypol and vitamin E in the diets of dairy bulls. Velasquez-Pereira J, et al. **J Dairy Sci** 1998 Sep;81(9):2475–84

THERAPEUTIC USE

Gossypol treatment of recurrent adult malignant gliomas. Bushunow P, et al. **J Neurooncol** 1999 May;43(1):79–86

GOSSYPOSE see **RAFFINOSE**

GOURDS see **CUCURBITACEAE**

GOUT

see related
GOUT SUPPRESSANTS

Gout and hyperuricemia. Harris MD, et al. **Am Fam Physician** 1999 Feb 15;59(4):925–34 (33 ref.)

Gout. Wyndham M. **Practitioner** 1998 Jul;242(1588):546 (0 ref.)

[Gout: physiopathology, diagnosis, course, treatment] Chazerain P, et al. **Rev Prat** 1998 Sep 1;48(13):1453–6 **(Fre)**

BLOOD

Serum uric acid in acute gout [letter; comment] Schlesinger N, et al. **Ann Rheum Dis** 1998 Jul;57(7):443–4. Comment on: Ann Rheum Dis 1997 Nov;56(11):696–7.

Total plasma homocysteine in patients with gout [letter] Istok R, et al. **J Rheumatol** 1999 Sep;26(9):2068–9

CHEMICALLY INDUCED

Occurrence of gouty tophi following acitretin therapy. Vanhooteghem O, et al. **Clin Exp Dermatol** 1998 Nov; 23(6):274–6

COMPLICATIONS

Vertebral erosion, paraplegia, and spinal gout. Pfister AK, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1430–1

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease [editorial] Johnson RJ, et al. **Am J Kidney Dis** 1999 Feb;33(2):225–34 (82 ref.)

Hyperlipidaemia in hyperuricaemia and gout. Emmerson B. **Ann Rheum Dis** 1998 Sep;57(9):509–10

Gout and secondary amyloid. Gumá M, et al. **Clin Rheumatol** 1999;18(1):54–5

Pasteurella multocida and gout in the first metatarsophalangeal joint [letter] Shapero C, et al. **J Am Podiatr Med Assoc** 1999 Jun;89(6):318–20

Recurrence of gout after total knee arthroplasty. Blyth P, et al. **J Arthroplasty** 1999 Apr;14(3):380–2

Kienböck's disease and gout. Shin AY, et al. **J Hand Surg [Br]** 1999 Jun;24(3):363–5 (9 ref.)

Low-back pain caused by spinal tophus--a complication of gout in a kidney transplant recipient. Peeters P, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3245–7

Displaced pathological patella fracture due to gout. Aboulafia AJ, et al. **Orthopedics** 1999 May;22(5):543–5

Dactylitis: implications for clinical practice. Rothschild BM, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):41–7

[Disseminated skin abnormalities due to gout] Bruin-Weller MS, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1339–40 **(Dut)**

DIAGNOSIS

Diagnosis and management of gout. Pittman JR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1799–806, 1810 (24 ref.)

Identification of crystals in synovial fluid. Dieppe P, et al. **Ann Rheum Dis** 1999 May;58(5):261–3

Gouty os trigonum tarsi: case report. Lai PL, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):509–13

Multicentric reticulohistiocytosis: a mimic of gout and rheumatoid arthritis. Horvath JR, et al. **Cleve Clin J Med** 1999 Mar;66(3):166–72

How well have diagnostic tests and therapies for gout been evaluated? Schlesinger N, et al. **Curr Opin Rheumatol** 1999 Sep;11(5): 1–5 (48 ref.)

Chronic tophaceous gout in a patient with a history of allopurinol toxicity. Naas JE, et al. **Cutis** 1998 Nov; 62(5):239–41

Gout in the elderly. Clinical presentation and treatment. Fam AG. **Drugs Aging** 1998 Sep;13(3):229–43 (74 ref.)

Gout: beyond the stereotype. Jones RE, et al. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):95–102; discussion 102–3; quiz 133

Deadly delay. Avery JK. **J Ark Med Soc** 1998 Oct; 95(5):203–4

[Gout in the area of the cervical vertebrae and the sternoclavicular joint] Kern A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):515–7 **(Ger)**

DRUG THERAPY

Diagnosis and management of gout. Pittman JR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1799–806, 1810 (24 ref.)

Effective management of gout: an analogy [see comments] Wortmann RL. **Am J Med** 1998 Dec;105(6):513–4 (08 ref.) . Comment in: Am J Med 1998 Dec;105(6):549–50.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Perez-Ruiz F, et al. **Ann Rheum Dis** 1998 Sep;57(9):545–9

Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient. Decaux G, et al. **Clin Nephrol** 1998 Oct;50(4):262–5

GOUT

How well have diagnostic tests and therapies for gout been evaluated? Schlesinger N, et al. **Curr Opin Rheumatol** 1999 Sep;11(5): 1-5 (48 ref.)

Gout in the elderly. Clinical presentation and treatment. Fam AG. **Drugs Aging** 1998 Sep;13(3):229-43 (74 ref.)

Stopping progression to tophaceous gout. When and how to use urate-lowering therapy. McDonald E, et al. **Postgrad Med** 1998 Dec;104(6):117-20, 123-4, 127

Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity [letter] Gillott TJ, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):85-6

[Multi-systemic toxicity of colchicine and renal failure: apropos of a case] Rosset L, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1953-7 (Eng. Abstr.) **(Fre)**

[Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases] Krüger K, et al. **Hautarzt** 1999 Feb;50(2):115-20 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology study of hyperuricemia and gout in a community population of Huangpu District in Shanghai. Chen S, et al. **Chin Med J (Engl)** 1998 Mar;111(3):228-30

Gout and pseudogout chronobiology [letter] Rovenský J, et al. **J Rheumatol** 1999 Jun;26(6):1426-7

The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. Braun WE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1366-9

ETHNOLOGY

Lipid abnormalities in Taiwan aborigines with gout. Chou CT, et al. **Metabolism** 1999 Jan;48(1):131-3

ETIOLOGY

Case report. Initial manifestation of gout after carpal tunnel release. Calderon MS, et al. **Br J Plast Surg** 1999 Jan; 52(1):76-7

The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956 [classical article] Vague J. **Nutrition** 1999 Jan;15(1):89-90; discussion 91

GENETICS

Identification of a new single nucleotide substitution on the hypoxanthine-guanine phosphoribosyltransferase gene (HPRT(Tsou) from a Taiwanese aboriginal family with severe gout. Chang SJ, et al. **J Rheumatol** 1999 Aug; 26(8):1802-7

METABOLISM

Effective management of gout: an analogy [see comments] Wortmann RL. **Am J Med** 1998 Dec;105(6):513-4 (08 ref.) . Comment in: Am J Med 1998 Dec;105(6):549-50.

Lipid abnormalities in Taiwan aborigines with gout. Chou CT, et al. **Metabolism** 1999 Jan;48(1):131-3

PATHOLOGY

Intra-articular tophus presenting as a loose body. Hammoudeh M, et al. **Clin Rheumatol** 1998;17(5):400-2

Cutaneous deposition diseases. Part II. Touart DM, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):527-44; quiz 545-6 (169 ref.)

Intradermal tophi in gout: a case-control study. Vázquez-Mellado J, et al. **J Rheumatol** 1999 Jan; 26(1):136-40

[Adaptive response in the reparation-imperfect gout cells] Zasukhina GD, et al. **Biull Eksp Biol Med** 1999 Apr; 127(4):442-5 **(Rus)**

PHYSIOPATHOLOGY

[Physiopathology and treatment of gout and hyperuricemia] Yamanaka H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):718-23 (11 ref.) **(Jpn)**

PREVENTION & CONTROL

Living with gout: preventing the fire [editorial; comment] Skeff KM. **Am J Med** 1998 Dec;105(6):549-50. Comment on: Am J Med 1998 Dec;105(6):513-4.

SURGERY

Chronic tophaceous gout in a patient with a history of allopurinol toxicity. Naas JE, et al. **Cutis** 1998 Nov; 62(5):239-41

GOUT SUPPRESSANTS

ADMINISTRATION & DOSAGE

'Until diarrhea occurs'? There's a maximum dosage to prevent colchicine toxicity. Lilley LL, et al. **Am J Nurs** 1999 Apr;99(4):12

Stopping progression to tophaceous gout. When and how to use urate-lowering therapy. McDonald E, et al. **Postgrad Med** 1998 Dec;104(6):117-20, 123-4, 127

Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity [letter] Gillott TJ, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):85-6

[Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases] Krüger K, et al. **Hautarzt** 1999 Feb;50(2):115-20 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Exposure to allopurinol and the risk of cataract extraction in elderly patients. Garbe E, et al. **Arch Ophthalmol** 1998 Dec;116(12):1652-6

Colchicine: an unusual cause of reversible azoospermia. Kirchin VS, et al. **BJU Int** 1999 Jan;83(1):156

ANCA-positive vasculitis associated with allopurinol therapy. Choi HK, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):743-4

Chronic tophaceous gout in a patient with a history of allopurinol toxicity. Naas JE, et al. **Cutis** 1998 Nov; 62(5):239-41

Colchicine-induced myoneuropathy in childhood. Harel L, et al. **Eur J Pediatr** 1998 Oct;157(10):853-5

Allopurinol induced transitory giant fixed drug eruption: an atypical expression [letter] Sehgal VN, et al. **J Dermatol** 1999 Mar;26(3):198-9

Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter. Gruberg L, et al. **Transplant Proc** 1999 Aug;31(5):2157-8

[Pseudotumorous presentation of neuro-Behçet: role of the withdrawal of colchicine?] Vignes S, et al. **Rev Med Interne** 1998 Jan;19(1):55-9 (Eng. Abstr.) **(Fre)**

[Multi-systemic toxicity of colchicine and renal failure: apropos of a case] Rosset L, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1953-7 (Eng. Abstr.) **(Fre)**

[Neurological side-effects of antiallergic drug, colchicine and glucocorticoids] Tanaka C, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):606-9 (12 ref.) **(Jpn)**

[Fatal liver necrosis due to allopurinol] Pereira S, et al. **Acta Med Port** 1998 Dec;11(12):1141-4 (15 ref.) (Eng. Abstr.) **(Por)**

PHARMACOKINETICS

Bioequivalence of allopurinol-containing tablet preparations. Barthel W, et al. **Int J Clin Pharmacol Ther** 1999 Mar; 37(3):148-52

PHARMACOLOGY

Cell death, phagocytosis, and neurogenesis in mouse olfactory epithelium and vomeronasal organ after colchicine treatment. Suzuki Y. **Ann N Y Acad Sci** 1998 Nov 30;855:252-4

Reduction of human recombinant type II phospholipase A2 and prostaglandin F2 alpha release by microtubule depolymerizing agents. Munns MJ, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):230-5

Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. Cicogna AC, et al. **Hypertension** 1999 Jan;33(1):60-5

Effect of colchicine on nerve growth factor-induced leukocyte accumulation and thermal hyperalgesia in the rat. Schuligoi R. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Aug;358(2):264-9

POISONING

Fatal colchicine overdose: report of a case and review of the literature. Milne ST, et al. **Am J Emerg Med** 1998 Oct; 16(6):603-8 (64 ref.)

[Severe colchicine poisoning (letter)] Rodríguez Cuartero A. **An Med Interna** 1999 Jan;16(1):53-4 **(Spa)**

THERAPEUTIC USE

Treatment of acne vulgaris with colchicine [letter] Sadjadi SJ, et al. **Acta Derm Venereol** 1998 Sep;78(5):388

Diagnosis and management of gout. Pittman JR, et al. **Am Fam Physician** 1999 Apr 1;59(7):1799-806, 1810 (24 ref.)

Effective management of gout: an analogy [see comments] Wortmann RL. **Am J Med** 1998 Dec;105(6):513-4 (08 ref.) . Comment in: Am J Med 1998 Dec;105(6):549-50.

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Perez-Ruiz F, et al. **Ann Rheum Dis** 1998 Sep;57(9):545-9

Gout: beyond the stereotype. Jones RE, et al. **Hosp Pract (Off Ed)** 1999 Jun 15;34(6):95-102; discussion 102-3; quiz 133

Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Ben-Chetrit E, et al. **Med Hypotheses** 1998 Nov; 51(5):377-80

Does colchicine also induce a clearance of the established amyloid deposits? [letter] Tuğlular S, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1042-3

Colchicine: 1998 update. Ben-Chetrit E, et al. **Semin Arthritis Rheum** 1998 Aug;28(1):48-59 (125 ref.)

[Physiopathology and treatment of gout and hyperuricemia] Yamanaka H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):718-23 (11 ref.) **(Jpn)**

[Effective long-term use of colchicine in secondary AA-amyloidosis] Rameev VV, et al. **Ter Arkh** 1999; 71(1):54-7 **(Rus)**

[Colchicine in the treatment of liver cirrhosis] Quijano-Pitman F. **Gac Med Mex** 1998 Sep-Oct;134(5):610 **(Spa)**

[Treatment of idiopathic pulmonary fibrosis with colchicine] Undurraga A, et al. **Rev Med Chil** 1998 Nov; 126(11):1345-53 (Eng. Abstr.) **(Spa)**

GOUTY ARTHRITIS see **ARTHRITIS, GOUTY**

GOVERNING BOARD

Deep & Wide. Health care boards look beyond their communities for new trustees. Bilchik GS. **Hosp Health Netw** 1999 Sep;73(9):52-6

The chairman as challenger [interview by Mary Grayson] Lewis C. **Hosp Health Netw** 1998 Oct 5;72(19):24-6, 28, 30

Conflicts of interest during a financial crisis [news] Rines B, et al. **Hosp Health Netw** 1999 Jan;73(1):24

The information needs of health agency board members: a health information system challenge. Zelmer AC, et al. **Medinfo** 1998;9 Pt 2:1167-70

ORGANIZATION & ADMINISTRATION

Physician-hospital integration strategies: impact on physician involvement in hospital governance. Kocher C, et al. **Health Care Manage Rev** 1998 Summer;23(3):38-47

Physician involvement in management and governance: the moderating effects of staff structure and composition. Succi MJ, et al. **Health Care Manage Rev** 1999 Winter;24(1):33-44

GOVERNMENT

Nurses have both direct and indirect influence on Congress. Branch K, et al. **Am J Nurs** 1999 Feb;99(2):24

Kentucky legislators' views on tobacco policy. Hahn EJ, et al. **Am J Prev Med** 1999 Feb;16(2):81-8

The "sausage factory" tour of the legislative process: an interactive orientation. Novotny TE, et al. **Am J Public Health** 1999 May;89(5):771-3

Former French ministers on trial over blood [news] Dorozynski A. **BMJ** 1999 Feb 13;318(7181):419

Will voters' response to health care reforms determine the fate of Mike Harris? Gray C. **CMAJ** 1999 Jun 1; 160(11):1623-4

The origin of ethics and social order in a society without state power. Yamamoto K. **Coll Antropol** 1999 Jun; 23(1):221-9

Preferable products mean a healthier Earth [news] **Environ Health Perspect** 1999 Apr;107(4):A188, A190

Autonomy and paternalism in communitarian society. Patient rights in Israel. Gross ML. **Hastings Cent Rep** 1999 Jul-Aug;29(4):13-20

Federal science policy. Changing battle lines, new fronts. Silberner J. **Hastings Cent Rep** 1999 Jul-Aug;29(4):6

BadgerCare: a case study of the elusive new federalism [comment] Bartels PL, et al. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):165-9. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):150-61.

The elusive new federalism [see comments] Spitz B. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):150-61. Comment in: Health Aff (Millwood) 1998 Nov-Dec;17(6):162-4. Comment in: Health Aff (Millwood) 1998 Nov-Dec;17(6):165-4. Comment in: Health Aff (Millwood) 1999 May-Jun;18(3):267-8.

'Assessing the new federalism' and state health policy [comment] [see comments] Well A, et al. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):162-4. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):150-61. Comment in: Health Aff (Millwood) 1999 May-Jun;18(3):267-8.

Sharing the responsibilities: the roles of the government. Gjerris A. **Int Clin Psychopharmacol** 1999 Jun;14 Suppl 3:S7-9 (9 ref.)

Seasonal affective disorder. Elwood TW. **J Allied Health** 1999 Summer;28(2):113-6

'Get the government out of my life' [letter; comment] Dimmich GW. **J Am Dent Assoc** 1998 Nov;129(11):1522, 1524. Comment on: J Am Dent Assoc 1998 Sep;129(9):1191-2, 1194.

Genuine federalism in the Russian health care system: changing roles of government. Chernichovsky D, et al. **J Health Polit Policy Law** 1999 Feb;24(1):115-44 (38 ref.)

Increasing government interest in the quality aspects of health care delivery [editorial] **J Qual Clin Pract** 1999 Jun; 19(2):77-8

Toward implementation of an urban health agenda: the role of government. Tallon JR Jr. **J Urban Health** 1998 Jun; 75(2):412-9

Billions in compensation for toxic oil poisoning victims [news] Bosch X. **JAMA** 1999 Jun 2;281(21):1975-6

What is the government's perspective? [see comments] Kauf TL. **Med Decis Making** 1999 Jan-Mar;19(1):98-9. Comment in: Med Decis Making 1999 Jan-Mar;19(1):100-1.

Government and society: yet another perspective [editorial; comment] Lipscomb J. **Med Decis Making** 1999 Jan-Mar; 19(1):100-1. Comment on: Med Decis Making 1999 Jan-Mar;19(1):98-9.

Patterns of death in world leaders. Pyenson LR, et al. **Mil Med** 1998 Dec;163(12):797–800

Congress examines childhood vaccine safety [news] Dove A. **Nat Med** 1999 Sep;5(9):970

The wages of spin [editorial] **Nature** 1999 May 27; 399(6734):285

UK panel formed to rebuild trust in government science advice [news] Masood E. **Nature** 1999 Feb 11;397(6719):458

Top BSE official denies charges of excessive secrecy [news] Masood E. **Nature** 1998 Oct 22;395(6704):734

Response to editorial in Neurourol Urodynam 17(2). Government's role in health care [letter] [see comments] Frankel J. **Neurourol Urodyn** 1998;17(6):639. Comment in: Neurourol Urodyn 1998 ;17(6):577–8.

Allergy--a public health issue: when should governments act? [editorial] Warner JO. **Pediatr Allergy Immunol** 1999 Feb;10(1):1–2

Do blacks believe that HIV/AIDS is a government conspiracy against them? Klonoff EA, et al. **Prev Med** 1999 May;28(5):451–7

Serum cholesterol trends among members of the Finnish parliament. Nikkari ST, et al. **Prev Med** 1999 Mar; 28(3):260–3

American history 101: presidents, vice presidents, and paralytic illness. Pascuzzi RM. **Semin Neurol** 1998; 18(4):533–6

Primary socialization theory. Developmental stages, spirituality, government institutions, sensation seeking, and theoretical implications. V. Oetting ER. **Subst Use Misuse** 1999 Jun;34(7):947–82

Curbing the epidemic: governments and the economics of tobacco control. The World Bank. **Tob Control** 1999 Summer;8(2):196–201

What should be the role of the state in the development of transplantation? Gäbel H. **Transplant Proc** 1999 Jun; 31(4):1782–4 (9 ref.)

What should be the role of the state in the development of transplantation? Lloveras J. **Transplant Proc** 1999 Jun; 31(4):1765–8 (7 ref.)

[Insurer Movir warns against government. Labor unsuitability in growth of free appeal (news)] **Tijdschr Diergeneeskd** 1999 Jan 1;124(1):17 **(Dut)**

[Department of Operativ Surgery and Clinical Anatomy of the I.P. Pavlov State Medical University of St. Petersburg--100 years] Semenov GM. **Morfologiia** 1999; 115(2):76–7 **(Rus)**

[Problems of public health in the State Report on Health Status of the Population of the Russian Federation] Goncharenko VL, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):20–1 **(Rus)**

[Provision of information on the activities of the State Sanitary-Epidemiologic Service] Kutstenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):53–5 (Eng. Abstr.) **(Rus)**

GOVERNMENT AGENCIES

The grant portfolio of the National Center for Medical Rehabilitation Research: the first five years [see comments] Deitz J, et al. **Arch Phys Med Rehabil** 1999 May;80(5):481–4 . Comment in: Arch Phys Med Rehabil 1999 May;80(5):479–80.

The Medical Devices Agency [editorial] Ludgate SM. **Br J Plast Surg** 1998 Sep;51(6):417–8

Urine drug testing for social service agencies. A Canadian experience. Fraser AD. **Clin Lab Med** 1998 Dec; 18(4):705–11

Timely toxicology. Medlin JF. **Environ Health Perspect** 1999 May;107(5):A256–8

Abortion reporting in the United States: an examination of the federal-state partnership. Saul R. **Fam Plann Perspect** 1998 Sep–Oct;30(5):244–7

NEA attacks the millennium bug. Nuclear Energy Agency [news] de la Ferté J. **Health Phys** 1999 Feb;76(2):202

DOE's technology garden. Kasper K. **Health Phys** 1999 Oct; 77(4):359–60

The submission from the Royal Society for the Promotion of Health on the proposed Food Standards Agency. **J R Soc Health** 1998 Jun;118(3):185–6

New research subjects in Grant-in-Aid for Cancer Research 1999–2000 from the Ministry of Health and Welfare, Japan [news] Asamura H. **Jpn J Clin Oncol** 1999 Apr;29(4):237

MD reviewers' role in the new anticancer drug approval process in the newly established Japanese regulatory agency, PMDEC (Pharmaceuticals and Medical Devices Evaluation Center) [editorial] Fujiwara Y. **Jpn J Clin Oncol** 1998 Nov;28(11):653–6

Not another European institution [editorial] [see comments] **Lancet** 1998 Oct 17;352(9136):1237. Comment in: Lancet 1999 Jan 23;353(9149):329.

Albumin and the Medicines Control Agency [letter] Roberts I, et al. **Lancet** 1999 Aug 21;354(9179):686

An iron fist in an iron glove. Mani MK. **Natl Med J India** 1999 Mar–Apr;12(2):81–3

French inquiry into misconduct is shelved [news] Butler D. **Nature** 1998 Oct 29;395(6705):829

Embattled French science agency says it is holding its own [news] Butler D. **Nature** 1999 Mar 25;398(6725):274

Energy department revises terms of Venter deal after complaints [news] Macilwain C. **Nature** 1999 Jan 14; 397(6715):93

Canada's blood agency up and running [news] Spurgeon D. **Nature** 1998 Oct 8;395(6702):534

DOE builds a web site for the physical sciences [news] Marshall E. **Science** 1999 Aug 6;285(5429):811

The first five years: a review of the collaboration between DHHR and the WVU School of Medicine. Withersty DJ, et al. **W V Med J** 1999 Mar–Apr;95(2):62–3

[French National Institute for observation of prescriptions and consumption of medicines. Prescription and consumption of antibiotics in ambulatory care] Bouvenot G. **Bull Acad Natl Med** 1999;183(3):601–9; discussion 609–13 (14 ref.) (Eng. Abstr.) **(Fre)**

[Clinical research centers: a great opportunity for internal medicine (editorial)] Azizi M, et al. **Rev Med Interne** 1998 Oct;19(10):697–9 **(Fre)**

[Kallidinogenase Reference Standard (Control 971) of National Institute of Health Sciences] Iwata M, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):168–9 (Eng. Abstr.) **(Jpn)**

[Cholecalciferol Reference Standard (Control 971) of National Institute of Health Sciences] Iwata M, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):174–6 (Eng. Abstr.) **(Jpn)**

[Ergocalciferol Reference Standard (Control 971) of National Institute of Health Sciences] Iwata M, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):180–2 (Eng. Abstr.) **(Jpn)**

[Thiamine Hydrochloride Solution Reference Standard (Control 971) of National Institute of Health Sciences] Kitajima A, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):183–4 (Eng. Abstr.) **(Jpn)**

[Tocopherol Acetate Reference Standard (Control 971) of National Institute of Health Sciences] Kitajima A, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):177–9 (Eng. Abstr.) **(Jpn)**

[Potassium Sucrose Octa Sulfate Reference Standard (Control 961) of National Institute of Health Sciences] Kitajima A, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):163–5 (Eng. Abstr.) **(Jpn)**

[Thrombin Reference Standard (Control 961) of National Institute of Health Sciences] Kitajima A, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):166–7 (Eng. Abstr.) **(Jpn)**

[Prednisolone Reference Standard (Control 971) of National Institute of Health Sciences] Kitajima A, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):185–8 (Eng. Abstr.) **(Jpn)**

[Retinol Acetate Reference Standard (Control 971) and Retinol Palmitate Reference Standard (Control 971) of National Institute of Health Sciences] Tanimoto T, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):170–3 (Eng. Abstr.) **(Jpn)**

[The scientific and practical activities of the Center for State Epidemiological Health Surveillance in Shchelkovo District, Moscow Province] Poliak VE. **Gig Sanit** 1999 Jan–Feb;(1):68–9 **(Rus)**

[Laboratory support of the State Sanitary and Epidemiologic Service under the new socioeconomic conditions] Kutsenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Jul–Aug;(4):27–9 (Eng. Abstr.) **(Rus)**

[The results of the scientific activities of the institutions under the jurisdiction of the Ministry of Public Health] Kartysh AP, et al. **Lik Sprava** 1998 Oct–Nov;(7):6–10 (Eng. Abstr.) **(Ukr)**

ECONOMICS

Consumer-choice markets: lessons from FEHBP mental health coverage. Foote SM, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):125–30

HISTORY

[The 30th anniversary of the State Institute for Physician Advanced Training of the Ministry of Defense of the Russian Federation] Petrov GM. **Voen Med Zh** 1998 Dec; 319(12):64–6 **(Rus)**

LEGISLATION & JURISPRUDENCE

Protection and advocacy system standing--to vindicate the rights of persons with disabilities. Gross GP. **Ment Phys Disabil Law Rep** 1998 Sep–Oct;22(5):674–82

[The National Medical Arbitration Commission] Soberanes-Fernández JL. **Gac Med Mex** 1999 Jan–Feb; 135(1):95–8 **(Spa)**

ORGANIZATION & ADMINISTRATION

There's a new sheriff at Tunney's Pasture [news] Gray C. **CMAJ** 1999 Aug 24;161(4):426–7

US government natural disaster assistance: historical analysis and a proposal for the future. Barnett BJ. **Disasters** 1999 Jun;23(2):139–55 (55 ref.)

Year 2000 issues [news] Busby B. **Health Phys** 1998 Dec; 75(6):570–1

Saving lives and keeping families safe: US Consumer Product Safety Commission. Church CB. **Inj Prev** 1998 Dec; 4(4):258–9

Criteria used by Health Canada's Product Safety bureau to determine whether or not regulations are needed to address the hazards associated with a given consumer product. Fortin Y. **Inj Prev** 1998 Dec;4(4):259–60

The Federal Employees Health Benefits Plan: implications for medicare reform. Feldman R, et al. **Inquiry** 1999 Summer;36(2):188–99

Hear no secrets, see no secrets, speak no secrets: secrecy in the Canadian drug approval system. Lexchin J. **Int J Health Serv** 1999;29(1):167–78

National Cancer Center Research Institute: history, current status, and priorities. Terada M. **Nat Med** 1998 Nov; 4(11):1221–4

Hot seat in the kitchen [editorial] **Nature** 1999 Feb 4; 397(6718):371

France abandons plan to reform national biomedical agency [news] Butler D. **Nature** 1998 Oct 15;395(6703):630

French researchers kick up a storm over CNRS 'reforms'. Centre National de la Recherche Scientifique [news] Butler D. **Nature** 1998 Oct 22;395(6704):729–30

Interactions between science, government and media on selection and testing of donors. Sazama K. **Vox Sang** 1998; 74 Suppl 2:503–6 (24 ref.)

[The characterization and analysis of the activities carried out by the Servizio di Igiene degli Alimenti e della Nutrizione (SIAN)] Spigone C, et al. **Ann Ig** 1998 Sep–Dec; 10(5–6):333–42 (Eng. Abstr.) **(Ita)**

[Role of the government for development of umbilical cord blood bank system in Japan] Yamamoto N. **Rinsho Byori** 1999 May;Suppl 110:1–6 (Eng. Abstr.) **(Jpn)**

[Modern information support for the state epidemiological health service] Rumiantsev GI, et al. **Gig Sanit** 1999 Mar–Apr;(2):63–5 **(Rus)**

[The use of modern information technologies for enhancing efficiency in the management of scientific research in the Ministry of Public Health system] Kartysh AP, et al. **Lik Sprava** 1998 Aug;(6):168–73 **(Ukr)**

GOVERNMENT, LOCAL see **LOCAL GOVERNMENT**

GOVERNMENT PROGRAMS

see related
NATIONAL HEALTH PROGRAMS

The Southern Cone Initiative against Chagas disease. Schofield CJ, et al. **Adv Parasitol** 1999;42:1–27 (90 ref.)

Governmental databases, hospital information systems, and clinical outcomes: big brother or big help? [editorial; comment] Fleisher LA, et al. **Anesth Analg** 1999 Oct; 89(4):811–3. Comment on: Anesth Analg 1999 Oct;89(4):814–22.

Mammography screening for breast cancer in Copenhagen April 1991–March 1997. Mammography Screening Evaluation Group. Lynge E. **APMIS Suppl** 1998;83:1–44

National blood program in Korea. Han KS, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):179–83

Can we deworm this wormy world? Bundy DA, et al. **Br Med Bull** 1998;54(2):421–32 (43 ref.)

A national program for control of acute respiratory tract infections: the Philippine experience. Dayrit ES. **Clin Infect Dis** 1999 Feb;28(2):195–9

Three new diseases listed for Japanese research on their treatment [news] **Front Med Biol Eng** 1999;9(1):93

Review of leprosy control activities in Yemen. al-Qubati Y, et al. **Int J Lepr Other Mycobact Dis** 1999 Jun;67(2):150–3

Federal role in nutrition education, research, and food assistance for women and their families. Mark S, et al. **J Am Diet Assoc** 1999 Jun;99(6):671–2

Affirmative action [letter; comment] Sunman W. **Lancet** 1999 Mar 6;353(9155):847. Comment on: Lancet 1999 Jan 2;353(9146):1.

Rol' i mesto prezidentskoi programmy "Deti Rossii" v profilaktike parazitarnykh boleznei [The role and place of the presidential program Russia's Children in the prevention of parasitic diseases] Sergiev VP. **Med Parazitol (Mosk)** 1998 Jul–Sep;(3):60–2 **(Eng, Rus)**

[Networks of care and diabetes: an obvious need] Giraud A. **Diabetes Metab** 1998 Nov;24 Suppl 3:15–7 (Eng. Abstr.) **(Fre)**

[EURO-Medicines: a European program for bringing into agreement public health policies on drugs] Calamo-Specchia F, et al. **Ann Ig** 1998 Sep–Dec; 10(5–6):405–12 (Eng. Abstr.) **(Ita)**

ECONOMICS

Few state tobacco dollars to go to control [news] Ault A. **Nat Med** 1999 Oct;5(10):1096

Italy promises to increase focus on rare diseases [news] Ballmaier M. **Nat Med** 1999 May;5(5):472–3

Bank backs Indian AIDS program again [news] Jayaraman KS. **Nat Med** 1999 Oct;5(10):1096

Scientists bemoan lack of finances for new center [news] Rouse R. **Nat Med** 1999 Apr;5(4):366

LEGISLATION & JURISPRUDENCE

Obtaining informed consent for treatment of mentally incompetent patients. A decade under New York's innovative approach. Sundram CJ, et al. **Int J Law Psychiatry** 1999 Mar–Apr;22(2):107–23

[Effects exercised by the new federal German social legislation SGB III on assessing the incapacity to work by the medical experts of German statutory sickness insurance bodies] Nüchtern E. **Gesundheitswesen** 1999 Jun;

61(6):299–302 (1 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Controlling the major Newcastle disease outbreak at Mangrove Mountain, NSW [news] **Aust Vet J** 1999 Jul; 77(7):472

Harstad injury prevention study: prevention of burns in young children by community based intervention. Ytterstad B, et al. **Inj Prev** 1998 Sep;4(3):176–80

Perinatal substance abuse treatment. Findings from focus groups with clients and providers. Howell EM, et al. **J Subst Abuse Treat** 1999 Jul–Sep;17(1–2):139–48

Editorials, September 1997 by W. C. S. Smith, P. Fine & D. K. Warndorff [letter; comment] Revankar CR. **Lepr Rev** 1998 Sep;69(3):305. Comment on: Lepr Rev 1997 Sep;68(3):195–200. Comment on: Lepr Rev 1997 Sep;68(3):201–2.

NIH appoints a director for its AIDS vaccine center [news] Birmingham K. **Nat Med** 1999 Apr;5(4):362

[The federal targetted programs Children of the North and Children of Refugee Families and of Forced Migrants. Their structure and tasks] Onishchenko GG, et al. **Med Parazitol (Mosk)** 1998 Jul–Sep;(3):3–6 **(Rus)**

[Children of the North--a national priority of Russia] Zaĭdfudim PKh. **Med Parazitol (Mosk)** 1998 Jul–Sep; (3):7–9 **(Rus)**

STANDARDS

Achieving dust lead clearance standards after lead hazard control projects: an evaluation of the HUD-recommended cleaning procedure and an abbreviated alternative. Dixon S, et al. **Appl Occup Environ Hyg** 1999 May;14(5):339–44

Racial bias in federal nutrition policy. Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151–7 (52 ref.)

STATISTICS & NUMERICAL DATA

Misleading government information on NHS costs [letter; comment] Kernick DP. **Lancet** 1999 Jan 30;353(9150):413 . Comment on: Lancet 1998 Nov 14;352(9140):1607.

[Occupational reintegration of mentally disabled in the labor market] Lüpkes HA. **Psychiatr Prax** 1999 Apr;26 Suppl 1:S16–20 **(Ger)**

[The results of the performance by the E. I. Martsinovskii Institute of Medical Parasitology and Tropical Medicine of the missions of the federal targetted programs Children of the North and Children of Refugee Families and of Forced Migrants in 1994–1997] Sergiev VP, et al. **Med Parazitol (Mosk)** 1998 Jul–Sep;(3):9–15 **(Rus)**

TRENDS

[Secondary prevention: an approach to improve the German drug abuse prevention system] Schmidt B, et al. **Gesundheitswesen** 1999 Mar;61(3):130–6 (58 ref.) (Eng. Abstr.) **(Ger)**

GOVERNMENT-SPONSORED PROGRAMS see **GOVERNMENT PROGRAMS**

GOVERNMENT, STATE see **STATE GOVERNMENT**

GP41(HIV) see **HIV ENVELOPE PROTEIN GP41**

GP120(HIV) see **HIV ENVELOPE PROTEIN GP120**

GP160(HIV) see **HIV ENVELOPE PROTEIN GP160**

GPI MEMBRANE ANCHORS see **GLYCOSYLPHOSPHATIDYLINOSITOLS**

GPIIB-IIIA RECEPTORS see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

GRAAFIAN FOLLICLE see **OVARIAN FOLLICLE**

GRADUATE RECORDS EXAMINATION see **EDUCATIONAL MEASUREMENT**

GRAFFI VIRUS see **LEUKEMIA VIRUSES, MURINE**

GRAFFI'S CHLOROLEUKEMIC STRAIN see **LEUKEMIA VIRUSES, MURINE**

GRAFT ENHANCEMENT, IMMUNOLOGIC

Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bonnet D, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):203–9

A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. Josien R, et al. **J Clin Invest** 1998 Dec 1;102(11):1920–6

Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Blajchman MA. **Vox Sang** 1998;74 Suppl 2:315–9 (29 ref.)

METHODS

Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Drobyski WR, et al. **Biol Blood Marrow Transplant** 1999; 5(4):222–30

Peripheral donor leukocytes prolong survival of rat renal allografts. Noris M, et al. **Kidney Int** 1999 Sep; 56(3):1101–12

GRAFT OCCLUSION, VASCULAR

Vein patching reduces neointimal thickening associated with prosthetic graft implantation. Gentile AT, et al. **Am J Surg** 1998 Dec;176(6):601–7

Access to occluded infrainguinal bypass grafts with a loopsnare. Nosher JL, et al. **J Vasc Surg** 1999 Apr; 29(4):745–7

[Immediate and 6-month results of balloon angioplasty in the treatment of intra-stent restenosis in symptomatic patients] Eltchaninoff H, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12):1459–63 (Eng. Abstr.) **(Fre)**

[Influence of alleles of apolipoprotein E on restenosis after coronary angioplasty in women] Flork L, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12):1475–9 (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Multiple coronary artery graft occlusion in a fatal case of heparin-induced thrombocytopenia. Burke AP, et al. **Chest** 1998 Nov;114(5):1492–5

A possible side-effect of human erythropoietin therapy: thrombosis of peripheral arterial reconstruction. Mingoli A. **Eur J Vasc Endovasc Surg** 1999 Sep;18(3):273–4

Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. Martino MA, et al. **J Am Coll Surg** 1998 Dec;187(6):616–9

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. Alderman EL, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):716–30

Aprotinin and vein graft occlusion--the controversy continues [editorial] Westaby S, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):731–3

COMPLICATIONS

Thymoma encasing last patent vein graft to the heart. Jaklitsch MT, et al. **J Thorac Cardiovasc Surg** 1999 Sep; 118(3):561–3

DIAGNOSIS

Assessment of coronary artery bypass grafts: value of different breath-hold MR imaging techniques. Kalden P, et al. **AJR Am J Roentgenol** 1999 May;172(5):1359–64

Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Moreno PR, et al. **Am J Cardiol** 1999 Aug 15;84(4):462–6, A9

Does blood flow accurately predict thrombosis or failure of hemodialysis synthetic grafts? A meta-analysis. Paulson WD, et al. **Am J Kidney Dis** 1999 Sep;34(3):478–85

Intradialytic serial vascular access flow measurements. Rehman SU, et al. **Am J Kidney Dis** 1999 Sep;34(3):471–7

Functional assessment of internal mammary artery bypass grafts: case reports and review of the literature. Seligman RW, et al. **Catheter Cardiovasc Interv** 1999 Feb; 46(2):218–22 (20 ref.)

Preoperative prediction of graft patency for infrapopliteal arterial bypass using pulse-generated runoff. Harris RA, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):429–33

Magnetic resonance angiography in axillofemoral grafting [letter; comment] Rao G. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):317. Comment on: J Cardiovasc Surg (Torino) 1998 Apr;39(2):251–2.

Differentiation between arterial and venous vessel occlusion by simultaneous measurement with laser Doppler flowmetry and photoplethysmography. Galla TJ, et al. **J Reconstr Microsurg** 1999 Jan;15(1):67–72

Long-term graft patency rates and clinical outcomes after revascularization for symptomatic traumatic internal carotid artery dissection. Vishteh AG, et al. **Neurosurgery** 1998 Oct;43(4):761–7; discussion 767–8

The importance of graft blood flow and peripheral outflow resistance for early patency in infrainguinal arterial reconstructions. Wölfle KD, et al. **Vasa** 1999 Feb; 28(1):34–41

[Micromechanical pressure sensors for medical evaluation of blood vessels and bypasses after surgical intervention] Zacheja J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:182–3 **(Ger)**

[Techniques for postoperative monitoring of tissue circulation after free microvascular tissue transplantation] Machens HG, et al. **Handchir Mikrochir Plast Chir** 1999 Mar; 31(2):107–12 (40 ref.) (Eng. Abstr.) **(Ger)**

[Control of the patency of coronary artery bypasses with contrast enhanced magnetic resonance angiography] Brenner P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1308–11 (Eng. Abstr.) **(Ger)**

[Significance of electron-beam tomography in the evaluation of the patency of aortocoronary bypasses] Knez A, et al. **Radiologe** 1998 Dec;38(12):1012–20 (Eng. Abstr.) **(Ger)**

[The assessment of the patency of coronary bypass vessels with a 2D T2-weighted turbo-spin-echo sequence (HASTE) in the breath-hold technic] Kalden P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):442–8 (Eng. Abstr.) **(Ger)**

[Imaging of aortic endoprostheses and their complications] Krauss M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):388–96 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Morphological abnormalities revealed after successful intra-arterial thrombolysis of infra-inguinal native arteries and bypasses. Sandbaek G, et al. **Acta Radiol** 1999 Jan; 40(1):23–8

Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. Teirstein PS, et al. **Am J Cardiol** 1999 Jun 15;83(12):1623–8

Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine [see comments] Fischell TA, et al. **Cathet Cardiovasc Diagn** 1998 Dec; 45(4):360–5. Comment in: Cathet Cardiovasc Diagn 1998 Dec;45(4):366–7. Comment in: Catheter Cardiovasc Interv 1999 Apr;46(4):508.

Cath lab brain attack: what to do? [editorial; comment] Grollman JH Jr. **Cathet Cardiovasc Diagn** 1998 Aug; 44(4):415–6. Comment on: Cathet Cardiovasc Diagn 1997 Aug;41(4):384–5.

Adenosine boluses: a cure for "no-reflow"? [editorial; comment] Kern MJ. **Cathet Cardiovasc Diagn** 1998 Dec; 45(4):366–7. Comment on: Cathet Cardiovasc Diagn 1998 Dec;45(4):360–5.

Iatrogenic brain attack: treatment and/or prevention? [letter; comment] Ceceña FA, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):120. Comment on: Cathet Cardiovasc Diagn 1998 Aug;44(4):412–4.

Antithrombotic therapy and venous graft disease. Schussheim AE, et al. **Curr Opin Cardiol** 1998 Nov;13(6):459–64 (43 ref.)

Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Makkar RR, et al. **Eur Heart J** 1998 Oct; 19(10):1538–46

Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis. Breuer M, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):266–70

Thrombolysis with i.v. recombinant human tissue-type plasminogen activator in patients with bypass graft occlusion: a good adjunctive therapeutic mode (preliminary and case reports). Agresta F, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):551–5

Use of a simple compression dressing to obtain hemostasis after pharmacologic thrombolysis of dialysis grafts. Barzel E. **J Vasc Interv Radiol** 1999 Sep;10(8):1039–42

New thrombolytic brush catheter in thrombosed polytetrafluoroethylene dialysis grafts: preclinical animal study. Castañeda F, et al. **J Vasc Interv Radiol** 1998 Sep–Oct;9(5):793–8

Dialysis graft declotting with very low dose urokinase: is it feasible to use "less and wait?" Duszak R Jr, et al. **J Vasc Interv Radiol** 1999 Feb;10(2 Pt 1):123–8

A multi-modal approach to the management of bypass graft failure. Greenberg RK, et al. **Vasc Med** 1998;3(3):215–20 (19 ref.)

ECONOMICS

Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: a prospective study that compares Impra versus Gore-tex grafts. Hurlbert SN, et al. **Cardiovasc Surg** 1998 Dec;6(6):652–6

ENZYMOLOGY

Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Porter KE, et al. **Eur J Vasc Endovasc Surg** 1999 May; 17(5):404–12

EPIDEMIOLOGY

Pulsed Doppler intraoperative flow assessment and midterm coronary graft patency. Louagie YA, et al. **Ann Thorac Surg** 1998 Oct;66(4):1282–7; discussion 1288

A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Cinat ME, et al. **Ann Vasc Surg** 1999 Mar;13(2):191–8

Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts. Fisher CM, et al. **Cardiovasc Surg** 1999 Aug;7(5):519–25

The correlation of early flow disturbances with the development of infrainguinal graft stenosis: a 10-year study of 341 autogenous vein grafts. Ihnat DM, et al. **J Vasc Surg** 1999 Jul;30(1):8–15

[Coronary stent implantation and restenosis. Can it be predicted by studying the genes? (editorial; comment)] Galve E. **Rev Esp Cardiol** 1999 Jul;52(7):481–4. Comment on: Rev Esp Cardiol 1999 Jul;52(7):475–80. **(Spa)**

ETIOLOGY

Spontaneous recanalization of postoperative severe graft stenosis. What is the cause and prognosis of the "string

sign" in the internal thoracic artery? Hata M, et al. **Ann Thorac Cardiovasc Surg** 1999 Feb;5(1):52–5

Immediate vein graft thrombectomy for acute occlusion after coronary artery bypass grafting. Saltman AE, et al. **Ann Thorac Surg** 1999 Jun;67(6):1775–6

Total arterial revascularization with an internal thoracic artery and radial artery T graft. Sundt TM 3rd, et al. **Ann Thorac Surg** 1999 Aug;68(2):399–404; discussion 404–5

Patency of experimental microvascular autografts of the common carotid artery after balloon dilatation in rats: a technical note and preliminary results. Friedrich RE. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):365–70

Acute coronary occlusion and in-stent thrombosis in a patient with essential thrombocythemia. Turgut T, et al. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):428–33

Immediate occlusion of in situ saphenous vein bypass grafts: a survey of 329 reconstructions. Albäck A, et al. **Eur J Surg** 1998 Oct;164(10):745–50

Factors influencing the development of vein-graft stenosis and their significance for clinical management. Idu MM, et al. **Eur J Vasc Endovasc Surg** 1999 Jan;17(1):15–21

Chlamydia pneumoniae in redo and first-time coronary artery bypass graft surgery [letter] Gurfinkel E. **J Am Coll Cardiol** 1999 Sep;34(3):953–4

Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. LeSar CJ, et al. **J Am Coll Surg** 1999 Jul;189(1):73–9; discussion 79–81

Thrombosis of an aortobifemoral bypass graft after total hip arthroplasty. Trousdale RT, et al. **J Arthroplasty** 1999 Apr; 14(3):386–90

Torsion and kinking of unsupported aortic endografts: treatment by endovascular intervention. Boyle JR, et al. **J Endovasc Surg** 1998 Aug;5(3):216–21

Puncture-induced deformity of a metallic stent within a dialysis access graft causing thrombotic failure: case report and description of salvage. Lane JD, et al. **J Vasc Interv Radiol** 1998 Sep–Oct;9(5):837–9

Infrainguinal aneurysm formation in arterialized autologous saphenous vein grafts [see comments] Cassina PC, et al. **J Vasc Surg** 1998 Nov;28(5):944–8. Comment in: J Vasc Surg 1999 Apr;29(4):756–7.

Infrainguinal aneurysm formation in arterialized autologous saphenous vein grafts [letter; comment] Dardik H. **J Vasc Surg** 1999 Apr;29(4):756–7. Comment on: J Vasc Surg 1998 Nov;28(5):944–8.

Association of smooth muscle cell phenotypic modulation with extracellular matrix alterations during neointima formation in rabbit vein grafts. Zhang WD, et al. **J Vasc Surg** 1999 Jul;30(1):169–83

Femoro-femoral graft after unilateral obstruction of aorto-bifemoral bypass. Testini M, et al. **Minerva Cardioangiol** 1998 Jan–Feb;46(1–2):15–9 (32 ref.)

Severe impairment of graft flow without electrocardiographic changes during coronary artery bypass grafting. Jakobsen HL, et al. **Scand Cardiovasc J** 1999;33(3):157–9

Occlusion of the abdominal aorta caused by enlargement of the false lumen after graft replacement for a DeBakey type IIIb dissecting aneurysm: report of a case. Koshino T, et al. **Surg Today** 1998;28(12):1295–9

[Effects of different vascular beds on the microstructural components and intimal hyperplasia of autogenous vein grafts in dogs] Huang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):1–4 (Eng. Abstr.) **(Chi)**

GENETICS

Coagulation factor V (Arg506-->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Moor E, et al. **Thromb Haemost** 1998 Aug; 80(2):220–4

[Coronary stent implantation and restenosis. Can it be predicted by studying the genes? (editorial; comment)] Galve E. **Rev Esp Cardiol** 1999 Jul;52(7):481–4. Comment on: Rev Esp Cardiol 1999 Jul;52(7):475–80. **(Spa)**

[D/D genotype of the gene for angiotensin converting enzyme as a risk factor for post-stent coronary restenosis (see comments)] Guarda E, et al. **Rev Esp Cardiol** 1999 Jul;52(7):475–80 (Eng. Abstr.). Comment in: Rev Esp Cardiol 1999 Jul;52(7):481–4. **(Spa)**

METABOLISM

Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo. Okada SS, et al. **Thromb Haemost** 1998 Jul;80(1):140–7

PATHOLOGY

Early morphology of accelerated vein graft atheroma in experimental vein grafts. Davies MG, et al. **Ann Vasc Surg** 1999 Jul;13(4):378–85

Late in-stent restenosis of the abdominal aorta in a patient with Takayasu's arteritis and related pathology. Ishibashi-Ueda H, et al. **Cardiovasc Intervent Radiol** 1999 Jul–Aug;22(4):333–6

Characterization of cellular density and determination of neointimal extracellular matrix constituents in human lower extremity vein graft stenoses. Gentile AT, et al. **Cardiovasc Surg** 1999 Jun;7(4):464–9

Neointimal response following rotational atherectomy compared to balloon angioplasty in a porcine model of coronary in-stent restenosis. McKenna CJ, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):332–6

Topography of cell replication in human vein graft stenoses. Westerband A, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II325–9; discussion II329–30

Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (review). Andres V. **Int J Mol Med** 1998 Jul;2(1):81–9 (152 ref.)

Retrieval and analysis of particulate debris after saphenous vein graft intervention. Webb JG, et al. **J Am Coll Cardiol** 1999 Aug;34(2):468–75

Late occlusion of microvascular vein grafts in replantation. Morrison WA, et al. **J Hand Surg [Am]** 1998 Nov; 23(6):1106–11

Coronary atherosclerosis and interventions: pathological sequences and restenosis. Yutani C, et al. **Pathol Int** 1999 Apr;49(4):273–90 (126 ref.)

PHYSIOPATHOLOGY

Usefulness of flow reserve in the left internal mammary artery to determine graft patency to the left anterior descending coronary artery. Voudris V, et al. **Am J Cardiol** 1999 Apr 15;83(8):1157–63

Rapid changes in the coagulant proteins on saphenous vein endothelium in response to arterial flow. Golledge J, et al. **Angiology** 1999 Sep;50(9):693–701

Involvement of dendritic cells in long-term aortocoronary saphenous vein bypass graft failure. Cherian SM, et al. **Cardiovasc Surg** 1999 Aug;7(5):508–18

Cause and treatment of symptomatic steals following the insertion of haemodialysis shunts [letter] Dodds SR. **Cardiovasc Surg** 1998 Dec;6(6):657–9

Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Syvänne M, et al. **Circulation** 1998 Nov 10; 98(19):1993–9

Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Iaccarino G, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3945–50

Distribution and localization of cells and collagens in the proliferated intima of arterially implanted autovein grafts. Tamaki M, et al. **Surg Today** 1999;29(7):614–25

[Flow dynamics of an over-dimensional end-to-side anastomosis in a circulatory model with numerical flow simulation] Krüger U, et al. **Biomed Tech (Berl)** 1998;43 Suppl:312–3 **(Ger)**

PREVENTION & CONTROL

MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model. Loftus IM, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:547–50

Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Mannion JD, et al. **Ann Thorac Surg** 1998 Dec;66(6):1948–52

Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Porter KE, et al. **Br J Surg** 1998 Oct;85(10):1373–7

Rescue of liver grafts from hepatic artery occlusion in living-related liver transplantation. Sakamoto Y, et al. **Br J Surg** 1999 Jul;86(7):886–9

Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: an experimental study. Makutani S, et al. **Cardiovasc Intervent Radiol** 1999 May–Jun;22(3):232–8

Re: Stent placement at the venous anastomosis of a dialysis graft: be cost-effective and demanding with regard to the result [letter; comment] Turmel-Rodrigues LA. **Cardiovasc Intervent Radiol** 1998 Sep–Oct;21(5):442. Comment on: Cardiovasc Intervent Radiol 1998 Mar–Apr;21(2):176–8.

Stents covered by an autologous arterial graft in porcine coronary arteries: feasibility, vascular injury and effect on neointimal hyperplasia. Stefanadis C, et al. **Cardiovasc Res** 1999 Feb;41(2):433–42

Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Côté G, et al. **Circulation** 1999 Jan 5–12;99(1):30–5

Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Hamon M, et al. **Drugs Aging** 1998 Oct;13(4):291–301 (100 ref.)

Evaluation of the long-term effectiveness of extraluminal and intraluminal vasodilators in an in vitro porcine model of arterial graft spasm. Montgomery WD, et al. **Eur J Cardiothorac Surg** 1996;10(12):1071–81; discussion 1081–2

Low-molecular weight heparin versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin. Logason K. **Eur J Surg Suppl** 1998;(581):40–1

Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. George SJ, et al. **Gene Ther** 1998 Nov;5(11):1552–60

A modified method of auxiliary partial liver transplantation in the rat. Wang YN, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):428–31

Effect of diameter of microvascular interposition vein grafts on vessel patency and free flap survival in the rat model. Harris JR, et al. **J Otolaryngol** 1999 Jun;28(3):152–7

Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study. Martin LG, et al. **J Vasc Interv Radiol** 1999 Apr; 10(4):389–96

Local recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy in microvascular surgery. Atiyeh BS, et al. **Microsurgery** 1999;19(6):265–71

Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Iaccarino G, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3945–50

Prevention of in-stent restenosis. Narins CR, et al. **Semin Interv Cardiol** 1998 Jun;3(2):91–103 (106 ref.)

Endovascular manipulation to restrict restenosis. Gershlick AH. **Vasc Med** 1998;3(3):177–88 (86 ref.)

[Secondary prevention of ischemic heart disease after coronary revascularization] Delacrétaz E, et al. **Schweiz Rundsch Med Prax** 1998 Nov 4;87(45):1497–503 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Comparison of colour Doppler ultrasound and digital subtraction angiography in the diagnosis of lower limb arterial disease. Nzeh DA, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):177–80

Carbon dioxide as a contrast agent to guide vascular interventional procedures. Eschelman DJ, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1265–70

Intraoperative angiography to assess graft patency after minimally invasive coronary bypass. Goldstein JA, et al. **Ann Thorac Surg** 1998 Dec;66(6):1978–82

Results of graft patency by immediate angiography in minimally invasive coronary artery surgery. Mack MJ, et al. **Ann Thorac Surg** 1999 Aug;68(2):383–9; discussion 389–90

Angiographic predictors of graft patency and disease progression after coronary artery bypass grafting with arterial and venous grafts. Manninen HI, et al. **Ann Thorac Surg** 1998 Oct;66(4):1289–94

Addendum to "Short-term angiographic and long-term clinical follow-up of a patient with a malexpanded vein graft stent" [letter; comment] Gavaliatsis IP, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):268. Comment on: Cathet Cardiovasc Diagn 1997 Aug;41(4):413–4.

Vein graft surveillance [letter; comment] Mahomed A. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):273–4. Comment on: Eur J Vasc Endovasc Surg 1998 May;15(5):394–7.

Post-mortem cast angiography in the diagnostics of graft complications in patients with fatal outcome following coronary artery bypass grafting (CABG). Weman SM, et al. **Int J Legal Med** 1999;112(2):107–14

Double-helical CT as a new tool for tracking of allograft atherosclerosis in heart transplant recipients. Shemesh J, et al. **Invest Radiol** 1999 Jul;34(7):485–8

Significance of graft occlusion and coronary atherosclerosis 5 years after coronary artery bypass grafting. A quantitative angiographic study with serial exercise testing. Korpilahti K, et al. **J Intern Med** 1999 May;245(5):545–52

Angiographic changes in saphenous vein grafts and atherosclerosis risk factors. A 5-year study with serial measurements of serum lipids and lipoproteins. Korpilahti K, et al. **Scand Cardiovasc J** 1998;32(6):343–51

RADIOTHERAPY

Radiation inhibition of arterial restenosis — a new frontier. Rubin P, et al. **Acta Oncol** 1999;38(4):407–24 (146 ref.)

Quantitative angiographic analysis of stent restenosis in the Scripps Coronary Radiation to Inhibit Intimal Proliferation Post Stenting (SCRIPPS) Trial. Lansky AJ, et al. **Am J Cardiol** 1999 Aug 15;84(4):410–4

Brachytherapy for the prevention of stenosis in a canine hemodialysis graft model: preliminary observations. Trerotola SO, et al. **Radiology** 1999 Sep;212(3):748–54

Endovascular brachytherapy in arteriovenous grafts for haemodialysis does not prevent development of stenosis [letter] El Sharouni SY, et al. **Radiother Oncol** 1998 Nov; 49(2):199–200

Radiation therapy to prevent stenosis of peripheral vascular accesses. Parikh S, et al. **Semin Radiat Oncol** 1999 Apr; 9(2):144–54 (48 ref.)

SURGERY

The impact of a community-wide vascular access program on the management of graft thromboses in a dialysis population of 495 patients. Cull DL, et al. **Am J Surg** 1999 Aug;178(2):113–6

Aortic valve replacement in a patient with previous coronary artery bypass grafting. Sugita T, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):288–9

Reinterventions for recurrent ischemic heart disease following a successful first re-do myocardial revascularization: predictors, indications and results. Kaul TK, et al. **Cardiovasc Surg** 1999 Apr;7(3):363–8

Managing the embolization problem during saphenous vein graft intervention [editorial; comment] Baim DS, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):155–6. Comment on: Catheter Cardiovasc Interv 1999 Jun;47(2):149–54.

Risk of distal embolization and infarction with transluminal extraction atherectomy in saphenous vein grafts and native coronary arteries. NACI Investigators. New Approaches

to Coronary Interventions [see comments] Moses JW, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):149–54. Comment in: Catheter Cardiovasc Interv 1999 Jun;47(2):155–6.

Revascularization of a thrombosed, previously stented aorto–renal graft using combined directional atherectomy and AngioJet thrombectomy. Seth A, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):85–8

Adjunctive abciximab improves outcomes during recanalization of totally occluded saphenous vein grafts using transluminal extraction atherectomy. Sullebarger JT, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):107–10

Long-term follow-up after coronary artery bypass grafting reoperation. Shapira I, et al. **Chest** 1999 Jun;115(6):1593–7

Percutaneous revascularization of occluded vein grafts : is it still a temptation to be resisted? [editorial; comment] Holmes DR Jr, et al. **Circulation** 1999 Jan 5–12;99(1):8–11 . Comment on: Circulation 1999 Jan 5–12;99(1):26–9.

Laser channels after percutaneous transmyocardial revascularization. Perin EC, et al. **Circulation** 1999 Apr 27;99(16):2218

Coronary artery bypass grafting after orthotopic heart transplantation. Musci M, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):163–8

Relationship of femorodistal bypass patency to clinical outcome. Iloprost Bypass International Study Group. Watson HR, et al. **Eur J Vasc Endovasc Surg** 1999 Jan; 17(1):77–83

Intravascular stenting of systemic venous baffle stenosis after corrective surgery for double outlet right ventricle with left isomerism. Miura T, et al. **Heart** 1999 Feb;81(2):218–20

Rotational atherectomy for in-stent restenosis: acute and long-term results of the first 100 cases. Sharma SK, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1358–65

Combined surgical and endovascular removal of thrombus entirely occluding a bifurcated aortic stent-graft. Rückert RI, et al. **J Endovasc Surg** 1998 Nov;5(4):323–8

Modified use of the arrow–trerotola percutaneous thrombolytic device for the treatment of thrombosed hemodialysis access grafts. Lazzaro CR, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1025–31

Forearm loop, upper arm straight, and brachial–internal jugular vein dialysis grafts: a comparison study of graft survival utilizing a combined percutaneous endovascular and surgical maintenance approach. Savader SJ, et al. **J Vasc Interv Radiol** 1999 May;10(5):537–45

Duplex scanning alone is not sufficient imaging before secondary procedures after lower extremity reversed vein bypass graft. Landry GJ, et al. **J Vasc Surg** 1999 Feb; 29(2):270–80; discussion 280–1

Aneurysm of a subclavian–vertebral artery saphenous vein bypass graft: case report. Takeuchi S, et al. **Neurosurgery** 1998 Nov;43(5):1212–4

Occlusion of the abdominal aorta caused by enlargement of the false lumen after graft replacement for a DeBakey type IIIb dissecting aneurysm: report of a case. Koshino T, et al. **Surg Today** 1998;28(12):1295–9

[IVUS-controlled aorto-ostial directional coronary atherectomy in higher grade stenosis of the central anastomosis of a sequential triple venous bypass] Schiele TM, et al. **Z Kardiol** 1998 Dec;87(12):954–60 (Eng. Abstr.) **(Ger)**

[Reconstruction of mediastinal veins in same side dialysis shunt] Haug M, et al. **Zentralbl Chir** 1999;124(1):2–6 (Eng. Abstr.) **(Ger)**

[Extraanatomical bypass as a reoperation in complication of major artery injury] Lokhvitskii SV, et al. **Khirurgiia (Mosk)** 1999;(1):55–6 **(Rus)**

THERAPY

Treatment of venous outflow stenoses in thigh grafts with Wallstents. Funaki B, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1591–6

Long-term outcome and determinants of event-free survival in patients treated with balloon angioplasty for in-stent restenosis. Alfonso F, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1268–70, A9

Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts. Watson PS, et al. **Am J Cardiol** 1999 Apr 1;83(7):1018–21

Cerebral embolism after mechanical thrombolysis of a clotted hemodialysis access [see comments] Briefel GR, et al. **Am J Kidney Dis** 1999 Aug;34(2):341–3. Comment in: Am J Kidney Dis 1999 Aug;34(2):361–3.

Ventilation–perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts. Petronis JD, et al. **Am J Kidney Dis** 1999 Aug;34(2):207–11

Access-related venous stenoses and occlusions: treatment with percutaneous transluminal angioplasty and Dacron–covered stents. Farber A, et al. **Cardiovasc Intervent Radiol** 1999 May–Jun;22(3):214–8

Percutaneous transluminal angioplasty of peripheral bypass stenoses. Hoksbergen AW, et al. **Cardiovasc Intervent Radiol** 1999 Jul–Aug;22(4):282–6

Re: Treatment of early TIPS occlusion with a polytetrafluoroethylene (PTFE)-covered zigzag stent [letter] Kawai N, et al. **Cardiovasc Intervent Radiol** 1999 May–Jun;22(3):264–5

The use of the Fogarty catheter in 1998. Hill B, et al. **Cardiovasc Surg** 1999 Apr;7(3):273–8 (7 ref.)

Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis. Berkompas DC. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):272–4

Percutaneous transluminal angioplasty of radial artery grafts. Blanchard D, et al. **Cathet Cardiovasc Diagn** 1998 Dec; 45(4):400–4

Complete left atrial obliteration due to localized tamponade after coronary artery perforation during PTCA. Dardas PS, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):61–3

Stent by stent crush: procedural outcome and angiographic follow-up. Eeckhout E, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):54–6

Coronary steal by IMA bypass graft side-branches: a novel therapeutic use of a new detachable embolization coil [see comments] Eisenhauer MD, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):301–6. Comment in: Cathet Cardiovasc Diagn 1998 Nov;45(3):307–9.

Does a LIMA side branch ever need occlusion? (Why I don't think so) [editorial; comment] Kern MJ. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):307–9 (20 ref.). Comment on: Cathet Cardiovasc Diagn 1998 Nov;45(3):301–6.

Transcatheter recanalization and subsequent stent implantation for the treatment of early postoperative thrombosis of modified Blalock–Taussig shunts in two children. Peuster M, et al. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):405–8

Case of successful percutaneous stenting of an in situ gastroepiploic–coronary bypass graft [see comments] Roriz R, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):67–9. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):118–9.

Emergency left main stenting in the management of postcoronary bypass graft surgery (CABG) ischemia. Shaikh J, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):64–6

Gastroepiploic bypass graft stenting [letter; comment] Feld S, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):118–9. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):67–9.

Yes reflow [editorial; comment] Heldman AW, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):404–5. Comment on: Catheter Cardiovasc Interv 1999 Aug;47(4):397–403.

Use of stents to treat kinks causing obstruction in a left internal mammary artery graft. Rerkpattanapipat P, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):223–6

Novel distal occluder washout method for prevention of no-reflow during stenting of saphenous vein grafts [see comments] Shaknovich A, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):397–403. Comment in: Catheter Cardiovasc Interv 1999 Aug;47(4):404–5.

Stenting of a stenotic radial artery coronary graft: a new therapeutic scenario in coronary artery disease. Patti G, et al. **G Ital Cardiol** 1999 Feb;29(2):149–51

Platelet IIb/IIIa antagonists followed by delayed stent implantation. A new treatment for vein graft lesions containing massive thrombus. Robinson N, et al. **Heart** 1999 Apr;81(4):434–7

PTCA of degenerated vein grafts: experience of two periods (1992–93 and 1996–97) in 780 patients. Reifart N, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:62–6

Utilisation of transluminal extraction atherectomy in the treatment of saphenous vein graft disease: two case reports. White HL, et al. **Int J Cardiol** 1998 Sep 1;66(1):11–5

Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. Köster R, et al. **J Am Coll Cardiol** 1999 Jul;34(1):25–32

Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study. Radke PW, et al. **J Am Coll Cardiol** 1999 Jul; 34(1):33–9

Duplex features of vein graft stenosis and the success of percutaneous transluminal angioplasty. Gonsalves C, et al. **J Endovasc Surg** 1999 Feb;6(1):66–72

Stent placement in a carotid artery bypass graft in a patient with Takayasu arteritis. Chapdelaine JP, et al. **J Vasc Interv Radiol** 1998 Sep–Oct;9(5):846–8

Hemodialysis graft mechanical thrombolysis with use of the Amplatz Thrombectomy Device: histopathologic evaluation of extracted myointimal tissue. Cooper SG, et al. **J Vasc Interv Radiol** 1999 Mar;10(3):285–8

Surgery versus percutaneous treatment of thrombosed dialysis access grafts: is there a best method? [comment] Gelbfish GA. **J Vasc Interv Radiol** 1998 Nov–Dec; 9(6):875–7. Comment on: J Vasc Interv Radiol 1997 May–Jun;8(3):313–27.

Treatment of acute aortorenal bypass graft thrombosis by means of primary stent placement and adjunctive thrombolysis. Morris CS, et al. **J Vasc Interv Radiol** 1998 Nov–Dec;9(6):961–3

Percutaneous mechanical declotting of dialysis grafts using a central approach: a summation of risks not acceptable in 1998 [letter; comment] Turmel-Rodrigues L. **J Vasc Interv Radiol** 1999 Mar;10(3):375–6. Comment on: J Vasc Interv Radiol 1998 Sep–Oct;9(5):833–6.

Thromboaspiration to treat inadvertent arterial emboli during dialysis graft declotting [letter; comment] Turmel-Rodrigues LA, et al. **J Vasc Interv Radiol** 1998 Sep–Oct;9(5):849–50. Commen' on: J Vasc Interv Radiol 1998 Jan–Feb;9(1 Pt 1):141–3.

Endovascular stent placement for angioplasty-induced venous rupture related to the treatment of hemodialysis grafts. Welber A, et al. **J Vasc Interv Radiol** 1999 May; 10(5):547–51

Thrombosed dialysis grafts: percutaneous mechanical declotting using a central venous approach [see comments] Zaetta JM, et al. **J Vasc Interv Radiol** 1998 Sep–Oct; 9(5):833–6. Comment in: J Vasc Interv Radiol 1999 Mar;10(3):375–6.

Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia–Cimino dialysis fistulas. Zaleski GX, et al. **J Vasc Interv Radiol** 1999 Feb;10(2 Pt 1):129–36

Surgical and endovascular intervention for infrainguinal vein graft stenosis. Avino AJ, et al. **J Vasc Surg** 1999 Jan; 29(1):60–70; discussion 70–1

Percutaneous revascularization of lesions with saphenous vein graft failure: influence of chronic total occlusion on early outcome. Yasuda H, et al. **Jpn Circ J** 1998 Sep; 62(9):687–90

Vascular gene therapy. Thomas JW, et al. **Radiographics** 1998 Nov–Dec;18(6):1373–94 (109 ref.)

Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Haage P, et al. **Radiology** 1999 Jul;212(1):175–80

Patency of Wallstents placed across the venous anastomosis of hemodialysis grafts after percutaneous recanalization [see comments] Patel RI, et al. **Radiology** 1998 Nov; 209(2):365–70. Comment in: Radiology 1999 May;211(2):586.

Treatment of in-stent restenosis. Mintz GS, et al. **Semin Interv Cardiol** 1998 Jun;3(2):117–21 (45 ref.)

[Stent restenosis: therapy concepts and possibilities for prevention] Radke PW, et al. **Med Klin** 1999 Feb 15; 94(2):88–92 (53 ref.) (Eng. Abstr.) **(Ger)**

[From surgical to interventional standby?] Reifart N, et al. **Z Kardiol** 1998;87 Suppl 3:8–11; discussion 14–5 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Comparison of colour Doppler ultrasound and digital subtraction angiography in the diagnosis of lower limb arterial disease. Nzeh DA, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):177–80

Tissue proliferation within and surrounding Palmaz–Schatz stents is dependent on the aggressiveness of stent implantation technique. Hoffmann R, et al. **Am J Cardiol** 1999 Apr 15;83(8):1170–4

Determinants of stent restenosis in chronic coronary occlusions assessed by intracoronary ultrasound. Werner GS, et al. **Am J Cardiol** 1999 Apr 15;83(8):1164–9

The predictive value of intraoperative duplex for early vein graft patency in lower extremity revascularization. MacKenzie KS, et al. **Ann Vasc Surg** 1999 May; 13(3):275–83

Role of transcutaneous ultrasound in evaluation of graft patency following minimally invasive coronary surgery. Gupta S, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S88–92

The formation of two layers detectable by intraoperative echocardiography is a reliable predictor of late thrombosis within the false lumen of a dissected aorta. Yoshida M, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):240–2

Surveillance of above-knee prosthetic femoropopliteal bypass. Aune S, et al. **Eur J Vasc Endovasc Surg** 1998 Dec; 16(6):509–12

Graft surveillance [letter] Lundell A. **Eur J Vasc Endovasc Surg** 1999 May;17(5):460–2

Vein graft surveillance [letter; comment] Mahomed A. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):273–4. Comment on: Eur J Vasc Endovasc Surg 1998 May;15(5):394–7.

Graft patency evaluation with colour-Doppler ultrasonography after bypass surgery in Takayasu's arteritis: a direct colour-flow lumen imaging method. Raninen RO, et al. **Eur J Vasc Endovasc Surg** 1998 Dec; 16(6):525–9

Duplex features of vein graft stenosis and the success of percutaneous transluminal angioplasty. Gonsalves C, et al. **J Endovasc Surg** 1999 Feb;6(1):66–72

AIUM technical bulletin--Color duplex imaging for graft surveillance of the autologous vein graft. American Institute of Ultrasound in Medicine. Lee W. **J Ultrasound Med** 1998 Dec;17(12):789–95

Duplex scanning alone is not sufficient imaging before secondary procedures after lower extremity reversed vein bypass graft. Landry GJ, et al. **J Vasc Surg** 1999 Feb; 29(2):270–80; discussion 280–1

Effect of outflow level and maximum graft diameter on the velocity parameters of reversed vein bypass grafts. Treiman GS, et al. **J Vasc Surg** 1999 Jul;30(1):16–25

Vein graft surveillance with scanhead tracking duplex ultrasound imaging: a preliminary report. Jong JM, et al. **Ultrasound Med Biol** 1998 Nov;24(9):1313–24

[The Doppler color detection of internal mammary artery anastomoses and a functional assessment of their patency (see comments)] Moreno R, et al. **Rev Esp Cardiol** 1999 Apr;52(4):253–8 (Eng. Abstr.). Comment in: Rev Esp Cardiol 1999 Apr;52(4):259–60. **(Spa)**

VETERINARY

Permanent implantation of a reinforced

polytetrafluoroethylene vascular graft for treatment of artificial defects of the teat cistern mucosa in cows. Metzger L, et al. **Am J Vet Res** 1999 Jan;60(1):56–62

GRAFT REJECTION

Acute rejection and delayed graft function--risk factors of graft loss. Boratyńska M, et al. **Ann Transplant** 1996; 1(2):19–22

Apoptosis in acute pulmonary allograft rejection and cytomegalovirus infection. Hansen PR, et al. **APMIS** 1999 May;107(5):529–33

Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. Dufour C, et al. **Bone Marrow Transplant** 1999 Apr;23(7):743–5

Flow cytometry cross-match before kidney transplantation in relation to early postransplant rejection. Slavcev A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S114–5

Short-term toxicity in pediatric marrow transplantation using related and unrelated donors. Vettenranta K, et al. **Bone Marrow Transplant** 1999 Mar;23(5):459–62

Retransplantation and the "noncompliant" patient. Seiden DJ, et al. **Camb Q Healthc Ethics** 1999 Summer;8(3):375–81

Evaluation of reaction of primate brain to grafted PC12 cells. Yoshida H, et al. **Cell Transplant** 1999 Jul–Aug;8(4):427–30

Heart rate variability as an assessment of acute rejection after heart transplantation. Chou CL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):561–7

A second unrelated bone marrow transplant: successful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system. Blau IW, et al. **Clin Lab Haematol** 1999 Apr;21(2):133–8

Severe late acute allograft rejection in a child after living-related auxiliary partial orthotopic liver transplantation for ornithine transcarbamylase deficiency. Komatsu H, et al. **Clin Transplant** 1999 Aug;13(4):300–4

Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time. Pelletier RP, et al. **Clin Transplant** 1998 Dec; 12(6):543–52

Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Taylor DO, et al. **Clin Transplant** 1999 Aug;13(4):296–9

Interactions between T lymphocytes and endothelial cells in allograft rejection. Briscoe DM, et al. **Curr Opin Immunol** 1998 Oct;10(5):525–31 (88 ref.)

Natural killer cells and their role in graft rejection. Manilay JO, et al. **Curr Opin Immunol** 1998 Oct;10(5):532–8 (77 ref.)

Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? De Vos P, et al. **Diabetes** 1999 Jul;48(7):1381–8

An ex vivo perfusion model to evaluate hyperacute rejection in a discordant pig-to-human combination. Fiane AE, et al. **Eur Surg Res** 1998;30(5):341–51

Analysis of sex-mismatched human corneal transplants by fluorescence in situ hybridization of the sex-chromosomes. Wollensak G, et al. **Exp Eye Res** 1999 Mar;68(3):341–6

Transplantation for hepatitis C: good news and bad news. Blendis L, et al. **Gastroenterology** 1999 Aug;117(2):502–3

Resistant graft failure overcome with allogenic peripheral blood plus bone marrow stem cells. Arslan O, et al. **Haematologia (Budap)** 1998;29(1):47–50

Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. De Geest S, et al. **J Heart Lung Transplant** 1998 Sep; 17(9):854–63

Salvage by volume reduction of chronic allograft rejection in emphysema. Schulman LL, et al. **J Heart Lung Transplant** 1999 Feb;18(2):107–12

Is acute rejection deleterious to long-term liver allograft function? Dousset B, et al. **J Hepatol** 1998 Oct;29(4):660–8

CD44 splice variants in draining lymph nodes precede allograft rejection of endocrine cells. Milde KF, et al. **J Mol Med** 1999 Jan;77(1):67–9

Anatomic variability of rejection in intestinal allografts after pediatric intestinal transplantation. Sigurdsson L, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):403–6

Early risk factors in pediatric renal transplantation at a single center. Talbot D, et al. **J Pediatr Surg** 1998 Sep; 33(9):1396–8

Elevated neointimal endothelin-1 in transplantation-associated arteriosclerosis of renal allograft recipients. Simonson MS, et al. **Kidney Int** 1998 Sep; 54(3):960–71

Hepatic Allograft Rejection and Evolving Immunosuppression Strategies. Proceedings of the AASLD/ILTS transplant course. Chicago, Illinois, USA. November 8, 1998. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S1–121

Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Wiesner RH, et al. **Liver Transpl Surg** 1999 Sep;5(5):388–400 (70 ref.)

Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Furth S, et al. **Pediatr Transplant** 1999 May; 3(2):146–9

Complications after intestinal transplantation: traditional and new [editorial] Goulet O. **Pediatr Transplant** 1999 May; 3(2):89–91

Acute pancreatic transplant rejection: evaluation with dynamic contrast-enhanced MR imaging compared with histopathologic analysis. Krebs TL, et al. **Radiology** 1999 Feb;210(2):437–42

Allograft rejection of small bowel transplantation in pigs. Nishida S, et al. **Surg Today** 1998;28(11):1138–45

The combined impact of donor age and acute rejection on long-term cadaver renal allograft survival. Knight RJ, et al. **Surgery** 1999 Mar;125(3):318–24

Extracorporeal photochemotherapy: a treatment for organ graft rejection [editorial] Heshmati F, et al. **Ther Apher** 1997 May;1(2):121–5 (25 ref.)

Usefulness of the QTc interval in predicting acute allograft rejection. Richartz BM, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):217–21

Clinical response and temporal patterns of acute cellular rejection: relationship to chronic transplant nephropathy. Ashraf S, et al. **Transpl Int** 1998;11 Suppl 1:S5–9

Changes at the extracellular matrix during acute and chronic rejection in human liver transplantation. Mueller AR, et al. **Transpl Int** 1998;11 Suppl 1:S377–82

Outcome of liver transplantation after acute rejection and sepsis. Avolio AW, et al. **Transplant Proc** 1998 Dec; 30(8):3962–6

Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Takaya S, et al. **Transplant Proc** 1999 Aug;31(5):2028–31

The role of cytokines and antioxidant status in graft quality prediction. Zivna H, et al. **Transplant Proc** 1999 Aug; 31(5):2094

Prognostic value of lymphocyte apoptosis in acute rejection of renal allografts. August C, et al. **Transplantation** 1999 Feb 27;67(4):581–5

Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Binet I, et al. **Transplantation** 1999 Mar 27;67(6):918–22

Temporal sequence of transcription of perforin, Fas ligand, and tumor necrosis factor-alpha genes in rejecting skin allografts. Borson ND, et al. **Transplantation** 1999 Mar 15; 67(5):672–80

Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts. Djamali A, et al. **Transplantation** 1998 Dec 27; 66(12):1793–801

Spontaneous acceptance or rejection of orthotopic liver transplants in outbred and partially inbred miniature swine. Flye MW, et al. **Transplantation** 1999 Sep 15;68(5):599–607

CD8+ T cells produce RANTES during acute rejection of murine allogeneic skin grafts. Koga S, et al. **Transplantation** 1999 Mar 27;67(6):854–64

Alloimmune-mediated apoptosis: comparison in mouse models of acute and chronic cardiac rejection. Koglin J, et al. **Transplantation** 1999 Mar 27;67(6):904–9

Immune-activation gene expression in clinically stable renal allograft biopsies: molecular evidence for subclinical rejection. Lipman ML, et al. **Transplantation** 1998 Dec 27; 66(12):1673–81

Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Lorber MI, et al. **Transplantation** 1999 Mar 27;67(6):897–903

Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. Papadimitriou JC, et al. **Transplantation** 1998 Dec 27;66(12):1741–5

Migration of dendritic cells to the draining lymph node after allogeneic or congeneic rat skin transplantation. Richters CD, et al. **Transplantation** 1999 Mar 27;67(6):828–32

Association of cytomegalovirus genotype with graft rejection after liver transplantation. Rosen HR, et al. **Transplantation** 1998 Dec 27;66(12):1627–31

Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Shoskes DA, et al. **Transplantation** 1998 Dec 27; 66(12):1697–701

Allogeneic bronchoalveolar lavage cells induce the histology and immunology of lung allograft rejection in recipient murine lungs: role of intercellular adhesion molecule-1 on donor cells. Wilkes DS, et al. **Transplantation** 1999 Mar 27;67(6):890–6

Extracorporeal ("ex vivo") connection of pig kidneys to humans. III. Studies of plasma complement activation and complement deposition in the kidney tissue. Bengtsson A, et al. **Xenotransplantation** 1998 Aug;5(3):176–83

Acute vascular rejection. Platt JL, et al. **Xenotransplantation** 1998 Aug;5(3):169–75 (41 ref.)

[Immunological rejection in rat embryonic brain tissue transplantation: experimental study] Liu J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jan;35(1):16–8 (Eng. Abstr.) **(Chi)**

[Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent] Ramelet AA, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):380–4 **(Fre)**

[Chronic glomerular rejection of a renal graft] Daniel L, et al. **Ann Pathol** 1999 Apr;19(2):143–4 **(Fre)**

[Detection of acute rejection of heart transplantation by Doppler color imaging] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1255–62 (30 ref.) (Eng. Abstr.) **(Fre)**

[Cytomegalovirus infection, a risk factor for acute graft rejection in renal transplant recipients. A case-controlled study] Bouedjoro-Camus MC, et al. **Presse Med** 1999 Mar 27;28(12):619–24 (30 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Role of circulating lipid abnormalities in chronic renal allograft rejection. Kasiske BL. **Kidney Int Suppl** 1999 Jul; 71:S28–30 (19 ref.)

CD4+ and CD8+ T cell subset distribution in the blood of small-bowel-grafted rats: modification during graft-versus-host disease. Marni A, et al. **Transpl Int** 1998; 11 Suppl 1:S467–71

Plasma proteolytic activity in liver transplant rejection. Scholz T, et al. **Transpl Int** 1999;12(2):100–7

Unbound cyclosporine and allograft rejection after heart transplantation. Akhlaghi F, et al. **Transplantation** 1999 Jan 15;67(1):54–9

The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. Dickson RC, et al. **Transplantation** 1999 Jul 27;68(2):247–53

[Soluble cell adhesion molecules in chronic renal graft rejection] Boratyńska M. **Pol Arch Med Wewn** 1998 Nov; 100(5):410–8 (Eng. Abstr.) **(Pol)**

CLASSIFICATION

The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. Winters GL, et al. **J Heart Lung Transplant** 1998 Aug;17(8):754–60

Acute and chronic hepatic allograft rejection: pathology and classification. Batts KP. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S21–9 (27 ref.)

Banff schema for grading liver allograft rejection: utility in clinical practice. Ormonde DG, et al. **Liver Transpl Surg** 1999 Jul;5(4):261–8

The association between acute rejection and chronic rejection in kidney transplantation. Humar A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1302–3

Correlation between Banff classification and reversal of acute renal rejection. Kokado Y, et al. **Transplant Proc** 1998 Nov; 30(7):3064–6

Correlation between Banff classification acute rejection scores and reversal of rejection. Park KK, et al. **Transplant Proc** 1998 Nov;30(7):3067–8

[The rejection of a hepatic graft] Pandrea I, et al. **Chirurgia (Bucur)** 1998 Nov–Dec;93(6):375–86 (80 ref.) (Eng. Abstr.) **(Rum)**

COMPLICATIONS

Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Husain AN, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):829–33

Rejection with heart failure after pediatric cardiac transplantation. Flippin MJ, et al. **Ann Thorac Surg** 1999 Jul;68(1):176–80

Allograft vasculopathy: diagnosing the nemesis of heart transplantation [editorial; comment] Young JB. **Circulation** 1999 Aug 3;100(5):458–60. Comment on: Circulation 1999 Aug 3;100(5):509–15.

Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Peschke B, et al. **Clin Nephrol** 1999 May; 51(5):290–5

Fever in dialysis patients with recently rejected renal allografts. Sever MS, et al. **Int J Artif Organs** 1998 Jul; 21(7):403–7

The impact of cytolytic therapy on bronchiolitis obliterans syndrome. Date H, et al. **J Heart Lung Transplant** 1998 Sep;17(9):869–75

Prothrombotic risk factors and acute kidney transplant rejection. Heidenreich S, et al. **Kidney Blood Press Res** 1998;21(2–4):293–5 (13 ref.)

Segmental glomerulopathy of early rejection. Rossmann P, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2399–401

FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3594–5

Posttransplant lymphoproliferative disease combined with ductopenic rejection: report of a case. Lee WY, et al. **Transplant Proc** 1998 Nov;30(7):3310–1

DIAGNOSIS

Post-transplantation lymphoproliferative disorder versus acute liver rejection: do we need a scoring system? Dietze O. **Adv Anat Pathol** 1998 Jan;5(1):30–5 (10 ref.)

Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Monaco AP, et al. **Am J Kidney Dis** 1999 Jan; 33(1):150–60 (47 ref.)

Lymphocyte subset analysis for the diagnosis of rejection and infection in recipients of liver transplants. Jindal RM, et al. **Am Surg** 1999 Jan;65(1):77–80

The role of cardiac troponin T to predict heart transplant rejection [letter] Anderson JR, et al. **Ann Thorac Surg** 1999 Sep;68(3):1121–2

Sensitive diagnosis of cardiac allograft rejection by detection of cytokine transcription in situ. Suzuki J, et al. **Cardiovasc Res** 1998 Nov;40(2):307–13

New method for detection of heart allograft rejection:

validation of sensitivity and reliability in a rat heterotopic allograft model. Morgan DC, et al. **Circulation** 1999 Sep 14;100(11):1236–41

Allograft vasculopathy: diagnosing the nemesis of heart transplantation [editorial; comment] Young JB. **Circulation** 1999 Aug 3;100(5):458–60. Comment on: Circulation 1999 Aug 3;100(5):509–15.

Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Müller TF, et al. **Clin Chim Acta** 1998 Aug 10;276(1):63–74

The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Kotb M, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):83–9

Noninvasive detection of cardiac transplant rejection using electronic monitoring. Eisen HJ. **Curr Opin Cardiol** 1999 Mar;14(2):151–4 (16 ref.)

Assessment of cardiac rejection by MR-imaging and MR-spectroscopy. Walpoth BH, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):426–30

Survival of cryopreserved fetal substantia nigra implanted into the rat brain in the two forms and estimation of the host brain reaction against graft. Kosno-Kruszewska E. **Folia Neuropathol** 1999;37(1):1–9

The first case report of the use of a zoom videoendoscope for the evaluation of small bowel graft mucosa in a human after intestinal transplantation. Kato T, et al. **Gastrointest Endosc** 1999 Aug;50(2):257–61

A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dtmax. Dambrin C, et al. **J Heart Lung Transplant** 1999 Jun; 18(6):524–31

Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. Kerman RH, et al. **J Heart Lung Transplant** 1998 Aug;17(8):789–94

Prognostic value of myocardial lactate dehydrogenase subunit ratio in heart transplant recipients. Missov E, et al. **J Heart Lung Transplant** 1998 Oct;17(10):959–68

Development of lymphocytotoxic antibodies among lung transplant recipients: preliminary results. Reynaud-Gaubert ML, et al. **J Heart Lung Transplant** 1998 Oct;17(10):980–3

Evaluation of plasma cyclic GMP assay as a screening test for detection of acute cardiac allograft rejection. Stobierska-Dzierzek B, et al. **J Heart Lung Transplant** 1998 Oct;17(10):969–71

The significance of atrial monophasic action potentials for monitoring rat cardiac allograft rejection. Tahara K, et al. **J Heart Lung Transplant** 1998 Oct;17(10):954–8

Cardiac troponin T is not a marker of biopsy-proven cellular rejection [letter; comment] [published erratum appears in J Heart Lung Transplant 1999 Jun;18(6):610] Vazquez-Rodriguez JM, et al. **J Heart Lung Transplant** 1999 Feb;18(2):172. Comment on: J Heart Lung Transplant 1998 Apr;17(4):395–8.

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats. Wada T, et al. **J Heart Lung Transplant** 1999 Jun;18(6):499–509

Limits of clinical signs and non-invasive techniques in detecting severe acute rejection. Bertoni E, et al. **J Nephrol** 1999 Mar-Apr;12(2):100–3

Serum lysozyme activity can differentiate infection from rejection in organ transplant recipients. Jones JW Jr, et al. **J Surg Res** 1999 Jun 15;84(2):134–7

The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. Drobyski WR, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):317–23

The utility of pacemaker evoked T wave amplitude for the noninvasive diagnosis of cardiac allograft rejection. Bainbridge AD, et al. **Pacing Clin Electrophysiol** 1999 Jun; 22(6 Pt 1):942–6

Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience. Bourge R, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2338–44

Intramyocardial electrogram variability in the monitoring of graft rejection after heart transplantation. Grasser B, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2345–9

Characteristics of the signal-averaged P wave in orthotopic heart transplant recipients. Volgman AS, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2327–30

Correlation of mucosal disaccharidase activities with histology in evaluation of rejection following intestinal transplantation [see comments] Kaufman SS, et al. **Pediatr Transplant** 1998 May;2(2):134–8. Comment in: Pediatr Transplant 1998 May;2(2):87–8.

Current status of diagnosis of small bowel rejection [editorial; comment] Tzakis AG, et al. **Pediatr Transplant** 1998 May; 2(2):87–8. Comment on: Pediatr Transplant 1998 May;2(2):134–8.

Complex posttransplantation abnormalities of renal allografts: evaluation with MR imaging. Ali MG, et al. **Radiology** 1999 Apr;211(1):95–100

The detection of chronic heart graft rejection by 31P NMR spectroscopy. Suzuki K, et al. **Surg Today** 1999;29(2):143–8

Pulmonary circulatory parameters as indices for the early detection of acute rejection after single lung transplantation. Yamamoto H, et al. **Surg Today** 1998; 28(9):900–6

Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Hammer S, et al. **Transpl Immunol** 1998 Dec;6(4):235–41

Intramyocardial electrograms for non-invasive rejection monitoring: initial experience with an infection-specific parameter. Grasser B, et al. **Transpl Int** 1998;11 Suppl 1:S508–11

P-glycoprotein expression is not a useful predictor of acute or chronic kidney graft rejection. Melk A, et al. **Transpl Int** 1999;12(1):10–7

C-reactive protein in the monitoring of acute rejection after heart transplantation. van Gelder T, et al. **Transpl Int** 1998; 11(5):361–4

Assessment of troponin-T for detection of clinical cardiac rejection. Walpoth BH, et al. **Transpl Int** 1998;11 Suppl 1:S502–7

Correlation between biopsies and noninvasive assessment of acute graft dysfunction. Akhtar F, et al. **Transplant Proc** 1998 Nov;30(7):3069

Significance of IL-2, IL-2R, IL-6, and TNF-alpha as a diagnostic test of acute rejection after renal transplantation. Cho WH, et al. **Transplant Proc** 1998 Nov;30(7):2967–9

Predictive indicators of rejection or infection in renal transplant patients. Daniel V, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1364–5

Predictive value of the CD45RO positive T-helper lymphocyte subset for acute cellular rejection during the early phase after kidney transplantation. Erren M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):319–21

Impairment of hepatic microcirculation as an early manifestation of acute rejection after clinical liver transplantation. Klar E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):385–7

Future trends in immunological monitoring of transplant patients. Masri MA, et al. **Transplant Proc** 1998 Nov; 30(7):2979–81

The development of chronic renal allograft rejection may be predicted early following transplantation. O'Malley KJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1352–3

Surrogate end points in chronic kidney graft rejection studies. Paul LC, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1293–4 (17 ref.)

Indications for determination of alpha-glutathione-s-transferase after liver transplantation. Platz KP, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):462–4

A novel monitoring of kidney allograft rejection with plasma EDA(+) fibronectin. Tanaka M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):310–1

Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Nicholson ML, et al. **Transplantation** 1999 Jul 27;68(2):236–41

[Blood flow in the isovolumetric relaxation phase in heart transplant patients. Its use in the noninvasive diagnosis of acute rejection] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):731–8 (Eng. Abstr.) **(Fre)**

[Expansion of the initial depolarized tissue zone in cardiac pacemaker stimulation] Leifhelm M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:508–9 **(Ger)**

[Nuclear matrix protein 22 levels in patients with renal transplantation] Kagebayashi Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep;89(9):774–9 (Eng. Abstr.) **(Jpn)**

[Differential diagnosis of the transplant rejection and herpesvirus-related infections in kidney transplant recipients] Baran EI, et al. **Klin Khir** 1998;(5):11–2 (Eng. Abstr.) **(Rus)**

[Diagnosis and therapy of acute rejection in patients after orthotopic heart transplantation] Schrameková E, et al. **Bratisl Lek Listy** 1998 Dec;99(12):644–6 (Eng. Abstr.) **(Slo)**

DRUG THERAPY

Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Shinn C, et al. **Am J Kidney Dis** 1999 Aug;34(2):304–7

Non-immune factors in chronic rejection. Is there a role for hypolipemic drugs? Pączek L, et al. **Ann Transplant** 1997; 2(2):65–9

The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: a preliminary study [see comments] Lam DS, et al. **Eye** 1998;12 (Pt 4):615–8. Comment in: Eye 1998 ;12 (Pt 4):609–10.

Graft rejection [editorial; comment] Tullo AB. **Eye** 1998;12 (Pt 4):609–10. Comment on: Eye 1998 ;12 (Pt 4):615–8.

Beneficial effects of treatment of early subclinical rejection: a randomized study. Rush D, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2129–34

Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. Carrier M, et al. **J Heart Lung Transplant** 1999 Jul;18(7):664–7 (9 ref.)

Rescue photochemotherapy for the treatment of acute cardiac rejection in the absence of cyclosporine maintenance therapy [letter] DeNofrio D, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1036–7

Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. Horning NR, et al. **J Heart Lung Transplant** 1998 Aug;17(8):761–7

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. Onsager DR, et al. **J Heart Lung Transplant** 1999 May;18(5):448–55

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. Parry N, et al. **J Heart Lung Transplant** 1999 May;18(5):441–7

Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Campistol JM, et al. **Kidney Int** 1999 Aug;56(2):714–9

Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Müller V, et al. **Kidney Int** 1999 May;55(5):2011–20

Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation [see comments] Schnuelle P, et al. **Kidney Int** 1999 Aug;56(2):738–46. Comment in: Kidney Int 1999 Aug;56(2):756–7.

Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis [see comments] Trouillot TE, et al. **Liver Transpl Surg** 1999 Sep;5(5):375–80 . Comment in: Liver Transpl Surg 1999 Sep;5(5):460–3.

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates [see comments] Kirk AD, et al. **Nat Med** 1999 Jun;5(6):686–93. Comment in: Nat Med 1999 Jun;5(6):616–7.

Mycophenolate-update after it has come of age [editorial] Grinyó JM. **Nephrol Dial Transplant** 1999 Jan;14(1):31–4 (14 ref.)

Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF. **Pediatr Transplant** 1998 Feb;2(1):35–9 (24 ref.)

Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):111–21

Early use of tacrolimus as rescue therapy for refractory liver allograft rejection. Charco R, et al. **Transpl Int** 1998;11 Suppl 1:S313–7

Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Filler G, et al. **Transpl Int** 1998;11 Suppl 1:S82–5

Tacrolimus for steroid-resistant liver rejection in children. Jara P, et al. **Transpl Int** 1998;11 Suppl 1:S275–7

Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. Reggiani P, et al. **Transpl Int** 1998;11 Suppl 1:S272–4

Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Theodorakis J, et al. **Transpl Int** 1998;11 Suppl 1:S86–9

Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. Campistol JM, et al. **Transplant Proc** 1999 Sep;31(6):2267–9

Effects of deoxyspergualin (DSG) administered in the chronic phase following kidney transplantation. Fudaba Y, et al. **Transplant Proc** 1998 Nov;30(7):3582–3

FK506 rescue therapy for acute renal allograft rejection. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3592–3

FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3594–5

Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. Hung CM, et al. **Transplant Proc** 1998 Nov;30(7):3589

Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. Jiang H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1203–5

Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience. Jirasiritham S, et al. **Transplant Proc** 1998 Nov;30(7):3576–7

Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Kato T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):396

Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients. Kliem V, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1312–3

CD26/DPP IV-mediated modulation of acute rejection. Korom S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):873

Usefulness of 15-deoxyspergualin for rejection in renal transplantation. Kozaki K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1138–9

Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Lo CM, et al. **Transplant Proc** 1998 Nov;30(7):3587–8

Low-dose OKT3 is not effective in the treatment of steroid-resistant acute renal allograft rejections. Lye WC, et al. **Transplant Proc** 1998 Nov;30(7):3106–7

Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid-responsive acute rejection. Morales E, et al. **Transplant Proc** 1999 Sep; 31(6):2248–9

Is the use of marginal liver grafts justified? Mueller AR, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):401–2

Effect of deoxyspergualin on acute and chronic rejection in renal transplantation. Nomura Y, et al. **Transplant Proc** 1998 Nov;30(7):3580–1

Effectiveness of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade. Papadimitriou JC, et al. **Transplant Proc** 1998 Dec;30(8):3945

Correlation between Banff classification acute rejection scores and reversal of rejection. Park KK, et al. **Transplant Proc** 1998 Nov;30(7):3067–8

Graft outcome in patients with biopsy-proven chronic renal allograft rejection. Peddi VR, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1308–9

High risk kidney transplant rejection treatment: cost savings from thymoglobulin. Schnitzler MA, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):269–71

Costs savings associated with thymoglobulin for treatment of acute renal transplant rejection in patient subsets. Schnitzler MA, et al. **Transplant Proc** 1999 May;31(3B Suppl):7S–8S

Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1184–8

The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design. Schroeder TJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):1S–6S (42 ref.)

Photopheresis after cardiac transplantation induces apoptosis. Schürfeld K, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):125–7

A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. Shu KH, et al. **Transplant Proc** 1998 Nov;30(7):3584–6

Rescue effect of FTY720 on acute renal rejection in dogs. Yuzawa K, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):872

Histological outcome of acute cellular rejection in kidney transplantation after treatment with methylprednisolone. Mazzucchi E, et al. **Transplantation** 1999 Feb 15; 67(3):430–4

Antithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection. Okada Y, et al. **Transplantation** 1999 Feb 27;67(4):526–8

ECONOMICS

Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Baker GM, et al. **Transplant Proc** 1998 Dec;30(8):4082–4

One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Khosla UM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):274–5

[Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-0157 Study in 224 patients (Germany)] Bachinger A, et al. **Chirurg** 1998 Sep;69(9):957–62 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice. Koglin J, et al. **Am J Pathol** 1998 Nov;153(5):1371–6

Time course and cellular localization of inducible nitric oxide synthases expression during cardiac allograft rejection. Worrall NK, et al. **Ann Thorac Surg** 1999 Mar;67(3):716–22

Attenuated acute cardiac rejection in NOS2 –/– recipients correlates with reduced apoptosis. Koglin J, et al. **Circulation** 1999 Feb 16;99(6):836–42

Expression of cell division cycle 2 kinase transcription in chronically rejected cardiac allografts of nonhuman primates. Schoenbeck A, et al. **Heart Vessels** 1997; 12(6):275–9

Inducible nitric oxide synthase expression in vascular and glomerular structures of human chronic allograft nephropathy. Romagnani P, et al. **J Pathol** 1999 Feb; 187(3):345–50

Urinary excretion of proteins and tubular enzymes in renal transplant patients. Donadio C, et al. **Ren Fail** 1998 Sep; 20(5):707–15

EPIDEMIOLOGY

Are all successful renal transplants really successful? Aultman DF, et al. **Am J Kidney Dis** 1999 Jul;34(1):61–4

Donor cardiac troponin T: a marker to predict heart transplant rejection. Vijay P, et al. **Ann Thorac Surg** 1998 Dec;66(6):1934–9

Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Stucki A, et al. **Blood** 1998 Oct 15;92(8):2742–9

Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. Nickerson P, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1801–5

Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. Sorof JM, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1324–30

Influence of donor factors on early function of graft kidneys. Suri D, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1317–23

Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Sankaran D, et al. **Kidney Int** 1999 Jul;56(1):281–8

Incidence, timing, and risk factors for acute and chronic rejection. Neuberger J. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S30–6 (34 ref.)

Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil. Wüthrich RP, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):394–9

The effect of acute rejection on long-term renal graft survival is mainly related to initial renal damage. Heaf JG, et al. **Transpl Int** 1998;11 Suppl 1:S26–31

Experience with the Wujciak-Opelz allocation system in a single center: an increase in HLA-DR mismatching and in early occurring acute rejection episodes [see comments] Vereerstraeten P, et al. **Transpl Int** 1998;11(5):378–81. Comment in: Transpl Int 1999;12(1):74.

Single-center analysis of the incidence of acute rejection in cadaveric renal allograft recipients induced with low-dose OKT3 with and without mycophenolate mofetil. Abdulbaki A, et al. **Transplant Proc** 1999 Aug;31(5):2112–3

No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Hillebrand GF, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1391–2

Rejection rate and incidence of acute tubular necrosis after pulsatile perfusion preservation. Kosieradzki M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):278–9

Postischemic reperfusion injury and allograft dysfunction: is allograft rejection the result of a fateful confusion by the immune system of danger and benefit? Land W. **Transplant Proc** 1999 Feb–Mar;31(1–2):332–6 (20 ref.)

Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation. Maggi U, et al. **Transplant Proc** 1998 Dec;30(8):3946–7

Predisposing factors in the development of chronic allograft dysfunction. Moray G, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1300–1

Should aging recipients of kidney grafts receive less immunosuppression? Palomar R, et al. **Transplant Proc** 1999 Sep;31(6):2277–8

Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Seydoux C, et al. **Transplant Proc** 1998 Dec;30(8):4037–43

Low systemic exposure to tacrolimus correlates with acute rejection. Undre NA, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):296–8

ETIOLOGY

A middle-aged woman with refractory graft dysfunction in the early posttransplant period. Geiger X, et al. **Am J Kidney Dis** 1999 May;33(5):998–1003

Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Vanholder R, et al. **Am J Kidney Dis** 1999 May;33(5):934–40

Late graft rejection and second infusion of bone marrow in children with aplastic anaemia [see comments] Eapen M, et al. **Br J Haematol** 1999 Jan;104(1):186–8. Comment in: Br J Haematol 1999 May;105(2):570–1.

Endothelial cells as antigen-presenting cells: role in human transplant rejection. Rose ML. **Cell Mol Life Sci** 1998 Sep; 54(9):965–78 (122 ref.)

Direct antigen presentation and chronic rejection [letter; comment] Hosenpud JD. **Circulation** 1999 May 25; 99(20):2710–11. Comment on: Circulation 1998 Apr 7;97(13):1257–63.

Rapidly progressive renal graft failure associated with interferon-alpha treatment in a patient with chronic myelogenous leukemia [letter] Bren A, et al. **Clin Nephrol** 1998 Oct;50(4):266–7

Male recipients of kidneys from female donors are at increased risk of graft loss from both rejection and technical failure. Vereerstraeten P, et al. **Clin Transplant** 1999 Apr; 13(2):181–6

Pathogenesis of chronic allograft nephropathy [editorial] Paul LC. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):635–7 (17 ref.)

Chronic rejection and chronic cyclosporin toxicity in renal allografts. Pascual M, et al. **Immunol Today** 1998 Nov; 19(11):514–9

Causes of corneal graft failure in India. Dandona L, et al. **Indian J Ophthalmol** 1998 Sep;46(3):149–52

The role of lipid lowering in transplantation. Wierzbicki AS. **Int J Clin Pract** 1999 Jan–Feb;53(1):54–9 (78 ref.)

Increase in orthotopic murine corneal transplantation rejection rate with anterior synechiae. Yamagami S, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2422–6

Characterization of allograft rejection in an experimental model of small intestinal transplantation. Hayashi M, et al. **J Gastrointest Surg** 1998 Jul–Aug;2(4):325–32

De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. Fedoseyeva EV, et al. **J Immunol** 1999 Jun 1; 162(11):6836–42

Instillation of allogeneic lung macrophages and dendritic cells cause differential effects on local IFN-gamma production, lymphocytic bronchitis, and vasculitis in recipient murine lungs. Wilkes DS, et al. **J Leukoc Biol** 1998 Nov;64(5):578–86

The role of CD8+ cells and CD11a in the rejection-reaction of the allogeneic microskin grafting. Lin SD, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Aug; 14(8):464–72

Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Lu CY, et al. **Kidney Int** 1999 Jun;55(6):2157–68 (153 ref.)

Use of older donor livers is associated with more extensive ischemic damage on intraoperative biopsies during liver transplantation [see comments] Deschênes M, et al. **Liver Transpl Surg** 1999 Sep;5(5):357–61. Comment in: Liver Transpl Surg 1999 Sep;5(5):458–9.

Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Totsuka E, et al. **Liver Transpl Surg** 1999 Sep;5(5):421–8

Discontinuing trimethoprim-sulfamethoxazole prophylaxis does not lead to increased risk of rejection in renal transplant patients with stable graft function [letter] McLaughlin K, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2428

De novo diabetes mellitus in kidney allografts: nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. Owda AK, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):2004–7

Evaluation of triggers for corneal graft rejection. Miedziak AI, et al. **Ophthalmic Surg Lasers** 1999 Feb;30(2):133–9

Initial endothelial cell density and chronic endothelial cell loss rate in corneal transplants with late endothelial failure. Nishimura JK, et al. **Ophthalmology** 1999 Oct; 106(10):1962–5

Early acute rejection and kidney allograft outcome in children [editorial; comment] Chavers B. **Pediatr Transplant** 1998 Nov;2(4):254–6 (13 ref.). Comment on: Pediatr Transplant 1998 Nov;2(4):294–8.

Renal graft survival in children with early acute rejection [see comments] Muñoz R, et al. **Pediatr Transplant** 1998 Nov;2(4):294–8. Comment in: Pediatr Transplant 1998 Nov;2(4):254–6.

Effect of parental donor sex on rejection in pediatric renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study. Neu AM, et al. **Pediatr Transplant** 1998 Nov;2(4):309–12

The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Tejani AH, et al. **Pediatr Transplant** 1998 Nov;2(4):318–24

Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Kucharská J, et al. **Physiol Res** 1998;47(6):399–404

Non-immune mechanisms of progressive graft dysfunction. Ritz E, et al. **Przegl Lek** 1998;55 Suppl 1:40

Alpha beta TCR+ T cells play a nonredundant role in the rejection of heart allografts in mice. Exner BG, et al. **Surgery** 1999 Aug;126(2):121–6

Hypertension accelerates the pace of chronic graft dysfunction in the rat. Szabo A, et al. **Transpl Int** 1998; 11 Suppl 1:S10–4

Postischemic reperfusion injury and allograft arteriosclerosis. Fellström B, et al. **Transplant Proc** 1998 Dec;30(8):4278–80 (36 ref.)

Immunologic and nonimmunologic risk factors of chronic rejection. Fellström B, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1304–5 (20 ref.)

Late renal allograft loss: noncompliance masquerading as chronic rejection. Gaston RS, et al. **Transplant Proc** 1999 Jun;31(4A):21S–23S

Ischemia reperfusion injury and chronic allograft rejection. Szabo A, et al. **Transplant Proc** 1998 Dec;30(8):4281–4 (59 ref.)

Chronic rejection and its risk factors. Tilney NL. **Transplant Proc** 1999 Feb–Mar;31(1–2A):41S–44S (42 ref.)

Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Knoflach A, et al. **Transplantation** 1999 Mar 27; 67(6):909–14

[Non-immunologic factors of failure of penetrating keratoplasties. Prospective study of 119 corneal grafts at the Nantes Hospital Center in 1995] Vabres B, et al. **J Fr Ophtalmol** 1999 Feb;22(1):33–8 (Eng. Abstr.) **(Fre)**

[Risk factors of chronic rejection in kidney transplantation, results of a single center study] Delmas S, et al. **Nephrologie** 1999;20(3):153–8 (Eng. Abstr.) **(Fre)**

GENETICS

Impact of the MHC-encoded HLA-DMA, DMB, and LMP2 gene polymorphisms on kidney graft outcome. Chevrier D, et al. **Hum Immunol** 1998 Oct;59(10):650–5

Genetic mapping of the embryonal carcinoma transplantation resistance locus Gt(B6) to mouse Chromosome 8. Muller AJ, et al. **Immunogenetics** 1999 Oct;49(11–12):949–56

Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism? Broekroelofs J, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2075–81

The role of DRB1 amino acid residue differences on donor-specific antibody production and acute rejection after cadaveric renal transplant. Adorno D, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):32–6

Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection [see comments] Ohdan H, et al. **J Clin Invest** 1999 Aug;104(3):281–90. Comment in: J Clin Invest 1999 Aug;104(3):227–8.

Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. El-Gamel A, et al.

J Heart Lung Transplant 1999 Jun;18(6):517-23

Adhesion molecule polymorphisms in chronic renal allograft failure. McLaren AJ, et al. **Kidney Int** 1999 May; 55(5):1977-82

Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Sankaran D, et al. **Kidney Int** 1999 Jul;56(1):281-8

Expression of tumor necrosis factor-alpha gene during allograft rejection following rat liver transplantation. Teramoto K, et al. **Liver** 1999 Feb;19(1):19-24

Role of the bcl-2/bax pathway in hepatocyte apoptosis during acute rejection after rat liver transplantation. Yamamoto H, et al. **Transpl Int** 1998;11 Suppl 1:S179-84

Cytokine gene polymorphisms and relevance to forms of rejection. Hutchinson IV, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):734-6 (17 ref.)

Genetic polymorphism in the IL-10 promoter region in renal transplantation. Kobayashi T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):755-6

Microchimerism in thymus is associated with up-regulated T helper type 1 cytokine transcription during cardiac allograft rejection in rats. Ota H, et al. **Transplantation** 1999 Jan 15;67(1):165-73

Comparative analysis of three genetic modifications designed to inhibit human serum-mediated cytolysis. Costa C, et al. **Xenotransplantation** 1999 Feb;6(1):6-16

IMMUNOLOGY

Posttransplantation cytotoxic immunoglobulin G is associated with a high rate of acute allograft dysfunctions in heart transplant recipients. Leprince P, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):586-92

Interferon-gamma-secreting T-cell populations in rejecting murine cardiac allografts: assessment by flow cytometry. Stinn JL, et al. **Am J Pathol** 1998 Nov;153(5):1383-92

T cell apoptosis in human heart allografts: association with lack of co-stimulation? Van Hoffen E, et al. **Am J Pathol** 1998 Dec;153(6):1813-24

Scintigraphy and immunohistology of antimyosin-Fab during graft rejection. Breuer M, et al. **Angiology** 1999 Jul; 50(7):563-71

Factors in xenograft rejection. Robson SC, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:261-76 (131 ref.)

Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells. Slavin S, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:37-44

Daily noninvasive rejection monitoring improves long-term survival in pediatric heart transplantation. Hetzer R, et al. **Ann Thorac Surg** 1998 Oct;66(4):1343-9

Extracellular matrix proteins: bystanders or active participants in the allograft rejection cascade? Coito AJ, et al. **Ann Transplant** 1996;1(3):14-8 (35 ref.)

Protection of heart and rejection of lymphocyte allografts from the same donor in recipients of donor-specific transfusions. Jasklowska-Englisz M, et al. **Ann Transplant** 1998;3(1):28-33

Chronic rejection from bedside to bench: role of T cells. Knoflach A, et al. **Ann Transplant** 1997;2(2):53-60 (139 ref.)

Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34-40 (61 ref.)

Pathways of antigen traffic from skin allotransplant to recipient lymph nodes--an evolutionarily developed route for initiation of rejection of foreign antigens. Olszewski WL, et al. **Ann Transplant** 1998;3(4):15-20 (38 ref.)

Antibodies and chronic organ graft rejection. Paul LC. **Ann Transplant** 1997;2(2):46-52 (98 ref.)

Sirolimus, a potent new immunosuppressive drug for organ transplantation. Stepkowski SM. **Ann Transplant** 1996; 1(3):19-25 (71 ref.)

Inflammatory mediators, cells and their products in acute host alloresponsiveness. Tilney NL, et al. **Ann Transplant** 1996;1(3):5-13 (97 ref.)

Immunophenotyping fish-to-mouse islet xenograft rejection: a time course study. Wright JR Jr, et al. **Ann Transplant** 1997;2(3):12-6

Clinical consequences of sensitisation to minor histocompatibility antigens before allogeneic bone marrow transplantation. Rufer N, et al. **Bone Marrow Transplant** 1998 Nov;22(9):895-8

Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection? Yoshida EM, et al. **Can J Gastroenterol** 1998 Sep;12(6):387-9

Immunodetection of lymphocyte subpopulations involved in allograft rejection in a teleost, Dicentrarchus labrax (L.). Abelli L, et al. **Cell Immunol** 1999 Feb 1;191(2):152-60

Endothelial cells as antigen-presenting cells: role in human transplant rejection. Rose ML. **Cell Mol Life Sci** 1998 Sep; 54(9):965-78 (122 ref.)

Analysis of the Th1/Th2 paradigm in transplantation: interferon-gamma deficiency converts Th1-type proislet allograft rejection to a Th2-type xenograft-like response. Simeonovic CJ, et al. **Cell Transplant** 1999 Jul-Aug; 8(4):365-73

A study of endothelial cell-lymphocyte responses in human renal transplantation. Abdulkarim AB, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):113-22

Hyperacute rejection from antibody against class II HLA antigens. Ghasemian SR, et al. **Clin Transplant** 1998 Dec; 12(6):569-71

Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Moudgil A, et al. **Clin Transplant** 1999 Apr;13(2):201-7

The immunology of corneal graft rejection. Rocha G, et al. **Crit Rev Immunol** 1998;18(4):305-25 (156 ref.)

Islet transplantation: present and future perspectives. Kenyon NS, et al. **Diabetes Metab Rev** 1998 Dec;14(4):303-13 (100 ref.)

Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. McCarthy JF, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):197-200

Anergic T cells act as suppressor cells in vitro and in vivo. Chai JG, et al. **Eur J Immunol** 1999 Feb;29(2):686-92

CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. Wise M, et al. **Eur J Immunol** 1999 Jan;29(1):156-67

An improved method for examining the corneal endothelium during graft rejection in the rat. Figueiredo FC, et al. **Exp Eye Res** 1998 Dec;67(6):625-30

Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. Gröne HJ, et al. **FASEB J** 1999 Aug; 13(11):1371-83

Direct and indirect antigen recognition: the pathways to allograft immune rejection. Benichou G. **Front Biosci** 1999 May 15;4:D476-80 (30 ref.)

Effects of complement suppression on xenograft survival in hyperacute rejection. Mukai S, et al. **Hiroshima J Med Sci** 1999 Mar;48(1):17-24

The metalloproteinase-mediated pathway is essential for generation of soluble HLA class I proteins by activated cells in vitro: proposed mechanism for soluble HLA release in transplant rejection. DeVito-Haynes LD, et al. **Hum Immunol** 1998 Jul;59(7):426-34

Intramolecular and intermolecular spreading during the course of organ allograft rejection. Suciu-Foca N, et al. **Immunol Rev** 1998 Aug;164:241-6 (42 ref.)

Direct and indirect recognition: the role of MHC antigens in graft rejection. Gould DS, et al. **Immunol Today** 1999 Feb;20(2):77-82 (28 ref.)

Paradoxical early immune activation during acceptance of liver allografts compared with rejection of skin grafts in a rat model of transplantation. Rokahr KL, et al. **Immunology** 1998 Oct;95(2):257-63

Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection. Wang JD, et al. **Immunology** 1998 Sep;95(1):56-61

CD40-CD154 interaction in experimental and human disease (review). Biancone L, et al. **Int J Mol Med** 1999 Apr; 3(4):343-53 (112 ref.)

T-cell-mediated immune responses in alloepithelial rejection after murine keratoepithelioplasty. Miyazaki D, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2590-7

Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Yamada J, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2614-21

Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. Grimm PC, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1582-9

T cell costimulatory blockade: new therapies for transplant rejection. Gudmundsdottir H, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1356-65 (72 ref.)

Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. Van Kooten C, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1526-34

The role of DRB1 amino acid residue differences on donor-specific antibody production and acute rejection after cadaveric renal transplant. Adorno D, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar;13(1):32-6

Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. Le Moine A, et al. **J Clin Invest** 1999 Jun;103(12):1659-67

CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. Afford SC, et al. **J Exp Med** 1999 Jan 18;189(2):441-6

m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. Cretney E, et al. **J Exp Med** 1999 Aug 2;190(3):435-44

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. van Elsas A, et al. **J Exp Med** 1999 Aug 2;190(3):355-66

Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection. Kawahara T, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S119-23 (55 ref.)

RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. Azzawi M, et al. **J Heart Lung Transplant** 1998 Sep;17(9):881-7

The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1195-200

Mixed hematopoietic chimerism prevents allograft vasculopathy. Kawaharada N, et al. **J Heart Lung Transplant** 1999 Jun;18(6):532-41

Role of selectin-dependent adhesion in cardiac allograft rejection. Yamazaki S, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1007-16

Increased expression of interleukin-4 during liver allograft rejection. Conti F, et al. **J Hepatol** 1999 May;30(5):935-43

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode. Lohse AW, et al. **J Hepatol** 1999 Jul;31(1):149-55

Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. Antonysamy MA, et al. **J Immunol** 1999 Jan 1;162(1):577-84

Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. Benichou G, et al. **J Immunol** 1999 Jan 1;162(1):352-8

Expression of L-selectin ligands by transformed endothelial cells enhances T cell-mediated rejection. Biancone L, et al. **J Immunol** 1999 May 1;162(9):5263-9

Human CD4+ T cells mediate rejection of porcine xenografts. Friedman T, et al. **J Immunol** 1999 May 1; 162(9):5256-62

Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. Heeger PS, et al. **J Immunol** 1999 Aug 15;163(4):2267-75

IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. Le Moine A, et al. **J Immunol** 1999 Oct 1;163(7):3778-84

Rejection of cardiac xenografts by CD4+ or CD8+ T cells. Lin Y, et al. **J Immunol** 1999 Jan 15;162(2):1206-14

Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. Lin Y, et al. **J Immunol** 1999 Sep 1;163(5):2850-7

Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection. Lukacher AE, et al. **J Immunol** 1999 Sep 15;163(6):3369-78

Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape. Matsuo M, et al. **J Immunol** 1999 Jun 1;162(11):6420-5

The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium: implications for xenotransplantation. Robinson LA, et al. **J Immunol** 1998 Dec 15;161(12):6931-8

Accelerated rejection of Fas ligand-expressing heart grafts. Takeuchi T, et al. **J Immunol** 1999 Jan 1;162(1):518-22

Linked suppression of skin graft rejection can operate through indirect recognition. Wise MP, et al. **J Immunol** 1998 Dec 1;161(11):5813-6

Dendritic cells/chimerism/alleviation of chronic allograft rejection. Murase N, et al. **J Leukoc Biol** 1999 Aug; 66(2):297-300 (15 ref.)

Fetal islet xenotransplantation in rodents and primates. Mandel TE. **J Mol Med** 1999 Jan;77(1):155-60 (43 ref.)

Analysis of the cellular reaction towards microencapsulated xenogeneic islets after intraperitoneal transplantation. Siebers U, et al. **J Mol Med** 1999 Jan;77(1):215-8

The effects of early and delayed immunosuppression in experimental tracheal transplantation with omentopexy. Maksoud-Filho JG, et al. **J Pediatr Surg** 1999 Aug; 34(8):1223-8

Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. Macchiarini P, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):831-43

Cytotoxic T lymphocytes directed against donor HLA class I antigens on airway epithelial cells are present in bronchoalveolar lavage fluid from lung transplant recipients during acute rejection. Nakajima J, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):565-71

The future of organ and tissue transplantation: can T-cell costimulatory pathway modifiers revolutionize the prevention of graft rejection? Harlan DM, et al. **JAMA** 1999 Sep 15;282(11):1076-82 (68 ref.)

Chronic rejection of mouse kidney allografts. Mannon RB, et al. **Kidney Int** 1999 May;55(5):1935-44

Low level of interleukin 10 synthesis during liver allograft rejection. Conti F, et al. **Lab Invest** 1998 Oct;78(10):1281-9

Primary liver disease as a determinant for acute rejection after liver transplantation. Seiler CA, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):259-63

Rank tests for matched survival data. Jung SH. **Lifetime Data Anal** 1999;5(1):67-79

Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Charlton M, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S107-14

Immunology of acute and chronic hepatic allograft rejection. Vierling JM. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S1-S20 (215 ref.)

A new rat model to study the correlation of cardiac and skeletal muscle allograft rejection. Blanchard J, et al. **Microsurgery** 1998;18(7):406-9

Indirect recognition of allo MHC peptides--potential role in human transplantation [editorial] Watschinger B.

Nephrol Dial Transplant 1999 Jan;14(1):8–11 (29 ref.)

Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Denton MD, et al. **Pediatr Transplant** 1998 Feb;2(1):6–15 (81 ref.)

Current understanding of chemokine involvement in allograft transplantation. Melter M, et al. **Pediatr Transplant** 1999 Feb;3(1):10–21 (113 ref.)

On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses. DeVries ME, et al. **Semin Immunol** 1999 Apr; 11(2):95–104 (76 ref.)

Platelets as participants in hyperacute guinea pig–to–rat lung xenorejection. Nonaka M, et al. **Surg Today** 1999; 29(3):255–9

HLA–A and –B alleles in cornea donors as risk factors for graft rejection. Creemers PC, et al. **Transpl Immunol** 1999 Mar;7(1):15–8

Effective chemokines and cytokines in the rejection of human retinal pigment epithelium (RPE) cell grafts. Enzmann V, et al. **Transpl Immunol** 1999 Mar;7(1):9–14

Pre–transplant donor–specific transfusions induce allograft rejection and IL–2 gene expression in the WKY––>F344 functional tolerance model of rat lung transplantation. Okada Y, et al. **Transpl Immunol** 1998 Sep;6(3):137–46

An association between antibodies specific for endothelial cells and renal transplant failure. Perrey C, et al. **Transpl Immunol** 1998 Jun;6(2):101–6

Trafficking of APC from liver allografts of Flt3L–treated donors: augmentation of potent allostimulatory cells in recipient lymphoid tissue is associated with a switch from tolerance to rejection. Steptoe RJ, et al. **Transpl Immunol** 1999 Mar;7(1):51–7

Kinetics of circulating cytotoxic T lymphocyte precursors that have a high avidity for donor antigens: correlation with the rejection status of the human cardiac allograft. van Emmerik NE, et al. **Transpl Immunol** 1998 Sep; 6(3):153–60

Redundancy of the cytokine network in the development of rejection after clinical heart transplantation. Baan CC, et al. **Transpl Int** 1998;11 Suppl 1:S512–4

Factors relevant for the induction of rejection by indirect recognition in a rat heart allograft model: effect of CTLA4Ig treatment on indirect alloactivation induced by immunization with donor MHC I peptides. Dufter C, et al. **Transpl Int** 1998;11 Suppl 1:S361–3

Analysis of the microcirculation during xenogeneic liver perfusion in the guinea pig––rat model. The contribution of leukocytes to the rejection process. Linke R, et al. **Transpl Int** 1998;11 Suppl 1:S457–60

In vivo migration of lymphocytes in chronically rejecting rat kidney allografts. Müller V, et al. **Transpl Int** 1999; 12(2):145–51

Postoperative production of anti–donor antibody and early graft loss due to vascular rejection in renal transplantation. Abe M, et al. **Transplant Proc** 1998 Nov;30(7):2963

The role of beta–pleated sheet DRB1 differences in acute rejection after cadaveric renal transplant. Adorno D, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):730–3

In vitro pretransplant mixed lymphocyte culture response and acute rejection episodes. Agrawal S, et al. **Transplant Proc** 1998 Nov;30(7):2974

Relation between ABO blood type antigen and antibody and acute vascular rejection in ABO incompatible kidney transplantation. Aikawa A, et al. **Transplant Proc** 1998 Nov; 30(7):3507–9

Analysis of rejection mechanisms in small bowel allotransplantation. Ashizuka S, et al. **Transplant Proc** 1998 Nov;30(7):3469–70

TAP1 mutant mice reject heart grafts from donors with no MHC disparity. Coelho V, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):900–1

Indirect allorecognition is involved in both acute and chronic allograft rejection. Fluck N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):842–3

Significance of anti–Gal IgG in chronic xenograft rejection. Galili U. **Transplant Proc** 1999 Feb–Mar;31(1–2):940–1 (14 ref.)

Kupffer cell expression of CD40L (CD154) in human chronic liver allograft rejection. Gaweco AS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):560–1

CD40 upregulation in TCR alpha/beta+ CD68+ cells and parenchymal CD40L induction and associated with NF–kappa B activation in chronic rejecting human renal allografts. Gaweco AS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1359–60

In vivo differentiation of alloreactive CD8+ T cells after murine cardiac allograft transplantation. Gilot BJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):130

Time course of chemokine expression in acutely rejecting rat kidneys. Grau V, et al. **Transplant Proc** 1999 May; 31(3):1571

Hyperacute rejection models: ex vivo xenoperfusion systems. Grinyo JM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):970–1 (15 ref.)

Chronic rejection: an update on the mechanism. Häyry P. **Transplant Proc** 1998 Dec;30(8):3993–5 (24 ref.)

Differential effect of an anti–CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. He G, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1239–41

Cytokine gene polymorphisms and relevance to forms of rejection. Hutchinson IV, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):734–6 (17 ref.)

Cytokine genotypes in allograft rejection: guidelines for immunosuppression. Hutchinson IV, et al. **Transplant Proc** 1998 Dec;30(8):3991–2 (11 ref.)

Chronic rejection in cyclosporin A treated renal allograft recipients with allopeptide reactive T cells. Iniotaki–Theodoraki A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1168–70

Expression of ICAM–1 and VCAM–1 in renal allograft rejection. Jeong HJ, et al. **Transplant Proc** 1998 Nov; 30(7):2953–4

Inhibition of IL–10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. Jiang H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1203–5

T cell–mediated effector mechanisms in the rejection of allogeneically transplanted hepatocytes. Kawahara T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):830–1

T–cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):342–3 (19 ref.)

Rejection of hamster cardiac xenografts by rat CD4+ or CD8+ T cells. Lin Y, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):959–60

Vascular rejection in cardiac transplantation. McCarthy JF, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):160

Expression of Fas/Fas ligand and apoptosis induction during renal allograft rejection. Matsuno T, et al. **Transplant Proc** 1998 Nov;30(7):2947–9

Donor cell population in the liver allograft reflects the recipient immune status. Meyer D, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):437

Apoptosis of alloreactive T cells in liver allografts during tolerance induction. Meyer D, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):474

CD30+ and CD27– lymphocytes in liver transplant: Th2 cytokine secretion. Minguela A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):516–8

Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. Nakai T, et al. **Transplant Proc** 1999 Sep;31(6):2661–4

Donor antigen–independent effector mechanisms of graft rejection: a novel cell surface target of IL–2–activated natural killer cells. Norin AJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):787–8

Acute rejection and the flow cytometry crossmatch. O'Malley KJ, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1216–7

Peripheral blood lymphocyte phenotype can predict rejection episodes after orthotopic liver transplantation. Perdigoto R, et al. **Transplant Proc** 1999 Sep;31(6):2418–20

Calcitriol induces apoptosis of incubated lymphocyte T cells from patients with acute renal graft rejection. Pérez R, et al. **Transplant Proc** 1999 Sep;31(6):2311–3

CD4 T cells acutely reject cardiac allografts via direct donor recognition. Pietra B, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):92

Mechanism of liver allograft rejection: indirect allorecognition. Renna–Molajoni E, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):409–10

Detection of allo– and autoantibodies in kidney transplantation by flow cytometry. Rodríguez PC, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):282–4

Involvement of Th1 subset in allogeneic keratinocyte rejection. Rouabhia M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):896

The role of cytokines in rejection of discordant xenotransplants. Saadi S, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):911–2 (18 ref.)

Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):851–3

Influence of clinical immunosuppression on proinflammatory cytokines and acute–phase proteins. Semenkov VF, et al. **Transplant Proc** 1998 Dec;30(8):4195

Immunosuppression through inhibition of interleukin–2/interleukin–2 receptor interaction. Soulillou JP. **Transplant Proc** 1999 Feb–Mar;31(1–2A):49S–51S (23 ref.)

Different roles for alpha 4–integrin/VCAM–1 and alpha 4/fibronectin interactions in allograft rejection. Stegall MD, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):786

The role of Fas/FasL apoptotic pathway in the development of chronic rejection. Subbotin V, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1397–8

Persistent allopeptide reactivity and epitope spreading in chronic rejection. Suciu–Foca N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):100–1

Indirect allorecognition of donor HLA–DR peptides in chronic rejection of heart allografts. Suciu–Foca N, et al. **Transplant Proc** 1998 Dec;30(8):3999–4000

Specific immunosuppression of the indirect recognition pathway. Suciu–Foca N, et al. **Transplant Proc** 1998 Dec; 30(8):4009–10

Specific immunosuppression of the indirect recognition pathway. Suciu–Foca N, et al. **Transplant Proc** 1998 Dec; 30(8):4060–1

Humoral immunity in acute cellular rejection after living–donor liver transplantation. Takakura K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):526–7

Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. Takeda M, et al. **Transplant Proc** 1998 Nov;30(7):3813–4

Complete reversal of acute rejection episodes after syngeneic retransplantation is associated with a TH1/TH2 shift. Tullius SG, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):340–1

Rejection of discordant skin xenografts by CD4– CD8– TCR alpha beta+ cells in CD4– and CD8–deficient mice. Umesue M, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):890–1

Integrins and T helper cell activation [see comments] van Seventer GA, et al. **Transplant Proc** 1998 Dec;30(8):4270–4 (60 ref.). Comment in: Transplant Proc 1998 Dec;30(8):4269.

Cellular immune reaction in hyperacute rejection. Wada S, et al. **Transplant Proc** 1998 Nov;30(7):3818–20

Inhibition of acute cardiac allograft rejection in immunoglobulin–deficient mice. Wasowska BA, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):136

Differences in cellular mechanisms between heart and skin graft rejection by in vitro and in vivo analyses. Yamamoto T, et al. **Transplant Proc** 1998 Nov;30(7):3854

Second–set rejection of skin allografts mediated by a T–cell subset in a chimeric mouse model. Yoshimura R, et al. **Transplant Proc** 1998 Nov;30(7):3858–9

CD8+ T lymphocytes account for acute accelerated allograft rejection in the rag mouse model. Yoshimura R, et al. **Transplant Proc** 1998 Nov;30(7):2952

Antithrombin III inhibits T and B lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Zuo XJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):847–8

Antithrombin III inhibits T– and B–lymphocyte activation in vitro and improves parameters of inflammation in a rat model of acute lung allograft rejection. Zuo XJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):816–7

Evidence for heat shock protein immunity in a rat cardiac allograft model of chronic rejection. Duquesnoy RJ, et al. **Transplantation** 1999 Jan 15;67(1):156–64

Contribution of CD40–CD154–mediated costimulation to an alloresponse in vivo. Förster E, et al. **Transplantation** 1999 May 15;67(9):1284–7

Prevention and restoration of second–set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Fu F, et al. **Transplantation** 1999 Feb 15;67(3):444–50

Repeat donor HLA–DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA–DR alloantibodies? Fuller A, et al. **Transplantation** 1999 Aug 27;68(4):589–91

Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. Kasahara M, et al. **Transplantation** 1999 Feb 27;67(4):568–75

A murine model of antibody–mediated hyperacute rejection by galactose–alpha(1,3)galactose antibodies in Gal o/o mice. McKenzie IF, et al. **Transplantation** 1998 Sep 27; 66(6):754–63

Anti–Gal antibody–mediated allograft rejection in alpha1,3–galactosyltransferase gene knockout mice: a model of delayed xenograft rejection. Pearse MJ, et al. **Transplantation** 1998 Sep 27;66(6):748–54

Impact of transfusions and acute rejection on posttransplantation donor antigen–specific responses in two study populations. Cooperative Clinical Trial in Transplantation Research Group. Reinsmoen NL, et al. **Transplantation** 1999 Mar 15;67(5):697–702

Immune mechanisms associated with the rejection of fetal murine proislet allografts and pig proislet xenografts: comparison of intragraft cytokine mRNA profiles. Simeonovic CJ, et al. **Transplantation** 1999 Apr 15; 67(7):963–71

Immunomodulation of fetal pig islet–like cell clusters by gamma–irradiation. Deol HS, et al. **Xenotransplantation** 1999 May;6(2):141–6

Intravital microscopic investigation of xenogeneic microcirculation and impact of complement depletion by cobra venom factor. Diefenbeck M, et al. **Xenotransplantation** 1998 Nov;5(4):262–73

T cell–mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Dorling A, et al. **Xenotransplantation** 1998 Nov;5(4):234–45 (119 ref.)

IgG, but not IgM, mediates hyperacute rejection in hepatic xenografting. Schraa EO, et al. **Xenotransplantation** 1999 May;6(2):110–6

Complement activation in discordant hepatic xenotransplantation. Tector AJ, et al. **Xenotransplantation** 1998 Nov;5(4):257–61

Intrathymic inoculation of donor antigen: an ineffective strategy for prolonging xenograft survival. Tran HM, et al. **Xenotransplantation** 1999 May;6(2):147–54

Failure of anti–Forssman antibodies to induce rejection of mouse heart xenografts. Wu GD, et al. **Xenotransplantation** 1999 May;6(2):90–7

[Xenogeneic antigens and immune response in pig to man xenograft] Li T, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):42–7 (29 ref.) (Eng. Abstr.) **(Chi)**

[Immunology in clinical practice. XXIII. Xenotransplantation] Schraa EO, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1455–60 (16 ref.) (Eng. Abstr.) **(Dut)**

[Prevention of intestinal allograft rejection by anti-adhesion molecule antibodies in a mouse model] Auber F, et al. **Chirurgie** 1998 Apr;123(2):122-30 (Eng. Abstr.) **(Fre)**

[Immunologic transplant reactions after non-mechanical corneal trepanation with the excimer laser] Seitz B, et al. **Ophthalmologe** 1998 Sep;95(9):607-18 (Eng. Abstr.) **(Ger)**

[Mechanisms of xenotransplant rejection] Candinas D, et al. **Zentralbl Chir** 1999;124(7):591-9 (73 ref.) (Eng. Abstr.) **(Ger)**

[Cellular immune reactivity in xenogenic "human-anti-pig" transplant combination] Herrlinger K, et al. **Zentralbl Chir** 1998;123(7):803-8 (Eng. Abstr.) **(Ger)**

[Graft rejection in experimental xenogenic transplantation of isolated islands of Langerhans of the pig] Jahr H, et al. **Zentralbl Chir** 1998;123(7):823-9 (73 ref.) (Eng. Abstr.) **(Ger)**

[Significance of the complement system for xenotransplantation: strategies for therapeutic intervention] Kirschfink M, et al. **Zentralbl Chir** 1998;123(7):793-7 (43 ref.) (Eng. Abstr.) **(Ger)**

[Monitoring of interleukin-8 in urine and in serum of patients after kidney transplantation] Boratyńska M. **Przegl Lek** 1998;55(11):576-80 (Eng. Abstr.) **(Pol)**

[Xenotransplantation of solid organs: study of rejection mechanisms and its prevention] Rodriguez Villa A, et al. **Rev Clin Esp** 1998 Oct;198(10):673-7 (63 ref.) **(Spa)**

METABOLISM

T lymphocyte adhesion mechanisms within inflamed human kidney: studies with a Stamper-Woodruff assay. Chakravorty SJ, et al. **Am J Pathol** 1999 Feb;154(2):503-14

Coenzyme Q10 depletion and mitochondrial energy disturbances in rejection development in patients after heart transplantation. Gvozdjáková A, et al. **Biofactors** 1999; 9(2-4):301-6

Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Masters RG, et al. **Circulation** 1999 Jul 20;100(3):287-91

TNF-alpha in acute cardiac transplant rejection. Azzawi M, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):41-9 (66 ref.)

Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Abdallah AN, et al. **Eur J Immunogenet** 1999 Aug;26(4):249-55

Peroxynitrite formation during rat hepatic allograft rejection. Yamaguchi Y, et al. **Hepatology** 1999 Mar;29(3):777-84

Expression of the c-kit proto-oncogene in rat hepatic allografts during acute rejection. Yamaguchi Y, et al. **Hepatology** 1999 Jan;29(1):133-9

Adult human cardiomyocytes coexpress vimentin and Ki67 in heart transplant rejection and in dilated cardiomyopathy. Behr TM, et al. **J Heart Lung Transplant** 1998 Aug; 17(8):795-800

Expression of CD44 in rat liver allografts during rejection. Fujisaki S, et al. **J Hepatobiliary Pancreat Surg** 1998; 5(2):196-9

Analysis of the Fas system and Bcl-2 in rat liver allograft rejection. Hiroyasu S, et al. **J Surg Res** 1999 Jun 15; 84(2):204-11

CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection. Gaweco AS, et al. **Kidney Int** 1999 Apr; 55(4):1543-52

The antiproliferative effect of glucocorticoids: is it related to induction of TGF-beta? [editorial] Almawi WY, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2450-2 (12 ref.)

The 60-kDa heat shock protein modulates allograft rejection. Birk OS, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27; 96(9):5159-63

Raised endothelin content in bronchoalveolar lavage fluid during lung allograft rejection in pigs. Aarnio P, et al. **Scand Cardiovasc J** 1998;32(5):301-4

Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):111-21

Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):122-33

Contribution of the expression of ICAM-1, HLA-DR and IL-2R to the diagnosis of acute rejection in renal allograft aspirative cytology. Ribeiro-David DS, et al. **Transpl Int** 1998;11 Suppl 1:S19-25

CMV increases collagen synthesis in chronic rejection in rat renal allograft. Inkinen K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1361

Upregulation of basic fibroblast growth factor during chronic intestinal rejection. Kouwenhoven EA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):590

Kidney graft-infiltrating cells synthesize significantly higher amounts of prostaglandin E2 pre and during acute rejection. Pestana M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):306-7

Myocardial nuclear factor-kappaB activity and nitric oxide production in rejecting cardiac allografts. Cooper M, et al. **Transplantation** 1998 Oct 15;66(7):838-44

Use of 2-[18F]fluoro-2-deoxyglucose as a potential agent in the prediction of graft rejection by positron emission tomography. Heelan BT, et al. **Transplantation** 1998 Oct 27;66(8):1101-3

Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance. Josien R, et al. **Transplantation** 1998 Oct 15;66(7):887-93

Vascular endothelial growth factor expression in human chronic renal allograft rejection. Pilmore HL, et al. **Transplantation** 1999 Mar 27;67(6):929-33

[Predictive value of IL-2R in renal tissue during acute renal allograft rejection] Yang J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Feb;35(2):119-22 (Eng. Abstr.) **(Chi)**

[The role of monocyte chemotactic peptide (MCP-1) in chronic renal allograft rejection] Boratyńska M. **Pol Arch Med Wewn** 1998 Apr;99(4):272-80 (Eng. Abstr.) **(Pol)**

[Interleukin-8 (IL-8) and lipid disorders in chronic renal graft rejection] Boratyńska M, et al. **Przegl Lek** 1998; 55(12):645-9 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies [see comments] Abrass CK, et al. **Am J Kidney Dis** 1999 Jan;33(1):11-20 . Comment in: Am J Kidney Dis 1999 Jan;33(1):138-9.

A puzzle solved [editorial; comment] Helderman JH. **Am J Kidney Dis** 1999 Jan;33(1):138-9. Comment on: Am J Kidney Dis 1999 Jan;33(1):11-20.

Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Choi JK, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):1015-8

Microcirculatory hemodynamics during the acute phase of free vascularized muscle allograft rejection. Siemionow M, et al. **Ann Plast Surg** 1998 Sep;41(3):275-82

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Demetris AJ, et al. **Ann Transplant** 1997;2(2):27-44 (288 ref.)

Intraglomerular fibronectin and laminin turn-over in chronically rejected kidney allografts in humans. Paczek L, et al. **Ann Transplant** 1996;1(1):41-3

Protocol biopsies in renal transplantation: research tool or clinically useful? Rush DN, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):691-4 (14 ref.)

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Prieto M, et al. **Hepatology** 1999 Jan;29(1):250-6

Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. Grimm PC, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1582-9

Eosinophil activation in cardiac and pulmonary acute allograft rejection [letter] Dosanjh AK, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1038

The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model. Hausen B, et al. **J Heart Lung Transplant** 1999 Jul;18(7):714-24

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. Hirt SW, et al. **J Heart Lung Transplant** 1999 Jun;18(6):542-8

Small airway obliteration in a new swine heterotopic lung and bronchial allograft model. Ikonen T, et al. **J Heart Lung Transplant** 1998 Oct;17(10):945-53

Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. Antonysamy MA, et al. **J Immunol** 1999 Jan 1;162(1):577-84

Scoring of skin rejection in a swine composite tissue allograft model. Zdichavsky M, et al. **J Surg Res** 1999 Jul;85(1):1-8

Myocardial pseudovascular tubes are present in the delayed rejection of pig-to-baboon orthotopic cardiac xenografts [letter; comment] Beranek JT. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1233-4. Comment on: J Thorac Cardiovasc Surg 1998 Jun;115(6):1342-9.

Correlation of chest radiographic findings with biopsy-proven acute lung rejection. Kundu S, et al. **J Thorac Imaging** 1999 Jul;14(3):178-84

Histological characteristics of interstitial renal allograft rejection. Nickeleit V, et al. **Kidney Blood Press Res** 1998; 21(2-4):230-2

Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report. Gaber LW, et al. **Kidney Int** 1999 Jun;55(6):2415-22

Acute and chronic hepatic allograft rejection: pathology and classification. Batts KP. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S21-9 (27 ref.)

Noninvasive videomicroscopic monitoring of rat small-bowel rejection. Hoppe H, et al. **Microsurgery** 1999; 19(2):89-94

Banff criteria as predictors of outcome following acute renal allograft rejection. Macdonald FI, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1692-7

Pathological evaluation of steroid withdrawal in pediatric renal transplant recipients. Aikawa A, et al. **Pediatr Transplant** 1999 May;3(2):131-8

Clinical relevance of in vitro propagation of activated lymphocytes from endomyocardial biopsy samples of pediatric heart transplant recipients. Webber SA, et al. **Pediatr Transplant** 1998 Aug;2(3):200-5

In vivo microscopic assessment of cremasteric microcirculation during hindlimb allograft rejection in rats. Ozer K, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1949-56

Interpretation of biopsy findings in the transplant liver. Jones KD, et al. **Semin Diagn Pathol** 1998 Nov;15(4):306-17 (39 ref.)

Acute vascular rejection: a clinical and morphological study. Castro MC, et al. **Transpl Int** 1998;11 Suppl 1:S15-8

Contribution of the expression of ICAM-1, HLA-DR and IL-2R to the diagnosis of acute rejection in renal allograft aspirative cytology. Ribeiro-David DS, et al. **Transpl Int** 1998;11 Suppl 1:S19-25

Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin induction. Cantarovich M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):79

Correlation of pretransplant allosensitization with severity of rejection biopsy. Clark J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):751-2

Predictive value of histopathology and function on outcome of renal allografts after acute rejection. Cosio FG, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):261-3

Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. Damotte D, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):593

Chronic pancreas allograft rejection: morphologic evidence of progression in needle biopsies and proposal of a grading scheme. Drachenberg CB, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):614

Quantitative analysis of PDGFA, PDGFB, PDGF receptor beta and TGF-beta 1 mRNA in cardiac transplant biopsies. Egan MK, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):131-2

Significance of eosinophil infiltration in cardiac rejection. Endoh M, et al. **Transplant Proc** 1998 Nov;30(7):3350

Histologic grading of acute renal allograft rejection. Gupta RK, et al. **Transplant Proc** 1999 May;31(3):1696-700

Medial cell apoptosis precedes the development of intimal hyperplasia after transient allogeneic exposure in a rat aortic allograft model of chronic rejection. Hare GM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1384-5

Apoptosis in acute cellular rejection in murine renal allotransplantation. Hayakawa K, et al. **Transplant Proc** 1998 Nov;30(7):2944-6

Pathophysiology and diagnosis of acute rejection. Häyry P. **Transplant Proc** 1999 Jun;31(4):1789

The influence of ischemia on the severity of chronic rejection in a rat ' .ag transplant model. Hirt SW, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):189-90

Differences between acute and chronic renal graft rejection on immunohistochemical staining of transforming growth factor beta-1. Iñigo P, et al. **Transplant Proc** 1999 Sep; 31(6):2309-10

Apoptosis in rat cardiac allograft rejection. Kageyama Y, et al. **Transplant Proc** 1998 Nov;30(7):2943

Strategy used to overcome graft atrophy in auxiliary partial orthotopic liver transplantation from a living donor for ornithine transcarbamylase deficiency. Kaibori M, et al. **Transplant Proc** 1998 Nov;30(7):3221-2

Incidence of allograft rejection after corneal transplantation using optisol-preserved corneas in mice. Kamiya K, et al. **Transplant Proc** 1999 Sep;31(6):2673-4

Discordant xenoheart transplantation with perfluorotributylamine/pluronic F-68 stem emulsion. Kawauchi M, et al. **Transplant Proc** 1998 Nov;30(7):3831-2

Experimental study of the role of nitric oxide in acute renal allograft rejection. Lu YP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):317-8

Apoptosis of alloreactive T cells in liver allografts during tolerance induction. Meyer D, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):474

Morphologic criteria of chronic renal allograft rejection. Mihatsch MJ, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1295-7

Borderline changes in kidney transplantation: evolution of treated cases versus nontreated. Palomar R, et al. **Transplant Proc** 1999 Sep;31(6):2314

Apoptosis and proliferation index in renal biopsies with early chronic rejection and in biopsies from donors older than 60 years. Pardo FJ, et al. **Transplant Proc** 1999 Sep; 31(6):2283-4

Clinical utility of late renal allograft biopsies. Park SB, et al. **Transplant Proc** 1998 Nov;30(7):3077-8

Allogeneic and xenogeneic vascular injury and protection. Pober JS, et al. **Transplant Proc** 1998 Dec;30(8):4168-9

Histopathology of hepatic allograft rejection after living-related liver transplantation. Sageshima J, et al. **Transplant Proc** 1998 Nov;30(7):3214-5

Transplant vasculopathy in early protocol renal allograft biopsies. Serón D, et al. **Transplant Proc** 1999 Sep; 31(6):2219-20

Analysis of Bcl-X in rat liver allograft: rejection-induced apoptosis is associated with up-regulation of Bcl-Xs expression. Shintaku S, et al. **Transplant Proc** 1998 Nov; 30(7):2941-2

Expression of Bcl-2/Bax mRNA in grafted liver during acute rejection after rat liver transplantation. Yamamoto H, et al. **Transplant Proc** 1998 Nov;30(7):2950-1

Complement causes allograft injury by cell activation rather than lysis [letter; comment] Baldwin WM 3rd, et al. **Transplantation** 1999 Jun 15;67(11):1498-9. Comment on: Transplantation 1998 May 15;65(9):1152-8.

Pathologic classification of chronic allograft nephropathy:

pathogenic and prognostic implications. Cosio FG, et al. **Transplantation** 1999 Mar 15;67(5):690–6

A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management. Dean DE, et al. **Transplantation** 1999 Sep 15;68(5):642–5

"Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Dell'Antonio G, et al. **Transplantation** 1999 Feb 15; 67(3):484–6

The significance of bronchus-associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? Hasegawa T, et al. **Transplantation** 1999 Feb 15;67(3):381–5

Mouse-to-rabbit xenotransplantation: a new small animal model of hyperacute rejection mediated by the classical complement pathway. Kerr SR, et al. **Transplantation** 1999 Feb 15;67(3):360–5

Histological outcome of acute cellular rejection in kidney transplantation after treatment with methylprednisolone. Mazzucchi E, et al. **Transplantation** 1999 Feb 15; 67(3):430–4

Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. Randhawa PS, et al. **Transplantation** 1999 Jan 15;67(1):85–9

Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Shen J, et al. **Transplantation** 1998 Sep 27; 66(6):692–8

Comparative histopathology of hepatic allografts and xenografts in the nonhuman primate. Luo Y, et al. **Xenotransplantation** 1998 Aug;5(3):197–206

[Rejection of the corneal allograft] Borderie V, et al. **J Fr Ophtalmol** 1998 Oct;21(8):596–618 (153 ref.) **(Fre)**

[Quantification of cell proliferation with the proliferation marker MIB-1 in endomyocardial biopsies after heart transplantation. An aid in diagnosis of graft rejection needing treatment?] Gerbaulet S, et al. **Z Kardiol** 1998 Aug; 87(8):613–21 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Human complement regulatory proteins protect swine lungs from xenogeneic injury. Yeatman M, et al. **Ann Thorac Surg** 1999 Mar;67(3):769–75

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Demetris AJ, et al. **Ann Transplant** 1997;2(2):27–44 (288 ref.)

The role of adhesion molecules in allotransplanted islet cells rejection. Prolongation of islet cells allograft survival by antiadhesion treatment. Socha-Urbanek K, et al. **Ann Transplant** 1998;3(4):5–9 (36 ref.)

Acute failure of the transplanted kidney--pathophysiology, diagnosis and prevention. Więcek A, et al. **Ann Transplant** 1996;1(4):5–9 (86 ref.)

Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. Schwaiblmair M, et al. **Chest** 1999 Aug; 116(2):332–9

Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. McLaren AJ, et al. **Clin Transplant** 1999 Jun;13(3):266–72

EGF and TGF-beta1 gene expression in chronically rejecting small bowel transplants. Kouwenhoven EA, et al. **Dig Dis Sci** 1999 Jun;44(6):1117–23

Donor and recipient family histories of hypertension influence renal impairment and blood pressure during acute rejections. Guidi E, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2102–7

Rethinking chronic allograft nephropathy: the concept of accelerated senescence. Halloran PF, et al. **J Am Soc Nephrol** 1999 Jan;10(1):167–81 (171 ref.)

Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. Knoflach A, et al. **J Am Soc Nephrol** 1999 May; 10(5):1059–66

Severe and early alteration of action potential during acute cardiac rejection in rats. Babuty D, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1085–93

A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? Cable DG, et al. **J Heart Lung Transplant** 1999 Mar;18(3):177–84

Diastolic dysfunction coincides with early mild transplant rejection: in situ measurements in a heterotopic rat heart transplant model. Yoshida S, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1049–56

Determination of hindlimb transplantation-induced vascular albumin leakage and leukocyte activation during the acute phase of rejection. Gudemez E, et al. **J Reconstr Microsurg** 1999 Feb;15(2):133–41

CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection. Gaweco AS, et al. **Liver Transpl Surg** 1999 Jan;5(1):1–7

Development of injury in a rat model of chronic renal allograft rejection: effect of dietary protein restriction. Bombas A, et al. **Transpl Int** 1999;12(1):18–26

Intramyocardial electrograms for non-invasive rejection monitoring: initial experience with an infection-specific parameter. Grasser B, et al. **Transpl Int** 1998;11 Suppl 1:S508–11

Hyaluronidase ameliorates rejection-induced edema. Johnsson C, et al. **Transpl Int** 1999;12(4):235–43

Increased expression of basic fibroblast growth factor during chronic rejection in intestinal transplants is associated with macrophage infiltrates. Kouwenhoven EA, et al. **Transpl Int** 1999;12(1):42–9

Early acute cellular rejection: no effect on late hepatic allograft function in man. Seiler CA, et al. **Transpl Int** 1999; 12(3):195–201

Hemodynamic profile in cirrhotic patients undergoing liver retransplantation due to chronic rejection. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2371

Xenogeneic rejection mechanisms shown by intravital microscopy. Hammer C, et al. **Transplant Proc** 1998 Dec; 30(8):4166–7

Pathophysiology and diagnosis of acute rejection. Häyry P. **Transplant Proc** 1999 Jun;31(4):1789

Chronic rejection of cadaveric renal allografts: role of acute rejection episodes. Khauli RB, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1306–7

Impairment of hepatic microcirculation as an early manifestation of acute rejection after clinical liver transplantation. Klar E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):385–7

Systemic hypertension accelerates chronic rejection of renal allografts in the rat. Kusaka M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):869

When does hyperacute rejection against xenohearts from newborn pigs develop in infantile monkeys? Lee MC, et al. **Transplant Proc** 1998 Nov;30(7):3824–5

Current knowledge of the pathogenesis of chronic allograft dysfunction. Paul LC. **Transplant Proc** 1999 Jun; 31(4):1793–5 (28 ref.)

Surrogate end points in chronic kidney graft rejection studies. Paul LC, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1293–4 (17 ref.)

Acute rejection of rat renal allografts is accelerated by donor brain death. Pratschke J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):874–5

Using ANN in selection of the most important variables in prediction of chronic renal allograft rejection progression. Simic-Ogrizovic S, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):368

Endothelin-1 receptor blockade and its effect on chronic rejection. Tang JL, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1249

Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and CMV infection in lung and heart-lung allograft recipients. Tikkanen J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):163–4

Oxidative stress in renal transplant recipients with chronic rejection: rationale for antioxidant supplementation. Vela C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1310–1

Myocardial nitric oxide synthase gene-expression and endothelial function in chronic rejection after cardiac transplantation. Wildhirt SM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):96–8

Donor brain death affects tempo and intensity of acute rejection of rat chronic allografts. Wilhelm MJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1008–9

The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. He G, et al. **Transplantation** 1999 Jan 15;67(1):131–7

Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance. Josien R, et al. **Transplantation** 1998 Oct 15;66(7):887–93

Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Tannapfel A, et al. **Transplantation** 1999 Apr 15;67(7):1079–83

Tumor necrosis factor-beta is associated with thymic apoptosis during acute rejection. Yamaguchi Y, et al. **Transplantation** 1998 Oct 15;66(7):894–902

PREVENTION & CONTROL

Drug substitution in transplantation: a National Kidney Foundation White Paper. Sabatini S, et al. **Am J Kidney Dis** 1999 Feb;33(2):389–97 (32 ref.)

A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Raofi V, et al. **Am J Surg** 1999 Apr;177(4):299–302

Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells. Slavin S, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:37–44

Revascularization and new bone formation in heat-treated bone grafts. Shimizu K, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):57–61

Camouflaging endothelial cells: does it prolong graft survival? Stuhlmeier KM, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):177–90

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Hale G, et al. **Blood** 1998 Dec 15;92(12):4581–90

Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Storb R, et al. **Blood** 1999 Aug 1;94(3):1131–6

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Hartman AR, et al. **Bone Marrow Transplant** 1998 Sep;22(5):439–43

Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Al-Rawithi S, et al. **Bone Marrow Transplant** 1998 Sep;22(5):485–90

Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Reis A, et al. **Br J Ophthalmol** 1998 Jun;82(6):700–3

Multiplicity of glucocorticoid action in inhibiting allograft rejection. Almawi WY, et al. **Cell Transplant** 1998 Nov-Dec;7(6):511–23 (199 ref.)

Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Palmer SM, et al. **Chest** 1999 Jul;116(1):127–33

Induction of immune tolerance in adult rabbits undergoing heterotopic cardiac transplantation. Yue X, et al. **Chin Med J (Engl)** 1998 May;111(5):387–90

Emerging strategies for the clinical application of rapamycin. Kahan BD. **Clin Biochem** 1998 Jul;31(5):341–4 (22 ref.)

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ. **Clin Biochem** 1998 Jul;31(5):329–33 (10 ref.)

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Henry ML. **Clin Transplant** 1999 Jun;13(3):209–20

Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Peddi VR, et al. **Clin Transplant** 1998 Oct; 12(5):401–5

Tacrolimus in kidney transplantation. Kliem V, et al. **Contrib Nephrol** 1998;124:103–16; discussion 116–25 (73 ref.)

The use of mycophenolate mofetil (Cellcept) in renal transplantation. Vanrenterghem Y. **Contrib Nephrol** 1998; 124:64–9; discussion 69–75 (31 ref.)

Protection of corneal allografts by CTLA4-Ig. Gebhardt BM, et al. **Cornea** 1999 May;18(3):314–20

Cytotoxic T lymphocytes and antibodies after orthotropic penetrating keratoplasty in rats treated with dichloromethylene diphosphonate encapsulated liposomes. Van der Veen G, et al. **Curr Eye Res** 1998 Oct; 17(10):1018–26

The use of antibodies against the IL-2 receptor in transplantation. Waldmann TA, et al. **Curr Opin Immunol** 1998 Oct;10(5):507–12 (66 ref.)

Cellular camouflage: fooling the immune system with polymers. Scott MD, et al. **Curr Pharm Des** 1998 Dec; 4(6):423–38 (59 ref.)

Acyclovir can abort rejection of punch grafts in herpes-simplex-induced lip leucoderma [letter] Malakar S, et al. **Dermatology** 1999;199(1):75

Basiliximab. Onrust SV, et al. **Drugs** 1999 Feb;57(2):207–13; discussion 214 (28 ref.)

Persisting alloantigen prevents primed CD45RC- CD4 T cells from inducing allograft rejection: implications for immunological memory. Yang CP, et al. **Eur J Immunol** 1999 Jul;29(7):2177–86

Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. DeBruyne LA, et al. **Gene Ther** 1998 Aug;5(8):1079–87

Efficacy of anti-intercellular adhesion molecule-1 immunotherapy on immune responses to allogeneic hepatocytes in mice. Bumgardner GL, et al. **Hepatology** 1998 Oct;28(4):1005–12

Immunosuppressive agents in organ transplantation. Magee CC, et al. **Hosp Med** 1999 May;60(5):364–9 (22 ref.)

The need to handicap the recipient's native liver in the rat model of heterotopic auxiliary liver transplantation. Fan YD, et al. **HPB Surg** 1999;11(4):225–33; discussion 233–4

Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Utku N, et al. **Immunity** 1998 Oct;9(4):509–18

C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Fiane AE, et al. **Immunopharmacology** 1999 May;42(1-3):231–43

Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Takeuchi I, et al. **Int J Urol** 1998 Sep;5(5):476–81

Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. Dantal J, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1709–15

T cell costimulatory blockade: new therapies for transplant rejection. Gudmundsdottir H, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1356–65 (72 ref.)

Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. Jassal SV, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1697–708 (87 ref.)

Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. Nickerson P, et al. **J Am Soc Nephrol** 1999 Aug;

10(8):1801–5

A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe). Ponticelli C, et al. **J Am Soc Nephrol** 1997 Apr; 8(4):638–46

Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection [see comments] Ohdan H, et al. **J Clin Invest** 1999 Aug;104(3):281–90. Comment in: J Clin Invest 1999 Aug;104(3):227–8.

Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. Boucek RJ Jr, et al. **J Heart Lung Transplant** 1999 May;18(5):460–9

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. Hausen B, et al. **J Heart Lung Transplant** 1999 Feb;18(2):150–9

Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. Meiser BM, et al. **J Heart Lung Transplant** 1998 Aug;17(8):782–8

Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. Ross DJ, et al. **J Heart Lung Transplant** 1998 Aug;17(8):768–74

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. Zuckermann A, et al. **J Heart Lung Transplant** 1999 May;18(5):432–40

Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. Newell KA, et al. **J Immunol** 1999 Sep 1;163(5):2358–62

Factors in discordant xenograft survival. Bach FH. **J Mol Med** 1999 Jan;77(1):161–4 (19 ref.)

Prevention of autoimmune but not allogeneic destruction of grafted islets by different therapeutic strategies. Kuttler B, et al. **J Mol Med** 1999 Jan;77(1):226–9

New approaches for control of anti-self reactivity in type 1 diabetes mellitus and transplantation of pancreatic islets. Slavin S, et al. **J Mol Med** 1999 Jan;77(1):223–5 (22 ref.)

Effect of a new immunosuppressant, FTY720, on joint allografts. Watanabe H, et al. **J Reconstr Microsurg** 1999 May;15(4):295–8

Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. Longoria J, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):714–8

Ex vivo transfection of transforming growth factor-beta1 gene to pulmonary artery segments in lung grafts. Yano M, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):705–13

A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. Shapiro R, et al. **J Urol** 1998 Dec;160(6 Pt 1):1982–5; discussion 1985–6

Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Cantarovich D, et al. **Kidney Int** 1998 Oct;54(4):1351–6

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P, et al. **Kidney Int** 1998 Sep; 54(3):938–44

Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Katznelson S. **Kidney Int Suppl** 1999 Jul;71:S117–21 (35 ref.)

The immunoreactive propensity of autoimmune hepatitis: is It corticosteroid-dependent after liver transplantation? [editorial; comment] Czaja AJ. **Liver Transpl Surg** 1999 Sep;5(5):460–3 (29 ref.). Comment on: Liver Transpl Surg 1999 Sep;5(5):375–80.

Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Herrero JI, et al. **Liver Transpl Surg** 1999 Sep;5(5):414–20

Use of antilymphocyte induction therapy in liver transplantation: A European perspective. Langrehr JM, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S71–84 (118 ref.)

Neoral/cyclosporine-based immunosuppression. Levy GA. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S37–47 (59 ref.)

Changing perspectives on the role of corticosteroids after liver transplantation. Lucey MR. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S58–63 (26 ref.)

Mycophenolate mofetil as induction therapy after liver transplantation. McDiarmid SV. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S85–9 (19 ref.)

Use of antilymphocyte induction therapy in liver transplantation. Wall WJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S64–70 (45 ref.)

Decreasing the risk of allogenic blood in the 21st century. Popovsky MA, et al. **Med Health R I** 1998 Dec; 81(12):392–5 (13 ref.)

Foetal rat pancreatic transplantation: posttransplantation development of foetal pancreatic iso- and allografts and suppression of rejection with mycophenolate mofetil (MMF) and cyclosporine based immunesuppression. du Toit D, et al. **Microsc Res Tech** 1998 Nov 15;43(4):347–55

Tolerizing B cells to jump the first hurdle in xenotransplantation [news] Fricker J. **Mol Med Today** 1998 Nov;4(11):462

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. Barr ML, et al. **N Engl J Med** 1998 Dec 10; 339(24):1744–51

Relapse of atypical haemolytic uraemic syndrome after kidney transplantation: role of ATG and failure of mycophenolate mofetil as rescue therapy. Davin JC, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):984–7

Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Grinyó JM, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2601–4

Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. Schmidt RH, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):979–83

Long-term insulin-secretory function of islets of Langerhans encapsulated with a layer of confluent chondrocytes for immunoisolation. Pollok JM, et al. **Pediatr Surg Int** 1999; 15(3-4):164–7

Early acute rejection and kidney allograft outcome in children [editorial; comment] Chavers B. **Pediatr Transplant** 1998 Nov;2(4):254–6 (13 ref.). Comment on: Pediatr Transplant 1998 Nov;2(4):294–8.

Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Chavers BM, et al. **Pediatr Transplant** 1997 Aug;1(1):22–8

Corticosteroid elimination in pediatric solid organ transplantation [editorial; comment] Fine RN, et al. **Pediatr Transplant** 1998 Feb;2(1):3–5 (23 ref.). Comment on: Pediatr Transplant 1998 Feb;2(1):30–4. Comment on: Pediatr Transplant 1998 Feb;2(1):64–9. Comment on: Pediatr Transplant 1998 Feb;2(1):70–5.

The potential role of rapamycin in pediatric transplantation as observed from adult studies. Kahan BD. **Pediatr Transplant** 1999 Aug;3(3):175–80 (32 ref.)

A prospective trial of steroid cessation after renal transplantation in pediatric patients treated with cyclosporine and mizoribine. Motoyama O, et al. **Pediatr Transplant** 1997 Aug;1(1):29–36

What is the role for mycophenolate mofetil in pediatric renal transplantation? Neu AM, et al. **Pediatr Transplant** 1999 Feb;3(1):83–7

A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients. Roberti I, et al. **Pediatr Transplant** 1999 Aug;3(3):231–5

Mycophenolate mofetil--is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79–82 (19 ref.). Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.

Tacrolimus in pediatric renal transplantation: a review. Shapiro R. **Pediatr Transplant** 1998 Nov;2(4):270–6 (50 ref.)

Use of fish oil to prevent graft rejection. Grimm H, et al. **Proc Nutr Soc** 1998 Nov;57(4):577–85

Religious reasons for discontinuation of immunosuppressive medications after renal transplant. Subach RA, et al. **Ren Fail** 1999 Mar;21(2):223–6

Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Qi Z, et al. **Scand J Immunol** 1998 Oct; 48(4):379–88

Organ transplants. New drug blocks rejection in monkeys [news] Vogel G. **Science** 1999 Jun 4;284(5420):1594–5

Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. Pou L, et al. **Ther Drug Monit** 1998 Dec;20(6):602–6

WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. Dresske B, et al. **Transpl Immunol** 1998 Dec; 6(4):243–9

Prevention of hyperacute rejection by phosphatidylinositol-anchored mini-complement receptor type 1. Mikata S, et al. **Transpl Immunol** 1998 Jun; 6(2):107–10

Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Qi Z, et al. **Transpl Immunol** 1998 Jun; 6(2):94–100

Development of injury in a rat model of chronic renal allograft rejection: effect of dietary protein restriction. Bombas A, et al. **Transpl Int** 1999;12(1):18–26

Factors relevant for the induction of rejection by indirect recognition in a rat heart allograft model: effect of CTLA4Ig treatment on indirect alloactivation induced by immunization with donor MHC I peptides. Dufter C, et al. **Transpl Int** 1998;11 Suppl 1:S361–3

Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y, et al. **Transpl Int** 1998;11 Suppl 1:S60–4

Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK, et al. **Transpl Int** 1998;11 Suppl 1:S303–9

Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. Morris-Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S78–81

Establishment of chimerism in donor liver with recipient-type bone marrow cells prior to liver transplantation produces marked suppression of allograft rejection in rats. Sanada O, et al. **Transpl Int** 1998;11 Suppl 1:S174–8

Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine. Schorlemmer HU, et al. **Transpl Int** 1998;11 Suppl 1:S340–4

Removal of anti-donor antibody by double-filtration plasmapheresis to prevent chronic rejection in kidney transplantation. Abe M, et al. **Transplant Proc** 1998 Nov; 30(7):3108–9

Effect of hepatocyte growth factor on chronic rejection in rat renal allografts. Azuma H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):854–5

Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Brennan DC, et al. **Transplant Proc** 1999 May;31(3B Suppl):16S–18S

Monitoring serum beta-2 microglobulin is useful for detecting patients with increased risk of acute rejection during reduction in immunosuppression. Câmara NO, et al. **Transplant Proc** 1998 Dec;30(8):4158–9

Increased dosage requirement and rejection after Neoral conversion in pediatric liver transplant patients. Cao S, et al. **Transplant Proc** 1998 Dec;30(8):4322–4

Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients. Carmellini M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1162–4

Primary prophylaxis with tacrolimus in kidney transplants in China. Cheng HM, et al. **Transplant Proc** 1998 Nov; 30(7):3590–1

Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. du Toit DF, et al. **Transplant Proc** 1998 Dec;30(8):4073–4

Immunosuppression with cyclosporin A in combination with mycophenolate mofetil suppresses rejection of allogeneic fetal rat pancreatic allografts. du Toit DF, et al. **Transplant Proc** 1998 Dec;30(8):4092–3

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Ekberg H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):267–8

Treatment with CTLA4-Ig inhibits rejection of liver allografts from Flt3-ligand-treated donors. Fu F, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):453

Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Fu F, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1244

Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3815–7

The suppression of heart and liver allograft rejection by liver suppressor factor one (LSF-1) and its possible human homologue. Goto S, et al. **Transplant Proc** 1998 Nov; 30(7):3578–9

Mechanisms of suppression of liver allograft rejection by LSF-1. Goto S, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):451–2

Hyperacute rejection models: ex vivo xenoperfusion systems. Grinyo JM, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):970–1 (15 ref.)

Transplanted hepatocytes infected with a complement receptor type 1 (CR1)-containing recombinant adenovirus are resistant to hyperacute rejection. Hammel JM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):939

Chronic allograft vasculopathy: new strategies for drug development. Häyry P. **Transplant Proc** 1998 Dec; 30(8):3989–90 (22 ref.)

Mycophenolate mofetil, cyclosporine, and steroids after renal transplantation: five-year results at a single center. Herrero JC, et al. **Transplant Proc** 1999 Sep;31(6):2263–4

Effect of low-molecular-weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Hisatomi K. **Transplant Proc** 1998 Dec;30(8):4337–9

Possible role of post renal transplant graft-versus-host antibodies in preventing acute graft rejection. Jakab J, et al. **Transplant Proc** 1998 Dec;30(8):3981–3

Monitoring of anti-rejection therapy by serum bile acids after liver transplantation. Klar E, et al. **Transplant Proc** 1998 Nov;30(7):3567–9

Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients. Kupin W, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1131–2

Postischemic reperfusion injury and kidney transplantation. Prologue. Land W. **Transplant Proc** 1998 Dec;30(8):4210–3

Comparison of two corticosteroid regimens in combination with CellCept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double-blind, randomized, multi-center study. M 55002 Study Group. Lebranchu Y. **Transplant Proc** 1999 Feb-Mar; 31(1-2):249–50

Anergic cells generated in vitro suppress rejection response to islet allografts. Luo Z, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):623

The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of

mycophenolic acid trough acid levels. Meiser BM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):84-7
Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Mulloy LL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1210-3
Mycophenolate mofetil in living donor renal allograft recipients. Park K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1133
Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients. Park K, et al. **Transplant Proc** 1998 Nov; 30(7):3575
Adverse effects of immunosuppressive drugs on long-term graft outcome. Paul LC. **Transplant Proc** 1998 Dec; 30(8):4001-4 (62 ref.)
Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients. Puig JM, et al. **Transplant Proc** 1999 Sep;31(6):2259-60
Use of gene therapy for tolerogenic signals. Qin L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):882-3
TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model. Richter M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):106-7
Chimeric liver established by recipient type bone marrow cell transplantation to donor before to liver transplantation produces marked suppression of allograft rejection in rats. Sanada O, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):704-6
Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):851-3
Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1184-8
Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4099-103
Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction. Senn B, et al. **Transplant Proc** 1998 Dec; 30(8):4075-6
Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Seydoux C, et al. **Transplant Proc** 1998 Dec;30(8):4037-43
FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. Song Z, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):981
Efficacy of perfluorotributylamine/pluronic F-68 stem-emulsion (FC43se) against hyperacute rejection in discordant lung xenografts. Sugawara Y, et al. **Transplant Proc** 1998 Nov;30(7):3826-30
Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. Terakura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):870-1
Effect of low molecular weight heparin on graft vascular disease in the rat cardiac allograft model. Teranishi K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):103-5
Prevention of chronic heart allograft rejection. Valantine-von Kaeppler HA. **Transplant Proc** 1999 Feb-Mar;31(1-2):1288-9 (8 ref.)
Early cellular rejection of pig kidney perfused with manipulated human blood to avoid hyperacute rejection. Vega A, et al. **Transplant Proc** 1999 Sep;31(6):2643-4
Oxidative stress in renal transplant recipients with chronic rejection: rationale for antioxidant supplementation. Vela C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1310-1
Can antibody prophylaxis allow sparing of other immunosuppressives? Vincenti F, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1246-8
Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Vincenti F. **Transplant Proc** 1999 Sep;31(6):2206-7
Preventive efficacy of 15-deoxyspergualin against progression of apoptotic cell death in acute rejection after rat liver transplantation. Yamamoto H, et al. **Transplant Proc** 1998 Dec;30(8):4104-5
Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Birkeland SA, et al. **Transplantation** 1999 May 15;67(9):1209-14
Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. Boillot O, et al. **Transplantation** 1998 Nov 15;66(9):1182-5
Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Fu F, et al. **Transplantation** 1999 Feb 15;67(3):444-50
Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Jordan SC, et al. **Transplantation** 1998 Sep 27;66(6):800-5
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Kahan BD, et al. **Transplantation** 1999 Jan 27;67(2):276-84
Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim YS, et al. **Transplantation** 1999 Aug 27;68(4):578-81
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Li Y, et al. **Transplantation** 1998 Nov 27;66(10):1387-8
Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B, et al. **Transplantation** 1999 Jan 15;67(1):110-5
Clinical strategy for the management of acute humoral rejection in kidney transplantation [letter; comment] Pollak R. **Transplantation** 1999 Aug 27;68(4):592-3. Comment on: Transplantation 1998 Dec 15;66(11):1460-4.
A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Salmela K, et al. **Transplantation** 1999 Mar 15;67(5):729-36
Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Shen J, et al. **Transplantation** 1998 Sep 27; 66(6):692-8
Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Stepkowski SM, et al. **Transplantation** 1998 Sep 27; 66(6):699-707
Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Troncoso P, et al. **Transplantation** 1999 Jan 15;67(1):145-51
Anti-MHC-II preventing graft rejection [comment] Vanhove B. **Transplantation** 1999 Jun 27;67(12):1515-6. Comment on: Transplantation 1999 Jun 27;67(12):1599-606.
Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Vu MD, et al. **Transplantation** 1998 Dec 27; 66(12):1575-80
Antagonizing leukotriene B4 receptors delays cardiac allograft rejection in mice. Weringer EJ, et al. **Transplantation** 1999 Mar 27;67(6):808-15
Suppression of allograft rejection with anti-alphabeta T cell receptor antibody in rat corneal transplantation. Yamagami S, et al. **Transplantation** 1999 Feb 27;67(4):600-4
CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Fowler DH, et al. **Vox Sang** 1998;74 Suppl 2:331-40 (60 ref.)
T cell-mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Dorling A, et al. **Xenotransplantation** 1998 Nov;5(4):234-45 (119 ref.)
Intravenous synthetic alphaGal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation. Romano E, et al. **Xenotransplantation** 1999 Feb;6(1):36-42
[Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants] van Gelder T, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1550-4 (19 ref.) (Eng. Abstr.) **(Dut)**
[Immuno-isolation of xenogenic islands of Langerhans in a tissue engineered autologous cartilage capsule] Pollok JM, et al. **Zentralbl Chir** 1998;123(7):830-3 (Eng. Abstr.) **(Ger)**
[Xenotransplantation of solid organs: study of rejection mechanisms and its prevention] Rodriguez Villa A, et al. **Rev Clin Esp** 1998 Oct;198(10):673-7 (63 ref.) **(Spa)**

RADIOGRAPHY

Correlation of chest radiographic findings with biopsy-proven acute lung rejection. Kundu S, et al. **J Thorac Imaging** 1999 Jul;14(3):178-84

RADIONUCLIDE IMAGING

The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. Vriens PW, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):844-53
Non-invasive diagnosis of acute heart- or lung-transplant rejection using radiolabeled annexin V. Blankenberg FG, et al. **Pediatr Radiol** 1999 May;29(5):299-305 (53 ref.)
Use of 2-[18F]fluoro-2-deoxyglucose as a potential agent in the prediction of graft rejection by positron emission tomography. Heelan BT, et al. **Transplantation** 1998 Oct 27;66(8):1101-3
[Evaluation of the usefulness of the antimyosin monoclonal antibody (AMA) uptake in the diagnosis of heart transplant (HT) rejection] Bello Arqués P, et al. **Rev Esp Med Nucl** 1999 Jun;18(3):190-6 (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Hartman AR, et al. **Bone Marrow Transplant** 1998 Sep;22(5):439-43
Intermediate term results of total lymphoid irradiation for the treatment of non-specific graft dysfunction after heart transplantation. Madden BP, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):663-6
Single-field total lymphoid irradiation in the treatment of refractory rejection after heart transplantation. Trachiotis GD, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1045-8

SURGERY

Outcome of liver retransplantation in children. Achilleos OA, et al. **Liver Transpl Surg** 1999 Sep;5(5):401-6
Prompt treatment of initial acute rejection episodes may improve long-term graft outcome. Tullius SG, et al. **Transpl Int** 1998;11 Suppl 1:S3-4

THERAPY

Endobronchial transfection of naked TGF-beta1 cDNA attenuates acute lung rejection. D'Ovidio F, et al. **Ann Thorac Surg** 1999 Sep;68(3):1008-13
CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Selleri C, et al. **Bone Marrow Transplant** 1998 Sep;22(6):605-7
Treatment of humoral rejection after heart transplantation. Grauhan O, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1184-94
Reversible severe vascular rejection after plasmapheresis. Mourani C, et al. **J Med Liban** 1998 Jan-Feb;46(1):40-2
Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. Salerno CT, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1063-9
Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report. Gaber LW, et al. **Kidney Int** 1999 Jun;55(6):2415-22
Treatment of liver allograft rejection. Millis JM. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S98-S106 (22 ref.)
Anti-lymphocyte antibodies late in the course of pediatric renal transplantation. Butani L, et al. **Pediatr Nephrol** 1999 Apr;13(3):192-4
Efficacy of renal vascular embolization versus surgical nephrectomy in the treatment of nonfunctioning renal allografts. Cofán F, et al. **Transplant Proc** 1999 Sep; 31(6):2244-5
Are there markers to initiate treatment of chronic rejection? Fellström B, et al. **Transplant Proc** 1999 Jun;31(4):1796-8 (30 ref.)
Photopheresis for recurrent acute rejection in cardiac transplantation. Giunti G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):128-9
Chronic rejection: new potential venues of therapy. Häyry P. **Transplant Proc** 1999 Jun;31(4):1799-800
New usage paradigms in antibody therapy: induction or true prophylaxis? Kirkman RL. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1234-5 (7 ref.)
The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. Dickson RC, et al. **Transplantation** 1999 Jul 27;68(2):247-53
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Woodle ES, et al. **Transplantation** 1999 Sep 15;68(5):608-16
[OKT3 treatment of refractory renal allograft rejection] Xu J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):223-5 (Eng. Abstr.) **(Chi)**
[Flow cytometry controlled induction therapy with ATG and noninvasive monitoring of rejection--a modern management concept after heart transplantation] Wagner FM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1566-7 (Eng. Abstr.) **(Ger)**
[Use of plasmapheresis in intensive therapy of acute steroid-resistant rejection reaction in renal transplants] Kazimirov VG, et al. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):62-5 (Eng. Abstr.) **(Rus)**
[Diagnosis and therapy of acute rejection in patients after orthotopic heart transplantation] Schrameková E, et al. **Bratisl Lek Listy** 1998 Dec;99(12):644-6 (Eng. Abstr.) **(Slo)**

ULTRASONOGRAPHY

Sonography: a useful tool to detect the mechanical causes of renal transplant dysfunction. Gottlieb RH, et al. **J Clin Ultrasound** 1999 Jul-Aug;27(6):325-33
Power Doppler imaging of acute renal transplant rejection. Sidhu MK, et al. **J Clin Ultrasound** 1999 May;27(4):171-5
Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography. Ducharme A, et al. **J Heart Lung Transplant** 1999 Jun;18(6):510-6
Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. Moidl R, et al. **J Heart Lung Transplant** 1999 Mar;18(3):194-201
Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. Venz S, et al. **Transpl Int** 1999;12(2):127-34
Utility of acoustic densitometry in graft rejection diagnosis in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep;31(6):2544
Usefulness of pulsed Doppler tissue imaging for noninvasive detection of cardiac rejection after heart transplantation. Fábregas RI, et al. **Transplant Proc** 1999 Sep;31(6):2545-7
Acute renal allograft rejection in the canine: evaluation with serial duplex Doppler ultrasonography. Takahashi S, et al. **Transplant Proc** 1999 May;31(3):1731-4

GRAFT RESTENOSIS, VASCULAR see **GRAFT OCCLUSION, VASCULAR**

GRAFT SURVIVAL

Transplantation of purified bovine islets into the thymus of non-immunosuppressed pigs [letter] Del Guerra S, et al. **Acta Diabetol** 1998 Oct;35(3):165–6

Monitoring interposition graft venous pressures at higher blood-flow rates improves sensitivity in predicting graft failure. Agarwal R, et al. **Am J Kidney Dis** 1999 Aug; 34(2):212–7

An endothelin receptor antagonist ameliorates injuries of sinusoid lining cells in porcine liver transplantation. Fukunaga K, et al. **Am J Surg** 1999 Jul;178(1):64–8

Host-graft circulation and vascular morphology in pancreatic tissue transplants in rats. Adeghate E. **Anat Rec** 1998 Aug; 251(4):448–59

The viability of liver graft for transplantation after prolonged warm ischaemia. Ong HS, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):25–30

Cryopreservation and transplantation of dog trachea. Zhao H, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:270–5

Effect of hyperbaric oxygen on survival of the composite ear graft in rats. Zhang F, et al. **Ann Plast Surg** 1998 Nov; 41(5):530–4

Acceptance of skin allografts in pigs by portal venous injection of donor bone marrow cells. Morita H, et al. **Ann Surg** 1999 Jul;230(1):114–9

Impact of graft ischemic time on outcomes after bilateral sequential single-lung transplantation. Ueno T, et al. **Ann Thorac Surg** 1999 Jun;67(6):1577–82

Protection of heart and rejection of lymphocyte allografts from the same donor in recipients of donor-specific transfusions. Jaskłowska-Englisz M, et al. **Ann Transplant** 1998;3(1):28–33

Hematopoetic progenitor cells transplantation in Poland: structure and clinical practice. Lange A, et al. **Ann Transplant** 1996;1(1):63–6

Tilapia Brockmann Bodies: an inexpensive, simple model for discordant islet xenotransplantation. Wright JR Jr, et al. **Ann Transplant** 1997;2(3):72–5 (35 ref.)

Survival of human parathyroid tissue xenotransplanted in nude mice after 9 to 55 months' cryopreservation. Smeds S, et al. **APMIS** 1999 Apr;107(4):445–50

Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Haut PR, et al. **Biol Blood Marrow Transplant** 1998;4(1):38–42

Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Leung W, et al. **Biol Blood Marrow Transplant** 1999;5(2):69–76

Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Przepiorka D, et al. **Biol Blood Marrow Transplant** 1999;5(2):94–7

Engraftment of ex vivo-expanded cord blood cells in NOD/SCID mice: what is the clinical relevance? [letter; comment] McNiece IK. **Blood** 1999 Jun 15;93(12):4445–6 . Comment on: Blood 1999 Feb 1;93(3):1097–105.

Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Piacibello W, et al. **Blood** 1999 Jun 1;93(11):3736–49

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Szilvassy SJ, et al. **Blood** 1999 Mar 1;93(5):1557–66

Peripheral blood CD34+ cell count reliably predicts autograft yield. Chapple P, et al. **Bone Marrow Transplant** 1998 Jul;22(2):125–30

Formation of fibrin clots in cryopreserved stem cell bags during thawing procedure: lack of impact on engraftment in autologous stem cell transplantation [letter] Mandanas RA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):303–4

Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Ringdén O, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S81–4

A comparative study on the efficacy of CD8-positive cells in enhancing allogeneic bone marrow engraftment: cell sorting vs microbead selection. Sen-Majumdar A, et al. **Bone Marrow Transplant** 1998 Sep;22(5):477–84

Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Stewart DA, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1237–43

Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Goldman JP, et al. **Br J Haematol** 1998 Nov;103(2):335–42

Lower limb surveillance following autologous vein bypass should be life long. McCarthy MJ, et al. **Br J Surg** 1998 Oct;85(10):1369–72

Isograft and xenograft of the subcommissural organ into the lateral ventricle of the rat and the formation of Reissner's fiber. Rodriguez S, et al. **Cell Tissue Res** 1999 Jun; 296(3):457–69

Effect of cryopreservation on the survival and function of murine islet isografts and allografts. Cattral MS, et al. **Cell Transplant** 1998 Jul-Aug;7(4):373–9

Pretreatment of crude pancreatic islets with mitomycin C (MMC) prolongs islet graft survival in a xenogeneic rat-to-mouse model. Grochowiecki T, et al. **Cell Transplant** 1998 Jul-Aug;7(4):411–2

Intraocular transplantation of E1A-immortalized retinal precursor cells. Seigel GM, et al. **Cell Transplant** 1998 Nov-Dec;7(6):559–66

The potential contribution of rejection to survival of transplanted human islets. Swift SM, et al. **Cell Transplant** 1998 Nov-Dec;7(6):599–606

The development of intracerebral cell-suspension implants is influenced by the grafting medium. Watts C, et al. **Cell Transplant** 1998 Nov-Dec;7(6):573–83

World transplant records--1997. **Clin Transpl** 1997;:385–434

Look-up survival tables for renal transplantation. Gjertson DW. **Clin Transpl** 1997;:337–83

Clinical aspects of sensitization. Katznelson S, et al. **Clin Transpl** 1997;:285–96

Effect of delayed graft function on short- and long-term kidney graft survival. Shoskes DA, et al. **Clin Transpl** 1997; :297–303

Spousal and other living renal donor transplants. Terasaki PI, et al. **Clin Transpl** 1997;:269–84

Correlation between von Willebrand factor levels and early graft function in clinical liver transplantation. Basile J, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):25–31

Serum total homocysteine concentration does not predict outcome in renal transplant recipients. Dimény E, et al. **Clin Transplant** 1998 Dec;12(6):563–8

Acute rejection following renal transplantation. Evidence that severity is the best predictor of subsequent graft survival time. Pelletier RP, et al. **Clin Transplant** 1998 Dec; 12(6):543–52

Male recipients of kidneys from female donors are at increased risk of graft loss from both rejection and technical failure. Vereerstraeten P, et al. **Clin Transplant** 1999 Apr; 13(2):181–6

The prognostic importance of severity and type of post-transplant proteinuria. Yildiz A, et al. **Clin Transplant** 1999 Jun;13(3):241–4

Strategies for tolerance induction in nonhuman primates. Hamawy MM, et al. **Curr Opin Immunol** 1998 Oct; 10(5):513–7 (26 ref.)

Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Kenyon NS, et al. **Diabetes** 1999 Jul;48(7):1473–81

Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. Knudsen LM, et al. **Eur J Haematol** 1998 Oct;61(4):229–34

Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Martínez C, et al. **Exp Hematol** 1999 Mar;27(3):561–8

Striatal transplantation in a transgenic mouse model of Huntington's disease. Dunnett SB, et al. **Exp Neurol** 1998 Nov;154(1):31–40

Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. Kaemmerer WF, et al. **Exp Neurol** 1999 Aug;158(2):301–11

Endothelial viability of organ-cultured corneas following penetrating keratoplasty. Harper CL, et al. **Eye** 1998;12 (Pt 5):834–8

Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Carella AM, et al. **Haematologica** 1998 Oct;83(10):904–9

Interstitial accumulation of Na+ and K+ during flush-out and cold storage of rat livers: implications for graft survival. Tian Yh, et al. **Hepatology** 1998 Nov; 28(5):1327–31

The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Jones ND, et al. **Int Immunol** 1998 Nov; 10(11):1637–46

Long-term basal forebrain cholinergic-rich grafts derived from trisomy 16 mice do not develop beta-amyloid pathology and neurodegeneration but demonstrate neuroinflammatory responses. Stahl T, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7–8):763–75

Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. Dantal J, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1709–15

Vascular graft healing: I. FTIR analysis of an implant model for studying the healing of a vascular graft. Lyman DJ, et al. **J Biomed Mater Res** 1999;48(2):172–86

Microchimerism of maternal origin persists into adult life. Maloney S, et al. **J Clin Invest** 1999 Jul;104(1):41–7

Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. Yasuda H, et al. **J Clin Invest** 1998 Nov 15; 102(10):1807–14

Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. Muramatsu K, et al. **J Hand Surg [Am]** 1999 May; 24(3):586–93

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenolate mofetil, cyclosporine A, and donor-specific transfusion. Gibson SW, et al. **J Heart Lung Transplant** 1999 Mar;18(3):185–9

Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation. Diaz MA, et al. **J Hematother** 1998 Aug;7(4):367–73

Use of collagen for standardization of PBSC graft quality evaluation: a multicenter comparative analysis of commercial collagen-based and methylcellulose-based colony-forming unit (CFU) assay kits. Mossuz P, et al. **J Hematother** 1998 Aug;7(4):351–9

Factors in discordant xenograft survival. Bach FH. **J Mol Med** 1999 Jan;77(1):161–4 (19 ref.)

Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. Bretzel RG, et al. **J Mol Med** 1999 Jan;77(1):140–3

Endotoxin impairs the engraftment of rat islets transplanted beneath the kidney capsule of C57BL/6-mice. Eckhardt T, et al. **J Mol Med** 1999 Jan;77(1):123–5

Isokinetic gradient centrifugation prolongs survival of pig islets xenografted into mice. Lau D, et al. **J Mol Med** 1999 Jan;77(1):175–7

Metabolic strategies to predict and improve intrahepatic islet graft function. Luzi L. **J Mol Med** 1999 Jan;77(1):49–56 (46 ref.)

Critical islet mass for successful porcine islet autotransplantation. Mellert J, et al. **J Mol Med** 1999 Jan; 77(1):126–9

Synergistic effect of microencapsulation and immunoalteration on islet allograft survival in bioartificial pancreas. Zekorn TD, et al. **J Mol Med** 1999 Jan; 77(1):193–8

Graft survival [letter; comment] Brundin P, et al. **J Neurosurg** 1999 Apr;90(4):804–6. Comment on: J Neurosurg 1998 Jun;88(6):1088–95.

Effect of diameter of microvascular interposition vein grafts on vessel patency and free flap survival in the rat model. Harris JR, et al. **J Otolaryngol** 1999 Jun;28(3):152–7

Impact of segmental grafts on pediatric liver transplantation--a review of the United Network for Organ Sharing Scientific Registry data (1990–1996). Sindhi R, et al. **J Pediatr Surg** 1999 Jan;34(1):107–10; discussion 110–1

Effects of hematoma on the short-term fate of experimental microvenous autografts. Bayramiçli M, et al. **J Reconstr Microsurg** 1998 Nov;14(8):575–86

Effect of cryopreservation on survival of composite tissue grafts. Zhang F, et al. **J Reconstr Microsurg** 1998 Nov; 14(8):559–64

Postnatal booster injections increase engraftment after in utero stem cell transplantation. Milner R, et al. **J Surg Res** 1999 May 1;83(1):44–7

Forearm loop, upper arm straight, and brachial-internal jugular vein dialysis grafts: a comparison study of graft survival utilizing a combined percutaneous endovascular and surgical maintenance approach. Savader SJ, et al. **J Vasc Interv Radiol** 1999 May;10(5):537–45

Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Giral-Classe M, et al. **Kidney Int** 1998 Sep;54(3):972–8

Stem cell engraftment and cell cycle phenotype. Quesenberry P, et al. **Leukemia** 1999 Apr;13 Suppl 1:S92–3

Race: a critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation? Eckhoff DE, et al. **Liver Transpl Surg** 1998 Nov;4(6):499–505

Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Moreso F, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):930–5

Delayed renal function and allograft survival: does the type of post transplant dialysis influence outcome? [letter] Weight SC, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2427–8

Calcitonin gene-related peptide improves skin flap survival and tissue inflammation. Gherardini G, et al. **Neuropeptides** 1998 Jun;32(3):269–73

Dietary amino acids as new and novel agents to enhance allograft survival. Alexander JW, et al. **Nutrition** 1999 Feb; 15(2):130–4

Long-term results of corneal graft survival in infants and children with peters anomaly. Yang LL, et al. **Ophthalmology** 1999 Apr;106(4):833–48

Pediatric renal transplantation: a review of the UNOS data. United Network for Organ Sharing. Cecka JM, et al. **Pediatr Transplant** 1997 Aug;1(1):55–64

Renal transplantation from donors aged < 6 years into children yields equal graft survival when compared to older donors [see comments] Filler G, et al. **Pediatr Transplant** 1997 Nov;1(2):119–23. Comment in: Pediatr Transplant 1997 Nov;1(2):101. Comment in: Pediatr Transplant 1997 Nov;1(2):102–3.

Hepatic artery thrombosis in pediatric liver transplantation: graft salvage after thrombectomy. Garcia-Gallont R, et al. **Pediatr Transplant** 1999 Feb;3(1):74–8

Evaluation of skin flap survival in rats [letter; comment] Akyürek M, et al. **Plast Reconstr Surg** 1999 Jan; 103(1):337–8. Comment on: Plast Reconstr Surg 1997 Jun;99(7):2030–3.

Survival of free tissue transfer following internal jugular venous thrombosis. Amato MM, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1406–8

Neutralising IL-12 activity as a strategy for prolonging allograft survival and preventing graft-versus-host disease. Orr DJ, et al. **Scott Med J** 1998 Aug;43(4):109–11 (24 ref.)

Deletion variant of hepatocyte growth factor prolongs allograft survival after liver transplantation in rats. Ikegami

T, et al. **Surgery** 1999 Jun;125(6):602–7

The combined impact of donor age and acute rejection on long-term cadaver renal allograft survival. Knight RJ, et al. **Surgery** 1999 Mar;125(3):318–24

Development of injury in a rat model of chronic renal allograft rejection: effect of dietary protein restriction. Bombas A, et al. **Transpl Int** 1999;12(1):18–26

The effect of acute rejection on long-term renal graft survival is mainly related to initial renal damage. Heaf JG, et al. **Transpl Int** 1998;11 Suppl 1:S26–31

Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Lange H, et al. **Transpl Int** 1999;12(1):2–9

Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK, et al. **Transpl Int** 1998;11 Suppl 1:S303–9

Long-term related kidney graft survival in high-risk patients after monitored donor-specific transfusion protocol. Padányi A, et al. **Transpl Int** 1998;11 Suppl 1:S110–4

A comparison of pediatric and adult kidney donors for adult recipients. Pugliese MR, et al. **Transpl Int** 1999;12(2):122–6

Renal graft survival in native and non-native European recipients. Roodnat JI, et al. **Transpl Int** 1999;12(2):135–40

Prompt treatment of initial acute rejection episodes may improve long-term graft outcome. Tullius SG, et al. **Transpl Int** 1998;11 Suppl 1:S3–4

Amino acids in rinse effluents as a predictor of graft function after transplantation of fatty livers in rats. v. Frankenberg M, et al. **Transpl Int** 1999;12(3):168–75

Report from studies of pediatric liver transplantation (SPLIT). SPLIT Research Group. **Transplant Proc** 1999 Feb-Mar;31(1–2):374–5

Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Abu-Elmagd KM, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):582–4

Renal transplantation and graft survival and its influencing factors. Agraz I, et al. **Transplant Proc** 1999 Sep; 31(6):2296–300

Does elimination of Kupffer cells prolong survival time in liver transplantation? Akamatsu Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):545–7

University of Wisconsin versus Eurocollins solution for kidney preservation: analysis of clinical outcome. Alshaibani K, et al. **Transplant Proc** 1998 Nov;30(7):3681–2

The kidney transplant program at King Faisal Specialist Hospital and Research Center: results of the last 10 years. Alshaibani K, et al. **Transplant Proc** 1998 Nov;30(7):3103–5

Preservation with a retrograde second flushing of Eurocollins in clinical lung transplantation. Alvarez A, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1088–90

Primary dysfunction after liver transplantation: donor or recipient fault? Avolio AW, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):434–6

Outcome of liver transplantation after acute rejection and sepsis. Avolio AW, et al. **Transplant Proc** 1998 Dec; 30(8):3962–6

Age and gender discrepancies in living related renal transplant donors and recipients. Avula S, et al. **Transplant Proc** 1998 Nov;30(7):3674

Experience of Jeddah Kidney Center in Pediatric Renal Transplantation. al Baba MA, et al. **Transplant Proc** 1998 Nov;30(7):3679–80

Kidneys from border-age donors in the cyclosporine era: long-term function and outcome. Berardinelli L, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):294–5

Potential use of marginal donors for pancreas transplantation. Bonham CA, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):612–3

Use of high-risk liver donors for urgent and elective liver transplantation. Briceño J, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):440–2

Transplantation of traumatized livers: is it safe? Broering DC, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):540

Liver donors: is age a risk factor? Busquests J, et al. **Transplant Proc** 1999 Sep;31(6):2480–1

Short and long-term success of organs transplanted from donors dying of acute methanol intoxication. Caballero F, et al. **Transplant Proc** 1999 Sep;31(6):2591–2

High kidney graft survival rates using non-heart-beating trauma donors. Cho YW, et al. **Transplant Proc** 1998 Nov; 30(7):3795–6

Donor fatty (steatotic) liver allografts in orthotopic liver transplantation. Chui AK, et al. **Transplant Proc** 1998 Nov; 30(7):3286–7

Liver transplantation in Catalonia from 1984 to 1997. Clèries M, et al. **Transplant Proc** 1999 Sep;31(6):2484

Impact of early vesico ureteral reflux on the transplanted kidney. Coosemans W, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):362–4

Predictive value of histopathology and function on outcome of renal allografts after acute rejection. Cosio FG, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):261–3

Factors related to allograft survival in recipients of the same donor. Cubero JJ, et al. **Transplant Proc** 1999 Sep; 31(6):2301

Marginal donors in liver transplantation: the role of donor age. De Carlis L, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):397–400

Effects of HLA matching on the results of kidney transplantation (81 case reports). De-Lin G, et al. **Transplant Proc** 1998 Nov;30(7):3498–9

Analysis of pig-MAP after small bowel transplantation in pigs. Escartin A, et al. **Transplant Proc** 1998 Dec; 30(8):4334–6

Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy. Faull RJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1155–6

Immunologically high-risk recipient strategies. First MR. **Transplant Proc** 1999 Feb-Mar;31(1–2):243–6 (26 ref.)

Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Fu F, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):1244

Endothelin antagonist improves viability of liver grafts from non-heart-beating donors. Fukunaga K, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):460–1

Effect of donor age on graft outcome after liver transplantation. Grande L, et al. **Transplant Proc** 1999 Sep; 31(6):2482–3

New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Groth CG, et al. **Transplant Proc** 1998 Dec;30(8):4064–5

Is renal graft survival predetermined by the recipient's cytokine profile? Haldar NA, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):289–90

Risk factors in renal transplantation and implications for immunosuppressive therapy. Halloran PF. **Transplant Proc** 1999 Feb-Mar;31(1–2):351–2

No differences in causes of graft failure in living related and cadaveric kidney transplantation in Hong Kong Chinese. Collaborative Transplant Study contributors in Hong Kong. Hawkins BR. **Transplant Proc** 1998 Nov; 30(7):3090–1

No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Hillebrand GF, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1391–2

Successful limb transplantation across a multi-minor barrier facilitated by preceding engraftment of T-cell-purged donor and recipient bone marrow. Hiotis SP, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):692–3

Pretransplant MLC in the presence of cyclosporine may predict renal allograft survival. Holman DM, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):746–7

Living donor liver transplantation: an 8-year experience with 379 consecutive cases. Inomata Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):381

Comparison of cadaveric renal allograft survival between multiorgan donors and kidney donors. Jang HJ, et al. **Transplant Proc** 1998 Nov;30(7):3664–5

Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation. Kaden J, et al. **Transplant Proc** 1998 Dec; 30(8):4011–4

Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Kato T, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):396

Early evaluation of graft viability using hepatic venous oxygen saturation in pig liver transplantation. Katsuramaki T, et al. **Transplant Proc** 1998 Nov;30(7):3748–9

Functional graft survival: the significance of patient death with a functioning graft. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):3099–100

Clinical outcome of cadaveric renal transplantation using "marginal donors". Kim SC, et al. **Transplant Proc** 1998 Nov;30(7):3079–80

Analysis of the factors affecting survival of renal transplant recipients. Kim ST, et al. **Transplant Proc** 1998 Nov; 30(7):3086–7

Correlation between Banff classification and reversal of acute renal rejection. Kokado Y, et al. **Transplant Proc** 1998 Nov; 30(7):3064–6

Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1151–4

Prevention of islet graft destruction in diabetic mice and rats by temporary anti-IL-2 receptor therapy: comparison of different strategies. Kuttler B, et al. **Transplant Proc** 1998 Dec;30(8):4140–2

Organ procurement policy: should we reduce cold ischemia times? Lange H, et al. **Transplant Proc** 1998 Dec; 30(8):4297–302

Kidney transplantation with living donors: better long-term survival. Melchor JL, et al. **Transplant Proc** 1999 Sep; 31(6):2294–5

Clinical outcome of intestinal transplantation at the University of Miami. Misiakos EP, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):569–71

Characterization and modulation of preservation/reperfusion injury after small bowel transplantation. Mueller AR, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):579–81

Is the use of marginal liver grafts justified? Mueller AR, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):401–2

Successful renal transplantation from non-heart-beating donors with a high creatinine. Nemoto T, et al. **Transplant Proc** 1998 Nov;30(7):3785–6

Examination of TNF-alpha and heat shock protein gene expression in ischemic injured livers from fasted and nonfasted rats. Nishihara M, et al. **Transplant Proc** 1998 Nov;30(7):3697–9

What is a reasonably short cold ischemia time in kidney transplantation? Offermann G. **Transplant Proc** 1998 Dec; 30(8):4291–3 (8 ref.)

Cadaver kidney graft outcome in relation to ischemia time and HLA match. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1998 Dec;30(8):4294–6

Is HLA matching worth the effort? Collaborative Transplant Study. Opelz G, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):717–20

Influence of renal function upon the outcome of liver retransplanted patients: results of a multivariate analysis. Parés D, et al. **Transplant Proc** 1999 Sep;31(6):2485–6

Single center experience of 1500 kidney transplants. Park K, et al. **Transplant Proc** 1998 Nov;30(7):3088–9

Graft outcome in patients with biopsy-proven chronic renal allograft rejection. Peddi VR, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1308–9

Synergy of class I and class II MHC deficiency (C1D and C2D) islets and early short-term suppression in achieving long-term islet graft survival and tolerance induction. Pittman K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):635–6

Indications for determination of alpha-glutathione-s-transferase after liver transplantation. Platz KP, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):462–4

Factors affecting development of function, level of function, and 36-month graft survival--multivariant analysis. Pokorna E, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):220–2

Orthotopic liver transplantation for hepatic-associated metabolic disorders. Pratschke J, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):382–4

Early steroid withdrawal after liver transplantation. Ramirez CB, et al. **Transplant Proc** 1998 Nov;30(7):3182–3

Effect of race on kidney transplant survival in non-European recipients. Roodnat JI, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):312–3

Passive transfer of anti-donor antibodies in a rat lung transplant model. Sano Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):198–9

Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. Sasaki K, et al. **Transplant Proc** 1998 Nov;30(7):3459–60

Temporary aortic shunt technique for porcine orthotopic liver transplantation. Sato M, et al. **Transplant Proc** 1998 Nov;30(7):3714–5

Clinical study of kidney transplantation in diabetic patients with end-stage renal disease. Sato S, et al. **Transplant Proc** 1998 Nov;30(7):3097–8

Long-term allograft survival in renal transplantation from elderly donors. Singh AK, et al. **Transplant Proc** 1998 Nov; 30(7):3659

Long-term results of combined kidney and liver transplantation in patients with nephropathy associated with liver disease. Soriano S, et al. **Transplant Proc** 1999 Sep;31(6):2306–7

Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Tanabe K, et al. **Transplant Proc** 1998 Nov;30(7):3168–70

Major infectious complications as a risk factor in kidney transplantation. Tomikawa S, et al. **Transplant Proc** 1998 Nov;30(7):3127–9

Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression. Tsai MK, et al. **Transplant Proc** 1998 Nov;30(7):3125–6

Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Ureña MA, et al. **Transplant Proc** 1998 Nov;30(7):3288–91

Long-term results in pediatric ABO-incompatible liver transplantation. Varela-Fascinetto G, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):467–8

Effect of delayed graft function on prognosis of renal transplantation. Yi-rong Y, et al. **Transplant Proc** 1998 Nov;30(7):3081–2

Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease. Andreoni KA, et al. **Transplantation** 1999 Jan 27; 67(2):262–6

The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Andresdottir MB, et al. **Transplantation** 1999 Sep 15;68(5):623–7

Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Bryan CF, et al. **Transplantation** 1998 Dec 27;66(12):1827–32

Prolongation of survival of primary renal allografts by feeding of donor spleen cells. Carr RI, et al. **Transplantation** 1998 Oct 27;66(8):976–82

Spontaneous acceptance or rejection of orthotopic liver transplants in outbred and partially inbred miniature swine. Flye MW, et al. **Transplantation** 1999 Sep 15;68(5):599–607

Prolonged survival of corneal allografts incubated in alloantibody fragments. Gebhardt BM, et al. **Transplantation** 1999 Feb 27;67(4):594–9

Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients. Li W, et al. **Transplantation** 1998 Dec 27;66(12):1587–96

Renal transplantation in end-stage sickle cell nephropathy. Ojo AO, et al. **Transplantation** 1999 Jan 27;67(2):291–5

Pediatric renal transplantation under tacrolimus-based immunosuppression. Shapiro R, et al. **Transplantation** 1999 Jan 27;67(2):299–303

A prospective, randomized trial of tacrolimus/prednisone

versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Shapiro R, et al. **Transplantation** 1999 Feb 15;67(3):411–5

Predominant expression of T helper 2 cytokines and altered expression of T helper 1 cytokines in long-term allograft survival induced by intrathymic immune modulation with donor class I major histocompatibility complex peptides. Shirwan H, et al. **Transplantation** 1998 Dec 27; 66(12):1802–9

Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Yang H, et al. **Transplantation** 1999 Mar 27;67(6):815–20

[The function of nitric oxide in the necrosis of avulsed skin flap in domestic pig] Guo J, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):65–8 (Eng. Abstr.) **(Chi)**

[Effects of hyperbaric oxygen on the skin graft survival] Jiang P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):91–3 (23 ref.) **(Chi)**

[Thin skin flap in the repair of defect of soft tissue of hand] Sun ZS. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):353–5 (Eng. Abstr.) **(Chi)**

[Adipose tissue transplantation and plastic surgery: review of basic research] Wang D, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):61–3 (12 ref.) **(Chi)**

[Can intestinal transplantation constitute treatment for intestinal failure?] Goulet O, et al. **Ann Chir** 1999; 53(5):412–21 (Eng. Abstr.) **(Fre)**

[Preoperative inoculation of CTLA4Ig combined with allogeneic dendritic cells prolongs rat renal allograft survival in a donor-specific fashion] Harada H. **Hokkaido Igaku Zasshi** 1999 May;74(3):189–98 (Eng. Abstr.) **(Jpn)**

[Transplanted nerve cells survive and are functional for many years] Björklund A, et al. **Lakartidningen** 1999 Aug 11; 96(32–33):3407–12 (20 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Dexamethasone increases survival and attenuates induction of inducible nitric oxide synthase in experimental skin flaps. Gribbe O, et al. **Ann Plast Surg** 1999 Feb;42(2):180–4

Effect of ME3277, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, on the survival of skin flaps [letter; comment] Morioka D, et al. **Ann Plast Surg** 1998 Oct; 41(4):452–3. Comment on: Ann Plast Surg 1997 Sep;39(3):317–29.

Pharmacological enhancement of cutaneous flap survival with topical dimethyl sulphoxide and hydrogen peroxide. Raposio E, et al. **Br J Plast Surg** 1998 Oct;51(7):551–4

Dexamethasone treatment prior to reperfusion improves the survival of skin flaps subjected to secondary venous ischaemia. Willemart G, et al. **Br J Plast Surg** 1998 Dec; 51(8):624–8

Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum. Dunnett SB, et al. **Cell Transplant** 1998 Nov–Dec;7(6):567–72

Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. Yamasaki T, et al. **Cell Transplant** 1998 Jul–Aug;7(4):403–6

FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Hwang MW, et al. **Circulation** 1999 Sep 21;100(12):1322–9

OKT3 in renal allografts: survival and complications [letter] D'Souza RJ, et al. **Clin Nephrol** 1999 Apr;51(4):257–8

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Henry ML. **Clin Transplant** 1999 Jun;13(3):209–20

Survival of rabbit limbal stem cell allografts after administration of cyclosporin A. Xu KP, et al. **Cornea** 1999 Jul;18(4):459–65

Cytotoxic T lymphocytes and antibodies after orthotropic penetrating keratoplasty in rats treated with dichloromethylene diphosphonate encapsulated liposomes. Van der Veen G, et al. **Curr Eye Res** 1998 Oct; 17(10):1018–26

The delta1-opioid receptor antagonist, 7-(benzospiroindanyl)naltrexone [correction of 7-benzylspiroindanylnaltrexone], prolongs renal allograft survival in a rat model [published erratum appears in Eur J Pharmacol 1998 Dec 11;363(1):91] Linner KM, et al. **Eur J Pharmacol** 1998 Jul 31;354(1):R3–5

Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation. Lapointe N, et al. **Eur Surg Res** 1999;31(3):259–66

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Naparstek E, et al. **Exp Hematol** 1999 Jul;27(7):1210–8

Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Takeuchi I, et al. **Int J Urol** 1998 Sep;5(5):476–81

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. Parry N, et al. **J Heart Lung Transplant** 1999 May;18(5):441–7

Pretreatment of human keratinocyte sheets with laminin 5 improves their grafting efficiency. Takeda A, et al. **J Invest Dermatol** 1999 Jul;113(1):38–42

Augmentation of cAMP improves muscle-flap survival and tissue inflammation in response to ischemia/reperfusion injury. Lille S, et al. **J Reconstr Microsurg** 1999 Jan; 15(1):37–45

Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate. Schwartz CF, et al. **J Surg Res** 1999 Sep;86(1):24–8

Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. Shapira OM, et al. **J Surg Res** 1999 Jul;85(1):83–7

Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. Tran HS, et al. **J Surg Res** 1999 May 15;83(2):136–40

Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat. Dragun D, et al. **Kidney Int** 1998 Dec;54(6):2113–22

Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation [see comments] Schnuelle P, et al. **Kidney Int** 1999 Aug;56(2):738–46. Comment in: Kidney Int 1999 Aug;56(2):756–7.

Effect of photodynamic therapy on the critical primary ischemic time of fasciocutaneous flaps. Belmont MJ, et al. **Laryngoscope** 1999 Jun;109(6):886–90

Lazaroid-enhanced survival of grafted dopamine neurons does not increase target innervation. Björklund L, et al. **Neuroreport** 1998 Aug 24;9(12):2815–9

Interleukin 10 treatment does not prolong experimental corneal allograft survival. Torres PF, et al. **Ophthalmic Res** 1999;31(4):297–303

Effect of parenteral pentoxifylline and topical nitroglycerin on skin flap survival. Karacaoğlan N, et al. **Otolaryngol Head Neck Surg** 1999 Feb;120(2):272–4

Effects of dimethylthiourea, melatonin, and hyperbaric oxygen therapy on the survival of reimplanted rabbit auricular composite grafts. Lim AA, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):231–7

Effects of vasoactive topical agents on the survival of dorsal skin flaps in rats. Smith DK, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):220–3

Coadministration of basic fibroblast growth factor and sucrose octasulfate (sucralfate) facilitates the rat dorsal flap survival and viability. Rashid MA, et al. **Plast Reconstr Surg** 1999 Mar;103(3):941–8

Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Qi Z, et al. **Scand J Immunol** 1998 Oct; 48(4):379–88

Prolonged rat heart allograft survival after treatment with angiotensin converting enzyme inhibitor or a calcium antagonist. Mjörnstedt L, et al. **Scand J Urol Nephrol** 1998 Sep;32(5):341–4

Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Jones JW Jr, et al. **Surgery** 1999 Aug;126(2):384–8

Comparison of immunomodulation by cyclosporin A and azathioprine on pancreatic xenograft survival. Gupta RC, et al. **Ther Apher** 1997 Nov;1(4):362–5

Better-surviving liver grafts by the injection of anti-CD2 antibody: the important roles of host CD8+ and CD2+CD28+ T cells in chronic graft rejection and beta type platelet-derived growth factor receptor (PDGFR-beta) expression on apoptotic liver grafts. Nakatsuji T. **Tohoku J Exp Med** 1999 Mar;187(3):215–25

Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. Jiang H, et al. **Transpl Int** 1999; 12(2):92–9

Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity. Lipkowitz GS, et al. **Transpl Int** 1999; 12(3):202–7

Orthotopic small bowel transplantation in pigs without steroids. Escartin A, et al. **Transplant Proc** 1999 Sep; 31(6):2567–8

Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin. Fiane AE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):934–5

Pretreatment of islets with mitomycin C and blockage of costimulatory signal induces unresponsiveness to islet xenografts. Grochowiecki T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):925

FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. Hoshino Y, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1224–6

Expression of heat shock proteins induced by L(+)-glutamine injection and survival of hypothermically stored heart grafts. Kojima R, et al. **Transplant Proc** 1998 Nov;30(7):3746–7

Comparison of the immunosuppressive and toxic effects of TII and azathioprine. Lulin M, et al. **Transplant Proc** 1998 Nov;30(7):3517–8

Prolongation of concordant xenograft survival by treatment with FTY720. Miyata Y, et al. **Transplant Proc** 1998 Dec; 30(8):4163–5

Comparative efficacy of liposomal FK506 with FK506. Moffatt SD, et al. **Transplant Proc** 1998 Dec;30(8):4066–7

Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1999 Feb–Mar;31(1–2):1147–8

Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Reis A, et al. **Transplant Proc** 1998 Dec;30(8):4344–7

Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4170–3

Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Szczech LA, et al. **Transplant Proc** 1999 May;31(3B Suppl):9S–11S (14 ref.)

Effect of low molecular weight heparin on graft vascular disease in the rat cardiac allograft model. Teranishi K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):103–5

Prolongation effect of FK506 on the survival of 3-day preserved kidney allografts in dogs. Watanabe K, et al. **Transplant Proc** 1998 Nov;30(7):3603–5

Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. Yamashita K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1178–9

Tamoxifen prolongs heart allograft survival in cyclosporine-treated female mice. Zou YP, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1222–3

1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Cantorna MT, et al. **Transplantation** 1998 Oct 15; 66(7):828–31

Combined anti-vascular cell adhesion molecule-1 and anti-leukocyte function-associated molecule-1 monoclonal antibody therapy does not prolong allograft survival in an ovine model of renal transplantation. Grooby WL, et al. **Transplantation** 1998 Oct 15;66(7):920–4

Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Hullett DA, et al. **Transplantation** 1998 Oct 15; 66(7):824–8

Long-term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy. Ustüner ET, et al. **Transplantation** 1998 Dec 27; 66(12):1581–7

Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Fiane AE, et al. **Xenotransplantation** 1999 Feb;6(1):52–65

Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice. Koulmanda M, et al. **Xenotransplantation** 1998 Aug;5(3):215–21

[The effect of vascular endothelial cell growth factor on survival of skin flap in rats] Wei P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):376–8 (Eng. Abstr.) **(Chi)**

[Genetic methods in experimental xenogenic nerve transplantation] Hebebrand D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1279–81 (Eng. Abstr.) **(Ger)**

GENETICS

Donor G protein beta3 subunit 825TT genotype is associated with reduced kidney allograft survival. Beige J, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1717–21

IMMUNOLOGY

Donor-specific tolerance induction in composite tissue allografts. Foster RD, et al. **Am J Surg** 1998 Nov; 176(5):418–21

Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells. Slavin S, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:37–44

Acquired systemic tolerance to islet allografts induced by intrathymic inoculation of alloantigens--a brief review. Oluwole SF, et al. **Ann Transplant** 1997;2(3):81–5

The role of adhesion molecules in allotransplanted islet cells rejection. Prolongation of islet cells allograft survival by antiadhesion treatment. Socha-Urbanek K, et al. **Ann Transplant** 1998;3(4):5–9 (36 ref.)

A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation. Blazar BR, et al. **Blood** 1998 Dec 1; 92(11):4453–63

Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bonnet D, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):203–9

Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Dreger P, et al. **Bone Marrow Transplant** 1999 Jul;24(2):153–61

Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Hägglund H, et al. **Bone Marrow Transplant** 1998 Jul;22(2):131–6

Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia. Mital MK, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):201–4

Overcoming the histocompatibility barrier: transferrins as carriers and modulators of immunogenic identity. Pierpaoli W. **Cell Transplant** 1998 Nov–Dec;7(6):541–8 (60 ref.)

Reassessment of the role of CD8+ T cells in the induction

of allograft tolerance by donor-specific blood transfusion. Douillard P, et al. **Eur J Immunol** 1999 Jun;29(6):1919-24

Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. Duan WM, et al. **Eur J Neurosci** 1998 Aug;10(8):2595-606

Effects of complement suppression on xenograft survival in hyperacute rejection. Mukai S, et al. **Hiroshima J Med Sci** 1999 Mar;48(1):17-24

Effect of IL-4 deletion on cardiac allograft survival in the BALB/c to 129Sv x C57BL/6 strain combination. Mottram P, et al. **Immunol Cell Biol** 1998 Dec;76(6):563-5

Donor-specific stimulation of peripheral blood mononuclear cells from recipients of orthotopic liver transplants is associated, in the absence of rejection, with type-2 cytokine production. Chung SW, et al. **Immunol Lett** 1998 Sep; 63(2):91-6

Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice. Eto M, et al. **Immunology** 1999 Mar;96(3):440-6

Paradoxical early immune activation during acceptance of liver allografts compared with rejection of skin grafts in a rat model of transplantation. Rokahr KL, et al. **Immunology** 1998 Oct;95(2):257-63

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Kreitman RJ, et al. **Int J Cancer** 1999 Mar 31; 81(1):148-55

Relationship between chimerism and tolerance in a kidney transplantation model. Fuchimoto Y, et al. **J Immunol** 1999 May 15;162(10):5704-11

An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. Gorczynski RM, et al. **J Immunol** 1999 Aug 1;163(3):1654-60

The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. Judge TA, et al. **J Immunol** 1999 Feb 15;162(4):1947-51

Accommodated xenografts survive in the presence of anti-donor antibodies and complement that precipitate rejection of naive xenografts. Lin Y, et al. **J Immunol** 1999 Sep 1;163(5):2850-7

Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts. Mandelbrot DA, et al. **J Immunol** 1999 Oct 1;163(7):3753-7

Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in "high risk" eyes. Yamada J, et al. **J Immunol** 1999 May 1;162(9):5247-55

Cold preservation of nerve grafts decreases expression of ICAM-1 and class II MHC antigens. Atchabahian A, et al. **J Reconstr Microsurg** 1999 May;15(4):307-11

Skin allograft survival following intrathymic injection of donor bone marrow. Cober SR, et al. **J Surg Res** 1999 Aug;85(2):204-8

Anti-TNF antibody modulates cytokine and MHC expression in cardiac allografts. Wei RQ, et al. **J Surg Res** 1999 Feb;81(2):123-8

Peripheral donor leukocytes prolong survival of rat renal allografts. Noris M, et al. **Kidney Int** 1999 Sep; 56(3):1101-12

Specific tolerance induction and organ transplantation. de Vries-van der Zwan A, et al. **Leuk Lymphoma** 1998 Sep; 31(1-2):131-42 (56 ref.)

Cold preserved nerve allografts: changes in basement membrane, viability, immunogenicity, and regeneration. Evans PJ, et al. **Muscle Nerve** 1998 Nov;21(11):1507-22

The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [see comments] Burlingham WJ, et al. **N Engl J Med** 1998 Dec 3;339(23):1657-64. Comment in: N Engl J Med 1998 Dec 3;339(23):1700-2. Comment in: N Engl J Med 1999 Apr 29;340(17):1369-70.

The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [letter; comment] Opelz G. **N Engl J Med** 1999 Apr 29;340(17):1369-70. Comment on: N Engl J Med 1998 Dec 3;339(23):1657-64.

Transplantation tolerance--the search continues [editorial; comment] Sanfilippo F. **N Engl J Med** 1998 Dec 3; 339(23):1700-2. Comment on: N Engl J Med 1998 Dec 3;339(23):1657-64.

Correlation between allograft survival and chimeric state after bone marrow infusion in rat small bowel transplantation. Bakonyi Neto A, et al. **Pediatr Transplant** 1999 Feb;3(1):67-73

Renal graft survival in children with early acute rejection [see comments] Muñoz R, et al. **Pediatr Transplant** 1998 Nov;2(4):294-8. Comment in: Pediatr Transplant 1998 Nov;2(4):254-6.

Prediction of graft prolongation by mixed lymphocyte culture following anti-CD4 monoclonal antibody treatment among different donor-recipient combinations. Hamano K, et al. **Surg Today** 1999;29(9):868-73

Better-surviving liver grafts by the injection of anti-CD2 antibody: the important roles of host CD8+ and CD2+CD28+ T cells in chronic graft rejection and beta type platelet-derived growth factor receptor (PDGFR-beta) expression on apoptotic liver grafts. Nakatsuji T. **Tohoku J Exp Med** 1999 Mar;187(3):215-25

Intrathymic administration of B cells induces prolonged survival of fully allogeneic cardiac grafts without prolonged deletion of donor-specific thymocytes. Niimi M, et al. **Transpl Immunol** 1998 Sep;6(3):177-81

Kupffer cell activation in the survival discrepancy between liver grafts from enterally and parenterally fed donors. Ishikawa T, et al. **Transpl Int** 1998;11 Suppl 1:S410-6

Induction of long-term heart graft survival in HLA class I transgenic mice by intrathymic injection of HLA class I peptides. Ando Y, et al. **Transplant Proc** 1998 Nov; 30(7):3890-1

Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Antonysamy MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):93

Three-month survival of HDAFF transgenic pig hearts transplanted into primates. Bhatti FN, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):958

Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival. Chang AC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):95

FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Chiba K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1230-3

Thymic and liver graft expression of CD95-L tolerizes allogeneic orthotopic liver grafts. Fändrich F, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):438-9

Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3815-7

Influence of Th1 and Th2 cytokine patterns on graft acceptance in pediatric liver transplantation. Ganschow R, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):465-6

Extension of graft survival with pulsed administration of donor dendritic cells. Gozzo J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1196

Adenovirus-mediated gene transfer of CTLA4IG gene results in prolonged survival of heart allograft. Guang-Lin M, et al. **Transplant Proc** 1998 Nov;30(7):2923-4

Anti-alpha beta-T cell receptor monoclonal antibody induces tolerance without dominant infiltration by Th2 cells into grafts. Hamano K, et al. **Transplant Proc** 1998 Nov; 30(7):3892

Study of immunologic mechanisms in xenogenic transplantation. Han DJ, et al. **Transplant Proc** 1998 Nov; 30(7):3811-2

Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. He G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1239-41

Induction of hyporesponsiveness and prolongation of cardiac allograft survival after jejunal administration of donor splenocytes and its abrogation by administration of gadolinium. Ishido N, et al. **Transplant Proc** 1998 Nov; 30(7):3881-2

Can intraoperative inoculation of donor splenocytes via the portal vein prolong allograft survival? Ishido N, et al. **Transplant Proc** 1998 Nov;30(7):3883-4

Role of microchimerism on long-term graft survival after donor-specific transfusion in a rat heart transplantation model. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3862-4

Contribution of passenger leukocytes to the induction and maintenance of heart allograft acceptance. Ko S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):158-9

The fate of donor splenic lymphocytes in a long-surviving host after combined pancrea/spleen transplantation in the rat. Kobayashi E, et al. **Transplant Proc** 1999 Sep; 31(6):2665-7

IL-10 is an effector molecule mediating urocanic acid-induced immunosuppression. Krulová M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1218-9

Immunosuppressive action of FTY720 for renal allograft a rat model. Kunikata S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1157-9

HLA epitopes for kidney allocation. Lee PC, et al. **Transplant Proc** 1998 Nov;30(7):3496-7

Abolition of anti-CD4-induced allotransplantation tolerance by exogenous IL-2. Lehmann M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1220-1

Recipient pretreatment with mammalian IL-10 prolongs mouse cardiac allograft survival by inhibition of anti-donor T cell responses. Li W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):115

Local production of CTLA4-Ig by adenoviral-mediated gene transfer to the pancreas induces permanent allograft survival and donor-specific tolerance. Liu C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):625-6

Study of donor-specific antigens in inducing tolerance and enhancing graft survival. Lu YP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):846

Hearts lacking donor-type APCs develop cardiac allograft vasculopathy. McLean AD, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):135

A composite graft of islet plus donor lymph node cells induced donor specific tolerance in a "low responder" rat combination with class I MHC disparity. Maeda A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):749-50

Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Magee JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1194

Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Markees TG, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):884-5

Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Mhoyan A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1189-91

Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Minguela A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):519-20

Effect of simultaneous infusion of donor bone marrow on hamster-to-rat heart xenograft survival. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3869-70

Induction of tolerance to an "untolerizable" strain by double-strain intrathymic inoculation in experimental rat cardiac transplantation. Mohiuddin MM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):838-9

Prolongation of rat fetal pancreas allograft survival using a nondepleting anti-CD4 monoclonal antibody W3/25. Muller CJ, et al. **Transplant Proc** 1998 Dec;30(8):4180-3

Effect of HLA matching on liver graft survival. Muro M, et al. **Transplant Proc** 1999 Sep;31(6):2477-9

Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. Nakai T, et al. **Transplant Proc** 1999 Sep;31(6):2661-4

Decreased gamma-IFN and IL-2 gene expression in regional lymph nodes of skin allografts is associated with increased allograft survival in the WKY F344 rat model. Nicolaidou E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):818-9

Intrathymic inoculation of donor B cells prolongs cardiac allograft survival by non-deletional mechanisms. Niimi M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):94

Effect of a new immunosuppressive agent, KF20444, in rat cardiac transplantation. Nomura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1206-7

Effect of mismatched combinations of HLA-A antigens on graft survival in the transplanted kidney. Ogahara S, et al. **Transplant Proc** 1998 Nov;30(7):3500-1

Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1998 Dec;30(8):4029-30

Cylexin: a P-selectin inhibitor prolongs heart allograft survival in hypersensitized rat recipients. Park IY, et al. **Transplant Proc** 1998 Nov;30(7):2927-8

Tolerance of rat cardiac allografts does not require donor-type "passenger" antigen presenting cells. Popma SH, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):840-1

Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Rastellini C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):646-7

Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival. Rastellini C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1242-3

Lack of accommodation after long-term survival of hamster xenografts in rats. Ribas Y, et al. **Transplant Proc** 1999 Sep;31(6):2633-4

Chimeric liver established by recipient type bone marrow cell transplantation to donor before to liver transplantation produces marked suppression of allograft rejection in rats. Sanada O, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):704-6

Impact of 70% partial hepatectomy on administration of donor leukocytes in cardiac transplantation in rats. Sato Y, et al. **Transplant Proc** 1998 Nov;30(7):3873-5

Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Schulz T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):591-2

Only a limited set of HLA epitopes is associated with organ graft loss. Segers A, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):721-3

Donor specific CDC lymphocyte crossmatch and five year allograft survival. Sharma RK, et al. **Transplant Proc** 1998 Nov;30(7):2966

Simultaneous inoculation of donor lymphocyte subsets with transplantation in a rat cardiac allograft model. Sho M, et al. **Transplant Proc** 1998 Nov;30(7):3876-8

Different roles for alpha 4-integrin/VCAM-1 and alpha 4/fibronectin interactions in allograft rejection. Stegall MD, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):786

Course and mechanism of tolerance induction after mouse liver transplantation. Sugioka A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):459

Engraftment of murine embryonic stem cells in neonatal rats. Sun J, et al. **Transplant Proc** 1998 Nov;30(7):2935-7

Prolonged small bowel allograft survival following repeated intrathymic injections of donor splenocytes and peripheral anti-lymphocyte treatment. Sun S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):588-9

Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. Suzuki T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1208-9

Role of indirect allorecognition pathway for prolongation of rat liver allograft survival. Takeda K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):432-3

Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. Takeda M, et al. **Transplant Proc** 1998 Nov;30(7):3813-4

Acceptance of islet allografts transplanted with Fas ligand expressing testicular allografts. Takeda Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):624

Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK, et al. **Transplant Proc** 1999

Feb-Mar;31(1-2):781
Rejection of discordant skin xenografts by CD4- CD8- TCR alpha beta+ cells in CD4- and CD8-deficient mice. Umesue M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):890-1
Allocation of cadaver kidneys according to HLA-DR matching alone would result in optimal graft outcome in most recipients. Vereerstraeten P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):739-41
Antigen load and liver allograft survival. Wang C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):455
Prolongation of cardiac allograft survival with intracoronary viral interleukin-10 gene transfer. Wang CK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):951-2
Differences in cellular mechanisms between heart and skin graft rejection by in vitro and in vivo analyses. Yamamoto T, et al. **Transplant Proc** 1998 Nov;30(7):3854
Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. Yoshimura N, et al. **Transplant Proc** 1998 Nov;30(7):3110-1
Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Dengler TJ, et al. **Transplantation** 1999 Feb 15;67(3):392-8
IgA class antibodies and flow cytometric cross-matching in renal transplantation. Doran TJ, et al. **Transplantation** 1999 Jan 27;67(2):309-14
The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Fredrich R, et al. **Transplantation** 1999 Feb 15;67(3):385-91
Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Fu F, et al. **Transplantation** 1999 Feb 15;67(3):444-50
Exploitation of the continuum between early ischemia/reperfusion injury and host alloresponsiveness: indefinite kidney allograft survival by treatment with a soluble P-selectin ligand and low-dose cyclosporine in combination. Kusaka M, et al. **Transplantation** 1999 May 15;67(9):1255-61
Requirement of CD4 cells for induction and maintenance of unresponsiveness in islet xenografted mice. Lu X, et al. **Xenotransplantation** 1998 Aug;5(3):207-14

PHYSIOLOGY

Are all successful renal transplants really successful? Aultman DF, et al. **Am J Kidney Dis** 1999 Jul;34(1):61-4
Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. Lechevallier E, et al. **Am J Kidney Dis** 1998 Dec;32(6):984-91
Intravenous glycine improves survival in rat liver transplantation. Schemmer P, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G924-32
Engraftment and multilineage expression of human bone marrow CD34- cells in vivo. Zanjani ED, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:220-31; discussion 231-2
Acute rejection and delayed graft function--risk factors of graft loss. Boratyńska M, et al. **Ann Transplant** 1996; 1(2):19-22
A new model of orthotopic penetrating corneal transplantation in the sheep: graft survival, phenotypes of graft-infiltrating cells and local cytokine production. Williams KA, et al. **Aust N Z J Ophthalmol** 1999 Apr; 27(2):127-35
Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Lee TH, et al. **Blood** 1999 May 1;93(9):3127-39
The resorption of vital and devitalized bone in vitro: significance for bone grafts. Kingsmill VJ, et al. **Calcif Tissue Int** 1999 Mar;64(3):252-6
Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection? Yoshida EM, et al. **Can J Gastroenterol** 1998 Sep;12(6):387-9
Forskolin-stimulated adenylylcyclase activity: a marker to assess islet cell viability following cold storage in different solutions and to predict islet cell function following transplantation. Kanazawa S, et al. **Cell Transplant** 1999 Jul-Aug;8(4):383-8
Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. McLaren AJ, et al. **Clin Transplant** 1999 Jun;13(3):266-72
Is donor age an important determinant of graft survival? Beck RW, et al. **Cornea** 1999 Sep;18(5):503-10 (29 ref.)
Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Yurek DM. **Exp Neurol** 1998 Oct; 153(2):195-202
Addition of fresh blood to intrastriatal grafts of embryonic mesencephalon into the hemiparkinsonian rat does not impair the survival of grafted dopaminergic neurones. Zietlow R, et al. **Exp Neurol** 1999 Mar;156(1):205-8
Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism? Broekroelofs J, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2075-81
A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. Josien R, et al. **J Clin Invest** 1998 Dec 1;102(11):1920-6
A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. Wilby MJ, et al. **J Neurosci** 1999 Mar 15;19(6):2301-12
Long-term survival of fetal porcine lateral ganglionic eminence cells in the hippocampus of rats. Jacoby DB, et al. **J Neurosci Res** 1999 Jun 15;56(6):581-94
Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain. Muir JK, et al. **J Neurotrauma** 1999 May; 16(5):403-14
Directing portal flow is essential for graft survival in auxiliary partial heterotopic liver transplantation in the dog. de Jonge J, et al. **J Pediatr Surg** 1999 Aug;34(8):1265-8
Management of the cadaveric donor of a renal transplant: more than optimizing renal perfusion? [editorial; comment] Lu CY. **Kidney Int** 1999 Aug;56(2):756-7. Comment on: Kidney Int 1999 Aug;56(2):738-46.
Effects of activated macrophages and fibroblast growth factor on random skin flap survival in swine. Bach KK, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1156-9
Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Bittencourt MC, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2059-64
Delayed implantation of nigral grafts improves survival of dopamine neurones and rate of functional recovery. Sinclair SR, et al. **Neuroreport** 1999 Apr 26;10(6):1263-7
Neural transplantation of human neuroteratocarcinoma (hNT) neurons into ischemic rats. A quantitative dose-response analysis of cell survival and behavioral recovery. Saporta S, et al. **Neuroscience** 1999;91(2):519-25
Comparable renal graft survival in African-American and Caucasian recipients. Ilyas M, et al. **Pediatr Nephrol** 1998 Sep;12(7):534-9
Spinal cord stimulation improves survival in ischemic skin flaps: an experimental study of the possible mediation by calcitonin gene-related peptide. Gherardini G, et al. **Plast Reconstr Surg** 1999 Apr;103(4):1221-8
The vascularized pig fibula bone flap model: effects of multiple segmental osteotomies on growth and viability. Gur E, et al. **Plast Reconstr Surg** 1999 Apr;103(5):1436-42
Locally administered vascular endothelial growth factor cDNA increases survival of ischemic experimental skin flaps. Taub PJ, et al. **Plast Reconstr Surg** 1998 Nov; 102(6):2033-9
Hyaluronidase ameliorates rejection-induced edema. Johnsson C, et al. **Transpl Int** 1999;12(4):235-43
Should pediatric kidneys be used in cadaveric kidney transplantation? Alshaibani K, et al. **Transplant Proc** 1998 Nov;30(7):3123-4
Cardiac preservation with nitroglycerine and cyclic adenosine monophosphate. Baxter K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1046-7
How to handle mycophenolate mofetil in combination with tacrolimus? Braun F, et al. **Transplant Proc** 1998 Dec; 30(8):4094-5
Withdrawal versus continuous cyclosporine therapy in kidney transplant recipients of one-haplotype-matched donors. Chew-Wong A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1106-9
Intraoperative reperfusion blood flow predicts post warm ischemic kidney transplant survival and efficacy of preservation maneuvers. Chiu C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1049-50
Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups. Cho S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):322-3
Prolonged hypertension (> 10 years) is a significant risk factor in older cadaver donor renal transplants. Cho YW, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1283
Effect of donor age on renal allograft survival. Degawa H, et al. **Transplant Proc** 1998 Nov;30(7):3660-1
Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension. Di Paolo S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1357-8
Long-term cardiac allograft survival in mice treated with malononitrilamide 715. Gerauer K, et al. **Transplant Proc** 1998 Dec;30(8):4205-6
Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization. Gorczynski RM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):577-8
The suppression of heart and liver allograft rejection by liver suppressor factor one (LSF-1) and its possible human homologue. Goto S, et al. **Transplant Proc** 1998 Nov; 30(7):3578-9
Role of graft cytokine expression in the tolerogenicity of neonatal skin allografts. Gozzo J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):813
Comparison of viral gene-deleted adenoviral vectors with the E1-deleted adenoviral vector in islets. Guo Z, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):794
FK 506 in cadaveric kidney transplantation from non-heart-beating donors. Hattori R, et al. **Transplant Proc** 1998 Nov;30(7):3801-3
Long-term results and risk factors of quadruple immunosuppression in renal transplantation. Hiesse C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1111-2
Paired kidneys as a study model for the analysis of factors affecting cadaveric renal allograft survival. Jang HJ, et al. **Transplant Proc** 1998 Nov;30(7):3669-70
Impact of donor age on long-term graft survival in living donor kidney transplantation. Kanematsu A, et al. **Transplant Proc** 1998 Nov;30(7):3118-9
Cytoprotective role of antioxidant stress protein induced by adenosine A1 receptor antagonist in rat heart ischemic injury. Katori M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1016-7
Nitric oxide donor induces upregulation of stress proteins in cold ischemic rat hearts. Katori M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1022-3
Hypertension in kidney transplantation recipients: effect on long-term renal allograft survival. Kim HC, et al. **Transplant Proc** 1998 Nov;30(7):3906-7
True living donor kidney weight-to-recipient body weight ratio influences posttransplant 1-year renal allograft function. Kim SI, et al. **Transplant Proc** 1998 Nov; 30(7):3120
Changes in cell cycling and apoptosis contribute to reduced effector cell generation among long-term heart transplant survivors. Kimball PM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):109-10
Arterial ketone body ratio in clinical liver transplantation. Kitabayashi K, et al. **Transplant Proc** 1998 Dec; 30(8):4356-9
Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Klupp J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1113-4
Long-term (10-month) pig islet xenograft tolerance using measured total lymphoid irradiation, splenectomy, short-term rabbit antithymocyte globulin, and deoxyspergualin without long-term immunosuppression. Llyung T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):962-3
L-arginine during liver procurement from non-heart-beating donor pigs: histological evaluation. López-Boado MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1069
Augmentation of microchimerism with donor bone marrow infusion in hamster-to-rat heart xenograft recipients. Miyata Y, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):694-5
Dynamic changes in xenogeneic microchimerism after hamster-to-rat lung and heart xenotransplantation. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3867-8
Effect of simultaneous infusion of donor bone marrow on hamster-to-rat heart xenograft survival. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3869-70
Analysis of donor-specific unresponsiveness to rat allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen. Motoyama K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1237-8
Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Neumann UP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1029-30
Flow cytometry crossmatch and kidney graft outcome. Piazza A, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):314-6
Acute rejection of rat renal allografts is accelerated by donor brain death. Pratschke J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):874-5
Depletion of IL-4 does not prevent tolerance induction in an allogeneic rat kidney transplantation model. Ritter T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):887-8
Prolonged patency of hamster aortic xenografts in rat by cryopreservation. Saito S, et al. **Transplant Proc** 1998 Nov; 30(7):3821-3
Saline with glutamine improves cold preserved small bowel graft mortality. Sakawaki T, et al. **Transplant Proc** 1998 Nov;30(7):3471-4
Selective hepatic denervation prior to organ harvest improves survival after liver transplantation. Schemmer P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):537
Splenectomy improves survival of HDAF transgenic pig kidneys in primates. Schmoeckel M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):961
Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4099-103
Impact of donor/recipient gender, age, HLA matching, and weight on short-term graft survival following living related renal transplantation. Shaheen FA, et al. **Transplant Proc** 1998 Nov;30(7):3655-8
Immunosuppressive effect of FTY 720 on rat pancreas allograft. Suzuki K, et al. **Transplant Proc** 1998 Nov; 30(7):3417-8
Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. Takada Y, et al. **Transplant Proc** 1998 Nov;30(7):3694-5
Efficacy of heat-shock proteins induced by severe fasting to protect rat livers preserved for 72 hours from cold ischemia/reperfusion injury. Takahashi Y, et al. **Transplant Proc** 1998 Nov;30(7):3700-2
Intermittent addition of shear stress may improve graft viability in rat small bowel transplantation. Takeuchi M, et al. **Transplant Proc** 1998 Nov;30(7):3461-3
Induction and maintenance of tolerance by CTLA-4IG in rat small bowel allografts. Tarumi K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):878-81

Operational tolerance of long-surviving cardiac xenografts (LSCX) is related to modification of the graft-in-residence and not to induced tolerance in the recipient: studies in retransplanted LSCX. Thomas F, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):966-7

Impact of delayed function on long-term graft survival after solid organ transplantation. Troppmann C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1290-2

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Grant D, et al. **Transplantation** 1999 Apr 27;67(8):1133-7

Enhanced hepatocyte growth factor expression associated with prolonged rat hepatic allograft survival in recipients pretreated with donor-specific blood. Ichiguchi O, et al. **Transplantation** 1999 Jan 15;67(1):115-23

Mouse-to-rabbit xenotransplantation: a new small animal model of hyperacute rejection mediated by the classical complement pathway. Kerr SR, et al. **Transplantation** 1999 Feb 15;67(3):360-5

Delayed graft function and renal allograft outcome [letter] Land W. **Transplantation** 1999 Aug 15;68(3):452-3

[3-phase bone scintigraphy of microsurgically attached bone transplants as early graft survival assessment] Soost F, et al. **Handchir Mikrochir Plast Chir** 1999 Jan;31(1):42-6 (Eng. Abstr.) **(Ger)**

[Intrarenal doppler flow analysis in patients with kidney transplantation and stable transplant function] Restrepo-Schäfer IK, et al. **Ultraschall Med** 1999 Jun; 20(3):87-92 (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Skin graft survival after external beam irradiation. Tadjalli HE, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1902-8

Effects of ultraviolet B irradiation on fetal pig islet-like cell clusters. Deol HS, et al. **Xenotransplantation** 1998 Nov; 5(4):292-7

[The effect of far infrared rays on the survival of randomized skin flap in the rat: an experimental study] Jiang P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):69-71 (Eng. Abstr.) **(Chi)**

GRAFT-VERSUS-HOST DISEASE see **GRAFT VS HOST DISEASE**

GRAFT VS HOST DISEASE

Successful resolution of severe graft versus host disease after liver transplantation correlating with disappearance of donor DNA from the peripheral blood. Paizis G, et al. **Aust N Z J Med** 1998 Dec;28(6):830-2

Discrepancy of clinical, radiographic and histopathologic findings in two children with chronic pulmonary graft-versus-host disease after HLA-identical sibling stem cell transplantation. Benesch M, et al. **Bone Marrow Transplant** 1998 Oct;22(8):809-12

Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bryson JS, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):363-72

Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Solano C, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1129-35

Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Zikos P, et al. **Haematologica** 1998 Oct; 83(10):896-903

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Machida U, et al. **N Engl J Med** 1999 Mar 11;340(10):810; discussion 811-2. Comment on: N Engl J Med 1998 Oct 22;339(17):1186-93.

[Chronic GVHD] Kodo H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):601-4 (9 ref.) **(Jpn)**

BLOOD

Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Kanda Y, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):751-4

IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Ferrà C, et al. **Haematologica** 1998 Dec;83(12):1082-7

CD4+ and CD8+ T cell subset distribution in the blood of small-bowel-grafted rats: modification during graft-versus-host disease. Marni A, et al. **Transpl Int** 1998; 11 Suppl 1:S467-71

Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Liem LM, et al. **Transplantation** 1999 Jan 15;67(1):59-65

CHEMICALLY INDUCED

Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient. Spaner D, et al. **Transplantation** 1998 Nov 15;66(9):1251-3

CLASSIFICATION

Methods for assessment of graft-versus-host disease [letter] Martin PJ, et al. **Blood** 1998 Nov 1;92(9):3479-81

Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Martino R, et al. **Bone Marrow Transplant** 1999 Aug;24(3):283-7

COMPLICATIONS

A follicular lichenoid eruption as manifestation of chronic graft-vs-host disease [letter] Valks R, et al. **Acta Derm Venereol** 1998 Sep;78(5):386

Acral keratotic graft versus host disease simulating warts. Kossard S, et al. **Australas J Dermatol** 1999 Aug; 40(3):161-3

Disseminated nocardiosis in a bone marrow transplant recipient with chronic GVHD. Bhave AA, et al. **Bone Marrow Transplant** 1999 Mar;23(5):519-21

Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. Oliveira JS, et al. **Bone Marrow Transplant** 1999 Jan;23(1):99-101

Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. Picardi M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):173-7

Pneumocystis cystoides intestinalis with pneumoperitoneum and pneumoretroperitoneum in a patient with extensive chronic graft-versus-host disease. Schulenburg A, et al. **Bone Marrow Transplant** 1999 Aug;24(3):331-3

Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Tse S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):397-9

Acute cutaneous graft-versus-host disease with ichthyosiform features [letter] Chao SC, et al. **Br J Dermatol** 1998 Sep;139(3):553-5

Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. Murai M, et al. **J Clin Invest** 1999 Jul;104(1):49-57

Orthopaedic manifestations of chronic graft-versus-host disease. Beredjiklian PK, et al. **J Pediatr Orthop** 1998 Sep-Oct;18(5):572-5

Angiitis of the central nervous system after allogeneic bone marrow transplantation? Padovan CS, et al. **Stroke** 1999 Aug;30(8):1651-6

Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Nevo S, et al. **Transplantation** 1999 Mar 15; 67(5):681-9

DIAGNOSIS

Pretransplant helper T-lymphocyte determination in bone marrow donors: acute graft-versus-host disease prediction and relation with long-term survival. Winandy M, et al. **Br J Haematol** 1999 Apr;105(1):288-94

Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Stone N, et al. **Clin Exp Dermatol** 1999 Jul;24(4):260-2

Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Ponec RJ, et al. **Gastrointest Endosc** 1999 May;49(5):612-21

Comparison of detection techniques for cytokine reverse transcriptase polymerase chain reaction; digoxigenin-labeled polymerase chain reaction permits sensitive detection of cytokine mRNA in rat heart allografts. Damoiseaux JG, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):185-93

DNA polymorphism analysis in transfusion-associated graft-versus-host disease. Warren LJ, et al. **J Paediatr Child Health** 1999 Feb;35(1):98-101

Intraepidermal bile pigment in skin biopsy specimens for graft-versus-host disease versus erythema multiforme. Dilday BR, et al. **Mod Pathol** 1998 Oct;11(10):1005-9

Unusual presentation of graft-versus-host disease in pediatric liver transplant recipients: evidence of late and recurrent disease. Pinna AD, et al. **Pediatr Transplant** 1999 Aug; 3(3):236-42

DRUG THERAPY

Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Greinix HT, et al. **Blood** 1998 Nov 1;92(9):3098-104

Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Marcellus DC, et al. **Blood** 1999 Jan 1;93(1):66-70

Methemoglobinemia secondary to clofazimine treatment for chronic graft-versus-host disease [letter] Moreira V, et al. **Blood** 1998 Dec 15;92(12):4872-3

A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Przepiorka D, et al. **Blood** 1998 Dec 1;92(11):4066-71

The use of topical cyclosporin A in ocular graft-versus-host-disease. Kiang E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):147-51

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Kostaridou S, et al. **Bone Marrow Transplant** 1998 Nov;22(9):919-21

Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M, et al. **Bone Marrow Transplant** 1999 Jan;23(2):145-50

Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Nagler RM, et al. **Bone Marrow Transplant** 1999 May; 23(10):1007-11

How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation [letter] Ruutu T, et al. **Bone Marrow Transplant** 1998 Sep; 22(6):614-5

Thalidomide for chronic GVHD [letter; comment] Sastry PS, et al. **Bone Marrow Transplant** 1998 Nov;22(9):933-4 . Comment on: Bone Marrow Transplant 1998 Apr;21(7):721-3.

Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. Wiesmann A, et al. **Bone Marrow Transplant** 1999 Jan;23(2):151-5

Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Poston RS, et al. **Circulation** 1999 Jul 6;100(1):67-74

Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Girardi M, et al. **J Dermatol Sci** 1999 Feb;19(2):106-13 (34 ref.)

Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Redding SW, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):183-7 (28 ref.)

Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Mehta P, et al. **Pediatrics** 1999 Apr;103(4):e44 (13 ref.)

Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Basara N, et al. **Transplant Proc** 1998 Dec;30(8):4087-9

Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec;30(8):4153-5

Potential usefulness of photochemotherapy using 8-methoxypsoralen in the treatment of posttransfusion graft-versus-host disease [letter] Nishimura M, et al. **Vox Sang** 1998;75(4):306-7

Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Ryo R, et al. **Vox Sang** 1999;76(4):241-6

EPIDEMIOLOGY

A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Ustün C, et al. **Biol Blood Marrow Transplant** 1999;5(1):28-35

Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Beelen DW, et al. **Blood** 1999 May 15;93(10):3267-75

High risk of transfusion-associated graft-versus-host disease with nonirradiated allogeneic blood transfusion in cardiac surgery [letter] Yasuura K, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1117-8

ETIOLOGY

Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia. Reiter E, et al. **Ann Hematol** 1998 Dec;77(6):283-6

Induction of hyperacute graft-vs-host disease after donor leukocyte infusions. Fernández-Herrera J, et al. **Arch Dermatol** 1999 Mar;135(3):304-8

Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. Drobyski WR, et al. **Biol Blood Marrow Transplant** 1999; 5(4):222-30

High risk of chronic graft-versus-host disease in unmanipulated allogeneic peripheral blood stem cell transplantation [letter; comment] Kalayoğlu-Beşişik S, et al. **Blood** 1998 Oct 15;92(8):2973-5. Comment on: Blood 1997 Dec 15;90(12):4705-9.

Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Przepiorka D, et al. **Blood** 1999 Aug 15;94(4):1465-70

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Ringdén O, et al. **Blood** 1999 Apr 1;93(7):2196-201

Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Carlens S, et al.

Bone Marrow Transplant 1999 Sep;24(6):629–35

Risk factors for chronic graft–versus–host disease after bone marrow transplantation: a retrospective single centre analysis. Carlens S, et al. **Bone Marrow Transplant** 1998 Oct;22(8):755–61

Autoaggression syndrome resembling acute graft–versus–host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. de Arriba F, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):621–4

Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft–versus–host reactions. Fuchs EJ, et al. **Bone Marrow Transplant** 1998 Aug;22(3):303–5

Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft–versus–host disease in partial T cell–depleted bone marrow transplantation. Gadisseur AP, et al. **Bone Marrow Transplant** 1999 May;23(10):1013–7

Acute graft–versus–host disease after bone marrow transplantation with a single HLA–DPB1*1001 mismatch: involvement of different TCRBV subsets. Gaschet J, et al. **Bone Marrow Transplant** 1998 Aug;22(4):385–92

Acute GVHD involving the gastrointestinal tract and infestation with Blastocystis hominis in a patient with chronic myeloid leukaemia following allogeneic bone marrow transplantation. Ghosh K, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1115–7

Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft–versus–host disease (GVHD). Gmeinhart B, et al. **Bone Marrow Transplant** 1999 Jun; 23(11):1197–9

A trend towards an increased incidence of chronic graft–versus–host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. Scott MA, et al. **Bone Marrow Transplant** 1998 Aug; 22(3):273–6

Helper and cytotoxic T cell precursor frequencies are not predictive for development of acute graft–versus–host disease after partially T cell–depleted HLA–identical sibling BMT. van der Meer A, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1049–55

Role of interleukin-12 in the development of acute graft–versus–host disease in bone marrow transplant patients. Yabe M, et al. **Bone Marrow Transplant** 1999 Jul; 24(1):29–34

Sclerodermatous graft–versus–host disease after donor leucocyte infusion. Jones–Caballero M, et al. **Br J Dermatol** 1998 Nov;139(5):889–92

Levels of soluble FasL and FasL gene expression during the development of graft–versus–host disease in DLT–treated patients. Das H, et al. **Br J Haematol** 1999 Mar; 104(4):795–800

Enhancement of graft–versus–tumor activity and graft–versus–host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient–derived tumor cell vaccine. Anderson LD Jr, et al. **Cancer Res** 1999 Apr 1;59(7):1525–30

GVL and GVHD following the infusion of a limited number of donor CD3 cells in the therapy of leukaemia relapse after bone marrow transplantation [letter] du Toit C, et al. **Eur J Haematol** 1999 Jan;62(1):68–9

Transfusion–associated graft–versus–host disease following exchange transfusion in a newborn [letter] Ozkan H, et al. **Eur J Pediatr** 1999 Apr;158(4):343

Transfusion associated graft versus host disease in an immunocompetent individual following coronary artery bypass grafting. Ahya R, et al. **Heart** 1998 Sep; 80(3):299–300

Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. Corvò R, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):497–503

Induction of autologous graft–versus–host disease after autologous peripheral blood stem cell transplantation. Nakamura H, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S457–61

Graft versus host disease in autologous stem cell transplantation. Marin GH, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):201–8

Th1 cytokines and NK cells participate in the development of murine syngeneic graft–versus–host disease. Flanagan DL, et al. **J Immunol** 1999 Aug 1;163(3):1170–7

Cyclosporin A–induced autologous graft–versus–host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. Wu DY, et al. **J Immunol** 1999 Jun 1; 162(11):6926–33

Graft versus host disease following blood transfusion during coronary artery bypass grafting. Shamsi TS, et al. **JPMA J Pak Med Assoc** 1998 Sep;48(9):279–81

Long–term follow–up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft–versus–host disease and graft–versus–leukemia, and the problem of extramedullary relapse. Singhal S, et al. **Leuk Lymphoma** 1999 Feb; 32(5–6):505–12

Transfusion medicine [letter; comment] Vandenberghe P, et al. **N Engl J Med** 1999 Jul 8;341(2):125; discussion 126–7 . Comment on: N Engl J Med 1999 Feb 11;340(6):438–47. Comment on: N Engl J Med 1999 Feb 18;340(7):525–33.

Ocular findings in allogeneic stem cell transplantation without total body irradiation. Kerty E, et al. **Ophthalmology** 1999 Jul;106(7):1334–8

Graft–versus–host disease. Case report and discussion. Eggleston TI, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):692–6

Mechanisms involved in graft–versus–host disease induced by the disparity of minor histocompatibility M1s antigens. Kawamura T, et al. **Scand J Immunol** 1999 Mar; 49(3):258–68

Graft–versus–host disease after intraoperative blood transfusion: a rare and lethal condition. Ohta M, et al. **Surgery** 1999 May;125(5):571–4

Transfusion–associated graft–versus–host disease: new insights and a route towards therapy? [editorial; comment] Williamson LM. **Transfus Med** 1998 Sep;8(3):169–72. Comment on: Transfus Med 1998 Sep;8(3):209–14.

High risk of transfusion–associated graft–versus–host disease with nonirradiated allogeneic blood transfusion in cardiac surgery [letter] Yasuura K, et al. **Transfusion** 1998 Nov–Dec;38(11–12):1117–8

Predicting graft–versus–host disease in HLA–identical bone marrow transplant: a comparison of T–cell frequency analysis and a human skin explant model. Dickinson AM, et al. **Transplantation** 1998 Oct 15;66(7):857–63

Changes in donor leukocytes during blood storage. Implications on post–transfusion immunomodulation and transfusion–associated GVHD. Mincheff M. **Vox Sang** 1998;74 Suppl 2:189–200

Transfusion–associated graft–versus–host disease in an immunocompetent patient following cardiac surgery. Rososhansky S, et al. **Vox Sang** 1999;76(1):59–63

Treatment of post–transfusion graft–versus–host disease with nafmostat mesilate, a serine protease inhibitor. Ryo R, et al. **Vox Sang** 1999;76(4):241–6

[Transfusion–associated graft–versus–host disease] Chen Z. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):291–2 **(Chi)**

[Post–transfusion graft–vs–host disease] Ito K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):532–6 (11 ref.) **(Jpn)**

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 2. Graft–versus–host disease (GVHD)] Morishita Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1502–9 (5 ref.) **(Jpn)**

[PBSCT and GVHD] Hino M, et al. **Rinsho Byori** 1999 May; Suppl 110:92–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Transfusion associated graft versus host disease (TA–GVHD)] Takahashi K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):605–8 (18 ref.) **(Jpn)**

GENETICS

Cytokine gene polymorphisms associating with severe acute graft–versus–host disease in HLA–identical sibling transplants. Middleton PG, et al. **Blood** 1998 Nov 15; 92(10):3943–8

A locus on chromosome 2 influences the development of acute graft–versus–host disease in a murine model. Harper JM, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1183–90

Strategy for mapping minor histocompatibility genes involved in graft–versus–host disease: a novel application of discordant sib pair methodology. Lunetta KL, et al. **Genet Epidemiol** 1998;15(6):595–607

Genetics of graft–versus–host disease, I. A locus on chromosome 1 influences development of acute graft–versus–host disease in a major histocompatibility complex mismatched murine model. Allen RD, et al. **Immunology** 1999 Feb;96(2):254–61

DNA polymorphism analysis in transfusion–associated graft–versus–host disease. Warren LJ, et al. **J Paediatr Child Health** 1999 Feb;35(1):98–101

Graft–versus–host disease in the rat: a genetic analysis in recombinant inbred strains of SHR x BN. Lx and BN. Lx x SHR sets. Panczak A, et al. **Transplant Proc** 1999 May; 31(3):1569–70

IMMUNOLOGY

Graft–vs.–host and graft–vs.–leukemia reactions after delayed infusions of donor T–subsets. Johnson BD, et al. **Biol Blood Marrow Transplant** 1999;5(3):123–32

HLAs and risk of acute graft–vs.–host disease after marrow transplantation from an HLA–identical sibling. Martin PJ, et al. **Biol Blood Marrow Transplant** 1998;4(3):128–33

Massive activation–induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft–versus–host disease. Brochu S, et al. **Blood** 1999 Jul 15;94(2):390–400

Direct alloreactivity by human cytotoxic T lymphocytes can Be inhibited by altered peptide ligand antagonism. Burrows SR, et al. **Blood** 1999 Feb 1;93(3):1020–4

Murine T lymphocytes incapable of producing macrophage inhibitory protein–1 are impaired in causing graft–versus–host disease across a class I but not class II major histocompatibility complex barrier. Serody JS, et al. **Blood** 1999 Jan 1;93(1):43–50

Graft–versus–leukemia effect and graft–versus–host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Tsukada N, et al. **Blood** 1999 Apr 15;93(8):2738–47

Role of CD28 in acute graft–versus–host disease. Yu XZ, et al. **Blood** 1998 Oct 15;92(8):2963–70

Acute skin GVHD following syngeneic BMT for CLL. Deane M, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1207–9

CD8+ cytotoxic T cell repertoire implicated in grafts–versus–leukemia effect in a murine bone marrow transplantation model. de La Selle V, et al. **Bone Marrow Transplant** 1999 May;23(9):951–8

The cytokine modulation of acute graft–versus–host disease. Ferrara JL. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S13–5 (37 ref.)

Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft–versus–host disease in partial T cell–depleted bone marrow transplantation. Gadisseur AP, et al. **Bone Marrow Transplant** 1999 May;23(10):1013–7

Cytokines in GvH and GvL. Holler E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S3–6 (18 ref.)

Keratinocyte apoptosis following bone marrow transplantation: evidence for CTL–dependent and –independent pathways. Jerome KR, et al. **Bone Marrow Transplant** 1998 Aug;22(4):359–66

Autoimmune diseases and autoimmunity post–bone marrow transplantation. Sherer Y, et al. **Bone Marrow Transplant** 1998 Nov;22(9):873–81 (83 ref.)

Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD [letter] Viret F, et al. **Bone Marrow Transplant** 1999 Jul;24(2):225–7

Autoantibodies in human chronic graft–versus–host disease after hematopoietic cell transplantation. Quaranta S, et al. **Clin Immunol** 1999 Apr;91(1):106–16

CD8(+), radiosensitive T cells of parental origin, oppose cells capable of down–regulating cytotoxicity in murine acute lethal graft–versus–host disease. Mann RA, et al. **Clin Immunol Immunopathol** 1998 Dec;89(3):260–70

Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Nagler A, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):161–7

Inhibition of Fas death pathway in cytotoxic T cells: an approach to prevent graft–versus–host disease [comment] Paillard F. **Hum Gene Ther** 1998 Jul 20;9(11):1528–9. Comment on: Hum Gene Ther 1998 Jul 20;9(11):1551–60.

Cell surface markers and circulating cytokines in graft versus host disease. Chang DM, et al. **Immunol Invest** 1999 Jan; 28(1):77–86

Involvement of both donor cytotoxic T lymphocytes and host NK1.1+ T cells in the thymic atrophy of mice suffering from acute graft–versus–host disease. Onoe Y, et al. **Immunology** 1998 Oct;95(2):248–56

Tumor necrosis factor– alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft–versus–host disease. Cooke KR, et al. **J Clin Invest** 1998 Nov 15;102(10):1882–91

Differential roles of IL–1 and TNF–alpha on graft–versus–host disease and graft versus leukemia. Hill GR, et al. **J Clin Invest** 1999 Aug;104(4):459–67

Differential effects of the absence of interferon–gamma and IL–4 in acute graft–versus–host disease after allogeneic bone marrow transplantation in mice. Murphy WJ, et al. **J Clin Invest** 1998 Nov 1;102(9):1742–8

IL–11 separates graft–versus–leukemia effects from graft–versus–host disease after bone marrow transplantation. Teshima T, et al. **J Clin Invest** 1999 Aug; 104(3):317–25

Donor–derived interferon gamma is required for inhibition of acute graft–versus–host disease by interleukin 12. Yang YG, et al. **J Clin Invest** 1998 Dec 15;102(12):2126–35

The effect of graft–versus–host disease on T cell production and homeostasis. Dulude G, et al. **J Exp Med** 1999 Apr 19;189(8):1329–42

Bone marrow NK1.1(–) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. Zeng D, et al. **J Exp Med** 1999 Apr 5;189(7):1073–81

Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. Buhlmann JE, et al. **J Immunol** 1999 Apr 15; 162(8):4373–6

The role of host (endogenous) T cells in chronic graft–versus–host autoimmune disease. Chen F, et al. **J Immunol** 1998 Dec 1;161(11):5880–5

Characterization of the pathogenic autoreactive T cells in cyclosporine–induced syngeneic graft–versus–host disease. Chen W, et al. **J Immunol** 1998 Dec 15;161(12):7040–6

The nephritogenic T cell response in murine chronic graft–versus–host disease. Meyers CM, et al. **J Immunol** 1998 Nov 15;161(10):5321–30

The role of interleukin–12 in preserving the graft–versus–leukemia effect of allogeneic CD8 T cells independently of GVHD. Yang YG, et al. **Leuk Lymphoma** 1999 May;33(5–6):409–20 (106 ref.)

Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen–specific cytotoxic T lymphocytes in patients with graft–versus–host disease. Mutis T, et al. **Nat Med** 1999 Jul;5(7):839–42

Oligoclonality of TCRint cells with a low diversity of TCR complementarity–determining region 3 in mice with graft–versus–host disease. Sugahara S, et al. **Scand J Immunol** 1998 Dec;48(6):592–604

The role of natural killer cell mediated caspases activation in a graft-versus-host disease model of semiallogeneic small bowel transplantation. Fändrich F, et al. **Transpl Immunol** 1999 Mar;7(1):1-7

Tolerance induction permits the development of graft-versus-host disease: donor-mediated attack following small bowel transplantation in mixed chimeras. Morrissey NJ, et al. **Transpl Immunol** 1999 Mar;7(1):19-25

One-way donor-recipient HLA-matching as a risk factor for graft-versus-host disease in living-related liver transplantation. Kiuchi T, et al. **Transpl Int** 1998;11 Suppl 1:S383-4

Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides. Schorlemmer HU, et al. **Transpl Int** 1998;11 Suppl 1:S448-51

Chronologic alteration of suppressive effects of serum from liver-grafted rats against graft versus host disease. Enoki T, et al. **Transplant Proc** 1998 Nov;30(7):3258-9

Possible role of post renal transplant graft-versus-host antibodies in preventing acute graft rejection. Jakab J, et al. **Transplant Proc** 1998 Dec;30(8):3981-3

Irradiation or temporal variations in immunosuppressive schedules do not prevent graft-versus-host disease following rat limb allotransplantation. Lui LT, et al. **Transplant Proc** 1998 Dec;30(8):3960-1

Early detection of the Fas-FasL system in hepatic graft-versus-host disease after rat small-bowel transplantation. Shiraishi M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):567-8

Pathogenic specificity of effector T lymphocytes in syngeneic graft-versus-host disease. Thoburn C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):684-6

Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Blazar BR, et al. **Transplantation** 1998 Nov 15;66(9):1220-9

Comparisons of alloreactive potential of clinical hematopoietic grafts. Leung W, et al. **Transplantation** 1999 Sep 15;68(5):628-35

Transfusion-associated graft-versus-host disease in an immunocompetent patient following cardiac surgery. Rososhansky S, et al. **Vox Sang** 1999;76(1):59-63

[Remarkable increase of CD8+ CD11a+ and CD8+ CD57- T cells in patients with post-transfusion graft-versus-host disease] Karasuno T, et al. **Rinsho Ketsueki** 1998 Sep; 39(9):716-8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 during nonsuppurative destructive cholangitis in a mouse graft-versus-host disease model. Howell CD, et al. **Hepatology** 1999 Mar; 29(3):766-76

Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis. Shephard SE, et al. **Photodermatol Photoimmunol Photomed** 1999 Apr; 15(2):64-74

PATHOLOGY

Image cytometry in early graft-versus-host disease. Fleming MG, et al. **Am J Dermatopathol** 1998 Oct;20(5):459-62

Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. Picardi M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):173-7

Transfusion-associated graft-versus-host disease: an in situ hybridization analysis of the infiltrating donor-derived cells in the cutaneous lesion. Tanei R, et al. **Dermatology** 1999; 199(1):20-4

Flow cytometric evaluation of activated eosinophils in graft versus host disease and hypereosinophilic conditions. Rumi C, et al. **Eur J Histochem** 1997;41 Suppl 2:45-6

Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Stüber E, et al. **Gut** 1999 Aug;45(2):229-35

Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. Yoo YH, et al. **J Cutan Pathol** 1998 Sep;25(8):426-34

Membranous nephropathy with chronic graft-versus-host disease in a bone marrow transplant recipient [letter] Yorioka N, et al. **Nephron** 1998 Nov;80(3):371-2

Composite tissue allografts in rats: IV. Graft-versus-host disease in recipients of vascularized bone marrow transplants. Ramsamooj R, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1365-71

A multivariate approach for assessing severity of acute graft-versus-host disease in bone marrow transplantation. Parrish RS, et al. **Stat Med** 1999 Feb 28;18(4):423-40

Fas/Apo-1 expression of human GVHD livers. Bone Marrow Transplantation Group. Wakabayashi T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):423-4

The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model. Dey B, et al. **Transplantation** 1999 Jul 15; 68(1):141-9

[Cutaneous manifestations of graft versus host reaction] Aractingi S, et al. **Ann Dermatol Venereol** 1998 Sep; 125(9):620-7 (51 ref.) **(Fre)**

PHYSIOPATHOLOGY

The role of cytokines in acute graft-versus-host disease. Hill GR, et al. **Cytokines Cell Mol Ther** 1997 Dec;3(4):257-66 (90 ref.)

Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Stüber E, et al. **Gastroenterology** 1998 Nov; 115(5):1205-15

Early detection of apoptosis and fas ligand expression in hepatic graft-versus-host disease after rat small bowel transplantation. Shiraishi M, et al. **J Surg Res** 1999 Sep; 86(1):136-44

Timing of lymphocyte transfusion and portal clamping for the development of lethal graft-versus-host disease in the rat. Kobayashi E, et al. **Surg Today** 1998;28(10):1036-41

Inhibition of nitric oxide synthesis reduces bacterial translocation during graft-versus-host disease after small bowel transplantation. Langrehr JM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):574

Graft-versus-host disease and function of intrahepatic islet grafts. Li H, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):639

PREVENTION & CONTROL

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Pelot MR, et al. **Biol Blood Marrow Transplant** 1999;5(3):133-43

Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Wingard JR, et al. **Biol Blood Marrow Transplant** 1998;4(3):157-63

Graft-versus-host disease and graft-versus-leukemia effect in mice grafted with peripheral newborn blood. de La Selle V, et al. **Blood** 1998 Nov 15;92(10):3968-75

Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor. del Rosario ML, et al. **Blood** 1999 May 15;93(10):3558-64

Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Grass JA, et al. **Blood** 1999 May 1;93(9):3140-7

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Hale G, et al. **Blood** 1998 Dec 15;92(12):4581-90

Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Krijanovski OI, et al. **Blood** 1999 Jul 15;94(2):825-31

Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Panoskaltsis-Mortari A, et al. **Blood** 1998 Nov 15;92(10):3960-7

Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Storb R, et al. **Blood** 1999 Aug 1;94(3):1131-6

Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Abdel-Mageed A, et al. **Bone Marrow Transplant** 1999 May;23(9):929-32

IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Brok HP, et al. **Bone Marrow Transplant** 1998 Nov;22(10):1005-10

Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL, et al. **Bone Marrow Transplant** 1998 Sep;22(6):541-5

Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Eiermann TH, et al. **Bone Marrow Transplant** 1999 Apr;23(8):779-81

Pre-treatment of transplant bone marrow cells with hydrocortisone and cyclosporin A alleviates graft-versus-host reaction in a murine allogeneic host-donor combination. Grcević D, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1145-52

Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Harris DT, et al. **Bone Marrow Transplant** 1999 Jan;23(2):137-44

A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Hattori K, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1283-9

Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, et al. **Bone Marrow Transplant** 1999 Mar;23(5):443-50

Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Jacobson P, et al. **Bone Marrow Transplant** 1998 Aug;22(3):217-25 (129 ref.)

Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Koh MB, et al. **Bone Marrow Transplant** 1999 May; 23(10):1071-9

Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Marini FC 3rd, et al. **Bone Marrow Transplant** 1999 May;23(9):907-15

Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M, et al. **Bone Marrow Transplant** 1999 Jan;23(2):145-50

Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Müller S, et al. **Bone Marrow Transplant** 1999 Sep;24(6):575-81

CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. O'Donnell PV, et al. **Bone Marrow Transplant** 1998 Nov;22(10):947-55

Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Paquette RL, et al. **Bone Marrow Transplant** 1998 Aug;22(4):351-7

Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. Preijers FW, et al. **Bone Marrow Transplant** 1999 May;23(10):1061-70

Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Przepiorka D, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1291-5

Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect [letter] Shaw PJ, et al. **Bone Marrow Transplant** 1999 Mar;23(6):632-3

The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation. Wagner JL, et al. **Bone Marrow Transplant** 1998 Jul;22(2):139-46

Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Weiss L, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1139-43

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Zander AR, et al. **Bone Marrow Transplant** 1999 May;23(9):889-93

A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K, et al. **Br J Haematol** 1999 Apr; 105(1):303-12

Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Jeong DC, et al. **Exp Hematol** 1999 Jul; 27(7):1219-25

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Naparstek E, et al. **Exp Hematol** 1999 Jul;27(7):1210-8

T-cell depletion of allogeneic bone marrow using anti-alphabetaTCR monoclonal antibody: prevention of graft-versus-host disease without affecting engraftment potential in rats. Neipp M, et al. **Exp Hematol** 1999 May; 27(5):860-7

Serine protease detection in mixed lymphocyte cultures: a histochemical method for possible prediction of graft-versus-host disease. Maiocchi MA, et al. **Haematologica** 1998 Aug;83(8):686-9

Transfusion associated graft versus host disease and its prevention [editorial] Williamson LM. **Heart** 1998 Sep; 80(3):211-2

Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation. Cahn JY, et al. **Hematol Cell Ther** 1999 Apr;41(2):31-7

Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Komesli S, et al. **Int J Immunopharmacol** 1999 May;21(5):349-58

Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. Brown RA, et al. **J Clin Oncol** 1999 Mar;17(3):806-12

European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. Reichart B, et al. **J Heart Lung Transplant** 1998 Aug;17(8):775-81

Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD). Okubo T, et al. **J Immunol** 1999 Apr 1; 162(7):4013-7

Reduction of toxicity of marrow transplantation in children with Fanconi anemia [comment] Harris RE. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):175-6. Comment on: J Pediatr Hematol Oncol 1999 May-Jun;21(3):237-9.

Mismatched transplants for refractory lymphoma? [comment] Falkenburg JH, et al. **Lancet** 1999 May 22;353(9166):1725-6 . Comment on: Lancet 1999 May 22;353(9166):1755-9.

Transplantation of anergic histoincompatible bone marrow cells [letter] de Carvalho Bittencourt M, et al. **N Engl J Med** 1999 Sep 30;341(14):1081-2

Hematopoietic stem-cell transplantation for acute leukemia

[letter; comment] van Bekkum DW, et al. **N Engl J Med** 1999 Mar 11;340(10):809-10; discussion 810-2. Comment on: N Engl J Med 1998 Oct 22;339(17):1186-93. Comment on: N Engl J Med 1998 Oct 22;339(17):1238-9.

A graft versus host disease prevention and management tool: a mechanism for improving continuity of care. Stolar K. **Oncol Nurs Forum** 1999 Jul;26(6):977-8

Adoptive immunotherapy. Hurwitz JL, et al. **Pediatr Infect Dis J** 1999 May;18(5):467-8

Keeping bone marrow grafts in check [news] Hagmann M. **Science** 1999 Jul 16;285(5426):310-1

Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Shlomchik WD, et al. **Science** 1999 Jul 16;285(5426):412-5

Tolerating differences. Sikorski R, et al. **Science** 1999 Jul 16;285(5426):357-8

Neutralising IL-12 activity as a strategy for prolonging allograft survival and preventing graft-versus-host disease. Orr DJ, et al. **Scott Med J** 1998 Aug;43(4):109-11 (24 ref.)

Tolerance in Mlsa mismatched chimeras prepared with allogeneic bone marrow alone or in combination with syngeneic bone marrow. Sefrioui H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):702-3

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bornhäuser M, et al. **Transplantation** 1999 Feb 27;67(4):499-504

Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Hebert MF, et al. **Transplantation** 1999 Mar 15;67(5):707-12

Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation. Hill GR, et al. **Transplantation** 1999 Jun 15;67(11):1478-80

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Novitzky N, et al. **Transplantation** 1999 Feb 27;67(4):620-6

Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341-3 (7 ref.)

[FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor] Nishida T, et al. **Rinsho Ketsueki** 1998 Aug;39(8):574-9 (Eng. Abstr.) **(Jpn)**

[Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors] Yagasaki H, et al. **Rinsho Ketsueki** 1999 May;40(5):382-9 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Chronic graft-versus-host disease treated with UVB phototherapy. Enk CD, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1179-83

[Eczema-like cutaneous graft versus host disease treated by UV-B therapy in a 2-year-old child] Tanasescu S, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):51-3 (Eng. Abstr.) **(Fre)**

SURGERY

Surgery for intestinal graft-versus-host disease: report of two cases. Evans J, et al. **Dis Colon Rectum** 1998 Dec; 41(12):1573-6

THERAPY

Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Smith EP, et al. **Biol Blood Marrow Transplant** 1998;4(1):27-37

Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Child FJ, et al. **Bone Marrow Transplant** 1999 May;23(9):881-7

Colostrum and severe gut GVHD [letter] Inoue M, et al. **Bone Marrow Transplant** 1998 Aug;22(4):402-3

Extracorporeal photophoresis in chronic cutaneous graft-versus-host disease [editorial] Russell-Jones R. **Bone Marrow Transplant** 1998 Oct;22(7):621-3

Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Wakui M, et al. **Bone Marrow Transplant** 1999 Mar;23(6):573-8

The effect of anti-gp39 treatment on the intestinal manifestations of acute murine graft-versus-host disease. Stüber E, et al. **Clin Immunol** 1999 Mar;90(3):334-9

"Suicide" gene for the control of graft-versus-host disease. Tiberghien P. **Curr Opin Hematol** 1998 Nov;5(6):478-82 (31 ref.)

Long-term extracorporeal photoimmunotherapy for treatment of chronic cutaneous graft-versus-host disease: observations in four patients. Dippel E, et al. **Dermatology** 1999;198(4):370-4

Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Brown GR, et al. **Gastroenterology** 1999 Mar;116(3):593-601

Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Verzeletti S, et al. **Hum Gene Ther** 1998 Oct 10;9(15):2243-51

Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Miwa K, et al. **Int Immunol** 1999 Jun;11(6):925-31

Therapeutic strategy for post-transfusion graft-vs.-host disease. Saigo K, et al. **Int J Hematol** 1999 Apr;69(3):147-51 (29 ref.)

Amelioration of graft versus host disease with anti-ICAM-1 therapy. Poritz LS, et al. **J Surg Res** 1998 Dec;80(2):280-6

Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Tse JC, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):988-1000 (81 ref.)

Graft versus host disease in a liver transplant patient with hepatitis B and hepatocellular carcinoma. Merhav HJ, et al. **Transplant Proc** 1999 Jun;31(4):1890-1

VETERINARY

Immune reactivity following CD40L blockade: role in autoimmune glomerulonephritis in susceptible recipients. Banu N, et al. **Autoimmunity** 1999;30(1):21-33

GRAFT VS HOST REACTION

see related
GRAFT VS HOST DISEASE

Evaluation of graft-host response for various tissue sources and animal models. Weber CJ, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:233-54

Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Pelot MR, et al. **Biol Blood Marrow Transplant** 1999;5(3):133-43

Transfusion associated graft versus host disease [letter] Ghrew MH, et al. **Heart** 1999 Aug;82(2):255-6

Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. Champlin R, et al. **J Clin Apheresis** 1999;14(1):45-9

Resistance to graft-versus-host reaction after segmental small bowel transplantation in rats. Watanabe K, et al. **Transplant Proc** 1998 Nov;30(7):3464-6

[Cutaneous manifestations of graft versus host reaction] Aractingi S, et al. **Ann Dermatol Venereol** 1998 Sep; 125(9):620-7 (51 ref.) **(Fre)**

IMMUNOLOGY

The IgG2a/IgA produced by the murine T560 B lymphoma that arose during a graft-versus-host reaction is polyreactive and somatically mutated. Phillips-Quagliata JM, et al. **Autoimmunity** 1999;29(3):215-33

Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Bobé P, et al. **Blood** 1999 Aug 1;94(3):1028-37

Cytokines in GvH and GvL. Holler E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S3-6 (18 ref.)

Impaired T-lymphocyte function in B-chronic lymphocytic leukaemia as measured by the local xenogeneic graft-versus-host reaction. Stark P, et al. **Clin Lab Haematol** 1999 Jun;21(3):187-91

Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Boughton BJ, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):1-6

Donor pretreatment with bone marrow cells for prevention of graft-versus-host reaction after small bowel transplantation. Kimura Y, et al. **Transplant Proc** 1998 Nov; 30(7):3885-7

[Immunology in clinical practice. XXIII. Xenotransplantation] Schraa EO, et al. **Ned Tijdschr Geneeskd** 1999 Jul 10;143(28):1455-60 (16 ref.) (Eng. Abstr.) **(Dut)**

[The mechanism of donor specific unresponsiveness in renal transplant recipients] Okimoto T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):118-28 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Regulatory function of factor-XIIIa-positive dendrocytes in incipient toxic epidermal necrolysis and graft-versus-host reaction. A hypothesis. Hermanns-Lê T, et al. **Dermatology** 1999;198(2):184-6

GRAFT VS LEUKEMIA EFFECT see **GRAFT VS TUMOR EFFECT**

GRAFT VS NEOPLASM EFFECT see **GRAFT VS TUMOR EFFECT**

GRAFT VS TUMOR EFFECT

Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation. Lee CK, et al. **Biol Blood Marrow Transplant** 1999;5(1):15-27

Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation [published erratum appears in Blood 1999 Mar 15;93(6):2141] [see comments] Baurmann H, et al. **Blood** 1998 Nov 15; 92(10):3582-90. Comment in: Blood 1999 Apr 15;93(8):2748-9.

Graft-versus-host disease and graft-versus-leukemia effect in mice grafted with peripheral newborn blood. de La Selle V, et al. **Blood** 1998 Nov 15;92(10):3968-75

Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. Müerköster S, et al. **Blood** 1999 Jun 15;93(12):4375-86

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Mutis T, et al. **Blood** 1999 Apr 1;93(7):2336-41

Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Pan L, et al. **Blood** 1999 Jun 15;93(12):4071-8

Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bryson JS, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):363-72

Graft-versus-myeloma. Mehta J, et al. **Bone Marrow Transplant** 1998 Nov;22(9):835-43 (67 ref.)

Graft-versus-leukemia is sufficient to induce remission in juvenile myelomonocytic leukemia. Orchard PJ, et al. **Bone Marrow Transplant** 1998 Jul;22(2):201-3

Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Anderson LD Jr, et al. **Cancer Res** 1999 Apr 1;59(7):1525-30

Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages. Müerköster S, et al. **Clin Cancer Res** 1998 Dec;4(12):3095-106

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. Vourka-Karussis U, et al. **Exp Hematol** 1999 Mar;27(3):461-9

Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Verzeletti S, et al. **Hum Gene Ther** 1998 Oct 10;9(15):2243-51

Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. Champlin R, et al. **J Clin Apheresis** 1999;14(1):45-9

Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. Clave E, et al. **J Immunother** 1999 Jan;22(1):1-6

Extramedullary relapse despite graft-versus-leukemia effect after bone marrow transplantation in a girl with juvenile myelomonocytic leukemia. Kressler EJ, et al. **Leuk Lymphoma** 1999 May;33(5-6):597-600

Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Varadi G, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):185-90

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Novitzky N, et al. **Transplantation** 1999 Feb 27;67(4):620-6

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Kolb HJ. **Vox Sang** 1998;74 Suppl 2:321-9 (71 ref.)

DRUG EFFECTS

Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Krijanovski OI, et al. **Blood** 1999 Jul 15;94(2):825-31

Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Elmaagacli AH, et al. **Bone Marrow Transplant** 1999 Apr;23(8):771-7

Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. Hartung G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S16-20

A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K, et al. **Br J Haematol** 1999 Apr; 105(1):303-12

Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity. Schirrmacher V, et al. **Clin Cancer Res** 1998 Nov; 4(11):2635-45

Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Brandenburg U, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):545-50

GENETICS

Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) [letter] [published erratum appears in Lancet 1999 Mar 6;353(9155):848] Mandigers CM, et al. **Lancet** 1998 Nov 7;352(9139):1522-3

IMMUNOLOGY

Minor transplantation antigens: mouse models for human host-versus-graft, graft-versus-host and graft-versus-leukemia reactions. Simpson E. **Arch Immunol Ther Exp (Warsz)** 1998;46(6):331-9 (60 ref.)

Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Johnson BD, et al. **Biol Blood Marrow Transplant** 1999;5(3):123-32

Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Hoyle C, et al. **Blood** 1998 Nov 1;92(9):3318-27

Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Ruggeri L, et al. **Blood** 1999 Jul 1;94(1):333-9

Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Tsukada N, et al. **Blood** 1999 Apr 15;93(8):2738-47

Cytokines in GvH and GvL. Holler E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S3-6 (18 ref.)

A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Yazaki M, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):129-37

Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. Spaner D. **Cancer Metastasis Rev** 1998 Jun; 17(2):249-57 (62 ref.)

Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Champlin R, et al. **Curr Opin Oncol** 1999 Mar;11(2):87-95 (84 ref.)

Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Boughton BJ, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):1-6

GVL and GVHD following the infusion of a limited number of donor CD3 cells in the therapy of leukaemia relapse after bone marrow transplantation [letter] du Toit C, et al. **Eur J Haematol** 1999 Jan;62(1):68-9

Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Kasai M, et al. **Int J Hematol** 1999 Feb;69(2):112-8

IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Teshima T, et al. **J Clin Invest** 1999 Aug; 104(3):317-25

Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice. Gresser I, et al. **J Interferon Cytokine Res** 1998 Sep; 18(9):667-79

Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Singhal S, et al. **Leuk Lymphoma** 1999 Feb; 32(5-6):505-12

The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Yang YG, et al. **Leuk Lymphoma** 1999 May;33(5-6):409-20 (106 ref.)

Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341-3 (7 ref.)

CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection. Fowler DH, et al. **Vox Sang** 1998;74 Suppl 2:331-40 (60 ref.)

PHYSIOLOGY

The graft-versus-leukemia effects of allogeneic cell therapy. Porter DL, et al. **Annu Rev Med** 1999;50:369-86 (80 ref.)

GRAFTING, BONE see **BONE TRANSPLANTATION**

GRAFTING, BONE MARROW see **BONE MARROW TRANSPLANTATION**

GRAFTING, BRAIN TISSUE see **BRAIN TISSUE TRANSPLANTATION**

GRAFTING, CORNEAL see **CORNEAL TRANSPLANTATION**

GRAFTING, FETAL TISSUE see **FETAL TISSUE TRANSPLANTATION**

GRAFTING, HEART see **HEART TRANSPLANTATION**

GRAFTING, HEART-LUNG see **HEART-LUNG TRANSPLANTATION**

GRAFTING, ISLETS OF LANGERHANS see **ISLETS OF LANGERHANS TRANSPLANTATION**

GRAFTING, KIDNEY see **KIDNEY TRANSPLANTATION**

GRAFTING, LIVER see **LIVER TRANSPLANTATION**

GRAFTING, LUNG see **LUNG TRANSPLANTATION**

GRAFTING, ORGAN see **ORGAN TRANSPLANTATION**

GRAFTING, PANCREAS see **PANCREAS TRANSPLANTATION**

GRAFTING, SKIN see **SKIN TRANSPLANTATION**

GRAFTING, TISSUE see **TISSUE TRANSPLANTATION**

GRAFTS see **TRANSPLANTS**

GRAIN see **CEREALS**

GRAM-NEGATIVE AEROBIC BACTERIA

[Ochrobactrum anthropi bacteremia in a patient with AIDS (letter)] Torres L, et al. **Med Clin (Barc)** 1998 Sep 19; 111(8):318 **(Spa)**

CHEMISTRY

Structure of sulfated O-specific polysaccharide of the marine bacterium Pseudoalteromonas marinoglutinosa KMM 232. Komandrova NA, et al. **Biochemistry (Mosc)** 1998 Oct; 63(10):1200-4

Detection and partial characterization of bacteriocin in the methanotrophic bacterium Methylobacter bovis. Starostina NG, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1122-5

Cycloprodigiosin hydrochloride obtained from Pseudoalteromonas denitrificans is a potent antimalarial agent. Kim HS, et al. **Biol Pharm Bull** 1999 May; 22(5):532-4

Structure of the O-specific polysaccharide from Pseudoalteromonas elyakovii sp. nov. CMM 162. Gorshkova RP, et al. **Carbohydr Res** 1998 Nov;313(1):61-4

Structural studies of an exopolysaccharide produced by Alteromonas macleodii subsp. fijiensis originating from a deep-sea hydrothermal vent. Rougeaux H, et al. **Carbohydr Res** 1998 Nov;312(1-2):53-9

Purification and characterization of chaperonins 60 and 10 from Methylobacillus glycogenes. Kawata Y, et al. **Cell Stress Chaperones** 1998 Sep;3(3):200-7

[Structure of glycerophosphate-containing O-specific polysaccharide from Pseudoalteromonas sp. KMM 639] Gorshkova RP, et al. **Bioorg Khim** 1998 Nov;24(11):839-41 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

RFLP of rRNA genes and sequencing of the 16S-23S rDNA intergenic spacer region of ammonia-oxidizing bacteria: a phylogenetic approach. Aakra A, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:123-30

Fundibacter jadensis gen. nov., sp. nov., a new slightly halophilic bacterium, isolated from intertidal sediment. Bruns A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:441-8

Methylopila capsulata gen. nov., sp. nov., a novel non-pigmented aerobic facultatively methylotrophic bacterium. Doronina NV, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1313-21

Description of Pseudaminobacter gen. nov. with two new species, Pseudaminobacter salicylatoxidans sp. nov. and Pseudaminobacter defluvii sp. nov. Kämpfer P, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:887-97

Roseovarius tolerans gen. nov., sp. nov., a budding bacterium with variable bacteriochlorophyll a production from hypersaline Ekho Lake. Labrenz M, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:137-47

Citromicrobium bathyomarinum, a novel aerobic bacterium isolated from deep-sea hydrothermal vent plume waters that contains photosynthetic pigment-protein complexes. Yurkov VV, et al. **J Bacteriol** 1999 Aug;181(15):4517-25

Massilia timonae gen. nov., sp. nov., isolated from blood of an immunocompromised patient with cerebellar lesions. La Scola B, et al. **J Clin Microbiol** 1998 Oct;36(10):2847-52

Proposal of Sphingomonas suberifaciens (van Bruggen, Jochimsen and Brown 1990) comb. nov., sphingomonas natatoria (Sly 1985) comb. nov., Sphingomonas ursincola (Yurkov et al. 1997) comb. nov., and emendation of the genus Sphingomonas. Yabuuchi E, et al. **Microbiol Immunol** 1999;43(4):339-49

Phylogeny and diversity of Achromatium oxaliferum. Glöckner FO, et al. **Syst Appl Microbiol** 1999 Feb; 22(1):28-38

Phylogenetic identification of two major nitrogen-fixing bacteria associated with sugarcane. Sievers M, et al. **Syst Appl Microbiol** 1998 Dec;21(4):505-8

Importance of Xanthobacter autotrophicus in toluene biodegradation within a contaminated stream. Tay ST, et al. **Syst Appl Microbiol** 1999 Feb;22(1):113-8

DRUG EFFECTS

In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Giacometti A, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3320-4

Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Taccetti G, et al. **Eur J Epidemiol** 1999 Jan;15(1):85-8

Direct antimicrobial susceptibility testing of gram-negative bacilli in blood cultures by an electrochemical method. Huang AH, et al. **J Clin Microbiol** 1998 Oct;36(10):2882-6

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages [see comments] Terg R, et al. **J Hepatol** 1998 Sep; 29(3):437-42. Comment in: J Hepatol 1998 Sep;29(3):490-4.

Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. Hanberger H, et al. **JAMA** 1999 Jan 6;281(1):67-71

[Occurrence of gram-negative non-fermenting rods in hemocultures and their sensitivity to antimicrobial agents] Hejnar P, et al. **Bratisl Lek Listy** 1998 Nov;99(11):573-8 (Eng. Abstr.) **(Cze)**

ENZYMOLOGY

Expression, purification, crystallization and preliminary x-ray analysis of the kappa-carrageenase from Pseudoalteromonas carrageenovora. Michel G, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):918-20

Haloalkane dehalogenase from Xanthobacter autotrophicus GJ10 refined at 1.15 A resolution. Ridder IS, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jul;55 (Pt 7):1273-90

Purification and characterization of the mutant enzyme W117Y of the dichloromethane dehalogenase from Methylophilus sp. strain DM11. Cai B, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:210-3

G-type nerve agent decontamination by Alteromonas prolidase. Cheng TC, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:253-8

Production of poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) and poly(4-hydroxybutyric acid) without subsequent degradation by Hydrogenophaga pseudoflava. Choi MH, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1570-7

Molecular cloning, expression and site-directed mutagenesis of glutathione S-transferase from Ochrobactrum anthropi. Favaloro B, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):573-9

Two short-chain dehydrogenases confer stereoselectivity for enantiomers of epoxypropane in the multiprotein epoxide carboxylating systems of Xanthobacter strain Py2 and Nocardia corallina B276. Allen JR, et al. **Biochemistry** 1999 Jan 5;38(1):247-56

Thermodynamic stability of a cold-active alpha-amylase from the Antarctic bacterium Alteromonas haloplanctis. Feller G, et al. **Biochemistry** 1999 Apr 6;38(14):4613-9

Alpha-galactosidase of the marine bacterium Pseudoalteromonas sp. KMM 701. Bakunina IY, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1209-15

The caa3 terminal oxidase of the thermohalophilic bacterium Rhodothermus marinus: a HiPIP:oxygen oxidoreductase lacking the key glutamate of the D-channel. Pereira MM, et al. **Biochim Biophys Acta** 1999 Sep 1;1413(1):1-13

Purification and characterization of the heat-labile alpha-amylase secreted by the psychrophilic bacterium TAC 240B. Chessa JP, et al. **Can J Microbiol** 1999 Jun; 45(6):452-7

Acceptor specificity of cellobiose phosphorylase from Cellvibrio gilvus: synthesis of three branched trisaccharides. Percy A, et al. **Carbohydr Res** 1998 Jun; 308(3-4):423-9

Alteromonas prolidase for organophosphorus G-agent decontamination. Cheng TC, et al. **Chem Biol Interact** 1999 May 14;119-120:455-62 (12 ref.)

Cloning and sequence analysis of the hemB gene of Rhodothermus marinus. Gudmundsdótir K, et al. **Curr Microbiol** 1999 Aug;39(2):103-5

Microbial dehalogenases: enzymes recruited to convert xenobiotic substrates. Copley SD. **Curr Opin Chem Biol** 1998 Oct;2(5):613-7 (39 ref.)

The laminarinase from thermophilic eubacterium Rhodothermus marinus--conformation, stability, and identification of active site carboxylic residues by site-directed mutagenesis. Krah M, et al. **Eur J Biochem** 1998 Oct 1;257(1):101-11

A methenyl tetrahydromethanopterin cyclohydrolase and a methenyl tetrahydrofolate cyclohydrolase in Methylobacterium extorquens AM1. Pomper BK, et al. **Eur J Biochem** 1999 Apr;261(2):475-80

Two intertwined methylation activities of the MmeI restriction-modification class-IIS system from Methylophilus methylotrophus. Tucholski J, et al. **Gene** 1998 Nov 26;223(1-2):293-302

Molecular analysis of the gene encoding a novel transglycosylative enzyme from Alteromonas sp. strain O-7 and its physiological role in the chitinolytic system. Tsujibo H, et al. **J Bacteriol** 1999 Sep;181(17):5461-6

The NADP-dependent methylene tetrahydromethanopterin dehydrogenase in Methylobacterium extorquens AM1. Vorholt JA, et al. **J Bacteriol** 1998 Oct;180(20):5351-6

Multiple genes involved in chitin degradation from the marine bacterium Pseudoalteromonas sp. strain S91. Techkarnjanaruk S, et al. **Microbiology** 1999 Apr;145 (Pt 4):925-34

The molecular structure of an unusual cytochrome c2 determined at 2.0 A; the cytochrome cH from Methylobacterium extorquens. Read J, et al. **Protein Sci**

1999 Jun;8(6):1232-40
Structures of the psychrophilic Alteromonas haloplanctis alpha-amylase give insights into cold adaptation at a molecular level. Aghajari N, et al. **Structure** 1998 Dec 15; 6(12):1503-16

GENETICS

Cloning and sequence analysis of the gene encoding Methylophilus methylotrophus cytochrome c", a unique protein with a perpendicular orientation of the histidinyl ligands. Price NJ, et al. **Biochim Biophys Acta** 1999 Sep 1;1413(1):55-61
Excision of IS492 requires flanking target sequences and results in circle formation in Pseudoalteromonas atlantica. Perkins-Balding D, et al. **J Bacteriol** 1999 Aug; 181(16):4937-48
Complete sequence of a 184-kilobase catabolic plasmid from Sphingomonas aromaticivorans F199. Romine MF, et al. **J Bacteriol** 1999 Mar;181(5):1585-602
Multiple genes involved in chitin degradation from the marine bacterium Pseudoalteromonas sp. strain S91. Techkarnjanaruk S, et al. **Microbiology** 1999 Apr;145 (Pt 4):925-34
A corrinoid-dependent catabolic pathway for growth of a Methylobacterium strain with chloromethane. Vannelli T, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4615-20
Amplified rDNA restriction analysis and further genotypic characterisation of metal-resistant soil bacteria and related facultative hydrogenotrophs. Brim H, et al. **Syst Appl Microbiol** 1999 May;22(2):258-68

GROWTH & DEVELOPMENT

Production of poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) and poly(4-hydroxybutyric acid) without subsequent degradation by Hydrogenophaga pseudoflava. Choi MH, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1570-7
A corrinoid-dependent catabolic pathway for growth of a Methylobacterium strain with chloromethane. Vannelli T, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4615-20
[Occurrence of gram-negative non-fermenting rods in hemocultures and their sensitivity to antimicrobial agents] Hejnar P, et al. **Bratisl Lek Listy** 1998 Nov;99(11):573-8 (Eng. Abstr.) **(Cze)**

IMMUNOLOGY

Sustained decrease of serum anti-galactose alpha 1-3-galactose antibodies in baboons by removing aerobic gram-negative bacteria from the bowel. Manez R, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):947-8

ISOLATION & PURIFICATION

Methylopila capsulata gen. nov., sp. nov., a novel non-pigmented aerobic facultatively methylotrophic bacterium. Doronina NV, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1313-21
Antarctobacter heliothermus gen. nov., sp. nov., a budding bacterium from hypersaline and heliothermal Ekho Lake. Labrenz M, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1363-72
Comparison of phenotypic and genotypic techniques for identification of unusual aerobic pathogenic gram-negative bacilli. Tang YW, et al. **J Clin Microbiol** 1998 Dec; 36(12):3674-9
[Characteristics of fauces microflora in children treated in intensive care units] Beloborodova NV, et al. **Antibiot Khimioter** 1998;43(8):16-22 (Eng. Abstr.) **(Rus)**

METABOLISM

Optimization of simultaneous chemical and biological mineralization of perchloroethylene. Büyüksönmez F, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2784-8
Morphological and biochemical properties of a Sphaerotilus sp. Isolated from paper mill slimes. Pellegrin V, et al. **Appl Environ Microbiol** 1999 Jan;65(1):156-62
Sequence of electron carriers in the process of methanol oxidation by a new obligate methylotrophic bacterium. Yang SS, et al. **Biochem Mol Biol Int** 1998 Nov; 46(4):807-19
Molecular structure of an unusual cytochrome c2 determined at 2.0 A; the cytochrome cH from Methylobacterium extorquens. Read J, et al. **Biochem Soc Trans** 1998 Aug; 26(3):S210
Membrane-bound electron transfer chain of the thermohalophilic bacterium Rhodothermus marinus: a novel multihemic cytochrome bc, a new complex III. Pereira MM, et al. **Biochemistry** 1999 Jan 26;38(4):1268-75
Membrane-bound electron transfer chain of the thermohalophilic bacterium Rhodothermus marinus: characterization of the iron-sulfur centers from the dehydrogenases and investigation of the high-potential iron-sulfur protein function by in vitro reconstitution of the respiratory chain. Pereira MM, et al. **Biochemistry** 1999 Jan 26;38(4):1276-83
Sphingomonas sp. strain Lep1: an aerobic degrader of 4-methylquinoline. Pfaller SL, et al. **Can J Microbiol** 1999 Jul;45(7):623-6
Properties of the methylcobalamin:H4folate methyltransferase involved in chloromethane utilization by Methylobacterium sp. strain CM4. Studer A, et al. **Eur J Biochem** 1999 Aug;264(1):242-9
Purification and characterization of a flavoprotein involved in the degradation of epoxyalkanes by Xanthobacter Py2. Westphal AH, et al. **Eur J Biochem** 1998 Oct 1;257(1):160-8
Complete sequence of a 184-kilobase catabolic plasmid from Sphingomonas aromaticivorans F199. Romine MF, et al. **J Bacteriol** 1999 Mar;181(5):1585-602

PHYSIOLOGY

Cell surface analysis techniques: What do cell preparation protocols do to cell surface properties? Pembrey RS, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2877-94
Citromicrobium bathyomarinum, a novel aerobic bacterium isolated from deep-sea hydrothermal vent plume waters that contains photosynthetic pigment-protein complexes. Yurkov VV, et al. **J Bacteriol** 1999 Aug;181(15):4517-25
Nutritional implications of gut overgrowth and selective decontamination of the digestive tract. Donnell SC, et al. **Proc Nutr Soc** 1998 Aug;57(3):381-7

ULTRASTRUCTURE

Morphological and biochemical properties of a Sphaerotilus sp. Isolated from paper mill slimes. Pellegrin V, et al. **Appl Environ Microbiol** 1999 Jan;65(1):156-62

GRAM-NEGATIVE AEROBIC RODS AND COCCI

Pacemaker lead infection and vertebral osteomyelitis presumed due to Cardiobacterium hominis. Nurnberger M, et al. **Clin Infect Dis** 1998 Oct;27(4):890-1
[The biological activity of a lipopolysaccharide from Ralstonia solanacearum ICMP 7859 and of its modified derivative] Varbanets LD, et al. **Mikrobiol Z** 1998 Jul-Aug; 60(4):80-7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

A [2Fe-2S] protein from the hyperthermophilic bacterium Aquifex aeolicus. Chatelet C, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):885-9
Structural determination of a 5-O-methyl-deaminated neuraminic acid (Kdn)-containing polysaccharide isolated from Sinorhizobium fredii. Gil-Serrano AM, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):585-94
An assessment of protein profiles from the marine oligotrophic ultramicrobacterium, Sphingomonas sp. strain RB2256. Fegatella F, et al. **Electrophoresis** 1999 Jul; 20(10):2094-8

CLASSIFICATION

Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Coenye T, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:405-13
Reclassification of Pseudomonas echinoides Heumann 1962, 343AL, in the genus Sphingomonas as Sphingomonas echinoides comb. nov. Denner EB, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1103-9
Hydrogenophilus thermoluteolus gen. nov., sp. nov., a thermophilic, facultatively chemolithoautotrophic, hydrogen-oxidizing bacterium. Hayashi NR, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:783-6
Sulfitobacter mediterraneus sp. nov., a new sulfite-oxidizing member of the alpha-Proteobacteria. Pukall R, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:513-9
Thauera mechernichensis sp. nov., an aerobic denitrifier from a leachate treatment plant. Scholten E, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1045-51
Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov. Wen A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:567-76
Degradation of various chlorophenols under alkaline conditions by gram-negative bacteria closely related to Ochrobactrum anthropi. Müller RH, et al. **J Basic Microbiol** 1998;38(4):269-81
CDC group IV c-2: a new Ralstonia species close to Ralstonia eutropha. Moissenet D, et al. **J Clin Microbiol** 1999 Jun;37(6):1777-81
Hymenobacter roseosalivarius gen. nov., sp. nov. from continental Antartica soils and sandstone: bacteria of the Cytophaga/Flavobacterium/Bacteroides line of phylogenetic descent. Hirsch P, et al. **Syst Appl Microbiol** 1998 Aug;21(3):374-383

DRUG EFFECTS

Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Quinn JP. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S117-24 (70 ref.)
Beta-lactamases and outer membrane investigations in beta-lactam-resistant Comamonas acidovorans strains. Ravaoarinoro M, et al. **Int J Antimicrob Agents** 1999 Jun; 12(1):27-31
[Evaluation of antibacterial activities of various antibiotics against glucose non-fermentative gram-negative rods other than Pseudomonas aeruginosa] Kouda M, et al. **Jpn J Antibiot** 1998 Jul;51(7):475-87 (Eng. Abstr.) **(Jpn)**
[A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-positive cocci and gram-negative cocci] Kuroyama M, et al. **Jpn J Antibiot** 1998 Dec;51(12):764-78 (14 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Crystallization and preliminary x-ray analysis of glutamate racemase from Aquifex pyrophilus, a hyperthermophilic bacterium. Hwang KY, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):927-8
Cloning and sequencing of a new Comamonas testosteroni gene encoding 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase. Möbus E, et al. **Adv Exp Med Biol** 1999;463:395-402
Functional and biochemical characterization of a recombinant 3-Deoxy-D-manno-octulosonic acid 8-phosphate synthase from the hyperthermophilic bacterium Aquifex aeolicus. Duewel HS, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):346-51
Evidence that pcpA encodes 2,6-dichlorohydroquinone dioxygenase, the ring cleavage enzyme required for pentachlorophenol degradation in Sphingomonas chlorophenolica strain ATCC 39723. Xu L, et al. **Biochemistry** 1999 Jun 15;38(24):7659-69
Cloning and nucleotide sequence of the gene encoding a serine proteinase inhibitor named marinostatin from a marine bacterium, Alteromonas sp. strain B-10-31. Miyamoto K, et al. **Biosci Biotechnol Biochem** 1998 Dec; 62(12):2446-9
Molecular cloning, expression, and characterization of a thermostable glutamate racemase from a hyperthermophilic bacterium, Aquifex pyrophilus. Kim SS, et al. **Extremophiles** 1999 Aug;3(3):175-83
Isolation of poly(beta-L-malic acid)-degrading bacteria and purification and characterization of the PMA hydrolase from Comamonas acidovorans strain 7789. Gödde C, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):365-72
The role of the Sphingomonas species UG30 pentachlorophenol-4-monooxygenase in p-nitrophenol degradation. Leung KT, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):247-53
Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):185-92 (52 ref.)
Substrate and binding specificities of bacterial polyhydroxybutyrate depolymerases. Kasuya K, et al. **Int J Biol Macromol** 1999 May;24(4):329-36
Improved production of poly(4-hydroxybutyrate) by Comamonas acidovorans and its freeze-fracture morphology. Sudesh K, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):79-85
Characterization of biosynthetic enzymes for ectoine as a compatible solute in a moderately halophilic eubacterium, Halomonas elongata. Ono H, et al. **J Bacteriol** 1999 Jan; 181(1):91-9
Catalytic properties of the 3-chlorocatechol-oxidizing 2, 3-dihydroxybiphenyl 1,2-dioxygenase from Sphingomonas sp. strain BN6. Riegert U, et al. **J Bacteriol** 1999 Aug; 181(16):4812-7
Extremely thermostable serine-type protease from Aquifex pyrophilus. Molecular cloning, expression, and characterization. Choi IG, et al. **J Biol Chem** 1999 Jan 8; 274(2):881-8
RNA polymerase of Aquifex pyrophilus: implications for the evolution of the bacterial rpoBC operon and extremely thermophilic bacteria. Klenk HP, et al. **J Mol Evol** 1999 May;48(5):528-41
[Extended-spectrum beta-lactamase producing gram negative rods infection] Kuwabara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):186-8 (4 ref.) **(Jpn)**
[Metallo-beta-lactamase producing gram negative rods infection] Kuwabara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):189-91 (6 ref.) **(Jpn)**

GENETICS

Construction and characterization of two recombinant bacteria that grow on ortho- and para-substituted chlorobiphenyls. Hrywna Y, et al. **Appl Environ Microbiol** 1999 May;65(5):2163-9
Genetic analysis of Comamonas acidovorans polyhydroxyalkanoate synthase and factors affecting the incorporation of 4-hydroxybutyrate monomer. Sudesh K, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3437-43
Analysis of the genome of the gram-negative moderate halophiles Halomonas and Chromohalobacter by using pulsed-field gel electrophoresis. Mellado E, et al. **Extremophiles** 1998 Nov;2(4):435-8
The role of the Sphingomonas species UG30 pentachlorophenol-4-monooxygenase in p-nitrophenol degradation. Leung KT, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):247-53
Improved production of poly(4-hydroxybutyrate) by Comamonas acidovorans and its freeze-fracture morphology. Sudesh K, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):79-85
Sulfitobacter mediterraneus sp. nov., a new sulfite-oxidizing member of the alpha-Proteobacteria. Pukall R, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:513-9

Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov. Wen A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:567–76

A functional 4-hydroxysalicylate/hydroxyquinol degradative pathway gene cluster is linked to the initial dibenzo-p-dioxin pathway genes in Sphingomonas sp. strain RW1. Armengaud J, et al. **J Bacteriol** 1999 Jun; 181(11):3452–61

RNA polymerase of Aquifex pyrophilus: implications for the evolution of the bacterial rpoBC operon and extremely thermophilic bacteria. Klenk HP, et al. **J Mol Evol** 1999 May;48(5):528–41

Adaptation of Comamonas testosteroni TA441 to utilize phenol: organization and regulation of the genes involved in phenol degradation. Arai H, et al. **Microbiology** 1998 Oct;144 (Pt 10):2895–903

Analysis of the replication region of the cryptic plasmid pHE1 from the moderate halophile Halomonas elongata. Vargas C, et al. **Mol Gen Genet** 1999 Jun;261(4–5):851–61

Genotypic diversity of Acidovorax strains isolated from activated sludge and description of Acidovorax defluvii sp. nov. Schulze R, et al. **Syst Appl Microbiol** 1999 May; 22(2):205–14

Evidence for massive gene exchange between archaeal and bacterial hyperthermophiles [letter] [published erratum appears in Trends Genet 1999 Jan;15(1):41] Aravind L, et al. **Trends Genet** 1998 Nov;14(11):442–4

ISOLATION & PURIFICATION

Endophthalmitis induced by Chryseomonas indologen [letter] Chang TS, et al. **Arch Ophthalmol** 1998 Nov;116(11):1533–4

Unusual clinical presentation of infection due to Flavimonas oryzihabitans. Giacometti A, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):645–8

Isolation of poly(beta-L-malic acid)-degrading bacteria and purification and characterization of the PMA hydrolase from Comamonas acidovorans strain 7789. Gödde C, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):365–72

Comamonas acidovorans contamination of dental unit waters. Stampi S, et al. **Lett Appl Microbiol** 1999 Jul;29(1):52–5

Munchausen's microbes? [letter] Meessen NE, et al. **N Engl J Med** 1998 Dec 3;339(23):1717–8

Ochrobactrum anthropi bacteremia associated with a catheter in an immunocompromised child and review of the pediatric literature. Saavedra J, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):658–60 (9 ref.)

Isolation of acidophilic methane-oxidizing bacteria from northern peat wetlands. Dedysh SN, et al. **Science** 1998 Oct 9;282(5387):281–4

Hymenobacter roseosalivarius gen. nov., sp. nov. from continental Antartica soils and sandstone: bacteria of the Cytophaga/Flavobacterium/Bacteroides line of phylogenetic descent. Hirsch P, et al. **Syst Appl Microbiol** 1998 Aug;21(3):374–383

METABOLISM

Contrasting effects of a nonionic surfactant on the biotransformation of polycyclic aromatic hydrocarbons to cis-dihydrodiols by soil bacteria. Allen CC, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1335–9

Construction and characterization of two recombinant bacteria that grow on ortho- and para-substituted chlorobiphenyls. Hrywna Y, et al. **Appl Environ Microbiol** 1999 May;65(5):2163–9

Comparison of the downstream pathways for degradation of nitrobenzene by Pseudomonas pseudoalcaligenes JS45 (2-aminophenol pathway) and by Comamonas sp. JS765 (catechol pathway). He Z, et al. **Arch Microbiol** 1999 Apr; 171(5):309–16

Degradation of explosive 2,4,6-trinitrotoluene by s-triazine degrading bacterium isolated from contaminated soil. Oh K, et al. **Bull Environ Contam Toxicol** 1998 Dec;61(6):702–8

Microbial degradation of nitrobenzene and mono-nitrophenol by bacteria enriched from municipal activated sludge. Zhao JS, et al. **Can J Microbiol** 1999 May;45(5):427–32

Bioconversion of pyrimidine by resting cells of quinoline-degrading bacteria. Fetzner S. **FEMS Microbiol Lett** 1999 Jul 15;176(2):291–9

Extracellular degradation of medium chain length poly(beta-hydroxyalkanoates) by Comamonas sp. Quinteros R, et al. **Int J Biol Macromol** 1999 Jun–Jul; 25(1–3):135–43

Degradation of various chlorophenols under alkaline conditions by gram-negative bacteria closely related to Ochrobactrum anthropi. Müller RH, et al. **J Basic Microbiol** 1998;38(4):269–81

Biomineralization of carbonates by Halomonas eurihalina in solid and liquid media with different salinities: crystal formation sequence. Rivadeneyra MA, et al. **Res Microbiol** 1998 Apr;149(4):277–87

PHYSIOLOGY

Thauera mechernichensis sp. nov., an aerobic denitrifier from a leachate treatment plant. Scholten E, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1045–51

GRAM-NEGATIVE ANAEROBIC BACTERIA

[Anaerobic pneumonia] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):392–5 (11 ref.) **(Jpn)**

CLASSIFICATION

Syntrophus aciditrophicus sp. nov., a new anaerobic bacterium that degrades fatty acids and benzoate in syntrophic association with hydrogen-using microorganisms. Jackson BE, et al. **Arch Microbiol** 1999 Jan;171(2):107–14

Aminomonas paucivorans gen. nov., sp. nov., a mesophilic, anaerobic, amino-acid-utilizing bacterium. Baena S, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:975–82

Haloanaerobium kushneri sp. nov., an obligately halophilic, anaerobic bacterium from an oil brine. Bhupathiraju VK, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:953–60

Caldicellulosiruptor kristjanssonii sp. nov., a cellulolytic, extremely thermophilic, anaerobic bacterium. Bredholt S, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:991–6

Coprothermobacter platensis sp. nov., a new anaerobic proteolytic thermophilic bacterium isolated from an anaerobic mesophilic sludge. Etchebehere C, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1297–304

Phylogenetic analysis of Formivibrio citricus, Propionivibrio dicarboxylicus, Anaerobiospirillum thomasii, Succinimonas amylolytica and Succinivibrio dextrinosolvens and proposal of Succinivibrionaceae fam. nov. Hippe H, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:779–82

Phylogeny of marine and freshwater Shewanella: reclassification of Shewanella putrefaciens NCIMB 400 as Shewanella frigidimarina. Reid GA, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:189–91

DRUG EFFECTS

Antimicrobial susceptibility of anaerobic and capnophilic bacteria isolated from odontogenic abscesses and rapidly progressive periodontitis. Eick S, et al. **Int J Antimicrob Agents** 1999 Jun;12(1):41–6

Inhibiting interspecies coaggregation of plaque bacteria with a cranberry juice constituent [published erratam appear in J Am Dent Assoc 1999 Jan;130(1):36 and 1999 Mar;130(3):332] Weiss EI, et al. **J Am Dent Assoc** 1998 Dec;129(12):1719–23

[Investigations into the occurrence and the antibiotic susceptibility of gram negative anaerobes of the genera Bacteroides, Prevotella, Porphyromonas and Fusobacterium in specimens obtained from diseased animals] Even H, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):379–86 (Eng. Abstr.) **(Ger)**

[Activity of trovafloxacin and ten other antimicrobials against gram negative anaerobic bacilli] Chávez M, et al. **Rev Esp Quimioter** 1998 Dec;11(4):349–52 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Beta-lactamase production by oral anaerobic gram-negative species in infants in relation to previous antimicrobial therapy. Nyfors S, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1591–4

A cold-active glucanase from the ruminal bacterium Fibrobacter succinogenes S85. Iyo AH, et al. **Appl Environ Microbiol** 1999 Mar;65(3):995–8

The biotin protein MadF of the malonate decarboxylase from Malonomonas rubra. Berg M, et al. **Arch Microbiol** 1998 Nov;170(6):464–8

Purification and characterization of the 3-chloro-4-hydroxy-phenylacetate reductive dehalogenase of Desulfitobacterium hafniense. Christiansen N, et al. **FEBS Lett** 1998 Oct 2;436(2):159–62

Two restriction endonucleases in Selenomonas ruminantium subsp. lactilytica. Pristaš P, et al. **Lett Appl Microbiol** 1998 Aug;27(2):83–5

The sodium ion translocating glutaconyl-CoA decarboxylase from Acidaminococcus fermentans: cloning and function of the genes forming a second operon. Braune A, et al. **Mol Microbiol** 1999 Jan;31(2):473–87

Structure of cytochrome c nitrite reductase. Einsle O, et al. **Nature** 1999 Jul 29;400(6743):476–80

GENETICS

Phylogenetic analysis of Formivibrio citricus, Propionivibrio dicarboxylicus, Anaerobiospirillum thomasii, Succinimonas amylolytica and Succinivibrio dextrinosolvens and proposal of Succinivibrionaceae fam. nov. Hippe H, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:779–82

The fermenting bacterium Malonomonas rubra is phylogenetically related to sulfur-reducing bacteria and contains a c-type cytochrome similar to those of sulfur and sulfate reducers. Kolb S, et al. **Syst Appl Microbiol** 1998 Aug;21(3):340–5

GROWTH & DEVELOPMENT

Caldicellulosiruptor kristjanssonii sp. nov., a cellulolytic, extremely thermophilic, anaerobic bacterium. Bredholt S, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:991–6

ISOLATION & PURIFICATION

Microbial communities associated with anaerobic benzene degradation in a petroleum-contaminated aquifer. Rooney-Varga JN, et al. **Appl Environ Microbiol** 1999 Jul; 65(7):3056–63

Detection of beer spoilage bacteria Megasphaera and Pectinatus by polymerase chain reaction and colorimetric microplate hybridization. Satokari R, et al. **Int J Food Microbiol** 1998 Dec 8;45(2):119–27

Coprothermobacter platensis sp. nov., a new anaerobic proteolytic thermophilic bacterium isolated from an anaerobic mesophilic sludge. Etchebehere C, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1297–304

Syntrophobacter fumaroxidans sp. nov., a syntrophic propionate-degrading sulfate-reducing bacterium. Harmsen HJ, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1383–7

Effect of initial periodontal therapy on the frequency of detecting Bacteroides forsythus, Porphyromonas gingivalis, and Actinobacillus actinomycetemcomitans. Takamatsu N, et al. **J Periodontol** 1999 Jun;70(6):574–80

Monitoring a widespread bacterial group: in situ detection of planctomycetes with 16S rRNA-targeted probes. Neef A, et al. **Microbiology** 1998 Dec;144 (Pt 12):3257–66

The use of biologically produced ferrihydrite for the isolation of novel iron-reducing bacteria. Straub KL, et al. **Syst Appl Microbiol** 1998 Aug;21(3):442–9

METABOLISM

Interactions between carbon and nitrogen metabolism in Fibrobacter succinogenes S85: a 1H and 13C nuclear magnetic resonance and enzymatic study. Matheron C, et al. **Appl Environ Microbiol** 1999 May;65(5):1941–8

Microbial communities associated with anaerobic benzene degradation in a petroleum-contaminated aquifer. Rooney-Varga JN, et al. **Appl Environ Microbiol** 1999 Jul; 65(7):3056–63

Syntrophus aciditrophicus sp. nov., a new anaerobic bacterium that degrades fatty acids and benzoate in syntrophic association with hydrogen-using microorganisms. Jackson BE, et al. **Arch Microbiol** 1999 Jan;171(2):107–14

Purification and characterization of triheme cytochrome c7 from the metal-reducing bacterium, Geobacter metallireducens. Afkar E, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):205–10

Syntrophobacter fumaroxidans sp. nov., a syntrophic propionate-degrading sulfate-reducing bacterium. Harmsen HJ, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1383–7

In vitro studies on the initial reactions of anaerobic ethylbenzene mineralization. Johnson HA, et al. **J Bacteriol** 1999 Sep;181(18):5662–8

The fermenting bacterium Malonomonas rubra is phylogenetically related to sulfur-reducing bacteria and contains a c-type cytochrome similar to those of sulfur and sulfate reducers. Kolb S, et al. **Syst Appl Microbiol** 1998 Aug;21(3):340–5

The use of biologically produced ferrihydrite for the isolation of novel iron-reducing bacteria. Straub KL, et al. **Syst Appl Microbiol** 1998 Aug;21(3):442–9

PHYSIOLOGY

Characterisation of cellulose-binding proteins that are involved in the adhesion mechanism of Fibrobacter intestinalis DR7. Miron J, et al. **Appl Microbiol Biotechnol** 1999 Apr;51(4):491–7

ULTRASTRUCTURE

Ultrastructural characterization of Anaerobiospirillum succiniciproducens and its differentiation from Campylobacter species. Wecke J, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):83–8

VIROLOGY

Lysogenic bacteriophage M1 from Selenomonas ruminantium: isolation, characterization and DNA sequence analysis of the integration site. Cheong JP, et al. **Microbiology** 1998 Aug;144 (Pt 8):2195–202

GRAM-NEGATIVE ANAEROBIC STRAIGHT, CURVED, AND HELICAL RODS

Periodontal disease in dogs. Etiopathogenesis, prevalence, and significance. Harvey CE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1111–28, vi (56 ref.)

CLASSIFICATION

Chlorobium ferrooxidans sp. nov., a phototrophic green sulfur bacterium that oxidizes ferrous iron in coculture with a "Geospirillum" sp. strain. Heising S, et al. **Arch Microbiol** 1999 Aug;172(2):116–24

ENZYMOLOGY

Pullulanase type I from Fervidobacterium pennavorans Ven5: cloning, sequencing, and expression of the gene and

biochemical characterization of the recombinant enzyme. Bertoldo C, et al. **Appl Environ Microbiol** 1999 May; 65(5):2084-91

Purification, characterization, and molecular analysis of thermostable cellulases CelA and CelB from Thermotoga neapolitana. Bok JD, et al. **Appl Environ Microbiol** 1998 Dec;64(12):4774-81

Influence of polymolecular events on inactivation behavior of xylose isomerase from Thermotoga neapolitana 5068. Hess JM, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):509-17

GENETICS

Pullulanase type I from Fervidobacterium pennavorans Ven5: cloning, sequencing, and expression of the gene and biochemical characterization of the recombinant enzyme. Bertoldo C, et al. **Appl Environ Microbiol** 1999 May; 65(5):2084-91

Genetically modified ruminal bacteria protect sheep from fluoroacetate poisoning. Gregg K, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3496-8

Organization of the chromosomal region containing the genes lexA and topA in Thermotoga neapolitana. Primary structure of LexA reveals phylogenetic relevance. Zverlov VV, et al. **Syst Appl Microbiol** 1999 May;22(2):174-8

ISOLATION & PURIFICATION

Bacteremia caused by a novel isolate resembling leptotrichia species in a neutropenic patient. Patel JB, et al. **J Clin Microbiol** 1999 Jun;37(6):2064-7

Anaerobiospirillum succiniciproducens septicaemia: important aspects of diagnosis and management. Goddard WW, et al. **J Infect** 1998 Jul;37(1):68-70

PHYSIOLOGY

Effect of rapid cooling and acidic pH on cellular homeostasis of Pectinatus frisingensis, a strictly anaerobic beer-spoilage bacterium. Chihib NE, et al. **Int J Food Microbiol** 1999 Jun 1;48(3):191-202

Sulfate-reducing bacteria in rice field soil and on rice roots. Wind T, et al. **Syst Appl Microbiol** 1999 May;22(2):269-79

ULTRASTRUCTURE

An unusual helical micro-organism found in the gut lumen of human subjects. Collins AJ, et al. **J Med Microbiol** 1999 Apr;48(4):401-5

GRAM-NEGATIVE BACTERIA

Delivery of DNA vaccines by attenuated intracellular bacteria. Dietrich G, et al. **Immunol Today** 1999 Jun; 20(6):251-3 (14 ref.)

C-reactive protein is useful in distinguishing Gram stain-negative bacterial meningitis from viral meningitis in children. Sormunen P, et al. **J Pediatr** 1999 Jun; 134(6):725-9

Experimentally induced infection of gerbils with cilia-associated respiratory bacillus. St. Clair MB, et al. **Lab Anim Sci** 1999 Aug;49(4):421-3

Afipia felis in hospital water supply in association with free-living amoebae [letter] La Scola B, et al. **Lancet** 1999 Apr 17;353(9161):1330

[Endotoxins in the workplace and in the environment] Danuser B, et al. **Schweiz Med Wochenschr** 1999 Mar 27; 129(12):475-83 (56 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Crystallization and preliminary X-ray crystallographic studies of the native and chemically modified anion-selective porin from Comamonas acidovorans. Zeth K, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1; 54 (Pt 4):650-3

Quantification of bacterial polyhydroxyalkanoic acids by Nile red staining. Gorenflo V, et al. **Appl Microbiol Biotechnol** 1999 Jun;51(6):765-72

A typical bacterial ornithine-containing lipid Nalpha-(D)-[3-(hexadecanoyloxy)hexadecanoyl]-ornithine is a strong stimulant for macrophages and a useful adjuvant. Kawai Y, et al. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):67-73

A new anti-MRSA antibiotic complex, WAP-8294A. I. Taxonomy, isolation and biological activities. Kato A, et al. **J Antibiot (Tokyo)** 1998 Oct;51(10):929-35

Influence of salt concentration on the cellular fatty acid composition of the moderately halophilic bacterium Halomonas salina. Valderrama MJ, et al. **Res Microbiol** 1998 Oct;149(9):675-9

CLASSIFICATION

Methylobacterium extorquens strain P14, a new methylotrophic bacteria producing poly-beta-hydroxybutyrate (PHB). Ostafin M, et al. **Acta Microbiol Pol** 1999;48(1):39-51

Differentiation of microorganisms based on pyrolysis-ion trap mass spectrometry using chemical ionization. Barshick SA, et al. **Anal Chem** 1999 Feb 1;71(3):633-41

Physiological diversity of the rhizosphere diazotroph assemblages of selected salt marsh grasses. Bagwell CE, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4276-82

Identification of a novel group of bacteria in sludge from a deteriorated biological phosphorus removal reactor. Nielsen AT, et al. **Appl Environ Microbiol** 1999 Mar; 65(3):1251-8

Investigations on different Ornithobacterium rhinotracheale "ORT" isolates. Hafez HM, et al. **Avian Dis** 1999 Jan-Mar; 43(1):1-7

Evaluation of CHROMagar orientation medium for the identification of surveillance cultures: a novel method. Rigby JL, et al. **Br J Biomed Sci** 1998 Dec;55(4):238-41

Marinobacter aquaeolei sp. nov., a halophilic bacterium isolated from a Vietnamese oil-producing well. Huu NB, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:367-75

Aquabacterium gen. nov., with description of Aquabacterium citratiphilum sp. nov., Aquabacterium parvum sp. nov. and Aquabacterium commune sp. nov., three in situ dominant bacterial species from the Berlin drinking water system. Kalmbach S, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:769-77

Fermentative bacteria from estuarine mud: phylogenetic position of Acidaminobacter hydrogenoformans and description of a new type of gram-negative, propionigenic bacterium as Propionibacter pelophilus gen. nov., sp. nov. Meijer WG, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1039-44

Marinospirillum gen. nov., with descriptions of Marinospirillum megaterium sp. nov., isolated from kusaya gravy, and transfer of Oceanospirillum minutulum to Marinospirillum minutulum comb. nov. Satomi M, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1341-8

The phylogenetic relationships of Caulobacter, Asticcacaulis and Brevundimonas species and their taxonomic implications. Sly LI, et al. **Int J Syst Bacteriol** 1999 Apr; 49 Pt 2:483-8

Studies on the phylogenetic relationships of melanogenic marine bacteria: proposal of Marinomonas mediterranea sp. nov. Solano F, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1241-6

Taxonomic characterization of denitrifying bacteria that degrade aromatic compounds and description of Azoarcus toluvorans sp. nov. and Azoarcus toluclasticus sp. nov. Song B, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1129-40

Sulfurospirillum barnesii sp. nov. and Sulfurospirillum arsenophilum sp. nov., new members of the Sulfurospirillum clade of the epsilon Proteobacteria. Stolz JF, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1177-80

Assignment of Centers for Disease Control group IVc-2 to the genus Ralstonia as Ralstonia paucula sp. nov. Vandamme P, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:663-9

Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov. Wen A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:567-76

Gram type-specific broad-range PCR amplification for rapid detection of 62 pathogenic bacteria [published erratum appears in J Clin Microbiol 1999 May;37(5):1660] Klausegger A, et al. **J Clin Microbiol** 1999 Feb;37(2):464-6

Prevalence and genetic variability of Arcobacter species in mechanically separated turkey. Manke TR, et al. **J Food Prot** 1998 Dec;61(12):1623-8

Comparison of two kinds of Biolog microplates (GN and ECO) in their ability to distinguish among aquatic microbial communities. Choi KH, et al. **J Microbiol Methods** 1999 Jun;36(3):203-13

Comparison of API 20NE and Biolog GN identification systems assessed by techniques of multivariate analyses. Truu J, et al. **J Microbiol Methods** 1999 Jun;36(3):193-201

Correlation between ability of Ornithobacterium rhinotracheale to agglutinate red blood cells and susceptibility to fosfomycin. Fitzgerald SL, et al. **Onderstepoort J Vet Res** 1998 Dec;65(4):317-20

Defluvibacter lusatiae gen. nov., sp. nov., a new chlorohenol-degrading member of the alpha-2 subgroup of proteobacteria. Fritsche K, et al. **Syst Appl Microbiol** 1999 May;22(2):197-204

CYTOLOGY

Quantitative immunofluorescence of regulated eps gene expression in single cells of Ralstonia solanacearum. Kang Y, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2356-62

DRUG EFFECTS

In vitro efficacy of N-duopropenide, a recently developed disinfectant containing quaternary ammonium compounds, against selected gram-positive and gram-negative organisms. Gutiérrez CB, et al. **Am J Vet Res** 1999 Apr; 60(4):481-4

PMX-622 (polymyxin B-dextran 70) does not alter in vitro activities of 11 antimicrobial agents. Fuchs PC, et al. **Antimicrob Agents Chemother** 1998 Oct;42(10):2765-7

Role of permeability in the activities of beta-lactams against gram-negative bacteria which produce a group 3 beta-lactamase. Matsumura N, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2084-6

Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms. Pankuch GA, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):3028-31

Synthesis and antibacterial activity of new cephalosporins with lactonyloxyimino moiety. Suh KH, et al. **Arch Pharm Res** 1994 Apr;17(2):87-92

Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics. Yoon SY, et al. **Arch Pharm Res** 1994 Dec;17(6):438-42

Synthesis of some thieno gamma lactam monocarboxylic acids with high antibacterial activity: a new look at an old molecular system. Kar GK, et al. **Bioorg Med Chem** 1998 Dec;6(12):2397-403

3-trifluoromethylcarbacephems: synthesis of broad spectrum antibacterial compounds. Cook GK, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1261-6

Killing of gram-negative bacteria by ciprofloxacin within both healthy human neutrophils and neutrophils with inactivated O2-dependent bactericidal mechanisms. Cantón E, et al. **Chemotherapy** 1999 Jul-Aug;45(4):268-76

Susceptibility surveillance among gram-negative bacilli at a cancer center. Jacobson K, et al. **Chemotherapy** 1999 Sep-Oct;45(5):325-34

In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Ling TK, et al. **Chemotherapy** 1999 Jan-Feb;45(1):22-7

Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Zhanel GG, et al. **Chemotherapy** 1998 Nov-Dec;44(6):391-6

Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Friedrich LV, et al. **Clin Infect Dis** 1999 May;28(5):1017-24

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Hancock RE. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S93-9 (60 ref.)

Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection [see comments] D'Agata EM, et al. **Crit Care Med** 1999 Jun;27(6):1090-5. Comment in: Crit Care Med 1999 Jun;27(6):1037-8.

Multiresistance of gram-negative bacteria in intensive care units: bad news from without [editorial; comment] Harbarth S, et al. **Crit Care Med** 1999 Jun;27(6):1037-8. Comment on: Crit Care Med 1999 Jun;27(6):1090-5.

Antibiotic restriction does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit [see comments] Toltzis P, et al. **Crit Care Med** 1998 Nov;26(11):1893-9. Comment in: Crit Care Med 1998 Nov;26(11):1790-1.

Antibiotic resistance in oral/respiratory bacteria. Roberts MC. **Crit Rev Oral Biol Med** 1998;9(4):522-40 (140 ref.)

Antimicrobial activity of merocyanine 540: a photosensitizing dye. Dunne WM Jr, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):101-5

Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Jones RN, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):85-94

Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Kugler KC, et al. **Diagn Microbiol Infect Dis** 1999 May;34(1):73-6

Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health. Marshall SA, et al. **Diagn Microbiol Infect Dis** 1999 Mar;33(3):181-6

Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Yamaguchi K, et al. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):123-34

Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT, et al. **Drugs Exp Clin Res** 1998;24(3):139-51

Utility of serial rectal swab cultures for detection of ceftazidime- and imipenem-resistant gram-negative bacilli from patients in the intensive care unit. Arbo MD, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):727-30

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechère JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):405-12 (48 ref.)

Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Pontani D, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):413-9

An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. Allaker RP, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):289-93

Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. Freestone PP, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):53-60

Resistance to third-generation cephalosporins in adult gram-negative bacillary meningitis. Lu CH, et al. **Infection** 1999 May-Jun;27(3):208-11

In vitro evaluation of G1: a novel antimicrobial compound. Blondeau JM, et al. **Int J Antimicrob Agents** 1999 Feb; 11(2):163-6

Postantibiotic and physiological effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens. Diarra MS, et al. **Int J Antimicrob Agents** 1999 Aug;12(3):229-37

In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates. López-Brea M, et al. **Int J Antimicrob Agents** 1999 Jun;12(1):33–9

In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections. Araque M, et al. **Intensive Care Med** 1998 Aug;24(8):839–44

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. Cormican M, et al. **Ir J Med Sci** 1998 Jul–Sep;167(3):155–9

Preparation and antimicrobial assessment of 2-thioether-linked quinolonyl-carbapenems. Hershberger PM, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):857–71

Korormicin, an antibiotic specific for gram-negative marine bacteria, strongly inhibits the respiratory chain-linked Na+-translocating NADH: quinone reductase from the marine Vibrio alginolyticus. Yoshikawa K, et al. **J Antibiot (Tokyo)** 1999 Feb;52(2):182–5

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. Blondeau JM. **J Antimicrob Chemother** 1999 May;43 Suppl B:1–11 (96 ref.)

Bactericidal properties of moxifloxacin and post-antibiotic effect. Boswell FJ, et al. **J Antimicrob Chemother** 1999 May;43 Suppl B:43–9

Pharmacodynamics of fluoroquinolones. Dalhoff A. **J Antimicrob Chemother** 1999 May;43 Suppl B:51–9

A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. Günseren F, et al. **J Antimicrob Chemother** 1999 Mar;43(3):373–8

Comparative in-vitro activities of topical antibiotics against conjunctival isolates [letter] Iqbal J, et al. **J Antimicrob Chemother** 1999 Apr;43(4):611–2

Killing kinetics of intracellular Afipia felis treated with amikacin. Le Pocher H, et al. **J Antimicrob Chemother** 1998 Dec;42(6):825–9

Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? Martinez JL, et al. **J Antimicrob Chemother** 1998 Dec;42(6):683–8 (64 ref.)

Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. Martinez-Freijo P, et al. **J Antimicrob Chemother** 1998 Dec;42(6):689–96

Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria. Piddock LJ, et al. **J Antimicrob Chemother** 1999 May;43 Suppl B:39–42

Factors associated with trimethoprim-resistant bacteria isolated from urine samples. Steinke DT, et al. **J Antimicrob Chemother** 1999 Jun;43(6):841–3

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Thomson KS, et al. **J Antimicrob Chemother** 1998 Aug;42(2):179–87

Effect of elevated oxygen and carbon dioxide on the surface growth of vegetable-associated micro-organisms. Amanatidou A, et al. **J Appl Microbiol** 1999 Mar; 86(3):429–38

Influence of organic matter, cations and surfactants on the antimicrobial activity of Melaleuca alternifolia (tea tree) oil in vitro. Hammer KA, et al. **J Appl Microbiol** 1999 Mar;86(3):446–52

Development of bacterial resistance to the third generation cephalosporins and their clinical use. Kolár M, et al. **J Chemother** 1999 Aug;11(4):260–5

Molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during nonoutbreak periods. D'Agata EM, et al. **J Clin Microbiol** 1999 Sep;37(9):3065–7

Evaluation of efficacy of Dettol-H in hospital use. Kapoor H, et al. **J Commun Dis** 1998 Sep;30(3):167–70

Antibacterial effects of N-sulfonated and N-sulfobenzoyl chitosan and application to oyster preservation. Chen CS, et al. **J Food Prot** 1998 Sep;61(9):1124–8

Antimicrobial resistance of gram-negative enteric bacteria from pigs in a nonantimicrobial-exposed herd before and after transportation. Langlois BE, et al. **J Food Prot** 1999 Jul;62(7):797–9

Susceptibility of antibiotic-resistant and antibiotic-sensitive foodborne pathogens to acid anionic sanitizers. Lopes JA. **J Food Prot** 1998 Oct;61(10):1390–5

Antibiotic resistance patterns among blood culture isolates in a Danish county 1981–1995. Kristensen B, et al. **J Med Microbiol** 1999 Jan;48(1):67–71

Facile total synthesis and antimicrobial activity of the marine fatty acids (Z)-2-methoxy-5-hexadecenoic acid and (Z)-2-methoxy-6-hexadecenoic acid. Carballeira NM, et al. **J Nat Prod** 1998 Dec;61(12):1543–6

Extended-spectrum beta-lactamases: a plague of plasmids [editorial; comment] Fierer J, et al. **JAMA** 1999 Feb 10; 281(6):563–4. Comment on: JAMA 1999 Feb 10;281(6):517–23.

Increase in sepsis due to multi-resistant enteric gram-negative bacilli in Papua New Guinea [letter] Duke T, et al. **Lancet** 1999 Jun 26;353(9171):2210–1

Worldwide proliferation of carbapenem-resistant gram-negative bacteria [letter] Kurokawa H, et al. **Lancet** 1999 Sep 11;354(9182):955

In-vitro antimicrobial activity and chemical composition of Sardinian Thymus essential oils. Cosentino S, et al. **Lett Appl Microbiol** 1999 Aug;29(2):130–5

An evaluation of the suitability of the European suspension test to reflect in vitro activity of antiseptics against clinically significant organisms. Payne DN, et al. **Lett Appl Microbiol** 1999 Jan;28(1):7–12

Antimicrobial effect of tetramethyldithiooxamide and its application as a biocide. Tabakova SV, et al. **Lett Appl Microbiol** 1998 Oct;27(4):189–92

A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Shen AY, et al. **Life Sci** 1999;64(9):813–25

Correlation between ability of Ornithobacterium rhinotracheale to agglutinate red blood cells and susceptibility to fosfomycin. Fitzgerald SL, et al. **Onderstepoort J Vet Res** 1998 Dec;65(4):317–20

Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Goldstein MH, et al. **Ophthalmology** 1999 Jul;106(7):1313–8

Preparation and antibiotic activity of monobactam analogues of nocardicins. Gerardin-Charbonnier C, et al. **Prep Biochem Biotechnol** 1999 Aug;29(3):257–72

Influence of salt concentration on the cellular fatty acid composition of the moderately halophilic bacterium Halomonas salina. Valderrama MJ, et al. **Res Microbiol** 1998 Oct;149(9):675–9

In vitro expression of beta-lactam-induced response by clinical gram-negative bacteria with the potential for inducible beta-lactamase production. Bongaerts G, et al. **Scand J Infect Dis** 1998;30(6):579–83

Impact and pattern of gram-negative bacteraemia during 6 y at a large university hospital. Harbarth S, et al. **Scand J Infect Dis** 1999;31(2):163–8

Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility. Srifuengfung S, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):96–9

Antimicrobial resistance—danger signs all around. Craig A. **Tenn Med** 1998 Nov;91(11):433, 435 (15 ref.)

Bacterial resistance, beta-lactam antibiotics and gramnegative bacteria at ICUs [editorial] Reisinger EC, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):537–8

Antibacterial activity of simple coumarins: structural requirements for biological activity. Kayser O, et al. **Z Naturforsch [C]** 1999 Mar–Apr;54(3–4):169–74

Antibacterial and cytotoxic natural and synthesized hydroquinones from sponge Ircinia spinosula. Mihopoulos N, et al. **Z Naturforsch [C]** 1999 May–Jun;54(5–6):417–23

Pyrrolizidine alkaloids from Echium rauwolfii and Echium horridum (Boraginaceae). el-Shazly A, et al. **Z Naturforsch [C]** 1999 May–Jun;54(5–6):295–300

[Mechanisms underlying resistance of the bacteria responsible for nosocomial infections] Mainardi JL, et al. **Pathol Biol (Paris)** 1998 Apr;46(4):253–60 (53 ref.) (Eng. Abstr.) **(Fre)**

[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)] Igari J, et al. **Jpn J Antibiot** 1999 Apr;52(4):279–91 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activity of carbapenem antibiotics against gram-negative bacilli] Kinoshita S, et al. **Jpn J Antibiot** 1998 Sep;51(9):551–60 (Eng. Abstr.) **(Jpn)**

[A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-negative bacilli] Kuroyama M, et al. **Jpn J Antibiot** 1999 Apr;52(4):333–52 (Eng. Abstr.) **(Jpn)**

[In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994--in vitro susceptibility surveillance.Levofloxacin-Surveillance Group] Yamaguchi K, et al. **Jpn J Antibiot** 1999 Feb; 52(2):75–92 (Eng. Abstr.) **(Jpn)**

Study of rapidity and quality for the VITEK susceptibility cards with 45 wells. Miyamoto H, et al. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):55–8 (Eng. Abstr.) **(Jpn)**

[Beta-lactam-resistance patterns of some gram-negative rods] Janicka G, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):12–4 (31 ref.) (Eng. Abstr.) **(Pol)**

[Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture] Lopes AA, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):196–200 (Eng. Abstr.) **(Por)**

[In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals] Sader HS, et al. **Rev Assoc Med Bras** 1998 Oct–Dec;44(4):283–8 (Eng. Abstr.) **(Por)**

[Antimicrobial and membranolytic activity of sterically hindered phenols] Petrykina ZM, et al. **Antibiot Khimioter** 1998;43(8):11–5 (Eng. Abstr.) **(Rus)**

[Investigation and identification of the antimicrobial component of the drug "Tomatol"] Vorob'ev AA, et al. **Antibiot Khimioter** 1999;44(3):15–8 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Crystallization and preliminary X-ray crystallographic analysis of a periplasmic tetrahaem flavocytochrome c3 from Shewanella frigidimarina NCIMB400 which has fumarate reductase activity. Bamford V, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1222–5

The biochemistry, physiology and genetics of PQQ and PQQ-containing enzymes. Goodwin PM, et al. **Adv Microb Physiol** 1998;40:1–80 (221 ref.)

Role of permeability in the activities of beta-lactams against gram-negative bacteria which produce a group 3 beta-lactamase. Matsumura N, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2084–6

Characterization of the meta-cleavage compound hydrolase gene involved in degradation of the lignin-related biphenyl structure by Sphingomonas paucimobilis SYK-6. Peng X, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2789–93

The alkene monooxygenase from Xanthobacter strain Py2 is closely related to aromatic monooxygenases and catalyzes aromatic monohydroxylation of benzene, toluene, and phenol. Zhou NY, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1589–95

The DmpA aminopeptidase from Ochrobactrum anthropi LMG7991 is the prototype of a new terminal nucleophile hydrolase family. Fanuel L, et al. **Biochem J** 1999 Jul 1; 341 (Pt 1):147–55

Identification of genes unique to Mo-independent nitrogenase systems in diverse diazotrophs. Loveless TM, et al. **Can J Microbiol** 1999 Apr;45(4):312–7

Phenylacetyl-CoA:acceptor oxidoreductase, a membrane-bound molybdenum-iron-sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica. Rhee SK, et al. **Eur J Biochem** 1999 Jun;262(2):507–15

Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Wright GD, et al. **Front Biosci** 1999 Jan 1; 4:D9–21 (91 ref.)

Studies on the phylogenetic relationships of melanogenic marine bacteria: proposal of Marinomonas mediterranea sp. nov. Solano F, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1241–6

Molecular analysis of a novel methanesulfonic acid monooxygenase from the methylotroph Methylosulfonomonas methylovora. de Marco P, et al. **J Bacteriol** 1999 Apr;181(7):2244–51

[Occurrence of extended spectrum beta-lactamases (ESBL) and inducible beta-lactamases (IBL) in clinical strains of gram-negative rods] Rokosz A, et al. **Med Dosw Mikrobiol** 1998;50(1–2):31–9 (Eng. Abstr.) **(Pol)**

GENETICS

Two intracellular symbiotic bacteria from the mulberry psyllid Anomoneura mori (Insecta, Homoptera). Fukatsu T, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3599–606

PCR detection of genes encoding nitrite reductase in denitrifying bacteria. Hallin S, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1652–7

Genetic analysis of biodegradation of tetralin by a Sphingomonas strain. Hernáez MJ, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1806–10

Quantitative immunofluorescence of regulated eps gene expression in single cells of Ralstonia solanacearum. Kang Y, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2356–62

New mobilizable vectors suitable for gene replacement in gram-negative bacteria and their use in mapping of the 3' end of the Xanthomonas campestris pv. campestris gum operon. Katzen F, et al. **Appl Environ Microbiol** 1999 Jan; 65(1):278–82

Genotypic and phenotypic responses of a riverine microbial community to polycyclic aromatic hydrocarbon contamination. Langworthy DE, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3422–8

Identification of a novel group of bacteria in sludge from a deteriorated biological phosphorus removal reactor. Nielsen AT, et al. **Appl Environ Microbiol** 1999 Mar; 65(3):1251–8

Cloning of a Lysobacter enzymogenes gene that encodes an arginyl endopeptidase (endoproteinase Arg-C). Wright DS, et al. **Biochim Biophys Acta** 1998 Dec 22;1443(3):369–74

The pKNOCK series of broad-host-range mobilizable suicide vectors for gene knockout and targeted DNA insertion into the chromosome of gram-negative bacteria. Alexeyev MF. **Biotechniques** 1999 May;26(5):824–6, 828

Molecular epidemiology of gram-negative bacteremia. Wendt C, et al. **Clin Infect Dis** 1999 Mar;28(3):605–10

Specific detection of Xylella fastidiosa Pierce's disease strains. Banks D, et al. **Curr Microbiol** 1999 Aug;39(2):85–8

Fingerprinting of mixed bacterial strains and BIOLOG gram-negative (GN) substrate communities by enterobacterial repetitive intergenic consensus sequence-PCR (ERIC-PCR). Di Giovanni GD, et al. **Curr Microbiol** 1999 Apr;38(4):217–23

Self perception in bacteria: quorum sensing with acylated homoserine lactones. Fuqua C, et al. **Curr Opin Microbiol** 1998 Apr;1(2):183–9 (59 ref.)

Microbial genome sequencing and pathogenesis. Tang CM, et al. **Curr Opin Microbiol** 1998 Feb;1(1):12–6 (45 ref.)

The chaperone/usher pathway: a major terminal branch of the general secretory pathway. Thanassi DG, et al. **Curr Opin Microbiol** 1998 Apr;1(2):223–31 (68 ref.)

Epidemiology of polyclonal gram-negative bacteremia. Wendt C, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):9–13

Genome evolution within the alpha Proteobacteria: why do some bacteria not possess plasmids and others exhibit more than one different chromosome? Moreno E. **FEMS Microbiol Rev** 1998 Oct;22(4):255–75 (159 ref.)

A new membrane-bound OprI lipoprotein expression vector. High production of heterologous fusion proteins in gram (-) bacteria and the implications for oral vaccination. Cote-Sierra J, et al. **Gene** 1998 Oct 9;221(1):25–34

Cloning and characterization of Planctomyces limnophilus rpoN: complementation of a Salmonella typhimurium rpoN mutant strain. Leary BA, et al. **Gene** 1998 Oct 9; 221(1):151–7

Expression of plastocyanin and cytochrome f of the cyanobacterium Phormidium laminosum in Escherichia coli and Paracoccus denitrificans and the role of leader peptides. Schlarb BG, et al. **Gene** 1999 Jul 8;234(2):275–83

Detecting linkage disequilibrium in bacterial populations. Haubold B, et al. **Genetics** 1998 Dec;150(4):1341–8

Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov. Wen A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:567–76

Class 1 integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. Martinez-Freijo P, et al. **J Antimicrob Chemother** 1998 Dec;42(6):689–96

Phylogenetic analysis of L4-mediated autogenous control of the S10 ribosomal protein operon. Allen T, et al. **J Bacteriol** 1999 Oct;181(19):6124–32

Conjugative mobilization of the rolling-circle plasmid pIP823 from Listeria monocytogenes BM4293 among gram-positive and gram-negative bacteria. Charpentier E, et al. **J Bacteriol** 1999 Jun;181(11):3368–74

Molecular analysis of a novel methanesulfonic acid monooxygenase from the methylotroph Methylosulfonomonas methylovora. de Marco P, et al. **J Bacteriol** 1999 Apr;181(7):2244–51

Control of Herbaspirillum seropedicae NifA activity by ammonium ions and oxygen. Souza EM, et al. **J Bacteriol** 1999 Jan;181(2):681–4

PCR methods and plasmid profile analysis for characterisation of Histophilus ovis strains. Appuhamy S, et al. **J Med Microbiol** 1998 Nov;47(11):987–92

Attachment of the chromosome to the cell poles: the strategy for the growth of bacteria in two and three dimensions. Koch AL, et al. **J Theor Biol** 1999 Jul 21;199(2):213–21

Genetic engineering of an industrial strain of Saccharopolyspora erythraea for stable expression of the Vitreoscilla haemoglobin gene (vhb). Brünker P, et al. **Microbiology** 1998 Sep;144 (Pt 9):2441–8

Identification and sequencing of the groE operon and flanking genes of Lawsonia intracellularis: use in phylogeny. Dale CJ, et al. **Microbiology** 1998 Aug;144 (Pt 8):2073–84

Specificity of the lipase-specific foldases of gram-negative bacteria and the role of the membrane anchor. El Khattabi M, et al. **Mol Gen Genet** 1999 Jun;261(4–5):770–6

The structural and functional organization of H-NS-like proteins is evolutionarily conserved in gram-negative bacteria. Bertin P, et al. **Mol Microbiol** 1999 Jan; 31(1):319–29

Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antiobiotics. Rice LB. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):120S–128S; discussion 133S–137S (44 ref.)

Divergence in the background: hard to measure but the key to being the best of the best [letter] Tuomanen E. **Trends Microbiol** 1999 Jul;7(7):271–2

Molecular fingerprinting of Riemerella anatipestifer by repetitive sequence PCR. Huang B, et al. **Vet Microbiol** 1999 Jun 30;67(3):213–9

Prevalence of Lawsonia intracellularis in selected pig herds in Korea as determined by PCR. Kim O, et al. **Vet Rec** 1998 Nov 21;143(21):587–9

GROWTH & DEVELOPMENT

Bacterial filament formation, a defense mechanism against flagellate grazing, is growth rate controlled in bacteria of different phyla. Hahn MW, et al. **Appl Environ Microbiol** 1999 Jan;65(1):25–35

Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides. Zhang L, et al. **Biochemistry** 1999 Jun 22;38(25):8102–11

Improved recovery of antibiotic-stressed microorganisms on inclusion of saponin in aerobic blood culture media. Elliott TS, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug; 17(8):566–9

Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. Freestone PP, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):53–60

Effect of ecological factors on the inhibitory spectrum and activity of bacteriocins. Günzle MG, et al. **Int J Food Microbiol** 1999 Feb 18;46(3):207–17

Effect of elevated oxygen and carbon dioxide on the surface growth of vegetable-associated micro-organisms. Amanatidou A, et al. **J Appl Microbiol** 1999 Mar; 86(3):429–38

Total counts, culturable and viable, and non-culturable microflora of a French mineral water: a case study. Defives C, et al. **J Appl Microbiol** 1999 Jun;86(6):1033–8

Development of a new medium for the isolation of Arcobacter spp. Johnson LG, et al. **J Food Prot** 1999 May; 62(5):456–62

Attachment of the chromosome to the cell poles: the strategy for the growth of bacteria in two and three dimensions. Koch AL, et al. **J Theor Biol** 1999 Jul 21;199(2):213–21

Inhibitory activity of Paenibacillus polymyxa SCE2 against human pathogenic micro-organisms. Seldin L, et al. **Lett Appl Microbiol** 1999 Jun;28(6):423–7

IMMUNOLOGY

Attempted infection of mice, rats and chickens by porcine strains of Lawsonia intracellularis. Collins AM, et al. **Aust Vet J** 1999 Feb;77(2):120–2

Vaccination of chickens against Ornithobacterium rhinotracheale infection. van Empel P, et al. **Avian Dis** 1998 Jul–Sep;42(3):572–8

Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Gangloff SC, et al. **Clin Infect Dis** 1999 Mar; 28(3):491–6

Recognition of gram-negative bacteria and endotoxin by the innate immune system. Ulevitch RJ, et al. **Curr Opin Immunol** 1999 Feb;11(1):19–22 (37 ref.)

Lipid A diversity and the innate host response to bacterial infection. Darveau RP. **Curr Opin Microbiol** 1998 Feb; 1(1):36–42 (63 ref.)

Analysis of functional regions of YPM, a superantigen derived from gram-negative bacteria. Ito Y, et al. **Eur J Biochem** 1999 Jul;263(2):326–37

[An antigenic analysis and the protective properties of the R-form lipopolysaccharides of gram-negative bacteria] Stanislavskiĭ ES, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):52–6 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Endoscopically guided cultures in chronic sinusitis. Nadel DM, et al. **Am J Rhinol** 1998 Jul–Aug;12(4):233–41

Use of antibacterial agents To elucidate the etiology of juvenile oyster disease (JOD) in Crassostrea virginica and numerical dominance of an alpha-proteobacterium in JOD-affected animals. Boettcher KJ, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2534–9

Microbiology of the oil fly, Helaeomyia petrolei. Kadavy DR, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1477–82

Isolation of a bacterial strain able to degrade branched nonylphenol. Tanghe T, et al. **Appl Environ Microbiol** 1999 Feb;65(2):746–51

New nitrogen-fixing microorganisms detected in oligotrophic oceans by amplification of Nitrogenase (nifH) genes. Zehr JP, et al. **Appl Environ Microbiol** 1998 Sep; 64(9):3444–50

Bacterial infections in infants 60 days and younger: epidemiology, resistance, and implications for treatment. Sadow KB, et al. **Arch Pediatr Adolesc Med** 1999 Jun; 153(6):611–4

Differences in the pathogenesis of bacteria isolated from contact-lens-induced infiltrative conditions. Willcox MD, et al. **Aust N Z J Ophthalmol** 1999 Jun–Aug;27(3–4):231–3

Isolation of Georgia variant (Georgia isolate 1992) infectious bronchitis virus but not Ornithobacterium rhinotracheale from a Kentucky broiler complex. Erbeck DH, et al. **Avian Dis** 1998 Jul–Sep;42(3):613–7

Detection of Lawsonia intracellularis in faeces of swine from the main producing regions in Brazil. Chiriboga AE, et al. **Can J Microbiol** 1999 Mar;45(3):230–4

Oropharyngeal Gram-negative bacillary carriage: a survey of 120 healthy individuals. Mobbs KJ, et al. **Chest** 1999 Jun;115(6):1570–5

Ochrobactrum anthropi as an agent of nosocomial septicemia in the setting of AIDS. Manfredi R, et al. **Clin Infect Dis** 1999 Mar;28(3):692–4

Recurrent gram-negative bacteremia: incidence and clinical patterns. Wendt C, et al. **Clin Infect Dis** 1999 Mar; 28(3):611–7

Specific detection of Xylella fastidiosa Pierce's disease strains. Banks D, et al. **Curr Microbiol** 1999 Aug;39(2):85–8

Direct bacterial identification from positive BacT/Alert blood cultures using MicroScan overnight and rapid panels. Waites KB, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):21–6

Identification of equine proliferative enteropathy [editorial; comment] Smith DG. **Equine Vet J** 1998 Nov;30(6):452–3 . Comment on: Equine Vet J 1998 Nov;30(6):549–52.

Improved recovery of antibiotic-stressed microorganisms on inclusion of saponin in aerobic blood culture media. Elliott TS, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug; 17(8):566–9

Association between institutionalization and carriage of multiresistant bacteria in the elderly at the time of admission to a general hospital. Eveillard M, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):133–6

Oral flora of elderly patients following acute medical admission. Preston AJ, et al. **Gerontology** 1999 Jan–Feb; 45(1):49–52

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Chow JW, et al. **Int J Antimicrob Agents** 1999 Jan;11(1):7–12 (16 ref.)

Bacteriologic and immunologic aspects of gram-negative folliculitis: a study of 46 patients. Neubert U, et al. **Int J Dermatol** 1999 Apr;38(4):270–4

Marinospirillum gen. nov., with descriptions of Marinospirillum megaterium sp. nov., isolated from kusaya gravy, and transfer of Oceanospirillum minutulum to Marinospirillum minutulum comb. nov. Satomi M, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1341–8

Lawsonia intracellularis-like organism infection in a miniature foal. Brees DJ, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):511–4, 483

Viable heterotrophic bacteria in water and sediment in 'Mar Piccolo' of Taranto (Ionian Sea, Italy). Cavallo RA, et al. **J Appl Microbiol** 1999 Jun;86(6):906–16

Total counts, culturable and viable, and non-culturable microflora of a French mineral water: a case study. Defives C, et al. **J Appl Microbiol** 1999 Jun;86(6):1033–8

Study of the micro-organisms associated with the fermented bread (khamir) produced from sorghum in Gizan region, Saudi Arabia. Gassem MA. **J Appl Microbiol** 1999 Feb; 86(2):221–5

Evaluation of Statens Serum Institut enteric medium for detection of enteric pathogens. Blom M, et al. **J Clin Microbiol** 1999 Jul;37(7):2312–6

Capillary electrophoresis-single-strand conformation polymorphism analysis for rapid identification of Pseudomonas aeruginosa and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. Ghozzi R, et al. **J Clin Microbiol** 1999 Oct; 37(10):3374–9

Septicemia caused by dysgonic fermenter 3 in a severely immunocompromised patient and isolation of the same microorganism from a stool specimen. Grob R, et al. **J Clin Microbiol** 1999 May;37(5):1617–8

Halotolerant and halophilic histamine-forming bacteria isolated during the ripening of salted anchovies (Engraulis encrasicholus). Hernández-Herrero MM, et al. **J Food Prot** 1999 May;62(5):509–14

Comparison of three protocols for the isolation of Arcobacter from poultry. Johnson LG, et al. **J Food Prot** 1999 Jun; 62(6):610–4

Antimicrobial resistance of gram-negative enteric bacteria from pigs in a nonantimicrobial-exposed herd before and after transportation. Langlois BE, et al. **J Food Prot** 1999 Jul;62(7):797–9

Microbiological quality of retail imported unprepared whole lettuces: a PHLS Food Working Group Study. Public Health Laboratory Service. Little C, et al. **J Food Prot** 1999 Apr;62(4):325–8

Prevalence and genetic variability of Arcobacter species in mechanically separated turkey. Manke TR, et al. **J Food Prot** 1998 Dec;61(12):1623–8

Rapid detection and counting of viable bacteria in vegetables and environmental water using a photon-counting TV camera. Miyamoto T, et al. **J Food Prot** 1998 Oct; 61(10):1312–6

Comparison of two kinds of Biolog microplates (GN and ECO) in their ability to distinguish among aquatic microbial communities. Choi KH, et al. **J Microbiol Methods** 1999 Jun;36(3):203–13

Microbiological study of the dripping waters in Altamira cave (Santillana del Mar, Spain). Laiz L, et al. **J Microbiol Methods** 1999 May;36(1–2):129–38

A simple extraction procedure for efficient routine detection of pathogenic bacteria in plant material by polymerase chain reaction. Llop P, et al. **J Microbiol Methods** 1999 Jul;37(1):23–31

Comparison of API 20NE and Biolog GN identification systems assessed by techniques of multivariate analyses. Truu J, et al. **J Microbiol Methods** 1999 Jun;36(3):193–201

Risk indicators for harboring periodontal pathogens. Umeda M, et al. **J Periodontol** 1998 Oct;69(10):1111–8

Cilia-associated respiratory bacillus infection and pneumonia in a pig. Hafner S, et al. **J Vet Diagn Invest** 1998 Oct; 10(4):373–5

Detection of Lawsonia intracellularis in swine using polymerase chain reaction methodology. Jordan DM, et al. **J Vet Diagn Invest** 1999 Jan;11(1):45–9

Isolation of cilia-associated respiratory (CAR) bacillus from pigs and calves and experimental infection of gnotobiotic pigs and rodents. Nietfeld JC, et al. **J Vet Diagn Invest** 1999 May;11(3):252–8

Evaluation of a commercial system for the identification of Ornithobacterium rhinotracheale. Post KW, et al. **J Vet Diagn Invest** 1999 Jan;11(1):97–9

Bacterial isolates from neutropenic febrile pediatric patients and their sensitivity patterns to antibiotics. Bhatti FN, et al. **JPMA J Pak Med Assoc** 1998 Sep;48(9):287–90

Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Bangladesh. Iqbal J, et al. **Jpn J Med Sci Biol** 1997 Dec;50(6):241–50

Detection of cilia-associated respiratory (CAR) bacillus in nasal-swab specimens from infected rats by use of polymerase chain reaction. Franklin CL, et al. **Lab Anim Sci** 1999 Feb;49(1):114–7

Degradation of 2,4,6-trichlorophenol by a specialized organism and by indigenous soil microflora: bioaugmentation and self-remediability for soil restoration. Andreoni V, et al. **Lett Appl Microbiol** 1998 Aug; 27(2):86–92

PCR differentiation of Escherichia coli from other gram-negative bacteria using primers derived from the nucleotide sequences flanking the gene encoding the universal stress protein. Chen J, et al. **Lett Appl Microbiol** 1998 Dec;27(6):369–71

An investigation of the presence of ultramicrocells in natural mineral water. Jones CR, et al. **Lett Appl Microbiol** 1999 Apr;28(4):275–9

Isolation of Arcobacter butzleri from ground water. Rice EW, et al. **Lett Appl Microbiol** 1999 Jan;28(1):31–5

Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit. Shah SS, et al.

Pediatr Infect Dis J 1999 Jul;18(7):591-5

CDC group IV c-2 bacteremia in a child with recurrent acute monoblastic leukemia. Thayu M, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):397-8

Factors that predict preexisting colonization with antibiotic-resistant gram-negative bacilli in patients admitted to a pediatric intensive care unit. Toltzis P, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):719-23

Occurrence, removal and seasonal variation of thermophilic campylobacters and Arcobacter in sewage sludge. Stampi S, et al. **Zentralbl Hyg Umweltmed** 1999 Jun;202(1):19-27

[Pyogenic infectious complications in recipients with allogenic kidneys: clinical and bacteriological aspects] Volynchik EP, et al. **Vestn Ross Akad Med Nauk** 1998;(6):56-8 (Eng. Abstr.) **(Rus)**

[Non fermentative gram negative bacilli isolated in a hospital laboratory] Ronconi M, et al. **Enferm Infecc Microbiol Clin** 1999 Jun-Jul;17(6):269-73 (Eng. Abstr.) **(Spa)**

[Community-acquired bacteremia and pneumonia caused by Stenotrophomonas maltophilia in a patient with AIDS (letter)] Sales P, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):437 **(Spa)**

METABOLISM

Methylobacterium extorquens strain P14, a new methylotrophic bacteria producing poly-beta-hydroxybutyrate (PHB). Ostafin M, et al. **Acta Microbiol Pol** 1999;48(1):39-51

Biosynthesis and molecular genetics of cephamycins. Cephamycins produced by actinomycetes. Liras P. **Antonie Van Leeuwenhoek** 1999 Jan-Feb;75(1-2):109-24 (85 ref.)

Enhancement of solubilization and biodegradation of polyaromatic hydrocarbons by the bioemulsifier alasan. Barkay T, et al. **Appl Environ Microbiol** 1999 Jun; 65(6):2697-702

Genetic analysis of biodegradation of tetralin by a Sphingomonas strain. Hernáez MJ, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1806-10

Removal of endotoxin during purification of poly(3-hydroxybutyrate) from gram-negative bacteria. Lee SY, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2762-4

Biofilms on indwelling urethral catheters produce quorum-sensing signal molecules in situ and in vitro. Stickler DJ, et al. **Appl Environ Microbiol** 1998 Sep; 64(9):3486-90

Isolation of a bacterial strain able to degrade branched nonylphenol. Tanghe T, et al. **Appl Environ Microbiol** 1999 Feb;65(2):746-51

Anaerobic degradation of 3-halobenzoates by a denitrifying bacterium. Häggblom MM, et al. **Arch Microbiol** 1999 Mar; 171(4):230-6

A sensitive, viable-colony staining method using Nile red for direct screening of bacteria that accumulate polyhydroxyalkanoic acids and other lipid storage compounds. Spiekermann P, et al. **Arch Microbiol** 1999 Jan; 171(2):73-80

Ultracytochemical localization of hydrogen peroxide production by dental plaque bacteria. Oyarzún A, et al. **Arch Oral Biol** 1998 Nov;43(11):907-10

Electrochemical concepts and techniques in the study of stainless steel ennoblement. Dickinson WH, et al. **Biodegradation** 1998;9(1):11-21 (43 ref.)

Bacterial milking: A novel bioprocess for production of compatible solutes. Sauer T, et al. **Biotechnol Bioeng** 1998 Feb 5;57(3):306-13

Antibiotic resistance caused by gram-negative multidrug efflux pumps. Nikaido H. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S32-41 (89 ref.)

Mechanisms of solute transport through outer membrane porins: burning down the house. Klebba PE, et al. **Curr Opin Microbiol** 1998 Apr;1(2):238-47 (86 ref.)

Bacterial solute uptake and efflux systems. Lolkema JS, et al. **Curr Opin Microbiol** 1998 Apr;1(2):248-53 (32 ref.)

Secretion of proteins and assembly of bacterial surface organelles: shared pathways of extracellular protein targeting. Lory S. **Curr Opin Microbiol** 1998 Feb;1(1):27-35 (71 ref.)

The chaperone/usher pathway: a major terminal branch of the general secretory pathway. Thanassi DG, et al. **Curr Opin Microbiol** 1998 Apr;1(2):223-31 (68 ref.)

Biodegradation of s-triazine compounds by a stable mixed bacterial community. Kontchou CY, et al. **Ecotoxicol Environ Saf** 1999 May;43(1):47-56

Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of gram-negative bacteria. Matsuzaki K, et al. **FEBS Lett** 1999 Apr 23;449(2-3):221-4

Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria. Farmer TH, et al. **FEMS Microbiol Lett** 1999 Jul 1;176(1):11-5

Fate of phenanthrene, pyrene and benzo[a]pyrene during biodegradation of crude oil added to two soils. Smith MJ, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):445-52

GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa. Filloux A, et al. **FEMS Microbiol Rev** 1998 Sep;22(3):177-98 (155 ref.)

Chromium-tolerant bacteria isolated from industrial effluents and their use in detoxication of hexavalent chromium. Shakoori AR, et al. **Folia Microbiol (Praha)** 1999;44(1):50-4

Lipoprotein release by bacteria: potential factor in bacterial pathogenesis. Zhang H, et al. **Infect Immun** 1998 Nov; 66(11):5196-201

Taxonomic characterization of denitrifying bacteria that degrade aromatic compounds and description of Azoarcus toluvorans sp. nov. and Azoarcus toluclasticus sp. nov. Song B, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1129-40

B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. Takaishi S, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):805-15

Degradation of 2,4,6-trichlorophenol by a specialized organism and by indigenous soil microflora: bioaugmentation and self-remediability for soil restoration. Andreoni V, et al. **Lett Appl Microbiol** 1998 Aug; 27(2):86-92

The degradation of sodium O,O-diethyl dithiophosphate by bacteria from metalworking fluids. Sherburn RE, et al. **Lett Appl Microbiol** 1999 Jan;28(1):61-5

Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Goffin C, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1079-93 (74 ref.)

Reasons why 'Leptospirillum'-like species rather than Thiobacillus ferrooxidans are the dominant iron-oxidizing bacteria in many commercial processes for the biooxidation of pyrite and related ores. Rawlings DE, et al. **Microbiology** 1999 Jan;145 (Pt 1):5-13 (34 ref.)

Transport of EDTA into cells of the EDTA-degrading bacterial strain DSM 9103. Witschel M, et al. **Microbiology** 1999 Apr;145 (Pt 4):973-83

Specificity of the lipase-specific foldases of gram-negative bacteria and the role of the membrane anchor. El Khattabi M, et al. **Mol Gen Genet** 1999 Jun;261(4-5):770-6

Production of acyl-homoserine lactone quorum-sensing signals by gram-negative plant-associated bacteria. Cha C, et al. **Mol Plant Microbe Interact** 1998 Nov;11(11):1119-29

A role for coenzyme M (2-mercaptoethanesulfonic acid) in a bacterial pathway of aliphatic epoxide carboxylation. Allen JR, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20; 96(15):8432-7

Type III secretion machines: bacterial devices for protein delivery into host cells. Galán JE, et al. **Science** 1999 May 21;284(5418):1322-8 (45 ref.)

Defluvibacter lusatiae gen. nov., sp. nov., a new chlorohenol-degrading member of the alpha-2 subgroup of proteobacteria. Fritsche K, et al. **Syst Appl Microbiol** 1999 May;22(2):197-204

Ushers and other doorkeepers. Bitter W, et al. **Trends Microbiol** 1999 Jan;7(1):4-6; discussion 6-7

The great escape: structure and function of the autotransporter proteins. Henderson IR, et al. **Trends Microbiol** 1998 Sep;6(9):370-8 (46 ref.)

The cytolethal distending toxin family. Pickett CL, et al. **Trends Microbiol** 1999 Jul;7(7):292-7 (26 ref.)

[Bacteriocins. Production, properties, application] Egorov NS, et al. **Antibiot Khimioter** 1999;44(6):33-40 (43 ref.) **(Rus)**

[Repression of catabolites in gram-positive and gram-negative bacteria] Gershanovich VN. **Mol Gen Mikrobiol Virusol** 1998;(4):12-8 (64 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Differences in the pathogenesis of bacteria isolated from contact-lens-induced infiltrative conditions. Willcox MD, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):231-3

Type III machines of Gram-negative pathogens: injecting virulence factors into host cells and more. Anderson DM, et al. **Curr Opin Microbiol** 1999 Feb;2(1):18-24 (76 ref.)

Secretion of proteins and assembly of bacterial surface organelles: shared pathways of extracellular protein targeting. Lory S. **Curr Opin Microbiol** 1998 Feb;1(1):27-35 (71 ref.)

Microbial genome sequencing and pathogenesis. Tang CM, et al. **Curr Opin Microbiol** 1998 Feb;1(1):12-6 (45 ref.)

Lipoprotein release by bacteria: potential factor in bacterial pathogenesis. Zhang H, et al. **Infect Immun** 1998 Nov; 66(11):5196-201

Edwardsiella tarda bacteraemia--complicated by acute pancreatitis and pyomyoma. Yang CH, et al. **J Infect** 1999 Mar;38(2):124-6

Divergence in the background: hard to measure but the key to being the best of the best [letter] Tuomanen E. **Trends Microbiol** 1999 Jul;7(7):271-2

PHYSIOLOGY

How did bacteria come to be? Koch AL. **Adv Microb Physiol** 1998;40:353-99 (84 ref.)

Quorum sensing and the cell-cell communication dependent regulation of gene expression in pathogenic and non-pathogenic bacteria. Hardman AM, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):199-210 (100 ref.)

Self perception in bacteria: quorum sensing with acylated homoserine lactones. Fuqua C, et al. **Curr Opin Microbiol** 1998 Apr;1(2):183-9 (59 ref.)

The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. El Ahmer OR, et al. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):27-36

Binding of bacteria to HEp-2 cells infected with influenza A virus. El Ahmer OR, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):331-41

Enhancement of in vitro cytopathogenicity by Acanthamoeba spp. following acquisition of bacterial endosymbionts. Fritsche TR, et al. **FEMS Microbiol Lett** 1998 Sep 15;166(2):231-6

Induction of cytokine synthesis by flagella from gram-negative bacteria may be dependent on the activation or differentiation state of human monocytes. Ciacci-Woolwine F, et al. **Infect Immun** 1999 Oct; 67(10):5176-85

Microglial activation by components of gram-positive and -negative bacteria: distinct and common routes to the induction of ion channels and cytokines. Prinz M, et al. **J Neuropathol Exp Neurol** 1999 Oct;58(10):1078-89

Prompt colonization of the hepaticojejunostomy and translocation of bacteria to liver after bile duct reconstruction. Chuang JH, et al. **J Pediatr Surg** 1998 Aug; 33(8):1215-8

Pilus biogenesis via the chaperone/usher pathway: an integration of structure and function. Hung DL, et al. **J Struct Biol** 1998 Dec 15;124(2-3):201-20 (119 ref.)

Differential induction of NO synthesis by gram-positive and gram-negative bacteria and their components in bovine monocyte-derived macrophages. Jungi TW, et al. **Microb Pathog** 1999 Jul;27(1):43-53

Type IV pili are involved in plant-microbe and fungus-microbe interactions. Dörr J, et al. **Mol Microbiol** 1998 Oct;30(1):7-17

Regulation of compatible solute accumulation in bacteria. Poolman B, et al. **Mol Microbiol** 1998 Jul;29(2):397-407 (65 ref.)

The Escherichia coli haemolysin secretion apparatus: a potential universal antigen delivery system in gram-negative bacterial vaccine carriers [letter] Spreng S, et al. **Mol Microbiol** 1999 Mar;31(5):1596-8

Antimicrobial properties and morphological characteristics of two Photorhabdus luminescens strains. Bondi M, et al. **New Microbiol** 1999 Apr;22(2):117-27

Adonia variegata (Coleoptera: Coccinellidae) bears maternally inherited flavobacteria that kill males only. Hurst GD, et al. **Parasitology** 1999 Feb;118 (Pt 2):125-34

A symphony of bacterial voices [news] Strauss E. **Science** 1999 May 21;284(5418):1302-4

[Thermoresistance of acid producing psychrotrophic bacteria isolated from milk] Alfenas R de C. **Arch Latinoam Nutr** 1999 Mar;49(1):72-5 (Eng. Abstr.) **(Por)**

[Phosphoenolpyruvate: carbohydrate phosphotransferase system and its role in physiology of gram-negative bacteria] Gershanovich VN. **Mol Gen Mikrobiol Virusol** 1998; (3):8-15 (84 ref.) **(Rus)**

RADIATION EFFECTS

[The study of biocide effectiveness of ultraviolet treatment in media stimulating space station environment] Vasin VB, et al. **Aviakosm Ekolog Med** 1998;32(3):62-6 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Bacterial filament formation, a defense mechanism against flagellate grazing, is growth rate controlled in bacteria of different phyla. Hahn MW, et al. **Appl Environ Microbiol** 1999 Jan;65(1):25-35

Structures of gram-negative cell walls and their derived membrane vesicles. Beveridge TJ. **J Bacteriol** 1999 Aug; 181(16):4725-33 (65 ref.)

[Electron microscopic study of pathogenic bacteria on environmental objects] Pavlova IB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct;(5):13-7 (Eng. Abstr.) **(Rus)**

VIROLOGY

A GroEL homologue from endosymbiotic bacteria of the whitefly Bemisia tabaci is implicated in the circulative transmission of tomato yellow leaf curl virus. Morin S, et al. **Virology** 1999 Mar 30;256(1):75-84

GRAM-NEGATIVE BACTERIAL INFECTIONS

Alcaligenes xylosoxidans endophthalmitis 8 months after cataract extraction. Swart J, et al. **Am J Ophthalmol** 1999 Mar;127(3):345-6

Ochrobactrum anthropi endophthalmitis after vitreous surgery [letter] Inoue K, et al. **Br J Ophthalmol** 1999 Apr; 83(4):502

Evolving concepts regarding the genus Aeromonas: an expanding Panorama of species, disease presentations, and unanswered questions. Janda JM, et al. **Clin Infect Dis** 1998 Aug;27(2):332-44 (122 ref.)

Acute disseminated encephalomyelitis following Pontiac fever. Spieker S, et al. **Eur Neurol** 1998 Oct;40(3):169-72

Haemolytic-uraemic syndrome in an adult male with Aeromonas hydrophila enterocolitis. Fang JS, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):439-40

[Anaerobic pneumonia] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):392-5 (11 ref.) **(Jpn)**

[Metallo-beta-lactamase producing gram negative rods infection] Kuwabara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):189-91 (6 ref.)

(Jpn)
[Extended-spectrum beta-lactamase producing gram negative rods infection] Kuwabara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):186-8 (4 ref.) (Jpn)
[Xanthomonas maltophilia pneumonia] Maruyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):389-91 (7 ref.) (Jpn)
[Concerning Capnocytophaga, taxonomic changes and bibliographic searches (letter; comment)] Salavert Lleti M, et al. **Med Clin (Barc)** 1999 Jan 16;112(1):37-8. Comment on: Med Clin (Barc) 1998 Jun 20;111(2):76. (Spa)
[Bacteremia caused by Stenotrophomonas maltophilia: a clinical-epidemiological study and resistance profile] Ubeda P, et al. **Rev Esp Quimioter** 1998 Sep;11(3):205-15 (Eng. Abstr.) (Spa)

BLOOD

An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Engel A, et al. **Infection** 1998 Jul-Aug;26(4):213-21
Images in clinical medicine. Capnocytophaga canimorsus sepsis [see comments] Alberio L, et al. **N Engl J Med** 1998 Dec 17;339(25):1827. Comment in: N Engl J Med 1999 May 13;340(19):1513-4.
Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Rønnestad A, et al. **Scand J Infect Dis** 1998;30(3):245-51

CHEMICALLY INDUCED

Copper exposure reduced the resistance of the catfish Saccobranchus fossilis to Aeromonas hydrophila infection. Khangarot BS, et al. **Bull Environ Contam Toxicol** 1999 Apr;62(4):490-5

COMPLICATIONS

Hemolytic uremic syndrome due to Capnocytophaga canimorsus bacteremia after a dog bite. Tobé TJ, et al. **Am J Kidney Dis** 1999 Jun;33(6):e5
Second-trimester abortion caused by Capnocytophaga sputigena: case report. Alanen A, et al. **Am J Perinatol** 1999;16(4):181-3
C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction [see comments] Hubacek JA, et al. **Circulation** 1999 Jun 29;99(25):3218-20. Comment in: Circulation 1999 Jun 29;99(25):3210-2.
Polymorphism of the lipopolysaccharide receptor (CD14) and myocardial infarction. New evidence for a role of gram-negative bacterial infection? [editorial; comment] Kane JP, et al. **Circulation** 1999 Jun 29;99(25):3210-2. Comment on: Circulation 1999 Jun 29;99(25):3218-20.
Capnocytophaga sepsis in a patient with Waldenström's macroglobulinemia. Guzman E, et al. **Clin Infect Dis** 1998 Aug;27(2):406-7
Infective endocarditis caused by Veillonella of dental origin. Prpić-Mehičić G, et al. **Coll Antropol** 1998 Dec;22 Suppl:39-43
Eikenella corrodens liver abscess complicated by endophthalmitis. Joseph A, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):709-11
Bacteriologic and immunologic aspects of gram-negative folliculitis: a study of 46 patients. Neubert U, et al. **Int J Dermatol** 1999 Apr;38(4):270-4
Oral health and systemic disease: periodontitis and cardiovascular disease. Beck JD, et al. **J Dent Educ** 1998 Oct;62(10):859-70 (44 ref.)
Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852-8 (20 ref.)
Community-acquired Chryseobacterium meningosepticum pneumonia and sepsis in a previously healthy child [letter] Sztajnbok J, et al. **J Infect** 1998 Nov;37(3):310-2
Edwardsiella tarda bacteraemia--complicated by acute pancreatitis and pyomyoma. Yang CH, et al. **J Infect** 1999 Mar;38(2):124-6
Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. Contreras A, et al. **J Periodontol** 1999 May;70(5):478-84
Respiratory foreign bodies and Eikenella corrodens brain abscess in two children. Sane SM, et al. **Pediatr Radiol** 1999 May;29(5):327-30
[Clinical study on 6 cases of urosepsis associated with septic shock] Miki M, et al. **Hinyokika Kiyo** 1998 Nov; 44(11):795-800 (Eng. Abstr.) (Jpn)
[Rapidly fatal prognosis caused by Aeromonas sobria septic shock in a patient with myelodysplastic syndrome] Fukuda M, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):257-8 (Jpn)
[Bacteremia with granulocytopenia--microbiology and empiric antibiotic treatment] Hammerstrøm J, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4370-5 (Eng. Abstr.) (Nor)

DIAGNOSIS

Septic arthritis due to Aeromonas veronii biotype sobria. Steinfeld S, et al. **Clin Infect Dis** 1998 Aug;27(2):402-3
A case of spontaneous peritonitis caused by Weeksella virosa. Boixeda D, et al. **Eur J Gastroenterol Hepatol** 1998 Oct; 10(10):897-8
Chorioamnionitis with intact membranes caused by Capnocytophaga sputigena. Douvier S, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):109-12 (23 ref.)
Ochrobactrum anthropi bacteremia. Jelveh N, et al. **Heart Lung** 1999 Mar-Apr;28(2):145-6
Is the limulus amebocyte lysate the sole predictor of septic episodes in major thermal injuries? Heggers JP, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):512-5
Rapid detection of the Chlamydiaceae and other families in the order Chlamydiales: three PCR tests. Everett KD, et al. **J Clin Microbiol** 1999 Mar;37(3):575-80
Primary Shewanella alga septicemia in a patient on hemodialysis. Iwata M, et al. **J Clin Microbiol** 1999 Jun; 37(6):2104-5
Two cases of Chromobacterium violaceum infection after injury in a subtropical region. Lee J, et al. **J Clin Microbiol** 1999 Jun;37(6):2068-70
Bacteremia caused by a novel isolate resembling leptotrichia species in a neutropenic patient. Patel JB, et al. **J Clin Microbiol** 1999 Jun;37(6):2064-7
Isolation of pathogenic bacteria from induced sputum from hospitalized children with pneumonia in Bangladesh. Utsunomiya Y, et al. **J Trop Pediatr** 1998 Dec;44(6):338-42
Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185-7 (17 ref.)
Capnocytophaga canimorsus sepsis [letter; comment] Ray S. **N Engl J Med** 1999 May 13;340(19):1513-4. Comment on: N Engl J Med 1998 Dec 17;339(25):1827.
Impact of simple screening criteria on utilization of low-yield bacterial stool cultures in a Children's Hospital. Zaidi AK, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1189-92
Septicaemia with Neisseria elongata ssp. nitroreducens in a patient with hypertrophic obstructive cardiomyopathia. Hofstad T, et al. **Scand J Infect Dis** 1998;30(2):200-1
Flavobacterium meningosepticum sepsis in an infant with a diarrheal prodrome. Springer SC, et al. **South Med J** 1999 Feb;92(2):225-7
[Beware of the dog! A syndrome resembling thrombotic thrombocytopenic purpura associated with Capnocytophaga canimorsus septicemia (letter)] Quilichini R, et al. **Rev Med Interne** 1998 Jun;19(6):451-2 (Fre)
[Fever and left submaxillar tumefaction of cyclic appearance] Caballero-Granado FJ, et al. **Enferm Infecc Microbiol Clin** 1999 Jun-Jul;17(6):309-10 (Spa)
[Meningitis by Aeromonas sobria following cranio-encephalic traumatism (letter)] Sarasqueta R, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):491-2 (Spa)
[Spontaneous bacterial peritonitis and sepsis due to Aeromonas hydrophila (letter)] Córdoba López A, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):208 (Spa)

DRUG THERAPY

Factors affecting gentamicin pharmacokinetics in septic patients. Tang GJ, et al. **Acta Anaesthesiol Scand** 1999 Aug; 43(7):726-30
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Kashuba AD, et al. **Antimicrob Agents Chemother** 1999 Mar; 43(3):623-9
Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Friedrich LV, et al. **Clin Infect Dis** 1999 May;28(5):1017-24
Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin. Lipsky BA, et al. **Clin Ther** 1999 Jun;21(6):954-65
Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group [see comments] Dhainaut JF, et al. **Crit Care Med** 1998 Dec; 26(12):1963-71. Comment in: Crit Care Med 1998 Dec;26(12):1927-31.
New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Periti P, et al. **Int J Antimicrob Agents** 1999 Jul;12(2):97-105 (74 ref.)
Microbiological characteristics in Japan. Antimicrobial resistance and susceptibility patterns. Inoue M. **Int J Hematol** 1998 Oct;68 Suppl 1:S13-4
In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections. Araque M, et al. **Intensive Care Med** 1998 Aug;24(8):839-44
AS-924, a novel bifunctional prodrug of ceftizoxime. Kasai M, et al. **J Antibiot (Tokyo)** 1999 May;52(5):491-500
Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy. Ko WC, et al. **J Clin Microbiol** 1998 Nov;36(11):3188-92
Ochrobactrum anthropi meningitis in a pre-term neonate [letter] Hay AJ, et al. **J Infect** 1999 Mar;38(2):134-5
Multidrug-resistant enterococci: the dawn of a new era in resistant pathogens. Antony SJ. **J Natl Med Assoc** 1998 Sep;90(9):537-40 (39 ref.)
Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Schimke J, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13875-80
Newer-generation fluoroquinolone antibiotics. Hedge DD. **S D J Med** 1998 Sep;51(9):349-50
Necrotizing soft tissue infection in heart transplantation recipients: two case reports. Chao CS, et al. **Transplant Proc** 1998 Nov;30(7):3347-9
Bacterial resistance, beta-lactam antibiotics and gramnegative bacteria at ICUs [editorial] Reisinger EC, et al. **Wien Klin Wochenschr** 1999 Jul 30;111(14):537-8
[Continuous versus intermittent cefepime infusion in critical care. Preliminary results] Georges B, et al. **Pathol Biol (Paris)** 1999 May;47(5):483-5 (Eng. Abstr.) (Fre)

EPIDEMIOLOGY

Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study. Mathews WC, et al. **Am J Epidemiol** 1998 Dec 15;148(12):1175-83
Oropharyngeal Gram-negative bacillary carriage: a survey of 120 healthy individuals. Mobbs KJ, et al. **Chest** 1999 Jun;115(6):1570-5
Recurrent gram-negative bacteremia: incidence and clinical patterns. Wendt C, et al. **Clin Infect Dis** 1999 Mar; 28(3):611-7
Molecular epidemiology of gram-negative bacteremia. Wendt C, et al. **Clin Infect Dis** 1999 Mar;28(3):605-10
Epidemiology of polyclonal gram-negative bacteremia. Wendt C, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):9-13
Seroprevalence of IgG antibodies to the chlamydia-like microorganism Simkania Z' by ELISA. Friedman MG, et al. **Epidemiol Infect** 1999 Feb;122(1):117-23
PCR-RFLP of outer membrane proteins gene of Dichelobacter nodosus: a new tool in the epidemiology of footrot. Ghimire SC, et al. **Epidemiol Infect** 1999 Jun; 122(3):521-8
Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Crowe M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):377-84
Stenotrophomonas maltophilia infection and colonization in the intensive care units of two community hospitals: A study of 143 patients. Gopalakrishnan R, et al. **Heart Lung** 1999 Mar-Apr;28(2):134-41
Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing. Alfieri N, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):553-6
The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. Sanyal SC, et al. **J Chemother** 1999 Feb; 11(1):28-33
Nosocomial gram-negative bacteremia in critically ill patients: epidemiologic characteristics and prognostic factors in 147 episodes. Jang TN, et al. **J Formos Med Assoc** 1999 Jul;98(7):465-73
A cluster of cases of infections due to Aeromonas hydrophila revealed by combined RAPD and ERIC-PCR. Davin-Regli A, et al. **J Med Microbiol** 1998 Jun; 47(6):499-504
Prevalence, in-vitro secretory activity, and cytotoxicity of Aeromonas species associated with childhood gastroenteritis in Chennai (Madras), India. Alavandi S, et al. **Jpn J Med Sci Biol** 1998 Nov;51(1):1-12
Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit. Shah SS, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):591-5
Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Rønnestad A, et al. **Scand J Infect Dis** 1998;30(3):245-51
Epidemiological typing of Alcaligenes xylosoxidans subsp. xylosoxidans by antibacterial susceptibility testing, fatty acid analysis, PAGE of whole-cell protein and pulsed-field gel electrophoresis. Knippschild M, et al. **Zentralbl Bakteriol** 1998 Jul;288(1):145-57

ETIOLOGY

Neutropenia is a risk factor for gram-negative bacillus bacteremia in human immunodeficiency virus-infected patients: results of a nested case-control study. Mathews WC, et al. **Am J Epidemiol** 1998 Dec 15;148(12):1175-83
Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia. Weber DJ, et al. **Am J Infect Control** 1999 Feb;27(1):59-63
Peritoneal dialysis-associated peritonitis caused by Alcaligenes xylosoxidans. El-Shahawy MA, et al. **Am J Nephrol** 1998;18(5):452-5 (32 ref.)
Postsplenectomy Capnocytophaga canimorsus sepsis presenting as an acute abdomen. Sawmiller CJ, et al. **Arch Surg** 1998 Dec;133(12):1362-5
CDC group IV c-2 bacteremia in stem cell transplant recipients [letter; comment] Martino R, et al. **Bone Marrow Transplant** 1998 Aug;22(4):401-2. Comment on: Bone Marrow Transplant 1997 Dec;20(11):1005-6.
Aeromonas hydrophila bacteremia acquired from an infected swimming pool. Blair JE, et al. **Clin Infect Dis** 1999 Jun; 28(6):1336-7
Pacemaker lead infection and vertebral osteomyelitis presumed due to Cardiobacterium hominis. Nurnberger M,

et al. **Clin Infect Dis** 1998 Oct;27(4):890-1

Unusual case of Aeromonas sobria cellulitis associated with the use of leeches. Fenollar F, et al.
Eur J Clin Microbiol Infect Dis 1999 Jan;18(1):72-3

Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit. Vu-Thien H, et al.
Eur J Clin Microbiol Infect Dis 1998 Oct;17(10):724-6

Ochrobactrum intermedium infection after liver transplantation. Möller LVM, et al. **J Clin Microbiol** 1999 Jan;37(1):241-4

Endemic nosocomial gram-negative bacteraemias resulting from contamination of intravenous heparin infusions. Playford EG, et al. **J Hosp Infect** 1999 May;42(1):21-6

Stenotrophomonas maltophilia endocarditis following dental treatment in a previously healthy patient [letter] Shimoni S, et al. **J Infect** 1998 Nov;37(3):305-6

Peritonitis due to Stenotrophomonas maltophilia in patients undergoing chronic peritoneal dialysis. Taylor G, et al. **Perit Dial Int** 1999 May-Jun;19(3):259-62

Nutritional implications of gut overgrowth and selective decontamination of the digestive tract. Donnell SC, et al. **Proc Nutr Soc** 1998 Aug;57(3):381-7

Streptobacillus moniliformis infection: 2 cases and a literature review. Hagelskjaer L, et al. **Scand J Infect Dis** 1998; 30(3):309-11 (23 ref.)

[Alcaligenes xylosoxydans: the origin of infection is most often an antiseptic solution (letter)] Boukadida J, et al. **Arch Pediatr** 1998 Oct;5(10):1172 **(Fre)**

[Sepsis due to DF2 (letter; comment)] San Román CM, et al. **Med Clin (Barc)** 1999 Jan 23;112(2):79. Comment on: Med Clin (Barc) 1998 Jun 20;111(2):76. **(Spa)**

GENETICS

Identifying genes that cause disease: HLA-B27, the paradigm, the promise, the perplexity. Martin TM, et al. **Br J Ophthalmol** 1998 Dec;82(12):1354-5

Polymorphism of the lipopolysaccharide receptor (CD14) and myocardial infarction. New evidence for a role of gram-negative bacterial infection? [editorial; comment] Kane JP, et al. **Circulation** 1999 Jun 29;99(25):3210-2. Comment on: Circulation 1999 Jun 29;99(25):3218-20.

Epidemiology of polyclonal gram-negative bacteremia. Wendt C, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):9-13

IMMUNOLOGY

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608-16 (88 ref.) . Comment in: Crit Care Med 1999 Aug;27(8):1682-3.

Lipid A diversity and the innate host response to bacterial infection. Darveau RP. **Curr Opin Microbiol** 1998 Feb; 1(1):36-42 (63 ref.)

Systemic infection of an immunocompromised patient with Methylobacterium zatmanii. Hornei B, et al.
J Clin Microbiol 1999 Jan;37(1):248-50

[Indices of immunity to endotoxin of gram-negative bacteria in intestinal dysbacteriosis] Kochurko LI, et al.
Zh Mikrobiol Epidemiol Immunobiol 1998 Sep-Oct;(5):25-7 (Eng. Abstr.) **(Rus)**

METABOLISM

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Wise R, et al. **Eur Respir J** 1999 Jul;14(1):221-9 (97 ref.)

Increased nitric oxide in infective gastroenteritis. Herulf M, et al. **J Infect Dis** 1999 Aug;180(2):542-5

Purification and characterization of enterotoxin produced by Aeromonas sobria. Fujii Y, et al. **Microbiol Immunol** 1998; 42(10):703-14

Mesophilic Aeromonas strains from different serogroups: the influence of growth temperature and osmolarity on lipopolysaccharide and virulence. Merino S, et al.
Res Microbiol 1998 Jun;149(6):407-16

MICROBIOLOGY

Low-level colonization and infection with ciprofloxacin-resistant gram-negative bacilli in a skilled nursing facility. Lee YL, et al. **Am J Infect Control** 1998 Dec;26(6):552-7

Endophthalmitis induced by Chryseomonas indologen [letter] Chang TS, et al. **Arch Ophthalmol** 1998 Nov;116(11):1533-4

Bloody diarrhea caused by Plesiomonas shigelloides proctitis in a human immunodeficiency virus-infected patient. Ahmad M, et al. **Clin Infect Dis** 1998 Sep;27(3):657

Ochrobactrum anthropi as an agent of nosocomial septicemia in the setting of AIDS. Manfredi R, et al.
Clin Infect Dis 1999 Mar;28(3):692-4

Bacteremia due to Capnocytophaga species in patients with neutropenia: high frequency of beta-lactamase-producing strains. Maury S, et al. **Clin Infect Dis** 1999 May; 28(5):1172-4

Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Quinn JP. **Clin Infect Dis** 1998 Aug;27 Suppl 1:S117-24 (70 ref.)

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608-16 (88 ref.) . Comment in: Crit Care Med 1999 Aug;27(8):1682-3.

Microbial genome sequencing and pathogenesis. Tang CM, et al. **Curr Opin Microbiol** 1998 Feb;1(1):12-6 (45 ref.)

Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Kugler KC, et al.
Diagn Microbiol Infect Dis 1999 May;34(1):73-6

Seroprevalence of IgG antibodies to the chlamydia-like microorganism 'Simkania Z' by ELISA. Friedman MG, et al. **Epidemiol Infect** 1999 Feb;122(1):117-23

Utility of serial rectal swab cultures for detection of ceftazidime- and imipenem-resistant gram-negative bacilli from patients in the intensive care unit. Arbo MD, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):727-30

Association between institutionalization and carriage of multiresistant bacteria in the elderly at the time of admission to a general hospital. Eveillard M, et al.
Eur J Clin Microbiol Infect Dis 1999 Feb;18(2):133-6

Unusual clinical presentation of infection due to Flavimonas oryzihabitans. Giacometti A, et al.
Eur J Clin Microbiol Infect Dis 1998 Sep;17(9):645-8

Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Munter RG, et al.
Eur J Clin Microbiol Infect Dis 1998 May;17(5):353-6 (18 ref.)

Ultrastructural characterization of Anaerobiospirillum succiniciproducens and its differentiation from Campylobacter species. Wecke J, et al.
FEMS Microbiol Lett 1999 Jan 1;170(1):83-8

Biochemical characteristics & secretory activity of Aeromonas species isolated from children with gastroenteritis in Chennai. Ananthan S, et al.
Indian J Med Res 1999 Apr;109:136-40

Resistance to third-generation cephalosporins in adult gram-negative bacillary meningitis. Lu CH, et al.
Infection 1999 May-Jun;27(3):208-11

Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Coenye T, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:405-13

Assignment of Centers for Disease Control group IVc-2 to the genus Ralstonia as Ralstonia paucula sp. nov. Vandamme P, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:663-9

Polyphasic taxonomy of the genus Shewanella and description of Shewanella oneidensis sp. nov. Venkateswaran K, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:705-24

Correlation between genotype and beta-lactamases of clinical and environmental strains of Stenotrophomonas maltophilia. Denton M, et al. **J Antimicrob Chemother** 1999 Apr;43(4):555-8

Population dynamics of Aeromonas spp. in an urban river watershed. Pettibone GW. **J Appl Microbiol** 1998 Oct; 85(4):723-30

Gram type-specific broad-range PCR amplification for rapid detection of 62 pathogenic bacteria [published erratum appears in J Clin Microbiol 1999 May;37(5):1660] Klausegger A, et al. **J Clin Microbiol** 1999 Feb;37(2):464-6

Massilia timonae gen. nov., sp. nov., isolated from blood of an immunocompromised patient with cerebellar lesions. La Scola B, et al. **J Clin Microbiol** 1998 Oct;36(10):2847-52

CDC group IV c-2: a new Ralstonia species close to Ralstonia eutropha. Moissenet D, et al.
J Clin Microbiol 1999 Jun;37(6):1777-81

Virulence factors of aeromonads--an emerging food borne pathogen problem. Agarwal RK, et al. **J Commun Dis** 1998 Jun;30(2):71-8 (70 ref.)

An in-vitro evaluation of the activity of chlorine against environmental and nosocomial isolates of Aeromonas hydrophila. Chamorey E, et al. **J Hosp Infect** 1999 Jan; 41(1):45-9

Anaerobiospirillum succiniciproducens septicaemia: important aspects of diagnosis and management. Goddard WW, et al. **J Infect** 1998 Jul;37(1):68-70

Nosocomial catheter-associated Flavobacterium odoratum bacteraemia in cancer patients [letter] Spanik S, et al.
J Med Microbiol 1998 Feb;47(2):183

Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. Hanberger H, et al. **JAMA** 1999 Jan 6;281(1):67-71

The type IV Aeromonas pilus (Tap) gene cluster is widely conserved in Aeromonas species. Barnett TC, et al.
Microb Pathog 1999 Feb;26(2):77-84

Molecular evidence for the existence of additional members of the order Chlamydiales. Ossewaarde JM, et al.
Microbiology 1999 Feb;145 (Pt 2):411-7

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17-1999. A 42-year-old asplenic man with gram-negative sepsis [clinical conference] **N Engl J Med** 1999 Jun 10;340(23):1819-26

Infection of a porous polyethylene orbital implant with Capnocytophaga. Wilson MW, et al.
Ophthal Plast Reconstr Surg 1998 Nov;14(6):398-402

Ochrobactrum anthropi bacteremia associated with a catheter in an immunocompromised child and review of the pediatric literature. Saavedra J, et al.
Pediatr Infect Dis J 1999 Jul;18(7):658-60 (9 ref.)

CDC group IV c-2 bacteremia in a child with recurrent acute monoblastic leukemia. Thayu M, et al.
Pediatr Infect Dis J 1999 Apr;18(4):397-8

Impact of simple screening criteria on utilization of low-yield bacterial stool cultures in a Children's Hospital. Zaidi AK, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1189-92

Fishtank water as a source of a rare case of Aeromonas hydrophila septicaemia [letter] Brink AJ, et al.
S Afr Med J 1998 Aug;88(8):1011-2

Experimental infections of Rana esculenta with Aeromonas hydrophila: a molecular mechanism for the control of the normal flora. Simmaco M, et al. **Scand J Immunol** 1998 Oct;48(4):357-63

Type III secretion machines: bacterial devices for protein delivery into host cells. Galán JE, et al. **Science** 1999 May 21;284(5418):1322-8 (45 ref.)

Epidemiological typing of Alcaligenes xylosoxidans subsp. xylosoxidans by antibacterial susceptibility testing, fatty acid analysis, PAGE of whole-cell protein and pulsed-field gel electrophoresis. Knippschild M, et al.
Zentralbl Bakteriol 1998 Jul;288(1):145-57

[Capnocytophaga canimorsus infections: a possibly fatal complication of bite wounds] Kramer AM, et al.
Tijdschr Diergeneeskd 1999 Feb 15;124(4):108-10 (19 ref.) (Eng. Abstr.) **(Dut)**

[Bacterial flora in chronic purulent maxillary sinusitis] Ziuzio S, et al. **Otolaryngol Pol** 1997;51 Suppl 25:179-83 (Eng. Abstr.) **(Pol)**

[Clinical manifestations of Stenotrophomas (Xanthomonas) maltophilia infection] Julve R, et al. **An Med Interna** 1998 Sep;15(9):476-80 (Eng. Abstr.) **(Spa)**

[Corneal abscess by Flavobacterium indologenes. A case report (letter)] Doiz O, et al.
Enferm Infecc Microbiol Clin 1999 Mar;17(3):149-50 **(Spa)**

[Community-acquired bacteremia and pneumonia caused by Stenotrophomonas maltophilia in a patient with AIDS (letter)] Sales P, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):437 **(Spa)**

[Ochrobactrum anthropi bacteremia in a patient with AIDS (letter)] Torres L, et al. **Med Clin (Barc)** 1998 Sep 19; 111(8):318 **(Spa)**

[Phenotype markers in strains of Aeromonas isolated in Cuba from children with an acute diarrheic disease] Bravo Fariñas L, et al. **Rev Cubana Med Trop** 1995;47(2):114-7 (Eng. Abstr.) **(Spa)**

MORTALITY

Impact and pattern of gram-negative bacteraemia during 6 y at a large university hospital. Harbarth S, et al.
Scand J Infect Dis 1999;31(2):163-8

PATHOLOGY

Aeromonas sobria infection with severe soft tissue damage and segmental necrotizing gastroenteritis in a patient with alcoholic liver cirrhosis. Itoh H, et al. **Pathol Int** 1999 Jun; 49(6):541-6

PHYSIOPATHOLOGY

Coexpression of inducible NO synthase and soluble guanylyl cyclase in colonic enterocytes: a pathophysiologic signaling pathway for the initiation of diarrhea by gram-negative bacteria? Closs EI, et al. **FASEB J** 1998 Dec;12(15):1643-9

PREVENTION & CONTROL

The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Beamer LJ, et al. **Biochem Pharmacol** 1999 Feb 1; 57(3):225-9 (34 ref.)

Evaluation of CHROMagar orientation medium for the identification of surveillance cultures: a novel method. Rigby JL, et al. **Br J Biomed Sci** 1998 Dec;55(4):238-41

Vaccination against enteric pathogens: from science to vaccine trials. Lindberg AA. **Curr Opin Microbiol** 1998 Feb;1(1):116-24 (35 ref.)

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial [see comments] Grangé JD, et al. **J Hepatol** 1998 Sep; 29(3):430-6. Comment in: J Hepatol 1998 Sep;29(3):490-4.

RADIOGRAPHY

Radiological pulmonary changes during gram-negative bacillary nosocomial bloodstream infection in premature infants. Cordero L, et al. **J Perinatol** 1998 Jul-Aug; 18(4):291-6

SURGERY

ERCP and pyogenic liver abscess. Lam YH, et al.
Gastrointest Endosc 1999 Sep;50(3):340-4

Arterial homografts in the management of infected axillofemoral prosthetic grafts. Bracale GC, et al.
J Cardiovasc Surg (Torino) 1999 Apr;40(2):271-4

Retroperitoneoscopic management of infected cysts in adult polycystic kidney disease. Hemal AK, et al. **Urol Int** 1999; 62(1):40-3

[The early cosmetic correction of the breast in the surgical treatment of acute lactation mastitis] Kuznetsov AA.
Klin Khir 1999;(6):25-6 (Eng. Abstr.) **(Rus)**

THERAPY

Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following

caesarean sections and hysterectomies. Al-Waili NS, et al. **Eur J Med Res** 1999 Mar 26;4(3):126–30

Vaccines and antibodies in the prevention and treatment of sepsis. Bhattacharjee AK, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):355–69, vii (63 ref.)

Antiendotoxin strategies. Hellman J, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):371–86, ix

Benign superior vena cava syndrome due to suppurative mediastinal lymphadenitis: anterior mediastinoscopic management. Roy D, et al. **Mayo Clin Proc** 1998 Dec; 73(12):1185–7 (17 ref.)

[Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms] Otero AJ, et al. **Rev Cubana Med Trop** 1998;50(1):31–5 (27 ref.) (Eng. Abstr.) **(Spa)**

TRANSMISSION

Molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during nonoutbreak periods. D'Agata EM, et al. **J Clin Microbiol** 1999 Sep;37(9):3065–7

Pseudo-outbreak of Aeromonas hydrophila isolates related to endoscopy. Esteban J, et al. **J Hosp Infect** 1999 Apr; 41(4):313–6

Life-threatening Capnocytophaga canimorsus infection after dog bite. Aslam A. **J R Soc Med** 1999 Mar;92(3):140–1

VETERINARY

16S rRNA gene sequence analysis of Photobacterium damselae and nested PCR method for rapid detection of the causative agent of fish pasteurellosis. Osorio CR, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2942–6

Attempted infection of mice, rats and chickens by porcine strains of Lawsonia intracellularis. Collins AM, et al. **Aust Vet J** 1999 Feb;77(2):120–2

Transmission of virulent footrot between sheep and goats. Ghimire SC, et al. **Aust Vet J** 1999 Jul;77(7):450–3

Isolation of Georgia variant (Georgia isolate 1992) infectious bronchitis virus but not Ornithobacterium rhinotracheale from a Kentucky broiler complex. Erbeck DH, et al. **Avian Dis** 1998 Jul–Sep;42(3):613–7

Vaccination of chickens against Ornithobacterium rhinotracheale infection. van Empel P, et al. **Avian Dis** 1998 Jul–Sep;42(3):572–8

Detection of Lawsonia intracellularis in faeces of swine from the main producing regions in Brazil. Chiriboga AE, et al. **Can J Microbiol** 1999 Mar;45(3):230–4

Ornithobacterium rhinotracheale infection in a turkey flock in Ontario. Abdul-Aziz TA, et al. **Can Vet J** 1999 May; 40(5):349–50

Fingerprinting of Flavobacterium psychrophilum isolates by ribotyping and plasmid profiling. Chakroun C, et al. **Dis Aquat Organ** 1998 Jul 30;33(3):167–77

Reproducible methods for experimental infection with Flavobacterium psychrophilum in rainbow trout Oncorhynchus mykiss. Madsen L, et al. **Dis Aquat Organ** 1999 May 31;36(3):169–76

Update on footrot in south-west Germany. Younan M, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Feb;106(2):66–7

Lawsonia intracellularis proliferative enteropathy in a weanling foal [see comments] Frank N, et al. **Equine Vet J** 1998 Nov;30(6):549–52. Comment in: Equine Vet J 1998 Nov;30(6):452–3.

Identification of equine proliferative enteropathy [editorial; comment] Smith DG. **Equine Vet J** 1998 Nov;30(6):452–3 . Comment on: Equine Vet J 1998 Nov;30(6):549–52.

Phenotypic characterization of the marine pathogen Photobacterium damselae subsp. piscicida. Thyssen A, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1145–51

Coenonia anatina gen. nov., sp. nov., a novel bacterium associated with respiratory disease in ducks and geese. Vandamme P, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:867–74

Lawsonia intracellularis-like organism infection in a miniature foal. Brees DJ, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):511–4, 483

Identification and management of an outbreak of Flavobacterium meningosepticum infection in a colony of South African clawed frogs (Xenopus laevis). Green SL, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1833–8, 1792–3

Cilia-associated respiratory bacillus infection and pneumonia in a pig. Hafner S, et al. **J Vet Diagn Invest** 1998 Oct; 10(4):373–5

Detection of Lawsonia intracellularis in swine using polymerase chain reaction methodology. Jordan DM, et al. **J Vet Diagn Invest** 1999 Jan;11(1):45–9

Aeromonas hydrophila isolated from cases of bovine seminal vesiculitis in south Brazil. Moro EM, et al. **J Vet Diagn Invest** 1999 Mar;11(2):189–91

Isolation of cilia-associated respiratory (CAR) bacillus from pigs and calves and experimental infection of gnotobiotic pigs and rodents. Nietfeld JC, et al. **J Vet Diagn Invest** 1999 May;11(3):252–8

Evaluation of a commercial system for the identification of Ornithobacterium rhinotracheale. Post KW, et al. **J Vet Diagn Invest** 1999 Jan;11(1):97–9

The prevalence of Aeromonas species in feces of horses with diarrhea. Hathcock TL, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):357–60

Experimentally induced infection of gerbils with cilia-associated respiratory bacillus. St. Clair MB, et al. **Lab Anim Sci** 1999 Aug;49(4):421–3

An improved growth medium for Flavobacterium psychrophilum. Daskalov H, et al. **Lett Appl Microbiol** 1999 Apr;28(4):297–9

Identification and grouping of Dichelobacter nodosus, using PCR and sequence analysis. John GH, et al. **Mol Cell Probes** 1999 Feb;13(1):61–5

Natural and experimental infections of Arcobacter in poultry. Wesley IV, et al. **Poult Sci** 1999 Apr;78(4):536–45

Development of a polymerase chain reaction assay for identification and detection of the fish pathogen Flavobacterium psychrophilum. Urdaci MC, et al. **Res Microbiol** 1998 Jul–Aug;149(7):519–30

Periodontal disease in dogs. Etiopathogenesis, prevalence, and significance. Harvey CE. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1111–28, vi (56 ref.)

Effect of florfenicol on the immune response of rainbow trout (Oncorhynchus mykiss). Lundén T, et al. **Vet Immunol Immunopathol** 1999 Mar 1;67(4):317–25

Bacteria isolated from arthritic and omphalatic lesions in lambs in England and Wales. Watkins GH, et al. **Vet J** 1998 Nov;156(3):235–8

The association of Flavobacterium columnare strains of high and low virulence with gill tissue of black mollies (Poecilia sphenops). Decostere A, et al. **Vet Microbiol** 1999 Jul 1; 67(4):287–98

Identification and characterisation of serogroup M among Nepalese isolates of Dichelobacter nodosus, the transmitting agent of footrot in small ruminants. Ghimire SC, et al. **Vet Microbiol** 1998 Jul;62(3):217–33

Molecular fingerprinting of Riemerella anatipestifer by repetitive sequence PCR. Huang B, et al. **Vet Microbiol** 1999 Jun 30;67(3):213–9

Molecular analysis of Dichelobacter nodosus isolated from footrot in sheep in Malaysia. Zakaria Z, et al. **Vet Microbiol** 1998 Jul;62(3):243–50

Outbreak of columnaris disease in tropical aquarium fish. Decostere A, et al. **Vet Rec** 1999 Jan 2;144(1):23–4

Prevalence of Lawsonia intracellularis in selected pig herds in Korea as determined by PCR. Kim O, et al. **Vet Rec** 1998 Nov 21;143(21):587–9

Isolation of spirochaetes from an incident of severe virulent ovine footrot. Naylor RD, et al. **Vet Rec** 1998 Dec 19–26; 143(25):690–1

Histopathological and electron microscopical observations on rainbow trout fry syndrome. Rangdale RE, et al. **Vet Rec** 1999 Mar 6;144(10):251–4

Aeromonas hydrophila associated with a severe outbreak of infection in farmed rabbits. Paniagua C, et al. **Zentralbl Hyg Umweltmed** 1998 Dec;201(4–5):423–30

Haemorrhagic septicaemia by Aeromonas salmonicida subsp. salmonicida in a black-tip reef shark (Carcharhinus melanopterus). Briones V, et al. **Zentralbl Veterinarmed [B]** 1998 Sep;45(7):443–5

[Investigations into the occurrence and the antibiotic susceptibility of gram negative anaerobes of the genera Bacteroides, Prevotella, Porphyromonas and Fusobacterium in specimens obtained from diseased animals] Even H, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):379–86 (Eng. Abstr.) **(Ger)**

GRAM-NEGATIVE CHEMOLITHOTROPHIC BACTERIA

CHEMISTRY

Genomic organization analysis of acidophilic chemolithotrophic bacteria using pulsed field gel electrophoretic techniques. Amils R, et al. **Biochimie** 1998 Nov;80(11):911–21

CLASSIFICATION

Identification and activities in situ of Nitrosospira and Nitrospira spp. as dominant populations in a nitrifying fluidized bed reactor. Schramm A; et al. **Appl Environ Microbiol** 1998 Sep;64(9):3480–5

Thiomicrospira chilensis sp. nov., a mesophilic obligately chemolithoautotrophic sulfuroxidizing bacterium isolated from a Thioploca mat. Brinkhoff T, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:875–9

Thiomicrospira kuenenii sp. nov. and Thiomicrospira frisia sp. nov., two mesophilic obligately chemolithoautotrophic sulfur-oxidizing bacteria isolated from an intertidal mud flat. Brinkhoff T, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:385–92

Phylogeny and photosynthetic features of Thiobacillus acidophilus and related acidophilic bacteria: its transfer to the genus Acidiphilium as Acidiphilium acidophilum comb. nov. Hiraishi A, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1389–98

GENETICS

Wide distribution and diversity of members of the bacterial kingdom Acidobacterium in the environment. Barns SM, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1731–7

Comparative diversity of ammonia oxidizer 16S rRNA gene sequences in native, tilled, and successional soils. Bruns MA, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2994–3000

In situ analysis of nitrifying biofilms as determined by in situ hybridization and the use of microelectrodes. Okabe S, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3182–91

Genomic organization analysis of acidophilic chemolithotrophic bacteria using pulsed field gel electrophoretic techniques. Amils R, et al. **Biochimie** 1998 Nov;80(11):911–21

Multiple copies of ammonia monooxygenase (amo) operons have evolved under biased AT/GC mutational pressure in ammonia-oxidizing autotrophic bacteria. Klotz MG, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):303–11

ISOLATION & PURIFICATION

Wide distribution and diversity of members of the bacterial kingdom Acidobacterium in the environment. Barns SM, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1731–7

Comparative diversity of ammonia oxidizer 16S rRNA gene sequences in native, tilled, and successional soils. Bruns MA, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2994–3000

METABOLISM

Something from almost nothing: carbon dioxide fixation in chemoautotrophs. Shively JM, et al. **Annu Rev Microbiol** 1998;52:191–230 (188 ref.)

Nitrous oxide production and methane oxidation by different ammonia-oxidizing bacteria. Jiang QQ, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2679–84

Identification and activities in situ of Nitrosospira and Nitrospira spp. as dominant populations in a nitrifying fluidized bed reactor. Schramm A, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3480–5

Biodeterioration of natural stone with special reference to nitrifying bacteria. Mansch R, et al. **Biodegradation** 1998; 9(1):47–64

PHYSIOLOGY

Preservation of some extremely thermophilic chemolithoautotrophic bacteria by deep-freezing and liquid-drying methods. Halik KA. **J Microbiol Methods** 1999 Mar;35(2):177–82

GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS

Primary Shewanella alga septicemia in a patient on hemodialysis. Iwata M, et al. **J Clin Microbiol** 1999 Jun; 37(6):2104–5

CLASSIFICATION

Pseudoalteromonas tunicata sp. nov., a bacterium that produces antifouling agents. Holmström C, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1205–12

Polyphasic taxonomy of the genus Shewanella and description of Shewanella oneidensis sp. nov. Venkateswaran K, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:705–24

Thauera linaloolentis sp. nov. and Thauera terpenica sp. nov., isolated on oxygen-containing monoterpenes (linalool, menthol, and eucalyptol) nitrate. Foss S, et al. **Syst Appl Microbiol** 1998 Aug;21(3):365–73

DRUG EFFECTS

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. Low DE. **Infect Dis Clin North Am** 1998 Sep;12(3):613–30, viii (124 ref.)

ENZYMOLOGY

Cold-active serine alkaline protease from the psychrotrophic bacterium Shewanella strain ac10: gene cloning and enzyme purification and characterization. Kulakova L, et al. **Appl Environ Microbiol** 1999 Feb;65(2):611–7

Structure and function of flavocytochrome c3, the soluble fumarate reductase from Shewanella NCIMB400. Reid GA, et al. **Biochem Soc Trans** 1998 Aug;26(3):418–21 (17 ref.)

Redox properties of flavocytochrome c3 from Shewanella frigidimarina NCIMB400. Turner KL, et al. **Biochemistry** 1999 Mar 16;38(11):3302–9

Substrate range of benzylsuccinate synthase from Azoarcus sp. strain T. Beller HR, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):147–53

Enzymatical properties of psychrophilic phosphatase I. Tsuruta H, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):690–5

Crystal structure of oxidized trimethylamine N-oxide reductase from Shewanella massilia at 2.5 A resolution. Czjzek M, et al. **J Mol Biol** 1998 Nov 27;284(2):435–47

GENETICS

Mechanisms of gene expression controlled by pressure in deep-sea microorganisms. Nakasone K, et al. **Extremophiles** 1998 Aug;2(3):149–54 (13 ref.)

Shewanella putrefaciens mtrB encodes an outer membrane protein required for Fe(III) and Mn(IV) reduction. Beliaev AS, et al. **J Bacteriol** 1998 Dec;180(23):6292–7

Molecular analysis of the trimethylamine N-oxide (TMAO) reductase respiratory system from a Shewanella species. Dos Santos JP, et al. **J Mol Biol** 1998 Nov 27;284(2):421–33

GROWTH & DEVELOPMENT

Growth differences of Capnocytophaga canimorsus strains and some other fastidious organisms on various Columbia-based blood agar media. Dusch H, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):362-6

ISOLATION & PURIFICATION

Pseudoalteromonas tunicata sp. nov., a bacterium that produces antifouling agents. Holmström C, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1205-12

METABOLISM

Fermented whey--an inexpensive feed source for a laboratory-scale selenium-bioremediation reactor system inoculated with Thauera selenatis. Bledsoe TL, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):682-5

The role of biomineralization in microbiologically influenced corrosion. Little B, et al. **Biodegradation** 1998;9(1):1-10

Simultaneous bioconversion of cellulose and hemicellulose to ethanol. Chandrakant P, et al. **Crit Rev Biotechnol** 1998; 18(4):295-331 (190 ref.)

Pseudoalteromonas tunicata sp. nov., a bacterium that produces antifouling agents. Holmström C, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1205-12

Shewanella putrefaciens mtrB encodes an outer membrane protein required for Fe(III) and Mn(IV) reduction. Beliaev AS, et al. **J Bacteriol** 1998 Dec;180(23):6292-7

Thauera linaloolentis sp. nov. and Thauera terpenica sp. nov., isolated on oxygen-containing monoterpenes (linalool, menthol, and eucalyptol) nitrate. Foss S, et al. **Syst Appl Microbiol** 1998 Aug;21(3):365-73

PATHOGENICITY

Bacteriophages in the evolution of pathogen-host interactions. Miao EA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9452-4 (31 ref.)

VIROLOGY

Bacteriophages in the evolution of pathogen-host interactions. Miao EA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9452-4 (31 ref.)

GRAM-NEGATIVE OXYGENIC PHOTOSYNTHETIC BACTERIA

METABOLISM

Structure and function of the cytochrome bc1 complex of mitochondria and photosynthetic bacteria. Crofts AR, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):501-9 (44 ref.)

GRAM-POSITIVE ASPOROGENOUS RODS

CLASSIFICATION

Phylogenetic and phenotypic evidence for the transfer of Eubacterium aerofaciens to the genus Collinsella as Collinsella aerofaciens gen. nov., comb. nov. Kageyama A, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:557-65

Cryptobacterium curtum gen. nov., sp. nov., a new genus of gram-positive anaerobic rod isolated from human oral cavities. Nakazawa F, et al. **Int J Syst Bacteriol** 1999 Jul; 49 Pt 3:1193-200

ENZYMOLOGY

Crystallization and preliminary X-ray studies of purine nucleoside phosphorylase from Cellulomonas sp. Bzowska A, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1; 54 (Pt 5):1061-3

Mannan-degrading enzymes from Cellulomonas fimi. Stoll D, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2598-605

Sequence of subunit a of the Na(+)-translocating F1F0-ATPase of Acetobacterium woodii: proposal for residues involved in Na+ binding. Rahlfs S, et al. **FEBS Lett** 1999 Jun 18;453(1-2):35-40

The cellulose-binding domains from Cellulomonas fimi beta-1, 4-glucanase CenC bind nitroxide spin-labeled cellooligosaccharides in multiple orientations. Johnson PE, et al. **J Mol Biol** 1999 Apr 2;287(3):609-25

GENETICS

Mannan-degrading enzymes from Cellulomonas fimi. Stoll D, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2598-605

Cloning of a novel prolidase gene from Aureobacterium esteraromaticum. Kabashima T, et al. **Biochim Biophys Acta** 1999 Jan 11;1429(2):516-20

GROWTH & DEVELOPMENT

Visualization and modelling of the thermal inactivation of bacteria in a model food. Bellara SR, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3095-9

ISOLATION & PURIFICATION

Cryptobacterium curtum gen. nov., sp. nov., a new genus of gram-positive anaerobic rod isolated from human oral cavities. Nakazawa F, et al. **Int J Syst Bacteriol** 1999 Jul; 49 Pt 3:1193-200

METABOLISM

Detection of a whitening fluorescent agent as an indicator of white paper biodegradation: a new approach to study the kinetics of cellulose hydrolysis by mixed cultures. Bichet-Hébé I, et al. **J Microbiol Methods** 1999 Aug; 37(2):101-9

GRAM-POSITIVE ASPOROGENOUS RODS, IRREGULAR

ISOLATION & PURIFICATION

Urinary tract infection due to Arcanobacterium bernardiae in a patient with a urinary tract diversion. Lepargneur JP, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun; 17(6):399-401

GRAM-POSITIVE ASPOROGENOUS RODS, REGULAR

IMMUNOLOGY

Effect of fetal calf serum on cytokine release by bone marrow-derived macrophages during infection with intracellular bacteria. Flesch IE, et al. **Immunobiology** 1999 Feb;200(1):120-7

GRAM-POSITIVE BACTERIA

Biocontrol of plant disease: a (gram-) positive perspective. Emmert EA, et al. **FEMS Microbiol Lett** 1999 Feb 1; 171(1):1-9 (47 ref.)

Delivery of DNA vaccines by attenuated intracellular bacteria. Dietrich G, et al. **Immunol Today** 1999 Jun; 20(6):251-3 (14 ref.)

Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria [letter] Schempp CM, et al. **Lancet** 1999 Jun 19;353(9170):2129

CHEMISTRY

Extrinsic protein stabilization by the naturally occurring osmolytes beta-hydroxyectoine and betaine. Knapp S, et al. **Extremophiles** 1999 Aug;3(3):191-8

Complete glycan structure of the S-layer glycoprotein of Aneurinibacillus thermoaerophilus GS4-97. Schäffer C, et al. **Glycobiology** 1999 Apr;9(4):407-14

Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin? Bootsma HJ, et al. **J Bacteriol** 1999 Aug;181(16):5090-3

Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Navarre WW, et al. **Microbiol Mol Biol Rev** 1999 Mar;63(1):174-229 (878 ref.)

CLASSIFICATION

Ignavigranum ruoffiae sp. nov., isolated from human clinical specimens. Collins MD, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:97-101

Succinispira mobilis gen. nov., sp. nov., a succinate-decarboxylating anaerobic bacterium. Janssen PH, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1009-13

Fermentative bacteria from estuarine mud: phylogenetic position of Acidaminobacter hydrogenoformans and description of a new type of gram-negative, propionigenic bacterium as Propionibacter pelophilus gen. nov., sp. nov. Meijer WG, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1039-44

Fusibacter paucivorans gen. nov., sp. nov., an anaerobic, thiosulfate-reducing bacterium from an oil-producing well. Ravot G, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1141-7

The family Coriobacteriaceae: reclassification of Eubacterium exiguum (Poco et al. 1996) and Peptostreptococcus heliotrinreducens (Lanigan 1976) as Slackia exigua gen. nov., comb. nov. and Slackia heliotrinireducens gen. nov., comb. nov., and Eubacterium lentum (Prevot 1938) as Eggerthella lenta gen. nov., comb. nov. Wade WG, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:595-600

Gram type-specific broad-range PCR amplification for rapid detection of 62 pathogenic bacteria [published erratum appears in J Clin Microbiol 1999 May;37(5):1660] Klausegger A, et al. **J Clin Microbiol** 1999 Feb;37(2):464-6

What are archaebacteria: life's third domain or monoderm prokaryotes related to gram-positive bacteria? A new proposal for the classification of prokaryotic organisms [see comments] Gupta RS. **Mol Microbiol** 1998 Aug; 29(3):695-707 (39 ref.). Comment in: Mol Microbiol 1999 Feb;31(3):1007-10.

DRUG EFFECTS

In vitro efficacy of N-duopropenide, a recently developed disinfectant containing quaternary ammonium compounds, against selected gram-positive and gram-negative organisms. Gutiérrez CB, et al. **Am J Vet Res** 1999 Apr; 60(4):481-4

In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Giacometti A, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3320-4

In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria. Malathum K, et al. **Antimicrob Agents Chemother** 1999 Apr;43(4):930-6

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Noskin GA, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2059-62

Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms. Pankuch GA, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):3028-31

Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. Tarantino PM Jr, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1982-7

Purification and genetic characterization of enterocin I from Enterococcus faecium 6T1a, a novel antilisterial plasmid-encoded bacteriocin which does not belong to the pediocin family of bacteriocins. Floriano B, et al. **Appl Environ Microbiol** 1998 Dec;64(12):4883-90

The pediocin AcH precursor is biologically active. Ray B, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2281-6

Synthesis and antibacterial activity of new cephalosporins with lactonyloxyimino moiety. Suh KH, et al. **Arch Pharm Res** 1994 Apr;17(2):87-92

Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics. Yoon SY, et al. **Arch Pharm Res** 1994 Dec;17(6):438-42

Synthesis of some thieno gamma lactam monocarboxylic acids with high antibacterial activity: a new look at an old molecular system. Kar GK, et al. **Bioorg Med Chem** 1998 Dec;6(12):2397-403

Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. Hlasta DJ, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1923-8

Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392. Ratcliffe RW, et al. **Bioorg Med Chem Lett** 1999 Mar 8;9(5):679-84

SAR studies of diaryltriazoles against bacterial two-component regulatory systems and their antibacterial activities. Sui Z, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1929-34

Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore. Wilkening RR, et al. **Bioorg Med Chem Lett** 1999 Mar 8;9(5):673-8

In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Ling TK, et al. **Chemotherapy** 1999 Jan-Feb;45(1):22-7

Antibiotic resistance in oral/respiratory bacteria. Roberts MC. **Crit Rev Oral Biol Med** 1998;9(4):522-40 (140 ref.)

In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates. Alcalá L, et al. **Diagn Microbiol Infect Dis** 1999 Jan; 33(1):27-31

In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan. Chang SC, et al. **Diagn Microbiol Infect Dis** 1999 Apr; 33(4):299-303

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. Diekema DJ, et al. **Diagn Microbiol Infect Dis** 1999 May;34(1):37-43

Antimicrobial activity of merocyanine 540: a photosensitizing dye. Dunne WM Jr, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):101-5

European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group. Felmingham D, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):563-71

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Jones RN, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):101-12 (65 ref.)

Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Jones RN, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):85-94

Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group. Jones RN, et al. **Diagn Microbiol Infect Dis** 1999 Jun;34(2):103-10

Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health. Marshall SA, et al. **Diagn Microbiol Infect Dis** 1999 Mar;33(3):181-6

Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT, et al. **Drugs Exp Clin Res** 1998;24(3):139-51

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Pechère JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):405-12 (48 ref.)

An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory

tract and gut microflora. Allaker RP, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):289-93

Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. Freestone PP, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):53-60

In vitro evaluation of G1: a novel antimicrobial compound. Blondeau JM, et al. **Int J Antimicrob Agents** 1999 Feb; 11(2):163-6

Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Grüneberg RN, et al. **Int J Antimicrob Agents** 1998 Nov;10(4):271-7

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates. Cormican M, et al. **Ir J Med Sci** 1998 Jul-Sep;167(3):155-9

Preparation and antimicrobial assessment of 2-thioether-linked quinolonyl-carbapenems. Hershberger PM, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):857-71

A novel glycopeptide carrying a 3-oxazolin-5-one ring obtained by intra-molecular cyclization. Panzone G, et al. **J Antibiot (Tokyo)** 1998 Sep;51(9):872-9

MJ347-81F4 A & B, novel antibiotics from Amycolatopsis sp.: taxonomic characteristics, fermentation, and antimicrobial activity. Sasaki T, et al. **J Antibiot (Tokyo)** 1998 Aug;51(8):715-21

Antimicrobial resistance in gram-positive pathogens isolated in the UK between October 1996 and January 1997. Andrews J, et al. **J Antimicrob Chemother** 1999 May; 43(5):689-98

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. Blondeau JM. **J Antimicrob Chemother** 1999 May;43 Suppl B:1-11 (96 ref.)

Bactericidal properties of moxifloxacin and post-antibiotic effect. Boswell FJ, et al. **J Antimicrob Chemother** 1999 May;43 Suppl B:43-9

Pharmacodynamics of fluoroquinolones. Dalhoff A. **J Antimicrob Chemother** 1999 May;43 Suppl B:51-9

Comparative in-vitro activities of topical antibiotics against conjunctival isolates [letter] Iqbal J, et al. **J Antimicrob Chemother** 1999 Apr;43(4):611-2

Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results. King A, et al. **J Antimicrob Chemother** 1998 Dec; 42(6):711-9

Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? Martinez JL, et al. **J Antimicrob Chemother** 1998 Dec;42(6):683-8 (64 ref.)

Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria. Piddock LJ, et al. **J Antimicrob Chemother** 1999 May;43 Suppl B:39-42

In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. Schülin T, et al. **J Antimicrob Chemother** 1998 Sep;42(3):297-301

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Thomson KS, et al. **J Antimicrob Chemother** 1998 Aug;42(2):179-87

The in-vitro activity of linezolid (U-100766) and tentative breakpoints. Wise R, et al. **J Antimicrob Chemother** 1998 Dec;42(6):721-8

Influence of organic matter, cations and surfactants on the antimicrobial activity of Melaleuca alternifolia (tea tree) oil in vitro. Hammer KA, et al. **J Appl Microbiol** 1999 Mar;86(3):446-52

The effect of dietary fatty acids on lactic acid bacteria associated with the epithelial mucosa and from faecalia of Arctic charr, Salvelinus alpinus (L.). Ringø E, et al. **J Appl Microbiol** 1998 Nov;85(5):855-64

Synergist effect of sucrose fatty acid esters on nisin inhibition of gram-positive bacteria. Thomas LV, et al. **J Appl Microbiol** 1998 Dec;85(6):1013-22

In vitro activity of LY 333328 against anaerobic gram-positive bacteria. Sillerström E, et al. **J Chemother** 1999 Apr;11(2):90-2

Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci. Chen YS, et al. **J Clin Microbiol** 1998 Oct;36(10):2996-3001

Evaluation of efficacy of Dettol-H in hospital use. Kapoor H, et al. **J Commun Dis** 1998 Sep;30(3):167-70

Antibacterial effects of N-sulfonated and N-sulfobenzoyl chitosan and application to oyster preservation. Chen CS, et al. **J Food Prot** 1998 Sep;61(9):1124-8

Susceptibility of antibiotic-resistant and antibiotic-sensitive foodborne pathogens to acid anionic sanitizers. Lopes JA. **J Food Prot** 1998 Oct;61(10):1390-5

Antibiotic resistance among clinically important gram-positive bacteria in the UK. Johnson AP. **J Hosp Infect** 1998 Sep;40(1):17-26 (77 ref.)

Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. Nelson RR. **J Hosp Infect** 1999 Aug;42(4):275-82 (70 ref.)

Antibiotic resistance patterns among blood culture isolates in a Danish county 1981-1995. Kristensen B, et al. **J Med Microbiol** 1999 Jan;48(1):67-71

In-vitro antimicrobial activity and chemical composition of Sardinian Thymus essential oils. Cosentino S, et al. **Lett Appl Microbiol** 1999 Aug;29(2):130-5

Lacticin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays. Galvin M, et al. **Lett Appl Microbiol** 1999 May;28(5):355-8

An evaluation of the suitability of the European suspension test to reflect in vitro activity of antiseptics against clinically significant organisms. Payne DN, et al. **Lett Appl Microbiol** 1999 Jan;28(1):7-12

Antimicrobial effect of tetramethyldithiooxamide and its application as a biocide. Tabakova SV, et al. **Lett Appl Microbiol** 1998 Oct;27(4):189-92

Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Goldstein MH, et al. **Ophthalmology** 1999 Jul;106(7):1313-8

Antimicrobial activity and stability of tingenone derivatives [letter] Sotanaphun U, et al. **Planta Med** 1999 Jun; 65(5):450-2

Preparation and antibiotic activity of monobactam analogues of nocardicins. Gerardin-Charbonnier C, et al. **Prep Biochem Biotechnol** 1999 Aug;29(3):257-72

Evidence for a bacteriocin-like substance produced by a new strain of Streptococcus sp., inhibitory to gram-positive food-borne pathogens. Gomez S, et al. **Res Microbiol** 1997 Dec;148(9):757-66

Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility. Srifuengfung S, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):96-9

Antimicrobial resistance--danger signs all around. Craig A. **Tenn Med** 1998 Nov;91(11):433, 435 (15 ref.)

Antibacterial activity of simple coumarins: structural requirements for biological activity. Kayser O, et al. **Z Naturforsch [C]** 1999 Mar-Apr;54(3-4):169-74

Antibacterial and cytotoxic natural and synthesized hydroquinones from sponge Ircinia spinosula. Mihopoulos N, et al. **Z Naturforsch [C]** 1999 May-Jun;54(5-6):417-23

Pyrrolizidine alkaloids from Echium rauwolfii and Echium horridum (Boraginaceae). el-Shazly A, et al. **Z Naturforsch [C]** 1999 May-Jun;54(5-6):295-300

[Mechanisms underlying resistance of the bacteria responsible for nosocomial infections] Mainardi JL, et al. **Pathol Biol (Paris)** 1998 Apr;46(4):253-60 (53 ref.) (Eng. Abstr.) **(Fre)**

[Emergence of Gram-positive bacteria in nosocomial transmission] Solignac M. **Presse Med** 1998 Jun;27 Suppl 3:21-6 (Eng. Abstr.) **(Fre)**

[In vitro activities of 23 antimicrobial agents against 4,993 gram-positive and gram-negative bacterial strains isolated from multicenter of Japan during 1994--in vitro susceptibility surveillance.Levofloxacin-Surveillance Group] Yamaguchi K, et al. **Jpn J Antibiot** 1999 Feb; 52(2):75-92 (Eng. Abstr.) **(Jpn)**

[Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics] Sawicka-Grzelak A, et al. **Med Dosw Mikrobiol** 1998;50(1-2):69-76 (Eng. Abstr.) **(Pol)**

[Increase in the frequency of norfloxacin and ciprofloxacin resistance of bacteria isolated from urine culture] Lopes AA, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):196-200 (Eng. Abstr.) **(Por)**

[In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals] Sader HS, et al. **Rev Assoc Med Bras** 1998 Oct-Dec;44(4):283-8 (Eng. Abstr.) **(Por)**

[Antimicrobial and membranolytic activity of sterically hindered phenols] Petrykina ZM, et al. **Antibiot Khimioter** 1998;43(8):11-5 (Eng. Abstr.) **(Rus)**

[Investigation and identification of the antimicrobial component of the drug "Tomatol"] Vorob'ev AA, et al. **Antibiot Khimioter** 1999;44(3):15-8 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. Tarantino PM Jr, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1982-7

DNA polymerase III of Gram-positive eubacteria is a zinc metalloprotein conserving an essential finger-like domain. Barnes MH, et al. **Biochemistry** 1998 Nov 3;37(44):15254-60

Molecular characterization of guanosine kinase gene from a facultative alkalophile, Exiguobacterium aurantiacum ATCC 35652. Usuda Y, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2-3):373-9

Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Wright GD, et al. **Front Biosci** 1999 Jan 1; 4:D9-21 (91 ref.)

Blue/white screening of recombinant plasmids in Gram-positive bacteria by interruption of alkaline phosphatase gene (phoZ) expression. Chaffin DO, et al. **Gene** 1998 Sep 28;219(1-2):91-9

Purification and molecular characterization of ortho-chlorophenol reductive dehalogenase, a key enzyme of halorespiration in Desulfitobacterium dehalogenans. van de Pas BA, et al. **J Biol Chem** 1999 Jul 16;274(29):20287-92

Presence of peptidase activities in different varieties of cheese. Gatti M, et al. **Lett Appl Microbiol** 1999 May; 28(5):368-72

GENETICS

Conjugation in gram-positive bacteria and kinetics of plasmid transfer. Andrup L. **APMIS Suppl** 1998;84:47-55 (53 ref.)

Genetic characterization and heterologous expression of brochocin-C, an antibotulinal, two-peptide bacteriocin produced by Brochothrix campestris ATCC 43754. McCormick JK, et al. **Appl Environ Microbiol** 1998 Dec; 64(12):4757-66

Molecular characterization of guanosine kinase gene from a facultative alkalophile, Exiguobacterium aurantiacum ATCC 35652. Usuda Y, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2-3):373-9

Blue/white screening of recombinant plasmids in Gram-positive bacteria by interruption of alkaline phosphatase gene (phoZ) expression. Chaffin DO, et al. **Gene** 1998 Sep 28;219(1-2):91-9

Gigantism in a bacterium, Epulopiscium fishelsoni, correlates with complex patterns in arrangement, quantity, and segregation of DNA. Bresler V, et al. **J Bacteriol** 1998 Nov;180(21):5601-11

Conjugative mobilization of the rolling-circle plasmid pIP823 from Listeria monocytogenes BM4293 among gram-positive and gram-negative bacteria. Charpentier E, et al. **J Bacteriol** 1999 Jun;181(11):3368-74

Organization of genes for tetrapyrrole biosynthesis in gram--positive bacteria. Johansson P, et al. **Microbiology** 1999 Mar;145 (Pt 3):529-38

A simple and rapid method for preparing genomic DNA from gram-positive bacteria. Sohail M. **Mol Biotechnol** 1998 Oct;10(2):191-3

CtsR, a novel regulator of stress and heat shock response, controls clp and molecular chaperone gene expression in gram-positive bacteria. Derré I, et al. **Mol Microbiol** 1999 Jan;31(1):117-31

Antimicrobial resistance in gram-positive bacteria: the myth of the MIC. Minimum inhibitory concentration. Rapp RP. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):112S-119S; discussion 133S-137S (40 ref.)

GROWTH & DEVELOPMENT

Influence of proline residues on the antibacterial and synergistic activities of alpha-helical peptides. Zhang L, et al. **Biochemistry** 1999 Jun 22;38(25):8102-11

Performance of serum-free broth media for growth of Renibacterium salmoninarum. Starliper CE, et al. **Dis Aquat Organ** 1998 Sep 11;34(1):21-6

Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. Freestone PP, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):53-60

Growth control of Listeria monocytogenes on cold-smoked salmon using a competitive lactic acid bacteria flora. Nilsson L, et al. **J Food Prot** 1999 Apr;62(4):336-42

Fate of gram-positive bacteria in reconditioned, pork-processing plant water. Palumbo SA, et al. **J Food Prot** 1999 Feb;62(2):194-7

Neutrophil response and microbiological findings around teeth and dental implants. Hultin M, et al. **J Periodontol** 1998 Dec;69(12):1413-8

Inhibitory activity of Paenibacillus polymyxa SCE2 against human pathogenic micro-organisms. Seldin L, et al. **Lett Appl Microbiol** 1999 Jun;28(6):423-7

Inhibition of bacterial pathogens by lactobacilli. Dembélé T, et al. **Zentralbl Bakteriol** 1998 Nov;288(3):395-401

IMMUNOLOGY

Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Kotb M. **Curr Opin Microbiol** 1998 Feb;1(1):56-65 (79 ref.)

Different prevalences of Renibacterium salmoninarum detected by ELISA in Alaskan chinook salmon Oncorhynchus tshawytscha spawned from freshwater and seawater. Meyers TR, et al. **Dis Aquat Organ** 1999 Jan 29;35(2):101-5

Evaluation of a whole cell, p57- vaccine against Renibacterium salmoninarum. Piganelli JD, et al. **Dis Aquat Organ** 1999 Apr 15;36(1):37-44

Antigenic and functional characterization of p57 produced by Renibacterium salmoninarum. Wiens GD, et al. **Dis Aquat Organ** 1999 Jun 23;37(1):43-52

Immunostimulatory properties of genomic DNA from different bacterial species. Neujahr DC, et al. **Immunobiology** 1999 Feb;200(1):106-19

Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Miettinen M, et al. **Infect Immun** 1998 Dec;66(12):6058-62

Gram positive bacteria induce IL-6 and IL-8 production in human alveolar macrophages and epithelial cells. Larsson BM, et al. **Inflammation** 1999 Jun;23(3):217-30

Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. Yoshimura A, et al. **J Immunol** 1999 Jul 1;163(1):1-5

Bacterial peptidoglycan polysaccharides in sterile human spleen induce proinflammatory cytokine production by human blood cells. Schrijver IA, et al. **J Infect Dis** 1999 Jun;179(6):1459-68

Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Calandra T, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11383-8

[The role of bacteria in allergic and pseudoallergic reactions] Szymaniak L, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):37-40 (31 ref.) (Eng. Abstr.) **(Pol)**

[Immuno-microbiological aspects of chronic bacterial prostatitis pathogenesis] Savitskaia KI, et al. **Vestn Ross Akad Med Nauk** 1999;(2):51-8 (Eng. Abstr.)

(Rus)

ISOLATION & PURIFICATION

Incidence of contamination of preserved saline solutions during normal use. Sweeney DF, et al. **CLAO J** 1999 Jul; 25(3):167–75

Direct bacterial identification from positive BacT/Alert blood cultures using MicroScan overnight and rapid panels. Waites KB, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):21–6

Development of a nested polymerase chain reaction for amplification of a sequence of the p57 gene of Renibacterium salmoninarum that provides a highly sensitive method for detection of the bacterium in salmonid kidney. Chase DM, et al. **Dis Aquat Organ** 1998 Nov 30; 34(3):223–9

Stethoscopes and otoscopes--a potential vector of infection? Cohen HA, et al. **Fam Pract** 1997 Dec;14(6):446–9

Pathogenesis of gram-positive bacterial endophthalmitis. Callegan MC, et al. **Infect Immun** 1999 Jul;67(7):3348–56

Culture-independent quantification of physiologically-active microbial groups in fermented foods using rRNA-targeted oligonucleotide probes: application to pozol, a Mexican lactic acid fermented maize dough. Ampe F, et al. **J Appl Microbiol** 1999 Jul;87(1):131–40

Viable heterotrophic bacteria in water and sediment in 'Mar Piccolo' of Taranto (Ionian Sea, Italy). Cavallo RA, et al. **J Appl Microbiol** 1999 Jun;86(6):906–16

Study of the micro-organisms associated with the fermented bread (khamir) produced from sorghum in Gizan region, Saudi Arabia. Gassem MA. **J Appl Microbiol** 1999 Feb; 86(2):221–5

Prospective evaluation of external ocular microbial growth and aqueous humor contamination during cataract surgery. Tervo T, et al. **J Cataract Refract Surg** 1999 Jan;25(1):65–71

Evaluation of Statens Serum Institut enteric medium for detection of enteric pathogens. Blom M, et al. **J Clin Microbiol** 1999 Jul;37(7):2312–6

Microbiological quality of retail imported unprepared whole lettuces: a PHLS Food Working Group Study. Public Health Laboratory Service. Little C, et al. **J Food Prot** 1999 Apr;62(4):325–8

Rapid detection and counting of viable bacteria in vegetables and environmental water using a photon-counting TV camera. Miyamoto T, et al. **J Food Prot** 1998 Oct; 61(10):1312–6

Microbiological study of the dripping waters in Altamira cave (Santillana del Mar, Spain). Laiz L, et al. **J Microbiol Methods** 1999 May;36(1–2):129–38

A simple extraction procedure for efficient routine detection of pathogenic bacteria in plant material by polymerase chain reaction. Llop P, et al. **J Microbiol Methods** 1999 Jul;37(1):23–31

Bacterial isolates from neutropenic febrile pediatric patients and their sensitivity patterns to antibiotics. Bhatti FN, et al. **JPMA J Pak Med Assoc** 1998 Sep;48(9):287–90

Increasing ciprofloxacin resistance among prevalent urinary tract bacterial isolates in Bangladesh. Iqbal J, et al. **Jpn J Med Sci Biol** 1997 Dec;50(6):241–50

Sensitive detection of Renibacterium salmoninarum in whole fry, blood, and other tissues of pacific salmon by reverse transcription-polymerase chain reaction. Rhodes LD, et al. **Mol Mar Biol Biotechnol** 1998 Dec;7(4):270–9

Specific oligonucleotide probes for in situ detection of a major group of gram-positive bacteria with low DNA G + C content. Meier H, et al. **Syst Appl Microbiol** 1999 May;22(2):186–96

[Intraocular contamination during cataract surgery according to surgical technique and type of implant] Feys J, et al. **J Fr Ophtalmol** 1999 Mar;22(2):213–4 (Eng. Abstr.) **(Fre)**

[Characteristics of fauces microflora in children treated in intensive care units] Beloborodova NV, et al. **Antibiot Khimioter** 1998;43(8):16–22 (Eng. Abstr.) **(Rus)**

[Pyogenic infectious complications in recipients with allogenic kidneys: clinical and bacteriological aspects] Volynchik EP, et al. **Vestn Ross Akad Med Nauk** 1998; (6):56–8 (Eng. Abstr.) **(Rus)**

METABOLISM

Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Sahl HG, et al. **Annu Rev Microbiol** 1998;52:41–79 (168 ref.)

Bacillus arsenicoselenatis, sp. nov., and Bacillus selenitireducens, sp. nov.: two haloalkaliphiles from Mono Lake, California that respire oxyanions of selenium and arsenic. Switzer Blum J, et al. **Arch Microbiol** 1998 Dec; 171(1):19–30

Bacterial solute uptake and efflux systems. Lolkema JS, et al. **Curr Opin Microbiol** 1998 Apr;1(2):248–53 (32 ref.)

Uptake kinetics of nucleic acid targeting dyes in S. aureus, E. faecalis and B. cereus: a flow cytometric study. Walberg M, et al. **J Microbiol Methods** 1999 Mar;35(2):167–76

Protein targeting to the bacterial cytoplasmic membrane. Fekkes P, et al. **Microbiol Mol Biol Rev** 1999 Mar; 63(1):161–73 (203 ref.)

Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Goffin C, et al. **Microbiol Mol Biol Rev** 1998 Dec;62(4):1079–93 (74 ref.)

Teaching an old bug new tricks [news; comment] Hendrickson W. **Nat Biotechnol** 1998 Oct;16(10):910–1. Comment on: Nat Biotechnol 1998 Oct;16(10):929–33.

[Bacteriocins. Production, properties, application] Egorov NS, et al. **Antibiot Khimioter** 1999;44(6):33–40 (43 ref.) **(Rus)**

[Repression of catabolites in gram-positive and gram-negative bacteria] Gershanovich VN. **Mol Gen Mikrobiol Virusol** 1998;(4):12–8 (64 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Elevated temperature treatment as a novel method for decreasing p57 on the cell surface of Renibacterium salmoninarum. Piganelli JD, et al. **Dis Aquat Organ** 1999 Apr 15;36(1):29–35

Pathogenesis of gram-positive bacterial endophthalmitis. Callegan MC, et al. **Infect Immun** 1999 Jul;67(7):3348–56

Lacticin 3147 displays activity in buffer against gram-positive bacterial pathogens which appear insensitive in standard plate assays. Galvin M, et al. **Lett Appl Microbiol** 1999 May;28(5):355–8

PHYSIOLOGY

Binding of bacteria to HEp-2 cells infected with influenza A virus. El Ahmer OR, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):331–41

Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase. Culebras E, et al. **Front Biosci** 1999 Jan 1;4:D1–8 (90 ref.)

Analysis of the bacterial surface ripening flora of German and French smeared cheeses with respect to their anti-listerial potential. Carnio MC, et al. **Int J Food Microbiol** 1999 Mar 1;47(1–2):89–97

Inhibition of Listeria monocytogenes by Carnobacterium spp. strains in a simulated cold smoked fish system stored at 4 degrees C. Duffes F, et al. **Int J Food Microbiol** 1999 Mar 1;47(1–2):33–42

Gigantism in a bacterium, Epulopiscium fishelsoni, correlates with complex patterns in arrangement, quantity, and segregation of DNA. Bresler V, et al. **J Bacteriol** 1998 Nov;180(21):5601–11

Microglial activation by components of gram-positive and -negative bacteria: distinct and common routes to the induction of ion channels and cytokines. Prinz M, et al. **J Neuropathol Exp Neurol** 1999 Oct;58(10):1078–89

Prompt colonization of the hepaticojejunostomy and translocation of bacteria to liver after bile duct reconstruction. Chuang JH, et al. **J Pediatr Surg** 1998 Aug; 33(8):1215–8

Human ileostomy glycoproteins as a model for small intestinal mucus to investigate adhesion of probiotics. Tuomola EM, et al. **Lett Appl Microbiol** 1999 Mar; 28(3):159–63

Differential induction of NO synthesis by gram-positive and gram-negative bacteria and their components in bovine monocyte-derived macrophages. Jungi TW, et al. **Microb Pathog** 1999 Jul;27(1):43–53

Evolution of conjugative plasmids from gram-positive bacteria [letter; comment] Firth N, et al. **Mol Microbiol** 1999 Mar;31(5):1598–600. Comment on: Mol Microbiol 1998 Aug;29(4):1029–38.

Regulation of compatible solute accumulation in bacteria. Poolman B, et al. **Mol Microbiol** 1998 Jul;29(2):397–407 (65 ref.)

Coupling physiology and gene regulation in bacteria: the phosphotransferase sugar uptake system delivers the signals. Stülke J, et al. **Naturwissenschaften** 1998 Dec; 85(12):583–92 (95 ref.)

Antimicrobial properties and morphological characteristics of two Photorhabdus luminescens strains. Bondi M, et al. **New Microbiol** 1999 Apr;22(2):117–27

A symphony of bacterial voices [news] Strauss E. **Science** 1999 May 21;284(5418):1302–4

Septic shock caused by gram-positive bacteria. Teti G. **Trends Microbiol** 1999 Mar;7(3):100–1

RADIATION EFFECTS

[The study of biocide effectiveness of ultraviolet treatment in media stimulating space station environment] Vasin VB, et al. **Aviakosm Ekolog Med** 1998;32(3):62–6 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Formation and structure of mixed bacterial communities. Tetz VV. **APMIS** 1999 Jul;107(7):645–54

GRAM-POSITIVE BACTERIAL INFECTIONS

Propionibacterium as a cause of postneurosurgical infection in patients with dural allografts: report of three cases. Jallo GI, et al. **Neurosurgery** 1999 May;44(5):1138–41

Recurrent enterococcal endophthalmitis following cataract surgery: a case report. Nasrallah FP, et al. **Ophthalmic Surg Lasers** 1999 Jun;30(6):481–2

Micrococcus luteus endocarditis: case report and review of the literature. Seifert H, et al. **Zentralbl Bakteriol** 1995 Oct; 282(4):431–5 (24 ref.)

[A case of subacute bacterial endocarditis caused by anaerobic Peptostreptococcus] Zhang J. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):Inside backcover **(Chi)**

[Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)] Kuwahara K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):182–5 (15 ref.) **(Jpn)**

BLOOD

Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Rønnestad A, et al. **Scand J Infect Dis** 1998;30(3):245–51

COMPLICATIONS

The management of brain abscess in a developing country: are the results any different? Joshi SM, et al. **Br J Neurosurg** 1998 Aug;12(4):325–8

Central nervous system infections due to Stomatococcus mucilaginosus in immunocompromised hosts. Goldman M, et al. **Clin Infect Dis** 1998 Nov;27(5):1241–6 (13 ref.)

Spondylitis caused by Peptostreptococcus. Rousseau MC, et al. **Clin Rheumatol** 1998;17(6):538–9

Stomatococcus mucilaginosus septicemia in a patient with acute lymphoblastic leukaemia. Treviño M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):505–7

Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. Yoneyama H, et al. **J Clin Invest** 1998 Dec 1;102(11):1933–41

Clones of Lactobacillus casei and Torulopsis glabrata associated with recurrent abdominal wall abscess. Lu PL, et al. **J Formos Med Assoc** 1999 May;98(5):356–60

Gas containing cavernous abscess secondary to an intra-abdominal abscess. Frank I, et al. **J Urol** 1999 Oct; 162(4):1382–3

Systemic lupus erythematosus complicated by necrotizing fasciitis. Mendez EA, et al. **Lupus** 1999;8(2):157–9

Successful transplantation of organs retrieved from a donor with enterococcal endocarditis. Caballero F, et al. **Transpl Int** 1998;11(5):387–9

[Meningitis due to Bacillus cereus in an infant with Reye syndrome] Ferroni A, et al. **Arch Pediatr** 1998 Oct; 5(10):1103–6 (Eng. Abstr.) **(Fre)**

[Bacteremia by Stomatococcus mucilaginosus in leukemic patients (letter)] Batista N, et al. **Enferm Infecc Microbiol Clin** 1999 May;17(5):254–5 **(Spa)**

[Bacteremia caused by Stomatococcus mucilaginosus in a neutropenic patient (letter)] Saavedra JM, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):42–3 **(Spa)**

DIAGNOSIS

Post-infectious glomerulonephritis in a patient with Gemella haemolysans endocarditis [letter] Zingaro L, et al. **Am J Med** 1999 Jan;106(1):125–6

Serological diagnosis of experimental Enterococcus faecalis endocarditis. Kjerulf A, et al. **APMIS** 1998 Oct; 106(10):997–1008

Infective endocarditis presenting as polyarthritis. Rambaldi M, et al. **Clin Rheumatol** 1998;17(6):518–20

Neonatal pericarditis. Vaideeswar P, et al. **Indian Pediatr** 1998 Nov;35(11):1129–31

Endocarditis due to Aerococcus urinae: diagnostic tests, fatty acid composition and killing kinetics. Zbinden R, et al. **Infection** 1999 Mar-Apr;27(2):122–4

Is the limulus amebocyte lysate the sole predictor of septic episodes in major thermal injuries? Heggers JP, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):512–5

Lactobacillus species identification, H2O2 production, and antibiotic resistance and correlation with human clinical status. Felten A, et al. **J Clin Microbiol** 1999 Mar; 37(3):729–33

Genetic relationship between blood and nonblood isolates from bacteremic patients determined by pulsed-field gel electrophoresis. Matsuda J, et al. **J Clin Microbiol** 1998 Oct;36(10):3081–4

Intravascular infection with Lactobacillus paracasei. Sturdee S, et al. **J Infect** 1998 Sep;37(2):184–6

Identification of clinically isolated vancomycin-resistant enterococci: comparison of API and BBL Crystal systems. Hamilton-Miller JM, et al. **J Med Microbiol** 1999 Jul; 48(7):695–6

Isolation of pathogenic bacteria from induced sputum from hospitalized children with pneumonia in Bangladesh. Utsunomiya Y, et al. **J Trop Pediatr** 1998 Dec;44(6):338–42

Phlegmonous gastritis in a haemodialysis patient with secondary amyloidosis. Joko T, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):196–8

[Propionibacterium acnes infectious endocarditis] Durupt S, et al. **Presse Med** 1998 Nov 21;27(36):1839–41 (21 ref.) (Eng. Abstr.) **(Fre)**

[Multiple abscesses (cerebral, splenic, cutaneous) and pulmonary infection] Camino X, et al. **Enferm Infecc Microbiol Clin** 1999 Apr;17(4):189–90 **(Spa)**

[Endocarditis of the native aortic valve due to Propionibacterium acnes (letter)] Jiménez-Navarro MF, et al. **Rev Clin Esp** 1999 May;199(5):331 (7 ref.) **(Spa)**

DRUG THERAPY

Vancomycin-resistant Enterococcus in liver transplant

patients. Orloff SL, et al. **Am J Surg** 1999 May; 177(5):418–22

Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Tam VH, et al. **Ann Pharmacother** 1999 May;33(5):600–6 (43 ref.)

Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis. Ferencz JR, et al. **Arch Ophthalmol** 1999 Aug;117(8):1023–7

Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant enterococcus infection. Dahms RA, et al. **Arch Surg** 1998 Dec;133(12):1343–6

Are new antibiotics on the horizon? Christiansen K. **Aust Fam Physician** 1998 Oct;27(10):890–4 (26 ref.)

Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Koc Y, et al. **Bone Marrow Transplant** 1998 Jul;22(2):207–9

Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Pawlotsky F, et al. **Br J Clin Pharmacol** 1998 Aug;46(2):163–7

The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Lautenbach E, et al. **Clin Infect Dis** 1998 Nov; 27(5):1259–65

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Matsumura S, et al. **Clin Infect Dis** 1998 Dec;27(6):1554–6

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Noskin GA, et al. **Clin Infect Dis** 1999 Mar; 28(3):689–90

Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Taylor SE, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov; 17(11):798–800

Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Tripodi MF, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):734–6

Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice. Onyeji CO, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):301–9

New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Periti P, et al. **Int J Antimicrob Agents** 1999 Jul;12(2):97–105 (74 ref.)

AS-924, a novel bifunctional prodrug of ceftizoxime. Kasai M, et al. **J Antibiot (Tokyo)** 1999 May;52(5):491–500

Study on the in-vitro activity of LY333328 against gram-positive cocci [letter] Mezzatesta ML, et al. **J Antimicrob Chemother** 1998 Aug;42(2):266–8

Alternate antimicrobial therapy for vancomycin-resistant enterococci burn wound infections. Heggers JP, et al. **J Burn Care Rehabil** 1998 Sep–Oct;19(5):399–403

Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. Engervall P, et al. **J Chemother** 1999 Aug;11(4):278–86

Antibiotic resistance among clinically important gram-positive bacteria in the UK. Johnson AP. **J Hosp Infect** 1998 Sep;40(1):17–26 (77 ref.)

Infective endocarditis and glycopeptides. Pittet D, et al. **J Infect** 1998 Sep;37(2):127–35 (50 ref.)

The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. Kim WJ, et al. **J Infect Dis** 1999 Jan;179(1):163–71

The kinetic profile of vancomycin in neonates. Silva R, et al. **J Pharm Pharmacol** 1998 Nov;50(11):1255–60

Vancomycin-resistant-enterococci--colonization of 24 patients on a pediatric oncology unit. Schuster F, et al. **Klin Padiatr** 1998 Jul–Aug;210(4):261–3

Vancomycin-resistant enterococci and use of avoparcin in animal feed: is there a link? [see comments] Collignon PJ. **Med J Aust** 1999 Aug 2;171(3):144–6. Comment in: Med J Aust 1999 Aug 2;171(3):117–8.

Vancomycin-resistant enterococci: causes and control [editorial; comment] Ferguson JK. **Med J Aust** 1999 Aug 2;171(3):117–8. Comment on: Med J Aust 1999 Aug 2;171(3):127–31. Comment on: Med J Aust 1999 Aug 2;171(3):133–6. Comment on: Med J Aust 1999 Aug 2;171(3):144–6.

Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pérez Mato S, et al. **Pediatr Infect Dis J** 1999 May;18(5):483–4

Vancomycin-resistant enterococcus infection is a rare complication in patients receiving PD on an outpatient basis. Ng R, et al. **Perit Dial Int** 1999 May–Jun;19(3):273–4

Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Klepser ME, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):1069–74

Risk factors for acquisition of gentamicin-resistant enterococcal infection: a case-controlled study. Viagappan M, et al. **Postgrad Med J** 1999 Jun;75(884):342–5

Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. Dhawan VK, et al. **West J Med** 1998 Nov;169(5):276–9

[Bacterial resistance during anti-acne antibiotic therapy. How to limit the risk] Piérard GE, et al. **Rev Med Liege** 1999 Feb;54(2):100–4 (Eng. Abstr.) **(Fre)**

[Glycopeptides (vancomycin, teicoplanin)--their place in the antibacterial therapy of patients in a high-risk group] Beloborodova NV. **Anesteziol Reanimatol** 1998 Jul–Aug; (4):23–7 (Eng. Abstr.) **(Rus)**

[Problem of antibiotic therapy of severe infections, due to polyresistant gram-positive microorganisms. Teicoplanin (Targocide): comparative evaluation of antimicrobial activity, clinical importance] Fomina IP. **Antibiot Khimioter** 1999;44(8):18–22 **(Rus)**

[Teicoplanin. New treatment potentials for gram-positive infections in the hospital (editorial)] Iakovlev SV. **Antibiot Khimioter** 1999;44(2):3–7 (10 ref.) **(Rus)**

[The current course and treatment of infectious endocarditis] Tiurin VP, et al. **Voen Med Zh** 1998 Sep;319:9):44–9, 95 (Eng. Abstr.) **(Rus)**

[Aminoglycoside-resistant enterococci a new bacterial hazard] Melhus A. **Lakartidningen** 1999 Apr 7; 96(14):1694–5 (18 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Carrier rate of resistant enterococci in a tertiary care hospital in Norway. Torfoss D, et al. **APMIS** 1999 Jun;107(6):545–9

Outbreak of pseudobacteremia due to multidrug-susceptible Enterococcus faecium. Baddour LM, et al. **Clin Infect Dis** 1999 Jun;28(6):1333–4

Emergence and epidemiology of vancomycin-resistant enterococci in Australia. Bell J, et al. **Commun Dis Intell** 1998 Oct 29;22(11):249–52

Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985–1996. Crowe M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):377–84

Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use [letter] Fishbane S, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):461–2

Spread of vancomycin-resistant enterococci: differences between the United States and Europe. Goossens H. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):546–51

Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Lautenbach E, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):318–23

Spread of vancomycin-resistant enterococci: why did it happen in the United States? Martone WJ. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):539–45 (72 ref.)

The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution. Tokars JI, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):171–5

Safety of industrial lactic acid bacteria. Adams MR. **J Biotechnol** 1999 Feb 19;68(2–3):171–8 (25 ref.)

Comparison of genomic methods for differentiating strains of Enterococcus faecium: assessment using clinical epidemiologic data. Savor C, et al. **J Clin Microbiol** 1998 Nov;36(11):3327–31

Epidemiology and control of vancomycin-resistant enterococci (VRE) in a renal unit. Brown AR, et al. **J Hosp Infect** 1998 Oct;40(2):115–24

Prevalence of colonization with vancomycin-resistant enterococci in various population groups in Berlin, Germany. Wendt C, et al. **J Hosp Infect** 1999 Jul; 42(3):193–200

The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. Kim WJ, et al. **J Infect Dis** 1999 Jan;179(1):163–71

Investigation of an outbreak of vancomycin-resistant Enterococcus faecium in a low prevalence university hospital. Hwang YS, et al. **J Investig Med** 1998 Dec; 46(9):435–43

Role of transposon Tn5482 in the epidemiology of vancomycin-resistant Enterococcus faecium in the pediatric oncology unit of a New York City Hospital. de Lencastre H, et al. **Microb Drug Resist** 1999 Summer; 5(2):113–29

Enterococcal bacteremia in children: a review of seventy-five episodes in a pediatric hospital. Das I, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1154–8

Endocarditis due to enterococcus faecalis: risk factors and outcome in twenty-one cases from a five year national survey [letter] Hricak V Jr, et al. **Scand J Infect Dis** 1998; 30(5):540–1

Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Rønnestad A, et al. **Scand J Infect Dis** 1998;30(3):245–51

Low faecal carrier rate of vancomycin resistant enterococci in Norwegian hospital patients. Simonsen GS, et al. **Scand J Infect Dis** 1998;30(5):465–8

Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteraemia. Suppola JP, et al. **Scand J Infect Dis** 1998; 30(2):153–7

[Emergence of Gram-positive bacteria in nosocomial transmission] Solignac M. **Presse Med** 1998 Jun;27 Suppl 3:21–6 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Koc Y, et al. **Bone Marrow Transplant** 1998 Jul;22(2):207–9

Pacemaker-induced endocarditis due to Propionibacterium acnes. Chua AG, et al. **Clin Infect Dis** 1998 Dec; 27(6):1541–2

A case of infective endotipsitis [letter; comment] Eversman D, et al. **Gastroenterology** 1999 Aug;117(2):514. Comment on: Gastroenterology 1998 Jul;115(1):110–5.

Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature. Gruson D, et al. **Hematol Cell Ther** 1998 Aug; 40(4):167–9

Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. Sriskandan S, et al. **Infect Dis Clin North Am** 1999 Jun;13(2):397–412 (99 ref.)

In vitro adhesion and platelet aggregation properties of bacteremia-associated lactobacilli. Kirjavainen PV, et al. **Infect Immun** 1999 May;67(5):2653–5

Abscess formation following spilled gallstones during laparoscopic cholecystectomy. Brueggemeyer MT, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):145–52

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

[The infectious complications of bronchial cancer] Klastersky J. **Rev Mal Respir** 1998 Sep;15(4):451–9 (31 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. Singh KV, et al. **J Infect Dis** 1998 Nov;178(5):1416–20

IMMUNOLOGY

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608–16 (88 ref.) . Comment in: Crit Care Med 1999 Aug;27(8):1682–3.

Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Kotb M. **Curr Opin Microbiol** 1998 Feb;1(1):56–65 (79 ref.)

Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody. Burkhart CG, et al. **Int J Dermatol** 1999 Mar;38(3):200–3

Functional roles of MCP-1 in Propionibacterium acnes-induced, T cell-mediated pulmonary granulomatosis in rabbits. Ichiyasu H, et al. **J Leukoc Biol** 1999 Apr; 65(4):482–91

[Skin reactions to antigens of propionibacterium acnes in patients with acne vulgaris treated with autovaccine] Zaluga E. **Ann Acad Med Stetin** 1998;44:65–85 (Eng. Abstr.) **(Pol)**

[The study on biology of bacteriophages and their usage in the treatment of bacterial diseases and on the influence of different bacteriophages on cytokine production by leukocytes in human peripheral blood] Koźmińska J, et al. **Otolaryngol Pol** 1997;51 Suppl 25:195–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Wise R, et al. **Eur Respir J** 1999 Jul;14(1):221–9 (97 ref.)

MICROBIOLOGY

Detection of vancomycin-resistant enterococci colonization in a children's hospital. Christenson JC, et al. **Am J Infect Control** 1998 Dec;26(6):569–71

Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Goetz AM, et al. **Am J Infect Control** 1998 Dec;26(6):558–62

Clonal diversity of vancomycin-resistant enterococci from an outbreak in a tertiary care university hospital. Pearce CL, et al. **Am J Infect Control** 1998 Dec;26(6):563–8

Genomic relationships between Enterococcus faecium strains from different sources and with different antibiotic resistance profiles evaluated by restriction endonuclease analysis of total chromosomal DNA using EcoRI and PvuII. Quednau M, et al. **Appl Environ Microbiol** 1999 Apr; 65(4):1777–80

Identification of aerobically and anaerobically induced genes in Enterococcus faecalis by random arbitrarily primed PCR. Shepard BD, et al. **Appl Environ Microbiol** 1999 Apr; 65(4):1470–6

The emergence of enterococci as a cause of nosocomial infection. Hunt CP. **Br J Biomed Sci** 1998 Jun;55(2):149–56 (108 ref.)

Peritonitis due to Rothia dentocariosa in a patient receiving continuous ambulatory peritoneal dialysis. Bibashi E, et al. **Clin Infect Dis** 1999 Mar;28(3):696

Septicemia due to Arthrobacter species in a neutropenic patient with acute lymphoblastic leukemia. Hsu CL, et al. **Clin Infect Dis** 1998 Nov;27(5):1334–5

Propionibacterium acnes sepsis in a previously healthy man. Praderio L, et al. **Clin Infect Dis** 1998 Nov;27(5):1330–1

Bacteremia due to motile Enterococcus species: clinical features and outcomes. Ratanasuwan W, et al. **Clin Infect Dis** 1999 May;28(5):1175–7

Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Rautio M,

et al. **Clin Infect Dis** 1999 May;28(5):1159–60

Iatrogenic meningitis due to Abiotrophia defectiva after myelography. Schlegel L, et al. **Clin Infect Dis** 1999 Jan; 28(1):155–6

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? [see comments] Opal SM, et al. **Crit Care Med** 1999 Aug;27(8):1608–16 (88 ref.) . Comment in: Crit Care Med 1999 Aug;27(8):1682–3.

Encapsulated Enterococcus faecalis: role of encapsulation in persistence in mouse peritoneum in absence of mouse lethality. Bottone EJ. **Diagn Microbiol Infect Dis** 1999 Jan; 33(1):65–8

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. Diekema DJ, et al. **Diagn Microbiol Infect Dis** 1999 May;34(1):37–43

Lactococcus garvieae endocarditis: report of a case and review of the literature. Fefer JJ, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):127–30

In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin. Isenberg HD, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):115–8

Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Jones RN, et al. **Diagn Microbiol Infect Dis** 1998 Nov;32(3):247–52

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Pfaller MA, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):283–97

Practical approach to the identification of clinically relevant Enterococcus species. Willey BM, et al. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):165–71

Proficiency of clinical laboratories in and near Monterrey, Mexico, to detect vancomycin-resistant enterococci. McDonald LC, et al. **Emerg Infect Dis** 1999 Jan–Feb; 5(1):143–6

Isolation of Alloiococcus otitidis from the external ear in children. Gómez-Hernando C, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):69–70

Urinary tract infection due to Arcanobacterium bernardiae in a patient with a urinary tract diversion. Lepargneur JP, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun; 17(6):399–401

Lactobacillus species as opportunistic pathogens in immunocompromised patients. Schlegel L, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):887–8

Three cases of serious infection caused by Aerococcus urinae. Schuur PM, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):368–71 (11 ref.)

Comparative evaluation of a commercial system for identification of gram-positive cocci. von Baum H, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):849–52

In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and neutropenic patients. von Eiff C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):890–2

Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Kurokawa I, et al. **Eur J Dermatol** 1999 Jan–Feb;9(1):25–8

Nucleotide sequence of IS1542, an insertion sequence identified within VanA glycopeptide resistance elements of enterococci. Darini AL, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):341–6

Presence of erm gene classes in gram-positive bacteria of animal and human origin in Denmark. Jensen LB, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):151–8

Images in Infectious Diseases in Obstetrics and Gynecology. Vaginal Lactobacillus phage plaques and electron micrograph. Tao L, et al. **Infect Dis Obstet Gynecol** 1998; 6(6):236

Pathogenesis of gram-positive bacterial endophthalmitis. Callegan MC, et al. **Infect Immun** 1999 Jul;67(7):3348–56

A novel means of self-protection, unrelated to toxin activation, confers immunity to the bactericidal effects of the Enterococcus faecalis cytolysin. Coburn PS, et al. **Infect Immun** 1999 Jul;67(7):3339–47

Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Shankar V, et al. **Infect Immun** 1999 Jan;67(1):193–200

Isolation of Enterococcus faecalis clinical isolates that efficiently adhere to human bladder carcinoma T24 cells and inhibition of adhesion by fibronectin and trypsin treatment. Shiono A, et al. **Infect Immun** 1999 Apr; 67(4):1585–92

Enterococcus faecalis endocarditis presenting as meningitis. Lin DP, et al. **Infection** 1998 Sep–Oct;26(5):304–5

Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin. Grüneberg RN, et al. **Int J Antimicrob Agents** 1998 Nov;10(4):271–7

Enterococci at the crossroads of food safety? Franz CM, et al. **Int J Food Microbiol** 1999 Mar 1;47(1–2):1–24 (199 ref.)

In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci [letter] Kariyama R, et al. **J Antimicrob Chemother** 1998 Dec;42(6):836–8

Description of Gemella sanguinis sp. nov., isolated from human clinical specimens. Collins MD, et al. **J Clin Microbiol** 1998 Oct;36(10):3090–3

Should genotypic testing be done on all phenotypically vancomycin- resistant enterococci detected in hospitals? [letter] Coombs GW, et al. **J Clin Microbiol** 1999 Apr; 37(4):1229–30

Gram type-specific broad-range PCR amplification for rapid detection of 62 pathogenic bacteria [published erratum appears in J Clin Microbiol 1999 May;37(5):1660] Klausegger A, et al. **J Clin Microbiol** 1999 Feb;37(2):464–6

Destructive knee joint infection caused by Peptostreptococcus micros: importance of early microbiological diagnosis. Riesbeck K, et al. **J Clin Microbiol** 1999 Aug;37(8):2737–9

Comparison of genomic methods for differentiating strains of Enterococcus faecium: assessment using clinical epidemiologic data. Savor C, et al. **J Clin Microbiol** 1998 Nov;36(11):3327–31

Vancomycin-resistant Enterococcus faecium colonization in children. Singh-Naz N, et al. **J Clin Microbiol** 1999 Feb; 37(2):413–6

Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period. Thal L, et al. **J Clin Microbiol** 1998 Nov; 36(11):3303–8

Isolation and epidemiological study of vancomycin-resistant Enterococcus faecium from patients of a haematological unit in Poland. Samet A, et al. **J Hosp Infect** 1999 Feb; 41(2):137–43

Lactobacillus endocarditis [letter] Mitchell AR, et al. **J Infect** 1999 May;38(3):200–1

Two cases of Enterococcus faecalis bacteremia associated with a hemodialysis machine [letter] Olver WJ, et al. **J Infect Dis** 1999 May;179(5):1312

Pathogenicity of Peptostreptococcus micros morphotypes and Prevotella species in pure and mixed culture. van Dalen PJ, et al. **J Med Microbiol** 1998 Feb;47(2):135–40

Identification of enterococci by ribotyping with horseradish-peroxidase-labelled 16S rDNA probes. Pryce TM, et al. **J Microbiol Methods** 1999 Jun;36(3):147–55

Detection of Alloiococcus otitis in mixed bacterial populations from middle-ear effusions of patients with otitis media. Beswick AJ, et al. **Lancet** 1999 Jul 31; 354(9176):386–9

Vancomycin resistant enterococci in New Zealand [letter] Kobayashi K, et al. **N Z Med J** 1999 Mar 26;112(1084):105

Whipple's syndrome (uveitis, B27-negative spondylarthropathy, meningitis, and lymphadenopathy) associated with Arthrobacter sp. infection. Bodaghi B, et al. **Ophthalmology** 1998 Oct;105(10):1891–6

Enterococcus avium endocarditis in an infant with tetralogy of Fallot. Swaminathan S, et al. **Pediatr Cardiol** 1999 May–Jun;20(3):227–8

Enterococci: new aspects of an old organism. Murray BE, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug; 111(4):328–34 (49 ref.)

Endocarditis caused by Abiotrophia species. Christensen JJ, et al. **Scand J Infect Dis** 1999;31(2):210–2

In Vitro activity of 6 antimicrobials against propionibacteria isolates from untreated acne papulopustulosa. Fluhr JW, et al. **Zentralbl Bakteriol** 1999 Feb;289(1):53–61

Species identification and antibiotic susceptibility of enterococci isolated from clinical specimens of hospitalized patients. Kaufhold A, et al. **Zentralbl Bakteriol** 1995 Oct; 282(4):507–18

[Vancomycin-resistant enterococci in pediatric hematology: don't panic!] Barbé G, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):408–11 (Eng. Abstr.) **(Fre)**

[Peptostreptococcus magnus osteoarticular infections after orthopedic surgery. 14 cases and pathogenicity factors] Felten A, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):442–8 (Eng. Abstr.) **(Fre)**

[Determination of the nosocomial origin of vancomycin-resistance strains of Enterococcus isolated from stool of patients in a hematology department] Trivier D, et al. **Pathol Biol (Paris)** 1999 May;47(5):430–6 (Eng. Abstr.) **(Fre)**

[Lactobacillus acidophilus endocarditis] Penot JP, et al. **Presse Med** 1998 Jun 13;27(21):1009–12 (Eng. Abstr.) **(Fre)**

[Bacterial flora of the mouth cavity and pharynx and postop wound infection in laryngeal cancer treatment] Lukomski M, et al. **Otolaryngol Pol** 1997;51 Suppl 25:184–7 (Eng. Abstr.) **(Pol)**

[Analysis of bacterial flora of the larynx: analysis of material collected in 1994–1996] Wilczyński K, et al. **Otolaryngol Pol** 1997;51 Suppl 25:188–92 (Eng. Abstr.) **(Pol)**

[Bacterial flora in chronic purulent maxillary sinusitis] Ziuzio S, et al. **Otolaryngol Pol** 1997;51 Suppl 25:179–83 (Eng. Abstr.) **(Pol)**

[Immuno-microbiological aspects of chronic bacterial prostatitis pathogenesis] Savitskaia KI, et al. **Vestn Ross Akad Med Nauk** 1999;(2):51–8 (Eng. Abstr.) **(Rus)**

[Bacteremia due to vancomycin-resistant enterococci in neutropenic cancer patients] Marron A, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):761–4 (Eng. Abstr.) **(Spa)**

[Evolution of resistance in the genus Enterococcus in strains isolated from blood] Peset V, et al. **Rev Esp Quimioter** 1998 Dec;11(4):322–6 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Pathological findings in lens capsule and silicone intraocular lens extracted from eye with chronic infectious endophthalmitis. Saika S, et al. **Jpn J Ophthalmol** 1998 Nov–Dec;42(6):456–60

Septicaemia and endomyocarditis caused by Aerococcus urinae. Gritsch W, et al. **Wien Klin Wochenschr** 1999 Jun 4;111(11):446–7

PHYSIOPATHOLOGY

Role of superoxide dismutase activity in the physiology of Porphyromonas gingivalis. Lynch MC, et al. **Infect Immun** 1999 Jul;67(7):3367–75

Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51–4 (19 ref.)

PREVENTION & CONTROL

Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Montecalvo MA, et al. **Ann Intern Med** 1999 Aug 17; 131(4):269–72

Observations on the risk of resistance with the extended use of vancomycin. McManus AT, et al. **Arch Surg** 1998 Nov; 133(11):1207–11

A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Pfundstein J, et al. **Clin Transplant** 1999 Jun;13(3):245–52

Control of transmission of vancomycin-resistant Enterococcus faecium in a long-term-care facility. Armstrong-Evans M, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):312–7

Lack of transmission of vancomycin-resistant enterococci in three long-term-care facilities. Greenaway CA, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):341–3

Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Lai KK, et al. **Infect Control Hosp Epidemiol** 1998 Sep; 19(9):647–52

Detection of clinically relevant genotypes of vancomycin-resistant enterococci in nosocomial surveillance specimens by PCR. Jayaratne P, et al. **J Clin Microbiol** 1999 Jun;37(6):2090–2

Epidemiology and control of vancomycin-resistant enterococci (VRE) in a renal unit. Brown AR, et al. **J Hosp Infect** 1998 Oct;40(2):115–24

Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. Nelson RR. **J Hosp Infect** 1999 Aug;42(4):275–82 (70 ref.)

Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. Ben-Nathan D, et al. **J Med Microbiol** 1999 May; 48(5):425–31

Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria [see comments] Grayson ML, et al. **Med J Aust** 1999 Aug 2;171(3):133–6 . Comment in: Med J Aust 1999 Aug 2;171(3):117–8.

VRE: pay attention to your mom [editorial] Thomas JR. **Mo Med** 1998 Nov;95(11):593

Control of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus in hospitalized children. Fisher MC. **Pediatr Infect Dis J** 1998 Sep; 17(9):825–6

Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Malik RK, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):352–6

RADIOGRAPHY

Pelvic abscess on plain radiograph. Moore JA, et al. **J Emerg Med** 1999 Jul–Aug;17(4):741–2

RADIONUCLIDE IMAGING

Detection of abscesses with Tc-99m HMPAO leukocyte scintigraphy depends on their stage and location. Shih WJ, et al. **Clin Nucl Med** 1999 Feb;24(2):111–4

SURGERY

ERCP and pyogenic liver abscess. Lam YH, et al. **Gastrointest Endosc** 1999 Sep;50(3):340–4

Intra-operative ultrasound-guided drainage of parotid abscess. Graham SM, et al. **J Laryngol Otol** 1998 Nov; 112(11):1098–100

THERAPY

Propionibacterium [correction of Proprionibacterium] acnes infections of cerebrospinal fluid shunts. Thompson TP, et al. **Childs Nerv Syst** 1998 Aug;14(8):378–80

Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following caesarean sections and hysterectomies. Al-Waili NS, et al. **Eur J Med Res** 1999 Mar 26;4(3):126–30

Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Clark WL, et al. **Ophthalmology** 1999 Sep;106(9):1665–70

[The percutaneous drainage with a pigtail catheter of multiple

pyogenic liver abscesses in a 7-year-old girl (letter)] Mendez R, et al. **Gastroenterol Hepatol** 1999 May; 22(5):260-1 (11 ref.) **(Spa)**

TRANSMISSION

External sources of vancomycin-resistant enterococci for intensive care units [see comments] Bonten MJ, et al. **Crit Care Med** 1998 Dec;26(12):2001-4. Comment in: Crit Care Med 1998 Dec;26(12):1942-3.

Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle [editorial; comment] Farr BM. **Crit Care Med** 1998 Dec; 26(12):1942-3 (14 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2001-4.

Nosocomial infections due to enterococci in patients with acute leukemia [letter] Fanci R, et al. **Haematologica** 1999 Jul;84(7):662-4

Prospective evaluation of external ocular microbial growth and aqueous humor contamination during cataract surgery. Tervo T, et al. **J Cataract Refract Surg** 1999 Jan;25(1):65-71

Transmission dynamics of epidemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in England and Wales. Austin DJ, et al. **J Infect Dis** 1999 Apr;179(4):883-91

Regional dissemination of vancomycin-resistant enterococci resulting from interfacility transfer of colonized patients. Trick WE, et al. **J Infect Dis** 1999 Aug;180(2):391-6

Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Austin DJ, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6908-13

VETERINARY

A sensitive nested reverse transcriptase PCR assay to detect viable cells of the fish pathogen Renibacterium salmoninarum in Atlantic salmon (Salmo salar L.). Cook M, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3042-7

Biodiversity of Lactococcus garvieae strains isolated from fish in Europe, Asia, and Australia. Eldar A, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1005-8

Molecular differentiation of Renibacterium salmoninarum isolates from worldwide locations. Grayson TH, et al. **Appl Environ Microbiol** 1999 Mar;65(3):961-8

Development of a nested polymerase chain reaction for amplification of a sequence of the p57 gene of Renibacterium salmoninarum that provides a highly sensitive method for detection of the bacterium in salmonid kidney. Chase DM, et al. **Dis Aquat Organ** 1998 Nov 30; 34(3):223-9

Lactococcus garvieae and Streptococcus iniae infections in rainbow trout Oncorhynchus mykiss: similar, but different diseases. Eldar A, et al. **Dis Aquat Organ** 1999 May 31; 36(3):227-31

Different prevalences of Renibacterium salmoninarum detected by ELISA in Alaskan chinook salmon Oncorhynchus tshawytscha spawned from freshwater and seawater. Meyers TR, et al. **Dis Aquat Organ** 1999 Jan 29;35(2):101-5

Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail. Nakai T, et al. **Dis Aquat Organ** 1999 Jun 23;37(1):33-41

Elevated temperature treatment as a novel method for decreasing p57 on the cell surface of Renibacterium salmoninarum. Piganelli JD, et al. **Dis Aquat Organ** 1999 Apr 15;36(1):29-35

Evaluation of a whole cell, p57- vaccine against Renibacterium salmoninarum. Piganelli JD, et al. **Dis Aquat Organ** 1999 Apr 15;36(1):37-44

Antigenic and functional characterization of p57 produced by Renibacterium salmoninarum. Wiens GD, et al. **Dis Aquat Organ** 1999 Jun 23;37(1):43-52

Antigenic analyses of cilia-associated respiratory (CAR) bacillus isolates by use of monoclonal antibodies. Hook RR Jr, et al. **Lab Anim Sci** 1998 Jun;48(3):234-9

Sensitive detection of Renibacterium salmoninarum in whole fry, blood, and other tissues of pacific salmon by reverse transcription-polymerase chain reaction. Rhodes LD, et al. **Mol Mar Biol Biotechnol** 1998 Dec;7(4):270-9

Bacteria isolated from arthritic and omphalatic lesions in lambs in England and Wales. Watkins GH, et al. **Vet J** 1998 Nov;156(3):235-8

Streptococcal suppurative lymphadenitis in a cat [letter] Bedford SW. **Vet Rec** 1999 Jan 2;144(1):28

GRAM-POSITIVE COCCI

Phlegmonous gastritis in a haemodialysis patient with secondary amyloidosis. Joko T, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):196-8

[Bacteremia caused by Stomatococcus mucilaginosus in a neutropenic patient (letter)] Saavedra JM, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):42-3 **(Spa)**

CHEMISTRY

Peptidoglycan fine structure of the radiotolerant bacterium Deinococcus radiodurans Sark. Quintela JC, et al. **J Bacteriol** 1999 Jan;181(1):334-7

CLASSIFICATION

Identification of lactic acid bacteria from chili bo, a Malaysian food ingredient. Leisner JJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):599-605

Comparative evaluation of a commercial system for identification of gram-positive cocci. von Baum H, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):849-52

Facklamia tabacinasalis sp. nov., from powdered tobacco. Collins MD, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1247-50

Aerococcus christensenii sp. nov., from the human vagina. Collins MD, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1125-8

Facklamia sourekii sp. nov., isolated from human sources. Collins MD, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:635-8

Vagococcus lutrae sp. nov., isolated from the common otter (Lutra lutra). Lawson PA, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1251-4

Tessaracoccus bendigoensis gen. nov., sp. nov., a gram-positive coccus occurring in regular packages or tetrads, isolated from activated sludge biomass. Maszenan AM, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:459-68

Description of Gemella sanguinis sp. nov., isolated from human clinical specimens. Collins MD, et al. **J Clin Microbiol** 1998 Oct;36(10):3090-3

CYTOLOGY

Tessaracoccus bendigoensis gen. nov., sp. nov., a gram-positive coccus occurring in regular packages or tetrads, isolated from activated sludge biomass. Maszenan AM, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:459-68

DRUG EFFECTS

Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers. Diekema DJ, et al. **Antimicrob Agents Chemother** 1999 Apr;43(4):940-3

Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. Dornbusch K, et al. **APMIS** 1999 May;107(5):505-13

In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin. Isenberg HD, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):115-8

Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America. Jones RN, et al. **Diagn Microbiol Infect Dis** 1998 Nov;32(3):247-52

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Pfaller MA, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):283-97

Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. Pontani D, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):413-9

In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against Micrococcus species and Stomatococcus mucilaginosus isolated from healthy subjects and neutropenic patients. von Eiff C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):890-2

Resistance problems in two university hospitals in Denmark. Jensen TG, et al. **Int J Antimicrob Agents** 1999 Jun; 12(1):71-3

In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates. López-Brea M, et al. **Int J Antimicrob Agents** 1999 Jun;12(1):33-9

Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres. Barry AL, et al. **J Antimicrob Chemother** 1998 Nov;42(5):651-5

Study on the in-vitro activity of LY333328 against gram-positive cocci [letter] Mezzatesta ML, et al. **J Antimicrob Chemother** 1998 Aug;42(2):266-8

[Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)] Igari J, et al. **Jpn J Antibiot** 1999 Apr;52(4):279-91 (Eng. Abstr.) **(Jpn)**

[A consideration on the results of nationwide surveillance of antimicrobial susceptibilities--gram-positive cocci and gram-negative cocci] Kuroyama M, et al. **Jpn J Antibiot** 1998 Dec;51(12):764-78 (14 ref.) (Eng. Abstr.) **(Jpn)**

Study of rapidity and quality for the VITEK susceptibility cards with 45 wells. Miyamoto H, et al. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):55-8 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Substrate specificity of Deinococcus radiodurans Fpg protein. Sentürker S, et al. **Biochemistry** 1999 Jul 20; 38(29):9435-9

Evaluation of proteolytic activity of micro-organisms isolated from dry cured ham. Rodriguez M, et al. **J Appl Microbiol** 1998 Nov;85(5):905-12

Glutamyl-tRNA(Gln) amidotransferase in Deinococcus radiodurans may be confined to asparagine biosynthesis. Curnow AW, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12838-43

GENETICS

Geographically diverse Australian isolates of Melissococcus pluton exhibit minimal genotypic diversity by restriction endonuclease analysis. Djordjevic SP, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):311-8

Presence of erm gene classes in gram-positive bacteria of animal and human origin in Denmark. Jensen LB, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):151-8

Damage to DNA purified from the radioresistant prokaryote, Deinococcus radiodurans, by acid heating. Imamura M, et al. **Int J Mol Med** 1999 Apr;3(4):391-5

Genetic relationship between blood and nonblood isolates from bacteremic patients determined by pulsed-field gel electrophoresis. Matsuda J, et al. **J Clin Microbiol** 1998 Oct;36(10):3081-4

Engineering a recombinant Deinococcus radiodurans for organopollutant degradation in radioactive mixed waste environments [see comments] Lange CC, et al. **Nat Biotechnol** 1998 Oct;16(10):929-33. Comment in: Nat Biotechnol 1998 Oct;16(10):910-1.

Combinatorial approach of bacteria to antibiotic resistance. Courvalin P. **Res Microbiol** 1999 Jul-Aug;150(6):367-73 (20 ref.)

Whole-genome shotgun optical mapping of Deinococcus radiodurans. Lin J, et al. **Science** 1999 Sep 3; 285(5433):1558-62

DNA sequences provide grist for microbiologists [news] Pennisi E. **Science** 1999 Feb 19;283(5405):1105-6

ISOLATION & PURIFICATION

Isolation of Deinococcus species from commercial oyster extract. Chan WF, et al. **Appl Environ Microbiol** 1999 Feb; 65(2):846-8

Isolation of Alloiococcus otitidis from the external ear in children. Gómez-Hernando C, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):69-70

Facklamia sourekii sp. nov., isolated from human sources. Collins MD, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:635-8

Facklamia tabacinasalis sp. nov., from powdered tobacco. Collins MD, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1247-50

Aerococcus christensenii sp. nov., from the human vagina. Collins MD, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1125-8

Vagococcus lutrae sp. nov., isolated from the common otter (Lutra lutra). Lawson PA, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1251-4

Detection of Alloiococcus otitis in mixed bacterial populations from middle-ear effusions of patients with otitis media. Beswick AJ, et al. **Lancet** 1999 Jul 31; 354(9176):386-9

METABOLISM

Ultracytochemical localization of hydrogen peroxide production by dental plaque bacteria. Oyarzún A, et al. **Arch Oral Biol** 1998 Nov;43(11):907-10

Biomineralization of carbonates by Marinococcus albus and Marinococcus halophilus isolated from the Salar de Atacama (Chile). Rivadeneyra MA, et al. **Curr Microbiol** 1999 Jul;39(1):53-7

Chromium-tolerant bacteria isolated from industrial effluents and their use in detoxication of hexavalent chromium. Shakoori AR, et al. **Folia Microbiol (Praha)** 1999;44(1):50-4

Repair of oxidized bases in the extremely radiation-resistant bacterium Deinococcus radiodurans. Bauche C, et al. **J Bacteriol** 1999 Jan;181(1):262-9

Interactions between pairs of bacteriocins from lactic bacteria. Mulet-Powell N, et al. **J Food Prot** 1998 Sep; 61(9):1210-2

PHYSIOLOGY

The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. El Ahmer OR, et al. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):27-36

RADIATION EFFECTS

Isolation of Deinococcus species from commercial oyster extract. Chan WF, et al. **Appl Environ Microbiol** 1999 Feb; 65(2):846-8

Damage to DNA purified from the radioresistant prokaryote, Deinococcus radiodurans, by acid heating. Imamura M, et al. **Int J Mol Med** 1999 Apr;3(4):391-5

Repair of oxidized bases in the extremely radiation-resistant bacterium Deinococcus radiodurans. Bauche C, et al. **J Bacteriol** 1999 Jan;181(1):262-9

GRAM-POSITIVE ENDOSPORE-FORMING BACTERIA

ENZYMOLOGY

The enzymatic activity of phosphoglycerate mutase from gram-positive endospore-forming bacteria requires Mn2+ and is pH sensitive. Chander M, et al. **Can J Microbiol** 1998 Aug;44(8):759-67

PHYSIOLOGY

Attachment tests of Pasteuria penetrans to the cuticle of plant and animal parasitic nematodes, free living nematodes and srf mutants of Caenorhabditis elegans. Mendoza de Gives P, et al. **J Helminthol** 1999 Mar;73(1):67–71

GRAM-POSITIVE ENDOSPORE-FORMING RODS

CLASSIFICATION

Gracilibacillus gen. nov., with description of Gracilibacillus halotolerans gen. nov., sp. nov.; transfer of Bacillus dipsosauri to Gracilibacillus dipsosauri comb. nov., and Bacillus salexigens to the genus Salibacillus gen. nov., as Salibacillus salexigens comb. nov. Wainø M, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:821–31

ENZYMOLOGY

Presence of Na(+)-stimulated V-type ATPase in the membrane of a facultatively anaerobic and halophilic alkaliphile. Kaieda N, et al. **FEMS Microbiol Lett** 1998 Oct 1;167(1):57–61

GENETICS

Phylogenetic status of Anaerobacter polyendosporus, an anaerobic, polysporogenic bacterium. Siunov AV, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1119–24

GRAM-POSITIVE NON-SPORE-FORMING RODS see **GRAM-POSITIVE ASPOROGENOUS RODS**

GRAM-POSITIVE RODS

ISOLATION & PURIFICATION

Characterization of two subsurface H2-utilizing bacteria, Desulfomicrobium hypogeium sp. nov. and Acetobacterium psammolithicum sp. nov., and their ecological roles. Krumholz LR, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2300–6

METABOLISM

Formation of hyodeoxycholic acid from muricholic acid and hyocholic acid by an unidentified gram-positive rod termed HDCA-1 isolated from rat intestinal microflora. Eyssen HJ, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3158–63

Microbial mineralization of diisopropanolamine. Gieg LM, et al. **Can J Microbiol** 1999 May;45(5):377–88

GRAMICIDIN

ADMINISTRATION & DOSAGE

Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status. Centola GM. **Contraception** 1998 Jul;58(1):35–8

ANALOGS & DERIVATIVES

Preparation and properties of novel gramicidin S analogs possessing a tri-, tetra- or pentamethylene bridge between ornithine side chains. Yamada K, et al. **J Pept Res** 1999 Jun;53(6):611–7

Synthesis and characterization of a new biotinylated gramicidin. Suarez E, et al. **J Pept Sci** 1998 Sep;4(6):371–7

ANALYSIS

An ion funnel interface for improved ion focusing and sensitivity using electrospray ionization mass spectrometry. Shaffer SA, et al. **Anal Chem** 1998 Oct 1;70(19):4111–9

CHEMICAL SYNTHESIS

Design and characterization of gramicidin channels. Greathouse DV, et al. **Methods Enzymol** 1999;294:525–50

CHEMISTRY

Modulating dipoles for structure-function correlations in the gramicidin A channel. Cotten M, et al. **Biochemistry** 1999 Jul 20;38(29):9185–97

Modulation of gramicidin channel structure and function by the aliphatic "spacer" residues 10, 12, and 14 between the tryptophans. Jude AR, et al. **Biochemistry** 1999 Jan 19; 38(3):1030–9

Environment- and sequence-dependent modulation of the double-stranded to single-stranded conformational transition of gramicidin A in membranes. Salom D, et al. **Biochemistry** 1998 Oct 6;37(40):14279–91

Comparison between the dynamics of lipid/gramicidin A systems in the lamellar and hexagonal phases: a solid-state 13C NMR study. Bouchard M, et al. **Biochim Biophys Acta** 1998 Dec 9;1415(1):181–92

NMR structure of C-terminally tagged gramicidin channels. Separovic F, et al. **Biochim Biophys Acta** 1999 Jan 12; 1416(1–2):48–56

Heterodimer formation and crystal nucleation of gramicidin D. Burkhart BM, et al. **Biophys J** 1998 Nov;75(5):2135–46

Noncontact dipole effects on channel permeation. I. Experiments with (5F-indole)Trp13 gramicidin A channels. Busath DD, et al. **Biophys J** 1998 Dec; 75(6):2830–44

Simulation study of a gramicidin/lipid bilayer system in excess water and lipid. I. Structure of the molecular complex. Chiu SW, et al. **Biophys J** 1999 Apr;76(4):1929–38

Simulation study of a gramicidin/lipid bilayer system in excess water and lipid. II. Rates and mechanisms of water transport. Chiu SW, et al. **Biophys J** 1999 Apr; 76(4):1939–50

Noncontact dipole effects on channel permeation. II. Trp conformations and dipole potentials in gramicidin A. Dorigo AE, et al. **Biophys J** 1999 Apr;76(4):1897–908

Electron-spin resonance study of aggregation of gramicidin in dipalmitoylphosphatidylcholine bilayers and hydrophobic mismatch. Ge M, et al. **Biophys J** 1999 Jan; 76(1 Pt 1):264–80

Experimental evidence for hydrophobic matching and membrane-mediated interactions in lipid bilayers containing gramicidin. Harroun TA, et al. **Biophys J** 1999 Feb;76(2):937–45

Theoretical analysis of hydrophobic matching and membrane-mediated interactions in lipid bilayers containing gramicidin. Harroun TA, et al. **Biophys J** 1999 Jun;76(6):3176–85

A lattice relaxation algorithm for three-dimensional Poisson-Nernst-Planck theory with application to ion transport through the gramicidin A channel. Kurnikova MG, et al. **Biophys J** 1999 Feb;76(2):642–56

Attenuation of proton currents by methanol in a dioxolane-linked gramicidin A channel in different lipid bilayers. Quigley EP, et al. **Biophys J** 1998 Dec; 75(6):2811–20

13C solid-state NMR of gramicidin A in a lipid membrane. Quist PO. **Biophys J** 1998 Nov;75(5):2478–88

Membrane surface-charge titration probed by gramicidin A channel conductance. Rostovtseva TK, et al. **Biophys J** 1998 Oct;75(4):1783–92

Distinctly different interactions of anesthetic and nonimmobilizer with transmembrane channel peptides. Tang P, et al. **Biophys J** 1999 Aug;77(2):739–46

Structural consequences of anesthetic and nonimmobilizer interaction with gramicidin A channels. Tang P, et al. **Biophys J** 1999 May;76(5):2346–50

The effects of gramicidin on electroporation of lipid bilayers. Troiano GC, et al. **Biophys J** 1999 Jun;76(6):3150–7

Polarization-modulated FTIR spectroscopy of lipid/gramicidin monolayers at the air/water interface. Ulrich WP, et al. **Biophys J** 1999 Mar;76(3):1639–47

Gramicidin D conformation, dynamics and membrane ion transport. Burkhart BM, et al. **Biopolymers** 1999; 51(2):129–44

Polymer water-soluble derivatives of polypeptide antibiotic, gramicidin-S based on reactive copolymers of N-(2-hydroxypropyl) methacrylamide. Solovskij M, et al. **J Controlled Release** 1999 Mar 8;58(1):1–8

Orientational constraints derived from hydrated powder samples by two-dimensional PISEMA. Tian F, et al. **J Magn Reson** 1998 Nov;135(1):227–31

Cation binding induced changes in 15N CSA in a membrane-bound polypeptide. Tian F, et al. **J Magn Reson** 1998 Dec;135(2):535–40

Cation transport: an example of structural based selectivity. Tian F, et al. **J Mol Biol** 1999 Feb 5;285(5):1993–2003

Convenient preparation of [Orn(Tfa)2]- and [Orn(Boc)2, Orn(Tfa)2]gramicidin S, versatile unsymmetrically protected derivatives of gramicidin S. Yamada K, et al. **J Pept Res** 1999 Aug;54(2):168–73

Preparation and properties of novel gramicidin S analogs possessing a tri-, tetra- or pentamethylene bridge between ornithine side chains. Yamada K, et al. **J Pept Res** 1999 Jun;53(6):611–7

Gramicidin channel controversy--the structure in a lipid environment. Andersen OS, et al. **Nat Struct Biol** 1999 Jul; 6(7):609; discussion 611–2

Gramicidin channel controversy--revisited [comment] Cross TA, et al. **Nat Struct Biol** 1999 Jul;6(7):610–1; discussion 611–2. Comment on: Nat Struct Biol 1998 Sep;5(9):749–50.

The Poisson-Nernst-Planck model. **Novartis Found Symp** 1999;225:146–52 (18 ref.)

The gramicidin-based biosensor: a functioning nano-machine. Cornell BA, et al. **Novartis Found Symp** 1999;225:231–49; discussion 249–54 (16 ref.)

Correlations of structure, dynamics and function in the gramicidin channel by solid-state NMR spectroscopy. Cross TA, et al. **Novartis Found Symp** 1999;225:4–16; discussion 16–22 (33 ref.)

Ionic interactions in multiply occupied channels. Dorman VL, et al. **Novartis Found Symp** 1999;225:153–67; discussion 167–9 (33 ref.)

Lorentzian noise in single gramicidin A channel formamidinium currents. Fairbanks TG, et al. **Novartis Found Symp** 1999;225:74–87; discussion 87–92

Can we use rate constants and state models to describe ion transport through gramicidin channels? Hladky SB. **Novartis Found Symp** 1999;225:93–107; discussion 107–12 (38 ref.)

Peptide-lipid interactions and mechanisms of antimicrobial peptides. Huang HW. **Novartis Found Symp** 1999; 225:188–200; discussion 200–6 (32 ref.)

Peptide influences on lipids. Killian JA, et al. **Novartis Found Symp** 1999;225:170–83; discussion 183–7

Design and characterization of gramicidin channels with side chain or backbone mutations. Koeppe RE 2nd, et al. **Novartis Found Symp** 1999;225:44–55; discussion 55–61 (38 ref.)

The binding site of sodium in the gramicidin A channel. Roux B, et al. **Novartis Found Symp** 1999;225:113–24; discussion 124–7 (35 ref.)

Introduction: gramicidin, a model ion channel. Wallace BA. **Novartis Found Symp** 1999;225:1–3

X-ray crystallographic structures of gramicidin and their relation to the Streptomyces lividans potassium channel structure. Wallace BA. **Novartis Found Symp** 1999; 225:23–32; discussion 33–7 (31 ref.)

Summary: what we have learned about gramicidin and other ion channels. Wallace BA. **Novartis Found Symp** 1999; 225:260–2

The conducting form of gramicidin A is a right-handed double-stranded double helix. Burkhart BM, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12950–5

Validation of the single-stranded channel conformation of gramicidin A by solid-state NMR. Kovacs F, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7910–5

Water: foldase activity in catalyzing polypeptide conformational rearrangements. Xu F, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9057–61

METABOLISM

Real-time fluorimetric analysis of gramicidin D- and alamethicin-induced K+ efflux from Sf9 and Cf1 insect cells. Guihard G, et al. **Biochemistry** 1999 May 11; 38(19):6164–70

Environment- and sequence-dependent modulation of the double-stranded to single-stranded conformational transition of gramicidin A in membranes. Salom D, et al. **Biochemistry** 1998 Oct 6;37(40):14279–91

Polylysine decelerates kinetics of negatively charged gramicidin channels as shown by sensitized photoinactivation. Krylov AV, et al. **FEBS Lett** 1998 Nov 27;440(1–2):235–8

The effects of ion binding. **Novartis Found Symp** 1999; 225:38–43

PHARMACOLOGY

Differential scanning calorimetric study of the effect of the antimicrobial peptide gramicidin S on the thermotropic phase behavior of phosphatidylcholine, phosphatidylethanolamine and phosphatidylglycerol lipid bilayer membranes. Prenner EJ, et al. **Biochim Biophys Acta** 1999 Mar 4;1417(2):211–23

Effect of gramicidin A on the dipole potential of phospholipid membranes. Shapovalov VL, et al. **Biophys J** 1999 Jul;77(1):299–305

Ion channels as tools to monitor lipid bilayer-membrane protein interactions: gramicidin channels as molecular force transducers. Andersen OS, et al. **Methods Enzymol** 1999; 294:208–24

GRAMINEAE see **GRASSES**

GRAMPUS see **DOLPHINS**

GRANA see **CHLOROPLASTS**

GRANISETRON

ADMINISTRATION & DOSAGE

Prophylactic antiemetic therapy with granisetron-dexamethasone combination in women undergoing breast surgery [see comments] Fujii Y, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1038–42. Comment in: Acta Anaesthesiol Scand 1999 Apr;43(4):486–7.

Stability of granisetron hydrochloride in two oral suspensions. Nahata MC, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2511–3

A granisetron-droperidol combination prevents postoperative vomiting in children. Fujii Y, et al. **Anesth Analg** 1998 Oct;87(4):761–5

Prophylactic oral antiemetics for preventing postoperative nausea and vomiting: granisetron versus domperidone. Fujii Y, et al. **Anesth Analg** 1998 Dec;87(6):1404–7

A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group. **Anticancer Drugs** 1999 Jun;10(5):465–70

A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin. Birch R, et al. **Bone Marrow Transplant** 1998 Oct;22(7):685–8

Oral granisetron prevents postoperative vomiting in children. Fujii Y, et al. **Br J Anaesth** 1998 Sep;81(3):390–2

A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs. Keihanshin Study Group of Hematological Malignancies. Tatsumi N, et al. **Cancer Chemother Pharmacol** 1999;43(5):379–84

Prophylactic therapy with combined granisetron and dexamethasone for the prevention of post-operative vomiting in children. Fujii Y, et al. **Eur J Anaesthesiol** 1999 Jun;16(6):376–9

GRANISETRON

Granisetron reduces post-operative vomiting in children: a dose-ranging study. Fujii Y, et al. **Eur J Anaesthesiol** 1999 Jan;16(1):62-5

Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies. Lehoczky O. **Eur J Gynaecol Oncol** 1998;19(5):449-52

Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy. Markman M, et al. **Gynecol Oncol** 1998 Oct;71(1):113-5

Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Zeidman A, et al. **Haematologia (Budap)** 1998;29(1):25-31

Combination of granisetron and droperidol in the prevention of nausea and vomiting after middle ear surgery. Fujii Y, et al. **J Clin Anesth** 1999 Mar;11(2):108-12

About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. Lehoczky O. **Neoplasma** 1999;46(2):73-9 (50 ref.)

[Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron] Ikeda H, et al. **Gan To Kagaku Ryoho** 1998 Oct; 25(12):1947-53 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Simultaneous measurement of blood and brain microdialysates of granisetron in rat by high-performance liquid chromatography with fluorescence detection. Huang CT, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1-2):251-5

METABOLISM

Comparative study of [3H]ramosetron and [3H]granisetron binding in the cloned human 5-hydroxytryptamine3 receptors. Akuzawa S, et al. **Jpn J Pharmacol** 1998 Nov; 78(3):381-4

PHARMACOKINETICS

Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Corrigan BW, et al. **Drug Metab Dispos** 1999 Jan;27(1):110-2

Pharmacokinetics of granisetron in rat blood and brain by microdialysis. Huang CT, et al. **Life Sci** 1999; 64(21):1921-31

PHARMACOLOGY

Serotoninergic modulation of cell volume response to estramustine: an image-analysis study on perifused individual glioma cells. Behnam-Motlagh P, et al. **Eur J Cancer** 1999 Jan;35(1):145-53

Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Fukunaka N, et al. **Gen Pharmacol** 1998 Nov; 31(5):775-81

5-HT3 receptor-channels coupled with Na+ influx in human T cells: role in T cell activation. Khan NA, et al. **J Neuroimmunol** 1999 Sep 1;99(1):53-60

5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats. Smith MI, et al. **Neurosci Lett** 1999 Aug 13;271(1):61-4

Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets. Endo T, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jun;100(3):243-53

THERAPEUTIC USE

Prevention of nausea and vomiting with granisetron, droperidol and metoclopramide during and after spinal anaesthesia for caesarean section: a randomized, double-blind, placebo-controlled trial. Fujii Y, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):921-5

Preoperative oral antiemetics for reducing postoperative vomiting after tonsillectomy in children: granisetron versus perphenazine. Fujii Y, et al. **Anesth Analg** 1999 Jun; 88(6):1298-301

Granisetron/dexamethasone combination for reducing nausea and vomiting during and after spinal anesthesia for cesarean section. Fujii Y, et al. **Anesth Analg** 1999 Jun;88(6):1346-50

Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery. Fujii Y, et al. **Anesth Analg** 1999 Aug;89(2):476-9

Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Abbott B, et al. **Bone Marrow Transplant** 1999 Feb;23(3):265-9

Granisetron-droperidol combination for the prevention of postoperative nausea and vomiting in female patients undergoing breast surgery. Fujii Y, et al. **Br J Anaesth** 1998 Sep;81(3):387-9

Prophylactic antiemetic therapy with a combination of granisetron and dexamethasone in patients undergoing middle ear surgery. Fujii Y, et al. **Br J Anaesth** 1998 Nov; 81(5):754-6

Prophylactic antiemetic therapy with granisetron in women undergoing thyroidectomy [see comments] Fujii Y, et al. **Br J Anaesth** 1998 Oct;81(4):526-8. Comment in: Br J Anaesth 1999 Mar;82(3):481-3.

Methodological problems arising from 'serial publishing' on the effectiveness of granisetron in PONV [letter; comment] Kranke P, et al. **Br J Anaesth** 1999 Mar;82(3):481-3. Comment on: Br J Anaesth 1998 Oct;81(4):526-8.

Oral granisetron for strabismus surgery in children. Munro HM, et al. **Can J Anaesth** 1999 Jan;46(1):45-8

Anti-emetic efficacy of prophylactic granisetron compared with perphenazine for the prevention of post-operative vomiting in children. Fujii Y, et al. **Eur J Anaesthesiol** 1999 May;16(5):304-7

Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Tsuchida Y, et al. **Int J Oncol** 1999 Apr;14(4):673-9

Antiemetic efficacy of granisetron: a randomized crossover study in patients receiving cisplatin-containing intraarterial chemotherapy. Uchida K, et al. **Jpn J Clin Oncol** 1999 Feb;29(2):87-91

Granisetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting after thyroidectomy. Fujii Y, et al. **Laryngoscope** 1999 Apr;109(4):664-7

Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. Bauduer F, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):341-7

Oral granisetron as prophylaxis for nausea and vomiting during fluorescein angiography. A multicentre, double-blind, randomised, parallel group, placebo-controlled study. Mattioli V, et al. **Minerva Anestesiol** 1998 Dec;64(12):553-61

Preoperative oral granisetron for the prevention of vomiting after strabismus surgery in children. Fujii Y, et al. **Ophthalmology** 1999 Sep;106(9):1713-5

Combination of granisetron and droperidol for the prevention of vomiting after paediatric strabismus surgery. Fujii Y, et al. **Paediatr Anaesth** 1999;9(4):329-33

Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets. Endo T, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):227-39

Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil). Devlin J, et al. **Rheumatology (Oxford)** 1999 Mar;38(3):280-2

[Efficacy of granisetron as anti-emetic agent for emesis induced by intra-arterial injection therapy for hepatocellular carcinoma] Ichida T, et al. **Gan To Kagaku Ryoho** 1998 Oct;25(12):1939-46 (Eng. Abstr.) **(Jpn)**

[Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia--a randomized comparative trial between granisetron alone and granisetron plus methylprednisolone] Ono K, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):821-8 (Eng. Abstr.) **(Jpn)**

[Clinical evaluation of granisetron (BRL43694) in nausea and vomiting induced by anticancer drugs--pediatrics] Sawada T, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1295-304 (Eng. Abstr.) **(Jpn)**

[Efficacy of granisetron in the prevention of emesis induced by conditioning chemotherapy for allogeneic bone marrow transplantation] Takeyama H, et al. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2095-9 (Eng. Abstr.) **(Jpn)**

GRANTS AND SUBSIDIES, EDUCATIONAL see **TRAINING SUPPORT**

GRANTS AND SUBSIDIES, GOVERNMENT see **FINANCING, GOVERNMENT**

GRANTS AND SUBSIDIES, HEALTH PLANNING see **HEALTH PLANNING SUPPORT**

GRANTS AND SUBSIDIES, RESEARCH see **RESEARCH SUPPORT**

GRANTS, PEER REVIEW see **PEER REVIEW, RESEARCH**

GRANULAR CELL MYOBLASTOMA see **GRANULAR CELL TUMOR**

GRANULAR CELL TUMOR

Granular cell tumor of the duodenum: a case report. Onoda N, et al. **Am J Gastroenterol** 1998 Oct;93(10):1993-4 (10 ref.)

Granular cell tumor of the extrahepatic biliary tract. Butler JD Jr, et al. **Am Surg** 1998 Nov;64(11):1033-6 (24 ref.)

[Granular cell tumor of the male breast. A case report] Calò PG, et al. **Minerva Chir** 1998 Dec;53(12):1043-6 (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Granular cell tumor with cirrhosis and transplantation. Fairchild RB, et al. **Transplantation** 1999 Jul 27;68(2):315-7

[Granular cell tumor: an infrequent cause of dysphonia in childhood] Lassaletta Atienza L, et al. **Acta Otorrinolaringol Esp** 1999 Jan-Feb;50(1):64-7 (Eng. Abstr.) **(Spa)**

CONGENITAL

Congenital granular-cell tumor of the gingiva. Tokar B, et al. **Pediatr Surg Int** 1998 Oct;13(8):594-6

DIAGNOSIS

Unique presentation of a granular cell tumor as a paratracheal mass. Gorman RC, et al. **Oncol Rep** 1998 Nov-Dec; 5(6):1551-4

Granular cell tumor of the trachea. Desai DP, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):595-8 (11 ref.)

Granular cell tumor of the subcutis: CT and MRI findings. A report of three cases. Kudawara I, et al. **Skeletal Radiol** 1999 Feb;28(2):96-9

[A case for diagnosis. Abrikossoff tumor] Kourda M, et al. **Ann Dermatol Venereol** 1999 May;126(5):441-2 **(Fre)**

EPIDEMIOLOGY

[Granular cell tumor. Epidemiology of 263 cases] Billeret Lebranchu V. **Arch Anat Cytol Pathol** 1999;47(1):26-30 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunoreactivity in granular cell tumours of the larynx. Lassaletta L, et al. **Auris Nasus Larynx** 1999 Jul; 26(3):305-10

METABOLISM

Congenital CD34-positive granular cell dendrocytosis. Chang SE, et al. **J Cutan Pathol** 1999 May;26(5):253-8

PATHOLOGY

Features of benign granular cell tumor on fine needle aspiration. Liu K, et al. **Acta Cytol** 1999 Jul-Aug; 43(4):552-7

Granular cell tumor: a review and update. Ordóñez NG. **Adv Anat Pathol** 1999 Jul;6(4):186-203 (208 ref.)

Pituitary adenomas and granular cell tumors. Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Tomita T, et al. **Am J Clin Pathol** 1999 Jun; 111(6):817-25

Granular cell tumor of the parotid. Said-Al-Naief N, et al. **Ann Diagn Pathol** 1999 Feb;3(1):35-8 (15 ref.)

Granular cell tumor of the pituitary stalk. Nishio S, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):144-7

Multiple cutaneous granular cell tumors of the scrotum. Altman CE, et al. **Cutis** 1999 Feb;63(2):77-80

Granular cell tumor of the toe. Peters JS, et al. **Cutis** 1998 Sep;62(3):147-8

Granular-cell tumor of the esophagus: report of a case with a cytologic diagnosis based on esophageal brushing. Córdoba A, et al. **Diagn Cytopathol** 1998 Dec;19(6):455-7

Granular cell tumor of the breast: report of a case. Kohashi T, et al. **Hiroshima J Med Sci** 1999 Mar;48(1):31-3

Atypical fibroxanthoma with granular cells [letter; comment] Orosz Z. **Histopathology** 1998 Jul;33(1):88-9. Comment on: Histopathology 1997 May;30(5):495-7. Comment on: Histopathology 1997 Nov;31(5):481-2.

An S100 negative granular cell tumor with malignant potential: report of a case. Schoedel KE, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):894-8

Granular cell foci of the uterus in Donryu rats. Sasahara K, et al. **J Comp Pathol** 1998 Aug;119(2):195-9

Multiple granular cell tumors and growth hormone deficiency in a child. Seiter S, et al. **Pediatr Dermatol** 1999 Jul-Aug;16(4):308-10

Eosinophilic and granular cell tumors of the breast. Damiani S, et al. **Semin Diagn Pathol** 1999 May;16(2):117-25 (49 ref.)

Oncocytic and granular cell neoplasms of the central nervous system and pituitary gland. Giangaspero F, et al. **Semin Diagn Pathol** 1999 May;16(2):91-7 (31 ref.)

Benign granular cell tumor of the breast: a misleading disease. Ventura L, et al. **Tumori** 1999 May-Jun;85(3):194-8

Malignant granular cell tumor at the retrotracheal space. Yang SW, et al. **Yonsei Med J** 1999 Feb;40(1):76-9

[Malignant granular cell tumors. Report of a case of anal localization (letter)] Bouraoui S, et al. **Ann Pathol** 1999 Apr;19(2):151-2 **(Fre)**

[Granular cell tumors of the skin of nonneural origin: report of 8 cases] Lacroix-Triki M, et al. **Ann Pathol** 1999 Apr; 19(2):94-8 (Eng. Abstr.) **(Fre)**

[Granular cell tumor and congenital epulis. Histochemical and immunohistochemical of 58 cases] Billeret-Lebranchu V, et al. **Arch Anat Cytol Pathol** 1999;47(1):31-7 (Eng. Abstr.) **(Fre)**

[Multiple granular cell tumor: case report and review of the literature] Nati S, et al. **Pathologica** 1998 Dec;90(6):798-800 (14 ref.) (Eng. Abstr.) **(Ita)**

[Abrikosoff's tumor of the soft palate. A case report] Bernat Gili A, et al. **An Otorrinolaringol Ibero Am** 1999;26(1):47-53 (Eng. Abstr.) **(Spa)**

[Granular cell tumor of the scrotum with high pseudoepithelioma tous hyperplasia] Medina Pérez M, et al. **Arch Esp Urol** 1999 Mar;52(2):169-70 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Calcified hypophyseal space-occupying tumor] Schaller B,

et al. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1265 **(Ger)**

SECONDARY

Malignant granular cell tumor: report of a case and review of the literature. Sonobe H, et al. **Pathol Res Pract** 1998; 194(7):507–13; discussion 515–6 (50 ref.)

SURGERY

Multiple granular cell tumors of the esophagus removed endoscopically: a case report. Esaki M, et al. **Gastrointest Endosc** 1998 Nov;48(5):536–9 (22 ref.)

Granular cell tumour of the ulnar nerve. Yasutomi T, et al. **J Hand Surg [Br]** 1999 Feb;24(1):122–4

Congenital granular-cell tumor of the gingiva. Tokar B, et al. **Pediatr Surg Int** 1998 Oct;13(8):594–6

[Thoracoscopic excision of an uncertain intramural esophagus tumor (granular cell tumor/Abrikossoff tumor)] Koch M, et al. **Chirurg** 1998 Sep;69(9):981–4 (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Granular cell tumor: a review of the pathology and histogenesis. Ordóñez NG, et al. **Ultrastruct Pathol** 1999 Jul–Aug;23(4):207–22 (154 ref.)

GRANULAR DYSTROPHY, CORNEAL see **CORNEAL DYSTROPHIES, HEREDITARY**

GRANULATION TISSUE

Conservative treatment of vaginal vault granulation tissue following total abdominal hysterectomy. Saropala N, et al. **Int J Gynaecol Obstet** 1998 Jul;62(1):55–8

BLOOD SUPPLY

Exogenous non-crosslinked collagen enhances granulation tissue formation in dermal excision wounds in guinea pigs. Redlich M, et al. **Matrix Biol** 1998 Dec;17(8–9):667–71

CHEMISTRY

A 16-kDa fragment of collagen type XIV is a novel neutrophil chemotactic factor purified from rat granulation tissue. Nakagawa H, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):642–5

Matrix metalloproteinase-1 in cholesteatoma, middle ear granulations and deep meatal skin: a comparative analysis. Banerjee AR, et al. **Clin Otolaryngol** 1998 Dec;23(6):515–9

CYTOLOGY

Vanadate and the absence of myofibroblasts in wound contraction. Ehrlich HP, et al. **Arch Surg** 1999 May; 134(5):494–501

The origin and mode of fibroblast migration and proliferation in granulation tissue. Spyrou GE, et al. **Br J Plast Surg** 1998 Sep;51(6):455–61

DRUG EFFECTS

Studies on the endothelin-1-induced contraction of rat granulation tissue pouch mediated by myofibroblasts. Goto T, et al. **Biochim Biophys Acta** 1998 Oct 21;1405(1–3):55–66

Evaluation of shikonin on granulation tissue formation compared with carrageenan. Sekine T, et al. **Biol Pharm Bull** 1998 Sep;21(9):950–2

Topical diflorasone ointment for treatment of recalcitrant, excessive granulation tissue. Mandrea E. **Dermatol Surg** 1998 Dec;24(12):1409–10

Effects of cimetidine and pentagastrin on surgical repair of gastric mucosa. Giovanoni M, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):574–83

Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Teixeira AS, et al. **Life Sci** 1999;64(8):655–62

Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Iocono JA, et al. **Wound Repair Regen** 1998 Sep–Oct;6(5):442–8

METABOLISM

Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Slight SH, et al. **Mol Cell Biochem** 1998 Dec;189(1–2):47–54

PATHOLOGY

Relative proportions of mononuclear cell types in periodontal lesions analyzed by immunohistochemistry. Lappin DF, et al. **J Clin Periodontol** 1999 Mar;26(3):183–9

Dupuytren's disease. The way forward? Fitzgerald AM, et al. **J Hand Surg [Br]** 1999 Aug;24(4):395–9 (56 ref.)

Cranio-caudal differences in granulation tissue formation: an experimental study in the rat. Märtson M, et al. **Wound Repair Regen** 1999 Mar–Apr;7(2):119–26

PHYSIOLOGY

Studies on the endothelin-1-induced contraction of rat granulation tissue pouch mediated by myofibroblasts. Goto T, et al. **Biochim Biophys Acta** 1998 Oct 21;1405(1–3):55–66

Release of mechanical tension triggers apoptosis of human fibroblasts in a model of regressing granulation tissue. Grinnell F, et al. **Exp Cell Res** 1999 May 1;248(2):608–19

Exogenous non-crosslinked collagen enhances granulation tissue formation in dermal excision wounds in guinea pigs. Redlich M, et al. **Matrix Biol** 1998 Dec;17(8–9):667–71

Cranio-caudal differences in granulation tissue formation: an experimental study in the rat. Märtson M, et al. **Wound Repair Regen** 1999 Mar–Apr;7(2):119–26

Subcutaneous tissue fibroblasts transfected with muscle and nonmuscle actins: A good in vitro model to study fibroblastic cell plasticity. Mounier N, et al. **Wound Repair Regen** 1999 Jan–Feb;7(1):45–52

SURGERY

Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Reinecke H, et al. **Circulation** 1999 Jul 13;100(2):193–202

Effective treatment of acne fulminans-associated granulation tissue with the pulsed dye laser. Friedlander SF. **Pediatr Dermatol** 1998 Sep–Oct;15(5):396–8

[Removal of a cochlea implant with chronic granulation labyrinthitis and foreign body reaction] Bertuleit H, et al. **Laryngorhinootologie** 1999 Jun;78(6):304–6 (Eng. Abstr.) **(Ger)**

GRANULOCYTE COLONY-STIMULATING FACTOR

see related
RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR

Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer. Krüger W, et al. **Med Oncol** 1999 Apr;16(1):17–22

ADMINISTRATION & DOSAGE

In vivo administration of granulocyte colony-stimulating factor increases the surface expression of sialyl-Lewis(x) on neutrophils in healthy volunteers. Ohsaka A, et al. **Acta Haematol** 1998;100(4):187–90

Aplastic anemia in pregnancy: treatment with cyclosporine and granulocyte-colony stimulating factor. Ohba T, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):458–61

Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Bertolini F, et al. **Ann Oncol** 1998 Aug;9(8):913–6

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Frasci G, et al. **Ann Oncol** 1999 Mar;10(3):355–8

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Vogelzang NJ, et al. **Ann Oncol** 1999 May;10(5):597–600

The in vivo and in vitro effects of rhG-CSF on allergic, haematological and biochemical variables. Kristensen KS, et al. **APMIS** 1998 Nov;106(11):1108–12

An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Volk EE, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):508–13 (62 ref.)

Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Jansen JH, et al. **Blood** 1999 Jul 1;94(1):39–45

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT [see comments] Kawano Y, et al. **Blood** 1998 Dec 1;92(11):4040–6. Comment in: Blood 1999 May 15;93(10):3565–6.

Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Ciernik IF, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):147–51

Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Couban S, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1199–205

Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Karthaus M, et al. **Bone Marrow Transplant** 1998 Oct;22(8):781–5

Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Lee KH, et al. **Bone Marrow Transplant** 1999 Sep;24(6):591–9

Delayed G-CSF after autologous bone marrow transplantation [letter; comment] Maiolino A, et al. **Bone Marrow Transplant** 1998 Oct;22(8):832. Comment on: Bone Marrow Transplant 1998 Feb;21(4):369–73.

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Martinez C, et al. **Bone Marrow Transplant** 1999 Jan;23(1):15–9

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Siegert W, et al. **Bone Marrow Transplant** 1998 Sep;22(6):579–83

Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Stewart DA, et al. **Bone Marrow Transplant** 1999 Jan; 23(2):111–7

Administration of G-CSF to normal individuals diminishes L-selectin+ T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin- T cells. Sugimori N, et al. **Bone Marrow Transplant** 1999 Jan; 23(2):119–24

Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Sato S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):68–71

Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Bai A, et al. **Exp Hematol** 1999 Feb;27(2):259–65

Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Ostergaard C, et al. **Infect Immun** 1999 Jul;67(7):3430–6

Effect of recombinant human granulocyte colony stimulating factor (lenograstim) on chemotherapy induced neutropenia in patients with urothelial cancer. Kotake T, et al. **Int J Urol** 1999 Feb;6(2):61–7

Concurrent G-CSF and chemotherapy [letter; comment] Livingston RB. **J Clin Oncol** 1998 Dec;16(12):3917. Comment on: J Clin Oncol 1998 Aug;16(8):2708–14.

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. Shapiro CL, et al. **J Clin Oncol** 1999 May;17(5):1435–41

Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. Toner GC, et al. **J Clin Oncol** 1998 Dec;16(12):3874–9

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. Gazitt Y, et al. **J Hematother** 1999 Apr;8(2):173–83

Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. Gaviria JM, et al. **J Infect Dis** 1999 May;179(5):1301–4

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. D'Hondt L, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):105–9

Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Höglund M. **Med Oncol** 1998 Dec; 15(4):229–33 (48 ref.)

Effect of subcutaneous granulocyte colony-stimulating factor injectate volume on drug efficacy, site complications, and client comfort. Comley AL, et al. **Oncol Nurs Forum** 1999 Jan–Feb;26(1):87–94

Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Koumakis G, et al. **Oncology** 1999;56(1):28–35

Effect of high-dose methylprednisolone and G-CSF treatments on lymphocyte subtypes in neutropenic children with acute lymphoblastic leukemia: a pilot study. Ozbek N, et al. **Pediatr Hematol Oncol** 1998 Nov–Dec; 15(6):539–44

Mobilization of peripheral blood progenitor cells using 16 versus 10 mg/kg/d G-CSF in children with malignancies. Kurekci AE, et al. **Pediatr Transplant** 1998 May;2(2):160–4

Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colony-stimulating factor therapy. Engles-Horton LL, et al. **Pharmacotherapy** 1999 Mar;19(3):356–62

Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Lane TA, et al. **Transfusion** 1999 Jan;39(1):39–47

The timing of granulocyte-colony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Lefrère F, et al. **Transfusion** 1999 Jun;39(6):561–4

Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer. Riccardi A, et al. **Tumori** 1998 Sep–Oct;84(5):540–6

[Growth factors in oncology: effectiveness and prospects] Ottmann OG, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1153–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Quality of life and cytokines in oncological therapy] Leitgeb C. **Wien Med Wochenschr** 1998;148(18):424–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation] Katagiri T, et al. **Rinsho Ketsueki** 1998 Dec;39(12):1149–56 (Eng. Abstr.) **(Jpn)**

[A trial for peripheral blood stem cell harvest by combination of G-CSF with ABVD regimen in the management of Hodgkin's disease] Suzuki A, et al. **Rinsho Ketsueki** 1999 Jan;40(1):16–21 (Eng. Abstr.) **(Jpn)**

GRANULOCYTE COLONY-STIMULATING FACTOR

ADVERSE EFFECTS

The effect of growth factor therapy on blast percentages [letter; comment] Cummings GH, et al. **Am J Clin Pathol** 1999 May;111(5):711-2. Comment on: Am J Clin Pathol 1998 Jun;109(6):675-81.

Leukocytoclastic vasculitis as a complication of granulocyte colony-stimulating factor (G-CSF) -- a case study. Andavolu MV, et al. **Ann Hematol** 1999 Feb;78(2):79-81

Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Kasper C, et al. **Ann Hematol** 1999 Feb;78(2):91-2

Blood stem cell procurement: donor safety issues. Anderlini P, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S35-9 (62 ref.)

Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell [letter] Keung YK, et al. **Bone Marrow Transplant** 1999 Jan;23(2):200-1

Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor [letter] Bachmeyer C, et al. **Br J Dermatol** 1998 Aug;139(2):354-5

Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Kaito K, et al. **Br J Haematol** 1998 Nov; 103(2):297-303

Apparent reactivation of a red cell alloantibody in a healthy individual after G-CSF administration. Norol F, et al. **Br J Haematol** 1998 Oct;103(1):256-8

A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Bitran JD, et al. **Clin Cancer Res** 1995 Feb;1(2):185-8

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Goldberg RM, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2363-70

An acute inflammatory response to the use of granulocyte colony-stimulating factor to prevent infections in patients with brain injury: what about the brain? [comment] [see comments] Whalen MJ, et al. **Crit Care Med** 1999 May; 27(5):1014-8 (43 ref.). Comment on: Crit Care Med 1998 Apr;26(4):748-54. Comment in: Crit Care Med 1999 May;27(5):1019-21.

Sweet's syndrome associated with granulocyte colony-stimulating factor. Hasegawa M, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):503-5

Linear IgA bullous dermatosis in a patient with acute lymphocytic leukemia: possible involvement of granulocyte colony-stimulating factor. Kano Y, et al. **Eur J Dermatol** 1999 Mar;9(2):122-5

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Einzig AI, et al. **Invest New Drugs** 1998; 16(1):29-36

Histopathology of cutaneous reaction to granulocyte colony-stimulating factor: another pseudomalignancy. Fariña MC, et al. **J Cutan Pathol** 1998 Nov;25(10):559-62

Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor [letter] Falzetti F, et al. **Lancet** 1999 Feb 13;353(9152):555

Case 23-1998: fat embolism [letter; comment] Bilgrami S, et al. **N Engl J Med** 1999 Feb 4;340(5):393-4. Comment on: N Engl J Med 1998 Jul 23;339(4):254-61.

Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization. Kobbe G, et al. **Oncol Rep** 1999 Sep-Oct;6(5):1151-2

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Couderc LJ, et al. **Respir Med** 1999 Jan;93(1):65-8 (16 ref.)

Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Froberg MK, et al. **Transfusion** 1999 Apr;39(4):410-4

Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor [letter] Vij R, et al. **Transfusion** 1999 May;39(5):542-3

[Sweet syndrome following therapeutic use of granulocyte colony stimulating factor] Veres K, et al. **Orv Hetil** 1999 May 9;140(19):1059-61 (Eng. Abstr.) **(Hun)**

[Hematopoietic growth factors and anaphylaxis (letter)] Balaguer AA, et al. **Med Clin (Barc)** 1999 May 1; 112(15):598 **(Spa)**

ANALYSIS

The immunohistochemical localization of the interferon-gamma and granulocyte colony-stimulating factor receptors during early amelogenesis in rat molars. Otsuji W, et al. **Arch Oral Biol** 1999 Feb;44(2):173-81

[A case of thymic carcinoma producing granulocyte colony-stimulating factor] Tada Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Dec;36(12):1043-7 (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Suppression of the granulocyte colony-stimulating factor response to Escherichia coli challenge by alcohol intoxication. Bagby GJ, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1740-5

BIOSYNTHESIS

IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis. Kennedy SM, et al. **Exp Hematol** 1999 Feb; 27(2):210-6

Apoptosis-mediated regulation of recombinant human granulocyte colony-stimulating factor production by genetically engineered fibroblasts. Kokubun M, et al. **Gene Ther** 1998 Jul;5(7):923-9

A mesenteric liposarcoma with production of granulocyte colony-stimulating factor. Nakamura A, et al. **Intern Med** 1998 Oct;37(10):884-90 (37 ref.)

Expansion of extrathymic T cells as well as granulocytes in the liver and other organs of granulocyte-colony stimulating factor transgenic mice: why they lost the ability of hybrid resistance. Kawamura H, et al. **J Immunol** 1999 May 15;162(10):5957-64

Expression of granulocyte colony-stimulating factor in recurrent glial tumors is inversely correlated with tumor progression. Stan AC, et al. **J Neuroimmunol** 1999 Feb 1; 94(1-2):66-73

Identification of the granulocyte colony-stimulating factor (G-CSF) producing cell population in human decidua and its biological action on trophoblast cell. Miyama M, et al. **Osaka City Med J** 1998 Jun;44(1):85-96

Differential effects of glucocorticoids on colony stimulating factors produced by neonatal mononuclear cells. Witek-Janusek L, et al. **Pediatr Res** 1999 Feb;45(2):224-9

[Two cases of bladder tumor producing granulocyte colony stimulating factor] Ito S, et al. **Hinyokika Kiyo** 1999 Jan; 45(1):57-60 (10 ref.) (Eng. Abstr.) **(Jpn)**

[CSF-producing tumor] Kitagawa S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):25-7 (7 ref.) **(Jpn)**

[Granulocyte colony-stimulating factor production in patients with chronic myelosis] Lisovskii MIa, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):94-7 **(Rus)**

BLOOD

Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Bux J, et al. **Br J Haematol** 1999 Jun;105(3):616-7

High serum levels of M-CSF and G-CSF in Kawasaki disease. Igarashi H, et al. **Br J Haematol** 1999 Jun; 105(3):613-5

Serum granulocyte colony-stimulating factor levels in patients with chronic neutropenia of childhood: modulation of G-CSF levels by myeloid precursor cell mass. Kobayashi M, et al. **Br J Haematol** 1999 May;105(2):486-90

A sandwich enzyme-linked immunoabsorbent assay for measurement of picogram quantities of murine granulocyte colony-stimulating factor. Granger J, et al. **J Immunol Methods** 1999 May 27;225(1-2):145-56

G-CSF, GM-CSF and IL-6 levels in cord blood: diminished increase of G-CSF and IL-6 in preterms with perinatal infection compared to term neonates. Weimann E, et al. **J Perinat Med** 1998;26(3):211-8

Increased circulating granulocyte colony-stimulating factor in acute Kawasaki disease. Inoue Y, et al. **Pediatr Int** 1999 Jun;41(3):330-3

Hematopoietic cytokine levels and in vitro colony formation assay in fetal anemia. Yamada H, et al. **Semin Thromb Hemost** 1998;24(5):485-90

CHEMISTRY

Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. Lu HS, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):1-11

Circular permutation of granulocyte colony-stimulating factor. Feng Y, et al. **Biochemistry** 1999 Apr 6; 38(14):4553-63

Purification and characterization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derivatives: KW-2228 and other derivatives. Yamasaki M, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1528-34

Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. Evidence that Glu19 of G-CSF interacts with Arg288 of the receptor. Layton JE, et al. **J Biol Chem** 1999 Jun 18;274(25):17445-51

DEFICIENCY

Functional deficiencies of peritoneal cells from gene-targeted mice lacking G-CSF or GM-CSF. Zhan Y, et al. **J Leukoc Biol** 1999 Feb;65(2):256-64

Granulocyte colony-stimulating factor deficiency in a rottweiler with chronic idiopathic neutropenia. Lanevschi A, et al. **J Vet Intern Med** 1999 Jan-Feb;13(1):72-5

DIAGNOSTIC USE

The "G-CSF test": the response to a single dose of granulocyte colony-stimulating factor predicts mobilization of hemopoietic progenitors in patients with hematologic malignancies. Mijovic A, et al. **Exp Hematol** 1999 Jul;27(7):1204-9

ECONOMICS

The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Le Corroller AG, et al. **Anticancer Drugs** 1998 Nov;9(10):917-24 (39 ref.)

The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Lyman GH, et al. **Eur J Cancer** 1998 Nov;34(12):1857-64

GENETICS

Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. Lu HS, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):1-11

Circular permutation of granulocyte colony-stimulating factor. Feng Y, et al. **Biochemistry** 1999 Apr 6; 38(14):4553-63

Enhanced secretion of human granulocyte colony-stimulating factor directed by a novel hybrid fusion peptide from recombinant Saccharomyces cerevisiae at high cell concentration. Bae CS, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):600-9

Stimulation of G-CSF gene expression in the macrophage cell line by contact with extracellular matrix proteins and a pre-B leukaemia cell line. Aoki Y, et al. **Cytokine** 1998 Aug;10(8):596-602

Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Berner R, et al. **Pediatr Res** 1998 Oct;44(4):469-77

Coexpression of G-CSF with an unglycosylated G-CSF receptor mutant results in secretion of a stable complex. Horan TP, et al. **Protein Expr Purif** 1998 Oct;14(1):45-53

IMMUNOLOGY

Counterregulatory control of the acute inflammatory response: granulocyte colony-stimulating factor has anti-inflammatory properties [comment] Heard SO, et al. **Crit Care Med** 1999 May;27(5):1019-21 (49 ref.). Comment on: Crit Care Med 1999 May;27(5):1014-8.

Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. Kobayashi S, et al. **Leuk Lymphoma** 1999 May;33(5-6):559-66

ISOLATION & PURIFICATION

Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. Pharmacokinetic and activity studies of single-dose administration in mice. Rotondaro L, et al. **Mol Biotechnol** 1999 Apr;11(2):117-28

METABOLISM

Functional differentiation signals mediated by distinct regions of the cytoplasmic domain of the granulocyte colony-stimulating factor receptor. Koay DC, et al. **Blood** 1999 Jun 1;93(11):3774-84

Circadian variation of granulocyte colony stimulating factor levels in man. Jilma B, et al. **Br J Haematol** 1999 Aug; 106(2):368-70

Esophageal small cell carcinoma with ectopic production of parathyroid hormone-related protein (PTHrp), secretin, and granulocyte colony-stimulating factor (G-CSF). Nagashima R, et al. **Dig Dis Sci** 1999 Jul;44(7):1312-6

Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Biethahn S, et al. **Exp Hematol** 1999 May;27(5):885-94

Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells. Querol S, et al. **Haematologica** 1999 Jun;84(6):493-8

Granulocyte colony-stimulating factor-producing primary pericardial mesothelioma. Horio H, et al. **Hum Pathol** 1999 Jun;30(6):718-20

Pancreatic cancer associated with granulocyte-colony stimulating factor production confirmed by immunohistochemistry. Ohtsubo K, et al. **J Clin Gastroenterol** 1998 Dec;27(4):357-60

Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease. Ina K, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):46-53

Soluble interleukin-6 receptor, interleukin-10 and granulocyte colony-stimulating factor in acute pyelonephritis: relationship to markers of bacterial virulence and renal function. Jacobson SH, et al. **Nephron** 1998 Dec;80(4):401-7

PHARMACOKINETICS

Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Terashi K, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):21-4

Stimulation of fetal granulopoiesis by intrauterine injection of recombinant human granulocyte colony- stimulating

factor into rat fetuses. Fukumasu Y, et al. **Biol Neonate** 1999;75(6):367–76

Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers. Houston AC, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):279–84

Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (lenograstim) administration. Hayashi N, et al. **J Clin Pharmacol** 1999 Jun;39(6):583–92

Pharmacokinetics and pharmacological effect of recombinant human granulocyte colony-stimulating factor conjugated to poly(styrene-co-maleic acid) in rats. Kunimasa JI, et al. **J Pharm Pharmacol** 1999 Jul;51(7):777–82

PHARMACOLOGY

In vivo administration of granulocyte colony-stimulating factor increases the surface expression of sialyl-Lewis(x) on neutrophils in healthy volunteers. Ohsaka A, et al. **Acta Haematol** 1998;100(4):187–90

Effects of granulocyte colony-stimulating factor on night sleep in humans. Schuld A, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 2):R1149–55

Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment. Meidlinger P, et al. **Ann Hematol** 1999 Jul;78(7):299–304

Impaired response of granulocyte-committed progenitor cells to stem cell factor and granulocyte colony-stimulating factor in human cyclic neutropenia. Takami A, et al. **Ann Hematol** 1999 Apr;78(4):197–9

The Src-like tyrosine kinase Hck is activated by granulocyte colony-stimulating factor (G-CSF) and docks to the activated G-CSF receptor. Ward AC, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):117–23

Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. Roecklein BA, et al. **Biol Blood Marrow Transplant** 1998;4(2):61–8

Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Franklin WA, et al. **Blood** 1999 Jul 1;94(1):340–7

In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro. Leavey PJ, et al. **Blood** 1998 Dec 1; 92(11):4366–74

Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Neipp M, et al. **Blood** 1998 Nov 1;92(9):3177–88

Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Takamatsu Y, et al. **Blood** 1998 Nov 1;92(9):3465–73

C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Wang X, et al. **Blood** 1999 Jul 15; 94(2):560–71

Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Watanabe T, et al. **Blood** 1999 Feb 15; 93(4):1157–63

Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice. Yang FC, et al. **Blood** 1999 Aug 1;94(3):950–8

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Ageitos AG, et al. **Bone Marrow Transplant** 1999 Jan; 23(1):63–9

Analysis of surface markers on CD34+ cells, isolated from cord blood and G-CSF primed peripheral blood. Barbosa IL, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S56

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bellucci R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):1–8

Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Blaise D, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1153–8

Use of G-CSF to mobilise PBSC in normal healthy donors--an international survey. Cleaver SA, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S29–31

Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. Hartung G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S16–20

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):625–30

Peripheral blood stem cell mobilization with granulocyte colony-stimulating factor and a harvesting procedure in pediatric donors. Kawano Y, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S32–4

Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N, et al. **Bone Marrow Transplant** 1999 Jan;23(2):125–9

Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Lie AK, et al. **Bone Marrow Transplant** 1998 Nov;22(9):853–7

G-CSF-mobilized PBSCT in children with AML in first complete remission [letter; comment] Madero L, et al. **Bone Marrow Transplant** 1999 May;23(9):975–6. Comment on: Bone Marrow Transplant 1998 Feb;21(4):375–82.

Characterization of peripheral blood progenitor cells mobilized by nartograstim (N-terminal replaced granulocyte colony-stimulating factor) in normal volunteers. Maruyama K, et al. **Bone Marrow Transplant** 1998 Aug;22(4):313–20

Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Rondelli D, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):631–7

Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Theilgaard-Mönch K, et al. **Bone Marrow Transplant** 1999 Feb;23(3):243–9

Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Wandt H, et al. **Bone Marrow Transplant** 1999 Apr; 23(8):763–70

Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Pei XH, et al. **Br J Cancer** 1999 Jan;79(1):40–6

Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia. Lejeune M, et al. **Br J Haematol** 1998 Sep;102(5):1284–91

Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo. Bönig HB, et al. **Cancer** 1999 Jul 15;86(2):340–8

The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Setti M, et al. **Cancer Immunol Immunother** 1999 Sep;48(6):287–96

Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony-stimulating factor in pediatric donors. Kawano Y, et al. **Cancer Res** 1999 Jul 15; 59(14):3321–4

G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. Pei XH, et al. **Clin Exp Metastasis** 1998 Aug;16(6):551–8

Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Hassan HT, et al. **Clin Lab Haematol** 1999 Feb;21(1):21–7

Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on neutrophil formation and function. Khwaja A, et al. **Curr Opin Hematol** 1994 May;1(3):216–20 (29 ref.)

Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. Knudsen LM, et al. **Eur J Haematol** 1998 Oct;61(4):229–34

Granulocyte colony-stimulating factor (G-CSF) may stimulate HIV-replication during cytostatic chemotherapy [letter] Weiner SM, et al. **Eur J Haematol** 1998 Nov; 61(5):354–5

Granulocyte-colony stimulating factor inhibits inducible nitric oxide synthase gene expression in pulmonary epithelial cells in vitro. Hoffmann G, et al. **Eur J Pharmacol** 1998 Oct 2;358(2):169–76

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Bowen S, et al. **Exp Hematol** 1999 Mar;27(3):425–32

Granulocyte colony-stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA. Horwitz ME, et al. **Exp Hematol** 1999 Jul;27(7):1160–7

Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product. Li K, et al. **Exp Hematol** 1999 Mar;27(3):526–32

Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Pierelli L, et al. **Exp Hematol** 1999 Mar;27(3):416–24

The development of bone changes induced in rats by recombinant human granulocyte colony-stimulating factor is suppressed by bisphosphonate. Suzuki M, et al. **Histol Histopathol** 1999 Jul;14(3):679–86

Inhibition of inducible nitric oxide synthase gene expression and nitric oxide synthesis in vascular smooth muscle cells by granulocyte-colony stimulating factor in vitro. Deetjen C, et al. **Immunopharmacology** 1999 Jun;43(1):23–30

Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants? Bialek R, et al. **Infection** 1998 Nov-Dec;26(6):375–8

Commitment of neutrophilic differentiation and proliferation of HL-60 cells coincides with expression of transferrin receptor. Effect of granulocyte colony stimulating factor on differentiation and proliferation. Kanayasu-Toyoda T, et al. **J Biol Chem** 1999 Sep 3;274(36):25471–80

Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. Rausch O, et al. **J Biol Chem** 1999 Feb 12;274(7):4096–105

The role of STAT3 in granulocyte colony-stimulating factor-induced enhancement of neutrophilic differentiation of Me2SO-treated HL-60 cells. GM-CSF inhibits the nuclear translocation of tyrosine-phosphorylated STAT3. Yamaguchi T, et al. **J Biol Chem** 1999 May 28; 274(22):15575–81

Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. Buzzi M, et al. **J Chemother** 1999 Aug;11(4):293–300

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Zimmerman TM, et al. **J Clin Apheresis** 1999;14(1):31–4

Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. Hermans MH, et al. **J Exp Med** 1999 Feb 15;189(4):683–92

G-CSF-mobilized leukapheresis products: cellular characteristics and clinical performance in allografting. Dlubek D, et al. **J Hematother** 1999 Apr;8(2):157–66

Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. Gaviria JM, et al. **J Infect Dis** 1999 Apr;179(4):1038–41

Granulocyte colony-stimulating factor modulates the pulmonary host response to endotoxin in the absence and presence of acute ethanol intoxication. Zhang P, et al. **J Infect Dis** 1999 Jun;179(6):1441–8

Granulocyte colony-stimulating factor activates protein kinase A in granulocytic but not monocytic precursors or neutrophils. Deshpande RV, et al. **J Interferon Cytokine Res** 1998 Aug;18(8):579–86

Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. Chakraborty A, et al. **J Leukoc Biol** 1998 Nov;64(5):675–80

Pharmacokinetics and pharmacological effect of recombinant human granulocyte colony-stimulating factor conjugated to poly(styrene-co-maleic acid) in rats. Kunimasa JI, et al. **J Pharm Pharmacol** 1999 Jul;51(7):777–82

Time-dependent effects of Klebsiella pneumoniae endotoxin on hepatic drug-metabolizing enzyme activity in rats. Nadai M, et al. **J Pharm Pharmacol** 1998 Aug;50(8):871–9

Differential gene expression of CINC, NOS II, and ICAM-1 in endotoxemic liver cells by rG-CSF. Wanner GA, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):216–21

Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells. Matsushita K, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):295–304 (94 ref.)

Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Tsuboi A, et al. **Leuk Res** 1999 May;23(5):499–505

Role of granulocyte colony-stimulating factor in infection and inflammation. Hartung T, et al. **Med Microbiol Immunol (Berl)** 1998 Oct;187(2):61–9 (113 ref.)

Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. Pharmacokinetic and activity studies of single-dose administration in mice. Rotondaro L, et al. **Mol Biotechnol** 1999 Apr;11(2):117–28

Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine act additively to enhance the hemopoietic spleen colony formation in irradiated mice. Hofer M, et al. **Physiol Res** 1999;48(1):37–42

Peripheral blood neutrophils of germ-free rats modified by in vivo granulocyte-colony-stimulating factor and exposure to natural environment. Ohkubo T, et al. **Scand J Immunol** 1999 Jan;49(1):73–7

PHYSIOLOGY

Alveolar type II-like cells release G-CSF as neutrophil chemotactic activity. Koyama S, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L687–93

Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils

stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. Suzuki K, et al. **Blood** 1999 Jan 1;93(1):341-9

Tyrosine-dependent and -independent mechanisms of STAT3 activation by the human granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending on G-CSF concentration. Ward AC, et al. **Blood** 1999 Jan 1;93(1):113-24

Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. Dong F, et al. **J Immunol** 1998 Dec 15;161(12):6503-9

Granulocyte colony-stimulating factor inhibits neutrophil apoptosis at the local site after severe head and thoracic injury. Ertel W, et al. **J Trauma** 1999 May;46(5):784-92; discussion 792-3

Role of granulocyte colony-stimulating factor in infection and inflammation. Hartung T, et al. **Med Microbiol Immunol (Berl)** 1998 Oct;187(2):61-9 (113 ref.)

Identification of the granulocyte colony-stimulating factor (G-CSF) producing cell population in human decidua and its biological action on trophoblast cell. Miyama M, et al. **Osaka City Med J** 1998 Jun;44(1):85-96

SECRETION

A case of granulocyte-colony stimulating factor producing gallbladder cancer. Omura N, et al. **Am J Gastroenterol** 1999 Jan;94(1):273-5

The secretion of cytokines and granulocyte colony stimulating factor by anaplastic and poorly differentiated thyroid carcinoma cell lines. Asakawa H, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):761-4

A novel human malignant fibrous histiocytoma cell line of the heart (MFH-H) with secretion of hematopoietic growth factors. Reinecke P, et al. **Anticancer Res** 1999 May-Jun;19(3A):1901-7

Secretion of IL-6, IL-8 and G-CSF by human endothelial cells in vitro in response to Staphylococcus aureus and staphylococcal exotoxins. Söderquist B, et al. **APMIS** 1998 Dec;106(12):1157-64

Enhanced secretion of human granulocyte colony-stimulating factor directed by a novel hybrid fusion peptide from recombinant Saccharomyces cerevisiae at high cell concentration. Bae CS, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):600-9

Granulocyte colony stimulating factor-producing diffuse malignant mesothelioma of pleura. Ohbayashi H, et al. **Intern Med** 1999 Aug;38(8):668-70

THERAPEUTIC USE

Effect of granulocyte/colony-stimulating factor on the onset of the adult respiratory distress syndrome. Takahashi Y, et al. **Acta Haematol** 1999;101(3):124-9

Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS). Chevreau C, et al. **Am J Clin Oncol** 1999 Jun;22(3):267-72

G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects [see comments] Kazzaz W, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1377-82 . Comment in: Am J Respir Crit Care Med 1999 May;159(5 Pt 1):1365-7.

Chédiak-Higashi-Steinbrinck syndrome (CHS) in a 27-year-old woman--effects of G-CSF treatment. Baldus M, et al. **Ann Hematol** 1999 Jul;78(7):321-7

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Hofmann WK, et al. **Ann Hematol** 1999 Mar; 78(3):125-30

Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Kern W, et al. **Ann Hematol** 1998 Sep;77(3):115-22

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Errante D, et al. **Ann Oncol** 1999 Feb;10(2):189-95

Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Graybill JR, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2467-73

Myeloid colony-stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984-8 (65 ref.)

Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Hellmich B, et al. **Arthritis Rheum** 1999 Aug;42(8):1752-6

Administration of daniplestim and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in nonhuman primates. Fleming WH, et al. **Biol Blood Marrow Transplant** 1999; 5(1):8-14

Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Estey EH, et al. **Blood** 1999 Apr 15;93(8):2478-84

Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Lee SJ, et al. **Blood** 1998 Oct 15;92(8):2725-9

Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Ozsahin H, et al. **Blood** 1998 Oct 15;92(8):2719-24

Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Weiss M, et al. **Blood** 1999 Jan 15;93(2):425-39 (173 ref.)

Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer. Charrier S, et al. **Bone Marrow Transplant** 1998 Nov;22(9):845-51

Peripheral blood stem cell collection from G-CSF-stimulated unrelated donors for second transplant. Dini G, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S41-5 (33 ref.)

Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Jansen J, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1251-6

Poor stem cell mobilizers--variation in response to G-CSF dose escalation [letter] Morris T, et al. **Bone Marrow Transplant** 1999 Aug;24(4):448-9

A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Ojeda E, et al. **Bone Marrow Transplant** 1999 Sep;24(6):601-7

Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Piccirillo N, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1245-50

G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. Prete A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S21-3

Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Reyes E, et al. **Br J Cancer** 1999 Apr; 80(1-2):229-35

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Scheithauer W, et al. **Br J Cancer** 1999 Aug;80(11):1797-802

Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA. Bellos F, et al. **Br J Haematol** 1998 Dec; 103(4):1192-7

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Comenzo RL, et al. **Br J Haematol** 1999 Mar;104(3):553-9

Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation. Ferrara F, et al. **Br J Haematol** 1999 Aug;106(2):520-3

Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Fruehauf S, et al. **Br J Haematol** 1999 Jun; 105(3):786-94

Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Okamoto S, et al. **Br J Haematol** 1999 Mar;104(3):569-73

Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Roberts MM, et al. **Br J Haematol** 1999 Mar;104(4):778-84

Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Younes A, et al. **Br J Haematol** 1998 Dec;103(3):678-83

High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers. Yeh KH, et al. **Breast Cancer Res Treat** 1998 Jun;49(3):237-44

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Pullarkat V, et al. **Cancer Immunol Immunother** 1999 Apr; 48(1):9-21

Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Rusthoven J, et al. **Cancer Prev Control** 1998 Aug;2(4):179-90

Hematopoietic growth factors and acute leukemia. Rowe JM, et al. **Cancer Treat Res** 1999;99:195-226 (129 ref.)

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Abbruzzese JL, et al. **Clin Cancer Res** 1996 Sep;2(9):1489-97

Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH, et al. **Clin Cancer Res** 1997 Sep;3(9):1519-26

Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Gandhi V, et al. **Clin Cancer Res** 1995 Feb;1(2):169-78

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Tolcher AW, et al. **Clin Cancer Res** 1997 May;3(5):755-60

Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Abdel-Dayem HM, et al. **Clin Nucl Med** 1999 May;24(5):319-22

Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Goldman S, et al. **Clin Perinatol** 1998 Sep;25(3):699-710 (32 ref.)

Counterregulatory control of the acute inflammatory response: granulocyte colony-stimulating factor has anti-inflammatory properties [comment] Heard SO, et al. **Crit Care Med** 1999 May;27(5):1019-21 (49 ref.). Comment on: Crit Care Med 1999 May;27(5):1014-8.

Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Fisher DC, et al. **Curr Opin Hematol** 1994 May;1(3):221-7 (46 ref.)

Granulocyte colony-stimulating factor-mobilized granulocyte concentrate transfusions. Price TH. **Curr Opin Hematol** 1998 Nov;5(6):391-5 (34 ref.)

In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. Hsu HC, et al. **Eur J Haematol** 1999 Jul; 63(1):11-8

Changing biodistribution of gallium during G-CSF treatment in non- Hodgkin's disease [letter] Maffioli LS, et al. **Eur J Nucl Med** 1999 Jan;26(1):68-9

Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits. Pless M, et al. **Exp Hematol** 1999 Jan;27(1):155-61

Haematopoietic growth factors in the treatment of myelodysplastic syndromes. Cazzola M. **Forum (Genova)** 1999 Jan-Mar;9(1):49-57

Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan. Tamura K. **Fukuoka Igaku Zasshi** 1999 Jun;90(6):279-85

Granulocyte colony-stimulating factor administered as a single intraperitoneal injection modifies the lethal dose95/30 in irradiated B6D2F1 mice [letter] Sureda A, et al. **Haematologica** 1998 Sep;83(9):863-4

The use of granulocyte colony stimulating factor to promote wound healing in a neutropenic patient after head and neck surgery. Cody DT 2nd, et al. **Head Neck** 1999 Mar; 21(2):172-5

G-CSF: a very efficient therapy in chronic autoimmune neutropenia. A brief review of the literature. Bauduer F. **Hematol Cell Ther** 1998 Oct;40(5):189-91 (23 ref.)

Different effect of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice. Buisman AM, et al. **Immunology** 1999 Aug;97(4):601-10

Successful treatment of pustulosis palmaris et plantaris with granulocyte colony stimulating factor in a patient with hereditary neutropenia. Hino M, et al. **Int J Hematol** 1998 Dec;68(4):453-6

Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Nishimura M, et al. **Int J Hematol** 1998 Aug; 68(2):203-11

Mesalazine-associated severe aplastic anemia successfully treated with antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor. Otsubo H, et al. **Int J Hematol** 1998 Dec;68(4):445-8

Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. Yoshida M, et al. **Int J Hematol** 1999 Feb; 69(2):81-8

Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus. Ambati BK, et al. **Int J Infect Dis** 1998-99 Winter;3(2):70-5

Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission. Shulman LN, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):1113-7

Sulphasalazine induced agranulocytosis revisited [letter] Murphy PT, et al. **Ir Med J** 1998 Dec;91(6):216

Potential risk of enhancing survival of infected cells [letter; comment] LeGrand EK. **J Am Vet Med Assoc** 1998 Dec

15;213(12):1698. Comment on: J Am Vet Med Assoc 1998 Oct 1;213(7):991-2.

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. Schröder CP, et al. **J Antimicrob Chemother** 1999 May;43(5):741-3

Mobilization of peripheral blood stem cells in children using G-CSF after carboplatin containing myelosuppressive chemotherapy. Rauck AM, et al. **J Clin Apheresis** 1998; 13(4):146-54

Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. Ward AC, et al. **J Exp Med** 1999 Aug 16;190(4):497-507

Neutrophils from AIDS patients treated with granulocyte colony-stimulating factor demonstrate enhanced killing of Mycobacterium avium [published erratum appears in J Infect Dis 1999 May;179(5):1315] George S, et al. **J Infect Dis** 1998 Nov;178(5):1530-3

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. Root RK, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S342-52 (126 ref.)

Soluble complement receptor 1 is increased in patients with leukemia and after administration of granulocyte colony-stimulating factor. Sadallah S, et al. **J Leukoc Biol** 1999 Jan;65(1):94-101

Colony-stimulating factors stimulate some treatments, continue to evolve [news] Volkers N. **J Natl Cancer Inst** 1999 Feb 3;91(3):210-2

Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. Sugawara Y, et al. **J Nucl Med** 1999 Sep;40(9):1456-62

Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries. Ishikawa K, et al. **J Trauma** 1999 Jun; 46(6):999-1007; discussion 1007-8

A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Narabayashi M, et al. **Jpn J Clin Oncol** 1999 Jun; 29(6):285-90

Involvement of granulocyte colony-stimulating factor in proliferation of adult T-cell leukemia cells. Matsushita K, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):295-304 (94 ref.)

Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Petit J, et al. **Leuk Lymphoma** 1999 Jun; 34(1-2):119-27

Granulocyte colony-stimulating factor in combination with intensive chemotherapy in the treatment of acute myeloid leukemia. Dombret H. **Leuk Res** 1998 Dec;22(12):1137-42 (29 ref.)

Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Morton J, et al. **Leuk Res** 1999 Feb;23(2):177-83

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Ohno R. **Leuk Res** 1998 Dec;22(12):1143-54 (62 ref.)

Growth factors in the treatment of acute lymphoblastic leukemia. Ottmann OG, et al. **Leuk Res** 1998 Dec; 22(12):1171-8 (30 ref.)

Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor. Samuelsson J, et al. **Leuk Res** 1999 May;23(5):513-7

Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Clarke V, et al. **Med Pediatr Oncol** 1999 May; 32(5):331-5

Leukocyte behavior in a free-flap model following chemotherapy and application of granulocyte colony-stimulating factor (GCSF). Peter FW, et al. **Microsurgery** 1998;18(4):290-7

Clinical appearance of a post-transplant lymphoma following G-CSF therapy [letter] Johnson DW, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1806-7

A phase I study of cisplatin i.p. and carboplatin i.v. with G-CSF in patients with ovarian cancer. Adachi S, et al. **Oncol Rep** 1999 Mar-Apr;6(2):311-5

Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Fujita A, et al. **Oncology** 1999;56(4):301-7

Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. Papadimitris C, et al. **Oncology** 1999;57(2):127-30

The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Mascarin M, et al. **Oral Oncol** 1999 Mar;35(2):203-8

Cohen syndrome with neutropenia-induced periodontitis managed with granulocyte colony-stimulating factor (G-CSF): case reports. Seow WK, et al. **Pediatr Dent** 1998 Sep-Oct;20(5):350-4

Recombinant human granulocyte colony-stimulating factor therapy for sepsis in infants with neutropenia [letter; comment] Yasui K, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1310-1. Comment on: Pediatrics 1998 Jul;102(1 Pt 1):6-13.

Thyrotoxicosis and antithyroid drugs [letter; comment] Majeed MR. **Postgrad Med J** 1998 Jun;74(872):382. Comment on: Postgrad Med J 1997 Jun;73(860):335-6.

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM, et al. **Semin Oncol** 1998 Oct;25(5):552-61 (48 ref.)

Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. Winfred RI, et al. **South Med J** 1999 Sep;92(9):918-20

Granulocyte-colony stimulating factor for the prevention of chemotherapy-induced febrile neutropenia in the adult cancer patient population of Southern Israel. Gilad J, et al. **Support Care Cancer** 1999 Jul;7(4):260-4

Granulocyte colony-stimulating factor and neutrophil-related changes in local host defense during recovery from shock and intra-abdominal sepsis. Davis KA, et al. **Surgery** 1999 Aug;126(2):305-13

Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Fukata S, et al. **Thyroid** 1999 Jan;9(1):29-31

Improved progenitor assay standardization using peripheral blood progenitor cells from a donor treated with granulocyte-colony-stimulating factor. Burger SR, et al. **Transfusion** 1999 May;39(5):451-6

Demonstration of drug-dependent antibodies in two patients with neutrophenia and successful treatment with granulocyte-colony-stimulating factor. Meyer O, et al. **Transfusion** 1999 May;39(5):527-30

Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Sato S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):521-2

Accidental overdose of melphalan per os in a 69-year-old woman treated for advanced endometrial carcinoma. Jirillo A, et al. **Tumori** 1998 Sep-Oct;84(5):611

[Therapeutic use of hematopoietic growth factors. II. GM-CSF and G-CSF] Royer B, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):255-66 (50 ref.) (Eng. Abstr.) **(Fre)**

[Questions on pneumology] Lebeau B. **Presse Med** 1998 Jul 4-11;27(24):1211-2 **(Fre)**

[Prescription of a hematopoietic growth factor, lenograstim, in current practice. Results and commentaries of a national survey from April 1995 to March 1996] Maurice-Tison S, et al. **Presse Med** 1998 Jul 4-11;27(24):1203-7, 211 (Eng. Abstr.) **(Fre)**

[Questions on oncology] Misset JL. **Presse Med** 1998 Jul 4-11;27(24):1209-10 **(Fre)**

[Questions on hematology] Rossi JF. **Presse Med** 1998 Jul 4-11;27(24):1207-8 **(Fre)**

[Iatrogenic agranulocytosis. Etiology, diagnosis, treatment] Sebahoun G. **Rev Prat** 1999 Jun 15;49(12):1355-60 **(Fre)**

[Effective treatment combining antithymocyte globulin, cyclosporin A, and granulocyte colony-stimulating factor for atypical paroxysmal nocturnal hemoglobinuria accompanied by bone marrow hypoplasia] Noji H, et al. **Rinsho Ketsueki** 1999 Mar;40(3):240-3 (Eng. Abstr.) **(Jpn)**

[Clinical use of hematopoietic growth factors in the treatment of acute myeloblastic leukemia] Tóthová E. **Vnitr Lek** 1998 Jun;44(6):373-7 (36 ref.) (Eng. Abstr.) **(Slo)**

[Continuous treatment with G-CSF in a case of infantile congenital neutropenia (letter; comment)] Fernández Galán MA, et al. **An Esp Pediatr** 1998 Nov;49(5):539-40. Comment on: An Esp Pediatr 1998 Jan;48(1):68-70. **(Spa)**

[Granulocyte transfusions. Return to the past (editorial)] Muncunill J. **Med Clin (Barc)** 1999 May 1;112(15):574-6 **(Spa)**

TOXICITY

Fatal G-CSF-induced pulmonary toxicity [letter] Ruiz-Argüelles GJ, et al. **Am J Hematol** 1999 Jan; 60(1):82-3

GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT

ADMINISTRATION & DOSAGE

A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Mori K, et al. **Cancer Chemother Pharmacol** 1999;43(6):467-70

A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor. Philip PA, et al. **Clin Oncol (R Coll Radiol)** 1999;11(2):84-9

Administration of recombinant human stem cell factor (rhSCF) and granulocyte-colony stimulating factor (rhG-CSF) to maternal and fetal rhesus monkeys (Macaca mulatta). Tarantal AF, et al. **Cytokine** 1999 Apr; 11(4):290-300

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer. Hochster H, et al. **Gynecol Oncol** 1999 Mar;72(3):292-7

[Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles] Gibaud S, et al. **Ann Pharm Fr** 1999 Jul;57(4):324-31 (Eng. Abstr.) **(Fre)**

[Granulocyte colony-stimulating factor in the newborn neutropenic patient] Castillo Salinas F, et al. **An Esp Pediatr** 1998 Dec;49(6):615-8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. Cho SG, et al. **J Korean Med Sci** 1998 Dec;13(6):685-8

Marked granulocytic proliferation induced by granulocyte colony-stimulating factor in the spleen simulating a myeloid leukemic infiltrate. Vasef MA, et al. **Mod Pathol** 1998 Nov;11(11):1138-41

BIOSYNTHESIS

Granulocyte colony-stimulating factor and parathyroid hormone related protein producing bladder cancer. Kamai T, et al. **J Urol** 1999 May;161(5):1565-6

BLOOD

Granulocyte colony-stimulating factor in the cord blood of premature neonates born to mothers with pregnancy-induced hypertension. Tsao PN, et al. **J Pediatr** 1999 Jul;135(1):56-9

CHEMISTRY

New cytokine dressings. I. Kinetics of the in vitro rhG-CSF, rhGM-CSF, and rhEGF release from the dressings. Grzybowski J, et al. **Int J Pharm** 1999 Jul 20;184(2):173-8

IMMUNOLOGY

Intravenous granulocyte colony-stimulating factor increases the release of tumour necrosis factor and interleukin-1beta into the cerebrospinal fluid, but does not inhibit the growth of Streptococcus pneumoniae in experimental meningitis. Schmidt H, et al. **Scand J Immunol** 1999 May;49(5):481-6

PHARMACOKINETICS

Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in rabbits and mice. Liu XW, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):44-8

PHARMACOLOGY

G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Fischmeister G, et al. **Ann Hematol** 1999 Mar;78(3):117-23

Does recombinant human granulocyte colony-stimulating factor really prime marrow stem cells in mice and humans? [letter; comment] Johnsen HE. **Blood** 1999 Jun 15; 93(12):4446-9. Comment on: Blood 1998 Nov 1;92(9):3489-90.

Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Pan L, et al. **Blood** 1999 Jun 15;93(12):4071-8

Human granulocyte colony-stimulating factor (G-CSF) stimulates the in vitro and in vivo development but not commitment of primitive multipotential progenitors from transgenic mice expressing the human G-CSF receptor. Yang FC, et al. **Blood** 1998 Dec 15;92(12):4632-40

Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo. Yamasaki M, et al. **Drugs Exp Clin Res** 1998;24(4):191-6

Effects of rhG-CSF on neutrophil functions and survival in sepsis induced diabetic rats. Cantürk Z, et al. **Endocr Res** 1998 May;24(2):141-57

Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Noda I, et al. **Int J Cancer** 1999 Jan 5;80(1):78-84

Graft engineering of G-CSF-mobilized allogeneic leukapheresis products by counterflow centrifugal elutriation after CD34 column adsorption. Skiera D, et al. **J Hematother** 1999 Jun;8(3):299-304

Suppression of G-CSF-mediated Stat signalling by IL-3. Steinman RA, et al. **Leukemia** 1999 Jan;13(1):54-61

THERAPEUTIC USE

"Idiopathic neutropenia" in very low birthweight infants. Juul SE, et al. **Acta Paediatr** 1998 Sep;87(9):963-8

Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective

method of increasing dose intensity. Weiss AJ, et al. **Am J Clin Oncol** 1999 Feb;22(1):38–41

Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Opal SM, et al. **Blood** 1999 May 15; 93(10):3467–72

Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF [letter] Miclea J, et al. **Bone Marrow Transplant** 1999 Aug;24(4):441–3

Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Waller CF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):19–24

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Frasci G, et al. **Breast Cancer Res Treat** 1998 May;49(1):13–26

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Alexopoulos K, et al. **Cancer Chemother Pharmacol** 1999;43(3):257–62

Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. Pusztai L, et al. **Cancer Chemother Pharmacol** 1999;43(1):86–91

Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection [see comments] Rewerts JM, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):991–2. Comment in: J Am Vet Med Assoc 1998 Dec 15;213(12):1698.

Restoring interleukin 2 production in AIDS patients [news] Dorrell S. **Mol Med Today** 1998 Dec;4(12):508

Rebound cerebrospinal fluid pleocytosis with elevated cytokine levels during recombinant human granulocyte colony-stimulating factor therapy for purulent meningitis. Isoyama K, et al. **Pediatr Int** 1999 Jun;41(3):304–6

Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Kocherlakota P, et al. **Pediatrics** 1998 Nov; 102(5):1107–11

Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor. Mezquita P, et al. **Thyroid** 1998 Sep;8(9):791–4

[Progression of multiple myeloma during treatment with recombinant G-CSF and absence of G-CSF and IL-6 cell surface receptors on malignant cells] Spička I, et al. **Cas Lek Cesk** 1998 Nov 2;137(21):660–3 (Eng. Abstr.) **(Cze)**

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

see related
RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Jaffee EM, et al. **Hum Gene Ther** 1998 Sep 1;9(13):1951–71

MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases. Dong XD, et al. **J Surg Oncol** 1999 May;71(1):36–45

ADMINISTRATION & DOSAGE

Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Cole DJ, et al. **Clin Cancer Res** 1997 Jun;3(6):867–73

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Schiller JH, et al. **Clin Cancer Res** 1996 Feb;2(2):319–30

Granulocyte macrophage-colony stimulating factor for treatment of chemotherapy extravasation. Shamseddine AI, et al. **Eur J Gynaecol Oncol** 1998;19(5):479–81

Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds. Malik IA, et al. **Eur J Surg** 1998 Oct; 164(10):737–44

GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly [letter] Pierri I, et al. **Haematologica** 1999 Jun;84(6):562–3

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. Straus DJ, et al. **J Clin Oncol** 1998 Nov;16(11):3601–6

Healing of chronic leg ulcers in diabetic necrobiosis lipoidica with local granulocyte-macrophage colony stimulating factor treatment. Remes K, et al. **J Diabetes Complications** 1999 Mar-Apr;13(2):115–8

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. Posey JA, et al. **J Immunother** 1999 Jul;22(4):371–9

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Thomas X, et al. **Leukemia** 1999 Aug;13(8):1214–20

Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Lane TA, et al. **Transfusion** 1999 Jan;39(1):39–47

Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma. Lümmen G, et al. **Urol Int** 1998;61(4):215–9

[Growth factors in oncology: effectiveness and prospects] Ottmann OG, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1153–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF] Will R, et al. **Urologe A** 1999 May;38(3):258–63 (Eng. Abstr.) **(Ger)**

[Local application of G-CSF, GM-CSF and EGF in treatment of wounds] Grzybowski J, et al. **Postepy Hig Med Dosw** 1999;53(1):75–86 (52 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Case of granulocyte colony-stimulating factor-induced Sweet's syndrome. Arbetter KR, et al. **Am J Hematol** 1999 Jun;61(2):126–9

Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Kasper C, et al. **Ann Hematol** 1999 Feb;78(2):91–2

Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Couderc LJ, et al. **Respir Med** 1999 Jan;93(1):65–8 (16 ref.)

Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF. Alvarado Ibarra ML, et al. **Rev Invest Clin** 1999 Mar-Apr;51(2):77–80

[Anaphylactic reaction after local injection of GM-CSF in venous leg ulcer (letter)] Dupre D, et al. **Ann Dermatol Venereol** 1999 Feb;126(2):161 **(Fre)**

[Hematopoietic growth factors and anaphylaxis (letter)] Balaguer AA, et al. **Med Clin (Barc)** 1999 May 1; 112(15):598 **(Spa)**

ANALYSIS

Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Gan J, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):236–42

Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin 6 and low levels of granulocyte-macrophage colony-stimulating factor. Calogero AE, et al. **Cytokine** 1998 Oct;10(10):814–8

Localization of granulocyte-macrophage colony-stimulating factor in the bovine reproductive tract. de Moraes AA, et al. **J Reprod Immunol** 1999 Mar;42(2):135–45

ANTAGONISTS & INHIBITORS

Glucocorticoid inhibits oxidized LDL-induced macrophage growth by suppressing the expression of granulocyte/macrophage colony-stimulating factor. Sakai M, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul; 19(7):1726–33

IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells. Larsson S, et al. **Br J Pharmacol** 1999 Jun;127(4):980–6

Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. Tanaka N, et al. **FEBS Lett** 1999 Jan 15;442(2–3):246–50

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents [see comments] Joseph IB, et al. **J Natl Cancer Inst** 1998 Nov 4;90(21):1648–53. Comment in: J Natl Cancer Inst 1998 Nov 4;90(21):1583–4. Comment in: J Natl Cancer Inst 1999 May 5;91(9):804–6.

BIOSYNTHESIS

Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Boursnell ME, et al. **Adv Exp Med Biol** 1998;451:379–84

Upper airway epithelial cells support eosinophil survival in vitro through production of GM-CSF and prostaglandin E2: regulation by glucocorticoids and TNF-alpha. Daffern PJ, et al. **Allergy Asthma Proc** 1999 Jul-Aug;20(4):243–53

Granulocyte macrophage-colony stimulating factor production by autologous endometrial co-culture is associated with outcome for in vitro fertilization patients with a history of multiple implantation failures. Spandorfer SD, et al. **Am J Reprod Immunol** 1998 Nov;40(5):377–81

Receptor clearance obscures the magnitude of granulocyte-macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Metcalf D, et al. **Blood** 1999 Mar 1;93(5):1579–85

Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Zhang X, et al. **Blood** 1998 Nov 15;92(10):3829–40

Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Filion MC, et al. **Br J Cancer** 1999 Jan;79(2):229–35

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Kielian T, et al. **Cancer Immunol Immunother** 1999 May-Jun;48(2–3):123–31

Diesel exhaust particulates upregulate histamine receptor mRNA and increase histamine-induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells [see comments] Terada N, et al. **Clin Exp Allergy** 1999 Jan;29(1):52–9. Comment in: Clin Exp Allergy 1999 Jan;29(1):4–8.

Cytokine regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) production by human retinal pigment epithelial cells. Crane IJ, et al. **Clin Exp Immunol** 1999 Feb;115(2):288–93

Regulation of interleukin-1-stimulated GMCSF mRNA levels in human endothelium. Patterson CE, et al. **Endothelium** 1998;6(1):45–59

In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Hensley C, et al. **Exp Dermatol** 1998 Dec;7(6):335–41

Hydrocortisone inhibits granulocyte-macrophage colony-stimulating factor production from normal human peripheral blood mononuclear cells and CD3+ T cells. Chikkappa G, et al. **Exp Hematol** 1998 Dec;26(13):1240–6

Interleukin-10 inhibits burst-forming unit-erythroid growth by suppression of endogenous granulocyte-macrophage colony-stimulating factor production from T cells. Oehler L, et al. **Exp Hematol** 1999 Feb;27(2):217–23

Expression of biologically active recombinant porcine GM-CSF by baculovirus gene expression system. Inumaru S, et al. **Immunol Cell Biol** 1998 Jun;76(3):195–201

Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation. Zhang D, et al. **Infect Immun** 1999 Apr; 67(4):1606–13

Distinct expression of RANTES and GM-CSF by lipopolysaccharide in human nasal fibroblasts but not in other airway fibroblasts. Nonaka M, et al. **Int Arch Allergy Immunol** 1999 Aug;119(4):314–21

GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice. Stämpfli MR, et al. **J Clin Invest** 1998 Nov 1; 102(9):1704–14

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. van Elsas A, et al. **J Exp Med** 1999 Aug 2;190(3):355–66

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. Bronte V, et al. **J Immunol** 1999 May 15; 162(10):5728–37

The role of Ets-1 in mast cell granulocyte-macrophage colony-stimulating factor expression and activation. McKinlay LH, et al. **J Immunol** 1998 Oct 15; 161(8):4098–105

Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. Soo Hoo W, et al. **J Immunol** 1999 Jun 15;162(12):7343–9

Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Watanabe M, et al. **Jpn J Clin Oncol** 1998 Sep; 28(9):559–62 (19 ref.)

Interleukin-6 and transforming growth factor-beta regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating factors in human thyroid follicular cells. Matsumura M, et al. **Life Sci** 1999;65(12):PL129–35

Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. Schelenz S, et al. **Med Mycol** 1999 Jun;37(3):183–94

Differential effects of glucocorticoids on colony stimulating factors produced by neonatal mononuclear cells. Witek-Janusek L, et al. **Pediatr Res** 1999 Feb;45(2):224–9

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):72–7 (55 ref.)

[mRNA expression of granulocyte-macrophage colony-stimulating factor in airway tissues of asthma guinea pigs: effect of triptolide] Jin Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Oct; 20(5):291–3 (Eng. Abstr.) **(Chi)**

[CSF-producing tumor] Kitagawa S.

Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):25-7 (7 ref.) **(Jpn)**

BLOOD

G-CSF, GM-CSF and IL-6 levels in cord blood: diminished increase of G-CSF and IL-6 in preterms with perinatal infection compared to term neonates. Weimann E, et al. **J Perinat Med** 1998;26(3):211-8

The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. Akbulut H, et al. **J Pineal Res** 1999 Jan;26(1):1-8

Granulocyte colony-stimulating factor deficiency in a rottweiler with chronic idiopathic neutropenia. Lanevschi A, et al. **J Vet Intern Med** 1999 Jan-Feb;13(1):72-5

Interleukin-4, interleukin-10, and granulocyte-macrophage colony stimulating factor in second-trimester serum from women with preeclampsia. Gratacós E, et al. **Obstet Gynecol** 1998 Nov;92(5):849-53

Evaluation of tumour necrosis factor alpha, interferon gamma and granulocyte-macrophage colony stimulating factor levels in juvenile chronic arthritis [letter] Yetgin S, et al. **Rheumatology (Oxford)** 1999 May;38(5):468-71

Circulating granulocyte macrophage colony-stimulating factor in plasma of patients with the systemic inflammatory response syndrome delays neutrophil apoptosis through inhibition of spontaneous reactive oxygen species generation. Fanning NF, et al. **Shock** 1999 Mar; 11(3):167-74

[Granulocyte macrophage-colony stimulating factor (GM-CSF) in diagnosis and monitoring of non-small cell lung cancer] Mroczko B, et al. **Pol Arch Med Wewn** 1998 Mar;99(3):195-202 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Characterization of the isoforms of PIXY321, a granulocyte-macrophage-colony stimulating factor-interleukin-3 fusion protein, separated by preparative isoelectric focusing on immobilized pH gradients. Balland A, et al. **J Chromatogr A** 1999 Jun 18; 846(1-2):143-56

DEFICIENCY

Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Reed JA, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L556-63

Fertility impairment in granulocyte-macrophage colony-stimulating factor-deficient mice. Robertson SA, et al. **Biol Reprod** 1999 Feb;60(2):251-61

Regulation of IFN-gamma production in granulocyte-macrophage colony-stimulating factor-deficient mice. Noguchi Y, et al. **Eur J Immunol** 1998 Dec;28(12):3980-8

Adenovirus-mediated granulocyte-macrophage colony-stimulating factor improves lung pathology of pulmonary alveolar proteinosis in granulocyte-macrophage colony-stimulating factor-deficient mice. Zsengellér ZK, et al. **Hum Gene Ther** 1998 Sep 20;9(14):2101-9

DRUG EFFECTS

Tetracycline-regulatable expression vectors tightly regulate in vitro gene expression of secreted proteins. Sturtz FG, et al. **Gene** 1998 Oct 23;221(2):279-85

GENETICS

Granulocyte-macrophage colony-stimulating factor (GM-CSF) modulates the expression of type VIII collagen mRNA in vascular smooth muscle cells and both are codistributed during atherogenesis. Plenz G, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1658-68

Role of CBP in glucocorticoid-induced gene repression. Adcock IM, et al. **Biochem Soc Trans** 1998 Aug;26(3):S255

Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. Iversen PO, et al. **Blood** 1998 Dec 1;92(11):4263-8

Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA. Worgall S, et al. **Blood** 1999 Jan 15;93(2):655-66

Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Hogge GS, et al. **Cancer Gene Ther** 1999 Jan-Feb; 6(1):26-36

Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Shi FS, et al. **Cancer Gene Ther** 1999 Jan-Feb; 6(1):81-8

A quantitative focus assay for titration of retroviruses that encode human granulocyte-macrophage colony-stimulating factor (GM-CSF). Feldman RA. **Cytokine** 1999 Jun;11(6):459-62

Silencer and enhancer regions in the human CD95 (Fas/APO-1) gene with sequence similarity to the granulocyte-macrophage colony-stimulating factor promoter: binding of single strand-specific silencer factors and AP-1 and NF-AT-like enhancer factors. Rudert F, et al. **DNA Cell Biol** 1998 Dec;17(12):991-1002

Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Sin JI, et al. **Eur J Immunol** 1998 Nov;28(11):3530-40

An upstream negative regulatory element in human granulocyte-macrophage colony-stimulating factor promoter is recognised by AP1 family members. Gramigni C, et al. **FEBS Lett** 1998 Nov 27;440(1-2):119-24

Calcium-induced stabilization of AU-rich short-lived mRNAs is a common default response. Klein N, et al. **Gene Expr** 1999;7(4-6):357-65

Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Cao X, et al. **Gene Ther** 1998 Aug; 5(8):1130-6

Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Nakazaki Y, et al. **Gene Ther** 1998 Oct;5(10):1355-62

Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hogge GS, et al. **Hum Gene Ther** 1998 Sep 1;9(13):1851-61

Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Stripecke R, et al. **Hum Gene Ther** 1998 Sep 20;9(14):2049-62

Expression of biologically active recombinant porcine GM-CSF by baculovirus gene expression system. Inumaru S, et al. **Immunol Cell Biol** 1998 Jun;76(3):195-201

A variant in the gene for GM-CSF, I117T, is associated with atopic asthma in a Swiss population of asthmatic children. Rohrbach M, et al. **J Allergy Clin Immunol** 1999 Jul; 104(1):247-8

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. Chiodoni C, et al. **J Exp Med** 1999 Jul 5;190(1):125-33

Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. Curiel-Lewandrowski C, et al. **J Immunol** 1999 Jul 1;163(1):174-83

GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. Kumar R, et al. **J Leukoc Biol** 1999 Jan;65(1):102-8

Early granulocyte-macrophage colony-stimulating factor expression by alveolar inflammatory cells during bleomycin-induced rat lung fibrosis. Andreutti D, et al. **Lab Invest** 1998 Dec;78(12):1493-502

A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Towers TL, et al. **Mol Cell Biol** 1999 Jun; 19(6):4191-9

Ovarian immune cells express granulocyte-macrophage colony-stimulating factor (GM-CSF) during follicular growth and luteinization in gonadotropin-primed immature rodents. Tamura K, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1-2):153-63

The expression, activity and regulation of granulocyte macrophage-colony stimulating factor in human endometrial epithelial and stromal cells. Chegini N, et al. **Mol Hum Reprod** 1999 May;5(5):459-66

Stabilization of granulocyte-macrophage colony-stimulating factor RNA in a human eosinophil-like cell line requires the AUUUA motifs. Esnault S, et al. **Proc Assoc Am Physicians** 1998 Nov-Dec;110(6):575-84

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Soiffer R, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13141-6

Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Laroia G, et al. **Science** 1999 Apr 16;284(5413):499-502

Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Zhai Y, et al. **Transpl Immunol** 1998 Sep;6(3):169-75

Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Cho JH, et al. **Vaccine** 1999 Mar 5;17(9-10):1136-44

Administration of multiple cytokine genes with anti-tumor activity inhibits both tumor incidence and tumor growth. Jang HS, et al. **Yonsei Med J** 1999 Aug;40(4):355-62

IMMUNOLOGY

A DNA vaccine against malignant melanoma coexpressing antigen and cytokine. Nawrath M, et al. **Adv Exp Med Biol** 1998;451:305-10

The implications of granulocyte-monocyte colony-stimulating factor (GM-CSF) in cytotoxicity of bone marrow transplantation. Toren A, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):199-206 (102 ref.)

Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Tripathi PK, et al. **Hybridoma** 1999 Apr. 18(2):193-202

Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Cao X, et al. **Immunology** 1999 Aug;97(4):616-25

Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Kamath AT, et al. **Immunology** 1999 Apr. 96(4):511-6

Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish. Kanellos TS, et al. **Immunology** 1999 Apr;96(4):507-10

GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. LeVine AM, et al. **J Clin Invest** 1999 Feb;103(4):563-9

Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. Operschall E, et al. **J Clin Virol** 1999 Jun;13(1-2):17-27

Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. Kitamura T, et al. **J Exp Med** 1999 Sep 20;190(6):875-80

A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. Rodriguez D, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):217-23

GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. Kumar R, et al. **J Leukoc Biol** 1999 Jan;65(1):102-8

Antigen activation of THP-1 human monocytic cells after stimulation with lipopolysaccharide from oral microorganisms and granulocyte-macrophage colony-stimulating factor. Baqui AA, et al. **J Periodontal Res** 1999 May;34(4):203-13

Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum. Argiro L, et al. **Vaccine** 1999 Jan;17(1):13-8

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Babai I, et al. **Vaccine** 1999 Mar 5; 17(9-10):1223-38

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Babai I, et al. **Vaccine** 1999 Mar 5;17(9-10):1239-50

[Phagocytosis and killing of Staphylococcus aureus by granulocytes in mice after granulocyte-macrophage colony stimulating factor (GM-CSF) injection] Czygier M, et al. **Med Dosw Mikrobiol** 1998;50(3-4):151-60 (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Frankel AE, et al. **Protein Expr Purif** 1999 Jun; 16(1):190-201

METABOLISM

Identification of a 14-3-3 binding sequence in the common beta chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF. Stomski FC, et al. **Blood** 1999 Sep 15; 94(6):1933-42

Keratoacanthomas have an immunosuppressive cytokine environment of increased IL-10 and decreased GM-CSF compared to squamous cell carcinomas. Lowes MA, et al. **Br J Cancer** 1999 Jul;80(10):1501-5

Binding of GM-CSF to adherent neutrophils activates phospholipase D. Hayes TS, et al. **Cell Signal** 1999 Mar; 11(3):195-204

GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Hamilos DL, et al. **Clin Exp Allergy** 1998 Sep;28(9):1145-52

Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF). Oshika Y, et al. **Eur J Cancer** 1998 Nov; 34(12):1958-61

The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Be'eri H, et al. **Eur J Neurosci** 1998 Aug; 10(8):2707-13

Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Park CS, et al. **Eur Respir J** 1998 Oct;

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

12(4):872-8
Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Biethahn S, et al. **Exp Hematol** 1999 May;27(5):885-94
Signal transduction pathways induced by GM-CSF in microglia: significance in the control of proliferation. Liva SM, et al. **Glia** 1999 Jun;26(4):344-52
Cloning of the murine beta5 integrin subunit promoter. Identification of a novel sequence mediating granulocyte-macrophage colony-stimulating factor-dependent repression of beta5 integrin gene transcription. Feng X, et al. **J Biol Chem** 1999 Jan 15; 274(3):1366-74
IL-10 and GM-CSF expression and the presence of antigen-presenting cells in chronic venous ulcers. Li YQ, et al. **J Surg Res** 1998 Oct;79(2):128-35
The expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) and its regulation by ovarian steroids in rat uterine stromal cells. Tamura K, et al. **Jpn J Pharmacol** 1999 Feb;79(2):257-62
Effect of inhaled glucocorticoid on the cellular profile and cytokine levels in induced sputum from asthmatic patients. Inoue H, et al. **Lung** 1999;177(1):53-62
Effects of granulocyte-macrophage colony-stimulating factor and cyclic AMP interaction on human neutrophil apoptosis. Tortorella C, et al. **Mediators Inflamm** 1998; 7(6):391-6
The expression, activity and regulation of granulocyte macrophage-colony stimulating factor in human endometrial epithelial and stromal cells. Chegini N, et al. **Mol Hum Reprod** 1999 May;5(5):459-66
Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor. Dijkers PF, et al. **Oncogene** 1999 Jun 3;18(22):3334-42
Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e. Ritchie A, et al. **Oncogene** 1999 Feb 18; 18(7):1465-77
Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge. Ohkubo K, et al. **Rhinology** 1998 Dec;36(4):156-61

PHARMACOKINETICS

Human acute myeloblastic leukemia-ascites model using the human GM-CSF- and IL-3-releasing transgenic SCID mice. Fukuchi Y, et al. **Ann Hematol** 1999 May; 78(5):223-31
Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Cole DJ, et al. **Clin Cancer Res** 1997 Jun;3(6):867-73

PHARMACOLOGY

Effect of recombinant human granulocyte macrophage-colony stimulating factor in long-term marrow cultures from patients with aplastic anemia. Martínez-Jaramillo G, et al. **Am J Hematol** 1999 Jun; 61(2):107-14
Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Reed JA, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L556-63
Oxidized LDL can induce macrophage survival, DNA synthesis, and enhanced proliferative response to CSF-1 and GM-CSF. Hamilton JA, et al. **Arterioscler Thromb Vasc Biol** 1999 Jan;19(1):98-105
Granulocyte-macrophage colony-stimulating factor (GM-CSF) modulates the expression of type VIII collagen mRNA in vascular smooth muscle cells and both are codistributed during atherogenesis. Plenz G, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1658-68
Establishment of a stable HL60 subline having the potential for monocytic differentiation using granulocyte-macrophage colony-stimulating factor: possible use for the study of monocytic differentiation and oxidative stress. Ujihara M, et al. **Atherosclerosis** 1998 Aug; 139(2):301-6
Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin. Ota J, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):779-86
Enhancement of chemotactic peptide-induced activation of phosphoinositide 3-kinase by granulocyte-macrophage colony-stimulating factor and its relation to the cytokine-mediated priming of neutrophil superoxide-anion production. Kodama T, et al. **Biochem J** 1999 Jan 15;337 (Pt 2):201-9
Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Armitage JO. **Blood** 1998 Dec 15;92(12):4491-508 (187 ref.)
Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Brossart P, et al. **Blood** 1998 Dec 1;92(11):4238-47
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Frankel AE, et al. **Blood** 1998 Dec 1;92(11):4279-86
Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Liu HM, et al. **Blood** 1998 Nov 15;92(10):3730-6
Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells. Ogata M, et al. **Blood** 1999 May 15;93(10):3225-32
Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Seymour JF, et al. **Blood** 1998 Oct 15;92(8):2657-67
Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Ageitos AG, et al. **Bone Marrow Transplant** 1999 Jan; 23(1):63-9
Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bonnet D, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):203-9
Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):625-30
Effect of intraperitoneally administered recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the cytotoxic potential of murine peritoneal cells. Klimp AH, et al. **Br J Cancer** 1999 Jan; 79(1):89-94
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Pei XH, et al. **Br J Cancer** 1999 Jan;79(1):40-6
Effect of granulocyte-macrophage colony-stimulating factor treatment on phenotype, cytokine release and cytotoxicity of circulating blood monocytes and monocyte-derived macrophages. Hennemann B, et al. **Br J Haematol** 1998 Sep;102(5):1197-203
The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. Hjertson M, et al. **Br J Haematol** 1999 Mar;104(3):516-22
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Samanci A, et al. **Cancer Immunol Immunother** 1998 Nov;47(3):131-42
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Setti M, et al. **Cancer Immunol Immunother** 1999 Sep;48(6):287-96
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients. Izquierdo MA, et al. **Clin Cancer Res** 1996 Oct; 2(10):1713-6
Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. Anderson JE, et al. **Curr Opin Hematol** 1994 May;1(3):203-9 (43 ref.)
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on neutrophil formation and function. Khwaja A, et al. **Curr Opin Hematol** 1994 May;1(3):216-20 (29 ref.)
Effects of granulocyte-macrophage colony-stimulating factor on incisional wound healing in an experimental diabetic rat model. Cantürk NZ, et al. **Endocr Res** 1999 Feb;25(1):105-16
Over expression of alpha M beta 2 integrin on peripheral blood human neutrophils stimulated with GM-CSF. Ricevuti G, et al. **Eur J Histochem** 1997;41 Suppl 2:41-2
CD1b expression in Molt-4 clones exposed to IL-4 and GM-CSF. Tricarico M, et al. **Eur J Histochem** 1997;41 Suppl 2:119-20
Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathway. Rabinovich GA, et al. **Eur J Immunol** 1999 Feb;29(2):563-70
Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Saha B, et al. **Eur J Immunol** 1999 Jul; 29(7):2319-29
Granulocyte-macrophage colony-stimulating factor enhances interleukin-1beta stimulated histamine release in the preovulatory rat ovary. Tamura K, et al. **Eur J Pharmacol** 1999 Jun 4;373(2-3):207-13
Modulation of histidine decarboxylase activity and cytokine synthesis in human leukemic cell lines: relationship with basophilic and/or megakaryocytic differentiation. Dy M, et al. **Exp Hematol** 1999 Aug;27(8):1295-305
Translocon-associated protein alpha transcripts are induced by granulocyte-macrophage colony-stimulating factor and exhibit complex alternative polyadenylation. Hirama T, et al. **FEBS Lett** 1999 Jul 23;455(3):223-7
Granulocyte-macrophage colony-stimulating factor and interleukin-3 potentiate interferon-gamma-mediated endothelin production by human monocytes: role of protein kinase C. Salh B, et al. **Immunology** 1998 Nov;95(3):473-9
Granulocyte-macrophage colony-stimulating factor and interleukin-3 cause basophil histamine release by a common pathway: downregulation by sodium. Tedeschi A, et al. **Immunology** 1999 Feb;96(2):164-70
Functional changes in THP-1 human monocytic cells after stimulation with lipopolysaccharide of oral microorganisms and granulocyte macrophage colony stimulating factor. Baqui AA, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):493-518
Cooperative stimulatory effects of tumor necrosis factor and granulocyte-macrophage colony-stimulating factor on the particular respiratory burst activity in human neutrophils: synergistic priming effect on concanavalin A-induced response, no interactive priming effect on the chemotactic peptide-induced response and additive triggering effect. Saeki K, et al. **Int J Hematol** 1998 Oct;68(3):269-78
GM-CSF increases in vitro the respiratory burst of human neutrophils after liver transplantation. Jaeger K, et al. **Intensive Care Med** 1999 Jun;25(6):612-5
Priming of human neutrophil respiratory burst by granulocyte/macrophage colony-stimulating factor (GM-CSF) involves partial phosphorylation of p47(phox). Dang PM, et al. **J Biol Chem** 1999 Jul 16;274(29):20704-8
Differential fMet-Leu-Phe- and platelet-activating factor-induced signaling toward Ral activation in primary human neutrophils. M'Rabet L, et al. **J Biol Chem** 1999 Jul 30;274(31):21847-52
Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. Al-Shami A, et al. **J Biol Chem** 1999 Feb 26;274(9):5333-8
The role of STAT3 in granulocyte colony-stimulating factor-induced enhancement of neutrophilic differentiation of Me2SO-treated HL-60 cells. GM-CSF inhibits the nuclear translocation of tyrosine-phosphorylated STAT3. Yamaguchi T, et al. **J Biol Chem** 1999 May 28; 274(22):15575-81
MRL/lpr and MRL+/+ macrophage DNA synthesis in the absence and the presence of colony-stimulating factor-1 and granulocyte-macrophage colony-stimulating factor. Hamilton JA, et al. **J Immunol** 1998 Dec 15;161(12):6802-11
Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. Gaviria JM, et al. **J Infect Dis** 1999 Apr;179(4):1038-41
Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. Williams MA, et al. **J Infect Dis** 1998 Nov; 178(5):1421-33
Direct comparison of the effects of CSF-1 (M-CSF) and GM-CSF on human monocyte DNA synthesis and CSF receptor expression. Finnin M, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):417-23
Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF. McLeish KR, et al. **J Leukoc Biol** 1998 Oct; 64(4):537-45
Involvement of JAK2, but not PI 3-kinase/Akt and MAP kinase pathways, in anti-apoptotic signals of GM-CSF in human eosinophils. Miike S, et al. **J Leukoc Biol** 1999 May; 65(5):700-6
Regulation of neutrophil FcgammaRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. Moulding DA, et al. **J Leukoc Biol** 1999 Jun;65(6):875-82
Granulocyte-macrophage colony-stimulating factor modulates tapasin expression in human neutrophils. El Ouakfaoui S, et al. **J Leukoc Biol** 1999 Feb;65(2):205-10
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia [letter] Kizaki M, et al. **J Natl Cancer Inst** 1998 Dec 16;90(24):1906-7
Granulocyte-macrophage colony-stimulating factor rescues human polymorphonuclear leukocytes from ultraviolet irradiation-accelerated apoptosis. Sweeney JF, et al. **J Surg Res** 1999 Jan;81(1):108-12
Granulocyte macrophage-colony stimulating factor reciprocally regulates alphav-associated integrins on murine osteoclast precursors. Inoue M, et al. **Mol Endocrinol** 1998 Dec;12(12):1955-62
Recombinant human granulocyte-macrophage colony-stimulating factor triggers interleukin-10 expression in the monocytic cell line U937. Lehmann MH. **Mol Immunol** 1998 Jun;35(8):479-85
Granulocyte-macrophage colony stimulating factor modulates the production of TNF alpha by differentiated U937 cells infected with Leishmania major. Arena A, et al. **New Microbiol** 1999 Jan;22(1):31-9
Assaying the granulocyte-macrophage colony-stimulating factor (GM-CSF) as a mitogen of immature cells in fetal blood cultures. Costa D, et al. **Prenat Diagn** 1999 Jan; 19(1):17-20
Induction of differentiation of pre-NKT cells to mature

Valpha14 NKT cells by granulocyte/macrophage colony-stimulating factor. Sato H, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7439-44

Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Flohé S, et al. **Shock** 1999 Jul;12(1):17-24

Differential activation of functionally distinct STAT5 proteins by IL-5 and GM-CSF during eosinophil and neutrophil differentiation from human CD34+ hematopoietic stem cells. Caldenhoven E, et al. **Stem Cells** 1998;16(6):397-403

A possible role for granulocyte macrophage-colony stimulating factor in modulating teratogen-induced effects. Savion S, et al. **Teratog Carcinog Mutagen** 1999; 19(3):171-82

Development of a recombinant growth factor and fusion protein: lessons from GM-CSF. Schuh JC, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):72-7 (55 ref.)

[The effect of GM-CSF on endothelin-1 and endothelin converting enzyme gene expression in human airway smooth muscle cells with or without theophylline incubation] Xu J, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Oct; 20(5):276-9 (Eng. Abstr.) **(Chi)**

[The dendritic cell differentiation and antigen-presenting function of the erythroleukemia cells induced by GM-CSF] Zhao Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct; 77(10):732-6 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Colony stimulating factors modulate the transcription of type VIII collagen in vascular smooth muscle cells. Plenz G, et al. **Atherosclerosis** 1999 May;144(1):25-32

Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha. Suzuki K, et al. **Blood** 1999 Jan 1;93(1):341-9

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Mellstedt H, et al. **Curr Opin Hematol** 1999 May;6(3):169-75 (61 ref.)

Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Nouri-Aria KT, et al. **Int Arch Allergy Immunol** 1998 Dec; 117(4):248-54

Differential influence of tyrosine residues of the common receptor beta subunit on multiple signals induced by human GM-CSF. Itoh T, et al. **J Allergy Clin Immunol** 1999 May; 103(5 Pt 2):S462-70

CSF-1 regulation of Il6 gene expression by murine macrophages: a pivotal role for GM-CSF. Evans R, et al. **J Leukoc Biol** 1998 Dec;64(6):810-6

Regulation of GM-CSF-induced dendritic cell development by TGF-beta1 and co-developing macrophages. Yamaguchi Y. **Microbiol Immunol** 1998;42(9):627-37

Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Reed JA, et al. **Proc Assoc Am Physicians** 1998 Jul-Aug;110(4):321-32 (56 ref.)

Colony-stimulating factors in rapid eye movement sleep and non-rapid eye movement sleep regulation. Kimura M, et al. **Psychiatry Clin Neurosci** 1999 Apr;53(2):105-7

SECRETION

Increase in granulocyte-macrophage-colony-stimulating factor secretion and the respiratory burst with decreased L-selectin expression in hyper-IgE syndrome patients. Vargas L, et al. **Ann Allergy Asthma Immunol** 1999 Sep; 83(3):245-51

A novel human malignant fibrous histiocytoma cell line of the heart (MFH-H) with secretion of hematopoietic growth factors. Reinecke P, et al. **Anticancer Res** 1999 May-Jun;19(3A):1901-7

Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Maeurer MJ, et al. **Clin Cancer Res** 1996 Jan;2(1):87-95

Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Pak AS, et al. **Clin Cancer Res** 1995 Jan;1(1):95-103

T lymphocytes downregulate granulocyte-macrophage colony-stimulating factor secretion from stimulated monocytes by increasing the secretion of monocyte-derived interleukin-10. Lenhoff S, et al. **Exp Hematol** 1999 Mar;27(3):410-5

CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1alpha, IL-6, and GM-CSF: implications for the interaction of keratinocytes with intraepidermal T lymphocytes. Naderi S, et al. **Int J Mol Med** 1999 Jun; 3(6):609-14

Induction of murine macrophage growth by oxidized low density lipoprotein is mediated by granulocyte macrophage colony-stimulating factor. Biwa T, et al. **J Biol Chem** 1998 Oct 23;273(43):28305-13

Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy. Aydin F, et al. **J Chemother** 1998 Oct;10(5):394-8

Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis. Itoh A, et al. **Respirology** 1998 Dec;3(4):247-51

THERAPEUTIC USE

Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Schoof DD, et al. **Adv Exp Med Biol** 1998;451:511-8

Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection [editorial] Deresinski SC. **AIDS** 1999 Apr 16;13(6):633-43 (136 ref.)

Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin. Shao Z, et al. **Am J Hematol** 1998 Nov; 59(3):185-91

Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. Myint YY, et al. **Am J Pathol** 1999 Feb;154(2):553-66

A question of balance [editorial; comment] Nelson S. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1365-7 (15 ref.). Comment on: Am J Respir Crit Care Med 1999 May;159(5 Pt 1):1377-82.

Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Bennett CL, et al. **Ann Oncol** 1999 Feb;10(2):177-82

Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Wagner W, et al. **Anticancer Res** 1999 Jan-Feb; 19(1B):799-803

Myeloid colony-stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984-8 (65 ref.)

Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Armitage JO. **Blood** 1998 Dec 15;92(12):4491-508 (187 ref.)

Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Miller LL, et al. **Blood** 1999 May 15;93(10):3250-8

Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor [letter] Stagno F, et al. **Blood** 1999 Aug 15;94(4):1479-80

Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Jansen J, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1251-6

Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Leleu X, et al. **Bone Marrow Transplant** 1999 Aug;24(4):417-20

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Comenzo RL, et al. **Br J Haematol** 1999 Mar;104(3):553-9

Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Stasi R, et al. **Br J Haematol** 1999 Apr; 105(1):141-8

Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Taylor DS, et al. **Br J Haematol** 1998 Nov; 103(2):304-7

Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Aruga A, et al. **Cancer Gene Ther** 1999 Jan-Feb;6(1):89-95

Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Miller PW, et al. **Cancer Gene Ther** 1998 Nov-Dec; 5(6):380-9

Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Shi FS, et al. **Cancer Gene Ther** 1999 Jan-Feb; 6(1):81-8

Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. Tseng SH, et al. **Cancer Gene Ther** 1999 Jul-Aug;6(4):302-12

The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. Aslan M, et al. **Cancer Immunol Immunother** 1998 Nov;47(3):176-81

Hematopoietic growth factors and acute leukemia. Rowe JM, et al. **Cancer Treat Res** 1999;99:195-226 (129 ref.)

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Small EJ, et al. **Clin Cancer Res** 1999 Jul;5(7):1738-44

Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Goldman S, et al. **Clin Perinatol** 1998 Sep;25(3):699-710 (32 ref.)

Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. Fisher DC, et al. **Curr Opin Hematol** 1994 May;1(3):221-7 (46 ref.)

Long-term disappearance of previous chromosomal abnormalities in myelodysplastic syndromes treated with low dose cytosine arabinoside and granulocyte/macrophage-colony stimulating factor [letter] Sastre JL, et al. **Haematologica** 1998 Aug;83(8):763-5

Response of colony stimulating factor in cancer chemotherapy induced myelosuppression--a case report. Gupta AK, et al. **Indian J Med Sci** 1998 Apr;52(4):161-2

Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus. Ambati BK, et al. **Int J Infect Dis** 1998-99 Winter;3(2):70-5

A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Nicolatou O, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):551-6

Pulmonary Kaposi's sarcoma in AIDS patients treated with combined chemotherapy and recombinant human granulocyte colony-stimulating factor. Mastroianni A, et al. **J Chemother** 1998 Oct;10(5):405-10

Misleading title and abstract in recent granulocyte-macrophage colony-stimulating factor trial [letter; comment] Grossman JS, et al. **J Clin Oncol** 1999 May;17(5):1644-5. Comment on: J Clin Oncol 1998 Sep;16(9):2930-6.

GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. Pierri I, et al. **J Exp Clin Cancer Res** 1999 Mar;18(1):55-60

Killing of Mycobacterium avium by neutrophils and monocytes from AIDS patients treated with recombinant granulocyte-macrophage colony-stimulating factor. Cinti S, et al. **J Infect Dis** 1999 Jul;180(1):229-33

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. Root RK, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S342-52 (126 ref.)

A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. Stravoravdi P, et al. **J Interferon Cytokine Res** 1999 Mar;19(3):221-5

Colony-stimulating factors stimulate some treatments, continue to evolve [news] Volkers N. **J Natl Cancer Inst** 1999 Feb 3;91(3):210-2

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. Wallenfriedman MA, et al. **J Neurosurg** 1999 Jun; 90(6):1064-71

GM-CSF treatment in patients with B-chronic lymphocytic leukemia. de Nully Brown P, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):365-8

Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections. Itälä M, et al. **Leuk Lymphoma** 1998 Dec;32(1-2):165-74

Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Kim CN, et al. **Leuk Res** 1999 Jun;23(6):527-38

Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Ohno R. **Leuk Res** 1998 Dec;22(12):1143-54 (62 ref.)

Growth factors in the treatment of acute lymphoblastic leukemia. Ottmann OG, et al. **Leuk Res** 1998 Dec; 22(12):1171-8 (30 ref.)

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Economopoulos T, et al. **Leukemia** 1999 Jul;13(7):1009-12

DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Hall PD, et al. **Leukemia** 1999 Apr; 13(4):629-33

GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF. Rozemuller H, et al. **Leukemia** 1998 Dec;12(12):1962-70

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments] Bendandi M, et al. **Nat Med** 1999 Oct;5(10):1171-7. Comment in: Nat Med 1999 Oct;5(10):1124.

Cancer vaccine strategies get bigger and better [news; comment] de Gruijl TD, et al. **Nat Med** 1999 Oct;

5(10):1124-5. Comment on: Nat Med 1999 Oct;5(10):1171-7.

Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Takahashi T, et al. **Nat Med** 1999 Apr; 5(4):434-8

Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Honkoop AH, et al. **Oncologist** 1999;4(2):106-11

GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Bez C, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):311-5

Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine. Mellstedt H, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):211-5 (21 ref.)

Granulocyte-macrophage colony stimulating factor (GM-CSF) in malignancy [letter; comment] Ozsoylu S. **Pediatr Hematol Oncol** 1998 Sep-Oct;15(5):471, 473. Comment on: Pediatr Hematol Oncol 1997 Nov-Dec;14(6):539-45.

A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Carr R, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):796-802

Safety of GM-CSF in patients with AIDS: a review of the literature. Ross SD, et al. **Pharmacotherapy** 1998 Nov-Dec; 18(6):1290-7 (50 ref.)

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Simmons SJ, et al. **Prostate** 1999 Jun 1; 39(4):291-7

High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Frankel AE, et al. **Protein Expr Purif** 1999 Jun; 16(1):190-201

Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Johnston EM, et al. **Semin Oncol** 1998 Oct;25(5):552-61 (48 ref.)

Local treatment of a chronic leg ulcer with GM-CSF in a patient with HIV infection [letter] Mastroianni A, et al. **Sex Transm Infect** 1999 Jun;75(3):203-4

Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Da Costa RM, et al. **Wound Repair Regen** 1999 Jan-Feb;7(1):17-25

[Hematopoietic growth factors in treatment of infections in children with cancer] Riikonen P. **Duodecim** 1995; 111(20):1931-5 (25 ref.) **(Fin)**

[Therapeutic use of hematopoietic growth factors. II. GM-CSF and G-CSF] Royer B, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):255-66 (50 ref.) (Eng. Abstr.) **(Fre)**

[Clinical use of hematopoietic growth factors in the treatment of acute myeloblastic leukemia] Tóthová E. **Vnitr Lek** 1998 Jun;44(6):373-7 (36 ref.) (Eng. Abstr.) **(Slo)**

TOXICITY

Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Perentesis JP, et al. **Clin Cancer Res** 1997 Mar; 3(3):347-55

GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT

ADMINISTRATION & DOSAGE

In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients. Kountouras J, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2295-302

Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. Davidson JA, et al. **J Immunother** 1998 Sep;21(5):389-98

Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer. Rucker R, et al. **J Immunother** 1999 Jan; 22(1):80-4

ADVERSE EFFECTS

Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment? Locker GJ, et al. **J Immunother** 1999 Jan;22(1):85-9

Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer. Cho SG, et al. **J Korean Med Sci** 1998 Dec;13(6):685-8

CHEMISTRY

New cytokine dressings. I. Kinetics of the in vitro rhG-CSF, rhGM-CSF, and rhEGF release from the dressings. Grzybowski J, et al. **Int J Pharm** 1999 Jul 20;184(2):173-8

IMMUNOLOGY

Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. McNeel DG, et al. **Blood** 1999 Apr 15;93(8):2653-9

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Wadhwa M, et al. **Clin Cancer Res** 1999 Jun;5(6):1353-61

PHARMACOKINETICS

Pharmacokinetics of recombinant human granulocyte macrophage colony-stimulating factor in Macaca mulatta. Wang RG, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan; 19(1):50-3

PHARMACOLOGY

Granulocyte-macrophage colony-stimulating factor and fluconazole enhance anti-cryptococcal activity of monocytes from AIDS patients. Tascini C, et al. **AIDS** 1999 Jan 14;13(1):49-55

G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Fischmeister G, et al. **Ann Hematol** 1999 Mar;78(3):117-23

Effects of stem cell factor and granulocyte macrophage-colony stimulating factor on survival of porcine type A spermatogonia cultured in KSOM. Dirami G, et al. **Biol Reprod** 1999 Jul;61(1):225-30

Characterization of HOX gene expression during myelopoiesis: role of HOX A5 in lineage commitment and maturation. Fuller JF, et al. **Blood** 1999 May 15; 93(10):3391-400

Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcgammaRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. Ottonello L, et al. **Blood** 1999 May 15; 93(10):3505-11

Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors. Sun Q, et al. **Blood** 1999 Sep 15;94(6):1943-51

Effect of granulocyte macrophage-colony stimulating factor on Langerhans cells in normal and healthy atopic subjects. Smith CH, et al. **Br J Dermatol** 1998 Aug;139(2):239-46

The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Coscarella A, et al. **Cytokine** 1998 Dec; 10(12):964-9

Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Buchwald UK, et al. **Eur J Med Res** 1999 Mar 26;4(3):85-94

Granulocyte-macrophage colony-stimulating factor induces the differentiation of murine erythroleukaemia cells into dendritic cells. Cao X, et al. **Immunology** 1998 Sep; 95(1):141-7

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-coated implants and their potential for reducing biomaterial-associated infection in neutropenic hosts. Różalska B, et al. **Zentralbl Bakteriol** 1998 Oct; 288(2):237-51

[The blood-simulating properties of a recombinant colony-stimulating factor and glycyram during cytostatic myelosuppression] Dygai AM, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):34-7 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Impaired phagocytosis and opsonisation towards group B streptococci in preterm infants [letter; comment] Jaswon MS, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar; 80(2):F160. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Jan;78(1):F46-50.

Healing of chronic leg ulcers in the hemoglobinopathies with perilesional injections of granulocyte-macrophage colony-stimulating factor [letter] Voskaridou E, et al. **Blood** 1999 May 15;93(10):3568-9

Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits. Shindo J, et al. **Circulation** 1999 Apr 27;99(16):2150-6

Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Wadhwa M, et al. **Clin Cancer Res** 1999 Jun;5(6):1353-61

Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Vazquez JA, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):781-3

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Madero L, et al. **Haematologica** 1999 Feb;84(2):133-7

A novel treatment of patients with chronic hepatitis C. Tsai NC, et al. **Hawaii Med J** 1999 Apr;58(4):85-8

Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Jaschke E, et al. **Int J Dermatol** 1999 May; 38(5):380-6

Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. Leong SP, et al. **J Immunother** 1999 Mar;22(2):166-74

Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte macrophage-colony stimulating factor: evidence of a previously unknown anabolic effect of erythropoietin? Fatouros M, et al. **J Lab Clin Med** 1999 Mar;133(3):253-9

A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. Cairo MS, et al. **J Pediatr** 1999 Jan;134(1):64-70

Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression. Coleman D, et al. **Toxicol Sci** 1998 Sep; 45(1):77-87

GRANULOCYTES

Extreme granulocytic leukocytosis [letter; comment] Tashima CK. **Am J Med** 1998 Oct;105(4):359. Comment on: Am J Med 1998 Jan;104(1):12-6.

Synergistic activation of mitogen-activated protein kinase by cyclic AMP and myeloid growth factors opposes cyclic AMP's growth-inhibitory effects. Lee AW. **Blood** 1999 Jan 15;93(2):537-53

Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report. Lee JJ, et al. **J Korean Med Sci** 1998 Aug; 13(4):434-6

Technetium-99m-labeled liposomes to image experimental colitis in rabbits: comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-IgG. Dams ET, et al. **J Nucl Med** 1998 Dec;39(12):2172-8

Bone marrow as multidimensional orbit oscillator after autologous bone marrow transplantation. Hajek D, et al. **Stem Cells** 1999;17(1):25-30

Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect. Rembacken BJ, et al. **Ther Apher** 1998 May;2(2):93-6

5th European Symposium on Platelet and Granulocyte Immunobiology. S'Agaro, Girona, Spain. 9-12 May 1998. Abstracts. **Transfus Med** 1998 Sep;8(3):243-80

CHEMISTRY

The major selenium-containing protein in human peripheral granulocytes. Liu Q, et al. **Biol Trace Elem Res** 1999 Jun; 68(3):193-207

The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G. Scott FL, et al. **Blood** 1999 Mar 15;93(6):2089-97

Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. Choi SY, et al. **Br J Pharmacol** 1999 Feb; 126(4):1050-6

Nitroblue tetrazolium test in patients with renal tumor in the course of embolization. Mantur M, et al. **Rocz Akad Med Bialymst** 1998;43:292-7

[Analysis of zinc concentrations in leukocytes and its application to patients with non-insulin-dependent diabetes mellitus] Takakura M. **Hokkaido Igaku Zasshi** 1998 Nov; 73(6):571-80 (Eng. Abstr.) **(Jpn)**

[Method of combined cytochemical staining of cells of the granulocyte and lymphoid series] Pigarevskii PV, et al. **Morfologiia** 1999;116(4):68-70 **(Rus)**

CYTOLOGY

A novel strategy for identifying differential gene expression: An improved method of differential display analysis. Kohroki J, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):365-7

Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Ilaria RL Jr, et al. **Blood** 1999 Jun 15;93(12):4154-66

All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Purton LE, et al. **Blood** 1999 Jul 15;94(2):483-95

D3: a gene induced during myeloid cell differentiation of Linlo c-Kit+ Sca-1(+) progenitor cells. Weiler SR, et al. **Blood** 1999 Jan 15;93(2):527-36

Cortisol inhibits apoptosis in carp neutrophilic granulocytes.

Weyts FA, et al. **Dev Comp Immunol** 1998 Sep-Dec; 22(5-6):563-72

Enhanced differentiation of HL-60 leukemia cells to macrophages induced by ciprofibrate. Bronfman M, et al. **Eur J Cell Biol** 1998 Nov;77(3):214-9

Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Biethahn S, et al. **Exp Hematol** 1999 May;27(5):885-94

Characterization and retroviral transduction of an early human lymphomyeloid precursor assayed in nonswitched long-term culture on murine stroma. Gan OI, et al. **Exp Hematol** 1999 Jun;27(6):1097-106

The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Ma Q, et al. **Immunity** 1999 Apr;10(4):463-71

Clonality analysis of granulocytes and T lymphocytes in healthy females by the PCR-based HUMARA method. Nakahara Y, et al. **Int J Hematol** 1999 Jun;69(4):237-43

Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. Rufer N, et al. **J Exp Med** 1999 Jul 19; 190(2):157-67

IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. Schwarzenberger P, et al. **J Immunol** 1998 Dec 1;161(11):6383-9

Optimal storage conditions for preserving granulocyte viability as monitored by Annexin V binding in whole blood. Hodge GL, et al. **J Immunol Methods** 1999 May 27;225(1-2):27-38

Reduction of meningeal macrophages does not decrease migration of granulocytes into the CSF and brain parenchyma in experimental pneumococcal meningitis. Trostdorf F, et al. **J Neuroimmunol** 1999 Oct 29; 99(2):205-10

The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia [letter] Castilla LH, et al. **Nat Genet** 1999 Oct;23(2):144-6

Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2. Kohzaki H, et al. **Oncogene** 1999 Jul 15;18(28):4055-62

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Røseth AG, et al. **Scand J Gastroenterol** 1999 Jan; 34(1):50-4

The ex vivo expansion of feline marrow cells leads to increased numbers of BFU-E and CFU-GM but a loss of reconstituting ability. Abkowitz JL, et al. **Stem Cells** 1998;16(4):288-93

Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis. Barnard MR, et al. **Transfusion** 1999 Jul; 39(7):735-41

[Döhle body] Kurokawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):96-7 (7 ref.) **(Jpn)**

[May-Hegglin anomaly] Shinjo K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):56-8 (13 ref.) **(Jpn)**

[Stem cell factor (SCF) supports granulocyte progenitor survival in mouse bone marrow cultures] Cáceres-Cortés JR, et al. **Rev Invest Clin** 1999 Mar-Apr;51(2):107-16 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis. Bacharach-Buhles M, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:79-82

The influence of radiographic contrast media on some granulocyte functions. Rasmussen F. **Acta Radiol Suppl** 1998;419:7-35 (294 ref.)

Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Stein GM, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1037-42

Opposing effects of protein kinase A and C on capacitative calcium entry into HL-60 promyelocytes. Song SK, et al. **Biochem Pharmacol** 1998 Sep 1;56(5):561-7

Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Stein GM, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):80-90

Stimulation of fetal granulopoiesis by intrauterine injection of recombinant human granulocyte colony- stimulating factor into rat fetuses. Fukumasu Y, et al. **Biol Neonate** 1999;75(6):367-76

Thiorphan stimulates clonal growth of GM-CFU in short-term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma. Stanović S, et al. **Biomed Pharmacother** 1998;52(9):397-402

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors. Thijsen SF, et al. **Br J Cancer** 1999 Mar;79(9-10):1406-12

Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by 2-(allylthio) pyrazine. Kong G, et al. **Cancer Lett** 1999 Sep 20;144(1):1-8

Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Bertagnolo V, et al. **Cancer Res** 1999 Feb 1;59(3):542-6

Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Nakagawa M, et al. **Circulation** 1998 Nov 24;98(21):2307-13

Effect of aminoguanidine on the generation of superoxide anion and nitric oxide by peripheral blood granulocytes of rats with streptozotocin-induced diabetes. Kędziora-Kornatowska KZ, et al. **Clin Chim Acta** 1998 Nov;278(1):45-53

Granulocyte colony-stimulating factor-mobilized granulocyte concentrate transfusions. Price TH. **Curr Opin Hematol** 1998 Nov;5(6):391-5 (34 ref.)

Alterations in adhesion molecule (CD11b/CD18 and CD62L) expression on granulocytes after chemotherapy. Engervall P, et al. **Eur J Clin Invest** 1998 Nov;28(11):924-9

In vitro effect of human recombinant growth hormone on lymphocyte and granulocyte function of healthy and uremic children. Derfalvi B, et al. **Immunol Lett** 1998 Aug; 63(1):41-7

Cellular responses to FMLP challenging: a mini-review. Panaro MA, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):397-419 (114 ref.)

Lysophosphatidylcholine abrogates the CR1 preserving effect of surfactant on quartz-exposed human granulocytes. Zetterberg G, et al. **Inflammation** 1999 Apr;23(2):179-89

Enhancement of all-trans-retinoic acid efficiency in granulocytic differentiation of HL-60 cells by incorporation into low density lipoprotein. Gueddari N, et al. **Int J Oncol** 1998 Nov;13(5):1069-75

Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro. Benko I, et al. **J Antimicrob Chemother** 1999 May;43(5):675-81

Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early-and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation. Cooper CL, et al. **J Cell Biochem** 1998 Nov 1;71(2):277-85

Granulocyte colony-stimulating factor activates protein kinase A in granulocytic but not monocytic precursors or neutrophils. Deshpande RV, et al. **J Interferon Cytokine Res** 1998 Aug;18(8):579-86

Marked granulocytic proliferation induced by granulocyte colony-stimulating factor in the spleen simulating a myeloid leukemic infiltrate. Vasef MA, et al. **Mod Pathol** 1998 Nov;11(11):1138-41

Differential effects of in vivo cadmium administration on lymphocytes and granulocytes in rats. Kataranovski M, et al. **Vet Hum Toxicol** 1999 Aug;41(4):200-4

[Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles] Gibaud S, et al. **Ann Pharm Fr** 1999 Jul;57(4):324-31 (Eng. Abstr.) **(Fre)**

[The effect of erythropoietin (rh-EPO) om in vitro proliferation of granulocyte/monocyte-determined stem cells in bone marrow and peripheral blood] Neumann U, et al. **Med Klin** 1999 Mar 15;94(3):133-6 (Eng. Abstr.) **(Ger)**

[Changes in the myeloperoxidase activity of human neutrophilic granulocytes and the amount of enzyme deriving from them under the effect of estrogen] Békési G, et al. **Orv Hetil** 1999 Jul 18;140(29):1625-30 (Eng. Abstr.) **(Hun)**

[Soluble proteins from Staphylococcus aureus can change expression of CD11b and CD62L, but not H_2O_2 production by human blood granulocytes] Onogawa T, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):328-35 (Eng. Abstr.) **(Jpn)**

[The effect of Cordafen (nifedipine) on endocytosis and bactericidal activity of polymorphonuclear granulocytes in peripheral blood] Misiewicz A, et al. **Przegl Lek** 1999; 56(4):267-9 (Eng. Abstr.) **(Pol)**

[Parameters of granulocyte phagocytic activity and their immunocorrection during chronic aflatoxicosis B1 and benzene intoxication] Belokrylov GA, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):430-2 **(Rus)**

[Content of fibroblasts, macrophages, granulocytes and lymphocytes in the connective tissue regenerate of the skin in wound healing as affected by noradrenaline, acetylcholine, propranolol and atropine] Grabovoĭ AN. **Morfologiia** 1999;116(4):41-5 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation. Marchisio M, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):346-51

Thioredoxin reductase is one of the selenoproteins in both promyelocytic and granulocytic HL-60 cells. Liu Q, et al. **Biol Trace Elem Res** 1999 Jun;68(3):209-23

A secreted proform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells. Sköld S, et al. **Blood** 1999 Feb 1;93(3):849-56

Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Bertagnolo V, et al. **Cancer Res** 1999 Feb 1;59(3):542-6

Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines. Uesugi Y, et al. **Eur J Haematol** 1999 Apr;62(4):239-45

Chemiluminescent determination of esterases in monocytes. da Fonseca LM, et al. **J Biolumin Chemilumin** 1998 Jul-Aug;13(4):195-200

Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Schettler V, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2588-93

IMMUNOLOGY

Comparative study on the effect of cyclic nucleotides related to the function of Biomphalaria glabrata hemocytes and human granulocytes. Bezerra FS, et al. **Acta Trop** 1999 Apr 30;72(3):275-80

Mouse granulated metrial gland cell cytotoxicity of Wehi 164 cells: is there a role for interleukin-3 and tumour necrosis factor-alpha? Stewart IJ, et al. **Am J Reprod Immunol** 1999 Jun;41(6):423-7

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. Krause T, et al. **Ann Oncol** 1999 Jan;10(1):79-85

The use of allele-specific recombinant Fc gamma receptor IIIb antigens for the detection of granulocyte antibodies. Bux J, et al. **Blood** 1999 Jan 1;93(1):357-62

In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Wang C, et al. **Clin Exp Immunol** 1999 Aug;117(2):261-8

Alterations in adhesion molecule (CD11b/CD18 and CD62L) expression on granulocytes after chemotherapy. Engervall P, et al. **Eur J Clin Invest** 1998 Nov;28(11):924-9

Interleukin-10: effects on phagocytosis and adhesion molecule expression of granulocytes and monocytes in a comparison with prednisolone. Buchwald UK, et al. **Eur J Med Res** 1999 Mar 26;4(3):85-94

SLP-76 expression is restricted to hemopoietic cells of monocyte, granulocyte, and T lymphocyte lineage and is regulated during T cell maturation and activation. Clements JL, et al. **J Immunol** 1998 Oct 15;161(8):3880-9

Expansion of extrathymic T cells as well as granulocytes in the liver and other organs of granulocyte-colony stimulating factor transgenic mice: why they lost the ability of hybrid resistance. Kawamura H, et al. **J Immunol** 1999 May 15;162(10):5957-64

High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria. Greve B, et al. **J Infect Dis** 1999 Jun;179(6):1584-6

Human T-cell leukemia virus type 1 can infect a wide variety of cells in mice. Feng R, et al. **Jpn J Cancer Res** 1999 Jan;90(1):48-54

99mTc-labeled chimeric anti-NCA 95 antigranulocyte monoclonal antibody for bone marrow imaging. Sarwar M, et al. **Radiat Med** 1998 Sep-Oct;16(5):391-7

Rapid diagnostic imaging of acute, nonclassic appendicitis by leukoscintigraphy with sulesomab, a technetium 99m-labeled antigranulocyte antibody Fab' fragment. LeukoScan Appendicitis Clinical Trial Group. Barron B, et al. **Surgery** 1999 Mar;125(3):288-96

Nomenclature of granulocyte alloantigens. ISBT Working Party on Platelet and Granulocyte Serology, Granulocyte Antigen Working Party. International Society of Blood Transfusion [letter] Bux J. **Transfusion** 1999 Jun;39(6):662-3

Hepatocyte transplantation--granulocytes and mononuclear cells recognize the surface of isolated autologous hepatocytes as non-self and destroy them. Olszewski WL, et al. **Transpl Int** 1998;11 Suppl 1:S367-71

Granulocyte function in dogs experimentally infected with a Swedish granulocytic Ehrlichia species. Lilliehöök I, et al. **Vet Immunol Immunopathol** 1999 Feb 1;67(2):141-52

Enhancement of phagocytosis and bacterial killing by heterophils from neonatal chicks after administration of Salmonella enteritidis-immune lymphokines. Genovese LL, et al. **Vet Microbiol** 1999 Mar 1;65(2):133-43

[A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)] Cailleux N, et al. **Rev Med Interne** 1998 Jun;19(6):434-7 (Eng. Abstr.) **(Fre)**

[Differential diagnosis of chronic inflammatory bowel diseases. Value of determination of autoantibodies pANCA, ASCA AND PAB (perinuclear antineutrophil cytoplasmic antibody, antibody against Saccharomyces cerevisiae, antibody against pancreas)] Seibold F, et al. **Fortschr Med** 1999 Feb 28;117(6):42-3 **(Ger)**

[Granulocyte function in premature infants before the 34th week of pregnancy and in mature newborn infants] Habermehl P, et al. **Klin Padiatr** 1999 May-Jun; 211(3):149-53 (Eng. Abstr.) **(Ger)**

[Phagocytosis and killing of Staphylococcus aureus by mouse granulocytes after interleukin-3 (IL-3) injection] Czygier M, et al. **Med Dosw Mikrobiol** 1998;50(3-4):141-9 (Eng. Abstr.) **(Pol)**

[Phagocytosis and killing of Staphylococcus aureus by granulocytes in mice after granulocyte-macrophage colony stimulating factor (GM-CSF) injection] Czygier M, et al. **Med Dosw Mikrobiol** 1998;50(3-4):151-60 (Eng. Abstr.) **(Pol)**

[Anti-neutrophil cytoplasmic antibodies ANCA in glomerulonephritis and systemic vasculitis with renal involvement--the frequency of occurrence and ability for granulocyte activation in vitro] Mazanowska O, et al. **Pol Arch Med Wewn** 1998 May;99(5):390-7 (Eng. Abstr.) **(Pol)**

GRANULOCYTES

METABOLISM

Analysis of phosphatidic acid molecular species using mass spectrometry. Wright SM, et al. **Biochem Soc Trans** 1998 Aug;26(3):S226

Lineage-specific modulation of calcium pump expression during myeloid differentiation. Launay S, et al. **Blood** 1999 Jun 15;93(12):4395-405

A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. Lucas DM, et al. **Blood** 1999 Mar 15;93(6):1922-33

Detection of lymphocytes and granulocytes expressing the mutant WASP message in carriers of Wiskott-Aldrich syndrome. Ariga T, et al. **Br J Haematol** 1999 Mar; 104(4):893-900

Long-term changes in tyrosine phosphorylation of the abundant nuclear proteins during granulocytic differentiation of HL-60 cells. Gineitis A, et al. **Cell Mol Life Sci** 1999 Feb;55(2):317-26

Myeloid cell-lineage and premylocytic-stage-specific-expression of themouse myeloperoxidase gene is controlled at initiation as well as elongation levels of transcription. Zhu JD. **Cell Res** 1999 Jun;9(2):107-34

The pattern of intracellular free amino acids in granulocytes from hemodialysis patients change to an oral protein supplement (granulocyte amino acids after protein in HD patients). Ivarsen P, et al. **Clin Nephrol** 1999 Aug; 52(2):110-8

HSP70 expression in granulocytes and lymphocytes of patients with polytrauma: comparison with plasma glutamine. Weingartmann G, et al. **Clin Nutr** 1999 Apr; 18(2):121-4

Pulmonary granulocyte kinetics in relation to endothelial and granulocyte activation. Ussov WY, et al. **Clin Sci (Colch)** 1999 May;96(5):525-31

Increment of nonreceptor tyrosine kinase Arg RNA as evaluated by semiquantitative RT-PCR in granulocyte and macrophage-like differentiation of HL-60 cells. Perego RA, et al. **Exp Cell Res** 1998 Nov 25;245(1):146-54

Nuclear association of tyrosine-phosphorylated Vav to phospholipase C-gamma1 and phosphoinositide 3-kinase during granulocytic differentiation of HL-60 cells. Bertagnolo V, et al. **FEBS Lett** 1998 Dec 28;441(3):480-4

Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. Tsai KJ, et al. **FEBS Lett** 1998 Oct 9;436(3):411-4

Yops of Yersinia enterocolitica inhibit receptor-dependent superoxide anion production by human granulocytes. Visser LG, et al. **Infect Immun** 1999 Mar;67(3):1245-50

The gene encoding the myeloid-related protein 14 (MRP14), a calcium-binding protein expressed in granulocytes and monocytes, contains a potent enhancer element in the first intron. Melkonyan H, et al. **J Biol Chem** 1998 Oct 9; 273(41):27026-32

S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. Vogl T, et al. **J Biol Chem** 1999 Sep 3;274(36):25291-6

Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. Nakajima H, et al. **J Immunol** 1999 Jan 1;162(1):5-8

Altered signal pathway in granulocytes from patients with hypercholesterolemia. Paragh G, et al. **J Lipid Res** 1999 Sep;40(9):1728-33

Regulation of VIP production and secretion by murine lymphocytes. Martinez C, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):126-38

Host defenses in the aged: evaluation of the balance between oxidizing species generation and reducing power in phagocyting human granulocytes. Chaves MM, et al. **Mech Ageing Dev** 1998 Aug 1;104(1):103-9

Regulation of MAC-1 (CD11b/CD18) expression on circulating granulocytes in endurance runners. Jordan J, et al. **Med Sci Sports Exerc** 1999 Mar;31(3):362-7

Retinoid X receptor (RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor alpha403 heterodimers is developmentally regulated during myeloid differentiation. Johnson BS, et al. **Mol Cell Biol** 1999 May; 19(5):3372-82

Radiolabelled mixed leukocytes and pure granulocytes with stabilized 99Tcm-exametazime. Hung JC, et al. **Nucl Med Commun** 1998 Oct;19(10):981-7

Effects of garlic preparations on superoxide production by phorbol ester activated granulocytes. Siegers CP, et al. **Phytomedicine** 1999 Mar;6(1):13-6

Peripheral-type benzodiazepine receptors in diagnostic subtypes of schizophrenic patients. Wodarz N, et al. **Psychiatry Res** 1998 Dec 14;81(3):363-9

MICROBIOLOGY

A simian model of human granulocytic ehrlichiosis. Foley JE, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):987-93

Changes in expression of the 44-kilodalton outer surface membrane antigen (p44 kD) for monitoring progression of infection and antimicrobial susceptibility of the human granulocytic ehrlichiosis (HGE) agent in HL-60 cells. Hsieh T, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):351-5

Quantification of the human granulocytic ehrlichiosis agent based on analysis of rRNA isolated from control and infected HL-60 cells. Wu JM, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):7-13

Human granulocytic ehrlichiosis in Europe: clinical and laboratory findings for four patients from Slovenia. Lotrič-Furlan S, et al. **Clin Infect Dis** 1998 Sep;27(3):424-8

Multiple p44 genes encoding major outer membrane proteins are expressed in the human granulocytic ehrlichiosis agent. Zhi N, et al. **J Biol Chem** 1999 Jun 18;274(25):17828-36

PATHOLOGY

Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Takahashi T, et al. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2199-204

Flt-3 ligand does not induce the growth of peripheral blood granulocyte-macrophage colony-forming cells in myeloproliferative disorders. Siitonen T, et al. **Eur J Haematol** 1999 Feb;62(2):103-8

Apoptotic features of peripheral blood granulocytes and monocytes during primary, acute HIV infection. Cossarizza A, et al. **Exp Cell Res** 1999 Feb 25;247(1):304-11

Long-term bone marrow cultures in Diamond-Blackfan anemia reveal a defect of both granulomacrophage and erythroid progenitors. Santucci MA, et al. **Exp Hematol** 1999 Jan;27(1):9-18

Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome. Atkinson TP, et al. **J Clin Immunol** 1998 Nov;18(6):430-9

Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors. Suzuki H, et al. **Leukemia** 1999 Jan; 13(1):130-4

[Apoptosis of peripheral leukocytes in patients with myelodysplastic syndromes] Hamada K, et al. **Rinsho Ketsueki** 1998 Nov;39(11):1079-84 (Eng. Abstr.) **(Jpn)**

[Adaptive potential of granulocytic stem cells in the bone marrow from preleukemic AKR mice] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):151-4 **(Rus)**

[Detection of PNH clones using flow cytometry in aplastic anemia and paroxysmal nocturnal hemoglobinuria] Forés R, et al. **Sangre (Barc)** 1999 Jun;44(3):199-203 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Granulocytes in the subarachnoid space of humans and rabbits with bacterial meningitis undergo apoptosis and are eliminated by macrophages. Nau R, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):472-80

Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Ferrero ME, et al. **Am J Clin Nutr** 1998 Dec;68(6):1208-14

Haemophagocytosis in the peripheral blood. Au WY, et al. **Br J Haematol** 1999 May;105(2):321

Examination of a rheological profile for blood using micropore filters. Jones JG, et al. **Br J Haematol** 1999 Jan; 104(1):100-7

Brain NPY Y1 receptors rapidly mediate the behavioral response to novelty and a compartment-specific modulation of granulocyte function in blood and spleen. von Hörsten S, et al. **Brain Res** 1998 Sep 28;806(2):282-6

Endothelin-1 and thromboxane A2 increase pulmonary vascular resistance in granulocyte-mediated lung injury. Schmeck J, et al. **Crit Care Med** 1998 Nov;26(11):1868-74

Differential effects of anti-rat CD11b monoclonal antibodies on granulocyte adhesiveness. Draškovič-Pavlovič B, et al. **Immunology** 1999 Jan;96(1):83-9

NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. Ward C, et al. **J Biol Chem** 1999 Feb 12;274(7):4309-18

Arrested maturation of granulocytes in copper deficient mice. Karimbakas J, et al. **J Nutr** 1998 Nov;128(11):1855-60

Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Offen D, et al. **Neurosci Lett** 1999 Jan 29;260(2):101-4

Bimodal granulocyte transit time through the human lung demonstrated by deconvolution analysis. Ussov WY, et al. **Respir Med** 1998 Sep;92(9):1163-6

Regulation of granulocyte apoptosis and implications for anti-inflammatory therapy [editorial] Chilvers ER, et al. **Thorax** 1998 Jul;53(7):533-4

Phytoalexin resveratrol (3-4'-5-trihydroxystilbene) modulates granulocyte and monocyte endothelial adhesion. Ferrero ME, et al. **Transplant Proc** 1998 Dec;30(8):4191-3

Hepatic extramedullary granulopoiesis after treatment with liver-stimulatory xenobiotics, in lpr mice. Sarraf CE, et al. **Ultrastruct Pathol** 1998 Nov-Dec;22(6):443-8

[The evaluation of granulocyte function before and after surgical treatment in patients with chronic inflammation of the middle ear and palatine tonsils] Zalewski P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:349-52 (Eng. Abstr.) **(Pol)**

[Reactions of granulocytic hematopoietic stem cells during experimental neurosis-inducing situations] Dygai AM, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):628-31 **(Rus)**

[Granulocyte transfusions. Return to the past (editorial)] Muncunill J. **Med Clin (Barc)** 1999 May 1;112(15):574-6 **(Spa)**

RADIATION EFFECTS

[Bone marrow recovery after irradiation of the spine] Schleicher UM, et al. **Strahlenther Onkol** 1999 Aug; 175(8):374-7 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Immunoscintigraphy (BW 250/183) in neonates and infants with fever of unknown origin. Gratz S, et al. **Nucl Med Commun** 1998 Nov;19(11):1037-45

TRANSPLANTATION

An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Volk EE, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):508-13 (62 ref.)

Granulocyte transfusion therapy. Schiffer CA. **Curr Opin Hematol** 1999 Jan;6(1):3-7 (41 ref.)

[The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(4):50-2 (25 ref.) **(Bul)**

ULTRASTRUCTURE

Ultrastructural characteristics and lysozyme content in hypergranular and variant type of acute promyelocytic leukaemia. Shaft D, et al. **Br J Haematol** 1998 Dec; 103(3):729-39

VIROLOGY

Pathogenesis of borna disease virus: granulocyte fractions of psychiatric patients harbor infectious virus in the absence of antiviral antibodies. Planz O, et al. **J Virol** 1999 Aug; 73(8):6251-6

GRANULOCYTIC LEUKEMIA see **LEUKEMIA, MYELOID**

GRANULOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

GRANULOCYTIC LEUKEMIA, CHRONIC, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

GRANULOCYTOPENIA see **AGRANULOCYTOSIS**

GRANULOMA

see related

TUBERCULOMA

[Pseudotumorous choroid granuloma in miliary tuberculosis] Benchekroun S, et al. **J Fr Ophtalmol** 1999 Aug-Sep; 22(7):771-5 (Eng. Abstr.) **(Fre)**

[Granulomatous amebic encephalitis (Acanthameba spp)] Hashimoto R, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):415-8 (6 ref.) **(Jpn)**

CHEMICALLY INDUCED

Necrobiotic palisading granuloma at injection site of disodium clodronate: A case report. Lalinga AV, et al. **Dermatology** 1999;198(4):394-5

The development of hepatic granulomas following interferon-alpha2b therapy for chronic hepatitis C infection. Ryan BM, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):349-51

Sarcoid granulomatosis after zirconium exposure with multiple organ involvement [letter] Werfel U, et al. **Eur Respir J** 1998 Sep;12(3):750

COMPLICATIONS

Cutaneous granulomas in a patient with common variable immunodeficiency [letter] Alvarez-Cuesta C, et al. **Acta Derm Venereol** 1999 Jul;79(4):334

Epibulbar allergic granulomatous nodules in a human immunodeficiency virus-positive patient. Godfrey DG, et al. **Am J Ophthalmol** 1998 Dec;126(6):844-6

Necrobiotic xanthogranuloma with paraproteinaemia. Randell PL, et al. **Australas J Dermatol** 1999 May; 40(2):114-5

Pelvi-ureteric obstruction by granuloma of the bladder mucosa after bacillus Calmette-Guérin perfusion for upper tract transitional cell carcinoma. Benejam Gual JM, et al. **BJU Int** 1999 Feb;83(3):346-7

Cutaneous granulomatous lesions in common variable immunodeficiency: complete resolution after intravenous immunoglobulins. Pujol RM, et al. **Dermatology** 1999; 198(2):156-8

Symptomatic Rathke's cleft cyst coexisting with central diabetes insipidus and hypophysitis: case report. Hama S, et al. **Endocr J** 1999 Feb;46(1):187-92

Xanthogranulomatous cholecystitis associated with a xanthogranulomatous pseudotumour on the left diaphragm. Roels K, et al. **Eur Radiol** 1999;9(6):1139-41

Epithelioid cell granulomas in chronic hepatitis C: immunohistochemical character and histological marker of favourable response to interferon-alpha therapy. Harada K, et al. **Histopathology** 1998 Sep;33(3):216-21

Spinal extradural compression caused by granuloma of brucellosis. Coskun E, et al. **Scand J Infect Dis** 1998; 30(3):311-3

Pulmonary small cell carcinoma associated with sarcoid

reactions: report of a case. Kamiyoshihara M, et al. **Surg Today** 1999;29(4):382–4
Coexistence of histoplasma granulomas and Warthin's tumor in the submaxillary salivary gland. Udoji WC. **Tenn Med** 1999 May;92(5):175–6
[Granulomatous skin lesions in Griscelli disease] Eyer D, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):727–8 **(Fre)**
[Mechanism of the development of tubulo-interstitial nephropathies due to collagen diseases, angiitis, or granuloma and its significance] Imai H, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1467–74 (9 ref.) **(Jpn)**
[Non-specific granulomatous prostatitis diagnosed with ultrasonography-guided transrectal biopsy] Herranz Amo F, et al. **Actas Urol Esp** 1998 Oct;22(9):757–61 (Eng. Abstr.) **(Spa)**
[Granuloma of bone marrow in myelodysplastic syndrome without excess of blasts (letter)] Rubio Barbón S, et al. **An Med Interna** 1998 Oct;15(10):562 **(Spa)**
[Fibrin-ring granulomas in an AIDS patient and disseminated infection by Mycobacterium avium-intracellulare (letter)] Payeras A, et al. **Enferm Infecc Microbiol Clin** 1998 Aug-Sep;16(7):343–4 **(Spa)**

DIAGNOSIS

Necrotic granuloma of the liver by human fascioliasis: imaging findings. Kim KA, et al. **Abdom Imaging** 1999 Sep-Oct;24(5):462–4
MR imaging of a hemorrhagic and granulomatous cyst of the ligamentum flavum with pathologic correlation. Mahallati H, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul; 20(6):1166–8
Granulomatous mastitis: mammographic and sonographic appearances. Han BK, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):317–20
The forgotten granuloma [letter] Worynski A, et al. **Aust N Z J Med** 1998 Oct;28(5):673–4
The transrectal ultrasound and MRI appearances of granulomatous prostatitis and its differentiation from carcinoma. Naik KS, et al. **Clin Radiol** 1999 Mar; 54(3):173–5
Petrous apex lesions: cholesterol granuloma. Palacios E, et al. **Ear Nose Throat J** 1999 Apr;78(4):234
Renal granulomatous sarcoidosis in childhood: a report of 11 cases and a review of the literature. Coutant R, et al. **Eur J Pediatr** 1999 Feb;158(2):154–9 (35 ref.)
Bone pain after lymphadenitis. Bartonella henselae granulomatous osteitis. Maggiore G, et al. **Eur J Pediatr** 1999 Feb;158(2):165–6
A tumour in the breast: vaccination granuloma as a differential diagnosis. Al-Suliman NN, et al. **Eur J Surg Oncol** 1999 Feb;25(1):34–7
Erdheim-Chester disease: a case report and literature overview. Kenn W, et al. **Eur Radiol** 1999;9(1):153–8 (42 ref.)
Pseudotuberculous pyelonephritis: a rare entity and a diagnostic pitfall [letter] Muldoon C, et al. **Histopathology** 1999 Aug;35(2):181–3
Granuloma multiforme (called Nkanu disease in the 1940s and Mkar disease in 1964) [letter] Garrett AS. **Int J Lepr Other Mycobact Dis** 1999 Jun;67(2):172–4
Ocular toxocariasis: a rare presentation of a posterior pole granuloma with an associated choroidal neovascular membrane. Lampariello DA, et al. **J Am Optom Assoc** 1999 Apr;70(4):245–52
Solitary cysticercus granuloma of the brainstem. Report of four cases. Lath R, et al. **J Neurosurg** 1998 Dec; 89(6):1047–51
Inflammatory granulomas: evaluation with proton MRS. Jayasundar R, et al. **NMR Biomed** 1999 May;12(3):139–44
Choroidal tuberculosis diagnosed by polymerase chain reaction. A clinicopathologic case report. Bowyer JD, et al. **Ophthalmology** 1999 Feb;106(2):290–4
Orbital subperiosteal hematoma, cholesterol granuloma, and infection. Evaluation with MR imaging and CT. Dobben GD, et al. **Radiol Clin North Am** 1998 Nov;36(6):1185–200
A case report of intraspinal paracoccidioidomycosis. do Valle AC, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun; 40(3):203–7
Solitary sarcoid granuloma of the cerebellopontine angle: a case report. Elias WJ, et al. **Surg Neurol** 1999 Feb; 51(2):185–90
[Granulomatous spondylodiscitis of the lumbar spine in chronic brucellosis] Scheck RJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):601–4 **(Ger)**
[Erdheim Chester disease: autonomous entity or expression of Langerhans cell histiocytosis? Report of a case] Popolizio T, et al. **Radiol Med (Torino)** 1999 May; 97(5):422–4 **(Ita)**
[A cryptococcal granuloma of the midbrain] Konovalov AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr-Jun; (2):33–6 (34 ref.) (Eng. Abstr.) **(Rus)**
[Hepatic granulomas, giant-cell arteritis and miliary tuberculosis (letter)] Pia Iglesias G, et al. **An Med Interna** 1999 Jan;16(1):47 **(Spa)**
[Cytomegalovirus granulomatous hepatitis in an immunocompetent patient] de la Serna-Higuera C, et al. **Gastroenterol Hepatol** 1999 May;22(5):230–1 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. Gupta AK, et al. **Clin Exp Dermatol** 1998 May;23(3):103–8
Granuloma regression after fixed duration therapy [letter] Salunkhe SR, et al. **Indian J Lepr** 1998 Jul-Sep;70(3):324
Steroids treatment of granulomatous hepatitis complicating Coxiella burnetii acute infection. Crespo M, et al. **Infection** 1999 Mar-Apr;27(2):132–3
Clotrimazole is an inhibitor of inflammatory angiogenesis and the metabolic activity in sponge granuloma. da Rocha e Silva M, et al. **Inflammation** 1998 Dec;22(6):643–51
Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas? Rajadhyaksha S, et al. **J Trop Pediatr** 1999 Jun;45(3):161–5

ENZYMOLOGY

Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Facchetti F, et al. **Am J Pathol** 1999 Jan;154(1):145–52

ETIOLOGY

Bilateral renal masses after local Bacillus Calmette-Guerin therapy for postcystectomy ureteral cancer. Squires FB, et al. **Abdom Imaging** 1999 Mar-Apr;24(2):200–1
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. **Am J Respir Crit Care Med** 1999 Aug; 160(2):736–55 (331 ref.)
Laryngeal granuloma caused by short-term endotracheal intubation. Kaneda N, et al. **Anesthesiology** 1999 May; 90(5):1482–3
Ablation of Teflon granulomas in the canine larynx with the free-electron laser. Lano CF Jr, et al. **Ann Otol Rhinol Laryngol** 1999 Jan;108(1):17–23
Lytic Paget disease as a cause of orbital cholesterol granuloma. Miller NR, et al. **Arch Ophthalmol** 1999 Aug; 117(8):1084–6
Activation of monocytes in vivo causes intracellular accumulation of lipoprotein-derived lipids and marked hypocholesterolemia--a possible pathogenesis of necrobiotic xanthogranuloma. Matsura F, et al. **Atherosclerosis** 1999 Feb;142(2):355–65
Granulomatous skin lesions in a patient with ataxia telangiectasia [letter] Sentürk N, et al. **Br J Dermatol** 1998 Sep;139(3):543–4
Vaccine-induced necrobiotic granuloma. Ajithkumar K, et al. **Clin Exp Dermatol** 1998 Sep;23(5):222–4
Xanthogranulomatous sialadenitis following diagnosis of Warthin's tumour: a possible complication of fine needle aspiration (FNA). Stephen MR, et al. **Cytopathology** 1999 Aug;10(4):276–9
Cat-scratch disease simulating a malignant process of the chest wall. Millot F, et al. **Eur J Pediatr** 1999 May; 158(5):403–5
A tumour in the breast: vaccination granuloma as a differential diagnosis. Al-Suliman NN, et al. **Eur J Surg Oncol** 1999 Feb;25(1):34–7
Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy. Ozbakkaloglu B, et al. **Int Urol Nephrol** 1999;31(1):49–53
Sarcoidosis associated with acute renal failure and increased levels of interleukin-6 in urine. Maniwa K, et al. **Intern Med** 1998 Sep;37(9):757–61
Distant cutaneous manifestation of Crohn's disease presenting as a granulomatous erysipelas-like lesion [letter] Dippel E, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):65–6
Systemic sarcoidosis presenting with multiple tattoo granulomas and an extra-tattoo cutaneous granuloma. Papageorgiou PP, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):51–3
The substance P receptor is necessary for a normal granulomatous response in murine schistosomiasis mansoni. Blum AM, et al. **J Immunol** 1999 May 15;162(10):6080–5
Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. Jankovic D, et al. **J Immunol** 1999 Jul 1;163(1):337–42
Granuloma formation and in vitro macrophage activation in mice by mycoloyl glycolipids from Nocardia asteroides and related taxa. Han Y, et al. **Osaka City Med J** 1998 Dec;44(2):201–17
Intubation granuloma in a neonate. Lam DW, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):447–8
Epithelioid cell granulomatosis of the lung: new insights and concepts. Popper HH. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):32–46 (62 ref.)
[Necrobiotic xanthogranulomatosis: a cutaneous manifestation of a monoclonal IgM gammopathy] Sève P, et al. **Rev Med Interne** 1998 May;19(5):338–40 (Eng. Abstr.) **(Fre)**
[Granulomatous prostatitis as collateral effect of intravesical immunotherapy with BCG] Mattei FM, et al. **Arch Ital Urol Androl** 1998 Sep;70(4):177–82 (Eng. Abstr.) **(Ita)**
[Tuberous lesion and nodular lymphangitis in an immunocompetent patient] Bretón Martínez JR, et al. **Rev Clin Esp** 1999 Jun;199(6):381–3 **(Spa)**

GENETICS

Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen-elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses. Warmington KS, et al. **Am J Pathol** 1999 May;154(5):1407–16
Monocyte chemotactic protein-1 gene expression and translation in formed granulomatous calcified tissue in vivo. Conti P, et al. **Calcif Tissue Int** 1999 Jan;64(1):57–62
Inhibition of bacterial cell wall-induced leukocyte recruitment and hepatic granuloma formation by TGF-beta gene transfer. Song X, et al. **J Immunol** 1999 Oct 1; 163(7):4020–6
Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Kaneko H, et al. **Lab Invest** 1999 Apr;79(4):379–86

IMMUNOLOGY

Type 1 T-helper cell predominance in granulomas of Crohn's disease. Kakazu T, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2149–55
Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CD8. Senaldi G, et al. **Cell Immunol** 1999 May 1;193(2):155–61
In situ expression of B7 and CD40 costimulatory molecules by normal human lung macrophages and epithelioid cells in tuberculoid granulomas. Soler P, et al. **Clin Exp Immunol** 1999 May;116(2):332–9
Nitric oxide and IL-10 production induced by PIII--a fraction of Schistosoma mansoni adult worm antigenic preparation--associated with downregulation of in vitro granuloma formation. Oliveira DM, et al. **Hum Immunol** 1999 Apr;60(4):305–11
Inhibition of protein kinases prevents lymphocyte activation by Schistosoma mansoni antigens and reduces in vitro [correction of in vivo] granuloma reaction [published erratum appears in Immunol Lett 1999 Apr 1;67(2):155] Almeida CA, et al. **Immunol Lett** 1998 Jul;62(3):137–43
TCR specificity in infection induced granulomas. Hogan LH, et al. **Immunol Lett** 1999 May 3;68(1):115–20 (36 ref.)
Extramedullar B lymphopoiesis in liver schistosomal granulomas: presence of the early stages and inhibition of the full B cell differentiation. Rossi MI, et al. **Int Immunol** 1999 Apr;11(4):509–18
CD40L is necessary for the priming of effector cells for lymphocytic and granulomatous experimental autoimmune thyroiditis. Peterson KE, et al. **J Autoimmun** 1999 Feb; 12(1):1–12
Propionibacterium acnes induces acute TNFalpha-mediated apoptosis of hepatocytes followed by inflammatory T-cell-mediated granulomatous hepatitis in mice. Chen YL, et al. **J Biomed Sci** 1999 Sep-Oct;6(5):349–56
Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. Agostini C, et al. **J Immunol** 1998 Dec 1;161(11):6413–20
The schistosome granuloma: characterization of lymphocyte migration, activation, and cytokine production. Rumbley CA, et al. **J Immunol** 1998 Oct 15;161(8):4129–37
Expression and participation of eotaxin during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granuloma formation. Ruth JH, et al. **J Immunol** 1998 Oct 15;161(8):4276–82
Secondary alveolar echinococcosis in lymphotoxin-alpha and tumour necrosis factor-alpha deficient mice: exacerbation of Echinococcus multilocularis larval growth is associated with cellular changes in the periparasitic granuloma. Amiot F, et al. **Parasite Immunol** 1999 Sep;21(9):475–83
Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. Falcão PL, et al. **Parasite Immunol** 1998 Oct;20(10):447–54
Schistosomal granuloma modulation. II. Specific immunogenic carbohydrates can modulate schistosome-egg-antigen-induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan; 85(1):14–8
Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls [published erratum appears in Proc Natl Acad Sci U S A 1999 Jun 22;96(13):7610] Apostolou I, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5141–6
Cells and cytokines involved in the pathogenesis of sarcoidosis. Moller DR. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):24–31 (59 ref.)

METABOLISM

Nitric oxide and IL-10 production induced by PIII--a fraction of Schistosoma mansoni adult worm antigenic preparation--associated with downregulation of in vitro granuloma formation. Oliveira DM, et al. **Hum Immunol** 1999 Apr;60(4):305–11
The kinetics of cytokine gene expression in the thyroids of

mice developing granulomatous experimental autoimmune thyroiditis. Tang H, et al. **J Autoimmun** 1998 Dec; 11(6):581–9

Enhanced expression of human metalloelastase (MMP–12) in cutaneous granulomas and macrophage migration. Vaalamo M, et al. **J Invest Dermatol** 1999 Apr; 112(4):499–505

Immunohistochemical evaluation of MRP–14 expression in epithelioid granuloma using monoclonal antibody 60B8. Arai K, et al. **J Investig Allergol Clin Immunol** 1999 Jan–Feb;9(1):21–6

MICROBIOLOGY

Role of macrophage scavenger receptors in hepatic granuloma formation in mice. Hagiwara SI, et al. **Am J Pathol** 1999 Mar;154(3):705–20

Granulomatous inflammation and the transmission of infection: schistosomiasis--and TB too? [see comments] Doenhoff MJ. **Immunol Today** 1998 Oct;19(10):462–7. Comment in: Immunol Today 1999 Jul;20(7):336–7. Comment in: Immunol Today 1999 Jul;20(7):337–8.

Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene–deficient mice intravenously infected with Mycobacterium avium. Ehlers S, et al. **Infect Immun** 1999 Jul;67(7):3571–9

Induction of granulomas in interferon–gamma gene–disrupted mice by avirulent but not by virulent strains of Mycobacterium tuberculosis. Sugawara I, et al. **J Med Microbiol** 1998 Oct;47(10):871–7

Systemic Bartonella henselae infection with hepatosplenic involvement. Ventura A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):52–6

Role of tumor necrosis factor–alpha in Mycobacterium–induced granuloma formation in tumor necrosis factor–alpha–deficient mice. Kaneko H, et al. **Lab Invest** 1999 Apr;79(4):379–86

Disseminated Bartonella infection with granulomatous hepatitis in a liver transplant recipient. Humar A, et al. **Liver Transpl Surg** 1999 May;5(3):249–51

[Granulomatous trichophytosis rubrum. Report of 2 cases] Yan L, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(6):556, inside back cover **(Chi)**

[Hepatic brucelloma: 2 cases and a review of the literature] Halimi C, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):513–7 (23 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

Granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with systemic lupus erythematosus. Koide J, et al. **Clin Rheumatol** 1998; 17(4):329–32

Granulomatous inflammation and the transmission of infection: schistosomiasis--and TB too? [see comments] Doenhoff MJ. **Immunol Today** 1998 Oct;19(10):462–7. Comment in: Immunol Today 1999 Jul;20(7):336–7. Comment in: Immunol Today 1999 Jul;20(7):337–8.

Granulomatous gastritis due to taeniasis. Uygur–Bayramiçli O, et al. **J Clin Gastroenterol** 1998 Dec;27(4):351–2

Solitary cysticercus granuloma of the brainstem. Report of four cases. Lath R, et al. **J Neurosurg** 1998 Dec; 89(6):1047–51

Immunization with PIII, a fraction of Schistosoma mansoni soluble adult worm antigenic preparation, affects nitric oxide production by murine spleen cells. de Oliveira DM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:175–80

Induction of protective immunity against Schistosoma mansoni infection by antigens purified from PIII, a fraction of adult worm, associated to the downregulation of granuloma formation. Gustavson S, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:191–6

Histoarchitecture of schistosomal granuloma development and involution: morphogenetic and biomechanical approaches. Lenzi HL, et al. **Mem Inst Oswaldo Cruz** 1998; 93 Suppl 1:141–51 (40 ref.)

Influence of dietary n–6 and n–3 lipids upon the development of pulmonary granulomas induced by Schistosoma mansoni eggs. Lima SF, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:197–8

Schistosomal granuloma modulation. I. Schistosoma mansoni worm antigens CAA and CCA prime egg–antigen–induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan;85(1):7–13

PATHOLOGY

Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma. Paulus W, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):377–82

Granulomatous myositis. Clinicopathologic study of 12 cases. Prayson RA. **Am J Clin Pathol** 1999 Jul;112(1):63–8

Interstitial granulomatous dermatitis with plaques. Aloi F, et al. **Am J Dermatopathol** 1999 Aug;21(4):320–3

Granulomatous mycosis fungoides: report of a case with some histopathologic features of granulomatous slack skin. Metzler G, et al. **Am J Dermatopathol** 1999 Apr; 21(2):156–60

Bronchoalveolar lavage fluid granulomas in a case of severe sarcoidosis. Hendricks MV, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):730–1

Breast carcinoma associated with necrotic granulomas in axillary lymph nodes. Sethi S, et al. **Ann Diagn Pathol** 1998 Dec;2(6):370–6

Postoperative granulomas of the endometrium: histological features after endometrial ablation. Silvernagel SW, et al. **Ann Diagn Pathol** 1997 Dec;1(2):82–90

Pulmonary hyalinizing granuloma. A limited form of Wegener's granulomatosis? Gorini M, et al. **Ann Ital Med Int** 1998 Jul–Sep;13(3):176–9

The use of a stereological method to estimate the volume of Schistosoma mansoni granulomas: the effect of zinc deficiency. Friis H, et al. **Ann Trop Med Parasitol** 1998 Oct;92(7):785–92

Chronic plaques in a patient with ataxia telangiectasia. Cutaneous granulomatous lesions in a patient with AT. Murakawa GJ, et al. **Arch Dermatol** 1998 Sep;134(9):1145, 1148

Granulomatous interstitial nephritis in extrapulmonary sarcoidosis. Utaş C, et al. **Clin Nephrol** 1999 Apr; 51(4):252–4 (8 ref.)

Pterygium with granuloma faciale–like histologic picture. Rausing A, et al. **Cornea** 1998 Sep;17(5):562–5

Spermatic granulomas resembling testicular neoplasia [letter] Divani S, et al. **Cytopathology** 1998 Oct;9(5):354–5

Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. Nestle FO, et al. **Dermatology** 1999;198(4):434–5

Granuloma faciale with extrafacial lesions. Roustan G, et al. **Dermatology** 1999;198(1):79–82 (13 ref.)

Dermatophytic granuloma caused by Microsporum canis in a heart–lung recipient. Voisard JJ, et al. **Dermatology** 1999; 198(3):317–9

Post–intubation granuloma and vocal fold erosion. Spiegel JR, et al. **Ear Nose Throat J** 1999 Jul;78(7):468

Bilateral periocular actinic granuloma in a patient with renal failure: a clinicopathologic study. Spraul CW, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):646–51

Xanthogranulomatous cystitis associated with malignant neoplasms of the bladder [published erratum appears in Histopathology 1998 Dec;33(6):590] Bates AW, et al. **Histopathology** 1998 Sep;33(3):212–5

Granulomatous inflammation in sigmoid diverticulitis: two diseases or one? Burroughs SH, et al. **Histopathology** 1998 Oct;33(4):349–53

Peritoneal rosetting microgranulomas in an incarcerated small bowel loop [letter] Lespi PJ, et al. **Histopathology** 1999 Feb;34(2):181–3

Xanthogranulomatous oophoritis--a case report. Naik M, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):89–91

Granulomatous gastritis presenting as gastric outlet obstruction: a case report. Spinzi G, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):410–3

Spermatic granulomata are experimentally induced in epididymides of mice receiving high–dose testosterone implants. I. A light–microscopical study. Itoh M, et al. **J Androl** 1999 Jul–Aug;20(4):551–8

Fish tank granuloma: response to treatment with clarithromycin [letter] Gimenez Garcia R, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):81–2

Hepatic granulomas. Lefkowitch JH. **J Hepatol** 1999;30 Suppl 1:40–5 (33 ref.)

Schistosome–infected IL–4 receptor knockout (KO) mice, in contrast to IL–4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile. Jankovic D, et al. **J Immunol** 1999 Jul 1;163(1):337–42

Local and systemic responses to iron–dextran injected into a granuloma pouch in the rat. Rodriguez MC, et al. **J Lab Clin Med** 1999 Jul;134(1):42–8

Clinical correlates of granulomas in muscle. Mozaffar T, et al. **J Neurol** 1998 Aug;245(8):519–24

Periglomerular granulomatous reaction in kidney biopsy. Bernheim J, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2959–60

A patient with diabetes insipidus and periorbital swellings; Erdheim–Chester disease. van der Lee I, et al. **Neth J Med** 1999 Aug;55(2):76–9

Lymphocytic and granulomatous hypophysitis: experience with nine cases [letter; comment] Mueller B, et al. **Neurosurgery** 1999 Feb;44(2):426–7. Comment on: Neurosurgery 1997 Apr;40(4):713–22; discussion 722–3.

Evidence for nitric oxide action on in vitro granuloma formation through pivotal changes in MIP–1alpha and IL–10 release in human schistosomiasis. Oliveira DM, et al. **Nitric Oxide** 1999;3(2):162–71

Morphometrical and immunopathological dissection of the hepatic Schistosoma haematobium granuloma in the murine host. Jacobs W, et al. **Parasite** 1998 Dec;5(4):299–306

Gastric cancer with sarcoid reactions in the regional lymph nodes, the stomach wall, and the splenic parenchyma: report of a case. Shigematsu H, et al. **Surg Today** 1999; 29(6):549–52

A transient emergence of hepatic granulomas in a patient with chronic hepatitis B. Kanno A, et al. **Tohoku J Exp Med** 1998 Aug;185(4):281–5

Xanthogranulomatous orchitis. Usamentiaga E, et al. **Urology** 1998 Nov;52(5):891–2

[Palisading granuloma] Vignon–Pennamen MD, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):615–9 (15 ref.) **(Fre)**

[Sclerosing lipogranuloma of the scrotum: a case report] Kodama K, et al. **Hinyokika Kiyo** 1999 Mar;45(3):211–4 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumonia caused by granulomatous Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome] Tanaka Y, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Aug; 36(8):690–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Granulomatous prostatitis. Review of 22 cases] Rodriguez Martínez JJ, et al. **Actas Urol Esp** 1998 Jul–Aug; 22(7):575–80 (13 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Clotrimazole is an inhibitor of inflammatory angiogenesis and the metabolic activity in sponge granuloma. da Rocha e Silva M, et al. **Inflammation** 1998 Dec;22(6):643–51

Role of cytokines in the formation and downregulation of hepatic circumoval granulomas and hepatic fibrosis in Schistosoma mansoni–infected mice. Cheever AW, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:25–32

PREVENTION & CONTROL

Enhanced Th1 and dampened Th2 responses synergize to inhibit acute granulomatous and fibrotic responses in murine schistosomiasis mansoni. Boros DL, et al. **Infect Immun** 1999 Mar;67(3):1187–93

Effects of the aqueous extract of Bridelia ferruginea stem bark on carrageenan–induced oedema and granuloma tissue formation in rats and mice. Olajide OA, et al. **J Ethnopharmacol** 1999 Jul;66(1):113–7

Experimental murine schistosomiasis in the absence of B7 costimulatory molecules: reversal of elicited T cell cytokine profile and partial inhibition of egg granuloma formation. Hernandez HJ, et al. **J Immunol** 1999 Mar 1;162(5):2884–9

RADIOGRAPHY

Musculoskeletal images. Granuloma of the buttock after uncemented total hip arthroplasty. Shen J, et al. **Can J Surg** 1999 Aug;42(4):250

Multiple cavitating nodules in a patient with hemoptysis. Meghjee S, et al. **Chest** 1999 Apr;115(4):1184–7

Does treatment change the outcome of seizures and computerized tomographic lesions in intracranial granulomas? Rajadhyaksha S, et al. **J Trop Pediatr** 1999 Jun;45(3):161–5

RADIOTHERAPY

Treatment of granuloma faciale with the 585–nm pulsed dye laser. Ammirati CT, et al. **Arch Dermatol** 1999 Aug; 135(8):903–5

Application of low intensity laser radiation in extravasal infiltrates caused by cytostatics in children with acute leukemia. Goranova V, et al. **Folia Med (Plovdiv)** 1999; 41(1):92–5

Granuloma faciale in a child successfully treated with the pulsed dye laser. Welsh JH, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):351–3

SURGERY

Ablation of Teflon granulomas in the canine larynx with the free–electron laser. Lano CF Jr, et al. **Ann Otol Rhinol Laryngol** 1999 Jan;108(1):17–23

Pars plana vitrectomy and subretinal surgery for ocular toxocariasis. Werner JC, et al. **Arch Ophthalmol** 1999 Apr; 117(4):532–4

THERAPY

Tumor necrosis factor (TNF) and a TNF–mimetic peptide modulate the granulomatous response to Mycobacterium bovis BCG infection in vivo. Roach DR, et al. **Infect Immun** 1999 Oct;67(10):5473–6

ULTRASONOGRAPHY

Granulomatous mastitis: gray–scale and color Doppler sonographic findings. Engin G, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):101–6

Endoscopic sonography in the diagnosis of xanthogranulomatous cholecystitis. Muguruma N, et al. **J Clin Ultrasound** 1999 Jul–Aug;27(6):347–50

Granulomatous angiopanniculitis of the breast: mammographic and sonographic findings. Kim EY, et al. **J Ultrasound Med** 1999 Jul;18(7):519–21

VETERINARY

Granuloma development in cattle after intratonsilar inoculation with Mycobacterium bovis. Palmer MV, et al. **Am J Vet Res** 1999 Mar;60(3):310–5

Adipsia and hypernatraemia in a dog with focal hypothalamic granulomatous meningoencephalitis. Mackay BM, et al. **Aust Vet J** 1999 Jan;77(1):14–7

Subcutaneous granuloma caused by Mycobacterium avium complex infection in a cat. Malik R, et al. **Aust Vet J** 1998 Sep;76(9):604–7

Case report: umbilical foreign–body granuloma in a lamb. Yeruham I, et al. **Berl Munch Tierarztl Wochenschr** 1999 Feb;112(2):44–5

An unusual manifestation of encephalitozoonosis in chinchilla rabbits. Levkut M, et al. **Can Vet J** 1998 Sep;39(9):576–7

Adult Dirofilaria repens in a subcutaneous granuloma on the chest of a dog. Bredal WP, et al. **J Small Anim Pract** 1998 Dec;39(12):595–7

Disseminated granulomas associated with nematode larvae in a shortfin mako shark. Borucinska JD, et al.

J Wildl Dis 1999 Jan;35(1):98–100
Spermatic granuloma in the ram: diagnosis by ultrasonography and semen characteristics. Karaca F, et al. **Vet Radiol Ultrasound** 1999 Jul–Aug;40(4):402–6
Feline skin granuloma associated with Mycobacterium avium. Stevenson K, et al. **Vet Rec** 1998 Jul 25; 143(4):109–10

VIROLOGY

Are granulomatous reactions in old zoster lesions due to an immune response to varicella zoster virus envelope glucoproteins? [letter] Nikkels AF, et al. **Clin Exp Dermatol** 1998 Sep;23(5):237–8
Systemic granulomatous arteritis associated with Epstein–Barr virus infection. Ban S, et al. **Virchows Arch** 1999 Mar;434(3):249–54
[Lung and bone marrow granulomas associated with human parvovirus B19 infection] Noguchi T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):589–93 (Eng. Abstr.) **(Jpn)**

GRANULOMA ANNULARE

COMPLICATIONS

Coexistence of allergic contact dermatitis and granuloma annulare in an HIV-1-infected patient: A casual association? [letter] Muñoz-Pérez MA, et al. **Am J Contact Dermat** 1999 Jun;10(2):100–1
Coexisting morphoea and granuloma annulare–are the conditions related? Ben-Amitai D, et al. **Clin Exp Dermatol** 1999 Mar;24(2):86–9
Hypercalcaemic acute renal failure--a complication of granuloma annulare elastolyticum. Ehehalt R, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2125–7

DIAGNOSIS

Annular skin lesions with a smooth surface. Hogan P. **Aust Fam Physician** 1998 Dec;27(12):1133–4 (0 ref.)
Annular elastolytic giant cell granuloma. Tock CL, et al. **Cutis** 1998 Oct;62(4):181–7 (30 ref.)
Subcutaneous granuloma annulare: MR imaging and literature review. Vandevenne JE, et al. **Eur Radiol** 1998; 8(8):1363–5 (9 ref.)
Annular lesions with beaded borders. Levine N. **Geriatrics** 1998 Dec;53(12):25
Granuloma annulare [letter] Hanson SG, et al. **Pediatrics** 1999 Jan;103(1):195–6
Subcutaneous granuloma annulare: MR imaging features in six children and literature review. Chung S, et al. **Radiology** 1999 Mar;210(3):845–9 (15 ref.)

DRUG THERAPY

Successful treatment of generalized granuloma annulare with polyethylene sheet bath PUVA [letter] Szegedi A, et al. **Acta Derm Venereol** 1999 Jan;79(1):84–5
Actinic granuloma and vitiligo treated with pentoxifylline [letter] Rubio FA, et al. **Int J Dermatol** 1998 Dec; 37(12):958–60
[Bath-PUVA therapy of granuloma annulare] Salomon N, et al. **Hautarzt** 1999 Apr;50(4):275–9 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Generalized granuloma annulare and hepatitis B vaccination. Wolf F, et al. **Eur J Dermatol** 1998 Sep;8(6):435–6

METABOLISM

The oligosaccharidic component of the glycoconjugates in lichen planus, granuloma annulare, seborrheic keratosis and plamoplantar keratoderma: lectin histochemical study. Gheri G, et al. **Histol Histopathol** 1999 Jul;14(3):697–704
[Immunohistologic determination of extracellular matrix components in granuloma annulare] Halagovec A, et al. **Cas Lek Cesk** 1999 Feb 22;138(4):116–8 (Eng. Abstr.) **(Slo)**

PATHOLOGY

Granuloma annulare localized to the palms. Hsu S, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):287–8
Actinically degenerate elastic tissue is the likely antigenic basis of actinic granuloma of the skin and of temporal arteritis. O'Brien JP, et al. **J Am Acad Dermatol** 1999 Feb; 40(2 Pt 1):214–22 (62 ref.)
Deep granuloma annulare (pseudorheumatoid nodule) in children: clinicopathologic study of 35 cases. McDermott MB, et al. **Pediatr Dev Pathol** 1998 Jul–Aug;1(4):300–8 (42 ref.)
Penile granuloma annulare. Narouz N, et al. **Sex Transm Infect** 1999 Jun;75(3):186–7
Granuloma annulare: an elastic tissue disease? Case report and literature review. Hanna WM, et al. **Ultrastruct Pathol** 1999 Jan–Feb;23(1):33–8 (13 ref.)

URINE

Amplification of DNA of Borrelia burgdorferi in urine samples of patients with granuloma annulare and lichen sclerosus et atrophicus [letter] [published erratum appears in Arch Dermatol 1999 Jul;135(7):786] Aberer E, et al. **Arch Dermatol** 1999 Feb;135(2):210–2

GRANULOMA, EOSINOPHILIC see **EOSINOPHILIC GRANULOMA**

GRANULOMA, FOREIGN-BODY

CHEMICALLY INDUCED

[Case for diagnosis. Major swelling of the penis] Boui M, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):339–40 **(Fre)**

COMPLICATIONS

Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report [letter] Langsam A. **Neurosurgery** 1999 Mar;44(3):689–91
Facial nerve dysfunction associated with cystic lesions of the mastoid. Hwang PH, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):668–72

DIAGNOSIS

Fine-needle aspiration diagnosis of foreign body granulomatous reaction presenting as an orbital mass: case report and review of the literature. Iyer VK, et al. **Diagn Cytopathol** 1998 Oct;19(4):290–2 (18 ref.)
Imaging features of simultaneous occurrence of renal and pancreatic foreign body granuloma due to chronically retained gauze: a case report. Kuo YT, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Feb; 15(2):104–9
Foreign body granuloma mimicking intracranial meningioma: case report and review of the literature. Feldman RP, et al. **Neurosurgery** 1999 Apr;44(4):855–8 (21 ref.)
Bilateral cholesterol granulomas of the temporal bone. Eby TL, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov–Dec;60(6):318–21
Subcochlear petrous cholesterol granuloma involving the infratemporal fossa. Lustig LR, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):685–9
[Case for diagnosis. Major swelling of the penis] Boui M, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):339–40 **(Fre)**

DRUG THERAPY

Incidence and significance of adverse effects of albendazole therapy in patients with a persistent solitary cysticercus granuloma. Rajshekhar V. **Acta Neurol Scand** 1998 Aug; 98(2):121–3
Antipsoriatic, anti-inflammatory, and analgesic effects of an extract of red propolis. Ledón N, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):274–6
Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Iocono JA, et al. **Wound Repair Regen** 1998 Sep–Oct;6(5):442–8

ETIOLOGY

Lung granulomatosis in a dental technician. Brancaleone P, et al. **Am J Ind Med** 1998 Dec;34(6):628–31
Foreign body granulomas due to injectable aesthetic microimplants. Rudolph CM, et al. **Am J Surg Pathol** 1999 Jan;23(1):113–7
Eosinophilic foreign body granuloma after multiple self-administered bee stings. Park JH, et al. **Br J Dermatol** 1998 Dec;139(6):1102–5
Cotton gauze foreign body granuloma following microvascular decompression. Parmar DN, et al. **Br J Neurosurg** 1999 Feb;13(1):87–9
Recurrence of intravenous talc granulomatosis following single lung transplantation. Cook RC, et al. **Can Respir J** 1998 Nov–Dec;5(6):511–4
Gallstone spilt granulomas caused by laparoscopic cholecystectomy. Xu Y, et al. **Chin Med J (Engl)** 1998 Jan; 111(1):92–3
Persistent granulomatous contact dermatitis due to palladium body-piercing ornaments. Jappe U, et al. **Contact Dermatitis** 1999 Feb;40(2):111–2
Cellulose granulomatosis of the lungs. Diaz-Ruiz MJ, et al. **Eur Radiol** 1999;9(6):1203–4
Postoperative textilomas: review of 14 cases. Fernandez Lobato R, et al. **Int Surg** 1998 Jan–Mar;83(1):63–6 (25 ref.)
Severe migratory granulomatous reactions to silicone gel in 3 patients. Teuber SS, et al. **J Rheumatol** 1999 Mar; 26(3):699–704
Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report [letter] Langsam A. **Neurosurgery** 1999 Mar;44(3):689–91
Extrusion and granuloma formation with mersilene mesh brow suspension. Mutlu FM, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):47–51 (17 ref.)
An unusual late reaction to facial injections. Constantinides M, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):557–60
Expanded polytetrafluoroethylene threads for lip augmentation induce foreign body granulomatous reaction. Hubmer MG, et al. **Plast Reconstr Surg** 1999 Apr; 103(4):1277–9
[The late dimensions and complications following paraffin injection into the breast] Dimitrov S, et al. **Akush Ginekol (Sofiia)** 1998;37(4):54–6 **(Bul)**
[Pulmonary textiloma revealed by hemoptysis 12 years after thoracotomy] Hadrami J, et al. **Rev Med Interne** 1998 Nov; 19(11):826–9 (Eng. Abstr.) **(Fre)**
[Intubation granulomas of the lacrimal ducts in patients with silicone implants] Beloglazov VG, et al. **Vestn Oftalmol** 1998 Sep–Oct;114(5):29–32 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[Effects of induction of anti-embryonation and anti-fecundity immunity on liver granuloma formation in mice infected with Schistosoma japonicum] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):768–70 (Eng. Abstr.) **(Chi)**

METABOLISM

Aluminum silicate-containing psammoma bodies in a cervicovaginal smear (Pap): cytological, ultrastructural, and radiographic microprobe studies. Li S, et al. **Diagn Cytopathol** 1999 Aug;21(2):122–4
Expression of NO-synthase in cells of foreign-body and BCG-induced granulomata in mice: influence of L-NAME on the evolution of the lesion. Kreuger MR, et al. **Immunology** 1998 Oct;95(2):278–82

PARASITOLOGY

Postoperative alveolar hydatid disease with cutaneous-subcutaneous involvement. Ambo M, et al. **J Dermatol** 1999 Jun;26(6):343–7 (12 ref.)

PATHOLOGY

Scleral and episcleral histological changes related to encircling explants in 20 eyes. D'Hermies F, et al. **Acta Ophthalmol Scand** 1999 Jun;77(3):279–85
Granulomatous 'foreign body reactions' contribute to exaggerated in-stent restenosis. Kornowski R, et al. **Coron Artery Dis** 1999;10(1):9–14
Cytology of peritoneal keratin granulomas [letter] Chen KT. **Diagn Cytopathol** 1999 Feb;20(2):105–7
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. Westra WH, et al. **Head Neck** 1998 Sep;20(6):515–21
Postoperative alveolar hydatid disease with cutaneous-subcutaneous involvement. Ambo M, et al. **J Dermatol** 1999 Jun;26(6):343–7 (12 ref.)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-1999. A 69-year-old man with exposure to talc and a pulmonary mass [clinical conference] N **Engl J Med** 1999 Jul 15;341(3):182–90

RADIOGRAPHY

Pulmonary cholesterol granulomas in patients with pulmonary artery hypertension: chest radiographic and CT findings. Nolan RL, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1317–9
Foreign body granuloma caused by prior gunshot wound mimicking malignant breast mass. Wakabayashi M, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):321–2
Imaging of carbon granulomas of the breast following carbon track localization. Patrikeos A, et al. **Clin Radiol** 1998 Nov; 53(11):845–8
Introgenic obscuration of radiologic findings deserves second look [letter] Crockett JC, et al. **J Am Osteopath Assoc** 1998 Oct;98(10):540–1
Radiology case of the month. Blastoma. Clasen C, et al. **J La State Med Soc** 1998 Dec;150(12):575–7

SURGERY

Postoperative textilomas: review of 14 cases. Fernandez Lobato R, et al. **Int Surg** 1998 Jan–Mar;83(1):63–6 (25 ref.)
Preoperative hearing predicts postoperative hearing. Blakley BW, et al. **Otolaryngol Head Neck Surg** 1998 Dec; 119(6):559–63
[The surgical treatment of oleogranulomas of the external genitalia in men] Kochanov DA, et al. **Urol Nefrol (Mosk)** 1998 Sep–Oct;(5):40–1 **(Rus)**

THERAPY

Intracranial foreign-body granuloma treated with anti-cytokine agents. Honma Y, et al. **Acta Neurochir (Wien)** 1998;140(7):725–6

VETERINARY

Computed tomography of cholesterinic granulomas in the choroid plexus of horses. Vink-Nooteboom M, et al. **Vet Radiol Ultrasound** 1998 Nov–Dec;39(6):512–6

GRANULOMA GANGRAENESCENS see **GRANULOMA, LETHAL MIDLINE**

GRANULOMA, GIANT CELL

COMPLICATIONS

Brown tumor in association with secondary hyperparathyroidism. A case report and review of the literature. Balon BP, et al. **Am J Nephrol** 1998;18(5):460–3
A dissection with a difference: an unusual case of ascending aortic dissection secondary to granulomatous aortitis. Crilley JG, et al. **Hosp Med** 1998 Nov;59(11):892–3
Unusual form of recurrent giant cell granuloma of the

mandible and lower extremities in a patient with neurofibromatosis type 1. Ruggieri M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):67–72

Cherubism: clinicopathologic features. Yamaguchi T, et al. **Skeletal Radiol** 1999 Jun;28(6):350–3 (19 ref.)

DIAGNOSIS

Giant cell reparative granuloma of the orbit. Mercado GV, et al. **Am J Ophthalmol** 1999 Apr;127(4):485–7

Combined central odontogenic fibroma and giant cell granuloma-like lesion of the mandible: report of a case and review of the literature. Mosqueda Taylor A, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1258–62 (24 ref.)

Unknown case. Dockery WD, et al. **Spine** 1999 Jan 15; 24(2):198–9

[Giant-cell reparative granuloma (GCRG). A review of the literature, the present state of knowledge and therapeutic suggestions] Fancello A, et al. **Minerva Stomatol** 1998 Sep; 47(9):399–407 (47 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Calcitonin treatment for central giant cell granulomas of the mandible: report of two cases. Pogrel MA, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):848–53

PATHOLOGY

Immunocytochemistry of fine-needle aspirates from central giant cell granuloma. Castro WH, et al. **Br J Oral Maxillofac Surg** 1998 Aug;36(4):301–3

Bilateral central giant cell granulomas in a patient with neurofibromatosis: report of a case and review of the literature. Ardekian L, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):869–72 (24 ref.)

Expansile lesion of the anterior maxilla [clinical conference] Walstad WR, et al. **J Oral Maxillofac Surg** 1999 May; 57(5):595–9

Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. de Souza PE, et al. **J Oral Pathol Med** 1999 Feb;28(2):54–8

16-year-old female with amenorrhea [clinical conference] Partington MD, et al. **Pediatr Neurosurg** 1998 Jan; 28(1):43–8

RADIOGRAPHY

Brown tumor and tumoral calcinosis 6 years after renal transplantation [letter] Dietl KH, et al. **Clin Nephrol** 1999 May;51(5):323–4

Giant cell reparative granuloma of the phalanx of the hand with aggressive radiographic features. Bertoni F, et al. **Skeletal Radiol** 1998 Oct;27(10):584–7 (11 ref.)

RADIONUCLIDE IMAGING

Giant cell granulamatous hypophysitis with remarkable uptake on Gallium-67 scintigraphy. Shimizu C, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):131–4

SURGERY

[Clinical analysis and therapeutic results of peripheral giant cell granuloma] Lewandowski B. **Pol Merkuriusz Lek** 1998 Aug;5(26):60–2 (Eng. Abstr.) **(Pol)**

GRANULOMA, GIANT CELL REPARATIVE see **GRANULOMA, GIANT CELL**

GRANULOMA, HODGKIN see **HODGKIN DISEASE**

GRANULOMA INGUINALE

[Granuloma inguinale (donovanosis)] Kojima H. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):14–7 (15 ref.) **(Jpn)**

COMPLICATIONS

Intrapelvic donovanosis presenting as a psoas abscess in two patients [letter] Mein J, et al. **Sex Transm Infect** 1999 Feb; 75(1):75–6

Extragenital donovanosis of the foot. Rao MV, et al. **Sex Transm Infect** 1998 Aug;74(4):298–9

DIAGNOSIS

A painless penile ulcer. Golledge C. **Aust Fam Physician** 1999 Jun;28(6):605

Diagnostic polymerase chain reaction for donovanosis. Carter J, et al. **Clin Infect Dis** 1999 May;28(5):1168–9

Missing the diagnosis of donovanosis in northern Australia [letter] Mein JK, et al. **Med J Aust** 1999 Jan 4;170(1):48

Granuloma inguinale (donovanosis) presenting as a neck mass in an infant. Govender D, et al. **Pediatr Surg Int** 1999; 15(2):129–31

EPIDEMIOLOGY

[Sexually transmitted bacterial diseases. 2. Granuloma inguinale, lymphogranuloma venereum, genital Chlamydia and Mycoplasma infection] Hofstetter AG. **Fortschr Med** 1999 Apr 30;117(12):26–8 **(Ger)**

ETHNOLOGY

Missing the diagnosis of donovanosis in northern Australia [letter] Mein JK, et al. **Med J Aust** 1999 Jan 4;170(1):48

MICROBIOLOGY

Donovanosis [editorial] Hart CA, et al. **J Med Microbiol** 1999 Aug;48(8):707–9 (23 ref.)

Ultrastructure of Calymmatobacterium granulomatis: comparison of culture with tissue biopsy specimens. Kharsany AB, et al. **J Med Microbiol** 1998 Dec; 47(12):1069–73

GRANULOMA, LARYNGEAL

COMPLICATIONS

Obstructing laryngeal granuloma. Shapiro NL, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):164

DRUG THERAPY

Topical inhalant steroid (budesonide, Pulmicort nasal) therapy in intubation granuloma. Roh HJ, et al. **J Laryngol Otol** 1999 May;113(5):427–32

Contact granulomas [letter] Hynes B. **J Otolaryngol** 1998 Oct; 27(5):310

ETIOLOGY

Vocal fold granuloma induced by rigid bronchoscopy. Heller AJ, et al. **Ear Nose Throat J** 1999 Mar;78(3):176–8, 180

SURGERY

A retrospective study of contact granuloma. Ylitalo R, et al. **Laryngoscope** 1999 Mar;109(3):433–6

GRANULOMA, LETHAL MIDLINE

DIAGNOSIS

Midline palatal perforation [clinical conference] Cottrell DA, et al. **J Oral Maxillofac Surg** 1999 Aug;57(8):990–5

[Nasal T-cell lymphoma of the lethal midline type. Case report and current aspects in the literature] Ullrich D, et al. **HNO** 1999 May;47(5):490–3 (Eng. Abstr.) **(Ger)**

[Nasal T-cell lymphoma as a differential diagnosis of the midline granuloma syndrome] Tigges G, et al. **Laryngorhinootologie** 1999 Mar;78(3):139–43 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Chronological changes in incidences of polymorphic reticulosis in Korea and Japan. Ohsawa M, et al. **Oncology** 1999 Apr;56(3):202–7

ETIOLOGY

Nasal cocaine abuse presenting as a central facial destructive granuloma. Sittel C, et al. **Eur Arch Otorhinolaryngol** 1998; 255(9):446–7 (5 ref.)

Chronological changes in incidences of polymorphic reticulosis in Korea and Japan. Ohsawa M, et al. **Oncology** 1999 Apr;56(3):202–7

PATHOLOGY

[A clinicopathological immunohistochemical and cytomorphometric study on midline T cell lymphoma] Zhou J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(2):137–40 (Eng. Abstr.) **(Chi)**

GRANULOMA, MALIGNANT see **HODGKIN DISEASE**

GRANULOMA, PERIAPICAL see **PERIAPICAL GRANULOMA**

GRANULOMA, PLASMA CELL

COMPLICATIONS

Fever of unknown origin due to inflammatory pseudotumour of lymph nodes. Knockaert DC, et al. **Acta Clin Belg** 1998 Dec;53(6):367–70 (10 ref.)

Esophageal inflammatory pseudotumor associated with a pseudodiverticulosis cyst: two inter-related lesions? Pimenta AP, et al. **Dis Esophagus** 1998 Oct;11(4):272–5

Inflammatory pseudotumor of the liver in a patient with human immunodeficiency virus infection. Tai YS, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1760–3

Inflammatory pseudotumor of the spleen associated with a cavernous hemangioma diagnosed at intra-operative cytology: report of a case and review of literature. Nasir A, et al. **In Vivo** 1999 Jan-Feb;13(1):87–92 (40 ref.)

Inflammatory pseudotumour of the bladder: a rare cause of haematuria. Rané AM, et al. **Int Urol Nephrol** 1998; 30(5):561–4

Inflammatory pseudotumor causing intestinal obstruction: diagnostic and therapeutic aspects. Ciftci AO, et al. **J Pediatr Surg** 1998 Dec;33(12):1843–5

Disseminated cutaneous plasmacellular granuloma associated with membranous glomerulonephritis. Querfeld U, et al. **Nephrol Dial Transplant** 1999 May;14(5):1268–71

Inflammatory pseudotumor of the liver in Kostmann's disease. Hsiao CC, et al. **Pediatr Surg Int** 1999; 15(3–4):266–9 (23 ref.)

DIAGNOSIS

Fine needle aspiration cytologic appearance of inflammatory pseudotumor of the liver. A case report. Malhotra V, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1325–8

Inflammatory pseudotumor of the urinary bladder with aberrant expression of cytokeratin. Report of a case with cytologic, immunocytochemical and cytogenetic findings. Sonobe H, et al. **Acta Cytol** 1999 Mar-Apr;43(2):257–62

Extraorbital inflammatory pseudotumor of the head and neck: CT and MR findings in three patients. De Vuysere S, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul;20(6):1133–9

Chronic inflammatory pseudotumor arising in the hepatobiliary-pancreatic system: progressive multisystemic organ involvement in four patients. Voss SD, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1049–54

Splenic inflammatory pseudotumor mimicking primary splenic malignancy [letter] Edoute Y, et al. **Haematologica** 1999 Aug;84(8):765–6

Pseudotumor of the liver: a challenging diagnosis. Borgonovo G, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1770–3

Inflammatory pseudotumor of the bladder: MR findings. Fujiwara T, et al. **J Comput Assist Tomogr** 1999 Jul-Aug; 23(4):558–61 (14 ref.)

Inflammatory pseudotumor of the liver: a rare benign tumor mimicking a malignancy. Lacaille F, et al. **Liver Transpl Surg** 1999 Jan;5(1):83–5

Inflammatory pseudotumor of the diaphragm. Höer J, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):387–90

Extragnathic fibromyxoma of bone versus inflammatory myofibroblastic tumor [letter] Flores-Corral MT, et al. **Skeletal Radiol** 1998 Aug;27(8):468–9

Renal inflammatory pseudotumor. Bell ND, et al. **South Med J** 1998 Nov;91(11):1050–3

[Inflammatory pseudotumors of the liver. Apropos of a pediatric case with radiological and ultrasonographic features and anatomopathological correlations] Vanthournout I, et al. **J Radiol** 1998 Jun;79(6):553–6 (Eng. Abstr.) **(Fre)**

[An entity not to be ignored: focal nodular myositis (letter)] Marie I, et al. **Rev Med Interne** 1998 May;19(5):359–60 **(Fre)**

[Plasma-cell granuloma of the mediastinum] Tazzioli G, et al. **Minerva Chir** 1998 Jun;53(6):549–51 (8 ref.) (Eng. Abstr.) **(Ita)**

[A fibrous pseudotumor of the tunica vaginalis testis. A report of a new case and a review of the literature] Garcia Carriazo M, et al. **Actas Urol Esp** 1999 Jan;23(1):68–70 (8 ref.) (Eng. Abstr.) **(Spa)**

[Inflammatory bladder pseudotumor] Arocena Lanz F, et al. **Arch Esp Urol** 1999 May;52(4):385–7 (Eng. Abstr.) **(Spa)**

[An actinomycotic inflammatory pseudotumor of the transverse colon (letter)] Diaz Morant V, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):206–7 **(Spa)**

[Inflammatory pseudotumor of the spleen. An old concept with many questions] Madrigal B, et al. **Sangre (Barc)** 1998 Jun;43(3):227–30 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Renal failure resulting from infiltration by inflammatory myofibroblastic tumor responsive to corticosteroid therapy. Williams ME, et al. **Am J Kidney Dis** 1998 Jun;31(6):E5

[Hepatic inflammatory pseudotumor: apropos a case with a response to steroid treatment] Fernández de la Puebla Giménez RA, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):14–7 (20 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Inflammatory pseudotumor of the liver and pregnancy. Maze GL, et al. **Am J Gastroenterol** 1999 Feb;94(2):529–30

A colon-derived inflammatory pseudotumor. Aalbers AG, et al. **Dig Dis Sci** 1999 Mar;44(3):578–81 (14 ref.)

ETIOLOGY

Inflammatory pseudotumour secondary to actinomyces infection. Evans J, et al. **Aust N Z J Surg** 1999 Jun; 69(6):467–9

Massive pelvic and femoral pseudotumoral osteolysis secondary to an uncemented total hip arthroplasty. Jeanrot C, et al. **Int Orthop** 1999;23(1):37–40

Aggressive wear-debris pseudotumor following total hip replacement. Langkamer VG, et al. **Orthopedics** 1999 Mar; 22(3):353–5

Progression from bronchopneumonia to inflammatory pseudotumor in a seven-year-old girl. Fiocchi A, et al. **Pediatr Pulmonol** 1999 Feb;27(2):138–40

GENETICS

Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Hussong JW, et al. **Mod Pathol** 1999 Mar;12(3):279–86

IMMUNOLOGY

A case of inflammatory pseudotumor of the liver causing

elevated serum CA19-9 levels. Ogawa T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2551-5

PATHOLOGY

Fine needle aspiration cytologic appearance of inflammatory pseudotumor of the liver. A case report. Malhotra V, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1325-8

Is calcifying fibrous pseudotumor a late sclerosing stage of inflammatory myofibroblastic tumor? Van Dorpe J, et al. **Am J Surg Pathol** 1999 Mar;23(3):329-35

Pathologic quiz case 1. Tumefactive fibroinflammatory lesion of the nasal cavity. Schulte DL, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb;125(2):228-9, 230

Pseudo-malignant laryngeal nodule (inflammatory myofibroblastic tumour) [letter; comment] Chaturvedi P, et al. **Histopathology** 1999 Mar;34(3):272-3. Comment on: Histopathology 1998 Mar;32(3):286-7.

Pathologic supracondylar fracture due to osteolytic pseudotumor of knee following cementless total knee replacement. Benevenia J, et al. **J Biomed Mater Res** 1998 Winter;43(4):473-7

Inflammatory pseudotumor in the mandibular retromolar region. Ide F, et al. **J Oral Pathol Med** 1998 Nov; 27(10):508-10

Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Hussong JW, et al. **Mod Pathol** 1999 Mar;12(3):279-86

Inflammatory pseudotumour of the liver--evidence for malignant transformation. Pecorella I, et al. **Pathol Res Pract** 1999;195(2):115-20

Inflammatory pseudotumor of the liver. Report of two cases. Yavuz E, et al. **Pathologica** 1998 Oct;90(5):463-6

Inflammatory pseudotumor of the liver in patients with recurrent pyogenic cholangitis: CT-histopathologic correlation. Yoon KH, et al. **Radiology** 1999 May; 211(2):373-9

Inflammatory pseudotumor of the abdomen: report of a case. Imabun S, et al. **Surg Today** 1998;28(11):1172-4 (13 ref.)

[Inflammatory pseudotumor of the intrahepatic biliary tract] Saint-Paul MC, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):581-4 (Eng. Abstr.) **(Fre)**

[Inflammatory pseudotumor of lymph nodes and hepatic regenerative nodular hyperplasia (letter)] Cotos Canca R, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):239 **(Spa)**

RADIOGRAPHY

Cholangiographic appearance of hepatic inflammatory pseudotumor and its pathogenic implication. Chan AO, et al. **Endoscopy** 1999 Jun;31(5):S39-40

Inflammatory pseudotumor of the liver in patients with recurrent pyogenic cholangitis: CT-histopathologic correlation. Yoon KH, et al. **Radiology** 1999 May; 211(2):373-9

[Maxillary pain and exophthalmos. Inflammatory pseudotumor of the maxillary sinus] Scheithauer MO, et al. **HNO** 1999 Jun;47(6):578-9 **(Ger)**

[3D-CT cystography of submucosal elevated lesion of the bladder: report of two cases] Ichikawa T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 Jan;59(1):34-6 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Tc-99m colloid and Ga-67 imaging of splenic inflammatory pseudotumor correlation with ultrasound, CT, and MRI. Suga K, et al. **Clin Nucl Med** 1999 May;24(5):334-7

Spontaneous regression of hepatic pseudotumor demonstrated by Ga-67 imaging. Young TH, et al. **Clin Nucl Med** 1998 Sep;23(9):624

SURGERY

Inflammatory pseudotumor of the pelvis: case report with review of recent developments. Dao AH, et al. **Am Surg** 1998 Dec;64(12):1188-91 (30 ref.)

Inflammatory pseudotumors of the lung. Cerfolio RJ, et al. **Ann Thorac Surg** 1999 Apr;67(4):933-6

Inflammatory pseudotumor of carotid artery: a case report. Kim GE, et al. **Cardiovasc Surg** 1999 Apr;7(3):342-7

Laparoscopic splenectomy for an inflammatory pseudotumor of the spleen: operative technique and case report. Tsugawa K, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1887-91

Pancreatic inflammatory tumour: a rare entity in childhood. Shankar KR, et al. **J R Coll Surg Edinb** 1998 Dec; 43(6):422-3 (10 ref.)

Inflammatory pseudotumor of the diaphragm. Höer J, et al. **Pediatr Surg Int** 1999 Jul;15(5-6):387-90

[Inflammatory pseudotumor of the lacrimal gland. Apropos of 2 cases] Chaoui Z, et al. **J Fr Ophtalmol** 1999 May; 22(5):562-5 (Eng. Abstr.) **(Fre)**

[Inflammatory pseudotumor of the lung in hilus lymph node histoplasmosis] Frey A, et al. **Chirurg** 1998 Oct; 69(10):1101-4 (Eng. Abstr.) **(Ger)**

[Multifocal inflammatory pseudotumor of the liver] Berloco P, et al. **Ann Ital Chir** 1998 May-Jun;69(3):371-7 (Eng. Abstr.) **(Ita)**

[Inflammatory pseudotumor of the lung] Bandoh S, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):504-8 (Eng. Abstr.) **(Jpn)**

VETERINARY

Inflammatory pseudotumor in a cat with cutaneous mycobacteriosis. Miller MA, et al. **Vet Pathol** 1999 Mar; 36(2):161-3

VIROLOGY

[Implications of Epstein-Barr virus in pathology. Inflammatory pseudotumors (comment)] Voigt JJ, et al. **Ann Pathol** 1998 Dec;18(6):514-5. Comment on: Ann Pathol 1998 Feb;18(1):16-28. **(Fre)**

GRANULOMA, PLASMA CELL, ORBITAL

DIAGNOSIS

Case report: 'Orbital pseudo-pseudotumour'--a fatal case of steroid-responsive painful ophthalmoplegia. Lee PS, et al. **Clin Radiol** 1998 Oct;53(10):774-7

Pain in Tolosa-Hunt syndrome. Gonzales GR. **J Pain Symptom Manage** 1998 Sep;16(3):199-204

Bilateral orbital metastases from breast carcinoma. A case of false pseudotumor. Toller KK, et al. **Ophthalmology** 1998 Oct;105(10):1897-901

Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. Weber AL, et al. **Radiol Clin North Am** 1999 Jan;37(1):151-68, xi (71 ref.)

[A case of big pseudotumor of the biorbit] Wang C, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):282 **(Chi)**

[Acute orbital myositis and idiopathic inflammatory pseudotumor in children: three cases] Grouteau E, et al. **Arch Pediatr** 1998 Feb;5(2):153-8 (Eng. Abstr.) **(Fre)**

[Calcifying pseudotumor of the orbits] Constantinidis J, et al. **HNO** 1998 Dec;46(12):993-7 (Eng. Abstr.) **(Ger)**

[64-year-old patient with recurrent left orbital pseudotumor] Roch B, et al. **Internist (Berl)** 1998 Aug;39(8):856-9 **(Ger)**

PATHOLOGY

Orbital psuedotumour with intracranial extension. A case report. Soares D, et al. **West Indian Med J** 1998 Jun; 47(2):68-71

RADIOGRAPHY

Presumed isolated inflammation of the superior oblique muscle in idiopathic orbital myositis. Stidham DB, et al. **Ophthalmology** 1998 Dec;105(12):2216-9

GRANULOMA, PLASMA CELL, PULMONARY

COMPLICATIONS

Inflammatory myofibroblastic tumor of the lung (inflammatory pseudotumor): uncommon cause of solitary pulmonary nodule. Zennaro H, et al. **Eur Radiol** 1999; 9(6):1205-7

Pituitary mass and inflammatory pseudotumours of lung and peritoneum [letter; comment] Naschitz JE, et al. **Postgrad Med J** 1998 Sep;74(875):575. Comment on: Postgrad Med J 1997 Nov;73(865):732-4.

DIAGNOSIS

Aggressive manifestations of inflammatory pulmonary pseudotumor in children. Hedlund GL, et al. **Pediatr Radiol** 1999 Feb;29(2):112-6

PATHOLOGY

Transthoracic fine-needle aspiration cytology of inflammatory pseudotumor, fibrohistiocytic type: a case report with immunohistochemical studies. Bakhos R, et al. **Diagn Cytopathol** 1998 Sep;19(3):216-20

SURGERY

[Inflammatory pseudotumor of the lung. An anatomoclinical study of a case report] Smahi AM, et al. **Chirurgie** 1999 Feb;124(1):73-6 (Eng. Abstr.) **(Fre)**

[A case of pulmonary plasma cell granuloma with a cavity] Udaka T, et al. **Kyobu Geka** 1999 May;52(5):419-21 (Eng. Abstr.) **(Jpn)**

GRANULOMA, PSEUDOPYOGENIC see **ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA**

GRANULOMA, PYOGENIC

CHEMICALLY INDUCED

Pyogenic granuloma-like lesions in a patient using topical tretinoin. MacKenzie-Wood AR, et al. **Australas J Dermatol** 1998 Nov;39(4):248-50

DIAGNOSIS

Pyogenic granuloma of the scrotum. Abdul Gaffoor PM. **Cutis** 1998 Dec;62(6):282

Multiple pyogenic granulomas in sigmoid colon. Chen TC, et al. **Gastrointest Endosc** 1999 Feb;49(2):257-9

Paediatric pyogenic granuloma presenting as a unilateral nasal polyp. Simo R, et al. **Rhinology** 1998 Sep;36(3):136-8

DRUG THERAPY

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Curettage or silver nitrate for pyogenic granulomas on the hand. Dollery W. **J Accid Emerg Med** 1999 Mar;16(2):140-1

ETIOLOGY

[Pyrogenic granuloma following eye muscle surgery] Schwarwey K, et al. **Klin Monatsbl Augenheilkd** 1999 Jun; 214(6):aA7-9 (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Exposure of expanded polytetrafluoroethylene-wrapped hydroxyapatite orbital implant: a report of two patients. Choo PH, et al. **Ophthal Plast Reconstr Surg** 1999 Mar; 15(2):77-8

PATHOLOGY

Intravenous pyogenic granuloma mimicking pleomorphic adenoma in a fine needle aspirate. A case report. Domanski HA. **Acta Cytol** 1999 May-Jun;43(3):439-41

Pyogenic granuloma of the glans penis. Maeda Y, et al. **Br J Urol** 1998 Nov;82(5):771-2

Cutaneous lesions of metastatic visceral malignancy mimicking pyogenic granuloma. Hager CM, et al. **Cancer Invest** 1999;17(6):385-90 (22 ref.)

Cutaneous metastasis from hepatocellular carcinoma resembling pyogenic granuloma. Kubota Y, et al. **Clin Exp Dermatol** 1999 Mar;24(2):78-80

Oral pyogenic granuloma in pregnancy [letter] Silverstein LH, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):331-2

Phacomatosis pigmentovascularis type IIb associated with Sturge-Weber syndrome and pyogenic granuloma. Hagiwara K, et al. **J Dermatol** 1998 Nov;25(11):721-9 (26 ref.)

Sublingual pyogenic granuloma of pregnancy. Suntra CR, et al. **J Otolaryngol** 1998 Aug;27(4):243-4

Lobular capillary hemangioma of the nasal cavity. Miller FR, et al. **Otolaryngol Head Neck Surg** 1999 May; 120(5):783-4

Multiple pyogenic granuloma of the penis. Tomasini C, et al. **Sex Transm Infect** 1998 Jun;74(3):221-2

RADIONUCLIDE IMAGING

Multiple pyogenic granuloma demonstrated by SPECT using 99Tcm-labelled red blood cells. Lin KJ, et al. **Br J Radiol** 1999 Apr;72(856):397-9

SURGERY

Case report of a bleeding nasal polyp during pregnancy. Scott PM, et al. **Ear Nose Throat J** 1999 Aug;78(8):592

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Curettage or silver nitrate for pyogenic granulomas on the hand. Dollery W. **J Accid Emerg Med** 1999 Mar;16(2):140-1

Treatment of pyogenic granuloma by shave excision and laser photocoagulation. Kirschner RE, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1346-9

GRANULOMA, RESPIRATORY TRACT

BLOOD

Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis [see comments] Iyonaga K, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep; 15(2):165-72. Comment in: Sarcoidosis Vasc Diffuse Lung Dis 1998 Sep;15(2):131-3.

CHEMICALLY INDUCED

Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Naccache JM, et al. **Am J Respir Crit Care Med** 1999 Jun; 159(6):2009-13

Granulomatous inflammatory response to recombinant filarial proteins of Brugia species. Rao UR, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):251-4

Identification of pathogenic T cells in patients with beryllium-induced lung disease. Fontenot AP, et al. **J Immunol** 1999 Jul 15;163(2):1019-26

COMPLICATIONS

Granulomatous bronchiolitis associated with Crohn's disease. Vandenplas O, et al. **Am J Respir Crit Care Med** 1998 Nov; 158(5 Pt 1):1676-9

DIAGNOSIS

Necrotizing sarcoid granulomatosis in a 14-yr-old female. Tauber E, et al. **Eur Respir J** 1999 Mar;13(3):703-5

[Pulmonary hyalinizing granuloma diagnosed by thoracoscopy] Kadoyama C, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):481-4 (Eng. Abstr.) **(Jpn)**

GRANULOMA, RESPIRATORY TRACT

ETIOLOGY

"Lifeguard lung": endemic granulomatous pneumonitis in an indoor swimming pool. Rose CS, et al. **Am J Public Health** 1998 Dec;88(12):1795–800

Identification of pathogenic T cells in patients with beryllium-induced lung disease. Fontenot AP, et al. **J Immunol** 1999 Jul 15;163(2):1019–26

Case of the season. Miliary pulmonary granulomatous disease. Secondary to BCG immunotherapy. Page J, et al. **Semin Roentgenol** 1999 Jul;34(3):165–8

GENETICS

Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. Bean AG, et al. **J Immunol** 1999 Mar 15;162(6):3504–11

IMMUNOLOGY

T and B cell independence of endothelial cell adhesion molecule expression in pulmonary granulomatous inflammation. Izzo AA, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):588–97

Polarization of the immune response to the single immunodominant epitope of p38, a major Schistosoma mansoni egg antigen, generates Th1- or Th2-type cytokines and granulomas. Chen Y, et al. **Infect Immun** 1999 Sep;67(9):4570–7

IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. Chiaramonte MG, et al. **J Immunol** 1999 Jan 15;162(2):920–30

Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. Hogaboam CM, et al. **J Immunol** 1999 Aug 15; 163(4):2193–201

T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. Löhning M, et al. **J Immunol** 1999 Apr 1;162(7):3882–9

IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. Yang X, et al. **J Immunol** 1999 Jan 15;162(2):1010–7

Functional roles of MCP-1 in Propionibacterium acnes-induced, T cell-mediated pulmonary granulomatosis in rabbits. Ichiyasu H, et al. **J Leukoc Biol** 1999 Apr; 65(4):482–91

METABOLISM

Collagen deposition in a non-fibrotic lung granuloma model after nitric oxide inhibition. Hogaboam CM, et al. **Am J Pathol** 1998 Dec;153(6):1861–72

MICROBIOLOGY

Diffuse alveolar damage in BCGosis: a rare complication of intravesical bacillus Calmette-Guérin therapy for transitional cell carcinoma. Tan L, et al. **Pathology** 1999 Feb;31(1):55–6

PATHOLOGY

Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Naccache JM, et al. **Am J Respir Crit Care Med** 1999 Jun; 159(6):2009–13

Granulomatous inflammatory response to recombinant filarial proteins of Brugia species. Rao UR, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):251–4

VIROLOGY

[Lung and bone marrow granulomas associated with human parvovirus B19 infection] Noguchi T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):589–93 (Eng. Abstr.) **(Jpn)**

GRANULOMA TELANGIECTICUM see **GRANULOMA, PYOGENIC**

GRANULOMA VENEREUM see **GRANULOMA INGUINALE**

GRANULOMATOSIS, LYMPHOMATOID see **LYMPHOMATOID GRANULOMATOSIS**

GRANULOMATOSIS, WEGENER'S see **WEGENER'S GRANULOMATOSIS**

GRANULOMATOUS CHEILITIS see **MELKERSSON-ROSENTHAL SYNDROME**

GRANULOMATOUS DISEASE, CHRONIC

Chronic granulomatous disease: six new cases. Martin Mateos MA, et al. **Allergol Immunopathol (Madr)** 1998 Sep-Oct; 26(5):241–9

[Chronic granulomatous disease (CGD)] Shibata A. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):81–3 (10 ref.) **(Jpn)**

COMPLICATIONS

Chronic granulomatous disease presenting in infancy with abdominal infection: case report. Vanoyan A, et al. **Can Assoc Radiol J** 1998 Dec;49(6):367–9

Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Jabado N, et al. **Clin Infect Dis** 1998 Dec; 27(6):1437–41

Colitis in chronic granulomatous disease resembling Crohn's disease: comparative analysis of CD68-positive cells between two disease entities. Mitomi H, et al. **Dig Dis Sci** 1999 Feb;44(2):452–6

Autosomal dominant granulomatous disease of childhood [letter; comment] Rotenstein D, et al. **J Pediatr** 1999 May; 134(5):663–4. Comment on: J Pediatr 1998 Sep;133(3):322–3. Comment on: J Pediatr 1998 Sep;133(3):450–2.

A case of chronic granulomatous disease in which the patient survived a recurrence of suspected Aspergillus brain abscess. Narita M. **Kansenshogaku Zasshi** 1999 Aug; 73(8):783–6

Aspergillus nidulans infection in chronic granulomatous disease. Segal BH, et al. **Medicine (Baltimore)** 1998 Sep; 77(5):345–54 (46 ref.)

Cutaneous purulent aspergillosis in a young man with chronic granulomatous disease. Chatzipanagiotou S, et al. **Mycoses** 1998 Nov;41(9–10):379–82

Multiple nodular pneumonitis in a three-week-old female infant. Narchi H, et al. **Pediatr Infect Dis J** 1999 May; 18(5):471, 485–6

DIAGNOSIS

Blau's syndrome and sarcoidosis [letter] James G. **Lancet** 1999 Sep 18;354(9183):1035

Sweet syndrome: an unusual presentation of chronic granulomatous disease in a child. Elliott SP, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):568–70

Multiple nodular pneumonitis in a three-week-old female infant. Narchi H, et al. **Pediatr Infect Dis J** 1999 May; 18(5):471, 485–6

[Primary liver abscess--suspected CGD (letter)] Valerius NH. **Ugeskr Laeger** 1998 Dec 14;160(51):7454 **(Dan)**

[Chronic granulomatous disease, disguised as bladder tumor. Potential source of diagnostic error] Kharchenko VP, et al. **Arkh Patol** 1999 Mar-Apr;61(2):37–40 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils. Ahlin A, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):420–4

Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease. Conte D, et al. **J Interferon Cytokine Res** 1999 Jul;19(7):705–10

ENZYMOLOGY

Transient association of the nicotinamide adenine dinucleotide phosphate oxidase subunits p47phox and p67phox with phagosomes in neutrophils from patients with X-linked chronic granulomatous disease. Allen LA, et al. **Blood** 1999 May 15;93(10):3521–30

Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. Dusi S, et al. **J Immunol** 1998 Nov 1;161(9):4968–74

EPIDEMIOLOGY

[Statistical evaluation of chronic granulomatous disease in Japan and basic studies for gene therapy for CGD patients] Nunoi H, et al. **Rinsho Byori** 1999 Jul;47(7):658–64 (Eng. Abstr.) **(Jpn)**

GENETICS

A novel mutation in the CYBB gene resulting in an unexpected pattern of exon skipping and chronic granulomatous disease. Noack D, et al. **Biochim Biophys Acta** 1999 Aug 30;1454(3):270–4

Transient association of the nicotinamide adenine dinucleotide phosphate oxidase subunits p47phox and p67phox with phagosomes in neutrophils from patients with X-linked chronic granulomatous disease. Allen LA, et al. **Blood** 1999 May 15;93(10):3521–30

Missense mutations in the gp91-phox gene encoding cytochrome b558 in patients with cytochrome b positive and negative X-linked chronic granulomatous disease. Kaneda M, et al. **Blood** 1999 Mar 15;93(6):2098–104

Elf-1 and PU.1 induce expression of gp91(phox) via a promoter element mutated in a subset of chronic granulomatous disease patients. Voo KS, et al. **Blood** 1999 May 15;93(10):3512–20

Reconstitution of NADPH oxidase activity in human X-linked chronic granulomatous disease myeloid cells after stable gene transfer using a recombinant adeno-associated virus 2 vector. Li LL, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):522–38

Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease. Roesler J, et al. **Exp Hematol** 1999 Mar;27(3):505–11

Nonhomologous recombination between the cytochrome b558 heavy chain gene (CYBB) and LINE-1 causes an X-linked chronic granulomatous disease. Kumatori A, et al. **Genomics** 1998 Oct 15;53(2):123–8

Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. Becker S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1561–70

Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR1) and the p47phox gene. Iwata M, et al. **Hum Genet** 1998 Oct;103(4):419–23

A novel mutation at a probable heme-binding ligand in neutrophil cytochrome b558 in atypical X-linked chronic granulomatous disease. Tsuda M, et al. **Hum Genet** 1998 Oct;103(4):377–81

Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox. Patiño PJ, et al. **Hum Mutat** 1999; 13(1):29–37

Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. Yoshida LS, et al. **J Biol Chem** 1998 Oct 23;273(43):27879–86

Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. Foster CB, et al. **J Clin Invest** 1998 Dec 15; 102(12):2146–55

IMMUNOLOGY

The p47(phox-/-) mouse model of chronic granulomatous disease has normal granuloma formation and cytokine responses to Mycobacterium avium and Schistosoma mansoni eggs. Segal BH, et al. **Infect Immun** 1999 Apr; 67(4):1659–65

Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. Murray HW, et al. **J Exp Med** 1999 Feb 15;189(4):741–6

METABOLISM

A novel H(+) conductance in eosinophils: unique characteristics and absence in chronic granulomatous disease. Bánfi B, et al. **J Exp Med** 1999 Jul 19;190(2):183–94

[Molecular basis of chronic granulomatous disease] Zekanowski C, et al. **Postepy Biochem** 1998;44(3):193–200 **(Pol)**

MICROBIOLOGY

Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease. Roilides E, et al. **J Clin Microbiol** 1999 Jan; 37(1):18–25 (38 ref.)

Nocardia farcinica pneumonia in chronic granulomatous disease. Shetty AK, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):961–4 (36 ref.)

PATHOLOGY

Discoid lupus erythematosus-like lesions and stomatitis. Botella R, et al. **Arch Dermatol** 1999 Jul;135(7):847, 850

Colitis in chronic granulomatous disease resembling Crohn's disease: comparative analysis of CD68-positive cells between two disease entities. Mitomi H, et al. **Dig Dis Sci** 1999 Feb;44(2):452–6

Chorioretinal lesions in patients and carriers of chronic granulomatous disease. Goldblatt D, et al. **J Pediatr** 1999 Jun;134(6):780–3

PHYSIOPATHOLOGY

O2 sensing is preserved in mice lacking the gp91 phox subunit of NADPH oxidase. Archer SL, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7944–9

RADIOGRAPHY

Oesophageal narrowing in chronic granulomatous disease [letter] Hoeffel JC, et al. **Eur J Radiol** 1999 Apr;30(1):77

RADIOTHERAPY

Effects of low dose ionizing radiation on murine chronic granulomatous tissue. Hildebrandt G, et al. **Strahlenther Onkol** 1998 Nov;174(11):580–8

THERAPY

Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells. Zentilin L, et al. **Ann Ist Super Sanita** 1998;34(4):447–55

Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Dinauer MC, et al. **Blood** 1999 Aug 1;94(3):914–22

Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation,

granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Ozsahin H, et al. **Blood** 1998 Oct 15;92(8):2719-24

Donor lymphocyte infusion at unstable mixed chimerism in an allogeneic BMT recipient for chronic granulomatous disease. Akioka S, et al. **Bone Marrow Transplant** 1998 Sep; 22(6):609-11

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Nagler A, et al. **Bone Marrow Transplant** 1999 Aug;24(3):339-42

Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. Becker S, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1561-70

Progress in gene therapy for chronic granulomatous disease. Malech HL. **J Infect Dis** 1999 Mar;179 Suppl 2:S318-25 (14 ref.)

Aspergillus osteomyelitis in a child who has p67-phox-deficient chronic granulomatous disease. Tsumura N, et al. **Kurume Med J** 1999;46(1):87-90

GRANULOMATOUS SLACK SKIN see **LYMPHOMA, T-CELL, CUTANEOUS**

GRANULOSA CELL TUMOR

Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Savage P, et al. **Clin Oncol (R Coll Radiol)** 1998;10(4):242-5

DIAGNOSIS

Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Cronjé HS, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):323-7

Combined inhibin and CA125 assays in the detection of ovarian cancer. Robertson DM, et al. **Clin Chem** 1999 May; 45(5):651-8

Inhibin forms in serum from postmenopausal women with ovarian cancers. Robertson DM, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):381-6

Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Lane AH, et al. **Gynecol Oncol** 1999 Apr;73(1):51-5

Bilateral granulosa cell tumor in a patient with blepharophimosis syndrome. Maede Y, et al. **Gynecol Oncol** 1999 May;73(2):335-6

Granulosa cell tumor of the ovary. Volders W, et al. **J Belge Radiol** 1998 Oct;81(5):256

Management quandary. Abnormal bleeding and a pelvic mass in an adolescent. Bacon J. **J Pediatr Adolesc Gynecol** 1999 May;12(2):103-4

DRUG THERAPY

Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor. Kudelka AP, et al. **Anticancer Drugs** 1998 Aug;9(7):621-3

Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study [see comments] Homesley HD, et al. **Gynecol Oncol** 1999 Feb; 72(2):131-7. Comment in: Gynecol Oncol 1999 Feb;72(2):129-30.

EPIDEMIOLOGY

Nationwide data on falling incidence of ovarian granulosa cell tumours concomitant with increasing use of ovulation inducers. Unkila-Kallio L, et al. **Hum Reprod** 1998 Oct; 13(10):2828-30

GENETICS

Monosomy 22 and trisomy 14 may be early events in the tumorigenesis of adult granulosa cell tumor. Van den Berghe I, et al. **Cancer Genet Cytogenet** 1999 Jul 1; 112(1):46-8

Granulosa cell tumor of the ovary. Immunohistochemical evidence of low proliferative activity and virtual absence of mutation of the p53 tumor-suppressor gene. Horny HP, et al. **Gynecol Obstet Invest** 1999;47(2):133-8

Inhibin subunit gene expression in ovarian cancer. Fuller PJ, et al. **Gynecol Oncol** 1999 May;73(2):273-9

Analysis of mutations in genes of the follicle-stimulating hormone receptor signaling pathway in ovarian granulosa cell tumors. Ligtenberg MJ, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2233-4

Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis. Keshava N, et al. **J Soc Gynecol Investig** 1999 Jan-Feb; 6(1):41-9

Hormonal regulation of proliferation of granulosa and Leydig cell lines derived from gonadal tumors of transgenic mice expressing the inhibin-alpha subunit promoter/simian virus 40 T-antigen fusion gene. Rilianawati, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1-2):9-17

IMMUNOLOGY

Granulosa cell tumour of the testis displaying immunoreactivity for inhibin. Morgan DR, et al. **BJU Int** 1999 Apr;83(6):731-2

PATHOLOGY

Sertoli cell tumor of the testis. Report of a case with imprint cytology findings. Terayama K, et al. **Acta Cytol** 1998 Nov-Dec;42(6):1458-60

Adult granulosa cell tumor of the ovary with foci of hepatic cell differentiation: a report of four cases and comparison with two cases of granulosa cell tumor with Leydig cells. Ahmed E, et al. **Am J Surg Pathol** 1999 Sep;23(9):1089-93

Granulosa cell tumor of the ovary. Immunohistochemical evidence of low proliferative activity and virtual absence of mutation of the p53 tumor-suppressor gene. Horny HP, et al. **Gynecol Obstet Invest** 1999;47(2):133-8

Extraovarian granulosa cell tumor. Robinson JB, et al. **Gynecol Oncol** 1999 Jul;74(1):123-7 (15 ref.)

Mouse model for malignant juvenile ovarian granulosa cell tumors. Beamer WG, et al. **Toxicol Pathol** 1998 Sep-Oct; 26(5):704-10 (57 ref.)

PHYSIOPATHOLOGY

An association of hypothalamic hamartoma, central precocious puberty and juvenile granulosa cell tumour in early childhood. Feilberg Jørgensen N, et al. **Horm Res** 1998;49(6):292-4

RADIOGRAPHY

Adult ovarian granulosa cell tumors: spectrum of sonographic and CT findings with pathologic correlation. Ko SF, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1227-33

RADIOTHERAPY

Radiotherapy for the treatment of metastatic granulosa cell tumor in the mediastinum: a case report. Lee IW, et al. **Gynecol Oncol** 1999 Jun;73(3):455-60 (12 ref.)

Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Wolf JK, et al. **Gynecol Oncol** 1999 Apr;73(1):35-41 (24 ref.)

SECONDARY

Bilateral juvenile granulosa--cell tumour with multiple metastases. A case report. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jun;44(6):158-60

Metastatic granulosa-cell tumor in the liver: cytopathologic findings and staining with inhibin. Ali SZ. **Diagn Cytopathol** 1998 Oct;19(4):293-7

Skeletal metastases from a granulosa-cell tumor of the ovary: report of a case diagnosed by fine-needle aspiration cytology. Thirumala SD, et al. **Diagn Cytopathol** 1998 Nov; 19(5):375-7

Granulosa-theca cell tumour of the ovaries. A late metastasizing tumour. Spencer HW, et al. **West Indian Med J** 1999 Mar;48(1):33-5

SURGERY

A case of Meigs' syndrome with a gigantic granulosa ovarian tumor. Papathanasiou K, et al. **Clin Exp Obstet Gynecol** 1998;25(1-2):61-3

[Therapeutic results in patients with malignant granulosa cell tumors at the Gynecologic Clinic of the city of Pécs] Krommer K, et al. **Orv Hetil** 1999 Jul 11;140(28):1583-6 (Eng. Abstr.) **(Hun)**

ULTRASONOGRAPHY

Adult ovarian granulosa cell tumors: spectrum of sonographic and CT findings with pathologic correlation. Ko SF, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1227-33

VETERINARY

Theriogenology question of the month. Persistent estrus caused by functional granulosa cell tumor of the left ovary. Purswell BJ, et al. **J Am Vet Med Assoc** 1999 Jul 15; 215(2):193-5

GRANULOSA CELLS

see related

OVARIAN FOLLICLE

Subpopulations of the granulosa layer differentiated by histo- and immunocytochemical methods in the preovulatory follicle of the rat. Szoltys M, et al. **Folia Histochem Cytobiol** 1999;37(2):91-2

In vitro growth of oocyte-granulosa cell complexes isolated from cryopreserved ovine tissue. Newton H, et al. **J Reprod Fertil** 1999 Jan;115(1):141-50

CHEMISTRY

Quantification of inhibin/activin alpha and betaA subunit messenger ribonucleic acid by competitive reverse transcription-polymerase chain reaction in chicken granulosa cells during follicular development. Safi M, et al. **Biol Reprod** 1998 Nov;59(5):1047-54

Localization, regulation and possible consequences of apoptotic protease-activating factor-1 (Apaf-1) expression in granulosa cells of the mouse ovary. Robles R, et al. **Endocrinology** 1999 Jun;140(6):2641-4

Hyperexpression of epidermal growth factor receptors in granulosa cells from women with polycystic ovary syndrome. Almahbobi G, et al. **Fertil Steril** 1998 Oct; 70(4):750-8

The effect of follicle-stimulating hormone (FSH) on the expression of FSH receptor in cultured rat granulosa cells. Tano M, et al. **Life Sci** 1999;64(12):1063-9

CYTOLOGY

Induction of apoptosis in luteinized granulosa cells by the MAP kinase kinase (MEK) inhibitor PD98059. Oliver RH, et al. **Biochem Biophys Res Commun** 1999 Sep 16; 263(1):143-8

The absence of p27Kip1, an inhibitor of G1 cyclin-dependent kinases, uncouples differentiation and growth arrest during the granulosa->luteal transition. Tong W, et al. **Cell Growth Differ** 1998 Sep;9(9):787-94

Effect of prolactin on the expression of luteinizing hormone receptors during cell differentiation in cultured rat granulosa cells. Hirakawa T, et al. **Endocrinology** 1999 Aug; 140(8):3444-51

Flow cytometric cell cycle analysis of two subpopulations of porcine granulosa cells. Duda M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):203-7

Effect of granulosa cell apoptosis on fecundity? [letter; comment] Cahill DJ. **Fertil Steril** 1998 Dec;70(6):1186-7. Comment on: Fertil Steril 1998 May;69(5):931-5.

Stimulation of early embryonic development in cattle by coculture with surfactant. Osada H, et al. **J Assist Reprod Genet** 1999 Jul;16(6):310-4

Populations of granulosa cells in small follicles of the sheep ovary. Lundy T, et al. **J Reprod Fertil** 1999 Mar; 115(2):251-62

Adenovirus-directed expression of a nonphosphorylatable mutant of CREB (cAMP response element-binding protein) adversely affects the survival, but not the differentiation, of rat granulosa cells. Somers JP, et al. **Mol Endocrinol** 1999 Aug;13(8):1364-72

Expression of CD44 in human cumulus and mural granulosa cells of individual patients in in-vitro fertilization programmes. Ohta N, et al. **Mol Hum Reprod** 1999 Jan; 5(1):22-8

Human granulosa cells express integrin alpha2 and collagen type IV: possible involvement of collagen type IV in granulosa cell luteinization. Yamada S, et al. **Mol Hum Reprod** 1999 Jul;5(7):607-17

DRUG EFFECTS

Induction of apoptosis in luteinized granulosa cells by the MAP kinase kinase (MEK) inhibitor PD98059. Oliver RH, et al. **Biochem Biophys Res Commun** 1999 Sep 16; 263(1):143-8

Diverse effects of tyrosine kinase inhibitors on follicle-stimulating hormone-stimulated estradiol and progesterone production from rat granulosa cells in serum-containing medium and serum-free medium containing epidermal growth factor. Haynes-Johnson D, et al. **Biol Reprod** 1999 Jul;61(1):147-53

Progesterone maintains large rat granulosa cell viability indirectly by stimulating small granulosa cells to synthesize basic fibroblast growth factor. Peluso JJ, et al. **Biol Reprod** 1999 Feb;60(2):290-6

Insulin-like growth factor binding protein-3: its biological effect on bovine granulosa cells. Spicer LJ, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):19-29

In vitro production of progesterone and estradiol by rat granulosa cells regulated by cabergoline and prolactin. Negishi H, et al. **Endocr Res** 1998 May;24(2):195-203

Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. Cecconi S, et al. **Endocrinology** 1999 Apr;140(4):1783-8

Troglitazone inhibits progesterone production in porcine granulosa cells. Gasic S, et al. **Endocrinology** 1998 Dec; 139(12):4962-6

Mechanisms of insulin-like growth factor I augmentation of follicle-stimulating hormone-induced porcine steroidogenic acute regulatory protein gene promoter activity in granulosa cells. LaVoie HA, et al. **Endocrinology** 1999 Jan;140(1):146-53

Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Alak BM, et al. **Fertil Steril** 1998 Dec;70(6):1126-30

Leptin inhibits gonadotrophin-stimulated granulosa cell progesterone production by antagonizing insulin action. Brannian JD, et al. **Hum Reprod** 1999 Jun;14(6):1445-8

Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome. Doldi N, et al. **Hum Reprod** 1999 May;14(5):1157-9

Aromatase activity of human granulosa cells in vitro: effects of gonadotrophins and follicular fluid. Guet P, et al. **Hum Reprod** 1999 May;14(5):1182-9

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Lin Y, et al. **Hum Reprod** 1999 Apr;14(4):885-8

Steroidogenesis in luteinized granulosa cell cultures varies with follicular priming regimen. Lobb DK, et al. **Hum Reprod** 1998 Aug;13(8):2064-7

Low oxygen inhibits but complex high-glucose medium

facilitates in vitro maturation of squirrel monkey oocyte-granulosa cell complexes. Yeoman RR, et al. **J Assist Reprod Genet** 1999 Feb;16(2):102-7

Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. Willis DS, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3984-91

Enhanced proliferation and progesterone production by porcine granulosa cells cultured with pseudorabies virus growth factor (PRGF). Pieklo R, et al. **J Physiol Pharmacol** 1999 Mar;50(1):129-37

Steroid regulation of progesterone synthesis in a stable porcine granulosa cell line: a role for progestins. Rodway MR, et al. **J Steroid Biochem Mol Biol** 1999 Mar; 68(5-6):173-80

Effects of nicotine administration on elemental concentrations in mouse granulosa cells, maturing oocytes and oviduct epithelium studied by X-ray microanalysis. Jin Z, et al. **J Submicrosc Cytol Pathol** 1998 Oct; 30(4):517-20

Alpha-tocopherol inhibits oxidative stress induced by cholestanetriol and 25-hydroxycholesterol in porcine ovarian granulosa cells. McCluskey S, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):217-25

Mechanisms of desensitization of follicle-stimulating hormone (FSH) action in a murine granulosa cell line stably transfected with the human FSH receptor complementary deoxyribonucleic acid. Manna PR, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):163-76

Control of FSH receptor mRNA expression in rat granulosa cells by 3',5'-cyclic adenosine monophosphate, activin, and follistatin. Minegishi T, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1-2):71-7

Effect of follicle stimulating hormone and insulin-like growth factors on proteolysis of insulin-like growth factor binding protein-4 in human granulosa cells. Iwashita M, et al. **Mol Hum Reprod** 1998 Apr;4(4):401-5

Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Kitawaki J, et al. **Mol Hum Reprod** 1999 Aug;5(8):708-13

ENZYMOLOGY

Expression of matrix metalloproteinases and their tissue inhibitor messenger ribonucleic acids in macaque periovulatory granulosa cells: time course and steroid regulation. Chaffin CL, et al. **Biol Reprod** 1999 Jul; 61(1):14-21

Evidence for ovarian granulosa stem cells: telomerase activity and localization of the telomerase ribonucleic acid component in bovine ovarian follicles. Lavranos TC, et al. **Biol Reprod** 1999 Aug;61(2):358-66

11 beta-Hydroxysteroid dehydrogenase enzyme activity in granulosa cells derived from ovarian follicles of in vitro fertilization patients. O'Shaughnessy A, et al. **Early Pregnancy** 1997 Sep;3(3):183-9

Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. Cecconi S, et al. **Endocrinology** 1999 Apr;140(4):1783-8

Spatio-temporal changes of prolyl 4-hydroxylase in granulosa cells during ovulation in eCG-hCG-treated immature rat ovaries. Nagai R, et al. **J Reprod Fertil** 1998 Jul;113(2):349-54

Functional and subcellular changes in the A-kinase-signaling pathway: relation to aromatase and Sgk expression during the transition of granulosa cells to luteal cells. Gonzalez-Robayna IJ, et al. **Mol Endocrinol** 1999 Aug; 13(8):1318-37

Effect of follicle stimulating hormone and insulin-like growth factors on proteolysis of insulin-like growth factor binding protein-4 in human granulosa cells. Iwashita M, et al. **Mol Hum Reprod** 1998 Apr;4(4):401-5

Inhibitory effects of nitric oxide on the expression and activity of aromatase in human granulosa cells. Kagabu S, et al. **Mol Hum Reprod** 1999 May;5(5):396-401

Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Kitawaki J, et al. **Mol Hum Reprod** 1999 Aug;5(8):708-13

In vitro evaluation of aromatase enzyme in granulosa cells using a [11C]vorozole binding assay. Kirilovas D, et al. **Steroids** 1999 Apr;64(4):266-72

METABOLISM

Control of the expression of luteinizing hormone receptor by local factors in rat granulosa cells. Tsuchiya M, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):185-92

Regulation of cAMP responsive element binding modulator isoforms in cultured rat ovarian granulosa cells. Kameda T, et al. **Biochim Biophys Acta** 1999 Apr 14;1445(1):31-8

The selective pathway and a high-density lipoprotein receptor (SR-BI) in ovarian granulosa cells of the mouse. Reaven E, et al. **Biochim Biophys Acta** 1999 Jan 4; 1436(3):565-76

Up-regulation of the alpha2,6-sialyltransferase messenger ribonucleic acid increases glycoconjugates containing alpha2, 6-linked sialic acid residues in granulosa cells during follicular atresia of porcine ovaries. Kimura Y, et al. **Biol Reprod** 1999 Jun;60(6):1475-82

Comparison of protein synthesis patterns in mouse cumulus cells and mural granulosa cells: effects of follicle-stimulating hormone and insulin on granulosa cell differentiation in vitro. Latham KE, et al. **Biol Reprod** 1999 Aug;61(2):482-92

Progesterone maintains large rat granulosa cell viability indirectly by stimulating small granulosa cells to synthesize basic fibroblast growth factor. Peluso JJ, et al. **Biol Reprod** 1999 Feb;60(2):290-6

Transforming growth factor beta receptor expression in hyperstimulated human granulosa cells and cleavage potential of the zygotes. Roy SK, et al. **Biol Reprod** 1998 Dec;59(6):1311-6

Acyl chain length-specific ceramide-induced changes in intracellular Ca2+ concentration and progesterone production are not regulated by tumor necrosis factor alpha in hen granulosa cells. Soboloff J, et al. **Biol Reprod** 1999 Feb;60(2):262-71

Mouse oocytes regulate granulosa cell steroidogenesis throughout follicular development. Vanderhyden BC, et al. **Biol Reprod** 1998 Dec;59(6):1296-301

The chicken homologue of zona pellucida protein-3 is synthesized by granulosa cells. Waclawek M, et al. **Biol Reprod** 1998 Nov;59(5):1230-9

Heterotrimetric Gi/o proteins control cyclic AMP oscillations and cytoskeletal structure assembly in primary human granulosa-lutein cells. Saltarelli D. **Cell Signal** 1999 Jun;11(6):415-33

Evidence for gonadotropin-releasing hormone receptor mRNA expression by estrogen in rat granulosa cells. Kogo H, et al. **Cell Tissue Res** 1999 Sep;297(3):459-65

Evidence for an inverse relationship between apoptosis and inducible nitric oxide synthase expression in rat granulosa cells: a possible role of nitric oxide in ovarian follicle atresia. Matsumi H, et al. **Endocr J** 1998 Dec;45(6):745-51

Tumor necrosis factor alpha inhibition of follicle-stimulating hormone-induced granulosa cell estradiol secretion in the human does not involve reduction of cAMP secretion but inhibition at post-cAMP site(s). Montgomery Rice V, et al. **Endocrine** 1999 Feb;10(1):19-23

Regulation of prostaglandin F2alpha-receptor mRNA in human granulosa-luteal cells by human chorionic gonadotrophin and prostaglandin F2alpha. Väänänen JE, et al. **Endocrine** 1998 Jun;8(3):261-7

Dual regulation of promoter II- and promoter If-derived cytochrome P450 aromatase transcripts in equine granulosa cells during human chorionic gonadotropin-induced ovulation: a novel model for the study of aromatase promoter switching. Boerboom D, et al. **Endocrinology** 1999 Sep;140(9):4133-41

Gonadotropin and steroid regulation of steroid receptor and aryl hydrocarbon receptor messenger ribonucleic acid in macaque granulosa cells during the periovulatory interval. Chaffin CL, et al. **Endocrinology** 1999 Oct;140(10):4753-60

Transcriptional and posttranscriptional regulation of intraovarian insulin-like growth factor-binding proteins by interleukin-1beta (IL-1beta): evidence for IL-1beta as an antiatretic principal. Chamoun D, et al. **Endocrinology** 1999 Aug;140(8):3488-95

Multiple elements and protein factors coordinate the basal and cyclic adenosine 3',5'-monophosphate-induced transcription of the lutropin receptor gene in rat granulosa cells. Chen S, et al. **Endocrinology** 1999 May;140(5):2100-9

Troglitazone inhibits progesterone production in porcine granulosa cells. Gasic S, et al. **Endocrinology** 1998 Dec; 139(12):4962-6

Pituitary adenylate cyclase-activating polypeptide is an auto/paracrine stimulator of acute progesterone accumulation and subsequent luteinization in cultured periovulatory granulosa/lutein cells. Gräs S, et al. **Endocrinology** 1999 May;140(5):2199-205

Effect of prolactin on the expression of luteinizing hormone receptors during cell differentiation in cultured rat granulosa cells. Hirakawa T, et al. **Endocrinology** 1999 Aug; 140(8):3444-51

Induction of Ad4BP/SF-1, steroidogenic acute regulatory protein, and cytochrome P450scc enzyme system expression in newly established human granulosa cell lines. Hosokawa K, et al. **Endocrinology** 1998 Nov; 139(11):4679-87

Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. Hosokawa K, et al. **Endocrinology** 1998 Nov;139(11):4688-700

Bcl-X(LONG) protein expression and phosphorylation in granulosa cells. Johnson AL, et al. **Endocrinology** 1999 Oct; 140(10):4521-9

Human chorionic gonadotropin induces an inverse regulation of steroidogenic acute regulatory protein messenger ribonucleic acid in theca interna and granulosa cells of equine preovulatory follicles. Kerban A, et al. **Endocrinology** 1999 Feb;140(2):667-74

Hormone-regulated and glucose-sensitive transport of dehydroascorbic acid in immature rat granulosa cells. Kodaman PH, et al. **Endocrinology** 1999 Aug; 140(8):3659-65

Dimeric inhibin A and B production are differentially regulated by hormones and local factors in rat granulosa cells. Lanuza GM, et al. **Endocrinology** 1999 Jun; 140(6):2549-54

Concerted regulation of low density lipoprotein receptor gene expression by follicle-stimulating hormone and insulin-like growth factor I in porcine granulosa cells: promoter activation, messenger ribonucleic acid stability, and sterol feedback. LaVoie HA, et al. **Endocrinology** 1999 Jan;140(1):178-86

Characterization of estrogen receptor-beta (ERbeta) messenger ribonucleic acid and protein expression in rat granulosa cells. O'Brien ML, et al. **Endocrinology** 1999 Oct; 140(10):4530-41

Expression and function of estrogen receptor subtypes in granulosa cells: regulation by estradiol and forskolin. Sharma SC, et al. **Endocrinology** 1999 Sep;140(9):4320-34

Cellular distribution and relative amounts of vascular endothelium growth factor mRNA in granulosa cells from human preovulatory follicles. Machelon V, et al. **Eur Cytokine Netw** 1999 Sep;10(3):393-402

The same luteinized granulosa-luteal cells from normal and superovulated human chorionic gonadotropin (hCG)-stimulated cycles contain hCG and insulin-like growth factor binding protein-1. Gersak K, et al. **Fertil Steril** 1999 May;71(5):902-6

Effect of growth hormone releasing hormone on luteinizing hormone stimulated progestin biosynthesis in cultured rat ovarian granulosa cells. Kotani E, et al. **Gynecol Endocrinol** 1998 Oct;12(5):307-13

Syndecan-4 expression is associated with follicular atresia in mouse ovary. Ishiguro K, et al. **Histochem Cell Biol** 1999 Jul;112(1):25-33

The expression of transforming growth factor alpha receptor protein and its activation in chicken ovarian granulosa cells of maturing follicles. Onagbesan OM, et al. **Histochem J** 1998 Sep;30(9):647-56

Mononuclear cell-modulation of granulosa cell steroidogenesis in rat: influence of ovarian cycle. Kumar A, et al. **Horm Metab Res** 1999 Aug;31(8):441-7

Leptin inhibits gonadotrophin-stimulated granulosa cell progesterone production by antagonizing insulin action. Brannian JD, et al. **Hum Reprod** 1999 Jun;14(6):1445-8

Oestradiol production by luteinized human granulosa cells: evidence of the stimulatory action of recombinant human follicle stimulating hormone. Földesi I, et al. **Hum Reprod** 1998 Jun;13(6):1455-60

Steroidogenesis in luteinized granulosa cell cultures varies with follicular priming regimen. Lobb DK, et al. **Hum Reprod** 1998 Aug;13(8):2064-7

Phospholipase C-beta and ovarian sex steroids in pig granulosa cells. Lieberherr M, et al. **J Cell Biochem** 1999 Jul 1;74(1):50-60

Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. Agarwal SK, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1072-6

Functional and molecular characterization of a muscarinic receptor type and evidence for expression of choline-acetyltransferase and vesicular acetylcholine transporter in human granulosa-luteal cells. Fritz S, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1744-50

Functional dopamine-1 receptors and DARPP-32 are expressed in human ovary and granulosa luteal cells in vitro. Mayerhofer A, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):257-64

Differential effects of amount of feeding on cell proliferation and progesterone production in response to gonadotrophins and insulin-like growth factor I by ovarian granulosa cells of broiler breeder chickens selected for fatness or leanness. Onagbesan OM, et al. **J Reprod Fertil** 1999 May; 116(1):73-85

Maintenance of oestradiol production and expression of cytochrome P450 aromatase enzyme mRNA in long-term serum-free cultures of pig granulosa cells. Picton HM, et al. **J Reprod Fertil** 1999 Jan;115(1):67-77

Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis. Keshava N, et al. **J Soc Gynecol Investig** 1999 Jan-Feb; 6(1):41-9

Effects of nicotine administration on elemental concentrations in mouse granulosa cells, maturing oocytes and oviduct epithelium studied by X-ray microanalysis. Jin Z, et al. **J Submicrosc Cytol Pathol** 1998 Oct; 30(4):517-20

Mechanisms of desensitization of follicle-stimulating hormone (FSH) action in a murine granulosa cell line stably transfected with the human FSH receptor complementary deoxyribonucleic acid. Manna PR, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1-2):163-76

Control of FSH receptor mRNA expression in rat granulosa cells by 3',5'-cyclic adenosine monophosphate, activin, and follistatin. Minegishi T, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1-2):71-7

Regulation of steroidogenesis in jc-410, a stable cell line of porcine granulosa origin. Rodway MR, et al. **Mol Cell Endocrinol** 1999 Feb 25;148(1-2):87-94

Hormone induction of progesterone receptor (PR) messenger ribonucleic acid and activation of PR promoter regions in ovarian granulosa cells: evidence for a role of cyclic adenosine 3',5'-monophosphate but not estradiol. Clemens JW, et al. **Mol Endocrinol** 1998 Aug;12(8):1201-14

Stat 5b and the orphan nuclear receptors regulate expression of the alpha2-macroglobulin (alpha2M) gene in rat ovarian granulosa cells. Dajee M, et al. **Mol Endocrinol** 1998 Sep; 12(9):1393-409

Follicle-stimulating hormone promotes histone H3 phosphorylation on serine-10. DeManno DA, et al. **Mol Endocrinol** 1999 Jan;13(1):91-105

Expression of interleukin-6 and interleukin-6 receptors in human granulosa lutein cells. Keck C, et al. **Mol Hum Reprod** 1998 Nov;4(11):1071-6

The mechanism of action of epidermal growth factor and transforming growth factor alpha on aromatase activity in granulosa cells from polycystic ovaries. Misajon A, et al. **Mol Hum Reprod** 1999 Feb;5(2):96–103

Expression of CD44 in human cumulus and mural granulosa cells of individual patients in in-vitro fertilization programmes. Ohta N, et al. **Mol Hum Reprod** 1999 Jan; 5(1):22–8

CD9 is expressed on the cell surface of human granulosa cells and associated with integrin alpha6beta1. Takao Y, et al. **Mol Hum Reprod** 1999 Apr;5(4):303–10

Identification and characterization of an ascorbic acid transporter in human granulosa-lutein cells. Zreik TG, et al. **Mol Hum Reprod** 1999 Apr;5(4):299–302

Homologous and heterologous ligands downregulate follicle-stimulating hormone receptor mRNA in porcine granulosa cells. Murphy BD, et al. **Mol Reprod Dev** 1999 Jun;53(2):198–207

Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Dierich A, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13612–7

Thyroid hormone inhibits aromatase activity in porcine thecal cells cultured alone and in coculture with granulosa cells. Gregoraszczuk EL, et al. **Thyroid** 1998 Dec; 8(12):1157–63

[Effects of endothelin-1 on the progesterone production of rat preovulatory ovarian granulosa cells] Zheng Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):171–3 (Eng. Abstr.) **(Chi)**

PATHOLOGY

N-cadherin-mediated human granulosa cell adhesion prevents apoptosis: a role in follicular atresia and luteolysis? Makrigiannakis A, et al. **Am J Pathol** 1999 May; 154(5):1391–406

Scavenger receptor class B type I in the rat ovary: possible role in high density lipoprotein cholesterol uptake and in the recognition of apoptotic granulosa cells. Svensson PA, et al. **Endocrinology** 1999 Jun;140(6):2494–500

Evidence for alternative pathways of granulosa cell death in healthy and slightly atretic bovine antral follicles. Van Wezel IL, et al. **Endocrinology** 1999 Jun;140(6):2602–12

Apoptotic cell death in human granulosa-lutein cells: a possible indicator of in vitro fertilization outcome. Oosterhuis GJ, et al. **Fertil Steril** 1998 Oct;70(4):747–9

PHYSIOLOGY

Relaxin secretion and gene expression in porcine granulosa and theca cells are stimulated during in vitro luteinization. Ohleth KM, et al. **Biol Reprod** 1999 Feb;60(2):499–507

Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Sidis Y, et al. **Biol Reprod** 1998 Oct;59(4):807–12

Expression of granulosa cell-specific genes and induction of apoptosis in conditionally immortalized granulosa cell lines established from H-2Kb-tsA58 transgenic mice. Walther N, et al. **Biol Reprod** 1999 May;60(5):1078–86

Effects of granulosa cells, cumulus cells, and oocyte density on in vitro fertilization in women. Khamsi F, et al. **Endocrine** 1999 Apr;10(2):161–6

In situ amplification of the cytochrome P-450 cholesterol side-chain cleavage enzyme mRNA in single porcine granulosa cells by IGF-1 and FSH acting alone or in concert. Winters TA, et al. **Endocrine** 1998 Aug;9(1):57–63

Expression and effect of adrenomedullin on rat granulosa cell. Abe K, et al. **Endocrinology** 1998 Dec;139(12):5263–6

Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. Kim JM, et al. **Endocrinology** 1999 May; 140(5):2307–17

Identification of link protein during follicle development and cumulus cell cultures in rats. Kobayashi H, et al. **Endocrinology** 1999 Aug;140(8):3835–42

Potentiation of Fas-mediated apoptosis of murine granulosa cells by interferon-gamma, tumor necrosis factor-alpha, and cycloheximide. Quirk SM, et al. **Endocrinology** 1998 Dec;139(12):4860–9

High expression of bovine alpha glutathione S-transferase (GSTA1, GSTA2) subunits is mainly associated with steroidogenically active cells and regulated by gonadotropins in bovine ovarian follicles. Rabahi F, et al. **Endocrinology** 1999 Aug;140(8):3507–17

Is hydrosalpinx fluid cytotoxic? Granot I, et al. **Hum Reprod** 1998 Jun;13(6):1620–4

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Lin Y, et al. **Hum Reprod** 1999 Apr;14(4):885–8

Are there any relationships between the fecundity of bilateral ovaries in an individual patient and the incidence of apoptotic granulosa cells? Moreira P, et al. **Hum Reprod** 1999 Jan;14(1):156–61

Optimal control of the cell dynamics in the granulosa of ovulatory follicles. Clément F. **Math Biosci** 1998 Sep; 152(2):123–42

Cloning of bovine estrogen receptor beta (ERbeta): expression of novel deleted isoforms in reproductive tissues. Walther N, et al. **Mol Cell Endocrinol** 1999 Jun 25; 152(1-2):37–45

Selective presence of the chemokine growth-regulated oncogene alpha (GROalpha) in the human follicle and secretion from cultured granulosa-lutein cells at ovulation. Karström-Encrantz L, et al. **Mol Hum Reprod** 1998 Nov; 4(11):1077–83

Human granulosa cells express integrin alpha2 and collagen type IV: possible involvement of collagen type IV in granulosa cell luteinization. Yamada S, et al. **Mol Hum Reprod** 1999 Jul;5(7):607–17

Control of oocyte growth and maturation by follicular cells and molecules present in follicular fluid. A review. Driancourt MA, et al. **Reprod Nutr Dev** 1998 Jul-Aug; 38(4):345–62 (120 ref.)

[Mechanism, regulation, and manipulations of follicular atresia] Monniaux D, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7-8):528–35 (57 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Porcine granulosa cells produce a progesterone secretion inhibitory activity. Denkova RT, et al. **Endocr Regul** 1999 Mar;33(1):33–7

Relaxin secretion by human granulosa cell culture is predictive of in-vitro fertilization-embryo transfer success. Stewart DR, et al. **Hum Reprod** 1999 Feb;14(2):338–44

ULTRASTRUCTURE

Intercellular bridges between granulosa cells and the oocyte in the elasmobranch Raya asterias. Andreuccetti P, et al. **Anat Rec** 1999 Jun 1;255(2):180–7

Production of cloned calves following nuclear transfer with cultured adult mural granulosa cells. Wells DN, et al. **Biol Reprod** 1999 Apr;60(4):996–1005

Ultrastructure and composition of Call-Exner bodies in bovine follicles. van Wezel IL, et al. **Cell Tissue Res** 1999 May;296(2):385–94

GRANULOSIS VIRUSES see **BACULOVIRIDAE**

GRANULOVIRUS see **BACULOVIRIDAE**

GRAPES see **ROSALES**

GRAPHITE

Penetrating pencil injury: an unusual case of child abuse. Lee AC, et al. **Child Abuse Negl** 1998 Jul;22(7):749–52

A general approach to desalting oligosaccharides released from glycoproteins. Packer NH, et al. **Glycoconj J** 1998 Aug;15(8):737–47

CHEMISTRY

Origin of graphitic carbon and pentlandite in matrix olivines in the Allende meteorite [see comments] Brearley AJ. **Science** 1999 Aug 27;285(5432):1380–2. Comment in: Science 1999 Aug 27;285(5432):1364–5.

DIAGNOSTIC USE

Quantitative analysis of pulmonary emphysema: three-dimensional fractal analysis of single-photon emission computed tomography images obtained with a carbon particle radioaerosol. Nagao M, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1657–63

Differences in airway closure between normal and asthmatic subjects measured with single-photon emission computed tomography and technegas. King GG, et al. **Am J Respir Crit Care Med** 1998 Dec;158(6):1900–6

GRASP see **HAND STRENGTH**

GRASSES

see related
POLLEN

Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. Baraldi E, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):262–6

Molecular analysis of bacterial community structure and diversity in unimproved and improved upland grass pastures. McCaig AE, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1721–30

Regional variations in grass pollen seasons in the UK, long-term trends and forecast models. Emberlin J, et al. **Clin Exp Allergy** 1999 Mar;29(3):347–56

Why the grass isn't always greener. Joyce S. **Environ Health Perspect** 1998 Aug;106(8):A378–85

Desulfovibrio zosterae sp. nov., a new sulfate reducer isolated from surface-sterilized roots of the seagrass Zostera marina. Nielsen JT, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:859–65

Variation in ruminants' preference for tall fescue hays cut either at sundown or at sunup. Fisher DS, et al. **J Anim Sci** 1999 Mar;77(3):762–8

Effects of ruminal administration of supplemental degradable intake protein and starch on utilization of low-quality warm-season grass hay by beef steers. Olson KC, et al. **J Anim Sci** 1999 Apr;77(4):1016–25

Behavior of steers grazing monocultures and binary mixtures of alfalfa and tall fescue. Seman DH, et al. **J Anim Sci** 1999 Jun;77(6):1402–11

Relationships among absorbents on the reduction of grass silage effluent and silage quality. Fransen SC, et al. **J Dairy Sci** 1998 Oct;81(10):2633–44

Nutrient content, dry matter yield, and species composition of cool-season pasture with management-intensive grazing. Martz FA, et al. **J Dairy Sci** 1999 Jul;82(7):1538–44

Mortality of horn fly (Diptera: Muscidae) larvae in bovine dung supplemented with loline alkaloids from tall fescue. Dougherty CT, et al. **J Med Entomol** 1998 Sep; 35(5):798–803

Electroantennogram and oviposition bioassay responses of Culex quinquefasciatus and Culex tarsalis (Diptera: Culicidae) to chemicals in odors from Bermuda grass infusions. Du YJ, et al. **J Med Entomol** 1999 Mar; 36(2):158–66

Tension pneumothorax secondary to grass head aspiration. Newson TP, et al. **Pediatr Emerg Care** 1998 Aug; 14(4):287–9 (12 ref.)

Cattle, hay and E. coli [letter; comment] Hancock DD, et al. **Science** 1999 Apr 2;284(5411):51–3. Comment on: Science 1998 Sep 11;281(5383):1666–8.

Alleviation of grass impaction in a flock of free-range hens. Christensen NH. **Vet Rec** 1998 Oct 3;143(14):397

Assessment of the risk of infestation of pastures by Ixodes ricinus due to their phyto-ecological characteristics. Méméteau S, et al. **Vet Res** 1998 Sep-Oct;29(5):487–96

CHEMISTRY

Biochemical characterization of 60S acidic ribosomal P proteins associated with CK-II from bamboo shoots and potent inhibitors of their phosphorylation in vitro. Maekawa T, et al. **Biol Pharm Bull** 1999 Jul;22(7):667–73

Efficiency of grass buffer strips and cropping system on off-site Dacthal movement. Antonious GF. **Bull Environ Contam Toxicol** 1999 Jul;63(1):25–32

Dynamic modeling of the cesium, strontium and ruthenium transfer to grass and vegetables. Renaud P, et al. **Health Phys** 1999 May;76(5):495–501

The effect of in vitro fermentation on specific gravity and sedimentation measurements of forage particles. Bailoni L, et al. **J Anim Sci** 1998 Dec;76(12):3095–103

Influence of Neotyphodium coenophialum on copper concentration in tall fescue. Dennis SB, et al. **J Anim Sci** 1998 Oct;76(10):2687–93

Comparison of Tifton 85 and Coastal bermudagrasses for yield, nutrient traits, intake, and digestion by growing beef steers. Mandebvu P, et al. **J Anim Sci** 1999 Jun; 77(6):1572–86

Prediction of laboratory and in situ protein fractions in legume and grass silages using near-infrared reflectance spectroscopy. Hoffman PC, et al. **J Dairy Sci** 1999 Apr; 82(4):764–70

The influence of acidic diets on the acid-base balance of dry cows and the effect of fertilization on the mineral content of grass. Pehrson B, et al. **J Dairy Sci** 1999 Jun; 82(6):1310–6

Effects of intrinsic potassium in artificially dried grass and supplemental potassium bicarbonate on apparent magnesium absorption in dry cows. Schonewille JT, et al. **J Dairy Sci** 1999 Aug;82(8):1824–30

Effects of some natural extracts on the acetylcholine release at the mouse neuromuscular junction. Re L, et al. **Pharmacol Res** 1999 Mar;39(3):239–45

DRUG EFFECTS

Molecular characterization of four beta-tubulin genes from dinitroaniline susceptible and resistant biotypes of Eleusine indica. Yamamoto E, et al. **Plant Mol Biol** 1999 Jan; 39(1):45–61

ENZYMOLOGY

Substrate specificity of the cytochrome P450 enzymes CYP79A1 and CYP71E1 involved in the biosynthesis of the cyanogenic glucoside dhurrin in Sorghum bicolor (L.) Moench. Kahn RA, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):9–18

Granule-bound starch synthase: structure, function, and phylogenetic utility. Mason-Gamer RJ, et al. **Mol Biol Evol** 1998 Dec;15(12):1658–73

Partial purification and characterisation of sugarcane neutral invertase. Vorster DJ, et al. **Phytochemistry** 1998 Oct; 49(3):651–5

A role for glutathione transferases functioning as glutathione peroxidases in resistance to multiple herbicides in black-grass. Cummins I, et al. **Plant J** 1999 May; 18(3):285–92

GENETICS

Widespread occurrence of the homologues of the early nodulin (ENOD) genes in Oryza species and related grasses. Reddy PM, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):148–54

Meiosis of wheat x lymegrass hybrids. Anamthawat-Jónsson K, et al. **Chromosome Res** 1998 Aug;6(5):339–43

Retrotransposon-related DNA sequences in the centromeres of grass chromosomes. Miller JT, et al. **Genetics** 1998 Dec; 150(4):1615–23

Isolation and characterization of a satellite DNA family in

the Saccharum complex. Alix K, et al. **Genome** 1998 Dec; 41(6):854–64

A fertile amphiploid between diploid wheat (Triticum tauschii) and crested wheat grass (Agropyron cristatum). Martin A, et al. **Genome** 1999 Jun;42(3):519–24

Patterns of genetic diversification within the Adh gene family in the grasses (Poaceae). Gaut BS, et al. **Mol Biol Evol** 1999 Aug;16(8):1086–97

Granule-bound starch synthase: structure, function, and phylogenetic utility. Mason-Gamer RJ, et al. **Mol Biol Evol** 1998 Dec;15(12):1658–73

Evolutionary dynamics of Ty1–copia group retrotransposons in grass shown by reverse transcriptase domain analysis. Matsuoka Y, et al. **Mol Biol Evol** 1999 Feb;16(2):208–17

Molecular variation in Leymus species and populations. Anamthawat-Jónsson K, et al. **Mol Ecol** 1999 Feb; 8(2):309–15

Quantitative chromosome map of the polyploid Saccharum spontaneum by multicolor fluorescence in situ hybridization and imaging methods. Ha S, et al. **Plant Mol Biol** 1999 Apr;39(6):1165–73

Molecular characterization of four beta-tubulin genes from dinitroaniline susceptible and resistant biotypes of Eleusine indica. Yamamoto E, et al. **Plant Mol Biol** 1999 Jan; 39(1):45–61

The mechanism of rhythmic ethylene production in sorghum. The role of phytochrome B and simulated shading [published erratum appears in Plant Physiol 1999 May;120(1):341] Finlayson SA, et al. **Plant Physiol** 1999 Mar;119(3):1083–9

Phosphoenolpyruvate carboxykinase in the C(4) monocot Urochloa panicoides is encoded by four differentially expressed genes. Finnegan PM, et al. **Plant Physiol** 1999 Aug;120(4):1033–42

High gene density is conserved at syntenic loci of small and large grass genomes. Feuillet C, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8265–70

GROWTH & DEVELOPMENT

The blooming of grass flower development. Schmidt RJ, et al. **Curr Opin Plant Biol** 1998 Feb;1(1):60–7 (66 ref.)

Starch supplementation of grass harvested at two stages of maturity prior to ensiling: intake, digestion, and degradability by dairy cows. De Visser H, et al. **J Dairy Sci** 1998 Aug;81(8):2221–7

Starch and stage of maturity of grass silage: site of digestion and intestinal nutrient supply in dairy cows. van Vuuren AM, et al. **J Dairy Sci** 1999 Jan;82(1):143–52

Embryo rescue following wide crosses. Sharma HC. **Methods Mol Biol** 1999;111:293–307 (45 ref.)

IMMUNOLOGY

Induction of allergy to new aeroallergens during specific immunotherapy (SIT) in grass pollen sensitive patients. Obtulowicz K, et al. **Allerg Immunol (Paris)** 1998 Oct; 30(8):250–4

Grass pollen specific sublingual/swallow immunotherapy in children: open-controlled comparison among different treatment protocols. Di Rienzo V, et al. **Allergol Immunopathol (Madr)** 1999 May–Jun;27(3):145–51

Occupational asthma caused by esparto grass (Stipa tenacissima) fibers. Baz G, et al. **Allergy** 1999 Jan;54(1):86–7

Physicochemical and immunologic characterization of low-molecular-weight allergoids of Dactylis glomerata pollen proteins. Cirković TD, et al. **Allergy** 1999 Feb; 54(2):128–34

Substitution of mainly lysyl groups of the proteins in an extract of Dactylis glomerata by succinic and maleic anhydrides [letter] Wheeler AW. **Allergy** 1999 Jul; 54(7):763–4

A nonspecific, single-stranded nuclease activity with characteristics of a topoisomerase found in a major grass pollen allergen: possible biological significance. Bufe A, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):1009–16

Grass pollen: trends and predictions [editorial] Burr ML. **Clin Exp Allergy** 1999 Jun;29(6):735–8 (26 ref.)

Sequence polymorphism of the group 1 allergen of Bermuda grass pollen. Chang ZN, et al. **Clin Exp Allergy** 1999 Apr; 29(4):488–96

Detection and quantification of group 4 allergens in grass pollen extracts using monoclonal antibodies [see comments] Fahlbusch B, et al. **Clin Exp Allergy** 1998 Jul;28(7):799–807 . Comment in: Clin Exp Allergy 1998 Jul;28(7):784–7.

Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model. Michils A, et al. **Clin Exp Allergy** 1999 Jun;29(6):832–9

Concentrations of major grass group 5 allergens in pollen grains and atmospheric particles: implications for hay fever and allergic asthma sufferers sensitized to grass pollen allergens. Schäppi GF, et al. **Clin Exp Allergy** 1999 May; 29(5):633–41

Grass pollen allergens: new developments [editorial; comment] Wissenbach M, et al. **Clin Exp Allergy** 1998 Jul; 28(7):784–7. Comment on: Clin Exp Allergy 1998 Jul;28(7):799–807.

A species-specific monoclonal antibody to Cynodon dactylon. Lovborg U, et al. **Int Arch Allergy Immunol** 1998 Dec;117(4):220–3

Grass allergy increases the risk of tree pollen sensitization: a warning to urban planners. Vieira FA, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):700–1

[Antigen specific immunoglobulin E to grass and weed pollens in the plasma of patients with seasonal allergic rhinitis] Silny W, et al. **Otolaryngol Pol** 1999;53(1):55–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Biosynthesis of cyanogenic glucosides in Triglochin maritima and the involvement of cytochrome P450 enzymes. Nielsen JS, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):121–30

Content and distribution of macro- and micro-elements in the body of pasture-fed young horses. Grace ND, et al. **Aust Vet J** 1999 Mar;77(3):172–6

Concentrations of macro- and micro-elements in the milk of pasture-fed thoroughbred mares. Grace ND, et al. **Aust Vet J** 1999 Mar;77(3):177–80

Plant and soil enantioselective biodegradation of racemic phenoxyalkanoic herbicides. Schneiderheinze JM, et al. **Chirality** 1999;11(4):330–7

Anti-tick effects of Stylosanthes humilis and Stylosanthes hamata on plots experimentally infested with Boophilus microplus larvae in Morelos, Mexico. Fernandez-Ruvalcaba M, et al. **Exp Appl Acarol** 1999 Feb; 23(2):171–5

Different techniques to study rumen fermentation characteristics of maturing grass and grass silage. Cone JW, et al. **J Dairy Sci** 1999 May;82(5):957–66

Development of a novel system to estimate protein degradability in legume and grass silages. Hoffman PC, et al. **J Dairy Sci** 1999 Apr;82(4):771–9

Predicting the effect of proteolysis on ruminal crude protein degradation of legume and grass silages using near-infrared reflectance spectroscopy. Hoffman PC, et al. **J Dairy Sci** 1999 Apr;82(4):756–63

The mechanism of rhythmic ethylene production in sorghum. The role of phytochrome B and simulated shading [published erratum appears in Plant Physiol 1999 May;120(1):341] Finlayson SA, et al. **Plant Physiol** 1999 Mar;119(3):1083–9

MICROBIOLOGY

Physiological diversity of the rhizosphere diazotroph assemblages of selected salt marsh grasses. Bagwell CE, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4276–82

Identification of Epichloë endophytes in planta by a microsatellite-based PCR fingerprinting assay with automated analysis. Moon CD, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1268–79

Fungal proteinase expression in the interaction of the plant pathogen Magnaporthe poae with its host. Sreedhar L, et al. **Gene** 1999 Jul 22;235(1–2):121–9

A taxonomic study of bacteria isolated from grasses: a proposed new species Pseudomonas graminis sp. nov. Behrendt U, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:297–308

Theriogenology question of the month. Toxicosis associated with fescue grass infected with the endophyte Neotyphodium coenophialum (formerly Acremonium coenophialum). Mirza MH, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1405–6

Postweaning performance of calves from Angus, Brahman, and reciprocal-cross cows grazing endophyte-infected tall fescue or common bermudagrass. Brown MA, et al. **J Anim Sci** 1999 Jan;77(1):25–31

Influence of Neotyphodium coenophialum on copper concentration in tall fescue. Dennis SB, et al. **J Anim Sci** 1998 Oct;76(10):2687–93

Vaccination against ergot alkaloids and the effect of endophyte-infected fescue seed-based diets on rabbits. Filipov NM, et al. **J Anim Sci** 1998 Sep;76(9):2456–63

Monocyte immune cell response and copper status in beef steers that grazed endophyte-infected tall fescue. Saker KE, et al. **J Anim Sci** 1998 Oct;76(10):2694–700

Distribution of fungal endophyte genotypes in doubly infected host grasses. Wille PA, et al. **Plant J** 1999 May; 18(4):349–58

PARASITOLOGY

Dynamics of pasture contamination by gastrointestinal nematodes of cattle under extensive management systems: proposal for strategic control. Almería S, et al. **Vet Parasitol** 1999 Jun 1;83(1):37–47

PHYSIOLOGY

Characterization of a desiccation-responsive small GTP-binding protein (Rab2) from the desiccation-tolerant grass Sporobolus stapfianus. O'Mahony PJ, et al. **Plant Mol Biol** 1999 Mar;39(4):809–21

POISONING

Suspected blue canary grass (Phalaris coerulescens) poisoning of horses. Colegate SM, et al. **Aust Vet J** 1999 Aug; 77(8):537–8

Abdominal lipomatosis attributed to tall fescue toxicosis in deer. Wolfe BA, et al. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1783–6, 1754

TOXICITY

Evaluation of physiologic indices in mice vaccinated with protein–ergotamine conjugates and fed an endophyte-infected fescue diet. Rice RL, et al. **Am J Vet Res** 1998 Oct;59(10):1258–62

GRASSHOPPERS

Field assessment of Beauveria bassiana (Balsamo) vuillemin and potential synergism with diflubenzuron for control of savanna grasshopper complex (Orthoptera) in Mali. Delgado FX, et al. **J Invertebr Pathol** 1999 Jan;73(1):34–9

ANATOMY & HISTOLOGY

Mechanosensory pegs constitute stridulatory files in grasshoppers. Hustert R, et al. **J Comp Neurol** 1999 Aug 2;410(3):444–56

Colocalisation of taurine- with transmitter-immunoreactivities in the nervous system of the migratory locust. Stevenson PA. **J Comp Neurol** 1999 Feb 1;404(1):86–96

Tracing of a neuronal network in the locust by pressure injection of markers into a synaptic neuropil. Heinrich R, et al. **J Neurosci Methods** 1998 Mar 13;80(1):81–9

CHEMISTRY

Primary structure of two major cuticular proteins from the migratory locust, Locusta migratoria, and their identification in polyacrylamide gels by mass spectrometry. Jensen C, et al. **Biochim Biophys Acta** 1998 Dec 8; 1429(1):151–62

Neuropeptides in insect sensory neurones: tachykinin-, FMRFamide- and allatotropin-related peptides in terminals of locust thoracic sensory afferents. Persson MGS, et al. **Brain Res** 1999 Jan 16;816(1):131–41

Purification, structural characterization, cloning and immunocytochemical localization of chemoreception proteins from Schistocerca gregaria. Angeli S, et al. **Eur J Biochem** 1999 Jun;262(3):745–54

Led-NPF-1 stimulates ovarian development in locusts. Cerstiaens A, et al. **Peptides** 1999;20(1):39–44

CLASSIFICATION

Chromosomal strategies for adaptation to univalency. Rebollo E, et al. **Chromosome Res** 1998 Nov;6(7):515–31

CYTOLOGY

Distribution and activation of different types of octopaminergic DUM neurons in the locust. Duch C, et al. **J Comp Neurol** 1999 Jan 5;403(1):119–34

EMBRYOLOGY

Patterns of embryonic neurogenesis in a primitive wingless insect, the silverfish, Ctenolepisma longicaudata: comparison with those seen in flying insects. Truman JW, et al. **Dev Genes Evol** 1998 Sep;208(7):357–68

Developmental expression and molecular characterization of two gap junction channel proteins expressed during embryogenesis in the grasshopper Schistocerca americana. Ganfornina MD, et al. **Dev Genet** 1999;24(1–2):137–50

Discrete roles for secreted and transmembrane semaphorins in neuronal growth cone guidance in vivo. Isbister CM, et al. **Development** 1999 May;126(9):2007–19

Tyrosine kinase inhibition produces specific alterations in axon guidance in the grasshopper embryo. Menon KP, et al. **Development** 1998 Oct;125(20):4121–31

ENZYMOLOGY

Cooperation of dopachrome conversion factor with phenoloxidase in the eumelanin pathway in haemolymph of Locusta migratoria (Insecta). Cherqui A, et al. **Insect Biochem Mol Biol** 1998 Nov;28(11):839–48

NADPH diaphorase histochemistry in the thoracic ganglia of locusts, crickets, and cockroaches: species differences and the impact of fixation. Ott SR, et al. **J Comp Neurol** 1999 Aug 2;410(3):387–97

GENETICS

Cloning of a cDNA encoding a novel cytochrome P450 from the insect Locusta migratoria: CYP6H1, a putative ecdysone 20-hydroxylase. Winter J, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):305–10

Nucleotide sequence and expression of the sn-glycerol-3-phosphate dehydrogenase gene in Locusta migratoria. Wilanowski TM, et al. **Biochim Biophys Acta** 1998 Dec 22;1443(3):414–8

Unusually high amount of inactive ribosomal DNA in the grasshopper Stauroderus scalaris. López-León MD, et al. **Chromosome Res** 1999;7(2):83–8

Chromosomal strategies for adaptation to univalency. Rebollo E, et al. **Chromosome Res** 1998 Nov;6(7):515–31

Cloning of the cDNA encoding Scg-SPRP, an unusual Ser-protease-related protein from vitellogenic female desert locusts (Schistocerca gregaria). Chiou SJ, et al. **Insect Biochem Mol Biol** 1998 Oct;28(10):801–8

Cloning and characterization of an ecdysone receptor cDNA from Locusta migratoria. Saleh DS, et al. **Mol Cell Endocrinol** 1998 Aug 25;143(1–2):91–9

GROWTH & DEVELOPMENT

Isolation, sequence determination, physical and physiological characterization of the neuroparsins and ovary maturing

parsins of Schistocerca gregaria. Girardie J, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):641–50

METABOLISM

Chloromethyl ketones are insulin-like stimulators of lipid synthesis in locust fat body. Lee MJ, et al. **Arch Insect Biochem Physiol** 1998;39(1):9–17

Locust corpora cardiaca contain an inactive adipokinetic hormone. Siegert KJ. **FEBS Lett** 1999 Mar 26; 447(2–3):237–40

Several isoforms of locustatachykinins may be involved in cyclic AMP-mediated release of adipokinetic hormones from the locust Corpora cardiaca. Nässel DR, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):401–12

Two major proteins from locust plasma are involved in coagulation and are specifically precipitated by laminarin, a beta-1,3-glucan. Duvic B, et al. **Insect Biochem Mol Biol** 1998 Dec;28(12):959–67

Distribution and activation of different types of octopaminergic DUM neurons in the locust. Duch C, et al. **J Comp Neurol** 1999 Jan 5;403(1):119–34

Immunolocalization of a tachykinin-receptor-like protein in the central nervous system of Locusta migratoria migratorioides and neobellieria bullata. Veelaert D, et al. **J Comp Neurol** 1999 May 10;407(3):415–26

An insect homolog of the vertebrate very low density lipoprotein receptor mediates endocytosis of lipophorins. Dantuma NP, et al. **J Lipid Res** 1999 May;40(5):973–8

Multiple interactions between insect lipoproteins and fat body cells: extracellular trapping and endocytic trafficking. Dantuma NP, et al. **J Lipid Res** 1998 Sep;39(9):1877–88

Multifactorial control of the release of hormones from the locust retrocerebral complex. Vullings HG, et al. **Microsc Res Tech** 1999 May 1;45(3):142–53 (105 ref.)

MICROBIOLOGY

Pathological and physiological responses of ring-necked pheasant chicks following dietary exposure to the fungus Metarhizium flavoviride, a biocontrol agent for locusts in Africa. Smits JE, et al. **J Wildl Dis** 1999 Apr;35(2):194–203

PARASITOLOGY

Successful parasitation of locusts by entomopathogenic nematodes is correlated with inhibition of insect phagocytes. van Sambeek J, et al. **J Invertebr Pathol** 1999 Mar;73(2):154–61

Amoebogregarina Nigra n. gen., n. comb. (Apicomplexa: Gregarinidae) from adult Melanoplus differentialis (Orthoptera: Acrididae) in southeastern Nebraska. Kula RR, et al. **J Parasitol** 1999 Apr;85(2):321–5

PHYSIOLOGY

Quantitative structure-activity studies of octopaminergic agonists and antagonists against nervous system of Locusta migratoria. Hirashima A, et al. **Bioorg Med Chem** 1998 Jul; 6(7):903–10

Immunocytochemistry of GABA in the central complex of the locust Schistocerca gregaria: identification of immunoreactive neurons and colocalization with neuropeptides. Homberg U, et al. **J Comp Neurol** 1999 Jul 5;409(3):495–507

Mechanosensory pegs constitute stridulatory files in grasshoppers. Hustert R, et al. **J Comp Neurol** 1999 Aug 2;410(3):444–56

Central and peripheral control of the trigger mechanism for kicking and jumping in the locust. Jellema T, et al. **J Comp Neurol** 1999 Feb 8;404(2):212–20

Synaptic activation of efferent neuromodulatory neurones in the locust Schistocerca gregaria. Baudoux S, et al. **J Exp Biol** 1998 Dec;201 (Pt 24):3339–54

Post-ingestive feedbacks and associative learning regulate the intake of unsuitable sterols in a generalist grasshopper. Behmer ST, et al. **J Exp Biol** 1999 Mar;202 (Pt 6):739–48

Muscle degeneration following remote nerve injury. Personius KE, et al. **J Neurobiol** 1998 Sep 15;36(4):497–508

Phase-dependent presynaptic modulation of mechanosensory signals in the locust flight system. Büschges A, et al. **J Neurophysiol** 1999 Feb;81(2):959–62

Reconfiguration of the respiratory network at the onset of locust flight. Ramirez JM. **J Neurophysiol** 1998 Dec; 80(6):3137–47

Relationship between afferent and central temporal patterns in the locust olfactory system. Wehr M, et al. **J Neurosci** 1999 Jan 1;19(1):381–90

Spatiotemporal structure of olfactory inputs to the mushroom bodies. Laurent G, et al. **Learn Mem** 1998 May–Jun; 5(1–2):124–32 (53 ref.)

New insights into adipokinetic hormone signaling. Vroemen SF, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):7–12 (40 ref.)

Physiology. Crossing over to the dark side [news] Whitfield J. **Nature** 1999 Jul 15;400(6741):218

Heat shock protects synaptic transmission in flight motor circuitry of locusts. Dawson-Scully K, et al. **Neuroreport** 1998 Aug 3;9(11):2589–93

Insect (Locusta migratoria migratorioides) test monitoring the toxicity of cyanobacteria. Hiripi L, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):605–8

New proctolin analogues and their myotropic effects on heart of yellow mealworm Tenebrio molitor L. and foregut of locust-Schistocerca gregaria L. Kuczer M, et al. **Pol J Pharmacol** 1998 Mar–Apr;50(2):143–50

Identification of the gregarization-associated dark-pigmentotropin in locusts through an albino mutant. Tawfik AI, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8; 96(12):7083–7

CO2 and heat have different effects on directed ventilation behavior of grasshoppers Melanoplus differentialis. Henderson DR, et al. **Respir Physiol** 1998 Dec; 114(3):297–307

Behaviorists listen in as animals call and croak [news] Bagla P. **Science** 1999 Sep 3;285(5433):1480–1

VIROLOGY

The genome of Melanoplus sanguinipes entomopoxvirus. Afonso CL, et al. **J Virol** 1999 Jan;73(1):533–52

GRATEFUL MED

ORGANIZATION & ADMINISTRATION

[International foreign bibliographic databases Medline and Internet Grateful Med V2.6. Presentation and how to use] Bloch-Mouillet E. **Sante** 1998 Sep–Oct;8(5):379–86 (8 ref.) (Eng. Abstr.) **(Fre)**

GRAVES' DISEASE

Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Terwee CB, et al. **Br J Ophthalmol** 1998 Jul;82(7):773–9

[Basedow's Disease. Proceedings of the Henning Symposium commemorating the 200th birthday anniversary of Carl Adolph von Basedow. Weimar, 16–17 April 1998] **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:5–72 **(Ger)**

[The surgical treatment of strabismus and diplopia in Graves-Basedow ophthalmopathy] Mirkiewicz-Sieradzka B, et al. **Klin Oczna** 1998;100(4):217–9 (Eng. Abstr.) **(Pol)**

BLOOD

Human leukocyte antigens associated with hyperthyroid Graves ophthalmology in Japanese patients. Ohtsuka K, et al. **Am J Ophthalmol** 1998 Dec;126(6):805–10

Quantitative measurements for type I deiodinase messenger ribonucleic acid in human peripheral blood mononuclear cells: mechanism of the preferential increase of T3 in hyperthyroid Graves' disease [published erratum appears in Biochem Biophys Res Commun 1998 Dec 30;253(3):902] Nishikawa M, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):642–6

The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Zimmermann-Belsing T, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):589–95

Analyses of the molecular forms of serum thyroglobulin from patients with Graves' disease, subacute thyroiditis or differentiated thyroid cancer by velocity sedimentation on sucrose gradient and Western blot [see comments] Druetta L, et al. **Eur J Endocrinol** 1998 Nov;139(5):498–507. Comment in: Eur J Endocrinol 1999 Jan;140(1):7–8.

Increased levels of serum interleukin-12 in Graves' disease. Tamaru M, et al. **Eur J Endocrinol** 1999 Aug;141(2):111–6

Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. Iitaka M, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3908–12

Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. Sonnet E, et al. **J Endocrinol Invest** 1999 Jun; 22(6):430–5

Increased serum concentration of interleukin-12 in patients with silent thyroiditis and Graves' disease. Hidaka Y, et al. **Thyroid** 1999 Feb;9(2):149–53

Increased serum soluble Fas in patients with Graves' disease. Hiromatsu Y, et al. **Thyroid** 1999 Apr;9(4):341–5

CHEMICALLY INDUCED

Graves' disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Todd A, et al. **Clin Lab Haematol** 1999 Feb;21(1):69–70

[Iodine-induced hyperthyroidism (iodine-induced Basedow's disease): a current disease picture] Henzen C, et al. **Schweiz Med Wochenschr** 1999 May 1;129(17):658–64 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

[Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy] Seegenschmiedt MH, et al. **Strahlenther Onkol** 1998 Sep;174(9):449–56 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Membranous glomerulonephritis associated with Graves' disease. Becker BA, et al. **Am J Kidney Dis** 1999 Feb; 33(2):369–73 (14 ref.)

Expulsion of an artificial eye in a patient with thyroid-associated ophthalmopathy and surgical anophthalmos [letter] Salvi M, et al. **Am J Med** 1999 Aug; 107(2):191–2

Graves' disease presenting with cholestatic jaundice. Barnes SC, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):677–9

Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Cantalamessa L, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1705–8

Thyrotoxic periodic paralysis in Mexican mestizo patients: a clinical, biochemical and HLA-serological study. Nellen H, et al. **Arch Med Res** 1999 Jan–Feb;30(1):74–6

Prevalence and management of elevated intraocular pressure in patients with Graves' orbitopathy. Kalmann R, et al. **Br J Ophthalmol** 1998 Jul;82(7):754–7

Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Kalmann R, et al. **Br J Ophthalmol** 1999 Apr; 83(4):463–5

Medullary thyroid carcinoma in Graves' disease [letter] Brändle M, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):545–6

A case of Graves' disease associated with autoimmune hepatitis and mixed connective tissue disease. Inoue K, et al. **Endocr J** 1999 Feb;46(1):173–7

Transient retinal arterial compromise in Graves' orbitopathy [letter] Ghabrial R, et al. **Eye** 1998;12 (Pt 3a):477–9

Prevalence and early diagnosis of coeliac disease in autoimmune thyroid disorders [see comments] Cuoco L, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):283–7. Comment in: Ital J Gastroenterol Hepatol 1999 May;31(4):288–9.

Bilateral inferior rectus muscle recession for correction of hypotropia in dysthyroid ophthalmopathy. Cruz OA, et al. **J Aapos** 1999 Jun;3(3):157–9

Graves' disease presenting as localized myxedema in a thigh donor graft site. Missner SC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):846–9

Chronic inflammatory demyelinating polyradiculoneurophathy and Graves' disease in an adolescent with Crohn's disease. Gómez R, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):91–4

Eyeball position in Graves orbitopathy and its significance for eyelid surgery. van den Bosch WA, et al. **Ophthal Plast Reconstr Surg** 1998 Sep;14(5):328–35

Orbital computed tomographic characteristics of globe subluxation in thyroid orbitopathy. Rubin PA, et al. **Ophthalmology** 1998 Nov;105(11):2061–4

Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Gómez Acotto C, et al. **Osteoporos Int** 1998; 8(5):455–9

Thyroid nodules in Graves' disease: classification, characterization, and response to treatment. Carnell NE, et al. **Thyroid** 1998 Jul;8(7):571–6

Thyroid nodules in Graves' disease: classification, characterization, and response to treatment [published erratum appears in Thyroid 1998 Nov;8(11):1079] Carnell NE, et al. **Thyroid** 1998 Aug;8(8):647–52

Parasitic nodule of the thyroid in a patient with Graves' disease. Shimizu M, et al. **Virchows Arch** 1999 Mar; 434(3):241–4

[Frequency of autoimmune diseases in 218 patients with autoimmune thyroid pathologies] Gaches F, et al. **Rev Med Interne** 1998 Mar;19(3):173–9 (Eng. Abstr.) **(Fre)**

[Thyroid gland hemiagenesis with Graves' disease] Mikosch P, et al. **Nuklearmedizin** 1999;38(1):35–7 (Eng. Abstr.) **(Ger)**

[Simultaneous occurrence of Graves' ophthalmopathy and autonomous thyroid nodules] Smolarz K, et al. **Nuklearmedizin** 1998;37(6):213–7 (Eng. Abstr.) **(Ger)**

[A rare case of hypokalemic thyrotoxic periodic paralysis in a Caucasian patient with Basedow's disease] Messina G, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):392–3 (Eng. Abstr.) **(Ita)**

[Interstitial pneumonia, pulmonary thrombotic microangiopathy, and hyperimmunoglobulinemia associated with Basedow's disease] Tojima H, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Apr;37(4):311–6 (Eng. Abstr.) **(Jpn)**

[Case of diabetic ketoacidosis due to subacute thyroiditis in NIDDM associated with Basedow's disease] Sugimura M, et al. **Nippon Naika Gakkai Zasshi** 1998 Oct 10; 87(10):2086–7 **(Jpn)**

[Painless (silent) thyroiditis] Ozawa Y. **Nippon Rinsho** 1999 Aug;57(8):1770–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Idiopathic thrombocytopenic purpura and Graves disease: pathogenic questioning of a rare association (letter)] Salgado Nevado V, et al. **An Med Interna** 1998 Sep; 15(9):509–10 **(Spa)**

[Treatment of Basedow-Graves' hyperthyroidism: retrospective analysis after 30 years] Pineda G, et al. **Rev Med Chil** 1998 Aug;126(8):953–62 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Monocular involuntary eyelid closure. Jacome DE. **Acta Neurol Scand** 1999 Feb;99(2):130–3

Antibody interference with the Abbott AxSym immunoassay for thyroid-stimulating hormone. Landau-Levine M, et al. **Clin Chim Acta** 1999 Mar;281(1–2):177–80

Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Wallaschofski H, et al. **Clin Endocrinol (Oxf)** 1999 Mar;

50(3):365–72

A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease. Watson PF, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):577–81

Measurement of red blood cell zinc concentration with Zn-test kit: discrimination between hyperthyroid Graves' disease and transient thyrotoxicosis. Sayama N, et al. **Endocr J** 1998 Dec;45(6):767–72

Multifocal fibrosclerosis presenting as Grave's orbitopathy. Bilateral exophthalmos associated with retroperitoneal and sellar fibrosis. van der Pol R, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Mar;237(3):256–8

Weight loss--despite a voracious appetite--and heat intolerance. Archer TP, et al. **Hosp Pract (Off Ed)** 1999 Jan 15;34(1):112, 118–20, 123

Recognizing thyrotoxicosis. Mazzaferri EL. **Hosp Pract (Off Ed)** 1999 May 15;34(5):43–6, 49–51, 55–6 passim

Case study: missed diagnosis and mistreatment of unrecognized comorbid Graves disease. Woolston JL, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jul; 38(7):861–4

Orbital lymphoma masquerading as thyroid ophthalmopathy. Boyce PJ. **J Am Optom Assoc** 1998 Oct;69(10):666–73

Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. Costagliola S, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):90–7

Isolation of radiochemically pure 125I-labeled human thyrotropin receptor and its use for the detection of pathological autoantibodies in sera from Graves' patients. Minich WB, et al. **J Endocrinol** 1999 Feb;160(2):239–45

A sneak peek: a case of early thyroid eye disease. Komorsky GS. **J Neuroophthalmol** 1999 Mar;19(1):54–5

Course of proptosis in patients with Graves' disease after endoscopic orbital decompression. Ulualp SO, et al. **Laryngoscope** 1999 Aug;109(8):1217–22

Diagnostic classification of autoantibody repertoires in endocrine ophthalmopathy using an artificial neural network. Grus FH, et al. **Ocul Immunol Inflamm** 1998 Mar; 6(1):43–50

The painful, protruding eye. Unilateral euthyroid Graves' ophthalmopathy. Adam A, et al. **Postgrad Med** 1999 Jun; 105(7):81–4

Color Doppler sonography patterns related to histological findings in Graves' disease. Morosini PP, et al. **Thyroid** 1998 Jul;8(7):577–82

[Graves' disease (clinical aspects of Graves' disease)] Iitaka M. **Nippon Rinsho** 1999 Aug;57(8):1755–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Differential diagnosis of transient destructive thyroiditis from hyperthyroid Graves' disease] Mori K, et al. **Nippon Rinsho** 1999 Aug;57(8):1899–903 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Acquired angioneurotic edema associated with Graves' disease and vitiligo (letter)] Losa Garcia JE, et al. **An Med Interna** 1999 Feb;16(2):106–7 (7 ref.) **(Spa)**

[Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995] Escobar Jiménez F, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):205–10 (Eng. Abstr.) **(Spa)**

[Thyrotoxic periodic palsy as presentation form and relapse of Graves-Basedow disease in a Spanish male (letter)] Molina Lacasa A, et al. **Rev Clin Esp** 1998 Aug;198(8):556 **(Spa)**

DRUG THERAPY

Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Benker G, et al. **Clin Endocrinol (Oxf)** 1998 Oct;49(4):451–7

Current management of thyroid-associated ophthalmopathy [comment] Kendall-Taylor P. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):11–2. Comment on: Clin Endocrinol (Oxf) 1998 Jul;49(1):21–8.

Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Maugendre D, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):127–32

Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey [see comments] Weetman AP, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):21–8. Comment in: Clin Endocrinol (Oxf) 1998 Jul;49(1):11–2.

Hunger sensation in Graves' disease before and after pharmacological therapy. Cugini P, et al. **Clin Ter** 1999 Mar-Apr;150(2):115–9

Insulin autoantibodies before and after carbimazole therapy in Asian Indian patients with Graves' disease. Goswami R, et al. **Diabetes Res Clin Pract** 1998 Jun;40(3):201–6

Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets. Paggi A, et al. **Eur Rev Med Pharmacol Sci** 1998 Jan-Feb; 2(1):11–9

Radioiodine treatment of Graves' disease in young people [see comments] Cheetham TD, et al. **Horm Res** 1998; 49(6):258–62. Comment in: Horm Res 1998 ;49(6):255–7.

Remission of insulin autoimmune syndrome in a patient with Grave's disease by treatment with methimazole. Okabe R, et al. **Intern Med** 1999 Jun;38(6):482–5

Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. Colao A, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3790–4

Thyroid controversy--stimulating antibodies. Davies TF, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3777–85 (41 ref.)

Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy. Zouvanis M, et al. **J Endocrinol Invest** 1998 Dec; 21(11):771–4

Outcome of Graves' disease after antithyroid drug treatment in Taiwan. Wang PW, et al. **J Formos Med Assoc** 1998 Sep;97(9):619–25

Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. Mussa GC, et al. **J Pediatr Endocrinol Metab** 1999 Jul-Aug;12(4):537–41

Fever or a soar throat after start of antithyroidal drugs? A medical emergency. Roeloffzen WW, et al. **Neth J Med** 1998 Sep;53(3):113–7

The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Mack WP, et al. **Ophthal Plast Reconstr Surg** 1999 Jul;15(4):260–71

Psychosocial factors influencing the short-term outcome of antithyroid drug therapy in Graves' disease. Yoshiuchi K, et al. **Psychosom Med** 1998 Sep-Oct;60(5):592–6

Wegener's granulomatosis in a patient receiving propylthiouracil for Graves' disease. Pillinger M, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):124–9 (31 ref.)

Graves' Disease during pregnancy--results of antithyroid drug therapy. Dwarakanath CS, et al. **Singapore Med J** 1999 Feb;40(2):70–3 (12 ref.)

Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies. Chung HK, et al. **Thyroid** 1999 Apr;9(4):393–9

Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Krassas GE, et al. **Thyroid** 1999 Jan;9(1):47–52

Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y, et al. **Thyroid** 1999 Aug;9(8):769–73

[Therapeutic effect and its mechanism exploration on mainly using traditional Chinese medicine of replenishing qi and nourishing yin in treating Graves disease] Zha LL. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):328–30 (Eng. Abstr.) **(Chi)**

[Fever due to antithyroid agents (see comments)] Shamelian SO, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):225–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):643–4. **(Dut)**

[Therapeutic controversies: the treatment of Graves' disease] Khalife A, et al. **Rev Med Liege** 1999 Jul;54(7):606–10 (Eng. Abstr.) **(Fre)**

[Attempted suicide with 400 thyroxine pills: what happened to the physician-patient relationship?] Martin-du Pan RC. **Rev Med Suisse Romande** 1999 Jun;119(6):493–6 (Eng. Abstr.) **(Fre)**

[Exacerbation of tics by prednisolone] Dietl T, et al. **Nervenarzt** 1998 Dec;69(12):1111–4 (Eng. Abstr.) **(Ger)**

[Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism] Dietlein M, et al. **Nuklearmedizin** 1999; 38(1):7–14 (Eng. Abstr.) **(Ger)**

[Administration of levothyroxine in the treatment of Basedow disease] Hörmann R. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:47–52 (24 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism in Graves' disease--antithyroid drug treatment] Schumm-Draeger PM. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:41–5 (16 ref.) (Eng. Abstr.) **(Ger)**

[A pediatric case of myeloperoxidase-antineutrophil cytoplasmic (ANCA)-related crescentic glomerulonephritis associated with propylthiouracil treatment for Graves' disease] Kawasaki Y, et al. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):612–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment of Graves' disease--antithyroid drug therapy] Onaya T. **Nippon Rinsho** 1999 Aug;57(8):1846–50 (5 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Ljunggren JG, et al. **Thyroid** 1998 Aug;8(8):653–9

EMBRYOLOGY

Fetal pituitary negative feedback at early gestational age. Rakover Y, et al. **Clin Endocrinol (Oxf)** 1999 Jun; 50(6):809–14

ENZYMOLOGY

Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity. Li Y, et al. **Eur J Clin Invest** 1998 Dec;28(12):1050–4

Cellular thyroid peroxidase (TPO), unlike purified TPO and adjuvant, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. Jaume JC, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1651–7

Impaired Na+,K+ATPase activity in red blood cells in euthyroid women treated with levothyroxine after total thyroidectomy for Graves' disease. De Riva C, et al. **Metabolism** 1998 Oct;47(10):1194–8

Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters. Shuja S, et al. **Thyroid** 1999 Jun;9(6):569–77

ETHNOLOGY

Thyroid-associated ophthalmopathy in black South African patients with Graves' disease: relationship to antiflavoprotein antibodies. Joffe B, et al. **Thyroid** 1998 Nov;8(11):1023–7

ETIOLOGY

Graves disease after bone marrow transplantation [letter] Takeshita A, et al. **Ann Intern Med** 1999 Jul 20;131(2):157

Radioiodine and thyroid eye disease [editorial] Walsh JP, et al. **BMJ** 1999 Jul 10;319(7202):68–9

Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. Nygaard B, et al. **J Endocrinol Invest** 1999 Jun;22(6):481–5

Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma. Regalbuto C, et al. **J Endocrinol Invest** 1999 Feb;22(2):147–50

Appearance of Graves'-like disease following regression of autonomously functioning thyroid nodules. Two case reports. Orsolon P, et al. **Minerva Endocrinol** 1998 Jun; 23(2):53–6

Development of Graves' hyperthyroidism from primary hypothyroidism in a case of thyroid hemiagenesis. Bando Y, et al. **Thyroid** 1999 Feb;9(2):183–7

Relapse of Graves' disease after subacute thyroiditis. Grunenberger F, et al. **Thyroid** 1998 Aug;8(8):683–5

Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Nygaard B, et al. **Thyroid** 1999 May;9(5):477–81

Graves' hyperthyroidism after postpartum thyroiditis. Shorey S, et al. **Thyroid** 1998 Dec;8(12):1117–22

[Triggering role of emotional stress and childbirth. Unexpected occurrence of Graves' disease compared to 96 cases of Hashimoto thyroiditis and 97 cases of thyroid nodules] Martin-du Pan RC. **Ann Endocrinol (Paris)** 1998 Jul;59(2):107–12 (Eng. Abstr.) **(Fre)**

[Pathogenesis of Graves' ophthalmopathy] Heufelder AE. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:35–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Etiology and pathophysiology of Graves' disease] Mann K, et al. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:29–34 (33 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

A new Graves disease-susceptibility locus maps to chromosome 20q11.2. International Consortium for the Genetics of Autoimmune Thyroid Disease. Tomer Y, et al. **Am J Hum Genet** 1998 Dec;63(6):1749–56

The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Vaidya B, et al. **Hum Mol Genet** 1999 Jul; 8(7):1195–9

TAP1 polymorphism identified in African-American Graves' disease patients. Ofosu MH, et al. **Immunol Invest** 1998 Jul-Sep;27(4–5):281–9

HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. Chen QY, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3182–6

Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study [see comments] Heward JM, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3394–7. Comment in: J Clin Endocrinol Metab 1998 Oct;83(10):3391–3.

The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. Heward JM, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2398–401

Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves' disease-1 (GD-1) close to multinodular goiter-1 (MNG-1). International Consortium for the Genetics of Autoimmune Thyroid Disease. Tomer Y, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4321–7

Demonstration of thyrotropin receptor mRNA in orbital fat and eye muscle tissues from patients with Graves' ophthalmopathy by in situ hybridization. Wu SL, et al. **J Endocrinol Invest** 1999 Apr;22(4):289–95

Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy [letter] Vaidya B, et al. **Lancet** 1999 Aug 28; 354(9180):743–4

Sharing of susceptibility loci between autoimmune diseases: lack of association of the insulin gene region with Graves' disease [letter] Allahabadia A, et al. **Thyroid** 1999 Mar; 9(3):317–8

Lack of association between polymorphism of the thyrotropin receptor gene and Graves' disease in United

Kingdom and Hong Kong Chinese patients: case control and family-based studies. Allahabadia A, et al. **Thyroid** 1998 Sep;8(9):777–80

What is the evidence of genetic factors in the etiology of Graves' disease? A brief review. Brix TH, et al. **Thyroid** 1998 Jul;8(7):627–34 (86 ref.)

What is the evidence of genetic factors in the etiology of Graves' disease? A brief review [published erratum appears in Thyroid 1998 Nov;8(11):1079] Brix TH, et al. **Thyroid** 1998 Aug;8(8):727–34 (86 ref.)

Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors. Grasso YZ, et al. **Thyroid** 1999 Jun;9(6):531–7

The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases [letter] Heward J, et al. **Thyroid** 1999 Jun;9(6):627–8

Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease. Siegmund T, et al. **Thyroid** 1998 Nov;8(11):1013–7

[Genetic risk markers in Graves' disease] Badenhoop K, et al. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:11–5 (15 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Dr Robert James Graves. Jay V. **Arch Pathol Lab Med** 1999 Apr;123(4):284

[Carl Adolph von Basedow--on the 200th anniversary of his birth] Meng W. **Z Arztl Fortbild Qualitatssich** 1999 Apr; 93 Suppl 1:5–10 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Gunji K, et al. **Autoimmunity** 1999;29(1):1–9

Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. Guo J, et al. **Autoimmunity** 1999;30(1):1–9

Signaling pathways involved in thyroid hyperfunction and growth in Graves' disease. Di Cerbo A, et al. **Biochimie** 1999 May;81(5):415–24 (118 ref.)

Expression of integrins of the beta1 family in thyroid cells from patients with Graves' disease in vivo and in vitro. Vitale M, et al. **Biochimie** 1999 May;81(5):477–84

Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease. Berisso GA, et al. **Bone Marrow Transplant** 1999 May;23(10):1091–2

Reactivity of anti-thyroid antibodies to thyroglobulin tryptic fragments: comparison of autoimmune and non-autoimmune thyroid diseases. Boechat LH, et al. **Braz J Med Biol Res** 1999 Apr;32(4):449–55

The effect of thyrotropin receptor antibodies on the proliferation of FRTL-5 cells and the expression of protooncogene c-fos mRNA. Fang P, et al. **Chin Med J (Engl)** 1998 May;111(5):412–5

The HLA-DQ associations with Graves' disease in Chinese children. Wong GW, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):493–5

Evidence of transient IgA anti-endomysial antibody positivity in a patient with Graves' disease. Carroccio A, et al. **Digestion** 1999 Jan-Feb;60(1):86–8

Antineutrophil cytoplasmic antibodies in autoimmune thyroid disorders. Afeltra A, et al. **Endocr Res** 1998 May; 24(2):185–94

Serial analysis of circulating T gamma/delta lymphocyte subpopulations in Graves' disease. Sasián S, et al. **Endocr Res** 1998 May;24(2):285–95

Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs. Akamizu T, et al. **Endocrinology** 1999 Apr;140(4):1594–601

Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Kita M, et al. **Endocrinology** 1999 Mar;140(3):1392–8

Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Laurberg P, et al. **Eur J Endocrinol** 1998 Dec;139(6):584–6

Lymphocyte traffic and homing in autoimmune thyroid disorders. Marazuela M. **Eur J Endocrinol** 1999 Apr; 140(4):287–90 (12 ref.)

Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLA-G*01012 allele. Castro MJ, et al. **Eur J Immunogenet** 1998 Aug;25(4):311–5

Thyroid antibodies in children of mothers with auto-immune thyroid disease. Heithorn R, et al. **Eur J Pediatr** 1999 Jan; 158(1):24–8

Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. Costagliola S, et al. **FEBS Lett** 1998 Oct 9;436(3):427–33

HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. Catálfamo M, et al. **Int Immunol** 1999 Feb; 11(2):269–77

Correlation of activated monocytes or B cells with T lymphocyte subsets in patients with Graves' disease. González A, et al. **Int J Mol Med** 1998 Jan;1(1):95–103

Graves', immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor. Di Cerbo A, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3283–92

Development of a luminescent bioassay for thyroid stimulating antibodies. Evans C, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):374–7

Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. Gunji K, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1255–62

Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study [see comments] Heward JM, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3394–7. Comment in: J Clin Endocrinol Metab 1998 Oct;83(10):3391–3.

Cellular thyroid peroxidase (TPO), unlike purified TPO and adjuvant, induces antibodies in mice that resemble autoantibodies in human autoimmune thyroid disease. Jaume JC, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1651–7

Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma. Regalbuto C, et al. **J Endocrinol Invest** 1999 Feb;22(2):147–50

Thyrotropin receptor antibodies in black South African patients with Graves' disease and their response to medical therapy. Zouvanis M, et al. **J Endocrinol Invest** 1998 Dec; 21(11):771–4

Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy [letter] Gilquin J, et al. **Lancet** 1998 Dec 12; 352(9144):1907–8

Diagnostic classification of autoantibody repertoires in endocrine ophthalmopathy using an artificial neural network. Grus FH, et al. **Ocul Immunol Inflamm** 1998 Mar; 6(1):43–50

Graves' disease as a model for anti-Gal involvement in autoimmune diseases. Galili U. **Subcell Biochem** 1999; 32:339–60 (53 ref.)

Autoantibodies reactive with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Bednarczuk T, et al. **Thyroid** 1999 Mar;9(3):289–95

Thyroid-associated ophthalmopathy in black South African patients with Graves' disease: relationship to antiflavoprotein antibodies. Joffe B, et al. **Thyroid** 1998 Nov;8(11):1023–7

Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay. Morgenthaler NG, et al. **Thyroid** 1999 May;9(5):466–75

Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. Nakazato N, et al. **Thyroid** 1999 Aug;9(8):775–9

Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y, et al. **Thyroid** 1999 Aug;9(8):769–73

Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Yang D, et al. **Thyroid** 1999 Mar; 9(3):305–10

[Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies] Rink T, et al. **Nuklearmedizin** 1999;38(5):156–9 (Eng. Abstr.) **(Ger)**

[An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease] Sato A, et al. **Nippon Rinsho** 1999 Aug;57(8):1904–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Autoantibody against Na+/I- symporter (NaIS)] Zeki K. **Nippon Rinsho** 1999 Aug;57(8):1824–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Organ-specific autoimmune diseases and cytokines] Hidaka Y, et al. **Rinsho Byori** 1999 Apr;47(4):335–9 (Eng. Abstr.) **(Jpn)**

[TSH receptor antibodies in the recurrent goiter after surgical treatment of Graves-Basedow disease] Janowska J, et al. **Pol Merkuriusz Lek** 1998 May;4(23):257–8 (Eng. Abstr.) **(Pol)**

METABOLISM

Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. Cao HJ, et al. **J Biol Chem** 1998 Nov 6;273(45):29615–25

A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. Ashhab Y, et al. **J Clin Endocrinol Metab** 1999 Aug; 84(8):2873–82

B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto's thyroiditis, but not in Graves' disease. Battifora M, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):4130–9

Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. Hansen C, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1409–13

Functional Fas ligand expression in thyrocytes from patients with Graves' disease [see comments] Hiromatsu Y, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2896–902. Comment in: J Clin Endocrinol Metab 1999 Aug;84(8):2593–5.

Thyrotoxicosis and low radioactive iodine uptake in a woman with Graves' disease. Wägner AM, et al. **Postgrad Med J** 1999 Feb;75(880):125–6

Frontal lobe proton magnetic-resonance spectroscopy in Graves' disease: a pilot study. Bhatara VS, et al. **Psychoneuroendocrinology** 1998 Aug;23(6):605–12

Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Boerner AR, et al. **Thyroid** 1998 Sep; 8(9):765–72

Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors. Grasso YZ, et al. **Thyroid** 1999 Jun;9(6):531–7

Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Lu R, et al. **Thyroid** 1999 Mar;9(3):297–303

CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. Okumura M, et al. **Thyroid** 1999 Apr;9(4):333–9

PATHOLOGY

Assessment of rapid morphological changes associated with elevated cAMP levels in human orbital fibroblasts. Reddy L, et al. **Exp Cell Res** 1998 Dec 15;245(2):360–7

Hyperthyroidism of Graves' disease: evidence for only unilateral involvement of the thyroid gland in a 31-year-old female patient. Dimai HP, et al. **J Endocrinol Invest** 1999 Mar;22(3):215–9

The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy. Gerding MN, et al. **J Endocrinol Invest** 1998 Jul-Aug; 21(7):459–62

Graves-Basedow disease goiter: a model of Bax-Bcl2 regulated apoptosis. Labat-Moleur F, et al. **Thyroid** 1999 May;9(5):483–92

[Hyperthyroidism and thyroid carcinoma--coincidence or association?] Oertli D, et al. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1910–4 (26 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Prolonged suppressed thyroid-stimulating hormone levels in hyperthyroidism in a neonate born to a mother with Graves' disease. Hojo M, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):483–5

Lack of female bias in a mouse model of autoimmune hyperthyroidism (Graves' disease). Jaume JC, et al. **Autoimmunity** 1999;29(4):269–72

Gaze evoked amaurosis in dysthyroid orbitopathy [letter] Bremner FD, et al. **Br J Ophthalmol** 1999 Apr;83(4):501

Flashing lights in thyroid eye disease: a new symptom described and (possibly) explained. Danks JJ, et al. **Br J Ophthalmol** 1998 Nov;82(11):1309–11

Thyroid stimulating immunoglobulin (TSI) in Graves' disease. Ochi Y, et al. **Endocr J** 1998 Dec;45(6):701–8 (35 ref.)

Regulation of breathing in hyperthyroidism: relationship to hormonal and metabolic changes. Pino-Garcia JM, et al. **Eur Respir J** 1998 Aug;12(2):400–7

Power spectral analysis of variations in heart rate in patients with hyperthyroidism or hypothyroidism. Inukai T, et al. **Horm Metab Res** 1998 Aug;30(8):531–5

Graves' disease: xenotransplantation model (athymic nude mice). Jungheim K, et al. **J Mol Med** 1999 Jan;77(1):185–8 (28 ref.)

A study on bronchial responsiveness to methacholine in subjects with untreated autoimmune hyperthyroidism. D'Amato M, et al. **Monaldi Arch Chest Dis** 1999 Jun; 54(3):209–11

Direct orbital manometry in patients with thyroid-associated orbitopathy. Riemann CD, et al. **Ophthalmology** 1999 Jul; 106(7):1296–302

Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease. Kashiwai T, et al. **Thyroid** 1998 Oct;8(10):881–5

Natural killer cell activity in patients with Graves' disease and Hashimoto's thyroiditis. Wenzel BE, et al. **Thyroid** 1998 Nov;8(11):1019–22

[Thyrotoxic neuromyopathies] Sidibe EH, et al. **Rev Neurol (Paris)** 1998 May;154(4):330–3 (Eng. Abstr.) **(Fre)**

[Changes in saccades in endocrine orbitopathy. Clarification of the contribution by H. D. Schworm et al. "Functional eye muscle changes in endocrine orbitopathy" (letter; comment)] Schworm HD, et al. **Ophthalmologe** 1998 Aug; 95(8):578–80. Comment on: Ophthalmologe 1997 Apr;94(9):290–4. **(Ger)**

[Etiology and pathophysiology of Graves' disease] Mann K, et al. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:29–34 (33 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Graves ophthalmopathy [letter; comment] Haddad HM. **Arch Ophthalmol** 1999 May;117(5):700. Comment on: Arch Ophthalmol 1998 Aug;116(8):1106–7.

GRAVES' DISEASE

PSYCHOLOGY

Chronic recurrent stress due to panic disorder does not precipitate Graves' disease. Chiovato L, et al. **J Endocrinol Invest** 1998 Dec;21(11):758–64

RADIOGRAPHY

Volumetric analysis of CT orbital images. Lutzemberger L, et al. **Med Biol Eng Comput** 1998 Nov;36(6):661–6

[The tomographic diagnosis of Basedow's orbitopathy] Costea I, et al. **Oftalmologia** 1998;45(4):68–70 (Eng. Abstr.) **(Rum)**

RADIONUCLIDE IMAGING

Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Gerding MN, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):373–9

Serendipitous detection of thyroid carcinoma in a patient with Graves' disease. Ahmad M, et al. **Clin Nucl Med** 1999 Jan;24(1):76

Increased F-18 fluorodeoxyglucose thyroidal uptake in Graves' disease. Santiago JF, et al. **Clin Nucl Med** 1999 Sep;24(9):714–5

The role of octreoscan in thyroid eye disease. Krassas GE, et al. **Eur J Endocrinol** 1999 May;140(5):373–5 (24 ref.)

Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Nocaudie M, et al. **Eur J Nucl Med** 1999 May;26(5):511–7

Retreatment of Graves' disease with radioiodine 131I [letter; comment] Charkes ND. **J Nucl Med** 1999 Jan;40(1):215–6 . Comment on: J Nucl Med 1998 Apr;39(4):712–6.

[F-qi-FDG PET of the thyroid gland in Graves' disease] Börner AR, et al. **Nuklearmedizin** 1998;37(7):227–33 (Eng. Abstr.) **(Ger)**

[Thyroid gland hemiagenesis with Graves' disease] Mikosch P, et al. **Nuklearmedizin** 1999;38(1):35–7 (Eng. Abstr.) **(Ger)**

[Change of 99m technetium-pertechnetate uptake by the thyroid under suppression (TcTus) induced by optimization of iodine supply in Germany] Reinhardt MJ, et al. **Nuklearmedizin** 1998;37(6):202–7 (Eng. Abstr.) **(Ger)**

[Simultaneous occurrence of Graves' ophthalmopathy and autonomous thyroid nodules] Smolarz K, et al. **Nuklearmedizin** 1998;37(6):213–7 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

The use of independent collimation in the treatment of Graves' ophthalmopathy. Snow A. **Br J Radiol** 1999 Apr; 72(856):389–91

Reversible cerebral hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia caused by hypothyroidism. Kinuya S, et al. **Clin Nucl Med** 1999 Sep; 24(9):666–8

The comparison of isodose plans: radiotherapy techniques in the treatment of thyroid ophtalmopathy. Samija M, et al. **Coll Antropol** 1999 Jun;23(1):167–74

Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Catargi B, et al. **Eur J Endocrinol** 1999 Aug; 141(2):117–21

Place of radiotherapy in the treatment of Graves' orbitopathy. Beckendorf V, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):805–15

Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. Bogazzi F, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):499–503

Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. Sabri O, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1229–33

Radioiodine is an effective, inexpensive, and safe treatment for Graves' hyperthyroidism, its immunological effects must be taken into account. Chiovato L, et al. **J Endocrinol Invest** 1999 Apr;22(4):310–2

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Marcocci C, et al. **J Endocrinol Invest** 1998 Jul–Aug; 21(7):468–71 (17 ref.)

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Weetman AP, et al. **J Endocrinol Invest** 1998 Jul–Aug; 21(7):472–5 (15 ref.)

Thyroid uptake of liquid versus capsule 131I tracers in hyperthyroid patients treated with liquid 131I. Rini JN, et al. **Thyroid** 1999 Apr;9(4):347–52

Radioiodine therapy and Graves' ophthalmopathy [letter] Spitzweg C, et al. **Thyroid** 1998 Dec;8(12):1193

[Treatment of Graves' ophthalmopathy with irradiation] Slampa P, et al. **Vnitr Lek** 1998 Aug;44(8):461–3 (Eng. Abstr.) **(Cze)**

[Radiotherapy only in severe, progressive endocrine orbitopathy: long-term results and comparison of various classification systems] Gusek-Schneider GC, et al. **Klin Monatsbl Augenheilkd** 1998 Aug;213(2):74–80 (Eng. Abstr.) **(Ger)**

[F-qi-FDG PET of the thyroid gland in Graves' disease] Börner AR, et al. **Nuklearmedizin** 1998;37(7):227–33 (Eng. Abstr.) **(Ger)**

[Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism] Dietlein M, et al. **Nuklearmedizin** 1999; 38(1):7–14 (Eng. Abstr.) **(Ger)**

[Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients] Khandani A, et al. **Nuklearmedizin** 1999;38(5):140–3 (Eng. Abstr.) **(Ger)**

[Deterioration of endocrine ophthalmology after radioiodine therapy in Graves' disease?] Weigand A, et al. **Nuklearmedizin** 1998;37(7):234–8 (Eng. Abstr.) **(Ger)**

[Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy] Seegenschmiedt MH, et al. **Strahlenther Onkol** 1998 Sep;174(9):449–56 (Eng. Abstr.) **(Ger)**

[Radioiodine therapy of Graves' disease--quality assurance and radiation protection] Reiners C. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:61–6 (40 ref.) (Eng. Abstr.) **(Ger)**

[Radioactive iodine (I-131) therapy] Kusakabe K, et al. **Nippon Rinsho** 1999 Aug;57(8):1855–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Expulsion of an artificial eye in a patient with thyroid-associated ophthalmopathy and surgical anophthalmos [letter] Salvi M, et al. **Am J Med** 1999 Aug; 107(2):191–2

Postoperative tetany in Graves disease: important role of vitamin D metabolites. Yamashita H, et al. **Ann Surg** 1999 Feb;229(2):237–45

A single technique to correct various degrees of upper lid retraction in patients with Graves' orbitopathy. Mourits MP, et al. **Br J Ophthalmol** 1999 Jan;83(1):81–4

Decrease in intraocular pressure after orbital decompression for thyroid orbitopathy. Dev S, et al. **Can J Ophthalmol** 1998 Oct;33(6):314–9

Post-operative thyroid status of patients with Graves' disease is determined by the responsiveness of thyrocyte to TSH under the present thyroid gland remnant. Yamashita H, et al. **Endocr J** 1998 Aug;45(4):513–7

Treatment of proptosis with fat removal orbital decompression in Graves' ophthalmopathy. Adenis JP, et al. **Eur J Ophthalmol** 1998 Oct–Dec;8(4):246–52

Endoscopic orbital decompression for thyroid eye disease. Asaria RH, et al. **Eye** 1998;12 (Pt 6):990–5

The incidence of diplopia following coronal and translid orbital decompression in Graves' orbitopathy. Paridaens D, et al. **Eye** 1998;12 (Pt 5):800–5

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Marcocci C, et al. **J Endocrinol Invest** 1998 Jul–Aug; 21(7):468–71 (17 ref.)

Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? Weetman AP, et al. **J Endocrinol Invest** 1998 Jul–Aug; 21(7):472–5 (15 ref.)

Graves' disease: xenotransplantation model (athymic nude mice). Jungheim K, et al. **J Mol Med** 1999 Jan;77(1):185–8 (28 ref.)

Balanced orbital decompression for Graves' ophthalmopathy. Shepard KG, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1648–53

Course of proptosis in patients with Graves' disease after endoscopic orbital decompression. Ulualp SO, et al. **Laryngoscope** 1999 Aug;109(8):1217–22

Early strabismus surgery for thyroid ophthalmopathy. Coats DK, et al. **Ophthalmology** 1999 Feb;106(2):324–9

Early relapse after operation for Graves' disease: postoperative hormone kinetics and outcome after subtotal, near-total, and total thyroidectomy. Hermann M, et al. **Surgery** 1998 Nov;124(5):894–900

Reoperation as treatment of relapse after subtotal thyroidectomy in Graves' disease. Hermann M, et al. **Surgery** 1999 May;125(5):522–8

Results of subtotal thyroidectomy for Graves' disease [see comments] Chou FF, et al. **Thyroid** 1999 Mar;9(3):253–7 . Comment in: Thyroid 1999 Mar;9(3):259–61.

Thyroidectomy for the treatment of Graves' disease [comment] Duh QY. **Thyroid** 1999 Mar;9(3):259–61. Comment on: Thyroid 1999 Mar;9(3):253–57.

Postoperative changes in thyrotropin-binding inhibitory immunoglobulin level in patients with Graves' disease: is subtotal thyroidectomy a suitable therapeutic option for patients of childbearing age with Graves' disease? Sugino K, et al. **World J Surg** 1999 Jul;23(7):727–31

[Complications of transpalpebral osseous orbital decompressions in thyroid orbitopathies] Spielmann AC, et al. **J Fr Ophtalmol** 1999 Mar;22(2):194–202 (Eng. Abstr.) **(Fre)**

[Postoperative complications and long-term results of the surgical treatment of immunogenic Basedow's disease] Möbius E, et al. **Dtsch Med Wochenschr** 1998 Oct 30; 123(44):1297–302 (Eng. Abstr.) **(Ger)**

[Deterioration of endocrine ophthalmology after radioiodine therapy in Graves' disease?] Weigand A, et al. **Nuklearmedizin** 1998;37(7):234–8 (Eng. Abstr.) **(Ger)**

[Surgical treatment of Graves' disease] Lorenz K, et al. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:57–60 (22 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment of Graves' disease] Okamoto T, et al. **Nippon Rinsho** 1999 Aug;57(8):1851–4 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of endocrine ophthalmopathy] Rødahl E, et al. **Tidsskr Nor Laegeforen** 1999 May 10; 119(12):1737–42 (Eng. Abstr.) **(Nor)**

[TSH receptor antibodies in the recurrent goiter after surgical treatment of Graves-Basedow disease] Janowska J, et al. **Pol Merkuriusz Lek** 1998 May;4(23):257–8 (Eng. Abstr.) **(Pol)**

THERAPY

Apparent cure of Graves-Basedow disease after sibling allogeneic bone marrow transplantation. Diez S, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):267–70

Controversies in the management of Graves' disease. Leech NJ, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):273–80 (53 ref.)

Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves' disease. Turton DB, et al. **Clin Nucl Med** 1998 Dec;23(12):810–4

The effect of pulsed electromagnetic field on patients with endocrine ophthalmopathy. Jankauskienė J, et al. **Eur J Ophthalmol** 1998 Oct–Dec;8(4):253–7

Treatment of Graves' disease in children and adolescents [editorial; comment] Grüters A. **Horm Res** 1998;49(6):255–7 (20 ref.). Comment on: Horm Res 1998 ;49(6):258–62.

Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. Rivkees SA, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):3767–76 (160 ref.)

Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Ljunggren JG, et al. **Thyroid** 1998 Aug;8(8):653–9

Treatment of endocrine ophthalmopathy. Wiersinga WM. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:67–72 (19 ref.)

[Treatment of endocrine orbital disease by elimination of the thyroid gland. The effect of unsuccessful elimination, severe pretibial myxedema and persistence of hypothyroidism after removal in long-term results] Váňa S, et al. **Vnitr Lek** 1998 Jul;44(7):387–90 (Eng. Abstr.) **(Cze)**

[Exophthalmos--what now?] Heufelder AE, et al. **Ther Umsch** 1999 Jul;56(7):408–14 (09 ref.) (Eng. Abstr.) **(Ger)**

[Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995] Escobar Jiménez F, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):205–10 (Eng. Abstr.) **(Spa)**

GRAVIDITY

see related
PARITY

Primipaternities in families: is the incidence of pregnancy-induced hypertensive disorders in multigravidas an anthropological marker of reproduction? Robillard PY, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):284–7

Hormonal choices after gestational diabetes. Subsequent pregnancy, contraception, and hormone replacement. Kjos SL, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B50–7 (86 ref.)

Placenta previa: effect of age, gravidity, parity and previous caesarean section. Abu-Heija AT, et al. **Gynecol Obstet Invest** 1999;47(1):6–8

Fertility and reproduction in women with anorexia nervosa: a controlled study. Bulik CM, et al. **J Clin Psychiatry** 1999 Feb;60(2):130–5; quiz 135–7

Motherhood and malaria [news] Miller LH, et al. **Nat Med** 1998 Nov;4(11):1244–5

Touch-plate and statolith formation in graviceptors of ephyrae which developed while weightless in space. Spangenberg DB, et al. **Scanning Microsc** 1996; 10(3):875–87; discussion 887–8

PHYSIOLOGY

Lymphocyte subpopulations in intrauterine growth retardation in women with or without previous pregnancies. Bartha JL, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):23–7

Revisiting the epidemiological standard of preeclampsia: primigravidity or primipaternity? Robillard PY, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):37–41

GRAVISTIMULATION see **GRAVITATION**

GRAVITATION

see related
GRAVITROPISM

Protein crystal growth in the advanced protein crystallization facility on the LMS mission: a comparison of Sulfolobus solfataricus alcohol dehydrogenase crystals grown on the ground and in microgravity. Esposito L, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):386–90

Influence of gravity on pulmonary venous flow velocity patterns: analysis of left and right pulmonary venous flow velocities in left and right decubitus positions. Izumi C, et al. **Am Heart J** 1999 Mar;137(3):419–26

All the fun of the fair [letter] Grimes S, et al. **Anaesthesia** 1999 Apr;54(4):408

Influence of gravity on cardiac performance. Pantalos GM, et al. **Ann Biomed Eng** 1998 Nov-Dec;26(6):931-43
Replication of passive whole-body linear displacements from inertial cues. Facts and mechanisms. Grasso R, et al. **Ann N Y Acad Sci** 1999 May 28;871:345-66
Bolus aggregation [letter; comment] Chang MW. **Arch Phys Med Rehabil** 1998 Nov;79(11):1481-2. Comment on: Arch Phys Med Rehabil 1998 Jun;79(6):691-6.
+Gz associated stenosis of the cervical spinal canal in fighter pilots. Hämäläinen O, et al. **Aviat Space Environ Med** 1999 Apr;70(4):330-4
Frequency of the "push-pull effect" in U.S. Air Force fighter operations. Michaud VJ, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1083-6
The "push-pull effect" and G-induced loss of consciousness accidents in the U.S. Air Force. Michaud VJ, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1104-6
Analysis of the Gz environment during air combat maneuvering in the F/A-18 fighter aircraft. Newman DG, et al. **Aviat Space Environ Med** 1999 Apr;70(4):310-5
Particulates from PTFE degradation in terrestrial and microgravity. Srivastava R, et al. **Aviat Space Environ Med** 1999 May;70(5):505-10
Role of gravity in the development of posture and locomotion in the neonatal rat. Clarac F, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):35-43 (49 ref.)
Does gravity influence the early stages of the development of the nervous system in an amphibian? Duprat AM, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):19-24 (38 ref.)
The effect of gravity on human recognition of disoriented objects. Leone G. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):203-14 (113 ref.)
Interaction of vestibular, somatosensory and visual signals for postural control and motion perception under terrestrial and microgravity conditions--a conceptual model. Mergner T, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):118-35 (67 ref.)
The sensorimotor and cognitive integration of gravity. Pozzo T, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):92-101 (42 ref.)
Effect of gravity on vestibular neural development. Ross MD, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):44-51 (61 ref.)
Gravity and space flight: effects on nutritional status. Smith SM, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jul; 2(4):335-8 (35 ref.)
Gravity influences the position of the dorsoventral axis in medaka fish embryos (Oryzias latipes). Fluck RA, et al. **Dev Growth Differ** 1998 Oct;40(5):509-18
Body position can be monitored in 3D using miniature accelerometers and earth-magnetic field sensors. Kemp B, et al. **Electroencephalogr Clin Neurophysiol** 1998 Dec; 109(6):484-8
Using leg muscles as shock absorbers: theoretical predictions and experimental results of drop landing performance. Minetti AE, et al. **Ergonomics** 1998 Dec;41(12):1771-91
Effects of centrifuging at 2g on rat long bone metaphyses. Vico L, et al. **Eur J Appl Physiol** 1999 Sep;80(4):360-6
Grip forces exerted against stationary held objects during gravity changes. Hermsdörfer J, et al. **Exp Brain Res** 1999 May;126(2):205-14
Graviresponses of certain ciliates and flagellates. Hemmersbach R, et al. **FASEB J** 1999;13 Suppl:S69-75 (62 ref.)
Statoliths motions in gravity-perceiving plant cells: does actomyosin counteract gravity? Volkmann D, et al. **FASEB J** 1999;13 Suppl:S143-7 (51 ref.)
Acoustic field interaction with a boiling system under terrestrial gravity and microgravity. Sitter JS, et al. **J Acoust Soc Am** 1998 Nov;104(5):2561-9
Gravity is an important but secondary determinant of regional pulmonary blood flow in upright primates. Glenny RW, et al. **J Appl Physiol** 1999 Feb;86(2):623-32
Cardiovascular and Valsalva responses during parabolic flight. Schlegel TT, et al. **J Appl Physiol** 1998 Nov; 85(5):1957-65
Effects of spaceflight on rhesus quadrupedal locomotion after return to 1G. Recktenwald MR, et al. **J Neurophysiol** 1999 May;81(5):2451-63
Effects of tilt of the gravito-inertial acceleration vector on the angular vestibuloocular reflex during centrifugation. Wearne S, et al. **J Neurophysiol** 1999 May;81(5):2175-90
Computation of inertial motion: neural strategies to resolve ambiguous otolith information. Angelaki DE, et al. **J Neurosci** 1999 Jan 1;19(1):316-27
How locomotor parameters adapt to gravity and body structure changes during gait development in children. Breniere Y. **Motor Control** 1999 Apr;3(2):186-204
Effect of altered gravity on the neurobiology of fish. Anken RH, et al. **Naturwissenschaften** 1999 Apr;86(4):155-67 (62 ref.)
Gravity affects the preferred vertical and horizontal in visual perception of orientation. Lipshits M, et al. **Neuroreport** 1999 Apr 6;10(5):1085-9
Mystery spots [editorial] Gregory R. **Perception** 1998; 27(5):503-4
The effect of labyrinthectomy on postural control of upside-down swimming catfish, Synodontis nigriventris, under pseudomicrogravity. Ohnishi K, et al. **Physiol Behav** 1999 Aug 1;67(1):89-93
Endoscopic surgery and telemedicine in microgravity: developing contingency procedures for exploratory class spaceflight. Jones JA, et al. **Urology** 1999 May;53(5):892-7
[Drawing movements and gravitational force: central or peripheral regulation?] Papaxanthis C, et al. **C R Seances Soc Biol Fil** 1998;192(1):187-93 (Eng. Abstr.) **(Fre)**
[Potential role of gravity in computerized tomography in neoplasms] Davi G, et al. **Radiol Med (Torino)** 1999 Jan-Feb;97(1-2):70-5 (Eng. Abstr.) **(Ita)**
[Correlation of fluctuations in the activity of the rat monooxygenase system with dynamics of tidal gravitational changes] Bortnikova GI, et al. **Biofizika** 1998 Jul-Aug; 43(4):600-2 (Eng. Abstr.) **(Rus)**
[The quantum gravitational therapy of myocarditis] Ovcharova AP. **Lik Sprava** 1999 Apr-May;(3):95-7 (Eng. Abstr.) **(Rus)**
[Laws of typological interactions of clino- and antiorthostatic systemic and cerebral circulation in children] Gavrikov KV, et al. **Vestn Ross Akad Med Nauk** 1999;(7):32-6 (Eng. Abstr.) **(Rus)**

GRAVITROPISM

AUX1 regulates root gravitropism in Arabidopsis by facilitating auxin uptake within root apical tissues. Marchant A, et al. **EMBO J** 1999 Apr 15;18(8):2066-73
Plant graviperception and gravitropism: a newcomer's view. Ranjeva R, et al. **FASEB J** 1999;13 Suppl:S135-41 (67 ref.)
Analysis of changes in relative elemental growth rate patterns in the elongation zone of Arabidopsis roots upon gravistimulation. Mullen JL, et al. **Planta** 1998 Nov; 206(4):598-603

GENETICS

Plant hormones: ins and outs of auxin transport. Leyser O. **Curr Biol** 1999 Jan 14;9(1):R8-R10
AtPIN2 defines a locus of Arabidopsis for root gravitropism control. Müller A, et al. **EMBO J** 1998 Dec 1; 17(23):6903-11
Root-growth behavior of the Arabidopsis mutant rgr1. Roles of gravitropism and circumnutation in the waving/coiling phenomenon. Mullen JL, et al. **Plant Physiol** 1998 Dec; 118(4):1139-45

PHYSIOLOGY

Plastid sedimentation kinetics in roots of wild-type and starch-deficient mutants of Arabidopsis. MacCleery SA, et al. **Plant Physiol** 1999 May;120(1):183-92

GRAVITY see **GRAVITATION**

GRAVITY, ALTERED

Oxygen cost of dynamic leg exercise on a cycle ergometer: effects of gravity acceleration. Girardis M, et al. **Acta Physiol Scand** 1999 Jul;166(3):239-46
Artificial gravity considerations for a mars exploration mission. Young LR. **Ann N Y Acad Sci** 1999 May 28; 871:367-78 (37 ref.)
Neurobiology of fish under altered gravity conditions. Anken RH, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):9-18 (36 ref.)
Adaptation in a rotating artificial gravity environment. Lackner JR, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):194-202 (36 ref.)
Influence of hypergravity on the development of monoaminergic systems in the rat spinal cord. Giménez y Ribotta M, et al. **Brain Res Dev Brain Res** 1998 Dec 7;111(2):147-57
A genetic effect of altered gravity: mutations induced by simulated hypogravity and hypergravity in microsatellite sequences of human tumor cells. Han ZB, et al. **Mutat Res** 1999 May 3;426(1):1-10

GRAVITY, ARTIFICIAL see **GRAVITY, ALTERED**

GRAVITY PERCEPTION

Geotaxis in 2-week-old Norway rats (Rattus norvegicus): A reevaluation. Kreider JC, et al. **Dev Psychobiol** 1999 Jul;35(1):35-42

PHYSIOLOGY

The role of somatosensory input for the perception of verticality. Anastasopoulos D, et al. **Ann N Y Acad Sci** 1999 May 28;871:379-83
Assessing otolith function by the subjective visual vertical. Böhmer A, et al. **Ann N Y Acad Sci** 1999 May 28; 871:221-31
The role of the otoliths in perception of the vertical and in path integration. Mittelstaedt H. **Ann N Y Acad Sci** 1999 May 28;871:334-44 (31 ref.)
Centrifugal force affects perception but not nystagmus in passive rotation. Mittelstaedt ML, et al. **Ann N Y Acad Sci** 1999 May 28;871:435-8
The sensorimotor and cognitive integration of gravity. Pozzo T, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):92-101 (42 ref.)
Development of postural control of gravity forces in children during the first 5 years of walking. Breniere Y, et al. **Exp Brain Res** 1998 Aug;121(3):255-62
Disentangling gravitational, environmental, and egocentric reference frames in spatial neglect. Karnath HO, et al. **J Cogn Neurosci** 1998 Nov;10(6):680-90
Humans use internal models to estimate gravity and linear acceleration. Merfeld DM, et al. **Nature** 1999 Apr 15; 398(6728):615-8
Vestibulo-ocular dysfunction induced by cortical damage in man: a case report. Ventre-Dominey J, et al. **Neuropsychologia** 1999 Jun;37(6):715-21
Biased postural vertical in humans with hemispheric cerebral lesions. Pérennou DA, et al. **Neurosci Lett** 1998 Aug 14; 252(2):75-8
Spatial and physical frames of reference in positioning a limb. Garrett SR, et al. **Percept Psychophys** 1998 Oct; 60(7):1206-15
Contribution of ankle, knee, and hip joints to the perception threshold for support surface rotation. Teasdale N, et al. **Percept Psychophys** 1999 May;61(4):615-24

GRAVITY SENSING see **GRAVITY PERCEPTION**

GRAVITY SUITS see **G SUITS**

GRAWITZ TUMOR see **CARCINOMA, RENAL CELL**

GRAY GRAMPUS see **DOLPHINS**

GRAY WHALE see **WHALES**

GRAYLINGS see **SALMONIDAE**

GREAT HORNED OWLS see **OWLS**

GREEK WORLD

Greek theories on eugenics [letter; comment] Galanakis E. **J Med Ethics** 1999 Feb;25(1):60-1. Comment on: J Med Ethics 1998 Aug;24(4):263-7.

HISTORY

Aging and the aged in "the Greek anthology". Wortley J. **Int J Aging Hum Dev** 1998;47(1):53-68
Greek theories on eugenics [see comments] Galton DJ. **J Med Ethics** 1998 Aug;24(4):263-7. Comment in: J Med Ethics 1999 Feb;25(1):60-1.

GREEN FROG see **RANA ESCULENTA**

GREEN MONKEY see **CERCOPITHECUS AETHIOPS**

GREEN PEPPER see **CAPSICUM**

GREEN SULFUR BACTERIA

CHEMISTRY

Electron transfer kinetics in purified reaction centers from the green sulfur bacterium Chlorobium tepidum studied by multiple-flash excitation. Kusumoto N, et al. **Biochemistry** 1999 Sep 14;38(37):12124-37
ENDOR and special TRIPLE resonance spectroscopy of photoaccumulated semiquinone electron acceptors in the reaction centers of green sulfur bacteria and heliobacteria. Muhiuddin IP, et al. **Biochemistry** 1999 Jun 1; 38(22):7159-67
In situ analysis of sulfur in the sulfur globules of phototrophic sulfur bacteria by X-ray absorption near edge spectroscopy. Prange A, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):446-54
Transient electron paramagnetic resonance spectroscopy on green-sulfur bacteria and heliobacteria at two microwave frequencies. van der Est A, et al. **Biochim Biophys Acta** 1998 Dec 1;1409(2):87-98
Exciton delocalization in the B808-866 antenna of the green bacterium Chloroflexus aurantiacus as revealed by ultrafast pump-probe spectroscopy. Novoderezhkin V, et al. **Biophys J** 1999 Jul;77(1):424-30
Exciton levels structure of antenna bacteriochlorophyll c aggregates in the green bacterium Chloroflexus aurantiacus as probed by 1.8-293 K fluorescence spectroscopy. Mauring K, et al. **FEBS Lett** 1999 Aug 6;456(2):239-42
The reaction center complex from the green sulfur bacterium Chlorobium tepidum: a structural analysis by scanning transmission electron microscopy. Rémigy HW, et al. **J Mol Biol** 1999 Jul 23;290(4):851-8
Auracyanin A from the thermophilic green gliding photosynthetic bacterium Chloroflexus aurantiacus represents an unusual class of small blue copper proteins. Van Driessche G, et al. **Protein Sci** 1999 May;8(5):947-57

CLASSIFICATION

Chlorobium ferrooxidans sp. nov., a phototrophic green sulfur bacterium that oxidizes ferrous iron in coculture with a "Geospirillum" sp. strain. Heising S, et al. **Arch Microbiol** 1999 Aug;172(2):116-24

ENZYMOLOGY

Distribution of ATPase and ATP-to-ADP phosphate exchange activities in magnesium chelatase subunits of Chlorobium vibrioforme and Synechocystis PCC6803. Petersen BL, et al. **Arch Microbiol** 1999 Feb;171(3):146-50

GREEN SULFUR BACTERIA

Sepiapterin reductase producing L-threo-dihydrobiopterin from Chlorobium tepidum. Cho SH, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):497-503

Structure and organization of a 25 kbp region of the genome of the photosynthetic green sulfur bacterium Chlorobium vibrioforme containing Mg-chelatase encoding genes. Petersen BL, et al. **Hereditas** 1998;129(2):131-42

GENETICS

Characterization of the group 1 and group 2 sigma factors of the green sulfur bacterium Chlorobium tepidum and the green non-sulfur bacterium Chloroflexus aurantiacus. Gruber TM, et al. **Arch Microbiol** 1998 Oct;170(4):285-96

Specific detection of green sulfur bacteria by in situ hybridization with a fluorescently labeled oligonucleotide probe. Tuschak C, et al. **Arch Microbiol** 1999 Mar; 171(4):265-72

Structure and organization of a 25 kbp region of the genome of the photosynthetic green sulfur bacterium Chlorobium vibrioforme containing Mg-chelatase encoding genes. Petersen BL, et al. **Hereditas** 1998;129(2):131-42

GROWTH & DEVELOPMENT

Chlorobium ferrooxidans sp. nov., a phototrophic green sulfur bacterium that oxidizes ferrous iron in coculture with a "Geospirillum" sp. strain. Heising S, et al. **Arch Microbiol** 1999 Aug;172(2):116-24

ISOLATION & PURIFICATION

Specific detection of green sulfur bacteria by in situ hybridization with a fluorescently labeled oligonucleotide probe. Tuschak C, et al. **Arch Microbiol** 1999 Mar; 171(4):265-72

METABOLISM

Electron transfer kinetics in purified reaction centers from the green sulfur bacterium Chlorobium tepidum studied by multiple-flash excitation. Kusumoto N, et al. **Biochemistry** 1999 Sep 14;38(37):12124-37

PHYSIOLOGY

Pheophytinization of bacteriochlorophyll c and energy transfer in cells of Chlorobium tepidum. Tokita S, et al. **Arch Microbiol** 1999 Jul;172(1):40-4

GREENHOUSE EFFECT

Global warming and the performance of drugs used to treat parasitic and other diseases. Arya SC. **Ann Trop Med Parasitol** 1999 Mar;93(2):207-8

Global climate change and weakened therapeutic agents against ischaemic heart diseases [letter] Arya SC. **Cardiology** 1998;90(4):309-10

Early action on climate change [news] **Environ Health Perspect** 1999 Apr;107(4):A187-8

Global warming and therapeutic intervention for hepatitis B and C virus infection [letter] Arya SC. **Hepatology** 1999 Feb;29(2):610-11

Global climate warming and performance of therapeutic agents in obstetrics and gynecology. Arya SC. **Int J Gynaecol Obstet** 1999 May;65(2):209-10

Global climate change and environmental health: proceedings of the 1997 annual conference of the Society for Occupational and Environmental Health. Kovats S, et al. **Int J Occup Environ Health** 1998 Jan-Mar;4(1):41-52 (7 ref.)

Global warming and therapeutic agents during travel [letter] Arya SC. **J Travel Med** 1999 Jun;6(2):150-1

Long-term trend toward earlier breeding in an American bird: a response to global warming? Brown JL, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5565-9

Climate forcings in the industrial era. Hansen JE, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12753-8 (47 ref.)

Global warming and efficacy of therapeutic agents for respiratory diseases [letter] Arya SC. **Respiration** 1999; 66(4):380-2

Climate change and its potential impacts on the Gulf Coast region of the United States. Tchounwou PB. **Rev Environ Health** 1999 Apr-Jun;14(2):91-102 (49 ref.)

[Exploration of the effects of el nino on cholera epidemic] Wang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):53-4 (12 ref.) **(Chi)**

[Role of biodiversity in maintaining Earth;s climate and and human civilization. Problems of geobiophysics] Karnaukhov AV, et al. **Biofizika** 1998 Nov-Dec; 43(6):1106-21 (Eng. Abstr.) **(Rus)**

[Is there a connection between biodiversity and the greenhouse effect] Rozanov SI. **Biofizika** 1998 Nov-Dec; 43(6):1101-5 (Eng. Abstr.) **(Rus)**

[The possible consequences of the probable global warming of the climate for the spread of blood-sucking ectoparasites and the pathogens they transmit] Alekseev AN. **Med Parazitol (Mosk)** 1998 Oct-Dec;(4):3-8 (Eng. Abstr.) **(Rus)**

GREENLAND RIGHT WHALE see **WHALES**

GRENZ RAYS see **X-RAYS**

GRIEF

Anticipatory grief in parents of dying children [letter; comment] Davis GF. **Am Fam Physician** 1999 May 1; 59(9):2435. Comment on: Am Fam Physician 1998 Oct 1;58(5):1211-2.

Dealing with loss in multiple pregnancies [letter] Pector EA. **Am Fam Physician** 1998 Dec;58(9):1969-70

The American Indian Holocaust: healing historical unresolved grief. Brave Heart MY, et al. **Am Indian Alsk Native Ment Health Res** 1998;8(2):56-78 (90 ref.)

Teaching and grieving. Akins SD. **Am J Nurs** 1999 Aug; 99(8):88

Tears for Stephanie. Knowing when a methodical response is appropriate--and when to express sorrow. Fink K. **Am J Nurs** 1999 May;99(5):25

A private place. Consolation for grieving families. Gaguski ME. **Am J Nurs** 1999 Apr;99(4):18-9

Some psychometric properties of the Texas Grief Inventory adjusted for miscarriage. Nikcevic AV, et al. **Br J Med Psychol** 1999 Jun;72 (Pt 2):171-8

Consensus criteria for traumatic grief. A preliminary empirical test. Prigerson HG, et al. **Br J Psychiatry** 1999 Jan;174:67-73 (17 ref.)

Owner response to companion animal death: development of a theory and practical implications. Adams CL, et al. **Can Vet J** 1999 Jan;40(1):33-9

Worried to death? [letter] Watkins LL, et al. **Circulation** 1999 Sep 14;100(11):1251-2

The role of the primary pediatrician when a child dies [editorial] Wessel MA. **Conn Med** 1998 Nov;62(11):677-8

Disease and the deceased [letter; comment] Chaiken B. **Hastings Cent Rep** 1998 Nov-Dec;28(6):4. Comment on: Hastings Cent Rep 1998 May-Jun;28(3):18-9; discussion 19-20.

Middle-range theory of chronic sorrow. Eakes GG, et al. **Image J Nurs Sch** 1998;30(2):179-84

The grief experienced by spousal caregivers of dementia patients: the role of place of care of patient and gender of caregiver. Rudd MG, et al. **Int J Aging Hum Dev** 1999; 48(3):217-40

Putting into words, putting to rest and putting aside the ancestors. How an analysand who was heir to the Armenian genocide of 1915 worked through mourning. Altounian J. **Int J Psychoanal** 1999 Jun;80 (Pt 3):439-48

Hope, counselling and complicated bereavement reactions. Cutcliffe JR. **J Adv Nurs** 1998 Oct;28(4):754-61

An exploration of anticipatory grief: the lived experience of people during their spouses' terminal illness and in bereavement. Duke S. **J Adv Nurs** 1998 Oct;28(4):829-39

Mourning in prison: mission impossible? Schetky DH. **J Am Acad Psychiatry Law** 1998;26(3):383-91

Classics revisited: Freud's "Mourning and melancholia". Lupi RS. **J Am Psychoanal Assoc** 1998;46(3):867-83

Prediction of complicated grief by positive and negative themes in narratives. Maercker A, et al. **J Clin Psychol** 1998 Dec;54(8):1117-36

"A grief observed": the experience of HIV-related illness and death among women in a clinic-based sample in New Haven, Connecticut. Ickovics JR, et al. **J Consult Clin Psychol** 1998 Dec;66(6):958-66

Culture and loss: a project of self-reflection. Lewis ML. **J Nurs Educ** 1998 Dec;37(9):398-400 (19 ref.)

Postadoptive reactions of the relinquishing mother: a review. Askren HA, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jul-Aug;28(4):395-400 (20 ref.)

A study of miscarriage: development and validation of the Perinatal Grief Intensity Scale. Hutti MH, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):547-55

Immune neglect: a source of durability bias in affective forecasting. Gilbert DT, et al. **J Pers Soc Psychol** 1998 Sep;75(3):617-38

Hiroshima and paper cranes: a technique to deal with death and grief. Davis TM, et al. **J Sch Health** 1998 Nov; 68(9):384-6

A piece of my mind. Too sad. Frey JJ 3rd. **JAMA** 1999 Jan 13;281(2):112-3

A piece of my mind. To whom shall I tell my grief? Herman J. **JAMA** 1999 Jul 14;282(2):111-2

Grief work of HIV positive persons and their survivors. Mallinson RK. **Nurs Clin North Am** 1999 Mar;34(1):163-77 (43 ref.)

Grief, depression, and coping in women undergoing infertility treatment. Lukse MP, et al. **Obstet Gynecol** 1999 Feb; 93(2):245-51

A view from the family: years after a loved one has died of ovarian cancer. Tarraza HM, et al. **Obstet Gynecol** 1999 Jan;93(1):38-40

The cultural context of death rituals and mourning practices. Kagawa-Singer M. **Oncol Nurs Forum** 1998 Nov-Dec; 25(10):1752-6 (32 ref.)

Grieving and death rituals of Latinos. Munet-Vilaró F. **Oncol Nurs Forum** 1998 Nov-Dec;25(10):1761-3 (16 ref.)

Recognizing and treating dysfunctional grief. Rancour P. **Oncol Nurs Forum** 1998 Sep;25(8):1310-1

Families' awareness of and response to dying. Yates P, et al. **Oncol Nurs Forum** 1999 Jan-Feb;26(1):113-20

Applying an empty-chair monologue paradigm to examine unresolved grief. Field NP, et al. **Psychiatry** 1998 Winter; 61(4):279-87

Clinical features of pathological grief reaction in elderly patients. Ishii H, et al. **Psychiatry Clin Neurosci** 1998 Dec; 52(6):571-6

Grief reactions treated in a psychiatric out-patient clinic. Nakamura Y. **Psychiatry Clin Neurosci** 1999 Jun; 53(3):357-63

Childhood attachment and loss experiences affect adult cardiovascular and cortisol function. Luecken LJ. **Psychosom Med** 1998 Nov-Dec;60(6):765-72

Post-abortion syndrome--a grief subverted [letter] Larsen J. **S Afr Med J** 1999 Jun;89(6):576

In honor of my father and my son. Bolton IM. **Suicide Life Threat Behav** 1998 Winter;28(4):355-7

Predicting grief symptomatology among the suddenly bereaved. Reed MD. **Suicide Life Threat Behav** 1998 Fall; 28(3):285-301 (52 ref.)

The suicide of a friend [letter] Shahzad K. **Suicide Life Threat Behav** 1998 Fall;28(3):322-3

[Unfulfilled desire for children--what is the grief for men?] Küchenhoff J. **Ther Umsch** 1999 May;56(5):260-4 (Eng. Abstr.) **(Ger)**

[Factors influencing grief due to bereavement among elderly widows and widowers] Terasaki A, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):512-25 (Eng. Abstr.) **(Jpn)**

[When the Easter morning does not alleviate grief] Daae C. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1074 **(Nor)**

[Grief, pain, life and happiness characterize the final period. Being a relative gives a hard-earned experience] Campbell-Chiru T. **Lakartidningen** 1999 Mar 3; 96(9):1034-9 **(Swe)**

[Support and counseling ease grief. An intervention project for recently bereaved elderly widows and widowers in Gothenburg] Grimby A. **Lakartidningen** 1999 Apr 14; 96(15):1838-42 (Eng. Abstr.) **(Swe)**

[When the expected child dies. Both emotional and practical support is important for the women affected] Rådestad I. **Lakartidningen** 1999 Mar 17;96(11):1311-5 (Eng. Abstr.) **(Swe)**

GRIEVANCES, EMPLOYEE see **EMPLOYEE GRIEVANCES**

GRIP see **HAND STRENGTH**

GRIPPE see **INFLUENZA**

GRISEOFULVIN

ADMINISTRATION & DOSAGE

Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Dhanaraju MD, et al. **Drug Dev Ind Pharm** 1998 Jun;24(6):583-7

CHEMISTRY

Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method. Wulff M, et al. **Eur J Pharm Sci** 1999 Aug;8(4):269-81

PHARMACOKINETICS

Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Dhanaraju MD, et al. **Drug Dev Ind Pharm** 1998 Jun;24(6):583-7

PHARMACOLOGY

Detection of chromosome loss and gain induced by griseofulvin, estramustine, and vanadate in binucleated lymphocytes using FISH analysis. Migliore L, et al. **Environ Mol Mutagen** 1999;34(1):64-8

Alteration of mRNA levels of delta-aminolevulinic acid synthase, ferrochelatase and heme oxygenase-1 in griseofulvin induced protoporphyria mice. Inafuku K, et al. **J Dermatol Sci** 1999 Apr;19(3):189-98

Griseofulvin-induced aneuploidy and meiotic delay in male mouse germ cells: detected by using conventional cytogenetics and three-color FISH. Qinghua S, et al. **Mutat Res** 1999 May 17;441(2):181-90

POISONING

Altered microtubule-associated tau messenger RNA isoform expression in livers of griseofulvin- and 3,5-diethoxycarbonyl-1, 4-dihydrocollidine-treated mice. Kenner L, et al. **Hepatology** 1999 Mar;29(3):793-800

THERAPEUTIC USE

A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Hussain I, et al. **Med Mycol** 1999 Apr;37(2):97-9

GRIVET MONKEY see **CERCOPITHECUS AETHIOPS**

GRIZZLY BEARS see **BEARS**

GRNA see **RNA, GUIDE**

GROEL PROTEIN

ANALYSIS

Localization of DnaK and GroEL in Vibrio cholerae. Jyot

J, et al. **FEMS Microbiol Lett** 1999 Mar 15;172(2):165–71

BIOSYNTHESIS

Overexpression of dnaK/dnaJ and groEL confers freeze tolerance to Escherichia coli. Chow KC, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):502–5

Increased solubility of glutathione S-transferase-P16 (GST-p16) fusion protein by co-expression of chaperones groes and groel in Escherichia coli. Luo ZH, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):471–7

CHEMISTRY

EPR mapping of interactions between spin-labeled variants of human carbonic anhydrase II and GroEL: evidence for increased flexibility of the hydrophobic core by the interaction. Persson M, et al. **Biochemistry** 1999 Jan 5; 38(1):432–41

Binding of polylysine to GroEL. Inhibition of the refolding of mMDH. Lau CK, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):282–9

Thermodynamics of nucleotide binding to the chaperonin GroEL studied by isothermal titration calorimetry: evidence for noncooperative nucleotide binding. Terada TP, et al. **Biochim Biophys Acta** 1999 May 18; 1431(2):269–81

On the role of symmetrical and asymmetrical chaperonin complexes in assisted protein folding. Hayer-Hartl MK, et al. **Biol Chem** 1999 May;380(5):531–40

ATP hydrolysis induces an intermediate conformational state in GroEL. Galán A, et al. **Eur J Biochem** 1999 Jan; 259(1–2):347–55

Interaction of 4,4'-dithiodipyridine with Cys(458) triggers disassembly of GroEL. Bochkareva E, et al. **J Biol Chem** 1999 Jul 23;274(30):20756–8

On the maximum size of proteins to stay and fold in the cavity of GroEL underneath GroES. Sakikawa C, et al. **J Biol Chem** 1999 Jul 23;274(30):21251–6

Conformational changes generated in GroEL during ATP hydrolysis as seen by time-resolved infrared spectroscopy. von Germar F, et al. **J Biol Chem** 1999 Feb 26; 274(9):5508–13

Exploring the kinetic requirements for enhancement of protein folding rates in the GroEL cavity. Betancourt MR, et al. **J Mol Biol** 1999 Apr 2;287(3):627–44

GroEL recognises sequential and non-sequential linear structural motifs compatible with extended beta-strands and alpha-helices. Chatellier J, et al. **J Mol Biol** 1999 Sep 10;292(1):163–72

Conformational changes in the chaperonin GroEL: new insights into the allosteric mechanism. de Groot BL, et al. **J Mol Biol** 1999 Mar 5;286(4):1241–9

An arginine residue (Arg101), which is conserved in many GroEL homologues, is required for interactions between the two heptameric rings. Jones S, et al. **J Mol Biol** 1998 Oct 2;282(4):789–800

NMR analysis of the binding of a rhodanese peptide to a minichaperone in solution. Kobayashi N, et al. **J Mol Biol** 1999 Sep 10;292(1):181–90

Identification of substrate binding site of GroEL minichaperone in solution. Tanaka N, et al. **J Mol Biol** 1999 Sep 10;292(1):173–80

Participation of chaperonin GroEL in the folding of D-glyceraldehyde-3-phosphate dehydrogenase. An approach based on the use of different oligomeric forms of the enzyme immobilized on sepharose. Bulatnikov IG, et al. **J Protein Chem** 1999 Jan;18(1):79–87

Nucleotide and Mg2+ induced conformational changes in GroEL can be detected by sulfhydryl labeling. Jai EA, et al. **J Protein Chem** 1999 Apr;18(3):387–96

GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2–3):129–41 (63 ref.)

GroEL accelerates the refolding of hen lysozyme without changing its folding mechanism [see comments] Coyle JE, et al. **Nat Struct Biol** 1999 Jul;6(7):683–90. Comment in: Nat Struct Biol 1999 Jul;6(7):597–600.

The oligomeric structure of GroEL/GroES is required for biologically significant chaperonin function in protein folding [published erratum appears in Nat Struct Biol 1999 Feb;6(2):200] Weber F, et al. **Nat Struct Biol** 1998 Nov; 5(11):977–85

Purification and characterization of Chromatium vinosum GroEL and GroES proteins overexpressed in Escherichia coli cells lacking the endogenous groESL operon. Dionisi HM, et al. **Protein Expr Purif** 1998 Nov;14(2):275–82

[Monomeric form of the molecular chaperone GroEL: structure, stability, and oligomerization] Surin AK, et al. **Bioorg Khim** 1999 May;25(5):358–64 (Eng. Abstr.) **(Rus)**

GENETICS

Cloning of the groE operon of the marine bacterium Vibrio harveyi using a lambda vector. Kuchanny D, et al. **Acta Biochim Pol** 1998;45(1):261–70

Role of adenine nucleotides, molecular chaperones and chaperonins in stabilization of DnaA initiator protein of Escherichia coli. Banecki B, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):39–48

High level expression of Thermococcus litoralis 4-alpha-glucanotransferase in a soluble form in Escherichia coli with a novel expression system involving minor arginine tRNAs and GroELS. Imamura H, et al. **FEBS Lett** 1999 Sep 3;457(3):393–6

Evaluation of intraspecies genetic variation within the 60 kDa heat-shock protein gene (groEL) of Bartonella species. Marston EL, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1015–23

Ancient gene duplication and differential gene flow in plastid lineages: the GroEL/Cpn60 example. Wastl J, et al. **J Mol Evol** 1999 Jan;48(1):112–7

Cloning and sequencing of the gene that codes for the Klebsiella pneumoniae GroEL-like protein associated with ankylosing spondylitis. Cancino-Diaz M, et al. **Microb Pathog** 1998 Jul;25(1):23–32

UV-A-induced expression of GroEL in the UV-A-resistant marine cyanobacterium Oscillatoria sp. NKBG 091600. Yamazawa A, et al. **Microbiology** 1999 Apr;145 (Pt 4):949–54

IMMUNOLOGY

The GroEL-like protein from Campylobacter rectus: immunological characterization and interleukin-6 and -8 induction in human gingival fibroblast. Hinode D, et al. **FEMS Microbiol Lett** 1998 Oct 1;167(1):1–6

Immunogenic epitopes of Salmonella typhi GroEL heat shock protein reactive with both monoclonal antibody and patients sera. Panchanathan V, et al. **Immunol Lett** 1998 Jun;62(2):105–9

METABOLISM

Phosphofructokinase interacts with molecular chaperonins GroEL and GroES. Melegh B, et al. **Acta Biol Hung** 1997; 48(4):399–407

Structure and function in GroEL-mediated protein folding. Sigler PB, et al. **Annu Rev Biochem** 1998;67:581–608 (83 ref.)

GroEL protects the sarcoplasmic reticulum Ca(++)-dependent ATPase from inactivation in vitro. Javed MU, et al. **Biochem Mol Biol Int** 1999 Apr; 47(4):631–8

Basis of substrate binding by the chaperonin GroEL. Wang Z, et al. **Biochemistry** 1999 Sep 28;38(39):12537–46

Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug-Sep;80(8–9):729–37 (49 ref.)

GroEL-GroES cycling: ATP and nonnative polypeptide direct alternation of folding-active rings. Rye HS, et al. **Cell** 1999 Apr 30;97(3):325–38

Analysis of interaction between chaperonin GroEL and its substrate using fluorescence correlation spectroscopy. Pack CG, et al. **Cytometry** 1999 Jul 1;36(3):247–53

ATP hydrolysis induces an intermediate conformational state in GroEL. Galán A, et al. **Eur J Biochem** 1999 Jan; 259(1–2):347–55

Subcellular localization and cytotoxic activity of the GroEL-like protein isolated from Actinobacillus actinomycetemcomitans. Goulhen F, et al. **Infect Immun** 1998 Nov;66(11):5307–13

A single-ring mitochondrial chaperonin (Hsp60-Hsp10) can substitute for GroEL-GroES in vivo. Nielsen KL, et al. **J Bacteriol** 1999 Sep;181(18):5871–5

The region of alpha-lactalbumin recognized by GroEL. Shimizu A, et al. **J Biochem (Tokyo)** 1998 Aug; 124(2):319–25

GroEL/GroES-dependent reconstitution of alpha2 beta2 tetramers of humanmitochondrial branched chain alpha-ketoacid decarboxylase. Obligatory interaction of chaperonins with an alpha beta dimeric intermediate. Chuang JL, et al. **J Biol Chem** 1999 Apr 9; 274(15):10395–404

Chaperone activity of a chimeric GroEL protein that can exist in a single or double ring form. Erbse A, et al. **J Biol Chem** 1999 Jul 16;274(29):20351–7

Analysis of GroE-assisted folding under nonpermissive conditions. Grallert H, et al. **J Biol Chem** 1999 Jul 16; 274(29):20171–7

GroEL traps dimeric and monomeric unfolding intermediates of citrate synthase. Grallert H, et al. **J Biol Chem** 1998 Dec 11;273(50):33305–10

Mechanisms for GroEL/GroES-mediated folding of a large 86-kDa fusion polypeptide in vitro. Huang YS, et al. **J Biol Chem** 1999 Apr 9;274(15):10405–12

"Half of the sites" binding of D-glyceraldehyde-3-phosphate dehydrogenase folding intermediate with GroEL. Li J, et al. **J Biol Chem** 1999 Apr 16;274(16):10790–4

GroEL under heat-shock. Switching from a folding to a storing function. Llorca O, et al. **J Biol Chem** 1998 Dec 4;273(49):32587–94

GroEL and GroES control of substrate flux in the in vivo folding pathway of phage P22 coat protein. Nakonechny WS, et al. **J Biol Chem** 1998 Oct 16;273(42):27236–44

Compensatory changes in GroEL/Gp31 affinity as a mechanism for allele-specific genetic interaction. Richardson A, et al. **J Biol Chem** 1999 Jan 1;274(1):52–8

Partitioning of rhodanese onto GroEL. Chaperonin binds a reversibly oxidized form derived from the native protein. Smith KE, et al. **J Biol Chem** 1998 Oct 30;273(44):28677–81

NH2-terminal sequence truncation decreases the stability of bovine rhodanese, minimally perturbs its crystal structure, and enhances interaction with GroEL under native conditions. Trevino RJ, et al. **J Biol Chem** 1999 May 14; 274(20):13938–47

Exploring the kinetic requirements for enhancement of protein folding rates in the GroEL cavity. Betancourt MR, et al. **J Mol Biol** 1999 Apr 2;287(3):627–44

The chaperonin GroEL binds to late-folding non-native conformations present in native Escherichia coli and murine dihydrofolate reductases. Clark AC, et al. **J Mol Biol** 1999 Jan 29;285(4):1777–88

GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2–3):129–41 (63 ref.)

Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Rantala I, et al. **Kidney Int** 1999 Jun;55(6):2274–80

Reconstitution of active dimeric ribulose bisphosphate carboxylase from an unfoleded state depends on two chaperonin proteins and Mg-ATP. Goloubinoff P, et al. **Nature** 1989 Dec 21–28;342(6252):884–9

GroES in the asymmetric GroEL14-GroES7 complex exchanges via an associative mechanism. Horowitz PM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2682–6

GroEL-GroES-mediated protein folding requires an intact central cavity. Wang JD, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12163–8

Recognition of partially-folded mitochondrial malate dehydrogenase by GroEL. Steady and time-dependent emission anisotropy measurements. Churchich JE. **Protein Sci** 1998 Dec;7(12):2587–94

[Quantitative analysis of inducible systems of Escherichia coli and Bacillus subtilis using radioimmunological methods] Suslov AV, et al. **Radiats Biol Radioecol** 1998 Jul-Aug; 38(4):495–501 (Eng. Abstr.) **(Rus)**

[Proteins induction by cysteamine in Escherichia coli cells] Suslov AV, et al. **Radiats Biol Radioecol** 1998 Jul-Aug; 38(4):488–94 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

GroEL-assisted and -unassisted refolding of mature and precursor adrenodoxin: the role of the precursor sequence. Bera AK, et al. **Arch Biochem Biophys** 1999 Jul 1; 367(1):89–94

The Escherichia coli chaperonin 60 (groEL) is a potent stimulator of osteoclast formation. Reddi K, et al. **J Bone Miner Res** 1998 Aug;13(8):1260–6

PHYSIOLOGY

The role of DnaK/DnaJ and GroEL/GroES systems in the removal of endogenous proteins aggregated by heat-shock from Escherichia coli cells. Kędzierska S, et al. **FEBS Lett** 1999 Mar 12;446(2–3):331–7

Thinking outside the box: new insights into the mechanism of GroEL-mediated protein folding [news; comment] Wang JD, et al. **Nat Struct Biol** 1999 Jul;6(7):597–600. Comment on: Nat Struct Biol 1999 Jul;6(7):683–90.

Chaperonin function: folding by forced unfolding. Shtilerman M, et al. **Science** 1999 Apr 30;284(5415):822–5

A GroEL homologue from endosymbiotic bacteria of the whitefly Bemisia tabaci is implicated in the circulative transmission of tomato yellow leaf curl virus. Morin S, et al. **Virology** 1999 Mar 30;256(1):75–84

TOXICITY

Subcellular localization and cytotoxic activity of the GroEL-like protein isolated from Actinobacillus actinomycetemcomitans. Goulhen F, et al. **Infect Immun** 1998 Nov;66(11):5307–13

GROENOUW'S DYSTROPHIES see **CORNEAL DYSTROPHIES, HEREDITARY**

GROES PROTEIN

BIOSYNTHESIS

Increased solubility of glutathione S-transferase-P16 (GST-p16) fusion protein by co-expression of chaperones groes and groel in Escherichia coli. Luo ZH, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):471–7

CHEMISTRY

On the maximum size of proteins to stay and fold in the cavity of GroEL underneath GroES. Sakikawa C, et al. **J Biol Chem** 1999 Jul 23;274(30):21251–6

Unfolding and refolding of Escherichia coli chaperonin GroES is expressed by a three-state model. Higurashi T, et al. **J Mol Biol** 1999 Aug 20;291(3):703–13

GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2–3):129–41 (63 ref.)

The oligomeric structure of GroEL/GroES is required for biologically significant chaperonin function in protein folding [published erratum appears in Nat Struct Biol 1999 Feb;6(2):200] Weber F, et al. **Nat Struct Biol** 1998 Nov; 5(11):977–85

Purification and characterization of Chromatium vinosum GroEL and GroES proteins overexpressed in Escherichia coli cells lacking the endogenous groESL operon. Dionisi HM, et al. **Protein Expr Purif** 1998 Nov;14(2):275–82

GENETICS

Cloning of the groE operon of the marine bacterium Vibrio

harveyi using a lambda vector. Kuchanny D, et al. **Acta Biochim Pol** 1998;45(1):261–70

Role of adenine nucleotides, molecular chaperones and chaperonins in stabilization of DnaA initiator protein of Escherichia coli. Banecki B, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):39–48

The GroES antigens of Mycobacterium avium and Mycobacterium paratuberculosis. Cobb AJ, et al. **Vet Microbiol** 1999 Jun 1;67(1):31–5

IMMUNOLOGY

T-cell recognition of mycobacterial GroES peptides in Thai leprosy patients and contacts. Chua-Intra B, et al. **Infect Immun** 1998 Oct;66(10):4903–9

METABOLISM

Phosphofructokinase interacts with molecular chaperonins GroEL and GroES. Melegh B, et al. **Acta Biol Hung** 1997; 48(4):399–407

Structure and function in GroEL-mediated protein folding. Sigler PB, et al. **Annu Rev Biochem** 1998;67:581–608 (83 ref.)

Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug-Sep;80(8–9):729–37 (49 ref.)

GroEL-GroES cycling: ATP and nonnative polypeptide direct alternation of folding-active rings. Rye HS, et al. **Cell** 1999 Apr 30;97(3):325–38

A single-ring mitochondrial chaperonin (Hsp60–Hsp10) can substitute for GroEL-GroES in vivo. Nielsen KL, et al. **J Bacteriol** 1999 Sep;181(18):5871–5

GroEL/GroES-dependent reconstitution of alpha2 beta2 tetramers of humanmitochondrial branched chain alpha-ketoacid decarboxylase. Obligatory interaction of chaperonins with an alpha beta dimeric intermediate. Chuang JL, et al. **J Biol Chem** 1999 Apr 9; 274(15):10395–404

Analysis of GroE-assisted folding under nonpermissive conditions. Grallert H, et al. **J Biol Chem** 1999 Jul 16; 274(29):20171–7

Mechanisms for GroEL/GroES-mediated folding of a large 86-kDa fusion polypeptide in vitro. Huang YS, et al. **J Biol Chem** 1999 Apr 9;274(15):10405–12

GroEL and GroES control of substrate flux in the in vivo folding pathway of phage P22 coat protein. Nakonechny WS, et al. **J Biol Chem** 1998 Oct 16;273(42):27236–44

GroEL/GroES: structure and function of a two-stroke folding machine. Xu Z, et al. **J Struct Biol** 1998 Dec 15; 124(2–3):129–41 (63 ref.)

GroES in the asymmetric GroEL14-GroES7 complex exchanges via an associative mechanism. Horowitz PM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2682–6

GroEL-GroES-mediated protein folding requires an intact central cavity. Wang JD, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12163–8

PHYSIOLOGY

The role of DnaK/DnaJ and GroEL/GroES systems in the removal of endogenous proteins aggregated by heat-shock from Escherichia coli cells. Kędzierska S, et al. **FEBS Lett** 1999 Mar 12;446(2–3):331–7

GROIN

The sportsman's groin. MacLeod DA, et al. **Br J Surg** 1999 Jul;86(7):849–50

Groin pain in athletes [letter; comment] Gibbon WW. **Lancet** 1999 Apr 24;353(9162):1444–5. Comment on: Lancet 1999 Feb 6;353(9151):439–43.

Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes: randomised trial [see comments] Hölmich P, et al. **Lancet** 1999 Feb 6;353(9151):439–43. Comment in: Lancet 1999 Apr 24;353(9162):1444. Comment in: Lancet 1999 Apr 24;353(9162):1444–5.

Groin pain in athletes [letter; comment] Syme G, et al. **Lancet** 1999 Apr 24;353(9162):1444. Comment on: Lancet 1999 Feb 6;353(9151):439–43.

Bilateral groin adenolymphoceles: an unusual presentation of chylous reflux. Guzmán AE, et al. **Lymphology** 1999 Jun;32(2):58–63

[Case report. Increase in bulk of the inguinal area in a pig] Heinritzi K. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov;26(6):307, 339–40 **(Ger)**

[A common symptom among athletes and persons who exercise. Correct treatment of groin pain requires a meticulous diagnosis] Ekstrand J. **Lakartidningen** 1999 Feb 3;96(5):480–3 (20 ref.) (Eng. Abstr.) **(Swe)**

ANATOMY & HISTOLOGY

Some structural characteristics of the inguinal region in the northern Croatia. Ledinsky M, et al. **Coll Antropol** 1998 Dec;22(2):515–24

INJURIES

Groin pain in the soccer athlete: fact, fiction, and treatment. Gilmore J. **Clin Sports Med** 1998 Oct;17(4):787–93, vii

The incidence and differential diagnosis of acute groin injuries in male soccer players. Ekstrand J, et al. **Scand J Med Sci Sports** 1999 Apr;9(2):98–103

Groin injuries in sport: treatment strategies. Lynch SA, et al. **Sports Med** 1999 Aug;28(2):137–44

INNERVATION

Regional correspondence between the ventral portion of the lumbar intervertebral disc and the groin mediated by a spinal reflex. A possible basis of discogenic referred pain. Takahashi Y, et al. **Spine** 1998 Sep 1;23(17):1853–8; discussion 1859

SURGERY

Virgin and recurrent groin hernia: a comparison of patient recovery following endoscopic preperitoneal herniorrhaphy. Ahmad SA, et al. **J Soc Laparoendosc Surg** 1997 Oct-Dec;1(4):337–40

Repair after radical groin dissection. Zografos GC, et al. **J Surg Oncol** 1999 Jun;71(2):117–9

The groin flap revisited--what the textbooks do not tell. Van Wingerden JJ. **S Afr J Surg** 1999 Feb;37(1):21–3

ULTRASONOGRAPHY

[Ultrasound assessment in diagnosis of uncomplicated inguinal hernia] Babkova IV, et al. **Khirurgiia (Mosk)** 1999; (2):46–50 (Eng. Abstr.) **(Rus)**

GROMMET INSERTION see **MIDDLE EAR VENTILATION**

GRONBLAD-STRANDBERG SYNDROME see **PSEUDOXANTHOMA ELASTICUM**

GROOMING

Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Clifford JJ, et al. **Neuropharmacology** 1998 Dec; 37(12):1595–602

DRUG EFFECTS

Opposite effects of CCK(B) agonists in grooming behaviour in rats: further evidence for two CCK(B) subsites. Ladurelle N, et al. **Br J Pharmacol** 1998 Jul;124(6):1091–8

Behavioral effects of anti-muscarinic, anti-serotonergic, and anti-NMDA treatments: hippocampal and neocortical slow wave electrophysiology predict the effects on grooming in the rat. Robertson BJ, et al. **Brain Res** 1999 Aug 14; 838(1–2):234–40

The expression of neuropeptide-induced excessive grooming behavior in dopamine D1 and D2 receptor-deficient mice. Drago F, et al. **Eur J Pharmacol** 1999 Jan 22; 365(2–3):125–31

Nicotine-induced grooming: a possible dopaminergic and/or cholinergic mechanism. Zarrindast MR, et al. **J Psychopharmacol** 1998;12(4):375–9

Effects of D1 dopamine receptor agonists on oral ethanol self-administration in rats: comparison with their efficacy to produce grooming and hyperactivity. Cohen C, et al. **Psychopharmacology (Berl)** 1999 Feb;142(1):102–10

PHYSIOLOGY

Vigilance during foraging and allogrooming in semi-free-ranging Barbary macaques. Chalmeau R, et al. **Folia Primatol (Basel)** 1998;69(6):381–5

Psychogenic alopecia in cats: 11 cases (1993–1996). Sawyer LS, et al. **J Am Vet Med Assoc** 1999 Jan 1;214(1):71–4

The hypothalamus: cross-roads of endocrine and behavioural regulation in grooming and aggression. Kruk MR, et al. **Neurosci Biobehav Rev** 1998;23(2):163–77 (122 ref.)

Serotonin2A receptor modulation of D1 dopamine receptor-mediated grooming behavior. Scalzitti JM, et al. **Pharmacol Biochem Behav** 1999 Jun;63(2):279–84

The mother rat's vomeronasal organ is involved in detection of dodecyl propionate, the pup's preputial gland pheromone. Brouette-Lahlou I, et al. **Physiol Behav** 1999 May;66(3):427–36

Effects of castration on grooming in goats. Mooring MS, et al. **Physiol Behav** 1998 Jul;64(5):707–13

Age-related changes in grooming behavior and motor activity in female rats. Scimonelli T, et al. **Physiol Behav** 1999 May;66(3):481–4

GROUNDNUTS see **PEANUTS**

GROUNDSEL see **SENECIO**

GROUP HEALTH INSURANCE see **INSURANCE, HEALTH**

GROUP HEALTH ORGANIZATIONS, PREPAID see **HEALTH MAINTENANCE ORGANIZATIONS**

GROUP HOMES

An exploratory analysis of women and men within a self-help, communal-living recovery setting: a new beginning in a new house. Ferrari JR, et al. **Am J Drug Alcohol Abuse** 1999 May;25(2):305–17

Put your money where your mouth is: direct and indirect measures of attitude toward community integration. Zsambok J, et al. **Am J Ment Retard** 1999 Jan;104(1):88–92

The initiation of mutual-help groups within residential treatment settings. Salem DA, et al. **Community Ment Health J** 1998 Aug;34(4):419–29

Behavioral disturbances and pharmacological treatment of patients with dementia in family caregiving: a 2-year follow-up. Elmståhl S, et al. **Int Psychogeriatr** 1998 Sep; 10(3):239–52

Improving staff nutritional practices in community-based group homes: evaluation, training, and management. Kneringer MJ, et al. **J Appl Behav Anal** 1999 Summer; 32(2):221–4

Interactions between group homes and neighbors: neighbor preferences. Cook JR. **J Behav Health Serv Res** 1998 Nov; 25(4):425–36

Improve quality in nursing homes or institute community placement? Implementation of OBRA for individuals with mental retardation. Spreat S, et al. **Res Dev Disabil** 1998 Nov-Dec;19(6):507–18

[Concept of apartment-sharing groups for children and adolescents treated with long-term ventilation] Schwerdt M. **Med Klin** 1999 Apr;94(1 Spec No):77–80 (Eng. Abstr.) **(Ger)**

[Community integrated living with reliable care in the service home: the status of young handicapped patients in a model project "House at Weinberg" in Stuttgart] Gerngross-Haas G. **Rehabilitation (Stuttg)** 1999 May;38(2):100–6 (Eng. Abstr.) **(Ger)**

[Community self-help houses as a form of community social support] Dąbrowski S, et al. **Psychiatr Pol** 1998 Jul-Aug; 32(4):453–61 (Eng. Abstr.) **(Pol)**

ECONOMICS

Staff recruitment challenges and interventions in agencies supporting people with developmental disabilities. Larson SA, et al. **Ment Retard** 1999 Feb;37(1):36–46

MANPOWER

Role clarity, perception of the organization and burnout amongst support workers in residential homes for people with intellectual disability: a comparison between a National Health Service trust and a charitable company. Blumenthal S, et al. **J Intellect Disabil Res** 1998 Oct;42 (Pt 5):409–17

ORGANIZATION & ADMINISTRATION

Opportunity and the promotion of activity among adults with severe intellectual disability living in community residences: the impact of training staff in active support. Jones E, et al. **J Intellect Disabil Res** 1999 Jun;43 (Pt 3):164–78

The TAPS project 32: social networks of two group homes ... 5 years on.Team for the Assessment of Psychiatric Services. Dayson D, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Sep;33(9):438–44

Does a hostel's managing agency determine the access to psychiatric services of its residents? Lucas B, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Oct; 33(10):497–500

STANDARDS

Comparison of two community alternatives to incarceration for chronic juvenile offenders. Chamberlain P, et al. **J Consult Clin Psychol** 1998 Aug;66(4):624–33

Housing placement and subsequent days homeless among formerly homeless adults with mental illness. Goldfinger SM, et al. **Psychiatr Serv** 1999 May;50(5):674–9

STATISTICS & NUMERICAL DATA

Family caregiving in dementia: prediction of caregiver burden 12 months after relocation to group-living care. Elmståhl S, et al. **Int Psychogeriatr** 1998 Jun;10(2):127–46

Hygienic practices and acute respiratory illness in family and group day care homes. St. Sauver J, et al. **Public Health Rep** 1998 Nov-Dec;113(6):544–51

UTILIZATION

Family and client perspectives on alternative residential settings for persons with severe mental illness. Friedrich RM, et al. **Psychiatr Serv** 1999 Apr;50(4):509–14

GROUP HOSPITALIZATION see **INSURANCE, HOSPITALIZATION**

GROUP IDENTIFICATION see **SOCIAL IDENTIFICATION**

GROUP PRACTICE

General practitioners' attitudes to the development of midwifery group practices [see comments] Fenwick N, et al. **Br J Gen Pract** 1998 Jul;48(432):1395–8. Comment in: Br J Gen Pract 1998 Nov;48(436):1787–8.

Putting patient care first when group practices break down [letter] [see comments] Thomson A. **Med J Aust** 1998 Nov 2;169(9):504. Comment in: Med J Aust 1999 Apr 5;170(7):343. Comment in: Med J Aust 1999 Apr 5;170(7):343–4.

Group practices: a note of urgency. Chetty M.

S Afr Med J 1998 Oct;88(10):1301-2
Unethical duels between departing physicians and their medical groups. Overlock M. **Tenn Med** 1999 Jan; 92(1):13-4
Forum on ethics. Group practice, medical records, and the patients. Sarre SG. **Tex Med** 1999 May;95(5):28-9

ECONOMICS

Meeting the information and budgetary requirements of primary care groups. Gilley J. **BMJ** 1999 Jan 16; 318(7177):168-9; discussion 169-70
Solutions prove elusive as Ontario seeks alternatives to FFS in remote areas. OReilly M. **CMAJ** 1998 Oct 6;159(7):840-1
Effects of a low-cost protocol on outcome and cost in a group practice setting [published erratum appears in J Clin Anesth 1998 Nov;10(7):616] Kirsch MA, et al. **J Clin Anesth** 1998 Aug;10(5):416-24

HISTORY

Audiovisual memoirs of Leaders in American Medicine. Russel V. Lee, M.D. Owen OE. **Pharos** 1999 Summer; 62(3):46-7

ORGANIZATION & ADMINISTRATION

The integration of primary care sports medicine into an academic emergency medicine practice: academic and revenue enhancement. Veenema KR. **Acad Emerg Med** 1999 Aug;6(8):828-32
CAPNA. Columbia Advanced Practice Nurse Associates. Boccuzzi NK. **Am J Nurs** 1998 Nov;98(11):34-5
The hard choice facing Australian GPs [letter] Cohen S. **Aust Fam Physician** 1999 May;28(5):427
Manage indirect practice expense the way you practice medicine: with information. Zeller TL, et al. **Dis Colon Rectum** 1999 May;42(5):579-89
Establishing a collaborative psychopharmacology practice: practical considerations. Grimaldi D, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):32-5 (11 ref.)
Replication of clinical innovations in multiple medical practices. Henley NS, et al. **Jt Comm J Qual Improv** 1998 Nov;24(11):623-39
Under one roof. Moran T. **Tex Med** 1999 May;95(5):45-8

STANDARDS

Comparison of patient satisfaction results during a period of rapid growth for a specialty group practice. Gawande SR, et al. **Am J Orthop** 1999 Apr;28(4):236-8
Satisfaction with obstetric care. Patient survey in a family practice shared-call group [see comments] Shapiro JL. **Can Fam Physician** 1999 Mar;45:651-7. Comment in: Can Fam Physician 1999 May;45:1151.
Approaches to the organization of multi-practice audits in primary health care in the UK. Khunti K, et al. **Int J Qual Health Care** 1999 Jun;11(3):221-6
Using a quality scorecard to measure and improve medical groups' performance. Belman MJ, et al. **Jt Comm J Qual Improv** 1999 May;25(5):239-51
Integrating clinical performance improvement across physician organizations: the PhyCor experience. Loeppke R, et al. **Jt Comm J Qual Improv** 1999 Feb;25(2):55-67

STATISTICS & NUMERICAL DATA

Few family physicians go it alone [news] Buske L. **CMAJ** 1999 Feb 9;160(3):304
Hiring of radiation oncologists by physician groups in 1997. Elliott SD, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):627-32

GROUP PRACTICE, DENTAL

LEGISLATION & JURISPRUDENCE

Independent judgment and unions. Sfikas PM. **J Am Dent Assoc** 1999 Aug;130(8):1231-2

GROUP PRACTICE, PREPAID

ECONOMICS

Competition through physician-managed care: the case for capitated multispecialty group practices. Tillinghast SJ. **Int J Qual Health Care** 1998 Oct;10(5):427-34

STANDARDS

Competition through physician-managed care: the case for capitated multispecialty group practices. Tillinghast SJ. **Int J Qual Health Care** 1998 Oct;10(5):427-34

GROUP PROCESSES

see related
SOCIAL CHANGE

College students' self-reported reasons for playing drinking games. Johnson TJ, et al. **Addict Behav** 1999 Mar-Apr; 24(2):279-86
Team leadership: network differences in women's and men's instrumental and expressive relations. Webster C, et al. **Adm Policy Ment Health** 1999 Jan;26(3):169-90
The relative importance of factors which influence order of injecting with a shared needle and syringe. Crisp BR, et al. **AIDS Care** 1998 Dec;10(6):713-21
Nurses dancing with wolves [editorial] Mason DJ. **Am J Nurs** 1999 Aug;99(8):7
Late-stage dementia and participation in therapeutic activities. Kovach CR, et al. **Appl Nurs Res** 1998 Nov; 11(4):167-73
Group vs individual well-child care [letter; comment] Derauf D. **Arch Pediatr Adolesc Med** 1999 Jan;153(1):92-3. Comment on: Arch Pediatr Adolesc Med 1998 Jun;152(6):579-84.
Assessing threats of targeted group violence: contributions from social psychology. Pynchon MR, et al. **Behav Sci Law** 1999;17(3):339-55 (52 ref.)
Significance of the role of self-study and group discussion. Holla SJ, et al. **Clin Anat** 1999;12(4):277-80
The perceived intentionality of groups. Bloom P, et al. **Cognition** 1999 May 3;71(1):B1-9
What's missing in our meetings? [letter] Volpintesta EJ. **Conn Med** 1999 Jun;63(6):357-8
The power of friendship: protection against an escalating cycle of peer victimization. Hodges EV, et al. **Dev Psychol** 1999 Jan;35(1):94-101
Children's interactions in triads: behavioral profiles and effects of gender and patterns of friendships among members. Lansford JE, et al. **Dev Psychol** 1999 Jan; 35(1):80-93
Black churches as therapeutic systems: a group process perspective. McRae MB, et al. **Health Educ Behav** 1998 Dec;25(6):778-89
The effects of group size and group economic factors on collaboration: a study of the financial performance of rural hospitals in consortia. Chan B, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):9-31
The advanced-stage therapy group. Berman A, et al. **Int J Group Psychother** 1998 Oct;48(4):499-518
Envy in the group-therapy process. Dubner MA. **Int J Group Psychother** 1998 Oct;48(4):519-31 (26 ref.)
The team meeting on a rapid turnover psychiatric ward: clinical illustration of a model for stages of group development. Jackson DA. **Int J Group Psychother** 1999 Jan;49(1):41-59
How to make nutrition education more meaningful through facilitated group discussions. Abusabha R, et al. **J Am Diet Assoc** 1999 Jan;99(1):72-6 (28 ref.)
A randomized, controlled trial of a group intervention to reduce fear of falling and associated activity restriction in older adults. Tennstedt S, et al. **J Gerontol B Psychol Sci Soc Sci** 1998 Nov;53(6):P384-92
Motivation, mobilization, and monitoring: the role of groups in health policy [editorial] Peterson MA. **J Health Polit Policy Law** 1999 Jun;24(3):415-20 (17 ref.)
The place of community in medical encounters. Hester DM. **J Med Philos** 1998 Aug;23(4):369-83
Nominal group technique: assessing staff concerns. Cawthorpe D, et al. **J Nurs Adm** 1999 Jul-Aug;29(7-8):11, 18, 37 passim
Curriculum revision: reaching faculty consensus through the Nominal Group Technique. Davis DC, et al. **J Nurs Educ** 1998 Oct;37(7):326-8
Strategies used in clinical postconference. Letizia M. **J Nurs Educ** 1998 Oct;37(7):315-7
Intergroup bias: status, differentiation, and a common in-group identity. Dovidio JF, et al. **J Pers Soc Psychol** 1998 Jul;75(1):109-20
Reducing intergroup bias: elements of intergroup cooperation. Gaertner SL, et al. **J Pers Soc Psychol** 1999 Mar;76(3):388-402
Social loafing under fatigue. Hoeksema-van Orden CY, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1179-90
Long-term outcome maximization and the reduction of interindividual-intergroup discontinuity. Insko CA, et al. **J Pers Soc Psychol** 1998 Sep;75(3):695-710
Diagnosing groups: the pooling, management, and impact of shared and unshared case information in team-based medical decision making. Larson JR Jr, et al. **J Pers Soc Psychol** 1998 Jul;75(1):93-108
Workplace drinking climate, stress, and problem indicators: assessing the influence of teamwork (group cohesion). Bennett JB, et al. **J Stud Alcohol** 1998 Sep;59(5):608-18
Cohesion predicts success in junior ice hockey. Salminen S, et al. **Percept Mot Skills** 1998 Oct;87(2):649-50
Effects of spatial grouping on the functional response of predators. Cosner C, et al. **Theor Popul Biol** 1999 Aug; 56(1):65-75
Theories of group intervention. Combs CJ. **Transplant Proc** 1999 Jun;31(4A):46S-47S

GROUP PURCHASING

see related
PURCHASING, HOSPITAL

Objectives of genetic counselling: differing views of purchasers, providers and users. Michie S, et al. **J Public Health Med** 1998 Dec;20(4):404-8

ECONOMICS

Purchasing Medicare prescription drug benefits: a new proposal [see comments] Etheredge L. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):7-19. Comment in: Health Aff (Millwood) 1999 Jul-Aug;18(4):20-2. Comment in: Health Aff (Millwood) 1999 Jul-Aug;18(4):23-4.

TRENDS

Pooled purchasing: who are the players? Long SH, et al. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):105-11

GROUP-SPECIFIC COMPONENT see **VITAMIN D-BINDING PROTEIN**

GROUP STRUCTURE

The impact of collective efficacy beliefs on effort and persistence in a group task. Greenlees IA, et al. **J Sports Sci** 1999 Feb;17(2):151-8

GROUP THERAPY see **PSYCHOTHERAPY, GROUP**

GROWTH

see related
CHILD DEVELOPMENT
PERSONALITY DEVELOPMENT

Growth and development four years after treatment for the Trichuris dysentery syndrome. Callender JE, et al. **Acta Paediatr** 1998 Dec;87(12):1247-9
Chlorinated contaminants, growth and thyroid function in schoolchildren from the Aral Sea region in Kazakhstan. Mazhitova Z, et al. **Acta Paediatr** 1998 Sep;87(9):991-5
Influence of breastfeeding and complementary food on growth between 5 and 10 months. Nielsen GA, et al. **Acta Paediatr** 1998 Sep;87(9):911-7
Long-term growth of children with congenital heart disease: a retrospective study. Schuurmans FM, et al. **Acta Paediatr** 1998 Dec;87(12):1250-5
Growth and body composition of preterm infants: influence of nutrient fortification of mother's milk in hospital and breastfeeding post-hospital discharge. Wauben IP, et al. **Acta Paediatr** 1998 Jul;87(7):780-5
Adolescent growth, development, and psychosocial aspects of sports participation: an overview. Patel DR, et al. **Adolesc Med** 1998 Oct;9(3):425-40, v (68 ref.)
Curve smoothing and transformations in the development of growth curves. Flegal KM. **Am J Clin Nutr** 1999 Jul; 70(1):163S-5S (9 ref.)
A new international growth reference for young children. Garza C, et al. **Am J Clin Nutr** 1999 Jul;70(1):169S-72S (5 ref.)
Effect of zinc supplementation on growth and body composition of Ugandan preschool children: a randomized, controlled, intervention trial [see comments] Kikafunda JK, et al. **Am J Clin Nutr** 1998 Dec;68(6):1261-6. Comment in: Am J Clin Nutr 1999 Jul;70(1):110-1. Comment in: Am J Clin Nutr 1999 Jul;70(1):111-3.
Comparison of growth status of patients with cystic fibrosis between the United States and Canada. Lai HC, et al. **Am J Clin Nutr** 1999 Mar;69(3):531-8
Child growth and nutritional status in a high-poverty community in eastern Kentucky. Crooks DL. **Am J Phys Anthropol** 1999 May;109(1):129-42
Growth patterns among seminomadic pastoralists (Datoga) of Tanzania. Sellen DW. **Am J Phys Anthropol** 1999 Jun; 109(2):187-209
Changes in growth patterns in Zagreb school children related to socio-economic background over the period 1973-1991. Prebeg Z. **Ann Hum Biol** 1998 Sep-Oct;25(5):425-39
An analysis of variance of the pubertal and midgrowth spurts for length and width. Sheehy A, et al. **Ann Hum Biol** 1999 Jul-Aug;26(4):309-31
Nutrition in early life: somatic growth and serum lipids. Boulton TJ, et al. **Ann Med** 1999 Apr;31 Suppl 1:7-12 (46 ref.)
Influence of a past history of Gambian sleeping sickness on physical growth, sexual maturity and academic performance of children in Fontem, Cameroon. Aroke AH, et al. **Ann Trop Med Parasitol** 1998 Dec;92(8):829-35
Growth in the first two years of uninfected children born to HIV-1 seropositive mothers. Agostoni C, et al. **Arch Dis Child** 1998 Aug;79(2):175-8
Growth in Sotos syndrome. Agwu JC, et al. **Arch Dis Child** 1999 Apr;80(4):339-42
Normal growth in cystic fibrosis associated with a specialised centre. Collins CE, et al. **Arch Dis Child** 1999 Sep; 81(3):241-6
Linear growth in prepubertal children with atopic dermatitis. Patel L, et al. **Arch Dis Child** 1998 Aug;79(2):169-72
Less diarrhoea but no change in growth: 15 years' data from three Gambian villages. Poskitt EM, et al. **Arch Dis Child** 1999 Feb;80(2):115-9; discussion 119-20
Adequacy of standards for assessment of growth and nutritional status in infancy and early childhood. Savage SA, et al. **Arch Dis Child** 1999 Feb;80(2):121-4
Growth of long-term survivors of liver transplantation. Viner RM, et al. **Arch Dis Child** 1999 Mar;80(3):235-40
Long-term effects of iron:zinc interactions on growth in rats. Bouglé D, et al. **Biol Trace Elem Res** 1999 Jan;67(1):37-48
Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. European Group for Blood and Marrow Transplantation. Cohen A, et al. **Bone Marrow Transplant** 1999 May;23(10):1043-7
Physical growth and fatness as related to physical activity in preadolescent girls. Raudsepp L, et al. **Coll Antropol**

1999 Jun;23(1):53-8
Physical activity patterns of rural Senegalese adolescent girls during the dry and rainy seasons measured by movement registration and direct observation methods. Bénéfice E, et al. **Eur J Clin Nutr** 1999 Aug;53(8):636-43
Using obese-specific charts of height and height velocity for assessment of growth in obese children and adolescents during weight excess reduction. Falorni A, et al. **Eur J Clin Nutr** 1999 Mar;53(3):181-8
Anthropometric indicators of human immunodeficiency virus infection in infants with early and late symptoms in the first months of life. Agostoni C, et al. **Eur J Pediatr** 1998 Oct;157(10):811-3
Chronic renal failure in infants: effect of strict conservative treatment on growth. Van Dyck M, et al. **Eur J Pediatr** 1998 Sep;157(9):759-62
Skeletal maturation in adolescence: a comparison between the Tanner-Whitehouse II and the Fels method. van Lenthe FJ, et al. **Eur J Pediatr** 1998 Oct;157(10):798-801
Primary hyperoxaluria 1: catch up growth and normalization of oxaluria 6 years after hepatorenal transplantation in a prepubertal boy. Walden U, et al. **Eur J Pediatr** 1999 Sep; 158(9):727-9
Consequences of limited exposure to elevated growth hormone in the mature oMt1a-oGH transgenic mouse. Oberbauer AM, et al. **Growth Dev Aging** 1998 Autumn; 62(3):87-93
Sibling correlations of skin pigmentation during growth. Rebato E, et al. **Hum Biol** 1999 Apr;71(2):277-93
Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis. Lozeva V, et al. **Inflamm Res** 1999 Feb; 48(2):81-5
The effects of accelerated growth rates and estrogen implants in prepubertal Holstein heifers on growth, feed efficiency, and blood parameters. Lammers BP, et al. **J Dairy Sci** 1999 Aug;82(8):1746-52
The effects of accelerated growth rates and estrogen implants in prepubertal Holstein heifers on estimates of mammary development and subsequent reproduction and milk production. Lammers BP, et al. **J Dairy Sci** 1999 Aug; 82(8):1753-64
The feasibility of using a postal survey method to assess the health and development of 7 year old children of different birth weight. Alderdice F, et al. **J Epidemiol Community Health** 1998 Jul;52(7):439-44
Dietary protein, growth and urea kinetics in severely malnourished children and during recovery. Badaloo A, et al. **J Nutr** 1999 May;129(5):969-79
Food deprivation and refeeding influence growth, nutrient retention and functional recovery of rats. Boza JJ, et al. **J Nutr** 1999 Jul;129(7):1340-6
Duration of breast-feeding and Bayley's Mental Developmental Index at 1 year of age. Paine BJ, et al. **J Paediatr Child Health** 1999 Feb;35(1):82-5
Excessive infantile growth and early pubertal growth spurt: typical features in patients with aspartylglycosaminuria [see comments] Arvio P, et al. **J Pediatr** 1999 Jun;134(6):761-3 . Comment in: J Pediatr 1999 Jun;134(6):666-7.
Blood lead concentration and children's anthropometric dimensions in the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Ballew C, et al. **J Pediatr** 1999 May;134(5):623-30
The pediatric growth curve as a cancer research tool [editorial; comment] Blatt J, et al. **J Pediatr** 1999 Feb; 134(2):138-40. Comment on: J Pediatr 1999 Feb;134(2):178-84.
Spontaneous growth and bone age development in a patient with 17alpha-hydroxylase deficiency: evidence of the role of sexual steroids in prepubertal bone maturation. Mayer EI, et al. **J Pediatr** 1999 Mar;134(3):371-5 (25 ref.)
Longitudinal evaluation of growth, puberty, and bone maturation in children with Williams syndrome. Partsch CJ, et al. **J Pediatr** 1999 Jan;134(1):82-9
Rapid somatic growth after birth in children with neuroblastoma: A survey of 1718 patients with childhood cancer in Kyushu-Okinawa district [see comments] Suminoe A, et al. **J Pediatr** 1999 Feb;134(2):178-84. Comment in: J Pediatr 1999 Feb;134(2):138-40.
Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. Tom A, et al. **J Pediatr** 1999 Apr;134(4):464-71
Nutrient intake and growth of infants with phenylketonuria undergoing therapy. Acosta PB, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):287-91
Linear growth and skeletal maturation in subjects with treated celiac disease. Gemme G, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):339-42
Growth hormone and insulin-like growth factor-I therapy promote protein deposition and growth in dexamethasone-treated piglets. Ward WE, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):404-10
Chondroblastoma during the growing age. Schuppers HA, et al. **J Pediatr Orthop B** 1998 Oct;7(4):293-7 (25 ref.)
Effects of maternal docosahexaenoic acid supplementation on visual function and growth of breast-fed term infants. Jensen CL, et al. **Lipids** 1999;34 Suppl:S225
Complementary feeding: a global perspective. Michaelsen KF, et al. **Nutrition** 1998 Oct;14(10):763-6 (33 ref.)
Growth and development considerations in the diagnosis of gingivitis and periodontitis in children. Bimstein E, et al. **Pediatr Dent** 1999 May-Jun;21(3):186-91 (80 ref.)
Trichorhinophalangeal syndrome type I in monozygotic twins discordant for hip pathology. Report on the morphological evolution of cone-shaped epiphyses and the unusual pattern of skeletal maturation. Naselli A, et al. **Pediatr Radiol** 1998 Nov;28(11):851-5 (9 ref.)
Target height as predicted by parental heights in a population-based study. Luo ZC, et al. **Pediatr Res** 1998 Oct;44(4):563-71
Somatic growth and renal function after unilateral nephrectomy for Wilms' tumor. Srinivas M, et al. **Pediatr Surg Int** 1998 Dec;14(3):185-8
Growth post renal-transplantation in children: lessons from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Fine RN. **Pediatr Transplant** 1997 Aug;1(1):85-9
Nutritional factors affecting growth before and after liver transplantation. Kelly DA. **Pediatr Transplant** 1997 Aug; 1(1):80-4
Growth and fatness at three to six years of age of children born small- or large-for-gestational age. Hediger ML, et al. **Pediatrics** 1999 Sep;104(3):e33
Dietary long-chain polyunsaturated fatty acids do not influence growth of term infants: A randomized clinical trial. Makrides M, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):468-75
Fruit juice intake is not related to children's growth. Skinner JD, et al. **Pediatrics** 1999 Jan;103(1):58-64
Rapid growth problems: ascites and skeletal deformities in broilers. Julian RJ. **Poult Sci** 1998 Dec;77(12):1773-80 (36 ref.)
Preliminary data touch off genetic food fight [news] Enserink M. **Science** 1999 Feb 19;283(5405):1094-5
Regulation of maternal behavior and offspring growth by paternally expressed Peg3. Li L, et al. **Science** 1999 Apr 9;284(5412):330-3
Intestinal geohelminthiasis and growth in pre-adolescent primary school children in Northeastern Peninsular Malaysia. Mahendra Raj S. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):112-7
Presenting information on growth distance and conditional velocity in one chart: practical issues of chart design. Cole TJ. **Stat Med** 1998 Dec 15;17(23):2697-707
Multi-level repeated measures growth modelling using extended spline functions. Pan H, et al. **Stat Med** 1998 Dec 15;17(23):2755-70
Longitudinal analysis of adolescent growth of foot length and stature of children living in Ogi area of Japan: a 12 years data. Liu KM, et al. **Z Morphol Anthropol** 1998; 82(1):87-101
[Modelization of growth between 0 and 3 years of age in children born in Toulouse in 1993-1994 and comparison with Sempé's growth curves] Cance-Rouzaud A, et al. **Arch Pediatr** 1999 Feb;6(2):145-50 (Eng. Abstr.) **(Fre)**
[Infants born with development disorders. What about the long-term statural development? What are the therapeutic possibilities?] Heinrichs C. **Rev Med Brux** 1998 Dec; 19(6):471-3 (Eng. Abstr.) **(Fre)**
[The overall nutritional quality of the diet is reflected in the growth of Nigerian children] Tarini A, et al. **Sante** 1999 Jan-Feb;9(1):23-31 (Eng. Abstr.) **(Fre)**
[Somatotype as an indicator of individual growth rates and maturation of a child] Sukhanova NN. **Gig Sanit** 1998 Sep-Oct;(5):36-7 (Eng. Abstr.) **(Rus)**
[Programs and politics on growth deficit (consequences of a line of research carried out in Chile)] Amigo H, et al. **Arch Latinoam Nutr** 1998 Dec;48(4):281-6 (Eng. Abstr.) **(Spa)**
[Athletic training of children and adolescents: growth and maturation more important than training for endurance in the young] Andrén-Sandberg A. **Lakartidningen** 1998 Oct 7;95(41):4480-4, 4487 (35 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Influence of dietary fat on the nutrient intake and growth of children from 1 to 5 y of age: the Special Turku Coronary Risk Factor Intervention Project. Lagström H, et al. **Am J Clin Nutr** 1999 Mar;69(3):516-23
Effect of daily and weekly micronutrient supplementation on micronutrient deficiencies and growth in young Vietnamese children. Thu BD, et al. **Am J Clin Nutr** 1999 Jan;69(1):80-6
Randomised controlled trial of recombinant human growth hormone in prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology. Maxwell H, et al. **Arch Dis Child** 1998 Dec;79(6):481-7
Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. Morley R, et al. **Arch Dis Child** 1999 Sep; 81(3):247-52
Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. da-Silva VA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):93-8
Delayed pubertal growth spurt and normal adult height attainment in boys receiving long-term alternate-day prednisone therapy. Polito C, et al. **Clin Pediatr (Phila)** 1999 May;38(5):279-85
Is resveratrol an estrogen agonist in growing rats? Turner RT, et al. **Endocrinology** 1999 Jan;140(1):50-4
Impact of zinc supplementation on subsequent growth and morbidity in Bangladeshi children with acute diarrhoea. Roy SK, et al. **Eur J Clin Nutr** 1999 Jul;53(7):529-34
Exposure to exogenous estrogens in food: possible impact on human development and health. Andersson AM, et al. **Eur J Endocrinol** 1999 Jun;140(6):477-85 (42 ref.)
Effect of the synthetic glucocorticoid, deflazacort, on body growth, pulsatile secretion of GH and thymolysis in the rat. Latta K, et al. **Eur J Endocrinol** 1999 May;140(5):441-6
Preparation of recombinant gilthead seabream (Sparus aurata) growth hormone and its use for stimulation of larvae growth by oral administration. Ben-Atia I, et al. **Gen Comp Endocrinol** 1999 Jan;113(1):155-64
The effect of different growth hormone administration frequencies on growth in growth hormone-deficient patients. Cavallo L, et al. **Horm Res** 1998;49 Suppl 2:73-7
Catch-up growth after childhood-onset substitution in primary hypothyroidism: is it a guide towards optimal growth hormone treatment in idiopathic growth hormone deficiency? Ranke MB, et al. **Horm Res** 1998;50(5):264-70
Growth and body composition in response to chemotherapy in children with acute lymphoblastic leukemia. Halton JM, et al. **Int J Cancer Suppl** 1998;11:81-4
Effect of long-term treatment with inhaled beclomethasone dipropionate on growth of asthmatic children. Inoue T, et al. **J Asthma** 1999;36(2):159-64
Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. Carel JC, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1973-8
Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study [see comments] Ranke MB, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1174-83. Comment in: J Clin Endocrinol Metab 1999 Apr;84(4):1172-3.
A mathematical model for predicting growth response to growth hormone replacement therapy--a useful clinical tool or an intellectual exercise? [editorial; comment] Rosenbloom AL. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1172-3. Comment on: J Clin Endocrinol Metab 1999 Apr;84(4):1174-83.
Oxidized derivatives of 7-dehydrocholesterol induce growth retardation in cultured rat embryos: a model for antenatal growth retardation in the Smith-Lemli-Opitz syndrome. Gaoua W, et al. **J Lipid Res** 1999 Mar;40(3):456-63
Increased height gain of children fed a high-protein diet during convalescence from shigellosis: a six-month follow-Up study. Kabir I, et al. **J Nutr** 1998 Oct; 128(10):1688-91
Long-term supplementation with iron does not enhance growth in malnourished Bangladeshi children. Rahman MM, et al. **J Nutr** 1999 Jul;129(7):1319-22
Effect on growth of inhaled steroid therapy [letter; comment] Brand PLP, et al. **J Pediatr** 1999 Feb;134(2):253. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):381-3. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):409-13. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):472-7.
Inhaled corticosteroids and growth velocity in children with asthma [letter] Purucker M, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):264-6
Short-term changes in lower leg length in children treated for acute lymphoblastic leukaemia. Ahmed SF, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb;12(1):75-80
Infant growth after in utero exposure to zidovudine [letter] Zuccotti GV, et al. **JAMA** 1999 Aug 11;282(6):527-9
Treatment of trichuris infection with albendazole [letter; comment] Beach MJ, et al. **Lancet** 1999 Jan 16; 353(9148):237-8. Comment on: Lancet 1998 Oct 3;352(9134):1103-8.
Randomised trial of albendazole and pyrantel in symptomless trichuriasis in children [see comments] Forrester JE, et al. **Lancet** 1998 Oct 3;352(9134):1103-8. Comment in: Lancet 1998 Oct 3;352(9134):1080-1. Comment in: Lancet 1999 Jan 16;353(9148):237-8. Comment in: Lancet 1999 Jan 16;353(9148):237; discussion 238. Comment in: Lancet 1998 Dec 12;352(9144):1935.
Treatment of trichuris infection with albendazole [letter; comment] Savioli L. **Lancet** 1999 Jan 16;353(9148):237; discussion 238. Comment on: Lancet 1998 Oct 3;352(9134):1103-8.
Albendazole for mass treatment of asymptomatic trichuris infections [comment] [see comments] Winstanley P. **Lancet** 1998 Oct 3;352(9134):1080-1. Comment on: Lancet 1998 Oct 3;352(9134):1103-8. Comment in: Lancet 1998 Dec 12;352(9144):1935.
Growth promotion by insulin-like growth factor I in hypophysectomized and diabetic rats. Zapf J. **Mol Cell Endocrinol** 1998 May 25;140(1-2):143-9 (25 ref.)
Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group [see comments] Hintz RL, et al. **N Engl J Med** 1999 Feb 18;340(7):502-7. Comment in: N Engl J Med 1999 Feb 18;340(7):557-9.
Growth hormone use in normal, short children--a plea for reason [editorial; comment] Oberfield SE. **N Engl J Med** 1999 Feb 18;340(7):557-9. Comment on: N Engl J Med 1999 Feb 18;340(7):502-7.
The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Czeizel AE, et al. **Neurotoxicol Teratol** 1999 Mar-Apr; 21(2):157-67

Effects of prenatal exposure to toluene on postnatal development and behavior in rats. Hougaard KS, et al. **Neurotoxicol Teratol** 1999 May-Jun;21(3):241-50

Effect of exposure to 3,3',4,4',5-pentachlorobiphenyl (PCB 126) throughout gestation and lactation on development and spatial delayed alternation performance in rats. Rice DC. **Neurotoxicol Teratol** 1999 Jan-Feb;21(1):59-69

Effects of alimentary intact proteins and their oligopeptide hydrolysate on growth, nitrogen retention, and small bowel adaptation in inflammatory turpentine rat. Zarrabian S, et al. **Nutrition** 1999 Jun;15(6):474-80

Inhaled corticosteroids and growth in children [see comments] Welch MJ. **Pediatr Ann** 1998 Nov;27(11):752-8 (38 ref.). Comment in: Pediatr Ann 1998 Nov;27(11):708.

Child and adolescent psychopharmacology. Important developmental issues. Tosyali MC, et al. **Pediatr Clin North Am** 1998 Oct;45(5):1021-35, vii (90 ref.)

Effects of environmental exposure to polychlorinated biphenyls and dioxins on birth size and growth in Dutch children. Patandin S, et al. **Pediatr Res** 1998 Oct; 44(4):538-45

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Rättyä J, et al. **Pediatries** 1999 Mar;103(3):588-93

Toxic and growth retarding effects of three plant extracts on Culex pipiens larvae (Diptera: Culicidae). El Hag EA, et al. **Phytother Res** 1999 Aug;13(5):388-92

Short-term anabolic effects of recombinant human growth hormone in young patients with a renal transplant. Ghio L, et al. **Transpl Int** 1998;11 Suppl 1:S69-72

Combinations of growth promoters in veal calves: consequences for screening and confirmation methods. Groot MJ, et al. **Zentralbl Veterinarmed A** 1998 Sep; 45(6-7):425-40

[The physical development of children living in a settlement with a high nitrate content in the drinking water] Gatseva P, et al. **Probl Khig** 1997;22:108-14 (Eng. Abstr.) **(Bul)**

[Inhaled corticosteroids and growth] Le Bourgeois M, et al. **Arch Pediatr** 1999 Mar;6(3):324-9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Growth and the assessment of body composition in children treated with the growth hormone] Marco Hernández M, et al. **An Esp Pediatr** 1999 Jun;50(6):587-93 (Eng. Abstr.) **(Spa)**

[Effect of maternal smoking on offspring growth] Salazar G, et al. **Rev Med Chil** 1998 Sep;126(9):1059-64 (Eng. Abstr.) **(Spa)**

[Asthma, inhalation steroids and growth of children. Effects on the body height are rare but growth check ups are justified] Marcus C, et al. **Lakartidningen** 1999 Jul 14; 96(28-29):3241-4 (26 ref.) **(Swe)**

GENETICS

Vitamin D receptor alleles predict growth and bone density in girls. Tao C, et al. **Arch Dis Child** 1998 Dec;79(6):488-93; discussion 493-4

Oncogenes and growth control. EMBL-SALK Conference, Heidelberg, Germany, 18-22 April 1998. Vousden K. **Biochim Biophys Acta** 1999 Jan 29;1423(1):R29-33

The molecular evolution of development. Purugganan MD. **Bioessays** 1998 Sep;20(9):700-11 (80 ref.)

Heterochronic genes in development and evolution. Slack F, et al. **Biol Bull** 1998 Dec;195(3):375-6 (9 ref.)

Genetic parameters of growth curve parameters in male and female chickens. Mignon-Grasteau S, et al. **Br Poult Sci** 1999 Mar;40(1):44-51

Growth and the distal tip of mouse chromosome 7. Graham CF, et al. **Genet Res** 1998 Dec;72(3):247-53 (66 ref.)

A 500-kb YAC and BAC contig encompassing the high-growth deletion in mouse chromosome 10 and identification of the murine Raidd/Cradd gene in the candidate region. Horvat S, et al. **Genomics** 1998 Nov 15; 54(1):159-64

Vitamin-D receptor genotype does not predict bone mineral density, bone turnover, and growth in prepubertal children. Baroncelli GI, et al. **Horm Res** 1999;51(3):150-6

Genetic trends and breed overlap derived from multiple-breed genetic evaluations of beef cattle for growth traits. Sullivan PG, et al. **J Anim Sci** 1999 Aug; 77(8):2019-27

Interval mapping of growth in divergent swine cross. Paszek AA, et al. **Mamm Genome** 1999 Feb;10(2):117-22

Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Oliverio MI, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15496-501

[Genes and intra-uterine growth retardation] Jeanpierre M. **Arch Pediatr** 1998;5 Suppl 4:332S-337S (46 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Minimum time intervals for serial measurements of growth in recumbent length or stature of individual children. Himes JH. **Acta Paediatr** 1999 Feb;88(2):120-5

Bone growth from 11 to 17 years: relationship to growth, gender and changes with pubertal status including timing of menarche. Magarey AM, et al. **Acta Paediatr** 1999 Feb; 88(2):139-46

Growth parameters in children with retinoblastoma. Peek AM, et al. **Acta Paediatr** 1999 Feb;88(2):181-5

Composition of long chain polyunsaturated fatty acids in human milk and growth of young infants in rural areas of northern China. Xiang M, et al. **Acta Paediatr** 1999 Feb; 88(2):126-31

Adolescent development: setting the stage for influencing health behaviors. Juszczak L, et al. **Adolesc Med** 1999 Feb; 10(1):1-11, v (65 ref.)

Involvement of hormonal circadian secretion in the growth of HIV-infected children. Rondanelli M, et al. **AIDS** 1998 Oct 1;12(14):1845-50

Evolution of human growth prolongation. Leigh SR, et al. **Am J Phys Anthropol** 1998 Nov;107(3):331-50 (84 ref.)

Age changes in some somatometric characters of the Assamese Muslims of Kamrup district, Assam. Begum G, et al. **Ann Hum Biol** 1999 May-Jun;26(3):203-17

Study of growth in rural school children from Buenos Aires, Argentina using upper arm muscle area by height and other anthropometric dimensions of body composition. Bolzan A, et al. **Ann Hum Biol** 1999 Mar-Apr;26(2):185-93

Development effects of thyroid hormone: the role of deiodinases in regulatory control. St Germain DL. **Biochem Soc Trans** 1999 Feb;27(2):83-8 (57 ref.)

Adipose tissue as an endocrine organ regulating growth, puberty, and other physiological functions. Pankov YA. **Biochemistry (Mosc)** 1999 Jun;64(6):601-9 (41 ref.)

Growth, development and differentiation: a functional food science approach. Koletzko B, et al. **Br J Nutr** 1998 Aug; 80 Suppl 1:S5-45 (417 ref.)

Infants in Trinidad excrete more 5-L-oxoproline (L-pyroglutamic acid) in urine than infants in England: an environmental not ethnic difference. Lenton C, et al. **Br J Nutr** 1998 Jul;80(1):51-5

Does raised intraocular pressure begin in utero? Foss AJ, et al. **Br J Ophthalmol** 1998 Oct;82(10):1125-30

Effect of dietary zinc content and sources on the growth, body zinc deposition and retention, zinc excretion and immune response in chickens. Mohanna C, et al. **Br Poult Sci** 1999 Mar;40(1):108-14

Peak and trough growth hormone (GH) concentrations influence growth and serum insulin like growth factor-1 (IGF-1) concentrations in short children. Achermann JC, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):301-8

Growth in children with craniopharyngioma following surgery. Tiulpakov AN, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):733-8

Adolescent growth is not associated with changes in flexibility. Feldman D, et al. **Clin J Sport Med** 1999 Jan; 9(1):24-9

Fish as models for the neuroendocrine regulation of reproduction and growth. Blázquez M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):345-64 (214 ref.)

Developmental effects on intersexual and intrasexual variation in growth and reproduction in a lizard with temperature-dependent sex determination. Crews D, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):229-41 (83 ref.)

Everything you wanted to know about sex a perspective on the first symposium on Comparative Neuroendocrinology of Vertebrate Reproduction and Growth: Molecular, Cellular and Organismal Aspects. Trudeau VL. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):411-6

Size control: cell proliferation does not equal growth. Su TT, et al. **Curr Biol** 1998 Sep 24;8(19):R687-9 (10 ref.)

Growth changes in children and adolescents with short-term diabetes [see comments] Bognetti E, et al. **Diabetes Care** 1998 Aug;21(8):1226-9. Comment in: Diabetes Care 1999 Jun;22(6):1012.

Poor metabolic control decreases the growth velocity of diabetic children [letter; comment] Gunczler P, et al. **Diabetes Care** 1999 Jun;22(6):1012. Comment on: Diabetes Care 1998 Aug;21(8):1226-9.

Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Silverman BL, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B142-9

The effect of lactic acid bacteria on intestinal metabolism and metabolic profile in gnotobiotic pigs. Bomba A, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Oct;105(10):384-9

Long-term somatic and mental development of children after periconceptional multivitamin supplementation. Dobó M, et al. **Eur J Pediatr** 1998 Sep;157(9):719-23

Good growth despite very low levels of insulin-like growth factors. Dötsch J, et al. **Eur J Pediatr** 1998 Sep;157(9):712-4

Effects of photoperiod on the cessation of growth during autumn in male red deer and growth hormone and insulin-like growth factor-I secretion. Webster JR, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):464-77

Absence of catch-down growth in Russell-Silver syndrome after short-term growth hormone treatment. Azcona C, et al. **Horm Res** 1999;51(1):47-9

Height velocity, body fat and menarcheal age of Indian girls. Rao S, et al. **Indian Pediatr** 1998 Jul;35(7):619-28

High serum leptin concentrations during catch-up growth of children born with intrauterine growth retardation. Jaquet D, et al. **J Clin Endocrinol Metab** 1999 Jun; 84(6):1949-53

Energy intake and utilization vary during development in rats. Iossa S, et al. **J Nutr** 1999 Aug;129(8):1593-6

Janus kinases and their role in growth and disease. Aringer M, et al. **Life Sci** 1999;64(24):2173-86 (111 ref.)

Changes in the physiological roles of neurotransmitters during individual development. Buznikov GA, et al. **Neurosci Behav Physiol** 1999 Jan-Feb;29(1):11-21 (105 ref.)

Clinical observations on catch-up growth in asthmatic children following withdrawal of inhaled glucocorticosteroids [letter] Saha MT, et al. **Pediatr Pulmonol** 1998 Oct;26(4):292-4

Monthly measurements of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in healthy prepubertal children: characterization and relationship with growth: the 1-year growth study. Gelander L, et al. **Pediatr Res** 1999 Mar;45(3):377-83

Rat milk and dietary long arginine3 insulin-like growth factor I promote intestinal growth of newborn rat pups. Staley MD, et al. **Pediatr Res** 1998 Oct;44(4):512-8

The relationship between stature, growth, and short-term changes in height and weight in normal prepubertal children. Tillmann V, et al. **Pediatr Res** 1998 Dec; 44(6):882-6

Maternal and pup contributions to different patterns of pup growth in Phodopus species. Stulberg SE, et al. **Physiol Behav** 1998 Jul;64(5):715-22

Dietary formulation with rendered spent hen meals on a total amino acid versus a digestible amino acid basis. Douglas MW, et al. **Poult Sci** 1999 Apr;78(4):556-60

The postnatal development of spinal sensory processing. Fitzgerald M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7719-22 (49 ref.)

Factors affecting growth after pediatric liver transplantation. McDiarmid SV, et al. **Transplantation** 1999 Feb 15; 67(3):404-11

[Regional differences in physical development and growth of children in nine cities of China] Li H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):92-4 (Eng. Abstr.) **(Chi)**

[Growth curves from birth to 6 years of age: growth in weight, height and cranial circumference according to sex] Remontet L, et al. **Arch Pediatr** 1999 May;6(5):520-9 (Eng. Abstr.) **(Fre)**

[Various ecological and physiological aspects of feeding and growth of the Baikal seal Pusa sibirica pups] Egorova LI, et al. **Zh Evol Biokhim Fiziol** 1998 Sep-Oct;34(5):591-7 **(Rus)**

[Peroxide metabolism on respiratory muscles: effect of growth, maturation and aging] Montecinos L, et al. **Rev Med Chil** 1999 Mar;127(3):269-75 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Effects of total-body irradiation on growth, thyroid and pituitary gland in rhesus monkeys. Bakker B, et al. **Radiother Oncol** 1999 May;51(2):187-92

GROWTH CONES

see related
NEURITES

CHEMISTRY

Ultrastructural observations on the expression of axonin-1: implications for the fasciculation of sensory axons during axonal outgrowth into the chick hindlimb. Xue Y, et al. **J Comp Neurol** 1999 Jun 7;408(3):299-317

DRUG EFFECTS

Rapid arrest of axon elongation by brefeldin A: a role for the small GTP-binding protein ARF in neuronal growth cones. Hess DT, et al. **J Neurobiol** 1999 Jan;38(1):105-15

Steroid hormone enhancement of neurite outgrowth in identified insect motor neurons involves specific effects on growth cone form and function. Matheson SF, et al. **J Neurobiol** 1999 Jan;38(1):27-45

Drosophila nerve cord culture: a tool for studying neural development. Wang YE, et al. **J Neurosci Methods** 1998 Nov 1;85(1):21-6

Docosahexaenoic acid decreases phospholipase A2 activity in the neurites/nerve growth cones of PC12 cells. Martin RE. **J Neurosci Res** 1998 Dec 15;54(6):805-13

Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons. Saito S. **Neurotoxicol Teratol** 1998 Jul-Aug;20(4):411-9

ENZYMOLOGY

Regulation of chick dorsal root ganglion growth cone filopodia by protein kinase C. Bonsall J, et al. **Brain Res** 1999 Aug 21;839(1):120-32

Regulation of neuronal growth cone filopodia by nitric oxide. Van Wagenen S, et al. **J Neurobiol** 1999 May;39(2):168-85

METABOLISM

Regulated actin cytoskeleton assembly at filopodium tips controls their extension and retraction. Mallavarapu A, et al. **J Cell Biol** 1999 Sep 6;146(5):1097-106

Growth cone neuropilin-1 mediates collapsin-1/Sema III facilitation of antero- and retrograde axoplasmic transport. Goshima Y, et al. **J Neurobiol** 1999 Jun 15;39(4):579-89

Rac1-dependent actin filament organization in growth cones is necessary for beta1-integrin-mediated advance but not for growth on poly-D-lysine. Kuhn TB, et al. **J Neurobiol** 1998 Dec;37(4):524-40

GROWTH CONES

Proteolytic fragments of Alzheimer's disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain. Beher D, et al. **J Neurochem** 1999 Apr;72(4):1564–73

Neurite outgrowth stimulated by neural cell adhesion molecules requires growth-associated protein-43 (GAP-43) function and is associated with GAP-43 phosphorylation in growth cones. Meiri KF, et al. **J Neurosci** 1998 Dec 15;18(24):10429–37

Birefringence imaging directly reveals architectural dynamics of filamentous actin in living growth cones. Katoh K, et al. **Mol Biol Cell** 1999 Jan;10(1):197–210

Polymerizing microtubules activate site-directed F-actin assembly in nerve growth cones. Rochlin MW, et al. **Mol Biol Cell** 1999 Jul;10(7):2309–27

Identification of a novel cortactin SH3 domain-binding protein and its localization to growth cones of cultured neurons. Du Y, et al. **Mol Cell Biol** 1998 Oct;18(10):5838–51

Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Takei K, et al. **Science** 1998 Nov 27;282(5394):1705–8

PHYSIOLOGY

Growth cone guidance: first steps towards a deeper understanding. Mueller BK. **Annu Rev Neurosci** 1999; 22:351–88 (176 ref.)

Plexin A is a neuronal semaphorin receptor that controls axon guidance. Winberg ML, et al. **Cell** 1998 Dec 23; 95(7):903–16

Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons. Liu CW, et al. **Cell Motil Cytoskeleton** 1999;43(3):232–42

DCC and netrins. Culotti JG, et al. **Curr Opin Cell Biol** 1998 Oct;10(5):609–13 (39 ref.)

Signal transduction underlying growth cone guidance by diffusible factors. Song HJ, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):355–63 (88 ref.)

A potential role for the OTX2 homeoprotein in creating early highways' for axon extension in the rostral brain. Ba-Charvet KT, et al. **Development** 1998 Nov; 125(21):4273–82

Changes in morphology and behaviour of retinal growth cones before and after crossing the midline of the mouse chiasm - a confocal microscopy study. Chan SO, et al. **Eur J Neurosci** 1998 Aug;10(8):2511–22

Positional specificities of retinal growth cones in the mouse superior colliculus. Llirbat B, et al. **Eur J Neurosci** 1999 Jun;11(6):2103–13

The mobile regulatory structures of the body. Wolf S. **Integr Physiol Behav Sci** 1999 Apr-Jun;34(2):103–9 (14 ref.)

Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. Paglini G, et al. **J Cell Biol** 1998 Oct 19;143(2):443–55

Axonal outgrowth of cultured neurons is not limited by growth cone competition. Lamoureux P, et al. **J Cell Sci** 1998 Nov;111 (Pt 21):3245–52

Fibroblast growth factor receptor signaling in Xenopus retinal axon extension. Lom B, et al. **J Neurobiol** 1998 Dec; 37(4):633–41

In vivo dynamics of axon pathfinding in the Drosophilia CNS: a time-lapse study of an identified motorneuron. Murray MJ, et al. **J Neurobiol** 1998 Dec;37(4):607–21

Cortical neurite outgrowth and growth cone behaviors reveal developmentally regulated cues in spinal cord membranes. Nagashima M, et al. **J Neurobiol** 1999 Jun 5;39(3):393–406

Response of retinal ganglion cell axons to striped linear gradients of repellent guidance molecules. Rosentreter SM, et al. **J Neurobiol** 1998 Dec;37(4):541–62

Filopodial adhesion does not predict growth cone steering events in vivo. Isbister CM, et al. **J Neurosci** 1999 Apr 1;19(7):2589–600

Myelin and collapsin-1 induce motor neuron growth cone collapse through different pathways: inhibition of collapse by opposing mutants of rac1. Kuhn TB, et al. **J Neurosci** 1999 Mar 15;19(6):1965–75

A single growth cone is capable of integrating simultaneously presented and functionally distinct molecular cues during target recognition. Rose D, et al. **J Neurosci** 1999 Jun 15; 19(12):4899–906

Drosophila nerve cord culture: a tool for studying neural development. Wang YE, et al. **J Neurosci Methods** 1998 Nov 1;85(1):21–6

Radixin is involved in lamellipodial stability during nerve growth cone motility. Castelo L, et al. **Mol Biol Cell** 1999 May;10(5):1511–20

Neuronal growth cone collapse triggers lateral extensions along trailing axons [published erratum appears in Nat Neurosci 1999 May;2(5):485] Davenport RW, et al. **Nat Neurosci** 1999 Mar;2(3):254–9

In vivo regulation of axon extension and pathfinding by growth-cone calcium transients. Gomez TM, et al. **Nature** 1999 Jan 28;397(6717):350–5

Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1. Höpker VH, et al. **Nature** 1999 Sep 2; 401(6748):69–73

Braking news: calcium in the growth cone. Goldberg DJ, et al. **Neuron** 1999 Mar;22(3):423–5 (20 ref.)

Phospholipase C-gamma and phosphoinositide 3-kinase mediate cytoplasmic signaling in nerve growth cone guidance. Ming G, et al. **Neuron** 1999 May;23(1):139–48

Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse [see comments] Nakamura F, et al. **Neuron** 1998 Nov;21(5):1093–100. Comment in: Neuron 1998 Nov;21(5):935–6.

The tyrosine kinase Abl and its substrate enabled collaborate with the receptor phosphatase Dlar to control motor axon guidance. Wills Z, et al. **Neuron** 1999 Feb;22(2):301–12

Growth cones exhibit enhanced cell-cell adhesion after neurotransmitter release. Tatsumi H, et al. **Neuroscience** 1999;92(3):855–65

The role of local actin instability in axon formation. Bradke F, et al. **Science** 1999 Mar 19;283(5409):1931–4

ULTRASTRUCTURE

Birefringence imaging directly reveals architectural dynamics of filamentous actin in living growth cones. Katoh K, et al. **Mol Biol Cell** 1999 Jan;10(1):197–210

Polymerizing microtubules activate site-directed F-actin assembly in nerve growth cones. Rochlin MW, et al. **Mol Biol Cell** 1999 Jul;10(7):2309–27

GROWTH DISORDERS

see related
BONE DISEASES, DEVELOPMENTAL
DWARFISM
GIGANTISM

25th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism and the 3rd International Workshop on Growth Hormone Insensitivity. Istanbul, Turkey, 24–27 April 1998. Proceedings and Abstracts. **Acta Paediatr Suppl** 1999 Feb; 88(428):1–210

Perspectives on overgrowth syndromes. Cohen MM Jr. **Am J Med Genet** 1998 Oct 2;79(4):234–7 (48 ref.)

Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Göthe S, et al. **Genes Dev** 1999 May 15;13(10):1329–41

Prenatal and postnatal blood lead level and head circumference in children to three years: preliminary results from the Mexico City Prospective Lead Study. Rothenberg SJ, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:165–72

Human developmental disorders and the Sonic hedgehog pathway. Ming JE, et al. **Mol Med Today** 1998 Aug; 4(8):343–9 (49 ref.)

BLOOD

Peak and trough growth hormone (GH) concentrations influence growth and serum insulin like growth factor-1 (IGF-1) concentrations in short children. Achermann JC, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):301–8

Adrenal steroid hormones in short children born small for gestational age. Dahlgren J, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):353–61

Constitutional delay in growth and puberty (CDGP) is associated with hypoleptinaemia. Gill MS, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):721–6

Circadian variation of plasma cortisol in prepubertal children with normal stature, short stature and growth hormone deficiency. Hermida RC, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):473–9

Correlation between cortisol and insulin-like growth factor-binding proteins (IGFBPs) under physiological conditions in children. Martinelli Jr CE, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):767–74

Peripheral plasma levels of human growth hormone releasing hormone (GHRH) during the sleep test in short children. Inoue S, et al. **Endocr J** 1998 Apr;45 Suppl:S71–5

Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy. Barreca A, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3534–41

Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. Ishikawa M, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):98–104

Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders. Bozzola M, et al. **J Endocrinol Invest** 1998 Dec;21(11):765–70

Human insulin induces a higher glucagon response to induced hypoglycemia in short normal children, compared to porcine insulin. Kanaka-Gantenbein C, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb;12(1):39–46

Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF-I treatment of children and adults with primary GH resistance (Laron syndrome). Laron Z, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):145–52

Six-hour and four-hour nocturnal sampling for growth hormone. Rose SR, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):167–73

Plasma insulin-like growth factor-1, type 1 procollagen, and serum tumor necrosis factor alpha in children recovering from Trichuris dysentery syndrome. Duff EM, et al. **Pediatrics** 1999 May;103(5):e69

CHEMICALLY INDUCED

Side-effects of high-dose fluticasone propionate in children [letter; comment] Todd GR. **Eur Respir J** 1999 Mar; 13(3):707–9. Comment on: Eur Respir J 1998 May;11(5):1167–77.

Relationship between low lead exposure and somatic growth in adolescents. Vivoli G, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:201–9

Growth failure and bone lesions due to desferrioxamine in thalassaemic patients. Caruso-Nicoletti M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:957–60

Anthelmintic treatment for infestation with Trichuris trichiura [letter; comment] Bundy D, et al. **Lancet** 1998 Dec 12;352(9144):1935. Comment on: Lancet 1998 Oct 3;352(9134):1080–1. Comment on: Lancet 1998 Oct 3;352(9134):1103–8.

On observational studies on growth effects of inhaled corticosteroids in asthma [letter] Russell G. **Pediatr Pulmonol** 1999 Apr;27(4):294–6

Clinical observations on catch-up growth in asthmatic children following withdrawal of inhaled glucocorticosteroids [letter] Saha MT, et al. **Pediatr Pulmonol** 1998 Oct;26(4):292–4

Dexamethasone-induced abnormalities in growth and bone metabolism in piglets are partially attenuated by growth hormone with no synergistic effect of insulin-like growth factor-I. Ward WE, et al. **Pediatr Res** 1998 Aug; 44(2):215–21

[Inhaled corticosteroids and growth] Le Bourgeois M, et al. **Arch Pediatr** 1999 Mar;6(3):324–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Growth and collagen synthesis disorders in asthmatic children treated with inhaled steroids] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):475–9 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Plasma metabolites after a lipid load in infants with congenital heart disease. Lundell KH, et al. **Acta Paediatr** 1999 Jul; 88(7):718–23

Infant and child growth and fatness and fat distribution in Guatemalan adults. Schroeder DG, et al. **Am J Epidemiol** 1999 Jan 15;149(2):177–85

Bilateral zonular cataract associated with the mitochondrial cytopathy of Pearson syndrome [letter; comment] Cruysberg JR. **Am J Ophthalmol** 1999 Feb;127(2):243–4. Comment on: Am J Ophthalmol 1998 Feb;125(2):260–1.

Otological manifestations of CHARGE association. Dhooge I, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):935–41

Pre- and postnatal growth retardation, scaling skin, moderate mental retardation and quadrispasticity, hypospadias grade 2 and hydro-uretero nephrosis, postaxial polydactyly. A distinct MCA/MR syndrome? Fryns JP, et al. **Clin Dysmorphol** 1998 Oct;7(4):275–7

Adolescent nonfunctioning pituitary adenoma with short stature. Tamura T, et al. **Endocr J** 1998 Apr;45 Suppl:S179–81

Simpson-Golabi-Behmel syndrome and attention deficit hyperactivity disorder in two brothers [letter] Savarirayan R, et al. **J Med Genet** 1999 Jul;36(7):574–6

Severity and timing of stunting in the first two years of life affect performance on cognitive tests in late childhood. Mendez MA, et al. **J Nutr** 1999 Aug;129(8):1555–62

Shwachman's syndrome: pathomorphosis and long-term outcome. Cipolli M, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):265–72

Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. Okada T, et al. **Pediatr Int** 1999 Feb;41(1):90–3

Melanocytic nevi in children treated with growth hormone. Wyatt D. **Pediatries** 1999 Oct;104(4 Pt 2):1045–50

[Cerebral anomalies associated with growth hormone insufficiency in children: major markers for diagnosis?] Arifa N, et al. **Arch Pediatr** 1999 Jan;6(1):14–21 (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature. Clayton PE, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):275–83 (44 ref.)

[Development of double-chambered right ventricle after surgical closure of a ventricular septal defect] Massin M. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):579–81 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Secular changes in anthropometric data in cystic fibrosis patients. Laursen EM, et al. **Acta Paediatr** 1999 Feb; 88(2):169–74

Growth of prepubertal children with juvenile chronic arthritis. Saha MT, et al. **Acta Paediatr** 1999 Jul;88(7):724–8

Tumors and nontumors in Sotos syndrome [letter] Cohen MM Jr. **Am J Med Genet** 1999 May 21;84(2):173–5

Metaphyseal growth arrest lines in psychosocial short stature. Khadilkar VV, et al. **Arch Dis Child** 1998 Sep;79(3):260–2

Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency. Mitchell H, et al. **Arch Dis Child** 1999 May; 80(5):443–7

Growth monitoring: testing the new guidelines. Mulligan J, et al. **Arch Dis Child** 1998 Oct;79(4):318–22

The strengths and limitations of parental heights as a predictor of attained height. Wright CM, et al. **Arch Dis Child** 1999 Sep;81(3):257–60

Changing practice in growth monitoring [editorial] Voss LD. **BMJ** 1999 Feb 6;318(7180):344–5

Relationship between serum and urinary insulin-like growth factor-I through childhood and adolescence: their use in the assessment of disordered growth. Hall CM, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):611-8

CHARGE association. Toriello HV. **Ear Nose Throat J** 1999 Jun;78(6):413 (4 ref.)

Percentile charts to determine the duration of child abuse by chronic malnutrition. Wehner F, et al. **Forensic Sci Int** 1999 Jun 28;102(2-3):173-80

The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans. Peino R, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:101-5 (38 ref.)

Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27-28 March 1998. Saggese G, et al. **Horm Res** 1998;50(6):320-40 (101 ref.)

Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency. Van den Broeck J, et al. **Horm Res** 1999;51(1):1-9 (74 ref.)

Growth charts suitable for evaluation of Indian children. Khadgawat R, et al. **Indian Pediatr** 1998 Sep;35(9):859-65

Ophthalmic findings in GAPO syndrome. Ilker SS, et al. **Jpn J Ophthalmol** 1999 Jan-Feb;43(1):48-52

Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Guzzaloni G, et al. **Minerva Endocrinol** 1998 Dec;23(4):99-104

Evidence that AEC syndrome and Bowen--Armstrong syndrome are variable expressions of the same disease. Zenteno JC, et al. **Pediatr Dermatol** 1999 Mar-Apr; 16(2):103-7

Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Carmi D, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1257-62

[Consensus 'diagnosis of short stature in children.' National Organization for Quality Assurance in Hospitals] de Muinck Keizer-Schrama SM. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2519-25 (8 ref.) (Eng. Abstr.) **(Dut)**

[Consensus 'Diagnosis of short stature in children' (letter)] Van Buuren S, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24; 143(30):1585-6 **(Dut)**

[Cerebral anomalies associated with growth hormone insufficiency in children: major markers for diagnosis?] Arifa N, et al. **Arch Pediatr** 1999 Jan;6(1):14-21 (Eng. Abstr.) **(Fre)**

[Height-weight growth retardation. Diagnostic trends] Brauner R. **Rev Prat** 1999 Mar 1;49(5):555-60 **(Fre)**

[Primary care population screening for growth] de la Puente ML, et al. **Aten Primaria** 1999 Apr 15;23(6):346-51 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Quality of life of young adults with idiopathic short stature: effect of growth hormone treatment. Dutch Growth Hormone Working Group. Rekers-Mombarg LT, et al. **Acta Paediatr** 1998 Aug;87(8):865-70

Effect of growth hormone (GH) during puberty in GH-deficient children: preliminary results from an ongoing randomized trial with different dose regimens. Albertsson Wikland K, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):80-4

Serum levels of insulin-like growth factor binding proteins in Ecuadorean children with growth hormone insensitivity. Burren CP, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):185-91; discussion 192

Final height in idiopathic growth hormone deficiency: the KIGS experience. KIGS International Board. Cutfield W, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):72-5

Final height of growth hormone-treated patients with growth hormone deficiency: the North American experience. Hintz RL. **Acta Paediatr Suppl** 1999 Feb; 88(428):70-1

Growth hormone insensitivity: our current understanding and future directions. Rosenfeld RG. **Acta Paediatr Suppl** 1999 Feb;88(428):209-10

Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children. Schwarze CP, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):200-8

Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis. Simon D, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):100-5

When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue. Tanaka T, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):85-8

Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. GHIS Collaborative Group. Underwood LE, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):182-4

High-dose growth hormone (GH) treatment in prepubertal GH-deficient children. Yokoya S, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):76-9

Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development. Annerén G, et al. **Arch Dis Child** 1999 Apr; 80(4):334-8

Metacarpal index in short stature before and during growth hormone treatment. Bettendorf M, et al. **Arch Dis Child** 1998 Aug;79(2):165-8

Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Lanes R, et al. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):197-202

Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Seminara S, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):125-30

Growth hormone therapy in children in Canada: what have we learned in the past decade from an unlimited supply of growth hormone? [editorial; comment] Dean H. **Clin Invest Med** 1999 Apr;22(2):60-2. Comment on: Clin Invest Med 1999 Apr;22(2):53-9.

Growth hormone therapy for non-growth hormone-deficient children with short stature. Guyda HJ. **Curr Opin Pediatr** 1998 Aug;10(4):416-21 (47 ref.)

Changes in levels of serum and urinary collagen-related substances in growth hormone deficient children following discontinuation of growth hormone therapy. Kuno T, et al. **Endocr J** 1998 Apr;45 Suppl:S151-3

GH and zinc treatments for short stature caused by steroid treatments in a young patient with autoimmune hepatitis (type 1). Mori Y, et al. **Endocr J** 1998 Apr;45 Suppl:S163-5

Changes in body composition and leptin levels during growth hormone (GH) treatment in short children with various GH secretory capacities. Matsuoka H, et al. **Eur J Endocrinol** 1999 Jan;140(1):35-42

Growth hormone secretagogues as therapeutic agents. Svensson J. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:107-9 (26 ref.)

Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hardin DS, et al. **Horm Metab Res** 1998 Oct;30(10):636-41

Weight relative to height before and during growth hormone therapy in prepubertal children. Kaplowitz PB, et al. **Horm Metab Res** 1998 Sep;30(9):565-9

Standardization of Growth Hormone Measurement, Evidence-Based Medicine. Proceedings of the 3rd KIGS/KIMS Expert Meeting on Growth and Growth Disorders. Sorrento, Italy, November 19-20, 1998. **Horm Res** 1999;51 Suppl 1:1-88

What observational studies can offer decision makers. Black N. **Horm Res** 1999;51 Suppl 1:44-9

Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature. Finkelstein BS, et al. **Horm Res** 1999;51 Suppl 1:67-72

Effects of recombinant human growth hormone on height and skeletal maturation in growth hormone-deficient children with and without severe pretreatment bone age delay. Frindik JP, et al. **Horm Res** 1999;51(1):15-9

Towards better decision making in growth hormone therapy. Pliskin JS. **Horm Res** 1999;51 Suppl 1:30-5

KIGS and KIMS as tools for evidence-based medicine. Ranke MB, et al. **Horm Res** 1999;51 Suppl 1:83-6

Catch-up growth after childhood-onset substitution in primary hypothyroidism: is it a guide towards optimal growth hormone treatment in idiopathic growth hormone deficiency? Ranke MB, et al. **Horm Res** 1998;50(5):264-70

Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Ranke MB, et al. **Horm Res** 1999; 51(3):128-34

Growth hormone treatment of Russell-Silver syndrome. Stanhope R, et al. **Horm Res** 1998;49 Suppl 2:37-40 (24 ref.)

Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Haffner D, et al. **J Am Soc Nephrol** 1998 Oct; 9(10):1899-907

Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy. Barreca A, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3534-41

Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. de Zegher F, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1558-61

Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal. Leger J, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3512-6

Insulin action in growth hormone-deficient and age-matched control rats: effect of growth hormone treatment. Daugaard JR, et al. **J Endocrinol** 1999 Jan;160(1):127-35

Can growth hormone treatment in boys without growth hormone deficiency impair testicular function? [see comments] Bertelloni S, et al. **J Pediatr** 1999 Sep; 135(3):367-70. Comment in: J Pediatr 1999 Sep;135(3):278-9.

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278-9 (11 ref.). Comment on: J Pediatr 1999 Sep;135(3):367-70.

Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. Rosenbloom AL. **J Pediatr** 1999 Sep;135(3):280-9 (45 ref.)

Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. Cavallo L, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:845-9

One-year treatment with recombinant human growth hormone of children with meningomyelocele and growth hormone deficiency: a comparison of supine length and arm span. Hochhaus F, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):153-9

New GH secretagogues and potential usefulness in thalassemia. Karydis I, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:857-62 (60 ref.)

Acute metabolic effects of human growth hormone on 15N-nitrogen balance in patients with thalassaemia as compared to patients with other types of short stature. Zachmann M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:851-6 (30 ref.)

Failure of IGF-I infusion to promote growth in Zn deficient hypophysectomized rats. Cha MC, et al. **J Trace Elem Med Biol** 1998 Nov;12(3):141-7

Growth hormone therapy in adults and children. Vance ML, et al. **N Engl J Med** 1999 Oct 14;341(16):1206-16 (99 ref.)

Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. Okada T, et al. **Pediatr Int** 1999 Feb;41(1):90-3

Effects of growth hormone in short children after renal transplantation. French Society of Pediatric Nephrology. Guest G, et al. **Pediatr Nephrol** 1998 Aug;12(6):437-46

Impact of growth hormone treatment on a Belgian population of short children with renal allografts. Janssen F, et al. **Pediatr Transplant** 1997 Nov;1(2):190-6

National Cooperative Growth Study: Guidance in Growth. Proceedings of the National Cooperative Growth Study 12th Annual Investigators Meeting. New Orleans, Louisiana, USA. October 8-11, 1998. **Pediatrics** 1999 Oct; 104(4 Pt 2):999-1049

Growth hormone stimulation test results as predictors of recombinant human growth hormone treatment outcomes: preliminary analysis of the national cooperative growth study database. Bright GM, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1028-31

Acid-base homeostasis in children with growth hormone deficiency. Glaser NS, et al. **Pediatrics** 1998 Dec; 102(6):1407-14

Regular monitoring of bone age is useful in children treated with growth hormone. Kaufman FR, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1039-42

Analysis of bone age data from national cooperative growth study substudy VII. Kemp SF, et al. **Pediatrics** 1999 Oct; 104(4 Pt 2):1031-6

Regular monitoring of bone age is not useful in children treated with growth hormone. Wilson DM. **Pediatrics** 1999 Oct;104(4 Pt 2):1036-9

Long-term experience with growth hormone treatment in children with chronic renal failure. Schaefer F, et al. **Perit Dial Int** 1999;19 Suppl 2:S467-72 (35 ref.)

Who benefits from growth hormone? Bareille P, et al. **Practitioner** 1998 Jun;242(1587):486-8 (11 ref.)

[Consensus 'diagnosis of short stature in children.' National Organization for Quality Assurance in Hospitals] de Muinck Keizer-Schrama SM. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2519-25 (8 ref.) (Eng. Abstr.) **(Dut)**

[Hormonal treatment of constitutionally tall children (letter; comment)] Drenth JJ. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1290. Comment on: Ned Tijdschr Geneeskd 1998 Mar 28;142(13):693-7. **(Dut)**

[New conditions for the use of growth hormone and outcomes for different indications] Rochiccioli P, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):296-9 (8 ref.) **(Fre)**

[New growth hormone secretagogues: from physiology to the first therapeutic applications] Ahnfelt-Rønne I, et al. **Arch Pediatr** 1998;5 Suppl 4:390S-396S (35 ref.) (Eng. Abstr.) **(Fre)**

[Growth hormone deficiency. Treatment with growth hormone and body composition] Antoniazzi F, et al. **Arch Pediatr** 1998;5 Suppl 4:327S-331S (Eng. Abstr.) **(Fre)**

[Does the growth hormone pharmacokinetic profile help to predict the treatment response?] Bozzola M, et al. **Arch Pediatr** 1998;5 Suppl 4:322S-326S (Eng. Abstr.) **(Fre)**

[Growth hormone treatment of children with short stature secondary to intrauterine growth retardation] Chaussain JL, et al. **Arch Pediatr** 1998;5 Suppl 4:345S-347S (Eng. Abstr.) **(Fre)**

[Hypopituitarism during the first year of life. A collaborative Italian study] De Luca Ff2p4, et al. **Arch Pediatr** 1998;5 Suppl 4:313S-317S (Eng. Abstr.) **(Fre)**

[Catch-up growth in growth hormone deficit children treated with GH since the first year of life] Huet F, et al. **Arch Pediatr** 1998;5 Suppl 4:318S-321S (Eng. Abstr.) **(Fre)**

[Critical evaluation of growth hormone treatment in children with chronic renal insufficiency] Perfumo F, et al. **Arch Pediatr** 1998;5 Suppl 4:354S-359S (39 ref.) (Eng. Abstr.) **(Fre)**

[Growth hormone treatment of familial hypophosphatemic rickets] Saggese G, et al. **Arch Pediatr** 1998;5 Suppl 4:360S-363S (Eng. Abstr.) **(Fre)**

[Infants born with development disorders. What about the long-term statural development? What are the therapeutic possibilities?] Heinrichs C. **Rev Med Brux** 1998 Dec; 19(6):471-3 (Eng. Abstr.) **(Fre)**

[Growth hormone in adolescents and in young adults] Saggese G, et al. **Minerva Pediatr** 1998 Jun;50(6):197-201 (34 ref.) **(Ita)**

EPIDEMIOLOGY

Natural history of growth hormone receptor deficiency. Rosenbloom AL, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):153-6; discussion 157 (19 ref.)

Height and weight measurements of Ibadan school children. Walker MB, et al. **Afr J Med Med Sci** 1996 Sep;25(3):273-6

Correlates of prenatal visceromegaly. Barr M Jr. **Am J Med Genet** 1998 Oct 2;79(4):249-52

Risk of linear growth retardation during the first two years of life: a new approach. Lei DL, et al. **Eur J Clin Nutr** 1999 Jun;53(6):456-60

Growth of children according to maternal and child HIV, immunological and disease characteristics: a prospective cohort study in Kinshasa, Democratic Republic of Congo. Bailey RC, et al. **Int J Epidemiol** 1999 Jun;28(3):532-40

Early linear growth retardation in Chongqing, China. Liu YX, et al. **J Paediatr Child Health** 1999 Jun;35(3):272-7

An aetiological profile of short stature in the Indian subcontinent. Zargar AH, et al. **J Paediatr Child Health** 1998 Dec;34(6):571-6

Risk analysis of poor health and growth failure of children in the central highlands of Guatemala. Immink MD, et al. **Soc Sci Med** 1999 Apr;48(8):997-1009

[Primary care population screening for growth] de la Puente ML, et al. **Aten Primaria** 1999 Apr 15;23(6):346-51 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Differences in growth among remote and town-dwelling aboriginal children in the Kimberley region of Western Australia. Rousham EK, et al. **Aust N Z J Public Health** 1998 Oct;22(6):690-4

ETIOLOGY

Secular changes in anthropometric data in cystic fibrosis patients. Laursen EM, et al. **Acta Paediatr** 1999 Feb; 88(2):169-74

Growth in Crohn's disease. Savage MO, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):89-92 (15 ref.)

Growth retardation in chronic diseases: possible mechanisms. Underwood LE. **Acta Paediatr Suppl** 1999 Feb; 88(428):93-6 (10 ref.)

Height and weight measurements of Ibadan school children. Walker MB, et al. **Afr J Med Med Sci** 1996 Sep;25(3):273-6

Prenatal alcohol use and offspring size at 10 years of age. Day NL, et al. **Alcohol Clin Exp Res** 1999 May;23(5):863-9

Screening for inborn errors of metabolism in children [letter; comment] Spencer A. **Am Fam Physician** 1999 Feb 15; 59(4):784, 786. Comment on: Am Fam Physician 1998 Jul;58(1):153-8.

Need to consider other causes of poor growth in Gambian children [letter] Bagott M. **Arch Dis Child** 1999 Sep; 81(3):279

Less diarrhoea but no change in growth: 15 years' data from three Gambian villages [letter] Moy R, et al. **Arch Dis Child** 1999 Sep;81(3):278-9

Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. Varan B, et al. **Arch Dis Child** 1999 Jul; 81(1):49-52

Growth disturbances after injuries of the proximal tibial epiphysis. Gautier E, et al. **Arch Orthop Trauma Surg** 1998; 118(1-2):37-41

Early diagnosis of cystic fibrosis can improve children's growth [letter; comment] Farrell PM. **BMJ** 1998 Oct 10; 317(7164):1017. Comment on: BMJ 1998 Feb 7;316(7129):404-5.

Rathke's cleft cyst as a cause of growth hormone deficiency and micropenis. Setian N, et al. **Childs Nerv Syst** 1999 May; 15(5):271-3

A 5-year-old boy with hepatomegaly and linear growth delay. Adamenko RS, et al. **Curr Opin Pediatr** 1998 Oct; 10(5):523-6

Intrauterine growth retardation and long-term effects on growth. Botero D, et al. **Curr Opin Pediatr** 1999 Aug; 11(4):340-7 (66 ref.)

Endocrine and metabolism [editorial] Root A. **Curr Opin Pediatr** 1998 Aug;10(4):411-5 (18 ref.)

Growth hormone treatment in a child with Williams-Beuren syndrome: a case report. Kuijpers GM, et al. **Eur J Pediatr** 1999 Jun;158(6):451-4

Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hardin DS, et al. **Horm Metab Res** 1998 Oct;30(10):636-41

Perianal disease, growth failure, and quality of life. Colletti RB. **Inflamm Bowel Dis** 1998 Aug;4(3):214-6 (35 ref.)

Isolated partial growth hormone deficient short stature with syringomyelia not associated with birth injury. Koga T, et al. **Intern Med** 1998 Aug;37(8):674-7

Growth plate cartilage formation and resorption are differentially depressed in growth retarded uremic rats. Cobo A, et al. **J Am Soc Nephrol** 1999 May;10(5):971-9

Maternal smoking during pregnancy, growth, and bone mass in prepubertal children. Jones G, et al. **J Bone Miner Res** 1999 Jan;14(1):146-51

Failure of exogenous IGF-I to restore normal growth in rats submitted to dietary zinc deprivation. Ninh NX, et al. **J Endocrinol** 1998 Nov;159(2):211-7

Physeal growth arrest of the distal phalanx of the thumb in an adolescent pianist: a case report [letter; comment] Kasdan ML. **J Hand Surg [Am]** 1998 Sep;23(5):956-7. Comment on: J Hand Surg [Am] 1998 May;23(3):532-5.

Symposium: Causes and Etiology of Stunting. Introduction. Frongillo EA Jr. **J Nutr** 1999 Feb;129(2S Suppl):529S-530S (21 ref.)

Giardia intestinalis is unlikely to be a major cause of the poor growth of rural Gambian infants. Lunn PG, et al. **J Nutr** 1999 Apr;129(4):872-7

Separate and joint effects of micronutrient deficiencies on linear growth. Rosado JL. **J Nutr** 1999 Feb;129(2S Suppl):531S-533S (25 ref.)

Burden of infection on growth failure. Stephensen CB. **J Nutr** 1999 Feb;129(2S Suppl):534S-538S (31 ref.)

Magnetic resonance imaging evaluation of the pituitary gland and hypothalamus in thalassaemic children with elevated serum ferritin levels. Lau KY, et al. **J Paediatr Child Health** 1998 Oct;34(5):463-6

Growth failure in cystic fibrosis. McNaughton SA, et al. **J Paediatr Child Health** 1999 Feb;35(1):86-92

The effect of adenotonsillectomy on serum insulin-like growth factor-I and growth in children with obstructive sleep apnea syndrome. Bar A, et al. **J Pediatr** 1999 Jul; 135(1):76-80

Effects of puberty on bone age maturation in a girl after medulloblastoma therapy. Marx M, et al. **J Pediatr Adolesc Gynecol** 1999 May;12(2):62-6

New GH secretagogues and potential usefulness in thalassemia. Karydis I, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:857-62 (60 ref.)

An explanation for growth impairment in chronic inflammation. Otley AR, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):350-1

Growth arrest resulting from unicameral bone cyst [letter; comment] Crawford AH. **J Pediatr Orthop** 1998 Nov-Dec; 18(6):824-5. Comment on: J Pediatr Orthop 1998 Mar-Apr;18(2):198-201.

Insulinlike growth factor 1 and insulinlike growth factor 3: indices of intestinal failure in children. Barksdale EM Jr, et al. **J Pediatr Surg** 1999 May;34(5):655-61; discussion 661-2

Intrauterine growth acceleration in the case of a severe form of mucopolysaccharidosis type VII. Tokieda K, et al. **J Perinat Med** 1998;26(3):235-9 (12 ref.)

Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: a comparative study. Soliman AT, et al. **J Trop Pediatr** 1999 Feb;45(1):23-30

Assessment of stature in children with orofacial clefting. Lipman TH, et al. **MCN Am J Matern Child Nurs** 1999 Sep-Oct;24(5):252-6

Delay of catch-up growth in very low birthweight infants. Kuschel CA, et al. **N Z Med J** 1999 Mar 26;112(1084):94-6

Growth failure in inflammatory bowel disease [editorial] McCartney S, et al. **Nutrition** 1999 Feb;15(2):169-71 (24 ref.)

Growth hormone deficiency following radiotherapy for orbital and parameningeal sarcomas. Goddard AG, et al. **Pediatr Hematol Oncol** 1999 Jan-Feb;16(1):23-33

Is endocrinological assessment and follow-up of children after bone marrow transplantation necessary? How, and for how long? [editorial; comment] Cohen A. **Pediatr Transplant** 1999 Feb;3(1):1-4 (23 ref.). Comment on: Pediatr Transplant 1999 Feb;3(1):38-44. Comment on: Pediatr Transplant 1999 Feb;3(1):60-6.

Endocrine complications of bone marrow transplantation in children [see comments] Legault L, et al. **Pediatr Transplant** 1999 Feb;3(1):60-6. Comment in: Pediatr Transplant 1999 Feb;3(1):1-4.

Growth failure after treatment of pediatric brain tumors. Clarson CL, et al. **Pediatrics** 1999 Mar;103(3):E37

Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127-43 (67 ref.)

Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention. Jacobson MS, et al. **Prev Med** 1998 Nov-Dec;27(6):775-80

Effect of prenatal gamma irradiation during the late fetal period on the postnatal development of the mouse. Hossain M, et al. **Teratology** 1999 Mar;59(3):133-8

[Radiodiagnosis and irradiated pregnancies] Foulquier JN, et al. **Ann Radiol (Paris)** 1997;40(4):225-36 (Eng. Abstr.) **(Fre)**

[Physiopathology of the somatotropin axis in chronic renal insufficiency] Cabrol S, et al. **Arch Pediatr** 1998;5 Suppl 4:348S-353S (44 ref.) (Eng. Abstr.) **(Fre)**

[Growth hormone treatment of children with short stature secondary to intrauterine growth retardation] Chaussain JL, et al. **Arch Pediatr** 1998;5 Suppl 4:345S-347S (Eng. Abstr.) **(Fre)**

[Severe anorexia in infants from Reunion Island: eight cases of the same disease? (letter)] Graber D, et al. **Arch Pediatr** 1998 Jan;5(1):90-2 **(Fre)**

[Critical evaluation of growth hormone treatment in children with chronic renal insufficiency] Perfumo F, et al. **Arch Pediatr** 1998;5 Suppl 4:354S-359S (39 ref.) (Eng. Abstr.) **(Fre)**

[Growth deficiency and renal tubular acidosis. The possible etiopathogenic mechanisms] Di Pietro A, et al. **Pediatr Med Chir** 1998 Jul-Aug;20(4):261-2 (Eng. Abstr.) **(Ita)**

GENETICS

Natural history of growth hormone receptor deficiency. Rosenbloom AL, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):153-6; discussion 157 (19 ref.)

Human growth disorders: molecular genetics of the growth hormone-insulin-like growth factor I axis. Rotwein P. **Acta Paediatr Suppl** 1999 Feb;88(428):148-51; discussion 152 (32 ref.)

Partial growth hormone insensitivity--idiopathic short stature is not always idiopathic. Saenger P. **Acta Paediatr Suppl** 1999 Feb;88(428):194-8 (20 ref.)

Relationship between phenotype and genotype in growth hormone insensitivity syndrome. Woods KA, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):158-62; discussion 163 (13 ref.)

Growth disorders caused by genetic defects in the growth hormone pathway. Cogan JD, et al. **Adv Pediatr** 1998; 45:337-61 (46 ref.)

X chromosome inactivation in carriers of Barth syndrome. Orstavik KH, et al. **Am J Hum Genet** 1998 Nov; 63(5):1457-63

Identical twins discordant for Sotos syndrome. Brown WT, et al. **Am J Med Genet** 1998 Oct 2;79(4):329-33

Acrodysplasia, severe ossification abnormalities with short stature, and fibular hypoplasia. Castriota-Scanderbeg A, et al. **Am J Med Genet** 1999 May 7;84(1):68-73

The Meier-Gorlin syndrome, or ear-patella-short stature syndrome, in sibs. Loeys BL, et al. **Am J Med Genet** 1999 May 7;84(1):61-7

Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Neri G, et al. **Am J Med Genet** 1998 Oct 2;79(4):279-83 (27 ref.)

Deletion of 8.5 Mb, including the FMR1 gene, in a male with the fragile X syndrome phenotype and overgrowth. Parvari R, et al. **Am J Med Genet** 1999 Apr 2;83(4):302-7

Deletion of the pseudoautosomal region in a male with a unique Y;13 translocation and short stature. Shanske A, et al. **Am J Med Genet** 1999 Jan 1;82(1):34-9

Mapping of a gene (MRXS9) for X-linked mental retardation, microcephaly, and variably short stature to Xq12-q21.31. Shrimpton AE, et al. **Am J Med Genet** 1999 May 28; 84(3):293-9

Microcephaly-lymphedema syndrome: report of a family with short stature as additional manifestation. Strenge S, et al. **Am J Med Genet** 1998 Dec 28;80(5):506-9

Mutchinick syndrome in a Japanese girl. Tonoki H, et al. **Am J Med Genet** 1999 Mar 12;83(2):96-9

Congenital heart defects in Sotos syndrome [letter] Tsukahara M, et al. **Am J Med Genet** 1999 May 21;84(2):172

Targeted disruption of the murine Nhe1 locus induces ataxia, growth retardation, and seizures. Bell SM, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C788-95

Biparental expression of IGFBP1 and IGFBP3 renders their involvement in the etiology of Silver-Russell syndrome unlikely. Eggermann K, et al. **Ann Genet** 1999;42(2):117-21

Characterization of a partial trisomy 16q with FISH. Report of a patient and review of the literature. Engelen JJ, et al. **Ann Genet** 1999;42(2):101-4 (17 ref.)

A syndrome of congenital ichthyosis, hypogonadism, small stature, facial dysmorphism, scoliosis and myogenic dystrophy. Stoll C, et al. **Ann Genet** 1999;42(1):45-50

A patient with 13q-syndrome with mild mental retardation and with growth retardation. Stoll C, et al. **Ann Genet** 1998; 41(4):209-12 (11 ref.)

Growth curves of children with Down syndrome. Toledo C, et al. **Ann Genet** 1999;42(2):81-90

A case of Costello syndrome with endocrine features. Yetkin I, et al. **Ann Genet** 1998;41(3):157-60

Infertility in a line of mice with the high growth mutation is due to luteal insufficiency resulting from disruption at the hypothalamic-pituitary axis. Cargill SL, et al. **Biol Reprod** 1999 Jul;61(1):283-7

Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. de Boer J, et al. **Cancer Res** 1999 Jul 15;59(14):3489-94

Two sisters with prenatal growth failure, disproportionate short stature, and feeding difficulties. Cameron FM, et al. **Clin Dysmorphol** 1998 Oct;7(4):269-74

Polymorphic variants within the homeobox gene MSX1: a candidate gene for developmental disorders. Hollway GE, et al. **Clin Genet** 1998 Aug;54(2):152-4

Mosaic supernumerary marker chromosome identified as a der(3) by FISH [letter] Rothemund H, et al. **Clin Genet** 1998 Dec;54(6):526-7

Transcriptional regulation by cyclic AMP is essential for development, reproduction and survival: lessons from the transgenic mice. Groussin L, et al. **Eur J Endocrinol** 1998 Dec;139(6):571-2

Evidence against a major role of PEG1/MEST in Silver-Russell syndrome. Riesewijk AM, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):114-20

A Japanese family with autosomal dominant growth hormone deficiency. Saitoh H, et al. **Eur J Pediatr** 1999 Aug; 158(8):624-7

Comparative analysis of a novel gene from the

Wolf-Hirschhorn/Pitt-Rogers-Danks syndrome critical region. Wright TJ, et al. **Genomics** 1999 Jul 15;59(2):203-12
Genetics of Silver-Russell syndrome. Wakeling EL, et al. **Horm Res** 1998;49 Suppl 2:32-6 (28 ref.)
Screening for mutations in the promoter and the coding region of the IGFBP1 and IGFBP3 genes in Silver-Russell syndrome patients. Eggermann K, et al. **Hum Hered** 1999 Jun;49(3):123-8
Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. Cano-Gauci DF, et al. **J Cell Biol** 1999 Jul 12;146(1):255-64
Cloning and expression of a novel chicken sulfotransferase cDNA regulated by GH. Cao H, et al. **J Endocrinol** 1999 Mar;160(3):491-500
Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. Miyake H, et al. **J Hum Genet** 1999;44(1):26-9
A clinical and molecular study of a patient with Simpson-Golabi-Behmel syndrome. Okamoto N, et al. **J Hum Genet** 1999;44(5):327-9
Two male patients with ring Y: definition of an interval in Yq contributing to Turner syndrome. Tzancheva M, et al. **J Med Genet** 1999 Jul;36(7):549-53
The D152H mutation found in growth hormone insensitivity syndrome impairs expression and function of human growth hormone receptor but is silent in rat receptor. Esposito N, et al. **J Mol Endocrinol** 1998 Aug;21(1):61-72
X-linked cardioskeletal myopathy and neutropenia (Barth syndrome)-MIM 302060 [editorial; comment] Barth PG, et al. **J Pediatr** 1999 Sep;135(3):273-6 (19 ref.). Comment on: J Pediatr 1999 Sep;135(3):311-5.
Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. Rosenbloom AL. **J Pediatr** 1999 Sep;135(3):280-9 (45 ref.)
Ophthalmologic findings in the Dubowitz syndrome. Rodden WS, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jan-Feb; 36(1):37-9
Skeletal dysplasias, growth retardation, reduced postnatal survival, and impaired fertility in mice lacking the SNF2/SWI2 family member ETL1. Schoor M, et al. **Mech Dev** 1999 Jul;85(1-2):73-83
Strain-dependent myeloid hyperplasia, growth deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene. LeCouter JE, et al. **Mol Cell Biol** 1998 Dec; 18(12):7455-65
Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II. Litingtung Y, et al. **Mol Gen Genet** 1999 Feb;261(1):100-5
Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Elchebly M, et al. **Nat Genet** 1999 Mar; 21(3):330-3
Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor. Rossi J, et al. **Neuron** 1999 Feb;22(2):243-52
Retinitis pigmentosa, mental retardation, marked short stature, and brachydactyly in two sibs. Lorda-Sanchez I, et al. **Ophthalmic Genet** 1999 Jun;20(2):127-31
Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. Bank RA, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1054-8
Short stature in a 46,XX male adolescent. Wu CJ, et al. **South Med J** 1999 Sep;92(9):921-3
[Growth hormone treatment of familial hypophosphatemic rickets] Saggese G, et al. **Arch Pediatr** 1998;5 Suppl 4:360S-363S (Eng. Abstr.) **(Fre)**
[Phenotype-genotype relations in growth hormone insensitivity] Savage MO, et al. **Arch Pediatr** 1998;5 Suppl 4:364S-370S (Eng. Abstr.) **(Fre)**

HISTORY

Vignettes from the history of overgrowth and related syndromes. Beckwith JB. **Am J Med Genet** 1998 Oct 2; 79(4):238-48

IMMUNOLOGY

[Cytokines and growth delay during chronic inflammatory diseases in children (editorial)] De Benedetti F, et al. **Arch Pediatr** 1999 May;6(5):499-502 **(Fre)**

METABOLISM

Overgrowth syndromes and the regulation of signaling complexes by proteoglycans. Selleck SB. **Am J Hum Genet** 1999 Feb;64(2):372-7 (30 ref.)
Metabolic effects of discontinuing growth hormone treatment. Cowan FJ, et al. **Arch Dis Child** 1999 Jun; 80(6):517-23
Insulin induced hypoglycaemia: comparison of glucose and glycerol concentrations in plasma and microdialysate from subcutaneous adipose tissue. Kamel A, et al. **Arch Dis Child** 1999 Jan;80(1):42-5
Changes in levels of serum and urinary collagen-related substances in growth hormone deficient children following discontinuation of growth hormone therapy. Kuno T, et al. **Endocr J** 1998 Apr;45 Suppl:S151-3
Acute metabolic effects of human growth hormone on 15N-nitrogen balance in patients with thalassaemia as compared to patients with other types of short stature. Zachmann M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:851-6 (30 ref.)
Hypercalciuria and urolithiasis in a case of Costello syndrome. Assadi FK, et al. **Pediatr Nephrol** 1999 Jan; 13(1):57-9
Insulin, branched-chain amino acids, and growth failure in uremia. Mak RH. **Pediatr Nephrol** 1998 Oct;12(8):637-42

MICROBIOLOGY

Helicobacter pylori infection and cytotoxic antigen associated gene "A" status in short children. Cacciari E, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr; 12(2):197-201
The rate of Helicobacter pylori infection in children with growth retardation [letter] Sauvé-Martin H, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):354-5

MORTALITY

Catch-up growth in childhood and death from coronary heart disease: longitudinal study. Eriksson JG, et al. **BMJ** 1999 Feb 13;318(7181):427-31

PATHOLOGY

Correlates of prenatal visceromegaly. Barr M Jr. **Am J Med Genet** 1998 Oct 2;79(4):249-52
Bladder carcinoma in Costello syndrome: report on a patient born to consanguineous parents and review. Franceschini P, et al. **Am J Med Genet** 1999 Sep 10;86(2):174-9 (26 ref.)
Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Neri G, et al. **Am J Med Genet** 1998 Oct 2;79(4):279-83 (27 ref.)
Nonsyndromal overgrowth in males with mild psychomotor delay. Neri G, et al. **Am J Med Genet** 1998 Oct 2; 79(4):291-3
Congenital heart defects in Sotos syndrome. Noreau DR, et al. **Am J Med Genet** 1998 Oct 2;79(4):327-8
Short stature, brachydactyly, nail dysplasia, and mental retardation: further observation of the Tonoki syndrome. Sorge G, et al. **Am J Med Genet** 1998 Dec 4;80(4):403-5
Organ growth in Rett syndrome: a postmortem examination analysis. Armstrong DD, et al. **Pediatr Neurol** 1999 Feb; 20(2):125-9

PHYSIOPATHOLOGY

Growth failure and pituitary function in CHARGE and VATER associations. Khadilkar VV, et al. **Arch Dis Child** 1999 Feb;80(2):167-70
Visual-proprioceptive mapping in children with developmental coordination disorder. Mon-Williams MA, et al. **Dev Med Child Neurol** 1999 Apr;41(4):247-54
Linear growth velocity in children with cerebral palsy. Samson-Fang L, et al. **Dev Med Child Neurol** 1998 Oct; 40(10):689-92
Food consumption of young stunted and non-stunted children in rural Zambia. Hautvast JL, et al. **Eur J Clin Nutr** 1999 Jan;53(1):50-9
Effects of recombinant human growth hormone on height and skeletal maturation in growth hormone-deficient children with and without severe pretreatment bone age delay. Frindik JP, et al. **Horm Res** 1999;51(1):15-9
Growth plate cartilage formation and resorption are differentially depressed in growth retarded uremic rats. Cobo A, et al. **J Am Soc Nephrol** 1999 May;10(5):971-9
Filipino children exhibit catch-Up growth from age 2 to 12 years. Adair LS. **J Nutr** 1999 Jun;129(6):1140-8
Growth deficiency and malnutrition in Bloom syndrome. Keller C, et al. **J Pediatr** 1999 Apr;134(4):472-9
Sleep, respiratory rate, and growth hormone in chronic neonatal lung disease. Fitzgerald D, et al. **Pediatr Pulmonol** 1998 Oct;26(4):241-9
Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Frindik JP, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1000-4
Acid-base homeostasis in children with growth hormone deficiency. Glaser NS, et al. **Pediatrics** 1998 Dec; 102(6):1407-14
[Physiopathology of the somatotropin axis in chronic renal insufficiency] Cabrol S, et al. **Arch Pediatr** 1998;5 Suppl 4:348S-353S (44 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Is endocrinological assessment and follow-up of children after bone marrow transplantation necessary? How, and for how long? [editorial; comment] Cohen A. **Pediatr Transplant** 1999 Feb;3(1):1-4 (23 ref.). Comment on: Pediatr Transplant 1999 Feb;3(1):38-44. Comment on: Pediatr Transplant 1999 Feb;3(1):60-6.

PSYCHOLOGY

Quality of life of young adults with idiopathic short stature: effect of growth hormone treatment. Dutch Growth Hormone Working Group. Rekers-Mombarg LT, et al. **Acta Paediatr** 1998 Aug;87(8):865-70
Short children: height is not the only problem [comment] Stabler B, et al. **Acta Paediatr** 1999 Jun;88(6):588-9. Comment on: Acta Paediatr 1999 Jun;88(6):602-9.
Patient attitudes and preferences regarding treatment: GH therapy for childhood short stature. Finkelstein BS, et al. **Horm Res** 1999;51 Suppl 1:67-72
A further report on a case of Floating-Harbor Syndrome in a mother and daughter. Rosen AC, et al. **J Clin Exp Neuropsychol** 1998 Aug;20(4):483-95
Recognition of children with psychosocial short stature: a spectrum of presentation. Gohlke BC, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):509-17

RADIOGRAPHY

Familial growth hormone deficiency associated with MRI abnormalities. Hamilton J, et al. **Am J Med Genet** 1998 Nov 2;80(2):128-32
Regular monitoring of bone age is useful in children treated with growth hormone. Kaufman FR, et al. **Pediatrics** 1999 Oct;104(4 Pt 2):1039-42
Regular monitoring of bone age is not useful in children treated with growth hormone. Wilson DM. **Pediatrics** 1999 Oct;104(4 Pt 2):1036-9

THERAPY

Pharmacological manipulation of height: qualitative review of study populations and designs [see comments] Taback SP, et al. **Clin Invest Med** 1999 Apr;22(2):53-9 (68 ref.). Comment in: Clin Invest Med 1999 Apr;22(2):60-2.
Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the Availability of Recombinant Human Growth Hormone Workshop held in Pisa, Italy, 27-28 March 1998. Saggese G, et al. **Horm Res** 1998;50(6):320-40 (101 ref.)
Use of nonautologous microencapsulated fibroblasts in growth hormone gene therapy to improve growth of midget swine. Cheng WT, et al. **Hum Gene Ther** 1998 Sep 20;9(14):1995-2003
Growth and management of short stature in thalassaemia major. Theodoridis C, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:835-44
Factors affecting growth and strategies for treatment in children after renal transplantation. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):176-82 (37 ref.)
Issues in the transition from childhood to adult growth hormone therapy. Allen DB. **Pediatrics** 1999 Oct;104(4 Pt 2):1004-10
Nutritional aspects of neuromuscular diseases. McCrory MA, et al. **Phys Med Rehabil Clin N Am** 1998 Feb;9(1):127-43 (67 ref.)
[Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes] Kato M. **Hokkaido Igaku Zasshi** 1998 Nov;73(6):613-25 (Eng. Abstr.) **(Jpn)**

VETERINARY

Infectious stunting syndrome associated with disturbances of mineral metabolism and bone development in broiler chickens. Sályi G, et al. **Acta Vet Hung** 1999;47(3):361-78
The in vitro propagation of stunting syndrome agent. Ali A, et al. **Avian Dis** 1998 Oct-Dec;42(4):657-66

GROWTH FACTOR RECEPTORS see **RECEPTORS, GROWTH FACTOR**

GROWTH FACTORS see **GROWTH SUBSTANCES**

GROWTH HORMONE, HUMAN METHIONYL see **SOMATREM**

GROWTH HORMONE, PITUITARY see **SOMATOTROPIN**

GROWTH HORMONE RECEPTORS see **RECEPTORS, SOMATOTROPIN**

GROWTH HORMONE-RELEASING FACTOR see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH HORMONE-RELEASING FACTOR(1-29)AMIDE see **SERMORELIN**

GROWTH HORMONE-RELEASING FACTOR 44 see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH HORMONE-RELEASING HORMONE see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH HORMONES PITUITARY, RECOMBINANT see **SOMATOTROPINS, RECOMBINANT**

GROWTH INHIBITORS

Growth-inhibitory activities of benzofuran and chromene derivatives toward Tenebrio molitor. Carrizo R, et al. **J Nat Prod** 1998 Oct;61(10):1209-11
Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Rousseau D, et al. **Oncogene** 1999 Jul 29;18(30):4313-25
Inhibitors of cell growth. Introduction. Macieira-Coelho A. **Prog Mol Subcell Biol** 1998;20:1-9 (59 ref.)

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

GROWTH INHIBITORS

ADMINISTRATION & DOSAGE

Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Mross K, et al. **Ann Oncol** 1998 Dec;9(12):1323-30

Chronopharmacologic aspects of continuous AcSDKP infusion in mice. Li XM, et al. **Exp Hematol** 1999 Jan; 27(1):19-27

ADVERSE EFFECTS

Cardiotoxicity of the antiproliferative compound fluorouracil. Becker K, et al. **Drugs** 1999 Apr;57(4):475-84 (95 ref.)

ANALYSIS

Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. Hsu CD, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1267-70

Localization of leukemia inhibitory factor and its receptor in human placenta throughout pregnancy. Sharkey AM, et al. **Biol Reprod** 1999 Feb;60(2):355-64

Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Lane AH, et al. **Gynecol Oncol** 1999 Apr;73(1):51-5

Epidermal growth factor and leukemia inhibitory factor levels in follicular fluid. Association with in vitro fertilization outcome. Özörnek MH, et al. **J Reprod Med** 1999 Apr;44(4):367-9

Hepatocyte growth inhibitory factor derived from HTLV-I(+) T-cell line is identical to IL-6. Kawai Y, et al. **Leuk Res** 1999 May;23(5):489-97

ANTAGONISTS & INHIBITORS

Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Kleeff J, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):268-73

BIOSYNTHESIS

Interleukin-4 (IL-4), but not IL-10, regulates the synthesis of IL-6, IL-8 and leukemia inhibitory factor by human bone marrow stromal cells. Denizot Y, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):83-92

Effects of lipid mediators on the synthesis of leukaemia inhibitory factor and interleukin 6 by human bone marrow stromal cells. Denizot Y, et al. **Cytokine** 1998 Oct; 10(10):781-5

Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Oreal E, et al. **Dev Dyn** 1998 Aug;212(4):522-32

Thyroid hormone and follicle-stimulating hormone regulate Müllerian-inhibiting substance messenger ribonucleic acid expression in cultured neonatal rat Sertoli cells. Arambepola NK, et al. **Endocrinology** 1998 Nov; 139(11):4489-95

Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Guimbaud R, et al. **Eur Cytokine Netw** 1998 Dec;9(4):607-12

Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Fotsis T, et al. **Eur J Biochem** 1999 Aug;263(3):757-64

Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins. Voyle RB, et al. **Exp Cell Res** 1999 Jun 15;249(2):199-211

Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Penkowa M, et al. **Glia** 1999 Feb 15;25(4):343-57

Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53. Wang JA, et al. **Int J Radiat Biol** 1999 Mar;75(3):301-16

Leukemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxis. Zheng X, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):136-44

In vivo and in vitro regulation of thyroid leukemia inhibitory factor (LIF): marker of hypothyroidism. Ren SG, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2883-7

Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study. Gouin F, et al. **J Orthop Res** 1999 Mar;17(2):301-5

Expression of leukaemia inhibitory factor in skin of patients with amyotrophic lateral sclerosis [letter] Hu J, et al. **Lancet** 1999 Jun 19;353(9170):2126-7

PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells. Perletti GP, et al. **Oncogene** 1999 Feb 4;18(5):1251-6

Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Yan DH, et al. **Oncogene** 1999 Jan 21;18(3):807-11

Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Hasegawa M, et al. **Rheumatology (Oxford)** 1999 Jul; 38(7):612-7

BLOOD

Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Wierzbowska A, et al. **Br J Haematol** 1999 May;105(2):412-9

Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity. Viallard JF, et al. **Eur Cytokine Netw** 1999 Mar;10(1):17-24

Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. Rey RA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):627-31

Antimüllerian hormone in patients with hypogonadotropic hypogonadism. Young J, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2696-9

CHEMICAL SYNTHESIS

Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Spicer JA, et al. **Anticancer Drug Des** 1999 Jun;14(3):281-9

Synthesis and antiproliferative activity of N-acylaspartic acid dimethyl esters. Schlitzer M, et al. **Anticancer Res** 1999 May-Jun;19(3A):2117-20

CHEMISTRY

Evidence for a dynamic structure of human neuronal growth inhibitory factor and for major rearrangements of its metal-thiolate clusters. Faller P, et al. **Biochemistry** 1999 Aug 3;38(31):10158-67

Metal-thiolate clusters in the C-terminal domain of human neuronal growth inhibitory factor (GIF). Hasler DW, et al. **Biochemistry** 1998 Oct 20;37(42):14966-73

DEFICIENCY

Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor. Bugga L, et al. **J Neurobiol** 1998 Sep 15;36(4):509-24

GENETICS

Effect of long-term ethanol consumption on ability to produce cytokine-induced neutrophil chemoattractant-1 in the rat liver and its gender difference. Yamada S, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):61S-66S

Leukemia inhibitory factor (LIF) and LIF receptor in human lung. Distribution and regulation of LIF release. Knight DA, et al. **Am J Respir Cell Mol Biol** 1999 Apr; 20(4):834-41

Structural and functional analysis of the rat metallothionein III genomic locus. Chapman GA, et al. **Biochim Biophys Acta** 1999 Jun 9;1445(3):321-9

Changes in uterine expression of leukemia inhibitory factor during pregnancy in the Western spotted skunk. Hirzel DJ, et al. **Biol Reprod** 1999 Feb;60(2):484-92

Differential temporal expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR alpha, LIFR beta, IL-6R alpha and gp130) in injured peripheral nerves. Ito Y, et al. **Brain Res** 1998 May 18; 793(1-2):321-7

Regulatory elements of the leukaemia inhibitory factor (LIF) promoter in murine bone marrow stromal cells. Göllner G, et al. **Cytokine** 1999 Sep;11(9):656-63

Paracrine induction of stem cell renewal by LIF-deficient cells: a new ES cell regulatory pathway. Dani C, et al. **Dev Biol** 1998 Nov 1;203(1):149-62

Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins. Voyle RB, et al. **Exp Cell Res** 1999 Jun 15;249(2):199-211

Oncostatin M transforms lymphoid tissue function in transgenic mice by stimulating lymph node T-cell development and thymus autoantibody production. Clegg CH, et al. **Exp Hematol** 1999 Apr;27(4):712-25

Growth inhibition by a triple ribozyme targeted to repetitive B2 transcripts. Crone TM, et al. **Hepatology** 1999 Apr; 29(4):1114-23

Administration of thymocytes derived from non-pregnant mice induces an endometrial receptive stage and leukaemia inhibitory factor expression in the uterus. Fujita K, et al. **Hum Reprod** 1998 Oct;13(10):2888-94

Activation of RB tumor suppressor protein and growth suppression of small cell lung carcinoma cells by reintroduction of p16INK4A gene. Sumitomo K, et al. **Int J Oncol** 1999 Jun;14(6):1075-80

Complex conserved organization of the mammalian leukemia inhibitory factor gene: regulated expression of intracellular and extracellular cytokines. Haines BP, et al. **J Immunol** 1999 Apr 15;162(8):4637-46

Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. Martin BK, et al. **J Immunol** 1999 Jun 1;162(11):6663-70

Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells [see comments] Cuthbert AP, et al. **J Natl Cancer Inst** 1999 Jan 6;91(1):37-45. Comment in: J Natl Cancer Inst 1999 Jan 6;91(1):4-6.

The levels of leukemia inhibitory factor mRNA in a Schwann cell line are regulated by multiple second messenger pathways. Nagamoto-Combs K, et al. **J Neurochem** 1999 May;72(5):1871-81

Expression of growth inhibitory factor (metallothionein-III) mRNA and protein following excitotoxic immature brain injury. Acarin L, et al. **J Neuropathol Exp Neurol** 1999 Apr;58(4):389-97

Differential gene expression of CINC, NOS II, and ICAM-1 in endotoxemic liver cells by rG-CSF. Wanner GA, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):216-21

Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. De Santa Barbara P, et al. **Mol Cell Biol** 1998 Nov;18(11):6653-65

Transcription factor GATA-4 enhances Müllerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-1. Tremblay JJ, et al. **Mol Endocrinol** 1999 Aug;13(8):1388-401

mRNA expression of leukaemia inhibitory factor (LIF) and its receptor subunits glycoprotein 130 and LIF-receptor-beta in bovine embryos derived in vitro or in vivo. Eckert J, et al. **Mol Hum Reprod** 1998 Oct; 4(10):957-65

Leukaemia inhibitory factor gene mutations in infertile women. Giess R, et al. **Mol Hum Reprod** 1999 Jun; 5(6):581-6

Cloning of leukemia inhibitory factor (LIF) and its expression in the uterus during embryonic diapause and implantation in the mink (Mustela vison). Song JH, et al. **Mol Reprod Dev** 1998 Sep;51(1):13-21

Enhanced expression of neurotrophic factors by C6 rat glioma cells after transfection with glia maturation factor. Zaheer A, et al. **Neurosci Lett** 1999 Apr 23;265(3):203-6

Magnocellular vasopressinergic neurons in explant cultures are rescued from cell death by ciliary neurotrophic factor and leukemia inhibiting factor. Vutskits L, et al. **Neuroscience** 1998 Dec;87(3):571-82

Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis. Fournier N, et al. **Oncogene** 1999 Jul 8; 18(27):4015-21

Isolation of growth suppressors from a cDNA expression library. Pestov DG, et al. **Oncogene** 1998 Dec 17; 17(24):3187-97

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Yu Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):214-9

[Study on growth and differentiation of ES cells transfected with LIF gene] Du XX, et al. **Shih Yen Sheng Wu Hsueh Pao** 1996 Dec;29(4):413-27 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Sprouting and regeneration after pyramidotomy and blockade of the myelin-associated neurite growth inhibitors NI 35/250 in adult rats. Raineteau O, et al. **Eur J Neurosci** 1999 Apr;11(4):1486-98

Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Kershaw MH, et al. **Oncol Res** 1998;10(3):133-42

ISOLATION & PURIFICATION

Isolation of a low-molecular-weight growth inhibitory factor from hybridoma cell cultures. Røe O, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):138-42

Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Wuyts A, et al. **Eur J Biochem** 1999 Mar;260(2):421-9

Control of glial number: purification from mammalian brain extracts of an inhibitor of astrocyte division. Abad-Rodriguez J, et al. **Glia** 1998 Jun;23(2):156-68

Purification and characterization of a novel vascular endothelial cell growth inhibitor secreted by macrophage-like U-937 cells. Nakano N, et al. **J Biochem (Tokyo)** 1999 Feb;125(2):368-74

A novel F box protein, NFB42, is highly enriched in neurons and induces growth arrest. Erhardt JA, et al. **J Biol Chem** 1998 Dec 25;273(52):35222-7

Isolation of a proliferation inhibitor factor from uterine myomatosis fibroblasts. Sánchez-Sánchez L, et al. **Prep Biochem Biotechnol** 1999 Feb;29(1):23-33

METABOLISM

Cytokine and chemokine induction using cell wall component and toxin derived from gram-positive bacteria in the rat middle ear. Kita H, et al. **Acta Otolaryngol** 1999; 119(4):446-52

Rb independent inhibition of cell growth by p15(INK4B). Aytac U, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):534-8

Growth factor synergism and antagonism in early neural crest development. Sieber-Blum M. **Biochem Cell Biol** 1998; 76(6):1039-50

Synergistic effects of colony-stimulating factor 1 and leukemia inhibitory factor in inducing early myeloid cell differentiation. Aperlo C, et al. **Cell Growth Differ** 1998 Nov;9(11):929-37

9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell

differentiation or cell death by blocking cell cycle progression through the S phase. Hatse S, et al. **Cell Growth Differ** 1999 Jun;10(6):435–46

Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein. Naeger LK, et al. **Cell Growth Differ** 1999 Jun;10(6):413–22

Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. Gouin F, et al. **Cytokine** 1999 Apr;11(4):282–9

Leukaemia inhibitory factor expression is inhibited by glucocorticoids through post-transcriptional mechanisms. Grosset C, et al. **Cytokine** 1999 Jan;11(1):29–36

Integration of a growth-suppressing BTB/POZ domain protein with the DP component of the E2F transcription factor. de la Luna S, et al. **EMBO J** 1999 Jan 4;18(1):212–28

TGF-beta1 inhibits NF-kappaB activity through induction of IkappaB-alpha expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-beta1. Azuma M, et al. **Exp Cell Res** 1999 Jul 10; 250(1):213–22

Presence of anti-Müllerian hormone correlates with absence of laminin alpha5 chain in differentiating rat testis and ovary. Fröjdman K, et al. **Histochem Cell Biol** 1999 May; 111(5):367–73

Anti-Müllerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia. Fénichel P, et al. **Hum Reprod** 1999 Aug;14(8):2020–4

Leukaemia inhibitory factor expression in human follicular fluid [letter; comment] Jean M, et al. **Hum Reprod** 1999 Feb;14(2):571. Comment on: Hum Reprod 1997 Jun;12(6):1233–9.

Functions of the N-glycans of rat leukemia inhibitory factor expressed in Chinese hamster ovary cells. Sasai K, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):999–1003

Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade. Aubert J, et al. **J Biol Chem** 1999 Aug 27;274(35):24965–72

Mannose 6-Phosphate/Insulin-like growth factor II receptor mediates internalization and degradation of leukemia inhibitory factor but not signal transduction. Blanchard F, et al. **J Biol Chem** 1999 Aug 27;274(35):24685–93

Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. Bousquet C, et al. **J Biol Chem** 1999 Apr 16; 274(16):10723–30

The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation. Cao W, et al. **J Biol Chem** 1998 Nov 20; 273(47):31534–40

GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the beta-myosin heavy chain gene in cardiac myocytes. Morimoto T, et al. **J Biol Chem** 1999 Apr 30;274(18):12811–8

Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains. Taupin JL, et al. **J Biol Chem** 1999 May 14; 274(20):14482–9

Leukemia inhibitory factor and oncostatin M influence the mineral phases formed in a murine heterotopic calcification model: a Fourier transform-infrared microspectroscopic study. Bohic S, et al. **J Bone Miner Res** 1998 Oct; 13(10):1619–32

Expression of leukemia-inhibitory factor as an autocrinal growth factor in human medulloblastomas. Liu J, et al. **J Cancer Res Clin Oncol** 1999 Aug-Sep;125(8-9):475–80

Induction of CINC (interleukin-8) production in rat liver by non-parenchymal cells. Ohkubo K, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):696–702

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Du W, et al. **Mol Cell Biol** 1999 Mar;19(3):1831–40

Modulation of cell proliferation by cytokeratins K10 and K16. Paramio JM, et al. **Mol Cell Biol** 1999 Apr; 19(4):3086–94

Anterograde transport of leukemia inhibitory factor within transected sciatic nerves. Bennett TM, et al. **Muscle Nerve** 1999 Jan;22(1):78–87

Modulation of the neurotransmitter release in rat cerebellar neurons by GRO beta. Ragozzino D, et al. **Neuroreport** 1998 Nov 16;9(16):3601–6

Immunolocalization of leukemia inhibitory factor in normal and denervated human muscle. Schoser BG, et al. **Neuroreport** 1998 Aug 24;9(12):2843–6

Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Khoshyomn S, et al. **Neurosurgery** 1999 Mar; 44(3):568–77; discussion 577–8

IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1. Kominsky S, et al. **Oncogene** 1998 Dec 10;17(23):2973–9

PHARMACOLOGY

Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Floege J, et al. **Am J Pathol** 1999 Jan;154(1):169–79

Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts. Varghese S, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E465–71

Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Spicer JA, et al. **Anticancer Drug Des** 1999 Jun;14(3):281–9

20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M, et al. **Anticancer Res** 1999 May-Jun;19(3A):1689–97

Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Lea MA, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1971–6

Antiproliferative effects of a product isolated from the gorgonian Rumphella aggregata. Nourry M, et al. **Anticancer Res** 1999 May-Jun;19(3A):1881–5

Antiproliferative and apoptosis-inducing effects of an antitumor glycoprotein from Streptococcus pyogenes. Yoshida J, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1865–71

Ceramide potentiates, but sphingomyelin inhibits, vitamin D-induced keratinocyte differentiation: comparison between keratinocytes and HL-60 cells. Pillai S, et al. **Arch Dermatol Res** 1999 May;291(5):284–9

Effects of leukemia inhibitory factor and oncostatin M on bone mineral formed in in vitro rat bone-marrow stromal cell culture: physicochemical aspects. Bohic S, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):506–13

Bistratene A induces a microtubule-dependent block in cytokinesis and altered stathmin expression in HL60 cells. Johnson WE, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):80–8

Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Kuzumaki T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):291–5

Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice. Trieu VN, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):377–81

Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump). Ishikawa T, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):569–76

Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Gao YH, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):767–72

Influence of genistein (4',5,7-trihydroxyisoflavone) on the growth and proliferation of testicular cell lines. Kumi-Diaka J, et al. **Biol Cell** 1998 Jul;90(4):349–54

Dihydrofolate reductase and cell growth activity inhibition by the beta-carboline-benzoquinolizidine plant alkaloid deoxytubulosine from Alangium lamarckii: its potential as an antimicrobial and anticancer agent. Rao KN, et al. **Bioorg Med Chem** 1999 Jun;7(6):1105–10

10-omega-phenylalkyl-9(10H)-anthracenones as inhibitors of keratinocyte growth with reduced membrane damaging properties. Müller K, et al. **Bioorg Med Chem Lett** 1998 Nov 17;8(22):3211–6

Significance of enhanced cytokine receptor expression by glucocorticoids [letter] Almawi WY, et al. **Blood** 1998 Nov 15;92(10):3979–80

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Byrd JC, et al. **Blood** 1998 Nov 15;92(10):3804–16

Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Dai J, et al. **Blood** 1999 Jan 1;93(1):268–77

The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Darnell G, et al. **Blood** 1999 Jul 15; 94(2):781–92

Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3. Niitsu N, et al. **Blood** 1998 Nov 1;92(9):3368–75

In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1. Pourtau J, et al. **Blood Coagul Fibrinolysis** 1998 Oct;9(7):609–15

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Watson SA, et al. **Br J Cancer** 1999 Sep;81(1):19–23

Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Yoo JY, et al. **Breast Cancer Res Treat** 1998 Sep;51(1):71–81

Apoptosis and suppression of tumor growth by artepillin C extracted from Brazilian propolis. Kimoto T, et al. **Cancer Detect Prev** 1998;22(6):506–15

Antitumor effect of medium-chain triglyceride and its influence on the self-defense system of the body. Kimoto Y, et al. **Cancer Detect Prev** 1998;22(3):219–24

Differential responses of staurosporine on protein kinase C activity and proliferation in two murine neuroblastoma cell lines. Mohan DR, et al. **Cancer Lett** 1999 May 24; 139(2):137–43

Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Smith JP, et al. **Cancer Lett** 1999 Jan 8;135(1):107–12

Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Hong SH, et al. **Cancer Res** 1999 May 1;59(9):2223–8

Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate [published erratum appears in Carcinogenesis 1999 Jul;20(7):1383] Liang YC, et al. **Carcinogenesis** 1999 Apr; 20(4):733–6

Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Yamamoto A, et al. **Cell Struct Funct** 1998 Feb;23(1):33–42

Growth inhibitory factor and zinc affect neural cell cultures in a tissue specific manner. Bruinink A, et al. **Chem Biol Interact** 1998 Oct 2;115(3):167–74

Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Ruef J, et al. **Circulation** 1999 Aug 10;100(6):659–65

Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard P, et al. **Clin Cancer Res** 1999 Jan; 5(1):35–42

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Xu FJ, et al. **Clin Cancer Res** 1997 Sep;3(9):1629–34

Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1-2):87–103 (96 ref.)

Advances in understanding of biological effects of interleukin-11, leukemia inhibitory factor, and macrophage inflammatory protein 1 alpha. Broxmeyer HE. **Curr Opin Hematol** 1994 May;1(3):197–202 (58 ref.)

The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Asgeirsson KS, et al. **Cytokine** 1998 Sep;10(9):720–8

Growth inhibition of human promonocytic leukaemic U937 cells by interferon gamma is irreversible and not cell cycle phase-specific. Joshi CV, et al. **Cytokine** 1999 Sep; 11(9):673–8

Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Skelton LA, et al. **Cytometry** 1998 Sep 1;33(1):56–66

Distinct roles of oncostatin M and leukemia inhibitory factor in the development of primordial germ cells and sertoli cells in mice. Hara T, et al. **Dev Biol** 1998 Sep 15; 201(2):144–53

Paracrine-mediated apoptosis in reproductive tract development. Roberts LM, et al. **Dev Biol** 1999 Apr 1; 208(1):110–22

Stimulatory effect of leukemia inhibitory factor on ACTH secretion of dispersed rat pituitary cells. Kim DS, et al. **Endocr Res** 1999 Feb;25(1):11–9

Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. King KL, et al. **Endocrine** 1998 Aug;9(1):45–55

The anti-proliferative agent jasplakinolide rearranges the actin cytoskeleton of plant cells. Sawitzky H, et al. **Eur J Cell Biol** 1999 Jun;78(6):424–33

Antiproliferative effect of the tripeptide pyroGlu-Phe-GlyNH2 on murine melanocytes: transitory delay of cell growth in vitro and the cell cycle specificity. Gembitsky DS, et al. **Exp Cell Res** 1998 Sep 15; 243(2):367–74

Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Hsieh TC, et al. **Exp Cell Res** 1999 May 25; 249(1):109–15

NA22598, a novel antitumor compound, reduces cyclin D1 levels, arrests cell cycle at G1 phase, and inhibits anchorage-independent growth of human tumor cells. Kawada M, et al. **Exp Cell Res** 1999 Jun 15;249(2):240–7

Mimosine arrests proliferating human cells before onset of DNA replication in a dose-dependent manner. Krude T. **Exp Cell Res** 1999 Feb 25;247(1):148–59

Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Lambrecht V, et al. **Exp Cell Res** 1998 Dec 15;245(2):239–44

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Platanias LC, et al. **Exp Hematol** 1999 Aug; 27(8):1315–21

Inhibition of cell proliferation by lithium is associated with interference in cdc2 activation. Smits VA, et al. **FEBS Lett** 1999 Aug 20;457(1):23–7

Recombinant human leukemia inhibitory factor enhances the development of preimplantation mouse embryo in vitro. Tsai HD, et al. **Fertil Steril** 1999 Apr;71(4):722–5

Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Gariboldi MB, et al. **Free Radic Biol Med** 1998 Apr; 24(6):913–23

Chronically denervated rat Schwann cells respond to GGF in vitro. Li H, et al. **Glia** 1998 Nov;24(3):290–303

Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Xaus J, et al. **Immunity** 1999 Jul;11(1):103–13

The cell cycle–specific growth-inhibitory factor produced by Actinobacillus actinomycetemcomitans is a cytolethal distending toxin. Sugai M, et al. **Infect Immun** 1998 Oct; 66(10):5008–19

Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068. Prevost GP, et al. **Int J Cancer** 1999 Oct 8; 83(2):283–7

Retinoic acid–mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. Weber E, et al. **Int J Cancer** 1999 Mar 15;80(6):935–43

The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo. Aidoudi S, et al. **Int J Hematol** 1998 Aug; 68(2):145–55

Insulin-like growth factor binding protein-3 does not mediate the interferon-dependent suppression of human ectocervical epithelial cell proliferation. Hembree JR, et al. **Int J Oncol** 1999 Jun;14(6):1163–8

Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Schröder C, et al. **Int J Oncol** 1998 Dec;13(6):1335–40

TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Voss M, et al. **Int J Oncol** 1999 Jan;14(1):93–101

Müllerian inhibiting substance improves longevity of motility and viability of fresh and cryopreserved sperm. Siow Y, et al. **J Androl** 1998 Sep–Oct;19(5):568–72

A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori. Burns BP, et al. **J Bacteriol** 1998 Nov;180(21):5574–9

Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes. Stephens JM, et al. **J Biol Chem** 1998 Nov 20; 273(47):31408–16

The box-1 region of the leukemia inhibitory factor receptor alpha-chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation. Zhang Y, et al. **J Biol Chem** 1998 Dec 18;273(51):34370–83

Bunazosin hydrochloride inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats by suppressing the response to growth factors. Hu WY, et al. **J Cardiovasc Pharmacol** 1998 Dec; 32(6):975–82

Application of reuterin produced by Lactobacillus reuteri 12002 for meat decontamination and preservation. El-Ziney MG, et al. **J Food Prot** 1999 Mar;62(3):257–61

Muscle protection following motor nerve repair in combination with leukemia inhibitory factor. Leong J, et al. **J Hand Surg [Am]** 1999 Jan;24(1):37–45

Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. Borron PJ, et al. **J Immunol** 1998 Nov 1;161(9):4599–603

Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor. Miller JS, et al. **J Immunol** 1999 Jun 15;162(12):7376–82

The proinflammatory and chondral activities of leukemia inhibitory factor in goat joints are partially a function of interleukin-1. Bell MC, et al. **J Interferon Cytokine Res** 1999 Feb;19(2):197–208

The butler did it: search for killer(s) of Kaposi's sarcoma cells in preparations of human chorionic gonadotropin [editorial; comment] Darzynkiewicz Z. **J Natl Cancer Inst** 1999 Jan 20;91(2):104–6. Comment on: J Natl Cancer Inst 1999 Jan 20;91(2):135–43.

Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin [see comments] Samaniego F, et al. **J Natl Cancer Inst** 1999 Jan 20;91(2):135–43. Comment in: J Natl Cancer Inst 1999 Jan 20;91(2):104–6.

CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. Giovannelli A, et al. **J Neuroimmunol** 1998 Dec 1;92(1–2):122–32

Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. Halfter H, et al. **J Neurooncol** 1998 Aug;39(1):1–18

Leukemia inhibitory factor and ciliary neurotrophic factor cause dendritic retraction in cultured rat sympathetic neurons. Guo X, et al. **J Neurosci** 1999 Mar 15; 19(6):2113–21

Tyrphostins that suppress the growth of human papilloma virus 16–immortalized human keratinocytes. Ben-Bassat H, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1442–57

Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. Sharma SK, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1475–81

A novel aminosteroid is active for proliferation inhibition and differentiation induction of human acute myeloid leukemia HL-60 cells. He Q, et al. **Leuk Res** 1999 Apr; 23(4):369–72

Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Iwai N, et al. **Lung Cancer** 1999 Mar; 23(3):209–22

Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Franzese O, et al. **Melanoma Res** 1998 Aug;8(4):323–8

Dithiothreitol enhances arsenic trioxide–induced apoptosis in NB4 cells. Gurr JR, et al. **Mol Pharmacol** 1999 Jul; 56(1):102–9

The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors. Paukovits JB, et al. **Mol Pharmacol** 1999 Oct;56(4):665–74

Macrocyclic Cu(II)tetraanhydroaminobenzaldehyde complex--antiproliferative activity in vitro and in vivo. Jantová S, et al. **Neoplasma** 1998;45(4):254–60

Recombinant human glial growth factor 2 (rhGGF2) improves functional recovery of crushed peripheral nerve (a double-blind study). Chen LE, et al. **Neurochem Int** 1998 Oct;33(4):341–51

Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion. Gill JS, et al. **Neuroscience** 1998 Dec;87(4):855–60

Leukaemia inhibitory factor prevents loss of p75-nerve growth factor receptor immunoreactivity in medial septal neurons following fimbria-fornix lesions. Panni MK, et al. **Neuroscience** 1999;89(4):1113–21

Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Fabbrizio E, et al. **Oncogene** 1999 Jul 29; 18(30):4357–63

Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Hartmann BL, et al. **Oncogene** 1999 Jan 21;18(3):713–9

CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells. Suzuki R, et al. **Oncogene** 1998 Oct 29; 17(17):2271–8

The growth-inhibiting epidermal pentapeptide, pyroGlu-glu-asp-ser-GlyOH, inhibits growth and alters gene expression in non-transformed NC3H10 and transformed TC3H10 fibroblasts. Liu Y, et al. **Oncol Rep** 1999 Mar–Apr;6(2):445–9

Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. Fibbi G, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):340–50

Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis. Kinoshita T, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7265–70

Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Reiser F, et al. **Proc Soc Exp Biol Med** 1998 Dec;219(3):211–6

Effects of myelotoxic agents on cytokine production in murine long-term bone marrow cultures. Hauser SP, et al. **Stem Cells** 1998;16(4):261–70

Primary culture of porcine PGCs requires LIF and porcine membrane-bound stem cell factor. Durcova-Hills G, et al. **Zygote** 1998 Aug;6(3):271–5

PHYSIOLOGY

The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Cawston TE, et al. **Arthritis Rheum** 1998 Oct;41(10):1760–71

Angiotensin II interferes with leukemia inhibitory factor–induced STAT3 activation in cardiac myocytes. Tone E, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):147–50

Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor–mediated growth arrest. Zuo Z, et al. **Biochemistry** 1999 Jul 13; 38(28):8849–57

Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Gentilini G, et al. **Blood** 1999 Jan 1; 93(1):25–33

Leukemia inhibitory factor and NGF regulate signal transducers and activators of transcription activation in sympathetic ganglia: convergence of cytokine- and neurotrophin-signaling pathways. Rajan P, et al. **Brain Res** 1998 Aug 17;802(1–2):198–204

Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. Kurian MS, et al. **Clin Cancer Res** 1995 Mar;1(3):343–9

A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1). Alevizopoulos K, et al. **EMBO J** 1998 Oct 15; 17(20):5987–97

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. Nicholson SE, et al. **EMBO J** 1999 Jan 15;18(2):375–85

High specificity of Müllerian-inhibiting substance signaling in vivo. Mishina Y, et al. **Endocrinology** 1999 May; 140(5):2084–8

Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Teixeira J, et al. **Endocrinology** 1999 Oct;140(10):4732–8

Astrocyte differentiation mediated by LIF in cooperation with BMP2. Nakashima K, et al. **FEBS Lett** 1999 Aug 20;457(1):43–6

The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237–43; discussion 244–6 (46 ref.)

CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM–mediated growth inhibition by up-regulation of egr-1. Han SS, et al. **Int Immunol** 1999 Jun;11(6):871–9

Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor–stimulated capillary endothelial cells. Lee TH, et al. **J Biol Chem** 1998 Oct 30;273(44):28805–12

A lymphoma growth inhibitor blocks some but not all prolactin-stimulated signaling pathways. Yamashita H, et al. **J Biol Chem** 1999 May 21;274(21):14699–705

Review: The role of leukaemia inhibitory factor in the establishment of pregnancy. Vogiagis D, et al. **J Endocrinol** 1999 Feb;160(2):181–90 (82 ref.)

Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. Schwarz MA, et al. **J Exp Med** 1999 Aug 2; 190(3):341–54

Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways. Arora T, et al. **J Immunol** 1999 Mar 15;162(6):3289–97

Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. Dong Q, et al. **J Immunol** 1999 Mar 15;162(6):3220–30

TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. Geissmann F, et al. **J Immunol** 1999 Apr 15;162(8):4567–75

TNF-alpha–induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation. Hu X, et al. **J Immunol** 1999 Sep 15;163(6):3106–15

Antiproliferative effect of IL-1 is mediated by p38 mitogen-activated protein kinase in human melanoma cell A375. Itoh S, et al. **J Immunol** 1999 Jun 15;162(12):7434–40

Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, enhances L-type Ca2+ current and [Ca2+]i transient in cardiomyocytes. Murata M, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):237–45

Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. Dowsing BJ, et al. **J Neurochem** 1999 Jul;73(1):96–104

Leukemia inhibitory factor augments neurotrophin expression and corticospinal axon growth after adult CNS injury. Blesch A, et al. **J Neurosci** 1999 May 1;19(9):3556–66

Differentiation of oligodendroglial progenitors derived from cortical multipotent cells requires extrinsic signals including activation of gp130/LIFbeta receptors. Marmur R, et al. **J Neurosci** 1998 Dec 1;18(23):9800–11

Cardiotrophin-1 requires LIFRbeta to promote survival of mouse motoneurons purified by a novel technique. Arce V, et al. **J Neurosci Res** 1999 Jan 1;55(1):119–26

Immunization of rats and sheep against granulosa cell–inhibitory factor from bovine follicular fluid increases the number of large follicles in rats and the ovulation rate in sheep. Hynes AC, et al. **J Reprod Fertil** 1999 May; 116(1):35–41

The role of anti-Müllerian hormone in gonadal development. Josso N, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):3–7 (23 ref.)

Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions [see comments] [published erratum appears in Nat Neurosci 1998 Aug;1(4):329] Thallmair M, et al. **Nat Neurosci** 1998 Jun;1(2):124–31. Comment in: Nat Neurosci 1998 Jun;1(2):85. Comment in: Nat Neurosci 1998 Jun;1(2):87–8.

Leukemia inhibitory factor regulates galanin/galanin message-associated peptide expression in cultured mouse dorsal root ganglia; with a note on in situ hybridization methodology. Kerekes N, et al. **Neuroscience** 1999; 89(4):1123–34

Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Cipriano SC, et al. **Oncogene** 1998 Sep 24;17(12):1549–56

p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Lukas J, et al. **Oncogene** 1999 Jul 8;18(27):3930–5

Growth inhibitors for mammary epithelial cells. Brandt R, et al. **Prog Mol Subcell Biol** 1998;20:197–248 (117 ref.)

Growth-inhibiting N-substituted endogenous peptides. Elgjo K, et al. **Prog Mol Subcell Biol** 1998;20:143–59 (81 ref.)

The growth-inhibitory effects of TGF beta. Herrera RE. **Prog Mol Subcell Biol** 1998;20:11–24 (101 ref.)

Growth inhibition of human fibroblasts in vitro. Macieira-Coelho A. **Prog Mol Subcell Biol** 1998;20:249–70 (72 ref.)

Big brothers are watching: the retinoblastoma family and growth control. Stiegler P, et al. **Prog Mol Subcell Biol** 1998;20:25–42 (107 ref.)

Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127–37 (163 ref.)

SECRETION

Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro. Uzumcu M, et al. **Am J Reprod Immunol** 1998 Aug;40(2):83–8

In-vivo administration of progesterone inhibits the secretion of endometrial leukaemia inhibitory factor in vitro. Hambartsoumian E, et al. **Mol Hum Reprod** 1998 Nov; 4(11):1039–44

Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Komarova EA, et al. **Oncogene** 1998 Sep 3;17(9):1089–96

THERAPEUTIC USE

Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Jacobs E, et al. **Br J Cancer** 1999 May;80(3–4):352–9

Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Tsuchikane E, et al. **Circulation** 1999 Jul 6;100(1):21–6

New frontiers in the management of chemotherapy-induced mucositis. Spijkervet FK, et al. **Curr Opin Oncol** 1998 Aug; 10 Suppl 1:S23–7 (15 ref.)

A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. Iseki H, et al. **J Gastrointest Surg** 1998 Jan–Feb;2(1):36–43

LIF (AM424), a promising growth factor for the treatment of ALS. Kurek JB, et al. **J Neurol Sci** 1998 Oct;160 Suppl 1:S106–13 (64 ref.)

Trapidil-mediated inhibition of CNS remyelination results from reduced numbers and impaired differentiation of oligodendrocytes. McKay JS, et al. **Neuropathol Appl Neurobiol** 1998 Dec;24(6):498–506

A novel cytotoxic agent for human carcinoid tumors. Litvak DA, et al. **Surgery** 1998 Dec;124(6):1071–6

TOXICITY

Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Shawver LK, et al. **Clin Cancer Res** 1997 Jul;3(7):1167–77

Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. Yano H, et al. **Mol Endocrinol** 1998 Nov;12(11):1708–20

Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Fujiwara Y, et al. **Toxicology** 1999 Apr 15; 133(2–3):147–57

GROWTH PLATE

see related

BONE DEVELOPMENT

Epiphyseal and physeal cartilage vascularization: a light microscopic and tritiated thymidine autoradiographic study of cartilage canals in newborn and young postnatal rabbit bone. Shapiro F. **Anat Rec** 1998 Sep;252(1):140–8

ANATOMY & HISTOLOGY

[Radiologic description of the growth plates of the atlas and axis in foals] Maierl J, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov; 26(6):341–5 (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

The microvascular anatomy of the physis as revealed by osteomedullography and correlated histology. Oni OO. **Orthopedics** 1999 Feb;22(2):239–41

CHEMISTRY

Immunolocalization of the cleavage of the aggrecan core protein at the Asn341-Phe342 bond, as an indicator of the location of the metalloproteinases active in the lysis of the rat growth plate. Lee ER, et al. **Anat Rec** 1998 Sep; 252(1):117–32

Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. Horner A, et al. **J Anat** 1999 May;194 (Pt 4):519–24

Demonstration of estrogen receptor-beta immunoreactivity in human growth plate cartilage. Nilsson LO, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):370–3

CYTOLOGY

Gravitational changes affect tibial growth plates according to Hert's curve. Montufar-Solis D, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 1):245–9

Aberrant death in dark chondrocytes of the avian growth plate. Erenpreisa J, et al. **Cell Death Differ** 1998 Jan; 5(1):60–6

Ovariectomy causes cell proliferation and matrix synthesis in the growth plate cartilage of the adult rat. Tajima Y, et al. **Histochem J** 1998 Jul;30(7):467–72

Monoclonal antibody enhanced stimulation of human growth hormone action in vitro using ovine costal cartilage growth plate chondrocytes. Mockridge JW, et al. **Horm Metab Res** 1998 Oct;30(10):610–3

Extracellular phosphate ions cause apoptosis of terminally differentiated epiphyseal chondrocytes. Mansfield K, et al. **J Cell Physiol** 1999 Jun;179(3):276–86

Chondrocyte death is linked to development of a mitochondrial membrane permeability transition in the growth plate. Rajpurohit R, et al. **J Cell Physiol** 1999 Jun; 179(3):287–96

1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2. Boyan BD, et al. **Steroids** 1999 Jan–Feb;64(1-2):129–36 (63 ref.)

In vivo incidence of apoptosis evaluated with the TdT FragEL DNA fragmentation detection kit in cartilage and bone cells of the rat tibia. Silvestrini G, et al. **Tissue Cell** 1998 Dec;30(6):627–33

DRUG EFFECTS

Prostaglandins mediate the effects of 1,25-(OH)2D3 and 24,25-(OH)2D3 on growth plate chondrocytes in a metabolite-specific and cell maturation-dependent manner. Schwartz Z, et al. **Bone** 1999 May;24(5):475–84

Measurement of biological activity of somatotropin in hypophysectomized rats. Zhu CJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):489–93

Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. Ishikawa Y, et al. **J Bone Miner Res** 1998 Sep; 13(9):1398–411

Immunohistochemical observations on the initial disorders of the epiphyseal growth plate in rats induced by high dose of vitamin A. Soeta S, et al. **J Vet Med Sci** 1999 Mar; 61(3):233–8

EMBRYOLOGY

Aberrant death in dark chondrocytes of the avian growth plate. Erenpreisa J, et al. **Cell Death Differ** 1998 Jan; 5(1):60–6

Aberrations of cell cycle and cell death in normal development of the chick embryo growth plate. Erenpreisa J, et al. **Mech Ageing Dev** 1999 May 17;108(3):227–38

The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Chung UI, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13030–5

ENZYMOLOGY

Immunolocalization of the cleavage of the aggrecan core protein at the Asn341-Phe342 bond, as an indicator of the location of the metalloproteinases active in the lysis of the rat growth plate. Lee ER, et al. **Anat Rec** 1998 Sep; 252(1):117–32

Developmental expression of creatine kinase isoenzymes in chicken growth cartilage. Hobson GM, et al. **J Bone Miner Res** 1999 May;14(5):747–56

GROWTH & DEVELOPMENT

c-Myc and Mxi1 immunoreactivities in the calcifying areas of the epiphyseal-plate cartilage matrix of growing rats. Toury R, et al. **Bone** 1999 Jun;24(6):555–63

Expression patterns of candidate genes for tibial dyschondroplasia in chicken growth plate chondrocytes separated on percoll density gradients. Jefferies D, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S22–3

Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Naski MC, et al. **Development** 1998 Dec;125(24):4977–88

Determinants of spatial polarity in the growth plate. Abad V, et al. **Endocrinology** 1999 Feb;140(2):958–62

The use of vertebral ring epiphyseal union for age estimation in two cases of unknown identity. Albert AM. **Forensic Sci Int** 1998 Oct 12;97(1):11–20

Growth plate cartilage formation and resorption are differentially depressed in growth retarded uremic rats. Cobo A, et al. **J Am Soc Nephrol** 1999 May;10(5):971–9

Developmental expression of creatine kinase isoenzymes in chicken growth cartilage. Hobson GM, et al. **J Bone Miner Res** 1999 May;14(5):747–56

Transplantation of epiphyseal plate allografts between animals of different ages. Stevens DG, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):398–403

A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Wang Y, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4455–60

Studies on growth cartilage in the horse and their application to aetiopathogenesis of dyschondroplasia (osteochondrosis) [see comments] Jeffcott LB, et al. **Vet J** 1998 Nov; 156(3):177–92 (124 ref.). Comment in: Vet J 1998 Nov;156(3):167–8.

INJURIES

Unusual distal radial epiphyseal injury in a child. Arora A, et al. **Injury** 1999 Mar;30(2):149–50

Injury to the growth plate after Pemberton osteotomy. Leet AI, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):169–76

Physeal growth arrest of the distal phalanx of the thumb in an adolescent pianist: a case report [letter; comment] Kasdan ML. **J Hand Surg [Am]** 1998 Sep;23(5):956–7. Comment on: J Hand Surg [Am] 1998 May;23(3):532–5.

Avascular necrosis of the distal phalangeal epiphysis following physeal fracture: a case report. Nissenbaum M. **J Hand Surg [Am]** 1999 May;24(3):633–7

Complications of Küntscher intramedullary nailing in a child: a case report. Hosny GA, et al. **J Pediatr Orthop B** 1999 Apr;8(2):100–2

MR imaging and pediatric fractures [letter] Petit P, et al. **Skeletal Radiol** 1999 Jun;28(6):362

[Fracture management during bone growth] Schlickewei W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:577–80 (9 ref.) (Eng. Abstr.) **(Ger)**

[Epiphyseal injuries of the distal tibia. Does MRI provide useful additional information?] Iwinska-Zelder J, et al. **Radiologe** 1999 Jan;39(1):25–9 (Eng. Abstr.) **(Ger)**

METABOLISM

A novel integral membrane protein is differentially expressed in the chick growth plate and maps to chromosome 1. Lester DH, et al. **Anim Genet** 1999 Aug;30(4):300–3

Immunofluorescent localization of estrogen receptor-alpha in growth plates of rabbits, but not in rats, at sexual maturity. Kennedy J, et al. **Bone** 1999 Jan;24(1):9–16

c-Myc and Mxi1 immunoreactivities in the calcifying areas of the epiphyseal-plate cartilage matrix of growing rats. Toury R, et al. **Bone** 1999 Jun;24(6):555–63

Ovariectomy causes cell proliferation and matrix synthesis in the growth plate cartilage of the adult rat. Tajima Y, et al. **Histochem J** 1998 Jul;30(7):467–72

Androgen receptors in bone-forming tissue. Noble B, et al. **Horm Res** 1999;51(1):31–6

Temporal and spatial expressions of transforming growth factor-betas and their receptors in epiphyseal growth plate. Matsunaga S, et al. **Int J Oncol** 1999 Jun;14(6):1063–7

Expression of thyroid hormone receptor isoforms in rat growth plate cartilage in vivo. Ballock Rt, et al. **J Bone Miner Res** 1999 Sep;14(9):1550–6

Preparation of a cDNA library and preliminary assessment of 1400 genes from mouse growth cartilage. Okihana H, et al. **J Bone Miner Res** 1999 Feb;14(2):304–10

Physiological importance of the 1,25(OH)2D3 membrane receptor and evidence for a membrane receptor specific for 24,25(OH)2D3. Pedrozo HA, et al. **J Bone Miner Res** 1999 Jun;14(6):856–67

Localization of Smads, the TGF-beta family intracellular signaling components during endochondral ossification. Sakou T, et al. **J Bone Miner Res** 1999 Jul;14(7):1145–52

Vitamin D3 metabolites regulate LTBP1 and latent TGF-beta1 expression and latent TGF-beta1 incorporation in the extracellular matrix of chondrocytes. Pedrozo HA, et al. **J Cell Biochem** 1999 Jan 1;72(1):151–65

Growth plate chondrocytes store latent transforming growth factor (TGF)-beta 1 in their matrix through latent TGF-beta 1 binding protein-1. Pedrozo HA, et al. **J Cell Physiol** 1998 Nov;177(2):343–54

Chondrocyte death is linked to development of a mitochondrial membrane permeability transition in the growth plate. Rajpurohit R, et al. **J Cell Physiol** 1999 Jun; 179(3):287–96

Spatiotemporal expression of alternatively spliced IGF-I mRNA in the rat costochondral growth plate. Lin WW, et al. **J Endocrinol** 1999 Mar;160(3):461–7

Parathyroid receptor gene expression by epiphyseal growth plates in rickets and tibial dyschondroplasia. Ben-Bassat S, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1-2):185–95

PATHOLOGY

Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Nuttall JD, et al. **Calcif Tissue Int** 1999 Jul;65(1):47–52

"Cell paralysis" as an intermediate stage in the programmed cell death of epiphyseal chondrocytes during development. Roach HI, et al. **J Bone Miner Res** 1999 Aug;14(8):1367–78

Local disappearance of epiphyseal growth plates in rats with hypervitaminosis A. Kodaka T, et al. **J Vet Med Sci** 1998 Jul;60(7):815–21

Rickets on MR images. Ecklund K, et al. **Pediatr Radiol** 1999 Sep;29(9):673–5

Premature partial closure and other deformities of the growth plate: MR imaging and three-dimensional modeling. Craig JG, et al. **Radiology** 1999 Mar;210(3):835–43

PHYSIOLOGY

Endochondral ossification is dependent on the mechanical properties of cartilage tissue and on intracellular signals in chondrocytes. Talts JF, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:74–85

Acellular calcified columns in the normal growth plate of mouse vertebrae. Yokozeki K, et al. **Arch Histol Cytol** 1998 Aug;61(3):269–76

BMP-5 deficiency alters chondrocytic activity in the mouse proximal tibial growth plate. Bailón-Plaza A, et al. **Bone** 1999 Mar;24(3):211–6

Ultrastructural modifications of the extracellular matrix upon calcification of growth plate cartilage as revealed by quick-freeze deep etching technique. Akisaka T, et al. **Calcif Tissue Int** 1998 Jul;63(1):47–56

A transversely isotropic biphasic model for unconfined compression of growth plate and chondroepiphysis. Cohen B, et al. **J Biomech Eng** 1998 Aug;120(4):491–6

Animal model of experimentally induced ectopic enchondral ossification in nude mice with xenograft of porcine

epiphyseal cartilage. Berns T, et al. **J Mol Med** 1999 Jan; 77(1):165–8

Micromechanical properties of epiphyseal trabecular bone and primary spongiosa around the physis: an in situ nanoindentation study. Lee FY, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):582–5

Cartilage to bone--angiogenesis leads the way [news; comment] Harper J, et al. **Nat Med** 1999 Jun;5(6):617–8. Comment on: Nat Med 1999 Jun;5(6):623–8.

The epiphyseal cartilage and growth of long bones in Rana catesbeiana. Felisbino SL, et al. **Tissue Cell** 1999 Jun; 31(3):301–7

PHYSIOPATHOLOGY

Growth arrest resulting from unicameral bone cyst [letter; comment] Crawford AH. **J Pediatr Orthop** 1998 Nov–Dec; 18(6):824–5. Comment on: J Pediatr Orthop 1998 Mar–Apr;18(2):198–201.

RADIATION EFFECTS

Sparing radiation-induced damage to the physis by radioprotectant drugs: laboratory analysis in a rat model. Tamurian RM, et al. **J Orthop Res** 1999 Mar;17(2):286–92

RADIOGRAPHY

Juxtaphyseal aneurysmal bone cysts. Rizzo M, et al. **Clin Orthop** 1999 Jul;(364):205–12

The microvascular anatomy of the physis as revealed by osteomedullography and correlated histology. Oni OO. **Orthopedics** 1999 Feb;22(2):239–41

SURGERY

Intraepiphyseal resection of the proximal tibia and its impact on lower limb growth. Manfrini M, et al. **Clin Orthop** 1999 Jan;(358):111–9

["Recurrent" epiphysiolysis capitis femoris--need for simultaneous stabilization of both hip joints] Plötz GM, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov–Dec;136(6):534–41 (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

Animal model of experimentally induced ectopic enchondral ossification in nude mice with xenograft of porcine epiphyseal cartilage. Berns T, et al. **J Mol Med** 1999 Jan; 77(1):165–8

Transplantation of epiphyseal plate allografts between animals of different ages. Stevens DG, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):398–403

ULTRASTRUCTURE

Ultrastructural modifications of the extracellular matrix upon calcification of growth plate cartilage as revealed by quick-freeze deep etching technique. Akisaka T, et al. **Calcif Tissue Int** 1998 Jul;63(1):47–56

GROWTH RETARDATION, INTRAUTERINE see **FETAL GROWTH RETARDATION**

GROWTH SUBSTANCES

see related

RECEPTORS, GROWTH FACTOR

Growth factors, auditory neurones and cochlear implants: a review. Marzella PL, et al. **Acta Otolaryngol** 1999; 119(4):407–12 (60 ref.)

25th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism and the 3rd International Workshop on Growth Hormone Insensitivity. Istanbul, Turkey, 24–27 April 1998. Proceedings and Abstracts. **Acta Paediatr Suppl** 1999 Feb; 88(428):1–210

Hormones, autacoids, neurotransmitters and growth factors. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):105–33

Upregulation of the angiogenic factor heparin affin regulatory peptide by progesterone in rat uterus. Milhiet PE, et al. **J Endocrinol** 1998 Sep;158(3):389–99

EU ban on four antibiotic growth promoters [letter] Cook R. **Vet Rec** 1999 Feb 6;144(6):158

[Ban on antimicrobial growth promoters: a safety advantage for consumers?] Althaus FR. **Schweiz Arch Tierheilkd** 1999; 141(3):103–7 (0 ref.) (Eng. Abstr.) **(Ger)**

[Antimicrobial growth promoters--retrospect and alternatives] Wanner M. **Schweiz Arch Tierheilkd** 1999; 141(3):93–7 (0 ref.) (Eng. Abstr.) **(Ger)**

[Structural biology of growth factors and growth factor receptors] Kohda D. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):338–46 (17 ref.) **(Jpn)**

[Uncultured status of pathogenic bacteria: known and possible factors of reversible process induction] Romanova IuM, et al. **Mol Gen Mikrobiol Virusol** 1998;(3):3–8 (52 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Pour on application of growth promoters in veal calves: analytical and histological results. Schilt R, et al. **Analyst** 1998 Dec;123(12):2665–70

An orally administered growth factor extract derived from bovine whey suppresses breath ethane in colitic rats. Porter SN, et al. **Scand J Gastroenterol** 1998 Sep;33(9):967–74

The influence of combined trophic factors on the success of fetal pancreas grafts. Desai DM, et al. **Transplantation** 1999 Aug 27;68(4):491–6

Use of antimicrobials--advice from the Veterinary Products Committee [news] **Vet Rec** 1999 Feb 20;144(8):190

[Use of growth factors in therapy of chronic wounds. Experimental, clinical and financial aspects] Vogt PM, et al. **Chirurg** 1998 Nov;69(11):1197–206 (30 ref.) (Eng. Abstr.) **(Ger)**

[The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men] Kozakowski J, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):306–12 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

EU says growth hormones pose health risk [news] Watson R. **BMJ** 1999 May 29;318(7196):1442

Use of virginiamycin as a growth promoter [letter] Barrow PA. **Vet Rec** 1998 Oct 24;143(17):483–4

[Health advice report on antimicrobial growth promotion (letter)] Jansegers L. **Tijdschr Diergeneeskd** 1999 May 1; 124(9):284–6 **(Dut)**

ANALYSIS

Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: a possible mechanism for escaping immune surveillance. Aslakson CJ, et al. **Am J Hematol** 1999 May;61(1):46–52

Alpha 1-acid glycoprotein affinity columns for the clean-up of adrenergic drugs. Brambilla G, et al. **Analyst** 1998 Dec; 123(12):2693–6

Detection of corticosteroids in injection sites and cocktails by MSn. De Wasch K, et al. **Analyst** 1998 Dec; 123(12):2415–22

A fast immunoassay for the screening of beta-agonists in hair. Haasnoot W, et al. **Analyst** 1998 Dec;123(12):2707–10

Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. McEvoy JD, et al. **Analyst** 1998 Dec; 123(12):2475–8

Pour on application of growth promoters in veal calves: analytical and histological results. Schilt R, et al. **Analyst** 1998 Dec;123(12):2665–70

Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Froberg K, et al. **Ann Clin Lab Sci** 1998 Nov–Dec;28(6):386–93

Comparison of growth factor expression in fetal and adult fibroblasts: a preliminary report. Broker BJ, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):676–80

Localization of connective tissue growth factor during the period of embryo implantation in the mouse. Surveyor GA, et al. **Biol Reprod** 1998 Nov;59(5):1207–13

Fibroblast growth factor (FGF)-9 immunoreactivity in senile plaques. Nakamura S, et al. **Brain Res** 1998 Dec 14; 814(1–2):222–5

Immunolocalization of cytokines and growth factors in oral submucous fibrosis. Haque MF, et al. **Cytokine** 1998 Sep; 10(9):713–9

The role of the bioassay in the evaluation of cytokines and growth factors for regulatory decision making. Finbloom DS. **Dev Biol Stand** 1999;97:89–93

The immunoassay of cytokines and growth factors in biological fluids. Kopp W, et al. **Dev Biol Stand** 1999; 97:29–37 (8 ref.)

Analytical characterisation of cytokines and growth factors. Mire-Sluis AR. **Dev Biol Stand** 1999;97:3–9 (17 ref.)

Bioassays for growth factors. Robinson CJ. **Dev Biol Stand** 1999;97:21–7 (10 ref.)

Levels of hepatic stimulator substance in liver regenerating process of partially hepatectomized rats pretreated with a single dose of carbon tetrachloride. Liakos AA, et al. **Dig Dis Sci** 1999 May;44(5):1046–53

Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Di Loreto C, et al. **Eur J Endocrinol** 1999 Aug;141(2):190–4

Lactic acid bacteria growth promoters from Spirulina platensis. Parada JL, et al. **Int J Food Microbiol** 1998 Dec 22;45(3):225–8

FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. Giri D, et al. **J Cell Physiol** 1999 Jul;180(1):53–60

Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9B are expressed in oocytes during early folliculogenesis. Aaltonen J, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2744–50

FGF7 protein expression in human breast carcinomas. Jacquemier J, et al. **J Pathol** 1998 Nov;186(3):269–74

Insulinlike growth factor I and insulinlike growth factor 3: indices of intestinal failure in children. Barksdale EM Jr, et al. **J Pediatr Surg** 1999 May;34(5):655–61; discussion 661–2

Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. Perbal B. **Mol Pathol** 1999 Apr;52(2):84–91

Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Gann PH, et al. **Prostate** 1999 Sep 1;40(4):248–55

ANTAGONISTS & INHIBITORS see GROWTH INHIBITORS

BIOSYNTHESIS

Cytokine and chemokine induction using cell wall component and toxin derived from gram-positive bacteria in the rat middle ear. Kita H, et al. **Acta Otolaryngol** 1999; 119(4):446–52

Induction of KGF, basic FGF, and TGFalpha mRNA expression during healing of experimental TM perforations. Ishibashi T, et al. **Acta Otolaryngol (Stockh)** 1998 Sep; 118(5):701–4

Hepatoma-derived growth factor-related protein (HRP)-1 gene in spermatogenesis in mice. Kuroda T, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):433–7

Growth factors and components for extracellular proteolysis are differentially expressed during in vitro maturation of bovine cumulus-oocyte complexes. Bieser B, et al. **Biol Reprod** 1998 Oct;59(4):801–6

Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Sidis Y, et al. **Biol Reprod** 1998 Oct;59(4):807–12

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Baretton GB, et al. **Br J Cancer** 1999 May; 80(3–4):546–55

Laminar shear stress-induced GRO mRNA and protein expression in endothelial cells. Hagiwara H, et al. **Circulation** 1998 Dec 8;98(23):2584–90

Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo. Utsunomiya I, et al. **Cytokine** 1998 Dec;10(12):956–63

Expression of activin and follistatin in the rat hypothalamus: anatomical association with gonadotropin-releasing hormone neurons and possible role of central activin in the regulation of luteinizing hormone release. MacConell LA, et al. **Endocrine** 1998 Dec;9(3):233–41

Expression of hepatocyte growth factor-like protein is repressed by retinoic acid and enhanced by cyclic adenosine 3',5'-monophosphate response element-binding protein (CREB)-binding protein (CBP). Muraoka RS, et al. **Endocrinology** 1999 Jan;140(1):187–96

Increased production of cytokines and growth factors by aortic allografts: A possible explanation for myointimal hyperplasia formation. Sterpetti AV, et al. **Eur Surg Res** 1999;31(4):297–304

Hepatocyte extracellular matrix modulates expression of growth factors and growth factor receptors in human colon cancer cells. Zvibel I, et al. **Exp Cell Res** 1998 Nov 25; 245(1):123–31

Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Kria L, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):702–8

Xanthine oxidase inhibition attenuates kupffer cell production of neutrophil chemoattractant following ischemia-reperfusion in rat liver. Matsumura F, et al. **Hepatology** 1998 Dec;28(6):1578–87

Expression of bovine activin-A and inhibin-A in recombinant baculovirus-infected Spodoptera frugiperda Sf 21 insect cells. Cronin CN, et al. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1129–45

Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: predominance of vascular endothelial growth factor. Campbell CL, et al. **Int J Cancer** 1999 Mar 15;80(6):868–74

Expression of cripto and amphiregulin in colon mucosa from high risk colon cancer families. De Angelis E, et al. **Int J Oncol** 1999 Mar;14(3):437–40

Expression of the neutrophil chemokine KC in the colon of mice with enterocolitis and by intestinal epithelial cell lines: effects of flora and proinflammatory cytokines. Song F, et al. **J Immunol** 1999 Feb 15;162(4):2275–80

Regulation of interleukin-12 by interleukin-10, transforming growth factor-beta, tumor necrosis factor-alpha, and interferon-gamma in human monocytes infected with Mycobacterium tuberculosis H37Ra. Fulton SA, et al. **J Infect Dis** 1998 Oct;178(4):1105–14

Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. Yamagami S, et al. **J Leukoc Biol** 1999 Jun;65(6):744–9

Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. Ohnishi H, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2411–22

Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. Planz B, et al. **J Urol** 1998 Nov;160(5):1850–5

FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. Ropiquet F, et al. **J Urol** 1999 Aug;162(2):595–9

Calphostin C induces expression of amphiregulin mRNA via reactive oxygen species in IEC-6 cells. Miyazaki Y, et al. **Life Sci** 1998;63(25):PL361–5

A novel growth differentiation factor-9 (GDF-9) related factor is co-expressed with GDF-9 in mouse oocytes during folliculogenesis. Laitinen M, et al. **Mech Dev** 1998 Nov;78(1–2):135–40

Regulation of keratinocyte growth factor expression in human endometrium: implications for hormonal

carcinogenesis. Li Y, et al. **Mol Carcinog** 1998 Dec; 23(4):217–25

Selective presence of the chemokine growth-regulated oncogene alpha (GROalpha) in the human follicle and secretion from cultured granulosa-lutein cells at ovulation. Karström-Encrantz L, et al. **Mol Hum Reprod** 1998 Nov; 4(11):1077–83

Expression of growth factors and their receptors in the postnatal rat cochlea. Malgrange B, et al. **Neurochem Res** 1998 Aug;23(8):1133–8

Regulation of cytokine-induced neutrophil chemoattractant in rat bone marrow-derived macrophages by inflammatory mediators. Crippen TL, et al. **Pathobiology** 1998; 66(6):293–301

Cytokines, growth factors, and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde, and LPS. Gutiérrez-Ruiz MC, et al. **Toxicology** 1999 Jun 15; 134(2–3):197–207

[Production of recombinant human keratinocyte growth factor in Escherichia coli cells] Ptitsyn LR, et al. **Bioorg Khim** 1998 Jul;24(7):523–9 (Eng. Abstr.) **(Rus)**

BLOOD

Effect of oil containing n-3 polyunsaturated fatty acids (PUFA) on the immune response and growth factors in piglets. Kaštel R, et al. **Acta Vet Hung** 1999;47(3):325–34

Establishment of the enzyme-linked immunosorbent assay for connective tissue growth factor (CTGF) and its detection in the sera of biliary atresia. Tamatani T, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):748–52

Evidence of nitric oxide, a flow-dependent factor, being a trigger of liver regeneration in rats. Wang HH, et al. **Can J Physiol Pharmacol** 1998 Dec;76(12):1072–9

Growth in children with craniopharyngioma following surgery. Tiulpakov AN, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):733–8

Circulating growth-regulator oncogene alpha contributes to neutrophil priming and interleukin-8-directed mucosal recruitment into chronic lesions of patients with Crohn's disease. Brandt E, et al. **Eur Cytokine Netw** 1998 Dec; 9(4):647–53

Influence of age and sex on serum concentrations of total dimeric activin A [see comments] Loria P, et al. **Eur J Endocrinol** 1998 Nov;139(5):487–92. Comment in: Eur J Endocrinol 1998 Nov;139(5):469–71.

4-Hydroxynonenal modifies the effects of serum growth factors on the expression of the c-fos proto-oncogene and the proliferation of HeLa carcinoma cells. Kreuzer T, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):42–9

Secretion of activin A in recurrent epithelial ovarian carcinoma. Lambert-Messerlian GM, et al. **Gynecol Oncol** 1999 Jul;74(1):93–7

Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. O'Connor AE, et al. **Hum Reprod** 1999 Mar;14(3):827–32

Cell surface markers and circulating cytokines in graft versus host disease. Chang DM, et al. **Immunol Invest** 1999 Jan; 28(1):77–86

Muscle strength and hormonal levels in adolescents: gender related differences. Ramos E, et al. **Int J Sports Med** 1998 Nov;19(8):526–31

Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. Souttou B, et al. **J Natl Cancer Inst** 1998 Oct 7; 90(19):1468–73

Serum growth factors in patients with pancreatic cancer. Meggiato T, et al. **Tumour Biol** 1999 Mar-Apr;20(2):65–71

CHEMISTRY

Peptide mapping and disulfide bond analysis of myeloid progenitor inhibitory chemokine and keratinocyte growth factor by matrix-assisted laser desorption ionization mass spectrometry. Navale V, et al. **Anal Biochem** 1999 Feb 1; 267(1):125–34

Characterization of free alpha- and beta-chains of recombinant macrophage-stimulating protein. Yoshikawa W, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):356–60

A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Kawamura K, et al. **Development** 1999 Jan;126(2):211–9

Partial purification of embryotrophic factors from human oviductal cells. Liu LP, et al. **Hum Reprod** 1998 Jun; 13(6):1613–9

Sensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment. Schroering A, et al. **J Biol Chem** 1998 Nov 13; 273(46):30643–50

Overexpression of CALNUC (nucleobindin) increases agonist and thapsigargin releasable Ca2+ storage in the Golgi. Lin P, et al. **J Cell Biol** 1999 Apr 19;145(2):279–89

Identification of the chondrogenic-inducing activity from bovine dentin (bCIA) as a low-molecular-mass amelogenin polypeptide. Nebgen DR, et al. **J Dent Res** 1999 Sep; 78(9):1484–94

Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor. Osslund TD, et al. **Protein Sci** 1998 Aug;7(8):1681–90

DEFICIENCY

Molecular characterization of the follicle defects in the growth differentiation factor 9-deficient ovary. Elvin JA, et al. **Mol Endocrinol** 1999 Jun;13(6):1018–34

[The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men] Kozakowski J, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):306–12 (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Guzzaloni G, et al. **Minerva Endocrinol** 1998 Dec;23(4):99–104

GENETICS

Effects of ethanol on gene expression in rat bone: transient dose-dependent changes in mRNA levels for matrix proteins, skeletal growth factors, and cytokines are followed by reductions in bone formation. Turner RT, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1591–9

Effect of long-term ethanol consumption on ability to produce cytokine-induced neutrophil chemoattractant-1 in the rat liver and its gender difference. Yamada S, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):61S–66S

Hyperoxia increases keratinocyte growth factor mRNA expression in neonatal rabbit lung. Charafeddine L, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L105–13

Rat hepatic stellate cells produce cytokine-induced neutrophil chemoattractant in culture and in vivo. Maher JJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G847–53

Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Simmons JG, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G817–27

Trefoil factor family (TFF)-domain peptides in the mouse: embryonic gastrointestinal expression and wounding response. Otto WR, et al. **Anat Embryol (Berl)** 1999 Jun; 199(6):499–508

Upregulation of keratinocyte growth factor during T-cell immunity in the gut mucosa. Bajaj-Elliott M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:184–7

Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Fearon U, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:619–21

Trefoil factor family domain peptides in murine gastrointestinal development and embryonic wounding. Otto WR, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:227–30

Keratinocyte growth factor and its receptor messenger RNA expression in nasal mucosa and nasal polyps. Ishibashi T, et al. **Ann Otol Rhinol Laryngol** 1998 Oct;107(10 Pt 1):885–90

Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Baumann KH, et al. **Arterioscler Thromb Vasc Biol** 1999 Jan;19(1):59–66

Lipopolysaccharides induce p8 mRNA expression in vivo and in vitro. Jiang YF, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):686–90

Stimulation of PC cell-derived growth factor (epithelin/granulin precursor) expression by estradiol in human breast cancer cells. Lu R, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):204–7

Goblet-cell-specific transcription of mouse intestinal trefoil factor gene results from collaboration of complex series of positive and negative regulatory elements. Itoh H, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):461–72

Pregnancy alters the in vitro responsiveness of the rabbit medial collateral ligament to neuropeptides: effect on mRNA levels for growth factors, cytokines, iNOS, COX-2, metalloproteinases and TIMPs. Hart DA, et al. **Biochim Biophys Acta** 1998 Oct 22;1408(1):35–43

Identification of a novel transcriptional regulatory element within the promoter region of the keratinocyte growth factor gene that mediates inducibility to cyclic AMP. Zhou J, et al. **Biochim Biophys Acta** 1999 Jul 7;1446(1-2):71–81

Molecular cloning of the ovine Growth/Differentiation factor-9 gene and expression of growth/differentiation factor-9 in ovine and bovine ovaries. Bodensteiner KJ, et al. **Biol Reprod** 1999 Feb;60(2):381–6

Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Kossakowska AE, et al. **Blood** 1999 Sep 15; 94(6):2080–9

Role of members of the Wnt gene family in human hematopoiesis. Van Den Berg DJ, et al. **Blood** 1998 Nov 1;92(9):3189–202

Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Devalaraja MN, et al. **Cancer Res** 1999 Mar 15;59(6):1372–7

Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. He Z, et al. **Cancer Res** 1999 Jul 1;59(13):3222–9

The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Lee SB, et al. **Cell** 1999 Sep 3;98(5):663–73

A new family of growth and differentiation factors derived from the N-terminal domain of proopiomelanocortin (N-POMC). Denef C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):317–24 (67 ref.)

Basement membrane and growth factor gene expression in normal and diabetic human retinas. Spirin KS, et al. **Curr Eye Res** 1999 Jun;18(6):490–9

Gene therapy of wounds with growth factors. Davidson JM, et al. **Curr Top Pathol** 1999;93:111–21 (27 ref.)

Assignment of ANGPT4, ANGPT1, and ANGPT2 encoding angiopoietins 4, 1 and 2 to human chromosome bands 20p13, 8q22.3-->q23 and 8p23.1, respectively, by in situ hybridization and radiation hybrid mapping. Grosios K, et al. **Cytogenet Cell Genet** 1999;84(1-2):118–20

Characterization of oocyte and follicle development in growth differentiation factor-9-deficient mice. Carabatsos MJ, et al. **Dev Biol** 1998 Dec 15;204(2):373–84

Expression and function of Gdf-5 during digit skeletogenesis in the embryonic chick leg bud. Merino R, et al. **Dev Biol** 1999 Feb 1;206(1):33–45

Characterization of GDF-10 expression patterns and null mice. Zhao R, et al. **Dev Biol** 1999 Aug 1;212(1):68–79

Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene. Colvin JS, et al. **Dev Dyn** 1999 Sep;216(1):72–88

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Luetteke NC, et al. **Development** 1999 Jun;126(12):2739–50

Expression of chicken fibroblast growth factor homologous factor (FHF)-1 and of differentially spliced isoforms of FHF-2 during development and involvement of FHF-2 in chicken limb development. Munoz-Sanjuan I, et al. **Development** 1999 Jan;126(2):409–21

derrière: a TGF-beta family member required for posterior development in Xenopus. Sun BI, et al. **Development** 1999 Apr;126(7):1467–82

Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. Beck S, et al. **DNA Cell Biol** 1999 Feb;18(2):157–64

The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Brigstock DR. **Endocr Rev** 1999 Apr;20(2):189–206 (158 ref.)

Molecular cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, and its expression in Chinese hamster ovary cells. Hiraki Y, et al. **Eur J Biochem** 1999 Mar;260(3):869–78

Cloning and expression of the human p8, a nuclear protein with mitogenic activity. Vasseur S, et al. **Eur J Biochem** 1999 Feb;259(3):670–5

A novel 25 bp tandem repeat within the human trefoil peptide gene TFF2 in 21q22.3: polymorphism and mammalian evolution. Kayademir T, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):121–8

Melanoma growth stimulatory activity (MGSA/GRO-alpha) chemokine genes incorporated into an African green monkey simian cytomegalovirus-derived stealth virus. Martin WJ. **Exp Mol Pathol** 1999 Apr;66(1):15–8

Involvement of cis-acting repressive element(s) in the 3'-untranslated region of human connective tissue growth factor gene. Kubota S, et al. **FEBS Lett** 1999 Apr 30; 450(1-2):84–8

Osmotic changes and ethanol modify TFF gene expression in gastrointestinal cell lines. Lüdeking A, et al. **FEBS Lett** 1998 Nov 13;439(1-2):180–4

Generation of multiple transcripts from the chicken chondromodulin-I gene and their expression during embryonic development. Shukunami C, et al. **FEBS Lett** 1999 Jul 30;456(1):165–70

Identification of newt connective tissue growth factor as a target of retinoid regulation in limb blastemal cells. Cash DE, et al. **Gene** 1998 Nov 5;222(1):119–24

Tracing the evolutionary origin of the TFF-domain, an ancient motif at mucous surfaces. Sommer P, et al. **Gene** 1999 Aug 5;236(1):133–6

Isolation of zebrafish gdf7 and comparative genetic mapping of genes belonging to the growth/differentiation factor 5, 6, 7 subgroup of the TGF-beta superfamily [see comments] Davidson AJ, et al. **Genome Res** 1999 Feb;9(2):121–9. Comment in: Genome Res 1999 Feb;9(2):99–100.

Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Levy MT, et al. **Hepatology** 1999 Jun;29(6):1768–78

Zonal regulation of gene expression during liver regeneration of urokinase transgenic mice. Locaputo S, et al. **Hepatology** 1999 Apr;29(4):1106–13

Fibroblast growth factor homologous factor 2 (FHF2): gene structure, expression and mapping to the Börjeson-Forssman-Lehmann syndrome region in Xq26 delineated by a duplication breakpoint in a BFLS-like patient. Gecz J, et al. **Hum Genet** 1999 Jan;104(1):56–63

Variable distribution of TFF2 (Spasmolysin) alleles in Europeans does not indicate predisposition to gastric cancer. dos Santos Silva E, et al. **Hum Hered** 1999 Jan; 49(1):45–7

Molecular cloning of the guinea pig GRO gene and its rapid expression in the tissues of lipopolysaccharide-injected guinea pigs. Yoshimura T, et al. **Int Arch Allergy Immunol** 1999 Jun;119(2):101–11

Translational control of growth factor and proto-oncogene expression. Willis AE. **Int J Biochem Cell Biol** 1999 Jan; 31(1):73–86 (77 ref.)

Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Frühwald MC, et al. **Int J Cancer** 1999 Apr 12;81(2):165–73

Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Niemeyer CC, et al. **Int J Cancer** 1999 May 17;81(4):588–91

Trefoil peptides are early markers of gastrointestinal maturation in the rat. Familari M, et al. **Int J Dev Biol** 1998 Sep;42(6):783–9

Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. Shukunami C, et al. **Int J Dev Biol** 1999 Jan;43(1):39–49

Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction. Dahiya R, et al. **Int J Impot Res** 1999 Aug;11(4):201–6

Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. el-Sakka AI, et al. **Int J Impot Res** 1999 Jun;11(3):123–32

Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Wilson SE, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2185–90

Genetic linkage mapping of the porcine fibroblast growth factor 7 (FGF7) gene. Kelly KA, et al. **J Anim Sci** 1998 Oct;76(10):2747–8

Expression of inhibin/activin subunits and their receptors and binding proteins in human preimplantation embryos. He ZY, et al. **J Assist Reprod Genet** 1999 Feb;16(2):73–80

Molecular cloning of mouse and bovine chondromodulin-II cDNAs and the growth-promoting actions of bovine recombinant protein. Shukunami C, et al. **J Biochem (Tokyo)** 1999 Mar;125(3):436–42

Biosynthesis of osteogenic growth peptide via alternative translational initiation at AUG85 of histone H4 mRNA. Bab I, et al. **J Biol Chem** 1999 May 14;274(20):14474–81

Bacterial lipopolysaccharide induces expression of the stress response genes hop and H411. Heine H, et al. **J Biol Chem** 1999 Jul 23;274(30):21049–55

Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. Murphy M, et al. **J Biol Chem** 1999 Feb 26;274(9):5830–4

The bovine mimecan gene. Molecular cloning and characterization of two major RNA transcripts generated by alternative use of two splice acceptor sites in the third exon. Tasheva ES, et al. **J Biol Chem** 1999 Jun 25; 274(26):18693–701

Differential expression of mucins and trefoil peptides in native epithelium, Barrett's metaplasia and squamous cell carcinoma of the oesophagus. Labouvie C, et al. **J Cancer Res Clin Oncol** 1999;125(2):71–6

Cutaneous rat wounds express c49a, a novel gene with homology to the human melanoma differentiation associated gene, mda-7. Soo C, et al. **J Cell Biochem** 1999 Jul 1;74(1):1–10

The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. Taupin D, et al. **J Clin Invest** 1999 May;103(9):R31–8

cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy. Anderson KM, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):705–19

Localized expression of BMP and GDF mRNA in the rodent brain. Söderström S, et al. **J Neurosci Res** 1999 Jun 1; 56(5):482–92

Immunodetection and partial cDNA sequence of the proteoglycan, superficial zone protein, synthesized by cells lining synovial joints. Schumacher BL, et al. **J Orthop Res** 1999 Jan;17(1):110–20

Angiotensin-dependent gene expression in the developing rat kidney. Hilgers KF, et al. **Kidney Int Suppl** 1998 Sep; 67:S146–8

Differential gene expression of CINC, NOS II, and ICAM-1 in endotoxemic liver cells by rG-CSF. Wanner GA, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):216–21

Cloning and characterization of peter pan, a novel Drosophila gene required for larval growth. Migeon JC, et al. **Mol Biol Cell** 1999 Jun;10(6):1733–44

Isolation of novel GRO genes and a phylogenetic analysis of the CXC chemokine subfamily in mammals. Modi WS, et al. **Mol Biol Evol** 1999 Feb;16(2):180–93

Transcription factor ATF2 cooperates with v-Jun to promote growth factor-independent proliferation in vitro and tumor formation in vivo. Huguier S, et al. **Mol Cell Biol** 1998 Dec;18(12):7020–9

Regulation of growth factor gene expression in degenerating motoneurons of the murine mutant wobbler: a cellular patch-sampling/RT-PCR study. Junier MP, et al. **Mol Cell Neurosci** 1998 Oct;12(3):168–77

Cytokine-inducible growth factor gene expression in human umbilical endothelial cells. Ko Y, et al. **Mol Cell Probes** 1999 Jun;13(3):203–11

Control of cell proliferation by Myc family genes. Eilers M. **Mol Cells** 1999 Feb 28;9(1):1–6 (70 ref.)

Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Hurvitz JR, et al. **Nat Genet** 1999 Sep;23(1):94–8

Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Glabinski AR, et al. **Neuroimmunomodulation** 1998 May-Aug; 5(3–4):166–71

Expression of immediate early gene cyr61 during the differentiation of immortalized embryonic hippocampal neuronal cells. Chung KC, et al. **Neurosci Lett** 1998 Oct 23;255(3):155–8

Expression and growth stimulatory effect of fibroblast growth factor 9 in human brain tumors. Todo T, et al. **Neurosurgery** 1998 Aug;43(2):337–46

Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Wenger C, et al. **Oncogene** 1999 Jan 28;18(4):1073–80

WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Pennica D, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14717–22

Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Valenzuela DM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1904–9

Inhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor). Zhang H, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14202–7

Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system. Hughes PE, et al. **Prog Neurobiol** 1999 Feb;57(4):421–50 (254 ref.)

AH receptor, ARNT, glucocorticoid receptor, EGF receptor, EGF, TGF alpha, TGF beta 1, TGF beta 2, and TGF beta 3 expression in human embryonic palate, and effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Abbott BD, et al. **Teratology** 1998 Aug;58(2):30–43

Modulation of serum growth factor signal transduction in Hepa 1-6 cells by acetaminophen: an inhibition of c-myc expression, NF-kappaB activation, and Raf-1 kinase activity. Boulares HA, et al. **Toxicol Sci** 1999 Apr; 48(2):264–74

The genome of cowpox virus contains a gene related to those encoding the epidermal growth factor, transforming growth factor alpha and vaccinia growth factor. da Fonseca FG, et al. **Virus Genes** 1999;18(2):151–60

[Biological wound tissue glue systems in wound healing] Stark GB, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:683–8 (Eng. Abstr.) **(Ger)**

[Molecular biology contributions to wound healing and practical applications] Werner S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:678–82 (14 ref.) (Eng. Abstr.) **(Ger)**

[Gene therapy in disorders of bone healing--an experimental model] Baltzer AW. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct; 136(5):Oa17 **(Ger)**

HISTORY

Renal growth factors: past, present and future. Schena FP, et al. **Am J Nephrol** 1999;19(2):308–12

Stanley Cohen--Nobel laureate for growth factor. Shampo MA, et al. **Mayo Clin Proc** 1999 Jun;74(6):600

IMMUNOLOGY

Virus-encoded modulators of cytokines and growth factors. Spriggs MK. **Cytokine Growth Factor Rev** 1999 Mar; 10(1):1–4 (33 ref.)

Antibodies to lens epithelium-derived growth factor (LEDGF) kill epithelial cells of whole lenses in organ culture [letter] Ayaki M, et al. **Exp Eye Res** 1999 Jul; 69(1):139–42

T-cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):342–3 (19 ref.)

ISOLATION & PURIFICATION

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Xu Y, et al. **Clin Cancer Res** 1995 Oct;1(10):1223–32

Lumichrome. A larval metamorphosis-inducing substance in the ascidian Hhalocynthia roretzi. Tsukamoto S, et al. **Eur J Biochem** 1999 Sep;264(3):785–9

Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Wuyts A, et al. **Eur J Biochem** 1999 Mar;260(2):421–9

Isolation of zebrafish gdf7 and comparative genetic mapping of genes belonging to the growth/differentiation factor 5, 6, 7 subgroup of the TGF-beta superfamily [see comments] Davidson AJ, et al. **Genome Res** 1999 Feb;9(2):121–9. Comment in: Genome Res 1999 Feb;9(2):99–100.

Extracellular product(s) of Staphylococcus aureus stimulate their own growth. Sakata N, et al. **Zentralbl Bakteriol** 1999 Jul;289(3):339–45

METABOLISM

Growth factors in continuous ambulatory peritoneal dialysis effluent. Their relation with peritoneal transport of small solutes. Lai KN, et al. **Am J Nephrol** 1999;19(3):416–22

Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin. Adamson IY, et al. **Am J Pathol** 1999 Sep;155(3):949–54

Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Germolec DR, et al. **Am J Pathol** 1998 Dec;153(6):1775–85

Pancreatic expression of keratinocyte growth factor leads to differentiation of islet hepatocytes and proliferation of duct cells. Krakowski ML, et al. **Am J Pathol** 1999 Mar; 154(3):683–91

Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Gustafsson T, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H679–85

Association of fat cell size and paracrine growth factors in development of hyperplastic obesity. Marques BG, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1898–908

Peptide growth factors regulate insulin-like growth factor binding protein production by fetal rat lung fibroblasts. Price WA. **Am J Respir Cell Mol Biol** 1999 Feb; 20(2):332–41

Growth factors and cytokines in pancreatic carcinogenesis. Friess H, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:110–21 (80 ref.)

Topical amikacin formulation induces fibroblast growth factor and cytokine release from human dermal fibroblasts. Baroni A, et al. **Arch Dermatol Res** 1999 May;291(5):296–9

In vitro regulation of expression of cartilage-derived morphogenetic proteins by growth hormone and insulinlike growth factor 1 in the bovine cricoid chondrocyte. Tomaski SM, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug;125(8):901–6

Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Suzuki F. **Biochem Biophys Res Commun** 1999 May 27;259(1):1–7 (46 ref.)

Epithelin/granulin growth factors: extracellular cofactors for HIV-1 and HIV-2 Tat proteins. Trinh DP, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):299–306

Growth factor synergism and antagonism in early neural crest development. Sieber-Blum M. **Biochem Cell Biol** 1998; 76(6):1039–50

Intestinal trefoil factor binds to intestinal epithelial cells and induces nitric oxide production: priming and enhancing effects of mucin. Tan XD, et al. **Biochem J** 1999 Mar 15; 338 (Pt 3):745–51

Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor. Hsu YR, et al. **Biochemistry** 1999 Feb 23;38(8):2523–34

Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Kubo M, et al. **Br J Dermatol** 1998 Aug; 139(2):192–7

Trefoil peptides and surgical disease. Longman RJ, et al. **Br J Surg** 1999 Jun;86(6):740–8 (69 ref.)

Immunohistochemical localization of connective tissue growth factor in the rat central nervous system. Kondo Y, et al. **Brain Res** 1999 Jul 10;834(1-2):146–51

Growth factor network disruption in prostate cancer progression. Ware JL. **Cancer Metastasis Rev** 1998–99; 17(4):443–7 (39 ref.)

Regulation of cardiovascular collagen synthesis by mechanical load. Bishop JE, et al. **Cardiovasc Res** 1999 Apr;42(1):27–44 (181 ref.)

Growth induction of hepatic stimulator substance in hepatocytes through its regulation on EGF receptors. An W, et al. **Cell Res** 1999 Mar;9(1):37–49

Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A. Koseki T, et al. **Cell Signal** 1998 Jul;10(7):517–21

Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Serneri GG, et al. **Circ Res** 1999 Jul 9;85(1):57–67

A human cell line isolated from fetal kidney produces an apparently erythroid-specific stimulating activity. Rodriguez MH, et al. **Cytokine** 1998 Aug;10(8):578–85

EGF-dependent lobule formation and FGF7-dependent stalk elongation in branching morphogenesis of mouse salivary epithelium in vitro. Morita K, et al. **Dev Dyn** 1999 Jun;215(2):148–54

Mechanisms of GDF-5 action during skeletal development. Francis-West PH, et al. **Development** 1999 Mar; 126(6):1305–15

Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor. Godden JL, et al. **Eur J Cancer** 1999 Mar; 35(3):473–80

Highly divergent amino termini of the homologous human ALR and yeast scERV1 gene products define species specific differences in cellular localization. Hofhaus G, et al. **Eur J Cell Biol** 1999 May;78(5):349–56

Internalization of growth factor-receptor complexes under the influence of antibodies initiates cell apoptosis in vitro. Lavrovsky VA, et al. **Eur J Cell Biol** 1999 Mar;78(3):194–8

Inhibins, activins and follistatins: a review of complex regulators of the reproductive system. Renier MA, et al. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):129–35 (49 ref.)

Salivary gland tissue kallikrein family and processing of growth factor precursors and proenzymes. Hosoi K, et al. **Eur J Morphol** 1998 Aug;36 Suppl:82–5

The effect of surgical wounding on tumour development. Hofer SO, et al. **Eur J Surg Oncol** 1999 Jun;25(3):231–43 (153 ref.)

The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44–57 (101 ref.)

Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Wilson SE, et al. **Exp Eye Res** 1999 Apr;68(4):377–97

Expression of fetal kidney growth factors in a kidney tumor line: role of FGF2 in kidney development. Drummond IA, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):522–33

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. Goetzl EJ, et al. **FASEB J** 1998 Dec;12(15):1589–98 (52 ref.)

Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2. Huang ST, et al. **FASEB J** 1999 Mar;13(3):467–76

The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. Cook GA, et al. **FEBS Lett** 1999 Jul 30;456(1):155–9

Three receptor genes for plasminogen related growth factors in the genome of the puffer fish Fugu rubripes. Cottage A, et al. **FEBS Lett** 1999 Jan 29;443(3):370–4

Site-directed mutagenesis of the A-factor receptor protein: Val-41 important for DNA-binding and Trp-119 important for ligand-binding. Sugiyama M, et al. **Gene** 1998 Nov 5;222(1):133–44

Induction of TFF1 gene expression in pancreas overexpressing transforming growth factor alpha. Ebert MP, et al. **Gut** 1999 Jul;45(1):105–11

Involvement of growth factors in the pathophysiology of polycystic ovary syndrome. Homburg R. **Gynecol Endocrinol** 1998 Dec;12(6):391–7 (43 ref.)

A fresh look at augmenter of liver regeneration in rats. Gandhi CR, et al. **Hepatology** 1999 May;29(5):1435–45

Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Paradis V, et al. **Hepatology** 1999 Oct;30(4):968–76

Molecular signaling in bone fracture healing and distraction osteogenesis. Liu Z, et al. **Histol Histopathol** 1999 Apr; 14(2):587–95 (90 ref.)

Growth factors in inflammatory bowel disease. Beck PL, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):44–60 (244 ref.)

Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Moretti S, et al. **Int J Cancer** 1999 Apr 20;84(2):160–8

Morphological alteration of cultured tracheobronchial epithelial cells is accompanied by the expression of chemokines, MCP-1 and CINC/gro, in rats. Yamamoto T, et al. **Int J Exp Pathol** 1998 Apr;79(2):81–92

Emerging roles for proteinases in cancer. Noël A, et al. **Invasion Metastasis** 1997;17(5):221–39 (103 ref.)

Bone morphogenetic proteins and growth and differentiation factors in the human cornea. You L, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):296–311

Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. Goldspink G. **J Anat** 1999 Apr;194 (Pt 3):323–34 (67 ref.)

Role of autocrine mediators in the regulation of embryo viability: lessons from animal models. O'Neill C. **J Assist Reprod Genet** 1998 Sep;15(8):460–5

Activin/follistatin and atherosclerosis--a review. Kozaki K, et al. **J Atheroscler Thromb** 1998;5(1):36–40 (41 ref.)

Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. Harrop JA, et al. **J Biol Chem** 1998 Oct 16;273(42):27548–56

Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions. Kumar S, et al. **J Biol Chem** 1999 Jun 11;274(24):17123–31

Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. Mikhailov D, et al. **J Biol Chem** 1999 Sep 3;274(36):25317–29

Glycosaminoglycans differentially bind HARP and modulate its biological activity. Vacherot F, et al. **J Biol Chem** 1999 Mar 19;274(12):7741–7

Chicken macrophage stimulating protein is a ligand of the receptor protein-tyrosine kinase Sea. Wahl RC, et al. **J Biol Chem** 1999 Sep 10;274(37):26361–8

A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. Wong L, et al. **J Biol Chem** 1999 Mar 26;274(13):8900–9

Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. Gu J, et al. **J Cell Biol** 1998 Nov 30; 143(5):1375–83

Import(ance) of growth factors in(to) the nucleus. Keresztes M, et al. **J Cell Biol** 1999 May 3;145(3):421–4 (46 ref.)

Overexpression of CALNUC (nucleobindin) increases agonist and thapsigargin releasable Ca2+ storage in the Golgi. Lin P, et al. **J Cell Biol** 1999 Apr 19;145(2):279–89

Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. Piek E, et al. **J Cell Physiol** 1999 Aug;180(2):141–9

Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. Aplin AE, et al. **J Cell Sci** 1999 Mar;112 (Pt 5):695–706

Receptor-mediated endocytosis of keratinocyte growth factor. Marchese C, et al. **J Cell Sci** 1998 Dec;111 (Pt 23):3517–27

Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. Derwahl M, et al. **J Clin Endocrinol Metab** 1999 Mar; 84(3):829–34 (91 ref.)

Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. Bajaj-Elliott M, et al. **J Clin Invest** 1998 Oct 15;102(8):1473–80

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. Kleeff J, et al. **J Clin Invest** 1998 Nov 1;102(9):1662–73

Growth factor release from thermally reversible tissue culture substrates. von Recum H, et al. **J Controlled Release** 1998 Nov 13;55(2–3):121–30

The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. Munro LM, et al. **J Endocrinol** 1999 May;161(2):341–7

Induction of CINC (interleukin-8) production in rat liver by non-parenchymal cells. Ohkubo K, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):696–702

Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. Wu SM, et al. **J Immunol** 1998 Oct 15; 161(8):4356–65

Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. Nanney LB, et al. **J Invest Dermatol** 1998 Oct;111(4):573–81

Kinases involved in MSP/RON signaling. Danilkovitch A, et al. **J Leukoc Biol** 1999 Mar;65(3):345–8 (47 ref.)

Beta cell proliferation and growth factors. Nielsen JH, et al. **J Mol Med** 1999 Jan;77(1):62–6 (49 ref.)

Immunodetection and partial cDNA sequence of the proteoglycan, superficial zone protein, synthesized by cells lining synovial joints. Schumacher BL, et al. **J Orthop Res** 1999 Jan;17(1):110–20

Expression of androgen receptor and growth factors in premalignant lesions of the prostate. Harper ME, et al. **J Pathol** 1998 Oct;186(2):169–77

Growth factor expression in the obstructed developing and mature rat kidney. Nguyen HT, et al. **Lab Invest** 1999 Feb; 79(2):171–84

Proteoglycans: master regulators of molecular encounter? Lander AD. **Matrix Biol** 1998 Nov;17(7):465–72 (39 ref.)

Cloning and characterization of peter pan, a novel Drosophila gene required for larval growth. Migeon JC, et al. **Mol Biol Cell** 1999 Jun;10(6):1733–44

Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Babic AM, et al. **Mol Cell Biol** 1999 Apr;19(4):2958–66

Parathyroid hormone-related protein is a positive regulator of keratinocyte growth factor expression by normal dermal fibroblasts. Blomme EA, et al. **Mol Cell Endocrinol** 1999 Jun 25;152(1–2):189–97

Molecular characterization of the follicle defects in the growth differentiation factor 9-deficient ovary. Elvin JA, et al. **Mol Endocrinol** 1999 Jun;13(6):1018–34

Paracrine actions of growth differentiation factor-9 in the mammalian ovary. Elvin JA, et al. **Mol Endocrinol** 1999 Jun;13(6):1035–48

Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Koutsilieris M, et al. **Mol Med** 1999 Feb;5(2):86–97

Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy [editorial] Wang SN, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2072–4 (12 ref.)

Modulation of the neurotransmitter release in rat cerebellar neurons by GRO beta. Ragozzino D, et al. **Neuroreport** 1998 Nov 16;9(16):3601–6

Nutritional aspects of manganese from experimental studies. Keen CL, et al. **Neurotoxicology** 1999 Apr–Jun; 20(2–3):213–23 (67 ref.)

Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Kato S, et al. **Oncology** 1998 Dec;55 Suppl 1:5–10 (32 ref.)

Modulatory proteins and processes in alliance with immune cells, mediators, and extracellular proteins in renal interstitial fibrosis. Wardle EN. **Ren Fail** 1999 Mar; 21(2):121–33 (110 ref.)

The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Cox G, et al. **Thorax** 1999 Feb; 54(2):169–79 (208 ref.)

Factors intrinsic to the neuron can induce and maintain its ability to promote axonal outgrowth: a role for BCL2? Holm K, et al. **Trends Neurosci** 1999 Jun;22(6):269–73 (37 ref.)

[Increase in the level of augmenter of liver regeneration mRNA in the rat regenerating liver after partial hepatectomy] Yang XM, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):599–601 (Eng. Abstr.) **(Chi)**

[Immunohistochemical studies on factors involved in after cataract] Shigemitsu T, et al. **Nippon Ganka Gakkai Zasshi** 1998 Aug;102(8):531–9 (Eng. Abstr.) **(Jpn)**

[Cytokines and growth factors as autocrine and paracrine modulators in the peri-implantation period] Alvarez Rodriguez C, et al. **Ginecol Obstet Mex** 1999 Feb;67:85–93 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat. Poulsen SS, et al. **Gut** 1998 Aug;43(2):240–7

PHARMACOLOGY

Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Lind M. **Acta Orthop Scand Suppl** 1998 Oct;283:2–37

Effect of antibiotic growth promoters and anticoccidials on growth of Clostridium perfringens in the caeca and on performance of broiler chickens. Elwinger K, et al. **Acta Vet Scand** 1998;39(4):433–41

Effects of growth factors and basement membrane proteins on the phenotype of U-373 MG glioblastoma cells as determined by the expression of intermediate filament proteins. Sultana S, et al. **Am J Pathol** 1998 Oct; 153(4):1157–68

Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Guo J, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L800–5

Interactions of keratinocyte growth factor with a nitrating species after marrow transplantation in mice. Haddad IY, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L391–400

Effects of growth factors and trefoil peptides on migration and replication in primary oxyntic cultures. Kato K, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1105–16

Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Sannes PL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L701–8

Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H2O2 exposure. Wu KI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L780–7

Keratinocyte growth factor enhances maturation of fetal rat lung type II cells. Chelly N, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):423–32

The modulation of gonadotrophic hormone action on the ovary by paracrine and autocrine factors. Campbell BK. **Anat Histol Embryol** 1999 Aug;28(4):247–51

Tritiated thymidine and bromodeoxyuridine double-labelling studies on growth factors and oral epithelial proliferation in the mouse. Thomson PJ, et al. **Arch Oral Biol** 1999 Sep; 44(9):721–34

Phosphatidylinositol 3-kinase is required for growth factor-induced amino acid uptake by vascular smooth muscle cells. Higaki M, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2127–32

Phosphatidylinositol 3-kinase and focal adhesion kinase are early signals in the growth factor-like responses to thrombospondin-1 seen in human vascular smooth muscle. Lymn JS, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep; 19(9):2133–40

Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Tardif G, et al. **Arthritis Rheum** 1999 Jun;42(6):1147–58

Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Zaman GJ, et al. **Biochem Pharmacol** 1999 Jan 1;57(1):57–64

Role of 2-amino-3-carboxy-1,4-naphthoquinone, a strong growth stimulator for bifidobacteria, as an electron transfer mediator for NAD(P)(+) regeneration in Bifidobacterium longum. Yamazaki S, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2–3):241–50

Mechanistic study on the roles of a bifidogenetic growth stimulator based on physicochemical characterization. Yamazaki S, et al. **Biochim Biophys Acta** 1998 Nov 27; 1425(3):516–26

Secretion of protease nexin-II/amyloid beta protein precursor by human colorectal carcinoma cells and its modulation by cytokines/growth factors and proteinase inhibitors. Seguchi K, et al. **Biol Chem** 1999 Apr; 380(4):473–83

Growth factor modulation of steroidogenic acute regulatory protein and luteinization in the pig ovary. Pescador N, et al. **Biol Reprod** 1999 Jun;60(6):1453–61

Activin A and follistatin regulate developmental competence of In vitro-produced bovine embryos. Yoshioka K, et al. **Biol Reprod** 1998 Nov;59(5):1017–22

Major biological effects of neurotrophic factors on retinal ganglion cells in mammals. Cui Q, et al. **Biol Signals Recept** 1998 Jul–Aug;7(4):220–6 (63 ref.)

Human growth factor-enhanced regeneration of transplantable human hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient mice. Cashman JD, et al. **Blood** 1999 Jan 15;93(2):481–7

Rapid differentiation of a rare subset of adult human lin(-)CD34(-)CD38(-) cells stimulated by multiple growth factors in vitro. Fujisaki T, et al. **Blood** 1999 Sep 15; 94(6):1926–32

Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Janowska-Wieczorek A, et al. **Blood** 1999 May 15; 93(10):3379-90

Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Liu RY, et al. **Blood** 1999 Apr 1;93(7):2369-79

Local administration of activin promotes fracture healing in the rat fibula fracture model. Sakai R, et al. **Bone** 1999 Aug;25(2):191-6

Effects of growth factors on the hair cells after ototoxic treatment of the neonatal mammalian cochlea in vitro. Romand R, et al. **Brain Res** 1999 Apr 17;825(1-2):46-58

Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Sullivan AM, et al. **Brain Res** 1999 Feb 6;818(1):176-9

Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Escaleira MT, et al. **Breast Cancer Res Treat** 1999 Mar;54(2):123-33

Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo. Bönig HB, et al. **Cancer** 1999 Jul 15;86(2):340-8

A combination of dietary protein depletion and PHA-induced gut growth reduce the mass of a murine non-Hodgkin lymphoma. Pryme IF, et al. **Cancer Lett** 1999 May 24;139(2):145-52

Nuclear matrix targeting of the protein kinase CK2 signal as a common downstream response to androgen or growth factor stimulation of prostate cancer cells. Guo C, et al. **Cancer Res** 1999 Mar 1;59(5):1146-51

Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Kornmann M, et al. **Cancer Res** 1998 Oct 1;58(19):4250-4

Osteogenic growth peptide enhances the rate of fracture healing in rabbits. Sun YQ, et al. **Cell Biol Int** 1998; 22(4):313-9

Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Tamatani M, et al. **Cell Death Differ** 1998 Oct;5(10):911-9

Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Moulin V, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Sep; 44(6):961-71

Alveolar epithelial fluid transport can be upregulated simultaneously in rats by two different mechanisms. Wang Y, et al. **Chest** 1999 Jul;116(1 Suppl):98S-100S

The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects. Rahim A, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):659-64

Inhibition of GROalpha-induced human endothelial cell proliferation by the alpha-chemokine inhibitor antileukinate. Fujisawa N, et al. **Cytokine** 1999 Mar; 11(3):231-8

FGF7 and FGF10 directly induce the apical ectodermal ridge in chick embryos. Yonei-Tamura S, et al. **Dev Biol** 1999 Jul 1;211(1):133-43

Endoderm differentiation and inductive effect of activin-treated ectoderm in Xenopus. Ninomiya H, et al. **Dev Growth Differ** 1999 Aug;41(4):391-400

Involvement of Smad proteins in the differentiation of pancreatic AR42J cells induced by activin A. Zhang YQ, et al. **Diabetologia** 1999 Jun;42(6):719-27

Convergent effects of growth factors, hormones, and fibronectin are necessary for the enterocyte differentiation of a colon adenocarcinoma cell line (HT29-D4). Rognoni JB, et al. **Differentiation** 1998 Sep;63(5):305-17

Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Douziech N, et al. **Endocrine** 1998 Oct;9(2):171-83

Recombinant growth differentiation factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles. Hayashi M, et al. **Endocrinology** 1999 Mar; 140(3):1236-44

erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Ignatoski KM, et al. **Endocrinology** 1999 Aug;140(8):3615-22

Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor 1 receptor. Swantek JL, et al. **Endocrinology** 1999 Jul;140(7):3163-9

Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agonists. Ochensberger B, et al. **Eur J Immunol** 1999 Jan;29(1):11-22

Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Sullivan AM, et al. **Eur J Neurosci** 1998 Dec;10(12):3681-8

Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Torsello A, et al. **Eur J Pharmacol** 1998 Nov 6; 360(2-3):123-9

Macrophage stimulating protein-induced epithelial cell adhesion is mediated by a PI3-K-dependent, but FAK-independent mechanism. Danilkovitch A, et al. **Exp Cell Res** 1999 May 1;248(2):575-82

p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Nakamura K, et al. **Exp Cell Res** 1999 Aug 1;250(2):351-63

Induction of proliferation in resting B-cells by a factor released by activated mouse spleen cells. Puri N, et al. **Exp Mol Med** 1998 Dec 31;30(4):199-204

In vitro expansion of a multipotent population of human neural progenitor cells. Carpenter MK, et al. **Exp Neurol** 1999 Aug;158(2):265-78

The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. Cook GA, et al. **FEBS Lett** 1999 Jul 30;456(1):155-9

Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Alak BM, et al. **Fertil Steril** 1998 Dec;70(6):1126-30

Keratinocyte growth factor promotes the survival, growth, and differentiation of preantral ovarian follicles. McGee EA, et al. **Fertil Steril** 1999 Apr;71(4):732-8

4-Hydroxynonenal modifies the effects of serum growth factors on the expression of the c-fos proto-oncogene and the proliferation of HeLa carcinoma cells. Kreuzer T, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):42-9

Abrogation of TGF-beta activity during retroviral transduction improves murine hematopoietic progenitor and repopulating cell gene transfer efficiency. Yu J, et al. **Gene Ther** 1998 Sep;5(9):1265-71

Neurotrophic growth factors stimulate glycosaminoglycan synthesis in identified retinal cell populations in vitro. Normand G, et al. **Glycobiology** 1998 Dec;8(12):1227-35

Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation. Denk PO, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr; 237(4):342-7

Effects of keratinocyte and hepatocyte growth factor in vivo: implications for retrovirus-mediated gene transfer to liver. Bosch A, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1747-54

Keratinocyte growth factor stimulates transduction of the respiratory epithelium by retroviral vectors. Zsengellér ZK, et al. **Hum Gene Ther** 1999 Feb 10;10(3):341-53

Partial purification of embryotrophic factors from human oviductal cells. Liu LP, et al. **Hum Reprod** 1998 Jun; 13(6):1613-9

The use of recombinant growth factors to promote human embryo development in serum-free medium. Sargent IL, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:239-48 (46 ref.)

FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons. Kanda T, et al. **Int J Dev Neurosci** 1999 Jun;17(3):191-200

ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines. Pegues JC, et al. **Int J Oncol** 1999 Jun;14(6):1169-76

Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. Wang M, et al. **Int J Oncol** 1999 Jun;14(6):1185-95

Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Farrell CL, et al. **Int J Radiat Biol** 1999 May;75(5):609-20

Angiotensin II is a growth factor in the peri-implantation rat embryo. Tebbs C, et al. **J Anat** 1999 Jul;195 (Pt 1):75-86

Effects of ractopamine HCl stereoisomers on growth, nitrogen retention, and carcass composition in rats. Ricke EA, et al. **J Anim Sci** 1999 Mar;77(3):701-7

Extracellular matrix-dependent activation of syndecan-1 expression in keratinocyte growth factor-treated keratinocytes. Määttä A, et al. **J Biol Chem** 1999 Apr 2; 274(14):9891-8

Artificial juxtacrine stimulation for tissue engineering. Ito Y, et al. **J Biomater Sci Polym Ed** 1998;9(8):879-90 (59 ref.)

Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. Bottazzi ME, et al. **J Cell Biol** 1999 Sep 20;146(6):1255-64

Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. Mori T, et al. **J Cell Physiol** 1999 Oct;181(1):153-9

Growth factor regulation of the amylase promoter in a differentiating salivary acinar cell line. Zheng C, et al. **J Cell Physiol** 1998 Dec;177(4):628-35

Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. Gillis P, et al. **J Cell Sci** 1999 Jun;112 (Pt 12):2049-57

Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans. Ghigo E, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):285-90

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. Korbonits M, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2489-95

Effects of activin on hormone secretion by single female rat pituitary cells: analysis by cell immunoblot assay. Miyamoto S, et al. **J Endocrinol** 1999 Jun;161(3):375-82

Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women. Arvat E, et al. **J Endocrinol Invest** 1998 Nov;21(10):673-9

Regulation of vascular endothelial growth factor secretion in human meningioma cells. Tsai JC, et al. **J Formos Med Assoc** 1999 Feb;98(2):111-7

Glucagon-like peptide 2 is a potent growth factor for small intestine and colon. Litvak DA, et al. **J Gastrointest Surg** 1998 Mar-Apr;2(2):146-50

Improvement in liver fibrosis, functionality and hemodynamics in CCl4-cirrhotic rats after injection of the Liver Growth Factor. Díaz-Gil JJ, et al. **J Hepatol** 1999 Jun;30(6):1065-72

Growth factors and gene expression in cultured rat hepatocytes. Grunnet N, et al. **J Hepatol** 1999 Jul; 31(1):117-22

A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor. Baly DL, et al. **J Immunol** 1998 Nov 1;161(9):4944-9

Activin A regulates the production of mature interleukin-1beta and interleukin-1 receptor antagonist in human monocytic cells. Ohguchi M, et al. **J Interferon Cytokine Res** 1998 Jul;18(7):491-8

Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. Varney ML, et al. **J Interferon Cytokine Res** 1999 Apr; 19(4):351-60

Migration of human keratinocytes in electric fields requires growth factors and extracellular calcium. Fang KS, et al. **J Invest Dermatol** 1998 Nov;111(5):751-6

Midbrain dopaminergic neurons are protected from radical induced damage by GDF-5 application. Short communication. Lingor P, et al. **J Neural Transm** 1999; 106(2):139-44

CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. Giovannelli A, et al. **J Neuroimmunol** 1998 Dec 1;92(1-2):122-32

The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. Robinson S, et al. **J Neurosci** 1998 Dec 15;18(24):10457-63

Quantification of Fos immunoreactivity in cortical cultures treated with growth factors. Bilsland JG, et al. **J Neurosci Methods** 1998 Oct 1;84(1-2):121-30

Isolation and culture of human neuromicrovascular endothelial cells for the study of angiogenesis in vitro. Lamszus K, et al. **J Neurosci Res** 1999 Feb 1;55(3):370-81

Biological actions of the epidermal growth factors-like domain peptides of mouse schwannoma-derived growth factor and human amphiregulin. Takenouchi T, et al. **J Pept Res** 1999 Feb;53(2):120-5

Angiotensin-II increases cytoplasmic calcium, cell number and total DNA for human periodontal ligamental cells in vitro. Lundergan WP, et al. **J Periodontal Res** 1999 May; 34(4):223-8

Periodontal ligament cells from insulin-dependent diabetics exhibit altered alkaline phosphatase activity in response to growth factors. Hobbs HC, et al. **J Periodontol** 1999 Jul; 70(7):736-42

Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. Miceli R, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):464-71

Enhanced proliferation and progesterone production by porcine granulosa cells cultured with pseudorabies virus growth factor (PRGF). Pieklo R, et al. **J Physiol Pharmacol** 1999 Mar;50(1):129-37

Specificity and synergism of polypeptide growth factors in stimulating the synthesis of proteoglycans and a novel high molecular weight anionic glycoprotein by articular chondrocyte cultures. Chopra R, et al. **J Rheumatol** 1998 Aug;25(8):1578-84

The regulation of oestrone sulphate formation in breast cancer cells. Purohit A, et al. **J Steroid Biochem Mol Biol** 1999 Feb;68(3-4):129-35

Keratinocyte growth factor-2 accelerates wound healing in incisional wounds. Jimenez PA, et al. **J Surg Res** 1999 Feb; 81(2):238-42

Gut-trophic effects of keratinocyte growth factor in rat small intestine and colon during enteral refeeding. Estivariz CF, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep-Oct; 22(5):259-67

Trefoil factor-2, human spasmolytic polypeptide, promotes branching morphogenesis in MCF-7 cells. Lalani EN, et al. **Lab Invest** 1999 May;79(5):537-46

FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Meyer C, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):577-81

Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. Rigamonti AE, et al. **Metabolism** 1999 Feb;48(2):176-82

The use of avoparcin as a growth promoter and the occurrence of vancomycin-resistant Enterococcus species in Norwegian poultry and swine production. Kruse H, et al. **Microb Drug Resist** 1999 Summer;5(2):135-9

Growth factors reverse the impaired sprouting of microvessels from aged mice. Arthur WT, et al. **Microvasc Res** 1998 May;55(3):260-70

Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Chausovsky A, et al. **Mol Biol Cell** 1998 Nov;9(11):3195-209

Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Nolan E, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):13-20

Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Ram PT, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1-2):53-64

Regulation of oligodendrocyte development. Orentas DM,

et al. **Mol Neurobiol** 1998 Dec;18(3):247-59 (90 ref.)

Beta-casomorphin-5 stimulates neurite outgrowth in a mouse neuroblastoma cell line (Neuro-2a). Sakaguchi M, et al. **Neurosci Lett** 1998 Jul 24;251(2):97-100

Activin co-operates with fibroblast growth factor 2 to regulate tyrosine hydroxylase expression in the basal forebrain ventricular zone progenitors. Daadi M, et al. **Neuroscience** 1998 Oct;86(3):867-80

Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms. Ensoli F, et al. **Neuroscience** 1998 Oct;86(3):881-93

Fibroblast growth factor-9 (glia-activating factor) stimulates proliferation and production of glial fibrillary acidic protein in human gliomas either in the presence or in the absence of the endogenous growth factor expression. Miyagi N, et al. **Oncol Rep** 1999 Jan-Feb;6(1):87-92

Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Varani J, et al. **Pathobiology** 1998;66(6):253-9

Characterization of a newly established human acinic cell adenocarcinoma cell line (HACC) originating from the salivary gland: morphological features and role of various growth factors on the growth of the HACC cell line. Fukuda T, et al. **Pathol Int** 1998 Oct;48(10):791-9

Differential behavioral effects of TFF peptides: injections of synthetic TFF3 into the rat amygdala. Schwarzberg H, et al. **Pharmacol Biochem Behav** 1999 Jan;62(1):173-8

Influence of growth factors on poultry myogenic satellite cells. McFarland DC. **Poult Sci** 1999 May;78(5):747-58 (139 ref.)

Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the mitogenic trefoil factor 2 in colon carcinoma cells. Efstathiou JA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2316-21

Growth factor-mediated Fyn signaling regulates alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression in rodent neocortical neurons [published erratum appears in Proc Natl Acad Sci U S A 1999 May 11;96(10):5890] Narisawa-Saito M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2461-6

Effects of angiogenic growth factors on endothelium-derived prostacyclin production by ovine uterine and placental arteries. Krishnamurthy P, et al. **Prostaglandins Other Lipid Mediat** 1999 Jan;57(1):1-12

Ceruloplasmin releases pH-induced inhibition of cell proliferation stimulated by growth factors. Alcain FJ, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):287-93

Comparative effect of growth hormone and pilorecercoid growth factor in the intestinal resection in rat. Candelas S, et al. **Rev Esp Enferm Dig** 1998 Sep;90(9):625-38 **(Eng, Spa)**

Chemokine stimulation of human neutrophil [Ca2+]i signaling in biologic environments. Hauser CJ, et al. **Shock** 1998 Nov;10(5):324-8

Thrombopoietin combined with early-acting growth factors effectively expands human hematopoietic progenitor cells in vitro. Hunnestad JA, et al. **Stem Cells** 1999;17(1):31-8

Integrated stimulation by CXC chemokines enhances PMN [Ca2+]i signaling in trauma and adult respiratory distress syndrome. Hauser CJ, et al. **Surgery** 1999 Aug; 126(2):208-15

Follistatin possesses trunk and tail organizer activity and lacks head organizer activity. Kablar B. **Tissue Cell** 1999 Feb;31(1):28-33

Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Danilenko DM. **Toxicol Pathol** 1999 Jan-Feb;27(1):64-71 (24 ref.)

In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent. Soler PM, et al. **Wound Repair Regen** 1999 May-Jun;7(3):172-8

Ideal concentration of growth factors in rabbit's flexor tendon culture. Kang HJ, et al. **Yonsei Med J** 1999 Feb; 40(1):26-9

[Protective effects of hepatic stimulator substance on experimental liver fibrosis in rats] Han W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):137, 167, 153 **(Chi)**

[In vitro stimulation of HTC hepatoma cell growth by recombinant human augmenter of liver regeneration (ALR)] Yang XM, et al. **Sheng Li Hsueh Pao** 1997 Oct; 49(5):557-61 (Eng. Abstr.) **(Chi)**

[Health council report: "Antimicrobial growth promoters"] Goettsch W, et al. **Tijdschr Diergeneeskd** 1999 Mar 1; 124(5):142-4 (13 ref.) (Eng. Abstr.) **(Dut)**

[The situation concerning antibiotic resistance from the viewpoint of the bacteriologist] Nicolet J, et al. **Schweiz Arch Tierheilkd** 1999;141(3):99-102 (0 ref.) (Eng. Abstr.) **(Fre)**

[Stimulation of the proliferation of metastatic cancer cells by environmental growth factors and cytokines] Yamori T, et al. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1209-13 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A growth supplement for "fastidious germs"] Tamargo Martinez I, et al. **Rev Cubana Med Trop** 1995;47(3):189-94 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Long-term effects of intracellular calcium and growth factors on excitation and contraction in smooth muscle. Hellstrand P. **Acta Physiol Scand** 1998 Dec;164(4):637-44 (43 ref.)

KGF prevents hyperoxia-induced reduction of active ion transport in alveolar epithelial cells. Borok Z, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1352-60

Cell type-specific requirement of the MAPK pathway for the growth factor action of gastrin. Stepan VM, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1363-72

Growth factors and their receptors in the olfactory system. Plendl J, et al. **Anat Histol Embryol** 1999 May;28(2):73-9 (78 ref.)

Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis. di Mola FF, et al. **Ann Surg** 1999 Jul;230(1):63-71

Osteoblast-derived growth factors enhance adriamycin-cytostasis of MCF-7 human breast cancer cells. Choki I, et al. **Anticancer Res** 1998 Nov-Dec; 18(6A):4213-24

Trophic and tropic factors in the development of the central nervous system. Nagtegaal ID, et al. **Arch Physiol Biochem** 1998 Jul;106(3):161-202 (386 ref.)

Molecular basis underlying functional pleiotropy of cytokines and growth factors. Hirano T. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):303-8 (58 ref.)

Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. LaRochelle WJ, et al. **Biochemistry** 1999 Feb 9; 38(6):1765-71

Characterization of 16- to 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings [published erratum appears in Biol Reprod 1998 Dec;59(6):1554] Ball DK, et al. **Biol Reprod** 1998 Oct;59(4):828-35

Growth factor and bcl-2 mediated survival during abortive proliferation of hybridoma cell line. Chung JD, et al. **Biotechnol Bioeng** 1998 Jan 20;57(2):164-71

Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Damstrup L, et al. **Br J Cancer** 1999 Jun;80(7):1012-9

Growth factor network disruption in prostate cancer progression. Ware JL. **Cancer Metastasis Rev** 1998-99; 17(4):443-7 (39 ref.)

Interleukin 8: an autocrine growth factor for malignant mesothelioma. Galffy G, et al. **Cancer Res** 1999 Jan 15; 59(2):367-71

BMP/GDF-signalling interactions during synovial joint development. Francis-West PH, et al. **Cell Tissue Res** 1999 Apr;296(1):111-9 (81 ref.)

Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Caplice NM, et al. **Circ Res** 1998 Dec 14-28;83(12):1264-70

Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Chiu JJ, et al. **Clin Cancer Res** 1996 Jan;2(1):215-21

Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Lu C, et al. **Clin Cancer Res** 1996 Aug;2(8):1417-25

Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Normanno N, et al. **Clin Cancer Res** 1996 Mar;2(3):601-9

Fetal growth. Styne DM. **Clin Perinatol** 1998 Dec; 25(4):917-38, vii (123 ref.)

A new family of growth and differentiation factors derived from the N-terminal domain of proopiomelanocortin (N-POMC). Denef C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):317-24 (67 ref.)

Growth factors and apoptosis in acute renal injury. Hammerman MR. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):419-24 (43 ref.)

Factors controlling hair-cell regeneration/repair in the inner ear. Staecker H, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):480-7 (52 ref.)

Keratinocyte growth factor: a unique player in epithelial repair processes. Werner S. **Cytokine Growth Factor Rev** 1998 Jun;9(2):153-65 (106 ref.)

GDF5 coordinates bone and joint formation during digit development. Storm EE, et al. **Dev Biol** 1999 May 1; 209(1):11-27

Xenopus GDF6, a new antagonist of noggin and a partner of BMPs. Chang C, et al. **Development** 1999 Aug; 126(15):3347-57

FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Qiao J, et al. **Development** 1999 Feb;126(3):547-54

Abrogation of the Cripto gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Xu C, et al. **Development** 1999 Feb; 126(3):483-94

Growth factors and the regulation of fetal growth. Hill DJ, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B60-9 (109 ref.)

Effect of growth factors and prostaglandin E2 on restitution and proliferation of rabbit esophageal epithelial cells. Jimenez P, et al. **Dig Dis Sci** 1998 Oct;43(10):2309-16

Activin from secondary follicles causes small preantral follicles to remain dormant at the resting stage. Mizunuma H, et al. **Endocrinology** 1999 Jan;140(1):37-42

Growth factors and vascular smooth muscle cell growth responses. Delafontaine P. **Eur Heart J** 1998 Jul;19 Suppl G:G18-22 (47 ref.)

Lumichrome. A larval metamorphosis-inducing substance in the ascidian Hhalocynthia roretzi. Tsukamoto S, et al. **Eur J Biochem** 1999 Sep;264(3):785-9

Activin: an endocrine or paracrine agent? [comment] Welt CK, et al. **Eur J Endocrinol** 1998 Nov;139(5):469-71. Comment on: Eur J Endocrinol 1998 Nov;139(5):487-92.

A hyperalgesic effect of intracerebroventricular cytokine-induced neutrophil chemoattractant-1 in the rat paw pressure test. Yamamoto J, et al. **Eur J Pharmacol** 1998 Dec 18;363(2-3):131-3

Thrombin: a novel renal growth factor. Grandaliano G, et al. **Exp Nephrol** 1999 Jan-Feb;7(1):20-5 (47 ref.)

Apoptosis induced by growth factor withdrawal in fibroblasts overproducing fructose 2,6-bisphosphate. Durante P, et al. **FEBS Lett** 1999 Apr 9;448(2-3):239-43

Gastrointestinal mucosal regeneration: role of growth factors. Jones MK, et al. **Front Biosci** 1999 Mar 15;4:D303-9 (79 ref.)

Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Gale NW, et al. **Genes Dev** 1999 May 1;13(9):1055-66 (76 ref.)

Neuronal patterning by BMPs: a requirement for GDF7 in the generation of a discrete class of commissural interneurons in the mouse spinal cord. Lee KJ, et al. **Genes Dev** 1998 Nov 1;12(21):3394-407

Regulation of gap junction communication by growth factors from non-neural cells to astroglia: a brief review. Reuss B, et al. **Glia** 1998 Sep;24(1):32-8 (56 ref.)

26th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism. Palma de Mallorca, October 1998. Proceedings and abstracts. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:1-163

Trefoil peptides. Wong WM, et al. **Gut** 1999 Jun;44(6):890-5 (88 ref.)

The biology of breast cancer. Nass SJ, et al. **Hematol Oncol Clin North Am** 1999 Apr;13(2):311-32 (123 ref.)

The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. Carmina E, et al. **Hum Reprod** 1999 Feb; 14(2):307-11

Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure. Gobé G, et al. **Immunol Cell Biol** 1999 Jun;77(3):279-86 (72 ref.)

Follistatin. Patel K. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1087-93 (17 ref.)

Growth-factor-dependent migration of human lung-cancer cells. Bredin CG, et al. **Int J Cancer** 1999 Jul 30; 82(3):338-45

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. De Luca A, et al. **Int J Cancer** 1999 Feb 9;80(4):589-94

The role of growth factor on regeneration of nitric oxide synthase (NOS)--containing nerves after cavernous neurotomy in the rats. Jung GW, et al. **Int J Impot Res** 1999 Aug;11(4):227-35

Growth factors: biological and clinical aspects. Ruifrok AC, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):877-81

Growth factors in bone. Solheim E. **Int Orthop** 1998; 22(6):410-6

Role of activin and other peptide growth factors in body patterning in the early amphibian embryo. Asashima M, et al. **Int Rev Cytol** 1999;191:1-52 (171 ref.)

Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Singh DP, et al. **Invest Ophthalmol Vis Sci** 1999 Jun;40(7):1444-51

Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3). Jedsadayanmata A, et al. **J Biol Chem** 1999 Aug 20; 274(34):24321-7

NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway. Lu Y, et al. **J Biol Chem** 1999 Apr 9; 274(15):10047-52

Keratinocyte growth factor down-regulates expression of the sucrase-isomaltase gene in Caco-2 intestinal epithelial cells. Zhou J, et al. **J Biol Chem** 1998 Dec 11;273(50):33367-73

Effects of GDF7/BMP12 on proliferation and alkaline phosphatase expression in rat osteoblastic osteosarcoma ROS 17/2.8 cells. Furuya K, et al. **J Cell Biochem** 1999 Feb 1;72(2):177-80

Processing and juxtacrine activity of membrane-anchored betacellulin. Tada H, et al. **J Cell Biochem** 1999 Mar 1; 72(3):423-34

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. Carpenter G. **J Cell Biol** 1999 Aug 23;146(4):697-702 (61 ref.)

Growth factors in the nucleolus? Pederson T. **J Cell Biol** 1998 Oct 19;143(2):279-81 (39 ref.)

Role of CDMP-1 in skeletal morphogenesis: promotion of mesenchymal cell recruitment and chondrocyte differentiation. Tsumaki N, et al. **J Cell Biol** 1999 Jan 11; 144(1):161-73

Growth factors and goitrogenesis. Bidey SP, et al. **J Endocrinol** 1999 Mar;160(3):321-32 (123 ref.)

Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195-8 (29 ref.)

Novel cardiovascular actions of the activins. Molloy CJ, et al. **J Endocrinol** 1999 May;161(2):179–85 (52 ref.)
A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187–93 (34 ref.)
Mechanism of progression of renal disease: growth factors and related mechanisms. Benigni A, et al. **J Hypertens Suppl** 1998 Sep;16(4):S9–12 (50 ref.)
Growth factors, apoptosis, and survival of mammary epithelial cells. Rosfjord EC, et al. **J Mammary Gland Biol Neoplasia** 1999 Apr;4(2):229–37 (89 ref.)
Regulation of neurogenesis by growth factors and neurotransmitters. Cameron HA, et al. **J Neurobiol** 1998 Aug;36(2):287–306 (204 ref.)
Keratinocyte growth factor enhances glutathione redox state in rat intestinal mucosa during nutritional repletion. Jonas CR, et al. **J Nutr** 1999 Jul;129(7):1278–84
Growth Factors and Polyamines in Mucosal Protection and Repair, International symposium. Cracow, Poland, September 12, 1998. Abstracts. **J Physiol Pharmacol** 1998 Sep;49 Suppl 2:1–21
Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. Wang Q, et al. **J Urol** 1999 Apr;161(4):1378–84
Involvement of growth-related protein in lipopolysaccharide-induced rabbit arthritis: cooperation between growth-related protein and IL-8, and interrelated regulation among TNFalpha, IL-1, IL-1 receptor antagonist, IL-8, and growth-related protein. Matsukawa A, et al. **Lab Invest** 1999 May;79(5):591–600
Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: an in vitro co-culture model of airway remodeling in asthma. Zhang S, et al. **Lab Invest** 1999 Apr;79(4):395–405
Roles of cytokines and cell cycle regulating substances in proliferation of cholesteatoma epithelium. Tanaka Y, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1102–7
Megakaryocyte growth factors and acute myeloid leukemia [letter] Kaushansky K. **Leukemia** 1999 Sep;13(9):1471
Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation. Moghal N, et al. **Mol Cell Biol** 1998 Nov; 18(11):6666–78
Roles of Genes and Growth Factors During Embryogenesis and Development of Endocrine Structures. Workshop proceedings. Geneva, Switzerland, September 18–20, 1997. **Mol Cell Endocrinol** 1998 May 25;140(1–2):1–178
Role of growth factors in shaping the developing somite. Hirsinger E, et al. **Mol Cell Endocrinol** 1998 May 25; 140(1–2):83–7 (20 ref.)
Defective whisker follicles and altered brainstem patterns in activin and follistatin knockout mice. Jhaveri S, et al. **Mol Cell Neurosci** 1998 Nov;12(4–5):206–19
Control of cell proliferation by Myc family genes. Eilers M. **Mol Cells** 1999 Feb 28;9(1):1–6 (70 ref.)
The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Spelsberg TC, et al. **Mol Endocrinol** 1999 Jun;13(6):819–28 (62 ref.)
Regulation of ion channel expression in neural cells by hormones and growth factors. Chew LJ, et al. **Mol Neurobiol** 1998 Dec;18(3):175–225 (374 ref.)
Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo [see comments] Ding J, et al. **Nature** 1998 Oct 15;395(6703):702–7. Comment in: Nature 1998 Oct 15;395(6703):641–3.
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Kong YY, et al. **Nature** 1999 Jan 28;397(6717):315–23
Pax6 controls radial glia differentiation in the cerebral cortex. Götz M, et al. **Neuron** 1998 Nov;21(5):1031–44
Trapidil-mediated inhibition of CNS remyelination results from reduced numbers and impaired differentiation of oligodendrocytes. McKay JS, et al. **Neuropathol Appl Neurobiol** 1998 Dec;24(6):498–506
Growth factors and the gastrointestinal tract. Murphy MS. **Nutrition** 1998 Oct;14(10):771–4 (33 ref.)
Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus. Gupta RW, et al. **Oncogene** 1998 Oct 29;17(17):2155–65
The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Lilly M, et al. **Oncogene** 1999 Jul 8;18(27):4022–31
Growth factors in age-related macular degeneration [letter; comment] Spraul CW, et al. **Ophthalmic Res** 1999; 31(3):243–4. Comment on: Ophthalmic Res 1997;29(5):341–53.
The rat Subcutaneous Air Sac model: a quantitative assay of antiangiogenesis in induced vessels. Lichtenberg J, et al. **Pharmacol Toxicol** 1999 Jan;84(1):34–40
The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Su ZZ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14400–5
Growth factors and gut function. Seare NJ, et al. **Proc Nutr Soc** 1998 Aug;57(3):403–8 (31 ref.)
The role of SHIP in growth factor induced signalling. Huber M, et al. **Prog Biophys Mol Biol** 1999;71(3–4):423–34 (72 ref.)
Endothelium-derived agents in pericyte function/dysfunction. Chakravarthy U, et al. **Prog Retin Eye Res** 1999 Jul;18(4):511–27 (108 ref.)
Histone acetylation in signal transduction by growth regulatory signals [see comments] Magnaghi-Jaulin L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):197–203 (105 ref.) . Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.
Peptide growth factors and signal transduction. Sidawy AN, et al. **Semin Vasc Surg** 1998 Sep;11(3):149–55 (64 ref.)
Growth factors and receptors in allograft arteriosclerosis. Delafontaine P, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):111–4 (41 ref.)
Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Dedhar S, et al. **Trends Cell Biol** 1999 Aug;9(8):319–23 (38 ref.)
Teeth. Where and how to make them. Peters H, et al. **Trends Genet** 1999 Feb;15(2):59–65 (57 ref.)
Bone- and non-bone-derived growth factors and effects on bone healing. Millis DL. **Vet Clin North Am Small Anim Pract** 1999 Sep; 29(5):1221–46 (173 ref.)
The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. van den Berg WB. **Z Rheumatol** 1999 Jun;58(3):136–41 (12 ref.)
[Neuronal growth factors—neurotrophins (see comments)] Meyer M, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2063–70 (40 ref.) (Eng. Abstr.). Comment in: Ugeskr Laeger 1999 May 24;161(21):3112–3. **(Dan)**
–Bioactive factors in milk– Buts JP. **Arch Pediatr** 1998 Mar; 5(3):298–306 (67 ref.) (Eng. Abstr.) **(Fre)**
[Role of leukocytes in the pathogenesis of trophic venous disorders] Carpentier PH. **J Mal Vasc** 1998 Oct;23(4):274–6 (23 ref.) (Eng. Abstr.) **(Fre)**
[New aspects of intrauterine growth promoters] Wiznitzer A, et al. **Harefuah** 1998 Sep;135(5–6):218–22 (38 ref.) **(Heb)**
[Signaling molecules involved in induction and early patterning of limb buds] Kawakami Y, et al. **Kaibogaku Zasshi** 1998 Dec;73(6):655–66 (97 ref.) (Eng. Abstr.) **(Jpn)**
[Growth factors in the process of inflammation and fibrosis in the lung] Matsuse T. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):413–20 (49 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular aspect of gastroduodenal ulcer healing] Terano A, et al. **Nippon Rinsho** 1998 Sep;56(9):2223–7 (18 ref.) **(Jpn)**
[New mechanism of insulin signal transduction: participation of the adenylate cyclase signal system in growth stimulating insulin effect] Plesneva SA, et al. **Zh Evol Biokhim Fiziol** 1998 Sep–Oct;34(5):529–38 **(Rus)**
[Trefoil peptides, cellular repair and progression (editorial)] Soriano A. **Gastroenterol Hepatol** 1999 Apr;22(4):188–90 (19 ref.) **(Spa)**

SECRETION

Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy. Näntö-Salonen K, et al. **Acta Paediatr** 1999 Jan; 88(1):29–33
Processing and juxtacrine activity of membrane-anchored betacellulin. Tada H, et al. **J Cell Biochem** 1999 Mar 1; 72(3):423–34
Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. Thornton MJ, et al. **J Invest Dermatol** 1998 Nov;111(5):727–32
The pathogenesis of benign prostatic hyperplasia: a proposed hypothesis and critical evaluation. Grayhack JT, et al. **J Urol** 1998 Dec;160(6 Pt 2):2375–80

STANDARDS

The role of the bioassay in the evaluation of cytokines and growth factors for regulatory decision making. Finbloom DS. **Dev Biol Stand** 1999;97:89–93
Biological standardization of cytokines and growth factors. Mire-Sluis AR, et al. **Dev Biol Stand** 1999;97:171–6

THERAPEUTIC USE

Enhanced tendon healing with GDF 5 and 6. Aspenberg P, et al. **Acta Orthop Scand** 1999 Feb;70(1):51–4
Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Barazzone C, et al. **Am J Pathol** 1999 May;154(5):1479–87
The future of recombinant growth factors in wound healing. Robson MC, et al. **Am J Surg** 1998 Aug;176(2A Suppl):80S–82S
Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Krijanovski OI, et al. **Blood** 1999 Jul 15;94(2):825–31
Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Panoskaltsis-Mortari A, et al. **Blood** 1998 Nov 15;92(10):3960–7
Osteonecrosis of the femoral head. Potential treatment with growth and differentiation factors. Mont MA, et al. **Clin Orthop** 1998 Oct;(355 Suppl):S314–35 (236 ref.)
Deterrents to the successful clinical use of growth factors that enhance protein anabolism. Wilmore DW. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):15–21 (45 ref.)
Gene therapy of wounds with growth factors. Davidson JM, et al. **Curr Top Pathol** 1999;93:111–21 (27 ref.)
Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Egger B, et al. **Dig Dis Sci** 1999 Apr;44(4):836–44
Cytokine-induced neutrophil chemoattractants in healing of gastric ulcers in rats: expression of >40-kDa chemoattractant in delayed ulcer healing by indomethacin. Yamada H, et al. **Dig Dis Sci** 1999 May;44(5):889–95
Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Tran CP, et al. **Gut** 1999 May;44(5):636–42
Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Anitua E. **Int J Oral Maxillofac Implants** 1999 Jul-Aug;14(4):529–35
Growth factors in bone. Solheim E. **Int Orthop** 1998; 22(6):410–6
The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities. Maghnie M, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3886–9
Immediate onset of DNA synthesis in remnant rat liver after 90% hepatectomy by an administration of follistatin. Kogure K, et al. **J Hepatol** 1998 Dec;29(6):977–84
Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. Sugahara K, et al. **J Pathol** 1998 Sep;186(1):90–8
Effects of fibrin glue and growth factors released from platelets on abdominal hernia repair with a resorbable PGA mesh: experimental study. Zieren J, et al. **J Surg Res** 1999 Aug;85(2):267–72
Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients. Bouabdallah R, et al. **Leukemia** 1999 Jun;13(6):950–6
A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Fujisawa N, et al. **Melanoma Res** 1999 Apr;9(2):105–14
Genetech enlightens other angiogenesis programs [news] Brower V. **Nat Biotechnol** 1999 Apr;17(4):326–7
Long-term discordant xenogeneic (porcine-to-primate) bone marrow engraftment in a monkey treated with porcine-specific growth factors. Sablinski T, et al. **Transplantation** 1999 Apr 15;67(7):972–7
EU ban on four antibiotic growth promoters [letter; comment] Taylor DJ. **Vet Rec** 1999 Feb 6;144(6):158. Comment on: Vet Rec 1999 Jan 2;144(1):27–8. Comment on: Vet Rec 1999 Jan 16;144(3):80. Comment on: Vet Rec 1999 Jan 23;144(4):104.
[Chemotherapy, interferon and growth factors in the selection of Philadelphia negative cells] Michallet M, et al. **Hematol Cell Ther** 1998 Oct;40(5):241–6 (47 ref.) **(Fre)**

TOXICITY

FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Ropiquet F, et al. **Int J Cancer** 1999 Jul 19;82(2):237–43
EU warns on growth-hormone cancer risk [news] Wadman M. **Nature** 1999 May 6;399(6731):8

URINE

Use of biosensors for rapid drug residue analysis without sample deconjugation or clean-up: a possible way forward. Elliott CT, et al. **Analyst** 1998 Dec;123(12):2469–73

GRYLLIDAE

ANATOMY & HISTOLOGY

Neural mapping of direction and frequency in the cricket cercal sensory system. Paydar S, et al. **J Neurosci** 1999 Mar 1;19(5):1771–81

CHEMISTRY

Cytoarchitecture of histamine-, dopamine-, serotonin- and octopamine-containing neurons in the cricket ventral nerve cord. Hörner M. **Microsc Res Tech** 1999 Jan 15–Feb 1; 44(2–3):137–65 (155 ref.)

DRUG EFFECTS

Quantifying the venom dose of the spider Cupiennius salei using monoclonal antibodies. Malli H, et al. **Toxicon** 1998 Dec;36(12):1959–69

EMBRYOLOGY

Vitellin processing and protein synthesis during cricket embryogenesis. Handley HL, et al. **Insect Biochem Mol Biol** 1998 Nov;28(11):875–85

ENZYMOLOGY

NADPH diaphorase histochemistry in the thoracic ganglia of locusts, crickets, and cockroaches: species differences and the impact of fixation. Ott SR, et al. **J Comp Neurol** 1999 Aug 2;410(3):387–97

PARASITOLOGY

Euryconema brevicauda n. sp. (Oxyurida: Thelastomatidae) a parasite of the mole cricket Neocurtilla claraziana

(Orthoptera: Gryllotalpidae) in Argentina. Camino NB, et al. **J Parasitol** 1999 Feb;85(1):75–6
Two new species of nematodes (Rhabditida: Diplogasteridae and Rhabditidae) parasites of Gryllodes laplatae (Orthoptera: Gryllidae) in Argentina. Reboredo GR, et al. **Mem Inst Oswaldo Cruz** 1998 Nov–Dec;93(6):763–6

PHYSIOLOGY

Physical and temporal scaling considerations in a robot model of cricket calling song preference. Lund HH, et al. **Artif Life** 1998 Winter;4(1):95–107
Distribution of input and output synapses on the central branches of bushcricket and cricket auditory afferent neurones: immunocytochemical evidence for GABA and glutamate in different populations of presynaptic boutons. Hardt M, et al. **J Comp Neurol** 1999 Jan 18;403(3):281–94
Digger wasp versus cricket: immediate actions of the predator's paralytic venom on the CNS of the prey. Ferber M, et al. **J Neurobiol** 1999 Feb 15;38(3):323–37
Cultured insect mushroom body neurons express functional receptors for acetylcholine, GABA, glutamate, octopamine, and dopamine. Cayre M, et al. **J Neurophysiol** 1999 Jan;81(1):1–14
Neural coding of sound frequency by cricket auditory receptors. Imaizumi K, et al. **J Neurosci** 1999 Feb 15; 19(4):1508–16
Immunocytochemical mapping of an RDL-like GABA receptor subunit and of GABA in brain structures related to learning and memory in the cricket Acheta domesticus. Strambi C, et al. **Learn Mem** 1998 May–Jun;5(1–2):78–89
A nested analysis of song groups and species boundaries in the Hawaiian cricket genus Laupala. Shaw KL. **Mol Phylogenet Evol** 1999 Mar;11(2):332–41

GS, STIMULATORY G-PROTEIN see **G-PROTEIN, STIMULATORY GS**

GSSG see **GLUTATHIONE DISULFIDE**

GT, TRANSDUCIN G-PROTEIN see **TRANSDUCIN**

GTP see **GUANOSINE TRIPHOSPHATE**

GTP-BINDING PROTEINS

BIOSYNTHESIS

Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Yoshioka K, et al. **Cancer Res** 1999 Apr 15;59(8):2004–10

BLOOD

Alpha2-adrenergic agonist modulation of [35S]GTPgammaS binding to guanine-nucleotide-binding-proteins in human platelet membranes. Gessi S, et al. **Life Sci** 1999; 64(16):1403–13

CHEMISTRY

Effect of cholesterol/phospholipid ratio on stimulatory GTP-binding protein function. Bai L, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1155–62
PhLPs and PhLOPs in the phosducin family of G beta gamma binding proteins. Craft CM, et al. **Biochemistry** 1998 Nov 10;37(45):15758–72
Conformational states of the nuclear GTP-binding protein Ran and its complexes with the exchange factor RCC1 and the effector protein RanBP1. Geyer M, et al. **Biochemistry** 1999 Aug 31;38(35):11250–60
Biochemical and crystallographic characterization of a Rho effector domain of the protein serine/threonine kinase N in a complex with RhoA. Maesaki R, et al. **J Struct Biol** 1999 Jun 15;126(2):166–70
Characterization of DRGs, developmentally regulated GTP-binding proteins, from pea and Arabidopsis. Devitt ML, et al. **Plant Mol Biol** 1999 Jan;39(1):75–82

GENETICS

Interferon-gamma and lipopolysaccharide induce mouse guanylate-binding protein 3 (mGBP3) expression in the murine macrophage cell line RAW264.7. Han BH. **Arch Pharm Res** 1999 Apr;22(2):130–6
Characterization of a GTP-binding protein in the ADP-ribosylation factor subfamily from Leishmania tarentolae. Sturm NR, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2–3):347–52
RhoN, a novel small GTP-binding protein expressed predominantly in neurons and hepatic stellate cells. Nishi M, et al. **Brain Res Mol Brain Res** 1999 Apr 6;67(1):74–81
GTP-binding proteins in plants. Bischoff F, et al. **Cell Mol Life Sci** 1999 Feb;55(2):233–56 (281 ref.)
A novel gene encoding a ras-like GTP-binding protein from Trypanosoma brucei: an evolutionary ancestor of the ras and rap genes of higher eukaryotes? Sowa MP, et al. **Gene** 1999 Apr 16;230(2):155–61
Characterization of a novel gene, PNUTL2, on human chromosome 17q22–q23 and its exclusion as the Meckel syndrome gene. Paavola P, et al. **Genomics** 1999 Jan 1; 55(1):122–5
Reduced IL-4–, lipopolysaccharide–, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. Itoh-Lindstrom Y, et al. **J Immunol** 1999 Sep 1;163(5):2425–31
Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages. Vestal DJ, et al. **J Interferon Cytokine Res** 1998 Nov; 18(11):977–85
A protein required for nuclear-protein import, Mog1p, directly interacts with GTP-Gsp1p, the Saccharomyces cerevisiae ran homologue. Oki M, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15388–93
MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Osaka M, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6428–33
Identification of a putative effector protein for rab11 that participates in transferrin recycling. Zeng J, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2840–5
Identification of a novel family of human Rab-like small GTP-binding proteins. Peng HL, et al. **Proc Natl Sci Counc Repub China B** 1999 Jan;23(1):38–44
[Use of a G-protein-coupled receptor to communicate. An evolutionary success] Bockaert J, et al. **C R Acad Sci III** 1998 Jul;321(7):529–51 (131 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

A new member of alpha 1-adrenoceptor-coupled G alpha h (transglutaminase II) family in pig heart: purification and characterization. Yoo SM, et al. **Exp Mol Med** 1998 Jun 30;30(2):81–6

METABOLISM

Guanine nucleotide binding proteins in cultured renal epithelia: studies with pertussis toxin and aldosterone. Sariban-Sohraby S, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):F10–7
Activation of PKC disrupts presynaptic inhibition by group II and group III metabotropic glutamate receptors and uncouples the receptor from GTP-binding proteins. Macek TA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:554–7
Low-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein. Goretzki L, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):381–6
Effect of cholesterol/phospholipid ratio on stimulatory GTP-binding protein function. Bai L, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1155–62
Calreticulin down-regulates both GTP binding and transglutaminase activities of transglutaminase II. Feng JF, et al. **Biochemistry** 1999 Aug 17;38(33):10743–9
Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Sawzdargo M, et al. **Brain Res Mol Brain Res** 1999 Feb 5;64(2):193–8
Uncoupling protein mRNA, mitochondrial GTP-binding, and T4 5'-deiodinase activity of brown adipose tissue in Daurian ground squirrel during hibernation and arousal. Liu XT, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):745–52
Inhibitory guanine nucleotide regulatory protein activation of mitogen-activated protein kinase in experimental hepatocellular carcinoma in vitro. McKillop IH, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):761–8
A new member of alpha 1-adrenoceptor-coupled G alpha h (transglutaminase II) family in pig heart: purification and characterization. Yoo SM, et al. **Exp Mol Med** 1998 Jun 30;30(2):81–6
The actin-based motility of intracellular Listeria monocytogenes is not controlled by small GTP-binding proteins of the Rho- and Ras-subfamilies. Ebel F, et al. **FEMS Microbiol Lett** 1999 Jul 1;176(1):117–24
The role of GTP-binding proteins in mechanochemical movements of microorganisms and their potential to form filamentous structures. Mikulik K. **Folia Microbiol (Praha)** 1998;43(4):339–52 (80 ref.)
Effector recognition by the small GTP-binding proteins Ras and Ral. Bauer B, et al. **J Biol Chem** 1999 Jun 18; 274(25):17763–70
Rab11BP/Rabphilin-11, a downstream target of rab11 small G protein implicated in vesicle recycling. Mammoto A, et al. **J Biol Chem** 1999 Sep 3;274(36):25517–24
Beyond nuclear transport. Ran-GTP as a determinant of spindle assembly. Kahana JA, et al. **J Cell Biol** 1999 Sep 20;146(6):1205–10 (29 ref.)
Regulation of the GTP-binding protein-based antilipolytic system of sheep adipocytes by growth hormone. Doris RA, et al. **J Endocrinol** 1998 Sep;158(3):295–303
Heterotrimeric and small molecular mass GTP-binding proteins of rat brain neuronal and glial nuclei. Bhullar RP, et al. **J Neurosci Res** 1999 Jan 1;55(1):80–6
The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins. Pederson KJ, et al. **Mol Microbiol** 1999 Apr;32(2):393–401
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP [see comments] de Rooij J, et al. **Nature** 1998 Dec 3;396(6710):474–7. Comment in: Nature 1998 Dec 3;396(6710):416–7.
A protein required for nuclear-protein import, Mog1p, directly interacts with GTP-Gsp1p, the Saccharomyces cerevisiae ran homologue. Oki M, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15388–93
Rnd proteins: a new family of Rho-related proteins that interfere with the assembly of filamentous actin structures and cell adhesion. Chardin P. **Prog Mol Subcell Biol** 1999; 22:39–50 (33 ref.)
GTP binding by class II transactivator: role in nuclear import [see comments] Harton JA, et al. **Science** 1999 Aug 27; 285(5432):1402–5. Comment in: Science 1999 Aug 27;285(5432):1367.
Perspectives: immunology. Regulating the regulator [comment] Mach B. **Science** 1999 Aug 27;285(5432):1367 . Comment on: Science 1999 Aug 27;285(5432):1402–5.
GEFs: structural basis for their activation of small GTP-binding proteins. Cherfils J, et al. **Trends Biochem Sci** 1999 Aug;24(8):306–11 (34 ref.)
G-protein-coupled, extracellular Ca(2+)-sensing receptor: a versatile regulator of diverse cellular functions. Brown EM, et al. **Vitam Horm** 1999;55:1–71 (247 ref.)

PHARMACOLOGY

The Rho-related protein Rad1 inhibits Ca2+ sensitization of rat smooth muscle. Loirand G, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):825–34
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis. Tong LJ, et al. **Mol Cell Biochem** 1998 Dec;189(1–2):55–61

PHYSIOLOGY

Rat liver GTP-binding proteins mediate changes in mitochondrial membrane potential and organelle fusion. Cortese JD. **Am J Physiol** 1999 Mar;276(3 Pt 1):C611–20
Vesicle formation: dynamic dynamin lives up to its name. Kirchhausen T. **Curr Biol** 1998 Nov 5;8(22):R792–4 (22 ref.)
C-type natriuretic peptide attenuates evoked dopamine efflux by influencing Goalpha. Takida S, et al. **Hypertension** 1999 Jan;33(1):124–9
The small GTP-binding protein RacG regulates uroid formation in the protozoan parasite Entamoeba histolytica. Guillén N, et al. **J Cell Sci** 1998 Jun;111 (Pt 12):1729–39
Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. Kouretas PC, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2669–82
Disruption of a dynamin homologue affects endocytosis, organelle morphology, and cytokinesis in Dictyostelium discoideum. Wienke DC, et al. **Mol Biol Cell** 1999 Jan; 10(1):225–43
A role for guanyl nucleotide-binding regulatory protein beta- and gamma-subunits in the expression of the adrenocorticotropin receptor. Qiu R, et al. **Mol Endocrinol** 1998 Dec;12(12):1879–87
The effects of interfering with GTP-binding proteins on the activation mechanism of calcium release-activated calcium current. Fierro L, et al. **Pflugers Arch** 1999 Mar; 437(4):547–52
Adrenoceptor-mediated regulation of myofibrillar Ca2+ sensitivity through the GTP-binding protein-related mechanisms: tension recording in beta-escin-skinned single rat cardiac cells with preserved receptor functions. Satoh S, et al. **Pflugers Arch** 1999 Apr;437(5):702–9
The small GTP-binding protein rac is a regulator of cell death in plants. Kawasaki T, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10922–6
[Evidence for a Ras/Ral signaling cascade] Urano T. **Seikagaku** 1998 Sep;70(9):1181–3 (15 ref.) **(Jpn)**

GTP CYCLOHYDROLASE

BIOSYNTHESIS

Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. Frank S, et al. **J Invest Dermatol** 1998 Dec; 111(6):1058–64
Coordinated induction of inducible nitric oxide synthase and GTP-cyclohydrolase I is dependent on inflammatory cytokines and interferon-gamma in HaCaT keratinocytes: implications for the model of cutaneous wound repair. Frank S, et al. **J Invest Dermatol** 1998 Dec;111(6):1065–71

CHEMISTRY

Purification and characterization of GTP cyclohydrolase I from Streptomyces tubercidicus, a producer of tubercidin. Yoo JC, et al. **Arch Pharm Res** 1998 Dec;21(6):692–7

DEFICIENCY

Oral phenylalanine loading profiles in symptomatic and asymptomatic gene carriers with dopa-responsive dystonia due to dominantly inherited GTP cyclohydrolase deficiency. Hyland K, et al. **J Inherit Metab Dis** 1999 May; 22(3):213–5
GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. Robinson R, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):86–9

GTP CYCLOHYDROLASE

GENETICS

Tetrahydrobiopterin metabolism and GTP cyclohydrolase I mutations in L-dopa-responsive dystonia. Bezin L, et al. **Adv Neurol** 1998;78:291-300 (93 ref.)

The effect of GTP cyclohydrolase-1 on tyrosine hydroxylase expression: implications in DOPA-responsive dystonia. Kang UJ, et al. **Adv Neurol** 1998;78:319-24

Decrease in GTP cyclohydrolase I gene expression caused by inactivation of one allele in hereditary progressive dystonia with marked diurnal fluctuation. Inagaki H, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):747-51

Complementation of the fol2 deletion in Saccharomyces cerevisiae by human and Escherichia coli genes encoding GTP cyclohydrolase I. Mancini R, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):521-7

GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice. Shimoji M, et al. **J Neurochem** 1999 Feb;72(2):757-64

GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. Robinson R, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):86-9

A novel de novo point mutation in the GTP cyclohydrolase I gene in a Japanese patient with hereditary progressive and dopa responsive dystonia [letter] Sasaki R, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):947

The reversed SoxS-binding site upstream of the ribA promoter in Escherichia coli. Koh YS, et al. **Mol Gen Genet** 1999 Mar;261(2):374-80

Linkage analysis of the hph-1 mutation and the GTP cyclohydrolase I structural gene. Montañez CS, et al. **Mol Genet Metab** 1999 Sep;68(1):91-2

Mutant GTP cyclohydrolase I in autosomal dominant dystonia and recessive hyperphenylalaninemia. Hirano M, et al. **Neurology** 1999 Jan 1;52(1):182-4

GCH1 mutation in a patient with adult-onset oromandibular dystonia. Steinberger D, et al. **Neurology** 1999 Mar 10; 52(4):877-9

A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive dystonia, familial form. Brique S, et al. **Neuroreport** 1999 Feb 25;10(3):487-91

A novel missense mutant inactivates GTP cyclohydrolase I in dopa-responsive dystonia. Hirano M, et al. **Neurosci Lett** 1999 Feb 5;260(3):181-4

[Molecular biology examinations of dopa-responsive dystonia] Romstad A, et al. **Ugeskr Laeger** 1999 May 17; 161(20):2960 **(Dan)**

ISOLATION & PURIFICATION

Purification and characterization of GTP cyclohydrolase I from Streptomyces tubercidicus, a producer of tubercidin. Yoo JC, et al. **Arch Pharm Res** 1998 Dec;21(6):692-7

METABOLISM

Protein kinase C phosphorylates and activates GTP cyclohydrolase I in rat renal mesangial cells. Lapize C, et al. **Biochem Biophys Res Commun** 1998 Oct 29; 251(3):802-5

Enzymes related to catecholamine biosynthesis in Tetrahymena pyriformis. Presence of GTP cyclohydrolase I. Nomura T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Aug; 120(4):753-60

Biosynthesis of pteridines. NMR studies on the reaction mechanisms of GTP cyclohydrolase I, pyruvoyltetrahydropterin synthase, and sepiapterin reductase. Bracher A, et al. **J Biol Chem** 1998 Oct 23; 273(43):28132-41

Histidine 179 mutants of GTP cyclohydrolase I catalyze the formation of 2-amino-5-formylamino-6-ribofuranosylamino-4(3H)-pyrimidinone triphosphate. Bracher A, et al. **J Biol Chem** 1999 Jun 11;274(24):16727-35

Potential of Escherichia coli GTP cyclohydrolase II for hydrolyzing 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. Kobayashi M, et al. **J Biol Chem** 1998 Oct 9; 273(41):26394-9

GTP cyclohydrolase I feedback regulatory protein is expressed in serotonin neurons and regulates tetrahydrobiopterin biosynthesis. Kapatos G, et al. **J Neurochem** 1999 Feb;72(2):669-75

GTP DIHYDROLASE see **GTP CYCLOHYDROLASE**

GTP 8-FORMYLHYDROLASE see **GTP CYCLOHYDROLASE**

GTP GAMMA S see **GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE)**

GTP PHOSPHOHYDROLASE

Rac and Rho. Ridley A. **Curr Biol** 1999 Mar 11;9(5):R156

Identification and characterization of a transcript for a novel Rac GTPase-activating protein in terminally differentiating 3T3-L1 adipocytes. Wooltorton EJ, et al. **DNA Cell Biol** 1999 Apr;18(4):265-73

The antibiotic micrococcin acts on protein L11 at the ribosomal GTPase centre. Porse BT, et al. **J Mol Biol** 1999 Mar 19;287(1):33-45

ANALYSIS

Identification of septins in neurofibrillary tangles in Alzheimer's disease. Kinoshita A, et al. **Am J Pathol** 1998 Nov;153(5):1551-60

ANTAGONISTS & INHIBITORS

Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Randak C, et al. **Biochem J** 1999 May 15;340 (Pt 1):227-35

Active site labeling of erythrocyte transglutaminase by o-phthalaldehyde. Matteucci G, et al. **Biol Chem** 1998 Jul; 379(7):921-4

Inhibition of GTPase activity of Gi proteins and decreased agonist affinity at M2 muscarinic acetylcholine receptors by spermine and methoctramine. Daeffler L, et al. **Br J Pharmacol** 1999 Jun;127(4):1021-9

BIOSYNTHESIS

Cell and tissue-type specific expression of Ras-related GTPase RhoB. Fritz G, et al. **Anticancer Res** 1999 May-Jun;19(3A):1681-8

Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells). Giandomenico V, et al. **Carcinogenesis** 1999 Jun; 20(6):1133-5

Hormonal control of "tissue" transglutaminase induction during programmed cell death in frog liver. Assisi L, et al. **Exp Cell Res** 1999 Mar 15;247(2):339-46

Rho GTPases are over-expressed in human tumors. Fritz G, et al. **Int J Cancer** 1999 May 31;81(5):682-7

Developmental expression of dynamin in the chick retinotectal system. Bergmann M, et al. **J Histochem Cytochem** 1999 Oct;47(10):1297-306

CHEMISTRY

Expression, purification and crystallization of a BH domain from the GTPase regulatory protein associated with focal adhesion kinase. Sheffield PJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):356-9

Dual function C-terminal domain of dynamin-1: modulation of self-assembly by interaction of the assembly site with SH3 domains. Scaife R, et al. **Biochemistry** 1998 Dec 22; 37(51):17673-9

Isomerization couples chemistry in the ATP sulfurylase-GTPase system. Wei J, et al. **Biochemistry** 1999 May 11;38(19):6311-6

Prediction of the GTPase activities by using the semiempirical molecular orbital theory. Kinoshita H, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1083-8

Dynamin: possible mechanism of "Pinchase" action. Kozlov MM. **Biophys J** 1999 Jul;77(1):604-16

Structural basis for activation of ARF GTPase: mechanisms of guanine nucleotide exchange and GTP-myristoyl switching. Goldberg J. **Cell** 1998 Oct 16;95(2):237-48

Dynamin spirals. Hinshaw JE. **Curr Opin Struct Biol** 1999 Apr;9(2):260-7 (64 ref.)

Crystal structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation. Owen DJ, et al. **EMBO J** 1998 Sep 15;17(18):5273-85

Use of CD and FT-IR to determine the secondary structure of purified proteins in the low-microgram range. Ascoli GA, et al. **Enantiomer** 1998;3(4-5):371-81

The structural basis for the regulation of tissue transglutaminase by calcium ions. Casadio R, et al. **Eur J Biochem** 1999 Jun;262(3):672-9

Structure of Gialpha1.GppNHp, autoinhibition in a galpha protein-substrate complex. Coleman DE, et al. **J Biol Chem** 1999 Jun 11;274(24):16669-72

Multiple distinct coiled-coils are involved in dynamin self-assembly. Okamoto PM, et al. **J Biol Chem** 1999 Apr 9;274(15):10277-86

A model for dynamin self-assembly based on binding between three different protein domains. Smirnova E, et al. **J Biol Chem** 1999 May 21;274(21):14942-7

GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase. Monsonego A, et al. **J Mol Biol** 1998 Oct 2;282(4):713-20

Molecular and cellular analysis of Grb2 SH3 domain mutants: interaction with Sos and dynamin. Vidal M, et al. **J Mol Biol** 1999 Jul 16;290(3):717-30

Crystal structure of ERA: a GTPase-dependent cell cycle regulator containing an RNA binding motif. Chen X, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8396-401

The helical domain of a G protein alpha subunit is a regulator of its effector. Liu W, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12878-83

[Studies of small GTPase Rab7 association with endosomes of cells expressing normal and mutant forms of epidermal growth factor receptors] Sokolova IP, et al. **Tsitologiia** 1998;40(10):862-8 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Two families of GTPases dominate the complex cellular response to IFN-gamma. Boehm U, et al. **J Immunol** 1998 Dec 15;161(12):6715-23

DRUG EFFECTS

Peptitergent PD1 affects the GTPase activity of rat brain cortical membranes. Bavec A, et al. **Peptides** 1999; 20(2):177-84

Potential drug targets: small GTPases that regulate leukocyte function. Benard V, et al. **Trends Pharmacol Sci** 1999 Sep; 20(9):365-70 (98 ref.)

GENETICS

Organization and chromosomal mapping of mouse Gh/tissue transglutaminase gene (Tgm2). Nanda N, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):151-6

The mouse ADP-ribosylation factor-like 4 gene: two separate promoters direct specific transcription in tissues and testicular germ cell. Jacobs S, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):259-65

Increased functional activity of elongation factor G with G16V mutation in the GTP-binding domain. Martemyanov KA, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1216-9

Cloning, genomic organization and chromosomal assignment of the mouse p190-B gene. Burbelo PD, et al. **Biochim Biophys Acta** 1998 Nov 26;1443(1-2):203-10

Expression of an ADP-ribosylation factor like gene, ARF4L, is induced after transient forebrain ischemia in the gerbil. Katayama T, et al. **Brain Res Mol Brain Res** 1998 May; 56(1-2):66-75

Mapping and sequencing of the murine 'tissue' transglutaminase (Tgm2) gene: absence of mutations in MRLlpr/lpr mice [letter] D'Amato M, et al. **Cell Death Differ** 1999 Mar;6(3):216-7

GTP-binding proteins in plants. Bischoff F, et al. **Cell Mol Life Sci** 1999 Feb;55(2):233-56 (281 ref.)

The Antirrhinum ERG gene encodes a protein related to bacterial small GTPases and is required for embryonic viability. Ingram GC, et al. **Curr Biol** 1998 Sep 24; 8(19):1079-82

Molecular characterization of rabE, a developmentally regulated Dictyostelium homolog of mammalian rab GTPases. Norian L, et al. **DNA Cell Biol** 1999 Jan; 18(1):59-64

Identification and functional characterization of the murine Rac2 gene promoter. Ou X, et al. **DNA Cell Biol** 1999 Mar;18(3):253-63

Stimulation of Ca2+-dependent exocytosis and arachidonic acid release in cultured mast cells (RBL-2H3) by a GTPase-deficient mutant of G alpha i3. Zussman A, et al. **Eur J Biochem** 1998 Nov 15;258(1):144-9

A RanBP1 mutation which does not visibly affect nuclear import may reveal additional functions of the ran GTPase system. Ouspenski II. **Exp Cell Res** 1998 Oct 10; 244(1):171-83

Localization of Rho GTPase in sea urchin eggs. Nishimura Y, et al. **FEBS Lett** 1998 Dec 11;441(1):121-6

Genetic interactions in yeast between Ypt GTPases and Arf guanine nucleotide exchangers. Jones S, et al. **Genetics** 1999 Aug;152(4):1543-56

Characterization of a novel gene, PNUTL2, on human chromosome 17q22-q23 and its exclusion as the Meckel syndrome gene. Paavola P, et al. **Genomics** 1999 Jan 1; 55(1):122-5

Neisseria gonorrhoeae PilA is an FtsY homolog. Arvidson CG, et al. **J Bacteriol** 1999 Feb;181(3):731-9

Cloning and analysis of the rnc-era-recO operon from Pseudomonas aeruginosa. Powell B, et al. **J Bacteriol** 1999 Aug;181(16):5111-3

Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation. Small K, et al. **J Biol Chem** 1999 Jul 23;274(30):21291-6

Rapid identification of thermotolerant Campylobacter jejuni, Campylobacter coli, Campylobacter lari, and Campylobacter upsaliensis from various geographic locations by a GTPase-based PCR-reverse hybridization assay. van Doorn LJ, et al. **J Clin Microbiol** 1999 Jun; 37(6):1790-6

Cloning and characterization of cDNAs for a bovine (Bos taurus) Mx protein. Ellinwood NM, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):745-55

The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene. Ronni T, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):773-81

Contribution of active zone subpopulation of vesicles to evoked and spontaneous release. Koenig JH, et al. **J Neurophysiol** 1999 Apr;81(4):1495-505

Rhes: A striatal-specific Ras homolog related to Dexras1. Falk JD, et al. **J Neurosci Res** 1999 Sep 15;57(6):782-8

Biochemical and molecular analyses of the C-terminal domain of Era GTPase from Streptococcus pneumoniae. Zhao G, et al. **Microbiology** 1999 Apr;145 (Pt 4):791-800

A signal recognition particle receptor gene from the early-diverging eukaryote, Giardia lamblia. Svärd SG, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):253-64

Identification of regulators for Ypt1 GTPase nucleotide cycling. Jones S, et al. **Mol Biol Cell** 1998 Oct; 9(10):2819-37

Distinct subclasses of small GTPases interact with guanine nucleotide exchange factors in a similar manner. Day GJ, et al. **Mol Cell Biol** 1998 Dec;18(12):7444-54

Characterization of the ORF YBR264c in Saccharomyces cerevisiae, which encodes a new yeast Ypt that is degraded

by a proteasome-dependent mechanism. Louvet O, et al. **Mol Gen Genet** 1999 Jun;261(4-5):589-600

Functional implications of genetic interactions between genes encoding small GTPases involved in vesicular transport in yeast. Yoo JS, et al. **Mol Gen Genet** 1999 Feb; 261(1):80-91

RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Aguirre-Ghiso JA, et al. **Oncogene** 1999 Aug 19; 18(33):4718-25

A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts. Mayer T, et al. **Oncogene** 1999 Mar 25;18(12):2117-28

Identification of a cis-regulatory element involved in phytochrome down-regulated expression of the pea small GTPase gene pra2. Inaba T, et al. **Plant Physiol** 1999 Jun; 120(2):491-500

Arabidopsis Rho-related GTPases: differential gene expression in pollen and polar localization in fission yeast. Li H, et al. **Plant Physiol** 1998 Oct;118(2):407-17

GTPase activity and biochemical characterization of a recombinant cotton fiber annexin. Shin H, et al. **Plant Physiol** 1999 Mar;119(3):925-34

Genetic interaction between YPT6 and YPT1 in Saccharomyces cerevisiae. Li B, et al. **Yeast** 1998 Jul; 14(10):915-22

IMMUNOLOGY

The function of small GTPases in signaling by immune recognition and other leukocyte receptors. Altman A, et al. **Adv Immunol** 1999;72:1-101 (561 ref.)

Identification of the autoantigen of celiac disease. Schuppan D, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:121-6 (21 ref.)

Intestinal antibodies against gliadin, tissue-transglutaminase, beta-lactoglobulin, and ovalbumin in patients with irritable bowel syndrome. Wahnschaffe U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:280-4

Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies. Uhlig H, et al. **Autoimmunity** 1998; 28(4):185-95

Autoantibodies to tissue transglutaminase as predictors of celiac disease [see comments] Dieterich W, et al. **Gastroenterology** 1998 Dec;115(6):1317-21. Comment in: Gastroenterology 1998 Dec;115(6):1584-94.

Tissue transglutaminase antibodies in dermatitis herpetiformis [letter] Porter WM, et al. **Gastroenterology** 1999 Sep; 117(3):749-50

Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease [see comments] Sulkanen S, et al. **Gastroenterology** 1998 Dec; 115(6):1322-8. Comment in: Gastroenterology 1998 Dec;115(6):1584-94.

Interferon-inducible Mx proteins in fish. Leong JC, et al. **Immunol Rev** 1998 Dec;166:349-63 (103 ref.)

Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. Bazzigaluppi E, et al. **J Autoimmun** 1999 Feb; 12(1):51-6

A monoclonal antibody to the COOH-terminal acidic portion of Ran inhibits both the recycling of Ran and nuclear protein import in living cells. Hieda M, et al. **J Cell Biol** 1999 Feb 22;144(4):645-55

Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. Dieterich W, et al. **J Invest Dermatol** 1999 Jul;113(1):133-6

Tissue transglutaminase: the Holy Grail for the diagnosis of celiac disease, at last? [editorial; comment] Fasano A. **J Pediatr** 1999 Feb;134(2):134-5. Comment on: J Pediatr 1999 Feb;134(2):166-71.

IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease [see comments] Troncone R, et al. **J Pediatr** 1999 Feb;134(2):166-71. Comment in: J Pediatr 1999 Feb;134(2):134-5.

ISOLATION & PURIFICATION

Expression, purification and crystallization of a BH domain from the GTPase regulatory protein associated with focal adhesion kinase. Sheffield PJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):356-9

Purification, characterization and crystallization of ERA, an essential GTPase from Escherichia coli. Chen X, et al. **FEBS Lett** 1999 Feb 26;445(2-3):425-30

Rab15 mediates an early endocytic event in Chinese hamster ovary cells. Zuk PA, et al. **J Biol Chem** 1999 Aug 6; 274(32):22303-12

Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages. Vestal DJ, et al. **J Interferon Cytokine Res** 1998 Nov; 18(11):977-85

METABOLISM

Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques. Zhang W, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):395-400

Role of small G proteins in yeast cell polarization and wall biosynthesis. Cabib E, et al. **Annu Rev Biochem** 1998; 67:307-33 (159 ref.)

A new role of ran GTPase. Nishimoto T. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):571-4 (69 ref.)

GTPase and transglutaminase are associated in the secretion of the rat anterior prostate. Spina AM, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):351-6

Evidence for a novel RasGAP-associated protein of 105 kDa in both mature trophoblasts and differentiating choriocarcinoma cells. Ye F, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):523-7

Molecular aspects of the endocytic pathway. Clague MJ. **Biochem J** 1998 Dec 1;336 (Pt 2):271-82 (237 ref.)

The mouse ADP-ribosylation factor-like 4 gene: two separate promoters direct specific transcription in tissues and testicular germ cell. Jacobs S, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):259-65

Gi-mediated tyrosine phosphorylation of Grb2 (growth-factor-receptor-bound protein 2)-bound dynamin-II by lysophosphatidic acid. Kranenburg O, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):11-4

Mixed-lineage kinase 2-SH3 domain binds dynamin and greatly enhances activation of GTPase by phospholipid. Rasmussen RK, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):119-24

Tyrosine-phosphorylation-dependent and rho-protein-mediated control of cellular phosphatidylinositol 4,5-bisphosphate levels. Rümenapp U, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):625-31

Restricting mobility of Gsalpha relative to the beta2-adrenoceptor enhances adenylate cyclase activity by reducing Gsalpha GTPase activity. Wenzel-Seifert K, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):519-24

Alpha 1B-adrenoceptor interacts with multiple sites of transglutaminase II: characteristics of the interaction in binding and activation. Feng JF, et al. **Biochemistry** 1999 Feb 16;38(7):2224-32

Calreticulin down-regulates both GTP binding and transglutaminase activities of transglutaminase II. Feng JF, et al. **Biochemistry** 1999 Aug 17;38(33):10743-9

Modulation of transducin GTPase activity by chimeric RGS16 and RGS9 regulators of G protein signaling and the effector molecule. McEntaffer RL, et al. **Biochemistry** 1999 Apr 20;38(16):4931-7

Dual function C-terminal domain of dynamin-1: modulation of self-assembly by interaction of the assembly site with SH3 domains. Scaife R, et al. **Biochemistry** 1998 Dec 22; 37(51):17673-9

Conformational change rate-limits GTP hydrolysis: the mechanism of the ATP sulfurylase-GTPase. Wei J, et al. **Biochemistry** 1998 Dec 8;37(49):17163-9

Increased functional activity of elongation factor G with G16V mutation in the GTP-binding domain. Martemyanov KA, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1216-9

EF-Tu, a GTPase odyssey. Krab IM, et al. **Biochim Biophys Acta** 1998 Nov 26;1443(1-2):1-22 (211 ref.)

Prediction of the GTPase activities by using the semiempirical molecular orbital theory. Kinoshita H, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1083-8

Interleukin-9-induced expression of M-Ras/R-Ras3 oncogene in T-helper clones. Louahed J, et al. **Blood** 1999 Sep 1;94(5):1701-10

Involvement of the actin cytoskeleton and p21rho-family GTPases in the pathogenesis of the human protozoan parasite Entamoeba histolytica. Godbold GD, et al. **Braz J Med Biol Res** 1998 Aug;31(8):1049-58 (69 ref.)

Structural and functional analysis of the ARF1-ARFGAP complex reveals a role for coatomer in GTP hydrolysis. Goldberg J. **Cell** 1999 Mar 19;96(6):893-902

Regulation of membrane trafficking: structural insights from a Rab/effector complex. Gonzalez L Jr, et al. **Cell** 1999 Mar 19;96(6):755-8 (22 ref.)

The Rho GTPases in macrophage motility and chemotaxis. Jones GE, et al. **Cell Adhes Commun** 1998;6(2-3):237-45 (40 ref.)

Microtubule depolymerization induces stress fibers, focal adhesions, and DNA synthesis via the GTP-binding protein Rho. Liu BP, et al. **Cell Adhes Commun** 1998 Jun; 5(4):249-55

Involvement of protein kinase C and rho GTPase in the nuclear signalling pathway by transforming growth factor-beta1 in rat-2 fibroblast cells. Choi SE, et al. **Cell Signal** 1999 Jan;11(1):71-6

Characterization of interactions of Nck with Sos and dynamin. Wunderlich L, et al. **Cell Signal** 1999 Jan; 11(1):25-9

Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Seasholtz TM, et al. **Circ Res** 1999 May 28;84(10):1186-93

Regulation of SRF activity by Rho family GTPases. Treisman R, et al. **Cold Spring Harb Symp Quant Biol** 1998; 63:643-51 (44 ref.)

Receptor-mediated substrate translocation through the nuclear pore complex without nucleotide triphosphate hydrolysis. Englmeier L, et al. **Curr Biol** 1999 Jan 14; 9(1):30-41

Byr4 and Cdc16 form a two-component GTPase-activating protein for the Spg1 GTPase that controls septation in fission yeast. Furge KA, et al. **Curr Biol** 1998 Aug 27; 8(17):947-54

The Rho1 effector Pkc1, but not Bni1, mediates signalling from Tor2 to the actin cytoskeleton. Helliwell SB, et al. **Curr Biol** 1998 Nov 5;8(22):1211-4

The ran GTPase regulates mitotic spindle assembly. Kalab P, et al. **Curr Biol** 1999 May 6;9(9):481-4

Dominant-negative inhibition of receptor-mediated endocytosis by a dynamin-1 mutant with a defective pleckstrin homology domain. Lee A, et al. **Curr Biol** 1999 Mar 11;9(5):261-4

Nuclear transport: randy couples. Macara IG. **Curr Biol** 1999 Jun 17;9(12):R436-9 (19 ref.)

Rho-family GTPases require the Arp2/3 complex to stimulate actin polymerizationin Acanthamoeba extracts. Mullins RD, et al. **Curr Biol** 1999 Apr 22;9(8):405-15

Distinct cellular effects and interactions of the Rho-family GTPase TC10. Neudauer CL, et al. **Curr Biol** 1998 Oct 22;8(21):1151-60

Importance of the pleckstrin homology domain of dynamin in clathrin-mediated endocytosis. Vallis Y, et al. **Curr Biol** 1999 Mar 11;9(5):257-60

Effectors for the Rho GTPases. Aspenström P. **Curr Opin Cell Biol** 1999 Feb;11(1):95-102 (44 ref.)

Who does the hair cell's 'do? Rho GTPases and hair-bundle morphogenesis. Kollmar R. **Curr Opin Neurobiol** 1999 Aug; 9(4):394-8 (40 ref.)

Maturation of phagosomes is accompanied by specific patterns of small GTPases. Meyer M, et al. **Electrophoresis** 1998 Oct;19(14):2528-35

Characterization of GAPCenA, a GTPase activating protein for Rab6, part of which associates with the centrosome. Cuif MH, et al. **EMBO J** 1999 Apr 1;18(7):1772-82

The rab7 GTPase controls the maturation of Salmonella typhimurium-containing vacuoles in HeLa cells. Méresse S, et al. **EMBO J** 1999 Aug 16;18(16):4394-403

The EH and SH3 domain Ese proteins regulate endocytosis by linking to dynamin and Eps15. Sengar AS, et al. **EMBO J** 1999 Mar 1;18(5):1159-71

Specific binding to a novel and essential Golgi membrane protein (Yip1p) functionally links the transport GTPases Ypt1p and Ypt31p. Yang X, et al. **EMBO J** 1998 Sep 1; 17(17):4954-63

The structural basis for the regulation of tissue transglutaminase by calcium ions. Casadio R, et al. **Eur J Biochem** 1999 Jun;262(3):672-9

The A26G replacement in the consensus sequence A-X-X-X-X-G-K-[T,S] of the guanine nucleotide binding site activates the intrinsic GTPase of the elongation factor 2 from the archaeon Sulfolobus solfataricus. De Vendittis E, et al. **Eur J Biochem** 1999 Jun;262(2):600-5

Domain structure, GTP-hydrolyzing activity and 7S RNA binding of Acidianus ambivalens ffh-homologous protein suggest an SRP-like complex in archaea. Moll R, et al. **Eur J Biochem** 1999 Jan;259(1-2):441-8

Primary structure and biochemical characterization of yeast GTPase-activating proteins with substrate preference for the transport GTPase Ypt7p. Vollmer P, et al. **Eur J Biochem** 1999 Feb;260(1):284-90

The ADP-ribosylation factor GTPase-activating protein Glo3p is involved in ER retrieval. Dogic D, et al. **Eur J Cell Biol** 1999 May;78(5):305-10

Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Jansson CC, et al. **Eur J Pharmacol** 1999 Jun 11; 374(1):137-46

The Rho GTPases have multiple effects on the actin cytoskeleton. Aspenström P. **Exp Cell Res** 1999 Jan 10; 246(1):20-5 (29 ref.)

Plant cell growth and differentiation may involve GAP regulation of Rac activity. Borg S, et al. **FEBS Lett** 1999 Jun 25;453(3):341-5

The small GTPases Rab5a, Rab5b and Rab5c are differentially phosphorylated in vitro. Chiariello M, et al. **FEBS Lett** 1999 Jun 18;453(1-2):20-4

ADP-ribosylation factor (ARF)-like 4, 6, and 7 represent a subgroup of the ARF family characterization by rapid nucleotide exchange and a nuclear localization signal. Jacobs S, et al. **FEBS Lett** 1999 Aug 13;456(3):384-8

C-terminal domains of human translation termination factors eRF1 and eRF3 mediate their in vivo interaction. Merkulova TI, et al. **FEBS Lett** 1999 Jan 22;443(1):41-7

Rhophilin, a small GTPase Rho-binding protein, is abundantly expressed in the mouse testis and localized in the principal piece of the sperm tail. Nakamura K, et al. **FEBS Lett** 1999 Feb 19;445(1):9-13

Interaction between the fission yeast nim1/cdr1 protein kinase and a dynamin-related protein. Pelloquin L, et al. **FEBS Lett** 1999 Jan 22;443(1):71-4

Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. Peng X, et al. **FEBS Lett** 1999 Mar 5;446(1):35-9

Arachidonic acid induces the activation of the stress-activated protein kinase, membrane ruffling and H2O2 production via a small GTPase Rac1. Shin EA, et al. **FEBS Lett** 1999 Jun 11;452(3):355-9

Transcytosis of immunoglobulin A in the mouse enterocyte occurs through glycolipid raft- and rab17-containing compartments. Hansen GH, et al. **Gastroenterology** 1999 Mar;116(3):610-22

Stress, superoxide, and signal transduction. Goldschmidt-Clermont PJ, et al. **Gene Expr** 1999; 7(4-6):255-60 (47 ref.)

Nuclear export of the small ribosomal subunit requires the ran-GTPase cycle and certain nucleoporins. Moy TI, et al. **Genes Dev** 1999 Aug 15;13(16):2118-33

A putative exchange factor for Rho1 GTPase is required for initiation of cytokinesis in Drosophila. Prokopenko SN, et al. **Genes Dev** 1999 Sep 1;13(17):2301–14

Detection and characterization, using fluoresceincadaverine, of amine acceptor protein substrates accessible to active transglutaminase expressed by rabbit articular chondrocytes. Lajemi M, et al. **Histochem J** 1998 Jul; 30(7):499–508

Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport. Dumanchin C, et al. **Hum Mol Genet** 1999 Jul;8(7):1263–9

Small GTPases in lymphocyte biology: Rho proteins take center stage. Henning S, et al. **Immunol Res** 1999; 20(1):29–42 (59 ref.)

Activation of Rho GTPases by Escherichia coli cytotoxic necrotizing factor 1 increases intestinal permeability in Caco-2 cells. Gerhard R, et al. **Infect Immun** 1998 Nov; 66(11):5125–31

16S rRNA is bound to era of Streptococcus pneumoniae. Meier TI, et al. **J Bacteriol** 1999 Sep;181(17):5242–9

Dynamin II is involved in endocytosis but not in the formation of transport vesicles from the trans-Golgi network. Kasai K, et al. **J Biochem (Tokyo)** 1999 Apr; 125(4):780–9

Src-mediated tyrosine phosphorylation of dynamin is required for beta2-adrenergic receptor internalization and mitogen-activated protein kinase signaling. Ahn S, et al. **J Biol Chem** 1999 Jan 15;274(3):1185–8

Second site suppressor mutations of a GTPase-deficient G-protein alpha-subunit. Selective inhibition of Gbeta gamma-mediated signaling. Apanovitch DM, et al. **J Biol Chem** 1998 Oct 30;273(44):28597–602

Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. Benard V, et al. **J Biol Chem** 1999 May 7;274(19):13198–204

The GTPase center protein L12 is required for correct ribosomal stalk assembly but not for Saccharomyces cerevisiae viability. Briones E, et al. **J Biol Chem** 1998 Nov 27;273(48):31956–61

RGS1 is expressed in monocytes and acts as a GTPase-activating protein for G-protein-coupled chemoattractant receptors. Denecke B, et al. **J Biol Chem** 1999 Sep 17;274(38):26860–8

Regions of Byr4, a regulator of septation in fission yeast, that bind Spg1 or Cdc16 and form a two-component GTPase-activating protein with Cdc16. Furge KA, et al. **J Biol Chem** 1999 Apr 16;274(16):11339–43

Distribution of ARF6 between membrane and cytosol is regulated by its GTPase cycle. Gaschet J, et al. **J Biol Chem** 1999 Jul 9;274(28):20040–5

The pleckstrin homology domains of dynamin isoforms require oligomerization for high affinity phosphoinositide binding. Klein DE, et al. **J Biol Chem** 1998 Oct 16; 273(42):27725–33

GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). Kochs G, et al. **J Biol Chem** 1999 Feb 12;274(7):4370–6

The calcineurin-dynamin 1 complex as a calcium sensor for synaptic vesicle endocytosis. Lai MM, et al. **J Biol Chem** 1999 Sep 10;274(37):25963–6

Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. Lin R, et al. **J Biol Chem** 1999 Aug 13;274(33):23633–41

Activation of the Rap1 GTPase by the B cell antigen receptor. McLeod SJ, et al. **J Biol Chem** 1998 Oct 30; 273(44):29218–23

Lipid products of phosphoinositide 3-kinase interact with Rac1 GTPase and stimulate GDP dissociation. Missy K, et al. **J Biol Chem** 1998 Nov 13;273(46):30279–86

EHSH1/intersectin, a protein that contains EH and SH3 domains and binds to dynamin and SNAP-25. A protein connection between exocytosis and endocytosis? Okamoto M, et al. **J Biol Chem** 1999 Jun 25;274(26):18446–54

Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases. Ren Y, et al. **J Biol Chem** 1998 Dec 25;273(52):34954–60

G protein alpha subunits activate tubulin GTPase and modulate microtubule polymerization dynamics. Roychowdhury S, et al. **J Biol Chem** 1999 May 7; 274(19):13485–90

Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho. A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases. Schoenwaelder SM, et al. **J Biol Chem** 1999 May 14;274(20):14359–67

Domains mediating intramolecular folding and oligomerization of MxA GTPase. Schumacher B, et al. **J Biol Chem** 1998 Oct 23;273(43):28365–70

The ADP-ribosylation factor (ARF)-related GTPase ARF-related protein binds to the ARF-specific guanine nucleotide exchange factor cytohesin and inhibits the ARF-dependent activation of phospholipase D. Schürmann A, et al. **J Biol Chem** 1999 Apr 2; 274(14):9744–51

Activation of cyclin-dependent kinase 2 (Cdk2) in growth-stimulated rat astrocytes. Geranylgeranylated Rho small GTPase(s) are essential for the induction of cyclin E gene expression. Tanaka T, et al. **J Biol Chem** 1998 Oct 9;273(41):26772–8

Dissociation of functional roles of dynamin in receptor-mediated endocytosis and mitogenic signal transduction. Whistler JL, et al. **J Biol Chem** 1999 Aug 27;274(35):24575–8

A built-in arginine finger triggers the self-stimulatory GTPase-activating activity of rho family GTPases. Zhang B, et al. **J Biol Chem** 1999 Jan 29;274(5):2609–12

The ribosome regulates the GTPase of the beta-subunit of the signal recognition particle receptor. Bacher G, et al. **J Cell Biol** 1999 Aug 23;146(4):723–30

Fibronectin matrix regulates activation of RHO and CDC42 GTPases and cell cycle progression. Bourdoulous S, et al. **J Cell Biol** 1998 Oct 5;143(1):267–76

Mitochondrial fusion in yeast requires the transmembrane GTPase Fzo1p. Hermann GJ, et al. **J Cell Biol** 1998 Oct 19;143(2):359–73

Dual function of Cyk2, a cdc15/PSTPIP family protein, in regulating actomyosin ring dynamics and septin distribution. Lippincott J, et al. **J Cell Biol** 1998 Dec 28; 143(7):1947–60

The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. Malliri A, et al. **J Cell Biol** 1998 Nov 16; 143(4):1087–99

The dynamin-related GTPase, Dnm1p, controls mitochondrial morphology in yeast. Otsuga D, et al. **J Cell Biol** 1998 Oct 19;143(2):333–49

The Drosophila Ral GTPase regulates developmental cell shape changes through the Jun NH(2)-terminal kinase pathway. Sawamoto K, et al. **J Cell Biol** 1999 Jul 26; 146(2):361–72

A human dynamin-related protein controls the distribution of mitochondria. Smirnova E, et al. **J Cell Biol** 1998 Oct 19;143(2):351–8

Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. Vickery RG, et al. **J Cell Biol** 1999 Jan 11;144(1):31–43

Chlamydia infection of epithelial cells expressing dynamin and Eps15 mutants: clathrin-independent entry into cells and dynamin-dependent productive growth. Boleti H, et al. **J Cell Sci** 1999 May;112 (Pt 10):1487–96

Participation of small GTPases in dorsal closure of the Drosophila embryo: distinct roles for Rho subfamily proteins in epithelial morphogenesis. Harden N, et al. **J Cell Sci** 1999 Feb;112 (Pt 3):273–84

The role of the ran GTPase in nuclear assembly and DNA replication: characterisation of the effects of Ran mutants. Hughes M, et al. **J Cell Sci** 1998 Oct;111 (Pt 20):3017–26

Rho family GTPases control entry of Shigella flexneri into epithelial cells but not intracellular motility. Mounier J, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2069–80

Cytoskeletal changes induced by GRAF, the GTPase regulator associated with focal adhesion kinase, are mediated by Rho. Taylor JM, et al. **J Cell Sci** 1999 Jan; 112 (Pt 2):231–42

The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Singh R, et al. **J Clin Invest** 1999 Jun;103(11):1561–70

Expression and localisation of dynamin and syntaxin during neural development and neuromuscular synapse formation. Noakes PG, et al. **J Comp Neurol** 1999 Aug 9;410(4):531–40

Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. Hashimoto A, et al. **J Exp Med** 1998 Oct 5;188(7):1287–95

Adenosine diphosphate (ADP)-ribosylation of the guanosine triphosphatase (GTPase) rho in resting peripheral blood human T lymphocytes results in pseudopodial extension and the inhibition of T cell activation. Woodside DG, et al. **J Exp Med** 1998 Oct 5;188(7):1211–21

Immunocytochemical study of endocytotic structures accumulated in HeLa cells transformed with a temperature-sensitive mutant of dynamin. Baba T, et al. **J Histochem Cytochem** 1999 May;47(5):637–48

Model of the ran-RCC1 interaction using biochemical and docking experiments. Azuma Y, et al. **J Mol Biol** 1999 Jun 18;289(4):1119–30

The neuronal architecture of Xenopus retinal ganglion cells is sculpted by rho-family GTPases in vivo. Ruchhoeft ML, et al. **J Neurosci** 1999 Oct 1;19(19):8454–63

Cupidin, an isoform of Homer/Vesl, interacts with the actin cytoskeleton and activated rho family small GTPases and is expressed in developing mouse cerebellar granule cells. Shiraishi Y, et al. **J Neurosci** 1999 Oct 1;19(19):8389–400

Correlation between self-association modes and GTPase activation of dynamin. Binns DD, et al. **J Protein Chem** 1999 Apr;18(3):277–90

Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. Li E, et al. **J Virol** 1998 Nov;72(11):8806–12

RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Pastey MK, et al. **J Virol** 1999 Sep;73(9):7262–70

MxA GTPase: oligomerization and GTP-dependent interaction with viral RNP target structures. Kochs G, et al. **Methods** 1998 Jul;15(3):255–63

Reaction dynamics of G-protein catalyzed hydrolysis of GTP as viewed by X-ray crystallographic snapshots of Gi alpha 1. Coleman DE, et al. **Methods Enzymol** 1999; 308:70–92

Purification and assembly of FtsZ. Lu C, et al. **Methods Enzymol** 1998;298:305–13

Purification, assembly, and localization of FtsZ. Mukherjee A, et al. **Methods Enzymol** 1998;298:296–305

Biochemical and molecular analyses of the C-terminal domain of Era GTPase from Streptococcus pneumoniae. Zhao G, et al. **Microbiology** 1999 Apr;145 (Pt 4):791–800

An RCC1-type guanidine exchange factor for the Ran G protein is found in the Plasmodium falciparum nucleus. Ji DD, et al. **Mol Biochem Parasitol** 1998 Sep 1;95(1):165–70

Sla1p is a functionally modular component of the yeast cortical actin cytoskeleton required for correct localization of both Rho1p-GTPase and Sla2p, a protein with talin homology. Ayscough KR, et al. **Mol Biol Cell** 1999 Apr; 10(4):1061–75

Regulation of cadherin function by Rho and Rac: modulation by junction maturation and cellular context. Braga VM, et al. **Mol Biol Cell** 1999 Jan;10(1):9–22

Differential distribution of dynamin isoforms in mammalian cells. Cao H, et al. **Mol Biol Cell** 1998 Sep;9(9):2595–609

Identification of regulators for Ypt1 GTPase nucleotide cycling. Jones S, et al. **Mol Biol Cell** 1998 Oct; 9(10):2819–37

Contribution of the GTPase domain to the subcellular localization of dynamin in the nematode Caenorhabditis elegans. Labrousse AM, et al. **Mol Biol Cell** 1998 Nov; 9(11):3227–39

Syndapin I, a synaptic dynamin-binding protein that associates with the neural Wiskott-Aldrich syndrome protein. Qualmann B, et al. **Mol Biol Cell** 1999 Feb; 10(2):501–13

Overexpression of a novel rho family GTPase, RacC, induces unusual actin-based structures and positively affects phagocytosis in Dictyostelium discoideum. Seastone DJ, et al. **Mol Biol Cell** 1998 Oct;9(10):2891–904

The small GTP-binding protein R-Ras can influence integrin activation by antagonizing a Ras/Raf-initiated integrin suppression pathway. Sethi T, et al. **Mol Biol Cell** 1999 Jun;10(6):1799–809

A Rab2 mutant with impaired GTPase activity stimulates vesicle formation from pre-Golgi intermediates. Tisdale EJ. **Mol Biol Cell** 1999 Jun;10(6):1837–49

Identification of darlin, a Dictyostelium protein with Armadillo-like repeats that binds to small GTPases and is important for the proper aggregation of developing cells. Vithalani KK, et al. **Mol Biol Cell** 1998 Nov;9(11):3095–106

Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis. Bobak DA. **Mol Cell Biochem** 1999 Mar;193(1–2):37–42 (28 ref.)

ASAP1, a phospholipid-dependent arf GTPase-activating protein that associates with and is phosphorylated by Src. Brown MT, et al. **Mol Cell Biol** 1998 Dec;18(12):7038–51

Distinct subclasses of small GTPases interact with guanine nucleotide exchange factors in a similar manner. Day GJ, et al. **Mol Cell Biol** 1998 Dec;18(12):7444–54

Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Robinson NG, et al. **Mol Cell Biol** 1999 May;19(5):3580–7

Interactions between a nuclear transporter and a subset of nuclear pore complex proteins depend on Ran GTPase. Seedorf M, et al. **Mol Cell Biol** 1999 Feb;19(2):1547–57

Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Tang Y, et al. **Mol Cell Biol** 1999 Mar;19(3):1881–91

The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Beites CL, et al. **Nat Neurosci** 1999 May;2(5):434–9

Structure and mutagenesis of the Dbl homology domain. Aghazadeh B, et al. **Nat Struct Biol** 1998 Dec; 5(12):1098–107

Functional changes in the structure of the SRP GTPase on binding GDP and Mg2+GDP. Freymann DM, et al. **Nat Struct Biol** 1999 Aug;6(8):793–801

Structures of Cdc42 bound to the active and catalytically compromised forms of Cdc42GAP. Nassar N, et al. **Nat Struct Biol** 1998 Dec;5(12):1047–52

Signal transduction. Rhapsody in G proteins [news; comment] Bos JL, et al. **Nature** 1999 Aug 26; 400(6747):820–1. Comment on: Nature 1999 Aug 26;400(6747):891–4.

Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i) [see comments] Mochizuki N, et al. **Nature** 1999 Aug 26;400(6747):891–4 . Comment in: Nature 1999 Aug 26;400(6747):820–1.

Human DNA helicase VIII: a DNA and RNA helicase corresponding to the G3BP protein, an element of the ras transduction pathway. Costa M, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):817–21

Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation. Cobellis G, et al. **Oncogene** 1998 Oct 22;17(16):2047–57

p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Genot E, et al. **Oncogene** 1998 Oct 1; 17(13):1731–8

Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation. Izawa I, et al. **Oncogene** 1998 Dec 3; 17(22):2863–71

NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent

of its Ras-GTPase accelerating activity. Mangues R, et al. **Oncogene** 1998 Oct 1;17(13):1705-16

A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Moorman JP, et al. **Oncogene** 1999 Jan 7;18(1):47-57

Small GTPase RhoD suppresses cell migration and cytokinesis. Tsubakimoto K, et al. **Oncogene** 1999 Apr 15; 18(15):2431-40

Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Zohn IM, et al. **Oncogene** 1998 Sep 17;17(11 Reviews):1415-38 (255 ref.)

GTPase activity and biochemical characterization of a recombinant cotton fiber annexin. Shin H, et al. **Plant Physiol** 1999 Mar;119(3):925-34

Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Kochs G, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2082-6

The GTPase activating factor for transducin in rod photoreceptors is the complex between RGS9 and type 5 G protein beta subunit. Makino ER, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1947-52

Rapid GTP binding and hydrolysis by G(q) promoted by receptor and GTPase-activating proteins. Mukhopadhyay S, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17; 96(17):9539-44

The small GTPase RalA targets filamin to induce filopodia. Ohta Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2122-8

Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. Rodnina MV, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9586-90

A mutation in the heterotrimeric stimulatory guanine nucleotide binding protein alpha-subunit with impaired receptor-mediated activation because of elevated GTPase activity. Warner DR, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4268-72

Small GTPases of the Rho family and cell transformation. Fort P. **Prog Mol Subcell Biol** 1999;22:159-81 (146 ref.)

Regulation of cytoskeleton and cell adhesion by Rho targets. Kaibuchi K. **Prog Mol Subcell Biol** 1999;22:23-38 (79 ref.)

Rho family proteins and regulation of the actin cytoskeleton. Ridley AJ. **Prog Mol Subcell Biol** 1999;22:1-22 (122 ref.)

The DH protein family, exchange factors for Rho-like GTPases. Stam JC, et al. **Prog Mol Subcell Biol** 1999; 22:51-83 (187 ref.)

Crosstalk between Rac and Rho [comment] Burridge K. **Science** 1999 Mar 26;283(5410):2028-9. Comment on: Science 1999 Mar 26;283(5410):2083-5.

Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Caron E, et al. **Science** 1998 Nov 27;282(5394):1717-21

Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Maekawa M, et al. **Science** 1999 Aug 6;285(5429):895-8

Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran [see comments] Ohba T, et al. **Science** 1999 May 21;284(5418):1356-8. Comment in: Science 1999 May 21;284(5418):1260-1.

Nuclear transport protein does double duty in mitosis [news; comment] Pennisi E. **Science** 1999 May 21;284(5418):1260-1 . Comment on: Science 1999 May 21;284(5418):1356-8. Comment on: Science 1999 May 21;284(5418):1359-62.

Facilitation of signal onset and termination by adenylyl cyclase. Scholich K, et al. **Science** 1999 Feb 26; 283(5406):1328-31

Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Staab JF, et al. **Science** 1999 Mar 5;283(5407):1535-8

Stimulation of microtubule aster formation and spindle assembly by the small GTPase Ran [see comments] Wilde A, et al. **Science** 1999 May 21;284(5418):1359-62. Comment in: Science 1999 May 21;284(5418):1260-1.

RGS proteins: more than just GAPs for heterotrimeric G proteins. De Vries L, et al. **Trends Cell Biol** 1999 Apr; 9(4):138-44 (67 ref.)

[Role of the multifunctional Trio protein in the control of the Rac1 and RhoA gtpase signaling pathways] Bellanger JM, et al. **C R Seances Soc Biol Fil** 1998;192(2):367-74 (Eng. Abstr.) **(Fre)**

[New targets of rho GTPases, mDia and Bnilp, and formin homology protein family] Watanabe N. **Seikagaku** 1998 Jul; 70(7):542-8 (19 ref.) **(Jpn)**

PHARMACOLOGY

Synergistic action of R-Ras and IGF-1 on Bcl-xL expression and caspase-3 inhibition in BaF3 cells: R-Ras and IGF-1 control distinct anti-apoptotic kinase pathways. Suzuki J, et al. **FEBS Lett** 1998 Oct 16;437(1-2):112-6

PHYSIOLOGY

Involvement of small GTPases in the regulation of smooth muscle contraction. Pfitzer G, et al. **Acta Physiol Scand** 1998 Dec;164(4):449-56 (62 ref.)

"Tissue" transglutaminase and apoptosis. Autuori F, et al. **Adv Biochem Eng Biotechnol** 1998;62:129-36 (63 ref.)

Regulation of endothelial cell myosin light chain kinase by Rho, cortactin, and p60(src). Garcia JG, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):L989-98

Rho-like GTPases: their role in cell adhesion and invasion. Michiels F, et al. **Biochem Soc Symp** 1999;65:125-46 (95 ref.)

Rab proteins. Martinez O, et al. **Biochim Biophys Acta** 1998 Aug 14;1404(1-2):101-12 (106 ref.)

Regulation of p21rac activation in human neutrophils. Geijsen N, et al. **Blood** 1999 Aug 1;94(3):1121-30

Signal transduction pathways regulated by the Rho family of small GTPases. Hall A. **Br J Cancer** 1999 Jul;80 Suppl 1:25-7 (17 ref.)

Characterization of the mammalian septin H5: distinct patterns of cytoskeletal and membrane association from other septin proteins. Xie H, et al. **Cell Motil Cytoskeleton** 1999;43(1):52-62

Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells. Imamura F, et al. **Clin Exp Metastasis** 1999 Mar;17(2):141-8

Vesicle formation: dynamic dynamin lives up to its name. Kirchhausen T. **Curr Biol** 1998 Nov 5;8(22):R792-4 (22 ref.)

Going for the GAP. McCormick F. **Curr Biol** 1998 Sep 24; 8(19):R673-4 (5 ref.)

Vac1p coordinates Rab and phosphatidylinositol 3-kinase signaling in Vps45p-dependent vesicle docking/fusion at the endosome. Peterson MR, et al. **Curr Biol** 1999 Feb 11;9(3):159-62

Transformation mediated by RhoA requires activity of ROCK kinases. Sahai E, et al. **Curr Biol** 1999 Feb 11; 9(3):136-45

Dynamin and its partners: a progress report. Schmid SL, et al. **Curr Opin Cell Biol** 1998 Aug;10(4):504-12 (93 ref.)

A role for Rho-like GTPases in the polarisation of mouse eight-cell blastomeres. Clayton L, et al. **Dev Biol** 1999 Jan 15;205(2):322-31

Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Iwata K, et al. **Eur J Biochem** 1999 Jul;263(2):596-602

Dietary modifications: food dependent autoimmunity in coeliac disease. Mowat AM. **Gut** 1998 Nov;43(5):599-600

Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Roberts AW, et al. **Immunity** 1999 Feb;10(2):183-96

M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. Quilliam LA, et al. **J Biol Chem** 1999 Aug 20;274(34):23850-7

Redundant and distinct functions for dynamin-1 and dynamin-2 isoforms. Altschuler Y, et al. **J Cell Biol** 1998 Dec 28;143(7):1871-81

A role for a protease in morphogenic responses during yeast cell fusion. Elia L, et al. **J Cell Biol** 1998 Sep 21; 142(6):1473-85

R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. Keely PJ, et al. **J Cell Biol** 1999 May 31; 145(5):1077-88

Rho GTPases control polarity, protrusion, and adhesion during cell movement. Nobes CD, et al. **J Cell Biol** 1999 Mar 22;144(6):1235-44

A human dynamin-related protein controls the distribution of mitochondria. Smirnova E, et al. **J Cell Biol** 1998 Oct 19;143(2):351-8

The small GTP-binding protein RacG regulates uroid formation in the protozoan parasite Entamoeba histolytica. Guillén N, et al. **J Cell Sci** 1998 Jun;111 (Pt 12):1729-39

Distinct roles for the small GTPases Cdc42 and Rho in endothelial responses to shear stress. Li S, et al. **J Clin Invest** 1999 Apr;103(8):1141-50

Septins: a highly conserved family of membrane-associated GTPases with functions in cell division and beyond. Trimble WS. **J Membr Biol** 1999 May 15;169(2):75-81 (43 ref.)

RhoA GTPase and serum response factor control selectively the expression of MyoD without affecting Myf5 in mouse myoblasts. Carnac G, et al. **Mol Biol Cell** 1998 Jul; 9(7):1891-902

Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis. Bobak DA. **Mol Cell Biochem** 1999 Mar;193(1-2):37-42 (28 ref.)

Essential role of the dynamin pleckstrin homology domain in receptor-mediated endocytosis. Achiriloaie M, et al. **Mol Cell Biol** 1999 Feb;19(2):1410-5

Control of growth and differentiation by Drosophila RasGAP, a homolog of p120 Ras-GTPase-activating protein. Feldmann P, et al. **Mol Cell Biol** 1999 Mar; 19(3):1928-37

Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular transformation, adhesion, and survival. Osada M, et al. **Mol Cell Biol** 1999 Sep;19(9):6333-44

Cell biology. Boa constrictor or rattlesnake? [news; comment] Kirchhausen T. **Nature** 1999 Apr 8;398(6727):470-1. Comment on: Nature 1999 Apr 8;398(6727):481-6.

Lipid membranes shape up [news; comment] Scales SJ, et al. **Nature** 1999 Sep 9;401(6749):123-4. Comment on: Nature 1999 Sep 9;401(6749):133-41.

Impairment of dynamin's GAP domain stimulates receptor-mediated endocytosis [see comments] Sever S, et al. **Nature** 1999 Apr 8;398(6727):481-6. Comment in: Nature 1999 Apr 8;398(6727):470-1.

The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. Burstein ES, et al. **Oncogene** 1998 Sep 24; 17(12):1617-23

Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. Murphy GA, et al. **Oncogene** 1999 Jul 1;18(26):3831-45

Anti-apoptotic function of Rac in hematopoietic cells. Nishida K, et al. **Oncogene** 1999 Jan 14;18(2):407-15

Rho GTP-binding proteins as targets for microbial pathogens. Boquet P, et al. **Prog Mol Subcell Biol** 1999; 22:183-99 (80 ref.)

Rho GTPases in development. Settleman J. **Prog Mol Subcell Biol** 1999;22:201-29 (135 ref.)

RhoGAPs and RhoGDIs, (His)tories of two families. Zalcman G, et al. **Prog Mol Subcell Biol** 1999;22:85-113 (125 ref.)

Functional diversity in the dynamin family. van der Bliek AM. **Trends Cell Biol** 1999 Mar;9(3):96-102 (64 ref.)

Is dynamin a regular motor or a master regulator? van der Bliek AM. **Trends Cell Biol** 1999 Jul;9(7):253-4 (12 ref.)

[Regulation of endothelial NO production by Rho GTPase] Laufs U, et al. **Med Klin** 1999 Apr 15;94(4):211-8 (36 ref.) (Eng. Abstr.) **(Ger)**

GTP-REGULATORY PROTEINS see **GTP-BINDING PROTEINS**

GTP RING-OPENING ENZYME see **GTP CYCLOHYDROLASE**

GTPASE see **GTP PHOSPHOHYDROLASE**

GUAIAC

Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Sinatra MA, et al. **Clin Chem** 1999 Jan;45(1):123-6

GUAIACOL

ANALOGS & DERIVATIVES

Hydrogen bonding and C-H...O interactions in 2,2'-dihydroxy-5,5'-dimethoxybiphenyl-3,3'-dicarbaldehyde. Gerkin RE. **Acta Crystallogr C** 1999 Jul 15;55 (Pt 7):1176-9

The influence of removing extracellular Ca2+ in the desensitization responses to capsaicin, zingerone and olvanil in rat trigeminal ganglion neurons. Liu L, et al. **Brain Res** 1998 Nov 2;809(2):246-52

Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. Lee E, et al. **Cancer Lett** 1998 Dec 25;134(2):163-8

METABOLISM

Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. Capeillère-Blandin C. **Biochem J** 1998 Dec 1;336 (Pt 2):395-404

Suicide inactivation of peroxidase by H2O2: kinetic equations for peroxidatic oxidation reaction of guaiacol and determination of the kinetic parameters. Moosavi Movahedi AA, et al. **Ital J Biochem** 1999 Mar;48(1):9-17

GUAIACOL GLYCERYL ETHER

ADVERSE EFFECTS

Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Pickens CL, et al. **Urology** 1999 Jul;54(1):23-7

ANALOGS & DERIVATIVES

Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Pickens CL, et al. **Urology** 1999 Jul;54(1):23-7

ANALYSIS

Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis. Pickens CL, et al. **Urology** 1999 Jul;54(1):23-7

PHARMACOLOGY

Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers. Demirbas S, et al. **Biopharm Drug Dispos** 1998 Nov;19(8):541-5

An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol [see comments] Rubin BK. **Chest** 1999 Jul;116(1):195-200 . Comment in: Chest 1999 Jul;116(1):6-8.

POISONING

Acute intoxication with guaifenesin, diphenhydramine, and chlorpheniramine. Wogoman H, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):199-202

GUAIFENESIN

GUAIFENESIN see **GUAIACOL GLYCERYL ETHER**

GUAIPHENESIN see **GUAIACOL GLYCERYL ETHER**

GUAIPHENESIN CARBAMATE see **METHOCARBAMOL**

GUANABENZ

ANALOGS & DERIVATIVES

Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. II. Description of a xanthine-dependent enzymatic activity in spleen cytosol. Dambrova M, et al. **Biochem Pharmacol** 1998 Nov 1; 56(9):1121-8

Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. I. Description of an enzymatic activity in spleen membranes. Uhlén S, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1111-9

Characterization of guanoxabenz reducing activity in rat brain. Dambrova M, et al. **Pharmacol Toxicol** 1998 Oct; 83(4):158-63

PHARMACOLOGY

Influence of arterial baroreceptors and intracerebroventricular guanabenz on synchronized renal nerve activity. Grisk O, et al. **Acta Physiol Scand** 1998 Jul;163(3):209-18

Recovery of cardiac norepinephrine concentration and tyrosine hydroxylase activity by the central alpha2-adrenoceptor agonist guanabenz in rats with aortic constriction. Takechi S, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):409-13

GUANACOS see **CAMELIDS, NEW WORLD**

GUANASE see **GUANINE DEAMINASE**

GUANAZOLO see **AZAGUANINE**

GUANETHIDINE

Interrupting the sympathetic outflow in causalgia and reflex sympathetic dystrophy. Intravenous regional guanethidine blockage is a safe and effective treatment [letter; comment] Lamacraft G, et al. **BMJ** 1998 Sep 12;317(7160):752-3. Comment on: BMJ 1998 Mar 14;316(7134):792-3.

The changes in the nervous structures under the chemical sympathectomy with guanethidine. Nozdrachev AD, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2-3):82-5

GUANFACINE

ADVERSE EFFECTS

Guanfacine and secondary mania in children. Horrigan JP, et al. **J Affect Disord** 1999 Aug;54(3):309-14

Seizure associated with bupropion and guanfacine [letter; comment] Namerow LB. **J Am Acad Child Adolesc Psychiatry** 1999 Jan;38(1):2-3. Comment on: J Am Acad Child Adolesc Psychiatry 1998 Jul;37(7):682-3.

Increased plasma valproate concentrations when coadministered with guanfacine. Ambrosini PJ, et al. **J Child Adolesc Psychopharmacol** 1998;8(2):143-7

Does guanfacine trigger mania in children? [letter] Horrigan JP, et al. **J Child Adolesc Psychopharmacol** 1998;8(2):149-50

PHARMACOLOGY

The alpha2-adrenoceptor agonists xylazine and guanfacine exert different central nervous system, but comparable peripheral effects in calves. Scholtysik G, et al. **J Vet Pharmacol Ther** 1998 Dec;21(6):477-84

Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Jäkälä P, et al. **Neuropsychopharmacology** 1999 Feb;20(2):119-30

Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Jäkälä P, et al. **Neuropsychopharmacology** 1999 Oct;21(4):495-502

Guanfacine, but not clonidine, improves planning and working memory performance in humans. Jäkälä P, et al. **Neuropsychopharmacology** 1999 May;20(5):460-70

GUANIDINE

Quantitative protein precipitation from guanidine hydrochloride-containing solutions by sodium deoxycholate/trichloroacetic acid. Arnold U, et al. **Anal Biochem** 1999 Jul 1;271(2):197-9

Guanidine-induced denaturation of beta-glycosidase from Sulfolobus solfataricus expressed in Escherichia coli. Catanzano F, et al. **Biochemistry** 1998 Oct 13; 37(41):14484-90

Unfolding of Plasmodium falciparum triosephosphate isomerase in urea and guanidinium chloride: evidence for a novel disulfide exchange reaction in a covalently cross-linked mutant. Gokhale RS, et al. **Biochemistry** 1999 Jan 5;38(1):423-31

Dynamic equilibrium unfolding pathway of human tumor necrosis factor-alpha induced by guanidine hydrochloride. Kim YR, et al. **Biochim Biophys Acta** 1999 Jan 11; 1429(2):486-95

The inactivation kinetics of papain by guanidine hydrochloride: a re-analysis. Wang ZX, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):84-92

Heat-stable pullulanase from Bacillus acidopullulyticus: characterization and refolding after guanidinium chloride-induced unfolding. Stefanova ME, et al. **Extremophiles** 1999 May;3(2):147-52

ANALOGS & DERIVATIVES

Anhydrous ammonioguanidinium(2+) and dihydrated bis[aminoguanidinium(1+)] hexafluorosilicates: new co-products of preparing ferroelectric ammonioguanidinium(2+) hexafluorozirconate. Ross CR 2nd, et al. **Acta Crystallogr B** 1999 Apr 1;55 (Pt 2):246-54

Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety. Adang AE, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3603-8

A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice. Ghosh P, et al. **Tumour Biol** 1999 Jan-Feb; 20(1):44-51

[Combined inhibition of monoamine oxidase] Nikol'skaia EB, et al. **Dokl Akad Nauk** 1999 Apr;365(6):829-31 **(Rus)**

CHEMISTRY

Guanidinium-based potentiometric SO2 gas sensor. Mowery MD, et al. **Anal Chem** 1999 Jan 1;71(1):201-4

Guanidine hydrochloride exerts dual effects on the tryptophan synthase alpha 2 beta 2 complex as a cation activator and as a modulator of the active site conformation. Fan YX, et al. **Biochemistry** 1999 Jun 15; 38(24):7881-90

Thermal versus guanidine-induced unfolding of ubiquitin. An analysis in terms of the contributions from charge-charge interactions to protein stability. Ibarra-Molero B, et al. **Biochemistry** 1999 Jun 22;38(25):8138-49

The peculiar nature of the guanidine hydrochloride-induced two-state denaturation of staphylococcal nuclease: a calorimetric study. Yang M, et al. **Biochemistry** 1999 Aug 24;38(34):11216-22

Evidence for the existence of an unfolding intermediate state for aminoacylase during denaturation in guanidine solutions. Bai JH, et al. **Biochim Biophys Acta** 1999 Feb 10;1430(1):39-45

Synthesis of protected guanidinium linked dinucleoside incorporable into an oligonucleotide using solid phase DNA methodology. Barawkar DA, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1517-20

Novel non-viral vectors for gene delivery: synthesis of a second-generation library of mono-functionalized poly-(guanidinium)amines and their introduction into cationic lipids. Byk G, et al. **Biotechnol Bioeng** 1998 Spring; 61(2):81-7

Structural characteristics of supramolecular assemblies formed by guanidinium-cholesterol reagents for gene transfection. Pitard B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2621-6

The magnitude of changes in guanidine-HCl unfolding m-values in the protein, iso-1-cytochrome c, depends upon the substructure containing the mutation. Hammack B, et al. **Protein Sci** 1998 Aug;7(8):1789-95

WW: An isolated three-stranded antiparallel beta-sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Koepf EK, et al. **Protein Sci** 1999 Apr;8(4):841-53

Biphasic denaturation of human placental alkaline phosphatase in guanidinium chloride. Hung HC, et al. **Proteins** 1998 Oct 1;33(1):49-61

METABOLISM

Studies of the denaturation patterns of bovine alpha-crystallin using an ionic denaturant, guanidine hydrochloride and a non-ionic denaturant, urea. Doss-Pepe EW, et al. **Exp Eye Res** 1998 Dec;67(6):657-79

PHARMACOLOGY

Multiple unfolded states of glutathione transferase bbGSTP1-1 by guanidinium chloride. Sacchetta P, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):100-6

Competitive inhibition of cathepsin C by guanidinium ions and reexamination of substrate inhibition. Cigić B, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):6-10

Evidence for kinetic intermediate states during the refolding of GdnHCl-denatured MM-creatine kinase. Characterization of a trapped monomeric species. Leydier C, et al. **Biochemistry** 1998 Dec 15;37(50):17579-89

The unusually slow unfolding rate causes the high stability of pyrrolidone carboxyl peptidase from a hyperthermophile, Pyrococcus furiosus: equilibrium and kinetic studies of guanidine hydrochloride-induced unfolding and refolding. Ogasahara K, et al. **Biochemistry** 1998 Dec 15;37(50):17537-44

Reversible thermal denaturation of human FGF-1 induced by low concentrations of guanidine hydrochloride. Blaber SI, et al. **Biophys J** 1999 Jul;77(1):470-7

Guanidinated casein hydrolysate stimulation of cholecystokinin release via pancreatic enzyme- and cholinergic-independent mechanisms in rats. Nishi T, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):1070-4

Induction of a spectroscopically defined transition by guanidinium hydrochloride on a recombinant calcium binding protein from Entamoeba histolytica. Gopal B, et al. **FEBS Lett** 1998 Dec 11;441(1):71-6

Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. Pfister T, et al. **J Biol Chem** 1999 Mar 12;274(11):6992-7001

The sequential mechanism of guanidine hydrochloride-induced denaturation of cAMP receptor protein from Escherichia coli. A fluorescent study using 8-anilino-1-naphthalenesulfonic acid. Malecki J, et al. **J Protein Chem** 1998 Nov;17(8):745-55

[Combined inhibition of monoamine oxidase] Nikol'skaia EB, et al. **Dokl Akad Nauk** 1999 Apr;365(6):829-31 **(Rus)**

GUANIDINE HYDROCHLORIDE see **GUANIDINE**

GUANIDINES

Proceedings of the 3rd International Symposium on Imidazoline Receptors. Bonn, Germany, July 22-24, 1998. **Ann N Y Acad Sci** 1999 Jun 21;881:1-454

Stability of RNA molecules stored in GITC. Gilleland RC, et al. **Biotechniques** 1998 Dec;25(6):944-6, 948

Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Pfeifer PH, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1190-9

Orthotopic transplantation of pig hearts harvested after 30 min of normothermic ischemia: controlled reperfusion with blood cardioplegia containing the Na+-H+-exchange inhibitor HOE 642. Martin J, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):607-14

Development of the Na+/H+ exchange inhibitor cariporide as a cardioprotective drug: from the laboratory to the GUARDIAN trial. Scholz W, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):61-70 (27 ref.)

[Seizure activity and lesions of neuronal cells by intrahippocampal injection of guanidinosuccinic acid in rats] Pan JC, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):561-7 (Eng. Abstr.) **(Chi)**

ADMINISTRATION & DOSAGE

Orally administered NHE1 inhibitor cariporide reduces acute responses to coronary occlusion and reperfusion. Humphreys RA, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H749-57

Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. Nagayama M, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1107-13

Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat. Uchida H, et al. **Transplantation** 1999 May 15;67(9):1269-74

[Effects of deoxyspergualin on proliferative glomerulonephritis] Hotta O, et al. **Nippon Jinzo Gakkai Shi** 1999 Jan;41(1):21-8 (Eng. Abstr.) **(Jpn)**

[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin] Matsukawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov; 95(11):1229-34 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

15-Deoxyspergualin and platelet aggregation in vitro [letter] Malyszko JS, et al. **Nephron** 1999;81(3):370-2

BLOOD

Rapid analysis of guanidino compounds in serum from nephritic patients using column-switching with isocratic elution. Inamoto Y, et al. **Biomed Chromatogr** 1998 Sep-Oct;12(5):239-47

Automatic system for the assay of guanidino compounds to assess uremic status and effect of hemodialysis. Nohara Y, et al. **Chem Pharm Bull (Tokyo)** 1998 Nov;46(11):1844-5

CHEMICAL SYNTHESIS

Modification of the thiourea linkage of a fluorescein-oligonucleotide conjugate to a guanidinium motif during ammonia deprotection. Dubey I, et al. **Bioconjug Chem** 1998 Sep-Oct;9(5):627-32

A labeled guanidine ligand for studying sweet taste. Feng Y, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):881-4

Liquid phase parallel synthesis of guanidines. Ho KC, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1517-20

Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles. Katsura Y, et al. **Bioorg Med Chem Lett** 1998 Jun 2;8(11):1307-12

Solid-phase synthesis of oligomeric deoxynucleic guanidine (DNG): a polycationic analogue of DNA. Linkletter BA,

et al. **Bioorg Med Chem Lett** 1998 Jun 2;8(11):1285-90
Synthesis and quantitative structure-activity relationships of N-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbonyl) guanidines as Na/H exchange inhibitors. Yamamoto T, et al. **Chem Pharm Bull (Tokyo)** 1998 Nov;46(11):1716-23
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide. Carmignani M, et al. **J Med Chem** 1999 Aug 12; 42(16):3116-25
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. Ding CZ, et al. **J Med Chem** 1999 Sep 9;42(18):3711-7
Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents. Hadrich D, et al. **J Med Chem** 1999 Aug 12;42(16):3101-8
Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. Katsura Y, et al. **J Med Chem** 1999 Jul 29;42(15):2920-6
Lipophilic 4-isoxazolyl-1,4-dihydropyridines: synthesis and structure-activity relationships. Natale NR, et al. **J Med Chem** 1999 Aug 12;42(16):3087-93
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. Soyka R, et al. **J Med Chem** 1999 Apr 8;42(7):1235-49

CHEMISTRY

Efficient formation of nitric oxide from selective oxidation of N-aryl N'-hydroxyguanidines by inducible nitric oxide synthase. Renodon-Cornière A, et al. **Biochemistry** 1999 Apr 13;38(15):4663-8
Cross-linking of proteins by Maillard processes--model reactions of D-glucose or methylglyoxal with butylamine and guanidine derivatives. Lederer MO, et al. **Bioorg Med Chem** 1998 Jul;6(7):993-1002
Design and construction of novel thrombin inhibitors featuring P3-P4 quaternary lactam dipeptide surrogates. Semple JE. **Bioorg Med Chem Lett** 1998 Sep 22; 8(18):2501-6
Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system. Wolin R, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2521-6

IMMUNOLOGY

pH dependence of antibody: hapten association. Livesay D, et al. **Mol Immunol** 1999 Apr;36(6):397-410
Positive skin reaction test in haemodialysis patients allergic to nafamostat mesilate [letter] Okada H, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2166-7

METABOLISM

Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Nadler SG, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):176-80
Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate. Clement B, et al. **Biochem Pharmacol** 1999 Aug 1;58(3):439-45
Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes, and ketoximes: mechanism of the oxidative cleavage of their C=N(OH) bond with formation of nitrogen oxides. Jousserandot A, et al. **Biochemistry** 1998 Dec 8;37(49):17179-91
Identification of an N-hydroxyguanidine reducing activity of xanthine oxidase. Dambrova M, et al. **Eur J Biochem** 1998 Oct 1;257(1):178-84
Nitrogen oxides and hydroxyguanidines: formation of donors of nitric and nitrous oxides and possible relevance to nitrous oxide formation by nitric oxide synthase. Southan GJ, et al. **Nitric Oxide** 1998;2(4):270-86

PHARMACOKINETICS

Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Hu ZJ, et al. **Intensive Care Med** 1999 May; 25(5):524-7

PHARMACOLOGY

Neuroprotective properties of aptiganel HCL (Cerestat) following controlled cortical impact injury. Kroppenstedt SN, et al. **Acta Neurochir Suppl (Wien)** 1998;71:114-6
Effect of chronic electrical stimulation and beta-GPA diet on GLUT4 protein concentration in rat skeletal muscle. Yaspelkis BB 3rd, et al. **Acta Physiol Scand** 1998 Jul; 163(3):251-9
Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats. Reckelhoff JF, et al. **Am J Hypertens** 1999 May;12(5):492-8
Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Wang D, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):174-82
Modulation of MAO activity by imidazoline and guanidine derivatives. Raasch W, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:313-31
Mixture-based heterocyclic combinatorial positional scanning libraries: discovery of bicyclic guanidines having potent antifungal activities against Candida albicans and Cryptococcus neoformans. Blondelle SE, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):106-14
Antifungal properties and target evaluation of three putative bacterial histidine kinase inhibitors. Deschenes RJ, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1700-3
Effect of aminoguanidine on lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney. Kędziora-Kornatowska K, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):577-83
Selectivity of the molecular chaperone-specific immunosuppressive agent 15-deoxyspergualin: modulation of Hsc70 ATPase activity without compromising DnaJ chaperone interactions. Brodsky JL. **Biochem Pharmacol** 1999 Apr 15;57(8):877-80
Photoactivatable peptides based on BMS-197525: a potent antagonist of the human thrombin receptor (PAR-1). Elliott JT, et al. **Bioorg Med Chem Lett** 1999 Jan 18; 9(2):279-84
Nitric oxide involvement in the toxicity of hydroxyguanidine in leukaemia HL60 cells. Everett SA, et al. **Br J Cancer Suppl** 1996 Jul;27:S172-6
Effects and interaction, of cariporide and preconditioning on cardiac arrhythmias and infarction in rat in vivo. Aye NN, et al. **Br J Pharmacol** 1999 Jun;127(4):1048-55
Pregnancy reduces brain sigma receptor function. Bergeron R, et al. **Br J Pharmacol** 1999 Aug;127(8):1769-76
Influence of aminoguanidine on parameters of liver injury and regeneration induced in rats by a necrogenic dose of thioacetamide. Diez-Fernández C, et al. **Br J Pharmacol** 1998 Sep;125(1):102-8
Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase. Kis A, et al. **Br J Pharmacol** 1999 Aug; 127(7):1545-50
Modulation of peroxynitrite- and hypochlorous acid-induced inactivation of alpha1-antiproteinase by mercaptoethylguanidine. Whiteman M, et al. **Br J Pharmacol** 1999 Apr;126(7):1646-52
In vitro inhibition of Na+,K(+)-ATPase activity from rat cerebral cortex by guanidino compounds accumulating in hyperargininemia. da Silva CG, et al. **Brain Res** 1999 Aug 14;838(1-2):78-84
Temporal characteristics of the protective effect of aminoguanidine on cerebral ischemic damage. Zhang F, et al. **Brain Res** 1998 Aug 17;802(1-2):104-10
Hydrogen peroxide induced impairment of post-ischemic ventricular function is prevented by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). Myers ML, et al. **Cardiovasc Res** 1998 Nov;40(2):290-6
Protective effect of nafamostat mesilate on injury of porcine hepatocytes by human plasma. Kawazoe Y, et al. **Cell Transplant** 1999 Jul-Aug;8(4):419-25
Inhibition of malaria-infected erythrocytes by deoxyspergualin: effect on in vitro growth of malarial cultures. Midorikawa Y, et al. **Chemotherapy** 1998 Nov-Dec;44(6):409-13
Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. Kędziora-Kornatowska KZ, et al. **Clin Chem Lab Med** 1998 Oct;36(10):771-5
Effect of aminoguanidine on the generation of superoxide anion and nitric oxide by peripheral blood granulocytes of rats with streptozotocin-induced diabetes. Kędziora-Kornatowska KZ, et al. **Clin Chim Acta** 1998 Nov;278(1):45-53
Brain ATP metabolism in hypoxia resistant mice fed guanidinopropionic acid. Holtzman D, et al. **Dev Neurosci** 1998;20(4-5):469-77
Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. He C, et al. **Diabetes** 1999 Jun; 48(6):1308-15
Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Degenhardt TP, et al. **Diabetes Res Clin Pract** 1999 Feb;43(2):81-9
Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Roufail E, et al. **Diabetologia** 1998 Dec;41(12):1419-25
Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists. Takeuchi K, et al. **Dig Dis Sci** 1999 Aug; 44(8):1703-9
Aminoguanidine induces constrictive vascular remodeling and inhibits smooth muscle cell death after balloon injury. Hansen PR, et al. **Eur J Pharmacol** 1999 May 14; 372(2):157-66
Effect of 1,1-dimethyl-2-[2-morpholinophenyl]guanidine fumarate on pancreatic islet function. Louchami K, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):289-97
Hydroxyguanidines inhibit peroxynitrite-induced oxidation. Southan GJ, et al. **Free Radic Biol Med** 1998 Nov 15; 25(8):914-25
Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells. Odaka C, et al. **Immunology** 1998 Nov;95(3):370-6
In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen. MacFarlane AS, et al. **Infect Immun** 1999 Feb;67(2):891-8
Inhibition of serum diamine oxidase discloses a constitutive putrescine release from cultured vascular smooth muscle cells. Nilsson BO, et al. **Inflamm Res** 1999 Apr;48(4):176-80
Efficacy of Nafamostat Mesilate for improving the performance of a bioartificial liver using porcine hepatocytes. Fujioka H, et al. **Int J Artif Organs** 1999 Jul; 22(7):505-10
Inhibition of nitric oxide synthase induction by 15-deoxyspergualin in a cultured macrophage cell line, J744A.1 activated with IFN-gamma and LPS. Nosaka C, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):297-304
Immunosuppressant deoxyspergualin-induced inhibition of cell proliferation is accompanied with an enhanced reduction of tetrazolium salt. Odaka C, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):45-51
Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. Kwon G, et al. **J Biol Chem** 1999 Jun 25; 274(26):18702-8
Two-dimensional stress-relaxation behavior of human skin as influenced by non-enzymatic glycation and the inhibitory agent aminoguanidine. Reihsner R, et al. **J Biomech** 1998 Nov;31(11):985-93
Cariporide, a highly selective Na+/H+ exchange inhibitor, suppresses the reperfusion-induced lethal arrhythmias and "overshoot" phenomenon of creatine phosphate in situ rat heart. Sugiyama A, et al. **J Cardiovasc Pharmacol** 1999 Jan; 33(1):116-21
Inhibition of inducible nitric oxide synthase delays gastric ulcer healing in the rat. Akiba Y, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S64-73
Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. Levitsky J, et al. **J Clin Pharmacol** 1998 Oct;38(10):887-97 (74 ref.)
Changes in fecal fat excretion from allo-intestine transplanted rats after discontinuance of immunosuppressive agents. Saito T, et al. **J Gastroenterol** 1999 Apr;34(2):182-8
A protease inhibitor attenuates gastric erosions and microcirculatory disturbance in the early period after thermal injury in rats. Yoshida M, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):104-8
Aminoguanidine supplementation delays the onset of senescence in vitro in dermal fibroblast-like cells from senescence-accelerated mice. Fujisawa H, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jul;54(7):B276-82
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety. Lebreton L, et al. **J Med Chem** 1999 Jan 28;42(2):277-90
New drugs for the Na+/H+ exchanger. Influence of Na+ concentration and determination of inhibition constants with a microphysiometer. Fischer H, et al. **J Membr Biol** 1999 Mar 1;168(1):39-45
An inhibitor of inducible nitric oxide synthase ameliorates experimental autoimmune myocarditis in Lewis rats. Shin T, et al. **J Neuroimmunol** 1998 Dec 1;92(1-2):133-8
Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats. Kawasaki-Yatsugi S, et al. **J Pharm Pharmacol** 1998 Aug;50(8):891-8
Biphasic insulin-releasing effect of BTS 67 582 in rats. Storey DA, et al. **J Pharm Pharmacol** 1998 Dec;50(12):1357-60
Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. Zingarelli B, et al. **J Pharmacol Exp Ther** 1998 Dec; 287(3):1048-55
Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition. Karmazyn M. **J Thromb Thrombolysis** 1999 Jul;8(1):33-8 (38 ref.)
Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts. Hachida M, et al. **Jpn Circ J** 1999 Apr;63(4):303-8
Histamine H2-receptor antagonism of T-593, an anti-ulcer agent: studies on aminopyrine accumulation in isolated canine gastric mucosal cells. Inoie M, et al. **Jpn J Pharmacol** 1998 Nov;78(3):313-22
Implication of endogenous nitric oxide in gastric mucosal protective effect of T-593, a novel anti-ulcer agent, in rats. Marubuchi S, et al. **Jpn J Pharmacol** 1999 Feb; 79(2):195-202
The effect of an insulin releasing agent, BTS 67582, on advanced glycation end product formation in vitro. Simpson AE, et al. **Life Sci** 1999;64(16):1427-34
Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Teixeira AS, et al. **Life Sci** 1999;64(8):655-62
Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Ihm SH, et al. **Metabolism** 1999 Sep;48(9):1141-5
Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. Piercy V, et al. **Metabolism** 1998 Dec;47(12):1477-80
Effect of methylcarbonylmethyl 2(S)-[4-(4-guanidinobenzoyloxy) phenyl] propionate

methanesulfonate (TT-S24) on pancreatic secretion in rats. Tagami H, et al. **Methods Find Exp Clin Pharmacol** 1998 Dec;20(10):855–60

ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP. Hambrock A, et al. **Mol Pharmacol** 1999 May;55(5):832–40

Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal cord neurones. D'Hooge R, et al. **Neurosci Lett** 1999 Apr 16; 265(2):83–6

Inhibition of nitric oxide production rescues LPS-induced fetal abortion in mice. Athanassakis I, et al. **Nitric Oxide** 1999 Jun;3(3):216–24

Guanidino group is involved in the stimulation of exocrine pancreatic secretion by protamine in normal and chronic bile-pancreatic juice-diverted rats. Hira T, et al. **Pancreas** 1999 Mar;18(2):165–71

S3226, a novel inhibitor of Na+/H+ exchanger subtype 3 in various cell types. Schwark JR, et al. **Pflugers Arch** 1998 Oct;436(5):797–800

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167–74 (50 ref.)

Histamine H2 receptor antagonism by T-593: studies on cAMP generation in Hepa cells expressing histamine H2 receptor. Tashiro T, et al. **Pharmacology** 1999 Jul; 59(1):1–10

Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects. Vesell ES, et al. **Pharmacology** 1999 Mar;58(3):140–6

Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Neufeld AH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9944–8

Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Tanaka Y, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10857–62

NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Aiglstorfer I, et al. **Regul Pept** 1998 Sep 25;75-76:9–21

FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Sugita H, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan;103(1):57–64

Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. Merino G, et al. **Res Vet Sci** 1999 Jun; 66(3):281–3

Influence of L-arginine, aminoguanidine, and NG-nitro-L-arginine methyl ester (L-name) on the survival rate in a rat model of hemorrhagic shock. Hua TC, et al. **Shock** 1999 Jan;11(1):51–7

Aminoguanidine inhibits inducible NOS and reverses cardiac dysfunction late after ischemia and reperfusion--implications for iNOS-mediated myocardial stunning. Wildhirt SM, et al. **Thorac Cardiovasc Surg** 1999 Jun;47(3):137–43

Inhibition of nitric oxide synthesis reduces bacterial translocation during graft-versus-host disease after small bowel transplantation. Langrehr JM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):574

Effect of 15-deoxyspergualine on coronary arteriosclerosis and platelet-derived growth factor-A mRNA expression in the transplanted heart. Zhang X, et al. **Transplant Proc** 1999 May;31(3):1706–9

Elimination of Kupffer cells and nafamostat mesilate rinse prevent reperfusion injury in liver grafts from agonal non-heart-beating donors. Tsukamoto S, et al. **Transplantation** 1999 Jun 15;67(11):1396–403

[Characteristics of T-593, a novel antiulcer agent, and each of its enantiomers on pharmacodynamics] Arai H, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):107–16 (Eng. Abstr.) **(Jpn)**

[Effect of T-593 on gastric bleeding and lesions induced by indomethacin and water-immersion stress in rats: improving effect of T-593 on reduced gastric mucosal blood flow in rats] Arai H, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):117–24 (Eng. Abstr.) **(Jpn)**

[Beta-guanidinopropionic acid prevents decrease in muscle performance and reduction in mitochondrial enzymes activation under gravitation unloading in rats] Nasledov GA, et al. **Dokl Akad Nauk** 1998 Nov;363(1):126–9 **(Rus)**

[Toxicity and radiation protective properties of 2(3)-guanidinoalkanethiols: structure-activity] Mandrugin AA, et al. **Radiats Biol Radioecol** 1999 Mar-Jun; 39(2-3):254–7 (Eng. Abstr.) **(Rus)**

[Inhibition of lipid peroxidation in erythrocytes by aminoguanidine, resorcylidine aminoguanidine and their oxygen and sulfur analogs in diabetic rats] Hrnčiarová M, et al. **Bratisl Lek Listy** 1998 Jul;99(7):364–7 (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia. Avkiran M. **Am J Cardiol** 1999 May 20;83(10A):10G–17G; discussion 17G–18G (64 ref.)

Sodium-hydrogen exchange inhibition: novel strategy to prevent myocardial injury following ischemia and reperfusion. Buerke M, et al. **Am J Cardiol** 1999 May 20; 83(10A):19G–22G (35 ref.)

GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes. Erhardt LR. **Am J Cardiol** 1999 May 20;83(10A):23G–25G

Protection of the myocardial cell during ischemia. Théroux P. **Am J Cardiol** 1999 May 20;83(10A):3G–9G (29 ref.)

A symposium: sodium-hydrogen exchange inhibition. Introduction. Théroux P. **Am J Cardiol** 1999 May 20; 83(10A):1G–2G

Efficacy of a drug combination of praziquantel, pyrantel pamoate, and febantel against giardiasis in dogs. Barr SC, et al. **Am J Vet Res** 1998 Sep;59(9):1134–6

Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans. Abe H, et al. **Artif Organs** 1992 Apr; 16(2):206–8

Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol. Iwama H, et al. **Br J Anaesth** 1998 Dec;81(6):963–4

Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine. Lochner A, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):267–77

The rescue effect of 15-deoxyspergualin on intraperitoneal microencapsulated xenoislets. Hsu BR, et al. **Cell Transplant** 1999 May-Jun;8(3):307–15

Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642). Linz W, et al. **Clin Exp Hypertens** 1998 Oct;20(7):733–49

Aminoguanidine ameliorates splanchnic hyposensitivity to glypressin in a haemorrhage-transfused rat model of portal hypertension. Chu CJ, et al. **Clin Sci (Colch)** 1998 Nov; 95(5):629–36

Treatment of septic shock in rats with nitric oxide synthase inhibitors and inhaled nitric oxide [see comments] Pedoto A, et al. **Crit Care Med** 1998 Dec;26(12):2021–8. Comment in: Crit Care Med 1998 Dec;26(12):1945–7.

Beneficial effects of mercaptoethylguanidine, an inhibitor of the inducible isoform of nitric oxide synthase and a scavenger of peroxynitrite, in a porcine model of delayed hemorrhagic shock. Szabó A, et al. **Crit Care Med** 1999 Jul;27(7):1343–50

Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+,K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats. Wada R, et al. **Diabetologia** 1999 Jun; 42(6):743–7

Lack of effects of the Na+/H+ exchanger inhibitor, cariporide against myocardial stunning in exercise-induced ischemia in dogs. Parent de Curzon O, et al. **Fundam Clin Pharmacol** 1998;12(6):646–8

Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Takeuchi I, et al. **Int J Urol** 1998 Sep;5(5):476–81

Na-H exchange inhibition with cariporide limits functional impairment caused by repetitive ischemia. Symons JD, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):853–62

Effect of camostat mesilate on urinary protein excretion in three patients with advanced diabetic nephropathy. Ikeda Y, et al. **J Diabetes Complications** 1999 Jan-Feb;13(1):56–8

Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. Muramatsu K, et al. **J Hand Surg [Am]** 1999 May; 24(3):586–93

Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. Brahn E, et al. **J Rheumatol** 1998 Sep;25(9):1785–93

Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Youssef S, et al. **Kidney Int** 1999 Mar;55(3):907–16

Combination of serine protease inhibitor FUT-175 and thromboxane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with subarachnoid hemorrhage. Kaminogo M, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):704–8; discussion 708–9

Inducible nitric oxide synthase expression after traumatic brain injury and neuroprotection with aminoguanidine treatment in rats. Wada K, et al. **Neurosurgery** 1998 Dec; 43(6):1427–36

Amelioration of virulent Babesia bovis infection in calves by administration of the nitric oxide synthase inhibitor aminoguanidine. Gale KR, et al. **Parasite Immunol** 1998 Sep;20(9):441–5

Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. Sawada M, et al. **Stroke** 1999 Mar;30(3):644–50

Effects of deoxyspergualin (DSG) administered in the chronic phase following kidney transplantation. Fudaba Y, et al. **Transplant Proc** 1998 Nov;30(7):3582–3

Inhibitory effect of 15-deoxyspergualin on coronary arteriosclerosis in the transplanted heart. Hachida M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):143–6

Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):2049–55

Usefulness of 15-deoxyspergualin for rejection in renal transplantation. Kozaki K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1138–9

Effect of deoxyspergualin on acute and chronic rejection in renal transplantation. Nomura Y, et al. **Transplant Proc** 1998 Nov;30(7):3580–1

Preventive efficacy of 15-deoxyspergualin against progression of apoptotic cell death in acute rejection after rat liver transplantation. Yamamoto H, et al. **Transplant Proc** 1998 Dec;30(8):4104–5

Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor. Ryo R, et al. **Vox Sang** 1999;76(4):241–6

[Histological study on healing of cryocautery-induced rat gastric ulcer treated with T-593] Doi Y, et al. **Nippon Yakurigaku Zasshi** 1999 Mar;113(3):167–76 (Eng. Abstr.) **(Jpn)**

[Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation] Mori Y, et al. **Nippon Yakurigaku Zasshi** 1998 Dec; 112(6):381–93 (Eng. Abstr.) **(Jpn)**

TOXICITY

Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor. Ikeda T, et al. **Anticancer Res** 1998 Nov-Dec; 18(6A):4259–65

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Kuin A, et al. **Br J Cancer** 1999 Feb;79(5-6):793–801

Developmental toxicity in rat fetuses exposed to the benzimidazole netobimin. Navarro M, et al. **Reprod Toxicol** 1999 Jul-Aug;13(4):295–302

Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat. Uchida H, et al. **Transplantation** 1999 May 15;67(9):1269–74

URINE

Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment? Schulze A, et al. **J Inherit Metab Dis** 1998 Jun; 21(3):268–71

GUANIDINIUM see **GUANIDINE**

GUANIDINIUM CHLORIDE see **GUANIDINE**

GUANINE

5-Methylcytosine in CpG sites and the reactivity of nearest neighboring guanines toward the carcinogen aflatoxin B1-8,9-epoxide. Ross MK, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):114–9

Parallel and antiparallel triple helices with G, A-containing third strands. Porumb H, et al. **Electrophoresis** 1999 Mar; 20(3):511–3

The Bloom's syndrome helicase unwinds G4 DNA. Sun H, et al. **J Biol Chem** 1998 Oct 16;273(42):27587–92

The base contents of A, C, G or U for the three codon positions and the total coding sequences show positive correlation. Wang J. **J Biomol Struct Dyn** 1998 Aug; 16(1):51–7

Guanine-adenine ligation-mediated polymerase chain reaction in vivo footprinting. Strauss EC, et al. **Methods Enzymol** 1999;304:572–84

Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Liu L, et al. **Nat Genet** 1999 Jan;21(1):128–32

G-quadruplex DNA: a target for drug design [news] Mergny JL, et al. **Nat Med** 1998 Dec;4(12):1366–7

Can G-C Hoogsteen-wobble pairs contribute to the stability of d(G. C-C) triplexes? Soliva R, et al. **Nucleic Acids Res** 1999 Jun 1;27(11):2248–55

ANALOGS & DERIVATIVES

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Shih C, et al. **Adv Enzyme Regul** 1998;38:135–52

Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Schultz RM, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):437–43

Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Worzalla JF, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3235–9

Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Bedard J, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):557–67

The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Neyts J, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3285–9

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Seifer M, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3200–8

Evaluation of anti-herpesvirus activity of (1S,2R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]- guanine (A-5021) in mice. Iwayama S, et al. **Antiviral Res** 1999 Jun;42(2):139–48

Comparison of antiviral compounds against human herpesvirus 6 and 7. Yoshida M, et al. **Antiviral Res** 1998

Dec;40(1-2):73-84
Possible relationship between conditions associated with chronic hypoxia and brain mitochondrial DNA deletions; reduction of genomic 8-hydroxyguanine levels in human brain tissues containing elevated levels of the human mitochondrial DNA4977 deletion. Zullo SJ, et al. **Arch Biochem Biophys** 1999 Jul 1;367(1):140-2
Nickel(II) inhibits the repair of O6-methylguanine in mammalian cells. Iwitzki F, et al. **Arch Toxicol** 1998 Nov; 72(11):681-9
Human MMH (OGG1) type 1a protein is a major enzyme for repair of 8-hydroxyguanine lesions in human cells. Monden Y, et al. **Biochem Biophys Res Commun** 1999 May 19;258(3):605-10
9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG). Compton ML, et al. **Biochem Pharmacol** 1999 Aug 15; 58(4):709-14
N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties. Hatse S, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):311-23
Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine. Loktionova NA, et al. **Biochem Pharmacol** 1999 Jul 15; 58(2):237-44
Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Xu-Welliver M, et al. **Biochem Pharmacol** 1999 Oct 15;58(8):1279-85
Metabolic fate of oxidized guanine ribonucleotides in mammalian cells. Hayakawa H, et al. **Biochemistry** 1999 Mar 23;38(12):3610-4
The C-terminal domain of the adenine-DNA glycosylase MutY confers specificity for 8-oxoguanine.adenine mispairs and may have evolved from MutT, an 8-oxo-dGTPase. Noll DM, et al. **Biochemistry** 1999 May 18;38(20):6374-9
Reaction and binding of oligodeoxynucleotides containing analogues of O6-methylguanine with wild-type and mutant human O6-alkylguanine-DNA alkyltransferase. Spratt TE, et al. **Biochemistry** 1999 May 25;38(21):6801-6
Chemiluminescence enzyme immunoassay of 8-oxoguanine in DNA. Bruskov VI, et al. **Biochemistry (Mosc)** 1999 Jul; 64(7):803-8
Repair and mutagenesis survey of 8-hydroxyguanine in bacteria and human cells. Le Page F, et al. **Biochimie** 1999 Jan-Feb;81(1-2):147-53 (54 ref.)
Identification of N2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. al-Abed Y, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2109-10
Triple helix stabilization properties of oligonucleotides containing 8-amino-2'-deoxyguanosine. Güimil García R, et al. **Bioorg Med Chem Lett** 1998 Nov 3;8(21):3011-6
Reactions of chloride salts of 7-amino-9-ethylguanine and 1-amino-3-methylbenzimidazoles with lead(IV) acetate: formation of 8-aza-9-ethylguanine and 1-methyl-1H-benzotriazoles. Kaiya T, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):961-4
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice. Bibby MC, et al. **Br J Cancer** 1999 Mar;79(9-10):1332-9
Relationship between O6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Chen ZP, et al. **Can J Neurol Sci** 1999 May;26(2):104-9
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Britten CD, et al. **Cancer Chemother Pharmacol** 1999;44(2):105-10
Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer. Phillips WP Jr, et al. **Cancer Chemother Pharmacol** 1999; 44(4):319-26
Human long-term culture initiating cells are sensitive to benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and protected after mutant (G156A) methylguanine methyltransferase gene transfer. Koç ON, et al. **Cancer Gene Ther** 1999 Jul-Aug;6(4):340-8
O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Spiro TP, et al. **Cancer Res** 1999 May 15;59(10):2402-10
Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine. Xu-Welliver M, et al. **Cancer Res** 1999 Apr 1;59(7):1514-9
Analysis of 8-hydroxyguanine in rat kidney genomic DNA after administration of a renal carcinogen, ferric nitrilotriacetate. Nomoto M, et al. **Carcinogenesis** 1999 May;20(5):837-41
Changes in levels of 8-hydroxyguanine in DNA, its repair and OGG1 mRNA in rat lungs after intratracheal administration of diesel exhaust particles. Tsurudome Y, et al. **Carcinogenesis** 1999 Aug;20(8):1573-6
Molecular dosimetry of endogenous and ethylene oxide-induced N7-(2-hydroxyethyl) guanine formation in tissues of rodents. Wu KY, et al. **Carcinogenesis** 1999 Sep; 20(9):1787-92
DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Seidel W, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1165-70
Mutagenicity of site-specifically located 1,N2-ethenoguanine in Chinese hamster ovary cell chromosomal DNA. Akasaka S, et al. **Chem Res Toxicol** 1999 Jun;12(6):501-7
C8-Arylguanine and C8-aryladenine formation in calf thymus DNA from arenediazonium ions. Gannett PM, et al. **Chem Res Toxicol** 1999 Mar;12(3):297-304
Molecular dosimetry of N-7 guanine adduct formation in mice and rats exposed to 1,3-butadiene. Koc H, et al. **Chem Res Toxicol** 1999 Jul;12(7):566-74
Peroxynitrite-induced reactions of synthetic oligonucleotides containing 8-oxoguanine. Tretyakova NY, et al. **Chem Res Toxicol** 1999 May;12(5):459-66
Synthesis of DNA oligonucleotides containing site-specifically incorporated O6-[4-oxo-4-(3-pyridyl)butyl]guanine and their reaction with O6-alkylguanine-DNA alkyltransferase. Wang L, et al. **Chem Res Toxicol** 1999 Feb;12(2):127-31
A gas chromatography/electron capture/negative chemical ionization high-resolution mass spectrometry method for analysis of endogenous and exogenous N7-(2-hydroxyethyl)guanine in rodents and its potential for human biological monitoring. Wu KY, et al. **Chem Res Toxicol** 1999 Aug;12(8):722-9
Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate. Berg SL, et al. **Clin Cancer Res** 1998 Nov;4(11):2891-4
O6-benzylguanine and its role in chemotherapy. Dolan ME, et al. **Clin Cancer Res** 1997 Jun;3(6):837-47 (126 ref.)
Leukocyte O6-alkylguanine-DNA alkyltransferase from human donors is uniformly sensitive to O6-benzylguanine. Gerson SL, et al. **Clin Cancer Res** 1999 Mar;5(3):521-4
Retroviral transfer of a bacterial alkyltransferase gene (ada) into human bone marrow cells protects against O6-benzylguanine plus 1, 3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Marathi UK, et al. **Clin Cancer Res** 1997 Feb;3(2):301-7
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Reese JS, et al. **Clin Cancer Res** 1999 Jan;5(1):163-9
Synthesis of creatol, a hydroxyl radical adduct of creatinine and its increase by puromycin aminonucleoside in isolated rat hepatocytes. Aoyagi K, et al. **Free Radic Res** 1998 Sep; 29(3):221-6
Reduction of 8-hydroxyguanine in human leukocyte DNA by physical exercise. Asami S, et al. **Free Radic Res** 1998 Dec;29(6):581-4
Excision repair of 8-hydroxyguanine in mammalian cells: the mouse Ogg1 protein as a model. Boiteux S, et al. **Free Radic Res** 1998 Dec;29(6):487-97
DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Koç ON, et al. **Hum Gene Ther** 1999 Apr 10;10(6):1021-30
Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. Conry RM, et al. **Immunopharmacology** 1998 Jul;40(1):1-9
Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. Franek F, et al. **Int J Oncol** 1999 Apr;14(4):745-52
Are calculated log P values for some guanine derivatives by different computer programs reliable? Kristl A, et al. **Int J Pharm** 1999 Apr 30;181(2):219-26
A method for direct cross-linking of DNA bases containing aromatic amino groups to proteins. Conlon KA, et al. **J Biochem Biophys Methods** 1999 Feb 8;38(3):181-9
Repair pathways for processing of 8-oxoguanine in DNA by mammalian cell extracts. Dianov G, et al. **J Biol Chem** 1998 Dec 11;273(50):33811-6
High-performance liquid chromatographic determination of N-[2-(hydroxyethyl)-N-(2-(7-guaninyl)ethyl)]methylamine, a reaction product between nitrogen mustard and DNA and its application to biological samples. Sperry ML, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25;716(1-2):187-93
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Friedman HS, et al. **J Clin Oncol** 1998 Nov;16(11):3570-5
Repair of DNA lesion O6-methylguanine in hepatocellular carcinogenesis. Major GN, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):355-66 (123 ref.)
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase. Farutin V, et al. **J Med Chem** 1999 Jul 1;42(13):2422-31
Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. McElhinney RS, et al. **J Med Chem** 1998 Dec 17;41(26):5265-71
Heterogeneous repair of N-methylpurines at the nucleotide level in normal human cells. Ye N, et al. **J Mol Biol** 1998 Nov 27;284(2):269-85
Estimation of aqueous solubility for some guanine derivatives using partition coefficient and melting temperature. Kristl A. **J Pharm Sci** 1999 Jan;88(1):109-10
Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment. Maze R, et al. **J Pharmacol Exp Ther** 1999 Sep; 290(3):1467-74
Infrequent mutations of the hOGG1 gene, that is involved in the excision of 8-hydroxyguanine in damaged DNA, in human gastric cancer. Shinmura K, et al. **Jpn J Cancer Res** 1998 Aug;89(8):825-8
Increased 8-hydroxyguanine in DNA and its repair activity in hamster and rat lung after intratracheal instillation of crocidolite asbestos. Yamaguchi R, et al. **Jpn J Cancer Res** 1999 May;90(5):505-9
8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Helbock HJ, et al. **Methods Enzymol** 1999;300:156-66 (22 ref.)
Formation of 8-oxoguanine in cellular DNA of Escherichia coli strains defective in different antioxidant defences. Alhama J, et al. **Mutagenesis** 1998 Nov;13(6):589-94
Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. Calléja F, et al. **Mutat Res** 1999 Apr 6; 425(2):185-94
The sensitization of cells treated with O6-methylguanine to alkylation damage is affected by the number of O6-methylguanine-DNA methyltransferase molecules escaped from inactivation. Citti L, et al. **Mutat Res** 1998 Dec 14;409(3):173-9
Tobacco BY-2 cells excise both 3-methyladenine and 7-methylguanine from methylated DNA. Kraszewska E, et al. **Mutat Res** 1998 Nov 12;409(2):91-5
Endogenous and background DNA adducts by methylating and 2-hydroxyethylating agents. Zhao C, et al. **Mutat Res** 1999 Mar 8;424(1-2):117-25
Increasing DNA repair capacity in bone marrow by gene transfer as a prospective tool in cancer therapy. Kleibl K, et al. **Neoplasma** 1998;45(4):181-6 (33 ref.)
Repair of 8-oxoguanine in DNA is deficient in Cockayne syndrome group B cells. Dianov G, et al. **Nucleic Acids Res** 1999 Mar 1;27(5):1365-8
The presence of two distinct 8-oxoguanine repair enzymes in human cells: their potential complementary roles in preventing mutation. Hazra TK, et al. **Nucleic Acids Res** 1998 Nov 15;26(22):5116-22
Synthesis of 2'-methylene-substituted 5-azapyrimidine, 6-azapyrimidine, and 3-deazaguanine nucleoside analogues as potential antitumor/antiviral agents. Liu MC, et al. **Nucleosides Nucleotides** 1999 Jan;18(1):55-72
Synthesis and inhibitory activity against phosphatidylinositol 4-kinase of echiguanine analogs. Saito Y, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):713-4
Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Allay E, et al. **Oncogene** 1999 Jun 24;18(25):3783-7
O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Davis BM, et al. **Prog Exp Tumor Res** 1999;36:65-81 (69 ref.)
Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer. Johnson D, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):1-2
Overview of MTA in the treatment of non-small cell lung cancer. Postmus PE, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 4):31-6 (35 ref.)
Possible rare involvement of O6-methylguanine formation as a significant mutational factor in mouse urinary bladder carcinogenesis models. Chen T, et al. **Teratog Carcinog Mutagen** 1998;18(3):101-10
Effects of O6-benzylguanine on growth and differentiation of P19 embryonic carcinoma cells treated with alkylating agents. Seeley MR, et al. **Teratog Carcinog Mutagen** 1998; 18(3):111-22
The effect of cotinine or cigarette smoke co-administration on the formation of O6-methylguanine adducts in the lung and liver of A/J mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Brown BG, et al. **Toxicol Sci** 1999 Jan;47(1):33-9
The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine against different herpes viruses. Neyts J, et al. **Transplantation** 1999 Mar 15;67(5):760-4

ANALYSIS

Effective recovery of bacterial DNA and percent-guanine-plus-cytosine-based analysis of community structure in the gastrointestinal tract of broiler chickens. Apajalahti JH, et al. **Appl Environ Microbiol** 1998 Oct;64(10):4084-8
Tissue distribution of DNA adducts in male Fischer rats exposed to 500 ppm of propylene oxide: quantitative analysis of 7-(2-hydroxypropyl)guanine by 32P-postlabelling. Segerbäck D, et al. **Chem Biol Interact** 1998 Oct 2;115(3):229-46
Mass spectral identification and positional mapping of aflatoxin B1-guanine adducts in oligonucleotides. Marzilli

LA, et al. **J Am Soc Mass Spectrom** 1998 Jul;9(7):676–82

A nonhyperthermophilic common ancestor to extant life forms [see comments] Galtier N, et al. **Science** 1999 Jan 8;283(5399):220–1. Comment in: Science 1999 Jan 8;283(5399):155, 157. Comment in: Science 1999 Feb 5;283(5403):792.

CHEMICAL SYNTHESIS

Inactivation of O6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. McElhinney RS, et al. **J Med Chem** 1998 Dec 17;41(26):5265–71

Production of guanine from NH(4)CN polymerizations. Levy M, et al. **J Mol Evol** 1999 Aug;49(2):165–8

Synthesis of 2'-methylene-substituted 5-azapyrimidine, 6-azapyrimidine, and 3-deazaguanine nucleoside analogues as potential antitumor/antiviral agents. Liu MC, et al. **Nucleosides Nucleotides** 1999 Jan;18(1):55–72

CHEMISTRY

Accelerated assembly of G-quadruplex structures by a small molecule. Han H, et al. **Biochemistry** 1999 Jun 1; 38(22):6981–6

FTIR and UV spectroscopy of parallel-stranded DNAs with mixed A*T/G*C sequences and their A*T/I*C analogues. Mohammadi S, et al. **Biochemistry** 1998 Nov 24; 37(47):16529–37

A novel vicinal lesion obtained from the oxidative photosensitization of TpdG: characterization and mechanistic aspects. Delatour T, et al. **Chem Res Toxicol** 1998 Sep;11(9):1005–13

Regiochemistry of nucleophilic attack by the guanine 2-amino group at the ring positions of nitrenium ions derived from carcinogenic polycyclic arylamines and nitroarenes: molecular orbital calculations and simple models. Ford GP, et al. **Chem Res Toxicol** 1999 Jan; 12(1):53–9

C8-Arylguanine and C8-aryladenine formation in calf thymus DNA from arenediazonium ions. Gannett PM, et al. **Chem Res Toxicol** 1999 Mar;12(3):297–304

32P-Postlabeling analysis of DNA adducts of styrene 7,8-oxide at the O6-position of guanine. Otteneder M, et al. **Chem Res Toxicol** 1999 Jan;12(1):93–9

A slipped replication intermediate model is stabilized by the syn orientation of N-2-aminofluorene- and N-2-(acetyl)aminofluorene-modified guanine at a mutational hotspot. Roy D, et al. **Chem Res Toxicol** 1998 Nov;11(11):1301–11

N2-amination of guanine to 2-hydrazinohypoxanthine, a novel in vivo nucleic acid modification produced by the hepatocarcinogen 2-nitropropane. Sodum RS, et al. **Chem Res Toxicol** 1998 Dec;11(12):1453–9

Are calculated log P values for some guanine derivatives by different computer programs reliable? Kristl A, et al. **Int J Pharm** 1999 Apr 30;181(2):219–26

Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. Bates PJ, et al. **J Biol Chem** 1999 Sep 10;274(37):26369–77

High affinity interactions of nucleolin with G-G-paired rDNA. Hanakahi LA, et al. **J Biol Chem** 1999 May 28; 274(22):15908–12

Nitrogen-15 chemical shifts in AT (adenine-thymine) and CG (cytosine-guanine) nucleic acid base pairs. Facelli JC. **J Biomol Struct Dyn** 1998 Dec;16(3):619–29

The biological implications of damage to DNA incorporating an 8-oxodeoxyguanine:cytosine basepair. Ninaber A, et al. **J Biomol Struct Dyn** 1998 Dec;16(3):651–61

Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase. Farutin V, et al. **J Med Chem** 1999 Jul 1;42(13):2422–31

Estimation of aqueous solubility for some guanine derivatives using partition coefficient and melting temperature. Kristl A. **J Pharm Sci** 1999 Jan;88(1):109–10

Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Scheeff ED, et al. **Mol Pharmacol** 1999 Sep;56(3):633–43

Guanine is the target for direct ionisation damage in DNA, as detected using excision enzymes. Melvin T, et al. **Nucleic Acids Res** 1998 Nov 1;26(21):4935–42

Dimerization of the guanine-adenine repeat strands of DNA. Vorlíčková M, et al. **Nucleic Acids Res** 1999 Jan 15; 27(2):581–6

An EPR study of the transfer and trapping of holes produced by radiation in guanine(thioguanine) hydrochloride single crystals. Herak JN, et al. **Radiat Res** 1999 Mar; 151(3):319–24

[Photoaffinity modification of human 80S ribosome using an analog of the mRNA-derivative of the hexaribonucleotide pUUUGUU, bearing an arylazide group on the guanine residue] Graifer DM, et al. **Mol Biol (Mosk)** 1999 Mar-Apr; 33(2):174–82 **(Rus)**

METABOLISM

Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA. Henderson ND, et al. **Anticancer Drug Des** 1998 Oct;13(7):749–68

Increased potency of an aptameric G-rich oligonucleotide is associated with novel functional properties of phosphorothioate linkages. Tam RC, et al. **Antisense Nucleic Acid Drug Dev** 1999 Jun;9(3):289–300

Triple helix formation by (G,A)-containing oligonucleotides: asymmetric sequence effect. Arimondo PB, et al. **Biochemistry** 1998 Nov 24;37(47):16627–35

Butadiene diolepoxide- and diepoxybutane-derived DNA adducts at N7-guanine: a high occurrence of diolepoxide-derived adducts in mouse lung after 1,3-butadiene exposure. Koivisto P, et al. **Carcinogenesis** 1999 Jul;20(7):1253–9

Oxidation of guanines in the iron-responsive element RNA: similar structures from chemical modification and recent NMR studies. Ciftan SA, et al. **Chem Biol** 1998 Dec; 5(12):679–87

Reactivity of guanine at m5CpG steps in DNA: evidence for electronic effects transmitted through the base pairs. Das A, et al. **Chem Biol** 1999 Jul;6(7):461–71

Persistence of N7-(2,3,4-trihydroxybutyl)guanine adducts in the livers of mice and rats exposed to 1,3-butadiene. Oe T, et al. **Chem Res Toxicol** 1999 Mar;12(3):247–57

Toxicokinetics of sulfur mustard and its DNA-adducts in the hairless guinea pig. Langenberg JP, et al. **Drug Chem Toxicol** 1998;21 Suppl 1:131–47

TSH receptor gene mutations and familial gestational hyperthyroidism. Asteria C. **Eur J Endocrinol** 1999 Aug; 141(2):93–4

ADP-ribosylation factor (ARF)-like 4, 6, and 7 represent a subgroup of the ARF family characterization by rapid nucleotide exchange and a nuclear localization signal. Jacobs S, et al. **FEBS Lett** 1999 Aug 13;456(3):384–8

Rat cultured astrocytes release guanine-based purines in basal conditions and after hypoxia/hypoglycemia. Ciccarelli R, et al. **Glia** 1999 Jan;25(1):93–8

Chloroacetonitrile (CAN) induces glutathione depletion and 8-hydroxylation of guanine bases in rat gastric mucosa. Ahmed AE, et al. **J Biochem Mol Toxicol** 1999; 13(3-4):119–26

The high mobility group domain protein Cmb1 of Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines. Fleck O, et al. **J Biol Chem** 1998 Nov 13;273(46):30398–405

Moloney murine sarcoma virus genomic RNAs dimerize via a two-step process: a concentration-dependent kissing-loop interaction is driven by initial contact between consecutive guanines. Ly H, et al. **J Virol** 1999 Sep; 73(9):7255–61

Triple helix formation: binding avidity of acridine-conjugated AG motif third strands containing natural, modified and surrogate bases opposed to pyrimidine interruptions in a polypurine target. Orson FM, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):810–6

Dehydromonocrotaline generates sequence-selective N-7 guanine alkylation and heat and alkali stable multiple fragment DNA crosslinks. Pereira TN, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5441–7

Escherichia coli MutY protein has a guanine-DNA glycosylase that acts on 7,8-dihydro-8-oxoguanine:guanine mispair to prevent spontaneous G:C-->C:G transversions. Zhang QM, et al. **Nucleic Acids Res** 1998 Oct 15; 26(20):4669–75

RADIATION EFFECTS

Long-range and short-range oxidative damage to DNA: photoinduced damage to guanines in ethidium-DNA assemblies. Hall DB, et al. **Biochemistry** 1998 Nov 10; 37(45):15933–40

Photosensitization of guanine-specific DNA damage by 2-phenylbenzimidazole and the sunscreen agent 2-phenylbenzimidazole-5-sulfonic acid. Stevenson C, et al. **Chem Res Toxicol** 1999 Jan;12(1):38–45

Guanine is the target for direct ionisation damage in DNA, as detected using excision enzymes. Melvin T, et al. **Nucleic Acids Res** 1998 Nov 1;26(21):4935–42

Oxidation of guanine in cellular DNA by solar UV radiation: biological role. Douki T, et al. **Photochem Photobiol** 1999 Aug;70(2):184–90

An EPR study of the transfer and trapping of holes produced by radiation in guanine(thioguanine) hydrochloride single crystals. Herak JN, et al. **Radiat Res** 1999 Mar; 151(3):319–24

TOXICITY

A slipped replication intermediate model is stabilized by the syn orientation of N-2-aminofluorene- and N-2-(acetyl)aminofluorene-modified guanine at a mutational hotspot. Roy D, et al. **Chem Res Toxicol** 1998 Nov;11(11):1301–11

URINE

Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Halliwell B. **Free Radic Res** 1998 Dec;29(6):469–86 (142 ref.)

GUANINE AMINASE see **GUANINE DEAMINASE**

GUANINE AMINOHYDROLASE see **GUANINE DEAMINASE**

GUANINE DEAMINASE

ANTAGONISTS & INHIBITORS

Synthesis and guanase inhibition studies of a novel ring-expanded purine analogue containing a 5:7-fused, planar, aromatic heterocyclic ring system. Rajappan V, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3649–52

Investigations into biochemical mode of inhibition of guanase by azepinomycin: synthesis and biochemical screening of several analogues of azepinomycin. Rajappan VP, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):835–6

GENETICS

Cloning and characterization of human guanine deaminase. Purification and partial amino acid sequence of the mouse protein. Yuan G, et al. **J Biol Chem** 1999 Mar 19; 274(12):8175–80

GUANINE NUCLEOTIDE REGULATORY PROTEINS see **GTP-BINDING PROTEINS**

GUANINE NUCLEOTIDES

ANALYSIS

Optimized analysis of intracellular adenosine and guanosine phosphates in Escherichia coli. Meyer S, et al. **Anal Biochem** 1999 Jun 15;271(1):43–52

BIOSYNTHESIS

Synthesis of adenine and guanine nucleotides at the 'inosinic branch point' in lymphocytes of leukemia patients. Carlucci F, et al. **Biochim Biophys Acta** 1999 May 31;1454(1):106–14

BLOOD

Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Chrzanowska M, et al. **Eur J Pharm Sci** 1999 Aug;8(4):329–34

CHEMISTRY

Crystal structure of an RNA 16-mer duplex R(GCAGAGUUAAAUCUGC)2 with nonadjacent G(syn).A+(anti) mispairs. Pan B, et al. **Biochemistry** 1999 Mar 2;38(9):2826–31

The 3' non-coding region of the Drosophila melanogaster HeT-A telomeric retrotransposon contains sequences with propensity to form G-quadruplex DNA. Abad JP, et al. **FEBS Lett** 1999 Jun 18;453(1-2):59–62

Fluorescence studies on association of human translation initiation factor eIF4E with mRNA cap-analogues. Wieczorek Z, et al. **Z Naturforsch [C]** 1999 Mar-Apr; 54(3-4):278–84

GENETICS

Re-examination of factors associated with expansion of CGG repeats using a single nucleotide polymorphism in FMR1. Gunter C, et al. **Hum Mol Genet** 1998 Nov;7(12):1935–46

METABOLISM

Regulation of guanine nucleotide turnover on Gi/Go by agonist-stimulated and spontaneously active muscarinic receptors in cardiac membranes. Quist E, et al. **Arch Biochem Biophys** 1999 Jan 1;361(1):57–64

Origin of guanine nucleotides in isolated heart mitochondria. McKee EE, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):466–72

Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. Rajamohan F, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):419–24

Kinetic control of guanine nucleotide binding to soluble Galpha(q). Chidiac P, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):39–48

Interaction of guanine nucleotides with the signal recognition particle from Escherichia coli. Jagath JR, et al. **Biochemistry** 1998 Nov 3;37(44):15408–13

The interaction between rac1 and its guanine nucleotide dissociation inhibitor (GDI), monitored by a single fluorescent coumarin attached to GDI. Newcombe AR, et al. **Biochemistry** 1999 May 25;38(21):6879–86

Effects of domain exchanges between Escherichia coli and mammalian mitochondrial EF-Tu on interactions with guanine nucleotides, aminoacyl-tRNA and ribosomes. Bullard JM, et al. **Biochim Biophys Acta** 1999 Jul 7; 1446(1-2):102–14

Partial characterization of two major liver I-compounds as unstable adducts which are readily hydrolyzed to unmodified guanine nucleotides. Zhou GD, et al. **Carcinogenesis** 1998 Oct;19(10):1863–6

The A26G replacement in the consensus sequence A-X-X-X-X-G-K-[T,S] of the guanine nucleotide binding site activates the intrinsic GTPase of the elongation factor 2 from the archaeon Sulfolobus solfataricus. De Vendittis E, et al. **Eur J Biochem** 1999 Jun;262(2):600–5

Characterization of GFR, a novel guanine nucleotide exchange factor for Rap1. Ichiba T, et al. **FEBS Lett** 1999 Aug 20;457(1):85–9

The molybdenum cofactor biosynthesis protein MobA from Rhodobacter capsulatus is required for the activity of molybdenum enzymes containing MGD, but not for xanthine dehydrogenase harboring the MPT cofactor. Leimkühler S, et al. **FEMS Microbiol Lett** 1999 May 15;

174(2):239–46
Inhibition of cellular growth by increased guanine nucleotide pools. Characterization of an Escherichia coli mutant with a guanosine kinase that is insensitive to feedback inhibition by GTP. Petersen C. **J Biol Chem** 1999 Feb 26; 274(9):5348–56
Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases. Ren Y, et al. **J Biol Chem** 1998 Dec 25;273(52):34954–60
Mutations at G:C base pairs predominate after replication of peroxyl radical-damaged pSP189 plasmids in human cells. Burcham PC, et al. **Mutagenesis** 1999 Jan; 14(1):135–40
A DNA polymerase stop assay for G-quadruplex-interactive compounds. Han H, et al. **Nucleic Acids Res** 1999 Jan 15; 27(2):537–42
A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia [published erratum appears in Proc Natl Acad Sci U S A 1999 Jan 5;96(1):318] Kawasaki H, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):13278–83

PHARMACOLOGY

Endothelin-B receptors activate Galpha13. Kitamura K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C930–7
Guanosine nucleotide analogs as inhibitors of alphavirus mRNA capping enzyme. Lampio A, et al. **Antiviral Res** 1999 May;42(1):35–46
A2a adenosine receptors: guanine nucleotide derivative regulation in porcine striatal membranes and digitonin soluble fraction. Costa B, et al. **Neurochem Int** 1998 Aug; 33(2):121–9
Design and SAR study of a novel class of nucleotide analogues as potent anti-HCMV agents. Nguyen-Ba N, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):821–7

PHYSIOLOGY

Guanine nucleotides, including GMP, antagonize kainate responses in Xenopus oocytes injected with chick cerebellar membranes. Aleu J, et al. **J Neurochem** 1999 May;72(5):2170–6
Effects of guanine nucleotides on adenosine and glutamate modulation of cAMP levels in optic tectum slices from chicks. Tasca CI, et al. **Neurochem Int** 1999 Mar; 34(3):213–20

GUANINE PHOSPHORIBOSYLTRANSFERASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

GUANINE POLYNUCLEOTIDES see **POLY G**

GUANOSINE

ANALOGS & DERIVATIVES

Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Bedard J, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):557–67
Immunochemical detection of N2-[1-(1-carboxy)ethyl]guanosine, an advanced glycation end product formed by the reaction of DNA and reducing sugars or L-ascorbic acid in vitro. Seidel W, et al. **Biochim Biophys Acta** 1998 Nov 27;1425(3):478–84
Oligoribonucleotides containing 8-oxo-7,8-dihydroguanosine and 8-oxo-7,8-dihydro-2'-O-methylguanosine: synthesis and base pairing properties. Kim SK, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):939–44
Reaction of guanosine with glucose under oxidative conditions. Seidel W, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2017–22
Cell proliferation induced by 8-oxoguanosine and 8-methylguanosine, two adducts produced by free radical attack on ribonucleosides and RNA. Kwee JK, et al. **Chem Biol Interact** 1998 Nov 6;116(1-2):61–77
Isolation of a MX-guanosine adduct formed at physiological conditions. Franzén R, et al. **Chemosphere** 1998 Jun; 36(13):2803–8
Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Keenan JA, et al. **Fertil Steril** 1999 Jul;72(1):135–41
Further evidence for a possible role of conformation in the immunogenicity and antigenicity of the oxidative DNA lesion, 8-oxo-2'deoxyguanosine. Cooke MS, et al. **Free Radic Res** 1998 May;28(5):459–69
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. Pourquier P, et al. **J Biol Chem** 1999 Mar 26;274(13):8516–23
Insertion of dGMP and dAMP during in vitro DNA synthesis opposite an oxidized form of 7,8-dihydro-8-oxoguanine. Duarte V, et al. **Nucleic Acids Res** 1999 Jan 15; 27(2):496–502
Preparation of N2, N2,7-trimethylguanosine affinity columns. Espuny R, et al. **Nucleosides Nucleotides** 1999 Jan; 18(1):125–36
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. Gu Z, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):891–2
Intracellular Leishmania amazonensis killing induced by the guanine nucleoside 8-bromoguanosine. Giorgio S, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):237–40
N-acetyl-L-cysteine protects against delta-aminolevulinic acid-induced 8-hydroxydeoxyguanosine formation. Yusof M, et al. **Toxicol Lett** 1999 May 20;106(1):41–7

ANALYSIS

Separation of G structures formed by a 27-mer guanosine-rich oligodeoxyribonucleotide by dye-ligand affinity chromatography. Alberghina G, et al. **J Chromatogr A** 1999 Apr 23;840(1):51–8

CHEMISTRY

Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Bedard J, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):557–67
Probing the role of metal ions in RNA catalysis: kinetic and thermodynamic characterization of a metal ion interaction with the 2'-moiety of the guanosine nucleophile in the Tetrahymena group I ribozyme. Shan SO, et al. **Biochemistry** 1999 Aug 24;38(34):10958–75
Reaction of guanosine with glucose under oxidative conditions. Seidel W, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2017–22
DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Seidel W, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1165–70
Identification of an ethenoformyl adduct formed in the reaction of the potent bacterial mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone with guanosine. Munter T, et al. **Chem Res Toxicol** 1999 Jan;12(1):46–52
Isolation of a MX-guanosine adduct formed at physiological conditions. Franzén R, et al. **Chemosphere** 1998 Jun; 36(13):2803–8
Oligomerization of activated D- and L-guanosine mononucleotides on templates containing D- and L-deoxycytidylate residues. Kozlov IA, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13448–52

GENETICS

Probing the interplay between the two steps of group I intron splicing: competition of exogenous guanosine with omega G. Zarrinkar PP, et al. **Biochemistry** 1998 Dec 22; 37(51):18056–63
An A/G-rich motif in the rat fibroblast growth factor-2 gene confers enhancer activity on a heterologous promoter in neonatal rat cardiac myocytes. Detillieux KA, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):169–76

ISOLATION & PURIFICATION

Isolation of isoguanosine from Croton tiglium and its antitumor activity. Kim JH, et al. **Arch Pharm Res** 1994 Apr;17(2):115–8

METABOLISM

Protonated 2'-aminoguanosine as a probe of the electrostatic environment of the active site of the Tetrahymena group I ribozyme. Shan SO, et al. **Biochemistry** 1999 Aug 24; 38(34):10976–88
Recognition of 2'-deoxyisoguanosine triphosphate by HIV-1 reverse transcriptase and mammalian cellular DNA polymerases. Lutz MJ, et al. **Bioorg Med Chem Lett** 1998 Mar 3;8(5):499–504
Adenosine deaminase and guanosine deaminase activities in sera of patients with viral hepatitis. Kalkan A, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun;94(3):383–6
Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Hauser IA, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):58–63
Derivatives of L-adenosine and L-guanosine as substrates for human deoxycytidine kinase. Gaubert G, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):857–60
Guanosine 2-NH2 groups of Escherichia coli RNase P RNA involved in intramolecular tertiary contacts and direct interactions with tRNA. Heide C, et al. **RNA** 1999 Jan; 5(1):102–16
Specificity from steric restrictions in the guanosine binding pocket of a group I ribozyme. Russell R, et al. **RNA** 1999 Feb;5(2):158–66

PHARMACOKINETICS

Intestinal absorption of acyclovir beta-glucoside: comparative study with acyclovir, guanosine, and kinetin beta-glucoside. Mizuma T, et al. **Pharm Res** 1999 Jan; 16(1):69–73

PHARMACOLOGY

Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Litsky ML, et al. **Brain Res** 1999 Mar 13; 821(2):426–32

GUANOSINE CYCLIC MONOPHOSPHATE-DEPENDENT PROTEIN KINASES see **CYCLIC GMP-DEPENDENT PROTEIN KINASES**

GUANOSINE CYCLIC 3',5'-MONOPHOSPHATE see **CYCLIC GMP**

GUANOSINE DIPHOSPHATE

ANALOGS & DERIVATIVES

GTP (gammaS) and GDP (betaS) as electron donors: new wine in old bottles. Peterson DA, et al. **Life Sci** 1999; 65(11):1135–40

CHEMISTRY

Crystal structures of the G protein Gi alpha 1 complexed with GDP and Mg2+: a crystallographic titration experiment. Coleman DE, et al. **Biochemistry** 1998 Oct 13; 37(41):14376–85
Vibrational study of phosphate modes in GDP and GTP and their interaction with magnesium in aqueous solution. Wang JH, et al. **Biospectroscopy** 1998;4(4):219–27
Crystal structure of intact elongation factor EF-Tu from Escherichia coli in GDP conformation at 2.05 A resolution. Song H, et al. **J Mol Biol** 1999 Jan 22;285(3):1245–56
GDP-fucose synthetase from Escherichia coli: structure of a unique member of the short-chain dehydrogenase/reductase family that catalyzes two distinct reactions at the same active site. Somers WS, et al. **Structure** 1998 Dec 15;6(12):1601–12

METABOLISM

Interaction sites of the C-terminal region of the cGMP phosphodiesterase inhibitory subunit with the GDP-bound transducin alpha-subunit. Liu Y, et al. **Biochem J** 1999 Jan 15;337 (Pt 2):281–8
Interaction of a novel GDP exchange inhibitor with the Ras protein. Ganguly AK, et al. **Biochemistry** 1998 Nov 10; 37(45):15631–7
The conserved arginine in rho-GTPase-activating protein is essential for efficient catalysis but not for complex formation with Rho.GDP and aluminum fluoride. Graham DL, et al. **Biochemistry** 1999 Jan 19;38(3):985–91
Invasion of the nucleotide snatchers: structural insights into the mechanism of G protein GEFs. Sprang SR, et al. **Cell** 1998 Oct 16;95(2):155–8 (20 ref.)
RAP1A GTP/GDP cycles determine the intracellular location of the late endocytic compartments and contribute to myogenic differentiation. Pizon V, et al. **Exp Cell Res** 1999 Jan 10;246(1):56–68
Stimulation by leptin of 3H GDP binding to brown adipose tissue of fasted but not fed rats. Surmely JF, et al. **Int J Obes Relat Metab Disord** 1998 Sep;22(9):923–6
The Caulobacter crescentus CgtA protein displays unusual guanine nucleotide binding and exchange properties. Lin B, et al. **J Bacteriol** 1999 Sep;181(18):5825–32
Activities of mutant Sar1 proteins in guanine nucleotide binding, GTP hydrolysis, and cell-free transport from the endoplasmic reticulum to the Golgi apparatus. Saito Y, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):816–23
Direct photoaffinity labeling of cysteine 211 or a nearby amino acid residue of beta-tubulin by guanosine 5'-diphosphate bound in the exchangeable site. Bai R, et al. **J Biol Chem** 1999 Apr 30;274(18):12710–4
Lipid products of phosphoinositide 3-kinase interact with Rac1 GTPase and stimulate GDP dissociation. Missy K, et al. **J Biol Chem** 1998 Nov 13;273(46):30279–86
Facilitated geranylgeranylation of shrimp ras-encoded p25 fusion protein by the binding with guanosine diphosphate. Huang CF, et al. **J Exp Zool** 1999 May 1;283(6):510–21
The structure of the Q69L mutant of GDP-Ran shows a major conformational change in the switch II loop that accounts for its failure to bind nuclear transport factor 2 (NTF2). Stewart M, et al. **J Mol Biol** 1998 Dec 18; 284(5):1517–27
Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. Kearn CS, et al. **J Neurochem** 1999 Jun; 72(6):2379–87
Identification of regulators for Ypt1 GTPase nucleotide cycling. Jones S, et al. **Mol Biol Cell** 1998 Oct; 9(10):2819–37
Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. Peyroche A, et al. **Mol Cell** 1999 Mar; 3(3):275–85
EF-G-dependent GTP hydrolysis induces translocation accompanied by large conformational changes in the 70S ribosome. Agrawal RK, et al. **Nat Struct Biol** 1999 Jul; 6(7):643–7
Functional changes in the structure of the SRP GTPase on binding GDP and Mg2+GDP. Freymann DM, et al. **Nat Struct Biol** 1999 Aug;6(8):793–801

PHARMACOLOGY

Mitochondrial proton leak in brown adipose tissue mitochondria of Ucp1-deficient mice is GDP insensitive. Monemdjou S, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1073–82

GUANOSINE DIPHOSPHATE FUCOSE

BIOSYNTHESIS

A high-yield, enzymatic synthesis of GDP-D-[3H]arabinose and GDP-L-[3H]fucose. Mengeling BJ, et al. **Anal Biochem** 1999 Feb 1;267(1):227-33

Activity of enzymes catalyzing formation of beta-L-fucosyl phosphate and GDP-beta-L-fucose in amphibian tissues and their application in chemo-enzymic synthesis of GDP-beta-L-fucose. Druzhinina TN, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):783-7

Stereochemical course and steady state mechanism of the reaction catalyzed by the GDP-fucose synthetase from Escherichia coli. Menon S, et al. **J Biol Chem** 1999 Sep 17;274(38):26743-50

Mutation in GDP-fucose synthesis genes of Sinorhizobium fredii alters Nod factors and significantly decreases competitiveness to nodulate soybeans. Lamrabet Y, et al. **Mol Plant Microbe Interact** 1999 Mar;12(3):207-17

GDP-4-keto-6-deoxy-D-mannose epimerase/reductase from Escherichia coli, a key enzyme in the biosynthesis of GDP-L-fucose, displays the structural characteristics of the RED protein homology superfamily. Rizzi M, et al. **Structure** 1998 Nov 15;6(11):1453-65

DEFICIENCY

A1/A2 blood group variant due to fucosylation deficiency in carbohydrate deficient glycoprotein syndrome type I? [letter] Heyne K, et al. **Eur J Pediatr** 1999 Feb;158(2):170

METABOLISM

A new type of carbohydrate-deficient glycoprotein syndrome due to a decreased import of GDP-fucose into the golgi. Lübke T, et al. **J Biol Chem** 1999 Sep 10; 274(37):25986-9

Decreased availability of GDP-L-fucose in a patient with LAD II with normal GDP-D-mannose dehydratase and FX protein activities. Körner C, et al. **J Leukoc Biol** 1999 Jul;66(1):95-8

GUANOSINE DIPHOSPHATE MANNOSE

METABOLISM

Chinese hamster ovary cells with reduced hexokinase activity maintain normal GDP-mannose levels. O'Rear JL, et al. **J Cell Biochem** 1999 Jan 1;72(1):56-66

Genetic evidence for the role of GDP-mannose in plant ascorbic acid (vitamin C) biosynthesis. Conklin PL, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4198-203

GUANOSINE DIPHOSPHATE SUGARS

BIOSYNTHESIS

A high-yield, enzymatic synthesis of GDP-D-[3H]arabinose and GDP-L-[3H]fucose. Mengeling BJ, et al. **Anal Biochem** 1999 Feb 1;267(1):227-33

METABOLISM

Glucosylation of glycosylphosphatidylinositol membrane anchors: identification of uridine diphosphate-glucose as the direct donor for side chain modification in Toxoplasma gondii using carbohydrate analogues. Striepen B, et al. **Biochemistry** 1999 Feb 2;38(5):1478-87

GUANOSINE DIPHOSPHOFUCOSE see **GUANOSINE DIPHOSPHATE FUCOSE**

GUANOSINE DIPHOSPHOMANNOSE see **GUANOSINE DIPHOSPHATE MANNOSE**

GUANOSINE MONOPHOSPHATE see **5'-GUANYLIC ACID**

GUANOSINE 5'-MONOPHOSPHATE see **5'-GUANYLIC ACID**

GUANOSINE PENTAPHOSPHATE

METABOLISM

The alarmone (p)ppGpp mediates physiological-responsive control at the sigma 54-dependent Po promoter. Sze CC, et al. **Mol Microbiol** 1999 Feb;31(4):1217-28

GUANOSINE PHOSPHATES see **GUANINE NUCLEOTIDES**

GUANOSINE PYROPHOSPHATE MANNOSE see **GUANOSINE DIPHOSPHATE MANNOSE**

GUANOSINE TETRAPHOSPHATE

METABOLISM

The alarmone (p)ppGpp mediates physiological-responsive control at the sigma 54-dependent Po promoter. Sze CC, et al. **Mol Microbiol** 1999 Feb;31(4):1217-28

Regulation of bacteriophage lambda development by guanosine 5'-diphosphate-3'-diphosphate. Slominska M, et al. **Virology** 1999 Sep 30;262(2):431-41

PHARMACOLOGY

Guanosine tetraphosphate-induced dissociation of open complexes at the Escherichia coli ribosomal protein promoters rplJ and rpsA P1: nanosecond depolarization spectroscopic studies. Raghavan A, et al. **Biophys Chem** 1998 Oct 5;75(1):21-32

The differential effects of guanosine tetraphosphate on open complex formation at the Escherichia coli ribosomal protein promoters rplJ and rpsA P1. Raghavan A, et al. **Biophys Chem** 1998 Oct 5;75(1):7-19

PHYSIOLOGY

Growth rate related concentration changes of the starvation response regulators sigmaS and ppGpp in glucose-limited fed-batch and continuous cultures of Escherichia coli. Teich A, et al. **Biotechnol Prog** 1999 Jan-Feb;15(1):123-9

Effect of ppGpp on Escherichia coli cyclopropane fatty acid synthesis is mediated through the RpoS sigma factor (sigmaS). Eichel J, et al. **J Bacteriol** 1999 Jan;181(2):572-6

Analysis of the effect of ppGpp on the ftsQAZ operon in Escherichia coli. Navarro F, et al. **Mol Microbiol** 1998 Aug; 29(3):815-23

GUANOSINE TRIPHOSPHATE

ANALOGS & DERIVATIVES

Metabolic fate of oxidized guanine ribonucleotides in mammalian cells. Hayakawa H, et al. **Biochemistry** 1999 Mar 23;38(12):3610-4

The effects of various GTP analogues on microtubule assembly. Muraoka M, et al. **Cell Struct Funct** 1999 Apr; 24(2):101-9

Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Rodriguez CO Jr, et al. **Clin Cancer Res** 1997 Nov;3(11):2107-13

Activation of Go-proteins by membrane depolarization traced by in situ photoaffinity labeling of galphao-proteins with [alpha32P]GTP-azidoanilide. Anis Y, et al. **J Biol Chem** 1999 Mar 12;274(11):7431-40

Structure of Gialpha1.GppNHp, autoinhibition in a galpha protein-substrate complex. Coleman DE, et al. **J Biol Chem** 1999 Jun 11;274(24):16669-72

Guanosine triphosphatase stimulation of oncogenic Ras mutants. Ahmadian MR, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7065-70

BLOOD

A twenty strain survey and backcross localization of the erythrocytic GTP concentration determining locus Gtpc on mouse chromosome 9. Wiebe GJ, et al. **Genome** 1999 Jun;42(3):447-52

CHEMISTRY

Excess nucleoside triphosphates (or zinc) allow recovery of alkaline phosphatase activity following refolding under reducing conditions. Ghosh N, et al. **Biochemistry** 1998 Nov 3;37(44):15542-7

Prediction of the GTPase activities by using the semiempirical molecular orbital theory. Kinoshita H, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1083-8

Vibrational study of phosphate modes in GDP and GTP and their interaction with magnesium in aqueous solution. Wang JH, et al. **Biospectroscopy** 1998;4(4):219-27

The crystal structure of Cys-tRNACys-EF-Tu-GDPNP reveals general and specific features in the ternary complex and in tRNA. Nissen P, et al. **Structure Fold Des** 1999 Feb 15;7(2):143-56

METABOLISM

Stimulation of glycosylphosphatidylinositol biosynthesis in mammalian cell-free systems by GTP hydrolysis: evidence for the involvement of membrane fusion. Stevens VL, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):577-84

Conformational change rate-limits GTP hydrolysis: the mechanism of the ATP sulfurylase-GTPase. Wei J, et al. **Biochemistry** 1998 Dec 8;37(49):17163-9

Increased functional activity of elongation factor G with G16V mutation in the GTP-binding domain. Martemyanov KA, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1216-9

Ribosomal protection from tetracycline mediated by Tet(O): Tet(O) interaction with ribosomes is GTP-dependent. Trieber CA, et al. **Biol Chem** 1998 Jul;379(7):847-55

Prediction of the GTPase activities by using the semiempirical molecular orbital theory. Kinoshita H, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1083-8

Structural basis for activation of ARF GTPase: mechanisms of guanine nucleotide exchange and GTP-myristoyl switching. Goldberg J. **Cell** 1998 Oct 16;95(2):237-48

Structural and functional analysis of the ARF1-ARFGAP complex reveals a role for coatomer in GTP hydrolysis. Goldberg J. **Cell** 1999 Mar 19;96(6):893-902

Ribosomal mechanics, antibiotics, and GTP hydrolysis [comment] Porse BT, et al. **Cell** 1999 May 14;97(4):423-6 (16 ref.). Comment on: Cell 1999 May 14;97(4):491-502.

Invasion of the nucleotide snatchers: structural insights into the mechanism of G protein GEFs. Sprang SR, et al. **Cell** 1998 Oct 16;95(2):155-8 (20 ref.)

The translocation of transportin-cargo complexes through nuclear pores is independent of both Ran and energy. Ribbeck K, et al. **Curr Biol** 1999 Jan 14;9(1):47-50

Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. Ren XD, et al. **EMBO J** 1999 Feb 1;18(3):578-85

RAP1A GTP/GDP cycles determine the intracellular location of the late endocytic compartments and contribute to myogenic differentiation. Pizon V, et al. **Exp Cell Res** 1999 Jan 10;246(1):56-68

Virus-specific capping of tobacco mosaic virus RNA: methylation of GTP prior to formation of covalent complex p126-m7GMP. Merits A, et al. **FEBS Lett** 1999 Jul 16; 455(1-2):45-8

Colocalization of phospholipase D1 and GTP-binding-defective mutant of ADP-ribosylation factor 6 to endosomes and lysosomes. Toda K, et al. **FEBS Lett** 1999 Jan 15;442(2-3):221-5

Inhibition of GTP binding to Rac2 by peroxynitrite: potential role for tyrosine modification. Rohn TT, et al. **Free Radic Biol Med** 1999 May;26(9-10):1321-31

Correlation of rat hepatic phenylalanine hydroxylase, with tetrahydrobiopterin and GTP concentrations. Guerin T, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1047-54

The Caulobacter crescentus CgtA protein displays unusual guanine nucleotide binding and exchange properties. Lin B, et al. **J Bacteriol** 1999 Sep;181(18):5825-32

Activities of mutant Sar1 proteins in guanine nucleotide binding, GTP hydrolysis, and cell-free transport from the endoplasmic reticulum to the Golgi apparatus. Saito Y, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):816-23

The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. Askjaer P, et al. **J Biol Chem** 1998 Dec 11;273(50):33414-22

Histidine 179 mutants of GTP cyclohydrolase I catalyze the formation of 2-amino-5-formylamino-6-ribofuranosylamino-4(3H)-pyrimidinone triphosphate. Bracher A, et al. **J Biol Chem** 1999 Jun 11;274(24):16727-35

Site-directed mutagenesis of yeast eEF1A. Viable mutants with altered nucleotide specificity. Cavallius J, et al. **J Biol Chem** 1998 Oct 30;273(44):28752-8

Phospholipase C-beta1 directly accelerates GTP hydrolysis by Galphaq and acceleration is inhibited by Gbeta gamma subunits. Chidiac P, et al. **J Biol Chem** 1999 Jul 9; 274(28):19639-43

Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras. Chiloeches A, et al. **J Biol Chem** 1999 Jul 9;274(28):19762-70

Quantitative assessment of EF-1alpha.GTP binding to aminoacyl-tRNAs, aminoacyl-viral RNA, and tRNA shows close correspondence to the RNA binding properties of EF-Tu. Dreher TW, et al. **J Biol Chem** 1999 Jan 8; 274(2):666-72

Pseudomonas aeruginosa exoenzyme S disrupts Ras-mediated signal transduction by inhibiting guanine nucleotide exchange factor-catalyzed nucleotide exchange. Ganesan AK, et al. **J Biol Chem** 1999 Jul 30;274(31):21823-9

GTP-bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). Kochs G, et al. **J Biol Chem** 1999 Feb 12;274(7):4370-6

Ran-dependent signal-mediated nuclear import does not require GTP hydrolysis by Ran. Schwoebel ED, et al. **J Biol Chem** 1998 Dec 25;273(52):35170-5

The function of the p190 Rho GTPase-activating protein is controlled by its N-terminal GTP binding domain. Tatsis N, et al. **J Biol Chem** 1998 Dec 18;273(51):34631-8

Tubulin folding cofactors as GTPase-activating proteins. GTP hydrolysis and the assembly of the alpha/beta-tubulin heterodimer. Tian G, et al. **J Biol Chem** 1999 Aug 20; 274(34):24054-8

Chloroplast FtsY, chloroplast signal recognition particle, and GTP are required to reconstitute the soluble phase of light-harvesting chlorophyll protein transport into thylakoid membranes. Tu CJ, et al. **J Biol Chem** 1999 Sep 17;274(38):27219-24

Ca2+/calmodulin stimulates GTP binding to the ras-related protein ral-A. Wang KL, et al. **J Biol Chem** 1999 May 21;274(21):14525-8

GTP hydrolysis links initiation and termination of nuclear import on the nucleoporin nup358. Yaseen NR, et al. **J Biol Chem** 1999 Sep 10;274(37):26493-502

GTP-dependent binding of ADP-ribosylation factor to coatomer in close proximity to the binding site for dilysine retrieval motifs and p23. Zhao L, et al. **J Biol Chem** 1999 May 14;274(20):14198-203

1H, 15N and 13C chemical shift assignment of the guanine nucleotide exchange domain of human Elongation Factor-one beta. Perez JM, et al. **J Biomol NMR** 1998 Oct;12(3):467-8

The ribosome regulates the GTPase of the beta-subunit of the signal recognition particle receptor. Bacher G, et al. **J Cell Biol** 1999 Aug 23;146(4):723-30

The GTP-binding protein Rho1p is required for cell cycle progression and polarization of the yeast cell. Drgonová J, et al. **J Cell Biol** 1999 Jul 26;146(2):373-87

Beyond nuclear transport. Ran-GTP as a determinant of spindle assembly. Kahana JA, et al. **J Cell Biol** 1999 Sep 20;146(6):1205-10 (29 ref.)
GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase. Monsonego A, et al. **J Mol Biol** 1998 Oct 2;282(4):713-20
The McrBC endonuclease translocates DNA in a reaction dependent on GTP hydrolysis. Panne D, et al. **J Mol Biol** 1999 Jul 2;290(1):49-60
Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. Kearn CS, et al. **J Neurochem** 1999 Jun; 72(6):2379-87
A protein friction model of the actin sliding movement generated by myosin in mixtures of MgATP and MgGTP in vitro. Imafuku Y, et al. **J Theor Biol** 1999 Aug 21; 199(4):359-70
MxA GTPase: oligomerization and GTP-dependent interaction with viral RNP target structures. Kochs G, et al. **Methods** 1998 Jul;15(3):255-63
On the advantages of imperfect energetic linkage. Leyh TS. **Methods Enzymol** 1999;308:48-70
Identification of regulators for Ypt1 GTPase nucleotide cycling. Jones S, et al. **Mol Biol Cell** 1998 Oct; 9(10):2819-37
Mutations in elongation factor 1beta, a guanine nucleotide exchange factor, enhance translational fidelity. Carr-Schmid A, et al. **Mol Cell Biol** 1999 Aug; 19(8):5257-66
Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth. Goi T, et al. **Mol Cell Biol** 1999 Mar; 19(3):1731-41
EF-G-dependent GTP hydrolysis induces translocation accompanied by large conformational changes in the 70S ribosome. Agrawal RK, et al. **Nat Struct Biol** 1999 Jul; 6(7):643-7
Arabidopsis thaliana 'extra-large GTP-binding protein' (AtXLG1): a new class of G-protein. Lee YR, et al. **Plant Mol Biol** 1999 May;40(1):55-64
The effect of ethylene and cytokinin on guanosine 5'-triphosphate binding and protein phosphorylation in leaves of Arabidopsis thaliana. Novikova GV, et al. **Planta** 1999 Apr;208(2):239-46
Rapid GTP binding and hydrolysis by G(q) promoted by receptor and GTPase-activating proteins. Mukhopadhyay S, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17; 96(17):9539-44
GTP binding by class II transactivator: role in nuclear import [see comments] Harton JA, et al. **Science** 1999 Aug 27; 285(5432):1402-5. Comment in: Science 1999 Aug 27;285(5432):1367.
Perspectives: immunology. Regulating the regulator [comment] Mach B. **Science** 1999 Aug 27;285(5432):1367 . Comment on: Science 1999 Aug 27;285(5432):1402-5.
Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran [see comments] Ohba T, et al. **Science** 1999 May 21;284(5418):1356-8. Comment in: Science 1999 May 21;284(5418):1260-1.
Nuclear transport protein does double duty in mitosis [news; comment] Pennisi E. **Science** 1999 May 21;284(5418):1356-8 . Comment on: Science 1999 May 21;284(5418):1356-8. Comment on: Science 1999 May 21;284(5418):1359-62.
Stimulation of microtubule aster formation and spindle assembly by the small GTPase Ran [see comments] Wilde A, et al. **Science** 1999 May 21;284(5418):1359-62. Comment in: Science 1999 May 21;284(5418):1260-1.
Structural basis of activation and GTP hydrolysis in Rab proteins. Dumas JJ, et al. **Structure** 1999 Apr 15;7(4):413-23
The N-terminal half of the brome mosaic virus 1a protein has RNA capping-associated activities: specificity for GTP and S-adenosylmethionine. Kong F, et al. **Virology** 1999 Jun 20;259(1):200-10

PHARMACOLOGY

The effects of various GTP analogues on microtubule assembly. Muraoka M, et al. **Cell Struct Funct** 1999 Apr; 24(2):101-9
Properties of purified lens transglutaminase and regulation of its transamidase/crosslinking activity by GTP. Murthy SN, et al. **Exp Eye Res** 1998 Sep;67(3):273-81
Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. Lohmann V, et al. **J Biol Chem** 1999 Apr 16;274(16):10807-15
GTP-dependent activation of urease apoprotein in complex with the UreD, UreF, and UreG accessory proteins. Soriano A, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11140-4

PHYSIOLOGY

Suppression of GTP/T alpha-dependent activation of cGMP phosphodiesterase by ADP-ribosylation by its gamma subunit in amphibian rod photoreceptor membranes. Bondarenko VA, et al. **Biochemistry** 1999 Jun 15; 38(24):7755-63
Going for the GAP. McCormick F. **Curr Biol** 1998 Sep 24; 8(19):R673-4 (5 ref.)
Generation of GTP-bound Ran by RCC1 is required for chromatin-induced mitotic spindle formation. Carazo-Salas RE, et al. **Nature** 1999 Jul 8;400(6740):178-81
Inosine monophosphate dehydrogenase: A molecular switch integrating pleiotropic GTP-dependent beta-cell functions. Metz SA, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug; 111(4):335-46 (86 ref.)
Coatomer, Arf1p, and nucleotide are required to bud coat protein complex I-coated vesicles from large synthetic liposomes. Spang A, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11199-204

GUANOSINE TRIPHOSPHATE PHOSPHOHYDROLASE see **GTP PHOSPHOHYDROLASE**

GUANOSINE 5'-(GAMMA-S)TRIPHOSPHATE see **GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE)**

GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE)

BLOOD

Alpha2-adrenergic agonist modulation of [35S]GTPgammaS binding to guanine-nucleotide-binding-proteins in human platelet membranes. Gessi S, et al. **Life Sci** 1999; 64(16):1403-13

METABOLISM

In vitro visualization of 5-HT receptors in rat brain using [35S]GTP gamma S binding. Beer MS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:265
Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTP gamma S and the novel, selective radioligand, [3H]-S 15535. Newman-Tancredi A, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:263-4
Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding. Beresford IJ, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1167-74
Kinetic control of guanine nucleotide binding to soluble Galpha(q). Chidiac P, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):39-48
Pharmacological characterization of dopamine-stimulated [35S]-guanosine 5'(gamma-thiotriphosphate) ([35S]GTPgammaS) binding in rat striatal membranes. Rinken A, et al. **Biochem Pharmacol** 1999 Jan 15; 57(2):155-62
Serotonin 5-HT(1B/1D) agonist-stimulated [(35)S]GTPgammaS binding in rat and guinea pig striatal membranes. Mize AL, et al. **Brain Res** 1999 Jul 31; 836(1-2):229-36
Inhibition of GTPgammaS-dependent L-isoaspartyl protein methylation by tyrosine kinase inhibitors in kidney. Bilodeau D, et al. **Cell Signal** 1999 Jan;11(1):45-52
Pyrazolopyridine derivatives act as competitive antagonists of brain adenosine A1 receptors: [35S]GTPgammaS binding studies. Ito H, et al. **Eur J Pharmacol** 1999 Jan 22;365(2-3):309-15
Methadone-induced desensitization of the delta-opioid receptor is mediated by uncoupling of receptor from G protein. Liu JG, et al. **Eur J Pharmacol** 1999 Jun 18; 374(2):301-8
Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord. Narita M, et al. **Eur J Pharmacol** 1998 Jun 26;351(3):383-7
Subtype-specific stimulation of [35S]GTPgammaS binding by recombinant alpha2-adrenoceptors. Peltonen JM, et al. **Eur J Pharmacol** 1998 Aug 21;355(2-3):275-9
Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Wainscott DB, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):117-24
Regulation of phospholipase D activity in synaptosomes permeabilized with Staphylococcus aureus alpha-toxin. Sarri E, et al. **FEBS Lett** 1998 Dec 4;440(3):287-90
Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Zhang G, et al. **Gene** 1999 Feb 4;227(1):89-99
Desensitization of human muscarinic acetylcholine receptor m2 subtypes is caused by their sequestration/internalization. Tsuga H, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):863-8
In vitro autoradiographic visualization of guanosine-5'-O-(3-[35S]thio)triphosphate binding stimulated by sphingosine 1-phosphate and lysophosphatidic acid. Waeber C, et al. **J Neurochem** 1999 Sep;73(3):1212-21
Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. DeLapp NW, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):946-55
Measurement of agonist-stimulated [35S]GTP gamma S binding to cell membranes. Lazareno S. **Methods Mol Biol** 1999;106:231-45 (43 ref.)
Effects of an agonist, allosteric modulator, and antagonist on guanosine-gamma-[35S]thiotriphosphate binding to liposomes with varying muscarinic receptor/Go protein stoichiometry. Jakubik J, et al. **Mol Pharmacol** 1998 Nov; 54(5):899-906
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. Newman-Tancredi A, et al. **Mol Pharmacol** 1999 Mar;55(3):564-74
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Romero J, et al. **Neurochem Int** 1999 Jun;34(6):473-82
Selective detection of adenosine A1 receptor-dependent G-protein activity in basal and stimulated conditions of rat brain [35S]guanosine 5'-(gamma-thio)triphosphate autoradiography. Laitinen JT. **Neuroscience** 1999; 90(4):1265-79
[Effects of newly isolated opioid peptides on G-protein activation: usefulness of [35S] GTP gamma S binding study and its practical application] Narita M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):107-16 (58 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Okadaic acid antagonizes the inhibitory action of internal GTP-gamma-S on the calcium current of dorsal raphe neurons but not that of 5-HT1A receptor activation. Kelly JS, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:220-3
Guanosine 5'-O-(3-thiotriphosphate)-induced O-2 generation in permeabilized neutrophils requires protein kinase C and phospholipase C but not tyrosine kinase or phospholipase D. Tamura M, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):257-63
Down-regulation of cannabinoid receptor agonist-stimulated [35S]GTP gamma S binding in synaptic plasma membrane from chronic ethanol exposed mouse. Basavarajappa BS, et al. **Brain Res** 1999 Jan 2;815(1):89-97
Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses. Dupuis DS, et al. **Brain Res Mol Brain Res** 1999 Apr 6; 67(1):107-23
Metal ion and guanine nucleotide modulations of agonist interaction in G-protein-coupled serotonin1A receptors from bovine hippocampus. Harikumar KG, et al. **Cell Mol Neurobiol** 1998 Oct;18(5):535-53
Autoradiographic studies of 5-HT1A-receptor-stimulated [35S]GTPgammaS-binding responses in the human and monkey brain. Dupuis DS, et al. **Eur J Neurosci** 1999 May; 11(5):1809-17
The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester-induced Ca2+-sensitization of smooth muscle. Fu X, et al. **FEBS Lett** 1998 Nov 27;440(1-2):183-7
Uptake by COPI-coated vesicles of both anterograde and retrograde cargo is inhibited by GTPgammaS in vitro. Nickel W, et al. **J Cell Sci** 1998 Oct;111 (Pt 20):3081-90
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol. Romero J, et al. **J Mol Neurosci** 1998 Oct;11(2):109-19
Radioligand assays for oestradiol and progesterone conjugated to protein reveal evidence for a common membrane binding site in the medial preoptic area-anterior hypothalamus and differential modulation by cholera toxin and GTPgammaS. Caldwell JD, et al. **J Neuroendocrinol** 1999 Jun;11(6):409-17
Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: evaluation of receptor states and modulation by guanine nucleotide. Hoare SR, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1323-33
GTP (gammaS) and GDP (betaS) as electron donors: new wine in old bottles. Peterson DA, et al. **Life Sci** 1999; 65(11):1135-40
In vitro reconstitution of microtubule plus end-directed, GTPgammaS-sensitive motility of Golgi membranes. Fullerton AT, et al. **Mol Biol Cell** 1998 Oct;9(10):2699-714

PHYSIOLOGY

Guanosine 5'-(3-O-Thio)triphosphate stimulates protein carboxyl methylation in cell membranes. Desrosiers RR, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):333-40
Three distinct steps in transport of vesicular stomatitis virus glycoprotein from the ER to the cell surface in vivo with differential sensitivities to GTP gamma S. Pepperkok R, et al. **J Cell Sci** 1998 Jul;111 (Pt 13):1877-88

GUANOSINETRIPHOSPHATASE see **GTP PHOSPHOHYDROLASE**

GUANYL CYCLASE see **GUANYLATE CYCLASE**

GUANYLATE CYCLASE

The guanylyl cyclase family of natriuretic peptide receptors. Schulz S, et al. **Vitam Horm** 1999;57:123-51 (99 ref.)

ANALYSIS

Functional receptors in the avian kidney for C-type natriuretic peptide. Brenner D, et al. **Endocrinology** 1999

Apr;140(4):1622-9
Immunolocalization of natriuretic peptide receptor B in the rat kidney. Bonhomme MC, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1777-86
Nitric oxide/cyclic guanosine monophosphate pathway in the peripheral and central auditory system of the rat. Fessenden JD, et al. **J Comp Neurol** 1999 Feb 1; 404(1):52-63
Differentially-altered vascular guanylate cyclase isoforms in experimental hypertensive rats. Lee J, et al. **J Korean Med Sci** 1999 Aug;14(4):386-92
Localization of nitric oxide synthase, NADPH diaphorase and soluble guanylyl cyclase in adult rabbit retina. Haberecht MF, et al. **Vis Neurosci** 1998 Sep-Oct; 15(5):881-90

ANTAGONISTS & INHIBITORS

Methylene blue, a soluble guanylyl cyclase inhibitor, reduces the sevoflurane minimum alveolar anesthetic concentration and decreases the brain cyclic guanosine monophosphate content in rats. Masaki E, et al. **Anesth Analg** 1999 Aug; 89(2):484-9
Efficacy of isatin analogues as antagonists of rat brain and heart atrial natriuretic peptide receptors coupled to particulate guanylyl cyclase. Medvedev AE, et al. **Biochem Pharmacol** 1999 Apr 15;57(8):913-5
Light inhibition of bovine retinal rod guanylyl cyclase mediated by beta gamma-transducin. Wolbring G, et al. **Biochemistry** 1999 Mar 2;38(9):2611-6
Involvement of cGMP in cellular melatonin responses. Bubis M, et al. **Biol Cell** 1999 Jan;91(1):45-9
Comparison of two soluble guanylyl cyclase inhibitors, methylene blue and ODQ, on sodium nitroprusside-induced relaxation in guinea-pig trachea. Hwang TL, et al. **Br J Pharmacol** 1998 Nov;125(6):1158-63
Influence of a selective guanylate cyclase inhibitor, and of the contraction level, on nitrergic relaxations in the gastric fundus. Lefebvre RA. **Br J Pharmacol** 1998 Aug; 124(7):1439-48
Failure of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes. Wegener JW, et al. **Br J Pharmacol** 1999 Jun;127(3):693-700
Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock [see comments] Zingarelli B, et al. **Crit Care Med** 1999 Sep;27(9):1701-7. Comment in: Crit Care Med 1999 Sep;27(9):2019-22.
Effects of guanylyl cyclase and protein kinase G inhibitors on vasodilatation in non-tolerant and tolerant bovine coronary arteries. De la Lande IS, et al. **Eur J Pharmacol** 1999 Apr 1;370(1):39-46
Evidence of involvement of guanylate cyclase in the prolongation of caeco-colonic transit time by indomethacin in mice [letter] Robert FS, et al. **J Diarrhoeal Dis Res** 1998 Dec;16(4):256-7
Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. Yiu P, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):195-6
The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Feelisch M, et al. **Mol Pharmacol** 1999 Aug;56(2):243-53
Mast cell degranulation in rat mesenteric venule: effects of L-NAME, methylene blue and ketotifen. Kimura M, et al. **Pharmacol Res** 1999 May;39(5):397-402

BIOSYNTHESIS

Three kinds of guanylate cyclase expressed in medaka photoreceptor cells in both retina and pineal organ. Hisatomi O, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):216-20
Chronic hyperammonemia in rats impairs activation of soluble guanylate cyclase in neurons and in lymphocytes: a putative peripheral marker for neurological alterations. Miñana MD, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):405-9
Human soluble guanylate cyclase: functional expression and revised isoenzyme family. Zabel U, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):51-7
Coexpression of inducible NO synthase and soluble guanylyl cyclase in colonic enterocytes: a pathophysiologic signaling pathway for the initiation of diarrhea by gram-negative bacteria? Closs EI, et al. **FASEB J** 1998 Dec;12(15):1643-9
Effect of dietary insulin on the response of suckling mice enterocytes to Escherichia coli heat-stable enterotoxin. al-Majali A, et al. **Vet Res** 1998 Nov-Dec;29(6):527-36

BLOOD

Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Bustin SA, et al. **Br J Cancer** 1999 Apr;79(11-12):1813-20

CHEMISTRY

Cellular applications of a sensitive and selective fiber-optic nitric oxide biosensor based on a dye-labeled heme domain of soluble guanylate cyclase. Barker SL, et al. **Anal Chem** 1999 Jun 1;71(11):2071-5
Development of p-benzoylbenzoylated [N,C,rANP(1-28)]pBNP32 (pBNP1) derivatives and affinity photolabeling of the bovine NPR-A receptor. Coupal M, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):81-6
Soluble guanylate cyclase: effect of YC-1 on ligation kinetics with carbon monoxide. Sharma VS, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):188-91
Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Kharitonov VG, et al. **Biochemistry** 1999 Aug 17;38(33):10699-706
Resonance raman characterization of the heme domain of soluble guanylate cyclase. Schelvis JP, et al. **Biochemistry** 1998 Nov 17;37(46):16289-97
Identification of a guanylyl cyclase-activating protein-binding site within the catalytic domain of retinal guanylyl cyclase 1. Sokal I, et al. **Biochemistry** 1999 Feb 2;38(5):1387-93
Guanylate cyclase and the .NO/cGMP signaling pathway. Denninger JW, et al. **Biochim Biophys Acta** 1999 May 5; 1411(2-3):334-50 (124 ref.)
The adenylyl and guanylyl cyclase superfamily. Hurley JH. **Curr Opin Struct Biol** 1998 Dec;8(6):770-7 (41 ref.)
Guanylyl cyclases with the topology of mammalian adenylyl cyclases and an N-terminal P-type ATPase-like domain in Paramecium, Tetrahymena and Plasmodium. Linder JU, et al. **EMBO J** 1999 Aug 2;18(15):4222-32
Intracellular fragments of the natriuretic peptide receptor-C (NPR-C) attenuate dopamine efflux. Kanwal S, et al. **Endocrinology** 1999 Mar;140(3):1118-24
Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). Murthy KS, et al. **J Biol Chem** 1999 Jun 18;274(25):17587-92
Activation of retinal guanylyl cyclase-1 by Ca2+-binding proteins involves its dimerization. Yu H, et al. **J Biol Chem** 1999 May 28;274(22):15547-55
Biochemical analysis of a dimerization domain mutation in RetGC-1 associated with dominant cone-rod dystrophy. Tucker CL, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9039-44
Topological mimicry and epitope duplication in the guanylyl cyclase C receptor. Nandi A, et al. **Protein Sci** 1998 Oct; 7(10):2175-83
Soluble guanylyl cyclase: structure and regulation. Koesling D, et al. **Rev Physiol Biochem Pharmacol** 1999;135:41-65 (91 ref.)

DEFICIENCY

NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Zhao L, et al. **Circulation** 1999 Feb 9;99(5):605-7

DRUG EFFECTS

1,25-Dihydroxyvitamin D3 upregulates natriuretic peptide receptor-C expression in mouse osteoblasts. Yanaka N, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E965-73
Modulators of soluble guanylyl cyclase [see comments] Koesling D. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Jul;358(1):123-6 (29 ref.). Comment in: Naunyn Schmiedebergs Arch Pharmacol 1998 Jul;358(1):111-2.

GENETICS

A retGC-1 mutation in autosomal dominant cone-rod dystrophy [letter] Perrault I, et al. **Am J Hum Genet** 1998 Aug;63(2):651-4
B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39-45 (73 ref.)
Functional consequences of a rod outer segment membrane guanylate cyclase (ROS-GC1) gene mutation linked with Leber's congenital amaurosis. Duda T, et al. **Biochemistry** 1999 Jan 12;38(2):509-15
A functional chimera of mammalian guanylyl and adenylyl cyclases. Weitmann S, et al. **Biochemistry** 1999 Mar 16; 38(11):3409-13
Assignment of GUCY1B2, the human homologue of a candidate gene for hypertension, to chromosome bands 13q14.2-->q14.3 by in situ hybridization. Malterer A, et al. **Cytogenet Cell Genet** 1999;85(3-4):256-7
Cloning, properties and tissue distribution of natriuretic peptide receptor-A of euryhaline eel, Anguilla japonica. Kashiwagi M, et al. **Eur J Biochem** 1999 Jan; 259(1-2):204-11
Assignment of GUCY1B2, the gene coding for the beta2 subunit of human guanylyl cyclase to chromosomal band 13q14.3 between markers D13S168 and D13S155. Behrends S, et al. **Genomics** 1999 Jan 1;55(1):126-7
Expression of membrane-bound and cytosolic guanylyl cyclases in the rat inner ear. Seebacher T, et al. **Hear Res** 1999 Jan;127(1-2):95-102
Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy. Kelsell RE, et al. **Hum Mol Genet** 1998 Jul;7(7):1179-84
Characterization of the soluble guanylyl cyclase beta-subunit gene in the mosquito Anopheles gambiae. Caccone A, et al. **Insect Mol Biol** 1999 Feb;8(1):23-30
Sequence analysis of cDNA and genomic DNA, and mRNA expression of the medaka fish homolog of mammalian guanylyl cyclase C. Mantoku T, et al. **J Biochem (Tokyo)** 1999 Mar;125(3):476-86
A disulfide-bridged mutant of natriuretic peptide receptor-A displays constitutive activity. Role of receptor dimerization in signal transduction. Labrecque J, et al. **J Biol Chem** 1999 Apr 2;274(14):9752-9
Tandem organization of medaka fish soluble guanylyl cyclase alpha1 and beta1 subunit genes. Implications for coordinated transcription of two subunit genes. Mikami T, et al. **J Biol Chem** 1999 Jun 25;274(26):18567-73
Identification of a novel guanylyl cyclase that is related to receptor guanylyl cyclases, but lacks extracellular and transmembrane domains. Simpson PJ, et al. **J Biol Chem** 1999 Feb 12;274(7):4440-6
Natriuretic peptides receptors in human aldosterone-secreting adenomas. Sarzani R, et al. **J Endocrinol Invest** 1999 Jul-Aug;22(7):514-8
Prenatal exposure to aluminum reduces expression of neuronal nitric oxide synthase and of soluble guanylate cyclase and impairs glutamatergic neurotransmission in rat cerebellum. Llansola M, et al. **J Neurochem** 1999 Aug; 73(2):712-8
Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. Yang RB, et al. **J Neurosci** 1999 Jul 15;19(14):5889-97
Escherichia coli lipopolysaccharide downregulates soluble guanylate cyclase in pulmonary artery smooth muscle. Scott WS, et al. **J Surg Res** 1998 Dec;80(2):309-14
Natriuretic peptide receptors, NPR-A and NPR-B, in cultured rabbit retinal pigment epithelium cells. Fujiseki Y, et al. **Jpn J Pharmacol** 1999 Mar;79(3):359-68
Localization of rat genes in the nitric oxide signaling pathway: candidates for the pathogenesis of complex diseases. Koike G, et al. **Mamm Genome** 1999 Jan; 10(1):71-3
A constitutively "phosphorylated" guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization. Potter LR, et al. **Mol Biol Cell** 1999 Jun; 10(6):1811-20
Rod outer segment membrane guanylate cyclase type 1 (ROS-GC1) gene: structure, organization and regulation by phorbol ester, a protein kinase C activator. Duda T, et al. **Mol Cell Biochem** 1998 Dec;189(1-2):63-70
Characterization of the chicken GCAP gene array and analyses of GCAP1, GCAP2, and GC1 gene expression in normal and rd chicken pineal. Semple-Rowland SL, et al. **Mol Vis** 1999 Jul 28;5:14
Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line. Becker EM, et al. **Nitric Oxide** 1999;3(1):55-66
Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Jaubert J, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10278-83
Biochemical analysis of a dimerization domain mutation in RetGC-1 associated with dominant cone-rod dystrophy. Tucker CL, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9039-44

IMMUNOLOGY

Characterization of a novel monoclonal antibody that senses nitric oxide-dependent activation of soluble guanylate cyclase. Tsuyama S, et al. **FEBS Lett** 1999 Jul 23; 455(3):291-4

METABOLISM

Regulation of NO-elicited pulmonary artery relaxation and guanylate cyclase activation by NADH oxidase and SOD. Gupte SA, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1535-42
Structure and activity of OK-GC: a kidney receptor guanylate cyclase activated by guanylin peptides. London RM, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F882-91
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats. Wu CC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1148-57
1,25-Dihydroxyvitamin D3 upregulates natriuretic peptide receptor-C expression in mouse osteoblasts. Yanaka N, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E965-73
Desensitization of guanylyl cyclases in cultured human airway smooth-muscle cells. Hamad AM, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):1087-95
B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39-45 (73 ref.)
Effect of heme oxygenase inhibitors on soluble guanylyl cyclase activity. Serfass L, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):8-16
Stimulation of membrane-bound guanylate cyclase activity by 17-beta estradiol. Chen ZJ, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):639-42
Pentaerithrityl tetranitrate and its phase I metabolites are potent activators of cellular cyclic GMP accumulation. Hinz B, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):658-61
Stimulation of soluble guanylate cyclase by superoxide dismutase is mediated by NO. Friebe A, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):527-31
Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Russwurm M, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):125-30

Regeneration of the ferrous heme of soluble guanylate cyclase from the nitric oxide complex: acceleration by thiols and oxyhemoglobin. Brandish PE, et al. **Biochemistry** 1998 Dec 1;37(48):16898–907

Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Kharitonov VG, et al. **Biochemistry** 1999 Aug 17;38(33):10699–706

A second calcium regulator of rod outer segment membrane guanylate cyclase, ROS-GC1: neurocalcin. Kumar VD, et al. **Biochemistry** 1999 Sep 28;38(39):12614–20

Regulation of nitric oxide-responsive recombinant soluble guanylyl cyclase by calcium. Parkinson SJ, et al. **Biochemistry** 1999 May 18;38(20):6441–8

Identification of a guanylyl cyclase-activating protein-binding site within the catalytic domain of retinal guanylyl cyclase 1. Sokal I, et al. **Biochemistry** 1999 Feb 2;38(5):1387–93

Structural changes in the heme proximal pocket induced by nitric oxide binding to soluble guanylate cyclase. Zhao Y, et al. **Biochemistry** 1998 Sep 8;37(36):12458–64

Role of soluble guanylate cyclase in the molecular mechanism underlying the physiological effects of nitric oxide. Severina IS. **Biochemistry (Mosc)** 1998 Jul;63(7):794–801 (52 ref.)

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Galle J, et al. **Br J Pharmacol** 1999 May; 127(1):195–203

Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation. Faraci FM, et al. **Brain Res** 1999 Mar 13;821(2):368–73

Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Ruetten H, et al. **Circ Res** 1999 Sep 17;85(6):534–41

Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production [see comments] Bauersachs J, et al. **Circulation** 1999 Jul 20;100(3):292–8. Comment in: Circulation 1999 Jul 20;100(3):216–8.

Activation of phospholipase C and guanylyl cyclase by endothelins in human trabecular meshwork cells. Haque MS, et al. **Curr Eye Res** 1998 Dec;17(12):1110–7

Partial characterization of guanylyl cyclase activity in calf thyroid. Bocanera LV, et al. **Endocr Res** 1999 May; 25(2):215–28

The relevance of N-linked glycosylation to the binding of a ligand to guanylate cyclase C. Hasegawa M, et al. **Eur J Biochem** 1999 Jul;263(2):338–46

Cloning, properties and tissue distribution of natriuretic peptide receptor-A of euryhaline eel, Anguilla japonica. Kashiwagi M, et al. **Eur J Biochem** 1999 Jan; 259(1–2):204–11

Activation of particulate guanylyl cyclase by Vibrio vulnificus hemolysin. Kook H, et al. **Eur J Pharmacol** 1999 Jan 22;365(2–3):267–72

The effects of oxygen radicals on the activity of nitric oxide synthase and guanylate cyclase. Kim SM, et al. **Exp Mol Med** 1998 Dec 31;30(4):221–6

Characterization of a novel monoclonal antibody that senses nitric oxide-dependent activation of soluble guanylate cyclase. Tsuyama S, et al. **FEBS Lett** 1999 Jul 23; 455(3):291–4

The guanylate cyclase-coupled natriuretic peptide receptor: a new target for prevention of cold ischemia-reperfusion damage of the rat liver. Gerbes AL, et al. **Hepatology** 1998 Nov;28(5):1309–17

Ultracytochemical study of guanylate cyclases A and B in light- and dark-adapted retinas. Spreca A, et al. **Histochem J** 1999 Jul;31(7):477–83

C-type natriuretic peptide attenuates evoked dopamine efflux by influencing Goalpha. Takida S, et al. **Hypertension** 1999 Jan;33(1):124–9

Sulfatide from the pig jejunum brush border epithelial cell surface is involved in binding of Escherichia coli enterotoxin b. Rousset E, et al. **Infect Immun** 1998 Dec; 66(12):5650–8

Three-dimensional structure of guanylyl cyclase activating protein-2, a calcium-sensitive modulator of photoreceptor guanylyl cyclases. Ames JB, et al. **J Biol Chem** 1999 Jul 2;274(27):19329–37

Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. Chrisman TD, et al. **J Biol Chem** 1999 Feb 12;274(7):4293–9

Molecular characterization of a third member of the guanylyl cyclase-activating protein subfamily. Haeseleer F, et al. **J Biol Chem** 1999 Mar 5;274(10):6526–35

Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP-dependent protein kinase. Idriss SD, et al. **J Biol Chem** 1999 Apr 2; 274(14):9489–93

Mapping sites in guanylyl cyclase activating protein-1 required for regulation of photoreceptor membrane guanylyl cyclases. Krylov DM, et al. **J Biol Chem** 1999 Apr 16;274(16):10833–9

EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase. Makino R, et al. **J Biol Chem** 1999 Mar 19;274(12):7714–23

Identification and characterization of a novel beta subunit of soluble guanylyl cyclase that is active in the absence of a second subunit and is relatively insensitive to nitric oxide. Nighorn A, et al. **J Biol Chem** 1999 Jan 22; 274(4):2525–31

15-Lipoxygenase catalytically consumes nitric oxide and impairs activation of guanylate cyclase. O'Donnell VB, et al. **J Biol Chem** 1999 Jul 16;274(29):20083–91

Dimerization of guanylyl cyclase-activating protein and a mechanism of photoreceptor guanylyl cyclase activation. Olshevskaya EV, et al. **J Biol Chem** 1999 Sep 3; 274(36):25583–7

Identification of a domain in guanylyl cyclase-activating protein 1 that interacts with a complex of guanylyl cyclase and tubulin in photoreceptors. Schrem A, et al. **J Biol Chem** 1999 Mar 5;274(10):6244–9

MAGUIN, a novel neuronal membrane-associated guanylate kinase-interacting protein. Yao I, et al. **J Biol Chem** 1999 Apr 23;274(17):11889–96

Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. Zabel U, et al. **J Biol Chem** 1999 Jun 25; 274(26):18149–52

Use of flow cytometry to measure the interaction between Escherichia coli heat-stable enterotoxin and its intestinal receptor in mice. Al-Majali AM, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):65–72

Angiotensin II modulates ANP-R2/ANP-C receptor-mediated inhibition of adenylyl cyclase in vascular smooth muscle cells: role of protein kinase C. Palaparti A, et al. **J Mol Cell Cardiol** 1998 Aug; 30(8):1471–82

Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Hoenicka M, et al. **J Mol Med** 1999 Jan;77(1):14–23

Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. Yang RB, et al. **J Neurosci** 1999 Jul 15;19(14):5889–97

Mesangial cells from diabetic NOD mice constitutively express increased density of atrial natriuretic peptide C receptors. Ardaillou N, et al. **Kidney Int** 1999 Apr; 55(4):1293–302

Characterization of the interaction of Escherichia coli heat-stable enterotoxixn (STa) with its intestinal putative receptor in various age groups of mice, using flow cytometry and binding assays. Al-Majali AM, et al. **Lab Anim Sci** 1999 Jun;49(3):254–9

Activation of particulate guanylyl cyclase by endothelins in cultured SV-40 transformed cat iris sphincter smooth muscle cells. Ding KH, et al. **Life Sci** 1999;64(3):161–74

A constitutively "phosphorylated" guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization. Potter LR, et al. **Mol Biol Cell** 1999 Jun; 10(6):1811–20

Rod outer segment membrane guanylate cyclase type 1 (ROS-GC1) gene: structure, organization and regulation by phorbol ester, a protein kinase C activator. Duda T, et al. **Mol Cell Biochem** 1998 Dec;189(1–2):63–70

Comparative binding study of rat natriuretic peptide receptor-A. Marquis M, et al. **Mol Cell Biochem** 1999 Apr; 194(1–2):23–30

Human A-type ANP receptor upregulation by PACAP and carbachol in neuroblastoma cells. Forgeur A, et al. **Mol Cell Endocrinol** 1999 Apr 25;150(1–2):189–93

Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation. Kreklau EL, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1–2):103–11

Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Chalimoniuk M, et al. **Mol Chem Neuropathol** 1998 Aug-Dec;35(1–3):77–95

S100B and S100A1 proteins in bovine retina:their calcium-dependent stimulation of a membrane-bound guanylate cyclase activity as investigated by ultracytochemistry. Rambotti MG, et al. **Neuroscience** 1999;92(3):1089–101

Maturational changes in ovine pulmonary vascular responses to inhaled nitric oxide. Powel V, et al. **Pediatr Pulmonol** 1999 Mar;27(3):157–66

Expression and characterization of the extracellular domain of guanylyl cyclase C from a baculovirus and Sf21 insect cells. Hasegawa M, et al. **Protein Expr Purif** 1999 Apr; 15(3):271–81

Mechanisms of regulation and functions of guanylyl cyclases. Foster DC, et al. **Rev Physiol Biochem Pharmacol** 1999; 135:1–39 (81 ref.)

Soluble guanylate cyclase and nitric oxide synthase in synaptosomal fractions of bovine retina. Margulis A, et al. **Vis Neurosci** 1998 Sep-Oct;15(5):867–73

[Guanylyl cyclases] Gorczyca WA. **Postepy Hig Med Dosw** 1999;53(2):209–22 (70 ref.) (Eng. Abstr.) **(Pol)**

[Interaction between guanylate cyclases in the kidney glomerulus] Lewko B. **Postepy Hig Med Dosw** 1999; 53(2):225–31 (17 ref.) (Eng. Abstr.) **(Pol)**

[The role of guanylate cyclase and arachidonic acid metabolites in the regulation of epithelium-dependent relaxation in the smooth muscle from the rat trachea] Kuskov MV, et al. **Biull Eksp Biol Med** 1999 Jan; 127(1):9–11 **(Rus)**

PHYSIOLOGY

Focus on: "G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor" [editorial; comment] Galligan JJ. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1407–8 (14 ref.). Comment on: Am J Physiol 1998 Dec;275(6 Pt 1):C1409–16.

Atrial natriuretic peptide clearance receptor participates in modulating endothelial permeability. Hempel A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1818–25

Inhibition of guanylate cyclase stimulation by NO and bovine arterial relaxation to peroxynitrite and H2O2. Iesaki T, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H978–85

G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor [see comments] Murthy KS, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1409–16. Comment in: Am J Physiol 1998 Dec;275(6 Pt 1):C1407–8.

Role of soluble guanylate cyclase in reactivation of choline esterase inhibited by phosphoorganic compounds. Pyatakova NV, et al. **Biochemistry (Mosc)** 1999 Jan; 64(1):91–4

A delayed role for nitric oxide-sensitive guanylate cyclases in a migratory population of embryonic neurons. Wright JW, et al. **Dev Biol** 1998 Dec 1;204(1):15–33

Regulation of natriuretic peptide receptors by thyrotropin in FRTL-5 rat thyroid cells: evidence for nonguanylate cyclase atrial natriuretic factor-binding sites in cells lacking the natriuretic peptide receptor C. Sellitti DF, et al. **Endocrinology** 1999 Mar;140(3):1365–74

Type B and type C natriuretic peptide receptors modulate intraocular pressure in the rabbit eye. Fernández-Durango R, et al. **Eur J Pharmacol** 1999 Jan 8;364(2–3):107–13

Functionally active catalytic domain is essential for guanylyl cyclase-linked receptor mediated inhibition of human aldosterone synthesis. Olson LJ, et al. **Mol Pharmacol** 1998 Nov;54(5):761–9

5'-GUANYLIC ACID

ANALOGS & DERIVATIVES

N2-hydroxyguanosine 5'-monophosphate is a time-dependent inhibitor of Escherichia coli guanosine monophosphate synthetase. Deras ML, et al. **Biochemistry** 1999 Jan 5;38(1):303–10

CHEMISTRY

Ternary conjugates of guanosine monophosphate as initiator nucleotides for the enzymatic synthesis of 5'-modified RNAs. Seelig B, et al. **Bioconjug Chem** 1999 May-Jun; 10(3):371–8

Interaction of Et2SnCl2 with 5'-IMP and 5'-GMP. Yang Z, et al. **J Inorg Biochem** 1998 Dec;72(3–4):133–40

METABOLISM

Virus-specific capping of tobacco mosaic virus RNA: methylation of GTP prior to formation of covalent complex p126-m7GMP. Merits A, et al. **FEBS Lett** 1999 Jul 16; 455(1–2):45–8

Rickettsia prowazekii transports UMP and GMP, but not CMP, as building blocks for RNA synthesis. Winkler HH, et al. **J Bacteriol** 1999 May;181(10):3238–41

Bicyclic monoterpene diols induce differentiation of S91 melanoma and PC12 pheochromocytoma cells by a cyclic guanosine-monophosphate-dependent pathway. Brown DA, et al. **Pigment Cell Res** 1999 Feb;12(1):36–47

PHARMACOLOGY

Responses to monosodium glutamate and guanosine 5'-monophosphate in rat fungiform taste cells. Lin W, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:407–11

PHYSIOLOGY

L-arginine modulates aggregation and intracellular cyclic 3,5-guanosine monophosphate levels in human platelets: direct effect and interplay with antioxidative thiol agent. Anfossi G, et al. **Thromb Res** 1999 Jun 1;94(5):307–16

GUANYLORIBONUCLEASE see **RIBONUCLEASE T1**

GUANYLYL IMIDODIPHOSPHATE

CHEMISTRY

Structure of Gialpha1.GppNHp, autoinhibition in a galpha protein-substrate complex. Coleman DE, et al. **J Biol Chem** 1999 Jun 11;274(24):16669–72

Structure of the nuclear transport complex karyopherin-beta2-Ran x GppNHp [see comments] Chook YM, et al. **Nature** 1999 May 20;399(6733):230–7. Comment in: Nature 1999 May 20;399(6733):208–10.

METABOLISM

Structure of a Ran-binding domain complexed with Ran bound to a GTP analogue: implications for nuclear transport. Vetter IR, et al. **Nature** 1999 Mar 4; 398(6722):39–46

PHARMACOLOGY

Weaning-induced development of delta-opioid receptors in rat brain: differential effects of guanine nucleotides and sodium upon ligand-receptor recognition. Kelly MD, et al. **Br J Pharmacol** 1998 Nov;125(5):979–86

A GppNHp-insensitivity factor modulates the activation of

beta-adrenoceptor-coupled Gs protein in rat cortex and cerebellum. Garnier V, et al. **Fundam Clin Pharmacol** 1999; 13(2):169-79

Inhibition of [3H]forskolin binding by Gpp[NH]p may reflect adenylate cyclase coupling to Gi. Garcia-Jiménez A, et al. **Neuroreport** 1999 Aug 2;10(11):2423-7

Inhibition of [3H]forskolin binding by Gpp[NH]p may reflect adenylyl cyclase coupling to Gi. Garcia-Jimenez A, et al. **Neuroreport** 1998 Oct 5;9(14):3329-33

GUERIN-STERN SYNDROME see **ARTHROGRYPOSIS**

GUEST RELATIONS see **HOSPITAL-PATIENT RELATIONS**

GUIDE RNA see **RNA, GUIDE**

GUIDED IMAGERY see **IMAGERY (PSYCHOTHERAPY)**

GUIDED TISSUE REGENERATION

Evaluation of porous collagen membrane in guided tissue regeneration. Zhang Q, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 May; 27(3):245-53

A clinical comparison of the new attachment obtained by guided tissue regeneration and coronally positioned flap techniques in the management of human molar furcation defects. Kerdvongbundit V, et al. **Aust Dent J** 1999 Mar; 44(1):31-9

A review of guided tissue regeneration. Ferris RT. **Int Dent J** 1998 Jun;48(3 Suppl 1):322-5 (31 ref.)

Guided tissue regeneration update. Laurell L, et al. **Int Dent J** 1998 Aug;48(4):386-98 (87 ref.)

Maintenance of regenerated bone beneath pontics: preliminary clinical report of 43 sites. Fugazzotto PA, et al. **Int J Oral Maxillofac Implants** 1999 May-Jun; 14(3):392-7

Sinus floor augmentation at the time of maxillary molar extraction: technique and report of preliminary results. Fugazzotto PA. **Int J Oral Maxillofac Implants** 1999 Jul-Aug;14(4):536-42

Patterned glass surfaces direct cell adhesion and process outgrowth of primary neurons of the central nervous system. Saneinejad S, et al. **J Biomed Mater Res** 1998 Oct; 42(1):13-9

Guided tissue regeneration in the treatment of human infrabony defects. Clinical, radiographical and microbiological results: a pilot study. Bratthall G, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):908-14

Long-term stability of the mucogingival complex following guided tissue regeneration in gingival recession defects. Scabbia A, et al. **J Clin Periodontol** 1998 Dec;25(12):1041-6

Alkaline phosphatase activity is upregulated in regenerating human periodontal cells. Kuru L, et al. **J Periodontal Res** 1999 Feb;34(2):123-7

The effect of transforming growth factor beta one (TGF-beta 1) on wound healing, with or without barrier membranes, in a Class II furcation defect in sheep. Mohammed S, et al. **J Periodontal Res** 1998 Aug;33(6):335-44

Monoclonal antibodies against integrin subunits alpha6 and beta1 inhibit migration of gingival epithelium in organ culture. Gräber HG, et al. **J Periodontol** 1999 Apr; 70(4):388-93

The effects of guided bone regeneration and grafting on implants placed into immediate extraction sockets. An experimental study in dogs. Kohal RJ, et al. **J Periodontol** 1998 Aug;69(8):927-37

Nature and attachment of cementum formed under guided conditions in human teeth. An electron microscopic study. Luder HU, et al. **J Periodontol** 1998 Aug;69(8):889-98

Use of alendronate in peri-implant defect regeneration. Meraw SJ, et al. **J Periodontol** 1999 Feb;70(2):151-8

Root coverage employing an envelope technique or guided tissue regeneration with a bioabsorbable membrane. Müller HP, et al. **J Periodontol** 1999 Jul;70(7):743-51

Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study. Sculean A, et al. **J Periodontol** 1999 Mar;70(3):255-62

Generalizability of the added benefits of guided tissue regeneration in the treatment of deep intrabony defects. Evaluation in a multi-center randomized controlled clinical trial. Tonetti MS, et al. **J Periodontol** 1998 Nov; 69(11):1183-92

Subpedicle connective tissue graft versus guided tissue regeneration with bioabsorbable membrane in the treatment of human gingival recession defects. Trombelli L, et al. **J Periodontol** 1998 Nov;69(11):1271-7

Long-term clinical outcomes of abutments treated with guided tissue regeneration. Cortellini P, et al. **J Prosthet Dent** 1999 Mar;81(3):307-11

Applications for guided bone regeneration in endodontic surgery. Mastromihalis N, et al. **N Y State Dent J** 1999 May;65(5):30-2

Guided tissue regeneration in the management of severe periodontal-endodontic lesions. Danesh-Meyer MJ. **N Z Dent J** 1999 Mar;95(419):7-10 (6 ref.)

[Current status and trends of guided tissue regeneration materials] Zhang Q, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):365-8 (28 ref.) **(Chi)**

[Guided tissue regeneration in endodontics. Part 1] Gagnon K, et al. **J Can Dent Assoc** 1999 Jul-Aug;65(7):394-8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Is periodontal guided tissue regeneration a reproducible technic? A review of the literature] Zahedi S, et al. **Rev Belge Med Dent** 1998;53(4):217-36 (116 ref.) (Eng. Abstr.) **(Fre)**

[A 3-year experience with guided tissue regeneration procedures] Windisch P, et al. **Fogorv Sz** 1998 Oct; 91(10):295-304 (Eng. Abstr.) **(Hun)**

[Materials for guided tissue regeneration in implantology. A review of the literature] Corica M. **Minerva Stomatol** 1998 Sep;47(9):417-24 (122 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Early bacterial accumulation on guided tissue regeneration membrane materials. An in vivo study. Zucchelli G, et al. **J Periodontol** 1998 Nov;69(11):1193-202

HISTORY

Tony Melcher's contributions to the regeneration of the periodontium. McCulloch CA. **J Dent Res** 1999 Jul; 78(7):1292-7

INSTRUMENTATION

Manufacturing and microscopical characterisation of polyurethane nerve guidance channel featuring a highly smooth internal surface. Soldani G, et al. **Biomaterials** 1998 Nov;19(21):1919-24

The use of 2 bioabsorbable barrier membranes in the treatment of interproximal intrabony periodontal defects. Mattson JS, et al. **J Periodontol** 1999 May;70(5):510-7

Adverse effects associated with a bioabsorbable guided tissue regeneration device in the treatment of human gingival recession defects. A clinicopathologic case report. Tatakis DN, et al. **J Periodontol** 1999 May;70(5):542-7

METHODS

Hydroxyapatite fiber reinforced poly(alpha-hydroxy ester) foams for bone regeneration. Thomson RC, et al. **Biomaterials** 1998 Nov;19(21):1935-43

Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration. Widmer MS, et al. **Biomaterials** 1998 Nov;19(21):1945-55

Multi-control analysis of 24-month clinical outcomes of guided tissue regeneration of deep periodontal pockets. Bokan I, et al. **Croat Med J** 1998 Dec;39(4):435-41

Tomodensitometric and histologic evaluation of the combined use of a collagen membrane and a hydroxyapatite spacer for guided bone regeneration: a clinical report. Benqué E, et al. **Int J Oral Maxillofac Implants** 1999 Mar-Apr;14(2):258-64

Treatment of peri-implant defects with guided bone regeneration: a comparative clinical study with various membranes and bone grafts. Lorenzoni M, et al. **Int J Oral Maxillofac Implants** 1998 Sep-Oct;13(5):639-46

Histomorphometric evaluation of extraction sockets and deficient alveolar ridges treated with allograft and barrier membrane: a pilot study. Smukler H, et al. **Int J Oral Maxillofac Implants** 1999 May-Jun;14(3):407-16

The 49th Annual Meeting of the Arbeitsgemeinschaft für Kieferchirurgie within the Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde, together with the Arbeitskreis Oralpathologie within the Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde, 21-23 May 1998, Bad Homburg, Germany [news] Schliephake H. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):158-9

Treatment of deep and shallow intrabony defects. A multicenter randomized controlled clinical trial. Cortellini P, et al. **J Clin Periodontol** 1998 Dec;25(12):981-7

Regenerative periodontal surgery with non-resorbable and biodegradable barriers: results after 24 months. Eickholz P, et al. **J Clin Periodontol** 1998 Aug;25(8):666-76

Reconstruction of anatomically complicated periodontal defects using a bioresorbable GTR barrier supported by bone mineral. A 6-month follow-up study of 6 cases. Lundgren D, et al. **J Clin Periodontol** 1999 Jan;26(1):56-62

Periodontal repair in dogs: histologic observations of guided tissue regeneration with a prostaglandin E1 analog/methacrylate composite. Trombelli L, et al. **J Clin Periodontol** 1999 Jun;26(6):381-7

Successful implant restoration with the use of barrier membranes. Malmquist JP. **J Oral Maxillofac Surg** 1999 Sep;57(9):1114-6 (22 ref.)

A bioactive glass particulate in the treatment of molar furcation invasions. Anderegg CR, et al. **J Periodontol** 1999 Apr;70(4):384-7

Guided tissue regeneration in Class II furcation involved maxillary molars: a controlled study of 8 split-mouth cases. Avera JB, et al. **J Periodontol** 1998 Sep;69(9):1020-6

The effect of postsurgical naproxen and a bioabsorbable membrane on osseous healing in intrabony defects. Bichara J, et al. **J Periodontol** 1999 Aug;70(8):869-77

Comparative clinical study of a bioabsorbable membrane and subepithelial connective tissue graft in the treatment of human gingival recession. Borghetti A, et al. **J Periodontol** 1999 Feb;70(2):123-30

Effect of allogenic freeze-dried demineralized bone matrix on guided tissue regeneration in dogs. Caplanis N, et al. **J Periodontol** 1998 Aug;69(8):851-6

Clinical evaluation of the treatment of class II furcation involvements with bioabsorbable barriers alone or associated with demineralized freeze-dried bone allografts [see comments] De Leonardis D, et al. **J Periodontol** 1999 Jan;70(1):8-12. Comment in: J Periodontol 1999 Jan;70(1):102-4.

Periodontal surgery of vertical bony defects with or without synthetic bioabsorbable barriers. 12-month results. Eickholz P, et al. **J Periodontol** 1998 Nov;69(11):1210-7

Guided tissue regeneration with bioabsorbable and expanded polytetrafluoroethylene barrier membranes in the treatment of naturally occurring periodontal defects in dogs. Elharar F, et al. **J Periodontol** 1998 Nov;69(11):1218-28

A comparison of 2 root coverage techniques: guided tissue regeneration with a bioabsorbable matrix style membrane versus a connective tissue graft combined with a coronally positioned pedicle graft without vertical incisions. results of a series of consecutive cases. Harris RJ. **J Periodontol** 1998 Dec;69(12):1426-34

Effects of bioabsorbable and non-resorbable barrier membranes on bone augmentation in rabbit calvaria. Ito K, et al. **J Periodontol** 1998 Nov;69(11):1229-37

Periodontal repair in intrabony defects treated with a calcium sulfate implant and calcium sulfate barrier. Kim CK, et al. **J Periodontol** 1998 Dec;69(12):1317-24

The use of autogenous periosteal grafts as barriers for the treatment of intrabony defects in humans. Kwan SK, et al. **J Periodontol** 1998 Nov;69(11):1203-9

The use of combined periodontal regenerative techniques [editorial; comment] McClain PK, et al. **J Periodontol** 1999 Jan;70(1):102-4. Comment on: J Periodontol 1999 Jan;70(1):8-12.

Use of lyodura for bone augmentation of osseous defects around dental implants. Peleg M, et al. **J Periodontol** 1999 Aug;70(8):853-60

Polymer-assisted regenerative therapy: case reports of 22 consecutively treated periodontal defects with a novel combined surgical approach. Rosen PS, et al. **J Periodontol** 1999 May;70(5):554-61

The effect of postsurgical antibiotics and a bioabsorbable membrane on regenerative healing in Class II furcation defects. Vest TM, et al. **J Periodontol** 1999 Aug; 70(8):878-87

Evaluation of a diphenylphosphorylazide-crosslinked collagen membrane for guided bone regeneration in mandibular defects in rats. Zahedi S, et al. **J Periodontol** 1998 Nov;69(11):1238-46

Topical and systemic antimicrobial therapy in guided tissue regeneration. Zucchelli G, et al. **J Periodontol** 1999 Mar; 70(3):239-47

[Guided tissue regeneration around dental implants in immediate extraction sockets: comparison of resorbable and nonresorbable membranes] Mao C, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Dec; 19(6):436-41 (Eng. Abstr.) **(Chi)**

[The GBR preparatory course of 4 June 1998 in Boston, USA. Guided bone regeneration] Hirt HP, et al. **Schweiz Monatsschr Zahnmed** 1998;108(11):1135-6 **(Ger)**

[The use of the TefGen membrane in periodontology] Loshkarev VP, et al. **Stomatologiia (Mosk)** 1999;78(2):57-8 (Eng. Abstr.) **(Rus)**

UTILIZATION

Successful implant restoration without the use of membrane barriers. Clarizio LF. **J Oral Maxillofac Surg** 1999 Sep; 57(9):1117-21 (38 ref.)

VETERINARY

Oral and periodontal tissue. Maintenance, augmentation, rejuvenation, and regeneration. Wiggs RB, et al. **Vet Clin North Am Small Anim Pract** 1998 Sep; 28(5):1165-88, vii (85 ref.)

GUIDELINE ADHERENCE

Use of evidence-based studies in the application of GAPS [letter; comment] Strasburger VC. **Am Fam Physician** 1998 Nov 1;58(7):1550, 1552. Comment on: Am Fam Physician 1998 May 1;57(9):2060, 2066. Comment on: Am Fam Physician 1998 May 1;57(9):2181-8, 2189-90.

Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? Carruthers SG. **Am Heart J** 1999 Sep; 138(3 Pt 2):256-60 (27 ref.)

Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Swales JD. **Am Heart J** 1999 Sep;138(3 Pt 2):231-7

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Sueta CA, et al. **Am J Cardiol** 1999 May 1; 83(9):1303-7

Resident's perspective on pharmacist-managed drug therapy protocols [letter; comment] Dib JG. **Am J Health Syst Pharm** 1998 Sep 1;55(17):1826-7. Comment on: Am J Hosp Pharm 1992 Jan;49(1):81-3.

Patient education model for increasing handwashing compliance. McGuckin M, et al. **Am J Infect Control** 1999 Aug;27(4):309-14

Evaluation of physician preferences for guideline implementation. Stone TT, et al. **Am J Med Qual** 1999

Jul-Aug;14(4):170-7
Effect of a comprehensive quality management process on compliance with protocol in an emergency medical dispatch center. Clawson JJ, et al. **Ann Emerg Med** 1998 Nov;32(5):578-84
Improving adherence to dementia guidelines through education and opinion leaders. A randomized, controlled trial. Gifford DR, et al. **Ann Intern Med** 1999 Aug 17; 131(4):237-46
Compliance with do-not-resuscitate orders for hospitalized patients transported to radiology departments [see comments] Heffner JE, et al. **Ann Intern Med** 1998 Nov 15;129(10):801-5. Comment in: Ann Intern Med 1998 Nov 15;129(10):831-3. Comment in: Ann Intern Med 1999 Jul 6;131(1):72-3.
Resuscitation and the radiologist [editorial] [comment] McDermott VG. **Ann Intern Med** 1998 Nov 15; 129(10):831-3. Comment on: Ann Intern Med 1998 Nov 15;129(10):801-5.
Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. McManus P, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):409-11
Compliance with radiation treatment guidelines in a provincial setting. Jackson SM, et al. **Cancer Prev Control** 1999 Jun;3(3):196-201
Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Iseman MD. **Chemotherapy** 1999;45 Suppl 2:34-40
Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Fowler VG Jr, et al. **Clin Infect Dis** 1998 Sep;27(3):478-86
An uncharted country [editorial] Macbeth F. **Clin Oncol (R Coll Radiol)** 1999;11(2):71-2
Following the rules in marketing [letter] Elston MJ. **CMAJ** 1999 Sep 21;161(6):685; discussion 685-6
Guidelines--not always an easy answer [letter; comment] Goertzen J. **CMAJ** 1999 Apr 6;160(7):983; discussion 983-4 . Comment on: CMAJ 1998 Oct 6;159(7):797-8. Comment on: CMAJ 1998 Oct 6;159(7):807-13.
Why don't family physicians follow clinical practice guidelines for cancer screening? Family Physician Study Group, Sociobehavioral Cancer Research Network, National Cancer Institute of Canada [editorial] [see comments] Tudiver F, et al. **CMAJ** 1998 Oct 6;159(7):797-8 . Comment in: CMAJ 1999 Apr 6;160(7):983; discussion 983-4.
Guidelines--not always an easy answer [letter; comment] Vandor T. **CMAJ** 1999 Apr 6;160(7):983; discussion 984. Comment on: CMAJ 1998 Oct 6;159(7):765-9. Comment on: CMAJ 1998 Oct 6;159(7):797-8. Comment on: CMAJ 1998 Oct 6;159(7):803-4.
A survey of the implementation of health service guidelines on arrangements for infection control in health trusts in the West Midlands. Hawker JI. **Commun Dis Public Health** 1999 Jan;2(1):54-8
Reasons for non-guideline-based antibiotic prescriptions for acute otitis media in The Netherlands. Damoiseaux RA, et al. **Fam Pract** 1999 Feb;16(1):50-3
Guidelines for low back pain: changes in GP management. Frankel BS, et al. **Fam Pract** 1999 Jun;16(3):216-22
Strategies to improve cancer screening in general practice: are guidelines the answer? Young JM, et al. **Fam Pract** 1999 Feb;16(1):66-70
How are health care organizations using clinical guidelines? Sisk JE. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):91-109
Organizational tactics for the successful assimilation of medical practice guidelines. Sonnad SS. **Health Care Manage Rev** 1998 Summer;23(3):30-7 (15 ref.)
ECRI position statement on the testing of medical devices for year 2000 compliance. **Health Devices** 1998 Dec; 27(12):413-8
Year 2000 testing of interfaced medical devices. **Health Devices** 1998 Dec;27(12):419-23
Barriers between guidelines and improved patient care: an analysis of AHCPR's Unstable Angina Clinical Practice Guideline. Agency for Health Care Policy and Research. Katz DA. **Health Serv Res** 1999 Apr;34(1 Pt 2):377-89
The REIT stuff. Do real estate investment trusts have what it takes to bridge hospital compliance gaps? Haugh R. **Hosp Health Netw** 1998 Nov 5;72(21):36-9, 3
Use of personal protective equipment and operating room behaviors in four surgical subspecialties: personal protective equipment and behaviors in surgery. Akduman D, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):110-4
Vancomycin in Oregon: who's using it and why. Cieslak PR, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):557-60
Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Jochimsen EM, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):106-9
Vancomycin use in a hospital with vancomycin restriction. Roghmann MC, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):60-3
Transmission of measles virus in healthcare settings during a communitywide outbreak. Steingart KR, et al. **Infect Control Hosp Epidemiol** 1999 Feb;20(2):115-9
Gene therapy: a new challenge for infection control [editorial; comment] Weber DJ, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):530-2. Comment on: Infect Control Hosp Epidemiol 1999 Aug;20(8):568-76.
Improving population-based cervical cancer screening in general practice: effects of a national strategy. Hermens RP, et al. **Int J Qual Health Care** 1999 Jun;11(3):193-200
Tailored outreach visits as a method for implementing guidelines and improving preventive care. Hulscher ME, et al. **Int J Qual Health Care** 1998 Apr;10(2):105-12
Management of asthma and COPD patients: feasibility of the application of guidelines in general practice. Jans MP, et al. **Int J Qual Health Care** 1998 Feb;10(1):27-34
Local implementation of national guidelines on lower urinary tract symptoms: what do general practitioners in Sydney, Australia suggest will work? Puech M, et al. **Int J Qual Health Care** 1998 Aug;10(4):339-43
Feasibility of a national cholesterol guideline in daily practice. A randomized controlled trial in 20 general practices. van der Weijden T, et al. **Int J Qual Health Care** 1999 Apr;11(2):131-7
The availability and cost of antibiotics for treating PID in the Central Region of Ghana and implications for compliance with national treatment guidelines. Bosu WK, et al. **Int J STD AIDS** 1998 Sep;9(9):551-3
Is your fee schedule compliant? Grindle D. **Iowa Med** 1999 May-Jun;89(3):21
A risk management audit: are we complying with the national guidelines for sedation by non-anaesthetists? Nicol MF. **J Accid Emerg Med** 1999 Mar;16(2):120-2
British Thoracic Society guidelines for the management of spontaneous pneumothorax: do we comply with them and do they work? Soulsby T. **J Accid Emerg Med** 1998 Sep; 15(5):317-21
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. Alexander KP, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2023-30
Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial [see comments] Shojania KG, et al. **J Am Med Inform Assoc** 1998 Nov-Dec;5(6):554-62. Comment in: J Am Med Inform Assoc 1998 Nov-Dec;5(6):585-6.
Uptake of research findings into clinical practice: a controlled study of the impact of a brief external intervention on the use of corticosteroids in preterm delivery [letter] Mant J, et al. **J Eval Clin Pract** 1999 Feb;5(1):73-9
Compliance with US asthma management guidelines and specialty care: a regional variation or national concern? Meng YY, et al. **J Eval Clin Pract** 1999 May;5(2):213-21
Implementing best practice guidelines: the influence of personal characteristics. Sturmberg JP. **J Eval Clin Pract** 1999 May;5(2):223-6
Practice guidelines for practicing doctors [editorial; comment] Weiss KB. **J Gen Intern Med** 1998 Oct; 13(10):714-5 (8 ref.). Comment on: J Gen Intern Med 1998 Oct;13(10):659-63.
Infection control--evidence into practice. Jenner EA, et al. **J Hosp Infect** 1999 Jun;42(2):91-104 (46 ref.)
The development and testing of the patient record pain management assessment tool. Wallace KG, et al. **J Nurs Care Qual** 1999 Apr;13(4):34-46
Compliance with universal precautions in correctional health care facilities. Gershon RR, et al. **J Occup Environ Med** 1999 Mar;41(3):181-9
Completion of the journey of care: Scottish Audit of Surgical Mortality (SASM). Stonebridge PA, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):185-6
Physician office-based diabetes care: comparison to guidelines for care. Hermayer KL, et al. **J S C Med Assoc** 1998 Nov;94(11):485-91
Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. Leviton LC, et al. **JAMA** 1999 Jan 6;281(1):46-52
Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. O'Connor GT, et al. **JAMA** 1999 Feb 17;281(7):627-33
The National Institutes of Health flexes its muscle--but why now? [news] Ault A. **Lancet** 1999 Jun 19;353(9170):2138
Compliance programs. Do I really need one? Cuzydlo C. **Mich Med** 1999 Mar;98(3):35-6
Year 2000 computer compliance. How will this affect you, doctor? Farrell K. **Mich Med** 1999 Jan;98(1):24-31 (0 ref.)
Monitoring clinical trials. Sharples K, et al. **N Z Med J** 1998 Aug 28;111(1072):322-5 (22 ref.)
FDA urged to comply with 1997 Reform Act [news] Fox JL. **Nat Biotechnol** 1998 Oct;16(10):901-2
Closing the gap. Carroll T. **Occup Health Saf** 1999 Jul; 68(7):28-33
Ethical requirements for occupational health research--compliance arrangements for a single company in relation to a recent major nuclear industry study. Kalman CJ. **Occup Med (Lond)** 1999 May;49(4):221-4
Evidence-based guidelines and critical pathways for quality improvement. Bergman DA. **Pediatrics** 1999 Jan;103(1 Suppl E):225-32
Adherence to AAP guidelines for well-child care under managed care. American Academy of Pediatrics. Byrd RS, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):536-40
How does home management of asthma exacerbations by parents of inner-city children differ from NHLBI guideline recommendations? National Heart, Lung, and Blood Institute. Warman KL, et al. **Pediatrics** 1999 Feb; 103(2):422-7
Photo(chemo)therapy in private practice in Belgium, France and The Netherlands. Faguer K, et al. **Photodermatol Photoimmunol Photomed** 1999 Apr; 15(2):59-63
A population-based survey of physician smoking cessation counseling practices. Goldstein MG, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):720-9
Intention-based critiquing of guideline-oriented medical care. Advani A, et al. **Proc AMIA Symp** 1998;:483-7
Long-term changes in compliance with clinical guidelines through computer-based reminders. Morgan MM, et al. **Proc AMIA Symp** 1998;:493-7
A computerized reminder for prophylaxis of deep vein thrombosis in surgical patients. Patterson R. **Proc AMIA Symp** 1998;:573-6
An implementation study of the PDRD primary care computerized guidelines. Jousimaa J, et al. **Scand J Prim Health Care** 1998 Sep;16(3):149-53
Perioperative antibiotics in nonemergency bowel surgery: a quality improvement project. Schell JA, et al. **South Med J** 1998 Oct;91(10):900-8
Changing practice patterns as a result of implementing the Agency for Health Care Policy and Research guideline in 20 primary care clinics. Roski J. **Tob Control** 1998 Winter;7 Suppl:S19-20; discussion S24-5
[Discrepancy between the guidelines and practice by family physicians in treating adults with an exacerbation of asthma or chronic obstructive pulmonary disease] Smeele IJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17;142(42):2304-8 (Eng. Abstr.) **(Dut)**
[Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care] Miravitlles M, et al. **Arch Bronconeumol** 1999 Apr;35(4):173-8 (Eng. Abstr.) **(Spa)**
[Design and applicability of a clinical guide for appropriate attention in acute respiratory infections] Flores-Hernandez S, et al. **Gac Med Mex** 1999 Mar-Apr;135(2):121-37 (Eng. Abstr.) **(Spa)**

ECONOMICS

Preventing neonatal group B streptococcal disease: cost-effectiveness in a health maintenance organization and the impact of delayed hospital discharge for newborns who received intrapartum antibiotics. Mohle-Boetani JC, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):703-10

LEGISLATION & JURISPRUDENCE

Voluntary euthanasia under control? Further empirical evidence from The Netherlands [see comments] Jochemsen H, et al. **J Med Ethics** 1999 Feb;25(1):16-21. Comment in: J Med Ethics 1999 Feb;25(1):3-4.
An instrument for assessing the quality of tobacco-control policies: the ACT-L scale. Klonoff EA, et al. **Prev Med** 1998 Nov-Dec;27(6):808-14

ORGANIZATION & ADMINISTRATION

A design model for computer-based guideline implementation based on information management services. Shiffman RN, et al. **J Am Med Inform Assoc** 1999 Mar-Apr;6(2):99-103

STANDARDS

Factors influencing managers' adherence to the Americans with Disabilities Act. Thakker D, et al. **Adm Policy Ment Health** 1999 Jan;26(3):213-9
Effect of pharmaceutical services on adherence to criteria-for-use guidelines in the operating room. Higgins B, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):977-82 (7 ref.)
The need for legal compliance plans in health institutions. Williams KG. **Am J Health Syst Pharm** 1999 May 15; 56(10):952, 954
Physician financial incentives and feedback: failure to increase cancer screening in Medicaid managed care. Hillman AL, et al. **Am J Public Health** 1998 Nov; 88(11):1699-701
When do HIV-infected persons start with antiretroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines. Reedijk M, et al. **Fam Pract** 1998 Dec;15(6):525-8
Management of interstitial lung disease: an audit at a university teaching hospital in Saudi Arabia. al-Mobeireek A. **Indian J Chest Dis Allied Sci** 1998 Oct-Dec;40(4):235-41
Compliance with methodological standards when evaluating ophthalmic diagnostic tests. Harper R, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1650-7
Barriers to compliance with screening guidelines for diabetic retinopathy [see comments] Mukamel DB, et al. **Ophthalmic Epidemiol** 1999 Mar;6(1):61-72. Comment in: Ophthalmic Epidemiol 1999 Mar;6(1):1-4.
Impact of policy and practice on the effectiveness of contact screening for tuberculosis. MacIntyre CR, et al. **Prev Med** 1998 Nov-Dec;27(6):830-7
[Psoriasis treatment in family practice now closer in agreement with the guidelines of the Dutch Society of General Practitioners (letter; comment)] Van de Kerkhof PC. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2540. Comment on: Ned Tijdschr Geneeskd 1998 Jun 13;142(24):1379-83. **(Dut)**

GUIDELINE ADHERENCE

STATISTICS & NUMERICAL DATA

Evaluation of two strategies for complying with state-mandated lead screening in the emergency department. Naussau-Suffolk Lead Committee, Naussau-Suffolk Lead Center. Orava S, et al. **Acad Emerg Med** 1999 Aug;6(8):849-51

Compliance with OSHA's respiratory protection standard in hospitals. Krishnan U, et al. **Am Ind Hyg Assoc J** 1999 Mar-Apr;60(2):228-36

Handwashing before entering the intensive care unit: what we learned from continuous video-camera surveillance. Nishimura S, et al. **Am J Infect Control** 1999 Aug; 27(4):367-9

Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population. Nestor A, et al. **Ann Allergy Asthma Immunol** 1998 Oct; 81(4):327-30

Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2 professional societies. Paniello RC, et al. **Arch Otolaryngol Head Neck Surg** 1999 Mar;125(3):309-13

Are smoke-free policies implemented and adhered to at sporting venues? Pikora T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):407-9

Effect of UK national guidelines on services to treat patients with acute low back pain: follow up questionnaire survey. Barnett AG, et al. **BMJ** 1999 Apr 3;318(7188):919-20

Doctors as patients: postal survey examining consultants and general practitioners adherence to guidelines. Forsythe M, et al. **BMJ** 1999 Sep 4;319(7210):605-8

No impact from active dissemination of the Ottawa Ankle Rules: further evidence of the need for local implementation of practice guidelines. Cameron C, et al. **CMAJ** 1999 Apr 20;160(8):1165-8

Incorporating preventive care recommendations into clinical practice: how do we bridge the gap? [editorial; comment] Douketis JD. **CMAJ** 1999 Apr 20;160(8):1171-2 (19 ref.) . Comment on: CMAJ 1999 Apr 20;160(8):1137-40.

Achieving compliance with pool fencing legislation in New Zealand: a survey of regulatory authorities. Morrison L, et al. **Inj Prev** 1999 Jun;5(2):114-8

Evidence of self-report bias in assessing adherence to guidelines. Adams AS, et al. **Int J Qual Health Care** 1999 Jun;11(3):187-92 (28 ref.)

Texas school menu compliance with US Dietary Guidelines for Americans. Friedman BJ, et al. **J Am Diet Assoc** 1998 Nov;98(11):1325-7

Measuring the effects of reminders for outpatient influenza immunizations at the point of clinical opportunity. Tang PC, et al. **J Am Med Inform Assoc** 1999 Mar-Apr; 6(2):115-21

Audit of regional screening guidelines for vestibular schwannoma. Dawes PJ, et al. **J Laryngol Otol** 1998 Sep; 112(9):860-4

Voluntary euthanasia under control? Further empirical evidence from The Netherlands [see comments] Jochemsen H, et al. **J Med Ethics** 1999 Feb;25(1):16-21. Comment in: J Med Ethics 1999 Feb;25(1):3-4.

Health and safety standards in New Zealand mortuaries. Walls CB. **N Z Med J** 1999 Aug 27;112(1094):311-3

Red blood cell transfusion practices in patients undergoing orthopedic surgery: a multi-institutional analysis. Audet AM, et al. **Orthopedics** 1998 Aug;21(8):851-8

Compliance with mammography guidelines: physician recommendation and patient adherence. May DS, et al. **Prev Med** 1999 Apr;28(4):386-94

Regional differences in infant immunization against hepatitis B: did intervention work? Takayama JI, et al. **Prev Med** 1999 Feb;28(2):160-6

[Follow-up after melanoma resection is more extensive than recommended in the practice guidelines, primarily for reassurance of the patient] Mijnhout GS, et al. **Ned Tijdschr Geneeskd** 1999 May 8;143(19):997-1001 (Eng. Abstr.) **(Dut)**

[Lack of adherence to the guidelines on the use of fresh frozen plasma] Venema D, et al. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1999-2002 (Eng. Abstr.) **(Dut)**

TRENDS

Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. Kaplan JE, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):228-35

Could the sky be falling? Blight CO. **Mich Med** 1999 Jan; 98(1):56

GUIDELINES

Authorship: "Law" and order. Gaeta TJ. **Acad Emerg Med** 1999 Apr;6(4):297-301 (19 ref.)

Recent trends and controversies in industry-sponsored clinical trials. Reed CR, et al. **Acad Emerg Med** 1999 Aug; 6(8):833-9 (37 ref.)

Learning objectives for medical student education--guidelines for medical schools: report I of the Medical School Objectives Project [see comments] **Acad Med** 1999 Jan;74(1):13-8. Comment in: Acad Med 1999 May;74(5):461-2.

Position papers, consensus reports, and guidelines: are they necessary? [editorial; comment] Muñoz-López F. **Allergol Immunopathol (Madr)** 1998 Jul-Aug;26(4):167-70 . Comment on: Allergol Immunopathol (Madr) 1998 Jul-Aug;26(4):171-94. **(Eng, Spa)**

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care. Stewart A, et al. **Am Heart J** 1999 May;137(5):S53-61

Compliance with OSHA's respiratory protection standard in hospitals. Krishnan U, et al. **Am Ind Hyg Assoc J** 1999 Mar-Apr;60(2):228-36

Analysis of third-party certification approaches using an occupational health and safety conformity-assessment model. Redinger CF, et al. **Am Ind Hyg Assoc J** 1998 Nov; 59(11):802-12 (48 ref.)

To patch or not to patch: what is your threshold for patch testing? [clinical conference] Brod BA, et al. **Am J Contact Dermat** 1999 Jun;10(2):94-7

Educational rotations in pharmacy-based investigational drug services. Steedman S, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24):2611-3

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part I: The reproduction and fertility testing guidelines. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):543-53 (75 ref.)

Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline. Claudio L, et al. **Am J Ind Med** 1999 Jun; 35(6):554-63 (67 ref.)

Tailored advice on exercise--does it make a difference? Bull FC, et al. **Am J Prev Med** 1999 Apr;16(3):230-9

An ounce of prevention ... what are the returns? Second edition, 1999. Messonnier ML, et al. **Am J Prev Med** 1999 Apr;16(3):248-63 (90 ref.)

Recommended data elements for firearm-related injury surveillance. Saltzman LE, et al. **Am J Prev Med** 1998 Oct; 15(3 Suppl):113-9

Are guidelines needed for the performance of invasive interventional procedures for minimally invasive cardiac surgery? [letter; comment] Lewis WR, et al. **Anesthesiology** 1999 Apr;90(4):1232. Comment on: Anesthesiology 1998 Aug;89(2):519-21.

Heat stress and protective clothing: an emerging approach from the United States. Bernard TE. **Ann Occup Hyg** 1999 Jul;43(5):321-7 (22 ref.)

Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309-19 (38 ref.)

International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297-308 (28 ref.)

Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. de Jong D, et al. **Ann Oncol** 1999 Mar;10(3):275-80

Preparing guidelines and documented clinical policies. Haward RA. **Ann Oncol** 1998 Oct;9(10):1073-8

Essential drugs for cancer therapy: a World Health Organization consultation. Sikora K, et al. **Ann Oncol** 1999 Apr;10(4):385-90 (29 ref.)

Proposed standardization of assessment protocols for plant molluscicides for use in self-help control programmes. Brackenbury TD. **Ann Trop Med Parasitol** 1998 Oct; 92(7):803-16

Guidelines for managing acute gastroenteritis based on a systematic review of published research. Murphy MS. **Arch Dis Child** 1998 Sep;79(3):279-84 (70 ref.)

We need simple guidelines for reporting rates of rheumatic diseases [letter; comment] McCarty DJ, et al. **Arthritis Rheum** 1999 Mar;42(3):585. Comment on: Arthritis Rheum 1997 Sep;40(9):1725.

Reference list. Position statements, guidelines, and other relevant papers. **ASHA Suppl** 1999 Mar-Apr;41(2 Suppl 19):47-9

Compliance with recommendations from a screening programme for diabetic retinopathy. Lee SJ, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):187-9

Inflight medical kits. Rayman RB. **Aviat Space Environ Med** 1998 Oct;69(10):1007-10

Is there consensus between breast cancer patients and providers on guidelines for breaking bad news? Girgis A, et al. **Behav Med** 1999 Summer;25(2):69-77

Guideline may help in prescribing vigabatrin [letter; comment] [see comments] Appleton RE. **BMJ** 1998 Nov 7;317(7168):1322. Comment on: BMJ 1997 Jan 18;314(7075):180-1. Comment in: BMJ 1999 Jan 2;318(7175):56-7. Comment in: BMJ 1999 Jan 2;318(7175):57.

Cholesterol screening and management guidelines Having several guidelines is confusing [letter; comment] Bulusu S. **BMJ** 1999 Apr 24;318(7191):1140. Comment on: BMJ 1998 Oct 24;317(7166):1125-30.

Use of guidelines should be evaluated in randomised controlled trials [letter] Kirwan JR. **BMJ** 1999 Sep 4; 319(7210):643

UK guidelines aim to improve pain management in children [news] Kmietowicz Z. **BMJ** 1999 Jul 10;319(7202):76

Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria [letter; comment] Ramsay LE, et al. **BMJ** 1999 Apr 24; 318(7191):1140-1. Comment on: BMJ 1998 Oct 24;317(7166):1125-30.

More on the Bristol affair. Audit was secret yet not confidential [letter; comment] Stirrat GM. **BMJ** 1999 Apr 10;318(7189):1010. Comment on: BMJ 1998 Dec 5;317(7172):1579-80.

Reporting on quality of life in RCTs. CONSORT guidelines should be expanded [letter; comment] Wright SP. **BMJ** 1999 Apr 24;318(7191):1142. Comment on: BMJ 1998 Oct 31;317(7167):1191-4.

Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Bone Marrow Transplant** 1999 Jul;24(2):119-21

Chemotherapy for ovarian cancer--a consensus statement on standard practice [editorial] [see comments] [published erratum appears in Br J Cancer 1999 Feb;79(3-4):690] Adams M, et al. **Br J Cancer** 1998 Dec;78(11):1404-6. Commeat in: Br J Cancer 1998 Dec;78(11):1402-3.

Role conflict and confidentiality in multidisciplinary athlete support programmes. Collins D, et al. **Br J Sports Med** 1999 Jun;33(3):208-11

How I treat: return to sport after post-viral fatigue. Young M. **Br J Sports Med** 1999 Jun;33(3):173

Checklists for excellence. Ketchum P. **Can Fam Physician** 1998 Oct;44:2193-201, 2204-12 **(Eng, Fre)**

Burning issues--a guide for patients. Gastrointestinal gas. Bursey RF. **Can J Gastroenterol** 1999 Jun;13(5):378 (0 ref.)

Colorectal cancer screening: A guide to the guidelines. Rex DK. **Can J Gastroenterol** 1999 Jun;13(5):397-402 (61 ref.)

Low-risk drinking guidelines: the scientific evidence. Bondy SJ, et al. **Can J Public Health** 1999 Jul-Aug;90(4):264-70 (83 ref.)

Do Ontarians drink in moderation? a baseline assessment against Canadian low risk drinking guidelines. Bondy SJ, et al. **Can J Public Health** 1999 Jul-Aug;90(4):272-6

Proposed air quality objectives for fine particulate air pollution. Guidotti TL. **Can J Public Health** 1999 Jul-Aug; 90(4):285-7

Validation and simplification of Bethesda guidelines for identifying apparently sporadic forms of colorectal carcinoma with microsatellite instability. Cravo ML, et al. **Cancer** 1999 Feb 15;85(4):779-85

Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Iro H, et al. **Cancer** 1998 Nov 15;83(10):2201-7

A summary of cancer screening guidelines. Lipskie TL. **Chronic Dis Can** 1998;19(3):112-30 (62 ref.)

Care of the nursing-home resident with diabetes. Funnell MM. **Clin Geriatr Med** 1999 May;15(2):413-22 (42 ref.)

Lumbar spine range of motion as a measure of physical and functional impairment: an investigation of validity. Nattrass CL, et al. **Clin Rehabil** 1999 Jun;13(3):211-8

Meeting the information needs of drug purchasers: the evolution of formulary submission guidelines. Langley PC. **Clin Ther** 1999 Apr;21(4):768-87; discussion 767

Guidelines for dyspepsia treatment in Japan [published erratum appears in Clin Ther 1999 Jan;21(1):278] Matsueda K. **Clin Ther** 1998;20 Suppl D:D13-21; discussion D22-32

Guidance for infection control in schools and nurseries. **Commun Dis Rep CDR Wkly** 1999 Jul 30;9(31):269

Guidelines for quality assurance in multicenter trials: a position paper. Knatterud GL, et al. **Control Clin Trials** 1998 Oct;19(5):477-93

Ethical considerations in the use of human tissues in research. Sobel ME, et al. **Cytometry** 1999 Aug 15;38(4):192-3

Guidelines for good scientific practice. Andersen D. **Dan Med Bull** 1999 Feb;46(1):60-1

A sleep medicine curriculum for otolaryngology-head and neck surgery. Davidson TM, et al. **Ear Nose Throat J** 1999 Sep;78(9):684-6, 688, 690 passim

IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids--recommendations 1997. Chester MA. **Eur J Biochem** 1998 Oct 15;257(2):293-8

Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556-61 (34 ref.)

Differences in the diagnostic criteria used by Japanese and Western pathologists to diagnose colorectal carcinoma. Isenberg G. **Gastrointest Endosc** 1999 Sep;50(3):446-7; discussion 447-8

Research in developing countries: taking "benefit" seriously. Glantz LH, et al. **Hastings Cent Rep** 1998 Nov-Dec; 28(6):38-42 (18 ref.)

What's in the dish? McGee G, et al. **Hastings Cent Rep** 1999 Mar-Apr;29(2):36-8

Research with human embryonic stem cells: ethical considerations. By Geron Ethics Advisory Board. Mendiola MM, et al. **Hastings Cent Rep** 1999 Mar-Apr; 29(2):31-6 (26 ref.)

Foresight, insight, oversight. White GB. **Hastings Cent Rep** 1999 Mar-Apr;29(2):41-2

New British recommendations for prevention of coronary heart disease in clinical practice [editorial] Faergeman O. **Heart** 1999 Apr;81(4):335

A psychiatric trainee's guide to the criminal courts. Lock

M, et al. **Hosp Med** 1999 Jun;60(6):402–6 (3 ref.)
Guidelines and recommendations for content, structure, and deployment of mutation databases. Scriver CR, et al. **Hum Mutat** 1999;13(5):344–50
International standards on mental work-load--the ISO 10,075 series. Nachreiner F. **Ind Health** 1999 Apr; 37(2):125–33 (14 ref.)
Trends in compliance with the guidelines for preventing the transmission of Mycobacterium tuberculosis among New Jersey hospitals, 1989 to 1996. Manangan LP, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):337–40
Revised UK guidelines for the control of methicillin-resistant Staphylococcus aureus in hospitals. Chadwick PR. **Int J Antimicrob Agents** 1999 Feb;11(2):89–91
Adequacy of the new guidelines on clinical evaluation of drug efficacy in acute uncomplicated cystitis. Kawada Y, et al. **Int J Antimicrob Agents** 1999 May;11(3–4):185–7; discussion 213–6
Guidelines and evaluation of new anti-infective drugs for treatment of urinary tract infections [editorial] Kunin CM. **Int J Antimicrob Agents** 1999 May;11(3–4):197–9; discussion 213–6
Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Naber KG. **Int J Antimicrob Agents** 1999 May; 11(3–4):189–96; discussion 213–6
How adequate are the new guidelines on clinical evaluation of bacteriological outcome in uncomplicated UTI? Norrby SR. **Int J Antimicrob Agents** 1999 May;11(3–4):183–4; discussion 213–6
Evolving participation of aboriginal communities in health research ethics review: the impact of the Inuvik workshop. Kaufert J, et al. **Int J Circumpolar Health** 1999 Apr; 58(2):134–44
Nutritional assessment in elderly care--a team approach. Gee P, et al. **Int J Lang Commun Disord** 1998;33 Suppl:273–8
PSA relapse definitions--the Vancouver Rules show superior predictive power [letter; comment] Pickles T, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):699–700. Comment on: Int J Radiat Oncol Biol Phys 1997 Mar 15;37(5):1035–41.
Dealing with the police. Howarth PA. **J Accid Emerg Med** 1999 Jul;16(4):287–8
VA aligns health professions education with healthcare priorities. Stevens DP, et al. **J Allied Health** 1998 Fall; 27(3):123–7
President's page: Evaluation and management documentation guidelines: proving accountability or just increasing hassle? [news] [published erratum appears in J Am Coll Cardiol 1999 Jun;33(7):following 2197] King SB 3rd. **J Am Coll Cardiol** 1999 Mar;33(3):895–6
ADA helps Shape Healthy People 2010; update on healthy weight partnership guidelines; regulatory comments [news; comment] **J Am Diet Assoc** 1999 Apr;99(4):420. Comment on: J Am Diet Assoc 1999 Apr;99(4):415, 418–9.
Authorship: can you claim a byline? Klein CJ, et al. **J Am Diet Assoc** 1999 Jan;99(1):77–9
Guide to available resources [letter] Bezilla TA. **J Am Osteopath Assoc** 1999 Jul;99(7):343–4
Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. Calabrese LH. **J Am Osteopath Assoc** 1999 Jun;99(6):313–21 (46 ref.)
Childhood blood lead screening in Arkansas: recommendations for health care providers. West R. **J Ark Med Soc** 1999 May;95(12):532–7
The application of the Task Force report in rural and frontier settings. Moss AH. **J Clin Ethics** 1999 Spring;10(1):42–8 (11 ref.)
Precautions against industrial accidents: experience in applying the Seveso II Directive in central and eastern European countries. Kaiser W, et al. **J Hazard Mater** 1999 Mar 1;65(1–2):59–75 (8 ref.)
Application of the Seveso Directive in France. Pineau JP. **J Hazard Mater** 1999 Mar 1;65(1–2):49–57 (7 ref.)
Tax exempt hospitals' condition improves with new physician recruitment guidelines. Seiffert JC. **J Ky Med Assoc** 1999 Jan;97(1):23–6
Medical screening: the next five years. Haddow P. **J Med Screen** 1999;6(2):58–9
A message from HCFA. Health Care Financing Administration [letter] DeParle NA. **J Miss State Med Assoc** 1999 Apr;40(4):128–9
Will Germany's good scientific practice guidelines prevent fraud? [news] Steimle S. **J Natl Cancer Inst** 1998 Nov 18; 90(22):1694–5
Racial bias in federal nutrition policy, Part II: Weak guidelines take a disproportionate toll. Bertron P, et al. **J Natl Med Assoc** 1999 Apr;91(4):201–8
Functional ability assessment: guidelines for the workplace. Colledge AL, et al. **J Occup Environ Med** 1999 Mar; 41(3):172–80 (27 ref.)
Accreditation by the National Committee on Quality Assurance (NCQA): a description. Bell D, et al. **J Okla State Med Assoc** 1999 May;92(5):234–7 (13 ref.)
Education. The baccalaureate revolution. Acord LG. **J Prof Nurs** 1999 Jan–Feb;15(1):5
Outcomes assessment: implications for nursing education. Thompson C, et al. **J Prof Nurs** 1999 May–Jun;15(3):170–8 (24 ref.)
International affairs. Irish nursing for the next millennium. Watson R. **J Prof Nurs** 1999 Jan–Feb;15(1):3
Guidelines for an office-based surgical facility: quality not bureaucracy [editorial] Kavic MS. **J Soc Laparoendosc Surg** 1998 Apr–Jun;2(2):121
Recent progress of the international harmonization of toxicological testing: impact and implementation of ICH guidelines. International Conference Harmonization. Igarashi T. **J Toxicol Sci** 1998 Jul;23 Suppl 2:255–7
Harmonization of genotoxicity testing requirements for pharmaceuticals. Sofuni T. **J Toxicol Sci** 1998 Jul;23 Suppl 2:262–4
Recommended guidelines for optimal design of a plastic surgery service during mass casualty events. Cohen M, et al. **J Trauma** 1998 Nov;45(5):960–8
Working through the public disclosure process mandated by use of 21 CFR 50.24 (exception to informed consent): guidelines for success. Santora TA, et al. **J Trauma** 1998 Nov;45(5):907–13
WHO releases stricter guidelines on emergency drug donations [news] Ahmad K. **Lancet** 1999 Sep 11; 354(9182):928
Call made for application of drug-donation guidelines [news] Bonn D. **Lancet** 1999 Jun 19;353(9170):2131
Implications of genetic testing for insurance in the UK. Morrison PJ. **Lancet** 1998 Nov 21;352(9141):1647–8
Long-chain polyunsaturated fatty acids in diets for infants: choices for recommending and regulating bodies and for manufacturers of dietary products. Koletzko B, et al. **Lipids** 1999 Feb;34(2):215–20 (34 ref.)
Summary of guidelines on organ allocation and patient listing for liver transplantation. Keeffe EB. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S108–14 (20 ref.)
Quality assurance guidelines for a biomedical information web system: the working experience of the BreakIT project. Sacile R, et al. **Med Inform Internet Med** 1999 Apr–Jun;24(2):109–20 (10 ref.)
New national guidelines for ethics committees are on the way [letter; comment] Chalmers D. **Med J Aust** 1999 Jul 5;171(1):53. Comment on: Med J Aust 1999 Jan 4;170(1):26–8.
Setting a national informatics agenda for nursing education and practice to prepare nurses to develop and use information technology. Gassert CA, et al. **Medinfo** 1998; 9 Pt 2:748–51
Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults. A report on recommendations from the Task Force on Community Preventive Services. **MMWR Morb Mortal Wkly Rep** 1999 Jun 18;48(RR-8):1–15
Indications for long-term oxygen therapy: a reappraisal. Zieliński J. **Monaldi Arch Chest Dis** 1999 Apr;54(2):178–82 (31 ref.)
Evaluation and management guidelines [letter; comment] Berenson RA. **N Engl J Med** 1999 Mar 18;340(11):889; discussion 890–1. Comment on: N Engl J Med 1998 Dec 3;339(23):1697–8. Comment on: N Engl J Med 1998 Dec 3;339(23):1705–8.
New guidelines for coding physicians' services--a step backward [see comments] Brett AS. **N Engl J Med** 1998 Dec 3;339(23):1705–8. Comment in: N Engl J Med 1999 Mar 18;340(11):889; discussion 890–1. Comment in: N Engl J Med 1999 Mar 18;340(11):889–90; discussion 890–1. Comment in: N Engl J Med 1999 Mar 18;340(11):890–1.
Evaluation and management guidelines [letter; comment] Field MH, et al. **N Engl J Med** 1999 Mar 18;340(11):889–90; discussion 890–1. Comment on: N Engl J Med 1998 Dec 3;339(23):1697–8. Comment on: N Engl J Med 1998 Dec 3;339(23):1705–8.
Evaluation and management guidelines--fatally flawed [editorial] [see comments] Kassirer JP, et al. **N Engl J Med** 1998 Dec 3;339(23):1697–8. Comment in: N Engl J Med 1999 Mar 18;340(11):889; discussion 890–1. Comment in: N Engl J Med 1999 Mar 18;340(11):889–90; discussion 890–1. Comment in: N Engl J Med 1999 Mar 18;340(11):890; discussion 890–1. Comment in: N Engl J Med 1999 Mar 18;340(11):890–1.
Evaluation and management guidelines [letter; comment] Loudermilk A. **N Engl J Med** 1999 Mar 18;340(11):890; discussion 890–1. Comment on: N Engl J Med 1998 Dec 3;339(23):1697–8.
Evaluation and management guidelines [letter; comment] Maddock RK Jr. **N Engl J Med** 1999 Mar 18;340(11):890–1. Comment on: N Engl J Med 1998 Dec 3;339(23):1697–8. Comment on: N Engl J Med 1998 Dec 3;339(23):1705–8.
Evaluation and management guidelines [letter; comment] Wetzler HP. **N Engl J Med** 1999 Mar 18;340(11):890; discussion 890–1. Comment on: N Engl J Med 1998 Dec 3;339(23):1697–8.
Monitoring clinical trials. Sharples K, et al. **N Z Med J** 1998 Aug 28;111(1072):322–5 (22 ref.)
Health and safety standards in New Zealand mortuaries. Walls CB. **N Z Med J** 1999 Aug 27;112(1094):311–3
Biosafety and regulation. Francisco M. **Nat Biotechnol** 1999 Jan;17(1):89
Stem cell debate heats up as guidelines are prepared [news] Birmingham K, et al. **Nat Med** 1999 Apr;5(4):366
Clarifying AIDS vaccine trial guidelines [letter; comment] Cohen J. **Nat Med** 1998 Oct;4(10):1091. Comment on: Nat Med 1998 Aug;4(8):874.
WMA to revise medical research guidelines. World Medical Association [news] Dove A. **Nat Med** 1999 Jun;5(6):598
NIH increase efforts to tackle obesity [news] Novak K. **Nat Med** 1998 Jul;4(7):752–3
WHO steps closer to its responsibilities [editorial] [see comments] **Nature** 1999 Mar 18;398(6724):175. Comment in: Nature 1999 May 27;399(6734):297.
WHO's bioethics code likely to stir debate [news] [see comments] Butler D. **Nature** 1999 Mar 18;398(6724):179. Comment in: Nature 1999 May 27;399(6734):297.
Lab guidelines aim to prevent misconduct [letter; comment] Clausen T. **Nature** 1999 Jan 14;397(6715):101. Comment on: Nature 1998 Oct 22;395(6704):727. Comment on: Nature 1998 Dec 3;396(6710):404.
NIH stem-cell guidelines face stormy ride [news] Wadman M. **Nature** 1999 Apr 15;398(6728):551
NIH strives to keep resource sharing alive [news] Wadman M. **Nature** 1999 May 27;399(6734):291
Guidelines point the way on genetics ethics [letter; comment] Wertz DC. **Nature** 1999 May 27;399(6734):297. Comment on: Nature 1999 Mar 18;398(6724):175. Comment on: Nature 1999 Mar 18;398(6724):179.
European best practice guidelines for the management of anaemia in patients with chronic renal failure. Cameron JS. **Nephrol Dial Transplant** 1999;14 Suppl 2:61–5 (7 ref.)
PHS guidelines for the management of health-care worker exposures to HIV--Part 1. **Oncology (Huntingt)** 1998 Sep; 12(9):1331–2, 1335–6, 1339 passim
Controversial E & M coding guidelines deferred [editorial] D'Ambrosia R. **Orthopedics** 1998 Aug;21(8):847
Presenting graphical information. Bryant TN. **Pediatr Allergy Immunol** 1999 Feb;10(1):4–13 (8 ref.)
Predictors of physician compliance with a published guideline on management of febrile infants. Zerr DM, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):232–8
Clinical guidelines and hospital discharges of children with acute urinary tract infections. Nuutinen M, et al. **Pediatr Nephrol** 1999 Jan;13(1):45–9
More on the DPT [letter; comment] Magistro CM. **Phys Ther** 1998 Oct;78(10):1119. Comment on: Phys Ther 1998 Jul;78(7):782–3.
Production and evaluation of guidelines for the management of inflammatory bowel disease: the Leicester experience. Read AM, et al. **Postgrad Med J** 1999 Mar;75(881):147–50
Breast disease: refer or a reassure? Saunders C, et al. **Practitioner** 1998 Mar;242(1584):216–9 (2 ref.)
Training for rural prehospital providers: a retrospective analysis from Montana. Pullum JD, et al. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):231–8
HCFA documentation guidelines and the need for discrete data: a golden opportunity for applied health informatics. Taragin MI, et al. **Proc AMIA Symp** 1998;:653–6
Competence to consent to voluntary psychiatric hospitalization: a test of a standard proposed by APA. American Psychiatric Association. Appelbaum BC, et al. **Psychiatr Serv** 1998 Sep;49(9):1193–6
Guidelines for prescribing psychiatrists in consultative, collaborative, and supervisory relationships. Sederer LI, et al. **Psychiatr Serv** 1998 Sep;49(9):1197–202
The International Conference on Harmonization Good Clinical Practice guideline. Dixon JR Jr. **Qual Assur** 1998 Apr–Jun;6(2):65–74
Inadequate assessment of the airway and ventilation in acute poisoning. A need for improved education? Cosgrove JF, et al. **Resuscitation** 1999 Apr–May;40(3):161–4
Panel pulls back report after NIH critique [news] Marshall E. **Science** 1998 Oct 30;282(5390):857,859
British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Taylor GP, et al. **Sex Transm Infect** 1999 Apr;75(2):90–7 (55 ref.)
What you need to know: guidelines to medical practitioners for proper maintenance of drugs and dispensing records (including controlled drugs). Yee SK. **Singapore Med J** 1998 Nov;39(11):520–2
Exercise stress testing. An overview of current guidelines. Lear SA, et al. **Sports Med** 1999 May;27(5):285–312 (91 ref.)
A framework establishing clear decision criteria for the assessment of drug efficacy. Huster WJ, et al. **Stat Med** 1998 Aug 15–30;17(15–16):1829–38 (23 ref.)
Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. Lewis JA. **Stat Med** 1999 Aug 15;18(15):1903–42
Guidelines for laparoscopic antireflux procedures [letter; comment] Ferguson MK. **Surg Endosc** 1998 Dec; 12(12):1451. Comment on: Surg Endosc 1997 May;11(5):413–26.
Research ethics committees: a regional approach. Macpherson CC. **Theor Med Bioeth** 1999 Apr;20(2):161–79
Helping people to stop smoking: the new smoking cessation guidelines [editorial] Britton J, et al. **Thorax** 1999 Jan; 54(1):1–2
The international harmonisation of guidelines in the future: a viewpoint from the industry. Ekman L. **Toxicol Lett** 1998 Dec 28;102–103:551–5
A Japanese view on a global toxicology testing program before ICH1 and after ICH4. Mitsumori K. **Toxicol Lett** 1998 Dec 28;102–103:557–60
BVPA guidelines on antimicrobial resistance [letter] Thorp B, et al. **Vet Rec** 1998 Aug 15;143(7):203
GMP in blood collection and processing. Wagstaff W. **Vox Sang** 1998;74 Suppl 2:513–21 (4 ref.)
Respect for patients should dominate health care decisions [comment] Alpers A. **West J Med** 1999 May;170(5):291–2 (11 ref.). Comment on: West J Med 1999 May;170(5):287–90.
Control of hepatitis A infection in the U.S. Le C.

West J Med 1999 Jun;170(6):324 (10 ref.)
Universal childhood immunization against hepatitis A: whoa! Takayama JI. **West J Med** 1999 Jun;170(6):325–6 (11 ref.)
Two challenges for research ethics: innovative treatment and fetal therapy [comment] Gates E.
Womens Health Issues 1999 Jul–Aug;9(4):208–10 (14 ref.)
. Comment on: Womens Health Issues 1999 Jul–Aug;9(4):194–8.
Why single out pregnant women? Comments on ACOG's recommendations for involving pregnant women in research [comment] Roche PA, et al.
Womens Health Issues 1999 Jul–Aug;9(4):202–5. Comment on: Womens Health Issues 1999 Jul–Aug;9(4):194–8.
Ethical considerations? A commentary on ACOG committee opinion 213: "Ethical considerations in research involving pregnant women" [comment] Sharpe VA.
Womens Health Issues 1999 Jul–Aug;9(4):199–201. Comment on: Womens Health Issues 1999 Jul–Aug;9(4):194–8.
[New WHO-classification of lung and pleural tumors] Wagenaar SS. **Ned Tijdschr Geneeskd** 1999 May 8; 143(19):984–90 (Eng. Abstr.) **(Dut)**
[Are guidelines for excision of melanoma pertinent?] Grosshans E. **Ann Dermatol Venereol** 1998 Sep; 125(9):637–40 **(Fre)**
[Guidelines--a misleading path for the physician? (editorial)] Hempelmann G, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Apr; 34(4):197 **(Ger)**
[The trouble with guidelines] Ulsenheimer K.
Anasthesiol Intensivmed Notfallmed Schmerzther 1999 Apr; 34(4):198–203 (0 ref.) **(Ger)**
[Role of guidelines in the context of future management of the social state] Sendler H. **Gesundheitswesen** 1998 Dec; 60(12):768–71 (Eng. Abstr.) **(Ger)**
[Guidelines for prescription drugs: special interests are counterproductive] Kirsten WD. **Internist (Berl)** 1999 Aug; 40(8):224–5 **(Ger)**
[The feasibility of preoperative autologous blood donation in children] Dada A, et al. **Klin Padiatr** 1999 Mar–Apr; 211(2):57–60 (23 ref.) (Eng. Abstr.) **(Ger)**
[The fight for guidelines] Bjørndal A.
Tidsskr Nor Laegeforen 1999 May 10;119(12):1729 **(Nor)**
[Clinical guidelines for primary health care] Holmen J, et al. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1794–7 (31 ref.) **(Nor)**
[Review of the regulations on quality control of human albumin] Poprzen V. **Vojnosanit Pregl** 1998 Sep–Oct; 55(5):529–31 **(Scc)**
[Reflexions on gifts from the pharmaceutical industry (editorial)] Pérez-Castro Ellendt E. **Arch Esp Urol** 1998 Dec;51(10):955–6 **(Spa)**

STANDARDS

Ethical issues in Alzheimer disease: the experience of a national Alzheimer society task force [see comments] Cohen CA, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13(2):66–70. Comment in: Alzheimer Dis Assoc Disord 1999 Apr–Jun;13(2):63–5.
The impact of clinical guidelines and clinical pathways on medical practice: effectiveness and medico-legal aspects. Cheah TS. **Ann Acad Med Singapore** 1998 Jul;27(4):533–9 (37 ref.)
Guidelines for clinical guidelines should distinguish between national and local production [letter; comment] Williams JG. **BMJ** 1999 Apr 3;318(7188):942. Comment on: BMJ 1998 Aug 15;317(7156):427–8.
Emerging standardization in pharmacoeconomics [comment] Mullins CD, et al. **Clin Ther** 1998 Nov–Dec;20(6):1194–202; discussion 1192–3. Comment on: Clin Ther 1995 Jan–Feb;17(1):109–25.
Appropriateness of international heat stress standards for use in tropical agricultural environments. McNeill MB, et al. **Ergonomics** 1999 Jun;42(6):779–97
Time for new rules on human subjects research? Dresser R.
Hastings Cent Rep 1998 Nov–Dec;28(6):23–4 (32 ref.)
A world of research subjects. Emanuel EJ.
Hastings Cent Rep 1998 Nov–Dec;28(6):25
Anti-dementia drugs [editorial] Allen H.
Int J Geriatr Psychiatry 1999 Apr;14(4):239–43
Interpretative guidelines for neuropsychiatric measures with dichotomously scored items. Woodard JL, et al.
Int J Geriatr Psychiatry 1999 May;14(5):385–8
Assessment of surgically induced astigmatism: toward an international standard [letter] [see comments] Goggin M, et al. **J Cataract Refract Surg** 1998 Dec;24(12):1548–50. Comment in: J Cataract Refract Surg 1998 Dec;24(12):1545.
Assessment of surgically induced astigmatism: toward an international standard II [letter; comment] [see comments] Goggin M, et al. **J Cataract Refract Surg** 1998 Dec; 24(12):1552–3. Comment on: J Cataract Refract Surg 1998 Jan;24(1):57–65. Comment in: J Cataract Refract Surg 1998 Dec;24(12):1545.
Reporting astigmatism data [editorial; comment] Koch DD. **J Cataract Refract Surg** 1998 Dec;24(12):1545 (8 ref.). Comment on: J Cataract Refract Surg 1998 Dec;24(12):1548–50. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1550–2. Comment on: J Cataract Refract Surg 1998 Dec;24(12):1552–3.
Format for reporting surgically induced astigmatism on aggregate data [letter; comment] [see comments] Naeser K. **J Cataract Refract Surg** 1998 Dec;24(12):1550–2. Comment on: J Cataract Refract Surg 1998 Jan;24(1):57–65. Comment on: J Cataract Refract Surg 1998 Mar;24(3):285–7. Comment in: J Cataract Refract Surg 1998 Dec;24(12):1545.
Carrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases. Miller RG. **J Child Neurol** 1999 Mar;14(3):173–9 (41 ref.)
Racial bias in federal nutrition policy. Part I: The public health implications of variations in lactase persistence. Bertron P, et al. **J Natl Med Assoc** 1999 Mar;91(3):151–7 (52 ref.)
Pharmaceutical development and specification of stereoisomers. Williams RC, et al.
J Pharm Biomed Anal 1998 Sep 1;17(6–7):917–24 (17 ref.)
The clinician's duty to protect third parties. Felthous AR.
Psychiatr Clin North Am 1999 Mar;22(1):49–60 (67 ref.)
Comparing 1997 Resuscitation Council (UK) recovery position with recovery position of 1992 European Resuscitation Council guidelines: a user's perspective. Doxey J. **Resuscitation** 1998 Dec;39(3):161–9
[Guidelines and costs (comment)] Casparie AF, et al.
Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2075–7 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2096–101. **(Dut)**
[Revised consensus Diagnosis of dementia syndromes' (letter; comment)] de Reus R, et al.
Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2375. Comment on: Ned Tijdschr Geneeskd 1998 Jun 20;142(25):1459–63. **(Dut)**
[Emphasizing of ethical criteria for medical scientific reporting and the Declaration of Helsinki (letter; comment)] Gebhardt DO. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):494–5. Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):33–6. **(Dut)**
[Infections and bacterial resistance in the community] Goettsch WG, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1296–9 (33 ref.) (Eng. Abstr.) **(Dut)**
[Legionella epidemic in the Netherlands] Hoepelman IM.
Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1192–6 (19 ref.) (Eng. Abstr.) **(Dut)**
[Growth promoting antimicrobials] Hoogkamp-Korstanje JA. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1293–5 (Eng. Abstr.) **(Dut)**
[A lack of understanding of the rulings by disciplinary committees (comment) (see comments)] Hubben JH.
Ned Tijdschr Geneeskd 1998 Aug 15;142(33):1851–3 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 15;142(33):1854–5. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2215. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2215–6. Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2216. **(Dut)**
[Locoregional radiotherapy after mastectomy not useful for all Dutch breast cancer patients (comment)] Leer JW, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):73–5 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):71–2. **(Dut)**
[Benign prostate hyperplasia; shared care reduces care load (comment)] Lycklama à Nijeholt AA.
Ned Tijdschr Geneeskd 1998 Nov 21;142(47):2556–7 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Nov 21;142(47):2563–8. **(Dut)**
[Sedation by non-anesthesiologists should be centralized for considerations of safety (comment)] Lycklama à Nijeholt-Hamstra EW, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1077–9 (8 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 May 22;143(21):1098–102. **(Dut)**
[Hearing impairment (letter)] Mülder HE, et al.
Ned Tijdschr Geneeskd 1998 Dec 5;142(49):2697; discussion 2697–8 **(Dut)**
[Economic evaluation in cardiology: background and application (letter; comment)] Naaborg R.
Ned Tijdschr Geneeskd 1998 Sep 26;142(39):2164–5. Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2083–6. **(Dut)**
[Risks of silicone breast implants unproven (see comments)] Nicolai JP. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2719–20 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 13;143(11):587. Comment in: Ned Tijdschr Geneeskd 1999 Mar 13;143(11):587; discussion 587–8. **(Dut)**
[Sedation by non-anesthesiologists should be centralized for safety reasons (letter)] Oei-Lim LB.
Ned Tijdschr Geneeskd 1999 Jul 31;143(31):1630–1 **(Dut)**
[Is the difference between the educational requirements and the final standards of medical studies a problem?] Okkes IM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2716–9 (Eng. Abstr.) **(Dut)**
[High-dose chemotherapy with stem cell support for solid tumors in adults] Rodenhuis S, et al.
Ned Tijdschr Geneeskd 1999 Apr 3;143(14):731–8 (32 ref.) (Eng. Abstr.) **(Dut)**
[Comments on a case of physician-assisted suicide of a patient with an organic psychiatric disorder (comment)] Schudel WJ. **Ned Tijdschr Geneeskd** 1999 Apr 24;143(17):884–6 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Apr 24;143(17):881–4. Comment on: Ned Tijdschr Geneeskd 1999 Apr 24;143(17):905–9. **(Dut)**
[Practice guidelines for physicians and related economic considerations (letter; comment)] Simoons ML, et al.
Ned Tijdschr Geneeskd 1999 Apr 17;143(16):874–5. Comment on: Ned Tijdschr Geneeskd 1999 Apr 10;143(15):776–8. **(Dut)**
[Retrieved memories of traumatic events in the youth] Spinhoven P, et al. **Ned Tijdschr Geneeskd** 1999 May 29; 143(22):1136–40 (Eng. Abstr.) **(Dut)**
[European strategy for control of resistance to antibiotics] Sprenger MJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1322–5 (Eng. Abstr.) **(Dut)**
[National guidelines for clinical decisions, a methodological view (comment)] Tijssen JG, et al.
Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2078–82 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2096–101. **(Dut)**
[Increased risk of death in critically ill patients after treatment with human albumin? (letter; comment)] van Aken WG, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2162–3 . Comment on: Ned Tijdschr Geneeskd 1998 Aug 15;142(33):1855–8. **(Dut)**
[The Organ Donation Law: changes in the procurement of organs and tissues for transplantation (see comments)] van der Vliet JA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2830–2 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Dec 26;142(52):2838–43. Comment in: Ned Tijdschr Geneeskd 1998 Dec 26;142(52):2865–9. **(Dut)**
[Optimizing the antibiotics policy in the Netherlands. IV. SWAB guidelines for antimicrobial therapy of adults with sepsis in hospitals (letter; comment)] van Leeuwen HJ.
Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1237. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):611–7. **(Dut)**
[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter; comment)] van Poeck KJ.
Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1234; discussion 1235. Comment on: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):295–300. **(Dut)**
[Elective cesarean section preferably after completion of a minimum of 38 weeks of pregnancy (letter; comment)] Van Roosmalen IJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2; 143(1):60. Comment on: Ned Tijdschr Geneeskd 1998 Oct 17;142(42):2300–3. **(Dut)**
[Hearing impairment (letter; comment)] van Schaik V.
Ned Tijdschr Geneeskd 1999 Mar 27;143(13):702. Comment on: Ned Tijdschr Geneeskd 1998 Dec 5;142(49):2696. **(Dut)**
[The place of long-acting beta 2 adrenergic agonists in the treatment of asthma and chronic obstructive lung disease (COPD) (see comments)] van Schayck CP, et al.
Ned Tijdschr Geneeskd 1999 Jan 16;143(3):137–40 (30 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):764. **(Dut)**
[Screening for Chlamydia trachomatis infection: which group should be targeted and at what price? (comment)] van Vloten WA. **Ned Tijdschr Geneeskd** 1999 Mar 27; 143(13):652–3 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):668–72. Comment on: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):672–6. Comment on: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):677–81. **(Dut)**
[Drug-dependent offenders committed for disciplinary action. Results of a cross-sectional survey] Seifert D, et al. **Nervenarzt** 1999 May;70(5):450–6 (Eng. Abstr.) **(Ger)**

GUIDELINES FOR HEALTH PLANNING see **HEALTH PLANNING GUIDELINES**

GUILLAIN-BARRE SYNDROME see **POLYRADICULONEURITIS**

GUILT

Kinds of therapy for persons with psychiatric disorders and their families [letter; comment] Griffin-Francell C.
Arch Psychiatr Nurs 1998 Dec;12(6):352–3. Comment on: Arch Psychiatr Nurs 1998 Aug;12(4):179–80.
Guilt, shame, and symptoms in children. Ferguson TJ, et al. **Dev Psychol** 1999 Mar;35(2):347–57
The pain of being borderline: dysphoric states specific to borderline personality disorder. Zanarini MC, et al.
Harv Rev Psychiatry 1998 Nov–Dec;6(4):201–7
Kleinian guilt, determinism, and free will: implications for clinical theory and treatment. Goodman G.
J Am Acad Psychoanal 1998 Spring;26(1):137–63 (52 ref.)
Are shame and guilt related to distinct self-discrepancies? A test of Higgins's (1987) hypotheses. Tangney JP, et al.
J Pers Soc Psychol 1998 Jul;75(1):256–68
Competence to confess: measuring understanding and suggestibility of defendants with mental retardation. Everington C, et al. **Ment Retard** 1999 Jun;37(3):212–20
Considerations on the vicissitudes of unconscious guilt feelings from pre-adolescence to early adolescence. Tsutsumi S. **Psychiatry Clin Neurosci** 1999 Feb;53(1):71–7
The meaning of guilt: a phenomenological description of employed mothers' experiences of guilt. Elvin-Nowak Y.
Scand J Psychol 1999 Mar;40(1):73–83

GUINEA PIGS

Mechanical load and primary guinea pig osteoarthrosis. Wei L, et al. **Acta Orthop Scand** 1998 Aug;69(4):351–7
Adenovirus pneumonia in guinea pigs. Finnie JW, et al.
Aust Vet J 1999 Mar;77(3):191–2

Severe gastritis in guinea-pigs infected with Helicobacter pylori. Sturegård E, et al. **J Med Microbiol** 1998 Dec; 47(12):1123-9

Alpha-mannosidosis in a guinea pig. Muntz FH, et al. **Lab Anim Sci** 1999 Aug;49(4):424-6

Ultrasonic diagnosis of ovarian cysts in ten guinea pigs. Beregi A, et al. **Vet Radiol Ultrasound** 1999 Jan-Feb; 40(1):74-6

ABNORMALITIES

Stereociliary anomaly in the guinea pig: effects of hair bundle rotation on cochlear sensitivity. Yoshida N, et al. **Hear Res** 1999 May;131(1-2):29-38

ANATOMY & HISTOLOGY

Venous drainage of the stomach in the golden hamster (Mesocricetus auratus) and the guinea pig (Cavia aperea f. porcellus). Leali FM, et al. **Anat Anz** 1998 Dec; 180(6):561-4

The planes of the utricular and saccular maculae of the guinea pig. Curthoys IS, et al. **Ann N Y Acad Sci** 1999 May 28; 871:27-34

NADPH-diaphorase positive myenteric neurons in the ileum of guinea-pig, rat, rabbit and cat: a comparative study. Wilhelm M, et al. **Eur J Morphol** 1998 Jul;36(3):143-52

The vertebrobasilar arterial system in guinea pig as compared with dog and human. Majewska-Michalska E. **Folia Morphol (Warsz)** 1998;57(2):121-31

The three-dimensional structure of myenteric neurons in the guinea-pig ileum. Hanani M, et al. **J Auton Nerv Syst** 1998 Jun 30;71(1):1-9

Regional differences in the sympathetic innervation of the guinea pig large intestine by neuropeptide Y- and tyrosine hydroxylase-immunoreactive nerves of divergent extrinsic origin. Browning KN, et al. **J Comp Neurol** 1999 Aug 9; 410(4):515-30

Dense innervation of Deiters' and Hensen's cells persists after chronic deefferentation of guinea pig cochleas. Fechner FP, et al. **J Comp Neurol** 1998 Oct 26;400(3):299-309

Regional distribution and extrinsic innervation of intrinsic cardiac neurons in the guinea pig. Leger J, et al. **J Comp Neurol** 1999 May 10;407(3):303-17

Arterial supply of limbic structures in the guinea pig. Librizzi L, et al. **J Comp Neurol** 1999 Sep 6;411(4):674-82

Synaptic organisation of neuropeptide-containing preganglionic boutons in lumbar sympathetic ganglia of guinea pigs. Murphy SM, et al. **J Comp Neurol** 1998 Sep 7;398(4):551-67

Mucosa of the guinea pig gastric corpus is innervated by myenteric neurones with specific neurochemical coding and projection preferences. Reiche D, et al. **J Comp Neurol** 1999 Aug 2;410(3):489-502

Descending auditory pathways: projections from the inferior colliculus contact superior olivary cells that project bilaterally to the cochlear nuclei. Schofield BR, et al. **J Comp Neurol** 1999 Jun 28;409(2):210-23

Projections of submucous neurons to the myenteric plexus in the guinea pig small intestine. Song ZM, et al. **J Comp Neurol** 1998 Sep 21;399(2):255-68

BLOOD

Novel techniques for in vivo hemolysis studies in guinea pigs. Tjatur Rasa FS, et al. **J Vet Med Sci** 1999 Feb;61(2):125-8

The hemolytic activity of bracken extracts in guinea pigs. Tjatur Rasa FS, et al. **J Vet Med Sci** 1999 Feb;61(2):129-33

GENETICS

Cloning and sequence of guinea pig interleukin 2 (IL-2). Takeyoshi M, et al. **Arch Toxicol** 1998 Oct;72(10):676-8

IMMUNOLOGY

Airway responsiveness to acetylcholine in congenitally bronchial-hypersensitive (BHS) and bronchial-hyposensitive (BHR) guinea pigs in vivo and in vitro. Yagi Y, et al. **Exp Anim** 1998 Jul;47(3):173-81

Calcium-independent haemolysis via the lectin pathway of complement activation in the guinea-pig and other species*. Zhang Y, et al. **Immunology** 1999 Aug; 97(4):686-92

METABOLISM

Glutathione reductase activity and flavin concentration in guinea-pig tissues. Suzuki M, et al. **Exp Anim** 1999 Jul; 48(3):199-202

Neurokinin-1 receptor localisation in guinea pig autonomic ganglia. Messenger JP, et al. **J Comp Neurol** 1999 Oct 4; 412(4):693-704

Diversity of the calretinin immunoreactivity in the dentate gyrus of gerbils, hamsters, guinea pigs, and laboratory shrews. Murakawa R, et al. **J Comp Neurol** 1999 Aug 30; 411(3):413-30

Hamsters and guinea pigs differ in their plasma lipoprotein cholesterol distribution when fed diets varying in animal protein, soluble fiber, or cholesterol content. Fernandez ML, et al. **J Nutr** 1999 Jul;129(7):1323-32

Immunohistochemical evidence for the presence of calbindin containing neurones in the myenteric plexus of the guinea-pig stomach. Reiche D, et al. **Neurosci Lett** 1999 Jul 30;270(2):71-4

Proteoglycan turnover during development of spontaneous osteoarthrosis in guinea pigs [published erratum appears in Osteoarthritis Cartilage 1999 Jan;7(1):154] Wei L, et al. **Osteoarthritis Cartilage** 1998 Nov;6(6):410-6

MICROBIOLOGY

Pulmonary lesions in guinea pigs experimentally infected with Actinobacillus pleuropneumoniae (A.p.) serovar 1. Perfumo CJ, et al. **J Vet Med Sci** 1999 Feb;61(2):163-5

PARASITOLOGY

Reproductivity of nine Trichinella isolates in guinea pigs and mice. Webster P, et al. **Acta Vet Scand** 1999;40(1):93-5

PHYSIOLOGY

Neurochemical distinction between skeletal muscle vasodilator neurons and pelvic vasodilator neurons in guinea-pigs. Morris JL, et al. **J Auton Nerv Syst** 1998 Jun 30;71(1):64-8

Neuronal control of the gastric sling muscle of the guinea pig. Yuan S, et al. **J Comp Neurol** 1999 Oct 4;412(4):669-80

[Vocalization response used for evaluation of pain-related behavior in guinea pigs] Ando R, et al. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):363-70 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Social influences on endocrine activity in guinea pigs, with comparisons to findings in nonhuman primates. Hennessy MB. **Neurosci Biobehav Rev** 1999 May;23(5):687-98 (102 ref.)

GUINEA WORM see **DRACUNCULUS**

GUINEA WORM INFECTION see **DRACUNCULIASIS**

L-GULARIC ACID see **GLUCARIC ACID**

GULF WAR SYNDROME see **PERSIAN GULF SYNDROME**

GULO see **CARNIVORA**

GUM ACACIA see **GUM ARABIC**

GUM ARABIC

ADVERSE EFFECTS

IgE antibodies specific for carbohydrates in a patient allergic to gum arabic (Acacia senegal). Fötisch K, et al. **Allergy** 1998 Nov;53(11):1043-51

GUM KARAYA see **KARAYA GUM**

GUMBORO DISEASE VIRUS see **INFECTIOUS BURSAL DISEASE VIRUS**

GUMS see **GINGIVA**

GUNS see **FIREARMS**

GUNTHER'S DISEASE see **PORPHYRIA, ERYTHROPOIETIC**

GUPPY see **POECILIA**

GUT GLUCAGON see **ENTEROGLUCAGON**

GUTTA-PERCHA

CHEMISTRY

Additional studies on the distribution of stresses during vertical compaction of gutta-percha in the root canal. Telli C, et al. **Br Dent J** 1999 Jul 10;187(1):32-7

GYMNASTICS

Water-gymnastics reduced the intensity of back/low back pain in pregnant women. Kihlstrand M, et al. **Acta Obstet Gynecol Scand** 1999 Mar;78(3):180-5

Energy and nutrient intakes of the United States National Women's Artistic Gymnastics Team. Jonnalagadda SS, et al. **Int J Sport Nutr** 1998 Dec;8(4):331-44

Longitudinal bone mineral density changes in female child artistic gymnasts. Nickols-Richardson SM, et al. **J Bone Miner Res** 1999 Jun;14(6):994-1002

Morphological and performance characteristics as drop-out indicators in female gymnasts. Claessens AL, et al. **J Sports Med Phys Fitness** 1998 Dec;38(4):305-9

Marrow MR signal abnormality associated with bilateral avulsive cortical irregularities in a gymnast. Posch TJ, et al. **Skeletal Radiol** 1998 Sep;27(9):511-4

[Process of high performance training--exemplified by gymnastics] Theiss P. **Wien Med Wochenschr** 1998; 148(10):228-30 (Eng. Abstr.) **(Ger)**

EDUCATION

Improving leaping ability in elite rhythmic gymnasts. Hutchinson MR, et al. **Med Sci Sports Exerc** 1998 Oct; 30(10):1543-7

INJURIES

Isolated fracture of the vertebral articular facet in a gymnast. A spondylolysis mimic. McCormack RG, et al. **Am J Sports Med** 1999 Jan-Feb;27(1):104-6

Simultaneous bilateral elbow dislocation in an international gymnast. Syed AA, et al. **Br J Sports Med** 1999 Apr; 33(2):132-3

Sports-related stress fracture of the clavicle: a case report. Roset-Llobet J, et al. **Int Orthop** 1998;22(4):266-8 (31 ref.)

[Gymnastic world championship in Lausanne: medical staffing] Gremion G, et al. **Rev Med Suisse Romande** 1998 Aug;118(8):709-11 **(Fre)**

[Traumatology and sports injuries in equestrian acrobatics in the adolescent] Horstmann T, et al. **Sportverletz Sportschaden** 1998 Jun;12(2):66-70 (Eng. Abstr.) **(Ger)**

[Fracture of the tarsal navicular bone in childhood--therapy and functional follow-up] Knorr P, et al. **Sportverletz Sportschaden** 1998 Jun;12(2):74-8 (Eng. Abstr.) **(Ger)**

[An increased risk of spinal injury in high performance gymnasts during pubertal growth?] Lohrer H. **Wien Med Wochenschr** 1998;148(10):235-8 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Hormonal responses to physical training in high-level peripubertal male gymnasts. Daly RM, et al. **Eur J Appl Physiol** 1998 Dec;79(1):74-81

Skull bone mass deficit in prepubertal highly-trained gymnast girls. Courteix D, et al. **Int J Sports Med** 1999 Jul; 20(5):328-33

Immediate effect of respiratory muscle stretch gymnastics and diaphragmatic breathing on respiratory pattern. Respiratory Muscle Conditioning Group. Ito M, et al. **Intern Med** 1999 Feb;38(2):126-32

A mathematical high bar-human body model for analysing and interpreting mechanical-energetic processes on the high bar. Arampatzis A, et al. **J Biomech** 1998 Dec; 31(12):1083-92

Mechanical energetic processes during the giant swing exercise before dismounts and flight elements on the high bar and the uneven parallel bars. Arampatzis A, et al. **J Biomech** 1999 Aug;32(8):811-20

A method for synchronising digitised video data. Yeadon MR, et al. **J Biomech** 1999 Sep;32(9):983-6

Effects of high-impact exercise on ultrasonic and biochemical indices of skeletal status: A prospective study in young male gymnasts. Daly RM, et al. **J Bone Miner Res** 1999 Jul;14(7):1222-30

Long-term recreational gymnastics, estrogen use, and selected risk factors for osteoporotic fractures. Uusi-Rasi K, et al. **J Bone Miner Res** 1999 Jul;14(7):1231-8

Cardiovascular stress and lactate formation during gymnastic routines. Goswami A, et al. **J Sports Med Phys Fitness** 1998 Dec;38(4):317-22

A two-segment simulation model of long horse vaulting. King MA, et al. **J Sports Sci** 1999 Apr;17(4):313-24

Ulnar variance and skeletal maturity of radius and ulna in female gymnasts. Beunen G, et al. **Med Sci Sports Exerc** 1999 May;31(5):653-7

[Nutritional behavior of female and male high performance gymnasts] Schwidergall S, et al. **Wien Med Wochenschr** 1998;148(10):243-4 (Eng. Abstr.) **(Ger)**

[Effect of high performance sports on puberty development of female and male gymnasts] Weimann E, et al. **Wien Med Wochenschr** 1998;148(10):231-4 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Self-perception in elite collegiate female gymnasts, cross-country runners, and track-and-field athletes. Saint-Phard D, et al. **Mayo Clin Proc** 1999 Aug;74(8):770-4

Participation motives of young Australian and Chinese gymnasts. Kirkby RJ, et al. **Percept Mot Skills** 1999 Apr; 88(2):363-73

GYMNODINIUM see **DINOFLAGELLIDA**

GYMNOSPERMS

CHEMISTRY

Trace elements in soil and coniferous needles. Blanusa M, et al. **Bull Environ Contam Toxicol** 1999 Jun;62(6):700-7

Two auronols from Pseudolarix amabilis. Li XC, et al. **J Nat Prod** 1999 May;62(5):767-9

Rhamnogalacturonan II from cell walls of Cryptomeria japonica. Edashige Y, et al. **Phytochemistry** 1998 Oct; 49(3):681-90

CLASSIFICATION

Sequence peculiarity of gnetalean legumin-like seed storage proteins. Shutov AD, et al. **J Mol Evol** 1998 Oct; 47(4):486-92

GYMNOSPERMS

ENZYMOLOGY

Proteolytic activity in relation to seasonal cambial growth and xylogenesis in Pinus banksiana. Iliev I, et al. **Phytochemistry** 1999 Mar;50(6):953–60

GENETICS

Sequence peculiarity of gnetalean legumin-like seed storage proteins. Shutov AD, et al. **J Mol Evol** 1998 Oct; 47(4):486–92

Phytochrome types in Picea and Pinus. Expression patterns of PHYA-Related types. Clapham DH, et al. **Plant Mol Biol** 1999 Jul;40(4):669–78

MADS about Gnetales. Frohlich MW. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8811–3 (29 ref.)

GROWTH & DEVELOPMENT

Proteolytic activity in relation to seasonal cambial growth and xylogenesis in Pinus banksiana. Iliev I, et al. **Phytochemistry** 1999 Mar;50(6):953–60

METABOLISM

Tolerance and biodegradation of m-toluate by Scots pine, a mycorrhizal fungus and fluorescent pseudomonads individually and under associative conditions. Sarand I, et al. **J Appl Microbiol** 1999 May;86(5):817–26

GYMNOTID see **ELECTRIC FISH**

GYNANDROBLASTOMA see **NEOPLASMS, GONADAL TISSUE**

GYNATRESIA

ETIOLOGY

Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Westendorp IC, et al. **Hum Reprod** 1998 Dec; 13(12):3347–50

SURGERY

Fluoroscopically guided hysteroscopic division of adhesions in severe Asherman syndrome. Broome JD, et al. **Obstet Gynecol** 1999 Jun;93(6):1041–3

THERAPY

Hysteroscopic treatment of severe Asherman's syndrome and subsequent fertility. Capella-Allouc S, et al. **Hum Reprod** 1999 May;14(5):1230–3

GYNECOLOGIC DISEASES see **GENITAL DISEASES, FEMALE**

GYNECOLOGIC NEOPLASMS see **GENITAL NEOPLASMS, FEMALE**

GYNECOLOGIC SURGICAL PROCEDURES

see related

GYNECOLOGY

Effect and placebo effect of acupressure (P6) on nausea and vomiting after outpatient gynaecological surgery. Alkaissi A, et al. **Acta Anaesthesiol Scand** 1999 Mar;43(3):270–4

Comparison of PCA nalbuphine and morphine in Chinese gynecologic patients. Ho ST, et al. **Acta Anaesthesiol Sin** 1998 Jun;36(2):65–70

Partial rollerball endometrial ablation: a modification of total ablation to treat menorrhagia without causing complications from intrauterine adhesions. McCausland AM, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1512–21

Gastro-esophageal reflux during day case gynaecological laparoscopy [letter; comment] Lee MT, et al. **Anaesthesia** 1999 Mar;54(3):303–4. Comment on: Anaesthesia 1998 Sep;53(9):921–4.

Anaesthesia for daycase gynaecological laparoscopy: a survey of clinical practice in the United Kingdom. Simpson RB, et al. **Anaesthesia** 1999 Jan;54(1):72–6

A comparison of the antiemetic effect of ondansetron and droperidol on patients undergoing gynecologic laparoscopy [letter; comment] Duncan M, et al. **Anesth Analg** 1998 Nov; 87(5):1213. Comment on: Anesth Analg 1997 Oct;85(4):797–800.

Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery. Fujii Y, et al. **Anesth Analg** 1999 Aug;89(2):476–9

Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Diemunsch P, et al. **Br J Anaesth** 1999 Feb;82(2):274–6

Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Frighetto L, et al. **Can J Anaesth** 1999 Jun;46(6):536–43

Advantages of spinal anesthesia in abdominal gynecologic surgery. Ghirardini G, et al. **Clin Exp Obstet Gynecol** 1998; 25(3):105–6

Fertility-sparing treatment of patients with ovarian cancer. McHale MT, et al. **Compr Ther** 1999 Mar;25(3):144–50 (28 ref.)

Endoscopic surgery. **Curr Opin Obstet Gynecol** 1998 Aug; 10(4):347–54

The virtues and pitfalls of minimally invasive surgery for gynecological malignancies: an update. Childers JM. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):51–9 (47 ref.)

Pre-emptive glycopyrrolate 0.2 mg and bradycardia during gynaecological laparoscopy with mivacurium. Ambrose C, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):710–3

Early postoperative feeding following major abdominal gynecologic surgery reduced the length of hospitalization [letter; comment] Barb MD, et al. **Gynecol Oncol** 1999 Jul; 74(1):152. Comment on: Gynecol Oncol 1997 Dec;67(3):235–40.

Fertility after laparoscopic management of deep endometriosis infiltrating the uterosacral ligaments. Chapron C, et al. **Hum Reprod** 1999 Feb;14(2):329–32

Resection of uterine septum using gynaecoradiological techniques. Karande VC, et al. **Hum Reprod** 1999 May; 14(5):1226–9

Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Li TC, et al. **Hum Reprod** 1999 Jul;14(7):1735–40

How long does laparoscopic surgery really take? Lessons learned from 1000 operative laparoscopies. Shushan A, et al. **Hum Reprod** 1999 Jan;14(1):39–43

A case-control study to compare the variability of operating time in laparoscopic and open surgery. Shushan A, et al. **Hum Reprod** 1999 Jun;14(6):1467–9

The role of bacterial vaginosis in infection after major gynecologic surgery. Lin L, et al. **Infect Dis Obstet Gynecol** 1999;7(3):169–74

Preoperative pulse wave velocity fails to predict hemodynamic responses to anesthesia and to surgical stimulation. Nakata Y, et al. **J Clin Anesth** 1999 Jun; 11(4):285–9

A practical approach to improving pain management for inpatient gynecological surgery patients. McGeary RA. **J Nurs Care Qual** 1999 Apr;13(4):83–5

The suprapubic cruciate incision for laparoscopic-assisted microceliotomy. Pelosi MA 3rd, et al. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):269–72

Results of the colposuspension operation in pre and postmenopausal incontinent women. Liapis A, et al. **Maturitas** 1998 Nov 30;31(1):69–75

[A comparative study of the efficacy of antibiotic prophylaxis with cephalosporins in operative gynecology] Doganov N, et al. **Akush Ginekol (Sofiia)** 1998;37(2):29–33 (Eng. Abstr.) **(Bul)**

[Progresses in the study of gynecology in China, 1997] Lang J. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):923–4 (0 ref.) **(Chi)**

[Antibiotic prophylaxis à la carte in self-contaminated gynecologic and obstetric surgery: importance of cefotaxime] Cisse CT, et al. **Dakar Med** 1997;42(2):127–31 (Eng. Abstr.) **(Fre)**

[Ondansetron. Prophylaxis and therapy of nausea and vomiting following major gynecologic procedures. Results of a national multicenter study] Biedler A, et al. **Anaesthesist** 1998 Aug;47(8):638–43 (Eng. Abstr.) **(Ger)**

[Remifentanil in gynecologic laparoscopy. A comparison of consciousness and circulatory effects of a combination with desflurane and propofol] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):552–6 (Eng. Abstr.) **(Ger)**

[Preoperative clarification as change and burden] Neises M. **Zentralbl Gynakol** 1999;121 Suppl 1:21–3 **(Ger)**

[Laparoscopic myomectomy] Dicker D, et al. **Harefuah** 1998 Oct;135(7–8):310–2 (8 ref.) **(Heb)**

[Use of remifentanil in ambulatory obstetric-gynecologic surgery. A dose-effect study] Marinangeli F, et al. **Minerva Anestesiol** 1999 Jul–Aug;65(7–8):491–7 (Eng. Abstr.) **(Ita)**

[Experience in introducing laparoscopic operations into the practice of the gynecology department of a military hospital] Romanovskiĭ VG, et al. **Voen Med Zh** 1999 May; 320(5):35–40 **(Rus)**

ADVERSE EFFECTS

Acute pancreatitis after gynecologic and obstetric surgery. Ramsey PS, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):542–6 (15 ref.)

Gynecologic laparoscopic surgery is not associated with an increase of serotonin metabolites excretion. Borgeat A, et al. **Anesth Analg** 1998 Nov;87(5):1104–8

Bladder and ureteral injury: prevention and management. Utrie JW Jr. **Clin Obstet Gynecol** 1998 Sep;41(3):755–63 (26 ref.)

Risk factors in wound infections after laparotomy in obstetrics and gynaecology. de la Fuente Fonnest I, et al. **Dan Med Bull** 1999 Jun;46(3):254–7

Myomectomy fever: testing the dogma. Iverson RE Jr, et al. **Fertil Steril** 1999 Jul;72(1):104–8

Gastrointestinal injuries during gynaecological laparoscopy. Chapron C, et al. **Hum Reprod** 1999 Feb;14(2):333–7

Second look after laparoscopic myomectomy. Dubuisson JB, et al. **Hum Reprod** 1998 Aug;13(8):2102–6

A French survey on gynaecological laparoscopy. Pierre F, et al. **Hum Reprod** 1998 Jul;13(7):1761

Frequency and yield of postoperative fever evaluation. Fanning J, et al. **Infect Dis Obstet Gynecol** 1998;6(6):252–5

Relationship of gynecologic surgery to constipation. Perry CP. **J Am Assoc Gynecol Laparosc** 1999 Feb;6(1):75–8

Postoperative hospital-acquired infection in Hungvuong Obstetric and Gynaecological Hospital, Vietnam. Tran TS, et al. **J Hosp Infect** 1998 Oct;40(2):141–7

Nausea and vomiting after laparoscopic gynecological surgery: a study of the incidence and the effects of tropisetron prophylaxis. Jakobsson J, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):51–5

Lysyl oxidase transcripts in peritoneal adhesions and incisional scars. Yaron Y, et al. **J Reprod Med** 1999 Mar; 44(3):253–6

Predicting risk of complications with gynecologic laparoscopic surgery [letter; comment] Chapron C, et al. **Obstet Gynecol** 1999 Feb;93(2):318–9. Comment on: Obstet Gynecol 1998 Sep;92(3):327–31.

Management of venous thrombosis and pulmonary embolism after gynecological surgery. Adachi T, et al. **Semin Thromb Hemost** 1998;24(5):437–42

Retained surgical sponge: an unusual cause of malabsorption. Sinha SK, et al. **Trop Gastroenterol** 1999 Jan–Mar; 20(1):42–4

[The bikini incision: nice, but not without painful complications (letter; comment)] Repelaer van Driel OJ. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2218. Comment on: Ned Tijdschr Geneeskd 1998 Jun 27;142(26):1481–3. **(Dut)**

[The influence of cumulative dexamethasone, promethazine and dextran 70 used as protection against intraperitoneal adhesions on selected parameters of humoral immunity in women operated on for infertility] Puchalski A. **Ann Acad Med Stetin** 1998;44:115–36 (Eng. Abstr.) **(Pol)**

[Urologic complications of gynecologic surgery and their treatment in our clinical data] Nagy V, et al. **Ceska Gynekol** 1998 Jun;63(3):192–5 (Eng. Abstr.) **(Slo)**

HISTORY

The history of operative gynecologic laparoscopy in Kentucky. Levine RL, et al. **J Ky Med Assoc** 1999 Feb; 97(2):67–8

Raoul Palmer, World War II, and transabdominal coelioscopy. Laparoscopy extends into gynecology. Litynski GS. **J Soc Laparoendosc Surg** 1997 Jul–Sep; 1(3):289–92

Hans Frangenheim--culdoscopy vs. laparoscopy, the first book on gynecological endoscopy, and "cold light". Litynski GS. **J Soc Laparoendosc Surg** 1997 Oct–Dec; 1(4):357–61

INSTRUMENTATION

One year of experience working with the aid of a robotic assistant (the voice-controlled optic holder AESOP) in gynaecological endoscopic surgery. Mettler L, et al. **Hum Reprod** 1998 Oct;13(10):2748–50

Reduction of cannula-related laparoscopic complications using a radially expanding access device. Galen DI, et al. **J Am Assoc Gynecol Laparosc** 1999 Feb;6(1):79–84

The use and maintenance of instruments for large loop excision of transformation zone at Ramathibodi Hospital. Bullangpoti W, et al. **J Med Assoc Thai** 1999 Jun; 82(6):577–80

Enhancing advanced surgical laparoscopy. Combined, routine use of microlaparoscopes and macrolaparoscopes. Hibbert ML, et al. **J Reprod Med** 1999 Jan;44(1):1–6

Clinical experience with an optical access trocar in gynecological laparoscopy-pelviscopy [see comments] Mettler L, et al. **J Soc Laparoendosc Surg** 1997 Oct–Dec; 1(4):315–8. Comment in: J Soc Laparoendosc Surg 1998 Jul–Sep;2(3):315.

[An ultrasonic scalpel for laparoscopic gynecologic surgery] Stanojević D, et al. **Srp Arh Celok Lek** 1998 May–Jun; 126(5–6):214–6 (Eng. Abstr.) **(Sec)**

METHODS

An anatomic and functional assessment of the discrete defect rectocele repair. Cundiff GW, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1451–6; discussion 1456–7

Site-specific fascial defects in the diagnosis and surgical management of enterocele. Miklos JR, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1418–22; discussion 1822–3

Paravaginal repair of lateral vaginal wall defects by fixation to the ischial periosteum and obturator membrane. Scotti RJ, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1436–45

The Noble-Mengert-Fish operation-revisited: a composite approach for persistent rectovaginal fistulas and complex perineal defects [published erratum appears in Am J Obstet Gynecol 1999 Jan;180(1 Pt 1):257] Veronikis DK, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1411–6; discussion 1416–7

Vesicovaginal fistula. Smith GL, et al. **BJU Int** 1999 Mar; 83(5):564–9; quiz 569–70 (40 ref.)

Management of vaginal vault prolapse [letter; comment] Constantine G. **Br J Obstet Gynaecol** 1998 Oct; 105(10):1127–8. Comment on: Br J Obstet Gynaecol 1998 Jan;105(1):13–7.

Long term follow up of hysteroscopic myomectomy assessed

by survival analysis. Hart R, et al.
Br J Obstet Gynaecol 1999 Jul;106(7):700–5

Vaginal vault suspension for prolapse after hysterectomy using an autologous fascial sling of rectus sheath [letter; comment] Jain S. **Br J Obstet Gynaecol** 1998 Dec; 105(12):1336. Comment on: Br J Obstet Gynaecol 1998 Jan;105(1):83–6.

Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer. Shepherd JH, et al.
Br J Obstet Gynaecol 1998 Aug;105(8):912–6

Skinning vulvectomy for the treatment of vulvar intraepithelial neoplasia 2–3: a study of 21 cases. Ayhan A, et al. **Eur J Gynaecol Oncol** 1998;19(5):508–10 (12 ref.)

Comparison of the modified Pereyra procedure using permanent suture material and Burch urethropexy. Jongen VH, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May; 84(1):7–11

The excision of uterine fibroids by vaginal myomectomy: a prospective study. Davies A, et al. **Fertil Steril** 1999 May; 71(5):961–4

Results of selective use of operative laparoscopy in gynecologic oncology. Jennings TS, et al.
Gynecol Oncol 1998 Sep;70(3):323–8

Second look after laparoscopic myomectomy. Dubuisson JB, et al. **Hum Reprod** 1998 Aug;13(8):2102–6

Hysteroscopic metroplasty in diethylstilboestrol–exposed and hypoplastic uterus: a report on 24 cases. Garbin O, et al. **Hum Reprod** 1998 Oct;13(10):2751–5

The Vecchietti procedure for surgical treatment of vaginal agenesis: comparison of laparoscopy and laparotomy. Borruto F, et al. **Int J Gynaecol Obstet** 1999 Feb; 64(2):153–8

Laparoscopic Burch urethropexy in a private clinical practice. Jacome EG, et al.
J Am Assoc Gynecol Laparosc 1999 Feb;6(1):39–44

Endoscopic septotomy: a new surgical approach to infantile hydrometrocolpos with imperforate hemivagina and ipsilateral renal agenesis. Amagai T, et al.
J Pediatr Surg 1999 Apr;34(4):628–31

Posterior sagittal transanorectal approach in patients with ambiguous genitalia: report of eight cases. Braz A.
Pediatr Surg Int 1999;15(2):108–10

Operative laparoscopy. Marana R, et al. **Rays** 1998 Oct–Dec; 23(4):742–8 **(Eng, Ita)**

Laparoscopic surgery of the fallopian tubes and ovaries. Dawood MY. **Semin Laparosc Surg** 1999 Jun;6(2):58–67 (50 ref.)

Laparoscopic management of ectopic pregnancy. Ghosh S, et al. **Semin Laparosc Surg** 1999 Jun;6(2):68–72 (23 ref.)

Laparoscopic colposuspension. Lawton V, et al.
Semin Laparosc Surg 1999 Jun;6(2):90–9

Laparoscopic myomectomy. Miskry T, et al.
Semin Laparosc Surg 1999 Jun;6(2):73–9 (40 ref.)

Prophylactic ureteral catheterization in gynecologic surgery. Kuno K, et al. **Urology** 1998 Dec;52(6):1004–8 (17 ref.)

[Combined gynecological operations] Atanasov B, et al.
Akush Ginekol (Sofiia) 1998;37(4):29–31 (Eng. Abstr.) **(Bul)**

[A surgical technic for cesarean section and gynecological laparotomy without suturing of the parietal and visceral peritoneum and the single–layer suturing of the uterus during the section (a review of the literature and initial experience)] Katsulov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):40–6 (25 ref.) **(Bul)**

[Electrosurgical loop procedures in ambulatory gynecology] Abrahamsson LO, et al. **Ugeskr Laeger** 1998 Sep 28; 160(40):5767–71 (40 ref.) (Eng. Abstr.) **(Dan)**

[Loop conization of cervix uteri in gynecological practice] Nellemann G, et al. **Ugeskr Laeger** 1998 Sep 28; 160(40):5783–6 (Eng. Abstr.) **(Dan)**

[Abdominal colposacroplexy for the treatment of vaginal vault prolapse with or without urinary stress incontinence] Occelli B, et al. **Ann Chir** 1999;53(5):367–77 (Eng. Abstr.) **(Fre)**

[Therapeutic posterior colpo–celiotomy. Authors' experience] Bognoni V, et al. **Minerva Ginecol** 1999 Apr; 51(4):153–5 (Eng. Abstr.) **(Ita)**

[The problems of ambulatory anesthesiology] Polushin IuS, et al. **Vestn Khir Im I I Grek** 1998;157(5):125–9 (Eng. Abstr.) **(Rus)**

[Intestinal obstruction in disseminated malignant tumors of the female genitalia: the surgical procedure and combined operations] Simonov NN, et al.
Vestn Khir Im I I Grek 1999;158(2):55–9 (Eng. Abstr.) **(Rus)**

[Raz's technics in the surgical treatment of stress urinary incontinence in women] Gutiérrez Baños JL, et al.
Actas Urol Esp 1999 May;23(5):417–23 (Eng. Abstr.) **(Spa)**

[Vaginal reconstruction in girls and young adults] Hensle TW, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):527–36 (24 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

'Listen, listen trust your own strange voice' (psychoanalytically informed conversations with a woman suffering serious illness). Jones A. **J Adv Nurs** 1999 Apr; 29(4):826–31

[Psychosocial impacts of surgical techniques] Hawighorst–Knapstein S, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:27–30 (12 ref.) **(Ger)**

[Possibilities and chances of psychological preparation for surgery: evaluation through gynecological patients] König Y. **Zentralbl Gynakol** 1999;121 Suppl 1:43–5 (Eng. Abstr.) **(Ger)**

[Anxiety and coping behavior before and after radical gynecological surgery] Schönefuss G, et al.
Zentralbl Gynakol 1999;121 Suppl 1:46–9 (Eng. Abstr.) **(Ger)**

STANDARDS

UK medicine: what are we to do? [see comments] Horton R. **Lancet** 1998 Oct 10;352(9135):1166. Comment in: Lancet 1998 Nov 14;352(9140):1626.

STATISTICS & NUMERICAL DATA

[Outpatient gynecologic surgery in public hospitals] Fernandez H. **Ann Chir** 1999;53(5):363–6 **(Fre)**

TRENDS

[The current status and developmental paths of surgical gynecology] Kira EF, et al. **Vestn Khir Im I I Grek** 1998; 157(5):49–52 (Eng. Abstr.) **(Rus)**

GYNECOLOGY

see related
GENITAL DISEASES, FEMALE
GYNECOLOGIC SURGICAL PROCEDURES
REPRODUCTIVE MEDICINE

Swedish gynecologists' and general practitioners' views on the climacteric period: knowledge, attitudes and management strategies. Andersson K, et al.
Acta Obstet Gynecol Scand 1998 Oct;77(9):909–16

Eating disorders and gynecology: knowledge and attitudes among clinicians. Morgan JF.
Acta Obstet Gynecol Scand 1999 Mar;78(3):233–9

Society for Maternal–Fetal Medicine 19th annual meeting. San Francisco, California, USA. January 18–23, 1999. Abstracts. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 2):S1–206

Summary of analysis of published articles: January 1 through December 31, 1998 [editorial] **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):511–2

The obstetrician–gynecologist's role in the practical management of polycystic ovary syndrome. Berga SL.
Am J Obstet Gynecol 1998 Dec;179(6 Pt 2):S109–S113 (28 ref.)

Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? Bonnar J. **Am J Obstet Gynecol** 1999 Apr;180(4):784–91

A controlled analysis of authorship trends over two decades. Khan KS, et al. **Am J Obstet Gynecol** 1999 Aug; 181(2):503–7

Friends in need. Presidential address. Kirk EP.
Am J Obstet Gynecol 1999 Jun;180(6 Pt 1):1450–3

Speculoscopy [letter; comment] Lonky SA.
Am J Obstet Gynecol 1999 Mar;180(3 Pt 1):772–3. Comment on: Am J Obstet Gynecol 1998 Aug;179(2):544–56.

Images, imagination and ideas: a perspective on the impact of ultrasonography on the practice of obstetrics and gynecology. Presidential address. Wade RV.
Am J Obstet Gynecol 1999 Aug;181(2):235–9

Ovarian cancer should be treated by specialist teams [news] Wise J. **BMJ** 1999 Jul 10;319(7202):77

Clinical audit of the process of referral to genitourinary medicine of patients found to be chlamydia positive in a family planning service. Tobin JM, et al.
Br J Fam Plann 1999 Jan;24(4):160–3

Gynecologists' perspectives regarding ovarian cancer. Fitch MI, et al. **Cancer Prev Control** 1999 Feb;3(1):68–76

Primary care for women: the role of the obstetrician–gynecologist. Brown CV.
Clin Obstet Gynecol 1999 Jun;42(2):306–13 (20 ref.)

Cystourethroscopy for the practicing gynecologist. Weinberger MW. **Clin Obstet Gynecol** 1998 Sep; 41(3):764–76 (20 ref.)

Do physicians assess lifestyle health risks during general medical examinations? A survey of general practitioners and obstetrician–gynecologists in Quebec [see comments] Maheux B, et al. **CMAJ** 1999 Jun 29;160(13):1830–4. Comment in: CMAJ 1999 Jun 29;160(13):1849–50.

Are HIV lookbacks worthwhile? Outcome of an exercise to notify patients treated by an HIV infected health care worker. Incident Management Teams [see comments] Donnelly M, et al. **Commun Dis Public Health** 1999 Jun; 2(2):126–9. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.

Bibliography. Current world literature. Gynecologic oncology and pathology. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):87–112

Adult and pediatric gynecology.
Curr Opin Obstet Gynecol 1998 Oct;10(5):411–29

Urogynecology. **Curr Opin Obstet Gynecol** 1998 Oct; 10(5):429–33

Practice implications [editorial; comment] Gambone JC.
Curr Opin Obstet Gynecol 1999 Feb;11(1):81. Comment on: Curr Opin Obstet Gynecol 1999 Feb;11(1):83–5.

Expectations about alternative therapies and women with gynecological cancer. Granai CO.
Curr Opin Obstet Gynecol 1999 Feb;11(1):3–10 (89 ref.)

Alternative care medicine: a time to learn [editorial] Grendys EC Jr. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):1–2

Ultrasound evaluation of pelvic masses: predictors of malignancy for the general gynecologist. van Nagell JR Jr, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):45–9 (24 ref.)

Depressive symptoms are often unrecognized in gynaecological practice. Buekens P, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Oct;81(1):43–5

"A fine conception—the experience of the Human Fertilisation and Embryology Authority (HFEA)". Speech to the 13th Congress of the European Association of Gynaecologists and Obstetricians (EAGO), Jerusalem, 11 May 1998. Deech R.
Eur J Obstet Gynecol Reprod Biol 1999 Jul;85(1):3–5

Thoughts on the patient–doctor relationship in obstetrics and gynecology. Ludwig H.
Eur J Obstet Gynecol Reprod Biol 1999 Jul;85(1):85–91 (59 ref.)

Criteria for selective screening of cervical Chlamydia trachomatis infection in women attending private gynecology practices. Warszawski J, et al.
Eur J Obstet Gynecol Reprod Biol 1999 Sep;86(1):5–10

Perceptions of cisplatin–related toxicity among ovarian cancer patients and gynecologic oncologists. Calhoun EA, et al. **Gynecol Oncol** 1998 Dec;71(3):369–75

ACOG committee opinion. Hepatitis virus infections in obstetrician–gynecologists. Number 199, February 1998. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1998 Jul;62(1):91–2

ACOG committee opinion. Hepatitis virus infections in obstetrician–gynecologists. Number 203, July 1998 (replaces No. 199, February 1998). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov; 63(2):203–4

ACOG committee opinion. Ethical issues related to expert testimony by obstetricians and gynecologists. Number 217, April 1999 (replaces number 56, October 1987). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):321–2 (3 ref.)

Global climate warming and performance of therapeutic agents in obstetrics and gynecology. Arya SC.
Int J Gynaecol Obstet 1999 May;65(2):209–10

The role of gynaecologists in women's health care—women's views. Hemminki E, et al. **Int J Qual Health Care** 1998 Feb;10(1):59–64

Presidential address: A field of dreams. Levine RL.
J Am Assoc Gynecol Laparosc 1999 Feb;6(1):1–4

Informed consent and the redefining of conception: a decision ill–conceived? Spinnato JA. **J Matern Fetal Med** 1998 Nov–Dec;7(6):264–8

The necessity for a progressing dialog between basic science and clinical research in obstetrics and gynecology. Graeff H. **J Obstet Gynaecol Res** 1998 Dec;24(6):427–32

North American Society for Pediatric and Adolescent Gynecology 12th annual meeting. Palm Beach, Florida, USA. May 28–31, 1998. Abstracts.
J Pediatr Adolesc Gynecol 1998 Nov;11(4):201–10

Yes, male physicians should care for adolescent females. Hewitt G, et al. **J Pediatr Adolesc Gynecol** 1999 May; 12(2):100–2 (9 ref.)

Adolescent communication. Nicoletti A.
J Pediatr Adolesc Gynecol 1999 May;12(2):105

Comparing women's views on family and sexual problems in family and gynecological practices. Himmel W, et al.
J Psychosom Obstet Gynaecol 1999 Sep;20(3):127–35

Communication during gynecological out–patient encounters. van Dulmen AM.
J Psychosom Obstet Gynaecol 1999 Sep;20(3):119–26

Society for Gynecologic Investigation 46th annual meeting. Atlanta, Georgia, USA. March 10–13, 1999. Abstracts.
J Soc Gynecol Investig 1999 Jan–Feb;6(1 Suppl):45A–231A

LiteratureWatch. **J Womens Health** 1998 Sep;7(7):925–32

LiteratureWatch. **J Womens Health** 1998 Oct;7(8):1058–65

Prescription attitudes among gynecologists towards two particular risk factors of osteoporosis: the patient's age and her bone mineral density. Rozenberg S, et al. **Maturitas** 1999 May 31;32(1):19–24

Attitudes of obstetricians and gynecologists toward hormone replacement therapy. Baron J, et al. **Med Decis Making** 1998 Oct–Dec;18(4):406–11

A survey of gynecologists' attitudes regarding decision making in the management of non–cancerous conditions that frequently result in hysterectomy. Dolan JG, et al. **Med Decis Making** 1999 Apr–Jun;19(2):186–92

RACOG and CME. Royal Australian College of Obstetricians and Gynaecologists [letter; comment] Hyslop RS. **Med J Aust** 1999 May 17;170(10):507. Comment on: Med J Aust 1999 Feb 1;170(3):121–4.

Obstetrician–gynecologists as primary care providers? How North Carolina HMOs decide [see comments] Guise JM, et al. **N C Med J** 1999 Jul–Aug;60(4):208–10. Comment in: N C Med J 1999 Jul–Aug;60(4):211.

Female urology/urogynecology [editorial] Blaivas JG.
Neurourol Urodyn 1999;18(3):161–2

American College of Obstetricians and Gynecologists (ACOG) 47th annual clinical meeting. Philadelphia, Pennsylvania, USA. May 15–19, 1999. Abstracts.
Obstet Gynecol 1999 Apr;93(4 Suppl):1S–105S

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

GYNECOLOGY

Domestic violence screening practices of obstetrician-gynecologists. Horan DL, et al. **Obstet Gynecol** 1998 Nov;92(5):785-9

Logistic regression models in obstetrics and gynecology literature. Khan KS, et al. **Obstet Gynecol** 1999 Jun; 93(6):1014-20 (21 ref.)

Ethical challenges in the managed practice of obstetrics and gynecology. McCullough LB, et al. **Obstet Gynecol** 1999 Feb;93(2):304-7

Knowledge and clinical practice regarding calcium nutrition among obstetrician-gynecologists. Power ML, et al. **Obstet Gynecol** 1999 Sep;94(3):421-6

Partner notification of sexually transmitted disease in an obstetric and gynecologic setting. Seubert DE, et al. **Obstet Gynecol** 1999 Sep;94(3):399-402

Obstetrics and gynecology: a unique surgical specialty. Youngblood JP. **Obstet Gynecol** 1999 Jan;93(1):1-4

Chronic gynaecological pain: an exploration of medical attitudes. Selfe SA, et al. **Pain** 1998 Aug;77(2):215-25

Loyalty conflicts in medical practice. A comparative study of general practitioners', paediatricians' and gynaecologists' assessments of three cases. Lynöe N, et al. **Scand J Prim Health Care** 1998 Sep;16(3):135-40

[New therapeutic possibilities for infertile couples, when the men suffer of azoospermia. The Danish Society of Obstetrics and Gynecology] Westh H, et al. **Ugeskr Laeger** 1999 Mar 15;161(11):1616 **(Dan)**

[Ethical recommendations 1998. Committee of the International Federation of Gynecology and Obstetrics (FIGO) on the Ethical Aspects of Human Reproduction and Women's Health] **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jun;28(3):278-82 **(Fre)**

[Analysis of medical catalog terms using the MAOUSSC model: application to Gyncecology-Obstetrics] Levêque J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Nov; 27(7):676-82 (Eng. Abstr.) **(Fre)**

[The role of the medical corps in a mass screening program for cervical cancer. The program "Female Health Action in 3 urban districts of Lyons] Mignotte H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):501-7 (Eng. Abstr.) **(Fre)**

[Pharmacoeconomics of menopause treatments: epidemiological data and hormonal and non-hormonal prescription attitude of Belgian gynecologists] Rozenberg S, et al. **Rev Med Brux** 1998 Sep;19(4):A195-8 (Eng. Abstr.) **(Fre)**

[52nd Congress of The German Society for Gynecology and Obstetrics. Nürnberg, 8-12 September 1998. Abstract] **Arch Gynecol Obstet** 1998;261 Suppl 1:S1-193, V-XII **(Ger)**

[XVI Academic meeting of German-speaking university teachers of gynecology and obstetrics. Monastery Seeon, April 29-May 1, 1999. Abstracts] **Gynakol Geburtshilfliche Rundsch** 1999;39(1):5-51 **(Ger)**

[Joint meeting of the Bavarian Society of Obstetrics and Gynaecology and the Austrian Society of Gynaecology and Obstetrics, Munich, Germany, June 2-5, 1999. Abstracts] **Gynakol Geburtshilfliche Rundsch** 1999; 39(2):57-105 **(Ger)**

[72nd Meeting of the Bavarian Society of Obstetrics and Gynecology. Bad Reichenhall, 21-23 May 1998] Bauerfeind I. **Gynakol Geburtshilfliche Rundsch** 1998; 38(3):166-8 **(Ger)**

[3rd Conference of the European Society of Infectious Diseases in Obstetrics and Gynecology (ESIDOG). Vienna, 2-4 May 1997] Hohlagschwandtner M, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):169-70 **(Ger)**

[Past and present of mycology in German gynecology and obstetrics] Mendling W. **Mycoses** 1998;41 Suppl 2:26-30 (23 ref.) (Eng. Abstr.) **(Ger)**

The so-called 'Science Citation Index' — miscellaneous, rankings for 1995 (E. Saling and A. Uphoff) and the Zeitschrift f"ur Geburtshilfe und Neonatologie (ZGN) (editorial) Holzgreve W. **Z Geburtshilfe Neonatol** 1999 Mar-Apr;203(2):51-4 **(Ger)**

[The importance of gender in the gynecologist-patient relationship] Szeverényi P, et al. **Orv Hetil** 1998 Oct 25; 139(43):2581-5 (Eng. Abstr.) **(Hun)**

[Comparison of family physicians' and gynecologists' use of the intrauterine device (IUD)] Menendez Villalva C, et al. **Aten Primaria** 1998 Dec;22(10):622-6 (Eng. Abstr.) **(Spa)**

[8th National Congress of Gynecology and Obstetrics 26-30 October 1998. Conference on "Philosophy, Bioethics and the Gynecologist"] Sereno Colón JA. **Ginecol Obstet Mex** 1999 May;67:193-5 **(Spa)**

ECONOMICS

Increased medical indemnities in Ireland [letter] McKenna PJ, et al. **Lancet** 1999 Aug 21;354(9179):685

Cost-effectiveness analysis: an introductory guide for clinicians. Macones GA, et al. **Obstet Gynecol Surv** 1999 Oct;54(10):663-72

EDUCATION

Performances of women and men in ob-gyn clerkships [letter; comment] Dubik M. **Acad Med** 1998 Nov;73(11):1125. Comment on: Acad Med 1998 Jan;73(1):101-2.

ACOG/AAFP guidelines for obstetrics and gynecology [letter; comment] Steiner E. **Am Fam Physician** 1999 Feb 15;59(4):774, 779, 784. Comment on: Am Fam Physician 1998 Jul;58(1):275-7.

Restructuring residency training in obstetrics and gynecology. Bissonnette JM, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):516-8 (8 ref.)

Response of obstetrics and gynecology program directors to a domestic violence lecture module. Chez RA, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):496-8

Teaching the pelvic organ prolapse quantitation system. Steele A, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1458-63; discussion 1463-4

Assessing the knowledge of future internists and gynecologists in caring for a woman with tetraplegia. Oshima S, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1270-6

Pressures of acute obstetrics on consultants. Reply from Royal College of Obstetricians and Gynaecologists [letter] Shaw RW. **BMJ** 1999 Jul 24;319(7204):256

IUD training in non specialist centres [letter] [see comments] Hosegood J. **Br J Fam Plann** 1998 Oct;24(3):113. Comment in: Br J Fam Plann 1999 Apr;25(1):29.

Continuing medical education: an opportunity for bringing about change in clinical practice. Burr R, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):940-5

Urology: an unfairly neglected discipline of medical training [letter] Driver KL. **CMAJ** 1999 Apr 6;160(7):986-7

Specialist registrar training in obstetrics and gynaecology: have we got it wrong? Wright CS. **Hosp Med** 1999 Apr; 60(4):291-3

Obstetrics and gynaecology in the Asia and Oceania region: requirements for postgraduate training and certification. Zaidi S. **J Obstet Gynaecol Res** 1999 Apr;25(2):71-85 (22 ref.)

Learning: women's health [editorial] Haseltine FP. **J Womens Health** 1998 Oct;7(8):935

Innovations in teaching obstetrics and gynaecology--the Theme Afternoon. Kevelighan EH, et al. **Med Educ** 1998 Sep;32(5):517-21

Development and use of military-unique standardized gynecology patients in military undergraduate medical education. Hines JF, et al. **Mil Med** 1999 Apr;164(4):280-2

Development and use of military-unique standardized gynecology patients for military residents in obstetrics and gynecology training programs. Zedek IJ, et al. **Mil Med** 1998 Nov;163(11):767-9

Motivation and reward factors that affect private physician involvement in an obstetrics and gynecology clerkship. Dodson MC. **Obstet Gynecol** 1998 Oct;92(4 Pt 1):628-33

Quantifying faculty teaching time in a department of obstetrics and gynecology. Emmons S. **Obstet Gynecol** 1998 Oct;92(4 Pt 1):633-8

Assessing clinical competence of medical students in women's health care: use of the objective structured clinical examination. Gilson GJ, et al. **Obstet Gynecol** 1998 Dec; 92(6):1038-43

Teaching critical appraisal to medical students in obstetrics and gynecology. Grimes DA, et al. **Obstet Gynecol** 1998 Nov;92(5):877-82

Effect of residency program merger on undergraduate medical student education in obstetrics and gynecology. Hines JF, et al. **Obstet Gynecol** 1999 Jul;94(1):144-7

Applications for residency programs in obstetrics and gynecology, 1996-1997. Jolly P, et al. **Obstet Gynecol** 1998 Nov;92(5):873-7

Cystic fibrosis and the National Institutes of Health consensus statement: are obstetrician-gynecologists ready to comply? Kuller JA, et al. **Obstet Gynecol** 1999 Apr;93(4):581-4

Oocyte donors as gynecologic teaching associates. Legro RS, et al. **Obstet Gynecol** 1999 Jan;93(1):147-50

A 5-year residency curriculum in obstetrics, gynecology, and family medicine. Mann WJ Jr, et al. **Obstet Gynecol** 1999 Aug;94(2):317-20

Development of a national course on research methodology for Canadian residents in obstetrics and gynecology. Reid RL, et al. **Obstet Gynecol** 1999 Feb;93(2):308-11

A survey of military residencies regarding 4th-year medical school clerkships. Satin AJ, et al. **Obstet Gynecol** 1999 Apr; 93(4):618-21

Practice management in obstetrics and gynecology residency curriculum. Williford LE, et al. **Obstet Gynecol** 1999 Sep; 94(3):476-9

The impact of the Lagos manual vacuum aspiration (MVA) training courses on medical education. Ogedengbe OK, et al. **West Afr J Med** 1998 Jul-Sep;17(3):210-2

[Teaching resources of a hospital Gynecology-Obstetrics service. Review of the literature and practical applications] Levêque J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May;28(2):171-8 (Eng. Abstr.) **(Fre)**

[Qualified continuing education according to the recommendations of DGAI and OGARI. Anesthesia in gynecology and obstetrics] Gogarten W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 May; 34(5):297-314 **(Ger)**

[Our university clinics need research--so does our specialty! (editorial)] Haller U, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):117-8 (Eng. Abstr.) **(Ger)**

[Tissue fragment diagnosis in gynecopathology] Löning T. **Pathologe** 1999 Jan;20(1):6-8 (Eng. Abstr.) **(Ger)**

[SUSILAP-G: a surgical simulator for training minimal invasive interventions in gynecology] Radetzky A, et al. **Zentralbl Gynakol** 1999;121(2):110-6 (Eng. Abstr.) **(Ger)**

[Recruitment and specialists' training in obstetrics and gynecology] Falck C, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):674-7 (Eng. Abstr.) **(Nor)**

[Retention of knowledge. III--Gynecology program] Bastos AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Mar-Apr;53(2):100-3 (Eng. Abstr.) **(Por)**

[A course in gynecology makes the gender perspective more obvious] Hultcrantz E, et al. **Lakartidningen** 1999 Feb 17; 96(7):753-6 **(Swe)**

HISTORY

Max Brödel (1870-1941) and Howard A. Kelly (1858-1943)--urogynecology and the birth of modern medical illustration. Schultheiss D, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):113-5

History of gynecological pathology. V. Dr. Walter Schiller. Gruhn JG, et al. **Int J Gynecol Pathol** 1998 Oct;17(4):380-6

Presentation of the 1998 Ian Donald Gold Medal to Sturla Eik-Nes. Maršál K. **Ultrasound Obstet Gynecol** 1999 Apr; 13(4):291-2

[The welcoming address on the occasion of the 50th anniversary of the Scientific Society of Obstetrics and Gynecology] Karag'ozov I. **Akush Ginekol (Sofiia)** 1998; 37(1):1-3 **(Bul)**

[40 years' since the founding of the Gynecologic Endocrinology Group in Prague-Podoli] Henzl MR. **Ceska Gynekol** 1998 Aug;63(4):346-8 **(Cze)**

[Some aspects of the life work of Ludwig Fraenkel (1870-1951) with special reference to his social gynecology and sexology studies] Hommel A, et al. **Zentralbl Gynakol** 1998;120(10):475-80 (Eng. Abstr.) **(Ger)**

[Hunting for "womanhood"] Forsmo S. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4753-7 **(Nor)**

[Obituary to Prof. Witold Michałkiewicz] Słomko Z. **Ginekol Pol** 1998 Nov;69(11):779-82 **(Pol)**

[Obituary to Professor, medical doctor Ireneusz Roszkowki] Troszyński M, et al. **Ginekol Pol** 1997 Sep;68(9):397-401 **(Pol)**

[History of gynecology and perinatology in Croatia. Midwifery. Clinics and hospitals in Zagreb] Dražančić A. **Lijec Vjesn** 1999 Mar;121(3):100-8 (Eng. Abstr.) **(Scr)**

[History of gynecology and perinatology in Croatia. Clinics and hospitals in Zagreb. Primary health care. Specialty societies of the Croatian Medical Association] Dražančic A. **Lijec Vjesn** 1999 Apr-May;121(4-5):154-61 (Eng. Abstr.) **(Scr)**

[Menstruation still full of myths] Bergqvist A. **Lakartidningen** 1999 Apr 14;96(15):1860-7 (28 ref.) **(Swe)**

INSTRUMENTATION

[SPIC: a training simulator for coelioscopic interventions with gynecologic purpose] Jambon AC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):536-43 (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

ACOG committee opinion. Institutional responsibility to provide legal representation. Number 204, July 1998. Committee on ethics. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov; 63(2):205

Medicolegal activity in obstetrical and gynaecological ultrasound. Woodrow NL, et al. **Med J Aust** 1999 Aug 2;171(3):147-50

Overview of the 1996 Professional Liability Survey [editorial] Griffin LP, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):77-80

[The report 'Late termination of pregnancy: caution and assessment' by the consultant group Late Termination of Pregnancy. Consultant Group Late Termination of Pregnancy (comment)] Wladimiroff JW, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2627-9 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Feb 13;143(7):381-2. **(Dut)**

MANPOWER

Changes and challenges for women in academic obstetrics and gynecology. Seltzer VL. **Am J Obstet Gynecol** 1999 Apr;180(4):837-48

Does the surgeon matter in the management of ovarian cancer? [editorial] Chan KK. **Br J Cancer** 1999 Jul; 80(10):1492-3

The 1999 residency match: finally, some good news for anesthesia. Sullivan P. **CMAJ** 1999 Apr 20;160(8):1200

METHODS

Gynecological health care for adolescents with developmental disabilities. Quint EH. **Adolesc Med** 1999 Jun;10(2):221-9, vi (35 ref.)

Sexual health risk assessment and counseling in primary care: how involved are general practitioners and obstetrician-gynecologists? [see comments] Haley N, et al. **Am J Public Health** 1999 Jun;89(6):899-902. Comment in: Am J Public Health 1999 Jun;89(6):815-8.

Initial assessment: the history in women with pelvic floor problems. Brubaker L. **Clin Obstet Gynecol** 1998 Sep; 41(3):657-62 (0 ref.)

How do UK gynaecologists manage endometrial carcinoma? A national survey. Rogerson L, et al. **Eur J Gynaecol Oncol** 1998;19(4):331–2

HPV typing and testing in gynaecological pathology: has the time come? [comment] Meijer CJ, et al. **Histopathology** 1998 Jul;33(1):83–6. Comment on: Histopathology 1997 Oct;31(4):301–3.

Pediatric and adolescent gynecology for the primary care pediatrician. Craighill MC. **Pediatr Clin North Am** 1998 Dec;45(6):1659–88 (28 ref.)

[The current potentials for optimal whole-blood transfusion and component therapy with blood products—erythrocytes in obstetrics and gynecology—the indications, means and methods] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998; 37(4):46–9 (25 ref.) **(Bul)**

[The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology] Nikolov A, et al. **Akush Ginekol (Sofiia)** 1998;37(4):50–2 (25 ref.) **(Bul)**

[Complications of laparoscopy in gynecology] Abboud J, et al. **Contracept Fertil Sex** 1999 May;27(5):383–7 (41 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

[Gynecologic oncologists and their practice in the U.S.A.] Tsukamoto N. **Gan To Kagaku Ryoho** 1999 Jan;26(1):69–75 (13 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Effective gynaecological practice and evidence-based medicine [editorial] Maresh MJ, et al. **Hosp Med** 1999 Apr; 60(4):236–7

ACOG practice bulletin. Premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Number 1, June 1998. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Oct;63(1):75–84 (70 ref.)

ACOG committee opinion. Delineation of obstetric-gynecologic primary care practice. Number 218, June 1999. Committee on Primary Care. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Aug;66(2):195

ACOG criteria set. Quality evaluation and improvement in practice. Cone biopsy of cervix. Number 32, April 1998. Committee on Quality Assessment. American College of Obstetricians and Gynecologists [corrected and republished article originally printed in Int J Gynaecol Obstet 1998 Aug;62(2):202–3] **Int J Gynaecol Obstet** 1998 Nov; 63(2):228–9

The adequacy of Papanicolaou smears as performed by family physicians and obstetrician-gynecologists. Fiscella K, et al. **J Fam Pract** 1999 Apr;48(4):294–8

Chaperone use by obstetrician/gynecologists. Johnson NR, et al. **J Reprod Med** 1999 May;44(5):423–7

UK medicine: what are we to do? [see comments] Horton R. **Lancet** 1998 Oct 10;352(9135):1166. Comment in: Lancet 1998 Nov 14;352(9140):1626.

Informed consent, patient choice, and physician responsibility [editorial] Cruikshank DP. **Obstet Gynecol** 1999 Jul; 94(1):142–3

A blueprint for academic obstetrics and gynecology. Gabbe SG, et al. **Obstet Gynecol** 1998 Dec;92(6):1033–7

Medical and osteopathic boards' positions on chaperones during gynecologic examinations. Stagno SJ, et al. **Obstet Gynecol** 1999 Sep;94(3):352–4

[No consensus on the definition, diagnosis and treatment of habitual abortion in the Netherlands] Goddijn M, et al. **Ned Tijdschr Geneeskd** 1999 Apr 24;143(17):897–902 (Eng. Abstr.) **(Dut)**

[Possible future of the project for quality assurance of indications and outcome in interventional cardiology and gynecology] Schilling J, et al. **Schweiz Med Wochenschr** 1999 Jun 5;129(22):841–6 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Estrogen replacement therapy in patients with endometrial cancer: a survey of prescription intention of Belgian gynecologists [letter] Rozenberg S, et al. **CA Cancer J Clin** 1999 May-Jun;49(3):190–2

Internet: personal use by obstetric and gynecological sonologists [editorial] Degani S. **Ultrasound Obstet Gynecol** 1998 Dec;12(6):375–6

TRENDS

Healing persons and therapeutic institutions. Bulger RJ. **Am J Obstet Gynecol** 1999 Apr;180(4):875–82

Time to discard the cookie cutter [comment] Droegemueller W. **Am J Obstet Gynecol** 1999 Apr;180(4):889–95. Comment on: Am J Obstet Gynecol 1998 Apr;178(4):635–40.

Managed care in obstetrics and gynecology: can our specialty survive? Harrison FN Jr. **Am J Obstet Gynecol** 1999 Aug; 181(2):328–31

Adjusting to the present: presidential address. Herbst AL. **Am J Obstet Gynecol** 1999 Apr;180(4):779–83

Premenstrual syndromes: closing the 20th century chapters. Halbreich U. **Curr Opin Obstet Gynecol** 1999 Jun; 11(3):265–70 (121 ref.)

On the future of the speciality of Obstetrics and Gynecology. A Dutch view [editorial] Bleker OP, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):125–8

Gender-specific medicine: the new profile of gynecology. Gruber DM, et al. **Gynecol Endocrinol** 1999 Feb;13(1):1–6 (36 ref.)

Gynecologic oncology-on the eve of the new millennium. Podratz KC. **Gynecol Oncol** 1999 Aug;74(2):157–62

The future of gene therapy in obstetrics and gynaecology [editorial] O'Brien PM. **Hosp Med** 1998 Oct;59(10):754–5

Obstetrics and gynecology. Stovall TG. **J Am Coll Surg** 1999 Feb;188(2):136–9 (25 ref.)

[Developments in surgical gynecology] Dapunt O. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):180–7 (Eng. Abstr.) **(Ger)**

[Individual therapy in gynecology is requested!—does evidence based medicine help?] Haller U. **Schweiz Med Wochenschr** 1999 Jan 12;129(1–2):41–5 **(Ger)**

[The millenium switch on 01 January 2000—a foreseeable crash for gynecologic and obstetrical software applications?] Merten R, et al. **Zentralbl Gynakol** 1998; 120(10):521–3 (Eng. Abstr.) **(Ger)**

[Electrotherapy in modern gynecology abroad] Strugatskii VM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar-Apr;(2):46–7 (25 ref.) **(Rus)**

GYNECOMASTIA

[Gynecomastia in men] Bullmann C, et al. **Fortschr Med** 1998 Dec 20;116(35–36):18–22 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Prolactogenic effects of risperidone in male patients—a preliminary study. Shiwach RS, et al. **Acta Psychiatr Scand** 1998 Jul;98(1):81–3

Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease [letter] Schürmann D, et al. **AIDS** 1998 Nov 12;12(16):2232–3

Gynecomastia with stavudine treatment in an HIV-positive patient [letter] Melbourne KM, et al. **Ann Pharmacother** 1998 Oct;32(10):1108

Gynecomastia associated with indinavir therapy. Caeiro JP, et al. **Clin Infect Dis** 1998 Dec;27(6):1539–40

Ga-67 uptake by the male breast under digitalis influence. Kumar M, et al. **Clin Nucl Med** 1998 Nov;23(11):779

Gynaecomastia associated with saquinavir therapy. Donovan B, et al. **Int J STD AIDS** 1999 Jan;10(1):49–50

Gynaecomastia in association with phenytoin and zonisamide in a patient having a CYP2C subfamily mutation [letter] Ikeda A, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov; 65(5):803–4

Gynecomastia with risperidone-fluoxetine combination. Benazzi F. **Pharmacopsychiatry** 1999 Jan;32(1):41

Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. Miller JA, et al. **South Med J** 1999 Jun;92(6):615–7

[Gynecomastia due to pravastatin (letter; comment)] Aerts J, et al. **Presse Med** 1999 Apr 17;28(15):787. Comment on: Presse Med 1994 Sep;23(28):1304–10. **(Fre)**

COMPLICATIONS

Prostatic adenocarcinoma with cutaneous metastases overlying oestrogen-induced gynaecomastia. Marcoval J, et al. **Clin Exp Dermatol** 1998 May;23(3):119–20

DIAGNOSIS

Hyperthyroidism with gynaecomastia as the initial complaint: a case report. Ho HK, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):594–6 (12 ref.)

ECONOMICS

Cost-effective management of gynecomastia. Bowers SP, et al. **Am J Surg** 1998 Dec;176(6):638–41

ENZYMOLOGY

Expression of pepsinogen C in gynecomastias and male breast carcinomas. Serra Díaz C, et al. **World J Surg** 1999 May; 23(5):439–45

ETIOLOGY

Cultural gynaecomastia [letter] Qureshi B. **Lancet** 1997 Oct 11;350(9084):1108

Gynaecomastia and raised oestradiol concentrations. Vierhapper H, et al. **Lancet** 1999 Feb 20;353(9153):640

Hormonal profile of patients with Leydig cell tumors: a urologic cause of gynecomastia. Xciarra A, et al. **Minerva Urol Nefrol** 1998 Dec;50(4):225–31 (108 ref.)

[Gynecomastia in childhood. Pathological causes unusual but serious] Kauf E. **Fortschr Med** 1998 Dec 20; 116(35–36):23–6 (Eng. Abstr.) **(Ger)**

[Gynecomastia in a male and ginseng (letter)] Palop V, et al. **Med Clin (Barc)** 1999 May 29;112(19):758 **(Spa)**

GENETICS

High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Csokay B, et al. **Cancer Res** 1999 Mar 1;59(5):995–8

[29-year-old patient with gynecomastia and small testis] Brand S, et al. **Internist (Berl)** 1999 Apr;40(4):437–41 **(Ger)**

HISTORY

Endocrinology and art. Martino E. **J Endocrinol Invest** 1999 Apr;22(4):317

PATHOLOGY

Fine needle aspiration cytology in the management of male breast masses. Nineteen years of experience [see comments] Joshi A, et al. **Acta Cytol** 1999 May-Jun;43(3):334–8. Comment in: Acta Cytol 1999 May-Jun;43(3):333.

Apocrine cells in a fine needle aspirate of gynecomastia. A case report. Pacchioni D, et al. **Acta Cytol** 1997 Jul-Aug; 41(4 Suppl):1329–31

RADIONUCLIDE IMAGING

Tc-99m sestamibi uptake in a patient with gynecomastia: a potential pitfall in the diagnosis of breast cancer. Gellett LR, et al. **Clin Nucl Med** 1999 Jun;24(6):466

[99mTc(V)-DMSA accumulation in gynecomastia] Ohta H. **Kaku Igaku** 1998 Nov;35(9):877–9 (Eng. Abstr.) **(Jpn)**

SURGERY

Indications for and results of surgical therapy for male gynecomastia. Colombo-Benkmann M, et al. **Am J Surg** 1999 Jul;178(1):60–3

The role of lipoaspiration in defeminization of Klinefelter syndrome: a case report. Berenguer B, et al. **Ann Plast Surg** 1999 Sep;43(3):306–8

Re: Eccentric skin resection and purse-string closure for skin reduction with mastectomy for gynecomastia [letter; comment] Botta SA. **Ann Plast Surg** 1999 May;42(5):571–2 . Comment on: Ann Plast Surg 1998 Oct;41(4):378–83.

The pinwheel technique: an adjunct to the periareolar approach in gynecomastia resection. Chiu DT, et al. **Ann Plast Surg** 1999 May;42(5):465–9

Correction of areolar depression in postsurgically treated gynecomastic patients. Hall WW, et al. **Ann Plast Surg** 1999 Apr;42(4):452–4

Re: Pursestring and skin excision in gynecomastia [letter; comment] Peled IJ. **Ann Plast Surg** 1999 Mar;42(3):343. Comment on: Ann Plast Surg 1998 Oct;41(4):378–83.

Eccentric skin resection and purse-string closure for skin reduction with mastectomy for gynecomastia [see comments] Smoot EC 3rd. **Ann Plast Surg** 1998 Oct; 41(4):378–83. Comment in: Ann Plast Surg 1999 Mar;42(3):343. Comment in: Ann Plast Surg 1999 May;42(5):571–2.

Gynaecomastia: have Webster's lessons been ignored? [letter; comment] Rexon CK. **J R Coll Surg Edinb** 1998 Dec; 43(6):430. Comment on: J R Coll Surg Edinb 1998 Apr;43(2):89–92.

[Gynecomastia. Management of diagnosis and therapy. Apropos of 52 cases] Vasseur C, et al. **Ann Chir** 1998; 52(2):146–57 (Eng. Abstr.) **(Fre)**

[Surgical therapy of gynecomastia and its results] Colombo-Benkmann M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1282–4 (Eng. Abstr.) **(Ger)**

THERAPY

Melatonin and painful gynecomastia. De Bleecker JL, et al. **Neurology** 1999 Jul 22;53(2):435–6

VETERINARY

Mammary gland uptake of sodium Tc-pertechnetate in a cat with a drug-induced gynecomastia. Patricelli AJ, et al. **Vet Radiol Ultrasound** 1999 Jan-Feb;40(1):87–8

GYPSIES

Colorectal cancer and the Muir-Torre syndrome in a Gypsy family: a review. Lynch HT, et al. **Am J Gastroenterol** 1999 Mar;94(3):575–80

Hereditary auditory, vestibular, motor, and sensory neuropathy in a Slovenian Roma (Gypsy) kindred. Butinar D, et al. **Ann Neurol** 1999 Jul;46(1):36–44

Severe limb girdle muscular dystrophy in Spanish gypsies: further evidence for a founder mutation in the gamma-sarcoglycan gene. Lasa A, et al. **Eur J Hum Genet** 1998 Jul-Aug;6(4):396–9

Influence of family tradition on reproductive behavior of Gypsy population. Semerdjieva M, et al. **Folia Med (Plovdiv)** 1999;41(1):116–20

Sexual culture of gypsy population. Semerdjieva M, et al. **Folia Med (Plovdiv)** 1998;40(3B Suppl 3):72–5

[Contraception: gypsy versus non-gypsy women] Reig Majoral S, et al. **Aten Primaria** 1999 Feb 15;23(2):63–7 (Eng. Abstr.) **(Spa)**

GENETICS

Identification of the 185delAG BRCA1 mutation in a Spanish Gypsy population. Diez O, et al. **Hum Genet** 1998 Dec; 103(6):707–8

C283Y mutation and other C-terminal nucleotide changes in the gamma-sarcoglycan gene in the Bulgarian Gypsy population. Todorova A, et al. **Hum Mutat** 1999;14(1):40–4

High frequency of the CCR5 deletion allele in Gypsies living in Hungary. Szalai C, et al. **Immunol Lett** 1998 Aug; 63(1):57–8

Population genetic data on four STR loci in a Hungarian

GYPSIES

Romany population. Füredi S, et al. **Int J Legal Med** 1999; 112(1):72–4

A linkage study of affective disorders in two Bulgarian Gypsy families: results for candidate regions on chromosomes 18 and 21. Kaneva R, et al. **Psychiatr Genet** 1998 Winter;8(4):245–9

STATISTICS & NUMERICAL DATA

Prevalence of multiple sclerosis in Gypsies and Bulgarians. Milanov I, et al. **Neuroepidemiology** 1999;18(4):218–22

GYPSUM see **CALCIUM SULFATE**

GYRATE ATROPHY

BLOOD

Hyperornithinaemia associated with gyrate atrophy of the choroid and retina: two cases from India. Christopher R, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):519–22

ENZYMOLOGY

Gyrate atrophy of the choroid and retina: lymphocyte ornithine-delta-aminotransferase activity in different mutations and carriers. Heinänen K, et al. **Pediatr Res** 1998 Sep;44(3):381–5

METABOLISM

Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia--clues to pathogenesis. Heinänen K, et al. **Eur J Clin Invest** 1999 May;29(5):426–31

PHYSIOPATHOLOGY

Colour vision in gyrate atrophy. Mäntyjärvi M, et al. **Vision Res** 1998 Nov;38(21):3409–12

GYRECTOMY see **PSYCHOSURGERY**

GYRUS CINGULI

ABNORMALITIES

Clinical-neuroendocrinological syndromes due to lesions of the cingulate gyrus in humans. Buklina SB. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):601–7

ANATOMY & HISTOLOGY

Subgenual cingulate cortex volume in first-episode psychosis. Hirayasu Y, et al. **Am J Psychiatry** 1999 Jul;156(7):1091–3

Organization of projections of rat retrosplenial cortex to the anterior thalamic nuclei. Shibata H. **Eur J Neurosci** 1998 Oct;10(10):3210–9

Hemispheric differences in variability of fissural patterns in parasylvian and cingulate regions of human brains. Ide A, et al. **J Comp Neurol** 1999 Jul 26;410(2):235–42

Fiber system linking the mid-dorsolateral frontal cortex with the retrosplenial/presubicular region in the rhesus monkey. Morris R, et al. **J Comp Neurol** 1999 May 3;407(2):183–92

CYTOLOGY

Associational projections of the anterior midline cortex in the rat: intracingulate and retrosplenial connections. Fisk GD, et al. **Brain Res** 1999 Apr 17;825(1–2):1–13

Nociceptive neurons in the macaque anterior cingulate activate during anticipation of pain. Koyama T, et al. **Neuroreport** 1998 Aug 3;9(11):2663–7

DRUG EFFECTS

Impairment of cingulothalamic learning-related neuronal coding in rabbits exposed to cocaine in utero: general and sex-specific effects. Taylor CL, et al. **Behav Neurosci** 1999 Feb;113(1):62–77

Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. O'Neill MF, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):839–46

Differential effects of post-training muscimol and AP5 infusions into different regions of the cingulate cortex on retention for inhibitory avoidance in rats. Mello e Souza T, et al. **Neurobiol Learn Mem** 1999 Sep;72(2):118–27

Dopamine and serotonin imbalances in the left anterior cingulate and pyriform cortices following the repeated intermittent administration of cocaine. Heidbreder CA, et al. **Neuroscience** 1999 Mar;89(3):701–15

METABOLISM

Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex [published erratum appears in Am J Psychiatry 1999 Oct;156(10):1666] Wu J, et al. **Am J Psychiatry** 1999 Aug;156(8):1149–58

PATHOLOGY

Contribution of the supplementary motor area and anterior cingulate gyrus to pathological grasping phenomena. Hashimoto R, et al. **Eur Neurol** 1998 Oct;40(3):151–8

PHYSIOLOGY

An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Peterson BS, et al. **Biol Psychiatry** 1999 May 15;45(10):1237–58 (100 ref.)

The emotional counting Stroop paradigm: a functional magnetic resonance imaging probe of the anterior cingulate affective division. Whalen PJ, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1219–28

Septocingulate and septohippocampal cholinergic pathways: involvement in working/episodic memory. Dougherty KD, et al. **Brain Res** 1998 Nov 9;810(1–2):59–71

Cardiovascular response to the injection of acetylcholine into the anterior cingulate region of the medial prefrontal cortex of unanesthetized rats. Crippa GE, et al. **Cereb Cortex** 1999 Jun;9(4):362–5

Hippocampal modulation of cingulo-thalamic neuronal activity and discriminative avoidance learning in rabbits. Kang E, et al. **Hippocampus** 1998;8(5):491–510

The counting Stroop: an interference task specialized for functional neuroimaging--validation study with functional MRI. Bush G, et al. **Hum Brain Mapp** 1998;6(4):270–82

Conceptual processing during the conscious resting state. A functional MRI study. Binder JR, et al. **J Cogn Neurosci** 1999 Jan;11(1):80–95

Sustained activity in the medial wall during working memory delays. Petit L, et al. **J Neurosci** 1998 Nov 15; 18(22):9429–37

A possible neurophysiological basis for psychological pain. Koyama T. **Med Hypotheses** 1998 Nov;51(5):439–40

Pain-related neurons in the human cingulate cortex. Hutchison WD, et al. **Nat Neurosci** 1999 May;2(5):403–5

Activation of different anterior cingulate foci in association with hypothesis testing and response selection. Elliott R, et al. **Neuroimage** 1998 Jul;8(1):17–29

Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Lambert PD, et al. **Neuropsychopharmacology** 1999 Aug; 21(2):229–37

Anticipatory coping of pain expressed in the human anterior cingulate cortex: a positron emission tomography study. Hsieh JC, et al. **Neurosci Lett** 1999 Feb 26;262(1):61–4

Role of the cingulate gyrus during the Wisconsin Card Sorting Test: a single photon emission computed tomography study in normal volunteers. Catafau AM, et al. **Psychiatry Res** 1998 Aug 26;83(2):67–74

Role for cingulate motor area cells in voluntary movement selection based on reward. Shima K, et al. **Science** 1998 Nov 13;282(5392):1335–8

PHYSIOPATHOLOGY

More stringent threshold needed [letter; comment] Spence SA. **Am J Psychiatry** 1999 May;156(5):803–4. Comment on: Am J Psychiatry 1997 Dec;154(12):1670–5.

The role of ventral medial wall motor areas in bimanual co-ordination. A combined lesion and activation study. Stephan KM, et al. **Brain** 1999 Feb;122 (Pt 2):351–68

Pure topographical disorientation due to right posterior cingulate lesion. Katayama K, et al. **Cortex** 1999 Apr; 35(2):279–82

Potential role of the anterior cingulate cortex in PTSD: review and hypothesis. Hamner MB, et al. **Depress Anxiety** 1999;9(1):1–14 (138 ref.)

Abnormal cingulate modulation of fronto-temporal connectivity in schizophrenia. Fletcher P, et al. **Neuroimage** 1999 Mar;9(3):337–42

Nociceptive neurons in the macaque anterior cingulate activate during anticipation of pain. Koyama T, et al. **Neuroreport** 1998 Aug 3;9(11):2663–7

RADIONUCLIDE IMAGING

More stringent threshold needed [letter; comment] Spence SA. **Am J Psychiatry** 1999 May;156(5):803–4. Comment on: Am J Psychiatry 1997 Dec;154(12):1670–5.

GYRUS DENTATUS see **DENTATE GYRUS**

H-2 ANTIGENS

BIOSYNTHESIS

Antigen presentation in syrian hamster cells: substrate selectivity of TAP controlled by polymorphic residues in TAP1 and differential requirements for loading of H2 class I molecules. Lobigs M, et al. **Immunogenetics** 1999 Oct; 49(11–12):931–41

Differential regulation of Dk and Kk major histocompatibility complex class I proteins on the cell surface after infection of murine cells by pseudorabies virus. Sparks-Thissen RL, et al. **J Virol** 1999 Jul;73(7):5748–56

CHEMISTRY

Murine class I major histocompatibility complex H-2Dd: expression, refolding and crystallization. Achour A, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):260–2

Origin, functions and chemistry of H-2 regulated odorants. Yamazaki K, et al. **Genetica** 1998–99;104(3):235–40 (59 ref.)

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Glithero A, et al. **Immunity** 1999 Jan;10(1):63–74

Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8alphaalpha ectodomain fragment in complex with H-2Kb. Kern PS, et al. **Immunity** 1998 Oct;9(4):519–30

T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative. Kessler B, et al. **J Biol Chem** 1999 Feb 5; 274(6):3622–31

A region of conformational variability outside the peptide-binding site of a class I MHC molecule. Kuhns ST, et al. **J Immunol** 1998 Dec 15;161(12):6745–50

Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. Li H, et al. **J Mol Biol** 1998;283(1):179–91

GENETICS

Nucleotide sequences of three H-2K and three H-2D complementary DNA clones coding mouse class I MHC heavy chain proteins. Wang M, et al. **Ann Transplant** 1996; 1(3):26–31

Different H2 haplotypes have a strong influence on oncogene action. Ember I, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):1181–5

Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. Hamano Y, et al. **Blood** 1998 Nov 15;92(10):3772–9

Positive selection of an H2-M3 restricted T cell receptor. Berg RE, et al. **Immunity** 1999 Jul;11(1):33–43

cDNA cloning, northern hybridization, and mapping analysis of a putative GDS-related protein gene at the centromeric ends of the human and mouse MHC regions. Ando A, et al. **Immunogenetics** 1999 Apr;49(4):354–6

Genomic organization and sequence of the H2-T24 gene. Crew MD, et al. **Immunogenetics** 1999 Jul;49(7–8):707–11

MHC characterization of ALR and ALS mice: respective similarities to the NOD and NON strains. Graser RT, et al. **Immunogenetics** 1999 Jul;49(7–8):722–6

CTL and sequence analyses of MHC class IB antigens Qa1(c) (H2-T23(r)) and Qa1(d) (H2-T23(f)). Hermel E, et al. **Immunogenetics** 1999 Jul;49(7–8):712–7

The mouse p52 subunit of the transcription/DNA repair factor TFIIH is located in the class III region of the H2 complex: cloning and sequence polymorphism. Lanning D, et al. **Immunogenetics** 1999 Jun;49(6):498–504

The mouse major histocompatibility complex: some assembly required. Amadou C, et al. **Immunol Rev** 1999 Feb; 167:211–21 (106 ref.)

Development and function of autospecific dual TCR+ T lymphocytes. Paterson RK, et al. **Int Immunol** 1999 Jan; 11(1):113–9

Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. Hattori M, et al. **J Immunol** 1999 Aug 15;163(4):1721–4

Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. Men Y, et al. **J Immunol** 1999 Mar 15;162(6):3566–73

Context-dependent immunogenicity of an S206G-substituted H-2Db-restricted simian virus 40 large T antigen epitope I variant. Mylin LM. **J Immunol** 1999 Feb 15;162(4):2171–9

Response to Listeria monocytogenes in mice lacking MHC class Ia molecules. Seaman MS, et al. **J Immunol** 1999 May 1;162(9):5429–36

Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2KbnullDbnull double knockout mice. Ureta-Vidal A, et al. **J Immunol** 1999 Sep 1;163(5):2555–60

Production and growth of conditionally immortal cell lines from the H-2KbtsA58 transgenic mouse. Noble M. **Methods Mol Biol** 1999;97:139–58 (93 ref.)

Major histocompatibility complex (MHC) class I KbDb -/- deficient mice possess functional CD8+ T cells and natural killer cells. Vugmeyster Y, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12492–7

Odortypes: their origin and composition. Yamazaki K, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1522–5

Loss of retrovirus production in JB/RH melanoma cells transfected with H-2Kb and TAP-1 genes. Li M, et al. **Virology** 1999 Jan 20;253(2):230–40

[Specific immune responses in H-2d mice after DNA immunization of HBV core gene] Huang Z, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):107–9 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Effects of altered antigen processing on T-cell responses toward murine T-lymphomas. Raes G, et al. **Adv Exp Med Biol** 1998;451:211–5

Effects of altered antigen processing on H-2Dk mediated NK inhibition in a murine T lymphoma model. Van Ginderachter J, et al. **Adv Exp Med Biol** 1998;451:237–40

Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor. del Rosario ML, et al. **Blood** 1999 May 15;93(10):3558–64

A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo. Cullen CM, et al. **Cell Immunol** 1999 Feb 25;

192(1):54-62
A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. Gallimore A, et al. **Eur J Immunol** 1998 Oct;28(10):3301-11
Alpha1/alpha2 domains of H-2D(d), but not H-2L(d), induce "missing self" reactivity in vivo--no effect of H-2L(d) on protection against NK cells expressing the inhibitory receptor Ly49G2. Johansson MH, et al. **Eur J Immunol** 1998 Dec;28(12):4198-206
Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2-DMa gene. Russell HI, et al. **Eur J Immunol** 1999 Mar;29(3):905-11
CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts. Wise M, et al. **Eur J Immunol** 1999 Jan;29(1):156-67
Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism. Malarkannan S, et al. **Immunity** 1999 Jun;10(6):681-90
Characterization of the culture filtrate-specific cytotoxic T lymphocyte response induced by Bacillus Calmette-Guérin vaccination in H-2b mice. Denis O, et al. **Int Immunol** 1999 Feb;11(2):209-16
Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide. Honda S, et al. **Int Immunol** 1998 Aug;10(8):1167-74
Peptide dependency of alloreactive CD4+ T cell responses. Mendiratta SK, et al. **Int Immunol** 1999 Mar;11(3):351-60
Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen. Schirmbeck R, et al. **Int Immunol** 1999 Jul;11(7):1093-102
On the diversity and heterogeneity of H-2(d)-restricted determinants and T cell epitopes from the major bee venom allergen. Texier C, et al. **Int Immunol** 1999 Aug; 11(8):1313-26
Host H-2 haplotype modulates the induction of host-versus-graft disease after the induction of neonatal tolerance to H-2 alloantigens. Ramos A, et al. **Int J Mol Med** 1998 Feb;1(2):431-7
Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. Stemmer C, et al. **J Biol Chem** 1999 Feb 26;274(9):5550-6
T cell affinity maturation by selective expansion during infection. Busch DH, et al. **J Exp Med** 1999 Feb 15; 189(4):701-10
Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. Nakamura MC, et al. **J Exp Med** 1999 Feb 1;189(3):493-500
Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. Yuasa T, et al. **J Exp Med** 1999 Jan 4;189(1):187-94
Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. Zeng D, et al. **J Exp Med** 1999 Apr 5;189(7):1073-81
Recognition of measles virus-infected cells by CD8+ T cells depends on the H-2 molecule. Neumeister C, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2583-91
CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. Agadjanyan MG, et al. **J Immunol** 1999 Mar 15;162(6):3417-27
A molecular basis for how a single TCR interfaces multiple ligands. Boesteanu A, et al. **J Immunol** 1998 Nov 1; 161(9):4719-27
Fine specificity and MHC restriction of trinitrophenyl-specific CTL. Franco A, et al. **J Immunol** 1999 Mar 15;162(6):3388-94
Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway. Guermonprez P, et al. **J Immunol** 1999 Feb 15; 162(4):1910-6
Alloreactive and syngeneic CTL are comparably dependent on interaction with MHC class I alpha-helical residues. Hornell TM, et al. **J Immunol** 1999 Sep 15;163(6):3217-25
Cutting edge: myelin basic protein-specific cytotoxic T cell tolerance is maintained in vivo by a single dominant epitope in H-2k mice. Huseby ES, et al. **J Immunol** 1999 Aug 1; 163(3):1115-8
The development of autoimmune inflammatory arthropathy in mice transgenic for the human T cell leukemia virus type-1 env-pX region is not dependent on H-2 haplotypes and modified by the expression levels of Fas antigen. Iwakura Y, et al. **J Immunol** 1998 Dec 15;161(12):6592-8
The importance of pairwise interactions between peptide residues in the delineation of TCR specificity. Leggatt GR, et al. **J Immunol** 1998 Nov 1;161(9):4728-35
A Theiler's virus alternatively initiated protein inhibits the generation of H-2K-restricted virus-specific cytotoxicity. Lin X, et al. **J Immunol** 1999 Jan 1;162(1):17-24
The mode of ligand recognition by two peptide:MHC class I-specific monoclonal antibodies. Messaoudi I, et al. **J Immunol** 1999 Sep 15;163(6):3286-94
Recognition of an MHC class I-restricted antigenic peptide can be modulated by para-substitution of its buried tyrosine residues in a TCR-specific manner. Saito NG, et al. **J Immunol** 1999 May 15;162(10):5998-6008
Assessment of the role of determinant selection in genetic control of the immune response to insulin in H-2b mice. Thayer WP, et al. **J Immunol** 1999 Sep 1;163(5):2549-54
In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes. von Herrath MG, et al. **J Immunol** 1998 Nov 1; 161(9):5087-96
Expanded cohorts of maternal CD8+ T-cells specific for paternal MHC class I accumulate during pregnancy. Zhou M, et al. **J Reprod Immunol** 1998 Oct;40(1):47-62
Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. Johnson AJ, et al. **J Virol** 1999 May;73(5):3702-8
Cell surface expression of H2 antigens on primary sensory neurons in response to acute but not latent herpes simplex virus infection in vivo. Pereira RA, et al. **J Virol** 1999 Aug;73(8):6484-9
Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area. Goyarts EC, et al. **Mol Immunol** 1998 Jul;35(10):593-607
Tolerance induction in mature T lymphocytes. Alferink J, et al. **Novartis Found Symp** 1998;215:191-6; discussion 196-9, 218-30
A two-step model for the induction of organ-specific autoimmunity. Limmer A, et al. **Novartis Found Symp** 1998; 215:159-67; discussion 167-71, 186-90
Morbidity and susceptibility of the mouse to Angiostrongylus cantonensis are not related to the H-2 complex. Aoki M, et al. **Parasitol Res** 1999 Aug;85(8-9):669-71
Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. DiLorenzo TP, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12538-43
Variant antigenic peptide promotes cytotoxic T lymphocyte adhesion to target cells without cytotoxicity. Shotton DM, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15571-6
Low responsiveness to immunization with immunoglobulin E/antigen and immunoglobulin G/antigen complexes in H-2Ab mice. Gustavsson S, et al. **Scand J Immunol** 1999 Jul;50(1):45-51
Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Alferink J, et al. **Science** 1998 Nov 13; 282(5392):1338-41
An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers. de Vries-van der Zwan A, et al. **Transpl Immunol** 1998 Sep;6(3):147-51
Use of a high-affinity peptide that aborts MHC-restricted cytotoxic T lymphocyte activity against multiple viruses in vitro and virus-induced immunopathologic disease in vivo. Oldstone MB, et al. **Virology** 1999 Apr 10; 256(2):246-57

ISOLATION & PURIFICATION

Murine class I major histocompatibility complex H-2Dd: expression, refolding and crystallization. Achour A, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):260-2

METABOLISM

Influence of N-glycan chain length on chaperone association and intracellular transport of major histocompatibility complex class I proteins. Bennett MJ, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):473-8
An allosteric mechanism controls antigen presentation by the H-2K(b) complex. Gakamsky DM, et al. **Biochemistry** 1999 Sep 14;38(37):12165-73
N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, et al. **Eur J Immunol** 1999 Jan;29(1):189-95
Lateral diffusion of GFP-tagged H2Ld molecules and of GFP-TAP1 reports on the assembly and retention of these molecules in the endoplasmic reticulum. Marguet D, et al. **Immunity** 1999 Aug;11(2):231-40
Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Speir JA, et al. **Immunity** 1999 Jan;10(1):51-61
H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1. Daws MR, et al. **Immunology** 1999 Aug;97(4):656-64
26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. Ben-Shahar S, et al. **J Biol Chem** 1999 Jul 30;274(31):21963-72
New synthetic non-peptide ligands for classical major histocompatibility complex class I molecules. Bianco A, et al. **J Biol Chem** 1998 Oct 30;273(44):28759-65
Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. Chen W, et al. **J Exp Med** 1999 Jun 7; 189(11):1757-64
NK and CTL recognition of a single chain H-2Dd molecule: distinct sites of H-2Dd interact with NK and TCR. Chung DH, et al. **J Immunol** 1999 Oct 1;163(7):3699-708
Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. George TC, et al. **J Immunol** 1999 Feb 15;162(4):2035-43
External and internal calibration of the MHC class I-specific receptor Ly49A on murine natural killer cells. Käse A, et al. **J Immunol** 1998 Dec 1;161(11):6133-8
Recognition of class I MHC by NK receptor Ly-49C: identification of critical residues. Lian RH, et al. **J Immunol** 1999 Jun 15;162(12):7271-6
Levels of Ly-49 receptor expression are determined by the frequency of interactions with MHC ligands: evidence against receptor calibration to a "useful" level. Manilay JO, et al. **J Immunol** 1999 Sep 1;163(5):2628-33
The mode of ligand recognition by two peptide:MHC class I-specific monoclonal antibodies. Messaoudi I, et al. **J Immunol** 1999 Sep 15;163(6):3286-94
Role of Bcl-2 in alpha beta T cell development in mice deficient in the common cytokine receptor gamma-chain: the requirement for Bcl-2 differs depending on the TCR/MHC affinity. Nakajima H, et al. **J Immunol** 1999 Jan 15;162(2):782-90
Alterations in TCR-MHC contacts subsequent to cross-recognition of class I MHC and singly substituted peptide variants. Ono T, et al. **J Immunol** 1998 Nov 15; 161(10):5454-63
Specific proteolytic cleavages limit the diversity of the pool of peptides available to MHC class I molecules in living cells. Serwold T, et al. **J Immunol** 1999 Apr 15; 162(8):4712-9
Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain. Suh WK, et al. **J Immunol** 1999 Feb 1;162(3):1530-40
Complex high affinity interactions occur between MHCI and superantigens. Chapes SK, et al. **J Leukoc Biol** 1998 Nov; 64(5):587-94
Differential association of beta2-microglobulin mutants with MHC class I heavy chains and structural analysis demonstrate allele-specific interactions. Shields MJ, et al. **Mol Immunol** 1999 Jun;36(9):561-73

PHYSIOLOGY

Spontaneous mutation at position 114 in H-2Kd affects cytotoxic T cell responses to influenza virus infection. Müllbacher A, et al. **Eur J Immunol** 1999 Apr; 29(4):1228-34
Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Pérarnau B, et al. **Eur J Immunol** 1999 Apr;29(4):1243-52
Maternal-fetal tolerance is maintained despite transgene-driven trophoblast expression of MHC class I, and defects in Fas and its ligand. Rogers AM, et al. **Eur J Immunol** 1998 Nov;28(11):3479-87
Origin, functions and chemistry of H-2 regulated odorants. Yamazaki K, et al. **Genetica** 1998-99;104(3):235-40 (59 ref.)
Antigens varying in affinity for the B cell receptor induce differential B lymphocyte responses. Kouskoff V, et al. **J Exp Med** 1998 Oct 19;188(8):1453-64
Recognition of the major histocompatibility complex restriction element modulates CD8(+) T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide. Sandberg JK, et al. **J Exp Med** 1999 Mar 15;189(6):883-94
Class I MHC molecule-mediated inhibition of Sindbis virus replication. Hahn YS, et al. **J Immunol** 1999 Jan 1; 162(1):69-77
The MHC class I molecule H-2Dp inhibits murine NK cells via the inhibitory receptor Ly49A. Olsson-Alheim MY, et al. **J Immunol** 1999 Jun 15;162(12):7010-4

H-7 see **1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE**

H 93-26 see **METOPROLOL**

H(+)ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

H(+)-K(+)-EXCHANGING ATPASE

ANTAGONISTS & INHIBITORS

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Van Rensburg CJ, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1023-8
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Adamek RJ, et al. **Am J Gastroenterol** 1998 Oct;93(10):1919-24
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. Wetscher GJ, et al. **Am J Surg** 1999 Mar;177(3):189-92
Anti-ulcer activity of newly synthesized acylquinoline derivatives. Cheon HG, et al. **Arch Pharm Res** 1999 Apr; 22(2):137-42
Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Myung SW, et al. **Arch Pharm Res** 1999 Apr;22(2):189-93
Syntheses of 2-[(3,5-dimethyl-4-methoxypyridyl)alkyl]-benzothiazolidine derivatives as a potential gastric

H+/K(+)-ATPase inhibitor. Yoon SH, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1909-12

Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration. Hussain FN, et al. **Br J Clin Pharmacol** 1998 Aug;46(2):173-5

Misoprostol vs omeprazole for ulcers associated with NSAIDs [letter; comment] Bell AD. **Can Fam Physician** 1998 Nov;44:2371-2. Comment on: Can Fam Physician 1998 Aug;44:1629-31.

The biochemical and pharmacological properties of a newly synthesized H+-K+ ATPase inhibitor, 2-dimethylamino-4,5-dihydrothiazolo[4,5:3,4]pyridol-[1,2-a]benzimidazol e. Chung YK, et al. **Can J Physiol Pharmacol** 1998 Sep;76(9):921-9

Does the rapid healing of duodenal ulcers mean longer remissions? Ahmed W, et al. **East Mediterr Health J** 1998 Dec;4(3):554-9

Effect of lansoprazole on human leukocyte function. Capodicasa E, et al. **Immunopharmacol Immunotoxicol** 1999 May;21(2):357-77

Pantoprazole lacks induction of CYP1A2 activity in man. Hartmann M, et al. **Int J Clin Pharmacol Ther** 1999 Apr; 37(4):159-64

Pantoprazole does not interact with the pharmacokinetics of carbamazepine. Huber R, et al. **Int J Clin Pharmacol Ther** 1998 Oct;36(10):521-4

A chimeric gastric H+,K+-ATPase inhibitable with both ouabain and SCH 28080. Asano S, et al. **J Biol Chem** 1999 Mar 12;274(11):6848-54

Inhibition of gastric H+, K(+)-ATPase by flavonoids: a structure-activity study. Murakami S, et al. **J Enzyme Inhib** 1999;14(2):151-66

Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. Takeuchi K, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):251-7

The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. Uchiyama K, et al. **J Pharm Pharmacol** 1999 Apr; 51(4):457-64

Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). Puscas I, et al. **J Pharmacol Exp Ther** 1999 Aug; 290(2):530-4

Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Uchiyama K, et al. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):115-22

Conformation-dependent inhibition of gastric H+,K+-ATPase by SCH 28080 demonstrated by mutagenesis of glutamic acid 820. Swarts HG, et al. **Mol Pharmacol** 1999 Mar;55(3):541-7

Gastroesophageal reflux: A critical factor in pediatric subglottic stenosis. Halstead LA. **Otolaryngol Head Neck Surg** 1999 May;120(5):683-8

[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment] Pospai D, et al. **Gastroenterol Clin Biol** 1998 Oct; 22(10):801-8 (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Colonic H+-K+-ATPase is induced and mediates increased HCO3- reabsorption in inner medullary collecting duct in potassium depletion. Nakamura S, et al. **Kidney Int** 1998 Oct;54(4):1233-9

H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori. Furuta T, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):384-90

BLOOD

Serum antibodies to H+,K+-ATPase, serum pepsinogen A and Helicobacter pylori in relation to gastric mucosa morphology in patients with low or low-normal concentrations of serum cobalamins. Lindgren A, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):583-8

CHEMISTRY

H,K-ATPase alpha subunit C-terminal membrane topology: epitope tags in the insect cell expression system. Smolka AJ, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):601-11

Structural difference in the H+,K+-ATPase between the E1 and E2 conformations. An attenuated total reflection infrared spectroscopy, UV circular dichroism and raman spectroscopy study. Raussens V, et al. **Eur J Biochem** 1999 May;262(1):176-83

Secondary structure of the membrane-bound domains of H+,K+-ATPase and Ca2+-ATPase, a comparison by FTIR after proteolysis treatment of the native membranes. Raussens V, et al. **FEBS Lett** 1998 Oct 23;437(3):187-92

1-anilino-8-naphtalene sulfonate probes a gastric HK-ATPase potassium site whose access requires ionophores. Festy F, et al. **J Membr Biol** 1998 Sep 15; 165(2):153-60

DRUG EFFECTS

Effect of melittin on ion transport across cell membranes. Yang S, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan; 18(1):3-5 (31 ref.)

GENETICS

Structural aspects of the gastric H,K ATPase: the M5/M6 domain and alpha beta association. Melle-Milovanovic D, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:147-62 (39 ref.)

The nongastric H+-K+-ATPases: molecular and functional properties. Jaisser F, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F812-24 (82 ref.)

Mutagenesis of glutamate 820 of the gastric H+,K+-ATPase alpha-subunit to aspartate decreases the apparent ATP affinity. Hermsen HP, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1-2):251-7

Ouabain-sensitive H,K-ATPase: tissue-specific expression of the mammalian genes encoding the catalytic alpha subunit. Pestov NB, et al. **FEBS Lett** 1998 Dec 4;440(3):320-4

Identification of a novel gene of the X,K-ATPase beta-subunit family that is predominantly expressed in skeletal and heart muscles. Pestov NB, et al. **FEBS Lett** 1999 Aug 6;456(2):243-8

Intrarenal distribution of the colonic H,K-ATPase mRNA in rabbit. Fejes-Tóth G, et al. **Kidney Int** 1999 Sep; 56(3):1029-36

IMMUNOLOGY

Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Suri-Payer E, et al. **Eur J Immunol** 1999 Feb;29(2):669-77

Identification of a gastritogenic epitope of the H/K ATPase beta-subunit. De Silva HD, et al. **Immunology** 1999 Jan; 96(1):145-51

Prediction of epitopes and production of monoclonal antibodies against gastric H,K-ATPase. Irnaten M, et al. **Protein Eng** 1998 Oct;11(10):949-55

METABOLISM

Sorting of P-type ATPases in polarized epithelial cells. Dunbar LA, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:289-95 (23 ref.)

H-K-ATPase in the RCCT-28A rabbit cortical collecting duct cell line. Campbell WG, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F237-45

Ammonium transport by the colonic H(+)-K(+)-ATPase expressed in Xenopus oocytes. Cougnon M, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):C280-7

The nongastric H+-K+-ATPases: molecular and functional properties. Jaisser F, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F812-24 (82 ref.)

Colonic H-K-ATPase beta-subunit: identification in apical membranes and regulation by dietary K depletion. Sangan P, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C350-60

A tyrosine-based signal regulates H-K-ATPase-mediated potassium reabsorption in the kidney. Wang T, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):F818-26

Gastric H+/K(+)-ATPase: targeting signals in the regulation of physiologic function. Caplan MJ. **Curr Opin Cell Biol** 1998 Aug;10(4):468-73 (51 ref.)

Nitric oxide-mediated regulation of gastric H+, K+-ATPase and alcohol dehydrogenase following ethanol-induced injury in rats. Bulut R, et al. **Dig Dis Sci** 1999 Jul;44(7):1417-22

Species-specific distribution of alpha-galactosyl epitopes on the gastric H/K ATPase beta-subunit: relevance to the binding of human anti-parietal cell autoantibodies. Stewart LA, et al. **Glycobiology** 1999 Jun;9(6):601-6

Chloride transport by the rabbit cortical collecting duct: dependence on H,K-ATPase. Zhou X, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2194-202

Chimeric domain analysis of the compatibility between H(+), K(+)-ATPase and Na(+),K(+)-ATPase beta-subunits for the functional expression of gastric H(+),K(+)-ATPase. Asano S, et al. **J Biol Chem** 1999 Aug 6;274(32):22257-65

Cation selectivity of gastric H,K-ATPase and Na,K-ATPase chimeras. Blostein R, et al. **J Biol Chem** 1999 Jun 25; 274(26):18374-81

The colonic H+,K+-ATPase functions as a Na+-dependent K+(NH4+)-ATPase in apical membranes from rat distal colon. Codina J, et al. **J Biol Chem** 1999 Jul 9;274(28):19693-8

Stabilization of the H,K-ATPase M5M6 membrane hairpin by K+ ions. Mechanistic significance for p2-type atpases. Gatto C, et al. **J Biol Chem** 1999 May 14;274(20):13737-40

ATP1AL1, a member of the non-gastric H,K-ATPase family, functions as a sodium pump. Grishin AV, et al. **J Biol Chem** 1998 Oct 23;273(43):27772-8

The beta-subunits of Na+,K+-ATPase and gastric H+,K+-ATPase have a high preference for their own alpha-subunit and affect the K+ affinity of these enzymes. Koenderink JB, et al. **J Biol Chem** 1999 Apr 23; 274(17):11604-10

1-anilino-8-naphtalene sulfonate probes a gastric HK-ATPase potassium site whose access requires ionophores. Festy F, et al. **J Membr Biol** 1998 Sep 15; 165(2):153-60

Role of apical H-K exchange and basolateral K channel in the regulation of intracellular pH in rat distal colon crypt cells. Ikuma M, et al. **J Membr Biol** 1998 Dec 1; 166(3):205-12

Possible evidence for transmembrane K(+)-H+ exchange system in guinea pig myocardium. Nagashima R, et al. **Jpn Heart J** 1999 May;40(3):351-64

[Reversible phosphorylation of catalytic subunit of monovalent cation-transporting ATPases by protein kinases and phosphatases] Kaya S. **Seikagaku** 1999 May; 71(5):341-5 (15 ref.) **(Jpn)**

[Sodium efflux through lymphocytic cell membranes in patients with acute myocardial infarction] Salomon P, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):542-50 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

H+-K+-ATPases: regulation and role in pathophysiological states. Silver RB, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F799-811 (82 ref.)

Gastric H(+),K(+)-adenosine triphosphatase beta subunit is required for normal function, development, and membrane structure of mouse parietal cells. Scarff KL, et al. **Gastroenterology** 1999 Sep;117(3):605-18

ULTRASTRUCTURE

beta-subunit assembly is essential for the correct packing and the stable membrane insertion of the H,K-ATPase alpha-subunit. Beggah AT, et al. **J Biol Chem** 1999 Mar 19;274(12):8217-23

H(+)-K(+)-TRANSPORTING ATPASE see **H(+)-K(+)-EXCHANGING ATPASE**

H(+) PUMP see **PROTON PUMP**

H(+)-TRANSPORTING ATP SYNTHASE

Linear and rotary molecular motors. Kinosita K Jr. **Adv Exp Med Biol** 1998;453:5-13; discussion 13-4 (34 ref.)

Trehalose-mediated protection of the plasma membrane H+-ATPase from Kluyveromyces lactis during freeze-drying and rehydration. Sampedro JG, et al. **Cryobiology** 1998 Sep;37(2):131-8

[F1-ATPase; the stepping rotary motor in ATP synthase] Noji H, et al. **Seikagaku** 1999 Jan;71(1):34-50 (45 ref.) **(Jpn)**

[ATP synthase] Shirakihara Y. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):538-45 (15 ref.) **(Jpn)**

ANALYSIS

Na,K-ATPase and V-ATPase in ovarian follicles of Drosophila melanogaster. Bohrmann J, et al. **Biol Cell** 1999 Mar;91(2):85-98

Distribution of V-ATPase in rat salivary glands. Roussa E, et al. **Eur J Morphol** 1998 Aug;36 Suppl:147-52

Postnatal development of H+ ATPase (proton-pump)-rich cells in rat epididymis. Breton S, et al. **Histochem Cell Biol** 1999 Feb;111(2):97-105

ANTAGONISTS & INHIBITORS

Tissue-selective inhibition of vacuolar acid pumps. Keeling DJ, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:195-201

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Stack WA, et al. **Am J Gastroenterol** 1998 Oct;93(10):1909-13

Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Zheng J, et al. **Biochem Biophys Res Commun** 1999 Aug 2; 261(2):499-503

Molecular dissection of the C-terminal regulatory domain of the plant plasma membrane H+-ATPase AHA2: mapping of residues that when altered give rise to an activated enzyme. Axelsen KB, et al. **Biochemistry** 1999 Jun 1;38(22):7227-34

(2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase. Nadler G, et al. **Bioorg Med Chem Lett** 1998 Dec 15; 8(24):3621-6

Influence of antiresorptive agent OST-766 on signal transduction pathways involved in parathyroid hormone action. Morris SA, et al. **Calcif Tissue Int** 1999 Feb; 64(2):148-53

Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Hoyumpa AM, et al. **Clin Ther** 1999 Apr;21(4):691-701

Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na+, K+ -ATPase of porcine cortex. Zheng J, et al. **Eur J Pharmacol** 1999 Feb 26;368(1):95-102

Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Yasuda S, et al. **Int J Clin Pharmacol Ther** 1999 May;37(5):249-53

Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Palokangas H, et al. **Mol Biol Cell** 1998 Dec;9(12):3561-78

[Proton pump inhibitors in pediatrics] Faure C, et al.

Arch Pediatr 1999 Jun;6(6):650-6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Medical treatment of gastroesophageal reflux with proton pump inhibitors] Vallot T, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S97-109 (93 ref.) **(Fre)**

BIOSYNTHESIS

Sequence of a cDNA encoding mouse F1F0-ATP synthase g subunit. Jeon D, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):767-8
Enzyme level of enterococcal F1Fo-ATPase is regulated by pH at the step of assembly [published erratum appears in Eur J Biochem 1999 Apr;261(2):591] Arikado E, et al. **Eur J Biochem** 1999 Jan;259(1-2):262-8
Biosynthesis of the vacuolar H+-ATPase accessory subunit Ac45 in Xenopus pituitary. Holthuis JC, et al. **Eur J Biochem** 1999 Jun;262(2):484-91
Cloning of the V-ATPase subunit G in plant: functional expression and sub-cellular localization. Rouquié D, et al. **FEBS Lett** 1998 Oct 23;437(3):287-92
Hypothyroidism leads to a decreased expression of mitochondrial F0F1-ATP synthase in rat liver. Guerrieri F, et al. **J Bioenerg Biomembr** 1998 Jun;30(3):269-76
Biosynthesis and regulation of the yeast vacuolar H+-ATPase. Kane PM. **J Bioenerg Biomembr** 1999 Feb; 31(1):49-56 (32 ref.)
Early steps in assembly of the yeast vacuolar H+-ATPase. Kane PM, et al. **J Biol Chem** 1999 Jun 11;274(24):17275-83
Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. Strasser JE, et al. **J Immunol** 1999 May 15;162(10):6148-54
The relationship between distal tubular proton secretion and dietary potassium depletion: evidence for up-regulation of H+ -ATPase. Bailey M, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1435-40
Phosphate as a limiting factor for the cell division of tobacco BY-2 cells. Sano T, et al. **Plant Cell Physiol** 1999 Jan; 40(1):1-8
Heterologous overexpression of membrane-anchored subunit II of spinach chloroplast ATP synthase and its detergent-free purification as a soluble protein. Tiburzy HJ, et al. **Z Naturforsch [C]** 1999 Mar-Apr;54(3-4):230-8

CHEMICAL SYNTHESIS

Chemical synthesis of yeast mitochondrial ATP synthase membranous subunit 8. Goetz M, et al. **J Pept Sci** 1999 Jun;5(6):245-50

CHEMISTRY

Rotational coupling in the F0F1 ATP synthase. Nakamoto RK, et al. **Annu Rev Biophys Biomol Struct** 1999;28:205-34 (130 ref.)
His(15) of subunit a of the Escherichia coli ATP synthase is important for the structure or assembly of the membrane sector F(o). Patterson AR, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):193-7
EPR detection of protein-derived radicals in the reaction of H(2)O(2) with Fe bound in mitochondrial F(1)ATPase. Polizio F, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):281-5
The structure of bovine mitochondrial F1-ATPase: an example of rotary catalysis. Leslie AG, et al. **Biochem Soc Trans** 1999 Feb;27(2):37-42 (22 ref.)
Topological and functional relationship of subunits F1-gamma and F0I-PVP(b) in the mitochondrial H+-ATP synthase. Gaballo A, et al. **Biochemistry** 1998 Dec 15;37(50):17519-26
The role of beta-Arg-182, an essential catalytic site residue in Escherichia coli F1-ATPase. Nadanaciva S, et al. **Biochemistry** 1999 Jun 15;38(24):7670-7
Quaternary structure of V1 and F1 ATPase: significance of structural homologies and diversities. Svergun DI, et al. **Biochemistry** 1998 Dec 22;37(51):17659-63
Subunit epsilon of the Escherichia coli ATP synthase: novel insights into structure and function by analysis of thirteen mutant forms. Xiong H, et al. **Biochemistry** 1998 Nov 17; 37(46):16423-9
Modification of the N-terminal polyserine cluster alters stability of the plasma membrane H(+)-ATPase from Saccharomyces cerevisiae. Hasper A, et al. **Biochim Biophys Acta** 1999 Aug 20;1420(1-2):214-22
Subunit D of the vacuolar H+-ATPase of Arabidopsis thaliana. Kluge C, et al. **Biochim Biophys Acta** 1999 Jun 9;1419(1):105-10
Contraction transitions of F1-F0 ATPase during catalytic turnover. Syroeshkin AV, et al. **Biochim Biophys Acta** 1998 Dec 1;1409(2):59-71
Topography of the yeast ATP synthase F0 sector. Velours J, et al. **Biochimie** 1998 Oct;80(10):793-801
A model of the quaternary structure of the Escherichia coli F1 ATPase from X-ray solution scattering and evidence for structural changes in the delta subunit during ATP hydrolysis. Svergun DI, et al. **Biophys J** 1998 Nov; 75(5):2212-9
Nucleotide and Mg2+ dependency of the thermal denaturation of mitochondrial F1-ATPase. Villaverde J, et al. **Biophys J** 1998 Oct;75(4):1980-8
Characterization of a mutant of Lactococcus lactis with reduced membrane-bound ATPase activity under acidic conditions. Amachi S, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1574-80
Structure of the ductin channel. Finbow ME, et al. **Biosci Rep** 1998 Dec;18(6):287-97 (33 ref.)
Comparison of H+-ATPase and Ca2+-ATPase suggests that a large conformational change initiates P-type ion pump reaction cycles. Stokes DL, et al. **Curr Biol** 1999 Jul 1;9(13):672-9
Structure of the P-type ATPases. Kühlbrandt W, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):510-6 (30 ref.)
Yeast mitochondrial F1F0-ATP synthase exists as a dimer: identification of three dimer-specific subunits. Arnold I, et al. **EMBO J** 1998 Dec 15;17(24):7170-8
Refolding of recombinant alpha and beta subunits of the Rhodospirillum rubrum F(0)F(1) ATP synthase into functional monomers that reconstitute an active alpha(1)beta(1)-dimer. Du Z, et al. **Eur J Biochem** 1999 Jul;263(2):430-7
Kinetic properties of a single nucleotide binding site on chloroplast coupling factor 1 (CF1). Günther S, et al. **Eur J Biochem** 1998 Dec 1;258(2):710-5
NMR studies of subunit c of the ATP synthase from Propionigenium modestum in dodecylsulphate micelles. Matthey U, et al. **Eur J Biochem** 1999 Apr;261(2):459-67
Conformational changes of the H+-ATPase from Escherichia coli upon nucleotide binding detected by single molecule fluorescence. Börsch M, et al. **FEBS Lett** 1998 Oct 23;437(3):251-4
Assembly of the yeast vacuolar proton-translocating ATPase. Graham LA, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):39-47 (32 ref.)
The structure of the vacuolar ATPase in Neurospora crassa. Margolles-Clark E, et al. **J Bioenerg Biomembr** 1999 Feb; 31(1):29-37 (51 ref.)
Subunit f of the yeast mitochondrial ATP synthase: topological and functional studies. Roudeau S, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):85-94
The role of the amino-terminal beta-barrel domain of the alpha and beta subunits in the yeast F1-ATPase. Yao B, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):95-104
Structure/function of the beta-barrel domain of F1-ATPase in the yeast Saccharomyces cerevisiae. Bakhtiari N, et al. **J Biol Chem** 1999 Jun 4;274(23):16363-9
Rotation of the epsilon subunit during catalysis by Escherichia coli F0F1-ATP synthase. Bulygin VV, et al. **J Biol Chem** 1998 Nov 27;273(48):31765-9
Structure of the membrane domain of subunit b of the Escherichia coli F0F1 ATP synthase. Dmitriev O, et al. **J Biol Chem** 1999 May 28;274(22):15598-604
Evidence for a salt bridge between transmembrane segments 5 and 6 of the yeast plasma-membrane H+-ATPase. Gupta SS, et al. **J Biol Chem** 1998 Dec 18;273(51):34328-34
Defining the domain of binding of F1 subunit epsilon with the polar loop of F0 subunit c in the Escherichia coli ATP synthase. Hermolin J, et al. **J Biol Chem** 1999 Jun 11; 274(24):17011-6
Transmembrane topography of the 100-kDa a subunit (Vph1p) of the yeast vacuolar proton-translocating ATPase. Leng XH, et al. **J Biol Chem** 1999 May 21; 274(21):14655-61
The proteolipid of the A(1)A(0) ATP synthase from Methanococcus jannaschii has six predicted transmembrane helices but only two proton-translocating carboxyl groups. Ruppert C, et al. **J Biol Chem** 1999 Sep 3;274(36):25281-4
The 20 C-terminal amino acid residues of the chloroplast ATP synthase gamma subunit are not essential for activity. Sokolov M, et al. **J Biol Chem** 1999 May 14; 274(20):13824-9
Cross-linking of two beta subunits in the closed conformation in F1-ATPase. Tsunoda SP, et al. **J Biol Chem** 1999 Feb 26;274(9):5701-6
A novel labeling approach supports the five-transmembrane model of subunit a of the Escherichia coli ATP synthase. Wada T, et al. **J Biol Chem** 1999 Jun 11;274(24):17353-7
1H, 13C, and 15N assignments and secondary structure of the high pH form of subunit c of the F1F0 ATP synthase [letter] Rastogi VK, et al. **J Biomol NMR** 1999 Jan; 13(1):91-2
Surface crystallisation of the plasma membrane H+-ATPase on a carbon support film for electron crystallography. Auer M, et al. **J Mol Biol** 1999 Apr 16;287(5):961-8
Novel features in the structure of bovine ATP synthase. Karrasch S, et al. **J Mol Biol** 1999 Jul 9;290(2):379-84
Connecting stalks in V-type ATPase. Boekema EJ, et al. **Nature** 1999 Sep 2;401(6748):37-8
The 2.8-A structure of rat liver F1-ATPase: configuration of a critical intermediate in ATP synthesis/hydrolysis. Bianchet MA, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11065-70
Energy transduction in the sodium F-ATPase of Propionigenium modestum [see comments] Dimroth P, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4924-9 . Comment in: Proc Natl Acad Sci U S A 1999 Apr 27;96(9):4735-7.
Structure of the subunit c oligomer in the F1Fo ATP synthase: model derived from solution structure of the monomer and cross-linking in the native enzyme. Dmitriev OY, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7785-90
The gamma-subunit rotation and torque generation in F1-ATPase from wild-type or uncoupled mutant Escherichia coli. Omote H, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7780-4
The rotary enzyme of the cell: the rotation of F1-ATPase. Noji H. **Science** 1998 Dec 4;282(5395):1844-5
ATP synthase: two motors, two fuels. Oster G, et al. **Structure** 1999 Apr 15;7(4):R67-72 (25 ref.)

DEFICIENCY

Insulinoma with hyperproinsulinemia during hypoglycemia and loss of expression of vacuolar-type H(+)-ATPase (V-ATPase) in the tumor tissue. Hiura A, et al. **Int J Pancreatol** 1999 Feb;25(1):11-6

GENETICS

Structure-function relationships in transmembrane segments 4, 5, and 6 of the yeast plasma-membrane H(+)-ATPase. Ambesi A, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:107-13
Mutational analysis of F1F0 ATPase: catalysis and energy coupling. Omote H, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:177-83 (33 ref.)
Organellar H(+)-ATPase--site directed mutagenesis and suppressor mutants. Perzov N, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:185-94
A highly polymorphic microsatellite within intron 5 of the porcine 54/56 kDa vacuolar H(+)-ATPase subunit gene (V-ATPase). Pfeiffer I, et al. **Anim Genet** 1998 Dec; 29(6):464-5
Decreased bone resorption, osteoclast differentiation, and expression of vacuolar H+-ATPase in antisense DNA-treated mouse metacarpal and calvaria cultures ex vivo. Laitala-Leinonen T, et al. **Antisense Nucleic Acid Drug Dev** 1999 Apr;9(2):155-69
Amino acid substitutions in the a subunit affect the epsilon subunit of F1F0 ATP synthase from Escherichia coli. Gardner JL, et al. **Arch Biochem Biophys** 1999 Jan 15; 361(2):302-8
The atpIBEXF operon coding for the F0 sector of the ATP synthase from the purple nonsulfur photosynthetic bacterium Rhodobacter capsulatus. Borghese R, et al. **Arch Microbiol** 1998 Oct;170(5):385-8
Acidic stimulation induces a negative regulatory factor that affects alternative exon selection in vitro in human ATP synthase gamma-subunit pre-mRNA. Hayakawa M, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):603-8
Inhibition of protein import into mitochondria by amphiphilic cations: potential targets and mechanism of action. Pavlov PF, et al. **Biochem Biophys Res Commun** 1998 Nov 9; 252(1):84-91
Subunit epsilon of the Escherichia coli ATP synthase: novel insights into structure and function by analysis of thirteen mutant forms. Xiong H, et al. **Biochemistry** 1998 Nov 17; 37(46):16423-9
Transcriptional activation of the F(1)F(0) ATP synthase alpha-subunit initiator element by USF2 is mediated by p300. Breen GA, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):169-76
Characterization of non-dominant lethal mutations in the yeast plasma membrane H+-ATPase gene. Martin-Castillo B, et al. **Biochim Biophys Acta** 1999 Feb 4;1417(1):32-6
Evidence of a subunit 4 (subunit b) dimer in favor of the proximity of ATP synthase complexes in yeast inner mitochondrial membrane. Spannagel C, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1-2):260-4
Cloning and expression analysis of vacuolar H+-ATPase 69-kDa catalytic subunit cDNA in citrus (Citrus unshiu marc.)1. Takanokura Y, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1-2):265-72
Sequence of a cDNA encoding mouse F1F0-ATP synthase g subunit. Jeon D, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):767-8
DNA-binding factors assemble in a sequence-specific manner on the maize mitochondrial atpA promoter. Chang CC, et al. **Curr Genet** 1999 Jun;35(5):506-11
ATP synthase 5' untranslated regions are specifically bound by chloroplast polypeptides. Hotchkiss TL, et al. **Curr Genet** 1999 Jun;35(5):512-20
Inheritance of a mitochondrial DNA defect and impaired glucose tolerance in BHE/Cdb rats. Mathews CE, et al. **Diabetologia** 1999 Jan;42(1):35-40
Isolation and mapping of a putative b subunit of human ATP synthase (ATP-BL) from human leukocytes. Sugimoto J, et al. **DNA Res** 1999 Feb 26;6(1):29-35
Epistatic interactions of deletion mutants in the genes encoding the F1-ATPase in yeast Saccharomyces cerevisiae. Lai-Zhang J, et al. **EMBO J** 1999 Jan 4; 18(1):58-64
Bioenergetic and structural consequences of allotopic expression of subunit 8 of yeast mitochondrial ATP synthase. The hydrophobic character of residues 23 and 24 is essential for maximal activity and structural stability of the enzyme complex. Roucou X, et al. **Eur J Biochem** 1999 Apr;261(2):444-51
Cloning of the V-ATPase subunit G in plant: functional expression and sub-cellular localization. Rouquié D, et al. **FEBS Lett** 1998 Oct 23;437(3):287-92
Subunit C of the vacuolar H+-ATPase of Hordeum vulgare. Tavakoli N, et al. **FEBS Lett** 1999 Jul 30;456(1):68-72
The Drosophila gene 2A5 complements the defect in mitochondrial F1-ATPase assembly in yeast lacking the molecular chaperone Atp11p. Wang ZG, et al. **FEBS Lett** 1999 Jun 11;452(3):305-8
Upstream stimulatory factor 2 activates the mammalian F1F0

ATP synthase alpha-subunit gene through an initiator element. Breen GA, et al. **Gene Expr** 1998;7(3):163-70

Suppression of a nuclear aep2 mutation in Saccharomyces cerevisiae by a base substitution in the 5'-untranslated region of the mitochondrial oli1 gene encoding subunit 9 of ATP synthase. Ellis TP, et al. **Genetics** 1999 Apr; 151(4):1353-63

Characterization of an allele-nonspecific intragenic suppressor in the yeast plasma membrane H+-ATPase gene (Pma1). Maldonado AM, et al. **Genetics** 1998 Sep; 150(1):11-9

Modeling the Leigh syndrome nt8993 T-->C mutation in Escherichia coli F1F0 ATP synthase. Hartzog PE, et al. **Int J Biochem Cell Biol** 1999 Jul;31(7):769-76

The multifunctional Drosophila melanogaster V-ATPase is encoded by a multigene family. Dow JA. **J Bioenerg Biomembr** 1999 Feb;31(1):75-83 (59 ref.)

On the role of the general transcription factor Sp1 in the activation and repression of diverse mammalian oxidative phosphorylation genes. Zaid A, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):129-35

ATP synthase of yeast mitochondria. Isolation of subunit j and disruption of the ATP18 gene. Arnold I, et al. **J Biol Chem** 1999 Jan 1;274(1):36-40

A novel family of yeast chaperons involved in the distribution of V-ATPase and other membrane proteins. Cohen A, et al. **J Biol Chem** 1999 Sep 17;274(38):26885-93

Complementation of the Saccharomyces cerevisiae plasma membrane H+-ATPase by a plant H+-ATPase generates a highly abundant fusicoccin binding site. Piotrowski M, et al. **J Biol Chem** 1998 Nov 6;273(45):30018-23

A new member of the Ig superfamily and a V-ATPase G subunit are among the predicted products of novel genes close to the TNF locus in the human MHC. Neville MJ, et al. **J Immunol** 1999 Apr 15;162(8):4745-54

Molecular cloning and chromosomal assignment of the porcine 54 and 56 kDa vacuolar H(+)-ATPase subunit gene (V-ATPase). Hui D, et al. **Mamm Genome** 1999 Mar; 10(3):266-70

Suppression of rho0 lethality by mitochondrial ATP synthase F1 mutations in Kluyveromyces lactis occurs in the absence of F0. Chen XJ, et al. **Mol Gen Genet** 1998 Sep; 259(5):457-67

A screen for lethal mutations in the chromosomal region 59AB suggests that bellwether encodes the alpha subunit of the mitochondrial ATP synthase in Drosophila melanogaster. Jacobs H, et al. **Mol Gen Genet** 1998 Sep; 259(4):383-7

Maturational changes in gene expression for adenine nucleotide translocator isoforms and betaF1-ATPase in rabbit heart. Portman MA, et al. **Mol Genet Metab** 1999 Feb;66(2):75-9

Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness [see comments] Karet FE, et al. **Nat Genet** 1999 Jan;21(1):84-90 . Comment in: Nat Genet 1999 Jan;21(1):67-8.

Spontaneous and photosensitiser-induced DNA single-strand breaks and formamidopyrimidine-DNA glycosylase sensitive sites at nucleotide resolutionin the nuclear and mitochondrial DNA of Saccharomyces cerevisiae. Meniel V, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):822-30

Phylogenetic transfer of organelle genes to the nucleus can lead to new mechanisms of protein integration into membranes. Michl D, et al. **Plant J** 1999 Jan;17(1):31-40

Expression analysis of two gene subfamilies encoding the plasma membrane H+-ATPase in Nicotiana plumbaginifolia reveals the major transport functions of this enzyme. Moriau L, et al. **Plant J** 1999 Jul;19(1):31-41

Tissue-specific expression of genes encoding isoforms of the mitochondrial ATPase beta subunit in Nicotiana sylvestris. Lalanne E, et al. **Plant Mol Biol** 1998 Nov;38(5):885-8

cDNA and genomic cloning of sugar beet V-type H+-ATPase subunit A and c isoforms: evidence for coordinate expression during plant development and coordinate induction in response to high salinity. Lehr A, et al. **Plant Mol Biol** 1999 Feb;39(3):463-75

The three copies of the ATP1 gene are arranged in tandem on chromosome II of Saccharomyces cerevisiae S288C. Takeda M, et al. **Yeast** 1999 Jul;15(10A):873-8

IMMUNOLOGY

F0 complex of the Escherichia coli ATP synthase. Not all monomers of the subunit c oligomer are involved in F1 interaction. Birkenhäger R, et al. **Eur J Biochem** 1999 Sep; 264(2):385-96

Microinjected antisera against ductin affect gastrulation in Drosophila melanogaster. Bohrmann J, et al. **Int J Dev Biol** 1998 Jul;42(5):709-21

ISOLATION & PURIFICATION

Purification of multisubunit membrane protein complexes: isolation of chloroplast FoF1-ATP synthase, CFo and CF1 by blue native electrophoresis. Neff D, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):569-75

Rapid purification of membrane extrinsic F1-domain of chloroplast ATP synthase in monodisperse form suitable for 3D-crystallization. Groth G, et al. **Eur J Biochem** 1999 Feb;260(1):15-21

A novel insect V-ATPase subunit M9.7 is glycosylated extensively. Merzendorfer H, et al. **J Biol Chem** 1999 Jun 11;274(24):17372-8

Isolation of supernumerary yeast ATP synthase subunits e and i. Characterization of subunit i and disruption of its structural gene ATP18. Vaillier J, et al. **J Biol Chem** 1999 Jan 1;274(1):543-8

Heterologous overexpression of membrane-anchored subunit II of spinach chloroplast ATP synthase and its detergent-free purification as a soluble protein. Tiburzy HJ, et al. **Z Naturforsch [C]** 1999 Mar-Apr;54(3-4):230-8

METABOLISM

Structure-function relationships in transmembrane segments 4, 5, and 6 of the yeast plasma-membrane H(+)-ATPase. Ambesi A, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:107-13

Subunit interactions coupling H+ transport and ATP synthesis in F1F0 ATP synthase. Fillingame RH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:163-8 (28 ref.)

Plasma membrane V-ATPases in proton-transporting cells of the mammalian kidney and osteoclast. Gluck SL, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:203-12 (84 ref.)

The second stalk: the delta-b subunit connection in ECF1F0. Ogilvie I, et al. **Acta Physiol Scand Suppl** 1998 Aug; 643:169-75 (32 ref.)

Mutational analysis of F1F0 ATPase: catalysis and energy coupling. Omote H, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:177-83 (33 ref.)

H+-ATPase in hyperkalemic distal renal tubular acidosis. Danesh FR, et al. **Am J Kidney Dis** 1998 Dec;32(6):1091-5; discussion 1095-7

Effect of acidification on the location of H+-ATPase in cultured inner medullary collecting duct cells. Alexander EA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):C758-63

Activation of H+-ATPase by hypotonicity: a novel regulatory mechanism for H+ secretion in IMCD cells. Amlal H, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F487-501

Upregulation of H+-ATPase in the distal nephron during potassium depletion: structural and functional evidence. Bailey MA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F878-84

Proton secretion in the male reproductive tract: involvement of Cl--independent HCO-3 transport. Breton S, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1134-42

Rotational coupling in the F0F1 ATP synthase. Nakamoto RK, et al. **Annu Rev Biophys Biomol Struct** 1999;28:205-34 (130 ref.)

Relationship between acid tolerance, cytoplasmic pH, and ATP and H+-ATPase levels in chemostat cultures of Lactococcus lactis. O'Sullivan E, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2287-93

Amino acid substitutions in the a subunit affect the epsilon subunit of F1F0 ATP synthase from Escherichia coli. Gardner JL, et al. **Arch Biochem Biophys** 1999 Jan 15; 361(2):302-8

Stability of the Escherichia coli ATP synthase F0F1 complex is dependent on interactions between gamma Gln-269 and the beta subunit loop beta Asp-301-beta Asp-305. Omote H, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):277-82

The plasma membrane H+-ATPase from Tradescantia stem and leaf tissue is modulated in vitro by cGMP. Suwastika IN, et al. **Arch Biochem Biophys** 1999 Jul 1;367(1):137-9

Comparative effects of Saccharomyces cerevisiae cultivation under copper stress on the activity and kinetic parameters of plasma-membrane-bound H(+)-ATPases PMA1 and PMA2. Fernandes AR, et al. **Arch Microbiol** 1999 Mar; 171(4):273-8

Glucose protection from MPP+-induced apoptosis depends on mitochondrial membrane potential and ATP synthase. Chalmers-Redman RM, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):440-7

Involvement of V-ATPases in the digestion of soft connective tissue collagen. Creemers LB, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):429-36

Rotation of Escherichia coli F(1)-ATPase. Noji H, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):597-9

Prodigiosins uncouple lysosomal vacuolar-type ATPase through promotion of H+/Cl- symport. Ohkuma S, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):731-41

Chemical cleavage of the overexpressed mitochondrial F1beta precursor with CNBr: a new strategy to construct an import-competent preprotein. Pavlov PF, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):95-103

Presence of a vacuolar H+-pyrophosphatase in promastigotes of Leishmania donovani and its localization to a different compartment from the vacuolar H+-ATPase. Rodrigues CO, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):759-66

Chloroplast thioredoxin mutants without active-site cysteines facilitate the reduction of the regulatory disulphide bridge on the gamma-subunit of chloroplast ATP synthase. Stumpp MT, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):157-63

The beta subunit of chloroplast ATP synthase (CF0CF1-ATPase) is phosphorylated by casein kinase II. Kanekatsu M, et al. **Biochem Mol Biol Int** 1998 Sep; 46(1):99-105

The structure of bovine mitochondrial F1-ATPase: an example of rotary catalysis. Leslie AG, et al. **Biochem Soc Trans** 1999 Feb;27(2):37-42 (22 ref.)

Molecular dissection of the C-terminal regulatory domain of the plant plasma membrane H+-ATPase AHA2: mapping of residues that when altered give rise to an activated enzyme. Axelsen KB, et al. **Biochemistry** 1999 Jun 1;38(22):7227-34

Influence of divalent cations on nucleotide exchange and ATPase activity of chloroplast coupling factor 1. Digel JG, et al. **Biochemistry** 1998 Dec 8;37(49):17209-15

The alpha 3(beta Y341W)3 gamma subcomplex of the F1-ATPase from the thermophilic Bacillus PS3 fails to dissociate ADP when MgATP is hydrolyzed at a single catalytic site and attains maximal velocity when three catalytic sites are saturated with MgATP. Dou C, et al. **Biochemistry** 1998 Nov 24;37(47):16757-64

Topological and functional relationship of subunits F1-gamma and F0I-PVP(b) in the mitochondrial H+-ATP synthase. Gaballo A, et al. **Biochemistry** 1998 Dec 15;37(50):17519-26

The oligomycin sensitivity conferring protein of rat liver mitochondrial ATP synthase: arginine 94 is important for the binding of OSCP to F1. Golden TR, et al. **Biochemistry** 1998 Sep 29;37(39):13871-81

The PLC1 encoded phospholipase C in the yeast Saccharomyces cerevisiae is essential for glucose-induced phosphatidylinositol turnover and activation of plasma membrane H+-ATPase. Coccetti P, et al. **Biochim Biophys Acta** 1998 Oct 21;1405(1-3):147-54

Modification of the N-terminal polyserine cluster alters stability of the plasma membrane H(+)-ATPase from Saccharomyces cerevisiae. Hasper A, et al. **Biochim Biophys Acta** 1999 Aug 20;1420(1-2):214-22

Effect of nitric oxide synthase induction on the expression of mitochondrial respiratory chain enzyme subunits in mixed cortical and astroglial cell cultures. Nicoletti VG, et al. **Biochimie** 1998 Oct;80(10):871-81

Animal plasma membrane energization by proton-motive V-ATPases. Wieczorek H, et al. **Bioessays** 1999 Aug; 21(8):637-48 (83 ref.)

Relationship of the Escherichia coli TrkA system of potassium ion uptake with the F0F1-ATPase under growth conditions without anaerobic or aerobic respiration. Trchounian A, et al. **Biosci Rep** 1998 Jun;18(3):143-54

ATP synthesis by F-type ATP synthase is obligatorily dependent on the transmembrane voltage. Kaim G, et al. **EMBO J** 1999 Aug 2;18(15):4118-27

Voltage-generated torque drives the motor of the ATP synthase. Kaim G, et al. **EMBO J** 1998 Oct 15; 17(20):5887-95

The noncatalytic site-deficient alpha3beta3gamma subcomplex and FoF1-ATP synthase can continuously catalyse ATP hydrolysis when Pi is present. Bald D, et al. **Eur J Biochem** 1999 Jun;262(2):563-8

Identification of subunit g of yeast mitochondrial F1F0-ATP synthase, a protein required for maximal activity of cytochrome c oxidase. Boyle GM, et al. **Eur J Biochem** 1999 Jun;262(2):315-23

Conformational changes of the H+-ATPase from Escherichia coli upon nucleotide binding detected by single molecule fluorescence. Börsch M, et al. **FEBS Lett** 1998 Oct 23;437(3):251-4

Role of the 14-3-3 proteins in the regulation of H+-ATPase activity in the plasma membrane of suspension-cultured sugar beet cells under cold stress. Chelysheva VV, et al. **FEBS Lett** 1999 Jul 30;456(1):22-6

Transient accumulation of elastic energy in proton translocating ATP synthase. Cherepanov DA, et al. **FEBS Lett** 1999 Apr 16;449(1):1-6

ATP-synthase of Rhodobacter capsulatus: coupling of proton flow through F0 to reactions in F1 under the ATP synthesis and slip conditions. Feniouk BA, et al. **FEBS Lett** 1999 Feb 26;445(2-3):409-14

Comparison of DeltapH- and Delta***φ***-driven ATP synthesis catalyzed by the H(+)-ATPases from Escherichia coli or chloroplasts reconstituted into liposomes. Fischer S, et al. **FEBS Lett** 1999 Sep 3; 457(3):327-32

Energy-dependent transformation of the catalytic activities of the mitochondrial F0 x F1-ATP synthase. Galkin MA, et al. **FEBS Lett** 1999 Apr 1;448(1):123-6

Enterococcus hirae vacuolar ATPase is expressed in response to pH as well as sodium. Ikegami M, et al. **FEBS Lett** 1999 Jul 2;454(1-2):67-70

Proton gradient-induced changes of the interaction between CF0 and CF1 related to activation of the chloroplast ATP synthase. Ponomarenko S, et al. **FEBS Lett** 1999 Jan 25; 443(2):136-8

Subunit C of the vacuolar H+-ATPase of Hordeum vulgare. Tavakoli N, et al. **FEBS Lett** 1999 Jul 30;456(1):68-72

Presence of Na(+)-stimulated V-type ATPase in the membrane of a facultatively anaerobic and halophilic alkaliphile. Kaieda N, et al. **FEMS Microbiol Lett** 1998 Oct 1;167(1):57-61

Upstream stimulatory factor 2 activates the mammalian F1F0 ATP synthase alpha-subunit gene through an initiator element. Breen GA, et al. **Gene Expr** 1998;7(3):163-70

Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat. Sundquist KT, et al. **Histochem Cell Biol** 1999 Jan;111(1):55-60

Presence of two enzymes, different from the F1F0-ATPase, hydrolyzing nucleotides in human term placental mitochondria. Uribe A, et al. **Int J Biochem Cell Biol** 1999 Feb;31(2):319-30

atp Mutants of Escherichia coli fail to grow on succinate due to a transport deficiency. Boogerd FC, et al. **J Bacteriol** 1998 Nov;180(22):5855-9

Diverse roles of single membrane organelles: factors establishing the acid lumenal pH. Futai M, et al.

J Biochem (Tokyo) 1998 Aug;124(2):259–67 (109 ref.)
Prodigiosins uncouple mitochondrial and bacterial F-ATPases: evidence for their H+/Cl- symport activity. Konno H, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):547–56
Properties of the V0V1 Na+-ATPase from Enterococcus hirae and its V0 moiety. Murata T, et al. **J Biochem (Tokyo)** 1999 Feb;125(2):414–21
Cooperativity between the enzymatic sites of F1-ATPase revisited by the use of HPLC methods. Berger G, et al. **J Bioenerg Biomembr** 1998 Dec;30(6):543–53
Structure and function of vacuolar Na+-translocating ATPase in Enterococcus hirae. Kakinuma Y, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):7–14 (41 ref.)
Structure and function of the A1A0-ATPases from methanogenic Archaea. Müller V, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):15–27 (84 ref.)
Relevance of divalent cations to ATP-driven proton pumping in beef heart mitochondrial F0F1-ATPase. Papageorgiou S, et al. **J Bioenerg Biomembr** 1998 Dec; 30(6):533–41
Subunit f of the yeast mitochondrial ATP synthase: topological and functional studies. Roudeau S, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):85–94
Activation and deactivation of F0F1-ATPase in yeast mitochondria. Schouppe C, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):105–17
The plasma membrane H+-V-ATPase from tobacco hornworm midgut. Wieczorek H, et al. **J Bioenerg Biomembr** 1999 Feb;31(1):67–74 (60 ref.)
The role of the amino-terminal beta-barrel domain of the alpha and beta subunits in the yeast F1-ATPase. Yao B, et al. **J Bioenerg Biomembr** 1999 Apr;31(2):95–104
ATP synthase of yeast mitochondria. Isolation of subunit j and disruption of the ATP18 gene. Arnold I, et al. **J Biol Chem** 1999 Jan 1;274(1):36–40
SNARE proteins regulate H(+)-ATPase redistribution to the apical membrane in rat renal inner medullary collecting duct cells. Banerjee A, et al. **J Biol Chem** 1999 Sep 10; 274(37):26518–22
Single copies of subunits d, oligomycin-sensitivity conferring protein, and b are present in the Saccharomyces cerevisiae mitochondrial ATP synthase. Bateson M, et al. **J Biol Chem** 1999 Mar 12;274(11):7462–6
Rotation of the epsilon subunit during catalysis by Escherichia coli F0F1-ATP synthase. Bulygin VV, et al. **J Biol Chem** 1998 Nov 27;273(48):31765–9
EPR spectroscopy of VO2+-ATP bound to catalytic site 3 of chloroplast F1-ATPase from Chlamydomonas reveals changes in metal ligation resulting from mutations to the phosphate-binding loop threonine (betaT168). Chen W, et al. **J Biol Chem** 1999 Mar 12;274(11):7089–94
A novel family of yeast chaperons involved in the distribution of V-ATPase and other membrane proteins. Cohen A, et al. **J Biol Chem** 1999 Sep 17;274(38):26885–93
Receptor-mediated targeting of fluorescent probes in living cells. Farinas J, et al. **J Biol Chem** 1999 Mar 19; 274(12):7603–6
Structure and properties of the vacuolar (H+)-ATPases. Forgac M. **J Biol Chem** 1999 May 7;274(19):12951–4 (67 ref.)
The vacuolar H+-ATPase of clathrin-coated vesicles is reversibly inhibited by S-nitrosoglutathione. Forgac M. **J Biol Chem** 1999 Jan 15;274(3):1301–5
Evidence for a salt bridge between transmembrane segments 5 and 6 of the yeast plasma-membrane H+-ATPase. Gupta SS, et al. **J Biol Chem** 1998 Dec 18;273(51):34328–34
Helical interactions and membrane disposition of the 16-kDa proteolipid subunit of the vacuolar H(+)-ATPase analyzed by cysteine replacement mutagenesis. Harrison MA, et al. **J Biol Chem** 1999 Sep 3;274(36):25461–70
Genetic fusions of subunit c in the F0 sector of H+-transporting ATP synthase. Functional dimers and trimers and determination of stoichiometry by cross-linking analysis. Jones PC, et al. **J Biol Chem** 1998 Nov 6; 273(45):29701–5
Protein transport into "complex" diatom plastids utilizes two different targeting signals. Lang M, et al. **J Biol Chem** 1998 Nov 20;273(47):30973–8
Single point mutations distributed in 10 soluble and membrane regions of the Nicotiana plumbaginifolia plasma membrane PMA2 H+-ATPase activate the enzyme and modify the structure of the C-terminal region. Morsomme P, et al. **J Biol Chem** 1998 Dec 25;273(52):34837–42
The vacuolar H+-ATPase of lemon fruits is regulated by variable H+/ATP coupling and slip. Müller ML, et al. **J Biol Chem** 1999 Apr 16;274(16):10706–16
Binding of the transition state analog MgADP-fluoroaluminate to F1-ATPase. Nadanaciva S, et al. **J Biol Chem** 1999 Mar 12;274(11):7052–8
Identification and reconstitution of an isoform of the 116-kDa subunit of the vacuolar proton translocating ATPase. Peng SB, et al. **J Biol Chem** 1999 Jan 22;274(4):2549–55
The second stalk composed of the b- and delta-subunits connects F0 to F1 via an alpha-subunit in the Escherichia coli ATP synthase. Rodgers AJ, et al. **J Biol Chem** 1998 Nov 6;273(45):29406–10
Kinetic analysis of tentoxin binding to chloroplast F1-ATPase. A model for the overactivation process. Santolini J, et al. **J Biol Chem** 1999 Jan 8;274(2):849–58
beta(1) integrin binds the 16-kDa subunit of vacuolar H(+)-ATPase at a site important for human papillomavirus E5 and platelet-derived growth factor signaling. Skinner MA, et al. **J Biol Chem** 1999 Aug 13;274(33):23119–27
Deletions in the second stalk of F1F0-ATP synthase in Escherichia coli. Sorgen PL, et al. **J Biol Chem** 1998 Oct 23;273(43):27873–8
Genetic probing of the stalk segments associated with M2 and M3 of the plasma membrane H+-ATPase from Saccharomyces cerevisiae. Soteropoulos P, et al. **J Biol Chem** 1998 Oct 9;273(41):26426–31
Effects of the inhibitors azide, dicyclohexylcarbodiimide, and aurovertin on nucleotide binding to the three F1-ATPase catalytic sites measured using specific tryptophan probes. Weber J, et al. **J Biol Chem** 1998 Dec 11;273(50):33210–5
Effect of the epsilon-subunit on nucleotide binding to Escherichia coli F1-ATPase catalytic sites. Weber J, et al. **J Biol Chem** 1999 Jul 2;274(27):19124–8
Solution structure of the epsilon subunit of the F1-ATPase from Escherichia coli and interactions of this subunit with beta subunits in the complex. Wilkens S, et al. **J Biol Chem** 1998 Oct 9;273(41):26645–51
LST1 is a SEC24 homologue used for selective export of the plasma membrane ATPase from the endoplasmic reticulum. Roberg KJ, et al. **J Cell Biol** 1999 May 17; 145(4):659–72
Intracellular trafficking of the vacuolar H+-ATPase accessory subunit Ac45. Jansen EJ, et al. **J Cell Sci** 1998 Oct;111 (Pt 20):2999–3006
Stage-dependent redistribution of the V-ATPase during bovine implantation. Skinner MA, et al. **J Histochem Cytochem** 1999 Oct;47(10):1247–54
Dysregulation of the mitochondrial ATP-synthase in respiratory chain defects: first experience. Das AM, et al. **J Inherit Metab Dis** 1998 Jun;21(3):220–3
Limits on the tightness of coupling in active transport. Krupka RM. **J Membr Biol** 1999 Jan 1;167(1):35–41 (18 ref.)
F1-ATP synthase beta-subunit and cytochrome c transcriptional regulation in right ventricular hemodynamic overload and hypertrophically stimulated cardiocytes. O'Brien TX, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):167–78
A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. Ezaki J, et al. **J Neurochem** 1999 Jun; 72(6):2573–82
Characterization of H+-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells. Benderra Z, et al. **Leukemia** 1998 Oct;12(10):1539–44
Regulation of intracellular pH and proton-potassium exchange in fermenting Escherichia coli grown anaerobically in alkaline medium. Trchounian A, et al. **Membr Cell Biol** 1998;12(1):67–78
Retrograde transport from the pre-Golgi intermediate compartment and the Golgi complex is affected by the vacuolar H+-ATPase inhibitor bafilomycin A1. Palokangas H, et al. **Mol Biol Cell** 1998 Dec;9(12):3561–78
Reversible association between the V1 and V0 domains of yeast vacuolar H+-ATPase is an unconventional glucose-induced effect. Parra KJ, et al. **Mol Cell Biol** 1998 Dec;18(12):7064–74
Anomalies of mitochondrial ATP synthase regulation in four different types of neuronal ceroid lipofuscinosis. Das AM, et al. **Mol Genet Metab** 1999 Apr;66(4):349–55
Ion pores made of mitochondrial ATP synthase subunit c in the neuronal plasma membrane and Batten disease. McGeoch JE, et al. **Mol Genet Metab** 1999 Apr; 66(4):387–92
Energy transduction in the F1 motor of ATP synthase. Wang H, et al. **Nature** 1998 Nov 19;396(6708):279–82
Rate of accumulation of Luxol Fast Blue staining material and mitochondrial ATP synthase subunit 9 in motor neuron degeneration mice. Rodman JS, et al. **Neurochem Res** 1998 Oct;23(10):1291–6
Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles. Terland O, et al. **Neuropharmacology** 1999 Jun;38(6):879–82
Proton ATPases in bacteria: comparison to Escherichia coli F1F0 as the prototype. Fillingame RH, et al. **Novartis Found Symp** 1999;221:218–29; discussion 229–34 (44 ref.)
Induction of cell transformation by mutated 16K vacuolar H+-atpase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells. Saito T, et al. **Oncogene** 1998 Oct 1;17(13):1673–80
Vacuolar and plasma membrane proton-adenosinetriphosphatases. Nelson N, et al. **Physiol Rev** 1999 Apr;79(2):361–85 (233 ref.)
Modulation of plasma membrane H+-ATPase activity differentially activates wound and pathogen defense responses in tomato plants. Schaller A, et al. **Plant Cell** 1999 Feb;11(2):263–72
Functional complementation of yeast vma1 delta cells by a plant subunit A homolog rescues the mutant phenotype and partially restores vacuolar H(+)-ATPase activity. Kim W, et al. **Plant J** 1999 Mar;17(5):501–10
A 100 kDa polypeptide associates with the V0 membrane sector but not with the active oat vacuolar H(+)-ATPase, suggesting a role in assembly. Li X, et al. **Plant J** 1999 Jan;17(1):19–30
The two major types of plant plasma membrane H+-ATPases show different enzymatic properties and confer differential pH sensitivity of yeast growth. Luo H, et al. **Plant Physiol** 1999 Feb;119(2):627–34
A phosphothreonine residue at the C-terminal end of the plasma membrane H+-ATPase is protected by fusicoccin-induced 14-3-3 binding. Olsson A, et al. **Plant Physiol** 1998 Oct;118(2):551–5
Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. Conboy IM, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6324–9
Uncoupling of transfer of the presequence and unfolding of the mature domain in precursor translocation across the mitochondrial outer membrane. Kanamori T, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3634–9
The gamma-subunit rotation and torque generation in F1-ATPase from wild-type or uncoupled mutant Escherichia coli. Omote H, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7780–4
Cancer research. A surprising partner for angiostatin [news] [see comments] Barinaga M. **Science** 1999 Mar 19; 283(5409):1831. Comment in: Science 1999 Apr 16;284(5413):433–4.
Angiostatin's partners [letter] Gillies RJ. **Science** 1999 Apr 16;284(5413):434
Angiostatin's partners [letter; comment] Martinez-Zaguilan R. **Science** 1999 Apr 16;284(5413):433–4. Comment on: Science 1999 Mar 19;283(5409):1831.
The rotary enzyme of the cell: the rotation of F1-ATPase. Noji H. **Science** 1998 Dec 4;282(5395):1844–5
Oxidative phosphorylation at the fin de siècle. Saraste M. **Science** 1999 Mar 5;283(5407):1488–93 (50 ref.)
[The Nobel Prize for chemistry in 1997--mitochondrial ATP synthase] Wojtczak L. **Postepy Biochem** 1998;44(1):2–5 **(Pol)**
[Reasons causing a lag period in the oxidative phosphorylation process. Isn't ATP an internal uncoupler of ATP synthetase?] Bronnikov GE, et al. **Biofizika** 1999 May-Jun;44(3):465–73 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Purification of multisubunit membrane protein complexes: isolation of chloroplast FoF1-ATP synthase, CFo and CF1 by blue native electrophoresis. Neff D, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):569–75
Structure of the ductin channel. Finbow ME, et al. **Biosci Rep** 1998 Dec;18(6):287–97 (33 ref.)
Structure, function and regulation of the vacuolar (H+)-ATPases. Forgac M. **FEBS Lett** 1998 Dec 4; 440(3):258–63 (106 ref.)
Structure and properties of the clathrin-coated vesicle and yeast vacuolar V-ATPases. Forgac M. **J Bioenerg Biomembr** 1999 Feb;31(1):57–65 (48 ref.)
Introduction: V-ATPases 1992–1998. Kane PM. **J Bioenerg Biomembr** 1999 Feb;31(1):3–5 (16 ref.)

TOXICITY

A toxic fusion protein accumulating between the mitochondrial membranes inhibits protein assembly in vivo. Beilharz T, et al. **J Biol Chem** 1998 Dec 25; 273(52):35268–72

ULTRASTRUCTURE

Molecular architecture of Manduca sexta midgut V1 ATPase visualized by electron microscopy. Radermacher M, et al. **FEBS Lett** 1999 Jun 25;453(3):383–6
Novel features in the structure of bovine ATP synthase. Karrasch S, et al. **J Mol Biol** 1999 Jul 9;290(2):379–84

H(+)-TRANSPORTING ATPASE see **H(+)-TRANSPORTING ATP SYNTHASE**

H-D ANTIBODIES see **ANTIBODIES, HETEROPHILE**

H-D ANTIGENS see **ANTIGENS, HETEROPHILE**

H-REFLEX

Understanding the "H" reflex in lumbosacral radiculopathy [editorial] Johnson EW. **Am J Phys Med Rehabil** 1999 Sep-Oct;78(5):407
Peripheral motor and sensory nerve conduction studies in haemodialysis patients. A study of 54 patients. Van den Neucker K, et al. **Electromyogr Clin Neurophysiol** 1998 Dec;38(8):467–74
[Use of H-reflex in the assessment of the excitability of spinal cord nociceptive neurons in man] Kukushkin ML, et al. **Anesteziol Reanimatol** 1998 Sep-Oct;(5):16–9 **(Rus)**
[The weakening of the inhibition of the H-reflex in patients with different sites of a hemispheric stroke] Levada OA, et al. **Lik Sprava** 1998 Aug;(6):64–7 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Different effect of high doses of naloxone on spinal reflexes in normal subjects and chronic paraplegic patients. Sandrini G, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):5–8
Magnetically induced motor evoked potentials and H-reflex during nembutal and ketamine anesthesia administration in rats. Chiba A, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jul;101(1):43–57

H-REFLEX

PHYSIOLOGY

Comparison of three methods for recording tibial H reflex: a clinical note. Nishida T, et al. **Am J Phys Med Rehabil** 1999 Sep-Oct;78(5):474-6

Contraction-induced upper extremity H reflexes: normative values. Bodofsky EB. **Arch Phys Med Rehabil** 1999 May; 80(5):562-5

Inhibitory casting decreases a vibratory inhibition index of the H-reflex in the spastic upper limb. Childers MK, et al. **Arch Phys Med Rehabil** 1999 Jun;80(6):714-6

Hoffmann-reflex is delayed during 6 degree head-down tilt with balanced traction. Haruna Y, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 1):220-4

Neural mechanisms of soleus H-reflex depression accompanying voluntary arm movement in standing humans. Kawanishi M, et al. **Brain Res** 1999 Jun 19; 832(1-2):13-22

The excitability of a motoneuron pool assessed by the H-reflex method is correlated with the susceptibility of Ia terminals to repetitive discharges in humans. Komiyama T, et al. **Brain Res** 1999 May 1;826(2):317-20

H-reflex modulations during voluntary and automatic movements following upper motor neuron damage. Leonard CT, et al. **Electroencephalogr Clin Neurophysiol** 1998 Dec;109(6):475-83

Modulation of the soleus H reflex with different velocities of passive movement of the arm. Hiraoka K, et al. **Electromyogr Clin Neurophysiol** 1999 Jan-Feb;39(1):21-6

H reflex excitability following voluntary muscle contraction of different duration. Manca M, et al. **Electromyogr Clin Neurophysiol** 1998 Sep;38(6):381-4

H-reflex recovery curve in syringomyelia. Nogués MA, et al. **Electromyogr Clin Neurophysiol** 1999 Apr-May; 39(3):149-54

Changes in the excitability of soleus muscle short latency stretch reflexes during human hopping after 4 weeks of hopping training. Voigt M, et al. **Eur J Appl Physiol** 1998 Nov;78(6):522-32

The time-course of preparatory spinal and cortico-spinal inhibition: an H-reflex and transcranial magnetic stimulation study in man. Hasbroucq T, et al. **Exp Brain Res** 1999 Jan;124(1):33-41

Comparison of the depression of H-reflexes following previous activation in upper and lower limb muscles in human subjects. Rossi-Durand C, et al. **Exp Brain Res** 1999 May;126(1):117-27

Effect of clenching levels on heteronymous H-reflex in human temporalis muscle. Svensson P, et al. **Exp Brain Res** 1999 Jun;126(4):467-72

Experimental jaw-muscle pain does not change heteronymous H-reflexes in the human temporalis muscle. Svensson P, et al. **Exp Brain Res** 1998 Aug;121(3):311-8

Postural modulation of the segmental reflex: effect of body tilt and postural sway. Trimble MH. **Int J Neurosci** 1998 Jul;95(1-2):85-100

Heteronymous H-reflex in temporal muscle motor units. Macaluso GM, et al. **J Dent Res** 1998 Dec;77(12):1960-4

Effect of manual segmental vibration on neuromuscular excitability. Hébert J, et al. **J Manipulative Physiol Ther** 1998 Oct;21(8):528-33

Barium carbonate intoxication: an electrophysiological study [letter] Kakar A, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):606-7

Phase-dependent inhibition of H-reflexes during walking in humans is independent of reduction in knee angular velocity. Garrett M, et al. **J Neurophysiol** 1999 Aug; 82(2):747-53

Muscle spindle afferent input to motoneurons in human masseter. Scutter SD, et al. **J Neurophysiol** 1999 Jul; 82(1):505-7

Evaluation of reciprocal inhibition of the soleus H-reflex during tonic plantar flexion in man. Petersen N, et al. **J Neurosci Methods** 1998 Oct 1;84(1-2):1-8

Operant conditioning of H-reflex increase in spinal cord--injured rats. Chen XY, et al. **J Neurotrauma** 1999 Feb;16(2):175-86

Relationship between ankle invertor H-reflexes and acute swelling induced by inversion ankle sprain. Hall RC, et al. **J Orthop Sports Phys Ther** 1999 Jun;29(6):339-44

The effect of transcranial magnetic stimulation on the soleus H reflex during human walking. Petersen N, et al. **J Physiol (Lond)** 1998 Dec 1;513 (Pt 2):599-610

Amplitude of the human soleus H reflex during walking and running. Simonsen EB, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):929-39

Studies of stimulus-evoked responses in single motoneurones in humans. Miles TS. **J Physiol Paris** 1999 Jan-Apr; 93(1-2):61-9 (14 ref.)

Weak with laughter [letter] Overeem S, et al. **Lancet** 1999 Sep 4;354(9181):838

The stretch reflex and H-reflex of the human soleus muscle during walking. Andersen JB, et al. **Motor Control** 1999 Apr;3(2):151-7

Consistent repeated M- and H-Wave recording in the hind limb of rats. Cliffer KD, et al. **Muscle Nerve** 1998 Nov; 21(11):1405-13

Observations on the variability of the H reflex in human soleus. Funase K, et al. **Muscle Nerve** 1999 Mar;22(3):341-6

The cutaneous silent period is mediated by spinal inhibitory reflex. Logigian EL, et al. **Muscle Nerve** 1999 Apr; 22(4):467-72

Single motor unit H reflexes recorded in thenar muscles at rest [letter] Wang FC, et al. **Muscle Nerve** 1999 Feb; 22(2):291-2

Modulatory action of noradrenergic system on spinal motoneurons in humans. Palmeri A, et al. **Neuroreport** 1999 Apr 26;10(6):1225-9

Trial-to-trial fluctuations in H-reflexes and motor evoked potentials in human wrist flexor. Funase K, et al. **Neurosci Lett** 1999 Aug 13;271(1):25-8

The effect of treadmill gait training on low-frequency depression of the soleus H-reflex: comparison of a spinal cord injured man to normal subjects. Trimble MH, et al. **Neurosci Lett** 1998 May 1;246(3):186-8

The effects of long-term bed rest on H-reflex and motor evoked potential in the human soleus muscle during standing. Yamanaka K, et al. **Neurosci Lett** 1999 May 7; 266(2):101-4

Contribution of a Ia muscle afferent activation to the rise of H reflexes and somatosensory evoked potentials in man. Drews H, et al. **Somatosens Mot Res** 1998;15(2):109-17

Cervical root compression monitoring by flexor carpi radialis H-reflex in healthy subjects. Sabbahi M, et al. **Spine** 1999 Jan 15;24(2):137-41

H-Y ANTIGEN

ANALYSIS

HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Rufer N, et al. **Transplantation** 1998 Oct 15;66(7):910-6

GENETICS

Mouse H-Y encoding Smcy gene and its X chromosomal homolog Smcx. Agulnik AI, et al. **Mamm Genome** 1999 Sep;10(9):926-9

IMMUNOLOGY

Shaping the repertoire of cytotoxic T-lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Pion S, et al. **Blood** 1999 Feb 1;93(3):952-62

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Halak BK, et al. **Cancer Res** 1999 Feb 15;59(4):911-7

All or none peripheral tolerance induction in H-Y antigen-specific TCR transgenic mice. Sheng B, et al. **Transpl Immunol** 1998 Jun;6(2):78-83

HA-RAS GENES see **GENES, RAS**

HABENULA

DRUG EFFECTS

Estrogen implants in the lateral habenular nucleus do not stimulate the onset of maternal behavior in female rats. Matthews Felton T, et al. **Horm Behav** 1999 Feb; 35(1):71-80

ENZYMOLOGY

Nitric oxide synthase activity reveals an asymmetrical organization of the frog habenulae during development: A histochemical and cytoarchitectonic study from tadpoles to the mature Rana esculenta, with notes on the pineal complex. Guglielmotti V, et al. **J Comp Neurol** 1999 Aug 30;411(3):441-54

METABOLISM

Ca2+ permeability and kinetics of glutamate receptors in rat medial habenula neurones: implications for purinergic transmission in this nucleus. Robertson SJ, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):539-49

Transient expression of calretinin in the trout habenulo-interpeduncular system during development. Porteros A, et al. **Neurosci Lett** 1998 Sep 18;254(1):9-12

The triangular septal nucleus as the major source of ATP release in the rat habenula: a combined neurochemical and morphological study. Sperlágh B, et al. **Neuroscience** 1998 Oct;86(4):1195-207

Occlusion of the femoral artery induced fos-like immunoreactive neurons in the lateral habenular nucleus projecting to the midbrain periaqueductal gray in the rat. Xie Q, et al. **Okajimas Folia Anat Jpn** 1998 Oct; 75(4):167-72

Cocaine-induced changes in glutamate and GABA immunolabeling within rat habenula and nucleus accumbens. Meshul CK, et al. **Synapse** 1998 Oct; 30(2):211-20

PHYSIOLOGY

Intact neurons of the lateral habenular nucleus are necessary for the nonhormonal, pup-mediated display of maternal behavior in sensitized virgin female rats. Felton TM, et al. **Behav Neurosci** 1998 Dec;112(6):1458-65

The fasciculus retroflexus controls the integrity of REM sleep by supporting the generation of hippocampal theta rhythm and rapid eye movements in rats. Valjakka A, et al. **Brain Res Bull** 1998 Sep 15;47(2):171-84

Involvement of medullary tail-flick related neurons in descending facilitation evoked by chemical stimulation of rat lateral habenular nucleus. Huang LX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):20-3

Estrogen implants in the lateral habenular nucleus do not stimulate the onset of maternal behavior in female rats. Matthews Felton T, et al. **Horm Behav** 1999 Feb; 35(1):71-80

Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Quick MW, et al. **Neuropharmacology** 1999 Jun;38(6):769-83

First and second order maternal behavior related afferents of the lateral habenula. Felton TM, et al. **Neuroreport** 1999 Mar 17;10(4):883-7

[Effects of habenula nucleus lesion on estrus cycle and fertility in the adult female rats] Ma L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):373-4 **(Chi)**

PHYSIOPATHOLOGY

Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion. Morris JS, et al. **Neuroimage** 1999 Aug;10(2):163-72

ULTRASTRUCTURE

Subnuclear organization of the rat habenular complexes. Andres KH, et al. **J Comp Neurol** 1999 Apr 28; 407(1):130-50

VIROLOGY

Selective targeting of habenular, thalamic midline and monoaminergic brainstem neurons by neurotropic influenza A virus in mice. Mori I, et al. **J Neurovirol** 1999 Aug; 5(4):355-62

HABILITATION see **REHABILITATION**

HABIT DISTURBANCES see **HABITS**

HABITS

Depth of sleep and sleep habits among enuretic and incontinent children. Nevéus T, et al. **Acta Paediatr** 1999 Jul;88(7):748-52

Habit control expectancy for drinking, smoking, and eating. Schneider HG, et al. **Addict Behav** 1998 Sep-Oct; 23(5):601-7

The septal region and memory. von Cramon DY, et al. **Adv Tech Stand Neurosurg** 1998;24:3-40 (162 ref.)

Photo quiz. All thumbs. Meffert JJ. **Am Fam Physician** 1998 Nov 1;58(7):1647-8

Body-rocking and other habits of college students and persons with mental retardation. Berkson G, et al. **Am J Ment Retard** 1999 Mar;104(2):107-16

Self-reported body-rocking and other habits in college students. Rafaeli-Mor N, et al. **Am J Ment Retard** 1999 Jan;104(1):1-10

Sleep habits in Native Brazilian Bororo children. Reimão R, et al. **Arq Neuropsiquiatr** 1999 Mar;57(1):14-7

Sleep habits in native Brazilian Terena children in the state of Mato Grosso do Sul, Brazil. Reimão R, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):703-7

Suppression and ritualistic behaviour in normal participants. Rassin E, et al. **Br J Clin Psychol** 1999 Jun;38 (Pt 2):195-201

Sympathetic activity and aging: relationship to smoking habits, physical fitness, blood volume, and intracellular signalling. Jensen EW. **Dan Med Bull** 1999 Apr; 46(2):106-17 (135 ref.)

Effect of a logopedic instruction program after adenoidectomy on open mouth posture: a single-blind study. Lembrechts D, et al. **Folia Phoniatr Logop** 1999; 51(3):117-23

Changes from within: improving lifestyle habits using personality type [news] Wennik RS. **J Am Diet Assoc** 1999 Jun;99(6):666-7

The driving habits of adults aged 60 years and older. Gallo JJ, et al. **J Am Geriatr Soc** 1999 Mar;47(3):335-41

Augmenting simplified habit reversal with an awareness enhancement device: preliminary findings. Rapp JT, et al. **J Appl Behav Anal** 1998 Winter;31(4):665-8

Habit-reversal treatment for children's stuttering: assessment in three settings. de Kinkelder M, et al. **J Behav Ther Exp Psychiatry** 1998 Sep;29(3):261-5

A review of behavioral and pharmacological treatments for habit disorders in individuals with mental retardation. Long ES, et al. **J Behav Ther Exp Psychiatry** 1998 Jun; 29(2):143-56 (100 ref.)

Health habit counseling amidst competing demands: effects of patient health habits and visit characteristics. Chernof BA, et al. **Med Care** 1999 Aug;37(8):738-47

A recalcitrant case of reflexive nose picking. Trigeminal trophic syndrome. Mishriki YY. **Postgrad Med** 1999 Sep; 106(3):175-6

Separating habit and recollection in young and older adults: effects of elaborative processing and distinctiveness. Hay JF, et al. **Psychol Aging** 1999 Mar;14(1):122-34

[Eating habits and cardiovascular risk factors. Epidemiologic study of the Tunisian Sahel] Ghannem H, et al. **Presse Med** 1999 May 22-29;28(19):1005-8 (Eng. Abstr.)

(Fre)
[Evaluation of measurements intended to develop regularity of blood donation] Folléa G, et al. **Transfus Clin Biol** 1998 Aug;5(4):241-50 (Eng. Abstr.) (Fre)

HABITUATION (PSYCHOPHYSIOLOGY)

Amphetamine-induced conditioned activity is insensitive to perturbations known to affect pavlovian conditioned responses in rats. Ahmed SH, et al. **Behav Neurosci** 1998 Oct;112(5):1167-76

Response patterns to repeated CO2 inhalation in individuals with high anxiety sensitivity. Beck JG, et al. **Behav Res Ther** 1999 Nov;37(11):1073-89

Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease. Edwards CM, et al. **Clin Sci (Colch)** 1998 Sep; 95(3):249-60

Infants selectively encode the goal object of an actor's reach. Woodward AL. **Cognition** 1998 Nov;69(1):1-34

Effect of a novel environment on resting heart rate in panic disorder. Larsen DK, et al. **Depress Anxiety** 1998;8(1):24-8

Habituation of P300 from visual stimuli. Ravden D, et al. **Int J Psychophysiol** 1998 Nov;30(3):359-65

Negative identity priming is contingent on stimulus repetition. Strayer DL, et al. **J Exp Psychol Hum Percept Perform** 1999 Feb;25(1):24-38

Repeated testing of prepulse inhibition and habituation of the startle reflex: a study in healthy human controls. Abel K, et al. **J Psychopharmacol** 1998;12(4):330-7

Two related forms of long-term habituation in the crab Chasmagnathus are differentially affected by scopolamine. Berón de Astrada M, et al. **Pharmacol Biochem Behav** 1999 May;63(1):109-18

Anticipatory responding, exclusive drug-context pairing and conditioned effects in sensitization to apomorphine-induced climbing in mice. Tirelli E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):505-18

Habituation and sensitization processes in depressive disorders. Miquel M, et al. **Psychopathology** 1999 Jan-Feb; 32(1):35-42

Habituation and sensitization as phenomena modeling learning processes in two groups of children: normally developing and mentally deficient in biofeedback research] Pecyna MB. **Pol Merkuriusz Lek** 1999 Feb;6(32):110-6 (Eng. Abstr.) (Pol)

DRUG EFFECTS

Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Gouzoulis-Mayfrank E, et al. **Behav Pharmacol** 1998 Nov; 9(7):561-6

Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Kopf SR, et al. **Neurobiol Learn Mem** 1999 Jan;71(1):50-61

Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Geyer MA. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:73-9 (47 ref.)

Effects of sustained cocaine exposure on sensorimotor gating of startle in rats. Martinez ZA, et al. **Psychopharmacology (Berl)** 1999 Mar;142(3):253-60

Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Vollenweider FX, et al. **Psychopharmacology (Berl)** 1999 Apr;143(4):365-72

[The role of the histaminergic receptor in the vestibular habituation: an experimental study] Kaźmierczak H, et al. **Otolaryngol Pol** 1998;52(4):447-50 (Eng. Abstr.) (Pol)

[The role of neurotransmitters in the vestibular habituation: an experimental study] Kaźmierczak H, et al. **Otolaryngol Pol** 1998;52(5):585-8 (Eng. Abstr.) (Pol)

GENETICS

Comparison of two sensitization paradigms of the acoustic startle response in Wistar and Sprague-Dawley rats. Pilz PK, et al. **Behav Genet** 1999 Jan;29(1):59-63

Effects of isolation rearing on startle reactivity, habituation, and prepulse inhibition in male Lewis, Sprague-Dawley, and Fischer F344 rats. Varty GB, et al. **Behav Neurosci** 1998 Dec;112(6):1450-7

The "anxiety state" and its relation with rat models of memory and habituation. Ribeiro RL, et al. **Neurobiol Learn Mem** 1999 Sep;72(2):78-94

PHYSIOLOGY

Spatial memory, habituation, and reactions to spatial and nonspatial changes in rats with selective lesions of the hippocampus, the entorhinal cortex or the subiculum. Galani R, et al. **Behav Brain Res** 1998 Nov;96(1-2):1-12

Effect of context salience on heart rate orienting and habituation in preweanling and periadolescent rats. Kraebel KS, et al. **Behav Neurosci** 1998 Oct;112(5):1080-91

Sustained attachment to the nipple in the newborn rat depends on experience with the nipple, milk, and the expression of oral grasping. Petrov ES, et al. **Behav Neurosci** 1999 Feb;113(1):211-21

Amphetamine-induced conditioned activity and sensitization: the role of habituation to the test context and the involvement of Pavlovian processes. Tirelli E, et al. **Behav Pharmacol** 1998 Sep;9(5-6):409-19

Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. Boutros NN, et al. **Biol Psychiatry** 1999 Apr 1;45(7):917-22

Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. Cadenhead KS, et al. **Biol Psychiatry** 1999 Feb 1;45(3):360-4

P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Oranje B, et al. **Biol Psychiatry** 1999 Apr 1;45(7):883-90

Dynamic changes of cognitive habituation and serotonin metabolism during the migraine interval [see comments] Evers S, et al. **Cephalalgia** 1999 Jun;19(5):485-91. Comment in: Cephalalgia 1999 Jun;19(5):477.

Prediction of migraine attacks [editorial; comment] Kropp P. **Cephalalgia** 1999 Jun;19(5):477. Comment on: Cephalalgia 1999 Jun;19(5):485-91.

Maternal corticotropin-releasing hormone and habituation in the human fetus. Sandman CA, et al. **Dev Psychobiol** 1999 Apr;34(3):163-73

The effect of serotonin depletion on motor activity habituation, and [3H]muscimol binding in the rat hippocampus. Bidziński A, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):5-12

alpha-melanocyte-stimulating hormone and habituation of prey-catching behavior in the Texas toad, Bufo speciosus. Olsen CM, et al. **Horm Behav** 1999 Aug;36(1):62-9

Decrement of the N1 auditory event-related potential with stimulus repetition: habituation vs. refractoriness. Budd TW, et al. **Int J Psychophysiol** 1998 Dec;31(1):51-68

Analysis and modeling of frequency-specific habituation of the goldfish vestibulo-ocular reflex. Dow ER, et al. **J Comput Neurosci** 1999 Jul-Aug;7(1):55-70

Involvement of the human cerebellum during habituation of the acoustic startle response: a PET study. Timmann D, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):771-3

Presynaptic calcium/calmodulin-dependent protein kinase II regulates habituation of a simple reflex in adult Drosophila. Jin P, et al. **J Neurosci** 1998 Nov 1;18(21):8955-64

Habituation of the initial responses to cold water immersion in humans: a central or peripheral mechanism? Tipton MJ, et al. **J Physiol (Lond)** 1998 Oct 15;512 (Pt 2):621-8

Human brain activation under controlled thermal stimulation and habituation to noxious heat: an fMRI study. Becerra LR, et al. **Magn Reson Med** 1999 May;41(5):1044-57

Context shift and protein synthesis inhibition disrupt long-term habituation after spaced, but not massed, training in the crab Chasmagnathus. Hermitte G, et al. **Neurobiol Learn Mem** 1999 Jan;71(1):34-49

Effect of environmental sound familiarity on dynamic neural activation/inhibition patterns: an ERD mapping study. Lebrun N, et al. **Neuroimage** 1998 Jul;8(1):79-92

Inhibition and habituation: preserved mechanisms of attentional selection in aging and Alzheimer's disease. Langley LK, et al. **Neuropsychology** 1998 Jul;12(3):353-66

Decrement of the response of a serotonergic modulatory neuron (the metacerebral cell) in Aplysia, during repeated presentation of appetitive (food) stimuli. Horn CC, et al. **Neurosci Lett** 1999 Jun 4;267(3):161-4

Strain differences in Fos expression following airpuff startle in Spontaneously Hypertensive and Wistar Kyoto rats. Palmer AA, et al. **Neuroscience** 1999 Mar;89(3):965-78

P300 habituation patterns: individual differences from ultradian rhythms. Lin E, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1111-25

The generalizability of capsaicin sensitization and desensitization. Prescott J. **Physiol Behav** 1999 Jul; 66(5):741-9

Effects of stimulus intensity, risetime, and duration on autonomic and behavioral responding: implications for the differentiation of orienting, startle, and defense responses. Turpin G, et al. **Psychophysiology** 1999 Jul;36(4):453-63

[The significance of synaptic neurotransmitters on the acquisition and retention of vestibular habituation] Mierzwiński J. **Otolaryngol Pol** 1998;52(6):747-9 (Pol)

HABRONEMA see **SPIRUROIDEA**

HABRONEMIASIS see **SPIRURIDA INFECTIONS**

HABU see **TRIMERESURUS**

HAEM OXYGENASE see **HEME OXYGENASE (DECYCLIZING)**

HAEMACCEL see **POLYGELINE**

HAEMATOBIA IRRITANS see **MUSCIDAE**

HAEMATOPINUS see **ANOPLURA**

HAEMOBARTONELLA see **ANAPLASMATACEAE**

HAEMOBARTONELLOSIS see **ANAPLASMATACEAE INFECTIONS**

HAEMONCHIASIS

DRUG THERAPY

PF1022A--a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. Scherkenbeck J, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1035-40

Anthelmintic resistance in sheep and goat farms on Peninsular Malaysia. Chandrawathani P, et al. **Vet Parasitol** 1999 May; 82(4):305-10

Decreased ivermectin and moxidectin sensitivity in Haemonchus contortus selected with moxidectin over 14 generations. Molento MB, et al. **Vet Parasitol** 1999 Sep 15;86(1):77-81

IMMUNOLOGY

Variation in resistance to haemonchosis: selection of female sheep resistant to Haemonchus contortus. Hooda V, et al. **J Helminthol** 1999 Jun;73(2):137-42

PREVENTION & CONTROL

Vaccination against the gastrointestinal nematode, Haemonchus contortus, using a purified larval surface antigen. Jacobs HJ, et al. **Vaccine** 1999 Jan 28;17(4):362-8

THERAPY

Biological control of Haemonchus contortus infective larvae in ovine faeces by administering an oral suspension of Duddingtonia flagrans chlamydospores to sheep. Mendoza de Gives P, et al. **J Helminthol** 1998 Dec;72(4):343-7

VETERINARY

Long-term effects of short-term provision of protein-enriched diets on resistance to nematode infection, and live-weight gain and wool growth in sheep. Datta FU, et al. **Int J Parasitol** 1999 Mar;29(3):479-88

The intramammary inflammatory response of genetically resistant Merino ewes infected with Haemonchus contortus. Thamsborg SM, et al. **Int J Parasitol** 1999 Mar; 29(3):451-8

Variation in resistance to haemonchosis: selection of female sheep resistant to Haemonchus contortus. Hooda V, et al. **J Helminthol** 1999 Jun;73(2):137-42

Biological control of Haemonchus contortus infective larvae in ovine faeces by administering an oral suspension of Duddingtonia flagrans chlamydospores to sheep. Mendoza de Gives P, et al. **J Helminthol** 1998 Dec;72(4):343-7

Immunization with an affinity purified protein extract from the adult parasite protects lambs against infection with Haemonchus contortus. Knox DP, et al. **Parasite Immunol** 1999 Apr;21(4):201-10

Further immunization and biochemical studies with a protective antigen complex from the microvillar membrane of the intestine of Haemonchus contortus. Smith SK, et al. **Parasite Immunol** 1999 Apr;21(4):187-99

The response of Nigerian West African Dwarf goats to experimental infections with Haemonchus contortus. Fakae BB, et al. **Res Vet Sci** 1999 Apr;66(2):147-58

Comparison of naturally acquired parasite burdens among Florida native, Rambouillet and crossbreed ewes. Amarante AF, et al. **Vet Parasitol** 1999 Aug 16;85(1):61-9

Nematode burdens and cellular responses in the abomasal mucosa and blood of Florida Native, Rambouillet and crossbreed lambs. Amarante AF, et al. **Vet Parasitol** 1999 Jan 28;80(4):311-24

Persistent activity of doramectin injectable formulation against experimental challenge with Haemonchus placei in cattle. Ballweber LR, et al. **Vet Parasitol** 1999 Sep 15; 86(1):1-4

Serum antibody response of Castellana sheep to Haemonchus contortus infection and challenge: relationship to abomasal worm burdens. Gómez-Muñoz MT, et al. **Vet Parasitol** 1999 Mar 15;81(4):281-93

The effects of urea supplementation on production and parasitological responses of sheep infected with Haemonchus contortus and Trichostrongylus colubriformis. Knox MR, et al. **Vet Parasitol** 1999 Jun 15; 83(2):123-35

The distribution of pepsinogen within the abomasa of cattle and sheep infected with Ostertagia spp. and sheep infected with Haemonchus contortus. Scott I, et al. **Vet Parasitol** 1999 Mar 31;82(2):145-59

Further studies on anthelmintic resistance in sheep at an organised farm in arid region of Rajasthan. Swarnkar CP, et al. **Vet Parasitol** 1999 Mar 22;82(1):81-4

Activity of eprinomectin in goats against experimental infections with Haemonchus contortus, Teladorsagia circumcincta and Trichostrongylus colubriformis. Chartier C, et al. **Vet Rec** 1999 Jan 23;144(4):99-100

The pharmacokinetics and efficacy of long-term low-level and split-dose administration of albendazole through in-feed formulations against ovine and caprine parasitic gastroenteritis. Sanyal PK. **Vet Res Commun** 1998 Nov; 22(7):467-77

Infection-induced protection against Haemonchus contortus in merino and manchego sheep. Relationship to serum antibody response. Gómez-Muñoz MT, et al. **Zentralbl Veterinarmed [B]** 1998 Oct;45(8):449-59

HAEMONCHUS

ANATOMY & HISTOLOGY

Chemo- and thermosensory neurons: structure and function in animal parasitic nematodes. Ashton FT, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):297–316 (49 ref.)

CHEMISTRY

Characterization of a hemoglobin-like protein from adult Haemonchus contortus. Fetterer RH, et al. **J Parasitol** 1999 Apr;85(2):295–300

A hemolytic factor from Haemonchus contortus alters erythrocyte morphology. Fetterer RH, et al. **Vet Parasitol** 1998 Dec 15;80(1):37–45

DRUG EFFECTS

Haemonchus contortus: characterization of a glutamate binding site in unselected and ivermectin-selected larvae and adults. Paiement J, et al. **Exp Parasitol** 1999 May; 92(1):32–9

Haemonchus contortus: effects of glutamate, ivermectin, and moxidectin on inulin uptake activity in unselected and ivermectin-selected adults. Paiement JP, et al. **Exp Parasitol** 1999 Jul;92(3):193–8

Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoproteins. Sangster NC, et al. **Exp Parasitol** 1999 Mar;91(3):250–7

Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus. Kwa MS, et al. **Int J Parasitol** 1998 Aug;28(8):1235–40

Comparative in vitro effects of closantel and selected beta-ketoamide anthelmintics on a gastrointestinal nematode and vertebrate liver cells. Bacon JA, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):190–8

Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Blackhall WJ, et al. **Mol Biochem Parasitol** 1998 Sep 15; 95(2):193–201

Flow cytometry analysis of drug transport mechanisms in Haemonchus contortus susceptible or resistant to anthelmintics. Kerboeuf D, et al. **Parasitol Res** 1999 Feb; 85(2):118–23

Unexpected increased thiabendazole tolerance in Haemonchus contortus resistant to anthelmintics by modulation of glutathione activity. Kerboeuf D, et al. **Parasitol Res** 1999 Aug;85(8–9):713–8

Anthelmintic resistance in sheep and goat farms on Peninsular Malaysia. Chandrawathani P, et al. **Vet Parasitol** 1999 May; 82(4):305–10

Decreased ivermectin and moxidectin sensitivity in Haemonchus contortus selected with moxidectin over 14 generations. Molento MB, et al. **Vet Parasitol** 1999 Sep 15;86(1):77–81

Further studies on anthelmintic resistance in sheep at an organised farm in arid region of Rajasthan. Swarnkar CP, et al. **Vet Parasitol** 1999 Mar 22;82(1):81–4

Comparison of six in vitro tests in determining benzimidazole and levamisole resistance in Haemonchus contortus and Ostertagia circumcincta of sheep. Várady M, et al. **Vet Parasitol** 1999 Jan 14;80(3):239–49

ENZYMOLOGY

The ruminant parasite Haemonchus contortus expresses an alpha1,3-fucosyltransferase capable of synthesizing the Lewis x and sialyl Lewis x antigens. DeBose-Boyd RA, et al. **Glycoconj J** 1998 Aug;15(8):789–98

Peroxide-supported in-vitro cytochrome P450 activities in Haemonchus contortus. Kotze AC. **Int J Parasitol** 1999 Mar;29(3):389–96

Analysis of helminth genetic data: comparative examples with Haemonchus contortus isozymes using exact tests or resampling procedures. Bentounsi B, et al. **Parasitol Res** 1999 Oct;85(10):855–7

Cloning and characterization of glutamate dehydrogenase (GDH) from the gut of Haemonchus contortus. Skuce PJ, et al. **Parasitology** 1999 Mar;118 (Pt 3):297–304

Haemonchus contortus: characterization and purification of excretory/secretory protease(s). Kocher DK, et al. **Zentralbl Veterinarmed [B]** 1998 Nov;45(9):567–72

GENETICS

Cloning, sequencing, and developmental expression levels of a novel glutamate-gated chloride channel homologue in the parasitic nematode Haemonchus contortus. Forrester SG, et al. **Biochem Biophys Res Commun** 1999 Jan 27; 254(3):529–34

Characterization of a hexokinase encoding cDNA of the parasitic nematode Hhaemonchus contortus. Schmitt-Wrede HP, et al. **Biochim Biophys Acta** 1999 Mar 19;1444(3):439–44

Analysis of sequence homogenisation in rDNA arrays of Haemonchus contortus by denaturing gradient gel electrophoresis. Gasser RB, et al. **Electrophoresis** 1998 Oct; 19(14):2391–5

Use of P-glycoprotein gene probes to investigate anthelmintic resistance in Haemonchus contortus and comparison with Onchocerca volvulus. Kwa MS, et al. **Int J Parasitol** 1998 Aug;28(8):1235–40

Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of Haemonchus contortus. Blackhall WJ, et al. **Mol Biochem Parasitol** 1998 Sep 15; 95(2):193–201

Cloning and localisation of an avermectin receptor-related subunit from Haemonchus contortus. Delany NS, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1–2):177–87

Analysis of helminth genetic data: comparative examples with Haemonchus contortus isozymes using exact tests or resampling procedures. Bentounsi B, et al. **Parasitol Res** 1999 Oct;85(10):855–7

Cloning and characterization of glutamate dehydrogenase (GDH) from the gut of Haemonchus contortus. Skuce PJ, et al. **Parasitology** 1999 Mar;118 (Pt 3):297–304

GROWTH & DEVELOPMENT

Haemonchus contortus: characterization of a glutamate binding site in unselected and ivermectin-selected larvae and adults. Paiement J, et al. **Exp Parasitol** 1999 May; 92(1):32–9

Comparison of naturally acquired parasite burdens among Florida native, Rambouillet and crossbreed ewes. Amarante AF, et al. **Vet Parasitol** 1999 Aug 16;85(1):61–9

The effects of urea supplementation on production and parasitological responses of sheep infected with Haemonchus contortus and Trichostrongylus colubriformis. Knox MR, et al. **Vet Parasitol** 1999 Jun 15; 83(2):123–35

Development and survival of infective larvae of nematode parasites of sheep on pasture in a cool tropical environment. Tembely S. **Vet Parasitol** 1998 Sep;79(1):81–7

IMMUNOLOGY

The intramammary inflammatory response of genetically resistant Merino ewes infected with Haemonchus contortus. Thamsborg SM, et al. **Int J Parasitol** 1999 Mar; 29(3):451–8

A tissue specific approach for analysis of membrane and secreted protein antigens from Haemonchus contortus gut and its application to diverse nematode species. Rehman A, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1–2):55–68

Vaccination against the gastrointestinal nematode, Haemonchus contortus, using a purified larval surface antigen. Jacobs HJ, et al. **Vaccine** 1999 Jan 28;17(4):362–8

Nematode burdens and cellular responses in the abomasal mucosa and blood of Florida Native, Rambouillet and crossbreed lambs. Amarante AF, et al. **Vet Parasitol** 1999 Jan 28;80(4):311–24

Serum antibody response of Castellana sheep to Haemonchus contortus infection and challenge: relationship to abomasal worm burdens. Gómez-Muñoz MT, et al. **Vet Parasitol** 1999 Mar 15;81(4):281–93

Cross-reactive antigens of Haemonchus contortus adult worms in Teladorsagia circumcincta infected goats. Molina JM, et al. **Vet Res** 1999 Jul–Aug;30(4):393–9

ISOLATION & PURIFICATION

The response of Nigerian West African Dwarf goats to experimental infections with Haemonchus contortus. Fakae BB, et al. **Res Vet Sci** 1999 Apr;66(2):147–58

METABOLISM

Superoxide dismutase and total antioxidant status of larvae and adults of Trichostrongylus colubriformis, Haemonchus contortus and Ostertagia circumcincta. Hadaś E, et al. **Parasitol Res** 1998 Aug;84(8):646–50

Unexpected increased thiabendazole tolerance in Haemonchus contortus resistant to anthelmintics by modulation of glutathione activity. Kerboeuf D, et al. **Parasitol Res** 1999 Aug;85(8–9):713–8

Flow cytometry analysis of drug transport mechanisms in Haemonchus contortus susceptible or resistant to anthelmintics. Kerboeuf D, et al. **Parasitol Res** 1999 Feb; 85(2):118–23

PHYSIOLOGY

Structural characterisation and pharmacology of KHEYLRFamide (AF2) and KSAYMRFamide (PF3/AF8) from Haemonchus contortus. Marks NJ, et al. **Mol Biochem Parasitol** 1999 May 25;100(2):185–94

Development and survival of infective larvae of gastrointestinal nematodes of cattle on pasture in central Kenya. Waruiru RM, et al. **Vet Res Commun** 1998 Jul; 22(5):315–23

HAEMOPHILUS

CLASSIFICATION

Detection of a common genotype among strains of Taylorella equigenitalis isolated from thoroughbred horses in Japan between 1994 and 1996. Matsuda M, et al. **J Basic Microbiol** 1999;39(2):127–30

Evaluation of two commercial kits and arbitrarily primed PCR for identification and differentiation of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, and Haemophilus paraphrophilus. Doğan B, et al. **J Clin Microbiol** 1999 Mar;37(3):742–7

Confirmation that PCR can be used to identify NAD-dependent and NAD-independent Haemophilus paragallinarum isolates. Miflin JK, et al. **Onderstepoort J Vet Res** 1999 Mar;66(1):55–7

Development of a PCR test for identification of Haemophilus somnus in pure and mixed cultures. Angen O, et al. **Vet Microbiol** 1998 Aug 28;63(1):39–48

Prevalence of Haemophilus parasuis serovars isolated in Spain from 1993 to 1997. Rúbies X, et al. **Vet Microbiol** 1999 Apr 19;66(3):245–8

DRUG EFFECTS

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Piddock LJ, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2956–60

[Inhibitors of beta-lactamases in the genus Haemophilus] Rodriguez-Avial López-Dóriga MC. **Rev Esp Quimioter** 1998 Dec;11(4):380–1 **(Spa)**

ENZYMOLOGY

An investigation into the influences of species and biotype on the type of IgA1 protease produced by isolates of Haemophilus. Senior BW, et al. **J Med Microbiol** 1999 Apr; 48(4):389–94

GENETICS

Small subunit rRNA gene sequences of Aeromonas salmonicida subsp. smithia and Haemophilus piscium reveal pronounced similarities with A. salmonicida subsp. salmonicida. Thornton JM, et al. **Dis Aquat Organ** 1999 Jan 29;35(2):155–8

Nucleotide sequences of genes coding for fimbrial proteins in a cryptic genospecies of Haemophilus spp. isolated from neonatal and genital tract infections. Gousset N, et al. **Infect Immun** 1999 Jan;67(1):8–15

GROWTH & DEVELOPMENT

Intracellular survival of Haemophilus somnus in bovine blood monocytes and alveolar macrophages. Gomis SM, et al. **Microb Pathog** 1998 Nov;25(5):227–35

IMMUNOLOGY

Protective role of maternal antibodies against Haemophilus parasuis infection. Solano-Aguilar GI, et al. **Am J Vet Res** 1999 Jan;60(1):81–7

Porcine reproductive and respiratory syndrome virus and Haemophilus parasuis antigen distribution in dually infected pigs. Segalés J, et al. **Vet Microbiol** 1999 Feb 12; 64(4):287–97

An immunodominant epitope on 40 kilodalton outer membrane protein is conserved among different strains of Haemophilus (Histophilus) somnus. Silva SV, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):449–56

ISOLATION & PURIFICATION

A monoclonal antibody-blocking enzyme-linked immunosorbent assay for the detection of serovar-specific antibodies to Haemophilus paragallinarum. Zhang P, et al. **Avian Dis** 1999 Jan–Mar;43(1):75–82

The association of titers to Haemophilus somnus, and other putative pathogens, with the occurrence of bovine respiratory disease and weight gain in feedlot calves. Martin SW, et al. **Can J Vet Res** 1998 Oct;62(4):262–7

Characterization of putative Haemophilus somnus isolates from tonsils of American bison (Bison bison). Ward AC, et al. **Can J Vet Res** 1999 Jul;63(3):166–9

Haemophilus aphrophilus meningitis complicated by hydrocephalus in an immunocompetent adult. Adeyemi-Doro FA, et al. **Infection** 1998 Nov–Dec; 26(6):405–7

Peritonitis caused by Haemophilus parainfluenzae in a patient undergoing continuous ambulatory peritoneal dialysis. Betriu C, et al. **J Clin Microbiol** 1999 Sep;37(9):3074–5

Haemophilus paraphrophilus; a rare cause of intracranial abscess. Hart AJ, et al. **J Infect** 1998 Jul;37(1):75–6

Confirmation that PCR can be used to identify NAD-dependent and NAD-independent Haemophilus paragallinarum isolates. Miflin JK, et al. **Onderstepoort J Vet Res** 1999 Mar;66(1):55–7

Biliary tract infection caused by Haemophilus parainfluenzae. Alvarez M, et al. **Scand J Infect Dis** 1999;31(2):212–3

Use of a PCR assay for Taylorella equigenitalis applied to samples from the United Kingdom. Chanter N, et al. **Vet Rec** 1998 Aug 22;143(8):225–7

PATHOGENICITY

Effect of porcine reproductive and respiratory syndrome virus infection on the clearance of Haemophilus parasuis by porcine alveolar macrophages. Solano GI, et al. **Can J Vet Res** 1998 Oct;62(4):251–6

HAEMOPHILUS DUCREYI

see related

CHANCROID

Standardization of the experimental model of Haemophilus ducreyi infection in human subjects. Al-Tawfiq JA, et al. **J Infect Dis** 1998 Dec;178(6):1684–7

CHEMISTRY

Identification of the znuA-encoded periplasmic zinc transport protein of Haemophilus ducreyi. Lewis DA, et al. **Infect Immun** 1999 Oct;67(10):5060-8

CLASSIFICATION

Molecular characterization of Haemophilus ducreyi strains from Jackson, Mississippi, and New Orleans, Louisiana. Haydock AK, et al. **J Infect Dis** 1999 Jun;179(6):1423-32

DRUG EFFECTS

Haemophilus ducreyi is susceptible to protegrin. Fortney K, et al. **Antimicrob Agents Chemother** 1998 Oct;42(10):2690-3

ENZYMOLOGY

Investigation of the kinetic mechanism of cytidine 5'-monophosphate N-acetylneuraminic acid synthetase from Haemophilus ducreyi with new insights on rate-limiting steps from product inhibition analysis. Samuels NM, et al. **Biochemistry** 1999 May 11; 38(19):6195-203

Neutropenia restores virulence to an attenuated Cu,Zn superoxide dismutase-deficient Haemophilus ducreyi strain in the swine model of chancroid. San Mateo LR, et al. **Infect Immun** 1999 Oct;67(10):5345-51

Haemophilus ducreyi produces a novel sialyltransferase. Identification of the sialyltransferase gene and construction of mutants deficient in the production of the sialic acid-containing glycoform of the lipooligosaccharide. Bozue JA, et al. **J Biol Chem** 1999 Feb 12;274(7):4106-14

GENETICS

The dnaK/dnaJ operon of Haemophilus ducreyi contains a unique combination of regulatory elements. Parsons LM, et al. **Gene** 1999 Jun 11;233(1-2):109-19

Characterization of a WaaF (RfaF) homolog expressed by Haemophilus ducreyi. Bauer BA, et al. **Infect Immun** 1999 Feb;67(2):899-907

Haemophilus ducreyi secretes a filamentous hemagglutinin-like protein. Ward CK, et al. **J Bacteriol** 1998 Nov;180(22):6013-22

Haemophilus ducreyi produces a novel sialyltransferase. Identification of the sialyltransferase gene and construction of mutants deficient in the production of the sialic acid-containing glycoform of the lipooligosaccharide. Bozue JA, et al. **J Biol Chem** 1999 Feb 12;274(7):4106-14

GROWTH & DEVELOPMENT

Effect of normal and immune sera on Haemophilus ducreyi 35000HP and its isogenic MOMP and LOS mutants. Hiltke TJ, et al. **Microb Pathog** 1999 Feb;26(2):93-102

IMMUNOLOGY

Prevalence of, antibody response to, and immunity induced by Haemophilus ducreyi hemolysin. Dutro SM, et al. **Infect Immun** 1999 Jul;67(7):3317-28

The immune response to Haemophilus ducreyi resembles a delayed-type hypersensitivity reaction throughout experimental infection of human subjects. Palmer KL, et al. **J Infect Dis** 1998 Dec;178(6):1688-97

Experimental infection of human volunteers with Haemophilus ducreyi does not confer protection against subsequent challenge. Al-Tawfiq JA, et al. **J Infect Dis** 1999 May;179(5):1283-7

ISOLATION & PURIFICATION

Comparison of culture media for the laboratory diagnosis of chancroid. Pillay A, et al. **J Med Microbiol** 1998 Nov; 47(11):1023-6

METABOLISM

The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase. Cortes-Bratti X, et al. **J Clin Invest** 1999 Jan; 103(1):107-15

PATHOGENICITY

Characterization of a Haemophilus ducreyi mutant deficient in expression of cytolethal distending toxin. Stevens MK, et al. **Infect Immun** 1999 Aug;67(8):3900-8

Target cell range of Haemophilus ducreyi hemolysin and its involvement in invasion of human epithelial cells. Wood GE, et al. **Infect Immun** 1999 Aug;67(8):3740-9

Examination of early interactions between Haemophilus ducreyi and host cells by using cocultured HaCaT keratinocytes and foreskin fibroblasts. Zaretzky FR, et al. **Infect Immun** 1999 Oct;67(10):5352-60

PHYSIOLOGY

Binding of Haemophilus ducreyi to extracellular matrix proteins. Bauer ME, et al. **Infect Immun** 1999 May; 67(5):2649-52

HAEMOPHILUS INFECTIONS

Proceedings of the 1st International Conference on Haemophilus influenzae type b Infection in Asia. Bali, Indonesia, December 17-19, 1996. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92-210

Haemophilus influenzae in Asia. Lee JW. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92

Summary statement: The First International Conference on Haemophilus influenzae type b infection in Asia. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S93-5

[Haemophilus influenzae pneumonia] Okimoto N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):377-80 (12 ref.) **(Jpn)**

[Urethritis caused by serotype B Haemophilus influenzae. Report of a case] Llanes Caballero R, et al. **Rev Cubana Med Trop** 1996;48(2):130-2 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Induction of cytokines and anti-cytokine autoantibodies in cerebrospinal fluid (CSF) during experimental bacterial meningitis. Bakhiet M, et al. **Clin Exp Immunol** 1998 Dec; 114(3):398-402

COMPLICATIONS

Course of IL-1beta, IL-6, IL-8, and TNF-alpha in the middle ear fluid of the guinea pig otitis media model induced by nonviable Haemophilus influenzae. Sato K, et al. **Ann Otol Rhinol Laryngol** 1999 Jun;108(6):559-63

Suspected Brazilian purpuric fever in a toddler with overwhelming Epstein-Barr virus infection. Virata M, et al. **Clin Infect Dis** 1998 Nov;27(5):1238-40

Congenital malformation of the inner ear associated with recurrent meningitis. Kimitsuki T, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S11-4

Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Mori M, et al. **Neurology** 1999 Apr 12;52(6):1282-4

Spontaneous disappearance of a middle cranial fossa arachnoid cyst after suppurative meningitis [see comments] Yoshioka H, et al. **Surg Neurol** 1998 Nov;50(5):487-91 (26 ref.). Comment in: Surg Neurol 1999 Jun;51(6):687-8.

[Epiglottitis: pathology in young children? (letter)] Nouyrigat V, et al. **Arch Pediatr** 1999 Jan;6(1):109-10 **(Fre)**

[Case of infectious abdominal aneurysm complicating influenza septicemia] Yamazaki S, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):342-3 **(Jpn)**

[Vaccinal failures after the immunization with vaccine against H. influenzae type B (letter)] Pineda Solas V, et al. **An Esp Pediatr** 1999 May;50(5):533-4 **(Spa)**

[Endocarditis caused by Haemophilus aphrophilus (letter)] Roca B, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):153 **(Spa)**

DIAGNOSIS

Reliability of parental history of antibiotic use for Filipino children admitted with acute lower respiratory tract infection. Sombrero L, et al. **Am J Trop Med Hyg** 1999 Mar;60(3):397-9

Unvaccinated child dies of Haemophilus influenzae type b infection. **Commun Dis Rep CDR Wkly** 1999 May 7; 9(19):167, 170

Isolation of Haemophilus influenzae in Central Asia. LaClaire L, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct; 17(10):746-7

Acute epiglottis [letter; comment] Kumar RK, et al. **J Paediatr Child Health** 1998 Dec;34(6):594. Comment on: J Paediatr Child Health 1998 Jun;34(3):306-7.

Development of an oligonucleotide-specific capture plate hybridization assay for detection of Haemophilus parasuis. Calsamiglia M, et al. **J Vet Diagn Invest** 1999 Mar; 11(2):140-5

[Usefulness of rapid antigen detection for the diagnosis of systemic infections due to Haemophilus influenzae] Ohkusu K, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):336-40 (Eng. Abstr.) **(Jpn)**

[Haemophilus influenzae type b osteoarthritis. A report of 7 cases and a review of the literature] Otero Reigada MC, et al. **An Esp Pediatr** 1998 Dec;49(6):594-602 (102 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Ketolide treatment of Haemophilus influenzae experimental pneumonia. Piper KE, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):708-10

Haemophilus influenzae associated scleritis. Sykes SO, et al. **Br J Ophthalmol** 1999 Apr;83(4):410-3

Resistance patterns of Haemophilus influenzae. Acar JF. **J Chemother** 1999 Feb;11 Suppl 1:44-50

Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996. Felmingham D, et al. **J Chemother** 1999 Feb;11 Suppl 1:5-21

Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study. Gallenga PE, et al. **Ophthalmologica** 1999;213(4):250-7

[Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia] Toyonaga Y, et al. **Jpn J Antibiot** 1999 Apr;52(4):322-32 (Eng. Abstr.) **(Jpn)**

[Inhibitors of beta-lactamases in the genus Haemophilus] Rodriguez-Avial López-Dóriga MC. **Rev Esp Quimioter** 1998 Dec;11(4):380-1 **(Spa)**

ECONOMICS

An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia. Miller MA. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S152-9

EPIDEMIOLOGY

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Jafari HS, et al. **Am J Public Health** 1999 Mar;89(3):364-8

A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. Wolff MC, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):263-6

Haemophilus influenzae type B disease at 11 pediatric centres, 1996-1997. Grewal S, et al. **Can Commun Dis Rep** 1998 Jul 1;24(13):105-8 **(Eng, Fre)**

Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae in Taiwan. Lin HC, et al. **J Formos Med Assoc** 1999 May;98(5):319-25

Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. Galil K, et al. **J Infect Dis** 1999 Jan;179(1):101-6

Oklahoma notes decline in Haemophilus influenzae: invasive Haemophilus influenzae disease among children aged < 5 years--Oklahoma, 1990-1997. Lee AK, et al. **J Okla State Med Assoc** 1999 Jun;92(6):276-7

From the Centers for Disease Control and Prevention. Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. **JAMA** 1999 Feb 3;281(5):409-10

Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. **MMWR Morb Mortal Wkly Rep** 1998 Nov 27; 47(46):993-8

Haemophilus influenzae type b disease in Thailand. Chotpitayasunondh T. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S191

A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S198-203

Epiglottitis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Garpenholt O, et al. **Pediatr Infect Dis J** 1999 Jun; 18(6):490-3

A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Gessner BD, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S179-82

The epidemiology of Haemophilus influenzae type b carriage among infants and young children in Santo Domingo, Dominican Republic. Gómez E, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):782-6

Haemophilus influenzae disease in children in India: a hospital perspective. John TJ, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S169-71

Haemophilus influenzae type b infections in Hong Kong. Lau YL, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S165-9

Epidemiology of systemic Haemophilus influenzae disease in Korean children. Lee HJ. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S185-9

Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S126-32

Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Slack MP, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S204-7

Invasive Haemophilus influenzae disease in India: a preliminary report of prospective multihospital surveillance. IBIS (Invasive Bacterial Infections Surveillance) Group. Steinhoff MC. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S172-5

The etiology of bacterial pneumonia and meningitis in Vietnam. Tran TT, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S192-4

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Wenger JD. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S132-6

Study on Haemophilus influenzae type b diseases in China: the past, present and future. Yang Y, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S159-65

Streptococcus pneumoniae and Haemophilus influenzae as etiological agents of conjunctivitis outbreaks in the region of Ribeirão Preto, SP, Brazil. Medeiros MI, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan-Feb;40(1):7-9

Epidemiology of invasive Haemophilus influenzae type b infections among children in Greece before the introduction of immunization. Tsolia MN, et al. **Scand J Infect Dis** 1998;30(2):165-8

Epidemiology of Haemophilus influenzae invasive disease in hospitalised Kelantanese children, 1985-1994. Nik Khairulddin NY, et al. **Singapore Med J** 1999 Feb; 40(2):96-100

[Impact of vaccination against Haemophilus influenzae on

the incidence of invasive infections from Haemophilus influenzae type B in the Nord-Pas-de-Calais region] Dumonceaux A, et al. **Arch Pediatr** 1999 Jun;6(6):617-24 (Eng. Abstr.) **(Fre)**

[Epidemiology of nasopharyngeal colonization by Streptococcus pneumoniae and Haemophilus influenzae in a closed community of young children] Moulin F, et al. **Arch Pediatr** 1999;6 Suppl 3:620s-624s **(Fre)**

[Epidemiology of invasive Hemophilus influenzae B infections in Bedouins and Jews; conjugate Hib vaccines] Gortzak-Uzan L, et al. **Harefuah** 1998 Sep;135(5-6):175-80, 256 (Eng. Abstr.) **(Heb)**

[Haemophilus influenzae serotype b invasive disease (editorial)] Campos J. **Med Clin (Barc)** 1999 Jan 16; 112(1):16-7 **(Spa)**

[Haemophilus influenzae type b invasive disease in Catalonia (1996)] Dominguez A, et al. **Med Clin (Barc)** 1999 Jan 16; 112(1):5-9 (Eng. Abstr.) **(Spa)**

[Haemophilus influenza type b invasive disease in the Community of Valencia. Study Group on Invasive Diseases] Morant A, et al. **Med Clin (Barc)** 1999 Jan 16; 112(1):20-3 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Femoral osteomyelitis after tooth extraction. Roberts DE. **Am J Orthop** 1998 Sep;27(9):624-6

Haemophilus aphrophilus osteomyelitis after dental prophylaxis. A case report. Dewire P, et al. **Clin Orthop** 1999 Jun;(363):196-202

Polyarticular septic arthritis caused by non-encapsulated haemophilus influenzae biotype I in a rheumatic adult. Melhus A, et al. **Scand J Infect Dis** 1998;30(6):630-1

[Recurrent spontaneous bacterial peritonitis due to encapsulated microorganisms (Haemophilus influenzae and Streptococcus pneumoniae) in a patient with liver cirrhosis (letter)] Salavert M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):30-1 (10 ref.) **(Spa)**

IMMUNOLOGY

Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. Adegbola RA, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):15-9

Kinetics of inflammatory cytokines in the clearance of non-typeable Haemophilus influenzae from the lung. Foxwell AR, et al. **Immunol Cell Biol** 1998 Dec;76(6):556-9

Transplacental transfer of H. influenzae type b antibody. John TJ. **Indian Pediatr** 1998 Sep;35(9):919-20

Haemophilus influenzae type b polysaccharides-protein conjugate vaccine elicits a more diverse antibody repertoire in infants than in adults. Adderson EE, et al. **J Immunol** 1998 Oct 15;161(8):4177-82

A novel mechanism for cytokine regulation: screening, selection, and characterization of anticytokine monoclonal and polyclonal autoantibodies. Bakhiet M, et al. **J Interferon Cytokine Res** 1999 May;19(5):439-45

Adaptation of Haemophilus influenzae to acquired and innate humoral immunity based on phase variation of lipopolysaccharide. Weiser JN, et al. **Mol Microbiol** 1998 Nov;30(4):767-75

Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease. Berthet F, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):156-60

[Antibody titer, immunologic memory and protective efficiency of the vaccine against Haemophilus influenzae type B. Vaccine Committee of the Spanish Association of Pediatrics] **An Esp Pediatr** 1999 Apr;50(4):341-5 **(Spa)**

METABOLISM

Localization of nontypeable Haemophilus influenzae endotoxin in the middle and inner ear during experimental otitis media. Demaria TF. **Acta Otolaryngol** 1999; 119(5):583-7

MICROBIOLOGY

Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Vila J, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):161-2

Intra- and interstrain differences of virulence among nontypeable Haemophilus influenzae strains. Melhus A, et al. **APMIS** 1998 Sep;106(9):858-68

Haemophilus influenzae pyelonephritis in adults [letter] [published erratum appears in Arch Intern Med 1999 Jun 28;159(12):1363] Reichman JM, et al. **Arch Intern Med** 1999 Feb 8;159(3):316

Increasing prevalence of ampicillin- resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Seki H, et al. **Chemotherapy** 1999 Jan-Feb;45(1):15-21

Identification of common lipooligosaccharide types in isolates from patients with otitis media by monoclonal antibodies against nontypeable Haemophilus influenzae 9274. Ueyama T, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):96-100

Recurrent ventriculoperitoneal shunt infection due to nontypeable Haemophilus influenzae. Lim ME, et al. **Clin Infect Dis** 1999 Jan;28(1):147-8

Septic arthritis caused by Haemophilus influenzae associated with endocarditis. Lesage V, et al. **Clin Rheumatol** 1998; 17(4):340-2

Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. Rao VK, et al. **FEMS Microbiol Rev** 1999 Apr;23(2):99-129 (206 ref.)

Nucleotide sequences of genes coding for fimbrial proteins in a cryptic genospecies of Haemophilus spp. isolated from neonatal and genital tract infections. Gousset N, et al. **Infect Immun** 1999 Jan;67(1):8-15

Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. Huebner RE, et al. **Int J Infect Dis** 1998 Jul-Sep; 3(1):18-25

Bacteriology of the middle meatus in children. Gordts F, et al. **Int J Pediatr Otorhinolaryngol** 1999 May 5; 48(2):163-7

Correlation between presence of viable bacteria and presence of endotoxin in middle-ear effusions. Dingman JR, et al. **J Clin Microbiol** 1998 Nov;36(11):3417-9

Haemophilus paraphrophilus; a rare cause of intracranial abscess. Hart AJ, et al. **J Infect** 1998 Jul;37(1):75-6

The pathogenic role of fimbriae of Haemophilus influenzae type b in murine bacteraemia and meningitis. Miyazaki S, et al. **J Med Microbiol** 1999 Apr;48(4):383-8

Contribution of in vivo 1H spectroscopy to the diagnosis of deep-seated brain abscess [letter] Sabatier J, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):120-1

Virulence Enhancement Agents for Haemophilus influenzae type B infection in mice. Sifontes Rodriguez S, et al. **Lab Anim Sci** 1999 Feb;49(1):95-8 (19 ref.)

Preseptal and orbital cellulitis in childhood. A changing microbiologic spectrum. Donahue SP, et al. **Ophthalmology** 1998 Oct;105(10):1902-5; discussion 1905-6

Incidence of Haemophilus influenzae in the throats of healthy infants with different feeding methods. Hokama T, et al. **Pediatr Int** 1999 Jun;41(3):277-80

Streptococcus pneumoniae and Haemophilus influenzae as etiological agents of conjunctivitis outbreaks in the region of Ribeirão Preto, SP, Brazil. Medeiros MI, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan-Feb;40(1):7-9

Biliary tract infection caused by Haemophilus parainfluenzae. Alvarez M, et al. **Scand J Infect Dis** 1999;31(2):212-3

[Sepsis caused by Haemophilus influenzae type B with septic arthritis in an infant] Bona G, et al. **Minerva Pediatr** 1998 May;50(5):193-6 (Eng. Abstr.) **(Ita)**

[Inhibitors of beta-lactamases in the genus Haemophilus] Rodríguez-Avial López-Dóriga MC. **Rev Esp Quimioter** 1998 Dec;11(4):380-1 **(Spa)**

PHYSIOPATHOLOGY

Fur and iron transport proteins in the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius. Smoot LM, et al. **J Med Microbiol** 1999 Jul;48(7):629-36

PREVENTION & CONTROL

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Jafari HS, et al. **Am J Public Health** 1999 Mar;89(3):364-8

Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. Talan DA, et al. **Ann Emerg Med** 1999 Jul; 34(1):109-11

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Vance E, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):735-41

Haemophilus influenzae type B infection. Levine O, et al. **Bull World Health Organ** 1998;76 Suppl 2:131-2

Towards a protein vaccine for nontypeable Haemophilus influenzae. Kyd JM, et al. **Clin Infect Dis** 1999 Feb; 28(2):238

Newer vaccines: like Marie Antoinette said, "let the poor eat cake" [letter; comment] Puliyel JM. **Indian Pediatr** 1998 Dec;35(12):1245-9. Comment on: Indian Pediatr 1998 Aug;35(8):791-5.

Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Bakaletz LO, et al. **Infect Immun** 1999 Jun;67(6):2746-62

A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia--ethical considerations [comment] Mulholland K, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):749-55 (22 ref.). Comment on: Int J Tuberc Lung Dis 1999 Sep;3(9):745-6.

Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. Kurono Y, et al. **J Infect Dis** 1999 Jul;180(1):122-32

A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S198-203

Haemophilus influenzae type b vaccines: history, choice and comparisons. Decker MD, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S113-6

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S117-22 (19 ref.)

The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Lagos R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S139-48

Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S95-113 (131 ref.)

Characterization of immune response as an indicator of Haemophilus influenzae type b vaccine efficacy. Madore DV. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S207-10

An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia. Miller MA. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S152-9

The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease? Mulholland EK, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S123-5

Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S126-32

The introduction of Haemophilus influenzae type b immunization into the United Kingdom: practical steps to assure success. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S136-9

Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Slack MP, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S204-7

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Wenger JD. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S132-6

Study on Haemophilus influenzae type b diseases in China: the past, present and future. Yang Y, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S159-65

Haemophilus influenzae type B vaccine. **S Afr Med J** 1999 Jul;89(7):738

Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Vaccine** 1999 Jan;17(2):134-41

[Antibody titer, immunologic memory and protective efficiency of the vaccine against Haemophilus influenzae type B. Vaccine Committee of the Spanish Association of Pediatrics] **An Esp Pediatr** 1999 Apr;50(4):341-5 **(Spa)**

[Vaccinal failures after the immunization with vaccine against H. influenzae type B (letter)] Pineda Solas V, et al. **An Esp Pediatr** 1999 May;50(5):533-4 **(Spa)**

VETERINARY

Protective role of maternal antibodies against Haemophilus parasuis infection. Solano-Aguilar GI, et al. **Am J Vet Res** 1999 Jan;60(1):81-7

Agents of the "suis-ide diseases" of swine: Actinobacillus suis, Haemophilus parasuis, and Streptococcus suis. MacInnes JI, et al. **Can J Vet Res** 1999 Apr;63(2):83-9 (52 ref.)

The association of titers to Haemophilus somnus, and other putative pathogens, with the occurrence of bovine respiratory disease and weight gain in feedlot calves. Martin SW, et al. **Can J Vet Res** 1998 Oct;62(4):262-7

Effect of porcine reproductive and respiratory syndrome virus infection on the clearance of Haemophilus parasuis by porcine alveolar macrophages. Solano GI, et al. **Can J Vet Res** 1998 Oct;62(4):251-6

Characterization of putative Haemophilus somnus isolates from tonsils of American bison (Bison bison). Ward AC, et al. **Can J Vet Res** 1999 Jul;63(3):166-9

Intracellular survival of Haemophilus somnus in bovine blood monocytes and alveolar macrophages. Gomis SM, et al. **Microb Pathog** 1998 Nov;25(5):227-35

Prevalence of Haemophilus parasuis serovars isolated in Spain from 1993 to 1997. Rubies X, et al. **Vet Microbiol** 1999 Apr 19;66(3):245-8

Porcine reproductive and respiratory syndrome virus and Haemophilus parasuis antigen distribution in dually infected pigs. Segalés J, et al. **Vet Microbiol** 1999 Feb 12; 64(4):287-97

Use of a PCR assay for Taylorella equigenitalis applied to samples from the United Kingdom. Chanter N, et al. **Vet Rec** 1998 Aug 22;143(8):225-7

[Determination of C-reactive protein and neopterin in serum of diseased and bacterially infected swine] Schrödl W, et al. **Berl Munch Tierarztl Wochenschr** 1998 Sep;111(9):321-5 (Eng. Abstr.) **(Ger)**

HAEMOPHILUS INFLUENZAE

Localization of nontypeable Haemophilus influenzae endotoxin in the middle and inner ear during experimental otitis media. Demaria TF. **Acta Otolaryngol** 1999; 119(5):583-7

Ketolide treatment of Haemophilus influenzae experimental pneumonia. Piper KE, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):708-10

Haemophilus influenzae pyelonephritis in adults [letter] [published erratum appears in Arch Intern Med 1999 Jun

28;159(12):1363] Reichman JM, et al. **Arch Intern Med** 1999 Feb 8;159(3):316

Structural changes in the rat middle ear mucosa due to endotoxin and eustachian tube obstruction. Nell MJ, et al. **Eur Arch Otorhinolaryngol** 1999;256(4):167–72

Kinetics of inflammatory cytokines in the clearance of non-typeable Haemophilus influenzae from the lung. Foxwell AR, et al. **Immunol Cell Biol** 1998 Dec;76(6):556–9

Hemophilus influenzae biotype III cellulitis in an adult. Lev EI, et al. **Infection** 1999 Jan–Feb;27(1):42–3

Oklahoma notes decline in Haemophilus influenzae: invasive Haemophilus influenzae disease among children aged < 5 years—Oklahoma, 1990–1997. Lee AK, et al. **J Okla State Med Assoc** 1999 Jun;92(6):276–7

Polyarticular septic arthritis caused by non-encapsulated haemophilus influenzae biotype I in a rheumatic adult. Melhus A, et al. **Scand J Infect Dis** 1998;30(6):630–1

Epidemiology of Haemophilus influenzae invasive disease in hospitalised Kelantanese children, 1985–1994. Nik Khairulddin NY, et al. **Singapore Med J** 1999 Feb; 40(2):96–100

[Impact of vaccination against Haemophilus influenzae on the incidence of invasive infections from Haemophilus influenzae type B in the Nord-Pas-de-Calais region] Dumonceaux A, et al. **Arch Pediatr** 1999 Jun;6(6):617–24 (Eng. Abstr.) **(Fre)**

[Epiglottitis: pathology in young children? (letter)] Nouyrigat V, et al. **Arch Pediatr** 1999 Jan;6(1):109–10 **(Fre)**

[Case of infectious abdominal aneurysm complicating influenza septicemia] Yamazaki S, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):342–3 **(Jpn)**

[Haemophilus influenzae pneumonia] Okimoto N, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):377–80 (12 ref.) **(Jpn)**

[Recurrent spontaneous bacterial peritonitis due to encapsulated microorganisms (Haemophilus influenzae and Streptococcus pneumoniae) in a patient with liver cirrhosis (letter)] Salavert M, et al. **Gastroenterol Hepatol** 1999 Jan; 22(1):30–1 (10 ref.) **(Spa)**

[Urethritis caused by serotype B Haemophilus influenzae. Report of a case] Llanes Caballero R, et al. **Rev Cubana Med Trop** 1996;48(2):130–2 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Identification of common lipooligosaccharide types in isolates from patients with otitis media by monoclonal antibodies against nontypeable Haemophilus influenzae 9274. Ueyama T, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):96–100

Outer membrane protein profiles of paired nasopharyngeal and middle ear isolates of nontypable Haemophilus influenzae from Mexican children with acute otitis media. Villaseñor-Sierra A, et al. **Clin Infect Dis** 1999 Feb; 28(2):267–73

Reference map of the low molecular mass proteins of Haemophilus influenzae. Fountoulakis M, et al. **Electrophoresis** 1998 Jul;19(10):1819–27

Secondary structure and molecular analysis of interstrain variability in the P5 outer-membrane protein of non-typable Haemophilus influenzae isolated from diverse anatomical sites. Webb DC, et al. **J Med Microbiol** 1998 Dec;47(12):1059–67

Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Manning DS, et al. **Microb Pathog** 1998 Jul;25(1):11–21

Design of protein purification pathways: application to the proteome of Haemophilus influenzae using heparin chromatography. Fountoulakis M, et al. **Protein Expr Purif** 1998 Oct;14(1):113–9

CLASSIFICATION

Rapid and simple Microtek biotyping method for Haemophilus influenzae. Secka O, et al. **Br J Biomed Sci** 1998 Sep;55(3):212–3

Recurrent ventriculoperitoneal shunt infection due to nontypeable Haemophilus influenzae. Lim ME, et al. **Clin Infect Dis** 1999 Jan;28(1):147–8

Suspected Brazilian purpuric fever in a toddler with overwhelming Epstein-Barr virus infection. Virata M, et al. **Clin Infect Dis** 1998 Nov;27(5):1238–40

Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Lipsitch M. **Emerg Infect Dis** 1999 May–Jun; 5(3):336–45

Subtyping of Haemophilus influenzae strains by pulsed-field gel electrophoresis. Saito M, et al. **J Clin Microbiol** 1999 Jul;37(7):2142–7

Nontypable Haemophilus influenzae meningitis. Cuthill SL, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):660–2

Pneumococcal and Haemophilus influenzae meningitis in a children's hospital in Ethiopia: serotypes and susceptibility patterns. Muhe L, et al. **Trop Med Int Health** 1999 Jun; 4(6):421–7

DRUG EFFECTS

Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. Bergman KL, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1291–3

Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Berry V, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3193–9

Escherichia coli ATCC 35218 as a quality control isolate for susceptibility testing of Haemophilus influenzae with haemophilus test medium. Butler DL, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):283–6

A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project Beta-Alert 1993–1997. Derecola A, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):185–6

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Doern GV, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):385–9

Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996–1997. Hogan PA, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3313–4

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Jacobs MR, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1901–8

Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. Johnson MM, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1862–5

Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay. Pankuch GA, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):3032–4

Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Vila J, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):161–2

Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria. Dornbusch K, et al. **APMIS** 1999 May;107(5):505–13

Increasing prevalence of ampicillin- resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Seki H, et al. **Chemotherapy** 1999 Jan–Feb;45(1):15–21

In vitro activities of macrolides against gram-positive aerobes, Haemophilus influenzae, Moraxella catarrhalis and Bacteroides fragilis in Taiwan. Wang FD, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr;62(4):230–5

Characterization of the inoculum effect with Haemophilus influenzae and beta-lactams. Balko T, et al. **Diagn Microbiol Infect Dis** 1999 Jan;33(1):47–58

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):45–50

Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. Biedenbach DJ, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):275–82

In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Jones RN, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):573–8

Strategies towards a better understanding of antibiotic action: folate pathway inhibition in Haemophilus influenzae as an example. Evers S, et al. **Electrophoresis** 1998 Aug; 19(11):1980–8

The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin. Dabernat H. **Int J Antimicrob Agents** 1999 Feb;11(2):139–43

A scientific perspective on macrolide susceptibility. Conclusion. Grimm H. **Int J Antimicrob Agents** 1999 Mar; 11 Suppl 1:S33–4

Selection of resistant variants of respiratory pathogens by quinolones. Sefton AM, et al. **Int J Antimicrob Agents** 1999 Jul;12(2):129–34

Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. Huebner RE, et al. **Int J Infect Dis** 1998 Jul–Sep; 3(1):18–25

Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group. Blondeau JM, et al. **J Antimicrob Chemother** 1999 Mar;43 Suppl A:25–30

In-vitro activity of levofloxacin, a new fluoroquinolone: evaluation against Haemophilus influenzae and Moraxella catarrhalis. Kitzis MD, et al. **J Antimicrob Chemother** 1999 Jun;43 Suppl C:21–6

Resistance patterns of Haemophilus influenzae. Acar JF. **J Chemother** 1999 Feb;11 Suppl 1:44–50

Molecular epidemiology of ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae. Gazagne L, et al. **J Clin Microbiol** 1998 Dec;36(12):3629–35

Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. Jones RN, et al. **J Clin Microbiol** 1999 Jun;37(6):1999–2002

Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae in Taiwan. Lin HC, et al. **J Formos Med Assoc** 1999 May;98(5):319–25

Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. Genin MJ, et al. **J Med Chem** 1998 Dec 17;41(26):5144–7

Concentrations and anti-Haemophilus influenzae activities of beta-casein phosphoforms in human milk. Kroening TA, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):486–91

Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. van Schilfgaarde M, et al. **Microb Pathog** 1999 May;26(5):249–62

Antimicrobial susceptibility patterns of Streptococcus pneumoniae and Haemophilus influenzae in a German pediatric hospital, 1993 to 1997. Berner R. **Pediatr Infect Dis J** 1998 Oct;17(10):925–7

Clinical implications of antibiotic resistance for management of acute otitis media. Klein JO. **Pediatr Infect Dis J** 1998 Nov;17(11):1084–9; discussion 1099–100

[New spectra of resistance of the main bacteria of the respiratory tract] Mariani-Kurkdjian P, et al. **Arch Pediatr** 1998;5 Suppl 1:14s–17s (12 ref.) (Eng. Abstr.) **(Fre)**

[In vitro demonstration of a true post-beta-lactamases inhibitor effect (PLIE) of clavulanic acid on Klebsiella pneumoniae and Haemophilus influenzae] Murbach V, et al. **Pathol Biol (Paris)** 1999 May;47(5):462–8 (Eng. Abstr.) **(Fre)**

[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)] Ikemoto H, et al. **Jpn J Antibiot** 1998 Jul;51(7):437–74 (Eng. Abstr.) **(Jpn)**

[Antimicrobial activities of beta-lactam antibiotics against clinically isolated Haemophilus influenzae] Takahashi T, et al. **Jpn J Antibiot** 1999 Apr;52(4):292–301 (Eng. Abstr.) **(Jpn)**

[Causative organisms of acute otitis media and acute sinusitis in children and their susceptibility of oral beta-lactam antibiotics] Takenaka M, et al. **Jpn J Antibiot** 1999 Feb; 52(2):162–71 (Eng. Abstr.) **(Jpn)**

[A growth supplement for "fastidious germs"] Tamargo Martinez I, et al. **Rev Cubana Med Trop** 1995;47(3):189–94 (Eng. Abstr.) **(Spa)**

[Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae] Cisterna R, et al. **Rev Esp Quimioter** 1998 Sep;11(3):245–50 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project Beta-Alert 1993–1997. Derecola A, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):185–6

Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996–1997. Hogan PA, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3313–4

Mapping the active site of the Haemophilus influenzae methionyl-tRNA formyltransferase: residues important for catalysis and tRNA binding. Newton DT, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):63–9

Structural symmetry: the three-dimensional structure of Haemophilus influenzae diaminopimelate epimerase. Cirilli M, et al. **Biochemistry** 1998 Nov 24;37(47):16452–8

Chemical mechanism of Haemophilus influenzae diaminopimelate epimerase. Koo CW, et al. **Biochemistry** 1999 Apr 6;38(14):4416–22

acs1 of Haemophilus influenzae type a capsulation locus region II encodes a bifunctional ribulose 5-phosphate reductase- CDP-ribitol pyrophosphorylase. Follens A, et al. **J Bacteriol** 1999 Apr;181(7):2001–7

The structure and function of the 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase from Haemophilus influenzae. Hennig M, et al. **J Mol Biol** 1999 Mar 26;287(2):211–9

The Haemophilus influenzae Hap serine protease promotes adherence and microcolony formation, potentiated by a soluble host protein. Hendrixson DR, et al. **Mol Cell** 1998 Dec;2(6):841–50

Catalytic properties of selenophosphate synthetases: comparison of the selenocysteine-containing enzyme from Haemophilus influenzae with the corresponding cysteine-containing enzyme from Escherichia coli. Lacourciere GM, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):44–8

Specific cleavage of simian virus 40 DNA by restriction endonuclease of Hemophilus influenzae. 1971 [classical article] Danna K, et al. **Rev Med Virol** 1999 Apr–Jun; 9(2):75–81

GENETICS

In vivo transposon mutagenesis in Haemophilus influenzae. Kraiss A, et al. **Appl Environ Microbiol** 1998 Dec;

64(12):4697-702

Distribution of a family of Haemophilus influenzae genes containing CCAA nucleotide repeating units. Morton DJ, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):303-9

Variable numbers of tandem repeat loci in genetically homogeneous Haemophilus influenzae strains alter during persistent colonisation of cystic fibrosis patients. Renders N, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):95-102

Fragmentation heterogenicity of 23S ribosomal RNA in Haemophilus species. Song XM, et al. **Gene** 1999 Apr 16; 230(2):287-93

hgpB, a gene encoding a second Haemophilus influenzae hemoglobin- and hemoglobin-haptoglobin-binding protein. Ren Z, et al. **Infect Immun** 1998 Oct;66(10):4733-41

HP0333, a member of the dprA family, is involved in natural transformation in Helicobacter pylori. Ando T, et al. **J Bacteriol** 1999 Sep;181(18):5572-80

Genome scanning in Haemophilus influenzae for identification of essential genes. Reich KA, et al. **J Bacteriol** 1999 Aug;181(16):4961-8

Role of CCAA nucleotide repeats in regulation of hemoglobin and hemoglobin-haptoglobin binding protein genes of Haemophilus influenzae. Ren Z, et al. **J Bacteriol** 1999 Sep;181(18):5865-70

Systems properties of the Haemophilus influenzae Rd metabolic genotype. Edwards JS, et al. **J Biol Chem** 1999 Jun 18;274(25):17410-6

Pulsed-field gel electrophoresis used to investigate genetic diversity of Haemophilus influenzae type b isolates in Australia shows differences between Aboriginal and non-Aboriginal isolates. Moor PE, et al. **J Clin Microbiol** 1999 May;37(5):1524-31

Characterisation of non-capsulate Haemophilus influenzae by repetitive extragenic palindromic (REP)-PCR. Jordens JZ. **J Med Microbiol** 1998 Nov;47(11):1031-4

Identification of Haemophilus influenzae Rd transformation genes using cassette mutagenesis. Dougherty BA, et al. **Microbiology** 1999 Feb;145 (Pt 2):401-9

An in silico evaluation of Tn916 as a tool for generalized mutagenesis in Haemophilus influenzae Rd. Hosking SL, et al. **Microbiology** 1998 Sep;144 (Pt 9):2525-30

Characterization of hgpA, a gene encoding a haemoglobin/haemoglobin-haptoglobin-binding protein of Haemophilus influenzae. Jin H, et al. **Microbiology** 1999 Apr;145 (Pt 4):905-14

Site-specific recombination at dif by Haemophilus influenzae XerC. Neilson L, et al. **Mol Microbiol** 1999 Feb; 31(3):915-26

Variation in expression of the Haemophilus influenzae HMW adhesins: a prokaryotic system reminiscent of eukaryotes. Dawid S, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2; 96(3):1077-82

Natural genetic exchange between Haemophilus and Neisseria: intergeneric transfer of chromosomal genes between major human pathogens. Kroll JS, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12381-5

Molecular nature of RAPD markers from Haemophilus influenzae Rd genome. Mori E, et al. **Res Microbiol** 1999 Mar;150(2):83-93

[Studies on microbial genome] Lu D. **Wei Sheng Wu Hsueh Pao** 1997 Aug;37(4):323-5 (5 ref.) **(Chi)**

[Computer analysis of regulatory signals in complete bacterial genomes. Participation of PurR binding] Mironov AA, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):127-32 **(Rus)**

GROWTH & DEVELOPMENT

In vitro inhibition of S. pneumoniae, nontypable H. influenzae and M. catharralis by alpha-hemolytic streptococci from healthy children. Tano K, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):49-56

Carbon dioxide requirements of Streptococcus pneumoniae and Haemophilus influenzae [letter] Flanagan PG, et al. **J Antimicrob Chemother** 1998 Nov;42(5):669-70

Use of Dorset egg medium for maintenance and transport of Neisseria meningitidis and Haemophilus influenzae type b. Wasas AD, et al. **J Clin Microbiol** 1999 Jun;37(6):2045-6

Incidence of Haemophilus influenzae in the throats of healthy infants with different feeding methods. Hokama T, et al. **Pediatr Int** 1999 Jun;41(3):277-80

Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Qiu J, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12641-6

IMMUNOLOGY

Serum antibodies specific to CD outer membrane protein of Moraxella catarrhalis, P6 outer membrane protein of non-typeable Haemophilus influenzae and capsular polysaccharides of Streptococcus pneumoniae in children with otitis media with effusion. Harabuchi Y, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):826-32

Enhancement of nasal clearance of nontypeable Haemophilus influenzae by oral immunization with outer membrane proteins. Suzuki M, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):864-9

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Vance E, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):735-41

Interlaboratory reproducibility of an enzyme-linked immunosorbent assay for quantitation of antibodies for Haemophilus influenzae type b polysaccharide [letter] Madore DV, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):446

Identification of common lipooligosaccharide types in isolates from patients with otitis media by monoclonal antibodies against nontypeable Haemophilus influenzae 9274. Ueyama T, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):96-100

Induction of cytokines and anti-cytokine autoantibodies in cerebrospinal fluid (CSF) during experimental bacterial meningitis. Bakhiet M, et al. **Clin Exp Immunol** 1998 Dec; 114(3):398-402

Towards a protein vaccine for nontypeable Haemophilus influenzae. Kyd JM, et al. **Clin Infect Dis** 1999 Feb; 28(2):238

Structural analysis of the lipopolysaccharide oligosaccharide epitopes expressed by a capsule-deficient strain of Haemophilus influenzae Rd. Risberg A, et al. **Eur J Biochem** 1999 Apr;261(1):171-80

Characteristics of the immunological response in the clearance of non-typeable Haemophilus influenzae from the lung. Foxwell AR, et al. **Immunol Cell Biol** 1998 Aug; 76(4):323-31

Characterization of the gene encoding a 26-kilodalton protein (OMP26) from nontypeable Haemophilus influenzae and immune responses to the recombinant protein. El-Adhami W, et al. **Infect Immun** 1999 Apr;67(4):1935-42

Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Bakaletz LO, et al. **Infect Immun** 1999 Jun;67(6):2746-62

Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Breukels MA, et al. **Infect Immun** 1999 Feb;67(2):789-93

Antigenic diversity and gene polymorphisms in Haemophilus influenzae. Gilsdorf JR. **Infect Immun** 1998 Nov; 66(11):5053-9 (91 ref.)

Immunologic and structural relationships of the minor pilus subunits among Haemophilus influenzae isolates. McCrea KW, et al. **Infect Immun** 1998 Oct;66(10):4788-96

Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung. Webb DC, et al. **Infect Immun** 1999 May;67(5):2138-44

Nontypeable Haemophilus influenzae: challenges in developing a vaccine. Kyd J, et al. **J Biotechnol** 1999 Aug 20;73(2-3):103-8 (34 ref.)

Determination of the molecular size distribution of Haemophilus influenzae type b-tetanus toxoid conjugate vaccines by size-exclusion chromatography. Parisi L, et al. **J Chromatogr A** 1999 Jun 25;847(1-2):209-11

Haemophilus influenzae type b polysaccharides-protein conjugate vaccine elicits a more diverse antibody repertoire in infants than in adults. Adderson EE, et al. **J Immunol** 1998 Oct 15;161(8):4177-82

Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. Kurono Y, et al. **J Infect Dis** 1999 Jul;180(1):122-32

Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. van Schilfgaarde M, et al. **Microb Pathog** 1999 May;26(5):249-62

Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Mori M, et al. **Neurology** 1999 Apr 12;52(6):1282-4

Induction of phagocyte-stimulating cytokines by in vitro stimulation of human peripheral blood mononuclear cells with Haemophilus influenzae. Arvå E, et al. **Scand J Immunol** 1999 Apr;49(4):411-6

Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin. Hotomi M, et al. **Vaccine** 1998 Dec; 16(20):1950-6

[Usefulness of rapid antigen detection for the diagnosis of systemic infections due to Haemophilus influenzae] Ohkusu K, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):336-40 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Bacteria in the middle ear and nasopharynx during tympanostomy tube insertion. Clary RA, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):301-4

Reliability of parental history of antibiotic use for Filipino children admitted with acute lower respiratory tract infection. Sombrero L, et al. **Am J Trop Med Hyg** 1999 Mar;60(3):397-9

Microbiologic characteristics of persistent otitis media. Brook I, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1350-2

Septic arthritis caused by Haemophilus influenzae associated with endocarditis. Lesage V, et al. **Clin Rheumatol** 1998; 17(4):340-2

Isolation of Haemophilus influenzae in Central Asia. LaClaire L, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct; 17(10):746-7

Variable numbers of tandem repeat loci in genetically homogeneous Haemophilus influenzae strains alter during persistent colonisation of cystic fibrosis patients. Renders N, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):95-102

Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media. Krasan GP, et al. **Infect Immun** 1999 Jan;67(1):449-54

Correlation between presence of viable bacteria and presence of endotoxin in middle-ear effusions. Dingman JR, et al. **J Clin Microbiol** 1998 Nov;36(11):3417-9

Coisolation of Streptococcus pneumoniae and Hameophilus influenzae from middle ear fluid and sputum: effect on MIC results [letter] Elliott JA, et al. **J Clin Microbiol** 1999 Jan; 37(1):277

Molecular epidemiological study of Haemophilus influenzae serotype b strains obtained from children with meningitis in Japan. Mitsuda T, et al. **J Clin Microbiol** 1999 Aug; 37(8):2548-52

Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. Murphy TF, et al. **J Infect Dis** 1999 Aug; 180(2):404-9

Microbiology of the middle meatus in children requiring adenotonsillectomy. Gordts F, et al. **J Laryngol Otol** 1999 Jan;113(1):24-7

Streptococcus pneumoniae and Haemophilus influenzae as etiological agents of conjunctivitis outbreaks in the region of Ribeirão Preto, SP, Brazil. Medeiros MI, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan-Feb;40(1):7-9

[Epidemiology of nasopharyngeal colonization by Streptococcus pneumoniae and Haemophilus influenzae in a closed community of young children] Moulin F, et al. **Arch Pediatr** 1999;6 Suppl 3:620s-624s **(Fre)**

METABOLISM

Comparison of the D-glutamate-adding enzymes from selected gram-positive and gram-negative bacteria. Walsh AW, et al. **J Bacteriol** 1999 Sep;181(17):5395-401

Glycosphingolipid binding specificities of Neisseria meningitidis and Haemophilus influenzae: detection, isolation, and characterization of a binding-active glycosphingolipid from human oropharyngeal epithelium. Hugosson S, et al. **J Biochem (Tokyo)** 1998 Dec 1; 124(6):1138-52

Isolated operator binding and ligand response domains of the TyrR protein of Haemophilus influenzae associate to reconstitute functional repressor. Zhao S, et al. **J Biol Chem** 1999 Jan 15;274(3):1842-7

Attachment of nontypable Haemophilus influenzae to human pharyngeal epithelial cells mediated by a ganglioside receptor. Kawakami K, et al. **Microbiol Immunol** 1998; 42(10):697-702

A method for the purification and refolding of a recombinant form of the nontypeable Haemophilus influenzae P5 outer membrane protein fused to polyhistidine. Webb DC, et al. **Protein Expr Purif** 1999 Feb;15(1):1-7

PATHOGENICITY

Course of IL-1beta, IL-6, IL-8, and TNF-alpha in the middle ear fluid of the guinea pig otitis media model induced by nonviable Haemophilus influenzae. Sato K, et al. **Ann Otol Rhinol Laryngol** 1999 Jun;108(6):559-63

Intra- and interstrain differences of virulence among nontypeable Haemophilus influenzae strains. Melhus A, et al. **APMIS** 1998 Sep;106(9):858-68

Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. Rao VK, et al. **FEMS Microbiol Rev** 1999 Apr;23(2):99-129 (206 ref.)

Stimulation of the adherence of Haemophilus influenzae to human lung epithelial cells by antimicrobial neutrophil defensins. Gorter AD, et al. **J Infect Dis** 1998 Oct; 178(4):1067-74

Fur and iron transport proteins in the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius. Smoot LM, et al. **J Med Microbiol** 1999 Jul;48(7):629-36

PHYSIOLOGY

Variation in the composition and pore function of major outer membrane pore protein P2 of Haemophilus influenzae from cystic fibrosis patients. Regelink AG, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):226-32

Fimbria-mediated enhanced attachment of nontypeable Haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells. Jiang Z, et al. **Infect Immun** 1999 Jan;67(1):187-92

Infection of primary human bronchial epithelial cells by Haemophilus influenzae: macropinocytosis as a mechanism of airway epithelial cell entry. Ketterer MR, et al. **Infect Immun** 1999 Aug;67(8):4161-70

Opacity-associated protein A contributes to the binding of Haemophilus influenzae to chang epithelial cells. Prasadarao NV, et al. **Infect Immun** 1999 Aug; 67(8):4153-60

Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms. van Furth AM, et al. **Infect Immun** 1999 Aug;67(8):3714-8

Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. Janson H, et al. **J Infect Dis** 1999 Sep;180(3):737-46

Adaptation of Haemophilus influenzae to acquired and innate

humoral immunity based on phase variation of lipopolysaccharide. Weiser JN, et al. **Mol Microbiol** 1998 Nov;30(4):767-75

VIROLOGY

Evolutionary relationships among diverse bacteriophages and prophages: all the world's a phage. Hendrix RW, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2192-7

HAEMOPHILUS INFLUENZAE TYPE B

Meningitis, Haemophilus

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Jafari HS, et al. **Am J Public Health** 1999 Mar;89(3):364-8

A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. Wolff MC, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):263-6

Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. Talan DA, et al. **Ann Emerg Med** 1999 Jul; 34(1):109-11

Haemophilus influenzae type B infection. Levine O, et al. **Bull World Health Organ** 1998;76 Suppl 2:131-2

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule. Bell F, et al. **Eur J Pediatr** 1999 Apr; 158(4):329-36

Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. Galil K, et al. **J Infect Dis** 1999 Jan;179(1):101-6

From the Centers for Disease Control and Prevention. Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. **JAMA** 1999 Feb 3;281(5):409-10

Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. **MMWR Morb Mortal Wkly Rep** 1998 Nov 27; 47(46):993-8

Proceedings of the 1st International Conference on Haemophilus influenzae type b Infection in Asia. Bali, Indonesia, December 17-19, 1996. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92-210

Haemophilus influenzae type b disease in Thailand. Chotpitayasunondh T. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S191

A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Gessner BD, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S179-82

The epidemiology of Haemophilus influenzae type b carriage among infants and young children in Santo Domingo, Dominican Republic. Gómez E, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):782-6

Epidemiology of systemic Haemophilus influenzae disease in Korean children. Lee HJ. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S185-9

Haemophilus influenzae in Asia. Lee JW. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92

Summary statement: The First International Conference on Haemophilus influenzae type b infection in Asia. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S93-5

Invasive Haemophilus influenzae disease in India: a preliminary report of prospective multihospital surveillance. IBIS (Invasive Bacterial Infections Surveillance) Group. Steinhoff MC. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S172-5

The etiology of bacterial pneumonia and meningitis in Vietnam. Tran TT, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S192-4

[Haemophilus influenzae type b meningitis in Apulia. Retrospective study from the years 1994-1995] Chironna M, et al. **Ann Ig** 1998 May-Jun;10(3):131-6 (Eng. Abstr.) **(Ita)**

[Haemophilus influenzae type b meningitis in the city and district of Naples: a retrospective study on hospitalizations in the period 1987-1995] Pizzuti R, et al. **Ann Ig** 1998 May-Jun;10(3):137-46 (Eng. Abstr.) **(Ita)**

[Haemophilus influenzae type b osteoarthritis. A report of 7 cases and a review of the literature] Otero Reigada MC, et al. **An Esp Pediatr** 1998 Dec;49(6):594-602 (102 ref.) (Eng. Abstr.) **(Spa)**

[Haemophilus influenzae type b invasive disease and meningococcal disease: incidence and characteristics in Barcelona, 1994-1995. Work Group IMS-IUSPC for Surveillance and Control of Meningitis] Beni C, et al. **Med Clin (Barc)** 1999 Jan 16;112(1):1-4 (Eng. Abstr.) **(Spa)**

[Haemophilus influenzae serotype b invasive disease (editorial)] Campos J. **Med Clin (Barc)** 1999 Jan 16; 112(1):16-7 **(Spa)**

[Haemophilus influenzae type b invasive disease in Catalonia (1996)] Dominguez A, et al. **Med Clin (Barc)** 1999 Jan 16; 112(1):5-9 (Eng. Abstr.) **(Spa)**

[Haemophilus influenza type b invasive disease in the Community of Valencia. Study Group on Invasive Diseases] Morant A, et al. **Med Clin (Barc)** 1999 Jan 16; 112(1):20-3 (Eng. Abstr.) **(Spa)**

GENETICS

Effect of multiple mutations in the hemoglobin- and hemoglobin-haptoglobin-binding proteins, HgpA, HgpB, and HgpC, of Haemophilus influenzae type b. Morton DJ, et al. **Infect Immun** 1999 Jun;67(6):2729-39

Susceptibility and genetic relatedness of invasive Haemophilus influenzae type b in Italy. Tarasi A, et al. **Microb Drug Resist** 1998 Winter;4(4):301-6

Cloning of the haemocin locus of Haemophilus influenzae type b and assessment of the role of haemocin in virulence. Murley YM, et al. **Microbiology** 1998 Sep;144 (Pt 9):2531-8

IMMUNOLOGY

Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Vesikari T, et al. **Acta Paediatr** 1999 May;88(5):513-20

Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Campagne G, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):837-42

Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Robinson MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F69-71

Somatic hypermutation in T-independent and T-dependent immune responses to Haemophilus influenzae type b polysaccharide. Adderson EE, et al. **Clin Immunol Immunopathol** 1998 Dec;89(3):240-6

Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. Adegbola RA, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):15-9

Natural Haemophilus influenzae type b capsular polysaccharide antibodies in 412 infants and children from West Africa (Burkina-Faso) and France: a cross-sectional serosurvey. Ballereau F, et al. **Eur J Epidemiol** 1999 Jul; 15(6):577-82

Prophylaxis of bacterial meningitis. Peltola H. **Infect Dis Clin North Am** 1999 Sep;13(3):685-710, viii (138 ref.)

Structural requirements of the major protective antibody to Haemophilus influenzae type b. Hougs L, et al. **Infect Immun** 1999 May;67(5):2503-14

Decreased frequency of rearrangement due to the synergistic effect of nucleotide changes in the heptamer and nonamer of the recombination signal sequence of the V kappa gene A2b, which is associated with increased susceptibility of Navajos to Haemophilus influenzae type b disease. Nadel B, et al. **J Immunol** 1998 Dec 1;161(11):6068-73

The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. Goldblatt D, et al. **J Infect Dis** 1999 Aug;180(2):538-41

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. Peltola H, et al. **J Infect Dis** 1999 Jan;179(1):223-9

The humoral immune response to Haemophilus influenzae type b: a mathematical model based on T-zone and germinal center B-cell dynamics. Rundell A, et al. **J Theor Biol** 1998 Oct 7;194(3):341-81

Placental transfer of IgG antibodies against Haemophilus influenzae type b capsular polysaccharide in Brazilian term and preterm newborns. Nagao AT, et al. **J Trop Pediatr** 1999 Jun;45(3):171-3

Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Sever MS, et al. **Nephron** 1999 Jan;81(1):55-9

Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease. Berthet F, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):156-60

A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S198-203

Haemophilus influenzae type b vaccines: history, choice and comparisons. Decker MD, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S113-6

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S117-22 (19 ref.)

Haemophilus influenzae disease in children in India: a hospital perspective. John TJ, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S169-71

The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Lagos R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S139-48

Haemophilus influenzae type b infections in Hong Kong. Lau YL, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S165-9

The rationale for population-based surveillance for Haemophilus influenzae type b meningitis. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S195-8

Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S95-113 (131 ref.)

Characterization of immune response as an indicator of Haemophilus influenzae type b vaccine efficacy. Madore DV. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S207-10

An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia. Miller MA. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S152-9

The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease? Mulholland EK, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S123-5

Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S126-32

Need for Haemophilus influenzae type b vaccination in Asia as evidenced by epidemiology of bacterial meningitis. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S148-51

The introduction of Haemophilus influenzae type b immunization into the United Kingdom: practical steps to assure success. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S136-9

Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Slack MP, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S204-7

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Wenger JD. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S132-6

Study on Haemophilus influenzae type b diseases in China: the past, present and future. Yang Y, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S159-65

Haemophilus influenzae type B vaccine. **S Afr Med J** 1999 Jul;89(7):738

Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Vaccine** 1999 Jan;17(2):134-41

A routine high-performance size-exclusion chromatography to determine molecular size distribution of Haemophilus influenzae type b conjugate vaccines. von Hunolstein C, et al. **Vaccine** 1999 Jan;17(2):118-25

[Antibody titer, immunologic memory and protective efficiency of the vaccine against Haemophilus influenzae type B. Vaccine Committee of the Spanish Association of Pediatrics] **An Esp Pediatr** 1999 Apr;50(4):341-5 **(Spa)**

[The coverage of vaccines systematically administered and of a vaccine against Haemophilus influenzae type b prior to its inclusion in the vaccinal calendar in the Valencian Community] Díez Domingo J, et al. **An Esp Pediatr** 1998 Dec;49(6):568-70 (Eng. Abstr.) **(Spa)**

[Introduction of a conjugate vaccine against Hib in Chile and Uruguay] Landaverde M, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):200-6 (Eng. Abstr.) **(Spa)**

[Vaccination against Haemophilus influenzae type b in Uruguay: experience and impact] Ruocco G, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):197-9 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Haemophilus influenzae type B disease at 11 pediatric centres, 1996-1997. Grewal S, et al. **Can Commun Dis Rep** 1998 Jul 1;24(13):105-8 **(Eng, Fre)**

Unvaccinated child dies of Haemophilus influenzae type b infection. **Commun Dis Rep CDR Wkly** 1999 May 7; 9(19):167, 170

Haemophilus influenzae meningitis in adults. Tang LM, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):27-32

Incidence of Haemophilus influenzae type b meningitis among children less than 5 years of age in Slovakia. Nováková E, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):409-13

Epidemiology of invasive Haemophilus influenzae type b infections among children in Greece before the introduction of immunization. Tsolia MN, et al. **Scand J Infect Dis** 1998;30(2):165-8

[Sepsis caused by Haemophilus influenzae type B with septic arthritis in an infant] Bona G, et al. **Minerva Pediatr** 1998 May;50(5):193-6 (Eng. Abstr.) **(Ita)**

[Vaccinal failures after the immunization with vaccine against H. influenzae type B (letter)] Pineda Solas V, et al. **An Esp Pediatr** 1999 May;50(5):533-4 **(Spa)**

PATHOGENICITY

The pathogenic role of fimbriae of Haemophilus influenzae type b in murine bacteraemia and meningitis. Miyazaki S, et al. **J Med Microbiol** 1999 Apr;48(4):383-8

Virulence Enhancement Agents for Haemophilus influenzae type B infection in mice. Sifontes Rodriguez S, et al. **Lab Anim Sci** 1999 Feb;49(1):95-8 (19 ref.)

Cloning of the haemocin locus of Haemophilus influenzae type b and assessment of the role of haemocin in virulence. Murley YM, et al. **Microbiology** 1998 Sep;144 (Pt 9):2531-8

HAEMOPHILUS INFLUENZAE VACCINES see **HAEMOPHILUS VACCINES**

HAEMOPHILUS PERTUSSIS

HAEMOPHILUS PERTUSSIS see **BORDETELLA PERTUSSIS**

HAEMOPHILUS PLEUROPNEUMONIAE see **ACTINOBACILLUS PLEUROPNEUMONIAE**

HAEMOPHILUS VACCINES

Newer vaccines: like Marie Antoinette said, "let the poor eat cake" [letter; comment] Puliyel JM. **Indian Pediatr** 1998 Dec;35(12):1245–9. Comment on: Indian Pediatr 1998 Aug;35(8):791–5.

Vaccine trials and ethics [editorial; comment] Hall AJ. **Int J Tuberc Lung Dis** 1999 Sep;3(9):745–6. Comment on: Int J Tuberc Lung Dis 1999 Sep;3(9):749–55.

A randomised trial of a Haemophilus influenzae type b conjugate vaccine in a developing country for the prevention of pneumonia--ethical considerations [comment] Mulholland K, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):749–55 (22 ref.). Comment on: Int J Tuberc Lung Dis 1999 Sep;3(9):745–6.

Proceedings of the 1st International Conference on Haemophilus influenzae type b Infection in Asia. Bali, Indonesia, December 17–19, 1996. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92–210

Epiglottitis in Sweden before and after introduction of vaccination against Haemophilus influenzae type b. Garpenholt O, et al. **Pediatr Infect Dis J** 1999 Jun; 18(6):490–3

Haemophilus influenzae in Asia. Lee JW. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S92

Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S95–113 (131 ref.)

The rationale for population-based surveillance for Haemophilus influenzae type b meningitis. Levine OS, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S195–8

Need for Haemophilus influenzae type b vaccination in Asia as evidenced by epidemiology of bacterial meningitis. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S148–51

Summary statement: The First International Conference on Haemophilus influenzae type b infection in Asia. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S93–5

An evaluation of the informed consent procedure used during a trial of a Haemophilus influenzae type B conjugate vaccine undertaken in The Gambia, West Africa. Leach A, et al. **Soc Sci Med** 1999 Jan;48(2):139–48

[Impact of vaccination against Haemophilus influenzae on the incidence of invasive infections from Haemophilus influenzae type B in the Nord-Pas-de-Calais region] Dumonceaux A, et al. **Arch Pediatr** 1999 Jun;6(6):617–24 (Eng. Abstr.) **(Fre)**

[Epidemiology of invasive Hemophilus influenzae B infections in Bedouins and Jews; conjugate Hib vaccines] Gortzak-Uzan L, et al. **Harefuah** 1998 Sep;135(5–6):175–80, 256 (Eng. Abstr.) **(Heb)**

ADMINISTRATION & DOSAGE

Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Robinson MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F69–71

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Vance E, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):735–41

Haemophilus influenzae type B infection. Levine O, et al. **Bull World Health Organ** 1998;76 Suppl 2:131–2

Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule. Bell F, et al. **Eur J Pediatr** 1999 Apr; 158(4):329–36

Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Petersen K, et al. **Int J Circumpolar Health** 1998; 57 Suppl 1:285–92

Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. Peltola H, et al. **J Infect Dis** 1999 Jan;179(1):223–9

Infant Hib vaccination and herd immunity [letter; comment] Rushdy A, et al. **J Pediatr** 1999 Feb;134(2):253–4. Comment on: J Pediatr 1997 Dec;131(6):869–73.

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Scheifele DW, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):240–5

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2–4–6–13 or 3–5–12 months of age. Carlsson RM, et al. **Pediatr Infect Dis J** 1998 Nov;17(11):1026–33

A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections. Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S198–203

Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. US Rhesus Rotavirus Vaccine Study Group. Markwick AJ, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):913–8

Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Peltola H. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S126–32

The introduction of Haemophilus influenzae type b immunization into the United Kingdom: practical steps to assure success. Salisbury DM. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S136–9

Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Wenger JD. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S132–6

An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Lee CY, et al. **Pediatrics** 1999 Jan;103(1):25–30

Haemophilus influenzae type B vaccine. **S Afr Med J** 1999 Jul;89(7):738

Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Hoppenbrouwers K, et al. **Vaccine** 1999 Feb 26; 17(7–8):875–86

[Vaccination against Haemophilus influenzae type b in Uruguay: experience and impact] Ruocco G, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):197–9 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Vaccines and their real or perceived adverse effects. Studies of adverse effects of vaccination have duty to present full picture [letter; comment] Bedford H, et al. **BMJ** 1999 May 29;318(7196):1487–8. Comment on: BMJ 1999 Jan 16;318(7177):193.

Public should be told that vaccines may have long term adverse effects [letter] [see comments] Classen JB, et al. **BMJ** 1999 Jan 16;318(7177):193. Comment in: BMJ 1999 May 29;318(7196):1487; discussion 1487–8. Comment in: BMJ 1999 May 29;318(7196):1487–8.

Vaccines and their real or perceived adverse effects. Authors' conclusions are at odds with investigators' [letter; comment] Jefferson TO, et al. **BMJ** 1999 May 29; 318(7196):1487; discussion 1487–8. Comment on: BMJ 1999 Jan 16;318(7177):193.

Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study [see comments] Karvonen M, et al. **BMJ** 1999 May 1; 318(7192):1169–72. Comment in: BMJ 1999 May 1;318(7192):1159–60.

Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. Galil K, et al. **J Infect Dis** 1999 Jan;179(1):101–6

CHEMISTRY

WHO/NIBSC-Co-sponsored Informal Workshop on the Use of Physicochemical Methods for the Characterization of Haemophilus influenzae type b Conjugate Vaccines. NIBSC, U.K., 22–23 June 1998. National Institute for Biological Standards and Control. Holliday MR, et al. **Biologicals** 1999 Mar;27(1):51–3

Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Costantino P, et al. **Vaccine** 1999 Mar 5;17(9–10):1251–63

Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Sturgess AW, et al. **Vaccine** 1999 Mar 5;17(9–10):1169–78

A routine high-performance size-exclusion chromatography to determine molecular size distribution of Haemophilus influenzae type b conjugate vaccines. von Hunolstein C, et al. **Vaccine** 1999 Jan;17(2):118–25

[Level of bacterial endotoxins in Haemophilus influenzae type b vaccines conjugated with toxoids (td, Di)] Aleksandrowicz J, et al. **Med Dosw Mikrobiol** 1998; 50(3–4):223–8 (Eng. Abstr.) **(Pol)**

ECONOMICS

Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Fendrick AM, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):126–36

An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia. Miller MA. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S152–9

IMMUNOLOGY

Cellular immune response of adenoidal and tonsillar lymphocytes to the P6 outer membrane protein of non-typeable Haemophilus influenzae and its relation to otitis media. Kodama H, et al. **Acta Otolaryngol** 1999; 119(3):377–83

Serum antibodies specific to CD outer membrane protein of Moraxella catarrhalis, P6 outer membrane protein of non-typeable Haemophilus influenzae and capsular polysaccharides of Streptococcus pneumoniae in children with otitis media with effusion. Harabuchi Y, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):826–32

Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Vesikari T, et al. **Acta Paediatr** 1999 May;88(5):513–20

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. Janoff EN, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):837–45

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Jafari HS, et al. **Am J Public Health** 1999 Mar;89(3):364–8

IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Parkkali T, et al. **Bone Marrow Transplant** 1999 Sep;24(6):671–8

Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. Huang LM, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Sep;31(3):180–6

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Halperin SA, et al. **Clin Infect Dis** 1999 May;28(5):995–1001

Antigenuria in Gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. Adegbola RA, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):15–9

Safety and immunogenicity of Haemophilus influenzae type b-tetanus toxoid conjugate, presented in a dual-chamber syringe with diphtheria-tetanus-pertussis and inactivated poliomyelitis combination vaccine. Langue J, et al. **Eur J Pediatr** 1999 Sep;158(9):717–22

Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines? Usonis V, et al. **Eur J Pediatr** 1999 May;158(5):398–402

Transplacental transfer of H. influenzae type b antibody. John TJ. **Indian Pediatr** 1998 Sep;35(9):919–20

Immunogenicity of Haemophilus influenzae type b vaccine in Indian infants [letter; comment] John TJ. **Indian Pediatr** 1998 Jul;35(7):685–8. Comment on: Indian Pediatr 1997 Sep;34(9):779–83.

Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Bakaletz LO, et al. **Infect Immun** 1999 Jun;67(6):2746–62

Regulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharide. Breukels MA, et al. **Infect Immun** 1999 Feb;67(2):789–93

Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues. Reason DC, et al. **Infect Immun** 1999 Feb;67(2):994–7

Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae. Wu TH, et al. **Infect Immun** 1999 Oct;67(10):5508–13

Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Petersen K, et al. **Int J Circumpolar Health** 1998; 57 Suppl 1:285–92

Haemophilus influenzae type b polysaccharides-protein conjugate vaccine elicits a more diverse antibody repertoire in infants than in adults. Adderson EE, et al. **J Immunol** 1998 Oct 15;161(8):4177–82

The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. Hougs L, et al. **J Immunol** 1999 Jan 1;162(1):224–37

The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. Goldblatt D, et al. **J Infect Dis** 1999 Aug;180(2):538–41

Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. Molrine DC, et al. **J Infect Dis** 1999 Feb;179(2):513–7

Immune response to Haemophilus influenzae type B vaccination in renal transplant recipients with well-functioning allografts. Sever MS, et al. **Nephron** 1999 Jan;81(1):55–9

Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease. Berthet F, et al.

Pediatr Allergy Immunol 1998 Aug;9(3):156–60

Haemophilus influenzae type b vaccines: history, choice and comparisons. Decker MD, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S113–6

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S117–22 (19 ref.)

The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: a framework for evaluating new vaccines in newly industrializing countries. Lagos R, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S139–48

Characterization of immune response as an indicator of Haemophilus influenzae type b vaccine efficacy. Madore DV. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S207–10

The Gambian Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease? Mulholland EK, et al. **Pediatr Infect Dis J** 1998 Sep;17(9 Suppl):S123–5

Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b–tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Nohynek H, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):25–30

Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Shinefield HR, et al. **Pediatr Infect Dis J** 1998 Nov;17(11):980–5

Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Slack MP, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9 Suppl):S204–7

Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age. Aristegui J, et al. **Vaccine** 1998 Dec;16(20):1976–81

Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Fusco PC, et al. **Vaccine** 1998 Nov; 16(19):1842–9

Priming effect, immunogenicity and safety of an Haemophilus influenzae type b–tetanus toxoid conjugate (PRP–T) and diphtheria–tetanus–acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Hoppenbrouwers K, et al. **Vaccine** 1999 Feb 26; 17(7–8):875–86

The effect of reconstitution of an Haemophilus influenzae type b–tentanus toxoid conjugate (PRP–T) vaccine on the immune responses to a diphtheria–tetanus–whole cell pertussis (DTwP) vaccine: a five-year follow-up. Hoppenbrouwers K, et al. **Vaccine** 1999 Jun 4; 17(20–21):2588–98

Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin. Hotomi M, et al. **Vaccine** 1998 Dec; 16(20):1950–6

Safety and immunogenicity of combined diphtheria–tetanus–pertussis (whole cell and acellular)–Haemophilus influenzae–b conjugate vaccines administered to Indonesian children. Richie E, et al. **Vaccine** 1999 Mar 17;17(11–12):1384–93

[The results of the registration clinical trials of the Act-Hib vaccine manufactured by the firm of Pasteur Mérieux Connaught, France] Gorbunov MA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):45–8 (Eng. Abstr.) **(Rus)**

[The coverage of vaccines systematically administered and of a vaccine against Haemophilus influenzae type b prior to its inclusion in the vaccinal calendar in the Valencian Community] Diez Domingo J, et al. **An Esp Pediatr** 1998 Dec;49(6):568–70 (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Campagne G, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):837–42

Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Dagan R, et al. **Vaccine** 1999 Jan;17(2):134–41

THERAPEUTIC USE

Influenza immunization of schoolchildren: can we interrupt community epidemics? Poland GA, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1280–2

[Antibody titer, immunologic memory and protective efficiency of the vaccine against Haemophilus influenzae type B. Vaccine Committee of the Spanish Association of Pediatrics] **An Esp Pediatr** 1999 Apr;50(4):341–5 **(Spa)**

[Vaccinal failures after the immunization with vaccine against H. influenzae type B (letter)] Pineda Solas V, et al. **An Esp Pediatr** 1999 May;50(5):533–4 **(Spa)**

TOXICITY

IgA nephropathy in mice following repeated administration of conjugated Haemophilus influenzae type B vaccine (PRP–T). Kavukçu S, et al. **Tokai J Exp Clin Med** 1997 Oct;22(4):167–74

HAEMOPHILUS VAGINALIS see **GARDNERELLA VAGINALIS**

HAEMOSPORINA

Therapeutic effects of some antihaematozoal drugs against Haemoproteus columbae in domestic pigeons. el-Metenawy TM. **DTW Dtsch Tierarztl Wochenschr** 1999 Feb;106(2):72

HAGEMAN FACTOR see **FACTOR XII**

HAGEMAN TRAIT see **FACTOR XII DEFICIENCY**

HAGFISH

ANATOMY & HISTOLOGY

Neuronal organization of the olfactory bulb in the hagfish, Eptatretus burgeri: a Golgi study. Iwahori N, et al. **J Hirnforsch** 1998;39(2):161–73

GENETICS

Evolutionary analysis of "hagfish amelogenin". Girondot M, et al. **Anat Rec** 1998 Dec;252(4):608–11 (16 ref.)

28S and 18S rDNA sequences support the monophyly of lampreys and hagfishes. Mallatt J, et al. **Mol Biol Evol** 1998 Dec;15(12):1706–18

IMMUNOLOGY

Identification of a homologue of CD59 in a cyclostome: implications for the evolutionary development of the complement system. dos Remedios NJ, et al. **Dev Comp Immunol** 1999 Jan–Feb;23(1):1–14

METABOLISM

Natriuretic peptide binding sites in the brain of the Atlantic hagfish, Myxine glutinosa. Donald JA, et al. **J Exp Zool** 1999 Sep 1;284(4):407–13

PHYSIOLOGY

Acrosome reaction in spermatozoa of the hagfish Eptatretus burgeri (Agnatha). Morisawa S. **Dev Growth Differ** 1999 Feb;41(1):109–12

Bicarbonate binding to hemoglobin links oxygen and carbon dioxide transport in hagfish. Fago A, et al. **Respir Physiol** 1999 May 3;115(3):309–15

HAILEY-HAILEY DISEASE see **PEMPHIGUS, BENIGN FAMILIAL**

HAIR

Childhood hypersensitivity pneumonitis probably caused by cat hair. Olesen HV, et al. **Acta Paediatr** 1998 Jul; 87(7):811–3

In favor of the subcutaneous forehead lift using the anterior hairline incision. Ullmann Y, et al. **Aesthetic Plast Surg** 1998 Sep–Oct;22(5):332–7

Effect of coat on rate of temperature increase in muscle during ultrasound treatment of dogs. Steiss JE, et al. **Am J Vet Res** 1999 Jan;60(1):76–80

Overcoming the beard [letter; comment] Alexander R. **Anaesthesia** 1999 Jan;54(1):100. Comment on: Anaesthesia 1998 Oct;53(10):1034–5.

The bearded airway [letter; comment] Hancock AC. **Anaesthesia** 1999 Apr;54(4):408. Comment on: Anaesthesia 1998 Oct;53(10):1034–5.

A close shave [letter; comment] Moore EW, et al. **Anaesthesia** 1999 Mar;54(3):305. Comment on: Anaesthesia 1998 Oct;53(10):1034–5.

Intubation through a hedge [letter] Smith RP, et al. **Anaesthesia** 1999 Apr;54(4):407–8

Overcoming the beard [letter; comment] Thomas DI. **Anaesthesia** 1999 Jan;54(1):100. Comment on: Anaesthesia 1998 Oct;53(10):1034–5.

The bearded airway [letter] [see comments] Vincent C, et al. **Anaesthesia** 1998 Oct;53(10):1034–5. Comment in: Anaesthesia 1999 Jan;54(1):100. Comment in: Anaesthesia 1999 Mar;54(3):305. Comment in: Anaesthesia 1999 Apr;54(4):408.

A hairy situation [letter] Johnson JO, et al. **Anesthesiology** 1999 Aug;91(2):595

Hair density in African Americans. Sperling LC. **Arch Dermatol** 1999 Jun;135(6):656–8

Keratitis and retinitis secondary to tarantula hair. Shrum KR, et al. **Arch Ophthalmol** 1999 Aug;117(8):1096–7

Pseudoinoculum barbae: beard-induced contact dermatitis. Bischof RO, et al. **Contact Dermatitis** 1998 Dec;39(6):317–8

Big hair news [news] **Environ Health Perspect** 1998 Feb; 106(2):A59

Susceptibility to infections and in vitro immune functions in cartilage-hair hypoplasia. Mäkitie O, et al. **Eur J Pediatr** 1998 Oct;157(10):816–20

Characterization of a new tissue-engineered human skin equivalent with hair. Michel M, et al. **In Vitro Cell Dev Biol Anim** 1999 Jun;35(6):318–26

Prevalence and incidence of hand dermatitis in hairdressing apprentices: results of the POSH study. Prevention of occupational skin disease in hairdressers. Uter W, et al. **Int Arch Occup Environ Health** 1998 Oct;71(7):487–92

Anovulation after precocious pubarche: early markers and time course in adolescence. Ibáñez L, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2691–5

Beard restoration using a free puboinguinal hair-bearing flap. Sasaki K, et al. **J Reconstr Microsurg** 1998 Oct;14(7):445–8

Hair tourniquet syndrome of the clitoris. Rich MA, et al. **J Urol** 1999 Jul;162(1):190–1

X-ray analysis of hair reveals breast cancer [news] Stephenson J. **JAMA** 1999 May 5;281(17):1578–9

Hazards of plastic hair balls and hair beads [letter] [see comments] Avotri K. **Pediatrics** 1998 Dec;102(6):1493. Comment in: Pediatrics 1999 Jul;104(1 Pt 1):132.

Plastic hair balls--A real hazard! [letter; comment] Jarrar R, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):132. Comment on: Pediatrics 1999 Jul;102(6):1493.

Sideburn reconstruction in secondary lifting. Juri J. **Plast Reconstr Surg** 1998 Nov;102(6):2241–3

Elemental and molecular imaging of human hair using secondary ion mass spectrometry. Gillen G, et al. **Scanning** 1999 May–Jun;21(3):173–81

Synthetic braids and limited neck extension [letter] Tomlin MK, et al. **South Med J** 1998 Dec;91(12):1183–4

Bladder stones of unusual shape in a male with paraplegia due to spinal cord injury who has been performing self-catheterisation. Vaidyanathan S, et al. **Spinal Cord** 1999 May;37(5):375–6

Nonshaved cranial neurosurgery. Ratanalert S, et al. **Surg Neurol** 1999 Apr;51(4):458–63

[Trichobezoars] Barzilai M, et al. **Harefuah** 1998 Aug; 135(3–4):97–101, 167 (Eng. Abstr.) **(Heb)**

[Syncope due to hair grooming (letter)] Silveira Cancela M, et al. **An Esp Pediatr** 1999 Jun;50(6):637–8 (9 ref.) **(Spa)**

ABNORMALITIES

Analysis of mutations in the XPD gene in Italian patients with trichothiodystrophy: site of mutation correlates with repair deficiency, but gene dosage appears to determine clinical severity. Botta E, et al. **Am J Hum Genet** 1998 Oct;63(4):1036–48

Cross-linked features of mouse pelage hair resistant to detergent extraction. Rice RH, et al. **Anat Rec** 1999 Feb 1;254(2):231–7

Elejalde syndrome--a melanolysosomal neurocutaneous syndrome: clinical and morphological findings in 7 patients. Duran-McKinster C, et al. **Arch Dermatol** 1999 Feb; 135(2):182–6

Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Fartasch M, et al. **Arch Dermatol** 1999 Jul; 135(7):823–32

Congenital and hereditary hair abnormalities. Dawber R. **Exp Dermatol** 1999 Aug;8(4):296–7

Recurrent bacterial vaginosis and Netherton's syndrome. Nicholls S, et al. **Int J STD AIDS** 1999 Mar;10(3):202–3

Increased incidence of cancer in patients with cartilage-hair hypoplasia. Mäkitie O, et al. **J Pediatr** 1999 Mar; 134(3):315–8

Scraggly, a new hair loss mutation on mouse chromosome 19. Herron BJ, et al. **Mamm Genome** 1999 Sep;10(9):864–9

What syndrome is this? Uncombable hair syndrome (Pili trianguli et canaliculi). Ang P, et al. **Pediatr Dermatol** 1998 Nov–Dec;15(6):475–6

Childhood vulval lichen sclerosus in a patient with ectodermal dysplasia and uncombable hair. Powell J, et al. **Pediatr Dermatol** 1998 Nov–Dec;15(6):446–9

Gray matter heterotopia and acute necrotizing encephalopathy in trichothiodystrophy. Wetzburger CL, et al. **Pediatr Neurol** 1998 Nov;19(5):392–4

ANATOMY & HISTOLOGY

Characteristic intraepidermal nerve fibre endings of the intervibrissal fur in the mystacial pad of the rat: morphological details revealed by intravital methylene blue staining and the zinc iodide-osmium tetroxide technique. Müller T. **J Anat** 1999 Jul;195 (Pt 1):147–52

CHEMISTRY

Detection of ethanol consumption by ELISA assay measurement of acetaldehyde adducts in murine hair. Watson RR, et al. **Alcohol** 1998 Nov;16(4):279–84

Validity of drug use reporting in a high-risk community sample: a comparison of cocaine and heroin survey reports with hair tests. Fendrich M, et al. **Am J Epidemiol** 1999 May 15;149(10):955–62

Methylmercury exposure biomarkers as indicators of neurotoxicity in children aged 7 years. Grandjean P, et al. **Am J Epidemiol** 1999 Aug 1;150(3):301–5

Noninvasive test for fragile X syndrome, using hair root analysis. Willemsen R, et al. **Am J Hum Genet** 1999 Jul; 65(1):98–103

Investigations into the effect of diet on modern human hair isotopic values. O'Connell TC, et al. **Am J Phys Anthropol** 1999 Apr;108(4):409–25

A fast immunoassay for the screening of beta-agonists in hair. Haasnoot W, et al. **Analyst** 1998 Dec;123(12):2707–10

Determination of testosterone in human hair by gas chromatography-selected ion monitoring mass spectrometry. Scherer C, et al. **Analyst** 1998 Dec;

123(12):2661–3
Multielement analysis of human hair and kidney stones by instrumental neutron activation analysis with the k0–standardization method. Abugassa I, et al. **Appl Radiat Isot** 1999 Jun;50(6):989–94
Organization of microfibrils in keratin fibers studied by X–ray scattering modelling using the paracrystal concept. Briki F, et al. **Biochim Biophys Acta** 1998 Dec 8;1429(1):57–68
Hair and serum calcium, iron, copper, and zinc levels during normal pregnancy at three trimesters. Huang HM, et al. **Biol Trace Elem Res** 1999 Aug;69(2):111–20
Mapping of ecoiogically unfavorable territories based on human hair composition. Kist AA, et al. **Biol Trace Elem Res** 1998 Summer;64(1–3):1–12
Hair concentrations of calcium, iron, and zinc in pregnant women and effects of supplementation. Leung PL, et al. **Biol Trace Elem Res** 1999 Sep;69(3):269–82
Ultrastructural and trace metal studies on radiographers' hair and nails. Majumdar S, et al. **Biol Trace Elem Res** 1999 Feb;67(2):127–38
Structural and trace element changes in scalp hair of radiographers. Man AC, et al. **Biol Trace Elem Res** 1998 Jul;63(1):11–8
High–performance liquid chromatography study on effects of permanent wave, dye and decolorant treatments on methamphetamine and amphetamine in hair. Takayama N, et al. **Biomed Chromatogr** 1999 Jun;13(4):257–61
Determination of phenytoin in sections of head hair: a preliminary study to evaluate the history of drug use. Tsatsakis AM, et al. **Boll Chim Farm** 1998 Dec; 137(11):459–66
Expression of a truncated form of hHb1 hair keratin in human breast carcinomas. Régnier CH, et al. **Br J Cancer** 1998 Dec;78(12):1640–4
Identification of X–linked severe combined immunodeficiency by mutation analysis of blood and hair roots. Ting SS, et al. **Br J Haematol** 1999 Jul;106(1):190–4
Hair analysis. New laboratory ability to test for substance use [editorial] McPhillips MA, et al. **Br J Psychiatry** 1998 Oct;173:287–90
Codeine concentration in hair after oral administration is dependent on melanin content. Kronstrand R, et al. **Clin Chem** 1999 Sep;45(9):1485–94
Deposition and retention of radiolabeled serum constituents in hair after systemic administration. Stout PR, et al. **Drug Metab Dispos** 1998 Sep;26(9):900–6
Neurotoxic effects of low–level methylmercury contamination in the Amazonian Basin. Lebel J, et al. **Environ Res** 1998 Oct;79(1):20–32
The Ice Man's diet as reflected by the stable nitrogen and carbon isotopic composition of his hair. Macko SA, et al. **FASEB J** 1999 Mar;13(3):559–62
Solid–phase microextraction (SPME) of drugs and poisons from biological samples. Junting L, et al. **Forensic Sci Int** 1998 Nov 9;97(2–3):93–100
Testing for anabolic steroids in hair from two bodybuilders. Kintz P, et al. **Forensic Sci Int** 1999 May 17;101(3):209–16
Hair analysis––a biological marker for passive smoking in pregnancy and childhood. Klein J, et al. **Hum Exp Toxicol** 1999 Apr;18(4):279–82
Trace metals in ancient hair from the Karluk Archaeological Site, Kodiak, Alaska. Egeland GM, et al. **Int J Circumpolar Health** 1999 Jan;58(1):52–6
Mitochondrial DNA in human hair shafts––existence of intra–individual differences? Hühne J, et al. **Int J Legal Med** 1999;112(3):172–5
Fast analysis of drugs in a single hair. Wainhaus SB, et al. **J Am Soc Mass Spectrom** 1998 Dec;9(12):1311–20
First identification of prednisone in human hair by liquid chromatography–ionspray mass spectrometry [letter] Cirimele V, et al. **J Anal Toxicol** 1999 May–Jun;23(3):225–6
Organochlorine pollutants in human hair [letter] Dauberschmidt C, et al. **J Anal Toxicol** 1998 Nov–Dec; 22(7):610–1
Detection of methadone, methadone metabolites, and other illicit drugs of abuse in hair of methadone–treatment subjects. Goldberger BA, et al. **J Anal Toxicol** 1998 Oct; 22(6):526–30
Quantitation of cocaine in human hair: the effect of centrifugation of hair digests. Höld KM, et al. **J Anal Toxicol** 1998 Oct;22(6):414–7
Highly sensitive quantitation of methamphetamine by time–resolved fluoroimmunoassay using a new europium chelate as a label. Kimura H, et al. **J Anal Toxicol** 1999 Jan–Feb;23(1):11–6
Evaluation of acetylcodeine as a specific marker of illicit heroin in human hair. Kintz P, et al. **J Anal Toxicol** 1998 Oct;22(6):425–9
Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy. Negrusz A, et al. **J Anal Toxicol** 1998 Oct;22(6):531–6
Solid–phase microextraction for cannabinoids analysis in hair and its possible application to other drugs. Strano–Rossi S, et al. **J Anal Toxicol** 1999 Jan–Feb;23(1):7–10
Amphetamines in hair by enzyme–linked immunosorbent assay. Sweeney SA, et al. **J Anal Toxicol** 1998 Oct; 22(6):418–24
The catalog of human hair keratins. I. Expression of the nine type I members in the hair follicle. Langbein L, et al. **J Biol Chem** 1999 Jul 9;274(28):19874–84
Determination of clenbuterol residues in bovine hair by using diphasic dialysis and gas chromatography–mass spectrometry. Fente CA, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 16; 726(1–2):133–9
Long–term detection of clenbuterol in human scalp hair by gas chromatography–high–resolution mass spectrometry. Machnik M, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19;723(1–2):147–55
Immunological screening of drugs of abuse and gas chromatographic–mass spectrometric confirmation of opiates and cocaine in hair. Segura J, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 5;724(1):9–21
High sensitivity simultaneous determination in hair of the major constituents of ecstasy (3,4–methylenedioxymethamphetamine, 3,4–methylenedioxyamphetamine and 3,4–methylene–dioxyethylamphetamine) by high–performance liquid chromatography with direct fluorescence detection. Tagliaro F, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19; 723(1–2):195–202
Determination of thyroxine in the hair of newborns by radioimmunoassay with high–performance liquid chromatographic confirmation. Tagliaro F, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1–2):77–82
Carbamazepine levels in head hair of patients under long–term treatment: a method to evaluate the history of drug use. Psillakis T, et al. **J Clin Pharmacol** 1999 Jan; 39(1):55–67
The measurement of testosterone in hair. Wheeler MJ, et al. **J Endocrinol** 1998 Oct;159(1):R5–8
Detection of anabolic steroids in head hair. Deng XS, et al. **J Forensic Sci** 1999 Mar;44(2):343–6
The detection of cocaine in hair specimens using micro–plate enzyme immunoassay. Moore C, et al. **J Forensic Sci** 1999 May;44(3):609–12
Forensic evidence based on mtDNA from dog and wolf hairs. Savolainen P, et al. **J Forensic Sci** 1999 Jan;44(1):77–81
Practical GC/MS analysis of oxidation dye components in hair fiber as a forensic investigative procedure. Tanada N, et al. **J Forensic Sci** 1999 Mar;44(2):292–6
Analysis of race effects on drug–test results. Hoffman BH. **J Occup Environ Med** 1999 Jul;41(7):612–4
A preliminary study of steroid reproductive hormones in human hair. Yang HZ, et al. **J Steroid Biochem Mol Biol** 1998 Dec;67(5–6):447–50
Health hazards due to clenbuterol residues in food [letter] Chan TY. **J Toxicol Clin Toxicol** 1999;37(4):517–9
Andrew Jackson's exposure to mercury and lead: poisoned president? Deppisch LM, et al. **JAMA** 1999 Aug 11; 282(6):569–71
Mercury in the hair of crematoria workers [letter] [see comments] Maloney SR, et al. **Lancet** 1998 Nov 14; 352(9140):1602. Comment in: Lancet 1999 Feb 6;353(9151):502.
Mercury in hair––but from where? [letter; comment] Nielsen JB, et al. **Lancet** 1999 Feb 6;353(9151):502. Comment on: Lancet 1998 Nov 14;352(9140):1602.
Nuclear insertion sequences of mitochondrial DNA predominate in hair but not in blood of elephants. Greenwood AD, et al. **Mol Ecol** 1999 Jan;8(1):133–7
Breast–cancer diagnosis using hair [letter; comment] Briki F, et al. **Nature** 1999 Jul 15;400(6741):226. Comment on: Nature 1999 Mar 4;398(6722):33–4.
Using hair to screen for breast cancer [letter] [see comments] James V, et al. **Nature** 1999 Mar 4;398(6722):33–4. Comment in: Nature 1999 Jul 15;400(6741):226.
Utility of caffeine analysis for forensic hair discrimination. Tanada N, et al. **Nippon Hoigaku Zasshi** 1998 Aug; 52(4):233–7
Documenting the diet in ancient human populations through stable isotope analysis of hair. Macko SA, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jan 29; 354(1379):65–75; discussion 75–6
Short– and long–term uses of calcium acetate do not change hair and serum zinc concentrations in hemodialysis patients. Hwang SJ, et al. **Scand J Clin Lab Invest** 1999 Apr; 59(2):83–7
Cadmium content in human kidney and hair in the Gdańsk region. Hać E, et al. **Sci Total Environ** 1998 Dec 11; 224(1–3):81–5
Trace element content of commercial shampoos: impact on trace element levels in hair. LeBlanc A, et al. **Sci Total Environ** 1999 May 7;229(1–2):121–4
Diagnosing intrauterine exposure to cocaine by hair testing: six years of clinical use. Koren G, et al. **Ther Drug Monit** 1998 Oct;20(5):478–80
Hair testing and doping control in sport. Kintz P. **Toxicol Lett** 1998 Dec 28;102–103:109–13 (17 ref.)
Indoor air pollution by lindane and DDT indicated by head hair samples of children. Neuber K, et al. **Toxicol Lett** 1999 Jun 30;107(1–3):189–92
[Determination of tissue chlorine, bromine and iodine concentrations in normal persons with neutron activation method] Hou X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):288–91 (Eng. Abstr.) **(Chi)**
[New discoveries in forensic medicine. Hair analysis] Kaempe B. **Ugeskr Laeger** 1999 Mar 29;161(13):1901–5 (16 ref.) (Eng. Abstr.) **(Dan)**
[Evidence of pesticide exposure by hair analysis] Cirimele V, et al. **Acta Clin Belg Suppl** 1999;1:59–63 (Eng. Abstr.) **(Fre)**
[Levels of cadmium in pubic hair of women with threatened abortion and in full–term pregnancy] Saadi E, et al. **Ginekol Pol** 1998 Dec;69(12):878–83 (Eng. Abstr.) **(Pol)**
[Levels of lead in pubic hair of women with threatened abortion and in full–term pregnancy] Saadi E, et al. **Ginekol Pol** 1998 Dec;69(12):889–94 (Eng. Abstr.) **(Pol)**
[Chemical elements in hair––biochemical and diagnostic aspects] Karczewski JK. **Postepy Hig Med Dosw** 1998; 52(3):283–95 (38 ref.) (Eng. Abstr.) **(Pol)**
[The evaluation of urine and hair total mercury content in occupationally exposed and non–exposed people] Ludwicki JK, et al. **Rocz Panstw Zakl Hig** 1998;49(4):447–55 (Eng. Abstr.) **(Pol)**
[Low zinc levels in metabolic X syndrome (mzX) patients measured by hair zinc composition analysis] Lukasiak J, et al. **Rocz Panstw Zakl Hig** 1998;49(2):241–4 (Eng. Abstr.) **(Pol)**
[Levels of total mercury in scalp hair of children and youth from the selected rural area of the Lublin district] Zaborowska W, et al. **Rocz Panstw Zakl Hig** 1999; 50(1):49–55 (Eng. Abstr.) **(Pol)**
[The informational significance of metal bioaccumulation in the hair of preschool children] Namazbaeva ZI, et al. **Gig Sanit** 1999 Jan–Feb;(1):34–6 (Eng. Abstr.) **(Rus)**
[Testing problems regarding narcotic substances in hair analysis] Kriukov VN, et al. **Sud Med Ekspert** 1999 May–Jun;42(3):18–20 (26 ref.) (Eng. Abstr.) **(Rus)**
[The characteristics of the macro– and trace element composition of the hair in the peoples of Asia, Africa and Latin America] Pavlov IuV, et al. **Sud Med Ekspert** 1999 Mar–Apr;42(2):16–8 (Eng. Abstr.) **(Rus)**

CYTOLOGY

Construction of a roller device for the collection of hair and fiber evidence. Swinton SF. **J Forensic Sci** 1999 Sep; 44(5):1089–90
Pterins in human hair follicle cells and in the synchronized murine hair cycle. Schallreuter KU, et al. **J Invest Dermatol** 1998 Oct;111(4):545–50
Localization of rat FGF–5 protein in skin macrophage–like cells and FGF–5S protein in hair follicle: possible involvement of two Fgf–5 gene products in hair growth cycle regulation. Suzuki S, et al. **J Invest Dermatol** 1998 Dec;111(6):963–72
Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. Takahashi T, et al. **J Invest Dermatol** 1999 Mar;112(3):310–6
Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)? Tobin DJ, et al. **J Invest Dermatol** 1998 Dec;111(6):941–7

DRUG EFFECTS

Medical treatments for balding in men. Scow DT, et al. **Am Fam Physician** 1999 Apr 15;59(8):2189–94, 2196 (13 ref.)
Unexpected benefits of anaesthesia [letter; comment] Gauntlett IS. **Anaesthesia** 1999 Jan;54(1):101. Comment on: Anaesthesia 1998 Aug;53(8):830.
Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis. Boonyaleepun S, et al. **Asian Pac J Allergy Immunol** 1999 Mar;17(1):59–62
Green hair: causes and management [news] Fisher AA. **Cutis** 1999 Jun;63(6):317–8
Hair shaft effects from cosmetics and styling. Gummer CL. **Exp Dermatol** 1999 Aug;8(4):317
Effect of exogenous prolactin on the hair growth cycle. Pearson AJ, et al. **Exp Dermatol** 1999 Aug;8(4):358–60
Hair growth–modulation by adrenergic drugs. Peters EM, et al. **Exp Dermatol** 1999 Aug;8(4):274–81
Effects of cyclosporin A, FK506 and steroid hormones on hair growth. Tsuji Y, et al. **Exp Dermatol** 1999 Aug; 8(4):366–7
Efficacy of topical sensitizers in the treatment of alopecia areata. Rokhsar CK, et al. **J Am Acad Dermatol** 1998 Nov; 39(5 Pt 1):751–61 (76 ref.)
The effect of bovine somatotropin treatment on production of lactating angora does with kids. Davis JJ, et al. **J Anim Sci** 1999 Jan;77(1):17–24
Effects of mimosine and 2,3–dihydroxypyridine on fiber shedding in Angora goats. Reis PJ, et al. **J Anim Sci** 1999 May;77(5):1224–9
[Maxilène and alopecia] Dubertret L. **Ann Dermatol Venereol** 1998 Apr;125(4):275 **(Fre)**
[Discoloration of hair under the effect of hyroxychloroquine (letter)] Lecocq P, et al. **Presse Med** 1999 Apr 10; 28(14):741 **(Fre)**

EMBRYOLOGY

Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. McGowan KM, et al. **J Cell Biol** 1998 Oct 19;143(2):469–86

ENZYMOLOGY

A novel serine protease overexpressed in the hair follicles of nude mice. Meier N, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):374–8
Dynamic expression of ornithine decarboxylase in hair

growth. Nancarrow MJ, et al. **Mech Dev** 1999 Jun; 84(1-2):161-4

GROWTH & DEVELOPMENT

Ruby laser-assisted hair removal: a preliminary report of the correlation between efficacy of treatment and melanin content of hair and the growth phases of hair at a specific site. Liew SH, et al. **Ann Plast Surg** 1999 Mar;42(3):255-8

Intact hair follicle innervation is not essential for anagen induction and development. Maurer M, et al. **Arch Dermatol Res** 1998 Oct;290(10):574-8

Hair cycle-dependent production of ACTH in mouse skin. Slominski A, et al. **Biochim Biophys Acta** 1998 Nov 19; 1448(1):147-52

Splitting hairs: dissecting roles of signaling systems in epidermal development. Oro AE, et al. **Cell** 1998 Nov 25; 95(5):575-8 (18 ref.)

Serum prolactin and dehydroepiandrosterone concentrations during the summer and winter hair growth cycles of mink (Mustela vison). Rose J, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Nov; 121(3):263-71

Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283-94 (78 ref.)

Sonic hedgehog signaling is essential for hair development. St-Jacques B, et al. **Curr Biol** 1998 Sep 24;8(19):1058-68

The control of hair growth. Jankovic SM, et al. **Dermatol Online J** 1998 Oct;4(1):2 (48 ref.)

WNT signaling in the control of hair growth and structure. Millar SE, et al. **Dev Biol** 1999 Mar 1;207(1):133-49

Manipulation of outer root sheath cell survival perturbs the hair-growth cycle. Pena JC, et al. **EMBO J** 1999 Jul 1; 18(13):3596-603

Cellular and developmental aspects of androgenetic alopecia. Jahoda CA. **Exp Dermatol** 1998 Oct;7(5):235-48 (102 ref.)

Effect of exogenous prolactin on the hair growth cycle. Pearson AJ, et al. **Exp Dermatol** 1999 Aug;8(4):358-60

Hair growth-modulation by adrenergic drugs. Peters EM, et al. **Exp Dermatol** 1999 Aug;8(4):274-81

Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Tobin DJ, et al. **Exp Dermatol** 1998 Oct;7(5):289-97

Effects of cyclosporin A, FK506 and steroid hormones on hair growth. Tsuji Y, et al. **Exp Dermatol** 1999 Aug; 8(4):366-7

Human scalp hair growth and loss evaluation methods: is there simple and reliable method? Van Neste D. **Exp Dermatol** 1999 Aug;8(4):299-301 (19 ref.)

Toxicological studies on procyanidin B-2 for external application as a hair growing agent. Takahashi T, et al. **Food Chem Toxicol** 1999 May;37(5):545-52

Hormones and hair patterning in men: a role for insulin-like growth factor 1? Signorello LB, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):200-3

Effects of bovine somatotropin and ruminally undegraded protein on feed intake, live weight gain, and mohair production by yearling Angora wethers. Davis JJ, et al. **J Anim Sci** 1999 May;77(5):1029-36

The potential role of skin protein kinase C isoforms alpha and delta in mouse hair growth induced by diphencyprone-allergic contact dermatitis. Li LF, et al. **J Dermatol** 1999 Feb;26(2):98-105

Alteration of skin protein kinase C alpha protein and mRNA levels during induced mouse hair growth. Li LF, et al. **J Dermatol** 1999 Apr;26(4):203-9

Partial regrowth of scalp hair in a patient treated with extracorporeal photochemotherapy and interferon alpha 2a [letter] Wollina U. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):261-2

Role of prolactin in regulating the onset of winter fur growth in mink (Mustela vison): A reconsideration. Johnston B, et al. **J Exp Zool** 1999 Sep 1;284(4):437-44

The Notch signalling pathway in hair growth. Powell BC, et al. **Mech Dev** 1998 Nov;78(1-2):189-92

Hairy mice offer hope for baldness remedy [news] Pennisi E. **Science** 1998 Nov 27;282(5394):1617,1619

[Pilar growth: VEGF and fibroblasts of the follicular papilla] Charvéron M, et al. **Ann Dermatol Venereol** 1998 Nov;125 Suppl 2:S9-11 **(Fre)**

[Androgenetic alopecia. Hair loss effectively stopped with 1 mg Finasterid] **Hautarzt** 1999 May;50(5 Suppl Haarausfal):1-4 **(Ger)**

METABOLISM

Ruby laser-assisted hair removal: a preliminary report of the correlation between efficacy of treatment and melanin content of hair and the growth phases of hair at a specific site. Liew SH, et al. **Ann Plast Surg** 1999 Mar;42(3):255-8

Correlation of mercury with selenium in human hair at a typical mercury-polluted area in China. Chai Z, et al. **Biol Trace Elem Res** 1998 Aug;63(2):95-104

Comparison of in vivo and in vitro deposition of rhodamine and fluorescein in hair. Stout PR, et al. **Drug Metab Dispos** 1998 Oct;26(10):943-8

Deposition of [3H]cocaine, [3H]nicotine, and [3H]flunitrazepam in mouse hair melanosomes after systemic administration. Stout PR, et al. **Drug Metab Dispos** 1999 Jun;27(6):731-5

Human fibroblast growth factor 10 expression in dermal papilla cells, outer root sheath cells and keratinocytes. Hamada K, et al. **Exp Dermatol** 1999 Aug;8(4):347-9

Point mutation in the helix termination peptide (HTP) of human type II hair keratin hHb6 causes monilethrix in five families. Korge BP, et al. **Exp Dermatol** 1999 Aug; 8(4):310-2

Fatty acids chemically bound to protein forms the hydrophic membrane of the hair cuticle. Rivett DE, et al. **Exp Dermatol** 1999 Aug;8(4):360-1

The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. Dai X, et al. **Genes Dev** 1998 Nov 1;12(21):3452-63

Faint lined (Fnl): a novel X-linked coat mutant in the mouse. Gormally E, et al. **Genet Res** 1998 Dec;72(3):211-6

The incorporation of drugs into hair: relationship of hair color and melanin concentration to phencyclidine incorporation. Slawson MH, et al. **J Anal Toxicol** 1998 Oct;22(6):406-13

Characterization of a 190-kilobase pair domain of human type I hair keratin genes. Rogers MA, et al. **J Biol Chem** 1998 Oct 9;273(41):26683-91

Desmoglein 3 anchors telogen hair in the follicle. Koch PJ, et al. **J Cell Sci** 1998 Sep;111 (Pt 17):2529-37

Ultrastructural localization of S100A3, a cysteine-rich, calcium binding protein, in human scalp hair shafts revealed by rapid-freezing immunocytochemistry. Takizawa T, et al. **J Histochem Cytochem** 1999 Apr;47(4):525-32

Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy [letter] Bernard L, et al. **Lancet** 1998 Nov 28;352(9142):1757-8

Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry. Lefebvre M, et al. **Life Sci** 1999;64(9):805-11

Transplacental pharmacokinetics of cocaine and benzoylecgonine in plasma and hair of rhesus monkeys. Bailey B, et al. **Reprod Toxicol** 1998 Sep-Oct;12(5):517-23

[Studies on mechanism of drug incorporation into hair] Kikura R, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):30-45 (142 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

A study of keratinolytic fungi in mountain sediments. I. Hair-baiting data. Ulfig K, et al. **Rocz Panstw Zakl Hig** 1998;49(4):469-79

PATHOLOGY

Nevoid hypertrichosis with multiple patches of hair that underwent almost complete spontaneous resolution. Dudding TE, et al. **Am J Med Genet** 1998 Sep 23; 79(3):195-6 (12 ref.)

Abnormal hair samples from patients with Alzheimer disease [letter] Bonafé JL, et al. **Arch Dermatol** 1998 Oct; 134(10):1300

Peeling skin syndrome with hair changes. Mevorah B, et al. **Dermatology** 1998;197(4):373-6

Björnstad syndrome in a patient with mental retardation. Van Buggenhout G, et al. **Genet Couns** 1998;9(3):201-4

PHYSIOLOGY

Effects of ambient temperature and scrotal fleece cover on scrotal and testicular temperatures in rams. Kastelic JP, et al. **Can J Vet Res** 1999 Apr;63(2):157-60

A comparison of hair bundle mechanoreceptors in sea anemones and vertebrate systems. Watson GM, et al. **Curr Top Dev Biol** 1999;43:51-84 (75 ref.)

Regulation of hair gene expression. Dunn SM, et al. **Exp Dermatol** 1999 Aug;8(4):341-2

The hydrophobic surface barrier of mammalian hair. Jones LN, et al. **Exp Dermatol** 1999 Aug;8(4):351-2

The companion layer and outer root sheath of the anagen hair follicle. Mahony D, et al. **Exp Dermatol** 1999 Aug; 8(4):329-31

The role of BMP-2 and BMP-4 in follicle initiation and the murine hair cycle. Wilson N, et al. **Exp Dermatol** 1999 Aug; 8(4):367-8

Patchy fur, a mouse coat mutation associated with X-Y nondisjunction, maps to the pseudoautosomal boundary region. Korobova O, et al. **Genomics** 1998 Dec 15; 54(3):556-9

Methods of hair removal. Olsen EA. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):143-55; quiz 156-7 (63 ref.)

Involvement of neurokinins in antidromic vasodilatation in hairy and hairless skin of the rat hindlimb. Häbler HJ, et al. **Neuroscience** 1999;89(4):1259-68

PHYSIOPATHGLOGY

Loose anagen syndrome. Sinclair R, et al. **Exp Dermatol** 1999 Aug;8(4):297-8

RADIATION EFFECTS

Structural and trace element changes in scalp hair of radiographers. Man AC, et al. **Biol Trace Elem Res** 1998 Jul;63(1):11-8

Curly hair following radiotherapy epilation [letter] Möhrenschlager M, et al. **Br J Dermatol** 1998 Oct; 139(4):746-7

TRANSPLANTATION

Layered wound closure [letter; comment] Epstein JS. **Dermatol Surg** 1999 Jan;25(1):78. Comment on: Dermatol Surg 1998 Oct;24(10):1079-82.

Power boosting the grafts in hair transplantation surgery. Evaluation of a new storage medium. Raposio E, et al. **Dermatol Surg** 1998 Dec;24(12):1342-5; discussion 1346

Update on hair transplantation techniques. Shiell R. **Exp Dermatol** 1999 Aug;8(4):303-4

The use of micrografts and minigrafts for the treatment of burn alopecia. Barrera A. **Plast Reconstr Surg** 1999 Feb; 103(2):581-4

The use of micrografts and minigrafts for the correction of the postrhytidectomy lost sideburn. Barrera A. **Plast Reconstr Surg** 1998 Nov;102(6):2237-40

Scalp autografts and hair transfer to the face in the burned child. MacLennan SE, et al. **Plast Reconstr Surg** 1998 Nov; 102(6):1865-8

Hair transplantation in women. Avram MR. **Semin Cutan Med Surg** 1999 Jun;18(2):172-6 (6 ref.)

A comparison of graft implantation techniques for hair transplantation. Whitworth JM, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):177-83 (7 ref.)

ULTRASTRUCTURE

Ultrastructural and trace metal studies on radiographers' hair and nails. Majumdar S, et al. **Biol Trace Elem Res** 1999 Feb;67(2):127-38

Hair shaft defects visualized after detergent extraction. Rice RH, et al. **Exp Dermatol** 1999 Aug;8(4):308-10

Myotonic dystrophy (Steinert disease): a morphologic and biochemical hair study. Amorosi B, et al. **Int J Dermatol** 1999 Jun;38(6):434-8

A quantitative method for analysing AFM images of the outer surfaces of human hair. Smith JR. **J Microsc** 1998 Sep;191 (Pt 3):223-8

Prenatal diagnosis of harlequin ichthyosis by the examination of keratinized hair canals and amniotic fluid cells at 19 weeks' estimated gestational age. Akiyama M, et al. **Prenat Diagn** 1999 Feb;19(2):167-71

Coeliac disease: always something to discover. Várkonyi A, et al. **Scand J Gastroenterol Suppl** 1998;228:122-9

VIROLOGY

Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. Boxman IL, et al. **J Clin Microbiol** 1999 Jul;37(7):2270-3

HAIR BALLS see **BEZOARS**

HAIR CELLS

Biology in pictures. A sense of colour. Holt JR. **Curr Biol** 1999 May 20;9(10):R351

ANATOMY & HISTOLOGY

Hair cell morphology and innervation in the basilar papilla of the emu (Dromaius novaehollandiae). Fischer FP. **Hear Res** 1998 Jul;121(1-2):112-24

CHEMISTRY

SNARE complex at the ribbon synapses of cochlear hair cells: analysis of synaptic vesicle- and synaptic membrane-associated proteins. Safieddine S, et al. **Eur J Neurosci** 1999 Mar;11(3):803-12

Localization of myosin-Ibeta near both ends of tip links in frog saccular hair cells. García JA, et al. **J Neurosci** 1998 Nov 1;18(21):8637-47

The supporting-cell antigen: a receptor-like protein tyrosine phosphatase expressed in the sensory epithelia of the avian inner ear. Kruger RP, et al. **J Neurosci** 1999 Jun 15; 19(12):4815-27

AMPA-type glutamate receptor subunits are expressed in the avian cochlear hair cells and ganglion cells. Reng D, et al. **Neuroreport** 1999 Jul 13;10(10):2137-41

CYTOLOGY

Hair cell formation in cultures of dissociated cells from the vestibular sensory epithelium of the bullfrog. Cristobal R, et al. **Am J Otol** 1998 Sep;19(5):660-8

Extrinsic Fabry-Perot interferometer for measuring the stiffness of ciliary bundles on hair cells. Barrett MD, et al. **IEEE Trans Biomed Eng** 1999 Mar;46(3):331-9

Proliferation of vertebrate inner ear supporting cells. Wilkins HR, et al. **J Neurobiol** 1999 Jun 15;39(4):527-35

Auditory hair cell precursors immortalized from the mammalian inner ear. Rivolta MN, et al. **Proc R Soc Lond B Biol Sci** 1998 Sep 7;265(1406):1595-603

Understanding of ears, bristles jumps a notch [news] Vogel G. **Science** 1998 Nov 13;282(5392):1235

[Dissociation and morphological observation of hair cells from chick basila papilla] Yang J, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Aug; 11(8):356-8 (Eng. Abstr.) **(Chi)**

DRUG EFFECTS

The protective effect of brain-derived neurotrophic factor after gentamicin ototoxicity. Lopez I, et al. **Am J Otol** 1999 May;20(3):317-24

HAIR CELLS

Attempt at hair cell neodifferentiation in developing and adult amikacin intoxicated rat cochleae. Parietti C, et al. **Brain Res** 1998 Nov 30;813(1):57-66

Effects of growth factors on the hair cells after ototoxic treatment of the neonatal mammalian cochlea in vitro. Romand R, et al. **Brain Res** 1999 Apr 17;825(1-2):46-58

Low calcium abolishes tip links and alters relative stereocilia motion in chick cochlear hair cells. Duncan RK, et al. **Hear Res** 1998 Oct;124(1-2):69-77

Round window administration of gentamicin: a new method for the study of ototoxicity of cochlear hair cells. Husmann KR, et al. **Hear Res** 1998 Nov;125(1-2):109-19

Determination of hair cell degeneration and hair cell death in neomycin treated cultures of the neonatal rat cochlea. Löwenheim H, et al. **Hear Res** 1999 Feb;128(1-2):16-26

Characterization of atypical cells in the juvenile rat organ of corti after aminoglycoside ototoxicity. Daudet N, et al. **J Comp Neurol** 1998 Nov 16;401(2):145-62

Transforming growth factor alpha with insulin stimulates cell proliferation in vivo in adult rat vestibular sensory epithelium. Kuntz AL, et al. **J Comp Neurol** 1998 Sep 28; 399(3):413-23

Concanavalin A protects hair cells against gentamicin ototoxicity in rat cochlear explant cultures. Zheng JL, et al. **J Neurobiol** 1999 Apr;39(1):29-40

The endogenous calcium buffer and the time course of transducer adaptation in auditory hair cells. Ricci AJ, et al. **J Neurosci** 1998 Oct 15;18(20):8261-77

Streptomycin ototoxicity and hair cell regeneration in the adult pigeon utricle. Frank TC, et al. **Laryngoscope** 1999 Mar;109(3):356-61

The bacterial Neo gene confers neomycin resistance to mammalian cochlear hair cells. Dulon D, et al. **Neuroreport** 1999 Apr 26;10(6):1189-93

EMBRYOLOGY

Delta-Notch signalling and the patterning of sensory cell differentiation in the zebrafish ear: evidence from the mind bomb mutant. Haddon C, et al. **Development** 1998 Dec; 125(23):4637-44

Effects of intense noise exposure on fetal sheep auditory brain stem response and inner ear histology. Gerhardt KJ, et al. **Ear Hear** 1999 Feb;20(1):21-32

ENZYMOLOGY

The supporting-cell antigen: a receptor-like protein tyrosine phosphatase expressed in the sensory epithelia of the avian inner ear. Kruger RP, et al. **J Neurosci** 1999 Jun 15; 19(12):4815-27

[Observation of AChE location in chicken cochlea] Nie C, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 May; 11(5):198-9, 208 (Eng. Abstr.) **(Chi)**

GROWTH & DEVELOPMENT

Who does the hair cell's 'do? Rho GTPases and hair-bundle morphogenesis. Kollmar R. **Curr Opin Neurobiol** 1999 Aug; 9(4):394-8 (40 ref.)

METABOLISM

The functional role of alternative splicing of Ca(2+)-activated K+ channels in auditory hair cells. Jones EM, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:379-85

2E4 (kaptin): a novel actin-associated protein from human blood platelets found in lamellipodia and the tips of the stereocilia of the inner ear. Bearer EL, et al. **Eur J Cell Biol** 1999 Feb;78(2):117-26

Ultrastructural localisation of spectrin in sensory and supporting cells of guinea-pig organ of Corti. Mahendrasingam S, et al. **Hear Res** 1998 Dec; 126(1-2):151-60

Hair cell protection from aminoglycoside ototoxicity by adenovirus-mediated overexpression of glial cell line-derived neurotrophic factor. Yagi M, et al. **Hum Gene Ther** 1999 Mar 20;10(5):813-23

GATA3 is downregulated during hair cell differentiation in the mouse cochlea. Rivolta MN, et al. **J Neurocytol** 1998 Sep;27(9):637-47

The electrical properties of auditory hair cells in the frog amphibian papilla. Smotherman MS, et al. **J Neurosci** 1999 Jul 1;19(13):5275-92

PATHOLOGY

Characterization of atypical cells in the juvenile rat organ of corti after aminoglycoside ototoxicity. Daudet N, et al. **J Comp Neurol** 1998 Nov 16;401(2):145-62

Leupeptin protects sensory hair cells from acoustic trauma. Wang J, et al. **Neuroreport** 1999 Mar 17;10(4):811-6

PHYSIOLOGY

Role of amino acids in cochlear degeneration: deprivation of cystine induces death of cochlear hair cells of guinea pigs in vitro. Sunami K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:19-21

Assessment of hair cell death using the dye extrusion method. Yamane H, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:7-11

The protective effect of brain-derived neurotrophic factor after gentamicin ototoxicity. Lopez I, et al. **Am J Otol** 1999 May;20(3):317-24

Electrical response properties of avian lagena type II hair cells: a model system for vestibular filtering. Ricci AJ, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R943-53

Stimulus processing by type II hair cells in the mouse utricle. Holt JR, et al. **Ann N Y Acad Sci** 1999 May 28;871:15-26

Mechanisms of hair cell tuning. Fettiplace R, et al. **Annu Rev Physiol** 1999;61:809-34 (148 ref.)

The transduction of very small hydrostatic pressures. Macdonald AG, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jan; 122(1):13-36 (153 ref.)

Delta1 expression during avian hair cell regeneration. Stone JS, et al. **Development** 1999 Feb;126(5):961-73

Neurotrophic factors modulate hair cells and their potassium currents in chick otocyst explants [published erratum appears in Eur J Neurosci 1999 May;11(5):1847] Sokolowski BH, et al. **Eur J Neurosci** 1999 Feb; 11(2):682-90

Distal separation of chick cochlear hair cell stereocilia: analysis of contact-constraint models. Duncan RK, et al. **Hear Res** 1999 Jan;127(1-2):22-30

Low calcium abolishes tip links and alters relative stereocilia motion in chick cochlear hair cells. Duncan RK, et al. **Hear Res** 1998 Oct;124(1-2):69-77

The tip link's role in asymmetric stereocilia motion of chick cochlear hair cells. Eisen MD, et al. **Hear Res** 1999 Jan; 127(1-2):14-21

Morphological polarizations of sensory hair cells in the three otolithic organs of a teleost fish: fluorescent imaging of ciliary bundles. Lu Z, et al. **Hear Res** 1998 Dec; 126(1-2):47-57

Responses of auditory nerve fibers innervating regenerated hair cells after local application of gentamicin at the round window of the cochlea in the pigeon. Müller M, et al. **Hear Res** 1999 May;131(1-2):153-69

Mechanisms and effects of transepithelial polarization in the isolated semicircular canal. Norris CH, et al. **Hear Res** 1998 Sep;123(1-2):31-40

Evidence for loss and recovery of chick brainstem auditory neurons during gentamicin-induced cochlear damage and regeneration. Park DL, et al. **Hear Res** 1998 Dec; 126(1-2):84-98

Potassium currents in auditory hair cells of the frog basilar papilla. Smotherman MS, et al. **Hear Res** 1999 Jun; 132(1-2):117-30

Extrinsic Fabry-Perot interferometer for measuring the stiffness of ciliary bundles on hair cells. Barrett MD, et al. **IEEE Trans Biomed Eng** 1999 Mar;46(3):331-9

Indirect synaptic inputs from filiform hair sensory neurons contribute to the receptive fields of giant interneurons in the first-instar cockroach. Hill ES, et al. **J Comp Physiol [A]** 1998 Oct;183(4):467-76

Functional expression of exogenous proteins in mammalian sensory hair cells infected with adenoviral vectors. Holt JR, et al. **J Neurophysiol** 1999 Apr;81(4):1881-8

The endogenous calcium buffer and the time course of transducer adaptation in auditory hair cells. Ricci AJ, et al. **J Neurosci** 1998 Oct 15;18(20):8261-77

Immunocytochemical and morphological evidence for intracellular self-repair as an important contributor to mammalian hair cell recovery. Zheng JL, et al. **J Neurosci** 1999 Mar 15;19(6):2161-70

An improved heterodyne laser interferometer for use in studies of cochlear mechanics. Cooper NP. **J Neurosci Methods** 1999 Apr 1;88(1):93-102

Position-dependent expression of inwardly rectifying K+ currents by hair cells of frog semicircular canals. Marcotti W, et al. **Neuroreport** 1999 Feb 25;10(3):601-6

Ionic currents and current-clamp depolarisations of type I and type II hair cells from the developing rat utricle. Lennan GW, et al. **Pflugers Arch** 1999 Jun;438(1):40-6

Static magnetic field and the inner ear. A functional study of hearing and vestibular function in man after exposure to a static magnetic field. Winther FO, et al. **Scand Audiol** 1999;28(1):57-9

A molecular mechanism for electrical tuning of cochlear hair cells. Ramanathan K, et al. **Science** 1999 Jan 8; 283(5399):215-7

PHYSIOPATHOLOGY

Therapeutic potential of neurotrophins for treatment of hearing loss. Gao WQ. **Mol Neurobiol** 1998 Winter; 17(1-3):17-31 (88 ref.)

ULTRASTRUCTURE

Hair cell loss in the aged guinea pig cochlea. Ingham NJ, et al. **Acta Otolaryngol (Stockh)** 1999 Jan;119(1):42-7

Keratin filament deployment and cytoskeletal networking in a sensory epithelium that vibrates during hearing. Mogensen MM, et al. **Cell Motil Cytoskeleton** 1998; 41(2):138-53

Effects of intense noise exposure on fetal sheep auditory brain stem response and inner ear histology. Gerhardt KJ, et al. **Ear Hear** 1999 Feb;20(1):21-32

Application of a platinum replica method to the study of the cytoskeleton of isolated hair cells, supporting cells and whole mounts of the organ of Corti. Leonova EV, et al. **Hear Res** 1999 Apr;130(1-2):137-54

Ultrastructural localisation of spectrin in sensory and supporting cells of guinea-pig organ of Corti. Mahendrasingam S, et al. **Hear Res** 1998 Dec; 126(1-2):151-60

Examination of the cupula and stereocilia of the horizontal semicircular canal in the toadfish Opsanus tau. Silver RB, et al. **J Comp Neurol** 1998 Dec 7;402(1):48-61

Non-coating fixation techniques or redundancy of conductive coating, low kV FE-SEM operation and combined SEM/TEM of biological tissues. Jongebloed WL, et al. **J Microsc** 1999 Feb;193 (Pt 2):158-70

GATA3 is downregulated during hair cell differentiation in the mouse cochlea. Rivolta MN, et al. **J Neurocytol** 1998 Sep;27(9):637-47

Middle ear instillation of gentamicin and streptomycin in chinchillas: morphologic appraisal of selective ototoxicity. Chen JM, et al. **J Otolaryngol** 1999 Jun;28(3):121-8

Hair bundle morphology on surviving hair cells of the chick basilar papilla exposed to intense sound. Erulkar JS, et al. **Scanning Microsc** 1996;10(4):1127-40; discussion 1140-2

Touch-plate and statolith formation in graviceptors of ephyrae which developed while weightless in space. Spangenberg DB, et al. **Scanning Microsc** 1996; 10(3):875-87; discussion 887-8

HAIR CELLS, INNER

ANATOMY & HISTOLOGY

Response phase: a view from the inner hair cell. Cheatham MA, et al. **J Acoust Soc Am** 1999 Feb;105(2 Pt 1):799-810

BLOOD SUPPLY

Quantitative immunogold cytochemistry reveals sources of glutamate release in inner ear ischemia. Matsubara A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:48-51

CYTOLOGY

Requirement for Brn-3c in maturation and survival, but not in fate determination of inner ear hair cells. Xiang M, et al. **Development** 1998 Oct;125(20):3935-46

Math1: an essential gene for the generation of inner ear hair cells. Bermingham NA, et al. **Science** 1999 Jun 11; 284(5421):1837-41

DRUG EFFECTS

New approaches for inner ear therapy with glutamate antagonists. Oestreicher E, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):174-8

Cleavage product from the NO donor NOC-5 and inner ear hair cell damage. Takayama M, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:12-8

Effects of BDNF and NT-3 on hair cell survival in guinea pig cochlea damaged by kanamycin treatment. Ruan RS, et al. **Neuroreport** 1999 Jul 13;10(10):2067-71

GROWTH & DEVELOPMENT

Age-related cochlear hair cell loss is enhanced in mice lacking copper/zinc superoxide dismutase. McFadden SL, et al. **Neurobiol Aging** 1999 Jan-Feb;20(1):1-8

IMMUNOLOGY

The ankle-link antigen: an epitope sensitive to calcium chelation associated with the hair-cell surface and the calycal processes of photoreceptors. Goodyear R, et al. **J Neurosci** 1999 May 15;19(10):3761-72

METABOLISM

Quantitative immunogold cytochemistry reveals sources of glutamate release in inner ear ischemia. Matsubara A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:48-51

Differential expression of the alpha 9 nicotinic acetylcholine receptor subunit in neonatal and adult cochlear hair cells. Simmons DD, et al. **Brain Res Mol Brain Res** 1998 May; 56(1-2):287-92

Evidence for differential regulation of calcium by outer versus inner hair cells: plasma membrane Ca-ATPase gene expression [published erratum appears in Hear Res 1998 Dec;126(1-2):214] Furuta H, et al. **Hear Res** 1998 Sep; 123(1-2):10-26

Fluorescence imaging of Na+ influx via P2X receptors in cochlear hair cells. Housley GD, et al. **Hear Res** 1998 May; 119(1-2):1-13

PATHOLOGY

An animal model of auditory neuropathy. Harrison RV. **Ear Hear** 1998 Oct;19(5):355-61

PHYSIOLOGY

Basilar papilla explants: a model to study hair cell regeneration-repair and protection. Frenz DA, et al. **Acta Otolaryngol (Stockh)** 1998 Sep;118(5):651-9

Factors controlling hair-cell regeneration/repair in the inner ear. Staecker H, et al. **Curr Opin Neurobiol** 1998 Aug; 8(4):480-7 (52 ref.)

GABA(A) receptor modulates the activity of inner hair cell afferents in guinea pig cochlea. Arnold T, et al. **Hear Res** 1998 Nov;125(1-2):147-53

Multiple modes of inner hair cell stimulation. Mountain DC, et al. **Hear Res** 1999 Jun;132(1-2):1-14

Response phase: a view from the inner hair cell. Cheatham MA, et al. **J Acoust Soc Am** 1999 Feb;105(2 Pt 1):799-810

Analog very large-scale integrated (VLSI) implementation of a model of amplitude-modulation sensitivity in the auditory brainstem. van Schaik A, et al.
J Acoust Soc Am 1999 Feb;105(2 Pt 1):811-21

Effect of membrane tension on gap junctional conductance of supporting cells in Corti's organ. Zhao HB, et al.
J Gen Physiol 1998 Oct;112(4):447-55

Frequency tuning of cochlear hair cells by differential splicing of BK channel transcripts [editorial; comment] Oberholtzer JC. **J Physiol (Lond)** 1999 Aug 1;518 (Pt 3):629. Comment on: J Physiol (Lond) 1999 Aug 1;518 (Pt 3):653-65.

Mechanoelectrical transduction assisted by Brownian motion: a role for noise in the auditory system. Jaramillo F, et al.
Nat Neurosci 1998 Sep;1(5):384-8

Age-related cochlear hair cell loss is enhanced in mice lacking copper/zinc superoxide dismutase. McFadden SL, et al. **Neurobiol Aging** 1999 Jan-Feb;20(1):1-8

The fast activating potassium current, I(K,f), in guinea-pig inner hair cells is regulated by protein kinase A. Jagger DJ, et al. **Neurosci Lett** 1999 Mar 26;263(2-3):145-8

Thyroid hormone receptor beta-dependent expression of a potassium conductance in inner hair cells at the onset of hearing. Rüsch A, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15758-62

ULTRASTRUCTURE

Tunnel crossing fibers and their synaptic connections within the inner hair cell region in the organ of corti in the maturing mouse. Sobkowicz HM, et al.
Anat Embryol (Berl) 1998 Nov;198(5):353-70

Novel membranous structures in apical and basal compartments of inner hair cells. Spicer SS, et al.
J Comp Neurol 1999 Jul 5;409(3):424-37

HAIR CELLS, OUTER

ABNORMALITIES

Stereociliary anomaly in the guinea pig: effects of hair bundle rotation on cochlear sensitivity. Yoshida N, et al.
Hear Res 1999 May;131(1-2):29-38

CHEMISTRY

Single-cell RT-PCR demonstrates expression of voltage-dependent chloride channels (ClC-1, ClC-2 and ClC-3) in outer hair cells of rat cochlea. Kawasaki E, et al. **Brain Res** 1999 Aug 14;838(1-2):166-70

Immunohistochemical localization of Ca2+/Calmodulin-dependent protein kinase IV in outer hair cells. Koyama M, et al. **J Histochem Cytochem** 1999 Jan;47(1):7-12

CYTOLOGY

Elastic properties of the composite outer hair cell wall. Spector AA, et al. **Ann Biomed Eng** 1998 Jan-Feb; 26(1):157-65

Mechanically evoked shortening of outer hair cells isolated from the guinea pig organ of Corti. Chan E, et al.
Hear Res 1999 Feb;128(1-2):166-74

Somatic stiffness of cochlear outer hair cells is voltage-dependent. He DZ, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8223-8

DRUG EFFECTS

Acetylcholine-induced phosphorylation in isolated outer hair cells. Szönyi M, et al. **Acta Otolaryngol (Stockh)** 1999 Mar; 119(2):185-8

Thimerosal-induced Ca2+ mobilization in isolated guinea pig cochlear outer hair cells. Chen L, et al.
Acta Otolaryngol Suppl (Stockh) 1998;539:28-33

Role of amino acids in cochlear degeneration: morphological changes in cochlear outer hair cells following glutamate application. Sunami K, et al.
Acta Otolaryngol Suppl (Stockh) 1998;538:22-5

The effect of quinine on outer hair cell shape, compliance and force. Jarboe JK, et al. **Hear Res** 1999 Jun; 132(1-2):43-50

Benzodiazepines alter cochleo-cochlear loop in humans. Morand N, et al. **Hear Res** 1998 Jul;121(1-2):71-6

Effects of lipophilic ions on outer hair cell membrane capacitance and motility. Wu M, et al. **J Membr Biol** 1998 Nov 15;166(2):111-8

Development of acetylcholine-induced responses in neonatal gerbil outer hair cells. He DZ, et al. **J Neurophysiol** 1999 Mar;81(3):1162-70

ATP-Induced Ca(2+) release in cochlear outer hair cells: localization of an inositol triphosphate-gated Ca(2+) store to the base of the sensory hair bundle. Mammano F, et al. **J Neurosci** 1999 Aug 15;19(16):6918-29

A sugar transporter as a candidate for the outer hair cell motor. Géléoc GS, et al. **Nat Neurosci** 1999 Aug;2(8):713-9

A potassium current in guinea-pig outer hair cells activated by ion channel blocker DCDPC. Jagger DJ, et al.
Neuroreport 1998 Dec 1;9(17):3887-91

Effects of BDNF and NT-3 on hair cell survival in guinea pig cochlea damaged by kanamycin treatment. Ruan RS, et al. **Neuroreport** 1999 Jul 13;10(10):2067-71

Kinetics of activation of a Ca2+-dependent K+ current induced by flash photolysis of caged carbachol in isolated guinea-pig outer hair cells. Chan E, et al.
Neurosci Lett 1998 Sep 18;254(1):45-8

GROWTH & DEVELOPMENT

Notch signalling pathway mediates hair cell development in mammalian cochlea [see comments] Lanford PJ, et al.
Nat Genet 1999 Mar;21(3):289-92. Comment in: Nat Genet 1999 Mar;21(3):253-4.

METABOLISM

Differential expression of the alpha 9 nicotinic acetylcholine receptor subunit in neonatal and adult cochlear hair cells. Simmons DD, et al. **Brain Res Mol Brain Res** 1998 May; 56(1-2):287-92

KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Kubisch C, et al. **Cell** 1999 Feb 5;96(3):437-46

Expression pattern of mammalian cochlea outer hair cell (OHC) mRNA: screening of a rat OHC cDNA library. Harter C, et al. **DNA Cell Biol** 1999 Jan;18(1):1-10

Evidence for differential regulation of calcium by outer versus inner hair cells: plasma membrane Ca-ATPase gene expression [published erratum appears in Hear Res 1998 Dec;126(1-2):214] Furuta H, et al. **Hear Res** 1998 Sep; 123(1-2):10-26

Fluorescence imaging of Na+ influx via P2X receptors in cochlear hair cells. Housley GD, et al. **Hear Res** 1998 May; 119(1-2):1-13

Cholinergic modulation of extracellular ATP-induced cytoplasmic calcium concentrations in cochlear outer hair cells. Wikström MA, et al. **J Physiol Paris** 1998 Oct-Dec; 92(5-6):345-9

Fibroblast growth factor receptor expression in outer hair cells of rat cochlea. Pickles JO, et al. **Neuroreport** 1998 Dec 21;9(18):4093-5

[Effects of streptomycin on ionic currents in isolated outer hair cells of guinea pig cochlea] Gu F, et al.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 May; 11(5):195-7 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

On inner ear function and the origin of oto-acoustic emissions. Fritze W, et al. **Acta Otolaryngol** 1999; 119(3):333-5

Changes in serum osmolarity influence the function of outer hair cells. Suckfüll M, et al. **Acta Otolaryngol** 1999; 119(3):316-21

Mechanically evoked shortening of outer hair cells isolated from the guinea pig organ of Corti. Chan E, et al.
Hear Res 1999 Feb;128(1-2):166-74

Cochlear outer hair cell electromotility can provide force for both low and high intensity distortion product otoacoustic emissions. Frolenkov GI, et al. **Hear Res** 1998 Dec;126(1-2):67-74

The effect of quinine on outer hair cell shape, compliance and force. Jarboe JK, et al. **Hear Res** 1999 Jun; 132(1-2):43-50

Nonlinear characteristics of electrically evoked otoacoustic emissions. Nakajima HH, et al. **Hear Res** 1998 Aug; 122(1-2):109-18

A four-state kinetic model of the temporary threshold shift after loud sound based on inactivation of hair cell transduction channels [published erratum appears in Hear Res 1999 Apr;130(1-2):231-2] Patuzzi R. **Hear Res** 1998 Nov;125(1-2):39-70 (75 ref.)

The Goldman-Hodgkin-Katz equation and graphical 'load-line' analysis of ionic flow through outer hair cells. Patuzzi R. **Hear Res** 1998 Nov;125(1-2):71-97 (46 ref.)

Nonlinear mechanics of the organ of Corti caused by Deiters cells. Böhnke F, et al. **IEEE Trans Biomed Eng** 1998 Oct; 45(10):1227-33

Nonlinear active force generation by cochlear outer hair cell. Spector AA, et al. **J Acoust Soc Am** 1999 Apr; 105(4):2414-20

Distortion component analysis of outer hair cell motility-related gating charge. Takahashi S, et al.
J Membr Biol 1999 Jun 1;169(3):199-207

Mechanical and electromotile characteristics of auditory outer hair cells. Spector AA, et al.
Med Biol Eng Comput 1999 Mar;37(2):247-51

Auditory collusion and a coupled couple of outer hair cells. Zhao HB, et al. **Nature** 1999 May 27;399(6734):359-62

Kinetics of activation of a Ca2+-dependent K+ current induced by flash photolysis of caged carbachol in isolated guinea-pig outer hair cells. Chan E, et al.
Neurosci Lett 1998 Sep 18;254(1):45-8

Density of motility-related charge in the outer hair cell of the guinea pig is inversely related to best frequency. Santos-Sacchi J, et al. **Neurosci Lett** 1998 Nov 13; 256(3):155-8

Outer hair cells isolated from the organ of corti exposed to increased hydrostatic pressure. Conradi P, et al.
ORL J Otorhinolaryngol Relat Spec 1999 Mar-Apr; 61(2):57-62

Effect of temperature on lateral wall mechanics of the guinea pig outer hair cell. Chen AY, et al.
Otolaryngol Head Neck Surg 1999 Jan;120(1):46-50

Regulation of ionic currents by protein kinase A and intracellular calcium in outer hair cells isolated from the guinea-pig cochlea. Jagger DJ, et al. **Pflugers Arch** 1999 Feb;437(3):409-16

Electrically driven motor in the outer hair cell: effect of a mechanical constraint. Adachi M, et al.
Proc Natl Acad Sci U S A 1999 Jun 22;96(13):7244-9

A model for amplification of hair-bundle motion by cyclical binding of Ca2+ to mechanoelectrical-transduction channels. Choe Y, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15321-6

Limiting dynamics of high-frequency electromechanical transduction of outer hair cells. Frank G, et al.
Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4420-5

Somatic stiffness of cochlear outer hair cells is voltage-dependent. He DZ, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8223-8

[Effects of efferent neurotransmitter acetylcholine and cochlear active substance ATP on cochlear outer hair cells] Xi J, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct; 27(4):331-4 (10 ref.) **(Chi)**

PHYSIOPATHOLOGY

Sensitivity of transient evoked and distortion product otoacoustic emissions to the direct effects of noise on the human cochlea. Vinck BM, et al. **Audiology** 1999 Jan-Feb; 38(1):44-52

ULTRASTRUCTURE

Stereociliary anomaly in the guinea pig: effects of hair bundle rotation on cochlear sensitivity. Yoshida N, et al.
Hear Res 1999 May;131(1-2):29-38

[Effect of experimental immunological otitis media on inner ear] Wang H, et al.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 Jul; 11(7):296-8 (Eng. Abstr.) **(Chi)**

HAIR CELLS, VESTIBULAR

CHEMISTRY

The combined effects of trkB and trkC mutations on the innervation of the inner ear. Fritzsch B, et al.
Int J Dev Neurosci 1998 Oct;16(6):493-505

Differential subcellular immunolocalization of voltage-gated calcium channel alpha1 subunits in the chinchilla cristae ampullaris. López I, et al. **Neuroscience** 1999;92(2):773-82

DRUG EFFECTS

Dose-dependent response of vestibular hair cells of guinea pigs following streptomycin ototoxiation. Nakagawa T, et al. **Acta Otolaryngol (Stockh)** 1998 Jul;118(4):530-3

Time-dependent response of vestibular hair cells of guinea pigs following high-dose applications of streptomycin. Nakagawa T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:32-5

Cycloheximide blocks the toxic effect of streptomycin in guinea pig vestibular hair cells. Nakagawa T, et al.
Acta Otolaryngol Suppl (Stockh) 1998;538:36-9

Recovery of the vestibulocolic reflex after aminoglycoside ototoxicity in domestic chickens. Goode CT, et al.
J Neurophysiol 1999 Mar;81(3):1025-35

METABOLISM

Glutamate-like immunoreactivity during hair cell recovery after gentamicin exposure in the chinchilla vestibular sensory periphery. Chin KW, et al. **Laryngoscope** 1999 Jul; 109(7 Pt 1):1037-44

PHYSIOLOGY

Miniature EPSPs and sensory encoding in the primary afferents of the vestibular lagena of the toadfish, Opsanus tau. Locke R, et al. **Ann N Y Acad Sci** 1999 May 28; 871:35-50

Distribution and time course of hair cell regeneration in the pigeon utricle. Dye BJ, et al. **Hear Res** 1999 Jul; 133(1-2):17-26

RADIOGRAPHY

Synaptic vesicle populations in saccular hair cells reconstructed by electron tomography. Lenzi D, et al.
J Neurosci 1999 Jan 1;19(1):119-32

HAIR COLOR

Elejalde syndrome--a melanolysosomal neurocutaneous syndrome: clinical and morphological findings in 7 patients. Duran-McKinster C, et al. **Arch Dermatol** 1999 Feb; 135(2):182-6

Transient quinonimines and 1,4-benzothiazines of pheomelanogenesis: new pulse radiolytic and spectrophotometric evidence. Napolitano A, et al.
Free Radic Biol Med 1999 Sep;27(5-6):521-8

Twenty-nail dystrophy and vitiligo: a rare association. Peloro TM, et al. **J Am Acad Dermatol** 1999 Mar;40(3):488-90

The incorporation of drugs into hair: relationship of hair color and melanin concentration to phencyclidine incorporation. Slawson MH, et al. **J Anal Toxicol** 1998 Oct;22(6):406-13

From Agouti to Pomc--100 years of fat blonde mice [news; comment] Barsh G. **Nat Med** 1999 Sep;5(9):984-5. Comment on: Nat Med 1999 Sep;5(9):1066-70.

Multiple factors in the evolution of animal coloration. Cloudsley-Thompson JL. **Naturwissenschaften** 1999 Mar;

HAIR COLOR

86(3):123-32 (78 ref.)

DRUG EFFECTS

Green hair: causes and management [news] Fisher AA. **Cutis** 1999 Jun;63(6):317-8

Cyclosporin A-induced hair darkening [letter] Rebora A, et al. **Int J Dermatol** 1999 Mar;38(3):229-30

GENETICS

Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Schiöth HB, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):488-91

Melanocortin receptors and antagonists regulate pigmentation and body weight. Jordan SA, et al. **Bioessays** 1998 Aug;20(8):603-6 (27 ref.)

Black hair follicular dysplasia, an autosomal recessive condition in dogs. Schmutz SM, et al. **Can Vet J** 1998 Oct; 39(10):644-6

The "spotted" locus maps to bovine chromosome 6 in a Hereford-Cross population. Grosz MD, et al. **J Hered** 1999 Jan-Feb;90(1):233-6

A new allelic series for the underwhite gene on mouse chromosome 15. Sweet HO, et al. **J Hered** 1998 Nov-Dec; 89(6):546-51

Close association between sequence polymorphism in the KIT gene and the roan coat color in horses. Marklund S, et al. **Mamm Genome** 1999 Mar;10(3):283-8

The spontaneous coat color mutant white nose (wn) maps to murine chromosome 15. Marks PW, et al. **Mamm Genome** 1999 Jul;10(7):750-2

A missense mutation in the bovine MGF gene is associated with the roan phenotype in Belgian Blue and Shorthorn cattle. Seitz JJ, et al. **Mamm Genome** 1999 Jul;10(7):710-2

Molecular and pharmacological characterization of dominant black coat color in sheep. Våge DI, et al. **Mamm Genome** 1999 Jan;10(1):39-43

A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice. Zheng B, et al. **Nucleic Acids Res** 1999 Jun 1; 27(11):2354-60

Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Strange RC, et al. **Pharmacogenetics** 1999 Jun; 9(3):269-76

Pigmentation, melanocortins and red hair [editorial] Rees JL, et al. **QJM** 1999 Mar;92(3):125-31

[Associations between the coat color and the blood-group system D antigens in horses] Kniazev SP, et al. **Genetika** 1999 Apr;35(4):499-503 (Eng. Abstr.) **(Rus)**

HAIR COLORANTS see **HAIR DYES**

HAIR DISEASES

CHEMICALLY INDUCED

Higher incidence of rolled hairs in renal transplant recipients: a possible complication of corticosteroid and cyclosporine therapy [letter] Seçkin D, et al. **Acta Derm Venereol** 1998 Sep;78(5):384

[Discoloration of hair under the effect of hyroxychloroquine (letter)] Lecocq P, et al. **Presse Med** 1999 Apr 10; 28(14):741 **(Fre)**

CLASSIFICATION

Folliculo-sebaceous cystic hamartoma is but the sebaceous end of tricho-sebo-folliculoma spectrum [letter; comment] Simón RS, et al. **J Cutan Pathol** 1999 Feb;26(2):109. Comment on: J Cutan Pathol 1998 Aug;25(7):341-53. Comment on: J Cutan Pathol 1998 Aug;25(7):354-64.

COMPLICATIONS

Poliosis associated with a giant congenital nevus [letter] Yosipovitch G, et al. **Arch Dermatol** 1999 Jul;135(7):859-61

Ectopia lentis et pupillae with patchy depigmentation of the skin, hair and lashes: a new association. Manitto MP, et al. **Eur J Ophthalmol** 1998 Jul-Sep;8(3):188-90

Björnstad syndrome in a patient with mental retardation. Van Buggenhout G, et al. **Genet Couns** 1998;9(3):201-4

Twenty-nail dystrophy and vitiligo: a rare association. Peloro TM, et al. **J Am Acad Dermatol** 1999 Mar;40(3):488-90

CONGENITAL

Congenital and hereditary hair abnormalities. Dawber R. **Exp Dermatol** 1999 Aug;8(4):296-7

DIAGNOSIS

Picture of the month. Pili torti. Gelles LN. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):647-8

Pilomatricoma: an alarming presentation. Parlette EC, et al. **Cutis** 1998 Nov;62(5):227-30

Floppy eyelid syndrome [letter; comment] McNab AA. **Ophthalmology** 1998 Nov;105(11):1977-8. Comment on: Ophthalmology 1998 Jan;105(1):165-9.

[Pilomatrixoma often not identified as such (comment)] Temming JF, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5; 142(49):2684-8 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):274-5. **(Dut)**

[The fully-symptomatic Netherton syndrome in the 11-year-old boy] Macura-Gina M, et al. **Wiad Lek** 1998; 51(11-12):531-4 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Allergic contact dermatitis from a medical device, followed by depigmentation. Reynaerts A, et al. **Contact Dermatitis** 1998 Oct;39(4):204-5

Hair and skin disorders as signs of mitochondrial disease. Bodemer C, et al. **Pediatrics** 1999 Feb;103(2):428-33

Hair and scalp conditions. Walkden V. **Practitioner** 1998 Apr; 242(1585):278-81 (4 ref.)

[Pilar dysplasia: an early marker of giant axonal neuropathy] Rybojad M, et al. **Ann Dermatol Venereol** 1998 Dec; 125(12):892-3 (Eng. Abstr.) **(Fre)**

GENETICS

Multiple pilomatrixomata and myotonic dystrophy: a familial association. Geh JL, et al. **Br J Plast Surg** 1999 Mar; 52(2):143-5 (17 ref.)

Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. de Boer J, et al. **Cancer Res** 1999 Jul 15;59(14):3489-94

Differential behaviors toward ultraviolet A and B radiation of fibroblasts and keratinocytes from normal and DNA-repair-deficient patients. Otto AI, et al. **Cancer Res** 1999 Mar 15;59(6):1212-8

Congenital and hereditary hair abnormalities. Dawber R. **Exp Dermatol** 1999 Aug;8(4):296-7

Monilethrix: a keratin hHb6 mutation is co-dominant with variable expression. Zlotogorski A, et al. **Exp Dermatol** 1998 Oct;7(5):268-72

The relative expression of mutated XPB genes results in xeroderma pigmentosum/Cockayne's syndrome or trichothiodystrophy cellular phenotypes. Riou L, et al. **Hum Mol Genet** 1999 Jun;8(6):1125-33

A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Cleaver JE, et al. **Hum Mutat** 1999; 14(1):9-22 (110 ref.)

A mutational hotspot in the 2B domain of human hair basic keratin 6 (hHb6) in monilethrix patients. Korge BP, et al. **J Invest Dermatol** 1998 Nov;111(5):896-9 (34 ref.)

Monilethrix: a novel mutation (Glu402Lys) in the helix termination motif and the first causative mutation (Asn114Asp) in the helix initiation motif of the type II hair keratin hHb6. Winter H, et al. **J Invest Dermatol** 1999 Aug;113(2):263-6

Restoration of open reading frame resulting from skipping of an exon with an internal deletion in the COL7A1 gene. Cserhalmi-Friedman PB, et al. **Lab Invest** 1998 Dec; 78(12):1483-92

A common human skin tumour is caused by activating mutations in beta-catenin. Chan EF, et al. **Nat Genet** 1999 Apr;21(4):410-3

Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH [see comments] Coin F, et al. **Nat Genet** 1998 Oct;20(2):184-8. Comment in: Nat Genet 1998 Oct;20(2):106-7.

From a DNA helicase to brittle hair [news; comment] Winkler GS, et al. **Nat Genet** 1998 Oct;20(2):106-7. Comment on: Nat Genet 1998 Oct;20(2):184-8.

Monilethrix--improvement by hormonal influences? Gebhardt M, et al. **Pediatr Dermatol** 1999 Jul-Aug; 16(4):297-300

[The syndrome of Comel-Netherton (trichorrhexis invaginata, ichthyosis linearis circumflexa and atopic eczema)] Sommer A. **Ned Tijdschr Geneeskd** 1998 Dec 5; 142(49):2709-10 **(Dut)**

IMMUNOLOGY

Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Stryk S, et al. **Pediatr Dermatol** 1999 Jan-Feb;16(1):19-22

METABOLISM

Expression of the hair stem cell-specific keratin 15 in pilar tumors of the skin. Kanitakis J, et al. **Eur J Dermatol** 1999 Jul-Aug;9(5):363-5

PATHOLOGY

Trichilemmal carcinoma in situ [letter] Sasaki Y, et al. **Acta Derm Venereol** 1998 Nov;78(6):474-5

Melanocytic matricoma: a report of two cases of a new entity. Carlson JA, et al. **Am J Dermatopathol** 1999 Aug; 21(4):344-9

Pilomatrix carcinoma of the eyelid. Cahill MT, et al. **Am J Ophthalmol** 1999 Apr;127(4):463-4

Ocular findings in ichthyosis follicularis, atrichia, and photophobia syndrome. Cursiefen C, et al. **Arch Ophthalmol** 1999 May;117(5):681-4

Primary systemic amyloidosis of the hair and nails [letter] Bedlow AJ, et al. **Clin Exp Dermatol** 1998 Nov;23(6):298-9

Malignant pilomatrixoma: a case report with fine needle aspiration (FNA) cytology. Deolekar MV, et al. **Cytopathology** 1999 Aug;10(4):270-5

Fine needle aspiration (FNA) cytology of pilomatrixoma: report of 14 cases and review of the literature. Viero RM, et al. **Cytopathology** 1999 Aug;10(4):263-9 (20 ref.)

Pilomatricoma in elderly individuals. Behnke N, et al. **Dermatology** 1998;197(4):391-3 (23 ref.)

Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Bremres RM, et al. **Eur J Cancer** 1999 Mar;35(3):433-7 (43 ref.)

Myotonic dystrophy (Steinert disease): a morphologic and biochemical hair study. Amorosi B, et al. **Int J Dermatol** 1999 Jun;38(6):434-8

Malignant pilomatricoma: a case report. Waxtein L, et al. **Int J Dermatol** 1998 Jul;37(7):538-40 (14 ref.)

A reappraisal on the modes of cell death in pilomatricoma. Nakamura T. **J Cutan Pathol** 1999 Mar;26(3):125-9

A clinical, microbiological, and histopathologic study of trichostasis spinulosa. Chung TA, et al. **J Dermatol** 1998 Nov;25(11):697-702

Eruptive vellus hair cyst in a patient with pachyonychia congenita. Lee HT, et al. **J Dermatol** 1999 Jun;26(6):402-4

Pilomatrix carcinoma of the face. Caubet-Biayna J, et al. **J Oral Maxillofac Surg** 1999 May;57(5):609-11

Pilomatrixoma of the eyelids and eyebrows in children and adolescents. Yap EY, et al. **Ophthal Plast Reconstr Surg** 1999 May;15(3):185-9

Pili torti with congenital deafness (Bjornstad syndrome): a case report. Loche F, et al. **Pediatr Dermatol** 1999 May-Jun;16(3):220-1

Bilateral choristomas in the ocular adnexa, lids, and posterior segment. Simons BD, et al. **Retina** 1998;18(4):380-2

[Clinicopathological study on 15 cases of pilomatrix carcinoma] Li X, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Apr;26(2):100-2 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Loose anagen syndrome. Sinclair R, et al. **Exp Dermatol** 1999 Aug;8(4):297-8

Monilethrix--improvement by hormonal influences? Gebhardt M, et al. **Pediatr Dermatol** 1999 Jul-Aug; 16(4):297-300

SURGERY

Surgical excision of pilomatrixoma of the head and neck: a retrospective review of 26 cases. Thomas RW, et al. **Ear Nose Throat J** 1999 Aug;78(8):541, 544-6, 548

Thermoablation treatment for trichiasis in trachoma using the semiconductor diode pumped laser. Oguz H, et al. **Eur J Ophthalmol** 1999 Apr-Jun;9(2):85-8

Bilamellar tarsal rotation is the preferred treatment for trachomatous trichiasis [letter; comment] West S, et al. **Surv Ophthalmol** 1999 Mar-Apr;43(5):468. Comment on: Surv Ophthalmol 1998 Jul-Aug;43(1):19-46.

THERAPY

Dermatography as a new treatment for alopecia areata of the eyebrows. van der Velden EM, et al. **Int J Dermatol** 1998 Aug;37(8):617-21

HAIR DYES

High-performance liquid chromatography study on effects of permanent wave, dye and decolorant treatments on methamphetamine and amphetamine in hair. Takayama N, et al. **Biomed Chromatogr** 1999 Jun;13(4):257-61

[Accidental paraphenylenediamine poisoning in an infant (letter)] Lahbabi MS, et al. **Arch Pediatr** 1998 Oct; 5(10):1168-9 **(Fre)**

ADVERSE EFFECTS

Immediate and delayed hypersensitivity to ammonium persulfate. Borelli S, et al. **Allergy** 1999 Aug;54(8):893-4

Contact urticaria and shock to hair dye. Pasche-Koo F, et al. **Allergy** 1998 Sep;53(9):904-5

Hair-color products and risk for non-Hodgkin's lymphoma: a population-based study in the San Francisco bay area. Holly EA, et al. **Am J Public Health** 1998 Dec; 88(12):1767-73

Chloroacetamide as a cause of contact dermatitis in hairdressing. Assier-Bonnet H, et al. **Contact Dermatitis** 1999 May;40(5):284-5

Allergy to 4-amino-3-nitrophenol in a hair dye. Blanco R, et al. **Contact Dermatitis** 1998 Sep;39(3):136

Patch test reactions and occupational dermatoses caused by hydrogen peroxide. Kanerva L, et al. **Contact Dermatitis** 1998 Sep;39(3):146

Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Nagata C, et al. **Leuk Res** 1999 Jan;23(1):57-62

Systemic lupus erythematosus (SLE) and hair treatment: a large community based case-control study. Hardy CJ, et al. **Lupus** 1999;8(7):541-4

Toxic beards? [letter] Gorlick GM. **Pediatrics** 1999 Jun;103(6 Pt 1):1313

CHEMISTRY

Practical GC/MS analysis of oxidation dye components in hair fiber as a forensic investigative procedure. Tanada N, et al. **J Forensic Sci** 1999 Mar;44(2):292-6

TOXICITY

Acute exposure to hair bleach causes airway hyperresponsiveness in a rabbit model. Mensing T, et al.

Eur Respir J 1998 Dec;12(6):1371-4

HAIR FOLLICLE

see related
FOLLICULITIS

In vitro maintenance of isolated hair follicles: current status and future development. Philpott M. **Exp Dermatol** 1999 Aug;8(4):317-9 (25 ref.)

Trichofolliculoma of the upper lip: report of a case. Mizutani H, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):135-6 (10 ref.)

A new method to improve penetration depth of dyes into the follicular duct: potential application for laser hair removal. Sumian CC, et al. **J Am Acad Dermatol** 1999 Aug; 41(2 Pt 1):172-5

Folliculo-sebaceous cystic hamartoma is a trichofolliculoma at its very late stage [see comments] Schulz T, et al. **J Cutan Pathol** 1998 Aug;25(7):354-64. Comment in: J Cutan Pathol 1999 Feb;26(2):109.

Unusual choristoma of the parotid gland in a girl. A possible trichoadenoma. Seifert G, et al. **Virchows Arch** 1999 Apr; 434(4):355-9

ABNORMALITIES

Picture of the month. Pili torti. Gelles LN. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):647-8

Black hair follicular dysplasia, an autosomal recessive condition in dogs. Schmutz SM, et al. **Can Vet J** 1998 Oct; 39(10):644-6

Gene-knockout mice with abnormal epidermal and hair follicular development. Yamanishi K. **J Dermatol Sci** 1998 Nov;18(2):75-89 (108 ref.)

Epidermal dysplasia and abnormal hair follicles in transgenic mice overexpressing homeobox gene MSX-2. Jiang TX, et al. **J Invest Dermatol** 1999 Aug;113(2):230-7

ANATOMY & HISTOLOGY

Wool follicle volume as a determinant of wool volume. Scobie DR. **Exp Dermatol** 1999 Aug;8(4):364-5

BLOOD SUPPLY

Hair innervation and vasculature. Hordinsky MK, et al. **Exp Dermatol** 1999 Aug;8(4):314

CHEMISTRY

Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Kozlowska U, et al. **Arch Dermatol Res** 1998 Dec; 290(12):661-8

The catalog of human hair keratins. I. Expression of the nine type I members in the hair follicle. Langbein L, et al. **J Biol Chem** 1999 Jul 9;274(28):19874-84

Hair follicle has a novel anagen-specific protein, mKAP13. Aoki N, et al. **J Invest Dermatol** 1998 Nov;111(5):804-9

Pterins in human hair follicle cells and in the synchronized murine hair cycle. Schallreuter KU, et al. **J Invest Dermatol** 1998 Oct;111(4):545-50

Localization of rat FGF-5 protein in skin macrophage-like cells and FGF-5S protein in hair follicle: possible involvement of two Fgf-5 gene products in hair growth cycle regulation. Suzuki S, et al. **J Invest Dermatol** 1998 Dec;111(6):963-72

Ruby laser-assisted hair removal success in relation to anatomic factors and melanin content of hair follicles. Liew SH, et al. **Plast Reconstr Surg** 1999 May;103(6):1736-43

CYTOLOGY

Human melanocytes grown in epidermal equivalents transfer their melanin to follicular outer root sheath keratinocytes. Limat A, et al. **Arch Dermatol Res** 1999 Jun;291(6):325-32

Manipulation of outer root sheath cell survival perturbs the hair-growth cycle. Pena JC, et al. **EMBO J** 1999 Jul 1; 18(13):3596-603

Repeated plucking and proliferative activity of follicle epidermal cells--significance for follicle cycle control. Gharzi A, et al. **Exp Dermatol** 1999 Aug;8(4):345-7

Analysis of the rat dermal papilla cell proteome. Kristensen DB, et al. **Exp Dermatol** 1999 Aug;8(4):339-40

A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. Botchkarev VA, et al. **FASEB J** 1999 Feb; 13(2):395-410

The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. Lyle S, et al. **J Cell Sci** 1998 Nov;111 (Pt 21):3179-88

Establishment of rat dermal papilla cell lines that sustain the potency to induce hair follicles from afollicular skin. Inamatsu M, et al. **J Invest Dermatol** 1998 Nov; 111(5):767-75

Pterins in human hair follicle cells and in the synchronized murine hair cycle. Schallreuter KU, et al. **J Invest Dermatol** 1998 Oct;111(4):545-50

Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs. Schilli MB, et al. **J Invest Dermatol** 1998 Oct;111(4):598-604

Analysis of apoptotic cell death in human hair follicles in vivo and in vitro. Soma T, et al. **J Invest Dermatol** 1998 Dec;111(6):948-54

Androgen-dependent beard dermal papilla cells secrete autocrine growth factor(s) in response to testosterone unlike scalp cells. Thornton MJ, et al. **J Invest Dermatol** 1998 Nov;111(5):727-32

Histodifferentiation of hair follicles in grafting of cell aggregates obtained by rotation culture of embryonic rat skin. Takeda A, et al. **Scand J Plast Reconstr Surg Hand Surg** 1998 Dec; 32(4):359-64

DRUG EFFECTS

The effects of fibroblast growth factors 1 and 2 on fibre growth of wool follicles in culture. Bond JJ, et al. **Acta Derm Venereol** 1998 Sep;78(5):337-42

Proanthocyanidins from grape seeds promote proliferation of mouse hair follicle cells in vitro and convert hair cycle in vivo. Takahashi T, et al. **Acta Derm Venereol** 1998 Nov; 78(6):428-32

Fibre growth of cultured wool follicles: effects of fibroblast growth factors 1 and 2. Bond JJ, et al. **Exp Dermatol** 1999 Aug;8(4):323-4

Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. Takahashi T, et al. **J Invest Dermatol** 1999 Mar;112(3):310-6

EMBRYOLOGY

De Novó hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Gat U, et al. **Cell** 1998 Nov 25;95(5):605-14

The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Foitzik K, et al. **Dev Biol** 1999 Aug 15;212(2):278-89

Association between mouse nude gene expression and the initiation of epithelial terminal differentiation. Lee D, et al. **Dev Biol** 1999 Apr 15;208(2):362-74

Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Karlsson L, et al. **Development** 1999 Jun;126(12):2611-21

Transglutaminase and major cornified cell envelope precursor proteins, loricrin, small proline-rich proteins 1 and 2, and involucrin are coordinately expressed in the sites defined to form hair canal in developing human hair follicle. Akiyama M, et al. **Exp Dermatol** 1999 Aug; 8(4):313-4

Expression of ornithine decarboxylase during embryonic development of wool follicles. Nancarrow MJ, et al. **Exp Dermatol** 1999 Aug;8(4):326-8

Cytokine localization during fetal wool follicle development. Thomas DG, et al. **Exp Dermatol** 1999 Aug;8(4):334-6

Dynamic expression of ornithine decarboxylase in hair growth. Nancarrow MJ, et al. **Mech Dev** 1999 Jun; 84(1-2):161-4

Selective activation of the versican promoter by epithelial-mesenchymal interactions during hair follicle development. Kishimoto J, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7336-41

ENZYMOLOGY

Finasteride is the main inhibitor of 5alpha-reductase activity in microdissected dermal papillae of human hair follicles. Hoffmann R, et al. **Arch Dermatol Res** 1999 Feb-Mar; 291(2-3):100-3

The expression of stratum corneum chymotryptic enzyme in human anagen hair follicles: further evidence for its involvement in desquamation-like processes. Ekholm E, et al. **Br J Dermatol** 1998 Oct;139(4):585-90

Hair follicle peptidylarginine deiminase. Rogers G, et al. **Exp Dermatol** 1999 Aug;8(4):362-3 (10 ref.)

GROWTH & DEVELOPMENT

Delayed telogen replacement in a boy's scalp. Guarrera M, et al. **Dermatology** 1998;197(4):335-7

Wool follicle culture: fibre production in response to alterations in culture conditions. Bates EJ, et al. **Exp Dermatol** 1999 Aug;8(4):324-5

Fibre growth of cultured wool follicles: effects of fibroblast growth factors 1 and 2. Bond JJ, et al. **Exp Dermatol** 1999 Aug;8(4):323-4

Follicle morphogenesis in vitro. Hynd PI, et al. **Exp Dermatol** 1999 Aug;8(4):350-1

The companion layer and outer root sheath of the anagen hair follicle. Mahony D, et al. **Exp Dermatol** 1999 Aug; 8(4):329-31

Nutrition and metabolism in isolated human hair follicles. Matheson HB, et al. **Exp Dermatol** i999 Aug;8(4):319-20

E- and P-cadherin expression during murine hair follicle morphogenesis and cycling. Müller-Röver S, et al. **Exp Dermatol** 1999 Aug;8(4):237-46

Distinct patterns of NCAM expression are associated with defined stages of murine hair follicle morphogenesis and regression. Müller-Röver S, et al. **J Histochem Cytochem** 1998 Dec;46(12):1401-10

Highly persistent label-retaining cells in the hair follicles of mice and their fate following induction of anagen. Morris RJ, et al. **J Invest Dermatol** 1999 Apr;112(4):470-5

Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. Takahashi T, et al. **J Invest Dermatol** 1999 Mar;112(3):310-6

Effects of maintaining solstice light and temperature on reproductive activity, coat growth, plasma prolactin and melatonin in goats. Gebbie FE, et al. **J Reprod Fertil** 1999 May;116(1):25-33

Hairline incisions [letter; comment] Camirand A. **Plast Reconstr Surg** 1999 Feb;103(2):736-7. Comment on: Plast Reconstr Surg 1998 May;101(6):1743.

Hairy mice offer hope for baldness remedy [news] Pennisi E. **Science** 1998 Nov 27;282(5394):1617,1619

Laboratory assessment of hair follicle growth. Stenn KS. **Skin Pharmacol Appl Skin Physiol** 1999 May-Jun; 12(3):154-7 (21 ref.)

IMMUNOLOGY

Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Tobin DJ, et al. **Exp Dermatol** 1998 Oct;7(5):289-97

INJURIES

Follicle trauma and the role of the dissecting microscope in hair transplantation. A multicenter study. Cooley JE, et al. **Dermatol Clin** 1999 Apr;17(2):307-12, viii; discussion 312-3

Traumatic alopecia. Whiting DA. **Int J Dermatol** 1999 May; 38 Suppl 1:34-44 (52 ref.)

INNERVATION

Intact hair follicle innervation is not essential for anagen induction and development. Maurer M, et al. **Arch Dermatol Res** 1998 Oct;290(10):574-8

Hair innervation and vasculature. Hordinsky MK, et al. **Exp Dermatol** 1999 Aug;8(4):314

Structure and innervation of the vibrissal follicle-sinus complex in the Australian water rat, Hydromys chrysogaster. Dehnhardt G, et al. **J Comp Neurol** 1999 Sep 6;411(4):550-62

METABOLISM

Basal cell carcinoma possibly originates from the outer root sheath and/or the bulge region of the vellus hair follicle. Krüger K, et al. **Arch Dermatol Res** 1999 May;291(5):253-9

Experience with laser hair transplantation in Orientals. Tsai RY, et al. **Dermatol Surg** 1998 Oct;24(10):1065-8

Basonuclin as a cell marker in the formation and cycling of the murine hair follicle. Weiner L, et al. **Differentiation** 1998 Sep;63(5):263-72

Expression of the hair stem cell-specific keratin 15 in pilar tumors of the skin. Kanitakis J, et al. **Eur J Dermatol** 1999 Jul-Aug;9(5):363-5

Expression of the intermediate filament keratin gene, K15, in the basal cell layers of epithelia and the hair follicle. Whitbread LA, et al. **Exp Cell Res** 1998 Nov 1; 244(2):448-59

Human fibroblast growth factor 10 expression in dermal papilla cells, outer root sheath cells and keratinocytes. Hamada K, et al. **Exp Dermatol** 1999 Aug;8(4):347-9

Amino acid transport in wool and hair follicles. Hynd PI, et al. **Exp Dermatol** 1999 Aug;8(4):325-6

Anti-androgens and estrogens: modulators of VEGF expression in cultured hair dermal papilla cells. Lachgar S, et al. **Exp Dermatol** 1999 Aug;8(4):336-8

Nutrition and metabolism in isolated human hair follicles. Matheson HB, et al. **Exp Dermatol** 1999 Aug;8(4):319-20

E- and P-cadherin expression during murine hair follicle morphogenesis and cycling. Müller-Röver S, et al. **Exp Dermatol** 1999 Aug;8(4):237-46

Prolactin receptor and insulin-like growth factor expression in wool follicles. Nixon AJ, et al. **Exp Dermatol** 1999 Aug; 8(4):355-7

Transglutaminase 1 in human hair follicle. Yoneda K, et al. **Exp Dermatol** 1999 Aug;8(4):368-9

Thrombospondin 1 is expressed by mesenchymal cells in mouse post-natal skin and hair follicle development. Pablos JL, et al. **Histochem J** 1998 Jul;30(7):461-5

Regulation of a hair follicle keratin intermediate filament gene promoter. Dunn SM, et al. **J Cell Sci** 1998 Dec;111 (Pt 23):3487-96

Desmoglein 3 anchors telogen hair in the follicle. Koch PJ, et al. **J Cell Sci** 1998 Sep;111 (Pt 17):2529-37

Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells. Jih DM, et al. **J Cutan Pathol** 1999 Mar; 26(3):113-8

An immunohistochemical study of the apocrine type of cutaneous mixed tumors with special reference to their follicular and sebaceous differentiation. Yamamoto O, et al. **J Cutan Pathol** 1999 May;26(5):232-41

Distinct patterns of NCAM expression are associated with defined stages of murine hair follicle morphogenesis and regression. Müller-Röver S, et al. **J Histochem Cytochem** 1998 Dec;46(12):1401-10

Gene expression of mouse S100A3, a cysteine-rich calcium-binding protein, in developing hair follicle. Kizawa K, et al. **J Invest Dermatol** 1998 Nov;111(5):879-86

The mRNA for protease nexin-1 is expressed in human dermal papilla cells and its level is affected by androgen. Sonoda T, et al. **J Invest Dermatol** 1999 Sep;113(3):308-13

A novel human type II cytokeratin, K6hf, specifically expressed in the companion layer of the hair follicle. Winter H, et al. **J Invest Dermatol** 1998 Dec;111(6):955-62

HAIR FOLLICLE

The Notch signalling pathway in hair growth. Powell BC, et al. **Mech Dev** 1998 Nov;78(1-2):189-92

The patchwork mouse phenotype: implication for melanocyte replacement in the hair follicle. Aubin-Houzelstein G, et al. **Pigment Cell Res** 1999 Jun;12(3):181-6

Horizontal and vertical pigment spread into surrounding piebald epidermis and hair follicles after suction blister epidermal grafting. Horikawa T, et al. **Pigment Cell Res** 1999 Jun;12(3):175-80

Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Lademann J, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Sep-Oct;12(5):247-56

[Hair follicles and vascular endothelial growth factor] Lachgar S, et al. **Ann Dermatol Venereol** 1998 Apr; 125(4):271-4 (32 ref.) **(Fre)**

PARASITOLOGY

Demodex-associated folliculitis [letter; comment] Forton F. **Am J Dermatopathol** 1998 Oct;20(5):536-7. Comment on: Am J Dermatopathol 1996 Dec;18(6):589-91.

PATHOLOGY

Quantitative image analysis of hair follicles in alopecia areata. Kim IH, et al. **Acta Derm Venereol** 1999 May;79(3):214-6

Selective photothermolysis of hair follicles by normal-mode ruby laser treatment. Walther T, et al. **Acta Derm Venereol** 1998 Nov;78(6):443-4

Trichoadenoma of the eyelid. Shields JA, et al. **Am J Ophthalmol** 1998 Dec;126(6):846-8

Hereditary perioral pigmented follicular atrophoderma associated with milia and epidermoid cysts. Inoue Y, et al. **Br J Dermatol** 1998 Oct;139(4):713-8 (27 ref.)

Recurrent malignant proliferating trichilemmal tumour: local management with ethanol injection. Takenaka H, et al. **Br J Dermatol** 1998 Oct;139(4):726-9

Apoptosis of hair follicle cells in the second-degree burn wound unders hypernatremic conditions. Harada T, et al. **Burns** 1998 Aug;24(5):464-9

Immunopathology of the human hair follicle. Jaworsky C, et al. **Dermatol Clin** 1999 Jul;17(3):561-8 (52 ref.)

Hair removal using a pulsed-intense light source. Tse Y. **Dermatol Clin** 1999 Apr;17(2):373-85, ix (25 ref.)

Roles for PDGF-A and sonic hedgehog in development of mesenchymal components of the hair follicle. Karlsson L, et al. **Development** 1999 Jun;126(12):2611-21

A histological study of hair follicles treated with a 3 msec pulsed ruby laser. McCoy S, et al. **Exp Dermatol** 1999 Aug; 8(4):352-4

Malignant proliferating trichilemmal tumours: an histopathological and immunohistochemical study of three cases with DNA ploidy and morphometric evaluation. Herrero J, et al. **Histopathology** 1998 Dec;33(6):542-6

Multiple follicular hamartomas with sweat gland and sebaceous differentiation, vermiculate atrophoderma, milia, hypotrichosis, and late development of multiple basal cell carcinomas. Pujol RM, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):853-7

The trichofolliculoma undergoes changes corresponding to the regressing normal hair follicle in its cycle [see comments] Schulz T, et al. **J Cutan Pathol** 1998 Aug; 25(7):341-53. Comment in: J Cutan Pathol 1999 Feb;26(2):109.

A clinical, microbiological, and histopathologic study of trichostasis spinulosa. Chung TA, et al. **J Dermatol** 1998 Nov;25(11):697-702

Hereditary multiple fibrofolliculomas, trichodiscomas and acrochordons: syndrome of Birt-Hogg-Dubé. Scalvenzi M, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):45-7

Histological study of hair follicles treated with a 3-msec pulsed ruby laser. McCoy S, et al. **Lasers Surg Med** 1999; 24(2):142-50

Apoptosis in abortive hair follicular components in the organoid nevus [letter] Nakamura T. **Pathol Int** 1999 May; 49(5):477-8

Merkel cell differentiation in trichoblastoma. Collina G, et al. **Virchows Arch** 1998 Oct;433(4):291-6

[Pilotropic T-cell lymphoma without mucinosis: 5 new cases] Azar J, et al. **Ann Dermatol Venereol** 1999 Mar;126(3):243-6 (Eng. Abstr.) **(Fre)**

[CD30 positive pilotropic lymphoma] Trémeau-Martinage C, et al. **Ann Dermatol Venereol** 1999 May;126(5):434-8 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Detection of apoptosis in hair follicles and acrosyringium of normal human scalp skin by labeling of nick ends of fragmented DNA. Kishimoto S, et al. **Arch Dermatol Res** 1999 May;291(5):300-2

Viability of isolated single hair follicles preserved at 4 degrees C. Kurata S, et al. **Dermatol Surg** 1999 Jan;25(1):26-9

Compositionally different desmosomes in the various compartments of the human hair follicle. Kurzen H, et al. **Differentiation** 1998 Sep;63(5):295-304

Elements of the interleukin-1 signaling system show hair cycle-dependent gene expression in murine skin. Hoffmann R, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):475-7

Sheep transgenesis with keratin and non-keratin genes: expression in the wool follicle for modified fibre properties and growth rates. Bawden CS, et al. **Exp Dermatol** 1999 Aug;8(4):342-3

Repeated plucking and proliferative activity of follicle epidermal cells--significance for follicle cycle control. Gharzi A, et al. **Exp Dermatol** 1999 Aug;8(4):345-7

Mechanism of action of androgen in human hair follicle. Itami S, et al. **Exp Dermatol** 1999 Aug;8(4):338-9 (13 ref.)

Analysis of the rat dermal papilla cell proteome. Kristensen DB, et al. **Exp Dermatol** 1999 Aug;8(4):339-40

Differential gene expression in the ovine wool follicle cycle. Rufaut NW, et al. **Exp Dermatol** 1999 Aug;8(4):332-4

Multiple roles for trichohyalin in the inner root sheath. Steinert PM, et al. **Exp Dermatol** 1999 Aug;8(4):331-2 (10 ref.)

What controls hair follicle cycling? Stenn KS, et al. **Exp Dermatol** 1999 Aug;8(4):229-33; discussion 233-6 (55 ref.)

The role of BMP-2 and BMP-4 in follicle initiation and the murine hair cycle. Wilson N, et al. **Exp Dermatol** 1999 Aug; 8(4):367-8

A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. Botchkarev VA, et al. **FASEB J** 1999 Feb; 13(2):395-410

The trichofolliculoma undergoes changes corresponding to the regressing normal hair follicle in its cycle [see comments] Schulz T, et al. **J Cutan Pathol** 1998 Aug; 25(7):341-53. Comment in: J Cutan Pathol 1999 Feb;26(2):109.

Principles of hair cycle control. Paus R. **J Dermatol** 1998 Dec;25(12):793-802 (6 ref.)

Gene-knockout mice with abnormal epidermal and hair follicular development. Yamanishi K. **J Dermatol Sci** 1998 Nov;18(2):75-89 (108 ref.)

Retardation of hair follicle development by the deletion of TrkC, high-affinity neurotrophin-3 receptor [letter] Botchkareva NV, et al. **J Invest Dermatol** 1999 Sep; 113(3):425-7

Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)? Tobin DJ, et al. **J Invest Dermatol** 1998 Dec;111(6):941-7

Skin appendageal macropores as a possible pathway for electrical current. Chizmadzhev YA, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(2):148-52

Detection of MELAS A3243G point mutation in muscle, blood and hair follicles. Sue CM, et al. **J Neurol Sci** 1998 Nov 26;161(1):36-9

The biology of hair follicles. Paus R, et al. **N Engl J Med** 1999 Aug 12;341(7):491-7 (55 ref.)

Involvement of a novel Tnf receptor homologue in hair follicle induction [see comments] Headon DJ, et al. **Nat Genet** 1999 Aug;22(4):370-4. Comment in: Nat Genet 1999 Aug;22(4):315-6.

Selective activation of the versican promoter by epithelial-mesenchymal interactions during hair follicle development. Kishimoto J, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7336-41

Role of hair papilla cells on induction and regeneration processes of hair follicles. Matsuzaki T, et al. **Wound Repair Regen** 1998 Nov-Dec;6(6):524-30 (46 ref.)

[Pilar growth: VEGF and fibroblasts of the follicular papilla] Charvéron M, et al. **Ann Dermatol Venereol** 1998 Nov;125 Suppl 2:S9-11 **(Fre)**

PHYSIOPATHOLOGY

The role of the hairless (hr) gene in the regulation of hair follicle catagen transformation. Panteleyev AA, et al. **Am J Pathol** 1999 Jul;155(1):159-71

Hair follicle biology, the sebaceous gland, and scarring alopecias. Stenn KS, et al. **Arch Dermatol** 1999 Aug; 135(8):973-4

RADIATION EFFECTS

The effect of ruby laser light on ex vivo hair follicles: clinical implications. Liew SH, et al. **Ann Plast Surg** 1999 Mar; 42(3):249-54

A histological study of hair follicles treated with a 3 msec pulsed ruby laser. McCoy S, et al. **Exp Dermatol** 1999 Aug; 8(4):352-4

UVB irradiation stimulates deposition of new elastic fibers by modified epithelial cells surrounding the hair follicles and sebaceous glands in mice. Starcher B, et al. **J Invest Dermatol** 1999 Apr;112(4):450-5

SURGERY

Hair removal using an Nd:YAG laser system. Littler CM. **Dermatol Clin** 1999 Apr;17(2):401-30, x (67 ref.)

Theoretical considerations in laser hair removal. Ross EV, et al. **Dermatol Clin** 1999 Apr;17(2):333-55, viii (78 ref.)

Recalcitrant scarring follicular disorders treated by laser-assisted hair removal: a preliminary report. Chui CT, et al. **Dermatol Surg** 1999 Jan;25(1):34-7

Histological study of hair follicles treated with a 3-msec pulsed ruby laser. McCoy S, et al. **Lasers Surg Med** 1999; 24(2):142-50

TRANSPLANTATION

The logic of follicular unit transplantation. Bernstein RM, et al. **Dermatol Clin** 1999 Apr;17(2):277-95, viii; discussion 296 (28 ref.)

Follicle trauma and the role of the dissecting microscope in hair transplantation. A multicenter study. Cooley JE, et al. **Dermatol Clin** 1999 Apr;17(2):307-12, viii; discussion 312-3

Creating a hairline. Pomerantz MA. **Dermatol Clin** 1999 Apr; 17(2):271-5, vii; discussion 276 (9 ref.)

Methodology of follicular unit hair transplantation. Stough D, et al. **Dermatol Clin** 1999 Apr;17(2):297-306, viii (7 ref.)

Combining vertical strips and the ellipse in saving time and follicles. Alkek DS. **Dermatol Surg** 1998 Oct;24(10):1061-3; discussion 1063-4

Viability of isolated single hair follicles preserved at 4 degrees C. Kurata S, et al. **Dermatol Surg** 1999 Jan;25(1):26-9

Experience with laser hair transplantation in Orientals. Tsai RY, et al. **Dermatol Surg** 1998 Oct;24(10):1065-8

A novel application of the infrared coagulator in hair transplantation. Significant reduction of width of the donor site wound [see comments] Warmuth IP, et al. **Dermatol Surg** 1998 Oct;24(10):1079-82. Comment in: Dermatol Surg 1999 Jan;25(1):78.

Repigmentation of vitiligo patches by transplantation of hair follicles [letter] Malakar S, et al. **Int J Dermatol** 1999 Mar; 38(3):237-8

ULTRASTRUCTURE

The companion layer and outer root sheath of the anagen hair follicle. Mahony D, et al. **Exp Dermatol** 1999 Aug; 8(4):329-31

VIROLOGY

Moloney murine leukemia virus infects cells of the developing hair follicle after neonatal subcutaneous inoculation in mice. Okimoto MA, et al. **J Virol** 1999 Mar; 73(3):2509-16

HAIR PREPARATIONS

Southern hybridization in shampoo. May BP. **Biotechniques** 1998 Oct;25(4):582

Red, dry skin on the face and scalp. Regular cleansing with shampoo is remedy for this condition. Levine N. **Geriatrics** 1999 Feb;54(2):19

Experience in treating recalcitrant scalp psoriasis with automated shampooing and debridement. King L Jr, et al. **J Am Acad Dermatol** 1999 Oct;41(4):638-51

Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. Lange DS, et al. **J Am Acad Dermatol** 1998 Dec;39(6):944-50

[Maxilène and alopecia] Dubertret L. **Ann Dermatol Venereol** 1998 Apr;125(4):275 **(Fre)**

ADVERSE EFFECTS

Urticaria due to occupational exposure to glyceryl monothioglycolate permanent wave solution [letter] Shelley WB, et al. **Acta Derm Venereol** 1998 Nov; 78(6):471-2

An epidemiological study of hand eczema. I. Prevalence and cumulative prevalence among hairdressers compared with a control group of teachers. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:8-11

An epidemiological study of hand eczema. II. Prevalence of atopic diathesis in hairdressers, compared with a control group of teachers. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:12-4

An epidemiological study of hand eczema. III. Characterization of hairdressers with and without hand eczema, regarding demographic factors and medical histories. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:15-7

An epidemiological study of hand eczema. IV. Degree and pattern of eczema in affected hairdressers, with and without atopic symptoms, compared with a control group of affected teachers. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:18-22

An epidemiological study of hand eczema. V. Prevalence among hairdresser trainees, compared with a general population of hairdressers. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:23-5

Chemical hair treatments and adverse pregnancy outcome among Black women in central North Carolina. Blackmore-Prince C, et al. **Am J Epidemiol** 1999 Apr 15; 149(8):712-6

Absence of esophageal injury in pediatric patients after hair relaxer ingestion. Ahsan S, et al. **Arch Otolaryngol Head Neck Surg** 1999 Sep;125(9):953-5

Scalp burns in elderly women--the perils of the perm. Wilson DI. **Burns** 1999 Mar;25(2):182-3

Premature sexual development in children following the use of estrogen- or placenta-containing hair products. Tiwary CM. **Clin Pediatr (Phila)** 1998 Dec;37(12):733-9 (29 ref.)

Allergic contact dermatitis from parabens in a tar shampoo. Cooper SM, et al. **Contact Dermatitis** 1998 Sep;39(3):140

Hairdresser's dermatitis caused by oak moss in permanent waving solution. Kanerva L, et al. **Contact Dermatitis** 1999 Jul;41(1):55-6

Banana hair conditioner and natural rubber latex allergy. Smith HR, et al. **Contact Dermatitis** 1998 Oct;39(4):202

Hair shaft effects from cosmetics and styling. Gummer CL. **Exp Dermatol** 1999 Aug;8(4):317

Organophosphate exposure and variant Creutzfeldt-Jakob disease [letter] Churchill D, et al. **Lancet** 1999 Apr 24; 353(9162):1410

Occupational skin and respiratory diseases among hairdressers. Leino T, et al.
Scand J Work Environ Health 1998 Oct;24(5):398–406
[The arrangement of hair salons: an efficient method to reduce risks] Plante R, et al. **Can J Public Health** 1999 Mar–Apr;90(2):125–6 **(Fre)**

CHEMISTRY

Contact urticaria from protein hydrolysates in hair conditioners. Niinimäki A, et al. **Allergy** 1998 Nov; 53(11):1078–82
High-performance capillary electrophoresis determination of pyrithione in antidandruff preparations and shampoos. Peña-Méndez EM, et al. **J Capillary Electrophor** 1997 Nov–Dec;4(6):269–72
Trace element content of commercial shampoos: impact on trace element levels in hair. LeBlanc A, et al.
Sci Total Environ 1999 May 7;229(1–2):121–4
[Shampoos: composition and clinical applications] Trüeb RM. **Hautarzt** 1998 Dec;49(12):895–901 (21 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Activity of chlorhexidine shampoos in vitro against Staphylococcus intermedius, Pseudomonas aeruginosa and Malassezia pachydermatis. Lloyd DH, et al. **Vet Rec** 1999 May 8;144(19):536–7
[Shampoos: composition and clinical applications] Trüeb RM. **Hautarzt** 1998 Dec;49(12):895–901 (21 ref.) (Eng. Abstr.) **(Ger)**

POISONING

Sudden death due to intravenous infusion of hair conditioner. Knight DM, et al. **Am J Forensic Med Pathol** 1998 Sep; 19(3):252–4

STANDARDS

Efficacy testing for hair care products. Höcker H.
Skin Pharmacol Appl Skin Physiol 1999 May–Jun; 12(3):158–65

TOXICITY

Toxicological studies on procyanidin B-2 for external application as a hair growing agent. Takahashi T, et al.
Food Chem Toxicol 1999 May;37(5):545–52

HAIR REMOVAL

A clinical overview of hair removal using lasers and light sources. Dierickx C, et al. **Dermatol Clin** 1999 Apr; 17(2):357–66, ix (25 ref.)
Hair removal using an Nd:YAG laser system. Littler CM. **Dermatol Clin** 1999 Apr;17(2):401–30, x (67 ref.)
Theoretical considerations in laser hair removal. Ross EV, et al. **Dermatol Clin** 1999 Apr;17(2):333–55, viii (78 ref.)
Hair removal using a pulsed-intense light source. Tse Y. **Dermatol Clin** 1999 Apr;17(2):373–85, ix (25 ref.)
Hair removal using the long-pulsed ruby laser. Williams RM, et al. **Dermatol Clin** 1999 Apr;17(2):367–72 (10 ref.)
Recalcitrant scarring follicular disorders treated by laser-assisted hair removal: a preliminary report. Chui CT, et al. **Dermatol Surg** 1999 Jan;25(1):34–7
Solar-induced postinflammatory hyperpigmentation after laser hair removal. Hasan AT, et al. **Dermatol Surg** 1999 Feb;25(2):113–5
Laser ablation of urethral hair. Neal DE Jr, et al.
Lasers Surg Med 1999;24(4):261–3
Trachoma: can trichiasis be treated with a sticking-plaster? A randomized clinical trial in China. Graz B, et al.
Trop Med Int Health 1999 Mar;4(3):222–8
[Preoperative skin preparation in abdominal surgery] Duron JJ, et al. **J Chir (Paris)** 1998 Nov;135(5):207–11 (31 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Local spread of molluscum contagiosum by electrolysis. Rich JD, et al. **Clin Infect Dis** 1999 May;28(5):1171
Laser hair removal affects sebaceous glands and sebum excretion: a pilot study. Manuskiatti W, et al.
J Am Acad Dermatol 1999 Aug;41(2 Pt 1):176–80
Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. Nanni CA, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):165–71
Ruby laser irradiation (694 nm) of human skin biopsies: assessment by electron spin resonance spectroscopy of free radical production and oxidative stress during laser depilation. Haywood RM, et al. **Photochem Photobiol** 1999 Sep;70(3):348–52

INSTRUMENTATION

A practical review of laser-assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby, and long-pulsed alexandrite lasers. Nanni CA, et al. **Dermatol Surg** 1998 Dec;24(12):1399–405; discussion 1405 (15 ref.)
Methods of hair removal. Olsen EA.
J Am Acad Dermatol 1999 Feb;40(2 Pt 1):143–55; quiz 156–7 (63 ref.)

METHODS

Selective photothermolysis of hair follicles by normal-mode ruby laser treatment. Walther T, et al.
Acta Derm Venereol 1998 Nov;78(6):443–4
A comparison of the long-pulse and short-pulse Alexandrite laser hair removal systems. Boss WK Jr, et al.
Ann Plast Surg 1999 Apr;42(4):381–4
The effect of ruby laser light on ex vivo hair follicles: clinical implications. Liew SH, et al. **Ann Plast Surg** 1999 Mar; 42(3):249–54
Ruby laser-assisted hair removal: a preliminary report of the correlation between efficacy of treatment and melanin content of hair and the growth phases of hair at a specific site. Liew SH, et al. **Ann Plast Surg** 1999 Mar;42(3):255–8
High-intensity flashlamp photoepilation: a clinical, histological, and mechanistic study in human skin. Sadick NS, et al. **Arch Dermatol** 1999 Jun;135(6):668–76
The removal of unwanted hair using a ruby laser. Gault DT, et al. **Br J Plast Surg** 1999 Apr;52(3):173–7
Hair removal using a long-pulsed alexandrite laser. Ash K, et al. **Dermatol Clin** 1999 Apr;17(2):387–99, ix (42 ref.)
Long-term epilation with long-pulsed neodimium:YAG laser. Bencini PL, et al. **Dermatol Surg** 1999 Mar; 25(3):175–8
Hair removal in 40 hirsute women with an intense laser-like light source. Schroeter CA, et al. **Eur J Dermatol** 1999 Jul–Aug;9(5):374–9
Laser depilation using a free-running long pulse ruby laser. Zachariae H, et al. **Exp Dermatol** 1999 Aug;8(4):301–2
Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. Nanni CA, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):165–71
Methods of hair removal. Olsen EA.
J Am Acad Dermatol 1999 Feb;40(2 Pt 1):143–55; quiz 156–7 (63 ref.)
A new method to improve penetration depth of dyes into the follicular duct: potential application for laser hair removal. Sumian CC, et al. **J Am Acad Dermatol** 1999 Aug; 41(2 Pt 1):172–5
Point-counterpoint: laser hair removal [comment] Bargman H. **J Cutan Med Surg** 1999 Jul;3(5):241. Comment on: J Cutan Med Surg 1999 Jul;3(5):239–40.
Point-counterpoint: electrolysis for permanent hair removal [see comments] Richards RN. **J Cutan Med Surg** 1999 Jul; 3(5):239–40. Comment in: J Cutan Med Surg 1999 Jul;3(5):241.
Evaluation comparing multiple treatments with a 2-msec and 10-msec alexandrite laser for hair removal. Goldberg DJ, et al. **Lasers Surg Med** 1999;25(3):223–8
Histological study of hair follicles treated with a 3-msec pulsed ruby laser. McCoy S, et al. **Lasers Surg Med** 1999; 24(2):142–50
Long-pulsed alexandrite laser-assisted hair removal at 5, 10, and 20 millisecond pulse durations. Nanni CA, et al.
Lasers Surg Med 1999;24(5):332–7
Hair removal with a non-coherent filtered flashlamp intense pulsed light source. Weiss RA, et al. **Lasers Surg Med** 1999; 24(2):128–32
Laser hair removal. **Med Lett Drugs Ther** 1999 Jul 30; 41(1058):68–9
Depilation in a 6-month-Old with hypertrichosis: A case report. Wendelin DS, et al. **Pediatr Dermatol** 1999 Jul–Aug; 16(4):311–3
Ruby laser-assisted hair removal success in relation to anatomic factors and melanin content of hair follicles. Liew SH, et al. **Plast Reconstr Surg** 1999 May;103(6):1736–43
Optical hair removal. Ort RJ, et al.
Semin Cutan Med Surg 1999 Jun;18(2):149–58 (42 ref.)
Lasers for removing unwanted hair and rejuvenating skin. Wheeland RG. **West J Med** 1998 Oct;169(4):228–9

HAIRLESS MICE see **MICE, INBRED HRS**

HAIRY CELL LEUKEMIA see **LEUKEMIA, HAIRY CELL**

HAIRY CELL LEUKEMIA, ATYPICAL see **LEUKEMIA, T-CELL, HTLV-II-ASSOCIATED**

HAJDU-CHENEY SYNDROME see **OSTEOLYSIS, ESSENTIAL**

HALCINONIDE

PHARMACOLOGY

A qualitative estimate of the influence of halcinonide concentration and urea on the reservoir formation in the stratum corneum. Clarys P, et al.
Skin Pharmacol Appl Skin Physiol 1999 Jan–Apr; 12(1–2):85–9

HALF-BODY IRRADIATION see **HEMIBODY IRRADIATION**

HALF-SIB MATING see **INBREEDING**

HALFWAY HOUSES

Tailoring and individualizing housing programs for homeless persons with chronic mental illness [clinical conference] Reilly EC, et al. **Harv Rev Psychiatry** 1999 Sep–Oct; 7(3):166–71
[Rehabilitation of psychiatric patients by half-way house admission--a catamnestic study] Meissner A.
Rehabilitation (Stuttg) 1998 Nov;37(4):199–204 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

A Safe Haven: an innovative approach to residential treatment of substance abuse. Uziel-Miller ND, et al.
Am J Public Health 1999 Sep;89(9):1430–1

HALITOSIS

COMPLICATIONS

The relationship between oral malodor, gingivitis, and periodontitis. A review. Ratcliff PA, et al.
J Periodontol 1999 May;70(5):485–9 (32 ref.)

DIAGNOSIS

Psychiatric patients presenting with primarily somatic symptoms: report of two cases. Turkson SN.
East Afr Med J 1998 Sep;75(9):556–7
Halitosis in children. Amir E, et al. **J Pediatr** 1999 Mar; 134(3):338–43
[Halitosis: a multidisciplinary problem] Bollen CM, et al.
Rev Med Liege 1999 Jan;54(1):32–6 (25 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Differentiation of mouth versus gut as site of origin of odoriferous breath gases after garlic ingestion. Suarez F, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G425–30
Halitosis: causes, diagnosis, and treatment [see comments] Ayers KM, et al. **N Z Dent J** 1998 Dec;94(418):156–60 (19 ref.). Comment in: N Z Dent J 1999 Jun;95(420):66.

MICROBIOLOGY

Negative correlation between oral malodour and numbers and activities of sulphate-reducing bacteria in the human mouth. Willis CL, et al. **Arch Oral Biol** 1999 Aug; 44(8):665–70
Halitosis and Helicobacter pylori: a possible relationship. Ierardi E, et al. **Dig Dis Sci** 1998 Dec;43(12):2733–7

THERAPY

Treatment of halitosis [letter; comment] Ingram CS.
N Z Dent J 1999 Jun;95(420):66. Comment on: N Z Dent J 1998 Dec;94(418):156–60.
[Halitosis: a multidisciplinary problem] Bollen CM, et al.
Rev Med Liege 1999 Jan;54(1):32–6 (25 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Halitosis in dogs and the effect of periodontal therapy. Rawlings JM, et al. **J Nutr** 1998 Dec;128(12 Suppl):2715S–2716S

HALLERVORDEN-SPATZ SYNDROME

[Progressive pallidal degeneration] Hasegawa K.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):74–7 (7 ref.) **(Jpn)**

COMPLICATIONS

[Therapeutic objectives and strategies in NBIA 1 (Hallovorden-Spatz syndrome)] Bruscoli F, et al.
Minerva Anestesiol 1998 Nov;64(11):529–34 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Hallervorden-Spatz syndrome. Differential diagnosis of early onset dementia] Lechner C, et al. **Nervenarzt** 1999 May;70(5):471–5 (Eng. Abstr.) **(Ger)**

PATHOLOGY

[A case of Hallervorden-Spatz disease with magnetic resonance imaging data] Ruiz-Sandoval JL, et al.
Rev Invest Clin 1998 May–Jun;50(3):249–53 (Eng. Abstr.) **(Spa)**

SURGERY

Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. Case report. Justesen CR, et al. **J Neurosurg** 1999 Mar;90(3):551–4

HALLOPEAU-SIEMENS DISEASE see **EPIDERMOLYSIS BULLOSA DYSTROPHICA**

HALLUCINATIONS

see related
HALLUCINOGENS

Verbal self-monitoring and auditory hallucinations in schizophrenia [letter] Johns LC, et al. **Lancet** 1999 Feb 6;353(9151):469–70
[Visual hallucinations in ophthalmological and neurological diseases] Kerty E. **Tidsskr Nor Laegeforen** 1998 Dec 10;

118(30):4738–41 (17 ref.) (Eng. Abstr.) **(Nor)**
[Visual hallucinations (letter)] Other A.
Tidsskr Nor Laegeforen 1998 Nov 20;118(28):4414 **(Nor)**
[Two cases of peduncular hallucinosis. Vivid, colorful and dancing images and figures] Liedholm LJ, et al.
Lakartidningen 1999 Apr 7;96(14):1712–5 (Eng. Abstr.) **(Swe)**

CHEMICALLY INDUCED

Lindane toxicity is preventable. Diaz JE.
Acad Emerg Med 1998 Nov;5(11):1126–8
A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration. Terao T, et al.
Acta Psychiatr Scand 1999 May;99(5):388–90; discussion 390–2
'Wake up and smell the roses'--a drug reaction to etidronate [letter] Burnet SP, et al. **Aust N Z J Med** 1999 Feb;29(1):93
Visual hallucinations due to radiocontrast media. Report of two cases and review of the literature [letter] Iliopoulou A, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):226–7 (18 ref.)
Acute overdose due to benzydamine. Gómez-López L, et al. **Hum Exp Toxicol** 1999 Jul;18(7):471–3
Peduncular hallucinosis related to propranolol self-poisoning: efficacy of intravenous glucagon [letter] Hazouard E, et al. **Intensive Care Med** 1999 Mar;25(3):336–7
LSD use and flashbacks in alcoholic patients. Batzer W, et al. **J Addict Dis** 1999;18(2):57–63
Methadone-induced hallucinations [letter] Katz LY.
J Am Acad Child Adolesc Psychiatry 1999 Apr;38(4):355–6
Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone? [letter; comment] Alcántara AG.
J Clin Psychopharmacol 1998 Dec;18(6):487–8. Comment on: J Clin Psychopharmacol 1996 Jun;16(3):238–41. Comment on: J Clin Psychopharmacol 1997 Aug;17(4):327–8.
Visual hallucinations associated with fluoxetine and sertraline [letter] Bourgeois JA, et al. **J Clin Psychopharmacol** 1998 Dec;18(6):482–3
Drug-induced musical hallucinations [letter; comment] Gordon AG. **J Nerv Ment Dis** 1998 Oct;186(10):652–3. Comment on: J Nerv Ment Dis 1998 Mar;186(3):192–4.
Medication-induced hallucination and cerebral blood flow in Parkinson's disease. Okada K, et al. **J Neurol** 1999 May; 246(5):365–8
Bizarre images and beta-adrenergic blocking agents: a unique case report. Rosenman RH, et al. **J Psychoactive Drugs** 1999 Apr-Jun;31(2):163–6
Visual hallucinations after quinapril [letter] Walker A.
N Z Med J 1999 Mar 12;112(1083):83
Intravenous levodopa in hallucinating PD patients [letter; comment] Friedman JH. **Neurology** 1999 Jan 1;52(1):219–20 . Comment on: Neurology 1998 Feb;50(2):515–7.
Central anticholinergic syndrome on therapeutic doses of cyproheptadine. Watemberg NM, et al. **Pediatrics** 1999 Jan; 103(1):158–60 (29 ref.)
[Psychiatric side effects of non-steroidal anti-inflammatory agents] Defromont L, et al. **Encephale** 1999 Jan-Feb; 25(1):11–5 (20 ref.) (Eng. Abstr.) **(Fre)**
[Hallucinations after voluntary ingestion of nutmeg: an unrecognized drug abuse (letter)] Servan J, et al.
Rev Neurol (Paris) 1998 Oct;154(10):708 **(Fre)**
[Levofloxacin-induced neurological adverse effects such as convulsion, involuntary movement (tremor, myoclonus and chorea like), visual hallucination in two elderly patients] Yasuda H, et al. **Nippon Ronen Igakkai Zasshi** 1999 Mar; 36(3):213–7 (Eng. Abstr.) **(Jpn)**
[Hallucinations after infusion of large doses of corticosteroids. A well-known and unusually well-reported side effect] Askmark H. **Lakartidningen** 1999 Mar 17;96(11):1336 **(Swe)**
[Cortisone--a Mene tekel?] Edsman CM. **Lakartidningen** 1999 Mar 17;96(11):1336–8 **(Swe)**

COMPLICATIONS

Psychotic symptoms in post-traumatic stress disorder. Ivezic S, et al. **Mil Med** 1999 Jan;164(1):73–5

DIAGNOSIS

On redefining hallucination [letter; comment] Aleman A, et al. **Am J Orthopsychiatry** 1998 Oct;68(4):656–9. Comment on: Am J Orthopsychiatry 1998 Apr;68(2):305–12.
Selective speech perception alterations in schizophrenic patients reporting hallucinated "voices". Hoffman RE, et al. **Am J Psychiatry** 1999 Mar;156(3):393–9
Insight into phosphene: a case with occipital lobe damage [letter] Kishi T, et al. **Gen Hosp Psychiatry** 1998 Jul; 20(4):260–1
Defining psychosis in PTSD [letter; comment] Pies R.
J Clin Psychiatry 1999 Aug;60(8):555–6. Comment on: J Clin Psychiatry 1999 Jan;60(1):29–32.
Word recognition, discrimination accuracy, and decision bias in schizophrenia: association with positive symptomatology and depressive symptomatology. Brébion G, et al.
J Nerv Ment Dis 1998 Oct;186(10):604–9
Auditory hallucinations: a comparison between patients and nonpatients. Honig A, et al. **J Nerv Ment Dis** 1998 Oct; 186(10):646–51
Behavioural disturbance and visual hallucinations in a 78 year old man [clinical conference] Schultz DW, et al.
J Neurol Neurosurg Psychiatry 1998 Dec;65(6):933–8
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Pappert EJ, et al.
Mov Disord 1999 Jan;14(1):117–21
The anatomy of conscious vision: an fMRI study of visual hallucinations. Ffytche DH, et al. **Nat Neurosci** 1998 Dec; 1(8):738–42
Peculiarity and reported childhood maltreatment. Berenbaum H. **Psychiatry** 1999 Spring;62(1):21–35
Cognitive processes in auditory hallucinations: attributional biases and metacognition. Baker CA, et al.
Psychol Med 1998 Sep;28(5):1199–208
'Alice in Wonderland' syndrome and Lilliputian hallucinations in a patient with a substance-related disorder. Takaoka K, et al. **Psychopathology** 1999 Jan-Feb; 32(1):47–9
Musical hallucinations and palinacousis. Terao T, et al.
Psychopathology 1999 Mar-Apr;32(2):57–9
[Visual hallucinations and illusions, symptoms frequently misdiagnosed by the practitioner] Borruat FX.
Klin Monatsbl Augenheilkd 1999 May;214(5):324–7 (16 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Cisapride in the treatment of visual hallucinations caused by vision loss: the Charles Bonnet syndrome. Ranen NG, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):264–6
Treating visual hallucinations with donepezil [letter] Burke WJ, et al. **Am J Psychiatry** 1999 Jul;156(7):1117–8
Peduncular hallucinosis related to propranolol self-poisoning: efficacy of intravenous glucagon [letter] Hazouard E, et al. **Intensive Care Med** 1999 Mar;25(3):336–7
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. Graham JM, et al.
J Neurol Neurosurg Psychiatry 1998 Nov;65(5):774–7

ETIOLOGY

Psychosis and hallucinations in Parkinson's disease. Godwin-Austen RB. **Adv Neurol** 1999;80:401–2 (9 ref.)
Hallucinations in Parkinson's disease; the clinical syndrome. Goetz CG. **Adv Neurol** 1999;80:419–23 (26 ref.)
Transient peduncular hallucinations secondary to brain stem compression by a cerebellar pilocytic astrocytoma. Nadvi SS, et al. **Br J Neurosurg** 1998 Dec;12(6):579–81
Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor. Hotta M, et al. **Endocr J** 1998 Dec;45(6):773–8
Unidirectional olfactory hallucination associated with ipsilateral unruptured intracranial aneurysm. Mizobuchi M, et al. **Epilepsia** 1999 Apr;40(4):516–9
Volitional monocular Lilliputian visual hallucinations and synesthesia. Jacome DE. **Eur Neurol** 1999 Jan;41(1):54–6
Case history of a patient with musical hallucinations and Parkinson's disease [letter] Clark J.
Int J Geriatr Psychiatry 1998 Dec;13(12):886–7
Visual hallucinations associated with Charles Bonnet Syndrome--an ever increasing diagnosis [letter] Dodd J, et al. **Ir Med J** 1999 May-Jun;92(4):344–5
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. Graham JM, et al.
J Neurol Neurosurg Psychiatry 1998 Nov;65(5):774–7
Visual hallucinations and palinopsia due to an occipital lobe tuberculoma. Werring DJ, et al.
J Neurol Neurosurg Psychiatry 1999 May;66(5):684
Peduncular hallucinosis following a transoral odontoidectomy for cranio-vertebral junction malformation. A case report. Qasho R, et al.
J Neurosurg Sci 1998 Mar;42(1):47–9
Listening to the voice hearers. Romme M.
J Psychosoc Nurs Ment Health Serv 1998 Sep;36(9):40–4
Auditory hallucinations and the bicameral mind [letter; comment] Olin R. **Lancet** 1999 Jul 10;354(9173):166. Comment on: Lancet 1999 Feb 20;353(9153):644.
The hills are alive with the sound of music [letter] Gordon AG. **Neuropsychiatry Neuropsychol Behav Neurol** 1999 Jul; 12(3):198–200
'Alice in Wonderland' syndrome and Lilliputian hallucinations in a patient with a substance-related disorder. Takaoka K, et al. **Psychopathology** 1999 Jan-Feb; 32(1):47–9
[A case of peduncular hallucination after aneurysmal subarachnoid hemorrhage] Nakagawa N, et al.
No To Shinkei 1999 Jan;51(1):65–8 (Eng. Abstr.) **(Jpn)**
[Hallucinogenic mushroom poisoning] Kamimura H.
Ryoikibetsu Shokogun Shirizu 1999;(27 Pt 2):676–8 (5 ref.) **(Jpn)**
[Possible intoxication by taxine: a report of 2 cases (letter)] Riaño Galán I, et al. **An Esp Pediatr** 1998 Aug;49(2):211 **(Spa)**
[Peduncular hallucinosis associated with a space occupying lesion of the brain stem] Leiva-Santana C, et al.
Rev Neurol 1999 Jun 16-30;28(12):1174–6 (Eng. Abstr.) **(Spa)**

GENETICS

The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. de la Fuente-Fernández R, et al. **Clin Neuropharmacol** 1999 Jul-Aug;22(4):226–30
Hallucinations: psychopathology meets functional genomics [editorial] Lesch KP. **Mol Psychiatry** 1998 Jul;3(4):278–81 (20 ref.)
A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Malhotra AK, et al. **Mol Psychiatry** 1998 Jul;3(4):328–32

HISTORY

Seeking Haydn's secrets [letter] Gordon AG.
Cerebrovasc Dis 1999 Jan-Feb;9(1):54
Visual hallucinations in the 19th century: research in a medical archive. di Diodoro D, et al. **J Nerv Ment Dis** 1998 Nov;186(11):716–21
Was Anna O.'s black snake hallucination a sleep paralysis nightmare? Dreams, memories, and trauma. Powell RA, et al. **Psychiatry** 1998 Fall;61(3):239–48

METABOLISM

Hallucinations: psychopathology meets functional genomics [editorial] Lesch KP. **Mol Psychiatry** 1998 Jul;3(4):278–81 (20 ref.)

NURSING

Instruments for assessment of auditory hallucinations. Frederick JA, et al. **Arch Psychiatr Nurs** 1998 Oct; 12(5):255–63 (24 ref.)

PHYSIOPATHOLOGY

Auditory hallucinations: phenomenology, neuropsychology and neuroimaging update. David AS.
Acta Psychiatr Scand Suppl 1999;395:95–104 (112 ref.)
New methods for studying hallucinated 'voices' in schizophrenia. Hoffman RE. **Acta Psychiatr Scand Suppl** 1999;395:89–94
Mechanisms of hallucinations [letter; comment] Feinberg I. **Am J Psychiatry** 1999 May;156(5):805–7. Comment on: Am J Psychiatry 1997 Dec;154(12):1683–9.
Complex visual hallucinations. Clinical and neurobiological insights. Manford M, et al. **Brain** 1998 Oct;121 (Pt 10):1819–40 (192 ref.)
Poor visual discrimination and visual hallucinations in Parkinson's disease. Diederich NJ, et al.
Clin Neuropharmacol 1998 Sep-Oct;21(5):289–95
Auditory hallucinations in nonpsychotic children with affective syndromes and migraines: report of 13 cases. Schreier HA. **J Child Neurol** 1998 Aug;13(8):377–82
Drug-induced musical hallucinations [letter; comment] Gordon AG. **J Nerv Ment Dis** 1998 Oct;186(10):652–3. Comment on: J Nerv Ment Dis 1998 Mar;186(3):192–4.
Spatial and temporal mapping of neural activity associated with auditory hallucinations [letter] [see comments] Lennox BR, et al. **Lancet** 1999 Feb 20;353(9153):644. Comment in: Lancet 1999 Jul 10;354(9173):166.
Steady state visually evoked potential correlates of auditory hallucinations in schizophrenia. Line P, et al.
Neuroimage 1998 Nov;8(4):370–6
Activation of Heschl's gyrus during auditory hallucinations [see comments] Dierks T, et al. **Neuron** 1999 Mar; 22(3):615–21. Comment in: Neuron 1999 Mar;22(3):414–5.
Cerebral perfusion in children with Alice in Wonderland syndrome. Kuo YT, et al. **Pediatr Neurol** 1998 Aug; 19(2):105–8
Hallucinations in the acute schizophrenic-type psychosis: effects of gender and age of illness onset. Sharma RP, et al. **Schizophr Res** 1999 May 4;37(1):91–5
[Palinopsia in Charles Bonnet syndrome (letter)] Ozsancak C, et al. **Presse Med** 1998 Feb 28;27(8):359 **(Fre)**

PSYCHOLOGY

Prelingually profoundly deaf schizophrenic patients who hear voices: a phenomenological analysis. du Feu M, et al.
Acta Psychiatr Scand 1999 Jun;99(6):453–9
Hallucinatory modalities in prelingually deaf schizophrenic patients: a retrospective analysis of 67 cases. Schonauer K, et al. **Acta Psychiatr Scand** 1998 Nov;98(5):377–83
Hallucinations in nonpsychotic children: more common than we think? Schreier HA.
J Am Acad Child Adolesc Psychiatry 1999 May;38(5):623–5
Command hallucinations, compliance, and risk assessment. Hersh K, et al. **J Am Acad Psychiatry Law** 1998;26(3):353–9
Relation between command hallucinations and dangerous behavior. Rudnick A. **J Am Acad Psychiatry Law** 1999; 27(2):253–7 (17 ref.)
Dangerous misidentification of people due to flashback phenomena in posttraumatic stress disorder. Silva JA, et al. **J Forensic Sci** 1998 Nov;43(6):1107–11
How hallucinations make themselves heard [comment] Frith C. **Neuron** 1999 Mar;22(3):414–5. Comment on: Neuron 1999 Mar;22(3):615–21.
Hallucinatory experiences in extreme-altitude climbers. Brugger P, et al.
Neuropsychiatry Neuropsychol Behav Neurol 1999 Jan; 12(1):67–71
Delusions and hallucinations in patients with borderline personality disorder. Suzuki H, et al.
Psychiatry Clin Neurosci 1998 Dec;52(6):605–10
Visual hallucinations in mild dementia. A rare occurrence of Lhermitte's hallucinosis. Leo RJ, et al.
Psychosomatics 1999 Jul-Aug;40(4):360–3

REHABILITATION

[Therapeutic problems of positively experienced hallucinations] Fischer RB. **Psychiatr Prax** 1999 Jul; 26(4):208 **(Ger)**

THERAPY

Effectiveness of cognitive therapy with coping training for persistent auditory hallucinations: a retrospective study of attenders of a psychiatric out-patient department. Jenner JA, et al. **Acta Psychiatr Scand** 1998 Nov;98(5):384–9

Dialogical engagement with voices: a single case study. Davies P, et al. **Br J Med Psychol** 1999 Jun;72 (Pt 2):179–87

A comparison of the long-term effectiveness of distraction and focusing in the treatment of auditory hallucinations. Haddock G, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):339–49

Individual cognitive-behavior therapy in the treatment of hallucinations and delusions: a review. Haddock G, et al. **Clin Psychol Rev** 1998 Nov;18(7):821–38 (84 ref.)

Auditory hallucinations: a review of psychological treatments. Shergill SS, et al. **Schizophr Res** 1998 Aug 17; 32(3):137–50 (65 ref.)

HALLUCINOGENS

Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins. Kendler KS, et al. **Acta Psychiatr Scand** 1999 May;99(5):368–76

Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness. Roberts TB. **Adv Mind Body Med** 1999 Spring; 15(2):139–47

A mesenteric mass in a chronic LSD user [letter] Berk SI, et al. **Am J Med** 1999 Aug;107(2):188–9

A concealed cause of recurrent renal failure in a patient with juvenile chronic arthritis. Hamilton J, et al. **Ann Rheum Dis** 1999 Jul;58(7):396–8

Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Schroeder U, et al. **Behav Brain Res** 1998 Dec; 97(1–2):59–68

Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. Rochester JA, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):137–42 (48 ref.)

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes. Efange SM, et al. **J Med Chem** 1998 Nov 5;41(23):4486–91

ADMINISTRATION & DOSAGE

Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Castner SA, et al. **Neuropsychopharmacology** 1999 Jan; 20(1):10–28

Concurrent progressive-ratio schedules to compare reinforcing effectiveness of different phencyclidine (PCP) concentrations in rhesus monkeys. Rodefer JS, et al. **Psychopharmacology (Berl)** 1999 May;144(2):163–74

ADVERSE EFFECTS

Dangerous form of marijuana [letter] Nelson LS, et al. **Ann Emerg Med** 1999 Jul;34(1):115–6

The seeds of the Hawaiian baby woodrose are a powerful hallucinogen [letter] Al-Assmar SE. **Arch Intern Med** 1999 Sep 27;159(17):2090

Retinal haemorrhage caused by "ecstasy" [letter] Jacks AS, et al. **Br J Ophthalmol** 1998 Jul;82(7):842–3

The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). Milosevic A, et al. **Community Dent Oral Epidemiol** 1999 Aug;27(4):283–7

Ecstasy pimples – a new facial dermatosis. Wollina U, et al. **Dermatology** 1998;197(2):171–3

Do hallucinogens cause residual neuropsychological toxicity? Halpern JH, et al. **Drug Alcohol Depend** 1999 Feb 1; 53(3):247–56 (103 ref.)

Ecstasy (MDMA) dependence. Jansen KL. **Drug Alcohol Depend** 1999 Jan 7;53(2):121–4

MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Schifano F, et al. **Drug Alcohol Depend** 1998 Sep 1;52(1):85–90

Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female. Magee C, et al. **Ir Med J** 1998 Oct–Nov;91(5):178

"Saturday night fever": ecstasy related problems in a London accident and emergency department. Williams H, et al. **J Accid Emerg Med** 1998 Sep;15(5):322–6

LSD use and flashbacks in alcoholic patients. Batzer W, et al. **J Addict Dis** 1999;18(2):57–63

Ecstasy: a common cause of severe acute hepatotoxicity. Andreu V, et al. **J Hepatol** 1998 Sep;29(3):394–7

Three cases of delirium after "ecstasy" ingestion. Alciati A, et al. **J Psychoactive Drugs** 1999 Apr–Jun;31(2):167–70

Short gastric artery perforation after use of 'ecstasy'. Williams A, et al. **J R Soc Med** 1998 Oct;91(10):541–2

Positron emission tomography findings in heavy users of MDMA [letter; comment] Holland J. **Lancet** 1999 Feb 13; 353(9152):592–3. Comment on: Lancet 1998 Oct 31;352(9138):1433–7.

Parkinsonism after taking ecstasy [letter] Mintzer S, et al. **N Engl J Med** 1999 May 6;340(18):1443

MDMA study [letter] Gijsman HJ, et al. **Neuropsychopharmacology** 1999 Oct;21(4):597

Is a single dose of MDMA harmless? [letter] Vollenweider FX, et al. **Neuropsychopharmacology** 1999 Oct; 21(4):598–600

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. Vollenweider FX, et al. **Neuropsychopharmacology** 1998 Oct;19(4):241–51

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Vollenweider FX, et al. **Neuroreport** 1998 Dec 1;9(17):3897–902

Blood flow and cerebral laterality in the mescaline model of psychosis. Hermle L, et al. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:85–91

Hyponatraemia and seizures after ecstasy use. Holmes SB, et al. **Postgrad Med J** 1999 Jan;75(879):32–3

Memory deficits associated with recreational use of "ecstasy" (MDMA). Morgan MJ. **Psychopharmacology (Berl)** 1999 Jan;141(1):30–6

[Neurotoxicity of the drug Ecstasy. Functional consequences of serotonergic hypoactivity] de Visme PG. **Ugeskr Laeger** 1998 Oct 12;160(42):6088–91 (40 ref.) (Eng. Abstr.) **(Dan)**

[Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)] van Tonningen-van Driel MM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):27–31 (Eng. Abstr.) **(Dut)**

[Acute liver failure (letter)] Friebe M, et al. **Internist (Berl)** 1998 Sep;39(9):999–1000 **(Ger)**

[Angel trumpets: case report of drug-induced psychosis caused by Brugmansia insigniis] Paetzold W, et al. **Psychiatr Prax** 1999 May;26(3):147–8 (Eng. Abstr.) **(Ger)**

[Cerebral hemorrhage and "ecstasy"] Schlaeppi M, et al. **Schweiz Rundsch Med Prax** 1999 Mar 25;88(13):568–72 (Eng. Abstr.) **(Ger)**

[Ecstasy--cool dope with long-lasting effects?] Liberg JP, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4384–7 (Eng. Abstr.) **(Nor)**

[Psychiatric disorders and consumption of ecstasy drug (MDMA): review of published case reports] Bango J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1998 Jul–Aug;26(4):260–3 (18 ref.) (Eng. Abstr.) **(Spa)**

[Acute hepatitis induced by Ecstasy (letter)] Indart Pérez A, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):499 **(Spa)**

[Ecstasy: idiosyncrasy, overdosage or collateral effects (letter)] Avila de Tomás JF. **Med Clin (Barc)** 1998 Oct 24;111(13):517–8 **(Spa)**

[Toxicity of ecstasy (letter; comment)] Mas M, et al. **Med Clin (Barc)** 1998 Oct 24;111(13):516–7. Comment on: Med Clin (Barc) 1998 Feb 7;110(4):156. **(Spa)**

ANALYSIS

Analysis of psilocybin and psilocin in Psilocybe subcubensis Guzmán by ion mobility spectrometry and gas chromatography-mass spectrometry. Keller T, et al. **Forensic Sci Int** 1999 Jan 11;99(2):93–105

A contribution to the improvement of accuracy in the quantitation of THC. Poortman-van der Meer AJ, et al. **Forensic Sci Int** 1999 Apr 12;101(1):1–8

Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. Sherlock K, et al. **J Accid Emerg Med** 1999 May; 16(3):194–7

2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market [see comments] Giroud C, et al. **J Anal Toxicol** 1998 Sep;22(5):345–54. Comment in: J Anal Toxicol 1999 May–Jun;23(3):227–8.

[Ecstasy and related drugs in biological materials (letter)] Christophersen AS, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):702 **(Nor)**

[The forensic chemical study of psilocybine-containing fungi] Babakhanian RV, et al. **Sud Med Ekspert** 1998 Nov–Dec; 41(6):24–6 (Eng. Abstr.) **(Rus)**

[The chromatographic analysis of phencyclidine, its metabolites and analogs in biological fluids] Veselovskaia NV, et al. **Sud Med Ekspert** 1999 Mar–Apr;42(2):20–5 (37 ref.) (Eng. Abstr.) **(Rus)**

ANTAGONISTS & INHIBITORS

Effects of "Ecstasy" blocked by serotonin reuptake inhibitors [letter] Stein DJ, et al. **J Clin Psychiatry** 1999 Jul;60(7):485

The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Johansson C, et al. **Pharmacol Toxicol** 1999 May; 84(5):226–33

BLOOD

Stability of phencyclidine in stored blood samples. Grieshaber A, et al. **J Anal Toxicol** 1998 Oct;22(6):515–9

CHEMICAL SYNTHESIS

Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Usami N, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1462–7

Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. Blair JB, et al. **J Med Chem** 1999 Mar 25;42(6):1106–11

CHEMISTRY

Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Kovar KA. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:69–72 (12 ref.)

HISTORY

LSD and the dualism between medical and social theories of mental illness. Snelders S. **Clio Med** 1998;49:103–20

Dr. Leary's Concord Prison Experiment: a 34-year follow-up study [see comments] Doblin R. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):419–26. Comment in: J Psychoactive Drugs 1998 Oct–Dec;30(4):427–8.

Reflections on the Concord Prison project and the follow-up study [comment] Metzner R. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):427–8. Comment on: J Psychoactive Drugs 1998 Oct–Dec;30(4):419–26.

Love potions and the ointment of witches: historical aspects of the nightshade alkaloids. Müller JL. **J Toxicol Clin Toxicol** 1998;36(6):617–27

History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Gouzoulis-Mayfrank E, et al. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:63–8

[Witch ointments and aphrodisiacs. A contribution to the cultural history of nightshade plants] Müller J. **Gesnerus** 1998;55(3–4):205–20 (Eng. Abstr.) **(Ger)**

METABOLISM

2-oxo-3-hydroxy-LSD: an important LSD metabolite? Verstraete AG, et al. **Acta Clin Belg Suppl** 1999;1:94–6

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Javitt DC, et al. **Biol Psychiatry** 1999 Mar 15;45(6):668–79

Sexual dimorphism in phencyclidine in vitro metabolism and pharmacokinetics in rats. Shelnutt SR, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1292–8

Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Nelson DL, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jan;359(1):1–6

PHARMACOKINETICS

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Javitt DC, et al. **Biol Psychiatry** 1999 Mar 15;45(6):668–79

Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. Fallon JK, et al. **Clin Chem** 1999 Jul;45(7):1058–69

The incorporation of drugs into hair: relationship of hair color and melanin concentration to phencyclidine incorporation. Slawson MH, et al. **J Anal Toxicol** 1998 Oct;22(6):406–13

Pharmacokinetics of Hoasca alkaloids in healthy humans. Callaway JC, et al. **J Ethnopharmacol** 1999 Jun; 65(3):243–56

Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. Mas M, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):136–45

Sexual dimorphism in phencyclidine in vitro metabolism and pharmacokinetics in rats. Shelnutt SR, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1292–8

Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain. Zubaran C, et al. **Neuropsychopharmacology** 1999 Jul; 21(1):119–26

PHARMACOLOGY

Spatial signal detection in rats is differentially disrupted by delta-9-tetrahydrocannabinol, scopolamine, and MK-801. Presburger G, et al. **Behav Brain Res** 1999 Feb 15; 99(1):27–34

Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Gouzoulis-Mayfrank E, et al. **Behav Pharmacol** 1998 Nov; 9(7):561–6

Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Sams-Dodd F. **Behav Pharmacol** 1997 Jun;8(2–3):196–215

Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Hutcheson DM, et al. **Br J Pharmacol** 1998 Dec;125(7):1567–77

Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat. Umino

A, et al. **Br J Pharmacol** 1998 May;124(2):377–85
Increased expression of zif268 mRNA in rat retrosplenial cortex following administration of phencyclidine. Shirayama Y, et al. **Brain Res** 1999 Aug 21;839(1):180–5
The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes. Wells GB, et al. **Brain Res Bull** 1999 Apr;48(6):641–7
Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. Usami N, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1462–7
Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Freedland CS, et al. **Drug Alcohol Depend** 1999 May 3;54(3):183–94
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Marek GJ, et al. **Drug Alcohol Depend** 1998 Jun–Jul;51(1–2):189–98 (80 ref.)
Effect of once weekly treatment with 3,4–methylenedioxymethamphetamine on schedule–controlled behavior in rats. Nagilla R, et al. **Eur J Pharmacol** 1998 Sep 25;358(1):1–8
Dependence of mesolimbic dopamine transmission on delta9–tetrahydrocannabinol. Tanda G, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):23–6
Serotonergic function after (+/–)3,4–methylene–dioxymethamphetamine ('Ecstasy') in humans. Gerra G, et al. **Int Clin Psychopharmacol** 1998 Jan;13(1):1–9
Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. Pomilio AB, et al. **J Ethnopharmacol** 1999 Apr;65(1):29–51
Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4–methylenedioxymethamphetamine in humans. Mas M, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):136–45
The Duboisia genus, Australian aborigines and suggestibility. de Rios MD, et al. **J Psychoactive Drugs** 1999 Apr–Jun; 31(2):155–61
Increased exploratory activity and altered response to LSD in mice lacking the 5–HT(5A) receptor. Grailhe R, et al. **Neuron** 1999 Mar;22(3):581–91
Serotonin and hallucinogens. Aghajanian GK, et al. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):16S–23S (49 ref.)
Neurometabolic effects of psilocybin, 3,4–methylenedioxyethylamphetamine (MDE) and d–methamphetamine in healthy volunteers. A double–blind, placebo–controlled PET study with [18F]FDG. Gouzoulis–Mayfrank E, et al. **Neuropsychopharmacology** 1999 Jun;20(6):565–81
Caveat emptor: researcher beware [editorial] Lieberman JA, et al. **Neuropsychopharmacology** 1999 Oct;21(4):471–3
Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Morgan MJ. **Neuropsychopharmacology** 1998 Oct;19(4):252–64
5–HT modulation of dopamine release in basal ganglia in psilocybin–induced psychosis in man––a PET study with [11C]raclopride. Vollenweider FX, et al. **Neuropsychopharmacology** 1999 May;20(5):424–33
Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain. Zubaran C, et al. **Neuropsychopharmacology** 1999 Jul; 21(1):119–26
Effects of diazepam, citalopram, methadone and naloxone on PCP–induced stereotyped behaviour and social isolation in the rat social interaction test. Sams–Dodd F. **Neurosci Biobehav Rev** 1998;23(2):287–93
Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Jentsch JD, et al. **Neuroscience** 1999 Mar;90(3):823–32
Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. O'Donnell P, et al. **Neuroscience** 1998 Dec;87(4):823–30
The anxiogenic–like and anxiolytic–like effects of MDMA on mice in the elevated plus–maze: a comparison with amphetamine. Lin HQ, et al. **Pharmacol Biochem Behav** 1999 Mar;62(3):403–8
Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Szumlinski KK, et al. **Pharmacol Biochem Behav** 1999 Jul;63(3):457–64
The acute effects of monoamine reuptake inhibitors on the stimulus effects of hallucinogens. Winter JC, et al. **Pharmacol Biochem Behav** 1999 Jul;63(3):507–13
Enhancement of morphine antinociception by ibogaine and noribogaine in morphine–tolerant mice. Sunder Sharma S, et al. **Pharmacology** 1998 Nov;57(5):229–32
The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Dittrich A. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:80–4 (17 ref.)
Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Geyer MA. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:73–9 (47 ref.)
Methodological issues of human experimental research with hallucinogens. Gouzoulis–Mayfrank E, et al. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:114–8 (20 ref.)
Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Kovar KA. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:69–72 (12 ref.)
Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Vollenweider FX. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:92–103 (125 ref.)
Further investigations of the serotonergic properties of the ibogaine–induced discriminative stimulus. Helsley S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):317–26
Behavioral profile of 3,4–methylenedioxy–methamphetamine (MDMA) in agonistic encounters between male mice. Navarro JF, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):327–34
Level of use of 3,4–methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Dafters RI, et al. **Psychopharmacology (Berl)** 1999 Jul;145(1):82–90
Delta9–THC training dose as a determinant for (R)–methanandamide generalization in rats. Järbe TU, et al. **Psychopharmacology (Berl)** 1998 Dec;140(4):519–22
Effects of synthetic delta9–tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Leweke FM, et al. **Psychopharmacology (Berl)** 1999 Mar;142(3):230–5
Cognitive performance in (+/–) 3,4–methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. McCann UD, et al. **Psychopharmacology (Berl)** 1999 Apr;143(4):417–25
Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Parrott AC, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):261–8
[Investigations on the effect of "ecstasy" on cerebral glucose metabolism: an 18–FDG PET study] Schreckenberger M, et al. **Nuklearmedizin** 1998;37(8):262–7 (Eng. Abstr.) **(Ger)**
[Ecstasy: a pharmacological review] Ferigolo M, et al. **Rev Saude Publica** 1998 Oct;32(5):487–95 (49 ref.) (Eng. Abstr.) **(Por)**

POISONING

Amphetamine derivative fatalities in South Australia––is "Ecstasy" the culprit? Byard RW, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):261–5
Mass ingestion of Jimson Weed by eleven teenagers. Tiongson J, et al. **Del Med J** 1998 Nov;70(11):471–6
Survival after massive "ecstasy" (MDMA) ingestion [letter] Regenthal R, et al. **Intensive Care Med** 1999 Jun; 25(6):640–1
Accidental ingestion of jimsonweed by an adolescent. Forno FJ Jr, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):502–4
Survival after massive ecstasy overdose [see comments] Ramcharan S, et al. **J Toxicol Clin Toxicol** 1998; 36(7):727–31. Comment in: J Toxicol Clin Toxicol 1999;37(3):341, 343. Comment in: J Toxicol Clin Toxicol 1999;37(3):345.
Recovery after Ecstasy intoxication [letter; comment] Rella JG, et al. **J Toxicol Clin Toxicol** 1999;37(3):341, 343. Comment on: J Toxicol Clin Toxicol 1998;36(7):727–31.
Ecstasy intoxication and gastric lavage [letter; comment] van Heijst A. **J Toxicol Clin Toxicol** 1999;37(3):345. Comment on: J Toxicol Clin Toxicol 1997;35(7):711–9. Comment on: J Toxicol Clin Toxicol 1998;36(7):727–31.
Fatal MDMA intoxication [letter; comment] de la Torre R, et al. **Lancet** 1999 Feb 13;353(9152):593. Comment on: Lancet 1998 Nov 28;352(9142):1751–2.
Fatal interaction between ritonavir and MDMA [letter] [see comments] Henry JA, et al. **Lancet** 1998 Nov 28; 352(9142):1751–2. Comment in: Lancet 1999 Feb 13;353(9152):593. Comment in: Lancet 1999 Feb 13;353(9152):593–4.
Fatal MDMA intoxication [letter; comment] Schwab M, et al. **Lancet** 1999 Feb 13;353(9152):593–4. Comment on: Lancet 1998 Nov 28;352(9142):1751–2.
Another PMA–related fatality in Adelaide [letter] Byard RW, et al. **Med J Aust** 1999 Feb 1;170(3):139–40
Death from hyponatraemia–induced cerebral oedema associated with MDMA ("Ecstasy") use. O'Connor A, et al. **N Z Med J** 1999 Jul 9;112(1091):255–6
Fatal peyote ingestion associated with Mallory–Weiss lacerations [letter] Nolte KB, et al. **West J Med** 1999 Jun; 170(6):328
[Poisoning with Coprinus atramentarius, a previously unknown hallucinogenic mushroom: report of two cases (letter)] Braclik M, et al. **Pol Arch Med Wewn** 1998 Sep; 100(3):285–6 **(Pol)**
[The morphofunctional changes in the internal organs in the modelling of poisonings by psilocybine–containing mushrooms] Babakhanian RV, et al. **Sud Med Ekspert** 1999 May–Jun;42(3):6–9 (Eng. Abstr.) **(Rus)**
[Hallucinogenic mushrooms popular again––sale via Internet] Westberg U, et al. **Lakartidningen** 1999 Feb 17;96(7):746–7 **(Swe)**

THERAPEUTIC USE

Hallucinogens and obsessive–compulsive disorder [letter; comment] Perrine DM. **Am J Psychiatry** 1999 Jul; 156(7):1123. Comment on: Am J Psychiatry 1997 Jul;154(7):1037–8.
Hallucinogens, serotonin and obsessive–compulsive disorder. Delgado PL, et al. **J Psychoactive Drugs** 1998 Oct–Dec; 30(4):359–66 (63 ref.)
Dr. Leary's Concord Prison Experiment: a 34–year follow–up study [see comments] Doblin R. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):419–26. Comment in: J Psychoactive Drugs 1998 Oct–Dec;30(4):427–8.
A method of conducting therapeutic sessions with MDMA. Greer GR, et al. **J Psychoactive Drugs** 1998 Oct–Dec; 30(4):371–9
Hallucinogens at the turn of the century: an introduction. Grob CS, et al. **J Psychoactive Drugs** 1998 Oct–Dec; 30(4):315–9 (30 ref.)
Treatment of alcoholism using psychedelic drugs: a review of the program of research. Mangini M. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):381–418 (225 ref.)
Reflections on the Concord Prison project and the follow–up study [comment] Metzner R. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):427–8. Comment on: J Psychoactive Drugs 1998 Oct–Dec;30(4):419–26.
Hallucinogenic drugs and plants in psychotherapy and shamanism. Metzner R. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):333–41 (46 ref.)
Psychoactive plants and ethnopsychiatric medicines of the Matsigenka. Shepard GH Jr. **J Psychoactive Drugs** 1998 Oct–Dec;30(4):321–32 (57 ref.)

TOXICITY

Effects of sustained phencyclidine exposure on sensorimotor gating of startle in rats. Martinez ZA, et al. **Neuropsychopharmacology** 1999 Jul;21(1):28–39
3,4–Methylenedioxy analogues of amphetamine: defining the risks to humans. Hegadoren KM, et al. **Neurosci Biobehav Rev** 1999 Mar;23(4):539–53 (163 ref.)
Acute toxicity of 3,4–methylenedioxymethamphetamine (MDMA) in Sprague–Dawley and Dark Agouti rats. Malpass A, et al. **Pharmacol Biochem Behav** 1999 Sep; 64(1):29–34
Maternal exposure to low doses of delta9–tetrahydrocannabinol facilitates morphine–induced place conditioning in adult male offspring. Rubio P, et al. **Pharmacol Biochem Behav** 1998 Nov;61(3):229–38

URINE

Stability study of LSD under various storage conditions. Li Z, et al. **J Anal Toxicol** 1998 Oct;22(6):520–5
False–positive LSD testing in urine samples from intensive care patients. Röhrich J, et al. **J Anal Toxicol** 1998 Sep; 22(5):393–5
Evaluation of the diagnostic performance of the Boehringer Mannheim CEDIA LSD assay. Verstraete AG, et al. **J Anal Toxicol** 1998 Nov–Dec;22(7):601–4
The determination of lysergide (LSD) in urine by high–performance liquid chromatography–isotope dilution mass spectrometry (IDMS). White SA, et al. **J Forensic Sci** 1999 Mar;44(2):375–9

HALLUX

Management of focal dystonia of the extensor hallucis longus muscle with botulinum toxin injection: a case report. Sherman AL, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1303–5
Great toe neuroarthropathy: a report of two cases. Beals TC, et al. **Foot Ankle Int** 1998 Sep;19(9):631–3 (6 ref.)
Intermediate to long–term follow–up of medial–approach dorsal cheilectomy for hallux rigidus. Easley ME, et al. **Foot Ankle Int** 1999 Mar;20(3):147–52
Results after cheilectomy in athletes with hallux rigidus. Mulier T, et al. **Foot Ankle Int** 1999 Apr;20(4):232–7
Clinical pearl: accentuated transverse hallucal skin crease––a cutaneous skin marker for hallux rigidus (osteoarthritis of the big toe joint). Lemont H, et al. **J Am Acad Dermatol** 1999 Apr;40(4):631–2
The Valenti procedure for hallux limitus: a long–term follow–up and analysis. Kurtz DH, et al. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):123–30
Giant cell tumor of the foot phalanges in children: a case report. Alvarez Ramos A, et al. **J Pediatr Orthop B** 1999 Apr;8(2):132–5 (19 ref.)
Chondromyxoid fibroma of the distal phalanx of the great toe: a tumor with unusual histological findings. Kim YS, et al. **Pathol Int** 1998 Sep;48(9):739–43
Disorders of the hallux sesamoid complex: MR features. Karasick D, et al. **Skeletal Radiol** 1998 Aug;27(8):411–8 (30 ref.)

ABNORMALITIES

Blepharophimosis, hypoplastic radius, hypoplastic left heart, telecanthus, hydronephrosis, fused metacarpals, and "prehensile" halluces: a new syndrome? Day–Salvatore D, et al. **Am J Med Genet** 1998 Dec 4;80(4):309–13
Thumb/hallux duplication and preaxial polydactyly type I. Orioli IM, et al. **Am J Med Genet** 1999 Jan 29;82(3):219–24
Congenital absence of the lateral metatarso–phalangeal sesamoid bone of the human hallux: a case report. Le Minor JM. **Surg Radiol Anat** 1999;21(3):225–7
[Hallux varus congenitus] Vispo–Seara JL, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov–Dec;136(6):542–7 (16 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Reconstruction of the great toe in a child using the Y–V pedicle elongation technique for a medial plantar flap.

Salon A, et al. **Br J Plast Surg** 1999 Mar;52(2):146–8
Avulsion fracture of the great toe: a case report. Rapoff AJ, et al. **Foot Ankle Int** 1999 May;20(5):337–9
Replantation of the great toe: two case reports. Sakamoto K, et al. **Foot Ankle Int** 1998 Sep;19(9):638–40
Hallucal sesamoid pain: causes and surgical treatment. Richardson EG. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):270–8 (18 ref.)
Trauma-induced Kaposi's sarcoma of the hallux. An unusual case. Berkowitz KD, et al. **J Am Podiatr Med Assoc** 1998 Oct;88(10):500–5
Management of hallux amputation. Levine SE, et al. **Orthopedics** 1999 Mar;22(3):330–3; quiz 334–5 (24 ref.)

INNERVATION

A comparison of train-of-four monitoring: mechanomyography at the thumb vs acceleromyography at the big toe. Heier T, et al. **Acta Anaesthesiol Scand** 1999 May;43(5):550–5
Joplin's neuroma or compression neuropathy of the plantar proper digital nerve to the hallux: clinicopathologic study of three cases. Still GP, et al. **J Foot Ankle Surg** 1998 Nov–Dec;37(6):524–30

PATHOLOGY

Unusual and memorable. Wright GD. **Ann Rheum Dis** 1999 May;58(5):263
Poroid hidradenoma. A case presentation. Whitmore RM, et al. **J Am Podiatr Med Assoc** 1998 Oct;88(10):510–3
Subungual exostosis [letter] Wang TC, et al. **J Dermatol** 1999 Jan;26(1):72–4

SURGERY

Scoring in forefoot surgery: a statistical evaluation of single variables and rating systems. Schneider W, et al. **Acta Orthop Scand** 1998 Oct;69(5):498–504
Reconstruction of the great toe in a child using the Y–V pedicle elongation technique for a medial plantar flap. Salon A, et al. **Br J Plast Surg** 1999 Mar;52(2):146–8
Replantation of the great toe: two case reports. Sakamoto K, et al. **Foot Ankle Int** 1998 Sep;19(9):638–40
Proximal phalanx osteotomy for the surgical treatment of hallux rigidus. Thomas PJ, et al. **Foot Ankle Int** 1999 Jan; 20(1):3–12
Management of hallux amputation. Levine SE, et al. **Orthopedics** 1999 Mar;22(3):330–3; quiz 334–5 (24 ref.)
[Panniculitis ossificans and review of the literature] Qi P, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):207–8 (8 ref.) (Eng. Abstr.) **(Chi)**
[Hallux valgus treated by Scarf osteotomy of the first metatarsus and the first phalanx associated with an adductor plasty. Apropos of 50 cases with a 2-year follow up] Jarde O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jul; 85(4):374–80 (Eng. Abstr.) **(Fre)**

HALLUX ABDUCTOVALGUS see **HALLUX VALGUS**

HALLUX VALGUS

DIAGNOSIS

[Selected anatomical features of the foot with hallux valgus] Orzechowski W, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):311–7 (Eng. Abstr.) **(Pol)**

GENETICS

[Hallux varus congenitus] Vispo-Seara JL, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov–Dec;136(6):542–7 (16 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Insertion of the abductor hallucis muscle in feet with and without hallux valgus. Brenner E. **Anat Rec** 1999 Mar; 254(3):429–34

PHYSIOPATHOLOGY

Clinical significance of increased mobility in the sagittal plane in patients with hallux valgus. Ito H, et al. **Foot Ankle Int** 1999 Jan;20(1):29–32

RADIOGRAPHY

Metatarsophalangeal and intermetatarsal angle: different values and interpretation of postoperative results dependent on the technique of measurement. Schneider W, et al. **Foot Ankle Int** 1998 Aug;19(8):532–6
Assessing sesamoid subluxation: how good is the AP radiograph? Talbot KD, et al. **Foot Ankle Int** 1998 Aug; 19(8):547–54
[Radiographic analysis of the orientation of the distal articular surface of the first metatarsal in the horizontal plane] Canovas F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):546–9 (Eng. Abstr.) **(Fre)**

SURGERY

Long-term results after Mitchell osteotomy in children and adolescents with hallux valgus. Karbowski A, et al. **Acta Orthop Belg** 1998 Sep;64(3):263–8
Follow-up results 17 years after resection arthroplasty of the great toe [published erratum appears in Arch Orthop Trauma Surg 1999;119(3–4):243] Flamme CH, et al. **Arch Orthop Trauma Surg** 1998;117(8):457–60
Biplanar chevron osteotomy. Chou LB, et al. **Foot Ankle Int** 1998 Sep;19(9):579–84
The crescentic shelf osteotomy [letter; comment] Cohen M. **Foot Ankle Int** 1999 Feb;20(2):140–3. Comment on: Foot Ankle Int 1998 Jul;19(7):425–9.
Stabilization of the Mitchell first metatarsal osteotomy using an intramedullary K-wire. Downing ND, et al. **Foot Ankle Int** 1999 May;20(5):301–2
Late results of modified Mitchell procedure for the treatment of hallux valgus. Fokter SK, et al. **Foot Ankle Int** 1999 May;20(5):296–300
Cerclage fibreux in the treatment of hallux valgus. Franzreb M, et al. **Foot Ankle Int** 1999 Apr;20(4):267–71
Modification of the Mitchell osteotomy. Freund EI. **Foot Ankle Int** 1999 May;20(5):303
Capsular closure after hallux valgus surgery. Freund EI. **Foot Ankle Int** 1999 Feb;20(2):137
Operative treatment for hallux valgus in children with cerebral palsy. Jenter M, et al. **Foot Ankle Int** 1998 Dec; 19(12):830–5
Modified Mitchell osteotomy for hallux valgus. Kuo CH, et al. **Foot Ankle Int** 1998 Sep;19(9):585–9
Metatarsophalangeal and intermetatarsal angle: different values and interpretation of postoperative results dependent on the technique of measurement. Schneider W, et al. **Foot Ankle Int** 1998 Aug;19(8):532–6
Basal closing wedge osteotomy for correction of hallux valgus and metatarsus primus varus: 10- to 22-year follow-up. Trnka HJ, et al. **Foot Ankle Int** 1999 Mar; 20(3):171–7
Clinical application of shape memory staples. Yetkin H, et al. **Foot Ankle Int** 1998 Aug;19(8):571–2
Complications after hallux valgus surgery. Richardson EG. **Instr Course Lect** 1999;48:331–42 (75 ref.)
Hallucal sesamoid pain: causes and surgical treatment. Richardson EG. **J Am Acad Orthop Surg** 1999 Jul–Aug; 7(4):270–8 (18 ref.)
The effect of hallux valgus correction on chronic plantar ulceration. A case report. Bryant AR, et al. **J Am Podiatr Med Assoc** 1999 Jul;89(7):358–63
Akin osteotomy with horizontal interosseous wire-loop fixation. Schlefman BS. **J Am Podiatr Med Assoc** 1999 Apr; 89(4):194–8
Tricorrectional bunionectomy for hallux abducto valgus. A comprehensive outcome study. Selner AJ, et al. **J Am Podiatr Med Assoc** 1999 Apr;89(4):174–82
Screw versus suture fixation of Mitchell's osteotomy. A prospective, randomised study. Calder JD, et al. **J Bone Joint Surg Br** 1999 Jul;81(4):621–4
Inherent stability of proximal first metatarsal osteotomies: a comparative analysis. Fillinger EB, et al. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):292–302
The crescentic first metatarsal basilar osteotomy for correction of metatarsus primus varus. Fox IM, et al. **J Foot Ankle Surg** 1999 May–Jun;38(3):203–7
Modified lapidus arthrodesis for adolescent hallux abducto valgus. Grace D, et al. **J Foot Ankle Surg** 1999 Jan–Feb; 38(1):8–13
Application of distal metaphyseal osteotomy for treatment of high intermetatarsal angle bunion deformities. Oloff LM, et al. **J Foot Ankle Surg** 1998 Nov–Dec;37(6):481–9
Allofix freeze-dried cortical bone pins as an alternative to synthetic absorbable polymeric pins: a preliminary study in short Z bunionectomies. Reed TM. **J Foot Ankle Surg** 1999 Jan–Feb;38(1):14–23; discussion 82
Stabilization of the Chevron procedure for hallux valgus deformity with a capsuloperiostal flap. Us K, et al. **J Foot Ankle Surg** 1999 Jan–Feb;38(1):2–7
Postoperative hallux valgus exercises. Weil LS Jr, et al. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):355
Surgical treatment for bunions in adolescents. Señaris-Rodriguez J, et al. **J Pediatr Orthop B** 1998 Jul; 7(3):210–6
Morton's neuroma following first metatarsal osteotomy. Breusch SJ, et al. **Orthopedics** 1998 Dec;21(12):1287–8
The Mitchell distal metatarsal osteotomy for hallux valgus--the Singapore General Hospital experience. Tan MY, et al. **Singapore Med J** 1998 Dec;39(12):547–50
[Evaluation of the Scarf osteotomy in hallux valgus related to distal metatarsal articular angle: a prospective study of 79 operated cases] Bonnel F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jul; 85(4):381–6 (Eng. Abstr.) **(Fre)**
[Hallux valgus treated by Scarf osteotomy of the first metatarsus and the first phalanx associated with an adductor plasty. Apropos of 50 cases with a 2-year follow up] Jarde O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jul; 85(4):374–80 (Eng. Abstr.) **(Fre)**
[Long-term outcome of arthroplasty of the first metatarsophalangeal joint] Flamme CH, et al. **Z Orthop Ihre Grenzgeb** 1998 May–Jun;136(3):250–4 (Eng. Abstr.) **(Ger)**
[Long-term results of basal wedge osteotomy in metatarsus primus varus in the young patient] Zembsch A, et al. **Z Orthop Ihre Grenzgeb** 1998 May–Jun;136(3):243–9 (Eng. Abstr.) **(Ger)**
[Keller-Brandes operation: long-term outcome in young patients with hallux valgus] Zembsch A, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar–Apr;137(2):181–8 (Eng. Abstr.) **(Ger)**
[Mitchell's osteotomy of hallux valgus] Oye C, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3765–7 (Eng. Abstr.) **(Nor)**

HALO EFFECT see **EFFECT MODIFIERS (EPIDEMIOLOGY)**

HALOARCULA

CLASSIFICATION

Haloarcula quadrata sp. nov., a square, motile archaeon isolated from a brine pool in Sinai (Egypt). Oren A, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1149–55

METABOLISM

Amino acid biosynthesis in the halophilic archaeon Haloarcula hispanica. Hochuli M, et al. **J Bacteriol** 1999 May;181(10):3226–37

VIROLOGY

His1, an archaeal virus of the Fuselloviridae family that infects Haloarcula hispanica. Bath C, et al. **J Virol** 1998 Nov;72(11):9392–5

HALOARCULA MARISMORTUI

ENZYMOLOGY

Relative role of anions and cations in the stabilization of halophilic malate dehydrogenase. Ebel C, et al. **Biochemistry** 1999 Jul 13;38(28):9039–47
The protein sequence of an archaeal catalase-peroxidase. Cannac-Caffrey V, et al. **Biochimie** 1998 Dec; 80(12):1003–11

HALOBACTERIACEAE

CHEMISTRY

Structural diversity of membrane lipids in members of Halobacteriaceae. Kamekura M, et al. **Biosci Biotechnol Biochem** 1999 Jun;63(6):969–72 (39 ref.)

CLASSIFICATION

Halobacteria: the evidence for longevity. Grant WD, et al. **Extremophiles** 1998 Aug;2(3):279–87 (60 ref.)
Diversity of extremely halophilic bacteria. Kamekura M. **Extremophiles** 1998 Aug;2(3):289–95 (47 ref.)
Moderately halophilic gram-positive bacterial diversity in hypersaline environments. Ventosa A, et al. **Extremophiles** 1998 Aug;2(3):297–304 (33 ref.)
Distribution and diversity of halophilic bacteria in a subsurface salt formation. Vreeland RH, et al. **Extremophiles** 1998 Aug;2(3):321–31
Proposal of a new halobacterial genus Natrinema gen. nov., with two species Natrinema pellirubrum nom. nov. and Natrinema pallidum nom. nov. McGenity TJ, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1187–96
Halogeometricum borinquense gen. nov., sp. nov., a novel halophilic archaeon from Puerto Rico. Montalvo-Rodriguez R, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1305–12

GENETICS

Halobacteria: the evidence for longevity. Grant WD, et al. **Extremophiles** 1998 Aug;2(3):279–87 (60 ref.)
Diversity of extremely halophilic bacteria. Kamekura M. **Extremophiles** 1998 Aug;2(3):289–95 (47 ref.)
Moderately halophilic gram-positive bacterial diversity in hypersaline environments. Ventosa A, et al. **Extremophiles** 1998 Aug;2(3):297–304 (33 ref.)
Halobacterial rhodopsins. Mukohata Y, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):649–57 (58 ref.)

ISOLATION & PURIFICATION

Distribution and diversity of halophilic bacteria in a subsurface salt formation. Vreeland RH, et al. **Extremophiles** 1998 Aug;2(3):321–31
Halogeometricum borinquense gen. nov., sp. nov., a novel halophilic archaeon from Puerto Rico. Montalvo-Rodriguez R, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1305–12
Haloanaerobacter salinarius sp. nov., a novel halophilic fermentative bacterium that reduces glycine-betaine to trimethylamine with hydrogen or serine as electron donors; emendation of the genus Haloanaerobacter. Mouné S, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:103–12

PHYSIOLOGY

Bioenergetic aspects of halophilism. Oren A. **Microbiol Mol Biol Rev** 1999 Jun;63(2):334–48 (142 ref.)

HALOBACTERIALES

HALOBACTERIALES

GENETICS

Novel plasmids from alkaliphilic halomonads. Fish SA, et al. **Plasmid** 1999 May;41(3):268–73

HALOBACTERIUM

CLASSIFICATION

Proposal of a new halobacterial genus Natrinema gen. nov., with two species Natrinema pellirubrum nom. nov. and Natrinema pallidum nom. nov. McGenity TJ, et al. **Int J Syst Bacteriol** 1998 Oct;48 Pt 4:1187–96

Proposal to transfer Halococcus turkmenicus, Halobacterium trapanicum JCM 9743 and strain GSL–11 to Haloterrigena turkmenica gen. nov., comb. nov. Ventosa A, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:131–6

ENZYMOLOGY

Amino acid residues involved in the catalytic mechanism of NAD–dependent glutamate dehydrogenase from Halobacterium salinarum [published erratum appears in Biochim Biophys Acta 1999 May 24;1427(3):417] Pérez–Pomares F, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):513–25

GENETICS

Functional expression of green fluorescent protein derivatives in Halobacterium salinarum. Nomura S, et al. **FEMS Microbiol Lett** 1998 Oct 15;167(2):287–93

Snapshot of a large dynamic replicon in a halophilic archaeon: megaplasmid or minichromosome? Ng WV, et al. **Genome Res** 1998 Nov;8(11):1131–41

Saturation mutagenesis of the TATA box and upstream activator sequence in the haloarchaeal bop gene promoter. Baliga NS, et al. **J Bacteriol** 1999 Apr;181(8):2513–8

Characterization of the genes for the biosynthesis of the compatible solute ectoine in the moderately halophilic bacterium Halomonas elongata DSM 3043. Cánovas D, et al. **Syst Appl Microbiol** 1998 Dec;21(4):487–97

IMMUNOLOGY

Effect of Halococcus morrhuae and Halobacterium saccharovorum on the activation of human peripheral blood lymphocytes. Montes MJ, et al. **Microbios** 1999; 98(391):141–7

PHYSIOLOGY

The transducer protein HtrII modulates the lifetimes of sensory rhodopsin II photointermediates. Sasaki J, et al. **Biophys J** 1998 Nov;75(5):2435–40

Studies of the electron transport chain of the euryarcheon Halobacterium salinarum: indications for a type II NADH dehydrogenase and a complex III analog. Sreeramulu K, et al. **J Bioenerg Biomembr** 1998 Oct;30(5):443–53

HALOBACTERIUM HALOBIUM

see related
PURPLE MEMBRANE

CHEMISTRY

Evidence for covalent attachment of diphytanylglyceryl phosphate to the cell–surface glycoprotein of Halobacterium halobium. Kikuchi A, et al. **J Biol Chem** 1999 Jun 18;274(25):18011–6

DRUG EFFECTS

Sites of interaction of streptogramin A and B antibiotics in the peptidyl transferase loop of 23 S rRNA and the synergism of their inhibitory mechanisms. Porse BT, et al. **J Mol Biol** 1999 Feb 19;286(2):375–87

GENETICS

Cloning and sequencing of the homologues of both the bacterial and eukaryotic initiation factor genes (hIF–2 and heIF–2 gamma) from archaeal Halobacterium halobium. Hasegawa Y, et al. **Biochem Mol Biol Int** 1998 Oct; 46(3):495–507

Exchange of Ser–4 for Val, Leu or Asn in the sequon Asn–Ala–Ser does not prevent N–glycosylation of the cell surface glycoprotein from Halobacterium halobium. Zeitler R, et al. **Glycobiology** 1998 Dec;8(12):1157–64

HALOBACTERIUM MARISMORTUI see **HALOARCULA MARISMORTUI**

HALOBACTERIUM SALINARIUM

see related
PURPLE MEMBRANE

CHEMISTRY

Existence of two L photointermediates of halorhodopsin from Halobacterium salinarium, differing in their protein and water FTIR bands. Chon YS, et al. **Biochemistry** 1999 Jul 20;38(29):9449–55

Time–resolved absorption and photothermal measurements with sensory rhodopsin I from Halobacterium salinarum. Losi A, et al. **Biophys J** 1999 Apr;76(4):2183–91

The structure of bacteriorhodopsin at 3.0 A resolution based on electron crystallography: implication of the charge distribution. Mitsuoka K, et al. **J Mol Biol** 1999 Feb 26; 286(3):861–82

Spectroscopic characterization of two soluble transducers from the Archaeon Halobacterium salinarum. Larsen RW, et al. **J Protein Chem** 1999 Apr;18(3):269–75

GENETICS

Long–distance effects of site–directed mutations on backbone conformation in bacteriorhodopsin from solid state NMR of [1–13C]Val–labeled proteins. Tanio M, et al. **Biophys J** 1999 Jul;77(1):431–42

Car: a cytoplasmic sensor responsible for arginine chemotaxis in the archaeon Halobacterium salinarum. Storch KF, et al. **EMBO J** 1999 Mar 1;18(5):1146–58

METABOLISM

Regulation of the bacteriorhodopsin photocycle and proton pumping in whole cells of Halobacterium salinarium. Joshi MK, et al. **Biochemistry** 1999 Jul 6;38(27):8786–93

Kreb's TCA cycle in Halobacterium salinarum investigated by 13C nuclear magnetic resonance spectroscopy. Ghosh M, et al. **Extremophiles** 1998 Nov;2(4):427–33

Bacterioopsin–triggered retinal biosynthesis is inhibited by bacteriorhodopsin formation in Halobacterium salinarium. Deshpande A, et al. **J Biol Chem** 1999 Aug 13; 274(33):23535–40

PHYSIOLOGY

Photoresponses of Halobacterium salinarum to repetitive pulse stimuli. Cercignani G, et al. **Biophys J** 1998 Sep; 75(3):1466–72

Identification of methylation sites and effects of phototaxis stimuli on transducer methylation in Halobacterium salinarum. Perazzona B, et al. **J Bacteriol** 1999 Sep; 181(18):5676–83

Protective roles of bacterioruberin and intracellular KCl in the resistance of Halobacterium salinarium against DNA–damaging agents. Shahmohammadi HR, et al. **J Radiat Res (Tokyo)** 1998 Dec;39(4):251–62

The specificity of interaction of archaeal transducers with their cognate sensory rhodopsins is determined by their transmembrane helices. Zhang XN, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):857–62

RADIATION EFFECTS

Photoresponses of Halobacterium salinarum to repetitive pulse stimuli. Cercignani G, et al. **Biophys J** 1998 Sep; 75(3):1466–72

HALOCOCCUS

CLASSIFICATION

Proposal to transfer Halococcus turkmenicus, Halobacterium trapanicum JCM 9743 and strain GSL–11 to Haloterrigena turkmenica gen. nov., comb. nov. Ventosa A, et al. **Int J Syst Bacteriol** 1999 Jan;49 Pt 1:131–6

IMMUNOLOGY

Effect of Halococcus morrhuae and Halobacterium saccharovorum on the activation of human peripheral blood lymphocytes. Montes MJ, et al. **Microbios** 1999; 98(391):141–7

HALOFERAX

METABOLISM

Degradation of 3–phenylpropionic acid by Haloferax sp. D1227. Fu W, et al. **Extremophiles** 1999 Jan;3(1):45–53

HALOFERAX MEDITERRANEI

ENZYMOLOGY

Fluorescence and quenching comparative studies of halophilic and bovine glutamate dehydrogenase. Ferrer J, et al. **J Photochem Photobiol B** 1998 Dec;47(2–3):148–54

HALOFERAX VOLCANII

ENZYMOLOGY

Expression, reactivation, and purification of enzymes from Haloferax volcanii in Escherichia coli. Connaris H, et al. **Biotechnol Bioeng** 1999 Jul 5;64(1):38–45

Gentisate 1,2–dioxygenase from Haloferax sp. D1227. Fu W, et al. **Extremophiles** 1998 Nov;2(4):439–46

Halophilic 20S proteasomes of the archaeon Haloferax volcanii: purification, characterization, and gene sequence analysis. Wilson HL, et al. **J Bacteriol** 1999 Sep; 181(18):5814–24

GENETICS

Heterologous expression in the Archaea: transcription from Pyrococcus furiosus gdh and mlrA promoters in Haloferax volcanii. Schreier HJ, et al. **Extremophiles** 1999 Jan; 3(1):11–9

Genetic identification of three ABC transporters as essential elements for nitrate respiration in Haloferax volcanii. Wanner C, et al. **Genetics** 1999 Aug;152(4):1417–28

Expression and heat–responsive regulation of a TFIIB homologue from the archaeon Haloferax volcanii. Thompson DK, et al. **Mol Microbiol** 1999 Sep; 33(5):1081–92

METABOLISM

Extensive proteolysis inhibits high–level production of eukaryal G protein–coupled receptors in the archaeon Haloferax volcanii. Patenge N, et al. **FEMS Microbiol Lett** 1999 Feb 1;171(1):27–35

HALOGENATED HYDROCARBONS see **HYDROCARBONS, HALOGENATED**

HALOGENS

ANALYSIS

[Roentgen contrast media, source for AOX–contamination of waste water by hospitals] Erbe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):420–3 (Eng. Abstr.) **(Ger)**

CHEMISTRY

Synthesis and pharmacological activities in mice of halogenated delta 9–tetrahydrocannabinol derivatives. Usami N, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1462–7

The nature of halogen substitution determines the mode of cytotoxicity of halopropanols. Hammond AH, et al. **Toxicol Appl Pharmacol** 1999 Mar 15;155(3):287–91

METABOLISM

A two–component tetrachlorohydroquinone reductive dehalogenase system from the lignin–degrading basidiomycete Phanerochaete chrysosporium. Reddy GV, et al. **Biochem Biophys Res Commun** 1999 Apr 21; 257(3):901–5

Haloperoxidases and their role in biotransformation reactions. Littlechild J. **Curr Opin Chem Biol** 1999 Feb;3(1):28–34 (54 ref.)

PHARMACOLOGY

Effect of Tn10/Tn5 transposons on the survival and mutation frequency of halogen light–irradiated AB1157 Escherichia coli K–12. Wójcik A, et al. **Mutagenesis** 1999 Jan; 14(1):129–34

HALOPERIDOL

ADMINISTRATION & DOSAGE

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose–ranging study vs. haloperidol. The Amisulpride Study Group. Puech A, et al. **Acta Psychiatr Scand** 1998 Jul;98(1):65–72

A randomized, placebo–controlled dose–comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Devanand DP, et al. **Am J Psychiatry** 1998 Nov;155(11):1512–20

Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Dorevitch A, et al. **Am J Psychiatry** 1999 Jan; 156(1):142–4

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double–blind study. Cohen–Mansfield J, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1733–40

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Tran PV, et al. **Br J Psychiatry** 1998 Jun;172:499–505

Optimal haloperidol dosage in first–episode psychosis. Zhang–Wong J, et al. **Can J Psychiatry** 1999 Mar; 44(2):164–7

An exploratory haloperidol–controlled dose–finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. Goff DC, et al. **J Clin Psychopharmacol** 1998 Aug;18(4):296–304

A double–blind study of adjunctive sertraline in haloperidol–stabilized patients with chronic schizophrenia. Lee MS, et al. **J Clin Psychopharmacol** 1998 Oct; 18(5):399–403

A poly(D,L–lactide–co–glycolide) microsphere depot system for delivery of haloperidol. Cheng YH, et al. **J Controlled Release** 1998 Nov 13;55(2–3):203–12

Chronic oral haloperidol and clozapine in rats: A behavioral evaluation. Schmitt U, et al. **Neuropsychobiology** 1999; 39(2):86–91

Co–administration of sertraline and haloperidol. Lee MS, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S193–8

Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Kern RS, et al. **Schizophr Bull** 1999;25(2):223–32

ADVERSE EFFECTS

Acute laryngeal dystonia related to neuroleptic agents [letter] Fines RE, et al. **Am J Emerg Med** 1999 May;17(3):319–20

Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Hummer M, et al. **Am J Psychiatry** 1999 Apr;156(4):631–3

Cardiotoxicity associated with use of intravenous haloperidol [letter] Furrows DC. **Aust N Z J Psychiatry** 1999 Apr; 33(2):284

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Beasley CM, et al. **Br J Psychiatry** 1999 Jan;174:23–30

Neuroleptic malignant syndrome in a burn patient. Still J, et al. **Burns** 1998 Sep;24(6):573–5

Urinary retention with sertraline, haloperidol, and clonazepam combination [letter] Benazzi F. **Can J Psychiatry** 1998 Dec;43(10):1051–2

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Jeste DV, et al. **J Am Geriatr Soc** 1999 Jun;47(6):716–9

Interaction between olanzapine and haloperidol [letter] Gomberg RF. **J Clin Psychopharmacol** 1999 Jun; 19(3):272–3

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Rosebush PI, et al. **Neurology** 1999 Mar 10;52(4):782–5

Lithium and haloperidol treatments differently affect the mononuclear leukocyte Galphas protein levels in bipolar affective disorder. Karege F, et al. **Neuropsychobiology** 1999 May;39(4):181–6

A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Yamashita H, et al. **Psychiatry Clin Neurosci** 1999 Apr; 53(2):291–3

Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E. Eranti VS, et al. **Psychopharmacology (Berl)** 1998 Dec;140(4):418–20

Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient. A case report. Tanaka K, et al. **Support Care Cancer** 1998 Nov;6(6):536–8

[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine] Hanel RA, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):833–7 (Eng. Abstr.) **(Por)**

ANALOGS & DERIVATIVES

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Moore DB, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S17–9

Neuroprotection from focal ischemia by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is dependent on treatment duration in rats. Harukuni I, et al. **Anesth Analg** 1998 Dec;87(6):1299–305

Failure to down regulate NMDA receptors in the striatum and nucleus accumbens associated with neuroleptic-induced dyskinesia. Hamid EH, et al. **Brain Res** 1998 Jun 15;796(1-2):291–5

Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Halliday GM, et al. **Exp Neurol** 1999 Jul; 158(1):155–63

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Ulrich S, et al. **Int Clin Psychopharmacol** 1999 Jul;14(4):219–28

p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Mienie LJ, et al. **Life Sci** 1999;65(5):535–42

In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pan LP, et al. **Pharmacogenetics** 1998 Oct;8(5):383–9

No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Mihara K, et al. **Ther Drug Monit** 1999 Jun;21(3):297–300

ANALYSIS

Persistence of haloperidol in human brain tissue. Kornhuber J, et al. **Am J Psychiatry** 1999 Jun;156(6):885–90

BLOOD

Trace analysis of haloperidol and its chiral metabolite in plasma by capillary electrophoresis. Wu SM, et al. **J Chromatogr A** 1999 Jun 18;846(1-2):239–43

Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. Walter S, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1-2):231–7

Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Yasui N, et al. **J Clin Psychopharmacol** 1999 Apr;19(2):149–54

Ovariectomy results in lower plasma haloperidol levels in rats following chronic administration. Grimm JW, et al. **Pharm Res** 1998 Oct;15(10):1640–2

Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Ulrich S, et al. **Pharmacopsychiatry** 1998 Sep;31(5):163–9

Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Hirokane G, et al. **Ther Drug Monit** 1999 Feb;21(1):82–6

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Shimoda K, et al. **Ther Drug Monit** 1999 Jun;21(3):293–6

CHEMISTRY

Solubility behaviour of haloperidol in individual solvents determination of partial solubility parameters. Subrahmanyam CV, et al. **Eur J Pharm Biopharm** 1999 May;47(3):289–94

Compatibility and stability of ternary admixtures of morphine with haloperidol or midazolam and dexamethasone or methylprednisolone. Vermeire A, et al. **Int J Pharm** 1999 Jan 15;177(1):53–67

HISTORY

[The discovery of haloperidol] Granger B. **Encephale** 1999 Jan-Feb;25(1):59–66 (Eng. Abstr.) **(Fre)**

METABOLISM

Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Usuki E, et al. **Drug Metab Rev** 1998 Nov;30(4):809–26 (106 ref.)

High-performance liquid chromatographic methods for the analysis of haloperidol and chlorpromazine metabolism in vitro by purified cytochrome P450 isoforms. Boehme CL, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 6; 718(2):259–66

p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Mienie LJ, et al. **Life Sci** 1999;65(5):535–42

Carbonyl reduction of timiperone in human liver cytosol. Shimoda K, et al. **Pharmacol Toxicol** 1998 Oct;83(4):164–8

Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Castagnoli N Jr, et al. **Pol J Pharmacol** 1999 Jan-Feb;51(1):31–8 (40 ref.)

PHARMACOKINETICS

An improved low-permeability in vitro-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Franke H, et al. **Brain Res** 1999 Feb 6;818(1):65–71

Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Mihara K, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):291–4

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. Hesslinger B, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):310–5

p-Fluorophenylglycine in the urine of baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Mienie LJ, et al. **Life Sci** 1999;65(5):535–42

An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Zhang-Wong J, et al. **Psychiatry Res** 1998 Dec 14;81(3):333–9

No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Mihara K, et al. **Ther Drug Monit** 1999 Jun;21(3):297–300

PHARMACOLOGY

Effects of haloperidol or SCH-23390 on ethanol-induced conditioned taste aversion. Risinger FO, et al. **Alcohol** 1999 Jun-Jul;18(2-3):139–45

Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Moots RJ, et al. **Ann Rheum Dis** 1999 Sep;58(9):585–7

Effects of haloperidol and d-amphetamine on working and reference memory performance in a spatial cone field task. Blokland A, et al. **Behav Pharmacol** 1998 Sep;9(5-6):429–36

Effects of single oral administrations of haloperidol and d-amphetamine on prepulse inhibition of the acoustic startle reflex in healthy male volunteers. Kumari V, et al. **Behav Pharmacol** 1998 Nov;9(7):567–76

Haloperidol-induced potentiation of latent inhibition: interaction with parameters of conditioning. Ruob C, et al. **Behav Pharmacol** 1998 May;9(3):245–53

Striatal enlargement in rats chronically treated with neuroleptic. Chakos MH, et al. **Biol Psychiatry** 1998 Oct 15;44(8):675–84

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Kern RS, et al. **Biol Psychiatry** 1998 Oct 15;44(8):726–32

Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Reavill C, et al. **Br J Pharmacol** 1999 Feb;126(3):572–4

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Duncan GE, et al. **Brain Res** 1998 Nov 23;812(1-2):65–75

Propranolol attenuates haloperidol-induced Fos expression in discrete regions of rat brain: possible brain regions responsible for akathisia. Ohashi K, et al. **Brain Res** 1998 Aug 17;802(1-2):134–40

Haloperidol induces Fos expression in the globus pallidus and substantia nigra of cynomolgus monkeys. Wirtshafter D, et al. **Brain Res** 1999 Jul 24;835(2):154–61

Interaction of benztropine and haloperidol actions on rat substantia nigra dopamine cell electrophysiological activity in vivo. Todd CL, et al. **Brain Res Bull** 1999 Jan 15; 48(2):219–22

Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Inoue A, et al. **Brain Res Mol Brain Res** 1998 Apr;55(2):285–92

Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Meng ZH, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):39–50

Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain. Nakahara T, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):238–42

Desensitization and enhancement of neurotensin/neuromedin N mRNA responses in subsets of rat caudate-putamen neurons following multiple administrations of haloperidol. Zahm DS, et al. **Brain Res Mol Brain Res** 1998 Aug 31; 59(2):196–204

Haloperidol effect on intracellular signals system coupled to alpha1-adrenergic receptor in rat cerebral frontal cortex. Borda T, et al. **Cell Signal** 1999 Apr;11(4):293–300

A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations. Stanzione P, et al. **Clin Neurophysiol** 1999 Jan;110(1):82–5

Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Tremblay PO, et al. **Eur J Neurosci** 1998 Nov;10(11):3546–55

Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine. Sebens JB, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):13–21

Chronic haloperidol alters dopamine receptors: effects of cocaine exposure during the preweaning period. Shi X, et al. **Eur J Pharmacol** 1999 Apr 16;370(3):241–9

Haloperidol-induced changes in glutathione and energy metabolism: effect of nicergoline. Vairetti M, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):67–72

Clozapine antagonizes the induction of striatal Fos expression by typical neuroleptics. Wirtshafter D. **Eur J Pharmacol** 1998 Oct 9;358(3):R1–3

Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat. Obuchowicz E, et al. **Eur Neuropsychopharmacol** 1999 Jan;9(1-2):51–9

Kinetic analysis of GM1 effects on haloperidol-induced dopaminergic supersensitivity. Palermo-Neto J, et al. **Gen Pharmacol** 1999 Feb;32(2):265–70

Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Yasui N, et al. **Int Clin Psychopharmacol** 1999 Mar;14(2):113–8

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. Ramaekers JG, et al. **J Clin Psychopharmacol** 1999 Jun;19(3):209–21

Distinct and interactive effects of d-amphetamine and haloperidol on levels of neurotensin and its mRNA in subterritories in the dorsal and ventral striatum of the rat. Zahm DS, et al. **J Comp Neurol** 1998 Nov 2;400(4):487–503

Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. Broderick PA, et al. **J Neural Transm** 1998; 105(6-7):749–67

A single neonatal dose of methamphetamine suppresses dentate granule cell proliferation in adult gerbils which is restored to control values by acute doses of haloperidol. Hildebrandt K, et al. **J Neural Transm** 1999;106(5-6):549–58

Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. Barrientos A, et al. **J Neurosci Res** 1998 Aug 15; 53(4):475–81

Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. Arvanov VL, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1000–6

S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. Millan MJ, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1002–14

Comparison of effects of haloperidol administration on amphetamine-stimulated dopamine release in the rat medial prefrontal cortex and dorsal striatum. Pehek EA. **J Pharmacol Exp Ther** 1999 Apr;289(1):14–23

Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. Yao JK, et al. **J Psychiatr Res** 1998 Nov-Dec;32(6):385–91

Effects of bromocriptine and haloperidol on prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/P2 auditory-evoked response in man. Abduljawad KA, et al. **J Psychopharmacol** 1999;13(1):3–9

A comparison of the effects of olanzapine, haloperidol and

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

placebo on cognitive and psychomotor functions in healthy elderly volunteers. Beuzen JN, et al. **J Psychopharmacol** 1999;13(2):152–8

Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man [letter] Martin-Iverson MT. **J Psychopharmacol** 1999;13(2):198–9

Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats. Elazar Z, et al. **Life Sci** 1999;64(13):1117–25

The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption. Joordens RJ, et al. **Life Sci** 1998;63(25):2227–32

Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Ossowska K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr; 359(4):280–7

Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Balijepalli S, et al. **Neuropharmacology** 1999 Apr;38(4):567–77

Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients. Fukuzako H, et al. **Neuropsychopharmacology** 1999 Oct;21(4):542–9

Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine. Pinna A, et al. **Neuropsychopharmacology** 1999 Jul;21(1):93–100

Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Pinna A, et al. **Neuropsychopharmacology** 1999 Jan;20(1):44–51

Globus pallidus lesions inhibit the induction of c-Fos by haloperidol in the basal ganglia output nuclei in rats. Miwa H, et al. **Neurosci Lett** 1998 Jun 26;250(1):29–32

Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Andreassen OA, et al. **Neuroscience** 1998 Dec;87(3):639–48

The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Andreassen OA, et al. **Neuroscience** 1999 Jan;88(1):27–35

Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release. Moore H, et al. **Neuroscience** 1999;88(3):811–22

Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Ward RP, et al. **Neuroscience** 1999 Mar;89(3):927–38

Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment. Arnaiz SL, et al. **Nitric Oxide** 1999 Jun;3(3):235–43

Dose dependency of sex differences in the effects of repeated haloperidol administration in avoidance conditioning in mice. Arenas MC, et al. **Pharmacol Biochem Behav** 1999 Apr;62(4):703–9

Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pretreatment. Basso AM, et al. **Pharmacol Biochem Behav** 1999 Feb;62(2):307–14

Modulatory effects of ascorbate, alone or with haloperidol, on a lever-release conditioned avoidance response task. Gulley JM, et al. **Pharmacol Biochem Behav** 1999 May; 63(1):125–9

Localizing haloperidol effects on sensorimotor gating in a predictive model of antipsychotic potency. Hart S, et al. **Pharmacol Biochem Behav** 1998 Sep;61(1):113–9

Effects of haloperidol on communicative and aggressive behavior in male mice with different experiences of aggression. Kudryavtseva NN, et al. **Pharmacol Biochem Behav** 1999 Jun;63(2):229–36

Haloperidol does not attenuate conditioned place preferences or locomotor activation produced by food- or heroin-predictive discriminative cues. McFarland K, et al. **Pharmacol Biochem Behav** 1999 Apr;62(4):631–41

Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice. Rodriguez-Arias M, et al. **Pharmacol Biochem Behav** 1999 Sep;64(1):123–30

Effects of repeated low dose administration and withdrawal of haloperidol on sexual behaviour of male rats. Tupala E, et al. **Pharmacol Toxicol** 1999 Jun;84(6):292–5

Influence of long-lasting administration of neuroleptics on cortical NMDA receptors and phencyclidine-induced deficit in the sensorimotor gating in rats. Ossowska K, et al. **Pol J Pharmacol** 1999 Jan-Feb;51(1):49–53 (41 ref.)

Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. Fischer V, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1129–39

Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not. Fowler SC, et al. **Psychopharmacology (Berl)** 1998 Nov;140(1):81–90

Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Japha K, et al. **Psychopharmacology (Berl)** 1999 Jun;144(4):347–54

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Krystal JH, et al. **Psychopharmacology (Berl)** 1999 Jul;145(2):193–204

Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. Mohr P, et al. **Psychopharmacology (Berl)** 1999 Jan;141(3):322–5

Characterizing withdrawal in rats following repeated drug administration using an amphetamine-vehicle-haloperidol drug discrimination. Stadler JR, et al. **Psychopharmacology (Berl)** 1999 Apr;143(3):219–26

Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Young CD, et al. **Psychopharmacology (Berl)** 1999 Jun;144(3):255–63

Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain. Frederick JA, et al. **Schizophr Res** 1999 Jul 27;38(1):7–12

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Kee KS, et al. **Schizophr Res** 1998 May 25;31(2-3):159–65

NMDA receptor blockade attenuates the haloperidol induction of Fos protein in the dorsal but not the ventral striatum. de Souza IE, et al. **Synapse** 1999 Jun 15; 32(4):243–53

Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs. Gueudet C, et al. **Synapse** 1999 Jul;33(1):71–9

Chronic clozapine, but not haloperidol, alters the response of mesoprefrontal dopamine neurons to stress and clozapine challenges in rats. Morrow BA, et al. **Synapse** 1999 Oct; 34(1):28–35

Enhancement of N-methyl-D-aspartate (NMDA) immunoreactivity in residual dendritic spines in the caudate-putamen nucleus after chronic haloperidol administration. Rodriguez JJ, et al. **Synapse** 1999 Sep 15; 33(4):289–303

[Inhibition of voltage-dependent K+ currents in rat C6 glioma cells by haloperidol and R(-)-NPA] Xie Z, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):45–53 (Eng. Abstr.) **(Chi)**

[Intercentral interactions during typical and atypical neuroleptics administration] Kachalova LM, et al. **Biull Eksp Biol Med** 1999 May;127(5):512–5 **(Rus)**

[Haloperidol induces changes in the electrocorticogram of rats with genetic petit mal epilepsy] Midzianovskaia IS. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov-Dec; 48(6):1111–4 (Eng. Abstr.) **(Rus)**

[The characteristics of the development of cataleptic phenomena during the action of a new Ukrainian neuroleptic--a butyrophenone derivative--in experiments on mice] Shapovalova VO, et al. **Fiziol Zh** 1999;45(3):114–7 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension. Maixner S, et al. **Am J Psychiatry** 1998 Nov;155(11):1600–2

Olanzapine versus haloperidol treatment in first-episode psychosis. Sanger TM, et al. **Am J Psychiatry** 1999 Jan; 156(1):79–87

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia [see comments] Breier A, et al. **Biol Psychiatry** 1999 Feb 15; 45(4):403–11. Comment in: Biol Psychiatry 1999 Feb 15;45(4):383–4.

Modulation of language processing in schizophrenia: effects of context and haloperidol on the event-related potential. Condray R, et al. **Biol Psychiatry** 1999 May 15; 45(10):1336–55

Predictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck R, et al. **Biol Psychiatry** 1998 Sep 15;44(6):475–82

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Tran PV, et al. **Br J Psychiatry** 1999 Jan;174:15–22

Successful treatment of catastrophic antiphospholipid syndrome in a pregnant woman [letter] Wislowska M. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):261

The use of haloperidol and valproate in children with Sydenham chorea. Ronchezel MV, et al. **Indian Pediatr** 1998 Dec;35(12):1215–8

A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Berk M, et al. **Int Clin Psychopharmacol** 1999 May;14(3):177–80

The treatment of negative symptoms: a clinical and methodological study. Lapierre YD, et al. **Int Clin Psychopharmacol** 1999 Mar;14(2):101–12

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Ulrich S, et al. **Int Clin Psychopharmacol** 1999 Jul;14(4):219–28

Haloperidol for Tourette's disorder plus selective mutism [letter] Rupp SN. **J Am Acad Child Adolesc Psychiatry** 1999 Jan;38(1):7

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis SL, et al. **J Clin Psychiatry** 1999;60 Suppl 19:38–45; discussion 46

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Tunis SL, et al. **Med Care** 1999 Jul; 37(7):678–91

Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Rosebush PI, et al. **Neurology** 1999 Mar 10;52(4):782–5

The use of haloperidol to treat nausea. Mickle J. **Oncol Nurs Forum** 1998 Sep;25(8):1309

Combined treatment of schizophrenic psychoses with haloperidol and valproate. Dose M, et al. **Pharmacopsychiatry** 1998 Jul;31(4):122–5

Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Chou JC, et al. **Psychiatry Res** 1998 Oct 19;81(1):51–5

Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Markianos M, et al. **Psychopharmacology (Berl)** 1999 Apr; 143(3):270–2

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Revicki DA, et al. **Qual Life Res** 1999 Aug;8(5):417–26

Alcohol dependence and hospitalization in schizophrenia. Gerding LB, et al. **Schizophr Res** 1999 Jul 27;38(1):71–5

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Tollefson GD, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S13–21

TOXICITY

Behavioural alterations in rats induced by single prenatal exposure of haloperidol. Singh KP, et al. **Indian J Exp Biol** 1998 Nov;36(11):1102–7

Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. Post A, et al. **J Neurosci** 1998 Oct 15;18(20):8236–46

Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14. Rasmussen E, et al. **J Pharmacol Exp Ther** 1999 Sep; 290(3):1337–46

Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Wadenberg ML, et al. **Neuropharmacology** 1999 Jan;38(1):151–6

Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Gao XM, et al. **Neuropsychopharmacology** 1998 Nov; 19(5):428–33

Postural effects of unilateral blockade of glutamatergic neurotransmission in the subthalamic nucleus on haloperidol-induced akinesia in rats. Miwa H, et al. **Neurosci Lett** 1998 Aug 21;252(3):167–70

HALOPHILES, EXTREME see **HALOBACTERIALES**

HALOTHANE

The respiratory effects of tramadol in children under halothane an anaesthesia. Bösenberg AT, et al. **Anaesthesia** 1998 Oct;53(10):960–4

Recovery characteristics of sevoflurane and halothane in preschool-aged children undergoing bilateral myringotomy and pressure equalization tube insertion. Davis PJ, et al. **Anesth Analg** 1999 Jan;88(1):34–8

Where wrong practice is a necessity [letter] Hooda S. **Anesth Analg** 1999 Jan;88(1):233

Recovery after halothane anaesthesia induced with thiopental, propofol-alfentanil or halothane for day-case adenoidectomy in small children. Viitanen H, et al. **Br J Anaesth** 1998 Dec;81(6):960–2

Induction characteristics of thiopentone/suxamethonium, propofol/alfentanil or halothane alone in children aged 1–3 years. Annila P, et al. **Eur J Anaesthesiol** 1999 Jun; 16(6):359–66

Effects of theophylline on human cerebral blood flow velocity during halothane and isoflurane anaesthesia. Mühling J, et al. **Eur J Anaesthesiol** 1999 Jun;16(6):380–6

Effects of the halothane genotype and slaughter weight on texture of pork. Monin G, et al. **J Anim Sci** 1999 Feb; 77(2):408–15

Modulation of receptive field properties of thalamic somatosensory neurons by the depth of anesthesia. Friedberg MH, et al. **J Neurophysiol** 1999 May; 81(5):2243–52

Pituitary-adrenocortical effects of methoxamine infusion on halothane anaesthetised ponies. Brodbelt DC, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):119–23

The cardiopulmonary effects of clenbuterol when administered to dorsally recumbent halothane-anaesthetised ponies--failure to increase arterial oxygenation. Lee YH, et al. **Res Vet Sci** 1998 Nov-Dec; 65(3):227–32

Effects of hypercapnia on endocrine and metabolic responses to anaesthesia in ponies. Taylor PM. **Res Vet Sci** 1998 Jul-Aug;65(1):41–6

Effects of hypoxia on endocrine and metabolic responses to anaesthesia in ponies. Taylor PM. **Res Vet Sci** 1999 Feb; 66(1):39–44

Effects of ketamine on the equine electroencephalogram during anesthesia with halothane in oxygen. Johnson CB, et al. **Vet Surg** 1999 Sep-Oct;28(5):380–5

Inhalation anaesthesia for the castration of piglets: CO2 compared to halothane. Kohler I, et al. **Zentralbl Veterinarmed A** 1998 Dec;45(10):625–33

[Propofol for intubation of infants after halothane induction] Schippel P, et al. **Anaesthesist** 1999 May;48(5):317–24 (Eng. Abstr.) **(Ger)**

[Effects of nitric oxide synthase inhibitor on skin blood flow responses to acute isovolemic hemodilution during halothane and isoflurane anesthesia] Hirose Y, et al. **Masui** 1998 Aug;47(8):918–24 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Sevoflurane causes more postoperative agitation in children than does halothane. Beskow A, et al. **Acta Anaesthesiol Scand** 1999 May;43(5):536–41

Halothane requirement--a comparison between laryngeal mask airway insertion and endotracheal tube intubation in pediatric patients. Li CY, et al. **Acta Anaesthesiol Sin** 1998 Mar;36(1):37–41

Halothane minimum alveolar anesthetic concentration and neuronal nitric oxide synthase activity of the dorsal horn and the locus ceruleus in rats. Fukuda T, et al. **Anesth Analg** 1999 Oct;89(4):1035–9

The anesthetic and physiologic effects of an intravenous administration of a halothane lipid emulsion (5% vol/vol). Musser JB, et al. **Anesth Analg** 1999 Mar;88(3):671–5

Halothane for supplementation of general anesthesia during cesarean section [letter] Baraka A, et al. **Can J Anaesth** 1999 Jan;46(1):95–6

Landiolol decreases a dysrhythmogenic dose of epinephrine in dogs during halothane anesthesia. Takahashi S, et al. **Can J Anaesth** 1999 Jun;46(6):599–604

Effects of sevoflurane anaesthesia on recovery in children: a comparison with halothane [see comments] Lapin SL, et al. **Paediatr Anaesth** 1999;9(4):299–304. Comment in: Paediatr Anaesth 1999 ;9(4):283–6.

ADVERSE EFFECTS

Preoperative anxiety is associated with a high incidence of problematic behavior on emergence after halothane anesthesia in boys. Aono J, et al. **Acta Anaesthesiol Scand** 1999 May;43(5):542–4

Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Portel L, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):107–10

Functional brain imaging during anesthesia in humans: effects of halothane on global and regional cerebral glucose metabolism. Alkire MT, et al. **Anesthesiology** 1999 Mar; 90(3):701–9

Anesthetic gas exposure in veterinary clinics. Korczynski RE. **Appl Occup Environ Hyg** 1999 Jun;14(6):384–90

Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation [see comments] Lo SK, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):635–9. Comment in: Eur J Gastroenterol Hepatol 1998 Aug;10(8):631–3.

Halothane hepatitis [comment] Neuberger J. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):631–3. Comment on: Eur J Gastroenterol Hepatol 1998 Aug;10(8):635–9.

Halothane and post-halothane exposure hepatitis [letter] Buchanan CC, et al. **N Z Med J** 1999 Jan 22; 112(1080):19–20

Halothane, children and original sources [letter] Donnelly J. **Paediatr Anaesth** 1999;9(4):367–8; discussion 368–9

Signs of an MH reaction [letter] Khalil SN, et al. **Paediatr Anaesth** 1999;9(3):277–8

[Sever acute pulmonary edema after peri-anesthetic laryngospasm in a newborn infant] Carré P, et al. **Ann Fr Anesth Reanim** 1998;17(9):1140–3 (Eng. Abstr.) **(Fre)**

[Fatal hepatitis in a young child: probable role of halothane] Mjahed K, et al. **Ann Fr Anesth Reanim** 1997;16(5):531–3 (Eng. Abstr.) **(Fre)**

[The effect of halothane, enflurane and isoflurane on the pharmacodynamics of mivacurium in children. G. Neidhart, C. Pabelick, I. Kuhn, M. Leuwer, J. Vetterman, AINS 31:293–297, 1996 (letter; comment)] Cramer R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):384. Comment on: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):293–7. **(Ger)**

[Neurotoxicity of inhalation anesthetics, halothane] Takagi A. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):505–6 (4 ref.) **(Jpn)**

[Malignant hyperthermia: difficulty in diagnosing susceptibility in Spain (letter)] Montes A, et al. **Rev Esp Anestesiol Reanim** 1999 Mar;46(3):130–2 **(Spa)**

ANALYSIS

Factitious halothane detection during trigger-free anesthesia in a malignant hyperthermia susceptible patient. Hawkes CA. **Can J Anaesth** 1999 Jun;46(6):567–70

[Evaluation of exposure to halothane and ethyl alcohol among technicians responsible for maintenance of anesthesia equipment] Kamieńska-Zyla M, et al. **Med Pr** 1998;49(3):275–9 (Eng. Abstr.) **(Pol)**

[Levels of "waste" halothane in operating rooms at gynecologic and obstetrical clinics--preliminary results] Prokeš B. **Med Pregl** 1998 Nov-Dec;51(11-12):532–6 (Eng. Abstr.) **(Scr)**

BLOOD

The effect of a right-to-left intracardiac shunt on the rate of rise of arterial and end-tidal halothane in children. Huntington JH, et al. **Anesth Analg** 1999 Apr;88(4):759–62

CHEMISTRY

Computer simulation study of synthetic 4-helix bundle that binds halothane. Woska AB, et al. **Toxicol Lett** 1998 Nov 23;100-101:377–85

HISTORY

Postoperative hepatic dysfunction in perspective. 1970 [classical article] Dykes MH. **Int Anesthesiol Clin** 1998 Fall; 36(4):155–62

Halothane. 1963 [classical article] Summers FW. **Int Anesthesiol Clin** 1998 Fall;36(4):83–96

IMMUNOLOGY

Halothane effect on formalin-induced paw edema and flinching in rat. Lee IO, et al. **J Korean Med Sci** 1999 Feb; 14(1):34–8

METABOLISM

Molecular dynamics simulation of a synthetic four-alpha-helix bundle that binds the anesthetic halothane. Davies LA, et al. **FEBS Lett** 1999 Jul 23;455(3):332–8

PHARMACOLOGY

Halothane decreases bacterial adherence in vitro. Batai I, et al. **Acta Anaesthesiol Scand** 1999 Aug;43(7):760–3

The direct effect of halothane on myocardial contraction in rat myocytes with poorly developed gap junctional intercellular communication. Kanaya N, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):91–6

Hepatolobectomy-induced depression of hepatic circulation and metabolism in the dog is counteracted by isoflurane, but not by halothane. Matsumoto N, et al. **Acta Anaesthesiol Scand** 1999 Sep;43(8):850–4

Caffeine- or halothane-induced contractures of masseter muscle are similar to those of vastus muscle in normal humans. Melton AT, et al. **Acta Anaesthesiol Scand** 1999 Aug;43(7):764–9

The influence of the concentration of volatile anesthetics on the stapedius reflex determined intraoperatively during cochlear implantation in children. Makhdoum MJ, et al. **Am J Otol** 1998 Sep;19(5):598–603

Effect of halothane on intracellular calcium oscillations in porcine tracheal smooth muscle cells. Pabelick CM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L81–9

The combined effects of halothane and lamotrigine on excitatory postsynaptic potentials and use-dependent block in the rat dentate gyrus in vitro. Frizelle HP, et al. **Anesth Analg** 1999 Aug;89(2):496–501

Halothane stimulates a Na+H+ antiporter involved in the regulation of intracellular pH in alveolar epithelial cells. Juvin P, et al. **Anesth Analg** 1999 Aug;89(2):480–3

Comparative myocardial depression of sevoflurane, isoflurane, and halothane in cultured neonatal rat ventricular myocytes. Kanaya N, et al. **Anesth Analg** 1998 Nov;87(5):1041–7

The effect of halothane on the amplitude and frequency characteristics of heart sounds in children. Manecke GR Jr, et al. **Anesth Analg** 1999 Feb;88(2):263–7

Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. Mather LE, et al. **Anesth Analg** 1999 Jul;89(1):230–5

Pretreatment with dexmedetomidine: altered indices of anesthetic depth for halothane in the neuraxis of cats. Schmeling WT, et al. **Anesth Analg** 1999 Mar;88(3):625–32

Halothane, but not the nonimmobilizers perfluoropentane and 1,2-dichlorohexafluorocyclobutane, depresses synaptic transmission in hippocampal CA1 neurons in rats. Taylor DM, et al. **Anesth Analg** 1999 Oct;89(4):1040–5

Halothane attenuates nitroglycerin-induced vasodilation and a decrease in intracellular Ca2+ in the rat thoracic aorta. Tsuchida H, et al. **Anesth Analg** 1999 Jul;89(1):49–54

ATX II, a sodium channel toxin, sensitizes skeletal muscle to halothane, caffeine, and ryanodine. Fletcher JE, et al. **Anesthesiology** 1999 May;90(5):1294–301

Contribution of peripheral chemoreception to the depression of the hypoxic ventilatory response during halothane anesthesia in cats. Ide T, et al. **Anesthesiology** 1999 Apr; 90(4):1084–91

Halothane attenuates calcium sensitization in airway smooth muscle by inhibiting G-proteins. Kai T, et al. **Anesthesiology** 1998 Dec;89(6):1543–52

Volatile anesthetics increase intracellular calcium in cerebrocortical and hippocampal neurons. Kindler CH, et al. **Anesthesiology** 1999 Apr;90(4):1137–45

Differential effects of sevoflurane, isoflurane, and halothane on Ca2+ release from the sarcoplasmic reticulum of skeletal muscle. Kunst G, et al. **Anesthesiology** 1999 Jul; 91(1):179–86

Halothane presynaptically depresses synaptic transmission in wild-type Drosophila larvae but not in halothane-resistant (har) mutants. Nishikawa K, et al. **Anesthesiology** 1999 Jun; 90(6):1691–7

Specific actions of halothane, isoflurane, and desflurane on sympathetic activity and A delta and C somatosympathetic reflexes recorded in renal nerves in dogs. Pac-Soo CK, et al. **Anesthesiology** 1999 Aug;91(2):470–8

Halothane induces calcium release from human skinned masseter muscle fibers. Reyford H, et al. **Anesthesiology** 1999 Apr;90(4):1019–25

Effects of halothane and isoflurane on fast and slow inactivation of human heart hH1a sodium channels. Stadnicka A, et al. **Anesthesiology** 1999 Jun;90(6):1671–83

Effects of halothane on synaptic neurotransmission to medullary expiratory neurons in the ventral respiratory group of dogs. Stuth EA, et al. **Anesthesiology** 1999 Sep; 91(3):804–14

Effects of halothane and isoflurane on beta-adrenoceptor-mediated responses in the vascular smooth muscle of rat aorta. Tanaka S, et al. **Anesthesiology** 1998 Nov;89(5):1209–17

Common genetic determinants of halothane and isoflurane potencies in Caenorhabditis elegans. van Swinderen B, et al. **Anesthesiology** 1998 Dec;89(6):1509–17

Microcirculatory response to halothane and isoflurane anesthesia. Kusza K, et al. **Ann Plast Surg** 1999 Jul; 43(1):57–66

Effects of halothane on mechanical response of skeletal muscle from malignant hyperthermia susceptible patients. Etchrivi TS, et al. **Arch Physiol Biochem** 1998 Oct; 106(4):318–24

Different anesthetic sensitivities of skeletal and cardiac isoforms of the Ca-ATPase. Karon BS, et al. **Biochemistry** 1999 Jul 20;38(29):9301–7

Halothane, an inhalational anesthetic agent, increases folding stability of serum albumin. Tanner JW, et al. **Biochim Biophys Acta** 1999 Feb 10;1430(1):46–56

Effects of anesthetics on the structure of a phospholipid bilayer: molecular dynamics investigation of halothane in the hydrated liquid crystal phase of dipalmitoylphosphatidylcholine. Tu K, et al. **Biophys J** 1998 Nov;75(5):2123–34

Mechanisms underlying the inotropic action of halothane on intact rat ventricular myocytes. Harrison SM, et al. **Br J Anaesth** 1999 Apr;82(4):609–21

Early and late post-ischaemic recovery of contractile function is affected to different degrees by isoflurane and halothane in the anaesthetized rabbit model. Ross SA, et al. **Br J Anaesth** 1998 Aug;81(2):224–9

Halothane enhances exocytosis of [3H]-acetylcholine without increasing calcium influx in rat brain cortical slices. Gomez RS, et al. **Br J Pharmacol** 1999 Jun;127(3):679–84

Presynaptic and postsynaptic actions of halothane at glutamatergic synapses in the mouse hippocampus. Kirson ED, et al. **Br J Pharmacol** 1998 Aug;124(8):1607–14

Volatile anesthetic inhibition of neuronal Ca channel currents expressed in Xenopus oocytes. Kamatchi GL, et al. **Brain Res** 1999 Jun 12;831(1-2):85–96

Halothane depresses action potential conduction in hippocampal axons. Mikulec AA, et al. **Brain Res** 1998 Jun 15;796(1-2):231–8

Volatile anesthetics directly activate baseline S K+ channels in aplysia neurons. Winegar BD, et al. **Brain Res** 1998 Oct 5;807(1-2):255–62

Effects of halothane and methoxyflurane on the hypothalamic-pituitary-adrenal axis in rat. Karuri AR, et al. **Brain Res Bull** 1998 Oct;47(3):205–9

Anesthetic modulation of myocardial ischemia and reperfusion injury in pigs: comparison between halothane and sevoflurane. Conradie S, et al. **Can J Anaesth** 1999 Jan;46(1):71–81

Anesthetic potency and cardiopulmonary effects of sevoflurane in goats: comparison with isoflurane and halothane. Hikasa Y, et al. **Can J Vet Res** 1998 Oct; 62(4):299–306

Halothane as a neuroprotectant during constant stimulation of the perforant path. Walker MC, et al. **Epilepsia** 1999 Mar;40(3):359–64

Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children. Michaloudis D, et al. **Eur J Anaesthesiol** 1998 Nov; 15(6):623–8

Two types of TTX-resistant and one TTX-sensitive Na+ channel in rat dorsal root ganglion neurons and their blockade by halothane. Scholz A, et al. **Eur J Neurosci** 1998 Aug;10(8):2547–56

Complex formation of skeletal muscle Ca2+-regulatory membrane proteins by halothane. Froemming GR, et al. **Eur J Pharmacol** 1999 Jan 15;365(1):91–102

Effects of halothane on renal hemodynamics and interstitial nitric oxide in rabbits. Nishiyama A, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):299–306

The influence of propofol and midazolam/halothane anesthesia on hepatic SvO2 and gastric mucosal pH during cardiopulmonary bypass. Christiansen CL, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):418–21

Cutaneous responsiveness of lumbar spinal dorsal horn neurons is reduced by general anesthesia, an effect dependent in part on GABAA mechanisms. Ota K, et al. **J Neurophysiol** 1998 Sep;80(3):1383–90

A system for the delivery of general anesthetics and other volatile agents to the fruit-fly Drosophila melanogaster. Walcourt A, et al. **J Neurosci Methods** 1998 Oct 1; 84(1-2):115–9

Effects of postischemic halothane administration on outcome from transient focal cerebral ischemia in the rat. Sarraf-Yazdi S, et al. **J Neurosurg Anesthesiol** 1999 Jan; 11(1):31–6

Influence of halothane on phospholipase A2 and enzymatic methylations in the rat retinal membranes. Sastry BV, et al. **J Ocul Pharmacol Ther** 1999 Apr;15(2):165–78

Endocrine and metabolic responses to plasma volume expansion during halothane anesthesia in ponies. Taylor

PM. **J Vet Pharmacol Ther** 1998 Dec;21(6):485–90

Medullary catecholaminergic projections to the ventrolateral periaqueductal gray region activated by halothane anaesthesia. Clement CI, et al. **Neuroscience** 1998 Oct; 86(4):1273–84

Inhibition of excitatory neurotransmitter-nitric oxide signaling pathway by inhalational anesthetics. Zuo Z, et al. **Neuroscience** 1999;93(3):1167–72

Can a difference in chest wall mechanics explain the lower respiratory drive during propofol versus halothane anesthesia in children? Brown K. **Pediatr Pulmonol** 1998 Sep;26(3):183–9

Effects of halothane and urethane-chloralose anaesthesia on the pressor and cerebrovascular responses to 7-NITROINDAZOLE, an inhibitor of nitric oxide synthase. Zagvazdin Y, et al. **Pharmacol Res** 1998 Nov; 38(5):339–46

Changes in plasma cortisol concentrations in bitches in response to different combinations of halothane and butorphanol, with or without ovariohysterectomy. Fox SM, et al. **Res Vet Sci** 1998 Sep–Oct;65(2):125–33

Skeletal muscle damage following halothane anaesthesia in the domestic fowl: plasma biochemical responses. Mitchell MA, et al. **Res Vet Sci** 1999 Aug;67(1):59–64

Cutaneous microdialysis in the rat: insertion trauma and effect of anaesthesia studied by laser Doppler perfusion imaging and histamine release. Groth L, et al. **Skin Pharmacol Appl Skin Physiol** 1998 May–Jun; 11(3):125–32

Mechanism of action of volatile anesthetics: effects of halothane on glutamate receptors in vitro. Perouansky M, et al. **Toxicol Lett** 1998 Nov 23;100–101:65–9

Effects of halothane and supporting membrane lipids on the activity of acetylcholinesterase. Tsukamoto I, et al. **Toxicol Lett** 1998 Nov 23;100–101:447–50

Effects on the intramuscular blood flow and cardiopulmonary function of anaesthetised ponies of changing from halothane to isoflurane maintenance and vice versa. Lee YH, et al. **Vet Rec** 1998 Dec 5;143(23):629–33

Effects of glucose infusion on the endocrine, metabolic and cardiorespiratory responses to halothane anaesthesia of ponies. Luna SP, et al. **Vet Rec** 1999 Jul 24;145(4):100–3

Prolonged sevoflurane, isoflurane and halothane anaesthesia in oxygen using rebreathing or non-rebreathing system in cats. Hikasa Y, et al. **Zentralbl Veterinarmed A** 1998 Nov; 45(9):559–75

[Sevoflurane (SEVOrane) as an inhalation anesthetic in dogs in comparison with halothane and isoflurane] Tacke S, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Nov; 26(6):369–77 (Eng. Abstr.) **(Ger)**

[The energy parameters of the liver mitochondria under the prolonged action of halothane in vitro] Ovchinnikov IV, et al. **Eksp Klin Farmakol** 1998 Jul–Aug;61(4):38–40 (Eng. Abstr.) **(Rus)**

[Discordance and cosegregation of swine halothane susceptibility and 1843 C-T mutation of their RYR1 locus responsible for the ryanodine receptor] Kniazev SP, et al. **Genetika** 1998 Dec;34(12):1648–54 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[Protective effects of halothane on ischemic reperfusion injury on rat perfused hearts] Honda O, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1292–6 (Eng. Abstr.) **(Jpn)**

TOXICITY

Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats. Zhang X, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):1004–9

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Eliasson E, et al. **Chem Biol Interact** 1998 Nov 6;116(1–2):123–41

1,1,1-Trifluoro-2,2-dichloroethane (HCFC-123) and 1,1,1-trifluoro-2-bromo-2-chloroethane (halothane) cause similar biochemical effects in rats exposed by inhalation for five days. Keller DA, et al. **Drug Chem Toxicol** 1998 Nov;21(4):405–15

Genotoxicity of inhalation anesthetics halothane and isoflurane in human lymphocytes studied in vitro using the comet assay. Jaloszyński P, et al. **Mutat Res** 1999 Feb 19; 439(2):199–206

Eltanolone (5-beta-pregnanolone) does not trigger, and attenuates halothane triggering of, malignant hyperthermia in malignant hyperthermia susceptible swine. Harrison GG, et al. **Pharmacol Res** 1999 Feb;39(2):103–6

Role of potassium channels in halothane-epinephrine arrhythmias. Zhang S, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jun;100(3):339–50

HALSTED MASTECTOMY see **MASTECTOMY, RADICAL**

HAMADRYAS see **PAPIO**

HAMAMELIDAE

Similarity in seasonal appearance between atmospheric birch-pollen grains and allergen in paucimicronic, size-fractionated ambient aerosol. Spieksma FT, et al. **Allergy** 1999 Mar;54(3):235–41

GENETICS

Characterization of Urtica dioica agglutinin isolectins and the encoding gene family. Does MP, et al. **Plant Mol Biol** 1999 Jan;39(2):335–47

Processing, targeting, and antifungal activity of stinging nettle agglutinin in transgenic tobacco. Does MP, et al. **Plant Physiol** 1999 Jun;120(2):421–32

HAMARTOMA

Oral-facial-digital syndrome with hypothalamic hamartoma, postaxial ray hypoplasia of the limbs, and vagino-cystic communication: a new variant? Fujiwara I, et al. **Am J Med Genet** 1999 Mar 12;83(2):77–81

Mesenchymal hamartoma of the liver. Murray JD, et al. **Am Surg** 1998 Nov;64(11):1097–103

Bifid scrotum, perineal hamartoma and high imperforate anus: a case report. Villarreal DH, et al. **Bol Asoc Med P R** 1998 Apr–Jun;90(4–6):93–4

Mesenchymal hamartoma of the liver--new insight into histogenesis. von Schweinitz D, et al. **J Pediatr Surg** 1999 Aug;34(8):1269–71

Pallister-Hall syndrome [letter; comment] Biesecker LG, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):556. Comment on: Otolaryngol Head Neck Surg 1997 Jan;116(1):129–33.

Spinal teratomas versus hamartomas [letter; comment] James HE. **Pediatr Neurosurg** 1998 Jul;29(1):53. Comment on: Pediatr Neurosurg 1997 Nov;27(5):242–5.

Hypothalamic hamartoma associated with multiple congenital abnormalities. Two patients and a review of reported cases. Tsugu H, et al. **Pediatr Neurosurg** 1998 Dec; 29(6):290–6 (31 ref.)

BLOOD

Gonadotrophin and prolactin secretory dynamics in girls with normal puberty, idiopathic precocious puberty and precocious puberty due to hypothalamic hamartoma. Uriarte MM, et al. **Clin Endocrinol (Oxf)** 1998 Sep; 49(3):363–8

CLASSIFICATION

How many types of biliary hamartomas and adenomas are there? Tsui WM. **Adv Anat Pathol** 1998 Jan;5(1):16–20 (28 ref.)

Folliculo-sebaceous cystic hamartoma is but the sebaceous end of tricho-sebo-folliculoma spectrum [letter; comment] Simón RS, et al. **J Cutan Pathol** 1999 Feb;26(2):109. Comment on: J Cutan Pathol 1998 Aug;25(7):341–53. Comment on: J Cutan Pathol 1998 Aug;25(7):354–64.

COMPLICATIONS

Syringocystadenoma papilliferum without an antecedent naevus sebaceous [letter] Koga T, et al. **Acta Derm Venereol** 1999 May;79(3):237

Vascular hamartoma: another cause of testicular torsion in a newborn [letter] Bodas A, et al. **Acta Paediatr** 1998 Aug; 87(8):910

Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. de Brito VN, et al. **Arch Dis Child** 1999 Mar;80(3):231–4

Retinal hamartoma in oral-facial-digital syndrome. Tsai PS, et al. **Arch Ophthalmol** 1999 Jul;117(7):963–5

Two cases of vasculitis of the urinary bladder: diagnostic and pathogenetic considerations. Fischer AH, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):903–6

Autonomic and hormonal ictal changes in gelastic seizures from hypothalamic hamartomas. Cerullo A, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 107(5):317–22

Iron deficiency anemia due to a Brunner's gland hamartoma. Zangara J, et al. **J Clin Gastroenterol** 1998 Dec;27(4):353–6

Spontaneous rupture of splenic hamartoma: a case report. Yoshizawa J, et al. **J Pediatr Surg** 1999 Mar;34(3):498–9 (8 ref.)

Brunner's gland hamartoma causing gastric outlet obstructive symptoms. Lingawi SS, et al. **South Med J** 1998 Oct; 91(10):964–5

Coexisting extraadrenal pheochromocytoma and von Meyenberg complexes: report of a case. Tanaka F, et al. **Surg Today** 1999;29(1):80–2

[Multiple trichodiscomas associated with colonic polyposis] Le Guyadec T, et al. **Ann Dermatol Venereol** 1998 Oct; 125(10):717–9 (Eng. Abstr.) **(Fre)**

[Fibrous hamartoma of the urachus. Report of a case complicated by strangulation of the stalk] Panero D, et al. **Minerva Chir** 1998 Dec;53(12):1047–9 (Eng. Abstr.) **(Ita)**

[A case of hypothalamic hamartoma manifesting gelastic seizure and multifocal independent seizure foci] Kitajima K, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):305–10 (Eng. Abstr.) **(Jpn)**

[Giant Brunner's gland hamartoma as a cause of intestinal subocclusion and hemorrhage (letter)] Madrigal B, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):459–60 (6 ref.) **(Spa)**

CONGENITAL

Prenatal diagnosis of a benign facial tumor. Magalhães JA, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):212–5 (20 ref.)

Congenital fibrous hamartoma of the hand: a case report. Janoyer M, et al. **J Pediatr Orthop B** 1999 Apr;8(2):129–31 (32 ref.)

DIAGNOSIS

Bile duct hamartomas (von Meyenburg complexes): value of MR imaging in diagnosis. Maher MM, et al. **Abdom Imaging** 1999 Mar–Apr;24(2):171–3

Midline spinal cord hamartomas: MR imaging features of two patients. Castillo M, et al. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):1169–71

Congenital cavernous sinus syndrome in a child with neurofibromatosis type 2. Yu CB, et al. **Can J Ophthalmol** 1999 Apr;34(2):101–3

Hamartoma of the suprasellar cistern in a 5-year-old girl. Boto GR, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):131–3

Benign triton tumor of the trigeminal nerve. Vajramani G, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):140–4 (8 ref.)

MR imaging of complex tail-gut cysts. Moulopoulos LA, et al. **Clin Radiol** 1999 Feb;54(2):118–22

Cranial MR imaging findings in Waardenburg syndrome: anophthalmia, and hypothalamic hamartoma. Sener RN. **Comput Med Imaging Graph** 1998 Sep–Oct;22(5):409–11

Ictal bradycardia in a patient with a hypothalamic hamartoma: a stereo-EEG study. Kahane P, et al. **Epilepsia** 1999 Apr;40(4):522–7

Huge hamartoma with inverted papilloma in the nasal cavity. Kaneko C, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S33–7

Hamartoma of the urinary bladder: case report and review of the literature. Brancatelli G, et al. **Eur Radiol** 1999; 9(1):42–4 (15 ref.)

Atypical MRI presentation of a small splenic hamartoma. Fernandez-Canton G, et al. **Eur Radiol** 1999;9(5):883–5

MRI, CT, US and ERCP in the evaluation of bile duct hamartomas (von Meyenburg complex): a case report. Wohlgemuth WA, et al. **Eur Radiol** 1998;8(9):1623–6

Chondroid hamartoma presenting as a neonatal nasal mass. Kim DW, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):253–9 (17 ref.)

Hamartoma of the urinary bladder. Ota T, et al. **Int J Urol** 1999 Apr;6(4):211–4 (10 ref.)

Iron deficiency anemia due to a Brunner's gland hamartoma. Zangara J, et al. **J Clin Gastroenterol** 1998 Dec;27(4):353–6

Unusual gastric polyp showing submucosal proliferation of glands: case report and literature review. Itoh K, et al. **J Gastroenterol** 1998 Oct;33(5):720–3 (23 ref.)

Biliary hamartomas: solitary and multiple lesions shown on current MR techniques including gadolinium enhancement. Semelka RC, et al. **J Magn Reson Imaging** 1999 Aug; 10(2):196–201

The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. Arita K, et al. **J Neurosurg** 1999 Aug; 91(2):212–20 (63 ref.)

Congenital fibrous hamartoma of the hand: a case report. Janoyer M, et al. **J Pediatr Orthop B** 1999 Apr;8(2):129–31 (32 ref.)

Familial multiple basaloid follicular hamartomas: A report of two affected sisters. Girardi M, et al. **Pediatr Dermatol** 1999 Jul–Aug;16(4):281–4

Malrotation in newborns following antenatal diagnosis of intra-abdominal cyst. Littlewood Teele R, et al. **Pediatr Radiol** 1998 Sep;28(9):717–21

Combined hamartoma of the retina and retinal pigment epithelium: a bilateral presentation. Blumenthal EZ, et al. **Retina** 1998;18(6):557–9

Surgical treatment of tracheal hamartoma. Taştepe AI, et al. **Scand Cardiovasc J** 1998;32(4):239–41

Fibrolipomatous hamartoma: pathognomonic on MR imaging. Marom EM, et al. **Skeletal Radiol** 1999 May; 28(5):260–4

[Phakomatosis pigmentovascularis (type IIIa)] Stadhouders-Keet SA, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1337 **(Dut)**

[Anemic hamartoma] Heid E. **Ann Dermatol Venereol** 1999 Jun–Jul;126(6–7):529–30 **(Fre)**

[What is a hamartoma? (letter; comment)] Revuz J. **Ann Dermatol Venereol** 1998 May;125(5):343. Comment on: Ann Dermatol Venereol 1998 Mar;125(3):165–6. **(Fre)**

[Combined hamartoma of the pigment epithelium and retina] Maalouf T, et al. **J Fr Ophtalmol** 1999 Aug–Sep;22(7):798 **(Fre)**

[An uncommon endotracheal finding] Vaylet F, et al. **Rev Mal Respir** 1999 Apr;16(2):222–3 **(Fre)**

[Atypical constellation of findings in Schimmelpenning-Feuerstein-Mims syndrome--case report and overview] Framme C, et al. **Klin Monatsbl Augenheilkd** 1998 Aug;213(2):97–103 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fibrous hamartoma of the urachus. Report of a case complicated by strangulation of the stalk] Panero D, et al. **Minerva Chir** 1998 Dec;53(12):1047–9 (Eng. Abstr.) **(Ita)**

[A case of tailgut cyst] Ito F, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):154–9 (22 ref.) **(Jpn)**

[Glial hamartoma of the papilla] Cernea P, et al. **Oftalmologia** 1998;44(3):84–7 (11 ref.) (Eng. Abstr.) **(Rum)**

[Observation of chondromatous hamartoma with the signs

of malignancy] Opanasenko NS, et al. **Klin Khir** 1999; (5):54–5 **(Rus)**

[A case of splenic hamartoma] Mustiatsé LZ, et al. **Vopr Onkol** 1998;44(6):738–9 **(Rus)**

DRUG THERAPY

Photodynamic therapy for nevus sebaceus with topical delta-aminolevulinic acid. Dierickx CC, et al. **Arch Dermatol** 1999 Jun;135(6):637–40

A cystic biliary tumour responding to regional fluorinated pyrimidine infusion. Hedayati B, et al. **Eur J Surg Oncol** 1998 Oct;24(5):451–2

Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. Feuillan PP, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):44–9

ETIOLOGY

Inflammatory linear verrucous epidermal naevus arising on a burn scar [letter] Lee IW, et al. **Acta Derm Venereol** 1999 Mar;79(2):164–5

GENETICS

Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice. Tamai Y, et al. **Cancer Res** 1999 Jun 15;59(12):2965–70

A functioning eccrine hamartoma associated with Down's syndrome (46, xx,–21,+t(21q21q). Nightingale KJ, et al. **Clin Exp Dermatol** 1998 Nov;23(6):264–6

Elastic nevus with normal expression of elastin and elastin-related proteins mRNAs. Ohnishi Y, et al. **Dermatology** 1999;198(3):307–9

Somatic mutations of the first 14 exons of APC in hamartomatous polyps of the colon. Kim JC, et al. **Hum Mutat (Online)** 1999 Oct;14(4):351–2

Third report of t(19q)(13.4) in mesenchymal hamartoma of liver with comments on link to embryonal sarcoma. Bove KE, et al. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):438–42

METABOLISM

Neurofollicular hamartoma with strong diffuse S-100 positivity: a case report. Xie DL, et al. **Am J Dermatopathol** 1999 Jun;21(3):253–5

The association of Becker nevus with hypersensitivity to androgens [letter] Nirdé P, et al. **Arch Dermatol** 1999 Feb; 135(2):212–4

Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus. Barrett TL, et al. **Mod Pathol** 1999 May;12(5):450–5

Mammary hamartomas: an immunohistochemical study of ten cases. Chiacchio R, et al. **Pathol Res Pract** 1999; 195(4):231–6

PATHOLOGY

Ectopic hamartomatous thymoma. Report of a case with fine needle aspiration biopsy findings. Hirokawa M, et al. **Acta Cytol** 1999 Mar–Apr;43(2):232–4

Fine needle aspiration cytology of fibrous hamartoma of infancy. Jadusingh IH. **Acta Cytol** 1997 Jul–Aug;41(4 Suppl):1391–3

The so-called striated muscle hamartoma is a hamartoma of cutaneous adnexa and mesenchyme, but not of striated muscle [letter] Grilli R, et al. **Acta Derm Venereol** 1998 Sep;78(5):390

Acrochordons are not a component of the Birt-Hogg-Dubé syndrome: does this syndrome exist? Case reports and review of the literature. De la Torre C, et al. **Am J Dermatopathol** 1999 Aug;21(4):369–74 (65 ref.)

Desmoplastic trichilemmoma arising within a nevus sebaceus. Rosón E, et al. **Am J Dermatopathol** 1998 Oct;20(5):495–7

Neurofollicular hamartoma with strong diffuse S-100 positivity: a case report. Xie DL, et al. **Am J Dermatopathol** 1999 Jun;21(3):253–5

Hypothalamic hamartoma: report of a case with unusual histologic features. Sharma MC, et al. **Am J Surg Pathol** 1998 Dec;22(12):1538–41

The spectrum of neurocristic cutaneous hamartoma: clinicopathologic and immunohistochemical study of three cases. Smith KJ, et al. **Ann Diagn Pathol** 1998 Aug; 2(4):213–23

Nevus sebaceus of Jadassohn associated with macro optic discs and conjunctival choristoma [letter] Kruse FE, et al. **Arch Ophthalmol** 1998 Oct;116(10):1379–81

Linear epidermal nevus and nevus sebaceus syndromes: a clinicopathologic study of 3 patients. Prayson RA, et al. **Arch Pathol Lab Med** 1999 Apr;123(4):301–5

Splenic vascular lesions: unusual features and a review of the literature. Lam KY, et al. **Aust N Z J Surg** 1999 Jun; 69(6):422–5 (64 ref.)

Brunner's gland hamartomas: report of three cases. Chen TM, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):271–6

Eccrine angiomatous hamartoma: report of seven cases. Cebreiro C, et al. **Clin Exp Dermatol** 1998 Nov;23(6):267–70

Genital variant of folliculosebaceous cystic hamartoma. Bolognia JL, et al. **Dermatology** 1998;197(3):258–60 (17 ref.)

Phacomatosis pigmentokeratotica: speckled-lentiginous nevus in association with nevus sebaceus. Langenbach N, et al. **Dermatology** 1998;197(4):377–80

Retrorectal cystic harmatoma (tailgut cyst) in an infant: case report. Rafindadi AH, et al. **East Afr Med J** 1998 Dec; 75(12):726–7

Clear cell epithelial cords in an ectopic hamartomatous thymoma [letter] Michal M, et al. **Histopathology** 1999 Jul; 35(1):89–90

Pancreatic hamartoma with Langerhans cell histiocytosis in a draining lymph node [letter] Wu SS, et al. **Histopathology** 1998 Nov;33(5):485–7

Nevus sebaceous syndrome. Jang IG, et al. **Int J Dermatol** 1999 Jul;38(7):531–3

Eccrine angiomatous hamartoma. Kwon OC, et al. **Int J Dermatol** 1998 Oct;37(10):787–9 (18 ref.)

Hamartomatous congenital melanocytic nevi showing secondary anetoderma-like changes. Cockayne SE, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):843–5

Eccrine angiomatous hamartoma: report of a case and literature review. Nakatsui TC, et al. **J Am Acad Dermatol** 1999 Jul;41(1):109–11 (31 ref.)

Multiple follicular hamartomas with sweat gland and sebaceous differentiation, vermiculate atrophoderma, milia, hypotrichosis, and late development of multiple basal cell carcinomas. Pujol RM, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):853–7

Folliculo-sebaceous cystic hamartoma is a trichofolliculoma at its very late stage [see comments] Schulz T, et al. **J Cutan Pathol** 1998 Aug;25(7):354–64. Comment in: J Cutan Pathol 1999 Feb;26(2):109.

Porokeratotic eccrine ostial and dermal duct nevus as nevus unius lateris in an Indian girl. Bhattacharya SN, et al. **J Dermatol** 1998 Oct;25(10):682–4

Solid mesenchymal hamartoma of the liver in adult. Chung JH, et al. **J Korean Med Sci** 1999 Jun;14(3):335–7

Pericoronal hamartomatous lesions in the opercula of teeth delayed in eruption: an immunohistochemical study of the extracellular matrix. Yonemochi H, et al. **J Oral Pathol Med** 1998 Oct;27(9):441–52

Peritoneal pseudomyxoma in a child with a gallbladder Peutz-Jeghers-like hamartomatous polyp: a case report. Guzmán P, et al. **J Pediatr Surg** 1998 Aug;33(8):1320–2

Cystic hamartoma of the renal pelvis: a rare pathologic entity. Mensch LS, et al. **Mod Pathol** 1999 Apr;12(4):417–21

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1999. A 33-year-old man with wide-complex tachycardia and a left ventricular mass [clinical conference] **N Engl J Med** 1999 Oct 14; 341(16):1217–24

Multiple pulmonary leiomyomatous hamartoma with secondary ossification. Kato N, et al. **Pathol Int** 1999 Mar; 49(3):222–5

A flesh-colored papule on the neck of a child [clinical conference] Chen SH, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):65–7

Fibrous hamartoma of infancy: current review. Dickey GE, et al. **Pediatr Dev Pathol** 1999 May–Jun;2(3):236–43 (55 ref.)

Malignant glial tumor arising from the site of a previous hamartoma/ganglioglioma: coincidence or malignant transformation? Mittler MA, et al. **Pediatr Neurosurg** 1999 Mar;30(3):132–4

[Hepatic mesenchymal hamartoma in children. Immunohistochemical, ultrastructural and flow cytometric case study] Justrabo E, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):964–8 (Eng. Abstr.) **(Fre)**

[Syringocystadenoma papilliferum and trichoblastoma within a sebaceous nevus] Karnbach C, et al. **Hautarzt** 1998 Aug; 49(8):654–6 (Eng. Abstr.) **(Ger)**

[Choristomatous and amartomatous malformations: which is the practical advantage of distinguishing them? (letter)] Cappello F. **Minerva Med** 1999 Jan–Feb;90(1–2):45–7 **(Ita)**

[Lhermitte-Duclos disease in a ten-year-old child: clinical follow-up and neuroimaging data from birth] Verdú A, et al. **Rev Neurol** 1998 Oct;27(158):597–600 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Paradoxical response to valproic acid in a patient with a hypothalamic hamartoma. Stecker MM, et al. **Ann Pharmacother** 1998 Nov;32(11):1168–72

An association of hypothalamic hamartoma, central precocious puberty and juvenile granulosa cell tumour in early childhood. Feilberg Jørgensen N, et al. **Horm Res** 1998;49(6):292–4

RADIOGRAPHY

Pulmonary hamartoma. Thomas JW, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1643

Jejunal intussusception secondary to Peutz--Jeghers type hamartoma diagnosed on angiography. Burton MJ, et al. **Clin Radiol** 1999 Jul;54(7):476–8

The role of mammography in the diagnostic approach of breast hamartomas. Aggelatou R, et al. **Eur J Gynaecol Oncol** 1998;19(4):399–400

Noncalcified pulmonary hamartomas: computed tomography enhancement patterns with histologic correlation. Potente G, et al. **J Thorac Imaging** 1999 Apr;14(2):101–4

Ectopia hepatica extrathoracica nuda associated with amelia and pulmonary agenesis. Sarin YK, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):378–9

Case of the season. Chest wall mesenchymal hamartoma. Shetty AK, et al. **Semin Roentgenol** 1998 Jul;33(3):215–7

RADIONUCLIDE IMAGING

Tc-99m methylene diphosphonate accumulation by a pulmonary hamartoma. Schechter LS. **Clin Nucl Med** 1998 Oct;23(10):695–6

Hypothalamic hamartomas and gelastic epilepsy: a spectroscopic study. Tasch E, et al. **Neurology** 1998 Oct; 51(4):1046–50

SURGERY

Malignant tumors associated with nevus sebaceous: therapeutic consequences. Beer GM, et al. **Aesthetic Plast Surg** 1999 May–Jun;23(3):224–7

Hamartoma of the suprasellar cistern in a 5-year-old girl. Boto GR, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):131–3

Computer simulation of a neurosurgical operation: craniotomy for hypothalamic hamartoma. Sgouros S, et al. **Childs Nerv Syst** 1998 Jul;14(7):322–7

Benign triton tumor of the trigeminal nerve. Vajramani G, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):140–4 (8 ref.)

Hamartoma of the larynx: a case of unusual bleeding after microlaryngoscopy. Hosal AS, et al. **Ear Nose Throat J** 1998 Nov;77(11):910–3

Endoscopic injection and polypectomy for bleeding Brunner's gland hamartoma [letter] Mukherjee S, et al. **Gastrointest Endosc** 1999 Oct;50(4):597–8

Surgically created fourth-third cranial nerve communication: temporary success in a child with bilateral third nerve hamartomas. Case report. Frisén L, et al. **J Neurosurg** 1999 Mar;90(3):542–5

Fourth-third nerve communication [letter] Menovsky T, et al. **J Neurosurg** 1999 Oct;91(4):721–2

Asymptomatic mesenchymal hamartoma of the liver can be treated by observation alone [letter; comment] Roebuck D. **J Pediatr Surg** 1998 Oct;33(10):1587. Comment on: J Pediatr Surg 1997 Oct;32(10):1495–8.

Giant hamartoma of the lung. Fujino S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1229–31

Acute respiratory distress syndrome following resection of a mesenchymal hamartoma of the liver. Fuchs J, et al. **Med Pediatr Oncol** 1999 Feb;32(2):151–3

Spinal cord hamartoma: case report. Riley K, et al. **Neurosurgery** 1999 May;44(5):1125–7; discussion 1127–8

Total gastrointestinal endoscopy in the management of Peutz-Jeghers syndrome. De Luca N, et al. **Postgrad Med J** 1998 Dec;74(878):745–7

Surgical treatment of tracheal hamartoma. Taştepe AI, et al. **Scand Cardiovasc J** 1998;32(4):239–41

[Gelastic seizures treated by partial resection of a hypothalamic hamartoma] Watanabe T, et al. **No Shinkei Geka** 1998 Oct;26(10):923–8 (Eng. Abstr.) **(Jpn)**

[Observation of chondromatous hamartoma with the signs of malignancy] Opanasenko NS, et al. **Klin Khir** 1999; (5):54–5 **(Rus)**

THERAPY

Treatment of port-wine stains with a noncoherent pulsed light source: a retrospective study. Raulin C, et al. **Arch Dermatol** 1999 Jun;135(6):679–83

Endobronchial hamartoma treated by an Nd-YAG laser: report of a case. Tajima H, et al. **Surg Today** 1998; 28(10):1078–80

ULTRASONOGRAPHY

Retrorectal cystic hamartoma: diagnosis using endorectal ultrasound. Scullion DA, et al. **Clin Radiol** 1999 May; 54(5):338–9

Prenatal diagnosis of a benign facial tumor. Magalhães JA, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):212–5 (20 ref.)

Characteristic EUS appearance of Brunner's gland hamartoma [letter; comment] Matsushita M, et al. **Gastrointest Endosc** 1999 May;49(5):670–2. Comment on: Gastrointest Endosc 1997 Aug;46(2):176–8.

Hamartoma of the mitral valve with blood cysts: a rare tumor detected by echocardiography. Abreu A, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):832–6

New sonographic appearance of hepatic mesenchymal hamartoma in childhood. Koumanidou C, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):164–7

Sonographic findings in Bartholin's gland hamartoma. Langer JE, et al. **J Clin Ultrasound** 1998 Nov–Dec; 26(9):465–9

Prenatal diagnosis of hepatic mesenchymal hamartoma. Dickinson JE, et al. **Prenat Diagn** 1999 Jan;19(1):81–4

VETERINARY

Bile duct hamartoma in a calf. De Bosschere H, et al. **Vet Rec** 1999 Feb 20;144(8):210–1

Progressive hindlimb paraparesis in a goat associated with a vascular hamartoma. Middleton JR, et al. **Vet Rec** 1999 Mar 6;144(10):264–5

HAMARTOMA SYNDROME, MULTIPLE

Transcatheter embolization of arteriovenous malformations in Cowden disease. Takaya N, et al. **Jpn Circ J** 1999 Apr;

63(4):326–9

COMPLICATIONS

Dysplastic gangliocytoma (Lhermitte–Duclos disease) associated with Cowden disease: report of a case and review of the literature for the genetic relationship between the two diseases. Murata J, et al. **J Neurooncol** 1999 Jan; 41(2):129–36 (36 ref.)

Lhermitte–Duclos disease as a component of Cowden's syndrome. Case report and review of the literature. Koch R, et al. **J Neurosurg** 1999 Apr;90(4):776–9 (31 ref.)

DIAGNOSIS

Biliary hamartomas: solitary and multiple lesions shown on current MR techniques including gadolinium enhancement. Semelka RC, et al. **J Magn Reson Imaging** 1999 Aug; 10(2):196–201

EPIDEMIOLOGY

Cowden disease: a cutaneous marker for increased risk of breast cancer. Schweitzer S, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):349–51

GENETICS

Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene [letter; comment] Kurose K, et al. **Am J Hum Genet** 1999 Jan;64(1):308–10. Comment on: Am J Hum Genet 1998 May;62(5):1020–2.

Inherited macrocephaly–hamartoma syndromes. DiLiberti JH. **Am J Med Genet** 1998 Oct 2;79(4):284–90 (51 ref.)

Severe Lhermitte–Duclos disease with unique germline mutation of PTEN. Sutphen R, et al. **Am J Med Genet** 1999 Feb 12;82(4):290–3

Germline PTEN mutation in a family with Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome. Zori RT, et al. **Am J Med Genet** 1998 Dec 4;80(4):399–402

Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations. Nelen MR, et al. **Eur J Hum Genet** 1999 Apr;7(3):267–73

Identification of PTEN mutations in five families with Bannayan–Zonana syndrome. Tok Celebi J, et al. **Exp Dermatol** 1999 Apr;8(2):134–9

Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in patients with Cowden disease. Chi SG, et al. **Gastroenterology** 1998 Nov;115(5):1084–9

Molecular and phenotypic markers of hamartomatous polyposis syndromes in the gastrointestinal tract. Entius MM, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):661–6 (26 ref.)

Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Houlston R, et al. **Hum Mol Genet** 1998 Nov;7(12):1907–12

PTEN mutation spectrum and genotype–phenotype correlations in Bannayan–Riley–Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Marsh DJ, et al. **Hum Mol Genet** 1999 Aug;8(8):1461–72

A heterozygous germline mutation of the PTEN/MMAC1 gene in a patient with Cowden disease. Iida S, et al. **Int J Mol Med** 1998 Mar;1(3):565–8

Novel mutation of the PTEN gene in an Italian Cowden's disease kindred. Scala S, et al. **Int J Oncol** 1998 Oct; 13(4):665–8

Some neoplasms and some hamartomatous syndromes: genetic considerations. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1998 Oct;27(5):363–9 (37 ref.)

Lack of chromosome 15q11–q13 region involvement in a family with Cowden disease/Bannayan–Zonana syndrome [letter; comment] Dasouki MJ, et al. **J Gastroenterol** 1998 Dec;33(6):928–9 (8 ref.). Comment on: J Gastroenterol 1997 Oct;32(5):696–9.

Germline PTEN mutations in Cowden syndrome–like families. Marsh DJ, et al. **J Med Genet** 1998 Nov; 35(11):881–5

Dysplastic gangliocytoma (Lhermitte–Duclos disease) associated with Cowden disease: report of a case and review of the literature for the genetic relationship between the two diseases. Murata J, et al. **J Neurooncol** 1999 Jan; 41(2):129–36 (36 ref.)

Identification of a novel PTEN mutation (L139X) in a patient with Cowden disease and Sjögren's syndrome. Raizis AM, et al. **Mol Pathol** 1998 Dec;51(6):339–41

PATHOLOGY

Pathological case of the month. Epidermal nevi. Elhassani SB. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):307–8

Multiple chondromatous hamartomas of the lung: a case report and review of the literature with special reference to Carney syndrome. Kiryu T, et al. **Cancer** 1999 Jun 15; 85(12):2557–61 (30 ref.)

Arteriovenous and lymphatic malformations, linear verrucous epidermal nevus and mild overgrowth: another hamartoneoplastic syndrome? Hennekam RC, et al. **Clin Dysmorphol** 1999 Apr;8(2):111–5

Similarities of cutaneous and breast pathology in Cowden's Syndrome. Schrager CA, et al. **Exp Dermatol** 1998 Dec; 7(6):380–90

Phenotypic findings of Cowden syndrome and Bannayan–Zonana syndrome in a family associated with a single germline mutation in PTEN. Celebi JT, et al. **J Med Genet** 1999 May;36(5):360–4

[A case of Cowden's disease associated with rectal carcinoid] Kitazoe K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov;95(11):1244–8 **(Jpn)**

PHYSIOPATHOLOGY

De novo status epilepticus due to multiple cerebral hamartomas. Greenfield LJ Jr, et al. **Neurology** 1999 Jul 13;53(1):237–8

RADIOGRAPHY

Filiform polyposis of the small bowel in a patient with multiple hamartoma syndrome (Cowden disease). Cho KC, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):501–2

HAMMAN–RICH SYNDROME see **PULMONARY FIBROSIS**

HAMSTER SPUMAVIRUS see **SPUMAVIRUS**

HAMSTERS

ANATOMY & HISTOLOGY

Stereological estimation of number and volume of pulmonary neuroepithelial bodies (NEBs) in neonatal hamster lungs. Bollé T, et al. **Microsc Res Tech** 1999 Jan 15–Feb 1; 44(2–3):190–4

EMBRYOLOGY

Molecular tunnels and boundaries for growing axons in the anterior commissure of hamster embryos. Pires–Neto MA, et al. **J Comp Neurol** 1998 Sep 21;399(2):176–88

GENETICS

The role of calcium channels in hamster CYP11B2 gene expression. Sarazin P, et al. **Endocr Res** 1998 Aug–Nov; 24(3–4):633–6

Delineation of genomic deletion in cardiomyopathic hamster. Sakamoto A, et al. **FEBS Lett** 1999 Mar 19;447(1):124–8

METABOLISM

Androgen receptor immunoreactivity in the male and female Syrian hamster brain. Wood RI, et al. **J Neurobiol** 1999 Jun 5;39(3):359–70

Neurokinin–1 receptor immunoreactivity in the nucleus of the solitary tract in the hamster. Davis BJ, et al. **Neuroreport** 1999 Apr 6;10(5):1003–6

PHYSIOLOGY

Circannual reproductive rhythm in the European hamster (Cricetus cricetus): demonstration of the existence of an annual phase of sensitivity to short photoperiod. Saboureau M, et al. **J Pineal Res** 1999 Jan;26(1):9–16

HAMSTERS, ARMENIAN see **CRICETULUS**

HAMSTERS, CHINESE see **CRICETULUS**

HAMSTERS, DJUNGARIAN see **PHODOPUS**

HAMSTERS, GOLDEN see **MESOCRICETUS**

HAMSTERS, GOLDEN SYRIAN see **MESOCRICETUS**

HAMSTERS, GREY see **CRICETULUS**

HAMSTERS, SIBERIAN see **PHODOPUS**

HAMSTERS, SYRIAN see **MESOCRICETUS**

HAND

Autogenous palmaris longus tendon as frontalis suspension material for ptosis correction in children [letter; comment] Naugle TC Jr, et al. **Am J Ophthalmol** 1999 Apr; 127(4):488–9. Comment on: Am J Ophthalmol 1998 Jul;126(1):109–15.

Palmar aneurysm accompanied by ipsilateral clubbing finger—a case report [published erratum appears in Angiology 1999 Mar;50(3):following 265] Abe K, et al. **Angiology** 1999 Jan;50(1):69–73

SHAFT syndrome revisited. Graham WP 3rd, et al. **Ann Plast Surg** 1999 Apr;42(4):411–6; discussion 416–7

Results of thoracoscopic sympathectomy for 96 cases of palmar hyperhidrosis. Tan V, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):244–6

Beryllium contamination inside vehicles of machine shop workers. Sanderson WT, et al. **Appl Occup Environ Hyg** 1999 Apr;14(4):223–30

A slowly growing tender plaque of the palm. Park JY, et al. **Arch Dermatol** 1999 Jun;135(6):707, 710

Bacterial contamination of the hands of hospital staff during routine patient care. Pittet D, et al. **Arch Intern Med** 1999 Apr 26;159(8):821–6

Grip strength and the risk of developing radiographic hand osteoarthritis: results from the Framingham Study. Chaisson CE, et al. **Arthritis Rheum** 1999 Jan;42(1):33–8

Topical DMSO treatment for pegylated liposomal doxorubicin–induced palmar–plantar erythrodysesthesia. Lopez AM, et al. **Cancer Chemother Pharmacol** 1999; 44(4):303–6

Serious hand sepsis and diabetes mellitus: specific tropical syndrome with western counterparts. Gill GV, et al. **Diabet Med** 1998 Oct;15(10):858–62 (27 ref.)

Twisted collagen fibrils in acrocyanosis. Kobayasi T, et al. **Eur J Dermatol** 1999 Jun;9(4):285–8

Fillet of finger flap for hand resurfacing after tumour excision. Schonauer F, et al. **Eur J Surg Oncol** 1999 Aug; 25(4):424–6

Isolated compartment syndrome of the hand after brachial embolectomy. Whatling PJ, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):446–7 (5 ref.)

Fungal infections of the hand. Amadio PC. **Hand Clin** 1998 Nov;14(4):605–12 (57 ref.)

Osteomyelitis of the hand. Barbieri RA, et al. **Hand Clin** 1998 Nov;14(4):589–603, ix (133 ref.)

Diabetic hand infections. Gunther SF, et al. **Hand Clin** 1998 Nov;14(4):647–56

Atypical hand infections. Hoyen HA, et al. **Hand Clin** 1998 Nov;14(4):613–34, ix (101 ref.)

Deep subfascial space infections. Jebson PJ. **Hand Clin** 1998 Nov;14(4):557–66, viii (15 ref.)

The history of hand infections. Kono M, et al. **Hand Clin** 1998 Nov;14(4):511–8, vii

Mimickers of hand infections. Louis DS, et al. **Hand Clin** 1998 Nov;14(4):519–29, vii (52 ref.)

Septic arthritis of the hand and wrist. Murray PM. **Hand Clin** 1998 Nov;14(4):579–87, viii (27 ref.)

Malignant fibrous histiocytoma in a child's hand [letter] Lim SC, et al. **Histopathology** 1998 Aug;33(2):191–2

Cancer risk among patients with finger and hand joint and temporo–mandibular joint prostheses in Denmark. Fryzek JP, et al. **Int J Cancer** 1999 May 31;81(5):723–5

Unusual manifestations of B–cell disorders. Case 1: multiple myeloma with predominant phalangeal involvement. Ozguroglu M, et al. **J Clin Oncol** 1999 Mar;17(3):1083–4

Patient and injury characteristics in the development of cold sensitivity of the hand: a prospective cohort study. Craigen M, et al. **J Hand Surg [Am]** 1999 Jan;24(1):8–15

The contribution of the intrinsic muscles to grip and pinch strength [see comments] Kozin SH, et al. **J Hand Surg [Am]** 1999 Jan;24(1):64–72. Comment in: J Hand Surg [Am] 1999 Jul;24(4):870–1.

Pacinian neurofibroma of the hand: a case report and literature review. MacLennan SE, et al. **J Hand Surg [Am]** 1999 Mar;24(2):413–6 (13 ref.)

A randomized biomechanical study of zone II human flexor tendon repairs analyzed in a linear model [see comments] Stein T, et al. **J Hand Surg [Am]** 1998 Nov;23(6):1043–5 . Comment in: J Hand Surg [Am] 1999 Jul;24(4):871–3.

Subcutaneous tissue emphysema of the hand secondary to noninfectious etiology: a report of two cases. van der Molen AB, et al. **J Hand Surg [Am]** 1999 May;24(3):638–41

Conservative versus operative treatment for Kienböck's disease. A retrospective study [letter; comment] Botelheiro JC. **J Hand Surg [Br]** 1999 Feb;24(1):139. Comment on: J Hand Surg [Br] 1998 Feb;23(1):33–6.

The radial forearm fascial flap as a salvage procedure for chronic tuberculosis of the hand and wrist. Cedidi C, et al. **J Hand Surg [Br]** 1998 Aug;23(4):476–8

Surgical management after doxorubicin and epirubicin extravasation [letter; comment] Fleming A, et al. **J Hand Surg [Br]** 1999 Jun;24(3):390. Comment on: J Hand Surg [Br] 1998 Oct;23(5):666–8.

Compartment syndrome of the hand following intra–arterial injection of heroin. Funk L, et al. **J Hand Surg [Br]** 1999 Jun;24(3):366–7

Myositis ossificans of the hand. Kusuma S, et al. **J Hand Surg [Br]** 1999 Feb;24(1):128–30

Extensive nodular sarcoidosis in the hand. Kwon B, et al. **J Hand Surg [Br]** 1997 Oct;22(5):676–8

A false aneurysm in the hand of a child. Simeonov LG. **J Hand Surg [Br]** 1998 Aug;23(4):555–6

The virtual hand. The Pulvertaft Prize Essay for 1996. Williams NW. **J Hand Surg [Br]** 1997 Oct;22(5):560–7

Hand therapy education: a global perspective. Frampton V. **J Hand Ther** 1998 Oct–Dec;11(4):239–43

The EndoHand: comparison with standard laparoscopic instrumentation. Jackman SV, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):253–8

Transthoracic endoscopic sympathectomy for palmar hyperhidrosis in children and adolescents: analysis of 350 cases. Lin TS. **J Laparoendosc Adv Surg Tech A** 1999 Aug; 9(4):331–4

Another dystonia [letter; comment] Partington MW. **J Med Genet** 1998 Oct;35(10):879. Comment on: J Med Genet 1998 Apr;35(4):314–8.

Ganglion cysts at Field Memorial Hospital. Field RJ Jr, et al. **J Miss State Med Assoc** 1999 Mar;40(3):82–6

Congenital fibrous hamartoma of the hand: a case report. Janoyer M, et al. **J Pediatr Orthop B** 1999 Apr;8(2):129–31 (32 ref.)

The design and development of a gloveless endoskeletal prosthetic hand. Doshi R, et al. **J Rehabil Res Dev** 1998 Oct;35(4):388–95

Groove sign in paraneoplastic palmar fasciitis [letter] Matteson EL. **J Rheumatol** 1998 Oct;25(10):2043–5

One swollen hand. Alevizaki M, et al. **Lancet** 1999 Aug 21; 354(9179):644

Constraint–induced movement therapy for focal hand dystonia in musicians [letter] [see comments] Candia V,

et al. **Lancet** 1999 Jan 2;353(9146):42. Comment in: Lancet 1999 Apr 10;353(9160):1273–4.
Intrathecal baclofen increases corticospinal output to hand muscles in multiple sclerosis. Auer C, et al. **Neurology** 1999 Apr 12;52(6):1298–9
When a rubber hand 'feels' what the real hand cannot. Rorden C, et al. **Neuroreport** 1999 Jan 18;10(1):135–8
Hand protection, Well in hand. Johnson LF.
Occup Health Saf 1998 Nov;67(11):44–6
Mucormycosis osteomyelitis in the hand. Stevanovic MV, et al. **Orthopedics** 1999 Apr;22(4):449–50
Necrotizing fasciitis caused by Vibrio damsela. Tang WM, et al. **Orthopedics** 1999 Apr;22(4):443–4
Nonradiopaque penetrating foreign body: "a sticky situation". Laor T, et al. **Pediatr Radiol** 1999 Sep;29(9):702–4
RTV silicone elastomers in hand prosthetics: properties, applications and techniques. Leow ME, et al.
Prosthet Orthot Int 1999 Aug;23(2):169–73
Thiemann's disease: a case report. Seçkin U, et al.
Rheumatol Int 1999;18(4):157–8
Metacarpal osteomyelitis complicating varicella-associated cellulitis of the hand: report of 2 cases. Aebi C, et al.
Scand J Infect Dis 1998;30(3):306–9
The long-term results of upper dorsal sympathetic ganglionectomy and endoscopic thoracic sympathectomy for palmar hyperhidrosis. Lin CL, et al. **Surg Today** 1999; 29(3):209–13
[Application of pedicled parumbilical axial skin flap in the repair of skin defect of upper extremity] Yu C, et al.
Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih 1997 Jul;11(4):224–5 (Eng. Abstr.) **(Chi)**
[Hand symptoms and pregnancy] de la Fuente Fonnest I, et al. **Ugeskr Laeger** 1998 Sep 28;160(40):5791–4 (Eng. Abstr.) **(Dan)**
[Carpal tunnel syndrome and hand edema in temporal arteritis] Jakobsen SA, et al. **Ugeskr Laeger** 1998 Oct 5; 160(41):5944–5 (Eng. Abstr.) **(Dan)**
[Rhabdomyosarcoma of the hand. Apropos of a case confined to the thenar eminence] Dumortier R, et al.
Ann Chir Plast Esthet 1998 Oct;43(5):563–6 (Eng. Abstr.) **(Fre)**
[Non-melanomatous malignant skin tumors of the hand] Glicenstein J. **Ann Chir Plast Esthet** 1998 Aug;43(4):401–9 (Eng. Abstr.) **(Fre)**
[The hand and rheumatism] Lioté F, et al.
Ann Radiol (Paris) 1997;40(3):182–8 (Eng. Abstr.) **(Fre)**
[Terminology collection of radiologic concepts of modern sectional imaging methods of the hand] Fiedler E, et al.
Handchir Mikrochir Plast Chir 1998 Jul;30(4):272–80 **(Ger)**
[The DASH(Disability of Arm-Shoulder-Hand) Questionnaire--a new instrument for evaluating upper extremity treatment outcome] Germann G, et al.
Handchir Mikrochir Plast Chir 1999 May;31(3):149–52 (Eng. Abstr.) **(Ger)**
[Unusual lymphedema of the upper extremity] Chatterjee T, et al. **Schweiz Med Wochenschr** 1999 Feb 20;129(7):292 **(Ger)**
[An elderly case of juvenile muscular atrophy in the unilateral upper extremity with tremor in both hands] Katsuoka H, et al. **Nippon Ronen Igakkai Zasshi** 1999 Apr;36(4):279–83 (Eng. Abstr.) **(Jpn)**
[Complications are frequent after surgery for excessive hand sweating. Patient should be informed about the risks] Claes G, et al. **Lakartidningen** 1999 Feb 24;96(8):930–2 **(Swe)**

ABNORMALITIES see HAND DEFORMITIES, CONGENITAL

ANATOMY & HISTOLOGY

Unilateral variation of the arterial pattern of the human upper extremity with a muscle variation of the hand. Yücel AH.
Acta Med Okayama 1999 Apr;53(2):61–5
Muscular anatomic variants of the wrist and hand: findings on MR imaging. Timins ME. **AJR Am J Roentgenol** 1999 May;172(5):1397–401
Fluctuating asymmetry and morphometric variation of hand bones. Livshits G, et al. **Am J Phys Anthropol** 1998 Sep; 107(1):125–36
Localization of the motor hand area using transcranial magnetic stimulation and functional magnetic resonance imaging. Boroojerdi B, et al. **Clin Neurophysiol** 1999 Apr; 110(4):699–704
A biometric study on the relationships between the deep palmar arch and the superficial palmar arch, the distal wrist and palmar creases. Olave E, et al.
Folia Morphol (Warsz) 1998;57(4):383–8
Variations of the superficial palmar arch. Ozkus K, et al.
Folia Morphol (Warsz) 1998;57(3):251–5
An anatomic study of the stabilizing ligaments of the trapezium and trapeziometacarpal joint. Bettinger PC, et al. **J Hand Surg [Am]** 1999 Jul;24(4):786–98
Anomalous extensor muscles of the hand: a review. Tan ST, et al. **J Hand Surg [Am]** 1999 May;24(3):449–55 (49 ref.)
Hand specialization, sympatry, and mixed-species associations in callitrichines. César J, et al. **J Hum Evol** 1999 Apr;36(4):349–78
Anisotropy in haptic curvature and shape perception. Pont SC, et al. **Perception** 1998;27(5):573–89
Fist position for skin grafting on the dorsal hand: I. Analysis of length of the dorsal hand surgery in hand positions. Burm JS, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1350–5
Evidence of hominid-like precision grip capability in the hand of the Miocene ape Oreopithecus. Moyá-Solá S, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):313–7
Instruments for minimally invasive surgery: principles of ergonomic handles. Matern U, et al. **Surg Endosc** 1999 Feb; 13(2):174–82

BLOOD SUPPLY

Modifications of arterial blood flow to the hand after carpal tunnel release. Schuind F, et al. **Acta Orthop Belg** 1998 Sep;64(3):296–300
Doppler spectral waveform analysis of arteries of the hand in patients with Raynaud's phenomenon as compared with healthy subjects. Chikui T, et al.
AJR Am J Roentgenol 1999 Jun;172(6):1605–9
Arterialization of the dorsum vein on the hand [letter] Lakhotia R, et al. **Anesth Analg** 1999 Jun;88(6):1425
Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40--a case report. Gouny P, et al. **Angiology** 1999 Jul;50(7):605–6
The Allen test. Cable DG, et al. **Ann Thorac Surg** 1999 Mar; 67(3):876–7
The hemodynamics of steal syndrome and its treatment. White JG, et al. **Ann Vasc Surg** 1999 May;13(3):308–12
The effects of age on human venous responsiveness to neuropeptide Y. Lambert ML, et al.
Br J Clin Pharmacol 1999 Jan;47(1):83–9
Capillary refill time in the hands and feet of normal newborn infants. Raju NV, et al. **Clin Pediatr (Phila)** 1999 Mar; 38(3):139–44
Inhibition of angiotensin-converting enzyme in human hand veins. Chalon S, et al. **Clin Pharmacol Ther** 1999 Jan; 65(1):58–65
Superior and inferior limb ischaemia in giant cell arteritis: angiography follow-up. García Vázquez JM, et al.
Clin Rheumatol 1999;18(1):61–5
No change in O2 saturation but measurable difference in thenar flexor power after radial artery harvest. Grossebner M, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):160–2
Magnetic resonance angiography of the hand. A review. Lee VS, et al. **Invest Radiol** 1998 Sep;33(9):687–98 (36 ref.)
Influence of localized auxiliary heating on hand comfort during cold exposure. Brajkovic D, et al.
J Appl Physiol 1998 Dec;85(6):2054–65
Recovery from mild hypothermia can be accelerated by mechanically distending blood vessels in the hand. Grahn D, et al. **J Appl Physiol** 1998 Nov;85(5):1643–8
Arterial reconstruction in the ischemic hand and wrist: effects on microvascular physiology and health-related quality of life. Koman LA, et al. **J Hand Surg [Am]** 1998 Sep; 23(5):773–82
Vascular disorders of the hand: surgeons' perspective. Levin LS, et al. **J Hand Ther** 1999 Apr-Jun;12(2):152–9 (14 ref.)
Vascular disorders of the hand: therapist's commentary. Talley M. **J Hand Ther** 1999 Apr-Jun;12(2):160–3 (42 ref.)
Complete removal plus dorsalis pedis flap for arteriovenous malformation in the hypothenar region. Minami A, et al.
J Reconstr Microsurg 1998 Oct;14(7):439–43
Noninvasive evaluation of hand circulation before radial artery harvest for coronary artery bypass grafting. Starnes SL, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):261–6
Acute arterial occlusions of the small vessels of the hand and forearm: treatment with regional urokinase therapy. Johnson SP, et al. **J Vasc Interv Radiol** 1999 Jul-Aug; 10(7):869–76
Management of dialysis access-associated steal syndrome: use of intraoperative duplex ultrasound scanning for optimal flow reduction. Shemesh D, et al. **J Vasc Surg** 1999 Jul; 30(1):193–5
Cutaneous vasodilation induced by local warming, sodium nitroprusside, and bretylium iontophoresis on the hand. Saumet JL, et al. **Microvasc Res** 1998 Nov;56(3):212–7
Kawasaki disease complicated by peripheral gangrene. Chang JS, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):139–42 (7 ref.)
The role of sclerotherapy in abnormal varicose hand veins. Duffy DM, et al. **Plast Reconstr Surg** 1999 Oct; 104(5):1474–9; discussion 1480–1
Angiologic observations following radial artery flap elevation: a case report. Ciria-Lloréns G, et al.
Surg Radiol Anat 1998;20(5):377–81
Hand-arm vibration syndrome with proximal ulnar artery occlusion. Noël B, et al. **Vasa** 1998 Aug;27(3):176–8
[Arterial perfusion disorders of the hand in 9 patients with arteriovenous fistula for hemodialysis] Tordoir JH, et al.
Ned Tijdschr Geneeskd 1999 May 22;143(21):1093–8 (Eng. Abstr.) **(Dut)**
[Maffucci syndrome: a false venous malformation? A case with hemangioendothelioma with fusiform cells] Enjolras O, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):512–5 (Eng. Abstr.) **(Fre)**
[Laser Doppler spectral analysis of patients with Raynaud's phenomenon during a standardized thermal test] Léger P.
Ann Dermatol Venereol 1998 Nov;125 Suppl 2:S28–9 **(Fre)**
[Painful ischemia of the extremities with T-cell lymphoma] Distelrath K, et al. **Hautarzt** 1999 Apr;50(4):284–7 (Eng. Abstr.) **(Ger)**
[Ultrasound image of the hypothenar hammer syndrome] Taute BM, et al. **Ultraschall Med** 1998 Oct;19(5):220–4 (Eng. Abstr.) **(Ger)**
[Bypass to the anterior interosseous artery of the arm: follow-up of 3 years] Enzler M, et al. **Vasa** 1998 Nov; 27(4):250–2 (Eng. Abstr.) **(Ger)**
[Arteriovenous malformations of the limbs treated with transcatheter embolization. Report of 3 cases] De Santis M, et al. **Radiol Med (Torino)** 1998 Nov;96(5):534–8 **(Ita)**

EMBRYOLOGY

Hand development in trisomy 21. Kjaer MS, et al.
Am J Med Genet 1998 Oct 12;79(5):337–42
Three-dimensional ultrasound examination of the fetal hands: normal and abnormal [see comments] Budorick NE, et al.
Ultrasound Obstet Gynecol 1998 Oct;12(4):227–34. Comment in: Ultrasound Obstet Gynecol 1998 Oct;12(4):225–6.
Three-dimensional ultrasonographic assessment of fetal hands and feet [see comments] Hata T, et al.
Ultrasound Obstet Gynecol 1998 Oct;12(4):235–9. Comment in: Ultrasound Obstet Gynecol 1998 Oct;12(4):225–6.

INJURIES see HAND INJURIES

INNERVATION

Near-nerve versus surface electrode recordings of sensory nerve conduction in patients with carpal tunnel syndrome. Smith T. **Acta Neurol Scand** 1998 Oct;98(4):280–2
Palmar cutaneous nerve recording and clarification of median premotor potential generators. Bergeron JW, et al.
Am J Phys Med Rehabil 1998 Sep-Oct;77(5):399–406
Ego-syntonic alien hand syndrome after right posterior cerebral artery stroke. Groom KN, et al.
Arch Phys Med Rehabil 1999 Feb;80(2):162–5
Clinical evaluation of the bionic glove. Popović D, et al.
Arch Phys Med Rehabil 1999 Mar;80(3):299–304
Satisfaction with and usage of a hand neuroprosthesis. Stroh Wuolle K, et al. **Arch Phys Med Rehabil** 1999 Feb; 80(2):206–13
Contribution of collateral sprouting to the sensory and sudomotor recovery in the human palm after peripheral nerve injury. Ahčan U, et al. **Br J Plast Surg** 1998 Sep; 51(6):436–43
Functional coupling of human cortical sensorimotor areas during bimanual skill acquisition. Andres FG, et al.
Brain 1999 May;122 (Pt 5):855–70
Spatial EEG synchronisation over sensorimotor hand areas in brisk and slow self-paced index finger movements. Stančák A Jr, et al. **Brain Topogr** 1998 Fall;11(1):23–31
Three-dimensional reconstruction of the human central sulcus reveals a morphological correlate of the hand area. Sastre-Janer FA, et al. **Cereb Cortex** 1998 Oct-Nov; 8(7):641–7
Physiological studies of the corticomotor projection to the hand after subcortical stroke. Byrnes ML, et al.
Clin Neurophysiol 1999 Mar;110(3):487–98
Sympathetic skin responses recorded from non-palmar and non-plantar skin sites: their role in the evaluation of thermal sweating. Matsunaga K, et al.
Electroencephalogr Clin Neurophysiol 1998 Sep; 108(5):482–9
Hand and joint paths during reaching movements with and without vision. Sergio LE, et al. **Exp Brain Res** 1998 Sep; 122(2):157–64
The precision of proprioceptive position sense. van Beers RJ, et al. **Exp Brain Res** 1998 Oct;122(4):367–77
Localizing value of bilateral cheiro-oral sensory impairment. Yasuda Y, et al. **Intern Med** 1998 Nov;37(11):982–5
Functional organization of tactile inputs from the hand in the cuneate nucleus and its relationship to organization in the somatosensory cortex. Xu J, et al. **J Comp Neurol** 1999 Aug 30;411(3):369–89
Innervation density of the base of the palm. Ruch DS, et al. **J Hand Surg [Am]** 1999 Mar;24(2):392–7
Hartmann's boutonnière: an anatomical study of digital neural loop penetrations in the palm. Gotani H, et al.
J Hand Surg [Br] 1999 Feb;24(1):35–7
Identification and preservation of Palmar cutaneous nerves during open carpal tunnel release. Tomaino MM, et al.
J Hand Surg [Br] 1998 Oct;23(5):607–8
Sensory alien hand syndrome [letter] Persaud RS.
J Neurol Neurosurg Psychiatry 1999 Jul;67(1):130–1
Detection of vibration transmitted through an object grasped in the hand. Brisben AJ, et al. **J Neurophysiol** 1999 Apr; 81(4):1548–58
Evidence for brainstem and supra-brainstem contributions to rapid cortical plasticity in adult monkeys. Xu J, et al.
J Neurosci 1999 Sep 1;19(17):7578–90
Evidence for strong synaptic coupling between single tactile afferents and motoneurones supplying the human hand. McNulty PA, et al. **J Physiol (Lond)** 1999 Aug 1;518 (Pt 3):883–93
Self-reported use of an implanted FES hand system by adolescents with tetraplegia. Davis SE, et al.
J Spinal Cord Med 1998 Jul;21(3):220–6
The effect of finger-movement speed of the dominant and the subdominant hand on cerebellar activation: A functional magnetic resonance imaging study. Jäncke L, et al. **Neuroimage** 1999 May;9(5):497–507
The sensory somatotopic map of the human hand demonstrated at 4 Tesla. Maldjian JA, et al.
Neuroimage 1999 Jul;10(1):55–62

Modulation of corticospinal output to human hand muscles following deprivation of sensory feedback. Rossi S, et al. **Neuroimage** 1998 Aug;8(2):163–75

Localization of the human frontal eye fields and motor hand area with transcranial magnetic stimulation and magnetic resonance imaging. Ro T, et al. **Neuropsychologia** 1999 Feb; 37(2):225–31

Abnormal increase in the corticomotor output to the affected hand during repetitive transcranial magnetic stimulation of the primary motor cortex in patients with writer's cramp. Siebner HR, et al. **Neurosci Lett** 1999 Mar 5;262(2):133–6

Neurilemoma originating from a deep branch of the ulnar nerve. Oguma H, et al. **Orthopedics** 1999 Mar;22(3):359–60

Median and ulnar nerves in the hand. Sable AW. **Phys Med Rehabil Clin N Am** 1998 Nov;9(4):737–53 (74 ref.)

Femoral nerve transfer for treatment of brachial plexus root avulsion. Gu YD, et al. **Plast Reconstr Surg** 1998 Nov; 102(6):1973–8; discussion 1979–80

The relative increase in skin temperature after stellate ganglion block is predictive of a complete sympathectomy of the hand [letter; comment] Ackerman WE 3rd, et al. **Reg Anesth Pain Med** 1999 May–Jun;24(3):275–6. Comment on: Reg Anesth Pain Med 1998 May–Jun;23(3):266–70.

[Ulnar nerve palsy in leprosy without skin changes: biopsy of the superficial branch of the ulnar nerve in the hand] de Freitas MR, et al. **Arq Neuropsiquiatr** 1998 Sep; 56(3B):585–94 (Eng. Abstr.) **(Por)**

MICROBIOLOGY

Flexor tenosynovitis in the hand caused by Mycobacterium terrae. Fodero J, et al. **Ann Plast Surg** 1999 Mar;42(3):330–2

Staphylococcus aureus isolation from the lesions, the hands, and anterior nares of patients with atopic dermatitis. Williams JV, et al. **J Emerg Med** 1999 Jan–Feb;17(1):207–11

Pseudo-outbreak of candidaemia with Candida parapsilosis [letter] Kappstein I, et al. **J Hosp Infect** 1998 Oct; 40(2):164–5

[Hue and cry over pens?] Uhoda I, et al. **Rev Med Liege** 1999 Jan;54(1):37–8 (18 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Offidani A, et al. **Acta Derm Venereol** 1998 Nov;78(6):463–5

Melanocytic nevi of palms and soles: a histological study according to the plane of section. Signoretti S, et al. **Am J Surg Pathol** 1999 Mar;23(3):283–7

Picture of the month. Tinea nigra. McKinlay JR, et al. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):305–6

Palmar fascial complex anatomy and pathology in Dupuytren's disease. Rayan GM. **Hand Clin** 1999 Feb; 15(1):73–86, vi–vii (45 ref.)

Correlation of segmental carpal tunnel pressures with changes in hand and wrist positions in patients with carpal tunnel syndrome and controls. Luchetti R, et al. **J Hand Surg [Br]** 1998 Oct;23(5):598–602

Hemophilic pseudotumor of the soft tissue of the hand: a case report. Hopkins JD, et al. **J Okla State Med Assoc** 1999 May;92(5):227–30

Images in clinical medicine. Hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu disease). Nicoleau A, et al. **N Engl J Med** 1999 Jun 10;340(23):1800

Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Michal M. **Pathol Res Pract** 1998;194(8):529–33

Syrinx hand. Cohen AR. **Pediatr Neurosurg** 1998 Sep; 29(3):160

Uniform fat suppression in hands and feet through the use of two-point Dixon chemical shift MR imaging. Maas M, et al. **Radiology** 1999 Jan;210(1):189–93

Primary synovial osteochondromatosis of the hand and wrist. Report of a series of 21 cases and literature review. Roulot E, et al. **Rev Rhum Engl Ed** 1999 May;66(5):256–66 (116 ref.)

Re: Assessment of disease activity in rheumatoid arthritis using magnetic resonance imaging: quantification of pannus volume in the hands [letter] Smith MD. **Rheumatology (Oxford)** 1999 Jul;38(7):680–1

[Surgical anatomy with special reference to reconstruction in severe hand injuries] Graf PF. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:968–70 (Eng. Abstr.) **(Ger)**

[Sulodexide in the treatment of right hand necrosis in diabetic patient performing exchanges of continuous ambulatory peritoneal dialysis (CAPD) by himself] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):301–3 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

The genetics of hand-clasping—a review and a familial study. Reiss M. **Ann Hum Biol** 1999 Jan–Feb;26(1):39–48 (47 ref.)

Normal values for total hand length, palm length and middle finger length in Malaysian newborns from 34–42 weeks of gestation. Halder D, et al. **Anthropol Anz** 1999 Mar; 57(1):69–75

Guidelines for force-travel combinations of push button switches for older populations. Rahman MM, et al. **Appl Ergon** 1998 Apr;29(2):93–100

Transfer of contaminants from surface to hands: experimental assessment of linearity of the exposure process, adherence to the skin, and area exposed during fixed pressure and repeated contact with surfaces contaminated with a powder. Brouwer DH, et al. **Appl Occup Environ Hyg** 1999 Apr;14(4):231–9

Electromyographic activity of the lumbar extensor muscles: effect of angle and hand position during Roman chair exercise. Mayer JM, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):751–5

Practice effects on the less-affected upper extremity after stroke. Pohl PS, et al. **Arch Phys Med Rehabil** 1999 Jun; 80(6):668–75

Crutch handle design: effect on palmar loads during ambulation. Sala DA, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1473–6

Functional control of the hand in tetraplegics based on residual synergistic EMG activity. Thorsen R, et al. **Artif Organs** 1999 May;23(5):470–3

Re: Portal JM, Romano PE: Ocular dominance, central, etc. and baseball [letter; comment] Laby DM, et al. **Binocul Vis Strabismus Q** 1998 Fall;13(3 3rd Qtr):165–6. Comment on: Binocul Vis Strabismus Q 1998 Summer–Winter;13(2 2nd Qtr):125–32.

Major review: ocular sighting dominance: a review and a study of athletic proficiency and eye–hand dominance in a collegiate baseball team [see comments] Portal JM, et al. **Binocul Vis Strabismus Q** 1998 Summer–Winter;13(2 2nd Qtr):125–32 (12 ref.). Comment in: Binocul Vis Strabismus Q 1998 Fall;13(3 3rd Qtr):165–6.

Three-dimensional kinematic analysis of influence of hand orientation and joint limits on the control of arm postures and movements. Wang X. **Biol Cybern** 1999 Jun; 80(6):449–63

Manual asymmetries in goal-directed movement: examination of the motor output hypothesis. Binsted G, et al. **Brain Cogn** 1998 Oct;38(1):102–10

Hand–mouth coordination, congenital absence of limb, and evidence for innate body schemas. Gallagher S, et al. **Brain Cogn** 1998 Oct;38(1):53–65

Reference frames and internal models for visuo-manual coordination: what can we learn from microgravity experiments? McIntyre J, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1–2):143–54 (77 ref.)

Corticospinal excitability modulation to hand muscles during movement imagery. Rossini PM, et al. **Cereb Cortex** 1999 Mar;9(2):161–7

Anticipation and execution of a simple reading task enhance corticospinal excitability. Seyal M, et al. **Clin Neurophysiol** 1999 Mar;110(3):424–9

Trigeminal sensory input elicited by electric or magnetic stimulation interferes with the central motor drive to the intrinsic hand muscles. Siebner HR, et al. **Clin Neurophysiol** 1999 Jun;110(6):1090–9

Waveform variation and size of sympathetic skin response: regional difference between the sole and palm recordings. Toyokura M. **Clin Neurophysiol** 1999 Apr;110(4):765–71

Dermal transfer of chlorpyrifos residues from residential surfaces: comparison of hand press, hand drag, wipe, and polyurethane foam roller measurements after broadcast and aerosol pesticide applications. Lu C, et al. **Environ Health Perspect** 1999 Jun;107(6):463–7

Muscle responses to simulated torque reactions of hand-held power tools. Armstrong T, et al. **Ergonomics** 1999 Jan; 42(1):146–59

Deafferentation and pointing with visual double-step perturbations. Bard C, et al. **Exp Brain Res** 1999 Apr; 125(4):410–6

Early motor influences on visuomotor transformations for reaching: a positive image of optic ataxia. Battaglia Mayer A, et al. **Exp Brain Res** 1998 Nov;123(1–2):172–89 (104 ref.)

Ocular perturbations and retinal/extraretinal information: the coordination of saccadic and manual movements. Binsted G, et al. **Exp Brain Res** 1999 Jul;127(2):193–206

Hitting moving targets. Continuous control of the acceleration of the hand on the basis of the target's velocity. Brenner E, et al. **Exp Brain Res** 1998 Oct;122(4):467–74

Effects of voluntary contraction on descending volleys evoked by transcranial electrical stimulation over the motor cortex hand area in conscious humans. Di Lazzaro V, et al. **Exp Brain Res** 1999 Feb;124(4):525–8

The influence of visual illusions on grasp position. Ellis RR, et al. **Exp Brain Res** 1999 Mar;125(2):109–14

Covariation between human intrinsic hand muscles of the silent periods and compound muscle action potentials evoked by magnetic brain stimulation: evidence for common inhibitory connections. Ho KH, et al. **Exp Brain Res** 1998 Oct;122(4):433–40

Motor-learning-related changes in piano players and non-musicians revealed by functional magnetic-resonance signals. Hund-Georgiadis M, et al. **Exp Brain Res** 1999 Apr;125(4):417–25

Effects of short-term adaptation of saccadic gaze amplitude on hand-pointing movements. Kröller J, et al. **Exp Brain Res** 1999 Feb;124(3):351–62

Developmental changes in prehension during childhood. Paré M, et al. **Exp Brain Res** 1999 Apr;125(3):239–47

Hand and joint paths during reaching movements with and without vision. Sergio LE, et al. **Exp Brain Res** 1998 Sep; 122(2):157–64

Hand deviations toward distractors. Evidence for response competition. Welsh TN, et al. **Exp Brain Res** 1999 Jul; 127(2):207–12

Finger movements induced by transcranial magnetic stimulation change with hand posture, but not with coil position. Wassermann EM, et al. **Hum Brain Mapp** 1998; 6(5–6):390–3

Influence of localized auxiliary heating on hand comfort during cold exposure. Brajkovic D, et al. **J Appl Physiol** 1998 Dec;85(6):2054–65

Prediction of upper extremity impact forces during falls on the outstretched hand. Chiu J, et al. **J Biomech** 1998 Dec; 31(12):1169–76

A method and device for measuring force transfers between the deep flexors in the musician's hand. Leijnse JN. **J Biomech** 1998 Sep;31(9):773–9

An instrumented wheel for kinetic analysis of wheelchair propulsion. Wu HW, et al. **J Biomech Eng** 1998 Aug; 120(4):533–5

Comparative analysis of diadochokinetic movements. Hermsdörfer J, et al. **J Electromyogr Kinesiol** 1999 Aug; 9(4):283–95

Analysis of voluntary finger movements during hand tasks by a motion analyzer. Nakamura M, et al. **J Electromyogr Kinesiol** 1998 Oct;8(5):295–303

The scaling of human grip configurations. Cesari P, et al. **J Exp Psychol Hum Percept Perform** 1999 Aug; 25(4):927–35

The effect of age-related stereotypes on response initiation and execution. Chasteen AL, et al. **J Gen Psychol** 1999 Jan;126(1):17–36

Neurophysiological findings in vibration-exposed male workers. Strömberg T, et al. **J Hand Surg [Br]** 1999 Apr; 24(2):203–9

The effects of arm elevation and overnight head-up tilt on forearm and hand volume. Boland RA, et al. **J Hand Ther** 1998 Jul–Sep;11(3):180–90

Hand function in workers with hand–arm vibration syndrome. Cederlund R, et al. **J Hand Ther** 1999 Jan–Mar; 12(1):16–24

A new tactile gnosis instrument in sensibility testing. Rosén B, et al. **J Hand Ther** 1998 Oct–Dec;11(4):251–7

An instrument evaluation framework: description and application to assessments of hand function. Rudman D, et al. **J Hand Ther** 1998 Oct–Dec;11(4):266–77

Reliability of the NK dexterity board. Turgeon TR, et al. **J Hand Ther** 1999 Jan–Mar;12(1):7–15

Hand function and tool behavior in early hominids. Susman RL. **J Hum Evol** 1998 Jul;35(1):23–46 (69 ref.)

Using practice led design research to develop an articulated mechanical analogy of the human hand. Rust C, et al. **J Med Eng Technol** 1998 Sep–Oct;22(5):226–32 (29 ref.)

Contact-evoked changes in EMG activity during human grasp. Collins DF, et al. **J Neurophysiol** 1999 May; 81(5):2215–25

Task-dependent viscoelasticity of human multijoint arm and its spatial characteristics for interaction with environments. Gomi H, et al. **J Neurosci** 1998 Nov 1;18(21):8965–78

Partial inactivation of the primary motor cortex hand area: effects on individuated finger movements. Schieber MH, et al. **J Neurosci** 1998 Nov 1;18(21):9038–54

Digital video: a tool for correlating neuronal firing patterns with hand motor behavior. Ro JY, et al. **J Neurosci Methods** 1998 Aug 1;82(2):215–31

Task-dependent modulation of 15–30 Hz coherence between rectified EMGs from human hand and forearm muscles. Kilner JM, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):559–70

Dissociation of the pathways mediating ipsilateral and contralateral motor-evoked potentials in human hand and arm muscles. Ziemann U, et al. **J Physiol (Lond)** 1999 Aug 1;518 (Pt 3):895–906

Distributions of sensory spots in the hand and two-point discrimination thresholds in the hand, face and mouth in dental students. Sato T, et al. **J Physiol Paris** 1999 May–Jun;93(3):245–50

On taking the grasping out of prehension [comment] Newell KM, et al. **Motor Control** 1999 Jul;3(3):285–8; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

Dissociated small hand muscle involvement in amyotrophic lateral sclerosis detected by motor unit number estimates. Kuwabara S, et al. **Muscle Nerve** 1999 Jul;22(7):870–3

The contribution of the interosseous muscles to the hypothenar compound muscle action potential [see comments] McGill KC, et al. **Muscle Nerve** 1999 Jan; 22(1):6–15. Comment in: Muscle Nerve 1999 Jan;22(1):4–5.

Bimanual coupling in amputees with phantom limbs. Franz EA, et al. **Nat Neurosci** 1998 Oct;1(6):443–4

Brain activation related to the change between bimanual motor programs. de Jong BM, et al. **Neuroimage** 1999 Mar; 9(3):290–7

Who tells one hand what the other is doing: the neurophysiology of bimanual movements. Donchin O, et al. **Neuron** 1999 May;23(1):15–8 (20 ref.)

Frequency representation in the human hand somatosensory cortex: a reappraisal. Hashimoto I, et al. **Neuroreport** 1999 Apr 6;10(5):959–63

Correlates of sequential elements of bimanual behavior in the neuronal activity of the neostriatum in monkeys. Orlov AA, et al. **Neurosci Behav Physiol** 1999 Jan–Feb;29(1):53–9

From eye to hand: planning goal-directed movements. Desmurget M, et al. **Neurosci Biobehav Rev** 1998 Oct; 22(6):761–88 (275 ref.)

The effects of muscular fatigue on the coordination of a multijoint movement in human. Forestier N, et al. **Neurosci Lett** 1998 Aug 21;252(3):187–90

Neural activity of supplementary and primary motor areas in monkeys and its relation to bimanual and unimanual movement sequences. Kazennikov O, et al. **Neuroscience** 1999 Mar;89(3):661–74

Intertester reliability of hand-held dynamometry: a concise summary of published research. Bohannon RW. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):899–902

Men and women holding hands: whose hand is uppermost? Chapell M, et al. **Percept Mot Skills** 1998 Aug;87(1):127–30

Pattern formation in polyrhythmic tapping at a self-paced tempo. Tajima M, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1160–8

Fetal and neonatal hand movement. Sparling JW, et al. **Phys Ther** 1999 Jan;79(1):24–39

Evaluation of hand sensibility with single and double latex gloves. Novak CB, et al. **Plast Reconstr Surg** 1999 Jan; 103(1):128–31

Mass and velocity: control parameters for throwing patterns. Southard D. **Res Q Exerc Sport** 1998 Dec;69(4):355–67

Force distribution across the heel of the hand during simulated manual chest compression. Baubin M, et al. **Resuscitation** 1997 Nov;35(3):259–63

Functional hand development in tetraplegia. Doll U, et al. **Spinal Cord** 1998 Dec;36(12):818–21

[Errors in targeted movements of the hand under the conditions of orbital space flight] Popov KE, et al. **Aviakosm Ekolog Med** 1999;33(2):3–5 (Eng. Abstr.) **(Rus)**

[The thermal imaging assessment of peripheral vascular reactions during local cold exposure in subjects with differing hypoxic resistances] Maksimova AL, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):109–14 **(Rus)**

[Main criteria for the occupational licensure of individualized hand protection against local vibration] Butkovskaia ZM, et al. **Med Tr Prom Ekol** 1999;(5):34–6 (Eng. Abstr.) **(Rus)**

[Single number index of vibratory and force load during hand-arm vibration] Denisov EI. **Med Tr Prom Ekol** 1999; (6):34–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Exposure-response relationship between hand-arm vibration and vibrotactile perception sensitivity. Lundström R, et al. **Am J Ind Med** 1999 May;35(5):456–64 .

Construct validity of the In-Hand Manipulation Test: a discriminant analysis with children without disability and children with spastic diplegia. Breslin DM, et al. **Am J Occup Ther** 1999 Jul–Aug;53(4):381–6

Wheelchair propulsion: descriptive comparison of hemiplegic and two-hand patterns during selected activities. Kirby RL, et al. **Am J Phys Med Rehabil** 1999 Mar–Apr; 78(2):131–5

The alien hand sign--case report and review of the literature. Tow AM, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):582–5 (29 ref.)

Partial status epilepticus associated with asomatognosia and alien hand-like behaviors [corrected] [published erratum appears in Arch Neurol 1999 Jan;56(1):24] Feinberg TE, et al. **Arch Neurol** 1998 Dec;55(12):1574–6

Comparison of nerve conduction techniques in 95 mild carpal tunnel syndrome hands. Kouyoumdjian JA, et al. **Arq Neuropsiquiatr** 1999 Jun;57(2A):195–7

Duration of symptomatology and median segmental sensory latency in 993 carpal tunnel syndrome hands (668 cases). Kouyoumdjian JA. **Arq Neuropsiquiatr** 1999 Jun; 57(2A):198–201

Abnormal cortical processing of voluntary muscle relaxation in patients with focal hand dystonia studied by movement-related potentials. Yazawa S, et al. **Brain** 1999 Jul;122 (Pt 7):1357–66

'Improved hand function remains after upper-limb tendon transfer and muscle release in children with hemiplegia' [letter; comment] Sköld A, et al. **Dev Med Child Neurol** 1999 Apr;41(4):284–5. Comment on: Dev Med Child Neurol 1998 Sep;40(9):612–21.

Is delayed nerve conduction associated with increased self-reported disability in individuals with hand symptoms? A population based study. Ferry S, et al. **J Rheumatol** 1998 Aug;25(8):1616–9

Surgical treatment of intractable epilepsy originating from the primary sensory area of the hand—case report. Asano E, et al. **Neurol Med Chir (Tokyo)** 1999 Mar;39(3):246–50

Monoparesis of the right hand following a localised infarct in the left "precentral knob". Tei H. **Neuroradiology** 1999 Apr;41(4):269–70

[Advanced education by the Diabetes Society. Diabetic cheiropathy and related diseases] Renner R. **MMW Fortschr Med** 1999 Jun 10;141(23):47–9 **(Ger)**

[Primary progressive limb-kinetic apraxia: a case report with an electrophysiological study] Shimo-Nakanishi Y, et al. **No To Shinkei** 1999 May;51(5):439–43 (Eng. Abstr.) **(Jpn)**

[The effect of drugs on hand function in rheumatoid arthritis] Curković B, et al. **Reumatizam** 1997;45(2):9–11 (Eng. Abstr.) **(Scr)**

RADIATION EFFECTS

Radiation exposure to the hands and the thyroid of the surgeon during intramedullary nailing. Müller LP, et al. **Injury** 1998 Jul;29(6):461–8

RADIOGRAPHY

Selenium-based digital radiography versus conventional film-screen radiography of the hands and feet: a subjective comparison. Piraino DW, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):177–84

Metacarpophalangeal pattern profile and bone age in Rett syndrome: further radiological clues to the diagnosis. Leonard H, et al. **Am J Med Genet** 1999 Mar 12;83(2):88–95

Establishing the level of digitization for wrist and hand radiographs for the third National Health and Nutrition Examination Survey. Ostchega Y, et al. **J Digit Imaging** 1998 Aug;11(3):116–20

Clinical evaluation of irreversible data compression for computed radiography of the hand. Uchida K, et al. **J Digit Imaging** 1998 Aug;11(3):121–5

Quantitative assessment of trabecular bone pattern identification. Kahana T, et al. **J Forensic Sci** 1998 Nov; 43(6):1144–7

Phalangeal cone-shaped epiphyses of the hand: their natural history, diagnostic sensitivity, and specificity in cartilage hair hypoplasia and the trichorhinophalangeal syndromes I and II. Giedion A. **Pediatr Radiol** 1998 Oct;28(10):751–8

Analysis of bone age data from national cooperative growth study substudy VII. Kemp SF, et al. **Pediatrics** 1999 Oct; 104(4 Pt 2):1031–6

Chondrosarcoma of the short tubular bones of the hands and feet. Cawte TG, et al. **Skeletal Radiol** 1998 Nov; 27(11):625–32

[Picture of the month] Hansen TM, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4417 **(Dan)**

[Radiology of the manual skeleton. 1. Inflammatory joint diseases and rheumatology] Uhl M. **Radiologe** 1999 May; 39(5):432–49 **(Ger)**

SURGERY

Tissue adhesives and applications in plastic and reconstructive surgery. Saltz R, et al. **Aesthetic Plast Surg** 1998 Nov–Dec;22(6):439–43

Malignant fibrous histiocytoma of the hand: multimodal therapy and extensor tendon reconstruction. Lohman R, et al. **Ann Plast Surg** 1998 Nov;41(5):544–9

Full-thickness skin graft from the ulnar aspect of the wrist to cover defects on the hand and digits. Park S, et al. **Ann Plast Surg** 1999 Feb;42(2):129–31

The distally based island posterior interosseous flap [letter; comment] Costa H. **Br J Plast Surg** 1998 Dec;51(8):650–1 . Comment on: Br J Plast Surg 1998 Dec;51(8):642–5.

'Improved hand function remains after upper-limb tendon transfer and muscle release in children with hemiplegia' [letter; comment] Sköld A, et al. **Dev Med Child Neurol** 1999 Apr;41(4):284–5. Comment on: Dev Med Child Neurol 1998 Sep;40(9):612–21.

Complications of the operative treatment of Dupuytren's disease. Boyer MI, et al. **Hand Clin** 1999 Feb;15(1):161–6, viii

Nosocomial infections in hand surgery. Calkins ER. **Hand Clin** 1998 Nov;14(4):531–45, vii (181 ref.)

The role of antibiotics in the management of elective and post-traumatic hand surgery. Hoffman RD, et al. **Hand Clin** 1998 Nov;14(4):657–66 (89 ref.)

Surgical treatment of Dupuytren's disease. Jabaley ME. **Hand Clin** 1999 Feb;15(1):109–26, vii

Open-palm technique and soft-tissue coverage in Dupuytren's disease. Lubahn JD. **Hand Clin** 1999 Feb; 15(1):127–36 (44 ref.)

Postoperative infection in hand surgery. Cause, prevention, and treatment. Shapiro DB. **Hand Clin** 1998 Nov; 14(4):669–81, x (127 ref.)

Medical hypnosis and orthopedic hand surgery: pain perception, postoperative recovery, and therapeutic comfort. Mauer MH, et al. **Int J Clin Exp Hypn** 1999 Apr; 47(2):144–61

Kienbock's disease: treatment by implantation of vascular pedicle and bone grafting. Moneim MS, et al. **Iowa Orthop J** 1998;18:67–73

Surgical pearl: the first dorsal web of the hand as a graft donor site for the defects on the hand and digits. Cheng ST, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):250–1

Low moments in my surgical career. Brand P. **J Hand Surg [Am]** 1999 Jul;24(4):662–7

The journal club and its role in hand surgery education. Melchior JA, et al. **J Hand Surg [Am]** 1998 Nov;23(6):972–6

Musculoskeletal outcome measures [letter; comment] Melhorn JM. **J Hand Surg [Am]** 1998 Nov;23(6):1115–7. Comment on: J Hand Surg [Am] 1998 Jan;23(1):1–2.

Portable mini-fluoroscopy improves operative efficiency in hand surgery. Wolf JM, et al. **J Hand Surg [Am]** 1999 Jan; 24(1):182–4

Operative fluoroscopy in hand and upper limb surgery. One hundred cases. Bain GI, et al. **J Hand Surg [Br]** 1997 Oct; 22(5):656–8

The first 30 years of the British Society for Surgery of the Hand. Barton NJ. **J Hand Surg [Br]** 1998 Dec;23(6):711–23

An unusual case of multiple recurrence of a glomangioma. Looi KP, et al. **J Hand Surg [Br]** 1999 Jun;24(3):387–9

Free tendon interposition grafting for the repair of ruptured extensor tendons in the rheumatoid hand. A clinical and biomechanical assessment. Mountney J, et al. **J Hand Surg [Br]** 1998 Oct;23(5):662–5

Ischaemia-reperfusion injury. Implications for the hand surgeon. al-Qattan MM. **J Hand Surg [Br]** 1998 Oct; 23(5):570–3 (37 ref.)

The V-Y Palmar flap. Rider MA, et al. **J Hand Surg [Br]** 1998 Oct;23(5):669–72

Risk factors and prophylactic tenosynovectomy for extensor tendon ruptures in the rheumatoid hand. Ryu J, et al. **J Hand Surg [Br]** 1998 Oct;23(5):658–61

Sintered bone implantation for the treatment of benign bone tumours in the hand. Taniguchi Y, et al. **J Hand Surg [Br]** 1999 Feb;24(1):109–12

Replantation in children. Yildiz M, et al. **Microsurgery** 1998; 18(7):410–3

Fist position for skin grafting on the dorsal hand: I. Analysis of length of the dorsal hand surgery in hand positions. Burm JS, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1350–5

The distally based forearm island flap in hand reconstruction [letter] Doğan T, et al. **Plast Reconstr Surg** 1999 Oct; 104(5):1581–2

Reconstructive hand surgery [clinical conference] Ejeskär A, et al. **Spinal Cord** 1999 Jul;37(7):475–9

[An anatomic study of the superficial radial nerve and its clinical implications] Leroux M, et al. **Ann Chir** 1998; 52(8):736–43 (Eng. Abstr.) **(Fre)**

[What's new in surgery of flexor tendons?] Ebelin M. **Ann Chir Plast Esthet** 1998 Dec;43(6):606–10 (Eng. Abstr.) **(Fre)**

[What's new in cosmetic surgery of the hand? Technical notes] Saffar P. **Ann Chir Plast Esthet** 1998 Dec;43(6):630–4 (Eng. Abstr.) **(Fre)**

[Humanitarian surgery of the hand. Our experience in Vietnam] Voche P, et al. **Ann Chir Plast Esthet** 1999 Feb; 44(1):64–71 (Eng. Abstr.) **(Fre)**

[Early and late treatment of iatrogenic injection damage] von Heimburg D, et al. **Chirurg** 1998 Dec;69(12):1378–82 (Eng. Abstr.) **(Ger)**

[What is the value of biomechanical knowledge for surgery of the hand?] Kummer B, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):212–8 (34 ref.) (Eng. Abstr.) **(Ger)**

[The palliative surgical treatment of paralysis of the hand] Colonna MR, et al. **Ann Ital Chir** 1998 Jul–Aug; 69(4):465–72 (Eng. Abstr.) **(Ita)**

[Report on 6-week visit of the Indiana Hand Center (Indianapolis, USA)] Doleżal SA. **Chir Narzadow Ruchu Ortop Pol** 1998;63(3):300–2 **(Pol)**

TRANSPLANTATION

Wearing your organ transplant on your sleeve [news] Caplan AL. **Hastings Cent Rep** 1999 Mar–Apr;29(2):52

Human hand allograft: report on first 6 months [see comments] Dubernard JM, et al. **Lancet** 1999 Apr 17; 353(9161):1315–20. Comment in: Lancet 1999 Apr 17;353(9161):1286–7.

Prospects for hand transplantation [comment] Foucher G. **Lancet** 1999 Apr 17;353(9161):1286–7. Comment on: Lancet 1999 Apr 17;353(9161):1315–20.

ULTRASONOGRAPHY

Doppler spectral waveform analysis of arteries of the hand in patients with Raynaud's phenomenon as compared with healthy subjects. Chikui T, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1605–9

High-frequency ultrasound examination of the wrist and hand. Bianchi S, et al. **Skeletal Radiol** 1999 Mar;28(3):121–9 (59 ref.)

[Ultrasound in the demonstration of a wood splinter in the hand] Hierholzer J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):169–70 **(Ger)**

HAND DEFORMITIES

CONGENITAL see HAND DEFORMITIES, CONGENITAL

EPIDEMIOLOGY

Prevalence of mutilans-like hand deformities in patients with seropositive rheumatoid arthritis. A prospective 20-year study. Yoshida M, et al. **Scand J Rheumatol** 1999; 28(1):38–40

GENETICS

Haploinsufficiency of the HOXA gene cluster, in a patient with hand-foot-genital syndrome, velopharyngeal insufficiency, and persistent patent Ductus botalli [letter] Devriendt K, et al. **Am J Hum Genet** 1999 Jul;65(1):249–51

Cephalometric analysis of families with dominantly inherited Crouzon syndrome: an aid to diagnosis in family studies. Murdoch-Kinch CA, et al. **Am J Med Genet** 1998 Jun 5;77(5):405–11

HAND DEFORMITIES, ACQUIRED

Expandable rings. A new solution to an old problem. Giddins GE. **J Hand Surg [Br]** 1997 Oct;22(5):580–1

COMPLICATIONS

Psychomotor development in children with triphalangeal thumbs. A preliminary study. Zguricas J, et al. **J Hand Surg [Br]** 1998 Aug;23(4):526–9

HAND DEFORMITIES, ACQUIRED

DIAGNOSIS

Restoring hand function in patients with severe polyneuropathy: the role of electromyography before tendon transfer surgery. Mackin GA, et al. **J Hand Surg [Am]** 1999 Jul;24(4):732–42

ECONOMICS

Hand burns in young patients--loss of self-sufficiency and economic productivity [letter; comment] Borman H, et al. **Ann Plast Surg** 1998 Sep;41(3):335. Comment on: Ann Plast Surg 1998 Mar;40(3):268–76.

ETIOLOGY

Assessment of mutilans-like hand deformities in chronic inflammatory joint diseases. A radiographic study of 52 patients. Belt EA, et al. **Ann Rheum Dis** 1999 Apr; 58(4):250–2

Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. van Vugt RM, et al. **Ann Rheum Dis** 1998 Sep;57(9):540–4

Volkmann's ischemic contracture of the upper extremity. Botte MJ, et al. **Hand Clin** 1998 Aug;14(3):483–97, x (128 ref.)

Reconstruction of intrinsic hand deformities. Lee FS, et al. **Hand Clin** 1998 Aug;14(3):499–506, xi (26 ref.)

Extensor tendon dislocation in cerebral palsy. Nossaman BC, et al. **J Hand Surg [Br]** 1999 Apr;24(2):233–4

The tragedy of deformity in childhood leprosy [letter] Hammond PJ, et al. **Lepr Rev** 1999 Jun;70(2):217–20

Expression of heat shock protein 27 in chromomycosis. Bayerl C, et al. **Mycoses** 1998 Dec;41(11–12):447–52

[Pachydermodactyly: seven new cases] Bardazzi F, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):247–50 (42 ref.) (Eng. Abstr.) **(Fre)**

[A deformed hand] Toussirot E, et al. **Rev Med Interne** 1998 Nov;19(11):835–6 **(Fre)**

MICROBIOLOGY

Chronic otitis and tenosynovitis in an elderly diabetic woman. Ortiz E, et al. **Postgrad Med J** 1999 Feb;75(880):121–3

RADIOGRAPHY

[Ulnar deviation and swan neck deformity of the hands and high titer antinuclear antibodies] Zuber M, et al. **Med Klin** 1998 Nov 15;93(11):684–5 **(Ger)**

SURGERY

Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. Eisenberg M, et al. **Br J Plast Surg** 1998 Dec;51(8):608–13

Operative correction of swan-neck and boutonniere deformities in the rheumatoid hand. Boyer MI, et al. **J Am Acad Orthop Surg** 1999 Mar–Apr;7(2):92–100

Abducted, hyperextended small finger deformity of nonneurologic etiology. Lourie GM, et al. **J Hand Surg [Am]** 1999 Mar;24(2):315–9

Arthroplasty of the hand and wrist: surgeon's perspective [see comments] Kozin SH. **J Hand Ther** 1999 Apr–Jun; 12(2):123–32 (63 ref.). Comment in: J Hand Ther 1999 Apr–Jun;12(2):133–4.

Indications for surgery in leprosy. Virmond M. **Lepr Rev** 1998 Sep;69(3):297–304 (0 ref.)

Adiposubcutaneous flap for reconstruction of first web space depression in ulnar paralysis in leprosy patients [letter] Prakash V, et al. **Plast Reconstr Surg** 1998 Dec; 102(7):2519–21

Introducing a solid model for reconstructing the severely deformed hand. Tanino R, et al. **Tokai J Exp Clin Med** 1997 Oct;22(4):141–9

[Experimental study and clinical application of arterialized venous skin flap] Chen J, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Sep;11(5):286–90 (Eng. Abstr.) **(Chi)**

[What's new in cosmetic surgery of the hand? Technical notes] Saffar P. **Ann Chir Plast Esthet** 1998 Dec;43(6):630–4 (Eng. Abstr.) **(Fre)**

[Humanitarian surgery of the hand. Our experience in Vietnam] Voche P, et al. **Ann Chir Plast Esthet** 1999 Feb; 44(1):64–71 (Eng. Abstr.) **(Fre)**

[Angulation deformity of a finger after local radiotherapy] Bocquet G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Jul; 84(4):373–6 (Eng. Abstr.) **(Fre)**

[Surgical treatment of Thibièrge-Weissenbach syndrome and other calcinoses of the hand. Case report and review of the literature] Kauschke T, et al. **Handchir Mikrochir Plast Chir** 1999 Jan;31(1):57–60 (21 ref.) (Eng. Abstr.) **(Ger)**

[Does the open palm technique for surgery of Dupuytren's contracture extend treatment and disability duration? A retrospective study] Krüger-Sayn M, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):269–71 (Eng. Abstr.) **(Ger)**

[Fibrolipomatous hamartoma of the nerve--a rare etiology of macrodactyly. A case report] Ruppert V, et al. **Handchir Mikrochir Plast Chir** 1999 Jan;31(1):53–6 (Eng. Abstr.) **(Ger)**

THERAPY

Intermittent compression for the treatment of the oedematous hand in hemiplegic stroke: a randomized controlled trial. Roper TA, et al. **Age Ageing** 1999 Jan;28(1):9–13

A review of the management of the hand in dystrophic epidermolysis bullosa. Mullett F. **J Hand Ther** 1998 Oct–Dec;11(4):261–5 (23 ref.)

HAND DEFORMITIES, CONGENITAL

An unusual carpal coalition associated with fifth ray anomalies in the hand. Gómez Robledo J. **J Hand Surg [Br]** 1998 Aug;23(4):537–8

CLASSIFICATION

Congenital hand problems. Terminology, etiology, and management. Netscher DT. **Clin Plast Surg** 1998 Oct; 25(4):537–52

Classification of the mirror hand–multiple hand spectrum. Al-Qattan MM, et al. **J Hand Surg [Br]** 1998 Aug; 23(4):534–6

COMPLICATIONS

Advanced carpal collapse associated with congenital hypoplastic thumb. Morris AD, et al. **J Hand Surg [Br]** 1999 Aug;24(4):489–92

DIAGNOSIS

MR imaging in longitudinal epiphyseal bracket in children. Mahboubi S, et al. **Pediatr Radiol** 1999 Apr;29(4):259–61

GENETICS

Brachydactyly type B: clinical description, genetic mapping to chromosome 9q, and evidence for a shared ancestral mutation. Gong Y, et al. **Am J Hum Genet** 1999 Feb; 64(2):570–7

Brachydactyly type B: linkage to chromosome 9q22 and evidence for genetic heterogeneity. Oldridge M, et al. **Am J Hum Genet** 1999 Feb;64(2):578–85

Fine mapping of the split-hand/split-foot locus (SHFM3) at 10q24: evidence for anticipation and segregation distortion. Ozen RS, et al. **Am J Hum Genet** 1999 Jun; 64(6):1646–54

Limb mammary syndrome: a new genetic disorder with mammary hypoplasia, ectrodactyly, and other Hand/Foot anomalies maps to human chromosome 3q27. van Bokhoven H, et al. **Am J Hum Genet** 1999 Feb;64(2):538–46

Further delineation of the Verloes-Koulischer-oro-acral syndrome [letter; comment] de Silva DC, et al. **Am J Med Genet** 1998 Dec 28;80(5):535–7. Comment on: Am J Med Genet 1992 Nov 15;44(5):605–7. Comment on: Am J Med Genet 1992 Nov 15;44(5):608–10.

Bilateral involvement of hands and legs in the Gollop-Wolfgang complex [letter] Endo A, et al. **Am J Med Genet** 1998 Dec 28;80(5):529–30

Clinical and molecular studies of brachydactyly type D. Robin NH, et al. **Am J Med Genet** 1999 Aug 6;85(4):413–8

Holt-Oram syndrome. Brockhoff CJ, et al. **Circulation** 1999 Mar 16;99(10):1395–6

Char syndrome, an inherited disorder with patent ductus arteriosus, maps to chromosome 6p12-p21. Satoda M, et al. **Circulation** 1999 Jun 15;99(23):3036–42

A new multiple congenital anomaly, mental retardation syndrome with preaxial brachydactyly, hyperphalangism, deafness and orodental anomalies. Temtamy SA, et al. **Clin Dysmorphol** 1998 Oct;7(4):249–55

Ontogeny of clenched-hand development in trisomy 18 fetuses: A serial transabdominal fetoscopic observation. Quintero RA, et al. **Fetal Diagn Ther** 1999 Mar–Apr; 14(2):68–70

A large family with type IV radial polydactyly. Seyhan A, et al. **J Hand Surg [Br]** 1998 Aug;23(4):530–3

Hand involvement in 13q deletion syndrome. Grindel SI, et al. **J Pediatr Orthop** 1999 Sep–Oct;19(5):620–3

The orthopaedic presentation and management of Sjögren-Larsson syndrome. Haddad FS, et al. **J Pediatr Orthop** 1999 Sep–Oct;19(5):617–9

EEM syndrome: report of a family and results of a ten-year follow-up. Balarin Silva V, et al. **Ophthalmic Genet** 1999 Jun;20(2):95–9

Retinitis pigmentosa, mental retardation, marked short stature, and brachydactyly in two sibs. Lorda-Sanchez I, et al. **Ophthalmic Genet** 1999 Jun;20(2):127–31

Molecular biology and congenital hand anomalies: from molecules and mutations to man. Witt PD, et al. **Plast Reconstr Surg** 1998 Nov;102(6):2254–67 (40 ref.)

An apology [letter] Witt PD. **Plast Reconstr Surg** 1999 Sep; 104(3):887

PATHOLOGY

Complex camptopolydactyly: an unusual hand malformation. Phadke SR, et al. **Am J Med Genet** 1999 Mar 19;83(3):191–2

Cleft palate, ptosis, digital anomalies and mental retardation: a new syndrome or a distal arthrogryposis variant? [letter] Boles RG. **Clin Dysmorphol** 1999 Jan;8(1):63–5

Brachydactyly type B with its distinct facies and 'Cooks syndrome' are the same entity. de Ravel TJ, et al. **Clin Dysmorphol** 1999 Jan;8(1):41–5

Dominant inheritance of cleft palate with minor abnormalities of hands and feet: a new syndrome? Kirk EP, et al. **Clin Dysmorphol** 1999 Jul;8(3):193–7

Ophthalmo-acromelic syndrome (Waardenburg) with split hand and polydactyly. Mégarbané A, et al. **Genet Couns** 1998;9(3):195–9

PHYSIOPATHOLOGY

Robinow syndrome, vaginal atresia, hematocolpos, and extra middle finger. Balci S, et al. **Am J Med Genet** 1998 Aug 27;79(1):27–9

PSYCHOLOGY

Intelligence and development in Aarskog syndrome. Logie LJ, et al. **Arch Dis Child** 1998 Oct;79(4):359–60

RADIOGRAPHY

Clinical and molecular studies of brachydactyly type D. Robin NH, et al. **Am J Med Genet** 1999 Aug 6;85(4):413–8

Relatively longer hand in patients with Ullrich-Turner syndrome. Uematsu A, et al. **Am J Med Genet** 1999 Jan 29;82(3):254–6

Brachydactyly type B: case report and further evidence for clinical heterogeneity. Slavotinek A, et al. **Clin Dysmorphol** 1999 Jul;8(3):165–71

Congenital anomalies of the hand. Smith JG, et al. **Clin Pediatr (Phila)** 1998 Aug;37(8):459–67

REHABILITATION

Treatment of congenital differences of the upper extremity: therapist's commentary. Fuller M. **J Hand Ther** 1999 Apr–Jun;12(2):174–7 (13 ref.)

SURGERY

Congenital contracture of the superficial flexor of the hand. Smrčka V, et al. **Acta Chir Plast** 1998;40(4):109–11

A sporadic case of tetramelic mirror-image polydactyly and unilateral tibial hypoplasia without associated anomalies. Borg DH, et al. **J Hand Surg [Br]** 1999 Aug;24(4):482–5

Congenital palmar nail syndrome. Al-Qattan MM, et al. **J Hand Surg [Br]** 1997 Oct;22(5):674–5

Congenital absence of flexor pollicis longus without hypoplasia of the thenar muscles. Thomas C, et al. **J Hand Surg [Br]** 1999 Jun;24(3):385–6

Double second toe transfer in congenital hand anomalies. Van Holder C, et al. **J Hand Surg [Br]** 1999 Aug; 24(4):471–5

Distraction and microvascular epiphysis transfer for radial club hand. Vilkki SK. **J Hand Surg [Br]** 1998 Aug; 23(4):445–52

The role of metacarpophalangeal pattern (MCPP) profile analysis in the treatment of triphalangeal thumbs. Description of a method and a case report. Zguricas J, et al. **J Hand Surg [Br]** 1997 Oct;22(5):631–5

Treatment of congenital differences of the upper extremity: surgeon's perspective. Lourie GM. **J Hand Ther** 1999 Apr–Jun;12(2):164–73 (30 ref.)

Axillary brachial plexus block for perioperative analgesia in 250 children. Fisher WJ, et al. **Paediatr Anaesth** 1999; 9(5):435–8

[Humanitarian surgery of the hand. Our experience in Vietnam] Voche P, et al. **Ann Chir Plast Esthet** 1999 Feb; 44(1):64–71 (Eng. Abstr.) **(Fre)**

[Analysis of hand function with the Millesi examination scale in patients with pollicisation after aplasia or hypoplasia of the thumb] Knabl JS, et al. **Handchir Mikrochir Plast Chir** 1998 Sep;30(5):317–24 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Prenatal sonographic diagnosis of VATER association. Tongsong T, et al. **J Clin Ultrasound** 1999 Sep;27(7):378–84

Prenatal diagnosis of distal arthrogryposis type 1. Dudkiewicz I, et al. **Skeletal Radiol** 1999 Apr;28(4):233–5

Three-dimensional ultrasound examination of the fetal hands: normal and abnormal [see comments] Budorick NE, et al. **Ultrasound Obstet Gynecol** 1998 Oct;12(4):227–34. Comment in: Ultrasound Obstet Gynecol 1998 Oct;12(4):225–6.

Three-dimensional ultrasonographic assessment of fetal hands and feet [see comments] Hata T, et al. **Ultrasound Obstet Gynecol** 1998 Oct;12(4):235–9. Comment in: Ultrasound Obstet Gynecol 1998 Oct;12(4):225–6.

HAND DERMATOSES

Hand eczema in a nurse [letter] **Hawaii Med J** 1999 Jun; 58(6):144

[Whitlow and phlegmon of the tendon sheaths. Diagnosis, evolution, treatment] Loy S, et al. **Rev Prat** 1998 Oct 1; 48(15):1723–8 (00 ref.) **(Fre)**

CHEMICALLY INDUCED

Ring-induced nail pitting? [letter] Grimm V, et al. **Acta Derm Venereol** 1999 Jan;79(1):82

Chemotherapy-induced acral erythema [letter] Vargas-Diez E, et al. **Acta Derm Venereol** 1999 Mar;79(2):173–5

An epidemiological study of hand eczema. I. Prevalence and cumulative prevalence among hairdressers compared with a control group of teachers. Holm JO, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;187:8–11

An epidemiological study of hand eczema. VI. A follow-up of hairdresser trainees, with the focus on various health complaints. Holm JO.
Acta Derm Venereol Suppl (Stockh) 1994;187:26-7

An epidemiological study of hand eczema. II. Prevalence of atopic diathesis in hairdressers, compared with a control group of teachers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:12-4

An epidemiological study of hand eczema. V. Prevalence among hairdresser trainees, compared with a general population of hairdressers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:23-5

An epidemiological study of hand eczema. III. Characterization of hairdressers with and without hand eczema, regarding demographic factors and medical histories. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:15-7

Formaldehyde allergy: A follow-up study. Agner T, et al. **Am J Contact Dermat** 1999 Mar;10(1):12-7

Occupational allergic contact dermatitis from cyanoacrylate. Conde-Salazar L, et al. **Am J Contact Dermat** 1998 Sep; 9(3):188-9

Onycholysis from nail lacquer: a complication of nail enhancement? Guin JD, et al. **Am J Contact Dermat** 1999 Mar;10(1):34-6

Occupational protein contact dermatitis to cornstarch in a paper adhesive. Guin JD, et al. **Am J Contact Dermat** 1999 Jun;10(2):83-8

Garlic-related dermatoses: case report and review of the literature. Jappe U, et al. **Am J Contact Dermat** 1999 Mar; 10(1):37-9

Irritant contact dermatitis caused by methyl iodide [letter] Knudsen HE, et al. **Am J Contact Dermat** 1999 Jun; 10(2):98-9

Allergic contact dermatitis caused by sorbic acid: rare occurrence [letter] Patrizi A, et al.
Am J Contact Dermat 1999 Mar;10(1):52

Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer [letter] Suehiro M, et al. **Br J Dermatol** 1998 Oct;139(4):748-9

Acral erythema induced by chemotherapy with cisplatin [letter] Vakalis D, et al. **Br J Dermatol** 1998 Oct; 139(4):750-1

Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Azurdia RM, et al. **Clin Exp Dermatol** 1999 Mar; 24(2):64-6

Pulpitis of the fingers from a shoe glue containing 1,2-benzisothiazolin-3-one (BIT). Ayadi M, et al.
Contact Dermatitis 1999 Feb;40(2):115-6

Contact allergy to methyl ethyl ketone peroxide and cobalt in the manufacture of fibreglass-reinforced plastics. Bhushan M, et al. **Contact Dermatitis** 1998 Oct;39(4):203

Octopus apollyon bite. Brazzelli V, et al.
Contact Dermatitis 1999 Mar;40(3):169-70

Glove powder affects skin roughness, one parameter of skin irritation. Brehler R, et al. **Contact Dermatitis** 1998 Nov; 39(5):227-30

Occupational hand dermatitis due to 1,2-benzisothiazolin-3-one in the water-softener manufacturing industry. Cooper SM, et al.
Contact Dermatitis 1999 Apr;40(4):221

Occupational allergic contact dermatitis from cassia (Chinese cinnamon) as a flavouring agent in coffee. De Benito V, et al. **Contact Dermatitis** 1999 Mar;40(3):165

Contact dermatitis caused by benzoyl peroxide in podiatrists. Dejobert Y, et al. **Contact Dermatitis** 1999 Mar;40(3):163

Palmoplantar dermatitis may be due to phenol-formaldehyde resin contact dermatitis. Downs AM, et al.
Contact Dermatitis 1998 Sep;39(3):147-8

Occupational allergic contact dermatitis from ceftiofur without cross-sensitivity. Garcia F, et al.
Contact Dermatitis 1998 Nov;39(5):260

Long-lasting contact urticaria from petrolatum mimicking dermatitis. Grin R, et al. **Contact Dermatitis** 1999 Feb; 40(2):110

Psoriasis of the hands köbnerizing in contact dermatitis. Hill VA, et al. **Contact Dermatitis** 1998 Oct;39(4):194

Eczematous reaction to hepatitis B vaccine. McKenna KE. **Contact Dermatitis** 1999 Mar;40(3):158-9

Occupational contact dermatitis from acrylic monomer in paint. Nakamura M, et al. **Contact Dermatitis** 1999 Apr; 40(4):228-9

Contact dermatitis from barley. Pereira F, et al.
Contact Dermatitis 1998 Nov;39(5):261-2

Allergic contact dermatitis from furaltadone in eardrops. Sánchez-Pérez J, et al. **Contact Dermatitis** 1999 Apr; 40(4):222

Allergic contact dermatitis in food handlers, with patch tests positive to Compositae mix but negative to sesquiterpene lactone mix. Shum KW, et al. **Contact Dermatitis** 1998 Oct; 39(4):207-8

Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis. Breier F, et al.
Dermatology 1998;197(3):271-3

Fixed drug eruption in hands caused by omeprazole. Kepekci Y, et al. **Int J Clin Pharmacol Ther** 1999 Jun;37(6):307-9

Occupational allergic contact dermatitis from unsaturated polyester resin in a car repair putty. Kanerva L, et al.
Int J Dermatol 1999 Jun;38(6):447-52

Allergic contact dermatitis due to pine wood [letter] Miranda-Romero A, et al.
J Eur Acad Dermatol Venereol 1999 Jan;12(1):69-70

Disseminated superficial actinic porokeratosis like drug eruption: a case report. Hwang SM, et al.
J Korean Med Sci 1999 Apr;14(2):227-9

Re: 'Finger discoloration due to silver nitrate exposure', December 1998 (J Roy Soc Health; 118 (6); 371-374) [letter; comment] Hawkes AJ. **J R Soc Health** 1999 Mar; 119(1):59. Comment on: J R Soc Health 1998 Dec;118(6):371-4.

Repeated hand urticaria due to contact with fishfood. Harvima RJ, et al. **Scand J Work Environ Health** 1999 Apr; 25(2):151-2

CLASSIFICATION

[True and false acrocyanoses] Amblard P. **Rev Prat** 1998 Oct 1;48(15):1665-8 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Psoriasis of the palms and soles in frequently associated with oropharyngeal Candida albicans. Skinner RB Jr, et al.
Acta Derm Venereol Suppl (Stockh) 1994;186:149-50

Sarcoidosis presenting as palmar erythema. Cliff S, et al.
Clin Exp Dermatol 1998 May;23(3):123-4

Palmoplantar keratoderma and leukokeratosis anogenitalis: the second case of a new disease. Lautenschlager S, et al.
Dermatology 1998;197(3):300-2

Tripe palms preceding squamous cell carcinoma of the lung by 11 months [letter] Stavrianeas NG, et al.
Dermatology 1999;198(2):173-4

A case of herpetic whitlow associated with erythema multiforme. de Ocariz MM, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):384-5

DIAGNOSIS

Hand eczema: evaluation of 250 patients. Duarte I, et al. **Am J Contact Dermat** 1998 Dec;9(4):216-23

Hand eczema: a 15-minute tour of the Louvre or how to mold frustration into the Winged Victory. Jordan WP.
Am J Contact Dermat 1998 Dec;9(4):240

Polymerase chain reaction-reverse cross-blot hybridization assay in the diagnosis of sporotrichoid Mycobacterium marinum infection. Posteraro B, et al. **Br J Dermatol** 1998 Nov;139(5):872-6

Hand dermatitis caused by ferns. de Cock PA, et al.
Contact Dermatitis 1998 Dec;39(6):324

A hand immersion test under laboratory-controlled usage conditions: the need for sensitive and controlled assessment methods. Paye M, et al. **Contact Dermatitis** 1999 Mar; 40(3):133-8

Fixed drug eruption in hands caused by omeprazole. Kepekci Y, et al. **Int J Clin Pharmacol Ther** 1999 Jun;37(6):307-9

Cutaneous phaeohyphomycosis due to Cladophialophora bantiana. Patterson JW, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):364-6

Dyschromatosis symmetrica hereditaria in an Indian family [letter] Hemanthkumar, et al. **J Dermatol** 1999 Aug; 26(8):544-5

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507-24, ix-x (6 ref.)

PCR-based diagnosis of a case of herpetic whitlow in an AIDS patient. Nogueira ML, et al.
Rev Inst Med Trop Sao Paulo 1998 Sep-Oct;40(5):317-9

[Pachydermodactyly: seven new cases] Bardazzi F, et al.
Ann Dermatol Venereol 1998 Apr;125(4):247-50 (42 ref.) (Eng. Abstr.) **(Fre)**

[Acral papular lichen myxedematosus] Gartner S, et al.
Hautarzt 1998 Nov;49(11):855-8 (Eng. Abstr.) **(Ger)**

[Fever and petechiae developing over several days] von Wichmann MA, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):379-80 **(Spa)**

[Pyoderma gangrenosum with an atypical location and a rapid response to cyclosporin A] Ferrer Rios T, et al.
Gastroenterol Hepatol 1999 May;22(5):227-9 (16 ref.) (Eng. Abstr.) **(Spa)**

[Fever, adenopathies and a papulopustular lesion of the finger] Bachiller Luque P, et al. **Rev Clin Esp** 1999 Apr; 199(4):253-4 **(Spa)**

DRUG THERAPY

Antipruritic potency of serotonin type 3 (5-HT3) receptor antagonists--a reply [letter; comment] Weisshaar E, et al. **Arch Dermatol** 1999 May;135(5):599-600. Comment on: Arch Dermatol 1998 Aug;134(8):925-6.

How to manage warts. Verbov J. **Arch Dis Child** 1999 Jan; 80(1):97-9

Cutaneous tuberculosis: efficient therapeutic response in a case with multiple lesions. Chinchilla D, et al. **Cutis** 1999 Jul;64(1):49-52

Treatment of cutaneous sarcoidosis using phonophoresis. Gogstetter DS, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):767-9

Botulinum toxin in the treatment of palmar hyperhidrosis [letter; comment] Holmes S, et al. **J Am Acad Dermatol** 1998 Dec;39(6):1040-1. Comment on: J Am Acad Dermatol 1998 Feb;38(2 Pt 1):227-9.

A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. Kurwa HA, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):414-8

Onychomycosis in a 2-year-old child successfully treated with oral terbinafine. Ungpakorn R, et al.
J Am Acad Dermatol 1998 Oct;39(4 Pt 1):654-5

A case of pre-Sézary syndrome preceded by hand lesions. Lee NH, et al. **J Dermatol** 1999 Jul;26(7):465-8

Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. Mancini AJ, et al.
Pediatr Dermatol 1998 Sep-Oct;15(5):337-41

PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Behrens S, et al. **Photodermatol Photoimmunol Photomed** 1999 Apr; 15(2):47-51

Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy. Grundmann-Kollmann M, et al.
Photodermatol Photoimmunol Photomed 1999 Apr; 15(2):87-9

[Clinical and experimental studies on composite divitriol infusion in treating tinea manum] Yang ZB, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1997 Mar; 17(3):150-1 (Eng. Abstr.) **(Chi)**

[Pyoderma gangrenosum with an atypical location and a rapid response to cyclosporin A] Ferrer Rios T, et al.
Gastroenterol Hepatol 1999 May;22(5):227-9 (16 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Prevalence of self-reported hand dermatosis in upper secondary school pupils. Yngveson M, et al.
Acta Derm Venereol 1998 Sep;78(5):371-4

An epidemiological study of hand eczema. VI. A follow-up of hairdresser trainees, with the focus on various health complaints. Holm JO.
Acta Derm Venereol Suppl (Stockh) 1994;187:26-7

An epidemiological study of hand eczema. V. Prevalence among hairdresser trainees, compared with a general population of hairdressers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:23-5

An epidemiological study of hand eczema. I. Prevalence and cumulative prevalence among hairdressers compared with a control group of teachers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:8-11

An epidemiological study of hand eczema. III. Characterization of hairdressers with and without hand eczema, regarding demographic factors and medical histories. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:15-7

An epidemiological study of hand eczema. II. Prevalence of atopic diathesis in hairdressers, compared with a control group of teachers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:12-4

An epidemiological study of hand eczema. IV. Degree and pattern of eczema in affected hairdressers, with and without atopic symptoms, compared with a control group of affected teachers. Holm JO, et al.
Acta Derm Venereol Suppl (Stockh) 1994;187:18-22

Prevalence and incidence of hand dermatitis in hairdressing apprentices: results of the POSH study. Prevention of occupational skin disease in hairdressers. Uter W, et al.
Int Arch Occup Environ Health 1998 Oct;71(7):487-92

Hand dermatitis in intensive care units. Forrester BG, et al.
J Occup Environ Med 1998 Oct;40(10):881-5

Occurrence of self reported hand eczema in Swedish bakers. Brisman J, et al. **Occup Environ Med** 1998 Nov;55(11):750-4

Occupational skin and respiratory diseases among hairdressers. Leino T, et al.
Scand J Work Environ Health 1998 Oct;24(5):398-406

Atopic dermatitis, conjunctivitis, and hand dermatitis among Swedish dental personnel, including use of personal protective devices. Lönnroth E, et al. **Swed Dent J** 1998; 22(3):105-15

ETIOLOGY

Hand eczema: evaluation of 250 patients. Duarte I, et al. **Am J Contact Dermat** 1998 Dec;9(4):216-23

Allergic contact dermatitis in American aircraft manufacture. Hackett JP. **Am J Contact Dermat** 1999 Sep;10(3):157-66

Hand eczema: a 15-minute tour of the Louvre or how to mold frustration into the Winged Victory. Jordan WP.
Am J Contact Dermat 1998 Dec;9(4):240

Alstroemeria L. (Peruvian lily). McGovern TW.
Am J Contact Dermat 1999 Sep;10(3):172-6

Stasis dermatitis of the hand associated with an iatrogenic arteriovenous fistula. Bilen N, et al. **Clin Exp Dermatol** 1998 Sep;23(5):208-10

Development of occupational skin diseases during vocational training in baker and confectioner apprentices: a follow-up study. Bauer A, et al. **Contact Dermatitis** 1998 Dec; 39(6):307-11

Toast-makers' fingers. Brooke R, et al.
Contact Dermatitis 1998 Aug;39(2):86

Active sensitization to budesonide and para-phenylenediamine from patch testing. Le Coz CJ, et al. **Contact Dermatitis** 1998 Sep;39(3):153-5

Nickel release from tools on the Swedish market. Lidén C, et al. **Contact Dermatitis** 1998 Sep;39(3):127-31

Occupational contact sensitivity to aluminium in a machine construction plant worker. Peters T, et al.
Contact Dermatitis 1998 Dec;39(6):322-3

Erythema multiforme associated with contact dermatitis to poison ivy: three cases and a review of the literature. Cohen LM, et al. **Cutis** 1998 Sep;62(3):139-42

HAND DERMATOSES

Botanical briefs: Peruvian lily--Alstroemeria (L.) spp. McGovern TW, et al. **Cutis** 1999 Mar;63(3):137-8

Dry palms, Candida, and dental plates, or, the importance of thorough examination. Talanin NY. **Cutis** 1999 Jul; 64(1):45

Guess What! Occupational contact psoriasis. Kanerva L, et al. **Eur J Dermatol** 1998 Apr-May;8(3):217-8

Prevalence and incidence of hand dermatitis in hairdressing apprentices: results of the POSH study. Prevention of occupational skin disease in hairdressers. Uter W, et al. **Int Arch Occup Environ Health** 1998 Oct;71(7):487-92

Occupational allergic contact dermatitis from olive oil in a masseur. Isaksson M, et al. **J Am Acad Dermatol** 1999 Aug; 41(2 Pt 2):312-5

Multicentric reticulohistiocytosis associated with recurrent breast carcinoma. Valencia IC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):864-6

Hand infections due to non-cholera Vibrio after injuries from St Peter's fish (Tilapia zillii). Said R, et al. **J Hand Surg [Br]** 1998 Dec;23(6):808-10

Latex glove allergy among hospital employees: a study in the north-west of England. Sinha A, et al. **Occup Med (Lond)** 1998 Sep;48(6):405-10

Contact dermatitis in Alstroemeria workers. van der Mei IA, et al. **Occup Med (Lond)** 1998 Sep;48(6):397-404

Infantile acropustulosis revisited: history of scabies and response to topical corticosteroids. Mancini AJ, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):337-41

[Tuberous lesion and nodular lymphangitis in an immunocompetent patient] Bretón Martínez JR, et al. **Rev Clin Esp** 1999 Jun;199(6):381-3 **(Spa)**

IMMUNOLOGY

Rowell's syndrome. Child FJ, et al. **Clin Exp Dermatol** 1999 Mar;24(2):74-7 (9 ref.)

METABOLISM

Expression of heat shock protein 27 in chromomycosis. Bayerl C, et al. **Mycoses** 1998 Dec;41(11-12):447-52

MICROBIOLOGY

Changes in bacterial flora associated with skin damage on hands of health care personnel. Larson EL, et al. **Am J Infect Control** 1998 Oct;26(5):513-21

White superficial onychomycosis of the fingernail caused by Trichophyton rubrum in an immunocompetent patient. Kornbleuth S, et al. **Cutis** 1999 Aug;64(2):99-100

PATHOLOGY

Pityriasis lichenoides chronica with acral distribution mimicking palmoplantar syphilid [letter] Chung HG, et al. **Acta Derm Venereol** 1999 May;79(3):239

Atypical involvement of the palms and soles in a varicella infection [letter] Nagore E, et al. **Acta Derm Venereol** 1999 Jul;79(4):322

Lichen nitidus of the palms: a case with peculiar histopathologic features. De Eusebio Murillo E, et al. **Am J Dermatopathol** 1999 Apr;21(2):161-4

Discoid lupus erythematosus-like lesions and stomatitis. Botella R, et al. **Arch Dermatol** 1999 Jul;135(7):847, 850

An ulcerated nodule associated with lymphadenopathy. Boyce S, et al. **Arch Dermatol** 1999 Aug;135(8):985, 988

Palmar ulceration. Guccione JL. **Arch Dermatol** 1999 Jul; 135(7):845-6, 848-9

Localized peeling skin syndrome: case report with ultrastructural study. Brusasco A, et al. **Br J Dermatol** 1998 Sep;139(3):492-5

Actinomycosis of 54 years' duration. Musher DM. **Clin Infect Dis** 1998 Oct;27(4):889

Prominent hyperkeratotic plantar and palmar warts. Matsumoto Y, et al. **Cutis** 1999 Feb;63(2):91-4

Purpuric lichen nitidus. Endo M, et al. **Eur J Dermatol** 1998 Jan-Feb;8(1):54-5

Pachydermodactyly [letter; comment] Kopera D, et al. **Int J Dermatol** 1999 Mar;38(3):237. Comment on: Int J Dermatol 1997 Oct;36(10):768-72.

Granuloma annulare localized to the palms. Hsu S, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):287-8

Sweet's syndrome associated with chronic myelogenous leukemia: demonstration of leukemic cells within a skin lesion. Urano Y, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):275-9

Acrokeratoelastoidosis of Costa: a primary disease of the elastic tissue? Fiallo P, et al. **J Cutan Pathol** 1998 Nov; 25(10):580-2

Sporadic reticulate acropigmentation of Kitamura on pale skin [letter] Albes B, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):71-2

Keratosis palmoplantaris varians of Wachters. Paoli S, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):33-7

Behçet's disease with unusual cutaneous lesions. Cantini F, et al. **J Rheumatol** 1998 Dec;25(12):2469-72

Solitary mastocytoma on the palm. Lee HP, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):386-7

'Two feet-one hand' syndrome. A recurring infection with a peculiar connection. Singri P, et al. **Postgrad Med** 1999 Aug;106(2):83-4

[Hyperpigmented spots on the lips, oral mucosa, fingers and nails] Paricio Rubio JF, et al. **Rev Clin Esp** 1998 Nov; 198(11):769-70 (13 ref.) **(Spa)**

PREVENTION & CONTROL

The combined use of moisturizers and occlusive gloves: an experimental study. Held E, et al. **Am J Contact Dermat** 1999 Sep;10(3):146-52

SURGERY

Alternative coverage of a tendon-exposing defect of the dorsum of the hand with a triple rhomboid flap [letter] von Heimburg D, et al. **Ann Plast Surg** 1999 Apr; 42(4):459-60

Use of a permanent acellular dermal allograft in recessive dystrophic epidermolysis bullosa involving the hands. Witt PD, et al. **Arch Dermatol** 1999 May;135(5):503-6

Recalcitrant viral warts: results of treatment with the KTP laser. Gooptu C, et al. **Clin Exp Dermatol** 1999 Mar; 24(2):60-3

Laugier-Hunziker syndrome: case report and treatment with the Q-switched Nd-Yag laser. Ferreira MJ, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):171-3

[Interdigital pilonidal sinus ("barber's disease")--a rare occupational disease] Jochims J, et al. **Chirurg** 1998 Nov; 69(11):1280-1 (Eng. Abstr.) **(Ger)**

THERAPY

Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. Spach DH, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):818-21

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507-24, ix-x (6 ref.)

HAND, FOOT AND MOUTH DISEASE

[Hand-foot and mouth disease] Sunakawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):173-4 (1 ref.) **(Jpn)**

COMPLICATIONS

Neurologic complications in children with enterovirus 71 infection [see comments] Huang CC, et al. **N Engl J Med** 1999 Sep 23;341(13):936-42. Comment in: N Engl J Med 1999 Sep 23;341(13):984-5.

[Hand-foot-mouth syndrome recurring during common variable deficiency] Le Cleach L, et al. **Ann Dermatol Venereol** 1999 Mar;126(3):251-3 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Accentuated viral exanthems in areas of inflammation. Messner J, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):345-6

EPIDEMIOLOGY

Sentinel surveillance for enterovirus 71, Taiwan, 1998. Wu TN, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):458-60

Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Cardosa MJ, et al. **Lancet** 1999 Sep 18; 354(9183):987-91

An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group [see comments] Ho M, et al. **N Engl J Med** 1999 Sep 23;341(13):929-35. Comment in: N Engl J Med 1999 Sep 23;341(13):984-5.

VIROLOGY

Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Cardosa MJ, et al. **Lancet** 1999 Sep 18; 354(9183):987-91

Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis [letter; comment] Lum LC, et al. **Lancet** 1998 Oct 24;352(9137):1391. Comment on: Lancet 1998 Aug 1;352(9125):367-8.

Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. AbuBakar S, et al. **Virus Res** 1999 May;61(1):1-9

HAND INJURIES

see related
WRIST INJURIES

The Michigan Hand Outcomes Questionnaire (MHQ): assessment of responsiveness to clinical change. Chung KC, et al. **Ann Plast Surg** 1999 Jun;42(6):619-22

Burns of the hand and upper limb--a review. Smith MA, et al. **Burns** 1998 Sep;24(6):493-505 (48 ref.)

High-pressure injection injuries to the hand. Schnall SB, et al. **Hand Clin** 1999 May;15(2):245-8, viii (23 ref.)

Time off work after occupational hand injuries. Skov O, et al. **J Hand Surg [Br]** 1999 Apr;24(2):187-9

The hand injury severity scoring system and workers' compensation cases in Wisconsin, USA. van der Molen AB, et al. **J Hand Surg [Br]** 1999 Apr;24(2):184-6

CHEMICALLY INDUCED

Helium vapour injury: a case report. Kumar P, et al. **Burns** 1999 May;25(3):265-8

COMPLICATIONS

Development of Peyronie's and Dupuytren's diseases in an individual after single episodes of trauma: a case report and review of the literature. Connelly TJ. **J Am Acad Dermatol** 1999 Jul;41(1):106-8 (40 ref.)

Keratoacanthoma centrifugum marginatum arising from a scar after skin injury. Watanabe D, et al. **J Dermatol** 1999 Aug;26(8):541-3

Patient and injury characteristics in the development of cold sensitivity of the hand: a prospective cohort study. Craigen M, et al. **J Hand Surg [Am]** 1999 Jan;24(1):8-15

Emergency medicine quiz. Clinched fist injury. Steele MT, et al. **Mo Med** 1999 Jan;96(1):11-2

DIAGNOSIS

Injuries to the hand and wrist. Huurman WW. **Adolesc Med** 1998 Oct;9(3):611-25, vii (12 ref.)

Penetrating pencil injury: an unusual case of child abuse. Lee AC, et al. **Child Abuse Negl** 1998 Jul;22(7):749-52

Overuse tendinitis of the intrinsic muscles [see comments] Silver JK, et al. **Orthopedics** 1998 Aug;21(8):891-4. Comment in: Orthopedics 1999 Mar;22(3):288-9.

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507-24, ix-x (6 ref.)

[Self-mutilating hand and finger injuries among physicians suspected of insurance fraud] Püschel K, et al. **Versicherungsmedizin** 1998 Dec 1;50(6):232-40 (Eng. Abstr.) **(Ger)**

ECONOMICS

Hand burns in young patients--loss of self-sufficiency and economic productivity [letter; comment] Borman H, et al. **Ann Plast Surg** 1998 Sep;41(3):335. Comment on: Ann Plast Surg 1998 Mar;40(3):268-76.

Gunshot wounds to the hand: management and economic impact. Chappell JE, et al. **Ann Plast Surg** 1999 Apr; 42(4):418-23

EPIDEMIOLOGY

"Outbreak" of hand injuries during Hajj festivities in Saudi Arabia. Rahman MM, et al. **Ann Plast Surg** 1999 Aug; 43(2):154-5

Pattern of hand injuries. Thomas AG, et al. **Indian Pediatr** 1998 Aug;35(8):763-5

Exposure-response relationship in the hand-arm vibration syndrome: an overview of current epidemiology research. Bovenzi M. **Int Arch Occup Environ Health** 1998 Nov; 71(8):509-19 (61 ref.)

Hand injuries in agricultural accidents. Hansen TB, et al. **J Hand Surg [Br]** 1999 Apr;24(2):190-2

The real incidence of percutaneous injuries in the operating room--a prospective study. Cassina PC, et al. **Swiss Surg** 1999;5(1):27-32

ETIOLOGY

Another cracking idea [letter; comment] Morrison WJ. **Anaesthesia** 1999 Mar;54(3):307-8. Comment on: Anaesthesia 1997 Oct;52(10):1020. Comment on: Anaesthesia 1998 Aug;53(8):830.

Gone fishing. Wolfe J. **Ann Emerg Med** 1999 Apr;33(4):471-2

Hand and arm injuries associated with repetitive manual work in industry: a review of disorders, risk factors and preventive measures. Muggleton JM, et al. **Ergonomics** 1999 May;42(5):714-39 (133 ref.)

Dogs bite bones too--a tale of fractures in adult hands. Aslam A, et al. **Injury** 1999 Jun;30(5):374-6

Full-thickness burn to the hand from an automobile airbag. Vitello W, et al. **J Burn Care Rehabil** 1999 May-Jun; 20(3):212-5

Upper-extremity self-amputation and replantation: 2 case reports and a review of the literature. Schlozman SC. **J Clin Psychiatry** 1998 Dec;59(12):681-6 (22 ref.)

Natural gas inflation injury of the upper extremity: a case report. Sena T, et al. **J Hand Surg [Am]** 1999 Jul;24(4):850-2

"Tug-of-war-hand": transforearm amputation by an unusual mechanism. Bruce WD, et al. **Orthopedics** 1999 Aug; 22(8):769-70

Overuse tendinitis [letter; comment] Goldner JL. **Orthopedics** 1999 Mar;22(3):288-9. Comment on: Orthopedics 1998 Aug;21(8):891-4.

[Hand injuries following fireworks (editorial)] Falck-Larsen C, et al. **Ugeskr Laeger** 1998 Dec 21;160(52):7569 **(Dan)**

[Hand injuries in the users of hydraulic wood-cutters] Holm R. **Ugeskr Laeger** 1998 Dec 7;160(50):7255-8 (Eng. Abstr.) **(Dan)**

[Occupational hand injuries. A population-based description of the incidence and referral to casualty departments] Skov O, et al. **Ugeskr Laeger** 1999 May 31;161(22):3285-8 (Eng. Abstr.) **(Dan)**

MICROBIOLOGY

Hand infections in the trauma patient. Tsai E, et al. **Hand Clin** 1999 May;15(2):373-86 (59 ref.)

PATHOLOGY

Movement dysfunction following repetitive hand opening and closing: anatomical analysis in Owl monkeys. Topp KS, et al. **Mov Disord** 1999 Mar;14(2):295-306

[Damage pattern caused by high pressure water jets and high pressure water abrasive jets to the hand] Axmann HD, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):263–8 (Eng. Abstr.) **(Ger)**

[Injuries of the extensor tendons: anatomy] Mentzel M. **Unfallchirurg** 1998 Nov;101(11):804–6 **(Ger)**

PREVENTION & CONTROL

Hand and arm injuries associated with repetitive manual work in industry: a review of disorders, risk factors and preventive measures. Muggleton JM, et al. **Ergonomics** 1999 May;42(5):714–39 (133 ref.)

A new test for cut resistance. Parrish E. **Occup Health Saf** 1999 Jan;68(1):72–3

PSYCHOLOGY

The surgeon as a hand patient: the clinical and psychological impact of hand and wrist fractures. Chin KR, et al. **J Hand Surg [Am]** 1999 Jan;24(1):59–63

Expanded profile of the SHAFT syndrome [letter; comment] Sennwald G. **J Hand Surg [Am]** 1998 Nov;23(6):1118–9. Comment on: J Hand Surg [Am] 1998 Jan;23(1):1–2. Comment on: J Hand Surg [Am] 1998 Jan;23(1):26–31.

RADIOGRAPHY

Sleight of hand? Stewart V. **Radiol Technol** 1999 Jan–Feb; 70(3):291–2

RADIONUCLIDE IMAGING

The usefulness of quantitative evaluation of three-phase scintigraphy in the diagnosis of post-traumatic reflex sympathetic dystrophy. Zyluk A. **J Hand Surg [Br]** 1999 Feb;24(1):16–21

REHABILITATION

Thumb reconstruction in a bilateral upper extremity amputee: an alternative to the Krukenburg procedure. Yu ZJ, et al. **J Hand Surg [Am]** 1999 Jan;24(1):194–7

Outcome following the rehabilitation of hand trauma patients. The importance of a subjective functional assessment. Watts AM, et al. **J Hand Surg [Br]** 1998 Aug;23(4):485–9

1998 ASHT presidential address. The truth is not negotiable: we can make a difference. American Society of Hand Therapists. Bell-Krotoski J. **J Hand Ther** 1999 Jan–Mar; 12(1):3–6

Digital diagnoses in a digital world [editorial] Flowers KR. **J Hand Ther** 1999 Jul–Sep;12(3):185–6

Hand care in the new millennium: therapist's commentary. Miller RE. **J Hand Ther** 1999 Apr–Jun;12(2):182–3

Bone and joint injury in the hand: therapist's commentary. Russell CR. **J Hand Ther** 1999 Apr–Jun;12(2):121–2 (3 ref.)

Treatment of flexor tendon injuries: therapist's commentary. Steelman P. **J Hand Ther** 1999 Apr–Jun;12(2):149–51 (12 ref.)

[Dynamic splinting after flexor tendon injuries of the hand in childhood] Fasching G, et al. **Handchir Mikrochir Plast Chir** 1998 Jul;30(4):243–8 (Eng. Abstr.) **(Ger)**

SURGERY

Serratus anterior free fascial flap for dorsal hand coverage. Fassio E, et al. **Ann Plast Surg** 1999 Jul;43(1):77–82

Serratus anterior–rib composite flap: anatomic studies and clinical application to hand reconstruction. Hui KC, et al. **Ann Plast Surg** 1999 Feb;42(2):132–6

The distally based ulnar artery forearm flap supplied by the dorsal carpal arch. Karacalar A, et al. **Ann Plast Surg** 1998 Sep;41(3):304–6

Use of a vein graft as a tendon sheath substitute following tendon repair: an innovative technique in tendon surgery [letter] Moosavi SR, et al. **Ann Plast Surg** 1999 Jul; 43(1):102–3

Acute hand burns in children: management and long-term outcome based on a 10-year experience with 698 injured hands. Sheridan RL, et al. **Ann Surg** 1999 Apr; 229(4):558–64

A case of old trapezoid fracture. Watanabe H, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):356–7

Impossible harvest of the posterior interosseous artery flap: a report of an individualised salvage procedure [see comments] Giunta R, et al. **Br J Plast Surg** 1998 Dec; 51(8):642–5. Comment in: Br J Plast Surg 1998 Dec;51(8):650–1.

The role of antibiotics in the management of elective and post-traumatic hand surgery. Hoffman RD, et al. **Hand Clin** 1998 Nov;14(4):657–66 (89 ref.)

The role of emergency free flaps for hand trauma. McCabe SJ, et al. **Hand Clin** 1999 May;15(2):275–88, viii–ix (18 ref.)

Treatment of composite tissue loss following hand and forearm trauma. Tomaino MM. **Hand Clin** 1999 May; 15(2):319–33, ix (31 ref.)

Replantation of multi-level hand severances. Pei GX, et al. **Injury** 1998 Jun;29(5):357–61

The use of the Millard "crane" flap for deep hand burns with exposed tendons and joints. Matsumura H, et al. **J Burn Care Rehabil** 1999 Jul–0Aug;20(4):316–9

The surgeon as a hand patient: the clinical and psychological impact of hand and wrist fractures. Chin KR, et al. **J Hand Surg [Am]** 1999 Jan;24(1):59–63

Upper extremity salvage using the tensor fascia lata flap: report of two cases. Smith AA, et al. **J Hand Surg [Am]** 1999 Mar;24(2):352–8

A randomized biomechanical study of zone II human flexor tendon repairs analyzed in an in vitro model. Stein T, et al. **J Hand Surg [Am]** 1998 Nov;23(6):1046–51

Osteocutaneous radial forearm flap for hand reconstruction. Yajima H, et al. **J Hand Surg [Am]** 1999 May;24(3):594–603

Federation of the European Societies for Surgery of the Hand 6th Congress Instructional Course. Fractures of the metacarpals and phalanges in adults and children. Bonn, Germany, 26–29 May 1999. Abstracts. **J Hand Surg [Br]** 1999;24 Suppl 1:1–30

Emergency reconstruction of a collateral ligament of a metacarpophalangeal joint using Dacron material. Lanzetta M, et al. **J Hand Surg [Br]** 1999 Jun;24(3):376–8

Ilizarov's technique used to expand skin from a groin flap. Low CK, et al. **J Hand Surg [Br]** 1999 Jun;24(3):361–2

Use of the "S" Quattro dynamic external fixator in the treatment of difficult hand fractures. Mullett JH, et al. **J Hand Surg [Br]** 1999 Jun;24(3):350–4

Reconstruction of large palmar defects of the hand using free flaps. Ninkovic MM, et al. **J Hand Surg [Br]** 1997 Oct;22(5):623–30

The role of low-profile titanium miniplates in emergency and elective hand surgery. O'Sullivan ST, et al. **J Hand Surg [Br]** 1999 Jun;24(3):347–9

Hand lacerations. An audit of clinical examination. Patel J, et al. **J Hand Surg [Br]** 1998 Aug;23(4):482–4

Bone and joint injury in the hand: surgeon's perspective. Leibovic SJ. **J Hand Ther** 1999 Apr–Jun;12(2):111–20 (17 ref.)

Hand care in the new millennium: surgeon's perspective. McAuliffe JA. **J Hand Ther** 1999 Apr–Jun;12(2):178–81 (12 ref.)

External fixator for the hand: a quick, cheap and effective method. McCulley SJ, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):99–102

Serratus fascia "sandwich" free-tissue transfer for complex dorsal hand and wrist avulsion injuries. Buehler MJ, et al. **J Reconstr Microsurg** 1999 Jul;15(5):315–20

Combined ischemic preconditioning and laser Doppler measurement for early division of pedicled groin flap. Cheng MH, et al. **J Trauma** 1999 Jul;47(1):89–95

Mutilating injuries to the hand: early amputation or repair and reconstruction. Arellano AO, et al. **Orthopedics** 1999 Jul;22(7):683–4 (18 ref.)

"Tug-of-war-hand": transforearm amputation by an unusual mechanism. Bruce WD, et al. **Orthopedics** 1999 Aug; 22(8):769–70

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507–24, ix–x (6 ref.)

Classification of the first web space free flap of the foot and its applications in reconstruction of the hand. Woo SH, et al. **Plast Reconstr Surg** 1999 Feb;103(2):508–17

Sequential transfer of free flap to two defects. Yousif NJ, et al. **Plast Reconstr Surg** 1998 Dec;102(7):2431–5

The groin flap revisited—what the textbooks do not tell. Van Wingerden JJ. **S Afr J Surg** 1999 Feb;37(1):21–3

Immediate autografting of bone in open fractures with bone loss of the hand: a preliminary report. Case reports. Stahl S, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):117–22

[Experimental and clinical study on the blood supply of the subdermal vascular network island flap] Yang Y, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1997 Jan;13(1):51–3 (Eng. Abstr.) **(Chi)**

[Primary microsurgical repair of multi-structural defects of hand] Sui H, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):81–2 (Eng. Abstr.) **(Chi)**

[Thin skin flap in the repair of defect of soft tissue of hand] Sun ZS. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):353–5 (Eng. Abstr.) **(Chi)**

[One stage repair and reconstruction for severe deep burns with compound tissue defects of upper limb] Wang N, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):23–5 (Eng. Abstr.) **(Chi)**

[Reform of the pedicled abdominal subcorium vascular-net flap and its clinical application] Xia S, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Sep;11(5):291–2 (Eng. Abstr.) **(Chi)**

[Dumbbell-shaped double-leaf flap for the repair of penetrating wound of palm with tissue defect] Xiao P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jul;11(4):226–8 (Eng. Abstr.) **(Chi)**

[Reconstruction of tendon sheath by autogenous vein graft in preventing adhesion] Yan D, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):38–9 (Eng. Abstr.) **(Chi)**

[The application of distally based fascial pedicled island flap to rapair wound of the extremities] Zhang D. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):359–61 (Eng. Abstr.) **(Chi)**

[Use of Schwamm Garamycin in surgery of the hand] Fialová L, et al. **Rozhl Chir** 1998 Sep;77(9):396–8 (Eng. Abstr.) **(Cze)**

[What's new in cosmetic surgery of the hand? Technical notes] Saffar P. **Ann Chir Plast Esthet** 1998 Dec;43(6):630–4 (Eng. Abstr.) **(Fre)**

[Humanitarian surgery of the hand. Our experience in Vietnam] Voche P, et al. **Ann Chir Plast Esthet** 1999 Feb; 44(1):64–71 (Eng. Abstr.) **(Fre)**

[Analgesia using continuous axillary block after surgery of severe hand injuries: self-administration versus continuous injection] Iskandar H, et al. **Ann Fr Anesth Reanim** 1998; 17(9):1099–103 (Eng. Abstr.) **(Fre)**

[Hand replantation: long-term functional results (apropos of 8 cases)] Tropet Y, et al. **Chirurgie** 1998 Apr;123(2):189–94 (Eng. Abstr.) **(Fre)**

[Surgical anatomy with special reference to reconstruction in severe hand injuries] Graf PF. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:968–70 (Eng. Abstr.) **(Ger)**

[The free "emergency" rectus abdominis flap transfer for coverage of complex hand injuries] Horch RE, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1194–6 (Eng. Abstr.) **(Ger)**

[Management and after-care of extensor tendon injuries of the hand] Partecke BD, et al. **Unfallchirurg** 1998 Nov; 101(11):807–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Are there guidelines for treatment of metacarpal fractures? Personal results and literature analysis of the last 12 years] Prokop A, et al. **Unfallchirurg** 1999 Jan;102(1):50–8 (34 ref.) (Eng. Abstr.) **(Ger)**

[Complex hand injuries. Importance of primary repair with free flaps] Schwabegger AH, et al. **Unfallchirurg** 1999 Apr; 102(4):292–7 (Eng. Abstr.) **(Ger)**

[Treatment of high-voltage electric injuries of the hand and forearm] Teot L, et al. **Ann Ital Chir** 1998 May–Jun; 69(3):317–23 (Eng. Abstr.) **(Ita)**

[Salvage surgery for severely mutilated hand: report of 2 cases] Jablecki J, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(3):221–6 (Eng. Abstr.) **(Pol)**

[Management of patients with pyogenic complications of long bones open fractures] Okhotskii VP, et al. **Khirurgiia (Mosk)** 1998;(10):51–3 (Eng. Abstr.) **(Rus)**

THERAPY

Gunshot wounds to the hand: management and economic impact. Chappell JE, et al. **Ann Plast Surg** 1999 Apr; 42(4):418–23

The misplaced left hook. Golledge C. **Aust Fam Physician** 1998 Aug;27(8):729

Physical therapy after hand injuries. Michlovitz S. **Hand Clin** 1999 May;15(2):261–73, viii (33 ref.)

The management of penetrating trauma to the hand. Nathan R. **Hand Clin** 1999 May;15(2):193–9, vii (22 ref.)

Effectiveness of the A–V impulse hand pump. Ramesh M, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):229–33

Closed continuous irrigation in the treatment of hand infections. Harris PA, et al. **J Hand Surg [Br]** 1999 Jun; 24(3):328–33

Overuse tendinitis of the intrinsic muscles [see comments] Silver JK, et al. **Orthopedics** 1998 Aug;21(8):891–4. Comment in: Orthopedics 1999 Mar;22(3):288–9.

[Accidents with fireworks. Hand lesions in children] Alves R, et al. **Acta Med Port** 1998 Nov;11(11):965–9 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Ultrasonic assistance in the diagnosis of hand flexor tendon injuries. Wang PT, et al. **Ann Plast Surg** 1999 Apr; 42(4):403–7

High-frequency ultrasound examination of the wrist and hand. Bianchi S, et al. **Skeletal Radiol** 1999 Mar;28(3):121–9 (59 ref.)

[Ultrasound in the demonstration of a wood splinter in the hand] Hierholzer J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):169–70 **(Ger)**

HAND-SCHUELLER-CHRISTIAN SYNDROME

[Hand-Schüller-Christian syndrome] Shimazaki C, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):376–9 (15 ref.) **(Jpn)**

HAND STRENGTH

Hand-grip strength predicts incident disability in non-disabled older men. Giampaoli S, et al. **Age Ageing** 1999 May;28(3):283–8

Construct validity of the In-Hand Manipulation Test: a discriminant analysis with children without disability and children with spastic diplegia. Breslin DM, et al. **Am J Occup Ther** 1999 Jul–Aug;53(4):381–6

Clinical interpretation of "grip strengths and required forces in accessing everyday containers in a normal population". Conti GE. **Am J Occup Ther** 1998 Sep;52(8):627–8

Grip strengths and required forces in accessing everyday containers in a normal population. Rice MS, et al. **Am J Occup Ther** 1998 Sep;52(8):621–6

The value of the pronated-grip view radiograph in assessing dynamic ulnar positive variance: a case report. Tomaino MM, et al. **Am J Orthop** 1999 Mar;28(3):180–1

The coordination of two-effector actions: spoon-feeding and intermanual prehension. Churchill A, et al. **Br J Psychol** 1999 May;90 (Pt 2):271–90

Maximum grip strength is not related to bone mineral density of the proximal femur in older adults. Foley KT, et al. **Calcif Tissue Int** 1999 Apr;64(4):291–4

Frequency domain heart rate variability and plasma norepinephrine level in the coronary sinus during handgrip exercise. Kurita A, et al. **Clin Cardiol** 1999 Mar; 22(3):207–12

Gaining independence in tetraplegia. Cleveland technique. Freehafer AA. **Clin Orthop** 1998 Oct;(355):282–9

Maximal grip force in chronic stroke subjects and its relationship to global upper extremity function. Boissy P, et al. **Clin Rehabil** 1999 Aug;13(4):354–62

Influence of posture and handgrip on the QT interval in left ventricular hypertrophy and in chronic heart failure. Davey P. **Clin Sci (Colch)** 1999 Apr;96(4):403–7

The reach-to-grasp movement in Parkinson's disease: response to a simultaneous perturbation of object position and object size. Castiello U, et al. **Exp Brain Res** 1999 Apr; 125(4):453–62

Visual distractors differentially interfere with the reaching and grasping components of prehension movements. Gangitano M, et al. **Exp Brain Res** 1998 Oct;122(4):441–52

Development of prehension movements in children: a kinematic study. Kuhtz-Buschbeck JP, et al. **Exp Brain Res** 1998 Oct;122(4):424–32

The effect of wrist angle on electrically evoked hand opening in patients with spastic hemiplegia. Cameron T, et al. **IEEE Trans Rehabil Eng** 1999 Mar;7(1):109–11

Control of FES thumb force using slip information obtained from the cutaneous electroneurogram in quadriplegic man. Haugland M, et al. **IEEE Trans Rehabil Eng** 1999 Jun; 7(2):215–27

Coronary Doppler intensity changes during handgrip: a new method to detect coronary vasomotor tone in coronary artery disease. Voci P, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):428–34

The contribution of the intrinsic muscles to grip and pinch strength [letter; comment] Mahaffey P. **J Hand Surg [Am]** 1999 Jul;24(4):870–1. Comment on: J Hand Surg [Am] 1999 Jan;24(1):64–72.

First metacarpal subsidence during pinch after ligament reconstruction and tendon interposition basal joint arthroplasty of the thumb. Yang SS, et al. **J Hand Surg [Am]** 1998 Sep;23(5):879–83

The detection of feigned hand weakness using the five position grip strength test. Tredgett M, et al. **J Hand Surg [Br]** 1999 Aug;24(4):426–8

Maximum grip strength in normal subjects from 20 to 64 years of age. Hanten WP, et al. **J Hand Ther** 1999 Jul–Sep; 12(3):193–200

When is a change a genuine change? A clinically meaningful interpretation of grip strength measurements in healthy and disabled women. Nitschke JE, et al. **J Hand Ther** 1999 Jan–Mar;12(1):25–30

The EndoHand: comparison with standard laparoscopic instrumentation. Jackman SV, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):253–8

Manipulative management of post-Colles' fracture weakness and diminished active range of motion. Kaufman RL, et al. **J Manipulative Physiol Ther** 1999 Feb;22(2):105–7

Mechanisms for age-related changes of fingertip forces during precision gripping and lifting in adults. Cole KJ, et al. **J Neurosci** 1999 Apr 15;19(8):3238–47

A prospective evaluation of upper extremity tendon transfers in children with cervical spinal cord injury. Mulcahey MJ, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):319–28

Midlife hand grip strength as a predictor of old age disability. Rantanen T, et al. **JAMA** 1999 Feb 10;281(6):558–60

Intertester reliability of manual muscle strength testing in leprosy patients. Brandsma JW, et al. **Lepr Rev** 1998 Sep; 69(3):257–66

Congenital hemiplegia in children at school age: assessment of hand function in the non-hemiplegic hand and correlation with MRI. Mercuri E, et al. **Neuropediatrics** 1999 Feb;30(1):8–13

The surface-weight illusion: on the contribution of grip force to perceived heaviness. Rinkenauer G, et al. **Percept Psychophys** 1999 Jan;61(1):23–30

A study of repeated lateral pinch grip in myotonic dystrophy. Nitz J, et al. **Physiother Res Int** 1999;4(1):1–11

Evidence of hominid-like precision grip capability in the hand of the Miocene ape Oreopithecus. Moyà-Solà S, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):313–7

Predicting 'normal' grip strength for rheumatoid arthritis patients. Fraser A, et al. **Rheumatology (Oxford)** 1999 Jun; 38(6):521–8

Evaluation of grip strength measurements after Colles' fracture: a methodological study. Lagerström C, et al. **Scand J Rehabil Med** 1999 Mar;31(1):49–54

Recovery of isometric grip strength after Colles' fracture: a prospective two-year study. Lagerström C, et al. **Scand J Rehabil Med** 1999 Mar;31(1):55–62

Brachial plexus and supraclavicular nerve injury caused by manual carotid compression for spontaneous carotid-cavernous sinus fistula. Komiyama M, et al. **Surg Neurol** 1999 Sep;52(3):306–9

[Circadian rhythm in hand grip strength in patients with rheumatoid arthritis] Curković B, et al. **Reumatizam** 1997; 45(2):6–8 (Eng. Abstr.) **(Ser)**

PHYSIOLOGY

A new manual power grip. Dawson NM, et al. **Acta Anat (Basel)** 1998;163(4):224–8

Effect of forearm rotation on grip strength. De Smet L, et al. **Acta Orthop Belg** 1998 Dec;64(4):360–2

Involvement of the human splanchnic circulation in pressor response induced by handgrip contraction. Waaler BA, et al. **Acta Physiol Scand** 1999 Jun;166(2):131–6

The relationship of peripheral motor nerve conduction velocity to age-associated loss of grip strength. Metter EJ, et al. **Aging (Milano)** 1998 Dec;10(6):471–8

Lack of association of anabolic hormone status and muscle strength with regional and whole body bone mineral density in healthy men aged 60–79 years. Taaffe DR, et al. **Aging (Milano)** 1999 Feb;11(1):4–11

Coefficient of variation in maximal and feigned static and dynamic grip efforts. Dvir Z. **Am J Phys Med Rehabil** 1999 May–Jun;78(3):216–21

Phase-dependent heartbeat modulation by muscle contractions during dynamic handgrip in humans. Niizeki K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1331–8

Prolongation of left atrial augmentation after handgrip stress in coronary artery disease: observation using pulsed Doppler flowmetry. Tanaka T, et al. **Angiology** 1999 Apr; 50(4):299–308

Effect of grip span on maximal grip force and fatigue of flexor digitorum superficialis. Blackwell JR, et al. **Appl Ergon** 1999 Oct;30(5):401–5

Grip strength and the risk of developing radiographic hand osteoarthritis: results from the Framingham Study. Chaisson CE, et al. **Arthritis Rheum** 1999 Jan;42(1):33–8

Neural activity related to reaching and grasping in rostral and caudal regions of rat motor cortex. Hyland B. **Behav Brain Res** 1998 Aug;94(2):255–69

Impaired grip-lift synergy in children with unilateral brain lesions. Forssberg H, et al. **Brain** 1999 Jun;122 (Pt 6):1157–68

Influence of grip strength on metacarpal bone mineral density in postmenopausal Japanese women: a cross-sectional study. Osei-Hyiaman D, et al. **Calcif Tissue Int** 1999 Mar; 64(3):263–6

Prehension with the ipsilesional hand after unilateral brain damage. Hermsdörfer J, et al. **Cortex** 1999 Apr; 35(2):139–61

Fingertip forces during object manipulation in children with hemiplegic cerebral palsy. II: bilateral coordination. Gordon AM, et al. **Dev Med Child Neurol** 1999 Mar; 41(3):176–85

Fingertip forces during object manipulation in children with hemiplegic cerebral palsy. I: anticipatory scaling. Gordon AM, et al. **Dev Med Child Neurol** 1999 Mar;41(3):166–75

Visual control of reaching and grasping in infants. McCarty ME, et al. **Dev Psychol** 1999 May;35(3):620–31

Effect of carpal tunnel syndrome on grip force coordination on hand tools. Lowe BD, et al. **Ergonomics** 1999 Apr; 42(4):550–64

Muscle metabolism from near infrared spectroscopy during rhythmic handgrip in humans. Boushel R, et al. **Eur J Appl Physiol** 1998 Dec;79(1):41–8

Heart rate deceleration during the grasping reflex. Nagy E, et al. **Eur J Pediatr** 1999 Jul;158(7):576–7

Contribution of the supplementary motor area and anterior cingulate gyrus to pathological grasping phenomena. Hashimoto R, et al. **Eur Neurol** 1998 Oct;40(3):151–8

Reprogramming of grip aperture in a double-step virtual grasping paradigm. Bock O, et al. **Exp Brain Res** 1999 Mar; 125(1):61–6

High postural constraints affect the organization of reaching and grasping movements. Bourdin C, et al. **Exp Brain Res** 1998 Oct;122(3):253–9

Light touch contribution to balance in normal bipedal stance. Clapp S, et al. **Exp Brain Res** 1999 Apr;125(4):521–4

Tactile impairments cannot explain the effect of age on a grasp and lift task. Cole KJ, et al. **Exp Brain Res** 1998 Aug;121(3):263–9

The role of visual feedback of hand position in the control of manual prehension. Connolly JD, et al. **Exp Brain Res** 1999 Apr;125(3):281–6

Facilitation of neuronal activity in somatosensory and posterior parietal cortex during prehension. Gardner EP, et al. **Exp Brain Res** 1999 Aug;127(4):329–54

Grip forces exerted against stationary held objects during gravity changes. Hermsdörfer J, et al. **Exp Brain Res** 1999 May;126(2):205–14

The effects of delay on the kinematics of grasping. Hu Y, et al. **Exp Brain Res** 1999 May;126(1):109–16

Motor redundancy during maximal voluntary contraction in four-finger tasks. Li ZM, et al. **Exp Brain Res** 1998 Sep; 122(1):71–8

The role of learned pictorial cues in the programming and control of grasping. Marotta JJ, et al. **Exp Brain Res** 1998 Aug;121(4):465–70

Target viewing time and velocity effects on prehension. Mason AH, et al. **Exp Brain Res** 1999 Jul;127(1):83–94

Sensorimotor interactions between pairs of fingers in bimanual and unimanual manipulative tasks. Ohki Y, et al. **Exp Brain Res** 1999 Jul;127(1):43–53

Developmental changes in prehension during childhood. Paré M, et al. **Exp Brain Res** 1999 Apr;125(3):239–47

Movement detection at the distal joint of the human thumb and fingers. Refshauge KM, et al. **Exp Brain Res** 1998 Sep; 122(1):85–92

Grip force adjustments induced by predictable load perturbations during a manipulative task. Serrien DJ, et al. **Exp Brain Res** 1999 Jan;124(1):100–6

Coordination among the body segments during reach-to-grasp action involving the trunk. Wang J, et al. **Exp Brain Res** 1998 Dec;123(3):346–50

Task-dependent deficits during object release in Parkinson's disease. Gordon AM. **Exp Neurol** 1998 Oct;153(2):287–98

Command-related distribution of regional cerebral blood flow during attempted handgrip. Nowak M, et al. **J Appl Physiol** 1999 Mar;86(3):819–24

Grip strength changes over 27 yr in Japanese-American men. Rantanen T, et al. **J Appl Physiol** 1998 Dec;85(6):2047–53

A distributed pressure sensor for biomechanical measurements. Pawluk DT, et al. **J Biomech Eng** 1998 Apr; 120(2):302–5

The scaling of human grip configurations. Cesari P, et al. **J Exp Psychol Hum Percept Perform** 1999 Aug; 25(4):927–35

Noise, information transmission, and force variability. Slifkin AB, et al. **J Exp Psychol Hum Percept Perform** 1999 Jun; 25(3):837–51

Anticipating load torques produced by voluntary movements. Wing AM, et al. **J Exp Psychol Hum Percept Perform** 1998 Dec;24(6):1571–81

Unit of measurement: newton (N) versus kilogram force (kgf) [letter; comment] Cholewicki J, et al. **J Hand Surg [Am]** 1998 Sep;23(5):952. Comment on: J Hand Surg [Am] 1997 Nov;22(6):995–1003. Comment on: J Hand Surg [Am] 1997 Nov;22(6):1004–10. Comment on: J Hand Surg [Am] 1997 Nov;22(6):1011–5.

Forearm muscle activation during power grip and release. Johanson ME, et al. **J Hand Surg [Am]** 1998 Sep; 23(5):938–44

The contribution of the intrinsic muscles to grip and pinch strength [see comments] Kozin SH, et al. **J Hand Surg [Am]** 1999 Jan;24(1):64–72. Comment in: J Hand Surg [Am] 1999 Jul;24(4):870–1.

A comparison of dominant and non-dominant hand strengths. Armstrong CA, et al. **J Hand Surg [Br]** 1999 Aug; 24(4):421–5

Hand-grip dynamometry provides a valid indication of upper extremity strength impairment in home care patients. Bohannon RW. **J Hand Ther** 1998 Oct–Dec;11(4):258–60

Dynamic versus static grip strength: how grip strength changes when the wrist is moved, and why dynamic grip strength may be a more functional measurement. LaStayo P, et al. **J Hand Ther** 1999 Jul–Sep;12(3):212–8

The effect of unilateral posteroventral pallidotomy on the kinematics of the reach to grasp movement. Bennett KM, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):479–87

Mechanisms for force adjustments to unpredictable frictional changes at individual digits during two-fingered manipulation. Birznieks I, et al. **J Neurophysiol** 1998 Oct; 80(4):1989–2002

Detection of vibration transmitted through an object grasped in the hand. Brisben AJ, et al. **J Neurophysiol** 1999 Apr; 81(4):1548–58

Contact-evoked changes in EMG activity during human grasp. Collins DF, et al. **J Neurophysiol** 1999 May; 81(5):2215–25

Control of fingertip forces in multidigit manipulation. Flanagan JR, et al. **J Neurophysiol** 1999 Apr;81(4):1706–17

Neuronal activity in somatosensory cortex of monkeys using a precision grip. I. Receptive fields and discharge patterns. Salimi I, et al. **J Neurophysiol** 1999 Feb;81(2):825–34

Neuronal activity in somatosensory cortex of monkeys using a precision grip. II. Responses To object texture and weights. Salimi I, et al. **J Neurophysiol** 1999 Feb; 81(2):835–44

Neuronal activity in somatosensory cortex of monkeys using a precision grip. III. Responses to altered friction perturbations. Salimi I, et al. **J Neurophysiol** 1999 Feb; 81(2):845–57

Control of grip force when tilting objects: effect of curvature of grasped surfaces and applied tangential torque. Goodwin AW, et al. **J Neurosci** 1998 Dec 15;18(24):10724–34

Postural hand synergies for tool use. Santello M, et al. **J Neurosci** 1998 Dec 1;18(23):10105–15

Cross-education of muscle strength is greater with stimulated than voluntary contractions. Hortobágyi T, et al. **Motor Control** 1999 Apr;3(2):205–19

On achieving strong inference in prehension research [comment] Marteniuk RG, et al. **Motor Control** 1999 Jul; 3(3):272–5; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

Computational implications of modeling grasping as a form of (multiple-parallel) reaching [comment] Morasso PG, et al. **Motor Control** 1999 Jul;3(3):276–9; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

Influence of intermittency and synergy on grasping [comment] Neilson PD. **Motor Control** 1999 Jul;3(3):280–4; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

On taking the grasping out of prehension [comment] Newell KM, et al. **Motor Control** 1999 Jul;3(3):285–8; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

Approaching grasping from different perspectives [comment] Rosenbaum D, et al. **Motor Control** 1999 Jul;3(3):289–97; discussion 316–25. Comment on: Motor Control 1999 Jul;3(3):237–71.

Is it pointing to grasping or grasping pointing? [comment] Savelsbergh GJ, et al. **Motor Control** 1999 Jul;3(3):298–301; discussion 316–25. Comment on: Motor Control 1999

Jul;3(3):237-71.
A new view on grasping [see comments] Smeets JB, et al. **Motor Control** 1999 Jul;3(3):237-71 (86 ref.). Comment in: Motor Control 1999 Jul;3(3):272-5; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):276-9; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):280-4; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):285-8; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):289-97; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):298-301; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):302-6; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):307-11; discussion 316-25. Comment in: Motor Control 1999 Jul;3(3):312-5; discussion 316-25.
What can be learned from Smeets and Brenner's model about the control of grasping? [comment] Steenbergen B. **Motor Control** 1999 Jul;3(3):302-6; discussion 316-25. Comment on: Motor Control 1999 Jul;3(3):237-71.
Grasp stiffness as a function of grasp force and finger span. Van Doren CL. **Motor Control** 1998 Oct;2(4):352-78 (78 ref.)
Temporal and spatial relationship between reaching and grasping. Commentary on "A new view on grasping" [comment] Wang J, et al. **Motor Control** 1999 Jul; 3(3):307-11; discussion 316-25. Comment on: Motor Control 1999 Jul;3(3):237-71.
The reach-to-grasp movement: A new look at an old problem? [comment] Weir P. **Motor Control** 1999 Jul; 3(3):312-5; discussion 316-25. Comment on: Motor Control 1999 Jul;3(3):237-71.
Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects. Bonfiglioli C, et al. **Neuropsychologia** 1998 Nov;36(11):1203-8
Impact of the surface slipperiness of grasped objects on their subsequent acceleration. Saels P, et al. **Neuropsychologia** 1999 Jun;37(6):751-6
Externally guided control of static grip forces by visual feedback-age and task effects in 3-6-year old children and in adults. Blank R, et al. **Neurosci Lett** 1999 Aug 13; 271(1):41-4
Posterior parietal areas specialized for eye movements (LIP) and reach (PRR) using a common coordinate frame. Andersen RA, et al. **Novartis Found Symp** 1998;218:109-22; discussion 122-8, 171-5 (32 ref.)
Construction of a reach-to-grasp. Gibson AR, et al. **Novartis Found Symp** 1998;218:233-45; discussion 245-51 (39 ref.)
Grasping an object: one movement, several components. Jeannerod M, et al. **Novartis Found Symp** 1998;218:5-16; discussion 16-20 (41 ref.)
Sensory input and control of grip. Johansson RS. **Novartis Found Symp** 1998;218:45-59; discussion 59-63 (40 ref.)
The importance of the cortico-motoneuronal system for control of grasp. Lemon RN, et al. **Novartis Found Symp** 1998;218:202-15; discussion 215-8 (39 ref.)
Grasping objects and grasping action meanings: the dual role of monkey rostroventral premotor cortex (area F5). Rizzolatti G, et al. **Novartis Found Symp** 1998;218:81-95; discussion 95-103 (46 ref.)
Color or brightness effects on grip strength? Dunwoody L. **Percept Mot Skills** 1998 Aug;87(1):275-8
Effect of viewed color on hand-grip strength. Keller LM, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):763-8
Development of visuomotor integration in learning to grasp a moving ball. Teixeira LA. **Percept Mot Skills** 1998 Dec; 87(3 Pt 1):931-6
Effects of repetitive handgrip training on endurance, specificity, and cross-education. Shields RK, et al. **Phys Ther** 1999 May;79(5):467-75
[Analysis of hand function with the Millesi examination scale in patients with pollicisation after aplasia or hypoplasia of the thumb] Knabl JS, et al. **Handchir Mikrochir Plast Chir** 1998 Sep;30(5):317-24 (Eng. Abstr.) **(Ger)**
[Single number index of vibratory and force load during hand-arm vibration] Denisov EI. **Med Tr Prom Ekol** 1999; (6):34-6 (Eng. Abstr.) **(Rus)**

HANDEDNESS see **LATERALITY**

HANDICAPPED see **DISABLED PERSONS**

HANDICAPPED CHILDREN see **DISABLED CHILDREN**

HANDLING (PSYCHOLOGY)

Infantile handling eliminates reversal learning deficit in rats prenatally exposed to alcohol. Lee MH, et al. **Alcohol** 1999 May;18(1):49-53
Cholinergic activation in frontal cortex and nucleus accumbens related to basic behavioral manipulations: handling, and the role of post-handling experience. Thiel CM, et al. **Brain Res** 1998 Nov 23;812(1-2):121-32
Effects of handling on extracellular levels of glutamate and other amino acids in various areas of the brain measured by microdialysis. Timmerman W, et al. **Brain Res** 1999 Jul 3;833(2):150-60
Naltrindole administration during the preweanling period and manipulation affect adrenocortical reactivity in young rats. Fernández B, et al. **Brain Res Dev Brain Res** 1999 Jan 11; 112(1):135-7
Comparisons of the densities of NADPHd reactive and nNOS immunopositive neurons in the hippocampus of three age groups of young nonhandled and handled rats. Veenman CL, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):229-43
Commentary: is maternal stimulation the mediator of the handling effect in infancy? Denenberg VH. **Dev Psychobiol** 1999 Jan;34(1):1-3 (15 ref.)
Dampening of the cortisol response to handling at 3 months in human infants and its relation to sleep, circadian cortisol activity, and behavioral distress. Larson MC, et al. **Dev Psychobiol** 1998 Dec;33(4):327-37
Altered challenge response in whitefish subchronically exposed in areas polluted by bleached kraft mill effluents. Lappivaara J, et al. **Ecotoxicol Environ Saf** 1999 Mar; 42(3):212-22
Long-term effects of prenatal stress and postnatal handling on age-related glucocorticoid secretion and cognitive performance: a longitudinal study in the rat. Vallée M, et al. **Eur J Neurosci** 1999 Aug;11(8):2906-16
Do early-life events permanently alter behavioral and hormonal responses to stressors? Anisman H, et al. **Int J Dev Neurosci** 1998 Jun-Jul;16(3-4):149-64 (104 ref.)
Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: implications for a neurodevelopmental animal model of schizophrenia. Shalev U, et al. **Int J Dev Neurosci** 1998 Jun-Jul;16(3-4):279-88
Long-term behavioural and neuroendocrine changes in Roman high-(RHA/Verh) and low-(RLA-Verh) avoidance rats following neonatal handling. Steimer T, et al. **Int J Dev Neurosci** 1998 Jun-Jul;16(3-4):165-74
Prenatal stress induces high anxiety and postnatal handling induces low anxiety in adult offspring: correlation with stress-induced corticosterone secretion. Vallée M, et al. **J Neurosci** 1997 Apr 1;17(7):2626-36
Evaluation of the white-coat effect in cats. Belew AM, et al. **J Vet Intern Med** 1999 Mar-Apr;13(2):134-42
Environmental enrichment and postnatal handling prevent spatial learning deficits in aged hypoemotional (Roman high-avoidance) and hyperemotional (Roman low-avoidance) rats. Escorihuela RM, et al. **Learn Mem** 1995 Jan-Feb;2(1):40-8
The effect of handling and immobilization on the response to acute pain in newborn infants. Porter FL, et al. **Pediatrics** 1998 Dec;102(6):1383-9
Different levels of Fos immunoreactivity after repeated handling and injection stress in two inbred strains of mice. Ryabinin AE, et al. **Pharmacol Biochem Behav** 1999 May; 63(1):143-51
Differential effects of neonatal handling on anxiety, corticosterone response to stress, and hippocampal glucocorticoid and serotonin (5-HT)2A receptors in Lewis rats. Durand M, et al. **Psychoneuroendocrinology** 1998 May; 23(4):323-35
Effects of early handling on amphetamine-induced locomotor activation and conditioned place preference in the adult rat. Campbell J, et al. **Psychopharmacology (Berl)** 1999 Apr;143(2):183-9
Young camelids in 'pets corners' [letter] Windsor RS. **Vet Rec** 1999 Feb 20;144(8):215

HANDWASHING

A simple hand hygiene exercise. Aspöck C, et al. **Am J Infect Control** 1999 Aug;27(4):370-2
Patient education model for increasing handwashing compliance. McGuckin M, et al. **Am J Infect Control** 1999 Aug;27(4):309-14
Handwashing before entering the intensive care unit: what we learned from continuous video-camera surveillance. Nishimura S, et al. **Am J Infect Control** 1999 Aug; 27(4):367-9
Compliance with handwashing [letter] McGuckin M. **Ann Intern Med** 1999 Aug 17;131(4):309-10
Hand hygiene in hospitals [letter] Mortimer PP. **Ann Intern Med** 1999 Oct 5;131(7):546
Compliance with handwashing in a teaching hospital. Infection Control Program [see comments] Pittet D, et al. **Ann Intern Med** 1999 Jan 19;130(2):126-30. Comment in: Ann Intern Med 1999 Jan 19;130(2):153-5.
Handwashing: simple, but effective. Daniels IR, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):117-8
Hand washing [editorial] **BMJ** 1999 Mar 13;318(7185):686
Wrist watches must be removed before washing hands [letter] Hartley JC, et al. **BMJ** 1999 Jan 30;318(7179):328
Hand washing. Hand washing is more common among healthcare workers than the public [letter] Hateley PM, et al. **BMJ** 1999 Aug 21;319(7208):519
Hand washing. Muslim teaching gives rules for when hands must be washed [letter] Katme AM. **BMJ** 1999 Aug 21; 319(7208):520
Hand washing. Handwashing facilities are inadequate [letter] Kesavan S. **BMJ** 1999 Aug 21;319(7208):518-9
Dermatitis associated with frequent hand washing should have been mentioned [letter] MacDermott R. **BMJ** 1999 Aug 21;319(7208):519
Hand washing. Healthcare workers washed their hands on only a third occasions [letter] Sen R, et al. **BMJ** 1999 Aug 21;319(7208):518
Hand washing. Why I don't wash my hands between each patient contact [letter] Weeks A. **BMJ** 1999 Aug 21; 319(7208):518
Hand washing and use of gloves while managing patients receiving mechanical ventilation in the ICU. Khatib M, et al. **Chest** 1999 Jul;116(1):172-5
Role of perceived danger in the mediation of obsessive-compulsive washing. Jones MK, et al. **Depress Anxiety** 1998;8(3):121-5
Washing our hands of the matter [editorial] Fred HL. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):11
Inactivation of respiratory syncytial virus by generic hand dishwashing detergents and antibacterial hand soaps. Contreras PA, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):57-8
Evaluation of a handwashing intervention to reduce respiratory illness rates in senior day-care centers. Falsey AR, et al. **Infect Control Hosp Epidemiol** 1999 Mar; 20(3):200-2
An observational study of hand washing and infection control practices by healthcare workers. Watanakunakorn C, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):858-60
Clinical correlation of a skin antisepsis model. McDonnell G, et al. **J Microbiol Methods** 1999 Feb;35(1):31-5
Super germs solution [letter; comment] Seaton K. **J Natl Med Assoc** 1998 Dec;90(12):738. Comment on: J Natl Med Assoc 1998 Jan;90(1):10-2.
Historical perspectives on health. Semmelweis: a lesson to relearn? Daniels IR. **J R Soc Health** 1998 Dec; 118(6):367-70
Antimicrobial effects of electrolytic products of sodium chloride--comparative evaluation with sodium hypochlorite solution and efficacy in handwashing. Hitomi S, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1176-81
Viral meningitis in child care center staff and parents: an outbreak of echovirus 30 infections. Mohle-Boetani JC, et al. **Public Health Rep** 1999 May-Jun;114(3):249-56
Hygienic practices and acute respiratory illness in family and group day care homes. St. Sauver J, et al. **Public Health Rep** 1998 Nov-Dec;113(6):544-51
[Hand-hygiene and sickness among small children attending day care centers. An intervention study] Ladegaard MB, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4396-400 (Eng. Abstr.) **(Dan)**
[Hue and cry over pens?] Uhoda I, et al. **Rev Med Liege** 1999 Jan;54(1):37-8 (18 ref.) (Eng. Abstr.) **(Fre)**
[The end of handwashing: to the next millennium with hygienic disinfection of hands] Widmer AF. **Schweiz Rundsch Med Prax** 1999 Apr 22;88(17):761-3 (6 ref.) **(Ger)**
[Hand hygiene] Lystad A. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2454 **(Nor)**

METHODS

Irritancy of scrubbing up for surgery with or without a brush. Kikuchi-Numagami K, et al. **Acta Derm Venereol** 1999 May;79(3):230-2
Effectiveness of hand-cleansing agents for removing Acinetobacter baumannii strain from contaminated hands. Cardoso CL, et al. **Am J Infect Control** 1999 Aug; 27(4):327-31
Comparison of the antibacterial efficacy of 4% chlorhexidine gluconate and 1% triclosan handwash products in an acute clinical ward. Faoagali JL, et al. **Am J Infect Control** 1999 Aug;27(4):320-6
Development and evaluation of a new alcohol-based surgical hand scrub formulation with persistent antimicrobial characteristics and brushless application. Hobson DW, et al. **Am J Infect Control** 1998 Oct;26(5):507-12
A close look at alcohol gel as an antimicrobial sanitizing agent. Paulson DS, et al. **Am J Infect Control** 1999 Aug; 27(4):332-8
Study of handwashing procedures in the bathrooms of Boston-area hospitals [letter] Stender J, et al. **Am J Infect Control** 1998 Aug;26(4):451-2
Handwashing with soap or alcoholic solutions? A randomized clinical trial of its effectiveness. Zaragoza M, et al. **Am J Infect Control** 1999 Jun;27(3):258-61
Hand washing. Alcohol hand rubs are better than soap and water [letter] Welbourn CR, et al. **BMJ** 1999 Aug 21; 319(7208):519
Effectiveness of a training program in reducing infections in toddlers attending day care centers [see comments] Carabin H, et al. **Epidemiology** 1999 May;10(3):219-27. Comment in: Epidemiology 1999 May;10(3):209-10.
Efficacy of hand disinfectants against vancomycin-resistant enterococci in vitro. Kampf G, et al. **J Hosp Infect** 1999 Jun;42(2):143-50

STANDARDS

It is time for action: improving hand hygiene in hospitals [editorial; comment] Boyce JM. **Ann Intern Med** 1999 Jan 19;130(2):153-5. Comment on: Ann Intern Med 1999 Jan 19;130(2):126-30.
Surgical hand disinfection with alcohols at various concentrations: parallel experiments using the new proposed European standards method. Rotter ML, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):778-81
Now wash your hands? A survey of hospital handwashing facilities. Kesavan S, et al. **J Hosp Infect** 1998 Dec; 40(4):291-3

HANDWRITING

see related
AGRAPHIA

Neuromotor Control in Handwriting and Drawing. Proceedings of the 8th International Graphonomics Society (IGS) Conference. Genoa, Italy, 24–28 August 1997. **Acta Psychol (Amst)** 1998 Nov;100(1–2):1–227

Masked form priming in writing words from pictures: evidence for direct retrieval of orthographic codes. Bonin P, et al. **Acta Psychol (Amst)** 1998 Sep;99(3):311–28

Elderly subjects are impaired in spatial coordination in fine motor control. Contreras-Vidal JL, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):25–35

The stability of pen-joint and interjoint coordination in loop writing. Meulenbroek RG, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):55–70

Exploitation of elasticity in copying geometrical patterns: the role of age, movement amplitude, and limb-segment involvement. Meulenbroek RG, et al. **Acta Psychol (Amst)** 1998 Sep;99(3):329–45

The 2/3 power law: when and why? Plamondon R, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):85–96

Handwriting and speech changes across the levodopa cycle in Parkinson's disease. Poluha PC, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):71–84

Can non-linear muscle dynamics explain the smoothness of handwriting movements? Sanguineti V, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):217–27

Functional properties of graphic workspace: assessment by means of a 3D geometric arm model. Schillings JJ, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):97–115

Low-frequency periodicity in the coordination of progressive handwriting. Thomassen AJ, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):133–44

Axial pen force increases with processing demands in handwriting. van Den Heuvel CE, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):145–59

Neuromotor control in handwriting and drawing: introduction and overview. van Galen GP, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):1–7

The influence of mental and motor load on handwriting movements in parkinsonian patients. van Gemmert AW, et al. **Acta Psychol (Amst)** 1998 Nov;100(1–2):161–75

Autosomal recessive rolandic epilepsy with paroxysmal exercise-induced dystonia and writer's cramp: delineation of the syndrome and gene mapping to chromosome 16p12–11.2. Guerrini R, et al. **Ann Neurol** 1999 Mar; 45(3):344–52

The equivalence of computerized and paper-and-pencil psychological instruments: implications for measures of negative affect. Schulenberg SE, et al. **Behav Res Methods Instrum Comput** 1999 May;31(2):315–21

Changes of somatosensory evoked potentials during writing with the dominant and non-dominant hands. Hoshiyama M, et al. **Brain Res** 1999 Jun 26;833(1):10–9

Using writing instruments: invariances in young children and adults. Greer T, et al. **Child Dev** 1998 Aug;69(4):888–902

Basal ganglia arteriovenous malformation presenting as "writer's cramp". Kurita H, et al. **Childs Nerv Syst** 1998 Jun;14(6):285–7

Abnormal contingent negative variation in writer's cramp. Hamano T, et al. **Clin Neurophysiol** 1999 Mar;110(3):508–15

Proprioceptive control of multijoint movement: unimanual circle drawing. Verschueren SM, et al. **Exp Brain Res** 1999 Jul;127(2):171–81

Proprioceptive control of multijoint movement: bimanual circle drawing. Verschueren SM, et al. **Exp Brain Res** 1999 Jul;127(2):182–92

Consistency of handwriting movements in dementia of the Alzheimer's type: a comparison with Huntington's and Parkinson's diseases. Slavin MJ, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):20–5

Micrographia in Huntington's disease [letter] Iwasaki Y, et al. **J Neurol Sci** 1999 Jan 1;162(1):106–7

Sketches from The Lancet. Doctors' handwriting. Kandela P. **Lancet** 1999 Mar 27;353(9158):1109

Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Chen R, et al. **Mov Disord** 1999 Mar;14(2):307–12

Emergent componential coding of a handwritten image database by neural self-organisation. Webber CJ. **Network** 1998 Nov;9(4):433–47

Deficient activation of the motor cortical network in patients with writer's cramp. Ibáñez V, et al. **Neurology** 1999 Jul 13;53(1):96–105

Metabolic abnormalities detected by 1H-MRS in dyscalculia and dysgraphia. Levy LM, et al. **Neurology** 1999 Aug 11; 53(3):639–41

Micrographia after thalamo-mesencephalic infarction [letter; comment] LeWitt PA. **Neurology** 1999 Jun 10;52(9):1921; discussion 1921–2. Comment on: Neurology 1998 Aug;51(2):625–7.

Micrographia after thalamo-mesencephalic infarction [letter; comment] Savoiardo M, et al. **Neurology** 1999 Jun 10; 52(9):1921–2. Comment on: Neurology 1998 Aug;51(2):625–7.

Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer's cramp. Siebner HR, et al. **Neurology** 1999 Feb;52(3):529–37

Parkinson's disease and the control of size and speed in handwriting. Van Gemmert AW, et al. **Neuropsychologia** 1999 Jun;37(6):685–94

Functional asymmetries in the quality of handwriting movements: a kinematic analysis. Phillips JG, et al. **Neuropsychology** 1999 Apr;13(2):291–7

Abnormal increase in the corticomotor output to the affected hand during repetitive transcranial magnetic stimulation of the primary motor cortex in patients with writer's cramp. Siebner HR, et al. **Neurosci Lett** 1999 Mar 5;262(2):133–6

Handwriting and emotional stress. Halder-Sinn P, et al. **Percept Mot Skills** 1998 Oct;87(2):457–8

Joseph Richman's signs for distinguishing genuine from simulated suicide notes. Lester D, et al. **Percept Mot Skills** 1998 Aug;87(1):242

Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Kuenstler U, et al. **Psychiatry Res** 1999 Feb 22;90(1):31–9

Planning and executing fast movement sequences: a comparison of speech and handwriting. Fuchs H, et al. **Res Q Exerc Sport** 1999 Jun;70(2):190–5

An evaluation of line quality in photocopied signatures. Dawson GA, et al. **Sci Justice** 1998 Jul–Sep;38(3):189–94

[Studies on basis and methods for examination of ruled characters] Wang C, et al. **Fa 1 Hsueh Tsa Chih** 1997; 13(4):205–7, 254 (Eng. Abstr.) **(Chi)**

[Writer's cramp treated with botulinum injections] Koelman JH, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1; 142(31):1768–71 (Eng. Abstr.) **(Dut)**

[A new look at dyslexia-dysorthography. Plea for an early recognition of that handicap] Leroy D. **Arch Pediatr** 1998 Dec;5(12):1383–6 (Eng. Abstr.) **(Fre)**

[Hue and cry over pens?] Uhoda I, et al. **Rev Med Liege** 1999 Jan;54(1):37–8 (18 ref.) (Eng. Abstr.) **(Fre)**

HANGANUTZIU-DEICHER ANTIBODIES see **ANTIBODIES, HETEROPHILE**

HANGANUTZIU-DEICHER ANTIGENS see **ANTIGENS, HETEROPHILE**

HANSEN'S DISEASE see **LEPROSY**

HANSENULA see **PICHIA**

HANTAAN VIRUS

Hemorrhagic fever (Puumala virus infection) with ocular involvement. Kontkanen M, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):713–6

CLASSIFICATION

[Serotyping of hemorrhagic fever with renal syndrome in Hubei province] Fang Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):272–4 (Eng. Abstr.) **(Chi)**

GENETICS

[Acute hantavirus infection caused by a genetically newly identified viral strain. Severe and complicated course of hemorrhagic fever with renal syndrome (nephropathia epidemica)] Lauer B, et al. **Med Klin** 1999 Jan 15; 94(1):39–44 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Sibold C, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):409–11

Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. Van Epps HL, et al. **J Virol** 1999 Jul;73(7):5301–8

ISOLATION & PURIFICATION

Hantavirus nephropathy in a child [letter] Eboriadou M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1040–1

METABOLISM

[Functional activity of hemagglutinins from Hantaan viruses strains and use of hemagglutinating antigens for serodiagnosis hemorrhagic fever with kidney syndrome] Kushnareva TV, et al. **Vopr Virusol** 1999 Jul–Aug; 44(4):186–90 (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Expression of ICAM-1 on the Hantaan virus-infected human umbilical vein endothelial cells. Song JS, et al. **Korean J Intern Med** 1999 Jul;14(2):47–54

HANTAVIRUS

An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Toro J, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):687–94

[Hantavirus infection] Kurata T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):90–3 (10 ref.) **(Jpn)**

CHEMISTRY

Phage-displayed peptides mimicking the discontinuous neutralization sites of puumala Hantavirus envelope glycoproteins. Heiskanen T, et al. **Virology** 1999 Sep 30; 262(2):321–32

CLASSIFICATION

A longitudinal study of Sin Nombre virus prevalence in rodents, southeastern Arizona. Kuenzi AJ, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):113–7

A major outbreak of hantavirus infection in Belgium in 1995 and 1996. Heyman P, et al. **Epidemiol Infect** 1999 Jun; 122(3):447–53

Nephropathia epidemica and Puumala virus in Austria. Aberle SW, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):467–72

New York 1 and Sin Nombre viruses are serotypically distinct viruses associated with hantavirus pulmonary syndrome. Gavrilovskaya I, et al. **J Clin Microbiol** 1999 Jan;37(1):122–6

A new Clethrionomys-derived hantavirus from Germany: evidence for distinct genetic sublineages of Puumala viruses in Western Europe. Heiske A, et al. **Virus Res** 1999 Jun; 61(2):101–12

[Hantaviruses--a global problem] Israeli E, et al. **Harefuah** 1998 Sep;135(5–6):236–9 **(Heb)**

GENETICS

Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America [published erratum appears in Emerg Infect Dis 1999 Mar–Apr;5(2):314] Monroe MC, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):75–86

Genetic evidence of Dobrava virus in Apodemus agrarius in Hungary. Scharninghausen JJ, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):468–70

Completion of the Tula hantavirus genome sequence: properties of the L segment and heterogeneity found in the 3' termini of S and L genome RNAs. Kukkonen SK, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2615–22

Isolation and characterization of Puumala hantavirus from Norway: evidence for a distinct phylogenetic sublineage. Lundkvist A, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2603–14

Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. Sibold C, et al. **J Virol** 1999 Jan;73(1):667–75

Isolation and characterization of a hantavirus from Lemmus sibiricus: evidence for host switch during hantavirus evolution. Vapalahti O, et al. **J Virol** 1999 Jul;73(7):5586–92

Stable expression of nucleocapsid proteins of Puumala and Hantaan virus in mammalian cells [published erratum appears in Virus Genes 1998;17(3):299] Welzel TM, et al. **Virus Genes** 1998;17(2):185–98

A new Clethrionomys-derived hantavirus from Germany: evidence for distinct genetic sublineages of Puumala viruses in Western Europe. Heiske A, et al. **Virus Res** 1999 Jun; 61(2):101–12

Genetic diversities of hantaviruses among rodents in Hokkaido, Japan and Far East Russia. Kariwa H, et al. **Virus Res** 1999 Feb;59(2):219–28

Nucleotide sequence and phylogenetic analysis of the medium (M) genomic RNA segments of three hantaviruses isolated in China. Shi X, et al. **Virus Res** 1998 Jul; 56(1):69–76

IMMUNOLOGY

Hantavirus-specific IgG, IgM, and IgA in acute and chronic renal disease versus congenital renal disease in the United States. Patnaik M, et al. **Am J Kidney Dis** 1999 Apr; 33(4):734–7

Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Sibold C, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):409–11

HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Koletzki D, et al. **Biol Chem** 1999 Mar;380(3):325–33

Seroprevalence of antibodies to hantavirus in health care workers and other residents of southern Argentina. Wells RM, et al. **Clin Infect Dis** 1998 Oct;27(4):895–6

Development of humoral cross-reactivity to the nucleocapsid protein of heterologous hantaviruses in nephropathia epidemica. Elgh F, et al. **FEMS Immunol Med Microbiol** 1998 Dec;22(4):309–15

New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. Ulrich R, et al. **J Biotechnol** 1999 Aug 20;73(2–3):141–53 (41 ref.)

Maternal transfer of Hantavirus antibodies in rats. Dohmae K, et al. **Lab Anim Sci** 1998 Aug;48(4):395–7

Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax). Cho HW, et al. **Vaccine** 1999 Jun 4; 17(20–21):2569–75

Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. Elbers AR, et al. **Vet Q** 1999 Apr;21(2):50–4

Hantavirus seropositivity in Israeli patients with renal failure. George J, et al. **Viral Immunol** 1998;11(2):103–8

[Anti-Hantavirus antibodies in school children in Salvador, Bahia] Mascarenhas-Batista AV, et al. **Rev Soc Bras Med Trop** 1998 Sep–Oct;31(5):433–40 (Eng.

Abstr.) **(Por)**

ISOLATION & PURIFICATION

Black Creek Canal Virus infection in Sigmodon hispidus in southern Florida. Glass GE, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):699–703

Isolation and genetic characterization of a hantavirus (Bunyaviridae: Hantavirus) from a rodent, Oligoryzomys microtis (Muridae), collected in northeastern Peru. Powers AM, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):92–8

Long-term hantavirus persistence in rodent populations in central Arizona. Abbott KD, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):102–12

Natural history of Sin Nombre virus in western Colorado. Calisher CH, et al. **Emerg Infect Dis** 1999 Jan–Feb; 5(1):126–34

Long-term studies of hantavirus reservoir populations in the southwestern United States: a synthesis. Mills JN, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):135–42

Statistical sensitivity for detection of spatial and temporal patterns in rodent population densities. Parmenter CA, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):118–25

First case of infection with hantavirus Dobrava in Germany. Meisel H, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):884–5

A major outbreak of hemorrhagic fever with renal syndrome in the Samara region, European Russia [letter] Alexeyev OA, et al. **Infection** 1998 Sep–Oct;26(5):322

Isolation and characterization of Dobrava hantavirus carried by the striped field mouse (Apodemus agrarius) in Estonia. Nemirov K, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):371–9

Polymerase chain reaction detection of Puumala virus RNA in formaldehyde-fixed biopsy material. Heiske A, et al. **Kidney Int** 1999 May;55(5):2062–9

Dobrava hantavirus in Russia [letter] Plyusnin A, et al. **Lancet** 1999 Jan 16;353(9148):207

Chronic renal dysfunction after Hantavirus infection [letter] Shutov AM, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):1041

The muskrat (Ondatra zibethicus) as a new reservoir for puumala-like hantavirus strains in Europe. Vahlenkamp M, et al. **Virus Res** 1998 Oct;57(2):139–50

METABOLISM

Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. Gavrilovskaya IN, et al. **J Virol** 1999 May;73(5):3951–9

PATHOGENICITY

A minority of seropositive wild bank voles (Clethrionomys glareolus) show evidence of current Puumala virus infection. Alexeyev OA, et al. **Epidemiol Infect** 1998 Oct; 121(2):419–25

PHYSIOLOGY

Ecologic studies of rodent reservoirs: their relevance for human health. Mills JN, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):529–37 (48 ref.)

A midcourse assessment of hantavirus pulmonary syndrome. Shope RE. **Emerg Infect Dis** 1999 Jan–Feb;5(1):172–4

HANTAVIRUS INFECTIONS

Acute polyarthritis associated with hantavirus infection. Lee EY, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2204–5

Hantavirus in the Americas. **Wkly Epidemiol Rec** 1999 Jun 4;74(22):173 **(Eng, Fre)**

[Hantavirus infection] Kurata T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):90–3 (10 ref.) **(Jpn)**

COMPLICATIONS

Chronic renal dysfunction after Hantavirus infection [letter] Shutov AM, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):1041

Hantavirus infection—new threats by an old virus [editorial] Welzel TM, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2731–3

Lack of serologic evidence for an association between Hantavirus infection and end-stage renal disease [letter] Settergren B, et al. **Nephron** 1998 Sep;80(1):93

DIAGNOSIS

Puumala virus infections in Finland: increased occupational risk for farmers. Vapalahti K, et al. **Am J Epidemiol** 1999 Jun 15;149(12):1142–51

First case of infection with hantavirus Dobrava in Germany. Meisel H, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec; 17(12):884–5

Polymerase chain reaction detection of Puumala virus RNA in formaldehyde-fixed biopsy material. Heiske A, et al. **Kidney Int** 1999 May;55(5):2062–9

[An outdoor person with high fever and flank pain] Beisland C, et al. **Tidsskr Nor Laegeforen** 1999 May 10; 119(12):1766–8 **(Nor)**

[Anti-Hantavirus antibodies in school children in Salvador, Bahia] Mascarenhas-Batista AV, et al. **Rev Soc Bras Med Trop** 1998 Sep–Oct;31(5):433–40 (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Puumala virus infections in Finland: increased occupational risk for farmers. Vapalahti K, et al. **Am J Epidemiol** 1999 Jun 15;149(12):1142–51

Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Sibold C, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):409–11

Risk factors for human hantavirus infection: Franco-Belgian collaborative case-control study during 1995–6 epidemic. Crowcroft NS, et al. **BMJ** 1999 Jun 26;318(7200):1737–8

A minority of seropositive wild bank voles (Clethrionomys glareolus) show evidence of current Puumala virus infection. Alexeyev OA, et al. **Epidemiol Infect** 1998 Oct; 121(2):419–25

A major outbreak of hantavirus infection in Belgium in 1995 and 1996. Heyman P, et al. **Epidemiol Infect** 1999 Jun; 122(3):447–53

Nephropathia epidemica and Puumala virus in Austria. Aberle SW, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):467–72

Hantavirus infection—haemorrhagic fever in the Balkans—potential nephrological hazards in the Kosovo war [editorial] Bugert JJ, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1843–4 (17 ref.)

Epidemiology of hantavirus infections in Europe [editorial] Mustonen J, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2729–31

[Diseases caused by hantaviruses] Majda-Stanisławska E, et al. **Przegl Epidemiol** 1998;52(3):245–53 (Eng. Abstr.) **(Pol)**

GENETICS

High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe puumala virus-induced nephropathia epidemica. Kanerva M, et al. **Scand J Infect Dis** 1998;30(5):532–4

HISTORY

Were hantaviruses eventually responsible for the lost Anasazi culture? [letter] Chastel C. **Acta Virol** 1998 Nov;42(5):353

IMMUNOLOGY

Development of humoral cross-reactivity to the nucleocapsid protein of heterologous hantaviruses in nephropathia epidemica. Elgh F, et al. **FEMS Immunol Med Microbiol** 1998 Dec;22(4):309–15

PATHOLOGY

Sin Nombre virus pathogenesis in Peromyscus maniculatus. Netski D, et al. **J Virol** 1999 Jan;73(1):585–91

PREVENTION & CONTROL

Maternal transfer of Hantavirus antibodies in rats. Dohmae K, et al. **Lab Anim Sci** 1998 Aug;48(4):395–7

[Hantaviruses—a global problem] Israeli E, et al. **Harefuah** 1998 Sep;135(5–6):236–9 **(Heb)**

RADIOGRAPHY

Hantaviruses: an overview and radiographic correlation. Vanderford V. **Radiol Technol** 1999 Mar–Apr;70(4):373–7 (10 ref.)

TRANSMISSION

Isolation and genetic characterization of a hantavirus (Bunyaviridae: Hantavirus) from a rodent, Oligoryzomys microtis (Muridae), collected in northeastern Peru. Powers AM, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):92–8

VETERINARY

Hantavirus (Bunyaviridae) infections in rodents from Orange and San Diego counties, California. Bennett SG, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):75–84

Black Creek Canal Virus infection in Sigmodon hispidus in southern Florida. Glass GE, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):699–703

Long-term hantavirus persistence in rodent populations in central Arizona. Abbott KD, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):102–12

Natural history of Sin Nombre virus in western Colorado. Calisher CH, et al. **Emerg Infect Dis** 1999 Jan–Feb; 5(1):126–34

Navigational instinct: a reason not to live trap deer mice in residences [letter] Calisher CH, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):175–6

A longitudinal study of Sin Nombre virus prevalence in rodents, southeastern Arizona. Kuenzi AJ, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):113–7

Long-term studies of hantavirus reservoir populations in the southwestern United States: a synthesis. Mills JN, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):135–42

Long-term studies of hantavirus reservoir populations in the southwestern United States: rationale, potential, and methods. Mills JN, et al. **Emerg Infect Dis** 1999 Jan–Feb; 5(1):95–101

Statistical sensitivity for detection of spatial and temporal patterns in rodent population densities. Parmenter CA, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):118–25

Relationships of deer mouse movement, vegetative structure, and prevalence of infection with Sin Nombre virus. Root JJ, et al. **J Wildl Dis** 1999 Apr;35(2):311–8

VIROLOGY

Isolation and characterization of Puumala hantavirus from Norway: evidence for a distinct phylogenetic sublineage. Lundkvist A, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2603–14

HANTAVIRUS PULMONARY SYNDROME

Update on emerging infections from the Centers for Disease Control and Prevention. Hantavirus pulmonary syndrome—Colorado and New Mexico, 1998. Cheney PR. **Ann Emerg Med** 1999 Jan;33(1):121–3

A midcourse assessment of hantavirus pulmonary syndrome. Shope RE. **Emerg Infect Dis** 1999 Jan–Feb;5(1):172–4

[Hantavirus and pulmonary pathology] Le Guenno B. **Rev Pneumol Clin** 1998 Dec;54(6):393–8 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

New World hantaviruses. Young JC, et al. **Br Med Bull** 1998; 54(3):659–73 (43 ref.)

Hantavirus pulmonary syndrome. Schussler JM, et al. **South Med J** 1999 Feb;92(2):233–5

[Hantavirus pulmonary syndrome in southern Chile (letter)] Navarrete M, et al. **Rev Med Chil** 1999 Mar;127(3):371–2 **(Spa)**

EPIDEMIOLOGY

Seroprevalence of antibodies to hantavirus in health care workers and other residents of southern Argentina. Wells RM, et al. **Clin Infect Dis** 1998 Oct;27(4):895–6

Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States. Engelthaler DM, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):87–94

An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Toro J, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):687–94

Hantavirus infection in the Four Corners region of USA in 1998 [letter] Rodriguez-Moran P, et al. **Lancet** 1998 Oct 24;352(9137):1353

Update: hantavirus pulmonary syndrome—United States, 1999. **MMWR Morb Mortal Wkly Rep** 1999 Jun 25; 48(24):521–5

ETIOLOGY

[New aspects of the pathogenesis of hantavirus infections. A systemic disease with general vascular changes] Linderholm M, et al. **Lakartidningen** 1999 Apr 28; 96(17):2083–6 (20 ref.) **(Swe)**

IMMUNOLOGY

Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Peters CJ, et al. **Annu Rev Med** 1999;50:531–45 (69 ref.)

METABOLISM

High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. Mori M, et al. **J Infect Dis** 1999 Feb;179(2):295–302

PREVENTION & CONTROL

Update: Hantavirus pulmonary syndrome—United States, 1999. **Can Commun Dis Rep** 1999 Aug 15;25(16):141 **(Eng, Fre)**

THERAPY

Hantavirus pulmonary syndrome treated with inhaled nitric oxide. Rosenberg RB, et al. **Pediatr Infect Dis J** 1998 Aug; 17(8):749–52

TRANSMISSION

Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. Chaparro J, et al. **J Hosp Infect** 1998 Dec;40(4):281–5

VIROLOGY

Emerging viral infections. Khabbaz RF. **Adv Pediatr Infect Dis** 1999;14:1–27 (111 ref.)

Genetic diversity and distribution of Peromyscus-borne hantaviruses in North America [published erratum appears in Emerg Infect Dis 1999 Mar–Apr;5(2):314] Monroe MC, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):75–86

New York 1 and Sin Nombre viruses are serotypically distinct viruses associated with hantavirus pulmonary syndrome. Gavrilovskaya I, et al. **J Clin Microbiol** 1999 Jan;37(1):122–6

HAPALE see **CALLITHRIX**

HAPALEMUR see **LEMURIDAE**

HAPLOIDY

Near-haploid common acute lymphoblastic leukaemia of

childhood with a second hyperdiploid line: a DNA ploidy and fluorescence in-situ hybridization study. Ma SK, et al. **Br J Haematol** 1998 Dec;103(3):750–5

Tex27, a gene containing a zinc-finger domain, is up-regulated during the haploid stages of spermatogenesis. de Luis O, et al. **Exp Cell Res** 1999 Jun 15;249(2):320–6

Mapping quantitative trait loci by genotyping haploid tissues. Wu RL. **Genetics** 1999 Aug;152(4):1741–52

RAPD mapping in a doubled haploid population of rice (Oryza sativa L.). Subudhi PK, et al. **Hereditas** 1999; 130(1):41–9

Micro- and macro-consequences of ooplasmic injections of early haploid male gametes. Sofikitis N, et al. **Hum Reprod Update** 1998 May-Jun;4(3):197–212 (87 ref.)

Production of haploid and diploid androgenetic zebrafish (including methodology for delayed in vitro fertilization). Corley-Smith GE, et al. **Methods Cell Biol** 1999;59:45–60 (27 ref.)

Haploid screens and gamma-ray mutagenesis. Walker C. **Methods Cell Biol** 1999;60:43–70 (34 ref.)

Production of androgenetic haploids in zebrafish with ultraviolet light. Ungar AR, et al. **Mol Mar Biol Biotechnol** 1998 Dec;7(4):320–6

HAPLORHINI

Development of a competitive ELISA for detection of primates infected with monkey B virus (Herpesvirus simiae). Blewett EL, et al. **J Virol Methods** 1999 Jan; 77(1):59–67

Indian government puts welfare of monkeys before biomedical research [news] Sharma DC. **Lancet** 1999 Aug 21;354(9179):659

Monkey dispute halts Indian drug tests [news] Jayaraman KS. **Nature** 1999 Jul 29;400(6743):393

Monkey business: CNS infections that will not go away [editorial; comment] Pachner AR, et al. **Neurology** 1998 Oct;51(4):935–7. Comment on: Neurology 1998 Oct;51(4):957–61.

ANATOMY & HISTOLOGY

Cranial capacity and performance on delay-response task correlated with principal sulcus length in monkeys. Redmond JC Jr. **Am J Phys Anthropol** 1999 May; 109(1):33–40

Anthropoid origins and the modern symphysis. Ravosa MJ. **Folia Primatol (Basel)** 1999 Mar-Apr;70(2):65–78 (85 ref.)

The primate neocortex in comparative perspective using magnetic resonance imaging. Rilling JK, et al. **J Hum Evol** 1999 Aug;37(2):191–223

fMRI provides new view of monkey brains [news] Barinaga M. **Science** 1998 Nov 20;282(5393):1397

CLASSIFICATION

Siamopithecus eocaenus, a late Eocene anthropoid primate from Thailand: its contribution to the evolution of anthropoids in Southeast Asia. Ducrocq S. **J Hum Evol** 1999 Jun;36(6):613–35

Phylogenetic analysis of anthropoid relationships. Ross C, et al. **J Hum Evol** 1998 Sep;35(3):221–306

GENETICS

The BC200 RNA gene and its neural expression are conserved in Anthropoidea (Primates). Skryabin BV, et al. **J Mol Evol** 1998 Dec;47(6):677–85

Australian report favors more monkey business [news] Rouse R. **Nat Med** 1999 Feb;5(2):133

How clonal are human mitochondria? Eyre-Walker A, et al. **Proc R Soc Lond B Biol Sci** 1999 Mar 7; 266(1418):477–83

IMMUNOLOGY

Cross-species reactivity of a panel of antibodies with monkey and porcine tissue. Carter AS, et al. **Xenotransplantation** 1999 May;6(2):123–30

METABOLISM

Presynaptic kainate receptors in the monkey striatum. Charara A, et al. **Neuroscience** 1999;91(4):1195–200

MICROBIOLOGY

Characterization of Bacteroides forsythus strains from cat and dog bite wounds in humans and comparison with monkey and human oral strains. Hudspeth MK, et al. **J Clin Microbiol** 1999 Jun;37(6):2003–6

PARASITOLOGY

Studies on infections with the Berok strain of Plasmodium cynomolgi in monkeys and mosquitoes. Collins WE, et al. **J Parasitol** 1999 Apr;85(2):268–72

PHYSIOLOGY

Recent advances in noninvasive techniques to monitor hormone-behavior interactions. Whitten PL, et al. **Am J Phys Anthropol** 1998;Suppl 27:1–23 (137 ref.)

Evolution of the cerebellum in primates: differences in relative volume among monkeys, apes and humans. Rilling JK, et al. **Brain Behav Evol** 1998;52(6):308–14

Is there a geniculohypothalamic tract in primates? A comparative immunohistochemical study in the circadian system of strepsirhine and haplorhine species. Chevassus-au-Louis N, et al. **Brain Res** 1998 Sep 14; 805(1-2):213–9

Idiothetic input into object-place configuration as the contribution to memory of the monkey and human hippocampus: a review. Gaffan D. **Exp Brain Res** 1998 Nov;123(1-2):201–9 (64 ref.)

Workshop EFP 1998: diet, foraging behaviour and time budgets in non-human primates: how field studies may help improve the welfare of captive primates. European Federation for Primatology [news] Winkler P. **Folia Primatol (Basel)** 1999 Jan-Feb;70(1):62–4

Monkey business builds a bridge to the human brain [news; comment] Paradiso MA. **Nat Neurosci** 1999 Jun;2(6):491–2 . Comment on: Nat Neurosci 1999 Jun;2(6):555–62.

Grasping objects and grasping action meanings: the dual role of monkey rostroventral premotor cortex (area F5). Rizzolatti G, et al. **Novartis Found Symp** 1998;218:81–95; discussion 95–103 (46 ref.)

Neural coding of 3D features of objects for hand action in the parietal cortex of the monkey. Sakata H, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Aug 29; 353(1373):1363–73

Origins and antiquity of X-linked triallelic color vision systems in New World monkeys. Boissinot S, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13749–54

From grasping to speech: imitation might provide a missing link [letter; comment] Miklósi A. **Trends Neurosci** 1999 Apr;22(4):151–2. Comment on: Trends Neurosci 1998 May;21(5):188–94.

Neuronal responses to orientation and motion contrast in cat striate cortex. Kastner S, et al. **Vis Neurosci** 1999 May-Jun; 16(3):587–600

How it is to be the brain of a monkey. Krüger J. **Z Naturforsch [C]** 1998 Jul-Aug;53(7-8):599–609

PSYCHOLOGY

Sleep, sleeping sites, and sleep-related activities: awakening to their significance. Anderson JR. **Am J Primatol** 1998; 46(1):63–75 (64 ref.)

How it is to be the brain of a monkey. Krüger J. **Z Naturforsch [C]** 1998 Jul-Aug;53(7-8):599–609

VIROLOGY

Relationships between simian and human enteroviruses. Pöyry T, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):635–8

HAPLOTYPES

Haploinsufficiency of the HOXA gene cluster, in a patient with hand-foot-genital syndrome, velopharyngeal insufficiency, and persistent patent Ductus botalli [letter] Devriendt K, et al. **Am J Hum Genet** 1999 Jul;65(1):249–51

Ancestral Asian source(s) of new world Y-chromosome founder haplotypes. Karafet TM, et al. **Am J Hum Genet** 1999 Mar;64(3):817–31

Evidence for effective suppression of recombination in the chromosome 17q21 segment spanning RNU2-BRCA1. Liu X, et al. **Am J Hum Genet** 1999 May;64(5):1427–39

Linkage-disequilibrium mapping of disease genes by reconstruction of ancestral haplotypes in founder populations. Service SK, et al. **Am J Hum Genet** 1999 Jun; 64(6):1728–38

Canadian Bardet-Biedl syndrome family reduces the critical region of BBS3 (3p) and presents with a variable phenotype. Young TL, et al. **Am J Med Genet** 1998 Aug 6;78(5):461–7

Lactase haplotype frequencies in Caucasians: association with the lactase persistence/non-persistence polymorphism. Harvey CB, et al. **Ann Hum Genet** 1998 May;62 (Pt 3):215–23

Different H2 haplotypes have a strong influence on oncogene action. Ember I, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):1181–5

Detection of a new compound heterozygote (del G916/G1401A) for lipoprotein lipase deficiency and a comparative haplotype analysis of the mutant lipoprotein lipase gene from Japanese patients [letter] Okubo M, et al. **Atherosclerosis** 1999 Jun;144(2):443–7

A novel haplotype of the endogenous retrovirus, HRES-1, in patients with multiple sclerosis and healthy individuals. Rasmussen HB, et al. **Autoimmunity** 1999;29(2):141–5

Mice carrying two t haplotypes: sperm populations with reduced Zona pellucida binding are deficient in capacitation. Si Y, et al. **Biol Reprod** 1999 Jul;61(1):305–11

HLA class II gene and haplotype diversity in the population of the island of Hvar, Croatia. Grubić Z, et al. **Coll Antropol** 1998 Jun;22(1):157–68

Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Hoffer MJ, et al. **Eur J Clin Invest** 1998 Oct;28(10):807–12

Reconstruction of a historical genealogy by means of STR analysis and Y-haplotyping of ancient DNA. Gerstenberger J, et al. **Eur J Hum Genet** 1999 May-Jun; 7(4):469–77

Haplotype and mutation analysis in Greek patients with Wilson disease. Loudianos G, et al. **Eur J Hum Genet** 1998 Sep-Oct;6(5):487–91

Analysis of FMR1 and flanking microsatellite markers in normal and fragile X chromosomes in Portugal: evidence for a "protector" haplotype. Peixoto A, et al. **Eur J Hum Genet** 1998 Sep-Oct;6(5):518–22

HLA antigens and haplotypes in IgA-deficient Brazilian paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281–5

Heterogeneity of HLA-DR2 haplotypes in Caucasoid Americans, African Americans, Chinese Americans, Native Americans and Xiamen Chinese. Lee A, et al. **Eur J Immunogenet** 1999 Aug;26(4):275–80

Distributions of HLA-DRB1/DQB1 alleles and haplotypes in the north-eastern Thai population: indicative of a distinct Thai population with Chinese admixtures in the central Thais. Romphruk AV, et al. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):129–33

Microsatellite mutations in spontaneously aborted embryos. Spandidos DA, et al. **Fertil Steril** 1998 Nov;70(5):892–5

Parental genotype reconstruction: applications of haplotype relative risk to incomplete parental data. Martin RB, et al. **Genet Epidemiol** 1998;15(5):471–90

Spatial and temporal distribution of the neutral polymorphisms in the last ZFX intron: analysis of the haplotype structure and genealogy. Jaruzelska J, et al. **Genetics** 1999 Jul;152(3):1091–101

No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses. Kawashima T, et al. **Hum Hered** 1998 Sep-Oct;48(5):271–4

New DNA polymorphisms define ethnically distinct haplotypes in the human transferrin receptor gene. Van Landeghem GF, et al. **Hum Hered** 1998 Sep-Oct; 48(5):245–50

Highly sensitive mutation screening by REF with low concentrations of urea: A blinded analysis of a 2-kb region of the p53 gene reveals two common haplotypes. Feng J, et al. **Hum Mutat** 1999;14(2):175–80

Intragenic single nucleotide polymorphism haplotype analysis of SUR1 mutations in familial hyperinsulinism. Glaser B, et al. **Hum Mutat** 1999;14(1):23–9

Selection in favor of the Ped fast haplotype occurs between mid-gestation and birth. Exley GE, et al. **Immunogenetics** 1999 Jul;49(7-8):653–9

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Jiménez P, et al. **Int J Cancer** 1999 Sep 24;83(1):91–7

Human Y-chromosomal STR haplotypes in a Kurdish population sample. Brinkmann C, et al. **Int J Legal Med** 1999;112(3):181–3

Human Y-chromosomal STR types in north Thailand. Horst B, et al. **Int J Legal Med** 1999;112(3):211–2

Y chromosome STR haplotypes: genetic and sequencing data of the Galician population (NW Spain). Pestoni C, et al. **Int J Legal Med** 1999;112(1):15–21

Y-chromosome STR haplotypes in an Italian population sample. Rossi E, et al. **Int J Legal Med** 1999;112(1):78–81

Historical recombinant sites in extended HLA haplotypes. D'Alfonso S, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar;13(1):8–13

The presence or absence of a retroviral long terminal repeat influences the genetic risk for type 1 diabetes conferred by human leukocyte antigen DQ haplotypes. Belgian Diabetes Registry. Donner H, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1404–8

Haplotype analysis of families with erythropoietic protoporphyria and novel mutations of the ferrochelatase gene. Wang X, et al. **J Invest Dermatol** 1999 Jul; 113(1):87–92

Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis. Chabás A, et al. **J Med Genet** 1998 Sep;35(9):775–7

Neutrality tests based on the distribution of haplotypes under an infinite-site model [letter] Depaulis F, et al. **Mol Biol Evol** 1998 Dec;15(12):1788–90

Amyloidosis in familial mediterranean fever is associated with a specific ancestral haplotype in the MEFV locus. Shohat M, et al. **Mol Genet Metab** 1998 Nov;65(3):197–202

A nested analysis of song groups and species boundaries in the Hawaiian cricket genus Laupala. Shaw KL. **Mol Phylogenet Evol** 1999 Mar;11(2):332–41

Relationship between tumour necrosis factor-alpha (TNFalpha) production and a specific multiple sclerosis (MS) associated TNF gene haplotype. Armstrong MA, et al. **Mult Scler** 1999 Jun;5(3):165–70

Terminal branch haplotype analysis: a novel approach to investigate newly arisen variants of mitochondrial DNA in natural populations. Chen JZ, et al. **Mutat Res** 1999 Jul 30;434(3):219–31

Molecular characterization of the maize Rp1-D rust resistance haplotype and its mutants. Collins N, et al. **Plant Cell** 1999 Jul;11(7):1365–76

Modeling stochastic gene expression: implications for haploinsufficiency. Cook DL, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15641–6

Y chromosomes point to Native American Adam [news] [see comments] Hutardo de Mendoza D, et al. **Science** 1999 Mar 5;283(5407):1439–40. Comment in: Science 1999 Mar 26;283(5410):2017.

Genetic clues revise view of Japanese roots [news] [see comments] Normile D. **Science** 1999 Mar 5; 283(5407):1426–7. Comment in: Science 1999 May 14;284(5417):1125.

Origin of the Amerindians [letter; comment] Pena SD. **Science** 1999 Mar 26;283(5410):2017. Comment on: Science 1999 Mar 5;283(5407):1439–40.

Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Langö–Warensjö A, et al. **Tissue Antigens** 1998 Oct;52(4):374–80

Effect of genetic selection and MHC haplotypes on lymphocyte proliferation and interleukin–2 like activity in chicken lines selected for high and low antibody production against sheep red blood cells. Gehad AE, et al. **Vet Immunol Immunopathol** 1999 Mar 29;68(1):13–24

[Haplotypes of the beta–globulin locus in Czechs and Slovaks with beta–thalassemia and structurally variant hemoglobins (published erratum appears in Vnitr Lek 1999 Jan;45(1):45)] Kynčlová E, et al. **Vnitr Lek** 1998 Sep;44(9):518–23 (Eng. Abstr.) **(Cze)**

[Prenatal diagnosis of recessive hereditary dystrophic epidermolysis bullosa with haplotype analysis of the type VII collagen gene] Bauer JW, et al. **Hautarzt** 1999 Feb; 50(2):121–6 (Eng. Abstr.) **(Ger)**

[Characterization of a novel wild–type t(wMPI) haplotype of the house mouse (Mus domesticus L.) from Peru] Shustrova IV, et al. **Genetika** 1999 Apr;35(4):556–8 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Genomic profiling of drug sensitivities via induced haploinsufficiency [see comments] Giaever G, et al. **Nat Genet** 1999 Mar;21(3):278–83. Comment in: Nat Genet 1999 Mar;21(3):245–6.

GENETICS

Characterization of ancestral and derived Y–chromosome haplotypes of New World native populations. Bianchi NO, et al. **Am J Hum Genet** 1998 Dec;63(6):1862–71

mtDNA haplogroup X: An ancient link between Europe/Western Asia and North America? Brown MD, et al. **Am J Hum Genet** 1998 Dec;63(6):1852–61

Assessment of linkage disequilibrium by the decay of haplotype sharing, with application to fine–scale genetic mapping. McPeek MS, et al. **Am J Hum Genet** 1999 Sep; 65(3):858–75

Combined use of biallelic and microsatellite Y–chromosome polymorphisms to infer affinities among African populations. Scozzari R, et al. **Am J Hum Genet** 1999 Sep; 65(3):829–46

Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes. Slaugenhaupt SA, et al. **Am J Hum Genet** 1999 Sep;65(3):773–8

Association of persistent bronchial hyperresponsiveness with beta2–adrenoceptor (ADRB2) haplotypes. A population study. D'amato M, et al. **Am J Respir Crit Care Med** 1998 Dec;158(6):1968–73

Polymorphic haplotypes of the interleukin–10 5' flanking region determine variable interleukin–10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Crawley E, et al. **Arthritis Rheum** 1999 Jun;42(6):1101–8

No association between D2 dopamine receptor (DRD2) "A" system alleles, or DRD2 haplotypes, and posttraumatic stress disorder. Gelernter J, et al. **Biol Psychiatry** 1999 Mar 1;45(5):620–5

The relationship of the –5, –8, and –24 variant alleles in African Americans to triosephosphate isomerase (TPI) enzyme activity and to TPI deficiency. Schneider A, et al. **Blood** 1998 Oct 15;92(8):2959–62

Polymorphism of the human beta3–adrenoceptor gene forms a well–conserved haplotype that is associated with moderate obesity and altered receptor function. Hoffstedt J, et al. **Diabetes** 1999 Jan;48(1):203–5

Transmission of DQ haplotypes to patients with type 1 diabetes. Kawasaki E, et al. **Diabetes** 1998 Dec; 47(12):1971–3

Crohn's disease–associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch–specific complications. Facklis K, et al. **Dis Colon Rectum** 1999 May;42(5):601–5; discussion 605–6

Haemoglobin F (HbF) levels in sickle–cell anaemia patients homozygous for the Bantu haplotype [letter] Mouélé R, et al. **Eur J Haematol** 1999 Aug;63(2):136–7

Effect of inbreeding avoidance on Hardy–Weinberg expectations: examples of neutral and selected loci. Robertson A, et al. **Genet Epidemiol** 1999;17(3):165–73

Multiple geographic sources of region V 9–bp deletion haplotypes in Brazilians. Alves–Silva J, et al. **Hum Biol** 1999 Apr;71(2):245–59

HLA genes and haplotypes in Ryukyuans suggest recent gene flow to the Okinawa Islands. Hatta Y, et al. **Hum Biol** 1999 Jun;71(3):353–65

Y–chromosome DNA haplotype 15 in Europe. Lucotte G, et al. **Hum Biol** 1999 Jun;71(3):431–7

Some atypical and rare sickle cell gene haplotypes in populations of Andhra Pradesh, India. Niranjan Y, et al. **Hum Biol** 1999 Jun;71(3):333–40

Fine–resolution mapping by haplotype evaluation: the examples of PFIC1 and BRIC [published erratum appears in Hum Genet 1999 Jun;104(6):528] Bull LN, et al. **Hum Genet** 1999 Mar;104(3):241–8

Founder–haplotype analysis in Fukuyama–type congenital muscular dystrophy (FCMD). Kobayashi K, et al. **Hum Genet** 1998 Sep;103(3):323–7

Major beta–globin gene mutations in eastern India and their associated haplotypes. Bandyopadhyay A, et al. **Hum Hered** 1999 Jul;49(4):232–5

Measured haplotype analysis of the angiotensin–I converting enzyme gene. Keavney B, et al. **Hum Mol Genet** 1998 Oct; 7(11):1745–51

TP53 mutation and haplotype analysis of two large African American families. Hung J, et al. **Hum Mutat** 1999; 14(3):216–21

Apparent trans–chromosomal antibody class switch in mice bearing an Igh(a) mu–chain transgene on an Igh(b) genetic background. Willers J, et al. **Immunobiology** 1999 Feb; 200(1):150–64

The polymorphisms of DYS388 and DYS392 on the Y chromosome in Japanese and German populations. Sasaki M, et al. **Int J Legal Med** 1999;112(2):132–3

Patterns of gene flow and population genetic structure in the canyon treefrog, Hyla arenicolor (Cope). Barber PH. **Mol Ecol** 1999 Apr;8(4):563–76

Loss of information due to ambiguous haplotyping of SNPs [letter] Hodge SE, et al. **Nat Genet** 1999 Apr;21(4):360–1

Extended tumour necrosis factor/HLA–DR haplotypes and asthma in an Australian population sample. Moffatt MF, et al. **Thorax** 1999 Sep;54(9):757–61

HLA–Cw alleles associated with HLA extended haplotypes and C2 deficiency. Clavijo OP, et al. **Tissue Antigens** 1998 Sep;52(3):282–5

HLA DPA1/DPB1 genotype and haplotype frequencies, and linkage disequilibria in Nigeria, Liberia, and Gabon. May J, et al. **Tissue Antigens** 1998 Sep;52(3):199–207

The same genetic regions encode minor histocompatibility antigens detected in the context of different MHC haplotypes. Klinge H, et al. **Transplantation** 1999 Apr 27; 67(8):1178–83

[HLA haplotypes in young myocardial infarct patients (a family study)] Kuz'mina AA, et al. **Ter Arkh** 1998; 70(8):33–7 (Eng. Abstr.) **(Rus)**

[HLA haplotypes in families with type 1 diabetes] Pérez F, et al. **Rev Med Chil** 1998 Dec;126(12):1455–63 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. Dawkins R, et al. **Immunol Rev** 1999 Feb;167:275–304 (167 ref.)

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257–74 (171 ref.)

Diversity of HLA–B17 alleles and haplotypes in East Asians and a novel Cw6 allele (Cw*0604) associated with B*5701. Inoue T, et al. **Tissue Antigens** 1999 Jun;53(6):534–44

HAPPINESS

Psychomotor retardation and anhedonia in depression. Lemke MR, et al. **Acta Psychiatr Scand** 1999 Apr; 99(4):252–6

Comparison of the frequency and enjoyability of pleasant events in cocaine abusers vs. non–abusers using a standardized behavioral inventory. Van Etten ML, et al. **Addiction** 1998 Nov;93(11):1669–80

Human factors for pleasure in product use. Jordan PW. **Appl Ergon** 1998 Feb;29(1):25–33

Let's focus on the positive [editorial] Jones S. **Arch Psychiatr Nurs** 1999 Jun;13(3):109–10

The effect of perceived control over eating on the life satisfaction of women and men: results from a community sample. Greeno CG, et al. **Int J Eat Disord** 1998 Dec; 24(4):415–9

Reducing indices of unhappiness among individuals with profound multiple disabilities during therapeutic exercise routines. Green CW, et al. **J Appl Behav Anal** 1999 Summer;32(2):137–46; quiz 146–7

Flowers and the environment: money and control of the health care delivery system [editorial] Floch MH. **J Clin Gastroenterol** 1998 Oct;27(3):185–6

The hope construct, will, and ways: their relations with self–efficacy, optimism, and general well–being. Magaletta PR, et al. **J Clin Psychol** 1999 May;55(5):539–51

The relationship between adult happiness and self–appraised childhood happiness and events. Freeman LJ, et al. **J Genet Psychol** 1999 Mar;160(1):46–54

Changes in attractiveness of elected, rejected, and precluded alternatives: a comparison of happy and unhappy individuals. Lyubomirsky S, et al. **J Pers Soc Psychol** 1999 Jun;76(6):988–1007

The effect of age on positive and negative affect: a developmental perspective on happiness. Mroczek DK, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1333–49

Emotion in speech: the acoustic attributes of fear, anger, sadness, and joy. Sobin C, et al. **J Psycholinguist Res** 1999 Jul;28(4):347–65

Personal or environmental causes of happiness: a longitudinal analysis. Lu L. **J Soc Psychol** 1999 Feb;139(1):79–90

Perception of happiness among elderly persons in metropolitan USA. Mookherjee HN. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):787–93

Psychometric evaluation of the Menstrual Joy Questionnaire. Heard KV, et al. **Psychol Rep** 1999 Feb;84(1):135–6

The Affect Grid: a moderately valid, nonspecific measure of pleasure and arousal. Killgore WD. **Psychol Rep** 1998 Oct;83(2):639–42

Zen and happiness. Lester D. **Psychol Rep** 1999 Apr;84(2):650

Perceived competence, social anxiety about physique, and enjoyment in testing situations among groups of mixed sex and girls only. Yin Z, et al. **Psychol Rep** 1999 Apr; 84(2):381–5

Anhedonia, positive and negative affect, and social functioning in schizophrenia. Blanchard JJ, et al. **Schizophr Bull** 1998;24(3):413–24

[Anhedonia--a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?] Heinz A. **Nervenarzt** 1999 May;70(5):391–8 (94 ref.) (Eng. Abstr.) **(Ger)**

[Subjective well–being and self acceptance] Makino Y, et al. **Shinrigaku Kenkyu** 1998 Jun;69(2):143–8 (Eng. Abstr.) **(Jpn)**

HAPPY PUPPET SYNDROME see **ANGELMAN SYNDROME**

HAPTENS

Purification of prostate–specific antigen from human serum by indirect immunosorption and elution with a hapten. Peter J, et al. **Anal Biochem** 1999 Aug 15;273(1):98–104

Haptenylation of antibodies during affinity purification: a novel and convenient procedure to obtain labeled antibodies for quantification and double labeling. Pitt JC, et al. **Histochem Cell Biol** 1998 Sep;110(3):311–22

ANALYSIS

Monoclonal antibody–based ELISAs for part–per–billion determination of polycyclic aromatic hydrocarbons: effects of haptens and formats on sensitivity and specificity. Li K, et al. **Anal Chem** 1999 Jan 15;71(2):302–9

Performance of competitive and indirect enzyme–linked immunosorbent assays, gel immunoprecipitation with native hapten polysaccharide, and standard serological tests in diagnosis of sheep brucellosis. Marin CM, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):269–72

Protein haptenation by drugs. Coleman JW. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:79–82 (16 ref.)

CHEMISTRY

Influence of the hapten design on the development of a competitive ELISA for the determination of the antifouling agent Irgarol 1051 at trace levels. Ballesteros B, et al. **Anal Chem** 1998 Oct 1;70(19):4004–14

Purified protein derivative (PPD) as an immunogen carrier elicits high antigen specificity to haptens. De Silva BS, et al. **Bioconjug Chem** 1999 May–Jun;10(3):496–501

Molecular modeling of hapten structure and relevance to broad specificity immunoassay of sulfonamide antibiotics. Spinks CA, et al. **Bioconjug Chem** 1999 Jul–Aug; 10(4):583–8

Design and syntheses of three haptens to generate catalytic antibodies that cleave amide bonds with nucleophilic catalysis. Ersoy O, et al. **Bioorg Med Chem** 1999 Feb; 7(2):279–86

Toward the antibody–catalyzed chemiluminescence. Design and synthesis of hapten. Sawa M, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):647–52

Comparison of the potentials of mean force for alanine tetrapeptide between integral equation theory and simulation. Prabhu NV, et al. **Biophys Chem** 1999 Apr 5; 78(1–2):113–26

'In vivo' models of hapten generation. Bolzacchini E, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:83–6 (11 ref.)

Synthesis of (19E)–3 beta,7 alpha–dihydroxy–17–oxoandrost–5–en–19–al 19–(O–carboxymethyl)oxime, a new hapten for 7 alpha–hydroxydehydroepiandrosterone (3 beta,7 alpha–dihydroxyandrost–5–en–17–one). Pouzar V, et al. **Steroids** 1998 Sep;63(9):454–8

17Beta–hydroxy–11alpha–(3'–sulfanylpropyl)oxy–estra–1,3,5(10)– trien–3–yl sulfamate--a novel hapten structure: toward the development of a specific enzyme immunoassay (EIA) for estra–1,3,5(10)–triene–3–yl sulfamates. Schwarz S, et al. **Steroids** 1999 Jul;64(7):460–71

DRUG EFFECTS

Endogenous galectins and effect of galectin hapten inhibitors on the differentiation of the chick mesonephros. Murphy KM, et al. **Dev Dyn** 1999 Jul;215(3):248–63

IMMUNOLOGY

A novel macrophage receptor enhances MHC II–peptide loading and surface expression of a hapten–protein conjugate. Weaver DJ Jr, et al. **Biol Cell** 1998 Sep; 90(5):427–38

A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis. Spivak DA, et al. **Bioorg Med Chem** 1999 Jun;7(6):1145–50

alpha–Mannosidase activity from antibody raised against a glucal antigen. Yu J. **Bioorg Med Chem Lett** 1998 May 19;8(10):1145–8

Synthesis of a Neu2en5Ac analog hapten and isolation of monoclonal antibody to Neu2en5Ac. Kamei H, et al.

HAPTENS

Carbohydr Res 1999 Feb 28;315(3-4):243-50
A method of stimulating an immune response with a hapten immobilized on a nitrocellulose membrane. Liu JJ, et al.

Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih 1995 Feb;28(1):13-20
Human T lymphocyte priming in vitro by haptenated autologous dendritic cells. Rustemeyer T, et al.
Clin Exp Immunol 1999 Aug;117(2):209-16
Effects of carrier and hapten array on the production of anti-hapten antibodies analyzed by two-dimensional affinity electrophoresis. Wang P, et al. **Electrophoresis** 1998 Jun;19(8-9):1506-10
Partial agonism and independent modulation of T cell receptor and CD8 in hapten-specific cytotoxic T cells. Preckel T, et al. **Eur J Immunol** 1998 Nov;28(11):3706-18
Distinct roles for transforming growth factor-beta2 and tumour necrosis factor-alpha in immune deviation elicited by hapten-derivatized antigen-presenting cells. Hecker KH, et al. **Immunology** 1999 Mar;96(3):372-80
Kinetics and intracellular pathways required for major histocompatibility complex II-peptide loading and surface expression of a fluorescent hapten-protein conjugate in murine macrophage. Weaver DJ Jr, et al. **Immunology** 1999 Apr;96(4):557-68
T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative. Kessler B, et al. **J Biol Chem** 1999 Feb 5; 274(6):3622-31
Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. Dal Porto JM, et al. **J Immunol** 1998 Nov 15;161(10):5373-81
Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. Pérez-Melgosa M, et al. **J Immunol** 1999 Aug 1;163(3):1123-7
Antigen-induced somatic diversification of rabbit IgH genes: gene conversion and point mutation. Winstead CR, et al. **J Immunol** 1999 Jun 1;162(11):6602-12
An improved method for the production of antibodies to lipophilic carboxylic hapten using small amount of hapten-carrier conjugate. Pauillac S, et al.
J Immunol Methods 1998 Nov 1;220(1-2):105-14
T cell activation by monoclonal antibodies bound to tumor cells by a cell surface displayed single-chain antibody. Rode HJ, et al. **J Immunol Methods** 1999 Apr 22; 224(1-2):151-60
A substance p agonist acts as an adjuvant to promote hapten-specific skin immunity. Niizeki H, et al.
J Invest Dermatol 1999 Apr;112(4):437-42
Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Gautherot E, et al.
J Nucl Med 1998 Nov;39(11):1937-43
pH dependence of antibody: hapten association. Livesay D, et al. **Mol Immunol** 1999 Apr;36(6):397-410
Influence of dietary lipid on hapten-specific UV-induced immunosuppression. Okotie-Eboh G, et al.
Photodermatol Photoimmunol Photomed 1998 Jun-Aug; 14(3-4):116-8
Genetic analysis of the maternally induced affinity enhancement in the non-Ox1 idiotypic antibody repertoire of the primary immune response to 2-phenyloxazolone. Lange H, et al. **Scand J Immunol** 1999 Jan;49(1):55-66
Autologous, hapten-modified vaccine as a treatment for human cancers. Berd D, et al. **Semin Oncol** 1998 Dec; 25(6):646-53 (25 ref.)
A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. Oscherwitz J, et al. **Vaccine** 1999 May 14;17(19):2392-9

METABOLISM

A selenium-containing abzyme, the activity of which surpassed the level of native glutathione peroxidase. Luo G, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:136-41
Comparison of antibody and albumin catalyzed hydrolysis of steroidal p-nitrophenylcarbonates. Riva S, et al.
Appl Biochem Biotechnol 1998 Oct;75(1):33-44
Differential potency of two crosslinking plant lectins to induce formation of haptenic-sugar-resistant aggregates of rat thymocytes by post-binding signaling. Timoshenko AV, et al. **FEBS Lett** 1999 Apr 16;449(1):75-8

PHARMACOLOGY

Inhibition of contact sensitizer-induced migration of human Langerhans cells by matrix metalloproteinase inhibitors. Lebre MC, et al. **Arch Dermatol Res** 1999 Jul-Aug; 291(7-8):447-52
Contact sensitizers decrease 33D1 expression on mature Langerhans cells. Herouet C, et al. **Eur J Dermatol** 1999 Apr-May;9(3):185-90
Temporal changes in disaccharide composition of dermatan sulfate in the skin after epicutaneous application of hapten [published erratum appears in J Dermatol Sci 1999 Feb;19(2):148-9] Kuwaba K, et al. **J Dermatol Sci** 1999 Jan;19(1):23-30
Photohapten TCSA painting plus UVA irradiation of murine skin augments the expression of MHC class II molecules and CD86 on Langerhans cells. Nishijima T, et al.
J Dermatol Sci 1999 Apr;19(3):202-7

THERAPEUTIC USE

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. Kraeber-Bodéré F, et al. **J Nucl Med** 1999 Jan; 40(1):198-204

HAPTOGLOBINS

ANALYSIS

Could serum haptoglobin concentration be used as a marker of hypersplenism in chronic liver disease? [letter] Ozatli D, et al. **Am J Gastroenterol** 1998 Dec;93(12):2641-2
Development of a simple enzyme immunoassay for blood haptoglobin concentration in cattle and its application in improving food safety. Saini PK, et al. **Am J Vet Res** 1998 Sep;59(9):1101-7
Mild or subclinical intravascular haemolysis subsequent to transcatheter occlusion of the patent arterial duct. Jamjureeruk V, et al. **Cardiol Young** 1999 Jan;9(1):58-62
Quantitation of human haptoglobin: comparative ELISA studies using adsorption and capture methods. Yee E, et al. **J Immunol Methods** 1999 May 27;225(1-2):125-30
Cross-reactivity of an automated human haptoglobin immunoturbidimetric assay for detection of haptoglobin in swine serum. Wiedmeyer CE, et al. **J Vet Diagn Invest** 1999 May;11(3):295-7
Detection of haptoglobin in the high-density lipoprotein and the very high-density lipoprotein fractions from sera of calves with experimental pneumonia and cows with naturally occurring fatty liver. Katoh N, et al.
J Vet Med Sci 1999 Feb;61(2):119-24
Favourable effect of K, Mg aspartate on serum proteins in aging rats. Chlebovská K, et al. **Mech Ageing Dev** 1999 May 3;108(2):127-38
Association of the haptoglobin phenotype (1-1) with falciparum malaria in Sudan. Elagib AA, et al.
Trans R Soc Trop Med Hyg 1998 May-Jun;92(3):309-11
Changes in concentrations of serum amyloid A protein, alpha 1-acid glycoprotein, haptoglobin, and C-reactive protein in feline sera due to induced inflammation and surgery. Kajikawa T, et al. **Vet Immunol Immunopathol** 1999 Mar 29;68(1):91-8
Interferon-alpha and haptoglobin in pigs selectively bred for high and low immune response and infected with Mycoplasma hyorhinis. Magnusson U, et al.
Vet Immunol Immunopathol 1999 May;68(2-4):131-7
Nephelometric determination of haptoglobin plasma concentrations in fattening pigs. Lipperheide C, et al.
Zentralbl Veterinarmed A 1998 Nov;45(9):543-50
[Measurement of haptoglobin by immunonephelometry using Immage (Beckmann): pay attention to interference by hemoglobin (letter)] Zerbani A, et al.
Ann Biol Clin (Paris) 1999 Jul-Aug;57(4):490 **(Fre)**
[The determination of haptoglobin in specimens of biological origin] Barsegiants LO. **Sud Med Ekspert** 1999 Jul-Aug; 42(4):6-12 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Effects of acanthoic acid on TNF-alpha gene expression and haptoglobin synthesis. Kang HS, et al.
Mediators Inflamm 1998;7(4):257-9

CHEMISTRY

Crystallization of the haptoglobin-hemoglobin complex. Przybylska M, et al.
Acta Crystallogr D Biol Crystallogr 1999 Apr;55 (Pt 4):883-4

DEFICIENCY

[Undetectable haptoglobin: a cause not to be forgotten (letter)] Chemlal K, et al. **Presse Med** 1998 Sep 26; 27(28):1432 **(Fre)**

GENETICS

Haptoglobin genotyping by allele-specific polymerase chain reaction amplification. Yano A, et al.
Acta Med Okayama 1998 Aug;52(4):173-81
A new method for haptoglobin phenotyping. Wassell J, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):609-12
Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Braeckman L, et al. **Atherosclerosis** 1999 Apr;143(2):383-8
Haptoglobin polymorphism and peripheral arterial occlusive disease. Delanghe J, et al. **Atherosclerosis** 1999 Aug; 145(2):287-92
Attenuation of haptoglobin gene expression by TGFbeta requires the MAP kinase pathway. Yu SJ, et al.
Biochem Biophys Res Commun 1999 Jun 16;259(3):544-9
Acute-phase induced phosphorylation of rat liver nucleoprotein p70 modulates its binding affinity for the haptoglobin gene. Grigorov I, et al.
Biochem Mol Biol Int 1998 Aug;45(5):1067-72
Participation of two isoforms of C/EBPbeta transcription factor in the acute-phase regulation of the rat haptoglobin gene. Grigorov I, et al. **Cell Biol Int** 1998;22(9-10):685-93
Effect of haptoglobin phenotypes on growth of Streptococcus pyogenes. Delanghe J, et al.
Clin Chem Lab Med 1998 Sep;36(9):691-6
Activation of haptoglobin gene expression by cAMP involves CCAAT/enhancer-binding protein isoforms in intestinal epithelial cells. Pelletier N, et al. **FEBS Lett** 1998 Nov 20; 439(3):275-80
Haptoglobin genotype and natural fertility in humans. Bottini N, et al. **Fertil Steril** 1999 Aug;72(2):293-6
Asthma and diabetes [letter] Bottini N, et al. **Lancet** 1999 Aug 7;354(9177):515-6
Peritoneal endometriotic lesions differentially express a haptoglobin-like gene. Piva M, et al. **Mol Hum Reprod** 1999 Jan;5(1):71-8
Chimerism in humans after intragenic recombination at the haptoglobin locus during early embryogenesis. Asakawa J, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10314-9
[Incidence and pattern of recurrent side effects in persons with different haptoglobin phenotypes during chemotherapy of pulmonary tuberculosis] Ubaidullaev AM, et al. **Probl Tuberk** 1998;(4):23-4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[The effects of occupational exposure to nitrogen dioxide (NO2) on the immunological parameters in workers] Rutowski J, et al. **Med Pr** 1998;49(4):341-51 (Eng. Abstr.) **(Pol)**

METABOLISM

Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary. Dobryszycka W, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(4):229-36
Reproducible and sensitive determination of charged oligosaccharides from haptoglobin by PNGase F digestion and HPAEC/PAD analysis: glycan composition varies with disease. Goodarzi MT, et al. **Glycoconj J** 1998 May; 15(5):469-75
hgpB, a gene encoding a second Haemophilus influenzae hemoglobin- and hemoglobin-haptoglobin-binding protein. Ren Z, et al. **Infect Immun** 1998 Oct;66(10):4733-41
Transport of intact porphyrin by HpuAB, the hemoglobin-haptoglobin utilization system of Neisseria meningitidis. Lewis LA, et al. **J Bacteriol** 1998 Nov; 180(22):6043-7
Role of CCAA nucleotide repeats in regulation of hemoglobin and hemoglobin-haptoglobin binding protein genes of Haemophilus influenzae. Ren Z, et al.
J Bacteriol 1999 Sep;181(18):5865-70
Disease-related variations of the glycosylation of haptoglobin in the dog. Andersson M, et al. **J Comp Pathol** 1998 Oct; 119(3):227-38
Haptoglobin transport into human ovarian follicles and its binding to apolipoprotein A-1. Porta A, et al. **Zygote** 1999 Feb;7(1):67-77

PHARMACOLOGY

Oxidative stress resulting from hemolysis and formation of catalytically active hemoglobin: protective strategies. Ziouzenkova O, et al. **Int J Clin Pharmacol Ther** 1999 Mar; 37(3):125-32

SECRETION

TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor. Berkova N, et al.
J Immunol 1999 May 15;162(10):6226-32

HARASSMENT, NONSEXUAL see **SOCIAL BEHAVIOR**

HARASSMENT, SEXUAL see **SEXUAL HARASSMENT**

HARBOR PORPOISES see **PORPOISES**

HARD OF HEARING PERSONS see **HEARING IMPAIRED PERSONS**

HARDERIAN GLAND

DRUG EFFECTS

High frequency of codon 61 K-ras A-->T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2 years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Sills RC, et al.
Carcinogenesis 1999 Apr;20(4):657-62
TSH and thyroid hormones induce the release of secretory granules in the harderian gland of hypophysectomized frogs, (Rana esculenta): morphological observations. Di Matteo L, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Oct;120(3):383-7
Effects of hexachlorobenzene on phospholipid and porphyrin metabolism in Harderian glands: a time-course study in two strains of rats. Cochón AC, et al. **Toxicol Lett** 1999 Jun 1;106(2-3):129-36

ENZYMOLOGY

Ultrastructural localization of acetylcholinesterase (AChE) activity in the chicken Harderian gland. Hiramatsu K, et al. **Histol Histopathol** 1999 Apr;14(2):445-51
Northern analysis of type II iodothyronine deiodinase mRNA

in rat Harderian gland. Araki O, et al. **Life Sci** 1998; 63(21):1843–8

INNERVATION

A parasympathetic ganglion innervating the harderian gland and lacrimal gland of the musk shrew (Suncus murinus): fluorescent tracing and immunohistochemical studies. Ito H, et al. **Exp Anim** 1999 Jul;48(3):145–52

METABOLISM

Immunohistochemical evidence for the presence of tryptophan hydroxylase and serotonin in the rodent Harderian gland. Djeridane Y, et al. **Cell Tissue Res** 1999 Jun;296(3):517–23

Sexual differences in branched chain amino acid metabolism into fatty acids and cholesterol in Harderian gland of golden hamster. Hida A, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):648–53

PHYSIOLOGY

Issues in measuring glucose metabolism of rat brain using PET: the effect of harderian glands on the frontal lobe. Fukuyama H, et al. **Neurosci Lett** 1998 Oct 16; 255(2):99–102

HARDNESS TESTS

METHODS

Reporting microhardness data in scientific publications [letter; comment] Pober R. **J Dent Res** 1998 Oct; 77(10):1766. Comment on: J Dent Res 1998 Jun;77(6):1404–14. Comment on: J Dent Res 1998 Jun;77(6):1435–45.

STANDARDS

The influence of antagonist standardization on wear. Krejci I, et al. **J Dent Res** 1999 Feb;78(2):713–9

HARDWARE, COMPUTER see **COMPUTERS**

HARELIP see **CLEFT LIP**

HARES see **LAGOMORPHA**

HARLEQUIN FETUS see **ICHTHYOSIS, LAMELLAR**

HARMALINE

PHARMACOLOGY

Influence of stimulation of the olivocerebellar pathway by harmaline on spatial learning in the rat. Meignin C, et al. **Brain Res** 1999 Apr 10;824(2):277–83

Systemic harmaline blocks associative and motor learning by the actions of the inferior olive. Welsh JP. **Eur J Neurosci** 1998 Nov;10(11):3307–20

Harmaline interactions with yeast invertase. Gill RK, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):86–90

HARMIDINE see **HARMALINE**

HARMINE

ANALOGS & DERIVATIVES

The high-affinity binding of [3H]norharman ([3H]beta-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver. Stawowy P, et al. **Biochem Pharmacol** 1999 Mar 1;57(5):511–20

Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Totsuka Y, et al. **Cancer Lett** 1999 Sep 1; 143(2):139–43

Structural determination of a mutagenic aminophenylnorharman produced by the co-mutagen norharman with aniline. Totsuka Y, et al. **Carcinogenesis** 1998 Nov;19(11):1995–2000

PHARMACOLOGY

Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Freedland CS, et al. **Drug Alcohol Depend** 1999 May 3;54(3):183–94

Pharmahuasca: human pharmacology of oral DMT plus harmine. Ott J. **J Psychoactive Drugs** 1999 Apr–Jun; 31(2):171–7 (65 ref.)

HARRINGTONINES

ADMINISTRATION & DOSAGE

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. O'Brien S, et al. **Blood** 1999 Jun 15; 93(12):4149–53

ANTAGONISTS & INHIBITORS

Inhibition of harringtonine-induced apoptosis by tetradecanoylphorbol acetate in human leukemia HL-60 cells. Meng FH, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):459–62

PHARMACOLOGY

Characteristics of harringtonine-resistant human leukemia HL60 cell. He QY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep;17(5):463–7

Resistance to apoptosis of harringtonine-resistant HL60 cells induced by tetrandrine. He QY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):545–9

[Effects of harringtonine on peroxidation and dynamic microstructure of membrane lipids of myocardial sarcoplasmic reticulum in rat] Zhu MY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):90–2 (Eng. Abstr.) **(Chi)**

[Effects of lithium chloride and harringtonine on the differentiation, proliferation and c-myc proto-oncogene expression of HL-60 cells] Li W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):151–3 (Eng. Abstr.) **(Chi)**

[Retardation of human drug-resistant HL-60 cell in G1 phase and induction of sensitive cell to apoptosis by cyclosporine A] He QY, et al. **Yao Hsueh Hsueh Pao** 1996;31(10):721–6 (Eng. Abstr.) **(Chi)**

TOXICITY

Characterization of H+-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells. Benderra Z, et al. **Leukemia** 1998 Oct;12(10):1539–44

HARTMANNELLA

METABOLISM

Signal transduction in the protozoan host Hartmannella vermiformis upon attachment and invasion by Legionella micdadei. Abu Kwaik Y, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3134–9

MICROBIOLOGY

Signal transduction in the protozoan host Hartmannella vermiformis upon attachment and invasion by Legionella micdadei. Abu Kwaik Y, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3134–9

PATHOGENICITY

Is the free-living ameba Hartmannella causing keratitis? [letter; comment] De Jonckheere JF, et al. **Clin Infect Dis** 1998 Nov;27(5):1337–8. Comment on: Clin Infect Dis 1998 Jan;26(1):187–8. Comment on: Clin Infect Dis 1998 Mar;26(3):773.

HARVEST MITES see **TROMBICULID MITES**

HASHIMOTO'S DISEASE see **THYROIDITIS, AUTOIMMUNE**

HASHISH see **CANNABIS**

HASHISH ABUSE see **MARIJUANA ABUSE**

HASHISH SMOKING see **MARIJUANA SMOKING**

HATE

Homophobia: an evolutionary analysis of the concept as applied to nursing. Richmond JP, et al. **J Adv Nurs** 1998 Aug;28(2):362–9 (95 ref.)

A case of mutual distrust. Kamau PK. **JAMA** 1999 Aug 4; 282(5):410

[Contempt and hatred: sociologic indications for an approach to current juvenile violence (letter)] Goudet B. **Sante Publique** 1999 Mar;11(1):77–85 (Eng. Abstr.) **(Fre)**

HAVERSIAN SYSTEM

ANATOMY & HISTOLOGY

Methods for improving the efficiency of estimating total osteon density in the human anterior mid-diaphyseal femur. Iwaniec UT, et al. **Am J Phys Anthropol** 1998 Sep; 107(1):13–24

Histomorphological study on pattern of fluid movement in cortical bone in goats. Qin L, et al. **Anat Rec** 1999 Aug 1;255(4):380–7

Morphology of the drifting osteon. Robling AG, et al. **Cells Tissues Organs** 1999;164(4):192–204

METABOLISM

Delayed osteon formation in long-bone diaphysis of an 11-year-old giant cow with dermal dysplasia. Mori R, et al. **J Vet Med Sci** 1999 Feb;61(2):101–6

PHYSIOLOGY

Histomorphological study on pattern of fluid movement in cortical bone in goats. Qin L, et al. **Anat Rec** 1999 Aug 1;255(4):380–7

Variations in the individual thick lamellar properties within osteons by nanoindentation. Rho JY, et al. **Bone** 1999 Sep; 25(3):295–300

A first estimation of prestress in so-called circularly fibered osteonic lamellae. Ascenzi MG. **J Biomech** 1999 Sep; 32(9):935–42

Estimates of the peak pressures in bone pore water. Zhang D, et al. **J Biomech Eng** 1998 Dec;120(6):697–703

PHYSIOPATHOLOGY

Micromechanics of osteonal cortical bone fracture. Guo XE, et al. **J Biomech Eng** 1998 Feb;120(1):112–7

ULTRASTRUCTURE

Rostrum of a toothed whale: ultrastructural study of a very dense bone. Zylberberg L, et al. **Bone** 1998 Sep;23(3):241–7

HAWKS see **RAPTORS**

HAWTHORN see **ROSALES**

HAWTHORNE EFFECT see **EFFECT MODIFIERS (EPIDEMIOLOGY)**

HAY FEVER

[Allergic rhinitis] Guez S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1999;120(2):137–43 **(Fre)**

BLOOD

Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season. Di Lorenzo G, et al. **Allergy Asthma Proc** 1999 Mar–Apr;20(2):119–25

Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Masamoto T, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):169–76

Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis. Kato M, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1213–4

Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels. Yu G, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):133–8

[Changes in functional activity of blood neutrophils in pollenosis patients: effects of specific immunotherapy] Ivanova IP, et al. **Ter Arkh** 1999;71(4):57–60 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Greisner WA 3rd, et al. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):185–8

Rhinitis symptoms in chronic fatigue syndrome. Baraniuk JN, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):359–65

Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Silkoff PE, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):368–72

Rhinitis alone or rhinitis plus asthma: what makes the difference? Magnan A, et al. **Eur Respir J** 1998 Nov; 12(5):1073–8

Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. Yawn BP, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):54–9

Allergies and vocal fold edema: a preliminary report. Jackson-Menaldi CA, et al. **J Voice** 1999 Mar;13(1):113–22

[Food and food additives hypersensitivity in adult asthmatics. II. Oral allergy syndrome in adult asthmatic with or without Japanese cedar hay fever] Arai Y, et al. **Arerugi** 1998 Aug;47(8):715–9 (Eng. Abstr.) **(Jpn)**

[Food allergy in children with pollinosis in the Western sea coast region] Czaja-Bulsa G, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):338–40 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Clinical evaluation of lumiward immunoassay system for detection of specific IgE associated with allergic rhinitis. Yamada K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:169–77

Anterior rhinomanometry in nasal allergen challenges. Ferreira MB, et al. **Allerg Immunol (Paris)** 1998 Nov; 30(9):295–7

Ultrasonic nebulization of hypertonic solution: a new method for obtaining specimens from nasal mucosa for morphologic and biochemical analysis in allergic rhinitis. Melillo G, et al. **Allergy** 1998 Aug;53(8):794–7

Histamine releasability after adenosine challenge in subjects with allergic and non-allergic rhinitis: possible implications for mast cell priming. Polosa R, et al. **Ann Ital Med Int** 1999 Apr–Jun;14(2):86–93

Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Silkoff PE, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):368–72

Nasal passage patency in patients with allergic rhinitis measured by acoustic rhinometry: nasal responses after allergen and histamine provocation. Miyahara Y, et al. **Auris Nasus Larynx** 1998 Sep;25(3):261–7

Repeated allergen challenge as a new research model for

studying allergic reactions. de Bruin-Weller MS, et al. **Clin Exp Allergy** 1999 Feb;29(2):159-65 (51 ref.)
Allergic rhinitis--making the correct diagnosis. Lund V. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:25-8 (15 ref.)
Clinical assessment and management of hayfever in general practice [editorial] Feeney T. **Ir Med J** 1999 May-Jun; 92(4):330
Item responsiveness of a rhinitis and asthma symptom score during a pollen season. Wasserfallen JB, et al. **J Asthma** 1999 Aug;36(5):459-65
Evaluation and management of allergic rhinitis. Hadley JA. **Med Clin North Am** 1999 Jan;83(1):13-25
Rhinoresistometry versus rhinomanometry--an evaluation. Temmel AF, et al. **Wien Klin Wochenschr** 1998 Sep 18; 110(17):612-5
[Cell response in the nasal mucosa in patients with hay fever during plant pollen season] Tarchalska-Kryńska B, et al. **Otolaryngol Pol** 1997;51 Suppl 25:203-6 (Eng. Abstr.) **(Pol)**
[Total allergen-specific IgE antibodies in the serum and skin reactivity induced by a mixture of pollens in allergic individuals] Paranos S, et al. **Vojnosanit Pregl** 1998 Nov-Dec;55(6):605-9 (Eng. Abstr.) **(Sec)**

DRUG THERAPY

Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Berkowitz RB, et al. **Allergy** 1999 Jan;54(1):64-9
Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. Giede-Tuch C, et al. **Allergy** 1998 Sep;53(9):857-62
Onset of action of mometasone [letter] Panasoff J. **Allergy** 1999 Aug;54(8):890
Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Berkowitz RB, et al. **Allergy Asthma Proc** 1999 May-Jun;20(3):167-72
Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Casale TB, et al. **Allergy Asthma Proc** 1999 May-Jun;20(3):193-8
Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Creticos P, et al. **Allergy Asthma Proc** 1998 Sep-Oct;19(5):285-94
Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Pullerits T, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1814-8
Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis. Hampel FC Jr, et al. **Am J Rhinol** 1999 Jan-Feb;13(1):55-62
Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season. Rosenthal R, et al. **Am J Rhinol** 1998 Nov-Dec; 12(6):427-33
Brompheniramine maleate: a double-blind, placebo-controlled comparison with terfenadine for symptoms of allergic rhinitis. Thoden WR, et al. **Am J Rhinol** 1998 Jul-Aug;12(4):293-9
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. Berger WE, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):535-41
Demonstration of therapeutic equivalence of generic and innovator beclomethasone in seasonal allergic rhinitis. SAR Study Group. Casale TB, et al. **Ann Allergy Asthma Immunol** 1999 May;82(5):435-41
Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Frieri M, et al. **Ann Allergy Asthma Immunol** 1998 Nov; 81(5 Pt 1):431-7
Nasal nitric oxide does not control basal nasal patency or acute congestion following allergen challenge in allergic rhinitis. Silkoff PE, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):368-72
Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy of seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe. Kremer B, et al. **Arzneimittelforschung** 1998 Sep; 48(9):924-30
Comparison of budesonide Turbuhaler with budesonide aqua in the treatment of seasonal allergic rhinitis. Rhinocort Study Group. Yang WH, et al. **Can Respir J** 1998 Nov-Dec;5(6):455-60
Rapid symptom relief in rhinitis. Bousquet J. **Clin Exp Allergy** 1999 Mar;29 Suppl 1:25-9
Antihistamines in severe/chronic rhinitis. Bousquet J. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:49-53 (23 ref.)
Rhinitis management: the patient's perspective. Juniper EF. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:34-8
Optimizing treatment options. Naclerio RM. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:54-9
Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. Proud D, et al. **Clin Exp Allergy** 1998 Jul; 28(7):868-75
Clinical assessment of antihistamines in rhinitis. Scadding GK. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:77-81 (23 ref.)
Management of rhinitis--the specialist's opinion. van Cauwenberge P. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:29-33
Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhinitics following exposure to nitrogen dioxide [see comments] Wang JH, et al. **Clin Exp Allergy** 1999 Feb;29(2):234-40. Comment in: Clin Exp Allergy 1999 Feb;29(2):150-4.
Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Sabbah A, et al. **Curr Med Res Opin** 1998;14(3):161-70
Advances in the pharmacological treatment of allergic rhinitis. Rusznak C, et al. **Curr Probl Dermatol** 1999; 28:102-18 (29 ref.)
Treating allergic rhinitis in pregnancy. Safety considerations. Mazzotta P, et al. **Drug Saf** 1999 Apr;20(4):361-75 (54 ref.)
Mometasone furoate. A review of its intranasal use in allergic rhinitis. Onrust SV, et al. **Drugs** 1998 Oct;56(4):725-45 (71 ref.)
N-acetyl-aspartyl-glutamic acid inhibits cellular recruitment and mediator release during the late allergen-induced nasal reaction. Miadonna A, et al. **Eur J Clin Pharmacol** 1998 Sep;54(7):515-20
Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine. Stone BM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):338
Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. Corren J, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):574-80
Pros and cons of the use of antihistamines in managing allergic rhinitis. Day J. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S395-9 (53 ref.)
Use of nasal steroids in managing allergic rhinitis. LaForce C. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S388-94 (90 ref.)
Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. Lieberman P. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S400-4 (39 ref.)
A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. Meltzer EO, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):107-14
Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. Persi L, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):591-4
Ideal pharmacotherapy for allergic rhinitis. Spector S. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S386-7 (18 ref.)
Pathophysiology and pharmacotherapy of allergic rhinitis. Foreword. Spector S. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S377
Same drug, different outcomes in the environmental exposure unit [letter; comment] Stone BD. **J Allergy Clin Immunol** 1999 Apr;103(4):715. Comment on: J Allergy Clin Immunol 1998 May;101(5):638-45.
The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. Sussman GL, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):100-6
Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. Wilson AM, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):598-604
Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. Golden SJ, et al. **J Am Osteopath Assoc** 1999 Jul;99(7 Suppl):S7-12 (35 ref.)
The best therapy for allergic rhinitis. Kane KY, et al. **J Fam Pract** 1998 Dec;47(6):415-6
Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis. Stern M, et al. **J Int Med Res** 1998 Dec;26(6):292-303
Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. Wright ED, et al. **Laryngoscope** 1999 Apr;109(4):551-6
Mometasone furoate nasal spray for allergic rhinitis. **Med Lett Drugs Ther** 1999 Feb 12;41(1046):16-7
Effects of fujibitol, a remedy for nasal symptoms of immediate and delayed type allergic reactions. Kakimoto M, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun; 21(5):353-6
Managing allergic rhinitis [news] Brown CS, et al. **Nurse Pract** 1999 May;24(5):107-11, 115-7, 120
[Allergic rhinitis. New therapy options] Blaeser-Kiel G. **Med Monatsschr Pharm** 1998 Oct;21(10):322-3 **(Ger)**
[The reasons for the use of theophylline in allergic rhinitis management] Kaniuk W, et al. **Otolaryngol Pol** 1998; 52(4):401-4 (30 ref.) (Eng. Abstr.) **(Pol)**
[Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis] Arcimowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):363-7 (Eng. Abstr.) **(Pol)**
[Clinical efficacy and safety of levocarbastine++ in the therapy in children suffering from seasonal allergic rhinitis and conjunctivitis who are less than 12 year of age] Kurzawa R, et al. **Pol Merkuriusz Lek** 1998 May; 4(23):269-72 (Eng. Abstr.) **(Pol)**
[Ebastine in the treatment of seasonal allergic rhinitis] Il'ina NI, et al. **Ter Arkh** 1998;70(9):79-81 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Hay fever--a Finnish nationwide study of adolescent twins and their parents. Räsänen M, et al. **Allergy** 1998 Sep; 53(9):885-90
Is month of birth a risk factor for subsequent development of pollen allergy in adults? Vovolis V, et al. **Allergy Asthma Proc** 1999 Jan-Feb;20(1):15-22
Changing prevalence of allergic rhinitis and asthma. Sly RM. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):233-48; quiz 248-52 (104 ref.)
Effect of tree and grass pollens and fungal spores on spring allergic rhinitis: a comparative study. Wu LY, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):137-43
Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990, and their relation to hay fever and chronic bronchitis. Huovinen E, et al. **Chest** 1999 Apr;115(4):928-36
Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Braun-Fahrländer C, et al. **Clin Exp Allergy** 1999 Jan; 29(1):28-34
Indoor survey of moulds and prevalence of mould atopy in Israel [see comments] Katz Y, et al. **Clin Exp Allergy** 1999 Feb;29(2):186-92. Comment in: Clin Exp Allergy 1999 Feb;29(2):148-9.
The prevalence of allergic rhinitis and nasal symptoms in Nottingham. Jones NS, et al. **Clin Otolaryngol** 1998 Dec; 23(6):547-54
Laryngeal symptoms in patients exposed to Japanese cedar pollen: allergic reactions and environmental pollution [letter] Naito K, et al. **Eur Arch Otorhinolaryngol** 1999; 256(4):209-11
Process and current status of the epidemiologic studies on cedar pollinosis in Japan. Tanihara S, et al. **J Epidemiol** 1999 Feb;9(1):20-6 (59 ref.)
The prevalence of allergic rhinosinusitis: a review. Jones NS, et al. **J Laryngol Otol** 1998 Nov;112(11):1019-30 (173 ref.)
[Prevalence and severity of bronchial asthma, allergic rhinitis and atopic dermatitis in Salzburg school children] Eder W, et al. **Wien Klin Wochenschr** 1998 Oct 16;110(19):669-77 (Eng. Abstr.) **(Ger)**
[Clinical follow-up of an epidemiologic study on asthma and allergies in childhood] Eder W, et al. **Wien Klin Wochenschr** 1998 Oct 16;110(19):678-85 (Eng. Abstr.) **(Ger)**
[Japanese cedar pollinosis in children in our allergy clinic] Masuda S, et al. **Arerugi** 1998 Nov;47(11):1182-9 (Eng. Abstr.) **(Jpn)**
[Prevalence rate of allergy to Japanese cedar pollen in Tokyo--from field investigation in 1996 by Tokyo Japanese Cedar Pollen Allergy Measurements and Review Committee] Nishihata S, et al. **Arerugi** 1999 Jun; 48(6):597-604 (Eng. Abstr.) **(Jpn)**
[Epidemiology of Japanese cedar pollinosis: result of the survey in Mibu-machi] Tanaka A, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Jan;102(1):35-41 (Eng. Abstr.) **(Jpn)**
[Respiratory tract symptoms in school children exposed to indoor and outdoor air pollution] Jędrychowski W, et al. **Pneumonol Alergol Pol** 1997;65(11-12):741-8 (Eng. Abstr.) **(Pol)**

ETIOLOGY

The clinical expression of allergy in the nose. van Cauwenberge P, et al. **Allergy** 1999 Feb;54(2):93-102 (82 ref.)
Prenatal factors and occurrence of rhinitis and eczema among offspring. Xu B, et al. **Allergy** 1999 Aug;54(8):829-36
Experimental models in rhinitis. Demoly P, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:72-6 (17 ref.)
Measles infection, measles vaccination and the effect of birth order in the aetiology of hay fever. Lewis SA, et al. **Clin Exp Allergy** 1998 Dec;28(12):1493-500
(1-->3)-beta-D-glucan may contribute to pollen sensitivity. Rylander R, et al. **Clin Exp Immunol** 1999 Mar;115(3):383-4
New insights in the pathogenesis of allergic rhinitis. Van Cauwenberge P, et al. **Curr Probl Dermatol** 1999;28:95-101 (35 ref.)
Repeated exposure to an ambient level of NO2 enhances asthmatic response to a nonsymptomatic allergen dose. Strand V, et al. **Eur Respir J** 1998 Jul;12(1):6-12
Umbilical cord blood mononuclear cell proliferative response to house dust mite does not predict the development of allergic rhinitis and asthma. Chan-Yeung M, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):317-21
Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: effect of topical corticosteroids. Christodoulopoulos P, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1036-44
Adjuvant activities of pyrene, anthracene, fluoranthene and benzo(a)pyrene in production of anti-IgE antibody to Japanese cedar pollen allergen in mice. Kanoh T, et al. **J Clin Lab Immunol** 1996;48(4):133-47
Relationship between early life respiratory illness, family size over time, and the development of asthma and hay fever: a seven year follow up study. Ponsonby AL, et al. **Thorax** 1999 Aug;54(8):664-9
[The role of aeroallergens monitoring in the allergological practice] Rapiejko P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:217-9 (5 ref.) (Eng. Abstr.) **(Pol)**
[The prophylaxis of allergic rhinitis] Rapiejko P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:220-2 (5 ref.) (Eng.

Abstr.) **(Pol)**

GENETICS

Hay fever--a Finnish nationwide study of adolescent twins and their parents. Räsänen M, et al. **Allergy** 1998 Sep; 53(9):885–90

Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Tanaka K, et al. **Clin Exp Allergy** 1999 Jun; 29(6):800–3

HISTORY

Elements of the history of our present concepts of anaphylaxis, hay fever and asthma. Becker EL. **Clin Exp Allergy** 1999 Jul;29(7):875–95

The historical background of allergic rhinopathy therapy. Passàli D, et al. **Rhinology** 1998 Sep;36(3):139–41

[Pollinosis: clinical aspects and epidemiology. Contribution of the Allergy Clinic 1948–1998] Schmid-Grendelmeier P. **Schweiz Rundsch Med Prax** 1998 Sep 30;87(40):1300–8 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Seasonal increase in specific IgE in serum induced by natural Japanese cedar pollen exposure in asymptomatic and symptomatic sensitized individuals. Kakinoki Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:152–5

Cry j 1-induced synthesis of interleukin-5 and interferon-gamma by peripheral blood mononuclear cells of patients with seasonal allergic rhinitis due to Japanese cedar pollens. Nakai Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:143–51

Changes in nasal responsiveness to histamine and to specific antigen after laser surgery. Terada N, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;537:38–42

Cells and cytokines in pollinosis. Carlos AG, et al. **Allerg Immunol (Paris)** 1998 Sep;30(7):204–6

Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. Fernvik E, et al. **Allergy** 1999 May;54(5):455–63

Elevated soluble tumor necrosis factor receptor levels in seasonal allergic rhinitis patients. Kato M, et al. **Allergy** 1999 Mar;54(3):278–82

Circulating eosinophil/basophil progenitors and nasal mucosal cytokines in seasonal allergic rhinitis. Linden M, et al. **Allergy** 1999 Mar;54(3):212–9

Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season. Nielsen LP, et al. **Allergy** 1998 Aug;53(8):778–85

The effect of immediate-hypersensitivity reactions on the level of SLPI, granulocyte elastase, alpha1-antitrypsin, and albumin in nasal secretions, by the method of unilateral antigen challenge. Westin U, et al. **Allergy** 1999 Aug; 54(8):857–64

Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Winther L, et al. **Allergy** 1999 May; 54(5):436–45

Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season. Di Lorenzo G, et al. **Allergy Asthma Proc** 1999 Mar-Apr;20(2):119–25

Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways. Erjefält JS, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):304–12

Changes in skin and nasal sensitivity to allergens and the course of rhinitis; a long-term follow-up study [see comments] Simola M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):152–6. Comment in: Ann Allergy Asthma Immunol 1999 Feb;82(2):131–2.

Effect of tree and grass pollens and fungal spores on spring allergic rhinitis: a comparative study. Wu LY, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):137–43

Effects of smoking and Japanese cedar pollinosis on lymphocyte subpopulations. Tanigawa T, et al. **Arch Environ Health** 1999 Mar-Apr;54(2):119–23

Inflammatory mechanisms underlying potentiation of effects of inhaled aeroallergens in response to nitrogen dioxide in allergic airways disease [editorial; comment] Krishna MT, et al. **Clin Exp Allergy** 1999 Feb;29(2):150–4 (31 ref.) . Comment on: Clin Exp Allergy 1999 Feb;29(2):234–40.

Nasal response to a single antigen challenge in patients with allergic rhinitis - inflammatory cell recruitment persists up to 48 hours. Miadonna A, et al. **Clin Exp Allergy** 1999 Jul; 29(7):941–9

Concentrations of major grass group 5 allergens in pollen grains and atmospheric particles: implications for hay fever and allergic asthma sufferers sensitized to grass pollen allergens. Schäppi GF, et al. **Clin Exp Allergy** 1999 May; 29(5):633–41

Laryngeal symptoms in patients exposed to Japanese cedar pollen: allergic reactions and environmental pollution [letter] Naito K, et al. **Eur Arch Otorhinolaryngol** 1999; 256(4):209–11

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Ball T, et al. **Eur J Immunol** 1999 Jun;29(6):2026–36

Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Bohle B, et al. **Eur J Immunol** 1999 Jul;29(7):2344–53

Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects. Endoh N, et al. **Eur Respir J** 1998 Jul;12(1):71–4

Development of pollen-induced allergic rhinitis with early and late phase nasal blockage in guinea pigs. Nabe T, et al. **Inflamm Res** 1998 Sep;47(9):369–74

Regulation of proinflammatory cytokines in seasonal allergic rhinitis. Bachert C, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):375–9

Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Nouri-Aria KT, et al. **Int Arch Allergy Immunol** 1998 Dec; 117(4):248–54

Clinical manifestations of the release of histamine and other inflammatory mediators. Naclerio R. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S382–5 (42 ref.)

Genetics and specific immune response in allergy to birch pollen and food: evidence of a strong, positive association between atopy and the HLA class II allele HLA-DR7. Sénéchal H, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):395–401

Highly heterogeneous Phl p 5-specific T cells from patients with allergic rhinitis differentially recognize recombinant Phl p 5 isoallergens. Würtzen P, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):115–22

Environmental antigen-induced IL-13 responses are elevated among subjects with allergic rhinitis, are independent of IL-4, and are inhibited by endogenous IFN-gamma synthesis. Li Y, et al. **J Immunol** 1998 Dec 15; 161(12):7007–14

Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. Wright ED, et al. **Laryngoscope** 1999 Apr;109(4):551–6

Allergic rhinitis. Nash DR. **Pediatr Ann** 1998 Dec; 27(12):799–808 (20 ref.)

Demonstration of bronchial eosinophil activity in seasonal allergic rhinitis by induced plasma exudation combined with induced sputum. Greiff L, et al. **Thorax** 1999 Jan; 54(1):33–6

[Evaluation of loretadine therapy by rhino-manometry in patients with allergic rhinitis] Kósa L. **Orv Hetil** 1999 Apr 11;140(15):829–32 (Eng. Abstr.) **(Hun)**

[Protective effect of oxatomide in infantile bronchial asthma. Double-blind study vs placebo] Giorgi PL, et al. **Minerva Pediatr** 1998 Jul-Aug;50(7-8):339–46 (22 ref.) (Eng. Abstr.) **(Ita)**

[Japanese cedar pollen allergen standardization: analysis of major allergens] Sakaguchi M. **Arerugi** 1998 Dec; 47(12):1233–6 (14 ref.) **(Jpn)**

[Evaluation of selected cellular immunity parameters in patients with seasonal allergic rhinitis] Jurkiewicz D. **Otolaryngol Pol** 1999;53(3):293–300 (Eng. Abstr.) **(Pol)**

[The evaluation of cellular immunity in patients with allergy to pollen] Jurkiewicz D. **Otolaryngol Pol** 1997;51 Suppl 25:207–12 (Eng. Abstr.) **(Pol)**

[Evaluation of changes in the course of seasonal allergic nasal mucosa inflammation] Jurkiewicz D. **Otolaryngol Pol** 1998; 52(3):363–5 (Eng. Abstr.) **(Pol)**

[Antigen specific immunoglobulin E to grass and weed pollens in the plasma of patients with seasonal allergic rhinitis] Silny W, et al. **Otolaryngol Pol** 1999;53(1):55–8 (Eng. Abstr.) **(Pol)**

[Platelet aggregation test in specific immunotherapy] Rogala B, et al. **Pneumonol Alergol Pol** 1999;67(3-4):126–36 (Eng. Abstr.) **(Pol)**

[Interleukin 4, total and allergen-specific immunoglobulin E antibodies in the blood of individuals with an atopic constitution] Paranos S, et al. **Srp Arh Celok Lek** 1998 Mar-Apr;126(3-4):92–6 (Eng. Abstr.) **(Scc)**

[Specific skin reactions induced by individual pollen preparations in hypersensitivity persons] Paranos S, et al. **Srp Arh Celok Lek** 1998 Sep-Oct;126(9–10):362–7 (Eng. Abstr.) **(Scc)**

METABOLISM

Aerodynamic influences on nasal nitric oxide output measurements. Djupesland PG, et al. **Acta Otolaryngol** 1999;119(4):479–85

Seasonal changes in phytohemagglutinin-induced cytokine synthesis by peripheral blood lymphocytes of patients with seasonal allergic rhinitis due to Japanese cedar pollens. Tsuda M, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:156–68

Nasal secretion analysis in allergic rhinitis, cystic fibrosis, and nonallergic fibromyalgia/chronic fatigue syndrome subjects. Baraniuk JN, et al. **Am J Rhinol** 1998 Nov-Dec; 12(6):435–40

Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. Frieri M, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):331–6

Exhaled and nasal NO levels in allergic rhinitis: relation to sensitization, pollen season and bronchial hyperresponsiveness. Henriksen AH, et al. **Eur Respir J** 1999 Feb;13(2):301–6

Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. KleinJan A, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):441–50

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. Masuyama K, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):610–7

[Histamine as a mediator of allergic inflammation (editorial)] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):232–5 (46 ref.) (Eng. Abstr.) **(Pol)**

NURSING

Managing allergic rhinitis [news] Brown CS, et al. **Nurse Pract** 1999 May;24(5):107–11, 115–7, 120

PHYSIOPATHOLOGY

Nasal reactivity to capsaicin in patients with seasonal allergic rhinitis during and after the pollen season. Kowalski ML, et al. **Allergy** 1999 Aug;54(8):804–10

The influence of female sex hormones on nasal reactivity in seasonal allergic rhinitis. Stübner UP, et al. **Allergy** 1999 Aug;54(8):865–71

Natural history of hay fever: a 23-year follow-up of college students. Greisner WA 3rd, et al. **Allergy Asthma Proc** 1998 Sep-Oct;19(5):271–5 (18 ref.)

Determination of cut-off positivity values in nasal challenge testing of patients with allergic rhinitis. Riario-Sforza GG, et al. **Allergy Asthma Proc** 1999 Mar-Apr;20(2):109–14

Occupational and allergic rhinitis: impact on worker productivity and safety. Slavin RG. **Allergy Asthma Proc** 1998 Sep-Oct;19(5):277–84 (58 ref.)

Decreased hydration state of the stratum corneum and reduced amino acid content of the skin surface in patients with seasonal allergic rhinitis. Tanaka M, et al. **Br J Dermatol** 1998 Oct;139(4):618–21

The inflammatory nature of allergic disease. Durham SR. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:20–4 (20 ref.)

Clinical manifestations of the release of histamine and other inflammatory mediators. Naclerio R. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S382–5 (42 ref.)

Pathophysiology and pharmacotherapy of allergic rhinitis. Foreword. Spector S. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S377

Lack of correlation between nonspecific nasal and bronchial reactivity in allergic rhinitis subjects. Plavec D, et al. **Lung** 1999;177(3):169–77

[The role of eosinophils in nasal hypersensitivity] Okamoto Y. **Arerugi** 1999 Jun;48(6):569–71 (4 ref.) **(Jpn)**

PREVENTION & CONTROL

[The prophylaxis of allergic rhinitis] Rapiejko P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:220–2 (5 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Changes in nasal responsiveness to histamine and to specific antigen after laser surgery. Terada N, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;537:38–42

THERAPY

Suppression of seasonal increase in serum interleukin-5 is linked to the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Hayashi M, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:133–42

Allergen-specific immunotherapy for allergic rhinitis: a new insight into its clinical efficacy and mechanism. Ohashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:178–90 (82 ref.)

Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Hordijk GJ, et al. **Allergol Immunopathol (Madr)** 1998 Sep-Oct; 26(5):234–40

Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Balda BR, et al. **Allergy** 1998 Aug;53(8):740–8

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Pradalier A, et al. **Allergy** 1999 Aug;54(8):819–28

Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis. Bertoni M, et al. **Ann Allergy Asthma Immunol** 1999 Jan;82(1):47–51

Successful immunotherapy. A partnership between consultant and general practitioner. Katelaris CH. **Aust Fam Physician** 1998 Aug;27(8):687–92 (9 ref.)

New treatments for allergic rhinitis. Tkachyk SJ. **Can Fam Physician** 1999 May;45:1255–60 (22 ref.)

Immunotherapy in allergic rhinitis: a prevention for asthma? Demoly P, et al. **Curr Probl Dermatol** 1999;28:119–23 (20 ref.)

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Ball T, et al. **Eur J Immunol** 1999 Jun;29(6):2026–36

A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn

sodium spray in the treatment of seasonal allergic rhinitis. Weiser M, et al. **Forsch Komplementarmed** 1999 Jun; 6(3):142–8

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis [see comments] La Rosa M, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):425–32. Comment in: J Allergy Clin Immunol 1999 Aug;104(2 Pt 1):267–70.

Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy. Rogala B, et al. **J Investig Allergol Clin Immunol** 1999 May–Jun;9(3):183–9

Potential effect of the administration of substance P and allergen therapy on immunoglobulin E-mediated allergic reactions in human subjects. Patterson R, et al. **J Lab Clin Med** 1999 Feb;133(2):189–99

Immunotherapy for allergic rhinitis [editorial; comment] Adkinson NF Jr. **N Engl J Med** 1999 Aug 12;341(7):522–4 . Comment on: N Engl J Med 1999 Aug 12;341(7):468–75.

Long-term clinical efficacy of grass-pollen immunotherapy [see comments] Durham SR, et al. **N Engl J Med** 1999 Aug 12;341(7):468–75. Comment in: N Engl J Med 1999 Aug 12;341(7):522–4.

How to treat allergic rhinitis. Lee NP, et al. **West J Med** 1999 Jul;171(1):31–4 (18 ref.)

[Effect of self-hypnosis in patients with pollinosis] Bircher A. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:47–9 (Eng. Abstr.) **(Ger)**

[Hyposensitization in allergic rhinoconjunctivitis (editorial; comment] Deitmer T. **HNO** 1999 Jul;47(7):601. Comment on: HNO 1999 Jul;47(7):602–10. **(Ger)**

[Specific immunotherapy (hyposensitization) in allergic rhinoconjunctivitis. Meta-analysis of effectiveness and side effects (see comments)] Klimek L, et al. **HNO** 1999 Jul; 47(7):602–10 (Eng. Abstr.). Comment in: HNO 1999 Jul;47(7):601. **(Ger)**

[Protective effect of acupuncture on allergen provoked rhinitis] Wolkenstein E, et al. **Wien Med Wochenschr** 1998; 148(19):450–3 (Eng. Abstr.) **(Ger)**

[Physiopathology and treatment of pollenosis] Saito Y. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):485–9 (4 ref.) **(Jpn)**

[Clinical evaluation of side effects during immunotherapy with Catalet T in patients with hay fever] Kurowski W, et al. **Pneumonol Alergol Pol** 1997;65(11–12):783–7 (Eng. Abstr.) **(Pol)**

[Platelet aggregation test in specific immunotherapy] Rogala B, et al. **Pneumonol Alergol Pol** 1999;67(3–4):126–36 (Eng. Abstr.) **(Pol)**

HAZARD MANAGEMENT see **SAFETY MANAGEMENT**

HAZARDOUS CHEMICALS see **HAZARDOUS SUBSTANCES**

HAZARDOUS MATERIALS see **HAZARDOUS SUBSTANCES**

HAZARDOUS SUBSTANCES

see related
HAZARDOUS WASTE

Embedding of laboratory wastes in clay or concrete blocks, with special reference to baking osmic acid and cacodylic acid wastes with clay. Murakami T, et al. **Acta Med Okayama** 1998 Dec;52(6):297–303

Occupational exposure to chemical and biological agents in the nonproduction departments of pulp, paper, and paper product mills: an international study. Teschke K, et al. **Am Ind Hyg Assoc J** 1999 Jan–Feb;60(1):73–83

Hospital evacuations due to hazardous materials incidents. Burgess JL. **Am J Emerg Med** 1999 Jan;17(1):50–2

Emergency department hazardous materials protocol for contaminated patients [see comments] Burgess JL, et al. **Ann Emerg Med** 1999 Aug;34(2):205–12. Comment in: Ann Emerg Med 1999 Aug;34(2):223–5.

Chemical incidents in the emergency department: if and when [editorial; comment] Pons P, et al. **Ann Emerg Med** 1999 Aug;34(2):223–5. Comment on: Ann Emerg Med 1999 Aug;34(2):205–9.

G-type nerve agent decontamination by Alteromonas prolidase. Cheng TC, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:253–8

The when, where, and how of environmental hazards [news] **Environ Health Perspect** 1999 May;107(5):A240–1

Migration patterns of children with cancer in Britain. Knox EG, et al. **J Epidemiol Community Health** 1998 Nov; 52(11):716–26

Optimization of non-thermal plasma for the treatment of gas streams. Yamamoto T. **J Hazard Mater** 1999 Jun 11; 67(2):165–81

Genetic and environmental risk factors for Parkinson's disease in a Chinese population. Chan DK, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):781–4

Fitness for duty evaluations in hazardous materials firefighters [see comments] Kales SN, et al. **J Occup Environ Med** 1998 Oct;40(10):925–31. Comment in: J Occup Environ Med 1999 Apr;41(4):213–5.

A thermal physiological comparison of two HAZMAT protective ensembles with and without active convective cooling. Williamson R, et al. **J Occup Environ Med** 1999 Jun;41(6):453–63

The OSPAR Commission and Ministerial Meeting, 20–24 July 1998, Sintra Lisbon [news] Gray J. **J Radiol Prot** 1998 Dec;18(4):306–10

Dangerous goods safety advisers [news] Guest RM. **J Radiol Prot** 1998 Dec;18(4):302–3

From the Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. **JAMA** 1999 Mar 3;281(9):787–9

Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. **MMWR Morb Mortal Wkly Rep** 1999 Feb 5;48(4):69–74

Butyl & Viton hand protection. Groce DF. **Occup Health Saf** 1999 Jul;68(7):42–5

Hazardous emissions in the lab. Hanna LM. **Occup Health Saf** 1998 Sep;67(9):42–4

Hazmat havoc. Luther E. **Occup Health Saf** 1998 Dec; 67(12):42–4

Wardrobe check for terrorist incidents. Zeigler JP. **Occup Health Saf** 1999 Jul;68(7):40, 45

Regulatory action criteria for filth and other extraneous materials.I. Review of hard or sharp foreign objects as physical hazards in food. Olsen AR. **Regul Toxicol Pharmacol** 1998 Dec;28(3):181–9 (61 ref.)

Ceaseless vigilance for chemical safety. Jenkins PG. **World Health Forum** 1998;19(3):261–7

[Association between household solid waste disposal and health, Belo Horizonte (MG), Brasil] Catapreta CA, et al. **Rev Panam Salud Publica** 1999 Feb;5(2):88–96 (Eng. Abstr.) **(Por)**

[Cleaning-up of environmental pollution after railway accidents with bulk chemical cargo] Kovaleva IV, et al. **Gig Sanit** 1998 Sep–Oct;(5):45–8 **(Rus)**

[New approaches to the evaluation of risk of acute poisoning during technogenic accidental emissions (for example, ammonia and chlorine)] Litvinov NN, et al. **Med Tr Prom Ekol** 1998;(9):1–12 (Eng. Abstr.) **(Rus)**

[Biosphere pollution with lead: its dimensions and trends in Russia] Snakin VV. **Med Tr Prom Ekol** 1999;(5):21–7 (Eng. Abstr.) **(Rus)**

[Risk of chemical disaster as a public health problem] Castro Delgado R, et al. **Rev Esp Salud Publica** 1998 Nov–Dec; 72(6):481–500 (33 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Validation of intratracheal instillation as an alternative for aerosol inhalation toxicity testing. Sabaitis CP, et al. **J Appl Toxicol** 1999 Mar–Apr;19(2):133–40

ADVERSE EFFECTS

Exposure to hazardous drugs: time to reevaluate your program? [editorial; comment] Harrison BR. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1403. Comment on: Am J Health Syst Pharm 1999 Jul 15;56(14):1427–32. Comment on: Am J Health Syst Pharm 1999 Jul 15;56(14):1433–6.

Barrier isolators as an alternative to a cleanroom [see comments] Tillett L. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1433–6. Comment in: Am J Health Syst Pharm 1999 Jul 15;56(14):1403.

A multidimensional evaluation of fire fighter training for hazardous materials response: first results from the IAFF Program. Cohen A. **Am J Ind Med** 1998 Oct;34(4):331–41 (12 ref.)

Lung health among boilermakers in Edmonton, Alberta. Hessel PA, et al. **Am J Ind Med** 1998 Oct;34(4):381–6

Interpreting the female excess among births to women with adverse chemical or occupational exposures [letter; comment] James WH. **Am J Ind Med** 1999 Jun;35(6):664–5 . Comment on: Am J Ind Med 1997 Nov;32(5):557–61.

Maternal occupational exposure to chemical substances and the risk of infants small-for-gestational-age. Seidler A, et al. **Am J Ind Med** 1999 Jul;36(1):213–22

Respiratory health hazards in agriculture. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 2):S1–S76

Control of substances hazardous to health: a continual process, not 'once for all'. Tearle P. **Commun Dis Public Health** 1999 Jan;2(1):75–6

Critical care medicine, terrorism and disasters: are we ready? [editorial; comment] Kvetan V. **Crit Care Med** 1999 May; 27(5):873–4 (15 ref.). Comment on: Crit Care Med 1999 May;27(5):1004–8.

Preparing hospitals for toxicological mass casualties events [see comments] Tur-Kaspa I, et al. **Crit Care Med** 1999 May;27(5):1004–8. Comment in: Crit Care Med 1999 May;27(5):873–4.

Inflammation, tumor necrosis factor, and toxicology [editorial] Luster MI. **Environ Health Perspect** 1998 Sep; 106(9):A418–9

Emergency planning and the acute toxic potency of inhaled ammonia. Michaels RA. **Environ Health Perspect** 1999 Aug;107(8):617–27

Determinants of the bronchial response to high molecular weight occupational agents in a dry aerosol form. Nguyen B, et al. **Eur Respir J** 1998 Oct;12(4):885–8

Prudent management of minors with occupational exposures to hazardous agents: the radiation protection "standard of care". Emery RJ, et al. **Inj Prev** 1998 Sep;4(3):232–5 (28 ref.)

Dumpers, rips, and other hazards for the environmental surfer [editorial] Langley J. **Inj Prev** 1999 Jun;5(2):84 (4 ref.)

Assignment of skin notation for MAK values and its legal consequences in Germany. Drexler H. **Int Arch Occup Environ Health** 1998 Oct;71(7):503–5

Hyperventilation following a large-scale hazardous-materials incident. Burgess JL, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):194–7

Environmental hazards for children in USA. Landrigan PJ. **Int J Occup Med Environ Health** 1998;11(2):189–94 (8 ref.)

Risk-informed selection of a highway trajectory in the neighborhood of an oil-refinery. Papazoglou IA, et al. **J Hazard Mater** 1999 Jun 11;67(2):111–44

Risk of adverse outcomes in pregnant women exposed to solvents. Hewitt JB, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):521–31

Fatal harmful substances or environmental exposures in agriculture, 1992 to 1996. Adekoya N, et al. **J Occup Environ Med** 1999 Aug;41(8):699–705

An environmental hazard assessment of low-level dermal exposure to hexavalent chromium in solution among chromium-sensitized volunteers. Fowler JF Jr, et al. **J Occup Environ Med** 1999 Mar;41(3):150–60

A mechanistic-based approach for assessing chemical hazards to parturition. Loch-Caruso R. **J Womens Health** 1999 Mar;8(2):235–48 (96 ref.)

Chemicals and menopause: effects on age at menopause and on health status in the postmenopausal period. Silbergeld EK, et al. **J Womens Health** 1999 Mar;8(2):227–34 (68 ref.)

Congenital abnormalities and indicators of germinal mutations in the vicinity of an acrylonitrile producing factory. Czeizel AE, et al. **Mutat Res** 1999 Jun 30; 427(2):105–23

Best estimate of the magnitude of mortality due to occupational exposure to hazardous substances. Morrell S, et al. **Occup Environ Med** 1998 Sep;55(9):634–41

Warning signs. O'Neal MA. **Occup Health Saf** 1997 Dec; 66(12):42–5

Hazmat training in California. Varney MR, et al. **Occup Health Saf** 1997 Dec;66(12):33–6

Chemical hazards faced by animal handlers. Meggs WJ. **Occup Med** 1999 Apr–Jun;14(2):213–24 (63 ref.)

Euthanasia hazards. Morrow WE. **Occup Med** 1999 Apr–Jun; 14(2):235–46 (52 ref.)

Evaluation of regional environmental and health hazards by applying synthetic measures. Dutkiewicz T, et al. **Rev Environ Health** 1998 Jul–Sep;13(3):111–29 (59 ref.)

[Preparation of the database and the homepage on chemical accidents relating to health hazard] Yamamoto M, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):132–6 (Eng. Abstr.) **(Jpn)**

[Use of a computerized information-modeling system in the evaluation of health hazards of formaldehyde] Amvros'ev PA, et al. **Gig Sanit** 1999 Jul–Aug;(4):55–7 **(Rus)**

[On the mechanism underlying general toxicity of chemicals] Atshabarov BA. **Med Tr Prom Ekol** 1998;(8):21–5 **(Rus)**

[Aspects of pneumoconioses morphogenesis] Loshchilov IuA. **Med Tr Prom Ekol** 1999;(5):41–2 **(Rus)**

[A new method of occupational evaluation of combined effect induced by chemical substance and physical load] Ust'iantsev SL. **Med Tr Prom Ekol** 1999;(5):32–3 (Eng. Abstr.) **(Rus)**

ANALYSIS

Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States [see comments] Connor TH, et al. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1427–32. Comment in: Am J Health Syst Pharm 1999 Jul 15;56(14):1403.

PAT program. Background and current status. **Appl Occup Environ Hyg** 1999 May;14(5):292–6

Portable infrared analyzers. Palassis J. **Appl Occup Environ Hyg** 1999 Aug;14(8):510–4

Exposure assessment of laboratory students. Tan YM, et al. **Appl Occup Environ Hyg** 1999 Aug;14(8):530–8

Medical costs and lost productivity from health conditions at volatile organic compound-contaminated superfund sites. Lybarger JA, et al. **Environ Res** 1998 Oct;79(1):9–19

Real-time measurement of sub-PPM concentrations of airborne chemicals in semiconductor manufacturing. Corn M, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:37–49

Biological monitoring of workers at a recently opened hazardous waste disposal site. Diaz-Barriga F, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:63–71

Precursors of dangerous substances formed in the loss of control of chemical systems. Cozzani V, et al. **J Hazard Mater** 1999 Mar 1;65(1–2):93–108 (28 ref.)

Bimetallic catalysts for continuous catalytic wet air oxidation of phenol. Fortuny A, et al. **J Hazard Mater** 1999 Jan 29; 64(2):181–93

An aqueous concentration model for riverine spills. Hibbs DE, et al. **J Hazard Mater** 1999 Jan 1;64(1):37–53

Processes controlling aqueous concentrations for riverine spills. Hibbs DE, et al. **J Hazard Mater** 1999 Jan 1; 64(1):57–73

A national survey of regional poison control centers' management of occupational exposure calls [published erratum appears in J Occup Environ Med 1999 May;41(5):404] Bresnitz EA, et al. **J Occup Environ Med** 1999 Feb;41(2):93–9

Screening of illicit toxic substances discharged in chemical toilet sludge. Robidoux PY, et al. **Qual Assur** 1998 Jan-Mar;6(1):23-44

The development and use of respirator response functions as part of a workplace exposure monitoring program for control of potential respir·tory hazards. Maxim LD, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):131-49

Spatiality, embodiment and hazards encountered in the making of pots. Bellaby P. **Soc Sci Med** 1999 May; 48(10):1321-32

[Biological surveillance: its utility for the evaluation of chemical risks] Berode M. **Rev Med Suisse Romande** 1999 Jul;119(7):573-7 **(Fre)**

CLASSIFICATION

[The prediction of the class of hazard of organic compounds by their structure] Zul'karnaev TR, et al. **Gig Sanit** 1999 Jan-Feb;(1):56-9 **(Rus)**

HISTORY

Chemical hormesis: its historical foundations as a biological hypothesis. Calabrese EJ, et al. **Toxicol Pathol** 1999 Mar-Apr;27(2):195-216 (128 ref.)

METABOLISM

Precursors of dangerous substances formed in the loss of control of chemical systems. Cozzani V, et al. **J Hazard Mater** 1999 Mar 1;65(1-2):93-108 (28 ref.)

Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. Greene N, et al. **SAR QSAR Environ Res** 1999;10(2-3):299-314

PHARMACOKINETICS

Dispersion and thermodynamics of clouds generated from spills of SO3 and oleum. Kapias T, et al. **J Hazard Mater** 1999 May 31;67(1):9-40

Heat transfer in large-scale heavy-gas dispersion. Nielsen M, et al. **J Hazard Mater** 1999 May 31;67(1):41-58

A modeling approach to account for toxicokinetic interactions in the calculation of biological hazard index for chemical mixtures. Haddad S, et al. **Toxicol Lett** 1999 Sep 5;108(2-3):303-8

[The percutaneous absorption of toxic industrial chemicals: the Dermal Exposure Network of the European Union (news)] Larese F, et al. **Med Lav** 1998 Nov-Dec; 89(6):538-44 **(Ita)**

PHARMACOLOGY

Hormesis as a default parameter in RfD derivation. Calabrese EJ, et al. **Hum Exp Toxicol** 1998 Aug;17(8):444-7

Implications of the hormesis hypothesis for risk perception and communication. Renn O. **Hum Exp Toxicol** 1998 Aug; 17(8):431-8 (37 ref.)

If hormesis exists...: implications for risk perception and communication. Slovic P. **Hum Exp Toxicol** 1998 Aug; 17(8):439-40 (9 ref.)

STANDARDS

Regulatory requirements for biocides on the market in the European Union according to Directive 98/8/EC. Rasmussen K, et al. **J Hazard Mater** 1999 Jun 30; 67(3):237-51

TOXICITY

Wound healing in earthworms Lumbricus terrestris: a cellular-based biomarker for assessing sublethal chemical toxicity. Cikutovic MA, et al. **Bull Environ Contam Toxicol** 1999 Apr;62(4):508-14

Incorporation of potential for multimedia exposure into chemical hazard scores for pollution prevention. Whaley DA, et al. **Drug Chem Toxicol** 1999 Feb;22(1):241-73

Regulatory implications of hormesis. Foran J. **Hum Exp Toxicol** 1998 Aug;17(8):441-3 (3 ref.)

Inhalation toxicity and genotoxicity of hydrochlorofluorocarbon (HCFC)-225ca and HCFC-225cb. Brock WJ, et al. **J Appl Toxicol** 1999 Mar-Apr;19(2):101-12

Feeding is inhibited by sublethal concentrations of toxicants and by heat stress in the nematode Caenorhabditis elegans: relationship to the cellular stress response. Jones D, et al. **J Exp Zool** 1999 Jul 1;284(2):147-57

The use of hematological effects in the development of minimal risk levels. Abadin HG, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):61-6 (34 ref.)

Health effects classification and its role in the derivation of minimal risk levels: developmental effects. Pohl HR, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):55-60 (39 ref.)

Expanded clinical observations in toxicity studies: historical perspectives and contemporary issues. Ross JF, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):17-26 (50 ref.)

Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. Greene N, et al. **SAR QSAR Environ Res** 1999;10(2-3):299-314

Effects of ammonium dinitramide on preimplantation embryos in Sprague-Dawley rats. Graeter LJ, et al. **Toxicol Ind Health** 1998 Nov-Dec;14(6):789-98

Are we on the threshold of a new theory of disease? Toxicant-induced loss of tolerance and its relationship to addiction and abdiction. Miller CS. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):284-94 (39 ref.)

Site-specific consultation for a chemical mixture. Pohl HR, et al. **Toxicol Ind Health** 1999 Aug;15(5):470-9

The marginalization of hormesis. Calabrese EJ, et al. **Toxicol Pathol** 1999 Mar-Apr;27(2):187-94 (84 ref.)

Chemicals, children and research $'s. Robertson WO. **Vet Hum Toxicol** 1998 Oct;40(5):308-9

[An approach to predicting the acute toxicity of chemical substances] Zul'karnaev TR, et al. **Gig Sanit** 1999 May-Jun; (3):54-61 **(Rus)**

URINE

Risk factors for exposure to arsenic at a hazardous waste site. Reif JS, et al. **J Expo Anal Environ Epidemiol** 1993; 3 Suppl 1:73-86

HAZARDOUS WASTE

A description of factors affecting hazardous waste workers' use of respiratory protective equipment. Salazar MK, et al. **Appl Occup Environ Hyg** 1999 Jul;14(7):470-8

Health effects of environmental contaminant exposure: an intrafile comparison of the Trichloroethylene Subregistry. Burg JR, et al. **Arch Environ Health** 1999 Jul-Aug; 54(4):231-41

In situ (mesocosm) assessment of immunotoxicity risks to small mammals inhabiting petrochemical waste sites. Propst TL, et al. **Chemosphere** 1999 Feb;38(5):1049-67

Dioxin and dibenzofuran concentrations in blood of a general population from Tarragona, Spain. Schuhmacher M, et al. **Chemosphere** 1999 Feb;38(5):1123-33

Calculation of human health risk-based screening levels (RBSLs) for petroleum. Vorhees DJ, et al. **Drug Chem Toxicol** 1999 Feb;22(1):293-310

Fertilizing or contaminating? [news] [published erratum appears in Environ Health Perspect 1999 Jun;107(6):A293] **Environ Health Perspect** 1999 Mar;107(3):A136-7

Do large-scale remedial and dredging events have the potential to release significant amounts of semivolatile compounds to the atmosphere? Chiarenzelli J, et al. **Environ Health Perspect** 1998 Feb;106(2):47-9 (32 ref.)

Poplar demand. Holton WC. **Environ Health Perspect** 1998 Sep;106(9):A438-40

Trading trash: why the U.S. won't sign on to the Basel convention. Schmidt CW. **Environ Health Perspect** 1999 Aug;107(8):A410-3

American Indians, hunting and fishing rates, risk, and the Idaho National Engineering and Environmental Laboratory. Burger J. **Environ Res** 1999 May;80(4):317-29

Comparison between supercritical carbon dioxide extraction and aqueous surfactant washing of an oily machining waste. Fu H, et al. **J Hazard Mater** 1999 Jun 11;67(2):197-213

Surrogate burns in deactivation furnace system. Shah JK. **J Hazard Mater** 1999 May 14;66(3):279-90

Elevated ovarian and thymic cell apoptosis in wild cotton rats inhabiting petrochemical-contaminated terrestrial ecosystems. Savabieasfahani M, et al. **J Toxicol Environ Health** 1999 Aug 27;57(8):521-7

[Body burden of polychlorinated biphenyl compounds in whole blood of 7-10-year-old children in the area of a hazardous waste incineration facility] Höldke B, et al. **Gesundheitswesen** 1998 Aug-Sep;60(8-9):505-12 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

A review of the effects of hazardous waste on reproductive health. Johnson BL. **Am J Obstet Gynecol** 1999 Jul; 181(1):S12-6 (20 ref.)

Risks of developing cancer relative to living near a municipal solid waste landfill site in Montreal, Quebec, Canada. Goldberg MS, et al. **Arch Environ Health** 1999 Jul-Aug; 54(4):291-6

Relationship between lead mining and blood lead levels in children. Murgueytio AM, et al. **Arch Environ Health** 1998 Nov-Dec;53(6):414-23

Effects of oral exposure to mining waste on in vivo dopamine release from rat striatum. Rodriguez VM, et al. **Environ Health Perspect** 1998 Aug;106(8):487-91

Residential exposure summary methodology for a reproductive health study of multiple hazardous waste sites. Marshall EG, et al. **J Expo Anal Environ Epidemiol** 1993; 3 Suppl 1:87-98

Analysis of an accident at a solvent recovery plant. Cozzani V, et al. **J Hazard Mater** 1999 Jun 11;67(2):145-61

Landfill sites and congenital abnormalities [letter; comment] Staff MG. **Lancet** 1998 Nov 21;352(9141):1705. Comment on: Lancet 1998 Aug 8;352(9126):423-7.

Site-specific consultation for a chemical mixture. Pohl HR, et al. **Toxicol Ind Health** 1999 Aug;15(5):470-9

Exporting hazards to developing countries. Menkes DB. **World Health Forum** 1998;19(4):412-6 (14 ref.)

[Biological effect of exposure to butadiene] Dobrzyńska MM, et al. **Rocz Panstw Zakl Hig** 1999;50(1):1-15 (128 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Bioassay-directed fractionation and chemical identification of mutagens in bioremediated soils. Brooks LR, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1435-40

Genotoxicity of bioremediated soils from the Reilly Tar site, St. Louis Park, Minnesota. Hughes TJ, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1427-33

Biological monitoring of workers at a recently opened hazardous waste disposal site. Diaz-Barriga F, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:63-71

Residential exposure summary methodology for a reproductive health study of multiple hazardous waste sites. Marshall EG, et al. **J Expo Anal Environ Epidemiol** 1993; 3 Suppl 1:87-98

Risk factors for exposure to arsenic at a hazardous waste site. Reif JS, et al. **J Expo Anal Environ Epidemiol** 1993; 3 Suppl 1:73-86

Analysis of an accident at a solvent recovery plant. Cozzani V, et al. **J Hazard Mater** 1999 Jun 11;67(2):145-61

[Public health relevant levels of pollutants in soil. Considerations for preventive, environmental health protection] Müller L. **Gesundheitswesen** 1998 Jul; 60(7):439-44 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

A new Hazardous Waste Index. Gupta JP, et al. **J Hazard Mater** 1999 May 31;67(1):1-7

[An alternative approach to the classification of hazards of industrial waste] Antomonov MIu. **Gig Sanit** 1999 Jul-Aug; (4):62-4 **(Rus)**

ECONOMICS

Superfund Basic Research: A state's perspective on health effects research needs [editorial] Pour AM. **Environ Health Perspect** 1999 Jan;107(1):A10-1

PREVENTION & CONTROL

Hazardous wastes in eastern and central Europe: technology and health effects. Carpenter DO, et al. **Environ Health Perspect** 1999 Apr;107(4):249-50

The control of major accident hazards: the land-use planning issue. Christou MD, et al. **J Hazard Mater** 1999 Mar 1; 65(1-2):151-78 (59 ref.)

Bioremediation of phenols and polycyclic aromatic hydrocarbons in creosote contaminated soil using ex-situ landtreatment. Guerin TF. **J Hazard Mater** 1999 Mar 19; 65(3):305-15

Photocatalytic decomposition of 4-chlorophenol over oxide catalysts. Hügül M, et al. **J Hazard Mater** 1999 Feb 15; 64(3):313-22

Precautions against industrial accidents: experience in applying the Seveso II Directive in central and eastern European countries. Kaiser W, et al. **J Hazard Mater** 1999 Mar 1;65(1-2):59-75 (8 ref.)

Application of the Seveso Directive in France. Pineau JP. **J Hazard Mater** 1999 Mar 1;65(1-2):49-57 (7 ref.)

Thermogravimetric study of thermal decontamination of soils polluted by hexachlorobenzene, 4-chlorobiphenyl, naphthalene, or n-decane. Risoul V, et al. **J Hazard Mater** 1999 Feb 15;64(3):295-311

Immobilization of chromium-contaminated soil by means of microwave energy. Tai HS, et al. **J Hazard Mater** 1999 Mar 19;65(3):267-75

STATISTICS & NUMERICAL DATA

Precursors of dangerous substances formed in the loss of control of chemical systems. Cozzani V, et al. **J Hazard Mater** 1999 Mar 1;65(1-2):93-108 (28 ref.)

HAZARDOUS WASTE, RADIOACTIVE see **RADIOACTIVE WASTE**

HAZARDOUS WASTE SITES see **HAZARDOUS WASTE**

HAZARDS, EQUIPMENT see **EQUIPMENT SAFETY**

HAZARDS MODELS see **PROPORTIONAL HAZARDS MODELS**

HB A1C see **HEMOGLOBIN A, GLYCOSYLATED**

HBA1 see **HEMOGLOBIN A, GLYCOSYLATED**

HBAG see **HEPATITIS B ANTIGENS**

HBCAG see **HEPATITIS B CORE ANTIGENS**

HBEAG see **HEPATITIS B E ANTIGENS**

HBGF-1 see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HBGF-2 see **FIBROBLAST GROWTH FACTOR, BASIC**

HBLV see **HERPESVIRUS 6, HUMAN**

HBSAG see **HEPATITIS B SURFACE ANTIGENS**

HCB see **HEXACHLOROBENZENE**

HCG see **GONADOTROPINS, CHORIONIC**

HCG, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

HCG-BETA see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

HCG RECEPTORS see **RECEPTORS, LH**

HCV ANTIBODIES see **HEPATITIS C ANTIBODIES**

HDL CHOLESTEROL see **LIPOPROTEINS, HDL CHOLESTEROL**

HEAD

see related
FACIAL BONES
SKULL

Characterization of the pulse signal over the human head by near infrared spectroscopy. Nolte C, et al. **Adv Exp Med Biol** 1998;454:115–23

Extraorbital inflammatory pseudotumor of the head and neck: CT and MR findings in three patients. De Vuysere S, et al. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):1133–9

Physiologic and thermal responses of male and female patients with multiple sclerosis to head and neck cooling. Ku YT, et al. **Am J Phys Med Rehabil** 1999 Sep–Oct; 78(5):447–56

Convective heat transfer around an infant head. Vuillerme V, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:310–7

Wegener's granulomatosis of the head and neck [letter; comment] Sittel C, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):999. Comment on: Ann Otol Rhinol Laryngol 1998 May;107(5 Pt 1):439–45.

Modeling of spreading cortical depression using a realistic head model. Wijesinghe RS, et al. **Brain Topogr** 1998 Fall; 11(1):3–12

Retrospective intermodality registration techniques for images of the head: surface-based versus volume-based. West J, et al. **IEEE Trans Med Imaging** 1999 Feb; 18(2):144–50

A fast and accurate method for registration of MR images of the head. Kotsas P, et al. **Int J Med Inf** 1998 Oct–Dec; 52(1–3):167–82

Sensitivity of human subjects to head-related transfer-function phase spectra. Kulkarni A, et al. **J Acoust Soc Am** 1999 May;105(5):2821–40

Speed dependency of motion pattern consistency. Peham C, et al. **J Biomech** 1998 Sep;31(9):769–72

The ability to reproduce the neutral zero position of the head. Christensen HW, et al. **J Manipulative Physiol Ther** 1999 Jan;22(1):26–8

Head and neck mycetoma. Supanakorn S, et al. **J Med Assoc Thai** 1998 Dec;81(12):1019–22

Eye–head coordination for the steering of locomotion in humans: an anticipatory synergy. Grasso R, et al. **Neurosci Lett** 1998 Sep 4;253(2):115–8

A sensor-weighted overlapping-sphere head model and exhaustive head model comparison for MEG. Huang MX, et al. **Phys Med Biol** 1999 Feb;44(2):423–40

Power deposition in the head and neck of an anatomically based human body model for plane wave exposures. Tinniswood AD, et al. **Phys Med Biol** 1998 Aug; 43(8):2361–78

The visual effects of head-mounted display (HMD) are not distinguishable from those of desk-top computer display. Peli E. **Vision Res** 1998 Jun;38(13):2053–66

[Effect of common head gear on horses] Preuschoft H, et al. **DTW Dtsch Tierarzti Wochenschr** 1999 Apr; 106(4):169–75 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Inherited macrocephaly–hamartoma syndromes. DiLiberti JH. **Am J Med Genet** 1998 Oct 2;79(4):284–90 (51 ref.)

Craniofacial variability index: a simple measure of normal and abnormal variation in the head and face. Ward RE, et al. **Am J Med Genet** 1998 Nov 16;80(3):232–40

Spasticity, mental retardation, macrocephaly and distinct craniofacial appearance: confirmation of a new subtype of complicated spastic paraplegia? Moog U, et al. **Genet Couns** 1998;9(3):211–3

Microcephaly and macrocephaly in autism. Fombonne E, et al. **J Autism Dev Disord** 1999 Apr;29(2):113–9

Intelligence test scores from infancy to adulthood for a craniopagus twin pair neurosurgically separated at 4 months of age. Lansdell H. **Psychol Rep** 1999 Feb; 84(1):209–17

ANATOMY & HISTOLOGY

Fifteen-year reproducibility of natural head posture: A longitudinal study. Peng L, et al. **Am J Orthod Dentofacial Orthop** 1999 Jul;116(1):82–5

Three-dimensional human head finite-element model validation against two experimental impacts. Willinger R, et al. **Ann Biomed Eng** 1999 May–Jun;27(3):403–10

The relationship between anthropometric measurements at birth: asthma and atopy in childhood. Gregory A, et al. **Clin Exp Allergy** 1999 Mar;29(3):330–3

Head circumference at birth and maternal factors related to cord blood total IgE. Oryszczyn MP, et al. **Clin Exp Allergy** 1999 Mar;29(3):334–41

A software implementation for detailed volume conductor modelling in electrophysiology using finite difference method. Kauppinen P, et al. **Comput Methods Programs Biomed** 1999 Feb;58(2):191–203

Head circumference in ELBW babies is associated with learning difficulties and cognition but not ADHD in the school-aged child. Stathis SL, et al. **Dev Med Child Neurol** 1999 Jun;41(6):375–80

Head posture and malocclusions. Solow B, et al. **Eur J Orthod** 1998 Dec;20(6):685–93

Reference structures for assessment of frontal head posture. Zepa I, et al. **Eur J Orthod** 1998 Dec;20(6):694–9

Influence of skull anisotropy for the forward and inverse problem in EEG: simulation studies using FEM on realistic head models. Marin G, et al. **Hum Brain Mapp** 1998; 6(4):250–69

Validation of object-induced MR distortion correction for frameless stereotactic neurosurgery. Dean D, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):810–6

Iterative reconstruction of single-shot spiral MRI with off resonance. Harshbarger TB, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):196–205

Volumetric visualization of head and neck CT data for treatment planning. Lee JS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):693–703

Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. Uematsu H, et al. **J Nucl Med** 1998 Dec;39(12):2121–7

Radiofrequency power calibration for magnetic resonance imaging using signal phase as indicator. Bosak E, et al. **Magn Reson Med** 1999 Mar;41(3):474–8

SAR and B1 field distributions in a heterogeneous human head model within a birdcage coil. Specific energy absorption rate. Collins CM, et al. **Magn Reson Med** 1998 Dec;40(6):847–56

Visual feedback to stabilize head position for fMRI. Thulborn KR. **Magn Reson Med** 1999 May;41(5):1039–43

Treatment of hypopituitarism in infancy. Effect on head circumference growth. Di Maio S, et al. **Minerva Pediatr** 1999 Apr;51(4):89–92

Brain size, head size, and intelligence quotient in monozygotic twins [letter] Anderson B. **Neurology** 1999 Jul 13;53(1):242–4

Small head size is related to low Mini-Mental State Examination scores in a community sample of nondemented older adults. Reynolds MD, et al. **Neurology** 1999 Jul 13; 53(1):228–9

Comments on 'Human magnetic resonance imaging at 8 T' [letter] Röschmann P. **NMR Biomed** 1999 Aug;12(5):315–9

A statistical approach to data analysis and 3-D geometric description of the human head and face. Shiang TY. **Proc Natl Sci Counc Repub China B** 1999 Jan;23(1):19–26

[Is head size modified by environmental factors?] Jaeger U, et al. **Z Morphol Anthropol** 1998;82(1):59–66 (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Effect of subcutaneous sumatriptan on head temperature in migraines. Parrinello G, et al. **Drugs Exp Clin Res** 1998; 24(4):197–205

Evaluation and treatment of head and neck venous vascular malformations. Pappas DC Jr, et al. **Ear Nose Throat J** 1998 Nov;77(11):914–6, 918–22

Characterization of human head vasculature by percolation parameters. Weis J, et al. **Magn Reson Imaging** 1999 Apr; 17(3):411–5

Head and neck vascular anomalies of childhood. Robertson RL, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):115–32 (59 ref.)

EMBRYOLOGY

The incidence and severity of shoulder dystocia correlates with a sonographic measurement of asymmetry in patients with diabetes. Cohen BF, et al. **Am J Perinatol** 1999; 16(4):197–201

Comparative study of shape, course, and disintegration of the rostral notochord in some vertebrates, especially humans. Barteczko K, et al. **Anat Embryol (Berl)** 1999 Oct; 200(4):345–66

Fetal ultrasound biometry: 1. Head reference values [letter; comment] Hutchon DJ. **Br J Obstet Gynaecol** 1999 Aug; 106(8):875–6. Comment on: Br J Obstet Gynaecol 1999 Feb;106(2):126–35.

Fetal ultrasound biometry: 1. Head reference values [see comments] Kurmanavicius J, et al. **Br J Obstet Gynaecol** 1999 Feb;106(2):126–35. Comment in: Br J Obstet Gynaecol 1999 Aug;106(8):875–6.

The anterior margin of the mammalian gastrula: comparative and phylogenetic aspects of its role in axis formation and head induction. Viebahn C. **Curr Top Dev Biol** 1999; 46:63–103 (201 ref.)

Myotube heterogeneity in developing chick craniofacial skeletal muscles. Marcucio RS, et al. **Dev Dyn** 1999 Mar; 214(3):178–94

Targeting gene expression to the head: the Drosophila orthodenticle gene is a direct target of the Bicoid morphogen. Gao Q, et al. **Development** 1998 Nov; 125(21):4185–93

Head induction in the chick by primitive endoderm of mammalian, but not avian origin. Knoetgen H, et al. **Development** 1999 Feb;126(4):815–25

Endophyll orients and organizes the early head region of the avian embryo. Callebaut M, et al. **Eur J Morphol** 1999 Feb;37(1):37–52

Six class homeobox genes in drosophila belong to three distinct families and are involved in head development. Seo HC, et al. **Mech Dev** 1999 May;83(1–2):127–39

Follistatin possesses trunk and tail organizer activity and lacks head organizer activity. Kablar B. **Tissue Cell** 1999 Feb;31(1):28–33

GROWTH & DEVELOPMENT

Expression and developmental regulation of the Hydra-RFamide and Hydra-LWamide preprohormone genes in Hydra: evidence for transient phases of head formation. Mitgutsch C, et al. **Dev Biol** 1999 Mar 1; 207(1):189–203

Otx expression during lamprey embryogenesis provides insights into the evolution of the vertebrate head and jaw. Tomsa JM, et al. **Dev Biol** 1999 Mar 1;207(1):26–37

Head circumference in ELBW babies is associated with learning difficulties and cognition but not ADHD in the school-aged child. Stathis SL, et al. **Dev Med Child Neurol** 1999 Jun;41(6):375–80

Hedgehog activates the EGF receptor pathway during Drosophila head development. Amin A, et al. **Development** 1999 Jun;126(12):2623–30

Functional equivalency between Otx2 and Otx1 in development of the rostral head. Suda Y, et al. **Development** 1999 Feb;126(4):743–57

Craniofacial growth in a whole rat head transplant: how does a non-functional head grow? Sugawara Y, et al. **J Craniofac Genet Dev Biol** 1999 Apr–Jun;19(2):102–8

Pre- and postnatal lead effect on head circumference: a case for critical periods. Rothenberg SJ, et al. **Neurotoxicol Teratol** 1999 Jan–Feb;21(1):1–11

Cranial growth unrestricted during treatment of deformational plagiocephaly. Kelly KM, et al. **Pediatr Neurosurg** 1999 Apr;30(4):193–9

INJURIES see HEAD INJURIES

INNERVATION

[Characteristics of the innervation of the head and neck] Neuhuber WL. **Orthopade** 1998 Dec;27(12):794–801 (56 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Image-guided fine-needle aspiration of the head and neck: five years' experience. Sack MJ, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1155–61

The head: excluding the brain and orbit. Forrest LJ. **Clin Tech Small Anim Pract** 1999 Aug;14(3):170–6 (36 ref.)

Prenatal and postnatal blood lead level and head circumference in children to three years: preliminary results from the Mexico City Prospective Lead Study. Rothenberg SJ, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:165–72

ENT aspects of the mummification of the head in ancient Egypt: an imaging study. Motamed M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):337–9

Neonatal head circumference and related indices of disturbed fetal development in schizophrenic patients. Cantor-Graae E, et al. **Schizophr Res** 1998 Aug 17;32(3):191–9

PHYSIOLOGY

Prone position may increase temperature around the head of the infant. Oriot D, et al. **Acta Paediatr** 1998 Sep; 87(9):1005–7

Otolith-canal interaction during pitch while rotating. Haslwanter T, et al. **Ann N Y Acad Sci** 1999 May 28; 871:410–3

Signal processing related to the vestibulo-ocular reflex during combined angular rotation and linear translation of the head. McCrea RA, et al. **Ann N Y Acad Sci** 1999 May 28;871:65–80

Human gaze stabilization for voluntary off-centric head rotations. Medendorp WP, et al. **Ann N Y Acad Sci** 1999 May 28;871:426–9

Head movement restriction and postural stability in patients with compensated unilateral vestibular loss. Karlberg M, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1448–50

Kinematic response of the neck to voluntary and involuntary flexion. Margulies SS, et al. **Aviat Space Environ Med** 1998 Sep;69(9):896–903

Unilateral vestibular deafferentation produces no long-term effects on human active eye–head coordination. Black RA, et al. **Exp Brain Res** 1998 Oct;122(3):362–6

Head orientation is aligned with take-off trajectory as chicks jump. Green PR. **Exp Brain Res** 1998 Oct;122(3):295–300

Effects of walking velocity on vertical head and body movements during locomotion. Hirasaki E, et al. **Exp Brain Res** 1999 Jul;127(2):117–30

Influence of head-to-trunk position on sound lateralization. Lewald J, et al. **Exp Brain Res** 1998 Aug;121(3):230–8

Spatial coding of eye movements relative to perceived earth and head orientations during static roll tilt. Wood SJ, et al. **Exp Brain Res** 1998 Jul;121(1):51–8

Heating of tissue by near-field exposure to a dipole: a model analysis. Riu PJ, et al. **IEEE Trans Biomed Eng** 1999 Aug; 46(8):911–7

Dolphin hearing: relative sensitivity as a function of point of application of a contact sound source in the jaw and head region. Møhl B, et al. **J Acoust Soc Am** 1999 Jun; 105(6):3421–4

Broadband performance of an active headrest. Rafaely B,

et al. **J Acoust Soc Am** 1999 Aug;106(2):787-93

Effects of viewing distance on the responses of horizontal canal-related secondary vestibular neurons during angular head rotation. Chen-Huang C, et al. **J Neurophysiol** 1999 May;81(5):2517-37

Contribution of the rostral fastigial nucleus to the control of orienting gaze shifts in the head-unrestrained cat. Pélisson D, et al. **J Neurophysiol** 1998 Sep;80(3):1180-96

Vertical eye position-dependence of the human vestibuloocular reflex during passive and active yaw head rotations. Thurtell MJ, et al. **J Neurophysiol** 1999 May;81(5):2415-28

Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. Yamamura H, et al. **J Neurophysiol** 1999 Feb;81(2):479-93

The anterior thalamic head-direction signal is abolished by bilateral but not unilateral lesions of the lateral mammillary nucleus. Blair HT, et al. **J Neurosci** 1999 Aug 1;19(15):6673-83

Firing properties of rat lateral mammillary single units: head direction, head pitch, and angular head velocity. Stackman RW, et al. **J Neurosci** 1998 Nov 1;18(21):9020-37

Resonant characteristics of the human head in relation to temporomandibular joint sounds. Prinz JF. **J Oral Rehabil** 1998 Dec;25(12):954-60

Effect of head position on vertical mandibular opening. Higbie EJ, et al. **J Orthop Sports Phys Ther** 1999 Feb;29(2):127-30

Galvanic vestibular stimulation modulates voluntary movement of the human upper body. Cauquil AS, et al. **J Physiol (Lond)** 1998 Dec 1;513 (Pt 2):611-9

Metrical effects on speech movements in children and adults. Goffman L, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):1003-15

Nonassociative and associative modification of head-waving produced by aversive tentacular stimuli in Aplysia. Fitzgerald KK, et al. **Learn Mem** 1997 Jan-Feb;3(5):366-75

Structural constraints on the coordination of concurrent rotations of the head and a steering device. Heuer H, et al. **Motor Control** 1999 Jan;3(1):39-66

Visual self-motion perception during head turns. Crowell JA, et al. **Nat Neurosci** 1998 Dec;1(8):732-7

A neural correlate for vestibulo-ocular reflex suppression during voluntary eye-head gaze shifts. Roy JE, et al. **Nat Neurosci** 1998 Sep;1(5):404-10

Failure of localized head cooling to reduce brain temperature in adult humans. Corbett RJ, et al. **Neuroreport** 1998 Aug 24;9(12):2721-5

Vertebral artery compression resulting from head movement: a possible cause of the sudden infant death syndrome. Pamphlett R, et al. **Pediatrics** 1999 Feb;103(2):460-8

Head orientation involvement in assessment of the subjective vertical during whole body tilt. Guerraz M, et al. **Percept Mot Skills** 1998 Oct;87(2):643-8

[The study of vertical vestibulo-ocular reflexes] Skliut IA, et al. **Aviakosm Ekolog Med** 1999;33(2):64-7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Surface friction in near-vertex head and neck impact increases risk of injury. Camacho DL, et al. **J Biomech** 1999 Mar;32(3):293-301

RADIATION EFFECTS

Long-term salivary effects of single-dose head and neck irradiation in the rat. Nagler RM, et al. **Arch Oral Biol** 1998 Apr;43(4):297-303

Comparison of numerical and experimental methods for determination of SAR and radiation patterns of handheld wireless telephones. Gandhi OP, et al. **Bioelectromagnetics** 1999;Suppl 4:93-101

Head and neck resonance in a rhesus monkey--a comparison with results from a human model. Tinniswood A, et al. **Phys Med Biol** 1999 Mar;44(3):695-704

RADIOGRAPHY

Variation of patient dose in head CT. Smith A, et al. **Br J Radiol** 1998 Dec;71(852):1296-301

Predictive models for difficult laryngoscopy and intubation. A clinical, radiologic and three-dimensional computer imaging study. Naguib M, et al. **Can J Anaesth** 1999 Aug;46(8):748-59

Registration of head CT images to physical space using a weighted combination of points and surfaces. Maurer CR Jr, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):753-61

Reduced partial volume artifacts using spiral computed tomography and an integrating interpolator. Heuscher DJ, et al. **Med Phys** 1999 Feb;26(2):276-86

Training issues in neuroradiology and head and neck radiology [comment] Dillon WP. **Radiology** 1998 Oct;209(1):15-6. Comment on: Radiology 1998 Oct;209(1):3-7. Comment on: Radiology 1998 Oct;209(1):8-14.

The American Society of Head and Neck Radiology. Head and neck imaging: the next 10 years [see comments] Mukherji SK. **Radiology** 1998 Oct;209(1):8-14. Comment in: Radiology 1998 Oct;209(1):15-6.

RADIONUCLIDE IMAGING

MIRD Pamphlet No. 15: Radionuclide S values in a revised dosimetric model of the adult head and brain. Medical Internal Radiation Dose. Bouchet LG, et al. **J Nucl Med** 1999 Mar;40(3):62S-101S

Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. Uematsu H, et al. **J Nucl Med** 1998 Dec;39(12):2121-7

SURGERY

Blood transfusion requirements in otolaryngology--head and neck surgery. Dulguerov P, et al. **Acta Otolaryngol (Stockh)** 1998 Sep;118(5):744-7

Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Ewig S, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):188-98

Clinical experience in end-to-side venous anastomoses with a microvascular anastomotic coupling device in head and neck reconstruction. DeLacure MD, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug;125(8):869-72

Re: Editorial 'Should there be a new specialty of head and neck surgery?' [letter] Grew NR, et al. **Br J Oral Maxillofac Surg** 1999 Jun;37(3):246-7

Should there be a new specialty of 'head and neck surgery'? [editorial] McGurk M. **Br J Oral Maxillofac Surg** 1998 Dec;36(6):405

Accuracy of registration methods in frameless stereotaxis. Helm PA, et al. **Comput Aided Surg** 1998;3(2):51-6

Cartilage reconstruction in head and neck surgery: comparison of resorbable polymer scaffolds for tissue engineering of human septal cartilage. Rotter N, et al. **J Biomed Mater Res** 1998 Dec 5;42(3):347-56

Osteogaleal pedicle flap of the occipital region for head and neck reconstruction--anatomic study. de Magalhães RP, et al. **J Otolaryngol** 1998 Aug;27(4):195-9

Intelligence test scores from infancy to adulthood for a craniopagus twin pair neurosurgically separated at 4 months of age. Lansdell H. **Psychol Rep** 1999 Feb;84(1):209-17

[Occipital pedicle forehead flap (letter)] Chavoin JP. **Ann Chir Plast Esthet** 1997 Jun;42(3):281 **(Fre)**

[Microsurgical reconstruction of the head and neck: experience of 63 free flaps] Costa H, et al. **Acta Med Port** 1998 Oct;11(10):855-70 (Eng. Abstr.) **(Por)**

[A posterolateral approach to the area of the craniovertebral transition] Shevelev IN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan-Mar;(1):40-6; discussion 46-7 (Eng. Abstr.) **(Rus)**

HEAD AND NECK NEOPLASMS

Verrucous carcinoma, then and now. Spiro RH. **Am J Surg** 1998 Nov;176(5):393-7

Pregnancy and malignant neoplasms of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):991-8 (82 ref.)

Minimum dataset for head and neck cancer [letter; comment] Johnson NW. **Br Dent J** 1999 Apr 24;186(8):368-9. Comment on: Br Dent J 1999 Jan 23;186(2):50.

Treatment of upper aerodigestive tract cancers in England and its effect on survival. Edwards DM, et al. **Br J Cancer** 1999 Sep;81(2):323-9

Joint meeting of the British, Netherlands and Scandinavian Associations of Head and Neck Oncologists. London, United Kingdom, 5-7 October 1998. Abstracts. **Clin Oncol (R Coll Radiol)** 1999;11(2):128-36

Guidelines, standards and protocols in head and neck cancer: tools not restraints [editorial] Birchall MA. **Clin Otolaryngol** 1999 Feb;24(1):1-2

Bibliography. Current world literature. Head and neck. **Curr Opin Oncol** 1999 May;11(3):B110-6

Possible branchiogenic carcinoma coinciding with metastatic papillary thyroid carcinoma. Muñoz Madero V, et al. **Eur J Surg Oncol** 1999 Feb;25(1):103-5

Role of chest CT scanning in the management of patients presenting with head and neck cancer. Houghton DJ, et al. **Head Neck** 1998 Oct;20(7):614-8

Second neoplasm in patients with head and neck cancer. León X, et al. **Head Neck** 1999 May;21(3):204-10

Nutritional and zinc status of head and neck cancer patients: an interpretive review. Prasad AS, et al. **J Am Coll Nutr** 1998 Oct;17(5):409-18 (38 ref.)

Summary of the proceedings of the United States and Japan Head and Neck Cancer Clinical Trials Summit, 19-20 September 1997, Kyoto, Japan. Matsuura H, et al. **J Cancer Res Clin Oncol** 1999 Jul;125(7):433-8

Pretherapy dental decisions in patients with head and neck cancer. A proposed model for dental decision support. Bruins HH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Sep;86(3):256-67 (71 ref.)

Benign mesenchymoma of the cheek: report of a case and review of the literature. Sakurai K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):74-9 (24 ref.)

Metachronous cancer: prognostic factors including prior irradiation. Dolan R, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):619-23

Plasmacytomas of the head and neck. Miller FR, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):614-8

Health impact of head and neck cancer. Terrell JE, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):852-9

Managing lumps in the neck. Mady SM. **Practitioner** 1998 Jun;242(1587):472-5 (4 ref.)

Lymphomas of the head and neck. Yuen A, et al. **Semin Oncol** 1999 Jun;26(3):338-45 (52 ref.)

[Cystic lymphangioma of the neck in children in Lome. Apropos of 13 cases] Tekou H, et al. **Tunis Med** 1998 Mar;76(3):24-7 **(Fre)**

[A computerized database for managing otorhinolaryngologic oncology patients] Mira E, et al. **Acta Otorhinolaryngol Ital** 1998 Jun;18(3):155-63 (Eng. Abstr.) **(Ita)**

[Mucosal malignant melanomas of the head and neck] Faye-Lund H, et al. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):789-91 (Eng. Abstr.) **(Nor)**

BLOOD

Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Ogawa T, et al. **Acta Otolaryngol Suppl** 1999;540:72-6

A new prognostic indicator for head and neck cancer--p53 serum antibodies? Gottschlich S, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2703-5

CYFRA 8/18 in head and neck cancer. Maass JD, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2699-701

Circulating intercellular adhesion molecule 1 (ICAM-1), E-selectin and vascular cell adhesion molecule 1 (VCAM-1) in head and neck cancer. Liu CM, et al. **Br J Cancer** 1999 Jan;79(2):360-2

Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kuo WR, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Mar;15(3):152-8

Micronucleated lymphocyte rates from head-and-neck cancer patients. Duffaud F, et al. **Mutat Res** 1999 Feb 19;439(2):259-66

Plasma retinoid levels in head and neck cancer patients: a comparison with healthy controls and the effect of retinyl palmitate treatment. Copper MP, et al. **Oral Oncol** 1999 Jan;35(1):40-4

[Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck] González Sánchez E, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):85-9 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

High angiogenic activity in cells isolated from cystic hygroma: role of bFGF. Maddalozzo J, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):45-8

Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Lingen MW, et al. **Cancer Res** 1998 Dec 1;58(23):5551-8

Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Giatromanolaki A, et al. **Clin Exp Metastasis** 1998 Oct;16(7):665-72

Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. Giatromanolaki A, et al. **Int J Cancer** 1999 Mar 15;80(6):810-7

CHEMICALLY INDUCED

A comparison of bleomycin-induced damage in lymphocytes and primary oral fibroblasts and keratinocytes in 30 subjects. Cloos J, et al. **Mutagenesis** 1999 Jan;14(1):87-93

Marijuana and cancer risk [letter; comment] Brigel P. **Postgrad Med** 1999 Jun;105(7):33, 36. Comment on: Postgrad Med 1998 Sep;104(3):63-4, 67-71, 75-6 passim.

CHEMISTRY

Analysis of glycosphingolipids of human head and neck carcinomas with comparison to normal tissue. Bolot G, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):125-35

Occurrence of monosialosyl pentahexaosylceramide GalNAc-GM1 as specific tumor-associated ganglioside of human head and neck squamous cell carcinomas. Bolot G, et al. **Cancer Lett** 1999 Jan 29;135(2):159-64

Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy. Rawal RM, et al. **Head Neck** 1999 May;21(3):192-7

Feasibility study of lactate imaging of head and neck tumors. Adalsteinsson E, et al. **NMR Biomed** 1998 Nov;11(7):360-9

CLASSIFICATION

Integrating radiological criteria into the classification of cervical lymph node disease [comment] Robbins KT. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):385-7. Comment on: Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):388-96.

An imaging-based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications [see comments] Som PM, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):388-96. Comment in: Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):385-7.

Oral cancer versus oropharyngeal cancer versus head and neck cancer [letter] Moreno López LA, et al. **Oral Oncol** 1998 Nov;34(6):576-7

[Chordomas. Analysis of 24 cases] Danilewicz M, et al. **Przegl Lek** 1999;56(2):115–8 (22 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Head and neck cancers associated with Madelung's disease. Chan ES, et al. **Ann Surg Oncol** 1999 Jun;6(4):395–7

A review of heterotopia and associated salivary gland neoplasms of the head and neck. Ferlito A, et al. **J Laryngol Otol** 1999 Apr;113(4):299–303 (54 ref.)

Competent gastrostomy for patients with head and neck cancer. Vassilopoulos PP, et al. **Support Care Cancer** 1998 Sep;6(5):479–81

[Squamous cell carcinoma of the ENT organs in the course of the HIV infection] Barry B, et al. **Ann Otolaryngol Chir Cervicofac** 1999 Jun;116(3):149–53 (11 ref.) (Eng. Abstr.) **(Fre)**

[Acute toxoplasmosis in coexistent non-Hodgkin lymphoma] Welge-Lüssen A, et al. **HNO** 1999 Jun;47(6):569–72 (Eng. Abstr.) **(Ger)**

CONGENITAL

A huge cystic hygroma of the neck associated with intraventricular haemorrhage in a term neonate. Yang AD, et al. **Acta Paediatr** 1999 Mar;88(3):344–6

The cesarean delivery of a twin gestation under 2 minimum alveolar anesthetic concentration isoflurane: one normal and one with a large neck mass. Gaiser RR, et al. **Anesth Analg** 1999 Mar;88(3):584–6

Congenital lateral cervical cysts of infancy. Mahomed A, et al. **J Pediatr Surg** 1998 Sep;33(9):1413–5

Cystic mass at the suprasternal notch of a newborn: congenital suprasternal dermoid cyst. Vittore CP, et al. **Pediatr Radiol** 1998 Dec;28(12):984–6

Hypothyroidism in a neonate following excision of a cervical teratoma. Chowdhary SK, et al. **Pediatr Surg Int** 1998 Dec; 14(3):212–3

[Cystic lymphangioma of the neck and mediastinum: are there acquired forms? Report of 37 cases] Riquet M, et al. **Rev Mal Respir** 1999 Feb;16(1):71–9 (89 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Ossifying fibromyxoid tumor misdiagnosed as follicular neoplasia. A case report. Lax S, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1261–4

Detection of perineural spread: fat is a friend [editorial; comment] Curtin HD. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1385–6. Comment on: AJNR Am J Neuroradiol 1998 Sep;19(8):1417–22.

Osseous anatomy of the pterygopalatine fossa. Daniels DL, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1423–32

Infantile fibromatosis of the neck with intracranial involvement: MR and CT findings. Flacke S, et al. **AJNR Am J Neuroradiol** 1999 May;20(5):923–5

Lymphoma: master of chicanery [editorial; comment] Mancuso A. **AJNR Am J Neuroradiol** 1998 Nov-Dec; 19(10):1808–9. Comment on: AJNR Am J Neuroradiol 1998 Nov-Dec;19(10):1849–51.

The "third-best" strategy for treating head and neck cancer [editorial; comment] Mancuso AA. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1191–2. Comment on: AJNR Am J Neuroradiol 1999 Aug;20(7):1215–20.

Thallium-201 single-photon emission CT versus CT for the detection of recurrent squamous cell carcinoma of the head and neck [see comments] Mukherji SK, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1215–20. Comment in: AJNR Am J Neuroradiol 1999 Aug;20(7):1191–2.

Imaging of head and neck paragangliomas with three-dimensional time-of-flight MR angiography. van den Berg R, et al. **AJR Am J Roentgenol** 1999 Jun; 172(6):1667–73

Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Bikhazi PH, et al. **Am J Otol** 1999 Sep;20(5):639–43

The role of fine-needle aspiration biopsy and flow cytometry in the evaluation of persistent neck adenopathy. Tarantino DR, et al. **Am J Surg** 1998 Nov;176(5):413–7

Fluorescence-guided biopsy in the diagnosis of an unknown primary cancer in patients with metastatic cervical lymph nodes. Kulapaditharom B, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):700–4

Prognostic factors in head and neck oncology: a critical appraisal for use in clinical practice. Chiesa F, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4769–76

CYFRA 8/18 in head and neck cancer. Maass JD, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2699–701

Head and neck cancer: a global perspective on epidemiology and prognosis. Sankaranarayanan R, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4779–86 (14 ref.)

Predictive factors for neoplasia and malignancy in a neck mass. Bhattacharyya N. **Arch Otolaryngol Head Neck Surg** 1999 Mar;125(3):303–7

Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Netterville JL, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1133–40

ENT malignancies. What the GP needs to know. Lyons B. **Aust Fam Physician** 1999 Mar;28(3):209–15 (9 ref.)

Fluorescence diagnostics and kinetic studies in the head and neck region utilizing low-dose delta-aminolevulinic acid sensitization. Wang I, et al. **Cancer Lett** 1999 Jan 8; 135(1):11–9

Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Brakenhoff RH, et al. **Clin Cancer Res** 1999 Apr;5(4):725–32

Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Homma A, et al. **Clin Cancer Res** 1999 Apr;5(4):801–6

Unusual MR appearance in a branchial cyst. Tahir M, et al. **Clin Radiol** 1999 Apr;54(4):263–4

Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Mendenhall WM, et al. **Head Neck** 1998 Dec; 20(8):739–44

Fourth branchial pouch anomalies: a study of six cases and review of the literature. Nicollas R, et al. **Int J Pediatr Otorhinolaryngol** 1998 Jun 1;44(1):5–10 (12 ref.)

HPV 18-induced pigmented bowenoid papulosis of the neck. Baron JM, et al. **J Am Acad Dermatol** 1999 Apr;40(4):633–4

Postirradiation primary Kaposi's sarcoma of the head and neck. De Pasquale R, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):312–4

Cutaneous metastasis presenting as facial lymphedema. Jang KA, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):637–8

Cancer curricula in U.S. dental schools. Rankin KV, et al. **J Cancer Educ** 1999 Spring;14(1):8–12

Unusual benign nerve sheath tumours. Sidhu BS, et al. **J Indian Med Assoc** 1998 Apr;96(4):123–5

Intramuscular haemangioma of head and neck region. Chaudhary N, et al. **J Laryngol Otol** 1998 Dec; 112(12):1199–201

Malignant schwannoma of the parapharyngeal space. al-Otieschan AA, et al. **J Laryngol Otol** 1998 Sep; 112(9):883–7

A clinic for the rapid processing of patients with neck masses. Vowles RH, et al. **J Laryngol Otol** 1998 Nov; 112(11):1061–4

Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. Califano J, et al. **J Natl Cancer Inst** 1999 Apr 7;91(7):599–604

Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. Uematsu H, et al. **J Nucl Med** 1998 Dec;39(12):2121–7

Thymic cyst mimicking a branchial cleft cyst. Dano I, et al. **J Otolaryngol** 1998 Aug;27(4):236–7

Branchiogenic carcinomas: do they exist? [letter; comment] Karmody CS. **J R Coll Surg Edinb** 1998 Oct;43(5):361–2 . Comment on: J R Coll Surg Edinb 1998 Feb;43(1):1–5.

Evaluation of the neck mass. Emery MT, et al. **J S C Med Assoc** 1998 Dec;94(12):548–52

Magnetic resonance navigation for head and neck lesions. Davis SP, et al. **Laryngoscope** 1999 Jun;109(6):862–7

Osteosarcoma of the head and neck: a review of the Johns Hopkins experience. Ha PK, et al. **Laryngoscope** 1999 Jun; 109(6):964–9

Computer-assisted three-dimensional reconstruction of head and neck tumors. Moharir VM, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1592–8

Clinical update on type II first branchial cleft cysts. Sichel JY, et al. **Laryngoscope** 1998 Oct;108(10):1524–7

Skin cancer of the head and neck. Hochman M, et al. **Med Clin North Am** 1999 Jan;83(1):261–82, xii (75 ref.)

The neck mass. McGuirt WF. **Med Clin North Am** 1999 Jan; 83(1):219–34

Giant cervico-mediastinal lipoma. A clinical case. Cutilli T, et al. **Minerva Stomatol** 1999 Jan-Feb;48(1-2):23–8 **(Eng, Ita)**

In vitro 1H MR spectroscopy of squamous cell carcinoma of the extracranial head and neck. Mukherji SK, et al. **Neuroimaging Clin N Am** 1998 Nov;8(4):835–47 (47 ref.)

Head and neck vascular anomalies of childhood. Robertson RL, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):115–32 (59 ref.)

Head and neck haemangiomas: contrast-enhanced three-dimensional MR angiography. Tetsumura A, et al. **Neuroradiology** 1999 Feb;41(2):140–3

Intracranial contrast-enhancing masses in infants with capillary haemangioma of the head and neck: intracranial capillary haemangioma? Tortori-Donati P, et al. **Neuroradiology** 1999 May;41(5):369–75

Recurrent pleomorphic adenoma of the head and neck. Yasumoto M, et al. **Neuroradiology** 1999 Apr;41(4):300–4

New biological markers may accurately predict prognosis in head and neck cancer patients [news] **Oncology (Huntingt)** 1998 Oct;12(10):1537

Current imaging techniques for head and neck tumors. Weissman JL, et al. **Oncology (Huntingt)** 1999 May; 13(5):697–709; discussion 713

Symptoms in early head and neck cancer: an inadequate indicator. Dolan RW, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):463–7

Occult cervical metastases: immunoperoxidase analysis of the pathologically negative neck. Enepekides DJ, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):713–7

Vascular lesion of the masseter presenting with phlebolith. Hessel AC, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):545–8

Extramedullary plasmacytoma in the anterior cervical region. Kakarlapudi VV, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):296–7

Aggressive cervical lymphoma presenting as airway obstruction. Oghalai JS, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):610–3

Teleconsultation in otolaryngology: live versus store and forward consultations. Sclafani AP, et al. **Otolaryngol Head Neck Surg** 1999 Jan;120(1):62–72

Cervical neurofibromas in children with NF-1. Chung CJ, et al. **Pediatr Radiol** 1999 May;29(5):353–6

MRI in the assessment of a newborn with cervical teratoma. Green JS, et al. **Pediatr Radiol** 1998 Sep;28(9):709–10

Pyriform sinus fistula appearing as a neck tumor in the neonatal period: a case report. Mizuno R, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):82–3

Neuroradiology case of the day. Alveolar soft part sarcoma. Greiner FG, et al. **Radiographics** 1999 Mar-Apr;19(2):542–5

Application of new imaging techniques for the evaluation of squamous cell carcinoma of the head and neck. Fischbein N, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):187–212 (103 ref.)

Imaging of perineural tumor spread in head and neck cancer. Ginsberg LE. **Semin Ultrasound CT MR** 1999 Jun; 20(3):175–86 (19 ref.)

Late presentation of branchial cyst. McClure MJ, et al. **Ulster Med J** 1998 Nov;67(2):129–31

[Sternocleidomastoid tumor] Sørensen A. **Ugeskr Laeger** 1998 Oct 5;160(41):5943–4 (Eng. Abstr.) **(Dan)**

[Referred earache; an important symptom of head-and-neck cancers (see comments)] de Bondt RB, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1;142(31):1753–6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Nov 21;142(47):2594. **(Dut)**

[Hypercalcemia associated with hyperleukocytosis, a new paraneoplastic syndrome] Peyrade F, et al. **Presse Med** 1998 Apr 11;27(14):658–60 (Eng. Abstr.) **(Fre)**

[Cervical ganglioneuroma. Review, apropos of a case] Barthelemy I, et al. **Rev Stomatol Chir Maxillofac** 1998 Nov;99(4):210–3 (15 ref.) (Eng. Abstr.) **(Fre)**

[Object analysis of cervical lymph nodes using MRI turbo-STIR sequence in cases of head and neck tumors] Okita W, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Jan; 102(1):1–7 (Eng. Abstr.) **(Jpn)**

[Selected biochemical tumor markers in clinical monitoring of head and neck neoplasm progression] Adamiak G. **Otolaryngol Pol** 1999;53(3):359–60 (181 ref.) **(Pol)**

[Tumor markers in monitoring of neoplasms] Adamiak G, et al. **Otolaryngol Pol** 1997;51 Suppl 25:20–2 (Eng. Abstr.) **(Pol)**

[Head and neck lymphomas in the material of the ENT department of Municipal Hospital in Gdynia in 1977–1996] Knurowska A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:73–7 (Eng. Abstr.) **(Pol)**

[Diagnostic problems in cases of neck tumors] Kubiczkowa J, et al. **Otolaryngol Pol** 1997;51 Suppl 25:16–9 (Eng. Abstr.) **(Pol)**

[The use of thermography for the laryngeal diagnosis] Murlewska A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:105–8 (Eng. Abstr.) **(Pol)**

[Cancer metastases to the cervical lymph nodes in an unknown primary location of the tumor] Vorob'ev Iul, et al. **Stomatologiia (Mosk)** 1998;77(5):34–7 (Eng. Abstr.) **(Rus)**

[Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck] González Sánchez E, et al. **Acta Otorrinolaringol Esp** 1999 Mar; 50(2):85–9 (Eng. Abstr.) **(Spa)**

[Update oN pediatric lymphomas of the head and neck] Jiménez J, et al. **Acta Otorrinolaringol Esp** 1998 Aug-Sep; 49(6):482–4 (Eng. Abstr.) **(Spa)**

[A comparative study of 9 cases of adrenal pheochromocytoma and 11 cases of extra-adrenal pheochromocytoma] Mediavilla García JD, et al. **Rev Clin Esp** 1999 Jun;199(6):343–8 (Eng. Abstr.) **(Spa)**

[Lymphomas of the head and neck] Saiz Ayala A, et al. **Sangre (Barc)** 1998 Dec;43(6):507–14 (27 ref.) **(Spa)**

[PET-findings in head-and neck cancers] Minn H, et al. **Nord Med** 1998 Nov;113(9):303–5 (Eng. Abstr.) **(Swe)**

DRUG THERAPY

Docetaxel in head and neck cancer: a review. Colevas AD, et al. **Am J Clin Oncol** 1998 Oct;21(5):482–6 (28 ref.)

Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Denic S. **Am J Clin Oncol** 1999 Feb;22(1):32–4

Sequential chemotherapy and radiotherapy for organ preservation in advanced resectable nonlaryngeal head and neck cancer. Khan A, et al. **Am J Clin Oncol** 1999 Aug; 22(4):403–7

Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group. Rosenthal MA, et al. **Am J Clin Oncol** 1998 Oct;21(5):509–12

Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. Sánchez Parra M, et al. **Am J Clin Oncol** 1999 Feb;22(1):6–7

Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Spencer SA, et al. **Am J Clin Oncol** 1999 Feb;22(1):1–5

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma

of the head and neck. Degardin M, et al. **Ann Oncol** 1998 Oct;9(10):1103-7

Does pain at tumor site during vinorelbine infusion affect treatment of recurrent head and neck cancer patients? [letter] De Marco S, et al. **Ann Oncol** 1999 Jul;10(7):865-6

Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Fountzilas G, et al. **Ann Oncol** 1999 Apr;10(4):475-8

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck [see comments] Hitt R, et al. **Ann Oncol** 1998 Dec;9(12):1347-9 . Comment in: Ann Oncol 1998 Dec;9(12):1265-7.

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Planting AS, et al. **Ann Oncol** 1999 Jun;10(6):693-700

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Schöffski P, et al. **Ann Oncol** 1999 Jan;10(1):119-22

The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy. Welters MJ, et al. **Ann Oncol** 1999 Jan;10(1):97-103

Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non tonsillar lymphomas. (Hellenic co-Operative Oncology Group). Economopoulos T, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4655-60

p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Giatromanolaki A, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4685-92

Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Koukourakis MI, et al. **Anticancer Res** 1999 May-Jun;19(3B):2305-9

Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Schöffski P, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4751-6 (37 ref.)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Couteau C, et al. **Br J Cancer** 1999 Oct;81(3):457-62 (29 ref.)

A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Etienne MC, et al. **Br J Cancer** 1999 Apr; 79(11-12):1864-9

PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Simon C, et al. **Br J Cancer** 1999 Jul; 80(9):1412-9

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Caponigro F, et al. **Cancer** 1999 Feb 15; 85(4):952-9

Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Dunphy FR, et al. **Cancer** 1999 Oct 1; 86(7):1362-7

Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma. Paltoo DN, et al. **Cancer Biochem Biophys** 1998 Oct;16(3):213-27

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Mantovani G, et al. **Cancer Immunol Immunother** 1998 Nov;47(3):149-56

Effect of cisplatin exposure on platinum accumulation and growth inhibition in human neoplastic and normal squamous epithelial cells of the mucosa of the upper-aerodigestive tract. Braakhuis BJ, et al. **Cancer Lett** 1999 Apr 26;138(1-2):217-20

Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Klocker J, et al. **Cancer Lett** 1998 Sep 11;131(1):113-5

Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Cao S, et al. **Clin Cancer Res** 1999 Jul;5(7):1925-34

Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas. Corvó R, et al. **Clin Cancer Res** 1997 Nov; 3(11):1993-7

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Fety R, et al. **Clin Cancer Res** 1998 Sep;4(9):2039-45

Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Minami H, et al. **Clin Cancer Res** 1999 Jun; 5(6):1325-30

Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Nishimura T, et al. **Clin Cancer Res** 1996 Nov;2(11):1859-65

Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Lankester KJ, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):208-10

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. Gamelin E, et al. **Crit Rev Oncol Hematol** 1999 Mar;30(1):71-9 (55 ref.)

Taxanes as radiosensitizers for head and neck cancer. Herscher LL, et al. **Curr Opin Oncol** 1999 May;11(3):183-6 (22 ref.)

Determination of tumor kinetics: strategies for the delivery of radiotherapy and chemotherapy. Ritter MA. **Curr Opin Oncol** 1999 May;11(3):177-82 (71 ref.)

Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced head and neck cancer. de Serdio JL, et al. **Head Neck** 1998 Sep; 20(6):489-96

A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Harrison LB, et al. **Head Neck** 1998 Sep;20(6):497-503

Electroporation therapy: a new approach for the treatment of head and neck cancer. Hofmann GA, et al. **IEEE Trans Biomed Eng** 1999 Jun;46(6):752-9

A clinical study to assess chlorpromazine as hypoxic cell sensitizer in head & neck cancer treated with conventional radiation. Huilgol NG, et al. **Indian J Cancer** 1998 Sep; 35(3):97-100

Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Blons H, et al. **Int J Cancer** 1999 Aug 20;84(4):410-5

Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells. Noda I, et al. **Int J Cancer** 1999 Jan 18; 80(2):279-84

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Rosier JF, et al. **Int J Radiat Biol** 1999 Feb;75(2):245-51

Chemotherapy alternated with radiotherapy in the treatment of advanced head and neck carcinoma: predictive factors of outcome. Sanguineti G, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):139-47

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Tishler RB, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1001-8

Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. Samlowski WE, et al. **Invest New Drugs** 1998-99;16(3):271-4

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Patel V, et al. **J Clin Invest** 1998 Nov 1;102(9):1674-81

Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. Haraf DJ, et al. **J Clin Oncol** 1999 Feb;17(2):638-44

Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. List MA, et al. **J Clin Oncol** 1999 Mar;17(3):1020-8

Neoadjuvant chemotherapy and radiotherapy for inoperable head and neck cancer: the LSU-Shreveport experience. Ampil FL, et al. **J La State Med Soc** 1998 Sep;150(9):413-7

Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Kübler AC, et al. **Lasers Surg Med** 1999;25(1):60-8

Improved photochemotherapy of malignant cells with daunomycin and the KTP laser. Paiva MB, et al. **Lasers Surg Med** 1998;23(1):33-9

Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Raney RB, et al. **Med Pediatr Oncol** 1999 Oct;33(4):362-71

Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mücke R, et al. **Mycoses** 1998 Nov;41(9-10):421-3

Treatment of head and neck cancer [letter; comment] Evans RA. **N Engl J Med** 1998 Oct 29;339(18):1330; discussion 1331. Comment on: N Engl J Med 1998 Jun 18;338(25):1798-804.

Treatment of head and neck cancer [letter; comment] Rescigno J, et al. **N Engl J Med** 1998 Oct 29;339(18):1330; discussion 1331. Comment on: N Engl J Med 1998 Jun 18;338(25):1798-804.

Treatment of head and neck cancer [letter; comment] Tobias JS. **N Engl J Med** 1998 Oct 29;339(18):1330-1. Comment on: N Engl J Med 1998 Jun 18;338(25):1798-804.

Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study. Mantovani G, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1499-505

Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients. Mantovani G, et al. **Oncol Rep** 1999 Mar-Apr;6(2):421-6

Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Kornek V, et al. **Oncology** 1999;56(1):24-7

Oral 5-FU alternatives for the treatment of head and neck cancer. Vokes EE, et al. **Oncology (Huntingt)** 1998 Oct; 12(10 Suppl 7):35-8 (26 ref.)

Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma. Zhong PQ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):139-44

Management of the neck in patients with head and neck cancer treated by concurrent chemotherapy and radiation. Weisman RA, et al. **Otolaryngol Clin North Am** 1998 Oct; 31(5):773-84 (27 ref.)

Erythropoietin for patients undergoing radiotherapy: a pilot study. Henke M, et al. **Radiother Oncol** 1999 Feb; 50(2):185-90

Chemoradiotherapy with carboplatin in continuous infusion in the locoregional control of advanced head and neck cancer. Marmiroli L, et al. **Rays** 1998 Jul-Sep;23(3):549-54 **(Eng, Ita)**

Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Shin DM, et al. **Semin Oncol** 1999 Feb;26(1 Suppl 2):100-5 (34 ref.)

Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Chougule PB, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):58-63

Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Dowell JE, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):97-101

Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Flood W, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):64-9

Toxicity antagonists in head and neck cancer. Trotti A. **Semin Radiat Oncol** 1998 Oct;8(4):282-91 (83 ref.)

Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Vokes EE, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):70-6

Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Wanebo HJ, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):77-84

Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. Jereczek-Fossa B, et al. **Strahlenther Onkol** 1998 Sep;174(9):457-61

[Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors] Mücke R, et al. **Strahlenther Onkol** 1999 May;175(5):213-7 (Eng. Abstr.) **(Ger)**

[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer] Inuyama Y, et al. **Gan To Kagaku Ryoho** 1999 Jan; 26(1):107-16 (Eng. Abstr.) **(Jpn)**

[Giant metastatic neck tumor responding to oral administration of UFT--a case report] Kawakami M, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):829-32 (Eng. Abstr.) **(Jpn)**

[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model] Uchida N, et al. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2267-74 (Eng. Abstr.) **(Jpn)**

[A combination of low-dose carboplatin (CBDCA) and radiation therapy in head and neck cancer patients--response and hematologenic toxicity] Watanabe N, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(1):101-6 (Eng. Abstr.) **(Jpn)**

[Glutathione and cisplatin resistance in head and neck cancer] Nishimura T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Feb;102(2):236-42 (Eng. Abstr.) **(Jpn)**

[Current results of the treatment of cervical metastatic lymph nodes by concurrent hyperfractionation of carboplatin and irradiation] de Serdio JL, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):554-60 (49 ref.) (Eng. Abstr.) **(Spa)**

[Acute pain due to vinorelbine] Cabrera Rodríguez J, et al. **Rev Clin Esp** 1998 Aug;198(8):514-6 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck. Kähäri VM, et al. **Adv Exp Med Biol** 1998;451:63-8

Genetic polymorphism of aldehyde dehydrogenase 2 in patients with upper aerodigestive tract cancer. Tanabe H, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):17S-20S

Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Bentz BG, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):781-7

Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Chan G, et al. **Cancer Res** 1999 Mar 1;59(5):991-4

EPIDEMIOLOGY

Parameningeal rhabdomyosarcoma. Report of 19 cases.

Oujilal A, et al. **Acta Otorhinolaryngol Belg** 1998; 52(3):235–40

Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Miguel RE, et al. **Am J Surg** 1998 Nov;176(5):428–9

Forty years of monitoring head and neck cancer in Norway--no good news. Mork J. **Anticancer Res** 1998 Sep–Oct;18(5B):3705–8

Head and neck cancer: a global perspective on epidemiology and prognosis. Sankaranarayanan R, et al. **Anticancer Res** 1998 Nov–Dec;18(6B):4779–86 (14 ref.)

Body-site distribution of melanocytic nevi in young Australian children. Harrison SL, et al. **Arch Dermatol** 1999 Jan;135(1):47–52

We need to talk about head and neck cancer datasets [editorial] [see comments] Monaghan N. **Br Dent J** 1999 Jan 23;186(2):50. Comment in: Br Dent J 1999 Apr 24;186(8):368–9.

Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Alexiou C, et al. **Cancer** 1999 Jun 1;85(11):2305–14

Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. Schlecht NF, et al. **Epidemiology** 1999 Jul;10(4):412–8

National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Hoffman HT, et al. **Head Neck** 1999 Jul;21(4):297–309

Infiltrating lipoma of the head and neck: a report of one pediatric case. Leroesy Y, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):91–5 (27 ref.)

Hemangiopericytoma of the head and neck. Carew JF, et al. **Laryngoscope** 1999 Sep;109(9):1409–11

Second malignant neoplasia in patients with T1 glottic cancer treated with radiation. Fujita M, et al. **Laryngoscope** 1998 Dec;108(12):1853–5

Dietary carotenoids and certain cancers, heart disease, and age-related macular degeneration: a review of recent research. Cooper DA, et al. **Nutr Rev** 1999 Jul;57(7):201–14 (120 ref.)

Head and neck and intra-oral soft tissue sarcomas. Gorsky M, et al. **Oral Oncol** 1998 Jul;34(4):292–6

Melanoma arising from the mucosal surfaces of the head and neck. Gorsky M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):715–9

[Cervical teratomas in the child (apropos of 8 cases)] Wandaogo A, et al. **Dakar Med** 1997;42(2):103–5 (16 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Rat tumors following fractionated irradiation. Bartel-Friedrich S, et al. **Anticancer Res** 1999 Jul–Aug; 19(4A):2725–6

Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Haraf DJ, et al. **Clin Cancer Res** 1996 Apr;2(4):755–62

Alcohol intake-associated skin and mucosal cancer. Merimsky O, et al. **Clin Dermatol** 1999 Jul–Aug; 17(4):447–55 (48 ref.)

Radiation induced sarcoma of the head and neck. Patel SG, et al. **Head Neck** 1999 Jul;21(4):346–54 (56 ref.)

Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Cheng L, et al. **Int J Cancer** 1999 Jun 21;84(3):220–4

Sunlight exposure, hat use, and squamous cell skin cancer on the head and neck. Bajdik CD, et al. **J Cutan Med Surg** 1998 Oct;3(2):68–73

Lateral cervical cleft: a previously unreported anomaly resulting from incomplete disappearance of the second pharyngeal (branchial) cleft. Gürsoy MH, et al. **J Pediatr Surg** 1999 Mar;34(3):488–90

Cervical myxofibrosarcoma in a renal allograft recipient treated with murine anti-CD3 monoclonal antibody therapy [letter] Soper CP, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1902–3

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809–14 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

p16 mutation frequency and clinical correlation in head and neck cancer. Danahey DG, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):285–8

Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. van Schothorst EM, et al. **Am J Hum Genet** 1998 Aug; 63(2):468–73

Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Bikhazi PH, et al. **Am J Otol** 1999 Sep;20(5):639–43

Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. Carew JF, et al. **Am J Surg** 1998 Nov;176(5):404–8

Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. de Andrade M, et al. **Ann Hum Genet** 1998 Nov;62 (Pt 6):505–10

Head and neck cancer and precancer: can we use molecular genetics to make better predictions? Partridge M. **Ann R Coll Surg Engl** 1999 Jan;81(1):1–11

p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck. Lavieille JP, et al. **Anticancer Res** 1998 Nov–Dec;18(6B):4741–9

Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Takes RP, et al. **Anticancer Res** 1998 Nov–Dec; 18(6B):4793–800

Detection of chromosome 11q13 amplification in head and neck cancer using fluorescence in situ hybridization. Wang MB, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):925–31

Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Blackwell JL, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug; 125(8):856–63

Spontaneous apoptosis and the expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Hotz MA, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):417–22

BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas. MPT Collaborators, St George's Hospital Collaborators. Gill S, et al. **Br J Cancer** 1999 Jul; 80(10):1565–8

The role of genetic factors in predisposition to squamous cell cancer of the head and neck [published erratum appears in Br J Cancer 1999 Jun;80(8):1302] Jefferies S, et al. **Br J Cancer** 1999 Feb;79(5–6):865–7 (26 ref.)

Bcl10 is not a target for frequent mutation in human carcinomas. Lambers AR, et al. **Br J Cancer** 1999 Jul; 80(10):1575–6

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Mineta H, et al. **Br J Cancer** 1998 Oct;78(8):1084–90

Microsatellite instability in squamous cell carcinomas of the head and neck related to field cancerization phenomena. Piccinin S, et al. **Br J Cancer** 1998 Nov;78(9):1147–51

Detection of point mutations by non-isotopic single strand conformation polymorphism. Pinheiro NA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):55–8

Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Pena JC, et al. **Cancer** 1999 Jan 1; 85(1):164–70

Abnormalities of tumor suppressor genes P16 and P15 in primary maxillofacial squamous cell carcinomas. Zhao Y, et al. **Cancer Genet Cytogenet** 1999 Jul 1;112(1):26–33

Analysis of genomic instability in squamous cell carcinoma of the head and neck using the random amplified polymorphic DNA method. Maeda T, et al. **Cancer Lett** 1999 Apr 26;138(1–2):183–8

Mutation analysis of hBUB1 in aneuploid HNSCC and lung cancer cell lines. Yamaguchi K, et al. **Cancer Lett** 1999 May 24;139(2):183–7

Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Duffey DC, et al. **Cancer Res** 1999 Jul 15; 59(14):3468–74

Cytogenetic and fluorescence in situ hybridization characterization of chromosome 1 rearrangements in head and neck carcinomas delineate a target region for deletions within 1p11-1p13. Jin Y, et al. **Cancer Res** 1998 Dec 15; 58(24):5859–65

Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Wan H, et al. **Cancer Res** 1999 Jul 15;59(14):3518–26

Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships. Califano J, et al. **Clin Cancer Res** 1999 Jul; 5(7):1862–7

Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck. Frank DK, et al. **Clin Cancer Res** 1998 Sep;4(9):2265–72

Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death. Frederick MJ, et al. **Clin Cancer Res** 1999 Feb;5(2):361–9

Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Gallo O, et al. **Clin Cancer Res** 1996 Sep;2(9):1577–82

Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. González MV, et al. **Clin Cancer Res** 1995 Sep;1(9):1043–9

Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract. Law JC, et al. **Clin Cancer Res** 1995 Jul;1(7):763–8

Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Lazar AD, et al. **Clin Cancer Res** 1998 Nov;4(11):2787–93

Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Lee DJ, et al. **Clin Cancer Res** 1997 Apr;3(4):501–5

Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck [published erratum appears in Clin Cancer Res 1999 Jan;5(1):222] Matthias C, et al. **Clin Cancer Res** 1998 Oct;4(10):2411–8

Allelic loss and replication errors at microsatellite loci on chromosome 11p in head and neck squamous carcinoma: association with aggressive biological features. El-Naggar AK, et al. **Clin Cancer Res** 1996 May;2(5):903–7

Overexpression and amplification of glutathione S-transferase pi gene in head and neck squamous cell carcinomas. Wang X, et al. **Clin Cancer Res** 1997 Jan; 3(1):111–4

Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Xia W, et al. **Clin Cancer Res** 1997 Jan;3(1):3–9

Genotypic analysis of flow-sorted and microdissected head and neck squamous lesions by whole-genome amplification. Coombes MM, et al. **Diagn Mol Pathol** 1998 Aug; 7(4):197–201

Microsatellite instability in double cancers of the esophagus and head and neck. Miyazato H, et al. **Dis Esophagus** 1999; 12(2):132–6

Fluorescent in situ hybridisation (FISH) characterisation of pericentromeric breakpoints on chromosome 5 in head and neck squamous cell carcinomas. Martins C, et al. **Eur J Cancer** 1999 Mar;35(3):498–501

FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Jin Y, et al. **Genes Chromosomes Cancer** 1998 Aug;22(4):312–20

Competitive PCR to detect eIF4E gene amplification in head and neck cancer. Sorrells DL, et al. **Head Neck** 1999 Jan; 21(1):60–5

Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Baysal BE, et al. **Hum Genet** 1999 Mar;104(3):219–25

Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Feenstra M, et al. **Hum Immunol** 1999 Aug;60(8):697–706

Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22-q23 in chief cells and the flow-sorted DNA aneuploid fraction. van Schothorst EM, et al. **Hum Pathol** 1998 Oct;29(10):1045–9

Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Blons H, et al. **Int J Cancer** 1999 Aug 20;84(4):410–5

Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene? Gallo O, et al. **Int J Cancer** 1999 Jul 19;82(2):180–6

Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Gasparotto D, et al. **Int J Cancer** 1999 Aug 20;84(4):432–6

Multiple regions of deletion on chromosome arm 13q in head-and-neck squamous-cell carcinoma. Gupta VK, et al. **Int J Cancer** 1999 Oct 22;84(5):453–7

Frequent allelic loss and homozygous deletion in chromosome band 8p23 in oral cancer. Ishwad CS, et al. **Int J Cancer** 1999 Jan 5;80(1):25–31

Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Morita S, et al. **Int J Cancer** 1999 Mar 1;80(5):685–8

P53 genotyping – an effective concept for molecular testing of head and neck cancer? Dahse R, et al. **Int J Mol Med** 1999 Sep;4(3):279–83

Tumor suppressor gene p16 (CDKN2A) mutation status and promoter inactivation in head and neck cancer. Riese U, et al. **Int J Mol Med** 1999 Jul;4(1):61–5

Progression of diploid tumor cells in aneuploid head and neck squamous cell carcinomas. Polackova J, et al. **Int J Oncol** 1999 Aug;15(2):315–20

Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. González MV, et al. **J Clin Pathol** 1998 Jul;51(7):520–4

Hereditary paraganglioma. Lemaire M, et al. **J Intern Med** 1999 Jul;246(1):113–6

The molecular genetics of head and neck cancer. Rowley H. **J Laryngol Otol** 1998 Jul;112(7):607–12 (54 ref.)

P53 expression and polysomies of chromosome 9, 17 in head and neck cancer prognosis. Charuruks N, et al. **J Med Assoc Thai** 1999 May;82(5):466–76

Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. Califano J, et al. **J Natl Cancer Inst** 1999 Apr 7;91(7):599–604

Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes [see comments] Cloos J, et al. **J Natl Cancer Inst** 1999 Jul 7; 91(13):1125–30. Comment in: J Natl Cancer Inst 1999 Jul 7;91(13):1097–8.

Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy [see comments] Mao L, et al. **J Natl Cancer Inst** 1998 Oct 21;90(20):1545–51 . Comment in: J Natl Cancer Inst 1998 Oct 21;90(20):1500–1.

Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles [editorial; comment] Westra WH, et al. **J Natl Cancer Inst** 1998 Oct 21;90(20):1500–1 . Comment on: J Natl Cancer Inst 1998 Oct 21;90(20):1545–51.

Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. Sorrells DL Jr, et al. **J Oral Maxillofac Surg** 1999 Mar;57(3):294–9

Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. Sorrells DL, et al. **J Surg Res** 1999 Jul;85(1):37–42

Microsatellite instability associated with primary head and neck cancers and secondary esophageal cancers. Kiriu H, et al. **Jpn J Clin Oncol** 1998 Dec;28(12):733–9

Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Kropveld A, et al. **Lab Invest** 1999 Mar;79(3):347–53

Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas. Lai S, et al. **Lab Invest** 1999 Mar;79(3):255–60

Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Alavi S, et al. **Laryngoscope** 1999 Jun;109(6):874–9

Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. Henderson YC, et al. **Laryngoscope** 1998 Oct; 108(10):1553–6

Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Nathan CA, et al. **Laryngoscope** 1999 Aug;109(8):1253–8 (18 ref.)

Chromosomal aberrations identified in culture of squamous carcinomas are confirmed by fluorescence in situ hybridisation. Worsham MJ, et al. **Mol Pathol** 1999 Feb; 52(1):42–6

Identification of individuals at high risk for head and neck carcinogenesis using chromosome aneuploidy detected by fluorescence in situ hybridization. Ai H, et al. **Mutat Res** 1999 Feb 19;439(2):223–32

Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Carroll PE, et al. **Oncogene** 1999 Mar 18;18(11):1935–44

Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Okami K, et al. **Oncogene** 1999 Jun 10;18(23):3541–5

Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. Sunwoo JB, et al. **Oncogene** 1999 Apr 22;18(16):2651–5

Researchers combine TP53 gene therapy and chemotherapy in advanced cancer [news] **Oncology (Huntingt)** 1998 Oct; 12(10):1517

A differential PCR system for the determination of CCND1 (cyclin D1) gene amplification in head and neck squamous cell carcinomas. Schneeberger C, et al. **Oral Oncol** 1998 Jul;34(4):257–60

Regional heterogeneity and intra-observer variability of DNA-content and cell proliferation markers determined by flow cytometry in head and neck tumours. Struikmans H, et al. **Oral Oncol** 1999 Mar;35(2):217–23

Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Chang J, et al. **Plast Reconstr Surg** 1999 Jan;103(1):1–9; discussion 10

Sex chromosome pentasomy (49,XXXXY) presenting as cystic hygroma at 16 weeks' gestation. Sepulveda W, et al. **Prenat Diagn** 1999 Mar;19(3):257–9

Prenatal diagnosis of de novo distal 5q duplication associated with hygroma colli, fetal oedema and complex cardiopathy. Witters I, et al. **Prenat Diagn** 1998 Dec;18(12):1304–7

[Mutation and methylation of CDKN2 gene in human head and neck carcinomas] Tao J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Jun;26(3):152–4 (Eng. Abstr.) **(Chi)**

[Plexiform neurofibroma and basal ganglia anomaly in Watson syndrome] Weber P, et al. **Klin Padiatr** 1999 May-Jun;211(3):172–4 (Eng. Abstr.) **(Ger)**

[The amplification of 11q13 DNA markers in squamous-cell carcinomas in the head-neck area: a correlation with the clinical course] Rödel C. **Strahlenther Onkol** 1998 Dec; 174(12):642–3 **(Ger)**

[Instability of micro-satellite sequences of DNA associated with genetic alterations in head and neck neoplasms. Review of the literature and preliminary results of a research plan] Pannone G, et al. **Minerva Stomatol** 1998 Nov;47(11):589–96 (75 ref.) (Eng. Abstr.) **(Ita)**

[Up-regulation of human chorionic gonadotropin alpha subunit gene and human mitochondrial cytochrome c oxidase subunit II gene in cis-Diamminedichloroplatinum(II)-resistant human head and neck squamous carcinoma cells] Higuchi E. **Hokkaido Igaku Zasshi** 1999 May;74(3):231–8 (Eng. Abstr.) **(Jpn)**

[Loss of heterozygosity of 3p21 and 9p21 in head and neck squamous cell carcinomas and its prognostic implication] Matsuura K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 May;102(5):613–21 (Eng. Abstr.) **(Jpn)**

[Preliminary study by flow cytometry of the cell cycle and DNA quantification in cytokeratin-positive cells in tumors of the head and neck] Górriz C, et al. **Acta Otorrinolaringol Esp** 1999 May;50(4):296–304 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Heimdal JH, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):281–4

Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects. Whiteside TL. **Adv Exp Med Biol** 1998;451:167–71

The effect of prostaglandin and its inhibitor on antibody-dependent cellular cytotoxicity against human squamous cell carcinoma of head and neck. Kim CD, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):455–9

The IgG1/G2 subclass shift--a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck. Anderhuber W, et al. **Br J Cancer** 1999 Apr;79(11–12):1777–81

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Huang SM, et al. **Cancer Res** 1999 Apr 15;59(8):1935–40

Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Kuss I, et al. **Clin Cancer Res** 1999 Feb; 5(2):329–34

Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Pak AS, et al. **Clin Cancer Res** 1995 Jan;1(1):95–103

Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Saito T, et al. **Clin Cancer Res** 1999 Jun;5(6):1263–73

Differences in immune status between well-nourished and malnourished head and neck cancer patients. van Bokhorst-De van der Schuer MA, et al. **Clin Nutr** 1998 Jun;17(3):107–11

Ex vivo interleukin (IL)-1 beta, IL-6, IL-12 and tumor necrosis factor-alpha responsiveness with monocytes from patients with head and neck carcinoma. Heimdal JH, et al. **Eur Arch Otorhinolaryngol** 1999;256(5):250–6

Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. van Hal NL, et al. **Int J Cancer** 1999 Sep 9;82(6):837–45

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Young MR, et al. **Int J Immunopharmacol** 1999 Apr;21(4):241–52 (35 ref.)

Reduced postoperative infections with an immune-enhancing nutritional supplement. Snyderman CH, et al. **Laryngoscope** 1999 Jun;109(6):915–21

Hodgkin's disease in a child with hyperimmunoglobulin E syndrome. Lin SJ, et al. **Pediatr Hematol Oncol** 1998 Sep-Oct;15(5):451–4

[Gastrointestinal cancer antigen and immunoglobulins G, A, M in patients with head cancer] Adamiak G, et al. **Otolaryngol Pol** 1998;52(6):655–60 (Eng. Abstr.) **(Pol)**

[The value of gastrointestinal antigens in the monitoring of patients with malignant head neoplasms] Adamiak G, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):69–71 (Eng. Abstr.) **(Pol)**

METABOLISM

Changes in head and neck tumor hypoxic fraction during split-course radiochemotherapy. Jund R, et al. **Ann Otol Rhinol Laryngol** 1999 Jan;108(1):73–8

Transforming growth factor beta receptors in verrucous and squamous cell carcinoma. Anderson M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug;125(8):849–54

Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Welters MJ, et al. **Br J Cancer** 1999 Jan;79(1):82–8

Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics. Fukuiwa T, et al. **Cancer** 1999 Feb 15;85(4):960–9

Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Knecht R, et al. **Cancer Res** 1999 Jun 15;59(12):2794–7

Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. Schlemmer HP, et al. **Cancer Res** 1999 May 15;59(10):2363–9

Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Chen Z, et al. **Clin Cancer Res** 1999 Jun;5(6):1369–79

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Fety R, et al. **Clin Cancer Res** 1998 Sep;4(9):2039–45

Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Franchi A, et al. **Clin Cancer Res** 1996 Oct;2(10):1801–8

Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Homma A, et al. **Clin Cancer Res** 1999 Apr;5(4):801–6

Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Kotelnikov VM, et al. **Clin Cancer Res** 1997 Jan;3(1):95–101

Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer. Los G, et al. **Clin Cancer Res** 1999 Jul; 5(7):1610–8

Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma. Muro-Cacho CA, et al. **Clin Cancer Res** 1999 Jun; 5(6):1243–8

Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Sauter ER, et al. **Clin Cancer Res** 1999 Apr;5(4):775–82

Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Sauter ER, et al. **Clin Cancer Res** 1995 Nov; 1(11):1407–12

Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Giatromanolaki A, et al. **Clin Exp Metastasis** 1998 Oct; 16(7):665–72

Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer. Jeannon JP, et al. **Clin Otolaryngol** 1998 Oct;23(5):420–4 (23 ref.)

Expression of retinoic acid receptor beta is associated with inhibition of keratinization in human head and neck squamous carcinoma cells. Zou CP, et al. **Differentiation** 1999 Jan;64(2):123–32

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Strojan P, et al. **Eur J Cancer** 1998 Jul; 34(8):1193–7

The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. de Bree R, et al. **Eur J Nucl Med** 1998 Nov;25(11):1562–5

Tissue oxygen distribution in head and neck cancer patients. Adam MF, et al. **Head Neck** 1999 Mar;21(2):146–53

Identification of sialyl Lewis-x in squamous cell carcinoma of the head and neck. Farmer RW, et al. **Head Neck** 1998 Dec;20(8):726–31

Reactive oxygen metabolites, antioxidants and head and neck cancer. Seidman MD, et al. **Head Neck** 1999 Aug; 21(5):467–79 (479 ref.)

p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Leung SY, et al. **Histopathology** 1998 Oct; 33(4):311–7

Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Reisser C, et al. **Int J Cancer** 1999 Jan 18;80(2):194–8

Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression. van Oijen MG, et al. **J Oral Pathol Med** 1998 Sep;27(8):367–75

p53 overexpression in oral mucosa in relation to smoking. van Oijen MG, et al. **J Pathol** 1999 Mar;187(4):469–74

[3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. Hammond JR, et al. **J Pharmacol Exp Ther** 1999 Mar; 288(3):1185–91

Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Eisma RJ, et al. **Laryngoscope** 1999 May;109(5):687–93

Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. Gabalski EC, et al. **Laryngoscope** 1998 Dec;108(12):1856–60

Nerve cell adhesion molecule expression in squamous cell carcinoma of the head and neck: a predictor of propensity toward perineural spread. McLaughlin RB Jr, et al. **Laryngoscope** 1999 May;109(5):821–6

Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma. Dorfman DM, et al. **Mod Pathol** 1998 Oct;11(10):989–94

Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Izzo JG, et al. **Oncogene** 1998 Nov 5;17(18):2313–22

Cervical lymph node involvement in head and neck cancer detectable as expression of a spliced transcript of type II keratin K5. McDonald LA, et al. **Oral Oncol** 1998 Jul; 34(4):276–83

[Oxygenation status of squamous cell carcinoma of the head and neck: comparison of primary tumors, their neck node metastases and normal tissue] Becker A, et al. **Strahlenther Onkol** 1998 Sep;174(9):484–6 (Eng. Abstr.) **(Ger)**

MORTALITY

p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Mineta H, et al. **Br J Cancer** 1998 Oct;78(8):1084–90

Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: results of a 6-year longitudinal study. De Boer MF, et al. **Cancer** 1998 Dec 15;83(12):2567–79

The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. van Bokhorst-de van der Schuer, et al. **Cancer** 1999 Aug 1;86(3):519–27

Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Lee DJ, et al. **Clin Cancer Res** 1997 Apr;3(4):501–5

Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Sauter ER, et al. **Clin Cancer Res** 1995 Nov; 1(11):1407–12

Improved survival in patients with head and neck cancer in the 1990s. Jones AS, et al. **Clin Otolaryngol** 1998 Aug; 23(4):319–25

Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. Berrino F, et al. **Eur J Cancer** 1998 Dec;34(14 Spec No):2154–61

Using TNM staging to predict survival in patients with squamous cell carcinoma of head & neck. Hall SF, et al. **Head Neck** 1999 Jan;21(1):30–8

Non-Hodgkin's lymphoma of the head and neck: a 30-year experience at the University of Florida. Nathu RM, et al. **Head Neck** 1999 May;21(3):247–54

The significance of DNA flow cytometry in predicting survival and delayed clinical manifestation of occult lymph node metastasis to the untreated neck in patients with oral squamous cell carcinoma. Hemmer J, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):405–10

Symptoms as an index of biologic behavior in head and neck cancer. Pugliano FA, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):380–6

Treatment of localized non-Hodgkin's lymphomas of the head and neck: focusing on cases of non-lethal midline granuloma. Sakata K, et al. **Radiat Oncol Investig** 1998; 6(4):161–9

[Loss of heterozygosity of 3p21 and 9p21 in head and neck squamous cell carcinomas and its prognostic implication] Matsuura K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 May;102(5):613–21 (Eng. Abstr.) **(Jpn)**

NURSING

Microvascular reconstruction of the head and neck after tumor ablation. Johnson PJ, et al. **AORN J** 1999 Jul; 70(1):30–3

PATHOLOGY

Fine needle aspiration cytology of a cervical lymph node lymphangioma in an adult. A case report. Bosch-Princep R, et al. **Acta Cytol** 1999 May-Jun;43(3):442–6

Fine needle aspiration biopsy of well-differentiated liposarcoma of the neck in a young female. A case report. Collins BT, et al. **Acta Cytol** 1999 May-Jun;43(3):452–6

Fine needle aspiration biopsy of a small round cell tumor exhibiting both neural and myogenic differentiation. A case report. Ravinsky E, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1320–4

Metastatic lymph-node clearance from head and neck epidermoid carcinomas following radiotherapy. Ohara K, et al. **Acta Oncol** 1999;38(2):261–6

Disease stage related in vitro responsiveness of peripheral blood T-lymphocytes in patients with head and neck carcinoma. Heimdal JH, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):887–91

Surgical excision margins: a pathologist's perspective. Batsakis JG. **Adv Anat Pathol** 1999 May;6(3):140–8 (35 ref.)

Carcinoma showing thymiclike differentiation (CASTLE tumor). Ahuja AT, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1225–8

Management of the clinically positive neck in organ preservation for advanced head and neck cancer. Dagum P, et al. **Am J Surg** 1998 Nov;176(5):448–52

Primary cervical malignant teratoma with a rib metastasis in an adult: five-year survival after surgery and chemotherapy. A case report with a review of the literature. Als C, et al. **Ann Oncol** 1998 Sep;9(9):1015–22 (51 ref.)

Papillary squamous cell carcinoma versus verrucous squamous cell carcinoma of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1999 Mar;108(3):318–22

Extramedullary solitary plasmacytoma of the head and neck. A clinicopathological study. Hotz MA, et al. **Ann Otol Rhinol Laryngol** 1999 May;108(5):495–500

Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma [see comments] Ollila DW, et al. **Ann Surg Oncol** 1999 Mar;6(2):150–4. Comment in: Ann Surg Oncol 1999 Mar;6(2):125–6.

The invasive front of carcinomas. The most important area for tumour prognosis? Bryne M, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4757–64 (63 ref.)

Ep-CAM--a marker for the detection of disseminated tumor cells in patients suffering from SCCHN. Chaubal S, et al. **Anticancer Res** 1999 May-Jun;19(3B):2237–42

The influence of differing dissection techniques on p53 as a possible indicator for local recurrences in carcinomas of the upper aerodigestive tract. Folz BJ, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2707–9

Using the TNM system to predict survival in squamous cell carcinoma of the head and neck. Hall SF, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4777–8

p53 mutations and p53, Waf-1, Bax and Bcl-2 expression in field cancerization of the head and neck. Lavieille JP, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4741–9

Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Mineta H, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4765–8

Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Takes RP, et al. **Anticancer Res** 1998 Nov-Dec; 18(6B):4793–800

Tpot and head and neck cancer: where are we now? Wilson GD. **Anticancer Res** 1998 Nov-Dec;18(6B):4801–5 (36 ref.)

Hypopigmented papules of the cheeks, neck, and shoulders. Vin-Christian K, et al. **Arch Dermatol** 1999 Apr; 135(4):463–4, 466–7

p53 immunolocalization in cell block preparations of squamous lesions of the neck: an adjunct to fine-needle aspiration diagnosis of malignancy. Khurana KK, et al. **Arch Pathol Lab Med** 1999 May;123(5):421–5

Syndecan-1 expression has prognostic significance in head and neck carcinoma. Anttonen A, et al. **Br J Cancer** 1999 Feb;79(3–4):558–64

Heterogeneity of squamous cell carcinomas of the head and neck in relation to clinicopathological variables. Mahmood JU, et al. **Br J Oral Maxillofac Surg** 1998 Dec;36(6):446–52

Differential diagnosis of lymph node lesions: a semiquantitative approach with colour Doppler ultrasound. Steinkamp HJ, et al. **Br J Radiol** 1998 Aug;71(848):828–33

Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Iro H, et al. **Cancer** 1998 Nov 15;83(10):2201–7

Nuchal-type fibroma: a clinicopathologic study of 52 cases. Michal M, et al. **Cancer** 1999 Jan 1;85(1):156–63

Morphology and function of human benign tumors and normal thyroid tissues maintained in severe combined immunodeficient mice. Fukuda K, et al. **Cancer Lett** 1998 Oct 23;132(1–2):153–8

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Sun SY, et al. **Cancer Res** 1999 May 15;59(10):2493–8

Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Drenning SD, et al. **Clin Cancer Res** 1998 Nov;4(11):2913–21

Cell kinetics of head and neck cancers. Kotelnikov VM, et al. **Clin Cancer Res** 1995 May;1(5):527–37

Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Myers JN, et al. **Clin Cancer Res** 1996 Jan;2(1):127–35

Immunohistochemical study of c-fos-positive lymphocytes infiltrated into human squamous cell carcinomas of the head and neck during radiation therapy and its clinical significance. Ogawa Y, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 1):2301–7

Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Oridate N, et al. **Clin Cancer Res** 1996 May;2(5):855–63

Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Wu Y, et al. **Clin Cancer Res** 1997 Nov;3(11):1915–21

Chest computerized tomography scanning in patients presenting with head and neck cancer. Houghton DJ, et al. **Clin Otolaryngol** 1998 Aug;23(4):348–50

Does a joint ultrasound guided cytology clinic optimize the cytological evaluation of head and neck masses? Robinson IA, et al. **Clin Radiol** 1999 May;54(5):312–6

Metastatic basal cell carcinoma to the lung. Berti JJ, et al. **Cutis** 1999 Mar;63(3):165–6 (12 ref.)

Fine needle cytology of palpable head and neck lesions: a comparison of sampling methods with and without suction. Allen SM, et al. **Cytopathology** 1999 Apr;10(2):97–106

Diagnosis of fibromatosis colli by fine needle aspiration (FNA) cytology. Pereira S, et al. **Cytopathology** 1999 Feb; 10(1):25–9

Aspiration cytology of a pleomorphic lipoma--a cautionary note. Verghese A, et al. **Cytopathology** 1999 Aug; 10(4):280–2 (4 ref.)

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105–10 (35 ref.)

Abdominal pain in a patient with melanoma. Datner EM, et al. **Dermatol Surg** 1998 Oct;24(10):1100–2 (19 ref.)

Fine-needle aspiration cytology and immunocytochemistry of soft-tissue tumors and osteo/chondrosarcomas of the head and neck. Skoog L, et al. **Diagn Cytopathol** 1999 Mar; 20(3):131–6

Head and neck mucosal melanoma: a 32-year review. Loree TR, et al. **Ear Nose Throat J** 1999 May;78(5):372–5

Minute invasive squamous cell carcinoma of the esophagus associated with head and neck cancer: a case report. Muto M, et al. **Endoscopy** 1999 May;31(4):S27–8

The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro. Nishino H, et al. **Eur Arch Otorhinolaryngol** 1998;255(9):468–72

Transition between solar keratosis and basal cell carcinoma. Shai A, et al. **Eur J Dermatol** 1999 Jan-Feb;9(1):35–8

Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Adams S, et al. **Eur J Nucl Med** 1998 Sep;25(9):1255–60

The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. de Bree R, et al. **Eur J Nucl Med** 1998 Nov;25(11):1562–5

Supraclavicular masses: results of a series of 309 cases biopsied by fine needle aspiration. Ellison E, et al. **Head Neck** 1999 May;21(3):239–46

Using TNM staging to predict survival in patients with squamous cell carcinoma of head & neck. Hall SF, et al. **Head Neck** 1999 Jan;21(1):30–8

Supraomohyoid neck dissection. Is it diagnostic or therapeutic? Kerrebijn JD, et al. **Head Neck** 1999 Jan; 21(1):39–42

Axillary nodal metastases in head and neck cancer. Koch WM. **Head Neck** 1999 May;21(3):269–72

Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Mendenhall WM, et al. **Head Neck** 1998 Dec; 20(8):739–44

Skin metastases from head and neck squamous cell carcinoma: incidence and impact. Pitman KT, et al. **Head Neck** 1999 Sep;21(6):560–5

Patterns of metastases to the upper jugular lymph nodes (the "submuscular recess"). Talmi YP, et al. **Head Neck** 1998 Dec;20(8):682–6

Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. Westra WH, et al. **Head Neck** 1998 Sep;20(6):515–21

Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Noda I, et al. **Int J Cancer** 1999 Jan 5;80(1):78–84

Involvement of cyclin D1-cdk5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model. Yin MB, et al. **Int J Cancer** 1999 Oct 29;83(3):341–8

Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. McLaughlin PJ, et al. **Int J Oncol** 1999 May;14(5):991–8

Cervical metastases of head and neck squamous cell carcinoma correlate with loss of heterozygosity on chromosome 16q. Wang X, et al. **Int J Oncol** 1999 Mar; 14(3):557–61

Aberrant second branchial cleft fistula. Gamble B, et al. **Int J Pediatr Otorhinolaryngol** 1998 Nov 15;46(1–2):103–7

Ewing's sarcoma of the head and neck in children. Vaccani JP, et al. **Int J Pediatr Otorhinolaryngol** 1999 May 25; 48(3):209–16

Skin cancer of the head and neck with incidental microscopic perineural invasion. McCord MW, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):591–5

Endothelial cell response to human head and neck squamous cell carcinomas involves downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and increased motility. Benefield J, et al. **Invasion Metastasis** 1997;17(4):210–20

The accuracy of fine-needle aspiration biopsy in the diagnosis of head and neck masses. Carroll CM, et al. **Ir J Med Sci** 1998 Jul-Sep;167(3):149–51

Extraparotid Warthin's tumor. Patterson JW, et al. **J Am Acad Dermatol** 1999 Mar;40(3):468–70

Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7). Pradier O, et al. **J Cancer Res Clin Oncol** 1999; 125(1):20–7

Lymphnode metastasis in head and neck squamous cells carcinoma: multivariate analysis of prognostic variables. Magnano M, et al. **J Exp Clin Cancer Res** 1999 Mar; 18(1):79–83

A parapharyngeal myxoid liposarcoma. Fagan JJ, et al. **J Laryngol Otol** 1999 Feb;113(2):179–82 (14 ref.)

Dendritic cell differentiation pathways of CD34+ cells from the peripheral blood of head and neck cancer patients. Lathers DM, et al. **J Leukoc Biol** 1999 May;65(5):623–8

Re: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma [letter; comment] Harari PM. **J Natl Cancer Inst** 1998 Oct 21;90(20):1571. Comment on: J Natl Cancer Inst 1998 Jul 1;90(13):972–7.

Primary melanoma [letter; comment] Savitz MH. **J Neurosurg** 1999 Mar;90(3):609–10. Comment on: J Neurosurg 1998 Oct;89(4):659–66.

Correlative 201Tl SPECT, MRI and ex vivo 201Tl uptake in detecting and characterizing cervical lymphadenopathy in head and neck squamous cell carcinoma. Valdés Olmos RA, et al. **J Nucl Med** 1999 Sep;40(9):1414–9

The value of a routine bone scan in a metastatic survey. Brown DH, et al. **J Otolaryngol** 1998 Aug;27(4):187–9

Lymph node sampling in localized neuroblastoma: a Pediatric Oncology Group study. Contador MP, et al. **J Pediatr Surg** 1999 Jun;34(6):967–74

Relationship of human papillomavirus to Schneiderian papillomas. Weiner JS, et al. **Laryngoscope** 1999 Jan; 109(1):21–6

Head and neck teratoma in a neonate [letter] Parise O Jr, et al. **Med Pediatr Oncol** 1999 Mar;32(3):232–3

Trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas. Boerman RH, et al. **Neurology** 1999 Jul 13;53(1):213–6

Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin- or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells. Zhang L, et al. **Nutr Cancer** 1999;33(2):165–73

Rhabdomyosarcoma: an overview. Dagher R, et al. **Oncologist** 1999;4(1):34–44 (80 ref.)

Cervical lymph node involvement in head and neck cancer detectable as expression of a spliced transcript of type II keratin K5. McDonald LA, et al. **Oral Oncol** 1998 Jul; 34(4):276–83

Increased number of proliferating cells in oral epithelium from smokers and ex-smokers. van Oijen MG, et al. **Oral Oncol** 1998 Jul;34(4):297–303

Treatment of the neck in melanoma. Byers RM. **Otolaryngol Clin North Am** 1998 Oct;31(5):833–9

Histologic evaluation of neck dissection specimens. Gillies EM, et al. **Otolaryngol Clin North Am** 1998 Oct; 31(5):759–71 (54 ref.)

Fine–needle aspiration biopsy: is anesthesia necessary? Cannon CR, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):458–9

Simple, new device for needle aspiration biopsy. Cannon CR, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):691–4

Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. Prehn RB, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):628–33

Symptoms as an index of biologic behavior in head and neck cancer. Pugliano FA, et al.
Otolaryngol Head Neck Surg 1999 Mar;120(3):380–6

Role of screening chest computed tomography in patients with advanced head and neck cancer. Tan L, et al.
Otolaryngol Head Neck Surg 1999 May;120(5):689–92

Inhibition of cell proliferation in head and neck squamous cell carcinoma cell lines with antisense cyclin D1. Wang MB, et al. **Otolaryngol Head Neck Surg** 1998 Dec; 119(6):593–9

Isolated mucoepidermoid carcinoma in the neck. Wani MK, et al. **Otolaryngol Head Neck Surg** 1998 Oct;119(4):398–9

Basaloid squamous carcinoma: a clinical comparison of two histologic types with poorly differentiated squamous cell carcinoma. Winzenburg SM, et al.
Otolaryngol Head Neck Surg 1998 Nov;119(5):471–5

Endovascular papillary angioendothelioma (Dabska tumor) [letter; comment] Fukunaga M. **Pathol Int** 1998 Oct; 48(10):840–1. Comment on: Pathol Int 1998 Feb;48(2):164–7.

A 10–year–old boy, HIV positive, develops progressive weakness [clinical conference] George T, et al.
Pediatr Neurosurg 1999 Apr;30(4):211–7

The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Begg AC, et al.
Radiother Oncol 1999 Jan;50(1):13–23

Midline posterior cervical cystic hygroma. Gidvani VK, et al. **South Med J** 1999 Mar;92(3):340–3

Malignant granular cell tumor at the retrotracheal space. Yang SW, et al. **Yonsei Med J** 1999 Feb;40(1):76–9

[Prognostic factors of cervical lymph metastases from squamous cell carcinomas the head and neck] Li X, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Aug; 11(8):339–42 (Eng. Abstr.) **(Chi)**

[Atypical involvement of undifferentiated carcinomas of the nasopharyngeal type. Apropos of 3 cases] Le Roy A, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Nov; 115(5):288–92 (Eng. Abstr.) **(Fre)**

[Cervical lymphangioma in adults. Description of 2 cases] Muñoz Herrera A, et al.
Ann Otolaryngol Chir Cervicofac 1998 Nov;115(5):299–302 (21 ref.) (Eng. Abstr.) **(Fre)**

[Clear cell sarcoma of soft tissues. Clinico–pathological and ultrastructural analysis of a case in the head–neck region and a literature review] Bisceglia M, et al. **Pathologica** 1998 Aug;90(4):391–6 (40 ref.) (Eng. Abstr.) **(Ita)**

[Report and World Congress on Head and Neck Oncology. Madrid, November 29–December 3, 1998] Namysłowski G, et al. **Otolaryngol Pol** 1999;53(3):367 **(Pol)**

[Rhabdomyosarcoma of the neck in adults] Fernández Pérez A, et al. **Acta Otorrinolaringol Esp** 1999 Apr;50(3):211–4 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The EXIT procedure facilitates delivery of an infant with a pretracheal teratoma. Shih GH, et al. **Anesthesiology** 1998 Dec;89(6):1573–5

Proceedings of the 3rd European Workshop on Basic Biology of Head and Neck Cancer: Finding Consensus on the Use of Prognostic Factors and Predictive Markers. Oslo, Norway, 28–31 August 1997. **Anticancer Res** 1998 Nov–Dec;18(6B):4727–806 (0 ref.)

Pharyngeal transport dysfunction consequent to an organ–sparing protocol. Kotz T, et al.
Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):410–3

A prospective, longitudinal study of pain in head and neck cancer patients. Chaplin JM, et al. **Head Neck** 1999 Sep; 21(6):531–7

Quality of life and oral function following radiotherapy for head and neck cancer. Epstein JB, et al. **Head Neck** 1999 Jan;21(1):1–11

Structural mobility in deglutition after single modality treatment of head and neck carcinomas with radiotherapy. Kendall KA, et al. **Head Neck** 1998 Dec;20(8):720–5

Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Huguenin PU, et al.
Int J Radiat Oncol Biol Phys 1999 Aug 1;45(1):47–52

Apoptosis, matters of life and death. Saunders MW, et al. **J Laryngol Otol** 1998 Sep;112(9):822–6 (33 ref.)

Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Chang J, et al.
Plast Reconstr Surg 1999 Jan;103(1):1–9; discussion 10

Opioid responsiveness in patients with advanced head and neck cancer. Mercadante S. **Support Care Cancer** 1998 Sep; 6(5):482–5

PREVENTION & CONTROL

Chemoprevention with interferon alfa and 13–cis retinoic acid in the adjunctive treatment of head and neck cancer. Büntzel J, et al. **Auris Nasus Larynx** 1998 Dec;25(4):413–8

Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Ki Hong W, et al.
Clin Cancer Res 1995 Jul;1(7):677–86 (64 ref.)

Regarding Peters, IJROBP 1998;40:527–528, and Lundahl, Foote, Bonner, et al., IJROBP 1998;40:529–534 [letter; comment] Moyses HM, et al.
Int J Radiat Oncol Biol Phys 1999 Mar 15;43(5):1171. Comment on: Int J Radiat Oncol Biol Phys 1998 Feb 1;40(3):527–8. Comment on: Int J Radiat Oncol Biol Phys 1998 Feb 1;40(3):529–34.

Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy [see comments] Mao L, et al. **J Natl Cancer Inst** 1998 Oct 21;90(20):1545–51 . Comment in: J Natl Cancer Inst 1998 Oct 21;90(20):1500–1.

Chemoprevention of head and neck and lung (pre)cancer. de Vries N, et al. **Recent Results Cancer Res** 1999;151:13–25 (47 ref.)

Chemoprevention in head and neck cancer: basic science and clinical application. Geyer C, et al. **Semin Radiat Oncol** 1998 Oct;8(4):292–301 (60 ref.)

PSYCHOLOGY

A prospective multicentre study in Sweden and Norway of mental distress and psychiatric morbidity in head and neck cancer patients. Hammerlid E, et al. **Br J Cancer** 1999 May; 80(5–6):766–74

Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: results of a 6–year longitudinal study. De Boer MF, et al. **Cancer** 1998 Dec 15;83(12):2567–79

A new short practical quality of life questionnaire for use in head and neck oncology outpatient clinics. Young PE, et al. **Clin Otolaryngol** 1998 Dec;23(6):528–32

The hidden experience of radiotherapy to the head and neck: a qualitative study of patients after completion of treatment. Wells M. **J Adv Nurs** 1998 Oct;28(4):840–8

Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–H&N35. Bjordal K, et al. **J Clin Oncol** 1999 Mar;17(3):1008–19

Breaking the bad news of cancer: the patient's perspective. Kim MK, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1064–7

Physical and psychosocial correlates of head and neck cancer: a review of the literature. De Boer MF, et al.
Otolaryngol Head Neck Surg 1999 Mar;120(3):427–36 (81 ref.)

Quality–of–life effects of psychosocial intervention in patients with head and neck cancer. Hammerlid E, et al.
Otolaryngol Head Neck Surg 1999 Apr;120(4):507–16

Correlates of health–related quality of life in upper aerodigestive tract cancer patients. Allison PJ, et al.
Qual Life Res 1998 Dec;7(8):713–22

Temporal assessment of quality of life of head and neck cancer patients receiving radical radiotherapy. Chawla S, et al. **Qual Life Res** 1999;8(1–2):73–8

[Smoking behavior and cognition for smoking cessation after diagnosis of head and neck cancer or stomach cancer] Hasuo S, et al. **Nippon Koshu Eisei Zasshi** 1998 Aug; 45(8):732–9 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Imaging quiz case 1. Solitary plasmacytoma of the sternum with soft tissue extension. Patel N, et al.
Arch Otolaryngol Head Neck Surg 1999 Mar;125(3):348, 350–1

Integrating radiological criteria into the classification of cervical lymph node disease [comment] Robbins KT.
Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):385–7 . Comment on: Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):388–96.

An imaging–based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications [see comments] Som PM, et al.
Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):388–96 . Comment in: Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):385–7.

The use of preoperative fistulography in patients with a second branchial cleft anomaly. Celis I, et al.
Eur Radiol 1998;8(7):1179–80

Ewing's sarcoma of the head and neck in children. Vaccani JP, et al. **Int J Pediatr Otorhinolaryngol** 1999 May 25; 48(3):209–16

Radiological staging of the chest and abdomen in head and neck squamous cell carcinoma--are computed tomography and ultrasound necessary? Nilssen EL, et al.
J Laryngol Otol 1999 Feb;113(2):152–4

18FDG–PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Paulus P, et al. **Laryngoscope** 1998 Oct;108(10):1578–83

Fourth branchial arch sinus: clinical presentation, diagnostic workup, and surgical treatment. Yang C, et al.
Laryngoscope 1999 Mar;109(3):442–6

Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. Prehn RB, et al. **Otolaryngol Head Neck Surg** 1998 Dec;119(6):628–33

Plane polarized x–ray fluorescence system for the in vivo measurement of platinum in head and neck tumours. Ali PA, et al. **Phys Med Biol** 1998 Aug;43(8):2337–45

Radiologic evaluation of neck metastases: the otolaryngologist's perspective. van den Brekel MW, et al.
Semin Ultrasound CT MR 1999 Jun;20(3):162–74 (93 ref.)

[Spiral CT of the head–neck area: the advantages of the early arterial phase in the detection of squamous–cell carcinomas] Conrad R, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jul;171(1):15–9 (Eng. Abstr.) **(Ger)**

[Aneurysm of the vertebral artery as a tumor of the neck] Bartnik W, et al. **Otolaryngol Pol** 1998;52(4):491–4 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Correlation of fine needle aspiration biopsy and fluoride–18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Collins BT, et al. **Acta Cytol** 1998 Nov–Dec;42(6):1325–9

The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Manolidis S, et al.
Acta Otolaryngol Suppl (Stockh) 1998;534:1–11

Monitoring of response to radiotherapy with fluorine–18 deoxyglucose PET of head and neck squamous cell carcinomas. Sakamoto H, et al.
Acta Otolaryngol Suppl (Stockh) 1998;538:254–60

Clinical utility of positron emission tomography with 18F–fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck [see comments] Fischbein NJ, et al.
AJNR Am J Neuroradiol 1998 Aug;19(7):1189–96. Comment in: AJNR Am J Neuroradiol 1998 Aug;19(7):1197.

PET and recurrent squamous cell carcinoma of the head and neck: a surgeon's view [see comments] Goodwin WJ.
AJNR Am J Neuroradiol 1998 Aug;19(7):1197. Comment in: AJNR Am J Neuroradiol 1998 Aug;19(7):1189–96.

The role of positron emission tomography in occult primary head and neck cancers [see comments] Safa AA, et al.
Cancer J Sci Am 1999 Jul–Aug;5(4):214–8. Comment in: Cancer J Sci Am 1999 Jul–Aug;5(4):205–7.

Positron emission tomography in cancer patient management [comment] Wahl RL. **Cancer J Sci Am** 1999 Jul–Aug; 5(4):205–7. Comment on: Cancer J Sci Am 1999 Jul–Aug;5(4):214–7.

Radioimmunoscintigraphy and biodistribution of technetium–99m–labeled monoclonal antibody U36 in patients with head and neck cancer. de Bree R, et al.
Clin Cancer Res 1995 Jun;1(6):591–8

Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer. de Bree R, et al. **Clin Cancer Res** 1995 Mar;1(3):277–86

Fluorine–18 fluorodeoxyglucose imaging using dual–head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Pai M, et al. **Clin Nucl Med** 1999 Jul;24(7):495–500

Role of PET FDG in the management of head and neck squamous cell cancer. Wong WL, et al.
Clin Oncol (R Coll Radiol) 1998;10(6):361–6 (41 ref.)

The predictive value of lymphoscintigraphy for nodal metastases of cutaneous melanoma. Stephens PL, et al.
Conn Med 1999 Jul;63(7):387–90

Preoperative assessment of cervical lymph nodes in head and neck cancer with fluorine–18 fluorodeoxyglucose using a dual–head coincidence camera: a pilot study. Stokkel MP, et al. **Eur J Nucl Med** 1999 May;26(5):499–503

Visualisation of a paraganglioma by technetium–99m–sestamibi scintigraphy. Piga M, et al.
J Endocrinol Invest 1999 Apr;22(4):296–300

Nuclear medicine in head and neck oncology: reality and perspectives. Chisin R. **J Nucl Med** 1999 Jan;40(1):91–5 (43 ref.)

FDG PET to evaluate combined intra–arterial chemotherapy and radiotherapy of head and neck neoplasms. Kitagawa Y, et al. **J Nucl Med** 1999 Jul;40(7):1132–7

Lymphoscintigraphy in tumors of the head and neck using double tracer technique. Klutmann S, et al.
J Nucl Med 1999 May;40(5):776–82

Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. Uematsu H, et al.
J Nucl Med 1998 Dec;39(12):2121–7

Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2–18F–fluoro–2–deoxy–D–glucose positron emission tomography. Farber LA, et al. **Laryngoscope** 1999 Jun; 109(6):970–5

Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Hanasono MM, et al. **Laryngoscope** 1999 Jun;109(6):880–5

Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? Leitha T, et al. **Nucl Med Biol** 1998 Aug;25(6):539–41

67Ga whole–body scintigraphy in the evaluation of head and neck squamous cell carcinoma. Murata Y, et al.
Nucl Med Commun 1999 Jul;20(7):599–607

111In–pentetreotide scintigraphy is superior to 123I–MIBG scintigraphy in the diagnosis and location of chemodectoma. Muros MA, et al. **Nucl Med Commun** 1998 Aug;19(8):735–42

201Tl imaging for differentiating between malignant and benign neck masses. Yiğitbaşi OG, et al.
Nucl Med Commun 1998 Jun;19(6):555–60

THE PAPER AND INK USED IN THE ORIGINAL PUBLICATION MAY AFFECT THE QUALITY OF THE MICROFORM EDITION.

The role of FDG PET in the clinical management of head and neck cancer. Stokkel MP, et al. **Oral Oncol** 1998 Nov; 34(6):466–71 (63 ref.)

Radioimmunoguided surgery in squamous cell carcinoma [letter] Argenzio V, et al. **Plast Reconstr Surg** 1999 Feb; 103(2):749–51

Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. AAssar OS, et al. **Radiology** 1999 Jan;210(1):177–81

Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Anzai Y, et al. **Radiology** 1999 Jul; 212(1):285–90

RADIOTHERAPY

Benefits of accelerated hyperfractionation for head and neck cancer. Cummings BJ. **Acta Oncol** 1999;38(2):131–6 (24 ref.)

The CHART regimen and morbidity. Dische S, et al. **Acta Oncol** 1999;38(2):147–52 (12 ref.)

How to optimize therapeutic ratio in brachytherapy of head and neck squamous cell carcinoma? Mazeron JJ, et al. **Acta Oncol** 1998;37(6):583–91

Evaluation of delivered dose changes during radiation therapy. Miszczyk L, et al. **Acta Oncol** 1999;38(2):197–201

Metastatic lymph-node clearance from head and neck epidermoid carcinomas following radiotherapy. Ohara K, et al. **Acta Oncol** 1999;38(2):261–6

Aspects on the optimal photon beam energy for radiation therapy. Söderström S, et al. **Acta Oncol** 1999;38(2):179–87

Characterization and radiosensitivity of fibroblasts derived from squamous cell carcinomas of the head and neck, and the surrounding oral mucosa. Stausbøl-Grøn B, et al. **Acta Oncol** 1998;37(7–8):697–700

The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation. Trott KR. **Acta Oncol** 1999;38(2):153–7 (28 ref.)

Pitfalls in estimating the influence of overall treatment time on local tumor control. Tucker SL. **Acta Oncol** 1999; 38(2):171–8 (49 ref.)

Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas. Sakamoto H, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:254–60

Meningioma after radiotherapy for Hodgkin's disease. Deutsch M, et al. **Am J Clin Oncol** 1999 Aug;22(4):361–3

Sequential chemotherapy and radiotherapy for organ preservation in advanced resectable nonlaryngeal head and neck cancer. Khan A, et al. **Am J Clin Oncol** 1999 Aug; 22(4):403–7

Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Spencer SA, et al. **Am J Clin Oncol** 1999 Feb;22(1):1–5

Radiotherapy followed by neck dissection for small head and neck cancers with advanced cervical metastases. Wang SJ, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):128–31

Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non tonsillar lymphomas. (Hellenic co-Operative Oncology Group). Economopoulos T, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4655–60

p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Giatromanolaki A, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4685–92

Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Koukourakis MI, et al. **Anticancer Res** 1999 May-Jun;19(3B):2305–9

Interstitial high dose rate brachytherapy in locally progressive or recurrent head and neck cancer. Krüll A, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2695–7

Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Wagner W, et al. **Anticancer Res** 1999 Jan-Feb; 19(1B):799–803

The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. Björk-Eriksson T, et al. **Br J Cancer** 1999 Jul;80(9):1400–4

Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Shafford EA, et al. **Br J Cancer** 1999 May;80(5–6):808–14

In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. Stausbøl-Grøn B, et al. **Br J Cancer** 1999 Mar; 79(7–8):1074–84

Conventional vs accelerated fractionation in head and neck cancer. Dobrowsky W, et al. **Br J Cancer Suppl** 1996 Jul; 27:S279–81

Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. Dubec JJ, et al. **Br J Radiol** 1998 Aug;71(848):872–5

Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. Mendenhall WM, et al. **Cancer Invest** 1998;16(8):594–603 (68 ref.)

The single-isocentre treatment of head and neck cancer: time gain using MLC and automatic set-up. De Meerleer GO, et al. **Cancer Radiother** 1999 May-Jun;3(3):235–41

Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas. Corvó R, et al. **Clin Cancer Res** 1997 Nov; 3(11):1993–7

bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Gallo O, et al. **Clin Cancer Res** 1996 Feb; 2(2):261–7

Immunohistochemical study of c-fos-positive lymphocytes infiltrated into human squamous cell carcinomas of the head and neck during radiation therapy and its clinical significance. Ogawa Y, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 1):2301–7

Expression of fas (CD95/APO-1) antigen induced by radiation therapy for diffuse B-cell lymphoma: immunohistochemical study. Ogawa Y, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2211–6

Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Lankester KJ, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):208–10

Brachial plexus neuropathy following mantle radiotherapy. Wadd NJ, et al. **Clin Oncol (R Coll Radiol)** 1998; 10(6):399–400

Determination of tumor kinetics: strategies for the delivery of radiotherapy and chemotherapy. Ritter MA. **Curr Opin Oncol** 1999 May;11(3):177–82 (71 ref.)

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105–10 (35 ref.)

Intensity-modulated radiotherapy: first results with this new technology on neoplasms of the head and neck. Kuppersmith RB, et al. **Ear Nose Throat J** 1999 Apr; 78(4):238, 241–6, 248 passim

Comments on Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma, Lartigau et al., Eur J Cancer 1998, 34, 856–861 [letter; comment] Stadler P. **Eur J Cancer** 1999 Jan; 35(1):161–2. Comment on: Eur J Cancer 1998 May;34(6):856–61.

Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Colletier PJ, et al. **Head Neck** 1998 Dec;20(8):674–81

Chemotherapy as a part of each treatment fraction in a twice-a-day hyperfractionated schedule: a new chemoradiotherapy approach for advanced head and neck cancer. de Serdio JL, et al. **Head Neck** 1998 Sep; 20(6):489–96

Quality of life and oral function following radiotherapy for head and neck cancer. Epstein JB, et al. **Head Neck** 1999 Jan;21(1):1–11

A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Harrison LB, et al. **Head Neck** 1998 Sep;20(6):497–503

Structural mobility in deglutition after single modality treatment of head and neck carcinomas with radiotherapy. Kendall KA, et al. **Head Neck** 1998 Dec;20(8):720–5

Postoperative radiation therapy for primary vs. recurrent squamous cell carcinoma of the head and neck: results of a comparative analysis. Regine WF, et al. **Head Neck** 1999 Sep;21(6):554–9

Brachytherapy for recurrent head and neck cancer. Senan S, et al. **Hematol Oncol Clin North Am** 1999 Jun; 13(3):531–42 (39 ref.)

Brachytherapy in cancer of the head and neck. Vikram B. **Hematol Oncol Clin North Am** 1999 Jun;13(3):525–9, vi

A clinical study to assess chlorpromazine as hypoxic cell sensitizer in head & neck cancer treated with conventional radiation. Huilgol NG, et al. **Indian J Cancer** 1998 Sep; 35(3):97–100

Continuous hyperfractionated accelerated radiotherapy in advanced head and neck malignancies. Mali HR, et al. **Indian J Cancer** 1998 Mar;35(1):19–26

The effects of radiation on craniofacial skeletal growth: a quantitative study. Denys D, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):7–13

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Rosier JF, et al. **Int J Radiat Biol** 1999 Feb;75(2):245–51

Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Butler EB, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):21–32

Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer. Cottrill CP, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):807–10

Feasibility and tolerance of pulsed dose rate interstitial brachytherapy. de Pree C, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):971–6

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Dobrowsky W, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):803–6

Irradiation induces increase of adhesion molecules and accumulation of beta2-integrin-expressing cells in humans. Handschel J, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):475–81

Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Huguenin PU, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):47–52

Initial clinical experience with a video-based patient positioning system. Johnson LS, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):205–13

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Lee DJ, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):811–5

Volumetric visualization of head and neck CT data for treatment planning. Lee JS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):693–703

Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Lee WR, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):1069–75

Quality assurance of serial tomotherapy for head and neck patient treatments. Low DA, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):681–92

Intraoperative electron beam radiotherapy for previously irradiated advanced head and neck malignancies. Nag S, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):1085–9

A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Nicolatou O, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):551–6

The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. Rode M, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):373–8

Chemotherapy alternated with radiotherapy in the treatment of advanced head and neck carcinoma: predictive factors of outcome. Sanguineti G, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):139–47

Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Stadler P, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 1;44(4):749–54

An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Tishler RB, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1001–8

Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI) [published erratum appears in Int J Radiat Oncol Biol Phys 1998 Dec 1;42(5):1181-2] Trotti A, et al. **Int J Radiat Oncol Biol Phys** 1998 Sep 1;42(2):257–61

A non-invasive immobilization system and related quality assurance for dynamic intensity modulated radiation therapy of intracranial and head and neck disease. Tsai JS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15; 43(2):455–67

The hidden experience of radiotherapy to the head and neck: a qualitative study of patients after completion of treatment. Wells M. **J Adv Nurs** 1998 Oct;28(4):840–8

Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. De Crevoisier R, et al. **J Clin Oncol** 1998 Nov;16(11):3556–62

Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. Haraf DJ, et al. **J Clin Oncol** 1999 Feb;17(2):638–44

Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. List MA, et al. **J Clin Oncol** 1999 Mar;17(3):1020–8

Endoscopic ultrasound-guided brachytherapy of head and neck tumours. A new procedure for controlled application. Maier W, et al. **J Laryngol Otol** 1999 Jan;113(1):41–8

Nasopharyngeal cancer with neck recurrence at 8 years and a lung metastasis at 15 years after the first definitive radiotherapy: a case report. Nozaki M, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):702–4

National Cancer Center has started proton therapy [news] Ogino T. **Jpn J Clin Oncol** 1999 Mar;29(3):179

Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Farber LA, et al. **Laryngoscope** 1999 Jun; 109(6):970–5

Spinal cord dose is higher than expected in head and neck radiation. Allison R, et al. **Med Dosim** 1999 Summer; 24(2):135–9

Technical management of a pregnant patient undergoing radiation therapy to the head and neck. Podgorsak MB, et al. **Med Dosim** 1999 Summer;24(2):121–8

Clinical considerations in the use of missing tissue compensators for head and neck cases. Sharma SC, et al. **Med Dosim** 1998 Winter;23(4):267–70

Dosimetric comparison of centered and off-centered posterior neck electron fields. Yorke ED, et al. **Med Dosim** 1998 Winter;23(4):284–7

Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Raney RB, et al. **Med Pediatr Oncol** 1999 Oct;33(4):362–71

Combined use of transverse and scout computed tomography scans to localize radioactive seeds in an interstitial brachytherapy implant. Yue N, et al. **Med Phys** 1999 Apr;

26(4):502–5
Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy. Mücke R, et al. **Mycoses** 1998 Nov;41(9–10):421–3
Treatment of head and neck cancer [letter; comment] Evans RA. **N Engl J Med** 1998 Oct 29;339(18):1330; discussion 1331. Comment on: N Engl J Med 1998 Jun 18;338(25):1798–804.
Treatment of head and neck cancer [letter; comment] Rescigno J, et al. **N Engl J Med** 1998 Oct 29;339(18):1330; discussion 1331. Comment on: N Engl J Med 1998 Jun 18;338(25):1798–804.
Treatment of head and neck cancer [letter; comment] Tobias JS. **N Engl J Med** 1998 Oct 29;339(18):1330–1. Comment on: N Engl J Med 1998 Jun 18;338(25):1798–804.
Head and neck cancer: altered fractionation schedules. Saunders MI. **Oncologist** 1999;4(1):11–6 (28 ref.)
The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Mascarin M, et al. **Oral Oncol** 1999 Mar;35(2):203–8
Elective irradiation of the N0 neck in squamous cell carcinoma of the upper aerodigestive tract. Shasha D, et al. **Otolaryngol Clin North Am** 1998 Oct;31(5):803–13 (48 ref.)
Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Tisch M, et al. **Otolaryngol Head Neck Surg** 1998 Oct;119(4):412–7
Temporal assessment of quality of life of head and neck cancer patients receiving radical radiotherapy. Chawla S, et al. **Qual Life Res** 1999;8(1–2):73–8
Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Smith BD, et al. **Radiat Oncol Investig** 1999; 7(3):125–44 (134 ref.)
Altered fractionation in radiotherapy for head and neck cancer: too early to close the race and announce the winner? [editorial; comment] Bentzen SM, et al. **Radiother Oncol** 1999 May;51(2):105–7. Comment on: Radiother Oncol 1999 May;51(2):113–21.
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Bernier J, et al. **Radiother Oncol** 1998 Aug;48(2):123–33
Three-dimensional dosimetry using polymer gel and magnetic resonance imaging applied to the verification of conformal radiation therapy in head-and-neck cancer. De Deene Y, et al. **Radiother Oncol** 1998 Sep;48(3):283–91
Altered fractionation: limited by mucosal reactions? Kaanders JH, et al. **Radiother Oncol** 1999 Mar;50(3):247–60 (89 ref.)
Overall treatment time and the conventional arm of the CHART trial in the radiotherapy of head and neck cancer. Robertson G, et al. **Radiother Oncol** 1999 Jan;50(1):25–8
The effect of independent collimator misalignment on the dosimetry of abutted half-beam blocked fields for the treatment of head and neck cancer. Rosenthal DI, et al. **Radiother Oncol** 1998 Dec;49(3):273–8
Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Serin M, et al. **Radiother Oncol** 1999 Jan;50(1):103–6
The potential benefit from individualised radiotherapy scheduling for head and neck tumours on the basis of both histological grade and kinetics. Slevin NJ, et al. **Radiother Oncol** 1999 May;51(2):109–11
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Stadler P, et al. **Radiother Oncol** 1998 Aug;48(2):157–64
Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Stausbøl-Grøn B, et al. **Radiother Oncol** 1999 Jan; 50(1):47–55
Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials [see comments] Stuschke M, et al. **Radiother Oncol** 1999 May;51(2):113–21. Comment in: Radiother Oncol 1999 May;51(2):105–7.
Chemoradiotherapy with carboplatin in continuous infusion in the locoregional control of advanced head and neck cancer. Marmiroli L, et al. **Rays** 1998 Jul-Sep;23(3):549–54 **(Eng, Ita)**
Altered fractionation trials in head and neck cancer. Ang KK. **Semin Radiat Oncol** 1998 Oct;8(4):230–6
Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Chougule PB, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):58–63
Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Dowell JE, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):97–101
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Flood W, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):64–9
The role of brachytherapy in head and neck cancer. Shasha D, et al. **Semin Radiat Oncol** 1998 Oct;8(4):270–81 (80 ref.)
Toxicity antagonists in head and neck cancer. Trotti A. **Semin Radiat Oncol** 1998 Oct;8(4):282–91 (83 ref.)
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Vokes EE, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):70–6
Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Wanebo HJ, et al. **Semin Radiat Oncol** 1999 Apr;9(2 Suppl 1):77–84
The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Frommhold H, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:31–4
Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. Jereczek-Fossa B, et al. **Strahlenther Onkol** 1998 Sep;174(9):457–61
Status report of the NAC particle therapy programme. Jones DT, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:30–2
Results of fast neutron therapy of adenoid cystic carcinoma of the salivary glands. Pötter R, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:65–8
Target localization and treatment verification for intensity modulated conformal radiation therapy of the head and neck region. The AZ-VUB experience. Akademisch Ziekenhuis-Vrije Universiteit Brussel. Verellen D, et al. **Strahlenther Onkol** 1998 Oct;174 Suppl 2:19–27
Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer [see comments] Bensadoun RJ, et al. **Support Care Cancer** 1999 Jul;7(4):244–52. Comment in: Support Care Cancer 1999 Jul;7(4):217–8.
[Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers] Horiot JC. **Bull Acad Natl Med** 1998;182(6):1247–60; discussion 1261 (Eng. Abstr.) **(Fre)**
[Chemoradiotherapy of carcinomas of the upper aerodigestive tract] Bourhis J, et al. **Cancer Radiother** 1998 Dec;2(6):679–88 (70 ref.) (Eng. Abstr.) **(Fre)**
[Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer] Grötz KA, et al. **Strahlenther Onkol** 1999 Aug;175(8):397–403; discussion 404 (Eng. Abstr.) **(Ger)**
[Simultaneous radiochemotherapy with carboplatin in patients with inoperable advanced stage III and IV head and neck tumors] Mücke R, et al. **Strahlenther Onkol** 1999 May;175(5):213–7 (Eng. Abstr.) **(Ger)**
[A combination of low-dose carboplatin (CBDCA) and radiation therapy in head and neck cancer patients—response and hematologenic toxicity] Watanabe N, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(1):101–6 (Eng. Abstr.) **(Jpn)**
[Efficiency evaluation of radiotherapy of recurrences after surgery in head and neck cancer] Zajusz A, et al. **Otolaryngol Pol** 1998;52(3):281–6 (Eng. Abstr.) **(Pol)**
[Stomatologic aspects of radiotherapy of head and neck tumors] Tahmiščija H, et al. **Med Arh** 1998;52(2):97–100 (Eng. Abstr.) **(Ser)**
[Current results of the treatment of cervical metastatic lymph nodes by concurrent hyperfractionation of carboplatin and irradiation] de Serdio JL, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):554–60 (49 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

Indications for the vastus lateralis flap in oral and maxillofacial surgery. Wolff KD. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):358–64
The effect of an oral prosthesis on the quality of life for head and neck cancer patients. Moroi HH, et al. **J Oral Rehabil** 1999 Apr;26(4):265–73
Physical and psychosocial correlates of head and neck cancer: a review of the literature. De Boer MF, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):427–36 (81 ref.)
Quality-of-life effects of psychosocial intervention in patients with head and neck cancer. Hammerlid E, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):507–16

SECONDARY

Testicular carcinoma metastatic to the neck. Lee JT, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):325–9
Delayed metastases in skin cancer of the head and neck: the case of the "known primary". Talmi YP, et al. **Ann Plast Surg** 1999 Mar;42(3):289–92
Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Greven KM, et al. **Cancer** 1999 Jul 1;86(1):114–8
Supraclavicular masses: results of a series of 309 cases biopsied by fine needle aspiration. Ellison E, et al. **Head Neck** 1999 May;21(3):239–46
Cutaneous metastasis presenting as facial lymphedema. Jang KA, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):637–8
The significance of DNA flow cytometry in predicting survival and delayed clinical manifestation of occult lymph node metastasis to the untreated neck in patients with oral squamous cell carcinoma. Hemmer J, et al. **J Craniomaxillofac Surg** 1998 Dec;26(6):405–10
Functional neck dissection: cure and functional results. Güney E, et al. **J Laryngol Otol** 1998 Dec;112(12):1176–8
Vascularization of reactively enlarged lymph nodes analyzed by color duplex sonography. Schroeder RJ, et al. **J Oral Maxillofac Surg** 1999 Sep;57(9):1090–5
Nasopharyngeal cancer with neck recurrence at 8 years and a lung metastasis at 15 years after the first definitive radiotherapy: a case report. Nozaki M, et al. **Jpn J Clin Oncol** 1998 Nov;28(11):702–4
Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Weisberger EC, et al. **Laryngoscope** 1999 Aug;109(8):1241–4
Occult cervical metastases: immunoperoxidase analysis of the pathologically negative neck. Enepekides DJ, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):713–7
Microscopic detection of occult malignancy in the adult tonsil. Reiter ER, et al. **Otolaryngol Head Neck Surg** 1999 Feb;120(2):190–4
Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. AAssar OS, et al. **Radiology** 1999 Jan;210(1):177–81
Radiologic evaluation of neck metastases: the otolaryngologist's perspective. van den Brekel MW, et al. **Semin Ultrasound CT MR** 1999 Jun;20(3):162–74 (93 ref.)
[Giant metastatic neck tumor responding to oral administration of UFT—a case report] Kawakami M, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):829–32 (Eng. Abstr.) **(Jpn)**
[Evaluation of the diagnostic value of color Doppler ultrasound examination of salivary gland neoplasms and metastatic tumors from the facial bones] Falkowski A. **Ann Acad Med Stetin** 1998;44:209–21 (Eng. Abstr.) **(Pol)**

SECRETION

Dopamine-secreting glomus vagale: a case report and histopathologic correlation. Levin RJ, et al. **Head Neck** 1998 Dec;20(8):753–7
Interleukin 13 is secreted by human head and neck tumours and does not modulate their growth in vitro. Mehrotra R. **Indian J Exp Biol** 1998 Aug;36(8):805–7

SURGERY

Plexiform schwannoma of the neck extending deeply to the mediastinum. Tomita K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:106–9
Surgical treatment of cancer extending from the retromolar fossa to the masticator space. Yamane H, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:239–43
Surgical excision margins: a pathologist's perspective. Batsakis JG. **Adv Anat Pathol** 1999 May;6(3):140–8 (35 ref.)
Management of patients after elective carotid artery resection. Mirza N, et al. **Am J Otolaryngol** 1999 Jan-Feb; 20(1):37–42
Hayes Martin lecture. The making of a specialty. Shah JP. **Am J Surg** 1998 Nov;176(5):398–403
Radiotherapy followed by neck dissection for small head and neck cancers with advanced cervical metastases. Wang SJ, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):128–31
An analysis of 26 "extended" pectoralis major musculocutaneous flaps in head and neck reconstruction [letter] Hatoko M, et al. **Ann Plast Surg** 1998 Oct;41(4):451
Functional outcomes of microsurgical reconstruction of delayed complications following head and neck cancer ablation. Mast BA. **Ann Plast Surg** 1999 Jan;42(1):40–5
Head and neck soft-tissue reconstruction using the vertical trapezius musculocutaneous flap [letter] Papadopoulos O, et al. **Ann Plast Surg** 1999 Apr;42(4):457–8
Parotid selective lymphadenectomy in malignant melanoma. Wells KE, et al. **Ann Plast Surg** 1999 Jul;43(1):1–6
A safe and rapid technique for modified neck dissection. Woods JE, et al. **Ann Plast Surg** 1999 Jul;43(1):90–5
The next revolution in general surgery: radioguided surgery [editorial; comment] Reintgen D, et al. **Ann Surg Oncol** 1999 Mar;6(2):125–6. Comment on: Ann Surg Oncol 1999 Mar;6(2):150–4.
Microvascular reconstruction of the head and neck after tumor ablation. Johnson PJ, et al. **AORN J** 1999 Jul; 70(1):30–3
Unsurpassed reliability of free flaps for head and neck reconstruction. Blackwell KE. **Arch Otolaryngol Head Neck Surg** 1999 Mar;125(3):295–9
Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? Cooney TR, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):379–82
Complications from planned, posttreatment neck dissections. Davidson BJ, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):401–5
Considerations in the surgical treatment of malignant melanoma [see comments] Fisher SR. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):116–7. Comment in: Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):110–5.
Experience and clinical judgment required in the treatment of malignant melanoma [comment] Hamaker RC. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):115–6. Comment on: Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):110–5.
Adherence of benign cervical teratomas to surrounding soft tissue [letter; comment] Kuhel WI. **Arch Otolaryngol Head Neck Surg** 1999 Feb;125(2):236–7. Comment on: Arch Otolaryngol Head Neck Surg 1998

Aug;124(8):927, 929.
Autologous and heterologous blood transfusion in head and neck cancer surgery. Moir MS, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug;125(8):864–8
Value of neck dissection in the treatment of patients with intermediate-thickness cutaneous malignant melanoma of the head and neck [see comments] Myers JN. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):110–5 . Comment in: Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):115–6. Comment in: Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):116–7.
Practice patterns and clinical guidelines for posttreatment follow-up of head and neck cancers: a comparison of 2 professional societies. Paniello RC, et al. **Arch Otolaryngol Head Neck Surg** 1999 Mar;125(3):309–13
Functional results after oropharyngeal reconstruction: a different perspective [letter; comment] Reece GP, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):474–7 . Comment on: Arch Otolaryngol Head Neck Surg 1998 Jun;124(6):625–30.
Total, subtotal, and partial surgical removal of cervicofacial lymphangiomas. Riechelmann H, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):643–8
Adult respiratory distress syndrome after microvascular free tissue reconstruction in head and neck malignancy. Logan SW, et al. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):371–4
Indications for the vastus lateralis flap in oral and maxillofacial surgery. Wolff KD. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):358–64
Superiority of end-to-side anastomosis with the internal jugular vein: the experience of 80 cases in head and neck microsurgical reconstruction. Yamamoto Y, et al. **Br J Plast Surg** 1999 Mar;52(2):88–91
Conservation surgery in head and neck cancer [editorial] Sheppard IJ, et al. **Clin Otolaryngol** 1998 Oct;23(5):385–7
Critical care for the severely ill head and neck patient [see comments] Downey RJ, et al. **Crit Care Med** 1999 Jan; 27(1):95–7. Comment in: Crit Care Med 1999 Jan;27(1):15.
A sleep medicine curriculum for otolaryngology–head and neck surgery. Davidson TM, et al. **Ear Nose Throat J** 1999 Sep;78(9):684–6, 688, 690 passim
Management of anesthesia in geriatric patients undergoing head and neck surgery. Moorthy SS, et al. **Ear Nose Throat J** 1999 Jul;78(7):496–8
Complications of head and neck surgery in the elderly. Shaari CM, et al. **Ear Nose Throat J** 1999 Jul;78(7):510–2
Combined infratemporal fossa and transfacial approach to excising massive tumors. Shahinian HK, et al. **Ear Nose Throat J** 1999 May;78(5):350, 353–6
Surgical excision of pilomatrixoma of the head and neck: a retrospective review of 26 cases. Thomas RW, et al. **Ear Nose Throat J** 1999 Aug;78(8):541, 544–6, 548
Selective neck dissections for squamous carcinoma of the upper aerodigestive tract: patterns of regional failure. Byers RM, et al. **Head Neck** 1999 Sep;21(6):499–505
Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Cooper JS, et al. **Head Neck** 1998 Oct;20(7):588–94
Complications of anterior craniofacial resection. Dias FL, et al. **Head Neck** 1999 Jan;21(1):12–20
Malnutrition and food intake in relation to quality of life in head and neck cancer patients. Hammerlid E, et al. **Head Neck** 1998 Sep;20(6):540–8
Free composite myo-osseous flap with serratus anterior and rib: indications in head and neck reconstruction [letter; comment] Ioannides C. **Head Neck** 1998 Oct;20(7):660–1. Comment on: Head Neck 1998 Mar;20(2):106–12.
Health states following head and neck cancer treatment: patient, health-care professional, and public perspectives. Jalukar V, et al. **Head Neck** 1998 Oct;20(7):600–8
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer. Sanguineti G, et al. **Head Neck** 1999 May;21(3):223–8
Varying impact of common carotid artery digital compression and internal carotid artery balloon test occlusion on cerebral hemodynamics. Sorteberg A, et al. **Head Neck** 1998 Dec;20(8):687–94
Complications of the myocutaneous platysma flap in intraoral reconstruction. Verschuur HP, et al. **Head Neck** 1998 Oct; 20(7):623–9
Excision of cervical cystic lymphangioma using injection of hydrocolloid dental impression material. A technical case report. Katsuno S, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):295–6 (7 ref.)
Complications after microsurgical tissue transfer in the head and neck region. Hoffmann J, et al. **J Craniomaxillofac Surg** 1998 Aug;26(4):255–9
Age as a risk factor in cervicofacial reconstruction. Pompei S, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):209–12
Unusual benign nerve sheath tumours. Sidhu BS, et al. **J Indian Med Assoc** 1998 Apr;96(4):123–5
Melanoma during pregnancy: a case report and review of the literature. Teplitzky S, et al. **J La State Med Soc** 1998 Nov;150(11):539–43 (19 ref.)
Psychological morbidity following laryngectomy: a pilot study. Gibson AR, et al. **J Laryngol Otol** 1999 Apr; 113(4):349–52
Functional neck dissection: cure and functional results. Güney E, et al. **J Laryngol Otol** 1998 Dec;112(12):1176–8
A visit to the Head and Neck surgery, Cancer Hospital, Beijing. Mason JD. **J Laryngol Otol** 1998 Sep;112(9):901
Minimizing complications in neck dissection. Talmi YP. **J Laryngol Otol** 1999 Feb;113(2):101–13 (92 ref.)
Congenital lateral cervical cysts of infancy. Mahomed A, et al. **J Pediatr Surg** 1998 Sep;33(9):1413–5
Cystic hygroma in an adult: a case report. Morley SE, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):57–8
Second free flaps in head and neck reconstruction. Amin AA, et al. **J Reconstr Microsurg** 1998 Aug;14(6):365–8; discussion 368–9
Microsurgical reconstruction of the through-and-through defect in head and neck cancer: is it worth it? Thoma A, et al. **J Reconstr Microsurg** 1999 Aug;15(6):401–8
Cervicothoracic tumors: results of resection by the "hemi-clamshell" approach [letter; comment] Rusca M, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1040. Comment on: J Thorac Cardiovasc Surg 1998 Feb;115(2):286–94; discussion 294–5.
Anterior approach to the superior sulcus tumors: the transmanubrial osteomuscular sparing approach [letter; comment] Spaggiari L, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1042–4. Comment on: J Thorac Cardiovasc Surg 1998 Oct;116(4):663–4.
Magnetic resonance navigation for head and neck lesions. Davis SP, et al. **Laryngoscope** 1999 Jun;109(6):862–7
Quality of life assessment in patients undergoing head and neck surgery as evaluated by lay caregivers. Deschler DG, et al. **Laryngoscope** 1999 Jan;109(1):42–6
Lateral thigh free flap for head and neck reconstruction. Hayden RE, et al. **Laryngoscope** 1999 Sep;109(9):1490–4
Impact of neck dissection on quality of life. Kuntz AL, et al. **Laryngoscope** 1999 Aug;109(8):1334–8
Reduced postoperative infections with an immune-enhancing nutritional supplement. Snyderman CH, et al. **Laryngoscope** 1999 Jun;109(6):915–21
Modified neck dissection for metastatic nonseminomatous testicular carcinoma. Weisberger EC, et al. **Laryngoscope** 1999 Aug;109(8):1241–4
Effects of hemimandibulectomy on quality of life. Wilson KM, et al. **Laryngoscope** 1998 Oct;108(10):1574–7
Three-dimensional reconstruction of types IV and V midfacial defects by free rectus abdominis myocutaneous (RAM) flap. Güler MM, et al. **Microsurgery** 1998; 18(3):148–51
Head and neck reconstruction using lateral thigh free flap: flap design. Ha B, et al. **Microsurgery** 1999;19(3):157–65
Measurement of blood flow and oxygen tension in adjacent tissues in pedicled and free flap head and neck reconstruction. Nabawi A, et al. **Microsurgery** 1999; 19(5):254–7
Temporal augmentation with a layered expanded polytetrafluoroethylene implant. Fedok FG, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):929–33
Postoperative hypertension effect of carotid sinus denervation. Ko C, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):150–2
Timing of percutaneous endoscopic gastrostomy tube placement in head and neck cancer patients. Raynor EM, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):479–82
Recurrent cutaneous melanoma of the head and neck. Zitsch RP 3rd, et al. **Otolaryngol Head Neck Surg** 1999 Mar; 120(3):391–3
Hypothyroidism in a neonate following excision of a cervical teratoma. Chowdhary SK, et al. **Pediatr Surg Int** 1998 Dec; 14(3):212–3
Survival of free tissue transfer following internal jugular venous thrombosis. Amato MM, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1406–8
Radioimmunoguided surgery in squamous cell carcinoma [letter] Argenzio V, et al. **Plast Reconstr Surg** 1999 Feb; 103(2):749–51
Reliability of the venae comitantes in venous drainage of the free radial forearm flaps. Demirkan F, et al. **Plast Reconstr Surg** 1998 Oct;102(5):1544–8
A method that preserves circulation during preparation of the pectoralis major myocutaneous flap in head and neck reconstruction. Kiyokawa K, et al. **Plast Reconstr Surg** 1998 Dec;102(7):2336–45
Factors associated with complications in microvascular reconstruction of head and neck defects. Singh B, et al. **Plast Reconstr Surg** 1999 Feb;103(2):403–11
Management of secondary soft-tissue deficits following microsurgical head and neck reconstruction by means of another free flap. Wei FC, et al. **Plast Reconstr Surg** 1999 Apr;103(4):1158–66
Axial pattern bilobed flap for the reconstruction of the midline forehead defects [letter; comment] Yenidunya MO. **Plast Reconstr Surg** 1999 Feb;103(2):737. Comment on: Plast Reconstr Surg 1993 Nov;92(6):1052–6.
Conservative neck surgery in squamous cell carcinoma. England RJ, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):91–4 (25 ref.)
[Synovial sarcoma in the head and neck with 3 case reports] Sun A, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Nov; 11(11):502–4 (Eng. Abstr.) **(Chi)**
[Vascular "tumors" and the rules of their surgical management] Enjolras O, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):455–89 (Eng. Abstr.) **(Fre)**
[Extracranial cephalic schwannomas. Apropos of 13 cases] Torossian JM, et al. **Ann Chir Plast Esthet** 1998 Oct; 43(5):541–7 (Eng. Abstr.) **(Fre)**
[Postoperative pain assessment in head and neck cancer surgery: benefit of patient controlled analgesia (PCA)] Bost P, et al. **Ann Otolaryngol Chir Cervicofac** 1999 Jun; 116(3):154–61 (Eng. Abstr.) **(Fre)**
[En bloc resection of the carotid axis in epidermoid carcinoma of the head and neck. Retrospective analysis of 7 cases] Kania R, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec;115(6):338–46 (Eng. Abstr.) **(Fre)**
[Proceedings of the 69th annual meeting of the German Society for ENT and for Head and Neck Surgery. 20–24 May 1998, Hannover, Germany] **Laryngorhinootologie** 1998 Nov;77(11):609–675 **(Ger)**
[The parotid gland as a filtering station of metastatic head-neck melanoma. Retrospective study of 884 patients] Schwipper V, et al. **Mund Kiefer Gesichtschir** 1998 Sep; 2(5):242–9 (Eng. Abstr.) **(Ger)**
[Percutaneous endoscopic gastrostomy: experience of three years] Taller A, et al. **Orv Hetil** 1999 Jun 13; 140(24):1347–52 (Eng. Abstr.) **(Hun)**
[Reconstructive strategies in head and neck cancer: case history review from 1992 to 1997 (154 cases)] Succo G, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4):249–58 (Eng. Abstr.) **(Ita)**
[Lymphorrhea after neck dissection] Nowaczyk MT. **Otolaryngol Pol** 1999;53(3):271–3 (Eng. Abstr.) **(Pol)**
[Efficiency evaluation of radiotherapy of recurrences after surgery in head and neck cancer] Zajusz A, et al. **Otolaryngol Pol** 1998;52(3):281–6 (Eng. Abstr.) **(Pol)**
[A large lipoma] Rokicki M, et al. **Wiad Lek** 1998; 51(9–10):450–2 (Eng. Abstr.) **(Pol)**
[Choice of the optimal variant of plastic surgery in head and neck tumors] Azizian RI, et al. **Vopr Onkol** 1998; 44(5):614–7 (Eng. Abstr.) **(Rus)**
[Surgical treatment for tumors of the upper thoracic aperture] Davidov MI, et al. **Vopr Onkol** 1999;45(3):301–5 (Eng. Abstr.) **(Rus)**

THERAPY

High dose etretinate and interferon-alpha--a phase I study in squamous cell carcinomas and transitional cell carcinomas. Roth AD, et al. **Acta Oncol** 1999;38(5):613–7
Changes in head and neck tumor hypoxic fraction during split-course radiochemotherapy. Jund R, et al. **Ann Otol Rhinol Laryngol** 1999 Jan;108(1):73–8
Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma. Gravis G, et al. **Anticancer Drugs** 1999 Apr;10(4):369–74
Chemo-immunotherapy in advanced head and neck cancer. Recchia F, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):773–7
Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Thomas SM, et al. **Anticancer Res** 1998 Nov-Dec; 18(6A):4393–8
Percutaneous fluoroscopic gastrostomy tube placement in patients with head and neck cancer. Beaver ME, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1141–4
Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-I trial. Gleich LL, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1097–104
Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Robbins KT, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):670–5
Use of alternative medicine among patients with head and neck cancer. Warrick PD, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):573–9
ENT malignancies. What the GP needs to know. Lyons B. **Aust Fam Physician** 1999 Mar;28(3):209–15 (9 ref.)
Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Gurnani M, et al. **Cancer Chemother Pharmacol** 1999;44(2):143–51
Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Liu TJ, et al. **Cancer Gene Ther** 1999 Mar-Apr;6(2):163–71
Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Ji L, et al. **Cancer Res** 1999 Jul 15;59(14):3333–9
Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Lingen MW, et al. **Cancer Res** 1998 Dec 1;58(23):5551–8
Health services research in head and neck cancer. Pfister DG, et al. **Cancer Treat Res** 1998;97:159–75 (87 ref.)
Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clayman GL, et al. **Clin Cancer Res** 1999 Jul;5(7):1715–22
Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Eicher SA, et al. **Clin Cancer Res** 1996 Oct;2(10):1659–64
Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Frank DK, et al. **Clin Cancer Res** 1998 Oct;4(10):2521–8
Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Gasparini G, et al. **Clin Cancer Res** 1995 Nov;1(11):1375–83

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Humerickhouse RA, et al. **Clin Cancer Res** 1999 Feb;5(2):291–8

Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Li D, et al. **Clin Cancer Res** 1999 Jun;5(6):1551–6

Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials. Overholt SM, et al. **Clin Cancer Res** 1997 Feb;3(2):185–91

Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy. Preisler HD, et al. **Clin Cancer Res** 1996 Sep;2(9):1453–60

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Wheeler RH, et al. **Curr Opin Oncol** 1999 May;11(3):187–90 (40 ref.)

The use of biological therapy in cancer of the head and neck. Myers JN. **Curr Probl Cancer** 1999 May-Jun;23(3):106–34 (131 ref.)

Percutaneous endoscopic gastrostomy using the Kleinsasser direct laryngoscope. Taller A, et al. **Endoscopy** 1998 Sep; 30(7):S85

Quality of life measurements of speech in the head and neck cancer patient population. Karnell LH, et al. **Head Neck** 1999 May;21(3):229–38

Patients' priorities among treatment effects in head and neck cancer: evaluation of a new assessment tool. Sharp HM, et al. **Head Neck** 1999 Sep;21(6):538–46

Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. Westra WH, et al. **Head Neck** 1998 Sep;20(6):515–21

Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II–IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Wollenberg B, et al. **Hum Gene Ther** 1999 Jan 1;10(1):141–7

Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. Chikamatsu K, et al. **Int J Cancer** 1999 Aug 12;82(4):532–7

Camouflage in head and neck region--a non-invasive option for skin lesions. Hell B, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):90–4

The outcome after perinatal management of infants with potential airway obstruction. Raveh E, et al. **Int J Pediatr Otorhinolaryngol** 1998 Dec 15;46(3):207–14

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Beitler JJ, et al. **Invest New Drugs** 1998;16(2):161–9

Cancer curricula in U.S. dental schools. Rankin KV, et al. **J Cancer Educ** 1999 Spring;14(1):8–12

First year after head and neck cancer: quality of life. Gritz ER, et al. **J Clin Oncol** 1999 Jan;17(1):352–60

Principles of gene therapy: prospects for the treatment of head and neck cancer. Green NK, et al. **J Laryngol Otol** 1998 Oct;112(10):913–20 (52 ref.)

FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. Kitagawa Y, et al. **J Nucl Med** 1999 Jul;40(7):1132–7

25 years' experience with lymphangiomas in children. Alqahtani A, et al. **J Pediatr Surg** 1999 Jul;34(7):1164–8

Long-term follow-up of nineteen cystic lymphangiomas treated with fibrin sealant. Castañón M, et al. **J Pediatr Surg** 1999 Aug;34(8):1276–9

Combined intratumor cisplatinum injection and Nd:YAG laser therapy. Graeber IP, et al. **Laryngoscope** 1999 Mar; 109(3):447–54

Osteosarcoma of the head and neck: a review of the Johns Hopkins experience. Ha PK, et al. **Laryngoscope** 1999 Jun; 109(6):964–9

Fluoroscopically placed percutaneous gastrostomies in the head and neck patient. Myssiorek D, et al. **Laryngoscope** 1998 Oct;108(10):1557–60

Current options in management of head and neck cancer patients. Correa AJ, et al. **Med Clin North Am** 1999 Jan; 83(1):235–46, xi (49 ref.)

Researchers combine TP53 gene therapy and chemotherapy in advanced cancer [news] **Oncology (Huntingt)** 1998 Oct; 12(10):1517

Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma. Goebel EA, et al. **Otolaryngol Head Neck Surg** 1998 Oct;119(4):331–6

Treatment of localized non-Hodgkin's lymphomas of the head and neck: focusing on cases of non-lethal midline granuloma. Sakata K, et al. **Radiat Oncol Investig** 1998; 6(4):161–9

Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Sumareva R, et al. **Radiat Oncol Investig** 1999;7(1):22–9

Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Brizel DM. **Semin Radiat Oncol** 1998 Oct; 8(4):237–46

[Clinical application of highly selected embolotherapy via external carotid artery in craniofacial diseases] Wang X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):517–20 (Eng. Abstr.) **(Chi)**

[Standards, Options and Recommendations (SOR) for good practices in dentistry for head and neck cancer patients] Maire F, et al. **Bull Cancer** 1999 Jul-Aug;86(7–8):640–65 (Eng. Abstr.) **(Fre)**

[Management of hematologic systemic diseases and rare tumor entities with manifestations in the oromaxillofacial area] Petrasch S. **Mund Kiefer Gesichtschir** 1998 Jul; 2(4):172–80 (74 ref.) (Eng. Abstr.) **(Ger)**

[23rd Congress of the European Society for Medical Oncology, 6–10 November 1998, Athens, Greece] Foggi P. **Clin Ter** 1998 Nov-Dec;149(6):401–7 **(Ita)**

[Comparison in strategies for advanced head and neck squamous cell carcinomas between Japan and western countries] Tsukuda M. **Gan To Kagaku Ryoho** 1999 Jan; 26(1):54–60 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Development of treatments for head and neck squamous cell carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1999 Jun; 26 Suppl 1:85–96 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Chordomas. Analysis of 24 cases] Danilewicz M, et al. **Przegl Lek** 1999;56(2):115–8 (22 ref.) (Eng. Abstr.) **(Pol)**

[Update oN pediatric lymphomas of the head and neck] Jiménez J, et al. **Acta Otorrinolaringol Esp** 1998 Aug-Sep; 49(6):482–4 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Favorable outcome in a fetus with an early-onset extensive cystic hygroma colli and intralesional hemorrhage. Chen CP, et al. **Am J Perinatol** 1998;15(11):601–5

Differential diagnosis of cervical lymph nodes in head and neck cancer by ultrasonography. Takeuchi Y, et al. **Auris Nasus Larynx** 1999 Jul;26(3):331–6

Prenatally diagnosed fetal neck teratoma. Case report and novel management options. Gagnon AL, et al. **Fetal Diagn Ther** 1998 Sep-Oct;13(5):266–70

Echo-enhancing sonography of a large-vessel hemangioma of the neck. Chou YH, et al. **J Clin Ultrasound** 1999 Oct; 27(8):465–8

Prenatal sonographic diagnosis of Cantrell's pentalogy with cystic hygroma in the first trimester. Hsieh YY, et al. **J Clin Ultrasound** 1998 Oct;26(8):409–12

Prenatally diagnosed cystic lymphangioma in infants. Suzuki N, et al. **J Pediatr Surg** 1998 Nov;33(11):1599–604

[Evaluation of the diagnostic value of color Doppler ultrasound examination of salivary gland neoplasms and metastatic tumors from the facial bones] Falkowski A. **Ann Acad Med Stetin** 1998;44:209–21 (Eng. Abstr.) **(Pol)**

VETERINARY

Clinical challenge. Subcutaneous mass; dermoid cyst. Fitzgerald SD. **J Zoo Wildl Med** 1998 Sep;29(3):349–51

VIROLOGY

Human papillomavirus as a risk factor for head and neck cancers--a case-control study. Nishioka S, et al. **Acta Otolaryngol Suppl** 1999;540:77–80

Low prevalence of human papillomavirus in a geographic region with a high incidence of head and neck cancer. Miguel RE, et al. **Am J Surg** 1998 Nov;176(5):428–9

Prevalence of human papilloma virus DNA in head and neck cancers carrying wild-type or mutant p53 tumor suppressor genes. Adams V, et al. **Anticancer Res** 1999 Jan-Feb; 19(1A):1–6

Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Mineta H, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4765–8

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Gillison ML, et al. **Curr Opin Oncol** 1999 May;11(3):191–9 (110 ref.)

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Carew JF, et al. **Hum Gene Ther** 1999 Jul 1;10(10):1599–606

Relationship of human papillomavirus to Schneiderian papillomas. Weiner JS, et al. **Laryngoscope** 1999 Jan; 109(1):21–6

HHV-8 is not associated with follicular dendritic cell tumours. Nayler SJ, et al. **Mol Pathol** 1998 Jun;51(3):168–70

Manifestations of AIDS in the head and neck. Reisacher WR, et al. **South Med J** 1999 Jul;92(7):684–97 (66 ref.)

HEAD BANGING see **STEREOTYPIC MOVEMENT DISORDER**

HEAD-DOWN TILT

see related
TILT-TABLE TEST

Hoffmann-reflex is delayed during 6 degree head-down tilt with balanced traction. Haruna Y, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 1):220–4

Effect of head-down tilt on brain water distribution. Caprihan A, et al. **Eur J Appl Physiol** 1999 Mar; 79(4):367–73

Energy and substrate metabolism during a 42-day bed-rest in a head-down tilt position in humans. Ritz P, et al. **Eur J Appl Physiol** 1998 Sep;78(4):308–14

Regional blood flow in conscious rats after head-down suspension. Somody L, et al. **Eur J Appl Physiol** 1998 Sep; 78(4):296–302

Intrauterine resuscitation by rapid urinary bladder instillation in a case of occult prolapse of an excessively long umbilical cord. Runnebaum IB, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):101–2

Otoconial agenesis in tilted mutant mice. Ornitz DM, et al. **Hear Res** 1998 Aug;122(1–2):60–70

Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Meyers C, et al. **Liver Transpl Surg** 1998 Nov;4(6):510–2

ADVERSE EFFECTS

An experimental study of death in a reverse suspension. Uchigasaki S, et al. **Am J Forensic Med Pathol** 1999 Jun; 20(2):116–9

Different responses of cerebral vessels to -30 degrees head-down tilt in humans. Hu Z, et al. **Aviat Space Environ Med** 1999 Jul;70(7):674–80

Further study on the carotid baroreflex system in the cardiovascular deconditioning induced by head-down tilt. Pannier B, et al. **Aviat Space Environ Med** 1998 Sep; 69(9):904–10

Lloyd-Davies position with Trendelenburg--a disaster waiting to happen? Horgan AF, et al. **Dis Colon Rectum** 1999 Jul;42(7):916–9; discussion 919–20

Holding the baby: head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux. Phillips GE, et al. **Eur Respir J** 1998 Oct;12(4):954–7

[Specific aspects of the nervous system and brain blood supply in women during prolonged anti-orthostatic hypokinesia] Chumak OB, et al. **Aviakosm Ekolog Med** 1999;33(2):9–12 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Ultrasound for the detection of intraperitoneal fluid: the role of Trendelenburg positioning. Abrams BJ, et al. **Am J Emerg Med** 1999 Mar;17(2):117–20

Changes in the sympathetic nervous system induced by 42 days of head-down bed rest. Sigaudo D, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):H1875–84

Different responses of cerebral vessels to -30 degrees head-down tilt in humans. Hu Z, et al. **Aviat Space Environ Med** 1999 Jul;70(7):674–80

Further study on the carotid baroreflex system in the cardiovascular deconditioning induced by head-down tilt. Pannier B, et al. **Aviat Space Environ Med** 1998 Sep; 69(9):904–10

Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during--6 degrees of head down tilt. Rosene JM, et al. **Aviat Space Environ Med** 1999 Jan; 70(1):15–21

Response to 45 degrees head-down tilt as measured by organ weight/body weight ratios and spiral computed tomography. Witten ML, et al. **Aviat Space Environ Med** 1999 Jan;70(1):11–4

Cardiorespiratory responses to bidirectional tilts in infants. Fifer WP, et al. **Early Hum Dev** 1999 Jul;55(3):265–79

Femoral to cerebral arterial blood flow redistribution and femoral vein distension during orthostatic tests after 4 days in the head-down tilt position or confinement. Arbeille P, et al. **Eur J Appl Physiol** 1998 Aug;78(3):208–18

Sympathetic responses to head-down rotations in humans. Hume KM, et al. **J Appl Physiol** 1999 Jun;86(6):1971–6

Resistance training affects GLUT-4 content in skeletal muscle of humans after 19 days of head-down bed rest. Tabata I, et al. **J Appl Physiol** 1999 Mar;86(3):909–14

Effects of exaggerated lithotomy position on ventilation and hemodynamics during radical perineal prostatectomy. Ryniak S, et al. **Scand J Urol Nephrol** 1998 May;32(3):200–3

[The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject] Noskov VB, et al. **Eksp Klin Farmakol** 1998 Jul-Aug;61(4):29–33 (Eng. Abstr.) **(Rus)**

HEAD INJURIES

see related
BRAIN INJURIES

Pediatric head injury: what is unique and different. James HE. **Acta Neurochir Suppl (Wien)** 1999;73:85–8 (43 ref.)

English surgeons call for improved management of head injury [news] Woodman R. **BMJ** 1999 Jun 12; 318(7198):1577

Serum-mediated osteogenic effects of head injury on cultured rat marrow stromal cells. Klein BY, et al. **Calcif Tissue Int** 1999 Sep;65(3):217–22

Primary end points in phase III clinical trials of severe head trauma: DRS versus GOS. The American Brain Injury Consortium Study Group. Choi SC, et al. **J Neurotrauma** 1998 Oct;15(10):771–6

Civil war head injury and twentieth-century treatment. Gruen MB, et al. **J Trauma** 1999 Jul;47(1):151–3

Early fracture fixation may be "just fine" after head injury: no difference in central nervous system outcomes. Scalea TM, et al. **J Trauma** 1999 May;46(5):839–46

Neurotrauma 1998. European meeting. Magdeburg, 1–3 October 1998. Abstracts. **Zentralbl Neurochir** 1998;

59(3):189-234

BLOOD

Correlation of computed tomography findings and serum brain damage markers following severe head injury. Raabe A, et al. **Acta Neurochir (Wien)** 1998;140(8):787-91; discussion 791-2

Elevated jugular venous oxygen saturation after severe head injury [see comments] Cormio M, et al. **J Neurosurg** 1999 Jan;90(1):9-15. Comment in: J Neurosurg 1999 Jul;91(1):167-9.

High jugular bulb oxygen saturation [letter; comment] Cruz J. **J Neurosurg** 1999 Jul;91(1):167-9. Comment on: J Neurosurg 1999 Jan;90(1):9-15.

Decreased soluble adhesion molecule L-selectin plasma concentrations after major trauma. Müller JC, et al. **J Trauma** 1998 Oct;45(4):705-8

S-100 serum levels after minor and major head injury. Rothoerl RD, et al. **J Trauma** 1998 Oct;45(4):765-7

[Severe head injuries: effects of pre-hospital mechanical ventilation on capnia] David JS, et al. **Ann Fr Anesth Reanim** 1999 Apr;18(4):398-402 (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Predictors of long-term outcome in severe head injury. Lai YC, et al. **Ann Acad Med Singapore** 1998 May;27(3):326-31

COMPLICATIONS

Posttraumatic smell loss: relationship of psychophysical tests and volumes of the olfactory bulbs and tracts and the temporal lobes. Yousem DM, et al. **Acad Radiol** 1999 May; 6(5):264-72

The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. van den Brink WA, et al. **Acta Neurochir (Wien)** 1999;141(5):509-14

Olfactory dysfunction in head injured workers. Ogawa T, et al. **Acta Otolaryngol Suppl** 1999;540:50-7

Isolated basilar artery occlusion by parietal dissection after severe chest and minor head trauma [letter] Gallerani M, et al. **Am J Emerg Med** 1998 Oct;16(6):614-6

Intracranial insertion of a nasogastric tube in a case of homicidal head trauma. Gianelli Castiglione A, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):329-34 (34 ref.)

Specific vocalized complaints in whiplash and minor head injury patients. Mallinson AI, et al. **Am J Otol** 1998 Nov; 19(6):809-13

Dizziness from whiplash and head injury: differences between whiplash and head injury. Mallinson AI, et al. **Am J Otol** 1998 Nov;19(6):814-8

Percutaneous endoscopic gastrostomy reduces total hospital costs in head-injured patients. Harbrecht BG, et al. **Am J Surg** 1998 Oct;176(4):311-4

Performance of psychotic and substance abuse patients with or without head injury on the Halstead-Reitan Battery. Collingwood LM, et al. **Appl Neuropsychol** 1999;6(2):88-95

Case of the month: education of the pathologist. Autopsy Committee of the College of American Pathologists. Hanzlick R, et al. **Arch Intern Med** 1999 May 10; 159(9):907-8

Case report: postconcussion syndrome after minor head injury. Wright SC. **Aviat Space Environ Med** 1998 Oct; 69(10):999-1000

Internuclear ophthalmoplegia following minor head injury: a case report. Constantoyannis C, et al. **Br J Neurosurg** 1998 Aug;12(4):377-9 (14 ref.)

Head injuries in the elderly [editorial] Maurice-Williams RS. **Br J Neurosurg** 1999 Feb;13(1):5-8

Lysine vasopressin in post-traumatic memory disorders: an uncontrolled pilot study. Eames P, et al. **Brain Inj** 1999 Apr;13(4):255-60

Carotid and vertebral artery injury following severe head or cervical spine trauma. Rommel O, et al. **Cerebrovasc Dis** 1999 Jul-Aug;9(4):202-9

Prognostic implications of hyperglycaemia in paediatric head injury. Chiaretti A, et al. **Childs Nerv Syst** 1998 Sep; 14(9):455-9

Surgery or conservative treatment in children with traumatic intracerebral haematoma. Mandera M, et al. **Childs Nerv Syst** 1999 May;15(5):267-9; discussion 270

Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia [see comments] Campbell W, et al. **Crit Care Med** 1999 Apr;27(4):798-801. Comment in: Crit Care Med 1999 Apr;27(4):692-3.

Measurement inside the box [editorial; comment] Gibbons KJ. **Crit Care Med** 1999 May;27(5):869-70 (11 ref.). Comment on: Crit Care Med 1999 May;27(5):978-84.

Hypocapnia does not alter hepatic blood flow or oxygen consumption in patients with head injury. Ichai C, et al. **Crit Care Med** 1998 Oct;26(10):1725-30

Delayed intracranial hypertension: relationship to leukocyte count. Souter MJ, et al. **Crit Care Med** 1999 Jan; 27(1):177-81

Does splanchnic ischemia occur in isolated neurotrauma? A prospective observational study. Venkatesh B, et al. **Crit Care Med** 1999 Jun;27(6):1175-80

Study of psychiatric consequences of closed head injury at the Kenyatta National Hospital. Sebit MB, et al. **East Afr Med J** 1998 Jun;75(6):332-5

Osmoregulation of vasopressin secretion in patients with the syndrome of inappropriate antidiuresis associated with central nervous system disorders. Kamoi K, et al. **Endocr J** 1999 Apr;46(2):269-77

Posttraumatic epilepsy risk factors: one-year prospective study after head injury. Angeleri F, et al. **Epilepsia** 1999 Sep;40(9):1222-30

Fatal native valve endocarditis due to Scedosporium apiospermum (Pseudallescheria boydii) following trauma. Sobottka I, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):387-9

Oral clonidine to control hypertension after head injury. Kariya N, et al. **Eur J Emerg Med** 1999 Mar;6(1):77-9

One adolescent's injury--a continuing saga. Tonkin R. **Inj Prev** 1999 Jun;5(2):88-9

An international case-control study of adult glioma and meningioma: the role of head trauma. Preston-Martin S, et al. **Int J Epidemiol** 1998 Aug;27(4):579-86

Bilateral reflex fracture of the coronoid process of the mandible. A case report. Philip M, et al. **Int J Oral Maxillofac Surg** 1999 Jun;28(3):195-6

Acute lung injury in head trauma patients. Mascia L, et al. **Intensive Care Med** 1998 Oct;24(10):1115-6 (4 ref.)

Extradural haematoma--a preventable cause of death. Caird J, et al. **Ir Med J** 1999 Mar;92(2):270-1

Early prediction of neurological outcome after falls in children: metabolic and clinical markers. Paret G, et al. **J Accid Emerg Med** 1999 May;16(3):186-8

The possible role of hypoxia in the formation of axonal bulbs. Kaur B, et al. **J Clin Pathol** 1999 Mar;52(3):203-9

Mild closed-head injury in children and adolescents: behavior problems and academic outcomes. Light R, et al. **J Consult Clin Psychol** 1998 Dec;66(6):1023-9

Medical management of posttraumatic headaches: pharmacological and physical treatment. Bell KR, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):34-48 (65 ref.)

Posttraumatic headache: neuropsychological and psychological effects and treatment implications. Martelli MF, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):49-69 (73 ref.)

Epidemiology and pathogenesis of posttraumatic headache. Packard RC. **J Head Trauma Rehabil** 1999 Feb;14(1):9-21 (78 ref.)

Clinical assessment of posttraumatic headaches. Zafonte RD, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):22-33

Posttraumatic headache: caveats and controversies. Zasler ND. **J Head Trauma Rehabil** 1999 Feb;14(1):1-8

Early onset pneumonia in neurosurgical intensive care unit patients. Berrouane Y, et al. **J Hosp Infect** 1998 Dec; 40(4):275-80

Cephalic tetanus. Shukla O, et al. **J Indian Med Assoc** 1998 Aug;96(8):254

Evaluating methods for estimating premorbid intellectual ability in closed head injury. Watt KJ, et al. **J Neurol Neurosurg Psychiatry** 1999 Apr;66(4):474-9

Brainstem lesions after head injury [letter] Cirak B, et al. **J Neurosurg** 1999 Sep;91(3):523-4; discussion 524-5

Fatal traumatic vertebral artery aneurysm rupture. Case report. Sahjpaul RL, et al. **J Neurosurg** 1998 Nov; 89(5):822-4

Brainstem lesions after head injury [letter] Sganzerla EP. **J Neurosurg** 1999 Sep;91(3):523; discussion 524-5

Outcome in severely head injured patients with and without multiple trauma. Baltas I, et al. **J Neurosurg Sci** 1998 Jun; 42(2):85-8

Extradural hematomas in children. Maggi G, et al. **J Neurosurg Sci** 1998 Jun;42(2):95-9

Is it possible to recover from uncal herniation? Analysis of 71 head injured cases. Uzan M, et al. **J Neurosurg Sci** 1998 Jun;42(2):89-94

Otological complications following basal skull fractures. Lancaster JL, et al. **J R Coll Surg Edinb** 1999 Apr; 44(2):87-90

The early critical phase of severe head injury: importance of apnea and dysfunctional respiration. Atkinson JL, et al. **J Trauma** 1998 Nov;45(5):941-5

Epidural hematoma in infants: a different entity? Beni-Adani L, et al. **J Trauma** 1999 Feb;46(2):306-11

Posttraumatic carotid cavernous fistula: frequency analysis of signs, symptoms, and disability outcomes after angiographic embolization. Fabian TS, et al. **J Trauma** 1999 Aug;47(2):275-81

Three-dimensional finite element analysis of subdural hematoma. Huang HM, et al. **J Trauma** 1999 Sep; 47(3):538-44

Association of head trauma with cervical spine injury, spinal cord injury, or both. Iida H, et al. **J Trauma** 1999 Mar; 46(3):450-2

Recurrent traumatic carotid-cavernous fistula caused by rupture of the detachable balloon. Lee ST, et al. **J Trauma** 1998 Nov;45(5):969-71

Standardized management of intracranial pressure: a preliminary clinical trial. McKinley BA, et al. **J Trauma** 1999 Feb;46(2):271-9

Mannitol osmotherapy in haemodynamically stable head injury patients--risk of sudden hypotension--a case report. Choudhary GN, et al. **JPMA J Pak Med Assoc** 1998 Jul; 48(7):220-1

Growing skull fractures. Yen CP, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Mar; 15(3):175-81

Blunt-head trauma associated with widespread water-diffusion changes [letter] Wieshmann UC, et al. **Lancet** 1999 Apr 10;353(9160):1242-3

Severe head injury combined with orthopedic and vascular trauma of the limbs. Vara-Thorbeck R, et al. **Langenbecks Arch Surg** 1998 Aug;383(3-4):252-8

Disturbances in plasma sodium in patients with war head injuries. Bačić A, et al. **Mil Med** 1999 Mar;164(3):214-7

Delayed unilateral post-traumatic tremor: localization studies using single-proton computed tomographic and magnetic resonance spectroscopy techniques. Newmark J, et al. **Mil Med** 1999 Jan;164(1):59-64

Immediate onset of positional vertigo following head injury [letter; comment] Hornibrook J. **N Z Med J** 1998 Sep 11; 111(1073):349. Comment on: N Z Med J 1998 Sep 11;111(1073):331-2.

Seasonal recurrent mania following head injury [letter] Gupta S, et al. **Natl Med J India** 1998 Nov-Dec;11(6):300-1

CSF rhinorrhoea from unusual site : report of two cases. Devi BI, et al. **Neurol India** 1999 Jun;47(2):152-4

Bilateral optic nerve injury. Mahapatra AK. **Neurol India** 1999 Jun;47(2):92-3

Heading injury precipitating subdural hematoma associated with arachnoid cysts--two case reports. Kawanishi A, et al. **Neurol Med Chir (Tokyo)** 1999 Mar;39(3):231-3

Post-traumatic pituitary apoplexy--two case reports. Uchiyama H, et al. **Neurol Med Chir (Tokyo)** 1999 Jan; 39(1):36-9

Clinical trials in head injury. Reinert MM, et al. **Neurol Res** 1999 Jun;21(4):330-8 (77 ref.)

Secondary insults during intrahospital transport of neurosurgical intensive care patients. Bekar A, et al. **Neurosurg Rev** 1998;21(2-3):98-101

Auditory evoked potentials and multiple personality measures in migraine and post-traumatic headaches. Wang W, et al. **Pain** 1999 Feb;79(2-3):235-42

Diplopia after head injury. Swischuk LE. **Pediatr Emerg Care** 1999 Jun;15(3):233-4

Cerebral complications of nonaccidental head injury in childhood. Gilles EE, et al. **Pediatr Neurol** 1998 Aug; 19(2):119-28

Pathogenesis of arachnoid cyst: congenital or traumatic? Choi JU, et al. **Pediatr Neurosurg** 1998 Nov;29(5):260-6

Predictors of posttraumatic convulsions in head-injured children. Ratan SK, et al. **Pediatr Neurosurg** 1999 Mar; 30(3):127-31

Cervical spine evaluation in obtunded or comatose pediatric trauma patients: A pilot study. Scarrow AM, et al. **Pediatr Neurosurg** 1999 Apr;30(4):169-75

Anxiety and closed head injury in young people. Thurber CA. **Pediatr Rehabil** 1998 Oct-Dec;2(4):149-55 (39 ref.)

Secondary change in the substantia nigra induced by incomplete infarct and minor hemorrhage in the basal ganglia due to traumatic middle cerebral arterial dissection [letter] Fujioka M, et al. **Stroke** 1999 Sep;30(9):1975-7

Successful treatment of traumatic acute posterior fossa subdural hematoma: report of two cases. Hećimović I, et al. **Surg Neurol** 1999 Mar;51(3):247-51

Skull osteolysis after mild head trauma: case report. Hećimović I, et al. **Surg Neurol** 1999 Jan;51(1):43-6

Multidisciplinary approach to traumatic intracranial aneurysms secondary to shotgun and handgun wounds. Horowitz MB, et al. **Surg Neurol** 1999 Jan;51(1):31-41; discussion 41-2 (20 ref.)

[Analysis of 36 cases of traumatic cerebral infarction] Gao Z, et al. **Fa I Hsueh Tsa Chih** 1997;13(4):220-1, 254 (Eng. Abstr.) **(Chi)**

[Post-traumatic intracranial hypertension and biochemical disorders: cases and consequences] Hans P. **Ann Fr Anesth Reanim** 1997;16(4):399-404 (46 ref.) (Eng. Abstr.) **(Fre)**

[Indications for monitoring intracranial pressure] Melon E. **Ann Fr Anesth Reanim** 1997;16(4):415-9 (28 ref.) (Eng. Abstr.) **(Fre)**

[Post-traumatic aneurysmal dissection of the extracranial internal carotid artery; helical computed tomographic and angiographic aspects: a case] Mignon F, et al. **J Radiol** 1999 Jun;80(6):585-7 (Eng. Abstr.) **(Fre)**

[Oculomotor paralysis and head trauma] Liguoro D, et al. **Neurochirurgie** 1998 Nov;44(4):253-7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Post-traumatic carotid-cavernous sinus fistula] Lemaitre J, et al. **Rev Med Brux** 1999 Apr;20(2):91-4 (Eng. Abstr.) **(Fre)**

[Cerebral hemorrhage during coumarin therapy] Budde T. **Dtsch Med Wochenschr** 1998 Nov 20;123(47):1431 **(Ger)**

['Frontal lobe syndrome' caused by severe head trauma or cerebrovascular diseases] Rommel O, et al. **Nervenarzt** 1999 Jun;70(6):530-8 (46 ref.) (Eng. Abstr.) **(Ger)**

[A case of traumatic dissecting aneurysm of the C1-2 portion of the internal carotid artery] Matsumoto Y, et al. **No Shinkei Geka** 1999 Jun;27(6):577-82 (Eng. Abstr.) **(Jpn)**

[A case of traumatic pseudoaneurysm of the middle meningeal artery treated with endovascular surgery] Okumura H, et al. **No Shinkei Geka** 1998 Oct;26(10):929-33 (Eng. Abstr.) **(Jpn)**

[FLAIR images of mild head trauma with transient amnesia] Wakamoto H, et al. **No Shinkei Geka** 1998 Nov; 26(11):985-90 (Eng. Abstr.) **(Jpn)**

[Two cases of recurrent bacterial meningitis following traumatic cerebrospinal fluid rinorrhea] Ikeda S, et al. **No To Hattatsu** 1999 Jan;31(1):76-9 (Eng. Abstr.) **(Jpn)**

[A case of multiple intracranial hematomas due to head

trauma] Ikeda K. **No To Shinkei** 1998 Oct;50(10):954–5 **(Jpn)**

[Clinical study on intracranial air in the severe head injury] Shuto T, et al. **No To Shinkei** 1999 Jul;51(7):615–9 (Eng. Abstr.) **(Jpn)**

[A case of post-traumatic autobiographic amnesia] Yoshimura N, et al. **No To Shinkei** 1999 Jan;51(1):55–7 (Eng. Abstr.) **(Jpn)**

[Post-traumatic parkinsonism] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):61–2 (13 ref.) **(Jpn)**

[MRI of traumatic superficial temporal artery aneurysm. Case report] Kloc W, et al. **Pol Merkuriusz Lek** 1999 Jun; 6(36):328–9 (Eng. Abstr.) **(Pol)**

[Chronic post-traumatic headache after mild head injuries] De Souza JA, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2A):243–8 (Eng. Abstr.) **(Por)**

[Risk factors in mild cranio-encephalic trauma] Valdovinos Mahave MC, et al. **Rev Clin Esp** 1998 Dec;198(12):829–32 (52 ref.) **(Spa)**

DIAGNOSIS

Imaging of nonaccidental head trauma in children [letter; comment] Griscom NT. **Acad Radiol** 1999 Jan;6(1):81. Comment on: Acad Radiol 1998 Mar;5(3):215–23.

Lightning strike to the head of a helmeted motorcyclist [letter] Junkins EP Jr, et al. **Am J Emerg Med** 1999 Mar; 17(2):213–4

Differences between minor head injuries and whip lash [letter] Fitzgerald DC. **Am J Otol** 1999 Jul;20(4):558–9

Treatment of head injuries. Valtonen S, et al. **Ann Chir Gynaecol** 1998;87(3):266–70 (9 ref.)

Minor head injury in children: current management practices of pediatricians, emergency physicians, and family physicians. Aitken ME, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1176–80

Evaluation of head injury in a pediatric emergency department: pretrauma and posttrauma system. Lavelle JM, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1220–4

Serum markers of brain damage and outcome prediction in patients after severe head injury. Raabe A, et al. **Br J Neurosurg** 1999 Feb;13(1):56–9

Recovery from mild head injury. Bernstein DM. **Brain Inj** 1999 Mar;13(3):151–72 (121 ref.)

Lucid interval in infantile fatal head trauma [letter; comment] Plunkett J. **Child Abuse Negl** 1998 Oct;22(10):943–6. Comment on: Child Abuse Negl 1997 Oct;21(10):929–40.

International Multicenter Study of Head Injury in Children. ISHIP Group. Murgio A, et al. **Childs Nerv Syst** 1999 Jul; 15(6–7):318–21

Sports-related head injuries. Chorley JN. **Curr Opin Pediatr** 1998 Aug;10(4):350–5 (62 ref.)

Evaluation of intellect and deficit specific information on the ability to fake memory deficits. Schwartz SM, et al. **Int J Law Psychiatry** 1998 Summer;21(3):261–72

Jugular bulb oximetry: the link between cerebral and systemic management of severe head injury [editorial] De Deyne C. **Intensive Care Med** 1999 May;25(5):430–1

Guidelines for the pre-hospital care of patients with severe head injuries. Working Group for Neurosurgical Intensive Care of the European Society of Intensive Care Medicine. Pick J. **Intensive Care Med** 1998 Nov;24(11):1221–5

Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. Raabe A, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec; 65(6):930–2

When fighting makes you see black holes instead of stars. Kosmorsky G, et al. **J Neuroophthalmol** 1998 Dec; 18(4):255–7

Early magnetic resonance imaging of brainstem lesions after severe head injury. Firsching R, et al. **J Neurosurg** 1998 Nov;89(5):707–12

Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. Wilson JT, et al. **J Neurotrauma** 1998 Aug;15(8):573–85

Development of a Bayesian Network for the prognosis of head injuries using graphical model selection techniques. Sakellaropoulos GC, et al. **Methods Inf Med** 1999 Mar; 38(1):37–42

Clinical indicators of intracranial injury in head-injured infants. Greenes DS, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):861–7

[How to describe and evaluate the clinical gravity of a head injury in order to define a therapeutic strategy at a given moment?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):27–35 (29 ref.) **(Fre)**

[What are the indications and modalities of different monitoring techniques?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):85–105 (48 ref.) **(Fre)**

[FLAIR images of mild head trauma with transient amnesia] Wakamoto H, et al. **No Shinkei Geka** 1998 Nov; 26(11):985–90 (Eng. Abstr.) **(Jpn)**

[Usefulness of T2* weighted magnetic resonance image in the diagnosis of head injury on chronic stage] Morioka T, et al. **No To Shinkei** 1999 Aug;51(8):703–8 (Eng. Abstr.) **(Jpn)**

[Management of minor head injuries in Norwegian hospitals--can the quality be improved?] Ingebrigtsen T, et al. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1874–6 (Eng. Abstr.) **(Nor)**

DRUG THERAPY

Challenges in translating the efficacy of neuroprotective agents in experimental models into knowledge of clinical benefits in head injured patients. Teasdale GM, et al. **Acta Neurochir Suppl (Wien)** 1999;73:111–6 (23 ref.)

CRASH trial is based on problematic meta-analysis [letter] Gregson B, et al. **BMJ** 1999 Aug 28;319(7209):578

Trial of steroids for treating head injury begins [news] Kmietowicz Z. **BMJ** 1999 May 29;318(7196):1441

Sufentanil, fentanyl, and alfentanil in head trauma patients: a study on cerebral hemodynamics [see comments] Albanèse J, et al. **Crit Care Med** 1999 Feb;27(2):407–11. Comment in: Crit Care Med 1999 Feb;27(2):262–3.

Corticosteroids in head injury--the CRASH trial. Yates D, et al. **J Accid Emerg Med** 1999 Mar;16(2):83–4 (5 ref.)

Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. Kelly DF, et al. **J Neurosurg** 1999 Jun;90(6):1042–52

Blunt vascular injuries of the head and neck: is heparinization necessary? Eachempati SR, et al. **J Trauma** 1998 Dec; 45(6):997–1004

Sample size review in a head injury trial with ordered categorical responses. Bolland K, et al. **Stat Med** 1998 Dec 30;17(24):2835–47

[What is the role of prophylactic anticonvulsant treatment after head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):135–7 **(Fre)**

ECONOMICS

Postpyloric enteral feeding costs for patients with severe head injury: blind placement, endoscopy, and PEG/J versus TPN. Ott L, et al. **J Neurotrauma** 1999 Mar;16(3):233–42

EPIDEMIOLOGY

The prevalence of non-standard helmet use and head injuries among motorcycle riders. Peek-Asa C, et al. **Accid Anal Prev** 1999 May;31(3):229–33

Increasing number and incidence of fall-induced severe head injuries in older adults: nationwide statistics in Finland in 1970–1995 and prediction for the future. Kannus P, et al. **Am J Epidemiol** 1999 Jan 15;149(2):143–50

Skateboarding: more dangerous than roller skating or in-line skating. Osberg JS, et al. **Arch Pediatr Adolesc Med** 1998 Oct;152(10):985–91

Variations in admissions to hospital for head injury and assault to the head. Part 1: Age and gender. Gilthorpe MS, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):294–300

Injury rates in Shotokan karate. Critchley GR, et al. **Br J Sports Med** 1999 Jun;33(3):174–7

Injuries to riders in the cross country phase of eventing: the importance of protective equipment. Whitlock MR. **Br J Sports Med** 1999 Jun;33(3):212–4

International Multicenter Study of Head Injury in Children. ISHIP Group. Murgio A, et al. **Childs Nerv Syst** 1999 Jul; 15(6–7):318–21

Alzheimer's disease in 22 twin pairs--13-year follow-up: hormonal, infectious and traumatic factors. Nee LE, et al. **Dement Geriatr Cogn Disord** 1999 Mar-Apr;10(2):148–51

Head injuries at a Provincial General Hospital in Kenya. Muyembe VM, et al. **East Afr Med J** 1999 Apr;76(4):200–5

The effect of helmets on the incidence and severity of head and cervical spine injuries in motorcycle and moped accident victims: a prospective analysis based on emergency department and trauma centre data. Van Camp LA, et al. **Eur J Emerg Med** 1998 Jun;5(2):207–11

Head injury and combat-related posttraumatic stress disorder. Chemtob CM, et al. **J Nerv Ment Dis** 1998 Nov; 186(11):701–8

Significance of vomiting after head injury. Nee PA, et al. **J Neurol Neurosurg Psychiatry** 1999 Apr;66(4):470–3

Head and neck injuries in young taekwondo athletes. Pieter W, et al. **J Sports Med Phys Fitness** 1999 Jun;39(2):147–53

Snowboard head injury: prospective study in Chino, Nagano, for two seasons from 1995 to 1997. Nakaguchi H, et al. **J Trauma** 1999 Jun;46(6):1066–9

A retrospective epidemiological analysis of non-accidental head injury in children in Scotland over a 15 year period. Barlow KM, et al. **Scott Med J** 1998 Aug;43(4):112–4

[Epidemiology of head injuries in Troms] Mortensen K, et al. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1870–3 (Eng. Abstr.) **(Nor)**

ETHNOLOGY

Variations in admission to hospital for head injury and assault to the head. Part 2: Ethnic group. Moles DR, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):301–8

ETIOLOGY

The frequency, antecedent events, and causal relationships of neurologic worsening following severe head injury. Executive Committee of the international Selfotel Trial. Ananda A, et al. **Acta Neurochir Suppl (Wien)** 1999; 73:99–102

Highchair accidents. Mayr JM, et al. **Acta Paediatr** 1999 Mar; 88(3):319–22

Increasing number and incidence of fall-induced severe head injuries in older adults: nationwide statistics in Finland in 1970–1995 and prediction for the future. Kannus P, et al. **Am J Epidemiol** 1999 Jan 15;149(2):143–50

Rear seat belt accessibility and occupant seat belt use in New York City taxicabs [letter] Manoach SM, et al. **Am J Public Health** 1998 Dec;88(12):1878

Three-dimensional human head finite-element model validation against two experimental impacts. Willinger R, et al. **Ann Biomed Eng** 1999 May-Jun;27(3):403–10

Car surfing: an uncommon cause of traumatic injury. Peterson T, et al. **Ann Emerg Med** 1999 Feb;33(2):192–4

Birth trauma in the head and neck. Hughes CA, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb;125(2):193–9

A modified crash brace position for aircraft passengers. Brownson P, et al. **Aviat Space Environ Med** 1998 Oct; 69(10):975–8

Bilateral frontal extradural haematomas caused by rupture of the superior sagittal sinus: case report. Kett-White R, et al. **Br J Neurosurg** 1999 Feb;13(1):77–8

The role of cranial MRI in identifying patients suffering from child abuse and presenting with unexplained neurological findings. Chabrol B, et al. **Child Abuse Negl** 1999 Mar; 23(3):217–28

Nonambulatory "pedestrians": infants injured by motor vehicles in driveways. Wright MS. **Clin Pediatr (Phila)** 1998 Aug;37(8):515–7

Head injuries at a Provincial General Hospital in Kenya. Muyembe VM, et al. **East Afr Med J** 1998 Jun;75(6):364–9

Golf is a dangerous game [letter] McGuffie AC, et al. **J Accid Emerg Med** 1998 Nov;15(6):437

Civilian gunshot wounds to the head with brain stem localization. A case report. Verlicchi A, et al. **J Neurosurg Sci** 1998 Dec;42(4):227–32

Head, neck, and facial injuries as markers of domestic violence in women. Perciaccante VJ, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):760–2; discussion 762–3

Analysis of missed cases of abusive head trauma [see comments] [published erratum appears in JAMA 1999 Jul 7;282(1):29] Jenny C, et al. **JAMA** 1999 Feb 17;281(7):621–6 . Comment in: JAMA 1999 Feb 17;281(7):657–9.

Ceiling fan injuries: the Townsville experience [letter; comment] Doherty SR. **Med J Aust** 1999 Jul 5;171(1):54–5 . Comment on: Med J Aust 1999 Feb 1;170(3):119–20.

Ceiling fan injuries: the Townsville experience [see comments] Potts JR. **Med J Aust** 1999 Feb 1;170(3):119–20 . Comment in: Med J Aust 1999 Jul 5;171(1):54–5.

Acute intracranial boxing-related injuries in U.S. Marine Corps recruits: report of two cases. Ross RT, et al. **Mil Med** 1999 Jan;164(1):68–70

Nonaccidental head injury in infants: "the shaken baby syndrome revisited". Conway EE Jr. **Pediatr Ann** 1998 Oct; 27(10):677–90 (60 ref.)

Golf related head injuries in children: the little tigers. McGuffie AC, et al. **Scott Med J** 1998 Oct;43(5):139–40

Golf-related head injuries [letter; comment] Parkinson D. **Surg Neurol** 1999 May;51(5):580–1. Comment on: Surg Neurol 1998 Dec;50(6):608.

Pediatric cranial golf injuries--an emerging contemporary phenomenon? [letter] [see comments] Rosenow JM, et al. **Surg Neurol** 1998 Dec;50(6):608. Comment in: Surg Neurol 1999 May;51(5):580–1.

GENETICS

Association of apolipoprotein E polymorphism with outcome after head injury. Teasdale GM, et al. **Lancet** 1997 Oct 11;350(9084):1069–71

HISTORY

Manfred Freiherr von Richthofen's medical record--was the "Red Baron" fit to fly? Allmers H. **Lancet** 1999 Aug 7; 354(9177):502–4

IMMUNOLOGY

Correlation between serum IL-6 and CRP levels and severity of head injury in children. Kalabalikis P, et al. **Intensive Care Med** 1999 Mar;25(3):288–92

METABOLISM

Is there a genetic basis for the deposition of beta-amyloid after fatal head injury? Graham DI, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):19–30

Pharmacokinetic alterations after severe head injury. Clinical relevance. Boucher BA, et al. **Clin Pharmacokinet** 1998 Sep; 35(3):209–21 (107 ref.)

Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury. Clark RS, et al. **FASEB J** 1999 May;13(8):813–21

Increased inspired oxygen concentration as a factor in improved brain tissue oxygenation and tissue lactate levels after severe human head injury. Menzel M, et al. **J Neurosurg** 1999 Jul;91(1):1–10

Early 1H magnetic resonance spectroscopy of acute head injury: four cases. Condon B, et al. **J Neurotrauma** 1998 Aug;15(8):563–71

Effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia on cerebral blood flow and metabolism, lactate, and extracellular glutamate in experimental head injury. Mori K, et al. **Neurol Res** 1998 Dec;20(8):719–26

MICROBIOLOGY

Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated

pneumonia. Ewig S, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):188–98

MORTALITY

Estimation of expected utility gained from the helmet law in Taiwan by quality-adjusted survival time. Tsauo JY, et al. **Accid Anal Prev** 1999 May;31(3):253–63

Re: Craniofacial injuries resulting from taxicab accidents in New York City [letter; comment] Talmor M, et al. **Ann Plast Surg** 1998 Sep;41(3):332. Comment on: Ann Plast Surg 1996 Jan;36(1):1–6.

Study of head injury victims in fatal road traffic accidents in Delhi. Banerjee KK, et al. **Indian J Med Sci** 1998 Sep; 52(9):395–8

Outcome in severely head injured patients with and without multiple trauma. Baltas I, et al. **J Neurosurg Sci** 1998 Jun; 42(2):85–8

Severe head injury in children: impact of risk factors on outcome. Feickert HJ, et al. **J Trauma** 1999 Jul;47(1):33–8

Severe pediatric head injury: myth, magic, and actual fact [letter] Bruce D. **Pediatr Neurosurg** 1998 Sep;29(3):164–5

PATHOLOGY

Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Geddes JF, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):171–8

Correlation of survival time with size of axonal swellings in diffuse axonal injury. Wilkinson AE, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):197–202

Multifactorial analysis of firearm wounds to the head with attention to anatomic location. Cina SJ, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):109–15

Centerfire frangible ammunition: wounding potential and other forensic concerns. Kaplan J, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):299–302

A penny (or peso) for your thoughts: an unusual intermediate target. Mallak C, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):230–3

Remarkable improvement of severe diffuse axonal injury without L-dopa treatment [letter; comment] Yoshikawa H, et al. **Brain Dev** 1999 Mar;21(2):140–1. Comment on: Brain Dev 1998 Mar;20(2):124–6.

Bruising in non-accidental head injured children; a retrospective study of the prevalence, distribution and pathological associations in 24 cases. Atwal GS, et al. **Forensic Sci Int** 1998 Sep 28;96(2–3):215–30

Suicidal hanging resulting in complete decapitation: a case report. Tracqui A, et al. **Int J Legal Med** 1999;112(1):55–7

Air weapon fatalities. Milroy CM, et al. **J Clin Pathol** 1998 Jul;51(7):525–9

Accidental decapitation: an unusual injury to a passenger in a vehicle. Kibayashi K, et al. **Med Sci Law** 1999 Jan; 39(1):82–4

A comparison of manual and semi-automated methods in the assessment of axonal injury. Gentleman SM, et al. **Neuropathol Appl Neurobiol** 1999 Feb;25(1):41–7

Olivary degeneration after intracranial haemorrhage or trauma: follow-up MRI. Suzuki M, et al. **Neuroradiology** 1999 Jan;41(1):9–12

[Extrapontine myelinolysis: treatment with TRH] Chemaly R, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):163–5 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The frequency, antecedent events, and causal relationships of neurologic worsening following severe head injury. Executive Committee of the international Selfotel Trial. Ananda A, et al. **Acta Neurochir Suppl (Wien)** 1999; 73:99–102

System analysis of patient management during the pre- and early clinical phase in severe head injury. Baethmann A, et al. **Acta Neurochir Suppl (Wien)** 1999;73:93–7

Altered excitability of the motor cortex after minor head injury revealed by transcranial magnetic stimulation. Chistyakov AV, et al. **Acta Neurochir (Wien)** 1998; 140(5):467–72

Correlation of survival time with size of axonal swellings in diffuse axonal injury. Wilkinson AE, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):197–202

Central nervous system metabolic and physiologic effects of laparoscopy. Moncure M, et al. **Am Surg** 1999 Feb; 65(2):168–72

Circadian rhythm of cerebral perfusion pressure and intracranial pressure in head injury. Kropyvnytskyy IV, et al. **Brain Inj** 1999 Jan;13(1):45–52

Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone. De Marinis L, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):741–7

Cerebrovascular pressure transmission analysis as a guide to the pathophysiology of raised intracranial pressure. Lewis SB. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):947–50 (40 ref.)

Dissociation of somatosensory and motor evoked potentials in non-comatose patients after head injury. Chistyakov AV, et al. **Clin Neurophysiol** 1999 Jun;110(6):1080–9

The relation between intracranial pressure and outcome in non-accidental head injury. Barlow KM, et al. **Dev Med Child Neurol** 1999 Apr;41(4):220–5

Poor outcome after hypoxia-ischemia in newborns is associated with physiological abnormalities during early recovery. Possible relevance to secondary brain injury after head trauma in infants. Brambrink AM, et al. **Exp Toxicol Pathol** 1999 Feb;51(2):151–62

Intracranial hypertension in head injury: management and results [see comments] Stocchetti N, et al. **Intensive Care Med** 1999 Apr;25(4):371–6. Comment in: Intensive Care Med 1999 Apr;25(4):348–9.

Surface friction in near-vertex head and neck impact increases risk of injury. Camacho DL, et al. **J Biomech** 1999 Mar;32(3):293–301

Quantification of post-concussion symptoms 3 months after minor head injury in 100 consecutive patients. Ingebrigtsen T, et al. **J Neurol** 1998 Sep;245(9):609–12

Bedside tests of saccades after head injury. Mulhall LE, et al. **J Neuroophthalmol** 1999 Sep;19(3):160–5

Hemodynamic characterization of intracranial pressure plateau waves in head-injury patients. Czosnyka M, et al. **J Neurosurg** 1999 Jul;91(1):11–9

Temporal changes in intracranial pressure in a modified experimental model of closed head injury. Engelborghs K, et al. **J Neurosurg** 1998 Nov;89(5):796–806

Propofol in the treatment of moderate and severe head injury: a randomized, prospective double-blinded pilot trial. Kelly DF, et al. **J Neurosurg** 1999 Jun;90(6):1042–52

Assessing disability after head injury: improved use of the Glasgow Outcome Scale. Pettigrew LE, et al. **J Neurosurg** 1998 Dec;89(6):939–43

Interhemispheric supratentorial intracranial pressure gradients in head-injured patients: are they clinically important? Sahuquillo J, et al. **J Neurosurg** 1999 Jan; 90(1):16–26

Granulocyte colony-stimulating factor inhibits neutrophil apoptosis at the local site after severe head and thoracic injury. Ertel W, et al. **J Trauma** 1999 May;46(5):784–92; discussion 792–3

Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury. Gando S, et al. **J Trauma** 1999 Jun;46(6):1070–6; discussion 1076–7

Hypothalamic dysfunction in acute head-injured patients with stress ulcer. Hwang SL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):554–60

Asymptomatic hyponaturemia in a patient with mild head injury due to syndrome of inappropriate diuretic hormone--a case report. Ishibashi A, et al. **Kurume Med J** 1999;46(2):123–5

Brain stem blood flow, pupillary response, and outcome in patients with severe head injuries. Ritter AM, et al. **Neurosurgery** 1999 May;44(5):941–8

Physiologic monitoring of circulatory dysfunction in patients with severe head injuries. Velmahos GC, et al. **World J Surg** 1999 Jan;23(1):54–8

[Progress of study on biomechanical mechanisms of head impact injury] Liu Y, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):73–6 (19 ref.) (Eng. Abstr.) **(Chi)**

[Proceedings of the XVIII Meeting of Neuroanesthesia and Resuscitation of the French Languages. Clermont-Ferrand, France, 21–22 November 1996] **Ann Fr Anesth Reanim** 1997;16(4):389–458 **(Fre)**

[Dissociative stupor--differential diagnosis of coma following injury] Hintze U, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):753–5 (Eng. Abstr.) **(Ger)**

[What kind of monitoring of intracranial pressure] Citerio G, et al. **Minerva Anestesiol** 1999 May;65(5):318–21 (24 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

The prevalence of non-standard helmet use and head injuries among motorcycle riders. Peek-Asa C, et al. **Accid Anal Prev** 1999 May;31(3):229–33

A modified crash brace position for aircraft passengers. Brownson P, et al. **Aviat Space Environ Med** 1998 Oct; 69(10):975–8

Skiing helmets. Rees-Jones A. **Br J Sports Med** 1999 Feb; 33(1):3 (10 ref.)

Injuries to riders in the cross country phase of eventing: the importance of protective equipment. Whitlock MR. **Br J Sports Med** 1999 Jun;33(3):212–4

Bicycle helmet promotion among low income preschool children. Britt J, et al. **Inj Prev** 1998 Dec;4(4):280–3

Helmet laws and health. Robinson D, et al. **Inj Prev** 1998 Sep;4(3):170–2

The circumstances and scope for prevention of maxillofacial injuries in cyclists. Harrison MG, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):82–6

JAMA Patient Page: head injury. **JAMA** 1999 Sep 8; 282(10):1010

Bicycle helmets: it's the law. Fisher NL. **Med Health R I** 1999 Aug;82(8):302–3

Head and face injuries in scholastic women's lacrosse with and without eyewear. Webster DA, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):938–41

Why do child cyclists in the United States remain unhelmeted? Bergman AB, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):107–9

[Far too few schoolchildren use protective helmets when bicycling. Review of the literature and questionnaires as basis for promotion of increased use of the helmets] Berg P, et al. **Lakartidningen** 1999 May 12;96(19):2383–6 (43 ref.) **(Swe)**

PSYCHOLOGY

P300 and stress in mild head injury patients. Granovsky Y, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 108(6):554–9

How well do standard clinical neuropsychological tests identify malingering? A preliminary analysis. van Gorp WG, et al. **J Clin Exp Neuropsychol** 1999 Apr;21(2):245–50

Neuropsychiatric sequelae one year after a minor head injury [see comments] Deb S, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):899–902. Comment in: J Neurol Neurosurg Psychiatry 1998 Dec;65(6):809.

Neuropsychiatric sequelae one year after a minor head injury [editorial; comment] Fleminger S. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):809. Comment on: J Neurol Neurosurg Psychiatry 1998 Dec;65(6):899–902.

Acute stress disorder: application to families of head-injured patients. Pittman D, et al. **J Neurosci Nurs** 1998 Aug; 30(4):253–6

Anxiety and depression disorders 5 years after severe injuries: a prospective follow-up study. Piccinelli M, et al. **J Psychosom Res** 1999 May;46(5):455–64

Towards a composite scoring solution for the Neurobehavioral Functioning Inventory. Weinfurt KP, et al. **Qual Life Res** 1999;8(1–2):17–24

RADIOGRAPHY

Correlation of computed tomography findings and serum brain damage markers following severe head injury. Raabe A, et al. **Acta Neurochir (Wien)** 1998;140(8):787–91; discussion 791–2

Detecting acute extraaxial blood with bone algorithm CT images. Lerner C. **AJR Am J Roentgenol** 1998 Dec; 171(6):1707

Sedation of intoxicated, agitated patients requiring CT to evaluate head injury [letter] Holger JS, et al. **Am J Emerg Med** 1999 May;17(3):321–3

Ballistic aspects of tandem-loaded cartridges of identical caliber. Rabl W, et al. **Int J Legal Med** 1999;112(1):58–61

Computed tomography of the head by the accident and emergency department--why 24 hour access is vital [see comments] MacNamara AF, et al. **J Accid Emerg Med** 1998 Sep;15(5):294–7. Comment in: J Accid Emerg Med 1999 Jan;16(1):75–6.

Prognostic value of early computerized tomography scanning following craniotomy for traumatic hematoma. Lubillo S, et al. **J Neurosurg** 1999 Oct;91(4):581–7

The utility of head computed tomography after minimal head injury. Nagy KK, et al. **J Trauma** 1999 Feb;46(2):268–70

Acute intracranial boxing-related injuries in U.S. Marine Corps recruits: report of two cases. Ross RT, et al. **Mil Med** 1999 Jan;164(1):68–70

Diplopia after head injury. Swischuk LE. **Pediatr Emerg Care** 1999 Jun;15(3):233–4

Commentary: head injury in children. Who needs a skull X-ray? Carty H, et al. **Pediatr Radiol** 1998 Nov; 28(11):815–6

Extracranial soft-tissue swelling: a normal postmortem radiographic finding or a sign of trauma? Strouse PJ, et al. **Pediatr Radiol** 1998 Aug;28(8):594–6

Trauma head CT interpretation by radiology residents versus staff radiologists [letter] Wysoki M. **Radiology** 1999 Jan; 210(1):283

[Head injuries in children: how to proceed without radiographs? (editorial)] Adamsbaum C, et al. **J Radiol** 1999 Aug;80(8):819–20, 822 **(Fre)**

[Skull and brain injuries in children] Fiebach JB, et al. **Radiologe** 1999 Jun;39(6):463–6 (Eng. Abstr.) **(Ger)**

[Minor head injury in adults. Results of the application of a guideline] Ciccarese E, et al. **Radiol Med (Torino)** 1998 Nov;96(5):480–4 (Eng. Abstr.) **(Ita)**

[Crushing head injuries: report of six cases] Sawauchi S, et al. **No Shinkei Geka** 1999 Jun;27(6):557–61 (Eng. Abstr.) **(Jpn)**

[Normal findings by computer tomography do not exclude CNS injury] Sojka P, et al. **Lakartidningen** 1999 Feb 10; 96(6):616 **(Swe)**

REHABILITATION

Using the measure of processes of care with parents of children hospitalized for head injury. Swaine BR, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):323–9

Musculoskeletal rehabilitation and sports medicine. 1. Head and spine injuries. Sherman AL, et al. **Arch Phys Med Rehabil** 1999 May;80(5 Suppl 1):S40–9 (109 ref.)

Treatment of aggression and irritability after head injury. Kant R, et al. **Brain Inj** 1998 Aug;12(8):661–6

Remediation of attention deficits in head injury. Nag S, et al. **Neurol India** 1999 Mar;47(1):32–9

[Radon baths and laser therapy in the rehabilitation of patients with the late sequelae of joint trauma to the head and neck] Kulikov NN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jan–Feb;(1):25–7 (Eng. Abstr.) **(Rus)**

SURGERY

Diabetes insipidus in neurosurgical patients. Wong MF, et al. **Ann Acad Med Singapore** 1998 May;27(3):340–3

General surgeons and the management of head injuries. Collins RE, et al. **Ann R Coll Surg Engl** 1999 May; 81(3):151–3

Total ear reconstruction in post burn deformity. Bhandari PS. **Burns** 1998 Nov;24(7):661–70

Self-inflicted gunshot wounds to the head during the war and post-war period. Vranković D, et al. **Injury** 1998 Jun; 29(5):369–73

Custom-made cast titanium implants produced with CAD/CAM for the reconstruction of cranium defects. Heissler E, et al. **Int J Oral Maxillofac Surg** 1998 Oct; 27(5):334–8

Prognostic value of early computerized tomography scanning following craniotomy for traumatic hematoma. Lubillo S, et al. **J Neurosurg** 1999 Oct;91(4):581–7

[What are the indications for neurosurgery in the early stage of head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):58–71 (31 ref.) **(Fre)**

[Postoperative wound infections. I. Population data and risk factors] Anielski R, et al. **Przegl Lek** 1998;55(3):101–8 (Eng. Abstr.) **(Pol)**

[Secondary neurosurgical management of craniocerebral war injuries] Antić B, et al. **Vojnosanit Pregl** 1999 Jan–Feb; 56(1):9–13 (Eng. Abstr.) **(Scc)**

[Primary neurosurgical treatment of craniocerebral war injuries] Antić B, et al. **Vojnosanit Pregl** 1998 Jul–Aug; 55(4):373–80 (Eng. Abstr.) **(Scc)**

THERAPY

System analysis of patient management during the pre- and early clinical phase in severe head injury. Baethmann A, et al. **Acta Neurochir Suppl (Wien)** 1999;73:93–7

Cervical collar-induced changes in intracranial pressure. Kolb JC, et al. **Am J Emerg Med** 1999 Mar;17(2):135–7

Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Ewig S, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):188–98

Meeting the standards for interhospital transfer of adults with severe head injury in the United Kingdom. Knowles PR, et al. **Anaesthesia** 1999 Mar;54(3):283–8

Treatment of head injuries. Valtonen S, et al. **Ann Chir Gynaecol** 1998;87(3):266–70 (9 ref.)

Minor head injury in children: current management practices of pediatricians, emergency physicians, and family physicians. Aitken ME, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1176–80

ABC of intensive care: neurological support. Grant IS, et al. **BMJ** 1999 Jul 10;319(7202):110–3 (0 ref.)

Recommendations from the Society of British Neurological Surgeons. Bartlett J, et al. **Br J Neurosurg** 1998 Aug; 12(4):349–52

Technique of removal of an impacted sharp object in a penetrating head injury using the lever principle. Rao GP, et al. **Br J Neurosurg** 1998 Dec;12(6):569–71

Remarkable improvement of severe diffuse axonal injury without L-dopa treatment [letter; comment] Yoshikawa H, et al. **Brain Dev** 1999 Mar;21(2):140–1. Comment on: Brain Dev 1998 Mar;20(2):124–6.

Management of the severely head injured patient. Baker AJ. **Can J Anaesth** 1999 May;46(5 Pt 2):R35–45 (40 ref.) **(Eng, Fre)**

Improved outcome after severe head injury with a new therapy based on principles for brain volume regulation and preserved microcirculation [see comments] Eker C, et al. **Crit Care Med** 1998 Nov;26(11):1881–6. Comment in: Crit Care Med 1998 Nov;26(11):1787–8.

Hypocapnia does not alter hepatic blood flow or oxygen consumption in patients with head injury. Ichai C, et al. **Crit Care Med** 1998 Oct;26(10):1725–30

Sports-related head injuries. Chorley JN. **Curr Opin Pediatr** 1998 Aug;10(4):350–5 (62 ref.)

Camouflage in head and neck region--a non-invasive option for skin lesions. Hell B, et al. **Int J Oral Maxillofac Surg** 1999 Apr;28(2):90–4

Guidelines for the pre-hospital care of patients with severe head injuries. Working Group for Neurosurgical Intensive Care of the European Society of Intensive Care Medicine. Piek J. **Intensive Care Med** 1998 Nov;24(11):1221–5

Intracranial hypertension in head injury: management and results [see comments] Stocchetti N, et al. **Intensive Care Med** 1999 Apr;25(4):371–6. Comment in: Intensive Care Med 1999 Apr;25(4):348–9.

Severe head injury: improvement of outcome [editorial; comment] Unterberg A. **Intensive Care Med** 1999 Apr; 25(4):348–9. Comment on: Intensive Care Med 1999 Apr;25(4):371–6.

Outcome after severe head injury treated by an integrated trauma system. Coats TJ, et al. **J Accid Emerg Med** 1999 May;16(3):182–5

Mild hypothermia: an alternative to deep hypothermia for achieving neuroprotection. Bell TE, et al. **J Cardiovasc Nurs** 1998 Oct;13(1):34–44 (35 ref.)

Hypothermia and head injury [letter; comment] Cruz J. **J Neurosurg** 1999 Mar;90(3):607–8. Comment on: J Neurosurg 1998 Aug;89(2):206–11.

Increased inspired oxygen concentration as a factor in improved brain tissue oxygenation and tissue lactate levels after severe human head injury. Menzel M, et al. **J Neurosurg** 1999 Jul;91(1):1–10

Little benefit from mild hypothermia therapy for severely head injured patients with low intracranial pressure. Shiozaki T, et al. **J Neurosurg** 1999 Aug;91(2):185–91

Is it possible to recover from uncal herniation? Analysis of 71 head injured cases. Uzan M, et al. **J Neurosurg Sci** 1998 Jun;42(2):89–94

Postpyloric enteral feeding costs for patients with severe head injury: blind placement, endoscopy, and PEG/J versus TPN. Ott L, et al. **J Neurotrauma** 1999 Mar;16(3):233–42

Completion rates and feasibility of outcome measures: experience in a multicenter clinical trial of systemic hypothermia for severe head injury. Scheibel RS, et al. **J Neurotrauma** 1998 Sep;15(9):685–92

Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Teasdale GM, et al. **J Neurotrauma** 1998 Aug;15(8):587–97 (23 ref.)

Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries. Ishikawa K, et al. **J Trauma** 1999 Jun; 46(6):999–1007; discussion 1007–8

Hypothermia-induced hypokalemia. Zydlewski AW, et al. **Mil Med** 1998 Oct;163(10):719–21

Paediatric head injury: incidence, aetiology and management. Lam WH, et al. **Paediatr Anaesth** 1999;9(5):377–85 (68 ref.)

[What are the treatment modalities of severe head injuries in the prehospital phase?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):36–46 (67 ref.) **(Fre)**

[Management of severe head injuries in the early stage. Recommendations] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):15–22 **(Fre)**

[What are the indications and modalities of medical treatments for intracranial hypertension from severe head injuries?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):108–22 (45 ref.) **(Fre)**

[What is the strategy for management of a multiple trauma patient with a severe head injury?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):123–34 (47 ref.) **(Fre)**

[Accidental intracerebral penetration of a nasal hemostatic probe] Adam JC, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):436–9 (Eng. Abstr.) **(Fre)**

[Severe head injuries: effects of pre-hospital mechanical ventilation on capnia] David JS, et al. **Ann Fr Anesth Reanim** 1999 Apr;18(4):398–402 (Eng. Abstr.) **(Fre)**

[Cranial injuries and management in emergency situations] Emery E, et al. **Rev Prat** 1999 Jun 1;49(11):1233–9 **(Fre)**

[Recommendations for the treatment of serious adult head injury. II. Medical treatment criteria. Societza Italiana di Anestesia, Analgesia, Rianimatiozione e Terpia Intensiva] Beretta L, et al. **Minerva Anestesiol** 1999 Apr;65(4):159–68 **(Ita)**

[Recommendations for the treatment of serious adult head injury. I. Initial evaluation, prehospital observation and treatment, hospitalization criteria, systemic and cerebral monitoring. Societza Italiana di Anestesia, Analgesia, Rianimatiozione e Terpia Intensiva] Procaccio F, et al. **Minerva Anestesiol** 1999 Apr;65(4):147–58 **(Ita)**

[Cerebral tissue oxygen monitoring: a useful thing?] Rossi S, et al. **Minerva Anestesiol** 1999 May;65(5):327–30 (19 ref.) (Eng. Abstr.) **(Ita)**

[Cranial trauma and multiple trauma: from the street to the operating room] Stocchetti N, et al. **Minerva Anestesiol** 1999 Jun;65(6):353–6 (6 ref.) (Eng. Abstr.) **(Ita)**

[Crucial evaluation of medical management in patients with cranial and brain injuries from the moment of the accident to the end of the diagnostics] Dybkowska K, et al. **Przegl Lek** 1998;55(12):650–3 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

[Hypothenar hammer syndrome] Houshian S, et al. **Ugeskr Laeger** 1999 Aug 16;161(33):4643–4 (Eng. Abstr.) **(Dan)**

HEAD INJURIES, CLOSED

see related
BRAIN INJURIES

Elderly patients with closed head trauma after a fall: mechanisms and outcomes. Nagurney JT, et al. **J Emerg Med** 1998 Sep–Oct;16(5):709–13

COMPLICATIONS

Outcome of traumatic optic neuropathy. Comparison between surgical and nonsurgical treatment. Mine S, et al. **Acta Neurochir (Wien)** 1999;141(1):27–30

Traumatic subdural pneumocephalus causing rise in intracranial pressure in the early phase of head trauma: report of two cases. Oge K, et al. **Acta Neurochir (Wien)** 1998;140(7):655–8 (13 ref.)

Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage. Talmor D, et al. **Anesth Analg** 1999 Oct;89(4):950–6

Bilateral dissection of the internal carotid artery at the base of the skull due to blunt trauma: incidence and severity. Alimi Y, et al. **Ann Vasc Surg** 1998 Nov;12(6):557–65

Extracranial repair of pediatric traumatic cerebrospinal fluid rhinorrhea. Ng M, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1125–30 (19 ref.)

Early prediction of persisting post-concussion symptoms following mild and moderate head injuries. King NS, et al. **Br J Clin Psychol** 1999 Mar;38 (Pt 1):15–25

Heading in soccer--time for a rethink? [editorial] Kernick DP. **Br J Gen Pract** 1999 Mar;49(440):171

The role of imagery in sexual arousal disturbances in the male traumatically brain injured individual. Crowe SF, et al. **Brain Inj** 1999 May;13(5):347–54

Utility of a microcomputer as an external memory aid for a memory-impaired head injury patient during in-patient rehabilitation. Kim HJ, et al. **Brain Inj** 1999 Feb; 13(2):147–50

A validity study of the WAIT in closed head injury. McDonald TW, et al. **Brain Inj** 1999 May;13(5):331–46

Intonation unit analysis of conversational discourse in closed head injury. Wozniak RJ, et al. **Brain Inj** 1999 Mar; 13(3):191–203

Aneurysm of the posterior inferior cerebellar artery caused by a traumatic perforating artery tear-out mechanism in a child. Sure U, et al. **Childs Nerv Syst** 1999 Jul; 15(6–7):354–6

Reactivation of posttraumatic stress disorder after minor head injury. Berthier ML, et al. **Depress Anxiety** 1998;8(1):43–7

Mild closed head injury in children compared to traumatic fractured bone; neurobehavioural sequelae in daily life 2 years after the accident. Overweg-Plandsoen WC, et al. **Eur J Pediatr** 1999 Mar;158(3):249–52

Exsanguination from impact head trauma; the explanation for the "empty heart" sign. Contostavlos DL. **Forensic Sci Int** 1998 Aug 12;95(3):201–12

Performance of individuals with severe long-term traumatic brain injury on time-, event-, and activity-based prospective memory tasks. Shum D, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):49–58

Reaction time indicators of attention deficits in closed head injury. Zahn TP, et al. **J Clin Exp Neuropsychol** 1999 Jun; 21(3):352–67

Cognitive and behavioral sequelae of closed head injury in older adults according to their significant others. Goldstein FC, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter; 11(1):38–44

Safety and efficacy of ECT in patients with head injury: a case series. Kant R, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter;11(1):32–7

Nonfluent aphasia after closed head trauma: report of a case. Stein M, et al. **J Oral Maxillofac Surg** 1999 Jun;57(6):745–8

Outcome of closed head injury in Malaysian children: neurocognitive and behavioural sequelae. Ong LC, et al. **J Paediatr Child Health** 1998 Aug;34(4):363–8

Slow information processing after very severe closed head injury: impaired access to declarative knowledge and intact application and acquisition of procedural knowledge. Timmerman ME, et al. **Neuropsychologia** 1999 Apr; 37(4):467–78

Does traumatic subarachnoid hemorrhage caused by diffuse brain injury cause delayed ischemic brain damage? Comparison with subarachnoid hemorrhage caused by ruptured intracranial aneurysms. Fukuda T, et al. **Neurosurgery** 1998 Nov;43(5):1040–9

[Painful Claude Bernard Horner syndrome: apropos of a painless carotid artery dissection] Ameline-Audelan V. **J Fr Ophtalmol** 1998 Oct;21(8):591–5 (Eng. Abstr.) **(Fre)**

[Remote results of conservative treatment of traumatic optic neuropathy] Mariak Z, et al. **Neurol Neurochir Pol** 1998 Sep–Oct;32(5):1165–72 (Eng. Abstr.) **(Pol)**

[Subjective complaints in patients after a closed head injury] Savanović V, et al. **Vojnosanit Pregl** 1999 Mar–Apr; 56(2):135–42 (Eng. Abstr.) **(Scc)**

DIAGNOSIS

Primary brainstem injury: benign course and improved survival. Bhatoe HS. **Acta Neurochir (Wien)** 1999; 141(5):515–9

Motor performance following a mild traumatic brain injury in children: an exploratory study. Gagnon I, et al. **Brain Inj** 1998 Oct;12(10):843–53

Corpus callosum damage and interhemispheric transfer of information following closed head injury in children. Benavidez DA, et al. **Cortex** 1999 Jun;35(3):315–36

Evaluation of the patient with closed head trauma: an evidence based approach. Cheung DS, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):9–23, vii (59 ref.)

Acute traumatic stroke: a case of bow hunter's stroke in a child. Duval EL, et al. **Eur J Emerg Med** 1998 Jun; 5(2):259–63

Investigation of the head injured patient. Swann IJ, et al. **J Accid Emerg Med** 1998 Sep;15(5):337–43 (49 ref.)

Later investigation of head injury. Swann IJ, et al. **J Accid Emerg Med** 1998 Sep;15(5):344–8

Crush head injuries in infants and young children neurologic and neuropsychologic sequelae. Prasad MR, et al. **J Child Neurol** 1999 Aug;14(8):496–501

Learning people's names following severe closed-head injury. Milders M. **J Clin Exp Neuropsychol** 1998 Apr;

20(2):237–44
A prospective analysis of the recovery of attention following pediatric head injury. Catroppa C, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):48–57
Cognitive outcome in children and adolescents following severe traumatic brain injury: influence of psychosocial, psychiatric, and injury-related variables. Max JE, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):58–68
Traumatic brain injury in children and adolescents: psychiatric disorders at one year. Max JE, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):290–7
1H spectroscopic imaging of acute head injury—evidence of diffuse axonal injury. Wild JM, et al. **MAGMA** 1999 May;8(2):109–15
Minor head trauma. Weight DG. **Psychiatr Clin North Am** 1998 Sep;21(3):609–24 (58 ref.)
[Diffusion-weighted MR imaging in a case of dissociative amnesia] Back T, et al. **Nervenarzt** 1998 Oct;69(10):909–12 (Eng. Abstr.) **(Ger)**
[Bilateral hypoglossal nerve paralysis as isolated neurological symptom after craniocerebral trauma] Noppeney U, et al. **Nervenarzt** 1999 Apr;70(4):357–8 (Eng. Abstr.) **(Ger)**
[Controversy regarding the sequelae of minor craniocervical trauma with special reference to neurobiological aspects of cognitive disorders] Radanov BP. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):365–73 (76 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Are vasopressors beneficial after cranial trauma? [letter; comment] Talmor D, et al. **Anesth Analg** 1999 Jun; 88(6):1423–4. Comment on: Anesth Analg 1998 Oct;87(4):751–3.
Tirilazad widens the therapeutic window for riluzole-induced attenuation of progressive cortical degeneration in an infant rat model of the shaken baby syndrome. Smith SL, et al. **J Neurotrauma** 1998 Sep; 15(9):707–19

EPIDEMIOLOGY

The epidemiology of sports-related traumatic brain injuries in the United States: recent developments. Thurman DJ, et al. **J Head Trauma Rehabil** 1998 Apr;13(2):1–8
[Craniocerebral trauma in sports. With recommendations for prevention] Weber J, et al. **Sportverletz Sportschaden** 1999 Mar;13(1):30–5 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Blood-brain barrier permeability, neutrophil accumulation and vascular adhesion molecule expression after controlled cortical impact in rats: a preliminary study. Whalen MJ, et al. **Acta Neurochir Suppl (Wien)** 1998;71:212–4
The role of cytokines in the neuropathology of stroke and neurotrauma. Feuerstein GZ, et al. **Neuroimmunomodulation** 1998 May–Aug;5(3–4):143–59 (163 ref.)

METABOLISM

Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Lomnitski L, et al. **Biochim Biophys Acta** 1999 Mar 30;1453(3):359–68
Wisconsin Card Sorting Test performance following head injury: dorsolateral fronto-striatal circuit activity predicts perseveration. Lombardi WJ, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):2–16
Metabolic responses and nutritional therapy in patients with severe head injuries. Wilson RF, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):11–27 (113 ref.)
Antioxidants attenuate acute toxicity of tumor necrosis factor-alpha induced by brain injury in rat. Trembovler V, et al. **J Interferon Cytokine Res** 1999 Jul;19(7):791–5
Infant rat model of the shaken baby syndrome: preliminary characterization and evidence for the role of free radicals in cortical hemorrhaging and progressive neuronal degeneration. Smith SL, et al. **J Neurotrauma** 1998 Sep; 15(9):693–705

MORTALITY

Vertebral artery trauma. Opeskin K, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):206–17 (84 ref.)

PATHOLOGY

Selective hippocampal damage to hypoxia after mild closed head injury in the rat. Katoh H, et al. **Acta Neurochir Suppl (Wien)** 1998;71:247–9
Diffuse neuronal perikaryon amyloid precursor protein immunoreactivity in a focal head impact model. Van Den Heuvel C, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:209–11
Effect of mechanogated membrane ion channel blockers on experimental traumatic brain oedema. Vaz R, et al. **Acta Neurochir (Wien)** 1998;140(4):371–4; discussion 375
Pontine axonal injury after brain trauma and nontraumatic hypoxic-ischemic brain damage. Oehmichen M, et al. **Int J Legal Med** 1999;112(4):261–7
A fiber-reinforced composite model of the viscoelastic behavior of the brainstem in shear. Arbogast KB, et al. **J Biomech** 1999 Aug;32(8):865–70
Wisconsin Card Sorting Test performance following head injury: dorsolateral fronto-striatal circuit activity predicts perseveration. Lombardi WJ, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):2–16
Neuropathologic characterization of a rodent model of closed head injury--addition of clinically relevant secondary insults does not significantly potentiate brain damage. Lammie GA, et al. **J Neurotrauma** 1999 Jul;16(7):603–15
Biophysical linkage between MRI and EEG coherence in closed head injury. Thatcher RW, et al. **Neuroimage** 1998 Nov;8(4):307–26
Multifocal cerebellar granular layer necrosis in traumatically head-injured lambs. Finnie JW, et al. **Vet Pathol** 1999 May; 36(3):256–8

PHYSIOPATHOLOGY

Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. Adelson PD, et al. **Acta Neurochir Suppl (Wien)** 1998;71:104–6
Determining cerebral perfusion pressure thresholds in severe head trauma. Lewis S, et al. **Acta Neurochir Suppl (Wien)** 1998;71:174–6
Effects of mild and moderate hypothermia on cerebral metabolism and glutamate in an experimental head injury. Mori K, et al. **Acta Neurochir Suppl (Wien)** 1998;71:222–4
Brain-stem auditory evoked potential monitoring in experimental diffuse brain injury. Rosahl SK, et al. **Acta Neurochir Suppl (Wien)** 1998;71:88–90
Evaluation of cerebrovascular CO2-reactivity and autoregulation in patients with post-traumatic diffuse brain swelling (diffuse injury III). Sahuquillo J, et al. **Acta Neurochir Suppl (Wien)** 1998;71:233–6
Early cerebral blood volume after severe traumatic brain injury in patients with early cerebral ischemia. Schröder ML, et al. **Acta Neurochir Suppl (Wien)** 1998;71:127–30
CSF dynamics in a rodent model of closed head injury. Schuhmann MU, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:300–2
Traumatic brain injury in the developing rat pup: studies of ICP, PVI and neurological response. Thomas S, et al. **Acta Neurochir Suppl (Wien)** 1998;71:135–7
Monitoring brain oxygen tension in severe head injury: the Rotterdam experience. van den Brink WA, et al. **Acta Neurochir Suppl (Wien)** 1998;71:190–4
Confabulation and delusional misidentification: a four year follow-up study. Mattioli F, et al. **Cortex** 1999 Jun; 35(3):413–22
A fiber-reinforced composite model of the viscoelastic behavior of the brainstem in shear. Arbogast KB, et al. **J Biomech** 1999 Aug;32(8):865–70
Relation between diffuse axonal injury and internal head structures on blunt impact. Nishimoto T, et al. **J Biomech Eng** 1998 Feb;120(1):140–7
Closed head injury in the rat induces whole body oxidative stress: overall reducing antioxidant profile. Shohami E, et al. **J Neurotrauma** 1999 May;16(5):365–76
Gastric emptying in male neurologic trauma. Kao CH, et al. **J Nucl Med** 1998 Oct;39(10):1798–801
Biophysical linkage between MRI and EEG coherence in closed head injury. Thatcher RW, et al. **Neuroimage** 1998 Nov;8(4):307–26
Event-related brain potentials reveal covert distractibility in closed head injuries. Kaipio ML, et al. **Neuroreport** 1999 Jul 13;10(10):2125–9

PREVENTION & CONTROL

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Huang W, et al. **Eur J Pharmacol** 1999 Feb 5; 366(2–3):127–35

PSYCHOLOGY

Depression after traumatic brain injury: conceptualization and treatment considerations. Ownsworth TL, et al. **Brain Inj** 1998 Sep;12(9):735–51 (71 ref.)
The patient, the teacher [editorial] Lee L. **Fam Med** 1999 Feb;31(2):133–4
Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. Dennis M, et al. **J Autism Dev Disord** 1999 Feb;29(1):5–17
Reconstructive memory bias in recall of neuropsychological symptomatology. Hilsabeck RC, et al. **J Clin Exp Neuropsychol** 1998 Jun;20(3):328–38
WISC-III index growth curve characteristics following traumatic brain injury. Wechsler Intelligence Scale for Children--Third Edition. Kay JB, et al. **J Clin Exp Neuropsychol** 1999 Apr;21(2):186–99
Retrieving familiar people's names in patients with severe closed-head injuries. Milders MW, et al. **J Clin Exp Neuropsychol** 1999 Apr;21(2):171–85
Direct and indirect memory measures of temporal order and spatial location: control versus closed-head injury participants. Vakil E, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1998 Oct; 11(4):212–7

RADIOGRAPHY

Clinical studies on diffuse axonal injury in patients with severe closed head injury. Wang H, et al. **Chin Med J (Engl)** 1998 Jan;111(1):59–62
[Post-traumatic aneurysm of the internal carotid artery with life-threatening epistaxis] Tomandl BF, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):437–40 **(Ger)**

REHABILITATION

Mild traumatic brain injury from motor vehicle accidents: factors associated with return to work. Ruffolo CF, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):392–8
Residential and home-based postacute rehabilitation of individuals with traumatic brain injury: a case control study. Willer B, et al. **Arch Phys Med Rehabil** 1999 Apr; 80(4):399–406
Keeping relatives informed by the internet [letter] Boots RJ, et al. **Lancet** 1999 Aug 7;354(9177):517–8

SURGERY

[Prepontine epidural hemorrhage] Müller JU, et al. **Zentralbl Neurochir** 1998;59(3):185–8 (8 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

External lumbar drainage in uncontrollable intracranial pressure in adults with severe head injury: a report of 7 cases. Willemse RB, et al. **Acta Neurochir Suppl (Wien)** 1998;71:37–9
Primary brainstem injury: benign course and improved survival. Bhatoe HS. **Acta Neurochir (Wien)** 1999; 141(5):515–9
Investigation of the head injured patient. Swann IJ, et al. **J Accid Emerg Med** 1998 Sep;15(5):337–43 (49 ref.)
Later investigation of head injury. Swann IJ, et al. **J Accid Emerg Med** 1998 Sep;15(5):344–8
Metabolic responses and nutritional therapy in patients with severe head injuries. Wilson RF, et al. **J Head Trauma Rehabil** 1998 Feb;13(1):11–27 (113 ref.)
Traumatic intraventricular hemorrhage treated with intraventricular recombinant-tissue plasminogen activator: technical case report. Grabb PA. **Neurosurgery** 1998 Oct; 43(4):966–9

HEAD LICE see **PEDICULUS**

HEAD MOVEMENTS

Computerized dynamic visual acuity test in the assessment of vestibular deficits. Herdman SJ, et al. **Am J Otol** 1998 Nov;19(6):790–6
Short form of the Dizziness Handicap Inventory: construction and validation through Rasch analysis. Tesio L, et al. **Am J Phys Med Rehabil** 1999 May–Jun; 78(3):233–41
Let's just call it the Bielschowsky head tilt test [editorial] Romano PE. **Binocul Vis Strabismus Q** 1998 Summer–Winter;13(2 2nd Qtr):93
Directional coding of three-dimensional movements by the vestibular semicircular canals. Rabbitt RD. **Biol Cybern** 1999 Jun;80(6):417–31
Optical high-precision three-dimensional position measurement system suitable for head motion tracking in frameless stereotactic radiosurgery. Kai J, et al. **Comput Aided Surg** 1998;3(5):257–63
Unilateral or asymmetric congenital ptosis, head posturing, and amblyopia. Fiergang DL, et al. **J Pediatr Ophthalmol Strabismus** 1999 Mar–Apr;36(2):74–7
Head impulses reveal loss of individual semicircular canal function. Aw ST, et al. **J Vestib Res** 1999;9(3):173–80
Comparison of two head autorotation tests. Hirvonen TP, et al. **J Vestib Res** 1999;9(2):119–25
Alternating episodes of vestibular nerve excitation and failure. Arbusow V, et al. **Neurology** 1998 Nov;51(5):1480–3
Apparent depth with retinal image motion of expansion and contraction yoked to head movement. Yajima T, et al. **Perception** 1998;27(8):937–49
Heading detection using motion templates and eye velocity gain fields. Beintema JA, et al. **Vision Res** 1998 Jul; 38(14):2155–79
Gaze and retinal-image-stability in two kinds of sequential looking tasks. Epelboim J. **Vision Res** 1998 Dec; 38(23):3773–84

DRUG EFFECTS

Head and whole-body jerking in guinea pigs are differentially modulated by 5-HT1A, 5-HT1B/1D and 5-HT2A receptor antagonists. Nielsen CK. **Eur J Pharmacol** 1998 Nov 20;361(2–3):185–90
Recovery of the vestibulocolic reflex after aminoglycoside ototoxicity in domestic chickens. Goode CT, et al. **J Neurophysiol** 1999 Mar;81(3):1025–35
Nitric oxide synthase inhibitors enhance 5-HT2 receptor-mediated behavior, the head-twitch response in mice. Kim HS, et al. **Life Sci** 1999;64(26):2463–70
The dropped head plus syndrome: quantitation of response to corticosteroids. Rose MR, et al. **Muscle Nerve** 1999 Jan; 22(1):115–8

PHYSIOLOGY

Passive sustained turning of the head induces asymmetric gain of the vestibulo-ocular reflex in healthy subjects. Padoan S, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;

118(6):778–82
Ventilatory response to passive head up tilt. Serrador JM, et al. **Adv Exp Med Biol** 1998;450:133–9
Locomotion and head scanning initiated by hypothalamic stimulation are inversely related. Sinnamon HM, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:560–2
The optokinetic cervico reflex during simulated helicopter flight. Braithwaite MG, et al. **Aviat Space Environ Med** 1998 Dec;69(12):1166–73
Kinematic response of the neck to voluntary and involuntary flexion. Margulies SS, et al. **Aviat Space Environ Med** 1998 Sep;69(9):896–903
Gender and effect of impact acceleration on neck motion. Morris CE, et al. **Aviat Space Environ Med** 1999 Sep; 70(9):851–6
Changes in heart rate and respiration rate in patients with vestibular dysfunction following head movements which provoke dizziness. Yardley L, et al. **Biol Psychol** 1998 Sep; 49(1–2):95–108
Numerical simulations of human head–neck dynamics. Huang SC. **Biomed Mater Eng** 1999;9(1):61–71
The effect of rotational head and neck movements on the afferent cerebral blood flow. Mawera G, et al. **Cent Afr J Med** 1998 Jun;44(6):148–52
Spatial view cells in the primate hippocampus: allocentric view not head direction or eye position or place. Georges-François P, et al. **Cereb Cortex** 1999 Apr–May; 9(3):197–212
The effect of muscle-tone–reducing procedures in athetotic head movements: partial nerve block by lidocaine and surgical release of the neck muscles. Saiki K, et al. **Clin Neurophysiol** 1999 Jul;110(7):1308–14
Lateral biases in head turning and the Moro response in the human newborn: are they both vestibular in origin? Rönnqvist L, et al. **Dev Psychobiol** 1998 Dec;33(4):339–49
Characteristics of slow and fast phases of the optocollic reflex (OCR) in head free pigeons (Columba livia): influence of flight behaviour. Gioanni H, et al. **Eur J Neurosci** 1999 Jan;11(1):155–66
Effect of head position on postural orientation and equilibrium. Barberini CL, et al. **Exp Brain Res** 1998 Sep; 122(2):175–84
Updating visual space during passive and voluntary head–in–space movements. Blouin J, et al. **Exp Brain Res** 1998 Sep;122(1):93–100
Horizontal vestibulo–ocular reflex and head stability in response to torso perturbations during visual search. Crane BT, et al. **Exp Brain Res** 1999 Apr;125(3):335–43
Nystagmus induced by circular head shaking in normal human subjects. Haslwanter T, et al. **Exp Brain Res** 1999 Jan;124(1):25–32
Amplitude of human head movements associated with horizontal saccades. Stahl JS. **Exp Brain Res** 1999 May; 126(1):41–54
Head direction cells in the primate pre–subiculum. Robertson RG, et al. **Hippocampus** 1999;9(3):206–19
Methods for diagnosis and treatment of stimulus–correlated motion in generic brain activation studies using fMRI. Bullmore ET, et al. **Hum Brain Mapp** 1999;7(1):38–48
Electromyographic analysis of the superior belly of the omohyoid muscle and anterior belly of the digastric muscle in tongue and head movements. Castro HA, et al. **J Electromyogr Kinesiol** 1999 Jun;9(3):229–32
Changes and implications of blood flow velocity of the vertebral artery during rotation and extension of the head. Li YK, et al. **J Manipulative Physiol Ther** 1999 Feb; 22(2):91–5
Contribution of the cerebellar flocculus to gaze control during active head movements. Belton T, et al. **J Neurophysiol** 1999 Jun;81(6):3105–9
Three–dimensional eye–head coordination during gaze saccades in the primate. Crawford JD, et al. **J Neurophysiol** 1999 Apr;81(4):1760–82
Integration of vestibular and head movement signals in the vestibular nuclei during whole–body rotation. Gdowski GT, et al. **J Neurophysiol** 1999 Jul;82(1):436–49
Influence of head position on the spatial representation of acoustic targets. Goossens HH, et al. **J Neurophysiol** 1999 Jun;81(6):2720–36
Firing behavior of vestibular neurons during active and passive head movements: vestibulo–spinal and other non–eye–movement related neurons. McCrea RA, et al. **J Neurophysiol** 1999 Jul;82(1):416–28
Human vestibuloocular reflex and its interactions with vision and fixation distance during linear and angular head movement. Paige GD, et al. **J Neurophysiol** 1998 Nov; 80(5):2391–404
Spatial alignment of rotational and static tilt responses of vestibulospinal neurons in the cat. Perlmutter SI, et al. **J Neurophysiol** 1999 Aug;82(2):855–62
Computation of inertial motion: neural strategies to resolve ambiguous otolith information. Angelaki DE, et al. **J Neurosci** 1999 Jan 1;19(1):316–27
Head direction cells in rats with hippocampal or overlying neocortical lesions: evidence for impaired angular path integration. Golob EJ, et al. **J Neurosci** 1999 Aug 15; 19(16):7198–211
Head movement in normal subjects during simulated brain imaging. Patterson H, et al. **J Nucl Med Technol** 1998 Dec; 26(4):257–61
Concomitant mandibular and head–neck movements during jaw opening–closing in man. Eriksson PO, et al. **J Oral Rehabil** 1998 Nov;25(11):859–70
The effect of head posture on direction and stability of mandibular closing movement. Yamada R, et al. **J Oral Rehabil** 1999 Jun;26(6):511–20
Independent control of head and gaze movements during head–free pursuit in humans. Collins CJ, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):299–314
"Torso Rotation" experiments. 4: the role of vision and the cervico–ocular reflex in compensation for a deficient VOR. Bouyer LJ, et al. **J Vestib Res** 1999;9(2):89–101
Somatosensory cuing of head–only rotational testing. Furman JM, et al. **J Vestib Res** 1999;9(3):189–95
MR imaging of cervical spine motion with HASTE. Duerinckx AJ, et al. **Magn Reson Imaging** 1999 Apr; 17(3):371–81
This way up: illusions and internal models in the vestibular system [news] Snyder L. **Nat Neurosci** 1999 May;2(5):396–8
Role of the lateral mammillary nucleus in the rat head direction circuit: a combined single unit recording and lesion study [published erratum appears in Neuron 1999 Jan;22(1):199] Blair HT, et al. **Neuron** 1998 Dec; 21(6):1387–97
Effects of lesion of pontomedullary reticular formation on visually triggered vertical and oblique head orienting movements in alert cats. Sasaki S, et al. **Neurosci Lett** 1999 Apr 9;265(1):13–6
Reaction times of head movements occurring in association with express saccades during human gaze shifts. Suzuki T, et al. **Neurosci Lett** 1998 Sep 18;254(1):61–4
Using the eye–movement system to control the head. Gilchrist ID, et al. **Proc R Soc Lond B Biol Sci** 1998 Oct 7;265(1408):1831–6
[Spasmus nutans: apropos of 16 cases] Doummar D, et al. **Arch Pediatr** 1998 Mar;5(3):264–8 (Eng. Abstr.) **(Fre)**
[Kinematic versus static MRI study of the cervical spine in patients with rheumatoid arthritis] Allmann KH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):22–7 (Eng. Abstr.) **(Ger)**
[Technique of registering active sagittal head movements in the process of studying vertical vestibuloocular reflexes] Skliut IA, et al. **Aviakosm Ekolog Med** 1999;33(1):59–61 (Eng. Abstr.) **(Rus)**

HEAD NURSES see **NURSING, SUPERVISORY**

HEAD PROTECTIVE DEVICES

Relationship of head restraint positioning to driver neck injury in rear–end crashes. Farmer CM, et al. **Accid Anal Prev** 1999 Nov;31(6):719–28
Cycle helmet effectiveness in New Zealand. Povey LJ, et al. **Accid Anal Prev** 1999 Nov;31(6):763–70
Estimation of expected utility gained from the helmet law in Taiwan by quality–adjusted survival time. Tsauo JY, et al. **Accid Anal Prev** 1999 May;31(3):253–63
Lightning strike to the head of a helmeted motorcyclist [letter] Junkins EP Jr, et al. **Am J Emerg Med** 1999 Mar; 17(2):213–4
Retrospective report on the effectiveness of a polyurethane football helmet cover on the repeated occurrence of cerebral concussions. Torg JS, et al. **Am J Orthop** 1999 Feb;28(2):128–32
Cycle helmets should not be compulsory [news] Carnall D. **BMJ** 1999 Jun 5;318(7197):1505
Skiing helmets. Rees–Jones A. **Br J Sports Med** 1999 Feb; 33(1):3 (10 ref.)
The effect of helmets on the incidence and severity of head and cervical spine injuries in motorcycle and moped accident victims: a prospective analysis based on emergency department and trauma centre data. Van Camp LA, et al. **Eur J Emerg Med** 1998 Jun;5(2):207–11
Effects of earplugs and protective headgear on auditory localization ability in the horizontal plane. Vause NL, et al. **Hum Factors** 1999 Jun;41(2):282–94
Helmet laws and health. Robinson D, et al. **Inj Prev** 1998 Sep;4(3):170–2
Inhalation challenge testing of latex–sensitive health care workers and the effectiveness of laminar flow HEPA–filtered helmets in reducing rhinoconjunctival and asthmatic reactions. Laoprasert N, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):998–1004
The circumstances and scope for prevention of maxillofacial injuries in cyclists. Harrison MG, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):82–6
Bicycle helmets: it's the law. Fisher NL. **Med Health R I** 1999 Aug;82(8):302–3
Have you heard. Hager LD. **Occup Health Saf** 1999 Mar; 68(3):38–40, 42–6
How effective are UV opaque face shields in UVB phototherapy cabins? Hamilton D, et al. **Photodermatol Photoimmunol Photomed** 1998 Jun–Aug; 14(3–4):134–5
Analysis of posterior plagiocephaly: deformational versus synostotic. Mulliken JB, et al. **Plast Reconstr Surg** 1999 Feb;103(2):371–80
Helmet and shoulder pad removal from a player with suspected cervical spine injury. A cadaveric model. Donaldson WF 3rd, et al. **Spine** 1998 Aug 15; 23(16):1729–32; discussion 1732–3
[Far too few schoolchildren use protective helmets when bicycling. Review of the literature and questionnaires as basis for promotion of increased use of the helmets] Berg P, et al. **Lakartidningen** 1999 May 12;96(19):2383–6 (43 ref.) **(Swe)**

ADVERSE EFFECTS

Helmet–mounted displays and facial injury in US Army AH–64A Apache accidents. Crowley JS. **J R Army Med Corps** 1998 Oct;144(3):144–7

UTILIZATION

The prevalence of non–standard helmet use and head injuries among motorcycle riders. Peek–Asa C, et al. **Accid Anal Prev** 1999 May;31(3):229–33
Bicycle helmet promotion among low income preschool children. Britt J, et al. **Inj Prev** 1998 Dec;4(4):280–3
Middle school students and bicycle helmet use: knowledge, attitudes, beliefs, and behaviors. Liller KD, et al. **J Sch Health** 1998 Oct;68(8):325–8
Why do child cyclists in the United States remain unhelmeted? Bergman AB, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):107–9

HEAD START PROGRAM see **EARLY INTERVENTION (EDUCATION)**

HEADACHE

Unusual headaches. Sztajnkrycer M, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):741–60, vi (104 ref.)
H is for headache. Hanlon VM. **J Emerg Med** 1999 Jan–Feb; 17(1):135
Headache and bilateral visual loss in a young hypothyroid Indian man. Wiesli P, et al. **J Endocrinol Invest** 1999 Feb; 22(2):141–3
Headache level during neuropsychological testing and test performance in patients with chronic posttraumatic headache. Lake AE 3rd, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):70–80
The criteria of the International Headache Society for Tolosa–Hunt syndrome need to be revised. Förderreuther S, et al. **J Neurol** 1999 May;246(5):371–7
Headache disorders. Saper JR. **Med Clin North Am** 1999 May;83(3):663–90, vi (14 ref.)
Focus on primary care diagnosis and management of headache in women. Marcus DA. **Obstet Gynecol Surv** 1999 Jun;54(6):395–402 (53 ref.)
A teenager complaining of headache. Walker B, et al. **Practitioner** 1998 May;242(1586):331–4, 337, 340 (1 ref.)
A psychiatric study of nonorganic chronic headache patients. Okasha A, et al. **Psychosomatics** 1999 May–Jun;40(3):233–8

CHEMICALLY INDUCED

The effects of tramadol on postoperative nausea, vomiting and headache after ENT surgery. A placebo–controlled comparison with equipotent doses of nalbuphine and pethidine. van den Berg AA, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):28–33
Interaction between the irreversible MAOIs and certain foods [letter] Beavis D. **Aust Fam Physician** 1999 Jul;28(7):650, 652
Drug abuse headache: recognition and management. Antonaci F. **Cephalalgia** 1998 Aug;18 Suppl 22:47–52; discussion 52–5 (43 ref.)
Indomethacin and nitrate–induced headache [editorial; comment] Thomsen LL. **Cephalalgia** 1998 Nov;18(9):591–2 . Comment on: Cephalalgia 1998 Nov;18(9):622–30.
Sumatriptan and ergotamine overuse and drug–induced headache: a clinicoepidemiologic study. Evers S, et al. **Clin Neuropharmacol** 1999 Jul–Aug;22(4):201–6
Statinopathy? [letter; comment] Rapoport D. **CMAJ** 1998 Oct 6;159(7):757. Comment on: CMAJ 1993 Nov 1;149(9):1233.
Headaches in the treatment of anal fissure [letter] Salgado G, et al. **Dis Colon Rectum** 1999 Aug;42(8):1106
Chronic misuse of paint thinners. Komiyama M, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):247
Drug–induced headaches [letter; comment] Dowson A. **Lancet** 1999 Jul 17;354(9174):254–5. Comment on: Lancet 1999 Jan 30;353(9150):378.
Headache after frequent use of serotonin agonists zolmitriptan and naratriptan [letter] [see comments] Limmroth V, et al. **Lancet** 1999 Jan 30;353(9150):378. Comment in: Lancet 1999 Apr 17;353(9161):1363. Comment in: Lancet 1999 Apr 17;353(9161):1363–4. Comment in: Lancet 1999 Jul 17;354(9174):254–5.
Headache after frequent triptan use [letter; comment] Mathew N. **Lancet** 1999 Apr 17;353(9161):1363–4. Comment on: Lancet 1999 Jan 30;353(9150):378.
Headache after frequent triptan use [letter; comment] Minton N, et al. **Lancet** 1999 Apr 17;353(9161):1363. Comment on: Lancet 1999 Jan 30;353(9150):378.
Possible idiosyncratic reaction to OC spray [letter] Macdonald HA. **N Z Med J** 1998 Aug 28;111(1072):327
Effects of exposure to isopropyl nitrite. Bulpitt DC, et al. **Occup Med (Lond)** 1998 Jul;48(5):345–6
–Headache: an unrecognized risk of ribavirin in infants? (letter)– Odièvre M, et al. **Arch Pediatr** 1998 Mar;5(3):347 **(Fre)**
[Drug–induced headache and its treatment] Barone–Kaganas I. **Schweiz Med Wochenschr** 1999 Mar 20;129(11):446–9 (Eng. Abstr.) **(Ger)**

HEADACHE

CLASSIFICATION

Hypnic headache syndrome [letter; comment] Ravishankar K. **Cephalalgia** 1998 Jul-Aug;18(6):358-9. Comment on: Cephalalgia 1998 Apr;18(3):123. Comment on: Cephalalgia 1998 Apr;18(3):152-6. Comment on: Cephalalgia 1998 Apr;18(3):157-8.

Headaches of an EBM believer [editorial] Walling AD. **Fam Med** 1999 Jul-Aug;31(7):503-5

Management of primary headache disorders. Chakravarty A, et al. **J Indian Med Assoc** 1998 Mar;96(3):84-8 (16 ref.)

[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter; comment)] Hofland E, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1235. Comment on: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):295-300. **(Dut)**

[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (see comments)] Koehler PJ. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):295-300 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1234; discussion 1235. Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1235. **(Dut)**

[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter; comment)] van Poeck KJ. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1234; discussion 1235. Comment on: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):295-300. **(Dut)**

[Forgotten by the media: the so-called "tension headache"] Masson C. **Presse Med** 1999 Jun 26;28(23):1240-1 **(Fre)**

[Psychosocial handicap due to chronic headaches. Evaluation of the inventory of Disabilities caused by Headache] Bauer B, et al. **Nervenarzt** 1999 Jun;70(6):522-9 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Headache and complement C'1-esterase inhibitor deficiency in Vietnamese immigrants living in southern California. Luong KV, et al. **Allergy Asthma Proc** 1999 Mar-Apr; 20(2):127-33

Trigeminal-autonomic cephalgias (TACs) [letter; comment] Peatfield R, et al. **Cephalalgia** 1998 Jul-Aug;18(6):358. Comment on: Cephalalgia 1998 Mar;18(2):85-90.

A 32-year-old pregnant woman with malaise, headache, nausea, right upper quadrant abdominal pain, and facial swelling. Levine S. **Chest** 1999 Jun;115(6):1729-30

[Headaches, vomiting and left homonymous lateral hemianopsia in a 25-year-old man] Mas JL, et al. **Rev Neurol (Paris)** 1999 Feb;155(2):158-64 **(Fre)**

[Tinnitus during headache: clinical-instrumental evaluation] Farri A, et al. **Acta Otorhinolaryngol Ital** 1999 Apr; 19(2):70-5 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Hypnic headache syndrome. Reply to Dr. Ravishankar [letter] Dodick DW, et al. **Cephalalgia** 1998 Dec; 18(10):712-3

Disability assessment as a basis for stratified care. Lipton RB. **Cephalalgia** 1998 Aug;18 Suppl 22:40-3; discussion 43-6 (10 ref.)

Differential diagnosis in headache--identifying migraine in primary care. Mathew NT. **Cephalalgia** 1998 Aug;18 Suppl 22:32-5; discussion 35-9

Epidural corticosteroid blockade in cervicogenic headache. Martelletti P, et al. **Eur Rev Med Pharmacol Sci** 1998 Jan-Feb;2(1):31-6

Chronic misuse of paint thinners. Komiyama M, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):247

Headache characteristics in subarachnoid haemorrhage and benign thunderclap headache. Linn FH, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):791-3

Cervicogenic headache: a critical review of the current diagnostic criteria. Leone M, et al. **Pain** 1998 Oct;78(1):1-5 (29 ref.)

Anticholinergic syndrome precipitated by opioid reversal [clinical conference] Hicks SD, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):328-9

Emergency medical services transport of patients with headache: mode of arrival may indicate serious etiology. Nemer JA, et al. **Prehosp Emerg Care** 1998 Oct-Dec; 2(4):304-7

The management of acute headache in adults in an acute admissions unit. Stevenson RJ, et al. **Scott Med J** 1998 Dec;43(6):173-6

[Headaches in a 26 year old woman. Sinus venous thrombosis in the sinus sagittal superior, at the confluens sinuum and sinus transversus] von Matt D, et al. **Schweiz Rundsch Med Prax** 1999 May 27;88(22):1009-11 **(Ger)**

[Headaches and facial pain] Boegner F. **Ther Umsch** 1999 Aug;56(8):450-4 (3 ref.) (Eng. Abstr.) **(Ger)**

[Headache] Vei AV, et al. **Klin Med (Mosk)** 1998;76(11):63-5 (9 ref.) **(Rus)**

[When a headache has to be investigated? (editorial)] Pascual J, et al. **An Med Interna** 1999 Apr;16(4):165-6 **(Spa)**

[Guidelines for headaches and dizziness for general physicians: analysis of their impact on visit frequency to outpatient neurological ambulatory services] de Toledo M, et al. **Neurologia** 1999 Mar;14(3):102-6 (Eng. Abstr.) **(Spa)**

[Headache, an oral lesion and amaurosis in a 60-year-old man] Ramírez Galleymore P, et al. **Rev Clin Esp** 1999 Apr; 199(4):247-8 **(Spa)**

DRUG THERAPY

Pericranial injection of local anesthetics for the management of resistant headaches. Brofeldt BT, et al. **Acad Emerg Med** 1998 Dec;5(12):1224-9

The use of sumatriptan in the treatment of postdural puncture headache after accidental lumbar puncture complicated a blood patch procedure [letter] [see comments] Sprigge JS. **Anaesthesia** 1999 Jan;54(1):95-6. Comment in: Anaesthesia 1999 Jun;54(6):611-2. Comment in: Anaesthesia 1999 Jun;54(6):612.

Sumatriptan was effective in electroconvulsive therapy (ECT) headache [letter] Oms A, et al. **Anesthesiology** 1998 Nov;89(5):1291-2

Greater occipital nerve blockade in cervicogenic headache. Vincent MB, et al. **Arq Neuropsiquiatr** 1998 Dec; 56(4):720-5

Cough headache responsive to methysergide. Bahra A, et al. **Cephalalgia** 1998 Sep;18(7):495-6

Acetylsalicylic acid in the treatment of headache. Limmroth V, et al. **Cephalalgia** 1999 Jul;19(6):545-51 (36 ref.)

Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Moreau T, et al. **Cephalalgia** 1998 Dec;18(10):687-9

Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Suhr B, et al. **Cephalalgia** 1999 Jan;19(1):44-9

Primary headache care delivery by nonspecialists in Brazil. Brazilian Headache Care Cooperative Group. Vincent MB, et al. **Cephalalgia** 1999 Jun;19(5):520-4

Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. De Vries P, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):61-74 (176 ref.)

Failure of long-term results of epidural steroid injection in cervicogenic headache [letter] Martelletti P, et al. **Eur Rev Med Pharmacol Sci** 1998 Jan-Feb;2(1):10

The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. Fullerton T, et al. **J Clin Pharmacol** 1999 Jan;39(1):17-29

Sumatriptan for post-ECT headache. Fantz RM, et al. **J ECT** 1998 Dec;14(4):272-4

Medical management of posttraumatic headaches: pharmacological and physical treatment. Bell KR, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):34-48 (65 ref.)

A triptan too far? [letter; comment] Meijler W. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):121; discussion 122. Comment on: J Neurol Neurosurg Psychiatry 1998 Feb;64(2):143-7.

A triptan too far? [letter; comment] van der Kuy PH, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):121; discussion 122. Comment on: J Neurol Neurosurg Psychiatry 1998 Feb;64(2):143-7.

Assessing and managing the patient with headaches. Weiss J. **Nurse Pract** 1999 Jul;24(7):18-20, 23-5, 28-9 passim quiz 36-7 (5 ref.)

Headache in childhood. Forsyth R, et al. **Pediatr Rev** 1999 Feb;20(2):39-45 (10 ref.)

Effective headache management. Strategies to help patients gain control over pain. Jackson CM. **Postgrad Med** 1998 Nov;104(5):133-6, 139-40, 143-7 (22 ref.)

Anticholinergic syndrome precipitated by opioid reversal [clinical conference] Hicks SD, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):328-9

Management of primary headache in emergency services of Santos and surrounding towns. Fragoso YD, et al. **Rev Paul Med** 1998 Mar-Apr;116(2):1650-3

[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter)] Spierings EL, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1235-6; discussion 1236-7 **(Dut)**

[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter; comment)] van Poeck KJ. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1234; discussion 1235. Comment on: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):295-300. **(Dut)**

[Intractable vomiting, convulsions and megaloblastic anemia: anamnesis, key to diagnosis] Schlaeppi M, et al. **Schweiz Med Wochenschr** 1999 Jul 3;129(26):993-5 (Eng. Abstr.) **(Fre)**

[Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication] Sarrecchia C, et al. **Ann Ital Med Int** 1998 Oct-Dec;13(4):237-9 (Eng. Abstr.) **(Ita)**

[Use of chlorpromazine in the treatment of headache at an emergency service] Da Costa AR, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):565-8 (Eng. Abstr.) **(Por)**

ECONOMICS

[Prevalence and indirect costs of headache in a Brazilian Company] Vincent M, et al. **Arq Neuropsiquiatr** 1998 Dec; 56(4):734-43 (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Prevalence of headache in children of a school from Curitiba, Brazil, comparing data obtained from children and parents. Antoniuk S, et al. **Arq Neuropsiquiatr** 1998 Dec; 56(4):726-33

Headache in children in Dutch general practice. van der Wouden JC, et al. **Cephalalgia** 1999 Apr;19(3):147-50

Headache in systemic lupus erythematosus and its relation to other disease manifestations. Amit M, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):467-70

Prevalence of headache syndromes in panic disorder. Marazziti D, et al. **Int Clin Psychopharmacol** 1999 Jul; 14(4):247-51

Somatic complaints and psychopathology in children and adolescents: stomach aches, musculoskeletal pains, and headaches. Egger HL, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jul;38(7):852-60

Headaches and psychopathology in children and adolescents. Egger HL, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Sep;37(9):951-8

Analgesic rebound headache in children and adolescents. Vasconcellos E, et al. **J Child Neurol** 1998 Sep;13(9):443-7

Incidence of ponticulus posterior of the atlas in migraine and cervicogenic headache. Wight S, et al. **J Manipulative Physiol Ther** 1999 Jan;22(1):15-20

Postdural puncture headache is not an age-related symptom in children: a prospective, open-randomized, parallel group study comparing a22-gauge Quincke with a 22-gauge Whitacre needle. Kokki H, et al. **Paediatr Anaesth** 1999; 9(5):429-34

School start and occurrence of headache. Anttila P, et al. **Pediatrics** 1999 Jun;103(6):e80

Headache occurrence and classification among distance runners. Swain R, et al. **W V Med J** 1999 Mar-Apr; 95(2):76-9

Headaches in persons attending polyclinics in Barbados. Hoyos MD. **West Indian Med J** 1998 Jun;47(2):59-63

[Hormones and headaches. Epidemiology, physiopathology and drug therapy] Evers S, et al. **Med Monatsschr Pharm** 1998 Oct;21(10):294-303 (77 ref.) **(Ger)**

[Prevalence and indirect costs of headache in a Brazilian Company] Vincent M, et al. **Arq Neuropsiquiatr** 1998 Dec; 56(4):734-43 (Eng. Abstr.) **(Por)**

[Headache incidence in a hospital community] Zétola VH, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):559-64 (Eng. Abstr.) **(Por)**

[Headache in a short-stay unit. A retrospective study of 140 cases] Lobera Gutiérrez de Pando E, et al. **An Esp Pediatr** 1999 Jun;50(6):562-5 (Eng. Abstr.) **(Spa)**

[Effectiveness of brain imaging in children with headache] Romero Sánchez J, et al. **An Esp Pediatr** 1998 Nov; 49(5):487-90 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Lumbar puncture first: an alternative model for the investigation of lone acute sudden headache. Schull MJ. **Acad Emerg Med** 1999 Feb;6(2):131-6

Effect of experience with spinal anaesthesia on the development of post-dural puncture complications. Flaatten H, et al. **Acta Anaesthesiol Scand** 1999 Jan; 43(1):37-41

Puncture technique and postural postdural puncture headache. A randomised, double-blind study comparing transverse and parallel puncture. Flaatten H, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1209-14

Postdural puncture headache and transient neurologic symptoms in children after spinal anaesthesia using cutting and pencil point paediatric spinal needles. Kokki H, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1076-82

Postdural puncture headache [letter; comment] el Tawil M. **Acta Anaesthesiol Scand** 1999 Apr;43(4):488. Comment on: Acta Anaesthesiol Scand 1999 Apr;43(4):488.

MR imaging with gadolinium in patients with and without post-lumbar puncture headache. Hannerz J, et al. **Acta Radiol** 1999 Mar;40(2):135-41

Autonomic dysreflexia presenting as a severe headache. McClain WA, et al. **Am J Emerg Med** 1999 May; 17(3):238-40

Headaches, idiopathic intracranial hypertension, and pseudopapilledema. Jacome DE. **Am J Med Sci** 1998 Dec; 316(6):408-10

All the fun of the fair [letter] Grimes S, et al. **Anaesthesia** 1999 Apr;54(4):408

Clinical dilemma: a patient with postdural puncture headache and acute leukemia [see comments] Bucklin BA, et al. **Anesth Analg** 1999 Jan;88(1):166-7. Comment in: Anesth Analg 1999 Jul;89(1):264. Comment in: Anesth Analg 1999 Aug;89(2):538.

Neurologic complications after placement of cerebrospinal fluid drainage catheters and needles in anesthetized patients: implications for regional anesthesia. Mayo Perioperative Outcomes Group. Grady RE, et al. **Anesth Analg** 1999 Feb; 88(2):388-92

Pneumocephalus with intense headache and unilateral pupillary dilatation after accidental dural puncture during epidural anesthesia for cesarean section. Laviola S, et al. **Anesth Analg** 1999 Mar;88(3):582-3

Sumatriptan was effective in electroconvulsive therapy (ECT) headache [letter] Oms A, et al. **Anesthesiology** 1998 Nov;89(5):1291-2

Worst headache and subarachnoid hemorrhage [letter; comment] Edlow JA. **Ann Emerg Med** 1999 Apr; 33(4):477-8. Comment on: Ann Emerg Med 1998 Sep;32(3 Pt 1):297-304.

Do patients with obstructive sleep apnea wake up with headaches? Loh NK, et al. **Arch Intern Med** 1999 Aug 9-23;159(15):1765-8

Post-lumbar puncture headache and backache in pediatrics: a case series and demonstration of magnetic resonance imaging findings. Atabaki S, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):770-3 (21 ref.)

Headache and drowsiness. Cameron JA. **Aust Fam Physician** 1998 Aug;27(8):725-6

What of cervicogenic headaches? [letter] Wilk V. **Aust Fam Physician** 1998 Oct;27(10):877-8

Case report: postconcussion syndrome after minor head injury. Wright SC. **Aviat Space Environ Med** 1998 Oct; 69(10):999-1000

Postdural puncture headache after combined spinal-epidural analgesia and anaesthesia [letter] Rowley C, et al. **Br J Anaesth** 1998 Oct;81(4):658-9

A sinus problem? Kalina P, et al. **Br J Radiol** 1998 Sep; 71(849):991-2

December 1998--16 year old female with headaches, lethargy and a sellar/suprasellar mass. Cummings TJ, et al. **Brain Pathol** 1999 Apr;9(2):425-6

Case of the month: August 1998 - 45 year old man with headache and ataxia. Günzel S, et al. **Brain Pathol** 1999 Jan;9(1):189-90

Second stage pushing correlates with headache after unintentional dural puncture in parturients. Angle P, et al. **Can J Anaesth** 1999 Sep;46(9):861-6

Postdural puncture headache in paediatric oncology patients. Burt N, et al. **Can J Anaesth** 1998 Aug;45(8):741-5

Postdural puncture headache after spinal anaesthesia in young orthopaedic outpatients using 27-g needles. Despond O, et al. **Can J Anaesth** 1998 Nov;45(11):1106-9

The epidural blood patch. Resolving the controversies. Duffy PJ, et al. **Can J Anaesth** 1999 Sep;46(9):878-86 (55 ref.)

Pre-eclampsia and eclampsia headache: classification recommendation [letter] **Cephalalgia** 1999 Jan;19(1):67-9

Whiplash-associated headache [letter; comment] Ferrari R. **Cephalalgia** 1998 Oct;18(8):585-6. Comment on: Cephalalgia 1998 Mar;18(2):101-5; discussion 72-3.

Significant reduction in post-lumbar puncture headache using an atraumatic needle. A double-blind, controlled clinical trial. Kleyweg RP, et al. **Cephalalgia** 1998 Nov;18(9):635-7; discussion 591

The dilemma of whiplash [letter; comment] Kwan O, et al. **Cephalalgia** 1998 Oct;18(8):586-7. Comment on: Cephalalgia 1998 Mar;18(2):101-5; discussion 72-3.

Headache after whiplash: a historical cohort study outside the medico-legal context. Obelieniene D, et al. **Cephalalgia** 1998 Oct;18(8):559-64

Further observations on postspinal headache [editorial; comment] Ramadan NM. **Cephalalgia** 1998 Dec; 18(10):657-8. Comment on: Cephalalgia 1998 Dec;18(10):697-703.

Headache as the initial manifestation of acute aortic dissection type A. Stöllberger C, et al. **Cephalalgia** 1998 Oct; 18(8):583-4

Pain location and associated symptoms in post-lumbar puncture headache [see comments] Vilming ST, et al. **Cephalalgia** 1998 Dec;18(10):697-703. Comment in: Cephalalgia 1998 Dec;18(10):657-8.

MRI findings in lumbar puncture headache syndrome: abnormal dural-meningeal and dural venous sinus enhancement. Bakshi R, et al. **Clin Imaging** 1999 Mar-Apr; 23(2):73-6

Evaluation of the patient with nontraumatic headache: an evidence based approach. Field AG, et al. **Emerg Med Clin North Am** 1999 Feb;17(1):127-52, ix (62 ref.)

Headaches from cellular telephones: are they real and what are the implications? Frey AH. **Environ Health Perspect** 1998 Mar;106(3):101-3

Seven-year review of requests for epidural blood patches for headache after dural puncture: referral patterns and the effectiveness of blood patches. Vercauteren MP, et al. **Eur J Anaesthesiol** 1999 May;16(5):298-303

Dolicho-vertebrobasilar abnormality and migraine-like attacks. Zambrino CA, et al. **Eur Neurol** 1999 Jan; 41(1):10-4

Neurological symptoms of the sick building syndrome: analysis of a questionnaire. Citterio A, et al. **Funct Neurol** 1998 Jul-Sep;13(3):225-30

An unusual cause of headache [see comments] Kyriakides C, et al. **Hosp Med** 1998 Nov;59(11):896-7. Comment in: Hosp Med 1999 Feb;60(2):146.

Prevalence of headache syndromes in panic disorder. Marazziti D, et al. **Int Clin Psychopharmacol** 1999 Jul; 14(4):247-51

Headache in Chiari malformation: a distinct clinical entity? Kesler R, et al. **J Am Osteopath Assoc** 1999 Mar;99(3):153-6

Headache: cortical vein thrombosis and response to anticoagulation. Minadeo JP, et al. **J Emerg Med** 1999 May-Jun;17(3):449-53

Posttraumatic headache: neuropsychological and psychological effects and treatment implications. Martelli MF, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):49-69 (73 ref.)

Epidemiology and pathogenesis of posttraumatic headache. Packard RC. **J Head Trauma Rehabil** 1999 Feb;14(1):9-21 (78 ref.)

Clinical assessment of posttraumatic headaches. Zafonte RD, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):22-33

Posttraumatic headache: caveats and controversies. Zasler ND. **J Head Trauma Rehabil** 1999 Feb;14(1):1-8

Posttraumatic tension pneumocephalus. Zasler ND. **J Head Trauma Rehabil** 1999 Feb;14(1):81-4

Craniofacial pain followed by scalp necrosis and stroke. An unusual presentation of the primary antiphospholipid syndrome [letter] Sanges G, et al. **J Neurol** 1999 Feb; 246(2):134-5

A blinding headache and two black eyes. Lawn ND, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):246-7

Commentary: salient aspects of research in pediatric headache and future directions [comment] Labbe EE. **J Pediatr Psychol** 1999 Apr;24(2):113-4. Comment on: J Pediatr Psychol 1999 Apr;24(2):91-109.

Chronic headaches--more than just an aching head? [news] **J Psychosoc Nurs Ment Health Serv** 1998 Sep;36(9):8-9

Postdural-puncture headache [letter] Kee WD. **Lancet** 1999 Aug 21;354(9179):680

Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics [letter] Lo SK, et al. **Lancet** 1999 Jun 12;353(9169):2038-9

Comparison of problem-based learning and lecture format in continuing medical education on headache diagnosis and management. Doucet MD, et al. **Med Educ** 1998 Nov; 32(6):590-6

Clinical problem-solving. A balancing act [see comments] Saha S, et al. **N Engl J Med** 1999 Feb 4;340(5):374-8. Comment in: N Engl J Med 1999 Jul 8;341(2):129; discussion 130. Comment in: N Engl J Med 1999 Jul 8;341(2):129-30.

Medicolegal issues: headache. Saper JR. **Neurol Clin** 1999 May;17(2):197-214 (63 ref.)

Nonpositional headache caused by spontaneous intracranial hypotension. Schievink WI, et al. **Neurology** 1998 Dec; 51(6):1768-9

Preliminary report: symptoms associated with mobile phone use [see comments] Hocking B. **Occup Med (Lond)** 1998 Sep;48(6):357-60. Comment in: Occup Med (Lond) 1998 Oct;48(7):472.

Cervicogenic headache: a critical review of the current diagnostic criteria. Leone M, et al. **Pain** 1998 Oct;78(1):1-5 (29 ref.)

Headaches in children. Molofsky WJ. **Pediatr Ann** 1998 Oct; 27(10):614-21

15-year-old young woman with morning headaches [clinical conference] Bowman R, et al. **Pediatr Neurosurg** 1998 Jul; 29(1):46-51

Headache and Chiari I malformation in the pediatric population. Weinberg JS, et al. **Pediatr Neurosurg** 1998 Jul; 29(1):14-8 (35 ref.)

Headache in childhood. Forsyth R, et al. **Pediatr Rev** 1999 Feb;20(2):39-45 (10 ref.)

What's causing this occipital headache? Cerebral dural venous sinus thrombosis. Vardhini BP, et al. **Postgrad Med** 1999 Jul;106(1):145-8

Fever, mucocutaneous haemorrhage, and severe headache during an epidemic of haemorrhagic fever. Dey AB, et al. **Postgrad Med J** 1998 Jul;74(873):433-5

Emergency medical services transport of patients with headache: mode of arrival may indicate serious etiology. Nemer JA, et al. **Prehosp Emerg Care** 1998 Oct-Dec; 2(4):304-7

The influence of the menstrual cycle in postdural puncture headache. Echevarria M, et al. **Reg Anesth Pain Med** 1998 Sep-Oct;23(5):485-90

Reply to Dr. Spencer regarding postdural puncture headache [letter; comment] Stasiuk R. **Reg Anesth Pain Med** 1999 Jul-Aug;24(4):377. Comment on: Reg Anesth Pain Med 1998 Jul-Aug;23(4):374-9; discussion 384-7.

A case of atypical pneumonia presenting with severe headache and disorientation. Diagnosis: Q fever (Coxiella burnetti). Julius P, et al. **Respiration** 1999;66(3):283-6

Occipital pain in osteoid osteoma of the atlas. A report of two cases. De Praeter MP, et al. **Spine** 1999 May 1; 24(9):912-4

Functional outcome and the effect of cranioplasty after retromastoid craniectomy for microvascular decompression. Lovely TJ, et al. **Surg Neurol** 1999 Feb; 51(2):191-7

Vanderbilt morning report. A 34-year-old man with fever and headache. Means J, et al. **Tenn Med** 1999 May; 92(5):180-1

HaNDL syndrome after "benign" OKT3-induced meningitis [letter] Thomas MC, et al. **Transplantation** 1999 May 27; 67(10):1384-5

[Lumbar puncture headache. Routines of Danish hospital departments compared with recommendations found in the literature] Winge K, et al. **Ugeskr Laeger** 1999 Apr 19; 161(16):2368-72 (20 ref.) (Eng. Abstr.) **(Dan)**

[Acute severe headache: a subarachnoidal hemorrhage?] Linn FH, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):545-50 (17 ref.) (Eng. Abstr.) **(Dut)**

[Headaches after spinal anesthesia: prospective multicenter study of a young adult population] Jeanjean P, et al. **Ann Fr Anesth Reanim** 1997;16(4):350-3 (Eng. Abstr.) **(Fre)**

[Post-lumbar puncture headache in children. Treatment with epidural autologous blood (blood patch)] Carbajal R, et al. **Arch Pediatr** 1998 Feb;5(2):149-52 (Eng. Abstr.) **(Fre)**

[Difficult headaches] Queyrel V, et al. **Rev Med Interne** 1998; 19 Suppl 2:315s-317s **(Fre)**

[When should Horton's disease be suspected?] Roblot P. **Rev Prat** 1999 Mar 15;49(6):593-7 (Eng. Abstr.) **(Fre)**

[Headache can often be treated by behavior therapy] **Fortschr Med** 1999 Mar 10;117(7):42-3 **(Ger)**

[Diagnosis and therapy of posttraumatic headache. Careful early mobilization prevents chronic condition] Keidel M, et al. **MMW Fortschr Med** 1999 Jun 3;141(22):45-7 **(Ger)**

[Periorbital pressure and papilledema.Papilledema, episcleral glaucoma and tinnitus in multiple dura fistulas and sinus thrombosis] Schütt F, et al. **Ophthalmologe** 1998 Dec; 95(12):844-5 **(Ger)**

[Headache, general malaise and left-side ptosis] Kissling S, et al. **Schweiz Rundsch Med Prax** 1998 Aug 26; 87(35):1109-12 (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and headache (editorial)] Marko P. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31-32):1261-2 **(Ger)**

[Otorhinolaryngologic causes of headache] Reiss M, et al. **Schweiz Rundsch Med Prax** 1999 May 27;88(22):992-7 (13 ref.) (Eng. Abstr.) **(Ger)**

[Head- and neck pain of non-dental origin] Lilly GE. **Fogorv Sz** 1998 Nov;91(11):337-46 (Eng. Abstr.) **(Hun)**

[Temporal arteritis as a cause of a terrible headache] Wiszniewska M, et al. **Neurol Neurochir Pol** 1999 Mar-Apr; 33(2):461-4 (Eng. Abstr.) **(Pol)**

[Chronic post-traumatic headache after mild head injuries] De Souza JA, et al. **Arq Neuropsiquiatr** 1999 Jun; 57(2A):243-8 (Eng. Abstr.) **(Por)**

[Role of nasosinusal endoscopic surgery in the treatment of headache and facial pain of rhinogenic origin] Campos A, et al. **Acta Otorrinolaringol Esp** 1998 Nov-Dec; 49(8):615-20 (Eng. Abstr.) **(Spa)**

[Recent-onset headache is a risk factor of intracranial lesion. A prospective study of 299 patients] Ortin Castaño A, et al. **An Med Interna** 1999 Apr;16(4):167-70 (Eng. Abstr.) **(Spa)**

[Prevention and treatment of headache due to intracranial hypotension] Arjona A. **Rev Neurol** 1998 Dec; 27(160):1027-33 (138 ref.) (Eng. Abstr.) **(Spa)**

[Painful ophthalmoplegia of sudden appearance in an elderly lady] Guerrero AL, et al. **Rev Neurol** 1998 Nov;27(159):872 **(Spa)**

MICROBIOLOGY

You're the flight surgeon. 35-year-old helicopter pilot with ehrlichiosis. Hetrick SM. **Aviat Space Environ Med** 1998 Dec;69(12):1217-8

NURSING

Assessing and managing the patient with headaches. Weiss J. **Nurse Pract** 1999 Jul;24(7):18-20, 23-5, 28-9 passim quiz 36-7 (5 ref.)

PARASITOLOGY

The role of corticosteroids in the treatment of cerebral schistosomiasis caused by Schistosoma mansoni: case report and discussion. Fowler R, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):47-50

Eosinophilic meningitis. An unusual cause of headache. Pinn TG. **Aust Fam Physician** 1999 Jul;28(7):690-1

PATHOLOGY

A sneezer's headache. Kurita H, et al. **Neurology** 1999 Aug 11;53(3):654-5

PHYSIOPATHOLOGY

Frequency of headaches associated with the cervical spine and relationships with anthropometric, muscle performance, and recreational factors. Grimmer K, et al. **Arch Phys Med Rehabil** 1999 May;80(5):512-21

Association of cerebral perfusion pressure with headache in women with pre-eclampsia. Belfort MA, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):814-21

Thermal sensitivity in unilateral headaches. Becser N, et al. **Cephalalgia** 1998 Dec;18(10):675-83; discussion 657

The SF-36 and the assessment of HRQoL [editorial] Dahlöf C. **Cephalalgia** 1998 Nov;18(9):592

On headache and the neck [editorial; comment] Davidoff RA. **Cephalalgia** 1999 Apr;19(3):135-6. Comment on: Cephalalgia 1999 Apr;19(3):179-85.

Trigger points and myofascial pain: toward understanding how they affect headaches. Davidoff RA. **Cephalalgia** 1998 Sep;18(7):436-48 (159 ref.)

Nonaneurysmal thunderclap headache with diffuse, multifocal, segmental, and reversible vasospasm. Dodick DW, et al. **Cephalalgia** 1999 Mar;19(2):118-23

Sensitivity to light and noise in tension-type and cervicogenic headache [editorial; comment] Drummond PD. **Cephalalgia** 1998 Jul-Aug;18(6):303. Comment on: Cephalalgia 1998 Jul-Aug;18(6):313-8. Comment on: Cephalalgia 1998 Jul-Aug;18(6):324-8.

Further clinical clarification of the muscle dysfunction in cervical headache [see comments] Jull G, et al. **Cephalalgia** 1999 Apr;19(3):179-85. Comment in: Cephalalgia 1999 Apr;19(3):135-6.

Quality of life in migraine and chronic daily headache patients. Monzón MJ, et al. **Cephalalgia** 1998 Nov; 18(9):638-43

The syndrome of spontaneous intracranial hypotension [see

comments] O'Carroll CP, et al. **Cephalalgia** 1999 Mar; 19(2):80–7. Comment in: Cephalalgia 1999 Mar;19(2):73.
Coping with pain in headache sufferers [editorial; comment] Passchier J. **Cephalalgia** 1999 Apr;19(3):135. Comment on: Cephalalgia 1999 Apr;19(3):165–73.
Clinical neurophysiology in childhood headache. Puca F, et al. **Cephalalgia** 1999 Apr;19(3):137–46 (76 ref.)
Coping styles of headache sufferers [see comments] Siniatchkin M, et al. **Cephalalgia** 1999 Apr;19(3):165–73. Comment in: Cephalalgia 1999 Apr;19(3):135.
Contingent negative variation in patients with chronic daily headache. Siniatchkin M, et al. **Cephalalgia** 1998 Oct; 18(8):565–9; discussion 531
Headache in childhood and adolescence [editorial; comment] Symon D. **Cephalalgia** 1998 Sep;18(7):419. Comment on: Cephalalgia 1998 Sep;18(7):449–54.
Photophobia and phonophobia in tension-type and cervicogenic headache [see comments] Vanagaite Vingen J, et al. **Cephalalgia** 1998 Jul–Aug;18(6):313–8. Comment in: Cephalalgia 1998 Jul–Aug;18(6):303.
Headache in children in Dutch general practice. van der Wouden JC, et al. **Cephalalgia** 1999 Apr;19(3):147–50
Neuropeptides in headache. Edvinsson L, et al. **Eur J Neurol** 1998 Jul;5(4):329–41 (92 ref.)
EEG evaluation in children and adolescents with chronic headaches. De Carlo L, et al. **Ear J Pediatr** 1999 Mar; 158(3):247–8
Event-related potentials (P300) in primary headache in childhood and adolescence. Evers S, et al. **J Child Neurol** 1998 Jul;13(7):322–6
Centro-temporal spikes in non-epileptic children: a long-term follow up. Verrotti A, et al. **J Paediatr Child Health** 1999 Feb;35(1):60–2
Correlation between structural and functional changes in brain in an idiopathic headache syndrome [see comments] May A, et al. **Nat Med** 1999 Jul;5(7):836–8. Comment in: Nat Med 1999 Jul;5(7):732–3.
A sneezer's headache. Kurita H, et al. **Neurology** 1999 Aug 11;53(3):654–5
Headache in children with centrotemporal spikes. Melchionda D, et al. **Neurophysiol Clin** 1999 Feb; 29(1):90–100
Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Ebersberger A, et al. **Neuroscience** 1999 Mar;89(3):901–7
Auditory evoked potentials and multiple personality measures in migraine and post-traumatic headaches. Wang W, et al. **Pain** 1999 Feb;79(2–3):235–42
[Hormones and headaches. Epidemiology, physiopathology and drug therapy] Evers S, et al. **Med Monatsschr Pharm** 1998 Oct;21(10):294–303 (77 ref.) **(Ger)**
[Headaches and facial pain] Boegner F. **Ther Umsch** 1999 Aug;56(8):450–4 (3 ref.) (Eng. Abstr.) **(Ger)**
[Study of mechanisms of action of amitriptyline and acupuncture using nociceptive flexor reflex in patients with chronic forms of headache] Amelin AV, et al. **Anesteziol Reanimatol** 1998 Sep–Oct;(5):19–21 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Intrathecal catheter as a secondary prophylaxis of postdural puncture headache [letter; comment] Malov SS. **Anesth Analg** 1999 Aug;89(2):538. Comment on: Anesth Analg 1999 Jan;88(1):166–7.
Preventing headache after lumbar puncture. Most doctors are unaware of features of headache after lumbar puncture [letter; comment] Sharma A. **BMJ** 1998 Dec 5; 317(7172):1588. Comment on: BMJ 1998 Jun 6;316(7146):1709–10.
Preventing headache after lumbar puncture. Evidence must come from randomised trails put together systematically [letter; comment] Sudlow C. **BMJ** 1998 Dec 5; 317(7172):1589. Comment on: BMJ 1998 Jun 6;316(7146):1709–10.
Preventing headache after lumbar puncture. Optimism generally quoted for epidural blood patching is unwarrented [letter; comment] Williams E, et al. **BMJ** 1998 Dec 5;317(7172):1588–9. Comment on: BMJ 1998 Jun 6;316(7146):1709–10.
Split calvarial graft cranioplasty for the prevention of headache after retrosigmoid resection of acoustic neuromas. Feghali JG, et al. **Laryngoscope** 1998 Oct; 108(10):1450–2
Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Yücel A, et al. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):51–4
[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter)] Spierings EL, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1235–6; discussion 1236–7 **(Dut)**

PSYCHOLOGY

Anxiety sensitivity and fear of pain in patients with recurring headaches. Asmundson GJ, et al. **Behav Res Ther** 1999 Aug; 37(8):703–13
Comorbidity of headache and depressive disorders. Mitsikostas DD, et al. **Cephalalgia** 1999 May;19(4):211–7
Coping styles of headache sufferers [see comments] Siniatchkin M, et al. **Cephalalgia** 1999 Apr;19(3):165–73. Comment in: Cephalalgia 1999 Apr;19(3):135.
Parental health attitudes, illnesses and supports and the referral of children to medical specialists. Gulhati A, et al. **Child Care Health Dev** 1998 Jul;24(4):295–313
Posttraumatic headache: neuropsychological and psychological effects and treatment implications. Martelli MF, et al. **J Head Trauma Rehabil** 1999 Feb;14(1):49–69 (73 ref.)
Does psychological testing help to predict the response to acupuncture or massage/relaxation therapy in patients presenting to a general neurology clinic with headache? Wylie KR, et al. **J Tradit Chin Med** 1997 Jun;17(2):130–9
Validity of an illness severity measure for headache in a population sample of migraine sufferers. Stewart WF, et al. **Pain** 1999 Feb;79(2–3):291–301
Comorbidity of headaches and depression in the elderly. Wang SJ, et al. **Pain** 1999 Sep;82(3):239–43
Auditory evoked potentials and multiple personality measures in migraine and post-traumatic headaches. Wang W, et al. **Pain** 1999 Feb;79(2–3):235–42
The impact of ergotamine-induced headache and ergotamine withdrawal on information processing. Evers S, et al. **Psychopharmacology (Berl)** 1999 Feb;142(1):61–7
[Headache is a question of feelings (letter)] Jensen JG. **Ugeskr Laeger** 1999 Mar 29;161(13):1940 **(Dan)**
[Psychosocial handicap due to chronic headaches. Evaluation of the inventory of Disabilities caused by Headache] Bauer B, et al. **Nervenarzt** 1999 Jun;70(6):522–9 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

A blinding headache and two black eyes. Lawn ND, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):246–7

RADIONUCLIDE IMAGING

Cerebral blood flow changes in pseudomigraine with pleocytosis analyzed by single photon emission computed tomography. A spreading depression mechanism? Fuentes B, et al. **Cephalalgia** 1998 Oct;18(8):570–3; discussion 531

REHABILITATION

Use of cervical spine manipulation under anesthesia for management of cervical disk herniation, cervical radiculopathy, and associated cervicogenic headache syndrome. Herzog J. **J Manipulative Physiol Ther** 1999 Mar–Apr;22(3):166–70

SURGERY

Radiofrequency cervical zygapophyseal joint neurotomy for cervicogenic headache: a prospective study of 15 patients. van Suijlekom HA, et al. **Funct Neurol** 1998 Oct–Dec; 13(4):297–303

THERAPY

Treatment for postdural puncture headache associated with late postpartum eclampsia. Van de Velde M, et al. **Acta Anaesthesiol Belg** 1999;50(2):99–102
An exploratory study of reflexological treatment for headache [see comments] Launsø L, et al. **Altern Ther Health Med** 1999 May;5(3):57–65. Comment in: Altern Ther Health Med 1999 May;5(3):39–40.
Clinical dilemma: a patient with postdural puncture headache and acute leukemia [see comments] Bucklin BA, et al. **Anesth Analg** 1999 Jan;88(1):166–7. Comment in: Anesth Analg 1999 Jul;89(1):264. Comment in: Anesth Analg 1999 Aug;89(2):538.
Postdural puncture headaches in special patient populations [letter; comment] Miguel R, et al. **Anesth Analg** 1999 Jul; 89(1):264. Comment on: Anesth Analg 1999 Jan;88(1):166–7.
Epidural fibrin glue injection stops persistent postdural puncture headache. Crul BJ, et al. **Anesthesiology** 1999 Aug;91(2):576–7
Medication-induced headache: overview and systematic review of therapeutic approaches. Zed PJ, et al. **Ann Pharmacother** 1999 Jan;33(1):61–72 (58 ref.)
The epidural blood patch. Resolving the controversies. Duffy PJ, et al. **Can J Anaesth** 1999 Sep;46(9):878–86 (55 ref.)
Efficiency of epidural blood patches in the obstetrics [letter; comment] Williams E, et al. **Can J Anaesth** 1998 Oct; 45(10):1031. Comment on: Can J Anaesth 1998 Feb;45(2):110–4.
Glycerol gangliotomy of the second dorsal cervical root in rats: an experimental study to evaluate a minimal invasive approach for the treatment of the chronic cervicogenic headache. Ludwig HC, et al. **Cephalalgia** 1998 Nov; 18(9):612–7
Seven months' delay for epidural blood patch in post-dural puncture headache. Ferre JP, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):257–8
Management of primary headache disorders. Chakravarty A, et al. **J Indian Med Assoc** 1998 Mar;96(3):84–8 (16 ref.)
A pilot study of a headache program in the workplace. The effect of education. Schneider WJ, et al. **J Occup Environ Med** 1999 Mar;41(3):202–9
Empirically supported treatments in pediatric psychology: recurrent pediatric headache [see comments] Holden EW, et al. **J Pediatr Psychol** 1999 Apr;24(2):91–109 (67 ref.). Comment in: J Pediatr Psychol 1999 Apr;24(2):110. Comment in: J Pediatr Psychol 1999 Apr;24(2):111–2. Comment in: J Pediatr Psychol 1999 Apr;24(2):113–4.
Commentary: recurrent headaches: making what works available to those who need it [comment] McGrath PJ. **J Pediatr Psychol** 1999 Apr;24(2):111–2. Comment on: J Pediatr Psychol 1999 Apr;24(2):91–109.
Dr. Gao Lishan's experience in treating pain syndromes by acupuncture. Cao W, et al. **J Tradit Chin Med** 1997 Dec; 17(4):266–71
Illustrative cases treated by the application of the extra point sishencong. Liu H. **J Tradit Chin Med** 1998 Jun;18(2):111–4
Does psychological testing help to predict the response to acupuncture or massage/relaxation therapy in patients presenting to a general neurology clinic with headache? Wylie KR, et al. **J Tradit Chin Med** 1997 Jun;17(2):130–9
Growing pain: 10-year research trends in the study of chronic pain and headache. Norton PJ, et al. **Pain** 1999 Jan;79(1):59–65
Chronic primary headache—reducing the risk of treatment. Cohen I. **S Afr Med J** 1998 Dec;88(12):1554–6 (42 ref.)
[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (letter; comment)] Hofland E, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1235. Comment on: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):295–300. **(Dut)**
[Chronic recurrent headache without neurological abnormalities. Practice guidelines of the Netherlands Society of Neurology (see comments)] Koehler PJ. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):295–300 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1234; discussion 1235. Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1235. **(Dut)**
[Post-lumbar puncture headache in children. Treatment with epidural autologous blood (blood patch)] Carbajal R, et al. **Arch Pediatr** 1998 Feb;5(2):149–52 (Eng. Abstr.) **(Fre)**
[Clinical hypnotherapy/self-hypnosis for unspecified, chronic and episodic headache without migraine and other defined headaches in children and adolescents] Gysin T. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:44–6 (Eng. Abstr.) **(Ger)**
[Drug-induced headache and its treatment] Barone-Kaganas I. **Schweiz Med Wochenschr** 1999 Mar 20;129(11):446–9 (Eng. Abstr.) **(Ger)**
[Study of mechanisms of action of amitriptyline and acupuncture using nociceptive flexor reflex in patients with chronic forms of headache] Amelin AV, et al. **Anesteziol Reanimatol** 1998 Sep–Oct;(5):19–21 (Eng. Abstr.) **(Rus)**
[Role of nasosinusal endoscopic surgery in the treatment of headache and facial pain of rhinogenic origin] Campos A, et al. **Acta Otorrinolaringol Esp** 1998 Nov–Dec; 49(8):615–20 (Eng. Abstr.) **(Spa)**
[Prevention and treatment of headache due to intracranial hypotension] Arjona A. **Rev Neurol** 1998 Dec; 27(160):1027–33 (138 ref.) (Eng. Abstr.) **(Spa)**

HEADGEAR, ORTHODONTIC see **EXTRAORAL TRACTION APPLIANCES**

HEALTH

Reproductive health in southern Africa: report of a WHO workshop. Hall P. **Afr J Reprod Health** 1997 Mar;1(1):97–9
Reproductive health issues in Africa [editorial] Rosenfield A. **Afr J Reprod Health** 1997 Mar;1(1):5–6
Launching the African Journal of Reproductive Health [editorial] Snow R, et al. **Afr J Reprod Health** 1997 Mar; 1(1):3–4
Yes, religion and spirituality do matter in health [letter; comment] Hamilton J. **Altern Ther Health Med** 1999 Jul; 5(4):18. Comment on: Altern Ther Health Med 1999 May;5(3):16–8.
Social psychophysiology, social circumstances, and health. Carroll D, et al. **Ann Behav Med** 1998 Fall;20(4):333–7 (80 ref.)
A commentary on Newman's theory of health as expanding consciousness. Yamashita M, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):65–75 (39 ref.)
Microalgal blooms: a global issue with negative impact in Chile. Lagos N. **Biol Res** 1998;31(4):375–86 (54 ref.)
Use of population attributable risk (PAR) in understanding the health benefits of physical activity. Bauman A. **Br J Sports Med** 1998 Dec;32(4):279–80
Accumulation of physical activity for health gains: what is the evidence? Hardman AE. **Br J Sports Med** 1999 Apr; 33(2):87–92 (58 ref.)
A preliminary description of responses of free-ranging rhesus monkeys to brief capture experiences: behavior, endocrine, immune, and health relationships. Laudenslager ML, et al. **Brain Behav Immun** 1999 Jun;13(2):124–37
Food, mood and health: a neurobiologic outlook. Prasad C. **Braz J Med Biol Res** 1998 Dec;31(12):1517–27 (60 ref.)
Popular weight loss diets. Health and exercise implications. Riley RE. **Clin Sports Med** 1999 Jul;18(3):691–701, ix (9 ref.)
Tannins and human health: a review. Chung KT, et al. **Crit Rev Food Sci Nutr** 1998 Aug;38(6):421–64 (311 ref.)
History of medicine and concepts of health [editorial] Bergdolt K. **Croat Med J** 1999 Jun;40(2):119–22
A votre sanity. Brenner S. **Curr Biol** 1998 Oct 22;8(21):R741

Fragments of tradition: revisiting the virtues of wine. Vintani PG. **Drugs Exp Clin Res** 1999;25(2-3):163-5
Redox state and health: a persisting challenge. Stroes ES, et al. **Eur J Clin Invest** 1998 Nov;28(11):884-5 (10 ref.)
Exposure to exogenous estrogens in food: possible impact on human development and health. Andersson AM, et al. **Eur J Endocrinol** 1999 Jun;140(6):477-85 (42 ref.)
Music for health: the five elements tonal system. Legge MF. **IEEE Eng Med Biol Mag** 1999 Mar-Apr;18(2):80-8
Masticatory function and its effects on general health. Nakata M. **Int Dent J** 1998 Dec;48(6):540-8 (78 ref.)
Proceedings of the 10th International Congress on Circumpolar Health. Anchorage, Alaska, USA. May 19-24, 1996. **Int J Circumpolar Health** 1998;57 Suppl 1:iii-xvii, 1-759
A historical review (1965-1997) of studies on class, health, and quality of life: a personal account. Navarro V. **Int J Health Serv** 1998;28(3):389-406
A concept analysis of personal transformation. Wade GH. **J Adv Nurs** 1998 Oct;28(4):713-9
Development and validation of a questionnaire designed to measure foot-health status. Bennett PJ, et al. **J Am Podiatr Med Assoc** 1998 Sep;88(9):419-28
Interaction of cattle health/immunity and nutrition. Galyean ML, et al. **J Anim Sci** 1999 May;77(5):1120-34 (82 ref.)
Detection of putative loci affecting milk production and composition, health, and type traits in a United States Holstein population. Ashwell MS, et al. **J Dairy Sci** 1998 Dec;81(12):3309-14
Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852-8 (20 ref.)
Cardiovascular oscillations: from a physiological curiosity to a probe of aging and health? [comment] Pagani M. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):B225-6. Comment on: J Gerontol A Biol Sci Med Sci 1999 May;54(5):B219-24.
1997 Sir William Refshauge Lecture. Skeletal muscle glucose metabolism during exercise: implications for health and performance. Hargreaves M. **J Sci Med Sport** 1998 Dec; 1(4):195-202 (59 ref.)
Clinic-based health information Web site for international travelers [letter] Licciardone JC, et al. **JAMA** 1998 Oct 21;280(15):1310
Research and the changing truths. Rana JS. **JPMA J Pak Med Assoc** 1998 Jul;48(7):227-8
A meta-analysis of the relationship between social support and well-being. Wang HH. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):717-26
The epidemiology of gender-discrepant illness. Gabriel SE. **Lupus** 1999;8(5):339-45
The conceptualization of health. Larson JS. **Med Care Res Rev** 1999 Jun;56(2):123-36 (50 ref.)
Natural defenses and autoprotection: naturotherapy, an old concept of healing in a new perspective. Lohff B, et al. **Med Hypotheses** 1998 Aug;51(2):147-51
Mechanisms of autoprotection and the role of stress-proteins in natural defenses, autoprotection, and salutogenesis. Schaefer J, et al. **Med Hypotheses** 1998 Aug;51(2):153-63 (94 ref.)
Biodiversity loss: a human health issue [editorial] Cassis G. **Med J Aust** 1998 Dec 7-21;169(11-12):568-9 (17 ref.)
Health a human right? [letter; comment] Prociv P. **Med J Aust** 1999 Jul 5;171(1):56. Comment on: Med J Aust 1999 Apr 5;170(7):295-6.
Ecosystem health and human well being: the mission of the international programme on plant bioassays. Gopalan HN. **Mutat Res** 1999 May 19;426(2):99-102
A virus questions human definitions of health. Anand AC. **Natl Med J India** 1998 Nov-Dec;11(6):290-1
Health inequalities: is there a 'Scottish effect'? [news] Kohli HS. **Natl Med J India** 1999 May-Jun;12(3):130-1
The associations between self-rated vision and hearing and functional status in middle age. Lee PP, et al. **Ophthalmology** 1999 Feb;106(2):401-5
Biodiversity: our greatest natural resource [editorial] Bailey BJ. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):291-5
Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Hansen MB, et al. **Physiol Res** 1998;47(5):307-27 (130 ref.)
Tips for a safe trip. **Postgrad Med** 1999 Jul;106(1):149-50
Advising patients about international travel. What they can do to protect their health and safety. Bratton RL. **Postgrad Med** 1999 Jul;106(1):57-64; quiz 143 (14 ref.)
Geology, Mineralogy, and Human Welfare. Proceedings of a colloquium. Irvine, California, USA. November 8-9, 1998. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3348-485
Diet, health and globalization: five key questions. Lang T. **Proc Nutr Soc** 1999 May;58(2):335-43 (86 ref.)
Tea and health: the underlying mechanisms. Weisburger JH. **Proc Soc Exp Biol Med** 1999 Apr;220(4):271-5 (42 ref.)
The role of gender in very old age: profiles of functioning and everyday life patterns. Smith J, et al. **Psychol Aging** 1998 Dec;13(4):676-95
Relocating gender and morbidity: examining men's and women's health in contemporary Western societies. Introduction to Special Issue on Gender and Health [editorial] Hunt K, et al. **Soc Sci Med** 1999 Jan;48(1):1-5
Nonlinearity in the epidemiology of complex health and disease processes. Philippe P, et al. **Theor Med Bioeth** 1998 Dec;19(6):591-607 (44 ref.)
[The health and hygiene problems of motor activity in childhood and adolescence] Iotova E. **Probl Khig** 1997; 22:124-35 (35 ref.) (Eng. Abstr.) **(Bul)**
[From the philosophy of medicine to bioethics, and back] Mauron A. **Rev Med Suisse Romande** 1998 Dec; 118(12):1009-12 **(Fre)**
[Construction and its characteristic on the concept of 'health culture'] Takizawa T. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):398-406 (42 ref.) (Eng. Abstr.) **(Jpn)**
[As the devil reads the Bible....(letter; comment)] Aasland OG. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3832-3. Comment on: Tidsskr Nor Laegeforen 1998 Sep 10;118(21):3312-5. **(Nor)**
[The extended concept of health--confusing as a concept and unmanageable in practice (see comments)] Andrews T. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3312-5 (19 ref.). Comment in: Tidsskr Nor Laegeforen 1998 Oct 10;118(24):3832-4. **(Nor)**
[Physicians cannot... A poster on reality orientation in health care (see comments)] Holmen J. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3168-71 (15 ref.). Comment in: Tidsskr Nor Laegeforen 1999 Mar 10;119(7):1000-1. **(Nor)**
[Freedom in a little box] Lie AK. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1471-3 (Eng. Abstr.) **(Nor)**
[Homeostasis parameters as indicators of human health] Malov IuS. **Klin Med (Mosk)** 1999;77(3):56-60 (25 ref.) **(Rus)**
[A theoretical approach to health and its measurement] Grujić V, et al. **Med Pregl** 1998 Jul-Aug;51(7-8):315-8 (Eng. Abstr.) **(Scr)**
[Special "Dr. Ignacio Chávez" lecture. Health and human development] Soberón G. **Gac Med Mex** 1999 Mar-Apr; 135(2):217-30 **(Spa)**
[Mineral water and health (letter)] Torre-López E. **Rev Invest Clin** 1998 Nov-Dec;50(6):541-2 **(Spa)**

EDUCATION see HEALTH EDUCATION

MANPOWER see HEALTH MANPOWER

HEALTH ALLIANCES see INSURANCE POOLS

HEALTH AND WELFARE PLANNING see HEALTH PLANNING

HEALTH BEHAVIOR

Trends in safe driving behaviors and in relation to trends in health maintenance behaviors in the USA: 1985-1995. Shinar D, et al. **Accid Anal Prev** 1999 Sep;31(5):497-503
Abuse history and health risk behaviors in pregnancy. Grimstad H, et al. **Acta Obstet Gynecol Scand** 1998 Oct; 77(9):893-7
Locus of control beliefs predicting oral and diabetes health behavior and health status. Kneckt MC, et al. **Acta Odontol Scand** 1999 Jun;57(3):127-31
A logistic regression model for analyzing the relation between dentists' attitudes, behavior, and knowledge in oral radiology. Svenson B, et al. **Acta Odontol Scand** 1998 Aug; 56(4):215-9
Correlates of occasional cigarette and marijuana use: are teens harm reducing? Resnicow K, et al. **Addict Behav** 1999 Mar-Apr;24(2):251-66
One-year prospective prediction of marijuana use cessation among youth at continuation high schools. Sussman S, et al. **Addict Behav** 1999 May-Jun;24(3):411-7
Long-term consequences of adolescent health behaviors: implications for adolescent health services. Hedberg VA, et al. **Adolesc Med** 1999 Feb;10(1):137-51, vii (97 ref.)
Adolescent development: setting the stage for influencing health behaviors. Juszczak L, et al. **Adolesc Med** 1999 Feb; 10(1):1-11, v (65 ref.)
The social environments of adolescents: associations between socioenvironmental factors and health behaviors during adolescence. Neumark-Sztainer D. **Adolesc Med** 1999 Feb; 10(1):41-55, v (54 ref.)
Rural and urban adolescents' perceptions of mental health. Chimonides KM, et al. **Adolescence** 1998 Winter; 33(132):823-32
The relationship of daily stress and health-related behaviors to adolescents' cholesterol levels. Coleman CA, et al. **Adolescence** 1998 Summer;33(130):447-60
Sexual and reproductive health among primary and secondary school pupils in Mwanza, Tanzania: need for intervention. Matasha E, et al. **AIDS Care** 1998 Oct; 10(5):571-82
Pathways family intervention for third-grade American Indian children. Teufel NI, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):803S-809S
Gender, health beliefs, health behaviors, and alcohol consumption. Minugh PA, et al. **Am J Drug Alcohol Abuse** 1998 Aug;24(3):483-97
Are long-term hormone replacement therapy users different from short-term and never users? Buist DS, et al. **Am J Epidemiol** 1999 Feb 1;149(3):275-81
Recent alcohol intake as estimated by the Health Habits and History Questionnaire, the Harvard Semiquantitative Food Frequency Questionnaire, and a more detailed alcohol intake questionnaire. McCann SE, et al. **Am J Epidemiol** 1999 Aug 15;150(4):334-40
Evaluation of an intervention to reduce sun exposure in children: design and baseline results. Milne E, et al. **Am J Epidemiol** 1999 Jul 15;150(2):164-73
Relationship of blood lead levels to personal hygiene habits in lead battery workers: Taiwan, 1991-1997. Chuang HY, et al. **Am J Ind Med** 1999 Jun;35(6):595-603
Gambling, drinking, smoking and other health risk activities among casino employees. Shaffer HJ, et al. **Am J Ind Med** 1999 Sep;36(3):365-78
Alcohol abusers in primary care: readiness to change behavior. Samet JH, et al. **Am J Med** 1998 Oct;105(4):302-6
Breast cancer awareness begins with you. Underwood PW. **Am J Nurs** 1998 Oct;98(10):80
Costs of maternal conditions attributable to smoking during pregnancy. Adams EK, et al. **Am J Prev Med** 1998 Oct; 15(3):212-9
Integrating theoretical approaches to promote physical activity. Epstein LH. **Am J Prev Med** 1998 Nov; 15(4):257-65
A population-based study of age and gender differences in patterns of health-related behaviors. Liang W, et al. **Am J Prev Med** 1999 Jul;17(1):8-17
Environmental and policy interventions to promote physical activity. Sallis JF, et al. **Am J Prev Med** 1998 Nov; 15(4):379-97 (73 ref.)
Assessment of health risk behaviors. A tool to inform consumers, providers, health care organizations, and purchasers [see comments] Thompson BL, et al. **Am J Prev Med** 1999 Jan;16(1):48-59. Comment in: Am J Prev Med 1999 Jan;16(1):70-4.
Commentary on assessment of health risk behaviors. A tool to inform consumers, providers, health care organizations, and purchasers [comment] Thompson RS. **Am J Prev Med** 1999 Jan;16(1):70-4. Comment on: Am J Prev Med 1999 Jan;16(1):48-59.
Correlates of objectively measured physical activity in preadolescent youth. Trost SG, et al. **Am J Prev Med** 1999 Aug;17(2):120-6
A world behaving badly: the global challenge for behavioral surveillance [editorial] McQueen DV. **Am J Public Health** 1999 Sep;89(9):1312-4 (26 ref.)
Explaining educational differences in mortality: the role of behavioral and material factors. Schrijvers CT, et al. **Am J Public Health** 1999 Apr;89(4):535-40
The effects of a health promotion-health protection intervention on behavior change: the WellWorks Study. Sorensen G, et al. **Am J Public Health** 1998 Nov; 88(11):1685-90
Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients. Weis SE, et al. **Am J Public Health** 1999 Jan; 89(1):73-5
Poverty area residence and changes in physical activity level: evidence from the Alameda County Study. Yen IH, et al. **Am J Public Health** 1998 Nov;88(11):1709-12
Cancer prevention among urban southwestern American Indian women: comparison to selected Year 2000 national health objectives. Risendal B, et al. **Ann Epidemiol** 1999 Aug;9(6):383-90
Genes and obesity: is there reason to change our behaviors? [editorial; comment] Weinsier RL. **Ann Intern Med** 1999 Jun 1;130(11):938-9. Comment on: Ann Intern Med 1999 Jun 1;130(11):873-82.
Health behaviors and pharmacotherapy. Kehoe WA, et al. **Ann Pharmacother** 1998 Oct;32(10):1076-86 (60 ref.)
Health psychology: mapping biobehavioral contributions to health and illness. Baum A, et al. **Annu Rev Psychol** 1999; 50:137-63 (208 ref.)
Understanding and promoting sexual and reproductive health behavior: theory and method. Fisher WA, et al. **Annu Rev Sex Res** 1998;9:39-76 (138 ref.)
Understanding women's risk of HIV infection in Thailand through critical hermeneutics. Ruangjiratain S, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):42-51 (28 ref.)
Nutrition and exercise in overweight and obese postpartum women. Morin K, et al. **Appl Nurs Res** 1999 Feb; 12(1):13-21
Culture and ethnicity in clinical care [see comments] Berger JT. **Arch Intern Med** 1998 Oct 26;158(19):2085-90. Comment in: Arch Intern Med 1999 Jun 28;159(12):1373-4.
Direct observation of health-habit counseling of adolescents. Goodwin MA, et al. **Arch Pediatr Adolesc Med** 1999 Apr; 153(4):367-73
Reducing obesity via a school-based interdisciplinary intervention among youth: Planet Health. Gortmaker SL, et al. **Arch Pediatr Adolesc Med** 1999 Apr;153(4):409-18
Douching: a problem for adolescent girls and young women. Merchant JS, et al. **Arch Pediatr Adolesc Med** 1999 Aug; 153(8):834-7 (47 ref.)
Three-year maintenance of improved diet and physical activity: the CATCH cohort. Child and Adolescent Trial for Cardiovascular Health. Nader PR, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):695-704
Comparison of health behaviour and oral/medical conditions in non-insulin-dependent (type II) diabetics and non-diabetics. Kawamura M, et al. **Aust Dent J** 1998 Oct; 43(5):315-20
Preventive health behaviour among general practitioners in Victoria. McCall L, et al. **Aust Fam Physician** 1999 Aug; 28(8):854-7
Barriers to the doctor as patient role. A cultural construct. Rogers T. **Aust Fam Physician** 1998 Nov;27(11):1009-13 (21 ref.)

Do personalised letters in Vietnamese increase cervical cancer screening among Vietnamese women? Del Mar C, et al. **Aust N Z J Public Health** 1998 Dec;22(7):824–5

Health actions and social class among older Australians. Kendig H, et al. **Aust N Z J Public Health** 1998 Dec; 22(7):808–13

Reasons for delayed compliance with the childhood vaccination schedule and some failings of computerised vaccination registers. Richards A, et al. **Aust N Z J Public Health** 1999 Jun;23(3):315–7

Predictors of sun protective behaviors among school students. Balanda KP, et al. **Behav Med** 1999 Spring; 25(1):28–35

Environmental factors, health-related habits, and serum selenium levels in cancer patients and healthy controls. Backović D, et al. **Biol Trace Elem Res** 1999 Jan; 67(1):55–62

Can social cognitive models contribute to the effectiveness of HIV-preventive behavioural interventions? A brief review of the literature and a reply to Joffe (1996; 1997) and Fife-Schaw (1997) [comment] Abraham C, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):297–310 (73 ref.). Comment on: Br J Med Psychol 1996 Sep;69 (Pt 3):169–90. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):65–73. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):75–83.

Perceptions of risk in motorcyclists: unrealistic optimism, relative realism and predictions of behaviour. Rutter DR, et al. **Br J Psychol** 1998 Nov;89 (Pt 4):681–96

Predictors of health risk behaviours among young adults: analysis of the National Population Health Survey. Allison KR, et al. **Can J Public Health** 1999 Mar–Apr;90(2):85–9

Low-risk drinking guidelines: the scientific evidence. Bondy SJ, et al. **Can J Public Health** 1999 Jul–Aug;90(4):264–70 (83 ref.)

The impact of embarrassment on condom purchase behaviour. Dahl DW, et al. **Can J Public Health** 1998 Nov–Dec;89(6):368–70

Injury in Canadian youth: a secondary analysis of the 1993–94 Health Behaviour in School-Aged Children Survey. King MA, et al. **Can J Public Health** 1998 Nov–Dec; 89(6):397–401

Stages of physical activity in the Alberta population. Mummery WK, et al. **Can J Public Health** 1998 Nov–Dec; 89(6):421–3

Health beliefs, health locus of control, and women's mammography behavior. Holm CJ, et al. **Cancer Nurs** 1999 Apr;22(2):149–56

Workshop report: research, policy and program planning on sun protective behaviours. Ashbury FD, et al. **Cancer Prev Control** 1998 Jun;2(3):129–32 (12 ref.)

Sun safety behaviours of alpine skiers and snowboarders in the western United States. Buller DB, et al. **Cancer Prev Control** 1998 Jun;2(3):133–9

Sun safety knowledge and behaviour: new data on which to build [editorial] From L. **Cancer Prev Control** 1998 Jun; 2(3):103–4

Canadian National Survey on Sun Exposure & Protective Behaviours: methods. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):105–9

Canadian National Survey on Sun Exposure & Protective Behaviours: youth at leisure. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):117–22

Canadian National Survey on Sun Exposure & Protective Behaviours: parents' reports on children. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):123–8

Canadian National Survey on Sun Exposure & Protective Behaviours: adults at leisure. Shoveller JA, et al. **Cancer Prev Control** 1998 Jun;2(3):111–6

Sleep schedules and daytime functioning in adolescents. Wolfson AR, et al. **Child Dev** 1998 Aug;69(4):875–87

Living a "shady life": sun-protective behaviour for Canadians. Adam JE. **CMAJ** 1999 May 18;160(10):1471–4 (26 ref.)

Behavioral science applied to cancer screening. Baker F. **Curr Opin Oncol** 1998 Sep;10(5):455–60 (38 ref.)

Assessment of behavioural risk factors associated with HIV infection among youth in Moshi rural district, Tanzania. Tengia-Kessy A, et al. **East Afr Med J** 1998 Sep; 75(9):528–32

Proposed model of the relationship of risk information seeking and processing to the development of preventive behaviors. Griffin RJ, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S230–S245

Chemoprevention versus behavioural modification in primary prevention of cancer [letter] Tokudome S. **Eur J Cancer Prev** 1999 Aug;8(4):365–7

Secondary prevention of coronary heart disease in clinical practice: special considerations for intensified lifestyle modification [comment] Martínez-Rubio A. **Eur J Clin Invest** 1999 May;29(5):365–8. Comment on: Eur J Clin Invest 1999 May;29(5):372–9.

Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty [see comments] Wallner S, et al. **Eur J Clin Invest** 1999 May; 29(5):372–9. Comment in: Eur J Clin Invest 1999 May;29(5):365–8.

Parental influences on adolescents' oral health behavior: two-year follow-up of the Norwegian Longitudinal Health Behavior Study participants. Astrøm AN. **Eur J Oral Sci** 1998 Oct;106(5):922–30

Condom use and HIV risk behaviors among U.S. adults: data from a national survey. Anderson JE, et al. **Fam Plann Perspect** 1999 Jan–Feb;31(1):24–8

Women's interest in vaginal microbicides. Darroch JE, et al. **Fam Plann Perspect** 1999 Jan–Feb;31(1):16–23

Stages of change across ten health risk behaviors for older adults. Nigg CR, et al. **Gerontologist** 1999 Aug;39(4):473–82

Health-related behaviors and the benefits of marriage for elderly persons. Schone BS, et al. **Gerontologist** 1998 Oct; 38(5):618–27

Early health-related behaviours and their impact on later life chances: evidence from the US. Burgess SM, et al. **Health Econ** 1998 Aug;7(5):381–99

Health knowledge and smoking among South African women. Jones AM, et al. **Health Econ** 1999 Mar;8(2):165–9

Controlling for the endogeneity of peer substance use on adolescent alcohol and tobacco use. Norton EC, et al. **Health Econ** 1998 Aug;7(5):439–53

Health behavior, quality of work life, and organizational effectiveness in the lumber industry. Donaldson SI, et al. **Health Educ Behav** 1999 Aug;26(4):579–91

Physical activity and minority women: a qualitative study. Eyler AA, et al. **Health Educ Behav** 1998 Oct;25(5):640–52

Breast cancer screening adherence: does church attendance matter? Fox SA, et al. **Health Educ Behav** 1998 Dec; 25(6):742–58

Religion's role in promoting health and reducing risk among American youth. Wallace JM Jr, et al. **Health Educ Behav** 1998 Dec;25(6):721–41

Trait anxiety, symptom perceptions, and illness-related responses among women with breast cancer in remission during a tamoxifen clinical trial. Cameron LD, et al. **Health Psychol** 1998 Sep;17(5):459–69

Assessment of irrational health beliefs: relation to health practices and medical regimen adherence [published erratum appears in Health Psychol 1999 May;18(3):220] Christensen AJ, et al. **Health Psychol** 1999 Mar; 18(2):169–76

Behavioral research on AIDS—protease inhibitors and the new millennium: comment on Kelly, Otto-Salaj, Sikkema, Pinkerton, and Bloom (1998). Ferrando S. **Health Psychol** 1998 Jul;17(4):307–9

Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Kelly JA, et al. **Health Psychol** 1998 Jul;17(4):310–9 (100 ref.)

Social control in personal relationships: impact on health behaviors and psychological distress. Lewis MA, et al. **Health Psychol** 1999 Jan;18(1):63–71

Manipulating self-efficacy in the exercise environment in women: influences on affective responses. McAuley E, et al. **Health Psychol** 1999 May;18(3):288–94

Experimental evidence for stages of health behavior change: the precaution adoption process model applied to home radon testing. Weinstein ND, et al. **Health Psychol** 1998 Sep;17(5):445–53

Wellness self-care by healthy older adults. Clark CC. **Image J Nurs Sch** 1998;30(4):351–5

The influence of personal protection, environmental hygiene and exposure to pesticides on the health of immigrant farm workers in a desert country. Gomes J, et al. **Int Arch Occup Environ Health** 1999 Jan;72(1):40–5

Oral health behaviour and the prevalence of oral manifestations of HIV infection in a group of HIV positive adults. Marcenes W, et al. **Int Dent J** 1998 Dec;48(6):557–62

Dental caries and oral health behaviour situation of children, mothers and schoolteachers in Wuhan, People's Republic of China. Petersen PE, et al. **Int Dent J** 1998 Jun; 48(3):210–6

A comparison of demographic characteristics of selected year 2000 health objectives for the United States, using behavioral risk factor surveillance system data for Alaska. Ingle DE, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:652–5

Hygiene behaviour in rural Nicaragua in relation to diarrhoea. Gorter AC, et al. **Int J Epidemiol** 1998 Dec; 27(6):1090–100

Does childhood socioeconomic status influence adult health through behavioural factors? van de Mheen H, et al. **Int J Epidemiol** 1998 Jun;27(3):431–7

Breakfast and mental health. Smith AP. **Int J Food Sci Nutr** 1998 Sep;49(5):397–402

Maintenance programmes after weight reduction—how useful are they? Mustajoki P, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):553–5 (21 ref.)

Smoking, diet, and health behaviors among lead-exposed blue-collar workers. Shahar DR, et al. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):101–6

The prevalence and determinants of health care-seeking behavior for urinary incontinence in United Arab Emirates women. Rizk DE, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(3):160–5

A first step incorporating smoking education into a Brazilian medical school curriculum: results of a survey to assess the cigarette smoking knowledge, attitudes, behaviour, and clinical practices of medical students. Daudt AW, et al. **J Addict Dis** 1999;18(1):19–29

Whither "culture" in adolescent health research? [comment] Fergerson G. **J Adolesc Health** 1998 Sep;23(3):150–2. Comment on: J Adolesc Health 1998 Sep;23(3):139–49.

Culture and adolescent development [editorial] Friedman HL. **J Adolesc Health** 1999 Jul:25(1):1–6

Comparability of a computer-assisted versus written method for collecting health behavior information from adolescent patients. Webb PM, et al. **J Adolesc Health** 1999 Jun; 24(6):383–8

Social support and locus of control as correlates of UK nurses' health-related behaviours. Callaghan P. **J Adv Nurs** 1998 Nov;28(5):1127–33

Health beliefs and their influence on United Kingdom nurses' health-related behaviours. Callaghan P. **J Adv Nurs** 1999 Jan;29(1):28–35

Health practices of adult Hispanic women. Higgins PG, et al. **J Adv Nurs** 1999 May;29(5):1105–12

The lived experience of patient prudence in health care. Larrabee JH, et al. **J Adv Nurs** 1998 Oct;28(4):802–8

Nurses' perceptions: issues that arise in caring for patients with diabetes. McDonald PE, et al. **J Adv Nurs** 1999 Aug; 30(2):425–30

A framework for the study of coping, illness behaviour and outcomes. Shaw C. **J Adv Nurs** 1999 May;29(5):1246–55

Effects of psycho-educational interventions on sexual health risks and psycho-social adaptation in young adults with genital herpes. Swanson JM, et al. **J Adv Nurs** 1999 Apr; 29(4):840–51

What really constitutes moderate dieting and health-promoting behaviors [letter; comment] [published erratum appears in J Am Diet Assoc 1999 Jun;99(6):664] Berg FM. **J Am Diet Assoc** 1999 Apr;99(4):410–1. Comment on: J Am Diet Assoc 1998 Oct;98(10):1127–35, 1255.

The DIET study: long-term outcomes of a cognitive-behavioral weight-control intervention in independent-living elders. Dietary Intervention: Evaluation of Technology. Dornelas EA, et al. **J Am Diet Assoc** 1998 Nov;98(11):1276–81

Motivations for using vitamin and mineral supplements. Neuhouser ML, et al. **J Am Diet Assoc** 1999 Jul;99(7):851–4

Demographic and psychosocial predictors of fruit and vegetable intakes differ: implications for dietary interventions. Trudeau E, et al. **J Am Diet Assoc** 1998 Dec; 98(12):1412–7

Mortality, health services use, and health behavior in a cohort of well older adults. Malmgren JA, et al. **J Am Geriatr Soc** 1999 Jan;47(1):51–9

A theoretical model for human health and the pet connection. Staats S, et al. **J Am Vet Med Assoc** 1999 Feb 15; 214(4):483–7

Arkansas women and osteoporosis: informed but still at risk. Turner L, et al. **J Ark Med Soc** 1999 Apr;95(11):493–4

You're never too old: a cancer education and risk reduction program for the elderly. List MA, et al. **J Cancer Educ** 1999 Summer;14(2):104–8

Risk beliefs and interest in counseling: focus-group interviews among first-degree relatives of breast cancer patients. Ryan EL, et al. **J Cancer Educ** 1999 Summer; 14(2):99–103

Readiness to change health behaviours among patients at high risk of cardiovascular disease. Doherty SC, et al. **J Cardiovasc Risk** 1998 Jun;5(3):147–53

Use of antacids in a general population: the impact of health-related variables, lifestyle and sociodemographic characteristics. Furu K, et al. **J Clin Epidemiol** 1999 Jun; 52(6):509–16

The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data. Schwandt P, et al. **J Clin Epidemiol** 1999 Aug;52(8):791–800

The relationship between tooth cleaning behaviour and flexibility of working time schedule. Abegg C, et al. **J Clin Periodontol** 1999 Jul;26(7):448–52

Relationships between stages of change in cigarette smokers and healthy lifestyle behaviors in a population of young military personnel during forced smoking abstinence. Clements-Thompson M, et al. **J Consult Clin Psychol** 1998 Dec;66(6):1005–11

Division of responsibility for asthma management tasks between caregivers and children in the inner city. Wade SL, et al. **J Dev Behav Pediatr** 1999 Apr;20(2):93–8

Health consciousness of young people in relation to their personality. Kikuchi Y, et al. **J Epidemiol** 1999 Apr; 9(2):121–31

Behavioral factors predicting serum cotinine concentrations of male smokers in a Japanese community. Nakayama T, et al. **J Epidemiol** 1999 Jun;9(3):143–5

Operationalisation of a demand/resource model of health: an explorative study. Freidl W, et al. **J Epidemiol Community Health** 1999 Mar;53(3):187–8

Social mobility and health related behaviours in young people. Karvonen S, et al. **J Epidemiol Community Health** 1999 Apr;53(4):211–7

Generational continuity and change in British Asian health and health behaviour. Williams R, et al. **J Epidemiol Community Health** 1998 Sep;52(9):558–63

Association of perceived family criticism with health behaviors. Fiscella K, et al. **J Fam Pract** 1999 Feb; 48(2):128–34

Hypertension in community-dwelling elders from a statewide study: implications for nonpharmacologic therapy. Ciesla JR, et al. **J Health Care Poor Underserved** 1998 Feb; 9(1):62–75

Regulating managed care: interest group competition for control and behavioral health care. Ross EC. **J Health Polit Policy Law** 1999 Jun;24(3):599–625 (58 ref.)

Risk, trust, and the HMO [editorial] Flood AB.

J Health Soc Behav 1998 Sep;39(3):187–8
The impact of education and heart attack on smoking cessation among middle-aged adults. Wray LA, et al. **J Health Soc Behav** 1998 Dec;39(4):271–94
Bringing community involvement into a Cretan primary/hospital care center: an evaluation of population habits and attitudes toward health care. Chatziarsenis M, et al. **J Med Syst** 1999 Apr;23(2):123–31
Randomized trial testing the effect of peer education at increasing fruit and vegetable intake. Buller DB, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1491–500
What ever happened to ...?: A 10-year retrospective [news] Nelson NJ. **J Natl Cancer Inst** 1999 Jan 20;91(2):114–7
Illness attitudes and coping process in subjects with panic attacks. Katerndahl DA. **J Nerv Ment Dis** 1999 Sep; 187(9):561–5
Combat exposure, posttraumatic stress disorder symptoms, and health behaviors as predictors of self-reported physical health in older veterans. Schnurr PP, et al. **J Nerv Ment Dis** 1999 Jun;187(6):353–9
The index of self-regulation: development and psychometric analysis. Fleury J. **J Nurs Meas** 1998 Summer;6(1):3–17
Development and validation of the avoidance of environmental tobacco smoke scale. Martinelli AM. **J Nurs Meas** 1998 Summer;6(1):75–86
Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. Rock CL, et al. **J Nutr** 1999 Apr;129(4):855–64
The Working Healthy Project: a worksite health-promotion trial targeting physical activity, diet, and smoking. Emmons KM, et al. **J Occup Environ Med** 1999 Jul;41(7):545–55
The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. The Health Enhancement Research Organization (HERO) Research Committee. Goetzel RZ, et al. **J Occup Environ Med** 1998 Oct;40(10):843–54
Do the psychosocial and behavioral changes that accompany motherhood influence the impact of pregnancy on long-term weight gain? Harris HE, et al. **J Psychosom Obstet Gynaecol** 1999 Jun;20(2):65–79
Determinants for dental visit behavior among Hong Kong Chinese in a longitudinal study. Lo EC, et al. **J Public Health Dent** 1998 Summer;58(3):220–7
Preventive oral health behaviors among African-Americans and whites in Detroit. Ronis DL, et al. **J Public Health Dent** 1998 Summer;58(3):234–40
Health-promoting behaviours in public health: testing the health promotion model. Blacconiere MJ, et al. **J R Soc Health** 1999 Mar;119(1):11–6
Nigerian university students' knowledge, perceptions, and behaviours about HIV/AIDS: are these students at risk? Harding AK, et al. **J R Soc Health** 1999 Mar;119(1):23–31
Youth Risk Behavior Surveillance--United States, 1997. State and Local YRBSS Coordinators. Kann L, et al. **J Sch Health** 1998 Nov;68(9):355–69
Middle school students and bicycle helmet use: knowledge, attitudes, beliefs, and behaviors. Liller KD, et al. **J Sch Health** 1998 Oct;68(8):325–8
Psychosocial factors associated with dieting behaviors among female adolescents. Pesa J. **J Sch Health** 1999 May; 69(5):196–201
Physical activity of adult Australians: epidemiological evidence and potential strategies for health gain. Bauman A, et al. **J Sci Med Sport** 1999 Mar;2(1):30–41 (69 ref.)
The influence of perceived responsibility and personality characteristics on the emotional and behavioral reactions to people with AIDS. Steins G, et al. **J Soc Psychol** 1999 Aug;139(4):487–95
Designated driving among college students. Barr A, et al. **J Stud Alcohol** 1998 Sep;59(5):549–54
Behavioral factors in the health status of urban populations. Breslow L. **J Urban Health** 1998 Jun;75(2):242–50
Social, behavioral, and demographic factors in emerging infections. Garrett L. **J Urban Health** 1998 Sep; 75(3):492–500
The relationship of reciprocity to self health care in older women. Craft BJ, et al. **J Women Aging** 1998;10(2):35–47
Gender role orientation as a correlate of perceived health, health behavior, and qualitative well-being in older women. Ruffing-Rahal MA, et al. **J Women Aging** 1998; 10(1):3–19
Prevalence of multiple cardiovascular disease risk factors among women in the United States, 1992 and 1995: the Behavioral Risk Factor Surveillance System. Greenlund KJ, et al. **J Womens Health** 1998 Nov;7(9):1125–33
Women, chronic disease, and the behavioral risk factor surveillance system. Mack KA. **J Womens Health** 1998 Oct; 7(8):949–54
Effect of lifestyle changes on coronary heart disease [letter; comment] Herbert PN. **JAMA** 1999 Jul 14;282(2):130; discussion 131–2. Comment on: JAMA 1998 Dec 16;280(23):2001–7.
Effect of lifestyle changes on coronary heart disease [letter; comment] Lear SA. **JAMA** 1999 Jul 14;282(2):131–2. Comment on: JAMA 1998 Dec 16;280(23):2001–7.
Socioeconomic factors and determinants of mortality [letter; comment] Manning GC. **JAMA** 1998 Nov 25;280(20):1745. Comment on: JAMA 1998 Jun 3;279(21):1703–8.
Effect of lifestyle changes on coronary heart disease [letter; comment] Miller M. **JAMA** 1999 Jul 14;282(2):130; discussion 131–2. Comment on: JAMA 1998 Dec 16;280(23):2001–7.
Intensive lifestyle changes for reversal of coronary heart disease [published erratum appears in JAMA 1999 Apr 21;281(15):1380] [see comments] Ornish D, et al. **JAMA** 1998 Dec 16;280(23):2001–7. Comment in: JAMA 1999 Jul 14;282(2):130; discussion 131–2. Comment in: JAMA 1999 Jul 14;282(2):131–2.
Socioeconomic factors and determinants of mortality [letter; comment] Smith GD, et al. **JAMA** 1998 Nov 25; 280(20):1744–5. Comment on: JAMA 1998 Jun 3;279(21):1703–8.
Knowledge, attitude and behaviour towards AIDS among educated youth in Lahore, Pakistan. Raza MI, et al. **JPMA J Pak Med Assoc** 1998 Jun;48(6):179–82
The Kuwaiti passion for food cannot be shaken [news] Kandela P. **Lancet** 1999 Apr 10;353(9160):1249
Varieties of reasoning in medical anthropology. Browner CH. **Med Anthropol Q** 1998 Sep;12(3):356–8
On the rationality of decision-making studies: Part 1: Decision models of treatment choice. Garro LC. **Med Anthropol Q** 1998 Sep;12(3):319–40
On the rationality of decision-making studies: Part 2: Divergent rationalities. Garro LC. **Med Anthropol Q** 1998 Sep;12(3):341–55
Methodological approaches to the study of reasoning. Mathews HF. **Med Anthropol Q** 1998 Sep;12(3):358–62
Homeopathic medicine in the city of Oaxaca, Mexico: patients' perspectives and observations. Whiteford MB. **Med Anthropol Q** 1999 Mar;13(1):69–78
Health habit counseling amidst competing demands: effects of patient health habits and visit characteristics. Chernof BA, et al. **Med Care** 1999 Aug;37(8):738–47
The relationship between continuity of care and the health behaviors of patients: does having a usual physician make a difference? Ettner SL. **Med Care** 1999 Jun;37(6):547–55
When asked, patients tell: disclosure of sensitive health-risk behaviors. Gerbert B, et al. **Med Care** 1999 Jan;37(1):104–11
An analysis of smoking patterns among older adults. Ruchlin HS. **Med Care** 1999 Jun;37(6):615–9
Time preferences and preventive health behavior: acceptance of the influenza vaccine. Chapman GB, et al. **Med Decis Making** 1999 Jul–Sep;19(3):307–14
A cluster-analytical approach toward physical activity and other health related behaviors. de Bourdeaudhuij I, et al. **Med Sci Sports Exerc** 1999 Apr;31(4):605–12
Effective health promotion and clinical care for large people. Lyons P, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1141–6
Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Kaufert P, et al. **Menopause** 1998 Winter; 5(4):197–202
Dietary supplement use in U.S. Army Special Operations candidates. Arsenault J, et al. **Mil Med** 1999 Jul; 164(7):495–501
An examination of body weight standards and the association between weight and health behaviors in the United States Air Force. Haddock CK, et al. **Mil Med** 1999 Jan; 164(1):51–4
Physician advice and individual behaviors about cardiovascular disease risk reduction--seven states and Puerto Rico, 1997. **MMWR Morb Mortal Wkly Rep** 1999 Feb 5;48(4):74–7
Self-reported physical inactivity by degree of urbanization--United States, 1996. **MMWR Morb Mortal Wkly Rep** 1998 Dec 25; 47(50):1097–100
Prevalence of selected maternal and infant characteristics, Pregnancy Risk Assessment Monitoring System (PRAMS), 1997. Colley Gilbert BJ, et al. **Mor Mortal Wkly Rep CDC Surveill Summ** 1999 Sep 24; 48(5):1–37
Cardiovascular disease risk factors and preventive practices among adults--United States, 1994: a behavioral risk factor atlas. Behavioral Risk Factor Surveillance System State Coordinators. Hahn RA, et al. **Mor Mortal Wkly Rep CDC Surveill Summ** 1998 Dec 11; 47(5):35–69
An assessment of the health habits of physicians. What's good for doctors is good for their patients. Kelley KS, et al. **N C Med J** 1998 Sep–Oct;59(5):302–3
Gains in life expectancy from medical interventions [letter; comment] Roizen MF, et al. **N Engl J Med** 1998 Dec 24; 339(26):1943; discussion 1944. Comment on: N Engl J Med 1998 Aug 6;339(6):380–6.
The health and health practices of doctors and their families. Richards JG. **N Z Med J** 1999 Mar 26;112(1084):96–9
The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49–70 (90 ref.)
Self-esteem and health behavior: theoretic and empirical links. Seigley LA. **Nurs Outlook** 1999 Mar–Apr;47(2):74–7 (36 ref.)
A theory of planned behavior-based structural model for breast-feeding. Duckett L, et al. **Nurs Res** 1998 Nov–Dec; 47(6):325–36
Predicting intentions to obtain a Pap smear among African American and Latina women: testing the theory of planned behavior. Jennings-Dozier K. **Nurs Res** 1999 Jul–Aug; 48(4):198–205
Food for health or wealth in the 21st century. Stitt S. **Nutr Health** 1998;12(4):203–13 (15 ref.)
Success habits of long-term gastric bypass patients. Cook CM, et al. **Obes Surg** 1999 Feb;9(1):80–2
The impact of wear time. Colton CE. **Occup Health Saf** 1998 Nov;67(11):26–30, 32–3
Weight concerns, weight control behaviors, and smoking initiation. Tomeo CA, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):918–24
Effects of computer feedback on adherence to exercise. Annesi JJ. **Percept Mot Skills** 1998 Oct;87(2):723–30
Commitment to physical activity and anxiety about physique among college women. Finkenberg ME, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1393–4
Measuring transitions through stages of exercise: application of latent transition analysis. Gebhardt WA, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1097–106
Cultural factors in exercise participation of older adults. Kirkby RJ, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):890
Exploring biases in self-reported exercising behavior heuristics based on recency, frequency, and preference. Matt GE, et al. **Percept Mot Skills** 1999 Feb;88(1):126–8
An informal look at use of bakery department tongs and tissues. Trinkaus J. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):801–2
Periconceptional use of folic acid amongst women of advanced maternal age. Brandenburg H, et al. **Prenat Diagn** 1999 Feb;19(2):132–5
A message from preventive medicine and your physician. **Prev Med** 1999 Apr;28(4):341–2
A pill for all by the year 2000? Barrett-Connor E. **Prev Med** 1999 Jun;28(6):600–7
Surveillance behavior of women with a reported family history of colorectal cancer. Clavel-Chapelon F, et al. **Prev Med** 1999 Feb;28(2):174–8
Effectiveness of a telephone outcall intervention to promote screening mammography among low-income women. Crane LA, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 2):S39–49
Cigarette smoking, alcohol consumption, and screening mammography among women ages 50 and older. Fredman L, et al. **Prev Med** 1999 Apr;28(4):407–17
Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Haapanen-Niemi N, et al. **Prev Med** 1999 Apr;28(4):343–8
Stage distributions for five health behaviors in the United States and Australia. Laforge RG, et al. **Prev Med** 1999 Jan;28(1):61–74
Predicting children's sunscreen use: application of the theories of reasoned action and planned behavior. Martin SC, et al. **Prev Med** 1999 Jul;29(1):37–44
Three-year prospective adherence to three breast cancer screening modalities. Solomon LJ, et al. **Prev Med** 1998 Nov–Dec;27(6):781–6
A sustainable behavioral intervention to increase condom use and reduce gonorrhea among sex workers in Singapore: 2-year follow-up. Wong ML, et al. **Prev Med** 1998 Nov–Dec;27(6):891–900
HIV risk factors among people with severe mental illness in urban and rural areas. Brunette MF, et al. **Psychiatr Serv** 1999 Apr;50(4):556–8
A scale for assessing sleep hygiene: preliminary data. Blake DD, et al. **Psychol Rep** 1998 Dec;83(3 Pt 2):1175–8
Differences in self-reported health behaviors between public health professionals and support staff. Oleckno WA, et al. **Psychol Rep** 1999 Feb;84(1):127–34
Sex differences in health attitudes and choice of health behaviors. Welsh MC, et al. **Psychol Rep** 1998 Dec;83(3 Pt 2):1161–2
Utility of the theory of planned behavior for understanding exercise during breast cancer treatment. Courneya KS, et al. **Psychooncology** 1999 Mar–Apr;8(2):112–22
Anxiety and adherence to breast self-examination in women with a family history of breast cancer. Brain K, et al. **Psychosom Med** 1999 Mar–Apr;61(2):181–7
Self-report evaluation of health behavior, stress vulnerability, and medical outcome of heart transplant recipients. Harper RG, et al. **Psychosom Med** 1998 Sep–Oct;60(5):563–9
Tracking of avoidance of alcohol use and smoking behavior in a fifth grade cohort over three years. Felton G, et al. **Public Health Nurs** 1999 Feb;16(1):32–40
An explanatory model of variables influencing health promotion behaviors in smoking and nonsmoking college students. Martinelli AM. **Public Health Nurs** 1999 Aug; 16(4):263–9
Health-enhancing behaviors correlated with breastfeeding among a national sample of mothers. Pesa JA, et al. **Public Health Nurs** 1999 Apr;16(2):120–4
Hopes towards 'healthy eating' [correction of 'healthy heating']: are we being realistic? [letter] Walker AR. **Public Health Nutr** 1999 Mar;2(1):75–6
Does participation in a structured high-intensity exercise program influence daily physical activity patterns in older adults? Washburn RA, et al. **Res Q Exerc Sport** 1999 Jun; 70(2):201–5
Multifactorial evaluation of a program for lifestyle behavior change in rehabilitation and secondary prevention of coronary artery disease. Lisspers J, et al. **Scand Cardiovasc J** 1999;33(1):9–16
Lessons from the Oslo Study Diet and Anti-smoking Trial: a qualitative study of long-term behaviour change. Cable TA, et al. **Scand J Public Health** 1999 Sep;27(3):206–12
Inequalities in health: evidence from Denmark of the

interaction of circumstances and health-related behaviour. Christiansen T, et al. **Scand J Public Health** 1999 Sep; 27(3):181-8

Gender differences in physical symptoms and illness behavior. A health diary study. Gijsbers van Wijk CM, et al. **Soc Sci Med** 1999 Oct;49(8):1061-74

Health behaviour and the school environment in New South Wales, Australia. McLellan L, et al. **Soc Sci Med** 1999 Sep; 49(5):611-9

Issues in promoting health. Mechanic D. **Soc Sci Med** 1999 Mar;48(6):711-8 (49 ref.)

Health related behavioural change in context: young people in transition. Pavis S, et al. **Soc Sci Med** 1998 Nov; 47(10):1407-18

Preventive behavior among recent immigrants: Russian-speaking women and cancer screening in Israel. Remennick LI. **Soc Sci Med** 1999 Jun;48(11):1669-84

Things ain't what they ought to be: social forces underlying racial disparities in rates of sexually transmitted diseases in a rural North Carolina county. Thomas JC, et al. **Soc Sci Med** 1999 Oct;49(8):1075-84

Achieving clinical behaviour change: a case of becoming indeterminate. Wood M, et al. **Soc Sci Med** 1998 Dec; 47(11):1729-38

Prioritising family health needs: a time--space analysis of women's health-related behaviours. Young R. **Soc Sci Med** 1999 Mar;48(6):797-813

HIV/AIDS in nonurban Alabama: risk activities and access to services among HIV-infected persons. Beltrami JF, et al. **South Med J** 1999 Jul;92(7):677-83

Sociodemographic characteristics and individual health behaviors. Shi L. **South Med J** 1998 Oct;91(10):933-41

The Berne-Munich Lifestyle Panel. Background and baseline results from a longitudinal health lifestyle survey. Abel T, et al. **Soz Praventivmed** 1999;44(3):91-106

Health behavior in persons with spinal cord injury: development and initial validation of an outcome measure. Pruitt SD, et al. **Spinal Cord** 1998 Oct;36(10):724-31

AIDS susceptibility in a migrant population: perception and behavior. McBride DC, et al. **Subst Use Misuse** 1999 Mar-Apr;34(4-5):633-52

Resiliency factors protecting against teenage alcohol use and smoking: influences of religion, religious involvement and values, and ethnicity in the Missouri Adolescent Female Twin Study. Heath AC, et al. **Twin Res** 1999 Jun; 2(2):145-55

Genetics of early cancer detection behaviours in Australian female twins. Treloar SA, et al. **Twin Res** 1999 Mar; 2(1):33-42

A behaviour risk factor survey in Jamaica. Figueroa JP, et al. **West Indian Med J** 1999 Mar;48(1):9-15

Reducing need and demand for medical services in high-risk persons. A health education approach. Fries JF, et al. **West J Med** 1998 Oct;169(4):201-7

Cognitive appraisal and cardiac risk reduction behavior following coronary angioplasty. Kimble LP. **West J Nurs Res** 1998 Dec;20(6):733-44

Wrestling the scale not the opponent. Harms R. **WMJ** 1998 Sep;97(8):37-8

Critical adolescent health issues: results of the 1997 Wisconsin Youth Risk Behavior Survey. White D, et al. **WMJ** 1998 Sep;97(8):23-4

Predictors of quality of life in women: hormone therapy self-efficacy and health-promoting behaviors. Ali NS. **Women Health** 1999;29(2):69-79

Health behavior change models and their socio-cultural relevance for breast cancer screening in African American women. Ashing-Giwa K. **Women Health** 1999;28(4):53-71 (69 ref.)

Health-promoting behaviors of rural adolescent women. Felton GM, et al. **Women Health** 1998;27(4):67-80

Smoking behaviors of women whose children attend an urban pediatric primary care clinic. Groner J, et al. **Women Health** 1998;28(2):19-32

Influence of self-care education on illness behaviors and health locus of control of Mexican American women. Kennedy CA, et al. **Women Health** 1999;28(3):1-13

Health related behaviors and cancer screening of lesbians: results from the Boston Lesbian Health Project. Roberts SJ, et al. **Women Health** 1999;28(4):1-12 (32 ref.)

Use of the transtheoretical model for behavioral change in women's health. Peipert JF, et al. **Womens Health Issues** 1998 Sep-Oct;8(5):304-9

[Utilizing the PRECEDE model to predict health examination behavior of the elderly] Chiou CJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jun; 15(6):348-58 (Eng. Abstr.) **(Chi)**

[Bullying as health hazard among school children] Due EP, et al. **Ugeskr Laeger** 1999 Apr 12;161(15):2201-6 (Eng. Abstr.) **(Dan)**

[Attitude of general practitioners to the importance of gender and diet in disease prevention] Hølund U, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):40-3 (Eng. Abstr.) **(Dan)**

[The effect of a reference program and a media campaign on the prevention of AIDS in general practice] Sandbaek A, et al. **Ugeskr Laeger** 1998 Oct 26;160(44):6348-52 (Eng. Abstr.) **(Dan)**

[Sun exposure behavior of children between 3-15 years of age living in Montpellier] Vergnes C, et al. **Ann Dermatol Venereol** 1999 Jun-Jul;126(6-7):505-12 (Eng. Abstr.) **(Fre)**

[Interaction of psychological and social factors in the care of AIDS virus carriers] Santiago Delefosse M. **Encephale** 1998 Nov-Dec;24(6):497-502 (Eng. Abstr.) **(Fre)**

[Eating disorders. Virtual identity and social contagion] Corcos M. **Presse Med** 1999 Jan 16;28(2):85-7 **(Fre)**

[Factors associated with survival in Kaposi's sarcoma in patients infected with the human immunodeficiency virus. Clinical Epidemiological Group for AIDS in Aquitaine] Cazorla C, et al. **Rev Epidemiol Sante Publique** 1999 Apr; 47(2):109-17 (Eng. Abstr.) **(Fre)**

[Behavior linked to orodental health in 12-year-old students in the province of Kadiogo, Burkina Faso] Tapsoba H, et al. **Sante Publique** 1998 Jun;10(2):219-24 (Eng. Abstr.) **(Fre)**

[Dream trip or nightmare--your counseling can decide. When a patient travels... 1. Advice for the the patient who enjoys travel] Knauer RH. **Fortschr Med** 1998 Oct 10; 116(28):47-8 **(Ger)**

[Attitudes and health status as determinants of participation in individually oriented health promotion] Wanek V, et al. **Gesundheitswesen** 1999 Jul;61(7):346-52 (Eng. Abstr.) **(Ger)**

[Lifestyle, mental health, and awareness of health among Japanese bus drivers] Hara S, et al. **Nippon Koshu Eisei Zasshi** 1998 Dec;45(12):1162-70 (Eng. Abstr.) **(Jpn)**

[Health promotion behavior, daily activities, and perceived transportation problems of elderly people living in a small town far from the nearest train station] Yoshimoto T, et al. **Nippon Ronen Igakkai Zasshi** 1998 Aug;35(8):619-25 (Eng. Abstr.) **(Jpn)**

[Relationships among health-promoting activities, going out and perceived transportation problems of elderly people living in a small town far from the nearest train station] Yoshimoto T, et al. **Nippon Ronen Igakkai Zasshi** 1999 Mar; 36(3):191-8 (Eng. Abstr.) **(Jpn)**

[Experience of family break-up during childhood--health and health behavior in adolescence] Breidablik HJ, et al. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2331-5 (Eng. Abstr.) **(Nor)**

[Effect of nutrition education on nutrition behaviors of investigated students' group] Pierzynowska J, et al. **Rocz Panstw Zakl Hig** 1998;49(4):491-8 (Eng. Abstr.) **(Pol)**

[Subjective evaluation of health status and motivation for improving it in able-bodied urban population of the European North of Russia] Viaz'min AM, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov-Dec;(6):19-23 (Eng. Abstr.) **(Rus)**

[The evolution of health and relationship habits of an adolescent cohort of Puerto de Sagunto (1995-1996)] Huertas Zarco I, et al. **Aten Primaria** 1999 Jan;23(1):8-14 (Eng. Abstr.) **(Spa)**

[Health-related behaviors in secondary-school students: sexual relations and tobacco, alcohol and cannabis consumption] Diez E, et al. **Gac Sanit** 1998 Nov-Dec; 12(6):272-80 (Eng. Abstr.) **(Spa)**

[Prescribed exercise can help the patient to change his habits] Hellénius ML, et al. **Lakartidningen** 1999 Jul 28; 96(30-31):3343-6 (34 ref.) **(Swe)**

ETHNOLOGY

Knowledge, attitudes, beliefs, and practices about HIV/AIDS in Kuwait. al-Owaish R, et al. **AIDS Educ Prev** 1999 Apr;11(2):163-73

Correlates of condom use stage of change: implications for intervention. Polacsek M, et al. **AIDS Educ Prev** 1999 Feb; 11(1):38-52

HIV risk behaviors, intentions, and perceptions among Namibian youth as assessed by a theory-based questionnaire. Stanton BF, et al. **AIDS Educ Prev** 1999 Apr;11(2):132-49

Ethnic differences in cancer risk behaviors through the transition out of high school. Baranowski T, et al. **Ethn Dis** 1999 Winter;9(1):94-103

The association between acculturation and health practices among middle-aged and elderly Latinas. Cantero PJ, et al. **Ethn Dis** 1999 Spring-Summer;9(2):166-80

Sun protection behaviors among African Americans. Hall HI, et al. **Ethn Dis** 1999 Winter;9(1):126-31

Examination of factor structure of the cognitive representations of hypertension scale for ethnic equivalence. Scisney-Matlock M, et al. **Ethn Dis** 1999 Winter;9(1):33-47

Perceptions of dementia, caregiving, and help seeking among Asian and Pacific Islander Americans. Braun KL, et al. **Health Soc Work** 1998 Nov;23(4):262-74 (67 ref.)

AIDS protection and contraception among African American, Hispanic, and white women. Hines AM, et al. **Health Soc Work** 1998 Aug;23(3):186-94

Fathering pregnancies: marking health-risk behaviors in urban adolescents. Guagliardo MF, et al. **J Adolesc Health** 1999 Jan;24(1):10-5

Preventive dental behaviors and their association with oral health status in older white men. Boehmer U, et al. **J Dent Res** 1999 Apr;78(4):869-77

The three leading causes of death in African Americans: barriers to reducing excess disparity and to improving health behaviors. Feldman RH, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):45-71

Protective factors in adolescent health behavior. Jessor R, et al. **J Pers Soc Psychol** 1998 Sep;75(3):788-800

The association between smoking and unhealthy behaviors among a national sample of Mexican-American adolescents. Pesa JA. **J Sch Health** 1998 Nov;68(9):376-80

Smoking and lipid cardiovascular risk factors in Vietnamese refugees in Australia. Bermingham M, et al. **Prev Med** 1999 Apr;28(4):378-85

Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Mandelblatt JS, et al. **Prev Med** 1999 Apr;28(4):418-25

HEALTH BENEFIT PLANS, EMPLOYEE

Getting our message across. Conrod B. **J Can Dent Assoc** 1998 Oct;64(9):657-8

PLICO response [letter; comment] Crosthwait MJ. **J Okla State Med Assoc** 1998 Dec;91(9):523. Comment on: J Okla State Med Assoc 1998 Nov;91(8):464.

Domestic partnership benefits at medical universities. O'Hanlan KA. **JAMA** 1999 Oct 6;282(13):1289, 1292

[Group health insurance and tax deductions] Ibern. **Gac Sanit** 1999 May-Jun;13(3):236-8 **(Spa)**

ECONOMICS

Does a fixed-dollar premium contribution lower spending? Buchmueller TC. **Health Aff (Millwood)** 1998 Nov-Dec; 17(6):228-35

Capturing mental health cost offsets [comment] England MJ. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):91-3. Comment on: Health Aff (Millwood) 1999 Mar-Apr;18(2):79-90.

Employment-based health insurance for children: why did coverage increase in the mid-1990s? Fronstin P. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):131-6

Class and benefits at the workplace. Gabel J, et al. **Health Aff (Millwood)** 1999 May-Jun;18(3):144-50

Justifying mental health care costs [comment] Goldman HH. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):94-5. Comment on: Health Aff (Millwood) 1999 Mar-Apr;18(2):79-90.

More evidence for the insurability of managed behavioral health care. Goldman W, et al. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):172-81

Cost of tax-exempt health benefits in 1998. Sheils J, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):176-81

Cost control: don't count employers out [letter; comment] Sheils JF. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):275-7 . Comment on: Health Aff (Millwood) 1998 Sep-Oct;17(5):128-40. Comment on: Health Aff (Millwood) 1998 Sep-Oct;17(5):141-6.

The effects of economic reform on health insurance and the financial burden for urban workers in China. Hu TW, et al. **Health Econ** 1999 Jun;8(4):309-21

Who gains and who loses with community rating for small business? Buchanan JL, et al. **Inquiry** 1999 Spring; 36(1):30-43

Health insurance choices in two-worker households: determinants of double coverage. Monheit AC, et al. **Inquiry** 1999 Spring;36(1):12-29

Paying more and losing ground: how employer cost-shifting is eroding health coverage of working families. Sheils JF, et al. **Int J Health Serv** 1999;29(3):485-518

How expensive are unlimited substance abuse benefits under managed care? Sturm R, et al. **J Behav Health Serv Res** 1999 May;26(2):203-10

Direct reimbursement [letter] Zacal GF. **J Can Dent Assoc** 1999 Feb;65(2):79

Mental health carve-outs: effects and implications. Grazier KL, et al. **Med Care Res Rev** 1999;56 Suppl 2:37-59 (40 ref.)

The American health care system [letter] Anstadt GW. **N Engl J Med** 1999 Sep 16;341(12):918

The American health care system [letter] Boren SD, et al. **N Engl J Med** 1999 Sep 16;341(12):918

The American health care system--employer-sponsored health coverage. Kuttner R. **N Engl J Med** 1999 Jan 21; 340(3):248-52

The American health care system [letter] Maun RA. **N Engl J Med** 1999 Sep 16;341(12):919

Employer-provider partnerships in advanced managed care: human assets risk management. Comstock ML. **Occup Med** 1998 Oct-Dec;13(4):645-61, iii (28 ref.)

Costs of employee behavioral health care by diagnosis. Peele PB, et al. **Psychiatr Serv** 1998 Dec;49(12):1549

Costs and utilization of substance abuse care in a privately insured population under managed care. Schoenbaum M, et al. **Psychiatr Serv** 1998 Dec;49(12):1573-8

An essential hospital package for South Africa--selection criteria, costs and affordability. Söderlund N. **S Afr Med J** 1999 Jul;89(7):757-65

LEGISLATION & JURISPRUDENCE

Moving Medicare to the FEHBP model, or how to make an elephant fly. Cain HP 2nd. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):25-39

Health insurance reform in the small-group market. Curtis R, et al. **Health Aff (Millwood)** 1999 May-Jun;18(3):151-60

Consumer-choice markets: lessons from FEHBP mental health coverage. Foote SM, et al. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):125-30

Small group reform and insurance provision by small firms, 1989-1995. Jensen GA, et al. **Inquiry** 1999 Summer;

36(2):176–87
The emerging convergence of the doctrine of informed consent and judicial reinterpretation of the Employee Retirement Income Security Act. Blackmon W. **J Leg Med** 1998 Sep;19(3):377–95 (101 ref.)
Employee health insurance/discrimination rules. Weber RD. **Mich Med** 1999 Feb;98(2):8–9
Managed care, liability, and ERISA. Stone AA. **Psychiatr Clin North Am** 1999 Mar;22(1):17–29 (40 ref.)

ORGANIZATION & ADMINISTRATION

Direct contracts, data sharing and employee risk selection: new stakes for patient privacy in tomorrow's health insurance markets. Studdert DM. **Am J Law Med** 1999; 25(2–3):233–65
Direct contracts. Running for coverage. Greene J. **Hosp Health Netw** 1998 Dec 5–20;72(23–24):61
The Federal Employees Health Benefits Plan: implications for medicare reform. Feldman R, et al. **Inquiry** 1999 Summer;36(2):188–99
Clinical utilization by uninsured workers in a contributory health plan. Garrison RJ, et al. **J Health Care Poor Underserved** 1999 May;10(2):169–77
Collaborating outside the box: three years later. Reinertsen JL, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):585–90
Patient empowerment: individual control of health benefits [editorial] Nirschl RP. **Orthopedics** 1999 Aug;22(8):727–8
Using employer purchasing power to improve the quality of perinatal care. Castles AG, et al. **Pediatrics** 1999 Jan; 103(1 Suppl E):248–54
An essential hospital package for South Africa—selection criteria, costs and affordability. Söderlund N. **S Afr Med J** 1999 Jul;89(7):757–65

STANDARDS

Making report cards work. Wicks EK, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):152–5
Count on quality. Larkin H. **Hosp Health Netw** 1998 Oct 5;72(19):32–4, 3
Anticipating market demand: tracking enrollee satisfaction and health over time [see comments] Allen H. **Int J Qual Health Care** 1998 Dec;10(6):521–30. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.
A major employer as a health care services laboratory [see comments] Reeve GR, et al. **Int J Qual Health Care** 1998 Dec;10(6):547–53. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.
Respondent selection by mail: obtaining probability samples of health plan enrollees. Gallagher PM, et al. **Med Care** 1999 Mar;37(3 Suppl):MS50–8
The impact of having parents report about both their own and their children's experiences with health insurance plans. Shaul JA, et al. **Med Care** 1999 Mar;37(3 Suppl):MS59–68
Improving the quality of health care. Health care through a Six Sigma lens [comment] Buck CR Jr. **Milbank Q** 1998; 76(4):749–53. Comment on: Milbank Q 1998 ;76(4):625–48, 511.

STATISTICS & NUMERICAL DATA

Inpatient treatment of comorbid psychiatric and substance abuse disorders: comparison of public sector and privately insured populations. Leslie DL, et al. **Adm Policy Ment Health** 1999 Mar;26(4):253–68
An assessment of Hawaii QUEST medical plans performance using Medicaid HEDIS measures, 1996–1997. Honbo L, et al. **Hawaii Med J** 1998 Oct;57(10):662, 664–70, 672–3
Behavioral health benefits in employer-sponsored health plans, 1997. Buck JA, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):67–78
Class and benefits at the workplace. Gabel J, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):144–50
Health benefits for the terminally ill: reality and perception. Gabel JR, et al. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):120–7
No exit? The effect of health status on dissatisfaction and disenrollment from health plans. Schlesinger M, et al. **Health Serv Res** 1999 Jun;34(2):547–76
The effect of methodological differences in two survey's estimates of the percentage of employers sponsoring health insurance. Hing E, et al. **Inquiry** 1999 Summer;36(2):212–20
Using choice-based conjoint to determine the relative importance of dental benefit plan attributes. Cunningham MA, et al. **J Dent Educ** 1999 May;63(5):391–9
Health Insurance Portability and Accountability Act of 1996: lessons from the States. Hing E, et al. **Med Care** 1999 Jul; 37(7):692–705
HEDIS measures and managed care enrollment. Scanlon DP, et al. **Med Care Res Rev** 1999;56 Suppl 2:60–84
A reappraisal of private employers' role in providing health insurance. Carrasquillo O, et al. **N Engl J Med** 1999 Jan 14;340(2):109–14
Rising health care costs: is this the turning point? Tyler T, et al. **Tenn Med** 1999 Jul;92(7):255–6

TRENDS

Managed behavioral health care in 1999: an industry at a crossroads. Findlay S. **Health Aff (Millwood)** 1999 Sep–Oct; 18(5):116–24
Changing the employer-sponsored health plan system: the views of employees in large firms. Lave JR, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):112–7
Pooled purchasing: who are the players? Long SH, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):105–11
Recent trends in self-insured employer health plans. Marquis MS, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):161–6
Why are workers uninsured? Employer-sponsored health insurance in 1997. Thorpe KE, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):213–8
Covering up. For small players, a big leap [news] Novarro L. **Hosp Health Netw** 1999 May;73(5):16
Wiring up, reaching out. Serb C. **Hosp Health Netw** 1999 May;73(5):28–32

UTILIZATION

Effect of declining mental health service use on employees of a large corporation. Rosenheck RA, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):193–203
Who gains and who loses with community rating for small business? Buchanan JL, et al. **Inquiry** 1999 Spring; 36(1):30–43
Population choice and variable selection in the estimation and application of risk models. Dudley RA, et al. **Inquiry** 1999 Summer;36(2):200–11
Health insurance choices in two-worker households: determinants of double coverage. Monheit AC, et al. **Inquiry** 1999 Spring;36(1):12–29
Urban-rural differences in employer-based health insurance coverage of workers. Coburn AF, et al. **Med Care Res Rev** 1998 Dec;55(4):484–96
Medicare spending by beneficiaries with various types of supplemental insurance. Khandker RK, et al. **Med Care Res Rev** 1999 Jun;56(2):137–55
Health care consumers: choices and constraints. McLaughlin CG. **Med Care Res Rev** 1999;56 Suppl 1:24–59; discussion 60–6 (83 ref.)

HEALTH BENEFITS see **INSURANCE BENEFITS**

HEALTH CAMPAIGNS see **HEALTH PROMOTION**

HEALTH CARE see **DELIVERY OF HEALTH CARE**

HEALTH CARE COALITIONS

Raising the bar: the use of performance guarantees by the Pacific Business Group on Health. Schauffler HH, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):134–42
Assisted living. Big brother [news] **Hosp Health Netw** 1998 Oct 20;72(20):16
Collective clout. Share the health. Castrey M. **Hosp Health Netw** 1998 Nov 20;72(22):43–4
Business unusual. Allina, winner of the 1998 McGaw Prize, is pioneering a new treatment: boosting health at the grassroots. Garber K. **Hosp Health Netw** 1999 Feb; 73(2):54–8
Direct contracts. Running for coverage. Greene J. **Hosp Health Netw** 1998 Dec 5–20;72(23–24):61
Reaching out to the underserved: a collaborative partnership to provide health care. Ahmed SM, et al. **J Health Care Poor Underserved** 1999 May;10(2):157–68
Faculty practice as partnership with a community coalition. Gale BJ. **J Prof Nurs** 1998 Sep–Oct;14(5):267–71
Developing a culturally competent work force: an opportunity for collaboration. Jones ME, et al. **J Prof Nurs** 1998 Sep–Oct;14(5):280–7

ORGANIZATION & ADMINISTRATION

The challenges of employing performance monitoring in public health community-based efforts: a case study. Payne CA. **J Community Health** 1999 Apr;24(2):159–70
From the board room to the community room: a health improvement collaboration that's working. Community Health Improvement Partners. **Jt Comm J Qual Improv** 1998 Oct;24(10):549–65
IMPROVE: bridge over troubled waters. Magnan S, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):566–78
Collaborating outside the box: three years later. Reinertsen JL, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):585–90

HEALTH CARE COSTS

see related
HEALTH EXPENDITURES

Medical cost containment: we can get there from here. Reynolds NC Jr, et al. **Acad Med** 1998 Oct;73(10):1036–8
Reducing healthcare costs: how suppliers can contribute. van Soest JK. **Acad Radiol** 1998 Sep;5 Suppl 2:S367–70
Outcomes and costs of a community support worker service for the severely mentally ill. Clarkson P, et al. **Acta Psychiatr Scand** 1999 Mar;99(3):196–206
Health care costs of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Percudani M, et al. **Acta Psychiatr Scand** 1999 Apr;99(4):274–80
Costs of services for schizophrenic patients in Norway. Rund BR, et al. **Acta Psychiatr Scand** 1999 Feb;99(2):120–5
Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA, et al. **AIDS** 1999 May 28;13(8):963–9
Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. Ratcliffe J, et al. **AIDS** 1998 Jul 30;12(11):1381–8
Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. Sculpher MJ, et al. **AIDS** 1998 Jul 30;12(11):1371–80
Alzheimer disease: where are we now? Where are we going? Khachaturian ZS, et al. **Alzheimer Dis Assoc Disord** 1998; 12 Suppl 3:S24–8
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective. Boccuzzi SJ. **Am Heart J** 1999 May;137(5):S120–2
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis. Mark DB, et al. **Am Heart J** 1999 May; 137(5):S38–40
The cost of using flow cytometry to evaluate bone marrow [letter; comment] Spira S. **Am J Clin Pathol** 1999 May; 111(5):710. Comment on: Am J Clin Pathol 1998 May;109(5):625–30.
Prediction of resource utilization and case cost for acute nonvariceal upper gastrointestinal hemorrhage at a Canadian community hospital. Marshall JK, et al. **Am J Gastroenterol** 1999 Jul;94(7):1841–6
The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. O'Connor JF, et al. **Am J Gastroenterol** 1999 Jun;94(6):1472–80
The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. McCombs JS, et al. **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2485–99
Health care costs associated with chronic hepatitis B. Metcalf M, et al. **Am J Health Syst Pharm** 1999 Feb 1;56(3):232–6
Costs of maternal conditions attributable to smoking during pregnancy. Adams EK, et al. **Am J Prev Med** 1998 Oct; 15(3):212–9
Health risk influence on medical care costs and utilization among 2,898 municipal employees. Weaver MT, et al. **Am J Prev Med** 1998 Oct;15(3):250–3
Depressive symptoms and health costs in older medical patients. Druss BG, et al. **Am J Psychiatry** 1999 Mar; 156(3):477–9
Comorbid dysthymia and substance disorder: treatment history and cost. Westermeyer J, et al. **Am J Psychiatry** 1998 Nov;155(11):1556–60
Earnings changes for depressed individuals treated by mental health specialists. Zhang M, et al. **Am J Psychiatry** 1999 Jan;156(1):108–14
Lifetime health and economic benefits of weight loss among obese persons. Oster G, et al. **Am J Public Health** 1999 Oct;89(10):1536–42
Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Asiedu K, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):1015–22
Cost effectiveness ratio: an often misunderstood term [letter; comment] Gan TJ, et al. **Anesth Analg** 1999 May; 88(5):1191–2. Comment on: Anesth Analg 1996 Aug;83(2):304–13. Comment on: Anesth Analg 1998 Feb;86(2):274–82.
An emergency department-based pneumococcal vaccination program could save money and lives. Stack SJ, et al. **Ann Emerg Med** 1999 Mar;33(3):299–303
Estimating the cost of medical care [editorial; comment] Wears RL. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):535–7. Comment on: Ann Emerg Med 1999 Oct;34(4 Pt 1):438–47.
The financial costs of gun violence [news] Gunderson L. **Ann Intern Med** 1999 Sep 21;131(6):483–4
Services, costs and appropriate outcomes in end of life care [editorial; comment] Higginson IJ, et al. **Ann Oncol** 1999 Feb;10(2):135–6. Comment on: Ann Oncol 1999 Feb;10(2):161–5.
Critical reviews of economic analyses in order to make health care decisions for cancer. Neymark N. **Ann Oncol** 1998 Nov;9(11):1167–72
Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer [see comments] Witteveen PO, et al. **Ann Oncol** 1999 Feb;10(2):161–5. Comment in: Ann Oncol 1999 Feb;10(2):135–6.
A proposal for structured abstracts of health economic studies. Mittmann N, et al. **Ann Pharmacother** 1998 Nov; 32(11):1244–6
Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Amazigo U, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S23–31 (27 ref.)
Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Benton B. **Ann Trop Med Parasitol** 1998 Apr; 92 Suppl 1:S33–9 (6 ref.)
Cameroon and Chad: cost recovery. Godin C. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S163–4
Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Mann WC, et al. **Arch Fam Med** 1999 May–Jun;8(3):210–7
Costs of health care use by women HMO members with a history of childhood abuse and neglect. Walker EA, et al. **Arch Gen Psychiatry** 1999 Jul;56(7):609–13

Atrial fibrillation: mortality, stroke, and medical costs [letter; comment] Gross CP, et al. **Arch Intern Med** 1998 Nov 9;158(20):2265–6. Comment on: Arch Intern Med 1998 Feb 9;158(3):229–34.

Burden of migraine in the United States: disability and economic costs. Hu XH, et al. **Arch Intern Med** 1999 Apr 26;159(8):813–8

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Yelin E, et al. **Arthritis Rheum** 1999 Jun;42(6):1209–18

Cost-effectiveness of digital cataract assessment. Dimock J, et al. **Aust N Z J Ophthalmol** 1999 Jun–Aug;27(3–4):208–10

Cataract, cost: curious questions [letter; comment] Kleinman DM. **Aust N Z J Ophthalmol** 1999 Apr;27(2):163. Comment on: Aust N Z J Ophthalmol 1999 Feb;27(1):3–7.

France abandons fines to control health costs [news] Dorozynski A. **BMJ** 1999 Jan 9;318(7176):76

PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS [editorial] Smith R. **BMJ** 1999 Jul 3; 319(7201):2–3

Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Freeman M, et al. **Bone Marrow Transplant** 1999 Sep;24(6):679–84

Health economics: a beginner's guide. Thornton JG. **Br J Hosp Med** 1998 Dec 10;58(11):547–50 (16 ref.)

Strong bones in later life: luxury or necessity? The view from Brazil:desirable but not yet feasible [comment] de Castro JA. **Bull World Health Organ** 1999;77(5):426–7. Comment on: Bull World Health Organ 1999 ;77(5):416–22.

Federal health budget 1999: part 2--health research, health information and prevention. Scully HE. **Can J Cardiol** 1999 May;15(5):525–8 **(Eng, Fre)**

Ocular Munchausen's syndrome, a costly disorder. Dhanda D, et al. **Can J Ophthalmol** 1999 Jun;34(4):226–8

What is the cost of admitting patients with transient ischaemic attacks to hospital? Gubitz G, et al. **Cerebrovasc Dis** 1999 Jul–Aug;9(4):210–4

Estimation of costs due to hospitalization for first-ever stroke patients in northern Taiwan. Chiu L, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 May;62(5):261–7

Admission to hospitals with on-site cardiac catheterization facilities :impact on long-term costs and outcomes. Krumholz HM, et al. **Circulation** 1998 Nov 10; 98(19):2010–6

The cost of treating community-acquired pneumonia. Niederman MS, et al. **Clin Ther** 1998 Jul–Aug;20(4):820–37

Treatment cost of acute exacerbations of chronic bronchitis. Niederman MS, et al. **Clin Ther** 1999 Mar;21(3):576–91

Smoking out the economics of tobacco use [letter] Harris WR. **CMAJ** 1999 Aug 24;161(4):367–8

Cost and productivity analysis of orthodontic care in Finland. Pietilä T, et al. **Community Dent Oral Epidemiol** 1998 Aug; 26(4):283–8

Longer-term clinical and economic benefits of offering acupuncture to patients with chronic low back pain assessed as suitable for primary care management. Thomas KJ, et al. **Complement Ther Med** 1999 Jun;7(2):91–100

Evaluation of costs in rheumatic diseases: a literature review. Ruof J, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):104–9 (29 ref.)

Last call for freedom (yours) [editorial] McCarthy JT. **Cutis** 1998 Nov;62(5):213

Fine needle aspiration (FNA) in the management of palpable masses in Ibadan: impact on the cost of care. Thomas JO, et al. **Cytopathology** 1999 Jun;10(3):206–10

The cost of dementia in Denmark: the Odense Study. Kronborg Andersen C, et al. **Dement Geriatr Cogn Disord** 1999 Jul–Aug;10(4):295–304

Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Ramsey SD, et al. **Diabetes Care** 1999 Mar; 22(3):382–7

Endoscopic ultrasound--costly or cost effective? [letter] Dill JE. **Dig Dis Sci** 1999 Sep;44(9):1792

Medical costs and lost productivity from health conditions at volatile organic compound-contaminated superfund sites. Lybarger JA, et al. **Environ Res** 1998 Oct;79(1):9–19

Payer costs of patients diagnosed with epilepsy. Griffiths RI, et al. **Epilepsia** 1999 Mar;40(3):351–8

Interventional cardiology and type of health care delivery system [letter; comment] Massarelli G, et al. **Eur Heart J** 1998 Sep;19(9):1411. Comment on: Eur Heart J 1998 Jan;19(1):40–54.

Costs of health care: a lopsided debate [editorial] Ell PJ, et al. **Eur J Nucl Med** 1999 May;26(5):435–6

The LIRCE principle: a risk-value score for the spine. Krämer J. **Eur Spine J** 1998;7(5):353–7

Societal and personal costs of obesity. Seidell JC. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 2:7–9 (15 ref.)

Therapy cost 2000: an electronic tool for evaluating the cost-effectiveness of therapeutic regimens [letter] Day D, et al. **Front Biosci** 1998 Dec 1;3:L3–4

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Silverstein MD, et al. **Gastroenterology** 1999 Jul;117(1):49–57

Effects of maternity-stay legislation on 'drive-through deliveries'. Udom NU, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):208–15

Mixed signals: public policy and the future of health care R&D. Weisbrod BA, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):112–25

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Lord J, et al. **Health Econ** 1999 Jun;8(4):323–33

Interpreting reported health-care costs. Neilson AR, et al. **Hosp Med** 1998 Oct;59(10):803–6

Rising cost of vaccinations--the scenario and possible solutions. John J. **Indian Pediatr** 1998 Oct;35(10):985–8

The role of cost analysis in deciding whether to provide laparoscopic cholecystectomy in remote communities. Voitk AJ, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:702–5

The measurement of indirect costs in the health economics evaluation literature. A review. Jacobs P, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):799–808 (43 ref.)

Economic evaluations in medicine: still more questions than answers? Grossi E. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):347–50

Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. Keiser P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):28–33

An estimate of the annual direct cost of treating cutaneous melanoma [letter] Kanzler MH. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):281–3

An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Ramsey SD, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):105–14

New study shows average per patient cost of HIV care in managed care setting stabilized in 1997 [news] **J Assoc Nurses AIDS Care** 1999 Jan–Feb;10(1):79

Costs of family planning programmes in fourteen developing countries by method of service delivery. Barberis M, et al. **J Biosoc Sci** 1997 Apr;29(2):219–33

Implementation and evaluation of stroke clinical pathways and the impact on cost of stroke care. Summers D, et al. **J Cardiovasc Nurs** 1998 Oct;13(1):69–87

Economic issues in lung cancer: a review. Goodwin PJ, et al. **J Clin Oncol** 1998 Dec;16(12):3900–12 (66 ref.)

Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. Green DM, et al. **J Clin Oncol** 1998 Dec;16(12):3744–51

Clozapine for refractory schizophrenia: the Illinois experience. Buckman RW, et al. **J Clin Psychiatry** 1999; 60 Suppl 1:18–22; discussion 28–30

Annual health outcomes and treatment costs for schizophrenia populations. Mauskopf JA, et al. **J Clin Psychiatry** 1999;60 Suppl 19:14–9; discussion 20–2

The costs of depression: direct and indirect; treatment versus nontreatment. Panzarino PJ Jr. **J Clin Psychiatry** 1998;59 Suppl 20:11–4 (28 ref.)

The economic impact of schizophrenia. Rice DP. **J Clin Psychiatry** 1999;60 Suppl 1:4–6; discussion 28–30 (6 ref.)

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis SL, et al. **J Clin Psychiatry** 1999;60 Suppl 19:38–45; discussion 46

Health care expenditures after introduction of a gatekeeper and a global budget in a Swiss health insurance plan. Etter JF, et al. **J Epidemiol Community Health** 1998 Jun; 52(6):370–6

A critical evaluation of clinical practice guidelines in neonatal medicine: does their use improve quality and lower costs? Merritt TA, et al. **J Eval Clin Pract** 1999 May;5(2):169–77

Lifetime costs for preventive medical services: a model. Filak AT Jr, et al. **J Fam Pract** 1999 Sep;48(9):706–10

Intimate partner violence against women: do victims cost health plans more? Wisner CL, et al. **J Fam Pract** 1999 Jun;48(6):439–43

Prospective cost-utility analysis of lung transplantation in The Netherlands: a comment on the pilot study by Gartner et al [letter; comment] van Enckevort PJ, et al. **J Heart Lung Transplant** 1999 May;18(5):496–7. Comment on: J Heart Lung Transplant 1997 Nov;16(11):1129–34.

The health care costs of heart failure in Sweden. Rydén-Bergsten T, et al. **J Intern Med** 1999 Sep; 246(3):275–84

Utilisation and costs of profession care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium) [letter; comment] Forbes RB, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):256–7. Comment on: J Neurol Neurosurg Psychiatry 1998 Apr;64(4):444–50.

The economic costs associated with body mass index in a workplace. Burton WN, et al. **J Occup Environ Med** 1998 Sep;40(9):786–92

Ethical and legal impediments to cost-efficient neonatal intensive care. Peabody JL. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S24–6 (29 ref.)

Detection and treatment of psychiatric illness in a general medical ward. a modified cost-benefit analysis [see comments] Gater RA, et al. **J Psychosom Res** 1998 Nov; 45(5):437–48. Comment in: J Psychosom Res 1998 Nov;45(5):433–6.

Shared care in HIV and AIDS: shifting care or shifting costs? Cartledge JD, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):376–9

Economic impact of automated primary screening for cervical cancer. Smith BL, et al. **J Reprod Med** 1999 Jun; 44(6):518–28

Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. Clarke AE, et al. **J Rheumatol** 1999 May;26(5):1068–75

Costs attributable to osteoarthritis. MacLean CH, et al. **J Rheumatol** 1998 Nov;25(11):2213–8

Effects of implementation of 18 clinical pathways on costs and quality of care among patients undergoing urological surgery. Chang PL, et al. **J Urol** 1999 Jun;161(6):1858–62

Academic managed care organizations and adverse selection under Medicaid managed care in Tennessee. Bailey JE, et al. **JAMA** 1999 Sep 15;282(11):1067–72

Health care fraud and abuse [see comments] Kalb PE. **JAMA** 1999 Sep 22–29;282(12):1163–8. Comment in: JAMA 1999 Sep 22–29;282(12):1179–81.

Fraud and abuse law [editorial; comment] Sage WM. **JAMA** 1999 Sep 22–29;282(12):1179–81. Comment on: JAMA 1999 Sep 22–29;282(12):1163–8.

Debt relief and health charges in Mozambique [letter; comment] Logie D, et al. **Lancet** 1999 Jun 12; 353(9169):2077–8. Comment on: Lancet 1999 May 1;353(9163):1519–21.

Cost-effectiveness of the diagnostic evaluation of vertigo. Stewart MG, et al. **Laryngoscope** 1999 Apr;109(4):600–5

Review of methods to determine VA health care costs. Barnett PG. **Med Care** 1999 Apr;37(4 Suppl Va):AS9–17 (40 ref.)

Determining costs in VA: research design problems and solutions illustrated with case studies. Menke TJ, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS18–26

How good are US studies of HIV costs of care? Rabeneck L, et al. **Med Care** 1999 Aug;37(8):748–59 (35 ref.)

Cost analysis in the Department of Veterans Affairs: consensus and future directions. Swindle R, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS3–8 (13 ref.)

Costs of smoking: a focus on maternal, childhood, and other short-run costs. Adams EK, et al. **Med Care Res Rev** 1999 Mar;56(1):3–29

Judgmental psychology. Contingent valuation. Schwartz A. **Med Decis Making** 1998 Oct–Dec;18(4):453–4

Health care insurance premiums project. **Mich Med** 1999 Feb; 98(2):19–21

Potential cost savings from legalizing physician-assisted suicide [letter; comment] Joe L. **N Engl J Med** 1998 Dec 10;339(24):1789–90. Comment on: N Engl J Med 1998 Jul 16;339(3):167–72.

Cost as a barrier to medical care [letter; comment] Lewkowski M. **N Engl J Med** 1999 Apr 22;340(16):1293 . Comment on: N Engl J Med 1998 Nov 26;339(22):1644–5.

Cost as a barrier to medical care in relation to unemployment rates [letter] [see comments] Nelson DE, et al. **N Engl J Med** 1998 Nov 26;339(22):1644–5. Comment in: N Engl J Med 1999 Apr 22;340(16):1293.

Doctor discontent [letter; comment] Ruane TJ. **N Engl J Med** 1999 Feb 25;340(8):651; discussion 652–3. Comment on: N Engl J Med 1998 Nov 19;339(21):1516–21.

Medical fraud. An ounce of compliance. Costante PA. **N J Med** 1999 Aug;96(8):47–8

Disease, drugs, decisions, and dollars [editorial; comment] Mushlin AI. **Neurology** 1999 Apr 12;52(6):1115–6. Comment on: Neurology 1999 Apr 12;52(6):1138–45.

Health care for all [editorial; comment] Blaivas JG. **Neurourol Urodyn** 1998;17(6):577–8. Comment on: Neurourol Urodyn 1998 ;17(6):639.

Is downsizing and disbanding specialty care teams a counterproductive strategy for cost reduction in health care? Ryder M, et al. **Nutrition** 1998 Sep;14(9):725–8 (40 ref.)

Cost-effectiveness analysis: an introductory guide for clinicians. Macones GA, et al. **Obstet Gynecol Surv** 1999 Oct;54(10):663–72

The cost of treating osteoporotic fractures in the United Kingdom female population. Dolan P, et al. **Osteoporos Int** 1998;8(6):611–7

Replacing abdominally implanted defibrillators: effect of procedure setting on cost. Vorperian VR, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):698–705

Home-based management can achieve intensification cost-effectively in type I diabetes. Dougherty G, et al. **Pediatrics** 1999 Jan;103(1):122–8

The coming clash: patient advocates vs. the public interest [letter] Petty W. **Pharos** 1999 Summer;62(3):49–50

A comparison of neural network models for the prediction of the cost of care for acute coronary syndrome patients. Ismael MB, et al. **Proc AMIA Symp** 1998;:533–7

Advanced prostate cancer: course, care, and cost implications. Beemsterboer PM, et al. **Prostate** 1999 Jul 1;40(2):97–104

The cost of not treating serious mental illness [letter] Torrey EF. **Psychiatr Serv** 1999 Aug;50(8):1087–8

Does economic evaluation have anything to offer the rheumatologist? [editorial] Hurst NP, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):2–5 (18 ref.)

Viagra--it's no free ride [news] van der Linde I. **S Afr Med J** 1998 Nov;88(11):1383

Health care costs [letter; comment] Andreopoulos S. **Science** 1999 Feb 5;283(5403):792–4. Comment on: Science 1999 Jan 1;283(5398):36–7.

Effects of medical research on health care and economy [see comments] Pardes H, et al. **Science** 1999 Jan 1;

283(5398):36–7. Comment in: Science 1999 Feb 5;283(5403):792–4.
Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). McNamee P, et al. **Soc Sci Med** 1999 Feb;48(3):331–41
The effects of prework functional screening on lowering an employer's injury rate, medical costs, and lost work days. Nassau DW. **Spine** 1999 Feb 1;24(3):269–74
The costs of body mass index levels in an employed population. Burton WN, et al. **Stat Bull Metrop Insur Co** 1999 Jul–Sep;80(3):8–14
Decreasing costs of stroke hospitalization in Toronto [letter] Tran C, et al. **Stroke** 1999 Jan;30(1):185–6
Cost implications of different surgical management strategies for primary hyperparathyroidism. Sosa JA, et al. **Surgery** 1998 Dec;124(6):1028–35; discussion 1035–6
Health care in black and white—racial differences in health resource use and outcomes. Mirvis DM. **Tenn Med** 1998 Dec;91(12):455–7
The cost to society of smoking cessation. Cohen D, et al. **Thorax** 1998 Aug;53 Suppl 2:S38–42 (47 ref.)
The Lloyd Roberts Lecture. The pluralist approach to the funding of health care. Rees-Mogg L. **Trans Med Soc Lond** 1996–97;113:11–7
Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Olin JW, et al. **Vasc Med** 1999;4(1):1–7
Cottage industry [editorial] Ward SD. **W V Med J** 1999 May–Jun;95(3):111
[Demographic and epidemiologic indicators of health care costs. Elderly and mentally ill are the most expensive ones within the health care services] Krasnik A. **Ugeskr Laeger** 1999 Jan 11;161(2):169–70 **(Dan)**
[Analysis of economic data and elaboration of professional guidelines (editorial)] Charvet-Protat S, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):19–23 (Eng. Abstr.) **(Fre)**
[Medical-economic aspects of treatment of gastroesophageal reflux] De Winter B, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S292–6 (21 ref.) **(Fre)**
[Cost of early management of chronic inflammatory intestinal disease] Rolland N, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):483–8 (Eng. Abstr.) **(Fre)**
[Evaluation of the cost of treatment for terminal chronic renal insufficiency. Thoughts on the value of this type of study and the role of the nephrologist] Pollini J, et al. **Nephrologie** 1998;19(5):245–53 (Eng. Abstr.) **(Fre)**
[Health economics of perinatal care and birth in Austria and Holland –a comparison] Brezinka C. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):196–210 (48 ref.) (Eng. Abstr.) **(Ger)**
[Diagnostic costs for ambulatory care patients] Keller O, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24; 87(51–52):1798–804 (Eng. Abstr.) **(Ger)**
[Let us help retired persons by reducing medical costs (letter)] Szabó G. **Orv Hetil** 1999 May 16;140(20):1143–4 **(Hun)**
[Crisis of medicine and information] Dri P. **Ann Ist Super Sanita** 1998;34(2):281–4 (Eng. Abstr.) **(Ita)**
[Anesthesia and health economics (editorial)] Piacevoli Q. **Minerva Anestesiol** 1998 Dec;64(12):541–4 **(Ita)**
[The economic evaluation of group examination for gastrointestinal disease in an electronics corporation—the cost-benefit analysis of follow-up study for peptic ulcer] Sumi Y. **Sangyo Eiseigaku Zasshi** 1999 Jan;41(1):1–10 (Eng. Abstr.) **(Jpn)**
[The Composite International Diagnostic Interview: possibilities of utilization for economic studies in psychiatry] Kiejna A, et al. **Psychiatr Pol** 1998 Jul–Aug; 32(4):463–79 (Eng. Abstr.) **(Pol)**
[The study of the costs of schizophrenia] Prot-Herczyńska K. **Psychiatr Pol** 1998 May–Jun;32(3):307–18 (Eng. Abstr.) **(Pol)**
[Economical benefits of one-day surgery treatment in children: 10 year of experience] Dzielicki J, et al. **Wiad Lek** 1998;51(11–12):474–9 (Eng. Abstr.) **(Pol)**
[Can medical care be less expensive? (letter)] Sušković T. **Lijec Vjesn** 1999 Mar;121(3):109–12 **(Scr)**
[The health costs of alcoholism] Portella E, et al. **Aten Primaria** 1998 Sep 30;22(5):279–84 (Eng. Abstr.) **(Spa)**
[Economic costs of diabetes mellitus: critical review and cost-benefit evaluation of proposed strategies for its reduction] Rubio JA, et al. **Aten Primaria** 1998 Sep 15; 22(4):239–55 **(Spa)**
[Human infection by Trypanosoma cruzi in Chile: epidemiology estimates and costs of care and treatment of the chagasic patient] Schenone H. **Bol Chil Parasitol** 1998 Jan–Jun;53(1–2):23–6 (Eng. Abstr.) **(Spa)**
[Health service coverage in Latin America and the Caribbean] Paganini JM. **Rev Panam Salud Publica** 1998 Nov;4(5):305–10 (Eng. Abstr.) **(Spa)**
[Pharmaceutical economics: scientific evaluation or commercial strategy?] Velásquez G. **Rev Panam Salud Publica** 1999 Jan;5(1):54–7 **(Spa)**
[Costs of interventions for patients with chronic renal disease] Arredondo A, et al. **Rev Saude Publica** 1998 Jun; 32(3):255–61 (Eng. Abstr.) **(Spa)**

HISTORY

[Charitable societies at medical institutions in Russia in the late XIX—early XX centuries] Gorelova LE, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):40–2 **(Rus)**

LEGISLATION & JURISPRUDENCE

A rock in a hard place. Gray C. **CMAJ** 1998 Oct 20; 159(8):991–3
Escalating health care costs: costs of litigation. Wehrmacher WH. **Compr Ther** 1998 Sep;24(9):455–9
Truth, bias, and the medical "expert" [see comments] Brahams D. **Lancet** 1999 Apr 24;353(9162):1380. Comment in: Lancet 1999 Jun 12;353(9169):2076.

STANDARDS

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care. Stewart A, et al. **Am Heart J** 1999 May;137(5):S53–61
Panel on cost-effectiveness in health and medicine recommendations: identifying costs. Manning WG Jr. **J Clin Psychiatry** 1999;60 Suppl 3:54–6; discussion 57–8
Interpretation of cost-effectiveness analyses [editorial; comment] Owens K. **J Gen Intern Med** 1998 Oct; 13(10):716–7 (9 ref.). Comment on: J Gen Intern Med 1998 Oct;13(10):664–9.
Controversies in economic evaluation in the rheumatic diseases [editorial; comment] Gabriel SE. **J Rheumatol** 1999 Sep;26(9):1859–60. Comment on: J Rheumatol 1999 Sep;26(9):1861–3.

STATISTICS & NUMERICAL DATA

Quality and costs of family planning as elicited by an adolescent mystery client trial in Nigeria. Olowu F. **Afr J Reprod Health** 1998 Apr;2(1):49–60
Clinical economics review: medical management of inflammatory bowel disease. Ward FM, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):15–25 (43 ref.)
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. DeLong ER, et al. **Am Heart J** 1999 May;137(5):S47–50
Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. Hlatky MA, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):376–83
The economic impact of geriatric hip fractures. Youm T, et al. **Am J Orthop** 1999 Jul;28(7):423–8 (47 ref.)
The direct health care costs of obesity in the United States. Allison DB, et al. **Am J Public Health** 1999 Aug; 89(8):1194–9
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Krahn M, et al. **Am J Public Health** 1998 Nov;88(11):1638–44
Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935–7
Urban trauma care is threatened by inadequate reimbursement. Fath JJ, et al. **Am J Surg** 1999 May; 177(5):371–4
The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Goldie SJ, et al. **Ann Intern Med** 1999 Jan 19;130(2):97–107
Methods for analyzing health care utilization and costs. Diehr P, et al. **Annu Rev Public Health** 1999;20:125–44 (35 ref.)
The economic cost of asthma in Singapore. Chew FT, et al. **Aust N Z J Med** 1999 Apr;29(2):228–33
Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Will BP, et al. **Br J Cancer** 1999 Mar;79(9–10):1428–36
Cost of malaria control in Sri Lanka. Konradsen F, et al. **Bull World Health Organ** 1999;77(4):301–9
Drug-related illnesses cost a fortune [letter] Hrushovetz SB. **Can Fam Physician** 1999 Mar;45:575, 577
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. Tung CY, et al. **Circulation** 1999 Jan 26;99(3):370–6
The cost of obesity in Canada [see comments] Birmingham CL, et al. **CMAJ** 1999 Feb 23;160(4):483–8. Comment in: CMAJ 1999 Feb 23;160(4):503–6. Comment in: CMAJ 1999 Jun 29;160(13):1821.
Call for action: preventing and managing the expansive and expensive obesity epidemic [editorial; comment] [see comments] Lau DC. **CMAJ** 1999 Feb 23;160(4):503–6 (43 ref.). Comment on: CMAJ 1999 Feb 23;160(4):483–8. Comment on: CMAJ 1999 Feb 23;160(4):513–25. Comment in: CMAJ 1999 Jun 29;160(13):1821.
Screening Mammography Program of British Columbia: pattern of use and health care system costs [see comments] Olivotto IA, et al. **CMAJ** 1999 Feb 9;160(3):337–41. Comment in: CMAJ 1999 Jul 13;161(1):17; discussion 18. Comment in: CMAJ 1999 Jul 13;161(1):17–8.
High cost of Chlamydia can be cut, researcher finds [news] Silversides A. **CMAJ** 1999 Apr 20;160(8):1119
The health and cost effects of substituting home care for inpatient acute care: a review of the evidence [see comments] Soderstrom L, et al. **CMAJ** 1999 Apr 20; 160(8):1151–5 (36 ref.). Comment in: CMAJ 1999 Aug 24;161(4):365–6.
Cost implications of cardiac rehabilitation in older patients. Taylor R, et al. **Coron Artery Dis** 1999;10(1):53–6
Anxiety amongst women with mild dyskaryosis: costs of an educational intervention. Baxter K, et al. **Fam Pract** 1999 Aug;16(4):353–9
Potential cost savings in residential care for Alzheimer's disease patients. Leon J, et al. **Gerontologist** 1999 Aug; 39(4):440–9
Health care for the elderly: how much? Who will pay for it? Fuchs VR. **Health Aff (Millwood)** 1999 Jan–Feb; 18(1):11–21
Alzheimer's disease care: costs and potential savings. Leon J, et al. **Health Aff (Millwood)** 1998 Nov–Dec;17(6):206–16
Effect of declining mental health service use on employees of a large corporation. Rosenheck RA, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):193–203
Bayesian estimation of cost-effectiveness ratios from clinical trials. Heitjan DF, et al. **Health Econ** 1999 May; 8(3):191–201
Estimation of a multiproduct cost function for physically frail older people. McNamee P, et al. **Health Econ** 1998 Dec; 7(8):701–10
Will the real elasticity of substitution 'in Norwegian dentistry' please stand up? Okunade AA. **Health Econ** 1999 May; 8(3):221–32
At what price significance? The effect of price estimates on statistical inference in economic evaluation. Rittenhouse BE, et al. **Health Econ** 1999 May;8(3):213–9
Resource costing for multinational neurologic clinical trials: methods and results. Schulman K, et al. **Health Econ** 1998 Nov;7(7):629–38
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Willan AR, et al. **Health Econ** 1999 May;8(3):203–11
Cost functions for dialysis facilities and the quality of dialysis [editorial; comment] Escarce JJ, et al. **Health Serv Res** 1999 Feb;33(6):1563–6. Comment on: Health Serv Res 1999 Feb;33(6):1567–92.
Economies of scope and home healthcare [comment] Kass DI. **Health Serv Res** 1998 Oct;33(4 Pt 1):947–51. Comment on: Health Serv Res 1997 Aug;32(3):313–24.
Analytic approaches for the evaluation of costs. Glick HA, et al. **Hepatology** 1999 Jun;29(6 Suppl):18S–22S
Economic considerations for the hepatologist. Provenzale D. **Hepatology** 1999 Jun;29(6 Suppl):13S–17S
Parachuting for charity: is it worth the money? A 5-year audit of parachute injuries in Tayside and the cost to the NHS. Lee CT, et al. **Injury** 1999 May;30(4):283–7
Cost implications of regionalizing open heart surgery units. Menke TJ, et al. **Inquiry** 1999 Spring;36(1):57–67
Options for aiding low-income Medicare beneficiaries. Moon M, et al. **Inquiry** 1998 Fall;35(3):346–56
Cost of health care for a community of older adults in an urban academic healthcare system [see comments] Callahan CM, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1371–7. Comment in: J Am Geriatr Soc 1998 Nov;46(11):1478–9.
Improvement in self-care may lower the increasing rate of medical expenses for community-dwelling older people in Japan [letter] Matsubayashi K, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1484–5
Medical cost for disability: a longitudinal observation of national health insurance beneficiaries in Japan. Tsuji I, et al. **J Am Geriatr Soc** 1999 Apr;47(4):470–6
New study showed average costs of care for HIV in managed care were lower for patients with undetectable viral loads [news] **J Assoc Nurses AIDS Care** 1999 Mar–Apr; 10(2):87–8
The economic burden of anxiety disorders in the 1990s. Greenberg PE, et al. **J Clin Psychiatry** 1999 Jul; 60(7):427–35
A prospective cohort study on National Health Insurance beneficiaries in Ohsaki, Miyagi Prefecture, Japan: study design, profiles of the subjects and medical cost during the first year. Tsuji I, et al. **J Epidemiol** 1998 Dec; 8(5):258–63
Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. Revicki DA, et al. **J Fam Pract** 1998 Dec;47(6):446–52
The effectiveness of cost-effectiveness analysis in containing costs [see comments] Azimi NA, et al. **J Gen Intern Med** 1998 Oct;13(10):664–9 (20 ref.). Comment in: J Gen Intern Med 1998 Oct;13(10):716–7.
Costs of coronary heart disease and stroke: the case of Sweden. Zethraeus N, et al. **J Intern Med** 1999 Aug; 246(2):151–9
Dying to pay: the cost of end-of-life care. Chochinov HM, et al. **J Palliat Care** 1998 Winter;14(4):5–15 (69 ref.)
The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. White KP, et al. **J Rheumatol** 1999 Apr;26(4):885–9
Actual and estimated replication costs for alcohol treatment modalities: case study from Project MATCH. Cisler R, et al. **J Stud Alcohol** 1998 Sep;59(5):503–12
The medical costs of gunshot injuries in the United States. Cook PJ, et al. **JAMA** 1999 Aug 4;282(5):447–54
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs [see comments] Wong JB, et al. **JAMA** 1998 Dec 23–30;280(24):2088–93. Comment in: JAMA 1999 Jun 9;281(22):2083; discussion 2084. Comment in: JAMA 1999 Jun 9;281(22):2083–4.
Long-term results of RITA-1 trial: clinical and cost

comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina [see comments] Henderson RA, et al. **Lancet** 1998 Oct 31;352(9138):1419–25. Comment in: ACP J Club 1998 Mar-Apr;130(2):30. Comment in: Lancet 1999 Jan 23;353(9149):321.

Misleading government information on NHS costs [letter; comment] Kernick DP. **Lancet** 1999 Jan 30;353(9150):413 . Comment on: Lancet 1998 Nov 14;352(9140):1607.

Cost as a study outcome: sensitivity of study conclusions to the method of estimating cost. Chapko MK, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS37–44

Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Helms LJ, et al. **Med Care** 1999 Jul;37(7):652–61

Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. Hynes D, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS27–36

Use of a cost accounting system to evaluate costs of a VA special program. Menke TJ, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS45–53

The high costs of death: should health plans get higher payments when members die? van Vliet RC, et al. **Med Care** 1998 Oct;36(10):1451–60

Costs and outcomes of a military bone marrow transplant program. Yoder LH. **Mil Med** 1998 Oct;163(10):661–6

Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries [see comments] Taylor DH Jr, et al. **N Engl J Med** 1999 Jan 28;340(4):293–9 . Comment in: N Engl J Med 1999 Jan 28;340(4):309–10.

Low-cost high-volume extracapsular cataract extraction with posterior chamber intraocular lens implantation in Nepal. Ruit S, et al. **Ophthalmology** 1999 Oct; 106(10):1887–92

Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial. Mugford M, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:75–97

Health care costs of formula-feeding in the first year of life. Ball TM, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):870–6

The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Lieu TA, et al. **Pediatrics** 1999 Jun;103(6):e72

Clinical and economic impact of enterovirus illness in private pediatric practice. Pichichero ME, et al. **Pediatrics** 1998 Nov;102(5):1126–34

Health status and health care costs for publicly funded patients with schizophrenia started on clozapine. Blieden N, et al. **Psychiatr Serv** 1998 Dec;49(12):1590–3

Patterns of health care costs associated with depression and substance abuse in a national sample. Druss BG, et al. **Psychiatr Serv** 1999 Feb;50(2):214–8

Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Schiller MJ, et al. **Psychiatr Serv** 1999 Feb;50(2):228–32

Health care and indemnity costs across the natural history of disability in occupational low back pain. Williams DA, et al. **Spine** 1998 Nov 1;23(21):2329–36

Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Ramaiah KD, et al. **Trop Med Int Health** 1999 Jan; 4(1):19–25

[Medical-economic evaluation of bronchial cancer] Vergnenegre A. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S38–9 **(Fre)**

[Misunderstanding of medical resource use by women] Gillet P, et al. **Rev Med Liege** 1999 Apr;54(4):214–23 (Eng. Abstr.) **(Fre)**

[Performance assessment by average case fee and special pay--is it worth it?] Langhans M, et al. **Gesundheitswesen** 1999 May;61(5):263–4 **(Ger)**

[Economic evaluation within the scope of clinical studies] Walshe R, et al. **Internist (Berl)** 1998 Sep;39(9):943–54 (72 ref.) **(Ger)**

[Influence of the unit of analysis on the studies of the factors of primary care resource utilization] Juncosa S, et al. **Gac Sanit** 1999 Jan-Feb;13(1):53–61 (Eng. Abstr.) **(Spa)**

TRENDS

Health care reform: has it really begun? Marks PA. **Acad Med** 1999 Mar;74(3):210–2

Genetic testing for Alzheimer disease: a view from Washington. Vladeck BC. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 3:S29–32

Trends in perceived cost as a barrier to medical care, 1991–1996. Nelson DE, et al. **Am J Public Health** 1999 Sep;89(9):1410–3

Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935–7

From the University of Washington to Washington University: a personal journey. Barner HB. **Ann Thorac Surg** 1999 Feb;67(2):301–4

Clinical trials and the cost of medical care [editorial] Conti CR. **Clin Cardiol** 1999 Sep;22(9):549–50

Tracking health care costs: what's new in 1998? [see comments] Ginsburg PB, et al. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):141–6 (12 ref.). Comment in: Health Aff (Millwood) 1999 Jan-Feb;18(1):275–7.

Managed care has become a dominant mode of paying for and delivering medical services [editorial] Brown M. **Health Care Manage Rev** 1998 Fall;23(4):5

Cost of employee assistance programs: comparison of national estimates from 1993 and 1995. French MT, et al. **J Behav Health Serv Res** 1999 Feb;26(1):95–103

Euro will challenge finances of healthcare systems in Europe [news] Birchard K. **Lancet** 1999 Jan 30;353(9150):389

Truth, bias, and the medical "expert" [see comments] Brahams D. **Lancet** 1999 Apr 24;353(9162):1380. Comment in: Lancet 1999 Jun 12;353(9169):2076.

The sensitivity and specificity of forecasting high-cost users of medical care. Meenan RT, et al. **Med Care** 1999 Aug; 37(8):815–23

Health care cost crisis in Pennsylvania: where are the physicians? Olmstead D. **Pa Med** 1999 Jun;102(6):7–8

The cost offsets of alcoholism treatment. Holder HD. **Recent Dev Alcohol** 1998;14:361–74 (42 ref.)

Impact on health service costs of medical technologies used in management of prostatic cancer. Holmberg H, et al. **Scand J Urol Nephrol** 1998 May;32(3):195–9

Guidelines as a strategy for preserving professional autonomy. Lee TH. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1889–92

Trends in medical care costs--evolving market forces. Vincenzino JV. **Stat Bull Metrop Insur Co** 1998 Jul-Sep; 79(3):8–15

Changing practice and costs of carotid endarterectomy in Toronto, Canada. Smurawska LT, et al. **Stroke** 1998 Oct; 29(10):2014–7

Rising health care costs: is this the turning point? Tyler T, et al. **Tenn Med** 1999 Jul;92(7):255–6

Great medicine--pity about the cost. Cooke J. **Ulster Med J** 1998 Jun;67 Suppl 1:63–5

[The cost of sickness in the Netherlands in 1994; the main determinants were advanced age and disabling conditions] Polder JJ, et al. **Ned Tijdschr Geneeskd** 1998 Jul 11; 142(28):1607–11 (Eng. Abstr.) **(Dut)**

["There is no cost explosion in public health service". Insurance contributions are hardly relevant for salary deductions (interview)] Reiners H. **Radiologe** 1999 Apr; 39(4):M75–6 **(Ger)**

HEALTH CARE DELIVERY see **DELIVERY OF HEALTH CARE**

HEALTH CARE FINANCING ADMINISTRATION (U.S.) see **UNITED STATES HEALTH CARE FINANCING ADMINISTRATION**

HEALTH CARE FRAUD see **FRAUD**

HEALTH CARE MARKET see **HEALTH CARE SECTOR**

HEALTH CARE POWER OF ATTORNEY see **ADVANCE DIRECTIVES**

HEALTH CARE PROVIDERS see **HEALTH PERSONNEL**

HEALTH CARE RATIONING

see related
PATIENT SELECTION

Setting priorities versus managing closures--what is the ethically most sound way of handling changes in the health care system? Hermerén G. **Acta Oncol** 1999;38(1):33–40

Ethics and allocation of health resources--the influence of poverty on health. Taipale V. **Acta Oncol** 1999;38(1):51–5 (50 ref.)

Influence of chronic disease, organ dysfunction and severity of illness on care restrictions in paediatric intensive care [letter] [see comments] Teik AG, et al. **Acta Paediatr** 1999 Jul;88(7):790–1. Comment in: Acta Paediatr 1999 Jul;88(7):704–5.

Does bedside rationing violate patients' best interests? An exploration of "moral hazard" [letter; comment] DiNubile MJ. **Am J Med** 1998 Oct;105(4):360–1. Comment on: Am J Med 1998 Jan;104(1):64–8.

Healing persons and therapeutic institutions. Bulger RJ. **Am J Obstet Gynecol** 1999 Apr;180(4):875–82

Does history repeat itself? [letter; comment] Gottlieb EL. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):17A. Comment on: Am J Orthod Dentofacial Orthop 1998 Aug;114(2):134–41.

Emergency department observation unit funding [letter] Ross MA, et al. **Ann Emerg Med** 1999 Aug;34(2):293–4

Rationing in child health services: a personal view. Macfarlane A. **Arch Dis Child** 1999 Jul;81(1):1–2

Physician-assisted suicide [letter; comment] Malter A. **Arch Intern Med** 1998 Dec 7-21;158(22):2513. Comment on: Arch Intern Med 1998 May 11;158(9):974–8.

The rationale for Healthy Start dialysis [editorial] Golper TA. **Blood Purif** 1999;17(1):1–9 (53 ref.)

Rationing of sildenafil. Older doctor derived great benefit from sildenafil [letter] **BMJ** 1999 Jun 12;318(7198):1620–1

Rationing of sildenafil. Summary of electronic responses [letter] **BMJ** 1999 Jun 12;318(7198):1621

Insider view of rationing down under [letter] Agnew TM, et al. **BMJ** 1998 Oct 24;317(7166):1154–5

Is there a rationale for rationing chronic dialysis? Two points need clarification [letter] Ahmad R. **BMJ** 1999 Jun 12; 318(7198):1619; discussion 1620

UK issues guidance on prescribing Viagra [news] Beecham L. **BMJ** 1999 Jan 30;318(7179):279

Population figures for capitation formulas need to be designed differently [letter] Carr-Hill R, et al. **BMJ** 1999 Apr 24; 318(7191):1145

Is there a rationale for rationing chronic dialysis? Question is difficult to address on basis of retrospective studies [letter; comment] Caskey FJ, et al. **BMJ** 1999 Jun 12; 318(7198):1619–20. Comment on: BMJ 1999 Jan 23;318(7178):217–23.

Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. Chandna SM, et al. **BMJ** 1999 Jan 23; 318(7178):217–23

Viagra: a botched test case for rationing [editorial; comment] [see comments] Chisholm J. **BMJ** 1999 Jan 30; 318(7179):273–4. Comment on: BMJ 1999 Jan 30;318(7179):273–4. Comment in: BMJ 1999 Jun 12;318(7198):1620. Comment in: BMJ 1999 Jun 26;318(7200):1763.

Rationing. Fidelity and stewardship are incompatible when attempted by same individual [letter; comment] Ellis SJ. **BMJ** 1999 Apr 3;318(7188):941. Comment on: BMJ 1998 Oct 10;317(7164):1002–4.

Is there a rationale for rationing chronic dialysis? Study's objectives were not achieved [letter; comment] Farrant T. **BMJ** 1999 Jun 12;318(7198):1619; discussion 1620. Comment on: BMJ 1999 Jan 23;318(7178):217–23.

Experience with rationing health care in New Zealand. Feek CM, et al. **BMJ** 1999 May 15;318(7194):1346–8

Rationing. The word must be used and the government must give a stronger lead [letter] Gaskell P. **BMJ** 1998 Nov 28;317(7171):1527

Rationing of sildenafil. True debate is needed [letter] Green A. **BMJ** 1999 Jun 12;318(7198):1620

Rationing of sildenafil. Nobody needs an erection at public expense [letter] Hayes S. **BMJ** 1999 Jun 12;318(7198):1620

Rationing. Better variables than QALYs in decision making may become apparent [letter; comment] Heasell S. **BMJ** 1999 Apr 3;318(7188):941. Comment on: BMJ 1995 Sep 23;311(7008):811. Comment on: BMJ 1998 Oct 10;317(7164):1000–2.

Rationing and the health authority. Hope T, et al. **BMJ** 1998 Oct 17;317(7165):1067–9

Puzzling out priorities. Why we must acknowledge that rationing is a political process [editorial] [see comments] Klein R. **BMJ** 1998 Oct 10;317(7164):959–60. Comment in: BMJ 1999 Apr 3;318(7188):940.

Rationing. Introduce new category of prescription charges, "full cost medicines" [letter] Ramsay-Baggs P. **BMJ** 1998 Nov 28;317(7171):1527

Rationing. Politicians, not doctors, must make the decisions about rationing [letter; comment] Rao JN. **BMJ** 1999 Apr 3;318(7188):940. Comment on: BMJ 1995 Sep 23;311(7008):811. Comment on: BMJ 1998 Oct 10;317(7164):959–60.

Views on rationing of treatments for erectile dysfunction are mixed [letter] Riley G, et al. **BMJ** 1999 Jun 26; 318(7200):1763

Devolution in Latin America has had poor effects on health care [letter] Sandiford P. **BMJ** 1999 Jul 3;319(7201):55

Conservatives blame rationing for winter crisis [news] Warden J. **BMJ** 1999 Jan 23;318(7178):216

Rationing. Use of representative health panel shows changes in public attitudes to rationing [letter; comment] Worth C. **BMJ** 1999 Apr 3;318(7188):941. Comment on: BMJ 1998 Oct 10;317(7164):1002–4.

Sanitary justice in scarcity. Kottow M. **Cad Saude Publica** 1999;15 Suppl 1:43–50

Ethical issues in managed and rationed care for children with severe neurological disabilities: a questionnaire survey. Mori K, et al. **Childs Nerv Syst** 1999 Jul;15(6–7):342–6

Waiting lists for health care: a necessary evil? [editorial] Davies RF. **CMAJ** 1999 May 18;160(10):1469–70

Debating the benefits of home care [letter; comment] Mullens JE. **CMAJ** 1998 Oct 20;159(8):918–9. Comment on: CMAJ 1998 Jul 28;159(2):135–6.

Rationing of hospital services in the Australian health system. Kovač M. **Croat Med J** 1998 Sep;39(3):339–45

Priority setting and scarce resources: case of the Federation of Bosnia and Herzegovina. Ljubić B, et al. **Croat Med J** 1998 Sep;39(3):276–80

Health care rationing in the aged: ethical and clinical perspectives. Howe EG, et al. **Drugs Aging** 1999 Jul; 15(1):37–47 (52 ref.)

Family planning funding through four federal-state programs, FY 1997. Gold RB, et al. **Fam Plann Perspect** 1999 Jul-Aug;31(4):176–81

Evidence-based medicine between explicit rationing, medical deontology and rights of patients. Frati P. **Forum (Genova)** 1998 Oct-Dec;8(4):383–94

Preferences for equity in health behind a veil of ignorance. Andersson F, et al. **Health Econ** 1999 Aug;8(5):369–78

Incorporating societal concerns for fairness in numerical valuations of health programmes. Nord E, et al. **Health Econ** 1999 Feb;8(1):25–39

Developing a strategy for the prevention of hip fractures in the elderly due to osteoporosis: the application of economics to the findings from a clinical trial. Phillips CJ, et al. **Int J Clin Pract** 1998 Jul-Aug;52(5):335–40 (29 ref.)

New labour and the third way in the British National Health Service. Powell M. **Int J Health Serv** 1999;29(2):353–70 (82 ref.)

Macro allocation in health: an ethically based model. Kluge EH, et al. **Int J Med Inf** 1998 Aug-Sep;51(2–3):205–13

Selection and outcome of ventricular assist device patients: the Muenster experience. Deng MC, et al. **J Heart Lung Transplant** 1998 Aug;17(8):817–25

Equitable rationing of highly specialised health care services for children: a perspective from South Africa. Landman WA, et al. **J Med Ethics** 1999 Jun;25(3):224–9

Data collection for nursing work force strategic planning in California. Sechrist KR, et al. **J Nurs Adm** 1999 Jun; 29(6):9–11, 29

Interpreter services in healthcare. Policy recommendations for healthcare agencies. Tang SY. **J Nurs Adm** 1999 Jun; 29(6):23–9

South African health-budget cuts hit premature newborns [news] [see comments] Baleta A. **Lancet** 1998 Oct 3; 352(9134):1129. Comment in: Lancet 1998 Dec 12;352(9144):1941.

Drug rationing comes out into the open in the UK [news] Dean M. **Lancet** 1999 Aug 21;354(9179):657

Performance of doctors [letter; comment] de Wildt G, et al. **Lancet** 1999 Jul 10;354(9173):165. Comment on: Lancet 1999 Apr 3;353(9159):1174–7.

Population requirement for primary hip-replacement surgery: a cross-sectional study [see comments] Frankel S, et al. **Lancet** 1999 Apr 17;353(9161):1304–9. Comment in: Lancet 1999 Jun 19;353(9170):2161.

Alice C is poor evidence against age-based rationing [letter; comment] Goodman NW. **Lancet** 1999 Feb 20; 353(9153):677–8. Comment on: Lancet 1998 Dec 5;352(9143):1849–51.

Measuring the burden of disease [letter; comment] Morrow RH, et al. **Lancet** 1998 Dec 5;352(9143):1859–61. Comment on: Lancet 1998 Sep 5;352(9130):757–8.

Estimating general-population utilities using one binary-gamble question per respondent. Bosch JL, et al. **Med Decis Making** 1998 Oct-Dec;18(4):381–90

Tests of preferential independence in the QALY model. Treadwell JR. **Med Decis Making** 1998 Oct-Dec; 18(4):418–28

Ethical guidelines for physician payment based on capitation [letter; comment] Criscione JR Jr. **N Engl J Med** 1999 Jan 28;340(4):322; discussion 322–3. Comment on: N Engl J Med 1998 Sep 3;339(10):689–93.

A new ethic for medicine? [letter; comment] Hall MA, et al. **N Engl J Med** 1998 Oct 29;339(18):1327–8; discussion 1328. Comment on: N Engl J Med 1998 Aug 6;339(6):397–8.

Potential cost savings from legalizing physician-assisted suicide [letter; comment] Joe L. **N Engl J Med** 1998 Dec 10;339(24):1789–90. Comment on: N Engl J Med 1998 Jul 16;339(3):167–72.

Doctor discontent [letter; comment] Mansheim BJ. **N Engl J Med** 1999 Feb 25;340(8):651–2; discussion 652–3 . Comment on: N Engl J Med 1998 Nov 19;339(21):1516–21.

Doctor discontent [letter; comment] Ruane TJ. **N Engl J Med** 1999 Feb 25;340(8):651; discussion 652–3. Comment on: N Engl J Med 1998 Nov 19;339(21):1516–21.

Rational (or rationing?) healthcare [editorial; comment] Fante RG, et al. **Ophthalmology** 1999 Sep;106(9):1649–50. Comment on: Ophthalmology 1999 Sep;106(9):1705–12.

The coming clash: patient advocates vs. the public interest [letter] Craner G. **Pharos** 1999 Summer;62(3):50

Oregon and health care spending [editorial; comment] Crawshaw R. **Pharos** 1998 Fall;61(4):26. Comment on: Pharos 1998 Fall;61(4):18–20, discussion 21–5.

The coming clash: patient advocates vs. the public interest [letter] Granat P. **Pharos** 1999 Summer;62(3):50–1

The coming clash: patient advocates vs. the public interest [see comments] Lamm RD. **Pharos** 1998 Fall;61(4):18–20; discussion 21–5. Comment in: Pharos 1998 Fall;61(4):26. Comment in: Pharos 1999 Spring;62(2):39; discussion 41. Comment in: Pharos 1999 Spring;62(2):39–40; discussion 41. Comment in: Pharos 1999 Spring;62(2):40; discussion 41. Comment in: Pharos 1999 Spring;62(2):41.

The coming clash: patient advocates vs. the public interest [letter] Petty W. **Pharos** 1999 Summer;62(3):49–50

Rationing medical care [editorial] Miller WT. **Semin Roentgenol** 1999 Jan;34(1):1–4

In defense and pursuit of equity and efficiency [comment] Adeyi O, et al. **Soc Sci Med** 1998 Dec;47(12):1899–900. Comment on: Soc Sci Med 1998 Dec;47(12):1891–6; discussion 1897–8.

Towards equity in health in an unequal society. Bloom G, et al. **Soc Sci Med** 1998 Nov;47(10):1529–38

Risk adjustment and hospital cost-based resource allocation, with an application to El Salvador. Fiedler JL, et al. **Soc Sci Med** 1999 Jan;48(2):197–212

In defence and pursuit of equity [see comments] Gilson L. **Soc Sci Med** 1998 Dec;47(12):1891–6; discussion 1897–8. Comment in: Soc Sci Med 1998 Dec;47(12):1899–900. Comment in: Soc Sci Med 1998 Dec;47(12):1901–3.

Survival vs. quality of life: a study of the Israeli public priorities in medical care. Shmueli A. **Soc Sci Med** 1999 Aug;49(3):297–302

Pursuing equity without getting beat [see comments] Tollman SM, et al. **Soc Sci Med** 1998 Dec;47(12):1901–3. Comment in: Soc Sci Med 1998 Dec;47(12):1891–6; discussion 1897–8.

The dream of consensus: finding common ground in a bioethical context. Koch T, et al. **Theor Med Bioeth** 1999 Jun;20(3):261–72

[A study in eight counties: can closure of infrequently used emergency service improve quality of care?] Dahlgren S, et al. **Lakartidningen** 1999 Jun 2;96(22):2732–4, 2736, 2738–9 **(Swe)**

[Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources] Lindholm L, et al. **Lakartidningen** 1999 Jun 9;96(23):2858–63, 2865–6 (Eng. Abstr.) **(Swe)**

ECONOMICS

Rationing dialysis in the United States: possible implications of capitated systems. Glover JJ, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):341–9

Resource constraints and moral pressures: can we still afford ourselves? Little M. **Aust N Z J Surg** 1998 Nov; 68(11):757–9

Painful justice: an ethical perspective on the allocation of trauma services in Australia. Sloane A. **Aust N Z J Surg** 1998 Nov;68(11):760–3

Funding long term care for older people. Redistribution of wealth from rich to poor is not function of a care service [letter] Heath I. **BMJ** 1999 Jul 3;319(7201):56

Economic Notes: opportunity cost. Palmer S, et al. **BMJ** 1999 Jun 5;318(7197):1551–2 (9 ref.)

The ethics of managed care financial incentives to limit care. Some thoughts for specialists. Latham SR. **Clin Plast Surg** 1999 Jan;26(1):115–21, viii–ix

Toward a broader view of values in cost-effectiveness analysis of health. Menzel P, et al. **Hastings Cent Rep** 1999 May-Jun;29(3):7–15

Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimality and equivalence. Laska EM, et al. **Health Econ** 1999 Mar;8(2):171–4

Algorithms for resource allocation of substance abuse prevention funds based on social indicators: a case study on state of Florida--Part 3. Kim S, et al. **J Drug Educ** 1998;28(4):283–306

Marginal medicine [letter; comment] David DS. **JAMA** 1999 Mar 24–31;281(12):1082; discussion 1083. Comment on: JAMA 1998 Sep 9;280(10):931–3.

Marginal medicine [letter; comment] Houghton ER. **JAMA** 1999 Mar 24–31;281(12):1082; discussion 1083. Comment on: JAMA 1998 Sep 9;280(10):931–3.

Marginal medicine [letter] Spitzer D. **JAMA** 1999 Mar 24–31; 281(12):1082; discussion 1083

Is the societal perspective in cost-effectiveness analysis useful for decision makers? Russell LB, et al. **Jt Comm J Qual Improv** 1999 Sep;25(9):447–54 (16 ref.)

Can we afford medical care for Alice C? [see comments] Levinsky NG. **Lancet** 1998 Dec 5;352(9143):1849–51. Comment in: Lancet 1999 Feb 20;353(9153):677–8.

Commentary: "efficiency and civility in maternity care" or "how much jello can a mother eat?" Reinhardt UE. **Med Care Res Rev** 1999 Mar;56(1):47–54

Power and sample size in cost-effectiveness analysis. Laska EM, et al. **Med Decis Making** 1999 Jul-Sep;19(3):339–43

Australian medical research: more resources and the right balance [letter; comment] Gaughwin MD. **Med J Aust** 1998 Nov 2;169(9):502–3. Comment on: Med J Aust 1998 Jun 1;168(11):535–6.

Casemix funding in Australia [letter; comment] Henderson DR. **Med J Aust** 1998 Oct 5;169(7):397–8. Comment on: Med J Aust 1998 Jun 1;168(11):558–62.

What is rationing? [letter; comment] Boren SD, et al. **N Engl J Med** 1999 Jul 15;341(3):213. Comment on: N Engl J Med 1999 Jan 14;340(2):144–6.

Rationality in medical treatment decisions: is there a sunk-cost effect? Bornstein BH, et al. **Soc Sci Med** 1999 Jul;49(2):215–22

Why the NHS should fund infertility services [editorial] Byrne PA, et al. **Ulster Med J** 1999 May;68(1):2–3

Lies, damn lies and cost-effectiveness. McGuigan JA. **Ulster Med J** 1998 Jun;67 Suppl 1:66–9

[Physicians held between two fires: between the exigencies of patients...and financial constraints] Daher M, et al. **J Med Liban** 1998 Nov-Dec;46(6):301–2 **(Fre)**

[A "gnomic" view of mandarins] Gautier R. **Rev Med Suisse Romande** 1998 Dec;118(12):1031–4 **(Fre)**

[Allocation problems within the context of limited financial resources] Gandjour A, et al. **Internist (Berl)** 1999 Mar; 40(3):255–9 (12 ref.) **(Ger)**

[Economic evaluation within the scope of clinical studies] Walshe R, et al. **Internist (Berl)** 1998 Sep;39(9):943–54 (72 ref.) **(Ger)**

[The duality of medical progress. On the contribution by Arnold M. The Janus head of medical technical progress (letter)] Eigler FW. **Med Klin** 1999 Jun 15;94(6):359 **(Ger)**

[Rationing in medicine from the economic viewpoint] Obermann K. **Med Klin** 1999 Feb 15;94(2):110–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Rationing in public health: what criteria, what priorities?] Wiedemann GJ, et al. **Med Klin** 1999 Feb 15;94(2):116–9 (Eng. Abstr.) **(Ger)**

[QALY or willingness to pay?] Steurer J. **Schweiz Rundsch Med Prax** 1999 Feb 18;88(8):333–8 **(Ger)**

[Political distribution problems of social security] Wagner G. **Z Gerontol Geriatr** 1998 Dec;31(6):377–81 (Eng. Abstr.) **(Ger)**

[Cost-effectiveness--limits between optimization and rationing] Ruof J, et al. **Z Rheumatol** 1998 Oct;57(5):340–4 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Rejecting organs: the organ allocation process and the Americans with Disabilities Act. Whitehead AT. **Am J Law Med** 1998;24(4):481–97 (0 ref.)

De facto health-care rationing by age. The law has no remedy. Kapp MB. **J Leg Med** 1998 Sep;19(3):323–49 (152 ref.)

National and local forces in organ allocation. Burdick JF. **Transplant Proc** 1999 Feb-Mar;31(1–2):1333–6

[Allocation problems within the scope of organ transplantation] Neuhaus P. **Internist (Berl)** 1999 Mar; 40(3):270–5 (0 ref.) **(Ger)**

[Fair distribution in transplantation medicine] Kliemt H. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:197–9 (Eng. Abstr.) **(Ger)**

METHODS

A resource-allocation model to enhance productivity of academic physicians. Blalock J, et al. **Acad Med** 1998 Oct; 73(10):1062–6

Evidence-based organ allocation. Zenios SA, et al. **Am J Med** 1999 Jul;107(1):52–61

The second phase of priority setting. Goodbye to the simple solutions: the second phase of priority setting in health care [see comments] Holm S. **BMJ** 1998 Oct 10; 317(7164):1000–2. Comment in: BMJ 1999 Apr 3;318(7188):941.

Allocative efficiency in the use of health resources in Portugal. do Rosário Giraldes M. **J Public Health Med** 1999 Mar;21(1):55–9

Rationing of health care--how should it be done? [see comments] Kleinert S. **Lancet** 1998 Oct 17;352(9136):1244 . Comment in: Lancet 1998 Dec 19–26;352(9145):2026.

A new ethic for medicine? [letter; comment] Blackwell B. **N Engl J Med** 1998 Oct 29;339(18):1327; discussion 1328 . Comment on: N Engl J Med 1998 Aug 6;339(6):397–8.

Geographic favoritism in liver transplantation [letter] Finder SG. **N Engl J Med** 1999 Mar 25;340(12):964; discussion 964–5

Geographic favoritism in liver transplantation [letter; comment] Freeman RB Jr. **N Engl J Med** 1999 Mar 25; 340(12):963; discussion 964–5. Comment on: N Engl J Med 1998 Oct 29;339(18):1322–5.

Geographic favoritism in liver transplantation [letter] Markowitz JS. **N Engl J Med** 1999 Mar 25;340(12):964; discussion 964–5

Geographic favoritism in liver transplantation [letter; comment] Rabkin JM. **N Engl J Med** 1999 Mar 25; 340(12):964–5. Comment on: N Engl J Med 1998 Oct 29;339(18):1322–5.

Geographic favoritism in liver transplantation [letter; comment] Stratta RJ, et al. **N Engl J Med** 1999 Mar 25; 340(12):964; discussion 964–5. Comment on: N Engl J Med 1998 Oct 29;339(18):1322–5.

Geographic favoritism in liver transplantation [letter; comment] Turcotte JG. **N Engl J Med** 1999 Mar 25; 340(12):963; discussion 964–5. Comment on: N Engl J Med 1998 Oct 29;339(18):1322–5.

Geographic favoritism in liver transplantation--unfortunate or unfair? [see comments] Ubel PA, et al. **N Engl J Med** 1998 Oct 29;339(18):1322–5. Comment in: N Engl J Med 1999 Mar 25;340(12):963; discussion 964–5. Comment in: N Engl J Med 1999 Mar 25;340(12):964; discussion 964–5. Comment in: N Engl J Med 1999 Mar 25;340(12):964–5.

How fair is cataract prioritisation? Halliwell T. **N Z Med J** 1998 Oct 23;111(1076):405–7

Parity with what? [editorial] Thienhaus OJ. **Psychiatr Serv** 1999 Feb;50(2):155

Treating the least well off [letter; comment] Thompson KS. **Psychiatr Serv** 1999 Feb;50(2):268. Comment on: Psychiatr Serv 1998 Oct;49(10):1273–4, 1290.

Case mix--for better or for worse? Cheah J, et al. **Singapore Med J** 1999 Jan;40(1):9–12

Linking measures of health gain to explicit priority setting by an area health service in Australia. Cromwell DA, et al. **Soc Sci Med** 1998 Dec;47(12):2067–74

ORGANIZATION & ADMINISTRATION

Reflective choice in health care: using information technology to present allocation options. Rai AK. **Am J Law Med** 1999;25(2–3):387–402

Solid organ transplantation. 2: Ethical considerations. Kefalides P. **Ann Intern Med** 1999 Jan 19;130(2):169–70

Demand, supply and allocation in Eurotransplant. Persijn GG, et al. **Ann Transplant** 1997;2(1):26–33

The selection of patients for breast reduction: should health commissions have a say? Horlock N, et al. **Br J Plast Surg** 1999 Mar;52(2):118–21

Psychoactive substance use (drug abuse) and a resource-oriented strategy to confront it in the eastern Mediterranean region. Mohit A. **East Mediterr Health J** 1998;4 Suppl:S149–64 (13 ref.)

Priority care for employees: a blessing in disguise? Brouwer WB, et al. **Health Econ** 1999 Feb;8(1):65–73 (21 ref.)

The economic consequences of reorganizing hospital services in Bishkek, Kyrgyzstan. Street A, et al. **Health Econ** 1999 Feb;8(1):53–64

Does managed care affect the supply and use of ICU services? Friedman B, et al. **Inquiry** 1999 Spring;36(1):68–77

Toward an ecosocial view of health. Levins R, et al.

Int J Health Serv 1999;29(2):261–93

Algorithms for resource allocation of substance abuse prevention funds based on composite risk-factor index score: a case study on state of Florida--Part 2. Kim S, et al. **J Drug Educ** 1998;28(3):169–84

Managed care: rationing without justice, but not unjustly [see comments] Buchanan A. **J Health Polit Policy Law** 1998 Aug;23(4):617–34 (16 ref.). Comment in: J Health Polit Policy Law 1998 Aug;23(4):687–95.

The Oregon Health Plan and the political paradox of rationing: what advocates and critics have claimed and what Oregon did. Jacobs L, et al. **J Health Polit Policy Law** 1999 Feb;24(1):161–80 (19 ref.)

Oregon's bold experiment: whatever happened to rationing? Leichter HM. **J Health Polit Policy Law** 1999 Feb; 24(1):147–60 (17 ref.)

Tensions in setting health care priorities for South Africa's children. Landman WA, et al. **J Med Ethics** 1998 Aug; 24(4):268–73 (30 ref.)

Allocation of donor organs [letter; comment] de Rave S. **Lancet** 1997 Oct 11;350(9084):1107. Comment on: Lancet 1997 Aug 2;350(9074):372.

Rationing of health care [letter; comment] Shenkin HA. **Lancet** 1998 Dec 19–26;352(9145):2026. Comment on: Lancet 1998 Oct 17;352(9136):1244.

An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Richter A, et al. **Med Decis Making** 1999 Apr–Jun;19(2):167–79

Improving the contribution of public health to NHS decision making: development of an instrument. Leach J, et al. **Public Health** 1998 Nov;112(6):393–8

The geographical assignment of cancer units: patient accessibility as an optimal allocation problem. Smallman-Raynor MR, et al. **Public Health** 1998 Nov; 112(6):379–83

[Different organizational modalities in perinatal care as a function of demographic context and budgetary constraints] Papiernik E. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:76–84 (17 ref.) **(Fre)**

[Program of medical information systems and resource allocation. How to optimize?] Vergnenegre A. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S22–3 **(Fre)**

STANDARDS

Rationing in cancer treatment: is the identification of essential cytotoxic drugs feasible? [editorial] Sessa C. **Ann Oncol** 1999 Apr;10(4):373–4 (5 ref.)

Ethics and managed care: reconstructing a system and refashioning a society [editorial; comment] [see comments] Loewy EH, et al. **Arch Intern Med** 1998 Dec 7–21; 158(22):2419–22. Comment on: Arch Intern Med 1998 Dec 7–21;158(22):2421–28. Comment in: Arch Intern Med 1999 Jun 28;159(12):1375–6.

The second phase of priority setting. Fairness as a problem of love and the heart: a clinician's perspective on priority setting [see comments] Sabin JE. **BMJ** 1998 Oct 10; 317(7164):1002–4. Comment in: BMJ 1999 Apr 3;318(7188):941.

Recasting the debate on multiple listing for transplantation through consideration of both principles and practice. Ankeny RA. **Camb Q Healthc Ethics** 1999 Summer; 8(3):330–9

A critique of UNOS liver allocation policy. United Network for Organ Sharing. Himma KE. **Camb Q Healthc Ethics** 1999 Summer;8(3):311–20

Expectations and outcomes in organ transplantation. McChesney LP, et al. **Camb Q Healthc Ethics** 1999 Summer;8(3):299–310

The ethics of competition in liver transplantation. Thomasma DC, et al. **Camb Q Healthc Ethics** 1999 Summer;8(3):321–9

In response to The ethics of organ transplantation [letter; comment] Marshall J Jr. **Conn Med** 1998 Nov;62(11):691–2 . Comment on: Conn Med 1998 Jun;62(6):367.

Redrawing the ethics map. Lamm RD. **Hastings Cent Rep** 1999 Mar–Apr;29(2):28–9

The ethics of accountability in managed care reform [see comments] Daniels N, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):50–64. Comment in: Health Aff (Millwood) 1998 Nov–Dec;17(6):252–3.

Rehabilitation: a luxury? Phipps EJ, et al. **J Head Trauma Rehabil** 1999 Jun;14(3):329–31

Does the "Thunderbirds syndrome" still exist. Simmons D, et al. **N Z Med J** 1998 Nov 27;111(1078):456–8

How old is old? The ethics of rationing [letter] Alderman J, et al. **Nurse Pract** 1999 Mar;24(3):25, 138

Balancing efficiency and need in allocating resources to the care of persons with serious mental illness. Callahan D. **Psychiatr Serv** 1999 May;50(5):664–6

Treating the least well off [letter] Phillips DE. **Psychiatr Serv** 1999 Feb;50(2):268–9

Obligation to the least well off in setting mental health service priorities: a consensus statement [see comments] Rosenheck R, et al. **Psychiatr Serv** 1998 Oct;49(10):1273–4, 1290. Comment in: Psychiatr Serv 1999 Feb;50(2):268.

Principles for priority setting in mental health services and their implications for the least well off. Rosenheck RA. **Psychiatr Serv** 1999 May;50(5):653–8

The ethics of resource allocation: the views of general practitioners in Lincolnshire, U.K. Baines DL, et al. **Soc Sci Med** 1998 Nov;47(10):1555–64

Ethics of resource allocation in developing countries: the case of Sri Lanka. Jayasinghe KS, et al. **Soc Sci Med** 1998 Nov;47(10):1619–25

"Communitarian claims" as an ethical basis for allocating health care resources. Mooney G. **Soc Sci Med** 1998 Nov; 47(9):1171–80 (47 ref.)

[Equity in health, between ethics and economy] Berlinguer G. **Rev Med Suisse Romande** 1998 Dec;118(12):989–93 **(Fre)**

STATISTICS & NUMERICAL DATA

Using work sampling to investigate staff time allocation in community mental health centers. Stevenson J, et al. **Adm Policy Ment Health** 1999 Mar;26(4):291–5

Referral rates and waiting lists: some empirical evidence. Goddard JA, et al. **Health Econ** 1998 Sep;7(6):545–9

Impact of the perception of viability on resource allocation in the neonatal intensive care unit. Sanders MR, et al. **J Perinatol** 1998 Sep–Oct;18(5):347–51

Weighted Census-based deprivation indices: their use in small areas. Saunders J. **J Public Health Med** 1998 Sep; 20(3):253–60

Do market-level hospital and physician resources affect small area variation in hospital use? Alexander JA, et al. **Med Care Res Rev** 1999 Mar;56(1):94–117

The relation between funding by the National Institutes of Health and the burden of disease [see comments] Gross CP, et al. **N Engl J Med** 1999 Jun 17;340(24):1881–7. Comment in: N Engl J Med 1999 Jun 17;340(24):1914–5.

TRENDS

Gender difference in health status and health care facilities in some social groups and subgroups of southern West Bengal, India. Chakrabarty M. **Coll Antropol** 1998 Jun; 22(1):259–76

Remedy presented for health inequalities in England [news] Ramsay S. **Lancet** 1998 Nov 28;352(9142):1759

HEALTH CARE REFORM

see related

SINGLE-PAYER SYSTEM

The Iron Lady: reform and be damned--a cost and benefits analysis of UK radiology post reform. Golding SJ. **Acad Radiol** 1998 Sep;5 Suppl 2:S357–8

Sliced down to the moral backbone? Ethical issues of structural reforms in healthcare organizations. Brommels M. **Acta Oncol** 1999;38(1):63–9 (22 ref.)

Equity in health and health care reforms. Glick SM. **Acta Oncol** 1999;38(4):469–73

The pharmacist as a healer [letter] Baron MF. **Am J Health Syst Pharm** 1999 Mar 15;56(6):576

Healing persons and therapeutic institutions. Bulger RJ. **Am J Obstet Gynecol** 1999 Apr;180(4):875–82

Cameroon and Chad: cost recovery. Godin C. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S163–4

The key to the door: Medicaid's role in improving health care for women and children. Rowland D, et al. **Annu Rev Public Health** 1999;20:403–26 (106 ref.)

Proactive measures needed for health care reform [letter; comment] Erwin K. **Arch Intern Med** 1999 Jun 28; 159(12):1370–1. Comment on: Arch Intern Med 1998 Aug 10–24;158(15):1626–32.

Reform or doctor bashing? [letter] Tait I. **Aust Fam Physician** 1998 Sep;27(9):779

Reconciliation and policy reform: is there a link? [editorial] Anderson I. **Aust N Z J Public Health** 1999 Jun;23(3):231–2

Reforming British primary care (again) [editorial] Groves T. **BMJ** 1999 Mar 20;318(7186):747–8

Elements of decentralisation in plans to reform NHS may prevail [letter; comment] Ham C. **BMJ** 1998 Sep 12; 317(7160):753. Comment on: BMJ 1998 Jul 4;317(7150):5.

Modernising mental health services. Strategy is driven by public opinion [letter; comment] Hawkins V. **BMJ** 1999 Mar 20;318(7186):806–7. Comment on: BMJ 1999 Jan 2;318(7175):3–4.

Modernising mental health services. Government has failed, not community care [letter; comment] Johnston T. **BMJ** 1999 Mar 20;318(7186):807. Comment on: BMJ 1999 Jan 2;318(7175):3–4.

Modernising mental health services. Strategy does not seem to be based on systematic evidence [letter] Johnstone P, et al. **BMJ** 1999 Mar 20;318(7186):806

Reforming the Russian health service. Toon PD. **BMJ** 1998 Sep 12;317(7160):741–2

Suggested reforms [letter; comment] Foote JR. **Br Dent J** 1999 Jan 23;186(2):52. Comment on: Br Dent J 1998 Oct 10;185(7):319.

What are family planning clinics for? [letter] Kirkman RJ. **Br J Fam Plann** 1998 Jan;23(4):140

State initiatives in health policy. Brown LD. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):604–13

Issues in employment and insurance. Gradison W. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):586–94

Drug policy reform: societal and clinical perspectives. Newman RG. **Bull N Y Acad Med** 1995 Winter; 72(2):321–34

Overview of challenges. Thier SO. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):570–4

Euthanasia and health reform in Canada. Stingl M. **Camb Q Healthc Ethics** 1998 Fall;7(4):348–62; discussion 363–70 (41 ref.)

Cutting and pasting in Quebec. Community health centres and health care reform [see comments] Blair L. **Can Fam Physician** 1999 Feb;45:261–4, 268–72. Comment in: Can Fam Physician 1999 May;45:1148. **(Eng, Fre)**

The war on healthcare professionals and healthcare delivery [editorial] Wiernik PH. **Cancer Invest** 1999;17(2):164–9

Costs of cancer care: is the community setting different than the academic? Bitran JD. **Cancer Treat Res** 1998;97:71–9

Delivering health and mental health care services to children in family foster care after welfare and health care reform. Simms MD, et al. **Child Welfare** 1999 Jan–Feb;78(1):166–83

Ambulatory obstetric management. Cohen AW. **Clin Obstet Gynecol** 1998 Sep;41(3):481–90 (18 ref.)

Will voters' response to health care reforms determine the fate of Mike Harris? Gray C. **CMAJ** 1999 Jun 1; 160(11):1623–4

Health sector reform in the Republic of Macedonia. Ivanovska L, et al. **Croat Med J** 1999 Jun;40(2):181–9

Slovenian experience on health care reform. Markota M, et al. **Croat Med J** 1999 Jun;40(2):190–4

Health care reform in Croatia: the consumers' perspective. Mastilica M, et al. **Croat Med J** 1998 Sep;39(3):256–66

New priorities for health sector reform in Central and Eastern Europe [editorial] Orešković S. **Croat Med J** 1998 Sep; 39(3):225–33

Rebuilding the healthcare system in Mostar: challenge and opportunity. Pyle GF, et al. **Croat Med J** 1998 Sep; 39(3):281–4

Primary health care revitalization in Azerbaijan. Qulieyeva DP, et al. **Croat Med J** 1999 Jun;40(2):210–5

Priorities of the Russian health care reform. Shishkin S. **Croat Med J** 1998 Sep;39(3):298–307

Staying the course. Fazio VW. **Dis Colon Rectum** 1998 Oct; 41(10):1217–22

Multiple perspectives on the evaluation of outcome in eastern Europe. Tomov T. **Epidemiol Psichiatr Soc** 1998 Sep–Dec; 7(3):173–7

Deinstitutionalization and psychiatric reform in Spain. Vázquez-Barquero JL, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(3):128–35

On spending other people's money. Shore MF. **Harv Rev Psychiatry** 1998 Jul–Aug;6(2):110–3

Change in medical care has come too fast. Holschuh FC. **Hawaii Med J** 1998 Oct;57(10):650

The ethics of accountability in managed care reform [see comments] Daniels N, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):50–64. Comment in: Health Aff (Millwood) 1998 Nov–Dec;17(6):252–3.

Modernizing Britain's National Health Service. Dobson F. **Health Aff (Millwood)** 1999 May–Jun;18(3):40–1

The cost of health system change: public discontent in five nations. Donelan K, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):206–16

Incremental change in the Australian health care system. Hall J. **Health Aff (Millwood)** 1999 May–Jun;18(3):95–110

More on reform of the NHS [letter; comment] Ham C. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):261–2. Comment on: Health Aff (Millwood) 1998 Jul–Aug;17(4):111–25.

Health care reform in Japan: the virtues of muddling through. Ikegami N, et al. **Health Aff (Millwood)** 1999 May–Jun; 18(3):56–75

Competition, cooperation, or control? Tales from the British National Health Service. Le Grand J. **Health Aff (Millwood)** 1999 May–Jun;18(3):27–39

Demographic issues in Medicare reform. McKusick D. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):194–207

Will the care be there? Vulnerable beneficiaries and Medicare reform. Moon M. **Health Aff (Millwood)** 1999 Jan–Feb; 18(1):107–17

Health care in Canada: incrementalism under fiscal duress. Naylor CD. **Health Aff (Millwood)** 1999 May–Jun; 18(3):9–26

Reforming the Australian health care system: a government perspective. Podger A. **Health Aff (Millwood)** 1999 May–Jun;18(3):111–3

Viewing the U.S. health care system from within: candid talk from HHS [interview by Uwe E. Reinhardt] Shalala DE. **Health Aff (Millwood)** 1999 May–Jun;18(3):47–55

History versus ideology: the Medicare reform debate [letter; comment] Stark F. **Health Aff (Millwood)** 1999 May–Jun; 18(3):265–7. Comment on: Health Aff (Millwood) 1999 Jan–Feb;18(1):92–106.

Dynamics of a changing health sphere: the United States, Britain, and Canada. Tuohy CH. **Health Aff (Millwood)** 1999 May–Jun;18(3):114–34

Policy-induced changes in Maori mortality patterns in the New Zealand economic reform period. Brown MC. **Health Econ** 1999 Mar;8(2):127–36

Health insurance, health reform, and outpatient mental health treatment: who benefits? Zuvekas SH. **Inquiry** 1999 Summer;36(2):127–46

The consequences of universalizing health services: children's use of health services in Catalonia. Rajmil L, et al. **Int J Health Serv** 1998;28(4):777–91

Nurse education in an international context: the contribution of contingency. Traynor M, et al. **Int J Nurs Stud** 1999 Feb;36(1):85–91

Bahrain: quality improvement in primary health care. Benjamin S, et al. **Int J Qual Health Care** 1998 Oct; 10(5):448–50

Crossing the boundary: changing mental models in the service of improvement. Berwick DM. **Int J Qual Health Care** 1998 Oct;10(5):435–41

Competition and quality among managed care plans in the USA. Boston University Health Care Management Program Group. Davidson SM, et al. **Int J Qual Health Care** 1998 Oct;10(5):411–9

Competition in context: the politics of health care reform in Europe. Freeman R. **Int J Qual Health Care** 1998 Oct; 10(5):395–401

Competition and quality in health care: the UK experience. Glennerster H. **Int J Qual Health Care** 1998 Oct; 10(5):403–10

Competition and quality: rhetoric and reality. Maynard A. **Int J Qual Health Care** 1998 Oct;10(5):379–84

Quality in consumer-driven health systems. Reinhardt UE. **Int J Qual Health Care** 1998 Oct;10(5):385–94

Competition on quality in managed care. Schoenbaum SC, et al. **Int J Qual Health Care** 1998 Oct;10(5):421–6

Competition and quality: looking for evidence for health care reforms [editorial] Thompson AG. **Int J Qual Health Care** 1998 Oct;10(5):371–3

Competition through physician-managed care: the case for capitated multispecialty group practices. Tillinghast SJ. **Int J Qual Health Care** 1998 Oct;10(5):427–34

The significance of health sector reform for lung health services. International Union Against Tuberculosis and Lung Disease (IUATLD), and the International Development Research Centre (IDRC). Paris. 7–8 December 1997. **Int J Tuberc Lung Dis** 1998 Dec; 2(12):1044–5

Enrolled nurse conversion: trapped into training. Dowswell T, et al. **J Adv Nurs** 1998 Sep;28(3):540–7

The new public management and the new nursing: related by rhetoric? Some reflections on the policy process and nursing. Hewison A. **J Adv Nurs** 1999 Jun;29(6):1377–84 (49 ref.)

Fund-holding and contracting for community nursing services: a selective review of the literature. Livesey H. **J Adv Nurs** 1998 Sep;28(3):483–90 (112 ref.)

Health care reform and the transformation of nursing in Hong Kong. Wong FK. **J Adv Nurs** 1998 Sep;28(3):473–82

Meeting of Commonwealth health related NGOs. Barbados November 12–15, 1998. Bodeker G. **J Altern Complement Med** 1999 Feb;5(1):98–101

Managed care and complementary and alternative medicine: lessons from the past and suggestions for the future [editorial; comment] Whitehouse PJ. **J Altern Complement Med** 1999 Feb;5(1):1–2. Comment on: J Altern Complement Med 1999 Feb;5(1):65–73.

Commission report signals the future look of Medicare [news] **J Am Diet Assoc** 1999 Mar;99(3):281

The health transition fund and the future of Canadian health care delivery. Innes G. **J Emerg Med** 1999 Jan–Feb; 17(1):157–8

Health sector reform [editorial] Haran D. **J Epidemiol Community Health** 1998 Dec;52(12):768–9

Issues of cost and quality: barriers to an informed debate. Carpenter CE, et al. **J Eval Clin Pract** 1998 May;4(2):131–9

Second order versus second rate [letter; comment] Baum JJ, et al. **J Fam Pract** 1999 Mar;48(3):228. Comment on: J Fam Pract 1998 Jul;47(1):62–7.

Public health: a powerful guide. Young QD. **J Health Care Finance** 1998 Fall;25(1):1–4

An end to outpatient chemotherapy? Medicare takes aim at reimbursement [news] Roemer J. **J Natl Cancer Inst** 1999 Sep 1;91(17):1444–5

Healthcare reform. Its effects on nurses. Corey-Lisle P, et al. **J Nurs Adm** 1999 Mar;29(3):30–7

The Cloutterbuck Minimum Data Matrix: a teaching mechanism for the new millennium. Cloutterbuck JC, et al. **J Nurs Educ** 1998 Dec;37(9):385–93 (70 ref.)

Midwifery in the 21st century. Recommendations from the Pew Health Professions Commission/UCSF Center for the Health Professions 1998 Taskforce on Midwifery [see comments] Paine LL, et al. **J Nurse Midwifery** 1999 Jul–Aug;44(4):341–8. Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):337–40.

Models of commissioning health services in the British National Health Service: a literature review. Chappel D, et al. **J Public Health Med** 1999 Jun;21(2):221–7 (75 ref.)

Health care reform and public health: a paper on population-based core functions. The Core Functions Project, U.S. Public Health Service, 1993. **J Public Health Policy** 1998;19(4):394–419

Comparison of the views of junior doctors, consultants and managers on work and training. Dilworth JP, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):344–50

A physician's reflections on 50 years of the NHS [editorial] Richmond J. **J R Coll Physicians Lond** 1998 Jul–Aug; 32(4):292–5

Reforming American healthcare: an interim report. Reinhardt UE. **J Rheumatol** 1999 Apr;26 Suppl 56:6–10

The long view: how genetic discoveries will aid healthcare reform. Fletcher JC. **J Womens Health** 1998 Sep; 7(7):817–23

US health system reform in the early 21st century. Ginzberg E. **JAMA** 1998 Nov 4;280(17):1539

Activist Young says "gathering storm" will propel a single-payer movement [interview by Rebecca Voelker] Young Q. **JAMA** 1998 Nov 4;280(17):1467–8

Health services researchers zero in on quality, policy, and practice in a changing health care system: report of the 15th annual meeting of the Association for Health Services Research. Kaegi L. **Jt Comm J Qual Improv** 1998 Nov; 24(11):658–71

Green light for German health [news] Kleinert S. **Lancet** 1998 Nov 7;352(9139):1534

Ethical implications of competition policy in healthcare. Komesaroff PA. **Med J Aust** 1999 Mar 15;170(6):266–8

Defence health reform and the post of the Surgeon General. Pearn JH. **Med J Aust** 1999 Mar 15;170(6):278–9

The changing US health care system: challenges for responsible public policy. Gold M. **Milbank Q** 1999; 77(1):3–37, iii

The chances for health care reform [letter] Burack J. **N Engl J Med** 1999 Oct 14;341(16):1235; discussion 1237

The chances for health care reform [letter] Kauffman BL, et al. **N Engl J Med** 1999 Oct 14;341(16):1235–6; discussion 1237

The chances for health care reform [letter] Rizza C. **N Engl J Med** 1999 Oct 14;341(16):1236–7

The chances for health care reform [letter] Weisman EB. **N Engl J Med** 1999 Oct 14;341(16):1236; discussion 1237

NPs: part of the Medicare reform solution [news] Sharp N. **Nurse Pract** 1999 Jun;24(6):105–7

Is downsizing and disbanding specialty care teams a counterproductive strategy for cost reduction in health care? Ryder M, et al. **Nutrition** 1998 Sep;14(9):725–8 (40 ref.)

Industrialized health care and midcareer crises. Attarian DE. **Pharos** 1999 Summer;62(3):48

Medical necessity: a moving target [editorial; comment] Mohl PC. **Psychiatr Serv** 1998 Nov;49(11):1391. Comment on: Psychiatr Serv 1998 Nov;49(11):1481–3.

Parity with what? [editorial] Thienhaus OJ. **Psychiatr Serv** 1999 Feb;50(2):155

South Africa's health reviewed [news] Jones JS. **S Afr Med J** 1999 Feb;89(2):112–4

TRC recommends fundamental health sector reform [news] Spencer Jones J. **S Afr Med J** 1998 Dec;88(12):1538

The impact of health care reform: a survey of victim and offender treatment providers. Berliner L, et al. **Sex Abuse** 1999 Jan;11(1):5–16

In defense and pursuit of equity and efficiency [comment] Adeyi O, et al. **Soc Sci Med** 1998 Dec;47(12):1899–900. Comment on: Soc Sci Med 1998 Dec;47(12):1891–6; discussion 1897–8.

Towards equity in health in an unequal society. Bloom G, et al. **Soc Sci Med** 1998 Nov;47(10):1529–38

The impact of market oriented reforms on choice and information: a case study of cataract surgery in outer London and Stockholm. Fotaki M. **Soc Sci Med** 1999 May; 48(10):1415–32

In defence and pursuit of equity [see comments] Gilson L. **Soc Sci Med** 1998 Dec;47(12):1891–6; discussion 1897–8. Comment in: Soc Sci Med 1998 Dec;47(12):1899–900. Comment in: Soc Sci Med 1998 Dec;47(12):1901–3.

Re-forming medical delivery systems: economic organization and dynamics of regional planning and managed competition. Perkins BB. **Soc Sci Med** 1999 Jan; 48(2):241–51

Pursuing equity without getting beat [see comments] Tollman SM, et al. **Soc Sci Med** 1998 Dec;47(12):1901–3. Comment in: Soc Sci Med 1998 Dec;47(12):1891–6; discussion 1897–8.

Medical, law, and business students' perceptions of the changing health care system. Wilkes M, et al. **Soc Sci Med** 1998 Oct;47(8):1043–9

The power of the individual [letter] Schlitt M. **Surg Neurol** 1999 Apr;51(4):466–7

How much does it cost? How much can be saved? [editorial; comment] Rhodes RS. **Surgery** 1999 Jan;125(1):102–3. Comment on: Surgery 1999 Jan;125(1):96–101.

[Networks of care and diabetes: an obvious need] Giraud A. **Diabetes Metab** 1998 Nov;24 Suppl 3:15–7 (Eng. Abstr.) **(Fre)**

[Should occupational medicine physicians be linked to future computerized medical record networks?] Boulay F, et al. **Presse Med** 1998 Apr 4;27(13):618–21 (Eng. Abstr.) **(Fre)**

[Speech given by Andrea Fischer, Minister of Health on the 102. German Physicians' Day in Cottbus 1999] Fischer A. **Internist (Berl)** 1999 Aug;40(8):232–3 **(Ger)**

[Change of course in health policy; from responsible citizen to dependent patient?] Vilmar K. **Internist (Berl)** 1999 Aug; 40(8):225–32 **(Ger)**

[Health reform 2000. Hard measures against contract physicians] Jentsch P. **MMW Fortschr Med** 1999 Jun 10; 141(23):61–2 **(Ger)**

[Managerial training as an instrument of change in health. The educational objectives and their verification in managerial training courses for the health administrators in the G. Sanelli Institute of Hygiene, 1988–1998] D'Alessandro D, et al. **Ann Ig** 1999 Mar–Apr;11(2):161–71 (Eng. Abstr.) **(Ita)**

[Health care provided by national health services and private insurance] Mariani L. **Clin Ter** 1998 Mar–Apr; 149(2):139–41 (Eng. Abstr.) **(Ita)**

[The French health care system and its reform] Matsuda S, et al. **Nippon Eiseigaku Zasshi** 1998 Oct;53(3):511–20 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Reforms of the British health care—paradigmatic shift, political rhetorics or challenge for health professionals?] Søreide O. **Tidsskr Nor Laegeforen** 1999 Jun 20; 119(16):2375–9 **(Nor)**

[Problem of protection of rights in the area of health and welfare of children and adolescents] Chicherin LP, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):37–42 (Eng. Abstr.) **(Rus)**

[Organization and effectiveness of the functioning of the cardiologic obstetric day hospital] Galkin RA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):24–6 (Eng. Abstr.) **(Rus)**

[Problems of public health in the State Report on Health Status of the Population of the Russian Federation] Goncharenko VL, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):20–1 **(Rus)**

[Methodologic approaches to modelling of a medical care system] Koretskii VL, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):26–7 **(Rus)**

[Improving the planning of sanitary and epidemiological institutions under current conditions] Kutsenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):34–6 (Eng. Abstr.) **(Rus)**

[Provision of information on the activities of the State Sanitary-Epidemiologic Service] Kutstenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):53–5 (Eng. Abstr.) **(Rus)**

[Evaluation of medico-social aid to adolescents] Leshkevich IA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct; (5):11–7 **(Rus)**

[Current concepts of economic interrelationships in the public health system] Livshits AA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):34–7 **(Rus)**

[International classification of diseases (tenth revision)] Ovcharov VK. **Probl Sotsialnoi Gig Istor Med** 1998 Jul–Aug;(4):23–7 **(Rus)**

[Main positions with respect to the formation of the planning and norm-setting basis of medical provision] Preobrazhenskaia VS, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):48–52 (Eng. Abstr.) **(Rus)**

[A promising program for public health and medical science in the Russian Federation] Shchepin OP. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):3–4 **(Rus)**

[Sociological study of the state and prospects of public health reform on a regional level] Tishuk EA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):3–7 **(Rus)**

[Conceptual substantiation of the application of the systems approach to assessment of the quality of medical care] Togunov IA. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):45–8 (Eng. Abstr.) **(Rus)**

[Preliminary results of an evaluation of the effectiveness of general practitioners' work] Tsarik GN. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):42–5 (Eng. Abstr.) **(Rus)**

[Role of socio-hygienic science in reforming national public health] Shchepin OP, et al. **Vestn Ross Akad Med Nauk** 1999;(7):54–9 (7 ref.) **(Rus)**

[A navigational guide for organizing and clarifying the health care debate] López-Casasnovas G. **Gac Sanit** 1999 May–Jun;13(3):226–32 (Eng. Abstr.) **(Spa)**

[Practice of medicine in the medico-social context in the year 2000] Cervera Soto S, et al. **Rev Esp Salud Publica** 1999 Jan–Feb;73(1):13–24 (Eng. Abstr.) **(Spa)**

[Why not a scientific approach in connection with reorganizations? (letter)] Lockner D. **Lakartidningen** 1999 Jun 16;96(24):2954 **(Swe)**

[Daring health reforms in Zambia (letter)] Malmodin B. **Lakartidningen** 1999 Feb 24;96(8):867 **(Swe)**

[Bold health care reforms in Zambia—inspired by Sweden] Nordström A, et al. **Lakartidningen** 1998 Nov 11; 95(46):5192–6 **(Swe)**

[The main trends in the reform of the surgical services in the regional administration, improvement of the quality and efficacy of surgical services to the population] Petrenko VIu. **Klin Khir** 1999;(4):46 **(Ukr)**

ECONOMICS

PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS [editorial] Smith R. **BMJ** 1999 Jul 3; 319(7201):2–3

Be not afraid! [letter] Katz SR. **Conn Med** 1998 Aug;62(8):504

United States health care delivery system, reform, and transition to managed care. Gill HS, et al. **Croat Med J** 1999 Jun;40(2):273–9

Financing of dental health care in the Federation of Bosnia and Herzegovina. Ivanković A, et al. **Croat Med J** 1999 Jun;40(2):166–74

Health reform and hospital financing in Georgia. Jorbenadze A, et al. **Croat Med J** 1999 Jun;40(2):221–36

Development of State Health Insurance System in Georgia. Kalandadze T, et al. **Croat Med J** 1999 Jun;40(2):216–20

Reform of health insurance in the Federation of Bosnia and Herzegovina. Ljubić B, et al. **Croat Med J** 1999 Jun; 40(2):160–5

Reform of health insurance in Croatia. Turek S. **Croat Med J** 1999 Jun;40(2):143–51

'Manacled competition': market reforms in German health care [see comments] Brown LD, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):76–91.

Comment in: Health Aff (Millwood) 1999 May-Jun;18(3):92-4.
Medicare reform: who pays and who benefits? McClellan M, et al. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):48-62
Good news about difficult decisions: the Canadian approach to hospital cost control. Roos NP, et al. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):239-46
The effects of economic reform on health insurance and the financial burden for urban workers in China. Hu TW, et al. **Health Econ** 1999 Jun;8(4):309-21
US and UK health economics: two disciplines separated by a common language? [see comments] Newhouse JP. **Health Econ** 1998 Aug;7 Suppl 1:S79-92. Comment in: Health Econ 1999 Mar;8(2):177; discussion 179-80.
Medicaid managed care and the marketplace. Ku L, et al. **Inquiry** 1998 Fall;35(3):332-45
Royal commission divided over reform of long-term UK care [news] Dean M. **Lancet** 1999 Mar 13;353(9156):907
Doctors, capitation payments and the first Labour Government. Baker AT. **N Z Med J** 1998 Dec 11; 111(1079):477-80
Replace Medicare with Americare [letter] Frankel G. **Tex Med** 1998 Oct;94(10):10-1
[The characteristics of the activities of epidemiological health institutions under the new economic conditions] Sharapov DF, et al. **Voen Med Zh** 1998 Aug;319(8):13-5, 95 (Eng. Abstr.) **(Rus)**
[The reform of primary health care: the economic, care and satisfaction results] Durán J, et al. **Aten Primaria** 1999 May 15;23(8):474-8 (Eng. Abstr.) **(Spa)**

HISTORY

Economic organization of medicine and the Committee on the Costs of Medical Care. Perkins BB. **Am J Public Health** 1998 Nov;88(11):1721-6
Reflections on a painful transition: from socialized to insurance medicine in Russia. Field MG. **Croat Med J** 1999 Jun;40(2):202-9
Family medicine as counterculture. 1979 [classical article] Stephens GG. **Fam Med** 1998 Oct;30(9):629-36
Where are we now in British health economics? Blaug M. **Health Econ** 1998 Aug;7 Suppl 1:S63-78
The ways and means of national health care reform, 1974 and beyond. Wainess FJ. **J Health Polit Policy Law** 1999 Apr;24(2):305-33
A fearsome enemy (1); A history of sanitation in the British Army 1899-1914. Thompson SV. **J R Army Med Corps** 1998 Oct;144(3):166-71
[Johann Georg Heine--treatment leeway for technical specialists after Bavarian medical reform in the early 19th century] Schwarzmann-Schafhauser D. **Sudhoffs Arch Z Wissenschaftsgesch** 1998;82(1):52-73 (Eng. Abstr.) **(Ger)**
[Zemstvo reform and zemstvo medicine in the middle Volga region] Kuz'min VIu. **Probl Sotsialnoi Gig Istor Med** 1998 Sep-Oct;(5):43-5 **(Rus)**

LEGISLATION & JURISPRUDENCE

The siren song of the elderly: Florida's nursing homes and the dark side of Chapter 400. Williamson JL. **Am J Law Med** 1999;25(2-3):423-43
Patient protection: health reform on the line [news] SoRelle R. **Circulation** 1999 Apr 6;99(13):1651-2
Why congress must regulate managed care. Norbeck TB. **Conn Med** 1998 Aug;62(8):492-3
Re: Article entitled "Legislatory framework for private medical practice in Uganda" by Joseph Konde-Lule and others appearing in this issue of EAMJ [letter; comment] Baraza R. **East Afr Med J** 1998 Sep;75(9):560. Comment on: East Afr Med J 1998 Sep;75(9):544-8.
Public opinion, knowledge, and Medicare reform. Bernstein J, et al. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):180-93
Moving Medicare to the FEHBP model, or how to make an elephant fly. Cain HP 2nd. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):25-39
Health insurance reform in the small-group market. Curtis R, et al. **Health Aff (Millwood)** 1999 May-Jun;18(3):151-60
Bolstering the safety net. Gage LS, et al. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):254-7
Covering prescription drugs under Medicare: for the good of the patients [see comments] Holmer AF. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):23-4. Comment in: Health Aff (Millwood) 1999 Jul-Aug;18(4):7-19.
Medicare reform: foundations respond to federal policy changes. LeRoy L, et al. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):255-7
Hidden assets: health insurance reform in New Jersey. Swartz K, et al. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):180-7
Looking back on health care reform: 'no easy choices' [interview by Larry Brown] Zelman W. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):61-8
Shaping the future of Medicare. Davis K. **Health Serv Res** 1999 Apr;34(1 Pt 2):295-306
Small group reform and insurance provision by small firms, 1989-1995. Jensen GA, et al. **Inquiry** 1999 Summer; 36(2):176-87
Scope of practice: turf battle or quality of care? [news] **J Am Diet Assoc** 1999 Aug;99(8):915
Restraint reduction and legal risk management. Kapp MB. **J Am Geriatr Soc** 1999 Mar;47(3):375-6
Slipping through the safety net: implications for women's health [editorial] Pearlman DN. **J Health Care Poor Underserved** 1998 Aug;9(3):217-21
The missing millions: organized labor, business, and the defeat of Clinton's Health Security Act. Gottschalk M. **J Health Polit Policy Law** 1999 Jun;24(3):489-529 (176 ref.)
Error in medicine: legal impediments to U.S. reform. Liang BA. **J Health Polit Policy Law** 1999 Feb;24(1):27-58 (101 ref.)
Dealing with "excluded providers": contracts that can bring trouble to physicians. Padgett PT. **J Ky Med Assoc** 1998 Nov;96(11):457-8 (8 ref.)
Medicare reform hangs in the balance [news] Greenberg DS. **Lancet** 1999 Mar 27;353(9158):1075
Health Insurance Portability and Accountability Act of 1996: lessons from the States. Hing E, et al. **Med Care** 1999 Jul; 37(7):692-705
Congressman Fred Upton: an advocate for physicians and patients. Pilon NS. **Mich Med** 1999 May;98(5):18-9
Doctors, capitation payments and the first Labour Government. Baker AT. **N Z Med J** 1998 Dec 11; 111(1079):477-80
Patient protections stalled in Congress. Boyer MM. **Pa Med** 1998 Sep;101(9):6
Regaining control of health care delivery. McCormick LH. **Pa Med** 1998 Sep;101(9):13
Managed care reform ... ground zero. Thompson DJ. **Pa Med** 1998 Sep;101(9):6, 19
[Perinatal care: advantages and disadvantage of network functioning. Analysis and point-of-view of decision-makers. "Periconceptology decree, first year"] Frydman R. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:247-8 **(Fre)**

METHODS

Health care in Egypt [letter; comment] Sallam I. **Lancet** 1998 Nov 14;352(9140):1632. Comment on: Lancet 1998 Jul 11;352(9122):123.

ORGANIZATION & ADMINISTRATION

The ramifications of regulatory reform. Moyers PA. **Am J Occup Ther** 1998 Oct;52(9):702-8 (28 ref.)
Here we go again: repeating implementation errors. Light DW. **BMJ** 1999 Sep 4;319(7210):616-8
The Ljubljana Charter on Reforming Health Care. 18 June 1996. **Bull World Health Organ** 1999;77(1):48-9
Towards evidence-based health care reform. Vienonen M, et al. **Bull World Health Organ** 1999;77(1):44-7
A modern public health crisis: a physician speaks about healthcare in post-Glasnost Russia [interview by Steve Heilig] **Camb Q Healthc Ethics** 1999 Spring;8(2):257-8
Response to "Euthanasia and health reform in Canada" by Michael Stingl (CQ vol 7, no 4). Euthanasia and justice. Reinders HS. **Camb Q Healthc Ethics** 1999 Spring; 8(2):238-40
Solid doctor-patient relationship. Key to the success of the new Canadian Blood System [news] Dion H. **Can Fam Physician** 1998 Nov;44:2582
Americanization of our health care [editorial] Mulligan PK. **Can Fam Physician** 1998 Nov;44:2351-3, 2363-5 (11 ref.) **(Eng, Fre)**
Closer to home: the case for experiential participation in health reform. Higgins JW. **Can J Public Health** 1999 Jan-Feb;90(1):30-4
The role of community organizations in the transformation of the health services delivery system in the Montreal metropolitan area. Rodriguez R, et al. **Can J Public Health** 1999 Jan-Feb;90(1):41-4
Ontario's attempt at primary care reform hits another snag. OReilly M. **CMAJ** 1998 Dec 1;159(11):1398-400
Reform of health insurance in the Federation of Bosnia and Herzegovina. Ljubić B, et al. **Croat Med J** 1999 Jun; 40(2):160-5
Reform of health insurance in Croatia. Turek S. **Croat Med J** 1999 Jun;40(2):143-51
Restructuring the primary health care services and changing profile of family physicians in Turkey. Ersoy F, et al. **Fam Pract** 1998 Dec;15(6):576-8
Attitudes of organized labor officials toward health care issues: an exploratory survey of Alabama labor officials. Fottler MD, et al. **Health Care Manage Rev** 1999 Spring; 24(2):71-82
Reorganization and consolidation of a safety program. Classic KL, et al. **Health Phys** 1999 Feb;76(2 Suppl):S27-31
When a leader is confronted with change. O'Neil E. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):95-6
The Federal Employees Health Benefits Plan: implications for medicare reform. Feldman R, et al. **Inquiry** 1999 Summer;36(2):188-99
Effects of state reforms on health insurance coverage of adults. Sloan FA, et al. **Inquiry** 1998 Fall;35(3):280-93
Medicare "premium supports". Swartz K. **Inquiry** 1999 Spring;36(1):5-7
An alternative approach to measuring the effects of insurance market reforms. Zuckerman S, et al. **Inquiry** 1999 Spring; 36(1):44-56
Internal practice barriers for non-physician practitioners in the veterans healthcare system. Kizer KW, et al. **J Allied Health** 1998 Fall-Winter;27(4):183-7
The doctor-patient relationship: challenges, opportunities, and strategies. Dorr Goold S, et al. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S26-33 (51 ref.)
Managed care and Medicaid reform in Tennessee: the impact of TennCare on access and health-seeking behavior. Lyons W, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):328-37
Genuine federalism in the Russian health care system: changing roles of government. Chernichovsky D, et al. **J Health Polit Policy Law** 1999 Feb;24(1):115-44 (38 ref.)
"Changing childbirth" in the United Kingdom: lessons for U.S. health policy. Declercq E. **J Health Polit Policy Law** 1998 Oct;23(5):833-59 (90 ref.)
Dialogue or monologue? The limits to lessons that can be learned. Fierlbeck K. **J Health Polit Policy Law** 1999 Jun; 24(3):627-34
German health care reform: the next steps. Jost T. **J Health Polit Policy Law** 1998 Aug;23(4):697-711 (42 ref.)
Health sector reform in Lebanon. Ammar W, et al. **J Med Liban** 1998 Nov-Dec;46(6):328-34 (18 ref.)
The opportunity that is nursing [editorial] O'Neill E, et al. **J Nurs Educ** 1998 Oct;37(7):287-8
Low morale in the British National Health Service (NHS): the causes and some proposals for improvement. NHS Consultants' Association. **J Public Health Policy** 1999; 20(2):133-7
The reform of the reform of the British National Health Service. Fisher P. **J Public Health Policy** 1999;20(2):138-48
The neoliberal triad of anti-health reforms: government budget cutting, deregulation, and privatization. Terris M. **J Public Health Policy** 1999;20(2):149-67
Labour's health reforms begin [news] Dean M. **Lancet** 1999 Apr 3;353(9159):1163
Ethics committees: is reform in order? [editorial; comment] [see comments] Loblay RH, et al. **Med J Aust** 1999 Jan 4;170(1):9-10 (16 ref.). Comment on: Med J Aust 1999 Jan 4;170(1):26-8. Comment in: Med J Aust 1999 Jul 5;171(1):51-2.
Physicians, take charge! Sawhney KK. **Mich Med** 1999 May; 98(5):56, 55
Can the Feres doctrine survive TRICARE, and should it? Shelley JJ. **Mil Med** 1998 Oct;163(10):682-6
Licensing of medical practitioners [letter; comment] Boswell R. **N Z Med J** 1998 Aug 28;111(1072):328; discussion 329 . Comment on: N Z Med J 1998 Jun 26;111(1068):235-6.
Hitting the wall [editorial] Anderson CA. **Nurs Outlook** 1999 Jul-Aug;47(4):153-4
The C.J. Shanaberger lecture: politics and change. Selbst PL. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):317-25
The Verona Initiative: a new "arena" for debate on health in Europe. Bertinato L. **Promot Educ** 1999 Mar;6(1):19-20, 37
Putting relationship back into the practice of medicine. Sluyter D. **Promot Educ** 1999 Mar;6(1):12-3
From rhetoric to reality: the changing face of public health nursing in southern Ontario. Rafael AR. **Public Health Nurs** 1999 Feb;16(1):50-9
Federal programs and Indian country: a time for reinvention [comment] Boufford JI, et al. **Public Health Rep** 1998 Jan-Feb;113(1):34-5. Comment on: Public Health 1998 Jan-Feb;113(1):22-33.
Challenges to Native American health care [see comments] Noren J, et al. **Public Health Rep** 1998 Jan-Feb; 113(1):22-33. Comment in: Public Health 1998 Jan-Feb;113(1):34-5.
From the horse's mouth: the regulations to the Medical Schemes Act--Part I. Masobe P. **S Afr Med J** 1999 May; 89(5):515-6
The reform of the rural cooperative medical system in the People's Republic of China: interim experience in 14 pilot counties. Carrin G, et al. **Soc Sci Med** 1999 Apr; 48(7):961-72
Drug policy in China: pharmaceutical distribution in rural areas. Dong H, et al. **Soc Sci Med** 1999 Mar;48(6):777-86
[The social security reform: wide-ranging effects on companies as well as occupational health services (see comments] Plomp HN, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1369-73 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1374-8. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1379-82. **(Dut)**
[Fractures and frontiers] Chabot JM. **Rev Prat** 1999 Feb 15; 49(4):407-8 **(Fre)**
[The management of medical care quality--the basis for reforming the treatment and diagnosis process] Savvin IuN, et al. **Voen Med Zh** 1999 Feb;320(2):30-9 **(Rus)**

STANDARDS

How to survive "mis-managed care" [editorial] Pulec JL. **Ear Nose Throat J** 1998 Nov;77(11):874
Reducing health inequalities: Britain's latest attempt. Illsley R. **Health Aff (Millwood)** 1999 May-Jun;18(3):45-6
Acting on the evidence to reduce inequalities in health. Marmot M. **Health Aff (Millwood)** 1999 May-Jun; 18(3):42-4
Identifying achievable benchmarks of care: concepts and methodology. Kiefe CI, et al. **Int J Qual Health Care** 1998 Oct;10(5):443-7
24-hour programs: great idea or unrealistic? Igoe JA, et al. **Occup Med** 1998 Oct-Dec;13(4):727-33, iv (16 ref.)
HMOs agree on standard site visit protocol [news] **Pa Med** 1998 Oct;101(10):2

STATISTICS & NUMERICAL DATA

Using health outcomes data to compare plans, networks and providers [see comments] Palmer RH. **Int J Qual Health Care** 1998 Dec;10(6):477–83. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.

TRENDS

The future of academic emergency medicine [editorial] Moorhead J. **Acad Emerg Med** 1999 Apr;6(4):255–8

Health care reform: has it really begun? Marks PA. **Acad Med** 1999 Mar;74(3):210–2

Problems and advantages for oncology in the new German Ländern [news] **Ann Oncol** 1999 Mar;10(3):247–8

More on a sustainable medicine. Massey RU. **Conn Med** 1998 Aug;62(8):499–500

Using outcomes data to compare plans, networks, and providers: what is the state of the art? [editorial; comment] Nerenz DR. **Int J Qual Health Care** 1998 Dec;10(6):463–5 . Comment on: Int J Qual Health Care 1998 Dec;10(6):477–83. Comment on: Int J Qual Health Care 1998 Dec;10(6):485–90. Comment on: Int J Qual Health Care 1998 Dec;10(6):491–501. Comment on: Int J Qual Health Care 1998 Dec;10(6):509–20. Comment on: Int J Qual Health Care 1998 Dec;10(6):521–30. Comment on: Int J Qual Health Care 1998 Dec;10(6):547–53.

Still attractive after all these years? Magnet hospitals in a changing health care environment. Buchan J. **J Adv Nurs** 1999 Jul;30(1):100–8

30th Bethesda Conference: The Future of Academic Cardiology. Task force 3: teaching. Gregoratos G, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1120–7

The future: imagine the possibilities, Part II--health care [editorial] Sullivan EJ. **J Prof Nurs** 1998 Sep–Oct; 14(5):261–2

Do targeted efforts for the rural underserved help kill comprehensive reform? Taylor DH Jr. **J Rural Health** 1999 Winter;15(1):55–60 (27 ref.)

Financing children's health care needs in the next century. Schoen C, et al. **J Urban Health** 1998 Dec;75(4):639–59 (26 ref.)

Sensitively restructuring health services in Kosovo [news] Agovino T. **Lancet** 1999 Sep 11;354(9182):927

Nothing exceeds like success: managed care comes to Medicaid in New York City. Sparer MS, et al. **Milbank Q** 1999;77(2):205–23, 174

Health care reform at the close of the 20th century. Blumenthal D. N **Engl J Med** 1999 Jun 17;340(24):1916–20

Impacting the future. Kroser LS. **Pa Med** 1998 Oct;101(10):10

Brundtland's World Health Organization: a test case for United Nations reform. Robbins A. **Public Health Rep** 1999 Jan–Feb;114(1):30–9

With cap in hand. Carmichael D. S **Afr Med J** 1998 Dec; 88(12):1552–3

[Italy: a national health service with a tumultuous history] Vicarelli G, et al. **Cah Sociol Demogr Med** 1999 Jan–Mar; 39(1):5–23 (Eng. Abstr.) **(Fre)**

[Public health in Bavaria. Social political principles, revision of responsibilities, prospects] Baumann R. **Gesundheitswesen** 1998 Aug;60 Suppl 1:S2–3 **(Ger)**

[Social change necessitates a reform of the medical profession. A contribution to the public health policy discussion regarding the future of health care in Germany] Kleeberg UR. **Med Klin** 1999 Jun 15;94(6):355–8 **(Ger)**

[Concept of development of public health and medical science in the Russian Federation] **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):4–10 **(Rus)**

HEALTH CARE RESEARCH see **HEALTH SERVICES RESEARCH**

HEALTH CARE SECTOR

see related
HEALTH SERVICES NEEDS AND DEMAND
MARKETING OF HEALTH SERVICES

Y2K repairs unfinished in health care sector [news] Landis NT. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1048, 1053, 1057

Health expenditure and finance: who gets what? Doherty J, et al. **Bull World Health Organ** 1999;77(2):156–9

Policy as product. Morality and metaphor in health policy discourse. Malone RE. **Hastings Cent Rep** 1999 May–Jun; 29(3):16–22

Mission statement rationales and organizational alignment in the not-for-profit health care sector. Bart CK, et al. **Health Care Manage Rev** 1998 Fall;23(4):54–69

The role of government in health insurance markets with adverse selection. Feldman R, et al. **Health Econ** 1998 Dec; 7(8):659–70 (32 ref.)

Internal markets and health care efficiency: a multiple-output stochastic frontier analysis. Gerdtham UG, et al. **Health Econ** 1999 Mar;8(2):151–64

Commentary: excess capacity, a commentary on markets, regulation, and values [comment] Friedman B. **Health Serv Res** 1999 Feb;33(6):1669–82 (31 ref.). Comment on: Health Serv Res 1999 Feb;33(6):1651–68.

Marshfield Clinic, physician networks, and the exercise of monopoly power. Greenberg W. **Health Serv Res** 1998 Dec;33(5 Pt 2):1461–76

Excess capacity: markets regulation, and values [see comments] Madden CW. **Health Serv Res** 1999 Feb; 33(6):1651–68 (31 ref.). Comment in: Health Serv Res 1999 Feb;33(6):1669–82.

Healtheon + WebMD. Hype helps, but success sells [news] **Hosp Health Netw** 1999 Jul;73(7):28

An interview with Jim Clark [interview by Michael Menduno] Clark J. **Hosp Health Netw** 1999 Feb;73(2):66–7

Quality in consumer-driven health systems. Reinhardt UE. **Int J Qual Health Care** 1998 Oct;10(5):385–94

Health informatics: linking investment to value. Stead WW, et al. **J Am Med Inform Assoc** 1999 Sep–Oct;6(5):341–8

Managed care in rural markets: availability and enrollment. Wysong JA, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):72–84

Selling bits and pieces of humans to make babies: The gift of the magi revisited. Cohen CB. **J Med Philos** 1999 Jun; 24(3):288–306

Biotechnology and commodification within health care. Hanson MJ. **J Med Philos** 1999 Jun;24(3):267–87

Commodifying the polyvalent good of health care. Kaveny MC. **J Med Philos** 1999 Jun;24(3):207–23

The commodification of medical and health care: the moral consequences of a paradigm shift from a professional to a market ethic. Pellegrino ED. **J Med Philos** 1999 Jun; 24(3):243–66

Thanks, but no thanks: breast cancer group declines funding [news] Roemer J. **J Natl Cancer Inst** 1999 Jan 20; 91(2):108–9

Rhetoric to practice: the challenge of collaboration of academe and industry. Mann S, et al. **J Nurs Educ** 1999 Jan;38(1):5–9

Health information in the developing world. Lown B, et al. **Lancet** 1998;.SII34–8

Commentary: "efficiency and civility in maternity care" or "how much jello can a mother eat?" Reinhardt UE. **Med Care Res Rev** 1999 Mar;56(1):47–54

The market for occupational medicine managed care. Leone FH, et al. **Occup Med** 1998 Oct–Dec;13(4):869–79, v (4 ref.)

Treating the least well off [letter] Phillips DE. **Psychiatr Serv** 1999 Feb;50(2):268–9

Health sector speaks in favour of tobacco bill. Naudé M. S **Afr Med J** 1998 Oct;88(10):1294

How competitive forces mold strategy in academic surgery [see comments] Souba WW. **Surgery** 1999 Jun; 125(6):616–29. Comment in: Surgery 1999 Jun;125(6):632–4.

Health care stocks make slow recovery. Williams B. **Tenn Med** 1999 Apr;92(4):121–2

Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin. Murozuka T, et al. **Vox Sang** 1999;76(3):181–6

[The phenomenon of globalization in the pharmaceutical industry] Barral E, et al. **Ann Pharm Fr** 1998;56(6):277–81 (Eng. Abstr.) **(Fre)**

HISTORY

Where are we now in British health economics? Blaug M. **Health Econ** 1998 Aug;7 Suppl 1:S63–78

LEGISLATION & JURISPRUDENCE

Increasing consolidation in healthcare markets: what are the antitrust policy implications? Haas-Wilson D, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1403–19 (28 ref.)

Antitrust enforcement in the healthcare industry: the expanding scope of state activity. Hellinger FJ. **Health Serv Res** 1998 Dec;33(5 Pt 2):1477–94 (35 ref.)

Senator Bill Frist responds to Y2K issues in the health care industry. **Tenn Med** 1999 May;92(5):171

ORGANIZATION & ADMINISTRATION

Social capital and community development: practitioner emptor. Labonte R. **Aust N Z J Public Health** 1999 Aug; 23(4):430–3 (12 ref.)

The implementation of business process reengineering in American and Canadian hospitals. Ho SJ, et al. **Health Care Manage Rev** 1999 Spring;24(2):19–31

Recent determinants of new entry of HMOs into a Medicare risk contract: a diversification strategy. Pai CW, et al. **Inquiry** 1999 Spring;36(1):78–89

An alternative approach to measuring the effects of insurance market reforms. Zuckerman S, et al. **Inquiry** 1999 Spring; 36(1):44–56

"We have the best doctors and the most advanced technology"--advertising in medicine [editorial] Parmley WW. **J Am Coll Cardiol** 1999 Mar;33(3):894

Managed care arrives in Latin America [editorial; comment] Pérez-Stable EJ. N **Engl J Med** 1999 Apr 8;340(14):1110–2 . Comment on: N Engl J Med 1999 Apr 8;340(14):1131–6.

The exportation of managed care to Latin America [see comments] Stocker K, et al. N **Engl J Med** 1999 Apr 8; 340(14):1131–6. Comment in: N Engl J Med 1999 Apr 8;340(14):1110–2.

Consumer is not king in the health-care marketplace [editorial] D'Ambrosia R. **Orthopedics** 1998 Dec; 21(12):1247

The impact of market oriented reforms on choice and information: a case study of cataract surgery in outer London and Stockholm. Fotaki M. **Soc Sci Med** 1999 May; 48(10):1415–32

Resource dependency, doctors and the state: quality control in Sweden. Garpenby P. **Soc Sci Med** 1999 Aug; 49(3):405–24

Mandatory pooling as a supplement to risk-adjusted capitation payments in a competitive health insurance market. Van Barneveld EM, et al. **Soc Sci Med** 1998 Jul; 47(2):223–32

STANDARDS

Improving the quality of health care. Regulatory realities and hopes [comment] Miller VG. **Milbank Q** 1998; 76(4):745–7. Comment on: Milbank Q 1998 ;76(4):709–31.

Towards equity in health in an unequal society. Bloom G, et al. **Soc Sci Med** 1998 Nov;47(10):1529–38

[Maintenance and obsolescence of medical devices] Ancellin J. **Ann Fr Anesth Reanim** 1999 Feb;18(2):258–60 (Eng. Abstr.) **(Fre)**

[Quality and accreditation in health facilities (letter; comment)] Maunand B. **Presse Med** 1998 Jun 13; 27(21):1013. Comment on: Presse Med 1998 Jan 31;27(4):166–71. **(Fre)**

STATISTICS & NUMERICAL DATA

Technology. It's gonna cost you [news] **Hosp Health Netw** 1998 Sep 20;72(18):12

The Health Care 250. Serb C. **Hosp Health Netw** 1999 Apr; 73(4):38–40, 42–4, 46–8

Estimating the indirect effect of hospitals via complementary health care firms. Greene BB Jr. **J Health Care Finance** 1998 Winter;25(2):67–74

TRENDS

Clinical nutrition: opportunity in a changing health care environment. Jensen GL, et al. **Am J Clin Nutr** 1998 Nov; 68(5):983–90

Social capital and its relevance to health and family policy. Leeder S, et al. **Aust N Z J Public Health** 1999 Aug; 23(4):424–9 (12 ref.)

Health plans' strategic responses to a changing marketplace [comment] Halvorson GC. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):28–9. Comment on: Health Aff (Millwood) 1999 Mar–Apr;18(2):7–24.

The managerial revolution in the U.S. health care sector: lessons from the U.S. economy. Herzlinger RE. **Health Care Manage Rev** 1998 Summer;23(3):19–29 (86 ref.)

Academic health centers in turbulent times: strategies for survival. Topping S, et al. **Health Care Manage Rev** 1999 Spring;24(2):7–18 (52 ref.)

Do you sincerely want to be rich? Reinhardt U. **Health Econ** 1999 Jun;8(4):355–62

Defining competition in markets: why and how? Bernstein AB, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1421–38 (35 ref.)

Nursing home performance under case-mix reimbursement: responding to heavy-care incentives and market changes. Davis MA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 1):815–34

Managed care, market power, and monopsony. Pauly MV. **Health Serv Res** 1998 Dec;33(5 Pt 2):1439–60

Trends. Info tech meets biz strategy [news] **Hosp Health Netw** 1998 Oct 20;72(20):13

The year that was--what it means for 1999. Blecher MB, et al. **Hosp Health Netw** 1998 Dec 5–20;72(23–24):26–8, 30–4

Strategic surgery. Feorene BT, et al. **Hosp Health Netw** 1999 Feb;73(2):68, 70

Off target [published erratum appears in Hosp Health Netw 1999 Mar;73(3):12] Hudson T, et al. **Hosp Health Netw** 1999 Jan;73(1):34–9

Fringe benefits. More séance than science? Leifer J. **Hosp Health Netw** 1998 Dec 5–20;72(23–24):66

Net profits. Menduno M. **Hosp Health Netw** 1999 Mar; 73(3):44–8, 50, 2

Boom vs. bust. Serb C. **Hosp Health Netw** 1999 Mar; 73(3):58–9, 2

High on health care [news] Serb C. **Hosp Health Netw** 1999 Feb;73(2):28

Mergers. Gentlemen's agreement. Washam C. **Hosp Health Netw** 1998 Sep 20;72(18):43–4

The future is in the present: the impact of generations. Aschenbrener CA. **J Am Coll Dent** 1998 Winter;65(4):23–8

The health care industry: in evolution or revolution? Cleverley WO. **J Health Care Finance** 1999 Summer; 25(4):2–14

Consolidation in the health care sector. Magel JS. **J Health Care Finance** 1999 Spring;25(3):22–8

The radical revolution of radiology. Nauert RC. **J Health Care Finance** 1998 Winter;25(2):9–19 (0 ref.)

Benchmarking physicians' practices: trends toward the millennium. Rodeghero JA. **J Health Care Finance** 1999 Summer;25(4):15–37

Markets, governments, and HMO development in the 1990s. Balla SJ. **J Health Polit Policy Law** 1999 Apr;24(2):215–38 (65 ref.)

Medicine and the market: a research agenda. Callahan D. **J Med Philos** 1999 Jun;24(3):224–42

More questions than answers: the commodification of health care. Wildes KW. **J Med Philos** 1999 Jun;24(3):307–11

Better health in developing countries: are sector-wide approaches the way of the future? Cassels A, et al. **Lancet** 1998 Nov 28;352(9142):1777–9

A survey of the Hong Kong health sector: past, present and

future. Gauld RD. **Soc Sci Med** 1998 Oct;47(7):927–39

HEALTH CARE SEEKING BEHAVIOR see **PATIENT ACCEPTANCE OF HEALTH CARE**

HEALTH CARE SURVEYS

Community-based survey of paediatric diarrhoeal morbidity and home treatment practices in Finland. Rautanen T, et al. **Acta Paediatr** 1998 Sep;87(9):986–90

Faculty and resident opinions regarding the role of morbidity and mortality conference. Harbison SP, et al. **Am J Surg** 1999 Feb;177(2):136–9

A survey of the practice of thoracic epidural analgesia in the United Kingdom. Romer HC, et al. **Anaesthesia** 1998 Oct;53(10):1016–22

Contacting GP surgeries over Christmas. Study seems more like investigative journalism than public health research [letter] Houghton PG. **BMJ** 1999 Aug 21;319(7208):513; discussion 514

Our Healthier Nation: are general practitioners willing and able to deliver? A survey of attitudes to and involvement in health promotion and lifestyle counselling. McAvoy BR, et al. **Br J Gen Pract** 1999 Mar;49(440):187–90

Application of the modified method of "rapid appraisal to assess community health needs" for making rapid city health profiles and city action plans for health. Sogoric S. **Croat Med J** 1998 Sep;39(3):267–75

The National Survey of Local Anaesthesia for Ocular Surgery [letter; comment] Eke T, et al. **Eye** 1998;12 (Pt 4):750. Comment on: Eye 1998;12 (Pt 3a):489.

Emotional reactions of haemophilia health care providers. Brown LK, et al. **Haemophilia** 1999 Mar;5(2):127–31

Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme. Jennings I, et al. **Haemophilia** 1998 Sep; 4(5):739–46

Medical care for haemophilia. Nuss R, et al. **Haemophilia** 1998 Nov;4(6):806–11

Performance. Managed care update [news] **Hosp Health Netw** 1998 Nov 20;72(22):17–8

How tumor markers are used in the routine follow-up of breast and colorectal cancer. A survey of 29 Italian hospitals. Gion M, et al. **Int J Biol Markers** 1998 Jul–Sep; 13(3):124–38

Patient satisfaction with clinical trial participation. Verheggen FW, et al. **Int J Qual Health Care** 1998 Aug; 10(4):319–30

Access to medical care for adolescents: results from the 1997 Commonwealth Fund Survey of the Health of Adolescent Girls. Klein JD, et al. **J Adolesc Health** 1999 Aug; 25(2):120–30

Age and anesthetic practice: a regional perspective. Travis KW, et al. **J Clin Anesth** 1999 May;11(3):175–86

Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. Guyatt GH, et al. **J Clin Epidemiol** 1999 Mar;52(3):187–92

Functional status of elderly home care users: do subjects, informal and professional caregivers agree? Santos-Eggimann B, et al. **J Clin Epidemiol** 1999 Mar; 52(3):181–6

Monitoring changes in home health care: a comparison of two national surveys. Mullner RM, et al. **J Med Syst** 1999 Feb;23(1):21–6

A population-based survey of immunization coverage in children aged 2 years and younger in New South Wales. Sullivan EA, et al. **J Paediatr Child Health** 1998 Aug; 34(4):342–5

The opioid contract in the management of chronic pain [see comments] Fishman SM, et al. **J Pain Symptom Manage** 1999 Jul;18(1):27–37. Comment in: J Pain Symptom Manage 1999 Jul;18(1):6–8.

Quality of paediatric IDDM care in Germany: a multicentre analysis. German Paediatric Diabetology Group. Hecker W, et al. **J Pediatr Endocrinol Metab** 1999 Jan–Feb; 12(1):31–8

Access to complementary medicine in general practice: survey in one UK health authority. Wearn AM, et al. **J R Soc Med** 1998 Sep;91(9):465–70

Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. Thumboo J, et al. **J Rheumatol** 1999 Jan;26(1):97–102

A survey of Norwegian telemedicine. Uldal SB. **J Telemed Telecare** 1999;5(1):32–7

National survey of the use of endomyocardial biopsy in Japan. Hiramitsu S, et al. **Jpn Circ J** 1998 Dec; 62(12):909–12

Mechanical ventilation in chronic respiratory insufficiency: report on an Italian nationwide survey. The Italian Telethon Committee and the AIPO Study Group on Pulmonary Rehabilitation and Intensive Care. Gasperini M, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):394–9

Development of a consumer survey for behavioral health services. Eisen SV, et al. **Psychiatr Serv** 1999 Jun; 50(6):793–8

The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. Roderick PJ, et al. **QJM** 1998 Aug;91(8):581–7

Perceived monogamy and type of clinic as barriers to seeking care for suspected STD or HIV infection: results from a brief survey of low-income women attending Women, Infants, and Children (WIC) clinics in Missouri. Crosby RA, et al. **Sex Transm Dis** 1999 Aug;26(7):399–403

Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the health survey for England. Dong W, et al. **Soc Sci Med** 1998 Dec; 47(11):1773–80

A survey of vision screening policy of preschool children in the United States. Ciner EB, et al. **Surv Ophthalmol** 1999 Mar–Apr;43(5):445–57

The case for standardization of transfusion medicine practices in French blood banks. Moncharmont P, et al. **Transfus Med** 1999 Mar;9(1):81–5

Trends in ipecac use: a survey of poison center staff. Marchbanks B, et al. **Vet Hum Toxicol** 1999 Feb;41(1):47–8

Women's Health Australia: recruitment for a national longitudinal cohort study. Brown WJ, et al. **Women Health** 1998;28(1):23–40

[Anesthetics in surgery] Auroy Y, et al. **Ann Fr Anesth Reanim** 1998;17(11):1324–41 **(Fre)**

[Anesthetics in obstetrics] Auroy Y, et al. **Ann Fr Anesth Reanim** 1998;17(11):1342–6 **(Fre)**

[Anesthetics according to characteristics of patients, establishments and indications] Auroy Y, et al. **Ann Fr Anesth Reanim** 1998;17(11):1311–6 **(Fre)**

[Synthesis and future prospects] Boulard G, et al. **Ann Fr Anesth Reanim** 1998;17(11):1387–91 **(Fre)**

[Justification of the survey] Clergue F, et al. **Ann Fr Anesth Reanim** 1998;17(11):1299–301 **(Fre)**

[Anesthetics for emergencies] Laxenaire MC, et al. **Ann Fr Anesth Reanim** 1998;17(11):1352–62 **(Fre)**

[Anesthetics for ambulatory patients] Laxenaire MC, et al. **Ann Fr Anesth Reanim** 1998;17(11):1363–73 **(Fre)**

[Organization and techniques of anesthesia] Laxenaire MC, et al. **Ann Fr Anesth Reanim** 1998;17(11):1317–23 **(Fre)**

[Anesthetics excluding surgery and obstetrics] Lienhart A, et al. **Ann Fr Anesth Reanim** 1998;17(11):1347–51 **(Fre)**

[Anesthetics and transfusion practices] Lienhart A, et al. **Ann Fr Anesth Reanim** 1998;17(11):1374–86 **(Fre)**

[Pharmacoepidemiology of diabetes: contribution of a survey of health insurance cases] Vauzellé-Kervroedan F, et al. **Diabetes Metab** 1999 Jun;25(2):163–71 (Eng. Abstr.) **(Fre)**

[A 1993–1995 epidemiological survey of home parenteral nutrition in approved centers for adults in France] Messing B, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):413–8 (Eng. Abstr.) **(Fre)**

[The role of the medical corps in a mass screening program for cervical cancer. The program "Female Health Action in 3 urban districts of Lyons] Mignotte H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Sep;27(5):501–7 (Eng. Abstr.) **(Fre)**

[Patient satisfaction as an index of the quality of medical care (according to data of a sociologic survey)] Abashin NN. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):31–3 (Eng. Abstr.) **(Rus)**

ECONOMICS

Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions [see comments] Barr D, et al. **Am J Public Health** 1999 Jan;89(1):19–24. Comment in: Am J Public Health 1999 Jan;89(1):11–3.

HISTORY

NHS at 50. The hospital surveys, 1942–44. National Health Service. Godber G. **Lancet** 1998 Jul 4;352(9121):49–50

METHODS

The use of inexpensive computer-based scanning survey technology to perform medical practice satisfaction surveys. Shumaker L, et al. **Am J Med Qual** 1998 Winter; 13(4):174–80

Mammography use by elderly women: a methodological comparison of two national data sources. May DS, et al. **Ann Epidemiol** 1998 Oct;8(7):439–44

Primer postcard improves postal survey response rates. Pirotta M, et al. **Aust N Z J Public Health** 1999 Apr; 23(2):196–7

The relevance of ethnic monitoring in the experience of Haringey Healthcare NHS trust community family planning clinics. Christopher E. **Br J Fam Plann** 1999 Jan; 24(4):123–7

Drug information services: initial experiences in Dresden [letter] Schwarz UI, et al. **Eur J Clin Pharmacol** 1998 Oct; 54(8):667–8

The National Survey of Local Anaesthesia for Ocular Surgery. I. Survey methodology and current practice. Eke T, et al. **Eye** 1999 Apr;13 (Pt 2):189–95

National survey of local anaesthesia for ocular surgery: early report [letter; comment] [see comments] Kamath G, et al. **Eye** 1998;12 (Pt 3a):489. Comment on: Eye 1997;11 (Pt 6):847–9. Comment in: Eye 1998;12 (Pt 4):750.

More physicians: improved availability or induced demand? Carlsen F, et al. **Health Econ** 1998 Sep;7(6):495–508

The effect of methodological differences in two survey's estimates of the percentage of employers sponsoring health insurance. Hing E, et al. **Inquiry** 1999 Summer;36(2):212–20

The design of Healthcare for Communities: a study of health care delivery for alcohol, drug abuse, and mental health conditions. Sturm R, et al. **Inquiry** 1999 Summer; 36(2):221–33

Reporting comparative results from hospital patient surveys. Rogers G, et al. **Int J Qual Health Care** 1999 Jun; 11(3):251–9

A randomised controlled trial of postal versus interviewer administration of a questionnaire measuring satisfaction with, and use of, services received in the year before death. Addington-Hall J, et al. **J Epidemiol Community Health** 1998 Dec;52(12):802–7

Special issues in assessing care of Medicaid recipients. Brown JA, et al. **Med Care** 1999 Mar;37(3 Suppl):MS79–88

Epilogue: Early lessons from CAHPS Demonstrations and Evaluations. Consumer Assessment of Health Plans Study. Carman KL, et al. **Med Care** 1999 Mar;37(3 Suppl):MS97–105

Consumer Assessment of Health Plans Study (CAHPS). Foreword. Crofton C, et al. **Med Care** 1999 Mar;37(3 Suppl):MS1–9 (25 ref.)

Comparing telephone and mail responses to the CAHPS survey instrument. Consumer Assessment of Health Plans Study. Fowler FJ Jr, et al. **Med Care** 1999 Mar;37(3 Suppl):MS41–9

Respondent selection by mail: obtaining probability samples of health plan enrollees. Gallagher PM, et al. **Med Care** 1999 Mar;37(3 Suppl):MS50–8

The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer Assessment of Health Plans Study. Harris-Kojetin LD, et al. **Med Care** 1999 Mar; 37(3 Suppl):MS10–21

Psychometric properties of the CAHPS 1.0 survey measures. Consumer Assessment of Health Plans Study. Hays RD, et al. **Med Care** 1999 Mar;37(3 Suppl):MS22–31

Using a hand-held computer to collect data in an orthopedic outpatient clinic: a randomized trial of two survey methods. McBride JS, et al. **Med Care** 1999 Jul;37(7):647–51

Making survey results easy to report to consumers: how reporting needs guided survey design in CAHPS. Consumer Assessment of Health Plans Study. McGee J, et al. **Med Care** 1999 Mar;37(3 Suppl):MS32–40

Special issues addressed in the CAHPS survey of Medicare managed care beneficiaries. Consumer Assessment of Health Plans Study. Schnaier JA, et al. **Med Care** 1999 Mar;37(3 Suppl):MS69–78

The impact of having parents report about both their own and their children's experiences with health insurance plans. Shaul JA, et al. **Med Care** 1999 Mar;37(3 Suppl):MS59–68

Accuracy of self-reported health services use and patterns of care among urban older adults. Wallihan DB, et al. **Med Care** 1999 Jul;37(7):662–70

Translating the CAHPS 1.0 Survey Instruments into Spanish. Consumer Assessment of Health Plans Study. Weidmer B, et al. **Med Care** 1999 Mar;37(3 Suppl):MS89–96

Counting the uninsured using state-level hospitalization data. Turner C, et al. **Public Health Rep** 1999 Mar–Apr; 114(2):149–56

The meaning of patient satisfaction: an explanation of high reported levels. Williams B, et al. **Soc Sci Med** 1998 Nov; 47(9):1351–9

[Methodology of the survey] Péquignot F, et al. **Ann Fr Anesth Reanim** 1998;17(11):1302–10 **(Fre)**

STANDARDS

Not listening to patients—the use and misuse of patient satisfaction studies. Crawford MJ, et al. **Int J Soc Psychiatry** 1999 Spring;45(1):1–6

STATISTICS & NUMERICAL DATA

The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: results from a survey of 1,500 physicians in the United States. Bach PB, et al. **Chest** 1999 Jun; 115(6):1563–9

What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Sclar DA, et al. **Int J Psychiatry Med** 1998; 28(4):407–19

Response rate in patient satisfaction research: an analysis of 210 published studies. Sitzia J, et al. **Int J Qual Health Care** 1998 Aug;10(4):311–7

National survey on prophylactic cranial irradiation: differences in practice patterns between medical and radiation oncologists. Cmelak AJ, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):157–62

Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Wang JJ, et al. **Invest Ophthalmol Vis Sci** 1999 Jan; 40(1):12–9

Unmet need for eyeglasses: results from the 1994 Robert Wood Johnson Access to Care Survey. Hodges LE, et al. **J Am Optom Assoc** 1999 Apr;70(4):261–5

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Shapiro MF, et al. **JAMA** 1999 Jun 23–30; 281(24):2305–15

[Information for patients with cancer of the colon: results of a survey of gastroenterologists, surgeons, and oncologists of the North region] Adenis A, et al. **Bull Cancer** 1998 Sep;85(9):803–8 (Eng. Abstr.) **(Fre)**

TRENDS

A survey of attitudes and knowledge of geriatricians to

driving in elderly patients. Gillespie ND, et al. **Age Ageing** 1999 Jan;28(1):53–7

A national survey of health-service use in Thai elders. Jitapunkul S, et al. **Age Ageing** 1999 Jan;28(1):67–71

Nursing home characteristics and the development of pressure sores and disruptive behaviour. Ooi WL, et al. **Age Ageing** 1999 Jan;28(1):45–52

HEALTH CARE SYSTEMS see **DELIVERY OF HEALTH CARE**

HEALTH CARE TEAM see **PATIENT CARE TEAM**

HEALTH CARE TECHNOLOGY see **TECHNOLOGY, MEDICAL**

HEALTH CENTERS, AMBULATORY see **AMBULATORY CARE FACILITIES**

HEALTH CLUBS see **FITNESS CENTERS**

HEALTH COSTS, EMPLOYER see **EMPLOYER HEALTH COSTS**

HEALTH DIARIES see **MEDICAL RECORDS**

HEALTH EDUCATION

see related
HEALTH PROMOTION

Promoting breastfeeding through health education at the time of immunizations: a randomized trial from Guinea Bissau [see comments] Jakobsen MS, et al. **Acta Paediatr** 1999 Jul;88(7):741–7. Comment in: Acta Paediatr 1999 Jul;88(7):703–4.

Effect of counselor and client education in nicotine addiction on smoking in substance abusers. Perine JL, et al. **Addict Behav** 1999 May–Jun;24(3):443–7

Alcohol education in licensed premises using brief intervention strategies. Reilly D, et al. **Addiction** 1998 Mar; 93(3):385–98

Tobacco, youth, and sports. Epps RP, et al. **Adolesc Med** 1998 Oct;9(3):483–90, vi (20 ref.)

Prioritizing education about condom use among sexually active adolescent females. Christ MJ, et al. **Adolescence** 1998 Winter;33(132):735–44

Effects of a unit of instruction in mental health on rural adolescents' conceptions of mental illness and attitudes about seeking help. Esters IG, et al. **Adolescence** 1998 Summer;33(130):469–76

Psychological education: studying adolescents' interests from their own perspective. Klingman A. **Adolescence** 1998 Summer;33(130):435–46

Adolescents' perceptions of substance abuse prevention strategies. Lisnov L, et al. **Adolescence** 1998 Summer; 33(130):301–11

Increased protected sex and abstinence among Namibian youth following a HIV risk-reduction intervention: a randomized, longitudinal study. Stanton BF, et al. **AIDS** 1998 Dec 24;12(18):2473–80

HIV/AIDS risks among Native American drug users: key findings from focus group interviews and implications for intervention strategies. Baldwin JA, et al. **AIDS Educ Prev** 1999 Aug;11(4):279–92

Factors influencing attitudes within AIDS service organizations toward the use of research-based HIV prevention interventions. DiFranceisco W, et al. **AIDS Educ Prev** 1999 Feb;11(1):72–86

This is my story: a descriptive analysis of a peer education HIV/STD risk reduction program for women living in housing developments. Downing M, et al. **AIDS Educ Prev** 1999 Jun;11(3):243–61

Perceived AIDS risk among adult arrestee injection drug users in Los Angeles county. Henson KD, et al. **AIDS Educ Prev** 1998 Oct;10(5):447–64

Continuing medical education versus clinic-based STD and HIV education interventions for primary care service providers: replication and extension. Neff JA, et al. **AIDS Educ Prev** 1998 Oct;10(5):417–32

Prevention of alcohol abuse-related birth effects—I. Public education efforts. Abel EL. **Alcohol Alcohol** 1998 Jul–Aug; 33(4):411–6 (45 ref.)

Risky single-occasion drinking amongst young people—definition, correlates, policy, and intervention: a broad overview of research findings. Murgraff V, et al. **Alcohol Alcohol** 1999 Jan–Feb;34(1):3–14 (99 ref.)

Education of nonscientists about new alcohol research: results of two types of presentations plus 6-month follow-up. Erickson CK, et al. **Alcohol Clin Exp Res** 1998 Dec;22(9):1890–7

Heart disease prevention begins in childhood [editorial; comment] McBride PE. **Am Fam Physician** 1999 Apr 15; 59(8):2093, 2097. Comment on: Am Fam Physician 1999 Apr 15;59(8):2211–8.

Interventions to reduce cardiovascular risk factors in children and adolescents [see comments] Washington RL. **Am Fam Physician** 1999 Apr 15;59(8):2211–8 (22 ref.). Comment in: Am Fam Physician 1999 Apr 15;59(8):2073, 2097.

Pathways: a culturally appropriate obesity-prevention program for American Indian schoolchildren. Davis SM, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):796S–802S

Process evaluation in a multisite, primary obesity-prevention trial in American Indian schoolchildren. Helitzer DL, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):816S–824S

Pathways family intervention for third-grade American Indian children. Teufel NI, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):803S–809S

Culturally sensitive AIDS educational videos for African American audiences: effects of source, message, receiver, and context. Herek GM, et al. **Am J Community Psychol** 1998 Oct;26(5):705–43

Reducing HIV risk-associated sexual behavior among African American adolescents: testing the generality of intervention effects. Jemmott JB 3rd, et al. **Am J Community Psychol** 1999 Apr;27(2):161–87

Evaluation of an intervention to reduce sun exposure in children: design and baseline results. Milne E, et al. **Am J Epidemiol** 1999 Jul 15;150(2):164–73

Simple reminder can boost pneumococcal vaccination rates, say researchers [news] **Am J Health Syst Pharm** 1998 Sep 15;55(18):1859, 1863

Health literacy rated low in one third of Medicare managed care enrollees [news] **Am J Health Syst Pharm** 1999 Apr 15;56(8):709–10

Consumer ads build awareness but not understanding of advertised medications, surveys reveal [news] **Am J Health Syst Pharm** 1998 Nov 15;55(22):2344, 2347

Evaluation of an occupational health education program among 11th grade students. Lerman Y, et al. **Am J Ind Med** 1998 Dec;34(6):607–13

"Block the sun, not the fun": evaluation of a skin cancer prevention program for child care centers. Crane LA, et al. **Am J Prev Med** 1999 Jul;17(1):31–7

Use of a preanesthetic video for facilitation of parental education and anxiolysis before pediatric ambulatory surgery [see comments] Cassady JF Jr, et al. **Anesth Analg** 1999 Feb;88(2):246–50. Comment in: Anesth Analg 1999 Feb;88(2):237–9.

Perioperative information and parental anxiety: the next generation [editorial; comment] Kain ZN. **Anesth Analg** 1999 Feb;88(2):237–9. Comment on: Anesth Analg 1999 Feb;88(2):246–50.

Validation of measures of parents' preoperative anxiety and anesthesia knowledge. Miller KM, et al. **Anesth Analg** 1999 Feb;88(2):251–7

A randomized trial of the use of print material and personal contact to improve mammography uptake among screening non-attenders in Singapore. Seow A, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):838–42

Psychosocial factors in nutrition education for hypercholesterolemic children. McHale SM, et al. **Ann Behav Med** 1998 Summer;20(3):233–40

The National Diabetes Education Program: changing the way diabetes is treated [editorial] Clark CM Jr. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):324–6

Health education's contributions to public health in the twentieth century: a glimpse through health promotion's rear-view mirror. Green LW. **Annu Rev Public Health** 1999;20:67–88 (125 ref.)

Personal commitments to achieve awareness and prevention [editorial] Dawes BS. **AORN J** 1998 Oct;68(4):536, 538, 540

Melanoma prevention: evaluation of a health education campaign for primary schools. Bastuji-Garin S, et al. **Arch Dermatol** 1999 Aug;135(8):936–40

Three-year maintenance of improved diet and physical activity: the CATCH cohort. Child and Adolescent Trial for Cardiovascular Health. Nader PR, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):695–704

Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Young P, et al. **Aust N Z J Med** 1999 Feb;29(1):59–65

Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behaviour concerning use of folic acid: cross sectional study. de Walle HE, et al. **BMJ** 1999 Jul 31;319(7205):291–2

Effect of discussion and deliberation on public's views of priority setting. More data are needed for readers to make judgment about study [letter] Hanratty B, et al. **BMJ** 1999 Jul 17;319(7203):189

Health information and interaction on the internet: a survey of female urinary incontinence. Sandvik H. **BMJ** 1999 Jul 3;319(7201):29–32

Sun awareness in school teachers. Fleming C, et al. **Br J Dermatol** 1998 Aug;139(2):280–4

Reducing consultations for symptoms of cystitis using a health education leaflet. Banks JC, et al. **Br J Gen Pract** 1998 Sep;48(434):1595–6

The Western New York Health Resources Project: developing access to local health information. Gray SA, et al. **Bull Med Libr Assoc** 1998 Jul;86(3):335–9

NOAH—New York Online Access to Health: library collaboration for bilingual consumer health information on the Internet. Voge S. **Bull Med Libr Assoc** 1998 Jul; 86(3):326–34

Effect of breastfeeding education on the feeding pattern and health of infants in their first 4 months in the Islamic Republic of Iran. Froozani MD, et al. **Bull World Health Organ** 1999;77(5):381–5

Vaccine safety resource materials for health-care providers and the public. Pless R. **Can Commun Dis Rep** 1998 Sep 1;24(17):141–4 **(Eng, Fre)**

Evaluation of the "Sunny Days, Healthy Ways" sun safety CD-ROM program for children in grades 4 and 5. Buller DB, et al. **Cancer Prev Control** 1999 Jun;3(3):188–95

Television as a medium for psycho-education in South Africa: analysis of calls to a mental health information centre after screening of a TV series on psychiatric disorders. Wessels C, et al. **Cent Afr J Med** 1999 Jan; 45(1):1–3

Preliminary experience with the Internet release of AIDA—an interactive educational diabetes simulator. Lehmann ED. **Comput Methods Programs Biomed** 1998 May;56(2):109–32 (42 ref.)

Contraceptive methods: knowledge sources rated by women and men. Virjo I, et al. **Contraception** 1999 Apr; 59(4):257–63

A retrospective examination of in-home educational visits to reduce childhood lead levels. Schultz B, et al. **Environ Res** 1999 May;80(4):364–8

Risk factors for Plasmodium vivax infection in the Lacandon forest, southern Mexico. Danis-Lozano R, et al. **Epidemiol Infect** 1999 Jun;122(3):461–9

Long-term effects of a psychoeducational psychotherapeutic intervention for schizophrenic outpatients and their key-persons—results of a five-year follow-up. Hornung WP, et al. **Eur Arch Psychiatry Clin Neurosci** 1999; 249(3):162–7

Cancer screening: an educational challenge? Moore MA, et al. **Eur J Cancer Prev** 1999 Feb;8(1):7–16 (113 ref.)

Changes in coronary risk profiles in employees after three years of multifactorial intervention. Martínez-González MA, et al. **Eur J Epidemiol** 1998 Oct;14(7):653–62

Genetic screening of targeted subpopulations: the role of communal discourse in evaluating sociocultural implications. Foster MW, et al. **Genet Test** 1997–98; 1(4):269–74

SOPHE: at the intersection of education, policy, and science and technology. Allegrante JP. **Health Educ Behav** 1999 Aug;26(4):457–64

Lay health advisor activity levels: definitions from the field. Altpeter M, et al. **Health Educ Behav** 1999 Aug; 26(4):495–512

Enhancing community participation in intervention research: farmworkers and agricultural chemicals in North Carolina. Arcury TA, et al. **Health Educ Behav** 1999 Aug; 26(4):563–78

Impact of the Working Well Trial on the worksite smoking and nutrition environment. Biener L, et al. **Health Educ Behav** 1999 Aug;26(4):478–94

Stages of change for increasing fruit and vegetable consumption among adults and young adults participating in the national 5-a-Day for Better Health community studies. Campbell MK, et al. **Health Educ Behav** 1999 Aug; 26(4):513–34

Exercise self-efficacy and its correlates among socioeconomically disadvantaged older adults. Clark DO, et al. **Health Educ Behav** 1999 Aug;26(4):535–46

Health behavior, quality of work life, and organizational effectiveness in the lumber industry. Donaldson SI, et al. **Health Educ Behav** 1999 Aug;26(4):579–91

Weight loss education: the challenge of a new paradigm. Gast J, et al. **Health Educ Behav** 1998 Aug;25(4):464–73 (43 ref.)

Promoting sun protection in children: rationale and challenges. Hill D, et al. **Health Educ Behav** 1999 Jun; 26(3):409–17

Early detection of cervical cancer among Native American women: a qualitative supplement to a quantitative study. Messer L, et al. **Health Educ Behav** 1999 Aug;26(4):547–62

The Falmouth Safe Skin Project: evaluation of a community program to promote sun protection in youth. Miller DR, et al. **Health Educ Behav** 1999 Jun;26(3):369–84

Improving breast cancer control among Latinas: evaluation of a theory-based educational program. Mishra SI, et al. **Health Educ Behav** 1998 Oct;25(5):653–70

Preventing the spread of genital warts: using fear appeals to promote self-protective behaviors. Witte K, et al. **Health Educ Behav** 1998 Oct;25(5):571–85

Chernobyl post-accident management: the ETHOS project. Dubreuil GH, et al. **Health Phys** 1999 Oct;77(4):361–72

Message framing and sunscreen use: gain-framed messages motivate beach-goers. Detweiler JB, et al. **Health Psychol** 1999 Mar;18(2):189–96

Personalized education improves hepatitis B vaccination rate among physicians in Saudi Arabia [letter] Memish ZA, et al. **Infect Control Hosp Epidemiol** 1998 Dec;19(12):887–8

Pediatric practice based evaluation of the Steps to Prevent Firearm Injury program. Oatis PJ, et al. **Inj Prev** 1999 Mar; 5(1):48–52

Risk behaviours and AIDS knowledge in a rural community of Senegal: relationship with sources of AIDS information. Lagarde E, et al. **Int J Epidemiol** 1998 Oct;27(5):890–6

Increasing inequality in ischaemic heart disease morbidity among employed men in Denmark 1981–1993: the need for a new preventive policy. Tüchsen F, et al. **Int J Epidemiol** 1999 Aug;28(4):640–4

Does childhood socioeconomic status influence adult health through behavioural factors? van de Mheen H, et al. **Int J Epidemiol** 1998 Jun;27(3):431–7

Cancer curricula for secondary schools: making the right choice. Pezza PE. **Int J Health Serv** 1998;28(3):593–602

Who should be educated? Education strategies: could children educate their parents? Basdevant A, et al. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S10–2;

discussion S12-3 (7 ref.)
How to tackle the problem early? The role of education in the prevention of obesity. Dietz W. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S7-9 (6 ref.)
How should the obese patient be managed? Possible approaches to a national obesity management network. Hainer V. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S14-8; discussion S18-9 (23 ref.)
School-based approaches for preventing and treating obesity. Story M. **Int J Obes Relat Metab Disord** 1999 Mar;23 Suppl 2:S43-51 (52 ref.)
Brief behavioural skills building intervention for female controlled methods of STD-HIV prevention: outcomes of a randomized clinical field trial. Kalichman SC, et al. **Int J STD AIDS** 1999 Mar;10(3):174-81
HIV knowledge, beliefs and sexual behavior of male heterosexual drug users and non-drug users attending an HIV testing clinic in Israel. Soskolne V, et al. **Isr J Psychiatry Relat Sci** 1998;35(4):307-17
Readability of skin cancer prevention brochures targeting parents of young children. Slaten D, et al. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):997-9
The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. Goldman L, et al. **J Am Coll Cardiol** 1999 Sep;34(3):768-76
The validity and reliability of an asthma knowledge questionnaire used in the evaluation of a group asthma education self-management program for adults with asthma. Allen RM, et al. **J Asthma** 1998;35(7):537-45
You're never too old: a cancer education and risk reduction program for the elderly. List MA, et al. **J Cancer Educ** 1999 Summer;14(2):104-8
Language differences in interpretation of breast cancer health messages. Roche RA, et al. **J Cancer Educ** 1998 Winter; 13(4):226-30
Exposure to a community-level HIV prevention intervention: who gets the message. Walls CT, et al. **J Community Health** 1998 Aug;23(4):281-99
Project DARE: no effects at 10-year follow-up. Lynam DR, et al. **J Consult Clin Psychol** 1999 Aug;67(4):590-3
Sun and the skin: evaluation of a sun awareness program for elementary school students. Gooderham MJ, et al. **J Cutan Med Surg** 1999 Jul;3(5):230-5
Skin cancer screening [letter; comment] Weary PE. **J Cutan Med Surg** 1998 Jul;3(1):49. Comment on: J Cutan Med Surg 1998 Jan;2(3):128-9.
Effectiveness of student assistance programs in Nebraska schools. Scott DM, et al. **J Drug Educ** 1999;29(2):165-74
Correction of normative misperceptions: an alcohol abuse prevention program. Steffian G. **J Drug Educ** 1999; 29(2):115-38
Association between health-related knowledge and the awareness of blood pressure readings. Japan Lifestyle Monitoring Study Group. Tanihara S, et al. **J Epidemiol** 1999 Aug;9(4):245-53
The increasing role of the lay press in patient medical education: help or hindrance? [editorial] Fitzgibbons TC, et al. **J Eval Clin Pract** 1998 May;4(2):85-7
Health literacy and the risk of hospital admission [see comments] Baker DW, et al. **J Gen Intern Med** 1998 Dec; 13(12):791-8. Comment in: J Gen Intern Med 1998 Dec;13(12):850-1.
Racial differences in menopause information and the experience of hot flashes. Grisso JA, et al. **J Gen Intern Med** 1999 Feb;14(2):98-103
Iron deficiency and maternal feeding practices among high-risk urban children. Venkateswaran R, et al. **J Health Care Poor Underserved** 1998 Nov;9(4):381-94
Acute respiratory disease survey in Tripura in case of children below five years of age. Deb SK. **J Indian Med Assoc** 1998 Apr;96(4):111-6
Is knowledge of health behavior associated with low birth weight? Mvula MM, et al. **J Matern Fetal Med** 1999 May-Jun;8(3):134-7
The use of patients in health care education: the need for ethical justification. Bindless L. **J Med Ethics** 1998 Oct; 24(5):314-9
Randomized trial testing the effect of peer education at increasing fruit and vegetable intake. Buller DB, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1491-500
Sun safety: avoiding noonday sun, wearing protective clothing, and the use of sunscreen [editorial; comment] [see comments] Turner M. **J Natl Cancer Inst** 1998 Dec 16; 90(24):1854-5. Comment on: J Natl Cancer Inst 1998 Dec 16;90(24):1873-80. Comment in: J Natl Cancer Inst 1999 Jul 7;91(13):1164-6.
Education of medical practitioners in otitis media management. Brown DH. **J Otolaryngol** 1998;27 Suppl 2:49-52
Preferences for participation in treatment decision making and information needs of parents of children with cancer: a pilot study. Pyke-Grimm KA, et al. **J Pediatr Oncol Nurs** 1999 Jan;16(1):13-24
The family educator: a professional resource for families. Wilson JH, et al. **J Psychosoc Nurs Ment Health Serv** 1999 Jun;37(6):22-7
Coverage and quality of oral cancer information in the popular press: 1987-98. Canto MT, et al. **J Public Health Dent** 1998 Summer;58(3):241-7
Health promoting schools in England--a way forward in development. Denman S. **J Public Health Med** 1999 Jun; 21(2):215-20
Towards the safer use of non-steroidal anti-inflammatory drugs. Day RO, et al. **J Qual Clin Pract** 1999 Mar; 19(1):51-3
An open letter to the Director General of the Cancer Research Campaign [letter] Goodman NW. **J R Coll Physicians Lond** 1999 Jan-Feb;33(1):93
Can we improve the uptake of gastroscopy in the population at risk for gastric cancer? The effect of home letter information. McCulloch P, et al. **J R Coll Surg Edinb** 1998 Dec;43(6):385-9
Alcohol risk reduction for fraternity and sorority members. Harrington NG, et al. **J Stud Alcohol** 1999 Jul;60(4):521-7
Travel health: perceptions and practices of travel consultants. Ivatts SL, et al. **J Travel Med** 1999 Jun;6(2):76-80
Travel advice given by pharmacists. Kodkani N, et al. **J Travel Med** 1999 Jun;6(2):87-93
Sources and appropriateness of medical advice for trekkers. Townend M. **J Travel Med** 1998 Jun;5(2):73-9
Effective health education in rural Gambia. Hoare K, et al. **J Trop Pediatr** 1999 Aug;45(4):208-14
Late twentieth century medicine: will, education, and the American dream [editorial] Healy BP. **J Womens Health** 1998 Sep;7(7):779-80
Making sense of hepatitis C [letter; comment] Hurtado K. **Lancet** 1999 Feb 6;353(9151):500. Comment on: Lancet 1998 Nov 7;352(9139):1485.
Breast screening in women aged 40-49 years [letter] Kopans DB. **Lancet** 1999 Sep 11;354(9182):946; discussion 947
Braving the peaks? Be prepared [news] Larkin M. **Lancet** 1999 Aug 28;354(9180):750
Breast screening in women aged 40-49 years [letter] van Bekkum DW. **Lancet** 1999 Sep 11;354(9182):946; discussion 947
Japan tackles sexually transmitted diseases [news] Watts J. **Lancet** 1999 Jul 31;354(9176):405
Men in India respond to HIV-1 education [news] Wunsch H. **Lancet** 1998 Oct 3;352(9134):1124
Aspartame and the internet [letter] Zehetner A, et al. **Lancet** 1999 Jul 3;354(9172):78
Preparation for menopause: prospective evaluation of a health education intervention for mid-aged women. Liao KL, et al. **Maturitas** 1998 Jun 17;29(3):215-24
New ways of teaching health informatics. van Bemmel JH. **MD Comput** 1999 May-Jun;16(3):14-5
Training shopkeepers and schoolchildren in medicine use: experiments in applied medical anthropology in east Africa. van der Geest S. **Med Anthropol Q** 1999 Jun;13(2):253-5
Melanoma in the elderly--a neglected public health challenge [editorial; comment] [see comments] Kelly JW. **Med J Aust** 1998 Oct 19;169(8):403-4. Comment on: Med J Aust 1998 Oct 19;169(8):410-4. Comment in: Med J Aust 1999 Apr 19;170(8):394-5.
Evaluation of a safety educational programme for the prevention of pesticide poisoning. Chen S, et al. **Med Law** 1998;89 Suppl 2:S91-8
Private-public sector co-operation to improve pesticide safety standards in developing countries. Ellis WW. **Med Law** 1998;89 Suppl 2:S112-22
Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Kaufert P, et al. **Menopause** 1998 Winter; 5(4):197-202
Stroke victims need to get to the hospital faster [news] **Minn Med** 1998 Sep;81(9):43
Back to school. Alliance takes AIDS prevention message to middle schools. Thistle J. **Minn Med** 1998 Oct; 81(10):24-5
Call for research and education to tackle 'environmental injustice' [news] Reichhardt T. **Nature** 1999 Mar 11; 398(6723):99
Guardians of the future [editorial] D'Auria D. **Occup Med (Lond)** 1999 Jan;49(1):1
Innovative breast cancer education programs for African-Americans. **Oncology (Huntingt)** 1999 Mar; 13(3):298, 303
Assessment of HIV/AIDS knowledge, attitudes and behaviour of high school students in Papua New Guinea. Friesen H, et al. **P N G Med J** 1996 Sep;39(3):208-13
Pediatricians' response to the demand for school health programming. Barnett S, et al. **Pediatrics** 1999 Apr; 103(4):e45
A community-based randomized trial encouraging sun protection for children [letter] Dietrich AJ. **Pediatrics** 1999 Aug;104(2 Pt 1):355
A community-based randomized trial encouraging sun protection for children. Dietrich AJ, et al. **Pediatrics** 1998 Dec;102(6):E64
Reducing violence: education, not regulation [letter] Riegel D. **Postgrad Med** 1999 Sep;106(3):33-4
New horizons in health. Proceedings of the XVIth World Conference on Health Promotion and Health Education. San Juan, Puerto Rico, June 1998. **Promot Educ** 1998 Sep-Dec;5(3-4):1-46 **(Eng, Fre, Spa)**
Immune function, mood, and perceived burden among caregivers participating in a psychoeducational intervention. Wilkins SS, et al. **Psychiatr Serv** 1999 Jun; 50(6):747-9
Group psychoeducation of relatives of schizophrenic patients: two-year experiences. Zhang M, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S344-7
Acculturative stress, depression, and suicidal ideation among Mexican-American adolescents: implications for the development of suicide prevention programs in schools. Hovey JD. **Psychol Rep** 1998 Aug;83(1):249-50
AIDS awareness of secondary school pupils in the northern province of South Africa. Peltzer K, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):955-8
Perceptions of quality of journals related to health education. Price JH, et al. **Psychol Rep** 1999 Feb;84(1):259-66
Delivering a very brief psychoeducational program to cancer patients and family members in a large group format. Cunningham AJ, et al. **Psychooncology** 1999 Mar-Apr; 8(2):177-82
Assessment of advice to reduce dietary fat and non-milk extrinsic sugar in a free-living male population. Drummond S, et al. **Public Health Nutr** 1999 Jun;2(2):187-97
Better surveillance and more awareness needed to deal with rise in antibiotic resistance [news] **Public Health Rep** 1998 Sep-Oct;113(5):386
CDC targets arthritis, a leading cause of disability [news] **Public Health Rep** 1999 Mar-Apr;114(2):102
Health education guides target Hispanic Americans [news] **Public Health Rep** 1999 May-Jun;114(3):206
Photo was "right on" [letter; comment] Krawetz DW. **Public Health Rep** 1999 Jan-Feb;114(1):6. Comment on: Public Health Rep 1998 Jul-Aug;113(4):296-7.
Radiology and Epcot celebrate new millennium with a patient education and information exhibit. Petasnick JP, et al. **Radiographics** 1999 Sep-Oct;19(5):1105-6
Evaluation of a university course to promote physical activity: project GRAD. Sallis JF, et al. **Res Q Exerc Sport** 1999 Mar;70(1):1-10
Challenges in health science education [editorial] Pick WM. **S Afr Med J** 1998 Nov;88(11):1406-7
First aid treatment for burns in children--a call for education [letter] Theunissen D, et al. **S Afr Med J** 1998 Nov; 88(11):1367-8
Patient and relative education in community psychiatry: a randomized controlled trial regarding its effectiveness. Merinder LB, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Jun;34(6):287-94
The learning curve: health education in STI clinics in South Africa. Reddy P, et al. **Soc Sci Med** 1998 Nov; 47(10):1445-53
Health promotion versus disease and care: failure to establish "blissful clarity" in British nurse education and practice. Smith P, et al. **Soc Sci Med** 1999 Jan;48(2):227-39
The impact of a family planning multimedia campaign in Bamako, Mali. Kane TT, et al. **Stud Fam Plann** 1998 Sep; 29(3):309-23
Short- and long-term effects of a pilot prevention program to reduce alcohol consumption. Werch CE, et al. **Subst Use Misuse** 1998 Sep;33(11):2303-21
Public perception of radiation: using the press to your advantage. Watanabe ME. **Teratology** 1999 Apr;59(4):316-7
A new health education strategy to reduce smoking among young people [letter] Jamrozik KD, et al. **Tob Control** 1998 Summer;7(2):194
Worldwide survey of education on tobacco in medical schools. Richmond RL, et al. **Tob Control** 1998 Autumn; 7(3):247-52
The tobacco industry and education and science organisations in New Zealand [letter] Thomson G. **Tob Control** 1998 Summer;7(2):194-5
Growth monitoring: family participation: effective community development. Meegan M, et al. **Trop Doct** 1999 Jan;29(1):23-7
Community involvement in the monitoring and evaluation of their children's progress. Morley D. **Trop Doct** 1999 Apr;29(2):70-2
Influence of self-care education on illness behaviors and health locus of control of Mexican American women. Kennedy CA, et al. **Women Health** 1999;28(3):1-13
[Effectiveness of videotape education for mothers of prematurity] Chen YJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Dec; 14(12):800-6 (Eng. Abstr.) **(Chi)**
[Insufficient guidelines on a public disease (letter; comment)] Plum P, et al. **Ugeskr Laeger** 1999 Mar 8;161(10):1431-2 . Comment on: Ugeskr Laeger 1999 Jan 18;161(3):239. **(Dan)**
[Health education in the French school system: principles and practical applications] Billon J. **Arch Pediatr** 1998 Feb; 5(2):194-8 (Eng. Abstr.) **(Fre)**
[Prevention of doping in sport in adolescents: evaluation of a health education based intervention] Laure P, et al. **Arch Pediatr** 1999 Aug;6(8):849-54 (Eng. Abstr.) **(Fre)**
[Information and education interventions on hygiene levels of a population in which trachoma exists in a hyperendemic and serious form] Chraibi-Hasseini K, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1997;74:45-55 (Eng. Abstr.) **(Fre)**
[Representations of mother to child transmission of AIDS, perception of the risk and health information messages in Burkina Faso] Taverne B. **Sante** 1999 May-Jun;9(3):195-9 (Eng. Abstr.) **(Fre)**
[The IMRED (introduction, methods, results, discussion) plan is also suitable for reviews in education and health promotion] Arwidson P, et al. **Sante Publique** 1998 Jun; 10(2):171-4 **(Fre)**
[From school health to national health education (editorial)] Halley des Fontaines V. **Sante Publique** 1998 Sep;

10(3):237–8 **(Fre)**

[Mind Zone--prevention in the techno-scene] Nitschke S. **Gesundheitswesen** 1998 Aug;60 Suppl 1:S56–8 (Eng. Abstr.) **(Ger)**

[Prevention of malignant melanoma] Blum A, et al. **Hautarzt** 1998 Nov;49(11):826–34 (54 ref.) (Eng. Abstr.) **(Ger)**

[Patient information: "Physicians in pathology: dedicated to life"] Stolte M. **Pathologe** 1999 Jan;20(1):84 **(Ger)**

[Reduced passive smoking exposure of children--parental behavior, possibilities for change and determinants] Szczepanski R, et al. **Pneumologie** 1999 Jan;53(1):37–42 (Eng. Abstr.) **(Ger)**

[Information strategy for physicians and public health regarding introduction of general hepatitis B vaccination in Switzerland] Bourquin C, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S72–4, S146–8 (Eng. Abstr.) **(Ger, Fre)**

[Health promotion in the basic education of teachers in Switzerland] Gretler S. **Soz Praventivmed** 1998; 43(5):239–46 (Eng. Abstr.) **(Ger)**

[When competence and creativeness coincide] Thorens JJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S75–7, S149–51 (Eng. Abstr.) **(Ger, Fre)**

[Acupuncture: an information therapy?] Nissel H. **Wien Med Wochenschr** 1998;148(19):439–42 (39 ref.) (Eng. Abstr.) **(Ger)**

[Project for the prevention of thyroid pathology and iodine prophylaxis education in the province of Campobasso] Aiello A, et al. **Ann Ist Super Sanita** 1998;34(3):423–4 (Eng. Abstr.) **(Ita)**

[Course on smoking cessation organized by the Italian League against Cancer in Florence: determinants of cessation at the end of the course and after 1 year] Gorini G, et al. **Epidemiol Prev** 1998 Jul–Sep;22(3):165–70 (Eng. Abstr.) **(Ita)**

[Impact of mass media on the use of health services. A systematic review of the literature] Grilli R, et al. **Epidemiol Prev** 1998 Apr–Jun;22(2):103–10 (35 ref.) (Eng. Abstr.) **(Ita)**

[Role and significance of information tools in occupational asthma] Moscato G, et al. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):128–30 (18 ref.) (Eng. Abstr.) **(Ita)**

[Role of school lunch in primary school education: a trial analysis of school teachers' views using an open-ended questionnaire] Inayama T, et al. **Nippon Koshu Eisei Zasshi** 1998 Dec;45(12):1115–26 (Eng. Abstr.) **(Jpn)**

[An Internet-based "distance" learning for health, environment and sustainable development "distance learning without a frontier"] Tamashiro H, et al. **Nippon Koshu Eisei Zasshi** 1999 Feb;46(2):130–3 (Eng. Abstr.) **(Jpn)**

[Health information in Manhattan and in Norway--what will become of the Norwegian efforts?] Lande RE. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):563–4 **(Nor)**

[Report on the Scientific Training Conference on "Rehabilitation of Patients with Neurological Complications in Diabetes"] Kwolek A. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1603–4 **(Pol)**

[Report from the conference on "safe and hygienic learning conditions as indispensable elements of elementary schools' functioning"] Ignar-Golinowska B, et al. **Rocz Panstw Zakl Hig** 1998;49(4):515–20 (Eng. Abstr.) **(Pol)**

[Effect of nutrition education on nutrition behaviors of investigated students' group] Pierzynowska J, et al. **Rocz Panstw Zakl Hig** 1998;49(4):491–8 (Eng. Abstr.) **(Pol)**

[Breastfeeding in shantytowns: an educational program through home visits] Souza MH, et al. **Arch Latinoam Nutr** 1998 Sep;48(3):231–5 (Eng. Abstr.) **(Por)**

[Health promotion and education: a diagnosis of sanitation conditions using participatory research and community education (São João dos Queiróz - Quixadá/Ceará, Brazil)] Mello DA, et al. **Cad Saude Publica** 1998 Jul–Sep; 14(3):583–95 (Eng. Abstr.) **(Por)**

[Assessment of the performance of Pastoral de Criança, a health support group, in promoting child survival and health education in Criciúma,a city in southern Brazil] Neumann NA, et al. **Rev Panam Salud Publica** 1999 Jun; 5(6):400–10 (Eng. Abstr.) **(Por)**

[Hygiene instruction--the basis of a healthy life style] Zholus BI. **Voen Med Zh** 1999 Feb;320(2):24–9 **(Rus)**

[The educating and informing of the population on HIV/AIDS problems in the Republic of Byelarus] Bykova VM. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):110–1 (Eng. Abstr.) **(Rus)**

[The role of educational programs on the prevention of HIV infection and the development of a healthy life style for adolescents] Mamchik TA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):113–4 (Eng. Abstr.) **(Rus)**

[Health education and prevention of AIDS] Cucić V, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):196–201 (46 ref.) **(Scc)**

[Evaluation of the effect of the health education intervention project "Healthy School"] Zivković M, et al. **Srp Arh Celok Lek** 1998 May–Jun;126(5–6):164–70 (Eng. Abstr.) **(Scc)**

[Health education as a factor in decreasing traffic accidents] Nikšić D, et al. **Med Arh** 1999;53(2):109–12 (Eng. Abstr.) **(Scr)**

[Knowledge of rabies in schoolchildren] Martinov-Cvejin M, et al. **Med Pregl** 1998;51 Suppl 1:47–50 (Eng. Abstr.) **(Scr)**

[Smoking prevention in Spanish schools] Barrueco M, et al. **Arch Bronconeumol** 1998 Nov;34(10):496–9 **(Spa)**

[Health education in climacteric (letter; comment)] Delgado Sánchez A. **Aten Primaria** 1998 Oct 15;22(6):404–5. Comment on: Aten Primaria 1997 Dec;20(10):536–42. **(Spa)**

[What is the goal of health education and community activities in primary care?] Turabián JL, et al. **Aten Primaria** 1998 Dec;22(10):662–6 **(Spa)**

[On young people, magazines, advertising and health education (letter)] Mosella MC, et al. **Gac Sanit** 1999 Mar–Apr;13(2):166–7 **(Spa)**

[Inhaled corticosteroids and asthma education] Gómez Tejada RA, et al. **Medicina (B Aires)** 1998;58(6):692–8 (Eng. Abstr.) **(Spa)**

[Educational intervention in schools for the prevention of smoking: evaluation of the process. Project: OCTOPUS] López González L, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):303–18 (27 ref.) (Eng. Abstr.) **(Spa)**

[Extracurricular activities of adolescents useful for smoking prevention programs. OCTOPUS team] López González ML, et al. **Rev Esp Salud Publica** 1999 May–Jun; 73(3):343–53 (Eng. Abstr.) **(Spa)**

[Health communication as a curriculum at United States universities] Alcalay R. **Rev Panam Salud Publica** 1999 Mar;5(3):192–6 (Eng. Abstr.) **(Spa)**

[Popular education and child nutrition: experience with women in a rural area of Mexico] Arenas-Monreal L, et al. **Rev Saude Publica** 1999 Apr;33(2):113–21 (Eng. Abstr.) **(Spa)**

[A new strategy in the fight against HIV/AIDS is needed. Inaccurate information is a waste of both money and energy (see comments)] Christenson B, et al. **Lakartidningen** 1998 Nov 18;95(47):5300–2. Comment in: Lakartidningen 1998 Dec 16;95(51–52):5863–4. **(Swe)**

[Incorrect marketing (letter)] Mellberg L. **Lakartidningen** 1999 Feb 17;96(7):718 **(Swe)**

ECONOMICS

Do poison centers save money...? What are the data? [editorial] Krenzelok EP. **J Toxicol Clin Toxicol** 1998; 36(6):545–7

Ghost of AIDS musical returns to haunt South Africa's health minister [news] Baleta A. **Lancet** 1998 Nov 21; 352(9141):1688

HISTORY

Great expectations: historical perspectives on genetic breast cancer testing. Lerner BH. **Am J Public Health** 1999 Jun; 89(6):938–44

Airing the issues: BBC radio and medicine over fifty years of the NHS. MacGregor S. **J R Coll Physicians Lond** 1998 Sep–Oct;32(5):446–51

LEGISLATION & JURISPRUDENCE

Traditional Chinese medicine and the dietary supplement health and educational act [editorial; comment] Upton R. **J Altern Complement Med** 1999 Apr;5(2):115–8. Comment on: J Altern Complement Med 1999 Apr;5(2):181–9.

Workers' right-to-know legislation: does it work? Kahan E, et al. **Occup Med (Lond)** 1999 Jan;49(1):11–5

MANPOWER

Evaluation of an AIDS training program for traditional healers in the Central African Republic. Somsé P, et al. **AIDS Educ Prev** 1998 Dec;10(6):558–64

Traditional healers as a source of information and advice for people with sexually transmitted diseases in rural Zambia [see comments] Ndubani P, et al. **Trop Doct** 1999 Jan;29(1):36–8. Comment in: Trop Doct 1999 Jan;29(1):1.

METHODS

Self-management health education for chronic HIV infection. Gifford AL, et al. **AIDS Care** 1999 Feb; 11(1):115–30

Persuasive communication about AIDS prevention: need for cognition determines the impact of message format. Bakker AB. **AIDS Educ Prev** 1999 Apr;11(2):150–62

Effectiveness of a specialized vs. traditional AIDS education program attended by homeless and drug-addicted women alone or with supportive persons. Nyamathi A, et al. **AIDS Educ Prev** 1998 Oct;10(5):433–46

Participatory action research for sustaining individual and community change: a model of HIV prevention education. Stevens PE, et al. **AIDS Educ Prev** 1998 Oct;10(5):387–402

The Women and Infants Demonstration Project: an integrated approach to AIDS prevention and research. Terry MA, et al. **AIDS Educ Prev** 1999 Apr;11(2):107–21

An evaluation of the use of drama to communicate HIV/AIDS information. Valente TW, et al. **AIDS Educ Prev** 1999 Jun;11(3):203–11

Low-fat school lunch programs: achieving acceptance. Demas A. **Am J Cardiol** 1998 Nov 26;82(10B):80T–82T

Coronary risk reduction through intensive community-based lifestyle intervention: the Coronary Health Improvement Project (CHIP) experience. Diehl HA. **Am J Cardiol** 1998 Nov 26;82(10B):83T–87T

Intervention for medical students: effective infection control. Calabro K, et al. **Am J Infect Control** 1998 Aug;26(4):431–6

Teaching kids about rabies. Dandoy S, et al. **Am J Public Health** 1999 Mar;89(3):413–4

The effect of plain packaging on response to health warnings [letter] Goldberg ME, et al. **Am J Public Health** 1999 Sep; 89(9):1434–5

Consequences in Georgia of a nationwide outbreak of Salmonella infections: what you don't know might hurt you. Mahon BE, et al. **Am J Public Health** 1999 Jan; 89(1):31–5

The reach and effectiveness of a national mass media-led smoking cessation campaign in The Netherlands. Mudde AN, et al. **Am J Public Health** 1999 Mar;89(3):346–50

A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use. Schwartz MD, et al. **Am J Public Health** 1999 Jun;89(6):924–6

QA and health education: two methodologies compared. Marinelli G. **Ann Ig** 1999 Jan–Feb;11(1):57–62

Self-administered preventive programme for sedentary workers: reducing musculoskeletal symptoms or increasing awareness? Coury HJ. **Appl Ergon** 1998 Dec;29(6):415–21

Safety pictograms: are they getting the message across? Davies S, et al. **Appl Ergon** 1998 Feb;29(1):15–23

Early effects of a school-based human immunodeficiency virus infection and sexual risk prevention intervention. Siegel DM, et al. **Arch Pediatr Adolesc Med** 1998 Oct; 152(10):961–70

The suitability of United States Pharmacopoeia Dispensory Information psychotropic drug leaflets for urban patients with limited reading skills. Wilson FL. **Arch Psychiatr Nurs** 1999 Aug;13(4):204–11

Olympics visitors need to be told about the dangers of the Australian surf [letter] Leahy S, et al. **Aust N Z J Public Health** 1999 Aug;23(4):442

Do media help or harm public health? [letter; comment] Stacey BG, et al. **Aust N Z J Public Health** 1998 Oct; 22(6):733–4. Comment on: Aust N Z J Public Health 1998 Feb;22(1):155–8.

Listeria awareness among new mothers in Western Australia. Torvaldsen S, et al. **Aust N Z J Public Health** 1999 Aug; 23(4):362–7

Advising parents of asthmatic children on passive smoking: randomised controlled trial. Irvine L, et al. **BMJ** 1999 May 29;318(7196):1456–9

The effectiveness of parents in promoting the development of road crossing skills in young children. Thomson JA, et al. **Br J Educ Psychol** 1998 Dec;68 (Pt 4):475–91

Sexual health advice at a day centre [letter] Gupta S. **Br J Fam Plann** 1999 Apr;25(1):29

Improving compliance with quinine + tetracycline for treatment of malaria: evaluation of health education interventions in Cambodian villages. Denis MB. **Bull World Health Organ** 1998;76 Suppl 1:43–9

Childhood burn injuries: circumstances of occurrences and their prevention in Ribeirão Preto, Brazil. Rossi LA, et al. **Burns** 1998 Aug;24(5):416–9

Scalds in children caused by water from electrical kettles: effect of prevention through information. Sheller JL, et al. **Burns** 1998 Aug;24(5):420–4

A program to reduce pesticide spraying in the indoor environment: evaluation of the 'Roach Coach' project. Campbell ME, et al. **Can J Public Health** 1999 Jul–Aug; 90(4):277–81

Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Lerman C, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 2):361–7

Who's afraid of the newspaper advice column? [editorial; comment] Entwistle V. **CMAJ** 1999 Aug 24;161(4):397–8 . Comment on: CMAJ 1999 Aug 24;161(4):393–5.

Assessing the quality of newspaper medical advice columns for elderly readers [see comments] Molnar FJ, et al. **CMAJ** 1999 Aug 24;161(4):393–5. Comment in: CMAJ 1999 Aug 24;161(4):397–8.

Informing women about folic acid [letter] Shepherd R. **CMAJ** 1998 Nov 17;159(10):1241–2

Application of a computer based education system for aged persons and issues arising during the field test. Inoue M, et al. **Comput Methods Programs Biomed** 1999 Apr; 59(1):55–60

Diarrhoea prevention in Bolivia through point-of-use water treatment and safe storage: a promising new strategy. Quick RE, et al. **Epidemiol Infect** 1999 Feb;122(1):83–90

Dutch research into the development and impact of computer-tailored nutrition education. Brug J. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S78–82 (21 ref.)

Population attitudes towards changing dietary habits and reliance on general practitioners in Spain. Serra-Majem LL, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S58–61

Moving beyond information: evaluation of a nutrition education tool based on a theoretical model. Ulmi S, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S49–53

The balance of positive and negative effects of specific messages in the evaluation of interventions for preventing HIV infection. Spadea T, et al. **Eur J Epidemiol** 1999 Feb; 15(2):109–17

Skin cancer prevention for children: a critical review. Buller DB, et al. **Health Educ Behav** 1999 Jun;26(3):317–43 (52 ref.)

Targeting "risky" gender ideologies: constructing a community-driven, theory-based HIV prevention intervention for youth. Laub C, et al. **Health Educ Behav** 1999 Apr;26(2):185–99

Evaluation of a three-year school-based intervention to increase adolescent sun protection. Lowe JB, et al. **Health Educ Behav** 1999 Jun;26(3):396–408

Communicating about youth's sun exposure risk to soccer coaches and parents: a pilot study in Georgia. Parrott R, et al. **Health Educ Behav** 1999 Jun;26(3):385–95

Effective presentation of radiation safety training--risk communication: an important function of radiation safety training. Johnson RH Jr. **Health Phys** 1999 Feb;76(2 Suppl):S10–5 (7 ref.)

Radiation safety instruction for non-radiation workers. Michel R, et al. **Health Phys** 1999 Feb;76(2 Suppl):S7–9

Effects of mailed advice on stress reduction among employees in Japan: a randomized controlled trial. Kawakami N, et al. **Ind Health** 1999 Apr;37(2):237–42

Dementia carer education and patient behaviour disturbance. Coen RF, et al. **Int J Geriatr Psychiatry** 1999 Apr; 14(4):302–6

Common reasons why peer education fails. Walker SA, et al. **J Adolesc** 1999 Aug;22(4):573–7 (10 ref.)

SAM's role in the dissemination of information. Society for Adolescent Medicine. Barnes HV, et al. **J Adolesc Health** 1998 Dec;23(6 Suppl):148–51

Youth action strategies in violence prevention. Carroll GB, et al. **J Adolesc Health** 1999 Jul;25(1):7–13

Use of Western-based HIV risk-reduction interventions targeting adolescents in an African setting. Fitzgerald AM, et al. **J Adolesc Health** 1999 Jul;25(1):52–61

Culture and adolescent development [editorial] Friedman HL. **J Adolesc Health** 1999 Jul;25(1):1–6

Health promotion and health education: what role should the nurse adopt in practice? Norton L. **J Adv Nurs** 1998 Dec;28(6):1269–75 (32 ref.)

Efficacy of informational letters on hepatitis B immunization rates in university students. Marron RL, et al. **J Am Coll Health** 1998 Nov;47(3):123–7

Innovative newsletter interventions improve fruit and vegetable consumption in healthy adults. Lutz SF, et al. **J Am Diet Assoc** 1999 Jun;99(6):705–9

Making media messages more suitable for health education in the African context. Hugo J, et al. **J Audiov Media Med** 1998 Sep;21(3):87–94

Acceptance by Swedish users of a multimedia program for primary and secondary prevention of malignant melanoma. Lindholm LH, et al. **J Cancer Educ** 1998 Winter; 13(4):207–12

Bridging cultures through the development of a cervical cancer screening video for Cambodian women in the United States. Mahloch J, et al. **J Cancer Educ** 1999 Summer;14(2):109–14

Integrating cancer risk assessment into a community health nursing course. Phillips JM, et al. **J Cancer Educ** 1999 Spring;14(1):47–51

Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions. Weinrich SP, et al. **J Cancer Educ** 1998 Winter;13(4):213–9

The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data. Schwandt P, et al. **J Clin Epidemiol** 1999 Aug;52(8):791–800

Self-administered diet history questionnaire developed for health education: a relative validation of the test-version by comparison with 3-day diet record in women. Sasaki S, et al. **J Epidemiol** 1998 Oct;8(4):203–15

Cancer control research and literacy [editorial] Michielutte R, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):281–97 (111 ref.)

"Healthometer"--an instrument for self-distributed health screening and prevention in the population. Spång L, et al. **J Med Syst** 1998 Oct;22(5):339–55

Women's wellness: an innovative approach to nursing education. Callister LC, et al. **J Nurs Educ** 1998 Sep; 37(6):268–70

A health education initiative: teaching college women about osteoporosis. Weiss M, et al. **J Nurs Educ** 1998 Sep; 37(6):271–4

Empowerment education for individuals with serious mental illness. Schofield R. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):35–40

Perceptions of alcoholics: the impact of personal characteristics. Brey RA, et al. **J Sch Health** 1999 Apr; 69(4):165–6

Electronic portfolios enhance health instruction. Corbett-Perez S, et al. **J Sch Health** 1999 Aug;69(6):247–9

Using cooperative learning groups to develop health-related cultural awareness. Doyle EI, et al. **J Sch Health** 1999 Feb; 69(2):73–6

Alien nation: a problem-solving activity for dealing with pertinent health issues. Duitsman D, et al. **J Sch Health** 1999 Mar;69(3):123–4

A nutrition relay race for preschool health education. Geiger BF. **J Sch Health** 1999 Mar;69(3):125

Promoting sun protection in elementary schools and child care settings: the SunSafe Project. Grant-Petersson J, et al. **J Sch Health** 1999 Mar;69(3):100–6

Distract me from my dreaded self: strategies to enhance self-esteem. Hamilton D, et al. **J Sch Health** 1998 Sep; 68(7):301–3

A replication study of Reducing the Risk, a theory-based sexuality curriculum for adolescents. Hubbard BM, et al. **J Sch Health** 1998 Aug;68(6):243–7

Developing a computer-assisted health knowledge quiz for preschool children. Nix ST, et al. **J Sch Health** 1999 Jan; 69(1):9–11

Using puppetry in a coordinated school health program. Synovitz LB. **J Sch Health** 1999 Apr;69(4):145–7 (46 ref.)

Ontario, Canada, high school teachers as enforcers in the war on drugs: what their students see and say. Warner J, et al. **J Sch Health** 1999 Aug;69(6):243–6

Using picture identification for research with preschool children. Wiley DC, et al. **J Sch Health** 1998 Aug; 68(6):227–30 (26 ref.)

Bright smiles, shining futures. Yehieli M, et al. **J Sch Health** 1999 Apr;69(4):162–4 (1 ref.)

Listening to Hispanic mothers: guidelines for teaching. Wilson AH, et al. **J Soc Pediatr Nurs** 1999 Jul–Sep; 4(3):125–7 (10 ref.)

Pregnant women and car restraints: beliefs and practices. Tyroch AH, et al. **J Trauma** 1999 Feb;46(2):241–5

A survey of general practice policies on travel medicine. Leggat PA, et al. **J Travel Med** 1998 Sep;5(3):149–52

Comparison of effectiveness of direct recording scale and dial scale [letter] Low AJ. **Lancet** 1998 Dec 5; 352(9143):1832

Treating HIV/AIDS information overload [see comments] Morris K. **Lancet** 1998 Dec 5;352(9143):1866. Comment in: Lancet 1999 Jan 30;353(9150):412.

Popular drama prompts interest in HIV in Japan [news] Watts J. **Lancet** 1998 Dec 5;352(9143):1840

The Internet and the changing roles of doctors, patients and families. Pemberton PJ, et al. **Med J Aust** 1998 Dec 7–21; 169(11–12):594–5

Lifestyle evaluation system to support health education. Sakuragi C, et al. **Medinfo** 1998;9 Pt 2:727–31

Mother-infant interaction: achieving synchrony. Leitch DB. **Nurs Res** 1999 Jan–Feb;48(1):55–8

An intervention to decrease cancer fatalism among rural elders. Powe BD, et al. **Oncol Nurs Forum** 1999 Apr; 26(3):583–8

AIDS in Papua New Guinea [editorial] Jenkins C. **P N G Med J** 1996 Sep;39(3):164–5

Urbanization, youth and sexuality: insights for an AIDS campaign for youth in Papua New Guinea. Jenkins C, et al. **P N G Med J** 1996 Sep;39(3):248–51

Knowledge about sexually transmitted diseases in rural and periurban communities of the Asaro Valley of Eastern Highlands Province: the health education component of an STD study. Lupiwa S, et al. **P N G Med J** 1996 Sep; 39(3):243–7

A STD/HIV prevention trial among adolescents in managed care. Boekeloo BO, et al. **Pediatrics** 1999 Jan;103(1):107–15

Increasing use of the female condom through video instruction. Zimmers E, et al. **Percept Mot Skills** 1999 Jun; 88(3 Pt 2):1071–7

Patients in cyberspace: information or confusion? [editorial] Ayonrinde O. **Postgrad Med J** 1998 Aug;74(874):449–50

Quit Today! A targeted communications campaign to increase use of the cancer information service by African American smokers. Boyd NR, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 2):S50–60

Evaluation of a health and nutrition education program in primary school children of Crete over a three-year period. Manios Y, et al. **Prev Med** 1999 Feb;28(2):149–59

Increasing fruit and vegetable consumption among callers to the CIS: results from a randomized trial. Marcus AC, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 2):S16–28

The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. O'Loughlin J, et al. **Prev Med** 1999 Mar;28(3):324–31

Increasing mammography among women aged 40–74 by use of a stage-matched, tailored intervention. Rakowski W, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):748–56

1% or less: a community-based nutrition campaign [see comments] Reger B, et al. **Public Health Rep** 1998 Sep–Oct; 113(5):410–9. Comment in: Public Health Rep 1998 Sep–Oct;113(5):420–3.

A community medicine project involving an educational session in sexually transmitted diseases for high school students. Scott JL, et al. **S D J Med** 1998 Sep;51(9):345–6

Impact of school-based teaching on students' opinions of organ donation and transplantation. Weaver M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1086–7

Postmenopausal women take steps to reduce their osteoporosis risk. Raab CA, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):211–8

An effective manual on breast self-examination. Devi R, et al. **World Health Forum** 1998;19(4):388–9

Help for women refugees. Miserez CB. **World Health Forum** 1998;19(3):320–3

[Information, misinformation and photo-education (editorial)] Dubertret L. **Ann Dermatol Venereol** 1999 Apr; 126(4):303–5 **(Fre)**

[Prevention of antibiotic resistance needs informed parents] Ovetchkine P. **Arch Pediatr** 1999 Mar;6(3):321–3 (Eng. Abstr.) **(Fre)**

[Tobacco, students, education and health] Chabot JM. **Rev Prat** 1999 Jan 1;49(1):70–1 **(Fre)**

[HIV prevention for migrant prostitutes] Nitschke-Ozbay H. **Zentralbl Gynakol** 1999;121(1):36–41 (5 ref.) (Eng. Abstr.) **(Ger)**

[The hygiene education and training of the population: the problems and the means for implementation] Stroev EA, et al. **Gig Sanit** 1999 Jan–Feb;(1):65–6 **(Rus)**

[Guides for food and nutrition. A didactic proposal] Shamah-Levy T, et al. **Arch Latinoam Nutr** 1997 Sep; 47(3):256–61 (Eng. Abstr.) **(Spa)**

[The effectiveness of an informational seminar on occupational health] Mirón Canelo JA, et al. **Aten Primaria** 1999 May 15;23(8):467–73 (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

A community-based health intervention programme in pastoral and agricultural Pokot communities in Western Kenya. Ettyang G. **Acta Paediatr Suppl** 1999 May; 88(429):41–2 (4 ref.)

Project Charlie [letter] Barlow J, et al. **Addiction** 1998 Dec; 93(12):1875–7

Educating young people about drugs: a systematic review. White D, et al. **Addiction** 1998 Oct;93(10):1475–87

Training nontraditional responders to use automated external defibrillators. Riegel B. **Am J Crit Care** 1998 Nov; 7(6):402–10 (36 ref.)

The Missouri Disability Epidemiology and Health Project. Andresen EM, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):63–71

Evaluation of a community-based program to improve infant immunization rates in rural Minnesota. Hellerstedt WL, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):50–7

The Abuela Project: safe cheese workshops to reduce the incidence of Salmonella typhimurium from consumption of raw-milk fresh cheese. Bell RA, et al. **Am J Public Health** 1999 Sep;89(9):1421–4

Reducing AIDS risk among port workers in Santos, Brazil. Hearst N, et al. **Am J Public Health** 1999 Jan;89(1):76–8

The effectiveness of a tobacco prevention program with adolescents living in a tobacco-producing region. Noland MP, et al. **Am J Public Health** 1998 Dec;88(12):1862–5

Increasing fruit and vegetable consumption through worksites and families in the treatwell 5-a-day study. Sorensen G, et al. **Am J Public Health** 1999 Jan;89(1):54–60

Smokeless tobacco cessation intervention for college athletes: results after 1 year. Walsh MM, et al. **Am J Public Health** 1999 Feb;89(2):228–34

The Cardiovascular Health Education Program: assessing the impact on rural and urban adolescents' health knowledge. MacDonald SA. **Appl Nurs Res** 1999 May;12(2):86–90

Health promoting schools: issues and future directions for Australia and the Asia Pacific Region. Rowling L, et al. **Asia Pac J Public Health** 1996–97;9:33–7 (41 ref.)

Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Marks R. **Australas J Dermatol** 1999 Feb;40(1):1–5 (28 ref.)

Firearm safety courses for elementary school-age children. Leonard KA. **Can J Public Health** 1999 Jan–Feb;90(1):35–6

Prevention of paediatric acquired brain injury: an interactive, elementary-school program. Morrongiello BA, et al. **Can J Public Health** 1998 Nov–Dec;89(6):391–6

ER docs happy as CPR training made compulsory in Ontario [news] Sibbald B. **CMAJ** 1999 May 18;160(10):1425

Cryptosporidium in water. Report of the consensus conference on Cryptosporidium in water, Melbourne, October 1998. Douglas R, et al. **Commun Dis Intell** 1999 Jun 10;23(6):170–2 (0 ref.)

Family Planning Association launches chlamydia awareness campaign. **Commun Dis Rep CDR Wkly** 1999 Aug 6; 9(32):281, 284

The action-oriented school health curriculum in the eastern Mediterranean region. Sulieman O. **East Mediterr Health J** 1998;4 Suppl:S130–6

Effect of an educational multimedia prostate program on the International Prostate Symptom Score. van Schaik P, et al. **Eur Urol** 1999;36(1):36–9

Expanding Internet access for health care consumers. Wilkins AS. **Health Care Manage Rev** 1999 Summer;24(3):30–41 (44 ref.)

Public health and health education in faith communities. Chatters LM, et al. **Health Educ Behav** 1998 Dec; 25(6):689–99

Skin cancer prevention: the problem, responses, and lessons learned. Graffunder CM, et al. **Health Educ Behav** 1999 Jun;26(3):308–16

Evaluation of a poison prevention lesson for kindergarten and third grade students [letter; comment] Liller KD. **Inj Prev** 1999 Mar;5(1):78. Comment on: Inj Prev 1998 Sep;4(3):218–21.

Evaluation of a poison prevention lesson for kindergarten and third grade students [see comments] Liller KD, et al. **Inj Prev** 1998 Sep;4(3):218–21. Comment in: Inj Prev 1999 Mar;5(1):78.

History of tobacco and the Inuit. Grey R. **Int J Circumpolar Health** 1998;57 Suppl 1:13–4

Education on health risks of smoking in Magadan, Russia. Holder T. **Int J Circumpolar Health** 1998;57 Suppl 1:493–4

The Sioux Lookout Diabetes Program: diabetes prevention and management in northwestern Ontario. Morrison N, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:364–9

Communication of risks: organization of a methylmercury campaign in the Cree communities of James Bay, Northern Quebec, Canada. Noël F, et al.

Int J Circumpolar Health 1998;57 Suppl 1:591–5

Creating alliances for disease management in industrial settings: a case study of HIV/AIDS in workers in South African gold mines. Williams B, et al. **Int J Occup Environ Health** 1998 Oct–Dec;4(4):257–64 (50 ref.)

We can make a difference. Rosebrook J. **Iowa Med** 1999 Jul–Aug;89(4):16–7

Organ donation awareness. It has to start somewhere. Rosebrook J. **Iowa Med** 1999 Jul–Aug;89(4):18

Injury control strategies: extending the quality and quantity of data relating to road traffic accidents in children. Henson R, et al. **J Accid Emerg Med** 1999 Mar;16(2):87–90 (33 ref.)

Regionalization of SAM and evolution of the international movement in adolescent health. Society for Adolescent Medicine. Cromer BA, et al. **J Adolesc Health** 1998 Dec; 23(6 Suppl):152–6 (0 ref.)

The effects of an intervention campaign to enhance seat belt use on campus. Clark MJ, et al. **J Am Coll Health** 1999 May;47(6):277–80

Combating sexual offenses on the college campus: keys to success. Vickio CJ, et al. **J Am Coll Health** 1999 May; 47(6):283–6

HIV/AIDS risk in the college population: modifying the culture in a private religious university. Sharts-Hopko NC, et al. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):72–9

Enhancing Cancer Pain Control among American Indians (ECPCAI): a study of the Ojibwe of Minnesota. Elliott BA, et al. **J Cancer Educ** 1999 Spring;14(1):28–33

Depression screening as an intervention against suicide. Jacobs DG. **J Clin Psychiatry** 1999;60 Suppl 2:42–5; discussion 51–2, 113–6

Knowledge and practices of preventing diarrhoea in malnourished children. McLennan JD. **J Diarrhoeal Dis Res** 1998 Dec;16(4):235–40

Assessment of drug abuse prevention curricula developed at the local level. Bosworth K. **J Drug Educ** 1998; 28(4):307–25

Implementation and process evaluation of a school-based drug abuse prevention program: Project Towards No Drug Abuse. Dent CW, et al. **J Drug Educ** 1998;28(4):361–75

Preliminary evaluation of a resiliency-based preschool substance abuse and violence prevention project. Dubas JS, et al. **J Drug Educ** 1998;28(3):235–55

Drug prevention with high risk families and young children. Hahn EJ, et al. **J Drug Educ** 1998;28(4):327–45

Twelfth grade follow-up of the effectiveness of a middle school-based substance abuse prevention program. Shope JT, et al. **J Drug Educ** 1998;28(3):185–97

A clinic-based mammography intervention targeting inner-city women. Taylor V, et al. **J Gen Intern Med** 1999 Feb;14(2):104–11

Preventing syphilis: lessons from a survey of two inner-city communities in Houston, Texas. Leonard L, et al. **J Health Care Poor Underserved** 1999 Aug;10(3):362–75

Easy-to-read consumer communications: a missing link in Medicaid managed care. Root J, et al. **J Health Polit Policy Law** 1999 Feb;24(1):1–26

Needles, syringes, injection drug users, and the Oklahoma State Medical Association. Dewberry GP Jr, et al. **J Okla State Med Assoc** 1999 May;92(5):231–3 (16 ref.)

A conference for the education of families who have a member with phenylketonuria. Kolb SE, et al. **J Pediatr Nurs** 1999 Aug;14(4):270–2

'Changing minds': banishing the stigma of mental illness [editorial] [see comments] White PD. **J R Soc Med** 1998 Oct;91(10):509–10. Comment in: J R Soc Med 1999 Mar;92(3):154.

Using the Open Airways curriculum to improve self-care for third grade children with asthma. Horner SD. **J Sch Health** 1998 Oct;68(8):329–33

A hearing conservation program for Wisconsin youth working in agriculture. Knobloch MJ, et al. **J Sch Health** 1998 Oct;68(8):313–8

Outcomes of a high school program to increase fruit and vegetable consumption: Gimme 5—a fresh nutrition concept for students. Nicklas TA, et al. **J Sch Health** 1998 Aug;68(6):248–53

The National Cholesterol Education Program: progress and prospects. Cleeman JI, et al. **JAMA** 1998 Dec 23–30; 280(24):2099–104

Proactive nursing: the evolution of a task force to help women with postpartum depression. Straub H, et al. **MCN Am J Matern Child Nurs** 1998 Sep–Oct;23(5):262–5

U.S. Army dietitians deploy in support of Cobra Gold: a humanitarian mission. Kemmer T, et al. **Mil Med** 1999 Jul; 164(7):488–94

Prevention and intervention strategies with children of alcoholics. Emshoff JG, et al. **Pediatrics** 1999 May;103(5 Pt 2):1112–21 (76 ref.)

Opening pathways to cancer screening for Vietnamese-American women: lay health workers hold a key. Bird JA, et al. **Prev Med** 1998 Nov–Dec;27(6):821–9

Effect of a media-led education campaign on breast and cervical cancer screening among Vietnamese-American women. Jenkins CN, et al. **Prev Med** 1999 Apr; 28(4):395–406

Durability and diffusion of the nutrition intervention in the Working Well Trial. Patterson RE, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):668–73

A randomized community trial to increase mammography utilization among low-income women living in public housing. Slater JS, et al. **Prev Med** 1998 Nov–Dec; 27(6):862–70

Three-year prospective adherence to three breast cancer screening modalities. Solomon LJ, et al. **Prev Med** 1998 Nov–Dec;27(6):781–6

Nutrition intervention for high-risk auto workers: results of the Next Step Trial. Tilley BC, et al. **Prev Med** 1999 Mar; 28(3):284–92

A sustainable behavioral intervention to increase condom use and reduce gonorrhea among sex workers in Singapore: 2-year follow-up. Wong ML, et al. **Prev Med** 1998 Nov–Dec;27(6):891–900

Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-based secondary prevention programme. Carlsson R. **Scand Cardiovasc J Suppl** 1998;50:1–20

Education as policy: the impact of education on marriage, contraception, and fertility in Colombia, Peru, and Bolivia. Heaton TB, et al. **Soc Biol** 1998 Fall–Winter; 45(3–4):194–213

The relationship between tobacco access and use among adolescents: a four community study [see comments] Altman DG, et al. **Soc Sci Med** 1999 Mar;48(6):759–75. Comment in: Soc Sci Med 1999 Mar;48(6):757–8.

'With the best of reasons': cervical cancer prevention policy and the suppression of sexual risk factor information. Braun V, et al. **Soc Sci Med** 1999 May;48(10):1463–74 (56 ref.)

[Overweight. II. Determinants of overweight and strategies for prevention (see comments)] Mathus-Vliegen EM. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1989–95 (52 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2374. **(Dut)**

[Health education in school] Berthon BS. **Sante Publique** 1998 Dec;10(4):459–71 **(Fre)**

[An improved system of hygiene education and instruction for specified population contingents] Kutsenko GI, et al. **Gig Sanit** 1999 May–Jun;(3):72–4 **(Rus)**

[Work with youth—the basis of educational programs aimed at the prevention of HIV infection] Agafonova OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):119–20 (Eng. Abstr.) **(Rus)**

[Health education of women in a rural setting: an interventional study] Vivas Broseta AM, et al. **Aten Primaria** 1999 Jun 15;24(1):32–8 (Eng. Abstr.) **(Spa)**

STANDARDS

Prevention of disturbed eating behaviour: a prospective intervention study in 14- to 19-year-old Swiss students. Buddeberg-Fischer B, et al. **Acta Psychiatr Scand** 1998 Aug;98(2):146–55

Tailored advice on exercise—does it make a difference? Bull FC, et al. **Am J Prev Med** 1999 Apr;16(3):230–9

A collaborative partnership to enhance school-based tobacco control policies in West Virginia. Center for Disease Control and Prevention. Tompkins NO, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):29–34

Who's afraid of the newspaper advice column? [editorial; comment] Entwistle V. **CMAJ** 1999 Aug 24;161(4):397–8 . Comment on: CMAJ 1999 Aug 24;161(4):393–5.

Assessing the quality of newspaper medical advice columns for elderly readers [see comments] Molnar FJ, et al. **CMAJ** 1999 Aug 24;161(4):393–5. Comment in: CMAJ 1999 Aug 24;161(4):397–8.

Prudent management of minors with occupational exposures to hazardous agents: the radiation protection "standard of care". Emery RJ, et al. **Inj Prev** 1998 Sep;4(3):232–5 (28 ref.)

Anaphylaxis and epinephrine auto-injector training: who will teach the teachers? Grouhi M, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):190–3

A randomized trial of a brief HIV risk reduction counseling intervention for women. Belcher L, et al. **J Consult Clin Psychol** 1998 Oct;66(5):856–61

The efficacy of a compact psychoeducational group training program for married couples. Kaiser A, et al. **J Consult Clin Psychol** 1998 Oct;66(5):753–60

Screening and brief intervention for high-risk college student drinkers: results from a 2-year follow-up assessment. Marlatt GA, et al. **J Consult Clin Psychol** 1998 Aug; 66(4):604–15

AIDS education and intervention trials among youths in factories: a pilot project. Sakondhavat C, et al. **J Med Assoc Thai** 1998 Nov;81(11):872–8

Provider attitudes and self-reported behaviors related to hormone replacement therapy. Rolnick SJ, et al. **Menopause** 1999 Fall;6(3):257–63

Hazmat training in California. Varney MR, et al. **Occup Health Saf** 1997 Dec;66(12):33–6

Health Promotion and Education [editorial] Blount HL. **Promot Educ** 1998 Sep–Dec;5(3–4):4, 88, 116 **(Eng, Fre, Spa)**

Behavior changes among crack-using rural and urban women. McCoy HV, et al. **Subst Use Misuse** 1999 Mar–Apr;34(4–5):667–84

[School health education in California. The policies and contents of The Health Framework] Watanabe M, et al. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):216–23 (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Alaska Native community assessment: health care services, knowledge of health issues, and health education. DeCourtney CA. **Int J Circumpolar Health** 1998;57 Suppl 1:656–61

Professional preparation of elementary teachers in Ohio: status of K–6 health education. Ubbes VA, et al. **J Sch Health** 1999 Jan;69(1):17–21

Exposure to and compliance with pediatric injury prevention counseling—United States, 1994. Quinlan KP, et al. **Pediatrics** 1998 Nov;102(5):E55

TRENDS

ASHP statement on the pharmacist's role in substance abuse prevention, education, and assistance. **Am J Health Syst Pharm** 1998 Aug 15;55(16):1721–4

Environmental learning 2000 [news] **Environ Health Perspect** 1998 Jan;106(1):A12

Intervention mapping: a process for developing theory- and evidence-based health education programs [see comments] Bartholomew LK, et al. **Health Educ Behav** 1998 Oct; 25(5):545–63 (62 ref.). Comment in: Health Educ Behav 1998 Oct;25(5):564–8; discussion 569–70.

The power of prevention [editorial] Howell JB. **J Am Acad Dermatol** 1999 Apr;40(4):623–5

An interactive perspective of health education for the tropical disease control: the schistosomiasis case. Schall VT. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:51–8

A new frontier in medical education. Johns MM. **Trans Am Clin Climatol Assoc** 1999;110:23–8; discussion 28–9

[Observations on the "pretherapeutic phase" of malignant melanoma of the skin 1988–1990 and 1993–1995] Jage G, et al. **Hautarzt** 1998 Nov;49(11):844–9 (Eng. Abstr.) **(Ger)**

UTILIZATION

Cancer control research and literacy [editorial] Michielutte R, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):281–97 (111 ref.)

HEALTH EDUCATION, DENTAL

Oral health among Liberian refugees in Ghana. Mickenautsch S, et al. **East Afr Med J** 1999 Apr;76(4):206–11

Patients and the Internet: guidance for evidence-based choices. Gregory-Head B. **J Am Coll Dent** 1999 Summer; 66(2):46–50

Public health dentistry: 2000 to 2020. Burry A. **J Can Dent Assoc** 1999 Mar;65(3):163–6

An evaluation of video instruction for an electric toothbrush. Comparative single-brushing cross-over study. Addy M, et al. **J Clin Periodontol** 1999 May;26(5):289–93

[Dentistry—no theme? (editorial)] Jäger P. **Schweiz Monatsschr Zahnmed** 1998;108(11):1067, 1069 **(Ger, Fre)**

[The dynamics of caries intensity during the hygienic instruction and specific prophylaxis of children in central Yakutia] Zenovskiĭ VP, et al. **Stomatologiia (Mosk)** 1998; 77(4):27–8 (Eng. Abstr.) **(Rus)**

MANPOWER

Korean dental hygienists' knowledge and opinions about etiology and prevention of dental caries. Moon HS, et al. **Community Dent Oral Epidemiol** 1998 Oct;26(5):296–302

METHODS

[Education of the patient (news)] Girsberger D. **Schweiz Monatsschr Zahnmed** 1999;109(8):876–8 **(Ger)**

HEALTH EXPENDITURES

see related

HEALTH CARE COSTS

Cost of providing sexually transmitted disease services in Bangkok. Forsythe S, et al. **AIDS** 1998;12 Suppl 2:S73–80

HCFA analysts say slow growth in health care spending is over; prescription drug costs will rise rapidly. Health Care Financing Administration [news] **Am J Health Syst Pharm** 1998 Nov 1;55(21):2230

Geographic variation in expenditures for Workers' Compensation hospitalized claims. Miller TR, et al. **Am J Ind Med** 1999 Feb;35(2):103–11

Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients [see comments] Fairfield KM, et al. **Arch Intern Med** 1998 Nov 9;158(20):2257–64. Comment in: Arch Intern Med 1999 May 24;159(10):1143–4.

New Labour's new maths is hype [letter; comment] Appleby J. **BMJ** 1998 Oct 3;317(7163):951. Comment on: BMJ 1998 Jul 25;317(7153):224–5.

Devolution in Swedish health care [editorial] Diderichsen F. **BMJ** 1999 May 1;318(7192):1156–7

Are African governments allocating sufficient resources to fight AIDS? [letter] Matchaba P. **BMJ** 1999 May 15; 318(7194):1351

Anaesthetists consume 3% of trust expenditure but affect 60% of trust income [letter; comment] Sharples A, et al. **BMJ** 1998 Dec 5;317(7172):1587. Comment on: BMJ 1998 Jan 3;316(7124):3–4. Comment on: BMJ 1998 Jun

13;316(7147):1827.
Health expenditure and finance: who gets what? Doherty J, et al. **Bull World Health Organ** 1999;77(2):156–9
Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Ozminkowski RJ, et al. **Clin Ther** 1998 Jul–Aug;20(4):780–96
Assisted living [editorial] DeCherney GS. **Del Med J** 1998 Oct;70(10):431–2
Different strokes for different folks: is one standard of disability possible? Cwikel J. **Disabil Rehabil** 1999 Aug; 21(8):379–81
Disability and health care expenditure data: a wide range of user experience is more important than standard definitions of disability. Joslyn E. **Disabil Rehabil** 1999 Aug; 21(8):382–4
Implications of alternative definitions of disability beyond health care expenditures. Kriegsman DM, et al. **Disabil Rehabil** 1999 Aug;21(8):388–91
Alternative definitions of disability: relationship to health-care expenditures [editorial] Müller D. **Disabil Rehabil** 1999 Aug;21(8):378
Family planning funding through four federal-state programs, FY 1997. Gold RB, et al. **Fam Plann Perspect** 1999 Jul–Aug;31(4):176–81
Medicare reform: who pays and who benefits? McClellan M, et al. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):48–62
HMO selection and Medicare costs: Bayesian MCMC estimation of a robust panel data tobit model with survival. Hamilton BH. **Health Econ** 1999 Aug;8(5):403–14
Interpreting reported health-care costs. Neilson AR, et al. **Hosp Med** 1998 Oct;59(10):803–6
A comparison of dental care expenditures and office-based medical care expenditures, 1987. Manski RJ, et al. **J Am Dent Assoc** 1999 May;130(5):659–66
Is family care associated with reduced health care expenditures? Doescher MP, et al. **J Fam Pract** 1999 Aug; 48(8):608–14
Returns on investment in public health: effect of public health expenditures on infant health, 1983–1990. Becker ER, et al. **J Health Care Finance** 1998 Fall;25(1):5–18
Markets, governments, and HMO development in the 1990s. Balla SJ. **J Health Polit Policy Law** 1999 Apr;24(2):215–38 (65 ref.)
Association of managed care market share and health expenditures for fee-for-service Medicare patients [see comments] Baker LC. **JAMA** 1999 Feb 3;281(5):432–7. Comment in: JAMA 1999 Feb 3;281(5):462–5. Comment in: JAMA 1999 Jul 21;282(3):235–6.
Managed care market share, fee-for-service Medicare, and information theory [letter; comment] Blanco C, et al. **JAMA** 1999 Jul 21;282(3):235–6. Comment on: JAMA 1999 Feb 3;281(5):432–7.
The economist's model of physician behavior [editorial; comment] Reinhardt UE. **JAMA** 1999 Feb 3;281(5):462–5 . Comment on: JAMA 1999 Feb 3;281(5):432–7.
Debt relief and health charges in Mozambique [letter; comment] Logie D, et al. **Lancet** 1999 Jun 12; 353(9169):2077–8. Comment on: Lancet 1999 May 1;353(9163):1519–21.
How much should we be spending on health services for Aboriginal and Torres Strait Islander people? [editorial] Mooney GH, et al. **Med J Aust** 1998 Nov 16;169(10):508–9
The American health care system [letter] LaPorta RF. **N Engl J Med** 1999 Sep 16;341(12):919–21
Purchasing population health: aligning financial incentives to improve health outcomes. Kindig DA. **Nurs Outlook** 1999 Jan–Feb;47(1):15–22 (87 ref.)
National expenditures for treatment of mental illness and substance abuse estimated at $79.3 billion in 1996 [news] **Psychiatr Serv** 1998 Nov;49(11):1508–9
The impact of over-the-counter availability of nasal sprays on sales, prescribing, and physician visits. Lundberg L, et al. **Scand J Prim Health Care** 1999 Mar;17(1):41–5
Willingness to pay: a feasible method for assessing treatment benefits in epilepsy? Stavem K. **Seizure** 1999 Feb;8(1):14–9
Smoking-attributable medical care costs in the USA. Miller VP, et al. **Soc Sci Med** 1999 Feb;48(3):375–91
[Financing of health in Lebanon. II. Financing sources and global expenses for health] Ammar W, et al. **J Med Liban** 1998 Jul–Aug;46(4):206–11 **(Fre)**
[Family expenses caused by pediatric hospitalization in Niamey (Niger)] Barennes H, et al. **Sante** 1998 Nov–Dec; 8(6):405–10 (Eng. Abstr.) **(Fre)**
[Speech given by Andrea Fischer, Minister of Health on the 102. German Physicians' Day in Cottbus 1999] Fischer A. **Internist (Berl)** 1999 Aug;40(8):232–3 **(Ger)**
[Change of course in health policy; from responsible citizen to dependent patient?] Vilmar K. **Internist (Berl)** 1999 Aug; 40(8):225–32 **(Ger)**
[Geographical distribution of medical expenditure for the aged insured by National Health Insurance in secondary medical care areas in Japan] Zhang T, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):526–35 (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

New York State Medicaid dentistry in the 1990s. Waldman HB, et al. **N Y State Dent J** 1999 Aug–Sep;65(7):18–21

STATISTICS & NUMERICAL DATA

Capitation for cardiologists: accepting risk for coronary artery disease under managed care. McNamara RL, et al. **Am J Cardiol** 1998 Nov 15;82(10):1178–82
X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment. **Am J Kidney Dis** 1999 Aug;34(2 Suppl 1):S124–39
Aboriginal health spending: more needed, but where? [editorial] McDermott R. **Aust N Z J Public Health** 1998 Oct;22(6):637–8
Optimal health care system [letter; comment] Labonte R. **Can J Public Health** 1999 Jan–Feb;90(1):65, 71. Comment on: Can J Public Health 1998 Sep–Oct;89(5):301–7.
Canadian health expenditures: where do we really stand internationally? Deber R, et al. **CMAJ** 1999 Jun 15; 160(12):1730–4
Screening Mammography Program of British Columbia: pattern of use and health care system costs [see comments] Olivotto IA, et al. **CMAJ** 1999 Feb 9;160(3):337–41. Comment in: CMAJ 1999 Jul 13;161(1):17; discussion 18. Comment in: CMAJ 1999 Jul 13;161(1):17–8.
Out-of-pocket payments for health care in Croatia: implications for equity. Miroslav M, et al. **Croat Med J** 1999 Jun;40(2):152–9
Health care financing and delivery in developing countries. Schieber G, et al. **Health Aff (Millwood)** 1999 May–Jun; 18(3):193–205
Uses and abuses of long-term Medicare cost estimates. White J. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):63–79
The black box of health care expenditure growth determinants. Barros PP. **Health Econ** 1998 Sep;7(6):533–44
The effects of economic reform on health insurance and the financial burden for urban workers in China. Hu TW, et al. **Health Econ** 1999 Jun;8(4):309–21
Unobserved heterogeneity and censoring in the demand for health care. López-Nicolás A. **Health Econ** 1998 Aug; 7(5):429–37
Insurance effects on US medical spending (1960–1993). Peden EA, et al. **Health Econ** 1998 Dec;7(8):671–87
Sensitivity of elasticity estimates for OECD health care spending: analysis of a dynamic heterogeneous data field. Roberts J. **Health Econ** 1999 Aug;8(5):459–72
The demand for healthcare among racial/ethnic subpopulations. Freiman MP. **Health Serv Res** 1998 Oct; 33(4 Pt 1):867–90
Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries. Gross DJ, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):241–54
Provider choice and use of mental health care: implications for gatekeeper models. Holmes AM, et al. **Health Serv Res** 1998 Dec;33(5 Pt 1):1263–84
Dental expenditures by selected dentist and practice characteristics. Brown LJ, et al. **J Am Dent Assoc** 1998 Oct;129(10):1474–9
Patterns of use of common major procedures in medical care of older adults. Levinsky NG, et al. **J Am Geriatr Soc** 1999 May;47(5):553–8
Financing structure dynamics and other determinants of Medicaid pharmaceutical expenditures, 1993–1996. Okunade AA. **J Health Care Finance** 1998 Fall;25(1):59–71
Personal costs associated with high-risk prenatal care attendance. Stringer M. **J Health Care Poor Underserved** 1998 Aug;9(3):222–35 (38 ref.)
The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. The Health Enhancement Research Organization (HERO) Research Committee. Goetzel RZ, et al. **J Occup Environ Med** 1998 Oct;40(10):843–54
Monitoring the impact of hospital downsizing on access to care and quality of care. Brownell MD, et al. **Med Care** 1999 Jun;37(6 Suppl):JS135–50
Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. Lillard LA, et al. **Med Care** 1999 Sep;37(9):926–36
A comparative study of the costliness of Manitoba hospitals. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS101–22
The unintended and unexpected impact of downsizing: costly hospitals become more costly. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS123–34
Adding up provincial expenditures on health care for Manitobans: a POPULIS project. Population Health Information System. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS60–82
Using the POPULIS framework for interprovincial comparisons of expenditures on health care. Population Health Information System. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS83–100
Medicare spending by beneficiaries with various types of supplemental insurance. Khandker RK, et al. **Med Care Res Rev** 1999 Jun;56(2):137–55
The case of disability in the family: impact on health care utilization and expenditures for nondisabled members. Altman BM, et al. **Milbank Q** 1999;77(1):39–75, iv
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium [see comments] Bozzette SA, et al. **N Engl J Med** 1998 Dec 24;339(26):1897–904. Comment in: N Engl J Med 1998 Dec 24;339(26):1926–8. Comment in: N Engl J Med 1999 May 13;340(19):1512–3.
The American health care system [letter] Menon M, et al. **N Engl J Med** 1999 Sep 16;341(12):917; discussion 920
Long-term care at home [letter] Wall T. **N Engl J Med** 1999 Sep 23;341(13):1005
Out-of-pocket expenditures of outpatients receiving chemotherapy. Moore K. **Oncol Nurs Forum** 1998 Oct; 25(9):1615–22
State estimates of total medical expenditures attributable to cigarette smoking, 1993. Miller LS, et al. **Public Health Rep** 1998 Sep–Oct;113(5):447–58
Health care expenditure on schizophrenia patients in Belgium. De Hert M, et al. **Schizophr Bull** 1998; 24(4):519–27
Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Martin BC, et al. **Schizophr Bull** 1998;24(3):479–88
Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Ramaiah KD, et al. **Trop Med Int Health** 1999 Jan; 4(1):19–25
[Relationship of utilization rate of health examination under the Elderly Act to medical expenditure and days of medical care for the elderly] Fukuda H, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):905–14 (Eng. Abstr.) **(Jpn)**

TRENDS

Medical care in the next century. Verstraete M. **Acta Cardiol** 1999 Apr;54(2):59–69 (43 ref.)
Paying for health care in the USA. Young DS, et al. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):1–9
Health spending, access, and outcomes: trends in industrialized countries. Anderson GF, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):178–92
Need to broaden the scope of defining 'health' [letter] Dornan DH. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):269
Functioning in a different health economy [letter; comment] Gabel JR. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):274–7 . Comment on: Health Aff (Millwood) 1998 Sep–Oct;17(5):128–40.
Health spending: questioning the assumptions [letter; comment] Ginsburg PB. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):272–4, 276–7. Comment on: Health Aff (Millwood) 1998 Sep–Oct;17(5):128–40.
National health expenditures in 1997: more slow growth. Levit K, et al. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):99–110
A global analysis of technological change in health care: the case of heart attacks. The TECH Investigators. McClellan M, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):250–5
Spending for mental health and substance abuse treatment, 1996 [published erratum appears in Health Aff (Millwood) 1998 Nov–Dec;17(6):254] McKusick D, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):147–57
The next ten years of health spending: what does the future hold? The Health Expenditures Projection Team [see comments] Smith S, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):128–40. Comment in: Health Aff (Millwood) 1999 Jan–Feb;18(1):272–4; discussion 276–7. Comment in: Health Aff (Millwood) 1999 Jan–Feb;18(1):274–5; discussion 276–7. Comment in: Health Aff (Millwood) 1999 Jan–Feb;18(1):275–7.
The next decade of health spending: a new outlook. The National Health Expenditures Projection Team. Smith S, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):86–95
The black box of health care expenditure growth determinants. Barros PP. **Health Econ** 1998 Sep;7(6):533–44
Trend analysis of dental expenditures by selected dentist and practice characteristics, 1985–1995. Brown LJ, et al. **J Am Dent Assoc** 1998 Nov;129(11):1615–21
The uncertain future of managed care [see comments] Ginzberg E. **N Engl J Med** 1999 Jan 14;340(2):144–6. Comment in: N Engl J Med 1999 Jul 15;341(3):213.
The American health care system—expenditures. Iglehart JK. **N Engl J Med** 1999 Jan 7;340(1):70–6
The association between for-profit hospital ownership and increased Medicare spending [see comments] Silverman EM, et al. **N Engl J Med** 1999 Aug 5;341(6):420–6. Comment in: N Engl J Med 1999 Aug 5;341(6):444–6.
When money is the mission—the high costs of investor-owned care [editorial; comment] Woolhandler S, et al. **N Engl J Med** 1999 Aug 5;341(6):444–6. Comment on: N Engl J Med 1999 Aug 5;341(6):420–6.
Equitable peer review. Lazarus A. **Psychiatr Serv** 1998 Dec; 49(12):1535–6, 1539
'Unfettered' hospitalisation in private sector no longer possible [news] Permain D. **S Afr Med J** 1998 Aug; 88(8):932, 934
Great medicine—pity about the cost. Cooke J. **Ulster Med J** 1998 Jun;67 Suppl 1:63–5
[The rationale for priority trends in reducing the regional expenditure risks in the social hygiene monitoring system] Lebedeva TM. **Gig Sanit** 1999 Mar–Apr;(2):68–9 **(Rus)**

HEALTH FACILITIES

The new interventional center: experiences after 12 months of operation. Loerum F, et al. **Acad Radiol** 1998 Sep;5 Suppl 2:S446–9
Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies. Cole EC, et al. **Am J Infect Control** 1998 Aug;

26(4):453–64 (96 ref.)
Posttraumatic fibromyalgia at pain facilities versus rheumatologists' offices: a commentary [comment] Fishbain DA, et al. **Am J Phys Med Rehabil** 1998 Nov–Dec; 77(6):562. Comment on: Am J Phys Med Rehabil 1994 Nov–Dec;73(6):403–12.
Medical devices and the Y2K problem. Olbrish KD. **Biomed Instrum Technol** 1998 Nov–Dec;32(6):570–2
Facilities and resources for diabetes care at regional health facilities in southern Ghana. Amoah AG, et al. **Diabetes Res Clin Pract** 1998 Nov;42(2):123–30
Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV–infected adults and adolescents in Ryan White–funded facilities in the United States. Kaplan JE, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):228–35
Compliance with universal precautions in correctional health care facilities. Gershon RR, et al. **J Occup Environ Med** 1999 Mar;41(3):181–9
[Dynamics of morbidity at health care institutions and penal labor facilities in the Udmurt Republic] Russkikh OE, et al. **Probl Tuberk** 1998;(4):13–4 (Eng. Abstr.) **(Rus)**

HISTORY

The Kansas City Field Station, 1950–1973. Chin TD. **Public Health Rep** 1999 Jul–Aug;114(4):377–80
[The Masaryk Homes and the Charles University Medical School in Prague] Mášová H. **Cas Lek Cesk** 1999 Feb 22; 138(4):122–3 **(Cze)**
[History of gynecology and perinatology in Croatia. Midwifery. Clinics and hospitals in Zagreb] Dražančić A. **Lijec Vjesn** 1999 Mar;121(3):100–8 (Eng. Abstr.) **(Scr)**

LEGISLATION & JURISPRUDENCE

[Judicial rights of patients in health facilities. Overview of current state of jurisdiction] Rieger HJ. **Dtsch Med Wochenschr** 1999 Feb 5;124(5):130–2 (10 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The challenge to health informatics for 1999–2000: form creative partnerships with industry and chief information officers to enable people to use information to improve health [editorial] Stead WW. **J Am Med Inform Assoc** 1999 Jan–Feb;6(1):88–9
Validation of training and competency of apheresis specialists: organizational guidelines for therapeutic apheresis facilities. **J Clin Apheresis** 1998;13(4):174–89
The information needs of health agency board members: a health information system challenge. Zelmer AC, et al. **Medinfo** 1998;9 Pt 2:1167–70
Clinical information systems for integrated healthcare networks. Teich JM. **Proc AMIA Symp** 1998;:19–28 (27 ref.)
[The building of a health center from the point of view of planners and doctors: a case study] Furtado LA, et al. **Rev Saude Publica** 1998 Dec;32(6):587–95 (Eng. Abstr.) **(Por)**
[Teaching (letter)] Gérvas J. **Aten Primaria** 1999 Mar 31; 23(5):317–8 **(Spa)**

STANDARDS

Accreditation manual for nephrology. Oliva D. **Int J Artif Organs** 1998 Nov;21(11):736–40
Accreditation and certification. Setti Bassanini MC. **Int J Artif Organs** 1998 Nov;21(11):730–5
[Conditions of development of the DBS/DH circular dated April 2, 1996 concerning endoscope disinfection procedures in health care sites] Labadie JC. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B60–5 **(Fre)**
[Quality and accreditation in health facilities (letter; comment)] Maunand B. **Presse Med** 1998 Jun 13; 27(21):1013. Comment on: Presse Med 1998 Jan 31;27(4):166–71. **(Fre)**

STATISTICS & NUMERICAL DATA

[Disinfectants in health service institutions and frequency of their use] Kieć–Swierczyńska M. **Med Pr** 1995;46(1):39–46 (Eng. Abstr.) **(Pol)**

SUPPLY & DISTRIBUTION

[Estimation of the blood donation necessary for self–sufficiency of blood products] Pinto V, et al. **Sangre (Barc)** 1999 Feb;44(1):38–43 (Eng. Abstr.) **(Spa)**
[Evaluation of the supplies, usage, and necessity of blood components in Asturias (1990–1995) Pinto V, et al. **Sangre (Barc)** 1999 Feb;44(1):44–8 (Eng. Abstr.) **(Spa)**
[Assessment of the acquisition, use and needs of plasma derivatives in Asturias (1990–1995)] Pinto V, et al. **Sangre (Barc)** 1999 Feb;44(1):49–54 (Eng. Abstr.) **(Spa)**

HEALTH FACILITIES, PROPRIETARY

ECONOMICS

The Health Care 250. Serb C. **Hosp Health Netw** 1999 Apr; 73(4):38–40, 42–4, 46–8

ORGANIZATION & ADMINISTRATION

The impact of ownership type on nursing home outcomes. Spector WD, et al. **Health Econ** 1998 Nov;7(7):639–53

HEALTH FACILITY ACQUISITION see **HEALTH FACILITY MERGER**

HEALTH FACILITY ADMINISTRATORS

The JIM interview. Daniel Porte, Jr, MD [interview] Porte D Jr. **J Investig Med** 1999 Mar;47(3):101–5
[Good laboratory management (GLM)—search of GLM by a manager] Takagi Y. **Rinsho Byori** 1999 Feb;Suppl 109:25–9 **(Jpn)**

EDUCATION

Health and medical informatics education for nurses and health service managers. Hovenga EJ. **Int J Med Inf** 1998 Jun;50(1–3):21–9

PSYCHOLOGY

Perception of supervisors of their role in primary health care programmes in Saudi Arabia. Jarallah JS, et al. **East Mediterr Health J** 1998 Dec;4(3):530–8
Cross–gender mentoring and career development in the health care industry. Walsh AM, et al. **Health Care Manage Rev** 1999 Summer;24(3):7–17
The effect of panel membership and feedback on ratings in a two–round Delphi survey: results of a randomized controlled trial. Campbell SM, et al. **Med Care** 1999 Sep; 37(9):964–8

HEALTH FACILITY CLOSURE

The fate of chronic in–patients after closure of psychiatric nursing homes in Norway: a personal follow–up 6 years later. Martinsen EW, et al. **Acta Psychiatr Scand** 1998 Nov; 98(5):360–5
The last armed service hospital [letter] Fulford P. **BMJ** 1999 May 1;318(7192):1213–4
High security facilities must not be closed until viable alternatives are in place [letter] Sayal K, et al. **BMJ** 1999 Jul 3;319(7201):59
Effects of hospital closure on mortality rates of the over–65 long–stay psychiatric population. Jackson GA, et al. **Int J Geriatr Psychiatry** 1998 Dec;13(12):836–9
The Qualyop Project. 1: Monitoring the dismantlement of Italian public psychiatric hospitals. Characteristics of patients scheduled for discharge. D'Avanzo B, et al. **Int J Soc Psychiatry** 1999 Summer;45(2):79–92
Relocating elderly people and nursing staff from the NHS to the independent sector. Lee S. **J Adv Nurs** 1998 Oct; 28(4):859–64
From the Centers for Disease Control and Prevention. Impact of closure of a sexually transmitted disease clinic on public health surveillance of sexually transmitted diseases—Washington, D.C., 1995. **JAMA** 1999 Jan 13; 281(2):127–8
An assessment of the potential for repatriating care from urban to rural Manitoba. Black C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS167–86
Impact of closure of a sexually transmitted disease clinic on public health surveillance of sexually transmitted diseases—Washington, D.C., 1995. **MMWR Morb Mortal Wkly Rep** 1998 Dec 18; 47(49):1067–9
Closing rural hospitals in Saskatchewan: on the road to wellness? James AM. **Soc Sci Med** 1999 Oct;49(8):1021–34
[Why has the International Center of Childhood been murdered? (editorial)] Deschamps JP. **Sante Publique** 1998 Dec;10(4):365–7 **(Fre)**
[Closure of pediatric clinics resulted in worsened care in county hospitals] Bergqvist G, et al. **Lakartidningen** 1999 Mar 3;96(9):1024–5 **(Swe)**
[A study in eight counties: can closure of infrequently used emergency service improve quality of care?] Dahlgren S, et al. **Lakartidningen** 1999 Jun 2;96(22):2732–4, 2736, 2738–9 **(Swe)**
[Physicians' responsibility in the health care crisis] Rosenhall L. **Lakartidningen** 1999 Feb 17;96(7):711–2; discussion 712–3 **(Swe)**

ECONOMICS

Closure of Royal Hospital Haslar is necessary [letter] Baird JA. **BMJ** 1999 Jul 10;319(7202):122–3
Hospital mergers and closures: survival of rural hospitals. Sinay UT. **J Rural Health** 1998 Fall;14(4):357–65
The unintended and unexpected impact of downsizing: costly hospitals become more costly. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS123–34
[Risk of survival of general hospitals is increasing (letter)] Boll G. **Chirurg** 1998 Nov;69(11):suppl 351 **(Ger)**

STATISTICS & NUMERICAL DATA

Juvenile suicide prompts closing of facility. Hayes LM. **Crisis** 1998;19(2):54–5
Home care. Anybody home? [news] **Hosp Health Netw** 1998 Sep 20;72(18):12
Monitoring the impact of hospital downsizing on access to care and quality of care. Brownell MD, et al. **Med Care** 1999 Jun;37(6 Suppl):JS135–50
The impact of the Mammography Quality Standards Act on the availability of mammography facilities. Fischer R, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):697–701
The crisis of elder care [editorial] Graham KY. **Public Health Nurs** 1998 Dec;15(6):387–8

TRENDS

[Back to the '70's (editorial)] Bauer M. **Psychiatr Prax** 1998 Nov;25(6):267–8 **(Ger)**

HEALTH FACILITY CONVERSION see **HEALTH FACILITY PLANNING**

HEALTH FACILITY ENVIRONMENT

Intensive care units: achieving utopia [editorial] Dracup K, et al. **Am J Crit Care** 1999 Mar;8(2):68–9
The effect of earplugs on sleep measures during exposure to simulated intensive care unit noise. Wallace CJ, et al. **Am J Crit Care** 1999 Jul;8(4):210–9
Is the air in your hospital making you sick? Wilburn S. **Am J Nurs** 1999 Jul;99(7):71
A stimulation–retreat special care unit for elders with dementing illness. Lawton MP, et al. **Int Psychogeriatr** 1998 Dec;10(4):379–95
Meal procedures in institutions for elderly people: a theoretical interpretation. Sidenvall B. **J Adv Nurs** 1999 Aug;30(2):319–28
A randomized trial of a combined physical activity and environmental intervention in nursing home residents: do sleep and agitation improve? Alessi CA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):784–91
Environmental characteristics of nursing homes and community–based settings, and the well–being of adults with intellectual disability. Heller T, et al. **J Intellect Disabil Res** 1998 Oct;42 (Pt 5):418–28
Painting collections in hospitals: humanity in medicine. James AE Jr. **J R Soc Health** 1998 Aug;118(4):227–30
[Virus resistance in a hospital environment: overview of the virucide activity of disinfectants used in liquid form] Soule H, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):693–703 (49 ref.) (Eng. Abstr.) **(Fre)**
[outbreak of invasive pulmonary mycosis in neutropenic hematologic patients in relation to remodelling construction work] Gaspar C, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):113–8 (Eng. Abstr.) **(Spa)**

STANDARDS

Outdoor wandering parks for persons with dementia: a survey of characteristics and use. Cohen–Mansfield J, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13(2):109–17
The nursing home at night: effects of an intervention on noise, light, and sleep. Schnelle JF, et al. **J Am Geriatr Soc** 1999 Apr;47(4):430–8
Environmental impact of the NICU on developmental outcomes. Blackburn S. **J Pediatr Nurs** 1998 Oct; 13(5):279–89 (60 ref.)

STATISTICS & NUMERICAL DATA

Ambient sound levels in a state psychiatric hospital. Holmberg SK, et al. **Arch Psychiatr Nurs** 1999 Jun; 13(3):117–26
Noise sources and levels in the Evgenidion Hospital intensive care unit. Tsiou C, et al. **Intensive Care Med** 1998 Aug; 24(8):845–7

HEALTH FACILITY MERGER

UCSF–Stanford health–care merger to create value for academic medicine. Van Etten P. **Acad Radiol** 1998 Sep; 5 Suppl 2:S375–6
Evidence based mergers? [editorial] Garside P. **BMJ** 1999 Feb 6;318(7180):345–6
Dangers of inpatient rehabilitation industry consolidation [letter; comment] Batavia AI. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):256–7. Comment on: Health Aff (Millwood) 1998 May–Jun;17(3):209–15.
UCSF/Stanford: building a 'prestige cartel' [comment] Goldsmith J. **Health Aff (Millwood)** 1999 Mar–Apr; 18(2):149–51. Comment on: Health Aff (Millwood) 1999 Mar–Apr;18(2):143–8.
Camelot or common sense? The logic behind the UCSF/Stanford merger. Van Etten P. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):143–8
Fragile future: a rural hospital weighs its options. Bybee B, et al. **Hosp Health Netw** 1999 May;73(5):20
Mergers. Gentlemen's agreement. Washam C. **Hosp Health Netw** 1998 Sep 20;72(18):43–4
Modern health care economics [editorial] Johnson RD Jr. **J S C Med Assoc** 1998 Oct;94(10):448–9
The truth about mergers and acquisitions. Recommendations for physicians in a dynamically changing health care environment. Ward RD. **Mich Med** 1999 Apr;98(4):24–30
Merger of top Californian medical schools turns sour [news] Dalton R. **Nature** 1999 Jul 22;400(6742):300

ECONOMICS

Evaluating hospital mergers [letter; comment] Colton RD, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):260–1.

HEALTH FACILITY MERGER

Comment on: Health Aff (Millwood) 1997 Nov-Dec;16(6):62-74.
Market power and hospital pricing: are nonprofits different? Melnick G, et al. **Health Aff (Millwood)** 1999 May-Jun; 18(3):167-73
Hospital sales. A deal behind every door. Gibson L. **Hosp Health Netw** 1998 Nov 5;72(21):47-8
Hospital mergers and closures: survival of rural hospitals. Sinay UT. **J Rural Health** 1998 Fall;14(4):357-65
United, Humana cancel planned merger [news] **Minn Med** 1998 Sep;81(9):42

LEGISLATION & JURISPRUDENCE

Politicians may not have same goals as clinicians with regard to mergers [letter] Sheldon T, et al. **BMJ** 1999 Jun 26; 318(7200):1762-3
HMO consolidations: how national mergers affect local markets. Feldman RD, et al. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):96-104
Increasing consolidation in healthcare markets: what are the antitrust policy implications? Haas-Wilson D, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1403-19 (28 ref.)
Antitrust enforcement in the healthcare industry: the expanding scope of state activity. Hellinger FJ. **Health Serv Res** 1998 Dec;33(5 Pt 2):1477-94 (35 ref.)
Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131-82 (0 ref.)
Nonprofit to for-profit hospital transactions: all roads lead to the attorney general's office. Moore BE. **J Health Care Finance** 1999 Spring;25(3):29-36
Rural hospital mergers, antitrust policy, and the Ukiah case. Blackstone EA, et al. **J Health Polit Policy Law** 1998 Dec; 23(6):949-71

ORGANIZATION & ADMINISTRATION

Learning from a merger opportunity. Francoeur DE. **Biomed Instrum Technol** 1999 Jan-Feb;33(1):45-9
Three rules for successfully merging clinical engineering departments. Piepenbrink J. **Biomed Instrum Technol** 1998 Sep-Oct;32(5):527-9
Hospital mergers can bring breath of fresh air, CEO says [interview by Heather Kent] Hassen P. **CMAJ** 1998 Dec 1;159(11):1401
Evaluating the sale of a nonprofit health system to a for-profit hospital management company: the Legacy Experience. King JG, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):103-21
Analysis of the rationale for, and consequences of, nonprofit and for-profit ownership conversions. Mark TL. **Health Serv Res** 1999 Apr;34(1 Pt 1):83-101
The tactical made practical. **Hosp Health Netw** 1998 Nov 5;72(21):40-1, 3
Hospital consolidation. Applying stakeholder analysis to merger life-cycle. Baker CM, et al. **J Nurs Adm** 1999 Mar; 29(3):11-20
Consolidation of trauma programs in the era of large health care delivery networks. Trooskin SZ, et al. **J Trauma** 1999 Mar;46(3):488-93
Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J. **Public Health Rep** 1999 Mar-Apr;114(2):108-19 (41 ref.)

STATISTICS & NUMERICAL DATA

Nonprofit hospital conversions and community benefits: new evidence from three states. Young GJ, et al. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):146-55

TRENDS

Time to rethink accreditation criteria for programs that train health professionals. Robiner WN, et al. **Acad Med** 1999 Feb;74(2):97-100
Consolidation in the health care sector. Magel JS. **J Health Care Finance** 1999 Spring;25(3):22-8

HEALTH FACILITY PLANNING

see related
FACILITY DESIGN AND CONSTRUCTION

Establishing community-orientated medical schools: key issues and steps in early planning. Hamad B. **Med Educ** 1999 May;33(5):382-9

LEGISLATION & JURISPRUDENCE

Nonprofit conversion: theory, evidence, and state policy options. Marsteller JA, et al. **Health Serv Res** 1998 Dec; 33(5 Pt 2):1495-535 (90 ref.)

ORGANIZATION & ADMINISTRATION

A comparison of measures of access to child health clinics and the implications for modelling the location of new clinics. Hyndman JC, et al. **Aust N Z J Public Health** 1999 Apr;23(2):189-95
Enhancing the family medicine curriculum in deliveries and emergency medicine as a way of developing a rural teaching site. Rodney WM, et al. **Fam Med** 1998 Nov-Dec; 30(10):712-9
[The organization of a digestive endoscopy unit] Bordas JM. **Gastroenterol Hepatol** 1999 Feb;22(2):93-9 **(Spa)**

HEALTH FACILITY SIZE

[Quality standards for hospital hygiene in intermediate and large hospitals in Switzerland: a recommended concept] Sax H, et al. **Schweiz Med Wochenschr** 1999 Feb 20; 129(7):276-84 (Eng. Abstr.) **(Ger)**

ECONOMICS

[Larger radiology clinics are superior to smaller facilities] Kuhn FP. **Radiologe** 1999 Apr;39(4):M73-4 **(Ger)**

TRENDS

[Hospital planning--an overview of the '90's. What are the effects on smaller hospitals?] Koselowski G, et al. **Chirurg** 1998 Nov;69(11):suppl 338-47 **(Ger)**

HEALTH FAIRS

Consumers rush to buy wares at Canada's travelling "health show" [news] Hass J. **CMAJ** 1999 Aug 24;161(4):429
A survey of African Americans at a community health fair. Brown CM, et al. **J Health Care Poor Underserved** 1998 Nov;9(4):357-66
A community care initiative: Maryland and Hopkins students take to the streets in Baltimore City. McCary J, et al. **Md Med J** 1999 Jan-Feb;48(1):26-32
[Early detection of diabetes in visitors to a health fair according to new definition of diabetes] Breidert M, et al. **Gesundheitswesen** 1998 Oct;60(10):572-5 (Eng. Abstr.) **(Ger)**

HEALTH FOOD

see related
DIET, MACROBIOTIC

Human semen quality in relation to dietary pesticide exposure and organic diet. Juhler RK, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):415-23
Functional foods: health boon or quackery? [editorial] Jacobson MF, et al. **BMJ** 1999 Jul 24;319(7204):205-6
Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? Macfarlane GT, et al. **BMJ** 1999 Apr 10;318(7189):999-1003 (48 ref.)
Health benefits of probiotics. Goldin BR. **Br J Nutr** 1998 Oct;80(4):S203-7 (24 ref.)
Prebiotics and synbiotics: concepts and nutritional properties. Roberfroid MB. **Br J Nutr** 1998 Oct;80(4):S197-202 (38 ref.)
Development of consumer probiotics for the US market. Sanders ME. **Br J Nutr** 1998 Oct;80(4):S213-8
European market developments in prebiotic- and probiotic-containing foodstuffs. Young J. **Br J Nutr** 1998 Oct;80(4):S231-3
Scientific and regulatory aspects of nutraceutical products in the United States. Kottke MK. **Drug Dev Ind Pharm** 1998 Dec;24(12):1177-95 (58 ref.)
Health food shops, risks of complementary medicine, and ethical standards of research [editorial; comment] Ernst E. **J R Coll Physicians Lond** 1998 Sep-Oct;32(5):399. Comment on: J R Coll Physicians Lond 1998 Sep-Oct;32(5):426-8.
Advice given by health food shops: is it clinically safe? [see comments] Vickers AJ, et al. **J R Coll Physicians Lond** 1998 Sep-Oct;32(5):426-8. Comment in: J R Coll Physicians Lond 1998 Sep-Oct;32(5).399.
Is organic food production feasible? Leckie J. **Nutr Health** 1999;13(2):109-19
Semen quality and sex hormones among organic and traditional Danish farmers. ASCLEPIOS Study Group. Larsen SB, et al. **Occup Environ Med** 1999 Feb;56(2):139-44
Results of a survey of small-animal practitioners on the perceived clinical efficacy and safety of an oral nutraceutical. Anderson MA, et al. **Prev Vet Med** 1999 Jan 1;38(1):65-73

ADVERSE EFFECTS

Acute cyanide toxicity caused by apricot kernel ingestion. Suchard JR, et al. **Ann Emerg Med** 1998 Dec;32(6):742-4
Should we fear "health foods"? [letter] Feingold RM. **Arch Intern Med** 1999 Jul 12;159(13):1502

CLASSIFICATION

Organic: What's in a name? [news] Fisher BE. **Environ Health Perspect** 1999 Mar;107(3):A 150-3

STANDARDS

International food committee agrees on organic food guidelines [news] Kapp C. **Lancet** 1999 Jul 24;354(9175):314

HEALTH INSURANCE see **INSURANCE, HEALTH**

HEALTH INSURANCE FOR AGED AND DISABLED, TITLE 18 see **MEDICARE**

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT

LEGISLATION & JURISPRUDENCE

American health care [letter; comment] Ross AE. **Can Fam Physician** 1998 Sep;44:1803-4. Comment on: Can Fam Physician 1998 Apr;44:733-5.
The Health Insurance Portability and Accountability Act of 1996: understanding the anti-kickback laws. Tomes JP. **J Health Care Finance** 1998 Winter;25(2):55-62 (9 ref.)
Cheaper and better. The congressional administrative simplification mandate facilitates the transition to electronic medical records. Tsai VW. **J Leg Med** 1998 Dec; 19(4):549-86
Health information technology and privacy: the legal perspective. Christiansen JR. **MD Comput** 1999 Jul-Aug; 16(4):15-6
Health Insurance Portability and Accountability Act of 1996: lessons from the States. Hing E, et al. **Med Care** 1999 Jul; 37(7):692-705

ORGANIZATION & ADMINISTRATION

Providing health insurance to the short-term unemployed. Baumgardner JR. **Inquiry** 1998 Fall;35(3):266-79
Patient empowerment: individual control of health benefits [editorial] Nirschl RP. **Orthopedics** 1999 Aug;22(8):727-8

HEALTH INSURANCE REIMBURSEMENT see **INSURANCE, HEALTH, REIMBURSEMENT**

HEALTH INSURANCE, VOLUNTARY see **INSURANCE, HEALTH**

HEALTH LEGISLATION see **LEGISLATION**

HEALTH MAINTENANCE ORGANIZATIONS

Evidence-based medicine [letter; comment] David DS. **Am J Med** 1998 Oct;105(4):361-2. Comment on: Am J Med 1997 Dec;103(6):529-35.
Managed care organizations' assessment of reimbursement for new technology, procedures, and drugs. Zarkowsky H. **Arch Pathol Lab Med** 1999 Aug;123(8):677-9 (2 ref.)
Providers' smoking cessation attitudes and practices for older patients. Kviz FJ, et al. **Behav Med** 1999 Summer; 25(2):53-61
The third dimension [letter] Carey PD. **Chest** 1998 Dec; 114(6):1797
Medical outcomes of care for breast cancer among health maintenance organization and fee-for-service patients. Vernon SW, et al. **Clin Cancer Res** 1995 Feb;1(2):179-84
Chronic pain management in a health maintenance organization. McCarberg B, et al. **Clin J Pain** 1999 Mar; 15(1):50-7
Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Cohen JA, et al. **Clin Ther** 1999 Jan;21(1):190-204
First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Selby JV, et al. **Diabetes Care** 1999 Jan;22(1):38-44
Risk and protective factors associated with screening for complications of diabetes in a health maintenance organization setting. Simon LP, et al. **Diabetes Care** 1999 Feb;22(2):208-12
Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Kinney W, et al. **Gynecol Oncol** 1998 Dec;71(3):428-30
How to teach residents about ethical managed care--even if the mention of "managed care" makes your blood boil. Sabin JE. **Harv Rev Psychiatry** 1999 May-Jun;7(1):64-7
Coverage clashes. No zeal to appeal [news] Blecher MB. **Hosp Health Netw** 1999 Apr;73(4):30
Do HMOs purposely stall in paying claims? [news] Davis R, et al. **Hosp Health Netw** 1999 Jul;73(7):22
Surrogate births. Born, but not free [news] Kelliher K. **Hosp Health Netw** 1999 Jun;73(6):30
Doctors & HMOs. From balking to brokering [news] Novarro L. **Hosp Health Netw** 1999 Jun;73(6):22, 24
Faith healing? Soul care [news] Novarro L. **Hosp Health Netw** 1999 Jun;73(6):20
Influenza immunization among Medicare beneficiaries enrolled in a health maintenance organization: 1994. Florida Medical Quality Assurance, Inc. **J Fla Med Assoc** 1998 Apr;85(1):19-20
On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc. **J Fla Med Assoc** 1998 Apr;85(1):25-6
Risk, trust, and the HMO [editorial] Flood AB. **J Health Soc Behav** 1998 Sep;39(3):187-8
HMO research network to focus on cancer prevention and control [news] Moulton G. **J Natl Cancer Inst** 1999 Aug 18;91(16):1363
Re: Race, prostate cancer survival, and membership in a large health maintenance organization [letter; comment] Roach M 3rd, et al. **J Natl Cancer Inst** 1999 May 5;91(9):801-3 . Comment on: J Natl Cancer Inst 1998 Jul 1;90(13):986-90.
Differences in providers' beliefs about benefits and risks of hormone replacement therapy in managed care. Exline JL, et al. **J Womens Health** 1998 Sep;7(7):879-84

Acceptability of a substitution of estrogen replacement therapy to women enrolled in a health maintenance organization. Gardner J, et al. **J Womens Health** 1998 Oct; 7(8):1027–31

Managed care market share, fee-for-service Medicare, and information theory [letter; comment] Blanco C, et al. **JAMA** 1999 Jul 21;282(3):235–6. Comment on: JAMA 1999 Feb 3;281(5):432–7.

Does use of potent antiretroviral therapy differ by health care setting? [letter; comment] Fessel J, et al. **JAMA** 1999 May 12;281(18):1696–7. Comment on: JAMA 1998 Nov 4;280(17):1497–503.

Variations in Medicare health maintenance organizations [editorial; comment] Retchin SM. **JAMA** 1999 Feb 24; 281(8):755–6. Comment on: JAMA 1999 Feb 24;281(8):720–6.

Modeling and evaluation of continuity of care in a staff model HMO. Citro R, et al. **MD Comput** 1998 Sep–Oct; 15(5):298–306

HMO insolvencies: physicians left holding the bag. **Mich Med** 1999 Jan;98(1):17–8 (0 ref.)

Dual agency, dual relationships, boundary crossings, and associated boundary violations: a survey of military and civilian psychiatrists. Hines AH, et al. **Mil Med** 1998 Dec; 163(12):826–33

Primary care providers. The view from where I stand [comment] Neelon FA. **N C Med J** 1999 Jul–Aug;60(4):211 . Comment on: N C Med J 1999 Jul–Aug;60(4):208–10.

Prenatal care for low-income women enrolled in a managed-care organization. Gazmararian JA, et al. **Obstet Gynecol** 1999 Aug;94(2):177–84

Gastrointestinal symptoms and use of medical care associated with child day care and health care plan among preschool children. Shi L, et al. **Pediatr Infect Dis J** 1999 Jul; 18(7):596–603

Comparison of perinatal outcomes among TennCare managed care organizations. Cooper WO, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):525–9

A new approach to managed care: the provider-run organization. Schwartz BJ, et al. **Psychiatr Q** 1998 Winter; 69(4):345–53

Treating advanced ovarian cancer within the health maintenance organization: a Kaiser Permanente approach. Rarick M. **Semin Oncol** 1999 Feb;26(1 Suppl 1):52–8 (10 ref.)

Should physicians unionize? Yes, it would curb HMO abuse [editorial] DeBakey ME, et al. **South Med J** 1999 Sep; 92(9):934–5

Medicare+Choice: reality sets in. Meyer A. **Tenn Med** 1999 Jan;92(1):9–12

An era of insurgency in medicine. Gunby RT Jr. **Tex Med** 1999 May;95(5):13–6

Forming community coalitions: "smoking stinks". Des Vaux Oakes J. **Tob Control** 1998 Winter;7 Suppl:S27–8; discussion S32–5

Smoking as a vital sign: a work in progress. Jessen J. **Tob Control** 1998 Winter;7 Suppl:S45–6; discussion S47–9

Waking the health plan giant: Group Health Cooperative stops counting sheep and starts counting key tobacco indicators. McAfee T. **Tob Control** 1998 Winter;7 Suppl:S41–4; discussion S47–9

Anti-tobacco media campaign for young people. Seghers T, et al. **Tob Control** 1998 Winter;7 Suppl:S29–30; discussion S32–5

ECONOMICS

Fiscal and patient care concerns [editorial] **Alaska Med** 1998 Oct–Dec;40(4):95

Survey of pharmacy benefit trends released [news] **Am J Health Syst Pharm** 1998 Aug 15;55(16):1663

1997 saw HMO membership up, hospital days down [news] **Am J Health Syst Pharm** 1999 Mar 15;56(6):505–6

Therapeutic interchange of conjugated and esterified estrogens in a managed care organization. Baluch WM, et al. **Am J Health Syst Pharm** 1999 Mar 15;56(6):537–42

The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. McCombs JS, et al. **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2485–99

Costs of health care use by women HMO members with a history of childhood abuse and neglect. Walker EA, et al. **Arch Gen Psychiatry** 1999 Jul;56(7):609–13

The progressive cost of complications in type 2 diabetes mellitus. Brown JB, et al. **Arch Intern Med** 1999 Sep 13; 159(16):1873–80

Rough seas in US managed care [editorial] **CMAJ** 1999 Sep 21;161(6):669, 671 **(Eng, Fre)**

Does a fixed-dollar premium contribution lower spending? Buchmueller TC. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):228–35

Medicaid managed care payment rates in 1998. Holahan J, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):217–27

Reversal of fortune: commercial HMOs in the Medicaid market. McCue MJ, et al. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):223–30

Impact of the BBA on Medicare HMO payments for rural areas. Schoenman JA. **Health Aff (Millwood)** 1999 Jan–Feb; 18(1):244–54

Price competition and hospital cost growth in the United States (1989–1994). Bamezai A, et al. **Health Econ** 1999 May;8(3):233–43

HMO selection and Medicare costs: Bayesian MCMC estimation of a robust panel data tobit model with survival. Hamilton BH. **Health Econ** 1999 Aug;8(5):403–14

Perceived financial incentives, HMO market penetration, and physicians' practice styles and satisfaction. Hadley J, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):307–21

Differences in resource use and costs of primary care in a large HMO according to physician specialty [see comments] Selby JV, et al. **Health Serv Res** 1999 Jun; 34(2):503–18. Comment in: Health Serv Res 1999 Jun;34(2):519–24.

Collective clout. Share the health. Castrey M. **Hosp Health Netw** 1998 Nov 20;72(22):43–4

Drug drag. Rx rising [news] Garber K. **Hosp Health Netw** 1999 Apr;73(4):26, 28

Medicare HMOs. Risk retreat [news] Greene J. **Hosp Health Netw** 1999 Sep;73(9):14, 16

Al wants more hair, less fat, and a better sex life ... and he wants his health plan to pay for it. Greene J. **Hosp Health Netw** 1999 Mar;73(3):36–40, 42, 2

Kicking the habit. Near-sighted on nicotine? Huff C. **Hosp Health Netw** 1998 Oct 5;72(19):48

Back-to-school bonus. Kaiser picks up the premiums—and helps displaced homemakers earn college diplomas. Huff C. **Hosp Health Netw** 1998 Oct 20;72(20):20, 3

Another vicious cycle? Serb C. **Hosp Health Netw** 1998 Oct 20;72(20):24–8, 30, 3

Do Medicare HMOs cost shift? Feldman R, et al. **Inquiry** 1998 Fall;35(3):315–31

Specialty contact capitation. Frank C, et al. **J Health Care Finance** 1999 Spring;25(3):17–21

Trust me: technical and institutional determinants of health maintenance organizations shifting risk to physicians. Sleeper S, et al. **J Health Soc Behav** 1998 Sep;39(3):189–200

Challenges in the NICU: questions or answers? Speer ME. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S1–5 (30 ref.)

The relationship between method of physician payment and patient trust [see comments] Kao AC, et al. **JAMA** 1998 Nov 18;280(19):1708–14. Comment in: JAMA 1998 Nov 18;280(19):1703–4. Comment in: JAMA 1999 Apr 7;281(13):1173–4.

Echoes across the Atlantic [editorial] **Lancet** 1999 Jul 31; 354(9176):351

Market forces and health-care systems [letter] Singer A. **Lancet** 1999 Sep 18;354(9183):1037–8

Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Helms LJ, et al. **Med Care** 1999 Jul;37(7):652–61

The impact of financial incentives on quality of health care. Dudley RA, et al. **Milbank Q** 1998;76(4):649–86, 511 (71 ref.)

The American health care system: Wall Street and health care. Kuttner R. **N Engl J Med** 1999 Feb 25;340(8):664–8

IBC fee schedule revisions prompt rebuttal. **Pa Med** 1998 Sep;101(9):1

Health care costs of formula-feeding in the first year of life. Ball TM, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):870–6

The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Lieu TA, et al. **Pediatrics** 1999 Jun;103(6):e72

Replace Medicare with Americare [letter] Frankel G. **Tex Med** 1998 Oct;94(10):10–1

Upping the ante. Moran T. **Tex Med** 1999 Jul;95(7):51–4

Standing on shaky ground. Moran T. **Tex Med** 1999 May; 95(5):32–4

Cost controls must not damage quality. Batchlor E, et al. **West J Med** 1999 Jun;170(6):379–80

Why HMOs are dumping their Medicaid patients. Gottlieb S. **West J Med** 1999 Jun;170(6):378–9

Whatever happened to professional courtesy? The illegality of waiving co-pays and deductibles. Barratt K. **WMJ** 1998 Nov;97(10):44–5

HISTORY

A quarter century of health maintenance [news] Mitka M. **JAMA** 1998 Dec 23–30;280(24):2059–60

LEGISLATION & JURISPRUDENCE

Perception is not always reality [editorial] Gorney M. **Ann Plast Surg** 1998 Oct;41(4):448–50

And then there was one [editorial] Morain WD. **Ann Plast Surg** 1999 Apr;42(4):455

Should government intervene to protect nonprofits? Bloche MG. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):7–25 (43 ref.)

HMO consolidations: how national mergers affect local markets. Feldman RD, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):96–104

Should Medicare HMO benefits be standardized? Fox PD, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):40–52

Marshfield Clinic, physician networks, and the exercise of monopoly power. Greenberg W. **Health Serv Res** 1998 Dec;33(5 Pt 2):1461–76

Discount fallout. Hammered & nailed [news] Haugh R. **Hosp Health Netw** 1999 Mar;73(3):18, 20

Should Congress pass a patient-protection law? [news] Waxman J, et al. **Hosp Health Netw** 1999 Jan;73(1):22

ERISA preemption and the legal liability of HMOs: possibilities for change. Lynk MV. **J Natl Med Assoc** 1998 Nov;90(11):645–7

US Senate passes patients' bill of rights [news] Rovner J. **Lancet** 1999 Jul 24;354(9175):316

Suing HMOs: patients should have the right [editorial] [see comments] D'Ambrosia R. **Orthopedics** 1998 Nov; 21(11):1169. Comment in: Orthopedics 1999 Feb;22(2):179, 261.

Suing the HMO has a risk [editorial; comment] Goldner JL. **Orthopedics** 1999 Feb;22(2):179, 261. Comment on: Orthopedics 1998 Nov;21(11):1169.

ERISA shield is cracked; HMOs open to liability. Improves legal atmosphere for physicians, patients. Employee Retirement Income Security Act [news] **Pa Med** 1999 Feb; 102(2):1–2

State insurance commissioner actions against health maintenance organizations for denial of emergency care. Neely KW, et al. **Prehosp Emerg Care** 1999 Jan–Mar; 3(1):19–22

New health options available under Medicare + Choice [news] **Public Health Rep** 1998 Sep–Oct;113(5):384

Closing the loophole. Maldonado M. **Tex Med** 1999 Jul; 95(7):46–9

Texas breaks new ground. Moran T. **Tex Med** 1998 Dec; 94(12):58–61

Mining a new legal theory. Moran T. **Tex Med** 1999 Feb; 95(2):28–30

Strength in numbers. Moran T. **Tex Med** 1999 Aug;95(8):42–5

MANPOWER

Labor. Unrest spreads [news] **Hosp Health Netw** 1998 Sep 20;72(18):14

Pay flap. Lone Star wars [news] Greene J. **Hosp Health Netw** 1999 Mar;73(3):26, 28

Nurse practitioners and physician assistants as primary care providers in institutional settings. Jacobson PD, et al. **Inquiry** 1998–99 Winter;35(4):432–46

Physician integration options. You're not cats, they're not ranchers. Cawley KJ, et al. **Mich Med** 1998 Dec; 97(12):10–1, 36

Mental health staffing in managed care organizations: a case study. Scheffler R, et al. **Psychiatr Serv** 1998 Oct; 49(10):1303–8

ORGANIZATION & ADMINISTRATION

Assurance opportunities for local health departments. Reid WM, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):128–33 (18 ref.)

Implementation of a hospitalist system in a large health maintenance organization: the Kaiser Permanente experience. Craig DE, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):355–9

Variations in the management of primary care: effect on cost in an HMO network. Rich EC, et al. **Arch Intern Med** 1998 Nov 23;158(21):2363–71

Universal emergency access under managed care: universal doubt or mission impossible? Larkin GL, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):213–25 (70 ref.)

Renal assessment practices and the effect of nurse case management of health maintenance organization patients with diabetes. Sikka R, et al. **Diabetes Care** 1999 Jan; 22(1):1–6

What could have saved John Worthy? **Hastings Cent Rep** 1998 Jul–Aug;28(4):S1–17

Bringing forth Medicare+Choice: HCFA's Robert A. Berenson [interview by John K Iglehart] Berenson RA. **Health Aff (Millwood)** 1999 Jan–Feb;18(1):144–9

Regaining public trust [see comments] Goldberg RK. **Health Aff (Millwood)** 1998 Nov–Dec;17(6):138–41. Comment in: Health Aff (Millwood) 1999 May–Jun;18(3):269.

Blue shield of California's Access+ HMO. Richard K, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):174–7

How to improve trust in health plans [letter; comment] Wolfson DB. **Health Aff (Millwood)** 1999 May–Jun; 18(3):269. Comment on: Health Aff (Millwood) 1998 Nov–Dec;17(6):138–41.

Physicians' financial incentives in five dimensions: a conceptual framework for HMO managers. Magnus SA. **Health Care Manage Rev** 1999 Winter;24(1):57–72 (70 ref.)

Affinity groups. Senior savvy is the first step. Babwin D. **Hosp Health Netw** 1998 Sep 20;72(18):44, 46

Out there care. There's strength in strange: Lifeguard, the HMO that doesn't act like one, boasts top ratings from consumers, fat profits, and zero debt. Haugh R. **Hosp Health Netw** 1999 Feb;73(2):60–4

Chronic care. Case-sensitive software. Pasternack A. **Hosp Health Netw** 1998 Oct 5;72(19):50

Recent determinants of new entry of HMOs into a Medicare risk contract: a diversification strategy. Pai CW, et al. **Inquiry** 1999 Spring;36(1):78–89

Consumer protection and the HMO backlash: are HMOs to blame for drive-through deliveries? Volpp KG, et al. **Inquiry** 1999 Spring;36(1):101–9

Chronic care clinics: a randomized controlled trial of a new model of primary care for frail older adults [see comments] Coleman EA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):775–83 . Comment in: J Am Geriatr Soc 1999 Jul;47(7):908–9.

Emergency contraception: preliminary report of a demonstration and evaluation project. Petitti DB, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):251–4

Consolidation in the health care sector. Magel JS. **J Health Care Finance** 1999 Spring;25(3):22–8

Managed care in rural markets: availability and enrollment.

Wysong JA, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):72–84

Markets, governments, and HMO development in the 1990s. Balla SJ. **J Health Polit Policy Law** 1999 Apr;24(2):215–38 (65 ref.)

United Health Care of North Carolina. Casey M, et al. **J Rural Health** 1998 Summer;14(3):200–10

Regence HMO Oregon. Casey M, et al. **J Rural Health** 1998 Summer;14(3):244–56

Missouri Advantage. Casey M, et al. **J Rural Health** 1998 Summer;14(3):257–67

NorthMed HMO. Christianson J, et al. **J Rural Health** 1998 Summer;14(3):233–43

Medical Associates HMO. Wellever A, et al. **J Rural Health** 1998 Summer;14(3):224–32

Rocky Mountain HMO. Wellever A, et al. **J Rural Health** 1998 Summer;14(3):211–23

Implications of HMOs for rural providers and consumers. Wellever A. **J Rural Health** 1998 Summer;14(3):268–73

Quality of care in investor-owned vs not-for-profit HMOs. Himmelstein DU, et al. **JAMA** 1999 Jul 14;282(2):159–63

Sam Ho, MD: idealist, innovator, entrepreneur [interview by Fitzhugh Mullan] Ho S. **JAMA** 1999 Mar 10; 281(10):947–51

Replication of clinical innovations in multiple medical practices. Henley NS, et al. **Jt Comm J Qual Improv** 1998 Nov;24(11):623–39

IMPROVE: bridge over troubled waters. Magnan S, et al. **Jt Comm J Qual Improv** 1998 Oct;24(10):566–78

Motives for health plan-academic health center relationships: journal review of the first quarter century. Parkerton PH. **Med Care Res Rev** 1999;56 Suppl 2:111–38

Obstetrician-gynecologists as primary care providers? How North Carolina HMOs decide [see comments] Guise JM, et al. **N C Med J** 1999 Jul-Aug;60(4):208–10. Comment in: N C Med J 1999 Jul-Aug;60(4):211.

Prevention of work-related disability. Feldstein A, et al. **Occup Med** 1998 Oct-Dec;13(4):841–50, v (13 ref.)

New times, old words, new meanings [editorial] Goldwyn RM. **Plast Reconstr Surg** 1999 Apr;103(4):1312

The primary care physician's view of managed care in 1998. Friedenberg RM. **Radiology** 1999 Feb;210(2):297–300

Building effective strategies to decrease tobacco use in a health maintenance organisation: Group Health Cooperative of Puget Sound. Curry SJ. **Tob Control** 1998 Winter;7 Suppl:S21–3; discussion S24–5

A comprehensive influenza campaign in a managed care setting. Pearson DC, et al. **Vaccine** 1998 Nov; 16(18):1718–21

Penn Health for Women: the evolution of a women's health program in an academic setting. Battistini M. **Womens Health Issues** 1999 May-Jun;9(3):162–75

STANDARDS

Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Mullooly J, et al. **Am J Epidemiol** 1999 Jan 15;149(2):186–94

Patterns of care for depressed older adults in a large-staff model HMO. Unützer J, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):235–43

Establishing realistic performance standards for community pharmacists' drug-use-review activities in managed care contracts [comment] Rupp MT. **Am J Health Syst Pharm** 1999 Mar 15;56(6):566–7. Comment on: Am J Health Syst Pharm 1998 Jun 1;55(11):1141–5.

Provider group characteristics & quality report card performance: a cross-sectional study in a managed care setting. Simon LP, et al. **Am J Med Qual** 1999 May-Jun; 14(3):138–45

Physician financial incentives and feedback: failure to increase cancer screening in Medicaid managed care. Hillman AL, et al. **Am J Public Health** 1998 Nov; 88(11):1699–701

Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee-for-service insurance. Soumerai SB, et al. **Arch Intern Med** 1999 Sep 27;159(17):2013–20

Joint Commission on Accreditation of Healthcare Organizations' expectations for transfusion medicine in health care organizations. Belanger AC. **Arch Pathol Lab Med** 1999 Jun;123(6):472–4 (3 ref.)

Raising the bar: the use of performance guarantees by the Pacific Business Group on Health. Schauffler HH, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):134–42

Quality of primary care practice in a large HMO according to physician specialty [see comments] Grumbach K, et al. **Health Serv Res** 1999 Jun;34(2):485–502. Comment in: Health Serv Res 1999 Jun;34(2):519–24.

Commentary: practice environment, specialty, and primary care [comment] O'Connor PJ. **Health Serv Res** 1999 Jun; 34(2):519–24. Comment on: Health Serv Res 1999 Jun;34(2):485–502. Comment on: Health Serv Res 1999 Jun;34(2):503–18.

You never call. Health plans overlook an easy step to keeping seniors satisfied. Serb C. **Hosp Health Netw** 1998 Oct 20; 72(20):32–3, 3

Medicaid beneficiaries' experiences in HMO and fee-for-service health care. Piña DL. **J Health Care Poor Underserved** 1998 Nov;9(4):433–48

Data-driven quality improvement for HMO patients: one agency's experience with OASIS and OBQI. Adams CE, et al. **J Nurs Adm** 1998 Oct;28(10):20–5

Accreditation by the National Committee on Quality Assurance (NCQA): a description. Bell D, et al. **J Okla State Med Assoc** 1999 May;92(5):234–7 (13 ref.)

A primer on clinical management guidelines in neonatology. Bowen FW. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S10–2 (36 ref.)

Quality of care in investor-owned vs not-for-profit HMOs. Himmelstein DU, et al. **JAMA** 1999 Jul 14;282(2):159–63

Objective and subjective measures of the quality of managed care in nursing homes. Schnelle JF, et al. **Med Care** 1999 Apr;37(4):375–83

Review of studies that compare the quality of cardiovascular care in HMO versus non-HMO settings. Seidman JJ, et al. **Med Care** 1998 Dec;36(12):1607–25 (51 ref.)

The impact of financial incentives on quality of health care. Dudley RA, et al. **Milbank Q** 1998;76(4):649–86, 511 (71 ref.)

Competition, quality of care, and the role of consumers. McLaughlin CG, et al. **Milbank Q** 1998;76(4):737–43

Improving the quality of health care. Observations from the field. Mattingly PH. **Milbank Q** 1998;76(4):733–5

State society pursues national Medicare policy change on admitting privileges [news] **Pa Med** 1999 Apr;102(4):4

HMOs agree on standard site visit protocol [news] **Pa Med** 1998 Oct;101(10):2

Clinical outcomes and maternal perceptions of an updated model of perinatal care. Lieu TA, et al. **Pediatrics** 1998 Dec;102(6):1437–44

Development of a consumer survey for behavioral health services. Eisen SV, et al. **Psychiatr Serv** 1999 Jun; 50(6):793–8

Satisfaction with managed care among persons with bipolar disorder. Scholle SH, et al. **Psychiatr Serv** 1999 Jun; 50(6):751

STATISTICS & NUMERICAL DATA

1997 saw HMO membership up, hospital days down [news] **Am J Health Syst Pharm** 1999 Mar 15;56(6):505–6

The Kaiser Permanente/USC Patient Consultation Study: change in quality of life. University of Southern California. Cody M, et al. **Am J Health Syst Pharm** 1998 Dec 15; 55(24):2615–20

The Kaiser Permanente/USC Patient Consultation Study: patient satisfaction with pharmaceutical services. University of Southern California. Johnson KA, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24):2621–9

How does managed care manage the frail elderly? The case of hospital readmissions in fee-for-service versus HMO systems. Experton B, et al. **Am J Prev Med** 1999 Apr; 16(3):163–72

Survey of health maintenance organization instructions to members concerning emergency department and 911 use [see comments] Neely KW, et al. **Ann Emerg Med** 1999 Jul;34(1):19–24. Comment in: Ann Emerg Med 1999 Jul;34(1):95–7.

Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Barton MB, et al. **Ann Intern Med** 1999 Apr 20; 130(8):651–7

Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization [see comments] Burman ML, et al. **Ann Intern Med** 1999 Jul 6;131(1):1–6. Comment in: Ann Intern Med 1999 Jul 6;131(1):60–2.

The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Annegers JF, et al. **Epilepsia** 1999 Apr;40(4):502–6

Managed care and technology diffusion: the case of MRI. Baker LC, et al. **Health Aff (Millwood)** 1998 Sep-Oct; 17(5):195–207

Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Potosky AL, et al. **Health Serv Res** 1999 Jun;34(2):525–46

Differences in discharge medication after acute myocardial infarction in patients with HMO and fee-for-service medical insurance [see comments] McCormick D, et al. **J Gen Intern Med** 1999 Feb;14(2):73–81. Comment in: J Gen Intern Med 1999 Feb;14(2):136–7.

Recent patterns of hormone replacement therapy use in a large managed care organization. Whitlock EP, et al. **J Womens Health** 1998 Oct;7(8):1017–26

Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison [see comments] Riley GF, et al. **JAMA** 1999 Feb 24;281(8):720–6. Comment in: JAMA 1999 Feb 24;281(8):755–6. Comment in: JAMA 1999 Jul 28;282(4):326–7.

Health maintenance organization penetration and the practice location choices of new physicians: a study of large metropolitan areas in the United States. Escarce JJ, et al. **Med Care** 1998 Nov;36(11):1555–66

Survival and treatment for colorectal cancer Medicare patients in two group/staff health maintenance organizations and the fee-for-service setting. Merrill RM, et al. **Med Care Res Rev** 1999 Jun;56(2):177–96

Enrollment trends in Medicare managed care plans. Buechner JS. **Med Health R I** 1998 Sep;81(9):302–3

Structured review of neonatal deaths in a managed care organisation. Escobar GJ, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):422–36

HMO physicians' use of referrals. Bachman KH, et al. **Soc Sci Med** 1999 Feb;48(4):547–57

Let the patients speak. Moran T. **Tex Med** 1998 Nov; 94(11):61–3

Use of and interest in alternative therapies among adult primary care clinicians and adult members in a large health maintenance organization. Gordon NP, et al. **West J Med** 1998 Sep;169(3):153–61

TRENDS

Medicare HMO promotions paint rosy picture, lack details [news] **Am J Health Syst Pharm** 1998 Oct 1;55(19):1968–9

Managed care in obstetrics and gynecology: can our specialty survive? Harrison FN Jr. **Am J Obstet Gynecol** 1999 Aug; 181(2):328–31

From the University of Washington to Washington University: a personal journey. Barner HB. **Ann Thorac Surg** 1999 Feb;67(2):301–4

Physicians' perceptions of autonomy and satisfaction in California. Burdi MD, et al. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):134–45

Long-term care in its infancy [editorial; comment] Boult C. **J Am Geriatr Soc** 1999 Feb;47(2):250–1. Comment on: J Am Geriatr Soc 1999 Feb;47(2):131–8. Comment on: J Am Geriatr Soc 1999 Feb;47(2):139–44.

New times, old words, new meanings [editorial] Goldwyn RM. **Plast Reconstr Surg** 1999 Apr;103(4):1312

The future of medicine and radiology: Part I. Friedenberg RM. **Radiology** 1999 Aug;212(2):301–4

UTILIZATION

The effectiveness of a clinical practice guideline for the management of presumed uncomplicated urinary tract infection in women. Saint S, et al. **Am J Med** 1999 Jun; 106(6):636–41

Managed care and the treatment of skin disease, 1995. Continued growth and emerging dominance [see comments] Stern RS. **Arch Dermatol** 1998 Sep; 134(9):1089–91. Comment in: Arch Dermatol 1998 Sep;134(9):1151–2.

Use of services by diabetes patients in managed care organizations. Development of a diabetes surveillance system. CDC Diabetes in Managed Care Work Group. Engelgau MM, et al. **Diabetes Care** 1998 Dec;21(12):2062–8

Can Medicare beneficiaries make informed choices? Hibbard JH, et al. **Health Aff (Millwood)** 1998 Nov-Dec; 17(6):181–93

HMO selection and Medicare costs: Bayesian MCMC estimation of a robust panel data tobit model with survival. Hamilton BH. **Health Econ** 1999 Aug;8(5):403–14

Differences in resource use and costs of primary care in a large HMO according to physician specialty [see comments] Selby JV, et al. **Health Serv Res** 1999 Jun; 34(2):503–18. Comment in: Health Serv Res 1999 Jun;34(2):519–24.

Use of primary care teams by HMOS for care of long-stay nursing home residents [see comments] Farley DO, et al. **J Am Geriatr Soc** 1999 Feb;47(2):139–44. Comment in: J Am Geriatr Soc 1999 Feb;47(2):250–1.

Mortality, health services use, and health behavior in a cohort of well older adults. Malmgren JA, et al. **J Am Geriatr Soc** 1999 Jan;47(1):51–9

Primary care of long-stay nursing home residents: approaches of three health maintenance organizations [see comments] Reuben DB, et al. **J Am Geriatr Soc** 1999 Feb; 47(2):131–8. Comment in: J Am Geriatr Soc 1999 Feb;47(2):250–1.

A comparison of asthma-related healthcare use between African-Americans and Caucasians belonging to a health maintenance organization (HMO). Blixen CE, et al. **J Asthma** 1999;36(2):195–204

Changes in usual sources of medical care between 1987 and 1992. Moy E, et al. **J Health Care Poor Underserved** 1998 May;9(2):126–39

Tracking the response to the Balanced Budget Act of 1997: impact on Medicare managed care enrollment in rural counties. McBride TD, et al. **J Rural Health** 1999 Winter; 15(1):67–77

The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Andrade SE, et al. **Med Care** 1999 Apr;37(4):424–30

Alcohol consumption and utilization of health services in a health maintenance organization. Armstrong MA, et al. **Med Care** 1998 Nov;36(11):1599–605

Gender, psychosocial factors and the use of medical services: a longitudinal analysis. Green CA, et al. **Soc Sci Med** 1999 May;48(10):1363–72

Rising health care costs: is this the turning point? Tyler T, et al. **Tenn Med** 1999 Jul;92(7):255–6

HEALTH MANPOWER

The specialty of allergy/immunology is not overrepresented in the physician workforce [editorial; comment] Bardana EJ Jr. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):77–9 . Comment on: Ann Allergy Asthma Immunol 1999 Aug;83(2):99–103.

Setting the record straight [letter] Smith J. **Can Fam Physician** 1999 Jul;45:1648–50

Ophthalmology workforce crisis [editorial; comment] Trope G. **Can J Ophthalmol** 1999 Apr;34(2):59–61. Comment on:

Can J Ophthalmol 1999 Apr;34(2):74–81. Comment on: Can J Ophthalmol 1999 Apr;34(2):82–7. **(Eng, Fre)**

Overpopulation of small animal veterinarians on Prince Edward Island [letter; comment] Osborne D. **Can Vet J** 1999 Apr;40(4):218. Comment on: Can Vet J 1999 Feb;40(2):89–93.

Manpower in respiratory medicine: a position paper of the Irish Thoracic Society. Brennan N. **Ir Med J** 1999 May–Jun;92(4):332–4

Nonphysician clinicians in the health care workforce [letter; comment] Cawley JF, et al. **JAMA** 1999 Feb 10; 281(6):509–10; discussion 511. Comment on: JAMA 1998 Sep 2;280(9):788–94. Comment on: JAMA 1998 Sep 2;280(9):795–802.

Nonphysician clinicians in the health care workforce [letter; comment] Pournadeali K, et al. **JAMA** 1999 Feb 10; 281(6):510–1; discussion 511. Comment on: JAMA 1998 Sep 2;280(9):788–94. Comment on: JAMA 1998 Sep 2;280(9):795–802.

CLASSIFICATION

Proposed changes to designations of medically underserved populations and health professional shortage areas: effects on rural areas. Goldsmith LJ, et al. **J Rural Health** 1999 Winter;15(1):44–54

EDUCATION see HEALTH OCCUPATIONS/education

LEGISLATION & JURISPRUDENCE

Sending a policy signal: state legislatures, medical schools, and primary care mandates. Weissert CS, et al. **J Health Polit Policy Law** 1998 Oct;23(5):743–70 (39 ref.)

ORGANIZATION & ADMINISTRATION

Planning the united Kingdom's medical workforce [letter] Pickersgill A. **BMJ** 1998 Oct 3;317(7163):951

The recruiting of staff for the health system in Greenland. Mulvad G. **Int J Circumpolar Health** 1998;57 Suppl 1:679–81

[Women and part-time employment in the medical profession (see comments] Vroom TM. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1167–71 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 May 29;143(22):1134–6. **(Dut)**

[Management of human resources, materials, and organization processes in radioprotection] Coppola V. **Radiol Med (Torino)** 1999 Jun;97(6):518–24 (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

Determining Ontario's supply and requirements for ophthalmologists in 2000 and 2005: 2. A comparison of projected supply and requirements [see comments] Persaud DD, et al. **Can J Ophthalmol** 1999 Apr;34(2):82–7. Comment in: Can J Ophthalmol 1999 Apr;34(2):59–61.

Loss of tuberculosis officers from a national tuberculosis programme: the Malawi experience, 1993–1997 [letter] Salaniponi FM, et al. **Int J Tuberc Lung Dis** 1999 Feb; 3(2):174–5

NASPE expert consensus statement: physician workforce in cardiac electrophysiology and pacing. NASPE task force, Washington, D.C. [see comments] Reynolds DW, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1646–55 (25 ref.) . Comment in: Pacing Clin Electrophysiol 1999 Apr;22(4 Pt 1):691.

TRENDS

The future physician workforce: an allergy–immunology specialist perspective [see comments] de Asis ML. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):99–103. Comment in: Ann Allergy Asthma Immunol 1999 Aug;83(2):77–9.

Commentary on "A study of the workforce in emergency medicine". Society for Academic Emergency Medicine [editorial; comment] [see comments] Cydulka RK, et al. **Ann Emerg Med** 1999 May;33(5):558–61. Comment on: Ann Emerg Med 1998 May;31(5):595–607. Comment in: Ann Emerg Med 1999 May;33(5):556–8.

Workforce study in emergency medicine: a perspective from academic emergency medicine [editorial; comment] Jacobson S, et al. **Ann Emerg Med** 1999 May;33(5):556–8 . Comment on: Ann Emerg Med 1998 May;31(5):595–607. Comment on: Ann Emerg Med 1999 May;33(5):558–61.

Determining Ontario's supply and requirements for ophthalmologists in 2000 and 2005: 1. Methods [see comments] Persaud DD, et al. **Can J Ophthalmol** 1999 Apr; 34(2):74–81. Comment in: Can J Ophthalmol 1999 Apr;34(2):59–61.

Concerns about size of MD workforce, medicine's future dominate CMA annual meeting. Sullivan P. **CMAJ** 1999 Sep 7;161(5):561–2

Recruiting. Sellers' market [news] **Hosp Health Netw** 1998 Oct 20;72(20):12

Supplementing state and national health care workforce planning: a regional effort. Imm IE, et al. **J Allied Health** 1998 Spring;27(2):77–82

Twenty-year trends in the Ohio generalist physician workforce. Williams PT. **J Fam Pract** 1998 Dec;47(6):434–9

Nonphysician clinicians in the health care workforce [letter; comment] Boodley CA, et al. **JAMA** 1999 Feb 10; 281(6):510; discussion 511. Comment on: JAMA 1998 Sep 2;280(9):788–94. Comment on: JAMA 1998 Sep 2;280(9):795–802. Comment on: JAMA 1998 Sep 2;280(9):825–6.

HEALTH OCCUPATIONS

Minority ethnic groups in health care professions [letter] Bedi R, et al. **Br Dent J** 1999 May 22;186(10):488

Determinants of microcomputer technology use: implications for education and training of health staff. Jayasuriya R. **Int J Med Inf** 1998 Jun;50(1–3):187–94

[Different professional groups must show respect for each other (letter)] Fernvall E. **Lakartidningen** 1999 Jan 20; 96(3):156 **(Swe)**

CLASSIFICATION

[The new health professions and professional intrusion] Moya Pueyo V. **An R Acad Nac Med (Madr)** 1998;115(2):419–32 **(Spa)**

EDUCATION

A compendium of higher education opportunities in health professions education. Casimano MD, et al. **Acad Med** 1998 Dec;73(12):1255–9

Continuing competence in the health professions. Grossman J. **Am J Occup Ther** 1998 Oct;52(9):709–15 (23 ref.)

Communication courses in Canadian graduate programs in health promotion. Yessis J, et al. **Can J Public Health** 1999 May–Jun;90(3):214–5

Education and training in health informatics: the IT-EDUCTRA project. Hasman A. **Int J Med Inf** 1998 Jun;50(1–3):179–85

Education and health informatics. Hasman A. **Int J Med Inf** 1998 Oct–Dec;52(1–3):209–16

Transformation of health care through innovative use of information technology: challenges for health and medical informatics education [editorial] Haux R, et al. **Int J Med Inf** 1998 Jun;50(1–3):1–6

Health and medical informatics education: perspectives for the next decade. Haux R. **Int J Med Inf** 1998 Jun; 50(1–3):7–19

Development and validation of an evaluation tool for multimedia resources in health education. Premkumar K, et al. **Int J Med Inf** 1998 Jun;50(1–3):243–50

Developing and implementing interprofessional learning in a Faculty of Health Professions. Banks S, et al. **J Allied Health** 1998 Fall;27(3):132–6

Systematic review of the effectiveness of interprofessional education: towards transatlantic collaboration. Barr H, et al. **J Allied Health** 1999 Summer;28(2):104–8 (26 ref.)

Information technology education for health professionals: opportunities and challenges. Haque SS, et al. **J Allied Health** 1998 Fall;27(3):167–72

University–community partnerships for health: a model interdisciplinary service-learning project. Rudmann SV, et al. **J Allied Health** 1999 Summer;28(2):109–12

VA aligns health professions education with healthcare priorities. Stevens DP, et al. **J Allied Health** 1998 Fall; 27(3):123–7

Building community: developing skills for interprofessional health professions education and relationship-centered care. NLN Appointed Interdisciplinary Health Education Panel. Walker PH, et al. **J Allied Health** 1998 Fall; 27(3):173–8 (14 ref.)

Acceptance by Swedish users of a multimedia program for primary and secondary prevention of malignant melanoma. Lindholm LH, et al. **J Cancer Educ** 1998 Winter; 13(4):207–12

Community health centers: unrecognized partners in health professions education. Cooksey JA, et al. **J Health Care Poor Underserved** 1999 Aug;10(3):349–61

An interdisciplinary palliative care course for practicing health professionals: ten years' experience. Latimer EJ, et al. **J Palliat Care** 1998 Winter;14(4):27–33

Interdisciplinary collaborative training for school-based health professionals. Papa PA, et al. **J Sch Health** 1998 Dec;68(10):415–9 (13 ref.)

Maintaining professional integrity in the midst of interdisciplinary collaboration. Lindeke LL, et al. **Nurs Outlook** 1998 Sep–Oct;46(5):213–8 (25 ref.)

[Managerial training as an instrument of change in health. The educational objectives and their verification in managerial training courses for the health administrators in the G. Sanelli Institute of Hygiene, 1988–1998] D'Alessandro D, et al. **Ann Ig** 1999 Mar–Apr;11(2):161–71 (Eng. Abstr.) **(Ita)**

[Need of teaching bioethics as a critical discipline] Santos y Vargas L. **P R Health Sci J** 1999 Mar;18(1):75–82 **(Spa)**

[Over 900 workers in different health professions have received qualification for stroke care] Britton M. **Lakartidningen** 1999 May 5;96(18):2232–4 **(Swe)**

MANPOWER see HEALTH MANPOWER

STANDARDS

[Definition of competence in the health professions] de Guevara y Guerrero JL. **An R Acad Nac Med (Madr)** 1998; 115(2):433–60 **(Spa)**

STATISTICS & NUMERICAL DATA

[Accidental exposure to blood and the risk of transmission of virus infections for various occupational groups in Amsterdam, 1986–1996] Berger CM, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17;142(42):2312–4 (Eng. Abstr.) **(Dut)**

HEALTH OCCUPATIONS MANPOWER see **HEALTH MANPOWER**

HEALTH OCCUPATIONS SCHOOLS see **SCHOOLS, HEALTH OCCUPATIONS**

HEALTH PERSONNEL

Why students drop out of the pipeline to health professions careers: a follow-up of gifted minority high school students. Thurmond VB, et al. **Acad Med** 1999 Apr; 74(4):448–51

Contact allergies in healthcare workers. Results from the IVDK. Schnuch A, et al. **Acta Derm Venereol** 1998 Sep; 78(5):358–63

Attitudes of healthcare professionals concerning extremely preterm infants in the delivery room. A regional study [letter] [see comments] Sizun J, et al. **Acta Paediatr** 1999 Jul;88(7):789–90. Comment in: Acta Paediatr 1999 Jul;88(7):708–9.

Improvement of inter-rater reliability of PANSS items and subscales by a standardized rater training. Müller MJ, et al. **Acta Psychiatr Scand** 1998 Aug;98(2):135–9

The role of providers in implementation of the National Kidney Foundation–Dialysis Outcomes Quality Initiative: Fresenius Medical Care North America perspective. Lazarus JM, et al. **Adv Ren Replace Ther** 1999 Jan; 6(1):59–66

Occupational risk of HIV infection among western health care professionals posted in AIDS endemic areas. de Graaf R, et al. **AIDS Care** 1998 Aug;10(4):441–52

Knowledge of HIV/AIDS among health care workers in China. Wu Z, et al. **AIDS Educ Prev** 1999 Aug;11(4):353–63

U.S. Public Health Service updates guidelines for HIV prophylaxis in health care workers. Morey SS. **Am Fam Physician** 1998 Dec;58(9):2165–8

Report updates recommendations for health workers exposed to HIV [news] **Am J Health Syst Pharm** 1998 Sep 1; 55(17):1755

Risk of hepatitis C virus infection in a population exposed to biological materials. Trevisan A, et al. **Am J Ind Med** 1999 May;35(5):532–5

APIC position paper: prevention of device-mediated bloodborne infections to health care workers. Association for Professionals in Infection Control and Epidemiology, Inc. **Am J Infect Control** 1998 Dec;26(6):578–80

Glove resistance to permeation by a 7.5% hydrogen peroxide sterilizing and disinfecting solution. Monticello MV, et al. **Am J Infect Control** 1999 Aug;27(4):364–6

Human Immunodeficiency Virus Postexposure Management of Healthcare Workers. Symposium proceedings. Atlanta, Georgia, USA. March 4–5, 1996. **Am J Med** 1997 May 19;102(5B):1–126

Emergency medical services. Arndt SD. **Am J Med** 1997 May 19;102(5B):104–5 (09 ref.)

Legal and ethical issues in revising human immunodeficiency virus postexposure protocols. Barnes M. **Am J Med** 1997 May 19;102(5B):111–2; discussion 113–4 (05 ref.)

Zidovudine safety and tolerance among uninfected healthcare workers: a brief update. Beekmann SE, et al. **Am J Med** 1997 May 19;102(5B):63–4

Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Bell DM. **Am J Med** 1997 May 19;102(5B):9–15 (56 ref.)

Human immunodeficiency virus postexposure management of healthcare workers: report of a workshop. Bell DM, et al. **Am J Med** 1997 May 19;102(5B):1–3

The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Blauvelt A. **Am J Med** 1997 May 19;102(5B):16–20 (31 ref.)

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117–24; discussion 125–6 (43 ref.)

Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)

Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Ciesielski CA, et al. **Am J Med** 1997 May 19;102(5B):115–6 (11 ref.)

Perspectives of healthcare workers. Cohen J, et al. **Am J Med** 1997 May 19;102(5B):102–3

Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)

Principles of clinical pharmacology in postexposure prophylaxis. Flexner CW. **Am J Med** 1997 May 19; 102(5B):32–8 (32 ref.)

Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Gerberding JL. **Am J Med** 1997 May 19;102(5B):85–9 (07 ref.)

Postexposure chemoprophylaxis against HIV: what are the implications for people with AIDS and the organizations

that serve them? Hodel D. **Am J Med** 1997 May 19; 102(5B):106–10 (10 ref.)
Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis. Ippolito G, et al. **Am J Med** 1997 May 19;102(5B):58–62
Failures of zidovudine postexposure prophylaxis. Jochimsen EM. **Am J Med** 1997 May 19;102(5B):52–5; discussion 56–7 (20 ref.)
Issues complicating the implementation of postexposure prophylaxis. L'Ecuyer PB, et al. **Am J Med** 1997 May 19; 102(5B):90–4 (50 ref.)
Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV–contaminated blood. Pinto LA, et al. **Am J Med** 1997 May 19;102(5B):21–4 (31 ref.)
Candidate antiretroviral agents for use in postexposure prophylaxis. Saag MS. **Am J Med** 1997 May 19; 102(5B):25–31 (38 ref.)
Toxicity of antiretroviral agents. Struble KA, et al. **Am J Med** 1997 May 19;102(5B):65–7; discussion 68–9 (00 ref.)
Clinicians set a dangerous precedent when they begin using a word like "queer" [letter; comment] Craig JN. **Am J Orthopsychiatry** 1999 Apr;69(2):267–9. Comment on: Am J Orthopsychiatry 1998 Jul;68(3):447–54.
Weight loss counseling by health care providers. Nawaz H, et al. **Am J Public Health** 1999 May;89(5):764–7
Health care worker disability due to latex allergy and asthma: a cost analysis. Phillips VL, et al. **Am J Public Health** 1999 Jul;89(7):1024–8
Care, cars and the millennium bug [letter] Hedayati B, et al. **Anaesthesia** 1999 Aug;54(8):821–2
Latex allergy: a patient and health care system emergency. Kelly KJ, et al. **Ann Emerg Med** 1998 Dec;32(6):723–9 (42 ref.)
Bacterial contamination of the hands of hospital staff during routine patient care. Pittet D, et al. **Arch Intern Med** 1999 Apr 26;159(8):821–6
Chromosomal aberrations in medical staff occupationally exposed to X-rays: a follow-up study. Kašuba V, et al. **Arh Hig Rada Toksikol** 1998 Mar;49(1):1–8
Preaching by the unconverted [editorial] Sanson-Fisher R, et al. **Aust N Z J Med** 1998 Aug;28(4):417–8
Attitudes towards people with a mental disorder: a survey of the Australian public and health professionals. Jorm AF, et al. **Aust N Z J Psychiatry** 1999 Feb;33(1):77–83
Is there consensus between breast cancer patients and providers on guidelines for breaking bad news? Girgis A, et al. **Behav Med** 1999 Summer;25(2):69–77
Spain launches campaign to stop health professionals smoking [news] Bosch X. **BMJ** 1999 Apr 17;318(7190):1027
Protecting breast feeding from breast milk substitutes. Health workers must be protected from conflicts of interest [letter; comment] Broadfoot M, et al. **BMJ** 1998 Oct 3; 317(7163):950. Comment on: BMJ 1998 Apr 11;316(7138):1103–4.
Hand washing. Hand washing is more common among healthcare workers than the public [letter] Hateley PM, et al. **BMJ** 1999 Aug 21;319(7208):519
Hand washing. Healthcare workers washed their hands on only a third occasions [letter] Sen R, et al. **BMJ** 1999 Aug 21;319(7208):518
Thiomersal sensitivity in health care workers [letter] Wray D. **Br Dent J** 1997 Nov 8;183(9):316
GP referrals to adult psychological services: a research agenda for promoting needs-led practice through the involvement of mental health clinicians. Ross H, et al. **Br J Med Psychol** 1999 Mar;72 (Pt 1):75–91 (87 ref.)
Escalating crisis in Canada's health workforce. Scully HE. **Can J Cardiol** 1999 Jul;15(7):751–3 **(Eng, Fre)**
Needle-stick injuries and HIV infection [editorial] Hurwitz JJ. **Can J Ophthalmol** 1999 Jun;34(4):189–90 **(Eng, Fre)**
Assessing the validity of tuberculin skin test readings by trained professionals and patients. Ozuah PO, et al. **Chest** 1999 Jul;116(1):104–6
Radiation safety for health care workers in the bronchoscopy suite. Jain P, et al. **Clin Chest Med** 1999 Mar;20(1):33–8, ix–x (25 ref.)
Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Ippolito G, et al. **Clin Infect Dis** 1999 Feb; 28(2):365–83 (122 ref.)
Seroprevalence of antibodies to hantavirus in health care workers and other residents of southern Argentina. Wells RM, et al. **Clin Infect Dis** 1998 Oct;27(4):895–6
Physician, protect thyself [see comments] Sibbald B. **CMAJ** 1998 Oct 20;159(8):987–9. Comment in: CMAJ 1999 Apr 20;160(8):1127.
Surveillance of health care workers exposed to bloodborne viruses at work: July 1997 to June 1999. **Commun Dis Rep CDR Wkly** 1999 Sep 3;9(36):319
Influenza immunisation and health care workers and other occupational groups. **Commun Dis Rep CDR Wkly** 1999 Aug 13;9(33):289, 292
Chance finding of hepatitis B e antigen carriage in pregnant woman highlights need for antenatal screening, and vaccination of health care workers. **Commun Dis Rep CDR Wkly** 1999 May 21;9(21):183, 186
Cross-border alliances in health care: international co-operation between health insurers and providers in the Euregio Meuse-Rhine. Hermans HE, et al. **Croat Med J** 1999 Jun;40(2):266–72
Do health professionals' attitudes interfere with the treatment of depression? Stern SL, et al. **Depress Anxiety** 1999; 9(4):151–5
Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Sessink PJ, et al. **Drug Saf** 1999 Apr;20(4):347–59 (113 ref.)
Needlestick and sharps injuries among health-care workers in Taiwan. Guo YL, et al. **Epidemiol Infect** 1999 Apr; 122(2):259–65
Endoscopy personnel and the transmission of Helicobacter pylori infection [editorial; comment] Kugathasan S, et al. **Gastrointest Endosc** 1998 Sep;48(3):317–8. Comment on: Gastrointest Endosc 1998 Sep;48(3):237–43.
Risk to the health care worker of HIV infection and how to minimize It. Cheung RJ, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):769–82 (110 ref.)
Natural rubber latex allergy, an epidemic in the health field. Lehman CW. **Hawaii Med J** 1999 Jun;58(6):152–5
Low response to hepatitis B vaccine in health care workers and medical students in Lisbon, Portugal [letter; comment] Marinho RT, et al. **Hepatology** 1998 Oct;28(4):1166. Comment on: Hepatology 1998 Feb;27(2):637.
A sharper point on using safer needles. Hudson T. **Hosp Health Netw** 1999 Sep;73(9):46–8, 50
Utilizing primary health care workers for case detection. Vijayakumaran P, et al. **Indian J Lepr** 1998 Apr–Jun; 70(2):203–10
Experience of pulse polio immunization amongst medical professionals [letter] Swami HM, et al. **Indian Pediatr** 1998 Oct;35(10):1031–2
Nosocomial tuberculosis exposure in an outpatient setting: evaluation of patients exposed to healthcare providers with tuberculosis. Bock NN, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):421–5
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. D'Amico R, et al. **Infect Control Hosp Epidemiol** 1999 Jun; 20(6):428–30
Tuberculosis, hepatitis B, rubella, rubeola, and varicella infection and immunity among medical school employees. L'Ecuyer PB, et al. **Infect Control Hosp Epidemiol** 1998 Dec;19(12):915–7
Age-specific rates of serological immunity in patients with a negative history for varicella infection [letter] Nordin J, et al. **Infect Control Hosp Epidemiol** 1998 Nov; 19(11):823–4
Controlling varicella in the healthcare setting: barriers to varicella vaccination among healthcare workers. Qureshi M, et al. **Infect Control Hosp Epidemiol** 1999 Jul; 20(7):516–8
Occupational exposure and voluntary human immunodeficiency virus testing: a survey of Maryland hospitals. Solomon L, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):430–2
Transmission of measles virus in healthcare settings during a communitywide outbreak. Steingart KR, et al. **Infect Control Hosp Epidemiol** 1999 Feb;20(2):115–9
Seroconversion rates in healthcare workers using a latex agglutination assay after varicella virus vaccination. Weinstock DM, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):504–7
Tuberculosis: what you don't know can hurt you [editorial; comment] Woeltje KF. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):626–8 (12 ref.). Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):629–34. Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):635–9.
Incidence of pertussis infection in healthcare workers. Wright SW, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):120–3
Breakthrough varicella infection in a healthcare worker despite immunity after varicella vaccination. Wurtz R, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):561–2
Risk of HCV infections among children with cancer and health-care workers in children's hospitals. Styczynski J, et al. **Infection** 1999 Jan–Feb;27(1):36–8
Seroprevalence of hepatitis A markers in subjects exposed to biological risk. Trevisan A, et al. **Int Arch Occup Environ Health** 1999 Mar;72(2):125–7
Mobilizing a health professional's workstation—results of an evaluation study. Buchauer A, et al. **Int J Med Inf** 1999 May;54(2):105–14
Healthcare professional's demand for knowledge in informatics. Vimarlund V, et al. **Int J Med Inf** 1999 Feb–Mar;53(2–3):107–13
Developing the role of the generic healthcare support worker: phase 1 of an action research study. Rolfe G, et al. **Int J Nurs Stud** 1999 Aug;36(4):323–34
Tolerance, compliance and psychological consequences of post-exposure prophylaxis in health-care workers. de la Tribonnière X, et al. **Int J STD AIDS** 1998 Oct;9(10):591–4
Increased risk of Mycobacterium tuberculosis infection related to the occupational exposures of health care workers in Chiang Rai, Thailand [see comments] Do AN, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):377–81. Comment in: Int J Tuberc Lung Dis 1999 May;3(5):363–4.
Health care workers and tuberculosis: the battle of a century [editorial; comment] Fennelly KP, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):363–4. Comment on: Int J Tuberc Lung Dis 1999 May;3(5):377–81.
Tuberculosis among health care workers in British Columbia. Pleszewski B, et al. **Int J Tuberc Lung Dis** 1998 Nov; 2(11):898–903
Use of Giger and Davidhizar's Transcultural Assessment Model by health professions. Dowd SB, et al. **Int Nurs Rev** 1998 Jul–Aug;45(4):119–22, 128
Reduction of latex aeroallergens and latex-specific IgE antibodies in sensitized workers after removal of powdered natural rubber latex gloves in a hospital. Allmers H, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):841–6
Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions. Laoprasert N, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):998–1004
Treatment of human immunodeficiency virus-positive patients with complementary and alternative medicine: a survey of practitioners. Calabrese C, et al. **J Altern Complement Med** 1998 Fall;4(3):281–7
A multifaceted educational approach to increasing awareness and use of physician data query (PDQ). Thiemann KM, et al. **J Cancer Educ** 1999 Summer;14(2):78–82
Recipient and provider perspectives of barriers to rural prenatal care. Omar MA, et al. **J Community Health Nurs** 1998;15(4):237–49
Emergency department management of occupational exposures to HIV-infected fluids. Torbati SS, et al. **J Emerg Med** 1999 Mar–Apr;17(2):261–4
Risk of cytomegalovirus infection among educators and health care personnel serving mentally disabled children. De Schryver A, et al. **J Infect** 1999 Jan;38(1):36–40
Radiation exposure from gallium-67-citrate patients. Castronovo FP Jr, et al. **J Nucl Med Technol** 1999 Mar; 27(1):57–61
ACOEM guidelines for protecting health care workers against tuberculosis. American College of Occupational and Environmental Medicine. **J Occup Environ Med** 1998 Sep; 40(9):765–7
Evaluation of the two-step tuberculin skin test in health care workers at an inner-city medical center. Hallak KM, et al. **J Occup Environ Med** 1999 May;41(5):393–6
Health care fraud enforcement in 1999. McCampbell RG. **J Okla State Med Assoc** 1999 Jun;92(6):273–5
Cost effectiveness of screening for clinical trials by research assistants versus senior investigators. Miller NL, et al. **J Psychiatr Res** 1999 Mar–Apr;33(2):81–5
Screening times with image intensifier in orthopaedic trauma surgery [letter; comment] **J R Coll Surg Edinb** 1998 Dec; 43(6):431. Comment on: J R Coll Surg Edinb 1998 Aug;43(4):265–6.
Ten essential clinical informatics skills. Coiera E. **J R Coll Surg Edinb** 1999 Aug;44(4):269–70
Improving patient care by reporting problems with medical devices. White GG, et al. **J Toxicol Clin Toxicol** 1998; 36(6):641–4
Expected long-term outcome after a tibial shaft fracture. Faergemann C, et al. **J Trauma** 1999 Apr;46(4):683–6
Prevalence of GBV-C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. El-Zayadi AR, et al. **J Virol Methods** 1999 Jun; 80(1):53–8
From the Centers for Disease Control and Prevention. Nosocomial group A streptococcal infections associated with asymptomatic health-care workers—Maryland and California, 1997. **JAMA** 1999 Mar 24–31;281(12):1077–8
A piece of my mind. Alton Small. Brezina D. **JAMA** 1998 Dec 9;280(22):1902
Improving patient compliance with HIV treatment regimens [letter; comment] Ungvarski PJ. **JAMA** 1998 Nov 25; 280(20):1745–6. Comment on: JAMA 1998 Jun 24;279(24):1977–83.
"Let me through—I'm an arts practitioner!". Martin C. **Lancet** 1999 Apr 24;353(9162):1451
The encouragement of 'perfect' health professionals [editorial] Humphris G, et al. **Med Educ** 1998 Sep; 32(5):452–5
Health care workers and their needs: the forgotten shadow of AIM research. Lillehaug SI, et al. **Medinfo** 1998;9 Pt 2:1232–6
A medical readiness model of health assessment or well-being in first-increment air combat command medical personnel. McRae-Bergeron CE, et al. **Mil Med** 1999 Jun; 164(6):379–88
Allergy to natural rubber latex. Yunginger JW. **Minn Med** 1998 Sep;81(9):27–30 (33 ref.)
Nosocomial group A streptococcal infections associated with asymptomatic health-care workers—Maryland and California, 1997. **MMWR Morb Mortal Wkly Rep** 1999 Mar 5;48(8):163–6
A cytokinesis-blocked micronucleus study of the radioadaptive response of lymphocytes of individuals occupationally exposed to chronic doses of radiation. Gourabi H, et al. **Mutagenesis** 1998 Sep;13(5):475–80
Recommendations for occupational exposures to HIV. Paul SM, et al. **N J Med** 1999 Jan;96(1):41–6
The mental health provider's view. Pollack DA. **New Dir Ment Health Serv** 1999 Spring;(81):25–32
Dose rate measurements from radiopharmaceuticals: implications for nuclear medicine staff and for children with radioactive parents. Greaves CD, et al. **Nucl Med Commun** 1999 Feb;20(2):179–87

Reductions in finger doses for radiopharmaceutical dispensing afforded by a syringe shield and an automatic dose dispenser. Montgomery A, et al. **Nucl Med Commun** 1999 Feb;20(2):189–94

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213–25 (11 ref.)

The risk of occupational exposure and infection with infectious disease. Sharbaugh RJ. **Nurs Clin North Am** 1999 Jun;34(2):493–508 (29 ref.)

Mandatory reporting of intimate partner violence by health care professionals: a policy review. Glass N, et al. **Nurs Outlook** 1998 Nov–Dec;46(6):279–83 (35 ref.)

Medical and osteopathic boards' positions on chaperones during gynecologic examinations. Stagno SJ, et al. **Obstet Gynecol** 1999 Sep;94(3):352–4

Exposure to blood borne viruses and the hepatitis B vaccination status among healthcare workers in inner London. Gyawali P, et al. **Occup Environ Med** 1998 Aug; 55(8):570–2

Exposure of health care workers to pentamidine isethionate. Beach JR, et al. **Occup Med (Lond)** 1999 May;49(4):243–5

A review of current literature on epidemiology of immediate glove irritation and latex allergy. Kujala V. **Occup Med (Lond)** 1999 Jan;49(1):3–9 (73 ref.)

Audit of immunization policy and practice of health care workers within National Health Service Trusts in England and Wales. Verow P, et al. **Occup Med (Lond)** 1999 May; 49(4):211–6

PHS guidelines for the management of health-care worker exposures to HIV—Part 1. **Oncology (Huntingt)** 1998 Sep; 12(9):1331–2, 1335–6, 1339 passim

PHS recommendations for the management of health-care worker exposures to HIV—Part 2. **Oncology (Huntingt)** 1998 Oct;12(10):1447–9, 1453–4, 1457 passim

Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)

Differences in self-reported health behaviors between public health professionals and support staff. Oleckno WA, et al. **Psychol Rep** 1999 Feb;84(1):127–34

Health care professionals' familiarity with non-pharmacological strategies for managing cancer pain. Zaza C, et al. **Psychooncology** 1999 Mar–Apr;8(2):99–111

Feelings of professional fulfilment and exhaustion in mental health personnel: the importance of organisational and individual factors. Thomsen S, et al. **Psychother Psychosom** 1999;68(3):157–64

AHCPR offers resources for consumers, providers, and health agencies. Agency for Health Care Policy and Research [news] **Public Health Rep** 1999 Mar–Apr; 114(2):107

Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C, et al. **Rapid Commun Mass Spectrom** 1998;12(20):1485–93

Competence of health professionals to check the carotid pulse. Ochoa FJ, et al. **Resuscitation** 1998 Jun;37(3):173–5

Nosocomial transmission of tuberculosis to health care workers in Mpumalanga [letter] Balt E, et al. **S Afr Med J** 1998 Nov;88(11):1363, 1366

Health promotion—are our health professionals well prepared? [letter] Setswe G. **S Afr Med J** 1999 May; 89(5):500

Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Cardell K, et al. **Scand J Infect Dis** 1999; 31(2):197–200

Mcnee bequest. Awareness of and protection against hepatitis B virus infection among healthcare workers in Nepal, 1997. Report on a period of elective study. Gyawali P. **Trans Med Soc Lond** 1996–97;113:91–3

Health-care professional perceptions of compliance behaviors in the prerenal and postrenal transplant patient. Collins DC, et al. **Transplant Proc** 1999 Jun;31(4A):16S–17S

Knowledge, attitude and practice of prednisolone prevention of chloroquine induced pruritus among Nigerian health workers. Ajayi AA, et al. **Trop Doct** 1998 Oct;28(4):210–1

Varicella vaccination of health-care workers. Burgess MA, et al. **Vaccine** 1999 Feb 26;17(7–8):765–9

How health care providers help battered women: the survivor's perspective. Gerbert B, et al. **Women Health** 1999;29(3):115–35

[New preventive possibilities in HIV infection] Nielsen JO. **Nord Med** 1998 Nov;113(9):287–9 (Eng. Abstr.) **(Dan)**

[A cluster of patients with puerperal fever in Gouda; a reiteration of the lesson by Semmelweis] Thewessen EA, et al. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1700–5 (Eng. Abstr.) **(Dut)**

[Guidelines in accidental injury of a caretaker in contact with a blood product in the framework of HIV infection] Daher M, et al. **J Med Liban** 1998 May–Jun;46(3):156–9 **(Fre)**

[Can we optimize radioprotection for medical workers?] Aubert B, et al. **J Radiol** 1998 Apr;79(4):307–12 (17 ref.) (Eng. Abstr.) **(Fre)**

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587–92 (9 ref.) **(Fre)**

[Latex allergy] Jeannet-Peter N. **Rev Med Suisse Romande** 1999 Mar;119(3):227–9 (5 ref.) **(Fre)**

[Action in cases of puncture injury by infected material] Gürtler L. **Fortschr Med** 1999 Jan 30;117(3):22–4 **(Ger)**

[Post-exposure prevention of HIV infection] Möst J. **Wien Med Wochenschr** 1998;148(23–24):547–9 (5 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation and prospectives of environmental-biologic monitoring and health surveillance in operating room personnel exposed to low doses of volatile anesthetics] Villa L, et al. **Ann Ig** 1997 Sep–Oct;9(5):363–71 **(Ita)**

[Tuberculosis among health care workers in Okinawa Prefecture] Nakasone T. **Kekkaku** 1999 Apr;74(4):389–95 (Eng. Abstr.) **(Jpn)**

[Source of information on salt intake in Japan and its influence on the understanding of nutrition guides on salt intake] Takemori K. **Nippon Koshu Eisei Zasshi** 1998 Sep; 45(9):841–5 **(Jpn)**

[Detection rate of TTV-DNA in healthy medical workers] Kakinuma K, et al. **Nippon Rinsho** 1999 Jun;57(6):1421–3 (Eng. Abstr.) **(Jpn)**

[Cytostatic drugs: occupational hazard to health care workers] Andrzejak R, et al. **Med Pr** 1999;50(1):61–5 (Eng. Abstr.) **(Pol)**

[Latex allergy in health services workers] Obtułowicz K, et al. **Pol Merkuriusz Lek** 1998 May;4(23):265–8 (Eng. Abstr.) **(Pol)**

[Headache incidence in a hospital community] Zétola VH, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):559–64 (Eng. Abstr.) **(Por)**

[Perception on and registration of alcohol abuse and alcohol-related diseases at a university general hospital] Rosa AA, et al. **Rev Assoc Med Bras** 1998 Oct–Dec; 44(4):335–9 (Eng. Abstr.) **(Por)**

[Results and goals of scientific research on "Work and health of medical personnel"] Korotich LP. **Med Tr Prom Ekol** 1998;(8):35–9 **(Rus)**

[On radiation safety of medical personnel and patients during X-ray studies in stomatology] Tulupov VP, et al. **Med Tr Prom Ekol** 1999;(6):41–3 **(Rus)**

[Organization of care for tuberculosis children who had contact with maternal hospital worker suffering from bacillar tuberculosis] Guseva EM, et al. **Probl Tuberk** 1998; (5):6–8 (Eng. Abstr.) **(Rus)**

[Sensitivity to latex and other rubber substances—an important occupational risk for health personnel (case report)] Kanceljak-Macan B, et al. **Lijec Vjesn** 1998 Jul–Aug;120(7–8):213–4 (Eng. Abstr.) **(Scr)**

[Smoking and primary care professionals: something is moving (editorial)] Nebot M, et al. **Aten Primaria** 1998 Sep 30;22(5):267–8 **(Spa)**

[Prevalence of antibodies against tetanus, diphtheria and Bordetella pertussis in health care professionals] Ortega P, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):135–7 (Eng. Abstr.) **(Spa)**

[Hepatitis C virus infection among the health personnel and prophylaxis with human immunoglobulin (letter)] Echevarría JM, et al. **Med Clin (Barc)** 1998 Oct 10; 111(11):438–9 **(Spa)**

[Violence in the hospital (letter)] Reyes Núñez M, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):78–9 **(Spa)**

[Factors associated with inadequate response to hepatitis B vaccination in health care personnel] Tolosa Martínez N, et al. **Rev Esp Salud Publica** 1998 Nov–Dec;72(6):509–15 (Eng. Abstr.) **(Spa)**

[Impact of secondary irradiation on operators during coronary arteriography] Ramírez A, et al. **Rev Med Chil** 1998 Jun;126(6):615–21 (Eng. Abstr.) **(Spa)**

[Participation of dental auxiliary personnel in local health systems (published erratum appears in Rev Panam Salud Publica 1999 Jun;5(6):422)] Frazão P, et al. **Rev Panam Salud Publica** 1999 Feb;5(2):106–15 (Eng. Abstr.) **(Spa)**

[Different professional groups must show respect for each other (letter)] Fernvall E. **Lakartidningen** 1999 Jan 20; 96(3):156 **(Swe)**

[When a simple advice and five minutes are not enough! Can smokers patient care professions help patients to quit smoking?] Uddenfeldt M. **Lakartidningen** 1999 Jun 30; 96(26–27):3150–2 **(Swe)**

ECONOMICS

[Social-economic significance of the work potential in the development of public health] Koretskiĭ VL, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):36–7 (Eng. Abstr.) **(Rus)**

EDUCATION

Improving communications with elderly patients [letter] Jasinevicius TR, et al. **Acad Med** 1999 May;74(5):465–6

Evidence-based medicine: not as simple as it seems. Taylor DK, et al. **Acad Med** 1998 Dec;73(12):1221–2 (8 ref.)

FDA's Rx for keeping educational programs free of industry bias. Zappala FN. **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2472, 2474

A simple hand hygiene exercise. Aspöck C, et al. **Am J Infect Control** 1999 Aug;27(4):370–2

HIV/AIDS mental health training for health care providers: an evaluation of three models. Neff JA, et al. **Am J Orthopsychiatry** 1999 Apr;69(2):240–6

The public health workforce: key to public health infrastructure [editorial] Gebbie KM. **Am J Public Health** 1999 May;89(5):660–1 (8 ref.)

Minimum competencies for public health personnel. Loos GP. **Asia Pac J Public Health** 1995;8(3):195–200

Counselling on breastfeeding: assessing knowledge and skills. Rea MF, et al. **Bull World Health Organ** 1999;77(6):492–8

American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources—professional education and availability of patient services. Walley DR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2886–7 (0 ref.)

The generation and implementation of the concept of health leadership development. Imam O. **East Mediterr Health J** 1998;4 Suppl:S125–9

On-the-job training through follow-up visits to improve the quality of family planning services. Ozek B, et al. **Eur J Contracept Reprod Health Care** 1998 Dec;3(4):201–6

Nutritional and cognitive status in elderly subjects living in service flats, and the effect of nutrition education on personnel. Irving GF, et al. **Gerontology** 1999 Jul–Aug; 45(4):187–94

Nonviolent (empathic) communication for health care providers. Rosenberg M, et al. **Haemophilia** 1998 Jul; 4(4):335–40

Swan-Ganz catheter: misconceptions, pitfalls, and incomplete user knowledge—an identified trilogy in need of correction. Brandstetter RD, et al. **Heart Lung** 1998 Jul–Aug;27(4):218–22 (40 ref.)

Training and supervision in effective cross-cultural mental health services. Bhui K, et al. **Hosp Med** 1998 Nov; 59(11):861–5 (20 ref.)

A training course in health technology assessment in Malaysia. Sivalal S, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):809–17

A descriptive survey to identify the perceived skills and community skill requirements of mental health staff. Bugge C, et al. **J Adv Nurs** 1999 Jan;29(1):218–28

Teaching front-line health and voluntary workers to assess and manage suicidal patients. Morriss R, et al. **J Affect Disord** 1999 Jan–Mar;52(1–3):77–83

The promise and pragmatism of interdisciplinary education. Stumpf SH, et al. **J Allied Health** 1999 Spring;28(1):30–2

Are we making progress with emergency contraception? Recent findings on American adults and health professionals. Delbanco SF, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):242–6

Emergency contraception: preliminary report of a demonstration and evaluation project. Petitti DB, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):251–4

Genetics education for primary care providers in community health settings. Kolb SE, et al. **J Community Health** 1999 Feb;24(1):45–59

Opportunity and the promotion of activity among adults with severe intellectual disability living in community residences: the impact of training staff in active support. Jones E, et al. **J Intellect Disabil Res** 1999 Jun;43 (Pt 3):164–78

Knowledge of travel medicine providers: analysis from a continuing education course. Gardner TB, et al. **J Travel Med** 1999 Jun;6(2):66–70

Evaluation of a programme of workshops for promoting the teaching of critical appraisal skills. Ibbotson T, et al. **Med Educ** 1998 Sep;32(5):486–91

The development of a questionnaire to assess the readiness of health care students for interprofessional learning (RIPLS). Parsell G, et al. **Med Educ** 1999 Feb;33(2):95–100

Approaches to experiential learning, course delivery and validation in medicine. A background document. Stanton F, et al. **Med Educ** 1999 Apr;33(4):282–97

Mass casualty triage knowledge of military medical personnel. Janousek JT, et al. **Mil Med** 1999 May; 164(5):332–5

Health worker performance after training in integrated management of childhood illness—Western Province, Kenya, 1996–1997. **MMWR Morb Mortal Wkly Rep** 1998 Nov 27;47(46):998–1001

Training for state-funded providers of assertive community treatment. Cook JA, et al. **New Dir Ment Health Serv** 1998 Fall;(79):55–64

An interactive approach to training teams and developing programs. Corrigan PW, et al. **New Dir Ment Health Serv** 1998 Fall;(79):3–12 (34 ref.)

A systems approach to developing staff training. Giffort DW. **New Dir Ment Health Serv** 1998 Fall;(79):25–33 (23 ref.)

Training professionals for rehabilitation teams. Lefley HP. **New Dir Ment Health Serv** 1998 Fall;(79):13–23 (22 ref.)

Developing health promoting practices: a transformative process. Hartrick G. **Nurs Outlook** 1998 Sep–Oct; 46(5):219–25

Videotaped training in alcohol counseling for obstetric care practitioners: a randomized controlled trial. Handmaker NS, et al. **Obstet Gynecol** 1999 Feb;93(2):213–8

HIV service provision and training needs in outpatient mental health settings. Satriano J, et al. **Psychiatr Q** 1999 Spring; 70(1):63–74

Workshop on spinal cord injuries (SCI) management: the Chiang Mai experience. Kovindha A, et al. **Spinal Cord** 1999 Mar;37(3):218–20

A training program to improve domestic violence identification and management in primary care: preliminary results. Thompson RS, et al. **Violence Vict** 1998 Winter;

13(4):395–410
Environmental health services in Europe. 4. Guidance on the development of educational and training curricula. Fitzpatrick M, et al. **WHO Reg Publ Eur Ser** 1999;84:i–viii, 1–198 (39 ref.)
[General knowledge of the performance of Mantoux–test procedure deemed inadequate (see comments)] Poortman GH, et al. **Ned Tijdschr Geneeskd** 1999 Apr 17; 143(16):851–5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1398–400. **(Dut)**
[Training in preventing assaultive behaviors for psychiatric professionals] Axer A, et al. **Psychiatr Pol** 1998 Jul–Aug; 32(4):433–41 (Eng. Abstr.) **(Pol)**
[Factors of social workers' training in a medical school for work in psychiatric and substance abuse rehabilitation clinics] Sidorov PI, et al.
Zh Nevrol Psikhiatr Im S S Korsakova 1999;99(5):41–3 (Eng. Abstr.) **(Rus)**

HISTORY

[Educated assistants, genius laboratory assistants and quiet volunteers — first women employed at the National Institute of Hygiene in 1919–1925] Gromulska M.
Rocz Panstw Zakl Hig 1998;49(4):401–8 **(Pol)**

LEGISLATION & JURISPRUDENCE

New Pew Health Professions Commission report released. Romig CL. **AORN J** 1999 Jan;69(1):260–2
The war on healthcare professionals and healthcare delivery [editorial] Wiernik PH. **Cancer Invest** 1999;17(2):164–9
Labor. Immigration eases [news] **Hosp Health Netw** 1998 Dec 5–20;72(23–24):16
Proliferation of non–physician providers as reported in the Journal of the American Medical Association (JAMA), 1998 [see comments] Catlin AJ, et al.
Image J Nurs Sch 1999;31(2):175–7. Comment in: Image J Nurs Sch 1999 ;31(2):160.
Independent judgment and unions. Sfikas PM.
J Am Dent Assoc 1999 Aug;130(8):1231–2
Health care professionals and treatment of HIV–positive patients. Is there an affirmative duty to treat under common law, the Rehabilitation Act, or the Americans with Disabilities Act? White CC. **J Leg Med** 1999 Mar; 20(1):67–113 (309 ref.)
182–day pre–suit notice requirement. Weber RD.
Mich Med 1999 Mar;98(3):8
The Cartwright Report ten years on: the obligations and rights of health consumers and providers [see comments] Townshend PL, et al. **N Z Med J** 1998 Oct 9; 111(1075):390–3. Comment in: N Z Med J 1999 Feb 26;112(1082):56–7.
Society persuades DPW to alter indemnification clause [news] **Pa Med** 1999 Mar;102(3):6
Health care employee criminal background checks. Barratt K. **WMJ** 1998 Oct;97(9):60–1
[Legal protection and attitude to disease (letter)] Meland E. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):569 **(Nor)**

MANPOWER see HEALTH MANPOWER

PSYCHOLOGY

AIDS & HIV: evidence of actual exposure––Majca v. Beekil. Sinclair PS. **Am J Law Med** 1998;24(4):513–4
NAMI: a convention worth noting. National Alliance for the Mentally Ill [editorial] Jones SL.
Arch Psychiatr Nurs 1999 Feb;13(1):1–2
Codependency in male and female helping professionals. Martsolf DS, et al. **Arch Psychiatr Nurs** 1999 Apr; 13(2):97–103
Experience, knowledge and attitudes of mental health staff regarding patients' problematic drug and alcohol use. Siegfried N, et al. **Aust N Z J Psychiatry** 1999 Apr; 33(2):267–73
Health at work in the general practice. Chambers R, et al. **Br J Gen Pract** 1998 Aug;48(433):1501–4
Stress and intervention strategies in mental health professionals. Rabin S, et al. **Br J Med Psychol** 1999 Jun; 72 (Pt 2):159–69 (64 ref.)
Smoking cessation, physicians, and medical office staff. Clinical tobacco intervention in Prince Edward Island. Rowan MS, et al. **Can Fam Physician** 1998 Nov;44:2433–40
Evolving attitudes [letter; comment] McNevin SH. **CMAJ** 1999 Jul 27;161(2):127–8. Comment on: CMAJ 1999 Feb 9;160(3):357–61.
Emotional reactions of haemophilia health care providers. Brown LK, et al. **Haemophilia** 1999 Mar;5(2):127–31
Swan–Ganz catheter: misconceptions, pitfalls, and incomplete user knowledge––an identified trilogy in need of correction. Brandstetter RD, et al. **Heart Lung** 1998 Jul–Aug;27(4):218–22 (40 ref.)
When a leader is confronted with change. O'Neil E.
Hosp Pract (Off Ed) 1998 Dec 15;33(12):95–6
A comparative study of the perceptions of British mental health nurses and psychiatrists of their work environment. Dallender J, et al. **J Adv Nurs** 1999 Jan;29(1):36–43
Synergy: working together with volunteers in community well woman clinics. Merrell J, et al. **J Adv Nurs** 1999 Aug; 30(2):489–96
Are we making progress with emergency contraception? Recent findings on American adults and health professionals. Delbanco SF, et al.
J Am Med Womens Assoc 1998;53(5 Suppl 2):242–6
Emergency contraception: preliminary report of a demonstration and evaluation project. Petitti DB, et al.
J Am Med Womens Assoc 1998;53(5 Suppl 2):251–4
Organizational culture and staff outcomes in services for people with intellectual disabilities. Hatton C, et al.
J Intellect Disabil Res 1999 Jun;43 (Pt 3):206–18
Longitudinal course and predictors of continuing distress following critical incident exposure in emergency services personnel. Marmar CR, et al. **J Nerv Ment Dis** 1999 Jan; 187(1):15–22
Exposure to violence and posttraumatic stress symptomatology among abortion clinic workers. Fitzpatrick KM, et al. **J Trauma Stress** 1999 Apr; 12(2):227–42
A method for evaluating health care providers' decision making: the Provider Decision Process Assessment Instrument. Dolan JG. **Med Decis Making** 1999 Jan–Mar; 19(1):38–41
Burnout as a clinical entity––its importance in health care workers. Felton JS. **Occup Med (Lond)** 1998 May; 48(4):237–50 (91 ref.)
The managed care revolution: how medical technologists have tolerated the change. Friday PJ, et al.
Occup Med (Lond) 1998 Oct;48(7):451–3
Differences in perception of quality of life issues between health professionals and patients with pancreatic cancer. Fitzsimmons D, et al. **Psychooncology** 1999 Mar–Apr; 8(2):135–43
Test of the Fishbein and Ajzen models as predictors of health care workers' glove use. Levin PF. **Res Nurs Health** 1999 Aug;22(4):295–307
Mental health, "burnout" and job satisfaction in a longitudinal study of mental health staff. Prosser D, et al.
Soc Psychiatry Psychiatr Epidemiol 1999 Jun;34(6):295–300
Explanations for stress and satisfaction in mental health professionals: a qualitative study. Reid Y, et al.
Soc Psychiatry Psychiatr Epidemiol 1999 Jun;34(6):301–8
Improving support for mental health staff: a qualitative study. Reid Y, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Jun; 34(6):309–15
Use of advance directives by health care workers and their families. Orlander JD. **South Med J** 1999 May;92(5):481–4
Clandestine abortion in Latin America: provider perspectives. Rodriguez K, et al. **Women Health** 1999;28(3):59–76
[Health personnel stress facing cancer and cancer patients] Natali F, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S196–7 **(Fre)**

STANDARDS

Pew Commission calls for ongoing competency assessment of health professionals, greater say for public on regulatory boards [news] **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2454, 2458
Patients' perception and satisfaction with health care professionals at primary care facilities in Trinidad and Tobago. Singh H, et al. **Bull World Health Organ** 1999; 77(4):356–60
Intersexuality: what should careproviders do now. Howe EG. **J Clin Ethics** 1998 Winter;9(4):337–44 (36 ref.)
The patient–provider relationship: opportunities as well as problems. Lo B. **J Gen Intern Med** 1999 Jan;14 Suppl 1:S41–4 (5 ref.)

STATISTICS & NUMERICAL DATA

Cancer mortality among women employed in health care occupations in 24 U.S. states, 1984–1993. Petralia SA, et al. **Am J Ind Med** 1999 Jul;36(1):159–65
Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza [letter; comment] Boersma B, et al. **Am J Infect Control** 1999 Apr; 27(2):177–8. Comment on: Am J Infect Control 1998 Jun;26(3):367–8.
RNA virus of hepatitis G (GB virus) prevalence in health care personnel [letter] Quirós E, et al.
Am J Infect Control 1999 Apr;27(2):176–7
Self–reported cumulative trauma symptoms among hospital employees: analysis of an upper–extremity symptom survey. Cancio LI, et al. **Am J Occup Ther** 1999 Mar–Apr; 53(2):227–30
Smoking and risk of total and fatal prostate cancer in United States health professionals. Giovannucci E, et al.
Cancer Epidemiol Biomarkers Prev 1999 Apr;8(4 Pt 1):277–82
A prospective study of physical activity and prostate cancer in male health professionals. Giovannucci E, et al.
Cancer Res 1998 Nov 15;58(22):5117–22
The recognition of occupational allergic contact dermatitis in Warsaw. Rudzki E, et al. **Contact Dermatitis** 1999 Mar; 40(3):165–6
Prevalence of Helicobacter pylori infection in medical professionals in Spain. Monés J, et al.
Eur J Gastroenterol Hepatol 1999 Mar;11(3):239–42
Rates of tuberculosis infection in healthcare workers providing services to HIV–infected populations. Terry Beirn Community Programs for Clinical Research on AIDS. Zahnow K, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):829–35
Occupational allergy to aldehydes in health care workers. Clinical observations. Experiments. Kieć–Swierczyńska M, et al. **Int J Occup Med Environ Health** 1998;11(4):349–58
Accidental exposures to blood and other body fluids in a large academic medical center [published erratum appears in J Am Coll Health 1999 May;47(6):291] Turner HS, et al. **J Am Coll Health** 1999 Mar;47(5):199–206
High prevalence of hepatitis G virus (HGV) infections in dialysis staff. Gärtner BC, et al.
Nephrol Dial Transplant 1999 Feb;14(2):406–8
Eye care utilization by older Americans: the SEE Project. Salisbury Eye Evaluation. Orr P, et al. **Ophthalmology** 1999 May;106(5):904–9
Smoking: rates and attitudes among health services staff in central Sydney, Australia [letter] Hughes AM, et al.
Tob Control 1998 Winter;7(4):441
Tuberculosis in health care workers in Malawi. Harries AD, et al. **Trans R Soc Trop Med Hyg** 1999 Jan–Feb;93(1):32–5
[Occupational problems from exposure to roentgen rays] Kluszczyński D, et al. **Med Pr** 1998;49(2):157–65 (Eng. Abstr.) **(Pol)**
[Smoking in health care workers. Identification of related factors] Carrión Valero F, et al. **Arch Bronconeumol** 1998 Sep;34(8):379–83 (Eng. Abstr.) **(Spa)**
[Health professionals and tobacco: a question of incompatibilities (letter)] González García MC, et al.
Aten Primaria 1999 Mar 31;23(5):318–9 **(Spa)**

SUPPLY & DISTRIBUTION see HEALTH MANPOWER

TRENDS

Proliferation of non–physician providers as reported in the Journal of the American Medical Association (JAMA), 1998 [see comments] Catlin AJ, et al.
Image J Nurs Sch 1999;31(2):175–7. Comment in: Image J Nurs Sch 1999 ;31(2):160.
Bracing for change: how American practice of interventional electrophysiology is being irrevocably altered [editorial] Saksena S. **J Interv Card Electrophysiol** 1999 Mar;3(1):5–6

HEALTH PHYSICS

see related
RADIATION MONITORING
RADIATION PROTECTION
RADIOMETRY

Issue dedicated to Karl Z. Morgan. **Health Phys** 1999 Jun; 76(6):599–695
44th Annual meeting of the Health Physics Society. Philadelphia, Pennsylvania, USA. 27 June–1 July, 1999. Abstracts. **Health Phys** 1999 Jun;76(6 Suppl):S105–96
1998 Elda E. Anderson Award. David E. Hintenlang. 43rd Annual Meeting of the Health Physics Society, Minneapolis, MN 12–16 July 1998. Bolch WE.
Health Phys 1998 Dec;75(6):560–1
Changes for Health Physics On–Line [news] Busby B.
Health Phys 1999 Jul;77(1):3–4
More on–line publishing [news] Busby B. **Health Phys** 1999 Jun;76(6):604
Making web pages [news] Busby B. **Health Phys** 1999 Mar; 76(3):236–7
1998 Founders Award. Francis X. Massé. 43rd Annual Meeting of the Health Physics Society, Minneapolis, MN 12–16 July 1998. Dinger KH. **Health Phys** 1998 Dec; 75(6):557–9
1998 William McAdams Outstanding Service Award. Dale H. Denham. 43rd Annual Meeting of the Health Physics Society, Minneapolis, MN 12–16 July 1998. Kirner NP.
Health Phys 1998 Dec;75(6):566–7
1998 National Registry of Radiation Protection Technologists Arthur F. Humm, Jr., Memorial Award. Norman R. Sunderland. 43rd Annual Meeting of the Health Physics Society, Minneapolis, MN 12–16 July 1998. Marshall DW. **Health Phys** 1998 Dec;75(6):568–9
1998 Distinguished Scientific Achievement Award. Bruce B. Boecker. 43rd Annual Meeting of the Health Physics Society, Minneapolis, MN 12–16 July 1998. Thomas RG.
Health Phys 1998 Dec;75(6):562–3
Radiation safety when a patient dies after therapy. Bybel B, et al. **J Nucl Med Technol** 1998 Sep;26(3):206–7
[Radiation exposure and computed tomography] Trigaux JP, et al. **Rev Mal Respir** 1999 Apr;16(2):127–36 (21 ref.) (Eng. Abstr.) **(Fre)**
[1st German Congress on Radiation Oncology, Radiobiology, and Physical Medicine. Baden–Baden, 18–21 November 1995. Abstracts] **Strahlenther Onkol** 1995 Nov;171 Suppl 1:1–98 **(Ger)**
[4th German Congress on Radiation Oncology, Radiobiology and Physical Medicine. Nurenberg, 7–10, November 1998. Abstracts] **Strahlenther Onkol** 1998 Nov;174 Spec No 1:1–134 **(Ger)**

EDUCATION

A logistic regression model for analyzing the relation between dentists' attitudes, behavior, and knowledge in oral radiology. Svenson B, et al. **Acta Odontol Scand** 1998 Aug; 56(4):215–9
Academic course selection [letter] Rea TM. **Health Phys** 1999 Apr;76(4):437
Training in the radiation sciences: opportunities in the United States and internationally. Seligman P.
Int J Occup Environ Health 1998 Jul–Sep;4(3):196–8

INSTRUMENTATION

In-vivo measurement of low energy photon emitters: room-temperature semiconductor diodes vs. large scintillators and germanium crystals. Genicot JL, et al. **Health Phys** 1999 Mar;76(3):288-99

ORGANIZATION & ADMINISTRATION

Communicating effectively with regulatory agencies in the licensing process. Ryan MT. **Health Phys** 1999 Feb;76(2 Suppl):S41-6 (20 ref.)

TRENDS

Experiences with high dose radiopeptide therapy: the health physics perspective. Espenan GD, et al. **Health Phys** 1999 Mar;76(3):225-35

HEALTH PLAN IMPLEMENTATION

Theory and practice for the implementation of 'in-house', continuous improvement participatory ergonomic programs. Haims MC, et al. **Appl Ergon** 1998 Dec; 29(6):461-72

Implementing problem-based learning in a family medicine clerkship. Washington ET, et al. **Fam Med** 1998 Nov-Dec; 30(10):720-6

Common reasons why peer education fails. Walker SA, et al. **J Adolesc** 1999 Aug;22(4):573-7 (10 ref.)

The conception of community children's nursing services in Northern Ireland. Baxter R, et al. **J Pediatr Nurs** 1998 Dec; 13(6):387-95

Enrollment in the State Child Health Insurance Program: a conceptual framework for evaluation and continuous quality improvement. Halfon N, et al. **Milbank Q** 1999; 77(2):181-204, 173

Balancing research and service: the experience of the cancer information service. Fleisher L, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S84-92

Tobacco cessation and youth: the feasibility of brief office interventions for adolescents. Schubiner H, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 3):A47-54

AHCPR clinical practice guideline on surgical pain management: adoption and outcomes. Devine EC, et al. **Res Nurs Health** 1999 Apr;22(2):119-30

Implementation of primary health care--package or process? [editorial] Chopra M, et al. **S Afr Med J** 1998 Dec; 88(12):1563-5

Implementation of substance use screening in prenatal clinics. Li C, et al. **S D J Med** 1999 Feb;52(2):59-64

[The DEGAM-concept--development, dissemination, implementation and evaluation of guidelines for general practice] Gerlach FM, et al. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):111-20 (Eng. Abstr.) **(Ger)**

ECONOMICS

Treatment of major depression before and after implementation of a behavioral health carve-out plan. Merrick EL. **Psychiatr Serv** 1998 Dec;49(12):1563-7

METHODS

Problems and perspective in programme management: the case of the National Onchocerciasis Control Programme in Nigeria. Jiya JJ. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S167-8

Problems and perspectives of managing an onchocerciasis control programme: a case study from Plateau state, Nigeria. Miri ES. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S121-8

The challenges of employing performance monitoring in public health community-based efforts: a case study. Payne CA. **J Community Health** 1999 Apr;24(2):159-70

ORGANIZATION & ADMINISTRATION

Community-based heart health promotion: perceptions of facilitators and barriers. Taylor SM, et al. **Can J Public Health** 1998 Nov-Dec;89(6):406-9

Heart health promotion: predisposition, capacity and implementation in Ontario Public Health Units, 1994-96. Taylor SM, et al. **Can J Public Health** 1998 Nov-Dec; 89(6):410-4

Evolution of the basic minimum needs/basic development needs approach in the eastern Mediterranean region. Sulieman O. **East Mediterr Health J** 1998;4 Suppl:S104-10

The implementation and enforcement of tobacco control laws: policy implications for activists and the industry. Jacobson PD, et al. **J Health Polit Policy Law** 1999 Jun; 24(3):567-98

European food and nutrition policies in action. The Maltese food and nutrition policy. **WHO Reg Publ Eur Ser** 1998; 73:149-55

European food and nutrition policies in action. Progress reports. **WHO Reg Publ Eur Ser** 1998;73:99-123

European food and nutrition policies in action. Framework and options for action on food and nutrition policies in European countries. **WHO Reg Publ Eur Ser** 1998; 73:157-66

European food and nutrition policies in action. Dilemmas and issues for Europe. Milio N, et al. **WHO Reg Publ Eur Ser** 1998;73:127-33

STANDARDS

European food and nutrition policies in action. Nutrition policies or plans of action in Europe. **WHO Reg Publ Eur Ser** 1998;73:167-76

STATISTICS & NUMERICAL DATA

Status of health promotion programme implementation in small-scale enterprises in Japan. Muto T, et al. **Occup Med (Lond)** 1999 Feb;49(2):65-70

TRENDS

Current efforts toward implementation of an urban health strategy: the Los Angeles experience. Finucane M. **J Urban Health** 1998 Jun;75(2):379-82

Toward implementation: managed care and delivery systems. Jacobs RP. **J Urban Health** 1998 Jun;75(2):424-9

The missing voice: impacts of health system change on low-income communities. Jones DR. **J Urban Health** 1998 Jun;75(2):430-7

Current efforts toward implementation of an urban health strategy: Boston. Rabkin MT. **J Urban Health** 1998 Jun; 75(2):383-90

Toward implementation of an agenda. Rosenfield A. **J Urban Health** 1998 Jun;75(2):408-11

Academic medicine and the urban health agenda. Rowe JW. **J Urban Health** 1998 Jun;75(2):420-3

Toward implementation of an urban health agenda: the role of government. Tallon JR Jr. **J Urban Health** 1998 Jun; 75(2):412-9

Current efforts toward implementation of an urban health strategy: the Henry Ford Health System. Whitelaw N, et al. **J Urban Health** 1998 Jun;75(2):356-66

[The "rehabilitation sciences" promotional emphasis--a promotional program and its implementation] Buschmann-Steinhage R, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S71-7 (Eng. Abstr.) **(Ger)**

HEALTH PLANNING

International emergency medicine and the recent development of emergency medicine worldwide. Arnold JL. **Ann Emerg Med** 1999 Jan;33(1):97-103

US health care: a look ahead to 2025. Ginzberg E. **Annu Rev Public Health** 1999;20:55-66 (32 ref.)

'The virtuous cycle': implications of the health and medical research strategic review [editorial] Sainsbury P, et al. **Aust N Z J Public Health** 1999 Feb;23(1):3-5, 19

Better benefits for health: plan to implement the central recommendation of the Acheson report. Black D, et al. **BMJ** 1999 Mar 13;318(7185):724-7

Food plan needed to reduce deaths from heart disease in Britain [news] Bryan J. **BMJ** 1998 Nov 7;317(7168):1274

Nutrition advocacy and national development: the PROFILES programme and its application. Burkhalter BR, et al. **Bull World Health Organ** 1999;77(5):407-15

Federal health budget 1999: part 2--health research, health information and prevention. Scully HE. **Can J Cardiol** 1999 May;15(5):525-8 **(Eng, Fre)**

Delivering health and mental health care services to children in family foster care after welfare and health care reform. Simms MD, et al. **Child Welfare** 1999 Jan-Feb;78(1):166-83

Implementing a system of enhanced surveillance for measles in Victoria. The Enhanced Measles Surveillance Working Party. **Commun Dis Intell** 1999 Feb 18;23(2):51-4

The national measles surveillance strategy. The National Centre for Disease Control Measles Elimination Advisory Committee. Heath T, et al. **Commun Dis Intell** 1999 Feb 18;23(2):41-50

Results of a survey of diagnosed HIV infections prevalent in 1996 in England and Wales. Molesworth AM. **Commun Dis Public Health** 1998 Dec;1(4):271-5

Health targets as an instrument for improving the rational framework of healthcare decisions. Dorange CT, et al. **Croat Med J** 1998 Sep;39(3):332-8

Priorities and priority-setting in health care in the Netherlands. Hermans H, et al. **Croat Med J** 1998 Sep; 39(3):346-55

Is public health between East and West? Analysis of wealth, health and mortality in Austria, Central and Eastern European Countries and Croatia relative to the European Union. Hofmarcher MM. **Croat Med J** 1998 Sep; 39(3):241-8

Application of the modified method of "rapid appraisal to assess community health needs" for making rapid city health profiles and city action plans for health. Sogoric S. **Croat Med J** 1998 Sep;39(3):267-75

Developmental psychopathology: a framework for planning child mental health [editorial] Cohen DJ, et al. **Epidemiol Psichiatr Soc** 1998 Sep-Dec;7(3):156-60

Strategic planning for health care in developing countries. Dowdeswell B. **Haemophilia** 1998;4 Suppl 2:41-5

Public health and international health-care development for persons with haemophilia: operation improvement and operation access. Evatt BL. **Haemophilia** 1998;4 Suppl 2:54-8

World Federation of Hemophilia developing world programmes. Lee CA. **Haemophilia** 1998;4 Suppl 2:59-63

Planning to reduce childhood blindness in India. Dandona L, et al. **Indian J Ophthalmol** 1998 Jun;46(2):117-22 (19 ref.)

Knowledge and opinions about dental human health resources planning in Mexico. Maupome G, et al. **Int Dent J** 1998 Feb;48(1):24-31

A diabetes-in-pregnancy center in Georgia (former USSR). Hod M, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):61-3

Laparoscopic surgery in the Cameroon. Raiga J, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):65-6

Medical informatics training programme to support the Romanian health care management information system. Bazavan M, et al. **Int J Med Inf** 1998 Jun;50(1-3):145-50

Nurse education in an international context: the contribution of contingency. Traynor M, et al. **Int J Nurs Stud** 1999 Feb;36(1):85-91

Early warning in the light of theories of technological change. Blume S. **Int J Technol Assess Health Care** 1998 Fall;14(4):613-23

Building for the future: adolescent pregnancy prevention. Brindis C. **J Am Med Womens Assoc** 1999 Summer; 54(3):129-32

Addressing health needs of female adolescents in modernizing countries. Diaz A. **J Am Med Womens Assoc** 1999 Summer; 54(3):158-60

New picture archiving and communications system plus new facility equals critical path planning challenge. Brye PE, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):130-3

Being prepared to protect the public health. Information for thinking the unthinkable and doing the essential [editorial] Ashton J, et al. **J Epidemiol Community Health** 1998 Nov; 52(11):702-3

Health impact assessment--theory into practice [editorial] Scott-Samuel A. **J Epidemiol Community Health** 1998 Nov; 52(11):704-5

Public health: a powerful guide. Young QD. **J Health Care Finance** 1998 Fall;25(1):1-4

Inequalities in mortality and illness in Trent NHS Region. Huff N, et al. **J Public Health Med** 1999 Mar;21(1):81-7

The Consumer Assessment of Health Plan Study (CAHPS) survey of children's health care. Homer CJ, et al. **Jt Comm J Qual Improv** 1999 Jul;25(7):369-77

Telematics in research planning processes: an example from global health. Greiner C, et al. **Med Inform (Lond)** 1998 Jul-Sep;23(3):215-22

Medical care at The Sun-Herald City to Surf fun run 1971-1998 [letter] Richards DA, et al. **Med J Aust** 1999 Apr 19;170(8):400

Prevalence of overweight among third- and sixth-grade children--New York City, 1996. **MMWR Morb Mortal Wkly Rep** 1998 Nov 20;47(45):980-4

Did Wellington have too many acute psychiatric beds in 1996? MacDonald J, et al. **N Z Med J** 1999 Jul 23; 112(1092):275-6

Assessment of spirituality and implications for service planning. Fallot RD. **New Dir Ment Health Serv** 1998 Winter;(80):13-23

Issues affecting the lives of older persons with developmental disabilities. Griswold KS, et al. **Psychiatr Serv** 1999 Mar; 50(3):315-7

CDC targets arthritis, a leading cause of disability [news] **Public Health Rep** 1999 Mar-Apr;114(2):102

WHO tags 1999-2000 vaccine, prepares flu pandemic plan [news] **Public Health Rep** 1999 May-Jun;114(3):211

Problem-based learning: application and possibilities in Brazil. Coelho-Filho JM, et al. **Rev Paul Med** 1998 Jul-Aug;116(4):1784-5

Health planning for the AIDS epidemic [letter] Mahomed FA. **S Afr Med J** 1999 Mar;89(3):220

Planning a worksite health promotion program: health profile of a population of Greek sailors [letter] Tsamandouraki K, et al. **Scand J Soc Med** 1998 Sep;26(3):181-2

Geography and mental health: a review. Holley HL. **Soc Psychiatry Psychiatr Epidemiol** 1998 Nov; 33(11):535-42 (106 ref.)

Australia's role in training and research in tropical medicine. Leggat PA. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):311-5 (22 ref.)

Planning physician supply: too hot, too cold, or just right? Mirvis DM. **Tenn Med** 1999 Sep;92(9):333-5

Penn Health for Women: the evolution of a women's health program in an academic setting. Battistini M. **Womens Health Issues** 1999 May-Jun;9(3):162-75

Programming for adolescent health and development. Report of a WHO/UNFPA/UNICEF Study Group on Programming for Adolescent Health. **World Health Organ Tech Rep Ser** 1999;886:i-vi, 1-260

[Overweight. II. Determinants of overweight and strategies for prevention (see comments)] Mathus-Vliegen EM. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1989-95 (52 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2374. **(Dut)**

[Health promotion--as a change of social systems] Hösli R. **Soz Praventivmed** 1998;43(5):229-38 (Eng. Abstr.) **(Ger)**

[Scarcity of physicians and hospitals--planning for the needs of yesterday (letter)] Claussen B. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):568-9 **(Nor)**

[Main positions with respect to the formation of the planning and norm-setting basis of medical provision] Preobrazhenskaia VS, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May-Jun;(3):48-52 (Eng. Abstr.) **(Rus)**

[Programs and politics on growth deficit (consequences of a line of research carried out in Chile)] Amigo H, et al. **Arch Latinoam Nutr** 1998 Dec;48(4):281-6 (Eng. Abstr.) **(Spa)**

HEALTH PLANNING

[Practice of preventive activities in primary care and objectives of the 1993-1995 Health Plan of Catalonia] Brugulat P, et al. **Aten Primaria** 1998 Oct 15;22(6):334-9 (Eng. Abstr.) **(Spa)**

[Health, environment and sustainable development in Mexico] **Rev Panam Salud Publica** 1998 Sep;4(3):208-10 (Eng. Abstr.) **(Spa)**

[Environmental primary care for the 21st century] **Rev Panam Salud Publica** 1998 Oct;4(4):290-6 (Eng. Abstr.) **(Spa)**

[In search of results of technical cooperation] Jourdan Hidalgo L, et al. **Rev Panam Salud Publica** 1999 Jun; 5(6):423-9 (Eng. Abstr.) **(Spa)**

ECONOMICS

State society testifies at tobacco settlement hearing. **Pa Med** 1999 Apr;102(4):1

METHODS

Using qualitative methods to develop contextually relevant measures and preventive interventions: an illustration. Dumka LE, et al. **Am J Community Psychol** 1998 Aug; 26(4):605-37

Enhancing cancer control: assessing cancer knowledge, attitudes, and beliefs in disadvantaged communities. Scroggins TG Jr, et al. **J La State Med Soc** 1999 Apr; 151(4):202-8

Purchasing population health: aligning financial incentives to improve health outcomes. Kindig DA. **Nurs Outlook** 1999 Jan-Feb;47(1):15-22 (87 ref.)

Using YPLL in health planning. McDonnell S, et al. **Public Health Rep** 1998 Jan-Feb;113(1):55-61

Geographic information systems and public health: mapping the future. Richards TB, et al. **Public Health Rep** 1999 Jul-Aug;114(4):359-60

Defining essential information needs and indicators. Bodart C, et al. **World Health Forum** 1998;19(3):303-9

ORGANIZATION & ADMINISTRATION

Childhood lead poisoning prevention [letter; comment] **Am J Public Health** 1999 Jul;89(7):1126-31. Comment on: Am J Public Health 1998 Dec;88(12):1871-7.

Childhood lead poisoning: the promise and abandonment of primary prevention [see comments] Needleman HL. **Am J Public Health** 1998 Dec;88(12):1871-7 (38 ref.). Comment in: Am J Public Health 1998 Dec;88(12):1759-60. Comment in: Am J Public Health 1999 Jul;89(7):1126-31.

Planning for better health outcomes requires indigenous perspective [editorial] Angus S, et al. **Aust N Z J Public Health** 1998 Oct;22(6):636-7

The evaluation of health development: the next methodological frontier? [editorial] Legge D. **Aust N Z J Public Health** 1999 Apr;23(2):117-8 (8 ref.)

Closer to home: the case for experiential participation in health reform. Higgins JW. **Can J Public Health** 1999 Jan-Feb;90(1):30-4

The dermatologist's Baedeker. Preparation for medical assistance missions. Norton SA. **Dermatol Clin** 1999 Jan; 17(1):187-208, ix-x (41 ref.)

The role of the WHO representative at country level: past, present and future prospects. al-Khawashky MI. **East Mediterr Health J** 1998;4 Suppl:S66-77; discussion S77-80

Co-ordination and ecology in practical cancer prevention. Moore MA, et al. **Eur J Cancer Prev** 1998 Oct;7(5):409-15

Eight years of experience in the first Romanian center of family planning and contraception. Constantin A, et al. **Eur J Contracept Reprod Health Care** 1999 Jun;4(2):57-60

Nursing manpower development and strategic planning in Greece. Plati C, et al. **Image J Nurs Sch** 1998;30(4):329-33

Food mail: the Canadian alternative to food stamps. Hill F. **Int J Circumpolar Health** 1998;57 Suppl 1:177-81

The potential for Ontario region's health information system to facilitate case management, program planning, and evaluation and to promote enhanced First Nations' control of health services. Johnson RJ. **Int J Circumpolar Health** 1998;57 Suppl 1:671-4

Food affordability in air stage communities. Lawn J, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:182-8

Infant nutrition program effectively prevents iron-deficiency anemia in a First Nations community. Sawchuk P, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:189-93

Perceptions of cancer and its causes among "Industrial Corridor" residents: the LMRICS Planning Project. Lower Mississippi River Interagency Cancer Study. Fick A, et al. **J La State Med Soc** 1999 Apr;151(4):182-8

The medical department in military operations other than war. Part I. Planning for deployment. Baker MS, et al. **Mil Med** 1999 Aug;164(8):572-9 (22 ref.)

Levels of medical support for United Nations peacekeeping operations. Seet B. **Mil Med** 1999 Jul;164(7):451-6 (24 ref.)

The Verona Initiative: a new "arena" for debate on health in Europe. Bertinato L. **Promot Educ** 1999 Mar;6(1):19-20, 37

Laying the foundation for Healthy People 2010. The first year of consultation. Maiese DR, et al. **Public Health Rep** 1998 Jan-Feb;113(1):92-5

European food and nutrition policies in action. Framework and options for action on food and nutrition policies in European countries. **WHO Reg Publ Eur Ser** 1998; 73:157-66

[Public health in a new coalition agreement (see comments)] Gunning-Schepers LJ. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1429-31 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Sep 12;142(37):2062-3. **(Dut)**

[Structuring action from using a model for planning health promotion programs] Proulx M, et al. **Can J Public Health** 1999 Jan-Feb;90(1):23-6 (Eng. Abstr.) **(Fre)**

STANDARDS

Linking epidemiology and disability measurement with mental health service policy and planning. Jenkins R. **Epidemiol Psichiatr Soc** 1998 May-Aug;7(2):120-6

TRENDS

Signs of the times? Massey RU. **Conn Med** 1998 Oct; 62(10):627-8

Setting health standards for the 21st century. Halperin JA. **J Am Pharm Assoc (Wash)** 1998 Nov-Dec;38(6):762-6

WHO and health planning--the past, the present and the future. Sapirie SA. **World Health Forum** 1998;19(4):382-7 (24 ref.)

HEALTH PLANNING COUNCILS

Pew Commission calls for ongoing competency assessment of health professionals, greater say for public on regulatory boards [news] **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2454, 2458

U.S. health system short on quality, consensus panel says [news] **Am J Health Syst Pharm** 1998 Dec 1;55(23):2458, 2463-4

Ardis D. Hoven, MD. AMA council on medical service [interview by Sue Tharp] Hoven AD. **J Ky Med Assoc** 1999 May;97(5):212-6

Cardiopulmonary resuscitation in Saudi Arabia. A proposal for the formation of a Pan-Arab Resuscitation Council [editorial; comment] Takrouri MS. **Middle East J Anesthesiol** 1998 Oct;14(6):393-7. Comment on: Middle East J Anesthesiol 1998 Oct;14(6):399-405.

Adolescent pregnancy. Changing the course. Schurmann A. **N J Med** 1999 Jul;96(7):37-40

LEGISLATION & JURISPRUDENCE

Doctors, the General Medical Council, and Bristol [see comments] Horton R. **Lancet** 1998 May 23; 351(9115):1525-6. Comment in: Lancet 1998 Jul 18;352(9123):231.

ORGANIZATION & ADMINISTRATION

Pharmacy organizations form credentialing council to integrate efforts [news] Landis NT. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2444, 2449-50, 2452

Medicines Control Council--setting the record straight [letter; comment] Folb PI. **S Afr Med J** 1998 Oct; 88(10):1278, 1280. Comment on: S Afr Med J 1998 Aug;88(8):923.

Medicine, economics and agenda-setting. Lewis JM, et al. **Soc Sci Med** 1999 Feb;48(3):393-405

Making the most of aid. Drager N, et al. **World Health Forum** 1998;19(3):286-92

HEALTH PLANNING GUIDELINES

Can data-driven benchmarks be used to set the goals of healthy people 2010? Allison J, et al. **Am J Public Health** 1999 Jan;89(1):61-5

The Ljubljana Charter on Reforming Health Care. 18 June 1996. **Bull World Health Organ** 1999;77(1):48-9

Controlling antimicrobial resistance. Health Canada proposes an integrated action plan for Canadians. Thomas RE. **Can Fam Physician** 1998 Sep;44:1901-5, 1907 (3 ref.) **(Eng, Fre)**

Intervention mapping: a process for developing theory- and evidence-based health education programs [see comments] Bartholomew LK, et al. **Health Educ Behav** 1998 Oct; 25(5):545-63 (62 ref.). Comment in: Health Educ Behav 1998 Oct;25(5):564-8; discussion 569-70.

Intervention mapping and the new health promotion [comment] Heaney CA. **Health Educ Behav** 1998 Oct; 25(5):564-8; discussion 569-70. Comment on: Health Educ Behav 1998 Oct;25(5):545-63.

Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. Aweeka FT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):350-7

Review of the "City Health Profiles" produced by WHO-Healthy Cities--do they present information on health and its determinants and what are their perceived benefits? Webster P. **J Epidemiol Community Health** 1999 Feb;53(2):125-7

EMS Agenda for the Future: where we are...where we want to be. Delbridge TR, et al. **Prehosp Emerg Care** 1998 Jan-Mar;2(1):1-12 (83 ref.)

HEALTH PLANNING ORGANIZATIONS

Public and private health initiatives in Kansas. Fonner E Jr. **J Health Care Finance** 1998 Fall;25(1):35-45

[Freiburg/Bad Säckingen Scientific Rehabilitation Research Group] Bengel J, et al. **Rehabilitation (Stuttg)** 1998 Nov; 37 Suppl 2:S78-83 (Eng. Abstr.) **(Ger)**

[Berlin-Brandenburg-Saxony Rehabilitation Research Group] Brennecke R, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S84-91 (Eng. Abstr.) **(Ger)**

HISTORY

[Establishment of the National Board of Health and Welfare in 1909. A compromise between expert knowledge and political and administrative interests of that time] Christensen N, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7589-92 **(Dan)**

ORGANIZATION & ADMINISTRATION

Conversation. The strength of the Nursing Work Force Development in New Mexico. Shane DL. **J Nurs Adm** 1999 Jan;29(1):4-8

TRENDS

[Introduction of the Bavarian Scientific Rehabilitation Group] Faller H, et al. **Rehabilitation (Stuttg)** 1998 Nov; 37 Suppl 2:S97-103 (Eng. Abstr.) **(Ger)**

[North Rhine-Westphalia Scientific Rehabilitation Group--"future strategies for rehabilitation"] Fischer J, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S104-10 (Eng. Abstr.) **(Ger)**

[Ulm Scientific Rehabilitation Research Group--"building blocks in rehabilitation"] Jacobi E, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S111-6 (Eng. Abstr.) **(Ger)**

[Lower Saxony/Bremen Scientific Rehabilitation Research Group] Petermann F, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S117-21 (Eng. Abstr.) **(Ger)**

[Saxony-Anhalt/Necklenburg-Vorpommern Scientific Rehabilitation Research Groups] Slesina W, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S122-7 (Eng. Abstr.) **(Ger)**

HEALTH PLANNING SUPPORT

TBI state demonstration grants. Helfer B. **J Head Trauma Rehabil** 1998 Apr;13(2):66-77

Public and private health initiatives in Kansas. Fonner E Jr. **J Health Care Finance** 1998 Fall;25(1):35-45

Bruntland makes waves in her first six months at the WHO [news] Birmingham K. **Nat Med** 1999 Mar;5(3):249

ECONOMICS

World Bank will lend more money to India for AIDS [news] Jayaraman KS. **Nat Med** 1998 Jul;4(7):750

ORGANIZATION & ADMINISTRATION

Preparing rural communities for managed care: lessons learned. Fasciano NJ, et al. **J Rural Health** 1999 Winter; 15(1):78-86

AHCPR-funded rural managed care centers: report from the field. Hartley D, et al. **J Rural Health** 1999 Winter; 15(1):87-93

HEALTH PLANNING TECHNICAL ASSISTANCE

HISTORY

[The World Health Organization and planning] de Azevedo AC. **Rev Med Chil** 1998 Jul;126(7 Suppl):11-8 (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Canada's International Immunization Initiative. Dafoe GH. **Can J Public Health** 1998 Nov-Dec;89(6):364 **(Eng, Fre)**

Preparing rural communities for managed care: lessons learned. Fasciano NJ, et al. **J Rural Health** 1999 Winter; 15(1):78-86

HEALTH PLANS, ACCOUNTABLE see **MANAGED COMPETITION**

HEALTH PLANS, PREPAID see **PREPAID HEALTH PLANS**

HEALTH POLICY

Race and health in America. Winston JA. **Acad Med** 1998 Oct;73(10):1084-5

Health-care policy toward medical imaging experience in some European countries. Kesteloot K, et al. **Acad Radiol** 1998 Sep;5 Suppl 2:S377-81

Government policy on medical radiology in Japan. Nakamura Y. **Acad Radiol** 1998 Sep;5 Suppl 2:S314

Radiology and health-care policy in the Czech Republic. Sprindrich J. **Acad Radiol** 1998 Sep;5 Suppl 2:S400-2

Changing preoperative fasting policies. Impact of a national consensus. Fasting S, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1188–91

Where do we stand? Research and policy issues concerning inequalities in health and in healthcare. Whitehead MM. **Acta Oncol** 1999;38(1):41–50 (55 ref.)

Science and alcohol policy at the local level: a respectful partnership. Holder HD, et al. **Addiction** 1998 Oct; 93(10):1467–73

An analysis of alcohol policy in Hungary. Who is in charge? Varvasovszky Z, et al. **Addiction** 1998 Dec;93(12):1815–27

Selective versus universal antenatal HIV testing: epidemiological and implementational factors in policy choice. Ades AE, et al. **AIDS** 1999 Feb 4;13(2):271–8

HIV testing for HIV prevention: a comparative analysis of policies in Britain, Hungary and Sweden. Danziger R. **AIDS Care** 1998 Oct;10(5):563–70

Down the road to deregulation. Chenet L, et al. **Alcohol Alcohol** 1998 Jul–Aug;33(4):337–40

Preventive care for the elderly: getting by in the absence of evidence [editorial; comment] Frame PS. **Am Fam Physician** 1999 Apr 1;59(7):1747–8, 1750. Comment on: Am Fam Physician 1999 Apr 1;59(7):1835–42.

CDC releases updated plan for emerging infectious diseases [see comments] Rose VL. **Am Fam Physician** 1999 Apr 15;59(8):2361–2, 2365. Comment in: Am Fam Physician 1999 Apr 15;59(8):2097–8, 2100.

Report of a National Institutes of Health--Centers for Disease Control and Prevention workshop on the feasibility of conducting a randomized clinical trial to estimate the long-term health effects of intentional weight loss in obese persons [see comments] Yanovski SZ, et al. **Am J Clin Nutr** 1999 Mar;69(3):366–72. Comment in: Am J Clin Nutr 1999 Mar;69(3):347–9.

The health of our children. Wilcox AJ. **Am J Epidemiol** 1999 Oct 1;150(7):665–6

Key findings of evidence-based reports announced [news] **Am J Health Syst Pharm** 1999 Mar 15;56(6):501–2

Infectious disease testing related to organ and tissue transplantation: results from a national laboratory survey. Domen RE. **Am J Infect Control** 1999 Jun;27(3):275–8

What should be the role of public health in newborn screening and prenatal diagnosis? Clayton EW. **Am J Prev Med** 1999 Feb;16(2):111–5 (20 ref.)

Policy issues relevant to evaluation of interactive health communication applications. The Science Panel on Interactive Communication and Health. Patrick K, et al. **Am J Prev Med** 1999 Jan;16(1):35–42

Policy statements adopted by the Governing Council of the American Public Health Association, November 18, 1998. **Am J Public Health** 1999 Mar;89(3):428–50

What's a mother to do? Welfare, work, and family [editorial; comment] Chavkin W. **Am J Public Health** 1999 Apr; 89(4):477–9 (13 ref.). Comment on: Am J Public Health 1999 Apr;89(4):502–5.

Frequency of policy recommendations in epidemiologic publications. Jackson LW, et al. **Am J Public Health** 1999 Aug;89(8):1206–11 (53 ref.)

Questioning epidemiology: objectivity, advocacy, and socially responsible science [editorial; comment] Krieger N. **Am J Public Health** 1999 Aug;89(8):1151–3. Comment on: Am J Public Health 1999 Aug;89(8):1175–80.

Mammography screening [letter; comment] Litaker JR. **Am J Public Health** 1999 Feb;89(2):254–5. Comment on: Am J Public Health 1998 May;88(5):832–3; discussion 834–5.

The role of state policies and programs in buffering the effects of poverty on children's immunization receipt. Mayer ML, et al. **Am J Public Health** 1999 Feb;89(2):164–70

Directly observed therapy and tuberculosis treatment completion. Novick and Lipsman re: Bayer et al [letter; comment] Novick LF, et al. **Am J Public Health** 1999 Apr; 89(4):604. Comment on: Am J Public Health 1998 Jul;88(7):1052–8.

The need for a home hygiene policy and guidelines on home hygiene. Beumer R, et al. **Ann Ig** 1999 Jan–Feb;11(1):11–26

Divergent illicit drug policies in Europe [news] **Ann Oncol** 1998 Dec;9(12):1257

Demand, supply and allocation in Eurotransplant. Persijn GG, et al. **Ann Transplant** 1997;2(1):26–33

Guidelines to assist national authorities with regard to the formulation of transplant policies and laws. Santiago-Delpin EA. **Ann Transplant** 1998;3(2):19–21

Psychiatry in transition: outcomes of mental health policy shift in Italy. Barbato A. **Aust N Z J Psychiatry** 1998 Oct; 32(5):673–9 (25 ref.)

Reconciliation and policy reform: is there a link? [editorial] Anderson I. **Aust N Z J Public Health** 1999 Jun;23(3):231–2

Rural public health matters [editorial] Keleher H. **Aust N Z J Public Health** 1999 Aug;23(4):342

Are smoke-free policies implemented and adhered to at sporting venues? Pikora T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):407–9

Health, history and reconciliation [editorial] Ring I, et al. **Aust N Z J Public Health** 1999 Jun;23(3):228–31

A 'whole of government' approach needed on indigenous health [editorial] Ring I. **Aust N Z J Public Health** 1998 Oct;22(6):639–40

Disability in older adults. 3: Policy implications. Chiriboga DA, et al. **Behav Med** 1999 Winter;24(4):171–80 (38 ref.)

Inequalities in health. Independent inquiry gives detailed recommendations [letter; comment] Ashton J. **BMJ** 1999 Feb 27;318(7183):601. Comment on: BMJ 1998 Nov 28;317(7171):1465–6.

Scottish doctors launch their manifesto [news] Beecham L. **BMJ** 1999 Jan 23;318(7178):214

Better benefits for health: plan to implement the central recommendation of the Acheson report. Black D, et al. **BMJ** 1999 Mar 13;318(7185):724–7

Being strategic about smoking [editorial] Chambers J. **BMJ** 1999 Jan 2;318(7175):1–2

Scottish white paper aims to tackle health divide [news] Christie B. **BMJ** 1999 Feb 27;318(7183):557

Real-time priority scoring system must be used for prioritisation on waiting lists [letter; comment] Davis B, et al. **BMJ** 1999 Jun 19;318(7199):1699. Comment on: BMJ 1997 Jan 11;314(7074):131–4. Comment on: BMJ 1998 Mar 21;316(7135):925–9. Comment on: BMJ 1998 Apr 4;316(7137):1092–3.

Labour's health policy is having paradoxical effect in Iberian countries [letter] Gené-Badia J. **BMJ** 1999 Feb 13; 318(7181):466–7

New labour and the NHS. [editorial] Ham C. **BMJ** 1999 Apr 24;318(7191):1092

Public policy and mental health legislation should be reconsidered [letter] Holloway F, et al. **BMJ** 1999 May 15;318(7194):1354

BMJ should cover health policies of all parties in Scottish election [letter; comment] Kerr M. **BMJ** 1999 May 1; 318(7192):1215. Comment on: BMJ 1999 Jan 9;318(7176):80.

Inequalities in health. Policies to reduce income inequalities are unlikely to eradicate inequalities in mortality [letter] Martikainen P, et al. **BMJ** 1999 Jul 31;319(7205):319

Devolution and health: challenges for Scotland and Wales. Pollock AM. **BMJ** 1999 May 1;318(7192):1195–8

The independent inquiry into inequalities in health is welcome, but its recommendations are too cautious and vague [editorial] [see comments] Smith GD, et al. **BMJ** 1998 Nov 28;317(7171):1465–6. Comment in: BMJ 1998 Dec 12;317(7173):1659. Comment in: BMJ 1999 Feb 27;318(7183):601.

Eradicating child poverty [editorial] Smith R. **BMJ** 1999 Jul 24;319(7204):203–4

Rescue thrombolysis for failure of primary thrombolysis cannot be justified [letter; comment] Sutton AG. **BMJ** 1999 Jan 23;318(7178):261. Comment on: BMJ 1998 Jul 11;317(7151):147.

Evidence based patient information. Local policies would be better than a national strategy [letter; comment] Thomas R. **BMJ** 1999 Feb 13;318(7181):462. Comment on: BMJ 1998 Jul 25;317(7153):225–6.

Long stay care and the NHS: discontinuities between policy and practice [see comments] Turrell AR, et al. **BMJ** 1998 Oct 3;317(7163):942–4 (21 ref.). Comment in: BMJ 1999 Mar 6;318(7184):668.

European union considers new plan to help refugees [news] Watson R. **BMJ** 1999 May 29;318(7196):1439

Drug and alcohol policies are rare at medical schools in UK [letter] Williams DF. **BMJ** 1999 Jul 10;319(7202):123

White paper on tobacco takes a laudable stance [letter] Yach D, et al. **BMJ** 1999 Feb 27;318(7183):604

The use of targets to improve the performance of health care providers: a discussion of government policy. Elkan R, et al. **Br J Gen Pract** 1998 Aug;48(433):1515–8

Health policy reforms and their impact on the practice of tropical medicine. Mills A. **Br Med Bull** 1998;54(2):503–13 (32 ref.)

State initiatives in health policy. Brown LD. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):604–13

Commonwealth Fund Initiatives. Davis K. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):624–6

Harm reduction drug policies and practice: international developments and domestic initiatives. Overview of a symposium. March 22, 1995. Drucker E, et al. **Bull N Y Acad Med** 1995 Winter;72(2):335–8

Harm reduction in Bern: from outreach to heroin maintenance. Haemmig RB. **Bull N Y Acad Med** 1995 Winter;72(2):371–9

Research on needle exchange: redefining the agenda. Hantman JA. **Bull N Y Acad Med** 1995 Winter; 72(2):397–412

Keynote address. The Margaret E. Mahoney Lecture and Symposium on the State of the Nation's Health. Lee PR. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):552–69

When science and politics collide: the federal response to needle-exchange programs. Lurie P. **Bull N Y Acad Med** 1995 Winter;72(2):380–96

Drug policy reform: societal and clinical perspectives. Newman RG. **Bull N Y Acad Med** 1995 Winter; 72(2):321–34

Overview of challenges. Thier SO. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):570–4

Methadone treatment by general practitioners in Amsterdam. van Brussel G. **Bull N Y Acad Med** 1995 Winter; 72(2):348–58

Harm reduction: Australia as a case study. Wodak A. **Bull N Y Acad Med** 1995 Winter;72(2):339–47

Response to special section: cloning: technology, policy, and ethics (CQ vol 7, no 2). Humanness, personhood, and a lamb named Dolly [comment] Koch T, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):241–5. Comment on: Camb Q Healthc Ethics 1998 Spring;7(2):145–9. Comment on: Camb Q Healthc Ethics 1998 Spring;7(2):163–7.

Science, rhetoric, and public discourse in genetic research. Lagay FL. **Camb Q Healthc Ethics** 1999 Spring;8(2):226–37 (33 ref.)

Screening mammography in Alberta: the politics of breast health [editorial] Irwin ML. **Can Assoc Radiol J** 1998 Oct; 49(5):307–10

Some provincial chapters adopting a more political stance. Kermode-Scott B. **Can Fam Physician** 1999 Jun;45:1425–9, 1432–7 **(Eng, Fre)**

Proposed air quality objectives for fine particulate air pollution. Guidotti TL. **Can J Public Health** 1999 Jul–Aug; 90(4):285–7

The war on healthcare professionals and healthcare delivery [editorial] Wiernik PH. **Cancer Invest** 1999;17(2):164–9

The challenge of health care delivery to the elderly patient with cardiovascular disease. Demographic, epidemiologic, fiscal, and health policy implications. Batchelor WB, et al. **Cardiol Clin** 1999 Feb;17(1):1–15, vii (71 ref.)

The perception of discrimination in the HIV policy among Czech gay men. Procházka I, et al. **Cent Eur J Public Health** 1998 Aug;6(3):192–4

AHA's new strategic impact goal designed to curb epidemic of cardiovascular disease and stroke [news] Fuster V, et al. **Circulation** 1999 May 11;99(18):2360

Genetic testing and insurance in the United Kingdom. Morrison PJ. **Clin Genet** 1998 Nov;54(5):375–9 (22 ref.)

Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Wheeler T, et al. **Clin Oncol (R Coll Radiol)** 1999; 11(3):169–73

Evaluating the impact of reference-based pricing [editorial; comment] Grootendorst P, et al. **CMAJ** 1999 Aug 10; 161(3):273–4. Comment on: CMAJ 1999 Aug 10;161(3):255–60.

The CMA's Health Information Privacy Code: does it go too far? [editoriall; comment] Hoey J. **CMAJ** 1998 Oct 20;159(8):953–4. Comment on: CMAJ 1998 Oct 20;159(8):997–1016.

Maternal nutrition, pregnancy outcome and public health policy [editorial] [see comments] Kramer MS. **CMAJ** 1998 Sep 22;159(6):663–5. Comment in: CMAJ 1999 Mar 9;160(5):633–4, 636.

The quandary of Creutzfeldt-Jakob disease [editorial; comment] Larke B. **CMAJ** 1998 Oct 6;159(7):789–92. Comment on: CMAJ 1998 Oct 6;159(7):771–4.

Chaos reigns at medical schools over hepatitis B testing. Sibbald B. **CMAJ** 1999 May 18;160(10):1492–3

Health Canada leery as US "nutraceutical" movement prepares to move north. Sibbald B. **CMAJ** 1999 Sep 21; 161(6):742

Primary care visits and health policy [editorial; see comments] Starfield B. **CMAJ** 1998 Oct 6;159(7):795–6. Comment in: CMAJ 1998 Oct 6;159(7):777–83.

What is the gonococcus telling us? [editorial] Donovan B. **Commun Dis Intell** 1998 Oct 1;22(10):216–7

Health targets as an instrument for improving the rational framework of healthcare decisions. Dorange CT, et al. **Croat Med J** 1998 Sep;39(3):332–8

For debate--Does health care save lives? [editorial] McKee M. **Croat Med J** 1999 Jun;40(2):123–8

Serum supply: policies and controls operating in New Zealand. Shailer C, et al. **Dev Biol Stand** 1999;99:71–7 (0 ref.)

Disability and health care expenditure data: a wide range of user experience is more important than standard definitions of disability. Joslyn E. **Disabil Rehabil** 1999 Aug; 21(8):382–4

Primary health care in the eastern Mediterranean region before and after Alma-Ata. Abdullatif AA. **East Mediterr Health J** 1998;4 Suppl:S85–102 (18 ref.)

Public health policy and the National Toxicology Program [editorial] Lucier GW, et al. **Environ Health Perspect** 1998 Oct;106(10):A470–1

Linking epidemiology and disability measurement with mental health service policy and planning. Jenkins R. **Epidemiol Psichiatr Soc** 1998 May–Aug;7(2):120–6

Co-ordination and ecology in practical cancer prevention. Moore MA, et al. **Eur J Cancer Prev** 1998 Oct;7(5):409–15

Chinese amend policy on sterilisation for genetic reasons [news] Pembrey M, et al. **Eur J Hum Genet** 1998 Nov–Dec; 6(6):533

The effects of shifts in the balance of care on general practice workload. Scott A, et al. **Fam Pract** 1999 Feb;16(1):12–7

Establishment of a successful donor embryo program: medical, ethical, and policy issues. Van Voorhis BJ, et al. **Fertil Steril** 1999 Apr;71(4):604–8

Debate about ultrasound screening policies. Antsaklis AJ. **Fetal Diagn Ther** 1998 Jul–Aug;13(4):209–15 (35 ref.)

European Commission--Directorate General DG XXIV Consumer Policy and Consumer Health Protection. Notes of Guidance for testing of cosmetic ingredients for their safety evaluation (Second Revision). Adopted: 20 December 1996. Revised: 16 January 1997. The Scientific Committee on Cosmetology of the European Commission. **Food Chem Toxicol** 1999 Apr;37(4):357–85

Deinstitutionalization and community care: social welfare policy as mental health policy. Goldman HH. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):219–22

Adam and the implant [news] MacDougall JC. **Hastings Cent Rep** 1998 Jul–Aug;28(4):47

HEALTH POLICY

Policy as product. Morality and metaphor in health policy discourse. Malone RE. **Hastings Cent Rep** 1999 May–Jun; 29(3):16–22

"Don't die of ignorance" [news] Nicholson RH. **Hastings Cent Rep** 1999 May–Jun;29(3):6

Should government intervene to protect nonprofits? Bloche MG. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):7–25 (43 ref.)

International health policy: common problems, alternative strategies. Davis K. **Health Aff (Millwood)** 1999 May–Jun; 18(3):135–43

Health services research and state policy in action [letter; comment] Farrell JL, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):257–8. Comment on: Health Aff (Millwood) 1998 Jan–Feb;17(1):139–51.

The new generation of nurse practitioners: is more enough? Harper DC, et al. **Health Aff (Millwood)** 1998 Sep–Oct; 17(5):158–64

The global pursuit of health policy lessons [editorial] Iglehart JK. **Health Aff (Millwood)** 1999 May–Jun;18(3):7–8

Health grantmakers and public policy. LeRoy L, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):230–2

Health policy grant making by foundations in the 1990s. Renz L, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):216–29 (26 ref.)

'More a link than a division': how Canada has learned from U.S. mental health policy. Rochefort DA, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):110–27

Mixed signals: public policy and the future of health care R&D. Weisbrod BA, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):112–25

'Assessing the new federalism' and state health policy [comment] [see comments] Well A, et al. **Health Aff (Millwood)** 1998 Nov–Dec;17(6):162–4. Comment on: Health Aff (Millwood) 1998 Nov–Dec;17(6):150–61. Comment in: Health Aff (Millwood) 1999 May–Jun;18(3):267–8.

The 39 steps: the mystery of health inequalities in the UK [editorial] [see comments] Birch S. **Health Econ** 1999 Jun; 8(4):301–8. Comment in: Health Econ 1999 Jun;8(4):281–2.

Policy-induced changes in Maori mortality patterns in the New Zealand economic reform period. Brown MC. **Health Econ** 1999 Mar;8(2):127–36

Inequalities in health: an introduction [editorial; comment] Maynard A. **Health Econ** 1999 Jun;8(4):281–2. Comment on: Health Econ 1999 Jun;8(4):283–8. Comment on: Health Econ 1999 Jun;8(4):297–9. Comment on: Health Econ 1999 Jun;8(4):301–8.

Commentary on the Acheson report [editorial] [see comments] Williams A. **Health Econ** 1999 Jun;8(4):297–9 . Comment in: Health Econ 1999 Jun;8(4):281–2.

SOPHE: at the intersection of education, policy, and science and technology. Allegrante JP. **Health Educ Behav** 1999 Aug;26(4):457–64

AHCPR focuses on information for health care decision makers. Eisenberg JM. **Health Serv Res** 1998 Oct;33(4 Pt 1):767–81 (11 ref.)

Health services research in workers' compensation medical care: policy issues and research opportunities. Himmelstein J, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):427–37

The role of government in "a society for all ages". Hudson RB. **Health Soc Work** 1999 May;24(2):155–60

Spend tobacco settlement funds outside health care? [news] Blumenthal R, et al. **Hosp Health Netw** 1999 Sep;73(9):24

Financing, demographic, and political problems confronting Medicare in the United States. Buerhaus PI. **Image J Nurs Sch** 1998;30(2):117–22

Nursing research and priorities in Africa, Asia, and Europe. Henry BM, et al. **Image J Nurs Sch** 1998;30(2):115–6

Reimbursement to advanced practice nurses (APNs) through Medicare [see comments] Wong ST. **Image J Nurs Sch** 1999;31(2):167–73. Comment in: Image J Nurs Sch 1999 ;31(2):160.

India's polio eradication efforts at cross roads [editorial] [see comments] John TJ. **Indian Pediatr** 1998 Apr;35(4):307–10 . Comment in: Indian Pediatr 1998 Nov;35(11):1136–41.

Implementation of a practical antibiotic policy in the Czech Republic. Kolár M, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):440–3

Awareness of periodontal diseases: the professional and the civil servant. Eaton KA. **Int Dent J** 1998 Jun;48(3 Suppl 1):248–55 (40 ref.)

A fundamental shift in the approach to international health by WHO, UNICEF, and the World Bank: instances of the practice of "intellectual fascism" and totalitarianism in some Asian countries. Banerji D. **Int J Health Serv** 1999; 29(2):227–59 (146 ref.)

The decline in U.S. cancer mortality from 1991 to 1995: what's behind the numbers? Clapp RW. **Int J Health Serv** 1998;28(4):747–55 (7 ref.)

Examining the "liberal media" claim: journalists' views on politics, economic and social policy (including health care), and media coverage. Croteau D. **Int J Health Serv** 1999; 29(3):627–55

Health and equity in the world in the era of "globalization". Navarro V. **Int J Health Serv** 1999;29(2):215–26

New labour and the third way in the British National Health Service. Powell M. **Int J Health Serv** 1999;29(2):353–70 (82 ref.)

Disenchantment, ambivalence, and the precautionary principle: the becalming of British health policy. Wainwright D. **Int J Health Serv** 1998;28(3):407–26

An educational intervention using the Agency for Health Care Policy and Research Depression Guidelines among internal medicine residents. Kick SD. **Int J Psychiatry Med** 1999;29(1):47–61

Public disclosure of health care performance reports: a response from the UK [comment] Coles J. **Int J Qual Health Care** 1999 Apr;11(2):104–5. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

Public disclosure of health care performance reports: what do we lose in giving information? [comment] Collopy BT. **Int J Qual Health Care** 1999 Apr;11(2):99–101. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

The Quality of Well-Being Scale: critical similarities and differences with SF-36 [see comments] Kaplan RM, et al. **Int J Qual Health Care** 1998 Dec;10(6):509–20. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.

Public disclosure of health care performance reports: experience, evidence and issues for policy [see comments] Leatherman S, et al. **Int J Qual Health Care** 1999 Apr; 11(2):93–8. Comment in: Int J Qual Health Care 1999 Apr;11(2):99–101. Comment in: Int J Qual Health Care 1999 Apr;11(2):102–3. Comment in: Int J Qual Health Care 1999 Apr;11(2):104–5.

Public disclosure of health care performance reports: comments and reflections from Sweden [comment] Mebius C. **Int J Qual Health Care** 1999 Apr;11(2):102–3. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

Policy issues in accreditation [editorial] Scrivens E. **Int J Qual Health Care** 1998 Feb;10(1):1–5

ICN on healthy ageing: a public health and nursing challenge. **Int Nurs Rev** 1999 Mar–Apr;46(2):60–1

HIV prevention in street youth. Walters AS. **J Adolesc Health** 1999 Sep;25(3):187–98 (67 ref.)

Health 21: The health for all policy framework for the WHO European Region [news] **J Adv Nurs** 1999 Aug;30(2):280

Nursing leadership: influencing and shaping health policy and nursing practice. Antrobus S, et al. **J Adv Nurs** 1999 Mar;29(3):746–53

Family care-giving for people with dementia: some implications for policy and professional practice. Clarke CL. **J Adv Nurs** 1999 Mar;29(3):712–20

Continuing care: developing a policy analysis for nursing. Maslin-Prothero S, et al. **J Adv Nurs** 1998 Sep;28(3):548–53

Systematic reviews and the practice of evidence-based dentistry: professional and policy implications. Ismail AI, et al. **J Am Coll Dent** 1999 Spring;66(1):5–12

ADA helps Shape Healthy People 2010; update on healthy weight partnership guidelines; regulatory comments [news; comment] **J Am Diet Assoc** 1999 Apr;99(4):420. Comment on: J Am Diet Assoc 1999 Apr;99(4):415, 418–9.

ADA joins national coding and provider classification projects [news] **J Am Diet Assoc** 1999 Jan;99(1):18

Position of the American Dietetic Association: dietary guidance for healthy children aged 2 to 11 years. **J Am Diet Assoc** 1999 Jan;99(1):93–101

A commentary on the new obesity guidelines from NIH. Ikeda JP, et al. **J Am Diet Assoc** 1999 Aug;99(8):918–9 (26 ref.)

Taking back young lives: policy issues for adolescent girls in the developing world. Bruce J, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):153–4, 160

Response to women's health issue [letter] Sarto GE. **J Am Med Womens Assoc** 1999 Summer;54(3):161; discussion 162

A review of the role of antibiotic policies in the control of antibiotic resistance. Gould IM. **J Antimicrob Chemother** 1999 Apr;43(4):459–65 (59 ref.)

Coming together to conquer cancer [letter] Stovall E, et al. **J Clin Oncol** 1999 Feb;17(2):730

Structural issues and policy in the primary care management of depression. Magruder KM, et al. **J Clin Psychiatry** 1999; 60 Suppl 7:45–51; discussion 52–3 (23 ref.)

Some AIDS-related policy issues and nursing students' willingness to provide AIDS care. Lal P, et al. **J Commun Dis** 1998 Mar;30(1):38–43

Listening to migrant voices: focus groups on health issues in south Georgia. Perilla JL, et al. **J Community Health Nurs** 1998;15(4):251–63

Deprivation and inequalities in women's health: smoking, an oral cancer, and child dental health. Pine CM. **J Dent Educ** 1999 Mar;63(3):276–80

Being prepared to protect the public health. Information for thinking the unthinkable and doing the essential [editorial] Ashton J, et al. **J Epidemiol Community Health** 1998 Nov; 52(11):702–3

Who will grasp the public health nettle in London? [editorial] Bardsley M, et al. **J Epidemiol Community Health** 1999 Jul;53(7):386–7

How many lives is equity worth? A proposal for equity adjusted years of life saved. Lindholm L, et al. **J Epidemiol Community Health** 1998 Dec;52(12):808–11

Health impact assessment--theory into practice [editorial] Scott-Samuel A. **J Epidemiol Community Health** 1998 Nov; 52(11):704–5

The lack of integration of clinical audit and the maintenance of medical dominance within British hospital trusts. McErlain-Burns TL, et al. **J Eval Clin Pract** 1999 Aug; 5(3):323–33 (36 ref.)

Health policy directions for evidence-based decision making in Canada [see comments] Noseworthy T, et al. **J Eval Clin Pract** 1999 May;5(2):227–42. Comment in: J Eval Clin Pract 1999 May;5(2):97–101.

Avoidable errors in health policy analysis [published erratum appears in J Gen Intern Med 1999 Jun;14(6):363] Asch DA, et al. **J Gen Intern Med** 1998 Nov;13(11):762–7

The negative effect of the clinical model of "health": implications for health care policy. Peters RM. **J Health Care Finance** 1998 Fall;25(1):78–92

The influence of governmental policy on community health partnerships and community care networks: an analysis of three cases. Gamm LD, et al. **J Health Polit Policy Law** 1998 Oct;23(5):771–94

Access to medical care under strain: new pressures in Canada and Australia. Gray G. **J Health Polit Policy Law** 1998 Dec;23(6):905–47 (111 ref.)

The conditions for state action in Florida's health-care market. Harkreader S, et al. **J Health Soc Behav** 1999 Jun; 40(2):159–74

Rubella immune status among healthcare workers in the Department of Obstetrics and Gynaecology of a regional hospital in Hong Kong: the need for a vaccination policy. Chan PK, et al. **J Hosp Infect** 1999 Jul;42(3):239–42

Decreased consumption of antimicrobial drugs after implementation of a new antibiotic policy in 1990 [letter] Krčméry V, et al. **J Hosp Infect** 1999 Jan;41(1):75–7

Pregnancy is special--let's make it safe [editorial] Mukherjee AK. **J Indian Med Assoc** 1998 Apr;96(4):101–2

Genetic medicine: an experiment in community-expert interaction. Schibeci R, et al. **J Med Ethics** 1999 Aug; 25(4):335–9

Recommendation to include colorectal cancer screening in public health policy. The European Group for Colorectal Cancer Screening. **J Med Screen** 1999;6(2):80–1

The first report of the National Screening Committee [editorial] Gray JA. **J Med Screen** 1998;5(4):169

British commence war on tobacco [news] **J Natl Cancer Inst** 1999 Jan 20;91(2):116

Maternal mortality in the developing world: many unanswered questions. Rizvi JH, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):149–51 (24 ref.)

Breastfeeding [letter; comment] Meier P, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):604–5. Comment on: J Obstet Gynecol Neonatal Nurs 1998 Jul–Aug;27(4):363.

Health care fraud and abuse. AMA Board of Trustees Report, Reference Committee B. **J Okla State Med Assoc** 1998 Oct;91(7):408–9

The third molar controversy: framing the controversy as a public health policy issue. Flick WG. **J Oral Maxillofac Surg** 1999 Apr;57(4):438–44; discussion 445 (29 ref.)

Policy statement on breastfeeding. The Australian College of Paediatrics. **J Paediatr Child Health** 1998 Oct; 34(5):412–3

Ethnic groups and our healthier nation: whither the information base? Aspinall PJ. **J Public Health Med** 1999 Jun;21(2):125–32

Should we be doing more to prevent Group C meningococcal infection in school age children? How can we decide? Round A, et al. **J Public Health Med** 1999 Mar;21(1):8–13

Policy options for prevention: the case of alcohol. Toomey TL, et al. **J Public Health Policy** 1999;20(2):192–213 (81 ref.)

The Australian National Medicinal Drug Policy. Sansom L. **J Qual Clin Pract** 1999 Mar;19(1):31–5 (10 ref.)

The submission from The Royal Society for the Promotion of Health on the communication from the Commission on the Development of Public Health Policy in the EC. **J R Soc Health** 1998 Oct;118(5):309–10

The submission from The Royal Society for the Promotion of Health on Government consultation document "Our Healthier Nation". **J R Soc Health** 1998 Aug;118(4):241–2

Policies for rural health care: they work ... sometimes [editorial] Ricketts TC. **J Rural Health** 1999 Winter; 15(1):7–10

Accessing Useful Information: Challenges in Health Policy and Public Health. Proceedings of a national forum. March 23, 1998. **J Urban Health** 1998 Dec;75(4):777–895

Quality of public health information: lessons from the field. Bialek R. **J Urban Health** 1998 Dec;75(4):853–63 (9 ref.)

Applied information quality: a framework for thinking about the quality of specific information. Bradley J. **J Urban Health** 1998 Dec;75(4):864–77 (8 ref.)

Web-based resources for retrieving health policy information: NLM and beyond. Cahn MA, et al. **J Urban Health** 1998 Dec;75(4):826–41 (26 ref.)

Sources used in health policy research and implications for information retrieval systems. Gray BH. **J Urban Health** 1998 Dec;75(4):842–52 (0 ref.)

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

Strategies for addressing priority information problems in health policy and public health. Lasker RD. **J Urban Health** 1998 Dec;75(4):888–95 (0 ref.)

Challenges to accessing useful information in health policy and public health: an introduction to a national forum held at the New York Academy of Medicine, March 23, 1998. Lasker RD. **J Urban Health** 1998 Dec;75(4):779–84 (0 ref.)

The retrieval problem for health policy and public health: knowledge bases and search engines. Lynch C. **J Urban Health** 1998 Dec;75(4):794–806 (0 ref.)

Information needs in public health and health policy: results

of recent studies. O'Carroll PW, et al. **J Urban Health** 1998 Dec;75(4):785–93 (3 ref.)

Meeting information needs in health policy and public health: roles for the Centers for Disease Control and Prevention. Ross D. **J Urban Health** 1998 Dec;75(4):884–7 (2 ref.)

Answering Kevorkian's challenge: is this the way we want to die? [editorial] Healy BP. **J Womens Health** 1998 Dec; 7(10):1185–6

Americans' views on children's health. Blendon RJ, et al. **JAMA** 1998 Dec 23–30;280(24):2122–7

Voters and health care in the 1998 election. Blendon RJ, et al. **JAMA** 1999 Jul 14;282(2):189–94

Marginal medicine [letter; comment] David DS. **JAMA** 1999 Mar 24–31;281(12):1082; discussion 1083. Comment on: JAMA 1998 Sep 9;280(10):931–3.

Marginal medicine [letter; comment] Houghton ER. **JAMA** 1999 Mar 24–31;281(12):1082; discussion 1083. Comment on: JAMA 1998 Sep 9;280(10):931–3.

Reports focus on bad, good in children's health [news] Marwick C. **JAMA** 1998 Dec 2;280(21):1814–5

Debate revived on hepatitis B vaccine value [news] Marwick C, et al. **JAMA** 1999 Jul 7;282(1):15–7

New advocates of adequate treatment say have no fear of pain or of prosecution [news] Marwick C. **JAMA** 1999 Feb 3;281(5):406–7

Marginal medicine [letter] Spitzer D. **JAMA** 1999 Mar 24–31; 281(12):1082; discussion 1083

Long-term effects of home visits on children's behavior [letter; comment] Temple P. **JAMA** 1999 Apr 21; 281(15):1376; discussion 1377. Comment on: JAMA 1998 Oct 14;280(14):1238–44.

Conference report. Measuring and improving the quality of care in health plans. Berman S. **Jt Comm J Qual Improv** 1999 Aug;25(8):434–9

Conservatives do U-turn on health policy [news] Dean M. **Lancet** 1999 May 1;353(9163):1505

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Golden B, et al. **Lancet** 1999 Jul 10;354(9173):158–9. Comment on: Lancet 1999 Mar 6;353(9155):773–80.

Planning and measuring basic research [news] Greenberg DS. **Lancet** 1999 Feb 27;353(9154):733

Weighing up disability [comment] James KC, et al. **Lancet** 1999 Jul 10;354(9173):87–8. Comment on: Lancet 1999 Jul 10;354(9173):111–5.

European breast-cancer meeting [letter; comment] Kunkler I. **Lancet** 1998 Nov 21;352(9141):1711. Comment on: Lancet 1998 Oct 10;352(9135):1200.

Clinton administration plans to expand access to methadone [news] McCarthy M. **Lancet** 1998 Oct 10;352(9135):1206

In-vitro fertilisation in Israel [letter] Schenker JG. **Lancet** 1999 Jun 19;353(9170):2163

Implications of age-based policies for influenza immunisation [letter] Watkins J, et al. **Lancet** 1999 Jan 16;353(9148):208–9

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Wolffers I. **Lancet** 1999 Jul 10;354(9173):158. Comment on: Lancet 1999 Mar 6;353(9155):773–80.

An assessment of the potential for repatriating care from urban to rural Manitoba. Black C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS167–86

Old questions, new audiences [editorial] Clancy CM, et al. **Med Care** 1999 Apr;37(4):329–32

Communicating with the public, communicating with each other. DeCoster C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS279–90

Associations between health status and utilities implications for policy. Lenert LA, et al. **Med Care** 1999 May; 37(5):479–89

From research to policy: what have we learned? Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS291–305 (37 ref.)

Managing health services: how the Population Health Information System (POPULIS) works for policymakers. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS27–41 (68 ref.)

Establishing a population data-based policy unit. Roos NP. **Med Care** 1999 Jun;37(6 Suppl):JS15–26 (29 ref.)

Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS10–4

Sandwell Health Action Zone puts on its 'SHOES'. Middleton J, et al. **Med Confl Surviv** 1998 Oct-Dec; 14(4):331–6

Physician Leadership on National Drug Policy: advocacy for an effective drug policy. Lewis DC. **Med Health R I** 1999 Mar;82(3):101–4

Men's health [editorial] Connell RW, et al. **Med J Aust** 1998 Sep 21;169(6):295–6 (12 ref.)

Health policy--the process and the politics [letter; comment] Gaughwin MD. **Med J Aust** 1999 Jul 5;171(1):56. Comment on: Med J Aust 1998 Mar 2;168(5):228–9.

Ethical implications of competition policy in healthcare. Komesaroff PA. **Med J Aust** 1999 Mar 15;170(6):266–8

Decision making in CPR [letter; comment] Mackay MJ. **Med J Aust** 1999 Jan 4;170(1):46. Comment on: Med J Aust 1999 May 3;170(9):453–4. Comment on: Med J Aust 1999 May 3;170(9):454.

Risky business: health risk assessment and public health policy on environmental carcinogens. Sim MR, et al. **Med J Aust** 1999 Apr 19;170(8):372–4 (15 ref.)

The Second National Mental Health Plan: an opportunity to take stock and move forward [see comments] Singh BS, et al. **Med J Aust** 1998 Oct 19;169(8):435–7 (14 ref.). Comment in: Med J Aust 1999 May 3;170(9):452.

Renewing Australia's mental health strategy [see comments] Whiteford HA. **Med J Aust** 1998 Oct 19;169(8):432–4 (12 ref.). Comment in: Med J Aust 1999 May 3;170(9):452.

The hospital doctor in legislation and medical deontology: tension between profession and institution. Schutyser K. **Med Law** 1998;17(4):519–44 (57 ref.)

The quantity and quality of exercise for healthy adults [letter] Winett RA, et al. **Med Sci Sports Exerc** 1999 Jun; 31(6):916–20

Artemisinin and its derivatives: the regulatory and policy implications for African countries. Salako L. **Med Trop (Mars)** 1998;58(3 Suppl):82–4

Public advocacy and allocation of federal funds for biomedical research. Dresser R. **Milbank Q** 1999; 77(2):257–74, 175

Physicians' perceptions of risk adjustment and health policy formation in Minnesota. Oberstar JV, et al. **Minn Med** 1999 Mar;82(3):43–8

The risks of lowering the cesarean-delivery rate [letter; comment] Satcher D. **N Engl J Med** 1999 Jul 1;341(1):54–5 . Comment on: N Engl J Med 1999 Jan 7;340(1):54–7.

Long-term care at home [letter] Somers AR. **N Engl J Med** 1999 Sep 23;341(13):1005

Executive summary and statement of goals of the report New Zealand Oral Health Goals for the New Millennium. **N Z Dent J** 1999 Jun;95(420):49–52

Dental amalgam [letter; comment] Godfrey ME. **N Z Med J** 1998 Aug 28;111(1072):326. Comment on: N Z Med J 1998 Jun 12;111(1067):217.

Breast cancer screening policy [letter; comment] Marshall B. **N Z Med J** 1998 Sep 11;111(1073):350. Comment on: N Z Med J 1998 Jun 26;111(1068):238.

Youth suicide rates [letter] [see comments] Robertson S. **N Z Med J** 1998 Aug 28;111(1072):326. Comment in: N Z Med J 1998 Oct 23;111(1076):415.

South Africa: setting the wrong example [editorial] **Nat Med** 1999 Jan;5(1):1

Uganda gives lessons in stemming the AIDS epidemic [editorial] **Nat Med** 1999 Sep;5(9):963

Conflict-of-interest problems lead to policy changes [news] [see comments] Birmingham K. **Nat Med** 1999 Jul; 5(7):717–8. Comment in: Nat Med 1999 Jul;5(7):713.

Public pressure alters French vaccination policy [news] Birmingham K. **Nat Med** 1998 Nov;4(11):1217

Iceland poised to sell exclusive rights to national health data [news] Masood E. **Nature** 1998 Dec 3;396(6710):395

Mandatory reporting of intimate partner violence by health care professionals: a policy review. Glass N, et al. **Nurs Outlook** 1998 Nov-Dec;46(6):279–83 (35 ref.)

In defense of a body mass index of 25 as the cut-off point for defining overweight [letter; comment] Bray GA. **Obes Res** 1998 Nov;6(6):461–2. Comment on: Obes Res 1998 Sep;6 Suppl 2:51S–209S.

New policies affecting health of PA children. **Pa Med** 1999 Apr;102(4):11

A medical research agenda for child maltreatment: negotiating the next steps. Theodore AD, et al. **Pediatrics** 1999 Jul;104(1 Pt 2):168–77

The patient and public policy [letter; comment] Atchley WA. **Pharos** 1999 Spring;62(2):39; discussion 41. Comment on: Pharos 1998 Fall;61(4):18–20; discussion 21–5.

The patient and public policy [letter; comment] Brendler SJ. **Pharos** 1999 Spring;62(2):41. Comment on: Pharos 1998 Fall;61(4):18–20; discussion 21–5.

The coming clash: patient advocates vs. the public interest [letter] Craner G. **Pharos** 1999 Summer;62(3):50

The patient and public policy [letter; comment] Ginzberg E. **Pharos** 1999 Spring;62(2):39–40; discussion 41. Comment on: Pharos 1998 Fall;61(4):18–20; discussion 21–5.

The coming clash: patient advocates vs. the public interest [letter] Granat P. **Pharos** 1999 Summer;62(3):50–1

The patient and public policy [letter; comment] Knopf M. **Pharos** 1999 Spring;62(2):40; discussion 41. Comment on: Pharos 1998 Fall;61(4):18–20; discussion 21–5.

Impact of policy and practice on the effectiveness of contact screening for tuberculosis. MacIntyre CR, et al. **Prev Med** 1998 Nov-Dec;27(6):830–7

Health and the national information infrastructure. Detmer DE. **Proc AMIA Symp** 1998;:2–7

Psychosocial rehabilitation services in community support systems: a review of outcomes and policy recommendations. Barton R. **Psychiatr Serv** 1999 Apr; 50(4):525–34

State policy and funding of services to families of adults with serious and persistent mental illness [published erratum appears in Psychiatr Serv 1999 Jun;50(6):824] Dixon L, et al. **Psychiatr Serv** 1999 Apr;50(4):551–3

Advisory council calls for development of new vaccines for tuberculosis [news] **Public Health** 1998 Nov-Dec; 113(6):485

No scientific justification to suspend hepatitis B immunization [news] **Public Health** 1998 Nov-Dec;113(6):487

European politicians need epidemiologists. O'Brien SJ, et al. **Public Health** 1998 Sep;112(5):287–8 (17 ref.)

No scientific justification to suspend hepatitis B immunization [news] **Public Health Rep** 1998 Nov-Dec;113(6):487

AHCPR offers resources for consumers, providers, and health agencies. Agency for Health Care Policy and Research [news] **Public Health Rep** 1999 Mar-Apr; 114(2):107

Response on drug policy [letter; comment] McDonough JR. **Public Health Rep** 1999 Mar-Apr;114(2):99–100. Comment on: Public Health Rep 1999 Jan-Feb;114(1):14–29.

The Initiative to Eliminate Racial and Ethnic Health Disparities is moving forward. Satcher D. **Public Health Rep** 1999 May-Jun;114(3):283–7

AHCPR clinical practice guideline on surgical pain management: adoption and outcomes. Devine EC, et al. **Res Nurs Health** 1999 Apr;22(2):119–30

Integrating women's perspectives on prenatal human immunodeficiency virus screening: toward a socially just policy. Mawn B. **Res Nurs Health** 1998 Dec;21(6):499–509

Why Archibald Cochrane used to call for effectiveness and efficiency? [editorial] Atallah AN. **Rev Paul Med** 1998 Jan-Feb;116(1):1601

Denying effective antiretroviral drugs to HIV-positive pregnant women--the national government's flawed decision [editorial] Lurie M, et al. **S Afr Med J** 1999 Jun; 89(6):621–3

Paradigmatic obstacles to improving the health of populations--implications for health policy. McKinlay JB. **Salud Publica Mex** 1998 Jul-Aug;40(4):369–79

Equity in the delivery of health care in Sweden. Gerdtham UG, et al. **Scand J Soc Med** 1998 Dec;26(4):259–64

Perinatal infections--problems in developing countries. Ho NK. **Singapore Med J** 1998 Jun;39(6):266–70

Health care of the elderly in Singapore. Ling SL. **Singapore Med J** 1998 Oct;39(10):435–6

Education as policy: the impact of education on marriage, contraception, and fertility in Colombia, Peru, and Bolivia. Heaton TB, et al. **Soc Biol** 1998 Fall-Winter; 45(3–4):194–213

The social impact of HIV testing: a comparative analysis of Britain and Sweden. Danziger R. **Soc Sci Med** 1999 Feb; 48(3):293–300 (40 ref.)

Implications of social class and race for urban public health policy making: a case study of HIV/AIDS and TB policy in Washington, DC. Dievler A, et al. **Soc Sci Med** 1999 Apr;48(8):1095–102

Drug policy in China: pharmaceutical distribution in rural areas. Dong H, et al. **Soc Sci Med** 1999 Mar;48(6):777–86

National health policies: sub-Saharan African case studies (1980–1990). Dugbatey K. **Soc Sci Med** 1999 Jul; 49(2):223–39

Resource dependency, doctors and the state: quality control in Sweden. Garpenby P. **Soc Sci Med** 1999 Aug; 49(3):405–24

A survey of the Hong Kong health sector: past, present and future. Gauld RD. **Soc Sci Med** 1998 Oct;47(7):927–39

Family planning policies and programmes in eight low-income countries: a comparative policy analysis. Lee K, et al. **Soc Sci Med** 1998 Oct;47(7):949–59

Medicine, economics and agenda-setting. Lewis JM, et al. **Soc Sci Med** 1999 Feb;48(3):393–405

Using social health insurance to meet policy goals. Normand C. **Soc Sci Med** 1999 Apr;48(7):865–9 (13 ref.)

Assessing heterogeneity and correlation of paired failure times with the bivariate frailty model. Xue X, et al. **Stat Med** 1999 Apr 30;18(8):907–18

Introduction: the three phases of harm reduction. An examination of emerging concepts, methodologies, and critiques. Erickson PG. **Subst Use Misuse** 1999 Jan; 34(1):1–7

A framework for the evaluation of activities and programs with harm-reduction objectives. Ogborne AC, et al. **Subst Use Misuse** 1999 Jan;34(1):69–82

Reducing the harms of drug policy: an economic perspective. Rasmussen DW, et al. **Subst Use Misuse** 1999 Jan; 34(1):49–67

Harm reduction: concepts and practice. A policy discussion paper. Riley D, et al. **Subst Use Misuse** 1999 Jan;34(1):9–24

The rhetoric of international drug control. Room R. **Subst Use Misuse** 1999 Oct;34(12):1689–707

Youth suicide prevention: a survey and analysis of policies and efforts in the 50 states. Metha A, et al. **Suicide Life Threat Behav** 1998 Summer;28(2):150–64

A survey of vision screening policy of preschool children in the United States. Ciner EB, et al. **Surv Ophthalmol** 1999 Mar-Apr;43(5):445–57

Poverty and health: a simple matter of money? Mirvis DM, et al. **Tenn Med** 1999 Jul;92(7):258–60

Development of cardiac transplant policy in Germany (part 1) [editorial] Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):1–4

Non-heart-beating donors and emergency health care systems. Alvarez J, et al. **Transplant Proc** 1999 Sep; 31(6):2215–6

Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. de Jong JC, et al. **Vaccine** 1999 Mar 17;17(11–12):1321–8

Informing Maternal and Child Health (MCH) policy through research. Ashley D, et al. **West Indian Med J** 1998 Dec; 47 Suppl 4:16–9

Health in Europe 1997. Report on the third evaluation of progress towards health for all in the European Region of WHO (1996–1997). **WHO Reg Publ Eur Ser** 1998; 83:i–vii, 1–90

A prelude to health for all. Pinder L, et al. **World Health Forum** 1998;19(3):235–8

National public health policies for prevention and care in urinary incontinence in the elderly. Melchior H, et al.

World J Urol 1998;16 Suppl 1:S71-3

[Establishment of the National Board of Health and Welfare in 1909. A compromise between expert knowledge and political and administrative interests of that time] Christensen N, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7589-92 **(Dan)**

[Prevention and research on prevention seen from a perspective of health policy] Iversen L. **Ugeskr Laeger** 1998 Nov 16;160(47):6795-9 (11 ref.) **(Dan)**

[Risk of prevention seen from a general medical perspective (editorial)] Lauritzen T, et al. **Ugeskr Laeger** 1998 Nov 16;160(47):6793 **(Dan)**

[Subspecialty blood transfusion medicine] Brand A, et al. **Ned Tijdschr Geneeskd** 1998 Jul 25;142(30):1733-4 (Eng. Abstr.) **(Dut)**

[Public health in a new coalition agreement (see comments)] Gunning-Schepers LJ. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1429-31 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Sep 12;142(37):2062-3. **(Dut)**

[National cancer fund (Koningin Wilhelmina Fonds) justifiably calls for continued focus on the cancer problem in Netherlands (see comments)] Pinedo HM, et al. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1499-502 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jul 17;143(29):1502-6. **(Dut)**

[Market effect on social security and occupational health services (comment) [see comments] Plomp HN, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1374-8 (10 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1369-73. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1379-82. **(Dut)**

[One year of Dutch Organ Donation Law) Schnabel P. **Ned Tijdschr Geneeskd** 1999 Mar 20;143(12):600-1 (Eng. Abstr.) **(Dut)**

[The SGO Health Research Promotion Program. XIII. Evaluation of the section 'Addiction Research'] van Rees-Wortelboer MM. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):38-41 (Eng. Abstr.) **(Dut)**

[The SGO Health Research Promotion Program. XIV. Final evaluation] van Rees-Wortelboer MM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):41-5 (Eng. Abstr.) **(Dut)**

[The non-vaccination policy in economic perspective] Dijkhuizen AA. **Tijdschr Diergeneeskd** 1999 Feb 1; 124(3):84-6 **(Dut)**

[The non-vaccination policy (letter)] van Logtestijn JG, et al. **Tijdschr Diergeneeskd** 1999 Mar 1;124(5):160-1 **(Dut)**

[Swiss life: not for all oldsters. Definition of poverty and the situation among the elderly (editorial)] Braam GP. **Tijdschr Gerontol Geriatr** 1999 Jun;30(3):102-4 **(Dut)**

[Drugs for Alzheimer disease: what will the minister decide] Verhey FR, et al. **Tijdschr Gerontol Geriatr** 1998 Dec; 29(6):278-9 **(Dut)**

[Pediatrics and family politics (letter)] Debauchez C. **Arch Pediatr** 1999 May;6(5):592 **(Fre)**

[Equity in health, between ethics and economy] Berlinguer G. **Rev Med Suisse Romande** 1998 Dec;118(12):989-93 **(Fre)**

[When the capital defends its power] Nyffeler R. **Rev Med Suisse Romande** 1999 May;119(5):437-8 **(Fre)**

[Physicians' role in prevention and health promotion policy: canton reports on health status] Raynault MF, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):653-6 (Eng. Abstr.) **(Fre)**

[Citizen forums: a contribution to the "health democracy"? (editorial)] Laurent-Beq A. **Sante Publique** 1999 Mar; 11(1):3-4 **(Fre)**

[Awareness of problems in the affluent society] Stamer G. **DTW Dtsch Tierarztl Wochenschr** 1999 Aug;106(8):366-70 (Eng. Abstr.) **(Ger)**

[Neonatal hearing screening--consequences for public health policy] Henke KD, et al. **Gesundheitswesen** 1999 Feb; 61(2):86-92 (51 ref.) (Eng. Abstr.) **(Ger)**

[Speech given by Andrea Fischer, Minister of Health on the 102. German Physicians' Day in Cottbus 1999] Fischer A. **Internist (Berl)** 1999 Aug;40(8):232-3 **(Ger)**

[Change of course in health policy; from responsible citizen to dependent patient?] Vilmar K. **Internist (Berl)** 1999 Aug; 40(8):225-32 **(Ger)**

[Are the politics in the eye?] Mehrle G. **Klin Monatsbl Augenheilkd** 1998 Nov;213(5):aA1 **(Ger)**

[BAR position paper on the future development of medical, vocational and social rehabilitation in the 14th Legislative Session. Federal Rehabilitation Council] **Rehabilitation (Stuttg)** 1999 Feb;38(1):38-43 **(Ger)**

[Is vaccination a private matter?] Ruef C. **Schweiz Med Wochenschr** 1999 Apr 3;129(13):495-8 (14 ref.) **(Ger)**

[Public health policy significance of life style medicine (editorial)] Halhuber M. **Versicherungsmedizin** 1998 Aug 1;50(4):122-3 **(Ger)**

[EURO-Medicines: a European program for bringing into agreement public health policies on drugs] Calamo-Specchia F, et al. **Ann Ig** 1998 Sep-Dec; 10(5-6):405-12 (Eng. Abstr.) **(Ita)**

[Tropical medicine and the pathology of poverty. New paradigms in international health policy] Stefanini A. **Ann Ig** 1998 Sep-Dec;10(5-6):387-93 (28 ref.) (Eng. Abstr.) **(Ita)**

[Relationship between research and health policy: a Canadian perspective. A research program of the National Health Service] Berrino F. **Epidemiol Prev** 1998 Apr-Jun; 22(2):67-9 **(Ita)**

[Role of regional institute of health on regional public health policy and activity] Tsuchida K, et al. **Nippon Koshu Eisei Zasshi** 1998 Oct;45(10):955-9 (14 ref.) **(Jpn)**

[Rehabilitation, regional political exercise (letter; comment)] Arnesen AR. **Tidsskr Nor Laegeforen** 1998 Oct 10; 118(24):3833. Comment on: Tidsskr Nor Laegeforen 1998 Aug 20;118(19):2937. **(Nor)**

[British health care--retrogression of the marketing principles] Bradley P, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3987-9 **(Nor)**

[Prioritization in theory and practice] Bruusgaard D. **Tidsskr Nor Laegeforen** 1999 Jun 10;119(15):2155 **(Nor)**

[Rehabilitation as a practice in district policy (letter; comment)] Dyrnes OJ. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4562. Comment on: Tidsskr Nor Laegeforen 1998 aug 20;118(19):2937. **(Nor)**

[Values and virtues in medicine] Fugelli P, et al. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1076 **(Nor)**

[Insufficient knowledge about Karl Evang (letter)] Harvei S. **Tidsskr Nor Laegeforen** 1999 Apr 30;119(11):1650 **(Nor)**

["The great idea" of Tony Blair] Helsingen N. **Tidsskr Nor Laegeforen** 1998 Nov 10;118(27):4253 **(Nor)**

[The committee on emergency medicine is wrong! Conclusions in connection with the remittance of the recommendation NOU 1998:9] Johansen D, et al. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3985-6 (Eng. Abstr.) **(Nor)**

[Freedom in a little box] Lie AK. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1471-3 (Eng. Abstr.) **(Nor)**

[Right delivery in the right place?] Lund E, et al. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1869 **(Nor)**

[Moderation--a virtue of necessity] Nylenna M. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1154-7 (33 ref.) (Eng. Abstr.) **(Nor)**

[Physician as assessor and gatekeeper] Solvang P. **Tidsskr Nor Laegeforen** 1999 Jun 10;119(15):2156 **(Nor)**

[Reforms of the British health care--paradigmatic shift, political rhetorics or challenge for health professionals?] Søreide O. **Tidsskr Nor Laegeforen** 1999 Jun 20; 119(16):2375-9 **(Nor)**

[Equality and brotherhood--values worth preserving in the health services] Westin S. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1474-9 (Eng. Abstr.) **(Nor)**

[Policy and collective health: a reflection on scientific production (1976-1992)] Burlandy L, et al. **Cad Saude Publica** 1998 Jul-Sep;14(3):543-54 (Eng. Abstr.) **(Por)**

[The national health system and health policies in the Brazilian dentistry literature, 1986-1993] Narvai PC, et al. **Cad Saude Publica** 1998 Jul-Sep;14(3):513-21 (Eng. Abstr.) **(Por)**

[The testing policy for HIV infection in Ukraine] Kobyshcha Iu. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):65-7 (Eng. Abstr.) **(Rus)**

[The main trends in the improvement of the activity of plague control institutions in the prevention of quarantine infections] Onishchenko GG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec; (6):37-41 **(Rus)**

[Health aspects of population policies] Sedlecki K, et al. **Med Pregl** 1998 Nov-Dec;51(11-12):541-5 (Eng. Abstr.) **(Scr)**

[The antibiotics policy in primary care (letter; comment)] Cruz Martos E, et al. **Aten Primaria** 1998 Nov 30;22(9):608 . Comment on: Aten Primaria 1998 Mar 31;21(5):315-20. **(Spa)**

[Advantages and disadvantages of an antibiotic policy (editorial)] López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):353-5 **(Spa)**

[On the heroin epidemic, its impact, its context, and health policy (editorial; comment)] Villalbí JR, et al. **Med Clin (Barc)** 1999 May 29;112(19):736-7. Comment on: Med Clin (Barc) 1999 May 29;112(19):721-5. **(Spa)**

[Sociopolitical issues in medical research] Gonzalo LM. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):119-20 **(Spa)**

[A medical commentary on the approval of RU-486] Pardo A. **Rev Med Univ Navarra** 1998 Oct-Dec;42(4):226-7 **(Spa)**

[Variations in transfusion practice in Spain] Fernández-Montoya A. **Sangre (Barc)** 1999 Feb;44(1):30-7 (Eng. Abstr.) **(Spa)**

[The smoking personnel is only a part of the necessary measures (letter)] Boëthius G. **Lakartidningen** 1999 Jul 28; 96(30-31):3319 **(Swe)**

[New methods for the measurement of the burden of disease in Sweden] Diderichsen F, et al. **Lakartidningen** 1999 May 5;96(18):2172-4 **(Swe)**

[Let the general practitioners go! Offer them other agreements as an alternative to the monopoly of county councils! (letter)] Olsson B, et al. **Lakartidningen** 1999 Mar 3;96(9):996 **(Swe)**

[A slow progress in health policy targets. Health care consumption in Dalby and Tierp over 20 years] Slaug B, et al. **Lakartidningen** 1998 Sep 23;95(39):4254-8 **(Swe)**

ECONOMICS

An expensive policy: the impact of inadequate funding for substance abuse treatment [editorial] Amaro H. **Am J Public Health** 1999 May;89(5):657-9 (32 ref.)

The World Bank and world health: focus on South Asia-I: Bangladesh. Abbasi K. **BMJ** 1999 Apr 17;318(7190):1066-9

Effects of maternity-stay legislation on 'drive-through deliveries'. Udom NU, et al. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):208-15

The political economy of Medicare. Vladeck BC. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):22-36

US and UK health economics: two disciplines separated by a common language? [see comments] Newhouse JP. **Health Econ** 1998 Aug;7 Suppl 1:S79-92. Comment in: Health Econ 1999 Mar;8(2):177; discussion 179-80.

New drugs for dementia: a commissioning nightmare? Johnson R. **Int J Geriatr Psychiatry** 1999 Apr;14(4):257-8

Seasonal affective disorder. Elwood TW. **J Allied Health** 1999 Summer;28(2):113-6

Economics and urban health. Davis K, et al. **J Urban Health** 1998 Jun;75(2):281-93

An African solution? [letter; comment] [see comments] Hopkinson N. **Lancet** 1999 May 1;353(9163):1530. Comment on: Lancet 1999 Feb 20;353(9153):603. Comment in: Lancet 1999 Jul 10;354(9173):165.

Managed care arrives in Latin America [editorial; comment] Pérez-Stable EJ. **N Engl J Med** 1999 Apr 8;340(14):1110-2 . Comment on: N Engl J Med 1999 Apr 8;340(14):1131-6.

Toward more healthful dietary patterns--a matter of policy [comment] Nestle M. **Public Health Rep** 1998 Sep-Oct; 113(5):420-3. Comment on: Public Health Rep 1998 Sep-Oct;113(5):410-9.

[Therapeutic options for HIV-infection should lead to increased utilization of HIV tests (letter; comment)] Boer K. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1395-6. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):598-9. **(Dut)**

HISTORY

Tuskegee: from science to conspiracy to metaphor [editorial; comment] [see comments] Thomas SB, et al. **Am J Med Sci** 1999 Jan;317(1):1-4. Comment on: Am J Med Sci 1999 Jan;317(1):5-8. Comment in: Am J Med Sci 1999 May;317(5):353.

The impact of health economics on health policy in England, and the impact of health policy on health economics, 1972-1997. Hurst J. **Health Econ** 1998 Aug;7 Suppl 1:S47-61

Dr. David E. Rogers and his legacy: the Robert Wood Johnson Health Policy Fellowship. Greenberg RM, et al. **J Urban Health** 1999 Mar;76(1):10-7

A quarter century of health maintenance [news] Mitka M. **JAMA** 1998 Dec 23-30;280(24):2059-60

LEGISLATION & JURISPRUDENCE

Protecting the rights and welfare of human research subjects. Ellis GB. **Acad Med** 1999 Sep;74(9):1008-9

Combination antiretroviral therapy for HIV infection: policies and practices [letter] Lansky A, et al. **AIDS** 1998 Aug 20;12(12):1552-3

Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98-101 (10 ref.)

Human immunodeficiency virus screening among pregnant women in France: results from the 1995 National Perinatal Survey. Vayssière C, et al. **Am J Obstet Gynecol** 1999 Mar; 180(3 Pt 1):564-70

Kentucky legislators' views on tobacco policy. Hahn EJ, et al. **Am J Prev Med** 1999 Feb;16(2):81-8

The "sausage factory" tour of the legislative process: an interactive orientation. Novotny TE, et al. **Am J Public Health** 1999 May;89(5):771-3

Maternal minimum-stay legislation: cost and policy implications. Raube K, et al. **Am J Public Health** 1999 Jun; 89(6):922-3

Towards a change in status of emergency contraception? [editorial] Cayley J. **Br J Fam Plann** 1998 Oct;24(3):93

Legal and regulatory issues. Dickens BM. **Bull World Health Organ** 1999;77(1):70-2

The view of the Health Council of The Netherlands. van Rongen E. **Bull World Health Organ** 1999;77(1):79-81

Maintaining a smoke-free policy: an observational and interview study at a university hospital in Sweden. Tillgren P, et al. **Eur J Cancer Prev** 1998 Oct;7(5):403-8

Redrawing the ethics map. Lamm RD. **Hastings Cent Rep** 1999 Mar-Apr;29(2):28-9

Turning pages, if not heads. Silberner J. **Hastings Cent Rep** 1999 Mar-Apr;29(2):6

Nonprofit conversion: theory, evidence, and state policy options. Marsteller JA, et al. **Health Serv Res** 1998 Dec; 33(5 Pt 2):1495-535 (90 ref.)

Budget battlers ... profiles. Hudson T, et al. **Hosp Health Netw** 1999 Jun;73(6):38-40, 42, 46

Wish lists: 1999 lobbying outlook. Meyer H. **Hosp Health Netw** 1999 Jan;73(1):64-6, 68, 70-2

The United States and the universality of human rights. Chomsky N. **Int J Health Serv** 1999;29(3):623-6

The U.S. health data privacy debate. Will there be comprehension before closure? Freeman P, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):316-31 (22 ref.)

Physician-assisted suicide and euthanasia in The Netherlands: a report to the House Judiciary Subcommittee on the

Constitution. **Issues Law Med** 1998 Winter;14(3):301–24
The perennial federal budget struggle. Elwood TW.
J Allied Health 1998 Fall;27(3):179–81
US Food and Drug Administration office of women's health: update. Sheppard A. **J Am Med Womens Assoc** 1999 Spring;54(2):97–8
The new NIH and FDA medical research policies: targeting gender, promoting justice. Baird KL.
J Health Polit Policy Law 1999 Jun;24(3):531–65 (35 ref.)
Rural hospital mergers, antitrust policy, and the Ukiah case. Blackstone EA, et al. **J Health Polit Policy Law** 1998 Dec; 23(6):949–71
The American Medical Political Action Committee: which senators get the money and why? Gutermuth K.
J Health Polit Policy Law 1999 Apr;24(2):357–82
The implementation and enforcement of tobacco control laws: policy implications for activists and the industry. Jacobson PD, et al. **J Health Polit Policy Law** 1999 Jun; 24(3):567–98
Money, politics, and medicine: the American Medical PAC's strategy of giving in U.S. house races. Wilkerson JD, et al. **J Health Polit Policy Law** 1999 Apr;24(2):335–55
Assessment of physician-assisted death by members of the public prosecution in The Netherlands [see comments] Cuperus-Bosma JM, et al. **J Med Ethics** 1999 Feb; 25(1):8–15. Comment in: J Med Ethics 1999 Feb;25(1):3–4.
Information dissemination and marketing in California. Harlow J, et al. **J Nurs Adm** 1999 Apr;29(4):6–8
"Distributive ethics" [editorial] McIntyre RV.
J Okla State Med Assoc 1998 Oct;91(7):383
Federally supported programs for children and their families. Velsor-Friedrich B. **J Pediatr Nurs** 1999 Feb;14(1):67–9
State and federal health priorities. Wakefield M.
J Prof Nurs 1999 Mar-Apr;15(2):72
Changing the present legal prohibitions on assisted suicide is a bad idea. Zimbelman J. **J Prof Nurs** 1999 May-Jun; 15(3):160–9 (46 ref.)
Zuma defends decision to make AIDS a notifiable disease [news] Baleta A. **Lancet** 1999 May 8;353(9164):1599
Implications of genetic testing for insurance in the UK. Morrison PJ. **Lancet** 1998 Nov 21;352(9141):1647–8
Management by objection? Public policies to protect choice in health plans. Brown LD. **Med Care Res Rev** 1999;56 Suppl 1:145–65; discussion 166–76
"Health law, ethics and policy: challenges and new avenues for the 21st century and new millennium". Bates PW.
Med Law 1999;18(1):13–46
Aging and developmental disabilities: demographic and policy issues affecting American families. Braddock D.
Ment Retard 1999 Apr;37(2):155–61
Support for academic medical centers--revisiting the 1997 Balanced Budget Act. Iglehart JK. **N Engl J Med** 1999 Jul 22;341(4):299–304
Genetics and insurance in Britain: why more than just the Atlantic divides the English-speaking nations. Wilkie T. **Nat Genet** 1998 Oct;20(2):119–21
Psychiatric emergency services: policy considerations. McCarthy NA. **New Dir Ment Health Serv** 1999 Summer; (82):85–92
Air pollution statistics in policy applications. Smith RI.
Novartis Found Symp 1999;220:227–39; discussion 239–42 (21 ref.)
Access to biomaterials: a growing health policy concern. Morgan A. **Pacing Clin Electrophysiol** 1998 Sep; 21(9):1822–3
From scientific evidence to child health policy. Cates KL.
Pediatr Ann 1998 Sep;27(9):554–9 (23 ref.)
Medicaid policy statement. American Academy of Pediatrics. Committee on Child Health Financing. **Pediatrics** 1999 Aug;104(2 Pt 1):344–7
An instrument for assessing the quality of tobacco-control policies: the ACT-L scale. Klonoff EA, et al.
Prev Med 1998 Nov-Dec;27(6):808–14
Perceptions of the effect of an impending restaurant smoking ban on dining-out experience. Wakefield M, et al.
Prev Med 1999 Jul;29(1):53–6
The role of the public sector in the development and implementation of animal health policies. Ekboir JM.
Prev Vet Med 1999 May 31;40(2):101–15 (25 ref.)
Limit children's work hours, report says [news; comment] **Public Health Rep** 1999 Mar-Apr;114(2):105. Comment on: Public Health Rep 1999 Mar-Apr;114(2):126–9.
Drug prohibition and public health: 25 years of evidence [see comments] Drucker E. **Public Health Rep** 1999 Jan-Feb;114(1):14–29 (55 ref.). Comment in: Public Health Rep 1999 Mar-Apr;114(2):99–100.
Genetic information and genetic discrimination how medical records vitiate legal protection. A comparative analysis of international legislation and policies. Rosén E.
Scand J Public Health 1999 Sep;27(3):166–72
Invoking, monitoring, and relinquishing a public health power: the health hold order. Potterat JJ, et al.
Sex Transm Dis 1999 Jul;26(6):345–9
Differentiating drugs by harm potential: the rational versus the feasible. Kalant H. **Subst Use Misuse** 1999 Jan; 34(1):25–34
Consensus for tobacco policy among former state legislators using the policy Delphi method. Hahn EJ, et al.
Tob Control 1999 Summer;8(2):137–40
[Therapeutic options for HIV-infections should lead to increased utilization of HIV tests (letter; comment)] Kleiverda G, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26; 143(26):1396–7. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):598–9. **(Dut)**
[Consequences for health policy on zoonosis control--national and international actions] Kothmann G.
DTW Dtsch Tierarztl Wochenschr 1999 Aug;106(8):363–6 (Eng. Abstr.) **(Ger)**

TRENDS

Medical schools and state legislatures as partners in a changing policy world. Weissert CS. **Acad Med** 1999 Feb; 74(2):95–6
Lessons from 12 years of comparative risk projects. Jones K, et al. **Annu Rev Public Health** 1999;20:159–72 (34 ref.)
Clinical progress and the future of HIV exceptionalism. Bayer R. **Arch Intern Med** 1999 May 24;159(10):1042–8 (45 ref.)
Changing policies in the Veterans Health Administration. Will they make a difference? [editorial] Jones DB.
Arch Ophthalmol 1999 Jan;117(1):106–7 (3 ref.)
Social capital and its relevance to health and family policy. Leeder S, et al. **Aust N Z J Public Health** 1999 Aug; 23(4):424–9 (12 ref.)
Impact of vaccines universally recommended for children--United States, 1990–1999.
Can Commun Dis Rep 1999 Jul 15;25(14):122–7 **(Eng, Fre)**
Medicare managed care: policy concerns. Williams K.
Clin Ther 1998 Nov-Dec;20(6):1292–300
The dream that never was: the rise and fall of socialized medicine in the United States of America [see comments] Katz SR. **Conn Med** 1998 Oct;62(10):619–20. Comment in: Conn Med 1998 Dec;62(12):741–2. Comment in: Conn Med 1999 Mar;63(3):179.
Signs of the times? Massey RU. **Conn Med** 1998 Oct; 62(10):627–8
In response to "The dream that never was: the rise and fall of socialized medicine in the United States of America" [letter; comment] [see comments] Slater GS. **Conn Med** 1998 Dec;62(12):741–2. Comment on: Conn Med 1998 Oct;62(10):619–20. Comment in: Conn Med 1999 Mar;63(3):179.
Emerging trends in mental health policy and practice. Mechanic D. **Health Aff (Millwood)** 1998 Nov-Dec; 17(6):82–98
Me and the system: the personal essay and health policy. Mullan F. **Health Aff (Millwood)** 1999 Jul-Aug; 18(4):118–24
Advances in understanding and treating mental illness: implications for policy. Norquist G, et al.
Health Aff (Millwood) 1999 Sep-Oct;18(5):32–47
What will the future hold for health care? Graham R.
Hosp Pract (Off Ed) 1999 Jun 15;34(6):37–40, 45
Changes in the nurse workforce [editorial; comment] Buerhaus PI. **Image J Nurs Sch** 1999;31(2):160. Comment on: Image J Nurs Sch 1999 ;31(2):161–6. Comment on: Image J Nurs Sch 1999 ;31(2):167–73. Comment on: Image J Nurs Sch 1999 ;31(2):175–7. Comment on: Image J Nurs Sch 1999 ;31(2):179–83.
Proliferation of non-physician providers as reported in the Journal of the American Medical Association (JAMA), 1998 [see comments] Catlin AJ, et al.
Image J Nurs Sch 1999;31(2):175–7. Comment in: Image J Nurs Sch 1999 ;31(2):160.
K. N. Rao Memorial Oration. Liberalization of the national economy-agenda for health care policy and administration. Anjanegulu G. **Indian J Public Health** 1998 Jul-Sep; 42(3):71–4
Trends in health insurance coverage, 1989–1997. Carrasquillo O, et al. **Int J Health Serv** 1999;29(3):467–83
The unemployment iceberg: what is beneath, behind, and ahead? Therborn G. **Int J Health Serv** 1999;29(3):545–63
Occupational health and safety policy in the UK: who is driving the agenda with the "greylisting" of health and safety activists? [editorial] Watterson A.
Int J Occup Environ Health 1998 Oct-Dec;4(4):275–7 (7 ref.)
Nursing ethics: the challenge of new directions in healthcare policy. Woods M. **Int Nurs Rev** 1998 Jul-Aug;45(4):107
Setting health standards for the 21st century. Halperin JA.
J Am Pharm Assoc (Wash) 1998 Nov-Dec;38(6):762–6
The new globalisation, food and health: is public health receiving its due emphasis? [editorial] Lang T.
J Epidemiol Community Health 1998 Sep;52(9):538–9
Reaping the fruits of research: promoting health equity for all. Pinn VW. **J Health Care Poor Underserved** 1998 Aug; 9(3):213–6
"Changing childbirth" in the United Kingdom: lessons for U.S. health policy. Declercq E.
J Health Polit Policy Law 1998 Oct;23(5):833–59 (90 ref.)
Social movements as catalysts for policy change: the case of smoking and guns. Nathanson CA.
J Health Polit Policy Law 1999 Jun;24(3):421–88 (146 ref.)
Motivation, mobilization, and monitoring: the role of groups in health policy [editorial] Peterson MA.
J Health Polit Policy Law 1999 Jun;24(3):415–20 (17 ref.)
Medical screening: the next five years. Haddow P.
J Med Screen 1999;6(2):58–9
Health policy, health services, and cancer pain management in the New South Africa. Beck SL.
J Pain Symptom Manage 1999 Jan;17(1):16–26
Head start: program and legislative update. Daley M.
J Pediatr Nurs 1999 Jun;14(3):186–8
Every child deserves Bright Futures. Ferguson SL.
J Pediatr Nurs 1999 Apr;14(2):123–4
The future of medical technology assessment [editorial] van den Heuvel WJ. **J Qual Clin Pract** 1998 Sep;18(3):161–2
The National Health Service: past and future. Langlands A.
J R Soc Med 1998;91 Suppl 36:8–10
Do targeted efforts for the rural underserved help kill comprehensive reform? Taylor DH Jr. **J Rural Health** 1999 Winter;15(1):55–60 (27 ref.)
Urban health policy. Brown LD. **J Urban Health** 1998 Jun; 75(2):273–80
Health policy agenda for the early 21st century. Ginzberg E. **J Urban Health** 1999 Mar;76(1):18–23
Over view of urban collaborative initiatives. Lasker RD.
J Urban Health 1998 Jun;75(2):391–400
Current efforts toward implementation of an urban health strategy: the Henry Ford Health System. Whitelaw N, et al. **J Urban Health** 1998 Jun;75(2):356–66
Nicaraguan health care [letter; comment] Adler F. **Lancet** 1999 Jan 30;353(9150):413. Comment on: Lancet 1998 Nov 14;352(9140):1622–4.
Mental care versus public safety in the UK [news] Dean M.
Lancet 1998 Dec 19–26;352(9145):1995
Improving the quality of health care. Quality at a crossroads. Coye MJ, et al. **Milbank Q** 1998;76(4):759–68
The obligation of mental health services to the least well off. Goldman HH. **Psychiatr Serv** 1999 May;50(5):659–63
Building the next generation of healthy people. Richmond JB. **Public Health Rep** 1999 May-Jun;114(3):212–7
IOM on core functions [letter] Shine KI, et al.
Public Health Rep 1999 Jan-Feb;114(1):6
A tale of two (low prevalence) cities: social movement organisations and the local policy response to HIV/AIDS. Petchey R, et al. **Soc Sci Med** 1998 Nov;47(9):1197–208
[Heterozygote detection for hemoglobinopathies: situation in the Netherlands as compared to the British (letter; comment)] Wierenga KJ, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):326–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):996–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):1019–22. **(Dut)**
[Health targets and health reporting--significance of a basis for health reporting to achieve health targets] Welteke R, et al. **Gesundheitswesen** 1999 Jul;61(7):340–5 (Eng. Abstr.) **(Ger)**
[Social change necessitates a reform of the medical profession. A contribution to the public health policy discussion regarding the future of health care in Germany] Kleeberg UR. **Med Klin** 1999 Jun 15;94(6):355–8 **(Ger)**
[Trend of health policy and hospital laboratory service--view from hospital management] Takahashi T.
Rinsho Byori 1999 Apr;47(4):313–7 (Eng. Abstr.) **(Jpn)**

HEALTH PRIORITIES

Setting priorities versus managing closures--what is the ethically most sound way of handling changes in the health care system? Hermerén G. **Acta Oncol** 1999;38(1):33–40
Identifying research priorities in reproductive health in Nigeria: report of a workshop. **Afr J Reprod Health** 1997 Mar;1(1):100
Reproductive health in southern Africa: report of a WHO workshop. Hall P. **Afr J Reprod Health** 1997 Mar;1(1):97–9
Reproductive health issues in Africa [editorial] Rosenfield A. **Afr J Reprod Health** 1997 Mar;1(1):5–6
Potential application of the dental aesthetic index to prioritize the orthodontic service needs in a publicly funded dental program. Danyluk K, et al.
Am J Orthod Dentofacial Orthop 1999 Sep;116(3):279–86
Emergency medical services outcomes project I (EMSOP I): prioritizing conditions for outcomes research. Maio RF, et al. **Ann Emerg Med** 1999 Apr;33(4):423–32
Priorities for research in emergency medical services for children: results of a consensus conference [see comments] Seidel JS, et al. **Ann Emerg Med** 1999 Feb;33(2):206–10 (9 ref.). Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.
Cancer prevention among urban southwestern American Indian women: comparison to selected Year 2000 national health objectives. Risendal B, et al. **Ann Epidemiol** 1999 Aug;9(6):383–90
Health to get a higher priority in post-devolution Scotland [news] [see comments] **BMJ** 1999 Jan 9;318(7176):80. Comment in: BMJ 1999 May 1;318(7192):1215.
The second phase of priority setting. Israel's basic basket of health services: the importance of being explicitly implicit. Chinitz D, et al. **BMJ** 1998 Oct 10; 317(7164):1005–7
Real-time priority scoring system must be used for prioritisation on waiting lists [letter; comment] Davis B, et al. **BMJ** 1999 Jun 19;318(7199):1699. Comment on: BMJ 1997 Jan 11;314(7074):131–4. Comment on: BMJ 1998 Mar 21;316(7135):925–9. Comment on: BMJ 1998 Apr 4;316(7137):1092–3.
"Healthy people 2010": national health objectives for the United States. Davis RM. **BMJ** 1998 Nov 28; 317(7171):1513–7
Effect of discussion and deliberation on the public's views of priority setting in health care: focus group study. Dolan P, et al. **BMJ** 1999 Apr 3;318(7188):916–9
Effect of discussion and deliberation on public's views of priority setting. More data are needed for readers to make judgment about study [letter] Hanratty B, et al. **BMJ** 1999

Jul 17;319(7203):189

The second phase of priority setting. Goodbye to the simple solutions: the second phase of priority setting in health care [see comments] Holm S. **BMJ** 1998 Oct 10; 317(7164):1000–2. Comment in: BMJ 1999 Apr 3;318(7188):941.

Puzzling out priorities. Why we must acknowledge that rationing is a political process [editorial] [see comments] Klein R. **BMJ** 1998 Oct 10;317(7164):959–60. Comment in: BMJ 1999 Apr 3;318(7188):940.

Strategy to reformulate waiting lists. Italy's public health system is changing from waiting times to priority [letter; comment] Mariotti G, et al. **BMJ** 1999 Jun 19; 318(7199):1698–9. Comment on: BMJ 1999 Jan 9;318(7176):78.

Research priorities in environmental health [editorial] Pershagen G. **BMJ** 1999 Jun 19;318(7199):1636–7

Health needs assessment is not required for priority setting [letter; comment] Petrou S. **BMJ** 1998 Oct 24; 317(7166):1154. Comment on: BMJ 1998 Apr 25;316(7140):1310–3. Comment on: BMJ 1998 Apr 25;316(7140):1379–82. Comment on: BMJ 1998 May 9;316(7142):1448–52.

The second phase of priority setting. Fairness as a problem of love and the heart: a clinician's perspective on priority setting [see comments] Sabin JE. **BMJ** 1998 Oct 10; 317(7164):1002–4. Comment in: BMJ 1999 Apr 3;318(7188):941.

Liberals propose new health forum [news] Warden J. **BMJ** 1998 Sep 12;317(7160):699

Putting evidence into practice [editorial] Smith C, et al. **Br J Fam Plann** 1999 Jan;24(4):115

Malaria vs. AIDS: time to re-evaluate priorities [letter] Hodgson K. **Can J Public Health** 1998 Sep–Oct;89(5):314

Malaria vs. AIDS: time to re-evaluate priorities [letter] Rudolph R. **Can J Public Health** 1998 Sep–Oct;89(5):314

Priorities for medium-term development in the health sector of Bosnia and Herzegovina. Adeyi O. **Croat Med J** 1998 Sep;39(3):285–7

Priorities and priority-setting in health care in the Netherlands. Hermans H, et al. **Croat Med J** 1998 Sep; 39(3):346–55

Health care system of the United States and its priorities: history and implications for other countries. Jahiel RI. **Croat Med J** 1998 Sep;39(3):316–31

Old priorities and new agenda of public health in India: is there a mismatch? Nayar KR. **Croat Med J** 1998 Sep; 39(3):308–15

Priorities of the Russian health care reform. Shishkin S. **Croat Med J** 1998 Sep;39(3):298–307

Medicine and its alternatives. Health care priorities in the Caribbean. Aarons DE. **Hastings Cent Rep** 1999 Jul–Aug; 29(4):23–7

Too little discussion of tobacco-related diseases and deaths [letter] Sarna L. **Image J Nurs Sch** 1998;30(4):310

Adolescent girls: an emerging priority [editorial] Bansal RD, et al. **Indian J Public Health** 1998 Jan–Mar;42(1):1–2

Infectious diseases control in India: confused priorities. Mathew A. **Indian Pediatr** 1998 Dec;35(12):1195–6

Prioritisation in speech and language therapy departments in Scotland and Malaysia. Santiago C, et al. **Int J Lang Commun Disord** 1998;33 Suppl:102–7

The preliminary economic evaluation of health technologies for the prioritization of health technology assessments. A discussion. Harper G, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):652–62

VA aligns health professions education with healthcare priorities. Stevens DP, et al. **J Allied Health** 1998 Fall; 27(3):123–7

College health needs to participate in the national STD debate. Rothenberger JH, et al. **J Am Coll Health** 1998 Nov;47(3):140–2

The post-graduate year: lineages, opportunities, dilemmas, and public priorities. Barker BD, et al. **J Dent Educ** 1999 Aug;63(8):611–4

Priorities for agenda building: mental health and primary care [editorial; comment] Lebowitz BD. **J Fam Pract** 1998 Nov; 47(5):341. Comment on: J Fam Pract 1998 Nov;47(5):379–84.

Rehabilitation: a luxury? Phipps EJ, et al. **J Head Trauma Rehabil** 1999 Jun;14(3):329–31

Allocative efficiency in the use of health resources in Portugal. do Rosário Giraldes M. **J Public Health Med** 1999 Mar;21(1):55–9

The Scottish Green Paper: beyond a healthy mind in a healthy body. Tannahill A. **J Public Health Med** 1998 Sep; 20(3):249–52

International environmental health: priorities from Huairou. Rossignol AM, et al. **J Public Health Policy** 1998; 19(3):319–30

Setting health priorities [letter; comment] Kerwin R. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):192–3. Comment on: J R Coll Physicians Lond 1998 Nov–Dec;32(6):510.

The submission from The Royal Society for the Promotion of Health on Government consultation document "Our Healthier Nation". **J R Soc Health** 1998 Aug;118(4):241–2

An HIV vaccine: how long must we wait? [editorial] [see comments] **Lancet** 1998 Oct 24;352(9137):1323. Comment in: Lancet 1999 Jan 16;353(9148):241.

In pursuit of quality: the National Institute for Clinical Excellence [see comments] Rawlins M. **Lancet** 1999 Mar 27;353(9158):1079–82. Comment in: Lancet 1999 Mar 27;353(9158):1028–9. Comment in: Lancet 1999 May 29;353(9167):1887.

Priorities for patient-centered research. Feussner JR. **Med Care** 1999 Sep;37(9):843–5 (11 ref.)

Men's health [editorial] Connell RW, et al. **Med J Aust** 1998 Sep 21;169(6):295–6 (12 ref.)

Priorities for research in emergency medical services for children: results of a consensus conference. Seidel JS, et al. **Pediatr Emerg Care** 1999 Feb;15(1):55–8 (9 ref.)

Obligation to the least well off in setting mental health service priorities: a consensus statement [see comments] Rosenheck R, et al. **Psychiatr Serv** 1998 Oct;49(10):1273–4, 1290. Comment in: Psychiatr Serv 1999 Feb;50(2):268.

Response of the Royal Institute of Public Health and Hygiene and the Society of Public Health to the Green Paper: our healthier nation. Beaver MW. **Public Health** 1998 Sep; 112(5):283–5

WHO launches Vision 2020 to combat avoidable blindness [news] **Public Health Rep** 1999 May–Jun;114(3):210

Advisory council calls for development of new vaccines for tuberculosis [news] **Public Health Rep** 1998 Nov–Dec; 113(6):485

Using YPLL in health planning. McDonnell S, et al. **Public Health Rep** 1998 Jan–Feb;113(1):55–61

The Initiative to Eliminate Racial and Ethnic Health Disparities is moving forward. Satcher D. **Public Health Rep** 1999 May–Jun;114(3):283–7

Medicine, economics and agenda-setting. Lewis JM, et al. **Soc Sci Med** 1999 Feb;48(3):393–405

Survival vs. quality of life: a study of the Israeli public priorities in medical care. Shmueli A. **Soc Sci Med** 1999 Aug;49(3):297–302

A systematic review of the literature on patient priorities for general practice care. Part 1: Description of the research domain. Wensing M, et al. **Soc Sci Med** 1998 Nov; 47(10):1573–88 (67 ref.)

A report from the Second International Forum for Primary Care Research on Low Back Pain. Reexamining priorities. Borkan JM, et al. **Spine** 1998 Sep 15;23(18):1992–6 (8 ref.)

Prevention services in primary care: taking time, setting priorities. Rafferty M. **West J Med** 1998 Nov;169(5):269–75

Health impact of earthquake, Turkey. **Wkly Epidemiol Rec** 1999 Sep 3;74(35):289 **(Eng, Fre)**

Progress towards global poliomyelitis eradication, as of May 1999. **Wkly Epidemiol Rec** 1999 May 28;74(21):165–70 **(Eng, Fre)**

[Prioritization problems in the prevention of ischemic heart disease] Hansen JF, et al. **Ugeskr Laeger** 1999 Feb 15; 161(7):973–4 **(Dan)**

[Prevention priorities in mental health in Geneva: a study using the Delphi technic] Schaller G, et al. **Sante Publique** 1998 Jun;10(2):191–201 (Eng. Abstr.) **(Fre)**

[Prioritization in theory and practice] Bruusgaard D. **Tidsskr Nor Laegeforen** 1999 Jun 10;119(15):2155 **(Nor)**

[Status of staff policy and priority tasks of the Ministry of Health of the Russian Federation on its improvement in accordance with the Concept of Development of Public Health and Medical Science in the Russian Federation] Dmitrieva TB, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May-Jun;(3):11–3 **(Rus)**

[Sociopolitical issues in medical research] Gonzalo LM. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):119–20 **(Spa)**

[Insufficient health care resources are optimally used in disaster medicine. The effect of every measure directs the prioritization] Björck I. **Lakartidningen** 1999 Sep 8; 96(36):3808–10 **(Swe)**

[Modified cost-benefit analysis takes equity into consideration. Treatment of brain tumors is more cost-effective than hip replacement] Lindholm L, et al. **Lakartidningen** 1999 Jun 2;96(22):2749–54 (Eng. Abstr.) **(Swe)**

[It should not be necessary for elderly patients with fractures to wait for surgery (letter) (see comments)] Lindsjö U. **Lakartidningen** 1999 Aug 11;96(32–33):3406. Comment in: Lakartidningen 1999 Aug 25;96(34):3512. **(Swe)**

[Disability because of hearing and speech disorders has low priority in society. Cooperation and resources are needed] Lundborg T, et al. **Lakartidningen** 1998 Oct 21; 95(43):4757–8 (5 ref.) **(Swe)**

[Concentrate on geriatrics (letter)] Selander G. **Lakartidningen** 1999 May 12;96(19):2331–2 **(Swe)**

[Which diseases are to be prioritized? (letter)] Simonsson M. **Lakartidningen** 1999 Jun 16;96(24):2956 **(Swe)**

[Wonder at the priority committee and its survey (letter)] Simonsson M. **Lakartidningen** 1999 Jun 9;96(23):2835 **(Swe)**

[How are the first days of life to be prioritized? Can we afford the obstetric care?] Wager J. **Lakartidningen** 1998 Sep 23;95(39):4204–5 **(Swe)**

ECONOMICS

Impact of the east Asian economic crisis on health and health care: Malaysia's response. Suleiman AB, et al. **Asia Pac J Public Health** 1998;10(1):5–9

WHO budget set to reflect new priorities [news] Brown P. **BMJ** 1999 Jan 23;318(7178):212

Principles for priority setting in mental health services and their implications for the least well off. Rosenheck RA. **Psychiatr Serv** 1999 May;50(5):653–8

[Rationing in public health: what criteria, what priorities?] Wiedemann GJ, et al. **Med Klin** 1999 Feb 15;94(2):116–9 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Bolstering the safety net. Gage LS, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):254–7

State and federal health priorities. Wakefield M. **J Prof Nurs** 1999 Mar–Apr;15(2):72

ORGANIZATION & ADMINISTRATION

Can data-driven benchmarks be used to set the goals of healthy people 2010? Allison J, et al. **Am J Public Health** 1999 Jan;89(1):61–5

USA gets to grips with priority-setting for health research [news] **Bull World Health Organ** 1999;77(4):362–3

Primary health care in the eastern Mediterranean region before and after Alma-Ata. Abdullatif AA. **East Mediterr Health J** 1998;4 Suppl:S85–102 (18 ref.)

The role of the WHO representative at country level: past, present and future prospects. al-Khawashky MI. **East Mediterr Health J** 1998;4 Suppl:S66–77; discussion S77–80

Identifying environmental health priorities for a whole nation: the use of principal environmental exposure pathways in the Philippines. Hertzman C, et al. **Int J Occup Environ Health** 1998 Apr–Jun;4(2):114–20

Tensions in setting health care priorities for South Africa's children. Landman WA, et al. **J Med Ethics** 1998 Aug; 24(4):268–73 (30 ref.)

Laying the foundation for Healthy People 2010. The first year of consultation. Maiese DR, et al. **Public Health Rep** 1998 Jan–Feb;113(1):92–5

Using social health insurance to meet policy goals. Normand C. **Soc Sci Med** 1999 Apr;48(7):865–9 (13 ref.)

[Public health priorities] Chabot JM. **Rev Prat** 1998 Feb 15; 48(4):425–6 **(Fre)**

[Children of the North--a national priority of Russia] Zaidfudim PKh. **Med Parazitol (Mosk)** 1998 Jul–Sep; (3):7–9 **(Rus)**

STANDARDS

Setting health priorities [editorial] [see comments] Watkins P. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):510. Comment in: J R Coll Physicians Lond 1999 Mar–Apr;33(2):192–3.

STATISTICS & NUMERICAL DATA

Africa faces reproductive crisis [editorial] Caldwell JC. **Afr J Reprod Health** 1997 Sep;1(2):10–4 **(Eng, Fre)**

Voters and health care in the 1998 election. Blendon RJ, et al. **JAMA** 1999 Jul 14;282(2):189–94

TRENDS

Mind matters: the importance of mental disorders in public health's 21st century mission [editorial; comment] Neugebauer R. **Am J Public Health** 1999 Sep;89(9):1309–11 (30 ref.). Comment on: Am J Public Health 1999 Sep;89(9):1315–8.

Keeping women and children last: America's war on the poor. Sidel R. **Int J Circumpolar Health** 1998;57 Suppl 1:23–6

Toward a new urban health model: moving beyond the safety net to save the safety net--resetting priorities for healthy communities. Anderson RJ, et al. **J Urban Health** 1998 Jun;75(2):367–78

Improving urban health. DeBuono BA. **J Urban Health** 1998 Jun;75(2):263–71

Urban health care: what works and why. Schroeder SA. **J Urban Health** 1998 Jun;75(2):349–55

Building the next generation of healthy people. Richmond JB. **Public Health Rep** 1999 May–Jun;114(3):212–7

[The rationale for priority trends in reducing the regional expenditure risks in the social hygiene monitoring system] Lebedeva TM. **Gig Sanit** 1999 Mar–Apr;(2):68–9 **(Rus)**

HEALTH PROFESSIONS see **HEALTH OCCUPATIONS**

HEALTH PROMOTION

see related

HEALTH BEHAVIOR

A decade of many gains in Americans' health. Satcher D. **Acad Med** 1999 Jul;74(7):808–9

Promoting breastfeeding through health education at the time of immunizations: a randomized trial from Guinea Bissau [see comments] Jakobsen MS, et al. **Acta Paediatr** 1999 Jul;88(7):741–7. Comment in: Acta Paediatr 1999 Jul;88(7):703–4.

Promoting breastfeeding in Guinea-Bissau [comment] Smedman L. **Acta Paediatr** 1999 Jul;88(7):703–4. Comment on: Acta Paediatr 1999 Jul;88(7):741–7.

Cross-cultural issues in prevention, health promotion, and risk reduction in adolescence. Bell DL, et al. **Adolesc Med** 1999 Feb;10(1):57–69, vi (55 ref.)

The psychological basis of health promotion for adolescents. DiClemente RJ. **Adolesc Med** 1999 Feb;10(1):13–22, v (37 ref.)

Adolescent health assessment and promotion in office and school settings. Fisher M. **Adolesc Med** 1999 Feb; 10(1):71–86, vi (65 ref.)

How legislation and health systems can promote adolescent health. Klerman LV. **Adolesc Med** 1999 Feb;10(1):23–40, v (28 ref.)
Sexually transmitted diseases, unintended pregnancy, and adolescent health promotion. Santelli JS, et al. **Adolesc Med** 1999 Feb;10(1):87–108, vi (180 ref.)
Promoting healthy eating and physical activity in adolescents. Story M, et al. **Adolesc Med** 1999 Feb;10(1):109–23, vi (43 ref.)
Health promotion for end-stage renal disease patients. Sadler JH. **Adv Ren Replace Ther** 1998 Oct;5(4):275–85 (58 ref.)
Problem-solving for better health: literature as a resource. Akhigbe F. **Afr J Med Med Sci** 1997 Sep–Dec; 26(3–4):205–8 (21 ref.)
'Ikigai' in older Japanese people. Nakanishi N. **Age Ageing** 1999 May;28(3):323–4
Risky single-occasion drinking amongst young people—definition, correlates, policy, and intervention: a broad overview of research findings. Murgraff V, et al. **Alcohol Alcohol** 1999 Jan–Feb;34(1):3–14 (99 ref.)
Heart disease prevention begins in childhood [editorial; comment] McBride PE. **Am Fam Physician** 1999 Apr 15; 59(8):2093, 2097. Comment on: Am Fam Physician 1999 Apr 15;59(8):2211–8.
Health screening in older women [see comments] Mouton CP, et al. **Am Fam Physician** 1999 Apr 1;59(7):1835–42 (54 ref.). Comment in: Am Fam Physician 1999 Apr 1;59(7):1747–8, 1750.
Interventions to reduce cardiovascular risk factors in children and adolescents [see comments] Washington RL. **Am Fam Physician** 1999 Apr 15;59(8):2211–8 (22 ref.). Comment in: Am Fam Physician 1999 Apr 15;59(8):2073, 2097.
Pathways family intervention for third-grade American Indian children. Teufel NI, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):803S–809S
Portion-size estimation training in second- and third-grade American Indian children. Weber JL, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):782S–787S
Marketing could be primary objective of managed care health promotion programs [news] **Am J Health Syst Pharm** 1998 Sep 1;55(17):1756, 1759
Smoking-cessation programs need to target college students [news] Christie-Smith D. **Am J Health Syst Pharm** 1999 Mar 1;56(5):416
An attempt to improve blood pressure control in the French population: information and outcome awareness at the general practitioner level. Poggi L, et al. **Am J Hypertens** 1998 Jul;11(7):905–8
Mediating variable framework in physical activity interventions. How are we doing? How might we do better? [published erratum appears in Am J Prev Med 1999 Jul;17(1):98] Baranowski T, et al. **Am J Prev Med** 1998 Nov;15(4):266–97 (95 ref.)
Cooper Institute/The American College of Sports Medicine. 1997 Physical Activity Interventions Conference. Blair SN, et al. **Am J Prev Med** 1998 Nov;15(4):255–6
Worksite physical activity interventions. Dishman RK, et al. **Am J Prev Med** 1998 Nov;15(4):344–61 (95 ref.)
Lifestyle physical activity interventions. History, short- and long-term effects, and recommendations. Dunn AL, et al. **Am J Prev Med** 1998 Nov;15(4):398–412 (77 ref.)
Integrating theoretical approaches to promote physical activity. Epstein LH. **Am J Prev Med** 1998 Nov; 15(4):257–65
Effectiveness of health promotion programs to increase motor vehicle occupant restraint use among young children. Grossman DC, et al. **Am J Prev Med** 1999 Jan; 16(1 Suppl):12–22
Physical activity interventions targeting older adults. A critical review and recommendations. King AC, et al. **Am J Prev Med** 1998 Nov;15(4):316–33 (86 ref.)
Physical activity interventions using mass media, print media, and information technology. Marcus BH, et al. **Am J Prev Med** 1998 Nov;15(4):362–78 (68 ref.)
Environmental and policy interventions to promote physical activity. Sallis JF, et al. **Am J Prev Med** 1998 Nov; 15(4):379–97 (73 ref.)
Evaluating interventions that promote the use of rear seats for children. Segui-Gomez M. **Am J Prev Med** 1999 Jan; 16(1 Suppl):23–9
Effects of physical activity interventions in youth. Review and synthesis. Stone EJ, et al. **Am J Prev Med** 1998 Nov; 15(4):298–315 (108 ref.)
Physical activity interventions in low-income, ethnic minority, and populations with disability. Taylor WC, et al. **Am J Prev Med** 1998 Nov;15(4):334–43 (38 ref.)
Linking health promotion with entertainment television. Langlieb AM, et al. **Am J Public Health** 1999 Jul; 89(7):1116–7
Public health interventions to encourage TB class A/B1/B2 immigrants to present for TB screening. Catlos EK, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1037–41
Active vs. passive methods of recruiting ethnic minority women to a health promotion program. Lee RE, et al. **Ann Behav Med** 1998 Fall;19(4):378–84
Evaluation of CHAMPS, a physical activity promotion program for older adults. Stewart AL, et al. **Ann Behav Med** 1998 Fall;19(4):353–61
Increasing stair use [letter; comment] Reisman AB, et al. **Ann Intern Med** 1999 Apr 6;130(7):616–7. Comment on: Ann Intern Med 1998 Sep 1;129(5):363–9.
Social, community, and preventive interventions. Reppucci ND, et al. **Annu Rev Psychol** 1999;50:387–418 (192 ref.)
Health education's contributions to public health in the twentieth century: a glimpse through health promotion's rear-view mirror. Green LW. **Annu Rev Public Health** 1999;20:67–88 (125 ref.)
Determinants of counseling in primary care pediatric practice: physician attitudes about time, money, and health issues. Cheng TL, et al. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):629–35
Telehealth and OSHA [letter] Miller MH. **ASHA** 1998 Fall; 40(4):57–8
Vietnamese women and Pap smears: issues in promotion. Cheek J, et al. **Aust N Z J Public Health** 1999 Feb; 23(1):72–6
Retailer education and cigarette sales to teenagers [letter] Cook D. **Aust N Z J Public Health** 1998 Dec;22(7):842
Do personalised letters in Vietnamese increase cervical cancer screening among Vietnamese women? Del Mar C, et al. **Aust N Z J Public Health** 1998 Dec;22(7):824–5
TARPARE: a method for selecting target audiences for public health interventions. Donovan RJ, et al. **Aust N Z J Public Health** 1999 Jun;23(3):280–4
Where should alcohol and tobacco interventions be provided? [editorial] Richmond R, et al. **Aust N Z J Public Health** 1998 Dec;22(7):745–6
Where should alcohol and tobacco interventions be provided? Another view [letter] Ward J, et al. **Aust N Z J Public Health** 1999 Jun;23(3):331–2
UK government announces sex health strategy [news] Madden V. **BMJ** 1999 Apr 3;318(7188):894
European plan to put obesity on governments' health agenda [news] Mayor S. **BMJ** 1999 Jun 12;318(7198):1574
Provision of health advice for UK medical students planning to travel overseas for their elective study period: questionnaire survey [see comments] Moss PJ, et al. **BMJ** 1999 Jan 16;318(7177):161–2. Comment in: BMJ 1999 Jan 16;318(7177):139–40.
Health, health promotion, and homelessness. Power R, et al. **BMJ** 1999 Feb 27;318(7183):590–2 (32 ref.)
Oral health promotion—opportunity knocks! Watt RG, et al. **Br Dent J** 1999 Jan 9;186(1):3–6
Health visitor screening versus vigilance: outcomes of programmes for detecting permanent childhood hearing loss in west Berkshire. Sutton GJ, et al. **Br J Audiol** 1999 Jun;33(3):145–56
Functional food science in Europe. **Br J Nutr** 1998 Aug;80 Suppl 1:S3–4
European market developments in prebiotic- and probiotic-containing foodstuffs. Young J. **Br J Nutr** 1998 Oct;80(4):S231–3
Changes in public attitudes to depression during the Defeat Depression Campaign. Paykel ES, et al. **Br J Psychiatry** 1998 Dec;173:519–22
Barriers to physical activity promotion by general practitioners and practice nurses. McKenna J, et al. **Br J Sports Med** 1998 Sep;32(3):242–7
Development of a knowledge scale about breast cancer and heredity (BCHK). Ondrusek N, et al. **Breast Cancer Res Treat** 1999 Jan;53(1):69–75
Malaria initiative gains momentum [news] **Bull World Health Organ** 1999;77(1):95
Antismoking campaigns fail in industrialized countries [news] **Bull World Health Organ** 1999;77(5):449
Prizes for weight loss. Englberger L. **Bull World Health Organ** 1999;77(1):50–3
Canada to welcome new guide to physical activity. Côté D. **Can J Cardiol** 1998 Oct;14(10):1200, 1203
A cardiovascular risk factor reduction clinic. Wilson TW, et al. **Can J Cardiol** 1999 Aug;15(8):887–91 **(Eng, Fre)**
Adherence to non-pharmacologic therapy for hypertension: problems and solutions. Fodor G, et al. **Can J Public Health** 1998 Sep–Oct;89(5):I12–5
Tobacco reduction: a continued health promotion challenge [editorial] Mangham C. **Can J Public Health** 1999 Mar–Apr;90(2):77–9 **(Eng, Fre)**
Evaluation of the promotional materials used during the measles mass immunization campaign in Ontario and British Columbia. Pelletier L, et al. **Can J Public Health** 1998 Sep–Oct;89(5):329–32
Workshop report: research, policy and program planning on sun protective behaviours. Ashbury FD, et al. **Cancer Prev Control** 1998 Jun;2(3):129–32 (12 ref.)
Sun safety behaviours of alpine skiers and snowboarders in the western United States. Buller DB, et al. **Cancer Prev Control** 1998 Jun;2(3):133–9
Promotion of breast cancer screening in communities: a research agenda [see comments] Olson KL, et al. **Cancer Prev Control** 1997 Aug;1(3):213–21. Comment in: Cancer Prev Control 1997 Aug;1(3):190–1.
Enabling children: participation as a new perspective on child-health promotion. de Winter M, et al. **Child Care Health Dev** 1999 Jan;25(1):15–23; discussion 23–5
Health effects of alcohol and alcoholism. Therapondos G, et al. **Clin Dermatol** 1999 Jul–Aug;17(4):381–9 (68 ref.)
Reaching the goals of "Healthy People 2000" regarding breastfeeding. Cadwell K. **Clin Perinatol** 1999 Jun; 26(2):527–37
Prevention of marital dysfunction: behavioral approaches and beyond. Sayers SL, et al. **Clin Psychol Rev** 1998 Sep; 18(6):713–44 (121 ref.)
Should physicians assess lifestyle risk factors routinely? [editorial; comment] Herbert CP. **CMAJ** 1999 Jun 29; 160(13):1849–50. Comment on: CMAJ 1999 Jun 29;160(13):1830–4.
Body composition in an employee health improvement program. Wittmann A. **Coll Antropol** 1998 Dec; 22(2):447–50
The national measles surveillance strategy. The National Centre for Disease Control Measles Elimination Advisory Committee. Heath T, et al. **Commun Dis Intell** 1999 Feb 18;23(2):41–50
Physician heal thyself: lifestyle education for medical students. Cohen M. **Complement Ther Med** 1999 Jun; 7(2):110–2
Safety assessment and potential health benefits of food components based on selected scientific criteria. ILSI North America Technical Committee on Food Components for Health Promotion. **Crit Rev Food Sci Nutr** 1999 May;39(3):203–316 (627 ref.)
Contributing to improved health through new knowledge: primary care teams and the unanswered questions [editorial] Kinmonth AL. **Diabet Med** 1998 Nov;15 Suppl 3:S10–3 (23 ref.)
Health promotion and diabetes risk factors in children [editorial; comment] Mobley CC. **Diabetes Care** 1999 Feb; 22(2):189–90. Comment on: Diabetes Care 1999 Feb;22(2):202–7.
Reaching and enrolling drug users for HIV prevention: a multi-site analysis. Cunningham-Williams RM, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):1–10
Oral health among Liberian refugees in Ghana. Mickenautsch S, et al. **East Afr Med J** 1999 Apr;76(4):206–11
Health promotion for coronary heart disease: past, present and future. Ebrahim S, et al. **Eur Heart J** 1998 Dec; 19(12):1751–7 (70 ref.)
Health aspects of fish and n-3 polyunsaturated fatty acids from plant and marine origin. de Deckere EA, et al. **Eur J Clin Nutr** 1998 Oct;52(10):749–53 (58 ref.)
The health benefits of physical activity in children and adolescents: implications for chronic disease prevention. Sothern MS, et al. **Eur J Pediatr** 1999 Apr;158(4):271–4 (33 ref.)
Increasing population levels of physical activity through primary care: GPs' knowledge, attitudes and self-reported practice. Lawlor DA, et al. **Fam Pract** 1999 Jun;16(3):250–4
The vagaries of self-reports of physical activity: a problem revisited and addressed in a study of exercise promotion in the over 65s in general practice. Sims J, et al. **Fam Pract** 1999 Apr;16(2):152–7
Attitudes to cardiovascular health promotion among GPs and practice nurses. Steptoe A, et al. **Fam Pract** 1999 Apr; 16(2):158–63
The role of general practice in promoting teenage health: a review of the literature. Walker ZA, et al. **Fam Pract** 1999 Apr;16(2):164–72 (105 ref.)
Motivating patients to change [editorial] Butler RN. **Geriatrics** 1999 Jan;54(1):3–4
International grant making by U.S. foundations. LeRoy L. **Health Aff (Millwood)** 1999 May–Jun;18(3):234–8
Strategic philanthropy: Pew's approach to matching needs with resources. Rimel RW. **Health Aff (Millwood)** 1999 May–Jun;18(3):228–33
Psychosocial factors associated with youth involvement in community activities promoting heart health. Altman DG, et al. **Health Educ Behav** 1998 Aug;25(4):489–500
Physical activity and minority women: a qualitative study. Eyler AA, et al. **Health Educ Behav** 1998 Oct;25(5):640–52
Impact of work site health promotion on stages of dietary change: the Working Well Trial. Glanz K, et al. **Health Educ Behav** 1998 Aug;25(4):448–63
Social support and readiness to make dietary changes. Sorensen G, et al. **Health Educ Behav** 1998 Oct; 25(5):586–98
Family process in health research: extending a family typology to a new cultural context. Fisher L, et al. **Health Psychol** 1998 Jul;17(4):358–66
Promoting good health in adolescents with disabilities. Zajicek-Farber ML. **Health Soc Work** 1998 Aug; 23(3):203–13
Service start-ups. Get physical [news] Blank D. **Hosp Health Netw** 1999 May;73(5):13
Geomagnetic evidence for the time-selecting concept of traditional Chinese health promotion. Jeng Y, et al. **IEEE Eng Med Biol Mag** 1999 Jul–Aug;18(4):94–9
Emphasis needed for primary prevention [letter] Posey K. **Image J Nurs Sch** 1999;31(2):107
Hepatitis B immunization coverage and awareness in middle and upper-class population in Chennai City [letter] Pai M, et al. **Indian Pediatr** 1998 Sep;35(9):922–3
Experience of pulse polio immunization amongst medical professionals [letter] Swami HM, et al. **Indian Pediatr** 1998 Oct;35(10):1031–2
A strategy for health promotion among unemployed people in Japan. Matoba T, et al. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S31–3
Concept on health promotion about the unemployed in Switzerland. Schiffer J. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S23–5
Health consequences of unemployment: "Disoccupazione & salute" is a prevention program at a local level. Villaret M, et al. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S26–7

Who should be educated? Education strategies: could children educate their parents? Basdevant A, et al. **Int J Obes Relat Metab Disord** 1999 May;23 Suppl 4:S10–2; discussion S12–3 (7 ref.)

Sociodemographic distribution of measures of body fatness among children and adolescents in New South Wales, Australia. Booth ML, et al. **Int J Obes Relat Metab Disord** 1999 May;23(5):456–62

Abdominal obesity reduction in indigenous men. Egger G, et al. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):564–9

Promoting physical activity: issues in primary health care. Hillsdon M. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S52–4

Quality assurance and iron deficiency in Egypt. Abubaker WA, et al. **Int J Qual Health Care** 1999 Apr;11(2):163–8

Impact of a social marketing campaign promoting dark-green leafy vegetables and eggs in central Java, Indonesia. de Pee S, et al. **Int J Vitam Nutr Res** 1998;68(6):389–98

Margaret Hilson is first winner of the ICN achievement award [news] **Int Nurs Rev** 1999 Jan–Feb;46(1):29

ICN and WMA stop tobacco use [news] **Int Nurs Rev** 1999 May–Jun;46(3):68

ICN on tobacco use: nurses can utilize their unique knowledge and experience to promote smoking cessation and prevent the spread of a public health crisis. **Int Nurs Rev** 1999 May–Jun;46(3):80–1

Do doctors benefit from their profession?--A survey of medical practitioners' health promotion and health safety practices [editorial] O'Connor M, et al. **Ir Med J** 1998 Dec; 91(6):206–9

Promoting adolescent mental health in primary care: a review of the literature. Walker Z, et al. **J Adolesc** 1998 Oct; 21(5):621–34 (104 ref.)

Resources revisited: salutogenesis from a lay perspective. Cowley S, et al. **J Adv Nurs** 1999 Apr;29(4):994–1004

The contribution of nursing to cancer prevention. Cutler LR. **J Adv Nurs** 1999 Jan;29(1):169–77 (71 ref.)

Are practice nurses an unexplored resource in the identification and management of alcohol misuse? Results from a study of practice nurses in England and Wales in 1995. Deehan A, et al. **J Adv Nurs** 1998 Sep;28(3):592–7

Health practices of adult Hispanic women. Higgins PG, et al. **J Adv Nurs** 1999 May;29(5):1105–12

Traditional Chinese medicine and the dietary supplement health and educational act [editorial; comment] Upton R. **J Altern Complement Med** 1999 Apr;5(2):115–8. Comment on: J Altern Complement Med 1999 Apr;5(2):181–9.

Evaluation of an STD-prevention program for Swedish university students. Tydén T, et al. **J Am Coll Health** 1998 Sep;47(2):70–5

For a healthful lifestyle: promoting cooperation among nutrition professionals and physical activity professionals. American College of Sports Medicine, the American Dietetic Association, International Food Information Council. **J Am Diet Assoc** 1999 Aug;99(8):994–7

Should hospital diets meet the dietary guidelines for healthy persons? [letter; comment] Chima CS. **J Am Diet Assoc** 1998 Dec;98(12):1400–1; discussion 1402. Comment on: J Am Diet Assoc 1998 Jun;98(6):639–41.

President's page: Nutrition messages on food packages--location, location, location. Coulston AM. **J Am Diet Assoc** 1998 Dec;98(12):1470

Setting the nation's health agenda [news] [see comments] Hahn NI. **J Am Diet Assoc** 1999 Apr;99(4):415, 418–9. Comment in: J Am Diet Assoc 1999 Apr;99(4):420.

Using disease-state management as the key to promoting employer sponsorship of medical nutrition therapy (continuing education credit). Israel DA, et al. **J Am Diet Assoc** 1999 May;99(5):583–8; quiz 589–90

Development and implementation of a school-based nutrition and fitness promotion program for ethnically diverse middle-school girls. Leslie J, et al. **J Am Diet Assoc** 1999 Aug;99(8):967–70

Should hospital diets meet the dietary guidelines for healthy persons? [letter; comment] Miller MA, et al. **J Am Diet Assoc** 1998 Dec;98(12):1401; discussion 1402. Comment on: J Am Diet Assoc 1998 Jun;98(6):639–41.

Should hospital diets meet the dietary guidelines for healthy persons? [letter; comment] [see comments] Traviss KA, et al. **J Am Diet Assoc** 1998 Dec;98(12):1400; discussion 1402 . Comment on: J Am Diet Assoc 1998 Jun;98(6):639–41. Comment in: J Am Diet Assoc 1999 Jul;99(7):793.

A managed care organization's attempt to increase influenza and pneumococcal immunizations for older adults in an acute care setting. Bloom HG, et al. **J Am Geriatr Soc** 1999 Jan;47(1):106–10

Taking back young lives: policy issues for adolescent girls in the developing world. Bruce J, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):153–4, 160

Creating a new framework for promoting the health of African-American female adolescents: beyond risk taking. Roberts L. **J Am Med Womens Assoc** 1999 Summer; 54(3):126–8

Student Movement of the Medicine/Public Health Initiative promotes nationwide preventive healthcare approach [letter] Cardarelli R, et al. **J Am Osteopath Assoc** 1998 Dec;98(12):675–6

Pine Bluff's health is mission of Shuffield Award winner. **J Ark Med Soc** 1999 Jun;96(1):18–9

Women's health promotion. Seward MH. **J Dent Educ** 1999 Mar;63(3):231–7

Is there evidence to show that fetal alcohol syndrome can be prevented? Murphy-Brennan MG, et al. **J Drug Educ** 1999;29(1):5–24 (67 ref.)

The Acheson report: beyond parenthood and apple pie? [editorial] Barnes R, et al. **J Epidemiol Community Health** 1999 Jun;53(6):322–3

How good is the Prevent model for estimating the health benefits of prevention? Brønnum-Hansen H. **J Epidemiol Community Health** 1999 May;53(5):300–5

Barriers to physical activity and socioeconomic position: implications for health promotion. Chinn DJ, et al. **J Epidemiol Community Health** 1999 Mar;53(3):191–2

Cardiovascular risk during early adult life. Risk markers among participants in "Live for Life" health promotion programme in Sweden. Persson LG, et al. **J Epidemiol Community Health** 1998 Jul;52(7):425–32

Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular disease. Weinehall L, et al. **J Epidemiol Community Health** 1999 Apr;53(4):243–50

The negative effect of the clinical model of "health": implications for health care policy. Peters RM. **J Health Care Finance** 1998 Fall;25(1):78–92

Madison physicians give of their time and of their mind. Weaver RA. **J Med Assoc Ga** 1999 Feb;88(1):11–2

Racial bias in federal nutrition policy, Part II: Weak guidelines take a disproportionate toll. Bertron P, et al. **J Natl Med Assoc** 1999 Apr;91(4):201–8

Faculty and student cross-cultural learning through teaching health promotion in the community. Moch SD, et al. **J Nurs Educ** 1999 May;38(5):238–40

Phytochemicals: biochemistry and physiology. Introduction. Hasler CM, et al. **J Nutr** 1999 Mar;129(3):756S–757S (8 ref.)

Functional foods and health promotion. Milner JA. **J Nutr** 1999 Jul;129(7 Suppl):1395S–7S (25 ref.)

Dietary isoflavones: biological effects and relevance to human health. Setchell KD, et al. **J Nutr** 1999 Mar; 129(3):758S–767S (148 ref.)

Promoting women's health via the World Wide Web. Hern MJ, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec; 27(6):606–10 (6 ref.)

Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. Morse G. **J Obstet Gynecol Neonatal Nurs** 1999 Mar–Apr; 28(2):165–74

Analysis of a worksite health promotion program's impact on job satisfaction. Peterson M, et al. **J Occup Environ Med** 1998 Nov;40(11):973–9

Developing guidelines for smoking cessation interventions for pregnant adolescents. Albrecht S, et al. **J Pediatr Nurs** 1999 Jun;14(3):150–6

Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. Booth RE, et al. **J Psychoactive Drugs** 1998 Jul–Sep; 30(3):269–78

Effectiveness of HIV risk reduction initiatives among out-of-treatment non-injection drug users. Cottler LB, et al. **J Psychoactive Drugs** 1998 Jul–Sep;30(3):279–90

Editors' introduction: HIV/AIDS interventions for out-of-treatment drug users. Inciardi JA, et al. **J Psychoactive Drugs** 1998 Jul–Sep;30(3):225–9

Theoretical models used to guide NIDA's cooperative agreement research and intervention efforts. National Institute on Drug Abuse. Stevens SJ, et al. **J Psychoactive Drugs** 1998 Jul–Sep;30(3):231–8

Healthy people 2000--how are we doing? [news] **J Psychosoc Nurs Ment Health Serv** 1999 Aug;37(8):10

Healthy housing--advice for students. Snaith C. **J Public Health Med** 1998 Dec;20(4):434–40

The Scottish Green Paper: beyond a healthy mind in a healthy body. Tannahill A. **J Public Health Med** 1998 Sep; 20(3):249–52

The submission from The Royal Society for the Promotion of Health on the communication from the Commission on the Development of Public Health Policy in the EC. **J R Soc Health** 1998 Oct;118(5):309–10

Health-promoting behaviours in public health: testing the health promotion model. Blacconiere MJ, et al. **J R Soc Health** 1999 Mar;119(1):11–6

Promoting oral health in institutionalised older adults: a nursing perspective. Holmes S. **J R Soc Health** 1998 Jun; 118(3):167–72 (64 ref.)

Health promotion, environmental health and Agenda 21. Scriven A, et al. **J R Soc Health** 1998 Apr;118(2):85–90

Our healthier nation [news] Shaw A. **J R Soc Health** 1998 Jun;118(3):139–40

Impact of lifestyle choices on female infertility. Silva PD, et al. **J Reprod Med** 1999 Mar;44(3):288–96 (121 ref.)

Promoting health in South Carolina: a charge to primary care providers. Underwood SM, et al. **J S C Med Assoc** 1999 Jun;95(6):236–40

Abstinence--more than a slogan [editorial] Villarruel AM. **J Soc Pediatr Nurs** 1998 Jul–Sep;3(3):91–2

Personal health among midlife women hospital employees. Angard N, et al. **J Womens Health** 1998 Dec;7(10):1289–93

Cardiac rehabilitation: gender differences in factors influencing participation. Lieberman L, et al. **J Womens Health** 1998 Aug;7(6):717–23

A healthy lifestyle. Meisler JG. **J Womens Health** 1999 Apr; 8(3):293–5

Women and wellness. Wootton JC. **J Womens Health** 1998 Oct;7(8):1049–51

JAMA patient page: exercise. **JAMA** 1999 Jan 27;281(4):394

JAMA Patient Page: fiber. **JAMA** 1999 Jun 2;281(21):2060

From disease prevention to health promotion. Breslow L. **JAMA** 1999 Mar 17;281(11):1030–3

An evidence-based approach to interactive health communication: a challenge to medicine in the information age. Science Panel on Interactive Communication and Health. Robinson TN, et al. **JAMA** 1998 Oct 14; 280(14):1264–9 (82 ref.)

Report of the twelfth International Symposium of the Foundation for Promotion of Cancer Research: Basic and Clinical Research in Breast Cancer. Abe K, et al. **Jpn J Clin Oncol** 1999 Aug;29(8):399–402

Improving health care, Part 5: Applying the Dartmouth clinical improvement model to community health. Speroff T, et al. **Jt Comm J Qual Improv** 1998 Dec;24(12):679–703

South African faces an AIDS crisis as government health campaigns fail [news] Baleta A. **Lancet** 1999 Feb 20; 353(9153):653

Health and wealth in the United Arab Emirates [news] Kandela P. **Lancet** 1999 Jun 12;353(9169):2047

Video-conferencing experiment heralds a new era in health promotion [news] Tattam A. **Lancet** 1999 Apr 17; 353(9161):1338

"Point four" the future [editorial] Freda MC. **MCN Am J Matern Child Nurs** 1999 Sep–Oct;24(5):223

Shedding light on bowel cancer prevention [editorial; comment] Bolin TD, et al. **Med J Aust** 1999 Mar 15; 170(6):244–5. Comment on: Med J Aust 1999 Mar 15;170(6):251–4.

A national approach to skin cancer prevention: the National SunSmart Schools Program [editorial] Dobbinson S, et al. **Med J Aust** 1998 Nov 16;169(10):513–4

Effective health promotion and clinical care for large people. Lyons P, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1141–6

A model for enhancing worldwide personal health and wellness. Marine S, et al. **Medinfo** 1998;9 Pt 2:1265–8

Cervical cancer screening knowledge, behaviors, and beliefs of Vietnamese women. Schulmeister L, et al. **Oncol Nurs Forum** 1999 Jun;26(5):879–87

Epidemiology and prevention of traffic injuries to urban children and adolescents. Durkin MS, et al. **Pediatrics** 1999 Jun;103(6):e74

Health benefits of a vegetarian diet. Key TJ, et al. **Proc Nutr Soc** 1999 May;58(2):271–5 (21 ref.)

Animal v. plant foods in human diets and health: is the historical record unequivocal? Nestle M. **Proc Nutr Soc** 1999 May;58(2):211–8 (87 ref.)

New horizons in health. Proceedings of the XVIth World Conference on Health Promotion and Health Education. San Juan, Puerto Rico, June 1998. **Promot Educ** 1998 Sep–Dec;5(3–4):1–46 **(Eng, Fre, Spa)**

An explanatory model of variables influencing health promotion behaviors in smoking and nonsmoking college students. Martinelli AM. **Public Health Nurs** 1999 Aug; 16(4):263–9

Evaluation of a university course to promote physical activity: project GRAD. Sallis JF, et al. **Res Q Exerc Sport** 1999 Mar;70(1):1–10

Should condom use be promoted for contraception to prevent transmission of sexual transmitted diseases and AIDS? ACSF Group. French National Survey of Sexual behavior. Bajos N, et al. **Rev Epidemiol Sante Publique** 1998 Nov; 46(5):391–7

The days of health and physical activity. Málková I. **Sb Lek** 1998;99(3):323–7

Four years experience of a cardiovascular opportunistic screening and prevention programme in the primary health care in Sollentuna, Sweden. Hellénius ML, et al. **Scand J Prim Health Care** 1999 Jun;17(2):111–5

Planning a worksite health promotion program: health profile of a population of Greek sailors [letter] Tsamandouraki K, et al. **Scand J Soc Med** 1998 Sep;26(3):181–2

Guidelines for the medical surveillance of shift workers. Costa G. **Scand J Work Environ Health** 1998;24 Suppl 3:151–5

Reducing coronary heart disease in the Australian Coalfields: evaluation of a 10-year community intervention. Higginbotham N, et al. **Soc Sci Med** 1999 Mar;48(5):683–92

Closing rural hospitals in Saskatchewan: on the road to wellness? James AM. **Soc Sci Med** 1999 Oct;49(8):1021–34

Promoting health, promoting women: the construction of female and professional identities in the discourse of community health workers. Ramirez-Valles J. **Soc Sci Med** 1998 Dec;47(11):1749–62

Determinants of the Permethrin Impregnated Bednets (PIB) in the Republic of Benin: the role of women in the acquisition and utilization of PIBs. Rashed S, et al. **Soc Sci Med** 1999 Oct;49(8):993–1005

Health promotion versus disease and care: failure to establish "blissful clarity" in British nurse education and practice. Smith P, et al. **Soc Sci Med** 1999 Jan;48(2):227–39

Community development through partnership: promoting health in an urban indigenous community in New Zealand. Voyle JA, et al. **Soc Sci Med** 1999 Oct;49(8):1035–50

Defecation practices of young children in a Peruvian shanty town. Yeager BA, et al. **Soc Sci Med** 1999 Aug; 49(4):531–41

Choosing change. Franke J. **Tex Med** 1999 Aug;95(8):34–41

Poland's world-leading health warnings [news] **Tob Control** 1998 Autumn;7(3):229–30

European smoke-free class competition [letter] Hanewinkel

R, et al. **Tob Control** 1998 Autumn;7(3):326

Quit and Win campaigns as a long-term anti-smoking intervention in North Karelia and other parts of Finland. Korhonen T, et al. **Tob Control** 1999 Summer;8(2):175–81

The "success" of Philip Morris' campaign on environmental tobacco smoke in The Netherlands [letter] Nellen MA, et al. **Tob Control** 1999 Summer;8(2):221–2

An evaluation of a theatre production to encourage non-smoking among elementary age children: 2 Smart 2 Smoke. Perry CL, et al. **Tob Control** 1999 Summer; 8(2):169–74

Impact of the Tobacco Price Support Program on tobacco control in the United States. Zhang P, et al. **Tob Control** 1998 Summer;7(2):176–82

The differential diagnosis and management of breast lumps in the tropics. Holcombe C, et al. **Trop Doct** 1999 Jan; 29(1):42–6 (17 ref.)

Growth monitoring: family participation: effective community development. Meegan M, et al. **Trop Doct** 1999 Jan;29(1):23–7

Community-based teaching of tropical diseases: an experience with filariasis. Norman G, et al. **Trop Doct** 1999 Apr;29(2):86–9

Enhancing participation of women of child-bearing age in a literacy for health project in southeastern Nigeria. Stephens TT, et al. **Trop Doct** 1999 Jan;29(1):12–8

Cancer awareness among a Nigerian population. Uche EE. **Trop Doct** 1999 Jan;29(1):39–40

Health promotion: issues and answers. Paul TJ, et al. **West Indian Med J** 1998 Dec;47 Suppl 4:49–52

Reducing need and demand for medical services in high-risk persons. A health education approach. Fries JF, et al. **West J Med** 1998 Oct;169(4):201–7

Latino children's health and the family-community health promotion model. Mendoza FS, et al. **West J Med** 1999 Feb;170(2):85–92

Diabetes outpatient project. Blustein J, et al. **WMJ** 1998 Sep; 97(8):58, 60

Wisconsin's Comprehensive School Health Program (CSHP). Gundersen DF. **WMJ** 1998 Sep;97(8):25–8

Good breakfast for good learning. Janowski J. **WMJ** 1998 Sep;97(8):33–6

Tracking and improving children's health. Kennedy M. **WMJ** 1998 Sep;97(8):39

"Run, Jane, run": central tensions in the current debate about enhancing women's health through exercise. Vertinsky P. **Women Health** 1998;27(4):81–111 (160 ref.) .

[Progresses in the study of child health in China, 1997] Ye G, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):941–2 (0 ref.) **(Chi)**

[Progress in the study on health preserving and recovery by integrated traditional and Western medicine] Zhou WQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Mar;17(3):131–5 (Eng. Abstr.) **(Chi)**

[Negative aspects of the Western life style and possibilities of intervention in patients with familial combined hyperlipidemia] Králiková E, et al. **Cas Lek Cesk** 1999 Apr 19;138(8):239–44 (Eng. Abstr.) **(Cze)**

[The effect of a reference program and a media campaign on the prevention of AIDS in general practice] Sandbaek A, et al. **Ugeskr Laeger** 1998 Oct 26;160(44):6348–52 (Eng. Abstr.) **(Dan)**

[Health Council report 'Osteoporosis.'Committee on Osteoporosis, National Health Council] van de Putte LB. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2502–5 (Eng. Abstr.) **(Dut)**

[Resilience: a new look at medical care and prevention (editorial)] Michaud PA. **Arch Pediatr** 1999 Aug; 6(8):827–31 **(Fre)**

[Evaluative research on the distribution of health videocassettes destined for a disadvantaged Montreal population] Beaudet NS, et al. **Can J Public Health** 1998 Sep–Oct;89(5):315–9 (Eng. Abstr.) **(Fre)**

[Impact of an information campaign on cardiovascular risk factors. 5-year results at the study town Epernon] Bruckert E, et al. **Presse Med** 1999 Mar 13;28(10):517–22 (Eng. Abstr.) **(Fre)**

[The IMRED (introduction, methods, results, discussion) plan is also suitable for reviews in education and health promotion] Arwidson P, et al. **Sante Publique** 1998 Jun; 10(2):171–4 **(Fre)**

[Increasing personal responsibility as a public health goal] Seger W. **Gesundheitswesen** 1999 Apr;61(4):214–7 (Eng. Abstr.) **(Ger)**

[The "stop violence" campaign of the Swiss Conference of Equality Officers] **Soz Praventivmed** 1998;43(5):217–20 (Eng. Abstr.) **(Ger)**

[Health promotion in the basic education of teachers in Switzerland] Gretler S. **Soz Praventivmed** 1998; 43(5):239–46 (Eng. Abstr.) **(Ger)**

[Health promotion--as a change of social systems] Hösli R. **Soz Praventivmed** 1998;43(5):229–38 (Eng. Abstr.) **(Ger)**

[Impact of mass media on the use of health services. A systematic review of the literature] Grilli R, et al. **Epidemiol Prev** 1998 Apr–Jun;22(2):103–10 (35 ref.) (Eng. Abstr.) **(Ita)**

[Prevention of alcohol-related problems. From therapy to primary health care: experience at the Udine "Healthy City"] Struzzo P. **Recenti Prog Med** 1999 Feb;90(2):69–72 (Eng. Abstr.) **(Ita)**

[Towards a pain-free hospital. A project and a campaign for the improvement of health care] Visentin M. **Recenti Prog Med** 1999 Jun;90(6):321–4 (Eng. Abstr.) **(Ita)**

[Development of a "self efficacy for health promotion scale" in community-dwelling elderly] Yokokawa Y, et al. **Nippon Koshu Eisei Zasshi** 1999 Feb;46(2):103–12 (Eng. Abstr.) **(Jpn)**

[Tobacco use prevention in Norway--a terrible example? (letter) (see comments)] Aagenaes O. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):999. Comment in: Tidsskr Nor Laegeforen 1999 Apr 20;119(10):1508. **(Nor)**

[The leading role of Norway in tobacco use prevention must be regained (see comments)] Glantz SA. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):987–8. Comment in: Tidsskr Nor Laegeforen 1999 Apr 30;119(11):1646. **(Nor)**

[Measures to promote healthy dietary habits among schoolchildren] Klepp KI, et al. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3306–9 (Eng. Abstr.) **(Nor)**

[Health aid for Eastern Europe--the Eurohealth program and Norwegian contribution] Wium P. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1489–91 (Eng. Abstr.) **(Nor)**

[Effect of nutrition education on nutrition behaviors of investigated students' group] Pierzynowska J, et al. **Rocz Panstw Zakl Hig** 1998;49(4):491–8 (Eng. Abstr.) **(Pol)**

[Health promotion and education: a diagnosis of sanitation conditions using participatory research and community education (São João dos Queiróz - Quixadá/Ceará, Brazil)] Mello DA, et al. **Cad Saude Publica** 1998 Jul–Sep; 14(3):583–95 (Eng. Abstr.) **(Por)**

[Experience of the Baby Friendly Hospital initiative] Lamounier JA. **Rev Assoc Med Bras** 1998 Oct–Dec; 44(4):319–24 (Eng. Abstr.) **(Por)**

[Assessment of the performance of Pastoral de Criança, a health support group, in promoting child survival and health education in Criciúma,a city in southern Brazil] Neumann NA, et al. **Rev Panam Salud Publica** 1999 Jun; 5(6):400–10 (Eng. Abstr.) **(Por)**

[Assessing breastfeeding status in an urban area of southeastern Brazil: use of a simplified method] Carvalhaes MA, et al. **Rev Saude Publica** 1998 Oct;32(5):430–6 (Eng. Abstr.) **(Por)**

[Preventive trends in medicine and "new" sciences of human health] Zakharchenko MP. **Gig Sanit** 1998 Sep–Oct; (5):62–4 **(Rus)**

[Today and tomorrow of the Ekaterinburg Medical Scientific Center of Preventive Medicine and Health Protection of Workers of industrial enterprises] Domnin SG. **Med Tr Prom Ekol** 1998;(8):6–10 **(Rus)**

[Soybeans--nutrition--health] Zakharov VP. **Voen Med Zh** 1999 Mar;320(3):50–1 **(Rus)**

[The role of educational programs on the prevention of HIV infection and the development of a healthy life style for adolescents] Mamchik TA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):113–4 (Eng. Abstr.) **(Rus)**

[Evaluation of a supervised physical exercise program in primary care] Guiu Viaplana A, et al. **Aten Primaria** 1998 Nov 15;22(8):486–90 (Eng. Abstr.) **(Spa)**

[On "The national tuberculosis control program for Spain" (letter; comment)] Canueto Quintero J, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):597–9. Comment on: Med Clin (Barc) 1998 Jan 17;110(1):25–31. **(Spa)**

[Health promotion in schools (editorial)] Garcia Garcia I. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):285–7 **(Spa)**

[Popular education and child nutrition: experience with women in a rural area of Mexico] Arenas-Monreal L, et al. **Rev Saude Publica** 1999 Apr;33(2):113–21 (Eng. Abstr.) **(Spa)**

[A new strategy in the fight against HIV/AIDS is needed. Inaccurate information is a waste of both money and energy (see comments)] Christenson B, et al. **Lakartidningen** 1998 Nov 18;95(47):5300–2. Comment in: Lakartidningen 1998 Dec 16;95(51–52):5863–4. **(Swe)**

ECONOMICS

Health risk influence on medical care costs and utilization among 2,898 municipal employees. Weaver MT, et al. **Am J Prev Med** 1998 Oct;15(3):250–3

Obtaining resources for evidence-based public health initiatives at the local level: insights from the Central Sydney Tobacco Control Plan. Rissel C, et al. **Aust N Z J Public Health** 1999 Feb;23(1):56–60

'Our healthier nation'? [editorial] Contoyannis P, et al. **Health Econ** 1999 Jun;8(4):289–96

The commercial sector: marketing diet and fitness responsibly. Conley R. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S55–8

The relationship between modifiable health risks and health care expenditures. An analysis of the multi-employer HERO health risk and cost database. The Health Enhancement Research Organization (HERO) Research Committee. Goetzel RZ, et al. **J Occup Environ Med** 1998 Oct;40(10):843–54

The hidden epidemic of cardiovascular disease [editorial] [see comments] **Lancet** 1998 Dec 5;352(9143):1795. Comment in: Lancet 1999 Feb 6;353(9151):503.

Cost-effectiveness of malaria control in sub-Saharan Africa. Goodman CA, et al. **Lancet** 1999 Jul 31;354(9176):378–85

Toward more healthful dietary patterns--a matter of policy [comment] Nestle M. **Public Health Rep** 1998 Sep–Oct; 113(5):420–3. Comment on: Public Health Rep 1998 Sep–Oct;113(5):410–9.

Monetary incentives: a useful strategy for enhancing enrollment and promoting participation in HIV/STD risk reduction interventions [editorial; comment] Diclemente R, et al. **Sex Transm Infect** 1998 Aug;74(4):239–40. Comment on: Sex Transm Infect 1998 Aug;74(4):253–55.

Smoking out the incentives for tobacco control in managed care settings. Warner KE. **Tob Control** 1998 Winter;7 Suppl:S50–4

[Basic principles of cost-benefit analysis in long-term treatment of risk factors] Szucs TD, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1958–64 (31 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

Why did the Nazis have the world's most aggressive anti-cancer campaign? Proctor RN. **Endeavour** 1999; 23(2):76–9

Stamps in cardiology. Antismoking campaigns. Davies MK, et al. **Heart** 1998 Jun;79(6):533

[Health Commission's activity and public health work in Skien and Langesund 1861–1900] Storesund A. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1106–11 (Eng. Abstr.) **(Nor)**

[Henryk Jordan (1842–1907)--a dedicated Krakow physician, health promotor and welfare worker] Kempa ME. **Przegl Lek** 1998;55(2):92–3 (Eng. Abstr.) **(Pol)**

[Diet in the Modern World: their relevance as a health conservation element] Gardeta P. **Rev Med Chil** 1998 Jul; 126(7):866–73 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Effects of enforcement of youth access laws on smoking prevalence. Jason LA, et al. **Am J Community Psychol** 1999 Apr;27(2):143–60

Older Americans Act: implications for nursing. Wallace DC, et al. **Nurs Outlook** 1999 Jul–Aug;47(4):181–5 (21 ref.)

Bridging from Jakarta. Nyamwaya D. **Promot Educ** 1998 Sep–Dec;5(3–4):11–2, 92, 120 **(Eng, Fre, Spa)**

Impediments to the enforcement of youth access laws. DiFranza JR, et al. **Tob Control** 1999 Summer;8(2):152–5

Improving the measurement and use of tobacco control "inputs" [editorial; comment] Wakefield MA, et al. **Tob Control** 1998 Winter;7(4):333–5. Comment on: Tob Control 1998 Winter;7(4):345–52.

An alternative tobacco control system [editorial; comment] Fagerström KO. **Wien Klin Wochenschr** 1998 Dec 11; 110(23):809–10. Comment on: Wien Klin Wochenschr 1998 Dec 11;110(23):811–6.

[Promotion and therapy of children with hearing loss (hearing aids)--statement of the DVfR Study Committee of Hearing, Voice and Speech Disorders] Salz W. **Rehabilitation (Stuttg)** 1999 May;38(2):136–40 **(Ger)**

[Health promotion and prevention in the Lucerne canton--1995 analysis and prospects] Mütsch M, et al. **Soz Praventivmed** 1998;43(5):247–53 (Eng. Abstr.) **(Ger)**

METHODS

Relationship of blood lead levels to personal hygiene habits in lead battery workers: Taiwan, 1991–1997. Chuang HY, et al. **Am J Ind Med** 1999 Jun;35(6):595–603

Promoting lifestyle changes. Lai SC, et al. **Am J Nurs** 1999 Apr;99(4):63–7

American College of Preventive Medicine practice policy. Tobacco-cessation patient counseling. Kattapong VJ, et al. **Am J Prev Med** 1998 Aug;15(2):160–2

A public health vs a risk-based intervention to improve cardiovascular health in elementary school children: the Cardiovascular Health in Children Study. Harrell JS, et al. **Am J Public Health** 1999 Oct;89(10):1529–35

Promoting the health and well-being of future generations [editorial] Schneider D, et al. **Am J Public Health** 1999 Feb;89(2):155–7 (34 ref.)

Another perspective for disease prevention interventions [letter] Winett R. **Am J Public Health** 1999 Oct; 89(10):1593–4

Understanding and promoting sexual and reproductive health behavior: theory and method. Fisher WA, et al. **Annu Rev Sex Res** 1998;9:39–76 (138 ref.)

The control of press cleaning solvent vapors in a small lithographic printing establishment. Crouch KG, et al. **Appl Occup Environ Hyg** 1999 May;14(5):329–38

Impact of a school-based interdisciplinary intervention on diet and physical activity among urban primary school children: eat well and keep moving. Gortmaker SL, et al. **Arch Pediatr Adolesc Med** 1999 Sep;153(9):975–83

Presenting the facts about smoking to adolescents: effects of an autonomy-supportive style. Williams GC, et al. **Arch Pediatr Adolesc Med** 1999 Sep;153(9):959–64

Barriers to Pacific women's use of cervical screening services. Jameson A, et al. **Aust N Z J Public Health** 1999 Feb; 23(1):89–92

A strategy for involving general practitioners in smoking control. Mullins R, et al. **Aust N Z J Public Health** 1999 Jun;23(3):249–51

Divisions of population health: quantum leap forward or rearranging the deckchairs? Sainsbury P. **Aust N Z J Public Health** 1999 Apr;23(2):119–25 (30 ref.)

Evaluation of doctors' reminders in emergency departments

to encourage cervical screening. Ward JE, et al. **Aust N Z J Public Health** 1999 Feb;23(1):95–8

Disability in older adults. 2: Physical activity as prevention. Carlson JE, et al. **Behav Med** 1999 Winter;24(4):157–68 (78 ref.)

Scare tactics cut smoking rates in Australia to all time low [news] Chapman S. **BMJ** 1999 Jun 5;318(7197):1508

Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial [see comments] Feder G, et al. **BMJ** 1999 Jun 5;318(7197):1522–6. Comment in: BMJ 1999 Jun 5;318(7197):1499–500.

The International Labour Organization and the health of seafarers and fishermen. **Bull Inst Marit Trop Med Gdynia** 1998;49(1–4):33–44

Active ageing makes the difference [editorial] Kalache A. **Bull World Health Organ** 1999;77(4):299

Strategies for osteoporosis treatment [comment] Kanis J. **Bull World Health Organ** 1999;77(5):431–2. Comment on: Bull World Health Organ 1999 ;77(5):416–22.

Preventing pneumococcal disease: a Canadian consensus conference. 16–18 February 1998. **Can Commun Dis Rep** 1999 Feb 15;25(4):25–35 (0 ref.) **(Eng, Fre)**

Complementary development of prevention and mental health promotion programs for Canadian children based on contemporary scientific paradigms. Breton JJ. **Can J Psychiatry** 1999 Apr;44(3):227–34 (76 ref.)

Before early childhood: prenatal influences, risks and opportunities [editorial] Muhajarine N. **Can J Public Health** 1999 Jul–Aug;90(4):221–3, 228 **(Eng, Fre)**

Communication courses in Canadian graduate programs in health promotion. Yessis J, et al. **Can J Public Health** 1999 May–Jun;90(3):214–5

Using participatory research to help promote the physical and mental health of female social workers in child welfare. Gold N. **Child Welfare** 1998 Nov–Dec;77(6):701–24

Royal College debates whether MDs should promote moderate consumption of alcohol [published erratum appears in CMAJ 1999 Jan 12;160(1):27] Harrison P. **CMAJ** 1998 Nov 17;159(10):1289–90

Effect of multiple patient reminders in improving diabetic retinopathy screening. A randomized trial. Halbert RJ, et al. **Diabetes Care** 1999 May;22(5):752–5

A procedure to determine the individually comfortable position of visual displays relative to the eyes. Jaschinski W, et al. **Ergonomics** 1999 Apr;42(4):535–49

What can we generalize from research on patient education and clinical health promotion to physician counseling on diet? Green LW. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S9–18 (92 ref.)

Strength and weakness of a nutrition communication strategy to health opinion formers: examples from a case study. Hølund U. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S54–7

A four week residential program for primary health care patients to control obesity and related heart risk factors: effective application of principles of learning and lifestyle change. Sjöström M, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S72–7

Personal responsibility for health? A review of the arguments and the evidence at century's end. Minkler M. **Health Educ Behav** 1999 Feb;26(1):121–40 (118 ref.)

Wellness self-care by healthy older adults. Clark CC. **Image J Nurs Sch** 1998;30(4):351–5

Historic and future health promotion contexts for nursing. Morgan IS, et al. **Image J Nurs Sch** 1998;30(4):379–83 (43 ref.)

Ergonomic strategies for improving working conditions in some developing countries in Asia. Kawakami T, et al. **Ind Health** 1999 Apr;37(2):187–98 (33 ref.)

Healthy child contests: making them more objective [letter] Prajapati NC. **Indian Pediatr** 1998 Nov;35(11):1142

Bicycle helmet promotion among low income preschool children. Britt J, et al. **Inj Prev** 1998 Dec;4(4):280–3

New approaches to smoking prevention in the north. Alekseeva NV, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:489–92

Communication about health and the risk effect of eating traditional food. Mulvad G, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:222–4

Health promotion partnerships: service and education addressing the health needs of vulnerable groups. Pflaum J, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:91–5

National campaigns to promote physical activity: can they make a difference? Cavill N. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S48–51

ICN on healthy ageing: a public health and nursing challenge. **Int Nurs Rev** 1999 Mar–Apr;46(2):60–1

Peer support and young people's health. Turner G. **J Adolesc** 1999 Aug;22(4):567–72

Lifestyle practices and the health promoting environment of hospital nurses. Hope A, et al. **J Adv Nurs** 1998 Aug; 28(2):438–47

Health promotion and health education: what role should the nurse adopt in practice? Norton L. **J Adv Nurs** 1998 Dec;28(6):1269–75 (32 ref.)

Hunger strikes: preventing harm to students [see comments] Dixon WC. **J Am Coll Health** 1999 Sep;48(2):87–90. Comment in: J Am Coll Health 1999 Sep;48(2):51–4.

Smoking among students: new pathways to prevention [editorial; comment] Keeling RP. **J Am Coll Health** 1999 Sep;48(2):51–4. Comment on: J Am Coll Health 1999 Sep;48(2):61–6. Comment on: J Am Coll Health 1999 Sep;48(2):67–71. Comment on: J Am Coll Health 1999 Sep;48(2):87–90. Comment on: J Am Coll Health 1999 Sep;48(2):93–5.

Using 3 data sources and methods to shape a nutrition campaign. Goldberg J, et al. **J Am Diet Assoc** 1999 Jun; 99(6):717–22; quiz 723–4, 776

Smoking initiation and escalation in early adolescent girls: one-year follow-up of a school-based prevention intervention for minority youth. Botvin GJ, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):139–43, 152

Four legs or two: up front with you--preventing tragedies by keeping children and pets out of the cargo areas of pickup trucks. McHugh EJ. **J Am Vet Med Assoc** 1999 Aug 1;215(3):332–4

Pretesting Spanish-language educational radio messages to promote timely and complete infant immunization in California. de Nuncio ML, et al. **J Community Health** 1999 Aug;24(4):269–84

Periconceptional folic acid in The Netherlands in 1995. Socioeconomic differences. de Walle HE, et al. **J Epidemiol Community Health** 1998 Dec;52(12):826–7

A survey of African Americans at a community health fair. Brown CM, et al. **J Health Care Poor Underserved** 1998 Nov;9(4):357–66

"Healthometer"--an instrument for self-distributed health screening and prevention in the population. Spång L, et al. **J Med Syst** 1998 Oct;22(5):339–55

The Working Healthy Project: a worksite health-promotion trial targeting physical activity, diet, and smoking. Emmons KM, et al. **J Occup Environ Med** 1999 Jul;41(7):545–55

Managing job strain: a randomized, controlled trial of an intervention conducted by mail and telephone. Pelletier KR, et al. **J Occup Environ Med** 1999 Apr;41(4):216–23

Nursing's role in NetWellness: a children and adolescent health information resource via the Web. Hern MJ, et al. **J Pediatr Nurs** 1999 Aug;14(4):222–30

Postscript: where do we go from here? Sloboda Z, et al. **J Psychoactive Drugs** 1998 Jul–Sep;30(3):307–14

Health promoting schools in England--a way forward in development. Denman S. **J Public Health Med** 1999 Jun; 21(2):215–20

Towards a secure evidence base for health promotion. Green J, et al. **J Public Health Med** 1999 Jun;21(2):133–9

Short-term impact of safer choices: a multicomponent, school-based HIV, other STD, and pregnancy prevention program. Coyle K, et al. **J Sch Health** 1999 May; 69(5):181–8

Preventing disease with stress management in elementary schools. Dombrowski MA. **J Sch Health** 1999 Mar; 69(3):126–7

Asset building: rhetoric versus reality--a cautionary note [letter] Price JH, et al. **J Sch Health** 1999 Aug;69(6):215–6

Building developmental assets: response to Price and Drake. Scales PC. **J Sch Health** 1999 Aug;69(6):217–8

Reducing risks and building developmental assets: essential actions for promoting adolescent health. Scales PC. **J Sch Health** 1999 Mar;69(3):113–9 (16 ref.)

Using puppetry in a coordinated school health program. Synovitz LB. **J Sch Health** 1999 Apr;69(4):145–7 (46 ref.)

Long-term effects of a community-wide alcohol server training intervention. Buka SL, et al. **J Stud Alcohol** 1999 Jan;60(1):27–36

Observations from the CDC: using health communications research to reduce birth defects. Daniel KL. **J Womens Health** 1999 Jan–Feb;8(1):19–22

Breastfeeding and maternal employment [letter; comment] [see comments] Knopf JH. **Lancet** 1998 Nov 21; 352(9141):1704. Comment on: Lancet 1998 Oct 3;352(9134)1083–4. Comment in: Lancet 1998 Dec 12;352(9144):1936.

Efficacy of home-based peer counselling to promote exclusive breastfeeding: a randomised controlled trial [see comments] Morrow AL, et al. **Lancet** 1999 Apr 10; 353(9160):1226–31. Comment in: Lancet 1999 Jul 10;354(9173):161–2.

Prevention: are we really reaching today's teens? Muscari ME. **MCN Am J Matern Child Nurs** 1999 Mar–Apr; 24(2):87–91 (7 ref.)

Skin cancer detection and prevention: a community program promoting sun safe behaviors. Rusonis ES, et al. **Md Med J** 1999 Jul–Aug;48(4):169–72

Health promotion projects: skill and attitude learning for medical students. Jones KV, et al. **Med Educ** 1999 Aug; 33(8):585–91

Providing culturally competent care: is there a role for health promoters? Poss JE. **Nurs Outlook** 1999 Jan–Feb;47(1):30–6 (54 ref.)

A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Rodewald LE, et al. **Pediatrics** 1999 Jan;103(1):31–8

A message from Preventive Medicine and your physician. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):657

Cancer information service-initiated outcalls to promote screening mammography among low-income and minority women: design and feasibility testing. Crane LA, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 2):S29–38

Effectiveness of a telephone outcall intervention to promote screening mammography among low-income women. Crane LA, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 2):S39–49

Promoting cancer screening among the first-degree relatives of breast and colorectal cancer patients: the design of two randomized trials. Marcus AC, et al. **Prev Med** 1999 Mar; 28(3):229–42

Direct measurement of sun protection in primary schools. Milne E, et al. **Prev Med** 1999 Jul;29(1):45–52

A preventive intervention program in adolescent schoolgirls: a longitudinal study. Santonastaso P, et al. **Psychother Psychosom** 1999;68(1):46–50

The effectiveness of health promotion counseling to family caregivers. Chen MY. **Public Health Nurs** 1999 Apr; 16(2):125–32

Fear, threat, and perceptions of efficacy from frightening skin cancer messages. Stephenson MT, et al. **Public Health Rev** 1998;26(2):147–74

Pre-test counselling for HIV--short and friendly please [letter] Mankazana M. **S Afr Med J** 1999 Jan;89(1):11–2

Helminth control as an entry point for health-promoting schools in KwaZulu-Natal. Taylor M, et al. **S Afr Med J** 1999 Mar;89(3):273–9

Emphasizing and promoting overall health and nontraditional treatments after a prostate cancer diagnosis. Moyad MA. **Semin Urol Oncol** 1999 May;17(2):119–24 (95 ref.)

Behavioural intervention trials for HIV/STD prevention in schools: are they feasible? Stephenson JM, et al. **Sex Transm Infect** 1998 Dec;74(6):405–8

Issues in promoting health. Mechanic D. **Soc Sci Med** 1999 Mar;48(6):711–8 (49 ref.)

Adolescent suicide prevention: acceptability of school-based programs among secondary school principals. Miller DN, et al. **Suicide Life Threat Behav** 1999 Spring;29(1):72–85

Impact of a gallery of posters on quitting smoking. Sansores RH, et al. **Tob Control** 1998 Winter;7(4):338–9

Maintenance of cardiovascular risk factor changes among middle-aged women in a lifestyle intervention trial. Simkin-Silverman LR, et al. **Womens Health** 1998 Fall; 4(3):255–71

Use of the transtheoretical model for behavioral change in women's health. Peipert JF, et al. **Womens Health Issues** 1998 Sep–Oct;8(5):304–9

[One year of Dutch Organ Donation Law) Schnabel P. **Ned Tijdschr Geneeskd** 1999 Mar 20;143(12):600–1 (Eng. Abstr.) **(Dut)**

[Obesity (letter; comment)] Stork J. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2374. Comment on: Ned Tijdschr Geneeskd 1998 Sep 5;142(36):1982–9. Comment on: Ned Tijdschr Geneeskd 1998 Sep 5;142(36):1989–95. **(Dut)**

[The SGO Health Research Promotion Program. XIV. Final evaluation] van Rees-Wortelboer MM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):41–5 (Eng. Abstr.) **(Dut)**

[How to prevent post-traumatic stress disorder before traumatization occurs?] Melançon G, et al. **Can J Psychiatry** 1999 Apr;44(3):253–8 (50 ref.) (Eng. Abstr.) **(Fre)**

[Public health professionals' perceptions regarding two dimensions of health promotion: the ecological approach and community participation] Richard L, et al. **Can J Public Health** 1999 Mar–Apr;90(2):99–103 (Eng. Abstr.) **(Fre)**

[Regional campaign promoting the use of sodium iodide: "a pinch of health"] Moscatelli R, et al. **Ann Ist Super Sanita** 1998;34(3):393–4 (Eng. Abstr.) **(Ita)**

[Results of cervix neoplasm prophylaxis in women examined during the health promotion program in the Central Railway Hospital] Ceran A, et al. **Przegl Lek** 1999; 56(1):45–7 (Eng. Abstr.) **(Pol)**

[Mass health-promotion measures among children's contingents in helminthiasis foci in the populated territories of the North in Khabarovsk Territory] Liberova RN, et al. **Med Parazitol (Mosk)** 1998 Jul–Sep;(3):46–8 **(Rus)**

[Experience in the health promotion of children in opisthorchiasis foci] Mikhailov MM, et al. **Med Parazitol (Mosk)** 1998 Jul–Sep;(3):49–51 **(Rus)**

[A comprehensive approach to health preservation] **Voen Med Zh** 1998 Dec;319(12):19–21 **(Rus)**

[Work experience in promoting the health of young recruits in a military district] Vorontsov AF, et al. **Voen Med Zh** 1998 Sep;319(9):17–20 **(Rus)**

[The promotion of adolescent health from a health center (letter) (published erratum appears in An Esp Pediatr 1998 Oct;49(4):440)] Ruiz-Lazaro PJ, et al. **An Esp Pediatr** 1998 Sep;49(3):329–30 **(Spa)**

[The health-promoting effect of physical exercises in the work of schoolchildren at computers] Aleksandrova MS. **Lik Sprava** 1998 Dec;(8):53–5 (Eng. Abstr.) **(Ukr)**

[The current health status of the adolescents and young people of Ukraine and the measures for its maintenance and improvement] Nahorna AM, et al. **Lik Sprava** 1998 Oct–Nov;(7):177–81 **(Ukr)**

ORGANIZATION & ADMINISTRATION

A health promotion intervention for families in a Medicaid managed care plan. Chande VT, et al. **Acad Emerg Med** 1999 Aug;6(8):823–7

Conversion with R. J. Hawke [interview] Hawke RJ. **Addiction** 1998 Dec;93(12):1761–3

Alcohol-related harm and alcohol consumption in Moscow before, during and after a major anti-alcohol campaign. Nemtsov AV. **Addiction** 1998 Oct;93(10):1501–10

A multidimensional evaluation of fire fighter training for

hazardous materials response: first results from the IAFF Program. Cohen A. **Am J Ind Med** 1998 Oct;34(4):331–41 (12 ref.)

Cancer prevention in rural primary care. An academic–practice partnership. Greene PG, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):58–62

Fruit and vegetable consumption and prevention of cancer: the Black Churches United for Better Health project. Campbell MK, et al. **Am J Public Health** 1999 Sep; 89(9):1390–6

Neighbors for a smoke free north side: evaluation of a community organization approach to promoting smoking cessation among African Americans. Fisher EB, et al. **Am J Public Health** 1998 Nov;88(11):1658–63

Countering pro-tobacco influences at the racetrack. Olson CK. **Am J Public Health** 1999 Sep;89(9):1431–2

Breast-feeding initiation in New York City, 1979 to 1996. Rosenberg KD, et al. **Am J Public Health** 1998 Dec; 88(12):1850–2

The effects of a health promotion–health protection intervention on behavior change: the WellWorks Study. Sorensen G, et al. **Am J Public Health** 1998 Nov; 88(11):1685–90

Health promoting schools: issues and future directions for Australia and the Asia Pacific Region. Rowling L, et al. **Asia Pac J Public Health** 1996–97;9:33–7 (41 ref.)

Planning for better health outcomes requires indigenous perspective [editorial] Angus S, et al. **Aust N Z J Public Health** 1998 Oct;22(6):636–7

The dissemination of a smoking cessation program to 23 antenatal clinics: the predictors of initial program adoption by managers. Cooke M, et al. **Aust N Z J Public Health** 1999 Feb;23(1):99–103

Commitment to improving indigenous health [editorial] Leeder SR. **Aust N Z J Public Health** 1998 Oct;22(6):635–6

European observatory will promote better health policy 165 [news] **BMJ** 1999 Feb 6;318(7180):352

Effects of the Heartbeat Wales programme. Programme that originated in Finland should be adopted [letter; comment] Capewell S, et al. **BMJ** 1999 Apr 17;318(7190):1072–3. Comment on: BMJ 1998 Sep 26;317(7162):886.

"Healthy people 2010": national health objectives for the United States. Davis RM. **BMJ** 1998 Nov 28; 317(7171):1513–7

Breast feeding: the baby friendly initiative. In Sri Lanka only quarter of babies under 4 months are exclusively breast fed [letter; comment] [see comments] Gunasekera DP, et al. **BMJ** 1998 Nov 14;317(7169):1386. Comment on: BMJ 1998 May 23;316(7144):1548–9. Comment in: BMJ 1999 Apr 24;318(7191):1140.

Safer sex at holiday centres: providing contraceptive services to seasonal workers. Hennink M, et al. **Br J Fam Plann** 1999 Jul;25(2):45–54

Our Healthier Nation: are general practitioners willing and able to deliver? A survey of attitudes to and involvement in health promotion and lifestyle counselling. McAvoy BR, et al. **Br J Gen Pract** 1999 Mar;49(440):187–90

Reducing osteoporosis: prevention during childhood and adolescence [comment] Mark S, et al. **Bull World Health Organ** 1999;77(5):423–4. Comment on: Bull World Health Organ 1999 ;77(5):416–22.

How many visits by health professionals are needed to make a difference in low birthweight? A dose-response study of the Toronto Healthiest Babies Possible program. Desjardins E, et al. **Can J Public Health** 1999 Jul–Aug; 90(4):224–8

Population health: determinants and interventions [editorial] Edwards N. **Can J Public Health** 1999 Jan–Feb;90(1):10–1 **(Eng, Fre)**

Heart health promotion: predisposition, capacity and implementation in Ontario Public Health Units, 1994–96. Taylor SM, et al. **Can J Public Health** 1998 Nov–Dec; 89(6):410–4

Community-based heart health promotion: perceptions of facilitators and barriers. Taylor SM, et al. **Can J Public Health** 1998 Nov–Dec;89(6):406–9

Primary health care in the eastern Mediterranean region before and after Alma-Ata. Abdullatif AA. **East Mediterr Health J** 1998;4 Suppl:S85–102 (18 ref.)

Cultural sensitivity in public health: defined and demystified. Resnicow K, et al. **Ethn Dis** 1999 Winter;9(1):10–21 (98 ref.)

Collaborative research to prevent HIV among male prison inmates and their female partners. Grinstead OA, et al. **Health Educ Behav** 1999 Apr;26(2):225–38

Do processes of change predict smoking stage movements? A prospective analysis of the transtheoretical model. Herzog TA, et al. **Health Psychol** 1999 Jul;18(4):369–75

Correlates of physical activity in a national sample of girls and boys in grades 4 through 12. Sallis JF, et al. **Health Psychol** 1999 Jul;18(4):410–5

Affinity groups. Senior savvy is the first step. Babwin D. **Hosp Health Netw** 1998 Sep 20;72(18):44, 46

"First aid for scalds" campaign: reaching Sydney's Chinese, Vietnamese, and Arabic speaking communities. King L, et al. **Inj Prev** 1999 Jun;5(2):104–8

An intervention to reduce playground equipment hazards. Roseveare CA, et al. **Inj Prev** 1999 Jun;5(2):124–8

Address by the president of the Inuit Circumpolar Conference. Kuptana R. **Int J Circumpolar Health** 1998;57 Suppl 1:6–9

Controlling tobacco use within prisons [letter] Awofeso N. **Int J Tuberc Lung Dis** 1999 Jun;3(6):547–8 (9 ref.)

HIV/AIDS: a South African perspective. Nzimande PN. **Int Nurs Rev** 1998 Nov–Dec;45(6):162

Tacit knowledge. Chambers DW. **J Am Coll Dent** 1998 Fall; 65(3):44–7

Call 1-888-NOT-2-LATE: promoting emergency contraception in the United States. Trussell J, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):247–50

The challenges of employing performance monitoring in public health community-based efforts: a case study. Payne CA. **J Community Health** 1999 Apr;24(2):159–70

A trial to increase mammography utilization among Los Angeles Hispanic women. Fox SA, et al. **J Health Care Poor Underserved** 1998 Aug;9(3):309–21

A project to reduce the burden of diabetes in the African-American Community: Project DIRECT. Engelgau MM, et al. **J Natl Med Assoc** 1998 Oct; 90(10):605–13

Preventing adverse outcomes: a population focus. Ervin NE, et al. **J Nurs Care Qual** 1999 Aug;13(6):25–31

Efforts of health promotion teams to improve the psychosocial work environment. Elo AL, et al. **J Occup Health Psychol** 1999 Apr;4(2):87–94

The submission from The Royal Society for the Promotion of Health on Government consultation document "Our Healthier Nation". **J R Soc Health** 1998 Aug;118(4):241–2

Health promotion in a hospital ward; reality or asking the impossible? Coakley AL. **J R Soc Health** 1998 Aug; 118(4):217–20 (25 ref.)

Promoting holistic child development: a collaborative school health approach. Haynes NM. **J Sch Health** 1998 Nov; 68(9):381–3 (9 ref.)

Lessons learned from the Hunter Region Health Promoting Schools Project in New South Wales, Australia. Lynagh M, et al. **J Sch Health** 1999 Aug;69(6):227–32

Encouraging schools to promote health: impact of the Western Australian School Health Project (1992–1995). McBride N, et al. **J Sch Health** 1999 Aug;69(6):220–6

Managed care, school health programs, and adolescent health services: opportunities for health promotion. Santelli J, et al. **J Sch Health** 1998 Dec;68(10):434–40 (46 ref.)

Establishing networks for health promoting schools in South Africa. Swart D, et al. **J Sch Health** 1999 Feb;69(2):47–50

Photovoice: a participatory action research strategy applied to women's health. Wang CC. **J Womens Health** 1999 Mar; 8(2):185–92

Editorials, September 1997 by W. C. S. Smith, P. Fine & D. K. Warndorff [letter; comment] Revankar CR. **Lepr Rev** 1998 Sep;69(3):305. Comment on: Lepr Rev 1997 Sep;68(3):195–200. Comment on: Lepr Rev 1997 Sep;68(3):201–2.

Improving world health—Australia's focus on the Pacific [editorial] [see comments] Theile DE. **Med J Aust** 1999 Apr 5;170(7):295–6. Comment in: Med J Aust 1999 Jul 5;171(1):56.

Information system for a periodic examination and health promotion center. Cho B, et al. **Medinfo** 1998;9 Pt 2:977–80

Models of intervention in menopause: proposal of a holistic or integral model. Olazábal Ulacia JC, et al. **Menopause** 1999 Fall;6(3):264–72 (50 ref.)

The Tripler LE3AN Program: a two-year follow-up report. James LC, et al. **Mil Med** 1999 Jun;164(6):389–95

A conceptual overview of a proactive health psychology service: the Tripler Health Psychology Model. James LC, et al. **Mil Med** 1999 Jun;164(6):396–400

Wellness intervention with pregnant soldiers. Lombardi W, et al. **Mil Med** 1999 Jan;164(1):22–9

Association of Women's Health, Obstetric and Neonatal Nurses' Health for Women and Newborns Program. **Nurs Outlook** 1999 Jan–Feb;47(1):37–8

Developing health promoting practices: a transformative process. Hartrick G. **Nurs Outlook** 1998 Sep–Oct; 46(5):219–25

American Academy of Nursing's Women's Health Expert Panel Recommendations for Women's Health and Women's Health Care [letter] Thomas KK. **Nurs Outlook** 1999 Jan–Feb;47(1):43

Are your workers protected to deaf? Klane J. **Occup Health Saf** 1998 Oct;67(10):90–4, 96

Global protection. Koppel W, et al. **Occup Health Saf** 1998 Oct;67(10):182–4

Drugs in the workplace. Rhodes D. **Occup Health Saf** 1998 Oct;67(10):136–8

Up on the roof. Sandow K. **Occup Health Saf** 1998 Oct; 67(10):170–1

A strategic approach to occupational injuries. Comstock ML. **Occup Med** 1998 Oct–Dec;13(4):823–40, v (23 ref.)

Prevention of work-related disability. Feldstein A, et al. **Occup Med** 1998 Oct–Dec;13(4):841–50, v (13 ref.)

A health promotion programme for oil refinery employees: changes of health promotion needs observed at three years. Talvi AI, et al. **Occup Med (Lond)** 1999 Feb;49(2):93–101

Why do child cyclists in the United States remain unhelmeted? Bergman AB, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):107–9

Health promotion for people with disabilities: the emerging paradigm shift from disability prevention to prevention of secondary conditions. Rimmer JH. **Phys Ther** 1999 May; 79(5):495–502 (39 ref.)

Closing the condom gap. **Popul Rep H** 1999 Apr;(9):1–35

Rationale for tobacco cessation interventions for youth. Lamkin L, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 3):A3–8

Correlates of the sustainability of community-based heart health promotion interventions. O'Loughlin J, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):702–12

Durability and diffusion of the nutrition intervention in the Working Well Trial. Patterson RE, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):668–73

Hygeia in a sea of Asclepiuses. Health promotion and education through a patient's eyes. Butler KL. **Promot Educ** 1999 Mar;6(1):14–7

Mobilising business through "partnerships for health promotion". New challenges and new opportunities. Davies R. **Promot Educ** 1999 Mar;6(1):21–4, 37

Perceived ownership in a community coalition. Armbruster C, et al. **Public Health Nurs** 1999 Feb;16(1):17–22

A comparison of urban versus rural experiences of nurses volunteering to promote health in churches. Chase-Ziolek M, et al. **Public Health Nurs** 1999 Aug;16(4):270–9

Community health nursing practice and the Roy Adaptation Model. Dixon EL. **Public Health Nurs** 1999 Aug; 16(4):290–300 (35 ref.)

Public health nursing in Japan: new opportunities for health promotion. Murashima S, et al. **Public Health Nurs** 1999 Apr;16(2):133–9 (16 ref.)

From rhetoric to reality: the changing face of public health nursing in southern Ontario. Rafael AR. **Public Health Nurs** 1999 Feb;16(1):50–9

"God brought all these churches together": issues in developing religion-health partnerships in an Appalachian community. Simpson MR, et al. **Public Health Nurs** 1999 Feb;16(1):41–9

Vitamin A deficiency in Bangladesh: a review and recommendations for improvement. Ahmed F. **Public Health Nutr** 1999 Mar;2(1):1–14 (58 ref.)

Building the next generation of healthy people. Richmond JB. **Public Health Rep** 1999 May–Jun;114(3):212–7

Role of the SEAMEO TROPMED Network in health human resources development. Southeast Asian Ministers of Education Organization. Tropical Medicine and Public Health. Chongsuphajaisiddhi T, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):299–310

Building effective strategies to decrease tobacco use in a health maintenance organisation: Group Health Cooperative of Puget Sound. Curry SJ. **Tob Control** 1998 Winter;7 Suppl:S21–3; discussion S24–5

Osteoporosis a critical problem in West Virginia. Smith K. **W V Med J** 1999 May–Jun;95(3):142

Health promotion in the workplace. Fedotov IA. **World Health Forum** 1998;19(4):390–6

A prelude to health for all. Pinder L, et al. **World Health Forum** 1998;19(3):235–8

From general hospital to Baby-Friendly hospital [letter] Satpathy R, et al. **World Health Forum** 1998;19(4):433–4

Programming for adolescent health and development. Report of a WHO/UNFPA/UNICEF Study Group on Programming for Adolescent Health. **World Health Organ Tech Rep Ser** 1999;886:i–vi, 1–260

[Structuring action from using a model for planning health promotion programs] Proulx M, et al. **Can J Public Health** 1999 Jan–Feb;90(1):23–6 (Eng. Abstr.) **(Fre)**

[Promoting health in health care organizations and hospitals? A survey of the French community in Belgium] Deccache A, et al. **Promot Educ** 1999 Mar;6(1):31–5, 25 (Eng. Abstr.) **(Fre)**

[Contribution of the work inspector physician to the protection of workers' health in the Neuchatel and Geneva cantons] Conne-Perréard E, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):559–63 **(Fre)**

[Health status of the populations of the Jura and Neuchatel cantons: evaluation and recommendations for prevention and health promotion] Graz B, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):657–60 (Eng. Abstr.) **(Fre)**

[Physicians' role in prevention and health promotion policy: canton reports on health status] Raynault MF, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):653–6 (Eng. Abstr.) **(Fre)**

[A cardiovascular health promotion program for 9–12 year old children and the community of Saint-Louis du Parc/Quebec] Renaud L, et al. **Sante Publique** 1998 Dec; 10(4):425–45 (Eng. Abstr.) **(Fre)**

[Evaluation of a community-oriented health promotion project "Mauren Aktiv"] Batliner B. **Soz Praventivmed** 1998; 43(5):262–8 (Eng. Abstr.) **(Ger)**

[The organizational status and tasks of sanatorium-health resort treatment and health promotion for children suffering as a result of the Chernobyl catastrophe] Drinevskii NP, et al. **Lik Sprava** 1998 Jul–Aug;(5):57–60 (Eng. Abstr.) **(Rus)**

STANDARDS

Prevention of disturbed eating behaviour: a prospective intervention study in 14- to 19-year-old Swiss students. Buddeberg-Fischer B, et al. **Acta Psychiatr Scand** 1998 Aug;98(2):146–55

"Ready to quit chew? " Smokeless tobacco cessation in rural Nebraska. Boyle RG, et al. **Addict Behav** 1999 Mar–Apr; 24(2):293–7

American College of Preventive Medicine public policy statement. Folic acid fortification of grain products in the U.S. to prevent neural tube defects. Bentley JR, et al.

HEALTH PROMOTION

Am J Prev Med 1999 Apr;16(3):264–7 (40 ref.)

Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Glasgow RE, et al. **Am J Public Health** 1999 Sep;89(9):1322–7 (88 ref.)

Emerging tobacco hazards in China. Double standards apply with importation of tobacco into developing countries [letter; comment] Lhatoo Y. **BMJ** 1999 Jun 5; 318(7197):1555. Comment on: BMJ 1998 Nov 21;317(7170):1411–22. Comment on: BMJ 1998 Nov 21;317(7170):1423–4.

Young people's health. What do teenagers want from their family doctors? [editorial] Herbert CP.
Can Fam Physician 1998 Nov;44:2349–51, 2361–3
(Eng, Fre)

Setting health standards for the 21st century. Halperin JA. **J Am Pharm Assoc (Wash)** 1998 Nov-Dec;38(6):762–6

DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. Charnock D, et al. **J Epidemiol Community Health** 1999 Feb;53(2):105–11

Generalizability theory: a unified approach to assessing the dependability (reliability) of measurements in the health sciences. VanLeeuwen DM, et al. **J Outcome Meas** 1998; 2(4):302–25

Policy statement on breastfeeding. The Australian College of Paediatrics. **J Paediatr Child Health** 1998 Oct; 34(5):412–3

The paucity of effects in community trials: is secular trend the culprit? Bauman KE, et al. **Prev Med** 1999 Apr; 28(4):426–9

Counseling youth in tobacco-use prevention: determinants of clinician compliance. Russos S, et al. **Prev Med** 1999 Jul;29(1):13–21

Health Promotion and Education [editorial] Blount HL.
Promot Educ 1998 Sep-Dec;5(3–4):4, 88, 116
(Eng, Fre, Spa)

New horizons in health--from vision to practice. Hagard S. **Promot Educ** 1998 Sep-Dec;5(3–4):5–6, 89, 117
(Eng, Fre, Spa)

Health promotion--are our health professionals well prepared? [letter] Setswe G. **S Afr Med J** 1999 May; 89(5):500

STATISTICS & NUMERICAL DATA

A comparison of demographic characteristics of selected year 2000 health objectives for the United States, using behavioral risk factor surveillance system data for Alaska. Ingle DE, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:652–5

Health-enhancing behaviors correlated with breastfeeding among a national sample of mothers. Pesa JA, et al.
Public Health Nurs 1999 Apr;16(2):120–4

Public awareness and attitudes towards epilepsy in the United Arab Emirates. Bener A, et al. **Seizure** 1998 Jun;7(3):219–22

Improving the measurement and use of tobacco control "inputs" [editorial; comment] Wakefield MA, et al.
Tob Control 1998 Winter;7(4):333–5. Comment on: Tob Control 1998 Winter;7(4):345–52.

TRENDS

Intervention mapping and the new health promotion [comment] Heaney CA. **Health Educ Behav** 1998 Oct; 25(5):564–8; discussion 569–70. Comment on: Health Educ Behav 1998 Oct;25(5):545–63.

Historic and future health promotion contexts for nursing. Morgan IS, et al. **Image J Nurs Sch** 1998;30(4):379–83 (43 ref.)

ICN on healthy ageing: a public health and nursing challenge.
Int Nurs Rev 1999 Mar-Apr;46(2):60–1

The power of prevention [editorial] Howell JB.
J Am Acad Dermatol 1999 Apr;40(4):623–5

Emerging concepts of health and health promotion. Raphael D. **J Sch Health** 1998 Sep;68(7):297–300

Brundtland sets out the challenges for WHO [news] McGregor A. **Lancet** 1999 May 22;353(9166):1774

A community approach to prenatal care. Yawn B.
Minn Med 1998 Dec;81(12):41–2

A pill for all by the year 2000? Barrett-Connor E.
Prev Med 1999 Jun;28(6):600–7

New horizons in health. Arroyo H. **Promot Educ** 1998 Sep-Dec;5(3–4):3–4, 87–8, 115–6 **(Eng, Fre, Spa)**

New horizons in health--from vision to practice. Hagard S. **Promot Educ** 1998 Sep-Dec;5(3–4):5–6, 89, 117
(Eng, Fre, Spa)

The power of partnership in health promotion. O'Byrne D. **Promot Educ** 1998 Sep-Dec;5(3–4):7–8, 90, 118
(Eng, Fre, Spa)

IOM on core functions [letter] Shine KI, et al.
Public Health Rep 1999 Jan-Feb;114(1):6

[Program of action by the Swiss Foundation for Health Promotion/1998–2002] **Soz Praventivmed** 1998;43(5):207–12
(Ger, Fre)

[Health promotion and public health (editorial)] Ackermann-Liebrich U. **Soz Praventivmed** 1998; 43(5):205–6 **(Ger, Fre)**

[A quality culture for health promotion!] Ruckstuhl B, et al. **Soz Praventivmed** 1998;43(5):221–8 (Eng. Abstr.)
(Ger)

[Health promotion in the neighborhood--resources and needs of neighborhood groups and institutions] Tschumper A. **Soz Praventivmed** 1998;43(5):254–61 (Eng. Abstr.) **(Ger)**

[Sanology as a science] Apanasenko GL, et al.
Lik Sprava 1998 Aug;(6):3–6 (Eng. Abstr.) **(Rus)**

UTILIZATION

Missed opportunities for prevention in general internal medicine [see comments] Brull R, et al. **CMAJ** 1999 Apr 20;160(8):1137–40. Comment in: CMAJ 1999 Apr 20;160(8):1171–2. Comment in: CMAJ 1999 Jul 27;161(2):126. Comment in: CMAJ 1999 Jul 27;161(2):126–7.

Status of health promotion programme implementation in small-scale enterprises in Japan. Muto T, et al.
Occup Med (Lond) 1999 Feb;49(2):65–70

[Need adjustment of utilization of occupational health promotion for reducing back pain? Results of an employee survey of the metal industry (published erratum appears in Gesundheitswesen 1999 Jan;61(1):51)] Wanek V, et al. **Gesundheitswesen** 1998 Dec;60(12):729–37 (Eng. Abstr.)
(Ger)

[The users of centers for AIDS information and prevention in the Comunidad Valenciana, Spain: a study based on cluster analysis] González Aracil J, et al. **Gac Sanit** 1999 Mar-Apr;13(2):102–8 (Eng. Abstr.) **(Spa)**

HEALTH PSYCHOLOGY see **BEHAVIORAL MEDICINE**

HEALTH RECORDS, PERSONAL see **MEDICAL RECORDS**

HEALTH RESORTS

Investigation into the use of alcohol at thermal spas: can a spa represent a place for primary prevention? [letter] Caputo F, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5):1072–3

The efficacy of complementary medical treatments, as used by spas: a review of the evidence. Tabacchi MH.
Altern Ther Health Med 1998 Nov;Suppl:1–5 (120 ref.)

Balneotherapy for rheumatic diseases at the Dead Sea [letter; comment] Sukenik S. **Int J Dermatol** 1998 Sep;37(9):717–8 . Comment on: Int J Dermatol 1997 Jul;36(7):481–92.

[Music and medicine (editorial)] Keel HJ.
Schweiz Rundsch Med Prax 1999 May 20;88(21):935–6
(Ger)

[Virkersund Spa. Changes in patient admission and therapeutic outcome over the last 15 years] Nilsen KH. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2465–8 (Eng. Abstr.) **(Nor)**

[Some pharmacodynamic properties of the "Marysieńka" healing water from the Cieplice-Zdrój springs] Banaszkiewicz W, et al. **Rocz Panstw Zakl Hig** 1998; 49(2):213–8 (Eng. Abstr.) **(Pol)**

[The radon therapy: radon inhalation spa in Kowary] Peńsko J, et al. **Rocz Panstw Zakl Hig** 1998;49(2):189–98 (Eng. Abstr.) **(Pol)**

[The organizational status and tasks of sanatorium-health resort treatment and health promotion for children suffering as a result of the Chernobyl catastrophe] Drinevskii NP, et al. **Lik Sprava** 1998 Jul-Aug;(5):57–60 (Eng. Abstr.) **(Rus)**

[Central hemodynamics as dependent on the method of bicycle exercise in sanatorium patients who have had a myocardial infarct] Efremushkin GG, et al. **Ter Arkh** 1998; 70(8):37–41 (Eng. Abstr.) **(Rus)**

[Air baths in the treatment of hypertension at the sanatorium stage] Kremnev IuA, et al. **Voen Med Zh** 1999 May; 320(5):40–4 **(Rus)**

[Marketing and the distribution of passes to health resorts of the Ministry of Defense of the Russian Federation] Maev EZ, et al. **Voen Med Zh** 1999 Feb;320(2):8–12, 96 (Eng. Abstr.) **(Rus)**

[The methodological and organizational aspects of selecting patients for sanatorium-health resort treatment] Semenov FM, et al. **Voen Med Zh** 1999 Jun;320(6):4–6, 96 (Eng. Abstr.) **(Rus)**

[The efficacy of treating patients with allergic diseases at a health resort with a gastroenterologic profile] Avdeeva EV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec;(6):29–30 (Eng. Abstr.) **(Rus)**

[The use of tissue preparations in the health resort treatment of cardiovascular diseases] Babov KD, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 May-Jun; (3):53–5 (41 ref.) **(Rus)**

[The rationalization of the management of the patient rehabilitation process at a sanatorium based on computer technology] Borisov VA.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 Mar-Apr; (2):35–9 **(Rus)**

[The detection of electrocardiographic disorders in the sleep obstructive apnea syndrome in sanatorium practice] Eroshina VA, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 May-Jun; (3):21–5 **(Rus)**

[The organizational problems of the physiotherapy service and of sanatorium-health resort care] Komarova LA.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 Jul-Aug;(4):43–5
(Rus)

[Ground-based speleo-climatic wards and the experience with their use in bronchial asthma] Krasnoshtein AE, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May-Jun; (3):25–8 (Eng. Abstr.) **(Rus)**

[The utilization of the natural factors of Cheder health resort in restorative therapy] Levitskii EF, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 Sep-Oct;(5):43–5
(Rus)

[The immunological indices of treatment efficacy in chronic pyelonephritis using low-mineralization carbonate and magnesium-calcium bicarbonate water at Kuka health resort] Mungalov NP.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 Jan-Feb; (1):38–40 **(Rus)**

[Trace elements and vitamins as activators of the adaptation reactions in combined health resort treatment] Povarenykh VA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec;(6):54–5 **(Rus)**

[Conceptual problems in the development of health resort science in Russia] Razumov AN.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 Nov-Dec;(6):3–6
(Rus)

[Medical tourism as the current trend in health resort medicine in Russia] Razumov AN, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1999 May-Jun; (3):46–9 **(Rus)**

[Some debatable trends in health resort matters] Semenov BN. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May-Jun; (3):49–52 **(Rus)**

[Carbon dioxide baths in the combined health resort treatment of children with autonomic vascular dystonia] Tikhomirova KS, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 Nov-Dec; (6):33–5 **(Rus)**

[New possibilities for the use of adaptation reactions in evaluating the results of health resort treatment] Zaripova TN, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May-Jun;(3):14–6 **(Rus)**

[Survey of Neisseria meningitidis carriers in the health resort of the Canary Islands] Garcia Rojas A, et al.
Rev Esp Salud Publica 1998 Sep-Oct;72(5):459–61 **(Spa)**

[The basis of the terms "therapeutic-prophylactic and medical institutions"] Deĭkun MP. **Lik Sprava** 1999 Apr-May; (3):165–8 **(Ukr)**

[The efficacy of using physical factors in patients with generalized periodontitis at a sanatorium-preventorium] Samoĭlovych VA. **Lik Sprava** 1998 Jun;(4):127–30 (Eng. Abstr.) **(Ukr)**

ECONOMICS

Letter to the editor about the article: is spa therapy cost-effective in rheumatic disorders? [letter; comment] Graber-Duvernay B. **Rev Rhum Engl Ed** 1998 Oct; 65(10):600–2. Comment on: Rev Rhum Engl Ed 1998 Mar;65(3):173–80.

HISTORY

[A little about the nineteenth-century history of a health resort in Ciechocinek] Kierzek A. **Przegl Lek** 1998; 55(6):357–9 (Eng. Abstr.) **(Pol)**

[The 60th anniversary of the Shmakovo Military Sanatorium] Kalutin VP. **Voen Med Zh** 1999 Jul;320(7):78–9 **(Rus)**

[The 65th anniversary of Chemitokvadzhe Sanatorium] Romasiuk SI, et al. **Voen Med Zh** 1999 May;320(5):90–2
(Rus)

[The contribution of the scientists of the Military Medical Academy to the development of Russian physiotherapy and health resort science (on the 200th anniversary of the Military Medical Academy and the 70th anniversary of the Department (Course) of Physiotherapy and Health Resort Science of the Military Medical Academy)] Ponomarenko GN.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 Nov-Dec; (6):6–11 **(Rus)**

[The history of the Central Research Institute of Health Resort Medicine and Physiotherapy] Semenov BN.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 May-Jun; (3):49–50 **(Rus)**

STANDARDS

Bioluminescent water quality monitoring of salt lake Shira. Kratasyuk VA, et al. **Luminescence** 1999 Jul-Aug; 14(4):193–5

[The problem of the development and revision of standards documents in the field of organizing sanatorium-health resort and physiotherapeutic care for the population of Russia] Razumov AN, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1998 Sep-Oct; (5):38–40 **(Rus)**

STATISTICS & NUMERICAL DATA

[New data on the size of the operational reserves of radon thermal springs at the Belokurikha deposit in the Altai] Loginov AA. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec;(6):50–1 **(Rus)**

HEALTH RESOURCES

see related
HEALTH CARE RATIONING

Classification trees. A possible method for iso-resource grouping in intensive care. Ridley S, et al. **Anaesthesia** 1998 Sep;53(9):833–40

HRGs for benchmarking and contractual arrangements: a poisoned chalice? Berridge DC, et al.

Ann R Coll Surg Engl 1998 Sep;80(5):367–9

Lessons learnt and future expectations of complex emergencies. Burkle FM. **BMJ** 1999 Aug 14; 319(7207):422–6

The Western New York Health Resources Project: developing access to local health information. Gray SA, et al. **Bull Med Libr Assoc** 1998 Jul;86(3):335–9

Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864–8 (2 ref.)

Cancer in developing countries: Part I—Cancer burden, resources, epidemiology, aetiology and clinical practice. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(4):219–25 (45 ref.)

Facilities and resources for diabetes care at regional health facilities in southern Ghana. Amoah AG, et al. **Diabetes Res Clin Pract** 1998 Nov;42(2):123–30

Comprehensive cardiac rehabilitation: is it cost–effective? Oldridge NB. **Eur Heart J** 1998 Nov;19 Suppl O:O42–50 (34 ref.)

Hospital–resource utilization and tuberculosis [editorial; comment] Brennan PJ. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):744–6. Comment on: Infect Control Hosp Epidemiol 1998 Oct;19(10):747–53.

Knowledge and opinions about dental human health resources planning in Mexico. Maupome G, et al. **Int Dent J** 1998 Feb;48(1):24–31

Ventilatory care in a selection of Ontario hospitals: bigger is not necessarily better! Critical Care Research Network (CCR–Net). Keenan SP, et al. **Intensive Care Med** 1998 Sep;24(9):946–52

Resources revisited: salutogenesis from a lay perspective. Cowley S, et al. **J Adv Nurs** 1999 Apr;29(4):994–1004

Operationalisation of a demand/resource model of health: an explorative study. Freidl W, et al. **J Epidemiol Community Health** 1999 Mar;53(3):187–8

Financing children's health care needs in the next century. Schoen C, et al. **J Urban Health** 1998 Dec;75(4):639–59 (26 ref.)

Disparities of health in African Americans. Davis CM, et al. **Nurs Clin North Am** 1999 Jun;34(2):345–57 (65 ref.)

The homeless as a vulnerable population. Strehlow AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):261–74 (50 ref.)

Nursing care of the elderly as a vulnerable population. Tullmann DF, et al. **Nurs Clin North Am** 1999 Jun; 34(2):333–44 (41 ref.)

Funding a school–based health center [letter] Nash K, et al. **Nurse Pract** 1999 Feb;24(2):142–6

Organization resources for families of children with deafness or hearing loss. Cherow E, et al. **Pediatr Clin North Am** 1999 Feb;46(1):153–62 (15 ref.)

Talking with women about personal health resources in general practice. Key questions about salutogenesis. Malterud K, et al. **Scand J Prim Health Care** 1998 Jun; 16(2):66–71

Resource dependency, doctors and the state: quality control in Sweden. Garpenby P. **Soc Sci Med** 1999 Aug; 49(3):405–24

National Institutes of Health (USA): role in tropical medicine research. Western KA. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):316–8 (0 ref.)

[AI–CARE: a multicentric study on unstable angina. Methodology and preliminary data of a project on the improvement of health care quality in Emilia–Romagna] Marzaloni M, et al. **G Ital Cardiol** 1998 Oct;28(10):1072–82 (Eng. Abstr.) **(Ita)**

[Moderation—a virtue of necessity] Nylenna M. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1154–7 (33 ref.) (Eng. Abstr.) **(Nor)**

[A study in eight counties: can closure of infrequently used emergency service improve quality of care?] Dahlgren S, et al. **Lakartidningen** 1999 Jun 2;96(22):2732–4, 2736, 2738–9 **(Swe)**

[Can health services manage a major disaster?] Edhag O, et al. **Lakartidningen** 1998 Oct 21;95(43):4695–6, 4699–700 **(Swe)**

[Cost–effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources] Lindholm L, et al. **Lakartidningen** 1999 Jun 9;96(23):2858–63, 2865–6 (Eng. Abstr.) **(Swe)**

[Disability because of hearing and speech disorders has low priority in society. Cooperation and resources are needed] Lundborg T, et al. **Lakartidningen** 1998 Oct 21; 95(43):4757–8 (5 ref.) **(Swe)**

[Physicians' responsibility in the health care crisis] Rosenhall L. **Lakartidningen** 1999 Feb 17;96(7):711–2; discussion 712–3 **(Swe)**

CLASSIFICATION

The development of Healthcare Resource Groups—Version 3. Benton PL, et al. **J Public Health Med** 1998 Sep; 20(3):351–8

ECONOMICS

The influence of chronic disease on resource utilization in common acute pediatric conditions. Financial concerns for children's hospitals. Silber JH, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):169–79

Resource constraints and moral pressures: can we still afford ourselves? Little M. **Aust N Z J Surg** 1998 Nov; 68(11):757–9

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non–institutionalised patients with Alzheimer's disease. Souêtre E, et al. **Br J Psychiatry** 1999 Jan;174:51–5

Resource costing for multinational neurologic clinical trials: methods and results. Schulman K, et al. **Health Econ** 1998 Nov;7(7):629–38

Stewardship: the distinguishing characteristic of not–for–profit health care [editorial] Maynard GF 3rd, et al. **Health Soc Work** 1998 Nov;23(4):243–8

[Allocation problems within the context of limited financial resources] Gandjour A, et al. **Internist (Berl)** 1999 Mar; 40(3):255–9 (12 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Role of the SEAMEO TROPMED Network in health human resources development. Southeast Asian Ministers of Education Organization. Tropical Medicine and Public Health. Chongsuphajaisiddhi T, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):299–310

STATISTICS & NUMERICAL DATA

Health care in Ethiopia. Payne D. **Can Fam Physician** 1998 Oct;44:2069–73, 2075–6

[Health resources in units of the Health Secretariat, 1997] **Salud Publica Mex** 1998 Jul–Aug;40(4):380–8 **(Spa)**

SUPPLY & DISTRIBUTION

[The lack of technical and human resources produces disincentive in primary care physicians (letter)] Alvarez Tutor E. **Aten Primaria** 1998 Sep 30;22(5):321 **(Spa)**

TRENDS

[Health promotion in the neighborhood—resources and needs of neighborhood groups and institutions] Tschumper A. **Soz Praventivmed** 1998;43(5):254–61 (Eng. Abstr.) **(Ger)**

[Trends of mortality from avoidable causes and expansion of municipal health resources in a southern Brazilian city] Scochi MJ. **Rev Saude Publica** 1999 Apr;33(2):129–36 (Eng. Abstr.) **(Por)**

UTILIZATION

Impact of stress single–photon emission computed tomography perfusion imaging on downstream resource utilization. Mishra JP, et al. **Am J Cardiol** 1999 May 1; 83(9):1401–3, A8

Prediction of resource utilization and case cost for acute nonvariceal upper gastrointestinal hemorrhage at a Canadian community hospital. Marshall JK, et al. **Am J Gastroenterol** 1999 Jul;94(7):1841–6

Developing a tool for analyzing medical care utilization of adult asthma patients in indemnity and managed care plans: can an episodes of care framework be used? Rosen AK, et al. **Am J Med Qual** 1998 Winter;13(4):203–12

Outcomes and resource utilization for patients with prolonged critical illness managed by university–based or community–based subspecialists. Bach PB, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1410–5

Reduction in health care resource utilization associated with extended–release theophylline. Schulz RM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):267–72 (23 ref.)

Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Lofland JH, et al. **Arch Intern Med** 1999 Apr 26;159(8):857–63

Patient–physician racial concordance and the perceived quality and use of health care. Saha S, et al. **Arch Intern Med** 1999 May 10;159(9):997–1004

Payment by salary or fee–for–service. Effect on health care resource use in the last year of life. Lee S, et al. **Can Fam Physician** 1999 Sep;45:2091–6

Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. Tung CY, et al. **Circulation** 1999 Jan 26;99(3):370–6

The independent effects of left ventricular ejection fraction on short–term outcomes and resource utilization following hospitalization for heart failure. Harjai KJ, et al. **Clin Cardiol** 1999 Mar;22(3):184–90

Caries preventive services for children and adolescents in Denmark, Iceland, Norway and Sweden: strategies and resource allocation. Wang NJ, et al. **Community Dent Oral Epidemiol** 1998 Aug;26(4):263–71

The Pediatric Risk of Mortality (PRISM) Score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Castello FV, et al. **Crit Care Med** 1999 May;27(5):985–8

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Hahn BA, et al. **Digestion** 1999 Jan–Feb;60(1):77–81

High rates of appendicectomy in a developing country: an attempt to contribute to a more rational use of surgical resources. Langenscheidt P, et al. **Eur J Surg** 1999 Mar; 165(3):248–52

Infants conceived using in–vitro fertilization do not over–utilize health care resources after the neonatal period. Leslie GI, et al. **Hum Reprod** 1998 Aug;13(8):2055–9

Medical–resource use for suspected tuberculosis in a New York City hospital [see comments] Griffiths RI, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):747–53. Comment in: Infect Control Hosp Epidemiol 1998 Oct;19(10):744–6.

Methods to estimate and analyze medical care resource use. An example from liver transplantation. Katz PP, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):366–79

Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group. Kovac A, et al. **J Clin Anesth** 1999 May;11(3):235–41

Capturing health care utilization after occupational low–back pain: development of an interviewer–administered questionnaire. Guzmán J, et al. **J Clin Epidemiol** 1999 May; 52(5):419–27

Demographic predictors of resource utilization for bleeding peptic ulcer disease: the Ontario GI Bleed Study. Marshall JK, et al. **J Clin Gastroenterol** 1999 Sep;29(2):165–70

Management of patients with acute myocardial infarction at five academic medical centers: clinical characteristics, resource utilization, and outcome. Matsui K, et al. **J Investig Med** 1999 Mar;47(3):134–40

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low–risk pediatric patients with cancer. Mullen CA, et al. **J Pediatr Hematol Oncol** 1999 May–Jun;21(3):212–8

The ICD–9–based illness severity score: a new model that outperforms both DRG and APR–DRG as predictors of survival and resource utilization. Rutledge R, et al. **J Trauma** 1998 Oct;45(4):791–9

Can physician profiles be trusted? [editorial; comment] Bindman AB. **JAMA** 1999 Jun 9;281(22):2142–3. Comment on: JAMA 1999 Jun 9;281(22):2098–105.

The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease [see comments] Hofer TP, et al. **JAMA** 1999 Jun 9; 281(22):2098–105. Comment in: JAMA 1999 Jun 9;281(22):2142–3.

Understanding resource use in liver transplantation [editorial; comment] Russell PS. **JAMA** 1999 Apr 21;281(15):1431–2 . Comment on: JAMA 1999 Apr 21;281(15):1381–6.

Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group [see comments] Showstack J, et al. **JAMA** 1999 Apr 21;281(15):1381–6. Comment in: JAMA 1999 Apr 21;281(15):1431–2.

Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV–related resources between HIV–infected women and men. Davidson AJ, et al. **Med Care** 1998 Dec;36(12):1676–84

Variation in inpatient resource use in the treatment of HIV: do the privately insured receive more care? [see comments] Joyce GF, et al. **Med Care** 1999 Mar;37(3):220–7. Comment in: Med Care 1999 Apr;37(4):325–8.

A clinical trial of a chest–pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators [see comments] Farkouh ME, et al. **N Engl J Med** 1998 Dec 24; 339(26):1882–8. Comment in: N Engl J Med 1998 Dec 24;339(26):1930–2. Comment in: N Engl J Med 1999 May 20;340(20):1596; discussion 1597. Comment in: N Engl J Med 1999 May 20;340(20):1596–7.

Impact of uracil/tegafur plus oral calcium folinate on resource utilization. Ollendorf D. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):42–3

A cohort study of resource use by medicaid children with asthma. Nash DR, et al. **Pediatrics** 1999 Aug:104(2 Pt 1):310–2

An assessment of the early management of spine problems and appropriateness of diagnostic imaging utilization. Boden SD, et al. **Phys Med Rehabil Clin N Am** 1998 May; 9(2):411–7, viii

Alternative measures of resource consumption in home care episodes. Madigan EA, et al. **Public Health Nurs** 1999 Jun; 16(3):198–204

Validity and reliability of Resource Utilization Groups (RUG–III) in Finnish long–term care facilities. Björkgren MA, et al. **Scand J Public Health** 1999 Sep;27(3):228–34

Improved health care resource utilization following video–EEG–confirmed diagnosis of nonepileptic psychogenic seizures. Martin RC, et al. **Seizure** 1998 Oct; 7(5):385–90

The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Crown WH, et al. **Stat Med** 1998 Sep 15;17(17):1943–58

Mechanical ventilation in critically ill cancer patients: outcome and utilisation of resources. Kongsgaard UE, et al. **Support Care Cancer** 1999 Mar;7(2):95–9

Reduced use of resources by early tracheostomy in ventilator–dependent patients with blunt trauma. Armstrong PA, et al. **Surgery** 1998 Oct;124(4):763–6; discussion 766–7

[Substance abuse among patients in a department of general medicine] Iversen PO, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4348–52 (Eng. Abstr.) **(Nor)**

[The effect of human immunodeficiency virus infection on the consumption of hospital resources. A correlation with the degree of immunodeficiency] Rovira Daudi E, et al. **An Med Interna** 1999 Jan;16(1):8–14 (Eng. Abstr.) **(Spa)**

HEALTH RESOURCES

[Is severity related to the utilization of resources? An exploration of the Duke Severity of Illness Scale (DUSOI)] Martinez C, et al. **Aten Primaria** 1998 Sep 30;22(5):285–92 (Eng. Abstr.) **(Spa)**

[Variability in resource utilization in primary care] Rodriguez Ortiz de Salazar B, et al. **Aten Primaria** 1999 Feb 28; 23(3):110–5 (Eng. Abstr.) **(Spa)**

[Influence of the unit of analysis on the studies of the factors of primary care resource utilization] Juncosa S, et al. **Gac Sanit** 1999 Jan–Feb;13(1):53–61 (Eng. Abstr.) **(Spa)**

[Utilization of medical resources for patients with irritable bowel syndrome in a tertiary hospital] Wasserman MJ, et al. **Rev Gastroenterol Mex** 1998 Jan–Mar;63(1):6–10 (Eng. Abstr.) **(Spa)**

HEALTH RESOURCES ADMINISTRATION (U.S.) see **UNITED STATES HEALTH RESOURCES AND SERVICES ADMINISTRATION**

HEALTH RISK APPRAISAL see **HEALTH STATUS INDICATORS**

HEALTH SERVICE AREA see **CATCHMENT AREA (HEALTH)**

HEALTH SERVICES

Use of complementary healthcare practices among chiropractors in the United States: a survey. Hawk C, et al. **Altern Ther Health Med** 1999 Jan;5(1):56–62

Lessons from Whitehall. Calman K. **BMJ** 1998 Dec 19–26; 317(7174):1718–20

Canadian Council on Health Services Accreditation: client-centred cancer staging standards. Colton M. **Cancer Prev Control** 1998 Dec;2(6):295–8

Health services research in breast cancer: background paper for a Canadian Breast Cancer Research Initiative workshop [see comments] Goel V. **Cancer Prev Control** 1998 Aug; 2(4):173–8. Comment in: Cancer Prev Control 1998 Aug;2(4):162.

The need to invest in health services research [editorial; comment] Iverson D. **Cancer Prev Control** 1998 Aug; 2(4):162. Comment on: Cancer Prev Control 1998 Aug;2(4):173–8.

AIDS is ... reflections on the Australian research response to the HIV and AIDS epidemics. Smith AM. **Int J Health Serv** 1998;28(4):793–810

Patient-led partner referral enhances sexually transmitted disease service delivery in two towns in the Central African Republic. Koumans EH, et al. **Int J STD AIDS** 1999 Jun; 10(6):376–82

Disabling occupational morbidity in the United States. An alternative way of seeing the Bureau of Labor Statistics' data. Courtney TK, et al. **J Occup Environ Med** 1999 Jan; 41(1):60–9

Evidence-based healthcare: a critical appraisal. Reerink E, et al. **J R Soc Med** 1998;91 Suppl 35:1

How will the health of the Inuit fare in their new land? [news] Ferry J. **Lancet** 1999 Jul 24;354(9175):312

Medical services continue to decline in Iraq [news] Kandela P. **Lancet** 1999 May 29;353(9167):1861

Health and human rights of the East Timorese. Silove D. **Lancet** 1999 Jun 12;353(9169):2067

Renewing Australia's mental health strategy [letter; comment] Fisher RB. **Med J Aust** 1999 May 3;170(9):452 . Comment on: Med J Aust 1998 Oct 19;169(8):432–4. Comment on: Med J Aust 1998 Oct 19;169(8):435–7.

Health, development and economics. Drèze J. **Natl Med J India** 1999 Jan–Feb;12(1):2–5

A note on competition and profit in medical care [letter] Rafferty FT. **Psychiatr Serv** 1999 Apr;50(4):567–8

Sustainable health development--sustainable health services [editorial] Tanner M. **Trop Med Int Health** 1998 Oct; 3(10):765–6

[The Federation for International Cooperation of Health Services and Systems Research Centers: a decade of activity (1988–1998)] Doan BD. **Cah Sociol Demogr Med** 1999 Jan–Mar;39(1):59–75 **(Fre)**

[Contribution to studies on the modern health care system in the Republic of Congo: geographical approach] Paka E, et al. **Sante** 1998 Nov–Dec;8(6):454–60 (Eng. Abstr.) **(Fre)**

[Motivation for the choice of complementary and mainstream medicine. Patients' behavior in a pluralistic medical system] Schär A, et al. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:10–3 (Eng. Abstr.) **(Ger)**

[Scarcity of physicians and hospitals--planning for the needs of yesterday (letter)] Claussen B. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):568–9 **(Nor)**

[Challenges for developing a comparative analytical model for health services] Hortale VA, et al. **Cad Saude Publica** 1999 Jan–Mar;15(1):79–88 (Eng. Abstr.) **(Por)**

[Theoretical principles of computerized case history of the patient in surgery] Bolgov MIu. **Klin Khir** 1999;(1):38–41 **(Rus)**

[Health care and patients' need for emergency medicine] Widgren BR, et al. **Lakartidningen** 1998 Oct 28; 95(44):4831–3 **(Swe)**

[The main trends in the reform of the surgical services in the regional administration, improvement of the quality and efficacy of surgical services to the population] Petrenko VIu. **Klin Khir** 1999;(4):46 **(Ukr)**

ECONOMICS

Health risk influence on medical care costs and utilization among 2,898 municipal employees. Weaver MT, et al. **Am J Prev Med** 1998 Oct;15(3):250–3

Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Amazigo U, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S23–31 (27 ref.)

Impact of the east Asian economic crisis on health and health care: Malaysia's response. Suleiman AB, et al. **Asia Pac J Public Health** 1998;10(1):5–9

Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy. Beck EJ, et al. **Int J STD AIDS** 1998 Sep;9(9):512–7

Complementary and alternative medicine: essential for the future of effective, affordable healthcare? [editorial] Jobst KA. **J Altern Complement Med** 1998 Fall;4(3):261–5

Federal government issues "workplan" detailing fraud and abuse initiatives aimed at physicians. **J Ky Med Assoc** 1998 Dec;96(12):481–3

Utilisation and costs of profession care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium) [letter; comment] Forbes RB, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):256–7. Comment on: J Neurol Neurosurg Psychiatry 1998 Apr;64(4):444–50.

The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. White KP, et al. **J Rheumatol** 1999 Apr;26(4):885–9

Pancreatic cancer: total costs and utilization of health services. Wilson LS, et al. **J Surg Oncol** 1999 Jul; 71(3):171–81

South African health-budget cuts hit premature babies [letter; comment] Cooper PA. **Lancet** 1998 Dec 12;352(9144):1941 . Comment on: Lancet 1998 Oct 3;352(9134):1129.

Health care and indemnity costs across the natural history of disability in occupational low back pain. Williams DA, et al. **Spine** 1998 Nov 1;23(21):2329–36

[Demographic and epidemiologic indicators of health care costs. Elderly and mentally ill are the most expensive ones within the health care services] Krasnik A. **Ugeskr Laeger** 1999 Jan 11;161(2):169–70 **(Dan)**

[How to finance health (editorial)] Guzzanti E. **Recenti Prog Med** 1999 Jun;90(6):306 **(Ita)**

[Activity and costs of diagnosis-related groups (DRG) of neurological services at the Virgen de las Nieves Hospital of Granada] Ortega-Moreno A, et al. **Rev Neurol** 1998 Sep; 27(157):453–8 (Eng. Abstr.) **(Spa)**

[Current status of neurosurgical services in the Ukraine and prospects of their development] Zozulia IuP, et al. **Klin Khir** 1999;(4):44–5 **(Ukr)**

[The methodological principles of the organization and economics of paid medical services] Nazar PS, et al. **Lik Sprava** 1998 Jul–Aug;(5):157–60 **(Ukr)**

HISTORY

[Social diseases in Poland during the in-between wars period] Więckowska E. **Wiad Lek** 1999;52(1–2):95–102 (Eng. Abstr.) **(Pol)**

[The history of the health service of Vologda Province] Limin BV, et al. **Gig Sanit** 1999 Mar–Apr;(2):70–4 **(Rus)**

[Role of the State in the medico-social protection of the population during the Great Patriotic War of 1941–1945 (according to the data of Upper Volga regions)] Semenova IIu. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):57–9 **(Rus)**

[For the 40th anniversary of the union of The 1st and The 2nd Moscow City Hospitals. Research schools of L.I. Sverzhevskiĭ, B.S. Preobrazhenskiĭ, V.T. Pal'chun] Grinchuk VI. **Vestn Otorinolaringol** 1999;(3):5–18 **(Rus)**

LEGISLATION & JURISPRUDENCE

106th Congress. Proposals could impact women's health. Reed S. **Am J Nurs** 1999 Mar;99(3):25

The business of health care [letter] Watters E. **ASHA** 1998 Fall;40(4):6, 57

South Korea cracks down on medical corruption [news] McManus J. **BMJ** 1999 Mar 13;318(7185):692

[Survey of public health services] Pavlica P. **Radiol Med (Torino)** 1999 Apr;97(4):296–302 **(Ita)**

[Eating disorders and the parliament (letter)] Navarro Izquierdo A. **An Esp Pediatr** 1998 Oct;49(4):433 **(Spa)**

MANPOWER

[Health organizations: how to attract and keep the best minds?] Aparo UL. **Ann Ig** 1999 May–Jun;11(3):245–6 **(Ita)**

ORGANIZATION & ADMINISTRATION see HEALTH SERVICES ADMINISTRATION

STANDARDS

Do health science concepts influence care? The case for a new landscape of aging [editorial] Cohen GD. **Am J Geriatr Psychiatry** 1998 Fall;6(4):273–6

Native American health care services--a dream job. Smith G. **ASHA** 1999 Mar–Apr;41(2):24–7

Development and validation of an inventory to measure satisfaction of users of family medicine clinics in Mexico. García-Peña MC, et al. **Psychol Rep** 1999 Apr;84(2):677–85

Health care concerns. Ausman JI. **Surg Neurol** 1998 Oct; 50(4):376–8

Health care in black and white--racial differences in health resource use and outcomes. Mirvis DM. **Tenn Med** 1998 Dec;91(12):455–7

[Clinical research, evaluation of care and quality assurance] Girard F, et al. **Therapie** 1998 Nov–Dec;53(6):559–63 (Eng. Abstr.) **(Fre)**

[Present situation of medical care for foreigners at medical facilities in Chiba City] Shima M, et al. **Nippon Koshu Eisei Zasshi** 1999 Feb;46(2):122–9 (Eng. Abstr.) **(Jpn)**

[Quality assessment of radiological diagnostic examinations from the perspective of radiological protection] Staniszewska MA. **Med Pr** 1999;50(1):15–23 (Eng. Abstr.) **(Pol)**

[Standardization. Sterilization standards and their impact on hospital services] Jakimiak B, et al. **Przegl Epidemiol** 1999; 53(1–2):187–96 (Eng. Abstr.) **(Pol)**

[Experience at the State Sanitary and Epidemiological Surveillance Center in the Republic of Dagestan] Omarieva EIa, et al. **Gig Sanit** 1999 Jul–Aug;(4):53–5 **(Rus)**

[Evaluation of medical services provided to patients with heart ischemia at medical institutions of various professional levels] Karachevtseva MA, et al. **Klin Med (Mosk)** 1998; 76(11):28–31 (Eng. Abstr.) **(Rus)**

[On radiation safety of medical personnel and patients during X-ray studies in stomatology] Tulupov VP, et al. **Med Tr Prom Ekol** 1999;(6):41–3 **(Rus)**

[Productivity patterns in medical departments. Working Group of Medical Services of Community Hospitals, Catalonia] Orta C, et al. **Med Clin (Barc)** 1999 May 1; 112(15):581–3 **(Spa)**

[Cross-sectional multicenter study of outpatient neurological care in the autonomous region of Valencia. Commission on Analysis of Quality of the Neurological Society of Valencia] Morera-Guitart J. **Rev Neurol** 1998 Sep; 27(157):438–46 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Health care needs and services utilization among sheltered and unsheltered Michigan homeless [letter] Douglass RL, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):5–18

Methodologic principles of cost analyses in the nursing, medical, and health services literature, 1990–1996. Chang WY, et al. **Nurs Res** 1999 Mar–Apr;48(2):94–104 (110 ref.)

SUPPLY & DISTRIBUTION

Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. Amazigo U, et al. **Ann Trop Med Parasitol** 1998 Apr;92 Suppl 1:S23–31 (27 ref.)

Native American health care services--a dream job. Smith G. **ASHA** 1999 Mar–Apr;41(2):24–7

Survey shows haphazard provision of UK stroke services [news] Pownall M. **BMJ** 1999 Apr 24;318(7191):1098

Restoring medical services in Kosovo will be a massive task [news] Richards T. **BMJ** 1999 Jun 19;318(7199):1646

Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Chitwood DD, et al. **Subst Use Misuse** 1999 Mar–Apr;34(4–5):727–46

[20-year-long professional experience of the Regional Center of Education of the Deaf and Hearing Aids] Pekarskiĭ SI, et al. **Vestn Otorinolaringol** 1998;(5):61–2 **(Rus)**

[The main trends in the reform of the surgical services in the regional administration, improvement of the quality and efficacy of surgical services to the population] Petrenko VIu. **Klin Khir** 1999;(4):46 **(Ukr)**

TRENDS

Epistemology of medicine [letter; comment] Finberg L. **Bull N Y Acad Med** 1995 Winter;72(2):540–1. Comment on: Bull N Y Acad Med 1995 Summer;72(1):95–117.

Special report: medical megatrends, 1999. Reece RL. **Conn Med** 1999 Mar;63(3):149–55

Presidential address. IPHA. Indian Public Health Association. Srivastava VK. **Indian J Public Health** 1998 Jul–Sep;42(3):62–5

Public health: where should we be in 10 years? [editorial] [see comments] Holland WW, et al. **J Epidemiol Community Health** 1998 May;52(5):278–9. Comment in: J Epidemiol Community Health 1999 Feb;53(2):128.

Health policy, health services, and cancer pain management in the New South Africa. Beck SL. **J Pain Symptom Manage** 1999 Jan;17(1):16–26

[Universal trends in medical care and key points in comprehensive care] Kawai T. **Rinsho Byori** 1999 Feb; Suppl 109:1–8 **(Jpn)**

[Improving the planning of sanitary and epidemiological institutions under current conditions] Kutsenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):34–6 (Eng. Abstr.) **(Rus)**

[Current status of neurosurgical services in the Ukraine and prospects of their development] Zozulia IuP, et al. **Klin Khir** 1999;(4):44–5 **(Ukr)**

UTILIZATION

Gender and cataract surgery in Sweden 1992-1997. A retrospective observational study based on the Swedish National Cataract Register. Lundström M, et al. **Acta Ophthalmol Scand** 1999 Apr;77(2):204–8

Health risk influence on medical care costs and utilization among 2,898 municipal employees. Weaver MT, et al. **Am J Prev Med** 1998 Oct;15(3):250–3

Health care utilization by older patients with coexisting dementia and depression. Kales HC, et al. **Am J Psychiatry** 1999 Apr;156(4):550–6

The importance of continuity of care in the likelihood of future hospitalization: is site of care equivalent to a primary clinician? Mainous AG 3rd, et al. **Am J Public Health** 1998 Oct;88(10):1539–41

Costs of health care use by women HMO members with a history of childhood abuse and neglect. Walker EA, et al. **Arch Gen Psychiatry** 1999 Jul;56(7):609–13

Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with steoarthritis of the knee. Mazzuca SA, et al. **Arthritis Rheum** 1999 Jun;42(6):1267–73

Utilization of healthcare resources for asthma in Singapore: demographic features and trends. Chew FT, et al. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2–3):57–68

Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study. Melville M, et al. **BMJ** 1999 Jul 24;319(7204):230–1

Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Acurcio F de A, et al. **Cad Saude Publica** 1998 Oct-Dec; 14(4):811–20

Record linkage as a research tool for office-based medical care. Finkelstein MM. **Can Fam Physician** 1999 Feb; 45:344–51

Why do patients seek family physicians' services for cold symptoms? [see comments] Keast DH, et al. **Can Fam Physician** 1999 Feb;45:335–40. Comment in: Can Fam Physician 1999 Aug;45:1859–60.

Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for nonmetastatic colorectal carcinoma. Cooper GS, et al. **Cancer** 1999 May 15;85(10):2124–31

Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors [see comments] Bourgault C, et al. **CMAJ** 1999 Aug 10; 161(3):255–60. Comment in: CMAJ 1999 Aug 10;161(3):273–4.

Edmonton Regional Palliative Care Program: impact on patterns of terminal cancer care. Bruera E, et al. **CMAJ** 1999 Aug 10;161(3):290–3

Utilization of health care resources by obese Canadians. Trakas K, et al. **CMAJ** 1999 May 18;160(10):1457–62

Health-related service utilization and HIV risk behaviors among HIV infected injection drug users and crack smokers. Booth RE, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1–2):69–78

Health care utilization and economic issues in irritable bowel syndrome. Gralnek IM. **Eur J Surg Suppl** 1998;(583):73–6

Responding to out-of-hours demand: the extent and nature of urgent need. Shipman C, et al. **Fam Pract** 1999 Feb; 16(1):23–7

Mental health/medical care cost offsets: opportunities for managed care [see comments] Olfson M, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):79–90. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):91–3. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):94–5.

Measuring the impact of health insurance with a correction for selection bias--a case study of Ecuador. Waters HR. **Health Econ** 1999 Aug;8(5):473–83

Hepatitis B immunization coverage and awareness in middle and upper-class population in Chennai City [letter] Pai M, et al. **Indian Pediatr** 1998 Sep;35(9):922–3

Medicaid and service use among homeless adults. Glied S, et al. **Inquiry** 1998–99 Winter;35(4):380–8

Is insurance for children enough? The link between parents' and children's health care use revisited. Hanson KL. **Inquiry** 1998 Fall;35(3):294–302

Alaska Native community assessment: health care services, knowledge of health issues, and health education. DeCourtney CA. **Int J Circumpolar Health** 1998;57 Suppl 1:656–61

The use of calendars to measure child illness in health interview surveys. Goldman N, et al. **Int J Epidemiol** 1998 Jun;27(3):505–12

Dementia care needs in an area population: case register data and morbidity survey estimates. Cooper B, et al. **Int J Geriatr Psychiatry** 1998 Aug;13(8):550–5

Effect of race on insurance coverage and health service use for HIV-infected gay men. Kass N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):85–92

Use of physician and acute care services by persons with and without Alzheimer's disease: a population-based comparison. Leibson C, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):864–9

Patterns of use of common major procedures in medical care of older adults. Levinsky NG, et al. **J Am Geriatr Soc** 1999 May;47(5):553–8

An investigation of the medical care utilization of children with severe asthma according to their type of insurance. Price MR, et al. **J Asthma** 1999 May;36(3):271–9

Health services utilization reporting in respiratory patients. Pharmacy Medication Monitoring Program Advisory Board. Ungar WJ, et al. **J Clin Epidemiol** 1998 Dec; 51(12):1335–42

Health behind bars: utilization and evaluation of medical care among jail inmates. Lindquist CH, et al. **J Community Health** 1999 Aug;24(4):285–303

Gender inequalities in health and health care services use in Catalonia (Spain). Fernandez E, et al. **J Epidemiol Community Health** 1999 Apr;53(4):218–22

Perceived control as a buffer in the use of health care services. Chipperfield JG, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 May;54(3):P146–54

The medically vulnerable: their health risks, health status, and use of physician care. Broyles RW, et al. **J Health Care Poor Underserved** 1999 May;10(2):186–200

Health care needs and services utilization among sheltered and unsheltered Michigan homeless [letter] Douglass RL, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):5–18

Utilisation and costs of profession care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium) [letter; comment] Forbes RB, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):256–7. Comment on: J Neurol Neurosurg Psychiatry 1998 Apr;64(4):444–50.

Impact of traumatic events and organizational response. A study of bank robberies. Miller-Burke J, et al. **J Occup Environ Med** 1999 Feb;41(2):73–83

Accessibility and health service utilization for asthma in Norfolk, England. Jones AP, et al. **J Public Health Med** 1998 Sep;20(3):312–7

Pancreatic cancer: total costs and utilization of health services. Wilson LS, et al. **J Surg Oncol** 1999 Jul; 71(3):171–81

Use of medical and mental health care by World War II survivors in The Netherlands. Bramsen I, et al. **J Trauma Stress** 1999 Apr;12(2):243–61

Health insurance status and cardiovascular disease risk factors among 50–64-year-old U.S. women: findings from the Third National Health and Nutrition Examination Survey. Ford ES, et al. **J Womens Health** 1998 Oct;7(8):997–1006

From the Centers for Disease Control and Prevention. Impact of arthritis and other rheumatic conditions on the health-care system--United States, 1997. **JAMA** 1999 Jun 16;281(23):2177–8

Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group [see comments] Bindman AB, et al. **JAMA** 1998 Oct 28;280(16):1416–20. Comment in: JAMA 1999 Jun 23-30;281(24):2282–3.

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Shapiro MF, et al. **JAMA** 1999 Jun 23–30; 281(24):2305–15

Patients' socio-demographics characteristics and utilization of health care: looking beyond appearances...at last [editorial; comment] Horner RD. **Med Care** 1999 Jan; 37(1):3–4. Comment on: Med Care 1999 Jan;37(1):68–77.

Accuracy of self-reported health services use and patterns of care among urban older adults. Wallihan DB, et al. **Med Care** 1999 Jul;37(7):662–70

Price controls and Medicare spending: assessing the volume offset assumption. Zuckerman S, et al. **Med Care Res Rev** 1998 Dec;55(4):457–78; discussion 479–83

Management of insulin-treated diabetes in Tasmania. McCarty DJ, et al. **Med J Aust** 1999 Apr 5;170(7):312–5

Health care insurance premiums project. **Mich Med** 1999 Feb; 98(2):19–21

The case of disability in the family: impact on health care utilization and expenditures for nondisabled members. Altman BM, et al. **Milbank Q** 1999;77(1):39–75, iv

Impact of arthritis and other rheumatic conditions on the health-care system--United States, 1997. **MMWR Morb Mortal Wkly Rep** 1999 May 7;48(17):349–53

Impact of uracil/tegafur plus oral calcium folinate on resource utilization. Ollendorf D. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):42–3

Health care utilization by older adults in response to painful orofacial symptoms. Riley JL 3rd, et al. **Pain** 1999 May; 81(1–2):67–75

Health care utilization by persons with severe and persistent mental illness. Berren MR, et al. **Psychiatr Serv** 1999 Apr; 50(4):559–61

Posttraumatic stress disorder and other predictors of health care consumption by Vietnam veterans. Marshall RP, et al. **Psychiatr Serv** 1998 Dec;49(12):1609–11

Depression among caregivers of the elderly in need of care and their service utilization: a pilot study. Arai Y, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):463–5

Hypochondriasis, somatization, and perceived health and utilization of health care services. Hollifield M, et al. **Psychosomatics** 1999 Sep-Oct;40(5):380–6

Musculoskeletal chronic pain in general practice. Studies of health care utilisation in comparison with pain prevalence. Andersson HI, et al. **Scand J Prim Health Care** 1999 Jun; 17(2):87–92

The impact of over-the-counter availability of nasal sprays on sales, prescribing, and physician visits. Lundberg L, et al. **Scand J Prim Health Care** 1999 Mar;17(1):41–5

Tiredness as a ticket of entry. The role of patients' beliefs and psychological symptoms in explaining frequent attendance. General Practice Fatigue Group. Ridsdale L, et al. **Scand J Prim Health Care** 1999 Jun;17(2):72–4

Review of social epidemiologic research on migrants' health: findings, methodological cautions, and theoretical perspectives. Friis R, et al. **Scand J Soc Med** 1998 Sep; 26(3):173–80 (58 ref.)

Health care utilization in the 10 years prior to diagnosis in obstructive sleep apnea syndrome patients. Ronald J, et al. **Sleep** 1999 Mar 15;22(2):225–9

Do ethnic groups use health services like the majority of the population? A study from Quebec, Canada. Blais R, et al. **Soc Sci Med** 1999 May;48(9):1237–45

Gender, psychosocial factors and the use of medical services: a longitudinal analysis. Green CA, et al. **Soc Sci Med** 1999 May;48(10):1363–72

Trends in health services utilization in eight provinces in China, 1989–1993. Henderson GE, et al. **Soc Sci Med** 1998 Dec;47(12):1957–71

National health care 'by-passing' in Bangladesh: a comparative study. Paul BK. **Soc Sci Med** 1999 Sep; 49(5):679–89

Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Chitwood DD, et al. **Subst Use Misuse** 1999 Mar-Apr;34(4–5):727–46

Effect of incentives on the use of indicated services in managed care. Pantilat SZ, et al. **West J Med** 1999 Mar; 170(3):137–42

[Do women misuse health services?] Olsen J, et al. **Ugeskr Laeger** 1998 Nov 2;160(45):6535 **(Dan)**

[Appropriateness of medical procedures: measurements and relations with needs and access to health care] Lang T. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):411–9 (Eng. Abstr.) **(Fre)**

[Misunderstanding of medical resource use by women] Gillet P, et al. **Rev Med Liege** 1999 Apr;54(4):214–23 (Eng. Abstr.) **(Fre)**

[Impact of mass media on the use of health services. A systematic review of the literature] Grilli R, et al. **Epidemiol Prev** 1998 Apr-Jun;22(2):103–10 (35 ref.) (Eng. Abstr.) **(Ita)**

[How women face a medical symptom: from the evaluation to health care selection] de la Cuesta-Benjumea C. **Salud Publica Mex** 1999 Mar-Apr;41(2):124–9 (Eng. Abstr.) **(Spa)**

HEALTH SERVICES ACCESSIBILITY

The perceptions of users about barriers to the use of free systematic oral care among Finnish pre-school children--a qualitative study. Lahti SM, et al. **Acta Odontol Scand** 1999 Jun;57(3):139–43

Equity in health and health care reforms. Glick SM. **Acta Oncol** 1999;38(4):469–73

Data needs in studies on equity in health and access to care--ethical considerations. Rosén M. **Acta Oncol** 1999; 38(1):71–5

Where do we stand? Research and policy issues concerning inequalities in health and in healthcare. Whitehead MM. **Acta Oncol** 1999;38(1):41–50 (55 ref.)

Barriers to care among persons living with HIV/AIDS in urban and rural areas. Heckman TG, et al. **AIDS Care** 1998 Jun;10(3):365–75

Is access to medical care associated with receipt of HIV testing and counselling? Mosen DM, et al. **AIDS Care** 1998 Oct;10(5):617–28

Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services [see comments] Gregory PM, et al. **Am Heart J** 1999 Sep; 138(3 Pt 1):507–17. Comment in: Am Heart J 1999 Sep;138(3 Pt 1):396–9.

Racial differences in the use of invasive cardiac procedures: A continuous quality improvement approach [editorial; comment] Sheifer SE, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):396–9. Comment on: Am Heart J 1999 Sep;138(3 Pt 1):507–17.

Obstacles to achieving adequate dialysis dose: compliance, education, transportation, and reimbursement. Latham CE. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S93–5

A framework for evaluating underutilization of health care services. Fetterolf DE. **Am J Med Qual** 1999 Mar-Apr; 14(2):89–97 (40 ref.)

When you're the health care consumer. Patton RM. **Am J Nurs** 1999 Jan;99(1 Pt 1):80

Jumping the broom toward eliminating health disparities. Presidential address. Hill WC. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1315–21

Pathologies of power: rethinking health and human rights. Farmer P. **Am J Public Health** 1999 Oct;89(10):1486–96

Human rights is a US problem, too: the case of women and HIV [comment] Gollub EL. **Am J Public Health** 1999 Oct; 89(10):1479–82. Comment on: Am J Public Health 1999 Oct;89(10):1514–21.

An analysis of frequent users of emergency care at an urban university hospital. Lucas RH, et al. **Ann Emerg Med** 1998 Nov;32(5):563–8

Access to health care, socioeconomic status, and health [letter; comment] Baltzan MA. **Ann Intern Med** 1999 Mar 2;130(5):452–3. Comment on: Ann Intern Med 1998 Sep 1;129(5):406–11. Comment on: Ann Intern Med 1998 Oct 1;129(7):567–72.

HEALTH SERVICES ACCESSIBILITY

Access to quality cancer care: consensus statement of the American Federation of Clinical Oncologic Societies. Edwards MJ. **Ann Surg Oncol** 1998 Oct-Nov;5(7):657-9 (0 ref.)

Primary health care. McElmurry BJ, et al. **Annu Rev Nurs Res** 1999;17:241-68 (165 ref.)

Clinical services for sleep disorders. Stores G, et al. **Arch Dis Child** 1998 Dec;79(6):495-7

Inequalities in health. Independent inquiry gives detailed recommendations [letter; comment] Ashton J. **BMJ** 1999 Feb 27;318(7183):601. Comment on: BMJ 1998 Nov 28;317(7171):1465-6.

WHO urges "coverage for all, not coverage of everything" [news] Brown P. **BMJ** 1999 May 15;318(7194):1305

Evaluating NHS direct. Early findings raise questions about expanding the service [editorial] Florin D, et al. **BMJ** 1999 Jul 3;319(7201):5-6

Barriers to referral in patients with angina: qualitative study. Gardner K, et al. **BMJ** 1999 Aug 14;319(7207):418-21

Meeting health needs of asylum seekers. White paper will make access to health care more difficult [letter; comment] Hogan H. **BMJ** 1999 Mar 6;318(7184):671. Comment on: BMJ 1998 Nov 21;317(7170):1444-6.

Refugees and primary care: tackling the inequalities [see comments] Jones D, et al. **BMJ** 1998 Nov 21; 317(7170):1444-6 (25 ref.). Comment in: BMJ 1999 Mar 6;318(7184):671.

Inequalities in health. Policies to reduce income inequalities are unlikely to eradicate inequalities in mortality [letter] Martikainen P, et al. **BMJ** 1999 Jul 31;319(7205):319

Inequalities in health. Early years of development are important contributors to health inequalities [letter] Mustart JF. **BMJ** 1999 Jul 31;319(7205):319-20

Dutch minister warns that illegal immigrants must receive care [news] Sheldon T. **BMJ** 1999 May 8;318(7193):1234

Tackling health inequalities in primary care [editorial] Smeeth L, et al. **BMJ** 1999 Apr 17;318(7190):1020-1

The independent inquiry into inequalities in health is welcome, but its recommendations are too cautious and vague [editorial] [see comments] Smith GD, et al. **BMJ** 1998 Nov 28;317(7171):1465-6. Comment in: BMJ 1998 Dec 12;317(7173):1659. Comment in: BMJ 1999 Feb 27;318(7183):601.

Eligibility criteria improve children's access to long term ventilation at home [letter; comment] Snelling S. **BMJ** 1999 Jun 19;318(7199):1699. Comment on: BMJ 1999 Jan 30;318(7179):295-9.

Barriers to accessing dental care: patient factors. Freeman R. **Br Dent J** 1999 Aug 14;187(3):141-4

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group workshop. Improvements in patient access to new anti-cancer medicines. **Br J Cancer** 1999 Jan;79(1):2-3

Systematic review of cancer treatment programmes in remote and rural areas. Campbell NC, et al. **Br J Cancer** 1999 Jun;80(8):1275-80

Cancer mortality by educational level in the city of Barcelona. Fernandez E, et al. **Br J Cancer** 1999 Feb; 79(3-4):684-9

Valuing ethnic diversity in primary care [editorial] Kai J. **Br J Gen Pract** 1999 Mar;49(440):171-2

Perceptions of care access: the experience of rural and urban women following brain injury. Sample PL, et al. **Brain Inj** 1998 Oct;12(10):855-74

Minority health. Collins KS. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):627-33

Women's health. Leiman JM. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):639-44

Introducing management principles into the supply and distribution of medicines in Tunisia. Garraoui A, et al. **Bull World Health Organ** 1999;77(6):525-9

The security blanket. Malik P. **Can J Cardiol** 1999 May; 15(5):533-4

Who is responsible for access to cardiac resources in Canada? Scully HE. **Can J Cardiol** 1999 Jan;15(1):27, 30-2 **(Eng, Fre)**

Physician resources. Smith ER. **Can J Cardiol** 1999 May; 15(5):609-12 **(Eng, Fre)**

Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864-8 (2 ref.)

American Cancer Society Lymphedema Workshop. Workgroup IV: Lymphedema treatment resources--professional education and availability of patient services. Walley DR, et al. **Cancer** 1998 Dec 15; 83(12 Suppl American):2886-7 (0 ref.)

Exploring the barriers to cervical screening in an urban Canadian setting. Fitch MI, et al. **Cancer Nurs** 1998 Dec; 21(6):441-9

On congenital heart disease in developing countries [editorial; comment] Ebels T. **Cardiol Young** 1998 Oct;8(4):425-7. Comment on: Cardiol Young 1998 Oct;8(4):437-9. Comment on: Cardiol Young 1998 Oct;8(4):486-90.

Cancer in developing countries: Part II--Cancer control: strategies and priorities. Martin WM. **Clin Oncol (R Coll Radiol)** 1998;10(5):283-7 (36 ref.)

Access to medical and health information in the developing world: an essential tool for change in medical education [editorial] Haddad H, et al. **CMAJ** 1999 Jan 12;160(1):63-4

Strategies to ensure delivery of hepatitis B vaccine to injecting drug users [editorial; comment] Heptonstall J. **Commun Dis Public Health** 1999 Sep;2(3):154-6. Comment on: Commun Dis Public Health 1999 Sep;2(3):174-7.

Dental services for adults with a learning disability: care managers' experiences and opinions. Pratelli P, et al. **Community Dent Health** 1998 Dec;15(4):281-5

Priorities and priority-setting in health care in the Netherlands. Hermans H, et al. **Croat Med J** 1998 Sep; 39(3):346-55

Evaluation and management of nonmelanoma skin cancer. The military perspective. Welch ML, et al. **Dermatol Clin** 1999 Jan;17(1):19-28, vii (16 ref.)

Access to diabetes treatment in northern Ethiopia. Alemu S, et al. **Diabet Med** 1998 Sep;15(9):791-4

Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users. Webber MP, et al. **Epidemiology** 1998 Nov;9(6):613-7

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50-1 (0 ref.)

Are variations in the use of carotid endarterectomy explained by population Need? A study of health service utilisation in two English health regions. Oliver SE, et al. **Eur J Vasc Endovasc Surg** 1999 Jun;17(6):501-6

Diabetes education program use and patient-perceived barriers to attendance. Graziani C, et al. **Fam Med** 1999 May;31(5):358-63

State abortion policy, geographic access to abortion providers and changing family formation [published erratum appears in Fam Plann Perspect 1999 Mar-Apr;31(2):80] Lichter DT, et al. **Fam Plann Perspect** 1998 Nov-Dec;30(6):281-7

Using pharmacies in Washington state to expand access to emergency contraception. Wells ES, et al. **Fam Plann Perspect** 1998 Nov-Dec;30(6):288-90

Pathways from symptoms to medical care: a descriptive study of symptom development and obstacles to early diagnosis in brain tumour patients. Salander P, et al. **Fam Pract** 1999 Apr;16(2):143-8

Using out-of-hours services: general practice or A&E? Shipman C, et al. **Fam Pract** 1997 Dec;14(6):503-9

Open access endoscopy in Britain: a service in evolution. Marshall JB. **Gastrointest Endosc** 1998 Dec;48(6):653-8

Tackling inequalities in health: experience in the UK. Crown J. **Gesundheitswesen** 1998 Nov;60(11):618-21

The Oregon report. Don't ask, don't tell. Foley K, et al. **Hastings Cent Rep** 1999 May-Jun;29(3):37-42

Managed care and technology diffusion: the case of MRI. Baker LC, et al. **Health Aff (Millwood)** 1998 Sep-Oct; 17(5):195-207

Dangers of inpatient rehabilitation industry consolidation [letter; comment] Batavia AI. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):256-7. Comment on: Health Aff (Millwood) 1998 May-Jun;17(3):209-15.

Disparities in access to Medicare managed care plans and their benefits. McBride TD. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):170-80

Mental health/medical care cost offsets: opportunities for managed care [see comments] Olfson M, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):79-90. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):91-3. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):94-5.

Blue shield of California's Access+ HMO. Richard K, et al. **Health Aff (Millwood)** 1999 May-Jun;18(3):174-7

Good news about difficult decisions: the Canadian approach to hospital cost control. Roos NP, et al. **Health Aff (Millwood)** 1998 Sep-Oct;17(5):239-46

Need to measure absolute, not relative, access to care [letter; comment] Schreiber S. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):259-60. Comment on: Health Aff (Millwood) 1998 May-Jun;17(3):169-80.

Linking injection drug users to medical services: role of street outreach referrals. Greenberg JB, et al. **Health Soc Work** 1998 Nov;23(4):298-309

Pathways to mental health services among inhabitants of a Mexican village. Salgado de Snyder VN, et al. **Health Soc Work** 1998 Nov;23(4):249-61

Mental health of elderly Asians in the UK. Ananthanarayanan TS, et al. **Hosp Med** 1999 Jun; 60(6):407-9 (32 ref.)

Need for NPs in developing countries [letter] Aboul-Enein F. **Image J Nurs Sch** 1999;31(2):106

Access to health care. Gulzar L. **Image J Nurs Sch** 1999; 31(1):13-9 (80 ref.)

Nursing in Greece in the 21st century [letter] Mahu CR. **Image J Nurs Sch** 1999;31(2):107-8

FDI statement. Improving access to oral health care. Fédération Dentaire Internationale. **Int Dent J** 1998 Dec; 48(6):549-51

Health service accessibility and deaths from asthma. Jones AP, et al. **Int J Epidemiol** 1999 Feb;28(1):101-5

The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Müller I, et al. **Int J Epidemiol** 1998 Oct;27(5):878-84

Encouraging speech and language development in exceptional circumstances. Coulter L. **Int J Lang Commun Disord** 1998;33 Suppl:506-8

Systems approach to childhood and adolescent obesity prevention and treatment in a managed care organization. Pronk NP, et al. **Int J Obes Relat Metab Disord** 1999 Mar; 23 Suppl 2:S38-42

Computed tomography of the head by the accident and emergency department--why 24 hour access is vital [see comments] MacNamara AF, et al. **J Accid Emerg Med** 1998 Sep;15(5):294-7. Comment in: J Accid Emerg Med 1999 Jan;16(1):75-6.

On site computed tomography in the district general hospital for severe head injury [letter; comment] Scholes NE. **J Accid Emerg Med** 1999 Jan;16(1):75-6. Comment on: J Accid Emerg Med 1998 Sep;15(5):294-7.

Access to and utilization of primary care services among HIV-infected women. Palacio H, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):293-300

Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment [see comments] Lewis DC. **J Addict Dis** 1999; 18(2):5-21 (82 ref.). Comment in: J Addict Dis 1999 ;18(2):1-4.

Adolescent girls' and boys' preferences for provider gender and confidentiality in their health care. Kapphahn CJ, et al. **J Adolesc Health** 1999 Aug;25(2):131-42

Access to medical care for adolescents: results from the 1997 Commonwealth Fund Survey of the Health of Adolescent Girls. Klein JD, et al. **J Adolesc Health** 1999 Aug; 25(2):120-30

Declining health care provision to adolescents and the need for considering culturally competent interventions [editorial] Martinez J. **J Adolesc Health** 1998 Oct; 23(4):189-90

Access to health care for Latina adolescents: a critical review. Rew L. **J Adolesc Health** 1998 Oct;23(4):194-204 (69 ref.)

People with Down's syndrome denied medical care [news] **J Adv Nurs** 1999 Aug;30(2):282-3

A socio-ecological approach to understanding barriers to prenatal care for women of low income. Sword W. **J Adv Nurs** 1999 May;29(5):1170-7

Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample. Armstrong KA, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):65-70, 78

Mental illness and substance abuse: implications for women's health and health care access. Reed BG, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):71-8 (171 ref.)

Pharmacy access to sterile syringes for injection drug users: attitudes of participants in a syringe exchange program. Junge B, et al. **J Am Pharm Assoc (Wash)** 1999 Jan-Feb; 39(1):17-22

Community solutions for access to medical care. McGrew CW. **J Ark Med Soc** 1998 Dec;95(7):275-6

The effects of maternal-child health service utilization on subsequent contraceptive use in Morocco. Hotchkiss DR, et al. **J Biosoc Sci** 1999 Apr;31(2):145-65

Effect of hospital type, insurance type, and gender on the treatment of cardiovascular disease in middle-aged adults. Glenn LL, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):102-13

Improved access to women's health services for Alaska natives through community health aide training. Sox CH, et al. **J Community Health** 1999 Aug;24(4):313-23

Accessibility and perceived value of health services in five western Illinois rural communities. Watts PR, et al. **J Community Health** 1999 Apr;24(2):147-57

Recipient and provider perspectives of barriers to rural prenatal care. Omar MA, et al. **J Community Health Nurs** 1998;15(4):237-49

Listening to migrant voices: focus groups on health issues in south Georgia. Perilla JL, et al. **J Community Health Nurs** 1998;15(4):251-63

Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. Carrieri MP, et al. **J Epidemiol Community Health** 1999 Jan;53(1):4-8

Weekend work. Balancing competing interests [editorial; comment] Tanio C. **J Gen Intern Med** 1999 Jan;14(1):66-7 . Comment on: J Gen Intern Med 1999 Jan;14(1):10-4.

Reaping the fruits of research: promoting health equity for all. Pinn VW. **J Health Care Poor Underserved** 1998 Aug; 9(3):213-6

Recent improvement in mental health services to lesbian and gay clients. Liddle BJ. **J Homosex** 1999;37(4):127-37

Ardis D. Hoven, MD. AMA council on medical service [interview by Sue Tharp] Hoven AD. **J Ky Med Assoc** 1999 May;97(5):212-6

A clinic for the rapid processing of patients with neck masses. Vowles RH, et al. **J Laryngol Otol** 1998 Nov; 112(11):1061-4

The midwifery solution to contemporary problems in American obstetrics. Baldwin KA. **J Nurse Midwifery** 1999 Jan-Feb;44(1):75-9

OCIHO chairman Deckert replies to Dewberry letter [letter; comment] Deckert GH, et al. **J Okla State Med Assoc** 1997 Nov-Dec;90(8):462-4. Comment on: J Okla State Med Assoc 1997 May-Jun;90(5):199-200. Comment on: J Okla State Med Assoc 1997 Jul-Aug;90(6):342-3.

Differences in physician access patterns to hospice care. Stillman MJ, et al. **J Pain Symptom Manage** 1999 Mar; 17(3):157-63

Commentary: recurrent headaches: making what works available to those who need it [comment] McGrath PJ. **J Pediatr Psychol** 1999 Apr;24(2):111-2. Comment on: J Pediatr Psychol 1999 Apr;24(2):91-109.

Pathways to care for alcohol use disorders. Commander MJ, et al. **J Public Health Med** 1999 Mar;21(1):65-9

Accessibility and health service utilization for asthma in Norfolk, England. Jones AP, et al. **J Public Health Med** 1998 Sep;20(3):312-7

Barriers to meeting the mental health needs of the Chinese community. Li PL, et al. **J Public Health Med** 1999 Mar; 21(1):74–80

Statin prescribing in Nottingham general practices: a cross-sectional study. Packham C, et al. **J Public Health Med** 1999 Mar;21(1):60–4

A Black look at the independent inquiry into inequalities in health. Black D. **J R Coll Physicians Lond** 1999 Mar–Apr; 33(2):148–9

Prospective study of high dependency care requirements and provision. Turner M, et al. **J R Coll Surg Edinb** 1999 Feb; 44(1):19–23

Residential differences in attitudes about barriers to using community-based services among older adults. Schoenberg NE, et al. **J Rural Health** 1998 Fall;14(4):295–304

Race and health care [editorial] Bryan CS. **J S C Med Assoc** 1999 Mar;95(3):116–8

Organizational correlates of access to primary care and mental health services in drug abuse treatment units. Friedmann PD, et al. **J Subst Abuse Treat** 1999 Jan; 16(1):71–80

Proceedings of the 4th annual Margaret E Mahoney Symposium on the State of the Nation's Health. **J Urban Health** 1998 Dec;75(4):615–776

Medicaid's impact on access to and utilization of health care services among racial and ethnic minority children. Hall AG. **J Urban Health** 1998 Dec;75(4):677–92 (25 ref.)

Challenges to accessing useful information in health policy and public health: an introduction to a national forum held at the New York Academy of Medicine, March 23, 1998. Lasker RD. **J Urban Health** 1998 Dec;75(4):779–84 (0 ref.)

"Staying close to shore": a context for older rural widows' use of health care [see comments] Porter EJ. **J Women Aging** 1998;10(4):25–39. Comment in: J Women Aging 1998 ;10(4):81–90.

Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group [see comments] Bindman AB, et al. **JAMA** 1998 Oct 28;280(16):1416–20. Comment in: JAMA 1999 Jun 23–30;281(24):2282–3.

Medicaid and children's access to care [letter; comment] Kaestner R. **JAMA** 1999 Apr 14;281(14):1273–4. Comment on: JAMA 1998 Nov 25;280(20):1789–93.

Anonymous HIV testing and medical care [letter; comment] Levi J. **JAMA** 1999 Jun 23–30;281(24):2282–3. Comment on: JAMA 1998 Oct 28;280(16):1416–20.

Better cancer patient care requires systemic changes [news] Marwick C. **JAMA** 1999 May 5;281(17):1575–6

Access to essential drugs in poor countries: a lost battle? Pécoul B, et al. **JAMA** 1999 Jan 27;281(4):361–7

Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998. UK NGO AIDS Consortium Working Group on Access to Treatment for HIV in Developing Countries [see comments] **Lancet** 1998 Oct 24;352(9137):1379–80 (0 ref.) . Comment in: Lancet 1999 Jan 9;353(9147):153.

Palestinian health care [letter] Dukker A. **Lancet** 1999 Sep 18;354(9183):1037

Access to treatment for HIV in developing countries [letter; comment] Kroes AC, et al. **Lancet** 1999 Jan 9;353(9147):153 . Comment on: Lancet 1998 Oct 24;352(9137):1379–80.

Patient preferences for location of care: implications for regionalization. Finlayson SR, et al. **Med Care** 1999 Feb; 37(2):204–9

Evaluating the effect of usual source of dental care on access to dental services: comparisons among diverse populations. Davidson PL, et al. **Med Care Res Rev** 1999 Mar; 56(1):74–93

Roadblocks to effective pain treatment. Stieg RL, et al. **Med Clin North Am** 1999 May;83(3):809–21, viii (48 ref.)

Cancer in the elderly: gathering the evidence [editorial] Yip D, et al. **Med J Aust** 1999 Jun 21;170(12):577–8

Attitudes toward menopause and hormone therapy among women with access to health care. Woods NF, et al. **Menopause** 1998 Fall;5(3):178–88

Health care for all [editorial; comment] Blaivas JG. **Neurourol Urodyn** 1998;17(6):577–8. Comment on: Neurourol Urodyn 1998 ;17(6):639.

Gatekeeping and authorization. Miles ML, et al. **New Dir Ment Health Serv** 1999 Spring;(81):65–73

Home care: addressing the needs of people living with AIDS and their caregivers. Baker S. **Nurs Clin North Am** 1999 Mar;34(1):201–12 (43 ref.)

Health problems of lesbian women. Saunders JM. **Nurs Clin North Am** 1999 Jun;34(2):381–91 (38 ref.)

Access to health care resources for family caregivers of elderly persons with dementia. Kelley LS, et al. **Nurs Outlook** 1999 Jan–Feb;47(1):8–14 (39 ref.)

Developing and implementing a pharmaceutical assistance program for low-income clients [letter] Brummet SK. **Nurse Pract** 1998 Nov;23(11):15–7

Abnormal Pap screening among Mexican-American women: impediments to receiving and reporting follow-up care. Hunt LM, et al. **Oncol Nurs Forum** 1998 Nov–Dec; 25(10):1743–9

Roundtable discussion. Investigational exclusion, clinical trials, and cancer. Goodman C. **Oncology (Huntingt)** 1998 Nov;12(11A):37–49

The attitude of health care professionals toward the availability of hospice services for cancer patients and their carers in Saudi Arabia. Almuzaini AS, et al. **Palliat Med** 1998 Sep;12(5):365–73

A critical evaluation of the potential benefits of public access defibrillation [letter] Cooper JS, et al. **Prehosp Emerg Care** 1998 Jan–Mar;2(1):87–8

Consensus panel report designed to remove barriers to substance abuse treatment for persons with disabilities [news] **Psychiatr Serv** 1999 Mar;50(3):435–6

Overcoming service barriers for homeless persons with serious psychiatric disorders. Calloway MO, et al. **Psychiatr Serv** 1998 Dec;49(12):1568–72

Improving access to family support organizations: a member survey of the AMI-Quebec Alliance for the Mentally Ill. Looper K, et al. **Psychiatr Serv** 1998 Nov;49(11):1491–2

Patients' views of routine hospital follow-up: a qualitative study of women with breast cancer in remission. Adewuyi-Dalton R, et al. **Psychooncology** 1998 Sep–Oct; 7(5):436–9

Medical assistance in the maritime community [letter] Nikolic N. **Public Health** 1998 Sep;112(5):353–4

A community-wide infant mortality review: findings and implications. McCloskey L, et al. **Public Health Rep** 1999 Mar–Apr;114(2):165–77

Sexual offender treatment in Europe: an impression of cross-cultural differences. Frenken J. **Sex Abuse** 1999 Jan; 11(1):87–93 (2 ref.)

Patterns of general health care and STD services use among high-risk youth in Denver participating in community-based urine chlamydia screening. Rietmeijer CA, et al. **Sex Transm Dis** 1998 Oct;25(9):457–63

Nursing home applications--reasons and possible interventions. Chan KM, et al. **Singapore Med J** 1998 Oct; 39(10):451–5

Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the health survey for England. Dong W, et al. **Soc Sci Med** 1998 Dec; 47(11):1773–80

Health and access to care: perspectives of homeless youth in Baltimore City, U.S.A. Ensign J, et al. **Soc Sci Med** 1998 Dec;47(12):2087–99

Effects of distances to hospital and GP surgery on hospital inpatient episodes, controlling for needs and provision. Haynes R, et al. **Soc Sci Med** 1999 Aug;49(3):425–33

Evaluating health service equity at a primary care clinic in Chilimarca, Bolivia. Kinman EL. **Soc Sci Med** 1999 Sep; 49(5):663–78

Effect of price and access on contraceptive use. Levin A, et al. **Soc Sci Med** 1999 Jul;49(1):1–15

Women's help-seeking patterns for depression. Van Hook MP. **Soc Work Health Care** 1999;29(1):15–34

Impact of minority physicians on health care. Thurmond VB, et al. **South Med J** 1998 Nov;91(11):1009–13 (25 ref.)

A comparison of the private sector in Asia and Africa. Barnish G. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):319–23

Analysis of Canadian population with potential geographic access to intravenous thrombolysis for acute ischemic stroke. Scott PA, et al. **Stroke** 1998 Nov;29(11):2304–10

Primary-care delivery for sickle cell patients in rural Georgia using telemedicine. Woods K, et al. **Telemed J** 1998 Winter; 4(4):353–61

Medicare rural hospital flexibility program. Jolley B. **Tenn Med** 1999 Sep;92(9):345–6

Health insurance: does it affect health? Mirvis DM. **Tenn Med** 1999 Mar;92(3):85–7

Perceived barriers to childhood immunization: a physician and parent survey in a southeastern urban/rural community. Nace NB, et al. **Tenn Med** 1999 Jul;92(7):265–8

Managing mental health. McEver M. **Tex Med** 1998 Nov; 94(11):74–6

Shortage amid surplus. Maldonado M. **Tex Med** 1999 Jul; 95(7):38–45

AIDS treatment in Africa [news] **Trop Doct** 1999 Jan;29(1):58

Barriers to the uptake of cataract surgery. Johnson JG, et al. **Trop Doct** 1998 Oct;28(4):218–20

Flaws in the out-patient flow at a semi-rural hospital in northern Namibia. Meguid T, et al. **Trop Doct** 1999 Apr; 29(2):80–5

Traditional healers as a source of information and advice for people with sexually transmitted diseases in rural Zambia [see comments] Ndubani P, et al. **Trop Doct** 1999 Jan;29(1):36–8. Comment in: Trop Doct 1999 Jan;29(1):1.

Locations for renal services--patient satisfaction surveys. Willis CE, et al. **Ulster Med J** 1998 Nov;67(2):110–4

The availability of activated charcoal and ipecac for home use. Nordt SP, et al. **Vet Hum Toxicol** 1999 Aug; 41(4):247–8 (10 ref.)

Treating the developmentally disabled. Doostan D, et al. **West J Med** 1999 Aug;171(2):92–6 (13 ref.)

How health care providers help battered women: the survivor's perspective. Gerbert B, et al. **Women Health** 1999;29(3):115–35

Managed care organizations and mammography: opportunities to serve underserved women. Reid WM, et al. **Women Health** 1999;28(4):13–28 (76 ref.)

Mothers in a new country: the role of culture and communication in Vietnamese, Turkish and Filipino women's experiences of giving birth in Australia. Small R, et al. **Women Health** 1999;28(3):77–101

The implications of affiliations between Catholic and non-Catholic health care organizations for availability of reproductive health services. Weisman CS, et al. **Womens Health Issues** 1999 May–Jun;9(3):121–34

[Equal access to health care for immigrants and refugees? (editorial)] Dyhr L. **Ugeskr Laeger** 1999 Aug 2;161(31):4371 **(Dan)**

[Access to Danish health care by immigrant women. Access to hospital care among immigrant women with breast cancer compared with Danish women] Nørredam M, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4385–8 (Eng. Abstr.) **(Dan)**

[Access to health services: difficulties encountered by refugees residing on Ile-de-France. Charity and full-coverage health care: two divergent concepts?] Delbecchi G, et al. **Presse Med** 1999 Jun 5;28(20):1075–9 (Eng. Abstr.) **(Fre)**

[Do we have to use an inefficient method for the evaluation of our health care system? (editorial)] Rodrigues JM. **Presse Med** 1998 Dec 5;27(38):1957–8 **(Fre)**

[Appropriateness of medical procedures: measurements and relations with needs and access to health care] Lang T. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):411–9 (Eng. Abstr.) **(Fre)**

[The Zurich Polyclinic for Oral Surgery: available for everyone (news)] Zysset AC. **Schweiz Monatsschr Zahnmed** 1999;109(6):697–8 **(Ger)**

[Accessibility to the specific pharmacotherapy for Parkinson disease, in Santiago de Chile] Chaná P, et al. **Rev Med Chil** 1998 Nov;126(11):1355–61 (Eng. Abstr.) **(Spa)**

[Health service coverage in Latin America and the Caribbean] Paganini JM. **Rev Panam Salud Publica** 1998 Nov;4(5):305–10 (Eng. Abstr.) **(Spa)**

[Mortality for diarrheic disease in Mexico: problem of accessibility or quality of care?] Reyes H, et al. **Salud Publica Mex** 1998 Jul–Aug;40(4):316–23 (Eng. Abstr.) **(Spa)**

[Increased equality of health is the aim of Infomedica] Holmberg B. **Lakartidningen** 1999 Feb 10;96(6):577 **(Swe)**

[The health care system in the USA does not welcome patients with "minor complaints". It takes days before they are seen by a family physician] Olson M. **Lakartidningen** 1998 Dec 2;95(49):5672–5 **(Swe)**

ECONOMICS

Reducing financial barriers to HIV-related medical care: does the Ryan White CARE Act make a difference? Marx R, et al. **AIDS Care** 1998 Oct;10(5):611–6

Cost as a barrier to condom use: the evidence for condom subsidies in the United States. Cohen D, et al. **Am J Public Health** 1999 Apr;89(4):567–8

Trends in perceived cost as a barrier to medical care, 1991–1996. Nelson DE, et al. **Am J Public Health** 1999 Sep;89(9):1410–3

Socioeconomic barriers to cataract surgery in Nepal: the South Asian cataract management study. Snellingen T, et al. **Br J Ophthalmol** 1998 Dec;82(12):1424–8

Essential drugs in the new international economic environment. Velásquez G, et al. **Bull World Health Organ** 1999;77(3):288–92

Children's feeding programs in Atlantic Canada: reducing or reproducing inequities? McIntyre L, et al. **Can J Public Health** 1999 May–Jun;90(3):196–200

Out-of-pocket payments for health care in Croatia: implications for equity. Miroslav M, et al. **Croat Med J** 1999 Jun;40(2):152–9

Justifying mental health care costs [comment] Goldman HH. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):94–5. Comment on: Health Aff (Millwood) 1999 Mar–Apr;18(2):79–90.

Incremental change in the Australian health care system. Hall J. **Health Aff (Millwood)** 1999 May–Jun;18(3):95–110

Characteristics of health plans that treat psychiatric patients. Zarin DA, et al. **Health Aff (Millwood)** 1999 Sep–Oct; 18(5):226–36

Income inequality in the UK [editorial] [see comments] Atkinson AB. **Health Econ** 1999 Jun;8(4):283–8. Comment in: Health Econ 1999 Jun;8(4):281–2.

The 39 steps: the mystery of health inequalities in the UK [editorial] [see comments] Birch S. **Health Econ** 1999 Jun; 8(4):301–8. Comment in: Health Econ 1999 Jun;8(4):281–2.

Inequalities in health: an introduction [editorial; comment] Maynard A. **Health Econ** 1999 Jun;8(4):281–2. Comment on: Health Econ 1999 Jun;8(4):283–8. Comment on: Health Econ 1999 Jun;8(4):297–9. Comment on: Health Econ 1999 Jun;8(4):301–8.

Commentary on the Acheson report [editorial] [see comments] Williams A. **Health Econ** 1999 Jun;8(4):297–9 . Comment in: Health Econ 1999 Jun;8(4):281–2.

The effect of change of health insurance on access to care. Burstin HR, et al. **Inquiry** 1998–99 Winter;35(4):389–97

Income inequality, social cohesion, and health: clarifying the theory--a reply to Muntaner and Lynch. Wilkinson RG. **Int J Health Serv** 1999;29(3):525–43

Improving access for Medicaid-insured children: focus on front-office personnel. Lam M, et al. **J Am Dent Assoc** 1999 Mar;130(3):365–73

Impact of travel distance on the disposition of patients presenting for emergency psychiatric care. Fortney JC, et al. **J Behav Health Serv Res** 1999 Feb;26(1):104–8

Visits to specialists under Medicare: socioeconomic advantage and access to care. Blustein J, et al. **J Health Care Poor Underserved** 1998 May;9(2):153–69

Termination from Medicaid: how does it affect access, continuity of care, and willingness to purchase insurance?

Weissman JS, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):122–37

Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. Corr B, et al. **J Neurol Sci** 1998 Oct;160 Suppl 1:S141–5

Access denied: taking action for medically underserved children. Redlener I. **J Urban Health** 1998 Dec; 75(4):724–31 (2 ref.)

Health care coverage and access for children in an urban state: the New York perspective. Tallon JR Jr, et al. **J Urban Health** 1998 Dec;75(4):693–701 (8 ref.)

The role of Medicaid in ensuring children's access to care [see comments] Newacheck PW, et al. **JAMA** 1998 Nov 25;280(20):1789–93. Comment in: JAMA 1999 Apr 14;281(14):1273–4.

Cost as a barrier to medical care [letter; comment] Lewkowski M. **N Engl J Med** 1999 Apr 22;340(16):1293 . Comment on: N Engl J Med 1998 Nov 26;339(22):1644–5.

Cost as a barrier to medical care in relation to unemployment rates [letter] [see comments] Nelson DE, et al. **N Engl J Med** 1998 Nov 26;339(22):1644–5. Comment in: N Engl J Med 1999 Apr 22;340(16):1293.

Adolescent health insurance coverage: recent changes and access to care. Newacheck PW, et al. **Pediatrics** 1999 Aug; 104(2 Pt 1):195–202

Social equity and access to the World Wide Web and E-mail: implications for design and implementation of medical applications. Mandl KD, et al. **Proc AMIA Symp** 1998; :215–9

Defending telepsychiatry [letter; comment] Chen DT, et al. **Psychiatr Serv** 1999 Feb;50(2):266; discussion 267–8. Comment on: Psychiatr Serv 1998 Oct;49(10):1287–90.

Impact of user charges and socio-economic environment on visits to paediatric trauma unit in Finland. Ahlamaa-Tuompo J, et al. **Scand J Soc Med** 1998 Dec; 26(4):265–9

Utilization of the psychiatric emergency service in Mannheim: ecological and distance-related aspects. Bürgy R, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Nov; 33(11):558–67

Medicaid managed care and low-income women: implications for access and satisfaction. Salganicoff A, et al. **Womens Health Issues** 1998 Nov-Dec;8(6):339–49; discussion 350–8

HISTORY

[Equality and brotherhood--values worth preserving in the health services] Westin S. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1474–9 (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)

Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? [see comments] Monath TP, et al. **Emerg Infect Dis** 1998 Oct–Dec; 4(4):698–702. Comment in: Emerg Infect Dis 1999 May-Jun;5(3):487–9.

Challenges in securing access to care for children. Halfon N, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):48–63

Karlin v. Foust United States District Court western District of Wisconsin June 19, 1997. Bostrom B. **Issues Law Med** 1999 Spring;14(4):377–88

Report of John G. Gianopoulos. Gianopoulos JG. **Issues Law Med** 1999 Spring;14(4):425–32

Report of Basil Jackson, M.D., Ph.D., Th.D., J.D., D.Litt. Jackson B. **Issues Law Med** 1999 Spring;14(4):443–52

Report of Sandra Mahkorn, M.D., M.P.H., M.S. Mahkorn S. **Issues Law Med** 1999 Spring;14(4):433–41

Report of Anne C. Speckhard, Ph.D. Speckhard AC. **Issues Law Med** 1999 Spring;14(4):453–63

Report of Peter R. Uhlenberg, Ph D. Uhlenberg PR. **Issues Law Med** 1999 Spring;14(4):391–423

Should emergency contraceptive pills be available without prescription? Ellertson C, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):226–9, 232 (48 ref.)

Legal issues in the reproductive health care of adolescents. Lieberman D, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):109–14

Coroners and lack of emergency department resources. Thompson J. **J Emerg Med** 1999 May-Jun;17(3):541–2

The rights of children to health care [editorial] Appleyard J. **J Med Ethics** 1998 Oct;24(5):293–4

Palestinian health care under siege. Pourgourides C. **Lancet** 1999 Jul 31;354(9176):420–1

Freedom of choice in birth, abortion and the place of conscientious objection. Kristan I. **Med Law** 1998; 17(4):603–10

The rise and fall of national and North Carolina policies addressing medication access for older adults. Altman HK. **N C Med J** 1999 Jul-Aug;60(4):198–202

[Alternative therapies after enactment of the Individual Health Care Professionals Act (Wet BIG)] Gevers JK. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):210–3 (Eng. Abstr.) **(Dut)**

[Is it necessary to continue admitting children to the general hospital?] Saint-Martin J. **Arch Pediatr** 1998;5 Suppl 2:212s–213s **(Fre)**

[Physician-patient relations: right or self determination. Path across the Atlantic regarding medical responsibility] Hervé C, et al. **Presse Med** 1998 Sep 19;27(27):1387–9 (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Access to care for the uninsured: is access to a physician enough? Mainous AG 3rd, et al. **Am J Public Health** 1999 Jun;89(6):910–2

Service system integration, access to services, and housing outcomes in a program for homeless persons with severe mental illness. Rosenheck R, et al. **Am J Public Health** 1998 Nov;88(11):1610–5

Improving access to disability benefits among homeless persons with mental illness: an agency-specific approach to services integration. Rosenheck R, et al. **Am J Public Health** 1999 Apr;89(4):524–8

Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.). Comment on: Am J Public Health 1999 Jun;89(6):834–9.

Managed care and people with disabilities: framing the issues. Sutton JP, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1312–6 (47 ref.)

A comparison of measures of access to child health clinics and the implications for modelling the location of new clinics. Hyndman JC, et al. **Aust N Z J Public Health** 1999 Apr;23(2):189–95

Walk-in health care [news] Warden J. **BMJ** 1999 Mar 20; 318(7186):756

Universal emergency access under managed care: universal doubt or mission impossible? Larkin GL, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):213–25 (70 ref.)

The dermatologist in military operations. Keeling JH, et al. **Dermatol Clin** 1999 Jan;17(1):209–34, x (36 ref.)

Race, ethnicity and disasters in the United States: a review of the literature. Fothergill A, et al. **Disasters** 1999 Jun; 23(2):156–73 (69 ref.)

Technician run open access exercise electrocardiography. Agrawal S, et al. **Heart** 1999 Sep;82(3):378–82

The accent's on access. Public and private hospitals join hands to improve health care for poorer Chicagoans. Novarro L. **Hosp Health Netw** 1998 Oct 5;72(19):20

Analysis of the organisational aspects of gastroenterology services in Italy. Capocaccia L, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):451–61 (13 ref.)

Arkansas Health Care Access Foundation begins its tenth year of helping Arkansas in need. Keller P. **J Ark Med Soc** 1998 Dec;95(7):277

Measuring the success of the Arkansas Health Care Access Foundation. Sawyer M. **J Ark Med Soc** 1998 Dec; 95(7):279–81

Nurses decrease barriers to health care by "hyperlinking" multiple-diagnosed women living with HIV/AIDS into care. Andersen MD, et al. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):55–65

Reaching out to the underserved: a collaborative partnership to provide health care. Ahmed SM, et al. **J Health Care Poor Underserved** 1999 May;10(2):157–68

Access to treatment for depression in a Medicaid population. Melfi CA, et al. **J Health Care Poor Underserved** 1999 May; 10(2):201–15

Health status and access to care among rural minorities. Mueller KJ, et al. **J Health Care Poor Underserved** 1999 May;10(2):230–49 (193 ref.)

Access to medical care under strain: new pressures in Canada and Australia. Gray G. **J Health Polit Policy Law** 1998 Dec;23(6):905–47 (111 ref.)

The Medicare Critical Access Hospital program: the first year. Reif SS, et al. **J Rural Health** 1999 Winter;15(1):61–6

European breast-cancer meeting [letter; comment] Kunkler I. **Lancet** 1998 Nov 21;352(9141):1711. Comment on: Lancet 1998 Oct 10;352(9135):1200.

Accessible dental care for children. McManus J, et al. **N Y State Dent J** 1999 Mar;65(3):24–6

The geographical assignment of cancer units: patient accessibility as an optimal allocation problem. Smallman-Raynor MR, et al. **Public Health** 1998 Nov; 112(6):379–83

HRSA's Models That Work Program: implications for improving access to primary health care. Crump RL, et al. **Public Health Rep** 1999 May-Jun;114(3):218–24

Does a hostel's managing agency determine the access to psychiatric services of its residents? Lucas B, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Oct; 33(10):497–500

Social movements and health insurance: a critical evaluation of voluntary, non-profit insurance schemes with case studies from Ghana and Cameroon. Atim C. **Soc Sci Med** 1999 Apr;48(7):881–96

The reform of the rural cooperative medical system in the People's Republic of China: interim experience in 14 pilot counties. Carrin G, et al. **Soc Sci Med** 1999 Apr; 48(7):961–72

Expanding contraceptive choice: findings from Brazil. Díaz M, et al. **Stud Fam Plann** 1999 Mar;30(1):1–16

Mammography facility trends across Wisconsin. Propeck PA, et al. **WMJ** 1998 Dec;97(11):39–42

[The diagnostic report as an aid for determination of referral to inpatient rehabilitation] Petermann F, et al. **Rehabilitation (Stuttg)** 1999 Feb;38(1):1–6 (Eng. Abstr.) **(Ger)**

STANDARDS

Potential barriers to the removal of Norplant among family planning clinic patients. Kalmuss D, et al. **Am J Public Health** 1998 Dec;88(12):1846–50

Hypertension control and access to medical care in the inner city. Kotchen JM, et al. **Am J Public Health** 1998 Nov; 88(11):1696–9

Managed health care organizations and emergency care. Emergency Medicine Practice Committee, American College of Emergency Physicians. **Ann Emerg Med** 1999 Jul;34(1):126–7

Needs of patients with learning disabilities are not being met [letter] Lakhani M, et al. **BMJ** 1999 Jun 26;318(7200):1764

AIDS as a lever for reducing inequality and increasing solidarity [letter] Martin J. **Bull World Health Organ** 1999; 77(4):364

Quality, accessibility, and contraceptive use in rural Tanzania. Mroz TA, et al. **Demography** 1999 Feb; 36(1):23–40

Household survey of access to and utilisation of emergency oral health care services in rural Tanzania. Ntabaye MK, et al. **East Afr Med J** 1998 Nov;75(11):649–53

Differential provision or acquisition of health care is related to one's race or gender [letter; comment] Neuhauser D, et al. **Ethn Dis** 1999 Winter;9(1):145–6. Comment on: Ethn Dis 1997 Spring-Summer;7(2):91–105.

Reducing health inequalities: Britain's latest attempt. Illsley R. **Health Aff (Millwood)** 1999 May-Jun;18(3):45–6

Acting on the evidence to reduce inequalities in health. Marmot M. **Health Aff (Millwood)** 1999 May-Jun; 18(3):42–4

On the measurement of the nation's equity adjusted health. Lindholm L, et al. **Health Econ** 1998 Nov;7(7):621–8

ACOG committee opinion. Condom availability for adolescents. Number 154 -- April 1995. Committee on Adolescent Health Care. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Jun;49(3):347–51

Improving women's access to emergency contraception: innovative information and service delivery strategies. Blanchard K. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):238–41 (23 ref.)

Relationship between ambulatory care accessibility and hospitalization for persons with advanced HIV disease. Laine C, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):313–27

Physician perceptions of barriers to care for inner-city Latino children with asthma. Lara M, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):27–44

Managed care in rural markets: availability and enrollment. Wysong JA, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):72–84

Increased cervical cytologic smear access through increased capacity [letter] Shaver JL. **J Reprod Med** 1998 Nov; 43(11):1005–6

Multi-method assessment of access to primary medical care in rural Colorado. Fryer GE Jr, et al. **J Rural Health** 1999 Winter;15(1):113–21

Barriers to seeking care following school vision screening in Rochester, Minnesota. Yawn BP, et al. **J Sch Health** 1998 Oct;68(8):319–24

"Press 1 for more options" [editorial] Haseltine FP. **J Womens Health** 1998 Nov;7(9):1069–70

The impact of geographic accessibility on the intensity and quality of depression treatment. Fortney J, et al. **Med Care** 1999 Sep;37(9):884–93

Telephone triage as a strategy to ensure 24-hour access to medical care after the closure of supporting medical activity. Flynn DM. **Mil Med** 1998 Oct;163(10):702–6

The impact of the Mammography Quality Standards Act on the availability of mammography facilities. Fischer R, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):697–701

Comparisons of immunisation accessibility between non-US born and US-born children in New York City. Sun WY, et al. **Public Health** 1998 Nov;112(6):405–8

Equity in the delivery of health care in Sweden. Gerdtham UG, et al. **Scand J Soc Med** 1998 Dec;26(4):259–64

Sociodemographic predictors and cultural barriers to help-seeking behavior by Latina and Anglo American battered women. West CM, et al. **Violence Vict** 1998 Winter;13(4):361–75

Action on low immunization uptake. Azubuike MC, et al. **World Health Forum** 1998;19(4):362–4

[Cesarean sections in Senegal: coverage of needs and quality of services] Cisse CT, et al. **Sante** 1998 Sep-Oct;8(5):369–77 (Eng. Abstr.) **(Fre)**

[Primary care: Innocent! (letter)] Regueiro Martínez A. **Aten Primaria** 1999 Jun 15;24(1):49 **(Spa)**

STATISTICS & NUMERICAL DATA

Adolescents' access to reproductive health and family planning services in Dakar (Senegal). Naré C, et al. **Afr J Reprod Health** 1997 Sep;1(2):15–25

Barriers to social services for HIV-infected urban migrators. Montoya ID, et al. **AIDS Educ Prev** 1998 Aug;10(4):366–79

Variations in the use of cardiac procedures in the Veterans Health Administration [see comments] Mirvis DM, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):706–13. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):588–9.

Overcrowding in the ED: an international symptom of health care system failure [editorial] Graff L.

Am J Emerg Med 1999 Mar;17(2):208–9

ED overcrowding in Taiwan: facts and strategies. Shih FY, et al. **Am J Emerg Med** 1999 Mar;17(2):198–202

Orthopedic patients' satisfaction with their health care plan: a study performed by the Research and Education Committee of the Texas Orthopaedic Association. Brinker MR, et al. **Am J Orthop** 1999 Aug;28(8):451–6; discussion 456–7

Health care access and seven-year change in cigarette smoking. The CARDIA Study. Kiefe CI, et al. **Am J Prev Med** 1998 Aug;15(2):146–54

The effect of a Medicaid managed care program on the adequacy of prenatal care utilization in Rhode Island. Griffin JF, et al. **Am J Public Health** 1999 Apr; 89(4):497–501

The impact of welfare reform on parents' ability to care for their children's health [see comments] Heymann SJ, et al. **Am J Public Health** 1999 Apr;89(4):502–5. Comment in: Am J Public Health 1999 Apr;89(4):477–9.

Premature mortality in the United States: the roles of geographic area, socioeconomic status, household type, and availability of medical care. Mansfield CJ, et al. **Am J Public Health** 1999 Jun;89(6):893–8

Dental care access and use among HIV-infected women [see comments] Shiboski CH, et al. **Am J Public Health** 1999 Jun;89(6):834–9. Comment in: Am J Public Health 1999 Jun;89(6):818–9.

Accessibility of primary care physicians' offices for people with disabilities. An analysis of compliance with the Americans With Disabilities Act. Grabois EW, et al. **Arch Fam Med** 1999 Jan–Feb;8(1):44–51

Commentary on caring for the uninsured and underinsured. Lee PP. **Arch Ophthalmol** 1999 Mar;117(3):392–3

Access barriers to health care for Latino children. Flores G, et al. **Arch Pediatr Adolesc Med** 1998 Nov; 152(11):1119–25

A comparison study of an elementary school-based health center: effects on health care access and use. Kaplan DW, et al. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):235–43

The horizontal equity of health care in New Zealand. Peacock D, et al. **Aust N Z J Public Health** 1999 Apr; 23(2):126–30

Health care in Ethiopia. Payne D. **Can Fam Physician** 1998 Oct;44:2069–73, 2075–6

Access to an outpatient cardiology consultation in southwestern Ontario. Massel D. **Can J Cardiol** 1999 Aug; 15(8):879–83 **(Eng, Fre)**

Drug access among homeless men in Toronto. Hwang SW, et al. **CMAJ** 1999 Apr 6;160(7):1021

The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Breen N, et al. **Ethn Dis** 1999 Winter;9(1):111–25

Access to family planning clinics--a local experience. Reed B, et al. **Eur J Contracept Reprod Health Care** 1999 Mar; 4(1):49–53

Abortion incidence and services in the United States, 1995–1996. Henshaw SK. **Fam Plann Perspect** 1998 Nov–Dec;30(6):263–70, 287

Access to and use of out-of-hours services by members of Vietnamese community groups in South London: a focus group study. Free C, et al. **Fam Pract** 1999 Aug; 16(4):369–74

Managed care for children: effect on access to care and utilization of health services. Szilagyi PG. **Future Child** 1998 Summer–Fall;8(2):39–59 (68 ref.)

Pressures on safety net access: the level of managed care penetration and uninsurance rate in a community. Cunningham PJ. **Health Serv Res** 1999 Apr;34(1 Pt 2):255–70

Access and use of medications in HIV disease. Smith SR, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):123–44

Differences in the use of health care facilities and patterns of general risk factors in farmers with and without occupational health care programs. Thelin A, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):170–6

Service utilization among homeless and runaway youth in Los Angeles, California: rates and reasons [corrected and republished article originally printed in J Adolesc Health 1999 Mar;24(3):190–200] De Rosa CJ, et al. **J Adolesc Health** 1999 Jun;24(6):449–58

Unmet need for eyeglasses: results from the 1994 Robert Wood Johnson Access to Care Survey. Hodges LE, et al. **J Am Optom Assoc** 1999 Apr;70(4):261–5

Availability of eye care services in Missouri nursing homes. Wingert TA, et al. **J Am Optom Assoc** 1999 Jul;70(7):470–4

Availability of primary care providers and pharmacists in the United States. Knapp KK, et al. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr;39(2):127–35

Barriers and facilitators to use of services following intensive family preservation services. Staudt M. **J Behav Health Serv Res** 1999 Feb;26(1):39–49

The three leading causes of death in African Americans: barriers to reducing excess disparity and to improving health behaviors. Feldman RH, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):45–71

Managed care and Medicaid reform in Tennessee: the impact of TennCare on access and health-seeking behavior. Lyons W, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):328–37

Medicaid beneficiaries' experiences in HMO and fee-for-service health care. Piña DL. **J Health Care Poor Underserved** 1998 Nov;9(4):433–48

Access to primary care for patients with diabetes at an urban public hospital walk-in clinic. Schiff RL, et al. **J Health Care Poor Underserved** 1998 May;9(2):170–83

Health status, needs, and health care barriers among the homeless. Wojtusik L, et al. **J Health Care Poor Underserved** 1998 May;9(2):140–52

The health status of veterans using mobile clinics in rural areas. Wray NP, et al. **J Health Care Poor Underserved** 1999 Aug;10(3):338–48

Access to complementary medicine in general practice: survey in one UK health authority. Wearn AM, et al. **J R Soc Med** 1998 Sep;91(9):465–70

Geographic variation in physician visits for uninsured children: the role of the safety net. Long SH, et al. **JAMA** 1999 Jun 2;281(21):2035–40

GIS/GPS to document increased access to community-based treatment for tuberculosis in Africa. Geographic information system/global positioning system [letter] Wilkinson D, et al. **Lancet** 1999 Jul 31;354(9176):394–5

Leprosy and disability control in the Guéra prefecture of Chad, Africa: do women have access to leprosy control services? Schäfer J. **Lepr Rev** 1998 Sep;69(3):267–78

Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery [see comments] Hannan EL, et al. **Med Care** 1999 Jan; 37(1):68–77. Comment in: Med Care 1999 Jan;37(1):3–4.

Patients' socio-demographics characteristics and utilization of health care: looking beyond appearances...at last [editorial; comment] Horner RD. **Med Care** 1999 Jan; 37(1):3–4. Comment on: Med Care 1999 Jan;37(1):68–77.

Access to health care services among people with disabilities receiving Medicaid. Hagglund KJ, et al. **Mo Med** 1999 Sep;96(9):447–53

A qualitative study of general practitioner access to diagnostic imaging services in the Central Region. Durham JA, et al. **N Z Med J** 1999 Jun 11;112(1089):211–4

Delay in gynecologic surgical treatment: a comparison of patients in managed care and fee-for-service plans. Chin S, et al. **Obstet Gynecol** 1999 Jun;93(6):922–7

Language barriers and resource utilization in a pediatric emergency department. Hampers LC, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1253–6

Access for low-income children: is health insurance enough? Rosenbach ML, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1167–74

Differential access to care for children with ADHD in special education programs. Bussing R, et al. **Psychiatr Serv** 1998 Sep;49(9):1226–9

Out-of-hours utilization in primary and secondary care. A favourable experience in a Finnish health centre. Toivanen A, et al. **Scand J Prim Health Care** 1998 Jun;16(2):72–5

HIV/AIDS in nonurban Alabama: risk activities and access to services among HIV-infected persons. Beltrami JF, et al. **South Med J** 1999 Jul;92(7):677–83

Access to health and human services for drug users: an urban/rural community systems perspective. Rivers JE, et al. **Subst Use Misuse** 1999 Mar–Apr;34(4–5):707–25

Pre-AIDS mortality and morbidity among injection drug users in Amsterdam and Baltimore: an ecological comparison. van Ameijden EJ, et al. **Subst Use Misuse** 1999 May;34(6):845–65

[Admission status of alcohol and drug-dependent patients in "high threshold" access to withdrawal treatment] Wagner HB, et al. **Psychiatr Prax** 1999 Jan;26(1):25–8 (Eng. Abstr.) **(Ger)**

[Sex-specific differences in risks and management of coronary heart disease] Scheuermann W, et al. **Z Kardiol** 1998 Jul;87(7):528–36 (47 ref.) (Eng. Abstr.) **(Ger)**

[Access to the pediatric ambulatory service at a university hospital] Franco SC, et al. **Rev Saude Publica** 1998 Aug; 32(4):352–60 (Eng. Abstr.) **(Por)**

TRENDS

International developments in abortion law from 1988 to 1998. Cook RJ, et al. **Am J Public Health** 1999 Apr; 89(4):579–86 (122 ref.)

Trends in small hospital medical services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2107–12

Trends in small hospital obstetric services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2117–24

Health spending, access, and outcomes: trends in industrialized countries. Anderson GF, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):178–92

Changes in access to care, 1977–1996: the role of health insurance. Zuvekas SH, et al. **Health Serv Res** 1999 Apr; 34(1 Pt 2):271–9

Development and future of open access echocardiography [editorial] de Bono D. **Hosp Med** 1998 Aug;59(8):600, 602

Summary and next steps in achieving universal access. Haggerty RJ. **J Urban Health** 1998 Dec;75(4):772–6 (0 ref.)

A difficult new year for the National Health Service [news] Dean M. **Lancet** 1999 Jan 9;353(9147):129

Monitoring the impact of hospital downsizing on access to care and quality of care. Brownell MD, et al. **Med Care** 1999 Jun;37(6 Suppl):JS135–50

Trends in health services utilization in eight provinces in China, 1989–1993. Henderson GE, et al. **Soc Sci Med** 1998 Dec;47(12):1957–71

HEALTH SERVICES ADMINISTRATION

Health to get a higher priority in post-devolution Scotland [news] [see comments] **BMJ** 1999 Jan 9;318(7176):80. Comment in: BMJ 1999 May 1;318(7192):1215.

Scottish doctors launch their manifesto [news] Beecham L. **BMJ** 1999 Jan 23;318(7178):214

Regionalization of health services in Canada: a critical perspective. Church J, et al. **Int J Health Serv** 1998; 28(3):467–86

The business value of health care information technology. Frisse MC. **J Am Med Inform Assoc** 1999 Sep–Oct; 6(5):361–7

Personalized health care and business success: can informatics bring us to the promised land? Ozbolt JG. **J Am Med Inform Assoc** 1999 Sep–Oct;6(5):368–73

Public health management [editorial] Hunter DJ. **J Epidemiol Community Health** 1998 Jun;52(6):342–3

Management forecast: optimizing the use of organizational and individual knowledge. Moss MT. **J Nurs Adm** 1999 Jan;29(1):57–62

A study to determine how needs assessment is being used to improve health. Hanlon P, et al. **Public Health** 1998 Sep;112(5):343–6

Presidential address: a clash of cultures--personal autonomy versus corporate bondage. Buchwald H. **Surgery** 1998 Oct; 124(4):595–603

[Managerial training as an instrument of change in health. The educational objectives and their verification in managerial training courses for the health administrators in the G. Sanelli Institute of Hygiene, 1988–1998] D'Alessandro D, et al. **Ann Ig** 1999 Mar–Apr;11(2):161–71 (Eng. Abstr.) **(Ita)**

[Work experience at the Yakutsk Urban Sanitary and Epidemiological Surveillance Center] Alekseev DA. **Gig Sanit** 1998 Sep–Oct;(5):69–70 **(Rus)**

[Administrative medicine should be a subject in medical training!] Collste L, et al. **Lakartidningen** 1999 Apr 14; 96(15):1809 **(Swe)**

[The main trends in the reform of the surgical services in the regional administration, improvement of the quality and efficacy of surgical services to the population] Petrenko VIu. **Klin Khir** 1999;(4):46 **(Ukr)**

LEGISLATION & JURISPRUDENCE

Decentralised health care in Canada [see comments] Armstrong P, et al. **BMJ** 1999 May 1;318(7192):1201–4. Comment in: BMJ 1999 May 1;318(7192):1155–6.

Decentralisation and equity of healthcare provision in Finland. Koivusalo M. **BMJ** 1999 May 1; 318(7192):1198–200

ORGANIZATION & ADMINISTRATION

Changing policies in the Veterans Health Administration. Will they make a difference? [editorial] Jones DB. **Arch Ophthalmol** 1999 Jan;117(1):106–7 (3 ref.)

The potential for Ontario region's health information system to facilitate case management, program planning, and evaluation and to promote enhanced First Nations' control of health services. Johnson RJ. **Int J Circumpolar Health** 1998;57 Suppl 1:671–4

Lessons from a failed information systems initiative: issues for complex organisations. Southon G, et al. **Int J Med Inf** 1999 Jul;55(1):33–46

Mutual accountability in partnerships: health agencies and community groups. Labonte R. **Promot Educ** 1999 Mar; 6(1):3–8, 36 (12 ref.)

New birth and death registration forms [letter; comment] McDonald KD. **S Afr Med J** 1998 Nov;88(11):1358. Comment on: S Afr Med J 1998 Aug;88(8):971–4.

Governmental steering of highly specialized medical services [editorial] [see comments] Forfang K. **Scand Cardiovasc J** 1998;32(4):197–9 (5 ref.). Comment in: Scand Cardiovasc J 1998;32(4):195.

[Economic evaluation in cardiology: background and application (letter; comment)] Naaborg R. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2164–5. Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2083–6. **(Dut)**

[Delivery of hospital discharge reports to health insurance and medical insurance medical services] Rieger HJ. **Dtsch Med Wochenschr** 1999 Apr 1;124(13):403–4 **(Ger)**

[A model of sanitary-epidemiological service management based on the example of the Sverdlovsk region] Rudakov IuE, et al. **Gig Sanit** 1998 Sep–Oct;(5):65–7 **(Rus)**

[Characteristics of the leadership of health center coordinators in the autonomous community of Murcia] Menárguez Puche JF, et al. **Aten Primaria** 1998 Dec; 22(10):636–41 (Eng. Abstr.) **(Spa)**

[The methodological principles of the organization and economics of paid medical services] Nazar PS, et al. **Lik Sprava** 1998 Jul–Aug;(5):157–60 **(Ukr)**

STANDARDS

Quality and accreditation in nephrology. The Italian perspective. Management and quality control. Quintaliani G, et al. **Int J Artif Organs** 1998 Nov;21(11):762–6

[Health organizations: how to attract and keep the best minds?] Aparo UL. **Ann Ig** 1999 May–Jun;11(3):245–6 **(Ita)**

HEALTH SERVICES ADMINISTRATION

TRENDS

[Application of the C.C.N.L, in the management if National Health Service. Experience of the USL 2 Pentria Agency in the introduction of the MBO (Management by Objectives) System] Ricci N, et al. **Ann Ig** 1999 May-Jun; 11(3):237–44 **(Ita)**

HEALTH SERVICES, ADOLESCENT see **ADOLESCENT HEALTH SERVICES**

HEALTH SERVICES FOR THE AGED

The attitudes of patients to integrated medical care [see comments] Bene J, et al. **Age Ageing** 1999 May;28(3):271–3 . Comment in: Age Ageing 1999 May;28(3):245–7.

A survey of attitudes and knowledge of geriatricians to driving in elderly patients. Gillespie ND, et al. **Age Ageing** 1999 Jan;28(1):53–7

Are new medical students interested in the introduction of public long-term care insurance in Japan? [letter] Naito M. **Age Ageing** 1999 Jan;28(1):84

Costing for long-term care: the development of Scottish health service resource utilization groups as a casemix instrument. Urquhart J, et al. **Age Ageing** 1999 Mar; 28(2):187–92

Care of the older Hong Kong Chinese population. Woo J, et al. **Age Ageing** 1998 Jul;27(4):423–6

ASHP therapeutic position statement on the recognition and treatment of depression in older adults: American Society of Health-System Pharmacists [see comments] **Am J Health Syst Pharm** 1998 Dec 1;55(23):2514–8. Comment in: Am J Health Syst Pharm 1998 Dec 1;55(23):2481.

Depression in older adults [editorial; comment] Patrias JM. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2481. Comment on: Am J Health Syst Pharm 1998 Dec 1;55(23):2514–8.

Public health in managed care: a randomized controlled trial of the effectiveness of postcard reminders. Clayton AE, et al. **Am J Public Health** 1999 Aug;89(8):1235–7

Day hospital rehabilitation for the elderly: a retrospective study. Wong SF, et al. **Ann Acad Med Singapore** 1998 Jul; 27(4):468–73

Understanding changing risk factor associations with increasing age in adults. Kaplan GA, et al. **Annu Rev Public Health** 1999;20:89–108 (62 ref.)

Preventive care of the elderly. Cohen J. **Aust Fam Physician** 1999 Jul;28(7):659–62

Optimising care of the hospitalised elderly. A literature review and suggestions for future research. Scott I. **Aust N Z J Med** 1999 Apr;29(2):254–64 (76 ref.)

Prescribing for the elderly patient: why do we need to exercise caution? Hughes SG. **Br J Clin Pharmacol** 1998 Dec;46(6):531–3

Immobility as a major cause of bone remodeling in residents of a long-stay geriatric ward. Bischoff H, et al. **Calcif Tissue Int** 1999 Jun;64(6):485–9

The challenge of health care delivery to the elderly patient with cardiovascular disease. Demographic, epidemiologic, fiscal, and health policy implications. Batchelor WB, et al. **Cardiol Clin** 1999 Feb;17(1):1–15, vii (71 ref.)

Promises and perils of managed care for older patients with cardiac disease. Friesinger GC, et al. **Cardiol Clin** 1999 Feb; 17(1):67–77, viii (83 ref.)

Specialized chronic care for dialysis patients--a five-year study. Jassal SV, et al. **Clin Nephrol** 1998 Aug;50(2):84–9

Cancer in the elderly [editorial] Brewin T. **Clin Oncol (R Coll Radiol)** 1998;10(5):281–2

The views of therapists on the use of a patient-held record in the care of stroke patients. Ayana M, et al. **Clin Rehabil** 1998 Aug;12(4):328–37

Factors affecting access to drug therapy in the elderly. Dombrower H, et al. **Drugs Aging** 1998 Oct;13(4):303–9

Health care rationing in the aged: ethical and clinical perspectives. Howe EG, et al. **Drugs Aging** 1999 Jul; 15(1):37–47 (52 ref.)

Outpatient care programmes for the elderly [letter; comment] Ekman I, et al. **Eur Heart J** 1999 Mar;20(5):393–4. Comment on: Eur Heart J 1998 Aug;19(8):1124–5. Comment on: Eur Heart J 1998 Aug;19(8):1254–60.

Functional ability among elderly people in three service settings: the discriminatory power of a new functional ability scale. Avlund K, et al. **Eur J Epidemiol** 1998 Dec; 14(8):783–90

Prescription medication use in older Americans: a national report card on prescribing. Rathore SS, et al. **Fam Med** 1998 Nov-Dec;30(10):733–9

Can GP input into discharge planning result in better outcomes for the frail aged: results from a randomized controlled trial. McInnes E, et al. **Fam Pract** 1999 Jun; 16(3):289–93

Participatory design of an Internet-based information system for aging services professionals. Ellis RD, et al. **Gerontologist** 1998 Dec;38(6):743–8

Improving a system of care for elderly persons in rural areas. Harris D, et al. **Gerontologist** 1999 Jun;39(3):362–7

A standardized menu for Goal Attainment Scaling in the care of frail elders. Yip AM, et al. **Gerontologist** 1998 Dec; 38(6):735–42

Ethnomethodologic analysis of accounts of feeding demented residents in long-term care. Pierson CA. **Image J Nurs Sch** 1999;31(2):127–31

Scenario--long-term care for the elderly. Tashiro J, et al. **Image J Nurs Sch** 1999;31(2):133–7

Disability and depressive symptoms in the elderly: the effects of instrumental support and its subjective appraisal. Wallsten SM, et al. **Int J Aging Hum Dev** 1999;48(2):145–59

The relationship between staff burnout/distress and interactions with residents in two residential homes for older people. Jenkins H, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):466–72

Impact of visual impairment on use of community support services by elderly persons: the Blue Mountains Eye Study. Wang JJ, et al. **Invest Ophthalmol Vis Sci** 1999 Jan; 40(1):12–9

Predictors of loneliness in elderly Korean immigrant women living in the United States of America. Kim O. **J Adv Nurs** 1999 May;29(5):1082–8

Continuing care: developing a policy analysis for nursing. Maslin-Prothero S, et al. **J Adv Nurs** 1998 Sep;28(3):548–53

Decision-making for percutaneous endoscopic gastrostomy among older adults in a community setting. Callahan CM, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1105–9

Randomized controlled trial of nurse case management of frail older people. Gagnon AJ, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1118–24

Functional status of elderly home care users: do subjects, informal and professional caregivers agree? Santos-Eggimann B, et al. **J Clin Epidemiol** 1999 Mar; 52(3):181–6

The combined effects of baseline vulnerability and acute hospital events on the development of functional dependence among community-living older persons. Gill TM, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jul; 54(7):M377–83

Educational implications of "real-life" community health care delivery to underserved elders by RN baccalaureate nursing students. Tanner EK, et al. **J Nurs Educ** 1998 Nov; 37(8):354–7

Faculty practice as partnership with a community coalition. Gale BJ. **J Prof Nurs** 1998 Sep-Oct;14(5):267–71

The pitfalls of the Golden Rule in caregiving. Maxfield MC, et al. **J Psychosoc Nurs Ment Health Serv** 1999 May; 37(5):46–7

Improving geriatric services [editorial] Black D. **J R Coll Physicians Lond** 1999 Mar-Apr;33(2):113

The management of cancer in the elderly. Ashkanani F, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):2–10 (65 ref.)

Income characteristics of rural older women and implications for health status. Barnes ND, et al. **J Women Aging** 1999; 11(1):27–37

Health care of the elderly in Japan. Hayashi K. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999;15 Suppl:S19–20

The effectiveness of videophones in home healthcare for the elderly [see comments] Nakamura K, et al. **Med Care** 1999 Feb;37(2):117–25. Comment in: Med Care 1999 Feb;37(2):115–6.

Hospital in the home: a randomised controlled trial [letter] Dickson HG, et al. **Med J Aust** 1999 Jul 19;171(2):109–10

Melanoma in the elderly--a neglected public health challenge [letter; comment] Heenan PJ, et al. **Med J Aust** 1999 Apr 19;170(8):394–5. Comment on: Med J Aust 1998 Oct 19;169(8):403–4. Comment on: Med J Aust 1998 Oct 19;169(8):410–4.

Hospital in the home: a randomised controlled trial [letter] Thomas JA. **Med J Aust** 1999 Jul 19;171(2):110–1

Treating depressed older adults in primary care: narrowing the gap between efficacy and effectiveness. Unützer J, et al. **Milbank Q** 1999;77(2):225–56, 174 (138 ref.)

Geriatrics and the limits of modern medicine. Goodwin JS. **N Engl J Med** 1999 Apr 22;340(16):1283–5

Geriatrics and the limits of medicine [letter] Weksler ME. **N Engl J Med** 1999 Sep 2;341(10):768–9

Rethinking geriatric nursing. Fulmer T, et al. **Nurs Clin North Am** 1998 Sep;33(3):387–94 (3 ref.)

Access to health care resources for family caregivers of elderly persons with dementia. Kelley LS, et al. **Nurs Outlook** 1999 Jan-Feb;47(1):8–14 (39 ref.)

Meeting the health care needs of the elderly [letter; comment] Moore JE. **Nurs Outlook** 1999 Mar-Apr;47(2):95. Comment on: Nurs Outlook 1998 Jul-Aug;46(4):149–50.

Safety issues in the pharmacologic management of chronic pain in the elderly. Shimp LA. **Pharmacotherapy** 1998 Nov-Dec;18(6):1313–22 (74 ref.)

Meeting the needs of unpartnered elders: a peer training program involving elders with myocardial infarction. Robinson E, et al. **Prog Cardiovasc Nurs** 1998 Fall; 13(4):13–23

Depression among caregivers of the elderly in need of care and their service utilization: a pilot study. Arai Y, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):463–5

Psychoendocrine concomitants in patients following a new design of a geriatric day-care unit. Lökk J. **Psychother Psychosom** 1998;67(6):323–7

Predictors of elders' and family caregivers' use of formal home services. Houde SC. **Res Nurs Health** 1998 Dec; 21(6):533–43

Ethics in long-term care. Are the principles different? Kuczewski MG. **Theor Med Bioeth** 1999 Jan;20(1):15–29

Systems of care for frail older persons. InterRAI. Steel K, et al. **Trans Am Clin Climatol Assoc** 1999;110:30–5; discussion 35–7

[Prevention of health problems and functional limitations among the elderly] Hendriksen C, et al. **Ugeskr Laeger** 1999 Jun 14;161(24):3638–40 **(Dan)**

[Control of nosocomial infections by multiresistant bacteria in geriatric services] Prieur B, et al. **Pathol Biol (Paris)** 1998 Apr;46(4):268–71 (17 ref.) (Eng. Abstr.) **(Fre)**

[Loss of autonomy in the elderly. Etiology, evaluation methods, consequences for medical-social management] Wolmark Y. **Rev Prat** 1998 Oct 15;48(16):1836–40 **(Fre)**

[Preventive nutritional services for the elderly] Millen BE. **Z Gerontol Geriatr** 1999 Jul;32 Suppl 1:I80–8 (85 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of the clients in a geriatric intermediate care facility located in the suburbs of an urban area and factors related to the discharge destinations desired by family caregivers] Watanabe M, et al. **Nippon Eiseigaku Zasshi** 1999 Jan;53(4):618–25 (Eng. Abstr.) **(Jpn)**

[The health and welfare system for elderly in France] Sauvaget C, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul; 45(7):664–74 (Eng. Abstr.) **(Jpn)**

[Health care within the research program of the EU for 1999-2002: age-related diseases and public health are prioritized] Olsson S. **Lakartidningen** 1999 Apr 28; 96(17):2108–10 **(Swe)**

[Concentrate on geriatrics (letter)] Selander G. **Lakartidningen** 1999 May 12;96(19):2331–2 **(Swe)**

ECONOMICS

The economic impact of geriatric hip fractures. Youm T, et al. **Am J Orthop** 1999 Jul;28(7):423–8 (47 ref.)

Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Mann WC, et al. **Arch Fam Med** 1999 May-Jun;8(3):210–7

Funding long term care for older people. Redistribution of wealth from rich to poor is not function of a care service [letter] Heath I. **BMJ** 1999 Jul 3;319(7201):56

Funding long term care for older people. Taxes ensure equal quality care for all at time it is needed [letter] Jolley D. **BMJ** 1999 Jul 3;319(7201):56

With respect to old age [editorial] Murphy E. **BMJ** 1999 Mar 13;318(7185):681–2

Ageing costs. Evidence to royal commission emphasises need for explicit standards and funding [editorial] Richards T. **BMJ** 1998 Oct 3;317(7163):896

Coronary artery bypass grafting in elderly patients: the price of success [editorial; comment] Cohen EA. **CMAJ** 1999 Mar 23;160(6):823–5 (13 ref.). Comment on: CMAJ 1999 Mar 23;160(6):805–11.

Direct costs of coronary artery bypass grafting in patients aged 65 years or more and those under age 65 [see comments] Naglie G, et al. **CMAJ** 1999 Mar 23; 160(6):805–11. Comment in: CMAJ 1999 Mar 23;160(6):823–5. Comment in: CMAJ 1999 Aug 24;161(4):365.

The cost of dementia in Denmark: the Odense Study. Kronborg Andersen C, et al. **Dement Geriatr Cogn Disord** 1999 Jul-Aug;10(4):295–304

Economic evaluation is essential in health care for the elderly. A viewpoint. Leidl R, et al. **Drugs Aging** 1998 Oct; 13(4):255–62 (34 ref.)

Restructuring Medicare for the next century: what will beneficiaries really need? Cassel CK, et al. **Health Aff (Millwood)** 1999 Jan-Feb;18(1):118–31

Health care for the elderly: how much? Who will pay for it? Fuchs VR. **Health Aff (Millwood)** 1999 Jan-Feb; 18(1):11–21

The effect of a redistribution system for health care for the elderly on the financial performance of health insurance societies in Japan. Babazono A, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):458–66

Cost of health care for a community of older adults in an urban academic healthcare system [see comments] Callahan CM, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1371–7. Comment in: J Am Geriatr Soc 1998 Nov;46(11):1478–9.

MediCaring: development and test marketing of a supportive care benefit for older people [see comments] Lynn J, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1058–64. Comment in: J Am Geriatr Soc 1999 Sep;47(9):1153–4.

Longevity may decrease medical costs [letter] Nakajoh K, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1161–2

Financing long-term care for elderly persons: what are the options? Amaradio L. **J Health Care Finance** 1998 Winter; 25(2):75–84 (23 ref.)

Visits to specialists under Medicare: socioeconomic advantage and access to care. Blustein J, et al. **J Health Care Poor Underserved** 1998 May;9(2):153–69

Outcome and cost of trauma among the elderly: a real-life model of a single-payer reimbursement system. Young JS, et al. **J Trauma** 1998 Oct;45(4):800–4

Royal commission divided over reform of long-term UK care [news] Dean M. **Lancet** 1999 Mar 13;353(9156):907

Can we afford medical care for Alice C? [see comments] Levinsky NG. **Lancet** 1998 Dec 5;352(9143):1849–51. Comment in: Lancet 1999 Feb 20;353(9153):677–8.

Views from funding agencies. The John A. Hartford Foundation. Regenstreif DI. **Med Care** 1998 Nov; 36(11):1521–3

Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). McNamee P, et al. **Soc Sci Med** 1999 Feb;48(3):331–41

[Repositioning social work with the elderly? Effect of competitive elements and new guidance models on the profile of a profession] Schmidt R, et al. **Z Gerontol Geriatr** 1998 Oct;31(5):304–12 (54 ref.) (Eng. Abstr.) **(Ger)**

[Geographical distribution of medical expenditure for the aged insured by National Health Insurance in secondary medical care areas in Japan] Zhang T, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):526–35 (Eng. Abstr.) **(Jpn)**

[Geriatric care and economic evaluation] Ikegami N, et al. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):299–307 (42 ref.) **(Jpn)**

HISTORY

[Older chronic patients and their care provisions in the first half of the twentieth century] Robben PB. **Tijdschr Gerontol Geriatr** 1998 Aug;29(4):168–76 (Eng. Abstr.) **(Dut)**

LEGISLATION & JURISPRUDENCE

De facto health-care rationing by age. The law has no remedy. Kapp MB. **J Leg Med** 1998 Sep;19(3):323–49 (152 ref.)

Older Americans Act: implications for nursing. Wallace DC, et al. **Nurs Outlook** 1999 Jul–Aug;47(4):181–5 (21 ref.)

[Relationship of utilization rate of health examination under the Elderly Act to medical expenditure and days of medical care for the elderly] Fukuda H, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):905–14 (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

Double jeopardy: the challenge of providing mental health services to older persons. Jenkins CL, et al. **Adm Policy Ment Health** 1998 Sep;26(1):65–74

An inter-network approach to providing mental health care to older persons: the case of Oneida County. Laditka SB, et al. **Adm Policy Ment Health** 1999 Mar;26(4):297–302

Primary care arrangements for elderly people in residential and nursing homes [letter; comment] Kavanagh S, et al. **BMJ** 1999 Mar 6;318(7184):666. Comment on: BMJ 1998 Aug 1;317(7154):322–7. Comment on: BMJ 1998 Aug 29;317(7158):552–3.

Long stay care and the NHS. Multidisciplinary assessment is needed [letter; comment] Primrose WR, et al. **BMJ** 1999 Mar 6;318(7184):668. Comment on: BMJ 1998 Oct 3;317(7163):942–4.

A randomized controlled trial of day hospital and day centre therapy. Burch S, et al. **Clin Rehabil** 1999 Apr;13(2):105–12

Psychosocial issues for cardiac rehabilitation with older individuals. McGee HM. **Coron Artery Dis** 1999; 10(1):47–51 (37 ref.)

Home-based multidisciplinary diagnosis and treatment of inner-city elders with dementia. Edwards DF, et al. **Gerontologist** 1999 Aug;39(4):483–8

Intermediate not indeterminate care. Bowman C, et al. **Hosp Med** 1998 Nov;59(11):877–9 (20 ref.)

Dementia care in the UK--a single service for all [editorial] Anderson DN. **Int J Geriatr Psychiatry** 1999 Jan;14(1):1–2

Ethical problems in care of the elderly: a Finnish perspective. Raatikainen R. **Int Nurs Rev** 1999 Mar–Apr;46(2):62–3

ICN on health ageing: A public health and nursing challenge. International Council of Nurses [news] **J Adv Nurs** 1999 Aug;30(2):280–1

Family care-giving for people with dementia: some implications for policy and professional practice. Clarke CL. **J Adv Nurs** 1999 Mar;29(3):712–20

Caring for vulnerable older adults in urban academic medical centers in a managed care environment [editorial; comment] Chang CF. **J Am Geriatr Soc** 1998 Nov; 46(11):1478–9. Comment on: J Am Geriatr Soc 1998 Nov;46(11):1371–7.

The Center for Continence: a different concept for an old problem [letter] Gruenwald I, et al. **J Am Geriatr Soc** 1999 Jul;47(7):912–3

Preventing disability and managing chronic illness in frail older adults: a randomized trial of a community-based partnership with primary care [see comments] Leveille SG, et al. **J Am Geriatr Soc** 1998 Oct;46(10):1191–8. Comment in: J Am Geriatr Soc 1998 Oct;46(10):1314–6.

Health care for older persons, a country profile: France. Nourhashemi F, et al. **J Am Geriatr Soc** 1998 Nov; 46(11):1431–3 (9 ref.)

International affairs. Caring for older people in the next millennium. Watson RA. **J Prof Nurs** 1999 May–Jun; 15(3):137

Improving geriatric services: sources of help. Advice from the Royal College of Physicians Committee on Geriatrics. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):152

A rude awakening: post-take ward round in the department of medicine for the elderly [see comments] Coni N. **J R Soc Med** 1998 Sep;91(9):471–4. Comment in: J R Soc Med 1998 Nov;91(11):612.

Dementia care [letter; comment] Smithard DG. **J R Soc Med** 1998 Aug;91(8):454. Comment on: J R Soc Med 1998 Jun;91(6):293.

Could the community social alarm system serve also as a primary health care service? Premik M, et al. **Med Arh** 1998;52(3):153–5

A support system to make care plan of elders. Tsutomu M, et al. **Medinfo** 1998;9 Pt 1:117–20

Geriatrics, prevention, and the remodeling of Medicare [editorial; comment] [see comments] Rowe JW. **N Engl J Med** 1999 Mar 4;340(9):720–1. Comment on: N Engl J Med 1999 Mar 4;340(9):669–76. Comment in: N Engl J Med 1999 Jul 29;341(5):369–70; discussion 370.

Progress in medicine for older patients. Aboud E, et al. **Practitioner** 1999 Mar;243(1596):190, 194–6, 201 (12 ref.)

Issues affecting the lives of older persons with developmental disabilities. Griswold KS, et al. **Psychiatr Serv** 1999 Mar; 50(3):315–7

Perceived ownership in a community coalition. Armbruster C, et al. **Public Health Nurs** 1999 Feb;16(1):17–22

The crisis of elder care [editorial] Graham KY. **Public Health Nurs** 1998 Dec;15(6):387–8

A model for building collective capacity in community-based programs: the Elderly in Need Project. Moyer A, et al. **Public Health Nurs** 1999 Jun;16(3):205–14

Health care of the elderly in Singapore. Ling SL. **Singapore Med J** 1998 Oct;39(10):435–6

Tsao Foundation's community geriatric services. Tsao MA, et al. **Singapore Med J** 1998 Oct;39(10):437–8

[The importance of the 'frailty-concept' in geriatric assessment] (editorial)] Slaets JP. **Tijdschr Gerontol Geriatr** 1998 Dec;29(6):276–8 **(Dut)**

[Types of ambulatory services for the elderly with cognitive and mental disturbances: current status] Heinik J, et al. **Harefuah** 1998 Aug;135(3–4):124–6 (19 ref.) **(Heb)**

[Proposals for the development of home care (editorial)] Gené Badia J, et al. **Aten Primaria** 1999 Mar 15;23(4):183–4, 186 **(Spa)**

STANDARDS

Patterns of care for depressed older adults in a large-staff model HMO. Unützer J, et al. **Am J Geriatr Psychiatry** 1999 Summer;7(3):235–43

One fourth of PBM pharmacists' phone calls lead to therapy changes [news] **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2464, 2468

Inquiry calls for checks on staff who work with elderly [news] Chadda D. **BMJ** 1999 Jan 30;318(7179):283

Systematic review of day hospital care for elderly people. The Day Hospital Group. Forster A, et al. **BMJ** 1999 Mar 27;318(7187):837–41

Ethical issues for otolaryngology and surgery in the elderly. Seidman MD, et al. **Ear Nose Throat J** 1999 Jun;78(6):422, 424–6, 428

Elderly community residents' evaluative criteria and preferences for formal and informal in-home services. Wielink G, et al. **Int J Aging Hum Dev** 1999;48(1):17–33

The role of carers in evaluating mental health services for older people. Dening T, et al. **Int J Geriatr Psychiatry** 1998 Dec;13(12):863–70

The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators. McAlister FA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):811–8 (74 ref.)

Aging-related clinical and health services research in Canada. Rockwood K, et al. **J Am Geriatr Soc** 1998 Nov; 46(11):1469–72 (66 ref.)

Quality medical management of the geriatric population using practice guidelines, physician-managed home health services, and continuous quality-improvement management strategies. Reaves LA, et al. **J Am Osteopath Assoc** 1999 May;99(5):265–9 (32 ref.)

Sequential audits of geriatric care: measuring change in structure and process and the contribution of clinical audit. Brocklehurst J, et al. **J R Coll Physicians Lond** 1998 Nov–Dec;32(6):564–7

Profiling care and benchmarking best practice in care of hospitalized elderly: the Geriatric Institutional Assessment Profile. Abraham IL, et al. **Nurs Clin North Am** 1999 Mar; 34(1):237–55

Quality care for the frail elderly [editorial] Mezey M, et al. **Nurs Outlook** 1998 Nov–Dec;46(6):291–2

Auditing outcomes from a medicine for the elderly service. Ramage L. **Scott Med J** 1997 Oct;42(5):156–7

The primary care of elder mistreatment. Hirsch CH, et al. **West J Med** 1999 Jun;170(6):353–8 (25 ref.)

Managing/understanding chronic disease: a call for papers. Wilkes MS, et al. **West J Med** 1999 Jun;170(6):326–7 (6 ref.)

[Care for elderly patients at an ENT clinic. Descriptive study] Calvo Boizas E, et al. **Acta Otorrinolaringol Esp** 1999 Jan–Feb;50(1):56–9 (Eng. Abstr.) **(Spa)**

[Elderly with fractures caused by osteoporosis should receive surgical treatment without delay!] Lindsjö U, et al. **Lakartidningen** 1998 Oct 7;95(41):4452, 4455 **(Swe)**

[Better assessment of the patients results in better nursing home care. A new system for development of geriatric care is being introduced] Ljunggren G. **Lakartidningen** 1998 Nov 4;95(45):4997–5000 (27 ref.) **(Swe)**

STATISTICS & NUMERICAL DATA

Factors related to the length of in-hospital stay of geriatric patients. Di Iorio A, et al. **Aging (Milano)** 1999 Jun; 11(3):150–4

Resettlement and the Health of the Nation Outcome Scales (HoNOS) in the elderly [letter] Ashaye O, et al. **Int J Geriatr Psychiatry** 1998 Aug;13(8):568–70

Medication use in nursing homes for elderly people. Furniss L, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):433–9 (61 ref.)

Morbidity of homebound versus inpatient elderly psychiatric patients [see comments] Pasternak R, et al. **Int Psychogeriatr** 1998 Jun;10(2):117–25. Comment in: Int Psychogeriatr 1999 Mar;11(1):105–6.

[Patient management in geriatric psychiatry by ambulatory care services. Results of an empirical analysis] Klostermann M, et al. **Z Gerontol Geriatr** 1998 Dec;31(6):426–37 (Eng. Abstr.) **(Ger)**

SUPPLY & DISTRIBUTION

Will elderly patients stand aside for younger patients in the queue for cardiac services? Mariotto A, et al. **Lancet** 1999 Aug 7;354(9177):467–70

TRENDS

Age-related geriatric medicine or integrated medical care? [editorial; comment] Onafowokan A, et al. **Age Ageing** 1999 May;28(3):245–7. Comment on: Age Ageing 1999 May;28(3):271–3.

Caring for an aging population [letter; comment] Nazerali N, et al. **CMAJ** 1998 Sep 22;159(6):647–8; discussion 649–50 . Comment on: CMAJ 1998 May 19;158(10):1275–84.

Geriatric demographics and the practice of otolaryngology [published erratum appears in Ear Nose Throat J 1999 Aug;78(8):548] Shapiro DP. **Ear Nose Throat J** 1999 Jun; 78(6):418–21 (5 ref.)

Formal and informal support: the great divide. Lyons KS, et al. **Int J Geriatr Psychiatry** 1999 Mar;14(3):183–92; discussion 192–6

Useful services for families: research findings and directions. Zarit SH, et al. **Int J Geriatr Psychiatry** 1999 Mar; 14(3):165–77; discussion 178–81

Long-term care in its infancy [editorial; comment] Boult C. **J Am Geriatr Soc** 1999 Feb;47(2):250–1. Comment on: J Am Geriatr Soc 1999 Feb;47(2):131–8. Comment on: J Am Geriatr Soc 1999 Feb;47(2):139–44.

Managed care for older people: a primer for the geriatrician. Reed RL, et al. **J Am Geriatr Soc** 1999 Feb;47(2):241–9 (43 ref.)

Community institutional healthcare: emergence from refugee status [editorial] Morris J, et al. **J R Soc Med** 1999 Jun; 92(6):271–2

The changing elderly population and future health care needs. Mechanic D. **J Urban Health** 1999 Mar;76(1):24–38 (21 ref.)

Medical care in aged-care facilities: new directions. Draper BM. **Med J Aust** 1999 Jul 19;171(2):94–6

The chance of a lifetime--nursing's golden opportunity [editorial] [see comments] Anderson CA. **Nurs Outlook** 1998 Jul–Aug;46(4):149–50. Comment in: Nurs Outlook 1999 Mar–Apr;47(2):95.

The effects of health changes on projections of health service needs for the elderly population of the United States. Singer BH, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15618–22

Current status of and challenges for dementia in Japan. Otsuka T. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S300–2

[Expand health services for the elderly] Sipsma DH. **Tijdschr Gerontol Geriatr** 1999 Aug;30(4):149–51 **(Dut)**

[Guide to geriatric treatment in Bremen] Wrobel N, et al. **Gesundheitswesen** 1999 Jul;61(7):353–9 (28 ref.) (Eng. Abstr.) **(Ger)**

[The rehabilitation of older people] Meier-Baumgartner HP. **Versicherungsmedizin** 1999 Mar 1;51(1):24–9 (24 ref.) (Eng. Abstr.) **(Ger)**

[Social work with the elderly--evaluation, crisis and perspectives (editorial)] Klie T, et al. **Z Gerontol Geriatr** 1998 Oct;31(5):301–3 **(Ger)**

[Basic functions and specialty standards of support management] Wissert M. **Z Gerontol Geriatr** 1998 Oct; 31(5):331–7 (19 ref.) (Eng. Abstr.) **(Ger)**

[Social work with the elderly--current orientation and strategies] Zeman P. **Z Gerontol Geriatr** 1998 Oct; 31(5):313–8 (34 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

A national survey of health-service use in Thai elders. Jitapunkul S, et al. **Age Ageing** 1999 Jan;28(1):67–71

Patterns of self-reported health care use in injured and uninjured older adults. Raina P, et al. **Age Ageing** 1999 May;28(3):316–8

Factors associated with use of community support services in an older Australian population. Wang JJ, et al. **Aust N Z J Public Health** 1999 Apr;23(2):147–53

Long stay care and the NHS. Scottish health resource utilisation groups measure is helpful [letter; comment] Brown G, et al. **BMJ** 1999 Mar 6;318(7184):668. Comment on: BMJ 1998 Oct 3;317(7163):942–4.

The cost of dementia in Denmark: the Odense Study. Kronborg Andersen C, et al. **Dement Geriatr Cogn Disord** 1999 Jul–Aug;10(4):295–304

A methodology for identifying married couples in Medicare data: mortality, morbidity, and health care use among the married elderly. Iwashyna TJ, et al. **Demography** 1998 Nov; 35(4):413–9

Elderly people with alcohol-related problems: where do they go? Mulinga JD. **Int J Geriatr Psychiatry** 1999 Jul;

14(7):564–6
Use of primary care teams by HMOS for care of long-stay nursing home residents [see comments] Farley DO, et al. **J Am Geriatr Soc** 1999 Feb;47(2):139–44. Comment in: J Am Geriatr Soc 1999 Feb;47(2):250–1.
Cost of Alzheimer's disease and related dementia in managed-medicare. Gutterman EM, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1065–71
Primary care of long-stay nursing home residents: approaches of three health maintenance organizations [see comments] Reuben DB, et al. **J Am Geriatr Soc** 1999 Feb;47(2):131–8. Comment in: J Am Geriatr Soc 1999 Feb;47(2):250–1.
Relationship between preventive health services and use of inpatient and outpatient care by residents aged 40 or older in 44 municipalities in Osaka Prefecture, Japan. Nakanishi N, et al. **J Epidemiol** 1998 Dec;8(5):264–71
Hospital use by an ageing cohort: an investigation into the association between biological, behavioural and social risk markers and subsequent hospital utilization. Hanlon P, et al. **J Public Health Med** 1998 Dec;20(4):467–76
Hospital readmission among older medical patients in Hong Kong. Kwok T, et al. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):153–6
Residential differences in attitudes about barriers to using community-based services among older adults. Schoenberg NE, et al. **J Rural Health** 1998 Fall;14(4):295–304
Caring for Japan's elderly [letter; comment] Arai Y, et al. **Lancet** 1998 Oct 24;352(9137):1393. Comment on: Lancet 1998 Sep 5;352(9130):798.
Eye care utilization by older Americans: the SEE Project. Salisbury Eye Evaluation. Orr P, et al. **Ophthalmology** 1999 May;106(5):904–9
Sexually transmitted infections in the elderly [letter] Gott M. **Sex Transm Infect** 1999 Apr;75(2):131
Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). McNamee P, et al. **Soc Sci Med** 1999 Feb;48(3):331–41
Attitudes toward service use among wife caregivers of frail older veterans. Dorfman LT, et al. **Soc Work Health Care** 1998;27(4):39–64
[Health service use and age among the elderly] Fukawa T. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):163–74 (Eng. Abstr.) **(Jpn)**
[Relationship of utilization rate of health examination under the Elderly Act to medical expenditure and days of medical care for the elderly] Fukuda H, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):905–14 (Eng. Abstr.) **(Jpn)**
[Study of the elderly in long form care facilities and home services] Kobayashi M. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):199–203 **(Jpn)**

HEALTH SERVICES, INDIGENOUS

Reviews have to be fair and unbiased [letter] Sung JJ, et al. **BMJ** 1999 Apr 24;318(7191):1145
The role of traditional healers in the fight against AIDS in Africa. Wootton JC. **J Altern Complement Med** 1999 Jun;5(3):225–8
[Routine practice of a surgeon in Yemen from the viewpoint of an indigenous and a humanitarian foreign colleague with repeated visits] al-Jamrah A, et al. **Chirurg** 1998 Oct;69(10):suppl 317–8 **(Ger)**

ECONOMICS

Aboriginal health spending: more needed, but where? [editorial] McDermott R. **Aust N Z J Public Health** 1998 Oct;22(6):637–8
How much should we be spending on health services for Aboriginal and Torres Strait Islander people? [editorial] Mooney GH, et al. **Med J Aust** 1998 Nov 16;169(10):508–9

ORGANIZATION & ADMINISTRATION

Planning for better health outcomes requires indigenous perspective [editorial] Angus S, et al. **Aust N Z J Public Health** 1998 Oct;22(6):636–7
Pap smear screening at an urban aboriginal health service: report of a practice audit and an evaluation of recruitment strategies. Hunt JM, et al. **Aust N Z J Public Health** 1998 Oct;22(6):720–5
Commitment to improving indigenous health [editorial] Leeder SR. **Aust N Z J Public Health** 1998 Oct;22(6):635–6
School screening in remote aboriginal communities--results of an evaluation. Paterson B, et al. **Aust N Z J Public Health** 1998 Oct;22(6):685–9
Improving cervical screening in a remote aboriginal community. Reath J, et al. **Aust N Z J Public Health** 1998 Oct;22(6):659–63
A 'whole of government' approach needed on indigenous health [editorial] Ring I. **Aust N Z J Public Health** 1998 Oct;22(6):639–40
Positions and training of the indigenous health workforce. Sibthorpe B, et al. **Aust N Z J Public Health** 1998 Oct;22(6):648–52
Keeping women and children last: America's war on the poor. Sidel R. **Int J Circumpolar Health** 1998;57 Suppl 1:23–6
Indigenous mental health care among Gurkha soldiers based in the United Kingdom [see comments] Jolly A. **J R Army Med Corps** 1999 Feb;145(1):15–7. Comment in: J R Army Med Corps 1999 Jun;145(2):109.
The Menzies School of Health Research offers a new paradigm of cooperative research. Mathews JD. **Med J Aust** 1998 Dec 7–21;169(11–12):625–9
Federal programs and Indian country: a time for reinvention [comment] Boufford JI, et al. **Public Health Rep** 1998 Jan–Feb;113(1):34–5. Comment on: Public Health 1998 Jan–Feb;113(1):22–33.
Challenges to Native American health care [see comments] Noren J, et al. **Public Health Rep** 1998 Jan–Feb;113(1):22–33. Comment in: Public Health 1998 Jan–Feb;113(1):34–5.
Use of hammocks in a rural hospital [letter] Campos-Navarro R. **World Health Forum** 1998;19(4):431–3

STANDARDS

Ethical issues in community health research: implications for First Nations and circumpolar indigenous peoples. Kaufert JM, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:33–7
Post-Soviet Russian indigenous health: the Sami people of the Kola Peninsula. Snellman A, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:636–8
Indigenous people and the social work profession: defining culturally competent services. Weaver HN. **Soc Work** 1999 May;44(3):217–25
Community perceptions of health, illness and care: identifying issues for indigenous communities. Kelaher M, et al. **Women Health** 1998;28(1):41–61 (36 ref.)

SUPPLY & DISTRIBUTION

Understanding and responding to the health and mental health needs of Asian refugees. Dhooper SS, et al. **Soc Work Health Care** 1998;27(4):65–82

TRENDS

Traditional healing among Alaska Natives. Craig R. **Int J Circumpolar Health** 1998;57 Suppl 1:10–2

HEALTH SERVICES MARKETING see **MARKETING OF HEALTH SERVICES**

HEALTH SERVICES MISUSE

Appropriate emergency medical services transport [editorial; comment] Krohmer JR. **Acad Emerg Med** 1999 Jan;6(1):5–7 . Comment on: Acad Emerg Med 1999 Jan;6(1):14–20.
Inappropriate prescribing for elderly outpatients. Aparasu RR, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):433–9
Overdiagnosis and overtreatment of Lyme disease leads to inappropriate health service use. Sigal LH. **Clin Exp Rheumatol** 1999 Jan–Feb;17(1):41 (3 ref.)
A European version of the Appropriateness Evaluation Protocol. Goals and presentation. The BIOMED I Group on Appropriateness of Hospital Use. Lang T, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):185–97
Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Shekelle PG, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):707–27
Planning cannot rely on emergencies arriving by ambulance [letter; comment] Cooke MW, et al. **J Accid Emerg Med** 1999 Jan;16(1):74–5. Comment on: J Accid Emerg Med 1998 Jul;15(4):212–5.
Inappropriate ambulance usage is a retrospective diagnosis [letter; comment] Wilson S, et al. **J Accid Emerg Med** 1999 Jan;16(1):75. Comment on: J Accid Emerg Med 1998 Jul;15(4):212–5.
Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jul;38(7):797–804
Electrical proarrhythmia: induction of inappropriate atrial therapies due to far-field R wave oversensing in a new dual chamber defibrillator. Wolpert C, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):859–63
Undertreatment of hypertension in a population-based study in The Netherlands. Klungel OH, et al. **J Hypertens** 1998 Sep;16(9):1371–8
[Experience with the use of criteria for evaluating the need for hospitalization in a surgery department] Hroboň P, et al. **Rozhl Chir** 1998 Sep;77(9):408–13 (Eng. Abstr.) **(Cze)**
[Many patients treated in the emergency department could be treated by a general practitioner on call] Laursen MB, et al. **Ugeskr Laeger** 1999 Aug 16;161(33):4624–7 (Eng. Abstr.) **(Dan)**
[Do women misuse health services?] Olsen J, et al. **Ugeskr Laeger** 1998 Nov 2;160(45):6535 **(Dan)**
[Overutilization and psychosocial factors: myth or reality? (letter; comment)] Báez K, et al. **Aten Primaria** 1999 May 31;23(9):555–7. Comment on: Aten Primaria 1998 Dec;22(10):627–30. **(Spa)**
[The use of resources. Unnecessary stays in pediatric surgical services] Jiménez Alvarez C, et al. **Cir Pediatr** 1999 Jan;12(1):11–5 (Eng. Abstr.) **(Spa)**
[A survey of "heavy consumers" of emergency care services in Stockholm. Six per cent of the patients accounted for a quarter of emergency consultations] Hansagi H, et al. **Lakartidningen** 1998 Nov 18;95(47):5320, 5323–4 (Eng. Abstr.) **(Swe)**

ECONOMICS

The problem of ambulance misuse: whose problem is it, anyway? [editorial; comment] Zachariah BS. **Acad Emerg Med** 1999 Jan;6(1):2–5. Comment on: Acad Emerg Med 1999 Jan;6(1):14–20.
Controlling workers' compensation medical care use and costs through utilization management. Wickizer TM, et al. **J Occup Environ Med** 1999 Aug;41(8):625–31

LEGISLATION & JURISPRUDENCE

Who gets second opinions? Wagner TH, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):137–45
Fraud and abuse. Understanding definitions and establishing compliance. Cuzydlo C. **Mich Med** 1999 Feb;98(2):40–2

STATISTICS & NUMERICAL DATA

Inappropriate use of emergency medical services transport: comparison of provider and patient perspectives [see comments] Richards JR, et al. **Acad Emerg Med** 1999 Jan;6(1):14–20. Comment in: Acad Emerg Med 1999 Jan;6(1):2–5. Comment in: Acad Emerg Med 1999 Jan;6(1):5–7.
Provision for clinic patients in the ED produces more nonemergency visits. Krakau I, et al. **Am J Emerg Med** 1999 Jan;17(1):18–20
Underuse and overuse of diagnostic testing for coronary artery disease in patients presenting with new-onset chest pain [see comments] Carlisle DM, et al. **Am J Med** 1999 Apr;106(4):391–8. Comment in: Am J Med 1999 Apr;106(4):484–5.
A framework for evaluating underutilization of health care services. Fetterolf DE. **Am J Med Qual** 1999 Mar–Apr;14(2):89–97 (40 ref.)
Dual provision or duplication? A survey of family planning provision. Singleton CD, et al. **Br J Fam Plann** 1999 Jul;25(2):41–4
Inappropriate use of the ambulance service. Little GF, et al. **Eur J Emerg Med** 1998 Sep;5(3):307–11
Inappropriate calls to an emergency medical despatch centre via cellular telephones--no impact of a once-only multimedia coverage. Martens P, et al. **Eur J Emerg Med** 1999 Mar;6(1):5–7
The National Breast Referral Guidelines have cut down inappropriate referrals in the under 50s. Cochrane RA, et al. **Eur J Surg Oncol** 1999 Jun;25(3):251–4
Risk of overtreatment with current peak flow criteria in self-management plans. Dutch CNSLD Study Group. Chronic Non-Specific Lung Disease. Douma WR, et al. **Eur Respir J** 1998 Oct;12(4):848–52
Responding to out-of-hours demand: the extent and nature of urgent need. Shipman C, et al. **Fam Pract** 1999 Feb;16(1):23–7
Overuse or underuse of endoscopy? The optimal indications. Rey JF. **Gastrointest Endosc** 1998 Dec;48(6):652–3
Frequent attenders without organic disease in a gastroenterology clinic. Patient characteristics and health care use. Bass C, et al. **Gen Hosp Psychiatry** 1999 Jan–Feb;21(1):30–8
The role of medical problems and behavioral risks in explaining patterns of prenatal care use among high-risk women. Clarke LL, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):145–70
Predictors of inappropriate hospital days in a department of internal medicine. Chopard P, et al. **Int J Epidemiol** 1998 Jun;27(3):513–9
Factors associated with inappropriate hospitalization days in internal medicine wards in Israel: a cross-national survey. Merom D, et al. **Int J Qual Health Care** 1998 Apr;10(2):155–62
Misuse of the London ambulance service: How much and why? Palazzo FF, et al. **J Accid Emerg Med** 1998 Nov;15(6):368–70
Primary care physician and patient factors that result in patients seeking emergency care in a hospital setting: the patient's perspective. Boushy D, et al. **J Emerg Med** 1999 May–Jun;17(3):405–12
Whither the almshouse? Overutilization and the role of the emergency department. Malone RE. **J Health Polit Policy Law** 1998 Oct;23(5):795–832
Assessing the extent to which hospitals are used for acute care purposes. DeCoster C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS151–66
Reproducibility of measures of overuse of cataract surgery by three physician panels. Tobacman JK, et al. **Med Care** 1999 Sep;37(9):937–45
Modifying use of pathology services [editorial; comment] [published erratum appears in Med J Aust 1999 Feb 1;170(3):144] Conyers RA. **Med J Aust** 1999 Jan 4;170(1):8–9 (11 ref.). Comment on: Med J Aust 1999 Jan 4;170(1):11–4.
A quality management intervention to improve clinical laboratory use in acute myocardial infarction [see comments] Isouard G. **Med J Aust** 1999 Jan 4;170(1):11–4 . Comment in: Med J Aust 1999 Jan 4;170(1):8–9.
How good is the quality of health care in the United States? Schuster MA, et al. **Milbank Q** 1998;76(4):517–63, 509 (75 ref.)
Are short-stay admissions to an acute general medical unit appropriate? Wellington Hospital experience. Burgess CD. **N Z Med J** 1998 Aug 28;111(1072):314–5
The relationship between perceived parental expectations and

pediatrician antimicrobial prescribing behavior. Mangione-Smith R, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):711-8

Improving the appropriateness of carotid endarterectomy: results of a prospective city-wide study. Wong JH, et al. **Stroke** 1999 Jan;30(1):12-5

[Misuse of emergency ambulance services] Krum-Møller DS, et al. **Ugeskr Laeger** 1999 Feb 8;161(6):797-9 (Eng. Abstr.) **(Dan)**

[Is hysterectomy rate too high? Rates falling--new drug and surgical alternatives?] Strobel E. **Fortschr Med** 1998 Aug 30;116(24):34-6 **(Ger)**

[Psychological malaise and the sociodemographic and familial characteristics of the over-user of primary care] Segovia Martínez A, et al. **Aten Primaria** 1998 Nov 30; 22(9):562-9 (Eng. Abstr.) **(Spa)**

TRENDS

Assessing the impact of continuous quality improvement on clinical practice: what it will take to accelerate progress [see comments] Shortell SM, et al. **Milbank Q** 1998; 76(4):593-624, 510 (106 ref.). Comment in: Milbank Q 1998 ;76(4):755-7.

HEALTH SERVICES NEEDS AND DEMAND

Equity in health and health care reforms. Glick SM. **Acta Oncol** 1999;38(4):469-73

Pneumonia: projected age-related needs for hospital services in Finland [letter] Timo K, et al. **Age Ageing** 1999 Jan; 28(1):83-4

In pursuit of folly. Stimmel B. **Am J Med** 1999 Jun; 106(6):655-9

The future physician workforce: an allergy-immunology specialist perspective [see comments] de Asis ML. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):99-103. Comment in: Ann Allergy Asthma Immunol 1999 Aug;83(2):77-9.

Managed care and people with disabilities: framing the issues. Sutton JP, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1312-6 (47 ref.)

Demand for and use of functional electrical stimulation systems and conventional orthoses in the spinal lesioned community of the UK. Maxwell DJ, et al. **Artif Organs** 1999 May;23(5):410-2

Long term displacement raises new health needs [news] Anderson P. **BMJ** 1999 Apr 17;318(7190):1029

Meeting the healthcare needs of refugees and asylum seekers [letter] Barr D, et al. **BMJ** 1999 May 8;318(7193):1291

Meeting health needs of asylum seekers. Practical approaches can make care easier [letter; comment] Matthews P. **BMJ** 1999 Mar 6;318(7184):671. Comment on: BMJ 1998 Nov 21;317(7170):1444-6.

Health needs assessment is not required for priority setting [letter; comment] Petrou S. **BMJ** 1998 Oct 24; 317(7166):1154. Comment on: BMJ 1998 Apr 25;316(7140):1310-3. Comment on: BMJ 1998 Apr 25;316(7140):1379-82. Comment on: BMJ 1998 May 9;316(7142):1448-52.

Needs of teenagers with chronic disability [letter; comment] Williams C. **BMJ** 1999 Apr 3;318(7188):945. Comment on: BMJ 1998 Oct 10;317(7164):960-1. Comment on: BMJ 1998 Oct 17;317(7165):1072-5.

Putting evidence into practice [editorial] Smith C, et al. **Br J Fam Plann** 1999 Jan;24(4):115

Good health care: patient and professional perspectives. Carroll L, et al. **Br J Gen Pract** 1998 Aug;48(433):1507-8

User perspective on needs and satisfaction with mental health services. PRiSM Psychosis Study. 8. Leese M, et al. **Br J Psychiatry** 1998 Nov;173:409-15

Strong bones in later life: luxury or necessity? The view from Tunisia: need for an inclusive approach [see comments] Ben Khalifa F. **Bull World Health Organ** 1999;77(5):427-8 . Comment in: Bull World Health Organ 1999 ;77(5):416-22.

Strong bones in later life: luxury or necessity? The view from Brazil:desirable but not yet feasible [comment] de Castro JA. **Bull World Health Organ** 1999;77(5):426-7. Comment on: Bull World Health Organ 1999 ;77(5):416-22.

Osteoporosis: a global perspective [comment] Wark JD. **Bull World Health Organ** 1999;77(5):424-6. Comment on: Bull World Health Organ 1999 ;77(5):416-22.

Hypertensive drug demand and reimbursement in public and private systems: a French-US comparison. Huttin C. **Cah Sociol Demogr Med** 1999 Jan-Mar;39(1):25-40

Economic analysis of expensive technologies: the case of erythropoietin [editorial; comment] Griggs JJ, et al. **Cancer** 1998 Dec 15;83(12):2427-9. Comment on: Cancer 1998 Dec 15;83(12):2588-96.

Utility assessment: methods and research. Chapman GB, et al. **Cancer Treat Res** 1998;97:13-23 (33 ref.)

Developing mental health services for Native American children. Barlow A, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):555-77, ix (45 ref.)

Public health aspects of breast cancer gene testing in Canada. Part 3: A model of potential need and demand [see comments] Elwood JM. **Chronic Dis Can** 1999;20(1):21-5 . Comment in: Chronic Dis Can 1999 ;20(1):1-2.

Proposed NIH budget increase too small to meet research needs [news] SoRelle R. **Circulation** 1999 May 25; 99(20):2604-5

Managed care of children with special health care needs: the ABC Program. Grossman LK, et al. **Clin Pediatr (Phila)** 1999 Mar;38(3):153-60

Health status of children with special health care needs: measurement issues and instruments. Kozinetz CA, et al. **Clin Pediatr (Phila)** 1999 Sep;38(9):525-33 (32 ref.)

Children with special health care needs and managed care [editorial] Van Dyke DC, et al. **Clin Pediatr (Phila)** 1999 Mar;38(3):161-3

Responding to the mental health needs of Latino children and families through school-based services. Garrison EG, et al. **Clin Psychol Rev** 1999 Mar;19(2):199-219 (98 ref.)

Health care needs versus health care wants [letter; comment] Rosenquist GE. **CMAJ** 1998 Sep 22;159(6):650. Comment on: CMAJ 1998 Mar 24;158(6):723-8. Comment on: CMAJ 1998 Mar 24;158(6):731-7. Comment on: CMAJ 1998 Mar 24;158(6):757-9.

How many drug rehabilitation places are needed in prisons to reduce the risk of bloodborne virus infection? Gore SM, et al. **Commun Dis Public Health** 1999 Sep;2(3):193-5

Orthodontic treatment demand--differences between urban and rural areas. Bergström K, et al. **Community Dent Health** 1998 Dec;15(4):272-6

Modeling and forecasting monthly patient volume at a primary health care clinic using univariate time-series analysis. Abdel-Aal RE, et al. **Comput Methods Programs Biomed** 1998 Jun;56(3):235-47

Priorities for medium-term development in the health sector of Bosnia and Herzegovina. Adeyi O. **Croat Med J** 1998 Sep;39(3):285-7

Organization of health care in Croatia: needs and priorities. Kovačić L, et al. **Croat Med J** 1998 Sep;39(3):249-55

Priority setting and scarce resources: case of the Federation of Bosnia and Herzegovina. Ljubić B, et al. **Croat Med J** 1998 Sep;39(3):276-80

Application of the modified method of "rapid appraisal to assess community health needs" for making rapid city health profiles and city action plans for health. Sogoric S. **Croat Med J** 1998 Sep;39(3):267-75

Developing needs led child and adolescent mental health services: issues and prospects. Harrington RC, et al. **Eur Child Adolesc Psychiatry** 1999 Mar;8(1):1-10

Legal abortion in Denmark during the past 25 years: aspects of public health and ethics. Goldstein H. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):155-9 (11 ref.)

Limitations of current surveillance programs for sexually transmitted infections and allied conditions affecting reproductive health care. Mårdh PA. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):147-54 (11 ref.)

Basic characteristics of hospital stroke services in Eastern Hungary. Mihálka L, et al. **Eur J Epidemiol** 1999 May; 15(5):461-6

Are variations in the use of carotid endarterectomy explained by population Need? A study of health service utilisation in two English health regions. Oliver SE, et al. **Eur J Vasc Endovasc Surg** 1999 Jun;17(6):501-6

Patients' priorities with respect to general practice care: an international comparison. European Task Force on Patient Evaluations of General Practice (EUROPEP). Grol R, et al. **Fam Pract** 1999 Feb;16(1):4-11

An office on Main Street. Health care dilemmas in small communities. Roberts LW, et al. **Hastings Cent Rep** 1999 Jul-Aug;29(4):28-37

A model for the Dutch pharmaceutical market. Canton E, et al. **Health Econ** 1999 Aug;8(5):391-402

Women's participation in rural credit programmes in Bangladesh and their demand for formal health care: is there a positive impact? Nanda P. **Health Econ** 1999 Aug; 8(5):415-28

Financing, demographic, and political problems confronting Medicare in the United States. Buerhaus PI. **Image J Nurs Sch** 1998;30(2):117-22

Periodontal needs of developing nations--the practitioner's view. Vecchini MF. **Int Dent J** 1998 Jun;48(3 Suppl 1):338-41 (24 ref.)

Trends in maternal mortality in Ilorin, Nigeria 1987-1996. Aboyeji AP. **Int J Gynaecol Obstet** 1998 Nov;63(2):183-4

Trends and causes of maternal mortality in Kazakhstan. Kaupova N, et al. **Int J Gynaecol Obstet** 1998 Nov; 63(2):175-81

Treatment delay and reliance on private physicians among patients with sexually transmitted diseases in China. Choi KH, et al. **Int J STD AIDS** 1999 May;10(5):309-15

Irish health care Web sites: a review. O'Mahony B. **Ir Med J** 1999 May-Jun;92(4):334-7

An exploratory study of demand for the health visiting service within a marketing framework. Collinson S, et al. **J Adv Nurs** 1998 Sep;28(3):499-507

The commissioning of nurse education by consortia in England: a quasi-market analysis. Francis B, et al. **J Adv Nurs** 1998 Sep;28(3):517-23

Health characteristics of elderly personal care home residents. Quinn ME, et al. **J Adv Nurs** 1999 Aug; 30(2):410-7

VA aligns health professions education with healthcare priorities. Stevens DP, et al. **J Allied Health** 1998 Fall; 27(3):123-7

Complementary and alternative medicine: the road ahead [editorial] Harkin T. **J Altern Complement Med** 1998 Winter;4(4):359-60

Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. Thompson AS, et al. **J Community Health** 1998 Dec;23(6):419-40

Poor women living with HIV: self-identified needs. Bunting SM, et al. **J Community Health Nurs** 1999;16(1):41-52

HIV infection in U.S. correctional systems: its effect on the community. Leh SK. **J Community Health Nurs** 1999; 16(1):53-63 (18 ref.)

Needs survey of Canadian rosacea patients [see comments] Shear NH, et al. **J Cutan Med Surg** 1999 Apr;3(4):178-81 . Comment in: J Cutan Med Surg 1999 Apr;3(4):176-7.

Development of a scale to measure information needs in cancer care. Degner LF, et al. **J Nurs Meas** 1998 Winter; 6(2):137-53

Comparison of palliative care needs of English- and non-English-speaking patients. Chan A, et al. **J Palliat Care** 1999 Spring;15(1):26-30

Models of commissioning health services in the British National Health Service: a literature review. Chappel D, et al. **J Public Health Med** 1999 Jun;21(2):221-7 (75 ref.)

Meeting women's need for a flexible abortion service: retrospective study of a specialist day-care unit. Lowy A, et al. **J Public Health Med** 1998 Dec;20(4):449-54

Lessons from dermatology--implications for future provision of specialist services [editorial] Black MM. **J R Coll Physicians Lond** 1999 May-Jun;33(3):208-11 (14 ref.)

Caring for children orphaned by AIDS [editorial] Moy R. **J Trop Pediatr** 1999 Apr;45(2):64-5

Opportunities to improve health care for low-income adolescents. Collins KS, et al. **J Urban Health** 1998 Dec; 75(4):660-76 (14 ref.)

Financing children's health care needs in the next century. Schoen C, et al. **J Urban Health** 1998 Dec;75(4):639-59 (26 ref.)

Observations from the CDC. The urgent need for new HIV/STD prevention options for women. Irwin K, et al. **J Womens Health** 1998 Nov;7(9):1081-6 (27 ref.)

Admission trends in a rural South African hospital during the early years of the HIV epidemic. Floyd K, et al. **JAMA** 1999 Sep 15;282(11):1087-91

Queuing for coronary angiography during severe supply-demand mismatch in a US public hospital: analysis of a waiting list registry [see comments] Rosanio S, et al. **JAMA** 1999 Jul 14;282(2):145-52. Comment in: JAMA 1999 Jul 14;282(2):184-5.

Community-oriented medical education in Glasgow: developing a community diagnosis exercise. Davison H, et al. **Med Educ** 1999 Jan;33(1):55-62

Female genital mutilation: responding to health needs [editorial] [see comments] Bayly CM. **Med J Aust** 1998 Nov 2;169(9):455-6. Comment in: Med J Aust 1999 Mar 15;170(6):285-6; discussion 286. Comment in: Med J Aust 1999 Mar 15;170(6):286.

Achieving standardization of health information in Canada by the year 2000. Fitzgerald C, et al. **Medinfo** 1998;9 Pt 1:425-8

Patient demand for integrative medicine [editorial] Foley C. **Minn Med** 1999 May;82(5):50-1

A world of opportunity... and need. Palmer K. **Minn Med** 1999 Jul;82(7):6-8, 45

Medical education and health needs of a community [letter] Chhabra S. **Natl Med J India** 1998 Nov-Dec;11(6):299

Disparities of health in African Americans. Davis CM, et al. **Nurs Clin North Am** 1999 Jun;34(2):345-57 (65 ref.)

A health promotion programme for oil refinery employees: changes of health promotion needs observed at three years. Talvi AI, et al. **Occup Med (Lond)** 1999 Feb;49(2):93-101

The obligation of mental health services to the least well off. Goldman HH. **Psychiatr Serv** 1999 May;50(5):659-63

Principles for priority setting in mental health services and their implications for the least well off. Rosenheck RA. **Psychiatr Serv** 1999 May;50(5):653-8

Contraceptive needs of women attending a genitourinary medicine clinic for the first time. Thompson C. **Sex Transm Infect** 1998 Dec;74(6):433-4

Nursing home applications--reasons and possible interventions. Chan KM, et al. **Singapore Med J** 1998 Oct; 39(10):451-5

The physically disabled in Singapore [editorial] Kua EH. **Singapore Med J** 1999 Feb;40(2):65-6

Is there a role for the obstetric flying squad in Peninsula Malaysia? Monga D, et al. **Singapore Med J** 1999 Feb; 40(2):78-80

Planning reproductive health in conflict: a conceptual framework. Busza J, et al. **Soc Sci Med** 1999 Jul; 49(2):155-71

Extending specialist palliative care to all? Field D, et al. **Soc Sci Med** 1999 May;48(9):1271-80

Effects of distances to hospital and GP surgery on hospital inpatient episodes, controlling for needs and provision. Haynes R, et al. **Soc Sci Med** 1999 Aug;49(3):425-33

Critical reflections on the politics of need: implications for public health. Robertson A. **Soc Sci Med** 1998 Nov; 47(10):1419-30

Prioritising family health needs: a time--space analysis of women's health-related behaviours. Young R. **Soc Sci Med** 1999 Mar;48(6):797-813

Understanding and responding to the health and mental health needs of Asian refugees. Dhooper SS, et al.

Soc Work Health Care 1998;27(4):65–82

Focusing on the border. Ortolon K. **Tex Med** 1999 May; 95(5):54–6

Third-party funding of health care services for the uninsured of Tarrant County. Young RA. **Tex Med** 1999 Jun; 95(6):50–4

Reducing need and demand for medical services in high-risk persons. A health education approach. Fries JF, et al. **West J Med** 1998 Oct;169(4):201–7

[Health care needs and their assessment. Part 2. The need for health and health care] Koupilová I, et al. **Cas Lek Cesk** 1999 Jan 25;138(3):67–9 (Eng. Abstr.) **(Cze)**

[Emergency echocardiography in Denmark] Friberg J, et al. **Ugeskr Laeger** 1998 Oct 19;160(43):6201–4 (Eng. Abstr.) **(Dan)**

[Infection hospitals--a continuous need?] Pedersen BK. **Ugeskr Laeger** 1999 Mar 29;161(13):1937 **(Dan)**

[Physicians held between two fires: between the exigencies of patients...and financial constraints] Daher M, et al. **J Med Liban** 1998 Nov-Dec;46(6):301–2 **(Fre)**

[Access to health services: difficulties encountered by refugees residing on Ile-de-France. Charity and full-coverage health care: two divergent concepts?] Delbecchi G, et al. **Presse Med** 1999 Jun 5;28(20):1075–9 (Eng. Abstr.) **(Fre)**

[Appropriateness of medical procedures: measurements and relations with needs and access to health care] Lang T. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):411–9 (Eng. Abstr.) **(Fre)**

[From the philosophy of medicine to bioethics, and back] Mauron A. **Rev Med Suisse Romande** 1998 Dec; 118(12):1009–12 **(Fre)**

[Public health priorities] Chabot JM. **Rev Prat** 1998 Feb 15; 48(4):425–6 **(Fre)**

[The care and health needs and quality of life in a sample of 260 cancer patients in the terminal phase] Bestagini P, et al. **Ann Ig** 1998 Sep-Dec;10(5-6):373–85 **(Ita)**

[Mental and physical impairment, socio-economic resources and care strategies in people with HIV infection] Mancinelli S, et al. **Ann Ig** 1998 May-Jun;10(3):189–99 (Eng. Abstr.) **(Ita)**

[The devising of a multidimensional questionnaire for assessing the needs of cancer patients in the terminal phase] Palombi L, et al. **Ann Ig** 1999 Mar-Apr;11(2):139–52 (Eng. Abstr.) **(Ita)**

[Health care provided by national health services and private insurance] Mariani L. **Clin Ter** 1998 Mar-Apr; 149(2):139–41 (Eng. Abstr.) **(Ita)**

[Investigation on daily life concerning patients with spinocerebellar degeneration] Hatta H, et al. **Nippon Koshu Eisei Zasshi** 1998 Dec;45(12):1142–50 (Eng. Abstr.) **(Jpn)**

[Health, environment and sustainable development in Mexico] **Rev Panam Salud Publica** 1998 Sep;4(3):208–10 (Eng. Abstr.) **(Spa)**

[Use of health services and progression of AIDS in persons with HIV infection in Belo Horizonte (Minas Gerais), Brazil] Acurcio F de A, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):331–40 (Eng. Abstr.) **(Spa)**

[Promotion of public health research: attempting to balance relevance and excellence] de los Rios R. **Rev Panam Salud Publica** 1999 Apr-May;5(4–5):309–15 (Eng. Abstr.) **(Spa)**

[In search of results of technical cooperation] Jourdan Hidalgo L, et al. **Rev Panam Salud Publica** 1999 Jun; 5(6):423–9 (Eng. Abstr.) **(Spa)**

[Health service coverage in Latin America and the Caribbean] Paganini JM. **Rev Panam Salud Publica** 1998 Nov;4(5):305–10 (Eng. Abstr.) **(Spa)**

[Better assessment of the patients results in better nursing home care. A new system for development of geriatric care is being introduced] Ljunggren G. **Lakartidningen** 1998 Nov 4;95(45):4997–5000 (27 ref.) **(Swe)**

ECONOMICS

What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis [see comments] Ortega A, et al. **Cancer** 1998 Dec 15;83(12):2588–96. Comment in: Cancer 1998 Dec 15;83(12):2427–9.

Price elasticities of demand for curative health care with control for sample selectivity on endogenous illness: an analysis for Sri Lanka. Akin JS, et al. **Health Econ** 1998 Sep;7(6):509–31

Discounting costs and effects: a reconsideration. van Hout BA. **Health Econ** 1998 Nov;7(7):581–94

Commentary: excess capacity, a commentary on markets, regulation, and values [comment] Friedman B. **Health Serv Res** 1999 Feb;33(6):1669–82 (31 ref.). Comment on: Health Serv Res 1999 Feb;33(6):1651–68.

Provider choice and use of mental health care: implications for gatekeeper models. Holmes AM, et al. **Health Serv Res** 1998 Dec;33(5 Pt 1):1263–84

Excess capacity: markets regulation, and values [see comments] Madden CW. **Health Serv Res** 1999 Feb; 33(6):1651–68 (31 ref.). Comment in: Health Serv Res 1999 Feb;33(6):1669–82.

Unmet treatment needs of drug users in Alaska: correlates and societal costs. Johnson ME, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:467–73

Tanzania: still optimistic after all these years? [see comments] Yudkin JS. **Lancet** 1999 May 1;353(9163):1519–21. Comment in: Lancet 1999 Jun 12;353(9169):2077–8. Comment in: Lancet 1999 Jul 10;354(173):165.

Managing the mismatch between blood supply and clinical demand [editorial; comment] Hetzel JR. **Med J Aust** 1998 Oct 19;169(8):407–8. Comment on: Med J Aust 1998 Oct 19;169(8):415–8.

Impact of user charges and socio-economic environment on visits to paediatric trauma unit in Finland. Ahlamaa-Tuompo J, et al. **Scand J Soc Med** 1998 Dec; 26(4):265–9

[Medical care of underage refugees] Tjon A Ten WE, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24;143(30):1569–72 (Eng. Abstr.) **(Dut)**

LEGISLATION & JURISPRUDENCE

Achieving better outcomes for Hawaii's children. Marquardt SP. **Hawaii Med J** 1998 Sep;57(9):617, 633

Pills, policies, and patients. Sardis JB. **Health Aff (Millwood)** 1999 Sep-Oct;18(5):156–62

ORGANIZATION & ADMINISTRATION

Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.). Comment on: Am J Public Health 1999 Jun;89(6):834–9.

A 'whole of government' approach needed on indigenous health [editorial] Ring I. **Aust N Z J Public Health** 1998 Oct;22(6):639–40

Understanding the needs of children following large-scale disasters and the role of government. Flynn BW, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jan;7(1):211–27, x (32 ref.)

Health promotion partnerships: service and education addressing the health needs of vulnerable groups. Pflaum J, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:91–5

Contraceptive technology and family planning services. Diaz S. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S85–90 (27 ref.)

Demand management: another marketing tool or a way to quality care? Mohler MJ, et al. **J Eval Clin Pract** 1998 May;4(2):103–11

The importance of health care. Holt R. **N J Med** 1999 Sep; 96(9):58

Epilepsy needs revisited: a revised epilepsy needs document for the UK. Brown S, et al. **Seizure** 1998 Dec;7(6):435–46 (38 ref.)

Developments in UK service provision for people with epilepsy: the impact of the NHS Executive Letter 95/120. Brown SW, et al. **Seizure** 1998 Jun;7(3):185–7

['Public health status and perspectives' 1997. VII. Health care needs and health care consumption] Stokx LJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1338–42 (Eng. Abstr.) **(Dut)**

[Public health priorities] Chabot JM. **Rev Prat** 1998 Feb 15; 48(4):425–6 **(Fre)**

[History of society for family group activity for patients receiving home visiting care] Yoshizumi R, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:646–50 (Eng. Abstr.) **(Jpn)**

STANDARDS

Determining the needs of spouses caring for aphasic partners. Denman A. **Disabil Rehabil** 1998 Nov;20(11):411–23

STATISTICS & NUMERICAL DATA

Use of health services by medically ill depressed elderly patients after hospital discharge. Koenig HG, et al. **Am J Geriatr Psychiatry** 1999 Winter;7(1):48–56

A longitudinal study of schoolchildren's experience in the North Carolina Dental Medicaid Program, 1984 through 1992. Robison VA, et al. **Am J Public Health** 1998 Nov; 88(11):1669–73

Methods for analyzing health care utilization and costs. Diehr P, et al. **Annu Rev Public Health** 1999;20:125–44 (35 ref.)

Public hospital utilisation during the 1997 Arafura Games [letter] O'Grady KA, et al. **Aust N Z J Public Health** 1999 Apr;23(2):218–9

The horizontal equity of health care in New Zealand. Peacock D, et al. **Aust N Z J Public Health** 1999 Apr; 23(2):126–30

Strong bones in later life: luxury or necessity? [see comments] Delmas PD, et al. **Bull World Health Organ** 1999; 77(5):416–22. Comment in: Bull World Health Organ 1999 ;77(5):423–4. Comment in: Bull World Health Organ 1999 ;77(5):424–6. Comment in: Bull World Health Organ 1999 ;77(5):426–7. Comment in: Bull World Health Organ 1999 ;77(5):427–8. Comment in: Bull World Health Organ 1999 ;77(5):429–30. Comment in: Bull World Health Organ 1999 ;77(5):430–1. Comment in: Bull World Health Organ 1999 ;77(5):431–2. Comment in: Bull World Health Organ 1999 ;77(5):433. Comment in: Bull World Health Organ 1999 ;77(5):434–5.

Young people's health. What do teenagers want from their family doctors? [editorial] Herbert CP. **Can Fam Physician** 1998 Nov;44:2349–51, 2361–3 **(Eng, Fre)**

Health care in Ethiopia. Payne D. **Can Fam Physician** 1998 Oct;44:2069–73, 2075–6

Determining Ontario's supply and requirements for ophthalmologists in 2000 and 2005: 2. A comparison of projected supply and requirements [see comments] Persaud DD, et al. **Can J Ophthalmol** 1999 Apr;34(2):82–7. Comment in: Can J Ophthalmol 1999 Apr;34(2):59–61.

Ophthalmology workforce crisis [editorial; comment] Trope G. **Can J Ophthalmol** 1999 Apr;34(2):59–61. Comment on: Can J Ophthalmol 1999 Apr;34(2):74–81. Comment on: Can J Ophthalmol 1999 Apr;34(2):82–7. **(Eng, Fre)**

Spatial analysis of Percutaneous Transluminal Coronary Angioplasty (PTCA) in Austria. Strauss R, et al. **Eur J Epidemiol** 1999 May;15(5):451–9

Why are new patients coming to the Eye Clinic? An analysis of the relative frequencies of ophthalmic disease amongst new patients attending hospital eye clinics in two separate locations [letter; comment] Vernon SA. **Eye** 1998;12 (Pt 3a):489–90. Comment on: Eye 1997;11 (Pt 6):865–8.

More physicians: improved availability or induced demand? Carlsen F, et al. **Health Econ** 1998 Sep;7(6):495–508

Referral rates and waiting lists: some empirical evidence. Goddard JA, et al. **Health Econ** 1998 Sep;7(6):545–9

Choice of hospital: comments on 'global budgets and excess demand for hospital care' [letter; comment] Kalant N. **Health Econ** 1998 Sep;7(6):557–9. Comment on: Health Econ 1997 Mar-Apr;6(2):187–96.

Unobserved heterogeneity and censoring in the demand for health care. López-Nicolás A. **Health Econ** 1998 Aug; 7(5):429–37

The demand for healthcare among racial/ethnic subpopulations. Freiman MP. **Health Serv Res** 1998 Oct; 33(4 Pt 1):867–90

The roles of Medicaid and economic factors in the demand for nursing home care. Reschovsky JD. **Health Serv Res** 1998 Oct;33(4 Pt 1):787–813

Dental services and needs in developing countries. Pack AR. **Int Dent J** 1998 Jun;48(3 Suppl 1):239–47 (71 ref.)

Unmet treatment needs of drug users in Alaska: correlates and societal costs. Johnson ME, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:467–73

The characteristics of Indian subcontinent origin elders newly referred to a psychogeriatric service. Odutoye K, et al. **Int J Geriatr Psychiatry** 1999 Jun;14(6):446–53

Reversible contraception: issues faced by emerging countries. Garza-Flores J. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S37–40

Contraceptives: regional perspectives, issues, and unmet needs--the European perspective. Newton J. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S25–30 (13 ref.)

Discussion--meeting contraceptive needs worldwide: the role of monthly combined injectables. Sciarra JJ. **Int J Gynaecol Obstet** 1998 Aug;62 Suppl 1:S41–2

The consequences of universalizing health services: children's use of health services in Catalonia. Rajmil L, et al. **Int J Health Serv** 1998;28(4):777–91

Assessment of rehabilitation needs in cancer patients. van Harten WH, et al. **Int J Rehabil Res** 1998 Sep;21(3):247–57

The distribution of community psychiatric nurses in England: are they where they should be? Buck D, et al. **J Adv Nurs** 1998 Sep;28(3):508–16

Accuracy of parent mental health service reporting: results from a reverse record-check study. Fendrich M, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Feb;38(2):147–55

Legacy of the secret war: medical needs in the UXO-contaminated areas in Laos. Morikawa M. **J Am Board Fam Pract** 1998 Nov-Dec;11(6):485–6

Unmet need for eyeglasses: results from the 1994 Robert Wood Johnson Access to Care Survey. Hodges LE, et al. **J Am Optom Assoc** 1999 Apr;70(4):261–5

Health care needs and services utilization among sheltered and unsheltered Michigan homeless [letter] Douglass RL, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):5–18

Health status, needs, and health care barriers among the homeless. Wojtusik L, et al. **J Health Care Poor Underserved** 1998 May;9(2):140–52

Development of scales to measure psychosocial care needs of children with seizures and their parents. 1. Austin J, et al. **J Neurosci Nurs** 1998 Jun;30(3):155–60

Psychosocial care needs of children with new-onset seizures. 2. McNelis A, et al. **J Neurosci Nurs** 1998 Jun;30(3):161–5

Psychosocial care needs of parents of children with new-onset seizures. 3. Shore C, et al. **J Neurosci Nurs** 1998 Jun;30(3):169–74

Workforce demand for neurosurgeons in the United States of America: a 13-year retrospective study. Friedlich DL, et al. **J Neurosurg** 1999 Jun;90(6):993–7

The homeless crisis and health care [news] **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):9

Can questionnaires replace clinical surveys to assess dental treatment needs of adults? Robinson PG, et al. **J Public Health Dent** 1998 Summer;58(3):250–3

More alike than different. Comparing the mental health needs of London and other inner city areas. Kisely S. **J Public Health Med** 1998 Sep;20(3):318–24

Using queueing theory to determine operating room staffing needs. Tucker JB, et al. **J Trauma** 1999 Jan;46(1):71–9

Using the POPULIS framework for interprovincial comparisons of expenditures on health care. Population Health Information System. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS83–100

Adding up provincial expenditures on health care for Manitobans: a POPULIS project. Population Health Information System. Shanahan M, et al. **Med Care** 1999

Jun;37(6 Suppl):JS60–82
Managing the mismatch between blood supply and clinical demand [editorial; comment] Hetzel JR. **Med J Aust** 1998 Oct 19;169(8):407–8. Comment on: Med J Aust 1998 Oct 19;169(8):415–8.
Cross-country truck drivers: a vulnerable population. Renner DA. **Nurs Outlook** 1998 Jul–Aug;46(4):164–8 (32 ref.)
Family-level services in oncology nursing: facts, fallacies, and realities revisited. Lewis FM. **Oncol Nurs Forum** 1998 Sep;25(8):1378–88
Pediatric ambulance utilization in a large American city: a systems analysis approach [see comments] Foltin GL, et al. **Pediatr Emerg Care** 1998 Aug;14(4):254–8. Comment in: Pediatr Emerg Care 1998 Dec;14(6):453–4.
The scope of unmet maternal health needs in pediatric settings. Kahn RS, et al. **Pediatrics** 1999 Mar;103(3):576–81
The family's special needs in disaster [editorial; comment] Mulligan-Smith D. **Prehosp Emerg Care** 1998 Oct–Dec; 2(4):334–5. Comment on: Prehosp Emerg Care 1998 Oct–Dec;2(4):285–8.
Variations in mental health needs and fee-for-service reimbursement for physicians in Ontario. Lin E, et al. **Psychiatr Serv** 1998 Nov;49(11):1445–51
Acceptance of nurse practitioners and physician assistants in meeting the perceived needs of rural communities. Baldwin KA, et al. **Public Health Nurs** 1998 Dec; 15(6):389–97
The crisis of elder care [editorial] Graham KY. **Public Health Nurs** 1998 Dec;15(6):387–8
Influence of immunopreventable diseases and AIDS on the demand of an infectious diseases department in Rio de Janeiro State, Brazil, in the course of thirty years (1965–1994). Setúbal S, et al. **Rev Inst Med Trop Sao Paulo** 1998 May–Jun;40(3):185–92
Equity in the delivery of health care in Sweden. Gerdtham UG, et al. **Scand J Soc Med** 1998 Dec;26(4):259–64
The perceived rehabilitation needs of a hospital-based outpatient sample of people with epilepsy. Chaplin JE, et al. **Seizure** 1998 Aug;7(4):329–35
Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Rabinowitz J, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Mar;34(3):141–6
"Communitarian claims" as an ethical basis for allocating health care resources. Mooney G. **Soc Sci Med** 1998 Nov; 47(9):1171–80 (47 ref.)
Attitudes toward service use among wife caregivers of frail older veterans. Dorfman LT, et al. **Soc Work Health Care** 1998;27(4):39–64
[Heart transplantation in the Netherlands, an option to be considered for 5 children per year on the average] Raymakers GJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1425–8 (Eng. Abstr.) **(Dut)**
[Different organizational modalities in perinatal care as a function of demographic context and budgetary constraints] Papiernik E. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:76–84 (17 ref.) **(Fre)**
[Cesarean sections in Senegal: coverage of needs and quality of services] Cisse CT, et al. **Sante** 1998 Sep–Oct;8(5):369–77 (Eng. Abstr.) **(Fre)**
[How are palliative care needs estimated in short-stay establishments? Apropos of an experience in Côte d'Or] Bouté C, et al. **Sante Publique** 1999 Mar;11(1):29–39 (Eng. Abstr.) **(Fre)**
[The need for the hospital treatment of surgical patients] Bobil BV, et al. **Voen Med Zh** 1998 Sep;319(9):12–6 **(Rus)**
[Demand of microbiological diagnosis by pediatricians from the Salamanca area] Mirón Canelo JA, et al. **An Esp Pediatr** 1999 May;50(5):463–6 (Eng. Abstr.) **(Spa)**
[A slow progress in health policy targets. Health care consumption in Dalby and Tierp over 20 years] Slaug B, et al. **Lakartidningen** 1998 Sep 23;95(39):4254–8 **(Swe)**

TRENDS

Medical schools and teaching hospitals--serving the needs of America's communities. Cohen JJ. **Acad Med** 1998 Nov; 73(11):1177
Content in context: medical education and society's needs. Maudsley RF. **Acad Med** 1999 Feb;74(2):143–5
Medical care in the next century. Verstraete M. **Acta Cardiol** 1999 Apr;54(2):59–69 (43 ref.)
Supply of and demand for physiatrists: review and update of the 1995 physical medicine and rehabilitation workforce study. A special report. The Lewin Group. **Am J Phys Med Rehabil** 1999 Sep–Oct;78(5):477–85
Projecting the need for hip replacement over the next three decades: influence of changing demography and threshold for surgery. Birrell F, et al. **Ann Rheum Dis** 1999 Sep; 58(9):569–72
Subspecialties in ophthalmology [letter; comment] Lee AG. **Arch Ophthalmol** 1999 Feb;117(2):288. Comment on: Arch Ophthalmol 1998 Jul;116(7):917–20.
Determining Ontario's supply and requirements for ophthalmologists in 2000 and 2005: 1. Methods [see comments] Persaud DD, et al. **Can J Ophthalmol** 1999 Apr; 34(2):74–81. Comment in: Can J Ophthalmol 1999 Apr;34(2):59–61.
The urology work force in Ontario for the 21st century: feast or famine? Pace KT, et al. **Can J Surg** 1999 Jun;42(3):181–9
Caring for an aging population [letter; comment] Nazerali N, et al. **CMAJ** 1998 Sep 22;159(6):647–8; discussion 649–50 . Comment on: CMAJ 1998 May 19;158(10):1275–84.
Signs of the times? Massey RU. **Conn Med** 1998 Oct; 62(10):627–8
Covering older Americans: forecast for the next decade. Glied S, et al. **Health Aff (Millwood)** 1999 Jan–Feb; 18(1):208–13
Current and future hospitalization after heart attack. Johansen H, et al. **Health Rep** 1998 Autumn;10(2):21–8 (Eng); 23–31 (Fre) **(Eng, Fre)**
Consolidation. Trauma trouble [news] Haugh R. **Hosp Health Netw** 1999 Jan;73(1):20, 22
Trends: immigration and technology. Miller BA. **J Am Coll Dent** 1998 Winter;65(4):36–8
HIV/AIDS units: is there still a need? [editorial] Morrison C. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):16–8
Postdoctoral education in dentistry: preparing dental practitioners to meet the oral health needs of America in the 21st century. Glassman P, et al. **J Dent Educ** 1999 Aug; 63(8):615–25
Young adult survivors of childhood cancer: attending to emerging medical and psychosocial needs [see comments] Richardson RC, et al. **J Pediatr Oncol Nurs** 1999 Jul; 16(3):136–44 (41 ref.). Comment in: J Pediatr Oncol Nurs 1999 Jul;16(3):115–6.
The changing elderly population and future health care needs. Mechanic D. **J Urban Health** 1999 Mar;76(1):24–38 (21 ref.)
The spectrum of disability [editorial] **Lancet** 1999 Aug 28; 354(9180):693
How can we help Iraqi people [letter] Tawfik R. **Lancet** 1999 Aug 7;354(9177):518
The sensitivity and specificity of forecasting high-cost users of medical care. Meenan RT, et al. **Med Care** 1999 Aug; 37(8):815–23
The rural health care workforce implications of practice guideline implementation. Yawn BP, et al. **Med Care** 1999 Mar;37(3):259–69
Community residential services would require expansion of 72% to serve everyone in community settings. Lakin KC, et al. **Ment Retard** 1999 Jun;37(3):251–4
The chance of a lifetime--nursing's golden opportunity [editorial] [see comments] Anderson CA. **Nurs Outlook** 1998 Jul–Aug;46(4):149–50. Comment in: Nurs Outlook 1999 Mar–Apr;47(2):95.
Current status of and challenges for dementia in Japan. Otsuka T. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S300–2
The needs and popularization of psychotherapy in Taiwan. Soong WT. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S229–32
Report calls for managed health care to be shaped to children's needs [news] **Public Health Rep** 1999 Jan–Feb; 114(1):7
The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. Roderick PJ, et al. **QJM** 1998 Aug;91(8):581–7
[An adolescent treatment unit: development and resistance (editorial)] Gautry P, et al. **Arch Pediatr** 1998 Aug; 5(8):839–43 **(Fre)**
[Success and vicissitudes on organizing urgent care in pediatrics: presentation of a project of urgent pediatric medico-surgical care] Stagnara J, et al. **Arch Pediatr** 1998; 5 Suppl 2:215s–216s **(Fre)**
[Need for psycho-oncologic management in Germany--a comparison of present status and future needs] Weis J, et al. **Psychother Psychosom Med Psychol** 1998 Sep–Oct; 48(9–10):417–24 (Eng. Abstr.) **(Ger)**
[Health promotion in the neighborhood--resources and needs of neighborhood groups and institutions] Tschumper A. **Soz Praventivmed** 1998;43(5):254–61 (Eng. Abstr.) **(Ger)**

UTILIZATION

Health habit counseling amidst competing demands: effects of patient health habits and visit characteristics. Chernof BA, et al. **Med Care** 1999 Aug;37(8):738–47
[Need adjustment of utilization of occupational health promotion for reducing back pain? Results of an employee survey of the metal industry (published erratum appears in Gesundheitswesen 1999 Jan;61(1):51)] Wanek V, et al. **Gesundheitswesen** 1998 Dec;60(12):729–37 (Eng. Abstr.) **(Ger)**
[An analysis of the relationship between morbidity and the level of demand for pediatric primary care. A study on 1359 children] Polo Martín P, et al. **An Esp Pediatr** 1998 Sep;49(3):273–9 (Eng. Abstr.) **(Spa)**
[An analysis of the demand for laboratory tests from primary care in a health area] de Gracia Gomis MC, et al. **Aten Primaria** 1999 Jan;23(1):26–31 (Eng. Abstr.) **(Spa)**

HEALTH SERVICES RESEARCH

Measuring the impact of prevention research on public health practice. Brownson RC, et al. **Am J Prev Med** 1999 Apr; 16(3 Suppl):72–9 (69 ref.)
Applied prevention research. Challenges of working with urban communities. Cohall A. **Am J Prev Med** 1999 Apr; 16(3 Suppl):16–7
Health services research: public benefits, personal privacy, and proprietary interests [editorial] Gostin LO, et al. **Ann Intern Med** 1998 Nov 15;129(10):833–5
Patient Outcomes Research Teams: contribution to outcomes and effectiveness research. Freund D, et al. **Annu Rev Public Health** 1999;20:337–59 (78 ref.)
Health services pathology: a new discipline? [letter; comment] Hilborne LH. **Arch Pathol Lab Med** 1999 Feb; 123(2):101. Comment on: Arch Pathol Lab Med 1998 May;122(5):409–11.
The importance of theories in health care. Alderson P. **BMJ** 1998 Oct 10;317(7164):1007–10 (13 ref.)
Development and evaluation of complex interventions in health services research: case study of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. Bradley F, et al. **BMJ** 1999 Mar 13; 318(7185):711–5 (25 ref.)
Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. McKee M, et al. **BMJ** 1999 Jul 31;319(7205):312–5 (22 ref.)
Theories in health care and research: theories of disability in health practice and research. Oliver M. **BMJ** 1998 Nov 21;317(7170):1446–9 (29 ref.)
A database designed for utilization management in diagnostic imaging. Stolberg HO, et al. **Can Assoc Radiol J** 1999 Aug; 50(4):227–32
Federal health budget 1999: part 2--health research, health information and prevention. Scully HE. **Can J Cardiol** 1999 May;15(5):525–8 **(Eng, Fre)**
Why research? Steele B. **Can J Cardiol** 1999 May; 15(5):529–31 **(Eng, Fre)**
Health services research in head and neck cancer. Pfister DG, et al. **Cancer Treat Res** 1998;97:159–75 (87 ref.)
Quality of life research: clinical applications. Reifel JL, et al. **Cancer Treat Res** 1998;97:1–12 (36 ref.)
Health service studies in the terminally ill cancer patient. Smith TJ. **Cancer Treat Res** 1998;97:81–97 (77 ref.)
Researching the grass roots [editorial] Osmun WE. **Clin Invest Med** 1998 Aug–Oct;21(4–5):211–2
Restructuring health services delivery research: a community-based model. Sellors JW, et al. **Clin Invest Med** 1998 Aug–Oct;21(4–5):203–8
Caring for an aging population [letter; comment] Hugenholtz H. **CMAJ** 1998 Sep 22;159(6):648; discussion 649–50. Comment on: CMAJ 1998 May 19;158(10):1275–84.
Service reviews in the Community Dental Service. Regional guidance produced by dental services managers and consultants in dental public health in the north west of England. Harding M, et al. **Community Dent Health** 1998 Dec;15(4):231–2
Bibliography. Current world literature. Epidemiology and health services research. **Curr Opin Rheumatol** 1999 Mar; 11(2):B25–36
The Oregon report. Don't ask, don't tell. Foley K, et al. **Hastings Cent Rep** 1999 May–Jun;29(3):37–42
Health services research and state policy in action [letter; comment] Farrell JL, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):257–8. Comment on: Health Aff (Millwood) 1998 Jan–Feb;17(1):139–51.
Defining competition in markets: why and how? Bernstein AB, et al. **Health Serv Res** 1998 Dec;33(5 Pt 2):1421–38 (35 ref.)
Assessing the performance of community systems for children. DuPlessis HM, et al. **Health Serv Res** 1998 Oct; 33(4 Pt 2):1111–42 (84 ref.)
Health services research in workers' compensation medical care: policy issues and research opportunities. Himmelstein J, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):427–37
Improving the quality of care for children in health systems. Homer CJ, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1091–109 (58 ref.)
Pushing good research to go farther [editorial; comment] Luft HS. **Health Serv Res** 1998 Dec;33(5 Pt 1):1185–90. Comment on: Health Serv Res 1998 Dec;33(5 Pt 1):1191–210.
Assessing the quality of healthcare provided to children. Mangione-Smith R, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1059–90 (80 ref.)
Planning and accountability at AHCPR: applying the quality message at home. Agency for Health Care Policy and Research. Simpson L, et al. **Health Serv Res** 1999 Jun; 34(2):461–83
Peer-reviewed journals and quality [editorial] Swartz K. **Inquiry** 1999 Summer;36(2):119–21
Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59–81 (127 ref.)
Mental health problems in primary care: a research agenda. Klinkman MS, et al. **Int J Psychiatry Med** 1998; 28(4):361–74 (68 ref.)
Priorities for agenda building: mental health and primary care [editorial] Lebowitz BD. **Int J Psychiatry Med** 1998; 28(4):375–8
Primary care research agenda: traveling the spectrum from efficacy to effectiveness [editorial] Oxman TE, et al. **Int J Psychiatry Med** 1998;28(4):357–9
Characteristics and course of major depression in older primary care patients. Schulberg HC, et al. **Int J Psychiatry Med** 1998;28(4):421–36
Report from the Department of Epidemiology, Social Medicine, and Health System Research, Medizinische Hochschule Hannover, Germany. **Int J Technol Assess Health Care** 1999 Winter;15(1):274–6

Can we measure the social importance of health care? Buck D, et al. **Int J Technol Assess Health Care** 1999 Winter; 15(1):89–107 (35 ref.)

A research registry: uses, development, and accuracy. Roos LL, et al. **J Clin Epidemiol** 1999 Jan;52(1):39–47

Large datasets: common uses and caveats. Safavi K. **J Cutan Med Surg** 1998 Oct;3(2):90–5

Recent progress in health services research: on the need for evidence-based debate [editorial] Miles A, et al. **J Eval Clin Pract** 1998 Nov;4(4):257–65

Avoidable errors in health policy analysis [published erratum appears in J Gen Intern Med 1999 Jun;14(6):363] Asch DA, et al. **J Gen Intern Med** 1998 Nov;13(11):762–7

From boardroom to bedside: bioethical implications of policy research for clinical practice. Asch DA. **J Investig Med** 1999 Jul;47(6):273–7

Evidence-based policy-making in the NHS: exploring the interface between research and the commissioning process. Harries U, et al. **J Public Health Med** 1999 Mar;21(1):29–36 (16 ref.)

Where do UK health services researchers publish their findings? Black N, et al. **J R Soc Med** 1999 Mar; 92(3):129–31

Evidence-based healthcare: flaws in the paradigm? Carr-Hill R. **J R Soc Med** 1998;91 Suppl 35:12–4

A rude awakening: post-take ward round in the department of medicine for the elderly [see comments] Coni N. **J R Soc Med** 1998 Sep;91(9):471–4. Comment in: J R Soc Med 1998 Nov;91(11):612.

Qualitative research and evidence-based healthcare. Popay J, et al. **J R Soc Med** 1998;91 Suppl 35:32–7 (11 ref.)

Evidence-based healthcare: what progress in the NHS? Walshe K. **J R Soc Med** 1998;91 Suppl 35:15–9

School nurses' perceptions of and experience with school health research. Price JH, et al. **J Sch Health** 1999 Feb; 69(2):58–62

Sources used in health policy research and implications for information retrieval systems. Gray BH. **J Urban Health** 1998 Dec;75(4):842–52 (0 ref.)

Avoiding the unintended consequences of growth in medical care: how might more be worse? Fisher ES, et al. **JAMA** 1999 Feb 3;281(5):446–53

Advances in medical care: promise, problems, and proper application [letter] Foucar E. **JAMA** 1999 Sep 8; 282(10):938; discussion 939

Service quality in health care. Kenagy JW, et al. **JAMA** 1999 Feb 17;281(7):661–5

Practice-based research networks answer primary care questions. Nutting PA, et al. **JAMA** 1999 Feb 24; 281(8):686–8

An evidence-based approach to interactive health communication: a challenge to medicine in the information age. Science Panel on Interactive Communication and Health. Robinson TN, et al. **JAMA** 1998 Oct 14; 280(14):1264–9 (82 ref.)

Advances in medical care: promise, problems, and proper application [letter] Volpintesta EJ. **JAMA** 1999 Sep 8; 282(10):938–9

Advances in medical care: promise, problems, and proper application [letter] Wolicki KT. **JAMA** 1999 Sep 8; 282(10):939

Conference report. Measuring and improving the quality of care in health plans. Berman S. **Jt Comm J Qual Improv** 1999 Aug;25(8):434–9

Sociological models and health care [letter; comment] Corrigan PW, et al. **Lancet** 1999 Jun 19;353(9170):2163. Comment on: Lancet 1999 Feb 6;353(9151):486–9.

Communicating with the public, communicating with each other. DeCoster C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS279–90

Building bridges. IV: Managed care research comes of age. Fraser I, et al. **Med Care Res Rev** 1999;56 Suppl 2:5–12

Children and managed care: what research can, can't, and should tell us about impact. Simpson L, et al. **Med Care Res Rev** 1999;56 Suppl 2:13–36

Quality of life as a construct in health and disability research. Brown M, et al. **Mt Sinai J Med** 1999 May;66(3):160–9

Neurology "with the bark off": tacrine, nursing home residents, and health services research [editorial; comment] Phillips CD, et al. **Neurology** 1999 Jan 15;52(2):227–30. Comment on: Neurology 1999 Jan 15;52(2):238–44.

Monitoring data and safety in the WHO Antenatal Care Trial. Bergsjø P, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:156–64

The practice of antenatal care: comparing four study sites in different parts of the world participating in the WHO Antenatal Care Randomised Controlled Trial. Piaggio G, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:116–41

Managing data for a randomised controlled clinical trial: experience from the WHO Antenatal Care Trial. WHO Antenatal Care Trial Research Group. Pinol A, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:142–55

Developing a research culture for palliative care. Richards MA, et al. **Palliat Med** 1998 Sep;12(5):399–403

Priorities for research in emergency medical services for children: results of a consensus conference. Seidel JS, et al. **Pediatr Emerg Care** 1999 Feb;15(1):55–8 (9 ref.)

The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)

Canadian budget. Health research gets fundamental overhaul [news] Kondro W. **Science** 1999 Feb 26;283(5406):1241

The use of research in local health service agencies. Anderson M, et al. **Soc Sci Med** 1999 Oct;49(8):1007–19

Evaluating health service equity at a primary care clinic in Chilimarca, Bolivia. Kinman EL. **Soc Sci Med** 1999 Sep; 49(5):663–78

Power between evaluator and community: research relationships within New Mexico's healthier communities. Wallerstein N. **Soc Sci Med** 1999 Jul;49(1):39–53

[The Federation for International Cooperation of Health Services and Systems Research Centers: a decade of activity (1988–1998)] Doan BD. **Cah Sociol Demogr Med** 1999 Jan–Mar;39(1):59–75 **(Fre)**

[Public health research requirement in Germany--opinion of the German Society for Public Health (DGPH), June 1998] Siegrist J. **Gesundheitswesen** 1998 Nov;60(11):706–8 **(Ger)**

[Berlin-Brandenburg-Saxony Rehabilitation Research Group] Brennecke R, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S84–91 (Eng. Abstr.) **(Ger)**

[Contribution of databases to regional and supra-regional quality improvement in rheumatologic treatment and patient management. Professional Society of Regional Cooperative Rheumatic Disease Centers] Zink A. **Z Rheumatol** 1998 Dec;57(6):442–5 (Eng. Abstr.) **(Ger)**

[Outcome research: rationales and objectives] Olivieri A, et al. **Tumori** 1998 Nov–Dec;84(6 Suppl 2):S3–6 (Eng. Abstr.) **(Ita)**

ECONOMICS

Radiological imaging: research on cost-effectiveness and the cost-effectiveness of research. Tengs TO. **Acad Radiol** 1999 Jan;6 Suppl 1:S120–7

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study? Chen C, et al. **Am Heart J** 1999 May;137(5):S71–4

Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry? Gagnon JP. **Am Heart J** 1999 May;137(5):S62–6

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective. Lee TH. **Am Heart J** 1999 May;137(5):S67–70

Funding clinical research: the need for information and longer term strategies. Feneley MR, et al. **Ann R Coll Surg Engl** 1999 May;81(3):145–50 (13 ref.)

Cost, quality of life and outcome measures in ovarian cancer. Abbas FM, et al. **Anticancer Drugs** 1998 Nov;9(10):859–67 (86 ref.)

Costs of intensive treatment and follow-up of patients with multiple myeloma. Buijt I, et al. **Anticancer Drugs** 1998 Nov;9(10):889–97

Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Patnaik A, et al. **Anticancer Drugs** 1998 Nov;9(10):869–78 (47 ref.)

A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Brazier J, et al. **Health Econ** 1999 Feb;8(1):41–51 (51 ref.)

The appropriate uses of qualitative methods in health economics. Coast J. **Health Econ** 1999 Jun;8(4):345–53

Incorporating societal concerns for fairness in numerical valuations of health programmes. Nord E, et al. **Health Econ** 1999 Feb;8(1):25–39

A review of the use of health status measures in economic evaluation. Brazier J, et al. **Health Technol Assess** 1999; 3(9):i–iv, 1–164 (1135 ref.)

The measurement of indirect costs in the health economics evaluation literature. A review. Jacobs P, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):799–808 (43 ref.)

The health transition fund and the future of Canadian health care delivery. Innes G. **J Emerg Med** 1999 Jan–Feb; 17(1):157–8

Evaluating the NHS research and development programme: will the programme give value for money? Buxton M, et al. **J R Soc Med** 1998;91 Suppl 35:2–6

Research funding opportunities at the Agency for Health Care Policy and Research. Jones CB, et al. **Nurs Outlook** 1999 Jul–Aug;47(4):156–61

HISTORY

A historical review (1965–1997) of studies on class, health, and quality of life: a personal account. Navarro V. **Int J Health Serv** 1998;28(3):389–406

LEGISLATION & JURISPRUDENCE

Health services research and personal health information: privacy concerns, new legislation and beyond [editorial] [see comments] Willison DJ. **CMAJ** 1998 Dec 1; 159(11):1378–80 (25 ref.). Comment in: CMAJ 1999 Apr 6;160(7):988.

Medical records and privacy: empirical effects of legislation. McCarthy DB, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):417–25

METHODS

A method for assessing emergency department performance using patient outcomes. Chamberlain JM, et al. **Acad Emerg Med** 1998 Oct;5(10):986–91

Controlled trial of the effect of length, incentives, and follow-up techniques on response to a mailed questionnaire. Hoffman SC, et al. **Am J Epidemiol** 1998 Nov 15; 148(10):1007–11

Role of surveillance in emerging health systems: measurement is essential but not sufficient [see comments] Lovett LL, et al. **Am J Infect Control** 1999 Apr;27(2):135–40. Comment in: Am J Infect Control 1999 Apr;27(2):77–8.

A framework for evaluating underutilization of health care services. Fetterolf DE. **Am J Med Qual** 1999 Mar–Apr; 14(2):89–97 (40 ref.)

How to detect effects: statistical power and evidence-based practice in occupational therapy research. Ottenbacher KJ, et al. **Am J Occup Ther** 1999 Mar–Apr;53(2):181–8 (38 ref.)

Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer. Hillner BE. **Anticancer Drugs** 1998 Nov;9(10):843–7 (23 ref.)

Economic evaluation of cancer treatments: methodological and practical issues. Uyl-de Groot CA, et al. **Anticancer Drugs** 1998 Nov;9(10):835–41

Economic evaluation of endocrine therapy in the treatment of breast cancer. Wait SH. **Anticancer Drugs** 1998 Nov; 9(10):849–57 (35 ref.)

Limitations of diagnostic paradigm: it doesn't explain "need" [letter; comment] Ustün TB, et al. **Arch Gen Psychiatry** 1998 Dec;55(12):1145–6; discussion 1147–8. Comment on: Arch Gen Psychiatry 1998 Feb;55(2):109–15.

Analysis and interpretation of cost data in randomised controlled trials: review of published studies [see comments] Barber JA, et al. **BMJ** 1998 Oct 31; 317(7167):1195–200 (34 ref.). Comment in: BMJ 1999 Jun 19;318(7199):1696–7.

Handling uncertainty in economic evaluations of healthcare interventions. Briggs AH, et al. **BMJ** 1999 Sep 4; 319(7210):635–8

Determining Ontario's supply and requirements for ophthalmologists in 2000 and 2005: 1. Methods [see comments] Persaud DD, et al. **Can J Ophthalmol** 1999 Apr; 34(2):74–81. Comment in: Can J Ophthalmol 1999 Apr;34(2):59–61.

Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556–61 (34 ref.)

A Bayesian approach to stochastic cost-effectiveness analysis. Briggs AH. **Health Econ** 1999 May;8(3):257–61

The appropriate uses of qualitative methods in health economics. Coast J. **Health Econ** 1999 Jun;8(4):345–53

Response-ordering effects: a methodological issue in conjoint analysis. Farrar S, et al. **Health Econ** 1999 Feb;8(1):75–9

A Bayesian approach to sensitivity analysis. Felli JC, et al. **Health Econ** 1999 May;8(3):263–8

Bayesian estimation of cost-effectiveness ratios from clinical trials. Heitjan DF, et al. **Health Econ** 1999 May; 8(3):191–201

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Lord J, et al. **Health Econ** 1999 Jun;8(4):323–33

Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Willan AR, et al. **Health Econ** 1999 May;8(3):203–11

Calculating the global burden of disease: time for a strategic reappraisal? [editorial] Williams A. **Health Econ** 1999 Feb; 8(1):1–8

A collaborative evaluation of a needle exchange program for youth. Weiker RL, et al. **Health Educ Behav** 1999 Apr; 26(2):213–24

Who is the marginal patient? Understanding instrumental variables estimates of treatment effects. Harris KM, et al. **Health Serv Res** 1998 Dec;33(5 Pt 1):1337–60

Issues in studying the effectiveness of health services for children. Lieu TA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1041–58 (49 ref.)

A claims data approach to defining an episode of care. Schulman KA, et al. **Health Serv Res** 1999 Jun;34(2):603–21

Long-term care research: demand, payment, and outcomes [editorial; comment] Siu AL. **Health Serv Res** 1998 Oct; 33(4 Pt 1):783–5. Comment on: Health Serv Res 1998 Oct;33(4 Pt 1):835–65.

The health of children. Szilagyi PG, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1001–39 (97 ref.)

Interpreting reported health-care benefits. Neilson AR, et al. **Hosp Med** 1999 Feb;60(2):134–7

A major employer as a health care services laboratory [see comments] Reeve GR, et al. **Int J Qual Health Care** 1998 Dec;10(6):547–53. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.

Using formative research to conceptualize and develop a marketing plan for student health services. Stephenson MT. **J Am Coll Health** 1999 Mar;47(5):237–9

Increasing physicians' awareness of the impact of statistics on research outcomes: comparative power of the t-test and and Wilcoxon Rank-Sum test in small samples applied research. Bridge PD, et al. **J Clin Epidemiol** 1999 Mar; 52(3):229–35

Three evaluation methods of a community health advocate program. Rodney M, et al. **J Community Health** 1998 Oct; 23(5):371–81

Performance management using health outcomes: in search of instrumentality. Davies HT. **J Eval Clin Pract** 1998 Nov;

4(4):359–62
Reviewing and selecting outcome measures for use in routine practice. Greenhalgh J, et al. **J Eval Clin Pract** 1998 Nov; 4(4):339–50
Action research--a model for introducing standardized health assessment in general practice: an exploratory study. Meadows KA, et al. **J Eval Clin Pract** 1998 Aug;4(3):225–9
Measuring subjective outcomes: rethinking reliability and validity. Elasy TA, et al. **J Gen Intern Med** 1998 Nov; 13(11):757–61
Estimating hospital inefficiency: does case mix matter? Rosko MD, et al. **J Med Syst** 1999 Feb;23(1):57–71
Assessing the effectiveness and optimal structure of trauma systems: a consensus among experts. Mann NC. **J Trauma** 1999 Sep;47(3 Suppl):S69–74
Research recommendations and proposed action items to facilitate trauma system implementation and evaluation. Mann NC, et al. **J Trauma** 1999 Sep;47(3 Suppl):S75–8
Review of methods to determine VA health care costs. Barnett PG. **Med Care** 1999 Apr;37(4 Suppl Va):AS9–17 (40 ref.)
Use of the Decision Support System for VA cost-effectiveness research. Barnett PG, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS63–70
Cost as a study outcome: sensitivity of study conclusions to the method of estimating cost. Chapko MK, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS37–44
Comparing outcomes: comparing systems [editorial; comment] Demakis JG. **Med Care** 1999 Jun;37(6):527–8. Comment on: Med Care 1999 Jun;37(6):529–37. Comment on: Med Care 1999 Jun;37(6):538–46.
More or less?: Methods to compare VA and non-VA health care costs. Hendricks AM, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS54–62 (29 ref.)
Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. Hynes D, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS27–36
Choices of methodology in pharmacoeconomics studies. Longo CJ. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS32–5
Use of claims data for research on treatment and outcomes of depression care. Melfi CA, et al. **Med Care** 1999 Apr; 37(4 Suppl Lilly):AS77–80
Determining costs in VA: research design problems and solutions illustrated with case studies. Menke TJ, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS18–26
Use of a cost accounting system to evaluate costs of a VA special program. Menke TJ, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS45–53
Cost analysis in the Department of Veterans Affairs: consensus and future directions. Swindle R, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS3–8 (13 ref.)
Accuracy of risk-adjusted mortality rate as a measure of hospital quality of care. Thomas JW, et al. **Med Care** 1999 Jan;37(1):83–92
Reproducibility of measures of overuse of cataract surgery by three physician panels. Tobacman JK, et al. **Med Care** 1999 Sep;37(9):937–45
Qualitative research: a path to better healthcare. Peat JK, et al. **Med J Aust** 1998 Sep 21;169(6):327–9 (20 ref.)
Evaluation research in occupational health services: general principles and a systematic review of empirical studies. Hulshof CT, et al. **Occup Environ Med** 1999 Jun; 56(6):361–77 (112 ref.)
Antenatal care in developing countries. Belizán JM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:1–3
Methodological considerations in the design of the WHO Antenatal Care Randomised Controlled Trial. Donner A, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:59–74
Conceptual bases and methodology for the evaluation of women's and providers' perception of the quality of antenatal care in the WHO Antenatal Care Randomised Controlled Trial. Langer A, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:98–115
Antenatal care in developed countries. Lindmark G, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:4–6
Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial. Mugford M, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:75–97
"Virtual" clinical trials: case control experiments utilizing a health services research workstation. Weiner MG, et al. **Proc AMIA Symp** 1998;:300–4
A holistic approach to the economic evaluation of health programs using institutionalist methodology. Jan S. **Soc Sci Med** 1998 Nov;47(10):1565–72
Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). McNamee P, et al. **Soc Sci Med** 1999 Feb;48(3):331–41
Production gains from health care: what should be included in cost-effectiveness analyses? Olsen JA, et al. **Soc Sci Med** 1999 Jul;49(1):17–26
The fake patient: a research experiment in a Ghanaian hospital. Van der Geest S, et al. **Soc Sci Med** 1998 Nov; 47(9):1373–81
[Methods and qualitative technics in primary care research (editorial; comment] Fernández de Sanmamed Santos MJ. **Aten Primaria** 1999 May 15;23(8):453–4. Comment on: Aten Primaria 1999 May 15;23(8):496–502. **(Spa)**
[Research and qualitative evaluation: the theoretical and conceptual bases (see comments)] Iñiguez Rueda L. **Aten Primaria** 1999 May 15;23(8):496–502. Comment in: Aten Primaria 1999 May 15;23(8):453–4. **(Spa)**

ORGANIZATION & ADMINISTRATION

Academic health centers can bridge the gulf between medicine and public health. Williams JF, et al. **Acad Med** 1999 May;74(5):484–7 (4 ref.)
Commitment to improving indigenous health [editorial] Leeder SR. **Aust N Z J Public Health** 1998 Oct;22(6):635–6
Methods in health service research. Evaluation of health interventions at area and organisation level. Ukoumunne OC, et al. **BMJ** 1999 Aug 7;319(7206):376–9 (24 ref.)
Waiting for peace: perspectives from action-oriented research on the humanitarian impasse in the Caucasus. Hansen G, et al. **Disasters** 1999 Sep;23(3):257–70 (0 ref.)
Promotion of evaluation as a strategy towards an effective substance prevention. Ostaszewski K. **Eur Addict Res** 1998 Sep;4(3):128–33 (33 ref.)
Outcomes and effectiveness research in the private sector. Mendelson DN, et al. **Health Aff (Millwood)** 1998 Sep–Oct; 17(5):75–90 (19 ref.)
From private club to professional network: an economic history of the Health Economists' Study Group, 1972–1997. Croxson B. **Health Econ** 1998 Aug;7 Suppl 1:S9–45
"Out-of-the-mainstream" youth as partners in collaborative research: exploring the benefits and challenges. Harper GW, et al. **Health Educ Behav** 1999 Apr;26(2):250–65
The collaboration process in HIV prevention and evaluation in an urban American Indian clinic for women. Klein D, et al. **Health Educ Behav** 1999 Apr;26(2):239–49
Collaborative community research consortium: a model for HIV prevention. Sanstad KH, et al. **Health Educ Behav** 1999 Apr;26(2):171–84
Organizing community research partnerships in the struggle against AIDS. Schensul JJ. **Health Educ Behav** 1999 Apr; 26(2):266–83 (47 ref.)
Violence in families: assessing prevention and treatment programs. **Health Serv Res** 1998 Oct;33(4 Pt 1):x–xii
AHCPR focuses on information for health care decision makers. Eisenberg JM. **Health Serv Res** 1998 Oct;33(4 Pt 1):767–81 (11 ref.)
Making Medicaid managed care research relevant. Gold M. **Health Serv Res** 1999 Feb;33(6):1639–50 (13 ref.)
Overview of issues in improving quality of care for children. McGlynn EA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):977–1000 (69 ref.)
Collaborative field research and training in occupational health and ergonomics. Kogi K. **Int J Occup Environ Health** 1998 Jul–Sep;4(3):189–95 (24 ref.)
Aging-related clinical and health services research in Canada. Rockwood K, et al. **J Am Geriatr Soc** 1998 Nov; 46(11):1469–72 (66 ref.)
Health professions students as research partners in community oriented primary care. Doyle DB, et al. **J Community Health** 1998 Oct;23(5):337–46
Research on managed care organizations in rural communities. Krein S, et al. **J Rural Health** 1998 Summer; 14(3):180–99 (84 ref.)
Building a research agenda: responding to the needs of Community and Migrant Health Centers. Mueller KJ, et al. **J Rural Health** 1998 Fall;14(4):289–94
Lessons in cooperation: an update on improving the quality of hospital care. Kabcenell A. **Jt Comm J Qual Improv** 1998 Oct;24(10):591–3
Agency for Health Care Policy and Research. Eisenberg JM. **Med Care** 1999 Mar;37(3):217–9
Managing health services: how the Population Health Information System (POPULIS) works for policymakers. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS27–41 (68 ref.)
From research to policy: what have we learned? Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS291–305 (37 ref.)
Establishing a population data-based policy unit. Roos NP. **Med Care** 1999 Jun;37(6 Suppl):JS15–26 (29 ref.)
Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS10–4
The Menzies School of Health Research offers a new paradigm of cooperative research. Mathews JD. **Med J Aust** 1998 Dec 7–21;169(11–12):625–9
The WHO antenatal care randomised controlled trial: rationale and study design. Villar J, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:27–58
Expanded Programme on Immunization (EPI). The Social Science and Immunization Research Project. **Wkly Epidemiol Rec** 1998 Sep 11;73(37):285–8 **(Eng, Fre)**
WHO and health research--some personal reflections. Nossal GJ. **World Health Forum** 1998;19(4):369–76

STANDARDS

Mental health services and research in the Arab world [see comments] Okasha A, et al. **Acta Psychiatr Scand** 1998 Nov;98(5):406–13 (6 ref.). Comment in: Acta Psychiatr Scand 1998 Nov;98(5):345–7.
Social work at the emergency department--comments [letter; comment] Tarim MK, et al. **Eur J Emerg Med** 1998 Sep; 5(3):365–6. Comment on: Eur J Emerg Med 1997 Dec;4(4):233–8.
Explicit guidelines for qualitative research: a step in the right direction, a defence of the 'soft' option, or a form of sociological imperialism? Chapple A, et al. **Fam Pract** 1998 Dec;15(6):556–61 (34 ref.)
Health economics has lost its way--or why David Kernick is (partly) right [letter; comment] McDonald R. **Health Econ** 1999 Mar;8(2):175–6. Comment on: Health Econ 1998 Nov;7(7):657.
Improving the quality of healthcare for children: implementing the results of the AHSR research agenda conference. Halfon N, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):955–76
Circumpolar health: science and health--what is missing? Foege W. **Int J Circumpolar Health** 1998;57 Suppl 1:15–8
Ethical issues in community health research: implications for First Nations and circumpolar indigenous peoples. Kaufert JM, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:33–7
Health services researchers zero in on quality, policy, and practice in a changing health care system: report of the 15th annual meeting of the Association for Health Services Research. Kaegi L. **Jt Comm J Qual Improv** 1998 Nov; 24(11):658–71
Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research. Minshall ME, et al. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS12–9
How good are US studies of HIV costs of care? Rabeneck L, et al. **Med Care** 1999 Aug;37(8):748–59 (35 ref.)

STATISTICS & NUMERICAL DATA

At what price significance? The effect of price estimates on statistical inference in economic evaluation. Rittenhouse BE, et al. **Health Econ** 1999 May;8(3):213–9
Increasing physicians' awareness of the impact of statistics on research outcomes: comparative power of the t-test and and Wilcoxon Rank-Sum test in small samples applied research. Bridge PD, et al. **J Clin Epidemiol** 1999 Mar; 52(3):229–35
Randomised controlled trials addressing Australian aboriginal health needs: a systematic review of the literature. Morris PS. **J Paediatr Child Health** 1999 Apr;35(2):130–5 (49 ref.)
Assessing the feasibility of recruiting a randomly selected sample of psychiatrists to participate in a national practice-based research network. West JC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Dec;33(12):620–3
A profile of health research in Jamaica 1991–1995. Essential National Health Research Task Force. Figueroa JP, et al. **West Indian Med J** 1998 Sep;47(3):89–93
[Proposed design for a randomized effectiveness study in social medicine] Michel E. **Gesundheitswesen** 1998 Aug-Sep;60(8–9):482–5 (Eng. Abstr.) **(Ger)**

TRENDS

A match made in heaven? Quality-related activities and quality research [editorial; comment] Fernandes CM. **Acad Emerg Med** 1999 Mar;6(3):165–6. Comment on: Acad Emerg Med 1999 Mar;6(3):191–5.
Improving the health of the American public requires a broad research agenda. Schroeder SA. **Acad Med** 1999 May; 74(5):530–1
Epidemiology and health services research [editorial] Gabriel SE. **Curr Opin Rheumatol** 1999 Mar;11(2):89–90
Health services research. Suarez-Almazor ME, et al. **Curr Opin Rheumatol** 1999 Mar;11(2):110–6 (49 ref.)
Strangers in the night: research and managed mental health care. Feldman S. **Health Aff (Millwood)** 1999 Sep–Oct; 18(5):48–51
Beyond health services research. Kindig DA. **Health Serv Res** 1999 Apr;34(1 Pt 2):205–14
Research and the acute-care hospital of the future [editorial; comment] Braithwaite J, et al. **Med J Aust** 1999 Apr 5; 170(7):292–3 (11 ref.). Comment on: Med J Aust 1999 Apr 5;170(7):325–8.
[Social inequality of health changes: implications for social health research and practice] Siegrist J. **Gesundheitswesen** 1998 Nov;60(11):614–7 (19 ref.) (Eng. Abstr.) **(Ger)**
[The North German Group for Rehabilitation Research] Deck R, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S92–6 **(Ger)**
[Introduction of the Bavarian Scientific Rehabilitation Group] Faller H, et al. **Rehabilitation (Stuttg)** 1998 Nov; 37 Suppl 2:S97–103 (Eng. Abstr.) **(Ger)**
[North Rhine-Westphalia Scientific Rehabilitation Group--"future strategies for rehabilitation"] Fischer J, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S104–10 (Eng. Abstr.) **(Ger)**
[Ulm Scientific Rehabilitation Research Group--"building blocks in rehabilitation"] Jacobi E, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S111–6 (Eng. Abstr.) **(Ger)**
[Current status and progress in scientific rehabilitation research] Koch U, et al. **Rehabilitation (Stuttg)** 1998 Nov; 37 Suppl 2:S66–70 (Eng. Abstr.) **(Ger)**
[Saxony-Anhalt/Necklenburg-Vorpommern Scientific Rehabilitation Research Groups] Slesina W, et al. **Rehabilitation (Stuttg)** 1998 Nov;37 Suppl 2:S122–7 (Eng. Abstr.) **(Ger)**
[Current responsibilities of health care research and political counseling] Wismar M. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):691–5 (15 ref.) (Eng. Abstr.) **(Ger)**

HEALTH SERVICES, WOMEN'S see **WOMEN'S**

HEALTH SERVICES

HEALTH STATUS

A decade of many gains in Americans' health. Satcher D. **Acad Med** 1999 Jul;74(7):808–9

Improving the health of the American public requires a broad research agenda. Schroeder SA. **Acad Med** 1999 May; 74(5):530–1

Measuring and incorporating patient preferences and utilities in the assessment of diagnostic technology. Fajardo LL. **Acad Radiol** 1999 Jan;6 Suppl 1:S113–4

Health profiles and quality of life. Greenfield S. **Acad Radiol** 1999 Jan;6 Suppl 1:S89–92; discussion 99

Rationale for and measurement of patient preferences and health-related quality of life. Hillman BJ. **Acad Radiol** 1998 Sep;5 Suppl 2:S277–9

Health profiles in quality of life: evaluation of diagnostic technologies. Jarvik JG. **Acad Radiol** 1999 Jan;6 Suppl 1:S93–7

Health profiles and quality of life: the radiologist's perspective. Kallmes DF. **Acad Radiol** 1999 Jan;6 Suppl 1:S98

Utility assessment and clinical trials of diagnostic interventions. Nease RF Jr. **Acad Radiol** 1999 Jan;6 Suppl 1:S103–8

Incorporating patient preferences and utilities in the assessment of diagnostic technology: response. Tosteson AN. **Acad Radiol** 1999 Jan;6 Suppl 1:S109–12

Locus of control beliefs predicting oral and diabetes health behavior and health status. Kneckt MC, et al. **Acta Odontol Scand** 1999 Jun;57(3):127–31

Inequalities in health--future threats to equity. Gunning-Schepers LJ, et al. **Acta Oncol** 1999;38(1):57–61

Where do we stand? Research and policy issues concerning inequalities in health and in healthcare. Whitehead MM. **Acta Oncol** 1999;38(1):41–50 (55 ref.)

Late neurological sequelae of non-hemolytic hyperbilirubinemia of healthy term neonates. Grimmer I, et al. **Acta Paediatr** 1999 Jun;88(6):661–3

Height, health and growth hormone [see comments] Samaras TT, et al. **Acta Paediatr** 1999 Jun;88(6):602–9 (61 ref.). Comment in: Acta Paediatr 1999 Jun;88(6):588–9.

Ten-year follow-up of children born before 29 gestational weeks: health, cognitive development, behaviour and school achievement. Stjernqvist K, et al. **Acta Paediatr** 1999 May;88(5):557–62

A community-based health intervention programme in pastoral and agricultural Pokot communities in Western Kenya. Ettyang G. **Acta Paediatr Suppl** 1999 May; 88(429):41–2 (4 ref.)

Health-related quality of life in intersexuality. Meyer-Bahlburg HF. **Acta Paediatr Suppl** 1999 Feb; 88(428):114–5 (14 ref.)

Patterns of comorbidity in relation to functioning (GAF) among general hospital psychiatric referrals. European Consultation-Liaison Workgroup. Alaja R, et al. **Acta Psychiatr Scand** 1999 Feb;99(2):135–40

Measuring health status in psychiatric community surveys: internal and external validity of the Spanish version of the SF-36. Ayuso-Mateos JL, et al. **Acta Psychiatr Scand** 1999 Jan;99(1):26–32

Internal and external validity of the WHO Well-Being Scale in the elderly general population. Heun R, et al. **Acta Psychiatr Scand** 1999 Mar;99(3):171–8

Adolescent health assessment and promotion in office and school settings. Fisher M. **Adolesc Med** 1999 Feb; 10(1):71–86, vi (65 ref.)

Progress in adolescent mental health. Weist MD, et al. **Adolesc Med** 1999 Feb;10(1):165–74, vii (33 ref.)

Language, self, meaning, and health. Booth R. **Adv Mind Body Med** 1999 Summer;15(3):171–5

Disclosure and health: an interview with James W. Pennebaker [interview by Harris Dienstfrey] [see comments] Pennebaker JW. **Adv Mind Body Med** 1999 Summer;15(3):161–3, 166–71; discussion 193–5. Comment in: Adv Mind Body Med 1999 Summer;15(3):179–84.

Expressing emotion, physical health, and emotional relief: a cognitive-social perspective. Rimé B. **Adv Mind Body Med** 1999 Summer;15(3):175–9

Written disclosure: evidence, potential mechanism, and potential treatment [comment] Smyth JM. **Adv Mind Body Med** 1999 Summer;15(3):179–84. Comment on: Adv Mind Body Med 1999 Summer;15(3):161–3, 166–71; discussion 193–5.

Inhibition, disclosure, and health: don't simply slash the Gordian knot. Traue HC, et al. **Adv Mind Body Med** 1999 Summer;15(3):184–93

The family and welfare in sub-Saharan Africa. 15–16 May, 1997, Cambridge, Massachusetts. Oni J, et al. **Afr J Reprod Health** 1997 Sep;1(2):108–9

Developing a summary measure of medical status. Fillenbaum GG, et al. **Aging (Milano)** 1998 Oct;10(5):395–400

Regional health assessment relating to mercury content of fish caught in the Yukon-Kuskokwim Delta rivers system [published erratum appears in Alaska Med 1999 Jan-Mar;41(1):15] Duffy LK, et al. **Alaska Med** 1998 Oct-Dec;40(4):75–7, 89

Alcohol consumption, alcohol-related problems, problem drinking, and socioeconomic status. van Oers JA, et al. **Alcohol Alcohol** 1999 Jan-Feb;34(1):78–88

Drinking pattern and alcohol-related medical disorders. Wetterling T, et al. **Alcohol Alcohol** 1999 May-Jun; 34(3):330–6

Is religiousness a correlate of absorption? Implications for psychophysiology, coping, and morbidity. Levin JS, et al. **Altern Ther Health Med** 1998 Nov;4(6):72–6

Adolescent health. American Academy of Family Physicians. **Am Fam Physician** 1999 Aug;60(2):660–2

Predictors of patient-reported physical and mental health 6 months after percutaneous coronary revascularization. Nash IS, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):422–9

Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Cohen RA, et al. **Am J Cardiol** 1999 May 1;83(9):1374–8

Relation between visceral fat and disease risk in children and adolescents. Goran MI, et al. **Am J Clin Nutr** 1999 Jul; 70(1):149S–56S (89 ref.)

Convergence of philosophy and science: the third international congress on vegetarian nutrition. Willett WC. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):434S–438S (41 ref.)

The effect of alcohol abuse on the health status of older adults seen in the emergency department. Friedmann PD, et al. **Am J Drug Alcohol Abuse** 1999 Aug;25(3):529–42

The effects of drinking on health of older adults. Graham K, et al. **Am J Drug Alcohol Abuse** 1998 Aug;24(3):465–81

Re: "Self-perceived health and 5-year mortality risks among the elderly in Shanghai, China" [letter; comment] Batty D. **Am J Epidemiol** 1999 Jul 15;150(2):219. Comment on: Am J Epidemiol 1998 May 1;147(9):880–90.

Self-reported health status and mortality in a multiethnic US cohort. McGee DL, et al. **Am J Epidemiol** 1999 Jan 1; 149(1):41–6

Wine and good subjective health. Poikolainen K, et al. **Am J Epidemiol** 1999 Jul 1;150(1):47–50

Measuring aspects of women's life and work for the study of variations in health. Dunnell K, et al. **Am J Ind Med** 1999 Jul;36(1):25–33 (15 ref.)

Hospital admissions through the emergency department: does insurance status matter? Sox CM, et al. **Am J Med** 1998 Dec;105(6):506–12

Determinants of health-related quality of life following elective total hip replacement. Hopman WM, et al. **Am J Med Qual** 1999 May-Jun;14(3):110–6

Health status in VA patients: results from the Veterans Health Study. Kazis LE, et al. **Am J Med Qual** 1999 Jan-Feb; 14(1):28–38

Jumping the broom toward eliminating health disparities. Presidential address. Hill WC. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1315–21

The VF-14 index of functional visual impairment in candidates for a corneal graft. Boisjoly H, et al. **Am J Ophthalmol** 1999 Jul;128(1):38–44

Utility values and diabetic retinopathy. Brown MM, et al. **Am J Ophthalmol** 1999 Sep;128(3):324–30

The relationship of self-rated vision and hearing to functional status and well-being among seniors 70 years and older. Lee P, et al. **Am J Ophthalmol** 1999 Apr;127(4):447–52

Skeletal evidence of health and disease in pre-contact Alaskan Eskimos and Aleuts. Keenleyside A. **Am J Phys Anthropol** 1998 Sep;107(1):51–70

The shape of our river. Healton CG. **Am J Prev Med** 1999 Apr;16(3 Suppl):1–4 (6 ref.)

An ounce of prevention ... what are the returns? Second edition, 1999. Messonnier ML, et al. **Am J Prev Med** 1999 Apr;16(3):248–63 (90 ref.)

Is cigarette smoking associated with impaired physical and mental functional status? An office-based survey of primary care patients. Woolf SH, et al. **Am J Prev Med** 1999 Aug; 17(2):134–7

Health status, somatization, and severity of posttraumatic stress disorder in Vietnam combat veterans with posttraumatic stress disorder. Beckham JC, et al. **Am J Psychiatry** 1998 Nov;155(11):1565–9

White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. Lenze E, et al. **Am J Psychiatry** 1999 Oct;156(10):1602–7

The impact of ethnicity, family income, and parental education on children's health and use of health services. Flores G, et al. **Am J Public Health** 1999 Jul;89(7):1066–71

The role of socioeconomic status gradients in explaining differences in US adolescents' health. Goodman E. **Am J Public Health** 1999 Oct;89(10):1522–8

Social capital and self-rated health: a contextual analysis. Kawachi I, et al. **Am J Public Health** 1999 Aug; 89(8):1187–93

"Whiting out" white privilege will not advance the study of how racism harms health [letter; comment] Krieger N, et al. **Am J Public Health** 1999 May;89(5):782–3; discussion 784–5. Comment on: Am J Public Health 1998 Sep;88(9):1297–8. Comment on: Am J Public Health 1998 Sep;88(9):1303–7.

Socioeconomic status and morbidity in the last years of life. Liao Y, et al. **Am J Public Health** 1999 Apr;89(4):569–72

Neighborhood environment and self-reported health status: a multilevel analysis. Malmström M, et al. **Am J Public Health** 1999 Aug;89(8):1181–6

The health of grandparents raising grandchildren: results of a national study. Minkler M, et al. **Am J Public Health** 1999 Sep;89(9):1384–9

Health care coverage and use of preventive services among the near elderly in the United States. Powell-Griner E, et al. **Am J Public Health** 1999 Jun;89(6):882–6

The duration and timing of exposure: effects of socioeconomic environment on adult health. Power C, et al. **Am J Public Health** 1999 Jul;89(7):1059–65

Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514–21 (79 ref.) . Comment in: Am J Public Health 1999 Oct;89(10):1476–8. Comment in: Am J Public Health 1999 Oct;89(10):1479–82.

Health status in obstructive sleep apnea: relationship with sleep fragmentation and daytime sleepiness, and effects of continuous positive airway pressure treatment. Bennett LS, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1884–90

A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Hajiro T, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1874–8

Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Hopkins RO, et al. **Am J Respir Crit Care Med** 1999 Jul; 160(1):50–6

Self-perception of health among elderly community dwellers in Singapore. Chan KM, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):461–7

Infant nutritional and health status, feeding practices in rural and urban Albania. Buonomo E, et al. **Ann Ig** 1998 May-Jun;10(3):163–71

Access to health care, socioeconomic status, and health [letter; comment] Baltzan MA. **Ann Intern Med** 1999 Mar 2;130(5):452–3. Comment on: Ann Intern Med 1998 Sep 1;129(5):406–11. Comment on: Ann Intern Med 1998 Oct 1;129(7):567–72.

Poverty and ill health: physicians can, and should, make a difference. McCally M, et al. **Ann Intern Med** 1998 Nov 1;129(9):726–33 (57 ref.)

Immigration and health: the Italian situation. Italian National Focal Point (NFP) of the AIDS & Mobility Project. Colucci A, et al. **Ann Ist Super Sanita** 1998;34(4):473–87

How best to ensure daily intake of antioxidants (from the diet and supplements) that is optimal for life span, disease, and general health. Dreosti I, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:463–76

Factors associated with fatigue in patients with systemic lupus erythematosus. Bruce IN, et al. **Ann Rheum Dis** 1999 Jun;58(6):379–81

Health and behaviour problems at 8 weeks as predictors of behaviour problems at 8 months. Spencer NJ, et al. **Arch Dis Child** 1999 Aug;81(2):166–8

The South Karelia Air Pollution Study: changes in respiratory health in relation to emission reduction of malodorous sulfur compounds from pulp mills. Jaakkola JJ, et al. **Arch Environ Health** 1999 Jul-Aug;54(4):254–63

Health-related quality of life and symptom profiles of female survivors of sexual abuse. Dickinson LM, et al. **Arch Fam Med** 1999 Jan-Feb;8(1):35–43

Medical conditions and the risk of motor vehicle crashes in men. Guibert R, et al. **Arch Fam Med** 1998 Nov-Dec; 7(6):554–8

Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Lean ME, et al. **Arch Intern Med** 1999 Apr 26;159(8):837–43

Provider-reported illness and absence due to illness among children attending child-care homes and centers in San Diego, Calif. Cordell RL, et al. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):275–80

Long-term outcomes and life satisfaction of adults who had pediatric spinal cord injuries. Vogel LC, et al. **Arch Phys Med Rehabil** 1998 Dec;79(12):1496–503

Psychosocial outcomes and health status in adults who have had juvenile rheumatoid arthritis: comment on the article by Peterson et al [letter; comment] Miller JJ 3rd. **Arthritis Rheum** 1998 Oct;41(10):1898–9. Comment on: Arthritis Rheum 1997 Dec;40(12):2235–40.

Subjective evaluation of chewing ability and self-rated general health status in elderly residents of Japan. Miura H, et al. **Asia Pac J Public Health** 1998;10(1):43–5

The health status and characteristics of hypertensives in Guam. Pinhey TK. **Asia Pac J Public Health** 1995; 8(3):177–80

Impact of the east Asian economic crisis on health and health care: Malaysia's response. Suleiman AB, et al. **Asia Pac J Public Health** 1998;10(1):5–9

Use of otoacoustic emissions to screen for hearing loss in critically ill patients. Hamill-Ruth RJ, et al. **Audiology** 1998 Nov-Dec;37(6):344–52

Comparison of health behaviour and oral/medical conditions in non-insulin-dependent (type II) diabetics and non-diabetics. Kawamura M, et al. **Aust Dent J** 1998 Oct; 43(5):315–20

A brief review of indigenous Australian health as it impacts on oral health. Martin-Iverson N, et al. **Aust Dent J** 1999 Jun;44(2):88–92 (53 ref.)

Planning for better health outcomes requires indigenous perspective [editorial] Angus S, et al. **Aust N Z J Public Health** 1998 Oct;22(6):636–7

The evaluation of health development: the next methodological frontier? [editorial] Legge D. **Aust N Z J Public Health** 1999 Apr;23(2):117–8 (8 ref.)

Aboriginal health spending: more needed, but where? [editorial] McDermott R. **Aust N Z J Public Health** 1998 Oct;22(6):637–8

Beneficial impact of the homelands movement on health outcomes in central Australian aborigines. McDermott R, et al. **Aust N Z J Public Health** 1998 Oct;22(6):653–8

The contribution of community health surveys to aboriginal health in the 1990s. Mak DB, et al. **Aust N Z J Public Health** 1998 Oct;22(6):645–7

Indigenous health: a special moral imperative. Morgan DL, et al. **Aust N Z J Public Health** 1998 Oct;22(6):731–2

A 'whole of government' approach needed on indigenous health [editorial] Ring I. **Aust N Z J Public Health** 1998 Oct;22(6):639–40

Divisions of population health: quantum leap forward or rearranging the deckchairs? Sainsbury P. **Aust N Z J Public Health** 1999 Apr;23(2):119–25 (30 ref.)

NZDep91: A New Zealand index of deprivation. Salmond C, et al. **Aust N Z J Public Health** 1998 Dec;22(7):835–7

SF-36 health survey reliability, validity and norms for New Zealand. Scott KM, et al. **Aust N Z J Public Health** 1999 Aug;23(4):401–6

Elementary education and its impact on health [editorial] Bansal R. **BMJ** 1999 Jan 16;318(7177):141

Social class in childhood and general health in adulthood: questionnaire study of contribution of psychological attributes. Bosma H, et al. **BMJ** 1999 Jan 2;318(7175):18–22

A different route to health: implications of transport policies. Dora C. **BMJ** 1999 Jun 19;318(7199):1686–9 (37 ref.)

Is it time for an Illich Collaboration to make available information on the harms of medical care? [letter] Edwards RH. **BMJ** 1999 Jan 2;318(7175):58

Income distribution, socioeconomic status, and self rated health in US. Authors ignored data in their study [letter; comment] Milyo J. **BMJ** 1999 May 22;318(7195):1417–8. Comment on: BMJ 1998 Oct 3;317(7163):917–21.

Xenotransmission of the socioeconomic gradient in health? A population based study [see comments] Moloo J, et al. **BMJ** 1998 Dec 19–26;317(7174):1686. Comment in: BMJ 1998 Dec 19–26;317(7174):1671–3.

Health, health promotion, and homelessness. Power R, et al. **BMJ** 1999 Feb 27;318(7183):590–2 (32 ref.)

Self-reporting of periodontal health status. Gilbert AD, et al. **Br Dent J** 1999 Mar 13;186(5):241–4

Clinical quality assurance indicators for oral status and treatment of a group of older adults. Ireland RS. **Br Dent J** 1998 Aug 22;185(4):192–5

A survey of dental professionals' health and well-being. Kay EJ, et al. **Br Dent J** 1997 Nov 8;183(9):340–5

The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research. Singh SD, et al. **Br J Clin Pharmacol** 1999 Jul;48(1):25–31

Peer victimisation at school and the health of secondary school students. Rigby K. **Br J Educ Psychol** 1999 Mar; 69 (Pt 1):95–104

Oral contraception and health: what do GPs monitor? [letter; comment] Rickenbach M. **Br J Gen Pract** 1998 Dec; 48(437):1874. Comment on: Br J Gen Pract 1998 Oct;48(435):1639–40. Comment on: Br J Gen Pract 1998 Oct;48(435):1657–62.

Absolutist thinking and health. Ostell A, et al. **Br J Med Psychol** 1999 Jun;72 (Pt 2):239–50

Maternal reports of child illness and the biochemical status of the child: the use of morbidity interviews in rural Bangladesh. Rousham EK, et al. **Br J Nutr** 1998 Nov; 80(5):451–6

Extent and appropriateness of benzodiazepine use. Results from an elderly urban community [see comments] Taylor S, et al. **Br J Psychiatry** 1998 Nov;173:433–8. Comment in: Br J Psychiatry 1998 Nov;173 :361–2.

Reducing cumulative lifetime disability: the compression of morbidity. Fries JF. **Br J Sports Med** 1998 Sep;32(3):193

Health problems of deep sea fishermen. Filikowski J, et al. **Bull Inst Marit Trop Med Gdynia** 1998;49(1–4):45–51

The state of health of seafarers in the Northern sea area in Russia. Mozer A, et al. **Bull Inst Marit Trop Med Gdynia** 1998;49(1–4):73–5

Proceedings of the Margaret E. Mahoney Symposium. The State of the Nation's Health. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):549–662

The health impact of economic sanctions. Garfield R, et al. **Bull N Y Acad Med** 1995 Winter;72(2):454–69

Light on population health status. Beyrer K, et al. **Bull World Health Organ** 1999;77(2):176–80

Injuries and noncommunicable diseases: emerging health problems of children in developing countries. Deen JL, et al. **Bull World Health Organ** 1999;77(6):518–24

Effect of breastfeeding education on the feeding pattern and health of infants in their first 4 months in the Islamic Republic of Iran. Froozani MD, et al. **Bull World Health Organ** 1999;77(5):381–5

Health inequalities and social group differences: what should we measure? Murray CJ, et al. **Bull World Health Organ** 1999;77(7):537–43

Effect of small burn injury on physical, social and psychological health at 3–4 months after discharge. Shakespeare V. **Burns** 1998 Dec;24(8):739–44

The health consequences of vertebral deformity in elderly Chinese men and women. Lau EM, et al. **Calcif Tissue Int** 1998 Jul;63(1):1–4

Proxy, health, and personal care preferences: implications for end-of-life care. Aikman PJ, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):200–10

The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Anand SS, et al. **Can J Cardiol** 1998 Nov; 14(11):1349–57

Modelling the community as a determinant of health. Birch S, et al. **Can J Public Health** 1998 Nov–Dec;89(6):402–5

Reducing economic disparity to achieve better health: modelling the effect of adjustments to income adequacy on self-reported morbidity among the elderly in Canada. Cairney J, et al. **Can J Public Health** 1998 Nov–Dec; 89(6):424–8

How reliable are selected scales from population-based health surveys? An analysis among seniors. Raina P, et al. **Can J Public Health** 1999 Jan–Feb;90(1):60–4

Public health responses to health inequalities. Raphael D. **Can J Public Health** 1998 Nov–Dec;89(6):380–1

Public perceptions of the relationship between poverty and health. Reutter L, et al. **Can J Public Health** 1999 Jan–Feb; 90(1):13–8

The clustering of severe behavioural, health and educational deficits in Canadian children: preliminary evidence from the National Longitudinal Survey of Children and Youth. Wade TJ, et al. **Can J Public Health** 1999 Jul–Aug; 90(4):253–9

The impact of Canada's animal health status on trade. Inch C, et al. **Can Vet J** 1999 Jun;40(6):435–9

Self-reported physical and emotional health of women in a low-fat, high-carbohydrate dietary trial (Canada). Leyenaar J, et al. **Cancer Causes Control** 1998 Dec; 9(6):601–10

Comparison of environmental quality in the districts of the Czech Republic with mortality pattern and selected health parameters. Svejdarová H, et al. **Cent Eur J Public Health** 1998 Nov;6(4):300–6

A model for the assessment and management of children with multiple disabilities. Cass H, et al. **Child Care Health Dev** 1999 May;25(3):191–211

The role of copper, molybdenum, selenium, and zinc in nutrition and health. Chan S, et al. **Clin Lab Med** 1998 Dec;18(4):673–85 (54 ref.)

Health sequelae of breastfeeding for the mother. Labbok MH. **Clin Perinatol** 1999 Jun;26(2):491–503, viii–ix (60 ref.)

Empirical foundations for writing in prevention and psychotherapy: mental and physical health outcomes. Esterling BA, et al. **Clin Psychol Rev** 1999 Jan;19(1):79–96 (76 ref.)

Application of statistical graphics to facilitate selection of health status measures for clinical practice and evaluative research. Stucki G, et al. **Clin Rheumatol** 1999;18(2):101–5

Gender difference in health status and health care facilities in some social groups and subgroups of southern West Bengal, India. Chakrabarty M. **Coll Antropol** 1998 Jun; 22(1):259–76

Health profile of two social groups living in a squatter settlement in Calcutta. Ray S, et al. **Coll Antropol** 1998 Jun;22(1):247–57

Inequalities in health—"it's the poor wot gets the blame" [editorial] Beal JF. **Community Dent Health** 1998 Dec; 15(4):229–30

Conference summary: assessing oral health outcomes—measuring health status and quality of life. Slade GD, et al. **Community Dent Health** 1998 Mar; 15(1):3–7

Health status of young Alaska Steller sea lion pups (Eumetopias jubatus) as indicated by blood chemistry and hematology. Rea LD, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):617–23

Physician heal thyself: lifestyle education for medical students. Cohen M. **Complement Ther Med** 1999 Jun; 7(2):110–2

Survival versus years of healthy life: which is more powerful as a study outcome? Diehr P, et al. **Control Clin Trials** 1999 Jun;20(3):267–79

Long-term outcome and functional health status following intensive care in Hong Kong [see comments] Short TG, et al. **Crit Care Med** 1999 Jan;27(1):51–7. Comment in: Crit Care Med 1999 Jan;27(1):4–5.

Evaluation of patient-perceived health status using the Medical Outcomes Survey Short-Form 36 in an intensive care unit population. Welsh CH, et al. **Crit Care Med** 1999 Aug;27(8):1466–71

Is public health between East and West? Analysis of wealth, health and mortality in Austria, Central and Eastern European Countries and Croatia relative to the European Union. Hofmarcher MM. **Croat Med J** 1998 Sep; 39(3):241–8

Toward health status insurance. Jahiel RI. **Croat Med J** 1999 Jun;40(2):129–42

Old priorities and new agenda of public health in India: is there a mismatch? Nayar KR. **Croat Med J** 1998 Sep; 39(3):308–15

Health status of refugees from former Yugoslavia: descriptive study of the refugees in the Netherlands. van den Heuevel WJ. **Croat Med J** 1998 Sep;39(3):356–60

The experience of dementia in China. Ikels C. **Cult Med Psychiatry** 1998 Sep;22(3):257–83

Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Merkel PA. **Curr Opin Rheumatol** 1998 Nov;10(6):589–94 (27 ref.)

Health-related quality of life in childhood epilepsy: the results of children's participation in identifying the components. Ronen GM, et al. **Dev Med Child Neurol** 1999 Aug;41(8):554–9

Behaviour of Finnish 3-year-old children. I: Effects of sociodemographic factors, mother's health, and pregnancy outcome. Uljas H, et al. **Dev Med Child Neurol** 1999 Jun; 41(6):412–9

Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Farup CE, et al. **Diabetes Care** 1998 Oct;21(10):1699–706

Correlates of physical activity in a sample of older adults with type 2 diabetes. Hays LM, et al. **Diabetes Care** 1999 May;22(5):706–12

Relation of glycemic control to diabetic complications and health outcomes. Klein R, et al. **Diabetes Care** 1998 Dec; 21 Suppl 3:C39–43

Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Testa MA, et al. **Diabetes Care** 1998 Dec;21 Suppl 3:C44–52

Disablement following stroke. Mayo NE, et al. **Disabil Rehabil** 1999 May–Jun;21(5–6):258–68

Activity limitation and chronic conditions in Canada's elderly, 1986–2011. Moore EG, et al. **Disabil Rehabil** 1999 May–Jun;21(5–6):196–210

Prevalence of unilateral hearing loss in children: the National Health and Nutrition Examination Survey II and the Hispanic Health and Nutrition Examination Survey. Lee DJ, et al. **Ear Hear** 1998 Aug;19(4):329–32

Health status of a population of infants born before 26 weeks gestation derived from routine data collected between 21 and 27 months post-delivery. Bohin S, et al. **Early Hum Dev** 1999 May;55(1):9–18

Self-perceived health in urban diabetic patients in Tanzania. Smide B, et al. **East Afr Med J** 1999 Feb;76(2):67–70

The impact of urbanization on health in the countries of the eastern Mediterranean region. Khosh-Chashm K. **East Mediterr Health J** 1998;4 Suppl:S137–48 (19 ref.)

Revision of the International Health Regulations. **Epidemiol Bull** 1998 Sep;19(3):14–6

Health in the Americas 1998. **Epidemiol Bull** 1998 Sep; 19(3):1–6

Self-efficacy and social support as mediators in the relation between disease severity and quality of life in patients with epilepsy. Amir M, et al. **Epilepsia** 1999 Feb;40(2):216–24

Development of the Quality of Life in Epilepsy Inventory for Adolescents: the QOLIE-AD-48. Cramer JA, et al. **Epilepsia** 1999 Aug;40(8):1114–21

Telephone validation of the Quality of Life in Epilepsy Inventory-89 (QOLIE-89). Leidy NK, et al. **Epilepsia** 1999 Jan;40(1):97–106

The association between acculturation and health practices among middle-aged and elderly Latinas. Cantero PJ, et al. **Ethn Dis** 1999 Spring-Summer;9(2):166–80

Racial/ethnic disparities in health: the interplay between discrimination and socioeconomic status. Ren XS, et al. **Ethn Dis** 1999 Spring-Summer;9(2):151–65

The relationship between ethnoracial group and functional level in older persons. Berkman CS, et al. **Ethn Health** 1998 Aug;3(3):175–88

Health-related quality of life for rural American Indians in New Mexico. Gilliland FD, et al. **Ethn Health** 1998 Aug; 3(3):223–9

Streamlining nutritional care for the physician's office. Wasson JH, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S97–100 (11 ref.)

Oral status of 81 subjects with eating disorders. Ohrn R, et al. **Eur J Oral Sci** 1999 Jun;107(3):157–63

Self reported health status and magnetic resonance imaging findings in patients with low back pain. Hollingworth W, et al. **Eur Spine J** 1998;7(5):369–75

Questions you didn't ask? COOP/WONCA Charts in clinical work and research. World Organization of Colleges, Academies and Academic Associations of General Practitioners/Family Physicists. Bentsen BG, et al. **Fam Pract** 1999 Apr;16(2):190–5

Metabolic control and morbidity of type 2 diabetic patients in a general practice network. Bouma M, et al. **Fam Pract** 1999 Aug;16(4):402–6

Outcome in general medical patients presenting with common symptoms: a prospective study with a 2-week and a 3-month follow-up. Kroenke K, et al. **Fam Pract** 1998 Oct;15(5):398–403

How does a change in the administration method affect the reliability of the COOP/WONCA Charts? World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians. Lam CL, et al. **Fam Pract** 1999 Apr;16(2):184–9

Influence of odour immissions from cellulose-paper industry on some health indicators. Georgieff D, et al. **Folia Med (Plovdiv)** 1999;41(1):38–42

Blood Pressure Variability in Health and Disease. Proceedings of a satellite symposium to the 17th scientific meeting of the International Society of Hypertension. Nancy, France, 5 June 1998. **Fundam Clin Pharmacol** 1998; 12 Suppl 1:1s–80s

Laboratory findings in acute schizophrenia. Relevance to medical management on emergency admission. Hatta K, et al. **Gen Hosp Psychiatry** 1999 May–Jun;21(3):220–7

Disclosure of true diagnosis in Japanese cancer patients. Hosaka T, et al. **Gen Hosp Psychiatry** 1999 May–Jun; 21(3):209–13

The contribution of personal resources to physical and mental health: looking into age and gender effects. Shmotkin D, et al. **Genet Soc Gen Psychol Monogr** 1999 Feb;125(1):5–25

Perceived social control as a mediator of the relationships among social support, psychological well-being, and perceived health. Bisconti TL, et al. **Gerontologist** 1999

Feb;39(1):94–103
Neighborhood deterioration, religious coping, and changes in health during late life. Krause N. **Gerontologist** 1998 Dec; 38(6):653–64
Health, valuation of life, and the wish to live. Lawton MP, et al. **Gerontologist** 1999 Aug;39(4):406–16
The role of depression in the association between self-rated physical health and clinically defined illness. Leibson CL, et al. **Gerontologist** 1999 Jun;39(3):291–8
Relationship between age and patients' current health state preferences. Sherbourne CD, et al. **Gerontologist** 1999 Jun; 39(3):271–8
Health status and satisfaction of asymptomatic HIV-positive haemophiliacs in Kyushu, Japan. Tanaka S, et al. **Haemophilia** 1999 Jan;5(1):56–62
Health states following head and neck cancer treatment: patient, health-care professional, and public perspectives. Jalukar V, et al. **Head Neck** 1998 Oct;20(7):600–8
Health insurance reform in the small-group market. Curtis R, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):151–60
Price elasticities of demand for curative health care with control for sample selectivity on endogenous illness: an analysis for Sri Lanka. Akin JS, et al. **Health Econ** 1998 Sep;7(6):509–31
The weighting exercise for the Swedish version of the EuroQol. Björk S, et al. **Health Econ** 1999 Mar;8(2):117–26
'Our healthier nation'? [editorial] Contoyannis P, et al. **Health Econ** 1999 Jun;8(4):289–96
Modelling the EuroQol data: a comparison of discrete choice conjoint and conditional preference modelling. Hakim Z, et al. **Health Econ** 1999 Mar;8(2):103–16
Economic evaluation in schistosomiasis: valuation of health states preferences. A research note. Kirigia JM. **Health Econ** 1998 Sep;7(6):551–6
On the measurement of the nation's equity adjusted health. Lindholm L, et al. **Health Econ** 1998 Nov;7(7):621–8
Estimation of a multiproduct cost function for physically frail older people. McNamee P, et al. **Health Econ** 1998 Dec; 7(8):701–10
Commentary on the Acheson report [editorial] [see comments] Williams A. **Health Econ** 1999 Jun;8(4):297–9 . Comment in: Health Econ 1999 Jun;8(4):281–2.
The religion-health connection: evidence, theory, and future directions. Ellison CG, et al. **Health Educ Behav** 1998 Dec; 25(6):700–20 (109 ref.)
Personal responsibility for health? A review of the arguments and the evidence at century's end. Minkler M. **Health Educ Behav** 1999 Feb;26(1):121–40 (118 ref.)
Psychological predictors of good health in three longitudinal samples of educated midlife women. Adams SH, et al. **Health Psychol** 1998 Sep;17(5):412–20
Do medical conditions affect cognition in older adults? Zelinski EM, et al. **Health Psychol** 1998 Nov;17(6):504–12
Work stress and health. Wilkins K, et al. **Health Rep** 1998 Winter;10(3):47–62 (ENG); 49–66 (FRE) **(Eng, Fre)**
No exit? The effect of health status on dissatisfaction and disenrollment from health plans. Schlesinger M, et al. **Health Serv Res** 1999 Jun;34(2):547–76
Changes in health status and quality of life and the impact of uncertainty in patients who survive life-threatening arrhythmias. Carroll DL, et al. **Heart Lung** 1999 Jul–Aug; 28(4):251–60
Health and development of children born after oocyte donation compared with that of those born after in-vitro fertilization, and parents' attitudes regarding secrecy. Söderström-Anttila V, et al. **Hum Reprod** 1998 Jul; 13(7):2009–15
A study of health and health related social problems in the geriatric population in a rural area of Tamil Nadu. Elango S. **Indian J Public Health** 1998 Jan–Mar;42(1):7–8
Pre-operational health status of a rural community living around the Kakrapar Atomic Power Station. Gadhia PK, et al. **Indian J Public Health** 1998 Oct–Dec;42(4):136–7, 140
Sociomedical problems of aged population in a rural area of Wardha district. Kishore S, et al. **Indian J Public Health** 1997 Apr–Jun;41(2):43–8
El Nino and its health impacts. **Indian Pediatr** 1998 Oct; 35(10):1041–4
Health impacts of climate change. **Indian Pediatr** 1998 May; 35(5):488
The International Commission of Occupational Health (ICOH) Working Group "Unemployment and Health". Proceedings. Paris, France, 25–26 September 1998. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S1–48
The ICOH Working Group "Unemployment and Health" Paris 25–26 September 1998: an introduction. International Commission of Occupational Health. Bertran J, et al. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S3–5
Unemployment and health [editorial] Weber A, et al. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S1
Health profile of the ageing population: the Swedish experience. Heyden G. **Int Dent J** 1998 Jun;48(3):167–72
Developing appropriate dental education systems: the impact of changes in oral health status and oral health care systems. Samarawickrama DY, et al. **Int Dent J** 1998 Aug; 48(4):412–6
Up-to-date studies of the Siberian population: international programs of the Institute of Internal Medicine. Alekseeva NV, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:714–6
Social and cultural factors as determinants of self-rated health in Greenland. Bjerregaard P, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:622–5
The human health programme under AMAP. AMAP Human Health Group. Arctic Monitoring and Assessment Program. Hansen JC. **Int J Circumpolar Health** 1998 Oct; 57(4):280–91 (6 ref.)
A comparison of demographic characteristics of selected year 2000 health objectives for the United States, using behavioral risk factor surveillance system data for Alaska. Ingle DE, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:652–5
A health profile of the Inuit of Nunavik: report of the Santé Québec Health Survey (1992). Jetté M. **Int J Circumpolar Health** 1998;57 Suppl 1:630–5
Antioxidants, infections and environmental factors in health and disease in northern Finland. Luoma P. **Int J Circumpolar Health** 1998 Jul;57(2–3):109–13 (40 ref.)
Well-being among Greenlandic students. Pedersen JM. **Int J Circumpolar Health** 1998;57 Suppl 1:639–41
Life control and health. Pietilä AM. **Int J Circumpolar Health** 1998 Jul;57(2–3):211–7 (51 ref.)
Post-Soviet Russian indigenous health: the Sami people of the Kola Peninsula. Snellman A, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:636–8
Well-being and health. Background to the northern Finland 1966 birth cohort research [editorial] Sorri M, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):82–3
Russian Academy of Medical Sciences (RAMS), Siberian Branch, activity in solving the medical problems of Russian Circumpolar regions. Trufakin VA, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:717–8
Medical surveillance of multinational peacekeepers deployed in support of the United Nations Mission in Haiti, June–October 1995. Gambel JM, et al. **Int J Epidemiol** 1999 Apr;28(2):312–8
Can children's health be predicted by perinatal health? Gissler M, et al. **Int J Epidemiol** 1999 Apr;28(2):276–80
The meaning and use of the cumulative rate of potential life lost. Lee WC. **Int J Epidemiol** 1998 Dec;27(6):1053–6
Health status of Persian Gulf War veterans: self-reported symptoms, environmental exposures and the effect of stress. Proctor SP, et al. **Int J Epidemiol** 1998 Dec;27(6):1000–10
Socioeconomic inequalities in health in the working population: the contribution of working conditions. Schrijvers CT, et al. **Int J Epidemiol** 1998 Dec;27(6):1011–8
Poverty area residence and changes in depression and perceived health status: evidence from the Alameda County Study. Yen IH, et al. **Int J Epidemiol** 1999 Feb;28(1):90–4
Do health factors affect memory performance in old age? Jelicic M, et al. **Int J Geriatr Psychiatry** 1999 Jul; 14(7):572–6
Embodying inequality: a review of concepts, measures, and methods for studying health consequences of discrimination. Krieger N. **Int J Health Serv** 1999; 29(2):295–352 (338 ref.)
Toward an ecosocial view of health. Levins R, et al. **Int J Health Serv** 1999;29(2):261–93
Monitoring the health consequences of welfare reform. Pappas G. **Int J Health Serv** 1998;28(4):703–13 (31 ref.)
Differences in the use of health care facilities and patterns of general risk factors in farmers with and without occupational health care programs. Thelin A, et al. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):170–6
Oxygen enrichment of room air to improve well-being and productivity at high altitude. West JB. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):187–93 (23 ref.)
Polychlorinated biphenyls and human health. Carpenter DO. **Int J Occup Med Environ Health** 1998;11(4):291–303 (86 ref.)
Personality disorder traits: prevalence and effects on health status in primary care patients. Hueston WJ, et al. **Int J Psychiatry Med** 1999;29(1):63–74
Maladaptive denial of physical illness: a useful new "diagnosis". Muskin PR, et al. **Int J Psychiatry Med** 1998; 28(4):463–77
Anticipating market demand: tracking enrollee satisfaction and health over time [see comments] Allen H. **Int J Qual Health Care** 1998 Dec;10(6):521–30. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.
The relationship between health status, social support and satisfaction with medical care among patients with systemic lupus erythematosus. Da Costa D, et al. **Int J Qual Health Care** 1999 Jun;11(3):201–7
Can patient satisfaction improve health among patients with angina pectoris? Guldvog B. **Int J Qual Health Care** 1999 Jun;11(3):233–40
Functional diagnosis as a tool in rehabilitation: a comparison of teachers and other employees. Berg JE, et al. **Int J Rehabil Res** 1998 Sep;21(3):273–84
How much physical activity is needed for good health? Shephard RJ. **Int J Sports Med** 1999 Jan;20(1):23–7
Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Portaels F, et al. **Int J Tuberc Lung Dis** 1999 Jul; 3(7):582–8 (42 ref.)
Alcohol use disorder is a risk factor for mortality among older public housing residents. Black BS, et al. **Int Psychogeriatr** 1998 Sep;10(3):309–27
Proxy-perceived prior health status and hospital outcome among the critically ill: is there any relationship? Diaz-Prieto A, et al. **Intensive Care Med** 1998 Jul; 24(7):691–8
Life stage, substance use and health decline in a community cohort of urban African Americans. Brunswick AF, et al. **J Addict Dis** 1999;18(1):53–71
Health status of juvenile offenders. A survey of young offenders appearing before the juvenile courts. Dolan M, et al. **J Adolesc** 1999 Feb;22(1):137–44
Peer support and young people's health. Turner G. **J Adolesc** 1999 Aug;22(4):567–72
Adolescent alcohol and drug abuse and health. Aarons GA, et al. **J Adolesc Health** 1999 Jun;24(6):412–21
Improving the health of youth: a community health perspective. Blum RW. **J Adolesc Health** 1998 Nov; 23(5):254–8
Correlates of physical and emotional health among Native American adolescents. Cummins JR, et al. **J Adolesc Health** 1999 Jan;24(1):38–44
Diversity, identity, and adolescent health [editorial] Fergerson G. **J Adolesc Health** 1998 Sep;23(3):125–6
Television viewing, physical activity, and health-related fitness of youth in the Québec Family Study. Katzmarzyk PT, et al. **J Adolesc Health** 1998 Nov;23(5):318–25
Gender differences in health and risk behaviors among bisexual and homosexual adolescents. Saewyc EM, et al. **J Adolesc Health** 1998 Sep;23(3):181–8
Health characteristics of elderly personal care home residents. Quinn ME, et al. **J Adv Nurs** 1999 Aug; 30(2):410–7
Dimensions of health-related quality of life in persons living with HIV disease. Sousa KH, et al. **J Adv Nurs** 1999 Jan; 29(1):178–87
Simple home program for frozen shoulder to improve patients' assessment of shoulder function and health status. O'Kane JW, et al. **J Am Board Fam Pract** 1999 Jul–Aug; 12(4):270–7
Relation of age and self-reported chronic medical condition status with dietary nutrient intake in the US population. Kant AK, et al. **J Am Coll Nutr** 1999 Feb;18(1):69–76
A health status assessment of the impact of weight loss following Roux-en-Y gastric bypass for clinically severe obesity. Choban PS, et al. **J Am Coll Surg** 1999 May; 188(5):491–7
The relationship between insomnia and mortality among community-dwelling older women. Althuis MD, et al. **J Am Geriatr Soc** 1998 Oct;46(10):1270–3
Is experience as a prisoner of war a risk factor for accelerated age-related illness and disability? Creasey H, et al. **J Am Geriatr Soc** 1999 Jan;47(1):60–4
Influence of companion animals on the physical and psychological health of older people: an analysis of a one-year longitudinal study. Raina P, et al. **J Am Geriatr Soc** 1999 Mar;47(3):323–9
The predictive value of combined hypoalbuminemia and hypocholesterolemia in high functioning community-dwelling older persons: MacArthur Studies of Successful Aging. Reuben DB, et al. **J Am Geriatr Soc** 1999 Apr;47(4):402–6
Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. Lund EM, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1336–41
Influence of mental states on somatic health in animals. McMillan FD. **J Am Vet Med Assoc** 1999 Apr 15; 214(8):1221–5 (56 ref.)
A theoretical model for human health and the pet connection. Staats S, et al. **J Am Vet Med Assoc** 1999 Feb 15; 214(4):483–7
Patient-reported health status in total joint replacement. Benroth R, et al. **J Arthroplasty** 1999 Aug;14(5):576–80
The impact of asthma on health-related quality of life. Schmier JK, et al. **J Asthma** 1998;35(7):585–97 (81 ref.)
Implementing outcome systems: lessons from a test of the BASIS-32 and the SF-36. Eisen SV, et al. **J Behav Health Serv Res** 1999 Feb;26(1):18–27
Testosterone and men's health. Booth A, et al. **J Behav Med** 1999 Feb;22(1):1–19
Culture, socioeconomic status, and coronary heart disease risk factors in an African American community. Dressler WW, et al. **J Behav Med** 1998 Dec;21(6):527–44
Social network in relation to plasma fibrinogen. Helminen A, et al. **J Biosoc Sci** 1997 Apr;29(2):129–39
Parental investment theory and birth sex ratios in Nepal. Strickland SS, et al. **J Biosoc Sci** 1997 Jul;29(3):283–95
Health outcome after total knee replacement in the very elderly. Birdsall PD, et al. **J Bone Joint Surg Br** 1999 Jul; 81(4):660–2
The health status of American Indians and Alaska Natives: 2. Lessons for cancer educators. Mahoney MC, et al. **J Cancer Educ** 1999 Spring;14(1):23–7 (34 ref.)
Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. Havranek EP, et al. **J Card Fail** 1999 Jun;5(2):85–91
Blood lipid and lipoprotein concentrations in active, sedentary, healthy and diseased men. Bailey DM, et al. **J Cardiovasc Risk** 1998 Oct–Dec;5(5–6):309–12
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Freda PU, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3808–16
Validity and utility of patient-reported health measures on hospital admission. Clark DO, et al. **J Clin Epidemiol** 1999 Jan;52(1):65–71
Effectiveness of cataract surgery in Barcelona, Spain site

results of an international study. Barcelona I-PORT investigators. International Patient Outcomes Research Team. Espallargues M, et al. **J Clin Epidemiol** 1998 Oct; 51(10):843–52

Effect of the method of administration, mail or telephone, on the validity and reliability of a respiratory health questionnaire. The Spanish Centers of the European Asthma Study. Galobardes B, et al. **J Clin Epidemiol** 1998 Oct;51(10):875–81

Health status measurement in Toxic Oil Syndrome. Gómez de la Cámara A, et al. **J Clin Epidemiol** 1998 Oct; 51(10):867–73

Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. Guyatt GH, et al. **J Clin Epidemiol** 1999 Mar;52(3):187–92

How should importance and severity ratings be combined for item reduction in the development of health status instruments? Marx RG, et al. **J Clin Epidemiol** 1999 Mar; 52(3):193–7

Perceived health over 3 years after percutaneous coronary balloon angioplasty. Permanyer-Miralda G, et al. **J Clin Epidemiol** 1999 Jul;52(7):615–23

A research registry: uses, development, and accuracy. Roos LL, et al. **J Clin Epidemiol** 1999 Jan;52(1):39–47

Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions. Rose MS, et al. **J Clin Epidemiol** 1999 May; 52(5):405–12

Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer [see comments] Sloan JA, et al. **J Clin Oncol** 1998 Nov; 16(11):3662–73. Comment in: J Clin Oncol 1999 Feb;17(2):738–40.

Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Tunis SL, et al. **J Clin Psychiatry** 1999;60 Suppl 19:38–45; discussion 46

Chronic fatigue syndrome: assessing symptoms and activity level. Jason LA, et al. **J Clin Psychol** 1999 Apr;55(4):411–24

Health behind bars: utilization and evaluation of medical care among jail inmates. Lindquist CH, et al. **J Community Health** 1999 Aug;24(4):285–303

Key health issues for dairy cattle--new and old. Wells SJ, et al. **J Dairy Sci** 1998 Nov;81(11):3029–35 (54 ref.)

Comparison of adjustment of school-age children with and without chronic conditions: results from community-based samples. Stein RE, et al. **J Dev Behav Pediatr** 1998 Aug; 19(4):267–72

Relationship between the level of activities of daily living and chronic medical conditions among the elderly. Kishimoto M, et al. **J Epidemiol** 1998 Dec;8(5):272–7

Agreement between self- and partner reports obtained by a self-administered questionnaire: medical and lifestyle information. Okamoto K, et al. **J Epidemiol** 1999 Jun; 9(3):183–9

Social capital: is it good for your health? Issues for a public health agenda [editorial] Baum F. **J Epidemiol Community Health** 1999 Apr;53(4):195–6

Determinants of self assessed health among Spanish older people living at home. Damian J, et al. **J Epidemiol Community Health** 1999 Jul;53(7):412–6

Gender inequalities in health and health care services use in Catalonia (Spain). Fernandez E, et al. **J Epidemiol Community Health** 1999 Apr;53(4):218–22

Operationalisation of a demand/resource model of health: an explorative study. Freidl W, et al. **J Epidemiol Community Health** 1999 Mar;53(3):187–8

Effect of a transient, geographically localised economic recovery on community health and income studied with longitudinal household cohort interview method. Glenn LL, et al. **J Epidemiol Community Health** 1998 Nov; 52(11):749–57

Assessment of the SF-36 version 2 in the United Kingdom. Jenkinson C, et al. **J Epidemiol Community Health** 1999 Jan;53(1):46–50

Contrasting evidence of the effectiveness of cosmetic surgery from two health related quality of life measures. Klassen A, et al. **J Epidemiol Community Health** 1999 Jul; 53(7):440–1

Health related lifestyle in adolescence predicts adult educational level: a longitudinal study from Finland. Koivusilta L, et al. **J Epidemiol Community Health** 1998 Dec;52(12):794–801

Association between educational level and health related quality of life in Spanish adults. Regidor E, et al. **J Epidemiol Community Health** 1999 Feb;53(2):75–82

The magnitude of differences in perceived general health associated with educational level in the regions of Spain. Regidor E, et al. **J Epidemiol Community Health** 1999 May; 53(5):288–93

Reported health, lifestyles, and use of health care of first generation immigrants in The Netherlands: do socioeconomic factors explain their adverse position? Reijneveld SA. **J Epidemiol Community Health** 1998 May; 52(5):298–304

Unemployment, depression, and health: a look at the African-American community. Rodriguez E, et al. **J Epidemiol Community Health** 1999 Jun;53(6):335–42

A higher prevalence of health problems in low income groups: does it reflect relative deprivation? Stronks K, et al. **J Epidemiol Community Health** 1998 Sep;52(9):548–57

Generational continuity and change in British Asian health and health behaviour. Williams R, et al. **J Epidemiol Community Health** 1998 Sep;52(9):558–63

Factors affecting general practice patient response rates to a postal survey of health status in England: a comparative analysis of three disease groups [letter] Meadows KA, et al. **J Eval Clin Pract** 1998 Aug;4(3):243–7

Evaluating changes in life expectancy and survival in the elderly. Walker AR, et al. **J Eval Clin Pract** 1999 Feb; 5(1):57–63

A study of the spatiotemporal health impacts of ozone exposure. Christakos G, et al. **J Expo Anal Environ Epidemiol** 1999 Jul-Aug;9(4):322–35

Respiratory function as measured by peak expiratory flow rate and PM10: six communities study. Lee JT, et al. **J Expo Anal Environ Epidemiol** 1999 Jul-Aug;9(4):293–9

The functional status of inner-city primary care patients. Diminished function in a family practice population and its potential determinants. Woolf SH, et al. **J Fam Pract** 1998 Oct;47(4):312–5

Smoking status as a vital sign. Ahluwalia JS, et al. **J Gen Intern Med** 1999 Jul;14(7):402–8

Sociodemographic characteristics and drinking status as predictors of older women's health. Vogeltanz ND, et al. **J Gen Psychol** 1999 Apr;126(2):135–47

Functional health and dental service use among older adults. Dolan TA, et al. **J Gerontol A Biol Sci Med Sci** 1998 Nov; 53(6):M413–8

Trends in health and ability to work among the older working-age population. Crimmins EM, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Jan;54(1):S31–40

Subjective health and mortality in French elderly women and men. Helmer C, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Mar;54(2):S84–92

Self-perceptions of health: a prospective analysis of mortality, control, and health. Menec VH, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Mar;54(2):P85–93

Age effects and health appraisal: a meta-analysis. Roberts G. **J Gerontol B Psychol Sci Soc Sci** 1999 Jan;54(1):S24–30

Self-rated health and adverse health outcomes: an exploration and refinement of the trajectory hypothesis. Wolinsky FD, et al. **J Gerontol B Psychol Sci Soc Sci** 1998 Nov;53(6):S336–40

The medically vulnerable: their health risks, health status, and use of physician care. Broyles RW, et al. **J Health Care Poor Underserved** 1999 May;10(2):186–200

Health status and access to care among rural minorities. Mueller KJ, et al. **J Health Care Poor Underserved** 1999 May;10(2):230–49 (193 ref.)

Health status, needs, and health care barriers among the homeless. Wojtusik L, et al. **J Health Care Poor Underserved** 1998 May;9(2):140–52

The health status of veterans using mobile clinics in rural areas. Wray NP, et al. **J Health Care Poor Underserved** 1999 Aug;10(3):338–48

Education and health in the Czech Republic. Hraba J, et al. **J Health Soc Behav** 1998 Dec;39(4):295–316

Interacting effects of multiple roles on women's health. Waldron I, et al. **J Health Soc Behav** 1998 Sep;39(3):216–36

The relationship between psychiatric and physical health in elderly people with intellectual disability. Cooper SA. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):54–60

The relationship between health status and blood pressure in urban African Americans. DeForge BR, et al. **J Natl Med Assoc** 1998 Nov;90(11):658–64

Subjective health status as a determinant of mortality among African-American elders. Onawola RS, et al. **J Natl Med Assoc** 1998 Dec;90(12):754–8

Self-reported health, and illness and the use of conventional and unconventional medicine and mind/body healing by Christian Scientists and others. Benson H, et al. **J Nerv Ment Dis** 1999 Sep;187(9):539–48

Quality of life in patients with panic disorder. Candilis PJ, et al. **J Nerv Ment Dis** 1999 Jul;187(7):429–34

The association of medical comorbidity in schizophrenia with poor physical and mental health. Dixon L, et al. **J Nerv Ment Dis** 1999 Aug;187(8):496–502

Combat exposure, posttraumatic stress disorder symptoms, and health behaviors as predictors of self-reported physical health in older veterans. Schnurr PP, et al. **J Nerv Ment Dis** 1999 Jun;187(6):353–9

The relationship between insight and suicidality among patients with schizophrenia. Schwartz RC, et al. **J Nerv Ment Dis** 1999 Jun;187(6):376–8

Some psychological and physical consequences in middle-aged adults of underfunded institutional care in childhood. Sigal JJ, et al. **J Nerv Ment Dis** 1999 Jan; 187(1):57–9

Psychological adjustment and self reported coping in stroke survivors with and without emotionalism [letter] Eccles S, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):125–6

Health status in 52 long-term survivors of pediatric brain tumors. Foreman NK, et al. **J Neurooncol** 1999 Jan; 41(1):47–53

Self-health appraisal: learning the difficulties of lifestyle change. Schank MJ. **J Nurs Educ** 1999 Jan;38(1):10–2

Supplement users differ from nonusers in demographic, lifestyle, dietary and health characteristics. Lyle BJ, et al. **J Nutr** 1998 Dec;128(12):2355–62

Nutrition and health outcomes associated with food insecurity and hunger. Olson CM. **J Nutr** 1999 Feb;129(2S Suppl):521S–524S (14 ref.)

Dimensions of "Functional Status" in trials or wasting. Shah JP. **J Nutr** 1999 Jan;129(1S Suppl):279S–281S

Prepregnant weight and weight gain during pregnancy: relationship to functional status, symptoms, and energy. Tulman L, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec;27(6):629–34

Impact of traumatic events and organizational response. A study of bank robberies. Miller-Burke J, et al. **J Occup Environ Med** 1999 Feb;41(2):73–83

Reported health status among farmers and nonfarmers in nine rural districts. Stiernström EL, et al. **J Occup Environ Med** 1998 Oct;40(10):917–24

The impact of socio-cultural and clinical factors on health-related quality of life reports among Hispanic and African-American cancer patients. Wan GJ, et al. **J Outcome Meas** 1999;3(3):200–15

Antenatal steroids, condition at birth and respiratory morbidity and mortality in very preterm infants. Ee L, et al. **J Paediatr Child Health** 1998 Aug;34(4):377–83

Clinical research in aboriginal health [editorial] Torzillo PJ. **J Paediatr Child Health** 1999 Apr;35(2):123–4 (5 ref.)

Prevalence of emotional and physical health concerns amongst young people in Victoria. Waters E, et al. **J Paediatr Child Health** 1999 Feb;35(1):28–33

Intestinal fructose absorption: clinical and molecular aspects. Corpe CP, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr; 28(4):364–74 (97 ref.)

Perinatal outcome and the social contract--interrelationships between health and humanity. Gorski PA. **J Perinatol** 1998 Jul-Aug;18(4):297–301

The influence of general health and socio-cultural variables on the periodontal condition of pregnant women. Machuca G, et al. **J Periodontol** 1999 Jul;70(7):779–85

"If I had it to do over again...": midlife review, midcourse corrections, and women's well-being in midlife. Stewart AJ, et al. **J Pers Soc Psychol** 1999 Feb;76(2):270–83

Healthy people 2000--how are we doing? [news] **J Psychosoc Nurs Ment Health Serv** 1999 Aug;37(8):10

Wartime stressors and health outcomes: women in the Persian Gulf War. Bell EA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Aug;36(8):19–25

Health status risk factors of people with severe and persistent mental illness. Farnam CR, et al. **J Psychosoc Nurs Ment Health Serv** 1999 Jun;37(6):16–21

Menopausal status: subjectively and objectively defined. Garamszegi C, et al. **J Psychosom Obstet Gynaecol** 1998 Sep;19(3):165–73

Religiosity is associated with affective and immune status in symptomatic HIV-infected gay men. Woods TE, et al. **J Psychosom Res** 1999 Feb;46(2):165–76

Components of self-reported oral health and general health in racial and ethnic groups. Atchison KA, et al. **J Public Health Dent** 1998 Fall;58(4):301–8

Changes in dental health and dental health habits from 3 to 5 years of age. Mattila ML, et al. **J Public Health Dent** 1998 Fall;58(4):270–4

Allocative efficiency in the use of health resources in Portugal. do Rosário Giraldes M. **J Public Health Med** 1999 Mar;21(1):55–9

Has SF-36's role physical measure fallen short? [letter] Johnson EM. **J Public Health Med** 1999 Jun;21(2):234

SF-36 scores vary by method of administration: implications for study design. Lyons RA, et al. **J Public Health Med** 1999 Mar;21(1):41–5

The two communities in Northern Ireland [letter; comment] Sloan D. **J Public Health Med** 1999 Mar;21(1):119–20. Comment on: J Public Health Med 1998 Jun;20(2):161–8.

A case-control study of the health status of male farmers registered at Ash Tree House Surgery, Kirkham, Lancashire. McCrone JC. **J R Soc Health** 1999 Mar; 119(1):32–5

Characteristics associated with marginal hearing loss and subjective well-being among a sample of older adults. Scherer MJ, et al. **J Rehabil Res Dev** 1998 Oct;35(4):420–6

Why not use OSRA? A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA. Birrell FN, et al. **J Rheumatol** 1998 Sep;25(9):1709–15

Health status in rheumatoid arthritis: cross cultural evaluation of a Portuguese version of the Arthritis Impact Measurement Scales 2 (BRASIL-AIMS2). Brandão L, et al. **J Rheumatol** 1998 Aug;25(8):1499–501

Evaluation of functional capacity in ankylosing spondylitis [editorial; comment] Dougados M, et al. **J Rheumatol** 1999 Jan;26(1):4–6. Comment on: J Rheumatol 1999 Jan;26(1):121–7.

Measuring disability in early juvenile rheumatoid arthritis: evaluation of a Norwegian version of the childhood Health Assessment Questionnaire. Flatø B, et al. **J Rheumatol** 1998 Sep;25(9):1851–8

Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. Gilboe IM, et al. **J Rheumatol** 1999 Aug;26(8):1694–700

The value of utility: assumptions underlying preferences and quality adjusted life years [editorial] [see comments] Guillemin F. **J Rheumatol** 1999 Sep;26(9):1861–3 (20 ref.) . Comment in: J Rheumatol 1999 Sep;26(9):1859–60.

Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis. Koh ET, et al. **J Rheumatol** 1998 Sep;25(9):1705–8

Socioeconomic status and health in women with systemic lupus erythematosus. Lotstein DS, et al. **J Rheumatol** 1998

Sep;25(9):1720–9
Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices. Moore AD, et al. **J Rheumatol** 1999 Jun; 26(6):1285–90
Applying the Sports Medicine Australia pre-exercise screening procedures: who will be excluded? Norton K, et al. **J Sci Med Sport** 1998 Jan;1(1):38–51
Sexual response in women with spinal cord injuries: implications for our understanding of the able bodied. Sipski ML, et al. **J Sex Marital Ther** 1999 Jan–Mar; 25(1):11–22
Perceived overqualification and health: a longitudinal analysis. Johnson GJ, et al. **J Soc Psychol** 1999 Feb; 139(1):14–28
Specific alcoholic beverages and physical and mental health among adolescents. Hansell S, et al. **J Stud Alcohol** 1999 Mar;60(2):209–18
Health status in veterans undergoing noninvasive lower extremity arterial evaluation. Kazmers A, et al. **J Surg Res** 1999 Jan;81(1):2–5
Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. Malik ML, et al. **J Trauma Stress** 1999 Apr;12(2):387–93
Modeling physical health and functional health status: the role of combat exposure, posttraumatic stress disorder, and personal resource attributes. Taft CT, et al. **J Trauma Stress** 1999 Jan;12(1):3–23
Proceedings of the 4th annual Margaret E Mahoney Symposium on the State of the Nation's Health. **J Urban Health** 1998 Dec;75(4):615–776
Health status and its determinants in urban populations. Omenn GS. **J Urban Health** 1998 Jun;75(2):219–27
Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. Jacobsen SJ, et al. **J Urol** 1999 Oct;162(4):1301–6
Health related quality of life in older men without prostate cancer. Litwin MS. **J Urol** 1999 Apr;161(4):1180–4
Income characteristics of rural older women and implications for health status. Barnes ND, et al. **J Women Aging** 1999; 11(1):27–37
Gender role orientation as a correlate of perceived health, health behavior, and qualitative well-being in older women. Ruffing-Rahal MA, et al. **J Women Aging** 1998; 10(1):3–19
Who cares? Grandparent/grandchild households. Solomon JC, et al. **J Women Aging** 1999;11(1):3–25
Personal health among midlife women hospital employees. Angard N, et al. **J Womens Health** 1998 Dec;7(10):1289–93
Early life stress, negative paternal relationships, and chemical intolerance in middle-aged women: support for a neural sensitization model. Bell IR, et al. **J Womens Health** 1998 Nov;7(9):1135–47
Late twentieth century medicine: will, education, and the American dream [editorial] Healy BP. **J Womens Health** 1998 Sep;7(7):779–80
From the Centers for Disease Control and Prevention. Health status of and intervention for US-bound Kosovar refugees--Fort Dix, New Jersey, May–July 1999. **JAMA** 1999 Sep 22–29;282(12):1122–3
Childhood malnutrition and postwar reconstruction in rural El Salvador: a community-based survey. Brentlinger PE, et al. **JAMA** 1999 Jan 13;281(2):184–90
Ethnic and socioeconomic factors as determinants of health status [letter; comment] Davis SK. **JAMA** 1998 Dec 16; 280(23):1989–90. Comment on: JAMA 1998 Jul 22–29;280(4):356–62.
Health and satisfaction among the elderly with chronic conditions: demographic differentials. Lu L, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Mar; 14(3):139–49
Centenarians: the older you get, the healthier you have been [letter] Hitt R, et al. **Lancet** 1999 Aug 21;354(9179):652
Health and wealth in the United Arab Emirates [news] Kandela P. **Lancet** 1999 Jun 12;353(9169):2047
Centenarians point the way to healthy ageing [news; comment] Larkin M. **Lancet** 1999 Mar 27;353(9158):1074 . Comment on: Lancet 1999 Jun 26;353(9171):2250.
Mothering skills and health in infancy: the Thousand Families study revisited [letter] Parker L, et al. **Lancet** 1999 Apr 3;353(9159):1151–2
Nuclear-test-veterans'survey prompts official inquiries [news] Tattam A. **Lancet** 1999 Jan 23;353(9149):299
Health of UK servicemen who served in Persian Gulf War [see comments] Unwin C, et al. **Lancet** 1999 Jan 16; 353(9148):169–78. Comment in: Lancet 1999 Jan 16;353(9148):162–3. Comment in: Lancet 1999 Apr 3;353(9159):1182–3. Comment in: Lancet 1999 Apr 3;353(9159):1183.
Health-related quality of life after liver transplantation: a meta-analysis. Bravata DM, et al. **Liver Transpl Surg** 1999 Jul;5(4):318–31
Culture, socioeconomic status, and physical and mental health in Brazil. Dressler WW, et al. **Med Anthropol Q** 1998 Dec;12(4):424–46
Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV-related resources between HIV-infected women and men. Davidson AJ, et al. **Med Care** 1998 Dec;36(12):1676–84
Assessing the performance of utility techniques in the absence of a gold standard. Giesler RB, et al. **Med Care** 1999 Jun; 37(6):580–8
Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial. Lorig KR, et al. **Med Care** 1999 Jan;37(1):5–14
The effects of marital dissolution and marital quality on health and health service use among women. Prigerson HG, et al. **Med Care** 1999 Sep;37(9):858–73
Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Scott-Lennox JA, et al. **Med Care** 1999 Sep;37(9):908–25
Older men's health. Sociocultural and ecological perspectives. Eckert JK, et al. **Med Clin North Am** 1999 Sep;83(5):1151–72, v (122 ref.)
Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Canadian Collaborative Cardiac Assessment Group. Lalonde L, et al. **Med Decis Making** 1999 Apr–Jun; 19(2):149–56
Computing population-based estimates of health-adjusted life expectancy. Rosenberg MA, et al. **Med Decis Making** 1999 Jan–Mar;19(1):90–7
Subjective health status and health values in the general population. Shmueli A. **Med Decis Making** 1999 Apr–Jun; 19(2):122–7
Men's health [editorial] Connell RW, et al. **Med J Aust** 1998 Sep 21;169(6):295–6 (12 ref.)
Improving indigenous health: social and environmental factors deserve as much attention as health services [letter; comment] Coory M. **Med J Aust** 1999 Feb 15;170(4):190–1 . Comment on: Med J Aust 1998 Nov 16;169(10):528–9, 532–3.
Aboriginal health: why is reconciliation necessary? Jackson LR, et al. **Med J Aust** 1999 May 3;170(9):437–40
Something particular in the air we breathe? [letter; comment] Robinson DL. **Med J Aust** 1999 Apr 5;170(7):342. Comment on: Med J Aust 1998 Nov 2;169(9):452–3.
Confidentiality and the courts [letter; comment] Wells DL. **Med J Aust** 1999 Jun 21;170(12):617–8. Comment on: Med J Aust 1999 Mar 1;170(5):222–4.
A simple, reliable method of assessing exercise capacity in patients with chronic heart failure. Asakuma S, et al. **Med Sci Sports Exerc** 1999 Jan;31(1):52–6
Self-reported chemical sensitivity and wartime chemical exposures in Gulf War veterans with and without decreased global health ratings. Bell IR, et al. **Mil Med** 1998 Nov; 163(11):725–32
Stress and health during medical humanitarian assistance missions. Britt TW, et al. **Mil Med** 1999 Apr;164(4):275–9
The mental health status of women in the Navy and Marine Corps: preliminary findings from the Perceptions of Wellness and Readiness Assessment. Hourani LL, et al. **Mil Med** 1999 Mar;164(3):174–81
A medical readiness model of health assessment or well-being in first-increment air combat command medical personnel. McRae-Bergeron CE, et al. **Mil Med** 1999 Jun; 164(6):379–88
The health status of Gulf War veterans: lessons learned from the Department of Veterans Affairs Health Registry. Murphy FM, et al. **Mil Med** 1999 May;164(5):327–31
The focus on women veterans who use Veterans Administration health care: the Veterans Administration Women's Health Project. Skinner KM, et al. **Mil Med** 1998 Nov;163(11):761–6
Health status of and intervention for U.S.-bound Kosovar refugees--Fort Dix, New Jersey, May–July 1999. **MMWR Morb Mortal Wkly Rep** 1999 Aug 27; 48(33):729–32
Valuing quality of life: results for New Zealand health professionals [see comments] Devlin N, et al. **N Z Med J** 1999 Mar 12;112(1083):68–71. Comment in: N Z Med J 1999 Jun 25;112(1090):239–40.
The outcome for patients with ME in New Zealand [letter; comment] Simpson LO. **N Z Med J** 1999 Mar 26; 112(1084):104–5. Comment on: N Z Med J 1999 Jun 25;112(1090):242.
Measuring health-related quality of life [letter; comment] Taylor WJ, et al. **N Z Med J** 1999 Jun 25;112(1090):239–40 . Comment on: N Z Med J 1999 Mar 12;112(1083):68–71.
Health, development and economics. Drèze J. **Natl Med J India** 1999 Jan–Feb;12(1):2–5
Gender gap in health decline in East Europe [letter] Weidner G. **Nature** 1998 Oct 29;395(6705):835
Seizure frequency and the health-related quality of life of adults with epilepsy. Leidy NK, et al. **Neurology** 1999 Jul 13;53(1):162–6
Word-stem completion priming in healthy aging and Alzheimer's disease: the effects of age, cognitive status, and encoding. Fleischman DA, et al. **Neuropsychology** 1999 Jan;13(1):22–30
Medical assessment in the psychiatric emergency service. Allen MH, et al. **New Dir Ment Health Serv** 1999 Summer; (82):21–8
Integration of mental and physical health concerns [editorial] Goetz RR, et al. **New Dir Ment Health Serv** 1999 Spring; (81):1–3
Disparities of health in African Americans. Davis CM, et al. **Nurs Clin North Am** 1999 Jun;34(2):345–57 (65 ref.)
Health problems of Asian and Latino immigrants. Flaskerud JH, et al. **Nurs Clin North Am** 1999 Jun;34(2):359–80 (118 ref.)
Health-related problems in a vulnerable population: pregnant teens and adolescent mothers. Lesser J, et al. **Nurs Clin North Am** 1999 Jun;34(2):289–99 (48 ref.)
Health problems of lesbian women. Saunders JM. **Nurs Clin North Am** 1999 Jun;34(2):381–91 (38 ref.)
The homeless as a vulnerable population. Strehlow AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):261–74 (50 ref.)
Nursing care of the elderly as a vulnerable population. Tullmann DF, et al. **Nurs Clin North Am** 1999 Jun; 34(2):333–44 (41 ref.)
Conceptualizing battered women as a vulnerable population: a case study report. Tyson S, et al. **Nurs Clin North Am** 1999 Jun;34(2):301–12 (48 ref.)
Health problems of gay and bisexual men. Ungvarski PJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):313–31 (86 ref.)
Health consequences of pregnancy and childbirth as perceived by women and clinicians. Kline CR, et al. **Obstet Gynecol** 1998 Nov;92(5):842–8
The occupational health status of hired farm workers. Villarejo D, et al. **Occup Med** 1999 Jul–Sep;14(3):613–35 (100 ref.)
Self-reported health problems among Swedish miners one year after unemployment. Friis L, et al. **Occup Med (Lond)** 1998 Jul;48(5):297–301
Health and employment after a diagnosis of occupational asthma: a descriptive study. Ross DJ, et al. **Occup Med (Lond)** 1998 May;48(4):219–25
The associations between self-rated vision and hearing and functional status in middle age. Lee PP, et al. **Ophthalmology** 1999 Feb;106(2):401–5
Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Wilson MR, et al. **Ophthalmology** 1998 Nov;105(11):2112–6
Health registers as a feasible means of measuring health status in childhood--a 7-year follow-up of the 1987 Finnish birth cohort. Gissler M, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):437–55
Gynecologic care of medically complicated adolescents. Owens K, et al. **Pediatr Clin North Am** 1999 Jun; 46(3):631–42, ix (33 ref.)
Consideration of the use of health status, functional outcome, and quality-of-life to monitor neonatal intensive care practice. Hack M. **Pediatrics** 1999 Jan;103(1 Suppl E):319–28 (110 ref.)
Pacifier use and morbidity in the first six months of life. North K, et al. **Pediatrics** 1999 Mar;103(3):E34
Black and white middle class children who have private health insurance in the United States. Weitzman M, et al. **Pediatrics** 1999 Jul;104(1 Pt 2):151–7
Leisure-time physical activity and self-perceived fitness of hospital employees. Drummond JL, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1256–8
Handedness and stress-related health problems. Hicks RA, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):1042
Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)
An alternative way to display SF-36 results for individual patients [letter] Steiner WA, et al. **Phys Ther** 1998 Oct; 78(10):1118–9
The health and socio-economic circumstances of British lone mothers over the last two decades. Shouls S, et al. **Popul Trends** 1999 Spring;(95):41–6
Stage of regular exercise and health-related quality of life. Laforge RG, et al. **Prev Med** 1999 Apr;28(4):349–60
Health and growth of water-buffalo calves in Nueva Ecija, the Philippines. Gundran RS, et al. **Prev Vet Med** 1999 May 31;40(2):87–100
A Cox proportional-hazards model with time-dependent covariates to evaluate the relationship between body-condition score and the risks of first insemination and pregnancy in a high-producing dairy herd. Suriyasathaporn W, et al. **Prev Vet Med** 1998 Dec 1; 37(1–4):159–72
Simulating patients with Parallel Health State Networks. Sumner W 2nd, et al. **Proc AMIA Symp** 1998;:438–42
The effects of health changes on projections of health service needs for the elderly population of the United States. Singer BH, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15618–22
Health status and health care costs for publicly funded patients with schizophrenia started on clozapine. Blieden N, et al. **Psychiatr Serv** 1998 Dec;49(12):1590–3
Health and self-care practices of persons with schizophrenia. Holmberg SK, et al. **Psychiatr Serv** 1999 Jun;50(6):827–9
The time dimension in stress responses: relevance for survival and health. Eriksen HR, et al. **Psychiatry Res** 1999 Jan 18;85(1):39–50 (72 ref.)
Repressive/defensive coping, endogenous opioids and health: how a life so perfect can make you sick [see comments] Jamner LD, et al. **Psychiatry Res** 1999 Jan 18;85(1):17–31 . Comment in: Psychiatry Res 1999 Jan 18;85(1):7–15.
Gender differences in the effects of bereavement-related psychological distress in health outcomes. Chen JH, et al. **Psychol Med** 1999 Mar;29(2):367–80
Psychiatric co-morbidity and hospital utilization in the general medical sector. Savoca E. **Psychol Med** 1999 Mar; 29(2):457–64
Are social supports in late midlife a cause or a result of successful physical ageing? Vaillant GE, et al.

Psychol Med 1998 Sep;28(5):1159–68
A mediational model of quality of life for individuals with severe mental health problems. Zissi A, et al. **Psychol Med** 1998 Sep;28(5):1221–30
Why do women treated for breast cancer report good health despite disease or disability? A pilot study. Justice B. **Psychol Rep** 1999 Apr;84(2):392–4
Assessing the multidimensionality of the 12-item General Health Questionnaire. Martin AJ. **Psychol Rep** 1999 Jun; 84(3 Pt 1):927–35
Health-related correlates of gambling on the British National Lottery. Reid S, et al. **Psychol Rep** 1999 Feb;84(1):247–54
Contribution of emotionally traumatic events and inheritance to the report of current physical health problems in 4042 Vietnam era veteran twin pairs [see comments] Eisen SA, et al. **Psychosom Med** 1998 Sep–Oct;60(5):533–9. Comment in: Psychosom Med 1998 Sep–Oct;60(5):540–2.
Diagnostic groups and depressed mood as predictors of 22-month mortality in medical inpatients. Herrmann C, et al. **Psychosom Med** 1998 Sep–Oct;60(5):570–7
Psychosocial factors and heart rate variability in healthy women. Horsten M, et al. **Psychosom Med** 1999 Jan–Feb; 61(1):49–57
Chronic stress and illness in children: the role of allostatic load. Johnston-Brooks CH, et al. **Psychosom Med** 1998 Sep–Oct;60(5):597–603
Is educational attainment associated with shared determinants of health in the elderly? Findings from the MacArthur Studies of Successful Aging. Kubzansky LD, et al. **Psychosom Med** 1998 Sep–Oct;60(5):578–85
Into the MIRE: stress, genetics, and disease [editorial; comment] Newberry BH. **Psychosom Med** 1998 Sep–Oct; 60(5):540–2. Comment on: Psychosom Med 1998 Sep–Oct;60(5):533–9.
A five-year study on the interactive effects of depression and physical illness on psychiatric unit length of stay. Sloan DM, et al. **Psychosom Med** 1999 Jan–Feb;61(1):21–5
Hypochondriasis, somatization, and perceived health and utilization of health care services. Hollifield M, et al. **Psychosomatics** 1999 Sep–Oct;40(5):380–6
Health and adverse selection into marriage: evidence from a study of the 1958 British birth cohort. Cheung YB, et al. **Public Health** 1998 Sep;112(5):309–11
What is a community? [editorial] Slack RC. **Public Health** 1998 Nov;112(6):361
Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301–6 (18 ref.)
The community health nursing implications of the self-reported health status of a local homeless population. Reichenbach EM, et al. **Public Health Nurs** 1998 Dec; 15(6):398–405
The effects of a walking exercise program on physical function and emotional state of elderly Korean women. Shin Y. **Public Health Nurs** 1999 Apr;16(2):146–54
Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Badia X, et al. **Qual Life Res** 1999 Jun; 8(4):303–10
Refining quality of life: validating a multidimensional factor measure in the severe mentally ill. Bishop SL, et al. **Qual Life Res** 1999;8(1-2):151–60
The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Bradley C, et al. **Qual Life Res** 1999; 8(1-2):79–91
The adaptations of a quality of life questionnaire for routine use in clinical practice: the Chronic Respiratory Disease Questionnaire in cystic fibrosis. Bradley J, et al. **Qual Life Res** 1999;8(1-2):65–71
A multi-attribute model of prostate cancer patient's preferences for health states. Chapman GB, et al. **Qual Life Res** 1999 May;8(3):171–80
Temporal assessment of quality of life of head and neck cancer patients receiving radical radiotherapy. Chawla S, et al. **Qual Life Res** 1999;8(1-2):73–8
A review of health-related quality-of-life concepts and measures for Parkinson's disease. Damiano AM, et al. **Qual Life Res** 1999 May;8(3):235–43 (30 ref.)
Impact of weight loss on health-related quality of life. Fontaine KR, et al. **Qual Life Res** 1999 May;8(3):275–7
The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Hawthorne G, et al. **Qual Life Res** 1999 May;8(3):209–24
The SF-36 as a health status measure for epilepsy: a psychometric assessment. Jacoby A, et al. **Qual Life Res** 1999 Jun;8(4):351–64
Health related quality of life and disease severity in patients with alpha-1 antitrypsin deficiency. Knebel AR, et al. **Qual Life Res** 1999 Jun;8(4):385–91
Use of the 12-item short-form (SF-12) Health Survey in an Australian heart and stroke population. Lim LL, et al. **Qual Life Res** 1999;8(1-2):1–8
A health-related quality of life measure for use in patients with onychomycosis: a validation study. Lubeck DP, et al. **Qual Life Res** 1999;8(1-2):121–9
A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Lubeck DP, et al. **Qual Life Res** 1999 Jun;8(4):337–44
Do we know what global ratings of health-related quality of life measure? Mozes B, et al. **Qual Life Res** 1999 May; 8(3):269–73
The competing effects of disease states on quality of life of the elderly: the case of urinary symptoms in men. Mozes B, et al. **Qual Life Res** 1999;8(1-2):93–9
Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome. Myers C, et al. **Qual Life Res** 1999;8(1-2):9–16
A new measure for assessing the health-related quality of life of patients with vertigo, dizziness or imbalance: the VDI questionnaire. Prieto L, et al. **Qual Life Res** 1999; 8(1-2):131–9
Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Ringdal K, et al. **Qual Life Res** 1999;8(1-2):25–43
Distinguishing between quality of life and health status in quality of life research: a meta-analysis. Smith KW, et al. **Qual Life Res** 1999 Aug;8(5):447–59
Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Stavem K. **Qual Life Res** 1999; 8(1-2):45–54
A Kiswahili version of the SF-36 Health Survey for use in Tanzania: translation and tests of scaling assumptions. Wagner AK, et al. **Qual Life Res** 1999;8(1-2):101–10
Measuring health-related quality of life in patients with venous leg ulcers. Walters SJ, et al. **Qual Life Res** 1999 Jun;8(4):327–36
Towards a composite scoring solution for the Neurobehavioral Functioning Inventory. Weinfurt KP, et al. **Qual Life Res** 1999;8(1-2):17–24
The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer. Weitzner MA, et al. **Qual Life Res** 1999; 8(1-2):55–63
Validation of the Kiswahili version of the SF-36 Health Survey in a representative sample of an urban population in Tanzania. Wyss K, et al. **Qual Life Res** 1999; 8(1-2):111–20
Statistical methods for epidemiologic studies of the health effects of air pollution. Navidi W, et al. **Res Rep Health Eff Inst** 1999 May;(86):1–50; discussion 51–6
Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Barley EA, et al. **Respir Med** 1998 Oct;92(10):1207–14
Performance of a short lung-specific health status measure in outpatients with chronic obstructive pulmonary disease. Stavem K, et al. **Respir Med** 1999 Jul;93(7):467–75
Health observation and health reporting in Europe. Aromaa A. **Rev Epidemiol Sante Publique** 1998 Dec;46(6):481–90
The health of farm workers--so much different, so much the same [editorial] Schenker M. **S Afr Med J** 1998 Sep; 88(9):1091–2
Daytime sleepiness in 40–64 year-old women in relation to somatic health and medical treatment. Asplund R, et al. **Scand J Prim Health Care** 1998 Jun;16(2):112–6
Impaired health status, and mental health, lower vitality and social functioning in women general practitioners in Sweden. A cross-sectional survey. Sundquist J, et al. **Scand J Prim Health Care** 1999 Jun;17(2):81–6
Inequalities in health: evidence from Denmark of the interaction of circumstances and health-related behaviour. Christiansen T, et al. **Scand J Public Health** 1999 Sep; 27(3):181–8
Health and re-employment in a five-year follow-up of long-term unemployed. Claussen B. **Scand J Public Health** 1999 Jun;27(2):94–100
Teaching social inequalities in health: barriers and opportunities. Muntaner C. **Scand J Public Health** 1999 Sep;27(3):161–5 (58 ref.)
Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Loge JH, et al. **Scand J Soc Med** 1998 Dec;26(4):250–8
To sing in a choir and be healthy--which are the mediating mechanisms? [letter] Mattsson B, et al. **Scand J Soc Med** 1998 Sep;26(3):238
Social differences in health in an affluent Danish county. Osler M, et al. **Scand J Soc Med** 1998 Dec;26(4):289–92
Planning a worksite health promotion program: health profile of a population of Greek sailors [letter] Tsamandouraki K, et al. **Scand J Soc Med** 1998 Sep;26(3):181–2
Predictors and consequences of unemployment in construction and forest work during a 5-year follow-up. Liira J, et al. **Scand J Work Environ Health** 1999 Feb; 25(1):42–9
Wives, husbands, and daughters of dementia patients: predictors of caregivers' mental and physical health. Sparks MB, et al. **Sch Inq Nurs Pract** 1998 Fall;12(3):221–34; discussion 235–8
Unequal health [news] Nemecek S. **Sci Am** 1999 Jan; 280(1):40–1
Aging in the third millennium. Schneider EL. **Science** 1999 Feb 5;283(5403):796–7
Physical activity and health in old age. McMurdo ME. **Scott Med J** 1997 Oct;42(5):154–5 (21 ref.)
Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Lehrner J, et al. **Seizure** 1999 Apr; 8(2):88–92
Does employment improve the health of lone mothers? The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Baker D, et al. **Soc Sci Med** 1999 Jul;49(1):121–31
Social position, social roles and women's health in England: changing relationships 1984–1993. Bartley M, et al. **Soc Sci Med** 1999 Jan;48(1):99–115
Gender matters: an integrated model for understanding men's and women's health. Bird CE, et al. **Soc Sci Med** 1999 Mar;48(6):745–55 (51 ref.)
Socioeconomic factors, perceived control and self-reported health in Russia. A cross-sectional survey. Bobak M, et al. **Soc Sci Med** 1998 Jul;47(2):269–79
Occupational class and the probability of long-term limiting illness. Borooah VK. **Soc Sci Med** 1999 Jul;49(2):253–66
Economic and health efficiency of education funding policy. Curtin TR, et al. **Soc Sci Med** 1999 Jun;48(11):1599–611
Discrepancies between self-reported and observed physical function in the elderly: the influence of response shift and other factors. Daltroy LH, et al. **Soc Sci Med** 1999 Jun; 48(11):1549–61
National health policies: sub-Saharan African case studies (1980–1990). Dugbatey K. **Soc Sci Med** 1999 Jul; 49(2):223–39
Making use of official statistics in research on gender and health status: recent British data. Dunnell K, et al. **Soc Sci Med** 1999 Jan;48(1):117–27 (26 ref.)
Income and health: what is the nature of the relationship? Ecob R, et al. **Soc Sci Med** 1999 Mar;48(5):693–705
Problematizing gender, work and health: the relationship between gender, occupational grade, working conditions and minor morbidity in full-time bank employees. Emslie C, et al. **Soc Sci Med** 1999 Jan;48(1):33–48
Health and access to care: perspectives of homeless youth in Baltimore City, U.S.A. Ensign J, et al. **Soc Sci Med** 1998 Dec;47(12):2087–99
Valuing temporary and chronic health states associated with breast screening. Johnston K, et al. **Soc Sci Med** 1998 Jul; 47(2):213–22
The effects of political and economic transitions on health and safety in Estonia: an Estonian-Swedish comparative study. Kaasik T, et al. **Soc Sci Med** 1998 Nov; 47(10):1589–99
Women's status and the health of women and men: a view from the States. Kawachi I, et al. **Soc Sci Med** 1999 Jan; 48(1):21–32
Morbidity and quality of life and the moderating effects of level of education in the elderly. Kempen GI, et al. **Soc Sci Med** 1999 Jul;49(1):143–9
Gender differences in illhealth in Finland: patterns, magnitude and change. Lahelma E, et al. **Soc Sci Med** 1999 Jan;48(1):7–19
Changing biocultural perspectives on health in the Andes [published erratum appears in Soc Sci Med 1998 Nov;47(9):1397] Leatherman T. **Soc Sci Med** 1998 Oct; 47(8):1031–41
Do women 'over-report' morbidity? Men's and women's responses to structured prompting on a standard question on long standing illness. Macintyre S, et al. **Soc Sci Med** 1999 Jan;48(1):89–98
Reliability of perceived health by sex and age. Martikainen P, et al. **Soc Sci Med** 1999 Apr;48(8):1117–22
Determinants of socioeconomic differences in change in physical and mental functioning. Martikainen P, et al. **Soc Sci Med** 1999 Aug;49(4):499–507
Issues in promoting health. Mechanic D. **Soc Sci Med** 1999 Mar;48(6):711–8 (49 ref.)
The relationship of community quality to the health of women and men. Molinari C, et al. **Soc Sci Med** 1998 Oct; 47(8):1113–20
Assessing variation in health status in the Andes: a biocultural model. Oths KS. **Soc Sci Med** 1998 Oct;47(8):1017–30
Health appraisal models in multiple sclerosis. Roberts G, et al. **Soc Sci Med** 1998 Jul;47(2):243–53
Helping others helps oneself: response shift effects in peer support. Schwartz CE, et al. **Soc Sci Med** 1999 Jun; 48(11):1563–75
Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Schwartz CE, et al. **Soc Sci Med** 1999 Jun;48(11):1531–48
Integrating response shift into health-related quality of life research: a theoretical model. Sprangers MA, et al. **Soc Sci Med** 1999 Jun;48(11):1507–15
Postpartum health in a Dhaka slum. Uzma A, et al. **Soc Sci Med** 1999 Feb;48(3):313–20
The influence of adult ill health on occupational class mobility and mobility out of and into employment in the The Netherlands. van de Mheen H, et al. **Soc Sci Med** 1999 Aug;49(4):509–18
The persisting effect of unemployment on health and social well-being in men early in working life. Wadsworth ME, et al. **Soc Sci Med** 1999 May;48(10):1491–9
Living in a housing co-operative for low income women: issues of identity, environment and control. Wasylishyn C, et al. **Soc Sci Med** 1998 Oct;47(7):973–81
Social class and health: the puzzling counter-example of British South Asians. Williams R, et al. **Soc Sci Med** 1998 Nov;47(9):1277–88
Clinical understanding and clinical implications of response shift. Wilson IB. **Soc Sci Med** 1999 Jun;48(11):1577–88
Understanding and responding to the health and mental health needs of Asian refugees. Dhooper SS, et al. **Soc Work Health Care** 1998;27(4):65–82
Health status of Orang Asli (aborigine) community in Pos

Piah, Sungai Siput, Perak, Malaysia. Norhayati binti Moktar M, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):58–61

Cornell Medical Index: a comparative study on health problems among Thai and Japanese nursing students. Osaka R, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):293–8

Responsiveness of common outcome measures for patients with low back pain. Taylor SJ, et al. **Spine** 1999 Sep 1; 24(17):1805–12

Replicability of SF-36 summary scores by the SF-12 in stroke patients. Pickard AS, et al. **Stroke** 1999 Jun; 30(6):1213–7

Peru 1996: results from the Demographic and Health Survey. **Stud Fam Plann** 1999 Mar;30(1):78–82

Uzbekistan 1996: results from the Demographic and Health Survey. **Stud Fam Plann** 1999 Mar;30(1):83–7

The relevance of problems and models to treatment outcome: a comparative study of two agencies. Keene J, et al. **Subst Use Misuse** 1999 Aug;34(10):1347–69 (30 ref.)

Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Burney RE, et al. **Surgery** 1999 Jun;125(6):608–14

Poverty and health: a simple matter of money? Mirvis DM, et al. **Tenn Med** 1999 Jul;92(7):258–60

Green tobacco sickness. McBride JS, et al. **Tob Control** 1998 Autumn;7(3):294–8 (33 ref.)

Psychosocial, behavioural, and health determinants of successful smoking cessation: a longitudinal study of Danish adults. Osler M, et al. **Tob Control** 1998 Autumn;7(3):262–7

The health effects of living near cement kilns; a symptom survey in Midlothian, Texas. Legator MS, et al. **Toxicol Ind Health** 1998 Nov–Dec;14(6):829–42

Evaluation of the state of health of living related kidney transplantation donors. Toronyi E, et al. **Transpl Int** 1998; 11 Suppl 1:S57–9

Quality of life in renal, hepatic, and heart transplant patients. Insensé B, et al. **Transplant Proc** 1999 Sep;31(6):2647–8

Liver transplantation: quality of life related to prognosis. Küchler T. **Transplant Proc** 1999 Feb–Mar;31(1–2):1404–5

Community involvement in the monitoring and evaluation of their children's progress. Morley D. **Trop Doct** 1999 Apr;29(2):70–2

Migration and health in the European Union [see comments] Carballo M, et al. **Trop Med Int Health** 1998 Dec; 3(12):936–44 (79 ref.). Comment in: Trop Med Int Health 1998 Dec;3(12):933–4.

Sociodemographic and health status characteristics with prostate cancer screening in a national cohort of middle-aged male veterans. Eisen SA, et al. **Urology** 1999 Mar;53(3):516–22

Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Lubeck DP, et al. **Urology** 1999 Jan;53(1):180–6

Health of dogs purchased from animal rescue centres [letter; comment] [see comments] DeVile CP. **Vet Rec** 1999 Feb 13;144(7):185. Comment on: Vet Rec 1999 Jan 9;144(2):35–8. Comment in: Vet Rec 1999 Feb 27;144(9):243.

Health of dogs purchased from animal rescue centres [letter; comment] Harding D. **Vet Rec** 1999 Feb 27;144(9):243. Comment on: Vet Rec 1999 Feb 13;144(7):185.

Health of dogs purchased from animal rescue centres [letter; comment] [see comments] Warnett AV. **Vet Rec** 1999 Feb 13;144(7):185. Comment on: Vet Rec 1999 Jan 9;144(2):35–8. Comment in: Vet Rec 1999 Feb 27;144(9):243.

Current estimates from the National Health Interview Survey, 1995. Benson V, et al. **Vital Health Stat 10** 1998 Oct;(199):1–428

Health status in the Caribbean. Has the faculty of medical sciences made a difference? Gibbs WN. **West Indian Med J** 1998 Jun;47(2):41–6

Health status of the elderly in the Marigot Health District, Dominica. Veen-de Vries NR, et al. **West Indian Med J** 1999 Jun;48(2):73–80

Health in Europe 1997. Report on the third evaluation of progress towards health for all in the European Region of WHO (1996–1997). **WHO Reg Publ Eur Ser** 1998; 83:i–vii, 1–90

European food and nutrition policies in action. Introduction. **WHO Reg Publ Eur Ser** 1998;73:1–7

Growing old doesn't mean growing ill. Kennedy M. **WMJ** 1998 Dec;97(11):28–9

For richer, for poorer, in sickness and in health: older widowed women's health, relationships and financial security. Byles JE, et al. **Women Health** 1999;29(1):15–30

The influence of symptoms, age, comorbidity and cancer site on physical functioning and mental health of geriatric women patients. Kurtz ME, et al. **Women Health** 1999; 29(3):1–12

Security and safe havens: health issues among women in mobile homes. Manderson L, et al. **Women Health** 1998; 28(1):83–96

The mental health status of young Hispanic women residing along the border: a twin cities comparison. Russell AY, et al. **Women Health** 1999;28(3):15–32

State profiles on women's health [published erratum appears in Womens Health Issues 1998 Nov–Dec;8(6):following table of contents] **Womens Health Issues** 1998;Suppl:1–209

Gynecologic health consequences to victims of interpersonal violence. Letourneau EJ, et al. **Womens Health Issues** 1999 Mar–Apr;9(2):115–20

Indicators of social and mental health [letter] Indrayan A. **World Health Forum** 1998;19(4):430–1

Health centres—the future of health depends on them. Kahssay HM. **World Health Forum** 1998;19(4):341–7; discussion 348–60 (6 ref.)

Health status of urban and rural elders in Korea. Yoo IY, et al. **Yonsei Med J** 1998 Oct;39(5):417–23

Environmental odours and somatic complaints. Steinheider B. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2–4):101–19

[Study on health status of 3,333 old people in Chengdu City, Sichuan Province] Shi Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):15–7 (Eng. Abstr.) **(Chi)**

[The relationships between the elderly loneliness and its factors of personal attributes, perceived health status and social support] Chang SH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jun; 15(6):337–47 (Eng. Abstr.) **(Chi)**

[Health, life style and living conditions in Greenland. The 1993–1994 Greenland health survey] Bjerregaard P, et al. **Ugeskr Laeger** 1999 Mar 15;161(11):1595–601 (Eng. Abstr.) **(Dan)**

["Sense of coherence", social class and health in a Danish population study] Due EP, et al. **Ugeskr Laeger** 1998 Dec 14;160(51):7424–9 (Eng. Abstr.) **(Dan)**

[Self-reported health and morbidity among adult Danes 1987–1994] Kjøller M, et al. **Ugeskr Laeger** 1999 May 17; 161(20):2948–54 (Eng. Abstr.) **(Dan)**

[Is health of the Danes ailing? (editorial)] Osler M. **Ugeskr Laeger** 1999 May 17;161(20):2926 **(Dan)**

['Public health status and perspectives' 1997. V. Effects of prevention] Jansen J, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1281–5 (Eng. Abstr.) **(Dut)**

['Public health status and perspectives' 1997. VI. Effects of health care] Schouten JS, et al. **Ned Tijdschr Geneeskd** 1998 Jun 6;142(23):1335–8 (Eng. Abstr.) **(Dut)**

[Physical activity in relation to sociodemographic variables and health status of adult men and women in Amsterdam, Doetinchen and Maastricht] Schuit AJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24;143(30):1559–64 (Eng. Abstr.) **(Dut)**

[Influence of pesticide residues on human health] Charlier CJ, et al. **Acta Clin Belg Suppl** 1999;1:44–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Relative importance of domestic pollution and atmospheric pollution on respiratory health] Nouvet G. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S177–8 **(Fre)**

[Indoor pollution and health] Kummer J. **Rev Med Brux** 1998 Sep;19(4):A363–6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Equity in health, between ethics and economy] Berlinguer G. **Rev Med Suisse Romande** 1998 Dec;118(12):989–93 **(Fre)**

[Health status of the populations of the Jura and Neuchatel cantons: evaluation and recommendations for prevention and health promotion] Graz B, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):657–60 (Eng. Abstr.) **(Fre)**

[Physicians' role in prevention and health promotion policy: canton reports on health status] Raynault MF, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):653–6 (Eng. Abstr.) **(Fre)**

[Health and pain] Vannotti M, et al. **Rev Med Suisse Romande** 1999 Apr;119(4):255–7 **(Fre)**

[Self-administered health questionnaire in the 8th school year] Woringer V. **Rev Med Suisse Romande** 1998 Nov; 118(11):969–73 **(Fre)**

[Tobacco, students, education and health] Chabot JM. **Rev Prat** 1999 Jan 1;49(1):70–1 **(Fre)**

[Centenarians: exceptional elderly?] Martin JP. **Rev Prat** 1998 Jan 15;48(2):121–3 (11 ref.) **(Fre)**

[Health and environment in Villeurbanne. Opinions of the population] Beyragued L, et al. **Sante Publique** 1998 Dec; 10(4):385–99 (Eng. Abstr.) **(Fre)**

[A general measure of well-being: outline of a quantitative approach] Bréda J, et al. **Sante Publique** 1999 Jun; 11(2):103–26 (Eng. Abstr.) **(Fre)**

[Animal rights and animal health on ecological farms] Hörning B. **DTW Dtsch Tierarztl Wochenschr** 1998 Aug; 105(8):313–21 (80 ref.) (Eng. Abstr.) **(Ger)**

[Effect of pets on human health: is there a correlation?] Alonso Y. **Gesundheitswesen** 1999 Jan;61(1):45–9 (Eng. Abstr.) **(Ger)**

[Health of school beginners] Ellsässer G. **Gesundheitswesen** 1998 Nov;60(11):632–7 (Eng. Abstr.) **(Ger)**

[Housing and health] Fiedler K. **Gesundheitswesen** 1998 Nov; 60(11):656–60 (5 ref.) (Eng. Abstr.) **(Ger)**

[Health situation of refugee children in Münster] Gardemann J, et al. **Gesundheitswesen** 1998 Nov;60(11):686–93 (53 ref.) (Eng. Abstr.) **(Ger)**

[Population health and development] Gostomzyk JG. **Gesundheitswesen** 1999 Feb;61(2):53–6 **(Ger)**

[Lifestyle, living conditions and health status—a cross-sectional study of the Saxon population in the period 1993 to 1994] Schuster S, et al. **Gesundheitswesen** 1999 Mar; 61(3):122–9 (Eng. Abstr.) **(Ger)**

[Attitudes and health status as determinants of participation in individually oriented health promotion] Wanek V, et al. **Gesundheitswesen** 1999 Jul;61(7):346–52 (Eng. Abstr.) **(Ger)**

[The tumor-cahexy syndrome. Poor general health—a complex problem] **Radiologe** 1998 Oct;38(10 Suppl):1–4 **(Ger)**

[Female life courses and health—results of a study of national survey data of 50–69-year-old women in East and West Germany] Bammann K, et al. **Soz Praventivmed** 1999; 44(2):65–77 (Eng. Abstr.) **(Ger)**

[Is subjective health status a good predictor of work resumption?] Weber A, et al. **Soz Praventivmed** 1998; 43(4):177–84 (Eng. Abstr.) **(Ger)**

[Comments on the topic of attesting to health status at arrest during medical emergency care] Allert S, et al. **Unfallchirurg** 1999 Feb;102(2):145–9 (Eng. Abstr.) **(Ger)**

[Study of the health status of subjects born with medical-assisted reproduction: the connexion between epidemiology and bioethics] Spagnolo A, et al. **Ann Ist Super Sanita** 1998;34(2):227–31 (Eng. Abstr.) **(Ita)**

[Nutritional status and dietary habits of children in the Province of Modena] Balli F, et al. **Pediatr Med Chir** 1999 Jan–Feb;21(1):13–7 (Eng. Abstr.) **(Ita)**

[Characteristics of the medical status and living conditions of the homeless registered as tuberculosis patients in Nagoya City] Yamanaka K, et al. **Kekkaku** 1999 Feb; 74(2):99–105 (Eng. Abstr.) **(Jpn)**

[Effects on health status in students from attending a "juku"] Iijima K, et al. **Nippon Koshu Eisei Zasshi** 1999 May; 46(5):343–50 (Eng. Abstr.) **(Jpn)**

[The effects of low intensity aerobic training on the physiological indexes and the quality of life in middle-aged white collar workers] Chikuji K, et al. **Sangyo Eiseigaku Zasshi** 1999 May;41(3):63–71 (Eng. Abstr.) **(Jpn)**

[Characteristics of work, life and health analyzed in a survey of a hundred thousand employees of small companies and self-employed persons] Hirose T, et al. **Sangyo Eiseigaku Zasshi** 1998 Sep;40(5):222–6 (Eng. Abstr.) **(Jpn)**

[Effects of aging on psychological and physiological function: differences in tree test, GHQ (general health questionnaire), aspiration task, and cardiovascular parameters] Sasaki N, et al. **Shinrigaku Kenkyu** 1998 Aug;69(3):229–34 (Eng. Abstr.) **(Jpn)**

[Assessment of patients' health status—review of the literature and assessment methods] Andreassen S, et al. **Nord Med** 1998 Dec;113(10):360–2 (31 ref.) (Eng. Abstr.) **(Nor)**

[Adolescents and health] Aarø LE. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2316 **(Nor)**

[Health of the pilots and flight safety] Arva PH. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3643–5 (Eng. Abstr.) **(Nor)**

[Experience of family break-up during childhood—health and health behavior in adolescence] Breidablik HJ, et al. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2331–5 (Eng. Abstr.) **(Nor)**

[War and health failure] Forsdahl A. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2455 **(Nor)**

[Home-brew and hillbilly culture: attitudes, hypocrisy and health] Hagestad K. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2007 **(Nor)**

[Migration and health—the connection?] Larsen O. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3748 **(Nor)**

[Social inequality and health from a historical point of view] Larsen O. **Tidsskr Nor Laegeforen** 1999 Jun 10; 119(15):2235–7 **(Nor)**

[Freedom in a little box] Lie AK. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1471–3 (Eng. Abstr.) **(Nor)**

[Significance of migration patterns on self-evaluated health among Norwegian women aged 34–69 years (see comments)] Lund E, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3752–5 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1998 Nov 20;118(28):4414. **(Nor)**

[Food and health—an international perspective] Norum KR, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3103 **(Nor)**

[Trans-fatty acids and health] Pedersen JI, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3474–80 (58 ref.) (Eng. Abstr.) **(Nor)**

[Women from Northern Norway as a negatively selected group (letter; comment)] Salvesen R. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4414. Comment on: Tidsskr Nor Laegeforen 1998 Oct 10;118(24):3752–5. **(Nor)**

[Food, ecology and public health—over all boundaries?] Westin S. **Tidsskr Nor Laegeforen** 1998 Sep 20; 118(22):3483–7 (21 ref.) **(Nor)**

[Health aid for Eastern Europe—the Eurohealth program and Norwegian contribution] Wium P. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1489–91 (Eng. Abstr.) **(Nor)**

[Clinimetrics in parkinsonism] Opara J. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1497–511 (29 ref.) (Eng. Abstr.) **(Pol)**

[On the healthy male aging: hormonal aspects] Mędraś M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):208–10 (22 ref.) (Eng. Abstr.) **(Pol)**

[The assessment of the functional state of elderly people by family physician with the help of EASY-Care questionnaire] Wojszel ZB, et al. **Pol Merkuriusz Lek** 1999

Mar;6(33):167–70 (Eng. Abstr.) **(Pol)**

[Diagnosis of healthy and depressed patients based on their speech patterns] Frolov MV, et al. **Aviakosm Ekolog Med** 1999;33(2):59–64 (Eng. Abstr.) **(Rus)**

[Mental working capacity and health status of young schoolchildren, taught according to various pedagogic systems] Antropova MV, et al. **Fiziol Cheloveka** 1998 Sep–Oct;24(5):80–4 **(Rus)**

[Effect of periodic hypoxia and the drug ABISIB on man's state and working capacity] Bushov IuV, et al. **Fiziol Cheloveka** 1998 Sep–Oct;24(5):111–5 **(Rus)**

[The chronobiological monitoring of health status and the cleanliness of the environment] Halberg F, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):84–90 **(Rus)**

[The health status of pupils in the middle grades of a high school of the arts] Burkhanov AI, et al. **Gig Sanit** 1999 May–Jun;(3):42–5 **(Rus)**

[Industrial hygiene and the health status of workers on track power-driven equipment] Kaptsov VA, et al. **Gig Sanit** 1999 Jan–Feb;(1):19–21 (Eng. Abstr.) **(Rus)**

[The evaluation of the working conditions and of the health status of workers in steam-flushing yards] Kaptsov VA, et al. **Gig Sanit** 1999 Mar–Apr;(2):12–6 **(Rus)**

[The evaluation of the effect of chemical and radiation factors on the health of the population in an industrial city] Konyshina LG, et al. **Gig Sanit** 1999 Mar–Apr;(2):37–40 (Eng. Abstr.) **(Rus)**

[An estimation of the effect of low doses of irradiation on the population in the area of the eastern Urals radioactive trace on the health status of offspring] Nasybullina GM, et al. **Gig Sanit** 1999 May–Jun;(3):18–20 (Eng. Abstr.) **(Rus)**

[The hygienic tasks in support of the epidemiological-health wellbeing of the population at the current stage (editorial)] Onishchenko GG. **Gig Sanit** 1999 Jan–Feb;(1):3–8 **(Rus)**

[The effect of their life style and ecological factors on the health status of pre-draft-age youth] Rakhmanov RS, et al. **Gig Sanit** 1999 Mar–Apr;(2):19–21 (Eng. Abstr.) **(Rus)**

[Health status of children and adolescents and risk factors in a geographic endemic area] Sakharev AG, et al. **Gig Sanit** 1999 Jul–Aug;(4):33–5 (Eng. Abstr.) **(Rus)**

[Assessing the health status of workers by using chemiluminescent study methods] Shakirov DF, et al. **Gig Sanit** 1999 May–Jun;(3):36–9 (Eng. Abstr.) **(Rus)**

[Experience in conducting research in the social hygiene monitoring system] Shishkina LI, et al. **Gig Sanit** 1999 May–Jun;(3):74–6 **(Rus)**

[Industrial health and the health status of trolley bus drivers] Svidovyĭ VI, et al. **Gig Sanit** 1999 May–Jun;(3):31–3 **(Rus)**

[The effect of the biological factors of an industrial environment on the health status of workers] Krasniuk EP, et al. **Lik Sprava** 1999 Jan–Feb;(1):11–8 (31 ref.) **(Rus)**

[The effect of Biotrit balsam and Biotrit C on the level of health] Sukmanskiĭ OI, et al. **Lik Sprava** 1999 Mar;(2):123–6 (Eng. Abstr.) **(Rus)**

[Aspects of healthy humans' response to hyperthermia] Andreeva LI, et al. **Med Tr Prom Ekol** 1999;(6):22–6 (Eng. Abstr.) **(Rus)**

[The dynamic indices of the body functional state in engineering and technical workers with different health statuses] Kharabadzhakh'ian AV, et al. **Med Tr Prom Ekol** 1998;(11):43–6 **(Rus)**

[Results and goals of scientific research on "Work and health of medical personnel"] Korotich LP. **Med Tr Prom Ekol** 1998;(8):35–9 **(Rus)**

[Quantitative evaluation of ecologically determined health risk among the population of industrial areas (on the example of the city of Angarsk)] Prusakov VM, et al. **Med Tr Prom Ekol** 1999;(5):12–20 (Eng. Abstr.) **(Rus)**

[The health status assessment in miners and metal workers based on immunological and bacteriological criteria] Trunova OA. **Med Tr Prom Ekol** 1999;(2):22–6 (Eng. Abstr.) **(Rus)**

[Health potential as a positive criterion in comprehensive assessment of the health status of workers engaged in tungsten plant] Flek VO, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):23–7 (Eng. Abstr.) **(Rus)**

[Social and hygienic characteristics of health of young athletes] Kasymova GP, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):21–4 (Eng. Abstr.) **(Rus)**

[Patients' opinions of their health status and the results of medical care] Kitsul IS. **Probl Sotsialnoi Gig Istor Med** 1998 Jul–Aug;(4):7–8 (Eng. Abstr.) **(Rus)**

[Systematic model of the sanologic status of children and adolescents] Simonov SN. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):27–30 (Eng. Abstr.) **(Rus)**

[Subjective evaluation of health status and motivation for improving it in able-bodied urban population of the European North of Russia] Viaz'min AM, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):19–23 (Eng. Abstr.) **(Rus)**

[Guarding the health of the border guards] Filipenko BM. **Voen Med Zh** 1999 May;320(5):4–7 **(Rus)**

[The health status of civilians subject to the draft for military service and the measures to improve the recruitment build-up of the Armed Forces of the Russian Federation] Kulikov VV, et al. **Voen Med Zh** 1998 Aug;319(8):18–20 **(Rus)**

[The immunological health of flight personnel: the concept and the approaches to its assessment] Ushakov IB, et al. **Voen Med Zh** 1998 Dec;319(12):43–50 **(Rus)**

[The weather and the human body] Grigor'ev II, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep–Oct;(5):53–6 **(Rus)**

[Data from an expedition to study a Siberian vegan settlement] Medkova IL, et al. **Vopr Pitan** 1998;(3):3–7 (Eng. Abstr.) **(Rus)**

[Social characteristics and health status of children entering foster care centers] Oliván Gonzalvo G. **An Esp Pediatr** 1999 Feb;50(2):151–5 (Eng. Abstr.) **(Spa)**

[High rate of early hospitalization in healthy newborns] Romero Sánchez J, et al. **An Esp Pediatr** 1999 May; 50(5):479–84 (Eng. Abstr.) **(Spa)**

[Gender differences in the influence of housework on health (see comments) Artazcoz L, et al. **Gac Sanit** 1999 May–Jun; 13(3):201–7 (Eng. Abstr.). Comment in: Gac Sanit 1999 May–Jun;13(3):173–6. **(Spa)**

[Chronic obstructive airways disease and perceived health (editorial)] Alonso J, et al. **Med Clin (Barc)** 1998 Nov 7; 111(15):580–2 (58 ref.) **(Spa)**

[Quality of life in relation to health and obesity in a primary care center] Barajas Gutiérrez MA, et al. **Rev Esp Salud Publica** 1998 May–Jun;72(3):221–31 (Eng. Abstr.) **(Spa)**

[Evaluation of health status using Survey SF-36: preliminary results in Mexico] Zúniga MA, et al. **Salud Publica Mex** 1999 Mar–Apr;41(2):110–8 (Eng. Abstr.) **(Spa)**

[Swedes living in costal regions are healthier and live longer. The Roseto effect in Finland? (letter)] Hyyppä MT. **Lakartidningen** 1999 May 19;96(20):2453 **(Swe)**

[The effect of ecological and microbiological factors on the health status of pregnant women with pyelonephritis and on their newborn infants] Iashchukevych MIe. **Lik Sprava** 1999 Apr–May;(3):42–4 (Eng. Abstr.) **(Ukr)**

[The working, life style and health conditions of welders (social hygiene research)] Matsko NV. **Lik Sprava** 1998 Jun;(4):133–5 (Eng. Abstr.) **(Ukr)**

[The current health status of the adolescents and young people of Ukraine and the measures for its maintenance and improvement] Nahorna AM, et al. **Lik Sprava** 1998 Oct–Nov;(7):177–81 **(Ukr)**

[An epidemiological analysis of the health status of the participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station] Ponomarenko VM, et al. **Lik Sprava** 1998 Dec;(8):39–41 (Eng. Abstr.) **(Ukr)**

HEALTH STATUS INDEX see **HEALTH STATUS INDICATORS**

HEALTH STATUS INDICATORS

Trends in safe driving behaviors and in relation to trends in health maintenance behaviors in the USA: 1985–1995. Shinar D, et al. **Accid Anal Prev** 1999 Sep;31(5):497–503

Evaluation of the quality of life of male snorers using the Nottingham Health Profile. Löth S, et al. **Acta Otolaryngol (Stockh)** 1998 Sep;118(5):723–7

Boys have more health problems in childhood than girls: follow-up of the 1987 Finnish birth cohort. Gissler M, et al. **Acta Paediatr** 1999 Mar;88(3):310–4

Nursery Neurobiologic Risk Score and outcome at 18 months. Lefebvre F, et al. **Acta Paediatr** 1998 Jul; 87(7):751–7

Estimating changes in unrecorded alcohol consumption in Norway using indicators of harm. Norström T. **Addiction** 1998 Oct;93(10):1531–8

Maternal mortality in Nigeria: the real issues. Harrison KA. **Afr J Reprod Health** 1997 Mar;1(1):7–13 (8 ref.)

Economic development and reproductive health in Africa [editorial] Okonofua F. **Afr J Reprod Health** 1997 Sep; 1(2):6–9 **(Eng, Fre)**

Validity and reliability of the Medical Outcomes Study Short Form-20 questionnaire as a measure of quality of life in elderly people living at home. Carver DJ, et al. **Age Ageing** 1999 Mar;28(2):169–74

Development of an activities of daily living scale to screen for dementia in an illiterate rural older population in India. Fillenbaum GG, et al. **Age Ageing** 1999 Mar;28(2):161–8

Developing a summary measure of medical status. Fillenbaum GG, et al. **Aging (Milano)** 1998 Oct;10(5):395–400

Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Shaw M, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1067–78

MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Daeppen JB, et al. **Am J Drug Alcohol Abuse** 1998 Nov;24(4):685–94

Rural epidemiology: insights from a rural population laboratory. Pearson TA, et al. **Am J Epidemiol** 1998 Nov 15;148(10):949–57

Health status versus quality of life in older patients: does the distinction matter? Covinsky KE, et al. **Am J Med** 1999 Apr;106(4):435–40

Morbidity assessment index for newborns: a composite tool for measuring newborn health. Verma A, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):701–8

Functional status of cortical and subcortical nonhemorrhagic stroke survivors and the effect of lesion laterality. Chae J, et al. **Am J Phys Med Rehabil** 1998 Sep–Oct;77(5):415–20

Functional outcomes of patients with multiple limb trauma. Czyrny JJ, et al. **Am J Phys Med Rehabil** 1998 Sep–Oct; 77(5):407–11

Uniform Data System for Medical Rehabilitation: report of first admissions for 1997. Fiedler RC, et al. **Am J Phys Med Rehabil** 1998 Sep–Oct;77(5):444–50

Risk factors for excess mortality in Harlem. Findings from the Harlem Household Survey. Fullilove RE, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):22–8

Health risk influence on medical care costs and utilization among 2,898 municipal employees. Weaver MT, et al. **Am J Prev Med** 1998 Oct;15(3):250–3

Rigorous statistical reliability, validity, and responsiveness testing of the Cincinnati knee rating system in 350 subjects with uninjured, injured, or anterior cruciate ligament-reconstructed knees. Barber-Westin SD, et al. **Am J Sports Med** 1999 Jul–Aug;27(4):402–16

Classification trees. A possible method for iso-resource grouping in intensive care. Ridley S, et al. **Anaesthesia** 1998 Sep;53(9):833–40

A call for caution in the interpretation of the observed smaller relative importance of risk factors in the elderly [editorial; comment] Howard G, et al. **Ann Epidemiol** 1998 Oct; 8(7):411–4 (13 ref.). Comment on: Ann Epidemiol 1998 Oct;8(7):415–21.

The Michigan Hand Outcomes Questionnaire (MHQ): assessment of responsiveness to clinical change. Chung KC, et al. **Ann Plast Surg** 1999 Jun;42(6):619–22

Rasch analysis of the Western Ontario MacMaster questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Wolfe F, et al. **Ann Rheum Dis** 1999 Sep;58(9):563–8

Health status assessment methods for adults: past accomplishments and future challenges. McHorney CA. **Annu Rev Public Health** 1999;20:309–35 (120 ref.)

Validation of an asthma symptom diary for interventional studies. Santanello NC, et al. **Arch Dis Child** 1999 May; 80(5):414–20

Performance of health-related quality-of-life instruments in a spinal cord injured population. Andresen EM, et al. **Arch Phys Med Rehabil** 1999 Aug;80(8):877–84

Health related quality of life in patients with total hip or knee replacement. Shields RK, et al. **Arch Phys Med Rehabil** 1999 May;80(5):572–9

Quality of life and traumatic spinal cord injury. Westgren N, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1433–9

Use of the SF-36 [letter; comment] Weber SC. **Arthroscopy** 1999 Mar;15(2):232–4. Comment on: Arthroscopy 1998 Mar;14(2):127–9.

Electromagnetic compatibility study of the in-vitro interaction of wireless phones with cardiac pacemakers. Schlegel RE, et al. **Biomed Instrum Technol** 1998 Nov–Dec; 32(6):645–55

Clinical engineers have a role to play in risk management. Shepherd M. **Biomed Instrum Technol** 1998 Nov–Dec; 32(6):605–6

Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis [see comments] Kennedy BP, et al. **BMJ** 1998 Oct 3; 317(7163):917–21. Comment in: BMJ 1999 May 22;318(7195):1417–8.

Use of health services by children. Objective measures of health status are essential [letter; comment] Leung WC. **BMJ** 1999 Mar 27;318(7187):877. Comment on: BMJ 1998 Oct;317(7165):1047–51.

Severe acute maternal morbidity: a pilot study of a definition of a near-miss [letter; comment] Penny J. **Br J Obstet Gynaecol** 1999 Apr;106(4):397. Comment on: Br J Obstet Gynaecol 1998 Sep;105(9):985–90.

Health expectancy indicators. Robine JM, et al. **Bull World Health Organ** 1999;77(2):181–5

Modelling the community as a determinant of health. Birch S, et al. **Can J Public Health** 1998 Nov–Dec;89(6):402–5

Population health: determinants and interventions [editorial] Edwards N. **Can J Public Health** 1999 Jan–Feb;90(1):10–1 **(Eng, Fre)**

Life expectancy at birth at the local level in Ontario. Manuel DG, et al. **Can J Public Health** 1999 Jan–Feb;90(1):52–4

The development of self-rated health during adolescence: an exploration of inter- and intra-cohort effects. Wade TJ, et al. **Can J Public Health** 1999 Mar–Apr;90(2):90–4

The lifestyle assessment questionnaire: an instrument to measure the impact of disability on the lives of children with cerebral palsy and their families. Mackie PC, et al. **Child Care Health Dev** 1998 Nov;24(6):473–86

Evaluating functional outcome in patients with lower extremity sarcoma. Davis AM, et al. **Clin Orthop** 1999 Jan; (358):90–100

Generic health status measures are unsuitable for measuring health status in severely disabled people. Kersten P, et al. **Clin Rehabil** 1999 Jun;13(3):219–28

Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. Sitzia J, et al. **Clin Rehabil** 1998 Oct;12(5):389–94

The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. Senerdem N, et al. **Clin Rheumatol** 1999;18(1):33–7

Using the ALPHA form in practice to assess antenatal psychosocial health. Antenatal Psychosocial Health Assessment. Reid AJ, et al. **CMAJ** 1998 Sep 22; 159(6):677–84

Assessing oral health outcomes for orthodontics--measuring health status and quality of life. O'Brien K, et al. **Community Dent Health** 1998 Mar;15(1):22–6

Improvement in quality of life during 5 years after coronary artery bypass grafting. Herlitz J, et al. **Coron Artery Dis** 1998;9(8):519–26

Validation of the spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease. López-Vivancos J, et al. **Digestion** 1999; 60(3):274–80

Changing demographic and vital statistics patterns in the region during the past 50 years. Hammoud EI. **East Mediterr Health J** 1998;4 Suppl:S58–65

The Spanish Version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31): translation, validity, and reliability. Torres X, et al. **Epilepsia** 1999 Sep;40(9):1299–304

Measuring quality of life in patients with coronary heart disease. Thompson DR, et al. **Eur Heart J** 1998 May; 19(5):693–5

Applicability of the Health Utilities Index to a population of childhood survivors of central nervous system tumours in the U.K. Glaser AW, et al. **Eur J Cancer** 1999 Feb; 35(2):256–61

The inter-rate reliability of a generic measure of severity of illness. Shiels C, et al. **Fam Pract** 1997 Dec;14(6):466–71

Cardiovascular health check in the elderly in one general practice: does it offer new information and lead to interventions? van den Berg PJ, et al. **Fam Pract** 1999 Aug; 16(4):389–94

A multinational study of the factorial structure and other characteristics of the Dartmouth COOP Functional Health Assessment Charts/WONCA. Westbury RC, et al. **Fam Pract** 1997 Dec;14(6):478–85

Validation of a specific quality of life questionnaire for functional digestive disorders [see comments] Chassany O, et al. **Gut** 1999 Apr;44(4):527–33. Comment in: Gut 1999 Apr;44(4):450–1.

The quality of quality of life [comment] Irvine EJ. **Gut** 1999 Apr;44(4):450–1. Comment on: Gut 1999 Apr;44(4):527–33.

On the measurement of the nation's equity adjusted health. Lindholm L, et al. **Health Econ** 1998 Nov;7(7):621–8

Health and mortality of the elderly: the grade of membership method, classification and determination. Portrait F, et al. **Health Econ** 1999 Aug;8(5):441–57

Income inequality and health: pathways and mechanisms. Kawachi I, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):215–27 (42 ref.)

Medical outcomes study short form 36: testing and cross-validating a second-order factorial structure for health system employees. Reed PJ. **Health Serv Res** 1998 Dec;33(5 Pt 1):1361–80

Empirically defined health states for depression from the SF-12. Sugar CA, et al. **Health Serv Res** 1998 Oct;33(4 Pt 1):911–28

The health of children. Szilagyi PG, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1001–39 (97 ref.)

A review of the use of health status measures in economic evaluation. Brazier J, et al. **Health Technol Assess** 1999; 3(9):i–iv, 1–164 (1135 ref.)

No anaesthetic: the best anaesthetic? **Hosp Med** 1999 Jun; 60(6):458

Malariometry in district Ratnagiri during 1988–1993. Jotkar R, et al. **Indian J Public Health** 1997 Apr-Jun;41(2):36–42

A multifactorial health risk questionnaire. Valty J, et al. **Int Arch Occup Environ Health** 1999 Jan;72 Suppl:S6–7

Circumpolar health: science and health--what is missing? Foege W. **Int J Circumpolar Health** 1998;57 Suppl 1:15–8

Maintaining public health into the 21st century: the impact of poverty, privatization, and politics. Sidel VW. **Int J Circumpolar Health** 1998;57 Suppl 1:19–22

Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59–81 (127 ref.)

Income inequality, social cohesion, and health: clarifying the theory--a reply to Muntaner and Lynch. Wilkinson RG. **Int J Health Serv** 1999;29(3):525–43

Distribution of waist-to-hip ratio, other indices of body fat distribution and obesity and associations with HDL cholesterol in children and young adults aged 4–19 years: The Third National Health and Nutrition Examination Survey. Gillum RF. **Int J Obes Relat Metab Disord** 1999 Jun;23(6):556–63

Implementing the SF-12 in an inner-city clinic: the importance of providing help. Jacobson JW, et al. **Int J Qual Health Care** 1998 Aug;10(4):355–6

Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Glick HA, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):419–30

A primer on lower extremity outcome measurement instruments. Saltzman CL, et al. **Iowa Orthop J** 1998; 18:101–11 (35 ref.)

Measuring excess risk of child mortality: an exploration of DHS I for Burundi, Uganda and Zimbabwe. McMurray C. **J Biosoc Sci** 1997 Jan;29(1):73–91

Short musculoskeletal function assessment questionnaire: validity, reliability, and responsiveness. Swiontkowski MF, et al. **J Bone Joint Surg Am** 1999 Sep;81(9):1245–60

Evaluating cataract surgery gains by assessing patients' quality of life using the VF-7. Uusitalo RJ, et al. **J Cataract Refract Surg** 1999 Jul;25(7):989–94

Special issue. Translating functional health and well-being: International Quality of Life Assessment (IQOLA) Project Studies of the SF-36 Health Survey. Issue dedicated to Denis Bucquet. **J Clin Epidemiol** 1998 Nov;51(11):891–1214

Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. Aaronson NK, et al. **J Clin Epidemiol** 1998 Nov;51(11):1055–68

Testing the measurement properties of the Spanish version of the SF-36 Health Survey among male patients with chronic obstructive pulmonary disease. Quality of Life in COPD Study Group. Alonso J, et al. **J Clin Epidemiol** 1998 Nov;51(11):1087–94

The Italian SF-36 Health Survey: translation, validation and norming. Apolone G, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1025–36

Tests of data quality, scaling assumptions, and reliability of the Danish SF-36. Bjorner JB, et al. **J Clin Epidemiol** 1998 Nov;51(11):1001–11

Differential item functioning in the Danish translation of the SF-36. Bjorner JB, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1189–202

The Danish SF-36 Health Survey: translation and preliminary validity studies. Bjorner JB, et al. **J Clin Epidemiol** 1998 Nov;51(11):991–9

Deriving a preference-based single index from the UK SF-36 Health Survey. Brazier J, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1115–28

Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. Bullinger M, et al. **J Clin Epidemiol** 1998 Nov;51(11):913–23

Evaluation of a multidimensional measure of dyspepsia-related health for use in a randomized clinical trial. Cook KF, et al. **J Clin Epidemiol** 1999 May; 52(5):381–92

Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. Fukuhara S, et al. **J Clin Epidemiol** 1998 Nov;51(11):1037–44

Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. Fukuhara S, et al. **J Clin Epidemiol** 1998 Nov;51(11):1045–53

Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. Gandek B, et al. **J Clin Epidemiol** 1998 Nov;51(11):1171–8

Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. Gandek B, et al. **J Clin Epidemiol** 1998 Nov;51(11):1149–58

Methods for validating and norming translations of health status questionnaires: the IQOLA Project approach. International Quality of Life Assessment. Gandek B, et al. **J Clin Epidemiol** 1998 Nov;51(11):953–9

Health status measurement in Toxic Oil Syndrome. Gómez de la Cámara A, et al. **J Clin Epidemiol** 1998 Oct; 51(10):867–73

Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. Grover SA, et al. **J Clin Epidemiol** 1999 Jan;52(1):49–55

Testing the equivalence of translations of widely used response choice labels: results from the IQOLA Project. International Quality of Life Assessment. Keller SD, et al. **J Clin Epidemiol** 1998 Nov;51(11):933–44

Use of structural equation modeling to test the construct validity of the SF-36 Health Survey in ten countries: results from the IQOLA Project. International Quality of Life Assessment. Keller SD, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1179–88

The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. Krabbe PF, et al. **J Clin Epidemiol** 1999 Apr;52(4):293–301

Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures. Kvien TK, et al. **J Clin Epidemiol** 1998 Nov;51(11):1077–86

Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey. Lam CL, et al. **J Clin Epidemiol** 1998 Nov;51(11):1139–47

The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. Leplège A, et al. **J Clin Epidemiol** 1998 Nov;51(11):1013–23

Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. Loge JH, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1069–76

An examination of self- and telephone-administered modes of administration for the Australian SF-36. Perkins JJ, et al. **J Clin Epidemiol** 1998 Nov;51(11):969–73

The Swedish SF-36 Health Survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. Persson LO, et al. **J Clin Epidemiol** 1998 Nov;51(11):1095–103

Proxy use of the Canadian SF-36 in rating health status of the disabled elderly. Pierre U, et al. **J Clin Epidemiol** 1998 Nov;51(11):983–90

Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: results from the IQOLA Project. International Quality of Life Assessment. Raczek AE, et al. **J Clin Epidemiol** 1998 Nov;51(11):1203–14

Testing Dutch and French translations of the SF-36 Health Survey among Belgian angina patients. Razavi D, et al. **J Clin Epidemiol** 1998 Nov;51(11):975–81

Translation and psychometric evaluation of a Chinese version of the SF-36 Health Survey in the United States. Ren XS, et al. **J Clin Epidemiol** 1998 Nov;51(11):1129–38

Adaptation and validation of the SF-36 Health Survey for use in Australia. Sanson-Fisher RW, et al. **J Clin Epidemiol** 1998 Nov;51(11):961–7

The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. Sullivan M, et al. **J Clin Epidemiol** 1998 Nov; 51(11):1105–13

Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment. Wagner AK, et al. **J Clin Epidemiol** 1998 Nov;51(11):925–32

Methods for testing data quality, scaling assumptions, and reliability: the IQOLA Project approach. International Quality of Life Assessment. Ware JE Jr, et al. **J Clin Epidemiol** 1998 Nov;51(11):945–52

The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. Ware JE Jr, et al. **J Clin Epidemiol** 1998 Nov;51(11):1159–65

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Ware JE Jr, et al. **J Clin Epidemiol** 1998 Nov;51(11):903–12

The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. Ware JE Jr, et al. **J Clin Epidemiol** 1998 Nov;51(11):1167–70

The big cities health inventory, 1997. Benbow N, et al. **J Community Health** 1998 Dec;23(6):471–89

Algorithms for resource allocation of substance abuse prevention funds based on social indicators: a case study on state of Florida--Part 3. Kim S, et al. **J Drug Educ** 1998;28(4):283–306

The choice of deprivation in measuring poorer health in Northamptonshire. Bradley PM. **J Epidemiol Community Health** 1999 Mar;53(3):189–90

Design, objectives, and lessons from a pilot 25 year follow up re-survey of survivors in the Whitehall study of London Civil Servants. Clarke R, et al. **J Epidemiol Community Health** 1998 Jun;52(6):364–9

Do housing tenure and car access predict health because they are simply markers of income or self esteem? A Scottish study. Macintyre S, et al. **J Epidemiol Community Health** 1998 Oct;52(10):657–64

The Short-Form 36 and older people: some problems encountered when using postal administration. Mallinson S. **J Epidemiol Community Health** 1998 May;52(5):324–8

Behavioural and biological correlates of physical functioning in middle aged office workers: the UK whitehall II study. Stafford M, et al. **J Epidemiol Community Health** 1998 Jun; 52(6):353–8

Action research--a model for introducing standardized health assessment in general practice: an exploratory study. Meadows KA, et al. **J Eval Clin Pract** 1998 Aug;4(3):225–9

Income inequality, primary care, and health indicators. Shi L, et al. **J Fam Pract** 1999 Apr;48(4):275–84

Measures of functional status in community-dwelling elders. Sherman SE, et al. **J Gen Intern Med** 1998 Dec; 13(12):817–23

Reliability of a patient-rated forearm evaluation questionnaire for patients with lateral epicondylitis. Overend TJ, et al. **J Hand Ther** 1999 Jan-Mar;12(1):31–7

Relationships between socioeconomic status and race-specific cervical cancer incidence in the United States, 1973–1992. Liu T, et al. **J Health Care Poor Underserved** 1998 Nov;9(4):420–32

Health screening for people with Down's syndrome. Piachaud J, et al. **J Intellect Disabil Res** 1998 Oct;42 (Pt 5):341–5

"Healthometer"--an instrument for self-distributed health screening and prevention in the population. Späng L, et al. **J Med Syst** 1998 Oct;22(5):339–55

The European Amyotrophic Lateral Sclerosis Health Profile Study. ALS-HPS Steering Group. Jenkinson C, et al. **J Neurol Sci** 1998 Oct;160 Suppl 1:S122–6

Rasch measurement for reducing the items of the Nottingham Health Profile. Prieto L, et al. **J Outcome Meas** 1998; 2(4):285–301

Improving health outcomes--a review of case studies from English health authorities. McColl A, et al. **J Public Health Med** 1998 Sep;20(3):302–11 (24 ref.)

Equality of health: dream or reality? Acheson D. **J R Coll Physicians Lond** 1999 Jan-Feb;33(1):70–7

A Black look at the independent inquiry into inequalities in health. Black D. **J R Coll Physicians Lond** 1999 Mar-Apr; 33(2):148–9

Generic health instruments, visual analog scales, and the measurement of clinical phenomena [editorial; comment] Graham B. **J Rheumatol** 1999 May;26(5):1022–3. Comment on: J Rheumatol 1999 May;26(5):1163–6.

Responsiveness of health status instruments to changes in

articular status and perceived health in patients with psoriatic arthritis. Husted JA, et al. **J Rheumatol** 1998 Nov; 25(11):2146–55

Pediatric Escola Paulista de Medicina Range of Motion Scale: a reduced joint count scale for general use in juvenile rheumatoid arthritis. Len C, et al. **J Rheumatol** 1999 Apr; 26(4):909–13

Generic health instruments do not comprehensively capture patient perceived improvement in patients with carpal tunnel syndrome [see comments] Vaile JH, et al. **J Rheumatol** 1999 May;26(5):1163–6. Comment in: J Rheumatol 1999 May;26(5):1022–3.

Assessing the reliability and responsiveness of 5 shoulder questionnaires. Beaton D, et al. **J Shoulder Elbow Surg** 1998 Nov–Dec;7(6):565–72

Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Tangelder MJ, et al. **J Vasc Surg** 1999 May; 29(5):913–9

Capturing the patient's view of change as a clinical outcome measure. Fischer D, et al. **JAMA** 1999 Sep 22–29; 282(12):1157–62

A comparative review of two screening instruments: the Aga Khan University Anxiety and Depression Scale and the self reporting questionnaire. Ali BS, et al. **JPMA J Pak Med Assoc** 1998 Mar;48(3):79–82

Body condition scoring: a rapid and accurate method for assessing health status in mice. Ullman-Culleré MH, et al. **Lab Anim Sci** 1999 Jun;49(3):319–23

Cultural invariance of likelihood ratios for the General Health Questionnaire [letter] Furukawa T, et al. **Lancet** 1999 Feb 13;353(9152):561–2

Measuring the burden of disease [letter; comment] Morrow RH, et al. **Lancet** 1998 Dec 5;352(9143):1859–61. Comment on: Lancet 1998 Sep 5;352(9130):757–8.

Health care in Burma [letter; comment] Wakai S. **Lancet** 1998 Oct 10;352(9135):1230. Comment on: Lancet 1998 Aug 15;352(9127):556.

Determining correspondence between scores on the EQ-5D "thermometer" and a 5-point categorical rating scale. Badia Llach X, et al. **Med Care** 1999 Jul;37(7):671–7

The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials. Keller SD, et al. **Med Care** 1999 May;37(5 Suppl):MS51–60

Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview. Keller SD, et al. **Med Care** 1999 May;37(5 Suppl):MS1–9 (77 ref.)

The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Kosinski M, et al. **Med Care** 1999 May;37(5 Suppl):MS10–22

The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Kosinski M, et al. **Med Care** 1999 May;37(5 Suppl):MS23–39

Associations between health status and utilities implications for policy. Lenert LA, et al. **Med Care** 1999 May; 37(5):479–89

Monitoring the health status and impact of treatment on Americans: the Medicare Beneficiary Health Status Registry. McBean AM, et al. **Med Care** 1999 Feb; 37(2):189–203

Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire. Shen W, et al. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS45–66

Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Silliman RA, et al. **Med Care** 1999 Apr;37(4):339–49

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Tunis SL, et al. **Med Care** 1999 Jul; 37(7):678–91

The PedsQL: measurement model for the pediatric quality of life inventory. Varni JW, et al. **Med Care** 1999 Feb; 37(2):126–39

Changes in the SF-36 in 12 months in a clinical sample of disadvantaged older adults. Wolinsky FD, et al. **Med Care** 1998 Nov;36(11):1589–98

Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Wyrwich KW, et al. **Med Care** 1999 May; 37(5):469–78

The conceptualization of health. Larson JS. **Med Care Res Rev** 1999 Jun;56(2):123–36 (50 ref.)

Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Gabriel SE, et al. **Med Decis Making** 1999 Apr–Jun;19(2):141–8

The relationship between health-state utilities and the SF-12 in a general population. Lundberg L, et al. **Med Decis Making** 1999 Apr–Jun;19(2):128–40

Should there be a breast cancer risk chart for New Zealand women? Richardson A, et al. **N Z Med J** 1999 Apr 23; 112(1086):129–30 (34 ref.)

WHOQOL-Hindi: a questionnaire for assessing quality of life in health care settings in India. World Health Organization Quality of Life [see comments] Saxena S, et al. **Natl Med J India** 1998 Jul–Aug;11(4):160–5. Comment in: Natl Med J India 1998 Jul–Aug;11(4):155–7.

Measuring health-related quality of life: an idea whose time has come [editorial; comment] Tan-Torres T. **Natl Med J India** 1998 Jul–Aug;11(4):155–7. Comment on: Natl Med J India 1998 Jul–Aug;11(4):160–5.

Generic measures to compare burden of disease [editorial; comment] Boers M. **Neth J Med** 1999 Mar;54(3):83–5. Comment on: Neth J Med 1999 Mar;54(3):86–95.

Purchasing population health: aligning financial incentives to improve health outcomes. Kindig DA. **Nurs Outlook** 1999 Jan–Feb;47(1):15–22 (87 ref.)

How healthy? Hunter S. **Occup Health Saf** 1999 May; 68(5):114–5

Development and sensitivity to visual impairment of the Low Vision Functional Status Evaluation (LVFSE). Ross CK, et al. **Optom Vis Sci** 1999 Apr;76(4):212–20

Outcome assessment after spinal fusion: why and how? Boden SD. **Orthop Clin North Am** 1998 Oct;29(4):717–28

Preoperative SF-36 responses as a predictor of reoperation following lumbar fusion. Glassman SD, et al. **Orthopedics** 1998 Nov;21(11):1201–3

WOMAC Osteoarthritis Index--additional dimensions for use in subjects with post-traumatic osteoarthritis of the knee. Western Ontario and MacMaster Universities. Roos EM, et al. **Osteoarthritis Cartilage** 1999 Mar;7(2):216–21

Health impact of head and neck cancer. Terrell JE, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):852–9

Health impact assessments of malaria and Ross River virus infection in the Southern Highlands Province of Papua New Guinea. Hii J, et al. **P N G Med J** 1997 Mar; 40(1):14–25

The experience of pain from the shoulder-neck area related to the total body pain, self-experienced health and mental distress. The Malmö Shoulder-Neck Study group. Ektor-Andersen J, et al. **Pain** 1999 Sep;82(3):289–95

Outcome measure for paediatric rehabilitation: use of the Functional Independence Measure for children (WeeFIM). A pilot study in Chinese children with neurodevelopmental disabilities. Yung A, et al. **Pediatr Rehabil** 1999 Jan–Mar; 3(1):21–8

Reliability of two measures of health-related quality of life in patients with multiple sclerosis. Pfennings L, et al. **Percept Mot Skills** 1998 Aug;87(1):111–4

Reliability of clinical balance outcome measures in the elderly. Giorgetti MM, et al. **Physiother Res Int** 1998; 3(4):274–83

Stage distributions for five health behaviors in the United States and Australia. Laforge RG, et al. **Prev Med** 1999 Jan;28(1):61–74

Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Lowensteyn I, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):730–7

CATCH/IT: a data warehouse to support comprehensive assessment for tracking community health. Berndt DJ, et al. **Proc AMIA Symp** 1998;:250–4

Three measures of functional outcome for lower limb amputees: a retrospective review. Treweek SP, et al. **Prosthet Orthot Int** 1998 Dec;22(3):178–85

The development of the Short Explanatory Model Interview (SEMI) and its use among primary-care attenders with common mental disorders. Lloyd KR, et al. **Psychol Med** 1998 Sep;28(5):1231–7

Assessment of the general health profile trends in the male population of Tallinn, Estonia. Volozh O, et al. **Public Health** 1998 Sep;112(5):303–8

Chicago report profiles. Big city health [news] **Public Health Rep** 1998 Jan–Feb;113(1):5

Using YPLL in health planning. McDonnell S, et al. **Public Health Rep** 1998 Jan–Feb;113(1):55–61

Testing a theory for health-related quality of life in cancer patients: a structural equation approach. Nuamah IF, et al. **Res Nurs Health** 1999 Jun;22(3):231–42

Evaluation of regional environmental and health hazards by applying synthetic measures. Dutkiewicz T, et al. **Rev Environ Health** 1998 Jul–Sep;13(3):111–29 (59 ref.)

Quantifying quality of life: overcoming an apparent paradox to meet an urgent need [editorial] Pouchot J. **Rev Rhum Engl Ed** 1998 Dec;65(12):741–4 (18 ref.)

Comparison of the Health Assessment Questionnaire and Arthritis Impact Measurement Scale in patients with psoriatic arthritis. Taccari E, et al. **Rev Rhum Engl Ed** 1998 Dec;65(12):751–8

Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Brazier JE, et al. **Rheumatology (Oxford)** 1999 Sep;38(9):870–7

Health status among farm workers in the Western Cape--collateral evidence from a study of occupational hazards. London L, et al. **S Afr Med J** 1998 Sep; 88(9):1096–101

Functional independence measure (FIM) [letter; comment] Dickson HG, et al. **Scand J Rehabil Med** 1999 Mar; 31(1):63–4. Comment on: Scand J Rehabil Med 1998 Mar;30(1):15–21.

A cross-validation of the comprehensive assessment of activities of daily living after stroke. Hsieh CL, et al. **Scand J Rehabil Med** 1999 Jun;31(2):83–8

Construct validity of the functional independence measure (FIM): questioning the unidimensionality of the scale and the "value" of FIM scores. Ravaud JF, et al. **Scand J Rehabil Med** 1999 Mar;31(1):31–41

Social differences in health in an affluent Danish county. Osler M, et al. **Scand J Soc Med** 1998 Dec;26(4):289–92

Socioeconomic differences in health indices, social networks and mortality among Swedish men. A study of men born in 1933. Rosengren A, et al. **Scand J Soc Med** 1998 Dec; 26(4):272–80

Indicators of human health in ecosystems: what do we measure? Cole DC, et al. **Sci Total Environ** 1998 Dec 11; 224(1–3):201–13 (81 ref.)

The health status of the Singaporean population as measured by a multi-attribute health status system. Wang Q, et al. **Singapore Med J** 1999 Jun;40(6):389–96

Gender differences in health in later life: the new paradox? Arber S, et al. **Soc Sci Med** 1999 Jan;48(1):61–76

A revised measure of symptom-specific health care use. Baker DW, et al. **Soc Sci Med** 1998 Nov;47(10):1601–9

Gender differences in structural and behavioral determinants of health: an analysis of the social production of health. Denton M, et al. **Soc Sci Med** 1999 May;48(9):1221–35

Is imposing risk awareness cultural imperialism? Førde OH. **Soc Sci Med** 1998 Nov;47(9):1155–9 (25 ref.)

Probabilities and health risks: a qualitative approach. Heyman B, et al. **Soc Sci Med** 1998 Nov;47(9):1295–306 (48 ref.)

The relationship between income inequality and population health [letter; comment] [published erratum appears in Soc Sci Med 1999 Jan;48(2):281] Judge K, et al. **Soc Sci Med** 1998 Oct;47(7):983–5. Comment on: Soc Sci Med 1998 Feb-Mar;46(4–5):567–79. Comment on: Soc Sci Med 1998 Aug;47(3):411–2.

Social capital and health: implications for public health and epidemiology. Lomas J. **Soc Sci Med** 1998 Nov; 47(9):1181–8 (40 ref.)

Social inequalities in health: are there gender differences? Matthews S, et al. **Soc Sci Med** 1999 Jan;48(1):49–60

Geographies of health perception in Québec: a multilevel perspective. Pampalon R, et al. **Soc Sci Med** 1999 May; 48(10):1483–90

"Death by proxy": ethics and classification in epidemiology. Plant AJ, et al. **Soc Sci Med** 1998 Nov;47(9):1147–53 (21 ref.)

Health appraisal models in multiple sclerosis. Roberts G, et al. **Soc Sci Med** 1998 Jul;47(2):243–53

Putting risk in its place: methodological considerations for investigating extreme event health risk. Smoyer KE. **Soc Sci Med** 1998 Dec;47(11):1809–24

Aggregation and the measurement of income inequality: effects on morbidity. Soobader MJ, et al. **Soc Sci Med** 1999 Mar;48(6):733–44

Risk factors for functional status decline in community-living elderly people: a systematic literature review [see comments] Stuck AE, et al. **Soc Sci Med** 1999 Feb; 48(4):445–69. Comment in: Soc Sci Med 1999 Feb;48(4):471–2.

Measuring quality of life in back patients: comparison of Health Status Questionnaire 2.0 and Quality of Life Inventory. Claiborne N, et al. **Soc Work Health Care** 1999; 28(3):77–94

Use of a subjective health measure on Chinese low back pain patients in Hong Kong. Leung AS, et al. **Spine** 1999 May 15;24(10):961–6

Replicability of SF-36 summary scores by the SF-12 in stroke patients. Pickard AS, et al. **Stroke** 1999 Jun; 30(6):1213–7

Using social indicators to predict addiction. Mammo A, et al. **Subst Use Misuse** 1998 Oct;33(12):2499–513

Preoperative left-ventricular ejection fraction does not influence the improvement in quality of life after coronary artery bypass surgery. Sjöland H, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):198–206

Current estimates from the National Health Interview Survey, 1995. Benson V, et al. **Vital Health Stat 10** 1998 Oct;(199):1–428

Defining essential information needs and indicators. Bodart C, et al. **World Health Forum** 1998;19(3):303–9

Indicators of social and mental health [letter] Indrayan A. **World Health Forum** 1998;19(4):430–1

[A study on the setting-up a high-risk scoring system for neonatal adverse outcomes] Li H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):13–5 (Eng. Abstr.) **(Chi)**

['Public health status and perspectives' 1997. IV. Health status and life expectancy weighted] Kramers PG, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1277–80 (Eng. Abstr.) **(Dut)**

[The Dutch version of 'Functional Status II(R)': a questionnaire measuring the functional health status of children] Post MW, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2675–9 (Eng. Abstr.) **(Dut)**

[The Dutch 'Rand General Health Rating Index for Children': a questionnaire measuring the general health status of children] Post MW, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2680–3 (Eng. Abstr.) **(Dut)**

[Global health indicators as predictors of mortality in elderly persons: a six-year prospective study] Lefrançois R, et al. **Can J Public Health** 1999 Jan–Feb;90(1):66–71 (Eng. Abstr.) **(Fre)**

[Analysis of the health risks in the workplace. Contribution of the work hygienist] Droz PO, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):565–8 **(Fre)**

[Evaluation of surgical risk in patients with COPD] Stucki A, et al. **Ther Umsch** 1999 Mar;56(3):151–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[The relationship between stress and health indicators in an urban population--from a study of subjects selected by sex

HEALTH STATUS INDICATORS

and age groups who underwent health check-ups in S city in Osaka Prefecture] Nakagawa Y, et al. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):407-19 (Eng. Abstr.) **(Jpn)**

[Assessment of patients' health status--review of the literature and assessment methods] Andreassen S, et al. **Nord Med** 1998 Dec;113(10):360-2 (31 ref.) (Eng. Abstr.) **(Nor)**

[Examination of the quality of life in post stroke patients] Broda W, et al. **Przegl Lek** 1999;56(2):152-6 (26 ref.) (Eng. Abstr.) **(Pol)**

[Importance of J. Brazy's neurobiological index. Prediction of the number and severity of complications in very low birth weight infants] Nunes A, et al. **Acta Med Port** 1998 Jul;11(7):615-21 (Eng. Abstr.) **(Por)**

[Income inequality and health: the case of Rio de Janeiro] Szwarcwald CL, et al. **Cad Saude Publica** 1999 Jan-Mar; 15(1):15-28 (Eng. Abstr.) **(Por)**

[Perinatal health: methodology and characteristics of the studied population] Bettiol H, et al. **Rev Saude Publica** 1998 Feb;32(1):18-28 (Eng. Abstr.) **(Por)**

[The comprehensive assessment of the health indices during the training of youth drafted for military service] Rakhmanov RS, et al. **Voen Med Zh** 1999 May;320(5):11-4 **(Rus)**

[A theoretical approach to health and its measurement] Grujić V, et al. **Med Pregl** 1998 Jul-Aug;51(7-8):315-8 (Eng. Abstr.) **(Scr)**

[New indicators of the health of populations] Dominguez Carmona M. **An R Acad Nac Med (Madr)** 1998; 115(4):957-68; discussion 968-71 **(Spa)**

[Health inequalities in the outlying towns of the urban sprawl of Granada] Ruiz Mariscal I, et al. **Aten Primaria** 1998 Sep 30;22(5):269-78 (Eng. Abstr.) **(Spa)**

[Demographic aspects in indigenous communities of 3 regions of Colombia] Piñeros-Petersen M, et al. **Salud Publica Mex** 1998 Jul-Aug;40(4):324-9 (Eng. Abstr.) **(Spa)**

HEALTH SURVEYS

Measuring health status in psychiatric community surveys: internal and external validity of the Spanish version of the SF-36. Ayuso-Mateos JL, et al. **Acta Psychiatr Scand** 1999 Jan;99(1):26-32

Mental health expectancy: an indicator to bridge the gap between clinical and public health perspectives of population mental health. Gispert R, et al. **Acta Psychiatr Scand** 1998 Sep;98(3):182-6

The Oklahoma Postmenopausal Women's Health Study: recruitment and characteristics of American Indian, Asian, Black, Hispanic, and Caucasian women. Gavaler JS, et al. **Alcohol Clin Exp Res** 1999 Feb;23(2):220-3

Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study [see comments] Liu S, et al. **Am J Clin Nutr** 1999 Sep;70(3):412-9. Comment in: Am J Clin Nutr 1999 Sep;70(3):307-8.

Place effects for areas defined by administrative boundaries. Boyle MH, et al. **Am J Epidemiol** 1999 Mar 15; 149(6):577-85

Alcohol intake assessment: the sober facts. Feunekes GI, et al. **Am J Epidemiol** 1999 Jul 1;150(1):105-12 (41 ref.)

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. Gulliford MC, et al. **Am J Epidemiol** 1999 May 1; 149(9):876-83

Neighborhood social environment and risk of death: multilevel evidence from the Alameda County Study. Yen IH, et al. **Am J Epidemiol** 1999 May 15;149(10):898-907

The VF-14 index of functional visual impairment in candidates for a corneal graft. Boisjoly H, et al. **Am J Ophthalmol** 1999 Jul;128(1):38-44

Influence of age-related maculopathy on visual functioning and health-related quality of life. Mangione CM, et al. **Am J Ophthalmol** 1999 Jul;128(1):45-53

Quality of life of low-vision patients and the impact of low-vision services. Scott IU, et al. **Am J Ophthalmol** 1999 Jul;128(1):54-62

Commentary on assessment of health risk behaviors. A tool to inform consumers, providers, health care organizations, and purchasers [comment] Thompson RS. **Am J Prev Med** 1999 Jan;16(1):70-4. Comment on: Am J Prev Med 1999 Jan;16(1):48-59.

Case vignette in a community-based study [letter; comment] Razali SM, et al. **Am J Psychiatry** 1999 Jan;156(1):158. Comment on: Am J Psychiatry 1997 Oct;154(10):1391-7.

The effectiveness of a short form of the Household Food Security Scale. Blumberg SJ, et al. **Am J Public Health** 1999 Aug;89(8):1231-4

A new twist in ecological studies [comment] Feinleib M. **Am J Public Health** 1998 Oct;88(10):1445-6. Comment on: Am J Public Health 1998 Oct;88(10):1484-9.

A population comparison of participants and nonparticipants in a health survey. Klesges RC, et al. **Am J Public Health** 1999 Aug;89(8):1228-31

Use of multiple surveys to estimate mortality among never, current, and former smokers: changes over a 20-year interval. Rosenbaum WL, et al. **Am J Public Health** 1998 Nov;88(11):1664-8

Evaluation of malaria surveillance using retrospective, laboratory-based active case detection in four southwestern states, 1995. Barat LM, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):910-4

IRB review: necessary, nice or needless? [letter; comment] Goodman K, et al. **Ann Epidemiol** 1999 Jan;9(1):68-70. Comment on: Ann Epidemiol 1998 Nov;8(8):479-81.

IRB review: necessary, nice, or needless? [editorial; comment] [see comments] Merz JF. **Ann Epidemiol** 1998 Nov;8(8):479-81. Comment on: Ann Epidemiol 1998 Nov;8(8):482-9. Comment in: Ann Epidemiol 1999 Jan;9(1):68-70.

Who participates in population based studies of visual impairment? The Salisbury Eye Evaluation project experience. Muñoz B, et al. **Ann Epidemiol** 1999 Jan; 9(1):53-9

Findings from the American College of Epidemiology's survey on Ethics guidelines. The American College of Epidemiology Ethics and Standards of Practice Committee [see comments] Prineas RJ, et al. **Ann Epidemiol** 1998 Nov; 8(8):482-9. Comment in: Ann Epidemiol 1998 Nov;8(8):479-81.

Chronic conditions and disabilities among seniors: an analysis of population-based health and activity limitation surveys. Raina P, et al. **Ann Epidemiol** 1998 Aug;8(6):402-9

Serum ascorbic acid and cardiovascular disease prevalence in U.S. adults: the Third National Health and Nutrition Examination Survey (NHANES III). Simon JA, et al. **Ann Epidemiol** 1999 Aug;9(6):358-65

Congestive heart failure in the community: trends in incidence and survival in a 10-year period [see comments] Senni M, et al. **Arch Intern Med** 1999 Jan 11;159(1):29-34. Comment in: Arch Intern Med 1998 Jan 11;159(1):15-7.

Factors associated with non-use of Pap test. A population survey. Hernández-Hernández DM, et al. **Arch Med Res** 1998 Autumn;29(3):263-70

Estimated alcohol consumption in the 1995 National Health Survey: some methodological issues. Donath S. **Aust N Z J Public Health** 1999 Apr;23(2):131-4

The contribution of community health surveys to aboriginal health in the 1990s. Mak DB, et al. **Aust N Z J Public Health** 1998 Oct;22(6):645-7

SF-36 health survey reliability, validity and norms for New Zealand. Scott KM, et al. **Aust N Z J Public Health** 1999 Aug;23(4):401-6

Women's health. Leiman JM. **Bull N Y Acad Med** 1995 Winter;72(2 Suppl):639-44

Light on population health status. Beyrer K, et al. **Bull World Health Organ** 1999;77(2):176-80

Predictors of health risk behaviours among young adults: analysis of the National Population Health Survey. Allison KR, et al. **Can J Public Health** 1999 Mar-Apr;90(2):85-9

How reliable are selected scales from population-based health surveys? An analysis among seniors. Raina P, et al. **Can J Public Health** 1999 Jan-Feb;90(1):60-4

Canadian National Survey on Sun Exposure & Protective Behaviours: methods. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):105-9

Canadian National Survey on Sun Exposure & Protective Behaviours: parents' reports on children. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):123-8

Canadian National Survey on Sun Exposure & Protective Behaviours: youth at leisure. Lovato CY, et al. **Cancer Prev Control** 1998 Jun;2(3):117-22

Canadian National Survey on Sun Exposure & Protective Behaviours: adults at leisure. Shoveller JA, et al. **Cancer Prev Control** 1998 Jun;2(3):111-6

The Juvenile Wellness and Health Survey (JWHS-76): a school based screening instrument for general and mental health in high school students. Steiner H, et al. **Child Psychiatry Hum Dev** 1998 Winter;29(2):141-55

A computerized school-based health assessment with rapid feedback to improve adolescent health. Bracken AC, et al. **Clin Pediatr (Phila)** 1998 Nov;37(11):677-83

Psychobiology of stroke: a neglected area [letter; comment] Simpson S, et al. **CMAJ** 1999 Mar 23;160(6):780-1. Comment on: CMAJ 1998 Sep 22;159(6):671-3.

Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Suematsu C, et al. **Diabetes Care** 1999 Feb; 22(2):228-32

Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. Tan CE, et al. **Diabetes Care** 1999 Feb; 22(2):241-7

Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. Shera AS, et al. **Diabetes Res Clin Pract** 1999 Apr; 44(1):49-58

Measuring disability with parsimony. Verbrugge LM, et al. **Disabil Rehabil** 1999 May-Jun;21(5-6):295-306

The factor-structure of the Self Reporting Questionnaire (SRQ-20) in South Africa. Cherian VI, et al. **East Afr Med J** 1998 Nov;75(11):654-6

Drinking water arsenic in Utah: A cohort mortality study. Lewis DR, et al. **Environ Health Perspect** 1999 May; 107(5):359-65

Non-participation bias in unlinked anonymous HIV-prevalence surveys in England and Wales. Duong T, et al. **Epidemiol Infect** 1999 Apr;122(2):267-72

Outcome of recruitment and report on participation rate in the New Mexico Elder Health Survey. Romero LJ, et al. **Ethn Dis** 1998 Autumn;8(3):350-9

Potential underreporting of energy intake in the Ontario Health Survey and its relationship with nutrient and food intakes. Pomerleau J, et al. **Eur J Epidemiol** 1999 Jul; 15(6):553-7

Survey of genetic screening for oocyte donors. Lewis V, et al. **Fertil Steril** 1999 Feb;71(2):278-81

Commentary: improving risk-adjustment models for capitation payment and global budgeting [see comments] Hornbrook MC. **Health Serv Res** 1999 Feb;33(6):1745-51. Comment in: Health Serv Res 1999 Feb;33(6):1727-44.

Risk-adjusted capitation based on the Diagnostic Cost Group Model: an empirical evaluation with health survey information [see comments] Lamers LM. **Health Serv Res** 1999 Feb;33(6):1727-44. Comment in: Health Serv Res 1999 Feb;33(6):1745-51.

Public health. Altered stats [news] **Hosp Health Netw** 1998 Nov 20;72(22):15

Immigrant health. What huddled masses? [news] **Hosp Health Netw** 1998 Oct 20;72(20):15

A survey of methods used to detect nosocomial legionellosis among participants in the National Nosocomial Infections Surveillance System. Fiore AE, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):412-6

Cancer risk in mutation carriers of DNA-mismatch-repair genes. Aarnio M, et al. **Int J Cancer** 1999 Apr 12; 81(2):214-8

Social and cultural factors as determinants of self-rated health in Greenland. Bjerregaard P, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:622-5

Determining the feasibility of the Canadian First Nations and Inuit regional (longitudinal) health surveys. O'Neil J, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:611-6

Developing and conducting a health risk behavior survey among school-aged students. Schiffkorn-Hansen MA, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:648-51

Physical activity assessment in population surveys: can it really be simplified? Dominguez-Berjón F, et al. **Int J Epidemiol** 1999 Feb;28(1):53-7

The use of calendars to measure child illness in health interview surveys. Goldman N, et al. **Int J Epidemiol** 1998 Jun;27(3):505-12

Physical activity and body composition: what do the national surveys reveal? Fentem PH, et al. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S8-14

The assessment of physical activity in individuals and populations: why try to be more precise about how physical activity is assessed? Wareham NJ, et al. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S30-8

Levels of physical activity, physical fitness and their relationship in the Northern Ireland Health and Activity Survey. MacAuley D, et al. **Int J Sports Med** 1998 Oct; 19(7):503-11

Do doctors benefit from their profession?--A survey of medical practitioners' health promotion and health safety practices [editorial] O'Connor M, et al. **Ir Med J** 1998 Dec; 91(6):206-9

Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. Justice AC, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):126-33

Parental permission in adolescent health research [letter; comment] O'Donnell LN. **J Adolesc Health** 1998 Nov; 23(5):252-3. Comment on: J Adolesc Health 1998 May;22(5):362.

Lessons learned about adolescent nutrition from the Minnesota Adolescent Health Survey. Neumark-Sztainer D, et al. **J Am Diet Assoc** 1998 Dec;98(12):1449-56

Patient survey to determine the necessity of Internet exposure for a general ophthalmology practice [letter] Scherer WJ, et al. **J Cataract Refract Surg** 1999 Jun;25(6):735-6

Accuracy of recall of occupational physical activity by questionnaire. Ainsworth BE, et al. **J Clin Epidemiol** 1999 Mar;52(3):219-27

Effect of the method of administration, mail or telephone, on the validity and reliability of a respiratory health questionnaire. The Spanish Centers of the European Asthma Study. Galobardes B, et al. **J Clin Epidemiol** 1998 Oct;51(10):875-81

Clinimetric and psychometric strategies for development of a health measurement scale. Marx RG, et al. **J Clin Epidemiol** 1999 Feb;52(2):105-11

Testing the measurement properties of the Short Form-36 Health Survey in a frail elderly population. Stadnyk K, et al. **J Clin Epidemiol** 1998 Oct;51(10):827-35

The feasibility of using a postal survey method to assess the health and development of 7 year old children of different birth weight. Alderdice F, et al. **J Epidemiol Community Health** 1998 Jul;52(7):439-44

Acute health effects of the Sea Empress oil spill. Lyons RA, et al. **J Epidemiol Community Health** 1999 May; 53(5):306-10

The Short-Form 36 and older people: some problems encountered when using postal administration. Mallinson S. **J Epidemiol Community Health** 1998 May;52(5):324-8

Public health surveys in Singapore [letter; comment] Tsakok AD. **J Epidemiol Community Health** 1998 Nov;52(11):764. Comment on: J Epidemiol Community Health 1997 Aug;51(4):394-9. Comment on: J Epidemiol Community Health 1998 Mar;52(3):181-5.

Factors affecting general practice patient response rates to a postal survey of health status in England: a comparative analysis of three disease groups [letter] Meadows KA, et

al. **J Eval Clin Pract** 1998 Aug;4(3):243–7
National human exposure assessment survey (NHEXAS): exploratory survey of exposure among population subgroups in EPA Region V. Pellizzari ED, et al. **J Expo Anal Environ Epidemiol** 1999 Jan–Feb;9(1):49–55
Monitoring changes in home health care: a comparison of two national surveys. Mullner RM, et al. **J Med Syst** 1999 Feb;23(1):21–6
Analyzing health surveys for cancer-related objectives. Graubard BI, et al. **J Natl Cancer Inst** 1999 Jun 16; 91(12):1005–16 (89 ref.)
Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey. Hewitt M, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1480–6
Heterogeneous distribution of amyotrophic lateral sclerosis patients with SOD–1 gene mutations: preliminary data on an Italian survey. Malaspina A, et al. **J Neurol Sci** 1999 Jan 15;162(2):201–4
SF–36 scores vary by method of administration: implications for study design. Lyons RA, et al. **J Public Health Med** 1999 Mar;21(1):41–5
Choosing a national survey to investigate smoking behaviour: making comparisons between the General Household Survey, the British Household Panel Survey and the Health Survey for England. Twigg L. **J Public Health Med** 1999 Mar;21(1):14–21
Youth Risk Behavior Surveillance--United States, 1997. State and Local YRBSS Coordinators. Kann L, et al. **J Sch Health** 1998 Nov;68(9):355–69
Methods of the NSW Schools Fitness and Physical Activity Survey, 1997. Booth ML, et al. **J Sci Med Sport** 1998 Jun; 1(2):111–24
Child mortality in Iraq [letter; comment] Zaidi S. **Lancet** 1997 Oct 11;350(9084):1105. Comment on: Lancet 1995 Dec 2;346(8988):1485.
Hypothesis testing of hazard ratio parameters in marginal models for multivariate failure time data. Cai J. **Lifetime Data Anal** 1999;5(1):39–53
Internet survey research and consent [letter; comment] Karlinsky H. **MD Comput** 1998 Sep–Oct;15(5):285. Comment on: MD Comput 1998 Mar–Apr;15(2):116–20.
Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Scott–Lennox JA, et al. **Med Care** 1999 Sep;37(9):908–25
The SF–36 Arthritis-Specific Health Index (ASHI): I. Development and cross–validation of scoring algorithms. Ware JE Jr, et al. **Med Care** 1999 May;37(5 Suppl):MS40–50
Subjective health status and health values in the general population. Shmueli A. **Med Decis Making** 1999 Apr–Jun; 19(2):122–7
IgM antibodies to Schistosoma mansoni gut–associated antigens for the study of schistosomiasis transmission in Ribeirão Pires, São Paulo. Camargo–Neves VL, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:273–8
Case ascertainment uncertainties in prevalence surveys of Parkinson's disease. Anderson DW, et al. **Mov Disord** 1998 Jul;13(4):626–32
Survey of multiple sclerosis in northern California. Northern California MS Study Group. Goodin DS. **Mult Scler** 1999 Apr;5(2):78–88
Validity of telephone interview data for vascular disease risk factors in a racially mixed urban community: the Northern Manhattan Stroke Study. Kargman DE, et al. **Neuroepidemiology** 1999;18(4):174–84
Health survey of former workers in a Norwegian coke plant: Part 2. Cancer incidence and cause specific mortality. Bye T, et al. **Occup Environ Med** 1998 Sep;55(9):622–6
Survey of injuries among West End performers. Evans RW, et al. **Occup Environ Med** 1998 Sep;55(9):585–93
Health survey of former workers in a Norwegian coke plant: Part. 1. Estimation of historical exposures. Romundstad PR, et al. **Occup Environ Med** 1998 Sep;55(9):616–21
Updated data on proximal femur bone mineral levels of US adults. Looker AC, et al. **Osteoporos Int** 1998;8(5):468–89
Participation in a mail survey: role of repeated mailings and characteristics of nonrespondents among recent mothers. Larroque B, et al. **Paediatr Perinat Epidemiol** 1999 Apr; 13(2):218–33
An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Caraceni A, et al. **Pain** 1999 Sep;82(3):263–74
The experience of pain from the shoulder–neck area related to the total body pain, self–experienced health and mental distress. The Malmö Shoulder–Neck Study group. Ektor–Andersen J, et al. **Pain** 1999 Sep;82(3):289–95
Questionnaires: the use and abuse of social survey methods in medical research. Eaden J, et al. **Postgrad Med J** 1999 Jul;75(885):397–400 (36 ref.)
Comparative studies on sleep disturbance in the elderly based on questionnaire assessments in 1983 and 1996. Yamaguchi N, et al. **Psychiatry Clin Neurosci** 1999 Apr;53(2):261–2
The development and validation of an instrument to assess acute sinus disease in children. Garbutt JM, et al. **Qual Life Res** 1999 May;8(3):225–33
The SF–36 as a health status measure for epilepsy: a psychometric assessment. Jacoby A, et al. **Qual Life Res** 1999 Jun;8(4):351–64
Use of the 12–item short–form (SF–12) Health Survey in an Australian heart and stroke population. Lim LL, et al. **Qual Life Res** 1999;8(1–2):1–8
Do we know what global ratings of health–related quality of life measure? Mozes B, et al. **Qual Life Res** 1999 May; 8(3):269–73
Comparison of Euroqol EQ–5D and SF–36 in patients with chronic fatigue syndrome. Myers C, et al. **Qual Life Res** 1999;8(1–2):9–16
Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ–C30 across populations by means of the Mokken Scaling Model. Ringdal K, et al. **Qual Life Res** 1999;8(1–2):25–43
A Kiswahili version of the SF–36 Health Survey for use in Tanzania: translation and tests of scaling assumptions. Wagner AK, et al. **Qual Life Res** 1999;8(1–2):101–10
Validation of the Kiswahili version of the SF–36 Health Survey in a representative sample of an urban population in Tanzania. Wyss K, et al. **Qual Life Res** 1999; 8(1–2):111–20
Cancer predictive value of cytogenetic markers used in occupational health surveillance programs. Hagmar L, et al. **Recent Results Cancer Res** 1998;154:177–84 (7 ref.)
Health observation and health reporting in Europe. Aromaa A. **Rev Epidemiol Sante Publique** 1998 Dec;46(6):481–90
Inhospital management of common lumbosciatic syndrome. An opinion survey among French rheumatologists. Legrand E, et al. **Rev Rhum Engl Ed** 1998 Jul–Sep; 65(7–9):483–8
Are health surveys among elderly people worthwhile? The Albertina Project. Lindgren AM, et al. **Scand J Prim Health Care** 1998 Jun;16(2):101–6
Short form 36 (SF–36) health survey: normative data from the general Norwegian population. Loge JH, et al. **Scand J Soc Med** 1998 Dec;26(4):250–8
Making use of official statistics in research on gender and health status: recent British data. Dunnell K, et al. **Soc Sci Med** 1999 Jan;48(1):117–27 (26 ref.)
Do women 'over–report' morbidity? Men's and women's responses to structured prompting on a standard question on long standing illness. Macintyre S, et al. **Soc Sci Med** 1999 Jan;48(1):89–98
Survey research vs clinical trials in evaluating the medical utility of marijuana [letter; comment] Doblin R, et al. **South Med J** 1998 Oct;91(10):989–91. Comment on: South Med J 1997 Feb;90(2):167–72.
The Berne–Munich Lifestyle Panel. Background and baseline results from a longitudinal health lifestyle survey. Abel T, et al. **Soz Praventivmed** 1999;44(3):91–106
Tanzania 1996: results from the demographic and health survey. **Stud Fam Plann** 1998 Sep;29(3):324–8
Nepal 1996: results from the family health survey. **Stud Fam Plann** 1998 Sep;29(3):329–33
Uzbekistan 1996: results from the Demographic and Health Survey. **Stud Fam Plann** 1999 Mar;30(1):83–7
Peru 1996: results from the Demographic and Health Survey. **Stud Fam Plann** 1999 Mar;30(1):78–82
The health and nutritional status of schoolchildren in Africa: evidence from school–based health programmes in Ghana and Tanzania. The Partnership for Child Development [published erratum appears in Trans R Soc Trop Med Hyg 1998 Jul–Aug;92(4):450] **Trans R Soc Trop Med Hyg** 1998 May–Jun;92(3):254–61
National Health Interview Survey: research for the 1995–2004 redesign. **Vital Health Stat 2** 1999 Jul; (126):1–119
The Medical Outcomes Research Project Pediatric Asthma Study. Helstad CP, et al. **WMJ** 1999 May–Jun;98(3):39–40, 38
Critical adolescent health issues: results of the 1997 Wisconsin Youth Risk Behavior Survey. White D, et al. **WMJ** 1998 Sep;97(8):23–4
Women's Health Australia: recruitment for a national longitudinal cohort study. Brown WJ, et al. **Women Health** 1998;28(1):23–40
Assessing physical activity among minority women: focus group results. Tortolero SR, et al. **Womens Health Issues** 1999 May–Jun;9(3):135–42
[Health, life style and living conditions in Greenland. The 1993–1994 Greenland health survey] Bjerregaard P, et al. **Ugeskr Laeger** 1999 Mar 15;161(11):1595–601 (Eng. Abstr.) **(Dan)**
[Eosinophilic cystitis. A survey] Grønlund A, et al. **Ugeskr Laeger** 1999 Feb 8;161(6):784–6 (Eng. Abstr.) **(Dan)**
[Use of a questionnaire for quick identification of the principal foci of urinary bilharziasis in central Ivory Coast] N'Goran EK, et al. **Med Trop (Mars)** 1998;58(3):253–60 (Eng. Abstr.) **(Fre)**
[Eating habits and cardiovascular risk factors. Epidemiologic study of the Tunisian Sahel] Ghannem H, et al. **Presse Med** 1999 May 22–29;28(19):1005–8 (Eng. Abstr.) **(Fre)**
[Comparison of two types of behavior and attitude surveys on alcohol, tobacco and illegal drug use] Guilbert P, et al. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):129–38 (Eng. Abstr.) **(Fre)**
[The Health Survey--outlook] Bellach BM. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S113–4 **(Ger)**
[The German Health Survey. 1997/98] Bellach BM, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S59–68 (Eng. Abstr.) **(Ger)**
[The German Health Survey as a pharmaco–epidemiologic instrument] Bertelsmann A, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S89–94 **(Ger)**
[The Bavarian Health Survey] Breunig M, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S101–3 **(Ger)**
[Environmental survey 1997/98] Krause C, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S77–82 **(Ger)**
[Data evaluation in the German Health Survey] Schroeder E, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S104–7 **(Ger)**
[Folic acid status] Thamm M, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S87–8 **(Ger)**
[The German Health Survey 1997/98--examination style] Thierfelder W, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S69–76 **(Ger)**
[External quality control in the German Health Survey 1997/98: concept and initial experiences] Winkler G, et al. **Gesundheitswesen** 1998 Dec;60 Suppl 2:S108–12 **(Ger)**
[Vascular risk factors associated with glaucoma--a survey of ophthalmologists] Erb C, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):A8–12 **(Ger)**
[Subjective assessment of self health and subjective morbidity in Germany. Results of a representative demographic survey] Hessel A, et al. **Psychother Psychosom Med Psychol** 1999 Aug;49(8):264–74 (Eng. Abstr.) **(Ger)**
[Freiburg Questionnaire of physical activity--development, evaluation and application] Frey I, et al. **Soz Praventivmed** 1999;44(2):55–64 (Eng. Abstr.) **(Ger)**
[Changing the order of questions on drug use in the Swiss Health Survey--does it effect prevalence assessment?] Gmel G. **Soz Praventivmed** 1999;44(3):126–36 (Eng. Abstr.) **(Ger)**
[Epidemiologic and statistical interaction models and consequences for regression analysis] Stronegger WJ, et al. **Soz Praventivmed** 1998;43(6):312–21 (Eng. Abstr.) **(Ger)**
[Current status of therapy of lymphedema in Austrian hospitals--a comprehensive Austrian survey] Döller W. **Wien Med Wochenschr** 1999;149(2–4):107–8 (Eng. Abstr.) **(Ger)**
[Current status of diagnosis of lymphedema--a comprehensive Austrian survey of hospitals and patients] Menzinger G. **Wien Med Wochenschr** 1999;149(2–4):96–7 (Eng. Abstr.) **(Ger)**
[Assessment of patients' health status--review of the literature and assessment methods] Andreassen S, et al. **Nord Med** 1998 Dec;113(10):360–2 (31 ref.) (Eng. Abstr.) **(Nor)**
[Experience in conducting research in the social hygiene monitoring system] Shishkina LI, et al. **Gig Sanit** 1999 May–Jun;(3):74–6 **(Rus)**
[A rare epidemic outbreak of acute intestinal infections among adults (Part 2)] Tibekin AT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov–Dec; (6):116–8 **(Rus)**
[A rare epidemic outbreak of acute intestinal infections among adults (Part 1)] Tibekin AT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov–Dec; (6):113–4 **(Rus)**
[Health surveys in the school environment: between rigor and opportunity (editorial)] Nebot M. **Gac Sanit** 1998 Nov–Dec;12(6):239–40 **(Spa)**
[Population reference values of the Spanish version of the Health Questionnaire SF–36] Alonso J, et al. **Med Clin (Barc)** 1998 Oct 10;111(11):410–6 (Eng. Abstr.) **(Spa)**
[New dimensions in international health and globalization (letter)] Barillas E. **Rev Panam Salud Publica** 1999 Sep; 6(3):220–1 **(Spa)**
[Evaluation of health status using Survey SF–36: preliminary results in Mexico] Zúniga MA, et al. **Salud Publica Mex** 1999 Mar–Apr;41(2):110–8 (Eng. Abstr.) **(Spa)**

HEALTH SYSTEMS PLANS

TRENDS

Current efforts toward implementation of an urban health strategy: the Henry Ford Health System. Whitelaw N, et al. **J Urban Health** 1998 Jun;75(2):356–66

HEALTH TECHNOLOGY see **TECHNOLOGY, MEDICAL**

HEALTH TRANSITION

Age–adjusted death rates: consequences of the Year 2000 standard. Sorlie PD, et al. **Ann Epidemiol** 1999 Feb; 9(2):93–100
Strong bones in later life: luxury or necessity? The view from Tunisia: need for an inclusive approach [see comments] Ben Khalifa F. **Bull World Health Organ** 1999;77(5):427–8 . Comment in: Bull World Health Organ 1999 ;77(5):416–22.
Strong bones in later life: luxury or necessity? [see comments] Delmas PD, et al. **Bull World Health Organ** 1999; 77(5):416–22. Comment in: Bull World Health Organ 1999 ;77(5):423–4. Comment in: Bull World Health Organ 1999 ;77(5):424–6. Comment in: Bull World Health Organ 1999 ;77(5):426–7. Comment in: Bull World Health Organ 1999 ;77(5):427–8. Comment in: Bull World Health Organ 1999 ;77(5):429–30. Comment in: Bull World Health Organ 1999 ;77(5):430–1. Comment in: Bull World Health Organ 1999

;77(5):431-2. Comment in: Bull World Health Organ 1999 ;77(5):433. Comment in: Bull World Health Organ 1999 ;77(5):434-5.

The global impact of HIV infection and disease. Nicoll A, et al. **Commun Dis Public Health** 1999 Jun;2(2):85-95 (54 ref.)

Suicide in Belarus. Kondrichin SV, et al. **Crisis** 1998; 19(4):167-71

Financing pharmaceuticals in transition economies. Kanavos P. **Croat Med J** 1999 Jun;40(2):244-59

International trends in rates of hypospadias and cryptorchidism. Paulozzi LJ. **Environ Health Perspect** 1999 Apr;107(4):297-302

Prevention: toward a golden age [editorial] Pechère JC. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):537-8

Four ways to teach PHC in a changing world. Shoultz J, et al. **Int Nurs Rev** 1998 Nov-Dec;45(6):187-91

Moving into the information era: does the current nursing paradigm still hold? Spitzer A. **J Adv Nurs** 1998 Oct; 28(4):786-93

Health care reform and the transformation of nursing in Hong Kong. Wong FK. **J Adv Nurs** 1998 Sep;28(3):473-82

Epidemiologic transitions. Caldwell JC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999;15 Suppl:S4-14

The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49-70 (90 ref.)

Meeting the health care needs of the elderly [letter; comment] Moore JE. **Nurs Outlook** 1999 Mar-Apr;47(2):95. Comment on: Nurs Outlook 1998 Jul-Aug;46(4):149-50.

The paucity of effects in community trials: is secular trend the culprit? Bauman KE, et al. **Prev Med** 1999 Apr; 28(4):426-9

Social position, social roles and women's health in England: changing relationships 1984-1993. Bartley M, et al. **Soc Sci Med** 1999 Jan;48(1):99-115

The effects of political and economic transitions on health and safety in Estonia: an Estonian-Swedish comparative study. Kaasik T, et al. **Soc Sci Med** 1998 Nov; 47(10):1589-99

Gender differences in illhealth in Finland: patterns, magnitude and change. Lahelma E, et al. **Soc Sci Med** 1999 Jan;48(1):7-19

Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Kunasol P, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):255-62 (32 ref.)

AIDS in India: recent trends in opportunistic infections. Misra SN, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):373-6

A subregional assessment of demographic and health trends in the Americas: 1980-1998. Castillo-Salgado C, et al. **Stat Bull Metrop Insur Co** 1999 Apr-Jun;80(2):2-12

The implications of affiliations between Catholic and non-Catholic health care organizations for availability of reproductive health services. Weisman CS, et al. **Womens Health Issues** 1999 May-Jun;9(3):121-34

[Decrease in the "healthy migrant effect": trends in the morbidity of foreign and German participants in the 1984-1992 Socioeconomic Panel] Lechner I, et al. **Gesundheitswesen** 1998 Dec;60(12):715-20 (Eng. Abstr.) **(Ger)**

HEALTH VISITORS see **COMMUNITY HEALTH NURSING**

HEALTHCARE INDUSTRY see **HEALTH CARE SECTOR**

HEALTHCARE SURVEYS see **HEALTH CARE SURVEYS**

HEALTHY WORKER EFFECT

Characteristics of the healthy survivor effect among male and female Hanford workers. Baillargeon J, et al. **Am J Ind Med** 1999 Apr;35(4):343-7

A review of the healthy worker effect in occupational epidemiology. Li CY, et al. **Occup Med (Lond)** 1999 May; 49(4):225-9 (27 ref.)

HEARING

consider also terms at ACOUSTIC and AUDIO-

see related
ACOUSTIC STIMULATION
AUDITORY PERCEPTION
BONE CONDUCTION

AAP recommends the development of universal newborn hearing screening programs. American Academy of Pediatrics. Rose VL. **Am Fam Physician** 1999 Sep 1; 60(3):1020

British Society of Audiology short papers meeting on experimental studies of hearing and deafness. London, United Kingdom, 15-16 September, 1998. Abstracts. **Br J Audiol** 1999 Apr;33(2):75-133

British Society of Audiology Short Papers Meeting on Experimental Studies of Hearing and Deafness. Nottingham, 22-23 September 1997. Abstracts [see comments] **Br J Audiol** 1998;32(2):69-128. Comment in: Br J Audiol 1998 Aug;32(4):255.

Sensory perception: supernormal hearing in the blind? Morgan M. **Curr Biol** 1999 Jan 28;9(2):R53-4 (5 ref.)

Inter-rater reliability as a reflection of ambiguity in the communication of deaf and normally-hearing children. Nicholas JG, et al. **J Commun Disord** 1999 Mar-Apr; 32(2):121-33; 133-4

Factors affecting hearing results after stapes surgery. Ueda H, et al. **J Laryngol Otol** 1999 May;113(5):417-21

Some issues in the statistical analysis of completely randomized and repeated measures designs for speech, language, and hearing research. Max L, et al. **J Speech Lang Hear Res** 1999 Apr;42(2):261-70

Preoperative hearing predicts postoperative hearing. Blakley BW, et al. **Otolaryngol Head Neck Surg** 1998 Dec; 119(6):559-63

Hearing results in pediatric patients after canal-wall-up and canal-wall-down mastoid surgery. Murphy TP, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):439-43

Standardized format for depicting hearing preservation results in the management of acoustic neuroma. Rappaport JM, et al. **Otolaryngol Head Neck Surg** 1999 Sep; 121(3):176-9

The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Sininger YS, et al. **Pediatr Clin North Am** 1999 Feb;46(1):1-14 (62 ref.)

Communication as social engagement: implications for interactions between deaf and hearing persons. Foster S. **Scand Audiol Suppl** 1998;49:116-24 (20 ref.)

Preservation of hearing in acoustic neuromas treated by gamma knife surgery. Thomassin JM, et al. **Stereotact Funct Neurosurg** 1998 Oct;70 Suppl 1:74-9

Suboccipital resection of a medial acoustic neuroma with hearing preservation. Snyder WE, et al. **Surg Neurol** 1999 May;51(5):548-52; discussion 552-3

Learning pop-out detection: building representations for conflicting target-distractor relationships. Ahissar M, et al. **Vision Res** 1998 Oct;38(20):3095-107

DRUG EFFECTS

The effects of midazolam on pure tone audiometry, speech audiometry, and audiological reaction times in human volunteers. Kelly DJ, et al. **Anesth Analg** 1999 May; 88(5):1064-8

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Rybak MJ, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1549-55

The effect of combined administration of cadmium and furosemide on auditory function in the rat. Whitworth CA, et al. **Hear Res** 1999 Mar;129(1-2):61-70

Once versus twice daily amikacin in neonates: prospective study on toxicity. Kotze A, et al. **J Paediatr Child Health** 1999 Jun;35(3):283-6

Gentamicin concentration and toxicity [letter; comment] Modi N, et al. **Lancet** 1998 Jul 4;352(9121):70. Comment on: Lancet 1998 May 9;351(9113):1407-8.

Toluene ototoxicity in rats: assessment of the frequency of hearing deficit by electrocochleography. Lataye R, et al. **Neurotoxicol Teratol** 1999 May-Jun;21(3):267-76

GENETICS

Development and maintenance of ear innervation and function: lessons from mutations in mouse and man. Fritzsch B, et al. **Am J Hum Genet** 1998 Nov;63(5):1263-70 (31 ref.)

Genetic associations in age-related hearing thresholds. Gates GA, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun; 125(6):654-9

Beginning of a molecular era in hearing and deafness. Robertson NG, et al. **Clin Genet** 1999 Mar;55(3):149-59 (145 ref.)

Earedness and handedness: distribution in a German sample with some family data. Reiss M, et al. **Cortex** 1999 Jun; 35(3):403-12

Identifying the genes of hearing, deafness, and dysequilibrium. Corwin JT. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12080-2

PHYSIOLOGY

Preservation of hearing in large acoustic neurinomas following removal via suboccipito-lateral approach. Fahlbusch R, et al. **Acta Neurochir (Wien)** 1998; 140(8):771-7; discussion 778

Measures of cochlear travelling wave delay in humans: I. Comparison of three techniques in subjects with normal hearing. Serbetçioğlu MB, et al. **Acta Otolaryngol** 1999; 119(5):537-43

The influence of an arterial and venous air embolism on the hearing level in laboratory mini pigs. Juncker C, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):803-7

Cochlear implantation influences contralateral hearing and vestibular responsiveness. Ribári O, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):225-8

Validation of hearing results in tympanoplasty: a preliminary report. Meyer AG, et al. **Acta Otorhinolaryngol Belg** 1998; 52(4):313-6

Stress and coping in hearing mothers of children with hearing loss: factors affecting mother and child adjustment. Calderon R, et al. **Am Ann Deaf** 1999 Mar;144(1):7-18

Characteristics of hearing families and their young deaf and hard of hearing children. Early intervention follow-up. Calderon R, et al. **Am Ann Deaf** 1998 Oct;143(4):347-62

Measurements of loudness growth in 1/2-octave bands for children and adults with normal hearing. Ellis MR, et al. **Am J Audiol** 1999 Jun;8(1):40-6

Quality of hearing preservation in acoustic neuroma surgery. Kanzaki J, et al. **Am J Otol** 1998 Sep;19(5):644-8

Auditory reaction times in patients with chronic tinnitus with normal hearing. Nieschalk M, et al. **Am J Otol** 1998 Sep; 19(5):611-8

Do cochlear nuclei contribute to auditory lateralization? A stereological evaluation of neuron numbers. Agar E, et al. **Ann Otol Rhinol Laryngol** 1999 Jul;108(7 Pt 1):661-5

The 40 Hz modulation-following response: prediction of low-frequency uncomfortable loudness levels in normally hearing adults. Parker D, et al. **Audiology** 1998 Nov-Dec; 37(6):372-81

Analyses of notches in audioscan and DPOAEs in subjects with normal hearing. Zhao F, et al. **Audiology** 1998 Nov-Dec;37(6):335-43

Role of acoustic striae in hearing: reflexive responses to elevated sound-sources. Sutherland DP, et al. **Behav Brain Res** 1998 Dec;97(1-2):1-12

Effects of neonatal undernutrition and binaural ear occlusion on neuronal development of the superior olivary complex of rats. Torrero C, et al. **Biol Neonate** 1999;75(4):259-71

Neonatal hearing screening using otoacoustic emissions elicited by maximum length sequences. Rasmussen AN, et al. **Br J Audiol** 1998 Dec;32(6):355-66

Impaired speech perception in poor readers: evidence from hearing and speech reading. de Gelder B, et al. **Brain Lang** 1998 Oct 1;64(3):269-81

Otologic and audiologic status of Russian children with cleft lip and palate. Seagle MB, et al. **Cleft Palate Craniofac J** 1998 Nov;35(6):495-9

Anesthesia and the electrophysiology of auditory consciousness. Pockett S. **Conscious Cogn** 1999 Mar; 8(1):45-61 (79 ref.)

Feeling the vibes: chordotonal mechanisms in insect hearing. Eberl DF. **Curr Opin Neurobiol** 1999 Aug;9(4):389-93 (40 ref.)

How do cochlear prostheses work? Rubinstein JT, et al. **Curr Opin Neurobiol** 1999 Aug;9(4):399-404 (55 ref.)

Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35-9 (32 ref.)

The identification of speech in noise by cochlear implant patients and normal-hearing listeners using 6-channel signal processors. Dorman MF, et al. **Ear Hear** 1998 Dec; 19(6):481-4

Aided growth of masking for speech and nonspeech signals. Fortune T. **Ear Hear** 1999 Jun;20(3):214-27

The effect of masker interaural time delay on the masking level difference in children with history of normal hearing or history of otitis media with effusion. Hall JW 3rd, et al. **Ear Hear** 1998 Dec;19(6):429-33

Characteristics of transient evoked otoacoustic emissions in normal-hearing and hearing-impaired children. Harrison WA, et al. **Ear Hear** 1999 Feb;20(1):75-86

Validity and repeatability of level-independent HL to SPL transforms. Scollie SD, et al. **Ear Hear** 1998 Oct; 19(5):407-13

Comparative light and electron microscopic study of the auditory organs of two species of fishes (pisces): Hyphessobrycon simulans (Ostariophysi) and Poecilia reticulata (Acanthopterygii). Hertwig I, et al. **Eur J Morphol** 1999 Feb;37(1):17-28

Significance of forebrain structures in acoustically guided behavior in anurans. Walkowiak W, et al. **Eur J Morphol** 1999 Apr;37(2-3):177-81

Spatial disparity affects visual-auditory interactions in human sensorimotor processing. Harrington LK, et al. **Exp Brain Res** 1998 Sep;122(2):247-52

Detection thresholds for brief sounds--are they a measure of auditory intensity integration? Krumbholz K, et al. **Hear Res** 1998 Oct;124(1-2):155-69

The relation between otoacoustic emissions and the broadening of the auditory filter for higher levels. Leeuw AR, et al. **Hear Res** 1998 Dec;126(1-2):1-10

Influence of spontaneous otoacoustic emissions on distortion product otoacoustic emission amplitudes. Ozturan O, et al. **Hear Res** 1999 Jan;127(1-2):129-36

Avian species differences in susceptibility to noise exposure. Ryals BM, et al. **Hear Res** 1999 May;131(1-2):71-88

PET imaging of cochlear-implant and normal-hearing subjects listening to speech and nonspeech. Wong D, et al. **Hear Res** 1999 Jun;132(1-2):34-42

Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Zheng QY, et al. **Hear Res** 1999 Apr; 130(1-2):94-107

Level discrimination of single tones in a multitone complex by normal-hearing and hearing-impaired listeners. Doherty KA, et al. **J Acoust Soc Am** 1999 Mar;105(3):1831-40

The recognition of sentences in noise by normal-hearing listeners using simulations of cochlear-implant signal processors with 6-20 channels. Dorman MF, et al. **J Acoust Soc Am** 1998 Dec;104(6):3583-5

Computer models for masked hearing experiments with beluga whales (Delphinapterus leucas). Erbe C, et al. **J Acoust Soc Am** 1999 May;105(5):2967-78

Effects of noise and spectral resolution on vowel and consonant recognition: acoustic and electric hearing. Fu

QJ, et al. **J Acoust Soc Am** 1998 Dec;104(6):3586–96

Effects of amplitude nonlinearity on phoneme recognition by cochlear implant users and normal-hearing listeners. Fu QJ, et al. **J Acoust Soc Am** 1998 Nov;104(5):2570–7

Acquisition of a tactile-alone vocabulary by normally hearing users of the Tickle Talker. Galvin KL, et al. **J Acoust Soc Am** 1999 Aug;106(2):1084–9

The underwater audiogram of the West Indian manatee (Trichechus manatus). Gerstein ER, et al. **J Acoust Soc Am** 1999 Jun;105(6):3575–83

Psychophysical measures of auditory nonlinearities as a function of frequency in individuals with normal hearing. Hicks ML, et al. **J Acoust Soc Am** 1999 Jan;105(1):326–38

Sound localization in noise in normal-hearing listeners. Lorenzi C, et al. **J Acoust Soc Am** 1999 Mar;105(3):1810–20

Dolphin hearing: relative sensitivity as a function of point of application of a contact sound source in the jaw and head region. Møhl B, et al. **J Acoust Soc Am** 1999 Jun; 105(6):3421–4

Measuring the threshold for speech reception by adaptive variation of the signal bandwidth. I. Normal-hearing listeners. Noordhoek IM, et al. **J Acoust Soc Am** 1999 May; 105(5):2895–902

Comments on "Elephant hearing" [J. Acoust. Soc. Am. 104, 1122–1123 (1998)] [letter; comment] O'Connell C, et al. **J Acoust Soc Am** 1999 Mar;105(3):2051–2. Comment on: J Acoust Soc Am 1998 Aug;104(2 Pt 1):1122–3.

Killer whale (Orcinus orca) hearing: auditory brainstem response and behavioral audiograms. Szymanski MD, et al. **J Acoust Soc Am** 1999 Aug;106(2):1134–41

Resolution of front-back ambiguity in spatial hearing by listener and source movement. Wightman FL, et al. **J Acoust Soc Am** 1999 May;105(5):2841–53

An overview of neural function and feedback control in human communication. Hood LJ. **J Commun Disord** 1998 Nov-Dec;31(6):461–9; quiz 469–70; 553

Developmental expression of the glycine transporter GLYT2 in the auditory system of rats suggests involvement in synapse maturation. Friauf E, et al. **J Comp Neurol** 1999 Sep 13;412(1):17–37

Class III beta-tubulin expression in sensory and nonsensory regions of the developing avian inner ear. Molea D, et al. **J Comp Neurol** 1999 Apr 5;406(2):183–98

Input-output relationships of the dorsal nucleus of the lateral lemniscus: possible substrate for the processing of dynamic spatial cues. Shneiderman A, et al. **J Comp Neurol** 1999 Jul 26;410(2):265–76

Peripheral frequency mis-match in the primitive ensiferan Cyphoderris monstrosa (Orthoptera: Haglidae). Mason AC, et al. **J Comp Physiol [A]** 1999 May;184(5):543–51

Seismic communication signals in the blind mole-rat (Spalax ehrenbergi): electrophysiological and behavioral evidence for their processing by the auditory system. Rado R, et al. **J Comp Physiol [A]** 1998 Oct;183(4):503–11

Auditory role of the suprabranchial chamber in gourami fish. Yan HY. **J Comp Physiol [A]** 1998 Sep;183(3):325–33

Sound localization in an Old-World fruit bat (Rousettus aegyptiacus): acuity, use of binaural cues, and relationship to vision. Heffner RS, et al. **J Comp Psychol** 1999 Sep; 113(3):297–306

Hearing in a megachiropteran fruit bat (Rousettus aegyptiacus). Koay G, et al. **J Comp Psychol** 1998 Dec; 112(4):371–82

Tympanal hearing in the sarcophagid parasitoid fly Emblemasoma sp.: the biomechanics of directional hearing. Robert D, et al. **J Exp Biol** 1999 Jul;202 (Pt 14):1865–76

Large-scale functional connectivity in associative learning: interrelations of the rat auditory, visual, and limbic systems. Mcintosh AR, et al. **J Neurophysiol** 1998 Dec;80(6):3148–62

Intracellular responses of onset chopper neurons in the ventral cochlear nucleus to tones: evidence for dual-component processing. Paolini AG, et al. **J Neurophysiol** 1999 May;81(5):2347–59

Detection of auditory signals by frog inferior collicular neurons in the presence of spatially separated noise. Ratnam R, et al. **J Neurophysiol** 1998 Dec;80(6):2848–59

Supporting cells contribute to control of hearing sensitivity. Flock A, et al. **J Neurosci** 1999 Jun 1;19(11):4498–507

Expression of the P2X(2) receptor subunit of the ATP-gated ion channel in the cochlea: implications for sound transduction and auditory neurotransmission. Housley GD, et al. **J Neurosci** 1999 Oct 1;19(19):8377–88

Conductive hearing loss produces a reversible binaural hearing impairment. Moore DR, et al. **J Neurosci** 1999 Oct 1;19(19):8704–11

The electrical properties of auditory hair cells in the frog amphibian papilla. Smotherman MS, et al. **J Neurosci** 1999 Jul 1;19(13):5275–92

Hearing preservation in vestibular schwannoma surgery [letter; comment] Rowed DW. **J Neurosurg** 1999 Feb; 90(2):374–6. Comment on: J Neurosurg 1998 May;88(5):840–5.

Middle fossa and hearing preservation [letter; comment] Whittaker CK, et al. **J Neurosurg** 1998 Nov;89(5):894. Comment on: J Neurosurg 1998 May;88(5):840–5.

Subjective assessment of temporomandibular joint sounds. Prinz JF. **J Oral Rehabil** 1998 Oct;25(10):765–9

Frequency tuning of cochlear hair cells by differential splicing of BK channel transcripts [editorial; comment] Oberholtzer JC. **J Physiol (Lond)** 1999 Aug 1;518 (Pt 3):629. Comment on: J Physiol (Lond) 1999 Aug 1;518 (Pt 3):653–65.

The dependence of the distortion product 2f1–f2 on primary levels in non-impaired human ears. Dhar S, et al. **J Speech Lang Hear Res** 1998 Dec;41(6):1307–18

Psychophysical sensitivity and physiological response to amplitude modulation in adult dyslexic listeners. Menell P, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):797–803

FO processing and the separation of competing speech signals by listeners with normal hearing and with hearing loss. Summers V, et al. **J Speech Lang Hear Res** 1998 Dec; 41(6):1294–306

Spatial and temporal mapping of neural activity associated with auditory hallucinations [letter] [see comments] Lennox BR, et al. **Lancet** 1999 Feb 20;353(9153):644. Comment in: Lancet 1999 Jul 10;354(9173):166.

Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Arriaga MA, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1682–5

Electrocochleographic and audiometric evaluation of hypobaric effect in Meniere's disease. Konrádsson KS, et al. **Laryngoscope** 1999 Jan;109(1):59–64

Hearing preservation in microvascular decompression for trigeminal neuralgia. Rizvi SS, et al. **Laryngoscope** 1999 Apr;109(4):591–4

Mechanical and electromotile characteristics of auditory outer hair cells. Spector AA, et al. **Med Biol Eng Comput** 1999 Mar;37(2):247–51

Long-term temporal integration in the anuran auditory system. Alder TB, et al. **Nat Neurosci** 1998 Oct;1(6):519–23

Gating of auditory responses in the vocal control system of awake songbirds. Schmidt MF, et al. **Nat Neurosci** 1998 Oct;1(6):513–8

Coincidence detection in the auditory system: 50 years after Jeffress. Joris PX, et al. **Neuron** 1998 Dec;21(6):1235–8 (20 ref.)

Absence of thyroid hormone receptor beta-retinoid X receptor interactions in auditory function and in the pituitary-thyroid axis. Barros AC, et al. **Neuroreport** 1998 Sep 14;9(13):2933–7

Mismatch negativity (MMN) as an index of auditory sensory memory deficit in cleft-palate and CATCH syndrome children. Cheour M, et al. **Neuroreport** 1998 Aug 24; 9(12):2709–12

Spontaneous regeneration and recovery of hearing function of the central auditory pathway in young rats. Ito J, et al. **Neurosci Lett** 1998 Oct 2;254(3):173–6

Age-related changes in GABA(A) receptor subunit composition and function in rat auditory system. Caspary DM, et al. **Neuroscience** 1999;93(1):307–12

Revision stapedectomy for incus erosion: long-term hearing. Krieger LW, et al. **Otolaryngol Head Neck Surg** 1998 Oct; 119(4):370–3

Partial labyrinthectomy with hearing preservation: frequency-specific data using tone-burst auditory brain stem response. Smouha EE, et al. **Otolaryngol Head Neck Surg** 1999 Feb;120(2):146–52

The sensory world of the platypus. Pettigrew JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Jul 29; 353(1372):1199–210 (38 ref.)

Comparing in vitro, in situ, and in vivo experimental data in a three-dimensional model of mammalian cochlear mechanics. Kolston PJ. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3676–81

Thyroid hormone receptor beta-dependent expression of a potassium conductance in inner hair cells at the onset of hearing. Rüsch A, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15758–62

An investigation of the auditory streaming effect using event-related brain potentials. Sussman E, et al. **Psychophysiology** 1999 Jan;36(1):22–34

European Consensus statement on neonatal hearing screening finalised at the European Consensus Development Conference on Neonatal Hearing Screening 15–16 May 1998, Milan, Italy. **Scand Audiol** 1998;27(4):259–60 (0 ref.)

Towards an ecological audiology: stereophonic listening chamber and acoustic environmental tests. Borg E, et al. **Scand Audiol** 1998;27(4):195–206

Measures of the binaural interaction component in human auditory brainstem response using objective detection criteria. Brantberg K, et al. **Scand Audiol** 1999;28(1):15–26

Effects of exercise training on hearing ability. Cristell M, et al. **Scand Audiol** 1998;27(4):219–24

Long-term test-retest reliability of category loudness scaling in normal-hearing subjects using pure-tone stimuli. Rasmussen AN, et al. **Scand Audiol** 1998;27(3):161–7

Static magnetic field and the inner ear. A functional study of hearing and vestibular function in man after exposure to a static magnetic field. Winther FO, et al. **Scand Audiol** 1999;28(1):57–9

[The 40 Hertz auditory event-related potential in chick: optimized recording conditions and threshold value] Xiao H, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Jun;11(6):258–61 (Eng. Abstr.) **(Chi)**

[Vestibular manifestations revealing acoustic neurinoma with normal hearing (letter)] Bertholon P, et al. **Presse Med** 1999 Jan 16;28(2):76 **(Fre)**

[Biomechanical 3D–FE model of the human cochlea] Böhnke F, et al. **Biomed Tech (Berl)** 1998;43 Suppl:26–7 **(Ger)**

[Prognostic factors for hearing preservation following observation-only versus stereotactic irradiation (STI) in patients with acoustic neuroma] Sakamoto T. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Oct;101(10):1250–9 (Eng. Abstr.) **(Jpn)**

[Speech audiometry using the American Word Lists for Japanese subjects with normal hearing] Shimizu T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Jul;101(7):879–83 (Eng. Abstr.) **(Jpn)**

[Auditory evoked potentials from brain stem determined in acoustic nerve neurinomas] Rostkowska-Nadolska B, et al. **Neurol Neurochir Pol** 1999 Jan-Feb;33(1):43–52 (Eng. Abstr.) **(Pol)**

[The application of otoacoustic emissions measurement in the assessment of the function of cochlear efferent fibers: the study of normal hearing subjects] Kotylo P, et al. **Otolaryngol Pol** 1999;53(1):87–93 (Eng. Abstr.) **(Pol)**

[Hearing sensitivity to contrast of sound spectrum patterns] Supin AIa, et al. **Dokl Akad Nauk** 1999 Apr;365(4):571–3 **(Rus)**

[Age-related changes in the auditory, speech and visual memories of boys and girls 6–12 years old] Davydova ElIu, et al. **Fiziol Cheloveka** 1999 Mar-Apr;25(2):14–20 **(Rus)**

HEARING AIDS

Measurements of loudness growth in 1/2-octave bands for children and adults with normal hearing. Ellis MR, et al. **Am J Audiol** 1999 Jun;8(1):40–6

A clinical trial of the ReSound IC4 hearing device. Walden BE, et al. **Am J Audiol** 1999 Jun;8(1):65–78

Is stapedectomy ever ethical?—Faulty premise, faulty conclusion [letter; comment] Gianoli GJ, et al. **Am J Otol** 1999 Jan;20(1):138–40; discussion 141. Comment on: Am J Otol 1998 Sep;19(5):541–3; discussion 544–5.

Long-term results with the titanium bone-anchored hearing aid: the U.S. experience. Wazen JJ, et al. **Am J Otol** 1998 Nov;19(6):737–41

Guided tissue generation in the temporal bone. Granström G, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):349–54

Percutaneous implants in the temporal bone for securing a bone conductor: surgical methods and results. van der Pouw CT, et al. **Ann Otol Rhinol Laryngol** 1999 Jun; 108(6):532–6 (18 ref.)

Comparison of speech perception in pediatric CLARION cochlear implant and hearing aid users. Svirsky MA, et al. **Ann Otol Rhinol Laryngol Suppl** 1999 Apr;177:104–9

Clinical evaluation of a full-digital in-the-ear hearing instrument. Boymans M, et al. **Audiology** 1999 Mar-Apr; 38(2):99–108

Sound localization for a virtual sound source in cases of chronic otitis media. Kawase T, et al. **Audiology** 1999 Mar-Apr;38(2):83–90

Loudness perception is influenced by long-term hearing aid use. Olsen SO, et al. **Audiology** 1999 Jul-Aug;38(4):202–5

Speech intelligibility in noisy environments with one- and two-microphone hearing aids. Wouters J, et al. **Audiology** 1999 Mar-Apr;38(2):91–8

Variable-speech-rate audiometry for hearing aid evaluation. Hosoi H, et al. **Auris Nasus Larynx** 1999 Jan;26(1):17–27

Cell surface characteristics of microbiological isolates from human percutaneous titanium implants in the head and neck. Holgers KM, et al. **Biomaterials** 1999 Jul; 20(14):1319–26

Use of a loudness model for hearing aid fitting: II. Hearing aids with multi-channel compression. Moore BC, et al. **Br J Audiol** 1999 Jun;33(3):157–70

Use of a loudness model for hearing-aid fitting. I. Linear hearing aids. Moore BC, et al. **Br J Audiol** 1998 Oct; 32(5):317–35

Psychometric evaluation of the Gothenburg Profile for measurement of experienced hearing disability and handicap: applications with new hearing aid candidates and experienced hearing aid users. Ringdahl A, et al. **Br J Audiol** 1998 Dec;32(6):375–85

Assessment of basal sound identification skills and communication abilities in profoundly deaf children fitted with hearing aids or a cochlear implant. van den Borne S, et al. **Clin Otolaryngol** 1998 Oct;23(5):455–61

Trial of a two-channel hearing aid (low-frequency compression-high-frequency linear amplification) with school age children. Bamford J, et al. **Ear Hear** 1999 Aug; 20(4):290–8

Client preferences for compression threshold in single-channel wide dynamic range compression hearing aids. Barker C, et al. **Ear Hear** 1999 Apr;20(2):127–39

Measuring Satisfaction with Amplification in Daily Life: the SADL scale. Cox RM, et al. **Ear Hear** 1999 Aug; 20(4):306–20

The National Acoustic Laboratories' procedure for selecting the saturation sound pressure level of hearing aids: theoretical derivation. Dillon H, et al. **Ear Hear** 1998 Aug; 19(4):255–66 (43 ref.)

Children's speech recognition in noise using omni-directional and dual-microphone hearing aid technology. Gravel JS, et al. **Ear Hear** 1999 Feb;20(1):1–11

Comparison of linear gain and wide dynamic range compression hearing aid circuits: aided speech perception measures. Jenstad LM, et al. **Ear Hear** 1999 Apr; 20(2):117–26

Comparison of two digital hearing aids. Knebel SB, et al. **Ear Hear** 1998 Aug;19(4):280–9

Recognition performance for four combinations of FM system and hearing aid microphone signals in adverse listening conditions. Pittman AL, et al. **Ear Hear** 1999 Aug; 20(4):279–89

Investigation of the profile of hearing aid performance in

experienced hearing aid users. Purdy SC, et al. **Ear Hear** 1998 Dec;19(6):473–80

Validity and repeatability of level-independent HL to SPL transforms. Scollie SD, et al. **Ear Hear** 1998 Oct; 19(5):407–13

Quantifying the contribution of audibility to recognition of compression-amplified speech. Souza PE, et al. **Ear Hear** 1999 Feb;20(1):12–20

The production of English inflectional morphology, speech production and listening performance in children with cochlear implants. Spencer LJ, et al. **Ear Hear** 1998 Aug; 19(4):310–8

Tolerable hearing aid delays. I. Estimation of limits imposed by the auditory path alone using simulated hearing losses. Stone MA, et al. **Ear Hear** 1999 Jun;20(3):182–92

The National Acoustic Laboratories' procedure for selecting the saturation sound pressure level of hearing aids: experimental validation. Storey L, et al. **Ear Hear** 1998 Aug;19(4):267–79

Auditory training in severely and profoundly hearing impaired toddlers: the development of auditory skills and verbal communication. Hoekstra CC, et al. **Int J Pediatr Otorhinolaryngol** 1999 Feb 15;47(2):201–4

Speech recognition, speech production and speech intelligibility in children with hearing aids versus implanted children. Löhle E, et al. **Int J Pediatr Otorhinolaryngol** 1999 Feb 15;47(2):165–9

System identification of feedback in hearing aids. Hellgren J, et al. **J Acoust Soc Am** 1999 Jun;105(6):3481–96

Constrained adaptation for feedback cancellation in hearing aids. Kates JM. **J Acoust Soc Am** 1999 Aug;106(2):1010–9

Perception of microphone noise in hearing instruments. Lee LW, et al. **J Acoust Soc Am** 1998 Dec;104(6):3364–7

Benefits of linear amplification and multichannel compression for speech comprehension in backgrounds with spectral and temporal dips. Moore BC, et al. **J Acoust Soc Am** 1999 Jan;105(1):400–11

Does hearing aid benefit increase over time? [letter; comment] Turner CW, et al. **J Acoust Soc Am** 1998 Dec; 104(6):3673–4. Comment on: J Acoust Soc Am 1998 Apr;103(4):1705–21.

Practice innovation: a methodological maze. Tolson D. **J Adv Nurs** 1999 Aug;30(2):381–90

Hearing aid effect in older females. Doggett S, et al. **J Am Acad Audiol** 1998 Oct;9(5):361–6

Loudness scaling revisited. Elberling C. **J Am Acad Audiol** 1999 May;10(5):248–60

Some limitations of evaluative investigations based solely on normed outcome measures. Gagné JP, et al. **J Am Acad Audiol** 1999 Jan;10(1):46–62

Dimensions of hearing aid outcome. Humes LE. **J Am Acad Audiol** 1999 Jan;10(1):26–39

The auditory steady-state response [editorial; comment] Jerger J. **J Am Acad Audiol** 1998 Oct;9(5):314. Comment on: J Am Acad Audiol 1998 Oct;9(5):315–31.

Managing hearing loss in a patient with Alzheimer disease. Palmer CV, et al. **J Am Acad Audiol** 1998 Aug;9(4):275–84

Objective evaluation of aided thresholds using auditory steady-state responses [see comments] Picton TW, et al. **J Am Acad Audiol** 1998 Oct;9(5):315–31. Comment in: J Am Acad Audiol 1998 Oct;9(5):314.

Telephone communication with in-the-ear hearing aids using acoustic and electromagnetic coupling. Plyler PN, et al. **J Am Acad Audiol** 1998 Dec;9(6):434–43

Field trial evaluations of a switched directional/omnidirectional in-the-ear hearing instrument. Preves DA, et al. **J Am Acad Audiol** 1999 May;10(5):273–84

Hearing aid outcome measures for children. Stelmachowicz PG. **J Am Acad Audiol** 1999 Jan;10(1):14–25; quiz 66

Explanation on "Long-term versus short-term hearing aid benefit" [letter] Surr RK, et al. **J Am Acad Audiol** 1998 Oct;9(5):398

Comparing the performance of the Widex SENSO digital hearing aid with analog hearing aids. Valente M, et al. **J Am Acad Audiol** 1998 Oct;9(5):342–60

Characteristics associated with marginal hearing loss and subjective well-being among a sample of older adults. Scherer MJ, et al. **J Rehabil Res Dev** 1998 Oct;35(4):420–6

A comparison of the aided performance and benefit provided by a linear and a two-channel wide dynamic range compression hearing aid. Humes LE, et al. **J Speech Lang Hear Res** 1999 Feb;42(1):65–79

Reduction in caregiver-identified problem behaviors in patients with Alzheimer disease post-hearing-aid fitting. Palmer CV, et al. **J Speech Lang Hear Res** 1999 Apr; 42(2):312–28

The effects of venting on in-the-ear, in-the-canal, and completely-in-the-canal hearing aid shell frequency responses: real-ear measures. Stuart A, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):804–13 (39 ref.)

A comparison of language achievement in children with cochlear implants and children using hearing aids. Tomblin JB, et al. **J Speech Lang Hear Res** 1999 Apr;42(2):497–509

Totally implantable hearing device for sensorineural hearing loss [letter] Zenner HP, et al. **Lancet** 1998 Nov 28; 352(9142):1751

Hearing aids. Klein AJ, et al. **Med Clin North Am** 1999 Jan; 83(1):139–51

Management of the child with sensorineural hearing loss. Medical, surgical, hearing aids, cochlear implants. Brookhouser PE, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):121–41 (76 ref.)

'Doctor, do I need a hearing aid?' [editorial] Beynon GJ, et al. **Practitioner** 1998 Jun;242(1587):421

Procedure for clinical testing of hearing aids. Andersen T, et al. **Scand Audiol** 1998;27(4):249–54

Clinical study of Widex Senso on first-time hearing aid users. Berninger E, et al. **Scand Audiol** 1999;28(2):117–25

Clinical study of a digital vs an analogue hearing aid. Bille M, et al. **Scand Audiol** 1999;28(2):127–35

Detectability of cochlear, acoustic nerve and brainstem potentials in a group of 'normal' preterm newborns recorded with insert earphone. Cornacchia L, et al. **Scand Audiol** 1998;27(4):213–7

Clinical evaluation of a portable digital hearing aid with narrow-band loudness compensation. Hidaka H, et al. **Scand Audiol** 1998;27(4):225–36

Control of hearing-aid saturated sound pressure level by frequency-shaped output compression limiting. McDermott HJ, et al. **Scand Audiol** 1999;28(1):27–38

A new more powerful bone-anchored hearing aid: first results. van der Pouw CT, et al. **Scand Audiol** 1998; 27(3):179–82

Speech tests as measures of outcome. Gatehouse S. **Scand Audiol Suppl** 1998;49:54–60

Non-linear signal processing in digital hearing aids. Lunner T, et al. **Scand Audiol Suppl** 1998;49:40–9

Potential perceptual bases for successful use of a vibrotactile speech perception aid. Bernstein LE, et al. **Scand J Psychol** 1998 Sep;39(3):181–6

Speech discrimination by elderly hearing instrument users. van Wyk L, et al. **S Afr J Commun Disord** 1997;44:99–108 (Eng. Abstr.) **(Afr)**

[Digital multi-filter auditory prosthesis: study of its efficiency in function of number of filters and their programming] Chouard CH, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Jun;115(3):118–28 (Eng. Abstr.) **(Fre)**

[Bone anchored hearing aid (BAHA): clinical evaluation] Jankowski R, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec;115(6):315–20 (Eng. Abstr.) **(Fre)**

[Guideline "Providing hearing aids" of the German Society for Ear, Nose and Throat Medicine and Head and Neck Surgery] **HNO** 1999 Feb;47(2):92–4 (8 ref.) **(Ger)**

[A totally implantable hearing aid for inner ear deafness: TICA LZ 3001] Leysieffer H, et al. **HNO** 1998 Oct; 46(10):853–63 (Eng. Abstr.) **(Ger)**

[First implantation of a totally implantable electronic hearing aid in patients with inner ear hearing loss] Zenner HP, et al. **HNO** 1998 Oct;46(10):844–52 (Eng. Abstr.) **(Ger)**

[Guidelines/algorithms of the German Society of Otorhinolaryngology, Head and Neck Surgery. Guideline: hearing aid management. German Society of Otorhinolaryngology. Head and Neck Surgery] Ganzer U. **Laryngorhinootologie** 1999 Apr;78(4):224–6 **(Ger)**

[Improvement of hearing aid fitting with digital aids and new fitting strategies] Schorn K, et al. **Laryngorhinootologie** 1999 Jan;78(1):14–9 (Eng. Abstr.) **(Ger)**

[Promotion and therapy of children with hearing loss (hearing aids)—statement of the DVfR Study Committee of Hearing, Voice and Speech Disorders] Salz W. **Rehabilitation (Stuttg)** 1999 May;38(2):136–40 **(Ger)**

[Measurements of directional hearing aid function] Prosser S, et al. **Acta Otorhinolaryngol Ital** 1998 Apr;18(2):70–3 (Eng. Abstr.) **(Ita)**

[Efficacy of middle ear surgery for patients with hearing aids and middle ear disease] Saito T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Mar;102(3):347–53 (Eng. Abstr.) **(Jpn)**

[Voice acoustic analysis in patients with a hearing aid or cochlear implant] Pruszewicz A, et al. **Otolaryngol Pol** 1998;52(6):695–700 (Eng. Abstr.) **(Pol)**

[Ways of using digital signal processing for expanding the potentials of hearing aids] Babkina LN, et al. **Vestn Otorinolaringol** 1998;(4):18–21 (Eng. Abstr.) **(Rus)**

[Prospective therapeutic trial of masking treatment in patients with tinnitus] Hernández Moñiz F, et al. **Acta Otorrinolaringol Esp** 1998 Aug–Sep;49(6):437–41 (Eng. Abstr.) **(Spa)**

[Modern hearing-aids at the cutting edge of microelectronics. Increased possibilities for individual customization] Arlinger S. **Lakartidningen** 1999 Aug 25;96(34):3524–8 (Eng. Abstr.) **(Swe)**

HISTORY

A bit of history on standards for acoustical measurements of hearing aids. Lybarger SF, et al. **Am J Audiol** 1999 Jun; 8(1):3–5

PSYCHOLOGY

Attitudes to hearing difficulty and hearing aids and the outcome of audiological rehabilitation. Brooks DN, et al. **Br J Audiol** 1998 Aug;32(4):217–26

Personality and the subjective assessment of hearing aids. Cox RM, et al. **J Am Acad Audiol** 1999 Jan;10(1):1–13

Perceived hearing aid benefit in relation to perceived needs. Schum DJ. **J Am Acad Audiol** 1999 Jan;10(1):40–5

The acceptance of hearing aids for children with otitis media with effusion. Jardine AH, et al. **J Laryngol Otol** 1999 Apr; 113(4):314–7

STANDARDS

A bit of history on standards for acoustical measurements of hearing aids. Lybarger SF, et al. **Am J Audiol** 1999 Jun; 8(1):3–5

Minimum Nordic requirements for clinical testing of hearing aids. Nordiska samarbetsorganet för handikappfrågor (Nordic Co-operation on Disability). Working group for harmonization of requirements on aids for hearing-impaired persons, June 1998. Hagermann B. **Scand Audiol** 1999;28(2):102–16

Clinical assessment of modern hearing aids. Arlinger SD. **Scand Audiol Suppl** 1998;49:50–3

[The usefulness of today's hearing aids—possibilities and limitations] Kiessling J. **MMW Fortschr Med** 1999 Jun 17; 141(24):32–4 (Eng. Abstr.) **(Ger)**

SUPPLY & DISTRIBUTION

Aural rehabilitation in the elderly: supply of hearing aids related to measured need and self-assessed hearing problems. Karlsson AK, et al. **Scand Audiol** 1998; 27(3):153–60

UTILIZATION

Current status and critical reflections on implantable hearing aids. Hüttenbrink KB. **Am J Otol** 1999 Jul;20(4):409–15 (21 ref.)

Accuracy of hearing aid use time as reported by experienced hearing aid wearers. Taubman LB, et al. **Ear Hear** 1999 Aug;20(4):299–305

The present situation of the use of hearing aids in rural areas of Sri Lanka: problems and future prospects. Furuta H, et al. **Int J Rehabil Res** 1998 Mar;21(1):103–7

Decreased use of hearing aids following training in hearing tactics. Andersson G. **Percept Mot Skills** 1998 Oct; 87(2):703–6

HEARING DISORDERS

see related
HEARING IMPAIRED PERSONS

An examination of two coteaching classrooms. Luckner JL. **Am Ann Deaf** 1999 Mar;144(1):24–34

On the relationships of high-frequency hearing loss and cochlear pathology to the acoustic startle response (ASR) and prepulse inhibition of the ASR in the BXD recombinant inbred series. McCaughran J Jr, et al. **Behav Genet** 1999 Jan;29(1):21–30

British Society of Audiology Short Papers Meeting on Experimental Studies of Hearing and Deafness. Nottingham, 22–23 September 1997. Abstracts [see comments] **Br J Audiol** 1998;32(2):69–128. Comment in: Br J Audiol 1998 Aug;32(4):255.

British Society of Audiology short papers meeting on experimental studies of hearing and deafness. London, United Kingdom, 15–16 September, 1998. Abstracts. **Br J Audiol** 1999 Apr;33(2):75–133

An analysis of the communication tactics used by hearing-impaired adults. Stephens SD, et al. **Br J Audiol** 1999 Feb;33(1):17–27

Organization resources for families of children with deafness or hearing loss. Cherow E, et al. **Pediatr Clin North Am** 1999 Feb;46(1):153–62 (15 ref.)

The role of the pediatrician in hearing loss. From detection to connection. Finitzo T, et al. **Pediatr Clin North Am** 1999 Feb;46(1):15–34, ix–x (25 ref.)

Language of early- and later-identified children with hearing loss. Yoshinaga-Itano C, et al. **Pediatrics** 1998 Nov; 102(5):1161–71

[Confusion in the care of hearing disorders (letter)] Jørgensen KE, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):54–5 **(Dan)**

[The Danish care of persons with hearing impairment. Medical-audiological aspects] Parving A. **Ugeskr Laeger** 1999 Jan 4;161(1):11–4 (10 ref.) **(Dan)**

[Disability because of hearing and speech disorders has low priority in society. Cooperation and resources are needed] Lundborg T, et al. **Lakartidningen** 1998 Oct 21; 95(43):4757–8 (5 ref.) **(Swe)**

CHEMICALLY INDUCED

Cisplatin ototoxicity: the importance of baseline audiometry. Nagy JL, et al. **Am J Clin Oncol** 1999 Jun;22(3):305–8

Teratogenic hearing loss: a clinical perspective. Dyer JJ, et al. **Am J Otol** 1998 Sep;19(5):671–8 (47 ref.)

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Parsons SK, et al. **Bone Marrow Transplant** 1998 Oct;22(7):669–74

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Elting LS, et al. **Cancer** 1998 Dec 15; 83(12):2597–607

Reversible pitch perception deficit due to carbamazepine. Kashihara K, et al. **Intern Med** 1998 Sep;37(9):774–5 (8 ref.)

Recovery of semicircular canal primary afferent activity in the pigeon after streptomycin ototoxicity. Li W, et al. **J Neurophysiol** 1998 Dec;80(6):3297–311

Toluene ototoxicity in rats: assessment of the frequency of hearing deficit by electrocochleography. Lataye R, et al. **Neurotoxicol Teratol** 1999 May–Jun;21(3):267–76

PAF- and histamine-receptor antagonists lessen allergen-induced hearing impairment in guinea pigs. Masuyama K, et al. **Prostaglandins Other Lipid Mediat** 1998 Jul;56(4):239–44

Audiological disturbances caused by long-term exposure to industrial solvents. Relation to the diagnosis of toxic encephalopathy. Niklasson M, et al. **Scand Audiol** 1998; 27(3):131-6

Age-related increase in auditory impairment in monkeys exposed in utero plus postnatally to methylmercury. Rice DC. **Toxicol Sci** 1998 Aug;44(2):191-6

[Aminoglycosides, their ototoxic effect] de la Rosa-Gálvez A, et al. **Gac Med Mex** 1998 Nov-Dec;134(6):705-11 (34 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Clinical applicability of transient evoked otoacoustic emissions: identification and classification of hearing loss. Hatzopoulos S, et al. **Audiol Neurootol** 1998 Nov-Dec; 3(6):402-18

COMPLICATIONS

Sensory impairment and driving: the Blue Mountains Eye Study. Ivers RQ, et al. **Am J Public Health** 1999 Jan; 89(1):85-7

Otological manifestations of CHARGE association. Dhooge I, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):935-41

Hearing loss in siderosis. Palacios E, et al. **Ear Nose Throat J** 1999 May;78(5):336

Otologic management in children with the CHARGE association. Shah UK, et al. **Int J Pediatr Otorhinolaryngol** 1998 Jul 10;44(2):139-47

Special population: HIV/AIDS among the deaf and hard of hearing. Gaskins S. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):75-8 (18 ref.)

Diabetes and hearing impairment in Mexican American adults: a population-based study. Ma F, et al. **J Laryngol Otol** 1998 Sep;112(9):835-9

The influence of pregnancy on sensation of ear problems--ear problems associated with healthy pregnancy. Tsunoda K, et al. **J Laryngol Otol** 1999 Apr;113(4):318-20

Neuro-otological and psychiatric abnormalities in a community sample of people with dizziness: a blind, controlled investigation [see comments] Yardley L, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):679-84. Comment in: J Neurol Neurosurg Psychiatry 1998 Nov;65(5):619.

Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17-25 (74 ref.)

The associations between self-rated vision and hearing and functional status in middle age. Lee PP, et al. **Ophthalmology** 1999 Feb;106(2):401-5

CONGENITAL

Screening for congenital hearing impairment: time for a change. Bamford J, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F73-6

Transient evoked otoacoustic emissions (TEOAEs) in new-borns: normative data. Paludetti G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):235-41

Neonatal screening for hearing disorders in infants at risk: incidence, risk factors, and follow-up. Meyer C, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):900-4

[A new method for detecting congenital hearing disorders. Infants are screened by measuring otoacoustic emissions (see comments)] Hergils L. **Lakartidningen** 1999 Mar 10; 96(10):1166-8 (15 ref.) (Eng. Abstr.). Comment in: Lakartidningen 1999 Jun 9;96(23):2835-6. **(Swe)**

DIAGNOSIS

Audioscan testing in patients with King-Kopetzky syndrome. Zhao F, et al. **Acta Otolaryngol** 1999;119(3):306-10

A TEOAE screening protocol based on linear click stimuli: performance and scoring criteria. Hatzopoulos S, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):135-9

European Consensus Statement on Neonatal Hearing Screening. Finalized at the European Consensus Development Conference on Neonatal Hearing Screening. Milan, 15-16 May 1998. **Acta Paediatr** 1999 Jan;88(1):107-8 (0 ref.)

Screening for visual and ocular disorders in children, evaluation of the system in Sweden. Kvarnström G, et al. **Acta Paediatr** 1998 Nov;87(11):1173-9

The role of educators of the deaf in the early identification of hearing loss. Arehart KH, et al. **Am Ann Deaf** 1999 Mar; 144(1):19-23

Stress and coping in hearing mothers of children with hearing loss: factors affecting mother and child adjustment. Calderon R, et al. **Am Ann Deaf** 1999 Mar;144(1):7-18

Identification of hearing loss after age 18 months is not early enough. Yoshinaga-Itano C, et al. **Am Ann Deaf** 1998 Dec; 143(5):380-7

The development of deaf and hard of hearing children identified early through the high-risk registry. Yoshinaga-Itano C, et al. **Am Ann Deaf** 1998 Dec; 143(5):416-24

AAP recommends the development of universal newborn hearing screening programs. American Academy of Pediatrics. Rose VL. **Am Fam Physician** 1999 Sep 1; 60(3):1020

Identifying hearing loss: parents' needs. Luterman D, et al. **Am J Audiol** 1999 Jun;8(1):13-8

Tone burst auditory brain stem response latency estimates of cochlear travel time in Meniere's disease, cochlear hearing loss, and normal ears. Murray JG, et al. **Am J Otol** 1998 Nov;19(6):854-9

Profile of hearing in patients with unilateral acoustic neuromas: the importance of the contralateral ear. Stipkovits EM, et al. **Am J Otol** 1998 Nov;19(6):834-9

Clinical interpretations of transient otoacoustic emissions. Qiu WW, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):370-8

Clinical applications of transiently evoked otoacoustic emissions in the pediatric population. Choi SS, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):132-8

Misleading advertisement [letter] Goldstein R. **ASHA** 1999 Jan-Feb;41(1):6-7

Let's hear it for our troops. Saving hearing--and money--in the military. Ohlin D. **ASHA** 1998 Fall;40(4):50-3

Clinical applicability of transient evoked otoacoustic emissions: identification and classification of hearing loss. Hatzopoulos S, et al. **Audiol Neurootol** 1998 Nov-Dec; 3(6):402-18

European Consensus Statement on Neonatal Hearing Screening [news] **Audiology** 1999 Mar-Apr;38(2):119

A longitudinal study of the validity of parental reporting in the detection of otitis media and related hearing impairment in infancy. Anteunis LJ, et al. **Audiology** 1999 Mar-Apr;38(2):75-82

Use of otoacoustic emissions to screen for hearing loss in critically ill patients. Hamill-Ruth RJ, et al. **Audiology** 1998 Nov-Dec;37(6):344-52

Sensitivity of transient evoked and distortion product otoacoustic emissions to the direct effects of noise on the human cochlea. Vinck BM, et al. **Audiology** 1999 Jan-Feb; 38(1):44-52

Is there still a consensus on impairment, disability and handicap in audiology? [editorial] Arnold P. **Br J Audiol** 1998 Oct;32(5):265-71

Is there still a consensus on impairment, disability and handicap in audiology? [letter] Hinchcliffe R. **Br J Audiol** 1999 Feb;33(1):67-8

Health visitor screening versus vigilance: outcomes of programmes for detecting permanent childhood hearing loss in west Berkshire. Sutton GJ, et al. **Br J Audiol** 1999 Jun;33(3):145-56

Anomalous screening outcomes from click-evoked otoacoustic emissions and auditory brainstem response tests. Wood S, et al. **Br J Audiol** 1998 Dec;32(6):399-410

A model for the assessment and management of children with multiple disabilities. Cass H, et al. **Child Care Health Dev** 1999 May;25(3):191-211

Sensitivity, specificity and predictive value of tympanometry in predicting a hearing impairment in otitis media with effusion. MRC Multi-Centre Otitis Media Study Group. **Clin Otolaryngol** 1999 Aug;24(4):294-300

Predicting audiometric status from distortion product otoacoustic emissions using multivariate analyses. Dorn PA, et al. **Ear Hear** 1999 Apr;20(2):149-63

Clinical findings for a group of infants and young children with auditory neuropathy. Rance G, et al. **Ear Hear** 1999 Jun;20(3):238-52

The European consensus development conference on neonatal hearing screening (Milan, 15-16 May, 1998). **Eur Arch Otorhinolaryngol** 1998;255(10):521-2 (0 ref.)

Screening for neonatal hearing defects European consensus statement. Lutman ME, et al. **Eur J Pediatr** 1999 Feb; 158(2):95-6 (4 ref.)

Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Zheng QY, et al. **Hear Res** 1999 Apr; 130(1-2):94-107

Otoacoustic emission-based hearing screening of a Greek NICU population. Apostolopoulos NK, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):41-8

European Consensus Statement on Neonatal Hearing Screening. Finalised at the European Consensus Development Conference on Neonatal Hearing Screening, 15-16 May 1998, Milan. Grandori F, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10;44(3):309-10 (0 ref.)

Distortion products otoacoustic emissions in diagnosis of hearing loss in Down syndrome. Hassmann E, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 15;45(3):199-206

Hearing screening in at-risk neonate cohort. Hess M, et al. **Int J Pediatr Otorhinolaryngol** 1998 Nov 15;46(1-2):81-9

Suggestion audiometry for non-organic hearing loss (pseudohypoacusis) in children. Hosoi H, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):11-21

Auditory screening in high-risk pre-term and full-term neonates using transient evoked otoacoustic emissions and brainstem auditory evoked potentials. Morlet T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):31-40

The case for change in early infant hearing screening in Ireland [editorial] Pitt T, et al. **Ir Med J** 1999 Apr; 92(3):292-4

Development of suprathreshold word recognition test for Russian-speaking patients. Aleksandrovsky IV, et al. **J Am Acad Audiol** 1998 Dec;9(6):417-25

Real-ear characteristics of the ALGO2 acoustic transducer assembly. Clark JL, et al. **J Am Acad Audiol** 1998 Dec; 9(6):426-33

Calculating hearing handicap [letter; comment] Dobie RA. **J Am Acad Audiol** 1999 Jan;10(1):63-5. Comment on: J Am Acad Audiol 1998 Apr;9(2):141-6.

Maurice H. Miller takes the editor to task [letter; comment] Miller MH. **J Am Acad Audiol** 1998 Aug;9(4):311-3. Comment on: J Am Acad Audiol 1998 Apr;9(2):95-104.

Comparing the performance of the Widex SENSO digital hearing aid with analog hearing aids. Valente M, et al. **J Am Acad Audiol** 1998 Oct;9(5):342-60

European Consensus Statement on Neonatal Hearing Screening [letter] Grandori F. **J Laryngol Otol** 1998 Dec; 112(12):1219 (2 ref.)

Neuro-otological and psychiatric abnormalities in a community sample of people with dizziness: a blind, controlled investigation [see comments] Yardley L, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):679-84. Comment in: J Neurol Neurosurg Psychiatry 1998 Nov;65(5):619.

European Consensus Statement on Neonatal Hearing Screening. Finalised at the European Consensus Development Conference on Neonatal Hearing Screening 15-16 May 1998, Milan [editorial] Tewfik TL, et al. **J Otolaryngol** 1999 Feb;28(1):1-2 (7 ref.) **(Eng, Fre)**

A project from the Biomedical and Health Programme European Commission - Biomed 2 -Directorate General XII. The European Consensus Development Conference on Neonatal Hearing Screening. Grandori F, et al. **J Perinat Med** 1998;26(4):330-1 (0 ref.)

Challenges to universal newborn hearing screening in a South Carolina Regional Medical Center. Corley VM, et al. **J S C Med Assoc** 1999 Feb;95(2):68-70

Sudden hearing loss and the need for immediate referral [letter] Grossan M. **Otolaryngol Head Neck Surg** 1999 Jul; 121(1):166-7

Interactive effects of the middle ear pathology and the associated hearing loss on transient-evoked otoacoustic emission measures. Koike KJ, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):238-44

Establishing the etiology of childhood hearing loss. Ohlms LA, et al. **Otolaryngol Head Neck Surg** 1999 Feb; 120(2):159-63

Is parental perception an accurate predictor of childhood hearing loss? A prospective study. Stewart MG, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):340-4

A trip through the ear in search of deafness [editorial] Altemeier WA 3rd. **Pediatr Ann** 1999 Jun;28(6):342-4

Detection of hearing loss in children. Applebaum EL. **Pediatr Ann** 1999 Jun;28(6):351-6 (8 ref.)

State programs for universal newborn hearing screening. Hayes D. **Pediatr Clin North Am** 1999 Feb;46(1):89-94 (13 ref.)

The case for early identification of hearing loss in children. Auditory system development, experimental auditory deprivation, and development of speech perception and hearing. Sininger YS, et al. **Pediatr Clin North Am** 1999 Feb;46(1):1-14 (62 ref.)

Factors influencing the efficacy of universal newborn hearing screening. Stein LK. **Pediatr Clin North Am** 1999 Feb; 46(1):95-105 (32 ref.)

A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Tomaski SM, et al. **Pediatr Clin North Am** 1999 Feb;46(1):35-48 (25 ref.)

Brainstem auditory-evoked potential evaluation in children with meningitis. Bao X, et al. **Pediatr Neurol** 1998 Aug; 19(2):109-12

Parental awareness and the detection of hearing loss. Borgstein BM, et al. **Pediatr Rehabil** 1998 Oct-Dec; 2(4):165-72

Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Erenberg A, et al. **Pediatrics** 1999 Feb;103(2):527-30

The newborn with hearing loss: detection in the nursery. Finitzo T, et al. **Pediatrics** 1998 Dec;102(6):1452-60

Audiometry in general practice: validation of a pragmatic pure-tone audiometry method. Karlsmose B, et al. **Scand Audiol** 1998;27(3):137-42

The parents' view on hearing screening in newborns. Feelings, thoughts and opinions on otoacoustic emissions screening. Magnuson M, et al. **Scand Audiol** 1999; 28(1):47-56

[Summary of the guideline 'Hearing impairement' from the Dutch College of General Practitioners. The Dutch College of General Practitioners (see comments)] Eekhof JA, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1813-6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1804-5. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1806-7. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1816-9. Comment in: Ned Tijdschr Geneeskd 1998 Dec 5;142(49):2696. **(Dut)**

[Evoked otoacoustic emissions in the newborn] François M. **Arch Pediatr** 1999;6 Suppl 2:351s-352s **(Fre)**

[Evoked otoacoustic emissions at birth: the Luxembourg experience] Panosetti E, et al. **Arch Pediatr** 1999;6 Suppl 2:353s-355s **(Fre)**

[Tuning-fork tests--outdated?] Reiss M. **Fortschr Med** 1999 Apr 30;117(12):18-20 (Eng. Abstr.) **(Ger)**

[Mid-latency auditory evoked responses in Alzheimer's disease: evaluation of P1 and P3 waves] Cordone A, et al. **Acta Otorhinolaryngol Ital** 1999 Apr;19(2):64-9 (Eng. Abstr.) **(Ita)**

[Distortion product otoacoustic emissions for the assessment of auditory sensitivity] Chida E. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov;101(11):1335-47 (Eng. Abstr.) **(Jpn)**

[Too delayed diagnosis of deafness and hearing disorders] Elverland HH. **Tidsskr Nor Laegeforen** 1998 Oct 30; 118(26):4063 **(Nor)**

[Tympanometry at a health center] Rasting P, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3426–30 (Eng. Abstr.) **(Nor)**

[Preliminary assessment of transient evoked acoustic emissions (TEOAE) in newborns depending on selected parameters of delivery complications with particular analysis of newborns with hypotrophy] Morawski K, et al. **Ginekol Pol** 1998 Dec;69(12):943–8 (Eng. Abstr.) **(Pol)**

[Audiological diagnosis in Military Medical Academy in Warsaw] Ligezinski A, et al. **Otolaryngol Pol** 1997;51 Suppl 25:271–3 (Eng. Abstr.) **(Pol)**

[Evoked otoacoustic emissions in the neonatal hearing screening] Rogowski M, et al. **Otolaryngol Pol** 1998; 52(4):441–5 (Eng. Abstr.) **(Pol)**

[A complete examination of hearing of preschool children is important (letter)] Konradsson K, et al. **Lakartidningen** 1998 Oct 28;95(44):4838 **(Swe)**

[Hearing tests of newborn infants will hopefully be introduced in the whole country! (letter; comment)] Westin B. **Lakartidningen** 1999 Jun 9;96(23):2835–6. Comment on: Lakartidningen 1999 Mar 10;96(10):1166–8. **(Swe)**

DRUG THERAPY

PAF- and histamine-receptor antagonists lessen allergen-induced hearing impairment in guinea pigs. Masuyama K, et al. **Prostaglandins Other Lipid Mediat** 1998 Jul;56(4):239–44

Thyroxine replacement attenuates hypothyroxinemia, hearing loss, and motor deficits following developmental exposure to Aroclor 1254 in rats. Goldey ES, et al. **Toxicol Sci** 1998 Sep;45(1):94–105

EPIDEMIOLOGY

Definition of hearing impairment and its effect on prevalence figures. A survey among senior citizens. Duijvestijn JA, et al. **Acta Otolaryngol** 1999;119(4):420–3

The European Consensus Development Conference on Neonatal Hearing Screening (Milan, May 15–16, 1998). Grandori F, et al. **Am J Audiol** 1999 Jun;8(1):19–20 (0 ref.)

Epidemiology of cerebral palsy in England and Scotland, 1984–9 [see comments] Pharoah PO, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F21–5. Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F158.

Health visitor screening versus vigilance: outcomes of programmes for detecting permanent childhood hearing loss in west Berkshire. Sutton GJ, et al. **Br J Audiol** 1999 Jun;33(3):145–56

Do we know the real need for hearing rehabilitation at the population level? Hearing impairments in the 5- to 75-year-old cross-sectional Finnish population. Uimonen S, et al. **Br J Audiol** 1999 Feb;33(1):53–9

Hearing and occupation. Uimonen S, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):156–61 (31 ref.)

The epidemiology of hearing impairment in an Australian adult population. Wilson DH, et al. **Int J Epidemiol** 1999 Apr;28(2):247–52

Otoacoustic emission criteria for neonatal hearing screening. Smyth V, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):9–15

Epidemiology and etiology of acquired hearing disorders in childhood in the Cologne area. Streppel M, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 1O;44(3):235–43

Hearing deficits at school age; the predictive value of otitis media in infants. Zielhuis GA, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 1O;44(3):227–34

Paediatric hearing loss in rural Pakistan. Elahi MM, et al. **J Otolaryngol** 1998 Dec;27(6):348–53

Neonatal screening for hearing disorders in infants at risk: incidence, risk factors, and follow-up. Meyer C, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):900–4

Prevalence and characteristics of children with serious hearing impairment in metropolitan Atlanta, 1991–1993. Van Naarden K, et al. **Pediatrics** 1999 Mar;103(3):570–5

ETIOLOGY

Hearing loss and automobile airbag deployments. Huelke DF, et al. **Accid Anal Prev** 1999 Nov;31(6):789–92

The influence of an arterial and venous air embolism on the hearing level in laboratory mini pigs. Juncker C, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):803–7

Clarifications requested re: cochlear modiolar defects [letter; comment] Gulya AJ. **Am J Otol** 1999 Jan;20(1):135–6. Comment on: Am J Otol 1998 May;19(3):306–12.

The effect of stapes surgery on high-frequency hearing in patients with otosclerosis [letter] Sennaroğlu L. **Am J Otol** 1999 Sep;20(5):702

Profile of hearing in patients with unilateral acoustic neuromas: the importance of the contralateral ear. Stipkovits EM, et al. **Am J Otol** 1998 Nov;19(6):834–9

Abnormal branching of facial nerve with ossicular anomalies: report of two cases. Takahashi H, et al. **Am J Otol** 1998 Nov;19(6):850–3

The effect of nasal continuous positive airway pressure on normal ears and on ears with stelectasis. Yung MW. **Am J Otol** 1999 Sep;20(5):568–72

A longitudinal study of the validity of parental reporting in the detection of otitis media and related hearing impairment in infancy. Anteunis LJ, et al. **Audiology** 1999 Mar–Apr;38(2):75–82

Sound localization for a virtual sound source in cases of chronic otitis media. Kawase T, et al. **Audiology** 1999 Mar–Apr;38(2):83–90

Irish government to set up tribunal for hearing loss in soldiers [news] Payne D. **BMJ** 1999 Mar 6;318(7184):626

Diabetes and hearing loss. Fowler PD, et al. **Clin Otolaryngol** 1999 Feb;24(1):3–8 (67 ref.)

Early ear problems and developmental problems at school age. Lindsay RL, et al. **Clin Pediatr (Phila)** 1999 Mar; 38(3):123–32 (30 ref.)

Clinical findings for a group of infants and young children with auditory neuropathy. Rance G, et al. **Ear Hear** 1999 Jun;20(3):238–52

Hearing in newborn infants of opiate-addicted mothers. Grimmer I, et al. **Eur J Pediatr** 1999 Aug;158(8):653–7

Otological problems in children with Turner's syndrome. Stenberg AE, et al. **Hear Res** 1998 Oct;124(1–2):85–90

Patulous eustachian tube in a case of adolescent anorexia nervosa. Karwautz A, et al. **Int J Eat Disord** 1999 Apr; 25(3):353–5

Epidemiology and etiology of acquired hearing disorders in childhood in the Cologne area. Streppel M, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 1O;44(3):235–43

Language, speech, and educational outcomes of otitis media. Gravel JS, et al. **J Otolaryngol** 1998;27 Suppl 2:17–25 (74 ref.)

Personal stereos and hearing loss [letter; comment] Cates C. **Lancet** 1999 Feb 27;353(9154):756. Comment on: Lancet 1999 Jan 2;353(9146):35.

Pervasive developmental delay in children presenting as possible hearing loss. Ho PT, et al. **Laryngoscope** 1999 Jan; 109(1):129–35

Hearing and otopathology in Crouzon syndrome. Orvidas LJ, et al. **Laryngoscope** 1999 Sep;109(9):1372–5

Long-term hearing results following vestibular surgery in Meniere's disease. Wazen JJ, et al. **Laryngoscope** 1998 Oct; 108(10):1470–3

Hearing loss. Weber PC, et al. **Med Clin North Am** 1999 Jan;83(1):125–37, ix

The flexible endaural tympanoplasty: pathology-guided, pathogenesis-oriented surgery for the middle ear. da Costa SS, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):413–41 (66 ref.)

Surgical modification of the difficult mastoid cavity. Dornhoffer JL. **Otolaryngol Head Neck Surg** 1999 Mar; 120(3):361–7

Establishing the etiology of childhood hearing loss. Ohlms LA, et al. **Otolaryngol Head Neck Surg** 1999 Feb; 120(2):159–63

Etiology of hearing loss in children. Nongenetic causes. Roizen NJ. **Pediatr Clin North Am** 1999 Feb;46(1):49–64, x (94 ref.)

Brainstem auditory-evoked potential evaluation in children with meningitis. Bao X, et al. **Pediatr Neurol** 1998 Aug; 19(2):109–12

Changes in hearing acuity in ambulance personnel. Price TG, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):308–11

Aetiology and risk indicators of hearing impairments in a one-year birth cohort for 1985–86 in northern Finland. Mäki-Torkko EM, et al. **Scand Audiol** 1998;27(4):237–47

[Mid-latency auditory evoked responses in Alzheimer's disease: evaluation of P1 and P3 waves] Cordone A, et al. **Acta Otorhinolaryngol Ital** 1999 Apr;19(2):64–9 (Eng. Abstr.) **(Ita)**

[The status of acoustic and vestibular function among the workers of phosphorus industry] Zhaisakova DE. **Vestn Otorinolaringol** 1999;(1):13–5 (Eng. Abstr.) **(Rus)**

GENETICS

Partial triplication of mtDNA in maternally transmitted diabetes mellitus and deafness [letter] Martin Negrier ML, et al. **Am J Hum Genet** 1998 Oct;63(4):1227–32

Description of a large kindred with autosomal dominant inheritance of branchial arch anomalies, hearing loss, and ear pits, and exclusion of the branchio-oto-renal (BOR) syndrome gene locus (chromosome 8q13.3). Stratakis CA, et al. **Am J Med Genet** 1998 Sep 23;79(3):209–14

Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Bikhazi PH, et al. **Am J Otol** 1999 Sep;20(5):639–43

Cracking the auditory genetic code: nonsyndromic hereditary hearing impairment. Lalwani AK, et al. **Am J Otol** 1999 Jan;20(1):115–32 (142 ref.)

Two cases of Townes-Brocks syndrome with previously undescribed anomalies [letter] Marlin S, et al. **Clin Dysmorphol** 1998 Oct;7(4):295–8

Genomics and hearing impairment. Keats BJ, et al. **Genome Res** 1999 Jan;9(1):7–16 (89 ref.)

The role of mouse mutants in the identification of human hereditary hearing loss genes. Probst FJ, et al. **Hear Res** 1999 Apr;130(1–2):1–6 (63 ref.)

The fundamental and medical impacts of recent progress in research on hereditary hearing loss. Kalatzis V, et al. **Hum Mol Genet** 1998;7(10):1589–97 (98 ref.)

A gene for autosomal dominant hearing impairment (DFNA14) maps to a region on chromosome 4p16.3 that does not overlap the DFNA6 locus. Van Camp G, et al. **J Med Genet** 1999 Jul;36(7):532–6

Auditory brainstem responses in Golden Syrian hamsters (Mesocricetus auratus) affected with the Wh gene. Amedofu GK, et al. **Lab Anim Sci** 1999 Apr;49(2):173–8

Ion channel defects in hereditary hearing loss. Holt JR, et al. **Neuron** 1999 Feb;22(2):217–9 (18 ref.)

A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Tomaski SM, et al. **Pediatr Clin North Am** 1999 Feb;46(1):35–48 (25 ref.)

Molecular markers for cell types of the inner ear and candidate genes for hearing disorders. Heller S, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11400–5

Deafness genes: expressions of surprise. Steel KP, et al. **Trends Genet** 1999 Jun;15(6):207–11 (37 ref.)

[Genetic type of progressive hearing loss] Martini A. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):21–7 (97 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Temporal loudness integration and spectral loudness summation in normal-hearing and hearing-impaired listeners. Garnier S, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):154–7

The relationship of self-rated vision and hearing to functional status and well-being among seniors 70 years and older. Lee P, et al. **Am J Ophthalmol** 1999 Apr;127(4):447–52

Tone burst auditory brain stem response latency estimates of cochlear travel time in Meniere's disease, cochlear hearing loss, and normal ears. Murray JG, et al. **Am J Otol** 1998 Nov;19(6):854–9

Murine model of autoimmune hearing loss induced by myelin protein P0. Matsuoka H, et al. **Ann Otol Rhinol Laryngol** 1999 Mar;108(3):255–64

Sensitivity of transient evoked and distortion product otoacoustic emissions to the direct effects of noise on the human cochlea. Vinck BM, et al. **Audiology** 1999 Jan–Feb; 38(1):44–52

Discriminability of vowel representations in cat auditory-nerve fibers after acoustic trauma. Miller RL, et al. **J Acoust Soc Am** 1999 Jan;105(1):311–25

The impact of vision and hearing impairments on health in old age [editorial; comment] Guralnik JM. **J Am Geriatr Soc** 1999 Aug;47(8):1029–31. Comment on: J Am Geriatr Soc 1999 Aug;47(8):930–5.

The prognostic value of sensory impairment in older persons [see comments] Reuben DB, et al. **J Am Geriatr Soc** 1999 Aug;47(8):930–5. Comment in: J Am Geriatr Soc 1999 Aug;47(8):1029–31.

Recovery of semicircular canal primary afferent activity in the pigeon after streptomycin ototoxicity. Li W, et al. **J Neurophysiol** 1998 Dec;80(6):3297–311

Therapeutic potential of neurotrophins for treatment of hearing loss. Gao WQ. **Mol Neurobiol** 1998 Winter; 17(1–3):17–31 (88 ref.)

Toluene ototoxicity in rats: assessment of the frequency of hearing deficit by electrocochleography. Lataye R, et al. **Neurotoxicol Teratol** 1999 May–Jun;21(3):267–76

Physiologic and behavioral approaches to pediatric hearing assessment. Folsom RC, et al. **Pediatr Clin North Am** 1999 Feb;46(1):107–20 (50 ref.)

[The acoustic characteristics of the vocalizations of hypoacusic children] Garbaruk VI. **Vestn Otorinolaringol** 1998;(4):62–4 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Significance of hearing preservation in acoustic neuroma surgery. Ishikawa K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;537:16–9

Successful prevention of retrocochlear hearing loss in murine experimental allergic encephalomyelitis with T cell receptor Vbeta8-specific antibody. Suzuki M, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):917–27

Screening for congenital hearing impairment: time for a change. Bamford J, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F73–6

Management of otitis media in a high risk population. Morris PS. **Aust Fam Physician** 1998 Nov;27(11):1021–9 (33 ref.)

A hearing conservation program for Wisconsin youth working in agriculture. Knobloch MJ, et al. **J Sch Health** 1998 Oct;68(8):313–8

Technical developments in intra-operative monitoring for the preservation of cranial motor nerves and hearing in skull base surgery. Schlake HP, et al. **Neurol Res** 1999 Jan; 21(1):11–24 (90 ref.)

Effects of chronic lithium on ototoxicity induced by gentamicin and amikacin in guinea-pigs. Sharifzadeh M, et al. **Pharmacol Toxicol** 1998 Nov;83(5):220–4

[Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity] Watanabe H, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Aug;101(8):967–78 (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Knowledge and attitudes about AIDS among deaf and hard of hearing persons. Woodroffe T, et al. **AIDS Care** 1998 Jun;10(3):377–86

Hearing loss in working life--some aspects of audiological rehabilitation. Backenroth GA, et al. **Int J Rehabil Res** 1998 Sep;21(3):331–3

Physiologic and behavioral approaches to pediatric hearing assessment. Folsom RC, et al. **Pediatr Clin North Am** 1999 Feb;46(1):107–20 (50 ref.)

Considerations in the education of children with hearing loss.

Matkin ND, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):143–52 (19 ref.)
Mental health of visually and hearing impaired students from the viewpoint of the University Personality Inventory. Yoshida T, et al. **Psychiatry Clin Neurosci** 1998 Aug; 52(4):413–8

REHABILITATION see REHABILITATION OF HEARING IMPAIRED

SURGERY

Ossiculoplasty with an intact stapes: superstructure versus footplate prosthesis placement. Moretz WH Jr. **Laryngoscope** 1998 Nov;108(11 Pt 2 Su 89):1–12
Can hearing improve after acoustic tumor radiosurgery? Niranjan A, et al. **Neurosurg Clin N Am** 1999 Apr; 10(2):305–15 (27 ref.)
Malleus-to-footplate prosthetic interposition: experience with 265 patients. Colletti V, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):437–44
Use of patient-specific estimates in patient evaluation and rehabilitation. Stephens D, et al. **Scand Audiol Suppl** 1998; 49:61–8
[Cochlear implant today and auditory brainstem implant in the future] Kaga K. **No To Shinkei** 1999 Feb;51(2):103–14 (21 ref.) **(Jpn)**

THERAPY

Measurements of loudness growth in 1/2-octave bands for children and adults with normal hearing. Ellis MR, et al. **Am J Audiol** 1999 Jun;8(1):40–6
A model for the assessment and management of children with multiple disabilities. Cass H, et al. **Child Care Health Dev** 1999 May;25(3):191–211
Tolerable hearing aid delays. I. Estimation of limits imposed by the auditory path alone using simulated hearing losses. Stone MA, et al. **Ear Hear** 1999 Jun;20(3):182–92
Auditory training in severely and profoundly hearing impaired toddlers: the development of auditory skills and verbal communication. Hoekstra CC, et al. **Int J Pediatr Otorhinolaryngol** 1999 Feb 15;47(2):201–4
Reduction in caregiver-identified problem behaviors in patients with Alzheimer disease post-hearing-aid fitting. Palmer CV, et al. **J Speech Lang Hear Res** 1999 Apr; 42(2):312–28
Therapeutic potential of neurotrophins for treatment of hearing loss. Gao WQ. **Mol Neurobiol** 1998 Winter; 17(1–3):17–31 (88 ref.)
Sudden hearing loss and the need for immediate referral [letter] Grossan M. **Otolaryngol Head Neck Surg** 1999 Jul; 121(1):166–7
A stepwise approach to the diagnosis and treatment of hereditary hearing loss. Tomaski SM, et al. **Pediatr Clin North Am** 1999 Feb;46(1):35–48 (25 ref.)
Minimum Nordic requirements for clinical testing of hearing aids. Nordiska samarbetsorganet för handikappfrågor (Nordic Co-operation on Disability). Working group for harmonization of requirements on aids for hearing-impaired persons, June 1998. Hagermann B. **Scand Audiol** 1999;28(2):102–16
Clinical assessment of modern hearing aids. Arlinger SD. **Scand Audiol Suppl** 1998;49:50–3
Speech tests as measures of outcome. Gatehouse S. **Scand Audiol Suppl** 1998;49:54–60
Non-linear signal processing in digital hearing aids. Lunner T, et al. **Scand Audiol Suppl** 1998;49:40–9
Cognition as a bridge between signal and dialogue: communication in the hearing impaired and deaf. Rönnberg J, et al. **Scand Audiol Suppl** 1998;49:101–8
[Summary of the guideline 'Hearing impairement' from the Dutch College of General Practitioners. The Dutch College of General Practitioners (see comments)] Eekhof JA, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1813–6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1804–5. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1806–7. Comment in: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1816–9. Comment in: Ned Tijdschr Geneeskd 1998 Dec 5;142(49):2696. **(Dut)**

HEARING IMPAIRED PERSONS

see related

DEAFNESS

Research on deafness. Doctoral dissertations. **Am Ann Deaf** 1999 Apr;144(2):213–7
Counseling the deaf and hearing-impaired. Jacobson J. **Am J Health Syst Pharm** 1999 Apr 1;56(7):610–1
Trends in educational placement and cost-benefit considerations in children with cochlear implants. Francis HW, et al. **Arch Otolaryngol Head Neck Surg** 1999 May; 125(5):499–505
Can unilateral hearing loss be a handicap in learning? [letter] Ito K. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1389–90
[Confusion in the care of hearing disorders (letter)] Jørgensen KE, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):54–5 **(Dan)**
[The Danish care of persons with hearing impairment. Medical-audiological aspects] Parving A. **Ugeskr Laeger** 1999 Jan 4;161(1):11–4 (10 ref.) **(Dan)**
[And the deaf were able to hear. Cochlear implantation (editorial)] Pedersen CB. **Ugeskr Laeger** 1999 Jan 4; 161(1):10 **(Dan)**

EDUCATION

Educational programs for deaf students. Schools and programs in the U.S. **Am Ann Deaf** 1999 Apr;144(2):79–147
Educational programs for deaf students. Schools and programs in Canada. **Am Ann Deaf** 1999 Apr;144(2):148–54
Educational programs for deaf students. Postsecondary programs. **Am Ann Deaf** 1999 Apr;144(2):155–63
University and college programs for personnel in deafness. **Am Ann Deaf** 1999 Apr;144(2):165–80
Programs for deaf-blind children and adults. **Am Ann Deaf** 1999 Apr;144(2):181–5
Attitudes of a group of primary school teachers towards the educational inclusion of hearing-impaired learners in regular classrooms. Keith K, et al. **S Afr J Commun Disord** 1998;45:39–50

PSYCHOLOGY

The functional assessment of deaf and hard of hearing students. Karchmer MA, et al. **Am Ann Deaf** 1999 Apr; 144(2):68–77
The assessment and treatment of deaf children with psychiatric disorders. Roberts C, et al. **J Child Psychol Psychiatry** 1999 Feb;40(2):151–67 (122 ref.)

REHABILITATION

Monitoring the environment: sound localization equipment for deaf-blind people. Borg E, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):146–9
Educational programs for deaf students. Supportive and rehabilitative programs. **Am Ann Deaf** 1999 Apr; 144(2):187–212

HEARING IMPAIRED REHABILITATION see REHABILITATION OF HEARING IMPAIRED

HEARING LOSS, BILATERAL

Hearing loss in critical care: an unappreciated phenomenon. Halpern NA, et al. **Crit Care Med** 1999 Jan;27(1):211–9 (80 ref.)

CHEMICALLY INDUCED

Carbamazepine-induced sensorineural hearing loss. de la Cruz M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb; 125(2):225–7
Lead exposure and hearing effects in children in Katowice, Poland. Osman K, et al. **Environ Res** 1999 Jan;80(1):1–8
[Relationship between a case of severe hearing loss and use of gentamycin in the pregnant mother] Sánchez Sainz-Trápaga C, et al. **An Esp Pediatr** 1998 Oct; 49(4):397–8 **(Spa)**

COMPLICATIONS

Pili torti with congenital deafness (Bjornstad syndrome): a case report. Loche F, et al. **Pediatr Dermatol** 1999 May-Jun;16(3):220–1

DIAGNOSIS

Enlarged vestibular aqueduct as a marker for hearing loss in children. Manolis EN, et al. **Clin Pediatr (Phila)** 1998 Nov;37(11):689–91
Perception of microphone noise in hearing instruments. Lee LW, et al. **J Acoust Soc Am** 1998 Dec;104(6):3364–7
Sound localization in noise in hearing-impaired listeners. Lorenzi C, et al. **J Acoust Soc Am** 1999 Jun;105(6):3454–63
Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment. Wessex Universal Neonatal Hearing Screening Trial Group [see comments] **Lancet** 1998 Dec 19–26;352(9145):1957–64 . Comment in: Lancet 1998 Dec 19–26;352(9145):1951–2.
Binaural interaction component in children at risk for central auditory processing disorders. Gopal KV, et al. **Scand Audiol** 1999;28(2):77–84
[Measurements of directional hearing aid function] Prosser S, et al. **Acta Otorhinolaryngol Ital** 1998 Apr;18(2):70–3 (Eng. Abstr.) **(Ita)**
[Early diagnosis of congenital hearing loss (letter; comment)] Ruud Hansen TW. **Tidsskr Nor Laegeforen** 1998 Nov 30; 118(29):4561. Comment on: Tidsskr Nor Laegeforen 1998 Oct 30;118(26):4076–8. **(Nor)**
[Early diagnosis of congenital hearing loss. Use of oto-acoustic emission tests in newborn infants with increased risk of hearing impairment (see comments)] Stødrdal K, et al. **Tidsskr Nor Laegeforen** 1998 Oct 30; 118(26):4076–8 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1998 Nov 30;118(29):4561. **(Nor)**

EPIDEMIOLOGY

Prevalence of hearing loss in older adults in Beaver Dam, Wisconsin. The Epidemiology of Hearing Loss Study. Cruickshanks KJ, et al. **Am J Epidemiol** 1998 Nov 1; 148(9):879–86

ETIOLOGY

Bilateral simultaneous hearing preservation mastoidectomy in otogenic meningitis. Job A, et al. **Ann Otol Rhinol Laryngol** 1998 Oct;107(10 Pt 1):872–5
Otological findings in idiopathic hyperphosphatasia. Sennaroğlu L, et al. **J Laryngol Otol** 1999 Feb; 113(2):158–60 (6 ref.)
Persistent bilateral hearing loss after shunt placement for hydrocephalus. Case report. Stoeckli SJ, et al. **J Neurosurg** 1999 Apr;90(4):773–5
Sudden hearing loss as a presenting manifestation of leukemia. Veling MC, et al. **Otolaryngol Head Neck Surg** 1999 Jun; 120(6):954–6
[Plasma cell leukemia (IgG kappa) presenting bilateral neurosensory hearing loss and left sixth cranial nerve plasy] Aikawa S, et al. **Rinsho Ketsueki** 1998 Jul;39(7):506–11 (Eng. Abstr.) **(Jpn)**

GENETICS

[Genetic causes of hearing loss--status and perspectives] Tranebjaerg L. **Tidsskr Nor Laegeforen** 1999 May 20; 119(13):1919–24 (34 ref.) (Eng. Abstr.) **(Nor)**
[Familial mixed hearing loss associated with X chromosome and stapedial gusher] Almodóvar Iñesta A, et al. **Acta Otorrinolaringol Esp** 1998 Aug-Sep;49(6):427–30 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cogan's syndrome: clinical significance of antibodies against the inner ear and cornea. Helmchen C, et al. **Acta Otolaryngol** 1999;119(5):528–36

PHYSIOPATHOLOGY

Precision contact of the fingertip reduces postural sway of individuals with bilateral vestibular loss. Lackner JR, et al. **Exp Brain Res** 1999 Jun;126(4):459–66
Evaluation of second-ear stapedotomy with the Glasgow benefit plot. de Bruijn AJ, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Mar-Apr; 61(2):92–7
Vestibular evoked myogenic potentials in patients with bilateral profound hearing loss. Ozeki H, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Mar-Apr; 61(2):80–3

PSYCHOLOGY

[Developmental problems and risks of children and adolescents with severe hearing impairment--a challenge for intervention by child and adolescent psychiatrists] Kammerer E. **Prax Kinderpsychol Kinderpsychiatr** 1999 May-Jun;48(5):351–65 (17 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Cochlear implants for adults obtaining marginal benefit from acoustic amplification: a European study. Fraysse B, et al. **Am J Otol** 1998 Sep;19(5):591–7
[Cochlear implant in the aged patient] Ouayoun M, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Jun;115(3):135–9 (Eng. Abstr.) **(Fre)**
[Measurements of directional hearing aid function] Prosser S, et al. **Acta Otorhinolaryngol Ital** 1998 Apr;18(2):70–3 (Eng. Abstr.) **(Ita)**

SURGERY

Basal turn cochleostomy via the middle fossa route for cochlear implant insertion. Colletti V, et al. **Am J Otol** 1998 Nov;19(6):778–84
Evaluation of second-ear stapedotomy with the Glasgow benefit plot. de Bruijn AJ, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Mar-Apr; 61(2):92–7

HEARING LOSS, CENTRAL

DIAGNOSIS

Binaural interaction component in children at risk for central auditory processing disorders. Gopal KV, et al. **Scand Audiol** 1999;28(2):77–84
Slope analysis of Auditory Brainstem Responses in children at risk of central auditory processing disorders. Gopal KV, et al. **Scand Audiol** 1999;28(2):85–90

PHYSIOPATHOLOGY

A distinct low-level mechanism for interaural timing analysis in human hearing. Griffiths TD, et al. **Neuroreport** 1998 Oct 26;9(15):3383–6
Neuroanatomical correlates to central deafness. Musiek FE, et al. **Scand Audiol Suppl** 1998;49:18–25

HEARING LOSS, CONDUCTIVE

CHEMICALLY INDUCED

[Types of hearing disorders in drug addicts and individuals drinking non-consumable alcohols] Lukomski M, et al. **Med Pr** 1999;50(1):37–42 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hearing loss and otitis media in velo-cardio-facial syndrome. Reyes MR, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):227–33

HEARING LOSS, CONDUCTIVE

A cross-sectional study of speech- and language-abilities of children with normal hearing, mild fluctuating conductive hearing loss, or moderate to profound sensoneurinal hearing loss. Schönweiler R, et al.
Int J Pediatr Otorhinolaryngol 1998 Aug 10;44(3):251-8

CONGENITAL

Proximal symphalangism and congenital conductive hearing loss: otologic aspects. Ensink RJ, et al. **Am J Otol** 1999 May;20(3):344-9 (17 ref.)
A patient-benefit evaluation of unilateral congenital conductive hearing loss presenting in adulthood: should it be repaired? Sperling NM, et al. **Laryngoscope** 1999 Sep; 109(9):1386-91

DIAGNOSIS

Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Levy CE, et al. **Am J Audiol** 1999 Jun;8(1):29-33
Accuracy of self-reported hearing loss. Nondahl DM, et al. **Audiology** 1998 Sep-Oct;37(5):295-301
Identification of permanent hearing loss in children: are the targets for outcome measures attainable? Fonseca S, et al. **Br J Audiol** 1999 Jun;33(3):135-43
Otoacoustic emissions in screening cleft lip and/or palate children for hearing loss--a feasibility study. Anteunis LJ, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):259-66
Conductive hearing loss in Beckwith-Wiedemann syndrome. Schick B, et al. **Int J Pediatr Otorhinolaryngol** 1999 May 5;48(2):175-9
Prediction of conductive hearing loss based on acoustic ear-canal response using a multivariate clinical decision theory. Piskorski P, et al. **J Acoust Soc Am** 1999 Mar; 105(3):1749-64
Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567-83 (56 ref.)
Audit of clinical judgements and actions in an audiological investigation of school entrant children screened positive for hearing loss. Holtby I, et al. **Public Health** 1998 Sep; 112(5):337-41
Excess cerumen: failure rate of black and Indian preschool children from Durban on the Middle Ear Screening Protocol (MESP). Bhoola D, et al.
S Afr J Commun Disord 1997;44:43-52
[Physical diagnostic procedures: whispered speech and tuning fork test (comment)] Grote JJ, et al.
Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1816-9 (10 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. **(Dut)**
[Interesting case no. 26. Disruption of the ossicular chain--an interesting differential otosclerosis diagnosis]
Courtellemont S, et al. **Laryngorhinootologie** 1999 Jul; 78(7):412-4 **(Ger)**
[Hearing status after stapedectomy with preservation or cutting of stapedius tendon] Gierek T, et al.
Otolaryngol Pol 1999;53(2):179-81 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Excess cerumen: failure rate of black and Indian preschool children from Durban on the Middle Ear Screening Protocol (MESP). Bhoola D, et al.
S Afr J Commun Disord 1997;44:43-52

ETIOLOGY

Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Levy CE, et al. **Am J Audiol** 1999 Jun;8(1):29-33
Proximal symphalangism and congenital conductive hearing loss: otologic aspects. Ensink RJ, et al. **Am J Otol** 1999 May;20(3):344-9 (17 ref.)
Audiological abnormalities in the Klippel-Feil syndrome. McGaughran JM, et al. **Arch Dis Child** 1998 Oct; 79(4):352-5
The acceptance of hearing aids for children with otitis media with effusion. Jardine AH, et al. **J Laryngol Otol** 1999 Apr; 113(4):314-7
Double cartilage block ossiculoplasty in chronic ear surgery. Harvey SA, et al. **Laryngoscope** 1999 Jun;109(6):911-4
[Exposed superior bulb of the internal jugular vein. Differential hearing loss diagnosis with pulse synchronous tinnitus] Tisch M, et al. **HNO** 1998 Nov;46(11):944-6 (Eng. Abstr.) **(Ger)**
[Interesting case no. 23. Abnormal site of the jugular vein, so-called right megabulbus] Schäfer S, et al.
Laryngorhinootologie 1999 Apr;78(4):227-9 **(Ger)**

GENETICS

Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35-9 (32 ref.)
[Small abnormality of the middle ear--a genetically-induced defect?] Thies C, et al. **HNO** 1998 Aug;46(8):757-61 (Eng. Abstr.) **(Ger)**

METABOLISM

Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35-9 (32 ref.)

PHYSIOPATHOLOGY

Toynbee Memorial Lecture 1997. Middle ear mechanics in normal, diseased and reconstructed ears. Merchant SN, et al. **J Laryngol Otol** 1998 Aug;112(8):715-31
Conductive hearing loss produces a reversible binaural hearing impairment. Moore DR, et al. **J Neurosci** 1999 Oct 1;19(19):8704-11
Conductive hearing loss results in a decrease in central auditory system activity in the young gerbil. Tucci DL, et al. **Laryngoscope** 1999 Sep;109(9):1359-71
Evaluation of second-ear stapedotomy with the Glasgow benefit plot. de Bruijn AJ, et al.
ORL J Otorhinolaryngol Relat Spec 1999 Mar-Apr; 61(2):92-7
A qualitative explanation of the Weber test. Blakley BW, et al. **Otolaryngol Head Neck Surg** 1999 Jan;120(1):1-4
Masking-level differences in older adults: the effect of the level of the masking noise. Pichora-Fuller MK, et al.
Percept Psychophys 1998 Oct;60(7):1197-205

PREVENTION & CONTROL

Double cartilage block ossiculoplasty in chronic ear surgery. Harvey SA, et al. **Laryngoscope** 1999 Jun;109(6):911-4

REHABILITATION

Psychometric evaluation of the Gothenburg Profile for measurement of experienced hearing disability and handicap: applications with new hearing aid candidates and experienced hearing aid users. Ringdahl A, et al.
Br J Audiol 1998 Dec;32(6):375-85
[Bone anchored hearing aid (BAHA): clinical evaluation] Jankowski R, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec;115(6):315-20 (Eng. Abstr.) **(Fre)**
[Sound transmission properties of synthetic prostheses in ossicular replacement during middle ear reconstruction] Linti C, et al. **Biomed Tech (Berl)** 1998;43 Suppl:418-9 **(Ger)**
[The rehabilitation of children with the initial forms of conductive hypoacusis due to recurrent acute otitis media] Drozdova MV, et al. **Vestn Otorinolaringol** 1998;(4):31-2 (Eng. Abstr.) **(Rus)**

SURGERY

Long-term results with the titanium bone-anchored hearing aid: the U.S. experience. Wazen JJ, et al. **Am J Otol** 1998 Nov;19(6):737-41
Percutaneous implants in the temporal bone for securing a bone conductor: surgical methods and results. van der Pouw CT, et al. **Ann Otol Rhinol Laryngol** 1999 Jun; 108(6):532-6 (18 ref.)
Cholesteatoma otitis media with intact ossicular chain. Sakagami M, et al. **Auris Nasus Larynx** 1999 Apr; 26(2):147-51
A patient-benefit evaluation of unilateral congenital conductive hearing loss presenting in adulthood: should it be repaired? Sperling NM, et al. **Laryngoscope** 1999 Sep; 109(9):1386-91
Evaluation of second-ear stapedotomy with the Glasgow benefit plot. de Bruijn AJ, et al.
ORL J Otorhinolaryngol Relat Spec 1999 Mar-Apr; 61(2):92-7
Stapedectomy in children. De la Cruz A, et al.
Otolaryngol Head Neck Surg 1999 Apr;120(4):487-92
[Materials for reconstruction of the middle ear] Geyer G.
HNO 1999 Feb;47(2):77-91 (182 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The acceptance of hearing aids for children with otitis media with effusion. Jardine AH, et al. **J Laryngol Otol** 1999 Apr; 113(4):314-7

HEARING LOSS, EXTREME see **DEAFNESS**

HEARING LOSS, FUNCTIONAL

[Hearing in old age. Hearing loss is never physiologic] Leithäuser D. **MMW Fortschr Med** 1999 Jun 17; 141(24):36-8 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

[Objective audiologic assessment of children treated with amikacin] Katona G, et al. **Orv Hetil** 1999 Jun 6; 140(23):1305-7 (Eng. Abstr.) **(Hun)**

DIAGNOSIS

Sound localization in the median sagittal plane by listeners with presbyacusis. Rakerd B, et al. **J Am Acad Audiol** 1998 Dec;9(6):466-79
Childhood pseudohypacusis in patients with high risk for actual hearing loss. Radkowski D, et al. **Laryngoscope** 1998 Oct;108(10):1534-8
[Functional hearing loss in children who were not aware of their hearing loss] Satoh H, et al.
Nippon Jibiinkoka Gakkai Kaiho 1998 Dec;101(12):1390-6 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Age-related hearing loss, vitamin B-12, and folate in elderly women. Houston DK, et al. **Am J Clin Nutr** 1999 Mar; 69(3):564-71
Hearing loss related to ototoxicity in children with cancer. Landier W. **J Pediatr Oncol Nurs** 1998 Oct;15(4):195-206

NURSING

Hearing loss related to ototoxicity in children with cancer. Landier W. **J Pediatr Oncol Nurs** 1998 Oct;15(4):195-206

PHYSIOPATHOLOGY

Masking-level differences in older adults: the effect of the level of the masking noise. Pichora-Fuller MK, et al.
Percept Psychophys 1998 Oct;60(7):1197-205

REHABILITATION

[The usefulness of today's hearing aids--possibilities and limitations] Kiessling J. **MMW Fortschr Med** 1999 Jun 17; 141(24):32-4 (Eng. Abstr.) **(Ger)**

SURGERY

[Stapedectomies. Retrospective study of 120 ears] Domenech E, et al. **An Otorrinolaringol Ibero Am** 1998;25(6):607-11 (Eng. Abstr.) **(Spa)**

HEARING LOSS, HIGH-FREQUENCY

CHEMICALLY INDUCED

Evaluation of organic solvent ototoxicity by the upper limit of hearing. Morioka I, et al. **Arch Environ Health** 1999 Sep-Oct;54(5):341-6
Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings. Christensen LA, et al. **J Am Acad Audiol** 1998 Aug;9(4):292-8

COMPLICATIONS

Auditory evoked potentials in vitiligo patients. Ozüer MZ, et al. **Scand Audiol** 1998;27(4):255-8

DIAGNOSIS

Speech audibility for listeners with high-frequency hearing loss. Turner CW, et al. **Am J Audiol** 1999 Jun;8(1):47-56
Aided growth of masking for speech and nonspeech signals. Fortune T. **Ear Hear** 1999 Jun;20(3):214-27
Auditory evoked potentials in vitiligo patients. Ozüer MZ, et al. **Scand Audiol** 1998;27(4):255-8

ETIOLOGY

[Chronic kidney failure and hearing disorders] Gurbanov FA. **Vestn Otorinolaringol** 1999;(1):16-8 (Eng. Abstr.) **(Rus)**

GENETICS

Nonsyndromic hearing impairment is associated with a mutation in DFNA5. Van Laer L, et al. **Nat Genet** 1998 Oct;20(2):194-7

PHYSIOPATHOLOGY

High-frequency hearing and reflex latency in patients with pigment disorder. Ardiç FN, et al. **Am J Otolaryngol** 1998 Nov-Dec;19(6):365-9
Influence of a 6-8 kHz audiometric notch on transient evoked otoacoustic emissions. Lucertini M, et al.
Eur Arch Otorhinolaryngol 1998;255(10):491-4
Perceptual consequences of peripheral hearing loss: do edge effects exist for abrupt cochlear lesions? Buss E, et al.
Hear Res 1998 Nov;125(1-2):98-108
[The perception of the frequency of tonal stimuli in a lesion of the sound-perceiving apparatus] Petrov SM.
Fiziol Cheloveka 1998 Nov-Dec;24(6):38-41 **(Rus)**

THERAPY

Speech audibility for listeners with high-frequency hearing loss. Turner CW, et al. **Am J Audiol** 1999 Jun;8(1):47-56

HEARING LOSS, NOISE-INDUCED

Inner ear damage in guinea pigs exposed to stable and impulse noise. Wang L, et al. **Chin Med J (Engl)** 1998 Apr; 111(4):354-7
Effects of noise on hearing. Clark WW, et al. **JAMA** 1999 May 5;281(17):1658-9
Noise-induced hearing loss: the future is hear. Cochlear pharmacology and noise trauma: prevention and progress-a joint symposium organized by The Novartis Foundation and the European Commission Concerted Action Against Noise. The Novartis Foundation London, UK, 1-2 May 1998. Abdulla S. **Mol Med Today** 1998 Jul;4(7):284-5
[Effect of noise on the health of the child] Garabedian EN.
Arch Pediatr 1999;6 Suppl 2:286s-288s **(Fre)**

COMPLICATIONS

Tinnitus and impulse noise-induced hearing loss in drop-forge operators. Sulkowski W, et al.
Int J Occup Med Environ Health 1999;12(2):177-82

Discriminability of vowel representations in cat auditory-nerve fibers after acoustic trauma. Miller RL, et al. **J Acoust Soc Am** 1999 Jan;105(1):311-25

One-year audiologic monitoring of individuals exposed to the 1995 Oklahoma City bombing. Van Campen LE, et al. **J Am Acad Audiol** 1999 May;10(5):231-47

DIAGNOSIS

Smoking as a risk factor in sensory neural hearing loss among workers exposed to occupational noise. Starck J, et al. **Acta Otolaryngol** 1999;119(3):302-5

The self-reported handicapping effect of hearing disabilities. Kramer SE, et al. **Audiology** 1998 Sep-Oct;37(5):302-12

Speech audiometry in noise-exposed workers: the SRT-PTA relationship revisited. Picard M, et al. **Audiology** 1999 Jan-Feb;38(1):30-43 (106 ref.)

Hearing parameters in noise exposed industrial workers. Celik O, et al. **Auris Nasus Larynx** 1998 Dec;25(4):369-75

On the behavioral characteristics of loud-music listening. Florentine M, et al. **Ear Hear** 1998 Dec;19(6):420-8

Effects of background noise on click-evoked otoacoustic emissions. Rhoades K, et al. **Ear Hear** 1998 Dec; 19(6):450-62

Topodiagnostic assessment of occupational noise-induced hearing loss using distortion-product otoacoustic emissions compared to the short increment sensitivity index test. Oeken J. **Eur Arch Otorhinolaryngol** 1999;256(3):115-21

The role of otoacoustic emissions in screening and evaluation of noise damage. Prasher D, et al. **Int J Occup Med Environ Health** 1999;12(2):183-92 (40 ref.)

A comparison of noise induced disability assessments in the UK and Poland. Raglan E, et al. **Int J Occup Med Environ Health** 1999;12(1):41-6

Transient-evoked otoacoustic emissions as a measure of noise-induced threshold shift. Marshall L, et al. **J Speech Lang Hear Res** 1998 Dec;41(6):1319-34

Latent cochlear damage in personal stereo users: a study based on click-evoked otoacoustic emissions [see comments] LePage EL, et al. **Med J Aust** 1998 Dec 7-21; 169(11-12):588-92. Comment in: Med J Aust 1998 Dec 7-21;169(11-12):587-8.

Determination of acute noise effects using distortion product otoacoustic emissions. Delb W, et al. **Scand Audiol** 1999; 28(2):67-76

[Evaluation of hearing by studying acoustic distortion products in noise-induced hearing loss] Ricci G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1999;120(2):117-21 (Eng. Abstr.) **(Fre)**

[Recommendations for medical documentation in suspected occupational hearing loss] Baldus S, et al. **HNO** 1999 Jul; 47(7):661-2 **(Ger)**

[Expert assessment of noise-induced hearing loss using the new K"onigstein Guideline. 2: Expert assessment] Brusis T. **HNO** 1999 Mar;47(3):211-9 **(Ger)**

[Recommendations for medical documentation in suspected occupationally-induced hearing loss] Baldus S, et al. **Laryngorhinootologie** 1999 Jul;78(7):410-1 **(Ger)**

[Evaluation of occupational exposure to infrasonic noise] Pawlaczyk-Luszczyńska M. **Med Pr** 1998;49(6):545-61 (Eng. Abstr.) **(Pol)**

[The effect of occupational exposure to noise among tractor drivers: assessment based on 'noise threshold'] Solecki L. **Med Pr** 1998;49(6):535-44 (Eng. Abstr.) **(Pol)**

[Assessment of otoacoustic emission usefulness for early detection of hearing impairment caused by noise] Trybalska G, et al. **Otolaryngol Pol** 1999;53(2):207-11 (Eng. Abstr.) **(Pol)**

[Current approaches to the problem of noise as an ecologic factor in aviation medicine] Vorob'ev OA, et al. **Med Tr Prom Ekol** 1999;(1):39-43 **(Rus)**

[Otological effects of the impulse noise] Pankova VB, et al. **Vestn Otorinolaringol** 1999;(1):10-2 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effects of nimodipine on noise-induced hearing loss. Boettcher FA, et al. **Hear Res** 1998 Jul;121(1-2):139-46

[Treatment results of acoustic trauma] Konopka W, et al. **Otolaryngol Pol** 1997;51 Suppl 25:281-4 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Targeted deletion of the cytosolic Cu/Zn-superoxide dismutase gene (Sod1) increases susceptibility to noise-induced hearing loss. Ohlemiller KK, et al. **Audiol Neurootol** 1999 Sep-Oct;4(5):237-46

Effect of acoustic trauma on cytochrome oxidase activity in stria vascularis. Hsu CJ, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec; 60(6):314-7

EPIDEMIOLOGY

Occupational noise-induced hearing loss surveillance in Michigan. Reilly MJ, et al. **J Occup Environ Med** 1998 Aug;40(8):667-74

ETHNOLOGY

Race/ethnicity differences in the prevalence of noise-induced hearing loss in a group of metal fabricating workers. Ishii EK, et al. **J Occup Environ Med** 1998 Aug;40(8):661-6

ETIOLOGY

Smoking as a risk factor in sensory neural hearing loss among workers exposed to occupational noise. Starck J, et al. **Acta Otolaryngol** 1999;119(3):302-5

Advantages and dangers of erbium laser application in stapedotomy. Häusler R, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):207-13

Hearing parameters in noise exposed industrial workers. Celik O, et al. **Auris Nasus Larynx** 1998 Dec;25(4):369-75

Low-altitude overflights of fighters and the risk of hearing loss. Kuronen P, et al. **Aviat Space Environ Med** 1999 Jul; 70(7):650-5

Two case reports of possible noise trauma after inflation of air bags in low speed car crashes [see comments] Buckley G, et al. **BMJ** 1999 Feb 20;318(7182):499-500. Comment in: BMJ 1999 May 22;318(7195):1421.

Noise-induced hearing loss in the noise-toughened auditory system. Ahroon WA, et al. **Hear Res** 1999 Mar; 129(1-2):101-10

Potentiation of octave-band noise induced auditory impairment by carbon monoxide. Chen GD, et al. **Hear Res** 1999 Jun;132(1-2):149-59

Intrinsic differences in hearing performances between ears revealed by the asymmetrical shooting posture in the army. Job A, et al. **Hear Res** 1998 Aug;122(1-2):119-24

Acute acoustic trauma--its features and management. Kersebaum M, et al. **J R Army Med Corps** 1998 Oct; 144(3):156-8

Hearing loss and use of personal stereos in young adults with antecedents of otitis media [letter] [see comments] Job A, et al. **Lancet** 1999 Jan 2;353(9146):35. Comment in: Lancet 1999 Feb 27;353(9154):756. Comment in: Lancet 1999 Apr 3;353(9159):1185.

Social noise and hearing loss [letter; comment] Smith P, et al. **Lancet** 1999 Apr 3;353(9159):1185. Comment on: Lancet 1999 Jan 2;353(9146):35.

Noise-induced hearing loss in young adults: the role of personal listening devices and other sources of leisure noise. Mostafapour SP, et al. **Laryngoscope** 1998 Dec; 108(12):1832-9

Latent cochlear damage in personal stereo users: a study based on click-evoked otoacoustic emissions [see comments] LePage EL, et al. **Med J Aust** 1998 Dec 7-21; 169(11-12):588-92. Comment in: Med J Aust 1998 Dec 7-21;169(11-12):587-8.

Otoacoustic emissions and recreational hearing loss [comment] Redhead JT. **Med J Aust** 1998 Dec 7-21; 169(11-12):587-8. Comment on: Med J Aust 1998 Dec 7-21;169(11-12):588-92.

Airbag deployment and hearing loss [letter] Morris MS, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):165-6

More on 'the invisible disability' [letter; comment] Barron L. **Postgrad Med** 1998 Nov;104(5):49; discussion 50. Comment on: Postgrad Med 1998 Sep;104(3):81-3, 87-90.

Determination of acute noise effects using distortion product otoacoustic emissions. Delb W, et al. **Scand Audiol** 1999; 28(2):67-76

[Toy cap pistols and their effect on hearing (see comments)] Fleischer G, et al. **HNO** 1998 Sep;46(9):815-20 (Eng. Abstr.). Comment in: HNO 1998 Sep;46(9):784-5. **(Ger)**

[Documentation of the effects of child cap pistols] Fleischer G, et al. **HNO** 1999 Jun;47(6):535-40 (Eng. Abstr.) **(Ger)**

[How dangerous are toy cap pistols for hearing? (comment)] Matéfi L, et al. **HNO** 1998 Sep;46(9):784-5. Comment on: HNO 1998 Sep;46(9):815-20. **(Ger)**

[Sociacusis. Non-occupationally induced hearing damage by noise, 2] Plath P. **HNO** 1998 Nov;46(11):947-52 (0 ref.) **(Ger)**

[Socio-acousis. Non-occupationally-induced hearing loss due to noise, 1] Plath P. **HNO** 1998 Oct;46(10):887-92 (46 ref.) **(Ger)**

[Peak sound pressure levels of gunshots from starter's pistols] Rothschild MA, et al. **HNO** 1998 Dec;46(12):986-92 (Eng. Abstr.) **(Ger)**

[Leisure time noise. Hearing damage in every 10th adolescent is possible (editorial)] Zenner HP. **HNO** 1999 Apr;47(4):225 **(Ger)**

[Hearing loss caused by leisure noise] Zenner HP, et al. **HNO** 1999 Apr;47(4):236-48 (69 ref.) (Eng. Abstr.) **(Ger)**

[The effect of occupational exposure to noise among tractor drivers: assessment based on 'noise threshold'] Solecki L. **Med Pr** 1998;49(6):535-44 (Eng. Abstr.) **(Pol)**

GENETICS

Targeted deletion of the cytosolic Cu/Zn-superoxide dismutase gene (Sod1) increases susceptibility to noise-induced hearing loss. Ohlemiller KK, et al. **Audiol Neurootol** 1999 Sep-Oct;4(5):237-46

Quantitative measure of genetic differences in susceptibility to noise-induced hearing loss in two strains of mice. Davis RR, et al. **Hear Res** 1999 Aug;134(1-2):9-15

PATHOLOGY

Leupeptin protects sensory hair cells from acoustic trauma. Wang J, et al. **Neuroreport** 1999 Mar 17;10(4):811-6

PHYSIOPATHOLOGY

Effects of background noise on click-evoked otoacoustic emissions. Rhoades K, et al. **Ear Hear** 1998 Dec; 19(6):450-62

Topodiagnostic assessment of occupational noise-induced hearing loss using distortion-product otoacoustic emissions compared to the short increment sensitivity index test. Oeken J. **Eur Arch Otorhinolaryngol** 1999;256(3):115-21

Noise-induced hearing loss in the noise-toughened auditory system. Ahroon WA, et al. **Hear Res** 1999 Mar; 129(1-2):101-10

Mechanisms in noise-induced permanent hearing loss: an evoked otoacoustic emission and auditory brainstem response study. Xu ZM, et al. **J Laryngol Otol** 1998 Dec; 112(12):1154-61

[Assessment of otoacoustic emission usefulness for early detection of hearing impairment caused by noise] Trybalska G, et al. **Otolaryngol Pol** 1999;53(2):207-11 (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Trends in hearing protector usage in American manufacturing from 1972 to 1989. Davis RR, et al. **Am Ind Hyg Assoc J** 1998 Oct;59(10):715-22

On the factors required for obtaining protection against noise trauma by prior acoustic experience [letter; comment] Canlon B, et al. **Hear Res** 1999 Jan;127(1-2):158-61. Comment on: Hear Res 1998 Feb;116(1-2):21-32.

Acquired resistance to acoustic trauma by sound conditioning is primarily mediated by changes restricted to the cochlea, not by systemic responses. Yamasoba T, et al. **Hear Res** 1999 Jan;127(1-2):31-40

Calcium channel blockers for prevention of noise trauma in otologic surgery. Maurer J, et al. **J La State Med Soc** 1998 Sep;150(9):400-5

New strategies for prevention and treatment of noise-induced hearing loss. Prasher D. **Lancet** 1998 Oct 17; 352(9136):1240-2

Leupeptin protects sensory hair cells from acoustic trauma. Wang J, et al. **Neuroreport** 1999 Mar 17;10(4):811-6

Have you heard. Hager LD. **Occup Health Saf** 1999 Mar; 68(3):38-40, 42-6

Are your workers protected to deaf? Klane J. **Occup Health Saf** 1998 Oct;67(10):90-4, 96

Beyond hearing loss. Madigan J. **Occup Health Saf** 1998 Oct; 67(10):84-9 (13 ref.)

[Effects of exposure to noise in oil-drilling well sites on cochlea in guinea pigs] Ye Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar; 32(2):103-5 (Eng. Abstr.) **(Chi)**

THERAPY

Acute acoustic trauma--its features and management. Kersebaum M, et al. **J R Army Med Corps** 1998 Oct; 144(3):156-8

New strategies for prevention and treatment of noise-induced hearing loss. Prasher D. **Lancet** 1998 Oct 17; 352(9136):1240-2

[Comparison of different treatments of acute acoustic trauma] Mingoutaud L, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998; 119(2):129-34 (Eng. Abstr.) **(Fre)**

HEARING LOSS, NONORGANIC see **HEARING LOSS, FUNCTIONAL**

HEARING LOSS, PARTIAL

CHEMICALLY INDUCED

Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. Sánchez-Alcaraz A, et al. **J Clin Pharm Ther** 1998 Oct;23(5):367-73

Low-frequency hearing loss following perinatal exposure to 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in rats. Crofton KM, et al. **Neurotoxicol Teratol** 1999 May-Jun; 21(3):299-301

["Sudden deafness" has not been classified as a side-effect. No compensation from the Drug Insurance Authority] Perman E. **Lakartidningen** 1999 Mar 10;96(10):1208 **(Swe)**

COMPLICATIONS

Association of NIDDM and hearing loss [see comments] Dalton DS, et al. **Diabetes Care** 1998 Sep;21(9):1540-4. Comment in: Diabetes Care 1999 Jan;22(1):180.

DIAGNOSIS

Accuracy of self-reported hearing loss. Nondahl DM, et al. **Audiology** 1998 Sep-Oct;37(5):295-301

A screening test of auditory comprehension for individuals with severe physical disability (PACST). Beaumont JG, et al. **Br J Clin Psychol** 1999 Mar;38 (Pt 1):1-4

Enlarged vestibular aqueduct as a marker for hearing loss in children. Manolis EN, et al. **Clin Pediatr (Phila)** 1998 Nov;37(11):689-91

Nonsense-syllable recognition in noise using monaural and binaural listening strategies. Arsenault MD, et al. **J Acoust Soc Am** 1999 Mar;105(3):1821-30

Auditory disorder in central nervous system miliary tuberculosis: case report. Stach BA, et al. **J Am Acad Audiol** 1998 Aug;9(4):305-10

Precursors to speech in infancy: the prediction of speech

and language disorders [see comments] Oller DK, et al. **J Commun Disord** 1999 Jul-Aug;32(4):223-45 (47 ref.). Comment in: J Commun Disord 1999 Jul-Aug;32(4):247-50.

The efficacy of early identification and intervention for children with hearing impairment. Downs MP, et al. **Pediatr Clin North Am** 1999 Feb;46(1):79-87 (23 ref.)

Otoacoustic emissions as a screening test for hearing impairment in children recovering from acute bacterial meningitis. Richardson MP, et al. **Pediatrics** 1998 Dec; 102(6):1364-8

Teacher accuracy in the identification of pre-school pupils with hearing loss. Chambers N, et al. **S Afr J Commun Disord** 1997;44:25-30

[The guideline 'Hearing impairment' of the Dutch College of General Practitioners; a comment from the family practitioner (comment)] Drijber NW. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1804-5 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. **(Dut)**

[Hearing impairment (letter)] Mülder HE, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2697; discussion 2697-8 **(Dut)**

[The guideline 'Hearing Impairment' of the Dutch College of General Practitioners; a comment from the Netherlands Society of Otolaryngology and Cervico-Facial Surgery (comment)] van der Hulst RJ. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1806-7 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. **(Dut)**

[Hearing impairment (letter; comment)] van Schaik V. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):702. Comment on: Ned Tijdschr Geneeskd 1998 Dec 5;142(49):2696. **(Dut)**

[Necessity of auditory and academic supervision in patients with unilateral hearing disorder. Retrospective study of 175 children] Watier-Launey C, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Jun;115(3):149-55 (Eng. Abstr.) **(Fre)**

[Word list for evaluating oral language perception in children with total and partial hearing impairment] Villalba Pérez A, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):151-7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Auditory ossicle abnormalities and hearing loss in the toothless (osteopetrotic) mutation in the rat and their improvement after treatment with colony-stimulating factor-1. Aharinejad S, et al. **J Bone Miner Res** 1999 Mar; 14(3):415-23

ENZYMOLOGY

Cu/Zn SOD deficiency potentiates hearing loss and cochlear pathology in aged 129,CD-1 mice. McFadden SL, et al. **J Comp Neurol** 1999 Oct 11;413(1):101-12

EPIDEMIOLOGY

Can unilateral hearing loss be a handicap in learning? [letter] Ito K. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1389-90

Prevalence of unilateral hearing loss in children: the National Health and Nutrition Examination Survey II and the Hispanic Health and Nutrition Examination Survey. Lee DJ, et al. **Ear Hear** 1998 Aug;19(4):329-32

[The frequency of hearing impairment in patients with diabetes mellitus type 2 (see comments)] Boomsma LJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1823-5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Sep 26;142(39):2163-4. **(Dut)**

[Prevalence and relevant background characteristics of deafness and severe hearing loss in the Netherlands] de Graaf R, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8; 142(32):1819-23 (Eng. Abstr.) **(Dut)**

ETIOLOGY

Auditory disorder in central nervous system miliary tuberculosis: case report. Stach BA, et al. **J Am Acad Audiol** 1998 Aug;9(4):305-10

Neurovascular decompression for tinnitus [letter; comment] Bayazit Y. **J Neurosurg** 1998 Dec;89(6):1072-3. Comment on: J Neurosurg 1998 Feb;88(2):232-6.

Automobile airbag impulse noise [letter; comment] Benecke JE Jr. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):166. Comment on: Otolaryngol Head Neck Surg 1998 Feb;118(2):228-34.

Recovery of hearing after removal of a large jugular foramen schwannoma: report of two cases. Yamakami I, et al. **Surg Neurol** 1999 Jan;51(1):60-5

[Hearing impairment (letter; comment)] Dankbaar WA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2696. Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. Comment on: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):702. **(Dut)**

[Increased hearing loss in patients with diabetes mellitus type 2 (letter; comment)] Polak BC, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2163-4. Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1823-5. **(Dut)**

[Unilateral neurosensory hearing loss as a manifestation of multiple sclerosis] Gurtubay Gálligo IG, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):147-9 (Eng. Abstr.) **(Spa)**

GENETICS

Auditory ossicle abnormalities and hearing loss in the toothless (osteopetrotic) mutation in the rat and their improvement after treatment with colony-stimulating factor-1. Aharinejad S, et al. **J Bone Miner Res** 1999 Mar; 14(3):415-23

PHYSIOPATHOLOGY

Minimal, progressive, and fluctuating hearing losses in children. Characteristics, identification, and management. Tharpe AM, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):65-78 (80 ref.)

REHABILITATION

Introduction to cochlear implants. Loizou PC. **IEEE Eng Med Biol Mag** 1999 Jan-Feb;18(1):32-42 (32 ref.)

SURGERY

Outcome analysis of children receiving tympanostomy tubes. Franklin JH, et al. **J Otolaryngol** 1998 Oct;27(5):293-7

[Extended indications for cochlear implantation. The Freiburg results in patients with residual hearing] Klenzner T, et al. **HNO** 1999 Feb;47(2):95-100 (Eng. Abstr.) **(Ger)**

THERAPY

Nonsurgical management of hearing loss. Mansour-Shousher R, et al. **Clin Geriatr Med** 1999 Feb;15(1):163-77, viii (17 ref.)

The efficacy of early identification and intervention for children with hearing impairment. Downs MP, et al. **Pediatr Clin North Am** 1999 Feb;46(1):79-87 (23 ref.)

[The guideline 'Hearing impairment' of the Dutch College of General Practitioners; a comment from the family practitioner (comment)] Drijber NW. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1804-5 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. **(Dut)**

[The guideline 'Hearing Impairment' of the Dutch College of General Practitioners; a comment from the Netherlands Society of Otolaryngology and Cervico-Facial Surgery (comment)] van der Hulst RJ. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1806-7 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813-6. **(Dut)**

HEARING LOSS, SENSORINEURAL

Characteristics of hearing families and their young deaf and hard of hearing children. Early intervention follow-up. Calderon R, et al. **Am Ann Deaf** 1998 Oct;143(4):347-62

Hearing impairment related to age in Usher syndrome types 1B and 2A. Wagenaar M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):441-5

Mutation in the zonadhesin-like domain of alpha-tectorin associated with autosomal dominant non-syndromic hearing loss. Alloisio N, et al. **Eur J Hum Genet** 1999 Feb-Mar;7(2):255-8

The role of consonant-vowel amplitude ratio in the recognition of voiceless stop consonants by listeners with hearing impairment. Sammeth CA, et al. **J Speech Lang Hear Res** 1999 Feb;42(1):42-55

Progressive sensorineural hearing loss in childhood. Berrettini S, et al. **Pediatr Neurol** 1999 Feb;20(2):130-6

[Analysis of sensorineural hearing loss in 77 children] Zhang S, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Jun;11(6):252-4 (Eng. Abstr.) **(Chi)**

[KID syndrome (keratitis, ichthyosis and deafness)] André N, et al. **Arch Pediatr** 1999 Mar;6(3):302-6 (29 ref.) (Eng. Abstr.) **(Fre)**

[Progressive sensorineural hearing loss: definition, classification, main etiological factors] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):9-12 **(Ita)**

[Epstein syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):314-5 (12 ref.) **(Jpn)**

[Fechtner syndrome] Ohata M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):322-5 (15 ref.) **(Jpn)**

[Susac syndrome: presentation of a new case (letter)] Castellanos MM, et al. **Neurologia** 1999 Jan;14(1):43-5 **(Spa)**

CHEMICALLY INDUCED

Ototoxicity associated with vinblastine. Moss PE, et al. **Ann Pharmacother** 1999 Apr;33(4):423-5

Carbamazepine-induced sensorineural hearing loss. de la Cruz M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb; 125(2):225-7

Comparison of distortion-product and transient evoked otoacoustic emissions with ABR threshold shift in chinchillas with ototoxic damage. Kakigi A, et al. **Auris Nasus Larynx** 1998 Sep;25(3):223-32

Ototoxicity due to hydroxychloroquine: report of two cases. Johansen PB, et al. **Clin Exp Rheumatol** 1998 Jul-Aug; 16(4):472-4

The effects of kanamycin injection into the fetal lamb cochlea. Meixner KE, et al. **Ear Nose Throat J** 1999 Mar; 78(3):196-8, 203-4

A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine [letter] Tibaldi C, et al. **Eur J Cancer** 1998 Jun;34(7):1133-4

Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings. Christensen LA, et al. **J Am Acad Audiol** 1998 Aug;9(4):292-8

Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. Littman TA, et al. **J Am Acad Audiol** 1998 Aug; 9(4):257-62

Metronidazole ototoxicity--report of two cases. Iqbal SM, et al. **J Laryngol Otol** 1999 Apr;113(4):355-7

Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. Cheung PY, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):233-9

Naproxen-associated sudden sensorineural hearing loss. McKinnon BJ, et al. **Mil Med** 1998 Nov;163(11):792-3

The frequency in New Zealand of a mitochondrial DNA mutation (1555 A to G) associated with aminoglycoside-induced hearing loss [letter] Scrimshaw BJ, et al. **N Z Med J** 1999 Jun 11;112(1089):216-7

[Types of hearing disorders in drug addicts and individuals drinking non-consumable alcohols] Lukomski M, et al. **Med Pr** 1999;50(1):37-42 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Sensorineural hearing loss, iritis and ankylosing spondylitis [letter] Raza K, et al. **Br J Rheumatol** 1998 Dec;37(12):1363

Björnstad syndrome in a patient with mental retardation. Van Buggenhout G, et al. **Genet Couns** 1998;9(3):201-4

A cross-sectional study of speech- and language-abilities of children with normal hearing, mild fluctuating conductive hearing loss, or moderate to profound sensoneurinal hearing loss. Schönweiler R, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 1O;44(3):251-8

A case of megalocornea-mental retardation syndrome complicated with bilateral sensorineural hearing impairment. Tominaga N, et al. **Pediatr Int** 1999 Aug; 41(4):392-4

Vertigo, hearing loss, and tinnitus. Raza SA, et al. **Postgrad Med J** 1998 Jun;74(872):375-7

[Treatment of sensorineural hearing loss with delayed onset of vertigo (report of 13 cases)] Lu Y, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Nov; 11(11):496-8 (Eng. Abstr.) **(Chi)**

[Hearing status in patients with pronounced chronic kidney insufficiency] Gurbanov FA. **Vestn Otorinolaringol** 1999; (2):39-41 (Eng. Abstr.) **(Rus)**

[Cogan's syndrome: apropos of a case (letter)] Gracia Ruiz ML, et al. **Rev Clin Esp** 1999 Feb;199(2):116 **(Spa)**

CONGENITAL

Volumetric neuroimaging in Usher syndrome: evidence of global involvement. Schaefer GB, et al. **Am J Med Genet** 1998 Aug 27;79(1):1-4

A new autosomal-dominant locus (DFNA12) is responsible for a nonsyndromic, midfrequency, prelingual and nonprogressive sensorineural hearing loss. Govaerts PJ, et al. **Am J Otol** 1998 Nov;19(6):718-23

Quiz case 2. Large vestibular aqueduct syndrome (LVAS). Lee D, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jul; 125(7):813, 815

Cochlear implant failure due to unexpected absence of the eighth nerve--a cautionary tale. Gray RF, et al. **J Laryngol Otol** 1998 Jul;112(7):646-9

Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness. Green GE, et al. **JAMA** 1999 Jun 16;281(23):2211-6

Semen analysis in the Usher syndrome type 2A. van Aarem A, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May-Jun; 61(3):126-30

Relative and attributable risks for moderate to profound bilateral sensorineural hearing impairment associated with lower birth weight in children 3 to 10 years old. Van Naarden K, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):905-10

DIAGNOSIS

Correlation between latency and amplitude of peak V in the brainstem auditory evoked potentials: intraoperative recordings in microvascular decompression operations. Hatayama T, et al. **Acta Neurochir (Wien)** 1998;140(7):681-7

Smoking as a risk factor in sensory neural hearing loss among workers exposed to occupational noise. Starck J, et al. **Acta Otolaryngol** 1999;119(3):302-5

Diagnostic potential of distortion product otoacoustic emissions in severe or profound sensorineural hearing loss. Park MS, et al. **Acta Otolaryngol (Stockh)** 1998 Jul; 118(4):496-500

Speech audibility for listeners with high-frequency hearing loss. Turner CW, et al. **Am J Audiol** 1999 Jun;8(1):47-56

Case report and discussion of hearing preservation after translabyrinthine excision of small acoustic tumors. Rizvi SS, et al. **Am J Otol** 1999 Mar;20(2):249-52

Hearing preservation in neurofibromatosis type 2. Slattery WH 3rd, et al. **Am J Otol** 1998 Sep;19(5):638-43

Electrocochleographic evaluation of hearing loss in acoustic neuromas. Tanaka F, et al. **Am J Otol** 1999 Jul;20(4):479-83

Sensorineural hearing loss after occlusion of the enlarged vestibular aqueduct. Welling DB, et al. **Am J Otol** 1999 May;20(3):338–43

Reliability of 80-Hz amplitude-modulation-following response detected by phase coherence. Aoyagi M, et al. **Audiol Neurootol** 1999 Jan–Feb;4(1):28–37

The effects of amplitude modulation on acoustic reflex decay. Cook RD, et al. **Audiol Neurootol** 1999 Mar–Apr; 4(2):104–13

Inner ear pressure in Menière's disease and fluctuating hearing loss determined by tympanic membrane displacement analysis. Bouccara D, et al. **Audiology** 1998 Sep–Oct;37(5):255–61

Clinical evaluation of a full-digital in-the-ear hearing instrument. Boymans M, et al. **Audiology** 1999 Mar–Apr; 38(2):99–108

The relationship between the uncomfortable loudness level and the acoustic reflex threshold for pure tones in normally-hearing and impaired listeners--a meta-analysis. Olsen SO. **Audiology** 1999 Mar–Apr;38(2):61–8

The prognostic value of electrocochleography in severely hearing-impaired infants. Schoonhoven R, et al. **Audiology** 1999 May–Jun;38(3):141–54

A study of the effects of cochlear loss on the auditory brainstem response (ABR) specificity and false positive rate in retrocochlear assessment. Watson DR. **Audiology** 1999 May–Jun;38(3):155–64

Analyses of notches in audioscan and DPOAEs in subjects with normal hearing. Zhao F, et al. **Audiology** 1998 Nov–Dec;37(6):335–43

Hearing parameters in noise exposed industrial workers. Celik O, et al. **Auris Nasus Larynx** 1998 Dec;25(4):369–75

Variable-speech-rate audiometry for hearing aid evaluation. Hosoi H, et al. **Auris Nasus Larynx** 1999 Jan;26(1):17–27

Identification of permanent hearing loss in children: are the targets for outcome measures attainable? Fonseca S, et al. **Br J Audiol** 1999 Jun;33(3):135–43

Implantable hearing devices for sensorineural hearing loss: a review of the audiometric data. Snik AF, et al. **Clin Otolaryngol** 1998 Oct;23(5):414–9

Distortion product otoacoustic emission and auditory brain stem response measures of pediatric sensorineural hearing loss with islands of normal sensitivity. Balfour PB, et al. **Ear Hear** 1998 Dec;19(6):463–72

Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Bess FH, et al. **Ear Hear** 1998 Oct;19(5):339–54

Children's speech recognition in noise using omni-directional and dual-microphone hearing aid technology. Gravel JS, et al. **Ear Hear** 1999 Feb;20(1):1–11

Characteristics of transient evoked otoacoustic emissions in normal-hearing and hearing-impaired children. Harrison WA, et al. **Ear Hear** 1999 Feb;20(1):75–86

Cross-modality matching: a tool for measuring loudness in sensorineural impairment. Hellman RP. **Ear Hear** 1999 Jun; 20(3):193–213

Transient evoked otoacoustic emissions in patients with normal hearing and in patients with hearing loss. Hussain DM, et al. **Ear Hear** 1998 Dec;19(6):434–49

Neuroaudiological effects in a case of fatal dimethylmercury poisoning. Musiek FE, et al. **Ear Hear** 1999 Jun;20(3):271–5

Quantifying the contribution of audibility to recognition of compression-amplified speech. Souza PE, et al. **Ear Hear** 1999 Feb;20(1):12–20

Keratinized epithelial folds [letter; comment] Di Bartolomeo JR. **Ear Nose Throat J** 1999 Apr;78(4):308. Comment on: Ear Nose Throat J 1999 Feb;78(2):76–8.

Four cases of familial hearing loss with large vestibular aqueducts [letter] Satoh H, et al. **Eur Arch Otorhinolaryngol** 1999;256(2):83–6

Magnetic resonance imaging of the inner ear in patients with idiopathic sudden sensorineural hearing loss. Stokroos RJ, et al. **Eur Arch Otorhinolaryngol** 1998;255(9):433–6

Otoacoustic emissions in screening cleft lip and/or palate children for hearing loss--a feasibility study. Anteunis LJ, et al. **Int J Pediatr Otorhinolaryngol** 1998 Aug 10; 44(3):259–66

A particular case of deafness-oligodontia syndrome. Marlin S, et al. **Int J Pediatr Otorhinolaryngol** 1998 Jun 1; 44(1):63–9

A comparison of monotic and dichotic complex-tone pitch perception in listeners with hearing loss. Arehart KH, et al. **J Acoust Soc Am** 1999 Aug;106(2):993–7

Psychometric functions for discrimination of two-component complex tones in listeners with normal hearing and listeners with hearing loss. Arehart KH, et al. **J Acoust Soc Am** 1999 Apr;105(4):2454–65

Nonsense-syllable recognition in noise using monaural and binaural listening strategies. Arsenault MD, et al. **J Acoust Soc Am** 1999 Mar;105(3):1821–30

Gap detection by early-deafened cochlear-implant subjects. Busby PA, et al. **J Acoust Soc Am** 1999 Mar;105(3):1841–52

The relation between identification and discrimination of vowels in young and elderly listeners. Coughlin M, et al. **J Acoust Soc Am** 1998 Dec;104(6):3597–607

Level discrimination of single tones in a multitone complex by normal-hearing and hearing-impaired listeners. Doherty KA, et al. **J Acoust Soc Am** 1999 Mar;105(3):1831–40

Sound localization in noise in hearing-impaired listeners. Lorenzi C, et al. **J Acoust Soc Am** 1999 Jun;105(6):3454–63

Further evaluation of a model of loudness perception applied to cochlear hearing loss. Moore BC, et al. **J Acoust Soc Am** 1999 Aug;106(2):898–907

Subjective effects of peak clipping and compression limiting in normal and hearing-impaired children and adults. Stelmachowicz PG, et al. **J Acoust Soc Am** 1999 Jan; 105(1):412–22

Proportional frequency compression of speech for listeners with sensorineural hearing loss. Turner CW, et al. **J Acoust Soc Am** 1999 Aug;106(2):877–86

Large vestibular aqueduct syndrome: an overlooked etiology for progressive childhood hearing loss. Callison DM, et al. **J Am Acad Audiol** 1998 Aug;9(4):285–91; quiz 314

Hearing improvement after resection of cerebellopontine angle meningioma: case study of the preoperative role of transient evoked otoacoustic emissions. Kileny PR, et al. **J Am Acad Audiol** 1998 Aug;9(4):251–6

Sensorineural hearing loss in ECMO survivors. Extracorporeal membraneous oxygenation. Mann T, et al. **J Am Acad Audiol** 1998 Oct;9(5):367–70

Auditory disorder in central nervous system miliary tuberculosis: case report. Stach BA, et al. **J Am Acad Audiol** 1998 Aug;9(4):305–10

One-year audiologic monitoring of individuals exposed to the 1995 Oklahoma City bombing. Van Campen LE, et al. **J Am Acad Audiol** 1999 May;10(5):231–47

Effects of acknowledging a hearing loss on social interactions. Blood IM, et al. **J Commun Disord** 1999 Mar–Apr;32(2):109–19; quiz 119–20

Prediscarge screening of very low birthweight infants by click evoked otoacoustic emissions. Gill AW, et al. **J Paediatr Child Health** 1998 Oct;34(5):456–9

Neural networks applied to retrocochlear diagnosis. Callan DE, et al. **J Speech Lang Hear Res** 1999 Apr;42(2):287–99

Auditory temporal order perception in younger and older adults. Fitzgibbons PJ, et al. **J Speech Lang Hear Res** 1998 Oct;41(5):1052–60

Older adult performance on the Communication Profile for the Hearing Impaired: gender difference. Garstecki DC, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):785–96

HINT list equivalency using older listeners. Hanks WD, et al. **J Speech Lang Hear Res** 1998 Dec;41(6):1335–40

FO processing and the separation of competing speech signals by listeners with normal hearing and with hearing loss. Summers V, et al. **J Speech Lang Hear Res** 1998 Dec; 41(6):1294–306

Limiting spectral resolution in speech for listeners with sensorineural hearing loss. Turner CW, et al. **J Speech Lang Hear Res** 1999 Aug;42(4):773–84

Aging and high-frequency hearing sensitivity. Wiley TL, et al. **J Speech Lang Hear Res** 1998 Oct;41(5):1061–72

Ultra high resolution nonenhanced fast spin echo magnetic resonance imaging: cost-effective screening for acoustic neuroma in patients with sudden sensorineural hearing loss. Daniels RL, et al. **Otolaryngol Head Neck Surg** 1998 Oct; 119(4):364–9

Asymmetric sensorineural hearing loss in a community-based population. Urben SL, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):809–14

Universal newborn hearing screening: should we leap before we look? [letter] Berg AL, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):351–2; discussion 354–5

Universal newborn hearing screening: should we leap before we look? [letter; comment] Mehl AL. **Pediatrics** 1999 Aug; 104(2 Pt 1):352–3; discussion 354–5. Comment on: Pediatrics 1999 Mar;103(3):670–2.

Universal newborn hearing screening: should we leap before we look? [comment] [see comments] Paradise JL. **Pediatrics** 1999 Mar;103(3):670–2. Comment on: Pediatrics 1997 Mar;99(3):318–33. Comment on: Pediatrics 1998 Feb;101(2):221–8. Comment in: Pediatrics 1999 Aug;104(2 Pt 1):352–3; discussion 354–5.

Audit of clinical judgements and actions in an audiological investigation of school entrant children screened positive for hearing loss. Holtby I, et al. **Public Health** 1998 Sep; 112(5):337–41

Clinical evaluation of a portable digital hearing aid with narrow-band loudness compensation. Hidaka H, et al. **Scand Audiol** 1998;27(4):225–36

A clinical study on the growth of distortion product otoacoustic emissions and hearing loss at 2 kHz in humans. Lind O. **Scand Audiol** 1998;27(4):207–12

[Physical diagnostic procedures: whispered speech and tuning fork test (comment)] Grote JJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1816–9 (10 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813–6. **(Dut)**

[Atypical Cogan syndrome: a case report and review of the literature] De Righetti F, et al. **Rev Med Suisse Romande** 1998 Oct;118(10):889–93 (50 ref.) **(Fre)**

[Diagnostic value of otoacoustic emissions. 1] Schmuziger N, et al. **HNO** 1998 Aug;46(8):769–76 **(Ger)**

[Diagnostic value of otoacoustic emissions. 2. Clinical applications of otoacoustic emissions] Schmuziger N, et al. **HNO** 1998 Sep;46(9):828–37 **(Ger)**

[Diagnostic and therapeutic approach to progressive sensorineural hearing loss] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):87–94 (45 ref.) (Eng. Abstr.) **(Ita)**

[Progressive sensorineural hearing loss in childhood] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):13–20 (97 ref.) (Eng. Abstr.) **(Ita)**

[A case of preserved otoacoustic emissions in a child with unilateral idiopathic severe sensorineural hearing loss] Namysłowski G, et al. **Otolaryngol Pol** 1999;53(1):101–5 (Eng. Abstr.) **(Pol)**

[Profound bilateral sensorineural hearing loss: a result of viral infections] Zientalska E, et al. **Otolaryngol Pol** 1999; 53(2):189–93 (Eng. Abstr.) **(Pol)**

[Hearing status in patients with pronounced chronic kidney insufficiency] Gurbanov FA. **Vestn Otorinolaringol** 1999; (2):39–41 (Eng. Abstr.) **(Rus)**

[A rush technique for the initial assessment of hearing disorders in pre-school and school children] Radionova EA. **Vestn Otorinolaringol** 1998;(5):9–11 (Eng. Abstr.) **(Rus)**

[Alternating signal speech audiometry in the diagnosis of central lesions of the acoustic analyzer] Ryndina AM, et al. **Vestn Otorinolaringol** 1998;(6):13–4 (Eng. Abstr.) **(Rus)**

[Study of the correspondence between pure tone and distorsion product otoacoustic emissions audiometrics: basis for an objective cochlear audiometrics model] Jürgens A, et al. **Acta Otorrinolaringol Esp** 1999 May;50(4):253–9 (Eng. Abstr.) **(Spa)**

[Bimastoid leads and bilateral stimulation in the recording of auditory-evoked brain-stem potentials] Oliva Domínguez M, et al. **Acta Otorrinolaringol Esp** 1999 Apr; 50(3):191–5 (Eng. Abstr.) **(Spa)**

[Prospective study with auditory evoked potentials of the brain stem in children at risk] Navarro Rivero B, et al. **An Esp Pediatr** 1999 Apr;50(4):357–60 (Eng. Abstr.) **(Spa)**

[Progression of profound perceptive deafness in children] Montalt J, et al. **An Otorrinolaringol Ibero Am** 1999; 26(3):225–39 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Stokroos RJ, et al. **Acta Otolaryngol (Stockh)** 1998 Jul;118(4):488–95

Management of idiopathic sudden sensorineural hearing loss. Haberkamp TJ, et al. **Am J Otol** 1999 Sep;20(5):587–92; discussion 593–5 (41 ref.)

Cogan's syndrome: unsuccessful outcome with early combination therapy. Covelli M, et al. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):479–83

Treatment of sudden sensorineural hearing loss with a continuous epidural block. Fujino M, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S18–21

What you need to know--hearing loss and inner ear diseases--can they be cured? Ruan RS, et al. **Singapore Med J** 1999 Jan;40(1):60–1 (5 ref.)

[Clinical and experimental study on bushen cong-er tablet in treating sensorineural hearing loss] Lin WS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):658–60 (Eng. Abstr.) **(Chi)**

[Treatments of idiopathic sudden sensorineural hearing loss: retrospective study of 144 cases] Mosnier I, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(2):119–28 (Eng. Abstr.) **(Fre)**

[Neuropeptides in the treatment of sensorineural hypoacusis in children] Pudov VI, et al. **Vestn Otorinolaringol** 1998; (4):22–4 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness [see comments] Karet FE, et al. **Nat Genet** 1999 Jan;21(1):84–90 . Comment in: Nat Genet 1999 Jan;21(1):67–8.

EPIDEMIOLOGY

Hereditary recessive progressive SNHL--what is the incidence? [letter; comment] Fitzgerald DC. **Am J Otol** 1999 Jan;20(1):136–7. Comment on: Am J Otol 1998 May;19(3):263–5.

ABR hearing screening for high-risk infants. Van Riper LA, et al. **Am J Otol** 1999 Jul;20(4):516–21

Auditory screening in neonates by means of transient evoked otoacoustic emissions: a report of 2,842 recordings. Aidan D, et al. **Ann Otol Rhinol Laryngol** 1999 Jun;108(6):525–31

Hearing in advanced age. A study of presbyacusis in 85-, 88- and 90-year-old people. Jönsson R, et al. **Audiology** 1998 Jul–Aug;37(4):207–18

Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Bess FH, et al. **Ear Hear** 1998 Oct;19(5):339–54

Evaluation of the use of a questionnaire to detect hearing loss in babies in China. Newton VE, et al. **Int J Pediatr Otorhinolaryngol** 1999 May 5;48(2):125–9

Relative and attributable risks for moderate to profound bilateral sensorineural hearing impairment associated with lower birth weight in children 3 to 10 years old. Van Naarden K, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):905–10

[Acoustic distortion products otoacoustic emissions (DPOAE) in neonatal screening] Luppari R, et al. **Acta Otorhinolaryngol Ital** 1999 Apr;19(2):57–63 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Intrameatal tumours presenting as a hearing disturbance: case reports of meningioma and lymphoma. Kawamura S, et

al. **Acta Neurochir (Wien)** 1998;140(7):675–9 (16 ref.)

Smoking as a risk factor in sensory neural hearing loss among workers exposed to occupational noise. Starck J, et al. **Acta Otolaryngol** 1999;119(3):302–5

Acute autoimmune sensorineural hearing loss associated with Crohn's disease. Bachmeyer C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2565–7

The effect of stapes surgery on high frequency hearing in patients with otosclerosis. Meyer SE. **Am J Otol** 1999 Jan; 20(1):36–40

High prevalence of sensorineural hearing loss among survivors of neonatal congenital diaphragmatic hernia. Western Canadian ECMO Follow-up Group. Robertson CM, et al. **Am J Otol** 1998 Nov;19(6):730–6

Successful cochlear implantation in a patient with MELAS syndrome. Rosenthal EL, et al. **Am J Otol** 1999 Mar; 20(2):187–90; discussion 190–1

Electron microscopic temporal bone histopathology in experimental pneumococcal meningitis. Rappaport JM, et al. **Ann Otol Rhinol Laryngol** 1999 Jun;108(6):537–47

Study of systemic lupus erythematosus in temporal bones. Sone M, et al. **Ann Otol Rhinol Laryngol** 1999 Apr; 108(4):338–44

Therapy of idiopathic sudden sensorineural hearing loss: antiviral treatment of experimental herpes simplex virus infection of the inner ear. Stokroos RJ, et al. **Ann Otol Rhinol Laryngol** 1999 May;108(5):423–8

Multichannel cochlear implantation in children with large vestibular aqueduct syndrome. Harker LA, et al. **Ann Otol Rhinol Laryngol Suppl** 1999 Apr;177:39–43

Audiological abnormalities in the Klippel–Feil syndrome. McGaughran JM, et al. **Arch Dis Child** 1998 Oct; 79(4):352–5

Causes of pediatric sensorineural hearing loss: yesterday and today. Billings KR, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):517–21

Risk factors for hearing loss from meningitis in children: the Children's Hospital experience. Woolley AL, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):509–14

Hearing parameters in noise exposed industrial workers. Celik O, et al. **Auris Nasus Larynx** 1998 Dec;25(4):369–75

Correlation of 3D MRI and clinical findings in the patients with sensorineural hearing loss and/or vertigo. Held P, et al. **Clin Imaging** 1998 Sep–Oct;22(5):309–22

Sensorineural hearing loss caused by NSAID-induced aseptic meningitis. Davison SP, et al. **Ear Nose Throat J** 1998 Oct; 77(10):820–1, 824–6

Vestibular aqueduct syndrome. Palacios E, et al. **Ear Nose Throat J** 1999 Sep;78(9):676

Hearing loss in neurofibromatosis type 1: report of two cases. Shamboul K, et al. **East Afr Med J** 1999 Feb;76(2):117–9

Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Ho WK, et al. **Head Neck** 1999 Sep;21(6):547–53

Evidence of an increased risk of hearing loss in heterozygous carriers in a Wolfram syndrome family. Ohata T, et al. **Hum Genet** 1998 Oct;103(4):470–4

Brainstem auditory evoked response in newborns with hyperbilirubinemia. Agrawal VK, et al. **Indian Pediatr** 1998 Jun;35(6):513–8

Otologic findings in a pediatric cohort with sickle cell disease. MacDonald CB, et al. **Int J Pediatr Otorhinolaryngol** 1999 Jan 25;47(1):23–8

Sensorineural hearing loss associated with otitis media with effusion in children. Mutlu C, et al. **Int J Pediatr Otorhinolaryngol** 1998 Dec 15;46(3):179–84

Large vestibular aqueduct syndrome: an overlooked etiology for progressive childhood hearing loss. Callison DM, et al. **J Am Acad Audiol** 1998 Aug;9(4):285–91; quiz 314

Sensorineural hearing loss in ECMO survivors. Extracorporeal membraneous oxygenation. Mann T, et al. **J Am Acad Audiol** 1998 Oct;9(5):367–70

Managing hearing loss in a patient with Alzheimer disease. Palmer CV, et al. **J Am Acad Audiol** 1998 Aug;9(4):275–84

Auditory disorder in central nervous system miliary tuberculosis: case report. Stach BA, et al. **J Am Acad Audiol** 1998 Aug;9(4):305–10

One-year audiologic monitoring of individuals exposed to the 1995 Oklahoma City bombing. Van Campen LE, et al. **J Am Acad Audiol** 1999 May;10(5):231–47

Bilateral sudden sensorineural hearing loss following non-otologic surgery. de la Cruz M, et al. **J Laryngol Otol** 1998 Aug;112(8):769–71 (16 ref.)

Solitary plasmacytoma of the skull base presenting with unilateral sensorineural hearing loss. Vijaya-Sekaran S, et al. **J Laryngol Otol** 1999 Feb;113(2):164–6 (13 ref.)

Does chronic otitis media cause sensorineural hearing loss? [letter; comment] Chasin M. **J Otolaryngol** 1998 Aug; 27(4):246. Comment on: J Otolaryngol 1998 Feb;27(1):17–20.

Sensorineural hearing loss and lupus [letter] Dayal VS, et al. **J Rheumatol** 1999 Sep;26(9):2065

Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndrome and antiphospholipid antibodies [letter; comment] Paira SO. **J Rheumatol** 1998 Dec;25(12):2476–7. Comment on: J Rheumatol 1998 Mar;25(3):589–92.

Sensorineural hearing loss in MELAS syndrome--case report. Chen JN, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Aug; 14(8):519–23

Is there a correlation between vascular loops and unilateral auditory symptoms? Makins AE, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1739–42

Acoustic neuroma surgery: absent auditory brainstem response does not contraindicate attempted hearing preservation. Roberson JB Jr, et al. **Laryngoscope** 1999 Jun; 109(6):904–10

The effect of hemodialysis on hearing using pure-tone audiometry and distortion-product otoacoustic emissions. Ozturan O, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov–Dec;60(6):306–13

Noonan's syndrome with sensorineural hearing loss and vestibular abnormalities. Foster CA, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):508–11

Labyrinthine fenestration in the guinea pig. Isaacson DJ, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):394–9

Sudden hearing loss as a presenting manifestation of leukemia. Veling MC, et al. **Otolaryngol Head Neck Surg** 1999 Jun; 120(6):954–6

Acute hearing loss after liposuction. Hecksteden K, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1534–6; discussion 1537–8

Further hearing loss during osteoporosis treatment with etidronate. Yaşil S, et al. **Postgrad Med J** 1998 Jun; 74(872):363–4

Changes in the auditory system related to cerebral circulation in the Ukraine population after the Chernobyl disaster. Rimar VV. **Rev Laryngol Otol Rhinol (Bord)** 1999; 120(2):89–92

Temporal arteritis and sensorineural hearing loss. Hausch RC, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):206–9

Large endolymphatic duct and sac syndrome--a case report. Tan TY. **Singapore Med J** 1999 May;40(5):359–61

Sensorineural hearing loss associated with Byler disease. Oshima T, et al. **Tohoku J Exp Med** 1999 Jan;187(1):83–8

[Megadolichobasilar artery as the etiology of sensorineural deafness in differential sudden deafness diagnosis] Otterstedde CR, et al. **HNO** 1999 May;47(5):494–6 (Eng. Abstr.) **(Ger)**

[Progressive sensorineural hearing loss: neoplastic causes] Bacciu S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):71–6 (27 ref.) (Eng. Abstr.) **(Ita)**

[Iatrogenic and non-iatrogenic factors as causes of progressive sensorineural hearing loss] De Capua B, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):55–8 (11 ref.) (Eng. Abstr.) **(Ita)**

[MRI in progressive sensorineural hearing loss] Ferrara P, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):80–6 (26 ref.) (Eng. Abstr.) **(Ita)**

[Sudden hearing loss complicating general surgery: report of a case and review of the literature] Maione A. **Acta Otorhinolaryngol Ital** 1998 Jun;18(3):172–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Progressive sensorineural hearing loss: metabolic, hormonal and vascular etiology] Ravecca F, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):42–50 (99 ref.) (Eng. Abstr.) **(Ita)**

[Progressive sensorineural hearing loss in cochlear otosclerosis] Sellari-Franceschini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):59–65 (59 ref.) (Eng. Abstr.) **(Ita)**

[Two cases of hearing disorder following general anesthesia] Nishida T, et al. **Masui** 1999 May;48(5):518–22 (Eng. Abstr.) **(Jpn)**

[Plasma cell leukemia (IgG kappa) presenting bilateral neurosensory hearing loss and left sixth cranial nerve plasy] Aikawa S, et al. **Rinsho Ketsueki** 1998 Jul;39(7):506–11 (Eng. Abstr.) **(Jpn)**

[Profound bilateral sensorineural hearing loss: a result of viral infections] Zientalska E, et al. **Otolaryngol Pol** 1999; 53(2):189–93 (Eng. Abstr.) **(Pol)**

[Hearing loss secondary to lumbar puncture] Aréchaga Orüe O, et al. **Acta Otorrinolaringol Esp** 1998 Nov–Dec; 49(8):647–9 (Eng. Abstr.) **(Spa)**

[Sudden hearing loss and uveitis as a form of presentation of neurosarcoidosis] García Berrocal JR, et al. **Acta Otorrinolaringol Esp** 1998 Aug–Sep;49(6):488–90 (Eng. Abstr.) **(Spa)**

[Unilateral neurosensory hearing loss as a manifestation of multiple sclerosis] Gurtubay Gálligo IG, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):147–9 (Eng. Abstr.) **(Spa)**

[Prospective study with auditory evoked potentials of the brain stem in children at risk] Navarro Rivero B, et al. **An Esp Pediatr** 1999 Apr;50(4):357–60 (Eng. Abstr.) **(Spa)**

[ENT changes in Crouzon's syndrome] Campos Del Alamo MA, et al. **An Otorrinolaringol Ibero Am** 1999;26(2):117–23 (Eng. Abstr.) **(Spa)**

GENETICS

Possible interaction between USH1B and USH3 gene products as implied by apparent digenic deafness inheritance [letter] Adato A, et al. **Am J Hum Genet** 1999 Jul;65(1):261–5

A gene for fluctuating, progressive autosomal dominant nonsyndromic hearing loss, DFNA16, maps to chromosome 2q23–24.3. Fukushima K, et al. **Am J Hum Genet** 1999 Jul;65(1):141–50

Fluctuating sensorineural hearing loss associated with enlarged vestibular aqueduct maps to 7q31, the region containing the Pendred gene. Abe S, et al. **Am J Med Genet** 1999 Feb 12;82(4):322–8

Family with low-grade neuroendocrine carcinoma of salivary glands, severe sensorineural hearing loss, and enamel hypoplasia. Michaels L, et al. **Am J Med Genet** 1999 Mar 19;83(3):183–6

Hereditary recessive progressive SNHL--what is the incidence? [letter; comment] Fitzgerald DC. **Am J Otol** 1999 Jan;20(1):136–7. Comment on: Am J Otol 1998 May;19(3):263–5.

A new autosomal-dominant locus (DFNA12) is responsible for a nonsyndromic, midfrequency, prelingual and nonprogressive sensorineural hearing loss. Govaerts PJ, et al. **Am J Otol** 1998 Nov;19(6):718–23

Hereditary postlingual sensorineural hearing loss mapping to chromosome Xq21. Manolis EN, et al. **Am J Otol** 1999 Sep;20(5):621–6

Cochlear implantation in a patient with profound hearing loss with the A1555G mitochondrial mutation. Tono T, et al. **Am J Otol** 1998 Nov;19(6):754–7

Autosomal dominant non-syndromal low-frequency sensorineural hearing impairment linked to chromosome 4p16 (DFNA14): statistical analysis of hearing threshold in relation to age and evaluation of vestibulo-ocular functions. Kunst H, et al. **Audiology** 1999 May–Jun; 38(3):165–73 (32 ref.)

Familial carotid body paragangliomas and sensorineural hearing-loss: a new syndrome. Lord RS, et al. **Cardiovasc Surg** 1999 Jan;7(1):134–8

KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Kubisch C, et al. **Cell** 1999 Feb 5;96(3):437–46

Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35–9 (32 ref.)

Autosomal-dominant, prelingual, nonprogressive sensorineural hearing loss: localization of the gene (DFNA8) to chromosome 11q by linkage in an Austrian family. Kirschhofer K, et al. **Cytogenet Cell Genet** 1998; 82(1–2):126–30

Four cases of familial hearing loss with large vestibular aqueducts [letter] Satoh H, et al. **Eur Arch Otorhinolaryngol** 1999;256(2):83–6

Phylogenetic analysis of mitochondrial DNA in Japanese pedigrees of sensorineural hearing loss associated with the A1555G mutation. Abe S, et al. **Eur J Hum Genet** 1998 Nov–Dec;6(6):563–9

A novel locus for Usher syndrome type II, USH2B, maps to chromosome 3 at p23–24.2. Hmani M, et al. **Eur J Hum Genet** 1999 Apr;7(3):363–7

DFNB20: a novel locus for autosomal recessive, non-syndromal sensorineural hearing loss maps to chromosome 11q25–qter. Moynihan L, et al. **Eur J Hum Genet** 1999 Feb–Mar;7(2):243–6

Identification of a locus on chromosome 7q31, DFNB14, responsible for prelingual sensorineural non-syndromic deafness. Mustapha M, et al. **Eur J Hum Genet** 1998 Nov–Dec;6(6):548–51

Hearing impairment and neurological dysfunction associated with a mutation in the mitochondrial tRNASer(UCN) gene. Verhoeven K, et al. **Eur J Hum Genet** 1999 Jan;7(1):45–51

A new mouse insertional mutation that causes sensorineural deafness and vestibular defects. Alagramam KN, et al. **Genetics** 1999 Aug;152(4):1691–9

Human DCTN1: genomic structure and evaluation as a candidate for Alström syndrome. Collin GB, et al. **Genomics** 1998 Nov 1;53(3):359–64

A second family with nonsyndromic sensorineural hearing loss linked to Xp21.2: refinement of the DFN4 locus within DMD. Pfister MH, et al. **Genomics** 1998 Nov 1; 53(3):377–82

Combined cochleo-saccular and neuroepithelial abnormalities in the Varitint-waddler-J (VaJ) mouse. Cable J, et al. **Hear Res** 1998 Sep;123(1–2):125–36

Refinement of genetic localization of the Alström syndrome on chromosome 2p12–13 by linkage analysis in a North African family. Macari F, et al. **Hum Genet** 1998 Dec; 103(6):658–61

The Usher syndrome in the Lebanese population and further refinement of the USH2A candidate region. Saouda M, et al. **Hum Genet** 1998 Aug;103(2):193–8

Non-syndromic hearing loss associated with enlarged vestibular aqueduct is caused by PDS mutations. Usami S, et al. **Hum Genet** 1999 Feb;104(2):188–92

Molecular analysis of the PDS gene in Pendred syndrome. Coyle B, et al. **Hum Mol Genet** 1998 Jul;7(7):1105–12

A Pro51Ser mutation in the COCH gene is associated with late onset autosomal dominant progressive sensorineural hearing loss with vestibular defects. de Kok YJ, et al. **Hum Mol Genet** 1999 Feb;8(2):361–6

Two frequent missense mutations in Pendred syndrome. Van Hauwe P, et al. **Hum Mol Genet** 1998 Jul;7(7):1099–104

Twelve novel myosin VIIA mutations in 34 patients with Usher syndrome type I: confirmation of genetic heterogeneity. Janecke AR, et al. **Hum Mutat** 1999; 13(2):133–40

Identification of three novel mutations in the MYO7A gene. Cuevas JM, et al. **Hum Mutat (Online)** 1999 Aug 19; 14(2):181

Analysis of DNA elements that modulate myosin VIIA expression in humans. Orten DJ, et al. **Hum Mutat (Online)** 1999 Oct;14(4):354

Progressive hearing loss, hypoplasia of the cochlea and

widened vestibular aqueducts are very common features in Pendred's syndrome. Cremers CW, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):113–23

Genetics and hearing loss: a review of Stickler syndrome. Nowak CB. **J Commun Disord** 1998 Sep–Oct;31(5):437–53; 453–4 (60 ref.)

Sensorineural hearing loss caused by mitochondrial DNA mutations: special reference to the A1555G mutation. Usami S, et al. **J Commun Disord** 1998 Sep–Oct; 31(5):423–34; quiz 434–5 (36 ref.)

Further refinement of the Usher 2A locus at 1q41. Bessant DA, et al. **J Med Genet** 1998 Sep;35(9):773–4

Usher syndrome type III (USH3) linked to chromosome 3q in an Italian family. Gasparini P, et al. **J Med Genet** 1998 Aug;35(8):666–7

Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness. Green GE, et al. **JAMA** 1999 Jun 16;281(23):2211–6

Progressive cochleovestibular impairment caused by a point mutation in the COCH gene at DFNA9. Bom SJ, et al. **Laryngoscope** 1999 Sep;109(9):1525–30

Clinical evidence for dystrophin dysfunction as a cause of hearing loss in locus DFN4. Pfister MH, et al. **Laryngoscope** 1999 May;109(5):730–5

The frequency in New Zealand of a mitochondrial DNA mutation (1555 A to G) associated with aminoglycoside-induced hearing loss [letter] Scrimshaw BJ, et al. **N Z Med J** 1999 Jun 11;112(1089):216–7

Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromic deafness with vestibular dysfunction. Robertson NG, et al. **Nat Genet** 1998 Nov;20(3):299–303

The Pendred syndrome gene encodes a chloride–iodide transport protein. Scott DA, et al. **Nat Genet** 1999 Apr; 21(4):440–3

Deafness linked to DFNA2: one locus but how many genes? [letter; comment] Van Hauwe P, et al. **Nat Genet** 1999 Mar;21(3):263. Comment on: Nat Genet 1998 Dec;20(4):370–3.

Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Klein CJ, et al. **Neurology** 1998 Nov;51(5):1462–4

Semen analysis in the Usher syndrome type 2A. van Aarem A, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May–Jun; 61(3):126–30

Atypical presentation of Waardenburg's syndrome type II. Knox G, et al. **Otolaryngol Head Neck Surg** 1999 May; 120(5):749

Clinical studies of families with hearing loss attributable to mutations in the connexin 26 gene (GJB2/DFNB1) [see comments] Cohn ES, et al. **Pediatrics** 1999 Mar; 103(3):546–50. Comment in: Pediatrics 1999 Mar;103(3):674.

Genetic deafness: a step closer [comment] Steel KP. **Pediatrics** 1999 Mar;103(3):674. Comment on: Pediatrics 1999 Mar;103(3):546–50.

Prevalence of hereditary hearing impairment in adults. Sakihara Y, et al. **Scand Audiol** 1999;28(1):39–46

Pendred's syndrome: identification of the genetic defect a century after its recognition. Kopp P. **Thyroid** 1999 Jan; 9(1):65–9 (47 ref.)

[Non-syndromic familial hearing impairment transmitted by mitochondrial inheritance] Morales Angulo C, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):93–9 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Cogan's syndrome: clinical significance of antibodies against the inner ear and cornea. Helmchen C, et al. **Acta Otolaryngol** 1999;119(5):528–36

Immune-mediated sensorineural hearing loss. Veldman J. **Auris Nasus Larynx** 1998 Sep;25(3):309–17 (54 ref.)

Recognition of a dominant epitope in bovine heat-shock protein 70 in inner ear disease. Bloch DB, et al. **Laryngoscope** 1999 Apr;109(4):621–5

[Progressive sensorineural hearing loss: immunologic etiology] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):33–41 (96 ref.) (Eng. Abstr.) **(Ita)**

[Immunological abnormalities in patients with etiology unknown sensorineural hearing loss] Takahashi M, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Oct;101(10):1260–5 (Eng. Abstr.) **(Jpn)**

METABOLISM

Vestibular and hearing loss in genetic and metabolic disorders. Gasparini P, et al. **Curr Opin Neurol** 1999 Feb; 12(1):35–9 (32 ref.)

MICROBIOLOGY

Time course of hearing loss in an animal model of pneumococcal meningitis. Kesser BW, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):628–37

[Progressive sensorineural hearing loss from infectious agents] Scasso CA, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):51–4 (18 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Sound lateralization and speech discrimination in patients with sensorineural hearing loss. Kubo T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:63–9

Microangiopathy of the brain and retina with hearing loss in a 50 year old woman: extending the spectrum of Susac's syndrome. Barker RA, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):641–3

PHYSIOPATHOLOGY

Congenital corneal dystrophy and progressive sensorineural hearing loss (Harboyan syndrome) [letter] Puga AC, et al. **Am J Med Genet** 1998 Nov 2;80(2):177–9

Correlation of acoustic threshold measures and spiral ganglion cell survival in severe to profound sensorineural hearing loss: implications for cochlear implantation. Incesulu A, et al. **Ann Otol Rhinol Laryngol** 1998 Nov; 107(11 Pt 1):906–11

Auditory neuropathy with preserved cochlear microphonics and secondary loss of otoacoustic emissions. Deltenre P, et al. **Audiology** 1999 Jul–Aug;38(4):187–95

Effect of signal duration on categorical loudness scaling in normal and in hearing-impaired listeners. Garnier S, et al. **Audiology** 1999 Jul–Aug;38(4):196–201

Loudness perception is influenced by long-term hearing aid use. Olsen SO, et al. **Audiology** 1999 Jul–Aug;38(4):202–5

A study of the effects of cochlear loss on the auditory brainstem response (ABR) specificity and false positive rate in retrocochlear assessment. Watson DR. **Audiology** 1999 May–Jun;38(3):155–64

Distortion-product otoacoustic emissions and selective sensorineural loss in IDDM. Di Nardo W, et al. **Diabetes Care** 1998 Aug;21(8):1317–21

Distortion product otoacoustic emission and auditory brain stem response measures of pediatric sensorineural hearing loss with islands of normal sensitivity. Balfour PB, et al. **Ear Hear** 1998 Dec;19(6):463–72

Comparative study of visual, auditory, and olfactory function in Usher syndrome. Seeliger M, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr;237(4):301–7

Sensorineural hearing loss during development: morphological and physiological response of the cochlea and auditory brainstem. Hardie NA, et al. **Hear Res** 1999 Feb;128(1–2):147–65

The relation between otoacoustic emissions and the broadening of the auditory filter for higher levels. Leeuw AR, et al. **Hear Res** 1998 Dec;126(1–2):1–10

Brainstem auditory evoked response in newborns with hyperbilirubinemia. Agrawal VK, et al. **Indian Pediatr** 1998 Jun;35(6):513–8

Temporal integration of loudness in listeners with hearing losses of primarily cochlear origin. Buus S, et al. **J Acoust Soc Am** 1999 Jun;105(6):3464–80

Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. Littman TA, et al. **J Am Acad Audiol** 1998 Aug; 9(4):257–62

Effects of acute thyroxin depletion on hearing in humans. Mra Z, et al. **Laryngoscope** 1999 Mar;109(3):343–50

Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromic deafness with vestibular dysfunction. Robertson NG, et al. **Nat Genet** 1998 Nov;20(3):299–303

A clinical study on the growth of distortion product otoacoustic emissions and hearing loss at 2 kHz in humans. Lind O. **Scand Audiol** 1998;27(4):207–12

[The application of auditory brainstem responses in hearing threshold evaluation] Sun H, et al. **Fa I Hsueh Tsa Chih** 1997;13(2):75–6, inside back cover (Eng. Abstr.) **(Chi)**

[The cochlea: modern physiologic insights into sensorineural hearing loss] Frijns JH, et al. **Ned Tijdschr Geneeskd** 1998 Apr 11;142(15):830–6 (17 ref.) (Eng. Abstr.) **(Dut)**

[Acute low-tone sensorineural hearing loss] Asakuma S. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Mar;102(3):299–304 (Eng. Abstr.) **(Jpn)**

[Transmastoid leads and bilateral stimulation in the recording of auditory-evoked brain-stem potentials] Oliva Dominguez M, et al. **Acta Otorrinolaringol Esp** 1999 Apr; 50(3):191–5 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Hair cell protection from aminoglycoside ototoxicity by adenovirus-mediated overexpression of glial cell line-derived neurotrophic factor. Yagi M, et al. **Hum Gene Ther** 1999 Mar 20;10(5):813–23

Prevention of hearing loss in experimental pneumococcal meningitis by administration of dexamethasone and ketorolac [published erratum appears in J Infect Dis 1999 Mar;179(3):753] Rappaport JM, et al. **J Infect Dis** 1999 Jan;179(1):264–8

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? Fowler KB, et al. **J Pediatr** 1999 Jul;135(1):60–4

Acoustic neuroma surgery: absent auditory brainstem response does not contraindicate attempted hearing preservation. Roberson JB Jr, et al. **Laryngoscope** 1999 Jun; 109(6):904–10

Could antioxidant therapy reduce the incidence of deafness following bacterial meningitis? Maurizi CP. **Med Hypotheses** 1999 Jan;52(1):85–7

PSYCHOLOGY

Physical and mental correlates of hearing impairment in the elderly in Japan. Naramura H, et al. **Audiology** 1999 Jan–Feb;38(1):24–9

It happened to us [letter] Hull RH. **J Am Acad Audiol** 1999 May;10(5):285–7

[An exogenous psychotraumatizing factor as one of the causes for the development of neurotic reactions in subjects suffering from sensorineural hypoacusis] Samoĭlova IG, et al. **Vestn Otorinolaringol** 1998;(4):15–7 (Eng. Abstr.) **(Rus)**

REHABILITATION

Clinical evaluation of a full-digital in-the-ear hearing instrument. Boymans M, et al. **Audiology** 1999 Mar–Apr; 38(2):99–108

Speech intelligibility in noisy environments with one- and two-microphone hearing aids. Wouters J, et al. **Audiology** 1999 Mar–Apr;38(2):91–8

Variable-speech-rate audiometry for hearing aid evaluation. Hosoi H, et al. **Auris Nasus Larynx** 1999 Jan;26(1):17–27

Trial of a two-channel hearing aid (low-frequency compression-high-frequency linear amplification) with school age children. Bamford J, et al. **Ear Hear** 1999 Aug; 20(4):290–8

Client preferences for compression threshold in single-channel wide dynamic range compression hearing aids. Barker C, et al. **Ear Hear** 1999 Apr;20(2):127–39

Children's speech recognition in noise using omni-directional and dual-microphone hearing aid technology. Gravel JS, et al. **Ear Hear** 1999 Feb;20(1):1–11

Comparison of two digital hearing aids. Knebel SB, et al. **Ear Hear** 1998 Aug;19(4):280–9

Recognition performance for four combinations of FM system and hearing aid microphone signals in adverse listening conditions. Pittman AL, et al. **Ear Hear** 1999 Aug; 20(4):279–89

Quantifying the contribution of audibility to recognition of compression-amplified speech. Souza PE, et al. **Ear Hear** 1999 Feb;20(1):12–20

The National Acoustic Laboratories' procedure for selecting the saturation sound pressure level of hearing aids: experimental validation. Storey L, et al. **Ear Hear** 1998 Aug;19(4):267–79

Cochlear implants in the geriatric population: benefits outweigh risks. Buchman CA, et al. **Ear Nose Throat J** 1999 Jul;78(7):489–94 (29 ref.)

Benefits of linear amplification and multichannel compression for speech comprehension in backgrounds with spectral and temporal dips. Moore BC, et al. **J Acoust Soc Am** 1999 Jan;105(1):400–11

Telephone communication with in-the-ear hearing aids using acoustic and electromagnetic coupling. Plyler PN, et al. **J Am Acad Audiol** 1998 Dec;9(6):434–43

Characteristics associated with marginal hearing loss and subjective well-being among a sample of older adults. Scherer MJ, et al. **J Rehabil Res Dev** 1998 Oct;35(4):420–6

Far-advanced otosclerosis [letter; comment] Iurato S, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov–Dec; 60(6):353–4. Comment on: ORL J Otorhinolaryngol Relat Spec 1997 Nov–Dec;59(6):332–5.

Clinical evaluation of a portable digital hearing aid with narrow-band loudness compensation. Hidaka H, et al. **Scand Audiol** 1998;27(4):225–36

Control of hearing-aid saturated sound pressure level by frequency-shaped output compression limiting. McDermott HJ, et al. **Scand Audiol** 1999;28(1):27–38

A new more powerful bone-anchored hearing aid: first results. van der Pouw CT, et al. **Scand Audiol** 1998; 27(3):179–82

Speech discrimination by elderly hearing instrument users. van Wyk L, et al. **S Afr J Commun Disord** 1997;44:99–108 (Eng. Abstr.) **(Afr)**

[Tullio phenomenon after cochlear implantation] Lesinski A, et al. **HNO** 1998 Jul;46(7):692–4 (Eng. Abstr.) **(Ger)**

[A totally implantable hearing aid for inner ear deafness: TICA LZ 3001] Leysieffer H, et al. **HNO** 1998 Oct; 46(10):853–63 (Eng. Abstr.) **(Ger)**

[First implantation of a totally implantable electronic hearing aid in patients with inner ear hearing loss] Zenner HP, et al. **HNO** 1998 Oct;46(10):844–52 (Eng. Abstr.) **(Ger)**

SURGERY

Cochlear nerve aplasia: its importance in cochlear implantation. Maxwell AP, et al. **Am J Otol** 1999 May; 20(3):335–7

Successful cochlear implantation in a patient with MELAS syndrome. Rosenthal EL, et al. **Am J Otol** 1999 Mar; 20(2):187–90; discussion 190–1

Cochlear implantation in a patient with profound hearing loss with the A1555G mitochondrial mutation. Tono T, et al. **Am J Otol** 1998 Nov;19(6):754–7

Perilymphatic fistula: a logical approach [comment] Gulya AJ. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1282–3. Comment on: Arch Otolaryngol Head Neck Surg 1998 Nov;124(11):1279–81.

Current status of perilymphatic fistula [comment] Jones R. **Arch Otolaryngol Head Neck Surg** 1998 Nov; 124(11):1281–2. Comment on: Arch Otolaryngol Head Neck Surg 1998 Nov;124(11):1279–81.

Results of cochlear implantation in patients with severe to profound hearing loss--implications for patient selection. Kiefer J, et al. **Audiology** 1998 Nov–Dec;37(6):382–95

Implantable hearing devices for sensorineural hearing loss: a review of the audiometric data. Snik AF, et al. **Clin Otolaryngol** 1998 Oct;23(5):414–9

HEARING LOSS, SENSORINEURAL

The large vestibular aqueduct syndrome: the role of cochlear implantation in its management. Temple RH, et al. **Clin Otolaryngol** 1999 Aug;24(4):301–6

Cochlear implants and electrical brainstem stimulation in sensorineural hearing loss. Laszig R, et al. **Curr Opin Neurol** 1999 Feb;12(1):41–4 (37 ref.)

Gap detection by early-deafened cochlear-implant subjects. Busby PA, et al. **J Acoust Soc Am** 1999 Mar;105(3):1841–52

Cochlear implant failure due to unexpected absence of the eighth nerve--a cautionary tale. Gray RF, et al. **J Laryngol Otol** 1998 Jul;112(7):646–9

A review of 308 cases of revision stapedectomy. Hammerschlag PE, et al. **Laryngoscope** 1998 Dec; 108(12):1794–800

Clinical design and evaluation of the prototype of a new digital audioprosthesis for profound hearing loss: speech recognition aspects. Urquiza R, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 May–Jun; 61(3):133–41

Cochlear implants in children with sensorineural inner ear hearing loss. Slattery WH 3rd, et al. **Pediatr Ann** 1999 Jun; 28(6):359–63 (11 ref.)

[Current status of cochlear implants in children] Ye X, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 May; 11(5):238–9 (8 ref.) **(Chi)**

[Indications for the cochlear implant in partial deafness of the adult] Meyer B, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Jun;115(3):140–8 (Eng. Abstr.) **(Fre)**

THERAPY

Speech audibility for listeners with high-frequency hearing loss. Turner CW, et al. **Am J Audiol** 1999 Jun;8(1):47–56

A clinical trial of the ReSound IC4 hearing device. Walden BE, et al. **Am J Audiol** 1999 Jun;8(1):65–78

Use of a loudness model for hearing aid fitting: II. Hearing aids with multi-channel compression. Moore BC, et al. **Br J Audiol** 1999 Jun;33(3):157–70

Assessment of basal sound identification skills and communication abilities in profoundly deaf children fitted with hearing aids or a cochlear implant. van den Borne S, et al. **Clin Otolaryngol** 1998 Oct;23(5):455–61

System identification of feedback in hearing aids. Hellgren J, et al. **J Acoust Soc Am** 1999 Jun;105(6):3481–96

Loudness scaling revisited. Elberling C. **J Am Acad Audiol** 1999 May;10(5):248–60

Field trial evaluations of a switched directional/omnidirectional in-the-ear hearing instrument. Preves DA, et al. **J Am Acad Audiol** 1999 May;10(5):273–84

A comparison of the aided performance and benefit provided by a linear and a two-channel wide dynamic range compression hearing aid. Humes LE, et al. **J Speech Lang Hear Res** 1999 Feb;42(1):65–79

Management of the child with sensorineural hearing loss. Medical, surgical, hearing aids, cochlear implants. Brookhouser PE, et al. **Pediatr Clin North Am** 1999 Feb; 46(1):121–41 (76 ref.)

Clinical study of Widex Senso on first-time hearing aid users. Berninger E, et al. **Scand Audiol** 1999;28(2):117–25

Clinical study of a digital vs an analogue hearing aid. Bille M, et al. **Scand Audiol** 1999;28(2):127–35

[Diagnostic and therapeutic approach to progressive sensorineural hearing loss] Berrettini S, et al. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):87–94 (45 ref.) (Eng. Abstr.) **(Ita)**

[Hyperbaric oxygenation therapy in idiopathic sudden sensory neural hearing loss] Shiraishi T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Dec;101(12):1380–4 (Eng. Abstr.) **(Jpn)**

[Hearing aid fitting in children treated at the Phoniatric Outpatient Clinic in Zabrze in years 1986–1990] Iwko J, et al. **Otolaryngol Pol** 1998;52(6):713–7 (Eng. Abstr.) **(Pol)**

VIROLOGY

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? Fowler KB, et al. **J Pediatr** 1999 Jul;135(1):60–4

HEARING PROTECTIVE DEVICES see **EAR PROTECTIVE DEVICES**

HEARING TESTS

European Consensus Statement on Neonatal Hearing Screening. Finalized at the European Consensus Development Conference on Neonatal Hearing Screening, Milan, 15–16 May 1998. **Acta Paediatr** 1999 Jan;88(1):107–8 (0 ref.)

Neurologic and otologic findings in Fisher's syndrome. Minoda R, et al. **Auris Nasus Larynx** 1999 Apr;26(2):153–8

Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Zheng QY, et al. **Hear Res** 1999 Apr; 130(1–2):94–107

The case for change in early infant hearing screening in Ireland [editorial] Pitt T, et al. **Ir Med J** 1999 Apr; 92(3):292–4

A project from the Biomedical and Health Programme European Commission – Biomed 2 –Directorate General XII. The European Consensus Development Conference on Neonatal Hearing Screening. Grandori F, et al. **J Perinat Med** 1998;26(4):330–1 (0 ref.)

A qualitative explanation of the Weber test. Blakley BW, et al. **Otolaryngol Head Neck Surg** 1999 Jan;120(1):1–4

Does choice of hearing selection criterion and reporting criteria affect the hearing preservation rate in vestibular schwannoma surgery? Da cruz MJ, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):313–7

[Evoked otoacoustic emissions at birth: the Luxembourg experience] Panosetti E, et al. **Arch Pediatr** 1999;6 Suppl 2:353s–355s **(Fre)**

[Neonatal hearing screening: screening test for hearing disorders in newborn infants. Report on the "European Consensus Development Conference on Neonatal Hearing Screening", Mailand, 15–16 May 1998] Welzl-Müller K. **HNO** 1998 Aug;46(8):704–7 (0 ref.) **(Ger)**

[Objective audiologic assessment of children treated with amikacin] Katona G, et al. **Orv Hetil** 1999 Jun 6; 140(23):1305–7 (Eng. Abstr.) **(Hun)**

[Tympanometry at a health center] Rasting P, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20;118(22):3426–30 (Eng. Abstr.) **(Nor)**

[A new method for detecting congenital hearing disorders. Infants are screened by measuring otoacoustic emissions (see comments)] Hergils L. **Lakartidningen** 1999 Mar 10; 96(10):1166–8 (15 ref.) (Eng. Abstr.). Comment in: Lakartidningen 1999 Jun 9;96(23):2835–6. **(Swe)**

[A complete examination of hearing of preschool children is important (letter)] Konrädsson K, et al. **Lakartidningen** 1998 Oct 28;95(44):4838 **(Swe)**

[Hearing tests of newborn infants will hopefully be introduced in the whole country! (letter; comment)] Westin B. **Lakartidningen** 1999 Jun 9;96(23):2835–6. Comment on: Lakartidningen 1999 Mar 10;96(10):1166–8. **(Swe)**

HISTORY

Alfred Gardiner Brown (1838–1882) M.R.C.S.Eng., F.R.C.S.(Ed.). His contribution to the history of the development of the tuning fork. Booth JB. **J Laryngol Otol** 1999 Apr;113(4):304–13

Early days of the tuning fork. Pearce JM. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):728, 733

INSTRUMENTATION

Cross-modality matching: a tool for measuring loudness in sensorineural impairment. Hellman RP. **Ear Hear** 1999 Jun; 20(3):193–213

METHODS

A reevaluation of the 512-Hz Rinne tuning fork test as a patient selection criterion for laser stapedotomy. Gordon MA, et al. **Am J Otol** 1998 Nov;19(6):712–7

Health visitor screening versus vigilance: outcomes of programmes for detecting permanent childhood hearing loss in west Berkshire. Sutton GJ, et al. **Br J Audiol** 1999 Jun;33(3):145–56

Maurice H. Miller takes the editor to task [letter; comment] Miller MH. **J Am Acad Audiol** 1998 Aug;9(4):311–3. Comment on: J Am Acad Audiol 1998 Apr;9(2):95–104.

Hearing screening in the newborn intensive care nursery: comparison of methods. Rhodes MC, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):799–808

Physiologic and behavioral approaches to pediatric hearing assessment. Folsom RC, et al. **Pediatr Clin North Am** 1999 Feb;46(1):107–20 (50 ref.)

[Tuning-fork tests--outdated?] Reiss M. **Fortschr Med** 1999 Apr 30;117(12):18–20 (Eng. Abstr.) **(Ger)**

[Studies of the evaluation of cochlea function with distortion product otoacoustic emission] Kashiwamura M. **Hokkaido Igaku Zasshi** 1998 Nov;73(6):641–62 (Eng. Abstr.) **(Jpn)**

[Distortion product otoacoustic emissions for the assessment of auditory sensitivity] Chida E. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov;101(11):1335–47 (Eng. Abstr.) **(Jpn)**

[Early diagnosis of congenital hearing loss. Use of oto-acoustic emission tests in newborn infants with increased risk of hearing impairment (see comments)] Stødal K, et al. **Tidsskr Nor Laegeforen** 1998 Oct 30; 118(26):4076–8 (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1998 Nov 30;118(29):4561. **(Nor)**

STANDARDS

Calculating hearing handicap [letter; comment] Dobie RA. **J Am Acad Audiol** 1999 Jan;10(1):63–5. Comment on: J Am Acad Audiol 1998 Apr;9(2):141–6.

Factors influencing the efficacy of universal newborn hearing screening. Stein LK. **Pediatr Clin North Am** 1999 Feb; 46(1):95–105 (32 ref.)

[Physical diagnostic procedures: whispered speech and tuning fork test (comment)] Grote JJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1816–9 (10 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Aug 8;142(32):1813–6. **(Dut)**

STATISTICS & NUMERICAL DATA

[Psychometric validation of the telephone memory test] Ortiz T, et al. **Actas Esp Psiquiatr** 1999 May–Jun;27(3):155–65 (Eng. Abstr.) **(Spa)**

HEART

consider also terms at CARDI- and MYOCARDI-

see related
ANGIOCARDIOGRAPHY
ANTI-ARRHYTHMIA AGENTS
BALLISTOCARDIOGRAPHY
CARDIOTONIC AGENTS
ELECTROCARDIOGRAPHY
MYOCARDIUM

Foreign bodies in the heart: surgical or medical therapy? [letter; comment] Actis Dato GM, et al. **Ann Thorac Surg** 1999 Jul;68(1):291–2. Comment on: Ann Thorac Surg 1998 Jun;65(6):1786–7.

Heat shock improves recovery and provides protection against global ischemia after hypothermic storage [see comments] Gowda A, et al. **Ann Thorac Surg** 1998 Dec; 66(6):1991–7. Comment in: Ann Thorac Surg 1999 Aug;68(2):628.

Bristol parents protest over removal of hearts [news] Dobson R. **BMJ** 1999 Feb 20;318(7182):486

Different tolerance to hypothermia and rewarming of isolated rat and guinea pig hearts. Aasum E, et al. **Cryobiology** 1999 May;38(3):243–9

The influence of temperature on metabolic and cellular protection of the heart during long-term ischemia: a study using P-31 magnetic resonance spectroscopy and biochemical analyses. Bernard M, et al. **Cryobiology** 1998 Dec;37(4):309–17

Observation of two inorganic phosphate NMR resonances in the perfused hypothermic rat heart. Gruwel MLH, et al. **Cryobiology** 1998 Dec;37(4):355–61

Fetal cardiocentesis in care of severe Kell immunisation. Bakos O, et al. **Fetal Diagn Ther** 1998 Nov–Dec;13(6):372–4

Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Chua CC, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):891–7

An original application of plasma expanders: heart-lung preservation. Spaggiari L, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):109–12

Multiple organ harvesting from a single donor for transplantation. A comparison of simple cooling technique and bypass technique. Takahashi T, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):347–53

Multi-dose crystalloid cardioplegia preserves intracellular sodium homeostasis in myocardium. Schepkin VD, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1643–51

Efficient transmural cardiac gene transfer by intrapericardial injection in neonatal mice. Zhang JC, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):721–32

Twenty-four-hour heart preservation using continuous cold perfusion and copper (II) complexes. Sellke FW, et al. **J Surg Res** 1998 Dec;80(2):171–6

New strategy for prolonging the preservation time of hearts for transplantation. Mesáros S, et al. **Physiol Res** 1997; 46(4):251–5

Outcome of machine-perfused non-heart-beating donor kidneys, not allocated within the Eurotransplant area. Kievit JK, et al. **Transpl Int** 1998;11 Suppl 1:S421–3

Cardiac preservation with nitroglycerine and cyclic adenosine monophosphate. Baxter K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1046–7

A reliable method for long-term (24-hour) hypothermic transport of cardiac graft. Ferrera R, et al. **Transplant Proc** 1998 Dec;30(8):4340–3

Protective effect of JTV519 (K201), a new 1,4-benzothiazepine derivative, on prolonged myocardial preservation. Hachida M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):996–1000

Effect of short-term coronary perfusion after cold storage for long-term heart preservation: a comparative study of University of Wisconsin solution and diluted blood as the perfusate. Hasegawa Y, et al. **Transplant Proc** 1998 Nov; 30(7):3772–3

Nitric oxide donor induces upregulation of stress proteins in cold ischemic rat hearts. Katori M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1022–3

Cytoprotective role of antioxidant stress protein induced by adenosine A1 receptor antagonist in rat heart ischemic injury. Katori M, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1016–7

Expression of heat shock proteins induced by L(+)-glutamine injection and survival of hypothermically stored heart grafts. Kojima R, et al. **Transplant Proc** 1998 Nov;30(7):3746–7

Estimation of mitochondrial damage in heart preservation. Kuznetsov AV, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):992

Cold cardioplegic preservation aggravates alloantibody mediated cardiac dysfunction due to an increase in vascular resistance. Leprince P, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):116–7

A new portable hypothermic perfusion apparatus for long-term heart preservation in canine models. Oshima K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1072–3

Evaluation of a new protection technique for heart preservation of non-heart-beating donors. Scheule AM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):118–9

Myocardial preservation in clinical cardiac transplantation. Wildhirt SM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):147–8

[Percutaneous extraction of a foreign body from the right

ventricle. Clinical case] Martin Carreira J, et al. **Rev Esp Cardiol** 1998 Sep;51(9):766–8 (Eng. Abstr.) **(Spa)**

ABNORMALITIES see HEART DEFECTS, CONGENITAL

ANATOMY & HISTOLOGY

Assessment of myocardial response to pharmacologic interventions using an improved MR imaging technique to estimate T2 values. Li D, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):141–5

Histological validation of myocardial microstructure obtained from diffusion tensor magnetic resonance imaging. Scollan DF, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2308–18

Distribution of the Purkinje fibres in the sheep heart. Ansari A, et al. **Anat Rec** 1999 Jan;254(1):92–7

Bulbus arteriosus of the antarctic teleosts. I. The white-blooded Chionodraco hamatus. Icardo JM, et al. **Anat Rec** 1999 Mar;254(3):396–407

The AV junction region of the heart: a comprehensive study correlating gross anatomy and direct three-dimensional analysis. Part I. Architecture and topography. Racker DK. **Anat Rec** 1999 Sep 1;256(1):49–63

Simulated epicardial potential maps during paced activation reflect myocardial fibrous structure. Hren R, et al. **Ann Biomed Eng** 1998 Nov–Dec;26(6):1022–35

Regional myocardial perfusion and mechanics: a model-based method of analysis. Mazhari R, et al. **Ann Biomed Eng** 1998 Sep–Oct;26(5):743–55

Optimization of cardiac fiber orientation for homogeneous fiber strain during ejection. Rijcken J, et al. **Ann Biomed Eng** 1999 May–Jun;27(3):289–97

Immunochemical localization of the metabotropic glutamate receptors in the rat heart. Gill SS, et al. **Brain Res Bull** 1999 Jan 15;48(2):143–6

Relationship of the dimension of cardiac structures to body size: an echocardiographic study in normal infants and children. Daubeney PE, et al. **Cardiol Young** 1999 Jul; 9(4):402–10

Evolutionary persistence of spongy myocardium in humans. Angelini A, et al. **Circulation** 1999 May 11;99(18):2475

James Jeffray: observations on the heart and on the peculiarities of the foetus. McDonald SW. **Clin Anat** 1999; 12(1):35–42

The Botallo mystery. Fransson SG. **Clin Cardiol** 1999 Jun; 22(6):434–6

Left ventricular geometry and function are related to electrocardiographic characteristics and diagnoses. Sundström J, et al. **Clin Physiol** 1998 Sep;18(5):463–70

An interactive 3D anisotropic cellular automata model of the heart. Siregar P, et al. **Comput Biomed Res** 1998 Oct; 31(5):323–47

Fast magnetic resonance imaging of the heart. Sakuma H, et al. **Eur J Radiol** 1999 Feb;29(2):101–13 (68 ref.)

A morphological study in broiler chick hearts. Aydinlioğlu A, et al. **Folia Morphol (Warsz)** 1998;57(4):357–62

Main tributaries of the coronary sinus in the adult human heart. Duda B, et al. **Folia Morphol (Warsz)** 1998; 57(4):363–9

Reference ranges for cardiac dimensions and blood flow velocity in preterm infants. Skelton R, et al. **Heart** 1998 Sep;80(3):281–5

Estimation and detection of myocardial tags in MR image without user-defined myocardial contours. Denney TS Jr. **IEEE Trans Med Imaging** 1999 Apr;18(4):330–44

Alterations in cardiac morphology and function in elite multi-disciplinary athletes. Whyte G, et al. **Int J Sports Med** 1999 May;20(4):222–6

Left ventricular shape analysis from three-dimensional echocardiograms. Munt BI, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):761–9

Anatomy of the pig heart: comparisons with normal human cardiac structure. Crick SJ, et al. **J Anat** 1998 Jul;193 (Pt 1):105–19

Wall thickness referenced to myocardial volume: a new noninvasive framework for cardiac mechanics. Denslow S, et al. **J Appl Physiol** 1999 Jul;87(1):211–21

Effect of endurance training on cardiac morphology in Alaskan sled dogs. Stepien RL, et al. **J Appl Physiol** 1998 Oct;85(4):1368–75

The architecture of the sinus node, the atrioventricular conduction axis, and the internodal atrial myocardium. Anderson RH, et al. **J Cardiovasc Electrophysiol** 1998 Nov; 9(11):1233–48 (51 ref.)

The architecture of the atrial musculature between the orifice of the inferior caval vein and the tricuspid valve: the anatomy of the isthmus. Cabrera JA, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1186–95

Spatiotemporal effects of syncytial heterogeneities on cardiac far-field excitations during monophasic and biphasic shocks. Fishler MG, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1310–24

Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass [see comments] de Simone G, et al. **J Hypertens** 1998 Aug;16(8):1207–14 . Comment in: J Hypertens 1998 Aug;16(8):1079.

Various ways of calculating echocardiographic left ventricular mass and their relative prognostic values [see comments] Muiesan ML, et al. **J Hypertens** 1998 Aug; 16(8):1201–6. Comment in: J Hypertens 1998 Aug;16(8):1079.

Left ventricular mass correlates with fat-free mass but not fat mass in adults. Whalley GA, et al. **J Hypertens** 1999 Apr;17(4):569–74

Left ventricular mass again: measurements and prognosis [comment] Zanchetti A. **J Hypertens** 1998 Aug;16(8):1079 . Comment on: J Hypertens 1998 Aug;16(8):1201–6. Comment on: J Hypertens 1998 Aug;16(8):1207–14.

Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for cardiac 31P MRS in humans. Löffler R, et al. **J Magn Reson** 1998 Oct;134(2):287–99

Fast 3D cardiac cine MR imaging. Alley MT, et al. **J Magn Reson Imaging** 1999 May;9(5):751–5

Experimental validation of an automated edge-detection method for a simultaneous determination of the endocardial and epicardial borders in short-axis cardiac MR images: application in normal volunteers. Furber A, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1006–14

Optimized outer volume suppression for single-shot fast spin-echo cardiac imaging. Le Roux P, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1022–32

Quantification of myocardial perfusion with FAST sequence and Gd bolus in patients with normal cardiac function. Vallée JP, et al. **J Magn Reson Imaging** 1999 Feb; 9(2):197–203

Improved field of view-reducing gradient insert: artifacts and application to cardiac imaging. Wiesler DG, et al. **J Magn Reson Imaging** 1999 Aug;10(2):209–15

Comparison of fast spiral, echo planar, and fast low-angle shot MRI for cardiac volumetry at .5T. Wiesmann F, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1033–9

Magnetic resonance imaging analysis of left ventricular function in normal and spontaneously hypertensive rats. Wise RG, et al. **J Physiol (Lond)** 1998 Dec 15;513 (Pt 3):873–87

Isolation, electron microscopic imaging, and 3-D visualization of native cardiac thin myofilaments. Spiess M, et al. **J Struct Biol** 1999 Jun 15;126(2):98–104

Cardiovascular measurements relevant to heart size in copper-deficient rats. Saari JT, et al. **J Trace Elem Med Biol** 1999 Jul;13(1–2):27–33

Cardiac anatomy, mass and function—great vessels. Kenn W. **MAGMA** 1998 Sep;6(2–3):88–90 (10 ref.)

In vitro verification of myocardial motion tracking from phase-contrast velocity data. Drangova M, et al. **Magn Reson Imaging** 1998 Oct;16(8):863–70

Quantification of gadolinium-DTPA concentrations for different inversion times using an IR-turbo flash pulse sequence: a study on optimizing multislice perfusion imaging. Fritz-Hansen T, et al. **Magn Reson Imaging** 1998 Oct;16(8):893–9

Segmented k-space fast cardiac imaging using an echo-train readout. Epstein FH, et al. **Magn Reson Med** 1999 Mar; 41(3):609–13

Novel real-time R-wave detection algorithm based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. Fischer SE, et al. **Magn Reson Med** 1999 Aug; 42(2):361–70

Quantitative regional blood volume studies in rat myocardium in vivo. Kahler E, et al. **Magn Reson Med** 1998 Oct;40(4):517–25

Improving contrast and tracking of tags in cardiac magnetic resonance images. Koerkamp MA, et al. **Magn Reson Med** 1999 May;41(5):973–82

Single-shot, motion insensitive cardiac imaging on a standard clinical system. Meyerand ME, et al. **Magn Reson Med** 1998 Dec;40(6):930–3

Multi-echo segmented k-space imaging: an optimized hybrid sequence for ultrafast cardiac imaging. Reeder SB, et al. **Magn Reson Med** 1999 Feb;41(2):375–85

Wavelet packet denoising of magnetic resonance images: importance of Rician noise at low SNR. Wood JC, et al. **Magn Reson Med** 1999 Mar;41(3):631–5

Further evaluation of the initial negative response in functional magnetic resonance imaging. Yacoub E, et al. **Magn Reson Med** 1999 Mar;41(3):436–41

Motion and deformation tracking for short-axis echo-planar myocardial perfusion imaging. Yang GZ, et al. **Med Image Anal** 1998 Sep;2(3):285–302

Regional glucose utilization in infarcted and remote myocardium: its relation to coronary anatomy and perfusion. Fragasso G, et al. **Nucl Med Commun** 1998 Jul; 19(7):625–32

Magnetic electroanatomical mapping for ablation of focal atrial tachycardias. Marchlinski F, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1621–35 (22 ref.)

Use of a real-time three-dimensional magnetic navigation system for radiofrequency ablation of accessory pathways. Worley SJ. **Pacing Clin Electrophysiol** 1998 Aug; 21(8):1636–45 (5 ref.)

Electron paramagnetic resonance imaging of the rat heart. Zweier JL, et al. **Phys Med Biol** 1998 Jul;43(7):1823–35

Wave propagation in cardiac tissue and effects of intracellular calcium dynamics (computer simulation study). Chudin E, et al. **Prog Biophys Mol Biol** 1998;69(2–3):225–36 (17 ref.)

Estimates of regional work in the canine left ventricle. Delhaas T, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):273–87 (53 ref.)

Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al. **Prog Biophys Mol Biol** 1998;69(2–3):333–51 (50 ref.)

Computational biology of the heart: from structure to function [editorial] McCulloch A, et al. **Prog Biophys Mol Biol** 1998;69(2–3):153–5

Finite element analysis of defibrillation fields in a human torso model for ventricular defibrillation. Min X, et al. **Prog Biophys Mol Biol** 1998;69(2–3):353–86

Validation of three-dimensional conduction models using experimental mapping: are we getting closer? Muzikant AL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):205–23

Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy. Vetter FJ, et al. **Prog Biophys Mol Biol** 1998;69(2–3):157–83 (142 ref.)

A spatial scale factor for electrophysiological models of myocardium. Winfree AT. **Prog Biophys Mol Biol** 1998; 69(2–3):185–203 (57 ref.)

Cardiac magnetic resonance imaging: technique and anatomy. Meduri A, et al. **Rays** 1999 Jan–Mar;24(1):4–18 **(Eng, Ita)**

Plain-film examination of the normal heart. Boxt LM. **Semin Roentgenol** 1999 Jul;34(3):169–80 (13 ref.)

Morphometric analyses to predict appropriate donor size for swine-to-human cardiac xenotransplantation. Allan JS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):975–7

Two-dimensional echocardiographic anatomy of the snake heart (Python molurus bivittatus). Snyder PS, et al. **Vet Radiol Ultrasound** 1999 Jan–Feb;40(1):66–72

[Cardiac MRI in adults: principles, current and future clinical applications] Croisille P, et al. **J Radiol** 1999 Sep; 80(9):1054–63 (Eng. Abstr.) **(Fre)**

[Three-dimensional reconstruction of echocardiographic section images. Methods, clinical value and future perspectives] Franke A, et al. **Dtsch Med Wochenschr** 1998 Oct 16;123(42):1245–9 (23 ref.) **(Ger)**

[Anatomico-functional changes in the right ventricle of the athlete] Sciomer S, et al. **Cardiologia** 1998 Nov; 43(11):1215–20 (Eng. Abstr.) **(Ita)**

[Morphofunctional reorganization of the myocardium in Muridae from regions with different level of anthropogenic pollution] Lushnikova EL, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):708–13 **(Rus)**

[The association of hematocrit with blood pressure and left ventricular mass in subjects over 55] González Quijada S, et al. **Rev Clin Esp** 1999 Apr;199(4):202–7 (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY see CORONARY VESSELS

CHEMISTRY see MYOCARDIUM/chemistry

CYTOLOGY see MYOCARDIUM/cytology

DRUG EFFECTS

How to study sympatho-vagal balance in arterial hypertension and the effect of antihypertensive drugs? Presciuttini B, et al. **Acta Cardiol** 1998;53(3):143–52 (67 ref.)

Effects of magnesium and glucose, insulin, potassium (GIK) solution on the action potential parameters of guinea-pig atrial muscle. Ingemansson MP, et al. **Acta Physiol Scand** 1998 Oct;164(2):173–9

Cardioprotective effect of moderate drinking: possible mediation by vital exhaustion. Conduit E, et al. **Alcohol Alcohol** 1998 Sep–Oct;33(5):528–32

Increase in beating rate of cultured chick cardiac myocytes by ethanol and inhibition of the increase by antiarrhythmic drugs. Nakamura K, et al. **Alcohol Clin Exp Res** 1999 Apr; 23(4 Suppl):81S–84S

Metabolic and electrocardiographic effects of albuterol in pediatric asthmatic patients treated in an emergency room setting. Del Río-Navarro B, et al. **Allergol Immunopathol (Madr)** 1999 Jan–Feb;27(1):18–23

Quantitative analysis of myocardial response to dobutamine by measurement of left ventricular wall motion using omnidirectional M-mode echocardiography. Iwado Y, et al. **Am J Cardiol** 1999 Mar 1;83(5):765–9

pH-dependent cocaine-induced cardiotoxicity. Wang RY. **Am J Emerg Med** 1999 Jul;17(4):364–9

"Tumescent" liposuction alert: deaths from lidocaine cardiotoxicity [letter] de Jong RH, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):101

Angiotensin converting enzyme inhibition by captopril influences cardiac work in healthy hearts. Derad I, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1290–6

Biomolecular changes in the aging myocardium: the effect of enalapril. Ferder L, et al. **Am J Hypertens** 1998 Nov; 11(11 Pt 1):1297–304

Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Swislocki AL, et al. **Am J Hypertens** 1999 Jun;12(6):581–9

Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Wang D, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):174–82

Fatty acid oxidation in the reperfused ischemic heart. Kantor PF, et al. **Am J Med Sci** 1999 Jul;318(1):3–14 (100 ref.)

Lipoxygenase metabolism of arachidonic acid in ischemic preconditioning and PKC-induced protection in heart. Chen W, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2094–101

Insulin does not change the intracellular distribution of hexokinase in rat heart. Doenst T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E558–67

Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. duBell

WH, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2041–52

Pretreatment with tyrosine kinase inhibitors partially attenuates ischemic preconditioning in rat hearts. Fryer RM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2009–15

Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Goldberg Y, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):C1207–15

Characterization of responses to neurokinin A in the isolated perfused guinea pig heart. Hoover DB, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1803–11

Metallothioncin inhibits ischemia–reperfusion injury in mouse heart. Kang YJ, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H993–7

Cardioprotective effects of KB–R7943: a novel inhibitor of the reverse mode of Na+/Ca2+ exchanger. Ladilov Y, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1868–76

Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs. Ma R, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H15–22

Adenosine A1 receptor–mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart [see comments] Norton GR, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H341–9. Comment in: Am J Physiol 1999 Mar;276(3 Pt 2):H1113–6.

BDM drives protein dephosphorylation and inhibits adenine nucleotide exchange in cardiomyocytes. Stapleton MT, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1260–6

INaCa and ICl(Ca) contribute to isoproterenol–induced delayed after depolarizations in midmyocardial cells. Zygmunt AC, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H1979–92

Physiologic response to dobutamine infusion during cardiac stress testing of dogs. McEntee K, et al. **Am J Vet Res** 1998 Sep;59(9):1160–5

Cardiorespiratory and anesthetic effects of propofol and thiopental in dogs. Quandt JE, et al. **Am J Vet Res** 1998 Sep;59(9):1137–43

The effects of the beta 2–agonist drug clenbuterol on taurine levels in heart and other tissues in the rat. Doheny MH, et al. **Amino Acids** 1998;15(1–2):13–25

Comparative myocardial depression of sevoflurane, isoflurane, and halothane in cultured neonatal rat ventricular myocytes. Kanaya N, et al. **Anesth Analg** 1998 Nov;87(5):1041–7

Blood pressure is maintained despite profound myocardial depression during acute bupivacaine overdose in pigs. Nyström EU, et al. **Anesth Analg** 1999 May;88(5):1143–8

Anesthetic preconditioning: not just for the heart? [editorial; comment] Lynch C 3rd. **Anesthesiology** 1999 Sep; 91(3):606–8. Comment on: Anesthesiology 1999 Sep;91(3):701–12.

Ionic mechanisms mediating the differential effects of methohexital and thiopental on action potential duration in guinea pig and rabbit isolated ventricular myocytes. Martynyuk AE, et al. **Anesthesiology** 1999 Jan;90(1):156–64

Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts [see comments] Novalija E, et al. **Anesthesiology** 1999 Sep; 91(3):701–12. Comment in: Anesthesiology 1999 Sep;91(3):606–8.

Effects of halothane and isoflurane on fast and slow inactivation of human heart hH1a sodium channels. Stadnicka A, et al. **Anesthesiology** 1999 Jun;90(6):1671–83

Isoflurane–enhanced recovery of canine stunned myocardium: role for protein kinase C? Toller WG, et al. **Anesthesiology** 1999 Sep;91(3):713–22

Basic fibroblast growth factor increases regional myocardial blood flow and salvages myocardium in the infarct border zone in a rabbit model of acute myocardial infarction. Hasegawa T, et al. **Angiology** 1999 Jun;50(6):487–95

Effect of antioxidant trace elements on the response of cardiac tissue to oxidative stress. Barandier C, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:138–55 (84 ref.)

Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Kumar D, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:156–68

Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antihypertensive drugs. Sen S. **Ann N Y Acad Sci** 1999 Jun 30;874:125–33

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Berry G, et al. **Ann Oncol** 1998 Jul;9(7):711–6

The high–dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic. Ghielmini M, et al. **Ann Oncol** 1999 May; 10(5):533–7

Anthracycline cardiotoxicity, no longer an issue? [editorial] Green M. **Ann Oncol** 1998 Jul;9(7):691–3

Controlled intermittent asystole: pharmacologic potentiation of vagal–induced asystole. Bufkin BL, et al. **Ann Thorac Surg** 1998 Oct;66(4):1185–90

Insulin improves functional and metabolic recovery of reperfused working rat heart. Doenst T, et al. **Ann Thorac Surg** 1999 Jun;67(6):1682–8

Nitric oxide–generating beta–adrenergic blocker nipradilol preserves postischemic cardiac function. Horimoto H, et al. **Ann Thorac Surg** 1999 Sep;68(3):844–9

The superiority of pinacidil over adenosine cardioplegia in blood–perfused isolated hearts. Jayawant AM, et al. **Ann Thorac Surg** 1998 Oct;66(4):1329–35; discussion 1335–6

Protective action of 17beta–estradiol in cardiac cells: implications for hyperkalemic cardioplegia. Jovanović S, et al. **Ann Thorac Surg** 1998 Nov;66(5):1658–61

Carnitine supplementation improves myocardial function in hearts from ischemic diabetic and euglycemic rats. Keller VA, et al. **Ann Thorac Surg** 1998 Nov;66(5):1600–3

Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems. Kolonias D, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):1277–83

Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF–187). Samelis GF, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3305–9

Inhibition of adriamycin cardiotoxicity by 5–fluorouracil: a potential free oxygen radical scavenger. Stathopoulos GP, et al. **Anticancer Res** 1998 Nov–Dec;18(6A):4387–92

Cell–permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin–induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Konorev EA, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):421–8

Does moxonidine increase cytotoxic activity of ethanol in rats? Preliminary report on the base of the ultrastructural study. Marczewski K, et al. **Arch Immunol Ther Exp (Warsz)** 1998;46(4):241–6

Endotoxin induces a second window of protection in the rat heart as determined by using p–nitro–blue tetrazolium staining, cardiac troponin T release, and histology. Zacharowski K, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2276–80

Effects of amlodipine on native cardiac Na+ channels and cloned alpha–subunits of cardiac Na+ channels. Inoue Y, et al. **Arzneimittelforschung** 1999 May;49(5):394–7

Studies of the cardioprotective effects of ascorbic acid in isolated rabbit hearts. Rump AF, et al. **Arzneimittelforschung** 1998 Nov;48(11):1078–82

Comparative determination of the cardioselectivity of taxine and verapamil in the isolated aorta, atrium and jejunum preparations of rabbits. Tekol Y, et al. **Arzneimittelforschung** 1999 Aug;49(8):673–8

Preconditioning–induced cardioprotection and release of the second messenger inositol (1,4,5)–trisphosphate are both abolished by neomycin in rabbit heart. Bauer B, et al. **Basic Res Cardiol** 1999 Feb;94(1):31–40

Adenosine attenuates in vivo myocardial stunning with minimal effects on cardiac energetics. Lasley RD, et al. **Basic Res Cardiol** 1998 Aug;93(4):303–12

Nitric oxide enhances the inotropic response to beta–adrenergic stimulation in the isolated guinea–pig heart. Prendergast BD, et al. **Basic Res Cardiol** 1998 Aug; 93(4):276–84

Mitogenic effect of PDGF–AA on cardiac fibroblasts. Simm A, et al. **Basic Res Cardiol** 1998;93 Suppl 3:40–3 (27 ref.)

Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties? Brurok H, et al. **Biochem Biophys Res Commun** 1999 Jan 27; 254(3):768–72

Effect of acetylsalicylic acid on nitric oxide production in infarcted heart in situ. Kimura A, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):874–8

Antioxidant agent nimesulid and beta–blocker metoprolol do not exert protective effects against rat mitochondrial DNA alterations in adriamycin–induced cardiotoxicity. Kotsinas A, et al. **Biochem Biophys Res Commun** 1999 Jan 27; 254(3):651–6

Effects of antisense oligonucleotides to the cardiac Na+/Ca2+ exchanger on calcium dynamics in cultured cardiac myocytes. Takahashi K, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):117–21

Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin. Yamamoto T, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):488–93

Effects of cyclosporin A on contractile activity and cytoskeleton in chick embryo cardiomyocytes. Kołcz J, et al. **Biochem Cell Biol** 1999;77(2):133–40

Evidence that cyclophilin–A protects cells against oxidative stress. Doyle V, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):127–32

Ca2+ mobilization in adult rat cardiomyocytes by angiotensin type 1 and 2 receptors. Shao Q, et al. **Biochem Pharmacol** 1998 May 1;55(9):1413–8

Suppression of cyclophilin–A activity in rat cardiomyocytes. Doyle V, et al. **Biochem Soc Trans** 1998 Nov;26(4):S328

The impairment of essential fatty acid metabolism as a key factor in doxorubicin–induced damage in cultured rat cardiomyocytes. Bordoni A, et al. **Biochim Biophys Acta** 1999 Aug 25;1440(1):100–6

Effects of high glucose on the hypoxic isolated guinea pig heart: interactions with ATP–dependent K+ channels? Gillessen S, et al. **Biochim Biophys Acta** 1999 Apr 19; 1427(2):256–64

Down–regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Memon RA, et al. **Biochim Biophys Acta** 1999 Aug 25;1440(1):118–26

Activation of a thioesterase specific for very–long–chain fatty acids by adrenergic agonists in perfused hearts. Neuman I, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):101–8

Effect of deferoxamine on post–hypoxic–ischemic reperfusion injury of the newborn lamb heart. Shadid M, et al. **Biol Neonate** 1999;75(4):239–49

Inhibition of rabbit heart carbonyl reductase by fatty acids. Imamura Y, et al. **Biol Pharm Bull** 1999 Jul;22(7):731–3

Electrophysiological effects of newly synthesized 1,4–pyridothiazepines on various guinea pig heart muscle preparations. Schade B. **Biol Pharm Bull** 1999 Jan; 22(1):31–6

Alterations in collagen metabolism and increased fibroproliferation in the heart in cerium–treated rats: implications for the pathogenesis of endomyocardial fibrosis. Prakash Kumar B, et al. **Biol Trace Elem Res** 1998 Jul;63(1):73–9

Hydroxyacyl derivatives of forskolin––their positive inotropic activity. Lal B, et al. **Bioorg Med Chem** 1998 Nov;6(11):2061–73

Comparison of the myocardial effects of desflurane and isoflurane in healthy patients: assessment by continuous oesophageal aortic blood flow echo–Doppler. Gueugniaud PY, et al. **Br J Anaesth** 1998 Dec;81(6):844–9

Mechanisms underlying the inotropic action of halothane on intact rat ventricular myocytes. Harrison SM, et al. **Br J Anaesth** 1999 Apr;82(4):609–21

Opioid receptor independent effects of morphine on membrane currents in single cardiac myocytes. Hung CF, et al. **Br J Anaesth** 1998 Dec;81(6):925–31

Effect of bupivacaine on ATP–dependent potassium channels in rat cardiomyocytes. Olschewski A, et al. **Br J Anaesth** 1999 Mar;82(3):435–8

Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart. Schlack W, et al. **Br J Anaesth** 1998 Dec; 81(6):913–9

Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1–receptor antagonist. Chaufour S, et al. **Br J Clin Pharmacol** 1999 May; 47(5):515–20

Inhibitors of the activity of poly (ADP–ribose) synthetase reduce the cell death caused by hydrogen peroxide in human cardiac myoblasts. Bowes J, et al. **Br J Pharmacol** 1998 Aug;124(8):1760–6

Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue. Brixius K, et al. **Br J Pharmacol** 1998 Sep;125(1):41–8

AMP is a partial agonist at the sheep cardiac ryanodine receptor. Ching LL, et al. **Br J Pharmacol** 1999 May; 127(1):161–71

Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis. Diochot S, et al. **Br J Pharmacol** 1999 Jan; 126(1):251–63

An inhibitor of poly (ADP–ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Docherty JC, et al. **Br J Pharmacol** 1999 Jul; 127(6):1518–24

Effects of tumour necrosis factor–alpha on left ventricular function in the rat isolated perfused heart: possible mechanisms for a decline in cardiac function. Edmunds NJ, et al. **Br J Pharmacol** 1999 Jan;126(1):189–96

Analysis of the atypical characteristics of adenosine receptors mediating negative inotropic and chronotropic responses of guinea–pig isolated atria and papillary muscles. Gardner NM, et al. **Br J Pharmacol** 1999 Aug;127(7):1619–26

Inhibition of the rapid component of the delayed–rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Jones SE, et al. **Br J Pharmacol** 1998 Nov;125(6):1138–43

The vasoconstrictor effect of 8–epi prostaglandin F2alpha in the hypoxic rat heart. Kromer BM, et al. **Br J Pharmacol** 1999 Mar;126(5):1171–4

Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. Litwin SE, et al. **Br J Pharmacol** 1999 Aug;127(7):1671–9

Functional analysis of desensitization of the beta–adrenoceptor signalling pathway in rat cardiac tissues following chronic isoprenaline infusion. McMartin L, et al. **Br J Pharmacol** 1999 Jun;127(4):1012–20

In vivo demonstration of H3–histaminergic inhibition of cardiac sympathetic stimulation by R–alpha–methyl–histamine and its prodrug BP 2.94 in the dog. Mazenot C, et al. **Br J Pharmacol** 1999 Jan; 126(1):264–8

Antiarrhythmic effect and its underlying ionic mechanism of 17beta–estradiol in cardiac myocytes. Nakajima T, et al. **Br J Pharmacol** 1999 May;127(2):429–40

Augmented myocardial ischaemia by nicotine––mechanisms and their possible significance. Schrör K, et al. **Br J Pharmacol** 1998 Sep;125(1):79–86

The antifungal antibiotic clotrimazole potently inhibits L–type calcium current in guinea–pig ventricular myocytes. Thomas GP, et al. **Br J Pharmacol** 1999 Apr; 126(7):1531–3

Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes. Wang GX, et al. **Br J Pharmacol** 1999 May;127(2):321–30

Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Wang H, et al. **Br J Pharmacol** 1999 Apr; 126(8):1725–34

Effects of chronic application of propranolol on beta–adrenergic signal transduction in heart ventricles from myopathic BIO TO2 and control hamsters. Witte K, et al. **Br J Pharmacol** 1998 Nov;125(5):1033–41

Role of Na+/Ca2+ exchange in endothelin–1–induced increases in Ca2+ transient and contractility in rabbit ventricular myocytes: pharmacological analysis with

KB-R7943. Yang HT, et al. **Br J Pharmacol** 1999 Apr; 126(8):1785–95

Histamine H1-receptor-mediated increase in the Ca2+ transient without a change in the Ca2+ current in electrically stimulated guinea-pig atrial myocytes. Yoshimoto K, et al. **Br J Pharmacol** 1998 Aug; 124(8):1744–50

Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts. Naim KL, et al.
Can J Physiol Pharmacol 1998 Jun;76(6):605–12

Modification of beta-adrenoceptors and adenylyl cyclase in hearts perfused with hypochlorous acid. Persad S, et al.
Can J Physiol Pharmacol 1998 Oct-Nov;76(10–11):961–6

Effect of vasoactive intestinal peptide on pacemaker location and heart rate in the dog atrium. Pintér A, et al.
Can J Physiol Pharmacol 1998 Apr;76(4):457–62

Individual effects of dietary EPA and DHA on the functioning of the isolated working rat heart. Sergiel JP, et al. **Can J Physiol Pharmacol** 1998 Jul-Aug; 76(7–8):728–36

Novel attributes of an androgenic steroid-mediated increase in cardiac end diastolic stiffness in rats. Trifunovic B, et al. **Can J Physiol Pharmacol** 1998 Jun;76(6):657–64

Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel. Della Torre P, et al.
Cancer Chemother Pharmacol 1999;44(2):138–42

Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Nazeyrollas P, et al. **Cancer Chemother Pharmacol** 1999;43(3):227–32

Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Salloum E, et al. **Cancer Invest** 1999; 17(3):171–80

Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes. DeAtley SM, et al. **Cancer Lett** 1999 Feb 8;136(1):41–6

Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L, et al. **Cancer Prev Control** 1999 Apr; 3(2):145–59

8th International Symposium on Cardiovascular Pharmacotherapy. Amsterdam, The Netherlands. March 28 April 1, 1999. Abstracts. **Cardiovasc Drugs Ther** 1999 Mar;13(1):1–86

Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle. Marschang H, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):573–83

Gallopamil activity on asynergic viable myocardium in acute myocardial infarction: insights on stunned and hibernating myocardium. Natale E, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):431–7

Cytoprotection against oxidative stress in rat isolated cardiomyocytes: effect of EUK 8, a nonprotein catalytic antioxidant [letter] Tanguy S, et al.
Cardiovasc Drugs Ther 1998 Sep;12(4):355–7

Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart. Tsuchida A, et al.
Cardiovasc Drugs Ther 1998 Sep;12(4):365–73

Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle. Alloatti G, et al.
Cardiovasc Res 1999 Mar;41(3):611–9

Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Bowes J, et al.
Cardiovasc Res 1999 Jan;41(1):126–34

Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Marano G, et al. **Cardiovasc Res** 1999 Apr;42(1):201–5

Terbutaline-induced desensitization of human cardiac beta 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Poller U, et al. **Cardiovasc Res** 1998 Oct;40(1):211–22

Physio-pharmacological evaluation of myocardial performance: an integrative approach. Shah AM, et al.
Cardiovasc Res 1998 Jul;39(1):148–54 (85 ref.)

Physiopharmacological evaluation of myocardial performance: how to study modulation by cardiac endothelium and related humoral factors? Sys SU, et al.
Cardiovasc Res 1998 Jul;39(1):136–47 (83 ref.)

Effects of prostaglandin F2 alpha on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes. Yew SF, et al.
Cardiovasc Res 1998 Dec;40(3):538–45

Captopril lowers coronary venous free radical concentration after direct current cardiac shocks. Pagan-Carlo LA, et al. **Chest** 1999 Aug;116(2):484–7

Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Sawyer DB, et al. **Circ Res** 1999 Feb 19;84(3):257–65

Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload. Tsushima RG, et al. **Circ Res** 1999 Jun 11;84(11):1302–9

Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Gao MH, et al.
Circulation 1999 Mar 30;99(12):1618–22

Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Glatter KA, et al.
Circulation 1999 Mar 2;99(8):1034–40

Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Ide T, et al.
Circulation 1999 Aug 17;100(7):690–2

In vivo transfer of a beta 2-adrenergic receptor gene into the pressure-overloaded rat heart enhances cardiac response to beta-adrenergic agonist. Kawahira Y, et al.
Circulation 1998 Nov 10;98(19 Suppl):II262–7; discussion II267–8

beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Kuschel M, et al. **Circulation** 1999 May 11;99(18):2458–65

Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Qi XL, et al. **Circulation** 1999 Sep 21;100(12):1338–45

Unique cardioprotective action of the new calcium antagonist mibefradil [see comments] Schulz R, et al. **Circulation** 1999 Jan 19;99(2):305–11. Comment in: Circulation 1999 Jan 19;99(2):198–200.

Impact of University of Wisconsin solution on clinical heart transplantation. A comparison with Stanford solution for extended preservation. Stringham JC, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II157–61; discussion II162

Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. Nóbrega AC, et al.
Clin Auton Res 1999 Feb;9(1):11–6

Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Zou Y, et al. **Clin Cancer Res** 1995 Nov;1(11):1369–74

Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Cottin Y, et al. **Clin Cardiol** 1998 Sep;21(9):665–70

Rapidly reversible cardiomyopathy associated with chronic ipecac ingestion. Ho PC, et al. **Clin Cardiol** 1998 Oct; 21(10):780–3

Alpha-tocopherol acetate significantly suppressed the increase in heart interstitial 8-hydroxydeoxyguanosine following myocardial ischemia and reperfusion in anesthetized rats. Yang CS, et al. **Clin Chim Acta** 1999 Jul; 285(1–2):163–8

A review of the cardiac systemic side-effects of antihistamines: ebastine. Moss AJ, et al.
Clin Exp Allergy 1999 Jul;29 Suppl 3:200–5 (14 ref.)

Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Taglialatela M, et al.
Clin Exp Allergy 1999 Jul;29 Suppl 3:182–9 (38 ref.)

Effect of enalapril treatment on the heart of normal rats. Mazzadi A, et al. **Clin Exp Hypertens** 1998 Nov; 20(8):867–84

Intracellular Ca2+ and adrenergic responsiveness of cardiac myocytes in streptozotocin-induced diabetes. Ha T, et al.
Clin Exp Pharmacol Physiol 1999 Apr;26(4):347–53

Inhibition of human cardiac fibroblast mitogenesis by blockade of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Hafizi S, et al.
Clin Exp Pharmacol Physiol 1999 Jul;26(7):511–3

Metabolic and functional effects of carbachol and ischaemic preconditioning in rat isolated heart. Pisarenko OI, et al.
Clin Exp Pharmacol Physiol 1999 Jan;26(1):26–31

Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. Leenen FH, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):522–35

Effect of sodium nitroprusside and L-arginine methyl ester on rat hearts stored at 4 degrees C for 24 h. Fagbemi OS, et al. **Clin Sci (Colch)** 1998 Nov;95(5):557–64

Second-generation antihistamines: the risk of ventricular arrhythmias. DuBuske LM. **Clin Ther** 1999 Feb; 21(2):281–95 (58 ref.)

Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Morganroth J, et al. **Clin Ther** 1999 May;21(5):818–28

Stimulatory effects of starfish sapogenins (Asterias amurensis and Lethasterias nanimensis chelifera) on molluscan heart (Spisula sachalinensis). Gorshkov BA, et al.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 Aug;120(2):235–9

Dobutamine: empirical generalizations vs. age appropriate evidence [editorial; comment] Kissoon N.
Crit Care Med 1999 Mar;27(3):466–7. Comment on: Crit Care Med 1999 Mar;27(3):558–64.

Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes [see comments] Kumar A, et al. **Crit Care Med** 1999 Feb; 27(2):286–92. Comment in: Crit Care Med 1999 Feb;27(2):231–2.

Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Pacher P, et al. **Curr Med Chem** 1999 Jun;6(6):469–80 (202 ref.)

Growth hormone-independent cardioprotective effects of hexarelin in the rat. Locatelli V, et al. **Endocrinology** 1999 Sep;140(9):4024–31

In vivo insulin signaling in the myocardium of streptozotocin-diabetic rats: opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos. Wang PH, et al. **Endocrinology** 1999 Mar;140(3):1141–50

Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice. Weiss RE, et al. **Endocrinology** 1998 Dec; 139(12):4945–52

Cardiodepression by tumor necrosis factor-alpha.
Müller-Werdan U, et al. **Eur Cytokine Netw** 1998 Dec; 9(4):689–91 (16 ref.)

Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization [see comments] Patel DJ, et al. **Eur Heart J** 1999 Jan;20(1):51–7. Comment in: Eur Heart J 1999 Jan;20(1):2–5.

Cardiovascular responses, arterial oxygen saturation and plasma catecholamine concentration during upper gastrointestinal endoscopy using conscious sedation with midazolam or propofol. Oei-Lim VL, et al.
Eur J Anaesthesiol 1998 Sep;15(5):535–43

Cardiovascular effects of Org 9487 under isoflurane anaesthesia in man. Osmer C, et al. **Eur J Anaesthesiol** 1998 Sep;15(5):585–9

Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Zimmermann N, et al.
Eur J Cardiothorac Surg 1998 Jul;14(1):70–5

Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs. Massart PE, et al. **Eur J Clin Invest** 1998 Oct;28(10):798–806

Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. Bisi G, et al. **Eur J Endocrinol** 1999 Apr; 140(4):322–7

Effect of ribose on cardiac adenine nucleotides in a donor model for heart transplantation. Müller C, et al.
Eur J Med Res 1998 Dec 16;3(12):554–8

Activation by Phoneutria nigriventer spider venom of autonomic nerve fibers in the isolated rat heart. Costa SK, et al. **Eur J Pharmacol** 1998 Dec 18;363(2–3):139–46

Effect of tedisamil on cell communication, impulse propagation, and excitability of the failing heart. De Mello WC, et al. **Eur J Pharmacol** 1999 May 21;372(3):241–6

Effects of enalapril on vasoactive intestinal peptide metabolism and tissue levels. Duggan KA, et al.
Eur J Pharmacol 1998 Sep 25;358(1):25–30

Comparison of cocaine and Na+ channel blockers on cardio-respiratory function in the rabbit. Erzouki HK, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):51–6

Effects of L-arginine on endothelial and cardiac function in rats with heart failure. Feng Q, et al.
Eur J Pharmacol 1999 Jul 2;376(1–2):37–44

Ion channels involved in the release of calcitonin gene-related peptide by low pH, prostacyclin and capsaicin in the isolated guinea-pig heart. Källner G, et al.
Eur J Pharmacol 1998 Jul 10;352(2–3):223–8

The electrical and mechanical response of adult guinea pig and rat ventricular myocytes to omega3 polyunsaturated fatty acids. Macleod JC, et al. **Eur J Pharmacol** 1998 Sep 4;356(2–3):261–70

Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats. Mori T, et al.
Eur J Pharmacol 1998 May 8;348(2–3):229–34

Effect of adrenomedullin on cAMP and cGMP levels in rat cardiac myocytes and nonmyocytes. Nishikimi T, et al.
Eur J Pharmacol 1998 Jul 24;353(2–3):337–44

Interaction between capsaicin and nitrate tolerance in isolated guinea-pig heart. Oroszi G, et al. **Eur J Pharmacol** 1999 Mar 5;368(2–3):R1–3

Beneficial effects of amiodarone in heart failure: interaction with beta-adrenoceptors rather than G proteins. Schnabel P, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):391–4

The inducible nitric oxide synthase in vascular and cardiac tissue. Stoclet JC, et al. **Eur J Pharmacol** 1999 Jun 30; 375(1–3):139–55 (226 ref.)

Endothelin release by capsaicin in isolated working rat heart. Szolcsányi J, et al. **Eur J Pharmacol** 1999 Jul 9; 376(3):247–50

Effects of the optical isomers of verapamil on electrophysiological properties of the heart in conscious dogs. Takahata O, et al. **Eur J Pharmacol** 1998 Aug 21; 355(2–3):159–66

Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats. Terada R, et al.
Eur J Pharmacol 1998 Sep 18;357(2–3):185–91

Effects of gender on the sensitivity of rat cardiac muscle to extracellular Ca2+. Wang SN, et al.
Eur J Pharmacol 1998 Nov 13;361(1):73–7

In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. Watson JM, et al. **Eur J Pharmacol** 1999 Apr 1;370(1):69–77

Both D-cis- and L-cis-diltiazem attenuate hydrogen peroxide-induced derangements in rat hearts. Xiao CY, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):387–98

Cardiac electrophysiological effects of platelet-derived substances. Flores NA, et al. **Exp Physiol** 1999 Mar; 84(2):253–74 (165 ref.)

The protective effect of iloprost, a PGL2 analogue, on ultratructure of ischemic and reperfused myocardial myocytes. Fitzl G, et al. **Exp Toxicol Pathol** 1999 Jan; 51(1):81–8

L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. Andrieu-Abadie N, et al. **FASEB J** 1999 Sep; 13(12):1501–10

Effect of short-term hormone replacement therapy on left

ventricular mass and contractile function. Sites CK, et al. **Fertil Steril** 1999 Jan;71(1):137–43

Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Dalloz F, et al. **Free Radic Biol Med** 1999 Apr; 26(7–8):785–800

Effects of quinidine, verapamil, nifedipine and ouabain on hysteresis in atrial refractoriness in the conscious dog: an approach to ionic mechanisms. Boucher M, et al. **Gen Pharmacol** 1999 Jan;32(1):47–50

Inhibitory cholinergic effects on the autonomously contractile bulbus cordis branchialis of the cephalopod Sepia officinalis L. Gebauer M, et al. **Gen Pharmacol** 1999 Jul;33(1):59–66

Electrophysiological effects of homocysteine in isolated rat right ventricular papillary muscles and left atria. Pacher P, et al. **Gen Pharmacol** 1999 Apr;32(4):439–43

Effects of CP-060S, a novel cardioprotective drug, on cardiac function and myocardial oxygen consumption. Suzuki Y, et al. **Gen Pharmacol** 1999 Jan;32(1):57–63

Mechanism of inhibition of the Na current by tocainide in guinea-pig isolated ventricular cells. Tanaka Y, et al. **Gen Pharmacol** 1999 May;32(5):541–50

Biphasic positive inotropic actions of doxorubicin in isolated guinea pig hearts: relation to Ca2+ release from the sarcoplasmic reticulum. Temma K, et al. **Gen Pharmacol** 1999 Sep;33(3):229–36

The effect of growth hormone on rat myocardial collagen. Brüel A, et al. **Growth Horm IGF Res** 1999 Apr;9(2):123–30

Protective effects of pretreatment with ginsenosides on cardiac and coronary vascular function after hypothermic rat heart preservation. Zhang JM, et al. **Hiroshima J Med Sci** 1999 Jun;48(2):65–70

Effects of ischaemia-reperfusion and cyclosporin-A on cardiac muscle ultrastructure. Jurado F, et al. **Histol Histopathol** 1998 Jul;13(3):761–74

Second degree atrio-ventricular block and cardiotoxicity secondary to envenomation by the scorpion Leiurus quinquestriatus ('yellow scorpion')--an indication for serotherapy? Shapira MY, et al. **Hum Exp Toxicol** 1998 Oct;17(10):541–3

Cardiac resistance to adriamycin in transgenic mice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Dell'Acqua G, et al. **Hum Gene Ther** 1999 May 20;10(8):1269–79

Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610. Beyer ME, et al. **Hypertension** 1999 Jan;33(1):145–52

Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. Cicogna AC, et al. **Hypertension** 1999 Jan;33(1):60–5

Role of calcium-sensitive tyrosine kinase Pyk2/CAKbeta/RAFTK in angiotensin II induced Ras/ERK signaling. Murasawa S, et al. **Hypertension** 1998 Oct;32(4):668–75

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Robert V, et al. **Hypertension** 1999 Apr;33(4):981–6

Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Yang XP, et al. **Hypertension** 1999 Jul;34(1):24–30

Indian red scorpion venom modulates spontaneous activity of rat right atria through the involvement of cholinergic and adrenergic systems. Alex AB, et al. **Indian J Exp Biol** 1999 May;37(5):455–60

Collagen profile in isoproterenol induced myocardial necrosis in rats. Nirmala C, et al. **Indian J Exp Biol** 1998 Aug; 36(8):763–7

Effect of silver leaf on circulating lipids and cardiac and hepatic enzymes. Sharma DC, et al. **Indian J Physiol Pharmacol** 1997 Jul;41(3):285–8

Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Hardenbergh PH, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):69–72

Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer. Fukuda M, et al. **Intern Med** 1999 May;38(5):436–8

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Noda T, et al. **Invest New Drugs** 1998;16(2):121–8

Cardiac metal contents after infusions of manganese. An experimental evaluation in the isolated rat heart. Brurok H, et al. **Invest Radiol** 1999 Jul;34(7):470–6

Effect of acetylsalicylate on cardiac and muscular pain induced by intracoronary and intra-arterial infusion of bradykinin in humans. Gaspardone A, et al. **J Am Coll Cardiol** 1999 Jul;34(1):216–22

Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. Luchner A, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1839–44

Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats. Kato K, et al. **J Appl Physiol** 1999 Mar;86(3):812–8

Histamine H3 activation depresses cardiac function in experimental sepsis. Li X, et al. **J Appl Physiol** 1998 Nov; 85(5):1693–701

Cardiorespiratory effects of O-isobutyl S-[2-(diethylamino)-ethyl] methylphosphonothioate -- a structural isomer of VX. Chang FC, et al. **J Appl Toxicol** 1998 Sep-Oct;18(5):337–47

Cardiac anticholinergic effects of procainamide and its N-acetylated metabolite: experimental pharmacological and radioligand binding studies. Boucher M, et al. **J Auton Pharmacol** 1998 Apr;18(2):83–7

Nitric oxide and N-acetylcysteine inhibit the activation of mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts [published erratum appears in J Biol Chem 1999 Jan 8;274(2):1180] Wang D, et al. **J Biol Chem** 1998 Dec 4;273(49):33027–34

On the mechanism of cesium-induced voltage and current tails in single ventricular myocytes. Shen JB, et al. **J Biomed Sci** 1999 May-Jun;6(3):161–75

Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. Nakamura W, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):855–8

Cytochalasin D as excitation-contraction uncoupler for optically mapping action potentials in wedges of ventricular myocardium [see comments] Wu J, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1336–47. Comment in: J Cardiovasc Electrophysiol 1998 Dec;9(12):1358–62.

Stimulation of long-chain fatty acid uptake by dipyridamole in isolated myocytes. Abdel-aleem S, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):43–8

Electrophysiologic effects of civamide (zucapsaicin) on canine cardiac tissue in vivo and in vitro. Arnar DO, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):875–83

Effect of cocaine on cardiac biochemical functions. Devi BG, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):1–6

Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. Drici MD, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):82–8

Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism. Drvota V, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):654–61

Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated? Jakubetz J, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):461–72

17-Beta estradiol regulation of myocardial glutathione and its role in protection against myocardial stunning in dogs. Kim YD, et al. **J Cardiovasc Pharmacol** 1998 Sep; 32(3):457–65

Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. McVey MJ, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):703–10

Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. Nijhawan N, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):219–28

Effects of the novel antimigraine agent, frovatriptan, on coronary and cardiac function in dogs. Parsons AA, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):995–1000

Sodium channel-blocking properties of spiradoline, a kappa receptor agonist, are responsible for its antiarrhythmic action in the rat. Pugsley MK, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):863–74

Effects of bimakalim on human cardiac action potentials: comparison with guinea pig and nicorandil and use-dependent study. Rouet R, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):255–63

Dual effect of cicletanine on the Na+-H+ exchanger in chick embryonic cardiomyocytes. Samain E, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):169–72

Disodium cromoglycate does not prevent terbutaline-induced desensitization of beta 2-adrenoceptor-mediated cardiovascular in vivo functions in human volunteers. Schäfers RF, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):822–7

The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. Shimizu M, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):78–81

Concentration-dependent block of sodium current in guinea pig ventricular myocytes by a class III antiarrhythmic agent, MS-551. Suzuki K, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):819–25

Perflubron emulsion improves tolerance to low-flow ischemia in isolated rabbit hearts. Symons JD, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):108–15

Relevance of inter- and intraventricular electrical dispersion to arrhythmogenesis in normal and ischaemic rabbit myocardium: a study with cromakalim, 5-hydroxydecanoate and glibenclamide. Wolk R, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):323–34

Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. Zhou M, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):355–61

Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. Drici MD, et al. **J Clin Psychopharmacol** 1998 Dec;18(6):477–81

More on potassium, the heart, and antipsychotic agents [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1999 Jun;19(3):201–2

Ultrastructural variations of rat myocardium due to Walterinnesia aegytia snake envenomation. al-Shammary FJ, et al. **J Electron Microsc (Tokyo)** 1998;47(6):637–43

Structure-activity relationship of cardiotonic flavonoids in guinea-pig papillary muscle. Itoigawa M, et al. **J Ethnopharmacol** 1999 Jun;65(3):267–72

Effects of age and gender on cardiovascular responses to phenylephrine. Turner MJ, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jan;54(1):M17–24

Cardioprotective effects of Lazaroid U-74389G on ischemia-reperfusion injury in canine hearts. Takahashi T, et al. **J Heart Lung Transplant** 1999 Apr;18(4):285–91

Cytokines increase neonatal cardiac myocyte calcium concentrations: the involvement of nitric oxide and cyclic nucleotides. Bick RJ, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):645–53

Adults with childhood-onset growth hormone deficiency: effects of growth hormone treatment on cardiac structure. Sartorio A, et al. **J Intern Med** 1997 Jun;241(6):515–20

Cardiac laterality and ventricular looping in retinoic acid-treated rat embryos. Kim JS, et al. **J Korean Med Sci** 1999 Apr;14(2):138–46

Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. Link G, et al. **J Lab Clin Med** 1999 Feb;133(2):179–88

Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines. Ding CZ, et al. **J Med Chem** 1999 Sep 9;42(18):3711–7

Persistent effects of doxorubicin on cardiac gene expression. Boucek RJ Jr, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1435–46

The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions. Brittsan AG, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1725–37

Endothelin-1 increases susceptibility of isolated rat hearts to ischemia/reperfusion injury by reducing coronary flow. de Groot MC, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2657–68

Effects of thapsigargin and KCl on the O2 use of the excised blood-perfused rat heart. Hata Y, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2137–43

Acute effects of thyroid hormone analogs on sodium currents in neonatal rat myocytes. Huang CJ, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):881–93

AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content. McCurdy DT 3rd, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1979–89

Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. Masson S, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1505–14

Regional differences in non-enzymatic antioxidants in the heart under control and oxidative stress conditions. Palace V, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):193–202

Galpha(i2), Galpha(i3)and Galpha(o) are all required for normal muscarinic inhibition of the cardiac calcium channels in nodal/atrial-like cultured cardiocytes. Ye C, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1771–81

Cardiovascular actions of cannabinoids and their generation during shock. Wagner JA, et al. **J Mol Med** 1998 Nov-Dec; 76(12):824–36 (121 ref.)

Ca(2+)-induced Ca(2+) release activates spontaneous miniature outward currents (SMOCs) in parasympathetic cardiac neurons. Merriam LA, et al. **J Neurophysiol** 1999 Aug;82(2):540–50

Heart hypoplasia in experimental congenital diaphragmatic hernia. Migliazza L, et al. **J Pediatr Surg** 1999 May; 34(5):706–10; discussion 710–1

KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. Anderson ME, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):996–1006

Fatty acid block of the transient outward current in adult human atrium. Crumb WJ Jr, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):386–91

Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. Drolet B, et al. **J Pharmacol Exp Ther** 1999 Mar; 288(3):1261–8

Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. Fulton D, et al. **J Pharmacol Exp Ther** 1998 Nov; 287(2):497–503

Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts. Furukawa Y, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1334–42

Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts. Hatta E, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):919–27

Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. Khalifa M, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):280–4

Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. Khalifa M, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):858–65

Temporal differences in actions of calcium channel blockers

on K+ accumulation, cardiac function, and high-energy phosphate levels in ischemic guinea pig hearts. Sato R, et al. **J Pharmacol Exp Ther** 1999 May;289(2):831–9

Lack of effect of McN-A-343 on membrane current and contraction in guinea pig ventricular myocytes. Shen JB, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):641–8

Electrophysiological effects of LU111995 on canine hearts: in vivo and in vitro studies. Sosunov EA, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):146–52

The relationship between the myocardial kinetics of meperidine and its effect on myocardial contractility: model-independent analysis and optimal regional model. Upton RN, et al. **J Pharmacol Exp Ther** 1999 Aug; 290(2):694–701

Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. Wang GW, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):938–44

Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart. Wu HY, et al. **J Pharmacol Exp Ther** 1998 Nov; 287(2):515–20

Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart. Chesnais JM, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):449–61

One calcium ion may suffice to open the tetrameric cardiac ryanodine receptor in rat ventricular myocytes. Fan JS, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):769–80

Isoform-specific regulation of the sodium pump by alpha- and beta-adrenergic agonists in the guinea-pig ventricle. Gao J, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):377–83

Modulation of rat cardiac sodium channel by the stimulatory G protein alpha subunit. Lu T, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):371–84

Effects of mibefradil, a blocker of T-type Ca2+ channels, in single myocytes and intact muscle of guinea-pig heart. Emanuel K, et al. **J Physiol Pharmacol** 1998 Dec; 49(4):577–90

Increase in vasopressin concentration and cardiodepressant activity in the blood dialysates after NMDA and hypertonic saline administration. Gorąca A. **J Physiol Pharmacol** 1998 Dec;49(4):561–75

Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. Tan DX, et al. **J Pineal Res** 1998 Oct;25(3):184–91

Enhancement of hypothermic heart preservation with fructose 1, 6-diphosphate. Niu W, et al. **J Surg Res** 1999 Jul;85(1):120–9

Age-related effects of St Thomas' Hospital cardioplegic solution on isolated cardiomyocyte cell volume. Danetz JS, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):467–76

Gene transfection of beta 2-adrenergic receptor into the normal rat heart enhances cardiac response to beta-adrenergic agonist. Kawahira Y, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):446–51

Toxic effects of cadmium and copper on the isolated heart of dogfish shark, Squalus acanthias. Wang R, et al. **J Toxicol Environ Health** 1999 Aug 13;57(7):507–19

Cardiac actions of erythromycin: influence of female sex. Drici MD, et al. **JAMA** 1998 Nov 25;280(20):1774–6

A calcium antagonist protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Maeda A, et al. **Jpn Circ J** 1999 Feb;63(2):123–9

Chronotropic, inotropic, dromotropic and coronary vasodilator effects of bisaramil, a new class I antiarrhythmic drug, assessed using canine isolated, blood-perfused heart preparations. Haruno A, et al. **Jpn J Pharmacol** 1999 Jul; 80(3):267–70

Acetylcholine-induced biphasic effect on the maximum upstroke velocity of action potential in mouse right atria: interaction with beta-adrenergic signaling cascade. Islam MA, et al. **Jpn J Pharmacol** 1998 Oct;78(2):181–90

Positive inotropic, negative chronotropic, and coronary vasoconstrictor effects of acetylcholine in isolated rat hearts: role of muscarinic receptors, prostaglandins, protein kinase C, influx of extracellular ca2+, intracellular Ca2+ release, and endothelium. Ateş S, et al. **Jpn J Physiol** 1998 Dec;48(6):483–91

Effects of selenium enriched reperfusion solutions on isolated guinea pig hearts. Sinci V, et al. **Keio J Med** 1998 Dec; 47(4):219–22

Daunorubicin cardiotoxicity in childhood cancer [letter] Samuel L, et al. **Lancet** 1998 Oct 3;352(9134):1150

Cardiotoxicity of doxorubicin: effects of 21-aminosteroids. Falcone G, et al. **Life Sci** 1998;63(17):1525–32

Thermal preconditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Ito H, et al. **Life Sci** 1999;64(9):755–61

Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rat. Jalil JE, et al. **Life Sci** 1999;64(18):1603–12

Age-related changes in thyroid hormone effects on glucose transporter isoforms of rat heart. Mooradian AD, et al. **Life Sci** 1999;65(10):981–9

Nicotine depresses the functions of multiple cardiac potassium channels. Wang H, et al. **Life Sci** 1999; 65(12):PL143–9

Cardiac effects of benzodiazepine receptor agonists and antagonists in the isolated rat heart: a comparative study. Zeegers A, et al. **Life Sci** 1998;63(16):1439–56

The effects of dietary alpha-linolenic acid compared with docosahexaenoic acid on brain, retina, liver, and heart in the guinea pig. Abedin L, et al. **Lipids** 1999 May; 34(5):475–82

Preliminary study on the suitability of a pharmacological bio-assay based on cardiac myocytes cultured over microfabricated microelectrode arrays. Denyer MC, et al. **Med Biol Eng Comput** 1998 Sep;36(5):638–44

Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study. Di Bello V, et al. **Med Sci Sports Exerc** 1999 Apr;31(4):514–21

Endurance exercise alters the contractile responsiveness of rat heart to extracellular Na+ and Ca2+. Lankford EB, et al. **Med Sci Sports Exerc** 1998 Oct;30(10):1502–9

Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension. Striffler JS, et al. **Metabolism** 1998 Oct;47(10):1199–204

Application of authentic peroxynitrite to biological materials. Ishida H, et al. **Methods Enzymol** 1999;301:402–9

Novel beneficial effects of defibrotide, an endothelium protecting agent, following ischemia and reperfusion in the isolated perfused rat heart. Shin YK, et al. **Methods Find Exp Clin Pharmacol** 1998 Jul-Aug; 20(6):463–71

Amphotericin B and cardiac toxicity--a case report. el-Dawlatly AA, et al. **Middle East J Anesthesiol** 1999 Feb;15(1):107–12

Effects of thyroid hormones on heart and kidney functions. Capasso G, et al. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):56–64

Growth hormone and the heart. Cittadini A, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):51–5 (39 ref.)

Effects of L-carnitine on mechanical recovery of isolated rat hearts in relation to the perfusion with glucose and palmitate. Löster H, et al. **Mol Cell Biochem** 1998 Aug; 185(1-2):65–75

Effects of amiodarone on cardiac function and mitochondrial oxidative phosphorylation during ischemia and reperfusion. Moreau D, et al. **Mol Cell Biochem** 1999 Apr; 194(1-2):291–300

Curcumin treatment modulates collagen metabolism in isoproterenol induced myocardial necrosis in rats. Nirmala C, et al. **Mol Cell Biochem** 1999 Jul;197(1-2):31–7

HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Chouabe C, et al. **Mol Pharmacol** 1998 Oct;54(4):695–703

Cardioprotective actions of KC 12291. I. Inhibition of voltage-gated Na+ channels in ischemia delays myocardial Na+ overload. Decking UK, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Nov; 358(5):547–53

Cardioprotective actions of KC 12291. II. Delaying Na+ overload in ischemia improves cardiac function and energy status in reperfusion. Hartmann M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Nov; 358(5):554–60

Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. van Eickels M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 May; 359(5):394–9

23Na NMR shift reagents enhance cardiac staircase effect in isolated perfused rat hearts. Simor T, et al. **NMR Biomed** 1999 Aug;12(5):267–74

Metoclopramide has no effect on abdominal activity of sestamibi in myocardial SPET. Weinmann P, et al. **Nucl Med Commun** 1999 Jul;20(7):623–5

A cardioactive peptide from the southern armyworm, Spodoptera eridania. Furuya K, et al. **Peptides** 1999; 20(1):53–61

Atenolol depresses post-ischaemic recovery in the isolated rat heart. Allibardi S, et al. **Pharmacol Res** 1999 Jun; 39(6):431–5

Polyamine analogue antiarrhythmics. Bergeron RJ, et al. **Pharmacol Res** 1998 Nov;38(5):367–80

Effects of the ionophore antibiotic monensin on hepatic biotransformations and target organ morphology in rats. Dacasto M, et al. **Pharmacol Res** 1999 Jan;39(1):5–10

Cardioprotective effect of enantiomers of cicletanine (BN50417, BN50418) in ischaemic/reperfused isolated working rat hearts: interaction with glibenclamide. Ferdinandy P, et al. **Pharmacol Res** 1999 Mar;39(3):225–31

Interplay between nitric oxide and CGRP by capsaicin in isolated guinea-pig heart. Oroszi G, et al. **Pharmacol Res** 1999 Aug;40(2):125–8

Midazolams cardiac depressant effects and their lack of reversal by flumazenil in isolated rabbit hearts. Ozturk T, et al. **Pharmacol Res** 1999 Apr;39(4):283–7

Drugs preventing Na+ and Ca2+ overload. Ravens U, et al. **Pharmacol Res** 1999 Mar;39(3):167–74 (50 ref.)

Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice. Al-Shabanah OA, et al. **Pharmacol Res** 1998 Sep;38(3):225–30

Midazolam is a safe agent by comparison with thiopentone on arrhythmias in ischaemia and reperfusion conditions in isolated perfused rat hearts. Süzer O, et al. **Pharmacol Res** 1998 Jun;37(6):461–8

Possible contribution of leukotrienes in the arrhythmogenic effects of digoxin on isolated guinea-pig hearts. Gök S, et al. **Pharmacology** 1998 Nov;57(5):279–84

Bopindolol: a slowly dissociating antagonist from the beta-adrenoceptors in guinea pig atria. Hosohata Y, et al. **Pharmacology** 1998 Oct;57(4):180–7

Enhancement by arginine vasopressin of the L-type Ca2+ current in guinea pig ventricular myocytes. Kurata S, et al. **Pharmacology** 1999 Jul;59(1):21–33

The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Klapperstück M, et al. **Pharmazie** 1999 Jan;54(1):61–8

New benzoxazine and benzothiazine derivatives--structure-activity relations in guinea-pig heart and smooth muscle preparations. Studenik C, et al. **Pharmazie** 1999 May;54(5):330–4

Antidepressant drugs and heart electrical field. Slaviček J, et al. **Physiol Res** 1998;47(4):297–300

Mechanism of action of verbascoside on the isolated rat heart: increases in level of prostacyclin. Pennacchio M, et al. **Phytother Res** 1999 May;13(3):254–5

Cardioprotective properties of hydrophilic pollen extract (HPE). Polański M, et al. **Pol J Pathol** 1998;49(2):109–12

New proctolin analogues and their myotropic effects on heart of yellow mealworm Tenebrio molitor L. and foregut of locust-Schistocerca gregaria L. Kuczer M, et al. **Pol J Pharmacol** 1998 Mar-Apr;50(2):143–50

Nifedipine does not impede clenbuterol-stimulated muscle hypertrophy. Murphy RJ, et al. **Proc Soc Exp Biol Med** 1999 Jul;221(3):184–7

Time- and voltage-dependent block of sodium channels expressed in Xenopus oocytes by RSD 921, a novel class I antiarrhythmic drug. Pugsley MK, et al. **Proc West Pharmacol Soc** 1998;41:75–6

Rapid and possibly nongenomic effects of testosterone on isolated and perfused rat heart. Rubio I, et al. **Proc West Pharmacol Soc** 1998;41:131–2

Nifedipine and extracellular water in dialysis arterial hypertension. Trovato GM, et al. **Recenti Prog Med** 1998 Sep;89(9):438–43

Modulation of chronotropic and inotropic heart vagus actions as a non-pressor effect of angiotensin II in the anaesthetized rat. Wicher C, et al. **Regul Pept** 1998 Jun 30;74(2-3):151–8

Cardiac dysfunction induced by low and high diet antioxidant levels comparing selenium and vitamin E in rats. Turan B, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 1):142–50

Relationship between decreased function and O2 consumption caused by cyclic GMP in cardiac myocytes and L-type calcium channels. Yan L, et al. **Res Exp Med (Berl)** 1998 Oct;198(3):109–21

Cardiorespiratory responses to glutamate microinjected into the medullary raphé. Bernard DG. **Respir Physiol** 1998 Jul; 113(1):11–21

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Ewer MS, et al. **Semin Oncol** 1999 Aug;26(4 Suppl 12):96–101

Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Sparano JA. **Semin Oncol** 1999 Jun;26(3 Suppl 9):14–9 (34 ref.)

Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Goldfarb RD, et al. **Shock** 1998 Oct;10(4):258–64

The effects of a new ultra-short-acting beta-adrenergic blocker, ONO-1101, on cardiac function during and after cardiopulmonary bypass. Ahmet I, et al. **Surg Today** 1999; 29(3):248–54

Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury. Szabó G, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):232–6

Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit. Rossoni G, et al. **Thromb Res** 1999 Jun 1;94(5):327–38

Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Sugiyama A, et al. **Toxicol Appl Pharmacol** 1998 Sep; 152(1):261–9

Effects of mercury on the isolated heart muscle are prevented by DTT and cysteine. Vassallo DV, et al. **Toxicol Appl Pharmacol** 1999 Apr 15;156(2):113–8

Mechanisms of Ca2+ antagonism in imipramine-induced toxicity of isolated adult rat cardiomyocytes. Watts JA, et al. **Toxicol Appl Pharmacol** 1998 Nov;153(1):95–101

Contrast medium- and mannitol-induced apoptosis in heart and kidney of SHR rats. Zhang J, et al. **Toxicol Pathol** 1999 Jul-Aug;27(4):427–35

Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. DeAtley SM, et al. **Toxicology** 1999 May 3;134(1):51–62

In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506. Al-Nasser IA. **Toxicology** 1998 Nov 16;131(2-3):175–81

Effects of equinatoxin II from Actinia equina (L.) on isolated rat heart: the role of direct cardiotoxic effects in equinatoxin II lethality. Bunc M, et al. **Toxicon** 1999 Jan; 37(1):109–23

Protective effect of JTV519 on prolonged myocardial preservation. Hachida M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1094

Beneficial effects of ginsenosides of stems and leaves on cardiac and coronary vascular functions after 12-hour rat heart preservation. Zhang JM, et al. **Transplant Proc** 1999 Aug;31(5):2175–8

Adenosine A3 receptors: novel ligands and paradoxical effects. Jacobson KA. **Trends Pharmacol Sci** 1998 May; 19(5):184–91 (44 ref.)

Betel nut chewing and cardiac arrhythmia [letter; comment] Chittivelu S, et al. **Vet Hum Toxicol** 1998 Dec;40(6):368 . Comment on: Vet Hum Toxicol 1998 Oct;40(5):287–9.

Comparison of cardiopulmonary effects of medetomidine–midazolam, acepromazine–butorphanol and midazolam–butorphanol in dogs. Kojima K, et al. **Zentralbl Veterinarmed A** 1999 Aug;46(6):353–9

[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus] Vitovec J, et al. **Vnitr Lek** 1998 Jun;44(6):336–41 (Eng. Abstr.) **(Cze)**

[Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism] Lopaschuk GD. **Presse Med** 1998 Dec 12;27(39):2100–4 (Eng. Abstr.) **(Fre)**

[Hemodynamic effects of a ventriculo–cisternal perfusion of bupivacaine] Schäfer MK, et al. **Anaesthesist** 1999 Apr; 48(4):218–23 (Eng. Abstr.) **(Ger)**

[Delayed cardiac effects of adjuvant doxorubicin and radiotherapy in breast cancer patients] Sack H. **Strahlenther Onkol** 1999 Jun;175(6):293–4 **(Ger)**

[Cardiac electrophysiological effect and clinical use of adenosine] Fazekas T, et al. **Orv Hetil** 1999 May 30; 140(22):1219–26 (52 ref.) (Eng. Abstr.) **(Hun)**

[Pathological action of endothelin–1 on the heart: coronary spasm and arrhythmia] Juhász–Nagy S. **Orv Hetil** 1999 Jun 20;140(25):1395–401 (49 ref.) (Eng. Abstr.) **(Hun)**

[Simvastatin and ischemia–reperfusion damage: its effects on apoptotic myocyte death and on the endothelial expression of nitric–oxide synthetase in an experimental model of the isolated rat heart] Di Napoli P, et al. **Cardiologia** 1999 Jan; 44(1):69–74 (Eng. Abstr.) **(Ita)**

[Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy] Lopez M. **Clin Ter** 1999 Jan–Feb;150(1):37–49 (82 ref.) (Eng. Abstr.) **(Ita)**

[The cardiotoxicity of anthracyclines administered in childhood] Iarussi D, et al. **G Ital Cardiol** 1998 Dec; 28(12):1431–40 (90 ref.) **(Ita)**

[Evaluation of late cardiac toxicity of anthracycline in childhood] Butera G, et al. **Minerva Pediatr** 1998 Apr; 50(4):111–9 (Eng. Abstr.) **(Ita)**

[Anthracyclines and the heart] Mazzarello GP, et al. **Recenti Prog Med** 1998 Sep;89(9):459–64 (30 ref.) (Eng. Abstr.) **(Ita)**

[Superoxide anion radical selectively increases Ca2+ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca2+ channel] Okabe E. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:58P–62P (Eng. Abstr.) **(Jpn)**

[The effect of new H1–receptor antagonists on cardiovascular system] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):360–2 (34 ref.) (Eng. Abstr.) **(Pol)**

[A histological analysis of the changes experimentally induced by cadmium in cardiac muscle tissue by a computerized method of image analysis] Coucelo JM, et al. **Rev Port Cardiol** 1998 Sep;17(9):735–40 (Eng. Abstr.) **(Por)**

[Spironolactone protection from hydralazine–induced stress in the rat myocardium] Póvoa R, et al. **Rev Port Cardiol** 1998 Sep;17(9):727–32 (Eng. Abstr.) **(Por)**

[Myocardial protection against cold stress with pravastatin] Póvoa R, et al. **Rev Port Cardiol** 1998 Oct;17(10):803–7 (Eng. Abstr.) **(Por)**

[Effects of dipeptides Gly–Pro, Pro–Gly, glycine, and proline on the cardiotropic effect of acetylcholine] Babskaia NE, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):139–41 **(Rus)**

[Antiarrhythmic effect of the antiopioid peptide nociceptin and its effect on fast Na+–channels in cardiomyocytes] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1998 Dec; 126(12):655–7 **(Rus)**

[The use of opiate receptor ligands for correction of heart electrical instability] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):399–401 **(Rus)**

[Effect of opioid peptides from food origins on the cardiotropic components of stress] Sokhanenkova NIu, et al. **Dokl Akad Nauk** 1998 Dec;363(6):839–42 **(Rus)**

[The age–related characteristics of the effect of dimethylsulfoxide on myocardial catalase activity in immobilization stress] Garbuzova VIu, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):62–4 (Eng. Abstr.) **(Rus)**

[The cardiotoxic properties of kordaron in acute myocardial ischemia and infarct] Spasov AA, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):25–30 (Eng. Abstr.) **(Rus)**

[The use of the antioxidant coenzyme Q10 as a cytoprotection variant in ischemic heart disease] Syrkin AL, et al. **Klin Med (Mosk)** 1998;76(7):24–8 **(Rus)**

[An amino acid metabolic complex in optimizing the cardiac hemodynamic characteristics of patients with ischemic heart disease] Berezin AE, et al. **Lik Sprava** 1998 Dec; (8):94–6 (Eng. Abstr.) **(Rus)**

[The subcellular pathophysiology of heart failure due to toxic–allergic myocarditis and the action of refracterin on intracardiac hemodynamics and the functional state of the 3 subcellular cardiomyocyte systems responsible for the act of contraction–relaxation] Karsanov NV, et al. **Patol Fiziol Eksp Ter** 1999 Jul–Sep;(3):3–8 (Eng. Abstr.) **(Rus)**

[The role of cardioxane (ICRF–187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer] Protasov DA, et al. **Vopr Onkol** 1998;44(6):718–21 (Eng. Abstr.) **(Rus)**

[The effect of L–arginine on the ultrastructure of atrial cardiomyocytes in experimental hypercholesterolemia] Stechenko LO, et al. **Fiziol Zh** 1999;45(1–2):72–9 (Eng. Abstr.) **(Ukr)**

[The modulating effect of endothelial relaxing factor on the reactivity of the myocardium and of arterial vascular strips] Zhukova AV. **Fiziol Zh** 1999;45(1–2):64–71 (Eng. Abstr.) **(Ukr)**

EMBRYOLOGY

Increase in beating rate of cultured chick cardiac myocytes by ethanol and inhibition of the increase by antiarrhythmic drugs. Nakamura K, et al. **Alcohol Clin Exp Res** 1999 Apr; 23(4 Suppl):81S–84S

Altered apoptosis levels in hearts of human fetuses with Down syndrome. Saphier CJ, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):962–5

Metabolic and cardiorespiratory responses to hypoxia in fetal sheep: adenosine receptor blockade. Chau A, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1805–11

beta–adrenergic modulation of L–type Ca2+–channel currents in early–stage embryonic mouse heart. Liu W, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H608–13

End–systolic myocardial stiffness is a load–independent index of contractility in stage 24 chick embryonic heart. Tobita K, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2102–8

Immunoreactivity of the ets–1 transcription factor correlates with areas of epithelial–mesenchymal transition in the developing avian heart. Macias D, et al. **Anat Embryol (Berl)** 1998 Oct;198(4):307–15

Ultrastructural study of the sinus venosus in embryos of the dogfish (Scyliorhinus canicula). Ramos C, et al. **Anat Embryol (Berl)** 1998 Dec;198(6):523–36

Lineage and development of the parasympathetic nervous system of the embryonic chick heart. Verberne ME, et al. **Anat Embryol (Berl)** 1998 Sep;198(3):171–84

Dynamic expression of a native chondroitin sulfate epitope reveals microheterogeneity of extracellular matrix organization in the embryonic chick heart. Capehart AA, et al. **Anat Rec** 1999 Feb 1;254(2):181–95

Does the subepicardial mesenchyme contribute myocardioblasts to the myocardium of the chick embryo heart? A quail–chick chimera study tracing the fate of the epicardial primordium. Männer J. **Anat Rec** 1999 Jun 1; 255(2):212–26

Contribution of the cervical sympathetic ganglia to the innervation of the pharyngeal arch arteries and the heart in the chick embryo. Verberne ME, et al. **Anat Rec** 1999 Aug 1;255(4):407–19

An autocrine function for transforming growth factor beta 3 in the atrioventricular endocardial cushion tissue formation during chick heart development. Nakajima Y, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:272–5

Extraembryonic venous obstructions lead to cardiovascular malformations and can be embryolethal. Hogers B, et al. **Cardiovasc Res** 1999 Jan;41(1):87–99

Rate of coronary vascularization during embryonic chicken development is influenced by the rate of myocardial growth. Tomanek RJ, et al. **Cardiovasc Res** 1999 Mar; 41(3):663–71

Modulation of alpha–actin and alpha–actinin proteins in cardiomyocytes by retinoic acid during development. Aránega AE, et al. **Cells Tissues Organs** 1999;164(2):82–9

Downregulation of connexin 45 gene products during mouse heart development. Alcoléa S, et al. **Circ Res** 1999 Jun 25;84(12):1365–79

Embryonic expression suggests an important role for CRP2/SmLIM in the developing cardiovascular system. Jain MK, et al. **Circ Res** 1998 Nov 16;83(10):980–5

Establishment of beta–adrenergic modulation of L–type Ca2+ current in the early stages of cardiomyocyte development. Maltsev VA, et al. **Circ Res** 1999 Feb 5; 84(2):136–45

Myocardial lactate metabolism in fetal and newborn lambs. Bartelds B, et al. **Circulation** 1999 Apr 13;99(14):1892–7

3D computer modeling of human cardiogenesis. Pentecost JO, et al. **Comput Med Imaging Graph** 1999 Jan–Feb; 23(1):45–9

TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial–mesenchymal cell transformation in the embryonic heart. Boyer AS, et al. **Dev Biol** 1999 Apr 15;208(2):530–45

Identification of a novel cardiac lineage–associated protein(cCLP–1): A candidate regulator of cardiogenesis. Ghatpande S, et al. **Dev Biol** 1999 Apr 1;208(1):210–21

Tinman function is essential for vertebrate heart development: elimination of cardiac differentiation by dominant inhibitory mutants of the tinman–related genes, XNkx2–3 and XNkx2–5. Grow MW, et al. **Dev Biol** 1998 Dec 1;204(1):187–96

The role of cell adhesion molecules in Drosophila heart morphogenesis: faint sausage, shotgun/DE–cadherin, and laminin A are required for discrete stages in heart development. Haag TA, et al. **Dev Biol** 1999 Apr 1; 208(1):56–69

Developmentally regulated tissue–associated cues influence axon sprouting and outgrowth and may contribute to target specificity. Harik TM, et al. **Dev Biol** 1999 Aug 15; 212(2):351–65

Retinoid signaling required for normal heart development regulates GATA–4 in a pathway distinct from cardiomyocyte differentiation. Kostetskii I, et al. **Dev Biol** 1999 Feb 15;206(2):206–18

Regulation of avian cardiac myogenesis by activin/TGFbeta and bone morphogenetic proteins. Ladd AN, et al. **Dev Biol** 1998 Dec 15;204(2):407–19

The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Mjaatvedt CH, et al. **Dev Biol** 1998 Oct 1; 202(1):56–66

Slug is a mediator of epithelial–mesenchymal cell transformation in the developing chicken heart. Romano LA, et al. **Dev Biol** 1999 Aug 1;212(1):243–54

Myocardialization of the cardiac outflow tract. van den Hoff MJ, et al. **Dev Biol** 1999 Aug 15;212(2):477–90

Connexin 43 expression reflects neural crest patterns during cardiovascular development. Waldo KL, et al. **Dev Biol** 1999 Apr 15;208(2):307–23

Roles for the winged helix transcription factors MF1 and MFH1 in cardiovascular development revealed by nonallelic noncomplementation of null alleles. Winnier GE, et al. **Dev Biol** 1999 Sep 15;213(2):418–31

Epithelial–mesenchymal transformation in the embryonic heart is mediated through distinct pertussis toxin–sensitive and TGFbeta signal transduction mechanisms. Boyer AS, et al. **Dev Dyn** 1999 Jan;214(1):81–91

WNT11 promotes cardiac tissue formation of early mesoderm. Eisenberg CA, et al. **Dev Dyn** 1999 Sep; 216(1):45–58

Analysis of Hox gene expression during early avian heart development. Searcy RD, et al. **Dev Dyn** 1998 Sep; 213(1):82–91

Hepatocyte growth factor expression in the developing myocardium: evidence for a role in the regulation of the mesenchymal cell phenotype and urokinase expression. Song W, et al. **Dev Dyn** 1999 Jan;214(1):92–100

Production of the transforming growth factor–beta binding protein endoglin is regulated during chick heart development. Vincent EB, et al. **Dev Dyn** 1998 Nov; 213(3):237–47

Stimulation of coronary vasculogenesis/angiogenesis by hypoxia in cultured embryonic hearts. Yue X, et al. **Dev Dyn** 1999 Sep;216(1):28–36

The MADS domain containing transcription factor cMef2a is expressed in heart and skeletal muscle during embryonic chick development. Buchberger A, et al. **Dev Genes Evol** 1999 Jun;209(6):376–81

The homeobox gene Pitx2: mediator of asymmetric left–right signaling in vertebrate heart and gut looping. Campione M, et al. **Development** 1999 Mar;126(6):1225–34

Retinoic acid is required in the mouse embryo for left–right asymmetry determination and heart morphogenesis. Chazaud C, et al. **Development** 1999 Jun;126(12):2589–96

The mammalian Tolloid–like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Clark TG, et al. **Development** 1999 Jun;126(12):2631–42

Vertebrate tinman homologues XNkx2–3 and XNkx2–5 are required for heart formation in a functionally redundant manner. Fu Y, et al. **Development** 1998 Nov; 125(22):4439–49

Tbx5 is essential for heart development. Horb ME, et al. **Development** 1999 Apr;126(8):1739–51

Neurofibromin modulation of ras activity is required for normal endocardial–mesenchymal transformation in the developing heart. Lakkis MM, et al. **Development** 1998 Nov;125(22):4359–67

Control of early cardiac–specific transcription of Nkx2–5 by a GATA–dependent enhancer. Lien CL, et al. **Development** 1999 Jan;126(1):75–84

Identification of upstream regulatory regions in the heart–expressed homeobox gene Nkx2–5. Reecy JM, et al. **Development** 1999 Feb;126(4):839–49

A GATA–dependent nkx–2.5 regulatory element activates early cardiac gene expression in transgenic mice. Searcy RD, et al. **Development** 1998 Nov;125(22):4461–70

The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Tanaka M, et al. **Development** 1999 Mar;126(6):1269–80

Complex modular cis–acting elements regulate expression of the cardiac specifying homeobox gene Csx/Nkx2.5. Tanaka M, et al. **Development** 1999 Apr;126(7):1439–50

Requirement of a novel gene, Xin, in cardiac morphogenesis. Wang DZ, et al. **Development** 1999 Mar;126(6):1281–94

Developmental remodeling and shortening of the cardiac outflow tract involves myocyte programmed cell death. Watanabe M, et al. **Development** 1998 Oct;125(19):3809–20

Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Wu H, et al. **Development** 1999 Aug; 126(16):3597–605

A retinoic acid–inducible transgenic marker of sino–atrial development in the mouse heart. Xavier–Neto J, et al. **Development** 1999 Jun;126(12):2677–87

Abrogation of the Cripto gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Xu C, et al. **Development** 1999 Feb; 126(3):483–94

Gestational age related changes in cardiac dynamics of the fetal baboon. Stark RI, et al. **Early Hum Dev** 1999 Jan;

53(3):219–37

Cyclin–dependent kinase inhibitor expression in human heart failure. A comparison with fetal development [see comments] Burton PB, et al. **Eur Heart J** 1999 Apr; 20(8):604–11. Comment in: Eur Heart J 1999 Apr;20(8):555–7.

Expression of cell–cycle regulators during heart development and failure [editorial; comment] Deprez RH, et al. **Eur Heart J** 1999 Apr;20(8):555–7 (7 ref.). Comment on: Eur Heart J 1999 Apr;20(8):604–11.

Regulation of the L–type Ca2+ channel during cardiomyogenesis: switch from NO to adenylyl cyclase–mediated inhibition. Ji GJ, et al. **FASEB J** 1999 Feb;13(2):313–24

Cardiac specific expression of the green fluorescent protein during early murine embryonic development. Fleischmann M, et al. **FEBS Lett** 1998 Dec 4;440(3):370–6

The orphan nuclear receptor COUP–TFII is required for angiogenesis and heart development. Pereira FA, et al. **Genes Dev** 1999 Apr 15;13(8):1037–49

Ventricular myocardium in control and growth–retarded human fetuses: growth in different tissue compartments and variation with fetal weight, gestational age, and ventricle size. Mayhew TM, et al. **Hum Pathol** 1999 Jun;30(6):655–60

The cardiac neural crest in Ambystoma mexicanum. Bashir NS, et al. **Int J Dev Biol** 1999 May;43(3):269–74

Amphibian embryos as a model system for organ engineering: in vitro induction and rescue of the heart anlage. Grunz H. **Int J Dev Biol** 1999 Jul;43(4):361–4

Computer–aided interactive three–dimensional reconstruction of the embryonic human heart. Whiten S, et al. **J Anat** 1998 Oct;193 (Pt 3):337–45 (13 ref.)

Plakoglobin is essential for myocardial compliance but dispensable for myofibril insertion into adherens junctions. Isac CM, et al. **J Cell Biochem** 1999 Jan 1;72(1):8–15

Functions of c–Jun in liver and heart development. Eferl R, et al. **J Cell Biol** 1999 May 31;145(5):1049–61

The heterotrimeric protein Go is required for the formation of heart epithelium in Drosophila. Frémion F, et al. **J Cell Biol** 1999 May 31;145(5):1063–76

Cre–loxP–mediated inactivation of the alpha6A integrin splice variant in vivo: evidence for a specific functional role of alpha6A in lymphocyte migration but not in heart development [published erratum appears in J Cell Biol 1998 Nov 30;143(5):following 1412] Gimond C, et al. **J Cell Biol** 1998 Oct 5;143(1):253–66

Calreticulin is essential for cardiac development. Mesaeli N, et al. **J Cell Biol** 1999 Mar 8;144(5):857–68

Bone morphogenetic protein–2 acts synergistically with transforming growth factor–beta3 during endothelial–mesenchymal transformation in the developing chick heart. Yamagishi T, et al. **J Cell Physiol** 1999 Jul; 180(1):35–45

Myofibrillogenesis in the developing chicken heart: assembly of Z–disk, M–line and the thick filaments. Ehler E, et al. **J Cell Sci** 1999 May;112 (Pt 10):1529–39

A novel role for cardiac neural crest in heart development. Waldo K, et al. **J Clin Invest** 1999 Jun;103(11):1499–507

Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. Schoenfeld JR, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2269–80

Regulation of voltage–gated K+ channel expression in the developing mammalian myocardium. Nerbonne JM. **J Neurobiol** 1998 Oct;37(1):37–59 (178 ref.)

Expression of the growth arrest genes (GAS and GADD) changes during organogenesis in the rat fetus. Rees WD, et al. **J Nutr** 1999 Aug;129(8):1532–6

Visualization of sulfated glycoconjugates in the chicken embryonic heart by whole–mount alcian blue staining. Wang PR, et al. **J Oral Sci** 1998 Dec;40(4):153–7

Doppler echocardiographic analysis of effects of tribromoethanol anesthesia on cardiac function in the mouse embryo: a comparison with pentobarbital. Huang GY, et al. **Lab Anim Sci** 1998 Apr;48(2):206–9

Evidence that FGF receptor signaling is necessary for endoderm–regulated development of precardiac mesoderm. Zhu X, et al. **Mech Ageing Dev** 1999 Apr 1;108(1):77–85

Novel expression of the goosecoid transcription factor in the embryonic mouse heart. Conway SJ. **Mech Dev** 1999 Mar; 81(1–2):187–91

The RNA–binding protein gene, hermes, is expressed at high levels in the developing heart. Gerber WV, et al. **Mech Dev** 1999 Jan;80(1):77–86

The role of the brachyury gene in heart development and left–right specification in the mouse. King T, et al. **Mech Dev** 1998 Dec;79(1–2):29–37

The pioneer gene, apontic, is required for morphogenesis and function of the Drosophila heart. Su MT, et al. **Mech Dev** 1999 Feb;80(2):125–32

Cell lineage tracing in heart development. Serluca FC, et al. **Methods Cell Biol** 1999;59:359–65 (18 ref.)

Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Ghatpande S, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):93–7 (50 ref.)

Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Lin CR, et al. **Nature** 1999 Sep 16;401(6750):279–82

Perinatal myocardial DNA and protein changes in the lamb: effect of cortisol in the fetus. Rudolph AM, et al. **Pediatr Res** 1999 Aug;46(2):141–6

Ontogeny and regulation of cardiac angiotensin types 1 and 2 receptors during fetal life in sheep. Samyn ME, et al. **Pediatr Res** 1998 Sep;44(3):323–9

Pacing–induced ventricular remodeling in the chick embryonic heart. Sedmera D, et al. **Pediatr Res** 1999 Jun; 45(6):845–52

Excessive microtubules are not responsible for depressed force per cross–bridge in cardiac neural–crest–ablated embryonic chick hearts. Hatcher CJ, et al. **Pflugers Arch** 1999 Aug;438(3):307–13

A regional gradient of cardiac intrinsic rhythmicity depicted in embryonic cultured multiple hearts. Sakai T, et al. **Pflugers Arch** 1998 Dec;437(1):61–9

Development of adrenergic and cholinergic cardiac control in larvae of the African clawed frog Xenopus laevis. Jacobsson A, et al. **Physiol Biochem Zool** 1999 May–Jun; 72(3):328–38

The elastic filament system in myogenesis. Fulton AB. **Rev Physiol Biochem Pharmacol** 1999;138:139–61 (70 ref.)

Requirement of type III TGF–beta receptor for endocardial cell transformation in the heart. Brown CB, et al. **Science** 1999 Mar 26;283(5410):2080–2

Developmental biology. How to get a heart in the right place [news] Vogel G. **Science** 1999 Jul 2;285(5424):23

GATA transcription factors and cardiac development. Charron F, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):85–91 (50 ref.)

Vertebrate tinman homologues and cardiac differentiation. Evans SM. **Semin Cell Dev Biol** 1999 Feb;10(1):73–83 (79 ref.)

Intersecting signalling and transcriptional pathways in Drosophila heart specification. Frasch M. **Semin Cell Dev Biol** 1999 Feb;10(1):61–71 (45 ref.)

Seeking a regulatory roadmap for heart morphogenesis. Harvey RP. **Semin Cell Dev Biol** 1999 Feb;10(1):99–107 (63 ref.)

Embryological basis for cardiac left–right asymmetry. Mercola M. **Semin Cell Dev Biol** 1999 Feb;10(1):109–16 (77 ref.)

Heart developmental biology. Introduction. Mohun TJ, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):59–60

Expression of MEF2 genes during human cardiac development. Iida K, et al. **Tohoku J Exp Med** 1999 Jan; 187(1):15–23

Cardiosensor mice and transcriptional subdomains of the vertebrate heart. Kelly RG, et al. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1–2):3–10 (59 ref.)

HAND proteins: molecular mediators of cardiac development and congenital heart disease. Srivastava D. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1–2):11–8 (42 ref.)

Altered hemodynamics in chick embryos after extraembryonic venous obstruction. Broekhuizen ML, et al. **Ultrasound Obstet Gynecol** 1999 Jun;13(6):437–45

ENZYMOLOGY see MYOCARDIUM/enzymology

GROWTH & DEVELOPMENT

Mouse very low–density lipoprotein receptor (VLDLR): gene structure, tissue–specific expression and dietary and developmental regulation. Tiebel O, et al. **Atherosclerosis** 1999 Aug;145(2):239–51

Influence of age on enzyme activities of pyrimidine metabolism in the chicken heart. Wegelin I, et al. **Biochem Mol Biol Int** 1998 Dec;46(6):1181–9

Preproenkephalin gene expression and [Met5]–enkephalin levels in the developing rat heart. McLaughlin PJ, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):160–7

Localization of annexin VI in the adult and neonatal heart. Luckcuck T, et al. **Cell Biol Int** 1998;22(3):199–205

Lack of regulation in the heart forming region of avian embryos. Ehrman LA, et al. **Dev Biol** 1999 Mar 1; 207(1):163–75

Notochord regulates cardiac lineage in zebrafish embryos. Goldstein AM, et al. **Dev Biol** 1998 Sep 15;201(2):247–52

A subpopulation of apoptosis–prone cardiac neural crest cells targets to the venous pole: multiple functions in heart development? Poelmann RE, et al. **Dev Biol** 1999 Mar 15; 207(2):271–86

Cyclin–dependent kinase inhibitor expression in human heart failure. A comparison with fetal development [see comments] Burton PB, et al. **Eur Heart J** 1999 Apr; 20(8):604–11. Comment in: Eur Heart J 1999 Apr;20(8):555–7.

Regulation of growth in the adult cardiomyocytes. Schlüter KD, et al. **FASEB J** 1999;13 Suppl:S17–22 (42 ref.)

Endothelin–1 induces expression of fetal genes through the interleukin–6 family of cytokines in cardiac myocytes. Saito S, et al. **FEBS Lett** 1999 Jul 30;456(1):103–7

The role of the GH/IGF–I axis for cardiac function and structure. Isgaard J, et al. **Horm Metab Res** 1999 Feb–Mar; 31(2–3):50–4 (62 ref.)

Prolonged L–arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Susic D, et al. **Hypertension** 1999 Jan;33(1 Pt 2):451–5

Cell cycle profiles and expressions of p21CIP1 AND P27KIP1 during myocyte development. Poolman RA, et al. **Int J Cardiol** 1998 Dec 1;67(2):133–42

A post–transcriptional compensatory pathway in heterozygous ventricular myosin light chain 2–deficient mice results in lack of gene dosage effect during normal cardiac growth or hypertrophy. Minamisawa S, et al. **J Biol Chem** 1999 Apr 9;274(15):10066–70

Context–dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx–2.5 and GATA–4. Shiojima I, et al. **J Biol Chem** 1999 Mar 19;274(12):8231–9

Expression of mitogen–activated protein kinase pathways during postnatal development of rat heart. Kim SO, et al. **J Cell Biochem** 1998 Nov 1;71(2):286–301

Changes in calcium uptake rate by rat cardiac mitochondria during postnatal development. Bassani RA, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2013–23

Dynamic left/right regionalisation of endogenous myosin light chain 3F transcripts in the developing mouse heart. Kelly RG, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1067–81

Postnatal development of peptidergic innervation of the canine heart. Kralios FA, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):215–25

Developmental regulation of the translational repressor NAT1 during cardiac development. Pak BJ, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1717–24

Microtubules are needed for dispersal of alpha–myosin heavy chain mRNA in rat neonatal cardiac myocytes. Perhonen M, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1713–22

Beta2–adrenergic receptor overexpression in the developing mouse heart: evidence for targeted modulation of ion channels. An R, et al. **J Physiol (Lond)** 1999 Apr 1;516 (Pt 1):19–30

Coenzyme Q10 supplementation and recovery from ischemia in senescent rat myocardium. Lönnrot K, et al. **Life Sci** 1999;64(5):315–23

Two blood pressure/cardiac mass quantitative trait loci on chromosome 3 in Dahl rats. Cicila GT, et al. **Mamm Genome** 1999 Feb;10(2):112–6

Arteriolar growth in the postnatal rat heart. Heron MI, et al. **Microvasc Res** 1999 Sep;58(2):183–6

Cooperative interaction between GATA–4 and GATA–6 regulates myocardial gene expression. Charron F, et al. **Mol Cell Biol** 1999 Jun;19(6):4355–65

Maturational changes in gene expression for adenine nucleotide translocator isoforms and betaF1–ATPase in rabbit heart. Portman MA, et al. **Mol Genet Metab** 1999 Feb;66(2):75–9

[Experimental–theoretical study of the force–interval relationship in the developing chicken myocardium] Solov'eva OE, et al. **Biofizika** 1999 Mar–Apr;44(2):337–49 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY see MYOCARDIUM/immunology

INJURIES see HEART INJURIES

INNERVATION

Cardiac sympathetic denervation in early stages of amyotrophic lateral sclerosis demonstrated by 123I–MIBG–SPECT. Druschky A, et al. **Acta Neurol Scand** 1999 May;99(5):308–14

Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms. Giubilei F, et al. **Alzheimer Dis Assoc Disord** 1998 Dec;12(4):356–61

Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction. Fallen EL, et al. **Am Heart J** 1999 May;137(5):863–9

Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Burger AJ, et al. **Am J Cardiol** 1999 Sep 15;84(6):687–91

Baroreflex and non–baroreflex modulation of vagal cardiac control after myocardial infarction. Grassi G, et al. **Am J Cardiol** 1999 Sep 1;84(5):525–9

Cardiac sympathetic activity as measured by myocardial 123–I–metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. Lotze U, et al. **Am J Cardiol** 1999 Jun 1;83(11):1548–51

Cardiac positron emission tomography imaging with [11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Vesalainen RK, et al. **Am J Cardiol** 1999 Sep 1;84(5):568–74

Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs. Ma R, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H15–22

Intrinsic neural regulation of the heart in the chronic, conscious dog. Priola DV, et al. **Am J Physiol** 1998 Jun; 274(6 Pt 2):H2074–84

Sensitivity of canine intrinsic cardiac neurons to H2O2 and hydroxyl radical. Thompson GW, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1434–40

Canine intrinsic cardiac neurons involved in cardiac regulation possess NK1, NK2, and NK3 receptors. Thompson GW, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1683–9

Lineage and development of the parasympathetic nervous system of the embryonic chick heart. Verberne ME, et al. **Anat Embryol (Berl)** 1998 Sep;198(3):171–84

Distribution of the Purkinje fibres in the sheep heart. Ansari A, et al. **Anat Rec** 1999 Jan;254(1):92–7

Contribution of the cervical sympathetic ganglia to the innervation of the pharyngeal arch arteries and the heart in the chick embryo. Verberne ME, et al. **Anat Rec** 1999 Aug 1;255(4):407–19

Volatile anesthetics reduce calcium current in parasympathetic neurons from bullfrog hearts. Hirota K, et al. **Anesth Analg** 1999 Jul;89(1):225–9

Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation.

Yeşil M, et al. **Angiology** 1999 Sep;50(9):729–33

Transmyocardial laser revascularization does not denervate the canine heart. Hirsch GM, et al. **Ann Thorac Surg** 1999 Aug;68(2):460–8; discussion 468–9

Differences in heart rate variability between cardioinhibitory and vasodepressor responses to head-up tilt table testing. Guzmán CE, et al. **Arch Med Res** 1999 May–Jun; 30(3):203–11

Anxiety and autonomic flexibility: a cardiovascular approach [corrected and republished article originally printed in Biol Psychol 1998 Mar;47(3):243–63] Friedman BH, et al. **Biol Psychol** 1998 Nov;49(3):303–23

Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission. Serone AP, et al. **Br J Pharmacol** 1999 May;127(1):99–108

Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria. Serone AP, et al. **Br J Pharmacol** 1999 May; 127(2):383–90

Control of negative inotropic vagal preganglionic neurons in the dog: synaptic interactions with substance P afferent terminals in the nucleus ambiguus? Blinder KJ, et al. **Brain Res** 1998 Nov 9;810(1–2):251–6

Negative inotropic vagal preganglionic neurons in the nucleus ambiguus of the cat: neuroanatomical comparison with negative chronotropic neurons utilizing dual retrograde tracers. Blinder KJ, et al. **Brain Res** 1998 Sep 7;804(2):325–30

Evidence for the collateral innervation of the esophagus and the heart from neurons in the compact formation of the nucleus ambiguus of the rat. Cheng SB, et al. **Brain Res** 1999 Jun 19;832(1–2):171–4

Neuropeptide Y (NPY) expression is increased in explanted guinea pig parasympathetic cardiac ganglia neurons. Lynch SW, et al. **Brain Res** 1999 May 8;827(1–2):70–8

A pharmacological and HPLC analysis of the excitatory transmitter of the cardiac ganglion in the heart of the isopod crustacean Bathynomus doederleini. Yazawa T, et al. **Can J Physiol Pharmacol** 1998 Jun;76(6):599–604

Abnormal myocardial adrenergic nerve function in orthostatic hypotension. Nakamura M, et al. **Cardiology** 1998 Dec;90(3):236–8

Parasympathetic tone affects electrocardiographic preconditioning during right coronary angioplasty. Tsuchiya Y, et al. **Cardiology** 1998 Oct;90(2):122–6

Myocardial ischaemia and the cardiac nervous system. Armour JA. **Cardiovasc Res** 1999 Jan;41(1):41–54 (119 ref.)

Acid-evoked currents in cardiac sensory neurons: A possible mediator of myocardial ischemic sensation. Benson CJ, et al. **Circ Res** 1999 Apr 30;84(8):921–8

Cardiac autonomic patterns preceding occasional vasovagal reactions in healthy humans. Furlan R, et al. **Circulation** 1998 Oct 27;98(17):1756–61

Sympathovagal balance: a critical appraisal [letter] Malik M. **Circulation** 1998 Dec 8;98(23):2643–4

Sympathovagal balance: a reappraisal [letter] Malliani A, et al. **Circulation** 1998 Dec 8;98(23):2640–3

Monoamine- and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia. Singh S, et al. **Circulation** 1999 Jan 26;99(3):411–9

Sympathovagal balance [letter] Sleight P, et al. **Circulation** 1998 Dec 8;98(23):2640

The reversibility of cardiac neuronal function after removal of a pheochromocytoma: an I-123 MIBG Scintigraphic Study. Agostini D, et al. **Clin Nucl Med** 1999 Jul; 24(7):514–8

Chronic fatigue syndrome: a hypothesis focusing on the autonomic nervous system. Pagani M, et al. **Clin Sci (Colch)** 1999 Jan;96(1):117–25 (82 ref.)

Developmentally regulated tissue-associated cues influence axon sprouting and outgrowth and may contribute to target specificity. Harik TM, et al. **Dev Biol** 1999 Aug 15; 212(2):351–65

Assessment of gastric neuropathy using electrogastrography in asymptomatic diabetic patients. Correlation with cardiac autonomic neuropathy. Mayaudon H, et al. **Diabetes Metab** 1999 Jun;25(2):138–42

Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Liao D, et al. **Environ Health Perspect** 1999 Jul;107(7):521–5

Influences of bilateral endoscopic transthoracic sympathicotomy on cardiac autonomic nervous activity. Tedoriya T, et al. **Eur J Cardiothorac Surg** 1999 Feb; 15(2):194–8

Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Delahaye N, et al. **Eur J Nucl Med** 1999 Apr; 26(4):416–24

Scintigraphically assessed cardiac sympathetic dysinnervation in poorly controlled type 1 diabetes mellitus: one-year follow-up with improved metabolic control. Muhr-Becker D, et al. **Exp Clin Endocrinol Diabetes** 1999;107(5):306–12

Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Hartmann F, et al. **Heart** 1999 Mar;81(3):262–70

Abnormal cardiac nerve function in syndrome X. Lanza GA. **Herz** 1999 Apr;24(2):97–106 (51 ref.)

Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Sakata K, et al. **Hypertension** 1999 Jun; 33(6):1447–52

Changes of autonomic tone before the onset of paroxysmal atrial fibrillation. Huang JL, et al. **Int J Cardiol** 1998 Oct 30;66(3):275–83

Parasympathetic withdrawal antedates dynamic myocardial ischemia in patients with syndrome X. Lee WL, et al. **Int J Cardiol** 1998 Oct 30;66(3):253–60

Exhaustive endurance training for 6–9 weeks did not induce changes in intrinsic heart rate and cardiac autonomic modulation in female athletes. Uusitalo AL, et al. **Int J Sports Med** 1998 Nov;19(8):532–40

Autonomic nervous system activity and the spontaneous initiation of ventricular tachycardia. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial. Shusterman V, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1891–9

NO-cGMP pathway accentuates the decrease in heart rate caused by cardiac vagal nerve stimulation. Sears CE, et al. **J Appl Physiol** 1999 Feb;86(2):510–6

Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. Choate JK, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2–3):100–8

Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. Darvesh S, et al. **J Auton Nerv Syst** 1998 Jul 15;71(2–3):75–84

Cardiac sympathetic denervation in Ross syndrome demonstrated by MIBG-SPECT. Druschky K, et al. **J Auton Nerv Syst** 1999 May 28;76(2–3):184–7

Expression and physiological actions of neuropeptide Y in guinea pig parasympathetic cardiac ganglia. Kennedy AL, et al. **J Auton Nerv Syst** 1998 Jul 15;71(2–3):190–5

Stellate neurones innervating the rat heart express N, L and P/Q calcium channels. Kukwa W, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):143–51

Right ventricular responses to vagus stimulation of fibers to discrete cardiac regions in dog hearts. Nakano H, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):179–88

Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat. Smith-White MA, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2–3):171–5

Cardiac parasympathetic stimulation via QRS-synchronous low-energy shocks in humans. Friedman PA, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):10–6

Projections of the dorsal motor nucleus of the vagus to cardiac ganglia of rat atria: an anterograde tracing study. Cheng Z, et al. **J Comp Neurol** 1999 Jul 26;410(2):320–41

Diurnal variation of autonomic nervous activity in the rat: investigation by power spectral analysis of heart rate variability. Hashimoto M, et al. **J Electrocardiol** 1999 Apr; 32(2):167–71

Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. Friedman HS, et al. **J Investig Med** 1999 Jul;47(6):293–303

Postnatal development of peptidergic innervation of the canine heart. Kralios FA, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):215–25

In situ and in vitro identification and characterization of cardiac ganglion neurons in the crab, Carcinus maenas. Saver MA, et al. **J Neurophysiol** 1999 Jun;81(6):2964–76

Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. Nakata T, et al. **J Nucl Cardiol** 1998 Nov-Dec;5(6):579–90

Washout of I-123 meta-iodobenzylguanidine for assessing cardiac sympathetic activity with progression of hypertension in Dahl salt-sensitive rats. Takatsu H, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):204–10

Impairment of cardiac neuronal function in acute myocarditis: iodine-123-MIBG scintigraphy study. Agostini D, et al. **J Nucl Med** 1998 Nov;39(11):1841–4

Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging. Estorch M, et al. **J Nucl Med** 1999 Jun;40(6):911–6

PET imaging of oxidative metabolism abnormalities in sympathetically denervated canine myocardium. Hutchins GD, et al. **J Nucl Med** 1999 May;40(5):846–53

Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. Merlet P, et al. **J Nucl Med** 1999 Jun; 40(6):917–23

Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. Sakata K, et al. **J Nucl Med** 1999 Jan;40(1):6–11

Physiological fluctuation of the human left ventricle sympathetic nervous system assessed by iodine-123-MIBG. Sakata K, et al. **J Nucl Med** 1998 Oct;39(10):1667–71

Sympathetic reinnervation demonstrated on serial iodine-123-metaiodobenzylguanidine SPECT images after cardiac transplantation. Toba M, et al. **J Nucl Med** 1998 Nov;39(11):1862–4

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. Toyama T, et al. **J Nucl Med** 1999 Feb;40(2):217–23

Mechanisms of verapamil inhibition of action potential firing in rat intracardiac ganglion neurons. Hogg RC, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1502–8

Bradykinin activates a cross-signaling pathway between sensory and adrenergic nerve endings in the heart: a novel mechanism of ischemic norepinephrine release? Seyedi N, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):656–63

Endogenous bradykinin activates ischaemically sensitive cardiac visceral afferents through kinin B2 receptors in cats. Tjen-A-Looi SC, et al. **J Physiol (Lond)** 1998 Jul 15;510 (Pt 2):633–41

Assessment of cardiac sympathetic regulation by respiratory-related arterial pressure variability in the rat. Yang CC, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):887–96

Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. Yue L, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):385–98

The sympathetic denervation induced by transmyocardial laser revascularization protects the affected tissue [letter; comment] Beranek JT. **J Thorac Cardiovasc Surg** 1999 Feb; 117(2):409. Comment on: J Thorac Cardiovasc Surg 1997 Dec;114(6):883–9; discussion 889–90.

Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Stevens MJ, et al. **Metabolism** 1999 Jan; 48(1):92–101

Hemisphere asymmetry in parasympathetic control of the heart. Wittling W, et al. **Neuropsychologia** 1998 May; 36(5):461–8

Labelling of rat vagal preganglionic neurones by carbocyanine dye DiI applied to the heart. Corbett EK, et al. **Neuroreport** 1999 Apr 26;10(6):1177–81

Clinical significance of denervated but viable myocardium in patients with recanalized acute myocardial infarction. Abe Y, et al. **Nucl Med Commun** 1999 Aug;20(8):727–35

Evaluation of regional cardiac sympathetic innervation in congenital long QT syndrome using 123I-MIBG scintigraphy. Momose M, et al. **Nucl Med Commun** 1998 Oct;19(10):943–51

A "dysautonomic" head-up tilt test pattern in elderly patients with neurocardiogenic syncope. Beck L, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1004–12

Evaluation of direct respiratory modulation of the QT interval variability. Emori T, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):842–8

Association between cardiac autonomic function and coping style in healthy subjects. Ramaekers D, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1546–52

Neurohormonal profile before and after beta-blockade in patients with neurocardiogenic syncope. Roul G, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1020–30

Dual chamber pacing for neurally mediated syncope with a prominent cardioinhibitory component. Shah CP, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):999–1003

Isoproterenol induced cardiovascular hypersensitiviy in nonpheochromocytoma patients with paroxysmal hyperadrenergic symptoms. Yamanouchi Y, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):268–75

Clinical experience with the holmium:YAG laser for transmyocardial laser revascularization and myocardial denervation as a mechanism. Sundt TM 3rd, et al. **Semin Thorac Cardiovasc Surg** 1999 Jan;11(1):19–23

Mechanisms of exercise response in the denervated heart after transplantation. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):1966–9

[Effects of intraventricular and epicardial application of adenosine on electrical activity of medullary PGL neurons] Ma XY, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):504–12 (Eng. Abstr.) **(Chi)**

[Effects of intraventricular injection of adenosine on renal sympathetic nerve activity] Ma XY, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):54–60 (Eng. Abstr.) **(Chi)**

[Progress in the study of actions of cardiac sympathetic nerve] Ma XY, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):341–3 (10 ref.) **(Chi)**

[Development of an analytic standard for evaluating heart rate variability in cardiovascular autonomic neuropathy in diabetes: comparison of short-term spectral analysis with Ewing's standard battery of reflex tests as reference method] Howorka K, et al. **Biomed Tech (Berl)** 1998;43 Suppl:568–9 **(Ger)**

[Fetal sinus bradycardia in the magnetocardiogram as an expression of sympatho-vagal imbalance in the 2nd trimester] Menéndez T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:238–9 **(Ger)**

[Significance of esophagocardiac reflexes for inducing thoracic pain] Holtmann G, et al. **Herz** 1999 Apr; 24(2):154–7 (23 ref.) (Eng. Abstr.) **(Ger)**

[Ictal syncopes. Cardiac sympathetic innervation disorder as the etiology?] Manitius-Robeck S, et al. **Nervenarzt** 1998 Aug;69(8):712–6 (Eng. Abstr.) **(Ger)**

[Cardiac autonomic tone in risk stratification after myocardial infarct: results of a prospective long-term study of 411 consecutive patients] Klingenheben T, et al. **Z Kardiol** 1999 Jun;88(6):400–9 (Eng. Abstr.) **(Ger)**

[Cardiac sympathetic nerve activity in ischemic heart failure] Richardt G, et al. **Z Kardiol** 1998;87 Suppl 2:33–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[The heterogeneity of myocardial sympathetic innervation in normal subjects: an assessment by iodine-123 metaiodobenzylguanidine scintigraphy] D'Alto M, et al. **Cardiologia** 1998 Nov;43(11):1231–6 (Eng. Abstr.) **(Ita)**

[Compromise of the cardiac autonomic nervous system in patients with Fontan-type circulation: preliminary data] Butera G, et al. **G Ital Cardiol** 1999 Mar;29(3):255–60 (Eng.

Abstr.) **(Ita)**

[Usefulness of heart rate variability for evaluating cardiac autonomic nervous function] Ohtsuka K, et al. **Rinsho Byori** 1998 Oct;46(10):1025–9 (Eng. Abstr.) **(Jpn)**

[Electron microscopy of the nervous apparatus of the heart sinoauricular zone in patients with idiopathic syndrome of long Q–T interval] Pavlovich ER. **Arkh Patol** 1998 Jul–Aug;60(4):23–8 (Eng. Abstr.) **(Rus)**

[Clinical and prognostic significance of the degree of delayed ventricular function and vegetative regulation of cardiac rhythm in myocardial infarction patients. Barbarash OL, et al. **Klin Med (Mosk)** 1999;77(2):44–7 (Eng. Abstr.) **(Rus)**

[The pharmacological blockade of the cardiac and gastric enteric ganglia by a new parasympatholytic] Remizov IM, et al. **Fiziol Zh** 1999;45(4):61–8 (Eng. Abstr.) **(Ukr)**

METABOLISM see MYOCARDIUM/metabolism

MICROBIOLOGY

Lyme disease: an active agent in dilated cardiomyopathy? [editorial; comment] Cuffe MS. **Am Heart J** 1999 Aug;138(2 Pt 1):198–9. Comment on: Am Heart J 1999 Aug;138(2 Pt 1):269–72.

Cardiac myocytes of hearts from patients with end-stage dilated cardiomyopathy do not contain Borrelia burgdorferi DNA [see comments] Suedkamp M, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):269–72. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):198–9.

Invasion of aortic and heart endothelial cells by Porphyromonas gingivalis. Deshpande RG, et al. **Infect Immun** 1998 Nov;66(11):5337–43

The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis. Gebbia JA, et al. **J Clin Invest** 1999 Jan;103(1):81–7

Demonstration of Chlamydia pneumoniae in cardiovascular tissues from children with Kawasaki disease. Normann E, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):72–3

PARASITOLOGY

Myocardial parasite persistence in chronic chagasic patients. Añez N, et al. **Am J Trop Med Hyg** 1999 May;60(5):726–32

Polymerase chain reaction amplification of three different Trypanosoma cruzi DNA sequences from human chagasic cardiac tissue. Olivares-Villagómez D, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):563–70

Prevalence of encysted apicomplexans in muscles of raptors. Lindsay DS, et al. **Vet Parasitol** 1999 Jan 28;80(4):341–4

Myocarditis associated with Theileria spp. in calves. Hervás J, et al. **Zentralbl Veterinarmed [B]** 1998 Sep;45(7):401–5

PATHOLOGY see MYOCARDIUM/pathology

PHYSIOLOGY

Volatile anaesthetics reduce adhesion of blood platelets under low-flow conditions in the coronary system of isolated guinea pig hearts. Heindl B, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):995–1003

How to study sympatho-vagal balance in arterial hypertension and the effect of antihypertensive drugs? Presciuttini B, et al. **Acta Cardiol** 1998;53(3):143–52 (67 ref.)

Effects of [Na+]o, [Ca2+]o and cyclopiazonic acid on decline of post-extrasystolic potentiation and twitch kinetics in guinea-pig and human myocardial preparations. Asgrimsson HJ, et al. **Acta Physiol Scand** 1999 Jul; 166(3):195–201

Physiological significance of absolute heart rate variability in postural change. Oida E, et al. **Acta Physiol Scand** 1999 Apr;165(4):421–2

Electrophysiological changes in rat ventricular and atrial myocardium at different stages of experimental diabetes. Pacher P, et al. **Acta Physiol Scand** 1999 May;166(1):7–13

Myoglobin function evaluated in working heart tissue. Gardner JD, et al. **Adv Exp Med Biol** 1998;454:509–17

Efficiency of skeletal and cardiac muscle. Gibbs CL, et al. **Adv Exp Med Biol** 1998;453:527–35; discussion 535–6

Optimizing the oxygen balance during initial reperfusion with 2,3-butanedione monoxime attenuates cardiac reperfusion injury. Habazettl H, et al. **Adv Exp Med Biol** 1998; 454:543–50

Work production and work absorption in muscle strips from vertebrate cardiac and insect flight muscle fibers. Maughan D, et al. **Adv Exp Med Biol** 1998;453:471–80 (9 ref.)

Prior preconditioning by ischemia or sevoflurane improves cardiac work per oxygen use in isolated guinea pig hearts after global ischemia. Novalija E, et al. **Adv Exp Med Biol** 1998;454:533–42

Ramp-rate dependent external work during ramp-load release in cardiac muscle. Okuyama H, et al. **Adv Exp Med Biol** 1998;453:515–25; discussion 525–6

Cross-bridge dynamics in the contracting heart. Peterson JN, et al. **Adv Exp Med Biol** 1998;453:117–23; discussion 123–4

Distinct kinetic properties of cardiac myosin isoforms revealed by in vitro studies. Sugiura S, et al. **Adv Exp Med Biol** 1998;453:125–30

Regulation of contraction in heart muscle. A Ca2+ gradient model for the Ca(2+)-induced Ca(2+)-release of the sarcoplasmic reticulum. Tameyasu T. **Adv Exp Med Biol** 1998;453:209–17; discussion 217–8

Response time of myocardial oxygen consumption to cardiac work jumps at 28 degrees C varies with exogenous carbon substrate. Tian X, et al. **Adv Exp Med Biol** 1998;454:501–8

Vascular endothelial cell–cardiac myocyte crosstalk in achieving a balance between energy supply and energy use. Winegrad S, et al. **Adv Exp Med Biol** 1998;453:507–14 (18 ref.)

Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure. Anzai T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1267–73

Electrophysiological mechanisms by which hypothyroidism delays repolarization in guinea pig hearts. Bosch RF, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H211–20

Effects of sympathetic nerve stimulation on membrane potential, [Ca2+]i, and force in the toad sinus venosus. Bramich NJ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H115–28

Effect of serum and mechanical stretch on skeletal alpha-actin gene regulation in cultured primary muscle cells. Carson JA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):C1438–48

Nonuniform responses of transmembrane potential during electric field stimulation of single cardiac cells. Cheng DK, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H351–62

Parasympathetic modulation of sinoatrial node pacemaker activity in rabbit heart: a unifying model. Demir SS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2221–44

The effects of mannitol, albumin, and cardioplegia enhancers on 24-h rat heart preservation. Dunphy G, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1591–8

What is the role of the AV node if the AV delay occurs before it? [letter; comment] Efimov IR. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1905–6; discussion H1906–9. Comment on: Am J Physiol 1998 Mar;274(3 Pt 2):H829–45.

Correlation of ventricular mechanosensory neurite activity with myocardial sensory field deformation. Foreman RD, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R979–89

Endocardial endothelium mediates luminal ACh-NO signaling in isolated frog heart. Gattuso A, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H633–41

Contamination of lymph from the major prenodal cardiac lymphatic in dogs. Geissler HJ, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1795–800

Rabbit polymorphonuclear leukocytes release a factor that causes constriction of the coronary vasculature. Hart-Favaloro JL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1322–8

Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Iaccarino G, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1298–306

Effects of isoflurane on [Ca2+]i, SR Ca2+ content, and twitch force in intact trabeculae. Jiang Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1360–9

Cardiac- and noncardiac-related coherence between sympathetic drives to muscles of different human limbs. Kocsis B, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1608–16

Evidence for increased cardiac compliance during exposure to simulated microgravity. Koenig SC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1343–52

High-density epicardial mapping during current injection and ventricular activation in rat hearts. Macchi E, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1886–97

Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Marrero MB, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):C1216–23

Cardiac performance and creatine kinase flux during inhibition of ATP synthesis in the perfused rat heart. Mateo P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H308–17

Ecto-5'-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. Miki T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1329–37

Heat acclimation induces changes in cardiac mechanical performance: the role of thyroid hormone. Mirit E, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R550–8

Mechanical activity in heart regulates translation of alpha-myosin heavy chain mRNA but not its localization. Nikcevic G, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2013–9

Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Pemberton CJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1200–8

Induction of 72-kDa heat shock protein does not produce second window of ischemic preconditioning in rat heart. Qian YZ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H224–34

Comparison of putative cooperative mechanisms in cardiac muscle: length dependence and dynamic responses. Rice JJ, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1734–54

Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Ritchie RH, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1370–4

Differential depression of myocardial function and metabolism by lactate and H+. Samaja M, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H3–8

Insulin action on heart and skeletal muscle glucose uptake in weight lifters and endurance athletes. Takala TO, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E706–11

Acute exercise can improve cardioprotection without increasing heat shock protein content. Taylor RP, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H1098–102

Canine intrinsic cardiac neurons involved in cardiac regulation possess NK1, NK2, and NK3 receptors. Thompson GW, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1683–9

Cardiovascular afferent signals and drinking in response to hypotension in dogs. Thrasher TN, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R795–801

Interaction between carotid baroregulation and the pulsating heart: a mathematical model. Ursino M. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1733–47

Electrical interactions among real cardiac cells and cell models in a linear strand. Wagner MB, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H391–400

Relation between activation sequence fluctuation and arrhythmogenicity in sodium-channel blockades. Watanabe T, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H971–7

Differential effects of ovariectomy on calcium activation of cardiac and soleus myofilaments. Wattanapermpool J, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H467–73

Oxygen delivery does not limit cardiac performance during high work states. Zhang J, et al. **Am J Physiol** 1999 Jul; 277(1 Pt 2):H50–7

Cardiopulmonary effects of bilateral hemithorax ventilation and diagnostic thoracoscopy in dogs. Faunt KK, et al. **Am J Vet Res** 1998 Nov;59(11):1494–8

Nitric oxide mediates either proliferation or cell death in cardiomyocytes. Involvement of polyamines. Pignatti C, et al. **Amino Acids** 1999;16(2):181–90

A fluorometric assay for cyclic guanosine 3',5'-monophosphate incorporating a Sep-Pak cartridge and enzymatic cycling. Seya K, et al. **Anal Biochem** 1999 Aug 1;272(2):243–9

In situ fiber-optic oxygen consumption measurements from a working mouse heart. Zhao Y, et al. **Anal Chem** 1999 Sep 1;71(17):3887–93

Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Bittner RE, et al. **Anat Embryol (Berl)** 1999 May;199(5):391–6

Gas tensions in cardiac lymph as a reflection of the interstitial space of the heart. Palmer AS, et al. **Angiology** 1998 Sep; 49(9):735–41

Influence of anisotropy on local and global measures of potential gradient in computer models of defibrillation. Eason J, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):840–9

Influence of gravity on cardiac performance. Pantalos GM, et al. **Ann Biomed Eng** 1998 Nov-Dec;26(6):931–43

Optimization of cardiac fiber orientation for homogeneous fiber strain during ejection. Rijcken J, et al. **Ann Biomed Eng** 1999 May-Jun;27(3):289–97

Myocardial response to disease, hormones and training. Proceedings of the XII Paavo Nurmi Symposium. Porvoo, Finland, June 1997. **Ann Med** 1998 Aug;30 Suppl 1:1–65

Coordinated role of vasoactive intestinal peptide and nitric oxide in cardioprotection. Das DK, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:297–308

Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Kumar D, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:156–68

Na+/H+ exchangers. Molecular diversity and relevance to heart. Orlowski J. **Ann N Y Acad Sci** 1999 Jun 30; 874:346–53 (81 ref.)

Cardiovascular actions of galanin. Potter E. **Ann N Y Acad Sci** 1998 Dec 21;863:170–4

A meta-analysis of published studies concerning the validity of thoracic impedance cardiography. Raaijmakers E, et al. **Ann N Y Acad Sci** 1999 Apr 20;873:121–7

Cardiopulmonary response to maximal exercise in young athletes following the Ross procedure. Oury JH, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S153–4

Modulation of coronary perfusion pressure can reverse cardiac dysfunction after brain death. Szabó G, et al. **Ann Thorac Surg** 1999 Jan;67(1):18–25; discussion 25–6

Correlation between heart rate variability and hypothermic storage in human cardiac transplant recipients. Biernat M, et al. **Ann Transplant** 1998;3(4):37–40

Impairment of cardiac performance by laparoscopy in patients receiving positive end-expiratory pressure. Kraut EJ, et al. **Arch Surg** 1999 Jan;134(1):76–80

Detection of the cardiac function by fractal dimension analysis. Yambe T, et al. **Artif Organs** 1999 Aug;23(8):751–6

Female exposure to high G: echocardiographic evaluation for chronic changes in cardiac function. Albery WB, et al. **Aviat Space Environ Med** 1998 Sep;69(9):857–61

Echocardiographic evaluation of female centrifuge subjects for chronic changes in cardiac function. Albery WB. **Aviat Space Environ Med** 1999 Jun;70(6):561–4

The intracellular Ca(2+)-homeostasis influences the frequency-dependent force-generation in man. Brixius K, et al. **Basic Res Cardiol** 1999 Jun;94(3):152–8

Variation in tau, the time constant for isovolumic relaxation, along the left ventricular base-to-apex axis. Davis KL, et al. **Basic Res Cardiol** 1999 Feb;94(1):41–8

Characterisation of the function of adult guinea-pig ventricular myocytes following co-culture with neonatal rat myocytes. Kent NS, et al. **Basic Res Cardiol** 1999 Feb; 94(1):9–14

Calcium-sensitivity of the SR calcium release channel in failing and nonfailing human myocardium. Schotten U, et al. **Basic Res Cardiol** 1999 Jun;94(3):145–51

Human cardiac fibroblasts and receptors for angiotensin II and bradykinin: a potential role for bradykinin in the modulation of cardiac extracellular matrix. Villarreal FJ, et al. **Basic Res Cardiol** 1998;93 Suppl 3:4–7

Adult KCNE1-knockout mice exhibit a mild cardiac cellular phenotype. Charpentier F, et al.

Biochem Biophys Res Commun 1998 Oct 29;251(3):806–10
Modulation of cardiac Ca2+ channels by IGF1. Solem ML, et al. **Biochem Biophys Res Commun** 1998 Nov 9; 252(1):151–5
Inhibition of crossbridge function in the normal human heart by hypoxic endothelial superfusate. Zacharzowsky UB, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):64–7
Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes. Stefanelli C, et al. **Biochim Biophys Acta** 1999 Jul 8;1450(3):406–13
Coenzyme Q10 improves the tolerance of the senescent myocardium to aerobic and ischemic stress: studies in rats and in human atrial tissue. Rosenfeldt FL, et al. **Biofactors** 1999;9(2–4):291–9
Mutations in the EF-hand motif impair the inactivation of barium currents of the cardiac alpha1C channel. Bernatchez G, et al. **Biophys J** 1998 Oct;75(4):1727–39
Inactivation of single cardiac Na+ channels in three different gating modes. Böhle T, et al. **Biophys J** 1998 Oct; 75(4):1740–8
Role of mitochondria in calcium regulation of spontaneously contracting cardiac muscle cells. Bowser DN, et al. **Biophys J** 1998 Oct;75(4):2004–14
Analysis of the mechanisms of mitochondrial NADH regulation in cardiac trabeculae. Brandes R, et al. **Biophys J** 1999 Sep;77(3):1666–82
Shape, size, and distribution of Ca(2+) release units and couplons in skeletal and cardiac muscles. Franzini-Armstrong C, et al. **Biophys J** 1999 Sep; 77(3):1528–39
Roles of electric field and fiber structure in cardiac electric stimulation. Knisley SB, et al. **Biophys J** 1999 Sep; 77(3):1404–17
Structural determinants of slow inactivation in human cardiac and skeletal muscle sodium channels. Vilin YY, et al. **Biophys J** 1999 Sep;77(3):1384–93
Effect of isoproterenol on the L-type Ca2+ current in cardiac cells from rats and hybernating ground squirrels. Kokoz YuM, et al. **Biosci Rep** 1999 Feb;19(1):17–25
Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline. Jones SE, et al. **Br J Pharmacol** 1998 Nov;125(6):1138–43
Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Wang H, et al. **Br J Pharmacol** 1999 Apr; 126(8):1725–34
Histamine H1-receptor-mediated increase in the Ca2+ transient without a change in the Ca2+ current in electrically stimulated guinea-pig atrial myocytes. Yoshimoto K, et al. **Br J Pharmacol** 1998 Aug; 124(8):1744–50
Echocardiographic examination of cardiac structure and function in elite cross trained male and female Alpine skiers. George KP, et al. **Br J Sports Med** 1999 Apr;33(2):93–8; discussion 99
Hemisphere asymmetry in sympathetic control of the human myocardium. Wittling W, et al. **Brain Cogn** 1998 Oct; 38(1):17–35
Rest-injected 201thallium in the evaluation of myocardial viability. Perrone-Filardi P, et al. **Cardiologia** 1999 Jun; 44(6):515–20 (31 ref.)
Regional differences in the delayed rectifier current (IKr and IKs) contribute to the differences in action potential duration in basal left ventricular myocytes in guinea-pig [see comments] Bryant SM, et al. **Cardiovasc Res** 1998 Nov; 40(2):322–31. Comment in: Cardiovasc Res 1998 Nov;40(2):248–50.
Cardiovascular phenotyping in mice. Doevendans PA, et al. **Cardiovasc Res** 1998 Jul;39(1):34–49 (125 ref.)
Coenzyme Q10 treatment improves the tolerance of the senescent myocardium to pacing stress in the rat. Rowland MA, et al. **Cardiovasc Res** 1998 Oct;40(1):165–73
Physio-pharmacological evaluation of myocardial performance: an integrative approach. Shah AM, et al. **Cardiovasc Res** 1998 Jul;39(1):148–54 (85 ref.)
Physiopharmacological evaluation of myocardial performance: how to study modulation by cardiac endothelium and related humoral factors? Sys SU, et al. **Cardiovasc Res** 1998 Jul;39(1):136–47 (83 ref.)
Is the slowly activating component of the delayed rectifier current, IKs' absent from undiseased human ventricular myocardium? [editorial; comment] Veldkamp MW. **Cardiovasc Res** 1998 Dec;40(3):433–5 (38 ref.). Comment on: Cardiovasc Res 1998 Dec;40(3):508–15.
Real time in situ confocal imaging of calcium wave in the perfused whole heart of the rat. Hama T, et al. **Cell Signal** 1998 May;10(5):331–7
Relation between spontaneous contraction and sarcoplasmic reticulum function in cultured neonatal rat cardiac myocytes. Kimura H, et al. **Cell Signal** 1998 May; 10(5):349–54
The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Dostal DE, et al. **Circ Res** 1999 Oct 1;85(7):643–50 (94 ref.)
Overexpression of the sarcolemmal calcium pump in the myocardium of transgenic rats [see comments] Hammes A, et al. **Circ Res** 1998 Nov 2;83(9):877–88. Comment in: Circ Res 1998 Nov 2;83(9):966–8.
Calcium pump overexpression and myocardial function. Implications for gene therapy of myocardial failure [editorial; comment] Hasenfuss G. **Circ Res** 1998 Nov 2; 83(9):966–8. Comment on: Circ Res 1998 Nov 2;83(9):877–88. Comment on: Circ Res 1998 Nov 2;83(9):889–97.
Mechanically driven contour-length adjustment in rat cardiac titin's unique N2B sequence: titin is an adjustable spring. Helmes M, et al. **Circ Res** 1999 Jun 11; 84(11):1339–52
Manipulation of cellular excitability by cell fusion: effects of rapid introduction of transient outward K+ current on the guinea pig action potential. Hoppe UC, et al. **Circ Res** 1999 Apr 30;84(8):964–72
Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency [see comments] Huang X, et al. **Circ Res** 1999 Jan 8–22;84(1):1–8. Comment in: Circ Res 1999 Jan 8–22;84(1):122–4.
Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Ing DJ, et al. **Circ Res** 1999 Jan 8–22;84(1):21–33
Slow conduction in cardiac tissue, I: effects of a reduction of excitability versus a reduction of electrical coupling on microconduction. Rohr S, et al. **Circ Res** 1998 Oct 19; 83(8):781–94
Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene. Schaap FG, et al. **Circ Res** 1999 Aug 20;85(4):329–37
Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Xiao RP, et al. **Circ Res** 1999 Jan 8–22;84(1):43–52
Hemodynamic effects of direct biventricular compression studied in isovolumic and ejecting isolated canine hearts. Artrip JH, et al. **Circulation** 1999 Apr 27;99(16):2177–84
New insight into the role of enhanced adrenergic receptor–effector coupling in the heart [editorial; comment] Feldman AM, et al. **Circulation** 1999 Aug 10;100(6):579–82 . Comment on: Circulation 1999 Aug 10;100(6):648–53.
Opening of potassium channels: the common cardioprotective link between preconditioning and natural hibernation? Kevelaitis E, et al. **Circulation** 1999 Jun 15; 99(23):3079–85
Sympathovagal balance: a critical appraisal [letter] Malik M. **Circulation** 1998 Dec 8;98(23):2643–4
Sympathovagal balance: a reappraisal [letter] Malliani A, et al. **Circulation** 1998 Dec 8;98(23):2640–3
Vagal cardiopulmonary reflexes after total cardiac deafferentation. Minisi AJ. **Circulation** 1998 Dec 8; 98(23):2615–20
Sympathovagal balance [letter] Sleight P, et al. **Circulation** 1998 Dec 8;98(23):2640
Is the antiarrhythmic effects of PA related to wavelength? [letter; comment] Tribulova N, et al. **Circulation** 1999 Apr 27;99(16):2220–1. Comment on: Circulation 1998 May 12;97(18):1828–36.
Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. Viswanathan PC, et al. **Circulation** 1999 May 11; 99(18):2466–74
Signaling pathways in reactive oxygen species–induced cardiomyocyte apoptosis. von Harsdorf R, et al. **Circulation** 1999 Jun 8;99(22):2934–41
Transient outward current, Ito1, is altered in cardiac memory. Yu H, et al. **Circulation** 1999 Apr 13; 99(14):1898–905
Paradoxical behavior of the QT interval during exercise and recovery and its relationship with cardiac memory. Moleiro F, et al. **Clin Cardiol** 1999 Jun;22(6):413–6
Metabolic and functional effects of carbachol and ischaemic preconditioning in rat isolated heart. Pisarenko OI, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):26–31
Exercise cardiac function in endurance-trained males versus females. Wiebe CG, et al. **Clin J Sport Med** 1998 Oct; 8(4):272–9
Both leg blood flow and the femoral blood flow pattern are related to left ventricular mass in elderly men. Lind L, et al. **Clin Physiol** 1999 May;19(3):275–6
Left ventricular geometry and function are related to electrocardiographic characteristics and diagnoses. Sundström J, et al. **Clin Physiol** 1998 Sep;18(5):463–70
Non-linear cardiac dynamics and morning dip: an unsound circadian rhythm. Yum MK, et al. **Clin Physiol** 1999 Jan; 19(1):56–67
Fractal dimension and approximate entropy of heart period and heart rate: awake versus sleep differences and methodological issues. Yeragani VK, et al. **Clin Sci (Colch)** 1998 Sep;95(3):295–301
Electrocardiographic consequences of a peripatetic lifestyle in gray wolves (Canis lupus). Constable P, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):557–63
Wavelength dependence of the optically recorded action potentials in guinea pig atrial muscles. Fujishiro N, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Feb; 122(2):235–40
Inter and intra-species-related differences in the regulation of the cardiac autonomic system. León-Velarde F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):819–23
An interactive 3D anisotropic cellular automata model of the heart. Siregar P, et al. **Comput Biomed Res** 1998 Oct; 31(5):323–47
Quantification of the local heartwall motion by magnetic resonance myocardial tagging. Stuber M, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):217–28
The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Bi W, et al. **Dev Biol** 1999 Jul 15;211(2):255–67
Ectopic expression of tropomyosin promotes myofibrillogenesis in mutant axolotl hearts. Zajdel RW, et al. **Dev Dyn** 1998 Dec;213(4):412–20
Effect of selenium deficiency on cardiac function of individuals with severe disabilities under long-term tube feeding [published erratum appears in Dev Med Child Neurol 1999 Feb;41(2):inside back cover] Saito Y, et al. **Dev Med Child Neurol** 1998 Nov;40(11):743–8
Cardiorespiratory stability of premature boys and girls during kangaroo care. Fischer CB, et al. **Early Hum Dev** 1998 Sep;52(2):145–53
Body position, sleep states, and cardiorespiratory activity in developing low birth weight infants. Sahni R, et al. **Early Hum Dev** 1999 Apr;54(3):197–206
Gestational age related changes in cardiac dynamics of the fetal baboon. Stark RI, et al. **Early Hum Dev** 1999 Jan; 53(3):219–37
Altered cardiac phenotype in transgenic mice carrying the delta337 threonine thyroid hormone receptor beta mutant derived from the S family. Gloss B, et al. **Endocrinology** 1999 Feb;140(2):897–902
The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Liu LS, et al. **Endocrinology** 1998 Nov;139(11):4531–9
Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Ojamaa K, et al. **Endocrinology** 1999 Jul;140(7):3170–6
The Denolin Lecture 1998. Towards measurement of coronary blood flow in patients and its alteration by interventions. Rutishauser W. **Eur Heart J** 1999 Aug; 20(15):1076–83 (43 ref.)
Effects of interval training at the ventilatory threshold on clinical and cardiorespiratory responses in elderly humans. Ahmaidi S, et al. **Eur J Appl Physiol** 1998 Jul;78(2):170–6
Influence of intact left atrial appendage on hemodynamic parameters of isolated guinea pig heart. Massoudy P, et al. **Eur J Med Res** 1998 Oct 14;3(10):470–4
Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Cheng J, et al. **Eur J Pharmacol** 1999 Jul 2; 376(1–2):189–201
9-Methyl-7-bromoeudistomin D induces Ca2+ release from cardiac sarcoplasmic reticulum. Seino-Umeda A, et al. **Eur J Pharmacol** 1998 Sep 18;357(2–3):261–5
The role of nitric oxide in the control by the vagal nerves of the heart of the ferret. Conlon K, et al. **Exp Physiol** 1998 Jul;83(4):469–80
Cardiac electrophysiological effects of platelet-derived substances. Flores NA, et al. **Exp Physiol** 1999 Mar; 84(2):253–74 (165 ref.)
Cardiac function and morphology studied by two-dimensional Doppler echocardiography in unsedated newborn pigs. Fugelseth D, et al. **Exp Physiol** 1999 Jan; 84(1):69–78
Mechanically induced potentials in fibroblasts from human right atrium. Kamkin A, et al. **Exp Physiol** 1999 Mar; 84(2):347–56
Regional differences in action potential characteristics and membrane currents of guinea-pig left ventricular myocytes. Main MC, et al. **Exp Physiol** 1998 Nov;83(6):747–61
Regulation of the L-type Ca2+ channel during cardiomyogenesis: switch from NO to adenylyl cyclase-mediated inhibition. Ji GJ, et al. **FASEB J** 1999 Feb;13(2):313–24
Possible involvement of [Ca2+]i level in the modulation of the current-voltage relationship for the fast Na+ current in late embryonic chick cardiomyocytes. Satoh H. **Gen Pharmacol** 1999 Mar;32(3):335–9
Computerised measurements of QT dispersion in healthy subjects. Gang Y, et al. **Heart** 1998 Nov;80(5):459–66
Normal long axis function [editorial] Henein MY, et al. **Heart** 1999 Feb;81(2):111–3
Change in cardiac diastolic function in neonates. Ichihashi K, et al. **Heart Vessels** 1997;12(5):216–20
The role of the GH/IGF-I axis for cardiac function and structure. Isgaard J, et al. **Horm Metab Res** 1999 Feb-Mar; 31(2–3):50–4 (62 ref.)
Hypertrophic responses of cardiomyocytes induced by endothelin-1 through the protein kinase C-dependent but Src and Ras-independent pathways. Yamazaki T, et al. **Hypertens Res** 1999 Jul;22(2):113–9
Thermoregulatory and cardiac responses of infant spontaneously hypertensive and Wistar-Kyoto rats to cold exposure. Kirby RF, et al. **Hypertension** 1999 Jun; 33(6):1465–9
Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. LaPointe MC, et al. **Hypertension** 1999 Jan;33(1 Pt 2):276–82
The forward and inverse problems of electrocardiography. Gulrajani RM. **IEEE Eng Med Biol Mag** 1998 Sep-Oct; 17(5):84–101, 122 (109 ref.)
New systems--analytical approaches to nonlinear coordination. Hoyer D, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):58–61
Nonlinear dynamics of the cardiorespiratory system [editorial] Hoyer D. **IEEE Eng Med Biol Mag** 1998

Nov-Dec;17(6):16
Nonlinear coordination of cardiovascular autonomic control. Hoyer D, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec; 17(6):17-21 (24 ref.)
Determinism in bivariate cardiorespiratory phase-space sets. Hoyer D, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec; 17(6):26-31
Detecting nonlinearity and phase synchronization with surrogate data. Palus M, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):40-5
Using mutual information to measure coupling in the cardiorespiratory system. Pompe B, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):32-9
Synchronization in noisy systems and cardiorespiratory interaction. Rosenblum MG, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):46-53
Analyzing entrainment of heartbeat and respiration with surrogates. Seidel H, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):54-7
Electrophysiologic models of heart cells and cell networks. Thakor NV, et al. **IEEE Eng Med Biol Mag** 1998 Sep-Oct; 17(5):73-83 (61 ref.)
Membrane polarization induced in the myocardium by defibrillation fields: an idealized 3-D finite element bidomain/monodomain torso model. Huang Q, et al. **IEEE Trans Biomed Eng** 1999 Jan;46(1):26-34
Electrical stimulation of cardiac tissue by a bipolar electrode in a conductive bath. Latimer DC, et al. **IEEE Trans Biomed Eng** 1998 Dec;45(12):1449-58
MCG simulations with a realistic heart-torso model. Ramon C, et al. **IEEE Trans Biomed Eng** 1998 Nov;45(11):1323-31
Influence of electrical coupling on early afterdepolarizations in ventricular myocytes. Saiz J, et al. **IEEE Trans Biomed Eng** 1999 Feb;46(2):138-47
Propagation in cardiac tissue adjacent to connective tissue: two-dimensional modeling studies. Street AM, et al. **IEEE Trans Biomed Eng** 1999 Jan;46(1):19-25
Analysis of defibrillation efficacy from myocardial voltage gradients with finite element modeling. Wang Y, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1025-36
Verapamil and TTX inhibit +Vmax but differentially alter the duration of action potential of adult chicken ventricular myocardium. Prakash P, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):123-30
Mammalian coronary perfusion--an improved laboratory device. Nayeem M. **Indian J Exp Biol** 1998 Sep;36(9):938-9
Dicrotic notch in females [letter] Hussain S, et al. **Indian J Physiol Pharmacol** 1998 Jul;42(3):421-2
Cardiac nociception induced rectal response: relation with haemodynamic changes. Koley J, et al. **Indian J Physiol Pharmacol** 1998 Apr;42(2):259-65
Heart development and function before birth [editorial] Thornburg KL, et al. **Indian Pediatr** 1998 May;35(5):409-13 (18 ref.)
Different left ventricular relaxation parameters in isolated working rat and guinea pig hearts. Influence of preload, afterload, temperature, and isoprenaline. Langer SF, et al. **Int J Card Imaging** 1998 Aug;14(4):229-40
Effects of exercise on natriuretic peptides and cardiac function in man [see comments] Barletta G, et al. **Int J Cardiol** 1998 Aug;65(3):217-25. Comment in: Int J Cardiol 1998 Nov 30;67(1):87.
Coronary blood flow velocity during apical versus septal pacing. Kolettis TM, et al. **Int J Cardiol** 1998 Sep 30; 66(2):203-5
US weight guidelines: is it also important to consider cardiorespiratory fitness? Lee CD, et al. **Int J Obes Relat Metab Disord** 1998 Aug;22 Suppl 2:S2-7
Influence of diet and/or exercise on body composition and cardiorespiratory fitness in obese women. Utter AC, et al. **Int J Sport Nutr** 1998 Sep;8(3):213-22
Effect of "living high-training low" on the cardiac functions at sea level. Liu Y, et al. **Int J Sports Med** 1998 Aug; 19(6):380-4
Cardiac responses to exercise in child distance runners. Rowland T, et al. **Int J Sports Med** 1998 Aug;19(6):385-90
Cardiopulmonary exercise testing in the pre-operative assessment of patients for repair of abdominal aortic aneurysm. Nugent AM, et al. **Ir J Med Sci** 1998 Oct-Dec; 167(4):238-41
The influence of age and gender on heart rate variability (HRV) [letter; comment] Ramaekers D, et al. **J Am Coll Cardiol** 1999 Mar;33(3):900-2. Comment on: J Am Coll Cardiol 1998 Mar 1;31(3):593-601.
Noninvasive assessment of the cardiac baroreflex: response to downward tilting and comparison with the phenylephrine method. Takahashi N, et al. **J Am Coll Cardiol** 1999 Jul;34(1):211-5
Effect of endogenous angiotensin II on renal nerve activity and its cardiac baroreflex regulation. Dibona GF, et al. **J Am Soc Nephrol** 1998 Nov;9(11):1983-9
Wall thickness referenced to myocardial volume: a new noninvasive framework for cardiac mechanics. Denslow S, et al. **J Appl Physiol** 1999 Jul;87(1):211-21
Influence of increased abdominal pressure on steady-state cardiac performance. Kitano Y, et al. **J Appl Physiol** 1999 May;86(5):1651-6
Beat-to-beat modulation of heart rate is coupled to coronary perfusion pressure in the isolated heart. Slovut DP, et al. **J Appl Physiol** 1999 Feb;86(2):694-700
Effect of endurance training on cardiac morphology in Alaskan sled dogs. Stepien RL, et al. **J Appl Physiol** 1998 Oct;85(4):1368-75
Comparison of cardiorespiratory reflexes in NK1 receptor knockout, heterozygous and wild-type mice in vivo. Butcher JW, et al. **J Auton Nerv Syst** 1998 Apr 30; 69(2-3):89-95
Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. Choate JK, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):100-8
Neuronal nitric oxide facilitates vagal chronotropic and dromotropic actions on the heart. Conlon K, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):136-46
Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity. Darvesh S, et al. **J Auton Nerv Syst** 1998 Jul 15;71(2-3):75-84
Effects of mental stress on cardiac and motor rhythms. Murata J, et al. **J Auton Nerv Syst** 1999 Jan 15;75(1):32-7
Nitric oxide modulates sympathetic control of left ventricular contraction in vivo in the dog. Takita T, et al. **J Auton Nerv Syst** 1998 Jul 15;71(2-3):69-74
Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo. Chu G, et al. **J Biol Chem** 1998 Dec 11;273(50):33674-80
Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. Colecraft HM, et al. **J Biol Chem** 1998 Nov 27;273(48):32158-66
Regulation of energy metabolism of the heart during acute increase in heart work. Goodwin GW, et al. **J Biol Chem** 1998 Nov 6;273(45):29530-9
G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling. Kuschel M, et al. **J Biol Chem** 1999 Jul 30;274(31):22048-52
Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2+) channel in transgenic mice. Loss of isoproterenol-induced contraction. Muth JN, et al. **J Biol Chem** 1999 Jul 30; 274(31):21503-6
A distribution-moment model of deactivation in cardiac muscle. Guccione JM, et al. **J Biomech** 1998 Nov; 31(11):1069-73
Variation of arterial compliance within the cardiac pressure pulse. MacWilliams BA, et al. **J Biomech** 1998 Sep; 31(9):867-71
The effects of cross-fiber deformation on axial fiber stress in myocardium. Zahalak GI, et al. **J Biomech Eng** 1999 Aug;121(4):376-85
The relationship between cardiac function and neuropsychological status among heart transplant candidates. Putzke JD, et al. **J Card Fail** 1998 Dec; 4(4):295-303
Effects of electroporation on the transmembrane potential distribution in a two-dimensional bidomain model of cardiac tissue. Aguel F, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):701-14
Differential effects of cytochalasin D and 2,3 butanedione monoxime on isometric twitch force and transmembrane action potential in isolated ventricular muscle: implications for optical measurements of cardiac repolarization [see comments] Biermann M, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1348-57. Comment in: J Cardiovasc Electrophysiol 1998 Dec;9(12):1358-62.
Functional origin of mammalian PR interval variations: a challenge for the 21st century [editorial; comment] Billette J. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):174-7 (22 ref.). Comment on: J Cardiovasc Electrophysiol 1999 Feb;10(2):168-73.
Atrial dispersion of refractoriness. Brachmann J, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S35-9 (14 ref.)
Effects of multisite ventricular pacing on cardiac function in normal dogs and dogs with heart failure. Fei L, et al. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):935-46
Spatiotemporal effects of syncytial heterogeneities on cardiac far-field excitations during monophasic and biphasic shocks. Fishler MG, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1310-24
A fungal metabolite that eliminates motion artifacts [editorial; comment] Jalife J, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1358-62. Comment on: J Cardiovasc Electrophysiol 1998 Dec;9(12):1336-47. Comment on: J Cardiovasc Electrophysiol 1998 Dec;9(12):1348-57.
Review of mechanisms by which electrical stimulation alters the transmembrane potential. Newton JC, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):234-43 (43 ref.)
Comparison of standard and irrigated radiofrequency ablation in the canine ventricle. Skrumeda LL, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1196-205
Field stimulation of isolated chick heart cells: comparison of experimental and theoretical activation thresholds. Stone BA, et al. **J Cardiovasc Electrophysiol** 1999 Jan; 10(1):92-107
Separation between virtual sources modifies the response of cardiac tissue to field stimulation. Susil RC, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):715-27
ECG of the "newborn" mouse (Mus domesticus) with specific reference to comparative AV transmission [see comments] van der Tweel LH, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):168-73. Comment in: J Cardiovasc Electrophysiol 1999 Feb;10(2):174-7.
Cytochalasin D as excitation-contraction uncoupler for optically mapping action potentials in wedges of ventricular myocardium [see comments] Wu J, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1336-47. Comment in: J Cardiovasc Electrophysiol 1998 Dec;9(12):1358-62.
Effects of spatial segmentation in the continuous model of excitation propagation in cardiac muscle. Wu J, et al. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):965-72
Effect of ambient temperature and cardiac stability on two methods of cardiac output measurement. Cathelyn J, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):93-101
Acute and nongenomic effects of testosterone on isolated and perfused rat heart. Ceballos G, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):691-7
Functions of c-Jun in liver and heart development. Eferl R, et al. **J Cell Biol** 1999 May 31;145(5):1049-61
Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. Choukroun G, et al. **J Clin Invest** 1998 Oct 1; 102(7):1311-20
The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. Gauthier C, et al. **J Clin Invest** 1998 Oct 1;102(7):1377-84
Beating the odds: a cardiomyocyte cell line at last. Leiden JM. **J Clin Invest** 1999 Mar;103(5):591-2
Flow profiles in the left anterior descending and the right coronary artery assessed by MR velocity quantification: effects of through-plane and in-plane motion of the heart. Marcus JT, et al. **J Comput Assist Tomogr** 1999 Jul-Aug; 23(4):567-76
Interindividual variability of multilead electrocardiographic recordings: influence of heart position. Hoekema R, et al. **J Electrocardiol** 1999 Apr;32(2):137-48
Estimation of epicardial activation maps from intravascular recordings. Kuenzler RO, et al. **J Electrocardiol** 1999 Apr; 32(2):77-92
Determinants of precordial QT dispersion in normal subjects. Lee KW, et al. **J Electrocardiol** 1998;31 Suppl:128-33
Unipolar stimulation of cardiac tissue. Roth BJ, et al. **J Electrocardiol** 1998;31 Suppl:6-12 (30 ref.)
Normal limits of ST segment measurements in posterior ECG leads. Taha B, et al. **J Electrocardiol** 1998;31 Suppl:178-9
Mechanisms underlying calcium sparks in cardiac muscle [published erratum appears in J Gen Physiol 1999 May;113(5):761] Cannell MB, et al. **J Gen Physiol** 1999 Mar;113(3):373-6 (29 ref.)
Role of calcium permeation in dihydropyridine receptor function. Insights into channel gating and excitation-contraction coupling. Dirksen RT, et al. **J Gen Physiol** 1999 Sep;114(3):393-403
Local control models of cardiac excitation-contraction coupling. A possible role for allosteric interactions between ryanodine receptors. Stern MD, et al. **J Gen Physiol** 1999 Mar;113(3):469-89
Right ventricular function in orthotopic total atrioventricular heart transplantation. Bittner HB, et al. **J Heart Lung Transplant** 1998 Aug;17(8):826-34
Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. London GM, et al. **J Hypertens Suppl** 1999 Jun;17(2):S3-6 (13 ref.)
Interrelation of tissue temperature versus flow velocity in two different kinds of temperature controlled catheter radiofrequency energy applications. Grumbrecht S, et al. **J Interv Card Electrophysiol** 1998 Jun;2(2):211-9
Pulsing microwave energy: a method to create more uniform myocardial temperature gradients. Haugh C, et al. **J Interv Card Electrophysiol** 1997 Feb;1(1):57-65
DENSE: displacement encoding with stimulated echoes in cardiac functional MRI. Aletras AH, et al. **J Magn Reson** 1999 Mar;137(1):247-52
Effect of acute increase of interstitial myocardial fluid on ventricular function in isolated working rat hearts. Barsotti A, et al. **J Med** 1998;29(3-4):137-58
Molecular characterization of an inwardly rectifying K+ channel from HeLa cells. Klein H, et al. **J Membr Biol** 1999 Jan 1;167(1):43-52
Effects of 2,3-butanedione 2-monoxime on Ca2+ release channels (ryanodine receptors) of cardiac and skeletal muscle. Tripathy A, et al. **J Membr Biol** 1999 Jun 1; 169(3):189-98
The role of glycolysis in myocardial calcium control. Aasum E, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1703-12
Age-related decrease in cardiac tolerance to oxidative stress. Abete P, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):227-36
Intracellular volumes and membrane permeability in rat hearts during prolonged hypothermic preservation with St Thomas and University of Wisconsin solutions. Askenasy N, et al. **J Mol Cell Cardiol** 1998 Jul;30(7):1329-39
Persistent effects of doxorubicin on cardiac gene expression. Boucek RJ Jr, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1435-46
Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress. Brar BK, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):135-46
LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. Comstock KL, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2761-75
Genomic organisation, alternative splicing and polymorphisms of the human cardiac troponin T gene.

Farza H, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1247–53

Comparison of the effects of ORG 30029, dobutamine and high perfusate calcium on function and metabolism in rat heart. Grandis DJ, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2605–12

Chromatin structure and cardiac gene expression. Huang WY, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1673–81 (74 ref.)

Hypoxia inhibits the changes in action potentials and ion channels during primary culture of neonatal rat ventricular myocytes. Kamiya K, et al. **J Mol Cell Cardiol** 1999 Sep; 31(9):1591–8

Consequences of the inhibition of the sarcoplasmic reticulum calcium ATPase on cardiac function and coronary flow in rabbit isolated perfused heart: role of calcium and nitric oxide. Khandoudi N, et al. **J Mol Cell Cardiol** 1998 Oct; 30(10):1967–77

Cardiac-specific overexpression of alpha1BAR regulates betaAR activity via molecular crosstalk. Lemire I, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1827–39

The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts. Mączewski M, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1735–47

Effects of angiotensin II on inotropy and intracellular Ca2+ handling in normal and hypertrophied rat myocardium. Meissner A, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2507–18

L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. Mukherjee R, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1899–916 (125 ref.)

Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility. Neumann J, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1991–2002

Tonic regulation of excitation-contraction coupling by basal protein kinase C activity in isolated cardiac myocytes. Nicolás JM, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2591–604

Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. Schoenfeld JR, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2269–80

Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. Schultz JE, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1817–25

Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. Torti SV, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1173–80

Oxidative stress induces DNA fragmentation and caspase activation via the c-Jun NH2-terminal kinase pathway in H9c2 cardiac muscle cells. Turner NA, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1789–801

Action potentials that mimic fibrillation activate sodium current. Ujhelyi MR, et al. **J Mol Cell Cardiol** 1999 Sep; 31(9):1673–84

Trace amounts of albumin protect against ischemia and reperfusion injury in isolated rat hearts. Watts JA, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1653–62

Sarcoplasmic reticulum function in murine ventricular myocytes overexpressing SR CaATPase. Yao A, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2711–8

Tuning the human heart molecular motors by myosin light chains. Morano I. **J Mol Med** 1999 Jul;77(7):544–55

Comparison of four motion correction techniques in SPECT imaging of the heart: a cardiac phantom study. O'Connor MK, et al. **J Nucl Med** 1998 Dec;39(12):2027–34

A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. Labhasetwar V, et al. **J Pharm Sci** 1998 Nov;87(11):1347–50

Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. Khalifa M, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):858–65

The erythrocyte-perfused "working heart" model: hemodynamic and metabolic performance in comparison to crystalloid perfused hearts. Podesser BK, et al. **J Pharmacol Toxicol Methods** 1999 Feb;41(1):9–15

Evidence for an electrogenic Na+-HCO3- symport in rat cardiac myocytes. Aiello EA, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):137–48

Low K+-induced hyperpolarizations trigger transient depolarizations and action potentials in rabbit ventricular myocytes. Akuzawa-Tateyama M, et al. **J Physiol (Lond)** 1998 Dec 15;513 (Pt 3):775–86

Properties of Ca2+ sparks evoked by action potentials in mouse ventricular myocytes. Bridge JH, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):469–78

Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. Fentzke RC, et al. **J Physiol (Lond)** 1999 May 15; 517 (Pt 1):143–57

A cytoplasmic factor, calpastatin and ATP together reverse run-down of Ca2+ channel activity in guinea-pig heart. Hao LY, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):687–99

How does beta-adrenergic stimulation increase the heart rate? The role of intracellular Ca2+ release in amphibian pacemaker cells. Ju YK, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):793–804

Age and gender differences in excitation-contraction coupling of the rat ventricle. Leblanc N, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):533–48

Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. Lee HC, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:153–68

Preferential regulation of rabbit cardiac L-type Ca2+ current by glycolytic derived ATP via a direct allosteric pathway. Losito VA, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):67–78

Force-velocity and power-load curves in rat skinned cardiac myocytes. McDonald KS, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):519–31

Respiratory and cardiac modulation of single sympathetic vasoconstrictor and sudomotor neurones to human skin. Macefield VG, et al. **J Physiol (Lond)** 1999 Apr 1;516 (Pt 1):303–14

Gating of skeletal and cardiac muscle sodium channels in mammalian cells. Sheets MF, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):425–36

Direct measurement of SR release flux by tracking 'Ca2+ spikes' in rat cardiac myocytes. Song LS, et al. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):677–91

Isoprenaline can activate the acetylcholine-induced K+ current in canine atrial myocytes via Gs-derived betagamma subunits. Sorota S, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):413–23

Cardiopulmonary baroreflex inhibition of sympathetic nerve activity is preserved with age in healthy humans. Tanaka H, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):249–54

Another trigger for the heartbeat. Trafford AW, et al. **J Physiol (Lond)** 1998 Nov 15;513 (Pt 1):1

ATP counteracts the rundown of gap junctional channels of rat ventricular myocytes by promoting protein phosphorylation. Verrecchia F, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):447–59

Elimination of the transient outward current and action potential prolongation in mouse atrial myocytes expressing a dominant negative Kv4 alpha subunit. Xu H, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:11–21

Heart period and heart period variability during sleep on the MIR space station. Gundel A, et al. **J Sleep Res** 1999 Mar;8(1):37–43

Metabolic and cardiovascular responses during work on a high ropes course. Watts PB, et al. **J Sports Med Phys Fitness** 1999 Mar;39(1):37–41

Attenuation of Ca paradox injury in guinea pig heart by K+ channel blocker, d-sotalol. Tribulova N, et al. **J Submicrosc Cytol Pathol** 1999 Jan;31(1):137–47

Dynamics of intramural scroll waves in three-dimensional continuous myocardium with rotational anisotropy. Berenfeld O, et al. **J Theor Biol** 1999 Aug 21;199(4):383–94

Regulation of cardiac sarcolemmal Na+/H+ exchanger activity: potential pathophysiological significance of endogenous mediators and oxidant stress. Avkiran M, et al. **J Thromb Thrombolysis** 1999 Jul;8(1):25–32 (84 ref.)

Functional and cellular regulation of the myocardial Na+/H+ exchanger. Fliegel L. **J Thromb Thrombolysis** 1999 Jul;8(1):9–14 (52 ref.)

Non-dipolarity of heart potentials estimated by magnetocardiography in normal subjects. Izumida N, et al. **Jpn Heart J** 1998 Nov;39(6):731–42

Myocardial electrogenesis and the electrocardiogram. Mashima S. **Jpn Heart J** 1999 Jan;40(1):1–9

Effects of myosin isozyme shift on curvilinearity of the left ventricular end-systolic pressure-volume relation of In situ rat hearts. Lee S, et al. **Jpn J Physiol** 1998 Dec;48(6):445–55

Protective effects of calpain inhibitor for prolonged hypothermic cardiac preservation. Saito T, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Apr;47(4):145–52

Effects of arteriovenous fistulas on cardiac oxygen supply and demand. Bos WJ, et al. **Kidney Int** 1999 May; 55(5):2049–53

Doppler echocardiographic analysis of effects of tribromoethanol anesthesia on cardiac function in the mouse embryo: a comparison with pentobarbital. Huang GY, et al. **Lab Anim Sci** 1998 Apr;48(2):206–9

Ligands for opioid and sigma-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress. Lishmanov YuB, et al. **Life Sci** 1999;65(1):PL13–7

M3 muscarinic receptor activation of a delayed rectifier potassium current in canine atrial myocytes. Shi H, et al. **Life Sci** 1999;64(21):PL251–7

n-3 fatty acids in the prevention of cardiac arrhythmias. Leaf A, et al. **Lipids** 1999;34 Suppl:S187–9 (23 ref.)

Proceedings of the 4th International Symposium: Magnetic Resonance in Cardiovascular Research. September 24–26, 1998, Würzburg, Germany. **MAGMA** 1998 Sep; 6(2–3):81–207

Assessment of myocardial viability with MR--the Cologne perspective. Baer FM, et al. **MAGMA** 1998 Sep; 6(2–3):140–2

Regional myocardial function with tissue phase mapping. Hennig J, et al. **MAGMA** 1998 Sep;6(2–3):145–6

MR-perfusion measurements: basic methodology and current status. Hiller KH, et al. **MAGMA** 1998 Sep;6(2–3):98–9 (7 ref.)

Creatine kinase knockout mice--what is the phenotype: heart. Ingwall JS. **MAGMA** 1998 Sep;6(2–3):120–1

Basic pulse sequences for fast cardiac MR imaging. Jakob PM, et al. **MAGMA** 1998 Sep;6(2–3):84–7 (12 ref.)

Cardiac anatomy, mass and function--great vessels. Kenn W. **MAGMA** 1998 Sep;6(2–3):88–90 (10 ref.)

In vivo 1H-MR spectroscopy of the human heart. Kreis R, et al. **MAGMA** 1998 Sep;6(2–3):164–7

Functional and metabolic evaluation of the hypertrophied heart using MRI and 31P-MRS. Lamb HJ, et al. **MAGMA** 1998 Sep;6(2–3):168–70

Human cardiac NMR spectroscopy--basic pulse sequences, signal processing and hardware requirements. Meininger M. **MAGMA** 1998 Sep;6(2–3):111–2

Mathematical model of energy transfer in hearts with inhibited or ablated creatine kinase system. Saks V, et al. **MAGMA** 1998 Sep;6(2–3):124–5 (3 ref.)

MR spectroscopy of transgenic mice. Spindler M, et al. **MAGMA** 1998 Sep;6(2–3):109–10 (5 ref.)

High-resolution MR imaging in mice. Wiesmann F, et al. **MAGMA** 1998 Sep;6(2–3):186–8

MR measurement of myocardial perfusion. Wilke N. **MAGMA** 1998 Sep;6(2–3):147

Novel real-time R-wave detection algorithm based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. Fischer SE, et al. **Magn Reson Med** 1999 Aug; 42(2):361–70

Particle trace visualization of intracardiac flow using time-resolved 3D phase contrast MRI. Wigström L, et al. **Magn Reson Med** 1999 Apr;41(4):793–9

Motion-selective encoding for fast cine imaging. Yang GZ, et al. **Magn Reson Med** 1999 Sep;42(3):430–5

Age peculiarities of changes in the contractile function of isolated rat hearts during prolonged perfusion. Frolkis VV, et al. **Mech Ageing Dev** 1998 Dec 1;106(1–2):173–82

Dependence of cardiac strength-interval curves on pacing rate. Bennett JA, et al. **Med Biol Eng Comput** 1999 Jan; 37(1):108–9

Consequences of static and pulsatile pressure on transmembrane exchanges during in vitro microdialysis: implication for studies in cardiac physiology. Siaghy EM, et al. **Med Biol Eng Comput** 1999 Mar;37(2):196–201

Evaluation of a lumped parameter model for isolated working rat hearts. Wright G, et al. **Med Biol Eng Comput** 1999 Mar;37(2):190–5

Electrocardiogram-correlated image reconstruction from subsecond spiral computed tomography scans of the heart. Kachelriess M, et al. **Med Phys** 1998 Dec;25(12):2417–31

Maximum likelihood estimation in calibrating a stereo camera setup. Muijtjens AM, et al. **Med Phys** 1999 Feb;26(2):310–8

Cardiopulmonary limitations to exercise in restrictive lung disease. Hsia CC. **Med Sci Sports Exerc** 1999 Jan;31(1 Suppl):S28–32 (15 ref.)

Systolic and diastolic cardiac function time intervals and exercise capacity in women. Libonati JR, et al. **Med Sci Sports Exerc** 1999 Feb;31(2):258–63

Classification of cardiorespiratory fitness without exercise testing. Matthews CE, et al. **Med Sci Sports Exerc** 1999 Mar;31(3):486–93

Cardiovascular responses to facial cooling are age and fitness dependent. Petrella RJ, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1163–8

Exercise cardiac function in young through elderly endurance trained women. Wiebe CG, et al. **Med Sci Sports Exerc** 1999 May;31(5):684–91

Regulation of cardiomyocyte apoptosis in ischemic reperfused mouse heart by glutathione peroxidase. Maulik N, et al. **Mol Cell Biochem** 1999 Jun;196(1–2):13–21

Changes in cardiac electrophysiology, morphology, tissue biochemistry and vascular reactions in glutathione depleted animals. Pacher P, et al. **Mol Cell Biochem** 1998 Aug; 185(1–2):183–90

The dynamic regulation of myocardial oxidative phosphorylation: analysis of the response time of oxygen consumption. van Beek JH, et al. **Mol Cell Biochem** 1998 Jul;184(1–2):321–44

Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Lu JT, et al. **Mol Cell Neurosci** 1999 Aug; 14(2):99–120

Turning off RB for a healthy heart? [news] Fricker J. **Mol Med Today** 1999 Feb;5(2):50–1

HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Chouabe C, et al. **Mol Pharmacol** 1998 Oct;54(4):695–703

Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts. Shi H, et al. **Mol Pharmacol** 1999 Mar;55(3):497–507

Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Melacini P, et al. **Muscle Nerve** 1999 Apr;22(4):473–9

A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Lee JK, et al. **Nat Med** 1998 Dec;4(12):1383–91

Multifractality in human heartbeat dynamics. Ivanov PC, et al. **Nature** 1999 Jun 3;399(6735):461–5

Circulation and the kidney. Basic physiological and pathophysiological concepts. Greger R. **Nephrol Dial Transplant** 1999;14 Suppl 4:35–7 (20 ref.)

Interaction of the autonomic nervous and the renin-angiotensin system in heart and kidney. Rump LC, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:38–9

Studies on structural changes of the carotid arteries and the heart in asymptomatic renal transplant recipients. Suwelack

B, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):160–5
The parabrachial nucleus mediates the decreased cardiac baroreflex sensitivity observed following short-term visceral afferent activation. Saleh TM, et al. **Neuroscience** 1998 Nov;87(1):135–46
23Na NMR shift reagents enhance cardiac staircase effect in isolated perfused rat hearts. Simor T, et al. **NMR Biomed** 1999 Aug;12(5):267–74
Cardiac lymphatic dynamics after ischemia and reperfusion--experimental model. Santos AC, et al. **Nucl Med Biol** 1998 Oct;25(7):685–8
Cardiac compliance in fetuses of diabetic women. Weiner Z, et al. **Obstet Gynecol** 1999 Jun;93(6):948–51
Extension of refractoriness in a model of cardiac defibrillation. Trayanova NA, et al. **Pac Symp Biocomput** 1999;:240–51
20th Annual scientific sessions of the North American Society of Pacing and Electrophysiology (NASPE). Toronto, Ontario, Canada. May 12–15, 1999. Abstracts. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 2):699–917
XIth World Symposium on Cardiac Pacing and Electrophysiology. Berlin, Germany, June 27–30, 1999. Abstracts. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 2):A1–216
Dynamic beat-to-beat QT-RR relationship during physiotherapy effort in elderly patients without primary heart disease. Arad M, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1240–4
Influence of age and low afterload on the stress-velocity relation of the left ventricle. De Wolf D, et al. **Pediatr Res** 1998 Oct;44(4):600–6
The developmental character of cardiac autonomic responses to an acute noxious event in 4- and 8-month-old healthy infants. Oberlander TF, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):519–25
Comparison of Na+–Ca2+ exchange current elicited from isolated rabbit ventricular myocytes by voltage ramp and step protocols. Convery MK, et al. **Pflugers Arch** 1999 May;437(6):944–54
An improved isolated, left ventricular ejecting, murine heart model. Functional and metabolic evaluation. De Windt LJ, et al. **Pflugers Arch** 1999 Jan;437(2):182–90
Perforated patch recording with beta-escin. Fan JS, et al. **Pflugers Arch** 1998 Nov;436(6):1021–3
Activation of PKC increases Na+–K+ pump current in ventricular myocytes from guinea pig heart. Gao J, et al. **Pflugers Arch** 1999 Apr;437(5):643–51
Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential. Hancox JC, et al. **Pflugers Arch** 1998 Nov;436(6):843–53
Does adrenaline modulate the Na+–Ca2+ exchanger in isolated toad pacemaker cells? Ju YK, et al. **Pflugers Arch** 1999 Aug;438(3):338–43
Activation of Ca2+–sensitive Cl– current by reverse mode Na+/Ca2+ exchange in rabbit ventricular myocytes. Kuruma A, et al. **Pflugers Arch** 1998 Nov;436(6):976–83
Cardioventilatory coupling in the anaesthetised rabbit, rat and guinea-pig. Larsen PD, et al. **Pflugers Arch** 1999 May; 437(6):910–6
The isolated working mouse heart: methodological considerations. Larsen TS, et al. **Pflugers Arch** 1999 May; 437(6):979–85
A Na+–activated K+ current (IK,Na) is present in guinea-pig but not rat ventricular myocytes. Lawrence C, et al. **Pflugers Arch** 1999 May;437(6):831–8
On the mechanism of the enhancement of delayed rectifier K+ current by extracellular ATP in guinea-pig ventricular myocytes. Matsubayashi T, et al. **Pflugers Arch** 1999 Apr; 437(5):635–42
On the mechanism of genistein-induced activation of protein kinase A-dependent Cl– conductance in cardiac myocytes. Obayashi K, et al. **Pflugers Arch** 1999 Aug;438(3):269–77
Expression environment determines K+ current properties: Kv1 and Kv4 alpha-subunit-induced K+ currents in mammalian cell lines and cardiac myocytes. Petersen KR, et al. **Pflugers Arch** 1999 Feb;437(3):381–92
A regional gradient of cardiac intrinsic rhythmicity depicted in embryonic cultured multiple hearts. Sakai T, et al. **Pflugers Arch** 1998 Dec;437(1):61–9
Lack of involvement of G proteins in the activation of cardiac CFTR Cl– current by genistein. Shuba LM, et al. **Pflugers Arch** 1999 May;437(6):796–803
Effects of hydroxyl radicals on KATP channels in guinea-pig ventricular myocytes. Tokube K, et al. **Pflugers Arch** 1998 Dec;437(1):155–7
Role of PKC in the effects of alpha1-adrenergic stimulation on Ca2+ transients, contraction and Ca2+ current in guinea-pig ventricular myocytes. Woo SH, et al. **Pflugers Arch** 1999 Feb;437(3):335–44
Antisense oligodeoxynucleotides of sulfonylurea receptors inhibit ATP-sensitive K+ channels in cultured neonatal rat ventricular cells. Yokoshiki H, et al. **Pflugers Arch** 1999 Feb;437(3):400–8
Distinct functional muscarinic receptors in guinea-pig gallbladder, ileum and atria. Karaalp A, et al. **Pharmacol Res** 1999 May;39(5):389–95
Comparison of cardiac-induced endogenous fields and power frequency induced exogenous fields in an anatomical model of the human body. Hart RA, et al. **Phys Med Biol** 1998 Oct;43(10):3083–99
Phospholamban: protein structure, mechanism of action, and role in cardiac function. Simmerman HK, et al. **Physiol Rev** 1998 Oct;78(4):921–47 (252 ref.)
Electrophysiological effects of Ageratum conyzoides L. on the guinea-pig heart. Garcia EA, et al. **Phytother Res** 1999 Mar;13(2):172–4
Disruption of myoglobin in mice induces multiple compensatory mechanisms. Gödecke A, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10495–500
Rat heart: a site of oxytocin production and action. Jankowski M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14558–63
Augmenting beta receptors in the heart: short-term gains offset by long-term pains? Limbird LE, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7125–7
Ca2+–induced inhibition of the cardiac Ca2+ channel depends on calmodulin. Qin N, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2435–8
The stretch-activation response may be critical to the proper functioning of the mammalian heart. Vemuri R, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1048–53
Blood flows and metabolic components of the cardiome. Bassingthwaighte JB, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):445–61
The role of calcium in the response of cardiac muscle to stretch. Calaghan SC, et al. **Prog Biophys Mol Biol** 1999; 71(1):59–90 (156 ref.)
Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Carmeliet E, et al. **Prog Biophys Mol Biol** 1998; 70(1):1–72 (433 ref.)
Modulation of ions channels and membrane receptors activities by mechanical interventions in cardiomyocytes: possible mechanisms for mechanosensitivity. Cazorla O, et al. **Prog Biophys Mol Biol** 1999;71(1):29–58 (143 ref.)
Modelling myocardial ischaemia and reperfusion. Ch'en FF, et al. **Prog Biophys Mol Biol** 1998;69(2–3):515–38
Wave propagation in cardiac tissue and effects of intracellular calcium dynamics (computer simulation study). Chudin E, et al. **Prog Biophys Mol Biol** 1998;69(2–3):225–36 (17 ref.)
Estimates of regional work in the canine left ventricle. Delhaas T, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):273–87 (53 ref.)
Physical and geometrical modeling for image-based recovery of left ventricular deformation. Duncan J, et al. **Prog Biophys Mol Biol** 1998;69(2–3):333–51 (50 ref.)
Future directions for combining molecular and continuum models in protein simulations. Huber GA. **Prog Biophys Mol Biol** 1998;69(2–3):483–96 (99 ref.)
Modelling the mechanical properties of cardiac muscle. Hunter PJ, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):289–331 (119 ref.)
Adaptive local regularization methods for the inverse ECG problem. Johnson CR, et al. **Prog Biophys Mol Biol** 1998; 69(2–3):405–23
Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Kohl P, et al. **Prog Biophys Mol Biol** 1999;71(1):91–138 (282 ref.)
Mechanosensitivity as an integrative system in heart: an audit. Lab MJ. **Prog Biophys Mol Biol** 1999;71(1):7–27 (144 ref.)
Computational biology of the heart: from structure to function [editorial] McCulloch A, et al. **Prog Biophys Mol Biol** 1998;69(2–3):153–5
Homogenization modeling for the mechanics of perfused myocardium. May-Newman K, et al. **Prog Biophys Mol Biol** 1998;69(2–3):463–81
Finite element analysis of defibrillation fields in a human torso model for ventricular defibrillation. Min X, et al. **Prog Biophys Mol Biol** 1998;69(2–3):353–86
Validation of three-dimensional conduction models using experimental mapping: are we getting closer? Muzikant AL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):205–23
Stress and strain as regulators of myocardial growth. Omens JH. **Prog Biophys Mol Biol** 1998;69(2–3):559–72
Ca(2+)-dependence of diastolic properties of cardiac sarcomeres: involvement of titin. Stuyvers BD, et al. **Prog Biophys Mol Biol** 1998;69(2–3):425–43
Cardiac mechano-electric feedback in man: clinical relevance. Taggart P, et al. **Prog Biophys Mol Biol** 1999; 71(1):139–54 (58 ref.)
Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy. Vetter FJ, et al. **Prog Biophys Mol Biol** 1998;69(2–3):157–83 (142 ref.)
A spatial scale factor for electrophysiological models of myocardium. Winfree AT. **Prog Biophys Mol Biol** 1998; 69(2–3):185–203 (57 ref.)
Modeling the cellular basis of altered excitation-contraction coupling in heart failure. Winslow RL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):497–514 (45 ref.)
The rhythmicity of sympathetic nerve activity. Malpas SC. **Prog Neurobiol** 1998 Oct;56(1):65–96 (245 ref.)
Regulation of gene expression in the endocrine heart. Durocher D, et al. **Recent Prog Horm Res** 1998;53:7–23; discussion 22–3 (79 ref.)
Dual mechanisms of Mg2+ block of ryanodine receptor Ca2+ release channel from cardiac sarcoplasmic reticulum. Kawano S. **Receptors Channels** 1998;5(6):405–16
Allometric algorithms and the work of the heart. Torrance RW. **Respir Physiol** 1998 Jul;113(1):95–9 (10 ref.)
Oxygen uptake and cardiac performance in obese and normal subjects during exercise. Salvadori A, et al. **Respiration** 1999;66(1):25–33
Does hypothermia or hyperkalemia influence the preconditioning response? Takeshima S, et al. **Scand Cardiovasc J** 1999;33(2):79–87
Embryological basis for cardiac left-right asymmetry. Mercola M. **Semin Cell Dev Biol** 1999 Feb;10(1):109–16 (77 ref.)
Impaired energy metabolism in hearts of septic baboons: diminished activities of Complex I and Complex II of the mitochondrial respiratory chain. Gellerich FN, et al. **Shock** 1999 May;11(5):336–41
Intrinsic myocardial function in hemorrhagic shock. McDonough KH, et al. **Shock** 1999 Mar;11(3):205–10
Basics of myocardial pump function. von Spiegel T, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:237–41 (28 ref.)
Expression of MEF2 genes during human cardiac development. Iida K, et al. **Tohoku J Exp Med** 1999 Jan; 187(1):15–23
Morphometric analyses to predict appropriate donor size for swine-to-human cardiac xenotransplantation. Allan JS, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):975–7
Cardiac function and myocardial energy level after prolonged hypothermic storage. Ku K, et al. **Transplant Proc** 1998 Nov;30(7):3331–3
Effectiveness of ischemic preconditioning on long-term myocardial preservation. Lu H, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1048
Orthotopic transplantation of pig hearts harvested from non-heart-beating donors. Martin J, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):153–4
Gq signaling in cardiac adaptation and maladaptation. Dorn GW 2nd, et al. **Trends Cardiovasc Med** 1999 Jan-Feb; 9(1–2):26–34 (84 ref.)
Doppler echocardiography. II. Color Doppler imaging. Bonagura JD, et al. **Vet Clin North Am Small Anim Pract** 1998 Nov; 28(6):1361–89, vii (27 ref.)
Doppler echocardiographic study of left ventricular diastole in non-anaesthetized healthy cats [published erratum appears in Vet J 1999 Mar;157(2):206] Santilli RA, et al. **Vet J** 1998 Nov;156(3):203–15
Morphology and amplitude values of the P and T waves in the electrocardiograms of Spanish-bred horses of different ages. Ayala I, et al. **Zentralbl Veterinarmed A** 1999 May;46(4):225–30
[An improvement on the adhesive electrode recording device] Li R, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):366–8 (Eng. Abstr.) **(Chi)**
[Voltage dependence of late Na channel with burst mode in isolated cardiac myocytes] Liu YM, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):483–90 (Eng. Abstr.) **(Chi)**
[Study model for isolated heart perfusion combined with NMR technique] Lu Z, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):230–4 (Eng. Abstr.) **(Chi)**
[Effects of endothelin on electrophysiological and contractile activity of guinea pig papillary muscles] Zhang Z, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):146–52 (Eng. Abstr.) **(Chi)**
[Electrocardiography at the present time: possibilities of ECG registration and interpretation] Overduin LM. **Tijdschr Diergeneeskd** 1998 Oct 15;123(20):590–2 **(Dut)**
[Detection of myocardial viability by stress echocardiography] Habis M. **Ann Cardiol Angeiol (Paris)** 1998 Dec;47(10):748–52 (43 ref.) (Eng. Abstr.) **(Fre)**
[Normal and pathological cardiac aging. Apropos of an exceptional case of longevity] Méry D, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92(4):419–25 (Eng. Abstr.) **(Fre)**
[How much blood flow is required by the myocardium?] Deussen A, et al. **Anaesthesist** 1999 Jul;48(7):449–51 (Eng. Abstr.) **(Ger)**
[Reconstruction of extended electric sources in a thoracic phantom using biomagnetic field measurements] Brauer H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:228–9 **(Ger)**
[Nitric oxide (NO). Its importance to heart function] Kojda G, et al. **Med Monatsschr Pharm** 1999 Apr;22(4):114–23 (93 ref.) **(Ger)**
[Functional imaging of the heart with electron-beam computed tomography] Becker A, et al. **Radiologe** 1998 Dec;38(12):1021–8 (Eng. Abstr.) **(Ger)**
[The aging heart: presbycardia] Rengo F, et al. **Cardiologia** 1998 Nov;43(11):1141–52 (150 ref.) **(Ita)**
[Anatomico-functional changes in the right ventricle of the athlete] Sciomer S, et al. **Cardiologia** 1998 Nov; 43(11):1215–20 (Eng. Abstr.) **(Ita)**
[Connection between electrophysiology and cardiac protection] Vassalle M. **Cardiologia** 1999 Jun;44(6):521–34 (85 ref.) (Eng. Abstr.) **(Ita)**
[Diagnostic imaging in the study of heart aging. Is the "senile heart" a fact?] Di Guglielmo L, et al. **Radiol Med (Torino)** 1999 Jun;97(6):449–60 (46 ref.) **(Ita)**
[Analysis of autocorrelation of cardiac rate as an indicator of cardiac memory] Guarini G, et al. **Recenti Prog Med** 1998 Sep;89(9):454–5 **(Ita)**
[What's in the name? (editorial)] Beppu S. **J Cardiol** 1998 Nov;32(5):344–5 **(Jpn)**
[Ischemic preconditioning in the aged heart--myocardial protective effect as compared with the mature heart] Uematsu M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep; 46(9):833–45 (Eng. Abstr.) **(Jpn)**

[Assessment of cardiac function and myocardial metabolism by nuclear medicine] Hasegawa S, et al. **Kaku Igaku** 1999 Apr;36(3):209–17 (20 ref.) (Eng. Abstr.) **(Jpn)**

[A modified method of cardiac functional analysis for ECG gated SPECT: study of functional G-maps] Onoguchi M, et al. **Kaku Igaku** 1998 Jul;35(6):385–93 (Eng. Abstr.) **(Jpn)**

[Defense mechanism of the myocardium] Miura M, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1588–94 (16 ref.) **(Jpn)**

[Thyroid hormones and the heart] Zyśko D. **Pol Merkuriusz Lek** 1999 Mar;6(33):157–60 (31 ref.) (Eng. Abstr.) **(Pol)**

[Effect of ionospheric parameters on the respiratory and cardiac system, function of the brain and higher nervous system activity in healthy people] Lushnov MS, et al. **Biofizika** 1998 Sep–Oct;43(5):840–3 (Eng. Abstr.) **(Rus)**

[Mathematical model of a generalized calcium buffer in cardiac muscle cells] Solov'eva OE, et al. **Biofizika** 1999 Jan–Feb;44(1):91–101 (Eng. Abstr.) **(Rus)**

[Age factor effects on the isolated heart contractile function during long-term perfusion] Frol'kis VV, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):505–9 **(Rus)**

[Determination of cardiomyocyte transmembrane potential with potential-sensitive fluorescent probes] Khankoeva AI, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):594–7 **(Rus)**

[Adrenergic and cholinergic factors in the cardiac regulation during rat ontogenesis] Sitdikov FG, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):318–20 **(Rus)**

[The phasic structure of the cardiac cycle in the normal left and right heart ventricles] Makaridze OV. **Fiziol Cheloveka** 1998 Jul–Aug;24(4):133–5 **(Rus)**

[Autoinduced myocardial tolerance to ischemia: the role of stress proteins in the mechanisms of its occurrence] Shevchenko IuL, et al. **Fiziol Cheloveka** 1999 Jan–Feb; 25(1):134–9 (49 ref.) **(Rus)**

[Cardiological aspects of adaptation to continuous low-energy nutrition] Efimov NV, et al. **Klin Med (Mosk)** 1999;77(2):24–7 (Eng. Abstr.) **(Rus)**

[Algorithms for measuring duration of ECG complexes] Lebedev VV, et al. **Med Tekh** 1998 Sep–Oct;(5):6–14 (Eng. Abstr.) **(Rus)**

[Need to correct indicators of "physiological norm" in pilots] Bednenko VS. **Med Tr Prom Ekol** 1999;(1):37–9 (Eng. Abstr.) **(Rus)**

[Systemic organization of the heart in adaptation of the body to repeated physical loads] Silkin IuR, et al. **Morfologiia** 1999;116(4):22–6 (Eng. Abstr.) **(Rus)**

[New evidence for cardiac biomechanics] Fatenkov VN. **Vestn Ross Akad Med Nauk** 1999;(2):44–50 (Eng. Abstr.) **(Rus)**

[The optimization of the arrangement of physiotherapeutic procedures based on the circadian dynamics of the cardiointervalographic indices] Kapilevich LV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov–Dec; (6):18–21 (Eng. Abstr.) **(Rus)**

[The effect of physical loading on the cardiorespiratory system indices of young schoolchildren] Lafauri IA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep–Oct;(5):47–8 **(Rus)**

[Effects of physical exercise on the cardiorespiratory system in children] Jaraba Caballero S, et al. **An Esp Pediatr** 1999 Apr;50(4):367–72 (Eng. Abstr.) **(Spa)**

[Structural and functional changes in the of heart of high-performance (canoeing) athletes] Galván O, et al. **Arch Inst Cardiol Mex** 1999 Jan–Feb;69(1):26–34 (Eng. Abstr.) **(Spa)**

[The biochemistry and physiology of Mg2+ in the heart and other organs] Rodriguez-Zavala JS. **Arch Inst Cardiol Mex** 1998 May–Jun;68(3):262–72 (55 ref.) **(Spa)**

[The first-choice technic for assessing myocardial viability. Stress echocardiography] Evangelista A. **Rev Esp Cardiol** 1998 Oct;51(10):801–5 (45 ref.) (Eng. Abstr.) **(Spa)**

[Regulation of cardiac output;an approximation at 3 levels: organic, cellular, and protein] Martienz Caro D, et al. **Rev Med Univ Navarra** 1999 Jan–Mar;43(1):29–40 (9 ref.) (Eng. Abstr.) **(Spa)**

[The interrelation of neural and humoral cardiogenic influences and their action on the blood circulation] Pavliuchenko VB. **Fiziol Zh** 1999;45(1–2):56–63 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Diabetic alteration of cardiac vago-sympathetic modulation assessed with tone-entropy analysis. Oida E, et al. **Acta Physiol Scand** 1999 Feb;165(2):129–34

Preconditioning does not attenuate cardiac dysfunction after global ischaemia in the guinea-pig. Valen G. **Acta Physiol Scand** 1998 Jul;163(3):219–25

Adaptation of hearts to chronic hypoxia increases tolerance to subsequent ischemia by increased nitric oxide production. Baker JE, et al. **Adv Exp Med Biol** 1998; 454:203–17

Alterations of myocardial contraction associated with a structural heart defect in embryonic chicks. Godt RE, et al. **Adv Exp Med Biol** 1998;453:453–8; discussion 459

Non invasive assessment of cardiac function in patients with bronchial asthma (BA) or chronic obstructive pulmonary disease (COPD). Bagnato GF, et al. **Allergol Immunopathol (Madr)** 1999 Jan–Feb;27(1):5–10

CA 125 and its relation to cardiac function. Nägele H, et al. **Am Heart J** 1999 Jun;137(6):1044–9

ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction. Piérard LA, et al. **Am Heart J** 1999 Mar; 137(3):500–11

Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Aurigemma GP, et al. **Am J Cardiol** 1999 Mar 1;83(5):792–4, A10

Prognostic utility of myocardial viability assessment. Iskander S, et al. **Am J Cardiol** 1999 Mar 1;83(5):696–702, A7 (81 ref.)

Resting diastolic function and left ventricular mass are related to exercise capacity in hypertensive men but not in women. Gharavi AG, et al. **Am J Hypertens** 1998 Oct;11(10):1252–7

Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure. Anzai T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1267–73

Cardiac impairment and nitric oxide synthase activity in the chronic portal vein-stenosed rat. Battarbee HD, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G363–72

Early captopril treatment prevents hypertrophydependent gene expression in hearts of SHR. Chen S, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1511–7

Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia. Cooper A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1482–8

Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Ferdinandy P, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1861–7

A canine model of chronic ischemic cardiomyopathy: characterization of regional flow-function relations. Firoozan S, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H446–55

Leukocyte activation does not mediate myocardial leukocyte retention during endotoxemia in rabbits. Goddard CM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1548–57

Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Grupp IL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1338–50

Increased calcium loading and inotropy without greater cell death in hypoxic rat cardiomyocytes. Kondo RP, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2272–82

Cardiac myofibrillar and sarcoplasmic reticulum function are not depressed in insulin-resistant JCR:LA-cp rats. Misra T, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1811–7

Cardiac electrical restitution properties and stability of reentrant spiral waves: a simulation study. Qu Z, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H269–83

Dispersion-based reentry: mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. Robert E, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H413–23

TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin. Saadane N, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H803–14

Altered ATP sensitivity of ATP-dependent K+ channels in diabetic rat hearts. Shimoni Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E568–76

Ventricular contractility in atrial fibrillation is predictable by mechanical restitution and potentiation. Suzuki S, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1513–9

Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Thai HM, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H873–80

Ca2+-independent inhibition of myocardial contraction by coronary effluent of hypoxic rat hearts. Yang ZK, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H623–32

Abnormal myocyte Ca2+ homeostasis in rabbits with pacing-induced heart failure. Yao A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1441–8

Transmembrane potential changes caused by monophasic and biphasic shocks. Zhou X, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 2):H1798–807

Reversal of hypocalcemia and decreased afterload in sepsis. Effect on myocardial systolic and diastolic function. Kovacs A, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1990–8

Ventilatory and cardiovascular responses to inspired He-O2 during exercise in chronic obstructive pulmonary disease. Oelberg DA, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1876–82

Cardiopulmonary dysfunction during minimally invasive thoraco-lumboendoscopic spine surgery. Vollmar B, et al. **Anesth Analg** 1999 Jun;88(6):1244–51

Heart in Stress. Proceedings of the Jubilee Symposium in conjunction with the 3rd International Congress of Pathophysiology. Helsinki, Finland, June 28–July 3, 1998. **Ann N Y Acad Sci** 1999 Jun 30;874:1–438

New insights into cardioprotection by ischemic preconditioning and other forms of stress. de Zeeuw S, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:178–91 (70 ref.)

Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Dhalla NS, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:100–10

Small heat shock proteins and protection against injury. Dillmann WH. **Ann N Y Acad Sci** 1999 Jun 30;874:66–8 (10 ref.)

Towards a theoretical understanding of stroke volume estimation with impedance cardiography. Faes TJ, et al. **Ann N Y Acad Sci** 1999 Apr 20;873:128–34

Cardiac adaptation to ischemia-reperfusion injury. Kingma JG Jr. **Ann N Y Acad Sci** 1999 Jun 30;874:83–99

Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antihypertensive drugs. Sen S. **Ann N Y Acad Sci** 1999 Jun 30;874:125–33

Pharmacologic enhancement of tolerance to ischemic cardiac stress using monophosphoryl lipid A. A comparison with antecedent ischemia. Zhao L, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:222–35 (65 ref.)

Adenosine-enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia. McCully JD, et al. **Ann Thorac Surg** 1999 Mar;67(3):699–704

Beta-adrenergic receptors and receptor signaling in heart failure. Post SR, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:343–60 (107 ref.)

Mechanisms of cardiac pain. Foreman RD. **Annu Rev Physiol** 1999;61:143–67 (167 ref.)

Comparison of cardiac response to managerial workload between men and women. Bortkiewicz A, et al. **Appl Human Sci** 1998 Jul;17(4):139–44

Electrocardiographic alterations in chronically Trypanosoma cruzi-infected persons exposed to cardiovascular factors. Berra H, et al. **Arch Med Res** 1998 Autumn;29(3):241–6

The heart is not necessarily empty at syncope. Davrath LR, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 1):213–9

Post-ejection thickening as a marker of viable myocardium. An echocardiographic study in patients with chronic coronary artery disease. Barletta G, et al. **Basic Res Cardiol** 1998 Aug;93(4):313–24

Generating and influencing Torsades de Pointes--like polymorphic ventricular tachycardia in isolated guinea pig hearts. Gerhardy A, et al. **Basic Res Cardiol** 1998 Aug; 93(4):285–94

Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Chockalingam A, et al. **Bone Marrow Transplant** 1999 May;23(10):1093–4

Ageing of the heart. Roffe C. **Br J Biomed Sci** 1998 Jun; 55(2):136–48 (63 ref.)

What is the relevance of apoptosis to the myocardium? Liu P, et al. **Can J Cardiol** 1999 Apr;15 Suppl B:8B–10B

Comparison of the contractile performance of the hypertrophied myocardium from spontaneous hypertensive rats and normotensive infarcted rats. Mill JG, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):387–94

Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart. Feldman AM, et al. **Cardiol Clin** 1998 Nov;16(4):677–89, ix (143 ref.)

Assessment of myocardial viability with stress echocardiography. Shan K, et al. **Cardiol Clin** 1999 Aug; 17(3):539–53, ix (77 ref.)

Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism [letter] Hasegawa J, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):599–600

Passive transmission of ischemic ST segment changes in low electrical resistance myocardial infarct scar in the pig. Cinca J, et al. **Cardiovasc Res** 1998 Oct;40(1):103–12

Subcellular remodeling and heart dysfunction in chronic diabetes [editorial] Dhalla NS, et al. **Cardiovasc Res** 1998 Nov;40(2):239–47 (130 ref.)

Current status of monophasic action potential recording: theories, measurements and interpretations. Franz MR. **Cardiovasc Res** 1999 Jan;41(1):25–40 (87 ref.)

Effect of 5-HT4 receptor stimulation on the pacemaker current I(f) in human isolated atrial myocytes [see comments] Pino R, et al. **Cardiovasc Res** 1998 Dec; 40(3):516–22. Comment in: Cardiovasc Res 1998 Dec;40(3):436–7.

The heart remembers. Rosen MR, et al. **Cardiovasc Res** 1998 Dec;40(3):469–82 (79 ref.)

Alterations of cross-bridge kinetics in human atrial and ventricular myocardium. Ruf T, et al. **Cardiovasc Res** 1998 Dec;40(3):580–90

Abnormal cardiac repolarization and impulse initiation in German shepherd dogs with inherited ventricular arrhythmias and sudden death. Sosunov EA, et al. **Cardiovasc Res** 1999 Apr;42(1):65–79

Infarcted hearts of mice and men [editorial; comment] Weber KT. **Cardiovasc Res** 1999 Mar;41(3):506–8. Comment on: Cardiovasc Res 1999 Mar;41(3):586–93.

Regional electrophysiological effects of hypokalaemia, hypomagnesaemia and hyponatraemia in isolated rabbit hearts in normal and ischaemic conditions. Wolk R, et al. **Cardiovasc Res** 1998 Dec;40(3):492–501

Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Undrovinas AI, et al. **Cell Mol Life Sci** 1999 Mar; 55(3):494–505

Signalling pathways for cardiac hypertrophy. Yamazaki T, et al. **Cell Signal** 1998 Nov;10(10):693–8 (59 ref.)

Cardiogenic oscillations on the airflow signal during continuous positive airway pressure as a marker of central apnea. Ayappa I, et al. **Chest** 1999 Sep;116(3):660–6

Attenuation of cardiac but not vascular component in baroreflex of spontaneously hypertensive rats. Han CJ, et al. **Chin J Physiol** 1998 Jun 30;41(2):107–12

Reduced subendocardial ryanodine receptors and consequent

effects on cardiac function in conscious dogs with left ventricular hypertrophy. Hittinger L, et al. **Circ Res** 1999 May 14;84(9):999–1006

Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Muthuchamy M, et al. **Circ Res** 1999 Jul 9; 85(1):47–56

Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. Traverse JH, et al. **Circ Res** 1999 Mar 5;84(4):401–8

Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Auerbach MA, et al. **Circulation** 1999 Jun 8;99(22):2921–6

Ischemic preconditioning in immature myocardium. Awad WI, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II206–13

Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Beanlands RS, et al. **Circulation** 1998 Nov 10; 98(19 Suppl):II51–6

Hibernation triggers and myocardial protection. Bolling SF, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II220–3; discussion II223–4

Myocardial recovery after ischemia and reperfusion injury is significantly impaired in hearts with transgenic overexpression of beta-adrenergic receptor kinase. Chen EP, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II249–53; discussion II253–4

Effects of partial left ventriculectomy on cardiac performance [letter] Fukamachi K, et al. **Circulation** 1998 Nov 10;98(19):2101–02

Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Jahns R, et al. **Circulation** 1999 Feb 9; 99(5):649–54

In vivo transfer of a beta 2-adrenergic receptor gene into the pressure-overloaded rat heart enhances cardiac response to beta-adrenergic agonist. Kawahira Y, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II262–7; discussion II267–8

Presence of angiographic coronary collaterals predicts myocardial recovery after coronary bypass surgery in patients with severe left ventricular dysfunction. Kozman H, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II57–61

Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Lazarus A, et al. **Circulation** 1999 Mar 2;99(8):1041–6

Cardiopulmonary interactions after Fontan operations [letter; comment] Macé L, et al. **Circulation** 1999 Jul 13; 100(2):211–2. Comment on: Circulation 1997 Dec 2;96(11):3934–42.

Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury. Malekan R, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II62–5; discussion II66

Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Mazel JA, et al. **Circulation** 1999 Apr 13; 99(14):1914–8

Effects of a monoclonal antibody to P-selectin on recovery of neonatal lamb hearts after cold cardioplegic ischemia. Nagashima M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II391–7; discussion II397–8

Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans. Nagueh SF, et al. **Circulation** 1999 Aug 3;100(5):490–6

Myocardial dysfunction in donor hearts. A possible etiology. Owen VJ, et al. **Circulation** 1999 May 18;99(19):2565–70

Endocardial activation mapping of ventricular tachycardia in patients : first application of a 32-site bipolar mapping electrode catheter. Schalij MJ, et al. **Circulation** 1998 Nov 17;98(20):2168–79

Cardiovascular collapse caused by electrocardiographically silent 60-Hz intracardiac leakage current. Implications for electrical safety. Swerdlow CD, et al. **Circulation** 1999 May 18;99(19):2559–64

Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. Nóbrega AC, et al. **Clin Auton Res** 1999 Feb;9(1):11–6

Cardiac function at rest in hypothyroidism evaluated by equilibrium radionuclide angiography. Tielens ET, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):497–502

Myocardial dysfunction in sepsis. Piper RD. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):951–4 (36 ref.)

Endothelium-smooth muscle interaction in cardiac transplantation. Skarsgard PL, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):836–40

Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. Leenen FH, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):522–35

Wall motion abnormalities in male elite orienteers are aggravated by exercise. Damm S, et al. **Clin Physiol** 1999 Mar;19(2):121–6

Reduced cardiac sympathetic autonomic tone after long-term nasal continuous positive airway pressure in obstructive sleep apnoea syndrome. Roche F, et al. **Clin Physiol** 1999 Mar;19(2):127–34

Different effects of simple anoxic lactic acidosis and simulated in vivo anoxic acidosis on turtle heart. Shi H, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Feb;122(2):173–80

Mechanisms and management of myocardial dysfunction in septic shock [editorial; comment] Carpati CM, et al. **Crit Care Med** 1999 Feb;27(2):231–2 (24 ref.). Comment on: Crit Care Med 1999 Feb;27(2):286–92.

Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Linden D, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 109(5):387–90

Growth hormone-independent cardioprotective effects of hexarelin in the rat. Locatelli V, et al. **Endocrinology** 1999 Sep;140(9):4024–31

The puzzle behind electrical chaos and sudden cardiac death in the structurally normal heart [editorial; comment] Brugada P, et al. **Eur Heart J** 1999 Mar;20(6):401–2. Comment on: Eur Heart J 1999 Mar;20(6):465–70.

Cardiac and peripheral responses to exercise in patients with chronic heart failure. Cohen-Solal A, et al. **Eur Heart J** 1999 Jul;20(13):931–45 (170 ref.)

Myocardial dysfunction in sepsis: mechanisms and therapeutic implications. Price S, et al. **Eur Heart J** 1999 May;20(10):715–24 (93 ref.)

Reduced cardiac stiffness following exercise is associated with preserved myocardial collagen characteristics in the rat. Woodiwiss AJ, et al. **Eur J Appl Physiol** 1998 Jul; 78(2):148–54

Does the extended use of arterial grafts compromise the myocardial recovery after coronary artery bypass grafting in left ventricular dysfunction? Jegaden O, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):353–9

The effect of the ultrashort beta-blocker esmolol on cardiac function recovery: an experimental study. Pirk J, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):199–203

Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Kalsi KK, et al. **Eur J Clin Invest** 1999 Jun;29(6):469–77

Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Nousiainen T, et al. **Eur J Haematol** 1998 Nov;61(5):347–53

Exercise-induced stunning continues for at least one hour: evaluation with quantitative gated single-photon emission tomography. Paul AK, et al. **Eur J Nucl Med** 1999 Apr; 26(4):410–5

Inhibition of P-selectin attenuates neutrophil-mediated myocardial dysfunction in isolated rat heart. Ohnishi M, et al. **Eur J Pharmacol** 1999 Feb 5;366(2–3):271–9

Interaction of adenosine and prostacyclin in coronary flow regulation after myocardial ischemia. Stangl V, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):43–50

Effects of selective nitric oxide synthase inhibition in hyperdynamic endotoxemia in dogs. Wolfard A, et al. **Eur Surg Res** 1999;31(4):314–23

Exsanguination from impact head trauma; the explanation for the "empty heart" sign. Contostavlos DL. **Forensic Sci Int** 1998 Aug 12;95(3):201–12

Myocardial regional diastolic dysfunction and left ventricular hypertrophy: insights by pulsed Doppler tissue imaging [editorial] Caso P, et al. **G Ital Cardiol** 1999 Apr;29(4):462–6 (30 ref.)

Early assessment of viable myocardium after acute myocardial infarction by low-dose echo-dobutamine. Castini D, et al. **G Ital Cardiol** 1998 Nov;28(11):1215–24

Long axis function in disease [editorial] Henein MY, et al. **Heart** 1999 Mar;81(3):229–31

Measurement of QT dispersion [editorial] Macfarlane PW. **Heart** 1998 Nov;80(5):421–3

Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Tiras MB, et al. **Hum Reprod** 1999 Aug;14(8):1949–52

The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Anderson KM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):402–7

Diastolic compliance is reduced in obese rabbits. Carroll JF, et al. **Hypertension** 1999 Mar;33(3):811–5

Cardiac consequences of prolonged exposure to an isolated increase in aortic stiffness. Lartaud-Idjouadiene I, et al. **Hypertension** 1999 Jul;34(1):63–9

Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Yang XP, et al. **Hypertension** 1999 Jul;34(1):24–30

Post-beta-receptor defect in isolated hearts of obese-hypertensive rabbits. Carroll JF. **Int J Obes Relat Metab Disord** 1999 Aug;23(8):863–6

Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. Hülsmann M, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1695–700

The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. Tang W, et al. **J Am Coll Cardiol** 1999 Sep;34(3):815–22

Longterm effects of pulmonary resection on cardiopulmonary function. Miyazawa M, et al. **J Am Coll Surg** 1999 Jul;189(1):26–33

Assessment of regional wall motion abnormalities with real-time 3-dimensional echocardiography. Collins M, et al. **J Am Soc Echocardiogr** 1999 Jan;12(1):7–14

Histamine H3 activation depresses cardiac function in experimental sepsis. Li X, et al. **J Appl Physiol** 1998 Nov; 85(5):1693–701

Effects of 5-day hypoxia on cardiac adrenergic neurotransmission in rats. Mardon K, et al. **J Appl Physiol** 1998 Sep;85(3):890–7

Effects of isoproterenol on myocardial structure and function in septic rats. Piper RD, et al. **J Appl Physiol** 1999 Mar; 86(3):993–1001

Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. Periasamy M, et al. **J Biol Chem** 1999 Jan 22;274(4):2556–62

Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. Sanbe A, et al. **J Biol Chem** 1999 Jul 23;274(30):21085–94

Genetically engineered mice: model systems for left ventricular failure [see comments] Kadambi VJ, et al. **J Card Fail** 1998 Dec;4(4):349–61 (59 ref.). Comment in: J Card Fail 1998 Dec;4(4):263–70.

Thoracic epidural anesthesia does not affect functional recovery from myocardial stunning in sevoflurane-anesthetized dogs. Meissner A, et al. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6):662–7

Case 4--1999. Myocardial function improvement after hemofiltration in a septic patient [clinical conference] Oppenheim-Eden A, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):484–9

Myocardial hypothermia: a potential therapeutic technique for acute regional myocardial ischemia. Hale SL, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):405–13 (29 ref.)

T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1258–68

Nonfluoroscopic endocardial catheter mapping of atrial fibrillation. Kuck KH, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S57–62

Class IC antiarrhythmic drugs, flecainide and pilsicainide, produce ST segment elevation simulating inferior myocardial ischemia. Nakamura W, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):855–8

Characteristics of ischemic and peri-ischemic regions during ventricular fibrillation in the canine heart. Rankovic V, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1090–100

Conduction properties of the crista terminalis in patients with typical atrial flutter: basis for a line of block in the reentrant circuit. Tai CT, et al. **J Cardiovasc Electrophysiol** 1998 Aug; 9(8):811–9

Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. Zabel M, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1279–84

The influence of cardiopulmonary function on outcome of veterans undergoing resectional therapy for lung cancer. Canver CC, et al. **J Cardiovasc Surg (Torino)** 1998 Aug; 39(4):497–501

Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. Colao A, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1518–23

Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. Wessely R, et al. **J Clin Invest** 1998 Oct 1;102(7):1444–53

Estimation of epicardial activation maps from intravascular recordings. Kuenzler RO, et al. **J Electrocardiol** 1999 Apr; 32(2):77–92

Effects of brain death on myocardial function and ischemic tolerance of potential donor hearts. Szabó G, et al. **J Heart Lung Transplant** 1998 Sep;17(9):921–30

Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. Watanabe K, et al. **J Hypertens** 1999 Aug;17(8):1161–8

Optical transmembrane potential recordings during intracardiac defibrillation-strength shocks. Clark DM, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):109–20

The effect of intravenous procainamide on the HV interval at electrophysiologic study. Girard SE, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):129–37

Unipolar recording in cardiac electrophysiologic studies. Kusumoto FM. **J Interv Card Electrophysiol** 1999 Jul; 3(2):121–7 (45 ref.)

Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. Campbell B, et al. **J Mol Cell Cardiol** 1999 Feb; 31(2):467–76

Improved myocardial tolerance to ischaemia in the diabetic rabbit. Hadour G, et al. **J Mol Cell Cardiol** 1998 Sep; 30(9):1869–75

Aging impairs functional, metabolic and ionic recovery from ischemia-reperfusion and hypoxia-reoxygenation. Headrick JP. **J Mol Cell Cardiol** 1998 Jul;30(7):1415–30

Modulation of adenosine effects in attenuation of ischemia and reperfusion injury in rat heart. Hirai K, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1803–15

Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. Kramer CM, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1773–8

Smooth muscle cell transplantation into myocardial scar tissue improves heart function. Li RK, et al. **J Mol Cell Cardiol** 1999 Mar;31(3):513–22

Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. Martinez ML, et al.

J Mol Cell Cardiol 1999 Sep;31(9):1617–25

Extracellular matrix regulation in the development of Syrian cardiomyopathic Bio 14.6 and Bio 53.58 hamsters. Masutomo K, et al. **J Mol Cell Cardiol** 1999 Sep; 31(9):1607–15

Beta-tropomyosin overexpression induces severe cardiac abnormalities. Muthuchamy M, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1545–57

Depressed myofilament co-operativity associated with post-cardioplegic myocardial depression. Powers FM, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1779–87

Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. Sharov VG, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1757–62

Insulin improves cardiac contractile function and oxygen utilization efficiency during moderate ischemia without compromising myocardial energetics. Tune JD, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2025–35

Activation of alpha1-adrenergic receptor during Ca2+ pre-conditioning elicits strong protection against Ca2+ overload injury via protein kinase C signaling pathway. Wang Y, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2423–35

Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. Zimmermann R, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1447–56

Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. Merlet P, et al. **J Nucl Med** 1999 Feb;40(2):224–31

Cardiac autonomic function during sleep in psychogenic and organic erectile dysfunction. Lavie P, et al. **J Sleep Res** 1999 Jun;8(2):135–42

Unpinning of a rotating wave in cardiac muscle by an electric field. Pumir A, et al. **J Theor Biol** 1999 Aug 7;199(3):311–9

Effects of electroacupuncture at neiguan on myocardial microcirculation in rabbits with acute myocardial ischemia. Cao Q, et al. **J Tradit Chin Med** 1998 Jun;18(2):134–9

Determinants of myocardial performance after blunt chest trauma. Moomey CB Jr, et al. **J Trauma** 1998 Dec; 45(6):988–96

Detection of a local slow potential preceding the surface QRS complex during non-preexcited impulse propagation--a phenomenon reflecting anterograde concealed conduction through the accessory pathway? Kobayashi Y, et al. **Jpn Circ J** 1998 Oct;62(10):760–4

Fas expression and apoptosis correlate with cardiac dysfunction in patients with dilated cardiomyopathy. Yamamura T, et al. **Jpn Circ J** 1999 Mar;63(3):149–54

Myocardial ischemia/reperfusion injury in the inducible nitric oxide synthase knockout mice. Xi L, et al. **Life Sci** 1999;65(9):935–45

Cytochemical demonstration of sites of hydrogen peroxide generation and increased vascular permeability in isolated pig hearts after ischaemia and reperfusion. Skepper JN, et al. **Microsc Res Tech** 1998 Sep 1;42(5):369–85

Tunnel capillaries of cardiac myocyte in pressure-overloaded rat heart-an ultrastructural three-dimensional study. Kobayashi M, et al. **Microvasc Res** 1999 May;57(3):258–72

Mitochondrial function as a determinant of recovery or death in cell response to injury. Di Lisa F, et al. **Mol Cell Biochem** 1998 Jul;184(1-2):379–91

Features of short-term myocardial hibernation. Heusch G, et al. **Mol Cell Biochem** 1998 Sep;186(1-2):185–93 (45 ref.)

Myocardial oxidative stress changes during compensated right heart failure in rats. Pichardo J, et al. **Mol Cell Biochem** 1999 Jun;196(1-2):51–7

Early ischemia-induced alterations of the outer mitochondrial membrane and the intermembrane space: a potential cause for altered energy transfer in cardiac muscle? Rossi A, et al. **Mol Cell Biochem** 1998 Jul; 184(1-2):401–8

Biochemical consequences of electrical pacing in ischemic-reperfused isolated rat hearts. Samaja M, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):245–9

Antioxidant-sensitive shortening of ventricular action potential in hyperthyroid rats is independent of lipid peroxidation. Venditti P, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1-2):15–23

Mechanical function and substrate oxidation in the neonatal pig heart subjected to pacing-induced tachycardia. Ascuitto RJ, et al. **Mol Genet Metab** 1999 Mar;66(3):212–23

Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Wang J, et al. **Nat Genet** 1999 Jan;21(1):133–7

Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Depre C, et al. **Nat Med** 1998 Nov; 4(11):1269–75

Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Laforêt P, et al. **Neurology** 1998 Nov;51(5):1454–6

Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Hoogerwaard EM, et al. **Neuromuscul Disord** 1999 Jul;9(5):347–51

Effects of obesity and weight loss on cardiac function and valvular performance. Karason K, et al. **Obes Res** 1998 Nov;6(6):422–9

Effects of 46 weeks of very-low-calorie-diet treatment on weight loss and cardiac function--a case report [letter] Rössner S. **Obes Res** 1998 Nov;6(6):462–3

Extension of refractoriness in a model of cardiac defibrillation. Trayanova NA, et al. **Pac Symp Biocomput** 1999;:240–51

The dynamic behavior of the diastolic slope of monophasic action potential can be related to the occurrence and maintenance of delayed afterdepolarization dependent arrhythmias. De Groot SH, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 1):49–59

Sagging body parts. Harthorne JW. **Pacing Clin Electrophysiol** 1999 Feb;22(2):375

"Sagging heart syndrome": a cause of acute lead dislodgment in two patients. Iskos D, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):371–5

Rate and time dependent effects of D-sotalol on the monophasic action potential after sudden increase of the heart rate. Melichercik J, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 1):65–72

QT dispersion in alpha-myosin heavy-chain familial hypertrophic cardiomyopathy mice. Bevilacqua LM, et al. **Pediatr Res** 1999 May;45(5 Pt 1):643–7

Cardiac cell volume: crystal clear or murky waters? A comparison with other cell types. Wright AR, et al. **Pharmacol Ther** 1998 Oct;80(1):89–121 (276 ref.)

Magnetocardiographic analysis of the two-dimensional distribution of intra-QRS fractionated activation. Müller HP, et al. **Phys Med Biol** 1999 Jan;44(1):105–20

Effect of chronic renal insufficiency on the function and metabolic parameters of the isolated rat heart. Tutterová M, et al. **Physiol Res** 1997;46(6):427–33

Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Dorn GW 2nd, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6400–5

Conditional lineage ablation to model human diseases. Lee P, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15; 95(19):11371–6

Postmitochondrial regulation of apoptosis during heart failure [comment] Reed JC, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7614–6 (60 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8144–9.

Ventricular fibrillation: one spiral or many? Evans SJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 22;265(1411):2167–70

Modelling myocardial ischaemia and reperfusion. Ch'en FF, et al. **Prog Biophys Mol Biol** 1998;69(2-3):515–38

Virtual electrode effects in defibrillation. Trayanova N, et al. **Prog Biophys Mol Biol** 1998;69(2-3):387–403

Improvement of preservation with cardioplegia induced by heat stress is mediated by calcitonin gene-related peptide. Song QJ, et al. **Regul Pept** 1999 Feb 5;79(2-3):141–5

Haemodynamics during liver transplantation in familial amyloidotic polyneuropathy: study of the intraoperative cardiocirculatory data of 50 patients. Viana J da S, et al. **Rev Port Cardiol** 1999 Jul-Aug;18(7-8):689–97

Plasma noradrenaline and neuropeptide-Y may not be of primary importance in the pathophysiology of cardiac involvement in systemic sclerosis. Kazzam E, et al. **Scand J Rheumatol** 1999;28(4):238–43

Heart failure simulated [news] Service RF. **Science** 1999 Apr 2;284(5411):33–4

Effect of amiloride on age-dependent cardiac dysfunction after ischemia/reperfusion in the isolated, perfused rat heart. Linakis JG, et al. **Shock** 1999 Mar;11(3):218–23

Carnitine deprivation adversely affects cardiac performance in the lipopolysaccharide- and hypoxia/reoxygenation-stressed piglet heart. Penn D, et al. **Shock** 1999 Feb;11(2):120–6

Effects of stroke localization on cardiac autonomic balance and sudden death. Tokgözoglu SL, et al. **Stroke** 1999 Jul; 30(7):1307–11

The role of coronary perfusion changes in cardiac dysfunction associated with brain death. Szabó G, et al. **Thorac Cardiovasc Surg** 1998 Dec;46(6):339–43

Effect of exercise induced hypoxaemia on myocardial repolarisation in severe chronic obstructive pulmonary disease. Smith RP, et al. **Thorax** 1998 Jul;53(7):572–6

Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit. Rossoni G, et al. **Thromb Res** 1999 Jun 1;94(5):327–38

Influence of brain death and cardiac preservation on systolic and diastolic function and coronary circulation in the cross-circulated canine heart. Szabó G, et al. **World J Surg** 1999 Jan;23(1):36–43

[Heart function and clinical observations of patients with severe congestive heart failure treated with milrinone] Lu G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):27–9 (Eng. Abstr.) **(Chi)**

[Physiopathological basis of the treatment of heart failure] Vinsonneau C, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1315–24 (Eng. Abstr.) **(Fre)**

[Myocardial viability. The concept of myocardial viability] Cachin JC. **Presse Med** 1998 Jun 13;27(21):1038–42 (30 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial viability. Myocardial viability post-infarct: contribution of dobutamine-echography] Monin JL, et al. **Presse Med** 1998 Jun 13;27(21):1050–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[A patient with muscle pain after a journey to the tropics. Myocardial involvement in proximal myotonic myopathy (see comments)] Held M, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1201–6 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1999 May 7;124(18):575. Comment in: Dtsch Med Wochenschr 1999 May 7;124(18):575–6. **(Ger)**

[Variation in the evoked ventricular potentials after the implantation of an endocardiac catheter; the correlation with stimulation thresholds] Azzarelli A, et al. **G Ital Cardiol** 1999 Jun;29(6):669–74 (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage and the heart] Martorano PP, et al. **Minerva Anestesiol** 1998 May;64(5):231–3 (16 ref.) (Eng. Abstr.) **(Ita)**

[Myocardial viability. Concept, physiopathology. Methods and diagnostic value] Aleixo A, et al. **Acta Med Port** 1998 May;11(5):465–71 (22 ref.) (Eng. Abstr.) **(Por)**

[Morpho-functional cardiac evaluation in young normotensive children of hypertensive patients. A prospective Doppler-echocardiographic study] de Almeida CM, et al. **Arq Bras Cardiol** 1998 Nov;71(5):681–6 (Eng. Abstr.) **(Por)**

[The status of the heart and coronary artery bed in experimental subclavian-pulmonary anastomosis and after its removal] Shormanov SV. **Arkh Patol** 1998 Nov-Dec; 60(6):27–30 (Eng. Abstr.) **(Rus)**

[Relation between mitochondrial respiratory function and postischemic recovery of the isolated heart contractility] Dzhavadov SA. **Biull Eksp Biol Med** 1998 Nov; 126(11):538–41 **(Rus)**

[Opiatergic mechanisms of cardioprotective and anti-arrhythmic effects of adaptation] Lishmanov IuB, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):167–70 **(Rus)**

[Effect of beta-endorphin on the afferent heart systems] Mikhailova SD, et al. **Biull Eksp Biol Med** 1998 Sep; 126(9):294–8 **(Rus)**

[Blockade of heat shock protein synthesis prevents cardioprotective effect of adaptation to physical exertion] Pshennikova MG, et al. **Biull Eksp Biol Med** 1998 Sep; 126(9):299–301 **(Rus)**

[The role of the muscarinic, adenosine and adrenoreceptors of the heart in the development of postischemic reperfusion ventricular fibrillation] Eliseev VV, et al. **Eksp Klin Farmakol** 1999 May-Jun;62(3):25–7 (Eng. Abstr.) **(Rus)**

[The detection of early disorders of the heart pumping function in patients with ischemic heart disease by using stress Doppler echocardiography] Dzizinskiĭ AA, et al. **Ter Arkh** 1999;71(2):72–5 (Eng. Abstr.) **(Rus)**

[The connection between late ventricular potentials and ventricular arrhythmias in hypertension patients with different forms of myocardial hypertrophy] Gusarov GV, et al. **Ter Arkh** 1998;70(8):48–52 (Eng. Abstr.) **(Rus)**

[The functional activity, energetics and survival of the heart under hypothermia] Aliukhin IuS. **Usp Fiziol Nauk** 1998 Jul-Sep;29(3):66–78 (52 ref.) (Eng. Abstr.) **(Rus)**

[The protective reaction of the myocardium to ischemic damage] Antonov AR, et al. **Vestn Ross Akad Med Nauk** 1998;(9):36–40 (Eng. Abstr.) **(Rus)**

[The clinical course and cardiohemodynamic status of patients with different variants of diphtheritic myocarditis] Amosova KM, et al. **Lik Sprava** 1998 Jun;(4):53–7 (Eng. Abstr.) **(Ukr)**

RADIATION EFFECTS

Magnetic induction at 60 Hz in the human heart: a comparison between the in situ and isolated scenarios. Dawson TW, et al. **Bioelectromagnetics** 1999;20(4):233–43

Radiotherapy considerations in patients with Hodgkin's disease who receive mediastinal radiotherapy and anthracycline-containing chemotherapy. Plowman PN. **Clin Oncol (R Coll Radiol)** 1998;10(6):384–91

Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Dalloz F, et al. **Free Radic Biol Med** 1999 Apr; 26(7-8):785–800

Angiogenesis and expression of tenascin after transmural laser revascularization. Gassler N, et al. **Histol Histopathol** 1999 Jan;14(1):81–7

Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Hardenbergh PH, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):69–72

Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer. Fukuda M, et al. **Intern Med** 1999 May;38(5):436–8

Microwave ablation of myocardial tissue: the effect of element design, tissue coupling, blood flow, power, and duration of exposure on lesion size. Thomas SP, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):72–8

Pulsing microwave energy: a method to create more uniform myocardial temperature gradients. Haugh C, et al. **J Interv Card Electrophysiol** 1997 Feb;1(1):57–65

Comparative pathology: radiation-induced coronary artery disease in man and animals. Virmani R, et al. **Semin Interv Cardiol** 1998 Sep-Dec;3(3-4):163–72 (25 ref.)

[Delayed cardiac effects of adjuvant doxorubicin and radiotherapy in breast cancer patients] Sack H. **Strahlenther Onkol** 1999 Jun;175(6):293–4 **(Ger)**

[Myocardial mast cell reaction during neoangiogenesis induced by YAG:Nd laser] Kozel' AI, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):116–8 **(Rus)**

[Effects of opioid peptides on ischemic myocardial arrhythmias during laser irradiation and disturbed heart sympathetic innervation] Mikhailova SD, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):374–7 **(Rus)**

[Participation of sympathetic innervation of the heart in the antiarrhythmic effect of intra-atrial laser irradiation] Mikhailova SD, et al. **Biull Eksp Biol Med** 1998 Nov;

126(11):522–6 **(Rus)**
[The effect of normobaric hypoxia on the indices of the cardiorespiratory and immune systems in the inhabitants of radiation-contaminated regions] Mel'nyk TO, et al. **Fiziol Zh** 1999;45(1-2):104–13 (Eng. Abstr.) **(Ukr)**
[The effect of ultraviolet irradiation of the blood on lung–heart hemodynamics in patients with ischemic heart disease and concomitant chronic obstructive bronchitis] Shut' SV. **Lik Sprava** 1999 Jan–Feb;(1):70–3 (Eng. Abstr.) **(Ukr)**

RADIOGRAPHY

A bullet in the heart. Wainsztein N, et al. **Circulation** 1999 Sep 21;100(12):1361
Buckling of the tethering catheter causes migration of a temporary caval filter to the right atrium. Kelly IM, et al. **Clin Radiol** 1999 Jun;54(6):398–401
Effect of aging on cardiothoracic ratio in women: a longitudinal study. Inoue K, et al. **Gerontology** 1999 Jan–Feb;45(1):53–8
Hypertrabeculated left ventricle in mitochondriopathy. Finsterer J, et al. **Heart** 1998 Dec;80(6):632
Myocardial perfusion defects and associated systemic ventricular dysfunction in congenitally corrected transposition of the great arteries. Hornung TS, et al. **Heart** 1998 Oct;80(4):322–6
Measurement of in vivo myocardial microcirculatory function with electron beam CT. Lerman LO, et al. **J Comput Assist Tomogr** 1999 May–Jun;23(3):390–8
Estimation of three-dimensional cardiac velocity fields: assessment of a differential method and application to three-dimensional CT data. Gorce JM, et al. **Med Image Anal** 1997 Apr;1(3):245–61
Electrocardiogram-correlated image reconstruction from subsecond spiral computed tomography scans of the heart. Kachelriess M, et al. **Med Phys** 1998 Dec;25(12):2417–31
Maximum likelihood estimation in calibrating a stereo camera setup. Muijtjens AM, et al. **Med Phys** 1999 Feb;26(2):310–8
Radiographic assessment of atrial dipole position in single pass lead VDD and DDD pacing. The Multicenter Study Group. Bongiorni MG, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2240–5
Blind estimation of compartmental model parameters. Di Bella EV, et al. **Phys Med Biol** 1999 Mar;44(3):765–80
Radiofrequency multielectrode catheter ablation in the atrium. Panescu D, et al. **Phys Med Biol** 1999 Apr; 44(4):899–915
Examination of the heart [editorial] Boxt LM. **Semin Roentgenol** 1999 Jul;34(3):164
Plain-film examination of the normal heart. Boxt LM. **Semin Roentgenol** 1999 Jul;34(3):169–80 (13 ref.)
Right atrial dilatation: major contributor to increased cardiothoracic ratio in cardiac transplant candidates. Aravot D, et al. **Transplant Proc** 1999 Jun;31(4):1887–8
Importance of the cardiothoracic ratio in the evaluation of cardiac transplant candidates. Berman M, et al. **Transplant Proc** 1999 Jun;31(4):1885–6
[Functional imaging of the heart with electron-beam computed tomography] Becker A, et al. **Radiologe** 1998 Dec;38(12):1021–8 (Eng. Abstr.) **(Ger)**
[The internal structure of soft and bony tissues studied by X-ray refraction introscopy] Manushkin AA, et al. **Vestn Rentgenol Radiol** 1998 Mar–Apr;(2):32–7 (Eng. Abstr.) **(Rus)**
[The X-ray characteristics of the status of the heart and vessels in patients with arterial hypertension exacerbated by a myocardial infarct] Tsallagova ZS, et al. **Vestn Rentgenol Radiol** 1998 Mar–Apr;(2):14–8 (Eng. Abstr.) **(Rus)**
[Radiologic lymphography of the human heart by doctor Alejandro Celis and collaborators] Quijano Pitman F. **Gac Med Mex** 1998 Nov–Dec;134(6):742 **(Spa)**

RADIONUCLIDE IMAGING

Cardiac sympathetic denervation in early stages of amyotrophic lateral sclerosis demonstrated by 123I-MIBG-SPECT. Druschky A, et al. **Acta Neurol Scand** 1999 May;99(5):308–14
Oxidative metabolism of the transplanted human heart assessed by positron emission tomography using C-11 acetate. Bengel FM, et al. **Am J Cardiol** 1999 May 15; 83(10):1503–5, A8
Impact of limited treadmill exercise on adenosine Tc-99m sestamibi single-photon emission computed tomographic myocardial perfusion imaging in coronary artery disease. Jamil G, et al. **Am J Cardiol** 1999 Aug 15;84(4):400–3
Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. Marin-Neto JA, et al. **Am J Cardiol** 1998 Nov 1;82(9):1001–7
Accuracy of single-photon emission computed tomography myocardial perfusion imaging in patients with stents in native coronary arteries. Milavetz JJ, et al. **Am J Cardiol** 1998 Oct 1;82(7):857–61
Limitations of radionuclide angiographic assessment of left ventricular systolic function before lung transplantation. Mal H, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1396–402
Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Suzuki J, et al. **Angiology** 1999 Jan;50(1):37–45
Simultaneous assessment of function and perfusion during dipyridamole-handgrip Tc-99m sestamibi imaging in chronic coronary artery disease. Massardo T, et al. **Ann Nucl Med** 1999 Apr;13(2):121–5
123I-MIBG myocardial scintigraphy in diabetic patients: relationship with 201Tl uptake and cardiac autonomic function. Nagamachi S, et al. **Ann Nucl Med** 1998 Dec; 12(6):323–31
Prediction of functional recovery and prognosis in patients with acute myocardial infarction by 123I-BMIPP and 201Tl myocardial single photon emission computed tomography: a multicenter trial. Nishimura T, et al. **Ann Nucl Med** 1998 Oct;12(5):237–48
Early and delayed Tc-99m-tetrofosmin myocardial SPECT in patients with left bundle branch block. Sugihara H, et al. **Ann Nucl Med** 1998 Oct;12(5):281–6
Effect of exercise-induced activation of sympathetic nerve activity on clearance of 123I-MIBG from the myocardium. Sugihara H, et al. **Ann Nucl Med** 1998 Aug;12(4):175–8
Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy. Sugihara H, et al. **Ann Nucl Med** 1998 Dec;12(6):349–54
Evaluation of the cardiac autonomic nervous system in spontaneously non-insulin-dependent diabetic rats by 123I-metaiodobenzylguanidine imaging. Togane Y. **Ann Nucl Med** 1999 Feb;13(1):19–26
A trial for the quantification of regional myocardial blood flow with continuous infusion of Tc-99m MIBI and dynamic SPECT. Tsuchida T, et al. **Ann Nucl Med** 1999 Feb;13(1):61–4
Diabetic cardiac autonomic dysfunction: parasympathetic versus sympathetic. Uehara A, et al. **Ann Nucl Med** 1999 Apr;13(2):95–100
Abnormal fatty acid metabolism in patients with coronary vasospasm. Watanabe K, et al. **Ann Nucl Med** 1999 Feb; 13(1):33–41
Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Watanabe K, et al. **Ann Nucl Med** 1998 Oct;12(5):261–6
Phase changes caused by hyperventilation stress in spastic angina pectoris analyzed by first-pass radionuclide ventriculography. Wu J, et al. **Ann Nucl Med** 1999 Feb; 13(1):13–8
Washout rate of 123I-metaiodobenzylguanidine increased by posture change or exercise in normal volunteers. Yano T, et al. **Ann Nucl Med** 1999 Apr;13(2):89–93
Predicting the effects on patients with dilated cardiomyopathy of beta-blocker therapy, by using iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) myocardial scintigraphy. Yoshinaga K, et al. **Ann Nucl Med** 1998 Dec; 12(6):341–7
111Indium antimyosin antibody imaging of primary myocardial involvement in systemic diseases. Sarda L, et al. **Ann Rheum Dis** 1999 Feb;58(2):90–5
Manufacture of strontium-82/rubidium-82 generators and quality control of rubidium-82 chloride for myocardial perfusion imaging in patients using positron emission tomography. Alvarez-Diez TM, et al. **Appl Radiat Isot** 1999 Jun;50(6):1015–23
Myocardial contrast and transesophageal echocardiographic study of the left coronary artery from the main pulmonary artery. Vargas-Barrón J, et al. **Arch Inst Cardiol Mex** 1998 May–Jun;68(3):253–5
Radiolabelled monoclonal antibodies (McAb): an alternate approach to the conventional methods for the assessment of cardiomyocyte damage in an experimental brain-death pig model. Haider KH, et al. **Arch Pharm Res** 1998 Oct; 21(5):496–502
Rest-redistribution 201-Tl single-photon emission CT imaging for determination of myocardial viability: relationship among viability, mode of therapy, and long-term prognosis. Morse RW, et al. **Chest** 1999 Jun; 115(6):1621–6
Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Auerbach MA, et al. **Circulation** 1999 Jun 8;99(22):2921–6
Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Hendel RC, et al. **Circulation** 1999 Jun 1;99(21):2742–9
Comparison of myocardial perfusion imaging and cardiac troponin I in patients admitted to the emergency department with chest pain. Kontos MC, et al. **Circulation** 1999 Apr 27;99(16):2073–8
Comparison between left ventricular electromechanical mapping and radionuclide perfusion imaging for detection of myocardial viability. Kornowski R, et al. **Circulation** 1998 Nov 3;98(18):1837–41
The reversibility of cardiac neuronal function after removal of a pheochromocytoma: an I-123 MIBG Scintigraphic Study. Agostini D, et al. **Clin Nucl Med** 1999 Jul; 24(7):514–8
False-positive antimyosin imaging caused by cardioversion-induced skeletal muscle uptake. Alberini JL, et al. **Clin Nucl Med** 1999 Jul;24(7):519–20
Coronary artery occlusion and myocardial infarction: a seldom encountered complication of blunt chest trauma. Banzo I, et al. **Clin Nucl Med** 1999 Feb;24(2):94–6
Tc-99m pyrophosphate uptake in small areas of myocardial injury produced by radiofrequency catheter ablation of arrhythmias. Bom HS, et al. **Clin Nucl Med** 1999 Jan; 24(1):57–9
Combined Tc-99m sestamibi first-pass radionuclide angiography and cardiac SPECT imaging during arbutamine infusion delivered by a computerized closed-loop system. Borges-Neto S, et al. **Clin Nucl Med** 1999 Jan;24(1):42–7
Tc-99m tetrofosmin myocardial perfusion imaging before and six months after percutaneous transluminal coronary angioplasty. Georgoulias P, et al. **Clin Nucl Med** 1998 Oct; 23(10):678–82
Incidental detection of a malignant thymic tumor by Tc-99m sestamibi cardiac imaging. Greyson ND, et al. **Clin Nucl Med** 1998 Nov;23(11):781–2
Altered radiopharmaceutical distribution in myeloma: bone tracer in the heart and heart tracer in the bone. Gupta AK, et al. **Clin Nucl Med** 1998 Dec;23(12):820–3
An ultrashort 1-day protocol of Tc-99m tetrofosmin. Hattori N, et al. **Clin Nucl Med** 1999 Feb;24(2):85–91
Adenosine challenge and boost protocols: new tools for myocardial perfusion imaging. Hurwitz R, et al. **Clin Nucl Med** 1999 Feb;24(2):92–3
Early duodenogastric reflux in Tc-99m tetrofosmin myocardial scintigraphy: a case report. Karayalcin B, et al. **Clin Nucl Med** 1998 Dec;23(12):844–5
The 24-hour Tl-201 image in dual isotope myocardial perfusion scintigraphy: clinical utility and prognostic significance. Kipper MS, et al. **Clin Nucl Med** 1998 Sep; 23(9):576–81
Prediction of myocardial viability: Tl-201 versus sestamibi versus teboroxime compared with FDG uptake. Kiser JW, et al. **Clin Nucl Med** 1998 Jul;23(7):432–6
Tl-201 myocardial SPECT in patients with systemic arterial diseases. Murata Y, et al. **Clin Nucl Med** 1998 Dec; 23(12):832–5
Off-peak detector mimicking ischemia on myocardial scan. Nitke SJ. **Clin Nucl Med** 1999 Apr;24(4):276
Hyperactivity in the lower sternal region with Tc-99m sestamibi: possible cardiac origin. Servais F, et al. **Clin Nucl Med** 1998 Jul;23(7):461–2
I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy. Utsunomiya K, et al. **Clin Nucl Med** 1999 Jun;24(6):418–20
Gated Tl-201 myocardial perfusion SPECT: application of energy window optimization. Wadhwa SS, et al. **Clin Nucl Med** 1999 Jul;24(7):479–82
Tl-201 myocardial perfusion SPECT: role of nitrate-augmented redistribution. Wadhwa SS, et al. **Clin Nucl Med** 1999 Jan;24(1):1–5
Tc-99m HDP uptake in cardiac amyloidosis. Wadhwa SS, et al. **Clin Nucl Med** 1999 Mar;24(3):156–8
Old traumatic ventricular septal defect seen on myocardial perfusion imaging. Wadhwa SS, et al. **Clin Nucl Med** 1999 Feb;24(2):135
Correlation of SPECT and PET cardiac images by a surface matching registration technique. Gilardi MC, et al. **Comput Med Imaging Graph** 1998 Sep–Oct;22(5):391–8
Delayed recovery of myocardial perfusion in acute myocardial infarction: a scintigraphic study after early thrombolytic treatment. Bouvier F, et al. **Coron Artery Dis** 1998;9(7):443–9
Mechanism of impaired left ventricular wall motion in the diabetic heart without coronary artery disease. Sakamoto K, et al. **Diabetes Care** 1998 Dec;21(12):2123–8
Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Vanzetto G, et al. **Diabetes Care** 1999 Jan;22(1):19–26
Two-year assessment by exercise Thallium scintigraphy of myocardial revascularization using bilateral internal mammary and gastroepiploic arteries. Jegaden O, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):131–4
Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. Bisi G, et al. **Eur J Endocrinol** 1999 Apr; 140(4):322–7
Three-dimensional contour detection of left ventricular myocardium using elastic surfaces. Biedenstein S, et al. **Eur J Nucl Med** 1999 Mar;26(3):201–7
Motion detection and correction using multi-rotation 180 degrees single-photon emission tomography for thallium myocardial imaging. Britten AJ, et al. **Eur J Nucl Med** 1998 Nov;25(11):1524–30
Respective roles of scatter, attenuation, depth-dependent collimator response and finite spatial resolution in cardiac single-photon emission tomography quantitation: a Monte Carlo study. el Fakhri GN, et al. **Eur J Nucl Med** 1999 May;26(5):437–46
Attenuation correction improves the detection of viable myocardium by thallium-201 cardiac tomography in patients with previous myocardial infarction and left ventricular dysfunction. Gallowitsch HJ, et al. **Eur J Nucl Med** 1999 May;26(5):459–66
Comparative myocardial uptake of technetium-99 m sestamibi and technetium-99m tetrofosmin one hour after stress injection. Gremillet E, et al. **Eur J Nucl Med** 1998 Nov;25(11):1502–10
Scintigraphic evaluation of myocardial ischaemia using a new fatty acid analogue: iodine-123-labelled

15-(p-iodophenyl)-9-(R, S)-methylpentadecanoic acid (9MPA). Hashimoto J, et al. **Eur J Nucl Med** 1999 Aug; 26(8):887-93

A study of myocardial muscarinic receptors in streptozotocin-induced diabetic rats using iodine-123 N-methyl-4-iododexetimide. Mardon K, et al. **Eur J Nucl Med** 1999 Jul;26(7):743-9

The kinetics of beta-methyl-substituted labelled fatty acids in ischaemic myocardium: an analysis in man and with a blood-perfused isolated heart model. Marie PY, et al. **Eur J Nucl Med** 1999 May;26(5):474-82

Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Nekolla SG, et al. **Eur J Nucl Med** 1998 Sep;25(9):1313-21

Exercise-induced stunning continues for at least one hour: evaluation with quantitative gated single-photon emission tomography. Paul AK, et al. **Eur J Nucl Med** 1999 Apr; 26(4):410-5

Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Schillaci O, et al. **Eur J Nucl Med** 1999 Jul;26(7):713-7

Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease. Thurnheer R, et al. **Eur J Nucl Med** 1999 Aug;26(8):812-7

Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. Utsunomiya K, et al. **Eur J Nucl Med** 1998 Dec; 25(12):1643-8

Nuclear medicine studies of the heart. Bengel FM, et al. **Eur Radiol** 1998;8(9):1698-706 (61 ref.)

Left ventricular dysfunction during dobutamine stress echocardiography in patients with syndrome X and positive myocardial perfusion scintigraphy. Fragasso G, et al. **G Ital Cardiol** 1999 Apr;29(4):383-90

Refractory angina despite patent coronary artery bypass grafts: treatment with transmyocardial laser revascularization and scintigraphic evidence of improved myocardial perfusion. Triggiani M, et al. **G Ital Cardiol** 1999 Jan;29(1):72-5

Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Kakuchi H, et al. **Heart** 1999 Feb; 81(2):148-52

Radionuclide techniques for myocardial viability and hibernation [editorial] Walton S. **Heart** 1999 Jan;81(1):6-7

Exercise four hour redistribution thallium-201 single photon emission computed tomography and exercise induced ST segment elevation in detecting the viable myocardium in patients with acute myocardial infarction. Yamagishi H, et al. **Heart** 1999 Jan;81(1):17-24

Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hamada M, et al. **Hypertens Res** 1998 Dec; 21(4):227-34

BMIPP imaging to assess functional outcome in patients with acute and chronic left ventricular dysfunction. Franken PR, et al. **Int J Card Imaging** 1999 Feb;15(1):27-34 (28 ref.)

Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Ishida Y, et al. **Int J Card Imaging** 1999 Feb;15(1):71-7 (20 ref.)

BMIPP-design and development. Knapp FF Jr, et al. **Int J Card Imaging** 1999 Feb;15(1):1-9 (61 ref.)

The role of early measurement of nitrogen-13 ammonia uptake for predicting contractile recovery after acute myocardial infarction. Lancellotti P, et al. **Int J Card Imaging** 1998 Aug;14(4):261-7; discussion 269-70

Cardiac BMIPP imaging in acute myocardial infarction. Nakata T, et al. **Int J Card Imaging** 1999 Feb;15(1):21-6 (24 ref.)

BMIPP in angina pectoris. Nishimura S, et al. **Int J Card Imaging** 1999 Feb;15(1):35-9 (20 ref.)

BMIPP compared with thallium redistribution. Taki J, et al. **Int J Card Imaging** 1999 Feb;15(1):49-59 (58 ref.)

Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79-89 (64 ref.)

Mental stress-induced silent myocardial ischemia detected during ambulatory ventricular function monitoring. Vassiliadis IV, et al. **Int J Card Imaging** 1998 Jun; 14(3):171-7

Efficacy and limitation of F-18-fluorodeoxyglucose positron emission tomography during fasting to assess myocardial viability in the acute phase of myocardial infarction. Nonogi H, et al. **Intern Med** 1998 Aug;37(8):653-61

Comparative prognostic value of automatic quantitative analysis versus semiquantitative visual analysis of exercise myocardial perfusion single-photon emission computed tomography. Berman DS, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1987-95

Cardiac sympathetic denervation in Ross syndrome demonstrated by MIBG-SPECT. Druschky K, et al. **J Auton Nerv Syst** 1999 May 28;76(2-3):184-7

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. Orimo S, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):189-94

Imaging guidelines for nuclear cardiology procedures, part 2. American Society of Nuclear Cardiology. **J Nucl Cardiol** 1999 Mar-Apr;6(2):G47-84

Nuclear cardiology in the literature. **J Nucl Cardiol** 1999 May-Jun;6(3):377

4th International Conference of Nuclear Cardiology. Athens, Greece, April 18-21, 1999. Abstracts. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 2):S1-132

Nuclear cardiology in the literature. **J Nucl Cardiol** 1998 Sep-Oct;5(5):544-5

Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):93-155

Clinical implication of down-scatter in attenuation-corrected myocardial SPECT. Almquist H, et al. **J Nucl Cardiol** 1999 Jul-Aug;6(4):406-11

Identification of severe right ventricular dysfunction and pressure overload by stress radionuclide myocardial perfusion SPECT imaging with gating. Arora R, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):375-6

Accuracy of 99mTc-tetrofosmin myocardial tomography in the evaluation of coronary artery disease. Azzarelli S, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):183-9

American Society of Nuclear Cardiology position statement on electrocardiographic gating of myocardial perfusion SPECT scintigrams. Bateman TM, et al. **J Nucl Cardiol** 1999 Jul-Aug;6(4):470-1

Establishing an approach for patients with recent coronary occlusion: identification of viable myocardium. Beanlands RS, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):298-305

Extent of myocardial viability in regions of left ventricular dysfunction by rest-redistribution thallium-201 imaging: a powerful predictor of outcome [editorial; comment] Beller GA, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):445-8 . Comment on: J Nucl Cardiol 1998 Jul-Aug;5(4):378-86.

Segmentation of gated Tl-SPECT images and computation of ejection fraction: a different approach. Brigger P, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):286-97

Development of respiratory gated myocardial SPECT system. Cho K, et al. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):20-8

Clinical review of attenuation-corrected cardiac SPECT. Corbett JR, et al. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):54-68 (109 ref.)

Electrocardiographically gated myocardial perfusion SPECT: technical principles and quality control considerations. Cullom SJ, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):418-25 (36 ref.)

Comparative performance of gated perfusion SPECT wall thickening, delayed thallium uptake, and F-18 fluorodeoxyglucose SPECT in detecting myocardial viability. DePuey EG, et al. **J Nucl Cardiol** 1999 Jul-Aug; 6(4):418-28

Comparison of Tc-99m sestamibi and Tl-201 gated perfusion SPECT. DePuey EG, et al. **J Nucl Cardiol** 1999 May-Jun; 6(3):278-85

The challenge of quantifying defect size and severity: reality versus algorithm [editorial] Eisner RL, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):362-71

Dobutamine-atropine stress myocardial perfusion SPECT imaging in the diagnosis of graft stenosis after coronary artery bypass grafting [see comments] Elhendy A, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):491-7. Comment in: J Nucl Cardiol 1998 Sep-Oct;5(5):533-7.

False-positive thallium-201 myocardial perfusion imaging caused by pectus excavatum. Georgeson S. **J Nucl Cardiol** 1998 Sep-Oct;5(5):542-3

Repeatability of automatic left ventricular cavity volume measurements from myocardial perfusion SPECT. Germano G, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):477-83

Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy. Gil VM, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):414-7

Interpretive reproducibility of stress Tc-99m sestamibi tomographic myocardial perfusion imaging. Golub RJ, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):257-69

Evaluation of myocardial viability by myocardial perfusion imaging: should nitrates be used? [editorial; comment] He ZX, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):527-32. Comment on: J Nucl Cardiol 1998 Sep-Oct;5(5):469-76.

Gated SPECT imaging: increasing the armamentarium of nuclear cardiology [editorial] [see comments] Heller GV. **J Nucl Cardiol** 1998 Jul-Aug;5(4):442-4. Comment in: J Nucl Cardiol 1998 Jul-Aug;5(4):442-4.

Use of rotating (cine) planar projection images in the interpretation of a tomographic myocardial perfusion study [editorial] Hendel RC, et al. **J Nucl Cardiol** 1999 Mar-Apr; 6(2):234-40

Stress test reporting [letter; comment] Humphreys GS. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):157. Comment on: J Nucl Cardiol 1998 May-Jun;5(3):365-6.

Correction of partial volume effects in myocardial SPECT. Hutton BF, et al. **J Nucl Cardiol** 1998 Jul-Aug;5(4):402-13

SPECT perfusion imaging after coronary artery bypass grafting [editorial; comment] Iskandrian AE. **J Nucl Cardiol** 1998 Sep-Oct;5(5):533-7. Comment on: J Nucl Cardiol 1998 Sep-Oct;5(5):491-7.

Effects of smoking on pulmonary uptake of technetium-99m methoxyisobutylisonitrile during myocardial perfusion imaging. Kao CH, et al. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):29-32

Complementary roles of antibody affinity and specificity for in vivo diagnostic cardiovascular targeting: how specific is antimyosin for irreversible myocardial damage? Khaw BA, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):316-23

Quantification of SPECT myocardial perfusion images: methodology and validation of the Yale-CQ method. Liu YH, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):190-204

Exercise testing with myocardial perfusion imaging in patients with normal baseline electrocardiograms: cost savings with a stepwise diagnostic strategy. Mattera JA, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):498-506

An introduction to attenuation correction. Miles J, et al. **J Nucl Cardiol** 1999 Jul-Aug;6(4):449-57 (39 ref.)

Do patient data ever exceed the partial volume limit in gated SPECT studies? Nichols K, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):484-90

Exercise-test Tc-99m tetrofosmin SPECT in patients with chronic ischemic left ventricular dysfunction: direct comparison with Ti-201 reinjection. Nicolai E, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):270-7

HL-91-technetium-99m: a new marker of viability in ischemic myocardium. Okada RD, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):306-15

Enhanced detection of reversible myocardial hypoperfusion by technetium 99m-tetrofosmin imaging and first-pass radionuclide angiography after nitroglycerin administration [see comments] Peix A, et al. **J Nucl Cardiol** 1998 Sep-Oct; 5(5):469-76. Comment in: J Nucl Cardiol 1998 Sep-Oct;5(5):527-32.

Combined assessment of left ventricular function and rest-redistribution regional myocardial thallium-201 activity for prognostic evaluation of patients with chronic coronary artery disease and left ventricular dysfunction [see comments] Petretta M, et al. **J Nucl Cardiol** 1998 Jul-Aug; 5(4):378-86. Comment in: J Nucl Cardiol 1998 Jul-Aug;5(4):445-8.

Quantitative evaluation of a comprehensive motion, resolution, and attenuation correction program: initial experience. Rigo P, et al. **J Nucl Cardiol** 1998 Sep-Oct; 5(5):458-68

The prognostic value of a normal Tc-99m sestamibi SPECT study in suspected coronary artery disease. Soman P, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):252-6

Washout of I-123 meta-iodobenzylguanidine for assessing cardiac sympathetic activity with progression of hypertension in Dahl salt-sensitive rats. Takatsu H, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):204-10

Assessment of the severity of coronary artery stenosis by the ratio of the regional washout rate determined by adenosine triphosphate stress Tl-201 SPECT. Teragawa H, et al. **J Nucl Cardiol** 1999 May-Jun;6(3):324-31

Quantitative myocardial perfusion SPECT. Tsui BM, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):507-22 (77 ref.)

Gated SPECT imaging 101. White MP, et al. **J Nucl Cardiol** 1998 Sep-Oct;5(5):523-6

A silver anniversary [editorial] Zaret BL. **J Nucl Cardiol** 1998 Jul-Aug;5(4):367-8

Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. Bengel FM, et al. **J Nucl Med** 1999 Jun;40(6):904-10

Myocardial glucose uptake measured with fluorodeoxyglucose: a proposed method to account for variable lumped constants. Botker HE, et al. **J Nucl Med** 1999 Jul;40(7):1186-96

Chest pain in women: dobutamine stress echocardiography or myocardial perfusion scintigraphy? [letter; comment] Brull DJ, et al. **J Nucl Med** 1999 Jul;40(7):1222-3. Comment on: J Nucl Med 1998 May;39(5):751-5. Comment on: J Nucl Med 1998 May;39(5):756-9.

Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers. De Geeter F, et al. **J Nucl Med** 1998 Nov;39(11):1850-6

Influence of methodology on the presence and extent of mismatching between 99mTc-MIBI and 123I-BMIPP in myocardial viability studies. Dobbeleir AA, et al. **J Nucl Med** 1999 May;40(5):707-14

Safety of dobutamine-atropine stress myocardial perfusion scintigraphy. Elhendy A, et al. **J Nucl Med** 1998 Oct; 39(10):1662-6

Nitrogen-13-ammonia and oxygen-15-water estimates of absolute myocardial perfusion in left ventricular ischemic dysfunction. Gerber BL, et al. **J Nucl Med** 1998 Oct; 39(10):1655-62

99mTc-tetrofosmin assessment of myocardial perfusion and viability in canine models of coronary occlusion and reperfusion. Glover DK, et al. **J Nucl Med** 1999 Jan; 40(1):142-9

Impact of reorientation algorithms on quantitative myocardial SPECT perfusion imaging. Haddad M, et al. **J Nucl Med** 1998 Nov;39(11):1864-9

Abnormality of myocardial oxidative metabolism in noninsulin-dependent diabetes mellitus. Hattori N, et al. **J Nucl Med** 1998 Nov;39(11):1835-40

Fasting and nonfasting iodine-123-iodophenylpentadecanoic acid myocardial SPECT imaging in coronary artery disease. Heller GV, et al. **J Nucl Med** 1998 Dec; 39(12):2019-22

Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. Hermansen F, et al. **J Nucl Med** 1998 Oct;39(10):1696-702

PET imaging of oxidative metabolism abnormalities in sympathetically denervated canine myocardium. Hutchins GD, et al. **J Nucl Med** 1999 May;40(5):846-53

Absent myocardial iodine-123-BMIPP uptake and platelet/monocyte CD36 deficiency. Hwang EH, et al. **J Nucl Med** 1998 Oct;39(10):1681-4

Iterative reconstruction based on median root prior in quantification of myocardial blood flow and oxygen metabolism. Katoh C, et al. **J Nucl Med** 1999 May; 40(5):862-7

Improved classifications of myocardial bull's-eye scintigrams with computer-based decision support system. Lindahl D, et al. **J Nucl Med** 1999 Jan;40(1):96-101

Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. Merlet P, et al. **J Nucl Med** 1999 Jun; 40(6):917-23

Influence of arrhythmias on gated SPECT myocardial perfusion and function quantification. Nichols K, et al. **J Nucl Med** 1999 Jun;40(6):924-34

Comparison of four motion correction techniques in SPECT imaging of the heart: a cardiac phantom study. O'Connor MK, et al. **J Nucl Med** 1998 Dec;39(12):2027-34

Identification of viable myocardium in patients with chronic coronary artery disease using rest-redistribution thallium-201 tomography: optimal image analysis. Pace L, et al. **J Nucl Med** 1998 Nov;39(11):1869-74

Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia. Renstrom B, et al. **J Nucl Med** 1998 Oct;39(10):1684-9

Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera. Sandler MP, et al. **J Nucl Med** 1998 Dec;39(12):2035-43 (71 ref.)

Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. Satoh A, et al. **J Nucl Med** 1999 Mar; 40(3):371-5

Cardiac 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation. Schäfers M, et al. **J Nucl Med** 1999 Jan;40(1):1-5

Detecting myocardial salvage after primary PTCA: early myocardial contrast echocardiography versus delayed sestamibi perfusion imaging. Sciagrà R, et al. **J Nucl Med** 1999 Mar;40(3):363-70

High-resolution cardiac PET in rabbits: imaging and quantitation of myocardial blood flow. Shimada K, et al. **J Nucl Med** 1998 Dec;39(12):2022-7

Myocardial uptake of the fatty acid analog 14-fluorine-18-fluoro-6-thia-heptadecanoic acid in comparison to beta-oxidation rates by tritiated palmitate. Stone CK, et al. **J Nucl Med** 1998 Oct;39(10):1690-6

Impact of attenuation correction by simultaneous emission/transmission tomography on visual assessment of 201Tl myocardial perfusion images [see comments] Vidal R, et al. **J Nucl Med** 1999 Aug;40(8):1301-9. Comment in: J Nucl Med 1999 Aug;40(8):1310-2.

Measurement of myocardial glucose uptake in patients with ischemic cardiomyopathy: application of a new quantitative method using regional tracer kinetic information. Wiggers H, et al. **J Nucl Med** 1999 Aug;40(8):1292-300

Assessment of myocardial viability using 123I-labeled iodophenylpentadecanoic acid at sustained low flow or after acute infarction and reperfusion. Yang JY, et al. **J Nucl Med** 1999 May;40(5):821-8

Insulin action on heart and skeletal muscle FDG uptake in patients with hypertriglyceridemia. Yokoyama I, et al. **J Nucl Med** 1999 Jul;40(7):1116-21

Nuclear cardiology, Part III: Scintigraphic evaluation of cardiac perfusion. Everaert H, et al. **J Nucl Med Technol** 1998 Sep;26(3):164-9; quiz 172-3

Pharmacology study of the neutral myocardial imaging agent technetium-99m-N(NOEt)2. Fang P, et al. **J Nucl Med Technol** 1999 Mar;27(1):54-6

Women's health issues and nuclear medicine, Part I: Women and heart disease. Mann A. **J Nucl Med Technol** 1999 Jun; 27(2):89-92; quiz 103, 105 (45 ref.)

How precisely do SPECT images reflect tracer uptake in myocardial infarction? A comparison of thallium-201 and technetium-99m using a myocardial phantom. Onoguchi M, et al. **J Nucl Med Technol** 1998 Dec;26(4):252-6

Modified preparation and rapid quality control test for technetium-99m-tetrofosmin. Patel M, et al. **J Nucl Med Technol** 1998 Dec;26(4):269-73

Simulated frame-loss artifacts in myocardial perfusion SPECT imaging: the difference between single- and dual-headed systems. Wolf GE. **J Nucl Med Technol** 1998 Dec;26(4):248-51

Residual cardiomyocytes and scintigraphic findings in advanced coronary artery disease: correlation with technetium-99m-tetrofosmin and thallium-201 single photon emission computed tomography. Fujino S, et al. **Jpn Circ J** 1999 Jan;63(1):64-7

Usefulness of exercise thallium-201 imaging in evaluation of low- and high-risk groups in coronary artery disease patients with disappearance of anginal episodes by anti-anginal drug therapy. Hanashi A, et al. **Jpn Heart J** 1998 Sep;39(5):597-609

Imaging modalities for detection of myocardial viability. Underwood R. **MAGMA** 1998 Sep;6(2-3):137-9

A multiresolution restoration method for cardiac SPECT imaging. Franquiz JM, et al. **Med Phys** 1998 Dec; 25(12):2469-75

Treatment of radioactive decay in pharmacokinetic modeling: influence on parameter estimation in cardiac 13N-PET. Glatting G, et al. **Med Phys** 1999 Apr;26(4):616-21

Improvement of the fluorine-18 fluorodeoxyglucose images in simultaneous F-18 FDG/Tc-99m collimated spect imaging. Knešaurek K, et al. **Med Phys** 1999 Jun; 26(6):917-23

Effect of filtering on the detection and localization of small Ga-67 lesions in thoracic single photon emission computed tomography images. Wells RG, et al. **Med Phys** 1999 Jul; 26(7):1382-8

Functional cardiac imaging in mice using Ta-178. Hartley CJ, et al. **Nat Med** 1999 Feb;5(2):237-9

Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. Cutler CS, et al. **Nucl Med Biol** 1999 Apr;26(3):305-16

Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Fujibayashi Y, et al. **Nucl Med Biol** 1999 Jan;26(1):117-21

Evaluation of 99mTc-mercaptoacetyltriglycine-biocytin as a new hepatobiliary imaging agent in mice coinjected with bilirubin. Kim M, et al. **Nucl Med Biol** 1999 Jan;26(1):43-9

Preliminary evaluation of 2-[4-[3-tert-butylamino)-2-hydroxypropoxy]phenyl]-3-methyl-6-me thoxy-4(3H)-quinazolinone ([+/-]HX-CH 44) as a selective beta1-adrenoceptor ligand for PET. Valette H, et al. **Nucl Med Biol** 1999 Jan;26(1):105-9

Clinical significance of denervated but viable myocardium in patients with recanalized acute myocardial infarction. Abe Y, et al. **Nucl Med Commun** 1999 Aug;20(8):727-35

Dynamic SPET parameters of 123I-MIBG cardiac imaging. Arbab AS, et al. **Nucl Med Commun** 1999 Jul;20(7):617-22

Comparison of ordered subsets expectation maximization and Chang's attenuation correction method in quantitative cardiac SPET: a phantom study. Dey D, et al. **Nucl Med Commun** 1998 Dec;19(12):1149-57

Regional glucose utilization in infarcted and remote myocardium: its relation to coronary anatomy and perfusion. Fragasso G, et al. **Nucl Med Commun** 1998 Jul; 19(7):625-32

Factors affecting and computation of myocardial perfusion reference images. Goris ML, et al. **Nucl Med Commun** 1999 Jul;20(7):627-35

Quantification of 99Tcm-sestamibi and 123I-BMIPP uptake for predicting functional outcome in chronically ischaemic dysfunctional myocardium. Hambye AS, et al. **Nucl Med Commun** 1999 Aug;20(8):737-45

The value and correlates of left ventricular cavity assessment in dipyridamole 201Tl SPET studies. Heiba SI, et al. **Nucl Med Commun** 1998 May;19(5):443-9

Gated metabolic positron emission tomography (GAPET) of the myocardium: 18F-FDG-PET to optimize recognition of myocardial hibernation. Hör G, et al. **Nucl Med Commun** 1998 Jun;19(6):535-45

Myocardial 123I-MIBG kinetics in acutely hypothyroid patients with differentiated thyroid carcinoma. Maini CL, et al. **Nucl Med Commun** 1999 Aug;20(8):719-26

Evaluation of regional cardiac sympathetic innervation in congenital long QT syndrome using 123I-MIBG scintigraphy. Momose M, et al. **Nucl Med Commun** 1998 Oct;19(10):943-51

Stress and rest myocardial SPET quantification with 201Tl and 99Tcm-tetrofosmin: a comparison. Moragas G, et al. **Nucl Med Commun** 1998 Jul;19(7):633-40

Effect of 360 degrees and 180 degrees rotation SPET acquisitions on myocardial polar map: comparison of 201Tl-, 99Tcm- and 123I-labelled radiopharmaceuticals. Nakajima K, et al. **Nucl Med Commun** 1998 Apr; 19(4):315-25

Extent of myocardial damage in regions with reverse redistribution at 3 h and at 24 h on 201Tl SPET: evaluation based on regional myocardial oxidative metabolism. Ohte N, et al. **Nucl Med Commun** 1998 Nov;19(11):1081-7

Nuclear cardiology in the UK: British Nuclear Cardiology Society survey 1994. Pennell DJ, et al. **Nucl Med Commun** 1998 Apr;19(4):305-13

The routine use of sublingual GTN with resting 99Tcm-tetrofosmin myocardial perfusion imaging. Thorley PJ, et al. **Nucl Med Commun** 1998 Oct;19(10):937-42

Metoclopramide has no effect on abdominal activity of sestamibi in myocardial SPET. Weinmann P, et al. **Nucl Med Commun** 1999 Jul;20(7):623-5

Effect of radiochemical purity of 99Tcm-Q12 on myocardial SPET image quality. Yu M, et al. **Nucl Med Commun** 1999 Aug;20(8):747-53

Paradoxical hypotension during dobutamine infusion for myocardial perfusion scintigraphy. Ergün EL, et al. **Nuklearmedizin** 1998;37(8):268-71

Influence of background correction in the estimation of myocardial uptake of 99mTc labelled perfusion imaging agents. Smith T, et al. **Phys Med Biol** 1998 Sep; 43(9):2695-702

Nuclear medicine imaging of endocarditis. Ivančević V, et al. **Q J Nucl Med** 1999 Mar;43(1):93-9 (77 ref.)

Cardiac positron emission tomography. Bergmann SR. **Semin Nucl Med** 1998 Oct;28(4):320-40 (129 ref.)

Fatty acids for myocardial imaging. Corbett JR. **Semin Nucl Med** 1999 Jul;29(3):237-58 (89 ref.)

Attenuation and scatter compensation in myocardial perfusion SPECT. Galt JR, et al. **Semin Nucl Med** 1999 Jul;29(3):204-20 (118 ref.)

Technetium-99m labeled myocardial perfusion imaging agents. Jain D. **Semin Nucl Med** 1999 Jul;29(3):221-36 (103 ref.)

The current role of infarct avid imaging. Khaw BA. **Semin Nucl Med** 1999 Jul;29(3):259-70 (59 ref.)

Gated SPECT imaging. Mansoor MR, et al. **Semin Nucl Med** 1999 Jul;29(3):271-8 (33 ref.)

Quantitative SPECT techniques. Watson DD. **Semin Nucl Med** 1999 Jul;29(3):192-203 (35 ref.)

Radionuclide techniques for the assessment of myocardial viability. Skoufis E, et al. **Tex Heart Inst J** 1998;25(4):272-9 (77 ref.)

Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Gottsauner-Wolf M, et al. **Thromb Haemost** 1999 Apr;81(4):522-6

[Clinical application of myocardial perfusion imaging with 99mTc-MIBI SPECT in the diagnosis of coronary artery disease] Guo X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):217-9 (Eng. Abstr.) **(Chi)**

[99mTc-MIBI myocardial perfusion imaging in patients with diabetes] Liang C, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):523-6 (Eng. Abstr.) **(Chi)**

[Correlation of SPECT myocardial stress scintigraphy with coronary angiography] Kaminek M, et al. **Vnitr Lek** 1998 Apr;44(4):187-91 (Eng. Abstr.) **(Cze)**

[Myocardial scintigraphy in Denmark (editorial)] Hesse B, et al. **Ugeskr Laeger** 1998 Nov 2;160(45):6501 **(Dan)**

[Nuclear cardiology in ischemic heart disease] Høilund-Carlsen PF, et al. **Ugeskr Laeger** 1999 Apr 26; 161(17):2510-4 (10 ref.) **(Dan)**

[Development of myocardial scintigraphy, coronary arteriography and revascularization techniques in Denmark during the last five years] Toft J, et al. **Ugeskr Laeger** 1998 Nov 2;160(45):6536-7 **(Dan)**

[Importance of dual isotope myocardial tomoscintigraphy in the detection of coronary disease in the graft among 96 heart transplant recipients] Pouillart F, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):235-41 (Eng. Abstr.) **(Fre)**

[Evaluation of a clinical and scintigraphic management strategy for cardiac risk before abdominal aorta surgery. Apropos of 982 surgical patients] Vanzetto G, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):211-8 (Eng. Abstr.) **(Fre)**

[Myocardial viability. Study of viability by myocardial scintigraphy] Pézard P, et al. **Presse Med** 1998 Jun 13; 27(21):1043-9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Severe bradyarrhythmia during myocardial perfusion scintigraphy with injection of dipyridamole (Persantine)] Bielen M, et al. **Rev Med Liege** 1999 Feb;54(2):105-8 (Eng. Abstr.) **(Fre)**

[The heterogeneity of myocardial sympathetic innervation in normal subjects: an assessment by iodine-123 metaiodobenzylguanidine scintigraphy] D'Alto M, et al. **Cardiologia** 1998 Nov;43(11):1231-6 (Eng. Abstr.) **(Ita)**

[Myocardial scintigraphy by the gated SPECT method in coronary disease patients with postischemic stunning] Bestetti A, et al. **G Ital Cardiol** 1999 Feb;29(2):143-8 (Eng. Abstr.) **(Ita)**

[Relationship between ventricular arrhythmias and myocardial fatty acid metabolism in patients with coronary heart disease: evaluation using iodine-123 beta-methyl-p-iodophenyl-pentadecanoic acid] Mori H, et al. **J Cardiol** 1999 Aug;34(2):61-9 (Eng. Abstr.) **(Jpn)**

[A significance of the washout of 123I-BMIPP in patients with vasospastic angina] Fukumitsu N, et al. **Kaku Igaku** 1999 May;36(4):369-74 (Eng. Abstr.) **(Jpn)**

[Assessment of cardiac function and myocardial metabolism by nuclear medicine] Hasegawa S, et al. **Kaku Igaku** 1999 Apr;36(3):209-17 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Use of 99mTc-labeled myocardial perfusion agents in the Kanto-Koshinetsu area] Hashimoto J, et al. **Kaku Igaku** 1998 Jul;35(6):443-50 (Eng. Abstr.) **(Jpn)**

[Serial change of TL/BMIPP dual SPECT myocardial scintigram in patients with acute myocardial infarction; meaning of chronic mismatch phenomenon] Iwasawa H, et al. **Kaku Igaku** 1999 May;36(4):349-55 (Eng. Abstr.) **(Jpn)**

[Relation between wall motion and scintigraphic uptake altered by the cut-off level on technetium-99m sestamibi tomographic imaging--the preferable cut-off levels according to tomographic uptake correlated with the wall motion] Kamada T, et al. **Kaku Igaku** 1999 Feb;36(2):131-8 (Eng. Abstr.) **(Jpn)**

[The usefulness of 123I-BMIPP myocardial SPECT in diagnosis for silent myocardial ischemia induced by vasospasm] Kawasaki T, et al. **Kaku Igaku** 1999 Jan; 36(1):45-50 (Eng. Abstr.) **(Jpn)**

[Evaluation of the safety and clinical feasibility of exercise 99mTc-MIBI SPECT using one day protocol--multicenter phase III clinical trial report] Kubo A, et al. **Kaku Igaku** 1998 Nov;35(9):929-38 (Eng. Abstr.) **(Jpn)**

[Scatter correction in myocardial thallium SPECT: needs for optimization of energy window settings in the energy window-based scatter correction techniques] Narita Y, et al. **Kaku Igaku** 1999 Feb;36(2):83-90 (Eng. Abstr.) **(Jpn)**

[A phantom study for the evaluation of the effect of the high uptake in the liver on technetium-99m myocardial perfusion SPECT images] Ohnishi H, et al. **Kaku Igaku** 1998 Jul;35(6):375-83 (Eng. Abstr.) **(Jpn)**

[Usefulness of myocardial scintigraphy with 99mTc-tetrofosmin for diagnosis in 2 cases of acute

coronary syndrome] Okano A, et al. **Kaku Igaku** 1998 Nov; 35(9):871–6 (Eng. Abstr.) **(Jpn)**

[Usefulness of 18F-FDG PET for diagnosis of cardiac sarcoidosis] Okumura W, et al. **Kaku Igaku** 1999 May; 36(4):341–8 (Eng. Abstr.) **(Jpn)**

[The compensation method for the effects of system resolution to the left ventricular volume measurements using QGS program] Takayama T, et al. **Kaku Igaku** 1998 Oct;35(8):721–6 (Eng. Abstr.) **(Jpn)**

[The relationship between discrepant areas on 201TlCl/123I-BMIPP myocardial scintigraphy, local wall motion, and glucose metabolism in patients with myocardial infarction] Tanaka A. **Kaku Igaku** 1998 Nov;35(9):857–69 (Eng. Abstr.) **(Jpn)**

[Usefulness of 123I-MIBG scintigraphy for prediction of effect of beta-blocker therapy in dilated cardiomyopathy] Tawarahara K, et al. **Kaku Igaku** 1998 Jul;35(6):413–20 (Eng. Abstr.) **(Jpn)**

[Present and future of nuclear medicine] Torizuka K. **Kaku Igaku** 1999 Feb;36(2):65–70 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Markedly decreased uptake with 123I-MIBG myocardial scintigraphy in a case with vasospastic angina] Watanabe K, et al. **Kaku Igaku** 1998 Oct;35(8):727–32 (Eng. Abstr.) **(Jpn)**

[Clinical significance of 123I-BMIPP myocardial SPECT] Yamazaki J. **Kaku Igaku** 1998 Jul;35(6):367–73 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Assessment of beta-methyl Iodophenyl pentadecanoic acid myocardial scintigraphy in patients with chronic pulmonary diseases] Matsumoto H, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Feb;37(2):119–24 (Eng. Abstr.) **(Jpn)**

[Evaluation of cardiac sympathetic nerve injuries due to surgical procedures for thoracic aorta using 123I metaiodobenzylguanidine(MIBG) scintigraphy] Miyamoto S, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):872 **(Jpn)**

[Combined scatter and attenuation correction for 201Tl myocardial perfusion SPECT using OS-EM algorithm] Matsuoka S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Nov; 58(13):751–7 (Eng. Abstr.) **(Jpn)**

[Myocardial perfusion imagings in acute coronary syndromes] Kobayashi H. **Nippon Rinsho** 1998 Oct; 56(10):2539–43 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Myocardial imaging using PET and SPECT] Tamaki N, et al. **Nippon Rinsho** 1998 Oct;56(10):2550–5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The first-choice technic for assessing myocardial viability. Cardiac perfusion gammagraphy] Coma-Canella I. **Rev Esp Cardiol** 1998 Oct;51(10):797–800 (16 ref.) (Eng. Abstr.) **(Spa)**

[Improvement of myocardial perfusion after transmyocardial laser revascularization] Magriñá J, et al. **Rev Esp Cardiol** 1999 Jun;52(6):437 **(Spa)**

[Obtaining myo-cardial perfusion images synchronized with the ECG (gated-SPEC) after injecting MIBI during exertion: comparative study with echocardiography in 95 patients for the assessment of left ventricular function] Fraile M, et al. **Rev Esp Med Nucl** 1998;17(6):413–8 (Eng. Abstr.) **(Spa)**

[Thallium-201 uptake in lung and heart with different types of stress. Study in healthy volunteers] Maceira AM, et al. **Rev Esp Med Nucl** 1999 Jun;18(3):197–203 (Eng. Abstr.) **(Spa)**

[Predictive value of the ergometric test stress parameters for myocardial ischemia according to SPECT thallium-201 scintigraphy] Prat H, et al. **Rev Med Chil** 1998 May; 126(5):497–503 (Eng. Abstr.) **(Spa)**

SECRETION see HEART/physiology

SURGERY see CARDIAC SURGICAL PROCEDURES

TRANSPLANTATION see HEART TRANSPLANTATION

ULTRASONOGRAPHY see ECHOCARDIOGRAPHY

ULTRASTRUCTURE see MYOCARDIUM/ultrastructure

VIROLOGY

Precise identification of gene products in hearts after in vivo gene transfection, using Sendai virus-coated proteoliposomes. Kawada T, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):408–13

Effects of taurine on L-type voltage-dependent Ca2+ channel in rat cardiomyocytes infected with coxsackievirus B3. Liu GX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May;19(3):238–40

Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Pauschinger M, et al. **Circulation** 1999 Mar 16; 99(10):1348–54

Induction of myocardial nitric oxide synthase by Coxsackie B3 virus in mice. Robinson NM, et al. **Eur J Clin Invest** 1999 Aug;29(8):700–7

Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Donahue JK, et al. **Gene Ther** 1998 May; 5(5):630–4

The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. Bowles NE, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):857–65

Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. Wessely R, et al. **J Clin Invest** 1998 Oct 1;102(7):1444–53

Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Klingel K, et al. **Lab Invest** 1998 Oct;78(10):1227–37

Detection of enteroviral sequence in endomyocardial tissues from patients with cardiac diseases in northern Brazil. Gomes M de L, et al. **Rev Soc Bras Med Trop** 1998 Sep-Oct;31(5):487–90

Subacute massive necrotizing myocarditis by canine parvovirus type 2 infection with diffuse leukoencephalomalacia in a puppy. Agungpriyono DR, et al. **Vet Pathol** 1999 Jan;36(1):77–80

Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Kandolf R, et al. **Virus Res** 1999 Aug;62(2):149–58 (46 ref.)

[Syncope in 3rd degree atrioventricular block. Detection of virus genome in the myocardium] Pauschinger M, et al. **Dtsch Med Wochenschr** 1998 Nov 27;123(48):1443–6 (Eng. Abstr.) **(Ger)**

HEART ABNORMALITIES see HEART DEFECTS, CONGENITAL

HEART ANEURYSM

see related
CORONARY ANEURYSM

Submitral aneurysm is not a false aneurysm [letter; comment] Cheng TO. **Circulation** 1999 Jul 13;100(2):212–3. Comment on: Circulation 1998 Oct 20;98(16):1698.

COMPLICATIONS

Atrial septal aneurysm in a patient with pseudoxanthoma elasticum. Bertulezzi G, et al. **Acta Cardiol** 1998;53(4):223–5

Role of apical aneurysm on the prognosis of chronic Chagas' disease [letter; comment] Bestetti RB. **Am J Cardiol** 1998 Dec 15;82(12):1561. Comment on: Am J Cardiol 1998 Jul 15;82(2):197–202.

Early postoperative stroke in a patient with an atrial septal aneurysm. Ide M, et al. **Anesth Analg** 1999 Aug;89(2):300–1

Myocardial abscess with salmonella infection [letter] Recio J, et al. **Ann Intern Med** 1999 Sep 21;131(6):477–8

Atypical chest pain from a left ventricular false aneurysm. Charig MJ, et al. **Clin Radiol** 1999 Mar;54(3):190–1

Subpulmonary obstruction in transposition of the great arteries due to aneurysm of the membranous ventricular septum. Calabrò R, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):97

Calcified subaortic left ventricular aneurysm causing right pulmonary artery obstruction in a child. Mohan JC, et al. **Int J Cardiol** 1998 Sep 30;66(2):195–7

Atrial septal aneurysm. Is it a benign finding? Valenzuela LF, et al. **Int J Cardiol** 1999 Apr 30;69(1):101–3

Ischemic neurologic event in a child as a result of ventricular septal aneurysm. Kowalski M, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1161–2

Long-term results of visually guided left ventricular reconstruction as single therapy to treat ventricular tachycardia associated with postinfarction anteroseptal aneurysm. Sosa E, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1133–43

Idiopathic left ventricular aneurysm: an unusual substrate of ventricular fibrillation and ventricular tachycardia. Proclemer A, et al. **J Interv Card Electrophysiol** 1998 Jun; 2(2):187–91

Multiple systemic emboli complicating the course of a patient with an atrial septal defect, an atrial septal aneurysm and an endocardial right atrial pacemaker lead. Johnson C, et al. **P R Health Sci J** 1998 Sep;17(3):281–4

Recurrent pseudoaneurysm of the left ventricle with subcutaneous herniation into the chest wall. A case report. Rao MS, et al. **Tex Heart Inst J** 1998;25(4):309–11

[Left ventricular aneurysm of indeterminate etiology revealed by an episode of ventricular tachycardia] Diop IB, et al. **Dakar Med** 1995;40(2):143–50 (30 ref.) (Eng. Abstr.) **(Fre)**

[Large right atrial aneurysm: rare cause of recurrent pulmonary embolism] Staubach P. **Z Kardiol** 1998 Nov; 87(11):894–9 (Eng. Abstr.) **(Ger)**

[Left ventricular aneurysm in a patient with mildly dilated cardiomyopathy] De Biase L, et al. **Cardiologia** 1999 Feb; 44(2):191–2 (Eng. Abstr.) **(Ita)**

[Aneurysm of the membranous ventricular septum with ventricular septal defect, mitral and tricuspid insufficiency] Tanaka K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):1009–13 (Eng. Abstr.) **(Jpn)**

[Subpulmonary obstruction caused by an aneurysm of the membranous ventricular septum. A study of 2 cases] Santos de Soto J, et al. **Rev Esp Cardiol** 1999 May;52(5):351–4 (10 ref.) (Eng. Abstr.) **(Spa)**

[Ischemic stroke and auricular septal aneurysm: six cases] Serrano-González C, et al. **Rev Neurol** 1998 Oct 27(158):658–62 (Eng. Abstr.) **(Spa)**

CONGENITAL

Treatment of congenital aneurysms of the left atrium and left atrial appendage. Zhao J, et al. **Tex Heart Inst J** 1999; 26(2):136–9

[A case of large congenital right ventricular outflow aneurysm] Honda K, et al. **Kyobu Geka** 1999 Sep; 52(10):846–9 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Clinical, anatomic, and echocardiographic characteristics of aneurysms of the mitral valve. Vilacosta I, et al. **Am J Cardiol** 1999 Jul 1;84(1):110–3, A9

Repeat syncopal attacks due to postsurgical right ventricular pseudoaneurysm. Calabrò R, et al. **Ann Thorac Surg** 1999 Jul;68(1):252–4

Left ventricular septal aneurysm. Dipchand AI, et al. **Circulation** 1998 Oct 20;98(16):1697

Chronic coronary artery dissection presenting as heart failure. Hobbs RE, et al. **Circulation** 1999 Jul 27;100(4):445

Magnetic resonance imaging features of submitral left ventricular aneurysm. Taneja K, et al. **Indian Heart J** 1998 Jul-Aug;50(4):453–5

Clinical and electrophysiologic features of idiopathic left ventricular aneurysm with sustained ventricular tachycardia. Tada H, et al. **Int J Cardiol** 1998 Nov 30; 67(1):27–38

Pseudoaneurysm of the left ventricle progressing from a subepicardial aneurysm. Koito H, et al. **Jpn Circ J** 1999 Jul;63(7):559–63

Multiple idiopathic left ventricular aneurysms in a Japanese woman. Harris GA Jr, et al. **Mil Med** 1999 Jun; 164(6):448–50

[Giant aneurysm of the inter-atrial septum] Akoudad H, et al. **Ann Med Interne (Paris)** 1999 Jan;150(1):61–6 (25 ref.) (Eng. Abstr.) **(Fre)**

[False aneurysm of the left ventricle. A sometimes late finding] Bernard F, et al. **Arch Mal Coeur Vaiss** 1998 Jun; 91(6):765–9 (Eng. Abstr.) **(Fre)**

[Right-left intra-atrial shunt in the absence of elevated pressures in the right cardiac cavities] Chaouat A, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3: S205 **(Fre)**

[Congenital left ventricular aneurysms and diverticula: clinical findings, diagnosis and course] Mayer K, et al. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1249–56 (Eng. Abstr.) **(Ger)**

[Difficulties in distinguishing left ventricular aneurysm from pseudoaneurysm. Case report] Hirnle T, et al. **Pol Arch Med Wewn** 1998 Mar;99(3):228–32 (Eng. Abstr.) **(Pol)**

[A giant aneurysm of the interatrial septum simulating cystic masses of the right atrium] Martins S, et al. **Rev Port Cardiol** 1999 Mar;18(3):319–21 **(Por)**

EPIDEMIOLOGY

Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Agmon Y, et al. **Circulation** 1999 Apr 20; 99(15):1942–4

ETIOLOGY

Left ventricular pseudoaneurysm after epicardial patch electrode placement. Maisel WH, et al. **Ann Thorac Surg** 1998 Dec;66(6):2102–4

Sudden death in an adult with a small ventricular septal defect and an aneurysmal membranous septum. Sarubbi B, et al. **Cardiol Young** 1999 Jan;9(1):99–103

Pseudoaneurysm of the left ventricle after isolated pericarditis and Staphylococcus aureus septicemia. de Boer HD, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):97–9

Left ventricular pseudoaneurysm complicating infective pericarditis. Moraes AN, et al. **Heart** 1999 Sep;82(3):393–4

Post-traumatic multilobated pseudoaneurysm of the left ventricle secondary to dissecting intramyocardial haematoma of the posterior wall: obstructive and fenestrated communication demonstrated by colour Doppler imaging. Mohan JC, et al. **Indian Heart J** 1998 Sep-Oct;50(5):539–41

Pseudoaneurysm of the left ventricular free wall caused by tumor infiltration. Lee PJ, et al. **J Am Soc Echocardiogr** 1999 Jul;12(7):604–6

Myocardial infarction-induced ventricular aneurysm in the presence of complete left bundle branch block: a case report suggesting a new electrocardiographic diagnostic criterion. Madias JE, et al. **J Electrocardiol** 1999 Apr;32(2):179–83

Combined left ventricular aneurysm and thoracic aortic pseudoaneurysm caused by blunt chest trauma. Adalia R, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1219–21

[Catheter-induced dissection of the right coronary ostium and aortic root] Wagdi P, et al. **Z Kardiol** 1999 Jul; 88(7):526–8 (Eng. Abstr.) **(Ger)**

[Apical hypertrophic cardiomyopathy followed by midventricular obstruction and apical aneurysm: a case report] Inoue T, et al. **J Cardiol** 1999 Apr;33(4):217–22 (Eng. Abstr.) **(Jpn)**

[Chagas disease in Virgem da Lapa, Minas Gerais, Brazil. IV. Clinical and epidemiological aspects of left ventricular aneurism] Borges-Pereira J, et al. **Rev Soc Bras Med Trop** 1998 Sep-Oct;31(5):457–63 (Eng. Abstr.) **(Por)**

[Pseudoaneurysm of the mitral-aortic fibrosa secondary to the partial detachment of a mechanical aortic prosthesis] Delgado C, et al. **Rev Esp Cardiol** 1999 May;52(5):348-50 (7 ref.) (Eng. Abstr.) **(Spa)**

[A giant left ventricular pseudoaneurysm secondary to an acute posteroinferior myocardial infarct] Fuertes Benecitez J, et al. **Rev Esp Cardiol** 1999 Feb;52(2):134 **(Spa)**

PARASITOLOGY

Heart aneurysm in Chagas' disease. de Oliveira JA. **Rev Inst Med Trop Sao Paulo** 1998 Sep-Oct;40(5):301-7

PATHOLOGY

Left ventricular aneurysm after myocardial infarction. HA JW, et al. **Clin Cardiol** 1998 Dec;21(12):917

Transmyocardial laser revascularization fails to prevent left ventricular functional deterioration and aneurysm formation after acute myocardial infarction in sheep. Malekan R, et al. **J Thorac Cardiovasc Surg** 1998 Nov; 116(5):752-62

Aneurysmal pouch on left coronary cusp accompanied by bacterial endocarditis. Nakayama M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):667-70

[Late recurrence of a large post-infarction left ventricular pseudo-aneurysm. A case report] Bodart JC, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91(9):1177-81 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Right-left intra-atrial shunt in the absence of elevated pressures in the right cardiac cavities] Chaouat A, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3: S205 **(Fre)**

RADIOGRAPHY

Totally calcified aneurysm of the left ventricle. Pratali S, et al. **G Ital Cardiol** 1998 Aug;28(8):942 **(Eng, Ita)**

RADIONUCLIDE IMAGING

Left ventricular aneurysm after myocardial infarction. HA JW, et al. **Clin Cardiol** 1998 Dec;21(12):917

Giant pseudoaneurysm of the left ventricle diagnosed by radionuclide ventriculography. Friedensohn A, et al. **Clin Nucl Med** 1998 Sep;23(9):623

Infection of a left ventricular aneurysm and massive splenomegaly demonstrated by In-111-labeled leukocyte scintigraphy. Rose DS, et al. **Clin Nucl Med** 1998 Oct; 23(10):721-2

SURGERY

Repair of ventricular aneurysm. Dor V. **Adv Card Surg** 1998; 10:25-41

Huge false aneurysm of left ventricular posterior wall following resection of an aneurysm of the left ventricular posterior wall [letter] Dubel HP, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):509-10

Submitral aneurysm [see comments] Kontozis L, et al. **Circulation** 1998 Oct 20;98(16):1698. Comment in: Circulation 1999 Jul 13;100(2):212-3.

Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functional results. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):413-8

Cardiocutaneous fistula. Danias PG, et al. **Heart** 1999 Mar; 81(3):325-6 (10 ref.)

Effects of reconstructive surgery for left ventricular anterior aneurysm on ventriculoarterial coupling [published erratum appears in Heart 1999 Apr;81(4):452] Fantini F, et al. **Heart** 1999 Feb;81(2):171-6

Chronic haemoptysis as delayed complication of ventricular aneurysmectomy. Kovac JD, et al. **Int J Cardiol** 1999 Jun 1;69(3):299-303

Linear repair versus ventricular reconstruction for treatment of left ventricular aneurysm: a 10-year experience. Vicol C, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):461-7

Three ventriculoplasty techniques applied to three left-ventricular pseudoaneurysms in the same patient. Akinci E, et al. **Tex Heart Inst J** 1999;26(1):87-9

Treatment of congenital aneurysms of the left atrium and left atrial appendage. Zhao J, et al. **Tex Heart Inst J** 1999; 26(2):136-9

Postinfarction left-ventricular aneurysm: regional stress, function, and remodeling after aneurysmectomy. Taniguchi K, et al. **Thorac Cardiovasc Surg** 1998 Oct;46(5):253-9

[Computer assisted open heart surgery. First case operated on with success] Carpentier A, et al. **C R Acad Sci III** 1998 May;321(5):437-42 (Eng. Abstr.) **(Fre)**

[Improvement of myocardial perfusion following left ventricular resection] Kulin L, et al. **Orv Hetil** 1999 Aug 8;140(32):1779-81 (Eng. Abstr.) **(Hun)**

[A successful repair of infective endocarditis accompanied by a pseudoaneurysm of the left ventricle] Takazawa A, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep;46(9):939-42 (Eng. Abstr.) **(Jpn)**

[A case of large congenital right ventricular outflow aneurysm] Honda K, et al. **Kyobu Geka** 1999 Sep; 52(10):846-9 (Eng. Abstr.) **(Jpn)**

[Mapping-guided focal cryoablation and endoaneurysmorrhaphy for a case of ischemic ventricular tachycardia with left ventricular aneurysm] Obayashi T, et al. **Kyobu Geka** 1999 Mar;52(3):229-33 (Eng. Abstr.) **(Jpn)**

[Transcutaneous creation of a left ventricular aneurysm model in mongrel dogs and experimental study of cardiomyoplasty] Otaki Y, et al. **Nippon Geka Gakkai Zasshi** 1999 Aug;100(8):517 **(Jpn)**

[The surgical treatment of postinfarct aneurysms of the left ventricle] Shevchenko IuL, et al. **Vestn Khir Im I I Grek** 1998;157(5):16-9 (Eng. Abstr.) **(Rus)**

[The surgical results in postinfarct aneurysms of the left ventricule and in coronary artery lesions] Mikheev AA, et al. **Voen Med Zh** 1998 Dec;319(12):27-30, 95 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Clinical characteristics and outcome in postinfarction pseudoaneurysm. Yeo TC, et al. **Am J Cardiol** 1999 Sep 1;84(5):592-5, A8

Incidence and clinical significance of interatrial shunting in patients with atrial septal aneurysm detected by contrast transesophageal echocardiography. Zhao BW, et al. **Angiology** 1999 Sep;50(9):745-53 (39 ref.)

Left ventricular aneurysm in the fetus: a diagnosis with a mixed prognosis [editorial; comment] McElhinney DB, et al. **Cardiol Young** 1999 Mar;9(2):123-6 (11 ref.). Comment on: Cardiol Young 1999 Mar;9(2):175-84.

Prenatal diagnosis of left ventricular aneurysm: a report of three cases and a review [see comments] Matias A, et al. **Cardiol Young** 1999 Mar;9(2):175-84 (22 ref.). Comment in: Cardiol Young 1999 Mar;9(2):123-6.

Giant interatrial septal aneurysm mimicking a right atrial tumor. Malaterre HR, et al. **Int J Card Imaging** 1998 Jun; 14(3):163-6

Right- and left-sided interatrial septal aneurysm mimicking atrial tumor and stroke. Malaterre HR, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):829-31

[Oval echo-free space at the atrioventricular sulcus] Koito H, et al. **J Cardiol** 1999 Apr;33(4):237-9 **(Jpn)**

[A pseudoaneurysm of the mitral-aortic intervalvular fibrosis after aortic valve replacement] Sousa L, et al. **Rev Port Cardiol** 1999 Feb;18(2):177-8 (Eng. Abstr.) **(Por)**

HEART ARREST

see related

RESUSCITATION

Drug-induced Brugada syndrome. Goethals P, et al. **Acta Cardiol** 1998;53(3):157-60

Apples and oranges. Resuscitation of heart arrest [letter; comment] Niemann JT, et al. **Ann Emerg Med** 1999 May; 33(5):601-3. Comment on: Ann Emerg Med 1998 Oct;32(4):490-2.

Cerebral metabolic profile, selective neuron loss, and survival of acute and chronic hyperglycemic rats following cardiac arrest and resuscitation. Hoxworth JM, et al. **Brain Res** 1999 Mar 13;821(2):467-79

Non-heart-beating organ donors as a source of kidneys for transplantation: a chart review. Campbell GM, et al. **CMAJ** 1999 Jun 1;160(11):1573-6

Cardiac arrest in Saudi Arabia: a 7-year experience in Riyadh. Conroy KM, et al. **J Emerg Med** 1999 Jul-Aug; 17(4):617-23

Cesarean delivery of twins during maternal cardiopulmonary arrest. Cardosi RJ, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):695-7

Experimental kidney transplantation in pigs from non-heart-beating donors: evaluation of renal artery flow. Alcoberro J, et al. **Transplant Proc** 1999 Sep;31(6):2348-9

Non-heart-beating donors and emergency health care systems. Alvarez J, et al. **Transplant Proc** 1999 Sep; 31(6):2215-6

High kidney graft survival rates using non-heart-beating trauma donors. Cho YW, et al. **Transplant Proc** 1998 Nov; 30(7):3795-6

FK 506 in cadaveric kidney transplantation from non-heart-beating donors. Hattori R, et al. **Transplant Proc** 1998 Nov;30(7):3801-3

The asystolic donor syndrome. Kim HC, et al. **Transplant Proc** 1998 Nov;30(7):3781-2

Experimental study of the cellular energy charge in pig kidney transplants from non-heart-beating donors. Luque P, et al. **Transplant Proc** 1999 Sep;31(6):2352-3

Non-heart-beating cadaveric organ donation as a result of inefficient brain death certification is a useful compromise in the Indian context. Mehra S, et al. **Transplant Proc** 1998 Nov;30(7):3804-5

Experimental model of non-heart-beating donors: oxidative stress metabolism in kidney after cardiac arrest (30 minutes of warm ischemia) and reimplantation 24 hours later. Montón S, et al. **Transplant Proc** 1999 Sep;31(6):2350-1

Single center analysis of non-heart-beating cadaveric donors. Tanaka S, et al. **Transplant Proc** 1998 Nov;30(7):3790-2

Microcirculatory disturbance is an obstacle to liver transplantation from agonal NHBD. Tsukamoto S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1091-3

Usefulness of Celsior in graft preservation of livers obtained from non heart beating donors in experimental (pigs) liver transplantation: comparative study with University of Wisconsin solution. Valero R, et al. **Transplant Proc** 1999 Sep;31(6):2433-4

Endothelin antagonist treatment for successful liver transplantation from non-heart-beating donors. Fukunaga K, et al. **Transplantation** 1999 Jan 27;67(2):328-32

[Definition of death and references on brain death, partial brain death and heart death] Angstwurm H. **Internist (Berl)** 1999 Mar;40(3):283-5 (3 ref.) **(Ger)**

[Difficulty to diagnose the cause of death in emergency room] Taki K, et al. **Nippon Hoigaku Zasshi** 1998 Aug;52(4):223-6 (Eng. Abstr.) **(Jpn)**

[Unnecessary cardiac death--a challenge!] Lexow K. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):781 **(Nor)**

BLOOD

Use of intraosseous blood to assess blood chemistries and hemoglobin during cardiopulmonary resuscitation with drug infusions [see comments] Johnson L, et al. **Crit Care Med** 1999 Jun;27(6):1147-52. Comment in: Crit Care Med 1999 Jun;27(6):1053-4.

Alterations of soluble L- and P-selectins during cardiac arrest and CPR. Gando S, et al. **Intensive Care Med** 1999 Jun;25(6):588-93

The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. Müllner M, et al. **Resuscitation** 1998 Aug;38(2):99-105

CHEMICALLY INDUCED

Ephedrine-induced complete atrioventricular block with ventricular asystole during rapid concomitant phenytoin infusion: a case report. Lin SY, et al. **Acta Anaesthesiol Sin** 1999 Mar;37(1):45-8

Succinylcholine-induced cardiac arrest in unsuspected becker muscular dystrophy--a case report. Wu CC, et al. **Acta Anaesthesiol Sin** 1998 Sep;36(3):165-8

Mibefradil (Posicor) induced sinus arrest [letter] Sanders P, et al. **Aust N Z J Med** 1998 Dec;28(6):836-7

Induction of anaesthesia with sevoflurane and low-dose remifentanil: asystole following laryngoscopy [letter] Wang J, et al. **Br J Anaesth** 1998 Dec;81(6):994-5

Sinus bradycardia and multiple episodes of sinus arrest following administration of ibutilide. Amin NB, et al. **Heart** 1998 Jun;79(6):628-9

Anaphylaxis due to suxamethonium--manifested at induction of anaesthesia by bradycardia and cardiac arrest. Porter JM, et al. **Ir J Med Sci** 1999 Apr-Jun;168(2):99-101

Labetalol does not lengthen asystole during electroconvulsive therapy. Dannon PN, et al. **J ECT** 1998 Dec;14(4):245-50

Sudden asystole during craniotomy: unrecognized phenytoin toxicity. Berry JM, et al. **J Neurosurg Anesthesiol** 1999 Jan;11(1):42-5

Fatal interaction between ritonavir and MDMA [letter] [see comments] Henry JA, et al. **Lancet** 1998 Nov 28; 352(9142):1751-2. Comment in: Lancet 1999 Feb 13;353(9152):593. Comment in: Lancet 1999 Feb 13;353(9152):593-4.

Effect of causing fetal cardiac asystole on second-trimester abortion. Elimian A, et al. **Obstet Gynecol** 1999 Jul; 94(1):139-41

[Convulsions and circulatory arrest from fluvoxamine and paroxetine poisoning (published erratum appears in Therapie 1998 Jul-Aug;53(4):401)] Chen Y, et al. **Therapie** 1998 Mar-Apr;53(2):165-7 **(Fre)**

COMPLICATIONS

Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: possible culprits for postcountershock arrhythmias? Niemann JT, et al. **Ann Emerg Med** 1999 Jul;34(1):1-7

In-hospital cardiopulmonary resuscitation: prearrest morbidity and outcome. de Vos R, et al. **Arch Intern Med** 1999 Apr 26;159(8):845-50

Anoxic-hypotensive brain injury: neuropsychological performance at 1 month as an indicator of recovery. Kaplan CP. **Brain Inj** 1999 Apr;13(4):305-10

Tribonat--a comprehensive summary of its properties [see comments] Bjerneroth G. **Crit Care Med** 1999 May; 27(5):1009-13 (76 ref.). Comment in: Crit Care Med 1999 May;27(5):875-6.

Buffer treatment for cardiac resuscitation: putting the cart before the horse? [editorial; comment] Gazmuri RJ. **Crit Care Med** 1999 May;27(5):875-6 (17 ref.). Comment on: Crit Care Med 1999 May;27(5):1009-13.

Why is cardiac arrest lasting more than five minutes associated with poor neurologic outcome? [editorial; comment] Prough DS, et al. **Crit Care Med** 1999 Jul; 27(7):1398-400. Comment on: Crit Care Med 1999 Jul;27(7):1335-42.

Depression and cardiac disease. Nemeroff CB, et al. **Depress Anxiety** 1998;8 Suppl 1:71-9 (97 ref.)

Lyme carditis: complete AV dissociation with episodic asystole presenting as syncope in the emergency department. Rosenfeld ME, et al. **J Emerg Med** 1999 Jul-Aug;17(4):661-4

Cerebral hypoxia after cardiopulmonary resuscitation [letter; comment] Berek K. **Lancet** 1999 Feb 27;353(9154):751. Comment on: Lancet 1998 Dec 5;352(9143):1808-12.

Cerebral hypoxia after cardiopulmonary resuscitation [letter; comment] Tirschwell DL, et al. **Lancet** 1999 Feb 27; 353(9154):750. Comment on: Lancet 1998 Dec

5;352(9143):1808–12.
Delayed postanoxic demyelination registry [letter; comment] Heckmann JG, et al. **Neurology** 1998 Oct;51(4):1235–6. Comment on: Neurology 1997 Nov;49(5):1400–4.
Alkaline buffers for correction of metabolic acidosis during cardiopulmonary resuscitation with focus on Tribonat--a review. Bjerneroth G. **Resuscitation** 1998 Jun;37(3):161–71 (170 ref.)
Changes in oxidative stress in the rat brain during post-cardiac arrest reperfusion, and the effect of treatment with the free radical scavenger idebenone. Grieb P, et al. **Resuscitation** 1998 Oct-Nov;39(1-2):107–13

DIAGNOSIS

Ultrasound detection of ventricular fibrillation disguised as asystole. Amaya SC, et al. **Ann Emerg Med** 1999 Mar; 33(3):344–6
Diabetic silent hearts and anesthesia: the duty to assess. Mangano DT. **J Clin Anesth** 1998 Nov;10(7):610–2
Cardiac asystole masquerading as temporal lobe epilepsy [letter; comment] Hood GA. **Mayo Clin Proc** 1999 May; 74(5):533. Comment on: Mayo Clin Proc 1998 Aug;73(8):784–6.
A preliminary study of the reliability of immediate vs. delayed interviews of cardiac arrest witnesses. Swor RA, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):110–4
[Circulatory arrest] Boulet N, et al. **Rev Prat** 1998 Jan 15; 48(2):193–7 **(Fre)**

DRUG THERAPY

Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. van Walraven C, et al. **Ann Emerg Med** 1998 Nov; 32(5):544–53
Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Wenzel V, et al. **Circulation** 1999 Mar 16;99(10):1379–84
Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs [see comments] Wenzel V, et al. **Crit Care Med** 1999 Mar;27(3):486–92. Comment in: Crit Care Med 1999 Mar;27(3):449–50.
On subgroups and groping for significance [letter; comment] Senn S, et al. **J Clin Epidemiol** 1998 Dec;51(12):1367–8. Comment on: J Clin Epidemiol 1997 Jul;50(7):753–5.
Innovative pharmacologic approaches to cardiopulmonary resuscitation. Frishman WH, et al. **J Clin Pharmacol** 1998 Sep;38(9):765–72 (70 ref.)
Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. Kanthasamy AG, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1340–8
Epinephrine for out-of-hospital cardiac arrest [letter; comment] Bakker J, et al. **N Engl J Med** 1999 Jun 3; 340(22):1763–4; discussion 1765. Comment on: N Engl J Med 1998 Nov 26;339(22):1595–601.
A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group [see comments] Gueugniaud PY, et al. **N Engl J Med** 1998 Nov 26; 339(22):1595–601. Comment in: N Engl J Med 1999 Jun 3;340(22):1763–4; discussion 1765. Comment in: N Engl J Med 1999 Jun 3;340(22):1764; discussion 1765.
Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. Kudenchuk PJ, et al. **N Engl J Med** 1999 Sep 16;341(12):871–8
Epinephrine for out-of-hospital cardiac arrest [letter; comment] Martens PR. **N Engl J Med** 1999 Jun 3; 340(22):1764; discussion 1765. Comment on: N Engl J Med 1998 Nov 26;339(22):1595–601.
Magnesium in cardiac arrest (the magic trial). Fatovich DM, et al. **Resuscitation** 1997 Nov;35(3):237–41
Aminophylline in undifferentiated out-of-hospital asystolic cardiac arrest. Mader TJ, et al. **Resuscitation** 1999 Jun; 41(1):39–45
Lack of a neuroprotective effect from N-acetylcysteine after cardiac arrest and resuscitation in a canine model. Silbergleit R, et al. **Resuscitation** 1999 Apr-May; 40(3):181–6

ENZYMOLOGY

Ultrastructural localization of thiamine pyrophosphatase in plasma membranes of brain phagocytes long time after cardiac arrest. Walski M, et al. **J Hirnforsch** 1998; 39(2):183–91
Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Schoerkhuber W, et al. **Stroke** 1999 Aug; 30(8):1598–603

EPIDEMIOLOGY

Weekly and seasonal variation in the incidence of cardiac arrests [see comments] Peckova M, et al. **Am Heart J** 1999 Mar;137(3):512–5. Comment in: Am Heart J 1999 Mar;137(3):384–5.
A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest [see comments] [published erratum appears in Ann Emerg Med 1999 Mar;33(3):358] Sirbaugh PE, et al. **Ann Emerg Med** 1999 Feb;33(2):174–84. Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.
Modeling the occurrence of cardiac arrest as a poisson process. Skogvoll E, et al. **Ann Emerg Med** 1999 Apr; 33(4):409–17
Out-of-hospital cardiac arrests in an urban/rural area during 1991 and 1996: have emergency medical service changes improved outcome? Absalom AR, et al. **Resuscitation** 1999 Jan;40(1):3–9
There is a difference in characteristics and outcome between women and men who suffer out of hospital cardiac arrest. Perers E, et al. **Resuscitation** 1999 Apr-May;40(3):133–40
Does race or socioeconomic status predict adverse outcome after out of hospital cardiac arrest: a multi-center study. Sayegh AJ, et al. **Resuscitation** 1999 Apr-May;40(3):141–6
Treatment of out-of-hospital cardiac arrest in Ljubljana: outcome report according to the 'Utstein' style. Tadel S, et al. **Resuscitation** 1998 Sep;38(3):169–76
Out-of-hospital cardiac arrests in Amsterdam and its surrounding areas: results from the Amsterdam resuscitation study (ARREST) in 'Utstein' style. Waalewijn RA, et al. **Resuscitation** 1998 Sep;38(3):157–67
[Incidence of anesthesia-related complications in Japan during 1997] **Masui** 1999 Mar;48(3):309–22 **(Jpn)**

ETIOLOGY

Metabolic acidosis in restraint-associated cardiac arrest: a case series. Hick JL, et al. **Acad Emerg Med** 1999 Mar; 6(3):239–43
The etiology of cardiac arrest in children and young adults: special considerations for ED management. Richman PB, et al. **Am J Emerg Med** 1999 May;17(3):264–70 (94 ref.)
Cardiac arrest as a possible sequela of critical airway management and intubation. Schwab TM, et al. **Am J Emerg Med** 1998 Oct;16(6):609–12
A case of seizure-related bradycardia and asystole. Smith-Demps C, et al. **Am J Emerg Med** 1998 Oct; 16(6):582–4
Suxamethonium and critical illness polyneuropathy [letter; comment] Biccard BM, et al. **Anaesth Intensive Care** 1998 Oct;26(5):590–1. Comment on: Anaesth Intensive Care 1997 Oct;25(5):502–13.
Intraoperative asystole and history of syncope [letter] Chilvers M, et al. **Anaesth Intensive Care** 1998 Oct; 26(5):593–4
An unfortunate cause of death [letter] Baigel GD. **Anaesthesia** 1999 Sep;54(9):917–8 (3 ref.)
A bronchogenic cyst in an infant causing tracheal occlusion and cardiac arrest. Harle CC, et al. **Anaesthesia** 1999 Mar; 54(3):262–5
A case of ventricular fibrillation in the prone position during back stabilisation surgery in a boy with Duchenne's muscular dystrophy. Reid JM, et al. **Anaesthesia** 1999 Apr; 54(4):364–7
Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Vaughan ST, et al. **Anaesthesia** 1998 Aug;53(8):804–7
Asystole under hypotensive epidural anesthesia [letter; comment] Sharrock NE. **Anesth Analg** 1998 Oct;87(4):982 . Comment on: Anesth Analg 1998 Apr;86(4):847–9.
Complete atrioventricular block and cardiac arrest following intravenous famotidine administration. Schoenwald PK, et al. **Anesthesiology** 1999 Feb;90(2):623–6
Cardiac asystole and bradycardia as a manifestation of left temporal lobe complex partial seizure. Locatelli ER, et al. **Ann Intern Med** 1999 Apr 6;130(7):581–3
Case of the month: incidental and not-so-incidental findings. Havlik DM, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1655–6
Leisure-time physical activity and the risk of primary cardiac arrest. Lemaitre RN, et al. **Arch Intern Med** 1999 Apr 12; 159(7):686–90
Acute spinal cord and head injury: case report and discussion of cardiac, respiratory and endocrine abnormalities. Johnson CD, et al. **Bol Asoc Med P R** 1998 Apr-Jun; 90(4–6):95–101
Sudden death and cerebral anoxia in a young woman with congenital ostial stenosis of the left main coronary artery. Knobel B, et al. **Catheter Cardiovasc Interv** 1999 Sep; 48(1):67–70
Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. Mehta AC, et al. **Chest** 1999 Feb;115(2):598–600
Fatal polyarteritis nodosa with massive mesenteric necrosis in a child. Mocan H, et al. **Clin Rheumatol** 1999;18(1):88–90
Cardiac arrest after uncomplicated right upper lobectomy. Lobato EB, et al. **J Cardiothorac Vasc Anesth** 1999 Feb; 13(1):105–6
Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. de Vreede-Swagemakers JJ, et al. **J Clin Epidemiol** 1999 Jul;52(7):601–7
Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study. Verma A, et al. **J Clin Neurophysiol** 1999 Jan;16(1):46–50
Would physicians override a do-not-resuscitate order when a cardiac arrest is iatrogenic? Casarett DJ, et al. **J Gen Intern Med** 1999 Jan;14(1):35–8
Cardiac asystole during arthroscopic surgery of the temporomandibular joint: a case report. Momota Y, et al. **J Oral Maxillofac Surg** 1999 Feb;57(2):189–91
Exercise and cardiovascular events: a double-edged sword? [editorial] Franklin BA. **J Sports Sci** 1999 Jun;17(6):437–42 (26 ref.)
Cardiac arrest caused by reperfusion injury after lumbar paraspinal compartment syndrome. Sava J, et al. **J Trauma** 1999 Jan;46(1):196–7
Delayed asystole following spinal anesthesia--a case report. Magboul MM, et al. **Middle East J Anesthesiol** 1999 Feb; 15(1):99–106
Deaths related to liposuction [letter] Ginsberg MM, et al. **N Engl J Med** 1999 Sep 23;341(13):1000; discussion 1002–3
Arrest treatment without verification. Clawson J, et al. **Prehosp Emerg Care** 1999 Jan-Mar;3(1):78
Delayed death after uncomplicated hot tub bathing in dogs and monkeys. Eshel GM, et al. **Resuscitation** 1998 Jun; 37(3):189–95
Cardiopulmonary resuscitation for clinicians [letter] Müllner M. **Resuscitation** 1998 Jun;37(3):197
Predicting inhospital cardiac arrest [letter; comment] Parr M, et al. **Resuscitation** 1998 Sep;38(3):199. Comment on: Resuscitation 1998 Jun;37(3):133–7.
Carbon dioxide narcosis-induced apnea in a rat model of cardiac arrest and resuscitation. Reid KH, et al. **Resuscitation** 1998 Sep;38(3):185–91
Recurrent cardiocirculatory arrest after kidney transplantation related to intravenous methylprednisolone bolus therapy [letter] Schult M, et al. **Transplantation** 1999 Jun 15;67(11):1497–8
[Spinal anesthesia and von Bezold-Jarisch reflex? (letter)] Amrouni K, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):468–9 **(Fre)**
[Coronary gas embolism after laparoscopic surgery] Popesco D, et al. **Ann Fr Anesth Reanim** 1997;16(4):381–5 (Eng. Abstr.) **(Fre)**
[Labile blood products from donors immunized against the HLA system. Apropos of a case of transfusional pulmonary edema] Fruchart MF, et al. **Transfus Clin Biol** 1998 Dec; 5(6):381–4 (Eng. Abstr.) **(Fre)**
[Brugada-Brugada syndrome--an ECG diagnosis at a glance!] Cron TA, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1965 **(Ger)**
[A successful case report of a patient who had severe aortic stenosis with cardiac arrest: bridge use of percutaneous cardiopulmonary support system (PCPS)] Kaneda K, et al. **Kyobu Geka** 1999 May;52(5):405–7 (Eng. Abstr.) **(Jpn)**
[A case of pulmonary fat embolism and cardiac arrest after prosthetic replacement of the femoral stem] Mori K, et al. **Masui** 1999 Apr;48(4):416–8 (Eng. Abstr.) **(Jpn)**
[Successful treatment by PCPS of cardiac arrest related to the use of bone cement in cementedendoprosthesis of the femoral head: a case report] Sugimoto K, et al. **Masui** 1998 Sep;47(9):1131–3 (Eng. Abstr.) **(Jpn)**
[A case of cardiac arrest after torsades de pointes due to prolonged QT interval syndrome possibly associated with subarachnoid hemorrhage] Yamaguchi S, et al. **Masui** 1999 Jun;48(6):644–6 (Eng. Abstr.) **(Jpn)**
[The issues of emergency medical system in patients with prehospital cardiac arrest complicating acute coronary syndrome in Japan] Nagao K, et al. **Nippon Rinsho** 1998 Oct;56(10):2666–74 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Special situations in resuscitation] Kloeck W, et al. **Arq Bras Cardiol** 1998 Dec;71 Suppl 1:29–42 **(Por)**

GENETICS

Brugada syndrome. Grace AA. **Lancet** 1999 Aug 7; 354(9177):445–6
Familial atrial standstill with coexistent atrial flutter. Balaji S, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1841–2

HISTORY

Management of acute myocardial infarction [letter; comment] Cohen HE. **Lancet** 1999 Feb 6;353(9151):498. Comment on: Lancet 1998 Nov 28;352(9142):1771–4.
From reviving the living to raising the dead; the making of cardiac resuscitation. Bains J. **Soc Sci Med** 1998 Nov; 47(9):1341–9
From wards 5 and 6 to Sainsburys (the history of out-of-hospital cardiac arrest.). Baskett PJ. **Ulster Med J** 1998 Jun;67 Suppl 1:74–7

MORTALITY

The researcher's toolbox [editorial; comment] Cone DC. **Acad Emerg Med** 1999 Feb;6(2):91–3. Comment on: Acad Emerg Med 1999 Feb;6(2):95–102.
What is the quality of life for survivors of cardiac arrest? A prospective study [see comments] Nichol G, et al. **Acad Emerg Med** 1999 Feb;6(2):95–102. Comment in: Acad Emerg Med 1999 Feb;6(2):91.
The problem of out-of-hospital cardiac-arrest prevalence of sudden death in Europe today. Holmberg M, et al. **Am J Cardiol** 1999 Mar 11;83(5B):88D–90D
Pediatric resuscitation and emergency medical services [editorial; comment] Quan L. **Ann Emerg Med** 1999 Feb; 33(2):214–7. Comment on: Ann Emerg Med 1999 Feb;33(2):174–84. Comment on: Ann Emerg Med 1999 Feb;33(2):195–205. Comment on: Ann Emerg Med 1999 Feb;33(2):206–10.
Pediatric cardiopulmonary resuscitation: a collective review [see comments] Young KD, et al. **Ann Emerg Med** 1999 Feb;33(2):195–205 (75 ref.). Comment in: Ann Emerg Med

1999 Feb;33(2):214–7.
Field triage of the pulseless trauma patient. Battistella FD, et al. **Arch Surg** 1999 Jul;134(7):742–5; discussion 745–6
Resuscitation from out-of-hospital cardiac arrest: is survival dependent on who is available at the scene? Soo LH, et al. **Heart** 1999 Jan;81(1):47–52
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. Elliott PM, et al. **J Am Coll Cardiol** 1999 May; 33(6):1596–601
Characteristics and outcome among patients with a suspected in-hospital cardiac arrest. Andréasson AC, et al. **Resuscitation** 1998 Oct–Nov;39(1–2):23–31
Predicting unsuccessful cardiopulmonary resuscitation (CPR): a comparison of three morbidity scores. Bowker L, et al. **Resuscitation** 1999 Feb–Mar;40(2):89–95
Long-term survival after out-of-hospital cardiac arrest: an 8-year follow-up. Kuilman M, et al. **Resuscitation** 1999 Jun;41(1):25–31
Survival from cardiac arrest in an accident and emergency department: use as a performance indicator? White SP, et al. **Resuscitation** 1999 Feb–Mar;40(2):97–102
[Cardiorespiratory arrest and afterwards what? (editorial; comment)] García-Guasch R, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):132–3 (20 ref.). Comment on: Med Clin (Barc) 1999 Jul 3;113(4):121–3. **(Spa)**
[Survival and the quality of life in extrahospital cardiorespiratory arrest (see comments)] Martín-Castro C, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):121–3 (Eng. Abstr.) . Comment in: Med Clin (Barc) 1999 Jul 3;113(4):132–3. **(Spa)**

NURSING

AEDs. Changing the way you respond to cardiac arrest. Automatic external defibrillators. Mancini ME, et al. **Am J Nurs** 1999 May;99(5):26–30; quiz 31
Being prepared for a pregnant code blue [see comments] Fillion DN. **MCN Am J Matern Child Nurs** 1998 Sep–Oct; 23(5):240–5 (15 ref.). Comment in: MCN Am J Matern Child Nurs 1999 Jan–Feb;24(1):53.
Pregnant code blue [letter; comment] Reece C. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):53. Comment on: MCN Am J Matern Child Nurs 1998 Sep–Oct;23(5):240–5.

PATHOLOGY

Neuronal stress response and neuronal cell damage after cardiocirculatory arrest in rats. Böttiger BW, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1077–87
Ultrastructural localization of thiamine pyrophosphatase in plasma membranes of brain phagocytes long time after cardiac arrest. Walski M, et al. **J Hirnforsch** 1998; 39(2):183–91
[Cardiomyocyte chondriome ultrastructure after clinical death and in the postresuscitation period in rats] Poliakova IA, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):95–100 **(Rus)**

PHYSIOPATHOLOGY

Dissociation of pituitary-adrenal and catecholamine activation after induced cardiac arrest and defibrillation. O'Leary MJ, et al. **Br J Anaesth** 1999 Feb;82(2):271–3
Left coronary pressure-flow relations of the beating and arrested rabbit heart at different ventricular volumes. Sipkema P, et al. **Cardiovasc Res** 1998 Oct;40(1):88–95
Deceleration-dependent shortening of the QT interval: a new electrocardiographic phenomenon? Gussak I, et al. **Clin Cardiol** 1999 Feb;22(2):124–6
Acidosis during cardiac arrest: a manifestation of inadequate perfusion [editorial; comment] Gazmuri RJ. **Crit Care Med** 1999 Sep;27(9):2055–6. Comment on: Crit Care Med 1999 Sep;27(9):1923–8.
Effect of arrest time and cerebral perfusion pressure during cardiopulmonary resuscitation on cerebral blood flow, metabolism, adenosine triphosphate recovery, and pH in dogs [see comments] Shaffner DH, et al. **Crit Care Med** 1999 Jul;27(7):1335–42. Comment in: Crit Care Med 1999 Jul;27(7):1398–400.
The Brugada syndrome in a Chinese population. Teo WS, et al. **Int J Cardiol** 1998 Aug;65(3):281–6
Neuronal stress response and neuronal cell damage after cardiocirculatory arrest in rats. Böttiger BW, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1077–87
Effects of the AMPA receptor antagonist NBQX on outcome of newborn pigs after asphyxic cardiac arrest. Brambrink AM, et al. **J Cereb Blood Flow Metab** 1999 Aug; 19(8):927–38
Successful orthotopic pig heart transplantation from non-heart-beating donors. Martin J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):597–606
Unexpected cardiac arrest during epidural anaesthesia. Mascotto G, et al. **Minerva Anestesiol** 1998 Jun;64(6):303–5
Ventricular asystole during vagus nerve stimulation for epilepsy in humans [see comments] Tatum WO 4th, et al. **Neurology** 1999 Apr 12;52(6):1267–9. Comment in: Neurology 1999 Apr 12;52(6):1117–8.
Measurement of myocardial contractility following successful resuscitation: quantitated left ventricular systolic function utilising non-invasive wall stress analysis. Müllner M, et al. **Resuscitation** 1998 Oct–Nov;39(1–2):51–9
Effect of the no-flow interval and hypothermia on cerebral blood flow and metabolism during cardiopulmonary resuscitation in dogs. Shaffner DH, et al. **Stroke** 1998 Dec; 29(12):2607–15
[From physiopathology to therapy: description of cardiac failure] Izumi T. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):411–5 (7 ref.) **(Jpn)**
[Mechanisms of actovegin effect on the central nervous system during postischemic period] Boiarinov GA, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):395–8 **(Rus)**

PREVENTION & CONTROL

Redefining resuscitation [editorial; comment] Hillman KM. **Aust N Z J Med** 1998 Dec;28(6):759–60. Comment on: Aust N Z J Med 1998 Dec;28(6):795–8.
Suboptimal ward care of critically ill patients. Active management should prevent cardiopulmonary arrests [letter; comment] Wood J, et al. **BMJ** 1999 Jan 2; 318(7175):51–2. Comment on: BMJ 1998 Jun 20;316(7148):1841–2. Comment on: BMJ 1998 Jun 20;316(7148):1853–8.
Ventricular pacemaker upgrade: experience, complications, and recommendations [letter; comment] Gribbin GM, et al. **Heart** 1998 Oct;80(4):420. Comment on: Heart 1998 Apr;79(4):383–7.
Recognising clinical instability in hospital patients before cardiac arrest or unplanned admission to intensive care. A pilot study in a tertiary-care hospital [see comments] Buist MD, et al. **Med J Aust** 1999 Jul 5;171(1):22–5. Comment in: Med J Aust 1999 Jul 5;171(1):8–9.
ACSM/AHA joint position statement. American College of Sports Medicine. American Heart Association [letter; comment] Cardinal BJ. **Med Sci Sports Exerc** 1999 Feb; 31(2):353–4. Comment on: Med Sci Sports Exerc 1998 Jun;30(6):1009–18.
Can some in-hospital cardio-respiratory arrests be prevented? A prospective survey [see comments] Smith AF, et al. **Resuscitation** 1998 Jun;37(3):133–7. Comment in: Resuscitation 1998 Sep;38(3):199.

PSYCHOLOGY

Long-acting psychotraumatic properties of a cardiac arrest experience. Ladwig KH, et al. **Am J Psychiatry** 1999 Jun; 156(6):912–9
Long-term cardiac arrest survivors of the Vienna emergency medical service. Eisenburger P, et al. **Resuscitation** 1998 Sep;38(3):137–43
[Survival and the quality of life in extrahospital cardiorespiratory arrest (see comments)] Martín-Castro C, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):121–3 (Eng. Abstr.) . Comment in: Med Clin (Barc) 1999 Jul 3;113(4):132–3. **(Spa)**

SURGERY

Management of cardiac arrest in operation theatre. Rajgor MB, et al. **J Indian Med Assoc** 1998 Nov;96(11):341–4 (8 ref.)
Radiofrequency catheter ablation in a haemodynamically compromised premature neonate with hydrops fetalis. Osborn DA, et al. **J Paediatr Child Health** 1999 Aug; 35(4):406–8
Emergency cardiopulmonary bypass for cardiac arrest refractory to pediatric advanced life support. Cochran JB, et al. **Pediatr Emerg Care** 1999 Feb;15(1):30–2
On scene thoracotomy: a case report. Craig R, et al. **Resuscitation** 1999 Jan;40(1):45–7
The management of non-traumatic cardiac arrest in the operating room with cardiopulmonary bypass. Karmy-Jones R, et al. **Resuscitation** 1999 Feb–Mar; 40(2):107–10

THERAPY

End-tidal carbon dioxide monitoring in cardiac arrest [letter; comment] Koetter KP, et al. **Acad Emerg Med** 1999 Jan; 6(1):88. Comment on: Acad Emerg Med 1998 Jun;5(6):637–46.
Forced hot air rewarming in hypothermic patients with cardiocirculatory arrest? [letter; comment] Mair P, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):1018–20. Comment on: Acta Anaesthesiol Scand 1997 Nov;41(10):1359–64.
Forward blood flow during cardiopulmonary resuscitation in patients with severe accidental hypothermia. An echocardiographic study. Mair P, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1139–44
Cardiopulmonary resuscitation: historical perspective to recent investigations. Thel MC, et al. **Am Heart J** 1999 Jan;137(1):39–48 (82 ref.)
Inherited thrombophilic syndromes and the use of ventricular assist devices. Carboni AF. **Am J Crit Care** 1999 Mar; 8(2):127–9
Helicopter transport of patients to tertiary care centers after cardiac arrest. Werman HA, et al. **Am J Emerg Med** 1999 Mar;17(2):130–4
Clinical findings and outcomes of intra-hemodialysis cardiopulmonary resuscitation. Lai M, et al. **Am J Nephrol** 1999;19(4):468–73
Early defibrillation programs. American College of Emergency Physicians. **Ann Emerg Med** 1999 Mar; 33(3):371
OPALS study [letter; comment] Cheng TO. **Ann Emerg Med** 1999 Feb;33(2):241. Comment on: Ann Emerg Med 1998 Aug;32(2):180–90.
Lengthening the chain of survival [letter; comment] Kuisma M. **Ann Emerg Med** 1998 Nov;32(5):636–7. Comment on: Ann Emerg Med 1998 Apr;31(4):471–7.
A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest. Nichol G, et al. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):517–25
Pediatric resuscitation and emergency medical services [editorial; comment] Quan L. **Ann Emerg Med** 1999 Feb; 33(2):214–7. Comment on: Ann Emerg Med 1999 Feb;33(2):174–84. Comment on: Ann Emerg Med 1999 Feb;33(2):195–205. Comment on: Ann Emerg Med 1999 Feb;33(2):206–10.
A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest [see comments] [published erratum appears in Ann Emerg Med 1999 Mar;33(3):358] Sirbaugh PE, et al. **Ann Emerg Med** 1999 Feb;33(2):174–84. Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.
Modifiable factors associated with improved cardiac arrest survival in a multicenter basic life support/defibrillation system: OPALS Study Phase I results. Ontario Prehospital Advanced Life Support. Stiell IG, et al. **Ann Emerg Med** 1999 Jan;33(1):44–50
Pediatric cardiopulmonary resuscitation: a collective review [see comments] Young KD, et al. **Ann Emerg Med** 1999 Feb;33(2):195–205 (75 ref.). Comment in: Ann Emerg Med 1999 Feb;33(2):214–7.
Epinephrine and outcome after cardiac arrest [letter; comment] Fromm RE Jr, et al. **Ann Intern Med** 1999 Jun 1;130(11):942–3. Comment on: Ann Intern Med 1998 Sep 15;129(6):450–6.
Epinephrine and outcome after cardiac arrest [letter; comment] Gause PE. **Ann Intern Med** 1999 Jun 1; 130(11):942; discussion 942–3. Comment on: Ann Intern Med 1998 Sep 15;129(6):450–6.
In-hospital cardiopulmonary resuscitation: prearrest morbidity and outcome. de Vos R, et al. **Arch Intern Med** 1999 Apr 26;159(8):845–50
Do we need a clinical decision rule for the discontinuation of cardiac arrest resuscitations? [editorial; comment] Sanders AB. **Arch Intern Med** 1999 Jan 25;159(2):119–21 . Comment on: Arch Intern Med 1999 Jan 25;159(2):129–34.
Derivation of a clinical decision rule for the discontinuation of in-hospital cardiac arrest resuscitations [see comments] van Walraven C, et al. **Arch Intern Med** 1999 Jan 25; 159(2):129–34. Comment in: Arch Intern Med 1999 Jan 25;159(2):119–21.
Field triage of the pulseless trauma patient. Battistella FD, et al. **Arch Surg** 1999 Jul;134(7):742–5; discussion 745–6
On-board defibrillators [letter; comment] McKenas DK. **Aviat Space Environ Med** 1999 May;70(5):533. Comment on: Aviat Space Environ Med 1999 Jan;70(1):87–8.
Airline use of automatic external defibrillators: shocking developments [see comments] Wolbrink A, et al. **Aviat Space Environ Med** 1999 Jan;70(1):87–8. Comment in: Aviat Space Environ Med 1999 May;70(5):533.
Treatment of out-of-hospital cardiac arrest with a low-energy impedance-compensating biphasic waveform automatic external defibrillator. The LIFE Investigators. Gliner BE, et al. **Biomed Instrum Technol** 1998 Nov–Dec; 32(6):631–44
Methyl isobutyl amiloride alters regional brain reperfusion after resuscitation from cardiac arrest in rats. Lauro KL, et al. **Brain Res** 1999 Jun 12;831(1–2):64–71
Every death is different. **Camb Q Healthc Ethics** 1998 Fall; 7(4):443–7
Perioperative cardiac arrest and resuscitation: do we know what we're doing? [editorial; comment] Bands C, et al. **Can J Anaesth** 1999 Jun;46(6):519–24. Comment on: Can J Anaesth 1999 Jun;46(6):529–35.
Perioperative resuscitation knowledge base [see comments] Porayko LD, et al. **Can J Anaesth** 1999 Jun;46(6):529–35 . Comment in: Can J Anaesth 1999 Jun;46(6):519–24.
Defining futility [letter; comment] Hoffer LJ. **CMAJ** 1999 Feb 9;160(3):309–10. Comment on: CMAJ 1998 Oct 6;159(7):817–21.
Simulated mouth-to-mouth ventilation and chest compressions (bystander cardiopulmonary resuscitation) improves outcome in a swine model of prehospital pediatric asphyxial cardiac arrest [see comments] Berg RA, et al. **Crit Care Med** 1999 Sep;27(9):1893–9. Comment in: Crit Care Med 1999 Sep;27(9):2048–50.
An appreciation of cardiac resuscitation [editorial; comment] Ewy GA. **Crit Care Med** 1999 Mar;27(3):449–50. Comment on: Crit Care Med 1999 Mar;27(3):486–92.
How do you spell basic life support? [editorial; comment] Gazmuri RJ, et al. **Crit Care Med** 1999 Sep;27(9):2048–50 . Comment on: Crit Care Med 1999 Sep;27(9):1893–9.
Influence of ambulance crew's length of experience on the outcome of out-of-hospital cardiac arrest. Soo LH, et al. **Eur Heart J** 1999 Apr;20(7):535–40
'Out-of-hospital cardiac arrests' treated by the West Midlands Ambulance Service over a 2-year period. Robinson JS, et al. **Eur J Anaesthesiol** 1998 Nov; 15(6):702–9
The role of a hospital-based flying squad in out-of-hospital cardiac arrest [editorial; comment] **Eur J Emerg Med** 1998 Sep;5(3):283. Comment on: Eur J Emerg Med 1998 Sep;5(3):285–7.

HEART ARREST

Advanced life support for out-of-hospital cardiac arrest--the changing role of a hospital-based flying squad [see comments] Gleeson AP, et al. **Eur J Emerg Med** 1998 Sep; 5(3):285-7. Comment in: Eur J Emerg Med 1998 Sep;5(3):283.

A matter of minutes. Using AEDs to improve cardiac arrest survival rates. **Health Devices** 1999 May-Jun;28(5-6):181-5

Approaches to modern management of cardiac arrest. Adgey AA, et al. **Heart** 1998 Oct;80(4):397-401 (64 ref.)

Adrenaline dosage and buffers in cardiac arrest. Adgey AA. **Heart** 1998 Oct;80(4):412-4 (10 ref.)

Empirical thrombolysis in catastrophic pulmonary embolism [letter; comment] Kelly J. **J Accid Emerg Med** 1999 Jul; 16(4):314. Comment on: J Accid Emerg Med 1999 Jan;16(1):76.

High doses of epinephrine may not be beneficial [news] **J Am Dent Assoc** 1999 Jan;130(1):33, 36

Cardiopulmonary resuscitation in the newborn intensive care unit [see comments] Barr P, et al. **J Paediatr Child Health** 1998 Dec;34(6):503-7. Comment in: J Paediatr Child Health 1998 Dec;34(6):500.

Improving survival following out-of-hospital cardiac arrest [letter] Asplin BR, et al. **JAMA** 1999 Sep 15;282(11):1033-4

Advancing cardiac resuscitation: lessons from externally controlled trials [editorial; comment] Olson CM, et al. **JAMA** 1999 Apr 7;281(13):1220-2. Comment on: JAMA 1998 Apr 7;281(13):1175-81. Comment on: JAMA 1998 Apr 7;281(13):1182-8.

Improved out-of-hospital cardiac arrest survival through the inexpensive optimization of an existing defibrillation program: OPALS study phase II. Ontario Prehospital Advanced Life Support [see comments] Stiell IG, et al. **JAMA** 1999 Apr 7;281(13):1175-81. Comment in: JAMA 1998 Apr 7;281(13):1220-2.

Advisory statements of the International Liaison Committee on Resuscitation (ILCOR) CPR in pregnancy [see comments] Takrouri MS, et al. **Middle East J Anesthesiol** 1998 Oct;14(6):399-405. Comment in: Middle East J Anesthesiol 1998 Oct;14(6):393-7.

A comparison of standard cardiopulmonary resuscitation and active compression-decompression resuscitation for out-of-hospital cardiac arrest. French Active Compression-Decompression Cardiopulmonary Resuscitation Study Group. Plaisance P, et al. **N Engl J Med** 1999 Aug 19;341(8):569-75

Implantation of permanent dual chamber pacemaker in a pregnant woman by transesophageal echocardiographic guidance. Antonelli D, et al. **Pacing Clin Electrophysiol** 1999 Mar;22(3):534-5

Special resuscitation issues encountered during air medical transport. Air Medical Services Committee of the National Association of EMS Physicians. Hankins DG, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):326-7

Outcomes of sudden cardiac arrest treated with defibrillation by emergency medical technicians (EMT-Ds) or paramedics in a two-tiered urban EMS system. Joyce SM, et al. **Prehosp Emerg Care** 1998 Jan-Mar;2(1):13-7

The impact of paramedics on out-of-hospital cardiac arrests in a rural community. Kriegsman WE Jr, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):274-9

A preliminary study of the reliability of immediate vs. delayed interviews of cardiac arrest witnesses. Swor RA, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):110-4

Out-of-hospital cardiac arrests in an urban/rural area during 1991 and 1996: have emergency medical service changes improved outcome? Absalom AR, et al. **Resuscitation** 1999 Jan;40(1):3-9

Lazarus phenomenon: another case? [letter; comment] Bradbury N. **Resuscitation** 1999 Jun;41(1):87. Comment on: Resuscitation 1998 Oct-Nov;39(1-2):125-8.

Do victims of an out-of-hospital cardiac arrest benefit from a training program for emergency medical dispatchers? Calle PA, et al. **Resuscitation** 1997 Nov;35(3):213-8

ResusSim 98--a PC advanced life support trainer. Christensen UJ, et al. **Resuscitation** 1998 Oct-Nov; 39(1-2):81-4

Improved haemodynamics and restoration of spontaneous circulation with constant aortic occlusion during experimental cardiopulmonary resuscitation. Gedeborg R, et al. **Resuscitation** 1999 Apr-May;40(3):171-80

Teaching adult resuscitation in the United States--time for a rethink. Kaye W, et al. **Resuscitation** 1998 Jun; 37(3):177-87 (110 ref.)

Comparison of two emergency response systems and their effect on survival from out of hospital cardiac arrest. Mitchell RG, et al. **Resuscitation** 1997 Nov;35(3):225-9

The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. Müllner M, et al. **Resuscitation** 1998 Aug;38(2):99-105

Maximisation of cerebral blood flow during experimental cardiopulmonary resuscitation does not ameliorate post-resuscitation hypoperfusion. Nozari A, et al. **Resuscitation** 1999 Jan;40(1):27-35

There is a difference in characteristics and outcome between women and men who suffer out of hospital cardiac arrest. Perers E, et al. **Resuscitation** 1999 Apr-May;40(3):133-40

Successful resuscitation using aminophylline in refractory cardiac arrest with asystole. Perouansky M, et al. **Resuscitation** 1998 Jul;38(1):39-41 (12 ref.)

Does race or socioeconomic status predict adverse outcome after out of hospital cardiac arrest: a multi-center study. Sayegh AJ, et al. **Resuscitation** 1999 Apr-May;40(3):141-6

A revised role for the hospital cardiac arrest team? Soar J, et al. **Resuscitation** 1998 Sep;38(3):145-9

Utstein registration used as a tool in organisational development. Weydahl PG, et al. **Resuscitation** 1999 Feb-Mar;40(2):103-6

Seven years' experience with early defibrillation by police and paramedics in an emergency medical services system. White RD, et al. **Resuscitation** 1998 Dec;39(3):145-51

Preliminary clinical outcome study of mild resuscitative hypothermia after out-of-hospital cardiopulmonary arrest. Yanagawa Y, et al. **Resuscitation** 1998 Oct-Nov; 39(1-2):61-6

Hospital resuscitation of cardiac arrest patients. Lim YH, et al. **Singapore Med J** 1999 Mar;40(3):165-70

[Defibrillation with an automatic external defibrillator outside the hospital: a life-saving, but restricted treatment? (letter; comment)] Huisman AW. **Ned Tijdschr Geneeskd** 1999 Apr 17;143(16):873. Comment on: Ned Tijdschr Geneeskd 1999 Feb 27;143(9):482-5. **(Dut)**

[Defibrillation with an automatic external defibrillator outside the hospital: a life-saving, but restricted treatment? (see comments)] Koster RW, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):482-5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 17;143(16):873. **(Dut)**

[Pre-hospitalization reanimation in cardiac arrest] Carli P, et al. **Presse Med** 1999 Feb 6;28(5):243-51 (39 ref.) (Eng. Abstr.) **(Fre)**

[Circulatory arrest] Boulet N, et al. **Rev Prat** 1998 Jan 15; 48(2):193-7 **(Fre)**

[Cardiopulmonary resuscitation. The effect of severe hypothermia on clinical outcome] Lamperti M, et al. **Minerva Anestesiol** 1998 Oct;64(10):459-64 (Eng. Abstr.) **(Ita)**

[Successful emergency coronary artery bypass grafting after use of a percutaneous cardiopulmonary support system in a patient with cardiopulmonary arrest secondary to acute myocardial infarction] Koyama T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1141-6 (Eng. Abstr.) **(Jpn)**

[Out-of-hospital cardiac arrest and the Utstein style: utilization of an international standardized format to evaluate surgical outcome] Sakamoto T. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):460-5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Special situations in resuscitation] Kloeck W, et al. **Arq Bras Cardiol** 1998 Dec;71 Suppl 1:29-42 **(Por)**

[Early defibrillation] Kloeck W, et al. **Arq Bras Cardiol** 1998 Dec;71 Suppl 1:17-8 **(Por)**

[Life support in pediatrics] Nadkarni V, et al. **Arq Bras Cardiol** 1998 Dec;71 Suppl 1:19-28 **(Por)**

[Life of more people with heart arrest outside hospital can be saved. Improved organization and education is required] Holmberg S, et al. **Lakartidningen** 1999 Apr 28; 96(17):2074-7 (15 ref.) **(Swe)**

VETERINARY

The effect of current frequency during waterbath stunning on the physical recovery and rate and extent of bleed out in turkeys. Mouchonière M, et al. **Poult Sci** 1999 Mar; 78(3):485-9

Impedance recordings to determine change in extracellular volume in the brain following cardiac arrest in broiler chickens. Ruis-Heutinck LF, et al. **Poult Sci** 1998 Sep; 77(9):1422-7

New thoughts on cardiopulmonary resuscitation. Evans AT. **Vet Clin North Am Small Anim Pract** 1999 May; 29(3):819-29, viii (35 ref.)

HEART ARREST, INDUCED

see related

CARDIOPLEGIC SOLUTIONS

Enflurane and isoflurane, but not halothane, protect against myocardial reperfusion injury after cardioplegic arrest with HTK solution in the isolated rat heart. Preckel B, et al. **Anesth Analg** 1998 Dec;87(6):1221-7

Differential immediate-early gene expression in ovine brain after cardiopulmonary bypass and hypothermic circulatory arrest. Bokesch PM, et al. **Anesthesiology** 1998 Oct; 89(4):961-8

Efficacy of contraction uncoupling by 2,3-butanedione monoxime during initial reperfusion versus cardioplegic arrest for protection of isolated hearts. Habazettl H, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):72-8

Can cardioplegia management influence cytokine responses during clinical cardiopulmonary bypass? Wan S, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):81-5

Simultaneous measurement of coronary sinus oxygen saturation and blood flow during terminal warm blood cardioplegia in coronary artery bypass grafting. Yasuda T, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):271-4

Antegrade cerebral perfusion with cold blood: a 13-year experience. Bachet J, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1874-8; discussion 1891-4

Retrograde cerebral perfusion for aortic operations through left thoractomy. Bartoccioni S, et al. **Ann Thorac Surg** 1999 Jun;67(6):1815-6

Myocardial perfusion during warm antegrade and retrograde cardioplegia: a contrast echo study [see comments] Borger MA, et al. **Ann Thorac Surg** 1999 Sep;68(3):955-61. Comment in: Ann Thorac Surg 1999 Sep;68(3):797-8.

Effects of cardioplegic flushing, storage, and reperfusion on coronary circulation in the pig. Budrikis A, et al. **Ann Thorac Surg** 1999 May;67(5):1345-9

As originally published in 1996: Endothelial effects of hemostatic devices for continuous cardioplegia or minimally invasive operations. Updated in 1999. Chavanon O, et al. **Ann Thorac Surg** 1999 Sep;68(3):1118-20

Risk analysis for aortic surgery using hypothermic circulatory arrest with retrograde cerebral perfusion. Deeb GM, et al. **Ann Thorac Surg** 1999 Jun;67(6):1883-6; discussion 1891-4

Antegrade selective cerebral perfusion in operations on the proximal thoracic aorta. Dossche KM, et al. **Ann Thorac Surg** 1999 Jun;67(6):1904-10; discussion 1919-21

Retrospective study of somatosensory evoked potential monitoring in deep hypothermic circulatory arrest. Ghariani S, et al. **Ann Thorac Surg** 1999 Jun;67(6):1915-8; discussion 1919-21

Protective action of 17beta-estradiol in cardiac cells: implications for hyperkalemic cardioplegia. Jovanović S, et al. **Ann Thorac Surg** 1998 Nov;66(5):1658-61

Distribution of cerebral flow using retrograde versus antegrade cerebral perfusion. Katz MG, et al. **Ann Thorac Surg** 1999 Apr;67(4):1065-9

Hypothermic cardiopulmonary bypass for spinal cord protection: rationale and clinical results. Kouchoukos NT, et al. **Ann Thorac Surg** 1999 Jun;67(6):1940-2; discussion 1953-8

Intermittent perfusion protects the brain during deep hypothermic circulatory arrest. Langley SM, et al. **Ann Thorac Surg** 1999 Jul;68(1):4-12; discussion 12-3

Cerebral metabolic suppression during hypothermic circulatory arrest in humans. McCullough JN, et al. **Ann Thorac Surg** 1999 Jun;67(6):1895-9; discussion 1919-21

Adenosine-enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia. McCully JD, et al. **Ann Thorac Surg** 1999 Mar;67(3):699-704

Circulatory arrest under moderate systemic hypothermia and cold retrograde cerebral perfusion. Moshkovitz Y, et al. **Ann Thorac Surg** 1998 Oct;66(4):1179-84

Effects of cyanosis and hypothermic circulatory arrest on lung function in neonatal lambs. Nagashima M, et al. **Ann Thorac Surg** 1999 Aug;68(2):499-504; discussion 504-5

Delayed impairment of cerebral oxygenation after deep hypothermic circulatory arrest in children. Pesonen EJ, et al. **Ann Thorac Surg** 1999 Jun;67(6):1765-70

Aortic valve replacement using circulatory arrest [letter; comment] Silberman S, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2158-9. Comment on: Ann Thorac Surg 1998 May;65(5):1313-5.

Aprotinin in deep hypothermic circulatory arrest. Smith CR, et al. **Ann Thorac Surg** 1999 Jul;68(1):278-86 (66 ref.)

Adenosine A3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Thourani VH, et al. **Ann Thorac Surg** 1999 Jun;67(6):1732-7

Increased intracerebral excitatory amino acids and nitric oxide after hypothermic circulatory arrest. Tseng EE, et al. **Ann Thorac Surg** 1999 Feb;67(2):371-6

Nitric oxide mediates neurologic injury after hypothermic circulatory arrest. Tseng EE, et al. **Ann Thorac Surg** 1999 Jan;67(1):65-71

Retrograde cerebral perfusion for aortic arch surgery: analysis of risk factors. Ueda Y, et al. **Ann Thorac Surg** 1999 Jun;67(6):1879-82; discussion 1891-4

Does retrograde cerebral perfusion affect risk factors for stroke and mortality after hypothermic circulatory arrest? Wong CH, et al. **Ann Thorac Surg** 1999 Jun;67(6):1900-3; discussion 1919-21

S-100beta release in hypothermic circulatory arrest and coronary artery surgery. Wong CH, et al. **Ann Thorac Surg** 1999 Jun;67(6):1911-4; discussion 1919-21

The effects of pulsatile versus nonpulsatile perfusion on blood viscoelasticity before and after deep hypothermic circulatory arrest in a neonatal piglet model. Undar A, et al. **Artif Organs** 1999 Aug;23(8):717-21

Lidocaine prolongs the safe duration of circulatory arrest during deep hypothermia in dogs. Zhou Y, et al. **Can J Anaesth** 1998 Jul;45(7):692-8

Retrograde replacement of the thoracic aorta under circulatory arrest and retrograde cerebral perfusion. Cartier R, et al. **Can J Surg** 1998 Oct;41(5):383-7

Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine. Lochner A, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):267-77

Cultured neonatal rat cardiomyocytes and 99mTc-sestamibi to assess the direct effects of cardioplegia. Camilleri L, et al. **Cardiovasc Surg** 1998 Dec;6(6):614-21

Hippocampal neuronal death following deep hypothermic circulatory arrest in dogs: involvement of apoptosis. Kin H, et al. **Cardiovasc Surg** 1999 Aug;7(5):558-64

Myocardial beta-blockade as an alternative to cardioplegic arrest during coronary artery surgery. Mehlhorn U, et al. **Cardiovasc Surg** 1999 Aug;7(5):549-57

Arresting donor hearts with extracellular-type cardioplegia prevents vasoconstriction induced by UW solution. Tanoue Y, et al. **Cardiovasc Surg** 1998 Dec;6(6):622-8

Phase 2 studies of adenosine cardioplegia. Cohen G, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II225-33

ATP-sensitive potassium channel activation before cardioplegia. Effects on ventricular and myocyte function. Dorman BH, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II176–83

Neurological function after deep hypothermic circulatory arrest in the rat. Kawaguchi AT, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II385–9; discussion II390

Albumin microbubble persistence during myocardial contrast echocardiography is associated with microvascular endothelial glycocalyx damage. Lindner JR, et al. **Circulation** 1998 Nov 17;98(20):2187–94

High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Nagashima M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II378–84

Effects of a monoclonal antibody to P-selectin on recovery of neonatal lamb hearts after cold cardioplegic ischemia. Nagashima M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II391–7; discussion II397–8

Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Tofukuji M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II242–6; discussion II247–8

Retrograde cerebral perfusion results in flow distribution abnormalities and neuronal damage. A magnetic resonance imaging and histopathological study in pigs. Ye J, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II313–8

Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest. Ashraf S, et al. **Eur J Cardiothorac Surg** 1999 Jul; 16(1):32–7

Warm ischemic time tolerance after ventilated non-heart-beating lung donation in piglets. Greco R, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):319–25

Beta-blockade versus Buckberg blood-cardioplegia in coronary bypass operation. Kuhn-Régnier F, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):67–74

Aspartate improves recovery of the recently infarcted rat heart after cardioplegic arrest. Rosenfeldt FL, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):185–90

Coronary sinus rupture secondary to retrograde cardioplegia. Agrawal D, et al. **Indian Heart J** 1998 Sep–Oct;50(5):542–4

Aprotinin versus epsilon-aminocaproic acid for aortic surgery using deep hypothermic circulatory arrest. Eaton MP, et al. **J Cardiothorac Vasc Anesth** 1998 Oct; 12(5):548–52

Cardiac troponin I cutoff values to predict postoperative cardiac complications after circulatory arrest and profound hypothermia. Godet G, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):272–5

An abnormal transesophageal echocardiography finding after retrograde cardioplegia. Kinkoph RJ 2nd, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):498–9

Assessment of arteriovenous blood flow during retrograde cerebral perfusion. Loubser PG. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):173–5

Case 4—1998. Cardiopulmonary bypass and hypothermic circulatory arrest for basilar artery aneurysm clipping [clinical conference] Weiss L, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):473–9

Ischemic threshold during cold blood cardioplegic arrest: monitoring with tissue pH and pO2. Carrier M, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):593–7

Plasma hypoxanthine levels during crystalloid and blood cardioplegias: warm blood cardioplegia increases hypoxanthine levels with a greater risk of oxidative stress. Quinlan GJ, et al. **J Cardiovasc Surg (Torino)** 1999 Feb; 40(1):65–9

Heart transplantation for hypoplastic left heart syndrome: modified technique for reducing circulatory arrest time Vricella LA, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1167–71

Influence of Bretschneider's cardioplegia on norepinephrine release from isolated perfused guinea-pig hearts. Gerber SH, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):89–99

Adenosine-induced transient asystole for management of a basilar artery aneurysm. Case report. Groff MW, et al. **J Neurosurg** 1999 Oct;91(4):687–90

Lung transplantation from ventilated non-heart-beating donors: experimental study in a neonatal swine model. Greco R, et al. **J Pediatr Surg** 1999 Feb;34(2):360–6

Pressure volume curves in arrested heterotopic rat heart isografts: role of improved myocardial protection. Starr JP, et al. **J Surg Res** 1999 Sep;86(1):123–9

Deep hypothermic circulatory arrest and retrograde cerebral perfusion. [letter; comment] Jonas RA. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):196–7. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):129–38.

Oxygenation strategy and neurologic damage after deep hypothermic circulatory arrest. I. Gaseous microemboli. Nollert G, et al. **J Thorac Cardiovasc Surg** 1999 Jun; 117(6):1166–71

Oxygenation strategy and neurologic damage after deep hypothermic circulatory arrest. II. hypoxic versus free radical injury. Nollert G, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1172–9

Neuropsychologic outcome after deep hypothermic circulatory arrest in adults. Reich DL, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):156–63

Postischemic hyperthermia exacerbates neurologic injury after deep hypothermic circulatory arrest. Shum-Tim D, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):780–92

Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision [see comments] Safi HJ, et al. **J Vasc Surg** 1998 Oct;28(4):591–8 . Comment in: J Vasc Surg 1999 Jul;30(1):196–7.

Regarding "Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision" [letter; comment] Westaby S. **J Vasc Surg** 1999 Jul;30(1):196–7. Comment on: J Vasc Surg 1998 Oct;28(4):591–8.

Effects of leukocyte-depleted warm blood cardioplegia on cardiac and endothelial function. Tomoeda H. **Kurume Med J** 1999;46(1):31–8

AgNORs in cardiomyocytes from surgical patients with coronary heart disease. Mamaev NN, et al. **Mol Pathol** 1998 Aug;51(4):218–21

Circulatory arrest with profound hypothermia during the surgical treatment of large internal carotid artery aneurysm--case report. Taki W, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):725–9

Hypothermic cardiac standstill for cerebral aneurysm surgery. Connolly ES Jr, et al. **Neurosurg Clin N Am** 1998 Oct;9(4):681–95 (95 ref.)

Removal of infected pacemaker leads with deep hypothermic circulatory arrest and open surgical exploration of the superior vena cava and innominate veins. Feldbaum DM, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):962–4

Ultrastructural changes in myocardium during mild hypothermic retrograde blood cardioplegia. Rainio P, et al. **Scand Cardiovasc J** 1998;32(6):353–9

Does hypothermia or hyperkalemia influence the preconditioning response? Takeshima S, et al. **Scand Cardiovasc J** 1999;33(2):79–87

Radical surgery of a giant Galen's vein aneurysm using total circulatory arrest: case report. Paladino J, et al. **Surg Neurol** 1999 Feb;51(2):153–7

Assessment of the myocardial protective effect of antegrade warm blood cardioplegia by measuring the release of biochemical markers. Kawahito K, et al. **Surg Today** 1999; 29(4):322–6

Myocardial protection: physiological principles, established techniques, new strategies. Proceedings of a symposium. Cologne, Germany, September 19–20, 1997. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:235–312

Ischemic preconditioning as an adjunct to crystalloid or blood cardioplegia for myocardial protection in routine coronary surgery. Cremer J, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:298–301

Myocardial protection for neonates and infants. Jonas RA. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:288–91 (27 ref.)

Clinical experience with blood cardioplegia. Schlensak C, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:282–5; discussion 286–7 (28 ref.)

Liver transplantation from non-heart-beating donors: effect of machine perfusion preservation and pentoxifylline. Uchiyama M, et al. **Transplant Proc** 1998 Nov; 30(7):3798–800

[Sensitivity, specificity, and impact on the surgical strategy of the perioperative neuromonitoring of somatic evoked potentials in vascular surgery performed with circulatory arrest under deep hypothermia] Ghariani S, et al. **Neurophysiol Clin** 1998 Sep;28(4):335–41 (Eng. Abstr.) **(Fre)**

[Adenosine-induced heart arrest for endovascular reconstruction of thoracic aneurysms of the aorta] Weigand MA, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):372–5 (Eng. Abstr.) **(Ger)**

[Correct translation of "cardioplegia" (letter)] Fujii J. **J Cardiol** 1999 Feb;33(2):117–8 **(Jpn)**

[A report of 4 cases of aortic operation using open proximal anastomosis under the hypothermic circulatory arrest and left lateral exposure] Doi K, et al. **Kyobu Geka** 1999 Aug; 52(9):751–5 (Eng. Abstr.) **(Jpn)**

[Influence of left ventricular wall thickening on myocardial injury in aortic valve replacement] Hosono M, et al. **Kyobu Geka** 1998 Dec;51(13):1099–103 (Eng. Abstr.) **(Jpn)**

[Comparison of protective effects of carnosine and acetylcarnosine during cardioplegia] Alabovskii VV, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):290–4 **(Rus)**

ADVERSE EFFECTS

The influence of collateral flow on the antegrade and retrograde distribution of cardioplegia in patients with an occluded right coronary artery. Aronson S, et al. **Anesthesiology** 1998 Nov;89(5):1099–107

Assessing the impact of cerebral injury after cardiac surgery: will determining the mechanism reduce this injury? Baumgartner WA, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1871–3; discussion 1891–4

Genesis of edema during orthograde and retrograde coronary perfusion [letter; comment] Döring V. **Ann Thorac Surg** 1999 Jan;67(1):289–90. Comment on: Ann Thorac Surg 1998 Feb;65(2):449–53.

Temporary neurological dysfunction after deep hypothermic circulatory arrest: a clinical marker of long-term functional deficit. Ergin MA, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1887–90; discussion 1891–4

Con: thiopental should not be used before deep hypothermic circulatory arrest in pediatric patients. Mossad EB, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):595–7

Pro: arguments for use of barbiturates in infants and children undergoing deep hypothermic circulatory arrest. Reid RW, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):591–4

Depressed myofilament co-operativity associated with post-cardioplegic myocardial depression. Powers FM, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1779–87

Preconditioning improves cardioplegia-related coronary microvascular smooth muscle hypercontractility: role of KATP channels. Matsuda N, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):438–45

Myocardial substrate uptake and oxidation during and after routine cardiac surgery. Pietersen HG, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):71–80

A novel sialyl Lewis X analog attenuates cerebral injury after deep hypothermic circulatory arrest. Shin'oka T, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1204–11

Anti-c5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. Tofukuji M, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1060–8

Experimental models of hypothermic circulatory arrest. Vannucci RC, et al. **Semin Pediatr Neurol** 1999 Mar; 6(1):48–54 (30 ref.)

Stenosis of the right coronary artery and retrograde cardioplegia predispose patients to atrial fibrillation after coronary artery bypass grafting. Pehkonen E, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):115–20

HISTORY

Myocardial protection: the rebirth of potassium-based cardioplegia. Shiroishi MS. **Tex Heart Inst J** 1999; 26(1):71–86

METHODS

Profound hypothermia and circulatory arrest with skull base approaches for treatment of complex posterior circulation aneurysms. Sullivan BJ, et al. **Acta Neurochir (Wien)** 1999; 141(1):1–11; discussion 11–2

Retrograde cardioplegia. Gates RN, et al. **Adv Card Surg** 1998;10:115–39 (50 ref.)

Warm blood cardioplegia reduces the fall in the intracellular concentration of taurine in the ischaemic/reperfused heart of patients undergoing aortic valve surgery. Ascione R, et al. **Amino Acids** 1998;15(4):339–50

Adenosine-induced transient cardiac arrest for placement of endovascular stent-grafts in the thoracic aorta [letter; comment] Weigand MA, et al. **Anesthesiology** 1998 Oct; 89(4):1037–8. Comment on: Anesthesiology 1998 Feb;88(2):534–6.

Cardioplegia delivery: more (or less) than what you see [editorial; comment] Aronson S. **Ann Thorac Surg** 1999 Sep; 68(3):797–8. Comment on: Ann Thorac Surg 1999 Sep;68(3):955–61.

Warm reperfusion and myocardial protection. Chocron S, et al. **Ann Thorac Surg** 1998 Dec;66(6):2003–7

Antegrade crystalloid cardioplegia vs antegrade/retrograde cold and tepid blood cardioplegia in CABG. Elwatidy AM, et al. **Ann Thorac Surg** 1999 Aug;68(2):447–53

Warm or cold continuous blood cardioplegia provides similar myocardial protection. Ericsson AB, et al. **Ann Thorac Surg** 1999 Aug;68(2):454–9

First report of the Port Access International Registry. Galloway AC, et al. **Ann Thorac Surg** 1999 Jan;67(1):51–6; discussion 57–8

Facile left ventricular deairing by administration of cardioplegia into the left ventricular vent. Gundry SR. **Ann Thorac Surg** 1998 Dec;66(6):2117–8

Randomized trial of intermittent antegrade warm blood versus cold crystalloid cardioplegia. Jacquet LM, et al. **Ann Thorac Surg** 1999 Feb;67(2):471–7

The importance of cardioplegic infusion pressure in neonatal myocardial protection. Kronon M, et al. **Ann Thorac Surg** 1998 Oct;66(4):1358–64

A practical method of differential hypothermia to permit use of a low pump oxygenator flow. Peirce EC 2nd, et al. **ASAIO J** 1998 Nov-Dec;44(6):763–9

Determination of cardiac troponin I forms in the blood of patients with acute myocardial infarction and patients receiving crystalloid or cold blood cardioplegia. Giuliani I, et al. **Clin Chem** 1999 Feb;45(2):213–22

Beating versus arrested heart revascularization: evaluation of myocardial function in a prospective randomized study. Ascione R, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):685–90

Elevated serum levels of S-100 after deep hypothermic arrest correlate with duration of circulatory arrest. Astudillo R, et al. **Eur J Cardiothorac Surg** 1996;10(12):1107–12; discussion 1113

Myocardial protection in operations requiring more than 2 h of aortic cross-clamping. Bar-El Y, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):271–5

Intermittent antegrade hyperkalaemic warm blood cardioplegia supplemented with magnesium prevents myocardial substrate derangement in patients undergoing coronary artery bypass surgery. Caputo M, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):596–601

The end of the cold era: from intermittent cold to intermittent warm blood cardioplegia. Caputo M, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):467–75 (60 ref.)

Intermittent warm blood cardioplegia does not provide adequate myocardial resuscitation after global ischaemia. Ericsson AB, et al. **Eur J Cardiothorac Surg** 1999 Aug; 16(2):233–9

A clinical comparative study between crystalloid and blood-based St Thomas' hospital cardioplegic solution. Ibrahim MF, et al. **Eur J Cardiothorac Surg** 1999 Jan; 15(1):75–83

Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients. Li G, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):653–7

Orthotopic transplantation of pig hearts harvested after 30 min of normothermic ischemia: controlled reperfusion with blood cardioplegia containing the Na+–H+–exchange inhibitor HOE 642. Martin J, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):607–14

The effect of the ultrashort beta-blocker esmolol on cardiac function recovery: an experimental study. Pirk J, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):199–203

Adenosine induced transient cardiac standstill in catheter interventional procedures for congenital heart disease. De Giovanni JV, et al. **Heart** 1998 Oct;80(4):330–3

Assessment of right ventricular function postretrograde cardioplegia by transesophageal echocardiography. Baslaim GM, et al. **J Card Surg** 1998 Jan;13(1):32–6

Development of blood cardioplegia and retrograde techniques: the experimenter/observer complex. Buckberg GD. **J Card Surg** 1998 May;13(3):163–70 (28 ref.)

Simultaneous selective cerebral perfusion and systemic circulatory arrest through the right axillary artery for aortic surgery. Byrne JG, et al. **J Card Surg** 1998 Jul;13(4):236–8

Pulmonary artery catheter in the coronary sinus: implications of a persistent left superior vena cava for retrograde cardioplegia. Hanson EW, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):448–9

Cardiac Troponin T to evaluate myocardial protection via intermittent cold blood or continuous warm blood cardioplegia in coronary artery bypass grafting. Astorri E, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):797–802

Tepid systemic perfusion and intermittent isothermic blood cardioplegia in coronary surgery. Luciani N, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):599–607

Multiple organ harvesting from a single donor for transplantation. A comparison of simple cooling technique and bypass technique. Takahashi T, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):347–53

Retrograde cardioplegia [editorial] Frater RW. **J Heart Valve Dis** 1999 Mar;8(2):118–9

Effectiveness of continuous warm blood cardioplegia in cardiac valve re-replacement. Nagaoka H, et al. **J Heart Valve Dis** 1999 Mar;8(2):124–30

Relationship between position of the coronary sinus catheter and distribution of cardioplegia. Tosson R, et al. **J Heart Valve Dis** 1999 Mar;8(2):120–3

A novel arresting solution for study of postmortem pressure--volume curves of the rat left ventricle. Rabkin DG, et al. **J Surg Res** 1998 Dec;80(2):221–8

Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia. Hendrikx M, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):452–9

Is alpha-stat management still justified for deep hypothermic circulatory arrest in adults? [letter] Miyamoto TA, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):569–70

Transapical aortic occlusion for cardioplegic delivery during reconstruction of thoracoabdominal aortic aneurysm with deep hypothermic circulatory arrest. Sasaguri S, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):186–8

Long-term myocardial preservation: effects of hyperkalemia, sodium channel, and Na/K/2Cl cotransport inhibition on extracellular potassium accumulation during hypothermic storage. Snabaitis AK, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):123–34

Does retrograde warm blood cardioplegic perfusion provide better protection of ischemic areas than antegrade warm blood cardioplegic perfusion? A magnetic resonance study in pig hearts. Ye J, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):994–1003

Hypothermic circulatory arrest and hypothermic perfusion for extensive disease of the thoracic and thoracoabdominal aorta. Kouchoukos NT. **Jpn J Thorac Cardiovasc Surg** 1999 Jan;47(1):1–5

Benefits and pitfalls of warm blood cardioplegia in heart valve replacement: systemic protective effects. Yuan SM. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Oct; 14(10):616–24

Recovery after prolonged cross-clamping tepid blood cardioplegia: report of a case. Katoh T, et al. **Surg Today** 1998;28(10):1095–7

The effect of graft perfusion with warm blood cardioplegia for cadaver heart transplantation. Suehiro K, et al. **Surg Today** 1999;29(9):890–6

Application of retrograde cerebral perfusion and moderate systemic hypothermic circulatory arrest for cavoatrial tumor resection. Beltz MS, et al. **Tech Urol** 1999 Jun; 5(2):87–91

Valve replacement under retrograde warm-blood cardioplegia. Results in 287 patients. Tolis GA, et al. **Tex Heart Inst J** 1998;25(3):185–93

Technical refinements in myocardial protection: infants--adults. Holper K, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:292–5; discussion 296–7 (20 ref.)

Coronary oxygen persufflation for long-term myocardial protection. Kuhn-Régnier F, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:308–12

Beta-blockade as an alternative to cardioplegia. Mehlhorn U, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:302–7

[Clinical advantages and myocardial protection of normothermal CPB--comparison with hypothermal CPB] Uno Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):671–6 (Eng. Abstr.) **(Jpn)**

[Intermittent warm blood cardioplegia--an experimental study] Yamada T. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):677–88 (Eng. Abstr.) **(Jpn)**

[A case report of coronary artery bypass grafting using hypothermic circulatory arrest technique for the severely calcified ascending aorta] Fujiwara H, et al. **Kyobu Geka** 1999 May;52(5):368–71 (Eng. Abstr.) **(Jpn)**

[Efficacy of terminal warm blood cardioplegia in combination with Bretschneider-HTK solution for myocardial protection] Morishita A, et al. **Kyobu Geka** 1999 Sep;52(10):831–5 (Eng. Abstr.) **(Jpn)**

[Comparison between intermittent antegrade warm blood cardioplegia and cold crystalloid cardioplegia in patients performed reoperation for valvular heart disease] Ota T, et al. **Kyobu Geka** 1999 Jan;52(1):69–73 (Eng. Abstr.) **(Jpn)**

[The efficiency of intermittent antegrade warm blood cardioplegia] Hirose M, et al. **Masui** 1999 Jan;48(1):48–52 (Eng. Abstr.) **(Jpn)**

[Efficacy of temporary heart arrest induced by intravenous ATP in endoluminal grafting] Ishikawa K, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):871–4 **(Jpn)**

VETERINARY

Circulatory arrest under hypothermic anesthesia using abdominal cavity cooling. Fujiki M, et al. **J Vet Med Sci** 1998 Nov;60(11):1237–42

HEART, ARTIFICIAL

Mean velocity and Reynolds stress measurements in the regurgitant jets of tilting disk heart valves in an artificial heart environment. Maymir JC, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):146–56

Assessment of the total artificial heart (TAH) pulsatility: the coalition between pulsatility and ejection time in TAH in vitro study. Nakata Ki, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):275–9

Implantation technique for the CardioWest total artificial heart. Arabia FA, et al. **Ann Thorac Surg** 1999 Aug; 68(2):698–704

Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. Copeland JG, et al. **Ann Thorac Surg** 1999 Aug;68(2):756–60

The CardioWest total artificial heart bridge to transplantation: 1993 to 1996 national trial. Copeland JG 3rd, et al. **Ann Thorac Surg** 1998 Nov;66(5):1662–9

Development of a totally implantable biventricular bypass centrifugal blood pump system. Nosé Y, et al. **Ann Thorac Surg** 1999 Aug;68(2):775–9

Present status of the total artificial heart at the University of Tokyo. Abe Y, et al. **Artif Organs** 1999 Mar;23(3):221–8

CardioWest total artificial heart: a retrospective controlled study. Arabia FA, et al. **Artif Organs** 1999 Feb;23(2):204–7

Current status and future directions for a total artificial heart with a past. Copeland JG. **Artif Organs** 1998 Nov; 22(11):998–1001

Ultracompact, completely implantable permanent use electromechanical ventricular assist device and total artificial heart. Honda N, et al. **Artif Organs** 1999 Mar; 23(3):253–61

Development of a flow-transformed pulsatile total artificial heart for total implantation. Imachi K, et al. **Artif Organs** 1992 Jun;16(3):308–13

All is not well with the artificial heart. Kolff WJ. **Artif Organs** 1992 Apr;16(2):118–22

Electrohydraulic-clamshell heart with energy converter inside the compliance reservoir. Kolff WJ, et al. **Artif Organs** 1992 Apr;16(2):123–30

Three-dimensional imaging of mitral and tricuspid annuli for total artificial heart implantation. Komoda T, et al. **Artif Organs** 1992 Oct;16(5):496–501

A ferrofluidic actuator for an implantable artificial heart. Mitamura Y, et al. **Artif Organs** 1992 Oct;16(5):490–5

The development of a control method for a total artificial heart using mixed venous oxygen saturation. Nakamura M, et al. **Artif Organs** 1999 Mar;23(3):235–41

The analysis of driving mode influence on energy dissipation in pneumatic artificial heart chambers. Nawrat Z, et al. **Artif Organs** 1998 Oct;22(10):898–904

Is a pulsatile cardiac prosthesis a dying dinosaur? [editorial] Nosé Y. **Artif Organs** 1992 Jun;16(3):233–4

Surface roughness of a metallic cardiac prosthesis [editorial] Nosé Y. **Artif Organs** 1999 Apr;23(4):297

Characterization of antithrombotic activity of lumbrokinase-immobilized polyurethane valves in the total artificial heart. Park Y, et al. **Artif Organs** 1999 Feb; 23(2):210–4

The 1991 Hastings Lecture. The artificial heart: paths, progress and patience. Pierce WS. **Artif Organs** 1992 Jun; 16(3):314–9

Development of totally implantable electromechanical artificial heart systems: Baylor ventricular assist system. Sasaki T, et al. **Artif Organs** 1992 Aug;16(4):407–13

Proposal of a new electromechanical total artificial heart: the TAH Serpentina. Sauer IM, et al. **Artif Organs** 1999 Mar;23(3):290–1

Wearable air supply for pneumatic artificial hearts and ventricular assist devices. Sipin AJ, et al. **Artif Organs** 1992 Aug;16(4):431–8

Noninvasive control of cardiac output for alternately ejecting dual-pusherplate pumps. Snyder AJ, et al. **Artif Organs** 1992 Apr;16(2):189–94

Development of a totally implantable electromechanical total artificial heart: Baylor TAH. Takatani S, et al. **Artif Organs** 1992 Aug;16(4):398–406

In vivo evaluation of the national cardiovascular center electrohydraulic total artificial heart. Tatsumi E, et al. **Artif Organs** 1999 Mar;23(3):242–8

Flow balance between the left and right cardiac output of an eccentric roller type total artificial heart. Wada H, et al. **Artif Organs** 1999 Aug;23(8):741–6

Diminished release of atrial natriuretic factor in calves with a total artificial heart. Windberger U, et al. **Artif Organs** 1992 Aug;16(4):392–7

A future prediction type artificial heart system. Yambe T, et al. **Artif Organs** 1999 Mar;23(3):268–73

Vagal nerve activity recording in the awake condition for the control of an artificial heart system. Yambe T, et al. **Artif Organs** 1999 Jun;23(6):529–31

Three-dimensional thoracic modeling for an anatomical compatibility study of the implantable total artificial heart. Zhang B, et al. **Artif Organs** 1999 Mar;23(3):229–34

Detection of total assist and sucking points based on pulsatility of a continuous flow artificial heart: in vitro evaluation. Araki K, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M708–11

Selection of a rechargeable internal back-up battery for a totally implantable artificial heart. Honda H, et al. **ASAIO J** 1999 Jul–Aug;45(4):339–43

Transcutaneous optical telemetry system with infrared laser diode. Inoue K, et al. **ASAIO J** 1998 Nov–Dec;44(6):841–4

Characterization and optimization of the flow pattern inside a diaphragm blood pump based on flow visualization techniques. Nakata M, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M714–8

Detection of total assist and sucking points based on the pulsatility of a continuous flow artificial heart: in vivo evaluation. Oshikawa M, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M704–7

Biomembrane mimicry provides improved thromboresistance for total artificial hearts. von Segesser LK, et al. **ASAIO J** 1999 May–Jun;45(3):211–4

Steady state hemodynamic and energetic characterization of the Penn State/3M Health Care Total Artificial Heart. Weiss WJ, et al. **ASAIO J** 1999 May–Jun;45(3):189–93

Origin of chaos in the circulation: open loop analysis with an artificial heart. Yambe T, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M700–3

Continuous monitoring of autonomic nerve information for the control of an artificial heart. Yambe T, et al. **ASAIO J** 1998 Sep–Oct;44(5):M696–9

Entrapment of PICC lines in mechanical heart valves can be fatal. **Health Devices** 1999 Sep;28(9):369–70

Static state hemodynamic variables estimation model for the moving-actuator type total artificial heart. Part II - Aortic pressure estimation. Om KS, et al. **Int J Artif Organs** 1999 Feb;22(2):108–12

Static state hemodynamic variables estimation model for the moving-actuator type total artificial heart. Part. I--cardiac output estimation. Om KS, et al. **Int J Artif Organs** 1999 Jan;22(1):21–6

Totally implantable artificial hearts and left ventricular assist devices: selecting impermeable polycarbonate urethane to manufacture ventricles. Yang M, et al. **J Biomed Mater Res** 1999 Spring;48(1):13–23

Successful use of Phoenix-7 total artificial heart. Wei J, et al. **Transplant Proc** 1998 Nov;30(7):3403–4

[Coagulation in heart transplant operations and in operations for applying ventricular assistance devices] Milazzo F, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):93–104 (77 ref.) **(Ita)**

[Mechanical extracorporeal circulation. Artificial heart. Percutaneous cardiopulmonary circulation. Part II] Ostrowska G. **Pol Merkuriusz Lek** 1999 Mar;6(33):146–51 (53 ref.) (Eng. Abstr.) **(Pol)**

[Cardiopulmonary percutaneous support. Indications and methods. Part I] Ostrowska G. **Pol Merkuriusz Lek** 1998 Sep;5(27):167–72 (34 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Thrombus with infection in total artificial heart animals. Chiang BY, et al. **Artif Organs** 1992 Aug;16(4):371–6

Infections with the CardioWest total artificial heart. Arabia FA, et al. **ASAIO J** 1998 Sep–Oct;44(5):M336–9

Postoperative pulmonary complications in calves after implantation of an electric total artificial heart. Kuroda H, et al. **ASAIO J** 1998 Sep–Oct;44(5):M613–8

NHLBI/FDA conference on thrombosis and infections with cardiovascular devices. **J Biomed Mater Res** 1998 Dec 5; 42(3):341–6 (0 ref.)

ECONOMICS

Development of total artificial heart with economical and

durability advantages. Yambe T, et al. **Int J Artif Organs** 1998 May;21(5):279–84

HISTORY

Willem Kolff: innovator, scholar, and world citizen. Kantrowitz A. **Artif Organs** 1998 Nov;22(11):983–4

Lessons learned from the grandfather of artificial organs. Mussivand T. **Artif Organs** 1998 Nov;22(11):985–7

To honor Dr. Willem J. Kolff [editorial] Nojiri C, et al. **Artif Organs** 1998 Nov;22(11):923–7

My life with Dr. Willem Kolff. Nosé Y. **Artif Organs** 1998 Nov;22(11):969–79

Dr. Willem J. (Pim) Kolff: the legend, my mentor. Olsen DB. **Artif Organs** 1998 Nov;22(11):980–2

History of the Kolff Laboratory turbine driven electrohydraulic artificial heart. Topaz SR, et al. **Artif Organs** 1998 Nov;22(11):988–92

TRENDS

Mechanical circulatory support systems: past, present, and future. Cooley DA. **Ann Thorac Surg** 1999 Aug;68(2):641–2

HEART-ASSIST DEVICES

Combining nonpharmacologic therapies for advanced heart failure: the Münster experience with the assist device–defibrillator combination. Deng MC, et al. **Am J Cardiol** 1999 Mar 11;83(5B):158D–160D

Myocardial adenine nucleotides, glycogen, and Na, K-ATPase in patients with idiopathic dilated cardiomyopathy requiring mechanical circulatory support. Ishino K, et al. **Am J Cardiol** 1999 Feb 1;83(3):396–9

Clinical experience with the percutaneous hemopump during high-risk coronary angioplasty. Scholz KH, et al. **Am J Cardiol** 1998 Nov 1;82(9):1107–10, A6

Mutual information discloses relationship between hemodynamic variables in artificial heart-implanted dogs. Osaka M, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1419–33

Proceedings of the 4th International Conference on Circulatory Support Devices for Severe Cardiac Failure. Houston, Texas, USA. October 3–5, 1997. **Ann Thorac Surg** 1999 Aug;68(2):633–794

Bethesda Conference: conference for the design of clinical trials to study circulatory support devices for chronic heart failure. **Ann Thorac Surg** 1998 Oct;66(4):1452–65

Biventricular cannulation for the Thoratec ventricular assist device. Arabia FA, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2119–20

Extracorporeal right to left atrial bypass to treat right ventricular failure. Arpesella G, et al. **Ann Thorac Surg** 1999 Jan;67(1):246–8

Development of the Nimbus/University of Pittsburgh innovative ventricular assist system. Butler KC, et al. **Ann Thorac Surg** 1999 Aug;68(2):790–4

Centrifugal pumps: description of devices and surgical techniques. Curtis JJ, et al. **Ann Thorac Surg** 1999 Aug; 68(2):666–71

A miniature implantable axial flow ventricular assist device. DeBakey ME. **Ann Thorac Surg** 1999 Aug;68(2):637–40

Left ventricular assist device improves survival in children with left ventricular dysfunction after repair of anomalous origin of the left coronary artery from the pulmonary artery. del Nido PJ, et al. **Ann Thorac Surg** 1999 Jan; 67(1):169–72

Bridging from acute to chronic devices. Dembitsky WP. **Ann Thorac Surg** 1999 Aug;68(2):724–8

Alternative technique of right-sided outflow cannula insertion for right ventricular support. Dewey TM, et al. **Ann Thorac Surg** 1998 Nov;66(5):1829–30

Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients. Fastenau DR, et al. **Ann Thorac Surg** 1999 Jul;68(1):137–42

Left ventricular assist system as a bridge to myocardial recovery. Frazier OH, et al. **Ann Thorac Surg** 1999 Aug; 68(2):734–41

Facile left ventricular deairing by administration of cardioplegia into the left ventricular vent. Gundry SR. **Ann Thorac Surg** 1998 Dec;66(6):2117–8

Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Hetzer R, et al. **Ann Thorac Surg** 1999 Aug;68(2):742–9

Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. Hetzer R, et al. **Ann Thorac Surg** 1998 Nov;66(5):1498–506

Infection during circulatory support with ventricular assist devices. Holman WL, et al. **Ann Thorac Surg** 1999 Aug; 68(2):711–6

Management of wound and left ventricular assist device pocket infection. Holman WL, et al. **Ann Thorac Surg** 1999 Sep;68(3):1080–2

Pseudointima in inflow conduits of left ventricular assist devices. Houel R, et al. **Ann Thorac Surg** 1999 Aug; 68(2):717–23

Current strategy of temporary circulatory support for severe cardiac failure after operation. Kitamura M, et al. **Ann Thorac Surg** 1999 Aug;68(2):662–5

Temporary pulsatile ventricular assist devices and biventricular assist devices. Körfer R, et al. **Ann Thorac Surg** 1999 Aug;68(2):678–83

Removing the causes of pulmonary hypertension [letter; comment] Krohn BG. **Ann Thorac Surg** 1998 Nov; 66(5):1862–3. Comment on: Ann Thorac Surg 1998 Feb;65(2):340–5.

Heart booster: a pericardial support device. Kung RT, et al. **Ann Thorac Surg** 1999 Aug;68(2):764–7

Beating heart coronary surgery supported by an axial blood flow pump. Lönn U, et al. **Ann Thorac Surg** 1999 Jan; 67(1):99–104

Clinical experience with 111 thoratec ventricular assist devices. McBride LR, et al. **Ann Thorac Surg** 1999 May; 67(5):1233–8; discussion 1238–9

Treatment of infected left ventricular assist device using antibiotic-impregnated beads. McKellar SH, et al. **Ann Thorac Surg** 1999 Feb;67(2):554–5

Extracorporeal membrane oxygenation for adult cardiac support: the Allegheny experience. Magovern GJ Jr, et al. **Ann Thorac Surg** 1999 Aug;68(2):655–61

Bridge to transplantation: the Penn State experience. Mavroidis D, et al. **Ann Thorac Surg** 1999 Aug;68(2):684–7

New technique for the outflow cannulation of right ventricular assist device. Minami K, et al. **Ann Thorac Surg** 1999 Sep;68(3):1092–3

Evaluation of a compressive-type skeletal muscle pump for cardiac assistance. Mizuhara H, et al. **Ann Thorac Surg** 1999 Jan;67(1):105–11

Progress with the HeartSaver Ventricular Assist Device. Mussivand T, et al. **Ann Thorac Surg** 1999 Aug;68(2):785–9

Acute and temporary ventricular support with BioMedicus centrifugal pump. Noon GP, et al. **Ann Thorac Surg** 1999 Aug;68(2):650–4

Development of a totally implantable biventricular bypass centrifugal blood pump system. Nosé Y, et al. **Ann Thorac Surg** 1999 Aug;68(2):775–9

Right ventricular infarction during left ventricular assist system support [letter; comment] Park SJ. **Ann Thorac Surg** 1999 Jan;67(1):290. Comment on: Ann Thorac Surg 1998 Mar;65(3):839–41.

Simplified technique for implantation of a left ventricular assist system after previous cardiac operations. Pasic M, et al. **Ann Thorac Surg** 1999 Feb;67(2):562–4

Preventing, minimizing, and managing postoperative bleeding. Pavie A, et al. **Ann Thorac Surg** 1999 Aug; 68(2):705–10

Permanent ventricular assist device support versus cardiac transplantation. Pennington DG, et al. **Ann Thorac Surg** 1999 Aug;68(2):729–33

Bridge to transplant with the Novacor left ventricular assist system. Robbins RC, et al. **Ann Thorac Surg** 1999 Aug; 68(2):695–7

The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Rose EA, et al. **Ann Thorac Surg** 1999 Mar;67(3):723–30

The AB-180 circulatory support system: summary of development and plans for phase I clinical trial. Savage EB, et al. **Ann Thorac Surg** 1999 Aug;68(2):768–74

100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Sun BC, et al. **Ann Thorac Surg** 1999 Aug;68(2):688–94

Cardiopulmonary support and extracorporeal membrane oxygenation for cardiac assist. von Segesser LK. **Ann Thorac Surg** 1999 Aug;68(2):672–7 (35 ref.)

A ventricular assist device powered by conditioned skeletal muscle. Whalen RL, et al. **Ann Thorac Surg** 1999 Aug; 68(2):780–4

Centrifugal blood pump with a magnetically suspended impeller. Akamatsu T, et al. **Artif Organs** 1992 Jun; 16(3):305–8

Rotary blood pump flow spontaneously increases during exercise under constant pump speed: results of a chronic study. Akimoto T, et al. **Artif Organs** 1999 Aug; 23(8):797–801

Blood flow in a continuous flow ventricular assist device. Allaire PE, et al. **Artif Organs** 1999 Aug;23(8):769–73

Improvement of the hydrodynamic response of a ventricular assist device: a false auricle solution. Antoranz JC, et al. **Artif Organs** 1992 Jun;16(3):301–5

Characterization of a magnetic bearing system and fluid properties for a continuous flow ventricular assist device. Baloh MJ, et al. **Artif Organs** 1999 Aug;23(8):792–6

Mechanical circulatory assist by a roller pump system using hydrophilic heparinized polymer coated tubing. Eguchi S, et al. **Artif Organs** 1992 Jun;16(3):299–301

Chronic survival of calves implanted with the DeBakey ventricular assist device. Fossum TW, et al. **Artif Organs** 1999 Aug;23(8):802–6

Test controller design, implementation, and performance for a magnetic suspension continuous flow ventricular assist device. Hilton EF, et al. **Artif Organs** 1999 Aug; 23(8):785–91

Ultracompact, completely implantable permanent use electromechanical ventricular assist device and total artificial heart. Honda N, et al. **Artif Organs** 1999 Mar; 23(3):253–61

Hemodynamic evaluation of a new left ventricular assist device: an integrated cardioassist catheter as a pulsatile left ventricle–femoral artery bypass. Ide H, et al. **Artif Organs** 1992 Jun;16(3):286–90

Belt worn control system and battery for the percutaneous model of the Jarvik 2000 heart. Jarvik R, et al. **Artif Organs** 1999 Jun;23(6):487–9

Pulsate regimes of the centrifugal pump operation for assisted circulation. Khaoustov AI, et al. **Artif Organs** 1999 Feb; 23(2):214–6

Evaluation of an implantable motor-driven left ventricular assist device. Kikugawa D, et al. **Artif Organs** 1999 Mar; 23(3):249–52

Clinical experience of left ventricular assist systems at the Heart Institute of Japan. Kitamura M, et al. **Artif Organs** 1999 Mar;23(3):286–9

Total vascular resistance and blood flow frequency during left ventricular assistance using a vibrating flow pump. Kobayashi S, et al. **Artif Organs** 1999 Aug;23(8):732–5

Estimation of the minimum pump speed to prevent regurgitation in the continuous flow left ventricular assist device: left ventricular drainage versus left atrial drainage [letter; comment] Konishi H. **Artif Organs** 1998 Dec; 22(12):1071–2. Comment on: Artif Organs 1997 Dec;21(12):1288–91.

Shaft/shaft-seal interface characteristics of a multiple disk centrifugal blood pump. Manning KB, et al. **Artif Organs** 1999 Jun;23(6):552–8

Development of design methods for a centrifugal blood pump with a fluid dynamic approach: results in hemolysis tests. Masuzawa T, et al. **Artif Organs** 1999 Aug;23(8):757–61

Analysis of optimal design configurations for a multiple disk centrifugal blood pump. Miller GE, et al. **Artif Organs** 1999 Jun;23(6):559–65

Techniques for optimization of pulsatile ventricular assist device support. Mills TC, et al. **Artif Organs** 1992 Apr; 16(2):218–21

Development of the Valvo pump: an axial flow pump implanted at the heart valve position. Mitamura Y, et al. **Artif Organs** 1999 Jun;23(6):566–71

Computational fluid dynamics analysis to establish the design process of a centrifugal blood pump: second report. Miyazoe Y, et al. **Artif Organs** 1999 Aug;23(8):762–8

Critical anatomic dimensions for intrathoracic circulatory assist devices. Mussivand T, et al. **Artif Organs** 1992 Jun; 16(3):281–5

New sequential synchronized driving system of intraaortic balloon pumping and left ventricular assist device: influence on endocardial viability ratio and renal blood flow in their combination. Nagasaka F, et al. **Artif Organs** 1992 Apr; 16(2):216–8

Computational simulation of flows in an entire centrifugal heart pump. Nakamura S, et al. **Artif Organs** 1999 Jun; 23(6):572–5

A new control method that estimates the backflow in a centrifugal pump. Nakata K, et al. **Artif Organs** 1999 Jun; 23(6):538–41

Flow visualization study to improve hemocompatibility of a centrifugal blood pump. Nishida M, et al. **Artif Organs** 1999 Aug;23(8):697–703

Chaotic dynamics in circulation with Tohoku University vibrating flow pump. Nitta S, et al. **Artif Organs** 1999 Jan; 23(1):119–23

Small soft left ventricular assist device powered by intraaortic balloon pump console for infants: a less expensive option. Nojiri C, et al. **Artif Organs** 1992 Aug;16(4):382–5

Blood contacting surface of titanium: is it the metal or the water? [editorial] Nosé Y. **Artif Organs** 1998 Dec; 22(12):1003–4

An emergency balloon occlusion system for a rotary blood pump left ventricular assist system. Ohtsuka G, et al. **Artif Organs** 1999 Aug;23(8):704–7

Long-term in vivo left ventricular assist device study for 284 days with Gyro PI pump. Ohtsuka G, et al. **Artif Organs** 1999 Jun;23(6):504–7

Rotary blood pumps: a new horizon [editorial] Olsen DB. **Artif Organs** 1999 Aug;23(8):695–6

Is cardiac function a sufficient criterion to wean a patient from circulatory support? [editorial] Orime Y, et al. **Artif Organs** 1992 Aug;16(4):329–30

Ex vivo evaluation of a roller screw linear muscle actuator for an implantable ventricular assist device using trained and untrained latissimus dorsi muscles. Sasaki Y, et al. **Artif Organs** 1999 Mar;23(3):262–7

Noninvasive monitoring of rotary blood pumps: necessity, possibilities, and limitations. Schima H, et al. **Artif Organs** 1992 Apr;16(2):195–202

Major organ function under mechanical support: comparative studies of pulsatile and nonpulsatile circulation. Sezai A, et al. **Artif Organs** 1999 Mar;23(3):280–5

Wearable air supply for pneumatic artificial hearts and ventricular assist devices. Sipin AJ, et al. **Artif Organs** 1992 Aug;16(4):431–8

Development of an ultracompact integrated heart-lung assist device. Tatsumi E, et al. **Artif Organs** 1999 Jun; 23(6):518–23

Sealing properties of mechanical seals for an axial flow blood pump. Tomioka J, et al. **Artif Organs** 1999 Aug; 23(8):708–11

A continuous and pulsatile flow circulation system for evaluation of cardiovascular devices. Vermette P, et al. **Artif Organs** 1998 Sep;22(9):746–52

A sealless centrifugal blood pump with passive magnetic and hydrodynamic bearings. Wampler R, et al. **Artif Organs** 1999 Aug;23(8):780–4

Motor feedback physiological control for a continuous flow ventricular assist device. Waters T, et al. **Artif Organs** 1999 Jun;23(6):480–6

The valvo-pump, an axial blood pump implanted at the heart valve position: concept and initial results. Yamazaki K, et

al. **Artif Organs** 1992 Jun;16(3):297-9
Peripheral vascular resistances during total left heart bypass with an oscillated blood flow. Yambe T, et al. **Artif Organs** 1999 Aug;23(8):747-50
Feasibility of a tiny Gyro centrifugal pump as an implantable ventricular assist device. Yoshikawa M, et al. **Artif Organs** 1999 Aug;23(8):774-9
Detection of suction and regurgitation of the implantable centrifugal pump based on the motor current waveform analysis and its application to optimization of pump flow. Yuhki A, et al. **Artif Organs** 1999 Jun;23(6):532-7
Echocardiographic evaluation of patients with a left ventricular device. Akosah KO, et al. **ASAIO J** 1998 Sep-Oct;44(5):M624-7
Implantable centrifugal pump with hybrid magnetic bearings. Bearnson GB, et al. **ASAIO J** 1998 Sep-Oct;44(5):M733-6
A computational and experimental comparison of two outlet stators for the Nimbus LVAD. Left ventricular assist device. Burgreen GW, et al. **ASAIO J** 1999 Jul-Aug; 45(4):328-33
High efficiency magnetic bearing for a rotary blood pump. Chen HM, et al. **ASAIO J** 1998 Sep-Oct;44(5):M728-32
Protection of platelet glycoprotein IIb/IIIa receptor complex preserves platelet function during in vitro ventricular assisted circulation. Chen JC, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M682-4
Left ventricular support with the implantable AB-180 centrifugal pump in sheep with acute myocardial infarction. Clark RE, et al. **ASAIO J** 1998 Nov-Dec;44(6):804-11
Time course of cytokine release and complement activation after implantation of the HeartMate left ventricular assist device. Corry DC, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M347-51
Neurohormonal changes after implantation of a left ventricular assist system. Delgado R 3rd, et al. **ASAIO J** 1998 Jul-Aug;44(4):299-302
Quality of life outcomes in left ventricular assist system inpatients and outpatients. Dew MA, et al. **ASAIO J** 1999 May-Jun;45(3):218-25
AB-180 circulatory support system: summary of development and phase I clinical trial. Griffin WP, et al. **ASAIO J** 1998 Sep-Oct;44(5):M719-24
In vivo evaluation of an intrathoracic ventricular assist device. Hendry P, et al. **ASAIO J** 1999 May-Jun; 45(3):123-6
Chronic animal health assessment during axial ventricular assistance: importance of hemorheologic parameters. Kameneva MV, et al. **ASAIO J** 1999 May-Jun;45(3):183-8
In vivo experiment leading to clinical application of an electrohydraulic ventricular assist device with magnetic coupling. Kim WG, et al. **ASAIO J** 1999 May-Jun; 45(3):215-7
Monitoring of cardiac function in patients with a left ventricle assist device. Kislukhin V, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M712-3
Vascular determinants of univentricular support. Kresh JY, et al. **ASAIO J** 1998 Sep-Oct;44(5):M330-5
Complement activation in patients undergoing mechanical circulatory support. Loebe M, et al. **ASAIO J** 1998 Sep-Oct;44(5):M340-6
Stable blood lubricated hydrodynamic journal bearing with magnetic loading. Malanoski SB, et al. **ASAIO J** 1998 Sep-Oct;44(5):M737-40
Durability testing of components for the Jarvik 2000 completely implantable axial flow left ventricular assist device. Marlinski E, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M741-4
Split-circulation assist device facilitates heart failure management and increases effects of intra-aortic balloon pumping. Miyawaki F, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M628-33
Fluid dynamic optimization of a ventricular assist device using particle image velocimetry. Mussivand T, et al. **ASAIO J** 1999 Jan-Feb;45(1):25-31
Numeric flow simulation for an innovative ventricular assist system secondary impeller. Nakamura S, et al. **ASAIO J** 1999 Jan-Feb;45(1):74-8
Recovery of cardiac function by long-term left ventricular support in patients with end-stage cardiomyopathy. Nakatani T, et al. **ASAIO J** 1998 Sep-Oct;44(5):M516-20
Results of chronic animal experiments with a new version of a magnetically suspended centrifugal pump. Nishimura K, et al. **ASAIO J** 1998 Sep-Oct;44(5):M725-7
Recent progress in the development of Terumo implantable left ventricular assist system. Nojiri C, et al. **ASAIO J** 1999 May-Jun;45(3):199-203
Long-term in vivo left ventricular assist device study with a titanium centrifugal pump. Ohtsuka G, et al. **ASAIO J** 1998 Sep-Oct;44(5):M619-23
A remote monitoring system for patients with implantable ventricular assist devices with a personal handy phone system. Okamoto E, et al. **ASAIO J** 1999 May-Jun; 45(3):194-8
Passive characteristics of conditioned skeletal muscle for ventricular assistance. Reichenbach SH, et al. **ASAIO J** 1999 Jul-Aug;45(4):344-9
Chronic implantation of a skeletal muscle energy convertor for cardiac assist devices: a preliminary report. Reichenbach SH, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M745-9
Initial tests with a new cardiac assist device. Reitan O, et al. **ASAIO J** 1999 Jul-Aug;45(4):317-21
Platelet glycoprotein IIb/IIIa inhibitor attenuates complement activation during in vitro ventricular assist circulation. Serna DL, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M352-5
Progress on development of the Nimbus-University of Pittsburgh axial flow left ventricular assist system. Thomas DC, et al. **ASAIO J** 1998 Sep-Oct;44(5):M521-4
A genetically engineered, nonthrombogenic cellular lining for LVADs: in vitro preconditioning before in vivo implantation. Tock CL, et al. **ASAIO J** 1999 May-Jun; 45(3):172-7
Muscle powered blood pump: design and initial test results. Trumble DR, et al. **ASAIO J** 1999 May-Jun;45(3):178-82
Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment. Tsau PH, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M634-7
Numeric modeling of the cardiovascular system with a left ventricular assist device. Zhou J, et al. **ASAIO J** 1999 Jan-Feb;45(1):83-9
Implantable cardiac assist devices. Zickler P. **Biomed Instrum Technol** 1998 Jul-Aug;32(4):420-3
Left ventricular assist devices and the failing heart: a bridge to recovery, a permanent assist device, or a bridge too far? [editorial; comment] Mann DL, et al. **Circulation** 1998 Dec 1;98(22):2367-9. Comment on: Circulation 1998 Dec 1;98(22):2383-89.
Clenbuterol increases stroke power and contractile speed of skeletal muscle for cardiac assist. Petrou M, et al. **Circulation** 1999 Feb 9;99(5):713-20
Nonthrombogenic, adhesive cellular lining for left ventricular assist devices. Scott-Burden T, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II339-45
Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. Torre-Amione G, et al. **Circulation** 1999 Sep 14; 100(11):1189-93
Copulsation balloon for right ventricular assistance: preliminary trials. Trumble DR, et al. **Circulation** 1999 Jun 1;99(21):2815-8
Jarvik 2000 heart: potential for bridge to myocyte recovery. Westaby S, et al. **Circulation** 1998 Oct 13;98(15):1568-74
Postpartum coronary artery dissection: emergency coronary artery bypass with ventricular assist device support. Samuels LE, et al. **Coron Artery Dis** 1998;9(7):457-60
Ventricular assistance for recovery of cardiac failure. Loebe M, et al. **Curr Opin Cardiol** 1999 May;14(3):234-48 (57 ref.)
The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi-centre study. El-Banayosy A, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):835-41
Left ventricular assist device as a bridge to partial left ventriculectomy. Frazier OH. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S20-5; discussion S39-43 (13 ref.)
The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Noirhomme P, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):63-7
Children may survive severe myocarditis with prolonged use of biventricular assist devices. Stiller B, et al. **Heart** 1999 Aug;82(2):237-40
Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary bypass. Babin-Ebell J, et al. **Heart Vessels** 1998;13(3):147-51
Role of PTCA and mechanical devices in cardiogenic shock. Shawl FA. **Indian Heart J** 1998 Oct;50 Suppl 1:57-61 (50 ref.)
Novacor left ventricular assist device: present experience [editorial] de Vivo F, et al. **Int J Artif Organs** 1999 Jan; 22(1):11-3
Hemodynamic properties of the hemopump HP14. Lachat M, et al. **Int J Artif Organs** 1999 Mar;22(3):155-9
Long-distance transportation of patients with a paracorporeal left ventricular assist device. Mestres CA, et al. **Int J Artif Organs** 1998 Jul;21(7):425-8
Prolonged nonpulsatile left heart bypass diminishes vascular contractility. Nishimura T, et al. **Int J Artif Organs** 1999 Jul;22(7):492-8
The enabler cannula pump: a novel circulatory support system. Nishimura Y, et al. **Int J Artif Organs** 1999 May; 22(5):317-23
Development and initial in vivo testing of a new hydraulic drive system (Paedipump) for circulatory support in infants. Reiss N, et al. **Int J Artif Organs** 1998 Jul;21(7):417-24
Bioelectrical impedance analysis before and after Novacor implantation. Stellato D, et al. **Int J Artif Organs** 1999 Mar; 22(3):151-4
Mechanical circulatory support after orthotopic heart transplantation. Tenderich G, et al. **Int J Artif Organs** 1998 Jul;21(7):414-6
The use of an implantable left ventricular assist device in a patient with cardiogenic shock following acute myocardial infarction. Chua TP, et al. **Int J Cardiol** 1998 Sep 1;66(1):55-8
Reports from the University HealthSystem Consortium. **Int J Technol Assess Health Care** 1999 Winter;15(1):267-74
Improved survival rates support left ventricular assist device implantation early after myocardial infarction. Chen JM, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1903-8
Totally implantable artificial hearts and left ventricular assist devices: selecting impermeable polycarbonate urethane to manufacture ventricles. Yang M, et al. **J Biomed Mater Res** 1999 Spring;48(1):13-23
Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. MacGowan GA, et al. **J Card Fail** 1998 Sep;4(3):169-75
Left ventricular apical cannulation for circulatory support. Jett GK. **J Card Surg** 1998 Jan;13(1):51-5
Anesthetic management of patients undergoing coronary artery bypass grafting with the use of an axial flow pump and a short-acting beta-blocker. Peterzén B, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):431-6
Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. Chen JM, et al. **J Heart Lung Transplant** 1999 Apr;18(4):351-7
Selection and outcome of ventricular assist device patients: the Muenster experience. Deng MC, et al. **J Heart Lung Transplant** 1998 Aug;17(8):817-25
The use of APACHE II scores to select candidates for left ventricular assist device placement. Acute Physiology and Chronic Health Evaluation. Gracin N, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1017-23
Vitamin K reduces bleeding in left ventricular assist device recipients. Kaplon RJ, et al. **J Heart Lung Transplant** 1999 Apr;18(4):346-50
Development of a ventricular assist device for out-of-hospital use. Mussivand T, et al. **J Heart Lung Transplant** 1999 Feb;18(2):166-71
Emergency versus elective/urgent left ventricular assist device implantation. Schmid C, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1024-8
Pediatric circulatory support. Sidiropoulos A, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1172-6
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. Stringham JC, et al. **J Heart Lung Transplant** 1999 Feb; 18(2):160-5
In vitro studies of gas bubble formation by mechanical heart valves. Biancucci BA, et al. **J Heart Valve Dis** 1999 Mar; 8(2):186-96
Treatment of severe cardiac contusion with a left ventricular assist device in a patient with multiple trauma. Chavanon O, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):189-90
Mechanical circulatory support for one thousand days or more with the Novacor N100 left ventricular assist device. Dohmen PM, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):1029-30
Mechanical circulatory support in children with cardiac disease. Duncan BW, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):529-42
Effects of postischemic left ventricular pressure-volume unloading on contractile recovery and myocardial blood flow in the regionally stunned canine heart. Nicolosi AC, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):181-8
Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. Spanier TB, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):404-13
Power output of pericardium-lined skeletal muscle ventricles, left ventricular apex to aorta configuration: up to eight months in circulation. Thomas GA, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1029-42
Bridge to recovery with the Abiomed BVS-5000 device in a patient with intractable ventricular tachycardia. Thomas NJ, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):831-2
Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Kawada T, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Mar;47(3):104-9
Investigation of unsteady flow in a model of a ventricular assist device by numerical modelling and comparison with experiment. König CS, et al. **Med Eng Phys** 1999 Jan; 21(1):53-64
The heartmate left ventricular assist system: first successful implantation in Missouri. Wilson WR, et al. **Mo Med** 1999 Jan;96(1):14-7
Implantable left ventricular assist devices. Goldstein DJ, et al. **N Engl J Med** 1998 Nov 19;339(21):1522-33 (88 ref.)
Successful treatment of postoperative right ventricular heart failure with the HIA-Medos-assist system in a 2-year-old girl. Busch U, et al. **Pediatr Cardiol** 1999 Mar-Apr; 20(2):161-3
Coronary artery bypass graft with biventricular microaxial pumps. Meyns B, et al. **Perfusion** 1999 Jul;14(4):287-90
Salvage of externally exposed ventricular assist devices. Turowski GA, et al. **Plast Reconstr Surg** 1998 Dec; 102(7):2425-30
Impact of new UNOS guidelines on donor heart allocation to circulatory assist device patients. Shinn JA. **Prog Cardiovasc Nurs** 1999 Winter;14(1):37-8
Cardiac assist devices. Pennington DG, et al. **Surg Clin North Am** 1998 Oct;78(5):691-704, vii
The HeartMate left ventricular assist system. Overview and 12-year experience. Frazier OH, et al. **Tex Heart Inst J** 1998;25(4):265-71
Bridging to cardiac transplantation with the Thoratec Ventricular Assist Device. El-Banayosy A, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:307-10
Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy--first results of the Halle Assist Induced

Recovery Study (HAIR). Milting H, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):48–50

Mechanical circulatory support with the Novacor LVAS: world-wide clinical results. Murali S. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:321–5

Worldwide experience with the TCI HeartMate system: issues and future perspective. Poirier VL. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:316–20

The MEDOS/HIA system: development, results, perspectives. Reul H. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:311–5

Effect of platelet inhibitors on thromboembolism after implantation of a Novacor N100--preliminary results. Schmid C, et al. **Thorac Cardiovasc Surg** 1998 Oct; 46(5):260–2

Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin. Fastenau DR, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):141–2

Our experience with mechanical circulatory support for end-stage heart failure. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):1994–6

Application of ventricular assist systems for end-stage cardiomyopathy patients as a bridge to heart transplant or recovery. Nakatani T, et al. **Transplant Proc** 1999 Aug; 31(5):2000–1

Left ventricular assist systems as a bridge to heart transplantation: the role and the strategy in Japan. Nishimura M, et al. **Transplant Proc** 1999 Aug;31(5):1997–9

Bridging to cardiac transplantation: a clinical laboratory for the development of mechanical alternatives to transplantation. Rose EA, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):120–2 (16 ref.)

Ventricular assist as a bridge to heart transplantation. Wang SS, et al. **Transplant Proc** 1998 Nov;30(7):3401–2

Cytokine induction owing to LVAD support in canine models. Yamagishi T, et al. **Transplant Proc** 1999 Aug; 31(5):1992–3

[Calculation of the flow through a new single cusp valve for heart assist systems] Goubergrits L, et al. **Biomed Tech (Berl)** 1998;43 Suppl:288–9 **(Ger)**

[A new heart valve for heart assist systems] Lambertz M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:514–5 **(Ger)**

[Ischemic cardiomyopathy--transplantation and bridging with mechanical assist systems] Feindt P, et al. **Z Kardiol** 1998;87 Suppl 2:181–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Renal, intestinal and whole body metabolic changes in pig LVAD model] Miyama M. **Hokkaido Igaku Zasshi** 1999 Jul;74(4):331–7 (Eng. Abstr.) **(Jpn)**

[Comparative study of artificial circulation for the liver after cardiogenic shock: pulsatile or nonpulsatile?] Kohjima T. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1117–25 (Eng. Abstr.) **(Jpn)**

[Microcirculation of kidney and skin during left ventricular assisted circulation--comparative studies of pulsatile and nonpulsatile assists] Sezai A, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1239–46 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Inherited thrombophilic syndromes and the use of ventricular assist devices. Carboni AF. **Am J Crit Care** 1999 Mar; 8(2):127–9

Mechanical circulatory support as a bridge to cardiac transplantation: toward the 21st century. Scherr K, et al. **Am J Crit Care** 1999 Sep;8(5):324–37; quiz 338–9 (150 ref.)

Murphy's law in cardiac surgery. Fischer C, et al. **Ann Thorac Surg** 1998 Nov;66(5):1795–7

Ventricular thrombus and subarachnoid bleeding during support with ventricular assist devices. Gruber EM, et al. **Ann Thorac Surg** 1999 Jun;67(6):1778–80

Cerebral embolism associated with left ventricular assist device support and successful therapy with intraarterial urokinase. Kasirajan V, et al. **Ann Thorac Surg** 1999 Apr; 67(4):1148–50

ABIOMED BVS 5000 system: repair of venous cannulation site for excessive bleeding. Krause TJ. **Ann Thorac Surg** 1998 Nov;66(5):1817

Late tamponade with mechanical circulatory support. Smart K, et al. **Ann Thorac Surg** 1998 Dec;66(6):2027–8

Hematological problems during the use of cardiac assist devices: clinical experiences in Japan. Tanaka K, et al. **Artif Organs** 1992 Apr;16(2):182–8

Induction of ventricular collapse by an axial flow blood pump. Amin DV, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M685–90

Concerning thromboembolism associated with left ventricular assist devices. Gross DR. **Cardiovasc Res** 1999 Apr;42(1):45–7 (30 ref.)

Atrophy of myocardium and its myocytes by left ventricular assist device [letter] Soloff LA. **Circulation** 1999 Aug 31; 100(9):1012

In vitro thrombogenicity testing of artificial organs. Paul R, et al. **Int J Artif Organs** 1998 Sep;21(9):548–52

Detection of left atrial thrombus by transesophageal echocardiography after left ventricular assist device decannulation. Lanquetot H, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):435–6

Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. Moazami N, et al. **J Heart Lung Transplant** 1998 Sep;17(9):876–80

Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Ankersmit HJ, et al. **Lancet** 1999 Aug 14;354(9178):550–5

Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:326–31

Successful treatment of a Novacor LVAD malfunction without repeat sternotomy. Hammel D, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):154–6

ECONOMICS

The logistics and cost-effectiveness of circulatory support: advantages of the ABIOMED BVS 5000. Couper GS, et al. **Ann Thorac Surg** 1999 Aug;68(2):646–9

Ventricular assist device programs: design and function. Van Meter CH Jr, et al. **Ann Thorac Surg** 1999 Aug;68(2):643–5

Cost effectiveness of artificial organ therapies. Mussivand T, et al. **ASAIO J** 1998 Jul-Aug;44(4):253–8

HISTORY

Michael DeBakey: taking challenges to heart [news] Larkin M. **Lancet** 1999 Apr 24;353(9162):1420

PSYCHOLOGY

Life with a left ventricular assist device: the patient's perspective. Savage LS, et al. **Am J Crit Care** 1999 Sep; 8(5):340–3

Cardiac ventricular support. Considerations for psychiatry. Petrucci R, et al. **Psychosomatics** 1999 Jul-Aug; 40(4):298–303

STANDARDS

Long-term mechanical circulatory support system reliability recommendation: American Society for Artificial Internal Organs and The Society of Thoracic Surgeons: long-term mechanical circulatory support system reliability recommendation. Pantalos GM, et al. **Ann Thorac Surg** 1998 Nov;66(5):1852–9

Evaluation of platelet adhesion and activation on materials for an implantable centrifugal blood pump. Takami Y, et al. **Artif Organs** 1998 Sep;22(9):753–8

Performance analysis of a cardiac assist device in counterpulsation. Chesler NC, et al. **J Biomech Eng** 1998 Aug;120(4):437–45

Optimized performance of the Abiomed BVS 5000: adjustment of the pump height based on Doppler control of the flow pattern. Lachat M, et al. **Perfusion** 1999 Jan; 14(1):59–67

TRENDS

Mechanical circulatory support as a bridge to cardiac transplantation: toward the 21st century. Scherr K, et al. **Am J Crit Care** 1999 Sep;8(5):324–37; quiz 338–9 (150 ref.)

Mechanical circulatory support systems: past, present, and future. Cooley DA. **Ann Thorac Surg** 1999 Aug;68(2):641–2

The Hemopump in 1997: a clinical, political, and marketing evolution. Sweeney MS. **Ann Thorac Surg** 1999 Aug; 68(2):761–3

Monitoring system for the totally implantable ventricular assist system by use of sensors for virtual reality. Yambe T, et al. **Int J Artif Organs** 1998 Jun;21(6):348–52

UTILIZATION

Evolving short-term and long-term mechanical assist for cardiac-failure -- a decade of experience in Münster. Tjan TD, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:294–7

HEART ATRIUM

see related

ATRIAL FUNCTION

Atrial septal aneurysm in a patient with pseudoxanthoma elasticum. Bertulezzi G, et al. **Acta Cardiol** 1998;53(4):223–5

Right auricular fibroelastoma and paradoxical embolic stroke. Vandergoten P, et al. **Acta Cardiol** 1999 Feb;54(1):49–50

Pancreatic metastasis of cardiac rhabdomyosarcoma diagnosed by fine needle aspiration. A case report. Khalbuss WE, et al. **Acta Cytol** 1999 May-Jun;43(3):447–51

Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Igarashi Y, et al. **Am Heart J** 1998 Dec;136(6):965–71

Echocardiographic and morphologic characteristics of left atrial myxoma and their relation to systemic embolism. Ha JW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1579–82, A8

Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Ozkan M, et al. **Am J Cardiol** 1998 Nov 1;82(9):1066–70

Endobronchial brachytherapy for recurrent thymoma showing endobronchial polypoid growth. Matsuguma H, et al. **Am J Clin Oncol** 1999 Feb;22(1):84–6

Primary cardiac angiosarcoma with right coronary artery-to-pericardial fistula--a case report. Reising C, et al. **Angiology** 1999 Sep;50(9):777–80

Implantation of a mechanical valve within the orifice of a mitral bioprosthesis in a case with severely calcified left atrium--a case report. Sakakibara Y, et al. **Angiology** 1998 Oct;49(10):857–60

Coronary artery fistula and atrial septal defect: a case report and brief review of the literature. Hijazi A, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):286–7 (11 ref.)

Inverted left atrial appendage presenting as a left atrial mass after cardiac surgery. Cohen AJ, et al. **Ann Thorac Surg** 1999 May;67(5):1489–91

Inverted left atrial appendage: an unusual complication in cardiac surgery. Fujiwara K, et al. **Ann Thorac Surg** 1999 May;67(5):1492–3; discussion 1493–4

Mitochondrial DNA deletions in human cardiac tissue show a gross mosaic distribution. Zhang C, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):152–7

Percutaneous retrieval of a central venous catheter sutured to the wall of the right atrium. Neuerburg JM, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):79–80

Fatal outcome in atrial migration of the Tempofilter. Rossi P, et al. **Cardiovasc Intervent Radiol** 1999 May-Jun; 22(3):227–31

Complete left atrial obliteration due to localized tamponade after coronary artery perforation during PTCA. Dardas PS, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):61–3

Non-surgical retrieval of a bullet embolus from the right heart. Kaushik VS, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):55–7

Extreme left atrial enlargement causing upward displacement and compression of the right pulmonary artery [letter] Mandalay A, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):115–6

Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Corrado G, et al. **Chest** 1999 Jan;115(1):140–3

An unusual cardiomegaly: the giant left atrium. Bertoli D, et al. **Clin Cardiol** 1998 Dec;21(12):918

Thrombolysis of mobile right atrial thrombi following severe pulmonary embolism. Cracowski JL, et al. **Clin Cardiol** 1999 Feb;22(2):151–4

Routine left atrial catheterization for the post-operative management of cardiac surgical patients: is the risk justified? Santini F, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):218–21

Formation of a left atrial ball thrombus from a large mural thrombus 4 days after an embolic episode. Iga K, et al. **Int J Cardiol** 1999 Jul 1;70(1):83–6

Atrial septal aneurysm. Is it a benign finding? Valenzuela LF, et al. **Int J Cardiol** 1999 Apr 30;69(1):101–3

Interaction between atrial pacing lead and epicardial ventricular wire resulting in unintended ventricular capture by pacemaker atrial output. Chen PS. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):1031

Intraoperative management for removal of tumor thrombus in the inferior vena cava or the right atrium with multiplane transesophageal echocardiography. Koide Y, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):641–7

Mural left atrial thrombus: a hidden danger accompanying cardiac surgery. Leslie D, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):649–50 (6 ref.)

Coronary sinus pacing initiates counterclockwise atrial flutter while pacing from the low lateral right atrium initiates clockwise atrial flutter. Analysis of episodes of direct initiation of atrial flutter. Suzuki F, et al. **J Electrocardiol** 1998 Oct;31(4):345–61

Improved definition of left atrial thrombus by tissue harmonic imaging. Ono M, et al. **J Ultrasound Med** 1999 Mar; 18(3):253–5

Renal angiomyolipoma associated with inferior vena caval and right atrial thrombus. Ito H, et al. **J Urol** 1999 Oct; 162(4):1371–2

Atrial epicardial pacing with long stimulus to P wave interval in a patient with arrhythmogenic right ventricular dysplasia complicated by right atrial thrombosis. Kazmierczak J, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1111–3

Percutaneous extraction of an abandoned coiled pacing lead. Lickfett L, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1100–2

Effects of left atrial dilatation on the endocardial atrial defibrillation threshold: a study in an ovine model of pacing induced dilated cardiomyopathy. Power JM, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1595–600

Massive biatrial myxomas in a child. Cilliers AM, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):150–1

Doppler echocardiography with extended transesophageal atrial pacing: predicting the efficacy of permanent atrial pacing in the patient with a small left ventricle and sinus node dysfunction. Liske MR, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):218–20

Treatment of congenital aneurysms of the left atrium and left atrial appendage. Zhao J, et al. **Tex Heart Inst J** 1999; 26(2):136–9

Combined surgical approach for sarcoma lung metastasis with atrial involvement. Torre W, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):125–7

[Atrial myxoma: cutaneous manifestations] Le Cam MT, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):32–4 (Eng. Abstr.) **(Fre)**

[Right-left intra-atrial shunt in the absence of elevated pressures in the right cardiac cavities] Chaouat A, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3: S205 **(Fre)**

[Extensive cavernous capillary hemangioma of the right atrium in a newborn infant] Bosk A, et al.

Z Geburtshilfe Neonatol 1999 May-Jun;203(3):120-2 (Eng. Abstr.) **(Ger)**

[Comment on the contribution: A. Hagendorff et al., Löffler fibroplastic endocarditis in the thrombotic stage in isolated right ventricular tissue eosinophilia (letter; comment)] Schwab J, et al. **Z Kardiol** 1998 Aug;87(8):644. Comment on: Z Kardiol 1998 Apr;87(4):293-9. **(Ger)**

[The role of the interatrial septum in development of supraventricular tachyarrhythmias of vagal origin in dogs] Sharifov OF, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Jul;84(7):561-88 (Eng. Abstr.) **(Rus)**

[Recurrent cerebral embolism as the main sign of atrial myxoma] Dominguez-Morán JA, et al. **Neurologia** 1999 Feb;14(2):90-3 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Isomerism of the atrial appendages [letter; comment] Anderson RH. **Am J Cardiol** 1999 Mar 1;83(5):818-9. Comment on: Am J Cardiol 1998 Nov 1;82(9):1147-9, A10.

Drainage of the inferior vena cava to the left atrium. Genoni M, et al. **Ann Thorac Surg** 1999 Feb;67(2):543-5

An unusual tethering of the bridging leaflets in atrioventricular septal defect producing a communication from left atrium to right ventricle. Delgado C, et al. **Cardiol Young** 1999 Jan;9(1):84-7

Isolated connection of the right superior caval vein to the left atrium: non-invasive neonatal diagnosis. Kakadekar AP, et al. **Cardiol Young** 1999 May;9(3):310-4

Atrial isomerism: a surgical experience. Sinzobahamvya N, et al. **Cardiovasc Surg** 1999 Jun;7(4):436-42

Transcatheter closure of an anomalous venous connection by a novel method. Maheshwari S, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):269-71

Coronary arteriovenous aneurysmatic fistula draining into the right atrium. Zuppiroli A, et al. **Circulation** 1998 Nov 3; 98(18):1946-8

The nature of the superior sinus venosus defect. Li J, et al. **Clin Anat** 1998;11(5):349-52

Aortic valve stenosis causing a left-to-right shunt in persistent left superior vena cava communicating with the left atrium. Wang SY, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):326-8

Anomalous drainage of right superior vena cava into the left atrium. Kothari SS, et al. **Indian Heart J** 1998 May-Jun; 50(3):332-4

Subdivided left atrium mimicking a cardiac tumor. Shimaya K, et al. **Int J Cardiol** 1999 Feb 28;68(2):235-8

An autopsy case of familial idiopathic dilatation of bilateral atria. Arao M, et al. **Intern Med** 1999 Aug;38(8):663-7

Bifid left atrial appendage with thrombus: source of thromboembolism. Herzog E, et al. **J Am Soc Echocardiogr** 1998 Sep;11(9):910-5

Chiari network: an interesting transesophageal echocardiographic finding [letter; comment] Mittal S, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):243. Comment on: J Cardiothorac Vasc Anesth 1998 Feb;12(1):96-101.

Mitral valve replacement through a giant left atrial appendage. Rikitake K, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):127-9

Repair of subdivided left atrium associated with a persistent left superior vena cava (van Son and Hambsch; J Thorac Cardiovasc Surg 1998;116:535) [letter; comment] Kreutzer C. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):880. Comment on: J Thorac Cardiovasc Surg 1998 Sep;116(3):535.

Tetralogy of Fallot with levoatrial cardinal vein. Fujiwara K, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):136-8

Combination of rare systemic venous anomalies in a child with ventricular septal defect [letter] Saxena A. **Pediatr Cardiol** 1999 Mar-Apr;20(2):170-1

Anomalous insertion of the superior or the inferior vena cava into the right atrium. Takeda K, et al. **Pediatr Cardiol** 1998 Nov-Dec;19(6):474-6

Congenital aneurysmal dilatation of the right atrium and co-existent anomalous origin of the right pulmonary artery in a neonatal pig (Sus scrofa). Gerlis LM, et al. **Vet Rec** 1999 Mar 27;144(13):350-1

[A case of coronary arterial fistula originating from both coronary artery and draining to the right atrium] Obana M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec; 46(12):1349-53 (Eng. Abstr.) **(Jpn)**

[Severe hypoxia due to persistent left supra vena cava draining to the left atrium after weaning from cardiopulmonary bypass in a patient with endocardial cushion defect] Yamada K, et al. **Masui** 1999 Apr; 48(4):410-2 (Eng. Abstr.) **(Jpn)**

[Absence of right atrioventricular connection. Morphological and clinical presentation when the dominant ventricle is morphologically right] Cavalini JF, et al. **Arq Bras Cardiol** 1998 Dec;71(6):793-6 (Eng. Abstr.) **(Por)**

ANATOMY & HISTOLOGY

Ventricular morphology and coronary arterial anatomy in hearts with isometric atrial appendages. Uemura H, et al. **Ann Thorac Surg** 1999 May;67(5):1403-11

Angiographic anatomy of the inferior right atrial isthmus in patients with and without history of common atrial flutter. Cabrera JA, et al. **Circulation** 1999 Jun 15; 99(23):3017-23

Determination of left atrial appendage morphology [letter] Ernst G, et al. **Circulation** 1998 Nov 24;98(21):2355

Koch's triangle in pediatric age: correlation with extra- and intracardiac parameters. Francalanci P, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1576-9

Koch's triangle sized up: anatomical landmarks in perspective of catheter ablation procedures. Inoue S, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1553-8

CHEMISTRY

Quinidine interactions with human atrial potassium channels: developmental aspects. Nenov NI, et al. **Circ Res** 1998 Dec 14-28;83(12):1224-31

Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue. Campbell DJ, et al. **Hypertension** 1999 Aug; 34(2):171-5

Identification of native atrial G-protein-regulated inwardly rectifying K+ (GIRK4) channel homomultimers. Corey S, et al. **J Biol Chem** 1998 Oct 16;273(42):27499-504

CYTOLOGY

Potentiation of stretch-induced atrial natriuretic peptide secretion by intracellular acidosis. Tavi P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H405-12

Distribution of intrinsic cardiac neurons in whole-mount guinea pig atria identified by multiple neurochemical coding. A confocal microscope study. Horackova M, et al. **Cell Tissue Res** 1999 Sep;297(3):409-21

[Atrial cardiomyocytes of the heterothermic animal in various physiological conditions] Vinogradova MS, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):353-6 **(Rus)**

DRUG EFFECTS

Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Crumb WJ Jr. **Br J Pharmacol** 1999 Feb;126(3):575-80

Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells. Ohmoto-Sekine Y, et al. **Br J Pharmacol** 1999 Feb;126(3):751-61

Propafenone blocks ATP-sensitive K+ channels in rabbit atrial and ventricular cardiomyocytes. Christé G, et al. **Eur J Pharmacol** 1999 Jun 4;373(2-3):223-32

Age-dependent decrease in the negative inotropic effect of carbachol on isolated human right atrium. Giessler C, et al. **Eur J Pharmacol** 1998 Sep 18;357(2-3):199-202

Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. Chen YJ, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):587-98

Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. Bosch RF, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):762-71

Terfenadine block of sodium current in canine atrial myocytes. Lu Y, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):507-13

Dose and rate-dependent effects of adenosine on atrial action potential duration in humans [see comments] Tebbenjohanns J, et al. **J Interv Card Electrophysiol** 1997 Feb;1(1):33-7. Comment in: J Interv Card Electrophysiol 1997 Feb;1(1):39-40.

Effects of mebudipine and dibudipine, two new calcium-channel blockers, on rat left atrium, rat blood pressure and human internal mammary artery. Mirkhani H, et al. **J Pharm Pharmacol** 1999 May;51(5):617-22

Pharmacological properties of pteleprenine, a quinoline alkaloid extracted from Orixa japonica, on guinea-pig ileum and canine left atrium. Seya K, et al. **J Pharm Pharmacol** 1998 Jul;50(7):803-7

Lack of protective effects of adenosine on the hypoxic and reoxygenated atria and ventricular strips of the rat. Varela A, et al. **J Physiol Biochem** 1999 Mar;55(1):17-23

Acetylcholine-induced biphasic effect on the maximum upstroke velocity of action potential in mouse right atria: interaction with beta-adrenergic signaling cascade. Islam MA, et al. **Jpn J Pharmacol** 1998 Oct;78(2):181-90

Effects of low temperature on the chronotropic and inotropic responses to zatebradine, E-4031 and verapamil in isolated perfused dog atria. Kasama M, et al. **Jpn J Pharmacol** 1998 Dec;78(4):493-9

Positive inotropism induced by androgens in isolated left atrium of rat: evidence for a cAMP-dependent transcriptional mechanism. Rubin JM, et al. **Life Sci** 1999; 65(10):1035-45

Modulation of the hyperpolarization-activated inward current (If) by antiarrhythmic agents in isolated human atrial myocytes. Hoppe UC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):635-40

High affinity regulation of cardiac Cl- and Ca2+ conductances by (13R)-spiroforskolin. Traebert M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Nov; 358(5):538-46

Cardiovascular activity of 14-deoxy-11,12-didehydroandrographolide in the anaesthetised rat and isolated right atria. Zhang C, et al. **Pharmacol Res** 1998 Dec;38(6):413-7

6-Benzylaminopurine: a plant derived cytokinin inducing positive inotropism by P2-purinoceptors. Froldi G, et al. **Planta Med** 1999 Apr;65(3):245-9

Differential effect of tetrandrine on aortic relaxation and chronotropic activity in rat isolated aorta and atria [letter] Wong KK. **Planta Med** 1998 Oct;64(7):663-5

[Comparison of atrial premature depolarization topography during vagal stimulation and humoral acetylcholine administration] Sharifov OF, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov;84(11):1174-90 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

The complete sequence and expression patterns of the atrial myosin heavy chain in the developing chick. Oana S, et al. **Biol Cell** 1998 Dec;90(9):605-13

Downregulation of atrial markers during cardiac chamber morphogenesis is irreversible in murine embryos. Gruber PJ, et al. **Development** 1998 Nov;125(22):4427-38

Prenatal diagnosis of intra-atrial cardiac echogenic foci. Petrikovsky B, et al. **Prenat Diagn** 1998 Sep;18(9):968-70

Regulation of chamber-specific gene expression in the developing heart by Irx4. Bao ZZ, et al. **Science** 1999 Feb 19;283(5405):1161-4

Patterning during organogenesis: genetic analysis of cardiac chamber formation. Yelon D, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):93-8 (31 ref.)

Fetal pulmonary venous flow into the left atrium relative to diastolic and systolic cardiac time intervals. Brezinka C, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):191-5

INJURIES

Delayed atrial rupture after blunt chest trauma. Hartung O, et al. **J Trauma** 1998 Oct;45(4):833-4

Pericardial drainage prior to operation contributes to surgical repair of traumatic cardiac injury. Sugimoto S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jan;47(1):31-5

INNERVATION

Anatomical study of the neural ganglionated plexus in the canine right atrium: implications for selective denervation and electrophysiology of the sinoatrial node in dog. Pauza DH, et al. **Anat Rec** 1999 Jul 1;255(3):271-94

Radial approach: a new concept in surgical treatment for atrial fibrillation. II. Electrophysiologic effects and atrial contribution to ventricular filling. Nitta T, et al. **Ann Thorac Surg** 1999 Jan;67(1):36-50

Role of N-type calcium channels in autonomic neurotransmission in guinea-pig isolated left atria. Serone AP, et al. **Br J Pharmacol** 1999 Jun;127(4):927-34

Relation between ligament of Marshall and adrenergic atrial tachyarrhythmia. Doshi RN, et al. **Circulation** 1999 Aug 24;100(8):876-83

Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. Olgin JE, et al. **Circulation** 1998 Dec 8;98(23):2608-14

Structure and location of accessory muscular atrioventricular connections [editorial; comment] Anderson RH, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1119-23 (20 ref.). Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1112-8.

Characterization of sinoatrial parasympathetic innervation in humans. Quan KJ, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1060-5

Effect of increased parasympathetic and sympathetic tone on internal atrial defibrillation thresholds in humans. Barold HS, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 2):238-42

Thoracoscopic epicardial radiofrequency ablation for vagal atrial fibrillation in dogs. Chevalier P, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):880-6

METABOLISM

Equine cardiodilatin/ atrial natriuretic peptide. Primary structure and immunohistochemical localization in auricular cardiocytes. Richter R, et al. **Acta Anat (Basel)** 1998;162(4):185-93

Relation between atrial coagulation activity and levels of coagulation markers in peripheral samples [letter] Peverill RE, et al. **Am J Cardiol** 1999 Sep 15;84(6):760-1

Potentiation of stretch-induced atrial natriuretic peptide secretion by intracellular acidosis. Tavi P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H405-12

Structure, G protein activation, and functional relevance of the cardiac G protein-gated K+ channel, IKACh. Wickman K, et al. **Ann N Y Acad Sci** 1999 Apr 30; 868:386-98

Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Fujii H, et al. **Ann Nucl Med** 1999 Feb;13(1):55-9

Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Wang Z, et al. **Circulation** 1998 Dec 1;98(22):2422-8

Antisense oligonucleotides against receptor kinase GRK2 disrupt target selectivity of beta-adrenergic receptors in atrial myocytes. Wellner-Kienitz MC, et al. **FEBS Lett** 1999 May 28;451(3):279-83

Functional activity of the CFTR Cl- channel in human myocardium. Yajima T, et al. **Heart Vessels** 1997; 12(6):255-61

Expression and distribution of brain natriuretic peptide in human right atria. Doyama K, et al. **J Am Coll Cardiol**

1998 Dec;32(7):1832–8

Receptor–independent activation of atrial muscarinic potassium channels in the absence of nucleotides. Otero AS, et al. **J Biol Chem** 1998 Oct 30;273(44):28868–72

Gene expression of the natriuretic peptide system in atrial tissue of patients with paroxysmal and persistent atrial fibrillation. Tuinenburg AE, et al.
J Cardiovasc Electrophysiol 1999 Jun;10(6):827–35

Connexin45, a major connexin of the rabbit sinoatrial node, is co–expressed with connexin43 in a restricted zone at the nodal–crista terminalis border. Coppen SR, et al.
J Histochem Cytochem 1999 Jul;47(7):907–18

B–type Ca2+ channels activated by chlorpromazine and free radicals in membrane of human atrial myocytes. Antoine S, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2623–36

Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. Lüss I, et al.
J Mol Cell Cardiol 1999 Jun;31(6):1299–314

Chamber–related differences in connexin expression in the human heart. Vozzi C, et al. **J Mol Cell Cardiol** 1999 May; 31(5):991–1003

Positive inotropism induced by androgens in isolated left atrium of rat: evidence for a cAMP–dependent transcriptional mechanism. Rubin JM, et al. **Life Sci** 1999; 65(10):1035–45

A positive GATA element and a negative vitamin D receptor–like element control atrial chamber–specific expression of a slow myosin heavy–chain gene during cardiac morphogenesis. Wang GF, et al. **Mol Cell Biol** 1998 Oct;18(10):6023–34

NADPH–diaphorase histochemistry during the acute cardiovascular changes after spinal cord injury in the rat. Rojas–Martinez R, et al. **Proc West Pharmacol Soc** 1998; 41:115–6

Effect of dipyridamole on prostanoid production in rat isolated atria. Peredo HA, et al.
Prostaglandins Leukot Essent Fatty Acids 1999 Feb; 60(2):125–8

Left atrial endocardium and prostacyclin. Nosaka S, et al.
Prostaglandins Other Lipid Mediat 1999 May;57(2–3):173–8

PATHOLOGY

Factors relating to left atrial enlargement in atrial fibrillation: "chicken or the egg" hypothesis [editorial; comment] Thamilarasan M, et al. **Am Heart J** 1999 Mar;137(3):381–3 . Comment on: Am Heart J 1999 Mar;137(3):494–9.

Bronchial–atrial fistula after lung transplant resulting in fatal air embolism. Karmy–Jones R, et al. **Ann Thorac Surg** 1999 Feb;67(2):550–1

Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation. Liu SK, et al.
Cardiology 1998 Oct;90(2):101–9

Transthoracic echo–guided transvenous biopsy of a right atrial mass [letter] Martí V, et al.
Cathet Cardiovasc Diagn 1998 Nov;45(3):349–50

Clinical manifestation and survival of patients with idiopathic bilateral atrial dilatation. Arima M, et al. **Intern Med** 1999 Feb;38(2):112–8

Primary cardiac angiosarcoma of the right atrium undiagnosed by transvenous endocardial tumor biopsy. Nitta R, et al. **Intern Med** 1998 Dec;37(12):1023–6

The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome. Rychik J, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):554–60

Human histopathologic findings following radiofrequency ablation of the tricuspid–inferior vena cava isthmus. Leonelli FM, et al. **J Cardiovasc Electrophysiol** 1999 Apr; 10(4):599–602

Morphological and physiological characteristics of discontinuous linear atrial ablations during atrial pacing and atrial fibrillation. Mitchell MA, et al.
J Cardiovasc Electrophysiol 1999 Mar;10(3):378–86

Clear cell sarcoma of kidney with tumor extension into the right atrium. Toyoda Y, et al.
J Cardiovasc Surg (Torino) 1998 Aug;39(4):489–91

Electroanatomic imaging using magnetic catheter tracking in the diagnosis and treatment of atrial arrhythmias. Wilber DJ, et al. **J Electrocardiol** 1998;31 Suppl:92–100 (25 ref.)

Electrophysiological properties of mechanosensitive atrial fibroblasts from chronic infarcted rat heart. Kiseleva I, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1083–93

Physiology and pathophysiology of the atria: its role in atrial fibrillation. Godtfredsen J. **J Thromb Thrombolysis** 1999 Jan;7(1):13–9 (51 ref.)

Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Kamiyama N.
Jpn Circ J 1998 Nov;62(11):837–43

Serial MRI of cerebral infarcts before and after removal of an atrial myxoma. Kawamura T, et al. **Neuroradiology** 1999 Aug;41(8):573–5

Cardiac myxoma with glandular component: case report and review of the literature. Lindner V, et al.
Pathol Res Pract 1999;195(4):267–72 (26 ref.)

[A case of mitral valve replacement and left atrial plication for infantile Marfan syndrome with giant left atrium due to mitral valve regurgitation] Kamikubo Y, et al.
Kyobu Geka 1999 Jul;52(7):579–82 (Eng. Abstr.) **(Jpn)**

[The removal of renal carcinoma thrombus extending to the right atrium by means of extracorporeal circulation: report of a case] Miyamoto M, et al. **Kyobu Geka** 1999 May; 52(5):364–7 (Eng. Abstr.) **(Jpn)**

[An autopsy case of elderly idiopathic enlargement of the right atrium] Ohshita T, et al.
Nippon Ronen Igakkai Zasshi 1999 Jan;36(1):59–64 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of right atrial wall infectious endocarditis complicated by by mycotic aortic aneurysm] Konovalov IuN, et al. **Klin Med (Mosk)** 1999;77(5):55–7 **(Rus)**

PHYSIOLOGY

Endogenous muscarinic activity attenuates adrenergic inotropic effects in field stimulated atrial myocardium from children with congenital heart defects. Borthne K, et al.
Acta Physiol Scand 1999 Jan;165(1):9–13

Electrophysiology and endocardial mapping of induced atrial fibrillation in patients with spontaneous atrial fibrillation. Saksena S, et al. **Am J Cardiol** 1999 Jan 15;83(2):187–93

Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Feng J, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1717–25

Atrial, B–type, and C–type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Woods RL, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1443–52

Evaluation of left atrial wall elasticity using acoustic microscopy. Masugata H, et al. **Angiology** 1999 Jul; 50(7):583–90

Aryl propanolamines: comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia. Cohen ML, et al.
Br J Pharmacol 1999 Feb;126(4):1018–24

Electrical conduction between the right atrium and the left atrium via the musculature of the coronary sinus. Antz M, et al. **Circulation** 1998 Oct 27;98(17):1790–5

Transmembrane potential properties at the core of functional reentrant wave fronts in isolated canine right atria. Athill CA, et al. **Circulation** 1998 Oct 13;98(15):1556–67

The intrinsic rate response of the isolated right atrium of the rat, Rattus norvegicus. Barrett CJ, et al.
Comp Biochem Physiol A Mol Integr Physiol 1998 Jul; 120(3):391–7

Muscarinic regulation of Ca2+ signaling in mammalian atrial and ventricular myocardium. Endoh M.
Eur J Pharmacol 1999 Jun 30;375(1–3):177–96 (104 ref.)

Junctional communication between isolated pairs of canine atrial cells is mediated by homogeneous and heterogeneous gap junction channels. Elenes S, et al.
J Cardiovasc Electrophysiol 1999 Jul;10(7):990–1004

The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. Hobbs WJ, et al. **J Cardiovasc Electrophysiol** 1999 Jun; 10(6):866–70

Projections of the dorsal motor nucleus of the vagus to cardiac ganglia of rat atria: an anterograde tracing study. Cheng Z, et al. **J Comp Neurol** 1999 Jul 26;410(2):320–41

Adenosine and atrial fibrillation [comment] Sung RJ.
J Interv Card Electrophysiol 1997 Feb;1(1):39–40. Comment on: J Interv Card Electrophysiol 1997 Feb;1(1):33–7.

Phospholamban modulates murine atrial contractile parameters and responses to beta–adrenergic agonists. Kadambi VJ, et al. **J Mol Cell Cardiol** 1998 Jul; 30(7):1275–84

Complications associated with rapid caffeine application to cardiac myocytes that are not voltage clamped. Zaniboni M, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2229–35

Role of genomic mechanisms on cAMP–dependent positive inotropism in isolated left atrium of rat. Rubin JM, et al.
Life Sci 1999;65(5):565–72

Mechanisms of thyroid hormone control over sensitivity and maximal contractile responsiveness to beta–adrenergic agonists in atria. Seppet EK, et al. **Mol Cell Biochem** 1998 ;ul;184(1–2):419–26

Change of atrial refractory period after short duration of rapid atrial pacing: regional differences and possible mechanisms. Lee SH, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):927–34

[Measuring the left atrial diameter with consideration given to the cardiac cycles (letter)] Kishikawa T, et al.
J Cardiol 1998 Nov;32(5):343–4 **(Jpn)**

[The involvement of muscarinic M1 receptor in the regulation of action potentials in mouse isolated right atria] Kimura I, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:128P–132P (Eng. Abstr.) **(Jpn)**

[Recording of atrial and ventricular signal averaged ECGs in patients with mitral valve prolapse syndrome] Banasiak W, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):302–5 (Eng. Abstr.) **(Pol)**

[Similarity of the effects of first–generation antiarrhythmia agents and decreased extracellular concentration of sodium ions on action potentials of atrial myocytes] Grigaliunene I, et al. **Biofizika** 1999 Mar–Apr;44(2):330–6 (Eng. Abstr.) **(Rus)**

[Comparison of atrial premature depolarization topography during vagal stimulation and humoral acetylcholine administration] Sharifov OF, et al.
Ross Fiziol Zh Im I M Sechenova 1998 Nov;84(11):1174–90 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Ablation of right and left ectopic atrial tachycardias using a three–dimensional nonfluoroscopic mapping system. Natale A, et al. **Am J Cardiol** 1998 Oct 15;82(8):989–92

Predictive value of prominent right atrial V waves in assessing the presence and severity of tricuspid regurgitation. Pitts WR, et al. **Am J Cardiol** 1999 Feb 15; 83(4):617–8, A10

Regional right and left atrial activation patterns during single– and dual–site atrial pacing in patients with atrial fibrillation. Prakash A, et al. **Am J Cardiol** 1998 Nov 15; 82(10):1197–204

Can right–sided atrioventricular sequential pacing provide benefit for selected patients with severe congestive heart failure? Sack S, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):124D–129D

Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. Welch PJ, et al.
Am J Cardiol 1999 Aug 15;84(4):420–5

Simulation of atrial activity by a phase response curve based model of a two–dimensional pacemaker cells array: the transition from a normal activation pattern to atrial fibrillation. Abramovich–Sivan S, et al. **Biol Cybern** 1999 Feb;80(2):141–53

Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia–induced atrial electrical remodeling. Fareh S, et al. **Circulation** 1998 Nov 17;98(20):2202–9

Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. Olgin JE, et al. **Circulation** 1998 Dec 8;98(23):2608–14

Alterations in atrial electrophysiology associated with chronic atrial fibrillation in man [see comments] Kamalvand K, et al. **Eur Heart J** 1999 Jun;20(12):888–95 . Comment in: Eur Heart J 1999 Jun;20(12):856–7.

Chronic atrial fibrillation – what is wrong with the atrium? [editorial; comment] Olsson SB. **Eur Heart J** 1999 Jun; 20(12):856–7. Comment on: Eur Heart J 1999 Jun;20(12):888–95.

Sjögren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Borda E, et al. **Int J Cardiol** 1999 Jul 1;70(1):23–32

Atrial standstill in a case of Kugelberg–Welander syndrome with cardiac involvement: an electrophysiologic study [letter] Liu YB, et al. **Int J Cardiol** 1999 Jul 31;70(2):207–10

Human atrial repolarization: effects of sinus rate, pacing and drugs on the surface electrocardiogram. Debbas NM, et al. **J Am Coll Cardiol** 1999 Feb;33(2):358–65

Influence of right ventricular stimulation site on left ventricular function in atrial synchronous ventricular pacing [see comments] Schwaab B, et al.
J Am Coll Cardiol 1999 Feb;33(2):317–23. Comment in: J Am Coll Cardiol 1999 Feb;33(2):324–6.

Capture window in human atrial fibrillation: evidence of an excitable gap. Capucci A, et al.
J Cardiovasc Electrophysiol 1999 Mar;10(3):319–27

Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. Chen SA, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):328–35

Congestive heart failure induced by recipient atrial tachycardia conducted to the donor atrium after orthotopic heart transplantation: complete regression after successful radiofrequency ablation. Gasparini M, et al.
J Cardiovasc Electrophysiol 1999 Mar;10(3):399–404

Locating ectopic foci. Hall K, et al.
J Cardiovasc Electrophysiol 1999 Mar;10(3):387–98

Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: possible roles of the ligament of Marshall. Hwang C, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):636–48

Electrophysiologic study and radiofrequency catheter ablation of isthmus–independent atrial flutter. Lai LP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):728–35

Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation. Nitta T, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):521–8

Mechanisms and clinical implications of atypical atrial flutter. Scheinman MM, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1153–7 (11 ref.)

Heterogeneous changes in electrophysiologic properties in the paroxysmal and chronically fibrillating human atrium. Tse HF, et al. **J Cardiovasc Electrophysiol** 1999 Feb; 10(2):125–35

Atrial sensing and AV synchrony in single lead VDD pacemakers: a prospective comparison to DDD devices with bipolar atrial leads. Wiegand UK, et al.
J Cardiovasc Electrophysiol 1999 Apr;10(4):513–20

Optimal target site for slow AV nodal pathway ablation: possibility of predetermined focal mapping approach using anatomic reference in the Koch's triangle. Yamane T, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):529–37

Focal source hypothesis of atrial fibrillation. Chen PS, et al. **J Electrocardiol** 1998;31 Suppl:32–4 (17 ref.)

The significance of atrial monophasic action potentials for monitoring rat cardiac allograft rejection. Tahara K, et al.
J Heart Lung Transplant 1998 Oct;17(10):954–8

The current status of single lead dual chamber sensing and pacing. Tse HF, et al. **J Interv Card Electrophysiol** 1998 Sep;2(3):255–67 (55 ref.)

Prospective evaluation of the quality and long–term stability of atrial signals in non–thoracotomy defibrillation electrodes: comparison of four different endocardial electrograms. Wolpert C, et al.
J Interv Card Electrophysiol 1998 Dec;2(4):351–5

Physiology and pathophysiology of the atria: its role in atrial fibrillation. Godtfredsen J. **J Thromb Thrombolysis** 1999 Jan;7(1):13–9 (51 ref.)

Comparison of automatic boundary detection and manual tracing technique in echocardiographic determination of left atrial volume. Zhang GC, et al. **Jpn Circ J** 1998 Oct; 62(10):755–9

Importance of retrograde atrial activation in atrial fibrillation genesis in the initiation of atrial fibrillation in Wolff-Parkinson-White syndrome. Comparison of atrial electrophysiologic parameters between patients with different atrial fibrillation genesis (initiation sites) in atria. Niwano S, et al. **Jpn Heart J** 1999 May;40(3):281–93

Atrial fibrillation after coronary artery bypass grafting. An increase in high-frequency atrial activity in patients with right coronary artery revascularization. Terada Y, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jan;47(1):6–13

Aortic input impedance and ventriculoarterial coupling following cardioversion/defibrillation. Bauernschmitt R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1047–53

Unusual left atrial activation during atrioventricular reentrant tachycardia. Weiss C, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):947–9

Should unipolar leads be implanted in the atrium? A Holter electrocardiographic comparison of threshold adapted unipolar and high sensitive bipolar sensing. Wiegand UK, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1601–8

Spontaneous closure of atrial septal defects. Helgason H, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):195–9

[Electrocardiographic signs of atrial overload in hypertension] Ouyang BA, et al.
Hunan I Ko Ta Hsueh Hsueh Pao 1997;22(6):503–7 (Eng. Abstr.) **(Chi)**

[Post-cardioversion atrial stunning: what do we need to know?] Carerj S, et al. **G Ital Cardiol** 1998 Oct; 28(10):1162–5 **(Ita)**

[Abnormalities of electrocardiographic P wave morphology and the relationship to electrophysiological parameters of the atrium in patients with idiopathic paroxysmal atrial fibrillation] Liu Z, et al. **J Cardiol** 1998 Sep;32(3):189–96 (Eng. Abstr.) **(Jpn)**

[Clinical efficacy of non-invasive evaluation of intra- and interatrial conduction in patients with ischemic heart disease] Shabrov AV, et al. **Ter Arkh** 1999;71(1):34–9 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Saddle embolus of the carotid bifurcation. A late complication of mediastinal radiotherapy. Fox AD, et al. **Eur J Vasc Endovasc Surg** 1999 Apr;17(4):360–2

RADIOGRAPHY

Simple single-section method for measurement of left and right atrial volumes with electron-beam CT. Budoff MJ, et al. **Acad Radiol** 1999 Aug;6(8):481–6

Angiographic anatomy of the inferior right atrial isthmus in patients with and without history of common atrial flutter. Cabrera JA, et al. **Circulation** 1999 Jun 15; 99(23):3017–23

Pellet embolization to the right atrium following double shotgun injury. Pollak S, et al. **Forensic Sci Int** 1999 Jan 4;99(1):61–9 (32 ref.)

Improved clinical efficacy of external cardioversion by fluoroscopic electrode positioning and comparison to internal cardioversion in patients with atrial fibrillation. Mehdirad AA, et al. **Pacing Clin Electrophysiol** 1999 Jan; 22(1 Pt 2):233–7

RADIONUCLIDE IMAGING

Increased fluorine-18 fluorodeoxyglucose uptake in the right atrial wall in a patient with atrial fibrillation. Fujii H, et al. **Clin Nucl Med** 1999 Feb;24(2):136–7

Isolated severe right atrial dilatation demonstrated on planar TI-201 myocardial imaging. Kumar M, et al.
Clin Nucl Med 1999 May;24(5):368–9

SECRETION

Modulation of noradrenaline release from the sympathetic nerves of human right atrial appendages by presynaptic EP3- and DP-receptors. Molderings GJ, et al.
Naunyn Schmiedebergs Arch Pharmacol 1998 Oct; 358(4):440–4

SURGERY

Cardiac myxoma in a 6-year-old child--constitutional symptoms mimicking rheumatic disease and the role of interleukin-6. Hövels-Gürich HH, et al. **Acta Paediatr** 1999 Jul;88(7):786–8

Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Rothman A, et al. **Am J Cardiol** 1999 Sep 15;84(6):682–6

Video-assisted minimal access in excision of left atrial myxoma [letter; comment] Anderson JR.
Ann Thorac Surg 1999 Aug;68(2):628. Comment on: Ann Thorac Surg 1998 Oct;66(4):1301–5. Comment on: Ann Thorac Surg 1998 Oct;66(4):1429–30.

Hepatoatrial anastomosis and tricuspid valve replacement in Budd-Chiari syndrome 8. Chiu CK, et al.
Ann Thorac Surg 1998 Nov;66(5):1803–4

Combined Rastelli and atrial switch procedure: a 10-year follow-up. Jacobs ML, et al. **Ann Thorac Surg** 1999 Aug; 68(2):570–1

Additional maneuvers to improve mitral valve exposure through the conventional left atriotomy [letter; comment] Kapoor L, et al. **Ann Thorac Surg** 1999 Jan;67(1):298–9. Comment on: Ann Thorac Surg 1998 Apr;65(4):1161–2.

Effective reduction of a giant left atrium by partial autotransplantation. Lessana A, et al. **Ann Thorac Surg** 1999 Apr;67(4):1164–5

Atrial flap anastomosis: an alternative technique for orthotopic heart transplantation [letter; comment] Sarsam MA. **Ann Thorac Surg** 1998 Nov;66(5):1868–9. Comment on: Ann Thorac Surg 1998 Apr;65(4):1163–4.

Atrial isomerism: a surgical experience. Sinzobahamvya N, et al. **Cardiovasc Surg** 1999 Jun;7(4):436–42

Linear atrial ablation with a diode laser and fiberoptic catheter. Keane D, et al. **Circulation** 1999 Oct 5; 100(14):e59–60

Bipolar radiofrequency catheter ablation creates confluent lesions at larger interelectrode spacing than does unipolar ablation from two electrodes in the porcine heart. Anfinsen OG, et al. **Eur Heart J** 1998 Jul;19(7):1075–84

Successful total correction of complete atrioventricular canal, total anomalous pulmonary venous drainage and unroofed coronary sinus in an infant. Alexi-Meskishvili V, et al.
Eur J Cardiothorac Surg 1999 Jan;15(1):95–6

Both atrial resection and superior vena cava replacement in sleeve pneumonectomy for advanced lung cancer. Ernst M, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):530–2

Pregnancy after atrial repair for transposition of the great arteries. Genoni M, et al. **Heart** 1999 Mar;81(3):276–7

Intra-cardiac shrapnel--innocuous or dangerous? Singh RS, et al. **Indian Heart J** 1998 Jul-Aug;50(4):451–2

Large gradient across a partially ligated left atrial appendage. Fisher DC, et al. **J Am Soc Echocardiogr** 1998 Dec; 11(12):1163–5

Catheter mounted coaxially moveable ablation electrode for the creation of linear transmural endocardial lesions. Morgan JM, et al. **J Cardiovasc Electrophysiol** 1999 Apr; 10(4):566–73

Blunt cardiac trauma: successful repair of right atrium rupture. Song MH, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):473–4

The bicaval anastomosis technique for orthotopic heart transplantation yields better atrial function than the standard technique: an echocardiographic automatic boundary detection study. Traversi E, et al.
J Heart Lung Transplant 1998 Nov;17(11):1065–74

Extended vertical transseptal approach versus conventional left atriotomy for mitral valve surgery. Masiello P, et al. **J Heart Valve Dis** 1999 Jul;8(4):440–4

Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option. El-Sabrout RA, et al. **J Vasc Surg** 1999 Mar;29(3):472–8

Fate of atrial flap used in repair of total anomalous pulmonary venous connection. Imoto Y, et al.
Jpn J Thorac Cardiovasc Surg 1999 Jun;47(6):288–90

Efficacy of multiple ring and coil electrode radiofrequency ablation catheters for the creation of long linear lesions in the atria. McRury ID, et al. **Med Eng Phys** 1998 Nov; 20(8):551–7

Acute inferior cardiac inflow obstruction resulting from inadvertent surgical closure of a prominent Eustachian valve mistaken for an atrial septal defect. Becker A, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):155–7

Adverse hemodynamic effects observed with inhaled nitric oxide after surgical repair of total anomalous pulmonary venous return. Rosales AM, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):224–6

A rare cause of right atrial mass: thrombus formation and infection complicating a ventriculoatrial shunt for hydrocephalus. Yavuzgil O, et al. **Surg Neurol** 1999 Jul; 52(1):54–60; discussion 60–1

[A case of mitral valve replacement and left atrial plication for infantile Marfan syndrome with giant left atrium due to mitral valve regurgitation] Kamikubo Y, et al.
Kyobu Geka 1999 Jul;52(7):579–82 (Eng. Abstr.) **(Jpn)**

[A combined surgery for locally invaded lung cancer] Starikov VI, et al. **Klin Khir** 1998;(5):23–4 (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty. Bainbridge AD, et al.
J Heart Lung Transplant 1999 May;18(5):407–13

ULTRASONOGRAPHY

Recurrent pulmonary emboli and thrombus attached to a permanently implanted pacemaker wire in pregnancy. Bilge M, et al. **Acta Cardiol** 1999 Apr;54(2):97–9

Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. Stroke Prevention in Atrial Fibrillation Investigators [see comments] Dittrich HC, et al. **Am Heart J** 1999 Mar;137(3):494–9. Comment in: Am Heart J 1999 Mar;137(3):381–3.

Influence of warfarin therapy on left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. Ito T, et al.
Am J Cardiol 1999 Oct 1;84(7):857–9, A8

Best method in clinical practice and in research studies to determine left atrial size. Lester SJ, et al. **Am J Cardiol** 1999 Oct 1;84(7):829–32

Left atrial enlargement in infancy secondary to a fistula from the proximal left coronary artery. Dhillon R, et al.
Cardiol Young 1999 Mar;9(2):228–9

The four-chamber view and its sensitivity in detecting congenital heart defects. Fernandez CO, et al.
Cardiology 1998 Dec;90(3):202–6

Witnessed embolization of a right atrial mass during transesophageal echocardiography: implications regarding the safety of esophageal intubation. Kwak KD, et al.
Chest 1999 May;115(5):1462–4

Comparative study of fluoroscopy and intracardiac echocardiographic guidance for the creation of linear atrial lesions. Epstein LM, et al. **Circulation** 1998 Oct 27; 98(17):1796–801

Intracavitary cardiac hydatid cyst and the wall sign criteria. El Fortia M, et al. **Eur J Ultrasound** 1998 Nov;8(2):115–7

Imaging of thrombi and assessment of left atrial appendage function: a prospective study comparing transthoracic and transoesophageal echocardiography. Omran H, et al.
Heart 1999 Feb;81(2):192–8

Narrowing of the superior vena cava-right atrium junction during radiofrequency catheter ablation for inappropriate sinus tachycardia: analysis with intracardiac echocardiography. Callans DJ, et al. **J Am Coll Cardiol** 1999 May;33(6):1667–70

Right lateral transthoracic approach mimicking standard transesophageal echocardiographic views in a patient with giant left atrium. Delgado C, et al.
J Am Soc Echocardiogr 1999 Apr;12(4):275–7

Large gradient across a partially ligated left atrial appendage. Fisher DC, et al. **J Am Soc Echocardiogr** 1998 Dec; 11(12):1163–5

Improved visualization of the left atrial appendage by transthoracic 2-dimensional tissue harmonic compared with fundamental echocardiographic imaging. Ono M, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1044–9

Low-power radiofrequency application and intracardiac echocardiography for creation of continuous left atrial linear lesions. Roithinger FX, et al.
J Cardiovasc Electrophysiol 1999 May;10(5):680–91

Left atrial thrombus detection with multiplane transesophageal echocardiography: an echocardiographic study with surgical verification. Koca V, et al.
J Heart Valve Dis 1999 Jan;8(1):63–6

Intracardiac echocardiographic imaging of right atrial appendage: mass vs. pectinate muscle [corrected and republished with original paging, article originally printed in J Interv Card Electrophysiol 1998 Sep; 2(3):247–8] Ren JF, et al. **J Interv Card Electrophysiol** 1998 Dec;2(4):247–8

Intracardiac echocardiographic imaging of right atrial appendage: mass vs. pectinate muscle [corrected and republished in J Interv Card Electrophysiol 1998 Dec;2(4):247–8] Ren JF, et al.
J Interv Card Electrophysiol 1998 Sep;2(3):247–8

Doppler sonographic evaluation of left atrial function after cardioversion of atrial fibrillation. Mattioli AV, et al.
J Ultrasound Med 1999 Apr;18(4):289–94

Prenatal diagnosis of intra-atrial cardiac echogenic foci. Petrikovsky B, et al. **Prenat Diagn** 1998 Sep;18(9):968–70

[Detection and surveillance of left atrial thrombosis by transesophageal echocardiography] Canavy I, et al.
Arch Mal Coeur Vaiss 1999 Jan;92(1):35–42 (29 ref.) (Eng. Abstr.) **(Fre)**

HEART AUSCULTATION

see related
PHONOCARDIOGRAPHY

The teaching of cardiac auscultation during internal medicine and family medicine training--a nationwide comparison. Mangione S. **Acad Med** 1998 Oct;73(10 Suppl):S10–2

Why are we using electronic fetal monitoring? [editorial; comment] Kripke CC. **Am Fam Physician** 1999 May 1; 59(9):2416, 2421–2. Comment on: Am Fam Physician 1999 May 1;59(9):2487–500.

In defense of the stethoscope [editorial; comment] [see comments] Adolph RJ. **Chest** 1998 Nov;114(5):1235–7. Comment on: Chest 1998 Nov;114(5):1283–8. Comment in: Chest 1999 Apr;115(4):1218–9.

The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation [see comments] Lok CE, et al. **Chest** 1998 Nov;114(5):1283–8. Comment in: Chest 1998 Nov;114(5):1235–7. Comment in: Chest 1999 Apr;115(4):1218–9.

Teaching cardiology auscultation. A wireless FM broadcast system [see comments] Martin CC, et al.
Tex Heart Inst J 1998;25(3):218–9. Comment in: Tex Heart Inst J 1999;26(2):160.

INSTRUMENTATION

[Physical diagnostics--auscultation of fetal heart sounds (letter; comment)] Molleman GM.
Ned Tijdschr Geneeskd 1999 Apr 10;143(15):817–8. Comment on: Ned Tijdschr Geneeskd 1999 Feb 27;143(9):455–8. **(Dut)**

METHODS

Accuracy of strategies for monitoring fetal heart rate in labor. Simpson N, et al. **Am J Perinatol** 1999;16(4):167–73

[Physical diagnostics--auscultation of fetal heart sounds (see

comments)] Nijhuis JG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):455–8 (14 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 10;143(15):817–8. **(Dut)**

VETERINARY

Auscultation in mild mitral regurgitation in dogs: observer variation, effects of physical maneuvers, and agreement with color Doppler echocardiography and phonocardiography. Pedersen HD, et al. **J Vet Intern Med** 1999 Jan–Feb;13(1):56–64

HEART BLOCK

Familial sick sinus syndrome with atrioventricular conduction disturbance. Isobe M, et al. **Jpn Circ J** 1998 Oct;62(10):788–90

Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: technical case report. Pile-Spellman J, et al. **Neurosurgery** 1999 Apr;44(4):881–6; discussion 886–7

BLOOD

Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Mazel JA, et al. **Circulation** 1999 Apr 13; 99(14):1914–8

CHEMICALLY INDUCED

Ephedrine-induced complete atrioventricular block with ventricular asystole during rapid concomitant phenytoin infusion: a case report. Lin SY, et al. **Acta Anaesthesiol Sin** 1999 Mar;37(1):45–8

Transient second-degree heart block during dipyridamole myocardial perfusion imaging. Preumont N, et al. **Acta Cardiol** 1998;53(5):275–7

Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Wettwer E, et al. **Br J Pharmacol** 1998 Oct;125(4):659–66

Latex anaphylaxis causing heart block: role of ranitidine. Patterson LJ, et al. **Can J Anaesth** 1999 Aug;46(8):776–8

Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy. Ng GA, et al. **Heart** 1999 Aug;82(2):163–9

Survival in a case of life-threatening flecainide overdose. Hanley NA, et al. **Intensive Care Med** 1998 Jul;24(7):740–2

Complete heart block as a rare complication of treatment with chloroquine. Reuss-Borst M, et al. **J Rheumatol** 1999 Jun;26(6):1394–5

Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Huang CH, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):965–7

Heart block following propofol in a child. Sochala C, et al. **Paediatr Anaesth** 1999;9(4):349–51

[Severe flecainide acetate poisoning. Apropos of a case] Maury P, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):273–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Third degree atrio-ventricular block induced by interferon alpha. Report of a case] Parrens E, et al. **Arch Mal Coeur Vaiss** 1999 Jan;92(1):53–6 (Eng. Abstr.) **(Fre)**

[Atrioventricular block secondary to topical ophthalmic beta blockers] Rubín López JM, et al. **Rev Esp Cardiol** 1999 Jul;52(7):532 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Early development of high-degree atrioventricular block in inferior acute myocardial infarction is predicted by a J-point/R-wave ratio above 0.5 on admission. Solodky A, et al. **Cardiology** 1998;90(4):274–9

Intermittent complete atrioventricular block associated with typical atrioventricular nodal reentrant tachycardia. Jenkins NP, et al. **Heart** 1998 Oct;80(4):418–9

An irregular, narrow QRS complex tachycardia with ventriculoatrial block: what is the tachycardia mechanism? Bogun F, et al. **J Cardiovasc Electrophysiol** 1999 May; 10(5):760–1

Ventriculoatrial block during atrioventricular nodal reentrant tachycardia utilizing multiple retrograde pathways. Ino T, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1206–13

Coexisting preexcitation syndrome and intermittent heart block presenting as neonatal seizures. Kanter RJ, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):736–40

Prominent bifid T waves observed in the QT prolongation caused by complete atrioventricular blockade in a hypokalemic diabetic patient. Oka-Manabe S, et al. **J Electrocardiol** 1999 Jul;32(3):289–92

Lyme carditis: complete AV dissociation with episodic asystole presenting as syncope in the emergency department. Rosenfeld ME, et al. **J Emerg Med** 1999 Jul–Aug;17(4):661–4

Inferior vena cava-tricuspid annulus isthmus is a critical site of unidirectional block during the induction of common atrial flutter. Poty H, et al. **J Interv Card Electrophysiol** 1998 Mar;2(1):57–69

Mitochondrial encephalomyopathy (Kearns-Sayre syndrome) with complete atrioventricular block: a case report. Kakura H, et al. **Jpn Circ J** 1998 Aug;62(8):623–5

Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block. Watanabe O, et al. **Pacing Clin Electrophysiol** 1999 Apr; 22(4 Pt 1):686–8

Heart block in patients with sleep apnoea. Becker HF, et al. **Thorax** 1998 Oct;53 Suppl 3:S29–32 (20 ref.)

[Mental disorders in a complete transverse heart block] Tsivil'ko MA, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(6):53–5 **(Rus)**

CONGENITAL

Congenital complete atrioventricular block in an infant with long QT syndrome. Koçak G, et al. **Acta Cardiol** 1998; 53(3):153–5

Chronotropic competence of the sinus node in congenital complete heart block. Menon A, et al. **Am J Cardiol** 1998 Nov 1;82(9):1119–21, A9

Perinatal monitoring of fetal well-being in the presence of congenital heart block. Friedman DM, et al. **Am J Perinatol** 1998;15(12):669–73

Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases. Falcini F, et al. **Ann Ital Med Int** 1998 Jul–Sep;13(3):169–72

DNA typing of maternal HLA in congenital complete heart block: comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Colombo G, et al. **Arthritis Rheum** 1999 Aug;42(8):1757–64

Maternal autoantibodies and congenital heart block: clues from two consecutive pregnancies, one in which there was congenital complete heart block and one in which the fetus was healthy. Horsfall AC, et al. **Arthritis Rheum** 1998 Nov; 41(11):2079–80

Recurrent miscarriage, congenital heart block and systemic lupus erythematosus. Julkunen H, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):26–7

ERV-3 envelope expression and congenital heart block: what does a physiological knockout teach us. de Parseval N, et al. **Autoimmunity** 1999;30(2):81–3

Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Mazel JA, et al. **Circulation** 1999 Apr 13; 99(14):1914–8

1:1 atrioventricular conduction in congenital complete heart block. McLeod KA, et al. **Heart** 1998 Nov;80(5):525–6

Sjögren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Borda E, et al. **Int J Cardiol** 1999 Jul 1;70(1):23–32

Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. Miranda ME, et al. **J Immunol** 1998 Nov 1;161(9):5061–9

Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in a murine model. Miranda-Carús ME, et al. **J Immunol** 1998 Dec 1; 161(11):5886–92

The increasing incidence of isolated congenital heart block in Finland [letter] Sirén MK, et al. **J Rheumatol** 1998 Sep; 25(9):1862–4

Role of HLA in congenital heart block: susceptibility alleles in mothers. Sirén MK, et al. **Lupus** 1999;8(1):52–9

Role of HLA in congenital heart block: susceptibility alleles in children. Sirén MK, et al. **Lupus** 1999;8(1):60–7

A new therapeutic approach to the fetus with congenital complete heart block: preemptive, targeted therapy with dexamethasone. Rosenthal D, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):689–91

Spontaneous resolution of atrioventricular dissociation in utero. Boris JR, et al. **Pediatr Cardiol** 1998 Nov–Dec; 19(6):487–9

The wandering pacemaker: intraperitoneal migration of an epicardially placed pacemaker and femoral nerve stimulation. Salim MA, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):164–6

Congenital heart block and associated cardiac pathology in neonatal lupus syndrome. Meckler KA, et al. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):136–42

Immune-mediated congenital heart block (CHB): identifying and counseling patients at risk for having children with CHB. Julkunen H, et al. **Semin Arthritis Rheum** 1998 Oct; 28(2):97–106

[Congenital atrioventricular block] Grolleau R, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:47–55 (Eng. Abstr.) **(Fre)**

[Neonatal lupus erythematosis and atrial-ventricular block. A case report and review of the literature] Ghayad E, et al. **J Med Liban** 1998 Jan–Feb;46(1):36–9 (Eng. Abstr.) **(Fre)**

[Doppler ultrasound of the umbilical vein in fetal 3rd degree atrioventricular block] Yaman C, et al. **Ultraschall Med** 1998 Jun;19(3):142–5 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Paroxysmal atrioventricular block induced during head-up tilt test. de Meester A, et al. **Acta Cardiol** 1999 Apr; 54(2):101–3

A new algorithm to determine complete isthmus conduction block after radiofrequency catheter ablation for typical atrial flutter. Johna R, et al. **Am J Cardiol** 1999 Jun 15; 83(12):1666–8, A6–7

Cases in electrocardiography. Zimmers T. **Am J Emerg Med** 1999 Jan;17(1):89–90

Successful treatment of a patient with cardiac lymphoma who presented with a complete atrioventricular block. Nagano M, et al. **Am J Hematol** 1998 Oct;59(2):171–4

Early development of high-degree atrioventricular block in inferior acute myocardial infarction is predicted by a J-point/R-wave ratio above 0.5 on admission. Solodky A, et al. **Cardiology** 1998;90(4):274–9

Misdiagnosis of new bifascicular block [letter] Madias JE. **Circulation** 1999 Sep 14;100(11):1250

Wide and narrow complexes in advanced A-V block. Hancock EW. **Hosp Pract (Off Ed)** 1998 Oct 15; 33(10):47–8, 51, 54

Value of programmed ventricular stimulation in patients with congenital heart disease [see comments] Alexander ME, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1033–44 . Comment in: J Cardiovasc Electrophysiol 1999 Aug;10(8):1045–8.

Transvenous cold mapping and cryoablation of the AV node in dogs: observations of chronic lesions and comparison to those obtained using radiofrequency ablation. Rodriguez LM, et al. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1055–61

ECG of the month. Semantics. Wenckebach phenomenon. Martinez-Lopez JI. **J La State Med Soc** 1999 Mar; 151(3):111–3

Fetal complete heart block: an expectant management. Uerpairojkit B, et al. **J Med Assoc Thai** 1998 Dec; 81(12):1003–8

Pharmacological stress testing of the His-Purkinje system in patients with bifascicular block. Englund A, et al. **Pacing Clin Electrophysiol** 1998 Oct;21(10):1979–87 (73 ref.)

Normal sinus rhythm in a patient with corrected transposition of great arteries after 30 years of complete heart block. Ngarmukos T, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1116–7

[A new diagnostic concept in cardiac pacing for the evaluation of the incidence of atrial arrhythmias. Results of the AIDA study] Defaye P, et al. **Arch Mal Coeur Vaiss** 1999 Jun;92(6):719–26 (Eng. Abstr.) **(Fre)**

[Brugada-Brugada syndrome--an ECG diagnosis at a glance!] Cron TA, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1965 **(Ger)**

[Rhythm and conduction disorders in formulating a judgment of work fitness] Picciotto D, et al. **Med Lav** 1998 Sep-Oct; 89(5):387–92 (Eng. Abstr.) **(Ita)**

[Holter electrocardiogram monitoring as an indicator of cardiac involvement of sarcoidosis] Kashiwabara K, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):45–50 (Eng. Abstr.) **(Jpn)**

[A rare case of pronounced disorders of atrioventricular conduction combined with a permanent form of atrial flutter] Berliner GB, et al. **Klin Med (Mosk)** 1998;76(7):60–1 (4 ref.) **(Rus)**

DRUG THERAPY

Effect of aminophylline in patients with atropine-resistant late advanced atrioventricular block during acute inferior myocardial infarction. Altun A, et al. **Clin Cardiol** 1998 Oct;21(10):759–62

In utero treatment of fetal complete heart block with terbutaline. A case report. Chan AY, et al. **J Reprod Med** 1999 Apr;44(4):385–7

Treatment of advanced atrioventricular block with beta-adrenergic blockade therapy. Abe H, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1097–9

The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Brady WJ, et al. **Resuscitation** 1999 Jun;41(1):47–55

EPIDEMIOLOGY

The prevalence and prognosis of third-degree atrioventricular conduction block: the Reykjavik study. Kojic EM, et al. **J Intern Med** 1999 Jul;246(1):81–6

The increasing incidence of isolated congenital heart block in Finland [letter] Sirén MK, et al. **J Rheumatol** 1998 Sep; 25(9):1862–4

Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651–63 (74 ref.)

ETIOLOGY

Creating yourself a disease. Portegies M, et al. **Acta Cardiol** 1998;53(6):365–6

Complete atrioventricular block and cardiac arrest following intravenous famotidine administration. Schoenwald PK, et al. **Anesthesiology** 1999 Feb;90(2):623–6

Mobitz type II AV block during spinal anesthesia. Shen CL, et al. **Anesthesiology** 1999 May;90(5):1477–8

Thyroid storm presenting as jaundice and complete heart block. Ho SC, et al. **Ann Acad Med Singapore** 1998 Sep; 27(5):748–51

Complete heart block caused by primary Sjögren's syndrome and hypopituitarism [letter] Baumgart DC, et al. **Ann Rheum Dis** 1998 Oct;57(10):635

Complete atrioventricular block during anesthesia. Mamiya K, et al. **Can J Anaesth** 1999 Mar;46(3):265–7

Complete heart block and polymorphic ventricular

tachycardia complicating myocardial infarction after occlusion of the first septal perforator with coronary stenting. Furgerson JL, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):434–7

Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Anselme F, et al. **Circulation** 1999 Feb 2;99(4):534–40

Mycoplasma pneumoniae and second-degree heart block. Chergui K, et al. **Clin Infect Dis** 1998 Dec;27(6):1534–5

Atrioventricular block occurring several months after radiofrequency ablation for the treatment of atrioventricular nodal re-entrant tachycardia. Elhag O, et al. **Heart** 1998 Jun;79(6):616–8

Importance and implications of the occurrence of AV block following radiofrequency ablation [editorial] Gaita F, et al. **Heart** 1998 Jun;79(6):534–5

Junctional ectopic tachycardia evolving into complete heart block. Henneveld H, et al. **Heart** 1998 Dec;80(6):627–8

Interventricular septal expansion of a sinus of Valsalva aneurysm: a rare cause of complete heart block. Walters MI, et al. **Heart** 1998 Aug;80(2):202–3

Second degree atrio-ventricular block and cardiotoxicity secondary to envenomation by the scorpion Leiurus quinquestriatus ('yellow scorpion')--an indication for serotherapy? Shapira MY, et al. **Hum Exp Toxicol** 1998 Oct;17(10):541–3

Catheter-induced mechanical trauma to accessory pathways during radiofrequency ablation: incidence, predictors and clinical implications. Belhassen B, et al. **J Am Coll Cardiol** 1999 Mar;33(3):767–74

Two-to-one AV block associated with the congenital long QT syndrome. Pruvot E, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):108–13

Transient complete atrioventricular block provoked by ventricular pacing in a patient with nonsustained ventricular tachycardia. Sasano T, et al. **J Electrocardiol** 1999 Apr;32(2):185–90

Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. Kaplan BM, et al. **J Interv Card Electrophysiol** 1997 Nov;1(3):175–88 (88 ref.)

Transient complete atrioventricular block following radiofrequency ablation of left free wall accessory pathway. Singh B, et al. **J Interv Card Electrophysiol** 1998 Sep; 2(3):305–7

Atrioventricular nodal reentrant tachycardia with atrioventricular block. Vora AM, et al. **J Interv Card Electrophysiol** 1997 Dec;1(4):287–9

Interference with an implantable defibrillator by an electronic antitheft-surveillance device [see comments] Santucci PA, et al. **N Engl J Med** 1998 Nov 5;339(19):1371–4. Comment in: N Engl J Med 1999 Apr 8;340(14):1117; discussion 1118–9. Comment in: N Engl J Med 1999 Apr 8;340(14):1117–8.

Advanced atrioventricular block in a 39-year-old man with acute rheumatic fever. Barold SS, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2025–8

Immediate and persistent complete heart block following a horse kick. Benitez RM, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):816–8

Sudden Wenckebach periods and their relationship to neurocardiogenic syncope. Castellanos A, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1580–8

A newborn with a complex congenital heart disease, atrioventricular block, and torsade de pointes ventricular tachycardia. Kantoch MJ, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2664–7

Cough-induced heart block. Lee D, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1270–1

Late complete atrioventricular block complicating radiofrequency catheter ablation of a left posteroseptal accessory pathway. Liu J, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2136–8

Unexpected complete AV block following transcatheter ablation of a left posteroseptal accessory pathway. Seidl K, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2139–42

Ventriculoatrial block during junctional rhythm in a patient undergoing radiofrequency ablation of the slow pathway. Suguta M, et al. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 1):655–7

Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. Okada T, et al. **Pediatr Int** 1999 Feb;41(1):90–3

Complete heart block complicating alcohol septal ablation for hypertrophic cardiomyopathy [letter; comment] Cheng TO. **Tex Heart Inst J** 1999;26(1):100. Comment on: Tex Heart Inst J 1998;25(4):318–9.

[Complete atrioventricular block during temporal lobe epilepsy. Apropos of a case] Kouakam C, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):265–8 (Eng. Abstr.) **(Fre)**

[What is your diagnosis? Perforation and dislocation of the ventricular electrode] Zuber M, et al. **Schweiz Rundsch Med Prax** 1998 Dec 10;87(50):1729–30 **(Ger)**

[A patient of polymyositis with severe myocardial damage and conduction block] Kuru S, et al. **Rinsho Shinkeigaku** 1999 Feb-Mar;39(2-3):356–9 (Eng. Abstr.) **(Jpn)**

[Prinzmetal's stenocardia complicated by a complete atrioventricular heart block] Kolomiets VI, et al. **Lik Sprava** 1999 Jan-Feb;(1):127–9 **(Rus)**

[Complete transitory atrioventricular block in Lyme disease] Batalla Celorio A, et al. **Rev Esp Cardiol** 1999 Jul; 52(7):529–31 (Eng. Abstr.) **(Spa)**

GENETICS

DNA typing of maternal HLA in congenital complete heart block: comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Colombo G, et al. **Arthritis Rheum** 1999 Aug;42(8):1757–64

Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series. Buckley AE, et al. **Heart** 1999 Jul;82(1):105–8

DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. Berul CI, et al. **J Clin Invest** 1999 Feb;103(4):R1–7

Role of HLA in congenital heart block: susceptibility alleles in mothers. Sirén MK, et al. **Lupus** 1999;8(1):52–9

Role of HLA in congenital heart block: susceptibility alleles in children. Sirén MK, et al. **Lupus** 1999;8(1):60–7

Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Wang J, et al. **Nat Genet** 1999 Jan;21(1):133–7

Variable clinical expression of Holt-Oram syndrome in three generations. Oğur G, et al. **Turk J Pediatr** 1998 Oct-Dec; 40(4):613–8

HISTORY

The Wenckebach phenomenon: a salute and comment on the centennial of its original description. Upshaw CB Jr, et al. **Ann Intern Med** 1999 Jan 5;130(1):58–63

To Wenckebach: a centenary salute [editorial] [see comments] Cooper J, et al. **Tex Heart Inst J** 1999;26(1):8–11. Comment in: Tex Heart Inst J 1999;26(2):159–60.

IMMUNOLOGY

Maternal autoantibodies and congenital heart block: clues from two consecutive pregnancies, one in which there was congenital complete heart block and one in which the fetus was healthy. Horsfall AC, et al. **Arthritis Rheum** 1998 Nov; 41(11):2079–80

Induction of antibodies reactive with SSA/Ro-SSB/La and development of congenital heart block in a murine model. Miranda-Carús ME, et al. **J Immunol** 1998 Dec 1; 161(11):5886–92

Immune-mediated congenital heart block (CHB): identifying and counseling patients at risk for having children with CHB. Julkunen H, et al. **Semin Arthritis Rheum** 1998 Oct; 28(2):97–106

MICROBIOLOGY

Bacillus popilliae endocarditis with prolonged complete heart block. Wu YJ, et al. **Am J Med Sci** 1999 Apr;317(4):263–5

MORTALITY

Relation between mode of pacing and long-term survival in the very elderly. Jahangir A, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1208–16

Enhanced frequency of autoimmune congenital heart block in female offspring [letter] Dörner T, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):380–2

PATHOLOGY

Histologic findings in the conduction system after cardiac transplantation and correlation with electrocardiographic findings. Calzolari V, et al. **Am J Cardiol** 1999 Sep 15; 84(6):756–9, A9

PHYSIOPATHOLOGY

Chronotropic competence of the sinus node in congenital complete heart block. Menon A, et al. **Am J Cardiol** 1998 Nov 1;82(9):1119–21, A9

Intrapartum fetal oxygen saturation monitoring in congenital fetal heart block. Begg L, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):271–4

Irregular rhythm in a man with unstable angina. Hancock EW. **Hosp Pract (Off Ed)** 1999 Jan 15;34(1):21–2

Investigating the dynamics of atrioventricular delay. Seidel H, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec; 17(6):22–5

Sjögren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Borda E, et al. **Int J Cardiol** 1999 Jul 1;70(1):23–32

Ventriculoatrial block during atrioventricular nodal reentrant tachycardia utilizing multiple retrograde pathways. Ino T, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1206–13

Intermittent anterograde conduction in an accessory pathway during atrial pacing: what is the mechanism? Maury P, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1394–6

Effects of blocked atrial beats on the atrioventricular nodal recovery property: facilitation or depression? Wu JM, et al. **J Cardiovasc Electrophysiol** 1998 May;9(5):481–90

Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. Kaplan BM, et al. **J Interv Card Electrophysiol** 1997 Nov;1(3):175–88 (88 ref.)

Quantitative analysis of surface P-wave morphology in isthmus ablation for type 1 atrial flutter: differentiation between complete isthmus block and slow isthmus conduction. Tada H, et al. **Jpn Circ J** 1999 Apr;63(4):244–8

Steady-state and dynamic behavior of ventricular repolarization and refractoriness in the dog: the effect of multiple cycle length changes and d-sotalol administration. Leerssen HM, et al. **Pacing Clin Electrophysiol** 1998 Sep; 21(9):1766–77

Rate dependent effects of procainamide on the threshold current for pacing in the setting of postrepolarization refractoriness in dogs. Leerssen HM, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):291–301

PREVENTION & CONTROL

Management of temporary epicardial ventricular pacing wires [letter] Pacifico AD. **J Card Surg** 1998 May;13(3):228

First-degree atrioventricular block in alprazolam overdose reversed by flumazenil. Mullins ME. **J Pharm Pharmacol** 1999 Mar;51(3):367–70 (17 ref.)

A new therapeutic approach to the fetus with congenital complete heart block: preemptive, targeted therapy with dexamethasone. Rosenthal D, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):689–91

Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Shinohara K, et al. **Obstet Gynecol** 1999 Jun;93(6):952–7

RADIONUCLIDE IMAGING

Imaging of adenosine bolus transit following intravenous administration: insights into antiarrhythmic efficacy. Ng GA, et al. **Heart** 1999 Aug;82(2):163–9

SURGERY

Slow pathway ablation in a patient with common atrioventricular nodal reentrant tachycardia and prolonged baseline PR interval. Saxena A, et al. **Indian Heart J** 1999 Jan-Feb;51(1):83–5

THERAPY

Perioperative transcutaneous pacemaker in patients with chronic bifascicular block or left bundle branch block and additional first-degree atrioventricular block. Gauss A, et al. **Acta Anaesthesiol Scand** 1999 Aug;43(7):731–6

Congenital complete atrioventricular block in an infant with long QT syndrome. Koçak G, et al. **Acta Cardiol** 1998; 53(3):153–5

Comparison of results of early reperfusion in patients with inferior wall acute myocardial infarction with and without complete atrioventricular block. Kimura K, et al. **Am J Cardiol** 1999 Sep 15;84(6):731–3, A8

Successful treatment of a patient with cardiac lymphoma who presented with a complete atrioventricular block. Nagano M, et al. **Am J Hematol** 1998 Oct;59(2):171–4

Third degree atrio-ventricular-block caused by malignant non-Hodgkin's lymphoma: an unusual indication for epicardial pacing. Aleksic I, et al. **Cardiovasc Surg** 1999 Apr;7(3):378–80 (12 ref.)

Images in cardiology. Pacemaker induced torsades de pointes tachycardia. Böhm A, et al. **Heart** 1998 Nov;80(5):466

Predictors of loss of atrioventricular synchrony in single lead VDD pacing. Hunziker P, et al. **Heart** 1998 Oct;80(4):390–2

Value of improved treadmill exercise capacity [letter; comment] Somauroo JD, et al. **Heart** 1999 Apr;81(4):451–2 . Comment on: Heart 1998 Oct;80(4):383–6.

"Value" of improved treadmill exercise capacity: lessons from a study of rate responsive pacing [see comments] Staniforth AD, et al. **Heart** 1998 Oct;80(4):383–6. Comment in: Heart 1999 Apr;81(4):451–2.

Human atrial repolarization: effects of sinus rate, pacing and drugs on the surface electrocardiogram. Debbas NM, et al. **J Am Coll Cardiol** 1999 Feb;33(2):358–65

Influence of right ventricular stimulation site on left ventricular function in atrial synchronous ventricular pacing [see comments] Schwaab B, et al. **J Am Coll Cardiol** 1999 Feb;33(2):317–23. Comment in: J Am Coll Cardiol 1999 Feb;33(2):324–6.

The current status of single lead dual chamber sensing and pacing. Tse HF, et al. **J Interv Card Electrophysiol** 1998 Sep;2(3):255–67 (55 ref.)

Polarization potentials causing pacemaker oversensing. Okreglicki A, et al. **Jpn Circ J** 1998 Nov;62(11):868–70

Radiographic assessment of atrial dipole position in single pass lead VDD and DDD pacing. The Multicenter Study Group. Bongiorni MG, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2240–5

Experience with a low profile bipolar, active fixation pacing lead in pediatric patients. Campbell RM, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1152–7

Long-term survival of VDD pacing. Chamberlain-Webber R, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2246–8

Absence of the superior vena cava: difficulties for pacemaker implantation. del Ojo JL, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1103–5

Optimizing the hemodynamic performance of the DDD pacemaker: impact of the atrioventricular delay on the pulmonary venous flow pattern. Douchet MP, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2261–8

Dual chamber pacing with a single-lead DDD pacing system. Naegeli B, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1013–9

First experience with an automatic sensing algorithm in single-lead VDD stimulation. Nowak B, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2232-5
Is atrial sensing of ventricular far-field signals important in single-lead VDD pacing? Nowak B, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2236-9
How reliable is atrial sensing in single-lead VDD pacing: comparison of three systems. Nowak B, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2226-31
Pacemaker therapy in premature children with high degree AV block. Nowak B, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2695-8
Paroxysmal atrial fibrillation and high degree AV block: use of single-lead VDDR pacing with mode switching. Nowak B, et al. **Pacing Clin Electrophysiol** 1998 Oct;21(10):1927-33
Quality of life in patients with complete heart block and paroxysmal atrial tachyarrhythmias: a comparison of permanent DDIR versus DDDR pacing with mode switch to DDIR. Provenier F, et al. **Pacing Clin Electrophysiol** 1999 Mar;22(3):462-8
Diagnosis of atrial undersensing in dual chamber pacemakers: impact of autodiagnostic features. Wiegand UK, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):894-902
Pacemaker therapy in a pediatric patient with hypertrophic obstructive cardiomyopathy and rapid intrinsic atrioventricular conduction. Mann C, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):229-31
Noninvasive external pacing in the newborn. Rein AJ, et al. **Pediatr Cardiol** 1999 Jul-Aug;20(4):290-2
[Syncope in a pacemaker patient. Regular pacemaker follow-up is essential] Stiefelhagen P. **Fortschr Med** 1998 Aug 20;116(22-23):33 **(Ger)**
[Value of spiro-ergometry and stress echocardiography on optimized programming of the upper frequency limit of dual chamber cardiac pacemakers] Krüger S, et al. **Z Kardiol** 1998 Oct;87(10):817-25 (Eng. Abstr.) **(Ger)**
[Anti-bradycardia ventricle stimulation during the vulnerable phase of the heart cycle in ICD system with DDD cardiac pacemaker function] Schibgilla V, et al. **Z Kardiol** 1998 Aug;87(8):640-3 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Perinatal monitoring of fetal well-being in the presence of congenital heart block. Friedman DM, et al. **Am J Perinatol** 1998;15(12):669-73
Role of fetal echocardiography in the management of isolated fetal heart block with ventricular rate <55 bpm. Singh GK, et al. **Am J Perinatol** 1998;15(12):661-8
TEE evidence of right atrial tachycardia with mechanical alternans, interatrial and atrioventricular 2:1 block. Oneglia C, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):829-30

VETERINARY

Intermittent heart block in a lethargic dog. Swinney GR, et al. **Aust Vet J** 1998 Oct;76(10):663, 667-8
ECG of the month. Atrioventricular block in a Muscovy duck [published erratum appears in J Am Vet Med Assoc 1999 Mar 1;214(5):665] Kushner LI. **J Am Vet Med Assoc** 1999 Jan 1;214(1):33-6

VIROLOGY

[Syncope in 3rd degree atrioventricular block. Detection of virus genome in the myocardium] Pauschinger M, et al. **Dtsch Med Wochenschr** 1998 Nov 27;123(48):1443-6 (Eng. Abstr.) **(Ger)**

HEART BYPASS, LEFT

Influence of the use of a bypass on the results of thoracoabdominal aortic aneurysm surgery. Schepens M, et al. **Acta Chir Belg** 1998 Oct;98(5):207-11
Left heart bypass reduces paraplegia rates after thoracoabdominal aortic aneurysm repair. Coselli JS, et al. **Ann Thorac Surg** 1999 Jun;67(6):1931-4; discussion 1953-8
Impact of left heart bypass on the results of thoracoabdominal aortic aneurysm repair. Schepens MA, et al. **Ann Thorac Surg** 1999 Jun;67(6):1963-7; discussion 1979-80
Effect of a balanced biventricular bypass system on left ventricular energies. Kodera K, et al. **Artif Organs** 1998 Sep;22(9):803-7
Diminished vasoconstrictive function caused by long-term nonpulsatile left heart bypass. Nishimura T, et al. **Artif Organs** 1999 Aug;23(8):722-6
Cardiac autonomic nervous function during long-term nonpulsatile left heart bypass. Nishinaka T, et al. **Artif Organs** 1999 Jun;23(6):500-3
Afferent and efferent nerve activity of arterial baroreceptor reflex under nonpulsatile systemic circulation. Shomura Y, et al. **Artif Organs** 1999 Jun;23(6):513-7
Arterial baroreceptor afferent activity in nonpulsatile systemic circulation. Shomura Y, et al. **Artif Organs** 1998 Dec;22(12):1056-63
Peripheral vascular resistances during total left heart bypass with an oscillated blood flow. Yambe T, et al. **Artif Organs** 1999 Aug;23(8):747-50
Prolonged nonpulsatile left heart bypass diminishes vascular contractility. Nishimura T, et al. **Int J Artif Organs** 1999 Jul;22(7):492-8
Exposure of circumflex branches in the tilted, beating porcine heart: echocardiographic evidence of right ventricular deformation and the effect of right or left heart bypass. Gründeman PF, et al. **J Thorac Cardiovasc Surg** 1999 Aug; 118(2):316-23

ADVERSE EFFECTS

An unusual cause of hypoxemia during aortic reconstruction. Isaac JL, et al. **J Cardiothorac Vasc Anesth** 1998 Oct; 12(5):563-4

INSTRUMENTATION

Detection of suction and regurgitation of the implantable centrifugal pump based on the motor current waveform analysis and its application to optimization of pump flow. Yuhki A, et al. **Artif Organs** 1999 Jun;23(6):532-7
Left heart bypass in the pig with a centrifugal pump using cannulae prepared for percutaneous placement. Walpoth BH, et al. **Int J Artif Organs** 1998 May;21(5):285-90
Surgical results for thoraco-abdominal aneurysm by modified DeBakey method using centrifugal biopump and renal cryopreservation. Yamashita C, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):399-404

METHODS

Percutaneous introduction of left atrial cannula for left heart bypass: utility of biplane transesophageal echocardiographic guidance for transseptal puncture. Kyo S, et al. **Artif Organs** 1992 Aug;16(4):386-91
Interventions for left main coronary artery disease: indications, technique and results. Park SJ. **Indian Heart J** 1998 Oct;50 Suppl 1:74-8 (30 ref.)
Severe pulmonary contusion with traumatic ventricular septal defect rescued using percutaneous cardiopulmonary support. Hirose Y, et al. **J Trauma** 1999 Mar;46(3):515-8
Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Kawada T, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Mar;47(3):104-9

HEART BYPASS, RIGHT

The effect of a right-to-left intracardiac shunt on the rate of rise of arterial and end-tidal halothane in children. Huntington JH, et al. **Anesth Analg** 1999 Apr;88(4):759-62
Effect of a balanced biventricular bypass system on left ventricular energies. Kodera K, et al. **Artif Organs** 1998 Sep;22(9):803-7
Possible sources of right-to-left shunting in patients following a total cavopulmonary connection. Buheitel G, et al. **Cardiol Young** 1998 Jul;8(3):358-63
Hyperventilation impairs oxygenation after bidirectional superior cavopulmonary connection. Bradley SM, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II372-6; discussion II376-7
Successful heart transplantation in a patient with Ivemark syndrome combined with situs inversus, single atrium and ventricle after total cavo-pulmonary connection. Berdat PA, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):631-4
Results after Norwood procedure and subsequent cavopulmonary anastomoses for typical hypoplastic left heart syndrome and similar complex cardiovascular malformations. Breymann T, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):117-24
Bi-directional cavopulmonary shunt: is accessory pulsatile flow, good or bad? van de Wal HJ, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):104-10
Pulmonary and caval flow dynamics after total cavopulmonary connection. Houlind K, et al. **Heart** 1999 Jan;81(1):67-72
Instantaneous pressure-flow velocity relations of systemic venous return in patients with univentricular circulation. Kaulitz R, et al. **Heart** 1999 Sep;82(3):294-9
Changes in pulmonary artery size before and after total cavopulmonary connection [letter; comment] Slavik Z, et al. **Heart** 1998 Aug;80(2):208-9. Comment on: Heart 1997 Nov;78(5):488-92.
Computational fluid dynamic and magnetic resonance analyses of flow distribution between the lungs after total cavopulmonary connection. Migliavacca F, et al. **IEEE Trans Biomed Eng** 1999 Apr;46(4):393-9
Bubble contrast echocardiography in detecting pulmonary arteriovenous shunting in children with univentricular heart after cavopulmonary anastomosis. Chang RK, et al. **J Am Coll Cardiol** 1999 Jun;33(7):2052-8
Determinants of Doppler pulmonary flow components [letter; comment] Teien DE. **J Am Coll Cardiol** 1998 Dec; 32(7):2103. Comment on: J Am Coll Cardiol 1997 Nov 15;30(6):1562-74.
Exposure of circumflex branches in the tilted, beating porcine heart: echocardiographic evidence of right ventricular deformation and the effect of right or left heart bypass. Gründeman PF, et al. **J Thorac Cardiovasc Surg** 1999 Aug; 118(2):316-23
Extracardiac cavopulmonary connection of fontan procedure with autologous pedicled pericardium without cardiopulmonary bypass [see comments] Okabe H, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1073-5. Comment in: J Thorac Cardiovasc Surg 1999 May;117(5):1046-7.
Effects of arteriovenous shunt on ventricular function in dog. Omoto T, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Mar; 47(3):116-20
Branch pulmonary artery growth after blalock-taussig shunts in tetralogy of fallot and pulmonary atresia with ventricular septal defect: a retrospective, echocardiographic study. Sabri MR, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):358-63
Conversion of right atrioventricular to total cavopulmonary anastomosis in the management of post-Fontan arrhythmia: report of a case. Yoshimura N, et al. **Surg Today** 1999; 29(3):284-7
The influence of different strategies on clinical outcome in patients undergoing total cavopulmonary connection. Knez I, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):101-5
[The role of bidirectional cavopulmonary shunt on selection of Fontan patients] Cho Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1317-23 (Eng. Abstr.) **(Jpn)**

HISTORY

Early Italian contributions to cavopulmonary shunt surgery. Karl TR, et al. **Ann Thorac Surg** 1999 Apr;67(4):1175
Cavo-pulmonary shunt: from the first experiments to clinical practice. Konstantinov IE, et al. **Ann Thorac Surg** 1999 Sep;68(3):1100-6

METHODS

Addition of a small curvature reduces power losses across total cavopulmonary connections. Gerdes A, et al. **Ann Thorac Surg** 1999 Jun;67(6):1760-4
Novel techniques of bidirectional Glenn shunt without cardiopulmonary bypass. Murthy KS, et al. **Ann Thorac Surg** 1999 Jun;67(6):1771-4
Bidirectional cavopulmonary anastomosis [editorial; comment] Karl TR. **Cardiol Young** 1999 Jan;9(1):2-3 (4 ref.). Comment on: Cardiol Young 1999 Jan;9(1):6-10.
New approach in partial cavopulmonary connection. Paulista PP, et al. **Cardiol Young** 1998 Jul;8(3):364-7
The real fate of pulmonary arteries after bidirectional superior cavopulmonary anastomosis: is there a need for concern? [see comments] Slavik Z, et al. **Cardiol Young** 1999 Jan;9(1):6-10 (28 ref.). Comment in: Cardiol Young 1999 Jan;9(1):2-3.
The right auricle tunnel as intercaval tunnel in total cavopulmonary connection may prevent atrial flutter. Waterbolk TW, et al. **Eur J Cardiothorac Surg** 1998 Dec; 14(6):590-5
Regarding "Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option" [letter] Nghiem DD. **J Vasc Surg** 1999 Sep;30(3):582-4
[A successful conversion of failed fontan circulation to total cavopulmonary connection in a case of tricuspid atresia without pulmonary stenosis] Kimura K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1147-51 (Eng. Abstr.) **(Jpn)**
[Total cavopulmonary connection for grown diminutive pulmonary artery after staged Blalock-Taussig shunt] Uchita S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov; 46(11):1194-9 (Eng. Abstr.) **(Jpn)**
[Concomitant mitral valvuloplasty and fenestrated total cavopulmonary connection: a case report] Yoshimura N, et al. **Kyobu Geka** 1999 Feb;52(2):139-42 (Eng. Abstr.) **(Jpn)**
[Evaluation of the complications of different types of right ventricular bypass by contrast echocardiography] Kreutzer EA, et al. **Arch Inst Cardiol Mex** 1999 Jan-Feb;69(1):40-6 (Eng. Abstr.) **(Spa)**

MORTALITY

Equivalent survival following cavopulmonary shunt: with or without the Fontan procedure. Yeh T Jr, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):111-6

HEART CATHETERIZATION

see related
PULMONARY WEDGE PRESSURE

Progression of renal artery stenosis in patients undergoing cardiac catheterization. Crowley JJ, et al. **Am Heart J** 1998 Nov;136(5):913-8
Nothin' but 'net? [editorial; comment] Garratt KN. **Am Heart J** 1999 Feb;137(2):187-9. Comment on: Am Heart J 1999 Feb;137(2):241-9.
Transcatheter device closure of ventricular septal defects: immediate results and intermediate-term follow-up. Kalra GS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):339-44
Implementation of a computerized cardiovascular information system in a private hospital setting [see comments] Taylor GS, et al. **Am Heart J** 1998 Nov; 136(5):792-803. Comment in: Am Heart J 1998 Nov;136(5):751-2.
Video networking of cardiac catheterization laboratories [see comments] Tobis J, et al. **Am Heart J** 1999 Feb; 137(2):241-9. Comment in: Am Heart J 1999 Feb;137(2):187-9.
Preoperative management of pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial septal defect. Atz AM, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1224-8
Fontan fenestration closure in the catheterization laboratory--echocardiographic evaluation of residual right to left shunts. Gomez C, et al. **Am J Cardiol** 1998 Nov 15;82(10):1304-6, A10-1

Insights into catheter/Doppler discrepancies in congenital aortic stenosis. Lemler MS, et al. **Am J Cardiol** 1999 May 15;83(10):1447–50

Angiographic findings in patients undergoing catheterization for recurrent symptoms within 30 days of successful coronary intervention. McPherson JA, et al. **Am J Cardiol** 1999 Sep 1;84(5):589–92, A8

Telephone reporting of the results of cardiac procedures: feasibility and primary care physician preferences. Blankenship JC, et al. **Am J Med** 1999 May;106(5):521–6

Right heart catheterization in acute lung injury: an observational study. Marinelli WA, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):69–76

Pediatric open heart operations without diagnostic cardiac catheterization. Pfammatter JP, et al. **Ann Thorac Surg** 1999 Aug;68(2):532–6

Transcatheter closure of a patent foramen ovale following mitral valve replacement. Skulski R, et al. **Ann Thorac Surg** 1999 Aug;68(2):582–3

Nonsurgical infarctectomy in acute experimental myocardial infarction. Stamatelopoulos SF, et al. **Artif Organs** 1998 Nov;22(11):993–7

The effect of early ambulation on hematoma formation and vascular complications following 7 French diagnostic cardiac catheterization. Singh N, et al. **Can J Cardiol** 1998 Oct;14(10):1223–7

Transcatheter closure of atrial septal defects within the oval fossa: medium-term results in children using the 'ASDOS'-technique. Hausdorf G, et al. **Cardiol Young** 1998 Oct;8(4):462–71

Acute coronary occlusion likely due to thrombus occurring during coronary angiography [letter] Dalby M. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):459–60

Problems with CD-ROM as a long-term archive medium in cardiac catheterizations [letter] Haude M, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):348–9

Catheter therapy for fontan baffle obstruction and leak, using an endovascular covered stent. Hijazi ZM, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):158–61

Interventional catheterization decreases plasma levels of atrial natriuretic peptide (ANP) in children with congenital heart defects. Zeevi B, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):27–32

Post-infarction ventricular septal defect: percutaneous transvenous temporary closure using a Swan-Ganz catheter. Abhyankar AD, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):208–10

Cine PACS: preprint. Balter S. **Catheter Cardiovasc Interv** 1999 May;47(1):85–90

Radiation safety in the cardiac catheterization laboratory: operational radiation safety. Balter S. **Catheter Cardiovasc Interv** 1999 Jul;47(3):347–53

Radiation risks to the patients and interventionalists: risk reduction [editorial; comment] Behrman RB, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):455–6. Comment on: Catheter Cardiovasc Interv 1999 Aug;47(4):449–54.

A prospective randomized trial of early ambulation following 8 French diagnostic cardiac catheterization [see comments] Bogart MA, et al. **Catheter Cardiovasc Interv** 1999 Jun; 47(2):175–8. Comment in: Catheter Cardiovasc Interv 1999 Jun;47(2):179–80.

Stents and Amplatzers: what's an interventionalist to do? [editorial; comment] Cheatham JP. **Catheter Cardiovasc Interv** 1999 May;47(1):39–40. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):36–8.

Lessons learned from the review of cardiac catheterization laboratories: a report from the Laboratory Survey Committee of the Society for Cardiac Angiography and Interventions. Dehmer GJ, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):24–31

Utility of cardiac catheterization in pediatric cardiac patients on ECMO. desJardins SE, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):62–7

Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Faber L, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):462–6

Simultaneous stent implantation for coarctation of the aorta and closure of patent ductus arteriosus using the Amplatzer duct occluder [see comments] Hakim F, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):36–8. Comment in: Catheter Cardiovasc Interv 1999 May;47(1):39–40.

Transcatheter closure of ventricular septal defects: are we there yet? [editorial; comment] Hijazi ZM. **Catheter Cardiovasc Interv** 1999 Jan;46(1):49–50. Comment on: Catheter Cardiovasc Interv 1999 Jan;46(1):43–8.

Transcatheter closure of ventricular septal defects using the Rashkind device: initial experience [see comments] Janorkar S, et al. **Catheter Cardiovasc Interv** 1999 Jan; 46(1):43–8. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):49–50.

"So how do you want to do this one?" [editorial; comment] Smith KM, et al. **Catheter Cardiovasc Interv** 1999 Jun; 47(2):179–80. Comment on: Catheter Cardiovasc Interv 1999 Jun;47(2):175–8.

Is transseptal left heart catheterization for bioprosthetic mitral valve evaluation really necessary? [letter] Zimarino M, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):112–3

Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Brookes CI, et al. **Circulation** 1998 Oct 27;98(17):1762–8

Recent advances in interventional pediatric cardiovascular disease. Maheshwari S, et al. **Curr Opin Pediatr** 1998 Oct; 10(5):532–7 (41 ref.)

Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder. Fischer G, et al. **Eur Heart J** 1999 Apr;20(7):541–9

Coronary pressure measurement and fractional flow reserve. Pijls NH, et al. **Heart** 1998 Dec;80(6):539–42 (19 ref.)

Cardiovascular Interventions, Coronary and Peripheral. Transcatheter Cardiovascular Therapeutics 10th annual symposium. Washington, D.C., USA. October 7–11, 1998. Proceedings. **Indian Heart J** 1998 Oct;50 Suppl 1:1–160

Percutaneous retrieval of a broken catheter fragment from the left common carotid artery. Calton R, et al. **Indian Heart J** 1999 Mar–Apr;51(2):212–4

Transcatheter closure of secundum atrial septal defect with atrial septal defect occlusion system (ASDOS): initial experience and short-term follow-up. Kalra GS, et al. **Indian Heart J** 1998 Jul–Aug;50(4):409–13

The status of the GE approach to the digital catheterization laboratory. Herro PJ. **Int J Card Imaging** 1998 Oct; 14(5):329–33 (0 ref.)

The Camtronics experience with the filmless digital catheterization laboratory. Kapp MA, et al. **Int J Card Imaging** 1998 Oct;14(5):343–8 (3 ref.)

The Kodak approach to digital cardiovascular imaging laboratories. Pelanek GA. **Int J Card Imaging** 1998 Oct; 14(5):335–42 (2 ref.)

Integrated image storage solution for the Cath department. Weterings RA. **Int J Card Imaging** 1998 Oct;14(5):349–56 (8 ref.)

Clinical value of parameters derived by the application of the proximal isovelocity surface area method in the assessment of mitral regurgitation. Miró Palau V, et al. **Int J Cardiol** 1999 Feb 28;68(2):209–16

Catheterization after myocardial infarction and the mismeasure of un-American inactivity [editorial; comment] Alter DA, et al. **J Am Coll Cardiol** 1999 Jul;34(1):23–4. Comment on: J Am Coll Cardiol 1999 Jul;34(1):12–9.

Comparing the U.S. and Canadian approaches to coronary angiography: what have we learned? [editorial; comment] Ayanian JZ, et al. **J Am Coll Cardiol** 1999 Jul;34(1):20–2 . Comment on: J Am Coll Cardiol 1999 Jul;34(1):12–9.

A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications [see comments] Batchelor WB, et al. **J Am Coll Cardiol** 1999 Jul;34(1):12–9. Comment in: J Am Coll Cardiol 1999 Jul;34(1):20–2. Comment in: J Am Coll Cardiol 1999 Jul;34(1):23–4.

Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. Boriani G, et al. **J Am Coll Cardiol** 1999 Feb;33(2):333–41

Aortic debris and coronary guiding catheters [letter; comment] Krainin FM. **J Am Coll Cardiol** 1999 Jul; 34(1):312. Comment on: J Am Coll Cardiol 1998 Dec;32(7):1861–5.

Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: initial clinical applications in children. Thanopoulos BD, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1395–9

Simultaneous Doppler and catheter transvalvular pressure gradients across St Jude bileaflet mitral valve prosthesis: in vivo study in a chronic animal model with pediatric valve sizes. Solowiejczyk DE, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1145–54

Intracardiac echocardiography to guide transseptal left heart catheterization for radiofrequency catheter ablation. Daoud EG, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):358–63

Nonfluoroscopic endocardial catheter mapping of atrial fibrillation. Kuck KH, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S57–62

Relationship between position of the coronary sinus catheter and distribution of cardioplegia. Tosson R, et al. **J Heart Valve Dis** 1999 Mar;8(2):120–3

Prospective randomized trial of external versus internal transcatheter cardioversion in patients with chronic atrial fibrillation. Paravolidakis KE, et al. **J Interv Card Electrophysiol** 1998 Sep;2(3):249–53

Cardiovascular catheters and accessories: ex vivo testing of ferromagnetism, heating, and artifacts associated with MRI. Shellock FG, et al. **J Magn Reson Imaging** 1998 Nov–Dec; 8(6):1338–42

Transcatheter laser-assisted balloon valvulotomy as primary treatment in newborn with pulmonary atresia and intact ventricular septum. Laohaprasitiporn D, et al. **J Med Assoc Thai** 1998 Dec;81(12):1009–14

Transcatheter occlusion of atrial septal defects: an initial experience with the Amplatzer septal occluder. Chan KY, et al. **J Paediatr Child Health** 1998 Aug;34(4):369–73

A simplified, practical approach to assessment of severity of mitral regurgitation by Doppler color flow imaging with proximal convergence: validation with concomitant cardiac catheterization. Chaliki HP, et al. **Mayo Clin Proc** 1998 Oct;73(10):929–35

Neonatal cardiac surgery. Cardarelli MG, et al. **Md Med J** 1998 Nov;47(5):230–4 (3 ref.)

Clinical findings in patients submitted to cardiac catheterization and coronary angiography at the Cardiovascular Center of Puerto Rico and the Caribbean: a pilot study. Pérez-Cardona CM, et al. **P R Health Sci J** 1998 Jun;17(2):117–22

Low energy intracardiac cardioversion of persistent atrial fibrillation. Santini M, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2641–50

Transcatheter closure of atrial septal defect guided by on-line transesophageal echocardiography. Chiang CW, et al. **Proc Natl Sci Counc Repub China B** 1998 Oct;22(4):144–9

Effects of radiographic contrast agents on thrombin formation and activity. Fay WP, et al. **Thromb Haemost** 1998 Aug;80(2):266–72

[A dramatic selective intubation (letter)] Bazin JE, et al. **Ann Fr Anesth Reanim** 1997;16(7):925–6 **(Fre)**

[Digital archiving of imaged heart catheter studies on CD-R. Detection of irreversible CD damage] Erbel R, et al. **Herz** 1998 Dec;23(8):526–9 (Eng. Abstr.) **(Ger)**

[Transcatheter closure of atrial septal defect] Zeevi B, et al. **Harefuah** 1998 Oct;135(7–8):271–5, 335 (Eng. Abstr.) **(Heb)**

[Transcatheter closure of atrial septal defects: initial clinical applications] Zimand S, et al. **Harefuah** 1998 Oct; 135(7–8):276–9, 335 (Eng. Abstr.) **(Heb)**

[Diagnostic catheterization and angiography in the examination of patients with ischemic heart disease] Baklanov DV, et al. **Vestn Rentgenol Radiol** 1998 Jul–Aug; (4):23–7 **(Rus)**

[Registry of activities of the Section of Hemodynamics and Interventional Cardiology in 1997] Soriano J, et al. **Rev Esp Cardiol** 1998 Dec;51(12):927–38 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Brachial plexus injury during cardiac catheterisation in children [letter; comment] Hansen TG, et al. **Acta Anaesthesiol Scand** 1999 Mar;43(3):364–5. Comment on: Acta Anaesthesiol Scand 1998 Aug;42(7):876–9.

Cerebral microemboli during left heart catheterization. Fischer A, et al. **Am Heart J** 1999 Jan;137(1):162–8

Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction. Brodie BR, et al. **Am J Cardiol** 1999 Jul 1;84(1):18–23

Thrombus formation after transcatheter closure of atrial septal defect. La Rosée K, et al. **Am J Cardiol** 1999 Aug 1;84(3):356–9, A9

Ultrasonic assessment of vascular complications in coronary angiography and angioplasty after transradial approach. Nagai S, et al. **Am J Cardiol** 1999 Jan 15;83(2):180–6

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Common bile duct necrosis after cardiac catheterization. Char D, et al. **Am J Gastroenterol** 1998 Dec;93(12):2597–8

Pericardial placement of a pulmonary arterial catheter [letter; comment] Browne DA, et al. **Anaesthesia** 1998 Aug; 53(8):825. Comment on: Anaesthesia 1998 Mar;53(3):290–2.

Infective endocarditis on an occluder closing an atrial septal defect. Bullock AM, et al. **Cardiol Young** 1999 Jan;9(1):65–7

Mild or subclinical intravascular haemolysis subsequent to transcatheter occlusion of the patent arterial duct. Jamjureeruk V, et al. **Cardiol Young** 1999 Jan;9(1):58–62

Acute complications in the current era of therapeutic cardiac catheterization for congenital heart disease. Zeevi B, et al. **Cardiol Young** 1999 May;9(3):266–72

Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures [see comments] Waigand J, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):157–64. Comment in: Catheter Cardiovasc Interv 1999 Jun;47(2):165–6.

Arrhythmogenic effect of ventriculography in patients with left ventricular dilation and/or hypertrophy. Serafi AS, et al. **Clin Sci (Colch)** 1998 Oct;95(4):453–8

Chronic radiodermatitis following cardiac catheterisation: a report of two cases and a brief review of the literature. Dehen L, et al. **Heart** 1999 Mar;81(3):308–12 (22 ref.)

Audit of cardiac catheterisation in a district general hospital: implications for training. Smith LD, et al. **Heart** 1999 May; 81(5):461–4

Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases [see comments] Keeley EC, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1861–5 . Comment in: J Am Coll Cardiol 1999 Jul;34(1):312.

Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures. The Mayo Clinic experience. Tsang TS, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1345–50

Complications associated with pediatric cardiac catheterization. Vitiello R, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1433–40

The valve of Vieussens: an important cause of difficulty in advancing catheters into the cardiac veins. Corcoran SJ, et al. **J Cardiovasc Electrophysiol** 1999 Jun;10(6):804–8

Treatment of acute neonatal vascular injuries--the utility of multiple interventions. Friedman J, et al. **J Pediatr Surg** 1999 Jun;34(6):940–5

Gastro-intestinal complications following neonatal cardiac catheterisation. Sweet DG, et al. **J Perinat Med** 1998; 26(3):196–200

Low molecular weight heparins in the cardiac catheterization laboratory. Montalescot G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):319–23 (27 ref.)

Arteriovenous fistulas induced by femoral arterial catheterization: percutaneous treatment. Ruebben A, et al. **Radiology** 1998 Dec;209(3):729–34

Single pulmonary nodule after cardiac catheterization. Jost R, et al. **Respiration** 1998;65(4):309

Retroperitoneal hemorrhage after cardiac catheterization causing a diagnostic dilemma. Goenka P, et al. **Tenn Med** 1998 Dec;91(12):461–2

[Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?] Gironet N, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):598–600 (Eng. Abstr.) **(Fre)**

[Iatrogenic vascular lesions after cardiac catheterization] Manuel-Rimbau E, et al. **Rev Esp Cardiol** 1998 Sep; 51(9):750–5 (Eng. Abstr.) **(Spa)**

ECONOMICS

Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison [see comments] Cooper CJ, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):430–6. Comment in: Am Heart J 1999 Sep;138(3 Pt 1):392–3.

Admission to hospitals with on-site cardiac catheterization facilities :impact on long-term costs and outcomes. Krumholz HM, et al. **Circulation** 1998 Nov 10; 98(19):2010–6

The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. Shaw LJ, et al. **J Am Coll Cardiol** 1999 Mar;33(3):661–9

Low-risk cardiac catheterization in a community hospital. Gruber T, et al. **N J Med** 1999 Sep;96(9):37–40

HISTORY

The Nobel chronicles. 1956: Werner Forssmann (1904–79); André Frédéric Cournand (1895–1988); and Dickinson Woodruff Richards, Jr (1895–1973). Raju TN. **Lancet** 1999 May 29;353(9167):1891

INSTRUMENTATION

Intracardiac Doppler hemodynamics and flow: new vector, phased-array ultrasound-tipped catheter. Bruce CJ, et al. **Am J Cardiol** 1999 May 15;83(10):1509–12, A9

Validation of the conductance catheter method for measurement of ventricular volumes under varying conditions relevant to cardiac surgery. Al-Khalidi AH, et al. **Am J Cardiol** 1998 Nov 15;82(10):1248–52

Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Sievert H, et al. **Am J Cardiol** 1998 Dec 1;82(11):1405–13

Endocardial potential mapping from a noncontact nonexpandable catheter: a feasibility study. Liu ZW, et al. **Ann Biomed Eng** 1998 Nov-Dec;26(6):994–1009

Emergency cannulation for proximal perfusion in descending thoracic aorta procedures. Neri E, et al. **Ann Thorac Surg** 1999 Aug;68(2):587–9

Novel ventricular apical cannula: in vitro evaluation using transparent, compliant ventricular casts. Curtis AS, et al. **ASAIO J** 1998 Sep-Oct;44(5):M691–5

Technology and application of ultraminiature catheter pressure transducers. Zimmer HG, et al. **Can J Cardiol** 1998 Oct;14(10):1259–66 (34 ref.)

Letter to the editor: re Hijazi [letter; comment] Abhaichand RK, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):456. Comment on: Cathet Cardiovasc Diagn 1997 Dec;42(4):388–93.

Another new perforating toy for the pediatric interventionalist treating neonates with pulmonary atresia and intact ventricular septum...as long as you live outside of the United States! [editorial; comment] Cheatham JP. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):43–4. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):37–42.

Successful transcatheter perforation of the atretic pulmonary valve membrane in a newborn using the new Coe radiofrequency end hole catheter. Cheatham JP, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):162–6

Re Antonellis and Patsilinakos. Catheterization of coronary arteries in the presence of tortuous iliac arteries [letter; comment] Hill JA. **Cathet Cardiovasc Diagn** 1998 Sep; 45(1):101. Comment on: Cathet Cardiovasc Diagn 1998 May;44(1):75–6.

Variability of radiation output dynamic range in modern cardiac catheterization imaging systems. Holmes DR, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):443–8

Impact of Doppler guidewire size and flow rates on intravascular velocity profiles. Jenni R, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):96–100

Catheterization of the pulmonary artery using a 3 French catheter in patients with congenital heart disease. Mori Y, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):45–50

Radiofrequency pulmonary valvotomy using a new 2-French catheter [see comments] Park IS, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):37–42. Comment in: Cathet Cardiovasc Diagn 1998 Sep;45(1):43–4.

Influence of the ratio between radial artery inner diameter and sheath outer diameter on radial artery flow after transradial coronary intervention. Saito S, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):173–8

Clinical application of a new rheolytic thrombectomy catheter system for massive pulmonary embolism. Voigtländer T, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):91–6

Mapping of atrial activation with a noncontact, multielectrode catheter in dogs. Kadish A, et al. **Circulation** 1999 Apr 13;99(14):1906–13

Clinical experience with a novel multielectrode basket catheter in right atrial tachycardias. Schmitt C, et al. **Circulation** 1999 May 11;99(18):2414–22

Thermal heterogenecity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter. Stefanadis C, et al. **Circulation** 1999 Apr 20; 99(15):1965–71

An in-vitro evaluation of aortic arch vessel perfusion characteristics comparing single versus multiple stream aortic cannulae. Joubert-Hübner E, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):359–64

Percutaneous retrieval of transsected rotablator coronary guidewire using Amplatz "Goose-Neck snare". Pande AK, et al. **Indian Heart J** 1998 Jul-Aug;50(4):439–42

"Overestimation" of catheter gradients by Doppler ultrasound in patients with aortic stenosis: a predictable manifestation of pressure recovery. Baumgartner H, et al. **J Am Coll Cardiol** 1999 May;33(6):1655–61

The snare-assisted technique for transcatheter coil occlusion of moderate to large patent ductus arteriosus: immediate and intermediate results. Ing FF, et al. **J Am Coll Cardiol** 1999 May;33(6):1710–8

Improved accuracy and precision of thermodilution cardiac output measurement using a dual thermistor catheter system. Lehmann KG, et al. **J Am Coll Cardiol** 1999 Mar; 33(3):883–91

Transcatheter coil occlusion of patent ductus arteriosus. Lertsapcharoen P, et al. **J Med Assoc Thai** 1999 Mar; 82(3):290–6

Failure to attain electrocardiogram-facilitated positioning of right atrial catheters when using the Arrow Antecubital Central Venous Catheterization Kit. Lanier WL. **J Neurosurg Anesthesiol** 1998 Oct;10(4):241–3

Transcatheter occlusion of patent ductus arteriosus with a new detachable coil system (DuctOcclud): a multicenter clinical trial. Oho S, et al. **Jpn Circ J** 1998 Jul;62(7):489–93

Successful prolonged use of an intracardiac catheter for dialysis. Chavanon O, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2015–6

Nonfluoroscopic localization of an amagnetic stimulation catheter by multichannel magnetocardiography. Fenici R, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1210–20

Nonfluoroscopic localization of an amagnetic catheter in a realistic torso phantom by magnetocardiographic and body surface potential mapping. Fenici R, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2485–91

Magnetocardiographic pacemapping for nonfluoroscopic localization of intracardiac electrophysiology catheters. Fenici R, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2492–9

Percutaneous extraction of an abandoned coiled pacing lead. Lickfett L, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1100–2

Feasibility and safety of two French electrode catheters in the performance of electrophysiological studies. Stabile G, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2506–9

Nonfluoroscopic guidance for catheter placement into the coronary sinus under direct vision using a balloon-tipped cardioscope. Yamamoto N, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1724–9

Transcatheter occlusion of residual patent ductus arteriosus after surgical ligation. Podnar T, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):126–30

Transvasal closure of interatrial defects using the Babic double-umbrella occluder system. Pfeiffer D, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):134–40

[Transcatheter occlusion of patent ductus arteriosus] Emmertsen K, et al. **Ugeskr Laeger** 1999 Jun 21; 161(25):3841–4 (Eng. Abstr.) **(Dan)**

[Local vascular complications after heart catheterization] Rüegger S, et al. **Ther Umsch** 1998 Sep;55(9):542–5 (Eng. Abstr.) **(Ger)**

[Risk of invasive diagnosis with retrograde catheterization of the left ventricle in patients with acquired aortic valve stenosis] Bartsch B, et al. **Z Kardiol** 1999 Apr;88(4):255–60 (Eng. Abstr.) **(Ger)**

[Catheter-induced dissection of the right coronary ostium and aortic root] Wagdi P, et al. **Z Kardiol** 1999 Jul; 88(7):526–8 (Eng. Abstr.) **(Ger)**

[The transvenous removal of definitive electrocatheters for stimulation and defibrillation: the indications, methods and results] Bongiorni MG, et al. **Cardiologia** 1998 Oct; 43(10):1105–9 **(Ita)**

[Apropos the reuse of catheters in electrophysiology] Inama G. **G Ital Cardiol** 1999 Mar;29(3):321–2 **(Ita)**

METHODS

Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison [see comments] Cooper CJ, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):430–6. Comment in: Am Heart J 1999 Sep;138(3 Pt 1):392–3.

Two versus six hours of bed rest following left-sided cardiac catheterization and a meta-analysis of early ambulation trials. Logemann T, et al. **Am J Cardiol** 1999 Aug 15; 84(4):486–8, A10

Ultrasonic assessment of vascular complications in coronary angiography and angioplasty after transradial approach. Nagai S, et al. **Am J Cardiol** 1999 Jan 15;83(2):180–6

Combined cardiac catheterization for uncomplicated ischemic heart disease in a Medicare population. Laine C, et al. **Am J Med** 1998 Nov;105(5):373–9

Biventricular cannulation for the Thoratec ventricular assist device. Arabia FA, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2119–20

Percutaneous closure of atrial septal defects. The role of transesophageal echocardiography. Pedra SR, et al. **Arq Bras Cardiol** 1999 Jan;72(1):59–69 **(Eng, Por)**

Percutaneous introduction of left atrial cannula for left heart bypass: utility of biplane transesophageal echocardiographic guidance for transseptal puncture. Kyo S, et al. **Artif Organs** 1992 Aug;16(4):386–91

Pulmonary artery catheterization in anaesthesia and intensive care. Gómez CM, et al. **Br J Anaesth** 1998 Dec; 81(6):945–56 (192 ref.)

Patient radiation doses during cardiac catheterization procedures. Betsou S, et al. **Br J Radiol** 1998 Jun; 71(846):634–9

Repetitive percutaneous transhepatic access for myocardial biopsy in pediatric cardiac transplant recipients. Book WM, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):167–9

Balloon mitral valvuloplasty: double vs single transseptal puncture [letter; comment] Cheng TO. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):471. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):33–6.

Subselective opacification of a left internal mammary artery graft in a tortuous subclavian artery: use of angioplasty technique and a Tracker catheter. Jones JA, et al. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):454–5

New method for placement of intracoronary stents in order to avoid their embolization in the intravascular space. Rokas SG, et al. **Cathet Cardiovasc Diagn** 1998 Oct; 45(2):183–7

Vessel-sparing technique for coil occlusion of the very small patent ductus arteriosus. Berman W Jr, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):338–9

Percutaneous translumbar cardiac catheterization and central venous line insertion: an alternative approach in children with congenital heart disease [see comments] Cheatham JP, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):187–92 . Comment in: Catheter Cardiovasc Interv 1999 Feb;46(2):193.

New approach to the diagnosis of patent ductus arteriosus during catheterization. Erdöl C, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):350–1

Placement of an intracoronary stent via translumbar puncture [see comments] Henry GA, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):340–2. Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):343.

Choice of venous access for cardiac catheterization in patients with congenital heart disease [editorial; comment] Hijazi ZM. **Catheter Cardiovasc Interv** 1999 Feb;46(2):193 . Comment on: Catheter Cardiovasc Interv 1999 Feb;46(2):187–92.

Transhepatic access: coming of age [editorial; comment] Johnston TA, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):46. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):41–5.

Use of vibrational angioplasty for the treatment of chronic total coronary occlusions: preliminary results [see comments] Michalis LK, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):98–104. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):105–6.

Transhepatic therapeutic cardiac catheterization: a new option for the pediatric interventionalist [see comments] Shim D, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):41–5. Comment in: Catheter Cardiovasc Interv 1999 May;47(1):46.

PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Taylor AJ, et al. **Chest** 1998 Dec;114(6):1570–4

Transatrial access to the normal pericardial space: a novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Verrier RL, et al. **Circulation** 1998 Nov 24;98(21):2331–3

LocaLisa: new technique for real-time 3-dimensional localization of regular intracardiac electrodes. Wittkampf FH, et al. **Circulation** 1999 Mar 16;99(10):1312–7

Randomized evaluation of four versus five French catheters for transfemoral coronary angiography. Metz D, et al. **Clin Cardiol** 1999 Jan;22(1):29–32

Hickmans in unusual places. Murphy JM, et al. **Clin Radiol** 1999 Feb;54(2):111–7

Routine left atrial catheterization for the post-operative management of cardiac surgical patients: is the risk justified? Santini F, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):218–21

The era of transcatheter closure of atrial septal defects [editorial] Rigby ML. **Heart** 1999 Mar;81(3):227–8

Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers. Walsh KP, et al. **Heart** 1999 Mar;81(3):257–61

Parallel conductance estimation by hypertonic dilution method with conductance catheter: effects of the bolus concentration and temperature. Herrera MC, et al. **IEEE Trans Biomed Eng** 1999 Jul;46(7):830–7

Transarterial approach of the pulmonary artery in anatomically corrected malposition of the great arteries by manipulating a catheter inverted with balloon floating maneuver. Lee ML, et al. **Int J Cardiol** 1998 Nov 30; 67(1):1–7

Left ventricular apical cannulation for circulatory support. Jett GK. **J Card Surg** 1998 Jan;13(1):51–5

Interventional cardiac catheterization. Pihkala J, et al. **Pediatr Clin North Am** 1999 Apr;46(2):441–64 (181 ref.)

[Utilization of transcutaneous anesthetics during heart catheterization] Paganelli F, et al. **Presse Med** 1998 Oct 10;27(30):1516–8 (Eng. Abstr.) **(Fre)**

[Interventional catheterization in pediatric cardiology] Massin M. **Rev Med Liege** 1999 Jan;54(1):22–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Heart catheterization via the femoral artery with a 4 French and mobilization at 2 hours] Conte L, et al. **G Ital Cardiol** 1999 May;29(5):529–32 (Eng. Abstr.) **(Ita)**

NURSING

An evaluation of an acuity system as it applies to a cardiac catheterization laboratory. Urbanowicz JA. **Comput Nurs** 1999 May–Jun;17(3):129–34

Revisiting the high-tech/high-touch dilemma [editorial] Carroll-Johnson RM. **Oncol Nurs Forum** 1998 Sep; 25(8):1299

PSYCHOLOGY

Revisiting the high-tech/high-touch dilemma [editorial] Carroll-Johnson RM. **Oncol Nurs Forum** 1998 Sep; 25(8):1299

STANDARDS

[Recommendation of the French Cardiology Society concerning diagnostic and interventional electrophysiology, permanent cardiac pacing and implantable automatic defibrillation] **Arch Mal Coeur Vaiss** 1999 Feb;92(2):243–51 **(Fre)**

STATISTICS & NUMERICAL DATA

Interventional cardiology in Europe 1995. Working Group Coronary Circulation of the European Society of Cardiology. Windecker S, et al. **Eur Heart J** 1999 Apr; 20(7):484–95

[Report on the structure and performance statistics of the heart catheterization laboratories in Germany. Results of a survey by the Committee of Clinical Cardiology of the German Society of Cardiology--Heart and Cardiovascular research throughout 1997] Gleichmann U, et al. **Z Kardiol** 1999 Mar;88(3):234–6 **(Ger)**

TRENDS

Toshiba's approach to the digital catheterization laboratory--full-digital system with DVD and network. Fujii S. **Int J Card Imaging** 1998;14 Suppl 1:27–30

Diagnostic and surgical trends, and epidemiology of coarctation of the aorta in a population-based study. Grech V. **Int J Cardiol** 1999 Feb 28;68(2):197–202

Neonatal cardiac catheterization: A 10-year transition from diagnosis to therapy. Shim D, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):131–3

[The current situation in training and education of assistant staff in interventional cardiology] Baberg HT, et al. **Z Kardiol** 1999 Feb;88(2):90–6 (Eng. Abstr.) **(Ger)**

UTILIZATION

Variations in the use of cardiac procedures: what is the explanation? [editorial; comment] Every NR, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):588–9. Comment on: Am Heart J 1999 Apr;137(4 Pt 1):706–13.

Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services [see comments] Gregory PM, et al. **Am Heart J** 1999 Sep; 138(3 Pt 1):507–17. Comment in: Am Heart J 1999 Sep;138(3 Pt 1):396–9.

Variations in the use of cardiac procedures in the Veterans Health Administration [see comments] Mirvis DM, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):706–13. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):588–9.

Racial differences in the use of invasive cardiac procedures: A continuous quality improvement approach [editorial; comment] Sheifer SE, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):396–9. Comment on: Am Heart J 1999 Sep;138(3 Pt 1):507–17.

Impact of an educational program on bilateral heart catheterization practice patterns. Malach M, et al. **Am J Med Qual** 1998 Winter;13(4):213–22

Use of cardiovascular procedures among black persons and white persons: a 7-year nationwide study in patients with renal disease [see comments] Daumit GL, et al. **Ann Intern Med** 1999 Feb 2;130(3):173–82. Comment in: Ann Intern Med 1999 Feb 2;130(3):231–3.

Ethnic differences in use of cardiovascular procedures: new insights and new challenges [editorial; comment] Kravitz RL. **Ann Intern Med** 1999 Feb 2;130(3):231–3. Comment on: Ann Intern Med 1999 Feb 2;130(3):173–82. Comment on: Ann Intern Med 1999 Feb 2;130(3):183–92.

Diagnostic cardiac catheterisation in a hospital without on-site cardiac surgery. Papaconstantinou HD, et al. **Heart** 1999 May;81(5):465–9

Gender and willingness to undergo invasive cardiac procedures. Saha S, et al. **J Gen Intern Med** 1999 Feb; 14(2):122–5

Race, sex, and physicians' referrals for cardiac catheterization [letter; comment] Davidoff F. **N Engl J Med** 1999 Jul 22; 341(4):285–7. Comment on: N Engl J Med 1999 Feb 25;340(8):618–26.

Race, sex, and physicians' referrals for cardiac catheterization [letter; comment] Helft G, et al. **N Engl J Med** 1999 Jul 22;341(4):285; discussion 286–7. Comment on: N Engl J Med 1999 Feb 25;340(8):618–26.

The effect of race and sex on physicians' recommendations for cardiac catheterization [see comments] [published erratum appears in N Engl J Med 1999 Apr 8;340(14):1130] Schulman KA, et al. **N Engl J Med** 1999 Feb 25; 340(8):618–26. Comment in: N Engl J Med 1999 Jul 22;341(4):279–83; discussion 286–7. Comment in: N Engl J Med 1999 Jul 22;341(4):285; discussion 286–7. Comment in: N Engl J Med 1999 Jul 22;341(4):285–7.

Misunderstandings about the effects of race and sex on physicians' referrals for cardiac catheterization [comment] Schwartz LM, et al. **N Engl J Med** 1999 Jul 22; 341(4):279–83; discussion 286–7. Comment on: N Engl J Med 1999 Feb 25;340(8):618–26.

Low-risk cardiac catheterization in a community hospital. Gruber T, et al. **N J Med** 1999 Sep;96(9):37–40

VETERINARY

[Percutaneous pericardiotomy with balloon catheter in the treatment of malignant pericardial effusion in dogs] Bussadori C, et al. **Radiol Med (Torino)** 1998 Nov; 96(5):503–6 (Eng. Abstr.) **(Ita)**

HEART CONDUCTION SYSTEM

see related

ARRHYTHMIA

QT dispersion in exercise-induced myocardial hypertrophy. Halle M, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):309–12

T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias. Armoundas AA, et al. **Am J Cardiol** 1998 Nov 1;82(9):1127–9, A9

Effects of revascularization after first acute myocardial infarction on the evolution of QRS complex changes (the DANAMI trial). DANish Trial in Acute Myocardial Infarction. Lyck F, et al. **Am J Cardiol** 1999 Feb 15; 83(4):488–92

Relation between negative U waves in precordial leads on the admission electrocardiogram and time course of left ventricular wall motion in anterior wall acute myocardial infarction. Tamura A, et al. **Am J Cardiol** 1999 Aug 1; 84(3):332–4, A8

Identification of P waves after the Cox-maze procedure: significance of right precordial leads V3R through V6R. Pasic M, et al. **Ann Thorac Surg** 1999 May;67(5):1292–4

Electrical conduction between the right atrium and the left atrium via the musculature of the coronary sinus. Antz M, et al. **Circulation** 1998 Oct 27;98(17):1790–5

Characterization of atrioventricular nodal reentry with continuous atrioventricular node conduction curve by double atrial extrastimulation. Kuo CT, et al. **Circulation** 1999 Feb 9;99(5):659–65

Is coronary revascularization the optimum strategy for patients with non-Q wave myocardial infarction? A point-counterpoint. Gersh BJ, et al. **Clin Cardiol** 1998 Dec; 21(12 Suppl 2):II18–22 (17 ref.)

Localization of sympathetic, parasympathetic and sensory neurons innervating the heart of the Beijing duck by means of the retrograde transport of horseradish peroxidase. Chen Y, et al. **J Vet Med Sci** 1999 Jan;61(1):1–5

ABNORMALITIES

Idiopathic paroxysmal atrial fibrillation induced by a focal discharge mechanism in the left superior pulmonary vein: possible roles of the ligament of Marshall. Hwang C, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):636–48

Coexisting preexcitation syndrome and intermittent heart block presenting as neonatal seizures. Kanter RJ, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):736–40

Radiofrequency catheter ablation of atrio-ventricular accessory pathways. Pitzalis MV, et al. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III15–22 (28 ref.)

[Permanent junctional reciprocating tachycardia (Coumel type): an unusual location of a retrograde accessory pathway] Mantovan R, et al. **G Ital Cardiol** 1999 Mar; 29(3):315–20 (9 ref.) (Eng. Abstr.) **(Ita)**

[Radiofrequency catheter ablation of two accessory pathways in patients with WPW Syndrome] Kalarus Z, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):551–5 (Eng. Abstr.) **(Pol)**

[Accessory pathways and supraventricular tachycardia] Navarčíková S. **Bratisl Lek Listy** 1999 May;100(5):263–6 (26 ref.) (Eng. Abstr.) **(Slo)**

ANATOMY & HISTOLOGY

The dimensions of the triangle of Koch in children. Goldberg CS, et al. **Am J Cardiol** 1999 Jan 1;83(1):117–20, A9

"Posteroseptal" accessory pathways [letter; comment] Anderson RH, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):422. Comment on: J Cardiovasc Electrophysiol 1998 Oct;9(10):1015–25.

The architecture of the sinus node, the atrioventricular conduction axis, and the internodal atrial myocardium. Anderson RH, et al. **J Cardiovasc Electrophysiol** 1998 Nov; 9(11):1233–48 (51 ref.)

Electroanatomic mapping for radiofrequency ablation of cardiac arrhythmias. Varanasi S, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):538–44

History. The specific conduction system in the left ventricle of the human heart. **J Interv Card Electrophysiol** 1997 Feb; 1(1):79

Use of a real-time three-dimensional magnetic navigation system for radiofrequency ablation of accessory pathways. Worley SJ. **Pacing Clin Electrophysiol** 1998 Aug; 21(8):1636–45 (5 ref.)

Validation of three-dimensional conduction models using experimental mapping: are we getting closer? Muzikant AL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):205–23

CYTOLOGY

Regional distribution and extrinsic innervation of intrinsic cardiac neurons in the guinea pig. Leger J, et al. **J Comp Neurol** 1999 May 10;407(3):303–17

DRUG EFFECTS

Caffeine ingestion: yet another wake-up call? [editorial; comment] Graboys TB, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):574–5. Comment on: Am Heart J 1998 Oct;136(4 Pt 1):643–6.

Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. Banasiak W, et al. **Am J Cardiol** 1999 Jan 1;83(1):112–4, A9

Hemodynamic and electrophysiologic effects of acute chocolate ingestion in young adults. Baron AM, et al. **Am J Cardiol** 1999 Aug 1;84(3):370–3, A10

Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Fesmire SI, et al. **Am J Cardiol** 1999 Aug 1;84(3):350–4, A9

Cardiovascular safety of fexofenadine HCl. Pratt CM, et al. **Am J Cardiol** 1999 May 15;83(10):1451–4 (23 ref.)

QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Stolt A, et al. **Am J Cardiol** 1999 Aug 1;84(3):364–6, A9

Use of adenosine in patients hospitalized in a university medical center. Knight BP, et al. **Am J Med** 1998 Oct; 105(4):275–80

A case of normalization of Wolff-Parkinson-White syndrome conduction during propofol anesthesia. Seki S, et al. **Anesthesiology** 1999 Jun;90(6):1779–81

Sympathetic activation in heart failure and its treatment with beta-blockade. Pepper GS, et al. **Arch Intern Med** 1999 Feb 8;159(3):225–34 (65 ref.)

Propofol does not affect the canine cardiac conduction system under autonomic blockade. Ikeno S, et al. **Can J Anaesth** 1999 Feb;46(2):148–53

Mechanism of procainamide-induced prevention of spontaneous wave break during ventricular fibrillation. Insight into the maintenance of fibrillation wave fronts. Kim YH, et al. **Circulation** 1999 Aug 10;100(6):666–74

The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. van Haarst AD, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):542–6

Altered cardiovascular autonomic regulation after salmeterol treatment in asthmatic children. Jartti TT, et al. **Clin Physiol** 1998 Jul;18(4):345–53

Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction [see comments] Parikka H, et al. **Eur Heart J** 1999 Jan; 20(2):111–20. Comment in: Eur Heart J 1999 Jan;20(2):86–8.

Effects of the optical isomers of verapamil on electrophysiological properties of the heart in conscious dogs. Takahata O, et al. **Eur J Pharmacol** 1998 Aug 21; 355(2–3):159–66

Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. Kühlkamp V, et al. **Int J Cardiol** 1999 Jun 1;69(3):271–9

Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Sarubbi B, et al. **Int J Cardiol** 1998 Sep 30;66(2):157–64

Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. Chen YJ, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):587–98

The effect of procainamide on T wave alternans. Kavesh NG, et al. **J Cardiovasc Electrophysiol** 1999 May; 10(5):649–54

Differential effect of adenosine on anterograde and retrograde fast pathway conduction in patients with atrioventricular nodal reentrant tachycardia. Souza JJ, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):820–4

QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. Nousiainen T, et al. **J Intern Med** 1999 Apr;245(4):359–64

ECG conduction delays associated with massive bupropion overdose. Paris PA, et al. **J Toxicol Clin Toxicol** 1998; 36(6):595–8

A case of AV reentrant tachycardia due to a concealed accessory pathway with retrograde conduction manifested by isoproterenol. Ahn YK, et al. **Jpn Circ J** 1998 Dec; 62(12):943–6

Electrophysiological effects of Ageratum conyzoides L. on the guinea-pig heart. Garcia EA, et al. **Phytother Res** 1999 Mar;13(2):172–4

EMBRYOLOGY

Conducting the embryonic heart: orchestrating development of specialized cardiac tissues. Gourdie RG, et al. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1–2):18–26 (44 ref.)

INJURIES

Catheter-induced mechanical trauma to accessory pathways during radiofrequency ablation: incidence, predictors and clinical implications. Belhassen B, et al. **J Am Coll Cardiol** 1999 Mar;33(3):767–74

METABOLISM

Subcellular localization of dystrophin and vinculin in cardiac muscle fibers and fibers of the conduction system of the chicken ventricle. Vohra MS, et al. **Cell Tissue Res** 1998 Oct;294(1):137–43

Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Kupershmidt S, et al. **Circ Res** 1999 Feb 5;84(2):146–52

Increased immunoexpression of atrial natriuretic peptide in the heart conduction system of the rat after cardiac sympathectomy. Hansson M, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2047–57

Met-enkephalin-induced mobilization of intracellular Ca2+ in rat intracardiac ganglion neurones. Smith AB, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):105–8

[Immunohistochemical study on SMDS using anti-actin monoclonal antibody] Luo B. **Fa I Hsueh Tsa Chih** 1997; 13(3):135–7, 192 inside back cover (Eng. Abstr.) **(Chi)**

PARASITOLOGY

[Cardiac neuronal depopulation in hamsters (Mesocricetus auratus) chronically infected with Trypanosoma cruzi] Chapadeiro E, et al. **Rev Soc Bras Med Trop** 1999 Jan–Feb; 32(1):35–9 (Eng. Abstr.) **(Por)**

PATHOLOGY

Histologic findings in the conduction system after cardiac transplantation and correlation with electrocardiographic findings. Calzolari V, et al. **Am J Cardiol** 1999 Sep 15; 84(6):756–9, A9

Histopathologic spectrum of the cardiac conducting tissue in traumatic and noncardiac sudden death patients under 30 years of age: an analysis of 100 cases. Cohle SD, et al. **Anat Pathol** 1998;3:53–76

Inflammation of the cardiac conduction system in a case of hyperthyroidism. Ortmann C, et al. **Int J Legal Med** 1999; 112(4):271–4

Quatrefoil reentry in myocardium: an optical imaging study of the induction mechanism. Lin SF, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):574–86

Electroanatomic imaging using magnetic catheter tracking in the diagnosis and treatment of atrial arrhythmias. Wilber DJ, et al. **J Electrocardiol** 1998;31 Suppl:92–100 (25 ref.)

Torsades de pointes in a case of hypertrophic cardiomyopathy with special reference to the pathologic findings of the heart including the conduction system. Kuboki K, et al. **Jpn Heart J** 1999 Mar;40(2):233–8

[Immunohistochemical findings in the heart conduction system] Bouška I, et al. **Soud Lek** 1998 Nov;43(4):55–7 (Eng. Abstr.) **(Cze)**

PHYSIOLOGY

Post-partum prolongation of the atrial repolarization in rabbit. Pacher P, et al. **Acta Physiol Scand** 1999 May; 166(1):1–5

Influence of right atrial pressure on the cardiac pacemaker response to vagal stimulation. Bolter CP, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1112–7

Cardiac inotropic, chronotropic, and dromotropic actions of subretrofacial neurons of cat RVLM. Campos RR, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1102–11

Parasympathetic modulation of sinoatrial node pacemaker activity in rabbit heart: a unifying model. Demir SS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2221–44

Correlation of ventricular mechanosensory neurite activity with myocardial sensory field deformation. Foreman RD, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R979–89

Low-frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity. Houle MS, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H215–23

Real-time measurement of cardiac vagal tone in conscious dogs. Little CJ, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H758–65

Extrinsic inputs to intrinsic neurons in the porcine heart in vitro. Smith FM. **Am J Physiol** 1999 Feb;276(2 Pt 2):R455–67

Effective epicardial resistance of rabbit ventricles. Baynham TC, et al. **Ann Biomed Eng** 1999 Jan–Feb;27(1):96–102

Radial approach: a new concept in surgical treatment for atrial fibrillation. II. Electrophysiologic effects and atrial contribution to ventricular filling. Nitta T, et al. **Ann Thorac Surg** 1999 Jan;67(1):36–50

Cardiac autonomic nervous function during long-term nonpulsatile left heart bypass. Nishinaka T, et al. **Artif Organs** 1999 Jun;23(6):500–3

Self-organization of the heartbeat as coordination among ventricular myocardial cells through mechano-electrical feedback. Hori S, et al. **Biol Cybern** 1999 Jan;80(1):1–10

Neural control of left ventricular contractility in the dog heart: synaptic interactions of negative inotropic vagal preganglionic neurons in the nucleus ambiguus with tyrosine hydroxylase immunoreactive terminals. Massari VJ, et al. **Brain Res** 1998 Aug 17;802(1–2):205–20

Should clinical cardiologists report total peripheral resistance or total peripheral conductance? Lautt WW. **Can J Cardiol** 1999 Jan;15(1):45–7

Spatiotemporal heterogeneity in the induction of ventricular fibrillation by rapid pacing: importance of cardiac restitution properties. Cao JM, et al. **Circ Res** 1999 Jun 11;84(11):1318–31

QT dispersion as an attribute of T-loop morphology. Kors JA, et al. **Circulation** 1999 Mar 23;99(11):1458–63

Regional differences in the recovery course of tachycardia-induced changes of atrial electrophysiological properties. Lee SH, et al. **Circulation** 1999 Mar 9; 99(9):1255–64

QT and dispersion of ventricular repolarization: the greatest fallacy in electrocardiography in the 1990s [letter; comment] Rautaharju PM. **Circulation** 1999 May 11; 99(18):2477–8. Comment on: Circulation 1998 Jun 30;97(25):2491–3. Comment on: Circulation 1998 Jun 30;97(25):2543–50.

Simultaneous multisite mapping of the right and the left atrial septum in the canine intact beating heart. Sun H, et al. **Circulation** 1999 Jul 20;100(3):312–9

Sympathetic rhythmicity in cardiac transplant recipients. van de Borne P, et al. **Circulation** 1999 Mar 30;99(12):1606–10

Optimum lead positioning for recording bipolar atrial electrocardiograms during sinus rhythm and atrial fibrillation. Waktare JE, et al. **Clin Cardiol** 1998 Nov; 21(11):825–30

The intrinsic rate response of the isolated right atrium of the rat, Rattus norvegicus. Barrett CJ, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):391–7

An advanced algorithm for solving partial differential equation in cardiac conduction. Qu Z, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1166–8

Activation of various G-protein coupled receptors modulates Ca2+ channel currents via PTX-sensitive and voltage-dependent pathways in rat intracardiac neurons. Jeong SW, et al. **J Auton Nerv Syst** 1999 Apr 16;76(1):68–74

Electrical and hemodynamic correlates of the maximal rate of pressure increase in the human left ventricle. Fried AG, et al. **J Card Fail** 1999 Mar;5(1):8–16

A role for the renin-angiotensin system in the evolution of cardiac memory. Ricard P, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):545–51

Anisotropy of cardiac tissue: a major determinant of conduction? Spach MS. **J Cardiovasc Electrophysiol** 1999 Jun;10(6):887–90

Multiple components in the unipolar electrogram: a simulation study in a three-dimensional model of ventricular myocardium. Taccardi B, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1062–84

Radiofrequency current application on immature porcine atrial myocardium: no evidence of areas of slow conduction after 12-month follow-up. Windhagen-Mahnert B, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1305–9

Temporal and positional variability of the ST segment during continuous vectorcardiography monitoring in healthy subjects. Nørgaard BL, et al. **J Electrocardiol** 1999 Apr; 32(2):149–58

Cardiac conduction: an interplay between membrane and gap junction. Rudy Y. **J Electrocardiol** 1998;31 Suppl:1–5

Aging alteration of cardiac vagosympathetic balance assessed through the tone–entropy analysis. Oida E, et al. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):M219–24

Divergence of endocardial QT interval components during programmed electrical stimulation including observations during induction of sustained ventricular tachyarrhythmias. Wyse DG, et al. **J Interv Card Electrophysiol** 1997 Feb; 1(1):23–31

Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts. Furukawa Y, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1334–42

A method for determining baroreflex-mediated sympathetic and parasympathetic control of the heart in pregnant and non-pregnant sheep. Lumbers ER, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):555–66

Influence of the hypothalamic paraventricular nucleus on cardiovascular neurones in the rostral ventrolateral medulla of the rat. Yang Z, et al. **J Physiol (Lond)** 1998 Dec 1;513 (Pt 2):521–30

Time dependence of anodal and cathodal refractory periods in cardiac tissue. Bennett JA, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1031–8

Transmembrane potential properties of atrial cells at different sites of a spiral wave reentry: cellular evidence for an excitable but nonexcited core. Karagueuzian HS, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2360–5

Slow potential-guided radiofrequency catheter ablation in atrioventricular nodal reentrant tachycardia: characteristics of the potential associated with successful ablation. Yamabe H, et al. **Pacing Clin Electrophysiol** 1998 Dec; 21(12):2631–40

A qualitative model for computer-assisted instruction in cardiology. Julen N, et al. **Proc AMIA Symp** 1998;:443–7

Validation of three-dimensional conduction models using experimental mapping: are we getting closer? Mazikant AL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):205–23

Anxiety reduces baroreflex cardiac control in older adults with major depression. Watkins LL, et al. **Psychosom Med** 1999 May–Jun;61(3):334–40

[Cellular automated detection for simulation of the impulse transmission with reference to anisotropy] Abdallah O, et al. **Biomed Tech (Berl)** 1998;43 Suppl:490–1 **(Ger)**

[Controversies on Mahaim's fibers] Anaclerio M, et al. **Cardiologia** 1998 Oct;43(10):1017–26 (62 ref.) **(Ita)**

[The functional specificity of the cardiac pacemaker system] Prosheva VI. **Usp Fiziol Nauk** 1998 Jul–Sep;29(3):79–91 (92 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Modelling and mapping of the cardiac electrical field. d'Alché EP. **Acta Cardiol** 1998;53(2):111–5

The effect of electroconvulsive therapy on QT dispersion. Güler N, et al. **Acta Cardiol** 1998;53(6):355–8

The sinus node and sinus node disease revisited. 1 Kindt H, et al. **Acta Cardiol** 1998;53(4):185–94 (116 ref.)

Photo quiz. A subtle ECG. Gentry BC, et al. **Am Fam Physician** 1999 May 1;59(9):2581–2

Effect of acute ischemia on QT dispersion [letter] Aytemir K, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):385–6

Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Karpanou EA, et al. **Am Heart J** 1998 Nov; 136(5):765–8

QT dispersion in athletic left ventricular hypertrophy. Mayet J, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):678–81

Relation between QT dispersion and slow intraventricular conduction in patients with acute anterior wall myocardial infarction. Mazur A, et al. **Am Heart J** 1999 Jan; 137(1):104–8

QT dispersion in patients with Duchenne-type progressive muscular dystrophy. Yotsukura M, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):672–7

Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation [see comments] Herweg B, et al. **Am J Cardiol** 1998 Oct 1;82(7):869–74. Comment in: Am J Cardiol 1999 Feb 1;83(3):476.

Predictive value of prominent right atrial V waves in assessing the presence and severity of tricuspid regurgitation. Pitts WR, et al. **Am J Cardiol** 1999 Feb 15; 83(4):617–8, A10

Dobutamine-induced ST-segment elevation in patients without myocardial infarction. Previtali M, et al. **Am J Cardiol** 1998 Dec 15;82(12):1528–30, A7

Mechanism of sustained monomorphic ventricular tachycardia in systemic sclerosis. Rankin AC, et al. **Am J Cardiol** 1999 Feb 15;83(4):633–6, A11

Relation of QT dispersion to infarct size and left ventricular wall motion in anterior wall acute myocardial infarction. Tamura A, et al. **Am J Cardiol** 1999 May 15;83(10):1423–6

QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Yi G, et al. **Am J Cardiol** 1998 Dec 15;82(12):1514–9

Face immersion in cold water induces prolongation of the QT interval and T-wave changes in children with nonfamilial long QT syndrome. Yoshinaga M, et al. **Am J Cardiol** 1999 May 15;83(10):1494–7, A8

Cold face test demonstrates parasympathetic cardiac dysfunction in familial dysautonomia. Hilz MJ, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1833–9

Reduced NO enhances the central gain of cardiac sympathetic afferent reflex in dogs with heart failure. Ma R, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H19–26

Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Van De Borne P, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R178–83

Cardiac sympathetic afferent sensitivity is enhanced in heart failure. Wang W, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H812–7

Characteristics of intracardiac potentials at successful ablation sites in concealed Wolff-Parkinson-White syndrome. Kawamura Y, et al. **Angiology** 1999 Aug; 50(8):665–70

Enhanced insulin response to oral glucose load in patients with angina pectoris associated with ST segment elevation in the absence of epicardial coronary arterial obstruction.

Nagai H, et al. **Angiology** 1998 Oct;49(10):815–26

Effect of acute haemorrhage on QRS amplitude of the lead II canine electrocardiogram. Della Torre PK, et al. **Aust Vet J** 1999 May;77(5):298–300

A critical commentary and treatise on myocardial repolarization [letter; comment] RuDusky BM. **Chest** 1998 Dec;114(6):1790–1. Comment on: Chest 1997 Mar;111(3):537–43. Comment on: Chest 1998 Mar;113(3):850–1.

Incidence, evolution, and spatial distribution of functional reentry during ventricular fibrillation in pigs. Rogers JM, et al. **Circ Res** 1999 Apr 30;84(8):945–54

Reentry and fibrillation in the mouse heart. A challenge to the critical mass hypothesis. Vaidya D, et al. **Circ Res** 1999 Jul 23;85(2):174–81

Rate-dependent conduction block of the crista terminalis in patients with typical atrial flutter: influence on evaluation of cavotricuspid isthmus conduction block. Arenal A, et al. **Circulation** 1999 Jun 1;99(21):2771–8

Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C-11 hydroxyephedrine. Bengel FM, et al. **Circulation** 1999 Apr 13;99(14):1866–71

Right atrial flutter due to lower loop reentry: mechanism and anatomic substrates. Cheng J, et al. **Circulation** 1999 Apr 6;99(13):1700–5

Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Hagendorff A, et al. **Circulation** 1999 Mar 23; 99(11):1508–15

Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Kass DA, et al. **Circulation** 1999 Mar 30;99(12):1567–73

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Li D, et al. **Circulation** 1999 Jul 6;100(1):87–95

Isoproterenol to evaluate resumption of conduction after right atrial isthmus ablation in type I atrial flutter. Nabar A, et al. **Circulation** 1999 Jun 29;99(25):3286–91

Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Nabar A, et al. **Circulation** 1999 Mar 23; 99(11):1441–5

Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Pastore JM, et al. **Circulation** 1999 Mar 16;99(10):1385–94

Cardiac sympathetic denervation after transmyocardial laser revascularization. Al-Sheikh T, et al. **Circulation** 1999 Jul 13;100(2):135–40

Cellular and ionic basis for T-wave alternans under long-QT conditions. Shimizu W, et al. **Circulation** 1999 Mar 23; 99(11):1499–507

Significance of late diastolic potential preceding Purkinje potential in verapamil-sensitive idiopathic left ventricular tachycardia. Tsuchiya T, et al. **Circulation** 1999 May 11; 99(18):2408–13

New insights regarding the atrial flutter reentrant circuit : studies in the canine sterile pericarditis model. Uno K, et al. **Circulation** 1999 Sep 21;100(12):1354–60

Electrophysiological delineation of the tachycardia circuit in atrioventricular nodal reentrant tachycardia. Yamabe H, et al. **Circulation** 1999 Aug 10;100(6):621–7

Deceleration-dependent shortening of the QT interval: a new electrocardiographic phenomenon? Gussak I, et al. **Clin Cardiol** 1999 Feb;22(2):124–6

Uncommon electrocardiographic changes corresponding to symptoms during recurrent pulmonary embolism as documented by computed tomography scans. Watanabe T, et al. **Clin Cardiol** 1998 Nov;21(11):858–61

Noninvasive exploration of cardiac autonomic neuropathy. Four reliable methods for diabetes? Ducher M, et al. **Diabetes Care** 1999 Mar;22(3):388–93

Increased dispersion of repolarization in patients with arrhythmogenic right ventricular dysplasia--a major electrophysiological factor responsible for malignant ventricular arrhythmias [editorial; comment] Amlie JP. **Eur Heart J** 1999 May;20(10):703–5. Comment on: Eur Heart J 1999 May;20(10):764–70.

QT dispersion in patients with arrhythmogenic right ventricular dysplasia [see comments] Benn M, et al. **Eur Heart J** 1999 May;20(10):764–70. Comment in: Eur Heart J 1999 May;20(10):703–5.

The value of the heart-rate corrected QT-interval for cardiovascular risk stratification [editorial; comment] Dekker JM. **Eur Heart J** 1999 Feb;20(4):250–1 (7 ref.). Comment on: Eur Heart J 1999 Feb;20(4):278–84.

The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens [see comments] Elming H, et al. **Eur Heart J** 1998 Sep;19(9):1391–400. Comment in: Eur Heart J 1998 Sep;19(9):1279–81.

Increased dispersion of ventricular repolarisation during stress test induced ischaemia [letter] Aytemir K, et al. **Heart** 1999 Feb;81(2):224

A new ECG sign of an accessory pathway in sinus rhythm: pseudo partial right bundle branch block. Lau EW, et al. **Heart** 1999 Aug;82(2):244–5

Electrophysiological determinant for induction of isthmus dependent counterclockwise and clockwise atrial flutter in humans. Lin JL, et al. **Heart** 1999 Jan;81(1):73–81

Change in heart rate variability preceding ST elevation in a patient with vasospastic angina pectoris. Ooie T, et al. **Heart Vessels** 1998;13(1):40–4

QT/corrected QT (QTc) intervals and QT/QTc dispersions in children with chronic renal failure. Koçak G, et al. **Int J Cardiol** 1999 Jul 1;70(1):63–7

Atrial standstill in a case of Kugelberg-Welander syndrome with cardiac involvement: an electrophysiologic study [letter] Liu YB, et al. **Int J Cardiol** 1999 Jul 31;70(2):207–10

Intraventricular conduction delay: a prognostic marker in chronic heart failure. Shamim W, et al. **Int J Cardiol** 1999 Jul 31;70(2):171–8

The relationship between diastolic function of the left ventricle and QT dispersion in patients with myocardial infarction. Szymański P, et al. **Int J Cardiol** 1999 Jun 1; 69(3):245–9

Heterogeneity of anterograde fast-pathway and retrograde slow-pathway conduction patterns in patients with the fast-slow form of atrioventricular nodal reentrant tachycardia: electrophysiologic and electrocardiographic considerations. Nawata H, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1731–40

Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation. Schumacher B, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):363–73

Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. El-Sherif N, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1415–23

Partial cavotricuspid isthmus block before ablation in patients with typical atrial flutter. Takahashi A, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1996–2002

Attenuation of ischemia-induced activation of cardiac sympathetic afferents following brief myocardial ischemia in cats. Abe T, et al. **J Auton Nerv Syst** 1998 Jun 30; 71(1):28–36

Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. Howorka K, et al. **J Auton Nerv Syst** 1998 Apr 30;69(2-3):164–72

Preexcitation in a child with syncope: where is the connection? Ganz LI, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):892–5

Repetitive electrical remodeling by paroxysms of atrial fibrillation in the goat: no cumulative effect on inducibility or stability of atrial fibrillation [see comments] Garratt CJ, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1101–8. Comment in: J Cardiovasc Electrophysiol 1999 Aug;10(8):1109–11.

The long QT syndrome with impaired atrioventricular conduction: a malignant variant in infants. Gorgels AP, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1225–32

New diagnostic finding to assess para-Hisian pacing observed in a patient with a permanent form of junctional reciprocating tachycardia. Hirao K, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1363–9

Cardiac arrhythmias: what do we need to know about basic mechanisms? Hoffman BF. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):414–6 (5 ref.)

Double multielectrode mapping catheters facilitate radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Hsieh MH, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):136–44

Shortening of the intraventricular conduction time in premature ventricular beats during ventricular extrastimulation: possible role of dimensional shortening of the conducting distance during ventricular systole. Kasai H, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):798–810

Short-term rapid ventricular pacing prolongs ventricular refractoriness in patients. Krebs ME, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1036–42

Electrophysiologic study and radiofrequency catheter ablation of isthmus-independent atrial flutter. Lai LP, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):728–35

Intermittent anterograde conduction in an accessory pathway during atrial pacing: what is the mechanism? Maury P, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1394–6

Morphological and physiological characteristics of discontinuous linear atrial ablations during atrial pacing and atrial fibrillation. Mitchell MA, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):378–86

Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation. Nitta T, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):521–8

Atrial macroreentry involving the myocardium of the coronary sinus: a unique mechanism for atypical flutter. Olgin JE, et al. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1094–9

Preexcitation secondary to fasciculoventricular pathways in children: a report of three cases. Sallee D 3rd, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):36–42

U wave: facts, hypotheses, misconceptions, and misnomers. Surawicz B. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1117–28 (35 ref.)

Conduction properties of the crista terminalis in patients with typical atrial flutter: basis for a line of block in the reentrant circuit. Tai CT, et al. **J Cardiovasc Electrophysiol** 1998 Aug; 9(8):811–9

Specific electrocardiographic features of manifest coronary vein posteroseptal accessory pathways [see comments] Takahashi A, et al. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1015–25. Comment in: J Cardiovasc Electrophysiol 1999 Mar;10(3):422.

T-loop morphology as a marker of cardiac events in the elderly. Kors JA, et al. **J Electrocardiol** 1998;31 Suppl:54–9

QRST integral analysis of body surface electrocardiographic mapping for assessing exercise-induced changes in the spatial distribution of local repolarization properties in patients with coronary artery disease and in patients with previous anterior infarction. Miyakoda H, et al. **J Electrocardiol** 1999 Apr;32(2):123–36

QT dispersion as a noninvasive predictor of inducible ventricular tachycardia. Stoletniy LN, et al. **J Electrocardiol** 1999 Apr;32(2):173–7

Simulation of late potentials and arrhythmias by use of a three-dimensional heart model: casuality of peri-infarctional slow conduction in ventricular fibrillation. Yamaki M, et al. **J Electrocardiol** 1999 Apr;32(2):115–21

QT interval measurement: Q to TApex or Q to TEnd? Davey PP. **J Intern Med** 1999 Aug;246(2):145–9

Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Landstedt-Hallin L, et al. **J Intern Med** 1999 Sep;246(3):299–307

Outpatient transseptal radiofrequency ablation of atrioventricular accessory pathways-ready for prime time? [comment] Estes NA 3rd. **J Interv Card Electrophysiol** 1999 Jul;3(2):177–9. Comment on: J Interv Card Electrophysiol 1999 Jul;3(2):173–6.

Right posterior atrioventricular ring: a location for different types of atrioventricular accessory connections. Gatzoulis KA, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):187–91

Characteristics of local electrograms with diastolic potentials: identification of different components of return pathways in ventricular tachycardia. Saito J, et al. **J Interv Card Electrophysiol** 1998 Sep;2(3):235–45

Safety and efficacy of outpatient transseptal radiofrequency ablation of atrioventricular accessory pathways [see comments] Sorbera C, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):173–5. Comment in: J Interv Card Electrophysiol 1999 Jul;3(2):177–9.

Identification of fiber orientation in left free-wall accessory pathways: implication for radiofrequency ablation. Tai CT, et al. **J Interv Card Electrophysiol** 1997 Nov;1(3):235–41

Recurrence of accessory pathway conduction after successful radiofrequency ablation: histological findings. Vassilikos VP, et al. **J Interv Card Electrophysiol** 1997 Dec;1(4):311–5

ECG of the month. Prematurity and destiny. Premature atrial impulses. Martinez-Lopez JI. **J La State Med Soc** 1998 Nov;150(11):509–11

Trigeminocardiac reflex during surgery in the cerebellopontine angle. Schaller B, et al. **J Neurosurg** 1999 Feb;90(2):215–20

Ventricular fibrillation and shortening, alternans and after-depolarizations of epicardial monophasic action potentials during coronary occlusion and reperfusion: effect of repetition of ischemia. Ito S, et al. **Jpn Circ J** 1999 Mar; 63(3):201–8

Decrease in the high frequency QRS components depending on the local conduction delay. Watanabe T, et al. **Jpn Circ J** 1998 Nov;62(11):844–8

Should digoxin be proscribed in elderly subjects in sinus rhythm free from heart failure? A population-based study. Casiglia E, et al. **Jpn Heart J** 1998 Sep;39(5):639–51

Dynamic changes of QT dispersion as a predictor of myocardial ischemia on exercise testing in patients with angina pectoris. Musha H, et al. **Jpn Heart J** 1999 Mar; 40(2):119–26

Importance of retrograde atrial activation in atrial fibrillation genesis in the initiation of atrial fibrillation in Wolff-Parkinson-White syndrome. Comparison of atrial electrophysiologic parameters between patients with different atrial fibrillation genesis (initiation sites) in atria. Niwano S, et al. **Jpn Heart J** 1999 May;40(3):281–93

Aortic input impedance and ventriculoarterial coupling following cardioversion/defibrillation. Bauernschmitt R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1047–53

Unipolar waveforms and monophasic action potentials in the characterization of slow conduction in human atrial flutter. Fenelon G, et al. **Pacing Clin Electrophysiol** 1998 Dec; 21(12):2580–7

Atypical AV nodal reentry with bystander accessory pathway: an unusual mechanism of preexcited tachycardia. Glikson M, et al. **Pacing Clin Electrophysiol** 1999 Feb; 22(2):390–2

Assessment of the coupling between RTapex and RR interval as an index of temporal dispersion of ventricular repolarization. Lombardi F, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2396–400

Electrical atrial remodeling assessed by monophasic action potential and atrial refractoriness in patients with structural heart disease. Lubinski A, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2440–4

Antidromic reciprocating tachycardia in patients with paraseptal accessory pathways: importance of critical delay in the reentry circuit. Man DC, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):386–9

Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651–63 (74 ref.)

A computer model of cardiac electrical activity for the

simulation of arrhythmias. Virag N, et al.
Pacing Clin Electrophysiol 1998 Nov;21(11 Pt 2):2366–71
Atrial vulnerability in patients with paroxysmal "lone" atrial fibrillation. Zimmermann M, et al.
Pacing Clin Electrophysiol 1998 Oct;21(10):1949–58
Cryothermal ablation: mechanism of tissue injury and current experience in the treatment of tachyarrhythmias. Lustgarten DL, et al. **Prog Cardiovasc Dis** 1999 May–Jun; 41(6):481–98 (88 ref.)
Usefulness of the QTc interval in predicting acute allograft rejection. Richartz BM, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):217–21
[Electrophysiology of the atrioventricular node during atrial fibrillation. II. The influence of atrial impulses] Meijler FL, et al. **Ned Tijdschr Geneeskd** 1999 Jun 12;143(24):1252–6 (22 ref.) (Eng. Abstr.) **(Dut)**
["Nonlinear differential equation for assessing the stability of heart muscle excitation"] Blank H.
Biomed Tech (Berl) 1998;43 Suppl:322–3 **(Ger)**
[Neurocardiogenic syncopes in patients with implanted pacemakers] Keim MW, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):953–7 (Eng. Abstr.) **(Ger)**
[Ventricular tachycardia masquerading as supraventricular tachycardia] Tomcsányi J, et al. **Orv Hetil** 1998 Nov 15; 139(46):2779–81 (Eng. Abstr.) **(Hun)**
[Dynamics of electrophysiological parameters of the heart conduction system in patients with alcoholism during long-term therapeutic-vocational rehabilitation] Anikin VV, et al. **Klin Med (Mosk)** 1998;76(12):39–42 (Eng. Abstr.) **(Rus)**
[Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis] Bazhanov NN, et al.
Klin Med (Mosk) 1998;76(10):32–5 (Eng. Abstr.) **(Rus)**
[Clinical efficacy of non-invasive evaluation of intra- and interatrial conduction in patients with ischemic heart disease] Shabrov AV, et al. **Ter Arkh** 1999;71(1):34–9 (Eng. Abstr.) **(Rus)**
[Cardiac rhythm and conduction disturbances during surgical correction of the patent atrioventricular canal] Taraian MV, et al. **Vestn Ross Akad Med Nauk** 1998;(6):32–5 **(Rus)**

SURGERY

Impact of arrhythmia circuit cryoablation during Fontan conversion for refractory atrial tachycardia. Deal BJ, et al. **Am J Cardiol** 1999 Feb 15;83(4):563–8
Spot welding the gap in atrial flutter ablation. Friedman PA, et al. **Circulation** 1999 Jun 22;99(24):3206–8
Nontransmural laser treatment incompletely denervates canine myocardium. Kwong KF, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II67–71; discussion II71–2
Catheter mounted coaxially moveable ablation electrode for the creation of linear transmural endocardial lesions. Morgan JM, et al. **J Cardiovasc Electrophysiol** 1999 Apr; 10(4):566–73
Low-power radiofrequency application and intracardiac echocardiography for creation of continuous left atrial linear lesions. Roithinger FX, et al.
J Cardiovasc Electrophysiol 1999 May;10(5):680–91
Radiofrequency catheter ablation of two right Mahaïm-like accessory pathways in a patient with Ebstein's anomaly. Berntsen RF, et al. **J Interv Card Electrophysiol** 1998 Sep; 2(3):293–9
Outpatient transseptal radiofrequency ablation of atrioventricular accessory pathways–ready for prime time? [comment] Estes NA 3rd. **J Interv Card Electrophysiol** 1999 Jul;3(2):177–9. Comment on: J Interv Card Electrophysiol 1999 Jul;3(2):173–6.
Right posterior atrioventricular ring: a location for different types of atrioventricular accessory connections. Gatzoulis KA, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):187–91
Radiofrequency ablation in older children and adolescents by an adult electrophysiology team. Manolis AS, et al.
J Interv Card Electrophysiol 1999 Mar;3(1):79–86
Effect of catheter tip length and position on lesion volume in temperature controlled RF ablation in canine tricuspid valve annulus. Mehdirad A, et al.
J Interv Card Electrophysiol 1998 Sep;2(3):279–84
Safety and efficacy of outpatient transseptal radiofrequency ablation of atrioventricular accessory pathways [see comments] Sorbera C, et al.
J Interv Card Electrophysiol 1999 Jul;3(2):173–5. Comment in: J Interv Card Electrophysiol 1999 Jul;3(2):177–9.
Recurrence of accessory pathway conduction after successful radiofrequency ablation: histological findings. Vassilikos VP, et al. **J Interv Card Electrophysiol** 1997 Dec;1(4):311–5
Successful radiofrequency ablation of an accessory pathway during pregnancy. Dominguez A, et al.
Pacing Clin Electrophysiol 1999 Jan;22(1 Pt 1):131–4
Radiofrequency catheter ablation of septal accessory pathways within the triangle of Koch: importance of energy titration testing other than the local electrogram characteristics for identifying the successful target site. Lin JL, et al. **Pacing Clin Electrophysiol** 1998 Oct; 21(10):1909–17
Late complete atrioventricular block complicating radiofrequency catheter ablation of a left posteroseptal accessory pathway. Liu J, et al.
Pacing Clin Electrophysiol 1998 Nov;21(11 Pt 1):2136–8
Unexpected complete AV block following transcatheter ablation of a left posteroseptal accessory pathway. Seidl K, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2139–42
Characteristics and radiofrequency catheter ablation of septal accessory atrioventricular pathways. Tai CT, et al.
Pacing Clin Electrophysiol 1999 Mar;22(3):500–11 (58 ref.)
[Criteria of localization of the bundle of Kent] Pisapia A, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:57–64 (Eng. Abstr.) **(Fre)**
[Radiofrequency catheter ablation of two accessory pathways in patients with WPW Syndrome] Kalarus Z, et al.
Pol Arch Med Wewn 1998 Dec;100(6):551–5 (Eng. Abstr.) **(Pol)**
[Type I atrial flutter radiofrequency ablation. Importance of bidirectional block of isthmus between the inferior vena cava and of tricuspid valve ring] Scanavacca M, et al.
Arq Bras Cardiol 1998 Nov;71(5):705–11 (Eng. Abstr.) **(Por)**
[The radiofrequency ablation of a left lateral accessory pathway during pre-excitation atrial fibrillation] Siller Rodríguez J, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr; 68(2):113–8 (10 ref.) (Eng. Abstr.) **(Spa)**
[Catheter ablation of accessory pathways in infants and children weighing less than 10 kg] Benito Bartolomé F, et al. **Rev Esp Cardiol** 1999 Jun;52(6):398–402 (Eng. Abstr.) **(Spa)**
[Analysis of local electrograms and characteristics of the ablation procedure in left-sided accessory pathways that required five or more pulses of radiofrequency] Mont L, et al. **Rev Esp Cardiol** 1999 Aug;52(8):570–6 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Noninvasive localization of accessory pathways in patients with Wolff-Parkinson-White syndrome with the use of myocardial Doppler imaging. Tuchnitz A, et al.
J Am Soc Echocardiogr 1999 Jan;12(1):32–40
[Echocardiography in the localization of the anomalous pathway in ventricular pre-excitation. Technics, usefulness and limits] Mele D, et al. **G Ital Cardiol** 1999 Jun; 29(6):730–8 (65 ref.) **(Ita)**

HEART CONTRACTILITY see **MYOCARDIAL CONTRACTION**

HEART DECOMPENSATION see **HEART FAILURE, CONGESTIVE**

HEART DEFECTS, CONGENITAL

Caring for infants with congenital heart disease and their families. Saenz RB, et al. **Am Fam Physician** 1999 Apr 1; 59(7):1857–68 (18 ref.)
Population-based study of congenital heart defects in Down syndrome. Freeman SB, et al. **Am J Med Genet** 1998 Nov 16;80(3):213–7
Pregnancy and congenital heart disease--maternal and fetal outcome. Sawhney H, et al.
Aust N Z J Obstet Gynaecol 1998 Aug;38(3):266–71
Cardiofaciocutaneous (CFC) syndrome. Schepis C, et al.
Australas J Dermatol 1999 May;40(2):111–3
A comparison of arterial versus venous-activated clotting time in patients with congenital heart disease undergoing cardiac catheterization. Zeevi B, et al.
Catheter Cardiovasc Interv 1999 Feb;46(2):194–6
Bibliography current world literature. **Coron Artery Dis** 1998; 9(10):703–11
Cardiac regression sequence: reversal of blood flow is diagnostic but not causative in an acardiac fetus. Ersch J, et al. **Early Hum Dev** 1998 Aug 28;52(1):81–5
The Denolin Lecture: The woman with congenital heart disease. Somerville J. **Eur Heart J** 1998 Dec;19(12):1766–75
Isolated congenital left ventricular diverticulum [letter] Bogers AJ. **Eur J Cardiothorac Surg** 1996;10(12):1147
Trisomy 2 in an acardiac twin in a triplet in-vitro fertilization pregnancy. Chaliha C, et al. **Hum Reprod** 1999 May; 14(5):1378–80
Piercing and tattooing in patients with congenital heart disease: patient and physician perspectives. Cetta F, et al.
J Adolesc Health 1999 Mar;24(3):160–2
Thermocoagulation for the early treatment of pregnancy with an acardiac twin. Rodeck C, et al. **N Engl J Med** 1998 Oct 29;339(18):1293–5
Congenital heart disease: six decades of progress. Olley PM.
Semin Pediatr Neurol 1999 Mar;6(1):3–11
[Coronary artery anomalies in the young] Pasquini L, et al.
Cardiologia 1998 Dec;43(12):1281–6 (23 ref.) **(Ita)**
[Thrombus of the right ventricle simulating a cardiac tumor--case report] Aleszewicz-Baranowska J, et al.
Przegl Lek 1998;55(12):673–5 (Eng. Abstr.) **(Pol)**

BLOOD

Prevalence of factor V Leiden in a population of patients with congenital heart disease. Ong BC, et al.
Can J Anaesth 1998 Dec;45(12):1176–80
Elevated plasma levels of adrenomedullin in congenital cyanotic heart disease. Yoshibayashi M, et al.
Clin Sci (Colch) 1999 Jun;96(6):543–7
Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest. Ashraf S, et al. **Eur J Cardiothorac Surg** 1999 Jul; 16(1):32–7
Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. Tutar HE, et al. **Int J Cardiol** 1999 Jul 1;70(1):57–62
Soluble L-selectin plasma concentrations in infants undergoing heart surgery: no association with capillary leak syndrome or need for respiratory support. Bührer C, et al. **Intensive Care Med** 1998 Oct;24(10):1093–8
Changes in plasma free and sulfoconjugated dopamine in patients with congenital heart disease who underwent cardiac operation. Yoshizumi M, et al.
Jpn J Thorac Cardiovasc Surg 1998 Aug;46(8):651–6
Plasma endothelin 1 concentrations in children with congenital heart defects. Jia B, et al. **Minerva Pediatr** 1998 Apr;50(4):99–103
HbF synthesis during stress erythropoiesis as determined by gamma-mRNA/non-alpha-mRNA quantification. Bard H, et al. **Pediatr Res** 1999 May;45(5 Pt 1):684–6
Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease. Zarembski DG, et al. **Pharmacotherapy** 1999 Feb;19(2):249–51
[The changes of plasma endothelin concentration and its clinical significance in pulmonary hypertension associated with congenital heart defects] Zhang S, et al.
Hunan I Ko Ta Hsueh Hsueh Pao 1997;22(5):425–7 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

A retinoic acid-inducible transgenic marker of sino-atrial development in the mouse heart. Xavier-Neto J, et al.
Development 1999 Jun;126(12):2677–87
Cardiac laterality and ventricular looping in retinoic acid-treated rat embryos. Kim JS, et al.
J Korean Med Sci 1999 Apr;14(2):138–46

COMPLICATIONS

Renal impairment in patients with long-standing cyanotic congenital heart disease. Dittrich S, et al. **Acta Paediatr** 1998 Sep;87(9):949–54
Plasma metabolites after a lipid load in infants with congenital heart disease. Lundell KH, et al. **Acta Paediatr** 1999 Jul; 88(7):718–23
Prospective echocardiographic analysis of progressive obstruction of the proximal pulmonary artery in congenital heart disease and obstructed pulmonary flow. Hiraishi S, et al. **Am Heart J** 1998 Nov;136(5):837–43
Blepharophimosis, hypoplastic radius, hypoplastic left heart, telecanthus, hydronephrosis, fused metacarpals, and "prehensile" halluces: a new syndrome? Day-Salvatore D, et al. **Am J Med Genet** 1998 Dec 4;80(4):309–13
Improvement of extreme hypoxemia during end-stage congenital heart disease using nasal nitric oxide. Cholley BP, et al. **Anesthesiology** 1998 Dec;89(6):1586–7
Otological manifestations of CHARGE association. Dhooge I, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):935–41
Pulmonary vein stenosis with normal connection: associated cardiac abnormalities and variable outcome. Breinholt JP, et al. **Ann Thorac Surg** 1999 Jul;68(1):164–8
Surgical management of total anomalous pulmonary venous drainage: impact of coexisting cardiac anomalies. Caldarone CA, et al. **Ann Thorac Surg** 1998 Nov;66(5):1521–6
Semiprone position relieved airway obstruction resulting from dilated pulmonary artery [letter] Yahagi N, et al.
Ann Thorac Surg 1999 Mar;67(3):892
Arrhythmias in the athlete with congenital heart disease: guidelines for participation. Liberthson RR.
Annu Rev Med 1999;50:441–52 (19 ref.)
Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. Varan B, et al. **Arch Dis Child** 1999 Jul; 81(1):49–52
Pulmonary arteriovenous fistulas in patients with left isomerism and cardiac malformations [editorial; comment] Amodeo A, et al. **Cardiol Young** 1998 Jul;8(3):283–4. Comment on: Cardiol Young 1998 Jul;8(3):290–4.
Pulmonary and systemic arteriovenous fistulas in patients with left isomerism [see comments] Kawata H, et al.
Cardiol Young 1998 Jul;8(3):290–4. Comment in: Cardiol Young 1998 Jul;8(3):283–4.
Mechanisms underlying aortic dilatation in congenital aortic valve malformation. Bonderman D, et al. **Circulation** 1999 Apr 27;99(16):2138–43
Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Rosenzweig EB, et al.
Circulation 1999 Apr 13;99(14):1858–65
Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Lutz J, et al. **Clin Chem Lab Med** 1999 Apr; 37(4):423–8
Spinal fusion in patients with congenital heart disease. Predictors of outcome. Coran DL, et al. **Clin Orthop** 1999 Jul;(364):99–107
Pregnancy in women with congenital heart defects: what are the risks? [editorial] Siu S, et al. **Heart** 1999 Mar; 81(3):225–6
Otologic management in children with the CHARGE association. Shah UK, et al.
Int J Pediatr Otorhinolaryngol 1998 Jul 10;44(2):139–47
Risk assessment of patients having congenital heart disease using electrophysiologic testing: finally, opening the right door...or, an impossible chore? [editorial; comment] Kanter RJ. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1045–8 (25

ref.). Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1033–44.
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. Simoes EA, et al. **J Pediatr** 1998 Oct;133(4):492–9
Cardiovascular malformations in experimental congenital diaphragmatic hernia. Losty PD, et al. **J Pediatr Surg** 1999 Aug;34(8):1203–7
A detailed histologic analysis of pulmonary arteriovenous malformations in children with cyanotic congenital heart disease. Duncan BW, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):931–8
A 61-year-old man with Holmes' heart [letter] Gabbarini F. **Lancet** 1999 Feb 20;353(9153):646
The myocardial profile of the cytosolic isozymes of creatine kinase is apparently not related to cyanosis in congenital heart disease. Kessler-Icekson G, et al. **Mol Med** 1999 Feb; 5(2):110–6
Gross and fine motor development is impaired in children with cyanotic congenital heart disease. Stieh J, et al. **Neuropediatrics** 1999 Apr;30(2):77–82
A newborn with a complex congenital heart disease, atrioventricular block, and torsade de pointes ventricular tachycardia. Kantoch MJ, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2664–7
Neurologic complications of pediatric cardiac, gastrointestinal, and renal diseases. Sanchez JL, et al. **Pediatr Ann** 1998 Oct;27(10):625–33 (58 ref.)
Results of surgical treatment of congenital heart defects in children with Down's syndrome. Malec E, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):351–4
Inhalation of low-dose nitric oxide to evaluate pulmonary vascular reactivity in children with congenital heart disease. Yasuda T, et al. **Pediatr Cardiol** 1999 Jul–Aug; 20(4):278–82
Technetium-99m hexamethyl propylenamine oxime lung clearance in the estimation of pulmonary hypertension in congenital heart disease: A preliminary comparative study with cardiac catheterization and pathology. Yener A, et al. **Pediatr Cardiol** 1999 Jul–Aug;20(4):271–7
Neurologic status of newborns with congenital heart defects before open heart surgery. Limperopoulos C, et al. **Pediatrics** 1999 Feb;103(2):402–8
Structural evidence of injury or malformation in the brains of children with congenital heart disease. Miller G, et al. **Semin Pediatr Neurol** 1999 Mar;6(1):20–6 (47 ref.)
Non-cardiac surgery and anaesthesia in children with congenital heart disease. Soyannwo OA, et al. **West Afr J Med** 1999 Apr–Jun;18(2):87–90
[Jacobsen's syndrome, thrombopenia and humoral immunodeficiency] Sirvent N, et al. **Arch Pediatr** 1998 Dec; 5(12):1338–40 (Eng. Abstr.) **(Fre)**
[Endocarditis in heart defects—incidence, diagnosis and prevention] Turina J. **Ther Umsch** 1998 Dec;55(12):773–8 (10 ref.) (Eng. Abstr.) **(Ger)**
[Neonatal endocarditis: report of a case] De Lazzari S, et al. **Pediatr Med Chir** 1999 Jan–Feb;21(1):35–6 (Eng. Abstr.) **(Ita)**
[Case report of tuberous sclerosis and congenital heart disease] Rocha G, et al. **Rev Port Cardiol** 1999 May; 18(5):497–500 (Eng. Abstr.) **(Por)**
[Congenital cyanotic heart disease and peripheral neurogenic tumor] Diez L, et al. **Rev Esp Med Nucl** 1999;18(1):43–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cardiovascular evaluation of the young athlete. Luckstead EF. **Adolesc Med** 1998 Oct;9(3):441–55, v (25 ref.)
Prospective diagnosis of alveolar capillary dysplasia in infants with congenital heart disease. Lane JR, et al. **Am J Cardiol** 1999 Sep 1;84(5):618–20, A9–10
Mixed type of total anomalous pulmonary venous connection. Imoto Y, et al. **Ann Thorac Surg** 1998 Oct;66(4):1394–7
Examination for cardiac malformations at six weeks of age. Gregory J, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F46–8
Presentation of congenital heart disease in infancy: implications for routine examination. Wren C, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F49–53
Down's syndrome, cardiac anomalies, and nuchal translucency [editorial; comment] Mol BW. **BMJ** 1999 Jan 9;318(7176):70–1. Comment on: BMJ 1999 Jan 9;318(7176):81–5.
Anomalous left coronary artery arising from the right pulmonary artery [letter] da Cruz E. **Cardiol Young** 1999 Jan;9(1):109
Detection of cardiovascular abnormalities in the nursery of a general hospital in the Amazon region: correlation with potential risk factors. Ferreira SM, et al. **Cardiol Young** 1999 Mar;9(2):163–8
Rare forms of isolation of the subclavian artery: echocardiographic diagnosis and surgical considerations [see comments] McElhinney DB, et al. **Cardiol Young** 1998 Jul;8(3):344–51. Comment in: Cardiol Young 1999 Mar;9(2):233–5.
Early clinical screening of neonates for congenital heart defects: the cases we miss. Meberg A, et al. **Cardiol Young** 1999 Mar;9(2):169–74
Catheterization of the pulmonary artery using a 3 French catheter in patients with congenital heart disease. Mori Y, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):45–50
Cardiovascular evaluation in thoracopagus twins. Casta A. **Circulation** 1999 Jul 6;100(1):103
Double-orifice mitral valve. Lee DI, et al. **Clin Cardiol** 1999 Jun;22(6):425
Preventing sudden death in student athletes. Weiner HR. **Compr Ther** 1999 Mar;25(3):151–4
CHARGE association. Toriello HV. **Ear Nose Throat J** 1999 Jun;78(6):413 (4 ref.)
Prognosis following prenatal diagnosis of heart malformations. Rodriguez JG, et al. **Early Hum Dev** 1998 Aug 28;52(1):13–20
Persisting spongy myocardium. A case indicating the difficulty of antenatal diagnosis. Winer N, et al. **Fetal Diagn Ther** 1998 Jul–Aug;13(4):227–32
Application of a low cost telemedicine link to the diagnosis of neonatal congenital heart defects by remote consultation. Mulholland HC, et al. **Heart** 1999 Aug;82(2):217–21
Imaging the heart in adult congenital heart disease [editorial] Stumper O. **Heart** 1998 Dec;80(6):535–6
Anomalous drainage of right superior vena cava into the left atrium. Kothari SS, et al. **Indian Heart J** 1998 May–Jun; 50(3):332–4
Acardiac anceps. Rajangam S, et al. **Indian Heart J** 1999 Jan–Feb;51(1):86–7
Magnetic resonance imaging of complex congenital heart disease. Yoo SJ, et al. **Int J Card Imaging** 1999 Apr; 15(2):151–60
Subdivided left atrium mimicking a cardiac tumor. Shimaya K, et al. **Int J Cardiol** 1999 Feb 28;68(2):235–8
Aortico-right ventricular tunnel. Talwar S, et al. **Int J Cardiol** 1999 Jul 31;70(2):201–5 (11 ref.)
Screening for congenital heart malformation in child health centres. Juttmann RE, et al. **Int J Epidemiol** 1998 Dec; 27(6):989–94
New real-time interactive cardiac magnetic resonance imaging system complements echocardiography. Yang PC, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2049–56
Hydrometrocolpos and polydactyly: a common neonatal presentation of Bardet-Biedl and McKusick-Kaufman syndromes. David A, et al. **J Med Genet** 1999 Aug; 36(8):599–603
The evolution of diagnostic trends in congenital heart disease: A population-based study. Grech V. **J Paediatr Child Health** 1999 Aug;35(4):387–91
Clinical characteristics of CHARGE syndrome. Ahn BS, et al. **Korean J Ophthalmol** 1998 Dec;12(2):130–4
Telemedicine consultations in congenital heart disease: assessment of advanced technical capabilities [see comments] Julsrud PR, et al. **Mayo Clin Proc** 1999 Aug; 74(8):758–63. Comment in: Mayo Clin Proc 1999 Aug;74(8):841–3.
Was DiGeorge's syndrome considered in the setting of conotruncal congenital cardiac defects? [letter; comment] Alexander D. **Md Med J** 1999 Jan–Feb;48(1):5. Comment on: Md Med J 1998 Aug;47(4):177–81.
Neonatal cardiac surgery. Cardarelli MG, et al. **Md Med J** 1998 Nov;47(5):230–4 (3 ref.)
Morphology of the atrioventricular valve in patients with right atrial isomerism [letter] Francalanci P, et al. **Pediatr Cardiol** 1998 Nov–Dec;19(6):501
Differentiation of systemic infection and congenital obstructive left heart disease in the very young infant. Pickert CB, et al. **Pediatr Emerg Care** 1998 Aug;14(4):263–7
MRI: complacency or ascendancy in the evaluation of congenital heart disease [editorial] Fellows KE, et al. **Pediatr Radiol** 1999 Jul;29(7):491–5
Failure to diagnose congenital heart disease in infancy. Kuehl KS, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):743–7
MR imaging of adult patients with congenital heart disease. Wimpfheimer O, et al. **Radiol Clin North Am** 1999 Mar; 37(2):421–38, vii (79 ref.)
Chest film diagnosis of congenital heart disease. Fayad LM, et al. **Semin Roentgenol** 1999 Jul;34(3):228–48 (46 ref.)
MRI and echocardiography: how do they compare in adults? Hartnell GG, et al. **Semin Roentgenol** 1998 Jul;33(3):252–61 (47 ref.)
Commercial availability and general clinical use of MR systems began about 1980 [editorial] Hubbard AM, et al. **Semin Roentgenol** 1998 Jul;33(3):214
Preoperative and postoperative MRI of congenital heart disease. Hubbard AM, et al. **Semin Roentgenol** 1998 Jul; 33(3):218–27 (57 ref.)
MRI and echocardiography in children: how do they compare? Marx GR, et al. **Semin Roentgenol** 1998 Jul; 33(3):281–92 (36 ref.)
Aortic arch and pulmonary artery anomalies in children. Weinberg PM, et al. **Semin Roentgenol** 1998 Jul; 33(3):262–80 (35 ref.)
Comparison of prenatal ultrasound and postmortem findings in fetuses and infants with congenital heart defects. Isaksen CV, et al. **Ultrasound Obstet Gynecol** 1999 Feb; 13(2):117–26
[Congenital cardiopathies in adult age. A growing problem. A new "subspecialty"? (editorial)] Almange C. **Arch Mal Coeur Vaiss** 1999 May;92(5):553–5 **(Fre)**
[What's new in pediatric cardiology?] Bonnet D, et al. **Arch Pediatr** 1999 Jul;6(7):777–80 (19 ref.) (Eng. Abstr.) **(Fre)**
[Pediatric consequences of prenatal diagnosis of heart abnormalities and rhythm problems] Le Bidois J. **Arch Pediatr** 1999;6 Suppl 2:233s–234s **(Fre)**
[Towards the disappearance of congenital heart disease?] Vernant P. **Rev Prat** 1999 Feb 15;49(4):360–2 **(Fre)**
[CHARGE association: 4 case reports] Siala Gaigi S, et al. **Tunis Med** 1999 May;77(5):297–302 (Eng. Abstr.) **(Fre)**
[Isolated abnormality ("noncompaction") of the myocardium in 3 children] Hussein A, et al. **Klin Padiatr** 1999 May–Jun; 211(3):175–8 (Eng. Abstr.) **(Ger)**
[The magnetic resonance tomography of complex congenital heart diseases in adults] Bremerich J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Apr;170(4):397–403 (30 ref.) (Eng. Abstr.) **(Ger)**
[Congenital left ventricular aneurysms and diverticula: clinical findings, diagnosis and course] Mayer K, et al. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1249–56 (Eng. Abstr.) **(Ger)**
[What is your diagnosis? Polysplenia syndrome (syn. cardiosplenic syndrome, Ivemark syndrome, left isometry, bilateral left-sidedness)] Hauser M, et al. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1339–44 **(Ger)**
[Pregnancy in mothers with congenital heart defects. An overview] Schmaltz AA, et al. **Z Geburtshilfe Neonatol** 1999 May–Jun;203(3):101–9 (68 ref.) (Eng. Abstr.) **(Ger)**
[Complex congenital cardiopathies in adults] Picchio FM, et al. **Cardiologia** 1998 Oct;43(10):999–1010 (101 ref.) **(Ita)**
[Prenatal cardiology. Suspicion to confirmation] Macedo AJ, et al. **Acta Med Port** 1998 Jul;11(7):655–8 (Eng. Abstr.) **(Por)**
[Absence of right atrioventricular connection. Morphological and clinical presentation when the dominant ventricle is morphologically right] Cavalini JF, et al. **Arq Bras Cardiol** 1998 Dec;71(6):793–6 (Eng. Abstr.) **(Por)**
[What is your diagnosis? Midline thoracic defect] García Angleu F, et al. **An Esp Pediatr** 1999 Apr;50(4):411–2 **(Spa)**

DRUG THERAPY

Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Thorne SA, et al. **Circulation** 1999 Jul 13;100(2):149–54
Prostaglandin E1 in infants with congenital heart disease: Indian experience. Saxena A, et al. **Indian Pediatr** 1998 Nov;35(11):1063–9
Critical pharmacologic management in the emergency department. Rosenberg NM, et al. **Pediatr Emerg Care** 1998 Oct;14(5):376–9
Brown fat necrosis in the setting of congenital heart disease and prostaglandin E1 use: a case report. Raboi CA, et al. **Pediatr Radiol** 1999 Jan;29(1):61–3
Inhaled nitric oxide and high concentrations of oxygen in pediatrics patients with congenital cardiopathy and pulmonary hypertension: report of five cases. de Carvalho WB, et al. **Rev Paul Med** 1998 Jan–Feb;116(1):1602–5

EMBRYOLOGY

Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Bruneau BG, et al. **Dev Biol** 1999 Jul 1;211(1):100–8
Expression of the Mf1 gene in developing mouse hearts: implication in the development of human congenital heart defects. Swiderski RE, et al. **Dev Dyn** 1999 Sep; 216(1):16–27
Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Wu H, et al. **Development** 1999 Aug; 126(16):3597–605
Use of hematoxylin stain to enhance evaluation of heart malformations in the fetal rat. Eggers J, et al. **Teratology** 1999 Mar;59(3):173–5

ENZYMOLOGY

The myocardial profile of the cytosolic isozymes of creatine kinase is apparently not related to cyanosis in congenital heart disease. Kessler-Icekson G, et al. **Mol Med** 1999 Feb; 5(2):110–6

EPIDEMIOLOGY

Nausea during pregnancy and congenital heart defects: a population-based case-control study. Boneva RS, et al. **Am J Epidemiol** 1999 Apr 15;149(8):717–25
Estimating the prevalence of malformation of the heart in the first year of life using capture-recapture methods. Smeeton NC, et al. **Am J Epidemiol** 1999 Oct 1; 150(7):778–85
The Italian Multicentric Study on Epidemiology of Congenital Heart Disease: first step of the analysis. Working Party of the Italian Society of Pediatric Cardiology. Bosi G, et al. **Cardiol Young** 1999 May; 9(3):291–9
On congenital heart disease in developing countries [editorial; comment] Ebels T. **Cardiol Young** 1998 Oct;8(4):425–7. Comment on: Cardiol Young 1998 Oct;8(4):437–9. Comment on: Cardiol Young 1998 Oct;8(4):486–90.
Detection of cardiovascular abnormalities in the nursery of a general hospital in the Amazon region: correlation with potential risk factors. Ferreira SM, et al. **Cardiol Young** 1999 Mar;9(2):163–8
Regional differences in birth prevalence of congenital heart disease in Malta. Grech V, et al. **Cardiol Young** 1999 Mar; 9(2):150–4

Seasonality in live births with congenital heart disease in Malta. Grech V. **Cardiol Young** 1999 Jul;9(4):396–401 (25 ref.)
Early clinical screening of neonates for congenital heart defects: the cases we miss. Meberg A, et al. **Cardiol Young** 1999 Mar;9(2):169–74
Is prevention of sudden death in young athletes feasible? ?biene G, et al. **Cardiologia** 1999 Jun;44(6):497–505 (70 ref.)
Syndromes and malformations associated with congenital heart disease in a population–based study. Grech V, et al. **Int J Cardiol** 1999 Feb 28;68(2):151–6
Automation of follow–up and data analysis of paediatric heart disease in Malta. Grech V, et al. **Int J Cardiol** 1999 Feb 28;68(2):145–9
Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus–infected women: the prospective P2C2 HIV Multicenter Study. P2C2 HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Lai WW, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1749–55
[A study on the genetic epidemiology of congenital heart disease] Liu CY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):224–6 (Eng. Abstr.) **(Chi)**
[Congenital cardiopathies: anatomo–clinical, prognostic, and therapeutic features apropos of 103 cases seen at the Cardiology Clinic of the Dakar University Hospital Center] Diop IB, et al. **Dakar Med** 1995;40(2):181–6 (16 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiologic and developmental aspects of congenital cardiopathies in the Sfax pediatric service: 123 cases] Chaabouni M, et al. **Tunis Med** 1999 May;77(5):264–71 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Cardiac anomalies in the Simpson–Golabi–Behmel syndrome. Lin AE, et al. **Am J Med Genet** 1999 Apr 23;83(5):378–81 (38 ref.)
Maternal Lyme disease and congenital heart disease: A case–control study in an endemic area. Strobino B, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):711–6
Maternal risk factors and major associated defects in infants with Down syndrome. Torfs CP, et al. **Epidemiology** 1999 May;10(3):264–70
Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus–infected women: the prospective P2C2 HIV Multicenter Study. P2C2 HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Lai WW, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1749–55
[Epidemiologic and developmental aspects of congenital cardiopathies in the Sfax pediatric service: 123 cases] Chaabouni M, et al. **Tunis Med** 1999 May;77(5):264–71 (Eng. Abstr.) **(Fre)**

GENETICS

A loss–of–function mutation in the endothelin–converting enzyme 1 (ECE–1) associated with Hirschsprung disease, cardiac defects, and autonomic dysfunction [letter] Hofstra RM, et al. **Am J Hum Genet** 1999 Jan;64(1):304–8
Seven new cases of Cayler cardiofacial syndrome with chromosome 22q11.2 deletion, including a familial case [letter] Bawle EV, et al. **Am J Med Genet** 1998 Oct 12; 79(5):406–10
Ebstein anomaly associated with rearrangements of chromosomal region 11q. de Lonlay–Debeney P, et al. **Am J Med Genet** 1998 Nov 2;80(2):157–9
Congenital heart defect in sibs with discordant karyotypes. Digilio MC, et al. **Am J Med Genet** 1998 Nov 2; 80(2):169–72
Genetic heterogeneity of isolated noncompaction of the left ventricular myocardium [letter; comment] Digilio MC, et al. **Am J Med Genet** 1999 Jul 2;85(1):90–1. Comment on: Am J Med Genet 1997 Oct 31;72(3):257–65.
Jagged1 mutations in patients ascertained with isolated congenital heart defects. Krantz ID, et al. **Am J Med Genet** 1999 May 7;84(1):56–60
Ventricular noncompaction and distal chromosome 5q deletion. Pauli RM, et al. **Am J Med Genet** 1999 Aug 6; 85(4):419–23
GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. Pehlivan T, et al. **Am J Med Genet** 1999 Mar 19; 83(3):201–6
Rare dental abnormalities seen in oculo–facio–cardio–dental (OFCD) syndrome: three new cases and review of nine patients. Schulze BR, et al. **Am J Med Genet** 1999 Feb 19;82(5):429–35 (9 ref.)
Congenital heart defects in Sotos syndrome [letter] Tsukahara M, et al. **Am J Med Genet** 1999 May 21;84(2):172
Associations between chromosomal anomalies and congenital heart defects: a database search. van Karnebeek CD, et al. **Am J Med Genet** 1999 May 21;84(2):158–66
A population study of chromosome 22q11 deletions in infancy. Goodship J, et al. **Arch Dis Child** 1998 Oct; 79(4):348–51
The CHARGE association: the role of tracheotomy. Roger G, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jan; 125(1):33–8
Right aortic arch with coarctation proximal to the right subclavian artery and Kommerell's diverticulum [letter] Momma K. **Cardiol Young** 1998 Jul;8(3):413–4
Isolation of the subclavian artery associated with chromosome 22q11 deletion [letter; comment] Momma K. **Cardiol Young** 1999 Mar;9(2):233–5. Comment on: Cardiol Young 1998 Jul;8(3):344–51.
Molecular genetics of congenital heart disease. A problem of faulty septation. [editorial] Schiaffino S, et al. **Circ Res** 1999 Feb 5;84(2):247–9
Adams–Oliver syndrome associated with cardiovascular malformations. Lin AE, et al. **Clin Dysmorphol** 1998 Oct; 7(4):235–41 (18 ref.)
Recent progress in the molecular genetics of congenital heart defects. Belmont JW. **Clin Genet** 1998 Jul;54(1):11–9 (91 ref.)
Developmental and genetic aspects of congenital heart disease. Srivastava D. **Curr Opin Cardiol** 1999 May; 14(3):263–8 (36 ref.)
Heart malformations in transgenic mice exhibiting dominant negative inhibition of gap junctional communication in neural crest cells. Sullivan R, et al. **Dev Biol** 1998 Dec 1;204(1):224–34
Expression of the Mf1 gene in developing mouse hearts: implication in the development of human congenital heart defects. Swiderski RE, et al. **Dev Dyn** 1999 Sep; 216(1):16–27
The mammalian Tolloid–like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Clark TG, et al. **Development** 1999 Jun;126(12):2631–42
Transgenic rescue of congenital heart disease and spina bifida in Splotch mice. Li J, et al. **Development** 1999 Jun; 126(11):2495–503
Fine mapping of Noonan/cardio–facio cutaneous syndrome in a large family. Legius E, et al. **Eur J Hum Genet** 1998 Jan;6(1):32–7
Prevalence of the microdeletion 22q11 in newborn infants with congenital conotruncal cardiac anomalies. Iserin L, et al. **Eur J Pediatr** 1998 Nov;157(11):881–4
Chromosome 22q11 microdeletion and congenital heart disease--a survey in a paediatric population. Yong DE, et al. **Eur J Pediatr** 1999 Jul;158(7):566–70
The cardiac mutant Mexican axolotl is a unique animal model for evaluation of cardiac myofibrillogenesis. Zajdel RW, et al. **Exp Cell Res** 1999 May 1;248(2):557–66
Chromosome 22q11 deletions in patients with selected outflow tract malformations. Frohn–Mulder IM, et al. **Genet Couns** 1999;10(1):35–41
The deletions of 22q11--the Portuguese experience. Gaspar IM, et al. **Genet Couns** 1999;10(1):51–7
Behavior problems and personality aspects of 40 children with velo–cardio–facial syndrome. Heineman–de Boer JA, et al. **Genet Couns** 1999;10(1):89–93
Congenital heart defects in patients with DiGeorge/velocardiofacial syndrome and del22q11. Marino B, et al. **Genet Couns** 1999;10(1):25–33 (73 ref.)
Retrospective analysis of feeding and speech disorders in 50 patients with velo–cardio–facial syndrome. Rommel N, et al. **Genet Couns** 1999;10(1):71–8
The behavioural phenotype in velo–cardio–facial syndrome (VCFS): from infancy to adolescence. Swillen A, et al. **Genet Couns** 1999;10(1):79–88 (17 ref.)
Catch 22--microdeletion 22q11 screening in patients with congenital heart defects. Von Beust G, et al. **Genet Couns** 1998;9(3):223–7
Advances in the molecular genetics of congenital structural heart disease. Mah CS, et al. **Genet Test** 1999;3(2):157–72 (153 ref.)
Isolation and characterization of a human gene containing a nuclear localization signal from the critical region for velo–cardio–facial syndrome on 22q11. Funke B, et al. **Genomics** 1998 Oct 15;53(2):146–54
Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Tennstedt C, et al. **Heart** 1999 Jul;82(1):34–9
Genomic organization and mutational analysis of KVLQT1, a gene responsible for familial long QT syndrome. Itoh T, et al. **Hum Genet** 1998 Sep;103(3):290–4
Guidelines for 22q11 deletion screening of patients with conotruncal defects [letter; comment] Digilio MC, et al. **J Am Coll Cardiol** 1999 May;33(6):1746–8. Comment on: J Am Coll Cardiol 1998 Aug;32(2):492–8.
Tricuspid atresia and conotruncal malformations in five families [letter] Bonnet D, et al. **J Med Genet** 1999 Apr; 36(4):349–50
22q11 deletions in patients with conotruncal heart defects. Worthington S, et al. **J Paediatr Child Health** 1998 Oct; 34(5):438–43
Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS). Mazzanti L, et al. **J Pediatr** 1998 Nov;133(5):688–92
The role of the brachyury gene in heart development and left–right specification in the mouse. King T, et al. **Mech Dev** 1998 Dec;79(1–2):29–37
Molecular genetic analysis of the DiGeorge syndrome among Korean patients with congenital heart disease. Hur H, et al. **Mol Cells** 1999 Feb 28;9(1):72–7
Congenital heart defects and 22q11 deletions: which genes count? Lindsay EA, et al. **Mol Med Today** 1998 Aug; 4(8):350–7 (56 ref.)
Congenital heart disease in mice deficient for the DiGeorge syndrome region [see comments] Lindsay EA, et al. **Nature** 1999 Sep 23;401(6751):379–83. Comment in: Nature 1999 Sep 23;401(6751):335–7.
Genetics. Engineering a broken heart [news; comment] Scambler PJ. **Nature** 1999 Sep 23;401(6751):335–7. Comment on: Nature 1999 Sep 23;401(6751):279–83.
Anomalies of genetic development as predictors of oculo–visual abnormalities in velo–cardio–facial syndrome. Crewther SG, et al. **Optom Vis Sci** 1998 Oct;75(10):748–57
Aortic arch anomalies associated with chromosome 22q11 deletion (CATCH 22). Momma K, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):97–102 (40 ref.)
Turner's syndrome: cardiologic profile according to the different chromosomal patterns and long–term clinical follow–Up of 136 nonpreselected patients. Prandstraller D, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):108–12
Different TBX5 interactions in heart and limb defined by Holt–Oram syndrome mutations. Basson CT, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2919–24
A gene that scrambles your heart [news; comment] Hagmann M. **Science** 1999 Feb 19;283(5405):1091,1093. Comment on: Science 1999 Feb 19;283(5405):1158–61.
A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects [see comments] Yamagishi H, et al. **Science** 1999 Feb 19;283(5405):1158–61. Comment in: Science 1999 Feb 19;283(5405):1091, 1093.
Risk factors for heart defects in Down syndrome [letter; comment] Faivre L, et al. **Teratology** 1999 Mar;59(3):132 . Comment on: Teratology 1998 Jul;58(1):6–12.
Congenital heart disease: a direct result of chromosomal duplication [letter; comment] Ferencz C, et al. **Teratology** 1999 Jan;59(1):3. Comment on: Teratology 1998 Jul;58(1):6–12.
Transgenic over–expression of a motor protein at high levels results in severe cardiac pathology. James J, et al. **Transgenic Res** 1999 Feb;8(1):9–22
HAND proteins: molecular mediators of cardiac development and congenital heart disease. Srivastava D. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1–2):11–8 (42 ref.)
Variable clinical expression of Holt–Oram syndrome in three generations. Oğur G, et al. **Turk J Pediatr** 1998 Oct–Dec; 40(4):613–8
[Susceptibility gene location of simple congenital heart defect by transmission disequilibrium test] Zhang K, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Aug; 16(4):239–41 (Eng. Abstr.) **(Chi)**
[A study on the genetic epidemiology of congenital heart disease] Liu CY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):224–6 (Eng. Abstr.) **(Chi)**
[What's new in pediatric cardiology?] Bonnet D, et al. **Arch Pediatr** 1999 Jul;6(7):777–80 (19 ref.) (Eng. Abstr.) **(Fre)**
[Congenital cardiovascular malformations and chromosome microdeletions in 22q11.2] Trost D, et al. **Dtsch Med Wochenschr** 1999 Jan 8;124(1–2):3–7 (Eng. Abstr.) **(Ger)**
[Genetics in cardiology. An update] Vosberg HP. **Internist (Berl)** 1999 May;40(5):522–33 (63 ref.) **(Ger)**

HISTORY

Summary of the 1998 annual meeting's scientific sessions. Martz EW. **Del Med J** 1999 Feb;71(2):77–80
50th anniversary historical article. Congenital heart disease. Engle MA. **J Am Coll Cardiol** 1999 Mar 15;33(4):905–8

METABOLISM

Plasma metabolites after a lipid load in infants with congenital heart disease. Lundell KH, et al. **Acta Paediatr** 1999 Jul; 88(7):718–23
Myocardial aerobic metabolism is impaired in a cell culture model of cyanotic heart disease. Merante F, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1673–81
Role of vitamin A in the formation of congenital heart defects. Sinning AR. **Anat Rec** 1998 Oct;253(5):147–53 (42 ref.)
Retinoic acid is required in the mouse embryo for left–right asymmetry determination and heart morphogenesis. Chazaud C, et al. **Development** 1999 Jun;126(12):2589–96
Measured versus predicted oxygen consumption in children with congenital heart disease. Laitinen PO, et al. **Heart** 1998 Dec;80(6):601–5
Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Culligan KG, et al. **Int J Mol Med** 1998 Dec;2(6):639–48 (120 ref.)
Increased energy expenditure in infants with cyanotic congenital heart disease. Leitch CA, et al. **J Pediatr** 1998 Dec;133(6):755–60
[The nutritional status of the child with congenital cardiopathy] Thompson Chagoyán OC, et al. **Arch Inst Cardiol Mex** 1998 Mar–Apr;68(2):119–23 (Eng. Abstr.) **(Spa)**

MORTALITY

Declining mortality from congenital heart disease related to innovations in diagnosis and treatment: a population–based study. Grech V, et al. **Cardiol Young** 1999 Jan;9(1):78–80
Results of 546 Blalock–Taussig shunts performed in 478 patients [see comments] Al Jubair KA, et al. **Cardiol Young** 1998 Oct;8(4):486–90. Comment in: Cardiol Young 1998 Oct;8(4):425–7.
Life insurance implications of mortality for up to 40 years after repair of congenital heart defects in childhood.

Cumming GR. **J R Soc Med** 1999 Feb;92(2):73–8 (28 ref.)
Professional misconduct: the Bristol case [see comments] Bolsin SN. **Med J Aust** 1998 Oct 5;169(7):369–72. Comment in: Med J Aust 1998 Oct 5;169(7):351–2. Comment in: Med J Aust 1998 Oct 5;169(7):352–3.

PATHOLOGY

Congenital heart defects in Sotos syndrome. Noreau DR, et al. **Am J Med Genet** 1998 Oct 2;79(4):327–8
Costello syndrome: report and review. van Eeghen AM, et al. **Am J Med Genet** 1999 Jan 15;82(2):187–93 (38 ref.)
Compression of the central airways by a dilated aorta in infants and children with congenital heart disease. McElhinney DB, et al. **Ann Thorac Surg** 1999 Apr; 67(4):1130–6
Inoperable pulmonary vascular disease in infants with congenital heart disease. Yamaki S, et al. **Ann Thorac Surg** 1998 Nov;66(5):1565–70
Persistence of the left superior caval vein: can it potentiate obstructive lesions of the left ventricle? Agnoleti G, et al. **Cardiol Young** 1999 May;9(3):285–90
Defective lateralisation in children with congenitally malformed hearts. Anderson RH, et al. **Cardiol Young** 1998 Oct;8(4):512–31 (39 ref.)
A strange complex of diffuse congenital cardiovascular disease and cardiomyopathy, with localised myocardial calcification [clinical conference] Gerlis LM, et al. **Cardiol Young** 1999 Jul;9(4):348–56
Acardiac acephalus: a case report and implications on expectant management. Law KS, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):334–8
Hypocalvaria associated with intrauterine growth retardation, facial dysmorphism, congenital heart disease and camptomelia. al-Gazali LI, et al. **Clin Dysmorphol** 1999 Apr;8(2):129–34
A boy with choanal atresia and cardiac defect: Burn-McKeown syndrome? Toriello HV, et al. **Clin Dysmorphol** 1999 Apr;8(2):143–5
From functional pulmonary atresia to right ventricular restriction. Long term follow up of Uhl's anomaly. Tumbarello R, et al. **Int J Cardiol** 1998 Dec 1;67(2):161–4
Tracheobronchial anomalies in children with congenital cardiac disease. Kazim R, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):553–5
Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Sabet HY, et al. **Mayo Clin Proc** 1999 Jan;74(1):14–26
Congenital hepatic fibrosis of heterotopic hepatic tissue. Zlatković M, et al. **Pathol Res Pract** 1998;194(7):523–6
Prosopo-thoracopagus conjoined twins and other cephalopagus-thoracopagus intermediates: case report and review of the literature. Spencer R, et al. **Pediatr Dev Pathol** 1998 Mar-Apr;1(2):164–71 (18 ref.)
[The acardiac fetus. Case report and review of the literature] Seket B, et al. **Tunis Med** 1998 Aug-Sep;76(8–9):271–5 **(Fre)**
[Single ventricle (cor trilocular biatriatum). A case report] Roos G, et al. **Pathologe** 1998 Nov;19(6):430–5 (27 ref.) (Eng. Abstr.) **(Ger)**
[Magnetic resonance in congenital cardiopathy. Part I] Midiri M, et al. **Radiol Med (Torino)** 1998 Oct;96(4):289–99 (26 ref.) **(Ita)**
[Magnetic resonance in congenital cardiopathy. Part II] Midiri M, et al. **Radiol Med (Torino)** 1998 Nov;96(5):425–33 (25 ref.) **(Ita)**
[Persistent common trunk. Anatamopathological study of 25 specimen] Muñoz Castellanos L, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):113–20 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Long-term growth of children with congenital heart disease: a retrospective study. Schuurmans FM, et al. **Acta Paediatr** 1998 Dec;87(12):1250–5
Endogenous muscarinic activity attenuates adrenergic inotropic effects in field stimulated atrial myocardium from children with congenital heart defects. Borthne K, et al. **Acta Physiol Scand** 1999 Jan;165(1):9–13
Alterations of myocardial contraction associated with a structural heart defect in embryonic chicks. Godt RE, et al. **Adv Exp Med Biol** 1998;453:453–8; discussion 459
Comparison of the right and left ventricle as a systemic ventricle during exercise in patients with congenital heart disease. Ohuchi H, et al. **Am Heart J** 1999 Jun; 137(6):1185–94
Comparison of echocardiographic acoustic quantification with off-line manual tracing for determining left ventricular volume and ejection fraction in pediatric patients. Hardy BG, et al. **Am J Cardiol** 1998 Dec 1; 82(11):1428–30, A9
SvO2 monitoring during spinal anesthesia and cesarean section in a parturient with severe cyanotic congenital heart disease. Lockhart EM, et al. **Anesthesiology** 1999 Apr; 90(4):1213–5
Elevation of atrial natriuretic peptide prohormone. Hemodynamic background of the elevation of N-terminal natriuretic peptide prohormone in children with congenital heart disease. Holmström H, et al. **Cardiol Young** 1999 Mar; 9(2):141–9
The basics of ventricular function. Penny DJ. **Cardiol Young** 1999 Mar;9(2):210–23 (49 ref.)
Cohen syndrome: evaluation of its cardiac, endocrine and radiological features. Kivitie-Kallio S, et al. **Clin Genet** 1999 Jul;56(1):41–50 (34 ref.)
Prognosis following prenatal diagnosis of heart malformations. Rodriguez JG, et al. **Early Hum Dev** 1998 Aug 28;52(1):13–20
Bi-directional cavopulmonary shunt: is accessory pulsatile flow, good or bad? van de Wal HJ, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):104–10
Clinical and haemodynamic correlates of heart rate variability in children with congenital heart disease. Massin M, et al. **Eur J Pediatr** 1998 Dec;157(12):967–71
Acardiac twins: pathophysiology, diagnosis, outcome and treatment. Six cases and review of the literature. Søgaard K, et al. **Fetal Diagn Ther** 1999 Jan-Feb;14(1):53–9 (34 ref.)
Cardiorespiratory response during exercise in patients with cyanotic congenital heart disease with and without a Fontan operation and in patients with congestive heart failure. Ohuchi H, et al. **Int J Cardiol** 1998 Oct 30; 66(3):241–51
Value of programmed ventricular stimulation in patients with congenital heart disease [see comments] Alexander ME, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1033–44 . Comment in: J Cardiovasc Electrophysiol 1999 Aug;10(8):1045–8.
Oxygen utilization and hemodynamic response during exercise in children after Fontan procedure. Miyairi T, et al. **Jpn Heart J** 1998 Sep;39(5):659–69
The role of the right ventricle during hypobaric hypoxic exercise: insights from patients after the Fontan operation. Garcia JA, et al. **Med Sci Sports Exerc** 1999 Feb; 31(2):269–76
Renal function in cyanotic congenital heart disease. Burlet A, et al. **Nephron** 1999;81(3):296–300
Misregulation of connexin43 gap junction channels and congenital heart defects. Dasgupta C, et al. **Novartis Found Symp** 1999;219:212–21; discussion 221–5 (21 ref.)
Reversed end-diastolic umbilical flow in a first-trimester fetus with congenital heart disease. Borrell A, et al. **Prenat Diagn** 1998 Oct;18(10):1001–5
Left-to-right cardiac shunts: comparison of measurements obtained with MR velocity mapping and with radionuclide angiography. Arheden H, et al. **Radiology** 1999 May; 211(2):453–8
Monitoring the central nervous system in children with congenital heart defects: clinical neurophysiological techniques. Rosenblatt B. **Semin Pediatr Neurol** 1999 Mar; 6(1):27–31 (29 ref.)
MRI for physiology and function in congenital heart disease: functional assessment of the heart preoperatively and postoperatively. Fogel MA, et al. **Semin Roentgenol** 1998 Jul;33(3):239–51 (71 ref.)
MRI for physiology and function: technical advances in MRI of congenital heart disease. Haselgrove JC, et al. **Semin Roentgenol** 1998 Jul;33(3):293–301 (20 ref.)
Altered hemodynamics in chick embryos after extraembryonic venous obstruction. Broekhuizen ML, et al. **Ultrasound Obstet Gynecol** 1999 Jun;13(6):437–45
[The mechanical properties of the lungs in patients with congenital heart defects in the immediate postoperative period] Zatevakhina MV, et al. **Anesteziol Reanimatol** 1998 Jul-Aug;(4):6–10 (Eng. Abstr.) **(Rus)**
[Studies on the function of external respiration in adults and children with anomalous position of the heart chordae] Domnitskaia TM, et al. **Ter Arkh** 1999;71(3):54–7 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Controlled study of preschool development after surgery for congenital heart disease. Wray J, et al. **Arch Dis Child** 1999 Jun;80(6):511–6
Commentary on social research about young people with congenital conditions [editorial; comment] Alderson P. **Cardiol Young** 1998 Jul;8(3):287–9. Comment on: Cardiol Young 1998 Jul;8(3):303–9.
Covert fears, anxiety and depression in congenital heart disease. Gupta S, et al. **Cardiol Young** 1998 Oct;8(4):491–9
Counselling strategies for parents of infants with congenital heart disease. Menahem S. **Cardiol Young** 1998 Jul; 8(3):400–7 (22 ref.)
Growing up with congenital heart disease: the dilemmas of adolescents and young adults [see comment] Tong EM, et al. **Cardiol Young** 1998 Jul;8(3):303–9. Comment on: Cardiol Young 1998 Jul;8(3):287–9.
Conflicting responses: the experiences of fathers of infants diagnosed with severe congenital heart disease. Clark SM, et al. **J Soc Pediatr Nurs** 1999 Jan-Mar;4(1):7–14
Waiting for Melissa. Bruehl C. **Pharos** 1999 Spring;62(2):24–6
[Chronic heart or lung disease and psychosocial stress] Spurkland I, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20; 119(2):209–13 (Eng. Abstr.) **(Nor)**

RADIOGRAPHY

Three-dimensional helical CT of pulmonary arteries in infants and children with congenital heart disease. Westra SJ, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):109–15
Estimating the effective dose to children undergoing heart investigations--a phantom study. Axelsson B, et al. **Br J Radiol** 1999 Apr;72(856):378–83
Images in cardiology. Congenital right pulmonary artery to left atrial fistula. Veldtman G, et al. **Heart** 1998 Aug; 80(2):162
Anomalous insertion of the superior or the inferior vena cava into the right atrium. Takeda K, et al. **Pediatr Cardiol** 1998 Nov-Dec;19(6):474–6
The vascular vise causing TAPVR type I to radiographically mimic TAPVR type III. Patton WL, et al. **Pediatr Radiol** 1999 May;29(5):323–6
Chest roentgenogram in the evaluation of heart defects in asymptomatic infants and children with a cardiac murmur: reproducibility and accuracy. Birkebaek NH, et al. **Pediatrics** 1999 Feb;103(2):E15
Plain film diagnosis of common cardiac anomalies in the adult. Baron MG. **Radiol Clin North Am** 1999 Mar; 37(2):401–20, vi (47 ref.)
Chest film diagnosis of congenital heart disease. Fayad LM, et al. **Semin Roentgenol** 1999 Jul;34(3):228–48 (46 ref.)

RADIONUCLIDE IMAGING

Abnormal brain perfusion demonstrated by Tc-99m MAA total-body scan in two children with complex congenital heart disease. Suga K, et al. **Ann Nucl Med** 1998 Oct; 12(5):297–302
Left-to-right cardiac shunts: comparison of measurements obtained with MR velocity mapping and with radionuclide angiography. Arheden H, et al. **Radiology** 1999 May; 211(2):453–8

REHABILITATION

Case studies of cycle exercise early after cardiothoracic surgery. Knight DR, et al. **J Cardiopulm Rehabil** 1999 May-Jun;19(3):186–9
Exercise testing as a rehabilitative/training tool. Calzolari A, et al. **Pediatr Cardiol** 1999 Jan-Feb;20(1):85–7; discussion 88 (32 ref.)

SURGERY

Functional evaluation of extracardiac ventriculopulmonary conduits and of the right ventricle with magnetic resonance imaging and velocity mapping. Holmqvist C, et al. **Am J Cardiol** 1999 Mar 15;83(6):926–32
Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Tomer A, et al. **Am J Hematol** 1999 May;61(1):53–61
Induced hypothermia in the postoperative management of refractory cardiac failure following paediatric cardiac surgery. Deakin CD, et al. **Anaesthesia** 1998 Sep; 53(9):848–53
A controlled study of transesophageal echocardiography to guide central venous catheter placement in congenital heart surgery patients. Andropoulos DB, et al. **Anesth Analg** 1999 Jul;89(1):65–70
Platelet hyporeactivity in young infants during cardiopulmonary bypass. Ichinose F, et al. **Anesth Analg** 1999 Feb;88(2):258–62
The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. Bailey JM, et al. **Anesthesiology** 1999 Apr; 90(4):1012–8
Intraaortic balloon pumping in children. Akomea-Agyin C, et al. **Ann Thorac Surg** 1999 May;67(5):1415–20
Direct neonatal ventriculo-arterial connections (REV): early results and future implications. Black MD, et al. **Ann Thorac Surg** 1999 Apr;67(4):1137–41
Damus-Kaye-Stansel connections in children with previously transected pulmonary arteries. Broekhuis E, et al. **Ann Thorac Surg** 1999 Feb;67(2):519–21
Repair of total anomalous pulmonary venous connection in infancy: experience from a developing country. Choudhary SK, et al. **Ann Thorac Surg** 1999 Jul;68(1):155–9
Modified Blalock-Taussig shunt with compensatory properties. Corno AF, et al. **Ann Thorac Surg** 1999 Jan; 67(1):269–70
Peritoneal dialysis after infant open heart surgery: observations in 27 patients. Dittrich S, et al. **Ann Thorac Surg** 1999 Jul;68(1):160–3
Drainage of the inferior vena cava to the left atrium. Genoni M, et al. **Ann Thorac Surg** 1999 Feb;67(2):543–5
Comparison of troponin-I and troponin-T after pediatric cardiovascular operation. Immer FF, et al. **Ann Thorac Surg** 1998 Dec;66(6):2073–7
Combined Rastelli and atrial switch procedure: a 10-year follow-up. Jacobs ML, et al. **Ann Thorac Surg** 1999 Aug; 68(2):570–1
Infant cardiopulmonary bypass: a procoagulant state. Jaggers JJ, et al. **Ann Thorac Surg** 1999 Aug;68(2):513–20
Current results with pediatric heart transplantation. Kanter KR, et al. **Ann Thorac Surg** 1999 Aug;68(2):527–30; discussion 530–1
Importance of acquired systemic-to-pulmonary collaterals in the Fontan operation. Kanter KR, et al. **Ann Thorac Surg** 1999 Sep;68(3):969–74; discussion 974–5
Repair of left ventricular diverticulum with ventricular bigeminy in an infant. Kawata H, et al. **Ann Thorac Surg** 1998 Oct;66(4):1421–3
The modified Fontan procedure: morphometry and surgical implications. Kiaffas MG, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1746–53
The incisional pulmonary artery band. Laks H, et al. **Ann Thorac Surg** 1999 Jun;67(6):1813–4

Extended Ross procedure for aortic valve stenosis and ascending aortic and arch hypoplasia. Laudito A, et al. **Ann Thorac Surg** 1999 Feb;67(2):560–1

Ischemic preconditioning in children undergoing open heart operation [letter; comment] Luo WJ. **Ann Thorac Surg** 1998 Dec;66(6):2163–4. Comment on: Ann Thorac Surg 1997 May;63(5):1268–74. Comment on: Ann Thorac Surg 1997 Nov;64(5):1320–4. Comment on: Ann Thorac Surg 1997 Dec;64(6):1874–6.

Pediatric coronary artery bypass for Kawasaki congenital, post arterial switch, and iatrogenic lesions. Mavroudis C, et al. **Ann Thorac Surg** 1999 Aug;68(2):506–12

The Society of Thoracic Surgeons National Congenital Heart Surgery Database Report: analysis of the first harvest (1994–1997). Mavroudis C, et al. **Ann Thorac Surg** 1999 Aug;68(2):601–24

Bidirectional Glenn shunt in association with congenital heart repairs: the 1(1/2) ventricular repair. Mavroudis C, et al. **Ann Thorac Surg** 1999 Sep;68(3):976–81; discussion 982

Heart/single-lung transplant for a "failed Fontan" with pulmonary A–V malformation. Mott AR, et al. **Ann Thorac Surg** 1999 Mar;67(3):841–3

Cardiac transplantation with single-lung pulmonary hypertension [letter; comment] Murphy DA, et al. **Ann Thorac Surg** 1999 Feb;67(2):592. Comment on: Ann Thorac Surg 1998 Mar;65(3):823–5.

Staged surgical approach to neonates with aortic obstruction and single-ventricle physiology. Odim JN, et al. **Ann Thorac Surg** 1999 Sep;68(3):962–7; discussion 968

Valved homograft conduit repair of the right heart in early infancy. Perron J, et al. **Ann Thorac Surg** 1999 Aug; 68(2):542–8

Delayed impairment of cerebral oxygenation after deep hypothermic circulatory arrest in children. Pesonen EJ, et al. **Ann Thorac Surg** 1999 Jun;67(6):1765–70

Pediatric open heart operations without diagnostic cardiac catheterization. Pfammatter JP, et al. **Ann Thorac Surg** 1999 Aug;68(2):532–6

Oxygen transport in critically ill infants after congenital heart operations. Rossi AF, et al. **Ann Thorac Surg** 1999 Mar; 67(3):739–44

Cardiac pacing in premature infants and neonates: steroid eluting leads and automatic output adaptation. Schmid FX, et al. **Ann Thorac Surg** 1999 May;67(5):1400–2

Progressive pulmonary autograft root dilatation and failure after Ross procedure. Takkenberg JJ, et al. **Ann Thorac Surg** 1999 Feb;67(2):551–3; discussion 553–4

Phenoxybenzamine improves systemic oxygen delivery after the Norwood procedure. Tweddell JS, et al. **Ann Thorac Surg** 1999 Jan;67(1):161–7; discussion 167–8

A 26-year review of pectus deformity repairs, including simultaneous intracardiac repair. Willekes CL, et al. **Ann Thorac Surg** 1999 Feb;67(2):511–8

Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Wippermann CF, et al. **Ann Thorac Surg** 1999 Jan;67(1):173–6

Surgical indication for congenital heart disease with extremely thickened media of small pulmonary arteries. Yamaki S, et al. **Ann Thorac Surg** 1998 Nov;66(5):1560–4

Strategies of myocardial protection for operation in chronic model of cyanotic heart disease. Zhang J, et al. **Ann Thorac Surg** 1998 Nov;66(5):1507–13

Complications of modified Blalock–Taussig shunts mimicking pulmonary disease. Coren ME, et al. **Arch Dis Child** 1998 Oct;79(4):361–2

Controlled study of preschool development after surgery for congenital heart disease. Wray J, et al. **Arch Dis Child** 1999 Jun;80(6):511–6

More on the Bristol affair. Look at this case again [letter] Cummings M. **BMJ** 1999 Apr 10;318(7189):1011

Anomalous origin of one pulmonary artery from the ascending aorta: 36 years' experience from one centre. Abu-Sulaiman RM, et al. **Cardiol Young** 1998 Oct; 8(4):449–54

On congenital heart disease in developing countries [editorial; comment] Ebels T. **Cardiol Young** 1998 Oct;8(4):425–7. Comment on: Cardiol Young 1998 Oct;8(4):437–9. Comment on: Cardiol Young 1998 Oct;8(4):486–90.

Experience with the Glenn anastomosis in the adult with cyanotic congenital heart disease. Elizari A, et al. **Cardiol Young** 1999 May;9(3):257–65

Results of 546 Blalock–Taussig shunts performed in 478 patients [see comments] Al Jubair KA, et al. **Cardiol Young** 1998 Oct;8(4):486–90. Comment in: Cardiol Young 1998 Oct;8(4):425–7.

Bidirectional cavopulmonary anastomosis [editorial; comment] Karl TR. **Cardiol Young** 1999 Jan;9(1):2–3 (4 ref.). Comment on: Cardiol Young 1999 Jan;9(1):6–10.

Rare forms of isolation of the subclavian artery: echocardiographic diagnosis and surgical considerations [see comments] McElhinney DB, et al. **Cardiol Young** 1998 Jul;8(3):344–51. Comment in: Cardiol Young 1999 Mar;9(2):233–5.

Banding of the pulmonary trunk in preparation for a Fontan operation. Sakamoto T, et al. **Cardiol Young** 1999 Jan; 9(1):49–54

The real fate of pulmonary arteries after bidirectional superior cavopulmonary anastomosis: is there a need for concern? [see comments] Slavik Z, et al. **Cardiol Young** 1999 Jan;9(1):6–10 (28 ref.). Comment in: Cardiol Young 1999 Jan;9(1):2–3.

Absence of aortic valvar leaflets with normally related great arteries and stiff left ventricle. Yasukochi S, et al. **Cardiol Young** 1999 May;9(3):338–9

Atrial isomerism: a surgical experience. Sinzobahamvya N, et al. **Cardiovasc Surg** 1999 Jun;7(4):436–42

Transcatheter closure of an anomalous venous connection by a novel method. Maheshwari S, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):269–71

Transcatheter recanalization and subsequent stent implantation for the treatment of early postoperative thrombosis of modified Blalock–Taussig shunts in two children. Peuster M, et al. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):405–8

Pulmonary risk factors compromising postoperative recovery after surgical repair for congenital heart disease. Bandla HP, et al. **Chest** 1999 Sep;116(3):740–7

L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Schulze-Neick I, et al. **Circulation** 1999 Aug 17; 100(7):749–55

Twelve deaths in Winnipeg: judge must ponder 48,000 pages of inquest testimony [see comments] Sibbald B. **CMAJ** 1998 Nov 17;159(10):1285–7. Comment in: CMAJ 1999 Feb 9;160(3):313.

RSV and the timing of surgery for congenital heart disease [editorial; comment] Boyer KM. **Crit Care Med** 1999 Sep; 27(9):2065–6. Comment on: Crit Care Med 1999 Sep;27(9):1974–81.

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome [see comments] Khongphatthanayothin A, et al. **Crit Care Med** 1999 Sep;27(9):1974–81. Comment in: Crit Care Med 1999 Sep;27(9):2065–6.

Recent advances in interventional pediatric cardiovascular disease. Maheshwari S, et al. **Curr Opin Cardiol** 1999 Jan; 14(1):73–8 (41 ref.)

Late postoperative follow-up of ostium secundum defect. Groundstroem KW, et al. **Eur Heart J** 1999 Jun; 20(12):904–9

Prediction of behavioural and emotional problems in children and adolescents with operated congenital heart disease. Utens EM, et al. **Eur Heart J** 1998 May;19(5):801–7

Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest. Ashraf S, et al. **Eur J Cardiothorac Surg** 1999 Jul; 16(1):32–7

Successful heart transplantation in a patient with Ivemark syndrome combined with situs inversus, single atrium and ventricle after total cavo-pulmonary connection. Berdat PA, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):631–4

Cardiac surgery with extracorporeal circulation in 23 infants weighing 2500 g or less: short and intermediate term outcome. Beyens T, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):165–72

Myocardial protection by pressure- and volume-controlled continuous hypothermic coronary perfusion in combination with Esmolol and nitroglycerine for correction of congenital heart defects in pediatric risk patients. Borowski A, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):243–9

Orthotopic cardiac transplantation for the failing Fontan circulation. Carey JA, et al. **Eur J Cardiothorac Surg** 1998 Jul;14(1):7–13; discussion 13–4

Induced hypothermia as salvage treatment for refractory cardiac failure following paediatric cardiac surgery. Dalrymple-Hay MJ, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):515–8

Repair of aortico-right ventricular tunnel. van Son JA, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):214–7 (10 ref.)

Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Vogt PR, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):639–44; discussion 644–5

The right auricle tunnel as intercaval tunnel in total cavopulmonary connection may prevent atrial flutter. Waterbolk TW, et al. **Eur J Cardiothorac Surg** 1998 Dec; 14(6):590–5

Equivalent survival following cavopulmonary shunt: with or without the Fontan procedure. Yeh T Jr, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):111–6

The feasibility of complete anatomical correction in the setting of discordant atrioventricular connections. Alva C, et al. **Heart** 1999 May;81(5):539–45

Use of self expanding stents in stenotic aortopulmonary shunts in adults with complex cyanotic heart disease. Bader R, et al. **Heart** 1999 Jul;82(1):27–9

Adenosine induced transient cardiac standstill in catheter interventional procedures for congenital heart disease. De Giovanni JV, et al. **Heart** 1998 Oct;80(4):330–3

Pulmonary and caval flow dynamics after total cavopulmonary connection. Houlind K, et al. **Heart** 1999 Jan;81(1):67–72

Instantaneous pressure-flow velocity relations of systemic venous return in patients with univentricular circulation. Kaulitz R, et al. **Heart** 1999 Sep;82(3):294–9

Intravascular stenting of systemic venous baffle stenosis after corrective surgery for double outlet right ventricle with left isomerism. Miura T, et al. **Heart** 1999 Feb;81(2):218–20

Inappropriate management of polycythaemia in adults with cyanotic congenital heart disease [letter; comment] Rosenthal E, et al. **Heart** 1998 Nov;80(5):532. Comment on: Heart 1998 Apr;79(4):315–6.

Sustained high pressure double balloon angioplasty of calcified conduits. Sreeram N, et al. **Heart** 1999 Feb; 81(2):162–5

Abnormalities in liver function and coagulation profile following the Fontan procedure. van Nieuwenhuizen RC, et al. **Heart** 1999 Jul;82(1):40–6

Computational fluid dynamic and magnetic resonance analyses of flow distribution between the lungs after total cavopulmonary connection. Migliavacca F, et al. **IEEE Trans Biomed Eng** 1999 Apr;46(4):393–9

Anomalous drainage of right superior vena cava into the left atrium. Kothari SS, et al. **Indian Heart J** 1998 May-Jun; 50(3):332–4

Adult cyanotic congenital heart disease: surgical experience. Mohanty SR, et al. **Indian Heart J** 1999 Mar-Apr; 51(2):186–92

Evolution of surgical trends in congenital heart disease: a population based study. Grech V, et al. **Int J Cardiol** 1998 Oct 30;66(3):285–92

Competitive pulmonary flow in infancy: the effect of respiration. Henneveld HT, et al. **Int J Cardiol** 1999 Jan; 68(1):9–12

Soluble L-selectin plasma concentrations in infants undergoing heart surgery: no association with capillary leak syndrome or need for respiratory support. Bührer C, et al. **Intensive Care Med** 1998 Oct;24(10):1093–8

Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Schulze-Neick I, et al. **Intensive Care Med** 1999 Jan;25(1):76–80

Bubble contrast echocardiography in detecting pulmonary arteriovenous shunting in children with univentricular heart after cavopulmonary anastomosis. Chang RK, et al. **J Am Coll Cardiol** 1999 Jun;33(7):2052–8

Troponin-I for prediction of early postoperative course after pediatric cardiac surgery. Immer FF, et al. **J Am Coll Cardiol** 1999 May;33(6):1719–23

Echocardiographic diagnosis alone for the complete repair of major congenital heart defects. Tworetzky W, et al. **J Am Coll Cardiol** 1999 Jan;33(1):228–33

Transesophageal echocardiography guidelines: return to bypass or to bypass the guidelines? [editorial; comment] Fyfe D. **J Am Soc Echocardiogr** 1999 May;12(5):343–4. Comment on: J Am Soc Echocardiogr 1999 Mar;12(3):165–72.

Adherence to physician training guidelines for pediatric transesophageal echocardiography affects the outcome of patients undergoing repair of congenital cardiac defects [see comments] Stevenson JG. **J Am Soc Echocardiogr** 1999 Mar;12(3):165–72. Comment in: J Am Soc Echocardiogr 1999 May;12(5):343–4.

The placement of central venous catheters in infants with cardiac shunts: safety measures and false alarms. Afifi S, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):445–7

The role of intraoperative transesophageal echocardiography during ventricular septation. Iwade M, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):439–41

Effects of phentolamine on tissue perfusion in pediatric cardiac surgery. Köner O, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):191–7

Classic Blalock–Taussig shunt in neonates. Yoshimura N, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):107–10

Evaluation of surgical effect on cardiovascular anomalies associated with corrected transposition of great arteries. Zhang RF, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):53–5

Nonmalignant hyperthermia on induction of anesthesia in a pediatric patient undergoing bidirectional Glenn procedure. Leung WK, et al. **J Clin Anesth** 1998 Aug;10(5):427–31

Mechanical valve replacement in congenital heart disease in children. Lubiszewska B, et al. **J Heart Valve Dis** 1999 Jan;8(1):74–9

Reconstruction of the mitral and aortic annuli for advanced management of the Shone complex. Terry SM, et al. **J Heart Valve Dis** 1999 May;8(3):343–5

Congenital bicuspid aortic valve: analysis of 63 surgical cases. Yotsumoto G, et al. **J Heart Valve Dis** 1998 Sep;7(5):500–3

Scintigraphic assessment of pulmonary and whole-body blood flow patterns after surgical intervention in congenital heart disease. Pruckmayer M, et al. **J Nucl Med** 1999 Sep; 40(9):1477–83

Repair of pediatric pectus deformity and congenital heart disease as a combined procedure. Gittes GK, et al. **J Pediatr Surg** 1999 Aug;34(8):1282–3

Life insurance implications of mortality for up to 40 years after repair of congenital heart defects in childhood. Cumming GR. **J R Soc Med** 1999 Feb;92(2):73–8 (28 ref.)

Long-term clinical and hemodynamic evaluation of porcine valved conduits implanted from the right ventricle to the pulmonary artery. Champsaur G, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):793–804

Left ventricular dysfunction after open repair of simple congenital heart defects [letter; comment] Chaturvedi RR, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):881–4. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):74–6. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):77–83.

The one and a half ventricle repair–we can do it, but should we do it? [editorial] Hanley FL. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):659–61

A successful treatment of serous leakage from a polytetrafluoroethylene Blalock–Taussig shunt with intravenous fibrinogen administration [letter] Hiramatsu Y,

et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1230–1

Experience with one and a half ventricle repair. Kreutzer C, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):662–8

Repair of subdivided left atrium associated with a persistent left superior vena cava (van Son and Hambsch; J Thorac Cardiovasc Surg 1998;116:535) [letter; comment] Kreutzer C. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):880. Comment on: J Thorac Cardiovasc Surg 1998 Sep;116(3):535.

Surgical management of progressive pulmonary venous obstruction after repair of total anomalous pulmonary venous connection. Lacour-Gayet F, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):679–87

Extravascular Doppler measurement of cardiac output in infants and children after operations for congenital heart disease. Lequier LL, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1223–5

Correction of cardiac defects through a right thoracotomy in children [letter; comment] Metras D, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1040–2. Comment on: J Thorac Cardiovasc Surg 1998 Aug;116(2):359–61.

Cryopreserved homograft valves in the pulmonary position: risk analysis for intermediate-term failure. Niwaya K, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):141–6; discussion 146–7

The role of cardiopulmonary bypass and surfactant in pulmonary decompensation after surgery for congenital heart disease. Paul DA, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1025–6

Early results of the extracardiac conduit Fontan operation. Petrossian E, et al. **J Thorac Cardiovasc Surg** 1999 Apr; 117(4):688–96

Results of 102 cases of complete repair of congenital heart defects in patients weighing 700 to 2500 grams. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):324–31

Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease [letter] Schlag G, et al. **J Thorac Cardiovasc Surg** 1998 Dec; 116(6):1082–3

Isolated atrioventricular discordance with solitus viscera, inverted atria, D-loop ventricles, and solitus normally related great arteries: report of a rare case with successful surgical management. Shimpo H, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):393–4 (5 ref.)

Volume-outcome relationships in cardiovascular operations: New York State, 1990–1995. Soliano JA, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):419–28; discussion 428–30

Single-stage repair of aortic arch obstruction and associated intracardiac defects with pulmonary homograft patch aortoplasty. Tchervenkov CI, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):897–904

The extracardiac Fontan procedure using a pedicled pericardial roll without cardiopulmonary bypass [letter; comment] Uemura H, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1046–7. Comment on: J Thorac Cardiovasc Surg 1998 Dec;116(6):1073–5.

Atrioventricular discordance: results of repair in 127 patients. Yeh T Jr, et al. **J Thorac Cardiovasc Surg** 1999 Jun; 117(6):1190–203

Fate of atrial flap used in repair of total anomalous pulmonary venous connection. Imoto Y, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jun;47(6):288–90

Changes in plasma free and sulfoconjugated dopamine in patients with congenital heart disease who underwent cardiac operation. Yoshizumi M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):651–6

In vitro flow visualization on the right ventricular outflow reconstruction utilizing extracardiac conduits: set-up of duplicator system and its clinical significance. Yuan SM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):691–7

Another paediatric cardiac inquiry for the UK [news] Ramsay S. **Lancet** 1999 Aug 7;354(9177):489

Congenitally bicuspid aortic valves: a surgical pathology study of 542 cases (1991 through 1996) and a literature review of 2,715 additional cases. Sabet HY, et al. **Mayo Clin Proc** 1999 Jan;74(1):14–26

Heart transplantation in the pediatric age-group and for end-stage congenital heart defects [editorial; comment] Shumway SJ. **Mayo Clin Proc** 1998 Oct;73(10):1025–6. Comment on: Mayo Clin Proc 1998 Oct;73(10):923–8.

Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team [see comments] Speziali G, et al. **Mayo Clin Proc** 1998 Oct;73(10):923–8. Comment in: Mayo Clin Proc 1998 Oct;73(10):1025–6.

Neonatal cardiac surgery. Cardarelli MG, et al. **Md Med J** 1998 Nov;47(5):230–4 (3 ref.)

Computational fluid dynamic simulations of cavopulmonary connections with an extracardiac lateral conduit. Migliavacca F, et al. **Med Eng Phys** 1999 Apr;21(3):187–93

Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Dorostkar PC, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1810–9

Catheter ablation in a patient with a congenital giant right atrial diverticulum presented as Wolff-Parkinson-White syndrome. Gaita F, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):382–5

Paired ventricular pacing: an alternative therapy for postoperative junctional ectopic tachycardia in congenital heart disease. Kohli V, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):706–10

Convective warming blankets improve peroperative heat preservation in congenital heart surgery. Schlünzen L, et al. **Paediatr Anaesth** 1998;8(5):397–401

Results of surgical treatment of congenital heart defects in children with Down's syndrome. Malec E, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):351–4

Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Tárnok A, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):113–25

Technetium-99m hexamethyl propylenamine oxime lung clearance in the estimation of pulmonary hypertension in congenital heart disease: A preliminary comparative study with cardiac catheterization and pathology. Yener A, et al. **Pediatr Cardiol** 1999 Jul-Aug;20(4):271–7

Successful conservative management of chylopericardium after bilateral Blalock-Taussig shunts. Isobe T, et al. **Pediatr Int** 1999 Aug;41(4):382–4

Neurologic status of newborns with congenital heart defects before open heart surgery. Limperopoulos C, et al. **Pediatrics** 1999 Feb;103(2):402–8

Recent advances in paediatric cardiopulmonary bypass. Elliott MJ. **Perfusion** 1999 Jul;14(4):237–46 (68 ref.)

Prescription and administration of around the clock analgesics in postoperative pediatric cardiovascular surgery patients. Higgins SS, et al. **Prog Cardiovasc Nurs** 1999 Winter;14(1):19–24

Inflammatory reactions following homograft insertion in children with congenital heart disease. Atiq M, et al. **Scand Cardiovasc J** 1998;32(5):285–8

Mechanisms of brain injury during infant cardiac surgery. du Plessis AJ. **Semin Pediatr Neurol** 1999 Mar;6(1):32–47 (215 ref.)

Developmental progress of children with congenital heart defects requiring open heart surgery. Majnemer A, et al. **Semin Pediatr Neurol** 1999 Mar;6(1):12–9 (52 ref.)

Intraoperative transesophageal echocardiography in congenital heart disease. Bengur AR, et al. **Semin Thorac Cardiovasc Surg** 1998 Oct;10(4):255–64 (41 ref.)

Pediatric cardiac surgery in the 1990s [published erratum appears in Surg Clin North Am 1999 Apr;79(2):IX] LeBlanc JG, et al. **Surg Clin North Am** 1998 Oct; 78(5):729–47 (58 ref.)

Experience with an adjustable pulmonary artery banding device in two cases: initial success--midterm failure. Däbritz S, et al. **Thorac Cardiovasc Surg** 1999 Feb; 47(1):51–2

The influence of different strategies on clinical outcome in patients undergoing total cavopulmonary connection. Knez I, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):101–5

Extracardiac repair versus intracardiac baffle repair of complex unroofed coronary sinus. van Son JA, et al. **Thorac Cardiovasc Surg** 1998 Dec;46(6):371–4

Intermediate and long-term results after pediatric heart transplantation: incidence and role of pretransplant diagnosis. Parisi F, et al. **Transpl Int** 1998;11 Suppl 1:S493–8

[Occult fibrin production during surgery in cyanotic congenital heart defects and extracorporeal circulation] Kučera V, et al. **Rozhl Chir** 1999 May;78(5):207–13 (Eng. Abstr.) **(Cze)**

[Immediate and mid-term results of surgery for aortic coarctation in children under 6 months of age] de Kerdaniel-Ariche I, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):607–12 (Eng. Abstr.) **(Fre)**

[Right postero-lateral thoracotomy for open heart surgery in infants and children. Indications and results] Houyel L, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):641–6 (Eng. Abstr.) **(Fre)**

[Treatment of obstruction of prosthetic conduct by percutaneous implantation of stents] Saliba Z, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):591–6 (Eng. Abstr.) **(Fre)**

[Congenital heart disease surgery in Senegal. Indications, evaluation and perspectives] Diop IB, et al. **Dakar Med** 1996;41(2):85–90 (Eng. Abstr.) **(Fre)**

[Sensitivity, specificity, and impact on the surgical strategy of the perioperative neuromonitoring of somatic evoked potentials in vascular surgery performed with circulatory arrest under deep hypothermia] Ghariani S, et al. **Neurophysiol Clin** 1998 Sep;28(4):335–41 (Eng. Abstr.) **(Fre)**

[Postoperative prognosis of congenital cardiac anomalies] Deuvaert FE, et al. **Rev Med Brux** 1998 Sep;19(4):A211–4 (9 ref.) (Eng. Abstr.) **(Fre)**

[Towards the disappearance of congenital heart disease?] Vernant P. **Rev Prat** 1999 Feb 15;49(4):360–2 **(Fre)**

[Indications criteria for total cavopulmonary anastomosis (Fontan operation)] Kraus M, et al. **Schweiz Med Wochenschr** 1999 May 29;129(21):793–8 (Eng. Abstr.) **(Ger)**

[Transesophageal electroconversion of atrial reentrant tachycardias early or late following surgery for congenital heart disease] Hessling G, et al. **Z Kardiol** 1999 Feb; 88(2):97–102 (Eng. Abstr.) **(Ger)**

[The role of a bidirectional cavopulmonary anastomosis in the correction and palliation of complex congenital cardiopathies] Iacona GM, et al. **G Ital Cardiol** 1998 Dec; 28(12):1372–7 (Eng. Abstr.) **(Ita)**

[A successful biventricular repair in an adult case with "common ventricle" and isomeric atrial appendages previously undergoing the conventional Glenn procedure] Yoshida M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov; 46(11):1177–81 (Eng. Abstr.) **(Jpn)**

[Single-dose and high-volume Bretschneider cardioplegic solution for congenital heart surgery] Asano H, et al. **Kyobu Geka** 1999 Jan;52(1):82–6 (Eng. Abstr.) **(Jpn)**

[Total anomalous of pulmonary venous connection in infants less than 3 months old] Hamawaki M, et al. **Kyobu Geka** 1999 Jul;52(7):559–62 (Eng. Abstr.) **(Jpn)**

[Partial median sternotomy for pediatric cardiac surgery] Iwaya F, et al. **Kyobu Geka** 1998 Sep;51(10):829–33 (Eng. Abstr.) **(Jpn)**

[Valve replacement in children] Matsubayashi K, et al. **Kyobu Geka** 1999 Apr;52(4):274–80 (Eng. Abstr.) **(Jpn)**

[Efficacy of intravenous administration of atrial natriuretic peptide after cardiac surgery in neonates and infants] Murakami E, et al. **Kyobu Geka** 1999 Sep;52(10):822–5 (Eng. Abstr.) **(Jpn)**

[Congenital ventricular diverticulum in a neonate: anesthetic considerations] Nakamichi S, et al. **Masui** 1999 Mar; 48(3):275–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic and perioperative management of 1000 cases of congenital heart surgery--massive vasodilator therapy and early extubation] Takeuchi M, et al. **Masui** 1999 Mar; 48(3):251–5 (Eng. Abstr.) **(Jpn)**

[Current view of the indications for surgical treatment of congenital heart diseases (editorial)] Atik E. **Arq Bras Cardiol** 1998 Jul;71(1):1–2 **(Por)**

[Complete cava-pulmonary conjunction in surgical treatment of heart abnormalities with a single functionally active ventricle] Dovgan' AM, et al. **Klin Khir** 1999;(1):13–5 (Eng. Abstr.) **(Rus)**

[Necrotizing enterocolitis in the postop period of cardiac surgery in the neonatal period] Sánchez Sánchez C, et al. **An Esp Pediatr** 1998 Aug;49(2):185–7 **(Spa)**

[Evaluation of the complications of different types of right ventricular bypass by contrast echocardiography] Kreutzer EA, et al. **Arch Inst Cardiol Mex** 1999 Jan-Feb;69(1):40–6 (Eng. Abstr.) **(Spa)**

[Fenestrated Fontan surgery in high risk patients] Ramírez Marroquín S, et al. **Arch Inst Cardiol Mex** 1998 Sep-Oct; 68(5):377–82 (Eng. Abstr.) **(Spa)**

THERAPY

Use of a venous double-lumen cannula for ECMO in a neonate with congenital heart disease [letter; comment] Hisatomi K, et al. **Ann Thorac Surg** 1998 Oct;66(4):1467–8 . Comment on: Ann Thorac Surg 1997 May;63(5):1298–302.

Interventional cardiology in congenital heart disease. Zabal C, et al. **Arch Inst Cardiol Mex** 1999 Jan-Feb;69(1):63–8

DuctOcclud--implant for transcatheter closure of patent ductus arteriosus. Moore JW, et al. **Biomed Tech (Berl)** 1999 Mar;44(3):46–51

Outcome of pregnancy in women with congenital heart disease. Schmaltz AA, et al. **Cardiol Young** 1999 Jan; 9(1):88–96 (68 ref.)

Acute complications in the current era of therapeutic cardiac catheterization for congenital heart disease. Zeevi B, et al. **Cardiol Young** 1999 May;9(3):266–72

Interventional catheterization decreases plasma levels of atrial natriuretic peptide (ANP) in children with congenital heart defects. Zeevi B, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):27–32

Percutaneous translumbar cardiac catheterization and central venous line insertion: an alternative approach in children with congenital heart disease [see comments] Cheatham JP, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):187–92 . Comment in: Catheter Cardiovasc Interv 1999 Feb;46(2):193.

Utility of cardiac catheterization in pediatric cardiac patients on ECMO. desJardins SE, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):62–7

Choice of venous access for cardiac catheterization in patients with congenital heart disease [editorial; comment] Hijazi ZM. **Catheter Cardiovasc Interv** 1999 Feb;46(2):193 . Comment on: Catheter Cardiovasc Interv 1999 Feb;46(2):187–92.

Stent implantation to create interatrial communications in patients with complex congenital heart disease. Pedra CA, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):310–3; discussion 314

Outpatient clinics for adults with congenital heart disease [letter; comment] Freeman LJ, et al. **Heart** 1999 Aug; 82(2):256. Comment on: Heart 1999 Jan;81(1):57–61.

Outpatient clinics for adults with congenital heart disease: increasing workload and evolving patterns of referral [see comments] Gatzoulis MA, et al. **Heart** 1999 Jan;81(1):57–61 . Comment in: Heart 1999 Aug;82(2):256.

Pulmonary vascular disease in pregnancy [letter] Oakley CM. **J Am Coll Cardiol** 1999 Jan;33(1):287

Transmural atrial pacing in patients with postoperative congenital heart disease. Johnsrude CL, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):351–7

Low dose oral anticoagulation therapy in Chinese children with congenital heart disease. Cheung YF, et al. **J Paediatr Child Health** 1998 Dec;34(6):563–7

Gastro-intestinal complications following neonatal cardiac catheterisation. Sweet DG, et al. **J Perinat Med** 1998; 26(3):196–200

Permanent pacing in patients with univentricular heart.

Warfield DA, et al. **Pacing Clin Electrophysiol** 1999 Aug; 22(8):1193–201

Neonatal cardiac catheterization: A 10-year transition from diagnosis to therapy. Shim D, et al. **Pediatr Cardiol** 1999 Mar–Apr;20(2):131–3

Interventional procedures for congenital heart disease. Mandell VS. **Radiol Clin North Am** 1999 Mar;37(2):439–61, vii (98 ref.)

The role of the pediatric neurologist in the management of children with congenital heart defects: a commentary. Shevell MI. **Semin Pediatr Neurol** 1999 Mar;6(1):64–6

[Medico-surgical management of childhood cardiopathy: results of the Liège experience] Massin MM, et al. **Rev Med Liege** 1999 Feb;54(2):95–9 (Eng. Abstr.) **(Fre)**

[Incidence and treatment of reactive infundibular obstruction after balloon dilatation of critical pulmonary valve stenoses] Buheitel G, et al. **Z Kardiol** 1999 May;88(5):347–52 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Abnormal three-vessel view on sonography: a clue to the diagnosis of congenital heart disease in the fetus. Yoo SJ, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):825–30

Diagnosis of heterotaxy syndrome by fetal echocardiography [see comments] Atkinson DE, et al. **Am J Cardiol** 1998 Nov 1;82(9):1147–9, A10. Comment in: Am J Cardiol 1999 Mar 1;83(5):818–9.

Micromultiplane transesophageal echocardiographic probe for intraoperative study of congenital heart disease repair in neonates, infants, children, and adults. Shiota T, et al. **Am J Cardiol** 1999 Jan 15;83(2):292–5, A7

Intraoperative transesophageal echocardiography for pediatric patients with congenital heart disease. Muhiudeen Russell IA, et al. **Anesth Analg** 1998 Nov;87(5):1058–76 (68 ref.)

Double-orifice mitral valve with multiple papillary muscles--a report of two patients. Mao JT, et al. **Angiology** 1999 Sep;50(9):771–5

Telemedicine in paediatric cardiology. Casey FA. **Arch Dis Child** 1999 Jun;80(6):497–9

Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study [see comments] Hyett J, et al. **BMJ** 1999 Jan 9;318(7176):81–5. Comment in: BMJ 1999 Jan 9;318(7176):70–1.

Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. Zosmer N, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):829–33

Right bundle branch block: a source of error in the Doppler assessment of right ventricular pressure in patients with a ventricular septal defect. Warren AE, et al. **Can J Cardiol** 1998 Sep;14(9):1165–7

Double-outlet right ventricle with intact ventricular septum in a foetus with trisomy-18. Patel CR, et al. **Cardiol Young** 1999 Jul;9(4):419–22

Sequential segmental approach to fetal congenital heart disease. Yoo SJ, et al. **Cardiol Young** 1999 Jul;9(4):430–44 (18 ref.)

The four-chamber view and its sensitivity in detecting congenital heart defects. Fernandez CO, et al. **Cardiology** 1998 Dec;90(3):202–6

Ultrasound evaluation of the fetal heart: is it possible? Izquierdo LA, et al. **Compr Ther** 1999 Apr;25(4):193–7 (20 ref.)

Three-dimensional echocardiography in congenital heart disease. Li J, et al. **Curr Opin Cardiol** 1999 Jan;14(1):53–9 (29 ref.)

Assessment of fetal cardiovascular function: ultrasound study of the fetal circulatory compartments. Achiron R, et al. **Curr Opin Obstet Gynecol** 1999 Apr;11(2):119–23 (27 ref.)

Echocardiography in adult congenital heart disease. Houston A, et al. **Heart** 1998 Nov;80 Suppl 1:S12–26 (87 ref.)

Assessment of the quality of neonatal echocardiographic images transmitted by ISDN telephone lines. Houston A, et al. **Heart** 1999 Aug;82(2):222–5

Mixed variety of total anomalous pulmonary venous connection: diagnosis by 2D echocardiography and Doppler colour flow imaging. Saxena A, et al. **Indian Heart J** 1999 Jan–Feb;51(1):65–8

Double chambered right ventricle: delineation by multiplane transoesophageal echocardiography. Sreeram N, et al. **Int J Cardiol** 1998 Oct 30;66(3):309–11

Remote telemedical interpretation of neonatal echocardiograms: impact on clinical management in a primary care setting. Randolph GR, et al. **J Am Coll Cardiol** 1999 Jul;34(1):241–5

Accuracy of prenatal echocardiographic diagnosis and prognosis of fetuses with conotruncal anomalies. Tometzki AJ, et al. **J Am Coll Cardiol** 1999 May;33(6):1696–701

Three-dimensional echocardiographic measurement of right ventricular volume in children with congenital heart disease validated by magnetic resonance imaging. Papavassiliou DP, et al. **J Am Soc Echocardiogr** 1998 Aug; 11(8):770–7

Transesophageal imaging of the mid to distal left pulmonary artery in congenital heart disease. Phoon CK, et al. **J Am Soc Echocardiogr** 1999 Aug;12(8):663–8

Incidence of complications in pediatric transesophageal echocardiography: experience in 1650 cases. Stevenson JG. **J Am Soc Echocardiogr** 1999 Jun;12(6):527–32

Adherence to physician training guidelines for pediatric transesophageal echocardiography affects the outcome of patients undergoing repair of congenital cardiac defects [see comments] Stevenson JG. **J Am Soc Echocardiogr** 1999 Mar;12(3):165–72. Comment in: J Am Soc Echocardiogr 1999 May;12(5):343–4.

First-trimester sonographic diagnosis of Cantrell's pentalogy with exencephaly. Bognoni V, et al. **J Clin Ultrasound** 1999 Jun;27(5):276–8

Prenatal sonographic diagnosis of Cantrell's pentalogy with cystic hygroma in the first trimester. Hsieh YY, et al. **J Clin Ultrasound** 1998 Oct;26(8):409–12

Prenatal sonographic diagnosis of ectopia cordis. Tongsong T, et al. **J Clin Ultrasound** 1999 Oct;27(8):440–5

Isolated noncompaction of the myocardium [letter] Jenni R, et al. **N Engl J Med** 1999 Mar 25;340(12):966–7

Prognostic markers in twin pregnancies with an acardiac fetus. Brassard M, et al. **Obstet Gynecol** 1999 Sep; 94(3):409–14

Fetal cardiac asymmetry: a marker for congenital heart disease. Kirk JS, et al. **Obstet Gynecol** 1999 Feb; 93(2):189–92

Primary care physicians' use of screening echocardiography. Bensky AS, et al. **Pediatrics** 1999 Apr;103(4):e40

Detection of fetal congenital heart disease in a low-risk population. Hafner E, et al. **Prenat Diagn** 1998 Aug; 18(8):808–15

Efficacy of routine fetal ultrasound screening for congenital heart disease in Isère County, France. Klein SK, et al. **Prenat Diagn** 1999 Apr;19(4):318–22

Ultrasound diagnosis of fetal diaphragmatic hernia and complex congenital heart disease at 12 weeks' gestation--a case report. Lam YH, et al. **Prenat Diagn** 1998 Nov; 18(11):1159–62

Prenatal diagnosis of congenital heart malformations: classification based on abnormalities detected by the four-chamber view. Leung MP, et al. **Prenat Diagn** 1999 Apr;19(4):305–13

Prenatal findings in trisomy 16q of paternal origin. Paladini D, et al. **Prenat Diagn** 1999 May;19(5):472–5 (28 ref.)

Evaluation of prenatal diagnosis of congenital heart disease. Stoll C, et al. **Prenat Diagn** 1998 Aug;18(8):801–7

40-MHZ echocardiography scanner for cardiovascular assessment of mouse embryos. Aristizábal O, et al. **Ultrasound Med Biol** 1998 Nov;24(9):1407–17

[Doppler imaging of myocardial tissue: useful in research of aid to the clinician?] Derumeaux G. **Ann Cardiol Angeiol (Paris)** 1998 Nov;47(9):664–7 **(Fre)**

[A new anatomical approach to congenital valve diseases by three-dimensional echocardiography] Acar P, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):583–90 (Eng. Abstr.) **(Fre)**

[Three different types of atrial septal defects in the same family] Cachat F, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):667–9 (Eng. Abstr.) **(Fre)**

[Evolution of ventricular septal defects. Relation to echocardiographic anatomy] Chantepie A, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):623–8 (Eng. Abstr.) **(Fre)**

[Percutaneous closure of ostium secundum atrial septal defects using the Amplatz device. Preliminary study on 29 patients] Rey C, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):565–70 (Eng. Abstr.) **(Fre)**

[Biventricular repair in neonates with hypoplasia of the left ventricle] Serraf A, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):597–605 (Eng. Abstr.) **(Fre)**

[Fetal echocardiography] Schleich JM, et al. **Arch Pediatr** 1998 Nov;5(11):1236–45 (43 ref.) (Eng. Abstr.) **(Fre)**

[Familial heterotaxy syndrome. Case report and review of the international literature] Cesko I, et al. **Orv Hetil** 1998 Nov 15;139(46):2775–8 (45 ref.) (Eng. Abstr.) **(Hun)**

[Congenital heart abnormalities and cardiac dysfunction: how prenatal diagnosis changed the chances for survival] Hajdú J, et al. **Orv Hetil** 1999 Apr 11;140(15):815–8 (Eng. Abstr.) **(Hun)**

[Transthoracic and transesophageal echocardiography in the study of adults with congenital cardiopathy and infectious endocarditis] Vargas Barrón J, et al. **Arch Inst Cardiol Mex** 1998 Jul–Aug;68(4):303–8 (Eng. Abstr.) **(Spa)**

VETERINARY

Comparative mapping of the DiGeorge region in the dog and exclusion of linkage to inherited canine conotruncal heart defects. Werner P, et al. **J Hered** 1999 Jul–Aug; 90(4):494–8

Radiographic assessment of congenital heart disease in calves using silhouette analysis. Farrow CS. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):379–89 (0 ref.)

VIROLOGY

RSV and the timing of surgery for congenital heart disease [editorial; comment] Boyer KM. **Crit Care Med** 1999 Sep; 27(9):2065–6. Comment on: Crit Care Med 1999 Sep;27(9):1974–81.

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome [see comments] Khongphatthanayothin A, et al. **Crit Care Med** 1999 Sep;27(9):1974–81. Comment in: Crit Care Med 1999 Sep;27(9):2065–6.

HEART DISEASE, ISCHEMIC see **MYOCARDIAL ISCHEMIA**

HEART DISEASES

see related

NEUROCIRCULATORY ASTHENIA

Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998. Alexander JH, et al. **Am Heart J** 1999 Mar;137(3):555–74

Chest 1998. The Clinical World Congress on Diseases of the Chest. Toronto, Ontario, Canada. November 8–12, 1998. Abstracts. **Chest** 1998 Oct;114(4 Suppl):249S–436S

Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Eckman MH, et al. **Chest** 1998 Nov;114(5 Suppl):699S–714S

Bibliography current world literature. **Coron Artery Dis** 1998; 9(9):617–22

Bibliography current world literature. **Coron Artery Dis** 1999; 10(2):119–23

Bibliography. Current world literature. **Coron Artery Dis** 1999 May;10(3):199–202

American Diabetes Association Annual Meeting, 1998: cardiac disease and related topics. Bloomgarden ZT. **Diabetes Care** 1998 Oct;21(10):1764–73

Driving and heart disease. Petch MC. **Eur Heart J** 1998 Aug; 19(8):1165–77

Pregnancy and the heart. Williams D. **Hosp Med** 1999 Feb; 60(2):100–4 (18 ref.)

Molecular aspects of adrenergic signal transduction in cardiac failure. Hajjar RJ, et al. **J Mol Med** 1998 Oct;76(11):747–55 (65 ref.)

Electrocardiographic changes in cardiac patients having dental extractions under a local anesthetic containing a vasopressor. Blinder D, et al. **J Oral Maxillofac Surg** 1998 Dec;56(12):1399–402; discussion 1402–3

The older man's heart and heart disease. Aronow WS. **Med Clin North Am** 1999 Sep;83(5):1291–303 (58 ref.)

Heart disease during pregnancy. Which cardiovascular changes reflect disease? [see comments] Villablanca AC. **Postgrad Med** 1998 Nov;104(5):149–56 (17 ref.). Comment in: Postgrad Med 1999 Feb;105(2):33–4.

Travelling with heart disease. Cleland J. **Practitioner** 1998 Feb;242(1583):130–3 (4 ref.)

Use of the 12-item short-form (SF-12) Health Survey in an Australian heart and stroke population. Lim LL, et al. **Qual Life Res** 1999;8(1–2):1–8

Annual scientific meeting of the Thoracic Society of Australia and New Zealand. Canberra, Australia, 26 February–3 March 1999. Abstracts. **Respirology** 1999 Jan; 4 Suppl:A1–68

Thromboembolism in the right side of the heart. Thompson CA, et al. **South Med J** 1999 Aug;92(8):826–30 (29 ref.)

[Cardiology in 1997] Jerie P. **Cas Lek Cesk** 1998 Oct 5; 137(19):585–9 (Eng. Abstr.) **(Cze)**

[Opening ceremonies of the European session of the French Society of Cardiology (15 January 1998)] Bertrand ME. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):783–7 **(Fre)**

[Is it possible to use the term "functional heart diseases"? (editorial)] Makolkin VI. **Ter Arkh** 1998;70(8):5–7 **(Rus)**

[Sex life of pregnant women with cardiopathies] Korbel M. **Ceska Gynekol** 1998 Aug;63(4):305–12 (Eng. Abstr.) **(Slo)**

[Registry of activities of the Section of Hemodynamics and Interventional Cardiology in 1997] Soriano J, et al. **Rev Esp Cardiol** 1998 Dec;51(12):927–38 (Eng. Abstr.) **(Spa)**

BLOOD

Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Igarashi Y, et al. **Am Heart J** 1998 Dec;136(6):965–71

Cholesterol: how low is low enough? Doctors have been slow in getting evidence on lowering cholesterol into practice [letter; comment] Wierzbicki AS, et al. **BMJ** 1999 Feb 20;318(7182):539. Comment on: BMJ 1998 Aug 15;317(7156):425–6.

Effect of acute high dose dobutamine administration on serum thyrotrophin (TSH). Lee E, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):487–92

Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Lainchbury JG, et al. **Clin Sci (Colch)** 1998 Nov; 95(5):547–55

Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Nousiainen T, et al. **Eur J Haematol** 1999 Feb;62(2):135–41

Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. La Vecchia L, et al. **G Ital Cardiol** 1998 Dec;28(12):1363–71

The Normal Haematocrit Trial in dialysis patients with cardiac disease [letter] Besarab A, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2043–4

Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Löwbeer C, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1948–55

The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Macdougall IC, et al.

Nephrol Dial Transplant 1998 Dec;13(12):3030–3 (18 ref.)
Serum S-100 protein in stroke and cardiac surgery [letter] Pisa EK. **Stroke** 1999 May;30(5):1153–4
[Elimination of angiotensin I in the lung after experimental cardiac lesion] Kalenikova EI, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):389–92 **(Rus)**

CHEMICALLY INDUCED

Cardiotoxicity of cytotoxic chemotherapy and its prevention. Selvaratnam G, et al. **Adverse Drug React Toxicol Rev** 1999 Jun;18(2):61–105 (340 ref.)
"Tumescent" liposuction alert: deaths from lidocaine cardiotoxicity [letter] de Jong RH, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):101
Nitric oxide synthesis inhibition modifies the cardiotoxicity of tetracaine and lidocaine. Heavner JE, et al. **Anesth Analg** 1999 Apr;88(4):717–22
Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Platel D, et al. **Br J Cancer** 1999 Sep;81(1):24–7
The current cardiac safety situation with antihistamines. Yap YG, et al. **Clin Exp Allergy** 1999 Mar;29 Suppl 1:15–24 (56 ref.)
Powerful AIDS drugs may promote heart disease [news] **Compr Ther** 1998 Sep;24(9):465
Cardiotoxicity of the antiproliferative compound fluorouracil. Becker K, et al. **Drugs** 1999 Apr;57(4):475–84 (95 ref.)
Cardiotoxicity of second-generation antihistamines [letter; comment] Roberts DJ. **Drugs** 1999 Jun;57(6):1033–4. Comment on: Drugs 1999 Jan;57(1):31–47.
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR, et al. **Drugs** 1998 Sep;56(3):385–403 (75 ref.)
Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors [see comments] Markman M, et al. **J Clin Oncol** 1998 Nov;16(11):3483–5. Comment in: J Clin Oncol 1998 Nov;16(11):3481–2.
Paclitaxel and cardiotoxicity [editorial; comment] [see comments] Perez EA. **J Clin Oncol** 1998 Nov;16(11):3481–2 . Comment on: J Clin Oncol 1998 Nov;16(11):3483–5. Comment in: J Clin Oncol 1999 May;17(5):1647–8.
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. Sartori TM, et al. **J Heart Lung Transplant** 1999 Jul;18(7):693–700
Cancer, heart disease, and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin [see comments] Steenland K, et al. **J Natl Cancer Inst** 1999 May 5; 91(9):779–86. Comment in: J Natl Cancer Inst 1999 May 5;91(9):745–6.
Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. Working PK, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1128–33
Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Ewer MS, et al. **Med Pediatr Oncol** 1998 Dec;31(6):512–5
Urban air pollution and cardiopulmonary ill health: a 14.5 year time series study. Prescott GJ, et al. **Occup Environ Med** 1998 Oct;55(10):697–704
Cytotoxicity of cadmium and characteristics of its transport in cardiomyocytes. Limaye DA, et al. **Toxicol Appl Pharmacol** 1999 Jan 1;154(1):59–66
Indirect cardiotoxic activity of the caecilian Siphonops paulensis (Gymnophiona, Amphibia) skin secretion. Schwartz EN, et al. **Toxicon** 1999 Jan;37(1):47–54
Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria. Sowunmi A, et al. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):446–8
Comparative cardiac effects of halofantrine and chloroquine plus chlorpheniramine in children with acute uncomplicated falciparum malaria. Sowunmi A, et al. **Trans R Soc Trop Med Hyg** 1999 Jan-Feb;93(1):78–83
[Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy] Lopez M. **Clin Ter** 1999 Jan-Feb;150(1):37–49 (82 ref.) (Eng. Abstr.) **(Ita)**
[Cardiac complications of antineoplastic chemotherapy] Wojtacki J. **Pol Arch Med Wewn** 1998 Nov;100(5):470–82 (45 ref.) **(Pol)**
[Cardiorespiratory disorders in drug addiction] Kochetkova EA, et al. **Ter Arkh** 1998;70(12):84–7 (81 ref.) **(Rus)**
[Giant intracavitary thrombi secondary to a heparin-induced thrombocytopenia-thrombosis syndrome] Fernández Ratero JA, et al. **Rev Esp Cardiol** 1999 Apr;52(4):269–72 (8 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Why heart disease mortality is low in France. Miscoding may explain Japan's low mortality from coronary heart disease [letter] Sekikawa A, et al. **BMJ** 1999 Jul 24; 319(7204):255
Proposal for an urgency classification in cardiac surgery [editorial] Scheld HH, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):183–7
[Meeting of the Pediatric Cardiology Subcommittee of the French Society of Cardiology] Rey C, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):671–81 **(Fre)**

COMPLICATIONS

Frequency of left atrial thrombus and spontaneous echocardiographic contrast in acute myocardial infarction. Bilge M, et al. **Am J Cardiol** 1999 Oct 1;84(7):847–9, A8
Prognostic factors in acute cardiogenic pulmonary edema. Le Conte P, et al. **Am J Emerg Med** 1999 Jul;17(4):329–32
Malnutrition, cardiac disease, and mortality: an integrated point of view [editorial] Bergström J, et al. **Am J Kidney Dis** 1998 Nov;32(5):834–41 (87 ref.)
Reactivation of Chagas' disease in a human immunodeficiency virus-infected patient leading to severe heart disease with a late positive direct microscopic examination of the blood. Sartori AM, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):784–6
Massive bilateral pulmonary embolism in a patient with subsequent occurrence of severe mitral regurgitation due to ruptured chordae tendineae--a case report. Hussain KM, et al. **Angiology** 1998 Oct;49(10):861–4
Successful percutaneous balloon mitral valvuloplasty in a patient with left atrial thrombus--a case report. Nseir G, et al. **Angiology** 1999 Mar;50(3):255–9
Early and late outcome after elective cardiac surgery in patients with cirrhosis. Bizouarn P, et al. **Ann Thorac Surg** 1999 May;67(5):1334–8
Fortnightly review: anticoagulation in heart disease. Hardman SM, et al. **BMJ** 1999 Jan 23;318(7178):238–44 (43 ref.)
Fiberoptic bronchoscopy in coronary care unit patients: indications, safety, and clinical implications. Dunagan DP, et al. **Chest** 1998 Dec;114(6):1660–7
Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Nolan J, et al. **Circulation** 1998 Oct 13;98(15):1510–6
Prevotella oralis homograft-valve endocarditis complicated by aortic-root abscess, intracardiac fistula, and complete heart block. Quaglio G, et al. **Clin Infect Dis** 1999 Mar; 28(3):685–6
Cardiac involvement in limited systemic sclerosis: non-invasive assessment in asymptomatic patients. Handa R, et al. **Clin Rheumatol** 1999;18(2):136–9
Sudden cardiac death. Sra J, et al. **Curr Probl Cardiol** 1999 Aug;24(8):461–538 (220 ref.)
The clinical implications of diabetic heart disease. Butler R, et al. **Eur Heart J** 1998 Nov;19(11):1617–27 (114 ref.)
Implantable loop recorder: evaluation of unexplained syncope. Kenny RA, et al. **Heart** 1999 Apr;81(4):431–3
Aorto-atrial fistula without aneurysm formation in Behçet's disease. Melua A, et al. **Heart** 1998 Aug;80(2):200–1
Formation of a left atrial ball thrombus from a large mural thrombus 4 days after an embolic episode. Iga K, et al. **Int J Cardiol** 1999 Jul 1;70(1):83–6
Noninvasive pressure support ventilation (NIPSV) with face mask in patients with acute cardiogenic pulmonary edema (ACPE) [see comments] Rusterholtz T, et al. **Intensive Care Med** 1999 Jan;25(1):21–8. Comment in: Intensive Care Med 1999 Jan;25(1):1–2.
Management of the older person with ventricular arrhythmias. Aronow WS. **J Am Geriatr Soc** 1999 Jul; 47(7):886–95 (93 ref.)
The clinical epidemiology of cardiac disease in chronic renal failure. Parfrey PS, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1606–15 (53 ref.)
Effect of cardiogenic and noncardiogenic pulmonary edema on histamine responsiveness in sheep. Snapper JR, et al. **J Appl Physiol** 1998 Nov;85(5):1635–42
Integrated approach for revascularization in multivessel coronary artery disease and porcelain aorta. Gaudino M, et al. **J Card Surg** 1998 Mar;13(2):140–2
Antithrombotic therapy in nonrheumatic/nonvalvular atrial fibrillation. Gersh BJ. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):461–71 (79 ref.)
Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope. Grubb BP, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):139–43
The pregnancy outcome of acyanotic heart disease. Chia P, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):267–73
Respiratory morbidity of hospitalized children with Trisomy 21. Hilton JM, et al. **J Paediatr Child Health** 1999 Aug; 35(4):383–6
Diabetes and decline in heart disease mortality in US adults. Gu K, et al. **JAMA** 1999 Apr 14;281(14):1291–7
Diabetes and decline in heart disease mortality [letter] Poothullil JM. **JAMA** 1999 Sep 22-29;282(12):1132
Acute renal failure in the cardiac care unit: etiologies, outcomes, and prognostic factors. Behrend T, et al. **Kidney Int** 1999 Jul;56(1):238–43
Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease. Johnston DL, et al. **Mayo Clin Proc** 1999 Apr;74(4):339–46
Multifocal coronary thromboembolism from a left ventricular thrombus [letter] Lanza GM, et al. **N Engl J Med** 1999 Sep 30;341(14):1083–4
Neurologic complications of pediatric cardiac, gastrointestinal, and renal diseases. Sanchez JL, et al. **Pediatr Ann** 1998 Oct;27(10):625–33 (58 ref.)
Cardiopulmonary bypass on a patient with malaria. Coley TJ, et al. **Perfusion** 1999 May;14(3):219–21
Oscillating thromboemboli within the extracranial internal carotid artery demonstrated by ultrasonography in patients with acute cardioembolic stroke. Kimura K, et al. **Ultrasound Med Biol** 1998 Oct;24(8):1121–4
[Pulmonary embolism of hydatic origin] Ben M'Rad S, et al. **Presse Med** 1998 Feb 7;27(5):205–7 (Eng. Abstr.) **(Fre)**
[Significance of atrial fibrillation, left atrial thrombus and severity of stenosis for risk of systemic embolism in patients with mitral stenosis] Sanada J, et al. **J Cardiol** 1999 Jan; 33(1):1–5 (Eng. Abstr.) **(Jpn)**
[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report] Soeki T, et al. **J Cardiol** 1999 Jun;33(6):339–45 (Eng. Abstr.) **(Jpn)**
[Radiographic diagnosis of cardiogenic pulmonary edema] Matsuyama S, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1999 May; 59(6):223–30 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Heart diseases and cerebrovascular disorders] Uchiyama S. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):851–7 (5 ref.) **(Jpn)**
[Pathophysiology and treatment of cardioembolic stroke] Yasaka M, et al. **Nippon Ronen Igakkai Zasshi** 1998 Oct; 35(10):735–40 (Eng. Abstr.) **(Jpn)**
[Aortic peri-valvular abscess, mycotic aneurysm of Valsalva sinus, and fistula to the right ventricle in a context of acute infectious endocarditis] Gouveia D, et al. **Acta Med Port** 1998 May;11(5):503–6 (Eng. Abstr.) **(Por)**
[Cardiac involvement in metabolic diseases (published erratum appears in Rev Port Cardiol 1999 Feb;18(2):131)] Pereira A, et al. **Rev Port Cardiol** 1999 Jan;18(1):53–7 (Eng. Abstr.) **(Por)**
[Cardioembolic stroke] Shevchenko IuL, et al. **Klin Med (Mosk)** 1998;76(12):13–8 (62 ref.) **(Rus)**

CONGENITAL

Congenital heart disease and parental consanguinity in South India [letter] Gnanalingham MG, et al. **Acta Paediatr** 1999 Apr;88(4):473–4
Adolescents with congenital heart disease: psychopathological implications. Masi G, et al. **Adolescence** 1999 Spring;34(133):185–91
Genetics of congenital heart disease: strategies. Feit LR. **Adv Pediatr** 1998;45:267–92 (81 ref.)
Young-Simpson syndrome: further delineation of a distinct syndrome with congenital hypothyroidism, congenital heart defects, facial dysmorphism, and mental retardation. Masuno M, et al. **Am J Med Genet** 1999 May 7;84(1):8–11
Evaluation of small caliber vascular prostheses implanted in small children: activated angiogenesis and accelerated calcification. Tomizawa Y, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M496–500
Myocardial ischaemia in children with isolated ventricular non-compaction. Junga G, et al. **Eur Heart J** 1999 Jun; 20(12):910–6
Septal cystic mass in the right atrium: echocardiographic evaluation. Ritter S, et al. **J Am Soc Echocardiogr** 1999 May;12(5):331–4
The evolution of diagnostic trends in congenital heart disease: A population-based study. Grech V. **J Paediatr Child Health** 1999 Aug;35(4):387–91
[Clinical case of the month. Inaugural myocardial infarction from a congenital coronary-cardiac fistula] Czajkowski V, et al. **Rev Med Liege** 1999 Jan;54(1):12–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Congenital heart diseases in adults] Olearchyk AS. **Klin Khir** 1998;(7):23–6 (Eng. Abstr.) **(Ukr)**

DIAGNOSIS

Cardiac MR imaging. Smith HJ. **Acta Radiol** 1999 Jan; 40(1):1–22 (99 ref.)
Preoperative assessment of cardiac risk in noncardiac major vascular surgery. Roghi A, et al. **Am J Cardiol** 1999 Jan 15;83(2):169–74
Elevation of serum cardiac troponin I in noncardiac and cardiac diseases other than acute coronary syndromes. Khan IA, et al. **Am J Emerg Med** 1999 May;17(3):225–9
Assessing diagnostic classification in an emergency department: implications for daily time series studies of air pollution. Stieb DM, et al. **Am J Epidemiol** 1998 Oct 1; 148(7):666–70
Telephone reporting of the results of cardiac procedures: feasibility and primary care physician preferences. Blankenship JC, et al. **Am J Med** 1999 May;106(5):521–6
Current use of adequate preparticipation history forms for heart disease screening of high school athletes. Gómez JE, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):723–6
Right axis deviation as a criterion for echocardiographic evaluation of aircrew candidates. Armstrong CR, et al. **Aviat Space Environ Med** 1998 Sep;69(9):833–6
A potentially powerful new tool for noninvasive diagnosis of cardiac abnormalities: the CUPID system for analysis of electrocardiograms in the frequency domain. Fisher JC. **Biomed Instrum Technol** 1998 Jul-Aug;32(4):387–400
Accuracy of visible retinal emboli for the detection of cardioembolic lesions requiring anticoagulation or cardiac surgery. Retinal Emboli of Cardiac Origin Study Group. Sharma S, et al. **Br J Ophthalmol** 1998 Jun;82(6):655–8
Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Niinuma H, et al. **Cardiology** 1998 Oct;90(2):89–94

Progression of cardiac involvement in patients with myotonic dystrophy, Becker's muscular dystrophy and mitochondrial myopathy during a 2-year follow-up. Stöllberger C, et al. **Cardiology** 1998 Dec;90(3):173-9

Images in cardiovascular medicine. Ruptured sinus of valsalva with aorta-to-right atrial fistula. Cullen S, et al. **Circulation** 1998 Dec 1;98(22):2503-4

Establishment of a clinically correlated human pericardial fluid bank: evaluation of intrapericardial diagnostic potential. Dickson TJ, et al. **Clin Cardiol** 1999 Jan;22(1 Suppl 1):I40-2

Disseminated aspergillus fumigatus infection: case report. Orem J, et al. **East Afr Med J** 1998 Jul;75(7):436-8

Cardioscopy: potential applications and benefit in cardiac surgery. Reuthebuch O, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):824-9

Images in cardiology. Dual atrial pathology as an incidental finding on thoracic computed tomography and echocardiography. Cotton JM, et al. **Heart** 1998 Nov; 80(5):508

Measurement error as a source of QT dispersion: a computerised analysis. Kors JA, et al. **Heart** 1998 Nov; 80(5):453-8

Measurement of QT dispersion [editorial] Macfarlane PW. **Heart** 1998 Nov;80(5):421-3

New developments in cardiac magnetic resonance imaging. Hartnell GG. **Hosp Med** 1998 Jul;59(7):567-73 (20 ref.)

New black blood pulse sequence for studies of the heart. Campos S, et al. **Int J Card Imaging** 1999 Apr;15(2):175-83

Breathhold cardiac MRI and MRA. Hartnell GG. **Int J Card Imaging** 1999 Apr;15(2):139-50 (32 ref.)

Extrauterine pelvic arteriovenous malformation mimicking the clinical presentation of structural heart disease. Chen SC, et al. **Int J Cardiol** 1999 Jun 1;69(3):305-8

Isolated left ventricular diverticulum in an adult. Boyd WC, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):468-70

What's wrong with electrocardiography? [see comments] Mirvis DM. **J Electrocardiol** 1998 Oct;31(4):313-6 (12 ref.) . Comment in: J Electrocardiol 1998 Oct;31(4):367-70.

The evolution of diagnostic trends in congenital heart disease: A population-based study. Grech V. **J Paediatr Child Health** 1999 Aug;35(4):387-91

Magnetic resonance imaging in cardiology. Bellenger N, et al. **J R Coll Physicians Lond** 1999 Jan-Feb;33(1):12-8

MR as a diagnostic tool in heart disease: what is the future? Pennell D. **MAGMA** 1998 Sep;6(2-3):189-90

Dynamic contrast-enhanced 3D breath hold MRA using a multiple variable orientation slab acquisition. Shetty AN, et al. **Magn Reson Imaging** 1999 Jul;17(6):837-41

Determination of the cause of death: its relationship to cardiac disease and autopsy findings [editorial; comment] Edwards JE. **Mayo Clin Proc** 1999 Jul;74(7):739. Comment on: Mayo Clin Proc 1999 Jul;74(7):651-7.

QT interval analysis on ambulatory electrocardiogram recordings: a selective beat averaging approach. Badilini F, et al. **Med Biol Eng Comput** 1999 Jan;37(1):71-9

The "heart patient": what tests are helpful? Rose DJ. **Med J Aust** 1999 Apr 5;170(7):330-6 (22 ref.)

Preparticipation physical evaluation: getting to the heart of the matter. Cantwell JD. **Med Sci Sports Exerc** 1998 Oct; 30(10 Suppl):S341-4

Does preseason screening for cardiac disease really work?: the British perspective. MacAuley D. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S345-50 (45 ref.)

Insights into the AHA scientific statement concerning cardiovascular preparticipation screening of competitive athletes. McGrew CA. **Med Sci Sports Exerc** 1998 Oct; 30(10 Suppl):S351-3

Introduction: pediatric cardiology exercise testing. Strong WB. **Pediatr Cardiol** 1999 Jan-Feb;20(1):1-3; discussion 89

Interventional cardiac catheterization. Pihkala J, et al. **Pediatr Clin North Am** 1999 Apr;46(2):441-64 (181 ref.)

Differential diagnoses of the heart disease program have better sensitivity than resident physicians. Fraser HS, et al. **Proc AMIA Symp** 1998;:622-6

Cardiac MR imaging: a guide for the beginner. Boxt LM. **Radiographics** 1999 Jul-Aug;19(4):1009-25; discussion 1026-8 (25 ref.)

Co-existing left atrial thrombus and myxoma in mitral stenosis--a diagnostic challenge. Sim EK, et al. **Singapore Med J** 1999 Jan;40(1):46-7

The third heart sound. Joshi N. **South Med J** 1999 Aug; 92(8):756-61 (46 ref.)

Should surgeons and anesthesiologists auscultate? [letter; comment] Victor S, et al. **Tex Heart Inst J** 1999;26(2):160 . Comment on: Tex Heart Inst J 1998;25(3):218-9.

Imaging of the heart. Campbell NP. **Ulster Med J** 1998 Jun; 67 Suppl 1:25-8 (8 ref.)

Advances in the care of children with heart disease. Fedderly RT, et al. **WMJ** 1998 Sep;97(8):47-50

[Measurement of central venous pressure at the jugular pulse wave] de Leeuw PW. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1692-6 (9 ref.) (Eng. Abstr.) **(Dut)**

[Value of transesophageal echocardiography in the diagnosis of peripheral embolic event] Chammas E, et al. **J Med Liban** 1998 Jul-Aug;46(4):194-8 (Eng. Abstr.) **(Fre)**

[Cardiac MRI in adults: principles, current and future clinical applications] Croisille P, et al. **J Radiol** 1999 Sep; 80(9):1054-63 (Eng. Abstr.) **(Fre)**

[Electrocardiography and clinical cases] Schoenfeld P, et al. **Rev Med Brux** 1998 Sep;19(4):A224-34 **(Fre)**

[Determining hemodynamic status using intramyocardial electrocardiograms] Hutten H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:88-9 **(Ger)**

[Cost-effectiveness of a rapid test for troponin in emergency admissions] Heeschen C, et al. **Dtsch Med Wochenschr** 1998 Oct 16;123(42):1229-34 (Eng. Abstr.) **(Ger)**

[Physician referral versus self-referral for initial outpatient cardiological examination] Wagdi P, et al. **Dtsch Med Wochenschr** 1998 Nov 13;123(46):1367-71 (Eng. Abstr.) **(Ger)**

[Progressive systemic scleroderma--prognosis determining involvement of internal organ systems] Mittag M, et al. **Hautarzt** 1998 Jul;49(7):545-51 (40 ref.) (Eng. Abstr.) **(Ger)**

[Which cardiologic diagnosis in patients with cerebral ischemia?] Fröhlig G. **Z Arztl Fortbild Qualitatssich** 1999 May;93(3):183-90 (32 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension] Agabiti-Rosei E, et al. **Cardiologia** 1999 Mar;44(3):299-312 (312 ref.) **(Ita)**

[Clinical significance of polysomnographic monitoring in cardiology] Bonsignore MR. **Cardiologia** 1998 Aug; 43(8):853-6 **(Ita)**

[Arterial hypertension and cardiac pathology. Diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO-SIC-SIIA. Assoziane Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell'Ipertensione Arteriosa] Agabiti-Rosei E, et al. **G Ital Cardiol** 1999 Mar;29(3):341-56 **(Ita)**

[Considerations on correct diagnosis of atypical electrocardiographic T-wave findings in young subjects] Picciotto D, et al. **Med Lav** 1998 Jul-Aug;89(4):316-22 (Eng. Abstr.) **(Ita)**

[The usefulness of echocardiography in prospective heart function evaluation in children on maintenance haemodialysis] Szczepanska M, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):128-31 (Eng. Abstr.) **(Pol)**

[Aspects of hypertensive heart in arterial hypertension and insulin-resistant syndrome] Didenko VA, et al. **Klin Med (Mosk)** 1999;77(6):28-33 (Eng. Abstr.) **(Rus)**

[Clinical and instrumental diagnosis of cardiac affection in patients with toxic diphtheria] Iushchuk ND, et al. **Ter Arkh** 1999;71(4):28-35 (Eng. Abstr.) **(Rus)**

[Nutritional evaluation and functional class in hospitalized cardiopathy patients] Herrera Franco R, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):153-6 (Eng. Abstr.) **(Spa)**

[The usefulness of CK-MB isoforms in heart disease] Alvarez Lorenzo A, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):182-8 (94 ref.) **(Spa)**

[Mobile thrombus in the right cardiac cavities in patients with severe pulmonary thromboembolism. Importance of echocardiography] Mesa Rubio D, et al. **Rev Esp Cardiol** 1998 Aug;51(8):680-3 (Eng. Abstr.) **(Spa)**

DIET THERAPY

Cholesterol lowering diets and coronary heart disease. Diet alone substantially reduces cholesterol in hypercholesterolaemia [letter; comment] Evans DW. **BMJ** 1999 Apr 3;318(7188):945. Comment on: BMJ 1998 Oct 31;317(7167):1253.

Interventional nutrition for cardiac disease. Freeman LM. **Clin Tech Small Anim Pract** 1998 Nov;13(4):232-7 (18 ref.)

DRUG THERAPY

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Hradec J, et al. **Am J Cardiol** 1999 May 15;83(10):1506-9, A8

Successful treatment of right heart thromboemboli with IV recombinant tissue-type plasminogen activator during continuous echocardiographic monitoring: a case series report. Greco F, et al. **Chest** 1999 Jul;116(1):78-82

Medical and surgical therapy for cardiac remodeling. Bozkurt B. **Curr Opin Cardiol** 1999 May;14(3):196-205 (73 ref.)

Local low-dose urokinase treatment of acquired intracardiac thrombi in preterm infants. Aspesberro F, et al. **Eur J Pediatr** 1999 Sep;158(9):698-701

Thrombolytic treatment of type A right atrial thrombi: description of three cases and review of the literature. Mezzani A, et al. **G Ital Cardiol** 1999 Apr;29(4):441-6 (24 ref.)

Development of echocardiography [letter] Densem CG, et al. **Hosp Med** 1999 Jan;60(1):71

AFMC study reveals cardiac care improving in Arkansas [news] **J Ark Med Soc** 1998 Oct;95(5):182-3

Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status? Winkel E, et al. **J Heart Lung Transplant** 1998 Aug;17(8):809-16

Adenosine and cardioprotection in the diseased heart. Kitakaze M, et al. **Jpn Circ J** 1999 Apr;63(4):231-43 (114 ref.)

Treatment of mobile left ventricular thrombus with low-molecular-weight heparin [letter] Mallory R, et al. **N Engl J Med** 1999 Sep 30;341(14):1082-3

Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II. Janssens U, et al. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 1):678-81

Effects of ACE inhibitor therapy on quality of life in patients with heart failure. Wolfel EE. **Pharmacotherapy** 1998 Nov-Dec;18(6):1323-34 (43 ref.)

[Arterial hypertension and cardiac pathology. Diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO-SIC-SIIA. Assoziane Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell'Ipertensione Arteriosa] Agabiti-Rosei E, et al. **G Ital Cardiol** 1999 Mar;29(3):341-56 **(Ita)**

[Thyroid hormones and the heart] Zyśko D. **Pol Merkuriusz Lek** 1999 Mar;6(33):157-60 (31 ref.) (Eng. Abstr.) **(Pol)**

[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease] da Silva PM. **Rev Port Cardiol** 1999 Jan;18(1):65-76 (66 ref.) (Eng. Abstr.) **(Por)**

ECONOMICS

Promises and perils of managed care for older patients with cardiac disease. Friesinger GC, et al. **Cardiol Clin** 1999 Feb; 17(1):67-77, viii (83 ref.)

ENZYMOLOGY

Clinical and therapeutic significance of the Na+,K+ pump*. Clausen T. **Clin Sci (Colch)** 1998 Jul;95(1):3-17

EPIDEMIOLOGY

Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Neuzil KM, et al. **Am J Epidemiol** 1998 Dec 1;148(11):1094-102

The effect of long-term dietary supplementation with antioxidants. Meydani M, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:352-60 (50 ref.)

Cardiac morbidity and operative mortality following lower-extremity amputation: the significance of multiple Eagle criteria. de Virgilio C, et al. **Ann Vasc Surg** 1999 Mar;13(2):204-8

Endovascular vs open abdominal aortic aneurysm repair: a comparison of cardiac morbidity and mortality. de Virgilio C, et al. **Arch Surg** 1999 Sep;134(9):947-50; discussion 950-1

Prevalence of heart disease diagnosed de novo in pregnancy in a West London population. Tan J, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1185-8

Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Nolan J, et al. **Circulation** 1998 Oct 13;98(15):1510-6

Studying populations and heart disease risk [news] SoRelle R. **Circulation** 1999 Feb 9;99(5):598-9

Heart disease and other causes of sudden death in young athletes. Maron BJ. **Curr Probl Cardiol** 1998 Sep; 23(9):477-529 (148 ref.)

Air pollution and hospital admissions for heart disease in eight U.S. counties [see comments] Schwartz J. **Epidemiology** 1999 Jan;10(1):17-22. Comment in: Epidemiology 1999 Jan;10(1):1-4.

Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma. Licker M, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):314-9

Perioperative catecholamine changes in cardiac risk patients. Sametz W, et al. **Eur J Clin Invest** 1999 Jul;29(7):582-7

Cardiovascular risk factors and educational attainment in Southern Spain: a study of a random sample of 3091 adults. Cirera L, et al. **Eur J Epidemiol** 1998 Dec;14(8):755-63

The clinical epidemiology of cardiac disease in chronic renal failure. Parfrey PS, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1606-15 (53 ref.)

Treatment of depression in patients with heart disease. Roose SP, et al. **J Clin Psychiatry** 1999;60 Suppl 20:34-7 (37 ref.)

Job control, personal characteristics, and heart disease. Bosma H, et al. **J Occup Health Psychol** 1998 Oct; 3(4):402-9

Cardiac risk for non-cardiac surgery [letter; comment] Alabdulgader A. **J R Coll Physicians Lond** 1999 Mar-Apr; 33(2):192. Comment on: J R Coll Physicians Lond 1998 Nov-Dec;32(6):545-7.

Cardiac risk for non-cardiac surgery [letter; comment] Milne MR, et al. **J R Coll Physicians Lond** 1999 Mar-Apr; 33(2):192. Comment on: J R Coll Physicians Lond 1998 Nov-Dec;32(6):545-7.

Behavioral risk factors for heart disease and the attempt to change risk behaviors among adult South Carolinians. Huang Y, et al. **J S C Med Assoc** 1999 Feb;95(2):64-7

Prevalence of heart disease in older women in a nursing home. Aronow WS. **J Womens Health** 1998 Nov; 7(9):1105-12 (50 ref.)

Perceived risks of heart disease and cancer among cigarette smokers. Ayanian JZ, et al. **JAMA** 1999 Mar 17; 281(11):1019-21

Sex differences in the epidemiology and outcomes of heart disease: population-based trends. Roger VV, et al. **Lupus** 1999;8(5):346-50

Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Yanagawa H, et al. **Pediatr Cardiol** 1999 Jul-Aug;20(4):248-51

Oestrogens and the heart. Rosano GM, et al. **Therapie** 1999 May-Jun;54(3):381-5 (28 ref.)

Risk issues in renal transplantation: cardiac aspects. Parfrey PS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):291–3 (20 ref.)

[Thrombosis of aortic valve prostheses: its incidence, morphological aspects and surgical treatment] Ismeno G, et al. **G Ital Cardiol** 1999 Mar;29(3):277–83 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Shoshin syndrome: two case reports representing opposite ends of the same disease spectrum. Shivalkar B, et al. **Acta Cardiol** 1998;53(4):195–9

Renal and cardiac manifestations of B-cell dyscrasias with nonamyloidotic monoclonal light chain and light and heavy chain deposition diseases. Gallo GR, et al. **Adv Nephrol Necker Hosp** 1998;28:355–82 (51 ref.)

Bronchopericardial fistula after placement of an automatic implantable cardioverter defibrillator: radiographic and CT findings. Nolan RL, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):365–8

Predictability of left ventricular thrombus by mitral regurgitation [letter; comment] Sharma ND, et al. **Am Heart J** 1999 Feb;137(2):373–5. Comment on: Am Heart J 1998 Feb;135(2 Pt 1):215–20.

Long-term prospective assessment of left ventricular thrombus in anterior wall acute myocardial infarction and implications for a rational approach to embolic risk. Domenicucci S, et al. **Am J Cardiol** 1999 Feb 15; 83(4):519–24

Thrombus formation after transcatheter closure of atrial septal defect. La Rosée K, et al. **Am J Cardiol** 1999 Aug 1;84(3):356–9, A9

Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Ozkan M, et al. **Am J Cardiol** 1998 Nov 1;82(9):1066–70

Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Yataco AR, et al. **Am J Cardiol** 1999 Mar 1;83(5):754–8

Fatal cardiac beta2-microglobulin amyloidosis in patients on long-term hemodialysis. Kawano M, et al. **Am J Kidney Dis** 1998 Mar;31(3):E4

The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Obici L, et al. **Am J Pathol** 1999 Sep;155(3):695–702

Acute cardiac herniation after radical pleuropneumonectomy. Self RJ, et al. **Anaesthesia** 1999 Jun;54(6):564–6

Adverse cardiac outcomes after noncardiac surgery in patients with prior percutaneous transluminal coronary angioplasty. Posner KL, et al. **Anesth Analg** 1999 Sep; 89(3):553–60

Accuracy of smokers' risk perceptions. Weinstein ND. **Ann Behav Med** 1998 Spring;20(2):135–40

False aneurysm of the left ventricle after a stab wound to the chest. Chukwuemeka A, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):94–6

Effects of particulate and gaseous air pollution on cardiorespiratory hospitalizations. Burnett RT, et al. **Arch Environ Health** 1999 Mar–Apr;54(2):130–9

Physician estimates of perioperative cardiac risk in patients undergoing noncardiac surgery. Devereaux PJ, et al. **Arch Intern Med** 1999 Apr 12;159(7):713–7

The human pericardium in vibroacoustic disease. Castelo Branco NA, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A54–62

Echocardiographic evaluation in 485 aeronautical workers exposed to different noise environments. Marciniak W, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A46–53

Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Mariotti E, et al. **Br J Haematol** 1998 Dec; 103(4):916–21

Perioperative cardiac risk assessment for noncardiac surgery. Mehta RH, et al. **Cardiologia** 1999 May;44(5):409–18 (75 ref.)

The role of oxidative stress in the genesis of heart disease [editorial] Singal PK, et al. **Cardiovasc Res** 1998 Dec; 40(3):426–32 (99 ref.)

Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Fraser KL, et al. **Chest** 1999 May;115(5):1321–8

Pericardial involvement in human immunodeficiency virus infection. Silva-Cardoso J, et al. **Chest** 1999 Feb; 115(2):418–22

Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Reed CE. **Chest Surg Clin N Am** 1999 May;9(2):449–57, xii (37 ref.)

Thrombolysis of mobile right atrial thrombi following severe pulmonary embolism. Cracowski JL, et al. **Clin Cardiol** 1999 Feb;22(2):151–4

Cardiac and autonomic evaluation in a pediatric population with human immunodeficiency virus. Plein D, et al. **Clin Cardiol** 1999 Jan;22(1):33–6

Pocket infection complicating inadvertent transarterial permanent pacing. Successful percutaneous explantation. Trigano JA, et al. **Clin Cardiol** 1999 Jul;22(7):492–3

The heart in systemic lupus erythematosus. Roberts WC, et al. **Curr Probl Cardiol** 1999 Jan;24(1):1–56 (117 ref.)

Gastropericardial fistula with pneumopericardium: an unusual complication of benign peptic ulceration. Cozart JC, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):387–90

Cardiocutaneous fistula. Danias PG, et al. **Heart** 1999 Mar; 81(3):325–6 (10 ref.)

Mechanical heart valves: an insight into thrombotic complications. Bharat V. **Indian Heart J** 1999 Jan–Feb; 51(1):59–63

Essential thrombocytosis associated with left ventricular dysfunction and large left ventricular thrombi. Calton R, et al. **Indian Heart J** 1998 Jul–Aug;50(4):436–8

Esophageal achalasia compressing the heart diagnosed by echocardiography [letter] Mates M, et al. **Int J Cardiol** 1998 Sep 30;66(2):225–7

Flail tricuspid valve in a patient with history of stab chest wound [letter] Morelli S, et al. **Int J Cardiol** 1998 Sep 1; 66(1):111–3

No serious late cardiac effects after adjuvant radiotherapy following mastectomy in premenopausal women with early breast cancer. Gustavsson A, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):745–54

Anorexia nervosa with left atrial failure. Mizuno R, et al. **Intern Med** 1998 Oct;37(10):857–60

Does the mouth put the heart at risk? Slavkin HC. **J Am Dent Assoc** 1999 Jan;130(1):109–13

Systemic lupus erythematosus: a review of the cardiac manifestations. Holmes D, et al. **J Ark Med Soc** 1999 Jan; 95(8):355–7 (11 ref.)

The brain-heart connection: cardiac effects of acute ischemic stroke. Kocan MJ. **J Cardiovasc Nurs** 1998 Oct;13(1):57–68; quiz 97 (39 ref.)

Aorto-atrial fistula associated with recurrent aortic dissection after ascending aorta replacement. Fujii H, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):817–9

Mural left atrial thrombus: a hidden danger accompanying cardiac surgery. Leslie D, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):649–50 (6 ref.)

A mediastinal schwannoma causing left atrial compression [letter] Mondillo S, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):319–20

Inhibition of adhesion molecules markedly ameliorates cytokine-induced sustained myocardial dysfunction in dogs in vivo. Momii H, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2637–50

Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc-fa cp rats. Sharkey LC, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1527–37

Cardiologic complications of subarachnoid hemorrhage. Di Pasquale G, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):33–6 (22 ref.)

Job control, personal characteristics, and heart disease. Bosma H, et al. **J Occup Health Psychol** 1998 Oct; 3(4):402–9

Childhood trauma and adult illness [news] **J Psychosoc Nurs Ment Health Serv** 1998 Sep;36(9):10–1

Left ventricular thrombus after seat-belt-related chest trauma. Hung MJ, et al. **J Trauma** 1999 Sep;47(3):599–601

Intrapericardial organized hematoma. A rare complication after open heart surgery. Kagaya S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jun;47(6):291–4

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial [see comments] Hansson L, et al. **Lancet** 1999 Feb 20; 353(9153):611–6. Comment in: Lancet 1999 Feb 20;353(9153):604–5. Comment in: Lancet 1999 Jul 3;354(9172):73. Comment in: ACP J Club 1999 Jul–Aug;131(1):18.

Cardiac involvement in systemic lupus erythematosus. Moder KG, et al. **Mayo Clin Proc** 1999 Mar;74(3):275–84 (100 ref.)

Cardiac dysfunction in twin-twin transfusion syndrome: a prospective, longitudinal study. Simpson LL, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 1):557–62

Surviving the cancer, surviving the treatment: acute cardiac and pulmonary toxicity. Camp-Sorrell D. **Oncol Nurs Forum** 1999 Jul;26(6):983–90 (34 ref.)

Complications of snoring, upper airway resistance syndrome, and obstructive sleep apnea syndrome in adults. Coleman J. **Otolaryngol Clin North Am** 1999 Apr;32(2):223–34 (39 ref.)

Malnutrition, cardiac disease, and mortality. Bergström J, et al. **Perit Dial Int** 1999;19 Suppl 2:S309–14 (66 ref.)

Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Gyenes G, et al. **Radiother Oncol** 1998 Aug;48(2):185–90

Cardiac involvement in human immunodeficiency virus infection. Cardoso JS. **Rev Port Cardiol** 1999 Feb; 18(2):217–20 (22 ref.)

Prolonged fever in a male patient with a pacemaker. von Hafe P, et al. **Rev Port Cardiol** 1999 Apr;18(4):449–51

A Dumon stent inserted for bronchial stenosis causing a left bronchopericardial fistula: report of a case. Sugiyama S, et al. **Surg Today** 1998;28(10):1091–4

Cardiovascular sequelae of fetal twin-to-twin transfusion syndrome: an echocardiographic perspective. Eidem BW. **Tex Heart Inst J** 1999;26(2):152–3

Aorto-right ventricular fistula: a late complication of aortic valve replacement. Roy D, et al. **Tex Heart Inst J** 1999; 26(2):140–2

[Evaluation of the cardiovascular risk in hypertensive patients: left ventricular hypertrophy] Gosse P, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:19–22 (18 ref.) (Eng. Abstr.) **(Fre)**

[Cardiovascular risk and the measurement of arterial pressure] Vaisse B, et al. **Arch Mal Coeur Vaiss** 1998 Sep; 91 Suppl:9–12 (22 ref.) (Eng. Abstr.) **(Fre)**

[Behcet disease with cardiac and pulmonary manifestations] Duchêne F, et al. **Presse Med** 1998 Oct 31;27(33):1674–6 (Eng. Abstr.) **(Fre)**

[Heart and thyroid] Col V, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):481–5 (24 ref.) **(Fre)**

[Impact of arterial hypertension on the heart] Herpin D. **Rev Prat** 1999 Mar 1;49(5):491–4 (Eng. Abstr.) **(Fre)**

[Atrial thrombosis following the low-energy DC internal countershock of chronic AF: considerations of a clinical case] Palermo P, et al. **G Ital Cardiol** 1998 Dec; 28(12):1413–7 (23 ref.) (Eng. Abstr.) **(Ita)**

[A case report of a coronary fistula from left coronary artery to left ventricle] Hibino N, et al. **Kyobu Geka** 1999 Jun; 52(6):488–91 (Eng. Abstr.) **(Jpn)**

[Evaluation of cranial CT findings of patients with muscular dystrophy: with a reference to cerebral vascular disease and cardiac complications] Konagaya M, et al. **No To Shinkei** 1999 Jul;51(7):621–6 (Eng. Abstr.) **(Jpn)**

[Late complications after treatment of Hodgkin's disease] Lund MB, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):933–7 (Eng. Abstr.) **(Nor)**

[Perinatal asphyxia and heart problems] Herdy GV, et al. **Arq Bras Cardiol** 1998 Aug;71(2):121–6 (Eng. Abstr.) **(Por)**

[Sickle cell trait: clinical presentation as acute liver failure] Ferrari AH, et al. **Arq Gastroenterol** 1998 Jan–Mar; 35(1):49–53 (Eng. Abstr.) **(Por)**

[A thrombus in the right atrium secondary to a fistulated aortic paravalvular abscess: apropos a case] Alvarez Vicente G, et al. **Rev Esp Cardiol** 1999 Feb;52(2):142–4 (Eng. Abstr.) **(Spa)**

[Heart pathology of extracardiac origin. XI. Cardiac repercussions of diabetes mellitus] Esmatjes E, et al. **Rev Esp Cardiol** 1998 Aug;51(8):661–70 (63 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Congenital heart disease and parental consanguinity in South India [letter] Gnanalingham MG, et al. **Acta Paediatr** 1999 Apr;88(4):473–4

A novel variant of transthyretin (Glu42Asp) associated with sporadic late-onset cardiac amyloidosis. Dupuy O, et al. **Amyloid** 1998 Dec;5(4):285–7

Bibliography. Current world literature. Molecular genetics. **Curr Opin Cardiol** 1999 May;14(3):B129–42

Bibliography. Current world literature. Cardiac failure. **Curr Opin Cardiol** 1999 May;14(3):B93–128

Proteomics in human disease: cancer, heart and infectious diseases. Jungblut PR, et al. **Electrophoresis** 1999 Jul; 20(10):2100–10 (66 ref.)

Genetics, aging, and the heart. Thurmon TF. **J La State Med Soc** 1998 Aug;150(8):356–66 (12 ref.)

Cardiac conduction defects associate with mutations in SCN5A. Schott JJ, et al. **Nat Genet** 1999 Sep;23(1):20–1

Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene. Weidenbach M, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):382–5

Molecular advances in cardiac and cardiovascular disease. Basile-Borgia A, et al. **Perfusion** 1999 Mar;14(2):89–99 (73 ref.)

[The contribution of genetics in the evaluation of cardiovascular risk] Amouyel P. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:13–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Genetics in cardiology. An update] Vosberg HP. **Internist (Berl)** 1999 May;40(5):522–33 (63 ref.) **(Ger)**

[Cardiology review. Molecular and genetic aspects of cardiopathies] Jay D. **Arch Inst Cardiol Mex** 1999 Mar–Apr;69(2):157–62 (52 ref.) **(Spa)**

HISTORY

Stamps in cardiology. Heart foundations on stamps (1). Davies MK, et al. **Heart** 1998 Dec;80(6):564

IMMUNOLOGY

Role of lymphocytes in heart disease [letter; comment] Blum A. **Circulation** 1998 Oct 13;98(15):1590. Comment on: Circulation 1998 Jan 6–13;97(1):19–22.

Cardiac autoimmunity in HIV related heart muscle disease. Currie PF, et al. **Heart** 1998 Jun;79(6):599–604

Pathogenesis of early cardiac myocyte damage after severe burns. Huang YS, et al. **J Trauma** 1999 Mar;46(3):428–32

[Analysis of immune disorders in patients with rheumatoid arthritis and heart involvement] Timofeev VT, et al. **Patol Fiziol Eksp Ter** 1998 Jul–Sep;(3):10–2 (Eng. Abstr.) **(Rus)**

METABOLISM

Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Spinler SA, et al. **Ann Pharmacother** 1998 Dec;32(12):1275–83 (40 ref.)

An inhibitor of nitric oxide synthase does not increase

contraction or beta-adrenoceptor sensitivity of ventricular myocytes from failing human heart. Harding SE, et al. **Cardiovasc Res** 1998 Dec;40(3):523-9

P-Glycoprotein in clinical cardiology [editorial; comment] Rodriguez I, et al. **Circulation** 1999 Feb 2;99(4):472-4. Comment on: Circulation 1999 Feb 2;99(4):552-7.

Fatty acid ethyl esters: potentially toxic products of myocardial ethanol metabolism. Beckemeier ME, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2487-94 (58 ref.)

Transforming growth factor beta-angiotensin II interaction: implications for cardiac and renal disease. Luft FC. **J Mol Med** 1999 Jul;77(7):517-8 (15 ref.)

Pathogenesis of early cardiac myocyte damage after severe burns. Huang YS, et al. **J Trauma** 1999 Mar;46(3):428-32

Human cardiac MR spectroscopy--clinical methods and applications. Beer M, et al. **MAGMA** 1998 Sep;6(2-3):113-5 (15 ref.)

Clinical cardiac magnetic resonance spectroscopy--present state and future directions. Neubauer S, et al. **Mol Cell Biochem** 1998 Jul;184(1-2):439-43

Heart disease. Good cholesterol news [news] Scott J. **Nature** 1999 Aug 26;400(6747):816-7, 819

Markers for cardiac damage: current status and future trends. Proceedings of the 7th Bergmeyer Conference on Improving the Clinical Value of Laboratory Data. Tutzing, Germany, 1999. **Scand J Clin Lab Invest Suppl** 1999; 230:1-181

Iron-mediated cardiovascular injury. Horwitz LD, et al. **Vasc Med** 1999;4(2):93-9 (68 ref.)

[Cardiology review. Molecular and genetic aspects of cardiopathies] Jay D. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):157-62 (52 ref.) **(Spa)**

MORTALITY

Dobutamine stress echocardiography prior to aortic surgery: long-term cardiac outcome. Bigatel DA, et al. **Ann Vasc Surg** 1999 Jan;13(1):17-22

Why heart disease mortality is low in France. Commentary: intrauterine nutrition may be important. Barker DJ. **BMJ** 1999 May 29;318(7196):1477-8

Updates for US heart disease death rates [news] Gottlieb S. **BMJ** 1999 Jan 9;318(7176):79

Women's risk of dying of heart disease is always greater than their risk of dying of breast cancer [letter; comment] Haybittle J. **BMJ** 1999 Feb 20;318(7182):539. Comment on: BMJ 1998 Nov 7;317(7168):1307-9.

Association between birth weight and death from heart disease. Data do not support association [letter; comment] Jarrett RJ. **BMJ** 1999 Jan 23;318(7178):259-60. Comment on: BMJ 1998 Jul 25;317(7153):241-5.

Why heart disease mortality is low in France: the time lag explanation. Law M, et al. **BMJ** 1999 May 29; 318(7196):1471-6

Why heart disease mortality is low in France. Commentary: heterogeneity of populations should be taken into account. Mackenbach JP, et al. **BMJ** 1999 May 29;318(7196):1478-9

Why heart disease mortality is low in France. Authors' hypothesis is wrong [letter; comment] Ravnskov U. **BMJ** 1999 Jul 24;319(7204):255-6. Comment on: BMJ 1999 May 29;318(7196):1471-6.

Why heart disease mortality is low in France. Miscoding may explain Japan's low mortality from coronary heart disease [letter] Sekikawa A, et al. **BMJ** 1999 Jul 24; 319(7204):255

Why heart disease mortality is low in France. Commentary: alcohol and other dietary factors may be important. Stampfer M, et al. **BMJ** 1999 May 29;318(7196):1476-7

Epidemiology vs physiology? Drinking water magnesium and cardiac mortality [editorial] Neutra RR. **Epidemiology** 1999 Jan;10(1):4-6

Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases. Tabib A, et al. **Eur Heart J** 1999 Jun;20(12):900-3

Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates. Collins AR, et al. **FASEB J** 1998 Oct;12(13):1397-400

Cancer, heart disease, and diabetes in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin [see comments] Steenland K, et al. **J Natl Cancer Inst** 1999 May 5; 91(9):779-86. Comment in: J Natl Cancer Inst 1999 May 5;91(9):745-6.

Diabetes and decline in heart disease mortality in US adults. Gu K, et al. **JAMA** 1999 Apr 14;281(14):1291-7

Diabetes and decline in heart disease mortality [letter] Poothullil JM. **JAMA** 1999 Sep 22-29;282(12):1132

Determination of the cause of death: its relationship to cardiac disease and autopsy findings [editorial; comment] Edwards JE. **Mayo Clin Proc** 1999 Jul;74(7):739. Comment on: Mayo Clin Proc 1999 Jul;74(7):651-7.

Trends in heart disease deaths in Olmsted County, Minnesota, 1979-1994 [see comments] Roger VL, et al. **Mayo Clin Proc** 1999 Jul;74(7):651-7. Comment in: Mayo Clin Proc 1999 Jul;74(7):739.

Disparities in mortality among racial and ethnic groups. Buechner JS. **Med Health R I** 1998 Dec;81(12):408-9

Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] González F. **N Engl J Med** 1998 Dec 31;339(27):2023-4. Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.

Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] Sklar AH, et al. **N Engl J Med** 1998 Dec 31;339(27):2023; discussion 2023-4 . Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.

Long-term survival after permanent pacemaker implantation in young adults: 30 year experience. Mayosi BM, et al. **Pacing Clin Electrophysiol** 1999 Mar;22(3):407-12

Suicide and heart disease. Lester D. **Percept Mot Skills** 1998 Oct;87(2):594

NURSING

Heart disease in women. Halm MA, et al. **Am J Nurs** 1999 Apr;99(4):26-31; quiz 32

Assessment of functional status in patients with cardiac disease. Coyne KS, et al. **Heart Lung** 1998 Jul-Aug; 27(4):263-73 (23 ref.)

Evaluation of a nurse-delivered smoking cessation intervention for hospitalized patients with cardiac disease. Johnson JL, et al. **Heart Lung** 1999 Jan-Feb;28(1):55-64

Spotlight article: patients' and nurses' knowledge of cardiac-related symptoms and cardiac misconceptions. (Newens AJ, McColl E, Bond S, Priest JF. Heart Lung 1996;25:190-9) [comment] Trego LL, et al. **Heart Lung** 1998 Jul-Aug;27(4):274-8. Comment on: Heart Lung 1996 May-Jun;25(3):190-9.

The concepts of expectation and satisfaction: do they capture the way patients evaluate their care? Staniszewska S, et al. **J Adv Nurs** 1999 Feb;29(2):364-72

Development of a family liaison model during operative procedures. Madigan CK, et al. **MCN Am J Matern Child Nurs** 1999 Jul-Aug;24(4):185-9

Heart Center nursing research: a team effort. Heart Center Nursing Research Work Group Members. Fullwood J, et al. **Prog Cardiovasc Nurs** 1999 Winter;14(1):25-9

PARASITOLOGY

Cardiac echinococcosis causing coronary artery disease. De Paulis R, et al. **Ann Thorac Surg** 1999 Jun;67(6):1791-3

Hydatid cyst of the interventricular septum in a 3.5-year-old child. Maroto LC, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2110-1

Parasitic infections of the heart. Baily GG. **J Infect** 1998 Jul;37(1):2-4 (16 ref.)

PATHOLOGY

The human pericardium in vibroacoustic disease. Castelo Branco NA, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A54-62

Control of apoptosis of cardiovascular fibroblasts: a novel drug target. Rupp H, et al. **Herz** 1999 May;24(3):225-31 (43 ref.)

Pathology of the heart in acquired immunodeficiency syndrome. Lanjewar DN, et al. **Indian Heart J** 1998 May-Jun;50(3):321-5

Microvascular involvement in cardiac pathology. Gavin JB, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2531-40 (130 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1999. A 33-year-old man with wide-complex tachycardia and a left ventricular mass [clinical conference] **N Engl J Med** 1999 Oct 14; 341(16):1217-24

Histological evidence for cell proliferation activity in cystic tumor (endodermal heterotopia) of the atrioventricular node. Arai T, et al. **Pathol Int** 1998 Nov;48(11):917-23

Two cases of mesothelial/monocytic incidental cardiac excrescences of the heart. Ikeda Y, et al. **Pathol Int** 1998 Aug;48(8):641-4

[Cardiac hydatid cyst in a child] Pérez Martínez A, et al. **Rev Esp Cardiol** 1999 Aug;52(8):625-7 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Aronson D, et al. **Am J Cardiol** 1999 Aug 15;84(4):449-53

Sexual activity and the cardiovascular patient: guidelines. Taylor HA Jr. **Am J Cardiol** 1999 Sep 9;84(5B):6N-10N (19 ref.)

What is the value of home (self) blood pressure monitoring in patients with hypertensive heart disease? Mengden T, et al. **Am J Hypertens** 1998 Jul;11(7):813-9

LPS pretreatment ameliorates peritonitis-induced myocardial inflammation and dysfunction: role of myocytes. Neviere RR, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H885-92

Myocardial response to disease, hormones and training. Proceedings of the XII Paavo Nurmi Symposium. Porvoo, Finland, June 1997. **Ann Med** 1998 Aug;30 Suppl 1:1-65

Heart in Stress. Proceedings of the Jubilee Symposium in conjunction with the 3rd International Congress of Pathophysiology. Helsinki, Finland, June 28-July 3, 1998. **Ann N Y Acad Sci** 1999 Jun 30;874:1-438

Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Watanabe K, et al. **Ann Nucl Med** 1998 Oct;12(5):261-6

Women and heart disease. Maxwell SR. **Basic Res Cardiol** 1998;93 Suppl 2:79-84 (33 ref.)

Current status of monophasic action potential recording: theories, measurements and interpretations. Franz MR. **Cardiovasc Res** 1999 Jan;41(1):25-40 (87 ref.)

Physiologic consequences of pneumonectomy. Consequences on the pulmonary function. Reed CE. **Chest Surg Clin N Am** 1999 May;9(2):449-57, xii (37 ref.)

Electrocardiographic repolarization abnormalities in familial dysautonomia: an indicator of cardiac autonomic dysfunction. Glickstein JS, et al. **Clin Auton Res** 1999 Apr; 9(2):109-12

Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix. Tyagi SC. **Clin Exp Hypertens** 1999 Apr;21(3):181-98 (52 ref.)

Bibliography. Current world literature. Cardiac failure. **Curr Opin Cardiol** 1999 May;14(3):B93-128

Myocardial ischaemia in children with isolated ventricular non-compaction. Junga G, et al. **Eur Heart J** 1999 Jun; 20(12):910-6

Hemodynamic correlates of atrial natriuretic peptide concentration in unselected patients with heart disease of different etiologies. La Vecchia L, et al. **G Ital Cardiol** 1998 Dec;28(12):1363-71

Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. Hozumi T, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1251-9

Impaired capillary hemodynamics in skeletal muscle of rats in chronic heart failure. Kindig CA, et al. **J Appl Physiol** 1999 Aug;87(2):652-60

Effect of cardiogenic and noncardiogenic pulmonary edema on histamine responsiveness in sheep. Snapper JR, et al. **J Appl Physiol** 1998 Nov;85(5):1635-42

Interactions between angiotensin II and nitric oxide during exercise in normal and heart failure rats. Symons JD, et al. **J Appl Physiol** 1999 Aug;87(2):574-81

Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc-fa cp rats. Sharkey LC, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1527-37

Fuzzy cluster analysis--a new method to predict future cardiac events in patients with positive stress tests. Peters RM, et al. **Jpn Circ J** 1998 Oct;62(10):750-4

Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Berns JS, et al. **Kidney Int** 1999 Jul;56(1):253-60

The effect of Tai Chi on cardiorespiratory function in patients with coronary artery bypass surgery. Lan C, et al. **Med Sci Sports Exerc** 1999 May;31(5):634-8

Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Laforêt P, et al. **Neurology** 1998 Nov;51(5):1454-6

Electrical atrial remodeling assessed by monophasic action potential and atrial refractoriness in patients with structural heart disease. Lubinski A, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2440-4

Regulation of beta-adrenoceptor signaling in cardiac function and disease. Dzimiri N. **Pharmacol Rev** 1999 Sep; 51(3):465-501 (357 ref.)

Molecular mechanisms of myocardial remodeling. Swynghedauw B. **Physiol Rev** 1999 Jan;79(1):215-62 (527 ref.)

Power of plasma N-terminal proatrial natriuretic factor to determine haemodynamics in patients with cardiac disease: relation to serum creatinine. Dahle MG, et al. **Scand J Clin Lab Invest** 1998 Aug;58(5):395-403

Flow-dependent vasodilation in the coronary circulation: alterations in diseased states. Mandinov L, et al. **Semin Interv Cardiol** 1998 Mar;3(1):5-12 (49 ref.)

Gq signaling in cardiac adaptation and maladaptation. Dorn GW 2nd, et al. **Trends Cardiovasc Med** 1999 Jan-Feb; 9(1-2):26-34 (84 ref.)

[Subarachnoid hemorrhage and the heart] Martorano PP, et al. **Minerva Anestesiol** 1998 May;64(5):231-3 (16 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Cardioprotective effect of moderate drinking: possible mediation by vital exhaustion. Conduit E, et al. **Alcohol Alcohol** 1998 Sep-Oct;33(5):528-32

Heart disease prevention begins in childhood [editorial; comment] McBride PE. **Am Fam Physician** 1999 Apr 15; 59(8):2093, 2097. Comment on: Am Fam Physician 1999 Apr 15;59(8):2211-8.

Cardioprotective effects of postmenopausal hormone treatment. Espeland MA. **Am J Cardiol** 1998 Nov 19; 82(10A):37S-39S (13 ref.)

The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies [letter; comment] Pahor M, et al. **Am J Cardiol** 1999 Mar 1; 83(5):819-20. Comment on: Am J Cardiol 1998 Nov 12;82(9B):15R-19R.

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Levey AS, et al. **Am J Kidney Dis** 1998 Nov;32(5):853-906

Protective effect of gamma-glutamylcysteinylethyl ester on dysfunction of the selenium-deficient rat heart. Okamoto T, et al. **Biochem Pharmacol** 1999 Apr 15;57(8):955-63

Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol. Deible CR, et al. **Biomaterials** 1998 Oct;19(20):1885-93

Effects of the Heartbeat Wales programme. Programme that originated in Finland should be adopted [letter; comment]

Capewell S, et al. **BMJ** 1999 Apr 17;318(7190):1072-3. Comment on: BMJ 1998 Sep 26;317(7162):886.

Evidence exists for some advertising claims made on the internet [letter; comment] Lawson S. **BMJ** 1999 May 29; 318(7196):1484. Comment on: BMJ 1998 Oct 17;317(7165):1069-71.

Hormone replacement therapy. Does it actually help with heart disease? Evans MF, et al. **Can Fam Physician** 1999 Apr;45:921-3

DHEA: panacea or snake oil? Sirrs SM, et al. **Can Fam Physician** 1999 Jul;45:1723-8 (35 ref.)

Elevated blood cholesterol and the prevention of heart disease [editorial; comment] MacLean DR, et al. **Can J Cardiol** 1999 Apr;15(4):407-8. Comment on: Can J Cardiol 1999 Apr;15(4):434-44. Comment on: Can J Cardiol 1999 Apr;15(4):445-51.

Heart health promotion: predisposition, capacity and implementation in Ontario Public Health Units, 1994-96. Taylor SM, et al. **Can J Public Health** 1998 Nov-Dec; 89(6):410-4

Community-based heart health promotion: perceptions of facilitators and barriers. Taylor SM, et al. **Can J Public Health** 1998 Nov-Dec;89(6):406-9

Preoperative cardiac preparation. Belzberg H, et al. **Chest** 1999 May;115(5 Suppl):82S-95S (158 ref.)

Preoperative cardiac risk assessment. Hollenberg SM. **Chest** 1999 May;115(5 Suppl):51S-57S (27 ref.)

Guide to Preventive Cardiology for Women.AHA/ACC Scientific Statement Consensus panel statement. Mosca L, et al. **Circulation** 1999 May 11;99(18):2480-4 (23 ref.)

Influence of thrombolytic therapy on the incidence of left ventricular thrombi after acute anterior myocardial infarction: role of successful reperfusion. Ileri M, et al. **Clin Cardiol** 1999 Jul;22(7):477-80

Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR, et al. **Drugs** 1998 Sep;56(3):385-403 (75 ref.)

A four week residential program for primary health care patients to control obesity and related heart risk factors: effective application of principles of learning and lifestyle change. Sjöström M, et al. **Eur J Clin Nutr** 1999 May;53 Suppl 2:S72-7

Factors related to cardiac sequelae of Kawasaki disease. Zhang T, et al. **Eur J Pediatr** 1999 Sep;158(9):694-7

Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Palace VP, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):746-61 (158 ref.)

Exploring self-efficacy as a predictor of disease management. Clark NM, et al. **Health Educ Behav** 1999 Feb;26(1):72-89

An assessment of the scientific basis for attempting to define the Dietary Reference Intake for beta carotene. Omenn GS. **J Am Diet Assoc** 1998 Dec;98(12):1406-9 (28 ref.)

Lacidipine prevents the hypertension and renal and cardiac changes induced by high-fructose diet in WKY rats. Cosenzi A, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):485-91

Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. Baldelli R, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):527-32

Oils for the heart [editorial] Chakrabarty MM. **J Indian Med Assoc** 1998 Oct;96(10):295-7

Effects of KRN4884 (a novel K+ channel opener), levcromakalim, nilvadipine and propranolol on endothelin-1-induced heart disorders in anesthetized rats. Harada K, et al. **Jpn J Pharmacol** 1998 Nov;78(3):261-8

"Doctor, is wine good for my heart?" Bradley KA, et al. **Lancet** 1999 May 29;353(9167):1815-6

Cardiotoxicity of doxorubicin: effects of 21-aminosteroids. Falcone G, et al. **Life Sci** 1998;63(17):1525-32

Is physical activity or aerobic power more influential on reducing cardiovascular disease risk factors? McMurray RG, et al. **Med Sci Sports Exerc** 1998 Oct;30(10):1521-9

Comparison between two programmes for reducing the levels of risk indicators of heart diseases among male professional drivers. Hedberg GE, et al. **Occup Environ Med** 1998 Aug; 55(8):554-61

Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Yanagawa H, et al. **Pediatr Cardiol** 1999 Jul-Aug;20(4):248-51

Correlates of the sustainability of community-based heart health promotion interventions. O'Loughlin J, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):702-12

[Can we reduce the cardiovascular risk in hypertensive patients? (editorial)] Plouin PF. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:7-8; discussion 29-30 **(Fre)**

[Intracardiac thrombosis and consecutive thromboembolisms in patients with heart valve diseases: predisposition and concepts for prevention] Piper C, et al. **Z Kardiol** 1998;87 Suppl 4:1-6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Connection between electrophysiology and cardiac protection] Vassalle M. **Cardiologia** 1999 Jun;44(6):521-34 (85 ref.) (Eng. Abstr.) **(Ita)**

[The benefit of a coronary stent in the reduction of major cardiac complications in acute coronary syndromes] Martínez-Ríos MA, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):121-6 (Eng. Abstr.) **(Spa)**

[New studies on the cardiac effect of estrogens in women. Hormone replacement as secondary prevention is not to be recommended] Schenck-Gustafsson K, et al. **Lakartidningen** 1999 Jan 6;96(1-2):4-5 **(Swe)**

PSYCHOLOGY

Adolescents with congenital heart disease: psychopathological implications. Masi G, et al. **Adolescence** 1999 Spring;34(133):185-91

Getting to the heart of denial. Robinson AW. **Am J Nurs** 1999 May;99(5):38-42; quiz 43

Self-efficacy for dietary behaviour concerning heart disease among Alexandria school pupils. Mounir GM, et al. **East Mediterr Health J** 1998 Dec;4(3):452-69

Exploring self-efficacy as a predictor of disease management. Clark NM, et al. **Health Educ Behav** 1999 Feb;26(1):72-89

Adaptation after treatment for heart disease: preliminary examination within a stress appraisal context. Delunas LR, et al. **Heart Lung** 1999 May-Jun;28(3):186-94

Spotlight article: patients' and nurses' knowledge of cardiac-related symptoms and cardiac misconceptions. (Newens AJ, McColl E, Bond S, Priest JF. Heart Lung 1996;25:190-9) [comment] Trego LL, et al. **Heart Lung** 1998 Jul-Aug;27(4):274-8. Comment on: Heart Lung 1996 May-Jun;25(3):190-9.

Psycho-social determinants and motivational phases in smoking behavior of cardiac inpatients. Bolman C, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):738-47

RADIOGRAPHY

Residents' Corner. Answer to case of the month #59. Cardiac herniation with torsion. Ouellette H, et al. **Can Assoc Radiol J** 1999 Feb;50(1):51-4

Angiographic anatomy of the inferior right atrial isthmus in patients with and without history of common atrial flutter. Cabrera JA, et al. **Circulation** 1999 Jun 15; 99(23):3017-23

Many cardiologists still unsure of electron beam computed tomography's benefit as a screening tool. SoRelle R. **Circulation** 1999 Jun 22;99(24):3090-1

The Kodak approach to digital cardiovascular imaging laboratories. Pelanek GA. **Int J Card Imaging** 1998 Oct; 14(5):335-42 (2 ref.)

[Heart diseases in thoracic radiographic images. 2] Eichstädt H, et al. **Radiologe** 1999 Feb;39(2):164-72 **(Ger)**

[Heart diseases in thoracic radiographic images. 1] Eichstädt H. **Radiologe** 1999 Jan;39(1):84-92 **(Ger)**

[Effects on vasomotor tone and hemostatic function of radiologic contrast media used during invasive cardiological procedures] De Caterina R, et al. **G Ital Cardiol** 1999 Sep;29(9):1047-52 (40 ref.) (Eng. Abstr.) **(Ita)**

[Coronarography in the diagnosis of left atrial thrombosis] NikolićG, et al. **Vojnosanit Pregl** 1998 Nov-Dec; 55(6):591-4 (Eng. Abstr.) **(Scc)**

[Congenital heart diseases in adults] Olearchyk AS. **Klin Khir** 1998;(7):23-6 (Eng. Abstr.) **(Ukr)**

RADIONUCLIDE IMAGING

Long-term prognostic value of preoperative dipyridamole thallium imaging and clinical indexes in patients with diabetes mellitus undergoing peripheral vascular surgery. Cohen MC, et al. **Am J Cardiol** 1999 Apr 1;83(7):1038-42

Diabetic cardiac autonomic dysfunction: parasympathetic versus sympathetic. Uehara A, et al. **Ann Nucl Med** 1999 Apr;13(2):95-100

Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency. Watanabe K, et al. **Ann Nucl Med** 1998 Oct;12(5):261-6

Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. Utsunomiya K, et al. **Eur J Nucl Med** 1998 Dec; 25(12):1643-8

Future aspects of BMIPP. Tamaki N, et al. **Int J Card Imaging** 1999 Feb;15(1):79-89 (64 ref.)

Imaging guidelines for nuclear cardiology procedures, part 2. American Society of Nuclear Cardiology. **J Nucl Cardiol** 1999 Mar-Apr;6(2):G47-84

4th International Conference of Nuclear Cardiology. Athens, Greece, April 18-21, 1999. Abstracts. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 2):S1-132

Cardiological applications of nuclear medicine [see comments] Schwaiger M, et al. **Lancet** 1999 Aug 21; 354(9179):661-6. Comment in: Lancet 1999 Aug 21;354(9179):616.

Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease. Johnston DL, et al. **Mayo Clin Proc** 1999 Apr;74(4):339-46

Dynamic SPET parameters of 123I-MIBG cardiac imaging. Arbab AS, et al. **Nucl Med Commun** 1999 Jul;20(7):617-22

Factors affecting and computation of myocardial perfusion reference images. Goris ML, et al. **Nucl Med Commun** 1999 Jul;20(7):627-35

Fatty acids for myocardial imaging. Corbett JR. **Semin Nucl Med** 1999 Jul;29(3):237-58 (89 ref.)

[Picture of the month. Hydatid cyst of cardiac localization] Sabouret P, et al. **Ann Cardiol Angeiol (Paris)** 1998 Dec; 47(10):767 **(Fre)**

[Assessment of global and regional LV function obtained by quantitative gated SPECT using 99mTc-tetrofosmin: comparison with left ventricular cineangiography and echocardiography] Ban K, et al. **Kaku Igaku** 1998 Nov; 35(9):881-5 (Eng. Abstr.) **(Jpn)**

[Evaluation of carbon monoxide cardiotoxicity in group poisonings] Pach J, et al. **Przegl Lek** 1998;55(10):505-7 (Eng. Abstr.) **(Pol)**

REHABILITATION

Cardiac rehabilitation in the elderly. Oldridge N. **Aging (Milano)** 1998 Aug;10(4):273-83 (68 ref.)

Current status of cardiac rehabilitation. Fletcher GF. **Am Fam Physician** 1998 Nov 15;58(8):1778-82 (24 ref.)

Referral patterns to a University-based cardiac rehabilitation program. Bittner V, et al. **Am J Cardiol** 1999 Jan 15; 83(2):252-5, A5

Exercise in cardiac rehabilitation. Bethell HJ. **Br J Sports Med** 1999 Apr;33(2):79-86 (128 ref.)

Adaptation after treatment for heart disease: preliminary examination within a stress appraisal context. Delunas LR, et al. **Heart Lung** 1999 May-Jun;28(3):186-94

A quality of life assessment package: disease specific measure for pacemaker and cardiac rehabilitation patients. Woodend AK, et al. **Int J Rehabil Res** 1998 Mar;21(1):71-8

Cardiac rehabilitation in older coronary patients. Ades PA. **J Am Geriatr Soc** 1999 Jan;47(1):98-105 (77 ref.)

Combined high-intensity strength and aerobic training in diverse phase II cardiac rehabilitation patients. Adams KJ, et al. **J Cardiopulm Rehabil** 1999 Jul-Aug;19(4):209-15

Injuries and muscle soreness during the one repetition maximum assessment in a cardiac rehabilitation population [see comments] Barnard KL, et al. **J Cardiopulm Rehabil** 1998 Jan-Feb;19(1):52-8. Comment in: J Cardiopulm Rehabil 1999 May-Jun;19(3):190-2.

Rethinking the place of psychological support groups in cardiopulmonary rehabilitation. Harper W, et al. **J Cardiopulm Rehabil** 1998 Jan-Feb;19(1):18-21

Telemedicine and cardiopulmonary rehabilitation: where do we stand? Shaw DK. **J Cardiopulm Rehabil** 1998 Jan-Feb; 19(1):59-61

Injuries and muscle soreness during the one repetition maximum assessment in a cardiac rehabilitation population [letter; comment] Verrill DE, et al. **J Cardiopulm Rehabil** 1999 May-Jun;19(3):190-2. Comment on: J Cardiopulm Rehabil 1998 Jan-Feb;19(1):52-8.

Role of resistance training in heart disease. McCartney N. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S396-402 (38 ref.)

A submaximal treadmill test for developing target ratings of perceived exertion for outpatient cardiac rehabilitation. Dunbar CC, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):755-9

Cardiopulmonary resuscitation training for family members of patients on cardiac rehabilitation programmes in Scotland. Richardson ME, et al. **Resuscitation** 1999 Jan; 40(1):11-9

[Experiences with ambulatory cardiologic rehabilitation] Augusta K. **Herz** 1999 Apr;24 Suppl 1:38-43 (Eng. Abstr.) **(Ger)**

[Rehabilitation with the "Ennepetal model"] Karoff M. **Herz** 1999 Apr;24 Suppl 1:67-72 (Eng. Abstr.) **(Ger)**

[Partial inpatient cardiologic after-care] Klempt HW, et al. **Herz** 1999 Apr;24 Suppl 1:32-7 (Eng. Abstr.) **(Ger)**

[Initial experiences with a comprehensive ambulatory rehabilitation program for heart patients] Saner H, et al. **Herz** 1999 Apr;24 Suppl 1:80-7 (Eng. Abstr.) **(Ger)**

[Comprehensive ambulatory rehabilitation for heart patients--1999 status] Saner H. **Herz** 1999 Apr;24 Suppl 1:88 **(Ger)**

[Experiences with ambulatory cardiologic phase II rehabilitation] Schönstedt S, et al. **Herz** 1999 Apr;24 Suppl 1:3-8 (Eng. Abstr.) **(Ger)**

[Ambulatory long-term rehabilitation of heart patients] Tegtbur U, et al. **Herz** 1999 Apr;24 Suppl 1:89-96 (Eng. Abstr.) **(Ger)**

[Ambulatory phase II rehabilitation of heart patients in the Rhine-Main district hospital: the Frankfurt model] Wendt T. **Herz** 1999 Apr;24 Suppl 1:24-31 (Eng. Abstr.) **(Ger)**

[Cardiac rehabilitation] Ceci V, et al. **Cardiologia** 1999 Jun; 44(6):543-78 (82 ref.) **(Ita)**

[Informed consent in cardiac rehabilitation (letter)] de Pablo Zarzosa C, et al. **Rev Esp Cardiol** 1999 May;52(5):362-3 **(Spa)**

SURGERY

Correlates of self-efficacy expectation and prediction of walking behavior in cardiac surgery elders. Jenkins LS, et al. **Ann Behav Med** 1998 Spring;20(2):99-103

Cardiac reoperations in octogenarians: analysis of outcomes. Blanche C, et al. **Ann Thorac Surg** 1999 Jan;67(1):93-8

First report of the Port Access International Registry. Galloway AC, et al. **Ann Thorac Surg** 1999 Jan;67(1):51-6; discussion 57-8

Platelet aggregation during cardiopulmonary bypass evaluated by a laser light-scattering method. Kawahito K, et al. **Ann Thorac Surg** 1999 Jan;67(1):79-84

A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. McCarthy PM, et al. **Ann Thorac Surg** 1999 May;67(5):1268-73

An unusual combination of cardiovascular surgical disorders. Najafi H, et al. **Ann Thorac Surg** 1999 Jan;67(1):241-4

Arterial conduits. Noda S, et al. **Ann Thorac Surg** 1999 Jan; 67(1):285-6

Transaortic video-assisted removal of a left ventricular thrombus. Tsukube T, et al. **Ann Thorac Surg** 1999 Sep; 68(3):1063-5

Expanding surgical options using minimally invasive techniques for cardio-aortic and aortic procedures. Svensson LG, et al. **Arch Surg** 1998 Nov;133(11):1160–5 (25 ref.)

Evaluation of small caliber vascular prostheses implanted in small children: activated angiogenesis and accelerated calcification. Tomizawa Y, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M496–500

The risk of cerebrovascular accident in patients with asymptomatic critical carotid artery stenosis who undergo open-heart surgery. Ali IM, et al. **Can J Surg** 1998 Oct; 41(5):374–8

The Fontan type procedure in patients with visceral heterotaxy [editorial; comment] Uemura H. **Cardiol Young** 1998 Oct;8(4):419–22. Comment on: Cardiol Young 1998 Oct;8(4):479–85.

The 'primeless pump': a novel technique for intraoperative blood conservation. Rousou JA, et al. **Cardiovasc Surg** 1999 Mar;7(2):228–35

Two studies: long-term cognitive decline after bypass surgery; Alzheimer's gene linked to earlier bypass [news] **Compr Ther** 1999 May;25(5):300–1

Medical and surgical therapy for cardiac remodeling. Bozkurt B. **Curr Opin Cardiol** 1999 May;14(3):196–205 (73 ref.)

Selection of appropriate patients with heart failure for aortocoronary bypass surgery. Letsou GV. **Curr Opin Cardiol** 1999 May;14(3):230–3 (12 ref.)

Minimally invasive pediatric cardiac surgery. Burke RP. **Curr Opin Pediatr** 1998 Oct;10(5):527–31 (21 ref.)

Pregnancy in open heart surgical patients at Kenyatta National Hospital. Ogendo SW. **East Afr Med J** 1999 Jan; 76(1):19–22

Cardiac surgery in the elderly. Dalrymple-Hay MJ, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):61–6

Clinical experience with heart transplantation in infants. Dapper F, et al. **Eur J Cardiothorac Surg** 1998 Jul;14(1):1–5; discussion 5–6

Flying after heart surgery [editorial] Treasure T, et al. **Heart** 1999 Jul;82(1):3–4

Right heart thrombus: the importance of early intervention. Cosgrove H, et al. **J Accid Emerg Med** 1999 Jul;16(4):291–2

Cardiac surgery. Verrier ED. **J Am Coll Surg** 1999 Feb; 188(2):104–10 (71 ref.)

Is cardiac surgery justified in patients in the ninth decade of life? Schmitz C, et al. **J Card Surg** 1998 Mar;13(2):113–9

Right atrial thrombus in a patient with stage IV carcinoma of the lung: is the surgical treatment the correct choice? Sabharwal P, et al. **J Cardiovasc Surg (Torino)** 1998 Oct; 39(5):689–90

Course guidelines for minimally invasive cardiac surgery. STS/AATS Ad Hoc Committee on New Technology Assessment. American Association for Thoracic Surgery. Cohn LH, et al. **J Thorac Cardiovasc Surg** 1998 Nov; 116(5):889–90

Cardiac surgery with cardiopulmonary bypass in patients with chronic renal failure. Durmaz I, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):306–15

Left atrial ball thrombi without mitral valve disease treated by surgical removal. Saito A, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Jul;46(7):592–4

New initiatives in minimally invasive cardiac surgery. Fonger JD. **Md Med J** 1998 Nov;47(5):253–6 (51 ref.)

The effect of Tai Chi on cardiorespiratory function in patients with coronary artery bypass surgery. Lan C, et al. **Med Sci Sports Exerc** 1999 May;31(5):634–8

Utility of proverb interpretation measures with cardiac transplant candidates. Dugbartey AT. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):883–9

Cardiopulmonary bypass on a patient with malaria. Coley TJ, et al. **Perfusion** 1999 May;14(3):219–21

Serum S-100 protein in stroke and cardiac surgery [letter] Pisa EK. **Stroke** 1999 May;30(5):1153–4

A successful case of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension with a thrombus in the right ventricle. Masuda M, et al. **Surg Today** 1999;29(5):478–81

Open-heart surgery in 48 patients via a small right anterolateral thoracotomy. Wang YQ, et al. **Tex Heart Inst J** 1999;26(2):124–8

Postoperative death should be followed by autopsy – an analysis of the autopsy findings of the years 1990 and 1991 in a heart surgery center. Deiwick M, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):82–7

Proposal for an urgency classification in cardiac surgery [editorial] Scheld HH, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):183–7

Clinical experience with blood cardioplegia. Schlensak C, et al. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:282–5; discussion 286–7 (28 ref.)

High risk of transfusion-associated graft-versus-host disease with nonirradiated allogeneic blood transfusion in cardiac surgery [letter] Yasuura K, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1117–8

Advances in the care of children with heart disease. Fedderly RT, et al. **WMJ** 1998 Sep;97(8):47–50

[Protamine allergy and cardiac surgery (letter)] Hynynen M, et al. **Duodecim** 1995;111(20):1969–70 **(Fin)**

[Complexity of PP intervals in a nonlinear model of patients after heart surgery intervention] Bieberle T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:294–5 **(Ger)**

[New techniques in heart surgery] Schüler S. **Biomed Tech (Berl)** 1998;43 Suppl:2–3 **(Ger)**

[The significance of endothelial adhesion molecules in heart surgery] Zünd G, et al. **Swiss Surg** 1998;Suppl 2:31–4 (33 ref.) (Eng. Abstr.) **(Ger)**

[Minimally invasive heart surgery--a fad or a clinically recognized therapy method?] Reichenspurner H, et al. **Z Kardiol** 1998 Aug;87(8):594–603 (32 ref.) (Eng. Abstr.) **(Ger)**

[A rare case of 2 free thrombi in left atrium with mitral stenosis] Mukai S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):789–92 (Eng. Abstr.) **(Jpn)**

[A case of left atrial thrombus complicated with coarctation of the aorta] Ishibashi Y, et al. **Kyobu Geka** 1999 Sep; 52(10):853–5 (Eng. Abstr.) **(Jpn)**

[Partial left ventriculectomy. Forgotten paradigms] Gottschall CA. **Arq Bras Cardiol** 1998 Oct;71(4):625–7 **(Por)**

THERAPY

New Frontiers in the Electrical Management of Cardiac Disorders. Proceedings of a symposium. Geneva, Switzerland, October 9–10, 1998. **Am J Cardiol** 1999 Mar 11;83(5B):1D–245D

Evolving indications for permanent pacing. Hayes DL. **Am J Cardiol** 1999 Mar 11;83(5B):161D–165D (36 ref.)

Development and evaluation of complex interventions in health services research: case study of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. Bradley F, et al. **BMJ** 1999 Mar 13; 318(7185):711–5 (25 ref.)

Promises and perils of managed care for older patients with cardiac disease. Friesinger GC, et al. **Cardiol Clin** 1999 Feb; 17(1):67–77, viii (83 ref.)

Percutaneous retrieval of a right atrioventricular embolus. Davies RP, et al. **Cardiovasc Intervent Radiol** 1998 Sep–Oct;21(5):433–5

Transhepatic access: coming of age [editorial; comment] Johnston TA, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):46. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):41–5.

Transhepatic therapeutic cardiac catheterization: a new option for the pediatric interventionalist [see comments] Shim D, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):41–5. Comment in: Catheter Cardiovasc Interv 1999 May;47(1):46.

Endothelium as a therapeutic target in heart failure [editorial] Drexler H. **Circulation** 1998 Dec 15;98(24):2652–5

Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure [see comments] Hambrecht R, et al. **Circulation** 1998 Dec 15;98(24):2709–15. Comment in: Circulation 1999 Jul 6;100(1):2–4.

Left ventricular assist devices and the failing heart: a bridge to recovery, a permanent assist device, or a bridge too far? [editorial; comment] Mann DL, et al. **Circulation** 1998 Dec 1;98(22):2367–9. Comment on: Circulation 1998 Dec 1;98(22):2383–89.

Jarvik 2000 heart: potential for bridge to myocyte recovery. Westaby S, et al. **Circulation** 1998 Oct 13;98(15):1568–74

Ventricular assistance for recovery of cardiac failure. Loebe M, et al. **Curr Opin Cardiol** 1999 May;14(3):234–48 (57 ref.)

Recent advances in interventional pediatric cardiovascular disease. Maheshwari S, et al. **Curr Opin Pediatr** 1998 Oct; 10(5):532–7 (41 ref.)

Interventional cardiology in people with diabetes [editorial] Fisher M. **Diabet Med** 1999 Jul;16(7):531–2

Coronary intervention in 21st century: the changing scenario. Chou TM, et al. **Indian Heart J** 1998 Oct;50 Suppl 1:145–52 (68 ref.)

Selection and outcome of ventricular assist device patients: the Muenster experience. Deng MC, et al. **J Heart Lung Transplant** 1998 Aug;17(8):817–25

Mechanical circulatory support in children with cardiac disease. Duncan BW, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):529–42

Exogenous control of cardiac gene therapy: evidence of regulated myocardial transgene expression after adenovirus and adeno-associated virus transfer of expression cassettes containing corticosteroid response element promoters. Lee LY, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):26–4, discussion 34–5

Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Berns JS, et al. **Kidney Int** 1999 Jul;56(1):253–60

Interventional cardiac catheterization. Pihkala J, et al. **Pediatr Clin North Am** 1999 Apr;46(2):441–64 (181 ref.)

Cardiac patient air medical transport in the northeast region of the United States. Oberg KC, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):297–303

[Management of heart diseases in children in this country in the process of development] Sidi D. **Arch Pediatr** 1999; 6 Suppl 2:308s–309s **(Fre)**

[Interventional catheterization in pediatric cardiology] Massin M. **Rev Med Liege** 1999 Jan;54(1):22–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Clinical significance of sleep apnea disorders after implantation of a cardioverter-defibrillator in patients with cardiac disease and sustained ventricular tachyarrhythmia] Fries R, et al. **Z Kardiol** 1998 Oct;87(10):826–31 (Eng. Abstr.) **(Ger)**

[Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension] Agabiti-Rosei E, et al. **Cardiologia** 1999 Mar;44(3):299–312 (312 ref.) **(Ita)**

ULTRASONOGRAPHY

Clinical and echocardiographic features of two large left atrial parietal thrombi. Vincelj J, et al. **Acta Med Croatica** 1999;53(1):45–7

Echocardiographic evaluation in patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Martinez-Vea A, et al. **Am J Kidney Dis** 1999 Aug; 34(2):264–72

A left-to-left shunt [letter] Pilz B, et al. **Am J Med** 1999 Apr;106(4):488–9

Echocardiography by a neonatologist [letter] Whitehall J. **Arch Dis Child** 1999 Jun;80(6):579

Echocardiographic evaluation in 485 aeronautical workers exposed to different noise environments. Marciniak W, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A46–53

Transthoracic echocardiography in perioperative medicine [letter] Hadi A, et al. **Can J Anaesth** 1999 Jun;46(6):616

Transesophageal echocardiographic assessment in trauma and critical care. Tousignant C. **Can J Surg** 1999 Jun; 42(3):171–5

Exercise echocardiography. Principles, methods, and clinical use. Bossone E, et al. **Cardiol Clin** 1999 Aug;17(3):447–60, vii (117 ref.)

Cardiac disease distribution among patients referred for echocardiography in Harare, Zimbabwe. Hakim JG, et al. **Cent Afr J Med** 1998 Jun;44(6):140–4

Witnessed embolization of a right atrial mass during transesophageal echocardiography: implications regarding the safety of esophageal intubation. Kwak KD, et al. **Chest** 1999 May;115(5):1462–4

Multiplane transesophageal echocardiography for assessing cardiac abnormalities: comparison to biplane imaging. Chou LP, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep;62(9):577–85

Images in cardiovascular medicine. Fungal whip beats the heart. Román AR, et al. **Circulation** 1999 Sep 14; 100(11):1249

Hydatid cysts of the heart. Vazan A, et al. **Circulation** 1999 Aug 17;100(7):e42–4

Mitral stenosis with left atrial thrombi. Ha JW, et al. **Clin Cardiol** 1999 Jul;22(7):491

Impending paradoxical embolism: a transesophageal echocardiographic image [see comments] Ku PM, et al. **Clin Cardiol** 1999 Jan;22(1):45. Comment in: Clin Cardiol 1999 May;22(5):328–9.

Ultrasonic videodensitometric analysis in scleroderma heart disease. Di Bello V, et al. **Coron Artery Dis** 1999; 10(2):103–10

Three-dimensional echocardiography. Roelandt JR, et al. **Curr Opin Cardiol** 1998 Nov;13(6):386–96 (100 ref.)

Pediatric echocardiography: applications and limitations. Phoon CK, et al. **Curr Probl Pediatr** 1999 Jul;29(6):157–85 (186 ref.)

Intracavitary cardiac hydatid cyst and the wall sign criteria. El Fortia M, et al. **Eur J Ultrasound** 1998 Nov;8(2):115–7

Three-dimensional transesophageal echocardiographic evaluation of large "croissant" thrombus in St. Jude's mitral prosthesis. Greco C, et al. **G Ital Cardiol** 1998 Oct; 28(10):1168 **(Eng, Ita)**

Apical mural thrombus: technical pitfalls. Carpenter K, et al. **Heart** 1998 Nov;80 Suppl 1:S6–8

Images in cardiology: Right coronary artery to coronary sinus fistula. Missouris CG, et al. **Heart** 1999 Mar;81(3):270

Quality issues for echocardiography in the community. Saltissi S, et al. **Heart** 1998 Nov;80 Suppl 1:S9–11

Images in cardiology: Biatrial thrombosis in cardiac amyloidosis. Santarone M, et al. **Heart** 1999 Mar;81(3):302

Systemic embolism during coronary artery bypass surgery. Vranckx P, et al. **Heart** 1999 Jan;81(1):24

Development and future of open access echocardiography [editorial] de Bono D. **Hosp Med** 1998 Aug;59(8):600, 602

Esophageal achalasia compressing the heart diagnosed by echocardiography [letter] Mates M, et al. **Int J Cardiol** 1998 Sep 30;66(2):225–7

Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. Barbetseas J, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1410–7

Adherence of albunex to an apical left ventricular thrombus. Bach DS. **J Am Soc Echocardiogr** 1999 Sep;12(9):761–2

Septal cystic mass in the right atrium: echocardiographic evaluation. Ritter S, et al. **J Am Soc Echocardiogr** 1999 May;12(5):331–4

Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography. Santarone M, et al. **J Am Soc Echocardiogr** 1999 Jun; 12(6):533–6

The role of transesophageal echocardiography in the diagnosis and treatment of right atrial thrombi. Schwartzbard AZ, et al. **J Am Soc Echocardiogr** 1999 Jan; 12(1):64–9

Enhanced endocardial visualization with noncontrast harmonic imaging during stress echocardiography. Skolnick DG, et al. **J Am Soc Echocardiogr** 1999 Jul; 12(7):559–63

What is the real clinical utility of echocardiography? A prospective observational study. Tam JW, et al.

J Am Soc Echocardiogr 1999 Sep;12(9):689–97
An unexpected intracardiac mass. Gibbs C, et al.
J Cardiothorac Vasc Anesth 1998 Dec;12(6):713–4
Detection of left atrial thrombus by transesophageal echocardiography after left ventricular assist device decannulation. Lanquetot H, et al.
J Cardiothorac Vasc Anesth 1998 Aug;12(4):435–6
Left atrial thrombus detection with multiplane transesophageal echocardiography: an echocardiographic study with surgical verification. Koca V, et al.
J Heart Valve Dis 1999 Jan;8(1):63–6
Improved definition of left atrial thrombus by tissue harmonic imaging. Ono M, et al. **J Ultrasound Med** 1999 Mar; 18(3):253–5
Differential diagnosis of left ventricular mural thrombi by myocardial contrast echocardiography: a preliminary study. Asanuma T, et al. **Jpn Circ J** 1999 Jan;63(1):50–2
Developments in cardiovascular ultrasound. Part 3: Cardiac applications. Moran CM, et al. **Med Biol Eng Comput** 1998 Sep;36(5):529–43 (127 ref.)
Images in clinical medicine. Heart in the heart. Schuler J, et al. **N Engl J Med** 1999 Sep 30;341(14):1045
Cardiac dysfunction in twin–twin transfusion syndrome: a prospective, longitudinal study. Simpson LL, et al.
Obstet Gynecol 1998 Oct;92(4 Pt 1):557–62
Advances in echocardiographic diagnostic modalities for the pediatrician. Frommelt MA, et al.
Pediatr Clin North Am 1999 Apr;46(2):427–39, xi (62 ref.)
Prenatal diagnosis of intra–atrial cardiac echogenic foci. Petrikovsky B, et al. **Prenat Diagn** 1998 Sep;18(9):968–70
Tissue Doppler imaging. Cardim N. **Rev Port Cardiol** 1998 Nov;17 Suppl 3:III65–8 (17 ref.)
Three dimensional echocardiography. Pinto FJ, et al.
Rev Port Cardiol 1998 Nov;17 Suppl 3:III59–63 (12 ref.)
Role of echocardiography in systemic arterial embolism. A review with recommendations. Egeblad H, et al.
Scand Cardiovasc J 1998;32(6):323–42 (168 ref.)
Left atrial ball thrombus in a patient without mitral valve disease. Nagumo M, et al. **Tokai J Exp Clin Med** 1997 Oct;22(4):159–61
[Doppler imaging of myocardial tissue: useful in research of aid to the clinician?] Derumeaux G.
Ann Cardiol Angeiol (Paris) 1998 Nov;47(9):664–7 **(Fre)**
[Transesophageal echocardiography]
Arch Mal Coeur Vaiss 1999 Jun;92(6):763–4 **(Fre)**
[Echocardiography. Its role in preoperative diagnosis of cardiac risk patients before non–cardiac surgical interventions] Böhm M. **Anaesthesist** 1998 Nov; 47(11):901–2 **(Ger)**
[The role of echocardiography in preoperative diagnosis of cardiac risk in patients before non–cardiac surgical interventions] Strom C, et al. **Anaesthesist** 1998 Nov; 47(11):903–11 (57 ref.) (Eng. Abstr.) **(Ger)**
[Improved structure identification with tissue Doppler echocardiography] Bartel T, et al. **Herz** 1998 Dec; 23(8):499–505 (Eng. Abstr.) **(Ger)**
[Echocardiography: indications] Günter C, et al.
Schweiz Rundsch Med Prax 1998 Nov 4;87(45):1491–6 (7 ref.) (Eng. Abstr.) **(Ger)**
[Medicine in images. Recurrent transient neurologic focal signs with chronic auricular fibrillation] Marin Ortuño F, et al. **Rev Clin Esp** 1998 Oct;198(10):709–10 **(Spa)**
[A double fistulous communication between the aortic root and both left cardiac chambers. Its diagnosis by multiplanar transesophageal echocardiography] Ribas Garau M, et al. **Rev Esp Cardiol** 1999 Feb;52(2):145–7 (6 ref.) (Eng. Abstr.) **(Spa)**
[A right atrial thrombus in transit: its echocardiographic diagnosis 72 hours before a pulmonary embolism] Valenzuela Garcia LF, et al. **Rev Esp Cardiol** 1999 Jan; 52(1):59–62 (7 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Measurement of creatine kinase MB in canine cardiac patients. Wyatt KM, et al. **Aust Vet J** 1998 Dec;76(12):826
Interventional nutrition for cardiac disease. Freeman LM.
Clin Tech Small Anim Pract 1998 Nov;13(4):232–7 (18 ref.)
Echocardiographic measurements in the Irish wolfhound: reference values for the breed. Vollmar AC.
J Am Anim Hosp Assoc 1999 Jul–Aug;35(4):271–7
What is your diagnosis? Peritoneopericardial diaphragmatic hernia with herniation of mineralized fetuses. Iwasaki M, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1775–6
Clinical assessment of left ventricular relaxation. Constable P, et al. **J Vet Intern Med** 1999 Jan–Feb;13(1):5–13 (40 ref.)
Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. Freeman LM, et al. **J Vet Intern Med** 1998 Nov–Dec;12(6):440–8
Doppler echocardiography. I. Pulsed–wave and continuous–wave examinations. Bonagura JD, et al.
Vet Clin North Am Small Anim Pract 1998 Nov; 28(6):1325–59, vii (56 ref.)
Doppler echocardiography. II. Color Doppler imaging. Bonagura JD, et al.
Vet Clin North Am Small Anim Pract 1998 Nov; 28(6):1361–89, vii (27 ref.)
Critical care cardiology. Marks SL, et al.
Vet Clin North Am Small Anim Pract 1998 Nov; 28(6):1567–93, x (89 ref.)
The effectiveness of taurine and levocarnitine in dogs with heart disease. Pion PD, et al.
Vet Clin North Am Small Anim Pract 1998 Nov; 28(6):1495–514, ix (43 ref.)
Clinical and analytical studies of sheep dosed with various preparations of Astragalus lusitanicus. Abdennebi EH, et al. **Vet Hum Toxicol** 1998 Dec;40(6):327–31
[Echo(cardiography) in the first and second line of practice] Garretsen JW. **Tijdschr Diergeneeskd** 1998 Oct 15; 123(20):592–3 **(Dut)**
[Electrocardiography at the present time: possibilities of ECG registration and interpretation] Overduin LM.
Tijdschr Diergeneeskd 1998 Oct 15;123(20):590–2 **(Dut)**

VIROLOGY

Enteroviral genome in native hearts may influence outcome of patients who undergo cardiac transplantation. Calabrese F, et al. **Diagn Mol Pathol** 1999 Mar;8(1):39–46
Detection of enteroviral sequence in endomyocardial tissues from patients with cardiac diseases in northern Brazil. Gomes M de L, et al. **Rev Soc Bras Med Trop** 1998 Sep–Oct;31(5):487–90

HEART ENLARGEMENT see **HEART HYPERTROPHY**

HEART FAILURE, CONGESTIVE

Self–reported differences between cardiologists and heart failure specialists in the management of chronic heart failure [see comments] Bello D, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):100–7. Comment in: Am Heart J 1999 Jul;138(1 Pt 1):14–6.
Contemporary issues in heart failure [editorial; comment] Ghali JK. **Am Heart J** 1999 Jul;138(1 Pt 1):5–8 (29 ref.) . Comment on: Am Heart J 1999 Jul;138(1 Pt 1):87–94.
Factors influencing knowledge of and adherence to self–care among patients with heart failure. Ni H, et al.
Arch Intern Med 1999 Jul 26;159(14):1613–9
Heart failure. Symposium proceedings. 21–24 April 1998.
Br J Clin Pharmacol 1998 Oct;46(4):360–2
Heart failure. Rich MW. **Cardiol Clin** 1999 Feb;17(1):123–35 (87 ref.)
Rat models of hypertension, cardiac hypertrophy and failure. Doggrell SA, et al. **Cardiovasc Res** 1998 Jul;39(1):89–105 (194 ref.)
Bibliography current world literature. **Coron Artery Dis** 1998; 9(10):703–11
Drugs, heart failure and quality of life: what are we achieving? What should we be trying to achieve? Doba N, et al. **Drugs Aging** 1999 Mar;14(3):153–63 (46 ref.)
Growth hormone treatment in chronic heart failure: lessons from the first 99 patients [editorial; comment] Cicoira M, et al. **Eur Heart J** 1998 Nov;19(11):1605–7. Comment on: Eur Heart J 1998 Nov;19(11):1740–11.
Health economics and quality of life issues in heart failure. Foreword. Erdmann E. **Eur Heart J** 1998 Dec;19 Suppl P:P1
Heart failure 101. Kuritzky L. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):96–8, 101
Judging the value of population–based disease management. Rector TS, et al. **Inquiry** 1999 Summer;36(2):122–6
2nd Annual scientific meeting of the Heart Failure Society of America. September 13–16, 1998. Abstracts.
J Card Fail 1998 Sep;4(3 Suppl 1):1–67
2nd Annual scientific meeting of the Japanese Heart Failure Society. Sapporo, October 15–17, 1998. Abstracts.
J Card Fail 1998 Sep;4(3 Suppl 2):19–125
Cardiac transgenic and gene–targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches [editorial; comment] Izumo S, et al. **J Card Fail** 1998 Dec; 4(4):263–70 (46 ref.). Comment on: J Card Fail 1998 Dec;4(4):349–61.
A 75–year–old man with congestive heart failure [clinical conference] Guyatt G. **JAMA** 1999 Jun 23–30; 281(24):2321–8
Time to focus on the more typical heart–failure patients [see comments] Krumholz HM. **Lancet** 1998 Jul 4;352(9121):3–4 . Comment in: Lancet 1998 Jul 4;352(9121):3–4.
Therapy for cardiac failure: treatments old and new. Pavia SV, et al. **Med J Aust** 1999 Sep 6;171(5):265–71 (32 ref.)
A simple, reliable method of assessing exercise capacity in patients with chronic heart failure. Asakuma S, et al.
Med Sci Sports Exerc 1999 Jan;31(1):52–6
Congestive heart failure in children. O'Laughlin MP.
Pediatr Clin North Am 1999 Apr;46(2):263–73 (15 ref.)
[Cardiac insufficiency and cardiomyopathies. Proceedings of the 4th national meeting of the French Society of Cardiology work group. Nice, France, 4–6 June 1998]
Arch Mal Coeur Vaiss 1998 Dec;91(12 Suppl):5–82 **(Fre)**
[Education of patients with heart failure] Bouhour JB.
Arch Mal Coeur Vaiss 1998 Nov;91(11):1407–10 (Eng. Abstr.) **(Fre)**
[Practical aspects of diagnosis, treatment and prognosis in chronic heart failure] Wagdi P. **Dtsch Med Wochenschr** 1999 Mar 12;124(10):291–5 (10 ref.) **(Ger)**
[Congestive heart failure in infancy and childhood] Schmaltz AA. **Klin Padiatr** 1999 Jan–Feb;211(1):1–10 (79 ref.) (Eng. Abstr.) **(Ger)**
[Heart failure. 1: acute heart failure] Dotzer F.
MMW Fortschr Med 1999 Jun 17;141(24):50–2 **(Ger)**
[Heart failure] Barretto AC, et al. **Arq Bras Cardiol** 1998 Oct;71(4):635–42 (67 ref.) **(Por)**
[Heart failure in the elderly. Differences and similarities with the young] Barretto AC, et al. **Arq Bras Cardiol** 1998 Dec; 71(6):801–6 (44 ref.) **(Por)**
[Predictive variables of early hospital readmission in cardiac failure] Jiménez Puente A, et al. **Rev Clin Esp** 1998 Dec; 198(12):799–804 (Eng. Abstr.) **(Spa)**
[Study and treatment of heart failure require new approaches. Natriuretic peptides can be safe and simple diagnostic and outcome measures] Lindstedt G, et al. **Lakartidningen** 1998 Nov 18;95(47):5311–5 (63 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

A novel biochemical approach to congestive heart failure: cardiac troponin T [see comments] Missov E, et al.
Am Heart J 1999 Jul;138(1 Pt 1):95–9. Comment in: Am Heart J 1999 Jul;138(1 Pt 1):9–12.
Cytokine generation capacities of monocytes are reduced in patients with severe heart failure. Shimokawa H, et al.
Am Heart J 1998 Dec;136(6):991–1002
Exercise–induced hemoconcentration in heart failure due to dilated cardiomyopathy. Agostoni P, et al.
Am J Cardiol 1999 Jan 15;83(2):278–80, A6
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Aukrust P, et al. **Am J Cardiol** 1999 Feb 1;83(3):376–82
Insulin–mediated glucose uptake in congestive heart failure [letter] Doehner W, et al. **Am J Cardiol** 1999 Sep 15; 84(6):761–2
Effects of amiodarone on tumor necrosis factor–alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Oral H, et al.
Am J Cardiol 1999 Feb 1;83(3):388–91
Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Yamaguchi S, et al. **Am J Cardiol** 1999 May 15; 83(10):1500–3, A8
Monitoring of cardiac troponin I in patients with acute heart failure. Chen YN, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):433–7
Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Nägele H, et al.
Anticancer Res 1999 Jul–Aug;19(4A):2531–4
Effects of hemodialysis on circulating adrenomedullin concentrations in patients with end–stage renal disease. Toepfer M, et al. **Blood Purif** 1998;16(5):269–74
Serum alpha 1–acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. Chu JS, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):408–10
TNF–alpha and heart failure. The difference between proof of principle and hypothesis testing [editorial; comment] Francis GS. **Circulation** 1999 Jun 29;99(25):3213–4. Comment on: Circulation 1999 Jun 29;99(25):3224–6.
Differential hormonal profiles of adrenomedullin and proadrenomedullin N–terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels. Etoh T, et al. **Clin Cardiol** 1999 Feb;22(2):113–7
Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise. Friedl W, et al. **Clin Chim Acta** 1999 Mar; 281(1–2):121–6
Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Manolis AJ, et al.
Clin Exp Hypertens 1998 Oct;20(7):717–31
How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Missouris CG, et al. **Clin Sci (Colch)** 1998 Jun;94(6):591–9
Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Anker SD, et al. **Eur Heart J** 1999 May;20(9):683–93
Hyperleptinaemia does not correlate with plasma catecholamine levels in chronic heart failure [letter] Böttner A, et al. **Eur Heart J** 1999 Jul;20(14):1051–2
The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Kiilavuori K, et al.
Eur Heart J 1999 Mar;20(6):456–64
Uric acid in chronic heart failure: a marker of chronic inflammation [see comments] Leyva F, et al.
Eur Heart J 1998 Dec;19(12):1814–22. Comment in: Eur Heart J 1998 Dec;19(12):1746–7.
Hyperleptinaemia in chronic heart failure. Relationships with insulin [see comments] Leyva F, et al. **Eur Heart J** 1998 Oct;19(10):1547–51. Comment in: Eur Heart J 1998 Oct;19(10):1421–2. Comment in: Eur Heart J 1999 Jul;20(14):1051–2.
Concentrations of angiotensin II, endothelin–1, and BNP in the coronary sinus and ascending aorta of patients with heart disease [letter] Kagaya Y, et al. **Heart** 1999 Jan; 81(1):102–3
Anomalous origin of the left coronary artery from the pulmonary artery [letter; comment] Knightingale AK, et al. **Heart** 1999 Jan;81(1):103. Comment on: Heart 1998 Dec;80(6):629–31.
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? MacFadyen RJ, et al. **Heart** 1999 Jul;82(1):57–61
Nocturnal desaturation in patients with stable heart failure [letter; comment] Ritter G. **Heart** 1998 Dec;80(6):633–4. Comment on: Heart 1998 Apr;79(4):394–9.
Changes of neurohumoral parameters and endothelin–1 in response to exercise in patients with mild to moderate congestive heart failure. Genth–Zotz S, et al.

Int J Cardiol 1998 Sep 30;66(2):137–42

The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Liu L, et al. **Int J Cardiol** 1999 Apr 30;69(1):77–82

Peak VO2 et al. for prognosis in heart failure? [letter; comment] Anker SD, et al. **J Am Coll Cardiol** 1999 Feb; 33(2):591–2. Comment on: J Am Coll Cardiol 1998 Mar 1;31(3):577–82.

Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. Dibbs Z, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1935–42

Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. Frustaci A, et al. **J Am Coll Cardiol** 1999 May; 33(6):1578–83

Does heart failure confer a hypercoagulable state? Virchow's triad revisited. Lip GY, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1424–6 (23 ref.)

Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. Tsutamoto T, et al. **J Am Coll Cardiol** 1999 Feb;33(2):530–7

Atrial natriuretic peptide and the development of congestive heart failure in the oldest old: a seven-year prospective study. Knight EL, et al. **J Am Geriatr Soc** 1999 Apr; 47(4):407–11

Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. Corbalan R, et al. **J Card Fail** 1998 Jun;4(2):115–9

Molecular forms of circulating adrenomedullin in patients with congestive heart failure. Hirayama N, et al. **J Endocrinol** 1999 Feb;160(2):297–303

The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. Jansson K, et al. **J Intern Med** 1999 May;245(5):435–43

Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. Nozaki N, et al. **J Mol Cell Cardiol** 1998 Oct; 30(10):2003–12

Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. Spanier TB, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):404–13

Magnesium dynamics and sympathetic nervous system activity in patients with chronic heart failure. Samejima H, et al. **Jpn Circ J** 1999 Apr;63(4):267–73

Endotoxins in chronic heart failure [letter] Brunkhorst FM. **Lancet** 1999 Aug 14;354(9178):599–600

Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Schirger JA, et al. **Mayo Clin Proc** 1999 Feb;74(2):126–30

Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure. Dickstein K, et al. **Scand Cardiovasc J** 1998;32(6):361–4

An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. Klinge R, et al. **Scand J Clin Lab Invest** 1998 Dec;58(8):683–91

[The oxygen-transport function of the blood and cell metabolism in patients with heart failure of different origins] Shlyk SV, et al. **Ter Arkh** 1999;71(2):78–80 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Basser RL, et al. **Ann Oncol** 1999 Jan;10(1):53–8

Minoxidil accelerates heart failure development in rats with ascending aortic constriction. Turcani M, et al. **Can J Physiol Pharmacol** 1998 Jun;76(6):613–20

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Ibrahim NK, et al. **Cancer Chemother Pharmacol** 1999;43(6):471–8

Detection of anthracycline-induced cardiotoxicity. Meinardi MT, et al. **Cancer Treat Rev** 1999 Aug;25(4):237–47 (116 ref.)

Carbon monoxide and hospital admissions for congestive heart failure: evidence of an increased effect at low temperatures. Morris RD, et al. **Environ Health Perspect** 1998 Oct;106(10):649–53

Chloroquine cardiomyopathy with conduction disorders. Baguet JP, et al. **Heart** 1999 Feb;81(2):221–3 (6 ref.)

Drug-induced heart failure. Feenstra J, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1152–62 (133 ref.)

Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy [letter; comment] Jerian S, et al. **J Clin Oncol** 1999 May;17(5):1647–8. Comment on: J Clin Oncol 1998 Nov;16(11):3481–2.

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. Ryberg M, et al. **J Clin Oncol** 1998 Nov;16(11):3502–8

Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. Shapiro CL, et al. **J Clin Oncol** 1998 Nov;16(11):3493–501

Neonatal effects of maternal consumption of blue cohosh [letter; comment] Wright IM. **J Pediatr** 1999 Mar; 134(3):384–5. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):550–2.

Heart failure with fludrocortisone in Addison's disease. Bhattacharyya A, et al. **J R Soc Med** 1998 Aug;91(8):433–4

Can oral beta2 agonists cause heart failure? [see comments] Jenne JW. **Lancet** 1998 Oct 3;352(9134):1081–2. Comment in: Lancet 1998 Nov 21;352(9141):1709–10.

Beta2 agonists and heart failure [letter; comment] Lindmark B, et al. **Lancet** 1998 Nov 21;352(9141):1709–10. Comment on: Lancet 1998 Oct 3;352(9134):1081–2.

Doxorubicin-induced cardiomyopathy [letter; comment] Swain SM. **N Engl J Med** 1999 Feb 25;340(8):654; discussion 655. Comment on: N Engl J Med 1998 Sep 24;339(13):900–5.

Cardiac risks with beta agonists [letter; comment] Lindmark B. **Thorax** 1998 Dec;53(12):1094–5. Comment on: Thorax 1998 Jul;53(7):558–62.

[Appetite depressants and pulmonary hypertension] Hellermann J, et al. **Ther Umsch** 1998 Sep;55(9):548–50 (Eng. Abstr.) **(Ger)**

[Two cases of circulatory failure after local infiltration of epinephrine during tonsillectomy] Murakawa T, et al. **Masui** 1998 Aug;47(8):955–62 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

The potential costs of upcoding for heart failure in the United States. Psaty BM, et al. **Am J Cardiol** 1999 Jul 1; 84(1):108–9, A9

A computerized method of identifying potentially preventable heart failure admissions. Thomas V, et al. **J Nurs Care Qual** 1999 Jun;13(5):1–10 (25 ref.)

Hypertensive heart failure: a report of 3 cases. Dosumu EA. **West Afr J Med** 1999 Apr–Jun;18(2):147–50

[Heart failure: limits of classification] Bokarev IN. **Klin Med (Mosk)** 1998;76(12):68–72 (22 ref.) **(Rus)**

COMPLICATIONS

Hypoxic hepatitis: a difficult diagnosis when the cardiomyopathy remains unrecognized course of liver enzymes follows an atypical pattern. A rt of two cases. Henrion J, et al. **Acta Gastro elg** 1998 Jul-Sep;61(3):385–9

Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Twidale N, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):647–57

Undetected cardiogenic shock in patients with congestive heart failure presenting to the emergency department. Ander DS, et al. **Am J Cardiol** 1998 Oct 1;82(7):888–91

Evaluation of left ventricular based pacing in patients with congestive heart failure and atrial fibrillation. Etienne Y, et al. **Am J Cardiol** 1999 Apr 1;83(7):1138–40, A9

Prevalence of depression in congestive heart failure. Havranek EP, et al. **Am J Cardiol** 1999 Aug 1;84(3):348–50, A9

Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. Levine TB, et al. **Am J Hypertens** 1998 Sep;11(9):1041–7

Hyperparathyroidism in congestive heart failure [letter; comment] Field MH. **Am J Med** 1999 Jul;107(1):102–3. Comment on: Am J Med 1997 Sep;103(3):197–207. Comment on: Am J Med 1998 May;104(5):508–9.

Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Walsh EE, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):791–5

Loculated pericardial effusion due to congestive heart failure: an unusual case of vanishing tumor—a case report. Sakamoto H, et al. **Angiology** 1999 Aug;50(8):683–7

Rejection with heart failure after pediatric cardiac transplantation. Flippin MJ, et al. **Ann Thorac Surg** 1999 Jul;68(1):176–80

Strength improvement of knee extensor muscles in patients with chronic heart failure by neuromuscular electrical stimulation. Quittan M, et al. **Artif Organs** 1999 May; 23(5):432–5

Congestive cardiac failure (CCF) as a cause of fatal stroke and all cause death. Jelinek MV, et al. **Aust N Z J Med** 1998 Dec;28(6):799–804

Heart failure in thyrotoxicosis, an approach to management. Choudhury RP, et al. **Br J Clin Pharmacol** 1998 Nov; 46(5):421–4

A case of thyrotoxicosis and reversible systolic cardiac dysfunction. Goldman LE, et al. **Can J Cardiol** 1999 Jul; 15(7):811–4

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Anker SD, et al. **Chest** 1999 Mar;115(3):836–47 (101 ref.)

The development of hyperventilation in patients with chronic heart failure and Cheyne-Strokes respiration: a possible role of chronic hypoxia. Fanfulla F, et al. **Chest** 1998 Oct; 114(4):1083–90

Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Li D, et al. **Circulation** 1999 Jul 6;100(1):87–95

Mechanisms and models in heart failure: A combinatorial approach. Mann DL. **Circulation** 1999 Aug 31; 100(9):999–1008 (78 ref.)

Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Solin P, et al. **Circulation** 1999 Mar 30;99(12):1574–9

Clinical significance of arterial blood gas analysis for detection and/or treatment of central sleep apnea in patients with heart failure [letter] Teramoto S, et al. **Circulation** 1999 May 25;99(20):2709–12

An unusual cardiomegaly: the giant left atrium. Bertoli D, et al. **Clin Cardiol** 1998 Dec;21(12):918

Loculated pericardial effusion detected on blood pool bone imaging. Minshew PT, et al. **Clin Nucl Med** 1999 Jul; 24(7):521

Success in using non-invasive mechanical ventilation is predicted by patient pathophysiology. A retrospective review of 199 patients. Krall SP, et al. **Del Med J** 1999 May;71(5):213–20

Surgical successful treatment of Cushing's syndrome in a pregnant patient complicated with severe cardiac involvement. Kamiya Y, et al. **Endocr J** 1998 Aug; 45(4):499–504

Leptin and cardiac cachexia: marker or mediator? [editorial; comment] Cleland JG, et al. **Eur Heart J** 1998 Oct; 19(10):1421–2 (15 ref.). Comment on: Eur Heart J 1998 Oct;19(10):1547–51.

Central sleep apnoea in congestive heart failure despite vagal denervation after bilateral lung transplantation. Solin P, et al. **Eur Respir J** 1998 Aug;12(2):495–8

Geriatrics photo quiz. Pulsus alternans. Shua-Haim JR, et al. **Geriatrics** 1999 Sep;54(9):17, 58

Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure. Crilley JG, et al. **Heart** 1998 Dec;80(6):620–2

Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Murdoch DR, et al. **Heart** 1999 Sep;82(3):352–6

Congenitally corrected transposition of the great arteries in an 80 year old woman. Roffi M, et al. **Heart** 1998 Jun; 79(6):622–3

Coexistent renal and heart failure: the importance of recognizing 'congestive cardio-renal failure'. Jones CH, et al. **Hosp Med** 1999 Jan;60(1):62–4 (24 ref.)

Treatment of ventricular arrhythmias in heart failure: drugs or devices. Gambhir DS. **Indian Heart J** 1998 Sep–Oct; 50(5):507–10 (34 ref.)

Unguarded tricuspid orifice and patent right ventricular outflow tract presenting with long-standing severe right heart failure in an adult. Mohan JC, et al. **Int J Cardiol** 1998 Sep 1;66(1):85–7

Suppressing sympathetic activation with clonidine on ventricular arrhythmias in congestive heart failure. Zhang YH, et al. **Int J Cardiol** 1998 Aug;65(3):233–8

Desensitization of the pulmonary adenylyl cyclase system: a cause of airway hyperresponsiveness in congestive heart failure? Borst MM, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):848–56

Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. Cacciatore F, et al. **J Am Geriatr Soc** 1998 Nov; 46(11):1343–8

Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. Philbin EF, et al. **J Am Geriatr Soc** 1999 Mar;47(3):302–8

Ventricular arrhythmia in postinfarction and congestive heart failure patients [letter; comment] Crystal E, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):420–1. Comment on: J Cardiovasc Electrophysiol 1998 Aug;9(8):864–91.

Renal effects of L-DOPA in heart failure. Grossman E, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):922–8

Cardiovascular disease and the kidney: an epidemiologic overview. Zanchetti A, et al. **J Cardiovasc Pharmacol** 1999; 33 Suppl 1:S1–6; discussion S41–3 (44 ref.)

Serum-free carnitine levels in children with heart failure. Ergür AT, et al. **J Trop Pediatr** 1999 Jun;45(3):168–9

Evaluation of the effect of haemodialysis on cardiac dysfunction in patients of chronic renal failure. Yazdani I, et al. **JPMA J Pak Med Assoc** 1998 Aug;48(8):230–2

Arterial thrombosis in heart failure [letter] Goto S, et al. **Lancet** 1998 May 23;351(9115):1558–9

Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure [comment] [see comments] MacDowall P, et al. **Lancet** 1998 Jul 4; 352(9121):13–6. Comment on: Lancet 1998 Jul 4;352(9121):3–4. Comment in: Lancet 1998 Aug 23;352(9128):656.

The association of quality of care and occurrence of in-hospital, treatment-related complications. Geraci JM, et al. **Med Care** 1999 Feb;37(2):140–8

Respiratory muscles in heart failure. Vassilakopoulos T, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):150–3 (25 ref.)

Apnea and periodic breathing during sleep [editorial; comment] Cherniack NS. **N Engl J Med** 1999 Sep 23; 341(13):985–7. Comment on: N Engl J Med 1999 Sep 23;341(13):949–54.

A mechanism of central sleep apnea in patients with heart failure [see comments] Javaheri S. **N Engl J Med** 1999 Sep 23;341(13):949–54. Comment in: N Engl J Med 1999 Sep 23;341(13):985–7.

Chronic eosinophilic pneumonia with pleural effusion. Rutgers SR, et al. **Neth J Med** 1999 May;54(5):191–6

Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. Garg RK, et al. **Prog Cardiovasc Dis** 1998 Nov–Dec;41(3):225–36 (76 ref.)

Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure. Seta K, et al. **Ren Fail** 1998 Sep;20(5):717–23

Stent implantation in an adult with coarctation of the aorta in the presence of advanced secondary heart failure. Alcibar J, et al. **Tex Heart Inst J** 1999;26(2):143–7

Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure. Naughton MT. **Thorax** 1998 Oct;53 Suppl 3:S37–40 (40 ref.)

Prognosis and sleep disordered breathing in heart failure. Wilcox I, et al. **Thorax** 1998 Oct;53 Suppl 3:S33–6 (24 ref.)

Treatment of central sleep apnoea in congestive heart failure with nasal ventilation. Willson GN, et al. **Thorax** 1998 Oct; 53 Suppl 3:S41–6

[Spontaneous ventilation in positive expiratory pressure in cardiogenic pulmonary edema. Prospective study] Bouquin V, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1243–8 (Eng. Abstr.) **(Fre)**

[Aspirin, oral anticoagulants, and heart failure] Gibelin P. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1377–81 (Eng. Abstr.) **(Fre)**

[Management of arrhythmias in patients with heart failure] Le Heuzey JY, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1371–6 (Eng. Abstr.) **(Fre)**

[Mechanism of spontaneous occurrence of tachycardia] Leenhardt A, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:17–22 (Eng. Abstr.) **(Fre)**

[Use of non-invasive positive pressure ventilation for cardiogenic pulmonary edema in emergency care units (editorial; comment)] Brochard L. **Presse Med** 1998 Jun 20;27(22):1105–7 (10 ref.) (Eng. Abstr.). Comment on: Presse Med 1998 Jun 20;27(22):1089–94. **(Fre)**

[Spontaneous positive end-expiratory pressure ventilation in elderly patients with cardiogenic pulmonary edema. Assessment in an emergency admissions unit (see comments)] L'Her E, et al. **Presse Med** 1998 Jun 20; 27(22):1089–94 (Eng. Abstr.). Comment in: Presse Med 1998 Jun 20;27(22):1105–7. **(Fre)**

[Coronary insufficiency associated with heart failure. Congress of the American Heart Association, Texas, 8–11 November 1998] Montagne O. **Presse Med** 1999 Jan 16; 28(2):82–4 **(Fre)**

[Sleep-related cardiac insufficiency and respiratory disorders. Prevalence, physiopathology, and treatment] Escourrou P, et al. **Rev Mal Respir** 1999 Apr;16(2):161–71 (Eng. Abstr.) **(Fre)**

[Acute hemodynamic pulmonary edema (cardiogenic or overload)] Michard F, et al. **Rev Prat** 1999 Feb 15; 49(4):415–8 (4 ref.) **(Fre)**

[Case report of serious cardiac insufficiency complicated by syncope] Galrinho A, et al. **Rev Port Cardiol** 1999 Jan; 18(1):59–60 (Eng. Abstr.) **(Por)**

[Hypertensive cardiopathy. From arterial hypertension to congestive heart failure] Nogueira JB. **Rev Port Cardiol** 1999 Jun;18(6):635–46 (41 ref.) (Eng. Abstr.) **(Por)**

[Anesthesia in a patient with along-standing congenital heart malformation of the complete atrioventricular canal type for non-cardiac surgery] Higuera Miguélez E, et al. **Rev Esp Anestesiol Reanim** 1999 Feb;46(2):85–7 (Eng. Abstr.) **(Spa)**

CONGENITAL

[Heart failure in utero: diagnosis and therapy] Schmidt KG. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1436–43 (18 ref.) (Eng. Abstr.) **(Ger)**

[Doppler ultrasound of the umbilical vein in fetal 3rd degree atrioventricular block] Yaman C, et al. **Ultraschall Med** 1998 Jun;19(3):142–5 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Prognostic assessment of end-stage cardiac failure. Vranckx P, et al. **Acta Cardiol** 1998;53(2):121–5 (35 ref.)

Heart failure: a diagnostic and therapeutic dilemma in elderly patients [see comments] Gillespie ND, et al. **Age Ageing** 1998 Jul;27(4):539–43 (50 ref.). Comment in: Age Ageing 1999 May;28(3):328–9.

A novel biochemical approach to congestive heart failure: cardiac troponin T [see comments] Missov E, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):95–9. Comment in: Am Heart J 1999 Jul;138(1 Pt 1):9–12.

Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. Brunner-La Rocca HP, et al. **Am J Cardiol** 1999 Sep 15;84(6):741–4, A9

Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Setsuta K, et al. **Am J Cardiol** 1999 Sep 1;84(5):608–11, A9

Detection of anthracycline-induced cardiotoxicity. Meinardi MT, et al. **Cancer Treat Rev** 1999 Aug;25(4):237–47 (116 ref.)

Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Franco F, et al. **Circulation** 1999 Jan 26;99(3):448–54

The assessment of patients with congestive heart failure as a manifestation of coronary artery disease. Ragosta M, et al. **Coron Artery Dis** 1998;9(10):645–51 (26 ref.)

The role of exercise-based prognosticating algorithms in the selection of patients for heart transplantation. Beniaminovitz A, et al. **Curr Opin Cardiol** 1999 Mar; 14(2):114–20 (28 ref.)

How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure [see comments] **Eur Heart J** 1998 Jul;19(7):990–1003 (199 ref.). Comment in: Eur Heart J 1999 Mar;20(5):393.

Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Selvais PL, et al. **Eur J Clin Invest** 1998 Aug;28(8):636–42

Heart failure: clinical implications of systolic and diastolic dysfunction. Tecce MA, et al. **Geriatrics** 1999 Aug; 54(8):24–8, 31–3 (31 ref.)

Diagnosis and treatment of diastolic heart failure. Weinberger HD. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):115–8, 121–2, 125–6 (12 ref.)

Bioelectrical impedance analysis before and after Novacor implantation. Stellato D, et al. **Int J Artif Organs** 1999 Mar; 22(3):151–4

Intraventricular conduction delay: a prognostic marker in chronic heart failure. Shamim W, et al. **Int J Cardiol** 1999 Jul 31;70(2):171–8

Pulsus paradoxus indicating heart failure in paroxysmal supraventricular tachycardia: easy detection by pulse oximetry [letter; comment] Frey B. **Intensive Care Med** 1999 Mar;25(3):333–4. Comment on: Intensive Care Med 1998 Mar;24(3):242–6.

Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. Metra M, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):943–50

Ileus, a clinical sign of congestive heart failure in older people [letter] Minezaki KK, et al. **J Am Geriatr Soc** 1999 Feb; 47(2):258–9

Non-physician supervision of cardiopulmonary exercise testing in chronic heart failure: safety and results of a preliminary investigation. Squires RW, et al. **J Cardiopulm Rehabil** 1999 Jul–Aug;19(4):249–53

Minimizing mistakes in clinical diagnosis. Ermenc B. **J Forensic Sci** 1999 Jul;44(4):810–3

Evolving therapeutic concepts and imaging in ischemic cardiomyopathy. Lahiri A, et al. **J Nucl Cardiol** 1998 Nov–Dec;5(6):598–608 (70 ref.)

Cutting edge of cardiomyopathy. Poepping I, et al. **Lancet** 1998 Nov 7;352(9139):1518

Adult emergency visits for chronic cardiorespiratory disease: does dyspnea matter? Parshall MB. **Nurs Res** 1999 Mar–Apr;48(2):62–70

Cardiac failure in children with pneumonia in Papua New Guinea. Shann F, et al. **Pediatr Infect Dis J** 1998 Dec; 17(12):1141–3

Isolated diastolic heart failure--what is it? Shiels P, et al. **Postgrad Med J** 1998 Aug;74(874):451–4 (31 ref.)

Heart failure clinical guideline. South African Medical Association Heart Failure Working Group. **S Afr Med J** 1998 Sep;88(9 Pt 2):1133–55

An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. Klinge R, et al. **Scand J Clin Lab Invest** 1998 Dec;58(8):683–91

How do GPs use clinical information in their judgements of heart failure? A clinical judgement analysis study. Skånér Y, et al. **Scand J Prim Health Care** 1998 Jun;16(2):95–100

Ventricular arrhythmias in congestive heart failure: clinical significance and management. Khoshnevis GR, et al. **Tex Heart Inst J** 1999;26(1):42–59 (149 ref.)

Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function [see comments] Stainback RF. **Tex Heart Inst J** 1999; 26(1):34–41 (45 ref.). Comment in: Tex Heart Inst J 1999;26(2):158.

Heart failure: Part I. First hospitalization and post-hospital care [see comments] Wilkes MS, et al. **West J Med** 1999 May;170(5):268–73. Comment in: West J Med 1999 May;170(5):253–4.

Congestive heart failure with preserved systolic function: is it a woman's disease? Samuel RS, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):219–22

[Predictors of sudden death and death from heart failure in patients with heart insufficiency are different] Madsen BK, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):34–9 (Eng. Abstr.) **(Dan)**

[QT-dispersion--analysis and prognostic implications] Schneider CA, et al. **Dtsch Med Wochenschr** 1999 Apr 1; 124(13):396–402 (44 ref.) **(Ger)**

[Heart failure: diagnosis and therapy] Horstmann E, et al. **Med Klin** 1998 Sep 15;93(9):555–6 **(Ger)**

[The prognostic value of type-1 myosin heavy chain in the skeletal muscle of patients with chronic heart failure of a mild-moderate degree] Serafini F, et al. **Cardiologia** 1998 Oct;43(10):1059–66 (Eng. Abstr.) **(Ita)**

[Position of internal medicine in the preoperative evaluation of circulatory functions] Fujii T. **Masui** 1998 Dec;47 Suppl:S142–8 (12 ref.) **(Jpn)**

[The European Project on Improvement of Heart Failure. The Diagnostic Study Group of the Working Group on Heart Failure of the European Society of Cardiology (editorial)] Madeira HC. **Rev Port Cardiol** 1999 Jul–Aug; 18(7–8):679–81 **(Por)**

[Role of respiratory function tests in differential diagnosis of respiratory and cardiac insufficiency] Grishin OV, et al. **Ter Arkh** 1999;71(4):13–7 (Eng. Abstr.) **(Rus)**

[QT interval dispersion in hospital patients admitted with cardiac insufficiency. Determinants and prognostic value] Bodí Peris V, et al. **Rev Esp Cardiol** 1999 Aug;52(8):563–9 (Eng. Abstr.) **(Spa)**

[Guidelines for the diagnosis and management of heart failure and cardiogenic shock. Informe del Grupo de Trabajo de Insuficiencia Carddiacade la Sociedad Espanñola de Cardiologia] Navarro-López F, et al. **Rev Esp Cardiol** 1999; 52 Suppl 2:1–54 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Heart failure: a diagnostic and therapeutic dilemma in elderly patients [letter; comment] Kausar SA. **Age Ageing** 1999 May;28(3):328–9. Comment on: Age Ageing 1998 Jul;27(4):539–43.

Treatment guidelines for heart failure stress multidrug approach. Morey SS. **Am Fam Physician** 1999 Jun; 59(11):3265–6

ACE inhibitor therapy: benefits and underuse [editorial] Smith SC Jr. **Am Fam Physician** 1999 Jan 1;59(1):35–6, 38

Carvedilol: the new role of beta blockers in congestive heart failure. Vanderhoff BT, et al. **Am Fam Physician** 1998 Nov 1;58(7):1627–34, 1641–2 (38 ref.)

Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998. **Am Heart J** 1999 Jan;137(1):180–6

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective. Boccuzzi SJ. **Am Heart J** 1999 May;137(5):S120–2

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure [see comments] Giustina A, et al. **Am Heart J** 1999 Jun;137(6):1035–43. Comment in: Am Heart J 1999 Jun;137(6):989–91.

Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors [see comments] Guazzi M, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):254–60 . Comment in: Am Heart J 1999 Aug;138(2 Pt 1):193–7.

Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Guazzi M, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):460–7

Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure [see comments] Hatzizacharias A, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):241–6. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):191–2.

Growth hormone therapy in patients with congestive heart failure: need for further research [editorial; comment] Johnson MR, et al. **Am Heart J** 1999 Jun;137(6):989–91 (21 ref.). Comment on: Am Heart J 1999 Jun;137(6):1035–43.

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. Kukin ML, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):261–8

Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Lin JL, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):658–65

Quality of care for patients hospitalized with heart failure at academic medical centers [see comments] Nohria A, et al. **Am Heart J** 1999 Jun;137(6):1028–34. Comment in: Am Heart J 1999 Jun;137(6):987–8.

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). O'Connor CM, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):78–86

Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial [see comments] Oliva F, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):247–53 . Comment in: Am Heart J 1999 Aug;138(2 Pt 1):191–2.

Effect of vesnarinone on cardiac function in patients with severe congestive heart failure [see comments] Scherrer-Crosbie M, et al. **Am Heart J** 1998 Nov; 136(5):769–77. Comment in: Am Heart J 1998 Nov;136(5):753–8.

Intermittent inotropes for advanced heart failure: inquiring minds want to know [editorial; comment] Silver MA. **Am Heart J** 1999 Aug;138(2 Pt 1):191–2. Comment on: Am Heart J 1999 Aug;138(2 Pt 1):241–6. Comment on: Am Heart J 1999 Aug;138(2 Pt 1):247–53.

Heart failure: A case for subspecialized care management [editorial; comment] Smith JJ, et al. **Am Heart J** 1999 Jul; 138(1 Pt 1):14–6. Comment on: Am Heart J 1999 Jul;138(1 Pt 1):100–7.

The interaction of ACE inhibitors and aspirin in heart failure: torn between two lovers [editorial; comment] Teerlink JR, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):193–7 (33 ref.). Comment on: Am Heart J 1999 Aug;138(2 Pt 1):254–60.

Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure [see comments] Weinfeld MS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):285–90. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):200–2.

Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Zannad F, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):672–80

Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. **Am J Cardiol** 1999 Jan 21;83(2A):1A–38A (404 ref.)

Effect of treatment on survival in an animal model of chronic heart failure. Bastien N, et al. **Am J Cardiol** 1998 Nov 19; 82(10A):50S–52S (11 ref.)

Effect of vasoactive therapy on heart rate variability in

patients with acutely decompensated congestive heart failure. Burger AJ, et al. **Am J Cardiol** 1999 Aug 15; 84(4):476–8, A10

Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Cusick DA, et al. **Am J Cardiol** 1998 Nov 1;82(9):1060–5

Cost effectiveness of carvedilol for heart failure. Delea TE, et al. **Am J Cardiol** 1999 Mar 15;83(6):890–6

Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Dickstein K, et al. **Am J Cardiol** 1999 Jun 15;83(12):1638–44

Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. Kanda M, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1274–7, A9

Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. Krombach RS, et al. **Am J Cardiol** 1999 Aug 19;84(4A):3L–15L

Effects of high-dose lisinopril–isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Levine AB, et al. **Am J Cardiol** 1998 Nov 15;82(10):1299–301, A10

Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Lowes BD, et al. **Am J Cardiol** 1999 Apr 15;83(8):1201–5

Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. O'Connor CM, et al. **Am J Cardiol** 1998 Oct 1;82(7):881–7

Effects of amiodarone on tumor necrosis factor–alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Oral H, et al. **Am J Cardiol** 1999 Feb 1;83(3):388–91

Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure. Packer M, et al. **Am J Cardiol** 1999 Aug 19;84(4A):1L–2L

Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Spallarossa P, et al. **Am J Cardiol** 1999 Aug 15; 84(4):430–3

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Sueta CA, et al. **Am J Cardiol** 1999 May 1; 83(9):1303–7

Pharmacist-managed carvedilol heart failure clinic [letter] Darlington MR. **Am J Health Syst Pharm** 1998 Aug 1; 55(15):1626

Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. Levine TB, et al. **Am J Hypertens** 1998 Sep;11(9):1041–7

Diuretic treatment and diuretic resistance in heart failure. Krämer BK, et al. **Am J Med** 1999 Jan;106(1):90–6 (70 ref.)

Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Gwathmey JK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1678–90

Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Sato N, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1699–705

Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Tappia PS, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H40–9

Interaction of ACE inhibitors and aspirin in patients with congestive heart failure. Song KH, et al. **Ann Pharmacother** 1999 Mar;33(3):375–7 (20 ref.)

Newer drug therapy for congestive heart failure. Coodley E. **Arch Intern Med** 1999 Jun 14;159(11):1177–83 (54 ref.)

Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Gattis WA, et al. **Arch Intern Med** 1999 Sep 13;159(16):1939–45

Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Havranek EP, et al. **Arch Intern Med** 1998 Oct 12;158(18):2024–8

Sympathetic activation in heart failure and its treatment with beta-blockade. Pepper GS, et al. **Arch Intern Med** 1999 Feb 8;159(3):225–34 (65 ref.)

Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. van Kraaij DJ, et al. **Arch Intern Med** 1999 Jul 26;159(14):1599–605

Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. Böhler S, et al. **Arzneimittelforschung** 1999 Apr;49(4):311–7

Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery. Hirata T, et al. **Arzneimittelforschung** 1999 Jun; 49(6):499–503

Effects of cytokines and nitric oxide on myocardial E-C coupling. Haque R, et al. **Basic Res Cardiol** 1998;93 Suppl 1:86–94 (98 ref.)

Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation. Su J, et al. **Basic Res Cardiol** 1999 Apr; 94(2):128–35

Coenzyme Q10 treatment in serious heart failure. Munkholm H, et al. **Biofactors** 1999;9(2–4):285–9

Drug cuts deaths from heart failure by a third [news] Gottlieb S. **BMJ** 1999 Jul 31;319(7205):276

Secondary prevention in acute myocardial infarction. Verapamil is alternative to beta blockers in patients without congestive heart failure [letter] Hansen JF. **BMJ** 1998 Oct 24;317(7166):1153

Clinical case studies in heart failure management. MacFadyen RJ, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):239–47 (72 ref.)

Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man [letter] Shiels P, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):337–8

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Struthers AD. **Br J Clin Pharmacol** 1999 May;47(5):479–82 (25 ref.)

Carvedilol for heart failure: more than just a beta-blocker? Cleland JG. **Br J Hosp Med** 1998 Nov 19–Dec 9; 58(10):493–7

Carvedilol [see comments] **Can Fam Physician** 1999 May; 45:1199–202, 1205–9. Comment in: Can Fam Physician 1999 May;45 :1133–4, 1140–1. **(Eng, Fre)**

Vascular and cardiac effects of amlodipine in acute heart failure in dogs. Isaac DL, et al. **Can J Cardiol** 1998 Nov; 14(11):1375–82

Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure. Sami M. **Can J Cardiol** 1999 May; 15 Suppl C:19C–23C

Possible adverse skin reaction to carvedilol. Simpson SH, et al. **Can J Cardiol** 1998 Oct;14(10):1277–9

Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. Eichhorn EJ. **Cardiol Clin** 1998 Nov;16(4):711–25, ix (196 ref.)

Effect of creatine phosphate on the contractile activity in acutely failing rat heart. Kőrge P, et al. **Cardiologia** 1998 Dec;43(12):1345–54

Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Anand I, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):291–9

Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure. Fauchier L, et al. **Cardiovasc Drugs Ther** 1998 Oct; 12(5):483–6

Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm. Huonker M, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):233–41

Pimobendan has a potent venodilating action in patients with congestive heart failure [letter] Matsumoto A, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):595–7

AT1-receptor antagonists for the treatment of chronic heart failure [editorial] Baan J Jr. **Cardiovasc Res** 1999 Jan; 41(1):14–5

Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure [editorial; comment] Hu K, et al. **Cardiovasc Res** 1999 Mar; 41(3):503–5. Comment on: Cardiovasc Res 1999 Mar;41(3):544–53.

Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Moe GW, et al. **Cardiovasc Res** 1998 Sep;39(3):571–9

Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Mulder P, et al. **Cardiovasc Res** 1998 Sep;39(3):600–8

Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Ohnishi M, et al. **Cardiovasc Res** 1998 Sep; 39(3):617–24

Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Richer C, et al. **Cardiovasc Res** 1999 Jan;41(1):100–8

Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats [see comments] Sandmann S, et al. **Cardiovasc Res** 1998 Aug; 39(2):339–50. Comment in: Cardiovasc Res 1998 Aug;39(2):276–7.

Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Shen YT, et al. **Cardiovasc Res** 1998 Aug;39(2):413–22

Cardioprotective activity of mibefradil [editorial; comment] van Zwieten PA. **Cardiovasc Res** 1998 Aug;39(2):276–7. Comment on: Cardiovasc Res 1998 Aug;39(2):339–50.

Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Ekelund UE, et al. **Circ Res** 1999 Sep 3;85(5):437–45

Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace? [editorial; comment] Walsh RA. **Circ Res** 1999 Apr 2;84(6):741–3. Comment on: Circ Res 1999 Apr 2;84(6):623–32. Comment on: Circ Res 1999 Apr 2;84(6):633–46. Comment on: Circ Res 1999 Apr 2;84(6):722–8. Comment on: Circ Res 1999 Apr 2;84(6):729–34. Comment on: Circ Res 1999 Apr 2;84(6):735–40.

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Baruch L, et al. **Circulation** 1999 May 25;99(20):2658–64

Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation [letter; comment] Davie A, et al. **Circulation** 1999 Jun 8; 99(22):2966; discussion 2966–7. Comment on: Circulation 1998 Sep 8;98(10):941–2. Comment on: Circulation 1998 Sep 8;98(10):953–60.

Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Davie AP, et al. **Circulation** 1999 Jul 20;100(3):268–73

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Deedwania PC, et al. **Circulation** 1998 Dec 8;98(23):2574–9

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure [see comments] Deswal A, et al. **Circulation** 1999 Jun 29;99(25):3224–6. Comment in: Circulation 1999 Jun 29;99(25):3213–4.

TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing [editorial; comment] Francis GS. **Circulation** 1999 Jun 29;99(25):3213–4. Comment on: Circulation 1999 Jun 29;99(25):3224–6.

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Hamroff G, et al. **Circulation** 1999 Mar 2; 99(8):990–2

Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure [see comments] Hornig B, et al. **Circulation** 1998 Dec 22–29;98(25):2842–8. Comment in: Circulation 1998 Dec 22–29;98(25):2788–90.

Sustained improvement in flow-mediated vasodilation after short-term administration of dobutamine in patients with severe congestive heart failure. Patel MB, et al. **Circulation** 1999 Jan 5–12;99(1):60–4

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Sütsch G, et al. **Circulation** 1998 Nov 24;98(21):2262–8

Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Vescovo G, et al. **Circulation** 1998 Oct 27;98(17):1742–9

Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Wada A, et al. **Circulation** 1999 Feb 2;99(4):570–7

The current role of amiodarone in patients with congestive heart failure. Bello D, et al. **Cleve Clin J Med** 1998 Oct; 65(9):479–89 (75 ref.)

Our new understanding of heart failure: the role of beta-blockers in treatment. Eichhorn EJ. **Cleve Clin J Med** 1998 Sep;65(8):428–35 (101 ref.)

Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure? Hobbs RE. **Cleve Clin J Med** 1998 Nov-Dec;65(10):539–42

The role of third-generation beta-blocking agents in chronic heart failure [published erratum appears in Clin Cardiol 1999 Mar;22(3):following table of contents] Bristow MR, et al. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I3–13 (76 ref.)

The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Colucci WS. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I20–4 (42 ref.)

Beta blockers: are they difficult to use in heart failure patients? [editorial] [see comments] Conti CR. **Clin Cardiol** 1999 Apr;22(4):255–6. Comment in: Clin Cardiol 1999 Jun;22(6):A27, 438.

Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels. Etoh T, et al. **Clin Cardiol** 1999 Feb;22(2):113–7

The effects of an angiotensin-converting inhibitor (enalapril) on patients with mild cardiac failure--evaluating cardiac function based on the relationship between daily walking pace and heart rate. Inooka E, et al. **Clin Cardiol** 1998 Dec; 21(12):893–8

Beta blockers: are they difficult to use in heart failure patients [letter; comment] Klibaner M. **Clin Cardiol** 1999 Jun; 22(6):A27, 438. Comment on: Clin Cardiol 1999 Apr;22(4):255–6.

Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. Kongstad-Rasmussen O, et al. **Clin Cardiol** 1998 Nov; 21(11):807–11

The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. Levine TB, et al. **Clin Cardiol** 1998 Dec; 21(12):899–904

Effects of dichloroacetate in patients with congestive heart failure. Lewis JF, et al. **Clin Cardiol** 1998 Dec; 21(12):888–92

Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Manolis AJ, et al.

Clin Exp Hypertens 1998 Oct;20(7):717–31

Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. Guazzi M, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):319–27

Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Guazzi M, et al. **Clin Sci (Colch)** 1999 Jan;96(1):17–22

How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Missouris CG, et al. **Clin Sci (Colch)** 1998 Jun;94(6):591–9

Effect of beta-blockade on baroreceptor and autonomic function in heart failure. Sanderson JE, et al. **Clin Sci (Colch)** 1999 Feb;96(2):137–46

Optimizing the use of ACE inhibitors in patients with congestive heart failure [editorial] Tsikouris JP. **Conn Med** 1999 Feb;63(2):91–3

Carvedilol and the Food and Drug Administration approval process: an introduction [comment] Fisher LD, et al. **Control Clin Trials** 1999 Feb;20(1):1–15. Comment on: Control Clin Trials 1999 Feb;20(1):16–39. Comment on: Control Clin Trials 1999 Feb;20(1):40–9; discussion 50–1.

Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing [see comments] Fisher LD. **Control Clin Trials** 1999 Feb;20(1):16–39. Comment in: Control Clin Trials 1999 Feb;20(1):1–15.

End-point interpretation in clinical trials: the case for discipline [see comments] Moyé LA. **Control Clin Trials** 1999 Feb;20(1):40–9; discussion 50–1. Comment in: Control Clin Trials 1999 Feb;20(1):1–15.

Medical management of heart failure secondary to coronary artery disease. Challapalli S, et al. **Coron Artery Dis** 1998; 9(10):659–74 (216 ref.)

The role of digitalis in the treatment of heart failure. Demers C, et al. **Coron Artery Dis** 1999 Sep;10(6):353–60 (29 ref.)

Growth hormone as a potential future therapy for congestive heart failure. Fazio S, et al. **Coron Artery Dis** 1999 Sep; 10(6):383–8 (43 ref.)

Beta-adrenergic blocking agents: past, present, and future perspectives. Franciosa JA. **Coron Artery Dis** 1999 Sep; 10(6):369–76

Potential future therapies: natriuretic peptides. Lisy O, et al. **Coron Artery Dis** 1999 Sep;10(6):389–94 (58 ref.)

Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond. Lombardi WL, et al. **Coron Artery Dis** 1999 Sep;10(6):361–8 (69 ref.)

Thyroid hormone and thyroid hormone analogues in the treatment of heart failure. Spooner PH, et al. **Coron Artery Dis** 1999 Sep;10(6):395–9 (33 ref.)

Angiotensin II receptor blockers. Thai H, et al. **Coron Artery Dis** 1999 Sep;10(6):377–81 (36 ref.)

Fighting fire with fire [editorial; comment] Kan H, et al. **Crit Care Med** 1998 Oct;26(10):1628–9 (11 ref.). Comment on: Crit Care Med 1998 Oct;26(10):1663–70.

Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Hegde SS, et al. **Curr Pharm Des** 1998 Dec;4(6):469–79 (57 ref.)

Beta-blocker therapy in heart failure: pathophysiology and clinical results. Carson PE. **Curr Probl Cardiol** 1999 Jul; 24(7):421–60 (74 ref.)

ACE inhibitor/CHF interim report. West Virginia Medical Institute. Sobel ER. **Del Med J** 1999 Jan;71(1):19–20

An interaction between digoxin and acarbose [letter] Ben-Ami H, et al. **Diabetes Care** 1999 May;22(5):860–1

Heart failure treatments: issues of safety versus issues of quality of life. Feenstra J, et al. **Drug Saf** 1999 Jan;20(1):1–7 (32 ref.)

Inappropriate use of digoxin in the elderly: how widespread is the problem and how can it be solved? Haas GJ, et al. **Drug Saf** 1999 Mar;20(3):223–30 (40 ref.)

Study on propionyl-L-carnitine in chronic heart failure. **Eur Heart J** 1999 Jan;20(1):70–6

Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol [see comments] Andersson B, et al. **Eur Heart J** 1999 Apr;20(8):575–83. Comment in: Eur Heart J 1999 Apr;20(8):560–1.

Why growth hormone therapy is efficient in heart failure? [letter; comment] Beranek JT. **Eur Heart J** 1999 Feb; 20(3):242–3. Comment on: Eur Heart J 1998 Apr;19(4):623–7.

Growth hormone treatment in chronic heart failure: lessons from the first 99 patients [editorial; comment] Cicoira M, et al. **Eur Heart J** 1998 Nov;19(11):1605–7. Comment on: Eur Heart J 1998 Nov;19(11):1740–11.

Health economic consequences of the pharmacological treatment of heart failure. Cleland JG. **Eur Heart J** 1998 Dec;19 Suppl P:P32–9 (53 ref.)

The ultimate follow-up [editorial; comment] Coats AJ. **Eur Heart J** 1999 Jan;20(2):85–6 (4 ref.). Comment on: Eur Heart J 1999 Jan;20(2):136–9.

Negative exercise trials in heart failure: result or design? [editorial; comment] Dickstein K. **Eur Heart J** 1998 Dec; 19(12):1747–9. Comment on: Eur Heart J 1998 Dec;19(12):1823–8.

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [see comments] Duprez DA, et al. **Eur Heart J** 1998 Sep; 19(9):1371–6. Comment in: Eur Heart J 1998 Sep;19(9):1273.

Do diuretics differ in terms of clinical outcome in congestive heart failure? Follath F. **Eur Heart J** 1998 Dec;19 Suppl P:P5–8 (37 ref.)

Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB. **Eur Heart J** 1998 Dec;19 Suppl P:P17–25 (27 ref.)

Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group [see comments] Hampton JR, et al. **Eur Heart J** 1998 Dec;19(12):1823–8. Comment in: Eur Heart J 1998 Dec;19(12):1747–9.

Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Hornig B, et al. **Eur Heart J** 1998 Jul;19 Suppl G:G48–53 (62 ref.)

A placebo-controlled study of growth hormone in patients with congestive heart failure. Isgaard J, et al. **Eur Heart J** 1998 Nov;19(11):1704–11

The NETWORK investigators [letter; comment] [see comments] McDonald K, et al. **Eur Heart J** 1998 Nov; 19(11):1740–1. Comment on: Eur Heart J 1998 Mar;19(3):481–9. Comment in: Eur Heart J 1998 Nov;19(11):1605–7.

Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Newby DE, et al. **Eur Heart J** 1998 Dec;19(12):1808–13

Treatment of congestive heart failure. Has the time come for decreased complexity? Rydén L, et al. **Eur Heart J** 1999 Jun;20(12):867–71 (22 ref.)

Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use. Silvestry FE, et al. **Eur Heart J** 1998 Aug; 19 Suppl I:I8–14 (54 ref.)

Should we still prescribe digoxin in mild-to-moderate heart failure? Is quality of life the issue rather than quantity? Soler-Soler J, et al. **Eur Heart J** 1998 Dec;19 Suppl P:P26–31 (18 ref.)

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I [see comments] Swedberg K, et al. **Eur Heart J** 1999 Jan; 20(2):136–9. Comment in: Eur Heart J 1999 Jan;20(2):85–6.

Beta-blockers for heart failure: is slowing of heart rate essential? [editorial; comment] Tendera M. **Eur Heart J** 1999 Apr;20(8):560–1 (5 ref.). Comment on: Eur Heart J 1999 Apr;20(8):575–83.

Differences in drug treatment of chronic heart failure between European countries [see comments] van Veldhuisen DJ, et al. **Eur Heart J** 1999 May;20(9):666–72 . Comment in: Eur Heart J 1999 May;20(9):637–8.

AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Willenheimer R, et al. **Eur Heart J** 1999 Jul;20(14):997–1008 (105 ref.)

Tolerance to ACE inhibitors after cardiac surgery. Manché A, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):55–60

Concurrent administration of amrinone with nitric oxide most improves PaO2/FiO2 in acute respiratory and cardiac failure. Yukioka H, et al. **Eur J Emerg Med** 1999 Jun; 6(2):161–4

Growth hormone for the failing heart. Hussain MA. **Eur J Endocrinol** 1998 Nov;139(5):476–8 (37 ref.)

Beneficial effects of amiodarone in heart failure: interaction with beta-adrenoceptors rather than G proteins. Schnabel P, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):391–4

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Yatsu T, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):239–46

Self administration of metolzaone reduces readmissions with decompensated congestive cardiac failure [letter] Broadley AJ, et al. **Heart** 1999 Sep;82(3):397–8

Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group. Bulpitt CJ, et al. **Heart** 1998 Jun;79(6):593–8

Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure. Crilley JG, et al. **Heart** 1998 Dec;80(6):620–2

Home inotrope treatment for intractable heart failure following heart transplantation. Dubrey SW, et al. **Heart** 1999 Aug;82(2):248–51

Does aspirin treatment influence vascular resistance and fluid filtration in patients with congestive heart failure? [letter] Galatius S, et al. **Heart** 1999 Mar;81(3):330

Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure. Kanaya Y, et al. **Heart** 1999 May;81(5):512–7

How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? MacFadyen RJ, et al. **Heart** 1999 Jul;82(1):57–61

Introducing new treatments in clinical practice: the Italian approach to beta blockers in heart failure [editorial] Maggioni AP, et al. **Heart** 1999 May;81(5):453–4

beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Spargias KS, et al. **Heart** 1999 Jan;81(1):25–32

Current and novel pharmacologic approaches in advanced heart failure. O'Connor CM, et al. **Heart Lung** 1999 Jul-Aug;28(4):227–42 (138 ref.)

High- vs low-dose ACE inhibition in chronic heart failure [news] **Hosp Med** 1999 Mar;60(3):220

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Brodsky S, et al. **Hypertension** 1998 Oct;32(4):746–52

Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Grassi G, et al. **Hypertension** 1999 Feb;33(2):671–5

Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Yasuda S, et al. **Hypertension** 1999 Jun;33(6):1374–8

Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. Hayano T, et al. **Int J Cardiol** 1999 Jan;68(1):47–56

The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Liu L, et al. **Int J Cardiol** 1999 Apr 30;69(1):77–82

Valsartan in heart failure patients previously untreated with an ACE inhibitor. Mazayev VP, et al. **Int J Cardiol** 1998 Aug;65(3):239–46

Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. Piepoli M, et al. **Int J Cardiol** 1998 Sep 1;66(1):1–10

The level of plasma neuroendocrine activity and the concentration of digoxin in the serum of patients with mild chronic heart failure. Jablecka A, et al. **Int J Clin Pharmacol Res** 1998;18(4):171–8

Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Pivac N, et al. **Int J Clin Pharmacol Res** 1998;18(3):121–8

First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Navookarasu NT, et al. **Int J Clin Pract** 1999 Jan-Feb;53(1):25–30

Amiodarone in congestive heart failure. Singh S. **Int J Clin Pract** 1998 Sep;52(6):432–5 (20 ref.)

Heart failure treatment: the state of Austrian clinical practice--the Cor survey. Cor Survey Study Group. Slany J. **Int J Clin Pract Suppl** 1998 May;94:37–42

Clinical implications for the Acute Infarction Ramipril Efficacy extension (AIREX) Study. Spargias KS, et al. **Int J Clin Pract Suppl** 1998 May;94:32–6

IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure. Heinz G, et al. **Intensive Care Med** 1999 Jun;25(6):620–4

Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. Azevedo ER, et al. **J Am Coll Cardiol** 1999 Jan;33(1):186–91

Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. Brunner-La Rocca HP, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1163–73 (135 ref.)

Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals? Ewy GA. **J Am Coll Cardiol** 1999 Feb;33(2):572–5 (33 ref.)

Etiology and response to drug treatment in heart failure. Follath F, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1167–72 (70 ref.)

Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. Havranek EP, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1174–81

Antiadrenergic effect of chronic amiodarone therapy in human heart failure. Kaye DM, et al. **J Am Coll Cardiol** 1999 May;33(6):1553–9

Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. Macdonald PS, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):924–31

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. Mills RM, et al. **J Am Coll Cardiol** 1999 Jul;34(1):155–62

The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. Rosario LB, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1819–24

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. van Veldhuisen DJ, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1811–8

Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure [see comments] Watanabe H, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1194–200. Comment in: J Am Coll Cardiol 1998 Nov;32(5):1468. Comment in: J Am Coll Cardiol 1999 Jun;33(7):2089–90.

Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Watson PS, et al. **J Am Coll Cardiol** 1999 May;33(6):1549–52

Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure. Forman DE, et al. **J Am Geriatr Soc** 1998 Dec;46(12):1550–4

Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. Philbin EF, et al. **J Am Geriatr Soc** 1999 Mar;47(3):302–8

Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Esler M, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2-3):210–9 (47 ref.)

Addressing the heart failure management gap [editorial] Cohn

JN. **J Card Fail** 1999 Mar;5(1):1-2

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure [see comments] Cohn JN, et al. **J Card Fail** 1999 Jun;5(2):155-60 . Comment in: J Card Fail 1999 Jun;5(2):77.

The angiotensin receptor blockers [editorial; comment] Cohn JN. **J Card Fail** 1999 Jun;5(2):77-8. Comment on: J Card Fail 1999 Jun;5(2):146-54. Comment on: J Card Fail 1999 Jun;5(2):155-60.

Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. Corbalan R, et al. **J Card Fail** 1998 Jun;4(2):115-9

Prescribing and emergency admissions for heart failure in greater Glasgow. Davie AP, et al. **J Card Fail** 1999 Mar; 5(1):3-7

Beta-blockade and amiodarone therapy: twin brothers from different parents [editorial; comment] Eichhorn EJ, et al. **J Card Fail** 1998 Dec;4(4):289-94 (64 ref.). Comment on: J Card Fail 1998 Dec;4(4):281-88.

Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm? [editorial; comment] From AH. **J Card Fail** 1998 Jun;4(2):127-9. Comment on: J Card Fail 1998 Jun;4(2):121-6.

Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group [see comments] Krum H, et al. **J Card Fail** 1998 Dec;4(4):281-8. Comment in: J Card Fail 1998 Dec;4(4):289-94.

Clinical trials in heart failure: can we expect the results to be replicated in clinical practice? [editorial; comment] Massie BM. **J Card Fail** 1998 Sep;4(3):243-7. Comment on: J Card Fail 1998 Sep;4(3):225-30; discussion 231.

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II [see comments] Pitt B, et al. **J Card Fail** 1999 Jun;5(2):146-54. Comment in: J Card Fail 1999 Jun;5(2):77.

Heart failure disease management: a critical review. Rich MW. **J Card Fail** 1999 Mar;5(1):64-75 (48 ref.)

The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure. Sato T, et al. **J Card Fail** 1998 Jun;4(2):139-44

Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. Sasaki T, et al. **J Cardiol** 1999 Jun;33(6):317-25

Beta-blockers for chronic heart failure: from prejudice to enlightenment. Cleland JG, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S52-60 (45 ref.)

Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. Francis GS. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S16-21 (71 ref.)

Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. Haïat R, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):953-9

Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. Kieback AG, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):629-36

Long-term administration of atrial natriuretic peptide in patients with acute heart failure. Kitashiro S, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):948-52

Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. O'Toole L, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):988-94

Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. van Campen LC, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S31-5 (50 ref.)

Current insights and new treatment options in heart failure. van Veldhuisen DJ, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:v-vi

Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart. Yano M, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):466-70

Influence of aetiology on the effects of treatment in heart failure. Cleland JG, et al. **J Cardiovasc Risk** 1999 Jun; 6(3):131-9 (87 ref.)

Left ventricular remodelling during treatment with beta-blockers. Ertl G, et al. **J Cardiovasc Risk** 1999 Jun; 6(3):145-50 (37 ref.)

The influence of beta-adrenergic blocking drugs on morbidity and mortality in heart failure. Fowler MB. **J Cardiovasc Risk** 1999 Jun;6(3):141-4 (17 ref.)

Beta-blockers and heart failure. Swedberg K. **J Cardiovasc Risk** 1999 Jun;6(3):129-30

Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. Suematsu F, et al. **J Clin Pharm Ther** 1999 Jun;24(3):203-8

Beta-blockers for the treatment of congestive heart failure. Johnson S, et al. **J Fam Pract** 1999 Apr;48(4):247-8

Angiotensin converting enzyme inhibitor use in congestive heart failure. Florida Medical Quality Assurance, Inc. **J Fla Med Assoc** 1998 Apr;85(1):21-4

The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. Pamboukian SV, et al. **J Heart Lung Transplant** 1999 Apr; 18(4):367-71

Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. Shaddy RE, et al. **J Heart Lung Transplant** 1999 Mar;18(3):269-74

Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. Stanek B, et al. **J Heart Lung Transplant** 1999 Apr;18(4):358-66

Calcium antagonists and sympathetic activity in congestive heart failure. Grassi G, et al. **J Hypertens Suppl** 1998 Oct; 16(6):S9-14 (43 ref.)

Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. Eisenman A, et al. **J Intern Med** 1999 Aug; 246(2):183-90

The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. Jansson K, et al. **J Intern Med** 1999 May;245(5):435-43

Calcium responsiveness in canine pacing-induced heart failure. Heusch G, et al. **J Mol Cell Cardiol** 1998 Aug; 30(8):1605-13

Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. Brunner-La Rocca HP, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):565-71

Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. Zhang X, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):742-51

Lessons to be learned: a case study approach diuretic therapy and a laxative causing electrolyte and water imbalance, loss of attention, a fall and subsequent fractures of the tibia and fibula in an elderly lady. Sankar NS, et al. **J R Soc Health** 1998 Aug;118(4):237-40

Clinical observation on treatment of obstinate heart failure by supplementing qi and activating blood flow. Shao J. **J Tradit Chin Med** 1997 Sep;17(3):187-9

Effect of relatively low dose amiodarone therapy on left ventricular function in patients with ventricular tachyarrhythmias. Yamada S, et al. **Jpn Circ J** 1998 Sep; 62(9):707-9

Should digoxin be proscribed in elderly subjects in sinus rhythm free from heart failure? A population-based study. Casiglia E, et al. **Jpn Heart J** 1998 Sep;39(5):639-51

Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure. Examination by 123I-MIBG imaging. Soeki T, et al. **Jpn Heart J** 1998 Nov;39(6):743-51

Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Wimmer A, et al. **Jpn Heart J** 1999 May;40(3):321-34

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial [see comments] **Lancet** 1999 Jan 2; 353(9146):9-13. Comment in: Lancet 1999 Jan 2;353(9146):2-3. Comment in: Lancet 1999 Mar 20;353(9157):1011-2. Comment in: Lancet 1999 Apr 17;353(9161):1360-1. Comment in: Lancet 1999 Apr 17;353(9161):1361. Comment in: ACP J Club 1999 Jul-Aug;131(1):5.

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comments] **Lancet** 1999 Jun 12;353(9169):2001-7. Comment in: Lancet 1999 Jun 12;353(9169):1988-9.

Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group [letter] Brooksby P, et al. **Lancet** 1999 Jul 31;354(9176):395-6

The Cardiac Insufficiency Bisoprolol Study II [letter; comment] Drummond GA, et al. **Lancet** 1999 Apr 17; 353(9161):1361. Comment on: Lancet 1999 Jan 2;353(9146):9-13.

Benefit of beta-blockers for heart failure [letter] Evans PH, et al. **Lancet** 1999 Aug 21;354(9179):682

Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Hermann HP, et al. **Lancet** 1999 Apr 17;353(9161):1321-3

Beta-blockers for mild to moderate heart failure [comment] [see comments] Krumholz HM. **Lancet** 1999 Jan 2; 353(9146):2-3. Comment on: Lancet 1999 Jan 2;353(9146):9-13. Comment in: Lancet 1999 Mar 20;353(9157):1011-2.

Digoxin and mortality in chronic heart failure. UK Heart Investigation [letter] Lindsay SJ, et al. **Lancet** 1999 Sep 18;354(9183):1003

The Cardiac Insufficiency Bisoprolol Study II [letter; comment] Poole-Wilson PA. **Lancet** 1999 Apr 17; 353(9161):1360-1. Comment on: Lancet 1999 Jan 2;353(9146):9-13.

Aldosterone antagonism in heart failure. Richards AM, et al. **Lancet** 1999 Sep 4;354(9181):789-90

Benefit of beta-blockers for heart failure: proven in 1999 [comment] Sharpe N. **Lancet** 1999 Jun 12;353(9169):1988-9 . Comment on: Lancet 1999 Jun 12;353(9169):2001-7.

Safety concerns about digoxin after acute myocardial infarction [letter] Spargias KS, et al. **Lancet** 1999 Jul 31; 354(9176):391-2

Spironolactone for heart failure. **Med Lett Drugs Ther** 1999 Sep 10;41(1061):81-2

Drugs for chronic heart failure. **Med Lett Drugs Ther** 1999 Jan 29;41(1045):12-4

Chronic heart failure and the quality of life [letter; comment] Alhaddad IA. **N Engl J Med** 1999 May 13;340(19):1511-2 . Comment on: N Engl J Med 1998 Dec 17;339(25):1810-6.

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators [see comments] Cohn JN, et al. **N Engl J Med** 1998 Dec 17;339(25):1810-6. Comment in: N Engl J Med 1998 Dec 17;339(25):1848-50. Comment in: N Engl J Med 1999 May 13;340(19):1511; discussion 1512. Comment in: N Engl J Med 1999 May 13;340(19):1511-2.

Carvedilol [letter; comment] Cohn LJ. **N Engl J Med** 1999 May 6;340(18):1443-4. Comment on: N Engl J Med 1998 Dec 10;339(24):1759-65.

Carvedilol [see comments] Frishman WH. **N Engl J Med** 1998 Dec 10;339(24):1759-65 (77 ref.). Comment in: N Engl J Med 1999 May 6;340(18):1443-4.

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [see comments] Pitt B, et al. **N Engl J Med** 1999 Sep 2;341(10):709-17. Comment in: N Engl J Med 1999 Sep 2;341(10):753-5.

Chronic heart failure and the quality of life [letter; comment] Pritzker MR. **N Engl J Med** 1999 May 13;340(19):1511; discussion 1512. Comment on: N Engl J Med 1998 Dec 17;339(25):1810-6. Comment on: N Engl J Med 1998 Dec 17;339(25):1848-50.

Inotropic therapy for heart failure [editorial; comment] [see comments] Stevenson LW. **N Engl J Med** 1998 Dec 17; 339(25):1848-50. Comment on: N Engl J Med 1998 Dec 17;339(25):1810-6. Comment in: N Engl J Med 1999 May 13;340(19):1511; discussion 1512.

Atrial fibrillation in heart failure [editorial; comment] Stevenson WG, et al. **N Engl J Med** 1999 Sep 16; 341(12):910-1. Comment on: N Engl J Med 1999 Sep 16;341(12):857-65.

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group [see comments] Torp-Pedersen C, et al. **N Engl J Med** 1999 Sep 16;341(12):857-65. Comment in: N Engl J Med 1999 Sep 16;341(12):910-1.

Aldosterone and spironolactone in heart failure [editorial; comment] Weber KT. **N Engl J Med** 1999 Sep 2; 341(10):753-5. Comment on: N Engl J Med 1999 Sep 2;341(10):709-17.

Diuretics in congestive heart failure: new evidence for old problems [editorial] Haller C. **Nephrol Dial Transplant** 1999 Jun;14(6):1358-60

Diuretic therapy and diuretic resistance in cardiac failure. Krämer BK, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:39-42 (34 ref.)

Using beta-blockers in the treatment of heart failure. Branum K. **Nurse Pract** 1999 Jul;24(7):75-7, 80, 83 (15 ref.)

Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure. Vecchia L, et al. **Pacing Clin Electrophysiol** 1999 Feb;22(2):397-9

Tumour necrosis factor as a potential target for the treatment of congestive heart failure [editorial; comment] Visioli F. **Pharmacol Res** 1999 Aug;40(2):91. Comment on: Pharmacol Res 1999 Aug;40(2):97-105.

Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Nawarskas JJ, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):1041-52 (86 ref.)

The use of statins following AMI [letter] Burgess MI. **Postgrad Med J** 1999 Jun;75(884):382-3

Recent advances in the drug treatment of heart failure. McAlister FA, et al. **Postgrad Med J** 1998 Nov; 74(877):658-61 (18 ref.)

Beta blocker treatment in heart failure. Carson PE. **Prog Cardiovasc Dis** 1999 Jan-Feb;41(4):301-21 (67 ref.)

The role of organic nitrates in the treatment of heart failure. Elkayam U, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb; 41(4):255-64 (62 ref.)

Cardiac glycosides in the next millennium. Hauptman PJ, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb;41(4):247-54 (53 ref.)

Parenteral inotropic support for advanced congestive heart failure. Leier CV, et al. **Prog Cardiovasc Dis** 1998 Nov-Dec;41(3):207-24 (111 ref.)

Calcium channel blockers in cardiac failure. Mahon N, et al. **Prog Cardiovasc Dis** 1998 Nov-Dec;41(3):191-206 (179 ref.)

Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Sander GE, et al. **Prog Cardiovasc Dis** 1999 Jan-Feb;41(4):265-300 (241 ref.)

Drug absorption in congestive heart failure: impact on management. Sica DA. **Prog Cardiovasc Nurs** 1999 Winter; 14(1):30-2 (32 ref.)

Update on the pharmacological management of congestive heart failure. Thomas B, et al. **Rev Port Cardiol** 1999 Jun; 18(6):619-25 (24 ref.)

Quality of care for Medicare patients hospitalized with heart failure in rural Georgia. Baker DW, et al. **South Med J** 1999 Aug;92(8):782-9

Outpatient management of congestive heart failure. Massin

EK. **Tex Heart Inst J** 1998;25(4):238–50 (86 ref.)
Heart failure: Part II. Wilkes MS, et al. **West J Med** 1999 Jun;170(6):339–42 (37 ref.)
[Heart function and clinical observations of patients with severe congestive heart failure treated with milrinone] Lu G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):27–9 (Eng. Abstr.) **(Chi)**
[On the integrated therapy of traditional and Western medicine in treating heart failure] Dong QZ. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Dec; 16(12):745–8 **(Chi)**
[Beta blockers in the treatment of chronic cardiac failure] Spinarová L, et al. **Vnitr Lek** 1998 Sep;44(9):558–62 (27 ref.) (Eng. Abstr.) **(Cze)**
[Is digoxin effective in the treatment of heart insufficiency in patients with sinus rhythm?] Henriksen OM, et al. **Ugeskr Laeger** 1999 May 31;161(22):3269–74 (33 ref.) (Eng. Abstr.) **(Dan)**
[Digoxin and heart insufficiency. An old pharmaceutical with new future (editorial)] Kjeldsen KP, et al. **Ugeskr Laeger** 1999 May 31;161(22):3264 **(Dan)**
[Risk factors for dying among ibopamine users (letter)] de Graeff PA, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1114–5 **(Dut)**
[Risk factors for dying among ibopamine users (letter)] Vandenbroucke JP. **Ned Tijdschr Geneeskd** 1999 Jul 31; 143(31):1631–2 **(Dut)**
[Revised insights and therapeutic goals in the treatment of chronic heart failure] van Veldhuisen DJ. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1507–11 (31 ref.) (Eng. Abstr.) **(Dut)**
[Place of beta blockaders in the treatment of heart failure] Pornin M, et al. **Ann Cardiol Angeiol (Paris)** 1998 Dec; 47(10):753–6 **(Fre)**
[Diuretic resistance: mechanisms and therapeutic possibilities] Imbs JL, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1383–8 (Eng. Abstr.) **(Fre)**
[Drugs of the future] Kamajda M. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1423–7 (Eng. Abstr.) **(Fre)**
[Can the results of large-scale clinical trials be applied to clinical practice?] Slama M, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1325–31 (Eng. Abstr.) **(Fre)**
[Drugs prescribed for chronic heart failure. Current data on their effectiveness] Andréjak M, et al. **Presse Med** 1998 Dec 12;27(39):2025–30 (Eng. Abstr.) **(Fre)**
[Heart failure: an indication for beta blockaders] Mahé I. **Presse Med** 1999 Jun 5;28(20):1072 **(Fre)**
[XIIIth World Congress of Cardiology (Rio de Janeiro, April 26–30, 1998). The importance of cardiac cellular metabolism] Meurin P. **Presse Med** 1998 Jun 13; 27(21):1026–7 **(Fre)**
[Role of beta-blockers in the treatment of cardiac insufficiency] Vandenbossche JL. **Rev Med Brux** 1998 Sep; 19(4):A386–8 (13 ref.) (Eng. Abstr.) **(Fre)**
[Clinical study of the month. The MERIT-HF study] Kulbertus H. **Rev Med Liege** 1999 Jul;54(7):623–4 (Eng. Abstr.) **(Fre)**
[Pharma-clinics. How I treat...symptomatic heart failure] Kulbertus H. **Rev Med Liege** 1999 Jul;54(7):625–8 (Eng. Abstr.) **(Fre)**
[Clinical trial of the month. The CIBIS-II study] Kulbertus H. **Rev Med Liege** 1999 Feb;54(2):128–9 (Eng. Abstr.) **(Fre)**
[The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study (editorial)] Schwinger RH. **Dtsch Med Wochenschr** 1999 Aug 27;124(34–35):987–8 **(Ger)**
[Spironolactone advantageous to heart failure patients] Brilla C. **Fortschr Med** 1999 May 20;117(14):48–9 **(Ger)**
[Heart failure and treatment of ventricular arrhythmias] Junga G, et al. **Schweiz Rundsch Med Prax** 1999 Feb 4; 88(6):215–22 (48 ref.) (Eng. Abstr.) **(Ger)**
[Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure] Wutte M, et al. **Wien Klin Wochenschr** 1998 Jul 31;110(13–14):473–8 (Eng. Abstr.) **(Ger)**
[Therapy of acute heart failure, medicamentous strategy] Kleber FX. **Z Kardiol** 1999 Jun;88(6):394–9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Hemodynamic effects of a single intravenous administration of prostaglandin E1 in a patient sample with chronic NYHA-stage II/III heart failure] Schrader N, et al. **Z Kardiol** 1998 Sep;87(9):683–90 (Eng. Abstr.) **(Ger)**
[Verapamil sensitive ventricular tachycardia with myocardial failure in a 2-year-old child] Winter K, et al. **Z Kardiol** 1999 May;88(5):369–73 (Eng. Abstr.) **(Ger)**
[Management of chronic heart failure] Tahy A. **Orv Hetil** 1998 Oct 25;139(43):2555–65 (50 ref.) (Eng. Abstr.) **(Hun)**
[Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis] Cice G, et al. **Cardiologia** 1999 Mar;44(3):289–94 (Eng. Abstr.) **(Ita)**
[ACE inhibitors in heart failure: the highest dose always and in every case?] Di Tano G, et al. **G Ital Cardiol** 1999 Jul; 29(7):816–23 (56 ref.) **(Ita)**
[An analysis of the decision process in the pharmacological treatment of a patient with chronic heart failure by means of a therapy management information system: the experience of the Montescano Heart Failure Unit] Opasich C, et al. **G Ital Cardiol** 1998 Nov;28(11):1278–87 (Eng. Abstr.) **(Ita)**
[The role of calcium antagonists in the therapy of congestive heart failure] Tiberti G, et al. **G Ital Cardiol** 1998 Jul; 28(7):818–23 (39 ref.) **(Ita)**
[The embolic risk and oral anticoagulant therapy in chronic heart failure] Urbinati S, et al. **G Ital Cardiol** 1999 Feb; 29(2):183–92 (52 ref.) **(Ita)**
[The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation] De Vecchis R, et al. **Minerva Cardioangiol** 1998 May;46(5):163–74 (Eng. Abstr.) **(Ita)**
[New therapeutic prospects in heart failure. ACE inhibitors and beta blockers] Capone A, et al. **Recenti Prog Med** 1999 Mar;90(3):136–42 (74 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of heart failure to improve the prognosis] Kitamura T, et al. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):416–22 (46 ref.) **(Jpn)**
[Circulatory diseases and anti-thrombotic therapy] Shimada K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):507–11 (10 ref.) **(Jpn)**
[Efficacy of angiotensin II receptor antagonists as a novel drug for the treatment of chronic heart failure--in comparison with ACE inhibitors] Kitakaze M, et al. **Nippon Rinsho** 1999 May;57(5):1148–57 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Trends in pharmacological treatment of congestive heart failure] Halawa B. **Pol Merkuriusz Lek** 1999 Mar; 6(33):152–6 (35 ref.) (Eng. Abstr.) **(Pol)**
[The influence of 3-month treatment with molsidomine on structure, function and some neurohormonal parameters in patients with chronic heart failure treated with digoxin, diuretic and angiotensin converting enzyme inhibitors] Spring A, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):315–8 (Eng. Abstr.) **(Pol)**
[Present day opinion about beta block treatment of congestive heart failure] Nessler J. **Przegl Lek** 1998;55(12):669–72 (33 ref.) (Eng. Abstr.) **(Pol)**
[Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure] Bocchi EA, et al. **Arq Bras Cardiol** 1998 Aug;71(2):169–73 (Eng. Abstr.) **(Por)**
[In search of new paradigms for the management of heart failure] Clausell N, et al. **Arq Bras Cardiol** 1998 Oct; 71(4):563–74 (118 ref.) **(Por)**
[Guidelines for the therapy of heart failure: importance of the treatment individualization] Ceia F. **Rev Port Cardiol** 1999 Apr;18(4):439–45 (26 ref.) (Eng. Abstr.) **(Por)**
[Practical advice on the treatment of cardiac insufficiency with beta-blockers. Announcement by the Italian Association of Hospital-based Cardiologists] Tavazzi L. **Rev Port Cardiol** 1999 May;18(5):556–7 **(Por)**
[Effect of trekrezan on the lipid peroxidation in patients with chronic cardiac insufficiency] Sabadyshin RO, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):186–8 **(Rus)**
[A comparison of the clinical efficacy of enalapril maleate analogs in patients with heart failure and ischemic heart disease] Dunaev VV, et al. **Eksp Klin Farmakol** 1998 Jul-Aug;61(4):20–2 (Eng. Abstr.) **(Rus)**
[Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure] Berezin AE, et al. **Klin Med (Mosk)** 1998;76(7):12–5 (43 ref.) **(Rus)**
[Mildronate in combined treatment of chronic cardiac insufficiency] Nedoshivin AO, et al. **Klin Med (Mosk)** 1999; 77(3):41–3 **(Rus)**
[Effectiveness of enap and oliphen combined treatment of chronic pulmonary hypertension] Shkol'nik MA, et al. **Klin Med (Mosk)** 1999;77(6):26–7 **(Rus)**
[Effect of renitek--an ACE inhibitor--versus cozaar--an angiotensin I receptors antagonists--on morphofunctional state of left ventricular myocardium in patients with symptomatic cardiac insufficiency] Vizir VA, et al. **Klin Med (Mosk)** 1999;77(3):20–2 (Eng. Abstr.) **(Rus)**
[The effect of diltiazem on the systemic hemodynamics of patients with heart failure due to ischemic heart disease] Koshlia EV. **Lik Sprava** 1998 Dec;(8):97–9 (Eng. Abstr.) **(Rus)**
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis] Ditiatkov AE, et al. **Probl Tuberk** 1999;(2):31–2 (Eng. Abstr.) **(Rus)**
[Gopten (trandolapril) in the treatment of chronic heart failure in patients with ischemic heart disease] Kakhnovskii IM, et al. **Ter Arkh** 1998;70(8):29–33 (Eng. Abstr.) **(Rus)**
[Beta-blockers in heart failure. From contraindicated therapy to the best documented one] Swedberg K. **Lakartidningen** 1999 Jun 16;96(24):2940–2 **(Swe)**
[Transcriptional signal pathway for cardiac hypertrophy is discovered. New base for new drugs against heart failure?] Sylvén C. **Lakartidningen** 1998 Nov 11;95(46):5189–90 **(Swe)**

ECONOMICS

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. Boyko WL Jr, et al. **Am Heart J** 1999 May; 137(5):S115–9
Cost effectiveness of carvedilol for heart failure. Delea TE, et al. **Am J Cardiol** 1999 Mar 15;83(6):890–6
The potential costs of upcoding for heart failure in the United States. Psaty BM, et al. **Am J Cardiol** 1999 Jul 1; 84(1):108–9, A9
The logistics and cost-effectiveness of circulatory support: advantages of the ABIOMED BVS 5000. Couper GS, et al. **Ann Thorac Surg** 1999 Aug;68(2):646–9
Ventricular assist device programs: design and function. Van Meter CH Jr, et al. **Ann Thorac Surg** 1999 Aug;68(2):643–5
Assessing the population burden from heart failure: need for sentinel population-based surveillance systems [editorial; comment] Goldberg RJ, et al. **Arch Intern Med** 1999 Jan 11;159(1):15–7. Comment on: Arch Intern Med 1998 Jan 11;159(1):29–34.
Cost-effectiveness analysis in clinical practice: the case of heart failure. Rich MW, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1690–700 (51 ref.)
Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure [see comments] Stewart S, et al. **Arch Intern Med** 1999 Feb 8;159(3):257–61. Comment in: ACP J Club 1999 Jul-Aug;131(1):6.
A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Noe LL, et al. **Clin Ther** 1999 May; 21(5):854–66
Health economic consequences of the pharmacological treatment of heart failure. Cleland JG. **Eur Heart J** 1998 Dec;19 Suppl P:P32–9 (53 ref.)
From cost of illness to cost-effectiveness in heart failure. Lévy E. **Eur Heart J** 1998 Dec;19 Suppl P:P2–4
Cost effective management programme for heart failure reduces hospitalisation [see comments] Cline CM, et al. **Heart** 1998 Nov;80(5):442–6. Comment in: Heart 1998 Nov;80(5):430–1. Comment in: ACP J Club 1999 May-Jun;130(3):81.
Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. Bennett SJ, et al. **Heart Lung** 1999 Mar-Apr;28(2):102–9
Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. Havranek EP, et al. **J Card Fail** 1999 Jun;5(2):85–91
The health care costs of heart failure in Sweden. Rydén-Bergsten T, et al. **J Intern Med** 1999 Sep; 246(3):275–84
[Costs and benefits of heart failure treatment] Gaspoz JM. **Schweiz Med Wochenschr** 1999 Jan 30;129(4):131–7 (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Tian H, et al. **Genes Dev** 1998 Nov 1;12(21):3320–4

ENZYMOLOGY

Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy? Vancura V, et al. **Am J Cardiol** 1999 Feb 1;83(3):461–2, A10
Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Kirchhefer U, et al. **Cardiovasc Res** 1999 Apr;42(1):254–61
Subcellular creatine kinase alterations. Implications in heart failure. De Sousa E, et al. **Circ Res** 1999 Jul 9;85(1):68–76
Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Dzeja PP, et al. **Circ Res** 1999 May 28;84(10):1137–43
Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Spinale FG, et al. **Circ Res** 1999 Aug 20;85(4):364–76
In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function [see comments] Akhter SA, et al. **Circulation** 1999 Aug 10; 100(6):648–53. Comment in: Circulation 1999 Aug 10;100(6):579–82.
Nitric oxide synthases in the failing human heart: a doubled-edged sword? [editorial; comment] Drexler H. **Circulation** 1999 Jun 15;99(23):2972–5 (31 ref.). Comment on: Circulation 1999 Jun 15;99(23):3009–16.
Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Kokkonen JO, et al. **Circulation** 1999 Apr 20; 99(15):1984–90
Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure. Simonini A, et al. **Heart** 1999 Mar;81(3):303–7
The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Sack MN, et al. **Int J Mol Med** 1998 Jan;1(1):17–24 (39 ref.)
Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. Stein B, et al. **J Am Coll Cardiol** 1998 Nov; 32(5):1179–86
Beta-receptor blockade decreases carnitine palmitoyl

transferase I activity in dogs with heart failure [see comments] Panchal AR, et al. **J Card Fail** 1998 Jun; 4(2):121–6. Comment in: J Card Fail 1998 Jun;4(2):127–9.
Induction of cardiac beta-adrenergic receptor kinase 1 in rat heart failure caused by coronary ligation. Ishigai Y, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1261–8
Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. Raju VS, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1581–9
Reduced myocardial Na+, K(+)-pump capacity in congestive heart failure following myocardial infarction in rats. Semb SO, et al. **J Mol Cell Cardiol** 1998 Jul; 30(7):1311–28
Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. Vejlstrup NG, et al. **J Mol Cell Cardiol** 1998 Jun; 30(6):1215–23
Pharmacological characterization of protein phosphatase activities in preparations from failing human hearts. Neumann J, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):188–93
Abnormalities in sarcolemmal phospholipase D and phospholipase C isoenzymes and in their interactions in post-infarcted failing hearts. Panagia V, et al. **Lipids** 1999; 34 Suppl:S73–4
Complete coding sequence of inducible nitric oxide synthase from human heart and skeletal muscle of patients with chronic heart failure. Adams V, et al. **Nitric Oxide** 1998; 2(4):242–9

EPIDEMIOLOGY

Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Haldeman GA, et al. **Am Heart J** 1999 Feb;137(2):352–60
Insights into the contemporary epidemiology and outpatient management of congestive heart failure [see comments] McAlister FA, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):87–94 . Comment in: Am Heart J 1999 Jul;138(1 Pt 1):5–8.
Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Vaur L, et al. **Am Heart J** 1999 Jan;137(1):49–58
Reproducibility of cardiopulmonary exercise testing in elderly patients with congestive heart failure. Marburger CT, et al. **Am J Cardiol** 1998 Oct 1;82(7):905–9
Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients. Ofili EO, et al. **Am J Cardiol** 1999 May 1;83(9):1350–5
Comparison of frequencies of left ventricular systolic and diastolic heart failure in Chinese living in Hong Kong. Yip GW, et al. **Am J Cardiol** 1999 Sep 1;84(5):563–7
Time-series analysis of the relation between influenza virus and hospital admissions of the elderly in Ontario, Canada, for pneumonia, chronic lung disease, and congestive heart failure. Upshur RE, et al. **Am J Epidemiol** 1999 Jan 1; 149(1):85–92
Risk factors for heart failure in the elderly: a prospective community-based study. Chen YT, et al. **Am J Med** 1999 Jun;106(6):605–12
Use of nonprescription medications by patients with congestive heart failure. Ackman ML, et al. **Ann Pharmacother** 1999 Jun;33(6):674–9
Assessing the population burden from heart failure: need for sentinel population-based surveillance systems [editorial; comment] Goldberg RJ, et al. **Arch Intern Med** 1999 Jan 11;159(1):15–7. Comment on: Arch Intern Med 1998 Jan 11;159(1):29–34.
Congestive heart failure in the community: trends in incidence and survival in a 10-year period [see comments] Senni M, et al. **Arch Intern Med** 1999 Jan 11;159(1):29–34 . Comment in: Arch Intern Med 1998 Jan 11;159(1):15–7.
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Ward MM. **Arthritis Rheum** 1999 Feb; 42(2):338–46
Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Aronow WS, et al. **Chest** 1999 Mar;115(3):867–8
Seasonal variation in chronic heart failure hospitalizations and mortality in France. Boulay F, et al. **Circulation** 1999 Jul 20;100(3):280–6
Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Senni M, et al. **Circulation** 1998 Nov 24;98(21):2282–9
The epidemiology of heart failure secondary to coronary artery disease. Goldman JH, et al. **Coron Artery Dis** 1998; 9(10):625–8 (20 ref.)
Incidence and aetiology of heart failure; a population-based study [see comments] Cowie MR, et al. **Eur Heart J** 1999 Mar;20(6):421–8. Comment in: Eur Heart J 1999 Mar;20(6):398–9.
Clinical epidemiology of heart failure: public and private health burden. McMurray JJ, et al. **Eur Heart J** 1998 Dec; 19 Suppl P:P9–16 (52 ref.)
Heart failure in the population at large; news from the real world [editorial; comment] Mosterd A. **Eur Heart J** 1999 Mar;20(6):398–9 (10 ref.). Comment on: Eur Heart J 1997 Feb;18(2):208–25. Comment on: Eur Heart J 1999 Mar;20(6):421–8.
Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Mosterd A, et al. **Eur Heart J** 1999 Mar;20(6):447–55
Diabetes mellitus and congestive heart failure. Further knowledge needed. Soläng L, et al. **Eur Heart J** 1999 Jun; 20(11):789–95 (65 ref.)
Atrial fibrillation in myocardial infarction complicated by heart failure: cause or consequence? [editorial; comment] Waldecker B. **Eur Heart J** 1999 May;20(10):710–2. Comment on: Eur Heart J 1999 May;20(10):748–54.
Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. Philbin EF, et al. **J Am Coll Cardiol** 1999 May; 33(6):1560–6
Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. Zannad F, et al. **J Am Coll Cardiol** 1999 Mar; 33(3):734–42
Heart failure in community-dwelling older persons: aims, design and adherence rate of the ICARe Dicomano project: an epidemiologic study. Insufficienza Cardiaca negli Anziani Residenti a Dicomano. Di Bari M, et al. **J Am Geriatr Soc** 1999 Jun;47(6):664–71
Increased pulse pressure and risk of heart failure in the elderly. Chae CU, et al. **JAMA** 1999 Feb 17;281(7):634–9
Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease [see comments] Tunstall-Pedoe H, et al. **Lancet** 1999 May 8;353(9164):1547–57. Comment in: Lancet 1999 May 8;353(9164):1540–1.
Anemia during the predialysis period: A key to cardiac damage in renal failure. Silverberg D, et al. **Nephron** 1998 Sep;80(1):1–5 (72 ref.)
Epidemiology of heart failure: contours of an impending epidemic? Mosterd A, et al. **Neth J Med** 1998 Dec; 53(6):235–44 (59 ref.)
Congestive heart failure with preserved systolic function: is it a woman's disease? Samuel RS, et al. **Womens Health Issues** 1999 Jul–Aug;9(4):219–22
[Epidemiology and economic impact of heart failure in France] Delahaye F, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1307–14 (Eng. Abstr.) **(Fre)**
[The prevalence and clinical characteristics of heart failure in a population sample of Calabria] Misuraca G, et al. **G Ital Cardiol** 1998 Dec;28(12):1385–90 (Eng. Abstr.) **(Ita)**
[Epidemiologic evaluation of cardiac decompensation and its impact on health costs] Bilora F, et al. **Minerva Cardioangiol** 1998 Jul–Aug;46(7–8):235–9 (Eng. Abstr.) **(Ita)**
[Heart failure in Brazil (editorial)] Albanesi Filho FM. **Arq Bras Cardiol** 1998 Oct;71(4):561–2 **(Por)**
[Clinico-statistical analysis of chronic cardiac failure] Tereshchenko SN, et al. **Ter Arkh** 1999;71(1):42–6 (Eng. Abstr.) **(Rus)**
[Trends of morbidity and mortality in chronic heart failure in Catalonia] Brotons C, et al. **Rev Esp Cardiol** 1998 Dec; 51(12):972–6 (Eng. Abstr.) **(Spa)**
[Predictors of readmission in patients with congestive heart failure] Castro P, et al. **Rev Med Chil** 1998 Oct; 126(10):1173–81 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Alexander M, et al. **Am Heart J** 1999 May;137(5):919–27
Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Aronow WS, et al. **Am J Cardiol** 1999 Sep 1;84(5):611–2, A9
Racial differences in the outcome of left ventricular dysfunction [see comments] [published erratum appears in N Engl J Med 1999 Jul 22;341(4):298] Dries DL, et al. **N Engl J Med** 1999 Feb 25;340(8):609–16. Comment in: N Engl J Med 1999 Jul 22;341(4):287; discussion 288. Comment in: N Engl J Med 1999 Jul 22;341(4):288.

ETIOLOGY

Alcohol and congestive heart failure. Waldenström A. **Alcohol Clin Exp Res** 1998 Oct;22(7 Suppl):315S–317S (30 ref.)
A "touch of sugar" can be fatal [editorial; comment] Clark CM Jr, et al. **Am Heart J** 1998 Nov;136(5):762–4. Comment on: Am Heart J 1998 Nov;136(5):919–27.
Diastolic dysfunction: old dog, new tricks [editorial; comment] Douglas PS. **Am Heart J** 1999 May;137(5):777–8 (9 ref.). Comment on: Am Heart J 1999 May;137(5):910–8.
Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy. Hung J, et al. **Am J Cardiol** 1998 Nov 15;82(10):1301–3, A10
Leukemic hyperleukocytosis-induced unstable angina and congestive heart failure [letter] McCormick J 3rd, et al. **Am J Emerg Med** 1999 Mar;17(2):217–9
Risk factors for heart failure in the elderly: a prospective community-based study. Chen YT, et al. **Am J Med** 1999 Jun;106(6):605–12
A novel heart failure model induced by sequential coronary artery occlusions and tachycardiac stress in awake pigs. Shen YT, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H388–98
Pattern of neuronal activation in rats with CHF after myocardial infarction. Vahid-Ansari F, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2140–6
Murphy's law in cardiac surgery. Fischer C, et al. **Ann Thorac Surg** 1998 Nov;66(5):1795–7
Congestive heart failure due to diastolic or systolic dysfunction. Frequency and patient characteristics in an ambulatory setting. Diller PM, et al. **Arch Fam Med** 1999 Sep-Oct;8(5):414–20
Profile for estimating risk of heart failure. Kannel WB, et al. **Arch Intern Med** 1999 Jun 14;159(11):1197–204
Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Guillevin L, et al. **Arthritis Rheum** 1999 Mar;42(3):421–30
Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery. Hirata T, et al. **Arzneimittelforschung** 1999 Jun; 49(6):499–503
The functional significance of ventricular geometry for the transition from hypertrophy to cardiac failure. Does a critical degree of structural dilatation exist? [editorial] Jacob R, et al. **Basic Res Cardiol** 1998 Dec;93(6):423–9 (55 ref.)
Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. Economou-Petersen E, et al. **Blood** 1998 Nov 1; 92(9):3455–9
Long term treatment of refractory congestive heart failure by continuous positive airway pressure [see comments] Leung RS, et al. **Can J Cardiol** 1999 Sep;15(9):1009–12. Comment in: Can J Cardiol 1999 Sep;15(9):959–60. **(Eng, Fre)**
Oxidative stress and the pathogenesis of heart failure. Ball AM, et al. **Cardiol Clin** 1998 Nov;16(4):665–75, viii–ix (127 ref.)
The role of cytokines in the failing human heart. Kapadia S, et al. **Cardiol Clin** 1998 Nov;16(4):645–56, viii (85 ref.)
Cytokines and heart failure. Kapadia SR. **Cardiol Rev** 1999 Jul–Aug;7(4):196–206 (88 ref.)
Coarctation of persistent right fifth aortic arch and pulmonary sequestration. Tomita H, et al. **Cardiol Young** 1998 Oct;8(4):509–11
Fibrosis, myocyte degeneration and heart failure in chronic experimental aortic regurgitation. Liu SK, et al. **Cardiology** 1998 Oct;90(2):101–9
Decreased type VI adenylyl cyclase mRNA concentration and Mg(2+)-dependent adenylyl cyclase activities and unchanged type V adenylyl cyclase mRNA concentration and Mn(2+)-dependent adenylyl cyclase activities in the left ventricle of rats with myocardial infarction and longstanding heart failure. Espinasse I, et al. **Cardiovasc Res** 1999 Apr;42(1):87–98
Endothelin and heart transplantation. Geny B, et al. **Cardiovasc Res** 1998 Sep;39(3):556–62 (69 ref.)
Infarcted hearts of mice and men [editorial; comment] Weber KT. **Cardiovasc Res** 1999 Mar;41(3):506–8. Comment on: Cardiovasc Res 1999 Mar;41(3):586–93.
Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Hirota H, et al. **Cell** 1999 Apr 16; 97(2):189–98
Use of the cardiopulmonary risk index [letter; comment] Epstein SK. **Chest** 1999 Jan;115(1):308–9. Comment on: Chest 1998 Jul;114(1):69–75.
Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure [see comments] Meguro T, et al. **Circ Res** 1999 Apr 2;84(6):735–40. Comment in: Circ Res 1999 Apr 2;84(6):741–3.
Cell death in acromegalic cardiomyopathy. Frustaci A, et al. **Circulation** 1999 Mar 23;99(11):1426–34
Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis. Frustaci A, et al. **Circulation** 1999 Mar 16; 99(10):1295–9
Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Iwanaga Y, et al. **Circulation** 1998 Nov 10;98(19):2065–73
Failure of women's hearts. Petrie MC, et al. **Circulation** 1999 May 4;99(17):2334–41 (91 ref.)
Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. Traverse JH, et al. **Circulation** 1999 Aug 3;100(5):564–5
Pregnancy-induced severe left ventricular systolic dysfunction in a patient with hypertrophic cardiomyopathy. Kazimuddin M, et al. **Clin Cardiol** 1998 Nov;21(11):848–50 (8 ref.)
Myotonic dystrophy associated with QT prolongation and torsade de pointes. Umeda Y, et al. **Clin Cardiol** 1999 Feb; 22(2):136–8
The role of nitric oxide in heart failure. Arstall MA, et al. **Coron Artery Dis** 1999 Jul;10(5):301–8 (115 ref.)
Clinical profile of patients with congestive heart failure due to coronary artery disease: stunned/hibernating myocardium, ischemia, scar. Challapalli S, et al. **Coron Artery Dis** 1998;9(10):629–44 (151 ref.)
The epidemiology of heart failure secondary to coronary artery disease. Goldman JH, et al. **Coron Artery Dis** 1998; 9(10):625–8 (20 ref.)
Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Anker SD, et al.

Curr Opin Cardiol 1999 May;14(3):211–6 (62 ref.)

Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi. Oyoo GO, et al. **East Afr Med J** 1999 Jan;76(1):23–7

Is sinus bradycardia a factor facilitating overt heart failure? Alboni P, et al. **Eur Heart J** 1999 Feb;20(4):252–5 (34 ref.)

Incidence and aetiology of heart failure; a population-based study [see comments] Cowie MR, et al. **Eur Heart J** 1999 Mar;20(6):421–8. Comment in: Eur Heart J 1999 Mar;20(6):398–9.

New perspectives on heart failure due to myocardial ischaemia. Fox KF, et al. **Eur Heart J** 1999 Feb; 20(4):256–62 (65 ref.)

QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Galinier M, et al. **Eur Heart J** 1998 Jul;19(7):1054–62

Hyperuricaemia and congestive heart failure: causation or association? [editorial; comment] Gottlieb S. **Eur Heart J** 1998 Dec;19(12):1746–7. Comment on: Eur Heart J 1998 Dec;19(12):1814–22.

Is apoptosis an important pathogenic factor in cardiovascular disease? [comment] Aukrust P, et al. **Eur J Clin Invest** 1999 May;29(5):369–71. Comment on: Eur J Clin Invest 1999 May;29(5):380–6.

Preventable causative factors leading to hospital admission with decompensated heart failure [see comments] Michalsen A, et al. **Heart** 1998 Nov;80(5):437–41. Comment in: Heart 1998 Nov;80(5):426–7. Comment in: Heart 1998 Nov;80(5):430–1.

Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Richards AM, et al. **Heart** 1999 Feb;81(2):114–20

Carcinoid heart disease from ovarian primary presenting with acute pericarditis and biventricular failure. Vergani D, et al. **Heart** 1998 Dec;80(6):623–6

Heart failure induced by pheochromocytoma: laparoscopic treatment and intraoperative changes of several new cardiovascular hormones. Col V, et al. **Horm Res** 1999; 51(1):50–2

An autopsy case of familial idiopathic dilatation of bilateral atria. Arao M, et al. **Intern Med** 1999 Aug;38(8):663–7

Etiology and response to drug treatment in heart failure. Follath F, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1167–72 (70 ref.)

Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. Zannad F, et al. **J Am Coll Cardiol** 1999 Mar; 33(3):734–42

Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. Aronow WS, et al. **J Am Geriatr Soc** 1998 Oct; 46(10):1280–1

Atrial natriuretic peptide and the development of congestive heart failure in the oldest old: a seven-year prospective study. Knight EL, et al. **J Am Geriatr Soc** 1999 Apr; 47(4):407–11

Congestive heart failure induced by recipient atrial tachycardia conducted to the donor atrium after orthotopic heart transplantation: complete regression after successful radiofrequency ablation. Gasparini M, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):399–404

Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. Cleland JG, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S17–29 (95 ref.)

Hypertension and the development of heart failure. de Leeuw PW, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S9–15 (59 ref.)

Different causes of heart failure need different treatment strategies. Hampton JR. **J Cardiovasc Pharmacol** 1999 Jun; 33 Suppl 3:S37–41 (25 ref.)

Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. Ruffolo RR Jr, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S22–30 (48 ref.)

Influence of aetiology on the effects of treatment in heart failure. Cleland JG, et al. **J Cardiovasc Risk** 1999 Jun; 6(3):131–9 (87 ref.)

The role of systolic blood pressure in determining risk for cardiovascular disease. Levy D. **J Hypertens Suppl** 1999 Feb;17(1):S15–8 (19 ref.)

Early-infantile type of galactosialidosis as a cause of heart failure and neonatal ascites. Claeys M, et al. **J Inherit Metab Dis** 1999 Jun;22(5):666–7

A 65-year-old woman with heart failure [clinical conference] Ghali JK, et al. **J La State Med Soc** 1998 Aug;150(8):350–4

Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure. Onishi K, et al. **J Pharmacol Exp Ther** 1999 Mar; 288(3):1214–22

Evidence of cell-mediated cardiac myocyte injury involved in the heart failure of a patient with progressive systemic sclerosis. Takahashi N, et al. **Jpn Circ J** 1999 Jan; 63(1):68–72

A case of malignant lymphoma with diastolic heart failure. Toko H, et al. **Jpn Circ J** 1998 Nov;62(11):863–7

Myocarditis and primary Sjögren's syndrome [letter] Levin MD, et al. **Lancet** 1999 Jul 10;354(9173):128–9

Isolated noncompaction of the myocardium [letter] Jenni R, et al. **N Engl J Med** 1999 Mar 25;340(12):966–7

Does acute volume overloading in the setting of left ventricular dysfunction and pulmonary hypertension affect the defibrillation threshold? Vigh AG, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):759–64

Cardiac failure in children with pneumonia in Papua New Guinea. Shann F, et al. **Pediatr Infect Dis J** 1998 Dec; 17(12):1141–3

Two-dimensional autoregressive analysis of carotid artery blood flow waveform in children with isolated atrial septal defect. Kojo M, et al. **Pediatr Int** 1999 Jun;41(3):292–8

Index of Suspicion. Case 3. Severe coarctation of the aorta. Germeroth O. **Pediatr Rev** 1998 Oct;19(10):333–6

Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Starc TJ, et al. **Pediatrics** 1999 Aug; 104(2):e14

The hibernating heart: reversible left ventricular dysfunction in chronic heart failure. Burn S, et al. **Postgrad Med J** 1999 Jul;75(885):419–21

Decompensated cor pulmonaleas the first manifestation of adult-onset myopathy. Kurz D, et al. **Respiration** 1998; 65(4):317–9

Life-threatening situations in sarcoidosis. James DG. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):134–9 (13 ref.)

Chronic heart failure--mechanisms and management. Lye M. **Scott Med J** 1997 Oct;42(5):138–40 (47 ref.)

Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function [letter; comment] Jay SJ. **Tex Heart Inst J** 1999;26(2):158 . Comment on: Tex Heart Inst J 1999;26(1):34–41.

Late night thoughts. Massin EK. **Tex Heart Inst J** 1999; 26(1):17–8

Reversible congestive heart failure caused by myocardial hibernation. Wilson JM. **Tex Heart Inst J** 1999;26(1):19–27 (58 ref.)

Hypertensive heart failure: a report of 3 cases. Dosumu EA. **West Afr J Med** 1999 Apr-Jun;18(2):147–50

[Revised insights and therapeutic goals in the treatment of chronic heart failure] van Veldhuisen DJ. **Ned Tijdschr Geneeskd** 1999 Jul 17;143(29):1507–11 (31 ref.) (Eng. Abstr.) **(Dut)**

[Acute multiple sclerosis, left ventricular failure and pulmonary edema] Melin J, et al. **Duodecim** 1995; 111(22):2170–4 **(Fin)**

[Selenium deficiency favors the appearance of heart failure after multiple injury] Briel A, et al. **Ann Fr Anesth Reanim** 1997;16(7):911–2 (Eng. Abstr.) **(Fre)**

[Multiple myeloma manifesting as cardiac insufficiency] Bennis A, et al. **Ann Med Interne (Paris)** 1999 Feb; 150(2):160–1 **(Fre)**

[Is the treatment of left ventricular systolic dysfunction different according to the etiology?] Bounhoure JP. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1359–64 (Eng. Abstr.) **(Fre)**

[Treatment of cardiac insufficiency: does treatment depend on whether its cause is ischemic or idiopathic?] Galinier M, et al. **Arch Mal Coeur Vaiss** 1999 Jun;92(6):727–32 (Eng. Abstr.) **(Fre)**

[On thyrotoxic heart failure (letter; comment)] Maunand B. **Presse Med** 1999 Apr 24;28(16):846. Comment on: Presse Med 1999 Jan 23;28(3):132–3. **(Fre)**

[Congestive heart failure in the aged. Causes and mechanisms of left ventricular dysfunction] Montagne O, et al. **Presse Med** 1999 Mar 27;28(12):658–60 (Eng. Abstr.) **(Fre)**

[A rare cause of right heart insufficiency: idiopathic dilatation of the right atrium (a case report) (letter)] Niakara A, et al. **Tunis Med** 1999 Mar;77(3):170–1 **(Fre)**

[The role of myocardial apoptosis in the development of heart failure] Andréka P, et al. **Orv Hetil** 1999 Jan 17; 140(3):135–42 (50 ref.) (Eng. Abstr.) **(Hun)**

[Natriuretic peptide receptors and heart failure] Andreassi MG, et al. **Cardiologia** 1999 Mar;44(3):241–8 (75 ref.) **(Ita)**

[Ischemic cardiopathy and congestive heart failure. The central theme of the cardiology of the future. Reflections on certain pathogenetic fideisms and technological plagiarisms (editorial)] Baroldi G. **G Ital Cardiol** 1998 Aug; 28(8):934–41 **(Ita)**

[Heart failure as clinical onset of essential mixed cryoglobulinemia] Bragagni G, et al. **Minerva Med** 1998 Jul-Aug;89(7-8):283–6 (Eng. Abstr.) **(Ita)**

[Sarcoidosis with hypercalcemia, urolithiasis, renal insufficiency, and heart failure] Nagayama M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):571–6 (Eng. Abstr.) **(Jpn)**

[Mechanism involved in the onset of heart failure] Sasayama S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1667–81 (114 ref.) **(Jpn)**

[An autopsied case of idiopathic portal hypertension accompanied by right heart failure secondary to pulmonary hypertension] Zenda T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1151–6 **(Jpn)**

[Congestive heart failure due to a combination of atrial fibrillation and tricuspid regurgitation: clinical course and echocardiographical analysis] Kotajima N, et al. **Rinsho Byori** 1999 Jan;47(1):83–8 (Eng. Abstr.) **(Jpn)**

[Ca2+ signaling in cardiac E-C coupling and its modulation in cardiac hypertrophy and heart failure] Endoh M. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1753–60 (55 ref.) **(Jpn)**

[Cardiorespiratory failure and diabetic autonomic neuropathy: a case report] Cánovas L, et al. **Rev Esp Anestesiol Reanim** 1998 Nov;45(9):397–400 (Eng. Abstr.) **(Spa)**

[Severe myocardial restriction secondary to massive calcification of the left ventricle] Caballero J, et al. **Rev Esp Cardiol** 1999 Jan;52(1):53 **(Spa)**

[Ventricular geometry and heart failure] Gómez Doblas JJ, et al. **Rev Esp Cardiol** 1999 Jan;52(1):47–52 (36 ref.) (Eng. Abstr.) **(Spa)**

[National and international guidelines ignore significant cause of heart failure. Diastolic dysfunction is often the cause of heart failure in the elderly and in women] Fagerberg B. **Lakartidningen** 1998 Nov 18;95(47):5305–8 (18 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Sanderson JE, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):653–7

Enhanced GRK5 expression in the hearts of cardiomyopathic hamsters, J2N-k. Takagi C, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):206–10

Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy. Wang J, et al. **Can J Cardiol** 1999 Jun;15(6):683–90 (50 ref.)

AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression [editorial; comment] Feldman AM, et al. **Circulation** 1999 Mar 23;99(11):1397–9. Comment on: Circulation 1999 Mar 23;99(11):1422–5.

Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Franco F, et al. **Circulation** 1999 Jan 26;99(3):448–54

Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure [see comments] Loh E, et al. **Circulation** 1999 Mar 23;99(11):1422–5. Comment in: Circulation 1999 Mar 23;99(11):1397–9.

Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Zolk O, et al. **Circulation** 1999 Apr 27;99(16):2118–23

Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure [published erratum appears in Heart 1999 Mar;81(3):330] Arbustini E, et al. **Heart** 1998 Dec; 80(6):548–58

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. Liggett SB, et al. **J Clin Invest** 1998 Oct 15;102(8):1534–9

Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Engelhardt S, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7059–64

HISTORY

50th anniversary historical article. Heart failure. Francis GS. **J Am Coll Cardiol** 1999 Feb;33(2):291–4

IMMUNOLOGY

The dynamic balance between heart function and immune activation [editorial; comment] Bachetti T, et al. **Eur Heart J** 1998 May;19(5):681–2. Comment on: Eur Heart J 1998 May;19(5):761–5.

Systemic inflammation in patients with heart failure [see comments] Hasper D, et al. **Eur Heart J** 1998 May; 19(5):761–5. Comment in: Eur Heart J 1998 May;19(5):681–2.

Pro-inflammatory cytokines and endothelium-dependent vasodilation in the forearm. Serial assessment in patients with congestive heart failure. Vanderheyden M, et al. **Eur Heart J** 1998 May;19(5):747–52

Postpartum onset of acute heart failure possibly due to postpartum autoimmune myocarditis. A report of three cases. Yagoro A, et al. **J Intern Med** 1999 Feb; 245(2):199–203

Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. Nozaki N, et al. **J Mol Cell Cardiol** 1998 Oct; 30(10):2003–12

Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Ankersmit HJ, et al. **Lancet** 1999 Aug 14;354(9178):550–5

Inflammatory mediators in heart failure: homogeneity through heterogeneity [comment] Mann DL. **Lancet** 1999 May 29;353(9167):1812–3. Comment on: Lancet 1999 May 29;353(9167):1838–42.

Endotoxin and immune activation in chronic heart failure: a prospective cohort study [see comments] Niebauer J, et al. **Lancet** 1999 May 29;353(9167):1838–42. Comment in: Lancet 1999 May 29;353(9167):1812–3.

Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Schirger JA, et al. **Mayo Clin Proc** 1999 Feb;74(2):126–30

[Gastrointestinal cancer-associated antigen (GICA) and intravascular hemolysis. Report of 2 cases and review of

the literature] Bianconcini G, et al. **Minerva Med** 1999 Mar; 90(3):73–9 (98 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Lung membrane diffusing capacity, heart failure, and heart transplantation. Mettauer B, et al. **Am J Cardiol** 1999 Jan 1;83(1):62–7

Can measurement of mixed venous oxygen saturation replace measurement of cardiac output in patients with advanced heart failure? Gawlinski A. **Am J Crit Care** 1998 Sep; 7(5):374–80; quiz 381–2

Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Barger PM, et al. **Am J Med Sci** 1999 Jul;318(1):36–42 (30 ref.)

Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. Khadour FH, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H1971–8

Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Sato N, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1699–705

Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Takeishi Y, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H53–62

Effects of cyclic adenosine monophosphate (cAMP) on sarcoplasmic reticulum Ca(2+)-loading in failing rabbit and human cardiac trabeculae. Denvir MA, et al. **Basic Res Cardiol** 1998 Oct;93(5):396–404

Frequency dependent force generation correlates with sarcoplasmic calcium ATPase activity in human myocardium. Frank K, et al. **Basic Res Cardiol** 1998 Oct; 93(5):405–11

Is the failing heart energy depleted? Katz AM. **Cardiol Clin** 1998 Nov;16(4):633–44, viii (111 ref.)

Nitric oxide in the failing myocardium. Sawyer DB, et al. **Cardiol Clin** 1998 Nov;16(4):657–64, viii (53 ref.)

Enhanced phosphorylation of phospholamban and downregulation of sarco/endoplasmic reticulum Ca2+ ATPase type 2 (SERCA 2) in cardiac sarcoplasmic reticulum from rabbits with heart failure. Currie S, et al. **Cardiovasc Res** 1999 Jan;41(1):135–46

Congestive heart failure: role of cross-bridge cycle kinetics [editorial] de Tombe PP. **Cardiovasc Res** 1998 Dec; 40(3):440–3 (41 ref.)

Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Dupuis J, et al. **Cardiovasc Res** 1998 Sep;39(3):609–16

Cellular and molecular aspects of contractile dysfunction in heart failure. Mittmann C, et al. **Cardiovasc Res** 1998 Aug; 39(2):267–75 (101 ref.)

Expression of Gi-2 alpha and Gs alpha in myofibroblasts localized to the infarct scar in heart failure due to myocardial infarction. Peterson DJ, et al. **Cardiovasc Res** 1999 Mar;41(3):575–85

Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide. Tønnessen T, et al. **Cardiovasc Res** 1998 Sep;39(3):633–43

Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Ide T, et al. **Circ Res** 1999 Aug 20;85(4):357–63

Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog [see comments] Recchia FA, et al. **Circ Res** 1998 Nov 16;83(10):969–79. Comment in: Circ Res 1998 Nov 16;83(10):1067–8.

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart [see comments] Bowling N, et al. **Circulation** 1999 Jan 26; 99(3):384–91. Comment in: Circulation 1999 Jan 26;99(3):334–7.

Effect of metoprolol administration on renal sodium handling in experimental congestive heart failure. DiBona GF, et al. **Circulation** 1999 Jul 6;100(1):82–6

Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Iaccarino G, et al. **Circulation** 1998 Oct 27;98(17):1783–9

Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Irwin MW, et al. **Circulation** 1999 Mar 23;99(11):1492–8

Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Kääb S, et al. **Circulation** 1998 Oct 6;98(14):1383–93

Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Katz SD, et al. **Circulation** 1999 Apr 27;99(16):2113–7

Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Li YY, et al. **Circulation** 1998 Oct 27;98(17):1728–34

Reduced sodium pump alpha1, alpha3, and beta1-isoform protein levels and Na+,K+-ATPase activity but unchanged Na+-Ca2+ exchanger protein levels in human heart failure. Schwinger RH, et al. **Circulation** 1999 Apr 27;99(16):2105–12

Beta-protein kinase C and hypertrophic signaling in human heart failure [editorial; comment] Simpson PC. **Circulation** 1999 Jan 26;99(3):334–7. Comment on: Circulation 1999 Jan 26;99(3):384–91.

Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. Torre-Amione G, et al. **Circulation** 1999 Sep 14; 100(11):1189–93

Clinical insights on the use of highly sensitive cardiac troponin assays. Missov ED, et al. **Clin Chim Acta** 1999 Jun 30;284(2):175–85 (31 ref.)

Clinical pharmacokinetics of oxaprozin. Davies NM. **Clin Pharmacokinet** 1998 Dec;35(6):425–36 (44 ref.)

Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. Guazzi M, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):319–27

Renal effects of brain natriuretic peptide in patients with congestive heart failure. Jensen KT, et al. **Clin Sci (Colch)** 1999 Jan;96(1):5–15

An overview of tumor necrosis factor alpha and the failing human heart. Torre-Amione G, et al. **Curr Opin Cardiol** 1999 May;14(3):206–10 (44 ref.)

Changes in myocardial protein expression in pacing-induced canine heart failure. Heinke MY, et al. **Electrophoresis** 1999 Jul;20(10):2086–93

Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development [see comments] Burton PB, et al. **Eur Heart J** 1999 Apr; 20(8):604–11. Comment in: Eur Heart J 1999 Apr;20(8):555–7.

Expression of cell-cycle regulators during heart development and failure [editorial; comment] Deprez RH, et al. **Eur Heart J** 1999 Apr;20(8):555–7 (7 ref.). Comment on: Eur Heart J 1999 Apr;20(8):604–11.

The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity. van Riemsdijk-van Overbeeke IC, et al. **Eur Heart J** 1999 Jun; 20(11):833–40

Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Liguori A, et al. **Eur J Clin Pharmacol** 1999 Apr; 55(2):117–24

Altered neuropeptide Y Y1 responses in mesenteric arteries in rats with congestive heart failure. Bergdahl A, et al. **Eur J Pharmacol** 1998 Nov 6;360(2-3):165–73

Muscle oxygenation kinetics measured by near-infrared spectroscopy during recovery from exercise in chronic heart failure. Belardinelli R. **G Ital Cardiol** 1998 Aug; 28(8):866–72

Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. Rocca HP, et al. **Heart** 1999 Feb;81(2):121–7

Myocardial osteopontin expression coincides with the development of heart failure. Singh K, et al. **Hypertension** 1999 Feb;33(2):663–70

Intense acute phase response in ischemic patients. Kaźmierczak E, et al. **Int J Cardiol** 1999 Jan;68(1):69–73

Humoral response in patients with chronic heart failure. Spinarová L, et al. **Int J Cardiol** 1998 Aug;65(3):227–32

Cerebral metabolic abnormalities in congestive heart failure detected by proton magnetic resonance spectroscopy. Lee CW, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1196–202

Should manipulation of myocardial substrate utilization patterns be a component of the congestive heart failure therapeutic paradigm? [editorial; comment] From AH. **J Card Fail** 1998 Jun;4(2):127–9. Comment on: J Card Fail 1998 Jun;4(2):121–6.

Influence of intensive physical training on urinary nitrate elimination and plasma endothelin-1 levels in patients with congestive heart failure. Callaerts-Végh Z, et al. **J Cardiopulm Rehabil** 1998 Nov-Dec;18(6):450–7

Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure. Carville C, et al. **J Cardiovasc Pharmacol** 1998 Oct; 32(4):562–70

Hemodynamic response to oxygen administration in chronic heart failure: role of chemoreflexes. Saadjian A, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):144–50

Caffeine increases renal renin secretion in a rat model of genetic heart failure. Tofovic SP, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):440–50

Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. Frantz S, et al. **J Clin Invest** 1999 Aug; 104(3):271–80

Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. Bleske BE, et al. **J Clin Pharmacol** 1998 Aug;38(8):708–14

Localization of the insulin-like growth factor system in a rat model of heart failure induced by myocardial infarction. Dean R, et al. **J Histochem Cytochem** 1999 May; 47(5):649–60

Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. Mujumdar VS, et al. **J Hypertens** 1999 Feb;17(2):261–70

Muscle unloading induces slow to fast transitions in myofibrillar but not mitochondrial properties. Relevance to skeletal muscle abnormalities in heart failure [published erratum appears in J Mol Cell Cardiol 1999 Apr;31(4):927] Bigard AX, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2391–401

Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition. Clair MJ, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2355–64

Overexpression of endothelium nitric oxide synthase reverses the diminished vasorelaxation in the hindlimb vasculature in ischemic heart failure in vivo. Gaballa MA, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1243–52

Reduced sarcoplasmic reticulum Ca(2+)-uptake and expression of phospholamban in left ventricular myocardium of dogs with heart failure. Gupta RC, et al. **J Mol Cell Cardiol** 1999 Jul;31(7):1381–9

Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. Kompa AR, et al. **J Mol Cell Cardiol** 1999 Jun; 31(6):1185–201

Frequency-dependent changes in contribution of SR Ca2+ to Ca2+ transients in failing human myocardium assessed with ryanodine. Schlotthauer K, et al. **J Mol Cell Cardiol** 1998 Jul;30(7):1285–94

Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. Schwinger RH, et al. **J Mol Cell Cardiol** 1999 Mar;31(3):479–91

Differential alterations in left and right ventricular G-proteins in congestive heart failure due to myocardial infarction. Sethi R, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2153–63

Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: II. Cytoskeletal remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):319–31

Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: III. Intercalated disc remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):333–43

Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. Karlsson MO, et al. **J Pharmacokinet Biopharm** 1998 Apr;26(2):207–46

Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. Zhang X, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):742–51

Increased exhaled nitric oxide and impaired oxygen uptake (VO2) kinetics during exercise in patients with chronic heart failure. Funakoshi T, et al. **Jpn Circ J** 1999 Apr; 63(4):255–60

The time from anaerobic threshold (AT) to respiratory compensation point reflects the rate of aerobic and anaerobic metabolism after the AT in chronic heart failure patients. Tanehata M, et al. **Jpn Circ J** 1999 Apr;63(4):274–7

Improved oxygen utilization during mild exercise in heart failure. Tanehata M, et al. **Jpn Circ J** 1998 Oct;62(10):741–4

Differential upregulation of rat Na-K-Cl cotransporter, rBSC1, mRNA in the thick ascending limb of Henle in different pathological conditions. Marumo R, et al. **Kidney Int** 1998 Sep;54(3):877–88

Increase in cardiac P2X1-and P2Y2-receptor mRNA levels in congestive heart failure. Hou M, et al. **Life Sci** 1999; 65(11):1195–206

Lower arterial glucose concentrations in lambs with aortopulmonary shunts after an 18-hour fast. Beaufort-Krol GC, et al. **Metabolism** 1999 Sep; 48(9):1082–8

Altered purine and glycogen metabolism in skeletal muscle during exercise in patients with heart failure. Kinugawa T, et al. **Metabolism** 1999 Apr;48(4):484–8

Pathogenesis of renal sodium retention in congestive heart failure. Andreoli TE. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):11–20 (46 ref.)

Calcineurin and human heart failure [letter] [see comments] Lim HW, et al. **Nat Med** 1999 Mar;5(3):246–7. Comment in: Nat Med 1999 Mar;5(3):266–7.

Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy. Schrier RW, et al. **Proc Assoc Am Physicians** 1998 Sep-Oct; 110(5):407–11 (46 ref.)

Drug absorption in congestive heart failure: impact on management. Sica DA. **Prog Cardiovasc Nurs** 1999 Winter; 14(1):30–2 (32 ref.)

Drug absorption in congestive heart failure: impact on management. Sica DA. **Prog Cardiovasc Nurs** 1999 Spring; 14(2):72–4 (32 ref.)

Pathogenesis of sodium and water retention in cardiac failure. Schrier RW, et al. **Ren Fail** 1998 Nov;20(6):773–81 (41 ref.)

Recognized molecular mechanisms of heart failure: approaches to treatment. Ceconi C, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II79–91 (120 ref.)

Heart failure and endothelin receptor antagonists. Miyauchi T, et al. **Trends Pharmacol Sci** 1999 May;20(5):210–7 (89 ref.)

MICROBIOLOGY

Congestive heart failure and septic abortion. Singh SK, et al. **Postgrad Med J** 1999 Feb;75(880):117–8

MORTALITY

Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Alexander M, et al. **Am Heart J** 1999 May;137(5):919–27

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart

failure: insights from the Flolan International Randomized Survival Trial (FIRST). O'Connor CM, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):78–86

Has the survival of the heart failure population changed? Lessons from trials. Cleland JG, et al. **Am J Cardiol** 1999 Mar 11;83(5B):112D–119D (54 ref.)

Predictors of death from congestive heart failure in hypertrophic cardiomyopathy. Ikeda H, et al. **Am J Cardiol** 1999 Apr 15;83(8):1280–3, A9

Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. O'Connor CM, et al. **Am J Cardiol** 1998 Oct 1;82(7):881–7

Rates of health services utilization and survival in patients with heart failure in the Department of Veterans Affairs medical care system. Ashton CM, et al. **Am J Med Qual** 1999 Jan-Feb;14(1):55–63

Correlation of the Agency for Health Care Policy and Research congestive heart failure admission guideline with mortality: peer review organization voluntary hospital association initiative to decrease events (PROVIDE) for congestive heart failure. Graff L, et al. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):429–37

Identifying patients at low risk of death from cardiac failure after operation for postinfarct ventricular tachycardia. Bourke JP, et al. **Ann Thorac Surg** 1999 Feb;67(2):404–10

Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Croft JB, et al. **Arch Intern Med** 1999 Mar 8;159(5):505–10

Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Havranek EP, et al. **Arch Intern Med** 1998 Oct 12;158(18):2024–8

Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure [see comments] Stewart S, et al. **Arch Intern Med** 1999 Feb 8;159(3):257–61. Comment in: ACP J Club 1999 Jul-Aug;131(1):6.

Mortality of the institutionalized old-old hospitalized with congestive heart failure. Wang R, et al. **Arch Intern Med** 1998 Dec 7-21;158(22):2464–8

Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Lanfranchi PA, et al. **Circulation** 1999 Mar 23;99(11):1435–40

Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995 [see comments] Brown AM, et al. **Eur Heart J** 1998 Jul;19(7):1063–9. Comment in: Eur Heart J 1998 Jul;19(7):975.

Risk stratification in chronic heart failure. Cowburn PJ, et al. **Eur Heart J** 1998 May;19(5):696–710 (211 ref.)

New perspectives on heart failure due to myocardial ischaemia. Fox KF, et al. **Eur Heart J** 1999 Feb; 20(4):256–62 (65 ref.)

Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. Murdoch DR, et al. **Eur Heart J** 1998 Dec;19(12):1829–35

Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I [see comments] Swedberg K, et al. **Eur Heart J** 1999 Jan; 20(2):136–9. Comment in: Eur Heart J 1999 Jan;20(2):85–6.

Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. Aaronson KD, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1189–95

Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. Senior R, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1848–54

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. Vasan RS, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1948–55

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure [see comments] Cohn JN, et al. **J Card Fail** 1999 Jun;5(2):155–60. Comment in: J Card Fail 1999 Jun;5(2):77.

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II [see comments] Pitt B, et al. **J Card Fail** 1999 Jun;5(2):146–54. Comment in: J Card Fail 1999 Jun;5(2):77.

Beta-blockers for the treatment of congestive heart failure. Johnson S, et al. **J Fam Pract** 1999 Apr;48(4):247–8

Can implantable defibrillators reduce non-arrhythmic mortality? Nisam S. **J Interv Card Electrophysiol** 1998 Dec; 2(4):371–5 (22 ref.)

Digoxin and mortality in chronic heart failure. UK Heart Investigation [letter] Lindsay SJ, et al. **Lancet** 1999 Sep 18;354(9183):1003

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease [see comments] Tunstall-Pedoe H, et al. **Lancet** 1999 May 8;353(9164):1547–57. Comment in: Lancet 1999 May 8;353(9164):1540–1.

A new casemix adjustment index for hospital mortality among patients with congestive heart failure. Polanczyk CA, et al. **Med Care** 1998 Oct;36(10):1489–99

[Risk factors for dying among ibopamine users (letter)] de Graeff PA, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1114–5 **(Dut)**

[Risk factors for dying among ibopamine users (letter)] Vandenbroucke JP. **Ned Tijdschr Geneeskd** 1999 Jul 31; 143(31):1631–2 **(Dut)**

[Evaluation of high amplification ECG and the study of sinus variability in the detection of patients at risk of sudden death] Brembilla-Perrot B, et al. **Ann Cardiol Angeiol (Paris)** 1998 May;47(5):329–33 (Eng. Abstr.) **(Fre)**

[Organ procurement from cardiac arrest donors: outcome of kidney grafts and recommendations] Benoit G, et al. **Presse Med** 1999 Jan 9;28(1):3–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Sudden death in heart failure] Guadalajara Boo JF, et al. **Arch Inst Cardiol Mex** 1999 Jan-Feb;69(1):80–8 (72 ref.) **(Spa)**

[Trends of morbidity and mortality in chronic heart failure in Catalonia] Brotons C, et al. **Rev Esp Cardiol** 1998 Dec; 51(12):972–6 (Eng. Abstr.) **(Spa)**

NURSING

Card sort: an assessment tool for the educational needs of patients with heart failure. Luniewski M, et al. **Am J Crit Care** 1999 Sep;8(5):297–302

The 'heart failure nurse' to help us close the gap between what we can and what we do achieve [editorial; comment] Balk AH. **Eur Heart J** 1999 May;20(9):632–3. Comment on: Eur Heart J 1999 May;20(9):673–82.

Effects of education and support on self-care and resource utilization in patients with heart failure [see comments] Jaarsma T, et al. **Eur Heart J** 1999 May;20(9):673–82. Comment in: Eur Heart J 1999 May;20(9):632–3.

Nurse led, multidisciplinary intervention in chronic heart failure [editorial; comment] McMurray JJ, et al. **Heart** 1998 Nov;80(5):430–1. Comment on: Heart 1998 Nov;80(5):437–41. Comment on: Heart 1998 Nov;80(5):442–6.

Factors influencing patient compliance with therapeutic regimens in chronic heart failure: A critical incident technique analysis. Strömberg A, et al. **Heart Lung** 1999 Sep-Oct;28(5):334–41

Perceived learning needs of patients with heart failure. Wehby D, et al. **Heart Lung** 1999 Jan-Feb;28(1):31–40

Discharge planning and home follow-up of the elderly patient with heart failure. Campbell RL, et al. **Nurs Clin North Am** 1998 Sep;33(3):497–513 (12 ref.)

Using beta-blockers in the treatment of heart failure. Branum K. **Nurse Pract** 1999 Jul;24(7):75–7, 80, 83 (15 ref.)

Learning needs of congestive heart failure patients. Frattini E, et al. **Prog Cardiovasc Nurs** 1998 Spring;13(2):11–6, 33

PATHOLOGY

Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Tomoda H. **Am J Cardiol** 1999 Jan 1;83(1):123–5, A9

Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Gwathmey JK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1678–90

Apoptosis in the failing heart. Narula J, et al. **Cardiol Clin** 1998 Nov;16(4):691–710, ix (78 ref.)

Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy. Suzuki M, et al. **Cardiovasc Res** 1998 Sep;39(3):589–99

Female-related skeletal muscle phenotype in patients with moderate chronic heart failure before and after dynamic exercise training. Tyni-Lenné R, et al. **Cardiovasc Res** 1999 Apr;42(1):99–103

Evolutionary persistence of spongy myocardium in humans. Angelini A, et al. **Circulation** 1999 May 11;99(18):2475

Grading, staging and scoring of left-ventricular hypertrophy, left-ventricular dilatation, asymptomatic left-ventricular dysfunction and chronic heart failure. Field ML, et al. **Eur Heart J** 1999 Sep;20(17):1224–33

Cardiomyocyte apoptosis and progression of heart failure to transplantation [see comments] Saraste A, et al. **Eur J Clin Invest** 1999 May;29(5):380–6. Comment in: Eur J Clin Invest 1999 May;29(5):369–71.

Gender-related differences in myocyte remodeling in progression to heart failure. Tamura T, et al. **Hypertension** 1999 Feb;33(2):676–80

Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. Adams V, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):959–65

New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. Gerdes AM, et al. **J Card Fail** 1998 Dec;4(4):343–8

Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. Schaufelberger M, et al. **J Card Fail** 1998 Sep;4(3):185–91

Effect of short- and long-term heart failure on small artery morphology and endothelial function in the rat. Buus NH, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):34–40

Mechanisms of cardiomyocyte dysfunction in heart failure following myocardial infarction in rats. Holt E, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1581–93

Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. Tamura T, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2175–81

Apoptosis of skeletal muscle myofibers and interstitial cells in experimental heart failure. Vescovo G, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2449–59

Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocyte molecular phenotype. Yue P, et al. **J Mol Cell Cardiol** 1998 Aug; 30(8):1615–30

Apoptosis and heart failure. Williams RS. **N Engl J Med** 1999 Sep 2;341(10):759–60 (1 ref.)

[A man of 60 with a constitutional syndrome, abdominal pain and heart failure (clinical conference)] **Rev Clin Esp** 1999 May;199(5):310–20 **(Spa)**

PHYSIOPATHOLOGY

Pathogenesis of heart failure. Changing conceptual paradigms. De Keulenaer GW, et al. **Acta Cardiol** 1998; 53(3):131–41 (103 ref.)

Dilatory responses to acetylcholine, calcitonin gene-related peptide and substance P in the congestive heart failure rat. Bergdahl A, et al. **Acta Physiol Scand** 1999 Jan;165(1):15–23

Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition. Naitoh M, et al. **Adv Exp Med Biol** 1998;449:445–6

Recent advances in the understanding of water metabolism in heart failure. Schrier RW, et al. **Adv Exp Med Biol** 1998; 449:415–26 (78 ref.)

Aggravated renal dysfunction and the acute management of advanced chronic heart failure [editorial; comment] Bart BA, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):200–2. Comment on: Am Heart J 1999 Aug;138(2 Pt 1):285–90.

Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Bonaduce D, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):273–84

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure [see comments] Giustina A, et al. **Am Heart J** 1999 Jun;137(6):1035–43. Comment in: Am Heart J 1999 Jun;137(6):989–91.

Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors [see comments] Guazzi M, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):254–60. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):193–7.

Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure [see comments] Hatzizacharias A, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):241–6. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):191–2.

Effects of exercise training on chronotropic incompetence in patients with heart failure. Keteyian SJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):233–40

A shuttle walk test for assessment of functional capacity in chronic heart failure. Morales FJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):291–8

A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. Piepoli M, et al. **Am Heart J** 1999 Jun;137(6):1050–6

Effects of short-acting and long-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Tomiyama H, et al. **Am Heart J** 1999 Mar;137(3):543–8

Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure [see comments] Weinfeld MS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):285–90. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):200–2.

Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity. Yoshikawa T, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):666–71

Effects of low altitude on exercise performance in patients with congestive heart failure after healing of acute myocardial infarction. Abinader EG, et al. **Am J Cardiol** 1999 Feb 1;83(3):383–7

Nasal oxygen effects on arterial carbon dioxide pressure and heart rate in chronic heart failure. Andreas S, et al. **Am J Cardiol** 1999 Mar 1;83(5):795–8, A10

Loss of bone mineral in patients with cachexia due to chronic heart failure. Anker SD, et al. **Am J Cardiol** 1999 Feb 15; 83(4):612–5, A10

Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). Anthonio RL, et al. **Am J Cardiol** 1999 Apr 15;83(8):1286–9, A10

Dynamic cyclic changes in coronary sinus caliber in patients with and without congestive heart failure. D'Cruz IA, et al. **Am J Cardiol** 1999 Jan 15;83(2):275–7, A6

Hypertension, heart failure, and endothelial function. Drexler H. **Am J Cardiol** 1998 Nov 19;82(10A):20S–22S (16 ref.)

Dobutamine-induced changes in pulmonary artery pressure in patients with congestive heart failure and their relation to abnormalities of lung diffusing capacity. Faggiano P, et al. **Am J Cardiol** 1998 Nov 15;82(10):1296–8, A10

Effect of right ventricular pacing in patients with complete left bundle branch block. Garrigue S, et al. **Am J Cardiol** 1999 Feb 15;83(4):600–4, A8

Heart rate variability in healthy children and in those with congenital heart disease both before and after operation. Heragu NP, et al. **Am J Cardiol** 1999 Jun 15;83(12):1654–7

Amlodipine therapy in congestive heart failure:

hemodynamic and neurohormonal effects at rest and after treadmill exercise. Krombach RS, et al. **Am J Cardiol** 1999 Aug 19;84(4A):3L–15L

Kinetics of oxygen uptake at onset of exercise related to cardiac output, but not to arteriovenous oxygen difference in patients with chronic heart failure. Matsumoto A, et al. **Am J Cardiol** 1999 Jun 1;83(11):1573–6, A8

Hemodynamic responses during leg press exercise in patients with chronic congestive heart failure. Meyer K, et al. **Am J Cardiol** 1999 Jun 1;83(11):1537–43

Comparison of left ventricular function during interval versus steady-state exercise training in patients with chronic congestive heart failure. Meyer K, et al. **Am J Cardiol** 1998 Dec 1;82(11):1382–7

Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. O'Connor CM, et al. **Am J Cardiol** 1999 May 1;83(9):1345–9

Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Paolisso G, et al. **Am J Cardiol** 1999 May 1;83(9):1338–44

Further evidence suggesting a limited role of digitalis in infants with circulatory congestion secondary to large ventricular septal defect. Seguchi M, et al. **Am J Cardiol** 1999 May 1;83(9):1408–11, A8

Left atrial energy in normal subjects, in patients with symptomatic mitral stenosis, and in patients with advanced heart failure. Stefanadis C, et al. **Am J Cardiol** 1998 Nov 15;82(10):1220–3

Potentials and limitations of the Valsalva maneuver as a method of differentiating between normal and pseudonormal left ventricular filling patterns. Wijbenga AA, et al. **Am J Cardiol** 1999 Jul 1;84(1):76–81

Can measurement of mixed venous oxygen saturation replace measurement of cardiac output in patients with advanced heart failure? Gawlinski A. **Am J Crit Care** 1998 Sep; 7(5):374–80; quiz 381–2

Abnormal renal vasodilation to an amino acid infusion in congestive heart failure: normalization by enalapril. Juncos LI, et al. **Am J Kidney Dis** 1999 Jan;33(1):43–51

Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure [letter; comment] Diez-Perez A, et al. **Am J Med** 1998 Oct;105(4):358–9. Comment on: Am J Med 1997 Sep;103(3):197–207.

Diuretic treatment and diuretic resistance in heart failure. Krämer BK, et al. **Am J Med** 1999 Jan;106(1):90–6 (70 ref.)

Osteoporosis overestimated in congestive heart failure [letter; comment] Mazess RB. **Am J Med** 1998 Oct;105(4):358. Comment on: Am J Med 1997 Sep;103(3):197–207.

Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure. Anzai T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1267–73

ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema. Liu JL, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H342–50

Reduced NO enhances the central gain of cardiac sympathetic afferent reflex in dogs with heart failure. Ma R, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H19–26

Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Matsumoto T, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1935–42

Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Nuss HB, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H80–91

Pattern of neuronal activation in rats with CHF after myocardial infarction. Vahid-Ansari F, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2140–6

Abnormal myocyte Ca2+ homeostasis in rabbits with pacing-induced heart failure. Yao A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1441–8

Diaphragm strength in chronic heart failure. Hughes PD, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):529–34

Effects of inhaled carbon dioxide and oxygen on cheyne-stokes respiration in patients with heart failure. Lorenzi-Filho G, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1490–8

Decreased baroreflex sensitivity assessed from phase IV of Valsalva maneuver in mild congestive heart failure. Rostagno C, et al. **Angiology** 1999 Aug;50(8):655–64

Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure. A randomized, controlled trial. Matsumoto A, et al. **Ann Intern Med** 1999 Jan 5; 130(1):40–4

From overload to failure: what happens inside the myocyte. Harding SE, et al. **Ann Med** 1998 Aug;30 Suppl 1:14–23 (75 ref.)

Programmed cell death in the progression of heart failure. Sabbah HN, et al. **Ann Med** 1998 Aug;30 Suppl 1:33–8 (45 ref.)

Beta-adrenergic receptors and receptor signaling in heart failure. Post SR, et al. **Annu Rev Pharmacol Toxicol** 1999; 39:343–60 (107 ref.)

Congestive heart failure due to diastolic or systolic dysfunction. Frequency and patient characteristics in an ambulatory setting. Diller PM, et al. **Arch Fam Med** 1999 Sep-Oct;8(5):414–20

Sympathetic activation in heart failure and its treatment with beta-blockade. Pepper GS, et al. **Arch Intern Med** 1999 Feb 8;159(3):225–34 (65 ref.)

Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. van Kraaij DJ, et al. **Arch Intern Med** 1999 Jul 26;159(14):1599–605

Numeric modeling of the cardiovascular system with a left ventricular assist device. Zhou J, et al. **ASAIO J** 1999 Jan-Feb;45(1):83–9

Angiotensin II and coronary artery disease, congestive heart failure, and sudden cardiac death. Dietz R, et al. **Basic Res Cardiol** 1998;93 Suppl 2:101–8 (34 ref.)

Physiology and pathophysiology of baroreceptor function and neuro-hormonal abnormalities in heart failure. Kirchheim HR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:1–22 (192 ref.)

Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Julius S, et al. **Blood Press** 1998;Suppl 3:5–13 (129 ref.)

Sympathetic control of circulation in hypertension and congestive heart failure. Lanfranchi A, et al. **Blood Press** 1998;Suppl 3:40–5 (39 ref.)

Blood pressure circadian rhythm and variability in subjects with severe heart failure. Moroni C, et al. **Blood Press** 1998 Nov;7(5-6):282–5

Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. Litwin SE, et al. **Br J Pharmacol** 1999 Aug;127(7):1671–9

Haemodynamic effects of a selective adenosine A2A receptor agonist, CGS 21680, in chronic heart failure in anaesthetized rats. Nekooeian AA, et al. **Br J Pharmacol** 1998 Oct;125(4):651–8

What is the relevance of apoptosis to the myocardium? Liu P, et al. **Can J Cardiol** 1999 Apr;15 Suppl B:8B–10B

Minoxidil accelerates heart failure development in rats with ascending aortic constriction. Turcani M, et al. **Can J Physiol Pharmacol** 1998 Jun;76(6):613–20

Diastolic function and dysfunction with exercise, hypertrophy, ischemia, and heart failure. Apstein CS, et al. **Cardiologia** 1998 Dec;43(12):1269–79 (81 ref.)

Central role of peripheral mechanisms in exercise intolerance in chronic heart failure: the muscle hypothesis. Piepoli M. **Cardiologia** 1998 Sep;43(9):909–17 (84 ref.)

Endothelin-1 in heart failure: does it play a role? Sam F, et al. **Cardiologia** 1998 Sep;43(9):889–92 (30 ref.)

Effectiveness of digitoxin versus trichlormethiazide/amiloride in congestive heart failure NYHA class II/III and sinus rhythm. Huonker M, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):233–41

Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. van der Ent M, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):387–94

Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril. van der Ent M, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):395–403

Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs. Choussat R, et al. **Cardiovasc Res** 1998 Sep;39(3):580–8

Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Undrovinas AI, et al. **Cell Mol Life Sci** 1999 Mar; 55(3):494–505

Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Herrera-Garza EH, et al. **Chest** 1999 Apr;115(4):1170–4 (21 ref.)

Sympathetic nervous response relative to the adenosine triphosphate supply-demand imbalance during exercise is augmented in patients with heart failure [published erratum appears in Chest 1999 May;115(5):1485] Kinugawa T, et al. **Chest** 1998 Nov;114(5):1295–300

Recovery kinetics of oxygen uptake and heart rate in patients with coronary artery disease and heart failure. Pavia L, et al. **Chest** 1999 Sep;116(3):808–13

Maximal exercise testing for the selection of heart transplantation candidates: limitation of peak oxygen consumption. Ramos-Barbón D, et al. **Chest** 1999 Feb; 115(2):410–7

Exercise-induced rise in arterial potassium in patients with chronic heart failure. Tanabe Y, et al. **Chest** 1999 Jul; 116(1):88–96

Inability to measure lung volumes in a man with congestive heart failure. Wolf KM, et al. **Chest** 1999 Jan;115(1):269–71

Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure. Ma J, et al. **Chin Med J (Engl)** 1998 Jan;111(1):17–23

Effects of amiodarone on cardiac electrophysiology in right ventricular rapid pacing-induced heart failure dogs. Zhou SX, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul; 19(4):363–8

Swelling-activated chloride current is persistently activated in ventricular myocytes from dogs with tachycardia-induced congestive heart failure. Clemo HF, et al. **Circ Res** 1999 Feb 5;84(2):157–65

Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. O'Rourke B, et al. **Circ Res** 1999 Mar 19; 84(5):562–70

Troponin I, stunning, hypertrophy, and failure of the heart [editorial; comment] Solaro RJ. **Circ Res** 1999 Jan 8–22; 84(1):122–4 (19 ref.). Comment on: Circ Res 1999 Jan 8–22;84(1):1–8. Comment on: Circ Res 1999 Jan 8–22;84(1):9–20.

Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. Traverse JH, et al. **Circ Res** 1999 Mar 5;84(4):401–8

Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. Winslow RL, et al. **Circ Res** 1999 Mar 19;84(5):571–86

Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Auricchio A, et al. **Circulation** 1999 Jun 15;99(23):2993–3001

Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Azevedo ER, et al. **Circulation** 1999 Jul 20;100(3):274–9

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Deedwania PC, et al. **Circulation** 1998 Dec 8;98(23):2574–9

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Goodfield NE, et al. **Circulation** 1999 Jun 15;99(23):2983–5

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Hasenfuss G, et al. **Circulation** 1998 Nov 17; 98(20):2141–7

Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy [see comments] Heymes C, et al. **Circulation** 1999 Jun 15;99(23):3009–16. Comment in: Circulation 1999 Jun 15;99(23):2972–5.

Mechanoenergetic alterations during the transition from cardiac hypertrophy to failure in Dahl salt-sensitive rats. Kameyama T, et al. **Circulation** 1998 Dec 22–29; 98(25):2919–29

Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Magri P, et al. **Circulation** 1998 Dec 22–29; 98(25):2849–54

Mechanisms and models in heart failure: A combinatorial approach. Mann DL. **Circulation** 1999 Aug 31; 100(9):999–1008 (78 ref.)

Increased superoxide in heart failure: a biochemical baroreflex gone awry [editorial; comment] Münzel T, et al. **Circulation** 1999 Jul 20;100(3):216–8. Comment on: Circulation 1999 Jul 20;100(3):292–8.

Respiratory muscles performance is related to oxygen kinetics during maximal exercise and early recovery in patients with congestive heart failure. Nanas S, et al. **Circulation** 1999 Aug 3;100(5):503–8

Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Narkiewicz K, et al. **Circulation** 1999 Jul 20;100(3):262–7

Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Pérez NG, et al. **Circulation** 1999 Mar 2;99(8):1077–83

Blood flow dynamics in heart failure. Shoemaker JK, et al. **Circulation** 1999 Jun 15;99(23):3002–8

Preserved vasodilator effect of bradykinin in dogs with heart failure. Su JB, et al. **Circulation** 1998 Dec 22–29; 98(25):2911–8

Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Tkacova R, et al. **Circulation** 1998 Nov 24; 98(21):2269–75

Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Wada A, et al. **Circulation** 1999 Feb 2;99(4):570–7

Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Yamauchi-Kohno R, et al. **Circulation** 1999 Apr 27;99(16):2171–6

The independent effects of left ventricular ejection fraction on short-term outcomes and resource utilization following hospitalization for heart failure. Harjai KJ, et al. **Clin Cardiol** 1999 Mar;22(3):184–90

Cardiac remodeling as a consequence and cause of progressive heart failure. Kurrelmeyer K, et al. **Clin Cardiol** 1998 Dec;21(12 Suppl 1):I14–9 (40 ref.)

Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. Chin-Dusting JP, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):645–52 (101 ref.)

The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. van der Sande FM, et al. **Clin Nephrol** 1998 Nov;50(5):301–8

Influence of posture and handgrip on the QT interval in left ventricular hypertrophy and in chronic heart failure. Davey P. **Clin Sci (Colch)** 1999 Apr;96(4):403–7

Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated

hypertrophy to heart failure in spontaneously hypertensive rats. Ikeda S, et al. **Clin Sci (Colch)** 1999 Aug;97(2):239–46

Investigation of distal aortic compliance and vasodilator responsiveness in heart failure due to proximal aortic stenosis in the guinea pig. Kingsbury MP, et al. **Clin Sci (Colch)** 1999 Mar;96(3):241–51

Respiratory correlates of muscle sympathetic nerve activity in heart failure. Naughton MT, et al. **Clin Sci (Colch)** 1998 Sep;95(3):277–85

Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Notarius CF, et al. **Clin Sci (Colch)** 1999 Jun;96(6):557–65

Nitric oxide and oxygen utilization: exercise, heart failure and diabetes. Zhao G, et al. **Coron Artery Dis** 1999 Jul; 10(5):315–20 (45 ref.)

Left ventricular systolic function after acute myocardial infarction: prognostic importance, relation to congestive heart failure and as a target for intervention. Køber L. **Dan Med Bull** 1999 Jun;46(3):235–48 (53 ref.)

Cardiac and peripheral responses to exercise in patients with chronic heart failure. Cohen-Solal A, et al. **Eur Heart J** 1999 Jul;20(13):931–45 (170 ref.)

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [see comments] Duprez DA, et al. **Eur Heart J** 1998 Sep; 19(9):1371–6. Comment in: Eur Heart J 1998 Sep;19(9):1273.

Endothelial function and dysfunction in heart failure. Ferrari R, et al. **Eur Heart J** 1998 Jul;19 Suppl G:G41–7 (78 ref.)

Neurobiology of respiratory-pattern training in congestive heart failure [letter] Friedman EH. **Eur Heart J** 1999 Jul; 20(14):1052–3

Sympathetic overactivity and exercise intolerance in heart failure: a cause-effect relationship [editorial; comment] Grassi G, et al. **Eur Heart J** 1999 Jun;20(12):854–5. Comment on: Eur Heart J 1999 Jun;20(12):880–7.

Resting muscle sympathetic nerve activity and peak oxygen uptake in heart failure and normal subjects [see comments] Notarius CF, et al. **Eur Heart J** 1999 Jun;20(12):880–7. Comment in: Eur Heart J 1999 Jun;20(12):854–5.

Aetiology and pathophysiological implications of oscillatory ventilation at rest and during exercise in chronic heart failure. Do Cheyne and Stokes have an important message for modern-day patients with heart failure? Piepoli MF, et al. **Eur Heart J** 1999 Jul;20(13):946–53 (65 ref.)

Aldosterone and artery compliance in heart failure [editorial; comment] Struthers A. **Eur Heart J** 1998 Sep;19(9):1273 (6 ref.). Comment on: Eur Heart J 1998 Sep;19(9):1371–6.

Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure. van Veldhuisen DJ, et al. **Eur Heart J** 1998 May;19(5):753–60

Non-invasive assessment of inspiratory muscle performance during exercise in patients with chronic heart failure. Vibarel N, et al. **Eur Heart J** 1998 May;19(5):766–73

Heart rate variability index in congestive heart failure: relation to clinical variables and prognosis. Wijbenga JA, et al. **Eur Heart J** 1998 Nov;19(11):1719–24

Transient oxygen uptake response to exercise characterizes functional capacity of the cardiocirculatory system in patients with chronic heart failure: a random stimulus approach. Takaki H, et al. **Eur J Appl Physiol** 1998 Sep; 78(4):333–9

The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Noirhomme P, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):63–7

Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Kalsi KK, et al. **Eur J Clin Invest** 1999 Jun;29(6):469–77

Effects of L-arginine on endothelial and cardiac function in rats with heart failure. Feng Q, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):37–44

Muscarinic receptors in the failing human heart. Giessler C, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):197–202 (70 ref.)

Acute hemodynamic and renal effects of adrenomedullin in rats with aortocaval shunt. Willenbrock R, et al. **Eur J Pharmacol** 1999 Mar 19;369(2):195–203

Effects of short-term exercise training in patients with heart failure. Tokmakova M, et al. **Folia Med (Plovdiv)** 1999; 41(1):68–71

Exercise capacity and skeletal muscle myosin heavy chains in CHF [editorial] Vescovo G, et al. **G Ital Cardiol** 1999 Feb;29(2):214–9 (49 ref.)

QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Bonnar CE, et al. **Heart** 1999 Mar;81(3):297–302

Heart rate variability and cardiac failure [letter; comment] Fauchier L, et al. **Heart** 1999 May;81(5):561–2. Comment on: Heart 1998 Sep;80(3):213–4.

Atrioventricular plane displacement during low dose dobutamine infusion predicts recovery of left ventricular dyssynergies [letter; comment] Kranidis A, et al. **Heart** 1998 Aug;80(2):208. Comment on: Heart 1997 Sep;78(3):230–6.

Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Leyva F, et al. **Heart** 1999 Sep;82(3):348–51

Heart rate variability and cardiac failure [editorial] [see comments] Lombardi F, et al. **Heart** 1998 Sep;80(3):213–4 (17 ref.). Comment in: Heart 1999 May;81(5):561; discussion 562. Comment in: Heart 1999 May;81(5):561–2.

Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent. Maguire SM, et al. **Heart** 1998 Aug; 80(2):141–5

Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. Newby DE, et al. **Heart** 1998 Aug;80(2):134–40

Heart rate variability and cardiac failure [letter; comment] Nolan J, et al. **Heart** 1999 May;81(5):561; discussion 562 . Comment on: Heart 1998 Sep;80(3):213–4.

Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. O'Keeffe ST, et al. **Heart** 1998 Oct;80(4):377–82

The pathophysiology of advanced heart failure. Baig MK, et al. **Heart Lung** 1999 Mar-Apr;28(2):87–101 (164 ref.)

Effects of nitric oxide inhibition on basal forearm blood flow in patients with nonischemic chronic heart failure. Yoshida H, et al. **Heart Vessels** 1998;13(3):142–6

The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Anderson KM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):402–7

Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. Cicogna AC, et al. **Hypertension** 1999 Jan;33(1):60–5

Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Grassi G, et al. **Hypertension** 1999 Feb;33(2):671–5

Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Yasuda S, et al. **Hypertension** 1999 Jun;33(6):1374–8

Effects of exercise position on the ventilatory responses to exercise in chronic heart failure. Armour W, et al. **Int J Cardiol** 1998 Sep 1;66(1):59–63

Central and peripheral components of chronic heart failure: determinants of exercise tolerance. Florea VG, et al. **Int J Cardiol** 1999 Jul 1;70(1):51–6

The ergoreflex in patients with chronic stable heart failure. Grieve DA, et al. **Int J Cardiol** 1999 Feb 28;68(2):157–64

Decreased left atrial appendage function is an important predictor of elevated left ventricular filling pressure in patients with congestive heart failure. Li YH, et al. **Int J Cardiol** 1999 Jan;68(1):39–45

Cardiorespiratory response during exercise in patients with cyanotic congenital heart disease with and without a Fontan operation and in patients with congestive heart failure. Ohuchi H, et al. **Int J Cardiol** 1998 Oct 30; 66(3):241–51

Is heart rate variability a reliable method to assess autonomic modulation in left ventricular dysfunction and heart failure? Assessment of autonomic modulation with heart rate variability. Scalvini S, et al. **Int J Cardiol** 1998 Nov 30; 67(1):9–17

Potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes. Tygesen H, et al. **Int J Cardiol** 1999 Feb 28;68(2):171–7

Respiratory muscle function in patients with neuromuscular disorders and cardiopulmonary diseases. Syabbalo N. **Int J Clin Pract** 1998 Jul-Aug;52(5):319–29 (129 ref.)

Pulsus paradoxus indicating heart failure in paroxysmal supraventricular tachycardia: easy detection by pulse oximetry [letter; comment] Frey B. **Intensive Care Med** 1999 Mar;25(3):333–4. Comment on: Intensive Care Med 1998 Mar;24(3):242–6.

Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II–III chronic heart failure independent of other peripheral alterations. Duscha BD, et al. **J Am Coll Cardiol** 1999 Jun; 33(7):1956–63

Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. Hambrecht R, et al. **J Am Coll Cardiol** 1999 Jan;33(1):174–9

Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group. Katz SD, et al. **J Am Coll Cardiol** 1999 Jul;34(1):170–6

Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure. Leclercq C, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1825–31

Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. Marwick TH, et al. **J Am Coll Cardiol** 1999 Mar;33(3):750–8

Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. Movsesian MA. **J Am Coll Cardiol** 1999 Aug;34(2):318–24 (60 ref.)

The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. Saad D, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1779–86

Relationship between exertional symptoms and functional capacity in patients with heart failure. Wilson JR, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1943–7

Renal function in high-output heart failure in rats: role of endogenous natriuretic peptides. Willenbrock R, et al. **J Am Soc Nephrol** 1999 Mar;10(3):572–80

Magnitude and time course of hemodynamic responses to Mueller maneuvers in patients with congestive heart failure. Hall MJ, et al. **J Appl Physiol** 1998 Oct;85(4):1476–84

Maintained exercise pressor response in heart failure. Shoemaker JK, et al. **J Appl Physiol** 1998 Nov;85(5):1793–9

Enhanced peripheral chemoreflex function in conscious rabbits with pacing-induced heart failure. Sun SY, et al. **J Appl Physiol** 1999 Apr;86(4):1264–72

Enhanced activity of carotid body chemoreceptors in rabbits with heart failure: role of nitric oxide. Sun SY, et al. **J Appl Physiol** 1999 Apr;86(4):1273–82

Volume expansion fails to normally activate neural pathways in the brain of conscious rabbits with heart failure. Akama H, et al. **J Auton Nerv Syst** 1998 Aug 27;73(1):54–62

Role of nitric oxide in ventricular dysfunction. Arstall MA, et al. **J Card Fail** 1998 Sep;4(3):249–60 (131 ref.)

Effects of short-term forearm exercise training on resistance vessel endothelial function in normal subjects and patients with heart failure. Bank AJ, et al. **J Card Fail** 1998 Sep; 4(3):193–201

Leg blood flow and increased potassium release during exercise in chronic heart failure: effect of physical training. Barlow CW, et al. **J Card Fail** 1998 Jun;4(2):105–14

AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns. Clair MJ, et al. **J Card Fail** 1998 Dec;4(4):311–23

Vascular alterations during the development and progression of experimental heart failure. Crespo MJ. **J Card Fail** 1999 Mar;5(1):55–63

Effects of dobutamine on ischemic vasodilation of the forearm in patients with severe congestive heart failure. Delehanty J, et al. **J Card Fail** 1999 Mar;5(1):25–30

Noblesse oblige [editorial] Francis GS. **J Card Fail** 1998 Jun; 4(2):91–3

Reversal of peripheral microvascular dysfunction during long-term treatment with the angiotensin-converting enzyme inhibitor fosinopril in congestive heart failure. Galatius S, et al. **J Card Fail** 1999 Mar;5(1):17–24

Regulation of regional norepinephrine spillover in heart failure: the effect of angiotensin II and beta-adrenergic agonists in the forearm circulation. Goldsmith SR, et al. **J Card Fail** 1998 Dec;4(4):305–10

Angiotensin II and sympathoactivation in heart failure. Goldsmith SR. **J Card Fail** 1999 Jun;5(2):139–45 (49 ref.)

Hemodynamic changes and neurohumoral regulation during development of congestive heart failure in a model of epinephrine-induced cardiomyopathy in conscious rabbits. Muders F, et al. **J Card Fail** 1999 Jun;5(2):109–16

Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. Nakamura M. **J Card Fail** 1999 Jun; 5(2):127–38 (110 ref.)

Differential roles of endothelin-1 in the development of secondary pulmonary hypertension in patients with left heart failure with or without acute exacerbation. Sasaki T, et al. **J Card Fail** 1999 Mar;5(1):38–45

Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action. Spinale FG, et al. **J Card Fail** 1998 Dec;4(4):325–32

Muscular performance in heart failure. Sunnerhagen KS, et al. **J Card Fail** 1998 Jun;4(2):97–104

Effects of multisite ventricular pacing on cardiac function in normal dogs and dogs with heart failure. Fei L, et al. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):935–46

Effect of short- and long-term heart failure on small artery morphology and endothelial function in the rat. Buus NH, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):34–40

Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. Francis GS. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S16–21 (71 ref.)

Endothelial control of vascular tone in chronic heart failure. Kiowski W, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S67–73 (73 ref.)

Maximal and submaximal exercise testing in heart failure. Metra M, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S36–45 (100 ref.)

Dissociation of the effects of forskolin and dibutyryl cAMP on force of contraction and phospholamban phosphorylation in human heart failure. Neumann J, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):157–62

Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. Tofovic SP, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):360–6

Ischemia and left ventricular dysfunction: a reciprocal relation? van Veldhuisen DJ, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S46–51

The role of angiotensin II AT1 receptor in the maintenance of hemodynamics in a canine model of coronary microembolization-induced heart failure. Wang J, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):335–40

Effects of beta-blockers on symptoms and exercise tolerance in patients with heart failure. Doughty RN, et al. **J Cardiovasc Risk** 1999 Jun;6(3):151–6 (49 ref.)

Local relation between oxidative metabolism and perfusion in leg muscles of patients with heart failure studied by magnetic resonance imaging and spectroscopy. Toussaint JF, et al. **J Heart Lung Transplant** 1998 Sep;17(9):892–900

QT interval measurement: Q to TApex or Q to TEnd? Davey PP. **J Intern Med** 1999 Aug;246(2):145–9

Beneficial effects of exercise training in heart failure patients with low cardiac output response to exercise – a comparison of two training models. Gordon A, et al. **J Intern Med** 1999 Aug;246(2):175–82

Secondary endothelial dysfunction: hypertension and heart

failure. Boulanger CM. **J Mol Cell Cardiol** 1999 Jan; 31(1):39–49 (120 ref.)
L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. Mukherjee R, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1899–916 (125 ref.)
Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. Schmidt U, et al. **J Mol Cell Cardiol** 1998 Oct; 30(10):1929–37
Captopril treatment improves the sarcoplasmic reticular Ca(2+) transport in heart failure due to myocardial infarction. Shao Q, et al. **J Mol Cell Cardiol** 1999 Sep; 31(9):1663–72
Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. Sharov VG, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1757–62
Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. Tamura T, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2175–81
Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: I. Regional hemodynamics and myocyte remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb; 31(2):307–17
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. Willette RN, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):48–53
Bicaval and standard techniques in orthotopic heart transplantation: medium-term experience in cardiac performance and survival. Aziz T, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):115–22
Effect of inhaled nitric oxide on left ventricular and pulmonary vascular function [letter; comment] Krohn BG. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):195–6. Comment on: J Thorac Cardiovasc Surg 1998 Mar;115(3):700–8.
Evidence for structural alterations in resistance arteries of patients with severe congestive heart failure. Mengden T, et al. **J Vasc Res** 1999 May–Jun;36(3):229–34
Short-term and long-term inhibition of endogenous atrial natriuretic peptide in dogs with early-stage heart failure. Fukai D, et al. **Jpn Circ J** 1998 Aug;62(8):604–10
Metaiodobenzylguanidine and heart rate variability in heart failure. Kurata C, et al. **Jpn Circ J** 1998 Oct;62(10):770–2
Magnesium dynamics and sympathetic nervous system activity in patients with chronic heart failure. Samejima H, et al. **Jpn Circ J** 1999 Apr;63(4):267–73
Early occurrence of respiratory muscle deoxygenation assessed by near-infrared spectroscopy during leg exercise in patients with chronic heart failure. Terakado S, et al. **Jpn Circ J** 1999 Feb;63(2):97–103
Relationship between exercise capacity and ventilatory equivalent for carbon dioxide in patients with stable old myocardial infarction. Kimura M, et al. **Jpn Heart J** 1999 Mar;40(2):127–34
Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Wimmer A, et al. **Jpn Heart J** 1999 May;40(3):321–34
Effects of intracoronary caffeine on left ventricular mechanoenergetics in Ca2+ overload failing rat hearts. Fujii W, et al. **Jpn J Physiol** 1998 Oct;48(5):373–81
Pathophysiology of renal fluid retention. Schrier RW, et al. **Kidney Int Suppl** 1998 Sep;67:S127–32 (62 ref.)
Sleep-disordered breathing in chronic stable heart failure. Lipkin DP. **Lancet** 1999 Aug 14;354(9178):531–2
Cardiovascular ageing and heart failure. Macdonald PS, et al. **Med J Aust** 1998 Nov 2;169(9):480–4 (56 ref.)
Gas exchange response to exercise in patients with chronic heart failure. Bellone A, et al. **Monaldi Arch Chest Dis** 1999 Feb;54(1):3–6
Hormones and hemodynamics in heart failure. Schrier RW, et al. **N Engl J Med** 1999 Aug 19;341(8):577–85 (60 ref.)
Chronic 17beta-estradiol augments relaxant role of basal nitric oxide in blood vessels from rats with heart failure. Nekooeian AA, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):671–7
Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure. Atsumi H, et al. **Nucl Med Commun** 1998 May;19(5):451–6
An unusual ECG from a patient with an atriobiventricular pacemaker. Connors SP, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1245–7
Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Varma S, et al. **Pharmacotherapy** 1999 Jul;19(7):860–9
Augmenting beta receptors in the heart: short-term gains offset by long-term pains? Limbird LE, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7125–7
Modeling the cellular basis of altered excitation-contraction coupling in heart failure. Winslow RL, et al. **Prog Biophys Mol Biol** 1998;69(2–3):497–514 (45 ref.)
Advanced systolic heart failure: emerging pathophysiology and current management. Albert NM. **Prog Cardiovasc Nurs** 1998 Summer;13(3):14–30 (77 ref.)
Effects of severity of long-standing congestive heart failure on pulmonary function. Dimopoulou I, et al. **Respir Med** 1998 Dec;92(12):1321–5
Contribution of lung function to exercise capacity in patients with chronic heart failure. Dimopoulou I, et al. **Respiration** 1999;66(2):144–9
Effects of dynamic cardiomyoplasty on left ventricular systolic and diastolic performance in an acute canine model. Matsui Y, et al. **Surg Today** 1998;28(11):1154–9
Pathophysiology of heart failure: a look at the future. Delgado RM 3rd, et al. **Tex Heart Inst J** 1999;26(1):28–33 (38 ref.)
Catecholamine refractoriness and their mechanisms in cardiocirculatory shock and chronic heart failure. Böhm M. **Thorac Cardiovasc Surg** 1998 Sep;46 Suppl 2:270–5; discussion 276 (41 ref.)
Value of sequential big endothelin plasma concentrations to predict rapid worsening of chronic heart failure. Stanek B, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):155–7
[Management of patients with symptoms on effort] Juillière Y, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1343–7 (Eng. Abstr.) **(Fre)**
[Physiopathological basis of the treatment of heart failure] Vinsonneau C, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1315–24 (Eng. Abstr.) **(Fre)**
[Congestive heart failure in the aged. Therapeutic management] Montagne O, et al. **Presse Med** 1999 Mar 27;28(12):664–8 (Eng. Abstr.) **(Fre)**
[Congestive heart failure in adults. Etiology, physiopathology, diagnosis, course, treatment] Lopes ME, et al. **Rev Prat** 1999 Apr 1;49(7):765–76 **(Fre)**
[Renin-angiotensin-aldosterone system and heart failure: therapeutic aspects] Castaigne A, et al. **Therapie** 1998 May–Jun;53(3):285–9 (13 ref.) (Eng. Abstr.) **(Fre)**
[Transthoracic recording of pulmonary venous flow for diagnosis of high pulmonary capillary wedge pressure] Kronik G, et al. **Acta Med Austriaca** 1999;26(1):1–7 (Eng. Abstr.) **(Ger)**
[Symbolic dynamics--an independent method for detecting nonlinear phenomena of heart rate regulation] Wessel N, et al. **Biomed Tech (Berl)** 1998;43 Suppl:510–1 **(Ger)**
[Transition of myocardial ischemia to heart failure] Ertl G, et al. **Z Kardiol** 1998 Sep;87(9):667–75 (36 ref.) (Eng. Abstr.) **(Ger)**
[Cardiac sympathetic nerve activity in ischemic heart failure] Richardt G, et al. **Z Kardiol** 1998;87 Suppl 2:33–6 (14 ref.) (Eng. Abstr.) **(Ger)**
[Intra- and extravascular volumes in congestive heart failure and their redistribution following extracorporeal ultrafiltration] Marenzi G, et al. **Cardiologia** 1998 Nov; 43(11):1193–200 (Eng. Abstr.) **(Ita)**
[Effects left ventricle asynchrony on systolic and diastolic function in patients with non-ischemic heart failure] Della Morte AM, et al. **Radiol Med (Torino)** 1998 Jul–Aug; 96(1–2):68–72 (Eng. Abstr.) **(Ita)**
[From physiopathology to therapy: description of cardiac failure] Izumi T. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):411–5 (7 ref.) **(Jpn)**
[The semiquantitative evaluation of systemic vascular resistances in heart failure via an analysis of Doppler aortic flow] Martins S, et al. **Rev Port Cardiol** 1999 Feb; 18(2):141–7 (Eng. Abstr.) **(Por)**
[Time integral of oxygen pulse for exercise submaximal levels in patients with heart insufficiency--correlation with maximal oxygen consumption] Martins S, et al. **Rev Port Cardiol** 1999 Jun;18(6):587–93 (Eng. Abstr.) **(Por)**
[The central hemodynamic characteristics of patients with postinfarct cardiosclerosis and heart failure] Koshlia EV. **Lik Sprava** 1999 Jan–Feb;(1):39–41 (Eng. Abstr.) **(Rus)**
[The subcellular pathophysiology of heart failure due to toxic-allergic myocarditis and the action of refracterin on intracardiac hemodynamics and the functional state of the 3 subcellular cardiomyocyte systems responsible for the act of contraction-relaxation] Karsanov NV, et al. **Patol Fiziol Eksp Ter** 1999 Jul–Sep;(3):3–8 (Eng. Abstr.) **(Rus)**
[Baroreceptor regulation in chronic heart failure] Chaban TI. **Lik Sprava** 1999 Apr–May;(3):20–4 (34 ref.) **(Ukr)**

PREVENTION & CONTROL

Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Hall WD. **Am Heart J** 1999 Sep;138(3 Pt 2):225–30 (21 ref.)
Cardioprotection for Duchenne's muscular dystrophy. Ishikawa Y, et al. **Am Heart J** 1999 May;137(5):895–902
Evidence based cardiology: prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. McKelvie RS, et al. **BMJ** 1999 May 22; 318(7195):1400–2 (32 ref.)
Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. Jasmin G, et al. **Cardiovasc Drugs Ther** 1998 Sep;12 Suppl 2:189–95
Chronic amlodipine treatment during the development of heart failure. Spinale FG, et al. **Circulation** 1998 Oct 20; 98(16):1666–74
Role of secondary prevention in congestive heart failure due to coronary artery disease. Brook RD, et al. **Coron Artery Dis** 1998;9(10):653–8 (22 ref.)
Prevention of relapse in patients with congestive heart failure: the role of precipitating factors. Feenstra J, et al. **Heart** 1998 Nov;80(5):432–6 (42 ref.)
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. Carraway JW, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):451–60
Doxorubicin-induced cardiomyopathy [letter; comment] Swain SM. **N Engl J Med** 1999 Feb 25;340(8):654; discussion 655. Comment on: N Engl J Med 1998 Sep 24;339(13):900–5.
From crisis intervention to preventive intervention. A new approach to the management of heart failure. Mehra MR. **Tex Heart Inst J** 1998;25(4):251–4
[Prevention of heart failure] Logeart D, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1333–41 (Eng. Abstr.) **(Fre)**
[Primordial prevention and control of the population burden of heart failure (editorial)] Rodríguez Artalejo F, et al. **Rev Esp Cardiol** 1998 Dec;51(12):977–8 **(Spa)**

PSYCHOLOGY

Card sort: an assessment tool for the educational needs of patients with heart failure. Luniewski M, et al. **Am J Crit Care** 1999 Sep;8(5):297–302
Quality of life outcomes in left ventricular assist system inpatients and outpatients. Dew MA, et al. **ASAIO J** 1999 May–Jun;45(3):218–25
Resuscitation in hospice. Henderson S, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):20; discussion 20–2
The meaning of hospital care, as narrated by elderly patients with chronic heart failure. Ekman I, et al. **Heart Lung** 1999 May–Jun;28(3):203–9
Becoming a patient with heart failure. Stull DE, et al. **Heart Lung** 1999 Jul–Aug;28(4):284–92
Functional status and depression among men and women with congestive heart failure. Murberg TA, et al. **Int J Psychiatry Med** 1998;28(3):273–91
Female patients with congestive heart failure: how they conceive their life situation. Mårtensson J, et al. **J Adv Nurs** 1998 Dec;28(6):1216–24
Cardiac ventricular support. Considerations for psychiatry. Petrucci R, et al. **Psychosomatics** 1999 Jul–Aug; 40(4):298–303
[Perspectives of patients with terminal renal failure: quality of life and psychological adjustment before and in the first year after heart transplantation] Riedmayr MI, et al. **Z Kardiol** 1998 Oct;87(10):808–16 (Eng. Abstr.) **(Ger)**
[The brain in congestive heart failure in the elderly. Cognitive functions in heart failure in the elderly (the CHF Italian Study II). The rationale and preliminary data] Rengo F, et al. **Cardiologia** 1998 Oct;43(10):1045–52 **(Ita)**

RADIOGRAPHY

Mediastinal lymphadenopathy and hazy mediastinal fat: new CT findings of congestive heart failure. Slanetz PJ, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1307–9
Images in cardiology. Vanishing tumour. Kodama M, et al. **Heart** 1998 Dec;80(6):611
Reproducibility of right and left ventricular volume measurements by electron-beam CT in patients with congestive heart failure. Schmermund A, et al. **Int J Card Imaging** 1998 Jun;14(3):201–9

RADIONUCLIDE IMAGING

Cardiac positron emission tomography imaging with [11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Vesalainen RK, et al. **Am J Cardiol** 1999 Sep 1;84(5):568–74
Prominent myocardial uptake on perfusion lung imaging. Ayar DC, et al. **Clin Nucl Med** 1999 Sep;24(9):700–1
Protein-losing enteropathy in congestive heart failure: diagnosis by means of a simple method. Chan FK, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1816–8
Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Ishida Y, et al. **Int J Card Imaging** 1999 Feb;15(1):71–7 (20 ref.)
Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. Cohen-Solal A, et al. **J Am Coll Cardiol** 1999 Mar;33(3):759–66
Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure. Atsumi H, et al. **Nucl Med Commun** 1998 May;19(5):451–6
Radionuclide techniques for the assessment of myocardial viability. Skoufis E, et al. **Tex Heart Inst J** 1998;25(4):272–9 (77 ref.)

REHABILITATION

Effects of low altitude on exercise performance in patients with congestive heart failure after healing of acute myocardial infarction. Abinader EG, et al. **Am J Cardiol** 1999 Feb 1;83(3):383–7
Exercise training in the treatment of heart failure: what is achieved and how? Balady GJ. **Ann Med** 1998 Aug;30 Suppl 1:61–5 (34 ref.)
Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure. Sturm B, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):746–50
Effects of aerobic exercise training on indices of ventricular repolarization in patients with chronic heart failure. Ali A, et al. **Chest** 1999 Jul;116(1):83–7
Exercise and physical therapy in elderly, more severely incapacitated patients in cardiac rehabilitation. Mathes P. **Coron Artery Dis** 1999;10(1):33–6 (43 ref.)
Modifying breathing patterns in chronic heart failure [editorial] [see comments] Bernardi L. **Eur Heart J** 1999

Jan;20(2):83–4. Comment in: Eur Heart J 1999 Jul;20(14):1052–3.
Neurobiology of respiratory-pattern training in congestive heart failure [letter] Friedman EH. **Eur Heart J** 1999 Jul; 20(14):1052–3
Effects of education and support on self-care and resource utilization in patients with heart failure [see comments] Jaarsma T, et al. **Eur Heart J** 1999 May;20(9):673–82. Comment in: Eur Heart J 1999 May;20(9):632–3.
A randomized controlled trial of inspiratory muscle training in stable chronic heart failure. Johnson PH, et al. **Eur Heart J** 1998 Aug;19(8):1249–53
Exercise training in chronic heart failure: is it really safe? [editorial; comment] Meyer K. **Eur Heart J** 1999 Jun; 20(12):851–3. Comment on: Eur Heart J 1999 Jun;20(12):872–9.
Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE) [see comments] Wielenga RP, et al. **Eur Heart J** 1999 Jun;20(12):872–9. Comment in: Eur Heart J 1999 Jun;20(12):851–3.
Exercise training in heart failure improves quality of life and exercise capacity. Willenheimer R, et al. **Eur Heart J** 1998 May;19(5):774–81
Exercise training in patients with CHF and heart transplant recipients. Braith RW. **Med Sci Sports Exerc** 1998 Oct; 30(10 Suppl):S367–78 (58 ref.)
Objective effects of a 6 months' endurance and strength training program in outpatients with congestive heart failure. Delagardelle C, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1102–7
[Rehabilitation by physical exercise in chronic heart failure] Broustet JP, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1399–405 (Eng. Abstr.) **(Fre)**

SURGERY

Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Twidale N, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):647–57
Heart rate variability in healthy children and in those with congenital heart disease both before and after operation. Heragu NP, et al. **Am J Cardiol** 1999 Jun 15;83(12):1654–7
Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Mahoney P, et al. **Am J Cardiol** 1999 Jun 1;83(11):1544–7
Dynamic cardiomyoplasty: at the crossroads. Acker MA. **Ann Thorac Surg** 1999 Aug;68(2):750–5 (38 ref.)
Implantation technique for the CardioWest total artificial heart. Arabia FA, et al. **Ann Thorac Surg** 1999 Aug; 68(2):698–704
Development of the Nimbus/University of Pittsburgh innovative ventricular assist system. Butler KC, et al. **Ann Thorac Surg** 1999 Aug;68(2):790–4
Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. Copeland JG, et al. **Ann Thorac Surg** 1999 Aug;68(2):756–60
Centrifugal pumps: description of devices and surgical techniques. Curtis JJ, et al. **Ann Thorac Surg** 1999 Aug; 68(2):666–71
A miniature implantable axial flow ventricular assist device. DeBakey ME. **Ann Thorac Surg** 1999 Aug;68(2):637–40
Bridging from acute to chronic devices. Dembitsky WP. **Ann Thorac Surg** 1999 Aug;68(2):724–8
Left ventricular assist system as a bridge to myocardial recovery. Frazier OH, et al. **Ann Thorac Surg** 1999 Aug; 68(2):734–41
Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Hetzer R, et al. **Ann Thorac Surg** 1999 Aug;68(2):742–9
Infection during circulatory support with ventricular assist devices. Holman WL, et al. **Ann Thorac Surg** 1999 Aug; 68(2):711–6
A survey on partial left ventriculectomy in the Asia-Pacific region. Izzat MB, et al. **Ann Thorac Surg** 1999 Feb; 67(2):387–91
Early experience with partial left ventriculectomy in the Asia-Pacific region. Izzat MB, et al. **Ann Thorac Surg** 1999 Jun;67(6):1703–7
Current results with pediatric heart transplantation. Kanter KR, et al. **Ann Thorac Surg** 1999 Aug;68(2):527–30; discussion 530–1
Current strategy of temporary circulatory support for severe cardiac failure after operation. Kitamura M, et al. **Ann Thorac Surg** 1999 Aug;68(2):662–5
Temporary pulsatile ventricular assist devices and biventricular assist devices. Körfer R, et al. **Ann Thorac Surg** 1999 Aug;68(2):678–83
Heart booster: a pericardial support device. Kung RT, et al. **Ann Thorac Surg** 1999 Aug;68(2):764–7
Extracorporeal membrane oxygenation for adult cardiac support: the Allegheny experience. Magovern GJ Jr, et al. **Ann Thorac Surg** 1999 Aug;68(2):655–61
Bridge to transplantation: the Penn State experience. Mavroidis D, et al. **Ann Thorac Surg** 1999 Aug;68(2):684–7
Progress with the HeartSaver Ventricular Assist Device. Mussivand T, et al. **Ann Thorac Surg** 1999 Aug;68(2):785–9
Acute and temporary ventricular support with BioMedicus centrifugal pump. Noon GP, et al. **Ann Thorac Surg** 1999 Aug;68(2):650–4
Development of a totally implantable biventricular bypass centrifugal blood pump system. Nosé Y, et al. **Ann Thorac Surg** 1999 Aug;68(2):775–9
Permanent ventricular assist device support versus cardiac transplantation. Pennington DG, et al. **Ann Thorac Surg** 1999 Aug;68(2):729–33
Bridge to transplant with the Novacor left ventricular assist system. Robbins RC, et al. **Ann Thorac Surg** 1999 Aug; 68(2):695–7
The AB-180 circulatory support system: summary of development and plans for phase I clinical trial. Savage EB, et al. **Ann Thorac Surg** 1999 Aug;68(2):768–74
100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Sun BC, et al. **Ann Thorac Surg** 1999 Aug;68(2):688–94
Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Nägele H, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2531–4
New developments in the treatment of cardiac failure. Westaby S, et al. **Arch Dis Child** 1999 Sep;81(3):276–7 (16 ref.)
Effect of a balanced biventricular bypass system on left ventricular energies. Kodera K, et al. **Artif Organs** 1998 Sep;22(9):803–7
Quality of life outcomes in left ventricular assist system inpatients and outpatients. Dew MA, et al. **ASAIO J** 1999 May-Jun;45(3):218–25
Ventricular radius reduction without resection: a computational analysis. Melvin DB. **ASAIO J** 1999 May-Jun;45(3):160–5
Split-circulation assist device facilitates heart failure management and increases effects of intra-aortic balloon pumping. Miyawaki F, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M628–33
Modified rapid ventricular pacing: a chronic model of heart failure for evaluation of new surgical therapies. Patel HJ, et al. **ASAIO J** 1998 Nov-Dec;44(6):799–803
Dynamic cardiomyoplasty in patients with end-stage heart failure: anaesthetic considerations. Lehmann A, et al. **Br J Anaesth** 1999 Jan;82(1):140–3
Maximal exercise testing for the selection of heart transplantation candidates: limitation of peak oxygen consumption. Ramos-Barbón D, et al. **Chest** 1999 Feb; 115(2):410–7
Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation [letter; comment] Davie A, et al. **Circulation** 1999 Jun 8; 99(22):2966; discussion 2966–7. Comment on: Circulation 1998 Sep 8;98(10):941–2. Comment on: Circulation 1998 Sep 8;98(10):953–60.
Coronary revascularization in patients with chronic heart failure. Sanchez JA, et al. **Coron Artery Dis** 1998; 9(10):685–9
Surgical therapy for severe heart failure. Frazier OH, et al. **Curr Probl Cardiol** 1998 Dec;23(12):721–64 (121 ref.)
Advances in heart transplantation. Winkel E, et al. **Dis Mon** 1999 Mar;45(3):62–87 (58 ref.)
Change in electrical stimulation regimen after cardiomyoplasty [letter; comment] Chekanov VS. **Eur Heart J** 1999 Mar;20(5):393. Comment on: Eur Heart J 1998 Feb;19(2):310–8.
Partial left ventriculectomy--the Batista procedure. Batista R. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S12–9; discussion S39–43 (0 ref.)
Early and intermediate results of left ventricular reduction surgery. Konertz W, et al. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S26–30; discussion S39–43
Dynamic cardiomyoplasty: time to wrap it up? [editorial] Hayward MP. **Heart** 1999 Sep;82(3):263–4
Partial left ventriculectomy: preoperative risk factors for perioperative mortality. Bestetti RB, et al. **Int J Cardiol** 1998 Dec 1;67(2):143–6
Ventricular reduction therapy: controlled clinical trials overdue [letter] Spodick DH. **J Am Coll Cardiol** 1999 Aug; 34(2):610–1
Partial left ventriculectomy in patients with dialated failing ventricle. Kawaguchi AT, et al. **J Card Surg** 1998 Sep-Oct; 13(5):335–42
Cardiomyoplasty and implantable cardioverter defibrillator: efficacy and safety of concomitant device implantation: sudden death and cardiomyoplasty. Lorusso R, et al. **J Card Surg** 1998 Mar;13(2):150–5
Emergency versus elective/urgent left ventricular assist device implantation. Schmid C, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1024–8
Left ventricular volume reduction for end-stage heart failure: intrapapillary or extrapapillary resection, mitral valve repair or replacement? Lim KH, et al. **J Heart Valve Dis** 1998 Sep;7(5):484–7
Pacing mode and long-term survival in elderly patients with congestive heart failure: 1980–1985. Brady PA, et al. **J Interv Card Electrophysiol** 1997 Nov;1(3):193–201
Bicaval and standard techniques in orthotopic heart transplantation: medium-term experience in cardiac performance and survival. Aziz T, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):115–22
Mechanical circulatory support for one thousand days or more with the Novacor N100 left ventricular assist device. Dohmen PM, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):1029–30
Improved cardiac function after catheter ablation in a patient with type B Wolff-Parkinson-White syndrome with an old myocardial infarction. Yamanaka S, et al. **Jpn Circ J** 1998 Nov;62(11):860–2
Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Ankersmit HJ, et al. **Lancet** 1999 Aug 14;354(9178):550–5
The heartmate left ventricular assist system: first successful implantation in Missouri. Wilson WR, et al. **Mo Med** 1999 Jan;96(1):14–7
Heart failure and ST segment depression in a child aged 6 weeks [letter] Dearlove OR, et al. **Paediatr Anaesth** 1999; 9(5):468–9
Plasma adrenomedullin level after cardiopulmonary bypass. Komai H, et al. **Perfusion** 1998 Sep;13(5):334–7
Effects of dynamic cardiomyoplasty on left ventricular systolic and diastolic performance in an acute canine model. Matsui Y, et al. **Surg Today** 1998;28(11):1154–9
Heart transplantation: approaching a new century. Radovancević B, et al. **Tex Heart Inst J** 1999;26(1):60–70 (69 ref.)
Successful reoperation after Batista partial left ventriculectomy demonstrates patient's hemodynamic recovery. Taşdemir O, et al. **Tex Heart Inst J** 1999; 26(2):132–5
Experience with an adjustable pulmonary artery banding device in two cases: initial success--midterm failure. Däbritz S, et al. **Thorac Cardiovasc Surg** 1999 Feb; 47(1):51–2
Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Schmid C, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):161–2
[Alternative surgical options to heart transplantation] Dreyfus G. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1413–22 (Eng. Abstr.) **(Fre)**
[Therapy of acute heart failure--surgical possibilities] Haverich A, et al. **Z Kardiol** 1999 Mar;88(3):173–8 (51 ref.) (Eng. Abstr.) **(Ger)**
[Batista procedure--partial left ventricular volume reduction--new approach to the surgical management of end stage congestive heart failure] Shinfeld A, et al. **Harefuah** 1998 Aug;135(3–4):118–20 (12 ref.) **(Heb)**
[Selection and evaluation of candidate patients for heart transplant] Castro PF, et al. **Rev Esp Cardiol** 1999 Aug; 52(8):604–16 (119 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Heart failure: a diagnostic and therapeutic dilemma in elderly patients [see comments] Gillespie ND, et al. **Age Ageing** 1998 Jul;27(4):539–43 (50 ref.). Comment in: Age Ageing 1999 May;28(3):328–9.
Insights into the contemporary epidemiology and outpatient management of congestive heart failure [see comments] McAlister FA, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):87–94 . Comment in: Am Heart J 1999 Jul;138(1 Pt 1):5–8.
Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Vaur L, et al. **Am Heart J** 1999 Jan;137(1):49–58
The Pacing Therapies for Congestive Heart Failure (PATH-CHF) study: rationale, design, and endpoints of a prospective randomized multicenter study. Auricchio A, et al. **Am J Cardiol** 1999 Mar 11;83(5B):130D–135D
Transvenous biventricular pacing for heart failure: can the obstacles be overcome? Auricchio A, et al. **Am J Cardiol** 1999 Mar 11;83(5B):136D–142D (22 ref.)
Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart". Böcker D, et al. **Am J Cardiol** 1999 Mar 11;83(5B):83D–87D (36 ref.)
Use of telemonitoring to decrease the rate of hospitalization in patients with severe congestive heart failure. Cordisco ME, et al. **Am J Cardiol** 1999 Oct 1;84(7):860–2, A8
Combining nonpharmacologic therapies for advanced heart failure: the Münster experience with the assist device-defibrillator combination. Deng MC, et al. **Am J Cardiol** 1999 Mar 11;83(5B):158D–160D
Resistance exercise training increases muscle strength, endurance, and blood flow in patients with chronic heart failure. Hare DL, et al. **Am J Cardiol** 1999 Jun 15; 83(12):1674–7, A7
Can right-sided atrioventricular sequential pacing provide benefit for selected patients with severe congestive heart failure? Sack S, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):124D–129D
Biventricular pacing in patients with congestive heart failure: two prospective randomized trials. The VIGOR CHF and VENTAK CHF Investigators. Saxon LA, et al. **Am J Cardiol** 1999 Mar 11;83(5B):120D–123D (20 ref.)
The implantable cardioverter defibrillator as a "bridge to transplant": a viable clinical strategy? Schmidinger H. **Am J Cardiol** 1999 Mar 11;83(5B):151D–157D (69 ref.)
Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. Stellbrink C, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):143D–150D
Impact of home health care on health care costs and hospitalization frequency in patients with heart failure. Wilson JR, et al. **Am J Cardiol** 1999 Feb 15;83(4):615–7, A10
Improving outcomes in congestive heart failure. Hisel T, et al. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1445–50 (66 ref.)
Bethesda Conference: conference for the design of clinical trials to study circulatory support devices for chronic heart failure. **Ann Thorac Surg** 1998 Oct;66(4):1452–65

Dynamic abdominal and thoracic aortomyoplasty in heart failure: assessment of counterpulsation. Cabrera Fischer EI, et al. **Ann Thorac Surg** 1999 Apr;67(4):1022–9

Removing the causes of pulmonary hypertension [letter; comment] Krohn BG. **Ann Thorac Surg** 1998 Nov; 66(5):1862–3. Comment on: Ann Thorac Surg 1998 Feb;65(2):340–5.

The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Rose EA, et al. **Ann Thorac Surg** 1999 Mar;67(3):723–30

Cost–effectiveness analysis in clinical practice: the case of heart failure. Rich MW, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1690–700 (51 ref.)

A remote monitoring system for patients with implantable ventricular assist devices with a personal handy phone system. Okamoto E, et al. **ASAIO J** 1999 May–Jun; 45(3):194–8

Numeric modeling of the cardiovascular system with a left ventricular assist device. Zhou J, et al. **ASAIO J** 1999 Jan–Feb;45(1):83–9

Dying from heart failure: lessons from palliative care. Many patients would benefit from palliative care at the end of their lives [editorial] Gibbs LM, et al. **BMJ** 1998 Oct 10; 317(7164):961–2

Current issues in cardiac care [editorial; comment] Laramée LA, et al. **Can Fam Physician** 1998 Dec;44:2607–10, 2617–20. Comment on: Can Fam Physician 1998 Dec;44 :2689–92, 2695–8. Comment on: Can Fam Physician 1998 Dec;44 :2709–17. **(Eng, Fre)**

Community management of heart failure [see comments] McKelvie RS. **Can Fam Physician** 1998 Dec;44:2689–92, 2695–8 (36 ref.). Comment in: Can Fam Physician 1998 Dec;44 :2607–10, 2617–20.

Optimizing disease management at a health care system level: the rationale and methods of the improving cardiovascular outcomes in Nova Scotia (ICONS) study. Cox JL. **Can J Cardiol** 1999 Jul;15(7):787–96 (64 ref.)

N–CPAP in the prevention of recurrent intubations and hospitalizations in a patient with refractory congestive heart failure. Parmar MS, et al. **Can J Cardiol** 1998 Nov; 14(11):1405–8 (22 ref.)

Continuous positive airway pressure and congestive heart failure [comment] Remmers JE. **Can J Cardiol** 1999 Sep; 15(9):959–60. Comment on: Can J Cardiol 1999 Sep;15(9):1009–12.

Improving outcomes in congestive heart failure: Val–HeFT. Valsartan in Heart Failure Trial. Cohn JN. **Cardiology** 1999; 91 Suppl 1:19–22

Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Philbin EF, et al. **Chest** 1999 Aug;116(2):346–54

Calcium pump overexpression and myocardial function. Implications for gene therapy of myocardial failure [editorial; comment] Hasenfuss G. **Circ Res** 1998 Nov 2; 83(9):966–8. Comment on: Circ Res 1998 Nov 2;83(9):877–88. Comment on: Circ Res 1998 Nov 2;83(9):889–97.

Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Auricchio A, et al. **Circulation** 1999 Jun 15;99(23):2993–3001

Randomized, controlled trial of long–term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Belardinelli R, et al. **Circulation** 1999 Mar 9;99(9):1173–82

Exercise training for heart failure: coming of age [editorial] Coats AJ. **Circulation** 1999 Mar 9;99(9):1138–40 (22 ref.)

Heart failure therapy: not as complicated as it looks [editorial] Mills RM, et al. **Clin Cardiol** 1999 May;22(5):333

Is Internet–based disease management on the way? OReilly M. **CMAJ** 1999 Apr 6;160(7):1039

Potential future therapies for heart failure: gene transfer of beta–adrenergic signaling components. Maurice JP, et al. **Coron Artery Dis** 1999 Sep;10(6):401–5 (33 ref.)

Exercise training in elderly patients with chronic heart failure [published erratum appears in Coron Artery Dis 1999;10(1):57] Wielenga RP, et al. **Coron Artery Dis** 1998; 9(11):765–70

Cardiac pacing in congestive heart failure. Yap YG, et al. **Coron Artery Dis** 1998;9(6):345–51 (42 ref.)

Pacing therapy for congestive heart failure: is it ready for prime time? [editorial] Naccarelli GV, et al. **Curr Opin Cardiol** 1999 Jan;14(1):1–3

The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment [editorial] Torre–Amione G. **Curr Opin Cardiol** 1999 May;14(3):193–5

Optimizing exercise training for subgroups of patients with chronic heart failure. Coats AJ. **Eur Heart J** 1998 Nov; 19 Suppl O:O29–34 (53 ref.)

Improving outcomes in heart failure [editorial; comment] [see comments] Cohn JN. **Eur Heart J** 1998 Aug;19(8):1124–5 . Comment on: Eur Heart J 1998 Aug;19(8):1254–60. Comment in: Eur Heart J 1999 Mar;20(5):393–4.

Feasibility of a nurse–monitored, outpatient–care programme for elderly patients with moderate–to–severe, chronic heart failure [see comments] Ekman I, et al. **Eur Heart J** 1998 Aug;19(8):1254–60. Comment in: Eur Heart J 1998 Aug;19(8):1124–5. Comment in: Eur Heart J 1999 Mar;20(5):393–4.

Outpatient care programmes for the elderly [letter; comment] Ekman I, et al. **Eur Heart J** 1999 Mar;20(5):393–4. Comment on: Eur Heart J 1998 Aug;19(8):1124–5. Comment on: Eur Heart J 1998 Aug;19(8):1254–60.

Heart failure management—a broader view required [editorial; comment] Sharpe N. **Eur Heart J** 1998 Jul; 19(7):975. Comment on: Eur Heart J 1998 Jul;19(7):1063–9.

The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end–stage heart failure. Noirhomme P, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):63–7

Multisite stimulation in refractory heart failure. Ansalone G, et al. **G Ital Cardiol** 1999 Apr;29(4):451–9 (2o ref.)

Resuscitation in hospice. Henderson S, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):20; discussion 20–2

Quality of care for two common illnesses in teaching and nonteaching hospitals. Ayanian JZ, et al. **Health Aff (Millwood)** 1998 Nov–Dec;17(6):194–205

Heart failure clinics: a possible means of improving care [editorial] Erhardt L, et al. **Heart** 1998 Nov;80(5):428–9

Heart failure clinics [editorial; comment] Strömberg A. **Heart** 1998 Nov;80(5):426–7. Comment on: Heart 1998 Nov;80(5):437–41.

Factors influencing patient compliance with therapeutic regimens in chronic heart failure: A critical incident technique analysis. Strömberg A, et al. **Heart Lung** 1999 Sep–Oct;28(5):334–41

Emerging role of pacing therapies for congestive heart failure [editorial] Gambhir DS. **Indian Heart J** 1999 Mar–Apr; 51(2):135–6, 217

The benefits of daily hemofiltration in the management of anuria in patients with severe heart failure (NYHA IV). Iorio L, et al. **Int J Artif Organs** 1998 Aug;21(8):457–9

Daily hemofiltration in severe heart failure [editorial] Iorio L. **Int J Artif Organs** 1998 Dec;21(12):778–80

Bioelectrical impedance analysis before and after Novacor implantation. Stellato D, et al. **Int J Artif Organs** 1999 Mar; 22(3):151–4

Elderly patients with heart failure: a study of satisfaction with care and quality of life. Candlish P, et al. **Int J Qual Health Care** 1998 Apr;10(2):141–6

Successful treatment of severe myocardial failure after postpartum haemorrhage with the use of an intra–aortic balloon pump. Mayr A, et al. **Intensive Care Med** 1999 Feb;25(2):223–5

Specialty–related disparities of readmission in patients with chronic heart failure: the importance of hospital–clinic cooperation. Sakakibara M, et al. **Intern Med** 1999 Sep; 38(9):705–9

Effect of intensive therapy for heart failure on the vasodilator response to exercise. Johnson W, et al. **J Am Coll Cardiol** 1999 Mar;33(3):743–9

Acute hemodynamic effects of biventricular DDD pacing in patients with end–stage heart failure. Leclercq C, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1825–31

Differences among geriatricians, general internists, and cardiologists in the care of patients with heart failure: a cautionary tale of quality assessment. Chin MH, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1349–54

The use of pacemakers as treatment for systolic dysfunction. Gottlieb SS. **J Card Fail** 1998 Jun;4(2):145–50 (68 ref.)

Patient preferences for heart failure treatment: utilities are valid measures of health–related quality of life in heart failure. Havranek EP, et al. **J Card Fail** 1999 Jun;5(2):85–91

Predicting short–term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. MacGowan GA, et al. **J Card Fail** 1998 Sep;4(3):169–75

Analysis of trends in hospitalizations for heart failure. Ni H, et al. **J Card Fail** 1999 Jun;5(2):79–84

A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators [see comments] Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8):864–91 (156 ref.) . Comment in: J Cardiovasc Electrophysiol 1999 Mar;10(3):420–1.

Ischemic and nonischemic heart failure do not require different treatment strategies. Abraham WT, et al. **J Cardiovasc Pharmacol** 1999 Jun;33 Suppl 3:S1–7 (58 ref.)

Different causes of heart failure need different treatment strategies. Hampton JR. **J Cardiovasc Pharmacol** 1999 Jun; 33 Suppl 3:S37–41 (25 ref.)

Enhancement of cardiac function after adenoviral–mediated in vivo intracoronary beta2–adrenergic receptor gene delivery. Maurice JP, et al. **J Clin Invest** 1999 Jul; 104(1):21–9

Comanagement of patients with congestive heart failure by family physicians and cardiologists: frequency, timing, and patient characteristics [see comments] Diller PM, et al. **J Fam Pract** 1999 Mar;48(3):188–95. Comment in: J Fam Pract 1999 Mar;48(3):177–9.

Care of patients with failing hearts: evidence for failures in clinical practice and health services research [editorial; comment] Ashton CM. **J Gen Intern Med** 1999 Feb; 14(2):138–40 (20 ref.). Comment on: J Gen Intern Med 1999 Feb;14(2):130–5.

Older persons' preferences for site of treatment in acute illness. Fried TR, et al. **J Gen Intern Med** 1998 Aug; 13(8):522–7

Comprehensive multidisciplinary programs for the management of patients with congestive heart failure [see comments] Philbin EF. **J Gen Intern Med** 1999 Feb; 14(2):130–5 (44 ref.). Comment in: J Gen Intern Med 1999 Feb;14(2):138–40.

The use of APACHE II scores to select candidates for left ventricular assist device placement. Acute Physiology and Chronic Health Evaluation. Gracin N, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1017–23

Beneficial effects of exercise training in heart failure patients with low cardiac output response to exercise – a comparison of two training models. Gordon A, et al. **J Intern Med** 1999 Aug;246(2):175–82

Evolving therapeutic concepts and imaging in ischemic cardiomyopathy. Lahiri A, et al. **J Nucl Cardiol** 1998 Nov–Dec;5(6):598–608 (70 ref.)

Heart failure management. Warner PM, et al. **J Nurs Adm** 1999 Jul–Aug;29(7–8):28–37

Management of heart failure. Tan LB, et al. **J R Coll Physicians Lond** 1999 Jan–Feb;33(1):25–30 (42 ref.)

Terminal care of heart failure [letter; comment] Lehman R. **Lancet** 1998 Oct 24;352(9137):1394. Comment on: Lancet 1998 Aug;352 Suppl 1:SI1–2.

Health care quality improvement in Rhode Island: congestive heart failure. Westrick W. **Med Health R I** 1998 Sep; 81(9):300–1 (10 ref.)

CAPD to improve quality of life in patients with refractory heart failure. Elhalel–Dranitzki M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3041–2 (16 ref.)

Multisite pacing as a supplemental treatment of congestive heart failure: preliminary results of the Medtronic Inc. InSync Study. Gras D, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2249–55

Triple chamber pacemaker for end–stage heart failure in a patient with a previously implanted automatic defibrillator. Le Franc P, et al. **Pacing Clin Electrophysiol** 1998 Aug; 21(8):1672–5

Exercise training in heart failure. Afzal A, et al. **Prog Cardiovasc Dis** 1998 Nov–Dec;41(3):175–90 (98 ref.)

Advanced systolic heart failure: emerging pathophysiology and current management. Albert NM. **Prog Cardiovasc Nurs** 1998 Summer;13(3):14–30 (77 ref.)

Hemodynamic effects of bilevel nasal positive airway pressure ventilation in patients with heart failure. Philip–Joët FF, et al. **Respiration** 1999;66(2):136–43

Recognized molecular mechanisms of heart failure: approaches to treatment. Ceconi C, et al. **Rev Port Cardiol** 1998 Oct;17 Suppl 2:II79–91 (120 ref.)

Heart failure clinical guideline. South African Medical Association Heart Failure Working Group. **S Afr Med J** 1998 Sep;88(9 Pt 2):1133–55

Chronic heart failure—mechanisms and management. Lye M. **Scott Med J** 1997 Oct;42(5):138–40 (47 ref.)

Acute heart failure. Delgado R 3rd, et al. **Tex Heart Inst J** 1998;25(4):255–9

The HeartMate left ventricular assist system. Overview and 12–year experience. Frazier OH, et al. **Tex Heart Inst J** 1998;25(4):265–71

From crisis intervention to preventive intervention. A new approach to the management of heart failure. Mehra MR. **Tex Heart Inst J** 1998;25(4):251–4

Treating relentlessly progressive congestive heart failure: what next? [editorial] Willerson JT, et al. **Tex Heart Inst J** 1998;25(4):235–7

Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:326–31

Evolving short–term and long–term mechanical assist for cardiac–failure — a decade of experience in Münster. Tjan TD, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:294–7

Efficacy of nasal continuous positive airway pressure therapy in chronic heart failure: importance of underlying cardiac rhythm. Kiely JL, et al. **Thorax** 1998 Nov;53(11):957–62

Our experience with mechanical circulatory support for end–stage heart failure. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):1994–6

Heart failure: Part I. First hospitalization and post–hospital care [see comments] Wilkes MS, et al. **West J Med** 1999 May;170(5):268–73. Comment in: West J Med 1999 May;170(5):253–4.

[Heart transplantation in the Netherlands, an option to be considered for 5 children per year on the average] Raymakers GJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1425–8 (Eng. Abstr.) **(Dut)**

[Therapeutic strategy of the management of acute heart failure] Bosio P, et al. **Arch Mal Coeur Vaiss** 1998 Nov; 91(11):1349–58 (Eng. Abstr.) **(Fre)**

[Is the treatment of left ventricular systolic dysfunction different according to the etiology?] Bounhoure JP. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1359–64 (Eng. Abstr.) **(Fre)**

[Heart failure management: a challenge for the 3rd millennium (editorial)] Desnos M. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1303 **(Fre)**

[Cellular cardiomyoplasty: state of the art, evaluation, and future possibilities] Hagège A, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1429–35 (Eng. Abstr.) **(Fre)**

[Comparison of apical and infundabular pacing in patients with primary dilated or ischemic cardiomyopathy] Le Helloco A, et al. **Arch Mal Coeur Vaiss** 1999 Jan; 92(1):19–26 (Eng. Abstr.) **(Fre)**

[Pacing and heart failure] Leclercq C, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1389–97 (Eng. Abstr.) **(Fre)**

[Diastolic cardiac failure: therapeutic modalities] Millaire A. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1365–9 (Eng. Abstr.) **(Fre)**

[Hemodynamic indications for DDD mode pacing therapy] Kowalski M, et al. **Dtsch Med Wochenschr** 1999 May 28; 124(21):647–9 (Eng. Abstr.) **(Ger)**

[Treatment guidelines--chronic heart failure. Recommendations for therapy of chronic heart failure of the Medical Commission of the German Medical Branch] **Z Arztl Fortbild Qualitatssich** 1999 Jan;93(1):45–8 **(Ger)**

[Guidelines for therapy of chronic heart failure. German Society of Cardiology--Heart and Cardiovascular Research] Hoppe UC, et al. **Z Kardiol** 1998 Aug;87(8):645–58 (136 ref.) **(Ger)**

[Status of intensified therapy and regionalized allocation of donor hearts in the management of patients with terminal heart failure] Nägele H, et al. **Z Kardiol** 1998 Sep; 87(9):676–82 (Eng. Abstr.) **(Ger)**

[Intra- and extravascular volumes in congestive heart failure and their redistribution following extracorporeal ultrafiltration] Marenzi G, et al. **Cardiologia** 1998 Nov; 43(11):1193–200 (Eng. Abstr.) **(Ita)**

[Management of ventricular arrhythmia in chronic congestive heart failure] Pulignano G, et al. **Clin Ter** 1998 Jul–Aug; 149(4):297–305 (63 ref.) (Eng. Abstr.) **(Ita)**

[Outpatient management program of patients with chronic heart failure] Cacciatore G, et al. **G Ital Cardiol** 1998 Oct; 28(10):1106–12 (Eng. Abstr.) **(Ita)**

[Reflections on the organizational problem of care for the patient with chronic heart failure] Opasich C, et al. **G Ital Cardiol** 1998 Aug;28(8):913–9 **(Ita)**

[Cardiomyocyte transplant--a new treatment for congestive heart failure?] Komeda M. **Nippon Geka Hokan** 1998 Mar 1;67(1):1–2 **(Jpn)**

[Extracorporeal membrane oxygenation in myocardial failure after pediatric heart surgery] Ramos A, et al. **Rev Esp Anestesiol Reanim** 1998 Dec;45(10):436–40 (Eng. Abstr.) **(Spa)**

[Guidelines for the diagnosis and management of heart failure and cardiogenic shock. Informe del Grupo de Trabajo de Insuficiencia Carddiacade la Sociedad Espanñola de Cardiologia] Navarro-López F, et al. **Rev Esp Cardiol** 1999; 52 Suppl 2:1–54 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

M-mode analysis of mitral annulus motion for detection of pseudonormalization of the mitral inflow pattern. Bruch C, et al. **Am J Cardiol** 1999 Sep 15;84(6):692–7

Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. Kono T, et al. **Am J Cardiol** 1999 Sep 1;84(5):578–82

Prognostic value of diastolic filling parameters derived using a novel image processing technique in patients > or = 70 years of age with congestive heart failure. Rich MW, et al. **Am J Cardiol** 1999 Jul 1;84(1):82–6

Diagnosing heart failure [letter; comment] Caruana L, et al. **Eur Heart J** 1999 Mar;20(5):393. Comment on: Eur Heart J 1998 Jul;19(7):990–1003.

Left atrioventricular plane displacement is related to both systolic and diastolic left ventricular performance in patients with chronic heart failure. Willenheimer R, et al. **Eur Heart J** 1999 Apr;20(8):612–8

Central role of echocardiography in the diagnosis and assessment of heart failure. British Society of Echocardiography. Cheesman MG, et al. **Heart** 1998 Nov; 80 Suppl 1:S1–5 (62 ref.)

Outcomes research: evaluating the impact of echocardiography in congestive heart failure [editorial; comment] Friesinger GC 2nd. **J Am Coll Cardiol** 1999 Jan; 33(1):171–3. Comment on: J Am Coll Cardiol 1999 Jan;33(1):164–70.

Effect of congestive heart failure on in vivo canine aortic elastic properties. Khan Z, et al. **J Am Coll Cardiol** 1999 Jan;33(1):267–72

Use of echocardiography in the management of congestive heart failure in the community [see comments] Senni M, et al. **J Am Coll Cardiol** 1999 Jan;33(1):164–70. Comment in: J Am Coll Cardiol 1999 Jan;33(1):171–3.

Two-dimensional and Doppler echocardiography for the assessment of congestive heart failure. Wilansky S. **Tex Heart Inst J** 1998;25(4):260–4 (33 ref.)

[Congestive heart failure in the aged. Diagnosis] Montagne O, et al. **Presse Med** 1999 Mar 27;28(12):661–3 (Eng. Abstr.) **(Fre)**

[Transthoracic recording of pulmonary venous flow for diagnosis of high pulmonary capillary wedge pressure] Kronik G, et al. **Acta Med Austriaca** 1999;26(1):1–7 (Eng. Abstr.) **(Ger)**

[Echocardiographic findings, pro-ANP and treatment in acute myocardial infarction without overt heart failure] Otterstad JE, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20; 119(19):2802–5 (10 ref.) (Eng. Abstr.) **(Nor)**

[The semiquantitative evaluation of systemic vascular resistances in heart failure via an analysis of Doppler aortic flow] Martins S, et al. **Rev Port Cardiol** 1999 Feb; 18(2):141–7 (Eng. Abstr.) **(Por)**

VETERINARY

Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. Ettinger SJ, et al. **J Am Vet Med Assoc** 1998 Dec 1;213(11):1573–7

Factors contributing to the decision for euthanasia of dogs with congestive heart failure. Mallery KF, et al. **J Am Vet Med Assoc** 1999 Apr 15;214(8):1201–4

Observations on the development of congestive heart failure in Irish wolfhounds with dilated cardiomyopathy. Brownlie SE, et al. **J Small Anim Pract** 1999 Aug;40(8):371–7

Plasma atrial and brain natriuretic peptide levels in dogs with congestive heart failure. Asano K, et al. **J Vet Med Sci** 1999 May;61(5):523–9

HEART FUNCTION TESTS

Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity. Yoshikawa T, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):666–71

Evaluation of cardiac functions in patients with thalassemia major. Küçük NO, et al. **Ann Nucl Med** 1999 Jun; 13(3):175–9

Modelling prognostic power of cardiac tests using rough sets. Komorowski J, et al. **Artif Intell Med** 1999 Feb; 15(2):167–91

Conductance artifacts in a novel in vitro model of ventriculothoracic electrical coupling. Hart JP, et al. **ASAIO J** 1999 Jan-Feb;45(1):64–8

Noninvasive assessment of the cardiac baroreflex: response to downward tilting and comparison with the phenylephrine method. Takahashi N, et al. **J Am Coll Cardiol** 1999 Jul;34(1):211–5

Prenatal diagnosis of long QT syndrome using fetal magnetocardiography. Hamada H, et al. **Prenat Diagn** 1999 Jul;19(7):677–80

Evaluation of cardiac function before and after liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep; 31(6):2369–70

[Information of patients preceding electrophysiologic diagnostic procedures] **Arch Mal Coeur Vaiss** 1999 Jan; 92(1):79–80 **(Fre)**

[Noninvasive reperfusion tests: myth or reality?] Mazzoni V, et al. **G Ital Cardiol** 1999 May;29(5):562–4; discussion 565–7 (21 ref.) **(Ita)**

[Obtaining myo-cardial perfusion images synchronized with the ECG (gated-SPEC) after injecting MIBI during exertion: comparative study with echocardiography in 95 patients for the assessment of left ventricular function] Fraile M, et al. **Rev Esp Med Nucl** 1998;17(6):413–8 (Eng. Abstr.) **(Spa)**

ECONOMICS

Coronary calcification by electron beam computed tomography and obstructive coronary artery disease: a model for costs and effectiveness of diagnosis as compared with conventional cardiac testing methods. Rumberger JA, et al. **J Am Coll Cardiol** 1999 Feb;33(2):453–62

METHODS

Assessing flow during minimally invasive coronary artery bypass: an Allen's test equivalent. Aronson S, et al. **Ann Thorac Surg** 1999 Apr;67(4):1173–4

Noninvasive in utero assessment of PR and QRS intervals from the fetal magnetocardiogram. Leuthold A, et al. **Early Hum Dev** 1999 Apr;54(3):235–43

Fetal heart rate variability and complexity in the course of pregnancy. Van Leeuwen P, et al. **Early Hum Dev** 1999 Apr;54(3):259–69

Comparison of cardiac output assessed by pulse-contour analysis and thermodilution in patients undergoing minimally invasive direct coronary artery bypass grafting. Buhre W, et al. **J Cardiothorac Vasc Anesth** 1999 Aug; 13(4):437–40

[The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide] De Sisti A, et al. **G Ital Cardiol** 1998 Dec;28(12):1391–9 (Eng. Abstr.) **(Ita)**

[The improvement of echocardiographic assessment of the left ventricle by the use of perflenapent and harmonic imaging] Olszewski R, et al. **Pol Merkuriusz Lek** 1998 Sep; 5(27):132–4 (Eng. Abstr.) **(Pol)**

STANDARDS

Heart rate variability standards [letter; comment] Kuo CD, et al. **Circulation** 1998 Oct 13;98(15):1589–90. Comment on: Circulation 1996 Mar 1;93(5):1043–65.

VETERINARY

Techniques for evaluation of right ventricular relaxation rate in horses and effects of inhalant anesthetics with and without intravenous administration of calcium gluconate. Grubb TL, et al. **Am J Vet Res** 1999 Jul;60(7):872–9

HEART HYPERTROPHY

Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Ritchie RH, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1370–4

Developed pressure data may provide misinformation when used alone to evaluate systolic function in isovolumetric left ventricle preparations. Murad N, et al. **Braz J Med Biol Res** 1999 Jun;32(6):773–6

Rat models of hypertension, cardiac hypertrophy and failure. Doggrell SA, et al. **Cardiovasc Res** 1998 Jul;39(1):89–105 (194 ref.)

Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. Sato Y, et al. **J Biol Chem** 1998 Oct 23;273(43):28470–7

Cardiac transgenic and gene-targeted mice as models of cardiac hypertrophy and failure: a problem of (new) riches [editorial; comment] Izumo S, et al. **J Card Fail** 1998 Dec; 4(4):263–70 (46 ref.). Comment on: J Card Fail 1998 Dec;4(4):349–61.

Calcineurin inhibitors and cardiac hypertrophy [letter] Luo Z, et al. **Nat Med** 1998 Oct;4(10):1092–3

CHEMICALLY INDUCED

Which course of dexamethasone? [letter; comment] Bloomfield FH, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F80. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Mar;78(2):F133–7.

Minoxidil-induced cardiac hypertrophy in guinea pigs. van der Velden J, et al. **Cell Mol Life Sci** 1999 May; 55(5):788–98

Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Yu F, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):71–4

Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Scheinowitz M, et al. **Exp Physiol** 1998 Sep;83(5):585–93

Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. Zou Y, et al. **J Biol Chem** 1999 Apr 2;274(14):9760–70

Chronic colchicine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Tsutsui H, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1203–13

2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor. Wolkowicz PE, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1405–12

Plasma and muscle polyamine levels in aerobically exercised rats treated with salbutamol. Cepero M, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1059–64

Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat. Burtea C, et al. **MAGMA** 1998 Dec;7(3):184–98

COMPLICATIONS

Factors relating to left atrial enlargement in atrial fibrillation: "chicken or the egg" hypothesis [editorial; comment] Thamilarasan M, et al. **Am Heart J** 1999 Mar;137(3):381–3 . Comment on: Am Heart J 1999 Mar;137(3):494–9.

The functional significance of ventricular geometry for the transition from hypertrophy to cardiac failure. Does a critical degree of structural dilatation exist? [editorial] Jacob R, et al. **Basic Res Cardiol** 1998 Dec;93(6):423–9 (55 ref.)

Coronary embolism in hypertrophic cardiomyopathy [letter] Hoshide S, et al. **Blood Coagul Fibrinolysis** 1998 Sep; 9(6):553–4

Extreme left atrial enlargement causing upward displacement and compression of the right pulmonary artery [letter] Mandalay A, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):115–6

Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Iwanaga Y, et al. **Circulation** 1998 Nov 10;98(19):2065–73

Atrial arrhythmia in atrial septal defect [letter] Conraads V, et al. **N Engl J Med** 1999 Aug 12;341(7):540–1

Spinal muscular atrophy-like picture, cardiomyopathy, and cytochrome c oxidase deficiency. Rubio-Gozalbo ME, et al. **Neurology** 1999 Jan 15;52(2):383–6

Sudden death due to ventricular septal defect. Cohle SD, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):327–32 (29 ref.)

[Mechanism of spontaneous occurrence of tachycardia] Leenhardt A, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92 Spec No 1:17–22 (Eng. Abstr.) **(Fre)**

[A rare cause of right heart insufficiency: idiopathic dilatation of the right atrium (a case report) (letter)] Niakara A, et al. **Tunis Med** 1999 Mar;77(3):170–1 **(Fre)**

CONGENITAL

Congenital hypertrichosis, osteochondrodysplasia, and cardiomegaly: Cantú syndrome. Robertson SP, et al. **Am J Med Genet** 1999 Aug 6;85(4):395–402

Adverse neonatal effects of maternal labetalol treatment. Crooks BN, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F150–1

Bilateral renal agenesis, cardiac hypertrophy and pancytopenia, a new syndrome? Lynch SA, et al.

Clin Dysmorphol 1998 Oct;7(4):285–8
[Congenital heart disease and nuchal translucency with normal karyotype. Report of 3 cases] Gicquel JM, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):625–8 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Clinical manifestation and survival of patients with idiopathic bilateral atrial dilatation. Arima M, et al. **Intern Med** 1999 Feb;38(2):112–8
Lipomatous hypertrophy of the atrial septum: diagnosis with fat suppressed MR imaging. Mortele KJ, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1172–4
Fetal cerebral AV-malformation and cardiomegaly, diagnostic and therapeutic problems. Keck C, et al. **J Perinat Med** 1998;26(3):225–30
Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat. Burtea C, et al. **MAGMA** 1998 Dec;7(3):184–98
Using an improved back-propagation learning method to diagnose the sites of cardiac hypertrophy. Ouyang N, et al. **MD Comput** 1999 Jan–Feb;16(1):79–81
[Diagnosis of hypertrophic cardiomyopathy. Validation of criteria using genetics] Charron P. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):65–8 (12 ref.) (Eng. Abstr.) **(Fre)**
["Cardiomegaly and pneumonia"—a misdiagnosis in long-standing achalasia] Endlicher E, et al. **Dtsch Med Wochenschr** 1999 Apr 1;124(13):386–90 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Fagan JM, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):100–3
What is apoptosis and what is its relevance to vascular biology? Hamet P. **Can J Cardiol** 1999 Apr;15 Suppl B:5B–7B
Calcineurin inhibition as therapy for cardiac hypertrophy and heart failure: requiescat in pace? [editorial; comment] Walsh RA. **Circ Res** 1999 Apr 2;84(6):741–3. Comment on: Circ Res 1999 Apr 2;84(6):623–32. Comment on: Circ Res 1999 Apr 2;84(6):633–46. Comment on: Circ Res 1999 Apr 2;84(6):722–8. Comment on: Circ Res 1999 Apr 2;84(6):729–34. Comment on: Circ Res 1999 Apr 2;84(6):735–40.
Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Bartunek J, et al. **Circulation** 1999 Jan 5–12;99(1):22–5
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Lakkis NM, et al. **Circulation** 1998 Oct 27;98(17):1750–5
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. Kuwajima M, et al. **FEBS Lett** 1999 Jan 29;443(3):261–6
Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Tea BS, et al. **Hypertension** 1999 Aug;34(2):229–35
Angiotensin blocking drugs and the heart beyond 2000. Morgan TO, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S243–7 (39 ref.)
Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients. Leenen FH. **J Hypertens Suppl** 1998 Oct;16(5):S9–15 (33 ref.)
Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin-converting enzyme inhibition. Coirault C, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):70–5
Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. Kai T, et al. **Jpn Circ J** 1998 Aug; 62(8):599–603
[Modelling of myocardial hypertrophy in vitro for solving problems of medicinal correction] Moiseeva OM, et al. **Tsitologiia** 1998;40(12):1025–30 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Early response kinase and PI 3-kinase activation in adult cardiomyocytes and their role in hypertrophy. Schlüter KD, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1655–63
Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Schlüter KD, et al. **Cardiovasc Res** 1998 Oct;40(1):174–81
Propranolol and bepridil attenuating levothyroxine-induced rat cardiac hypertrophy and mitochondrial Ca2+ Mg(2+)-ATPase activity elevation. Chen DD, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):516–8
Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? [see comments] Olson EN, et al. **Circ Res** 1999 Apr 2;84(6):623–32 (113 ref.). Comment in: Circ Res 1999 Apr 2;84(6):633–46. Comment in: Circ Res 1999 Apr 2;84(6):741–3.
The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Sack MN, et al. **Int J Mol Med** 1998 Jan;1(1):17–24 (39 ref.)
Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation. Small K, et al. **J Biol Chem** 1999 Jul 23;274(30):21291–6
Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. Choukroun G, et al. **J Clin Invest** 1999 Aug; 104(4):391–8
Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats. Boateng SY, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2683–94
Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase protein expression in compensated primary and secondary human cardiac hypertrophy. Schotten U, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1483–94
[Expression of mitogen-activated protein kinase in hypertrophic myocardium in SHRsp] Wang M, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):680–2 (Eng. Abstr.) **(Chi)**
[Polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase genes in people with arterial hypertension, left ventricular hypertrophy, and hypertrophic cardiomyopathy] Stepanov VA, et al. **Genetika** 1998 Nov;34(11):1578–81 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats. Wählander H, et al. **Acta Physiol Scand** 1999 Feb;165(2):143–54
Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor [see comments] Ozkahya M, et al. **Am J Kidney Dis** 1999 Aug; 34(2):218–21. Comment in: Am J Kidney Dis 1999 Aug;34(2):359–61.
Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Tamamori M, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2036–40
Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Dhalla NS, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:100–10
Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Holtz J. **Basic Res Cardiol** 1998;93 Suppl 2:92–100 (65 ref.)
Cardiac hypertrophy in copper-deficient rats is owing to increased mitochondria. Mao S, et al. **Biol Trace Elem Res** 1998 Summer;64(1–3):175–84
Left atrial enlargement in infancy secondary to a fistula from the proximal left coronary artery. Dhillon R, et al. **Cardiol Young** 1999 Mar;9(2):228–9
Modulation of the pacemaker current If by beta-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats. Cerbai E, et al. **Cardiovasc Res** 1999 Apr;42(1):121–9
Insulin resistance in patients with cardiac hypertrophy [see comments] Paternostro G, et al. **Cardiovasc Res** 1999 Apr; 42(1):246–53. Comment in: Cardiovasc Res 1999 Apr;42(1):12–4.
Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats. Zolk O, et al. **Cardiovasc Res** 1998 Jul;39(1):242–56 (144 ref.)
Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Aikawa R, et al. **Circ Res** 1999 Mar 5;84(4):458–66
Cellular distribution of Ca2+ pumps and Ca2+ release channels in rat cardiac hypertrophy induced by aortic stenosis. Anger M, et al. **Circulation** 1998 Dec 1; 98(22):2477–86
Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease. Brahimi M, et al. **Clin Sci (Colch)** 1998 Sep;95(3):261–7
Electrocardiographic consequences of a peripatetic lifestyle in gray wolves (Canis lupus). Constable P, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):557–63
Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Dutka DP, et al. **Heart** 1999 Feb; 81(2):141–7
Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. Schultz JE, et al. **J Clin Invest** 1999 Sep;104(6):709–19
Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. Kobori H, et al. **J Endocrinol** 1999 Jan;160(1):43–7
Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. Kai T, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2045–9
Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients. Leenen FH. **J Hypertens Suppl** 1998 Oct;16(5):S9–15 (33 ref.)
Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. Dotti MT, et al. **J Neurol** 1998 Nov;245(11):723–6
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. Jalil A, et al. **Life Sci** 1999;64(13):1137–44
Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. Okada T, et al. **Pediatr Int** 1999 Feb;41(1):90–3
[Ca2+ signaling in cardiac E-C coupling and its modulation in cardiac hypertrophy and heart failure] Endoh M. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1753–60 (55 ref.) **(Jpn)**

GENETICS

Chymase gene locus is not associated with myocardial infarction and is not linked to heart size or blood pressure. Pfeufer A, et al. **Am J Cardiol** 1998 Oct 15;82(8):979–81
Early captopril treatment prevents hypertrophydependent gene expression in hearts of SHR. Chen S, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1511–7
In vitro analysis of SERCA2 gene regulation in hypertrophic cardiomyocytes and increasing transfection efficiency by gene-gun biolistics. Eizema K, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:111–24
Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Wagner M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:1–10 (36 ref.)
Clinical expression in patients with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutation [letter; comment] Doi YL, et al. **Circulation** 1999 Jul 27;100(4):448–9. Comment on: Circulation 1998 Jun 9;97(22):2230–6.
Genetic determination of cardiac mass in normotensive rats: results from an F344xWKY cross. Sebkhi A, et al. **Hypertension** 1999 Apr;33(4):949–53
Cardiac hypertrophic and developmental regulation of the beta-tubulin multigene family. Narishige T, et al. **J Biol Chem** 1999 Apr 2;274(14):9692–7
Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation. Small K, et al. **J Biol Chem** 1999 Jul 23;274(30):21291–6
Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. Xie Z, et al. **J Biol Chem** 1999 Jul 2;274(27):19323–8
cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy. Anderson KM, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):705–19
Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. Schoenfeld JR, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2269–80
Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Depre C, et al. **Nat Med** 1998 Nov; 4(11):1269–75
Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice. Honda H, et al. **Oncogene** 1999 Jul 1;18(26):3821–30
Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Engelhardt S, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7059–64
Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Mende U, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13893–8

METABOLISM

Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Barger PM, et al. **Am J Med Sci** 1999 Jul;318(1):36–42 (30 ref.)
The molecular mechanism of cardiac hypertrophy and failure. Yamazaki T, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:38–48 (43 ref.)
Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Saadane N, et al. **Br J Pharmacol** 1999 Jul;127(5):1165–76
G alpha 13 stimulates gene expression and increases cell size in cultured neonatal rat ventricular myocytes. Finn SG, et al. **Cardiovasc Res** 1999 Apr;42(1):140–8
Paracrine hypertrophic factors from cardiac non-myocyte cells downregulate the transient outward current density and Kv4.2 K+ channel expression in cultured rat cardiomyocytes. Guo W, et al. **Cardiovasc Res** 1999 Jan; 41(1):157–65
Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. Nishiyama A, et al. **Cardiovasc Res** 1998 Nov;40(2):343–51
Angiotensin and endothelin: messengers that couple ventricular stretch to the Na+/H+ exchanger and cardiac hypertrophy [editorial] Dostal DE, et al. **Circ Res** 1998 Oct 19;83(8):870–3
Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Serneri GG, et al. **Circ Res** 1999 Jul 9;85(1):57–67
Cellular distribution of Ca2+ pumps and Ca2+ release channels in rat cardiac hypertrophy induced by aortic stenosis. Anger M, et al. **Circulation** 1998 Dec 1; 98(22):2477–86
Beta-protein kinase C and hypertrophic signaling in human heart failure [editorial; comment] Simpson PC. **Circulation** 1999 Jan 26;99(3):334–7. Comment on: Circulation 1999 Jan 26;99(3):384–91.
Myocardial beta-adrenergic reactivity in volume overload-induced cardiac hypertrophy in the rat. Communal C, et al. **Fundam Clin Pharmacol** 1998;

12(4):411-9
Myocardial beta-adrenergic reactivity in pressure overload-induced cardiac hypertrophy in the rat. Communal C, et al. **Fundam Clin Pharmacol** 1998; 12(6):590-8
Signaling pathways mediating the response to hypertrophic stress in the heart. Force T, et al. **Gene Expr** 1999; 7(4-6):337-48 (74 ref.)
Heat shock protein expression in hearts hypertrophied by genetic and nongenetic hypertension. Iwabuchi K, et al. **Heart Vessels** 1998;13(1):30-9
c-Src activation plays a role in endothelin-dependent hypertrophy of the cardiac myocyte. Kovačič B, et al. **J Biol Chem** 1998 Dec 25;273(52):35185-93
Perindopril effects on angiotensin I elimination in lung after experimental myocardial injury induced by intracoronary microembolization in rats. Kalenikova EI, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):608-15
Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice. Tsoporis JN, et al. **J Clin Invest** 1998 Oct 15;102(8):1609-16
Morphometric and biochemical characteristics of ventricular hypertrophy in male rainbow trout (Oncorhynchus mykiss). Clark RJ, et al. **J Exp Biol** 1998 May;201 (Pt 10):1541-52
Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. Poolman RA, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2121-35
Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. Wambolt RB, et al. **J Mol Cell Cardiol** 1999 Mar; 31(3):493-502
Cellular mechanisms of cardiac hypertrophy. Sugden PH, et al. **J Mol Med** 1998 Oct;76(11):725-46 (307 ref.)
Inhibitory effect of tranilast on hypertrophic collagen production in the spontaneously hypertensive rat heart. Umemura K, et al. **Jpn J Pharmacol** 1998 Oct;78(2):161-7
Differential influence of fasting and BM13.907 treatment on growth and phenotype of pressure overloaded rat heart. Rupp H, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):209-15
Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy. Rabindranauth P, et al. **Res Exp Med (Berl)** 1998 Jul;198(1):11-21

MORTALITY

Clinical manifestation and survival of patients with idiopathic bilateral atrial dilatation. Arima M, et al. **Intern Med** 1999 Feb;38(2):112-8

PATHOLOGY

Are interatrial band myocytes maximally hypertrophied in normal canine hearts? Dolber PC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1225-35
Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. King KL, et al. **Endocrine** 1998 Aug;9(1):45-55
Hypertrophic responses of cardiomyocytes induced by endothelin-1 through the protein kinase C-dependent but Src and Ras-independent pathways. Yamazaki T, et al. **Hypertens Res** 1999 Jul;22(2):113-9
Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Onodera T, et al. **Hypertension** 1998 Oct;32(4):753-7
A post-transcriptional compensatory pathway in heterozygous ventricular myosin light chain 2-deficient mice results in lack of gene dosage effect during normal cardiac growth or hypertrophy. Minamisawa S, et al. **J Biol Chem** 1999 Apr 9;274(15):10066-70
Morphometric and biochemical characteristics of ventricular hypertrophy in male rainbow trout (Oncorhynchus mykiss). Clark RJ, et al. **J Exp Biol** 1998 May;201 (Pt 10):1541-52
Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. Autelitano DJ, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1515-23
Chronic colchicine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Tsutsui H, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1203-13
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. Duncan AM, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):295-303
Reversing effects of DDPH on cardiac hypertrophy and increased collagen content induced by partial narrowing of abdominal aorta. Zhang Z, et al. **J Tongji Med Univ** 1997;17(3):147-50
[An autopsy case of elderly idiopathic enlargement of the right atrium] Ohshita T, et al. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):59-64 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors] Frolov VA, et al. **Biull Eksp Biol Med** 1999 May;127(5):506-9 **(Rus)**
[Arterial hypertension, cardiomegaly, heart failure and interstitial pulmonary images (clinical conference)] **Medicina (B Aires)** 1998;58(5 Pt 1):515-21 **(Spa)**

PHYSIOPATHOLOGY

Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Grupp IL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1338-50
Microtubules modulate cardiomyocyte beta-adrenergic response in cardiac hypertrophy. Palmer BM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1707-16
Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Dhalla NS, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:100-10
Myocardial response to stress in cardiac hypertrophy and heart failure: effect of antihypertensive drugs. Sen S. **Ann N Y Acad Sci** 1999 Jun 30;874:125-33
Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Wagner M, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:1-10 (36 ref.)
Endothelium-dependent vasodilatation in Sprague-Dawley rats with postinfarction hypertrophy: lack of endothelial dysfunction in vitro. Brandes RP, et al. **Basic Res Cardiol** 1998 Dec;93(6):463-9
Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. K.-Laflamme A, et al. **Can J Physiol Pharmacol** 1998 Jun; 76(6):665-75
Comparison of the contractile performance of the hypertrophied myocardium from spontaneous hypertensive rats and normotensive infarcted rats. Mill JG, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):387-94
Diastolic function and dysfunction with exercise, hypertrophy, ischemia, and heart failure. Apstein CS, et al. **Cardiologia** 1998 Dec;43(12):1269-79 (81 ref.)
Cardiac variant of Fabry's disease mimicking hypertrophic cardiomyopathy. Chimenti C, et al. **Cardiologia** 1999 May; 44(5):469-73
Signalling pathways for cardiac hypertrophy. Yamazaki T, et al. **Cell Signal** 1998 Nov;10(10):693-8 (59 ref.)
Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Shorofsky SR, et al. **Circ Res** 1999 Mar 5;84(4):424-34
Troponin I, stunning, hypertrophy, and failure of the heart [editorial; comment] Solaro RJ. **Circ Res** 1999 Jan 8-22; 84(1):122-4 (19 ref.). Comment on: Circ Res 1999 Jan 8-22;84(1):1-8. Comment on: Circ Res 1999 Jan 8-22;84(1):9-20.
Clinical expression in patients with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutation [letter; comment] Doi YL, et al. **Circulation** 1999 Jul 27;100(4):448-9. Comment on: Circulation 1998 Jun 9;97(22):2230-6.
Mechanoenergetic alterations during the transition from cardiac hypertrophy to failure in Dahl salt-sensitive rats. Kameyama T, et al. **Circulation** 1998 Dec 22-29; 98(25):2919-29
Glucose transporter upregulation improves ischemic tolerance in hypertrophied failing heart. Takeuchi K, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II234-9; discussion II240-1
Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. Kai T, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):206-11
Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart. Pan J, et al. **Heart Vessels** 1998; 13(4):199-208
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Anderson NH, et al. **Hypertension** 1999 Jan;33(1 Pt 2):248-55
Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. Iaccarino G, et al. **Hypertension** 1999 Jan;33(1 Pt 2):396-401
Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Tea BS, et al. **Hypertension** 1999 Aug;34(2):229-35
Effects of myocardial hypertrophy on neural reflexes controlling cardiovascular function. Meyrelles SS, et al. **J Auton Nerv Syst** 1998 Nov 10;73(2-3):135-42
Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes. Straznicka M, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):229-36
Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. Choukroun G, et al. **J Clin Invest** 1998 Oct 1; 102(7):1311-20
Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. Kai T, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2045-9
Sympatho-adrenal mechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine? Bobik A, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S51-4 (32 ref.)
Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. Kramer CM, et al. **J Mol Cell Cardiol** 1998 Sep;30(9):1773-8
Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **J Mol Cell Cardiol** 1999 May;31(5):949-70 (156 ref.)
Effects of angiotensin II on inotropy and intracellular Ca2+ handling in normal and hypertrophied rat myocardium. Meissner A, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2507-18
L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. Mukherjee R, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1899-916 (125 ref.)
Signal transduction and transcriptional adaptation in embryonic heart development and during myocardial hypertrophy. Ghatpande S, et al. **Mol Cell Biochem** 1999 Jun;196(1-2):93-7 (50 ref.)
Differential influence of fasting and BM13.907 treatment on growth and phenotype of pressure overloaded rat heart. Rupp H, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):209-15
A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Abdellatif M, et al. **Mol Cell Biol** 1998 Nov;18(11):6729-36
Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Dorn GW 2nd, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6400-5
[Mechanism involved in the onset of heart failure] Sasayama S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1667-81 (114 ref.) **(Jpn)**
[Transcriptional signal pathway for cardiac hypertrophy is discovered. New base for new drugs against heart failure?] Sylvén C. **Lakartidningen** 1998 Nov 11;95(46):5189-90 **(Swe)**

PREVENTION & CONTROL

Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. Brosnan MJ, et al. **Am J Hypertens** 1999 Jul;12(7):724-31
Cardiovascular effects of captopril and enalapril in obese Zucker rats. Duarte J, et al. **Eur J Pharmacol** 1999 Jan 22;365(2-3):225-32
Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis. Kalkman EA, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):339-48
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Oi S, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):139-48
Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats. Kristek F. **Exp Physiol** 1998 Sep;83(5):595-603
Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Brodsky S, et al. **Hypertension** 1998 Oct;32(4):746-52
Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. Ambrose J, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):433-9
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. Carraway JW, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):451-60
Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction. Yoshida K, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):357-65
Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. Kyselovic J, et al. **J Hypertens** 1998 Oct;16(10):1515-22
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction. Yoshida K, et al. **Jpn Circ J** 1998 Sep;62(9):680-6
Calcineurin inhibitors and cardiac hypertrophy. Force T, et al. **Lancet** 1999 Apr 17;353(9161):1290-2
Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Lijnen P, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun;21(5):363-74 (113 ref.)

RADIOGRAPHY

An unusual cardiomegaly: the giant left atrium. Bertoli D, et al. **Clin Cardiol** 1998 Dec;21(12):918
Effect of aging on cardiothoracic ratio in women: a longitudinal study. Inoue K, et al. **Gerontology** 1999 Jan-Feb;45(1):53-8

RADIONUCLIDE IMAGING

[Assessment of enlarged left atrium with 99mTc-tetrofosmin SPECT and echocardiography] Taniguchi Y, et al. **Kaku Igaku** 1998 Jul;35(6):421-6 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Left atrial enlargement in infancy secondary to a fistula from the proximal left coronary artery. Dhillon R, et al. **Cardiol Young** 1999 Mar;9(2):228-9
An unusual cardiomegaly: the giant left atrium. Bertoli D, et al. **Clin Cardiol** 1998 Dec;21(12):918
Right lateral transthoracic approach mimicking standard

transesophageal echocardiographic views in a patient with giant left atrium. Delgado C, et al.
J Am Soc Echocardiogr 1999 Apr;12(4):275-7
Cardiac changes in fetuses secondary to immune hemolytic anemia and their relation to hemoglobin and catecholamine concentrations in fetal blood. Oberhoffer R, et al.
Ultrasound Obstet Gynecol 1999 Jun;13(6):396-400
[A rare cause of right heart insufficiency: idiopathic dilatation of the right atrium (a case report) (letter)] Niakara A, et al. **Tunis Med** 1999 Mar;77(3):170-1 **(Fre)**

HEART INJURIES

[Penetrating gunshot wound of left heart ventricle] Nosov SS, et al. **Khirurgiia (Mosk)** 1998;(12):55 **(Rus)**

CHEMICALLY INDUCED

A simple reproducible model of free radical-injured isolated heart induced by 1,1-diphenyl-2-picryl-hydrazyl (DPPH). Jin ZQ, et al. **J Pharmacol Toxicol Methods** 1998 Mar; 39(2):63-70

COMPLICATIONS

Commotio cordis: sudden cardiac death in athletes. Futterman LG, et al. **Am J Crit Care** 1999 Jul;8(4):270-2
Recurrent pericardial effusion due to gunshot wound of the heart in a hemodynamically stable child--a case report. Tutar HE, et al. **Angiology** 1999 Apr;50(4):337-40 (12 ref.)
Damage-induced arrhythmias: reversal of excitation-contraction coupling. ter Keurs HE, et al.
Cardiovasc Res 1998 Dec;40(3):444-55 (70 ref.)
Self-inflicted intramyocardial injury [letter; comment] Frankel KM. **Chest** 1998 Oct;114(4):1225. Comment on: Chest 1998 Feb;113(2):531-4.
An isolated ventricular septal defect as a consequence of penetrating injury to the heart. Těšínský L, et al.
Eur J Cardiothorac Surg 1999 Feb;15(2):221-3
Post-traumatic multilobated pseudoaneurysm of the left ventricle secondary to dissecting intramyocardial haematoma of the posterior wall: obstructive and fenestrated communication demonstrated by colour Doppler imaging. Mohan JC, et al. **Indian Heart J** 1998 Sep-Oct;50(5):539-41
Acute traumatic cardiac tamponade treated solely by percutaneous pericardial drainage. Graham CA, et al.
Injury 1998 Jul;29(6):473-4
Ventricular tachycardia as a consequence of a suicidal stabbing injury to the heart. Rakovec P, et al.
J Cardiovasc Electrophysiol 1999 Jun;10(6):894
Traumatic tricuspid regurgitation complicating endocarditis and right-to-left intracardiac shunt. A case report of successful operation. Liu YB, et al.
J Cardiovasc Surg (Torino) 1998 Oct;39(5):663-5
Treatment of severe cardiac contusion with a left ventricular assist device in a patient with multiple trauma. Chavanon O, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):189-90
Commotio cordis and atrial fibrillation [letter] Ghose RR. **N Z Med J** 1998 Oct 9;111(1075):394
Right coronary artery dissection and acute infarction due to blunt trauma: report of a case. Kawahito K, et al.
Surg Today 1998;28(9):971-3

DIAGNOSIS

Blunt traumatic rupture of the heart: case report and selected review. Shalaby RI, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):123-9
A bullet in the heart. Wainsztein N, et al. **Circulation** 1999 Sep 21;100(12):1361
Bullet in the heart. Mahenthiran J, et al. **Clin Cardiol** 1999 Feb;22(2):128
Cardiac injury from an air gun pellet: a case report. Alaminos Mingorance M, et al. **Eur J Pediatr Surg** 1999 Jun; 9(3):184-5
Improved detection of radiofrequency current-induced minor myocardial injury by cardiac troponin T measurement. Sribhen K, et al. **J Med Assoc Thai** 1999 Mar;82(3):256-62
Troponin T in legal medicine [letter] Dressler J, et al.
Lancet 1998 Jul 4;352(9121):38
Perforation of the right ventricular free wall by an active fixation transvenous cardioverter defibrillator lead. Shohat-Zabarski R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1118-9
Blunt cardiac rupture. Fulton JO, et al. **S Afr J Surg** 1998 Nov;36(4):132-5
[Ventricular rupture after blunt thoracic trauma] Byhahn C, et al. **Anaesthesiol Reanim** 1999;24(2):47-50 (Eng. Abstr.) **(Ger)**
[The characteristics of the diagnosis, intensive therapy and surgical procedure in contusions of the heart] Gumanenko EK, et al. **Vestn Khir Im I I Grek** 1998;157(4):53-6 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Release kinetics of cardiac troponin I and cardiac troponin T in effluents from isolated perfused rabbit hearts after graded experimental myocardial contusion. Bertinchant JP, et al. **J Trauma** 1999 Sep;47(3):474-80

EPIDEMIOLOGY

Penetrating cardiac trauma at an urban trauma center: a 22-year perspective. Thourani VH, et al. **Am Surg** 1999 Sep;65(9):811-6; discussion 817-8

ETIOLOGY

Effects of repeated electrical defibrillations on cardiac troponin I levels. Joglar JA, et al. **Am J Cardiol** 1999 Jan 15;83(2):270-2, A6
Indwelling catheter-induced right ventricular rupture. Nuño IN, et al. **Ann Thorac Surg** 1999 Sep;68(3):1085-6
Septal branch right ventricular fistula: a complication in coronary artery snaring. Tanemoto K, et al.
Ann Thorac Surg 1999 Jul;68(1):246-8
Percutaneous closure of a left ventricular perforation post balloon mitral valvotomy. Ruiz CE, et al.
Catheter Cardiovasc Interv 1999 Sep;48(1):78-83
Perforation of the right ventricle: a complication of blind placement of a chest tube into the postpneumonectomy space. Kopec SE, et al. **Chest** 1998 Oct;114(4):1213-5
High-voltage injury resulting in permanent right heart dysfunction. McGill MP, et al. **Chest** 1999 Feb;115(2):586-7
Right ventricular rupture during closed-chest cardiopulmonary resuscitation after pneumonectomy with pericardiotomy: a case report. Kempen PM, et al.
Crit Care Med 1999 Jul;27(7):1378-9
Penetrating injuries of heart and great vessels in patients wounded during the 1992-1994 war in Bosnia and Herzegovina. Delibegović Dedić S, et al. **Croat Med J** 1999 Mar;40(1):85-7
Isolated pericardial rupture with left-sided haematothorax after blunt chest trauma. Verkroost MW, et al.
Eur J Cardiothorac Surg 1998 Nov;14(5):517-9
Minor myocardial damage and inflammatory response after three different procedures of left anterior descending artery revascularization. De Paulis R, et al. **G Ital Cardiol** 1999 Apr;29(4):375-82
Late complications following permanent pacemaker implantation or elective unit replacement. Harcombe AA, et al. **Heart** 1998 Sep;80(3):240-4
Flail tricuspid valve in a patient with history of stab chest wound [letter] Morelli S, et al. **Int J Cardiol** 1998 Sep 1; 66(1):111-3
Catheter-induced mechanical trauma to accessory pathways during radiofrequency ablation: incidence, predictors and clinical implications. Belhassen B, et al.
J Am Coll Cardiol 1999 Mar;33(3):767-74
Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. Hurst TM, et al. **J Am Coll Cardiol** 1999 Aug;34(2):402-8
Elective internal mammary node irradiation: it is not an all or nothing question [letter; comment] Marks LB, et al.
J Clin Oncol 1998 Dec;16(12):3918. Comment on: J Clin Oncol 1998 Aug;16(8):2579-82. Comment on: J Clin Oncol 1998 Aug;16(8):2625-31. Comment on: J Clin Oncol 1998 Aug;16(8):2886-9.
Biomechanical predictor of commotio cordis in high-speed chest impact. Bir CA, et al. **J Trauma** 1999 Sep;47(3):468-73
Cardiac nail gun injuries: lessons learned. Vosswinkel JA, et al. **J Trauma** 1999 Sep;47(3):588-90 (21 ref.)
Recovery after prolonged cross-clamping tepid blood cardioplegia: report of a case. Katoh T, et al.
Surg Today 1998;28(10):1095-7
[Traumatic coronary dissection caused by deceleration. Report of a case] Sosner P, et al.
Arch Mal Coeur Vaiss 1999 Jan;92(1):65-8 (Eng. Abstr.) **(Fre)**
[Heart perforation following transvenous implantation of a cardiac pacemaker] Trigano JA, et al. **Presse Med** 1999 Apr 24;28(16):836-40 (Eng. Abstr.) **(Fre)**
[Throat discomfort developing immediately after left ventriculography] Matsushita T, et al. **J Cardiol** 1999 Aug; 34(2):97-9 **(Jpn)**
[Comparison of myocardial injuries due to CO2 laser and Ho:YAG Laser in transmyocardial laser revascularization] Nakamura M, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec; 99(12):873 **(Jpn)**
[Totally implantable venous systems and cardiac tamponade. Apropos of a case (letter)] Casas Garcia MC, et al.
Rev Esp Anestesiol Reanim 1999 Jan;46(1):48-9 **(Spa)**

HISTORY

[Wounds of the heart and their surgical treatment. 1927 (excerpts from the book) (classical article)] Dzhanelidze Iulu. **Vestn Khir Im I I Grek** 1998;157(3):107-10 **(Rus)**
[Heart injuries] Quijano-Pitman F. **Gac Med Mex** 1999 Mar-Apr;135(2):200 **(Spa)**

METABOLISM

Morphological findings of 'cardiac concussion' due to experimental blunt impact to the precordial region. Guan DW, et al. **Forensic Sci Int** 1999 Mar 29;100(3):211-20

MORTALITY

Prolonged activity after an ultimately fatal gunshot wound to the heart: case report. Juvin P, et al.
Am J Forensic Med Pathol 1999 Mar;20(1):10-2

PHYSIOPATHOLOGY

Cellular cardiomyoplasty improves diastolic properties of injured heart. Atkins BZ, et al. **J Surg Res** 1999 Aug; 85(2):234-42
Disruptive forces for swine heart, liver, and spleen: their breaking stresses. Seki S, et al. **J Trauma** 1998 Dec; 45(6):1079-83

RADIOGRAPHY

Images in cardiovascular medicine. Sewing needle transfixing the posterior wall of the left ventricle causes death. Rossi MA, et al. **Circulation** 1999 Feb 16;99(6):843-4
Blunt vena azygos trauma: report of a case and review of world literature. Sharma OP, et al. **J Trauma** 1999 Jan; 46(1):192-5 (17 ref.)

RADIONUCLIDE IMAGING

Old traumatic ventricular septal defect seen on myocardial perfusion imaging. Wadhwa SS, et al. **Clin Nucl Med** 1999 Feb;24(2):135

SURGERY

Penetrating cardiac injuries. Mittal V, et al. **Am Surg** 1999 May;65(5):444-8
Successful repair of blunt cardiac rupture involving both ventricles. Duda AM, et al. **Cardiovasc Surg** 1999 Mar; 7(2):263-5
Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Reinecke H, et al. **Circulation** 1999 Jul 13;100(2):193-202
Intra-cardiac shrapnel--innocuous or dangerous? Singh RS, et al. **Indian Heart J** 1998 Jul-Aug;50(4):451-2
Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures. The Mayo Clinic experience. Tsang TS, et al.
J Am Coll Cardiol 1998 Nov;32(5):1345-50
Blunt cardiac trauma: successful repair of right atrium rupture. Song MH, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):473-4
Comparison of staples versus sutures in the repair of penetrating cardiac wounds. Mayrose J, et al. **J Trauma** 1999 Mar;46(3):441-3; discussion 443-4
Cardiac nail gun injuries: lessons learned. Vosswinkel JA, et al. **J Trauma** 1999 Sep;47(3):588-90 (21 ref.)
Successful surgical management of penetrating cardiac injury. Yamada S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):953-6
[Application of heparin-coated PCPS for traumatic cardiac rupture: report of a case] Doi K, et al. **Kyobu Geka** 1998 Sep;51(10):817-20 (Eng. Abstr.) **(Jpn)**
[Successful repair of tricuspid regurgitation due to blunt trauma] Hige K, et al. **Kyobu Geka** 1998 Nov; 51(12):1047-50 (Eng. Abstr.) **(Jpn)**
[A repeated wound of the heart] Maloshtan AV, et al.
Klin Khir 1998;(9-10):87 **(Rus)**
[The successful treatment of a heart wound in severe combined closed trauma] Gumanenko EK, et al.
Vestn Khir Im I I Grek 1998;157(4):103-4 **(Rus)**
[Wounds of the heart (editorial)] Shevchenko IuL.
Vestn Khir Im I I Grek 1998;157(5):9-15 (Eng. Abstr.) **(Rus)**

THERAPY

Coronary vessel perforation during balloon angioplasty: a case report [see comments] Hadjimiltiades S, et al.
Cathet Cardiovasc Diagn 1998 Dec;45(4):417-20. Comment in: Cathet Cardiovasc Diagn 1998 Dec;45(4):421.
The cure for a rainy day [editorial; comment] Heuser RR. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):421. Comment on: Cathet Cardiovasc Diagn 1998 Dec;45(4):417-20.
Percutaneous closure of a left ventricular perforation post balloon mitral valvotomy. Ruiz CE, et al.
Catheter Cardiovasc Interv 1999 Sep;48(1):78-83
Treatment of severe cardiac contusion with a left ventricular assist device in a patient with multiple trauma. Chavanon O, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):189-90

ULTRASONOGRAPHY

Blunt cardiac rupture: the utility of emergency department ultrasound. Symbas NP, et al. **Ann Thorac Surg** 1999 May; 67(5):1274-6
Delayed rupture of the mitral valve complicating blunt chest trauma. Farmery AD, et al. **J Accid Emerg Med** 1998 Nov; 15(6):422-3
The role of ultrasound in patients with possible penetrating cardiac wounds: a prospective multicenter study. Rozycki GS, et al. **J Trauma** 1999 Apr;46(4):543-51; discussion 551-2
[Evaluation of penetrating heart wounds by echocardiography] Sipak M, et al.
Pneumonol Alergol Pol 1997;65(11-12):822-5 (Eng. Abstr.) **(Pol)**

HEART-LUNG BYPASS see **CARDIOPULMONARY BYPASS**

HEART-LUNG MACHINE

see related
OXYGENATORS

Development of an ultracompact integrated heart-lung assist device. Tatsumi E, et al. **Artif Organs** 1999 Jun; 23(6):518-23

Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy [see comments] Wendel HP, et al.
J Cardiothorac Vasc Anesth 1999 Aug;13(4):388-92. Comment in: J Cardiothorac Vasc Anesth 1999 Aug;13(4):379-81.

In vitro evaluation of new surface coatings for extracorporeal circulation. Baksaas ST, et al. **Perfusion** 1999 Jan;14(1):11-9

Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, nonocclusive roller pumps and centrifugal pumps. Hansbro SD, et al.
Perfusion 1999 Jan;14(1):3-10

[Regulation of the heart-lung machine: systems analysis] Hexamer M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:328-9 **(Ger)**

[Development of a predictive MIMO regulator for heart-lung machines based on a model of extracorporeal circulation] Schwarzhaupt A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:336-7 **(Ger)**

[Significance of the heart-lung machine for the concept of minimal invasive heart surgery] Redling F, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:1516-9 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Two studies: long-term cognitive decline after bypass surgery; Alzheimer's gene linked to earlier bypass [news] **Compr Ther** 1999 May;25(5):300-1

STANDARDS

Biomaterials and cardiovascular devices. Macnair R, et al. **Proc Inst Mech Eng [H]** 1998;212(6):465-71 (42 ref.)

HEART-LUNG TRANSPLANTATION

Multiple leiomyosarcomas of both donor and recipient origin arising in a heart-lung transplant patient. Somers GR, et al. **Am J Surg Pathol** 1998 Nov;22(11):1423-8

Heart/single-lung transplant for a "failed Fontan" with pulmonary A-V malformation. Mott AR, et al.
Ann Thorac Surg 1999 Mar;67(3):841-3

Cardiac transplantation with single-lung pulmonary hypertension [letter; comment] Murphy DA, et al.
Ann Thorac Surg 1999 Feb;67(2):592. Comment on: Ann Thorac Surg 1998 Mar;65(3):823-5.

Heart-lung transplantation for primary pulmonary hypertension. Whyte RI, et al. **Ann Thorac Surg** 1999 Apr; 67(4):937-41; discussion 941-2

Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758-64 (21 ref.)

Worldwide Transplant Center directory. Heart/lung transplants. **Clin Transpl** 1997;:525-30

Clamshell or sternotomy for double lung or heart-lung transplantation? Macchiarini P, et al.
Eur J Cardiothorac Surg 1999 Mar;15(3):333-9

Recurrent Pneumocystis carinii colonization in a heart-lung transplant recipient on long-term trimethoprim-sulfamethoxazole prophylaxis. Faul JL, et al.
J Heart Lung Transplant 1999 Apr;18(4):384-7

Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. Hertz MI, et al.
J Heart Lung Transplant 1998 Sep;17(9):913-20

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. Onsager DR, et al. **J Heart Lung Transplant** 1999 May;18(5):448-55

Non-Hodgkin lymphoma after heart-lung transplantation: response to chemotherapy. Haas RJ, et al.
Med Pediatr Oncol 1999 Mar;32(3):229-30

Heart lung transplantation in a patient with end stage lung disease due to common variable immunodeficiency [see comments] Hill AT, et al. **Thorax** 1998 Jul;53(7):622-3. Comment in: Thorax 1998 Jul;53(7):619.

Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Wreghitt TG, et al. **Transpl Int** 1999;12(4):254-60

First successful heart-lung transplantation for cystic fibrosis in Israel. Aravot D, et al. **Transplant Proc** 1999 Jun; 31(4):1875-7

Breakthrough Pneumocystis carinii infections in lung and heart-lung transplant patients with chemoprophylaxis. Halme M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):197

Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Knoop C, et al.
Transplantation 1998 Oct 15;66(7):932-5

[Pulmonary thromboendarterectomy with video-angioscopy and circulatory arrest: an alternative to cardiopulmonary transplantation and post-embolism pulmonary artery hypertension] Dartevelle P, et al. **Chirurgie** 1998 Feb; 123(1):32-40 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Berry GT, et al.
Arch Neurol 1999 Apr;56(4):481-4

Dermatophytic granuloma caused by Microsporum canis in a heart-lung recipient. Voisard JJ, et al. **Dermatology** 1999; 198(3):317-9

Parvovirus B19 infection in thoracic organ transplant recipients. Calvet A, et al. **J Clin Virol** 1999 Jun; 13(1-2):37-42

Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Hammer S, et al. **Transpl Immunol** 1998 Dec;6(4):235-41

Ganciclovir prophylaxis after lung and heart-lung transplantation. Halme M, et al. **Transpl Int** 1998;11 Suppl 1:S499-501

IMMUNOLOGY

Dynamic changes in xenogeneic microchimerism after hamster-to-rat lung and heart xenotransplantation. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3867-8

METHODS

Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats. Chung WS, et al. **Microsurgery** 1999;19(2):71-7 (66 ref.)

PATHOLOGY

Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Hiemann NE, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):149-51

PHYSIOLOGY

Cardiopulmonary exercise testing before and after lung and heart-lung transplantation. Schwaiblmair M, et al.
Am J Respir Crit Care Med 1999 Apr;159(4 Pt 1):1277-83

Pulmonary ischemia/reperfusion injury: a quantitative study of structure and function in isolated heart-lungs of the rat. Fehrenbach H, et al. **Anat Rec** 1999 May 1;255(1):84-9

Detailed analysis of cell profiles in peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and CMV infection in lung and heart-lung allograft recipients. Tikkanen J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):163-4

PSYCHOLOGY

[Chronic heart or lung disease and psychosocial stress] Spurkland I, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20; 119(2):209-13 (Eng. Abstr.) **(Nor)**

STATISTICS & NUMERICAL DATA

Organ transplantation in Austria [letter] Fetz H.
Ann Transplant 1996;1(4):68

Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for thoracic organ transplantation. Keck BM, et al. **Clin Transpl** 1997;:29-43

Lung and heart-lung transplantation at the University of Pittsburgh. McCurry KR, et al. **Clin Transpl** 1997;:209-18

Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration. De Meester J, et al. **J Heart Lung Transplant** 1999 Jun; 18(6):563-71

Thoracic transplantation in 1998. Conte JV Jr.
Md Med J 1998 Nov;47(5):235-40 (8 ref.)

Review of the current state of thoracic transplantation: a national prospective cohort study. UK Cardiothoracic Transplant Audit Steering Group. Anyanwu AC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):165

Intrathoracic organ transplantation in Thailand. Ongcharit C, et al. **Transplant Proc** 1998 Nov;30(7):3385-6

HEART MASSAGE

Force distribution across the heel of the hand during simulated manual chest compression. Baubin M, et al.
Resuscitation 1997 Nov;35(3):259-63

The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. Müllner M, et al.
Resuscitation 1998 Aug;38(2):99-105

[Hepatic lesions after effective external cardiac massage--an iatrogenic complication not to be overlooked] Froment P, et al. **Swiss Surg** 1998;(5):225-7 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Liver laceration in the hemodynamically unstable post-cardiac massage patient: early recognition and management--case report. Rosen J, et al. **J Trauma** 1999 Aug;47(2):408-9

METHODS

The effect of rescuer fatigue on the quality of chest compressions. Ochoa FJ, et al. **Resuscitation** 1998 Jun; 37(3):149-52

HEART MITOCHONDRIA see **MITOCHONDRIA, HEART**

HEART MURMURS

see related
HEART AUSCULTATION
HEART SOUNDS
PHONOCARDIOGRAPHY

DIAGNOSIS

Heart murmurs in pediatric patients: when do you refer? McConnell ME, et al. **Am Fam Physician** 1999 Aug; 60(2):558-65 (06 ref.)

Cross-sectional echocardiographic demonstration of duct-related intimal tissue plaques within the pulmonary artery. Gennery AR, et al. **Cardiol Young** 1999 Jan; 9(1):81-3

Images in cardiovascular medicine. Austin Flint murmur. Oshinski J, et al. **Circulation** 1998 Dec 15;98(24):2782-3

Comparative study of clinical evaluation of heart murmurs by general pediatricians and pediatric cardiologists [see comments] Rajakumar K, et al. **Clin Pediatr (Phila)** 1999 Sep;38(9):511-8. Comment in: Clin Pediatr (Phila) 1999 Sep;38(9):519-20.

Murmurs associated with mitral annular calcification and aortic sclerosis. Miller AJ, et al. **Gerontology** 1999; 45(2):115-9

A bedside clinical prediction rule for detecting moderate or severe aortic stenosis. Etchells E, et al.
J Gen Intern Med 1998 Oct;13(10):699-704

Does this patient have aortic regurgitation? Choudhry NK, et al. **JAMA** 1999 Jun 16;281(23):2231-8

Development of a cardiac acoustic mapping system. Cozic M, et al. **Med Biol Eng Comput** 1998 Jul;36(4):431-7

Evaluation of the pediatric patient with a cardiac murmur. Pelech AN. **Pediatr Clin North Am** 1999 Apr;46(2):167-88 (44 ref.)

EPIDEMIOLOGY

Prevalence and clinical significance of cardiac murmurs in neonates. Ainsworth S, et al.
Arch Dis Child Fetal Neonatal Ed 1999 Jan;80(1):F43-5

ETIOLOGY

Heart murmurs in pediatric patients: when do you refer? McConnell ME, et al. **Am Fam Physician** 1999 Aug; 60(2):558-65 (06 ref.)

Cardiac murmur associated with an abnormal chest x-ray film. Myers RB, et al. **Chest** 1998 Nov;114(5):1459-62

Aortic stenosis [letter; comment] Frank MN. **Clin Cardiol** 1999 Jun;22(6):438. Comment on: Clin Cardiol 1998 Nov;21(11):845.

Innocent murmur and the pediatrician [editorial; comment] Noonan J. **Clin Pediatr (Phila)** 1999 Sep;38(9):519-20. Comment on: Clin Pediatr (Phila) 1999 Sep;38(9):511-8.

A 30-month-old child with systolic murmur and temporal bruit. Narchi H. **Eur J Pediatr** 1999 Jan;158(1):77-8

Systolic ejection murmurs in the era of modern cardiology: what do we really know? [editorial; comment] Murgo JP. **J Am Coll Cardiol** 1998 Nov 15;32(6):1596-602 (47 ref.). Comment on: J Am Coll Cardiol 1998 Nov 15;32(6):1589-95.

Increased intraventricular velocities: an unrecognized cause of systolic murmur in adults [see comments] Spooner PH, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1589-95. Comment in: J Am Coll Cardiol 1998 Nov 15;32(6):1596-602.

Heart murmurs, valvular regurgitation and electrical disturbances in copper-deficient genetically hypertensive, hypertrophic cardiomyopathic rats. Shiry LJ, et al.
J Am Coll Nutr 1999 Feb;18(1):51-60

Prevalence of infective endocarditis in patients with systemic lupus erythematosus. Miller CS, et al.
J Am Dent Assoc 1999 Mar;130(3):387-92

Pulmonary stenosis: defect-specific diagnostic accuracy of heart murmurs in children. Danford DA, et al.
J Pediatr 1999 Jan;134(1):76-81

Dynamic left ventricular outflow tract obstruction in acute coronary syndromes: an important cause of new systolic murmur and cardiogenic shock. Haley JH, et al.
Mayo Clin Proc 1999 Sep;74(9):901-6

Asymptomatic murmurs [letter; comment] Cheng TO.
Postgrad Med J 1998 Nov;74(877):701. Comment on: Postgrad Med J 1997 Sep;73(863):597-8.

A novel approach to understanding a mysterious murmur in a young adult after surgical repair of tetralogy of Fallot. Kinney JB Jr, et al. **West J Med** 1998 Oct;169(4):230-1

RADIOGRAPHY

Chest roentgenogram in the evaluation of heart defects in asymptomatic infants and children with a cardiac murmur: reproducibility and accuracy. Birkebaek NH, et al.
Pediatrics 1999 Feb;103(2):E15

HEART NEOPLASMS

Primary cardiac myofibroblastic sarcoma, case report and review of diagnosis and treatment of cardiac tumors. Dhillon G, et al. **Bol Asoc Med P R** 1998 Jul-Dec; 90(7-12):130-3

Left ventricular hemangioma. Manasse E, et al.
Eur J Cardiothorac Surg 1999 Jun;15(6):864-6

Cardiac lipomas. Description of 3 cases. Grande AM, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):813–5

Cardiac hemangioendothelioma. Hongquan Y, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):655–8 (10 ref.)

Cardiac myxoma: diagnostic approach, surgical treatment and follow-up. A twenty years experience. Jelič J, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):113–7

Intra-atrial myxomas, clinical-pathologic correlation based on two case studies including historical review. Roscher AA, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):131–7 (18 ref.)

Myxoma of the mitral valve prolapsing into the left atrium and ventricle: report of a case. Matsui Y, et al. **Surg Today** 1998;28(10):1105–7

[A case report of cavernous hemangioma of the left atrial epicardium] Hara T, et al. **Kyobu Geka** 1998 Nov; 51(12):1027–9 (Eng. Abstr.) **(Jpn)**

[Primary tumors of heart] Nechaenko MA, et al. **Khirurgiia (Mosk)** 1999;(8):23–7 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Increased endothelin-receptor density in myxomatous canine mitral valve leaflets. Mow T, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):254–60

CLASSIFICATION

Primary pediatric cardiac tumors: a 17 year experience. Sallee D, et al. **Cardiol Young** 1999 Mar;9(2):155–62

COMPLICATIONS

Sudden death with malignant hemangioendothelioma originating in the pericardium--a case report. Yoshida A, et al. **Angiology** 1999 Jul;50(7):607–11

A primary osteosarcoma of the heart as a cause of recurrent peripheral arterial emboli. Jahns R, et al. **Ann Oncol** 1998 Jul;9(7):775–8

Mitral valve repair after excision of a fibrolipoma. Caralps JM, et al. **Ann Thorac Surg** 1998 Nov;66(5):1808–9

Carney complex: in a patient with multiple blue naevi and lentigines, suspect cardiac myxoma. Bleasel NR, et al. **Australas J Dermatol** 1999 Aug;40(3):158–60

Left ventricular myxoma. Gabe ED, et al. **Can J Cardiol** 1999 Mar;15(3):341–2

Critical obstruction of the right ventricular outflow tract by a primary hemangioendothelioma in a seven month old. Robinson HA, et al. **Cardiol Young** 1999 Mar;9(2):185–8

Third degree atrio-ventricular-block caused by malignant non-Hodgkin's lymphoma: an unusual indication for epicardial pacing. Aleksic I, et al. **Cardiovasc Surg** 1999 Apr;7(3):378–80 (12 ref.)

Cardiac papillary fibroelastoma: aA rare cause of ischemic stroke in the young. Giannesini C, et al. **Cerebrovasc Dis** 1999 Jan-Feb;9(1):45–9

Primary pericardial mesothelioma with cardiac tamponade and distant metastasis: case report. Chung CM, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):498–502

Fibroelastoma and embolic stroke [letter] Veinot JP. **Circulation** 1999 May 25;99(20):2709–12

Asymptomatic right atrial leiomyosarcoma with tricuspid valve obstruction in a young female patient. Kornberg A, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):635–8

Expandable stents compared to conventional plastic endoprostheses in malignant oesophageal obstruction, especially in cardiac cancer and fistulas: the experience of the Netherlands Cancer Institute [see comments] Taal BG, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10(9):745–52 . Comment in: Eur J Gastroenterol Hepatol 1998 Sep;10(9):737–9.

Non-surgical CHOP cures right ventricular outflow obstruction. Halcox JP. **Heart** 1999 Apr;81(4):445–6

Massive intrapericardial lipoma, a rare cause of breathlessness. Investigations and management. Doshi S, et al. **Int J Cardiol** 1998 Sep 30;66(2):211–5

Ventricular tachycardia in a patient with cardiac lipoma. Fukushima KK, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1161

72-year-old man with exertional chest discomfort. Kozak KR, et al. **Mayo Clin Proc** 1999 Jul;74(7):723–6

Infected cardiac myxoma. Case report and literature review. Revankar SG, et al. **Medicine (Baltimore)** 1998 Sep; 77(5):337–44 (74 ref.)

Serial MRI of cerebral infarcts before and after removal of an atrial myxoma. Kawamura T, et al. **Neuroradiology** 1999 Aug;41(8):573–5

Use of an implantable cardioverter defibrillator in an eight-month-old infant with ventricular fibrillation arising from a myocardial fibroma. Park JK, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 1):138–9

A left atrial myxoma presenting as a cerebrovascular accident. Bayir H, et al. **Pediatr Neurol** 1999 Aug; 21(2):569–72

Tuberous sclerosis with intracardiac rhabdomyoma in a fetus with trisomy 21: case report and review of literature. Krapp M, et al. **Prenat Diagn** 1999 Jul;19(7):610–3 (26 ref.)

Unusual course of right atrial myxoma, masked by acute abdominal pain, and complicated by pulmonary embolus. Bitner M, et al. **Scand Cardiovasc J** 1998;32(6):371–3

[Papillary fibroelastoma. A rare etiology of strokes in young patients] Bailbé M, et al. **Rev Med Interne** 1998 Feb; 19(2):119–22 (Eng. Abstr.) **(Fre)**

[Cardiac tamponade due to a right atrial myxoma] Ciliberti D, et al. **Cardiologia** 1998 Oct;43(10):1101–3 (5 ref.) (Eng. Abstr.) **(Ita)**

[A case of typical carcinoid accompanied with left atrium myxoma] Kitami A, et al. **Kyobu Geka** 1999 Apr; 52(4):333–5 (Eng. Abstr.) **(Jpn)**

[Metastatic endometrial sarcoma of the right ventricular outflow tract associated with disseminated intravascular coagulopathy] Matsumoto N, et al. **Kyobu Geka** 1999 May; 52(5):401–4 (Eng. Abstr.) **(Jpn)**

[Ventricular outflow tract obstruction by cardiac tumors during ACTH therapy of an infant with tuberous sclerosis] Yoshimi S, et al. **No To Hattatsu** 1999 Mar;31(2):165–70 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Left atrial myxoma and isquemic stroke in a child] Takakura IT, et al. **Arq Bras Cardiol** 1998 Aug;71(2):135–7 (Eng. Abstr.) **(Por)**

[Case report of tuberous sclerosis and congenital heart disease] Rocha G, et al. **Rev Port Cardiol** 1999 May; 18(5):497–500 (Eng. Abstr.) **(Por)**

[Recurrent cerebral embolism as the main sign of atrial myxoma] Domínguez-Morán JA, et al. **Neurologia** 1999 Feb;14(2):90–3 (Eng. Abstr.) **(Spa)**

[Myxoma of the left ventricle: a cause of syncope in an adolescent] Delgado LJ, et al. **Rev Esp Cardiol** 1998 Aug; 51(8):674–6 (Eng. Abstr.) **(Spa)**

[Myxoma and antiphospholipid antibody syndrome] Quintanilla S, et al. **Rev Med Chil** 1998 Jun;126(6):670–6 (Eng. Abstr.) **(Spa)**

CONGENITAL

Resection of a large right atrial hemangioma in a neonate after prenatal diagnosis. Eckstein FS, et al. **Ann Thorac Surg** 1999 Sep;68(3):1074–5

Neonatal cardiac rhabdomyoma. Kalgutkar A, et al. **Indian Pediatr** 1998 Dec;35(12):1228–30

Primary intracardiac yolk sac tumor. Parvathy U, et al. **Pediatr Cardiol** 1998 Nov-Dec;19(6):495–7

[Extensive cavernous capillary hemangioma of the right atrium in a newborn infant] Bosk A, et al. **Z Geburtshilfe Neonatol** 1999 May-Jun;203(3):120–2 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Cardiac myxoma in a 6-year-old child--constitutional symptoms mimicking rheumatic disease and the role of interleukin-6. Hövels-Gürich HH, et al. **Acta Paediatr** 1999 Jul;88(7):786–8

Lung cancer mimicking acute myocardial infarction on electrocardiogram. Yao NS, et al. **Am J Emerg Med** 1999 Jan;17(1):86–8

Successful treatment of a patient with cardiac lymphoma who presented with a complete atrioventricular block. Nagano M, et al. **Am J Hematol** 1998 Oct;59(2):171–4

Primary cardiac angiosarcoma with right coronary artery-to-pericardial fistula--a case report. Reising C, et al. **Angiology** 1999 Sep;50(9):777–80

Getting to the heart of the matter. Pyne D, et al. **Ann Rheum Dis** 1999 Jun;58(6):332–3

Epithelioid and spindle-celled leiomyosarcoma of the heart. Report of 2 cases and review of the literature. Pins MR, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):782–8 (23 ref.)

Multiple rhabdomyomas in monozygotic twins. Zamith MM, et al. **Cardiol Young** 1999 Mar;9(2):200–2

Transthoracic echo-guided transvenous biopsy of a right atrial mass [letter] Marti V, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):349–50

Left atrial myxomas presenting with right hand weakness. Yuan R, et al. **Conn Med** 1999 May;63(5):261–4

Cutaneous findings associated with cardiac myxomas. Greeson DM, et al. **Cutis** 1998 Dec;62(6):275–80; quiz 186

Results of treatment of 17 patients with heart tumour. Gersak B, et al. **Eur J Surg Oncol** 1999 Jun;25(3):302–5

Cardiac rhabdomyosarcoma: diagnosis by MR imaging. Villacampa VM, et al. **Eur Radiol** 1999;9(4):634–7

Cardiac angiosarcoma: early diagnosis. A case report. Cucchi G, et al. **G Ital Cardiol** 1999 May;29(5):555–7 (20 ref.)

Right coronary artery aneurysm simulating right intraatrial mass. Vallebona A, et al. **G Ital Cardiol** 1999 Feb; 29(2):220–1 **(Eng, Ita)**

Primary right atrial angiosarcoma mimicking acute pericarditis, pulmonary embolism, and tricuspid stenosis. Ananthasubramaniam K, et al. **Heart** 1999 May;81(5):556–8

Images in cardiology. Fibrosarcoma of the heart. Lim YT, et al. **Heart** 1998 Oct;80(4):369

Images in cardiology. Rapid progression of pericardial malignant mesothelioma. Tjeerdsma G, et al. **Heart** 1998 Jun;79(6):618

Syncope two years after hysterectomy. Dizon MN, et al. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):37–8

A case of primary cardiac lymphoma: utility of serum soluble interleukin-2 receptor for noninvasive diagnosis. Makishima H, et al. **Int J Cardiol** 1998 Aug;65(3):291–3

Subdivided left atrium mimicking a cardiac tumor. Shimaya K, et al. **Int J Cardiol** 1999 Feb 28;68(2):235–8

Localized pericarditis with calcifications mimicking a pericardial tumor. Iseki H, et al. **Intern Med** 1999 Apr; 38(4):355–8

Pericardial mesothelioma: an incidental intraoperative diagnosis. Griffin M, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):471–4

Vascular hamartoma of the left ventricle. Miche E, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):479–82

Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. Wu C, et al. **J Clin Oncol** 1998 Dec; 16(12):3913–5

Atrial myxoma: a review of clinical experience at Srinagarind Hospital. Silaruks S, et al. **J Med Assoc Thai** 1999 Feb; 82(2):107–14

Primary pericardial synovial sarcoma with detection of the chimeric transcript SYT-SSX. Oizumi S, et al. **Jpn Circ J** 1999 Apr;63(4):330–2

72-year-old man with exertional chest discomfort. Kozak KR, et al. **Mayo Clin Proc** 1999 Jul;74(7):723–6

Late diastolic tumor "plop" in an asymptomatic case of right atrial myxoma. Bukša M, et al. **Med Arh** 1999;53(2):77–9

Primary cardiac lymphoma. A case report and review. Montalbetti L, et al. **Minerva Cardioangiol** 1999 May; 47(5):175–82 **(Eng, Ita)**

Squamous cell metastasis from the tongue to the myocardium presenting as pericardial effusion. Rivkin A, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):593–5

Massive biatrial myxomas in a child. Cilliers AM, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):150–1

Intrapericardial teratoma diagnosed prenatally in a twin fetus. Valioulis I, et al. **Pediatr Surg Int** 1999;15(3–4):284–6

Co-existing left atrial thrombus and myxoma in mitral stenosis--a diagnostic challenge. Sim EK, et al. **Singapore Med J** 1999 Jan;40(1):46–7

Ventricular myxoma presenting as acute visual loss. Abo-Auda WS, et al. **Tenn Med** 1998 Oct;91(10):391–2

[Atrial myxoma: cutaneous manifestations] Le Cam MT, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):32–4 (Eng. Abstr.) **(Fre)**

[Papillary fibroelastoma of the heart. A review of 20 cases] Loire R, et al. **Arch Anat Cytol Pathol** 1999;47(1):19–25 (Eng. Abstr.) **(Fre)**

[Left atrial myxoma and anicteric cholestasis (letter)] André M, et al. **Rev Med Interne** 1998 Sep;19(9):672–3 **(Fre)**

[37-year-old patient with myalgia, arthralgia, pseudovasculitis and palpitations] Schimpf R, et al. **Internist (Berl)** 1998 Sep;39(9):974–7 **(Ger)**

[MRI diagnosis of cardiac myxomas: sequence evaluation and differential diagnosis] Sommer T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):156–62 (Eng. Abstr.) **(Ger)**

[Left ventricular papillary fibroelastomas without relation to a heart valve--a report of 2 cases] Hagemeyer J, et al. **Z Kardiol** 1998 Nov;87(11):900–5 (Eng. Abstr.) **(Ger)**

[Diagnosis of an intramyocardial hematoma via MRI after a traumatic myocardial infarct] Wittlinger T, et al. **Z Kardiol** 1999 Feb;88(2):147–53 (Eng. Abstr.) **(Ger)**

[The accidental diagnosis of a left atrial myxoma in an 80-year-old female] Tondi S, et al. **G Ital Cardiol** 1998 Aug;28(8):909–12 (12 ref.) (Eng. Abstr.) **(Ita)**

[Thrombus of the right ventricle simulating a cardiac tumor--case report] Aleszewicz-Baranowska J, et al. **Przegl Lek** 1998;55(12):673–5 (Eng. Abstr.) **(Pol)**

[Giant left atrial myxoma] Cruz JF, et al. **Arq Bras Cardiol** 1998 Nov;71(5):717–8 (Eng. Abstr.) **(Por)**

[A giant aneurysm of the interatrial septum simulating cystic masses of the right atrium] Martins S, et al. **Rev Port Cardiol** 1999 Mar;18(3):319–21 **(Por)**

[Diagnostic and prognostic aspects of myxoma syndrome] Konstantinov BA, et al. **Klin Med (Mosk)** 1999;77(1):22–6 (Eng. Abstr.) **(Rus)**

[Cardiac fibroma: diagnosis and surgical treatment] Rueda Núñez F, et al. **An Esp Pediatr** 1999 Feb;50(2):177–80 **(Spa)**

[Cardiac tumors. Our experience with 4 cases] Torres Borrego J, et al. **An Esp Pediatr** 1999 Jan;50(1):61–4 (24 ref.) **(Spa)**

[Fortuitous diagnosis of an undifferentiated large cell carcinoma during cardiac surgery] Abad C, et al. **Rev Esp Cardiol** 1999 Jul;52(7):523–5 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Llombart-Cussac A, et al. **Br J Cancer** 1998 Dec;78(12):1624–8

Successful treatment of intracaval and atrial extension of rhabdomyosarcoma without surgical excision: an unusual presentation. Akyüz C, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):313–4

[Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report] Rhomberg W, et al. **Strahlenther Onkol** 1999 Mar;175(3):102–4 (17 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Primary pediatric cardiac tumors: a 17 year experience. Sallee D, et al. **Cardiol Young** 1999 Mar;9(2):155–62

[The National Registry of Cardiac Tumors (the 1996-1997 report)] García Gallego F, et al. **Rev Esp Cardiol** 1999 Jan; 52(1):13–20 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Myxoma of mitral valve associated with infective endocarditis. Toda R, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jun;47(6):285–7

[Extrapleural mesothelioma] Lalowicz I.

Pol Merkuriusz Lek 1999 Jan;6(31):47–9 (31 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Evidence for a second genetic locus in Carney complex. Irvine AD, et al. **Br J Dermatol** 1998 Oct;139(4):572–6

Evidence for genetic heterogeneity of the Carney complex (familial atrial myxoma syndromes). Milunsky J, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):173–6

Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Casey M, et al. **Circulation** 1998 Dec 8;98(23):2560–6

Syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). Legius E, et al. **Genet Couns** 1998;9(4):287–90

DNA ploidy and proliferative index of cardiac myxoma. Majumdar N, et al. **Indian Heart J** 1998 Sep–Oct; 50(5):535–8

Synovial sarcoma with t(X:18) chromosomal translocation, cardiac involvement, and peripheral embolus [clinical conference] Hall TC, et al. **Med Pediatr Oncol** 1999 Feb; 32(2):141–5

IMMUNOLOGY

A case of interleukin-6-producing malignant fibrous histiocytoma originating in the heart. Deguchi H, et al. **Jpn J Clin Oncol** 1999 Aug;29(8):382–6

Primary lymphomas of the heart in immunocompetent patients. Presentation of two cases with one 12 year survival. Analysis of surgical implications. Gosalbez F, et al. **Minerva Cardioangiol** 1999 Mar;47(3):75–9

METABOLISM

Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer. Hsu NY, et al. **Clin Cancer Res** 1999 Jul;5(7):1752–7

Granulocyte colony-stimulating factor-producing primary pericardial mesothelioma. Horio H, et al. **Hum Pathol** 1999 Jun;30(6):718–20

NURSING

Metastases that interfere with circulation. Joyce M, et al. **Semin Oncol Nurs** 1998 Aug;14(3):230–9 (43 ref.)

PARASITOLOGY

Primary cardiac hydatid cyst in a child. Cytologic diagnosis of a case. López-Ríos F, et al. **Acta Cytol** 1997 Jul–Aug; 41(4 Suppl):1387–90

PATHOLOGY

Calcified papillary fibroelastoma of the tricuspid valve. Paelinck B, et al. **Acta Cardiol** 1998;53(3):165–7

Pancreatic metastasis of cardiac rhabdomyosarcoma diagnosed by fine needle aspiration. A case report. Khalbuss WE, et al. **Acta Cytol** 1999 May–Jun;43(3):447–51

Primary cardiac hydatid cyst in a child. Cytologic diagnosis of a case. López-Ríos F, et al. **Acta Cytol** 1997 Jul–Aug; 41(4 Suppl):1387–90

Echocardiographic and morphologic characteristics of left atrial myxoma and their relation to systemic embolism. Ha JW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1579–82, A8

Lipoma of the mitral valve in a child. Vadmal MS, et al. **Ann Clin Lab Sci** 1998 Jul–Aug;28(4):242–5

Polypoid osteosarcoma of the left atrium: report of a new case with autopsy confirmation and review of the literature. Zanella M, et al. **Ann Diagn Pathol** 1998 Jun;2(3):167–72 (31 ref.)

Primary lymphoma of the heart: report of a case with histological diagnosis of the transvenously biopsied intracardiac tumor. Daus H, et al. **Ann Hematol** 1998 Sep; 77(3):139–41

A novel human malignant fibrous histiocytoma cell line of the heart (MFH-H) with secretion of hematopoietic growth factors. Reinecke P, et al. **Anticancer Res** 1999 May–Jun;19(3A):1901–7

Protocol for the examination of specimens from patients with primary cardiac tumors: a basis for checklists. Cancer Committee, College of American Pathologists. Hammond EH. **Arch Pathol Lab Med** 1999 Jan;123(1):20–2

Cardiac angiosarcoma: an unusual presentation with cutaneous metastases. Pomper GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):273–6

Intrapericardial yolk sac tumor associated with acute myocarditis. Sicari MC, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):241–3

Neoplastic pericardial disease. Analysis of 26 patients. Soufen HN, et al. **Arq Bras Cardiol** 1999 Jan;72(1):51–8 **(Eng, Por)**

Cardiac neoplasms at the Canadian Reference Centre for Cancer Pathology. Veinot JP, et al. **Can J Cardiol** 1999 Mar;15(3):311–9

Tumors of the heart and pericardium. McAllister HA Jr, et al. **Curr Probl Cardiol** 1999 Feb;24(2):57–116 (144 ref.)

Proliferating cell nuclear antigen expression grossly over-estimates cellular proliferation in cardiac myxomas. Roskell DE, et al. **Eur J Med Res** 1999 Mar 26;4(3):105–6

Echocardiography of a right atrial mass in hepatocellular carcinoma. Yoshitomi Y, et al. **Heart Vessels** 1998; 13(1):45–8

Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Donsbeck AV, et al. **Histopathology** 1999 Apr; 34(4):295–304

Primary malignant peripheral nerve sheath tumour of the heart. Pauwels P, et al. **Histopathology** 1999 Jan;34(1):56–9

Appraisal of histogenesis of cardiac myxoma: our experience of 78 cases and review of literature. Chopra P, et al. **Indian Heart J** 1999 Jan–Feb;51(1):69–74 (30 ref.)

Cardiac malignant pheochromocytoma with bone metastases. Arai A, et al. **Intern Med** 1998 Nov;37(11):940–4

Primary cardiac angiosarcoma of the right atrium undiagnosed by transvenous endocardial tumor biopsy. Nitta R, et al. **Intern Med** 1998 Dec;37(12):1023–6

Embolization of pulmonary pseudoaneurysms secondary to metastatic synovial sarcoma of the right atrium. Bean SH, et al. **J Vasc Interv Radiol** 1999 May;10(5):649–52

Primary cardiac lymphoma in an immunocompetent woman. Begueret H, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):423–8

Successful treatment of intracaval and atrial extension of rhabdomyosarcoma without surgical excision: an unusual presentation. Akyüz C, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):313–4

Leiomyosarcoma of the heart and its pulmonary metastasis, both with prominent osteoclast-like multinucleated giant cells expressing tartrate-resistant acid phosphatase activity. Katoh M, et al. **Pathol Int** 1999 Jan;49(1):74–8

An autopsy case of a malignant pericardial mesothelioma in a Japanese young man. Watanabe M, et al. **Pathol Int** 1999 Jul;49(7):658–62

Intracardiac yolk sac tumor in an infant girl. Graf M, et al. **Pathol Res Pract** 1999;195(3):193–7

Cardiac myxoma with glandular component: case report and review of the literature. Lindner V, et al. **Pathol Res Pract** 1999;195(4):267–72 (26 ref.)

Metastatic cardiac angiosarcoma of the cervical spine. Case report. Shapiro S, et al. **Spine** 1999 Jun 1;24(11):1156–8

Atriocaval mesothelioma in a male Sprague-Dawley rat. Peano S, et al. **Toxicol Pathol** 1998 Sep–Oct;26(5):695–8

[Pathology of primary cardiac neoplasms] Paraf F. **Ann Pathol** 1999 Jun;19(3):212–22 (38 ref.) **(Fre)**

[Papillary fibroelastoma: a cardiac tumor rarely reported in children] Hami BB, et al. **Arch Anat Cytol Pathol** 1999; 47(1):53–6 (Eng. Abstr.) **(Fre)**

[Clinical expression of papillary fibroelastoma. Apropos of a case] Gully C, et al. **Arch Mal Coeur Vaiss** 1998 Jun; 91(6):777–82 (10 ref.) (Eng. Abstr.) **(Fre)**

[Synovial sarcoma of the pericardium] Langner K, et al. **Pathologe** 1998 Nov;19(6):442–6 (Eng. Abstr.) **(Ger)**

[Percutaneous transvenous biopsy for the diagnosis of a right atrial myxoma] Nardi P, et al. **G Ital Cardiol** 1999 Mar; 29(3):308–11 (5 ref.) (Eng. Abstr.) **(Ita)**

[Anatomopathological and immunohistochemical findings in 6 cardiac myxomas] Matturri L, et al. **Minerva Med** 1998 Sep;89(9):335–9 (Eng. Abstr.) **(Ita)**

[A case of metastatic liver tumor of the fallopian tube carcinoma which spreaded through IVC to right atrium] Yamazaki K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1032–6 **(Jpn)**

[Mesothelium and malignant mesothelioma of the pericardium] Likhachev IuP, et al. **Arkh Patol** 1999 Mar–Apr;61(2):11–5 (Eng. Abstr.) **(Rus)**

[Neonatal cardiac rhabdomyoma: case report and clinico-epidemiologic considerations] Lima-Rogel V, et al. **Arch Inst Cardiol Mex** 1998 Sep–Oct;68(5):421–5 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Primary cardiac lymphoma in an immunocompetent woman. Begueret H, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):423–8

PSYCHOLOGY

Atrial myxoma with psychiatric presentation. Saravay SM, et al. **Psychosomatics** 1998 Sep–Oct;39(5):453–5

RADIOGRAPHY

Synovial sarcoma arising from the pericardium: radiographic and CT findings. Kojima KY, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):246–7

Right atrial metastatic melanoma detected by dynamic contrast enhanced spiral CT. Burn PR, et al. **Br J Radiol** 1999 Apr;72(856):395–6

A surgical gauze appearing as a retrocardiac mass in a patient after coronary artery bypass surgery. Unverdorben M, et al. **Eur J Radiol** 1999 Mar;29(3):273–5

[Primary non-Hodgkin's lymphoma of the heart] Scherrer A, et al. **J Radiol** 1998 Dec;79(12):1530–1 **(Fre)**

RADIONUCLIDE IMAGING

Detection of cardiac myxoma by F-18 FDG PET. Agostini D, et al. **Clin Nucl Med** 1999 Mar;24(3):159–60

Primary myocardial lymphoma demonstrated by Tl-201, Tc-99m sestamibi, and Ga-67 SPECT. Kosuda S, et al. **Clin Nucl Med** 1998 Jul;23(7):482–3

Fluorine-18-fluorodeoxyglucose PET identification of cardiac metastasis arising from uterine cervical carcinoma. Shimotsu Y, et al. **J Nucl Med** 1998 Dec;39(12):2084–7

[Sick sinus syndrome after chemotherapy for malignant lymphoma with right atrial tumor at initial presentation] Miyata A, et al. **Rinsho Ketsueki** 1998 Dec;39(12):1190–3 (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

[Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report] Rhomberg W, et al. **Strahlenther Onkol** 1999 Mar;175(3):102–4 (17 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Coil embolization of coronary supply to a cardiac metastasis. Valentin A, et al. **Am J Cardiol** 1999 Mar 1;83(5):809–10, A11

Lung cancer mimicking acute myocardial infarction on electrocardiogram. Yao NS, et al. **Am J Emerg Med** 1999 Jan;17(1):86–8

Unusual cause of intraoperative hypotension diagnosed with transoesophageal echocardiography in a patient with renal cell carcinoma. Plowman AN, et al. **Anaesth Intensive Care** 1999 Feb;27(1):63–5

Pelvic leiomyoma in the right atrium. Katsumata T, et al. **Ann Thorac Surg** 1998 Dec;66(6):2095–6

Cardiac metastases from malignant melanoma. Gibbs P, et al. **Cancer** 1999 Jan 1;85(1):78–84 (38 ref.)

Metastatic germ cell tumor to the heart presenting with syncope. Vohra A, et al. **Clin Cardiol** 1999 Jun;22(6):429–33 (13 ref.)

Resection of a right atrial metastatic melanoma with unknown origin of primary tumor. Bossert T, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):373–5

Metastatic malignant melanoma as an intracavitary obstructive mass in the right heart [letter] Petropoulakis PN, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):538–40

Syncope two years after hysterectomy. Dizon MN, et al. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):37–8

Metastatic renal cell carcinoma invading right ventricular myocardium without caval involvement. Santo-Tomas M, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):811–2

Acute myocardial infarction: a rare presentation of pancreatic carcinoma. Cook MA, et al. **J Clin Gastroenterol** 1999 Apr; 28(3):271–2

Cardiac tamponade originating from primary gastric signet ring cell carcinoma. Sakai Y, et al. **J Gastroenterol** 1999 Apr;34(2):250–2

Images in hepatology. Extension of hepatocellular carcinoma into the heart. Wigmore SJ, et al. **J Hepatol** 1999 Jul; 31(1):160

Metastatic follicular carcinoma of thyroid to pericardium. Chiewvit S, et al. **J Med Assoc Thai** 1998 Oct; 81(10):799–802

Fluorine-18-fluorodeoxyglucose PET identification of cardiac metastasis arising from uterine cervical carcinoma. Shimotsu Y, et al. **J Nucl Med** 1998 Dec;39(12):2084–7

Malignant hemangioendothelioma presenting as multifocal intraskeletal lesions during pregnancy. A case report. Ilasi JA, et al. **J Reprod Med** 1999 Jan;44(1):49–52

Unusual clinical evolution of a paratesticular alveolar rhabdomyosarcoma in a child. de Camargo B, et al. **Med Pediatr Oncol** 1999 Oct;33(4):422–4

Squamous cell metastasis from the tongue to the myocardium presenting as pericardial effusion. Rivkin A, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):593–5

Anitschkow cells in the human heart. Satoh F, et al. **Pathol Int** 1999 Jan;49(1):85–7

Right intraventricular metastasis of squamous cell carcinoma of the uterine cervix: an autopsy case and literature review. Senzaki H, et al. **Pathol Int** 1999 May;49(5):447–52 (33 ref.)

Neoplastic thrombotic endocarditis of the tricuspid valve in a patient with carcinoma of the thyroid. Report of a case. Bussani R, et al. **Pathol Res Pract** 1999;195(2):121–4

Low-grade endometrial stromal sarcoma with intracardiac extension. Evolution of extensive smooth muscle differentiation and usefulness of immunohistochemistry for its recognition and distinction from intravenous leiomyomatosis. Mikami Y, et al. **Pathol Res Pract** 1999; 195(7):501–8

Metastases that interfere with circulation. Joyce M, et al. **Semin Oncol Nurs** 1998 Aug;14(3):230–9 (43 ref.)

Amiodarone for control of recurrent ventricular tachycardia secondary to cardiac metastasis. Leak D. **Tex Heart Inst J** 1998;25(3):198–200

Combined surgical approach for sarcoma lung metastasis with atrial involvement. Torre W, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):125–7

Cardiac metastasis of a malignant fibrous histiocytoma occupying the right ventricle and infiltrating the myocardium. Wankmüller H, et al. **Ultraschall Med** 1998 Jun;19(3):139–41

Testicular carcinoma with superior vena cava obstruction and atrial extension. Low LL, et al. **Urology** 1999 Aug; 54(2):363–4

[Cardiac metastasis of chondrosarcoma: a case report] Fichaux O, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):165–8 (Eng. Abstr.) **(Fre)**

[Clinical case of the month. Metastatic endocarditis: clinical observation and review of the literature] Graas MP, et al. **Rev Med Liege** 1998 Oct;53(10):588–91 (12 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac metastasis of a plasmacytoma with clinical manifestations of an extensive pulmonary embolism. Obstruction of the right ventricular outflow tract] Kurzidim K, et al. **Dtsch Med Wochenschr** 1998 Nov 13;

123(46):1372-7 (Eng. Abstr.) **(Ger)**
[Metastatic endometrial sarcoma of the right ventricular outflow tract associated with disseminated intravascular coagulopathy] Matsumoto N, et al. **Kyobu Geka** 1999 May; 52(5):401-4 (Eng. Abstr.) **(Jpn)**

SURGERY

Intraoperative management of a pediatric patient undergoing cardiac tumor resection with the aid of transesophageal and epicardial echocardiography. Kawahito S, et al. **Anesth Analg** 1999 May;88(5):1048-50
Surgical treatment of 22 cardiac myxomas: A review. Tsukamoto S, et al. **Ann Thorac Cardiovasc Surg** 1999 Jun; 5(3):146-9
Video-assisted minimal access in excision of left atrial myxoma [letter; comment] Anderson JR. **Ann Thorac Surg** 1999 Aug;68(2):628. Comment on: Ann Thorac Surg 1998 Oct;66(4):1301-5. Comment on: Ann Thorac Surg 1998 Oct;66(4):1429-30.
Mitral valve repair after excision of a fibrolipoma. Caralps JM, et al. **Ann Thorac Surg** 1998 Nov;66(5):1808-9
Resection of a large right atrial hemangioma in a neonate after prenatal diagnosis. Eckstein FS, et al. **Ann Thorac Surg** 1999 Sep;68(3):1074-5
A malignant primary cardiac pheochromocytoma. Jirari A, et al. **Ann Thorac Surg** 1999 Aug;68(2):565-6
Video-assisted minimal access in excision of left atrial myxoma [see comments] Ko PJ, et al. **Ann Thorac Surg** 1998 Oct;66(4):1301-5. Comment in: Ann Thorac Surg 1999 Aug;68(2):628.
Operative strategies for resection of pulmonary sarcomas extending into the left atrium. Korst RJ, et al. **Ann Thorac Surg** 1999 Apr;67(4):1165-7
Left ventricular fibroma masquerading as postinfarction myocardial rupture. Lee KA, et al. **Ann Thorac Surg** 1999 Aug;68(2):580-2 (6 ref.)
Cardiac pheochromocytoma: resection after diagnosis by 111-indium octreotide scan. Lin JC, et al. **Ann Thorac Surg** 1999 Feb;67(2):555-8 (8 ref.)
Surgical resection of intracardiac gastrinoma. Noda S, et al. **Ann Thorac Surg** 1999 Feb;67(2):532-3
Cardiac autotransplant for surgical treatment of a malignant neoplasm. Reardon MJ, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1793-5
Six-year survival after excision of cardiac malignant lymphoma. Takagi M, et al. **Ann Thorac Surg** 1998 Nov; 66(5):1810-1
Mobilization of the anterior mitral leaflet for excision of a left ventricular myxoma. Talwalkar NG, et al. **Ann Thorac Surg** 1999 May;67(5):1476-8
Cardiac explantation and autotransplantation. Wagner S, et al. **AORN J** 1999 Jul;70(1):99-100, 102, 104-7; quiz 108-12 (13 ref.)
Primary cardiac angiosarcoma with superior vena caval syndrome: review of surgical resection and interventional management of venous inflow obstruction. Uchita S, et al. **Can J Cardiol** 1998 Oct;14(10):1283-5
Ventricular myxoma [letter] Maish M, et al. **Can J Surg** 1998 Oct;41(5):410
Cardiac metastases from malignant melanoma. Gibbs P, et al. **Cancer** 1999 Jan 1;85(1):78-84 (38 ref.)
Extrapericardial solitary fibrous tumour of the pericardium. Andreani SM, et al. **Eur J Cardiothorac Surg** 1998 Jul; 14(1):98-100
Resection of a right atrial metastatic melanoma with unknown origin of primary tumor. Bossert T, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):373-5
Video-assisted cardiac surgery for intracardiac tumors. Chang YS, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S160-5
Mitral valve repair for anterior leaflet papillary fibroelastoma: two case descriptions and a literature review. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):103-7 (36 ref.)
Results of treatment of 17 patients with heart tumour. Gersak B, et al. **Eur J Surg Oncol** 1999 Jun;25(3):302-5
Cardiac papillary fibroelastoma: report of two cases. Fiorani B, et al. **G Ital Cardiol** 1999 Sep;29(9):1027-9
Recurrent myxoma of the left ventricle. Case report and review of the literature. Bortolotti U, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):233-5 (8 ref.)
Left atrial approach to big myxoma with angiographically visible neovascularity. Report of one case. Centofanti P, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):391-3
The long term results of treatment of heart myxomas with special attention to very rare myxoma of the right ventricle. Gawdzinski MP, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):121-9
Surgical management of right atrial myxomas. A 15 year experience with review of the literature. Selvaraj A, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):101-5
Left ventricular rhabdomyoma. A case report. Stellingwerff GC, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):131-3
Recurrent left-sided heart leiomyosarcoma: should heart transplantation be legitimate? Babatasi G, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1133-8
Conservative surgery for atrioventricular valve myxoma. Roques F, et al. **J Heart Valve Dis** 1999 Jul;8(4):460-2
Primary pericardial synovial sarcoma: a case report and literature review. Al-Rajhi N, et al. **J Surg Oncol** 1999 Mar;70(3):194-8 (18 ref.)
Cardiac valve papillary fibroelastoma: surgical excision for revealed or potential embolization. Grinda JM, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):106-10
Treatment of life-threatening huge atrial myxoma: report of two cases. Asai Y, et al. **Surg Today** 1999;29(8):813-6
Application of retrograde cerebral perfusion and moderate systemic hypothermic circulatory arrest for cavoatrial tumor resection. Beltz MS, et al. **Tech Urol** 1999 Jun; 5(2):87-91
Minimally invasive extirpation of a left-ventricular myxoma. Gulbins H, et al. **Thorac Cardiovasc Surg** 1999 Apr; 47(2):129-30
[Leiomyosarcoma of the heart and great vessels] Babatasi G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jul-Sep; 47(7):451-8 (43 ref.) (Eng. Abstr.) **(Fre)**
[Clinical, anatomical-pathological and therapeutic correlates of benign intracavitary heart tumors] Vicol C, et al. **Chirurg** 1998 Dec;69(12):1357-61 (Eng. Abstr.) **(Ger)**
[Clinical experience with surgical management of atrial myxoma] Simonfalvi I, et al. **Orv Hetil** 1999 May 16; 140(20):1103-6 (Eng. Abstr.) **(Hun)**
[Primary cardiac synovial sarcoma--a case report] Fujioka M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep; 46(9):923-7 (Eng. Abstr.) **(Jpn)**
[Cardiac hemangioma of the right ventricle--report of a case] Harada H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Jul; 46(7):629-33 (16 ref.) (Eng. Abstr.) **(Jpn)**
[A case of cardiac lipoma in the ventricular septum] Kato Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):1057-60 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Right ventricular myxoma in a 71-year-old female] Kumamoto T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):733-6 (Eng. Abstr.) **(Jpn)**
[Primary leiomyosarcoma of the heart, report of a case and review of the literature] Myojin K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1339-44 (16 ref.) (Eng. Abstr.) **(Jpn)**
[A case of primary cardiac malignant fibrous histiocytoma] Baba T, et al. **Kyobu Geka** 1998 Sep;51(10):849-52 (Eng. Abstr.) **(Jpn)**
[Coronary artery fistula with left atrial myxoma: report of a case] Murakawa T, et al. **Kyobu Geka** 1998 Nov; 51(12):1035-8 (Eng. Abstr.) **(Jpn)**
[Echo-guided extirpation of huge left atrial myxoma] Ota T, et al. **Kyobu Geka** 1999 Feb;52(2):109-11 (Eng. Abstr.) **(Jpn)**
[Surgical removal of right atrial myxoma with severe hypoxemia caused by right to left shunt through persistent foramen ovale] Saito H, et al. **Kyobu Geka** 1998 Dec; 51(13):1135-6 (Eng. Abstr.) **(Jpn)**
[Successful removal of a left ventricular fibroma in a 10-year-old patient] Yoshimura Y, et al. **Kyobu Geka** 1998 Nov;51(12):1043-6 (Eng. Abstr.) **(Jpn)**
[Cardiac fibroma: diagnosis and surgical treatment] Rueda Núñez F, et al. **An Esp Pediatr** 1999 Feb;50(2):177-80 **(Spa)**

THERAPY

Combined surgical and medical approach to intravenous leiomyomatosis with cardiac extension. Hameleers JA, et al. **Acta Chir Belg** 1999 Apr;99(2):92-4
Successful treatment of a patient with cardiac lymphoma who presented with a complete atrioventricular block. Nagano M, et al. **Am J Hematol** 1998 Oct;59(2):171-4
Long-term remission after resection, chemotherapy, and irradiation of a metastatic myxoma. Bernet F, et al. **Ann Thorac Surg** 1998 Nov;66(5):1791-2
[Diagnostic and prognostic aspects of myxoma syndrome] Konstantinov BA, et al. **Klin Med (Mosk)** 1999;77(1):22-6 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Echocardiographic and morphologic characteristics of left atrial myxoma and their relation to systemic embolism. Ha JW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1579-82, A8
Unusual cause of intraoperative hypotension diagnosed with transoesophageal echocardiography in a patient with renal cell carcinoma. Plowman AN, et al. **Anaesth Intensive Care** 1999 Feb;27(1):63-5
Intracardiac leiomyomatosis: echocardiographic features. Kullo IJ, et al. **Chest** 1999 Feb;115(2):587-91
Prenatal detection of a pericardial teratoma. Daniels CJ, et al. **Circulation** 1999 Jan 19;99(2):E1-2
Primary cardiac malignancy masquerading as mitral valve stenosis. Subbarao VD, et al. **Circulation** 1999 May 4; 99(17):2342-4
Benign intracardiac teratoma detected prenatally. Case report and review of the literature. Campagne G, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):105-8 (28 ref.)
Echocardiography of a right atrial mass in hepatocellular carcinoma. Yoshitomi Y, et al. **Heart Vessels** 1998; 13(1):45-8
Giant interatrial septal aneurysm mimicking a right atrial tumor. Malaterre HR, et al. **Int J Card Imaging** 1998 Jun; 14(3):163-6
Myxoma of the mitral valve: diagnosis by 2-dimensional and 3-dimensional echocardiography. Handke M, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):773-6
Right- and left-sided interatrial septal aneurysm mimicking atrial tumor and stroke. Malaterre HR, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):829-31
Transthoracic echocardiographic power motion tissue imaging of an intracardiac tumor that could not be seen with conventional transthoracic echocardiographic recordings. Maxted WC Jr, et al. **J Am Soc Echocardiogr** 1998 Oct;11(10):989-91
Left atrial leiomyosarcoma: double occurrence and double recurrence--report of one case. Minardi G, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1171-6 (38 ref.)
Prenatal diagnosis of intrapericardial teratoma: a case report. Fujimori K, et al. **J Obstet Gynaecol Res** 1999 Apr; 25(2):133-6
Prenatal diagnosis of tuberous sclerosis in monozygotic twins with cardiac masses. Gushiken BJ, et al. **J Ultrasound Med** 1999 Feb;18(2):165-8
Prenatal diagnosis of cardiac osteoma: a case report. Fung TY, et al. **Prenat Diagn** 1998 Nov;18(11):1209-11
In utero diagnosis of intrapericardial teratoma: a case for in utero open fetal surgery. Riskin-Mashiah S, et al. **Prenat Diagn** 1998 Dec;18(12):1328-30
In utero diagnosis of cardiac hemangioma. Tseng JJ, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):363-5
[Ultrasonography in the diagnosis of heart carcinoma metastasis from liver cancer. Report of 2 cases] Gao M, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):366 **(Chi)**
[Congenital generalized dropsy and intrapericardial fetal teratoma. Report of a case of prenatal diagnosis] Lindner V, et al. **Ann Pathol** 1999 Apr;19(2):131-4 (Eng. Abstr.) **(Fre)**
[Cardiac myxoma in patients over 75 years of age. Report of 19 cases] Bire F, et al. **Arch Mal Coeur Vaiss** 1999 Mar; 92(3):323-8 (Eng. Abstr.) **(Fre)**
[Papillary fibroelastoma. Report of 3 cases] Carmi D, et al. **Arch Mal Coeur Vaiss** 1999 Mar;92(3):331-5 (Eng. Abstr.) **(Fre)**
[Multi-plane transesophageal echocardiography in cardiac angiosarcoma. Apropos of a case] Rojas M, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1289-93 (Eng. Abstr.) **(Fre)**
[Papillary fibroelastoma of the heart (giant Lambl excrescence). Clinical-anatomical study on 10 surgically treated patients] Loire R, et al. **Presse Med** 1998 Apr 25; 27(16):753-7 (Eng. Abstr.) **(Fre)**
[What is your diagnosis? Papillary fibroelastoma of the right coronary aortic sinus--embolism with 2 transient cerebral ischemia attacks] Günter C, et al. **Schweiz Rundsch Med Prax** 1998 Aug 12;87(33):1009-11 **(Ger)**
[A 70-year-old woman with left atrial mass] Kataoka H. **J Cardiol** 1999 May;33(5):283-5 **(Jpn)**
[A papillary fibroelastoma of the left ventricule in the presence of a mitral valve prosthesis. A case report and review of the literature] Román Herrera L, et al. **Arch Inst Cardiol Mex** 1998 May-Jun;68(3):232-8 (57 ref.) (Eng. Abstr.) **(Spa)**
[Cardiac primary lymphoma] Roca L, et al. **Medicina (B Aires)** 1998;58(6):736-8 (Eng. Abstr.) **(Spa)**
[Isolated left ventricular myxoma discovered incidentally by echocardiography] Ramirez Moreno A, et al. **Rev Esp Cardiol** 1998 Sep;51(9):763-5 (Eng. Abstr.) **(Spa)**

VETERINARY

Benign masses in the pericardium of two dogs. Simpson DJ, et al. **Aust Vet J** 1999 Apr;77(4):225-9
Spontaneous pericardial mesothelioma in a rhesus monkey. Chandra M, et al. **J Med Primatol** 1999 Jun;28(3):142-4
Intrapericardial neoplasia in dogs. Girard C, et al. **J Vet Diagn Invest** 1999 Jan;11(1):73-8
Cardiac tumors in dogs: 1982-1995. Ware WA, et al. **J Vet Intern Med** 1999 Mar-Apr;13(2):95-103
Metastatic intracavitary cardiac aortic body tumor in a dog. Cho KO, et al. **J Vet Med Sci** 1998 Nov;60(11):1251-3

HEART RATE

Power spectral analysis of heart rate variability by autoregressive modelling and fast Fourier transform: a comparative study. Fagard RH, et al. **Acta Cardiol** 1998; 53(4):211-8
Electronic fetal monitoring: what's reassuring? [see comments] Berkus MD, et al. **Acta Obstet Gynecol Scand** 1999 Jan;78(1):15-21. Comment in: Acta Obstet Gynecol Scand 1999 Aug;78(7):657-8.
Telemetric registration of heart rate and blood pressure in the same unrestrained goats during pregnancy, lactation and the non-pregnant, non-lactating period. Hydbring E, et al. **Acta Physiol Scand** 1999 Feb;165(2):135-41
Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. Bonaduce D, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):273-84
A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Katz A, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):32-8
Effects of exercise training on chronotropic incompetence in patients with heart failure. Keteyian SJ, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):233-40
Preserved diagnostic utility of dobutamine stress echocardiography in pacemaker-dependent patients with absolute chronotropic incompetence. Oral H, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):364-8

Neurohumoral activations in congestive heart failure: correlations with cardiac function, heart rate variability, and baroreceptor sensitivity. Yoshikawa T, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):666–71

Heart rate variability and occurrence of ventricular arrhythmias during balloon occlusion of a major coronary artery. Airaksinen KE, et al. **Am J Cardiol** 1999 Apr 1; 83(7):1000–5

What is the ideal rate-adaptive sensor for patients with implantable cardioverter defibrillators: lessons from cardiac pacing. Alt E. **Am J Cardiol** 1999 Mar 11;83(5B):17D–23D (10 ref.)

Comparison of ramp versus step protocols for exercise testing in patients > or = 60 years of age. Bader DS, et al. **Am J Cardiol** 1999 Jan 1;83(1):11–4

Clinical significance of multiple sensor options: rate response optimization, sensor blending, and trending. Clémenty J, et al. **Am J Cardiol** 1999 Mar 11;83(5B):166D–171D (20 ref.)

Effects of physical training on heart rate variability in patients on hemodialysis. Deligiannis A, et al. **Am J Cardiol** 1999 Jul 15;84(2):197–202

Relation of mean heart rate and heart rate variability in patients with left ventricular dysfunction. Hedman AE, et al. **Am J Cardiol** 1999 Jul 15;84(2):225–8

Heart rate variability in carcinoid heart disease. Hoffmann J, et al. **Am J Cardiol** 1999 Jan 1;83(1):128–31, A9

Influence of heart rate on stroke volume variability in atrial fibrillation in patients with normal and impaired left ventricular function. Kerr AJ, et al. **Am J Cardiol** 1998 Dec 15;82(12):1496–500

Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Lanza GA, et al. **Am J Cardiol** 1998 Dec 1;82(11):1323–8

Comparison of cardiopulmonary responses in obese women using ramp versus step treadmill protocols. McInnis KJ, et al. **Am J Cardiol** 1999 Jan 15;83(2):289–91, A7

Heart rate dynamics before spontaneous onset of ventricular fibrillation in patients with healed myocardial infarcts. Mäkikallio TH, et al. **Am J Cardiol** 1999 Mar 15;83(6):880–4

Fractal analysis of heart rate dynamics as a predictor of mortality in patients with depressed left ventricular function after acute myocardial infarction. TRACE Investigators. TRAndolapril Cardiac Evaluation. Mäkikallio TH, et al. **Am J Cardiol** 1999 Mar 15;83(6):836–9

Chronotropic competence of the sinus node in congenital complete heart block. Menon A, et al. **Am J Cardiol** 1998 Nov 1;82(9):1119–21, A9

Effect of end-stage renal disease on decreased heart rate variability. Steinberg AA, et al. **Am J Cardiol** 1998 Nov 1;82(9):1156–8, A10

Predictors and significance of atrial rhythm before and six months after percutaneous balloon mitral commissurotomy. Wang A, et al. **Am J Cardiol** 1999 Jan 1;83(1):125–8, A9

Face immersion in cold water induces prolongation of the QT interval and T-wave changes in children with nonfamilial long QT syndrome. Yoshinaga M, et al. **Am J Cardiol** 1999 May 15;83(10):1494–7, A8

Heart rate is a simplistic marker of mortality in acute myocardial infarction. Futterman LG, et al. **Am J Crit Care** 1999 May;8(3):197–9 (4 ref.)

Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. Greenland P, et al. **Am J Epidemiol** 1999 May 1;149(9):853–62

Characterization of autonomic dysfunction in patients with irritable bowel syndrome by means of heart rate variability studies. Adeyemi EO, et al. **Am J Gastroenterol** 1999 Mar; 94(3):816–23

Heart rate variability and autonomic function during sleep in fragile X syndrome [letter] Ferri R, et al. **Am J Med Genet** 1999 Apr 2;83(4):296–7

Demonstration of nonlinear components in heart rate variability of healthy persons. Braun C, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1577–84

Large-magnitude, transient, bradycardic events in rabbits. Roach D, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R243–9

31P NMR studies of creatine kinase flux in M-creatine kinase-deficient mouse heart. Van Dorsten FA, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1191–9

Baroreflex control of heart rate in a canine model of obstructive sleep apnea. Brooks D, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1293–7

Entrainment of blood pressure and heart rate oscillations by periodic breathing. Lorenzi-Filho G, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1147–54

Relief of chronic pain may be accompanied by an increase in a measure of heart rate variability. Storella RJ, et al. **Anesth Analg** 1999 Aug;89(2):448–50

Effects of emergency ambulance transportation on heart rate, blood pressure, corticotropin, and cortisol [letter] Witzel K. **Ann Emerg Med** 1999 May;33(5):598–9

Linear and nonlinear properties of heart rate variability: influence of obesity. Gastaldelli A, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:249–54

Role of the basolateral amygdala in panic disorder. Shekhar A, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:747–50

Diabetic cardiac autonomic dysfunction: parasympathetic versus sympathetic. Uehara A, et al. **Ann Nucl Med** 1999 Apr;13(2):95–100

Correlation between heart rate variability and hypothermic storage in human cardiac transplant recipients. Biernat M, et al. **Ann Transplant** 1998;3(4):37–40

High heart rate: a risk factor for cardiovascular death in elderly men. Palatini P, et al. **Arch Intern Med** 1999 Mar 22;159(6):585–92

Radial basis function neural networks for the characterization of heart rate variability dynamics. Bezerianos A, et al. **Artif Intell Med** 1999 Mar;15(3):215–34

Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Christensen JH, et al. **Atherosclerosis** 1999 Jul;145(1):181–6

The effect of single engine fixed wing air transport on rate-responsive pacemakers. De Rotte AA, et al. **Aviat Space Environ Med** 1999 Sep;70(9):892–6

Role of arterial baroreceptor function on cardiovascular adjustments to acute and chronic dynamic exercise. Krieger EM, et al. **Biol Res** 1998;31(3):273–9 (33 ref.)

Blood pressure and heart rate responses to cold pressor test in patients admitted to hospital due to chest pain. Sevre K, et al. **Blood Press** 1999;8(2):110–3

Temporal stability of ambulatory blood pressure and heart rate in youths. Harshfield GA, et al. **Blood Press Monit** 1999 Apr;4(2):87–90

Surgical stress attenuates reflex heart rate response to hypotension. Kohno N, et al. **Can J Anaesth** 1998 Aug; 45(8):746–52

Influence of age on ambulatory electrocardiogram-derived heart rate variability. Soejima K, et al. **Can J Cardiol** 1999 Feb;15(2):181–4

A typical pattern of activation in the right atrium during paroxysmal atrial fibrillation: the washing-machine phenomenon. Adam M, et al. **Cardiologia** 1999 Jan; 44(1):63–8

Additional predictive value of heart rate variability in high-risk patients surviving an acute myocardial infarction. Lanza GA, et al. **Cardiologia** 1999 Mar;44(3):249–53

Neurocardiac and cerebral responses evoked by esophageal vago-afferent stimulation in humans: effect of varying intensities. Kamath MV, et al. **Cardiovasc Res** 1998 Dec; 40(3):591–9

Recovery kinetics of oxygen uptake and heart rate in patients with coronary artery disease and heart failure. Pavia L, et al. **Chest** 1999 Sep;116(3):808–13

Short-term rhythms of the cardiorespiratory system and their significance in neonatology. Patzak A. **Chronobiol Int** 1999 May;16(3):249–68 (159 ref.)

Heart rate variability as an assessment of acute rejection after heart transplantation. Chou CL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):561–7

Screening of obstructive sleep apnea syndrome by heart rate variability analysis. Roche F, et al. **Circulation** 1999 Sep 28;100(13):1411–5

Exercise test in Parkinson's disease. Reuter I, et al. **Clin Auton Res** 1999 Jun;9(3):129–34

The effects of an angiotensin-converting inhibitor (enalapril) on patients with mild cardiac failure--evaluating cardiac function based on the relationship between daily walking pace and heart rate. Inooka E, et al. **Clin Cardiol** 1998 Dec; 21(12):893–8

Frequency domain heart rate variability and plasma norepinephrine level in the coronary sinus during handgrip exercise. Kurita A, et al. **Clin Cardiol** 1999 Mar; 22(3):207–12

Wavelet transform analysis of heart rate variability during dipyridamole-induced myocardial ischemia: relation to angiographic severity and echocardiographic dyssynergy. Petretta M, et al. **Clin Cardiol** 1999 Mar;22(3):201–6

Current clinical applications of heart rate variability. Stys A, et al. **Clin Cardiol** 1998 Oct;21(10):719–24 (38 ref.)

Effect of a novel environment on resting heart rate in panic disorder. Larsen DK, et al. **Depress Anxiety** 1998;8(1):24–8

An automatic device for the assessment of cardiovascular autonomic function. Weston PJ, et al. **Diabet Med** 1998 Aug;15(8):700–4

Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Laitinen T, et al. **Diabetes** 1999 Jun;48(6):1295–9

Evidence of defective cardiovascular regulation in insulin-dependent diabetic patients without clinical autonomic dysfunction. Weston PJ, et al. **Diabetes Res Clin Pract** 1998 Dec;42(3):141–8

Ratings of perceived exertion (RPE) during cycling exercises at constant power output. Garcin M, et al. **Ergonomics** 1998 Oct;41(10):1500–9

Cardiovascular reactivity in Zimbabwe. Taylor TR, et al. **Ethn Dis** 1999 Spring-Summer;9(2):264–71

Heart rate variability and prognosis in coronary artery disease [letter] Fauchier L, et al. **Eur Heart J** 1999 Aug; 20(15):1135–6

Energy intake and expenditure: validation of a diet history by heart rate monitoring, activity diary and doubly labeled water. Rothenberg E, et al. **Eur J Clin Nutr** 1998 Nov; 52(11):832–8

Toward a heart rate and axillary temperature chronome in schizophrenia: gauge of disease severity. Denisov M, et al. **Funct Neurol** 1999 Jan-Mar;14(1):13–20

Agency, communion, and cardiovascular reactivity during marital interaction. Smith TW, et al. **Health Psychol** 1998 Nov;17(6):537–45

A new physiological method for heart rate correction of the QT interval. Davey P. **Heart** 1999 Aug;82(2):183–6

Heart rate variability and cardiac failure [letter; comment] Fauchier L, et al. **Heart** 1999 May;81(5):561–2. Comment on: Heart 1998 Sep;80(3):213–4.

Heart rate variability and cardiac failure [editorial] [see comments] Lombardi F, et al. **Heart** 1998 Sep;80(3):213–4 (17 ref.). Comment in: Heart 1999 May;81(5):561; discussion 562. Comment in: Heart 1999 May;81(5):561–2.

Heart rate variability and cardiac failure [letter; comment] Nolan J, et al. **Heart** 1999 May;81(5):561; discussion 562 . Comment on: Heart 1998 Sep;80(3):213–4.

Change in heart rate variability preceding ST elevation in a patient with vasospastic angina pectoris. Ooie T, et al. **Heart Vessels** 1998;13(1):40–4

Power spectral analysis of variations in heart rate in patients with hyperthyroidism or hypothyroidism. Inukai T, et al. **Horm Metab Res** 1998 Aug;30(8):531–5

Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Benetos A, et al. **Hypertension** 1999 Jan;33(1):44–52

Appropriate regulation of renin and blood pressure in 45-kb human renin/human angiotensinogen transgenic mice. Catanzaro DF, et al. **Hypertension** 1999 Jan;33(1 Pt 2):318–22

Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Minami J, et al. **Hypertension** 1999 Jan;33(1 Pt 2):586–90

Need for a revision of the normal limits of resting heart rate. Palatini P. **Hypertension** 1999 Feb;33(2):622–5

Effect of sinoaortic deafferentation on renal wrap hypertension. VanNess JM, et al. **Hypertension** 1999 Jan; 33(1 Pt 2):476–81

ECG beat detection using filter banks. Afonso VX, et al. **IEEE Trans Biomed Eng** 1999 Feb;46(2):192–202

Spin-offs from blood pressure and heart rate studies for health care and space research. Halberg F, et al. **In Vivo** 1999 Jan-Feb;13(1):67–76 (133 ref.)

Differences in heart rate variability between young and elderly normal men during graded head up tilt. Akatsu J, et al. **Ind Health** 1999 Jan;37(1):68–75

Shift work-related problems in 16-h night shift nurses (1): Development of an automated data processing system for questionnaires, heart rate, physical activity and posture. Fukuda H, et al. **Ind Health** 1999 Apr;37(2):219–27

Rate pressure product and oxygen saturation in tourists at approximately 3000 m above sea level. Nishihara F, et al. **Int Arch Occup Environ Health** 1998 Nov;71(8):520–4

Spatial features in body surface potential maps of patients with ventricular tachyarrhythmias with or without coronary artery disease. Stellbrink C, et al. **Int J Cardiol** 1999 Jul 31;70(2):109–18

Haemodynamic response to an isometric exercise test in obese patients: influence of autonomic dysfunction. Valensi P, et al. **Int J Obes Relat Metab Disord** 1999 May;23(5):543–9

The effects of repeated occlusion measurement on blood pressure and pulse rate. Tomaka J, et al. **Int J Psychophysiol** 1998 Nov;30(3):353–8

Cardio-respiratory load of exercise training in patients with severe COPD. Rooyackers JM, et al. **Int J Rehabil Res** 1998 Sep;21(3):259–71

The Conconi test: a controversial concept for the determination of the anaerobic threshold in young rowers. Bourgois J, et al. **Int J Sports Med** 1998 Nov;19(8):553–9

The ventilatory threshold, heart rate, and endurance performance: relationships in elite cyclists. Hoogeveen AR, et al. **Int J Sports Med** 1999 Feb;20(2):114–7

Exhaustive endurance training for 6-9 weeks did not induce changes in intrinsic heart rate and cardiac autonomic modulation in female athletes. Uusitalo AL, et al. **Int J Sports Med** 1998 Nov;19(8):532–40

Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. Farshi R, et al. **J Am Coll Cardiol** 1999 Feb;33(2):304–10

Variation of P-QRS relation during atrioventricular node reentry tachycardia. Taniguchi Y, et al. **J Am Coll Cardiol** 1999 Feb;33(2):376–84

Estimation of energy expenditure from heart rate measurements in cattle maintained under different conditions. Brosh A, et al. **J Anim Sci** 1998 Dec; 76(12):3054–64

The effect of shot biopsy on behavior, salivary cortisol, and heart rate in slaughter pigs. Geverink NA, et al. **J Anim Sci** 1999 Jul;77(7):1614–9

Relationship between activity levels, aerobic fitness, and body fat in 8- to 10-yr-old children. Rowlands AV, et al. **J Appl Physiol** 1999 Apr;86(4):1428–35

Subtyping stereotypic behavior in children: the association between stereotypic behavior, mood, and heart rate. Willemsen-Swinkels SH, et al. **J Autism Dev Disord** 1998 Dec;28(6):547–57

Psychosocial stress-induced heart rate reactivity and atherogenesis: cause or correlation? Sharpley CF. **J Behav Med** 1998 Oct;21(5):411–32 (110 ref.)

Differences between ECG and pulse when measuring heart rate and reactivity under two physical and two psychological stressors. Sharpley CF, et al. **J Behav Med** 1999 Jun;22(3):285–301

Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. Feron O, et al. **J Biol Chem** 1998 Nov 13;273(46):30249–54

Increased plasma epinephrine but not reduced heart rate variability leads to ventricular arrhythmias in patients with acute myocardial infarction. Ejima J, et al. **J Cardiol** 1998 Aug;32(2):69–75

Differences among heart rate variability measures after anesthesia and cardiac surgery. Storella RJ, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):451–3

Parasympathetic inhibition of sympathetic effects on pacemaker location and rate in hearts of anesthetized dogs. Miyashita Y, et al. **J Cardiovasc Electrophysiol** 1999 Aug; 10(8):1066–76

Right vagal nerve stimulation during minimally invasive direct coronary artery bypass grafting in dogs. A preliminary study. Hayashi I, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):469–71

The autonomic control of heart rate and insulin resistance in young adults. Flanagan DE, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1263–7

Image vividness as a psychophysiological regulator in Posttraumatic Stress Disorder. Laor N, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):39–48

A noninvasive radiotelemetry system to monitor heart rate for assessing stress responses of bovines. Lefcourt AM, et al. **J Dairy Sci** 1999 Jun;82(6):1179–87

Beat-to-beat QRS variability in the 12-lead ECG and the detection of coronary artery disease. Sörnmo L, et al. **J Electrocardiol** 1998 Oct;31(4):336–44

Cost of walking and locomotor impairment [published erratum appears in J Electromyogr Kinesiol 1999 Jun;9(3):235] Bernardi M, et al. **J Electromyogr Kinesiol** 1999 Apr;9(2):149–57

Preserved blood pressure and heart rate circadian rhythm in early stage Alzheimer's disease [see comments] Cugini P, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jun; 54(6):M304–8. Comment in: J Gerontol A Biol Sci Med Sci 1999 Jun;54(6):M309–11.

Commentary: Chronomes: time structures within the physiological range identify early disease risk aiming at primary prevention [comment] Halberg F, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jun;54(6):M309–11. Comment on: J Gerontol A Biol Sci Med Sci 1999 Jun;54(6):M304–8.

Power spectra of arterial pressure and heart rate in streptozotocin-induced diabetes in rats. Fazan R Jr, et al. **J Hypertens** 1999 Apr;17(4):489–95

Changes in short-term variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. Verwaerde P, et al. **J Hypertens** 1999 Aug;17(8):1135–43

Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Jensen-Urstad K, et al. **J Intern Med** 1999 Jan;245(1):57–61

Correlation of acute and chronic defibrillation threshold with upper limit of vulnerability determined in normal sinus rhythm. Birgersdotter-Green U, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):155–61

Influence of a Biokinergia session on cardiorespiratory and metabolic adaptations of trained subjects. Flore P, et al. **J Manipulative Physiol Ther** 1998 Nov–Dec;21(9):621–8

Heart rate monitoring as a field method for estimating energy expenditure as evaluated by the doubly labeled water method. Kashiwazaki H. **J Nutr Sci Vitaminol (Tokyo)** 1999 Jan;45(1):79–94

Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability [see comments] To J, et al. **J Pediatr** 1999 Sep;135(3):363–6. Comment in: J Pediatr 1999 Sep;135(3):276–7.

Cardiovascular reactivity and neuroticism: results from a laboratory and controlled ambulatory stress protocol. Schwebel DC, et al. **J Pers** 1999 Feb;67(1):67–92

Power spectral analysis of heart rate variability in type A females during a psychomotor task. Sato N, et al. **J Psychosom Res** 1998 Aug;45(2):159–69

Relationship between physiological factors and clinical pain in dogs scored using a numerical rating scale. Holton LL, et al. **J Small Anim Pract** 1998 Oct;39(10):469–74

Cardiovascular stress and lactate formation during gymnastic routines. Goswami A, et al. **J Sports Med Phys Fitness** 1998 Dec;38(4):317–22

The cardiovascular responses of male subjects to kung fu techniques. Expert/novice paradigm. Jones MA, et al. **J Sports Med Phys Fitness** 1998 Dec;38(4):323–9

Twenty-four-hour ambulatory blood pressure and heart rate monitoring in combat-related posttraumatic stress disorder. Muraoka MY, et al. **J Trauma Stress** 1998 Jul;11(3):473–84

Impaired chronotropic response to exercise stress testing as a predictor of mortality [see comments] Lauer MS, et al. **JAMA** 1999 Feb 10;281(6):524–9. Comment in: JAMA 1999 Feb 10;281(6):565–6.

Metaiodobenzylguanidine and heart rate variability in heart failure. Kurata C, et al. **Jpn Circ J** 1998 Oct;62(10):770–2

Heart rate variability before spontaneous episodes of ventricular tachycardia originating from right ventricular outflow tract in patients without organic heart disease. Yoshida A, et al. **Jpn Circ J** 1998 Oct;62(10):745–9

Cyclic bursts of ventricular premature contractions of more than one minute intervals. Takayanagi K, et al. **Jpn Heart J** 1999 Mar;40(2):135–44

Physiological parameters determined at OBLA vs. a fixed heart rate of 175 beats x min-1 in an incremental test performed by amateur and professional cyclists. Chicharro JL, et al. **Jpn J Physiol** 1999 Feb;49(1):63–9

Power spectral analysis of heart rate variability for assessment of diurnal variation of autonomic nervous activity in miniature swine. Kuwahara M, et al. **Lab Anim Sci** 1999 Apr;49(2):202–8

Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction [see comments] Schmidt G, et al. **Lancet** 1999 Apr 24; 353(9162):1390–6. Comment in: Lancet 1999 Apr 24;353(9162):1377–9.

n-3 fatty acids and the risk of sudden cardiac death assessed by 24-hour heart rate variability. Christensen JH, et al. **Lipids** 1999;34 Suppl:S197

Comparison of heart rate variability spectra using generic relationships of their input signals. Mitov IP, et al. **Med Biol Eng Comput** 1998 Sep;36(5):573–80

Fractal organization of the pointwise correlation dimension of the heart rate. Nahshoni E, et al. **Med Hypotheses** 1998 Nov;51(5):367–76

The slow pulse: is a pacemaker necessary? Corcoran SJ, et al. **Med J Aust** 1999 Jun 7;170(11):556–61 (20 ref.)

Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Hayano J, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1480–8

Intraoperative stress experienced by surgeons and assistants. Yamamoto A, et al. **Ophthalmic Surg Lasers** 1999 Jan; 30(1):27–30

Dynamic beat-to-beat QT-RR relationship during physiotherapy effort in elderly patients without primary heart disease. Arad M, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1240–4

Time trends in the intracardiac potential recorded by pacemaker telemetry: comparison between steroid-eluting small area electrodes. Bernasconi M, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1164–72

Sudden Wenckebach periods and their relationship to neurocardiogenic syncope. Castellanos A, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1580–8

Automatic adjustment of pacemaker stimulation output correlated with continuously monitored capture thresholds: a multicenter study. European Microny Study Group [see comments] Clarke M, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1567–75. Comment in: Pacing Clin Electrophysiol 1999 Jan;22(1 Pt 1):143. Comment in: Pacing Clin Electrophysiol 1999 Apr;22(4 Pt 1):693–4.

An integrated dual sensor system automatically optimized by target rate histogram. Leung SK, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1559–66

Correlation waveform analysis to discriminate monomorphic ventricular tachycardia from sinus rhythm using stored electrograms from implantable defibrillators. Michaud GF, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1146–51

Heel lancing in term new-born infants: an evaluation of pain by frequency domain analysis of heart rate variability. Lindh V, et al. **Pain** 1999 Mar;80(1-2):143–8

A regional gradient of cardiac intrinsic rhythmicity depicted in embryonic cultured multiple hearts. Sakai T, et al. **Pflugers Arch** 1998 Dec;437(1):61–9

In situ and laboratory assessment of heart rate in a Mediterranean limpet using a noninvasive technique. Santini G, et al. **Physiol Biochem Zool** 1999 Mar-Apr; 72(2):198–204

The stretch-activation response may be critical to the proper functioning of the mammalian heart. Vemuri R, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1048–53

Stretch-induced changes in heart rate and rhythm: clinical observations, experiments and mathematical models. Kohl P, et al. **Prog Biophys Mol Biol** 1999;71(1):91–138 (282 ref.)

Cardiac pacing and coronary hemodynamics. Kyriakides ZS, et al. **Prog Cardiovasc Dis** 1999 May-Jun;41(6):471–80 (54 ref.)

Dissociating beliefs about heart rates and actual heart rates in patients with cardiac pacemakers. Windmann S, et al. **Psychophysiology** 1999 May;36(3):339–42

MINI-LOGGER--reliability and validity for estimating energy expenditure and heart rate in adolescents. Troutman SR, et al. **Res Q Exerc Sport** 1999 Mar;70(1):70–4

A comparison of peak heart rates elicited by the 1-mile run/walk and the progressive aerobic cardiovascular endurance run. Vincent SD, et al. **Res Q Exerc Sport** 1999 Mar;70(1):75–8

Locomotor, cardiocirculatory and metabolic adaptations to training in Andalusian and Anglo-Arabian horses. Muñoz A, et al. **Res Vet Sci** 1999 Feb;66(1):25–31

Impact of shift work on cardiovascular functions in a 10-year follow-up study. Murata K, et al. **Scand J Work Environ Health** 1999 Jun;25(3):272–7

Heart period variability during vagal nerve stimulation. Setty AB, et al. **Seizure** 1998 Jun;7(3):213–7

Is QT interval a marker of subclinical atherosclerosis in nondiabetic subjects? The insulin resistance atherosclerosis study (IRAS). Festa A, et al. **Stroke** 1999 Aug; 30(8):1566–71

Heart rate variability and quality of life following kidney and pancreas-kidney transplantation. Hathaway DK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):643–4

Beat averaging alternatives for transmitral Doppler flow velocity images. Hall AF, et al. **Ultrasound Med Biol** 1998 Sep;24(7):971–9

[Optimalization of rate adaptation using Holter functions in DDD/R pacemakers] Novotný T, et al. **Vnitr Lek** 1998 Jun;44(6):342–6 (Eng. Abstr.) **(Cze)**

[Heart rate: a cardiovascular risk factor. Cannes, France, June 5–6, 1998. Proceedings] **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):387–439 **(Fre)**

[Heart rate: relative risk and absolute risk] Beaufils M. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):387–92 (Eng. Abstr.) **(Fre)**

[Heart rate and mortality] Benetos A. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):393–400 (Eng. Abstr.) **(Fre)**

[Variability of heart rate after heart surgery under extracorporeal circulation: aortocoronary bypass or aortic valve replacement] Bronner F, et al. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):549–54 (Eng. Abstr.) **(Fre)**

[Picture of the month. Reduction of heart rate variability after myocardial infarct] Copie X, et al. **Ann Cardiol Angeiol (Paris)** 1998 May;47(5):359–60 **(Fre)**

[Heart rate: mechanical risk] Gosse P. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):401–3 (Eng. Abstr.) **(Fre)**

[Heart rate: risk factor, risk marker] Gosse P. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):438–9 (Eng. Abstr.) **(Fre)**

[Modifications of heart rate and blood pressure during pregnancy] Mounier-Véhier C, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):429–37 (Eng. Abstr.) **(Fre)**

[Heart rate and diabetes mellitus] Mounier-Vehier C, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):420–4 (Eng. Abstr.) **(Fre)**

[Heart rate and lipids] Mounier-Véhier C, et al. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):425–8 (Eng. Abstr.) **(Fre)**

[Heart rate and sympathetic risk] Siché JP. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):404–10 (Eng. Abstr.) **(Fre)**

[Measurement of heart rate] Siché JP. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):411–4 (Eng. Abstr.) **(Fre)**

[Paradoxal lowering of parasympathetic indices in myasthenic patients] Douchet MP, et al. **Arch Mal Coeur Vaiss** 1999 Jun;92(6):711–7 (Eng. Abstr.) **(Fre)**

[Measurement of energy expenditure of children in habitual living conditions] Gottrand F. **Arch Pediatr** 1998 Sep; 5(9):1020–2 (19 ref.) (Eng. Abstr.) **(Fre)**

[Relation of defibrillation threshold on shock duration and discharge capacity. Determination of chronoaxis-rheobase relations of defibrillators] Wagner SM, et al. **Biomed Tech (Berl)** 1998;43 Suppl:358–9 **(Ger)**

[Investigations into synchronisation of heart rate and musical rhythm in a relaxation therapy in patients with cancer pain] Reinhardt U. **Forsch Komplementarmed** 1999 Jun; 6(3):135–41 (Eng. Abstr.) **(Ger)**

[Music and heart rate variability. Study of the effect of music on heart rate variability in healthy adolescents] Escher J, et al. **Schweiz Rundsch Med Prax** 1999 May 20;88(21):951–2 (Eng. Abstr.) **(Ger)**

[Effects of reperfusion and coronary reocclusion on the variability of heart rate in patients with acute myocardial infarction] Pizzi C, et al. **Cardiologia** 1999 Feb;44(2):181–6 (Eng. Abstr.) **(Ita)**

[The predictive value of junctional beats during the radiofrequency transcatheter ablation of the slow pathway of the nodal reentry circuit] Stabile G, et al. **G Ital Cardiol** 1999 May;29(5):549–54 (Eng. Abstr.) **(Ita)**

[Analysis of autocorrelation of cardiac rate as an indicator of cardiac memory] Guarini G, et al. **Recenti Prog Med** 1998 Sep;89(9):454–5 **(Ita)**

[Evaluation of therapy for dilated cardiomyopathy with heart failure by iodine-123 metaiodobenzylguanidine imaging: comparison with heart rate variability power spectral analysis] Li S, et al. **J Cardiol** 1998 Nov;32(5):323–9 (Eng. Abstr.) **(Jpn)**

[Development and evaluation of a new target heart rate formula for the adequate exercise training level in healthy subjects] Narita K, et al. **J Cardiol** 1999 May;33(5):265–72 (Eng. Abstr.) **(Jpn)**

[Exercise capacity in children late after aortic valve replacement using the Konno procedure] Shimokawa T, et al. **Kyobu Geka** 1999 Apr;52(4):281–5 (Eng. Abstr.) **(Jpn)**

[The effects of low-doses of fentanyl, buprenorphine and pentazocine on circulatory responses to endotracheal intubation] Adachi Y, et al. **Masui** 1998 Dec;47(12):1478–81 (Eng. Abstr.) **(Jpn)**

[Hemorrhage exerts different effects on variabilities of heart rate and blood pressure in dogs] Kawase M, et al. **Masui** 1998 Aug;47(8):925–32 (Eng. Abstr.) **(Jpn)**

[Changes of arterial blood pressure and heart rate during induction of anesthesia with propofol--efficacy of propofol titration using bispectral index as an indicator] Masuda T, et al. **Masui** 1999 Jun;48(6):621–6 (Eng. Abstr.) **(Jpn)**

[Evaluation of autonomic nervous system function with heart rate variability analysis in patients with hyperthyroidism and during euthyroidism after pharmacologic and surgical treatment] Barczyński M, et al. **Folia Med Cracov** 1997; 38(3-4):27–35 (Eng. Abstr.) **(Pol)**

[Use of fourier row as a method for analyzing the course of circadian heart rate in patients with left ventricular

ejection fraction impairment] Walichiewicz P, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):477–86 (Eng. Abstr.) **(Pol)**

[Effect of variations of the geomagnetic field and solar activity on human physiological indicators] Doronin VN, et al. **Biofizika** 1998 Jul–Aug;43(4):647–53 (Eng. Abstr.) **(Rus)**

[Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis] Bazhanov NN, et al. **Klin Med (Mosk)** 1998;76(10):32–5 (Eng. Abstr.) **(Rus)**

[Variations of cardiac cycle length in patients with coronary heart disease before and after aortic coronary bypass surgery] Kudrov MK, et al. **Vestn Ross Akad Med Nauk** 1998;(6):28–32 (Eng. Abstr.) **(Rus)**

[The activation patterns during atrial fibrillation in an experimental model] Chorro FJ, et al. **Rev Esp Cardiol** 1999 May;52(5):327–38 (Eng. Abstr.) **(Spa)**

[Effect of the location of myocardial infarction on the variability of heart rate: a study during the acute phase] González Sánchez A, et al. **Rev Esp Cardiol** 1998 Aug; 51(8):642–7 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Slow EEG-power spectra correlate with haemodynamic changes during laryngoscopy and intubation following induction with fentanyl or sufentanil. Freye E, et al. **Acta Anaesthesiol Belg** 1999;50(2):71–6

Hemodynamic effects of epinephrine associated to an epidural clonidine–bupivacaine mixture during combined lumbar epidural and general anesthesia. Senard M, et al. **Acta Anaesthesiol Belg** 1998;49(3):167–73

Comparison of propofol–fentanyl or midazolam–fentanyl intravenous anaesthesia for carotid endarterectomy. Dárdai E, et al. **Acta Chir Hung** 1998;37(3–4):177–82

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus–infected subjects. Noormohamed FH, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1047–52

Improved autonomic neurocardial balance in short–term abstinent alcoholics treated with acamprosate. Agelink MW, et al. **Alcohol Alcohol** 1998 Nov–Dec;33(6):602–5

Motivational effects of alcohol on memory consolidation and heart rate in social drinkers. Bruce KR, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4):693–701

Effects of alcohol use and gender on the dynamics of EKG time–series data. DePetrillo PB, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4):745–50

Increase in beating rate of cultured chick cardiac myocytes by ethanol and inhibition of the increase by antiarrhythmic drugs. Nakamura K, et al. **Alcohol Clin Exp Res** 1999 Apr; 23(4 Suppl):81S–84S

Long–term beta–blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Lin JL, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):658–65

Effects of short–acting and long–acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Tomiyama H, et al. **Am Heart J** 1999 Mar;137(3):543–8

Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24–hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). Anthonio RL, et al. **Am J Cardiol** 1999 Apr 15;83(8):1286–9, A10

Maintenance of sinus rhythm with oral d,l–sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l–Sotalol Atrial Fibrillation/Flutter Study Group. Benditt DG, et al. **Am J Cardiol** 1999 Aug 1;84(3):270–7

Effect of vasoactive therapy on heart rate variability in patients with acutely decompensated congestive heart failure. Burger AJ, et al. **Am J Cardiol** 1999 Aug 15; 84(4):476–8, A10

Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. Frick M, et al. **Am J Cardiol** 1999 Jul 1;84(1):104–8, A9

Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery. Geelen P, et al. **Am J Cardiol** 1999 Aug 1;84(3):345–7, A8–9

Chronotropic response, safety, and accuracy of dobutamine stress echocardiography in patients with atrial fibrillation and known or suspected coronary artery disease. Hobday TJ, et al. **Am J Cardiol** 1998 Dec 1;82(11):1425–7, A9

Cardiovascular effects of sildenafil citrate and recommendations for its use. Kloner RA, et al. **Am J Cardiol** 1999 Sep 9;84(5B):11N–17N (21 ref.)

Efficacy of amiodarone for the termination of persistent atrial fibrillation. Kochiadakis GE, et al. **Am J Cardiol** 1999 Jan 1;83(1):58–61

Digoxin versus placebo for conversion of acute atrial fibrillation to sinus rhythm [letter; comment] Veloso HH, et al. **Am J Cardiol** 1999 Apr 15;83(8):1300–1. Comment on: Am J Cardiol 1998 Sep 1;82(5):584–8.

Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Ylitalo A, et al. **Am J Cardiol** 1999 Mar 15; 83(6):885–9

Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Zimetbaum PJ, et al. **Am J Cardiol** 1999 Feb 1;83(3):450–2, A9

Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis. Fukuhara M, et al. **Am J Hypertens** 1999 May;12(5):519–23

Effects of antihypertensive single–drug therapy on heart rate. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Materson BJ, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 2):9S–11S

Changes in blood pressure and heart rate variability during dental surgery. Matsumura K, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1376–80

Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. White WB, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):806–14

The effect of chronic nitric oxide synthase inhibition on blood pressure and heart rate in unrestrained pregnant rats as recorded by radiotelemetry. Buhimschi CS, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):159–64

Beta–blocker eyedrops and nocturnal arterial hypotension. Hayreh SS, et al. **Am J Ophthalmol** 1999 Sep;128(3):301–9

Effects of 17beta–estradiol on sympathetic activity and pressor response to phenylephrine in ovariectomized rats. He XR, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1202–8

Gastric motor and cardiovascular effects of insulin in dorsal vagal complex of the rat. Krowicki ZK, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G964–72

Autonomic control of heart rate in dogs treated chronically with morphine. Napier LD, et al. **Am J Physiol** 1998 Dec; 275(6 Pt 2):H2199–210

Intrinsic neural regulation of the heart in the chronic, conscious dog. Priola DV, et al. **Am J Physiol** 1998 Jun; 274(6 Pt 2):H2074–84

Oxygen saturation, pulse rate, and particulate air pollution: A daily time–series panel study [see comments] Pope CA3rd, et al. **Am J Respir Crit Care Med** 1999 Feb; 159(2):365–72. Comment in: Am J Respir Crit Care Med 1999 Feb;159(2):354–6.

Characterization of parasympatholytic chronotropic responses following intravenous administration of atropine to clinically normal dogs. Rishniw M, et al. **Am J Vet Res** 1999 Aug;60(8):1000–3

Evaluation of remifentanil for control of haemodynamic response to tracheal intubation. McAtamney D, et al. **Anaesthesia** 1998 Dec;53(12):1223–7

Hemodynamic responses induced by dopamine and dobutamine in anesthetized patients premedicated with clonidine. Ohata H, et al. **Anesth Analg** 1999 Oct; 89(4):843–8

The effect of heart rate control on myocardial ischemia among high–risk patients after vascular surgery [see comments] Raby KE, et al. **Anesth Analg** 1999 Mar; 88(3):477–82. Comment in: Anesth Analg 1999 Mar;88(3):475–6. Comment in: Anesth Analg 1999 Sep;89(3):801.

Sevoflurane speeds recovery of baroreflex control of heart rate after minor surgical procedures compared with isoflurane. Tanaka M, et al. **Anesth Analg** 1999 Aug; 89(2):284–9

Effective dose of isoproterenol–containing test dose in anesthetized children [letter; comment] Tanaka M, et al. **Anesth Analg** 1999 May;88(5):1189–90. Comment on: Anesth Analg 1998 Sep;87(3):549–52.

Individualizing beta–adrenergic blocker therapy: patient–specific target–based heart rate control [editorial; comment] Tuman KJ, et al. **Anesth Analg** 1999 Mar; 88(3):475–6 (10 ref.). Comment on: Anesth Analg 1999 Mar;88(3):477–82.

Heart rate control and ischemia [letter; comment] Zaugg M, et al. **Anesth Analg** 1999 Sep;89(3):801. Comment on: Anesth Analg 1999 Mar;88(3):477–82.

Amplified amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome: improvement by inopamil but not by melatonin. van de Luit L, et al. **Angiology** 1998 Nov;49(11):903–8

Structure of new imidazoline derivatives and their cardiovascular effect in rats. Krzystanek E, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:106–9

Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. Schäfer U, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:97–101

Mechanism of the sympathoinhibition produced by the clonidine–like drugs rilmenidine and moxonidine. Szabo B, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:253–64

Rate control and sinus rhythm maintenance in atrial fibrillation: national trends in medication use, 1980–1996. Stafford RS, et al. **Arch Intern Med** 1998 Oct 26; 158(19):2144–8

The effects of stroma–free and dextran–conjugated hemoglobin on hemodynamics and carotid blood flow in hemorrhaged guinea pigs. Caron A, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jan; 27(1):49–64

Antihypertensive effects of the novel potassium channel activator SKP–450 and its major metabolites in rats. Shin HS, et al. **Arzneimittelforschung** 1998 Oct;48(10):969–78

Effect of inotropic interventions on the force–frequency relation in the human heart. Bavendiek U, et al. **Basic Res Cardiol** 1998;93 Suppl 1:76–85

Digitalis therapy--relevance of heart rate reduction. Erdmann E. **Basic Res Cardiol** 1998;93 Suppl 1:156–9 (23 ref.)

Beta–blocker treatment in heart failure. Role of heart rate reduction. Lechat P. **Basic Res Cardiol** 1998;93 Suppl 1:148–55 (58 ref.)

Influence of forskolin on the force–frequency behavior in nonfailing and end–stage failing human myocardium. Pieske B, et al. **Basic Res Cardiol** 1998;93 Suppl 1:66–75

Adrenergic regulation of the force–frequency effect. Ross J Jr. **Basic Res Cardiol** 1998;93 Suppl 1:95–101 (32 ref.)

Rate–dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Weirich J, et al. **Basic Res Cardiol** 1998;93 Suppl 1:125–32 (33 ref.)

The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Collins ED, et al. **Behav Pharmacol** 1998 Nov;9(7):587–98

Glibenclamide–sensitive hypotension produced by helodermin assessed in the rat. Horikawa N, et al. **Biol Pharm Bull** 1998 Dec;21(12):1290–3

Homeopathic effect on heart rate variability. Ruiz G, et al. **Br Homeopath J** 1999 Jul;88(3):106–11

Respiratory sinus arrhythmia and clinical signs of anaesthesia in children. Blues CM, et al. **Br J Anaesth** 1998 Sep; 81(3):333–7

Evaluation of the effect on heart rate variability of a beta2–adrenoceptor agonist and antagonist using non–linear scatterplot and sequence methods. Hanratty CG, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):157–66

Analysis of the atypical characteristics of adenosine receptors mediating negative inotropic and chronotropic responses of guinea–pig isolated atria and papillary muscles. Gardner NM, et al. **Br J Pharmacol** 1999 Aug;127(7):1619–26

Desensitization of ET(A) endothelin receptor–mediated negative chronotropic response in right atria--species difference and intracellular mechanisms. Ono K, et al. **Br J Pharmacol** 1998 Oct;125(4):787–97

Optimization of magnetic resonance imaging parameters for left ventricular wall motion studies at 0.5 T. Pennell DJ, et al. **Br J Radiol** 1998 Oct;71(850):1033–9

Inhibition of cardiovascular activity following microinjection of novel opioid–like neuropeptide nociceptin (orphanin FQ) into the rat rostral ventrolateral medulla. Chu X, et al. **Brain Res** 1999 May 22;829(1–2):134–42

Endomorphins decrease heart rate and blood pressure possibly by activating vagal afferents in anesthetized rats. Kwok EH, et al. **Brain Res** 1998 Aug 24;803(1–2):204–7

Effect of noradrenergic inputs on the cardiovascular depressor responses to stimulation of central nucleus of the amygdala. Roder S, et al. **Brain Res** 1999 Feb 13; 818(2):531–5

Impaired arterial baroreflex regulation of heart rate after blockade of P2–purinoceptors in the nucleus tractus solitarius. Scislo TJ, et al. **Brain Res Bull** 1998 Sep 1; 47(1):63–7

Diltiazem–lidocaine combination for the attenuation of cardiovascular responses to tracheal intubation in hypertensive patients. Fujii Y, et al. **Can J Anaesth** 1998 Oct;45(10):933–7

Haemodynamic effects of induction of general anaesthesia with propofol during epidural anaesthesia. Kasaba T, et al. **Can J Anaesth** 1998 Nov;45(11):1061–5

The effect of sinus node depression on heart rate variability in humans using zatebradine, a selective bradycardic agent. Khaykin Y, et al. **Can J Physiol Pharmacol** 1998 Jul–Aug; 76(7–8):806–10

Estrogen enhances baroreflex control of heart rate in conscious ovariectomized rats. el–Mas MM, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):381–6

Nimodipine inhibits the pressor activity of diaspirin–crosslinked hemoglobin (DCLHb) in the rat. Rioux F, et al. **Can J Physiol Pharmacol** 1998 Oct–Nov; 76(10–11):983–8

Effects of intravenously administered glycopyrrolate in anesthetized horses. Dyson DH, et al. **Can Vet J** 1999 Jan; 40(1):29–32

Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure. Fauchier L, et al. **Cardiovasc Drugs Ther** 1998 Oct; 12(5):483–6

Differential rate and potassium–dependent effects of the class III agents d–sotalol and dofetilide on guinea pig papillary muscle. Marschang H, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):573–83

Evaluation of the effect on heart rate variability of some agents acting at the beta–adrenoceptor using nonlinear scatterplot and sequence methods. Silke B, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):439–48

Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Tzivoni D, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):239–44

Effect of verapamil on heart rate variability after an acute myocardial infarction. Danish Verapamil Infarction Trial II. Vaage–Nilsen M, et al. **Cardiovasc Drugs Ther** 1998 Jul; 12(3):285–90

Nebivolol: comparison of the effects of dl–nebivolol, d–nebivolol, l–nebivolol, atenolol, and placebo on exercise–induced increases in heart rate and systolic blood pressure. Van Nueten L, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):339–44

Cardiovascular effects of total soyasaponin in central nervous system and its relationship with monoamine transmitters. Guo JH, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May; 17(3):239–41

Altered alpha 1-adrenoceptor subtypes mediated cardiac function after treatment of propranolol to rats. Li W, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):237–40

Effects of moxonidine injected into rostral ventrolateral medulla on blood pressure, heart rate, and renal sympathetic nerve activity in rats. Xu YF, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):415–8

Mathematical treatment of autonomic oscillations [letter] Eckberg DL. **Circulation** 1999 Oct 12;100(15):e63–4

Myocardial bridging [letter] Elson SH. **Circulation** 1999 Jun 29;99(25):3324–5

Cocaine stimulates the human cardiovascular system via a central mechanism of action. Vongpatanasin W, et al. **Circulation** 1999 Aug 3;100(5):497–502

Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Botto GL, et al. **Clin Cardiol** 1998 Nov;21(11):837–40

Significance of reduction in heart rate in cardiovascular disease. Hjalmarson A. **Clin Cardiol** 1998 Dec;21(12 Suppl 2):II3–7 (15 ref.)

The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. Jansson K, et al. **Clin Cardiol** 1999 Jun; 22(6):397–402

Effects of acute alcohol infusion on duration and dispersion of QT interval in male patients with coronary artery disease and in healthy controls. Rossinen J, et al. **Clin Cardiol** 1999 Sep;22(9):591–4

Effect of aprindine on heart rate variability indices in patients with ischemic heart disease. Takase B, et al. **Clin Cardiol** 1999 Feb;22(2):107–12

Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Barbey JT, et al. **Clin Pharmacol Ther** 1999 Jul;66(1):91–9

Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. Pariente-Khayat A, et al. **Clin Pharmacol Ther** 1999 Aug;66(2):136–9

A central gamma-aminobutyric acid mechanism in cardiac vagal control in man revealed by studies with intravenous midazolam. Farmer MR, et al. **Clin Sci (Colch)** 1998 Sep; 95(3):241–8

Effect of adenosine on heart rate variability in humans. Rongen GA, et al. **Clin Sci (Colch)** 1999 Jun;96(6):597–604

Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Rush CR, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1–2):1–12

Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Palatini P. **Drugs** 1999 May;57(5):713–24 (82 ref.)

Succinate sumatriptan evaluation by Doppler echocardiography in patients with migraine. Paterna S, et al. **Drugs Exp Clin Res** 1998;24(3):159–63

Inappropriate rise in heart rate caused by intravenous administration of trospium chloride during upper gastrointestinal endoscopy [letter] Hasselkus W. **Endoscopy** 1998 Aug;30(6):580

Heart rate increase after intravenous administration of trospium chloride and scopolamine during endoscopic retrograde cholangiopancreatography [letter] Pfeiffer A, et al. **Endoscopy** 1999 Aug;31(6):507

Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol [see comments] Andersson B, et al. **Eur Heart J** 1999 Apr;20(8):575–83. Comment in: Eur Heart J 1999 Apr;20(8):560–1.

Beta-blockers for heart failure: is slowing of heart rate essential? [editorial; comment] Tendera M. **Eur Heart J** 1999 Apr;20(8):560–1 (5 ref.). Comment on: Eur Heart J 1999 Apr;20(8):575–83.

Comparison of intravenous metoprolol, verapamil and diltiazem on the attenuation of haemodynamic changes associated with tracheal extubation. Yörükoğlu D, et al. **Eur J Anaesthesiol** 1999 Jul;16(7):462–7

Relationship of blood pressure, heart rate and behavioral mood state to norepinephrine kinetics in younger and older men following caffeine ingestion. Arciero PJ, et al. **Eur J Clin Nutr** 1998 Nov;52(11):805–12

Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. Ericsson H, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):61–7

The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients—assessment by spectral analysis of heart rate and blood pressure variability. Salo TM, et al. **Eur J Clin Pharmacol** 1999 May;55(3):191–8

In vivo and in vitro action of endothelin-1 on goat cerebrovascular bed. Fernández N, et al. **Eur J Pharmacol** 1998 May 8;348(2–3):199–211

Effect of muscimol on cholinomimetic-induced cardiovascular responses in rats. Onat F, et al. **Eur J Pharmacol** 1998 Dec 4;362(2–3):173–81

Autonomic mechanisms in the acute cardiovascular effects of cocaine in conscious rats. Poon J, et al. **Eur J Pharmacol** 1998 Dec 18;363(2–3):147–52

Effects of the optical isomers of verapamil on electrophysiological properties of the heart in conscious dogs. Takahata O, et al. **Eur J Pharmacol** 1998 Aug 21; 355(2–3):159–66

Haemodynamic responses to subconjunctival mydriatic agents (Mydricaine) used for maintenance of perioperative mydriasis in patients undergoing vitreoretinal surgery. Jayamanne DG, et al. **Eye** 1998;12 (Pt 5):792–4

Comparison of the cardiovascular effects of 2.5% phenylephrine and 10% phenylephrine during ophthalmic surgery. Malhotra R, et al. **Eye** 1998;12 (Pt 6):973–5

Effect of interferon therapy on heart rate and sympathetic nervous system. Yamamoto T, et al. **Fukuoka Igaku Zasshi** 1998 Jul;89(7):207–15

The pharmacological basis and pathophysiological significance of the heart rate-lowering property of diltiazem. O'Connor SE, et al. **Fundam Clin Pharmacol** 1999;13(2):145–53 (56 ref.)

Ethanol abolishes clonidine-induced impairment of baroreflex control of heart rate in conscious rats. El-Mas MM. **Gen Pharmacol** 1999 Feb;32(2):207–14

Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. Ricci D, et al. **Gen Pharmacol** 1999 Jan;32(1):29–34

Caffeine attenuates vasovagal reactions in female first-time blood donors. Sauer LA, et al. **Health Psychol** 1999 Jul; 18(4):403–9

Predicting the effect of D,L-sotalol on ventricular tachycardia inducibility from the RR variability response. Brembilla-Perrot B, et al. **Heart** 1999 Sep;82(3):307–11

The functional significance of chronotropic incompetence during dobutamine stress test. Elhendy A, et al. **Heart** 1999 Apr;81(4):398–403

Potential interests of heart rate lowering drugs. Laperche T, et al. **Heart** 1999 Apr;81(4):336–41 (44 ref.)

Angiotensin II modulates cardiovascular autonomic control in the absence of baroreflex loading. Vaile JC, et al. **Heart** 1998 Aug;80(2):127–33

Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Minami J, et al. **Hypertens Res** 1998 Sep; 21(3):215–9

Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Anderson NH, et al. **Hypertension** 1999 Jan;33(1 Pt 2):248–55

Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Mori TA, et al. **Hypertension** 1999 Aug;34(2):253–60

Effect of hyoscine butylbromide and atropine on heart rate during nocturnal sleep. Gitanjali B, et al. **Indian J Exp Biol** 1998 Dec;36(12):1216–20

Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study. Capucci A, et al. **Int J Cardiol** 1999 Feb 28;68(2):187–96

Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. Hayano T, et al. **Int J Cardiol** 1999 Jan;68(1):47–56

Effect of antiarrhythmic therapy with intravenous loading dose of amiodarone: evidence for an altered response in diabetic patients. Iervasi G, et al. **Int J Clin Pharmacol Res** 1998;18(3):109–20

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Sundberg S, et al. **Int J Clin Pharmacol Ther** 1998 Dec;36(12):629–35

Pharmacokinetics and hemodynamic effects of diltiazem in healthy volunteers: comparing resting with the effect of exercise. Yeung PK, et al. **Int J Clin Pharmacol Ther** 1999 Aug;37(8):413–6

Nisoldipine coat-core and heart rate response during treatment of hypertension. Zannad F. **Int J Clin Pract** 1999 Jan-Feb;53(1):65–71

Spectral analysis of heart rate variability and pulmonary responses to topical applications of 2% aminophylline-based thigh cream. Marks BL, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23(2):198–202

Effects of desipramine on autonomic input to the heart. Walsh BT, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep; 38(9):1186–92

Nitric oxide donors can increase heart rate independent of autonomic activation. Hogan N, et al. **J Appl Physiol** 1999 Jul;87(1):97–103

Slowing and attenuation of baroreflex heart rate control with nitrous oxide in exercising men. Ostlund A, et al. **J Appl Physiol** 1999 Aug;87(2):830–4

Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs. Petroianu G, et al. **J Appl Toxicol** 1998 Jul-Aug; 18(4):293–8

Comparison of the baroreceptor-heart rate reflex effects of moxonidine, rilmenidine and clonidine in conscious rabbits. Godwin SJ, et al. **J Auton Nerv Syst** 1998 Oct 15; 72(2–3):195–204

Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Lazzeri C, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):152–9

Influence of sino-aortic barodenervation on the cardiovascular effects of imidazoline-like drugs. Medvedev OS, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):205–9

Effects of dexmedetomidine, an alpha2-adrenoceptor agonist, on renal sympathetic nerve activity, blood pressure, heart rate and central venous pressure in urethane-anesthetized rabbits. Xu H, et al. **J Auton Nerv Syst** 1998 Jun 30; 71(1):48–54

Spectral analysis of intercycle heart fluctuations in the diethyl-ether-anaesthetized or pithed rat treated with prazosin, dl-propranolol, endothelin-1, alpha-r atriopeptin and ACE-inhibitors. Bernardi M, et al. **J Auton Pharmacol** 1998 Oct;18(5):271–80

Blood pressure control in kidney transplant recipients: influence of immunosuppression. Gerhardt U, et al. **J Auton Pharmacol** 1999 Feb;19(1):49–54

Effects of acute clonidine administration on power spectral analysis of heart rate variability in healthy humans. Lazzeri C, et al. **J Auton Pharmacol** 1998 Oct;18(5):307–12

Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid. Vidrio H, et al. **J Auton Pharmacol** 1998 Dec;18(6):363–9

A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients undergoing coronary artery bypass surgery. Searle NR, et al. **J Cardiothorac Vasc Anesth** 1999 Feb; 13(1):20–5

Cardiovascular responses produced by microinjection of serotonin-receptor agonists into the paraventricular nucleus in conscious rats. Bell AA, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):175–80

Cocaine-induced cardiovascular effects: lack of evidence for a central nervous system site of action based on hemodynamic studies with cocaine methiodide. Dickerson LW, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):36–42

Bradykinin B2-receptor-mediated positive chronotropic effect of bradykinin in isolated rat atria. Li Q, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):452–6

Relationships between heart rate and heart rate variability: study in conscious rats. Mangin L, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):601–7

Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. Nakamura K, et al. **J Cardiovasc Pharmacol** 1999 Jun; 33(6):876–82

Short-term increase and long-term decrease of blood pressure in response to oxytocin-potentiating effect of female steroid hormones. Petersson M, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):102–8

Long-acting lacidipine versus short-acting nifedipine in the treatment of asymptomatic acute blood pressure increase. Sánchez M, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):479–84

Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods. Silke B, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):859–67

Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy. Avramov MN, et al. **J Clin Anesth** 1998 Aug;10(5):394–400

Interaction of bradykinin and angiotensin-(1–7) in the central modulation of the baroreflex control of the heart rate. Bomtempo CA, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1797–804

Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. Pancera P, et al. **J Hypertens** 1999 Apr;17(4):513–21

Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients. Petretta M, et al. **J Hypertens** 1999 May;17(5):707–13

Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. Bian JS, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2103–10

Systemic beta-blockade with once daily Betimol or Timoptic-XE. Stewart WC, et al. **J Ocul Pharmacol Ther** 1999 Jun;15(3):225–31

Nicotine-induced perturbations on heart rate, body temperature and locomotor activity daily rhythms in rats. Pelissier AL, et al. **J Pharm Pharmacol** 1998 Aug; 50(8):929–34

Effects of verapamil, zatebradine, and E-4031 on the pacemaker location and rate in response to sympathetic stimulation in dog hearts. Furukawa Y, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1334–42

A novel cardiotonic agent SCH00013 acts as a Ca++ sensitizer with no chronotropic activity in mammalian cardiac muscle. Sugawara H, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):214–22

In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. Willette RN, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):48–53

How does beta-adrenergic stimulation increase the heart rate? The role of intracellular Ca2+ release in amphibian pacemaker cells. Ju YK, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):793–804

Pharmacological control of rate and maintenance of sinus rhythm. Ezekowitz MD, et al. **J Thromb Thrombolysis** 1999 Jan;7(1):33–8 (49 ref.)

Acetylcholine-induced biphasic effect on the maximum upstroke velocity of action potential in mouse right atria: interaction with beta-adrenergic signaling cascade. Islam MA, et al. **Jpn J Pharmacol** 1998 Oct;78(2):181–90

Attenuation of heart-rate variability in postmenopausal women on progestin-containing hormone replacement therapy [letter] [see comments] Christ M, et al. **Lancet** 1999 Jun 5;353(9168):1939–40. Comment in: Lancet 1999 Jul 17;354(9174):256.

Hormone replacement therapy and heart-rate variability [letter; comment] Hayward CS, et al. **Lancet** 1999 Jul 17; 354(9174):256. Comment on: Lancet 1999 Jun 5;(9168):1939–40.

Chronopharmacological effects on nicotine repeated

administration on heart rate, body temperature and locomotor activity circadian rhythms in rats. Pelissier AL, et al. **Life Sci** 1998;63(24):2189–97

5–Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats. Villalón CM, et al. **Life Sci** 1999;64(20):1839–47

Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non–desensitized agonist–like effects. Wallukat G, et al. **Life Sci** 1999;64(6–7):465–9

Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Paolisso G, et al. **Metabolism** 1999 Jun;48(6):755–62

Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Hattori Y. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):123–31 (113 ref.)

Cardiovascular and pharmacokinetic interactions between nicorandil and adjunctive propranolol, atenolol or diltiazem in conscious dogs. Humphrey SJ. **Methods Find Exp Clin Pharmacol** 1998 Nov;20(9):779–91

Limited sex differences in response to "binge" smoked cocaine use in humans. Evans SM, et al. **Neuropsychopharmacology** 1999 Sep;21(3):445–54

The effects of morphine on supraspinal and propriospinal somatocardiac reflexes in anesthetized rats. Uchida S, et al. **Neurosci Lett** 1999 Jul 16;269(3):161–4

Heart rate variability in neonatal rats after perinatal cocaine exposure. Hseu SS, et al. **Neurotoxicol Teratol** 1998 Nov–Dec;20(6):601–5

Systemic NO synthase inhibition blunts the chronotropic, but not the inotropic response to isoprenaline in man. Schmetterer L, et al. **Nitric Oxide** 1999 Jun;3(3):209–15

Elevation of the pacing threshold: a side effect in a patient with pacemaker undergoing therapy with doxorubicin and vincristine. Wilke A, et al. **Oncology** 1999;56(2):110–1

Anesthetic efficacy and heart rate effects of the supplemental intraosseous injection of 2% mepivacaine with 1:20,000 levonordefrin. Guglielmo A, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):284–93

Effects of a selective A1–adenosine receptor agonist on heart rate and heart rate variability during permanent atrial fibrillation. Piot O, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2459–64

Cardiac side effects of long–acting beta–2 agonist salmeterol in asthmatic children. Tunaoğlu FS, et al. **Pediatr Int** 1999 Feb;41(1):28–31

Neural transmitters and a peptide modulate Drosophila heart rate. Zornik E, et al. **Peptides** 1999;20(1):45–51

Lithium chloride–induced cardiovascular changes in rabbits are mediated by adenosine triphosphate–sensitive potassium channels. Abdel–Zaher AO, et al. **Pharmacol Res** 1999 Apr; 39(4):275–82

Pharmacology of nebivolol. Mangrella M, et al. **Pharmacol Res** 1998 Dec;38(6):419–31 (95 ref.)

Cardiovascular activity of 14–deoxy–11,12–didehydroandrographolide in the anaesthetised rat and isolated right atria. Zhang C, et al. **Pharmacol Res** 1998 Dec;38(6):413–7

The cardiovascular effects of amperozide: interactions with cocaine. Jones EA, et al. **Pharmacol Toxicol** 1999 Feb; 84(2):53–8

Caffeine–induced modifications of heart rate, temperature, and motor activity circadian rhythms in rats. Pelissier AL, et al. **Physiol Behav** 1999 Aug 1;67(1):81–8

Breakfast cereal and caffeinated coffee: effects on working memory, attention, mood, and cardiovascular function. Smith AP, et al. **Physiol Behav** 1999 Aug 1;67(1):9–17

Cardiovascular effects of the essential oil of Croton nepetaefolius in rats: role of the autonomic nervous system. Lahlou S, et al. **Planta Med** 1999 Aug;65(6):553–7

Early cardiovascular alterations following experimental spinal cord injury. Larios F, et al. **Proc West Pharmacol Soc** 1998;41:117–9

NADPH–diaphorase histochemistry during the acute cardiovascular changes after spinal cord injury in the rat. Rojas–Martinez R, et al. **Proc West Pharmacol Soc** 1998; 41:115–6

Differential chronergy of propranolol effects on heart rate in healthy and hypertensive subjects. Ruiz–Vega H, et al. **Proc West Pharmacol Soc** 1998;41:71–2

Effects of dothiepin on delayed conduction produced by ventricular arrhythmia in the canine heart after myocardial infarction. Nishimoto M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):335–50

Little evidence that "denicotinized" menthol cigarettes have pharmacological effects: an EEG/heart–rate/subjective–response study. Pritchard WS, et al. **Psychopharmacology (Berl)** 1999 Apr;143(3):273–9

Repeated limited access to i.v. cocaine self–administration: conditioned autonomic rhythmicity illustrating "predictive homeostasis". Tornatzky W, et al. **Psychopharmacology (Berl)** 1999 Jul;145(2):144–52

Cardiorespiratory responses to intracerebroventricular injection of neuropeptide Y in anaesthetised dogs. Morton KD, et al. **Regul Pept** 1999 May 31;81(1–3):81–8

Modulation of chronotropic and inotropic heart vagus actions as a non–pressor effect of angiotensin II in the anaesthetized rat. Wicher C, et al. **Regul Pept** 1998 Jun 30;74(2–3):151–8

Characterisation of the cardiovascular pharmacology of medetomidine in the horse and sheep. Bryant CE, et al. **Res Vet Sci** 1998 Sep–Oct;65(2):149–54

The effect of phenylpropanolamine on the urethral pressure and heart rate is retained after repeated short–term administration in the unanaesthetized, conscious dog. Gillberg PG, et al. **Scand J Urol Nephrol** 1998 May; 32(3):171–6

Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. Scheinin H, et al. **Ther Drug Monit** 1999 Apr;21(2):141–51

Atropine prophylaxis of the postreperfusion syndrome in liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2377

[Effects of alpha and beta blocker properties of parahydroxybenzonitrile on the cardiovascular system of rats] Cheav SL, et al. **Ann Pharm Fr** 1998;56(5):205–8 (Eng. Abstr.) **(Fre)**

[Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents] Sugi K. **J Cardiol** 1999 Mar;33 Suppl 1:59–64 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats] Karasawa A, et al. **Nippon Yakurigaku Zasshi** 1999 May; 113(5):317–26 (Eng. Abstr.) **(Jpn)**

[The variability of the heart rate in the first 24 hours after fibrinolytic therapy in acute myocardial infarct] Bordalo–Sá AL, et al. **Rev Port Cardiol** 1999 Mar; 18(3):261–5 (Eng. Abstr.) **(Por)**

[Participation of mu– and delta–opioid receptors in the vagotropic activity of met–enkephalin] Osadchii OE, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):502–5 **(Rus)**

[Effects leu–enkephalin and dalargin on the cardiac activity in rats during stimulation of postganglionic sympathetic fibers with low frequency impulses] Sitdikov FG, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):140–3 **(Rus)**

[Effect of vagus nerve stimulation on the rat heart rate during blocking of beta–adrenergic receptors with obzidan] Zefirov TL, et al. **Biull Eksp Biol Med** 1998 Dec; 126(12):612–4 **(Rus)**

GENETICS

Heritability of heart rate variability: the Framingham Heart Study. Singh JP, et al. **Circulation** 1999 May 4; 99(17):2251–4

PHYSIOLOGY

Long–term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Athyros VG, et al. **Acta Cardiol** 1998;53(4):201–9

Neurocardiology: the benefits of irregularity. The basics of methodology, physiology and current clinical applications. Aubert AE, et al. **Acta Cardiol** 1999 Jun;54(3):107–20 (107 ref.)

Twenty–four–hour heart rate variability to assess autonomic function in Parkinson's disease. Mastrocola C, et al. **Acta Neurol Scand** 1999 Apr;99(4):245–7

Heart rate variability in the neonate and infant: analytical methods, physiological and clinical observations. Rosenstock EG, et al. **Acta Paediatr** 1999 May;88(5):477–82

Physiological significance of absolute heart rate variability in postural change. Oida E, et al. **Acta Physiol Scand** 1999 Apr;165(4):421–2

Diabetic alteration of cardiac vago–sympathetic modulation assessed with tone–entropy analysis. Oida E, et al. **Acta Physiol Scand** 1999 Feb;165(2):129–34

Relationship between blood pressure and heart–rate variability during graded head–up tilt. Yokoi Y, et al. **Acta Physiol Scand** 1999 Feb;165(2):155–61

Pulmonary training may alter exertional dyspnea and fatigue via an exercise–like training effect of a lowered heart rate. Swanson GD. **Adv Exp Med Biol** 1998;450:231–6

Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. Lauer MS, et al. **Am Heart J** 1999 May;137(5):903–9

Time–dependent changes of HRV after PTCA [letter; comment] Ozcan M, et al. **Am Heart J** 1999 Feb; 137(2):375–6. Comment on: Am Heart J 1998 May;135(5 Pt 1):755–61.

Effect of exercise training on heart rate variability in healthy older adults. Stein PK, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):567–76

Prognostic significance of double product and inadequate double product response to maximal symptom–limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. GISSI–2 Investigators. Grupo Italiano per lo Studio della Sopravvivenza nell–Infarto Miocardico. Villella M, et al. **Am Heart J** 1999 Mar;137(3):443–52

Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease. Watkins LL, et al. **Am Heart J** 1999 Mar;137(3):453–7

Nasal oxygen effects on arterial carbon dioxide pressure and heart rate in chronic heart failure. Andreas S, et al. **Am J Cardiol** 1999 Mar 1;83(5):795–8, A10

Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Aronson D, et al. **Am J Cardiol** 1999 Aug 15;84(4):449–53

Effect of beta–adrenergic blocker therapy on the circadian rhythm of heart rate variability in patients with chronic stable angina pectoris. Burger AJ, et al. **Am J Cardiol** 1999 Feb 15;83(4):596–8, A8

Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Burger AJ, et al. **Am J Cardiol** 1999 Sep 15;84(6):687–91

Heart rate variability after coronary artery bypass grafting [letter; comment] Demirel S, et al. **Am J Cardiol** 1999 Aug 15;84(4):496–7. Comment on: Am J Cardiol 1999 Mar 1;83(5):776–9, A9.

Heart rate variability in healthy children and in those with congenital heart disease both before and after operation. Heragu NP, et al. **Am J Cardiol** 1999 Jun 15;83(12):1654–7

Interaction of a commercial heart rate monitor with implanted pacemakers. Joglar JA, et al. **Am J Cardiol** 1999 Mar 1;83(5):790–2, A10

Heart rate variability in obesity and the effect of weight loss. Karason K, et al. **Am J Cardiol** 1999 Apr 15;83(8):1242–7

Sequential changes in heart rate variability after coronary artery bypass grafting [see comments] Kuo CD, et al. **Am J Cardiol** 1999 Mar 1;83(5):776–9, A9. Comment in: Am J Cardiol 1999 Aug 15;84(4):496–7.

Usefulness of tilt test–induced patterns of heart rate and blood pressure using a two–stage protocol with glyceryl trinitrate provocation in patients with syncope of unknown origin. Kurbaan AS, et al. **Am J Cardiol** 1999 Sep 15;84(6):665–70

Age–related changes of cardiac parasympathetic modulation after vasovagal syncope. Lagi A, et al. **Am J Cardiol** 1999 Mar 15;83(6):977–80, A10

Effect of endurance exercise training on heart rate variability at rest in healthy young and older men. Levy WC, et al. **Am J Cardiol** 1998 Nov 15;82(10):1236–41

Cardiac sympathetic activity as measured by myocardial 123–I–metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. Lotze U, et al. **Am J Cardiol** 1999 Jun 1;83(11):1548–51

Heart rate variability and fatty acid content of blood cell membranes: a dose–response study with n–3 fatty acids. Christensen JH, et al. **Am J Clin Nutr** 1999 Sep;70(3):331–7

Familial aggregation of resting blood pressure and heart rate in a sedentary population: the HERITAGE Family Study. Health, Risk Factors, Exercise Training, and Genetics. An P, et al. **Am J Hypertens** 1999 Mar;12(3):264–70

Association between resting heart rate and hypertension treatment in a general population. Ferrières J, et al. **Am J Hypertens** 1999 Jun;12(6):628–31

The physiological determinants and risk correlations of elevated heart rate. Palatini P, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 2):3S–8S (56 ref.)

Heart rate and the rate–pressure product as determinants of cardiovascular risk in patients with hypertension. White WB. **Am J Hypertens** 1999 Feb;12(2 Pt 2):50S–55S (17 ref.)

Relation between heart rate and problem behaviors. Freeman RL, et al. **Am J Ment Retard** 1999 Jul;104(4):330–45

Changes in 24–hour heart rate variability during normal pregnancy. Stein PK, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):978–85

The influence of ocular pulsatility on scanning laser Doppler flowmetry. Sullivan P, et al. **Am J Ophthalmol** 1999 Jul; 128(1):81–7

O2 consumption and heart rate in developing zebrafish (Danio rerio): influence of temperature and ambient O2. Barrionuevo WR, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R505–13

Influence of right atrial pressure on the cardiac pacemaker response to vagal stimulation. Bolter CP, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1112–7

Heart rate and behavior of fur seals: implications for measurement of field energetics. Boyd IL, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H844–57

Cardiac inotropic, chronotropic, and dromotropic actions of subretrofacial neurons of cat RVLM. Campos RR, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1102–11

Hemodynamic responses to electrical stimulation of the aortic depressor nerve in awake rats. De Paula PM, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R31–8

Even slight movements disturb analysis of cardiovascular dynamics. Fortrat JO, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H261–7

Role of nitric oxide in regulation of renal sympathetic nerve activity during hemorrhage in conscious rats. Fujisawa Y, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H8–14

A nonlinear explanation of aging–induced changes in heartbeat dynamics. Giuliani A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1455–61

Uncoupling of the autonomic and cardiovascular systems in acute brain injury. Goldstein B, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1287–92

Low–frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity. Houle MS, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H215–23

Autonomic control of vasovagal syncope. Jardine DL, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):H2110–5

Modulation of force–frequency relation by phospholamban in genetically engineered mice. Kadambi VJ, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2245–50

Simultaneous identification of static and dynamic vagosympathetic interactions in regulating heart rate. Kawada T, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R782–9

Contrasting cardiovascular effects following central and

peripheral injections of trout galanin in trout. Le Mével JC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1118–26
Circadian blood pressure and heart rate rhythms in mice. Li P, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R500–4
Renal denervation supersensitivity revisited. Lohmeier TE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1239–46
Ecto-5'-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ. Miki T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1329–37
Neuronal uptake affects dynamic characteristics of heart rate response to sympathetic stimulation. Nakahara T, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R140–6
Autonomic control of heart rate in dogs treated chronically with morphine. Napier LD, et al. **Am J Physiol** 1998 Dec; 275(6 Pt 2):H2199–210
Phase-dependent heartbeat modulation by muscle contractions during dynamic handgrip in humans. Niizeki K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1331–8
Nonstationarity and 1/f noise characteristics in heart rate. Pilgram B, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R1–9
Information scaling properties of heart rate variability. Roach DE, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):H1970–8
Heart rate surges during REM sleep are associated with theta rhythm and PGO activity in cats. Rowe K, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R843–9
Aging and spectral characteristics of the nonharmonic component of 24-h heart rate variability. Sakata S, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1724–31
Further evidence that BAT thermogenesis modulates cardiac rate in infant rats. Sokoloff G, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1712–7
Vasopressin acts in the area postrema to attenuate the exercise pressor reflex in anesthetized cats. Stebbins CL, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2): H2116–22
Pseudoaffective cardioautonomic responses to gastric distension in rats. Tougas G, et al. **Am J Physiol** 1999 Jul; 277(1 Pt 2):R272–8
Blood pressure and heart rate in the ovine fetus: ontogenic changes and effects of fetal adrenalectomy. Unno N, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H248–56
Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3. Walker JK, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1214–21
Nitric oxide-independent activation of soluble guanylyl cyclase contributes to endotoxin shock in rats. Wu CC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1148–57
Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Annane D, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):458–65
Target dyspnea ratings predict expected oxygen consumption as well as target heart rate values. Mejia R, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1485–9
Transesophageal atrial pacing can facilitate beta-adrenergic blockade and heart rate control [letter] Roth JV. **Anesth Analg** 1999 Oct;89(4):1070
Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Lagana B, et al. **Angiology** 1999 Feb;50(2):143–8
Some touching situations: the relationship between gender and contextual variables in cardiovascular responses to human touch. Nilsen WJ, et al. **Ann Behav Med** 1998 Fall; 20(4):270–6
Influence of sinoaortic barodenervation on the hypotensive effects of imidazoline-like drugs in stroke-prone spontaneously hypertensive rats. Medvedev OS, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:295–9
Importance of imidazoline receptors in the cardiovascular responses of clonidine in sinoaortic denervated rats. Ricci D, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:290–4
Insights from the study of heart rate variability. Stein PK, et al. **Annu Rev Med** 1999;50:249–61 (94 ref.)
Enhanced circasemiseptan (about 3.5-day) variation in the heart rate of cancer patients? Blank M, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):853–5
Heart rate variability; an index for monitoring and analyzing human autonomic activities. Kobayashi H, et al. **Appl Human Sci** 1999 Mar;18(2):53–9 (49 ref.)
The divergent ventilatory and heart rate response to moderate hypercapnia in infants with apnoea of infancy. Katz-Salamon M, et al. **Arch Dis Child** 1998 Sep; 79(3):231–6
Pyramidal control of heart rate and arterial pressure in cats. Sequeira H, et al. **Arch Ital Biol** 1999 Feb;137(1):47–62
Differences in heart rate variability between cardioinhibitory and vasodepressor responses to head-up tilt table testing. Guzmán CE, et al. **Arch Med Res** 1999 May-Jun; 30(3):203–11
Validity and reproducibility of crutch force and heart rate measurements to assess energy expenditure of paraplegic gait. IJzerman MJ, et al. **Arch Phys Med Rehabil** 1999 Sep; 80(9):1017–23
Heart rate variability and progression of coronary atherosclerosis. Huikuri HV, et al. **Arterioscler Thromb Vasc Biol** 1999 Aug;19(8):1979–85
A mechanistic analysis of the force-frequency relation in non-failing and progressively failing human myocardium. Alpert NR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:23–32 (22 ref.)
Heart rate variability and electrical stability. Fetsch T, et al. **Basic Res Cardiol** 1998;93 Suppl 1:117–24 (36 ref.)
Force-frequency relation in patients with left ventricular hypertrophy and failure. Kass DA. **Basic Res Cardiol** 1998; 93 Suppl 1:108–16
Heart rate as a determinant of L-type Ca2+ channel activity: mechanisms and implication in force-frequency relation. Lemaire S, et al. **Basic Res Cardiol** 1998;93 Suppl 1:51–9
Left ventricular restoring forces: modulation by heart rate and contractility. LeWinter MM, et al. **Basic Res Cardiol** 1998;93 Suppl 1:143–7 (21 ref.)
Influence of left ventricular pressures and heart rate on myocardial high-energy phosphate metabolism. Neubauer S. **Basic Res Cardiol** 1998;93 Suppl 1:102–7 (23 ref.)
Electrophysiological aspects of changes in heart rate. Ravens U, et al. **Basic Res Cardiol** 1998;93 Suppl 1:60–5 (40 ref.)
Influence of SR Ca(2+)-ATPase and Na(+)-Ca(2+)-exchanger on the force-frequency relation. Schillinger W, et al. **Basic Res Cardiol** 1998;93 Suppl 1:38–45 (38 ref.)
Autonomic control of heart rate: pharmacological and nonpharmacological modulation. Vanoli E, et al. **Basic Res Cardiol** 1998;93 Suppl 1:133–42 (54 ref.)
An evaluation of the impact of social support manipulations on cardiovascular reactivity to laboratory stressors. Anthony JL, et al. **Behav Med** 1999 Summer;25(2):78–87
Effect of context salience on heart rate orienting and habituation in preweanling and periadolescent rats. Kraebel KS, et al. **Behav Neurosci** 1998 Oct;112(5):1080–91
Conditional entropy approach for the evaluation of the coupling strength. Porta A, et al. **Biol Cybern** 1999 Aug; 81(2):119–29
Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease. Carney RM, et al. **Biol Psychiatry** 1999 Feb 15;45(4):458–63
Analysis of heart rate variability in posttraumatic stress disorder patients in response to a trauma-related reminder. Cohen H, et al. **Biol Psychiatry** 1998 Nov 15;44(10):1054–9
Nocturnal and daytime panic attacks--comparison of sleep architecture, heart rate variability, and response to sodium lactate challenge. Sloan EP, et al. **Biol Psychiatry** 1999 May 15;45(10):1313–20
Heart period variability and depressive symptoms: gender differences. Thayer JF, et al. **Biol Psychiatry** 1998 Aug 15;44(4):304–6
Anxiety and autonomic flexibility: a cardiovascular approach [corrected and republished article originally printed in Biol Psychol 1998 Mar;47(3):243–63] Friedman BH, et al. **Biol Psychol** 1998 Nov;49(3):303–23
The synchronization of electrodermal activity and heart rate and its relationship to energetic arousal: a time series approach. Kettunen J, et al. **Biol Psychol** 1998 Aug; 48(3):209–25
Hypertension and pain sensitivity: effects of gender and cardiovascular reactivity. Nyklíček I, et al. **Biol Psychol** 1999 Jun;50(2):127–42
The continuing problem of incorrect heart rate estimation in psychophysiological studies: an off-line solution for cardiotachometer users. Reyes del Paso GA, et al. **Biol Psychol** 1998 Aug;48(3):269–79
Using minute ventilation for ambulatory estimation of additional heart rate. Wilhelm FH, et al. **Biol Psychol** 1998 Sep;49(1-2):137–50
Changes in heart rate and respiration rate in patients with vestibular dysfunction following head movements which provoke dizziness. Yardley L, et al. **Biol Psychol** 1998 Sep; 49(1-2):95–108
Allometry of ECG waves in mammals. Günther B, et al. **Biol Res** 1997;30(4):167–70
Importance of the blood pressure-heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133–8 (30 ref.)
Is greater than normal nocturnal heart rate in children with renal scars a predictor of reflux nephropathy? Pomeranz A, et al. **Blood Press Monit** 1998;3(6):369–72
Alteration of diurnal rhythms of blood pressure and heart rate to workers exposed to radiofrequency electromagnetic fields. Szmigielski S, et al. **Blood Press Monit** 1998; 3(6):323–30
Cardioventilatory coupling: effects of IPPV. Larsen PD, et al. **Br J Anaesth** 1999 Apr;82(4):546–50
Normative data of sympathetic skin response and RR interval variation in Turkish children. Akyüz G, et al. **Brain Dev** 1999 Mar;21(2):99–102
Negative inotropic vagal preganglionic neurons in the nucleus ambiguus of the cat: neuroanatomical comparison with negative chronotropic neurons utilizing dual retrograde tracers. Blinder KJ, et al. **Brain Res** 1998 Sep 7;804(2):325–30
Spinal cholinergic inhibition of the pressor response to skeletal muscle activation. Hand GA, et al. **Brain Res** 1999 Aug 7;837(1-2):143–51
Comparison of three methods for the determination of baroreflex sensitivity in conscious rats. Farah VM, et al. **Braz J Med Biol Res** 1999 Mar;32(3):361–9
Post-exercise changes in blood pressure, heart rate and rate pressure product at different exercise intensities in normotensive humans. Forjaz CL, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1247–55
Endogenous vasopressin and the central control of heart rate during dynamic exercise. Michelini LC. **Braz J Med Biol Res** 1998 Sep;31(9):1185–95 (52 ref.)
Evaluation of electromyographic activity and heart rate responses to isometric exercise. The role played by muscular mass and type. Silva E, et al. **Braz J Med Biol Res** 1999 Jan;32(1):115–20
Association between aerobic capacity and carotid-cardiac baroreflex responsiveness in women. Culham TL, et al. **Can J Appl Physiol** 1998 Oct;23(5):444–55
Reproducibility of resting heart rate variability with short sampling periods. Marks BL, et al. **Can J Appl Physiol** 1999 Aug;24(4):337–48
Heart rate behavior in children with atrial septal defect. Massin MM, et al. **Cardiology** 1998;90(4):269–73
Heart rate variability as a marker of myocardial perfusion. Schechter D, et al. **Cardiology** 1998;90(4):239–43
Is affect aversive to young children with autism? Behavioral and cardiac responses to experimenter distress. Corona R, et al. **Child Dev** 1998 Dec;69(6):1494–502
Circadian blood pressure and heart rate profiles in normotensive patients with mild hyperthyroidism. Kohno I, et al. **Chronobiol Int** 1998 Jul;15(4):337–47
Long-term heart rate fluctuations in postoperative and brain-dead patients. Tamura T, et al. **Chronobiol Int** 1998 Nov;15(6):633–46
Purification of masked temperature data from humans: some preliminary observations on a comparison of the use of an activity diary, wrist actimetry, and heart rate monitoring. Waterhouse J, et al. **Chronobiol Int** 1999 Jul; 16(4):461–75
Muscle metaboreflex contribution to sinus node regulation during static exercise: insights from spectral analysis of heart rate variability. Iellamo F, et al. **Circulation** 1999 Jul 6;100(1):27–32
Impaired force-frequency relations in patients with hypertensive left ventricular hypertrophy. A possible physiological marker of the transition from physiological to pathological hypertrophy. Inagaki M, et al. **Circulation** 1999 Apr 13;99(14):1822–30
Heart rate variability standards [letter; comment] Kuo CD, et al. **Circulation** 1998 Oct 13;98(15):1589–90. Comment on: Circulation 1996 Mar 1;93(5):1043–65.
Investigating feed-forward neural regulation of circulation from analysis of spontaneous arterial pressure and heart rate fluctuations. Legramante JM, et al. **Circulation** 1999 Apr 6;99(13):1760–6
Sympathovagal balance: a critical appraisal [letter] Malik M. **Circulation** 1998 Dec 8;98(23):2643–4
Sympathovagal balance: a reappraisal [letter] Malliani A, et al. **Circulation** 1998 Dec 8;98(23):2640–3
Autonomic modification of the atrioventricular node during atrial fibrillation: role in the slowing of ventricular rate. Mazgalev TN, et al. **Circulation** 1999 Jun 1;99(21):2806–14
Mathematical treatment of autonomic oscillations [letter] Myers CW. **Circulation** 1999 Oct 12;100(15):e64
Cardiac interbeat interval dynamics from childhood to senescence : comparison of conventional and new measures based on fractals and chaos theory. Pikkujämsä SM, et al. **Circulation** 1999 Jul 27;100(4):393–9
Origins of heart rate variability. Inducibility and prevalence of a discrete, tachycardic event. Roach D, et al. **Circulation** 1999 Jun 29;99(25):3279–85
Cardiac neural changes before vasovagal syncope [letter] Swenne CA, et al. **Circulation** 1999 Oct 12;100(15):e67
Heart rate variability is altered following spinal cord injury. Bunten DC, et al. **Clin Auton Res** 1998 Dec;8(6):329–34
Heart rate variability in patients with the first and recurrent myocardial infarction. Ristimäe T, et al. **Clin Auton Res** 1998 Aug;8(4):195–9
Neurally mediated hypotension and autonomic dysfunction measured by heart rate variability during head-up tilt testing in children with chronic fatigue syndrome. Stewart J, et al. **Clin Auton Res** 1998 Aug;8(4):221–30
The effects of exposure to moderate altitude on cardiovascular autonomic function in normal subjects. Veglio M, et al. **Clin Auton Res** 1999 Jun;9(3):123–7
Effects of heart rate on arterial compliance in men. Liang YL, et al. **Clin Exp Pharmacol Physiol** 1999 Apr;26(4):342–6
Augmented exercise plasma noradrenaline with impaired chronotropic responsiveness in patients with hypertrophic cardiomyopathy. Omodani H, et al. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):1018–23
Pacemaking in the heart: the interplay of ionic currents. Saint DA. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):841–6
Neurogenic ST depression in stroke. Chua HC, et al. **Clin Neurol Neurosurg** 1999 Mar;101(1):44–8
Early autonomic dysfunction in patients with diabetes mellitus assessed by spectral analysis of heart rate and blood pressure variability. Laederach-Hofmann K, et al. **Clin Physiol** 1999 Mar;19(2):97–106
Accuracy of a novel real-time microprocessor QRS detector for heart rate variability assessment. Loimaala A, et al. **Clin Physiol** 1999 Jan;19(1):84–8
Reproducibility of abnormal heart rate variability indices: the case of hypertensive sleep apnoea syndrome. Salo TM, et al. **Clin Physiol** 1999 May;19(3):258–68
Apnoea-associated heart rate changes among preterm and full-term infants exposed to hyperthermia. Tirosh E, et al. **Clin Physiol** 1998 Jul;18(4):331–5
Differences in autonomic modulation of heart rate during arm and leg exercise. Tulppo MP, et al. **Clin Physiol** 1999 Jul;19(4):294–9
Short-term variability of blood pressure and heart rate in Guillain-Barré syndrome without respiratory failure. Annane D, et al. **Clin Sci (Colch)** 1999 Jun;96(6):613–21
Heart rate control of blood pressure variability in children: a study in subjects with fixed ventricular pacemaker rhythm. Constant I, et al. **Clin Sci (Colch)** 1998 Jul; 95(1):33–42

Elevated heart rate variability in physically active young and older adult women. Davy KP, et al. **Clin Sci (Colch)** 1998 Jun;94(6):579–84

Heart rate variability in 1-day-old infants born at 4330 m altitude. Mortola JP, et al. **Clin Sci (Colch)** 1999 Feb; 96(2):147–53

Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Notarius CF, et al. **Clin Sci (Colch)** 1999 Jun;96(6):557–65

Autonomic modulation of heart rate and blood pressure in hypertensive subjects with symptoms of anxiety. Piccirillo G, et al. **Clin Sci (Colch)** 1998 Jul;95(1):43–52

Cardiovascular autonomic testing in adolescents with type 1 (insulin-dependent) diabetes mellitus: an 18-month follow-up study. Scaramuzza A, et al. **Clin Sci (Colch)** 1998 Jun;94(6):615–21

Fractal dimension and approximate entropy of heart period and heart rate: awake versus sleep differences and methodological issues. Yeragani VK, et al. **Clin Sci (Colch)** 1998 Sep;95(3):295–301

The chaotic component of human heart rate variability shows a circadian periodicity as documented by the correlation dimension of the time-qualified sinusal R-R intervals. Curione M, et al. **Clin Ter** 1998 Nov-Dec;149(6):409–12

The autocorrelation of cardiac beat as a method of research of the heart's memory (first communication). Guarini G, et al. **Clin Ter** 1998 May-Jun;149(3):215–7

The intrinsic rate response of the isolated right atrium of the rat, Rattus norvegicus. Barrett CJ, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):391–7

Design of a PC-based system for time-domain and spectral analysis of heart rate variability. Adelmann HG. **Comput Biomed Res** 1999 Feb;32(1):77–92

A novel algorithm for the heart rate variability analysis of short-term recordings: polar representation of respiratory sinus arrhythmia. Migeotte PF, et al. **Comput Biomed Res** 1999 Feb;32(1):56–66

Heart rate dynamics during sinusoidal exercise: comparison of the control system between children and adults. Fukuba Y, et al. **Comput Methods Programs Biomed** 1999 Jul; 60(1):35–44

The trigonometric regressive spectral analysis--a method for mapping of beat-to-beat recorded cardiovascular parameters on to frequency domain in comparison with Fourier transformation. Rüdiger H, et al. **Comput Methods Programs Biomed** 1999 Jan;58(1):1–15

Assessing sequential irregularity of both endocrine and heart rate rhythms. Pincus SM, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):281–91 (53 ref.)

Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Koszycki D, et al. **Depress Anxiety** 1998;8(1):1–7

A further investigation of the developmental emergence of fear-potentiated startle in rats. Hunt PS. **Dev Psychobiol** 1999 May;34(4):281–91

Inhibition of the expression of conditioned cardiac responses in the developing rat. Hunt PS, et al. **Dev Psychobiol** 1998 Nov;33(3):221–33

Behavioral inhibition, heart period, and respiratory sinus arrhythmia in young children. Marshall PJ, et al. **Dev Psychobiol** 1998 Nov;33(3):283–92

Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Liao D, et al. **Diabetes Care** 1998 Dec; 21(12):2116–22

The natural history of recently diagnosed autonomic neuropathy over a period of 2 years. Karamitsos DT, et al. **Diabetes Res Clin Pract** 1998 Oct;42(1):55–63

Postprandial changes of sympathovagal balance measured by heart rate variability. Lu CL, et al. **Dig Dis Sci** 1999 Apr; 44(4):857–61

Cardiorespiratory responses to bidirectional tilts in infants. Fifer WP, et al. **Early Hum Dev** 1999 Jul;55(3):265–79

Development of baroreflex influences on heart rate variability in preterm infants. Mazursky JE, et al. **Early Hum Dev** 1998 Nov;53(1):37–52

Diurnal rhythms of fetal and maternal heart rate in the baboon. Stark RI, et al. **Early Hum Dev** 1999 Jul; 55(3):195–209

Relating heart rate and rate of perceived exertion in two simulated occupational tasks. MacKinnon SN. **Ergonomics** 1999 May;42(5):761–6

The value of the heart-rate corrected QT-interval for cardiovascular risk stratification [editorial; comment] Dekker JM. **Eur Heart J** 1999 Feb;20(4):250–1 (7 ref.). Comment on: Eur Heart J 1999 Feb;20(4):278–84.

The revival of heart rate [editorial] Ferrari R, et al. **Eur Heart J** 1999 Jun;20(12):853–4

Heart rate variability and heart rate in healthy volunteers. Is the female autonomic nervous system cardioprotective? Ramaekers D, et al. **Eur Heart J** 1998 Sep;19(9):1334–41

Heart rate variability and ischaemia in patients with coronary heart disease and stable angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Weber F, et al. **Eur Heart J** 1999 Jan;20(1):38–50

Anthropometric, lifestyle and metabolic determinants of resting heart rate. A population study. Zhang J, et al. **Eur Heart J** 1999 Jan;20(2):103–10

Oxygen uptake, heart rate and blood lactate concentration during a normal training session of an aerobic dance class. De Angelis M, et al. **Eur J Appl Physiol** 1998 Jul; 78(2):121–7

Sympathetic nervous system representation in time and frequency domain indices of heart rate variability. Polanczyk CA, et al. **Eur J Appl Physiol** 1998 Dec; 79(1):69–73

Heart rate deflection compared to 4 mmol x l(-1) lactate threshold during incremental exercise and to lactate during steady-state exercise on an arm-cranking ergometer in paraplegic athletes. Schmid A, et al. **Eur J Appl Physiol** 1998 Jul;78(2):177–82

Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Delahaye N, et al. **Eur J Nucl Med** 1999 Apr; 26(4):416–24

Clinical and haemodynamic correlates of heart rate variability in children with congenital heart disease. Massin M, et al. **Eur J Pediatr** 1998 Dec;157(12):967–71

Heart rate deceleration during the grasping reflex. Nagy E, et al. **Eur J Pediatr** 1999 Jul;158(7):576–7

Contribution of the autonomic nervous system to blood pressure and heart rate variability changes in early experimental hyperthyroidism. Safa-Tisseront V, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):247–55

Cardiovascular responses elicited by linear acceleration in humans. Yates BJ, et al. **Exp Brain Res** 1999 Apr; 125(4):476–84

Effects of acute and chronic starvation on central and peripheral noradrenaline turnover, blood pressure and heart rate in the rat. El Fazaa S, et al. **Exp Physiol** 1999 Mar; 84(2):357–68

Cardiovascular regulation and analysis of blood pressure--heart rate variability interactions. Parati G, et al. **Fundam Clin Pharmacol** 1999;13(1):11–5 (29 ref.)

Cardiovascular regulation and analysis of blood pressure-heart rate variability interactions. Parati G, et al. **Fundam Clin Pharmacol** 1998;12 Suppl 1:48s–56s (29 ref.)

Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Bernasconi P, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Aug;236(8):571–6

The influence of the maternal heart rate on the uterine artery pulsatility index in the pregnant ewe. Ochi H, et al. **Gynecol Obstet Invest** 1999;47(2):73–5

Psychosocial mediators of racial differences in nighttime blood pressure dipping among normotensive adults. Ituarte PH, et al. **Health Psychol** 1999 Jul;18(4):393–402

Lipid reactivity to stress: II. Biological and behavioral influences. Stoney CM, et al. **Health Psychol** 1999 May; 18(3):251–61

Cardiovascular reactivity and central adiposity in older African Americans. Waldstein SR, et al. **Health Psychol** 1999 May;18(3):221–8

Inadequate sympathovagal balance in response to orthostatism in patients with unexplained syncope and a positive head up tilt test. Kouakam C, et al. **Heart** 1999 Sep;82(3):312–8

Five minute recordings of heart rate variability for population studies: repeatability and age-sex characteristics. Sinnreich R, et al. **Heart** 1998 Aug;80(2):156–62

Psychophysiological manifestations of anxiety in patients undergoing electrophysiology studies. Cupples SA, et al. **Heart Lung** 1998 Nov-Dec;27(6):374–86

Dynamic nonlinear vago-sympathetic interaction in regulating heart rate. Sunagawa K, et al. **Heart Vessels** 1998;13(4):157–74 (49 ref.)

Heart rate and subsequent blood pressure in young adults: the CARDIA study. Kim JR, et al. **Hypertension** 1999 Feb; 33(2):640–6

Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Narkiewicz K, et al. **Hypertension** 1998 Dec;32(6):1039–43

Increased central angiotensin and osmotic responses in the Ren-2 transgenic rat. Nishioka T, et al. **Hypertension** 1999 Jan;33(1 Pt 2):385–8

Analyzing entrainment of heartbeat and respiration with surrogates. Seidel H, et al. **IEEE Eng Med Biol Mag** 1998 Nov-Dec;17(6):54–7

New statistical method for detection and quantification of respiratory sinus arrhythmia. Dinh TP, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1161–5

A characterization of HRV's nonlinear hidden dynamics by means of Markov models. Silipo R, et al. **IEEE Trans Biomed Eng** 1999 Aug;46(8):978–86

Effect of working hours on cardiovascular-autonomic nervous functions in engineers in an electronics manufacturing company. Sasaki T, et al. **Ind Health** 1999 Jan;37(1):55–61

Shift work-related problems in 16-h night shift nurses (2): Effects on subjective symptoms, physical activity, heart rate, and sleep. Takahashi M, et al. **Ind Health** 1999 Apr; 37(2):228–36

Vagal nerve activity and the high frequency peak of the heart rate variability. Yambe T, et al. **Int J Artif Organs** 1999 May;22(5):324–8

Balloon mitral valvuloplasty: comparison of haemodynamic and echocardiographic assessment of mitral stenosis at different heart rates in the catheterisation laboratory. Harcombe AA, et al. **Int J Cardiol** 1999 Mar 15;68(3):253–9

Higher heart rate variability of smokers after acute myocardial infarction. Nishiue T, et al. **Int J Cardiol** 1999 Feb 28;68(2):165–9

Exaggerated heart rate oscillations during two meditation techniques. Peng CK, et al. **Int J Cardiol** 1999 Jul 31; 70(2):101–7

Is heart rate variability a reliable method to assess autonomic modulation in left ventricular dysfunction and heart failure? Assessment of autonomic modulation with heart rate variability. Scalvini S, et al. **Int J Cardiol** 1998 Nov 30; 67(1):9–17

Pulse oxygen saturation and neurologic assessment in human neonates after vaginal and cesarean delivery. Gonzales GF, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):63–6

Effects of exercise load and breathing frequency on heart rate and blood pressure variability during dynamic exercise. Cottin F, et al. **Int J Sports Med** 1999 May;20(4):232–8

Heart rate response to professional road cycling: the Tour de France. Lucía A, et al. **Int J Sports Med** 1999 Apr; 20(3):167–72

The impact of a new emotional self-management program on stress, emotions, heart rate variability, DHEA and cortisol. McCraty R, et al. **Integr Physiol Behav Sci** 1998 Apr-Jun;33(2):151–70

Stability of heartbeat interval distributions in chronic high altitude hypoxia. Meyer M, et al. **Integr Physiol Behav Sci** 1998 Oct-Dec;33(4):344–62

Approximate entropy and point correlation dimension of heart rate variability in healthy subjects. Storella RJ, et al. **Integr Physiol Behav Sci** 1998 Oct-Dec;33(4):315–20

Heart rate variability and sustained attention in ADHD children. Börger N, et al. **J Abnorm Child Psychol** 1999 Feb;27(1):25–33

Limited myocardial contractile reserve and chronotropic incompetence in patients with chronic Chagas' disease: assessment by dobutamine stress echocardiography. Acquatella H, et al. **J Am Coll Cardiol** 1999 Feb;33(2):522–9

Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. Fauchier L, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1203–7

Association of chronotropic incompetence with echocardiographic ischemia and prognosis. Lauer MS, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1280–6

The influence of age and gender on heart rate variability (HRV) [letter; comment] Ramaekers D, et al. **J Am Coll Cardiol** 1999 Mar;33(3):900–2. Comment on: J Am Coll Cardiol 1998 Mar 1;31(3):593–601.

Chronotropic competence in endurance trained heart transplant recipients: heart rate is not a limiting factor for exercise capacity. Richard R, et al. **J Am Coll Cardiol** 1999 Jan;33(1):192–7

Autonomic nervous system activity and the spontaneous initiation of ventricular tachycardia. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial. Shusterman V, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1891–9

Circadian heart rate rhythms in Japanese centenarians. Shimizu K, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1094–9

Failure of autoresuscitation in weanling mice: significance of cardiac glycogen and heart rate regulation. Deshpande P, et al. **J Appl Physiol** 1999 Jul;87(1):203–10

Stroke volume decline during prolonged exercise is influenced by the increase in heart rate. Fritzsche RG, et al. **J Appl Physiol** 1999 Mar;86(3):799–805

Human fetuses have nonlinear cardiac dynamics. Groome LJ, et al. **J Appl Physiol** 1999 Aug;87(2):530–7

Heart rate during exercise with leg vascular occlusion in spinal cord-injured humans. Kjaer M, et al. **J Appl Physiol** 1999 Mar;86(3):806–11

Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat. MacLean DA, et al. **J Appl Physiol** 1998 Oct;85(4):1583–92

The physiological strain index applied to heat-stressed rats. Moran DS, et al. **J Appl Physiol** 1999 Mar;86(3):895–901

Wavelet transform to quantify heart rate variability and to assess its instantaneous changes. Pichot V, et al. **J Appl Physiol** 1999 Mar;86(3):1081–91

NO-cGMP pathway accentuates the decrease in heart rate caused by cardiac vagal nerve stimulation. Sears CE, et al. **J Appl Physiol** 1999 Feb;86(2):510–6

Beat-to-beat modulation of heart rate is coupled to coronary perfusion pressure in the isolated heart. Slovut DP, et al. **J Appl Physiol** 1999 Feb;86(2):694–700

Validity of the heart rate deflection point as a predictor of lactate threshold during running. Vachon JA, et al. **J Appl Physiol** 1999 Jul;87(1):452–9

Enkephalin inhibits vagal control of heart rate, contractile force and coronary blood flow in the canine heart in vivo. Caffrey JL. **J Auton Nerv Syst** 1999 May 28;76(2-3):75–82

Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. Choate JK, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):100–8

Neuronal nitric oxide facilitates vagal chronotropic and dromotropic actions on the heart. Conlon K, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):136–46

Influence of duration and hour of recording on spectral measurements of heart rate variability. Fauchier L, et al. **J Auton Nerv Syst** 1998 Aug 27;73(1):1–6

Arterial tonometry in the measurement of the effects of innocuous mechanical stimulation of the neck on heart rate

and blood pressure. Fujimoto T, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):109-15

Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. Howorka K, et al. **J Auton Nerv Syst** 1998 Apr 30;69(2-3):164-72

Chaos and spectral analyses of heart rate variability during head-up tilting in essential hypertension. Kagiyama S, et al. **J Auton Nerv Syst** 1999 May 28;76(2-3):153-8

Effect of nitric oxide synthase inhibition on the sympatho-vagal contol of heart rate. Sears CE, et al. **J Auton Nerv Syst** 1998 Aug 27;73(1):63-73

Autonomic dysfunction in vitamin B12 deficiency: a heart rate variability study. Sözen AB, et al. **J Auton Nerv Syst** 1998 Jun 30;71(1):25-7

Nonevaluative social support reduces cardiovascular reactivity in young women during acutely stressful performance situations. Fontana AM, et al. **J Behav Med** 1999 Feb;22(1):75-91

The evaluation of heart rate biofeedback using a multi-element design. Weems CF. **J Behav Ther Exp Psychiatry** 1998 Jun;29(2):157-62

Light and diurnal cycle affect human heart rate: possible role for the circadian pacemaker. Scheer FA, et al. **J Biol Rhythms** 1999 Jun;14(3):202-12

Heart rate variability preceding onset of atrial fibrillation. Andresen D, et al. **J Cardiovasc Electrophysiol** 1998 Aug; 9(8 Suppl):S26-9 (12 ref.)

Atrial fibrillation--maintaining sinus rhythm versus ventricular rate control: the PIAF trial. Pharmacological Intervention in Atrial Fibrillation. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S121-6 (29 ref.)

Atrioventricular nodal modification and atrioventricular junctional ablation for control of ventricular rate in atrial fibrillation. Narasimhan C, et al. **J Cardiovasc Electrophysiol** 1998 Aug;9(8 Suppl):S146-50 (32 ref.)

Differing rate dependence and temporal distribution of repolarization alternans in patients with and without ventricular tachycardia. Narayan SM, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):61-71

Heart rate variability and the prone position under general versus spinal anesthesia. Tetzlaff JE, et al. **J Clin Anesth** 1998 Dec;10(8):656-9

Interaction between neuronal nitric oxide synthase and inhibitory G protein activity in heart rate regulation in conscious mice. Jumrussirikul P, et al. **J Clin Invest** 1998 Oct 1;102(7):1279-85

Sensitizing stimulation causes a long-term increase in heart rate in Aplysia californica. Krontiris-Litowitz J. **J Comp Physiol [A]** 1999 Aug;185(2):181-6

Heart rate responses to altered ambient oxygen in early (days 3-9) chick embryos in the intact egg. Akiyama R, et al. **J Comp Physiol [B]** 1999 Mar;169(2):85-92

Heart rate responses to social interactions in free-moving rhesus macaques (Macaca mulatta): a pilot study. Aureli F, et al. **J Comp Psychol** 1999 Mar;113(1):59-65

Fear of people by cows and effects on milk yield, behavior, and heart rate at milking. Rushen J, et al. **J Dairy Sci** 1999 Apr;82(4):720-7

Endpoint of ECT-induced elevation in heart rate. Swartz CM, et al. **J ECT** 1999 Jun;15(2):125-8

Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences. Extramiana F, et al. **J Electrocardiol** 1999 Jan;32(1):33-43

Diurnal variation of autonomic nervous activity in the rat: investigation by power spectral analysis of heart rate variability. Hashimoto M, et al. **J Electrocardiol** 1999 Apr; 32(2):167-71

Heart rate variability and left ventricular dilatation early after myocardial infarction. Nishiue T, et al. **J Electrocardiol** 1999 Jul;32(3):263-8

Power spectral analysis of short-term RR interval and arterial blood pressure oscillations in the lizard, Gallotia galloti: effects of sympathetic blockade. De Vera L, et al. **J Exp Zool** 1999 Feb 1;283(2):113-20

Differential effects of aging on heart rate variability and blood pressure variability [see comments] Fluckiger L, et al. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):B219-24 . Comment in: J Gerontol A Biol Sci Med Sci 1999 May;54(5):B225-6.

Cardiovascular oscillations: from a physiological curiosity to a probe of aging and health? [comment] Pagani M. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):B225-6. Comment on: J Gerontol A Biol Sci Med Sci 1999 May;54(5):B219-24.

Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation. Raczak G, et al. **J Heart Lung Transplant** 1999 May;18(5):399-406

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats. Wada T, et al. **J Heart Lung Transplant** 1999 Jun;18(6):499-509

Heart rate variability in severe aortic stenosis. Vukasovic JL, et al. **J Heart Valve Dis** 1999 Mar;8(2):143-8

Reversed day-night ambulatory blood pressure profile and blunted heart rate variability of unknown cause in a hypertensive patient. De Backer TL, et al. **J Hum Hypertens** 1999 Jul;13(7):493-4

Baroreflex control of heart rate is impaired in pre-eclampsia. Molino P, et al. **J Hum Hypertens** 1999 Mar;13(3):179-83

Spectral analysis of heart rate variability in elderly non-dipper hypertensive patients. Rizzo V, et al. **J Hum Hypertens** 1999 Jun;13(6):393-8

Heart rate as marker of sympathetic activity. Grassi G, et al. **J Hypertens** 1998 Nov;16(11):1635-9

Power spectral analysis of the heart rate in hypertensive patients with and without left ventricular hypertrophy: the effect of a left ventricular mass reduction. Muiesan ML, et al. **J Hypertens** 1998 Nov;16(11):1641-50

An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. Narkiewicz K, et al. **J Hypertens** 1999 Feb;17(2):245-9

Role of endogenous nitric oxide in the nucleus tratus solitarii on baroreflex control of heart rate in spontaneously hypertensive rats. Pontieri V, et al. **J Hypertens** 1998 Dec; 16(12 Pt 2):1993-9

Linkage of the Na,K-ATPase alpha 2 and beta 1 genes with resting and exercise heart rate and blood pressure: cross-sectional and longitudinal observations from the Quebec Family Study. Rankinen T, et al. **J Hypertens** 1999 Mar;17(3):339-49

Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism. Safa-Tisseront V, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1989-92

Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. Verdecchia P, et al. **J Hypertens** 1998 Sep;16(9):1335-43

"Rate-drop response" cardiac pacing for vasovagal syncope. Rate-Drop Response Investigators Group. Benditt DG, et al. **J Interv Card Electrophysiol** 1999 Mar;3(1):27-33

Review article: heart rate and blood pressure control in vasovagal syncope. Benditt DG, et al. **J Interv Card Electrophysiol** 1998 Mar;2(1):25-32 (68 ref.)

Atrioventricular node reentrant tachycardia in patients with a prolonged AH interval during sinus rhythm: clinical features, electrophysiologic characteristics and results of radiofrequency ablation. Lee SH, et al. **J Interv Card Electrophysiol** 1997 Dec;1(4):305-10

Nonpharmacologic validation of the intrinsic heart rate in cardiac transplant recipients. Strobel JS, et al. **J Interv Card Electrophysiol** 1999 Mar;3(1):15-8

Alterations in heart rate following radiofrequency ablation in the treatment of reentrant supraventricular arrhythmias: relation to alterations in autonomic tone. Verdino RJ, et al. **J Interv Card Electrophysiol** 1997 Sep;1(2):145-51

Vital sign changes during infant magnetic resonance examinations. Taber KH, et al. **J Magn Reson Imaging** 1998 Nov-Dec;8(6):1252-6

Rationale for assessing the effects of manipulative therapy on autonomic tone by analysis of heart rate variability. Eingorn AM, et al. **J Manipulative Physiol Ther** 1999 Mar-Apr;22(3):161-5 (51 ref.)

Comparison of the heart rate variability parameters obtained from the electrocardiogram and the blood pressure wave. Carrasco S, et al. **J Med Eng Technol** 1998 Sep-Oct; 22(5):195-205

Spectral analysis of heart period variance (HPV)—a tool to stratify risk following myocardial infarction. Láng E, et al. **J Med Eng Technol** 1998 Nov-Dec;22(6):248-56

Inactivation of (Gialpha) proteins increases arrhythmogenic effects of beta-adrenergic stimulation in the heart. Grimm M, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):1917-28

Cardiovascular responses to a pet snake. Alonso Y. **J Nerv Ment Dis** 1999 May;187(5):311-3

Twenty-four-hour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barré syndrome. Flachenecker P, et al. **J Neurol Sci** 1999 Jun 1; 165(2):144-53

Heart rate variability and plasma catecholamines in patients during opioid detoxification. McDonald T, et al. **J Neurosurg Anesthesiol** 1999 Jul;11(3):195-9

Trigeminocardiac reflex during temporomandibular joint arthroscopy: report of a case. Roberts RS, et al. **J Oral Maxillofac Surg** 1999 Jul;57(7):854-6

Use of the heart rate monitor to modulate physical activity in adolescents with congenital aortic stenosis: an innovative approach. Bar-Mor G, et al. **J Pediatr Nurs** 1999 Aug; 14(4):273-7

Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. Damiano BP, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):671-8

The compliance of the porcine pulmonary artery depends on pressure and heart rate. Kornet L, et al. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):917-26

Differential effects of harassment on cardiovascular and salivary cortisol stress reactivity and recovery in women and men. Earle TL, et al. **J Psychosom Res** 1999 Feb; 46(2):125-41

Sympathetic activity in alexithymics with mother's low care. Fukunishi I, et al. **J Psychosom Res** 1999 Jun;46(6):579-89

Cardiac autonomic nervous system activity during presleep wakefulness and stage 2 NREM sleep. Burgess HJ, et al. **J Sleep Res** 1999 Jun;8(2):113-22

Heart rate variability and apnea during sleep in Down's syndrome. Ferri R, et al. **J Sleep Res** 1998 Dec;7(4):282-7

Heart period and heart period variability during sleep on the MIR space station. Gundel A, et al. **J Sleep Res** 1999 Mar;8(1):37-43

Impairment of daytime cerebrovascular reactivity in patients with obstructive sleep apnoea syndrome. Placidi F, et al. **J Sleep Res** 1998 Dec;7(4):288-92

Use of heart rate monitors by endurance athletes: lessons from triathletes. O'Toole ML, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):181-7 (21 ref.)

Emotions, heart rate and performance in archery. A case study. Robazza C, et al. **J Sports Med Phys Fitness** 1999 Jun;39(2):169-76

Heart rate and blood lactate responses during competitive Olympic boardsailing. Guével A, et al. **J Sports Sci** 1999 Feb;17(2):135-41

Physiological responses and perceptions of exertion in a step aerobics session. Sutherland R, et al. **J Sports Sci** 1999 Jun; 17(6):495-503

Load assessment of the static posture and weight holding in terms of pulmonary ventilation and heart rate. Yang L, et al. **J Tongji Med Univ** 1997;17(3):156-9

Effects of exercise training on the heart rate variability and QT dispersion of patients with acute myocardial infarction. Fujimoto S, et al. **Jpn Circ J** 1999 Aug;63(8):577-82

Role of circadian rhythmicity in the heart rate variability preceding non-sustained ventricular tachycardia. Ooie T, et al. **Jpn Circ J** 1998 Dec;62(12):887-92

Heart rate variability analysis of patients with idiopathic left ventricular outflow tract tachycardia: role of triggered activity. Shimoike E, et al. **Jpn Circ J** 1999 Aug; 63(8):629-35

Analysis of heart rate variability during head-up tilt testing in a patient with idiopathic postural orthostatic tachycardia syndrome (POTS). Sumiyoshi M, et al. **Jpn Circ J** 1999 Jun;63(6):496-8

Clinical study on accentuated antagonism in the regulation of heart rate in children. Miyazoe H, et al. **Jpn Heart J** 1998 Jul;39(4):481-7

Uremic autonomic neuropathy studied by spectral analysis of heart rate. Vita G, et al. **Kidney Int** 1999 Jul;56(1):232-7

Effect of water on arteries [letter] Joannidès R, et al. **Lancet** 1999 Aug 7;354(9177):516

Stability of the blood lactate-heart rate relationship in competitive athletes. Foster C, et al. **Med Sci Sports Exerc** 1999 Apr;31(4):578-82

Oxygen uptake, heart rate, and blood lactate responses during and following karate training. Imamura H, et al. **Med Sci Sports Exerc** 1999 Feb;31(2):342-7

The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction. Pokan R, et al. **Med Sci Sports Exerc** 1998 Oct; 30(10):1475-80

The heart rate turn point reliability and methodological aspects. Pokan R, et al. **Med Sci Sports Exerc** 1999 Jun; 31(6):903-7

Exercise training and heart rate variability in older people. Schuit AJ, et al. **Med Sci Sports Exerc** 1999 Jun; 31(6):816-21

Reliability of peak-lactate, heart rate, and plasma volume following the Wingate test. Weinstein Y, et al. **Med Sci Sports Exerc** 1998 Sep;30(9):1456-60

Changes in pulse rate among the civilian population during air-raid alerts in the city of Zagreb. Gregurek R, et al. **Mil Med** 1998 Dec;163(12):850-2

Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Lu JT, et al. **Mol Cell Neurosci** 1999 Aug; 14(2):99-120

Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Yildiz A, et al. **Nephron** 1998 Sep;80(1):57-60

Pavlovian heart rate and jaw movement conditioning in the rabbit: effects of medial prefrontal lesions. McLaughlin J, et al. **Neurobiol Learn Mem** 1999 Mar;71(2):150-66

EEG and cardiac activation during periodic leg movements in sleep: support for a hierarchy of arousal responses. Sforza E, et al. **Neurology** 1999 Mar 10;52(4):786-91

No effects of pulsed high-frequency electromagnetic fields on heart rate variability during human sleep. Mann K, et al. **Neuropsychobiology** 1998 Nov;38(4):251-6

Both medial prefrontal and amygdala central nucleus lesions abolish heart rate classical conditioning, but only prefrontal lesions impair reversal of eyeblink differential conditioning. Chachich M, et al. **Neurosci Lett** 1998 Dec 4;257(3):151-4

One-to-one synchronization between the cardiac sympathetic nerve stimuli and heart beats in rats. Masuda Y. **Neurosci Lett** 1998 Apr 3;245(2):73-6

Constriction of the ear pinna vascular bed accompanies the trigeminal depressor response in rabbits. Yu YH, et al. **Neurosci Lett** 1998 Oct 23;255(3):172-4

Nitrergic stimulation of the locus coeruleus modulates blood pressure and heart rate in the anaesthetized rat. Yao ST, et al. **Neuroscience** 1999;91(2):621-9

A comparative study of activity and dual sensor: activity and minute ventilation pacing responses to ascending and descending stairs. Alt E, et al. **Pacing Clin Electrophysiol** 1998 Oct;21(10):1862-8

Comparison of normal sinus rhythm and pacing rate in children with minute ventilation single chamber rate adaptive permanent pacemakers. Celiker A, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2100-4

Evaluation of direct respiratory modulation of the QT interval variability. Emori T, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):842-8

Analysis of heart rate variability five minutes before the onset of paroxysmal atrial fibrillation. Fioranelli M, et al.

Pacing Clin Electrophysiol 1999 May;22(5):743–9
Evolution of changes in the ventricular rhythm during paroxysmal atrial fibrillation. Gallagher MM, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2450–4
Heart rate variability during head–up tilt testing in patients with suspected neurally mediated syncope. Grimm W, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2411–5
Age and gender influences on rate and duration of paroxysmal atrial fibrillation. Hnatkova K, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2455–8
Exercise response of the recipient atrial remnant after orthotopic cardiac transplantation: implications for recipient atrial triggered pacing. Holt ND, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2331–7
Change of atrial refractory period after short duration of rapid atrial pacing: regional differences and possible mechanisms. Lee SH, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):927–34
Baroreflex sensitivity and heart rate variability in coronary disease compared to dilated cardiomyopathy. Menz V, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2416–9
Evaluation of autonomic influences on QT dispersion using the head–up tilt test in healthy subjects. Nakagawa M, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1158–63
Normal sinus rhythm in a patient with corrected transposition of great arteries after 30 years of complete heart block. Ngarmukos T, et al. **Pacing Clin Electrophysiol** 1999 Jul; 22(7):1116–7
Rate adaptive atrial pacing in the bradycardia tachycardia syndrome. Schwaab B, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2571–9
Correlation of heart rate variability parameters and QT interval in patients after PTCA of infarct related coronary artery as an indicator of improved autonomic regulation. Szydlo K, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2407–10
Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing. Ylitalo K, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1064–70
Age–related variation in left ventricular myocardial contractile state expressed by the stress velocity relation. Crepaz R, et al. **Pediatr Cardiol** 1998 Nov–Dec;19(6):463–7
Autonomic changes and heart rate variability in children with neurocardiac syncope. Sehra R, et al. **Pediatr Cardiol** 1999 Jul–Aug;20(4):242–7
Heart rate modifications related to spontaneous body movements in sleeping premature and full–term newborns. Curzi–Dascalova L, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):515–8
The developmental character of cardiac autonomic responses to an acute noxious event in 4– and 8–month–old healthy infants. Oberlander TF, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):519–25
More awakenings and heart rate variability during supine sleep in preterm infants. Goto K, et al. **Pediatrics** 1999 Mar; 103(3):603–9
Perceptions of the heart–rate guide. Faigenbaum AD, et al. **Percept Mot Skills** 1998 Aug;87(1):315–20
Comparison of heart–rate intensity and duration between sport games and traditional cardiovascular activities. Hannon JC, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1453–4
A field test comparison of hiking stick use on heartrate and rating of perceived exertion. Jacobson BH, et al. **Percept Mot Skills** 1998 Oct;87(2):435–8
Lavender aromatherapy in recovery from exercise. Romine IJ, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):756–8
Heart rate variability during manual restraint in chicks from high– and low–feather pecking lines of laying hens. Korte SM, et al. **Physiol Behav** 1999 Jan 1–15;65(4–5):649–52
Blood pressure and heart rate rhythmicity: differential effects of late pregnancy. Stoynev AG, et al. **Physiol Behav** 1999 Apr;66(2):269–75
The role of pulmocutaneous baroreceptors in the control of lymphatic heart rate in the toad Bufo marinus. Crossley DA 2nd, et al. **Physiol Biochem Zool** 1999 Jan–Feb; 72(1):109–15
Development of cardiorespiratory patterns associated with terrestrial apneas in free–ranging southern elephant seals. Falabella V, et al. **Physiol Biochem Zool** 1999 Jan–Feb; 72(1):64–70
The autonomic nervous control of heart rate in ducks during voluntary diving. McPhail LT, et al. **Physiol Biochem Zool** 1999 Mar–Apr;72(2):164–9
Field test of a paradigm: hysteresis of heart rate in thermoregulation by a free–ranging lizard (Pogona barbata). Grigg GC, et al. **Proc R Soc Lond B Biol Sci** 1999 Jun 22;266(1425):1291–7
Interictal change in cardiac autonomic function associated with EEG abnormalities and clinical symptoms: a longitudinal study following acute deterioration in two patients with temporal lobe epilepsy. Toichi M, et al. **Psychiatry Clin Neurosci** 1998 Oct;52(5):499–505
Heart rate and blood pressure in panic disorder, major depression, and comorbid panic disorder with major depression. Townsend MH, et al. **Psychiatry Res** 1998 Jun 15;79(2):187–90
Association of heart rate and heart–rate variability with scores on the emotion profile index in patients with acute coronary heart disease. Catipović–Veselica K, et al. **Psychol Rep** 1999 Apr;84(2):433–42
Vocal expression of anger and cardiovascular reactivity within dyadic interactions. Sargent CA, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):809–16
Neuroendocrine and cardiovascular response to sexual arousal and orgasm in men. Krüger T, et al. **Psychoneuroendocrinology** 1998 May;23(4):401–11
Cardiac activity during sleep onset. Burgess HJ, et al. **Psychophysiology** 1999 May;36(3):298–306
Effects of the presentation of false heart–rate feedback on the performance of two common heartbeat–detection tasks. Phillips GC, et al. **Psychophysiology** 1999 Jul;36(4):504–10
Sleep state and vagal regulation of heart period patterns in the human newborn: an extension of the polyvagal theory. Porges SW, et al. **Psychophysiology** 1999 Jan;36(1):14–21
Emotion processing in three systems: the medium and the message. Simons RF, et al. **Psychophysiology** 1999 Sep; 36(5):619–27
Cardiorespiratory symptoms in response to physiological arousal. Barsky AJ, et al. **Psychosom Med** 1998 Sep–Oct; 60(5):604–9
Heart rate variability in insomniacs and matched normal sleepers. Bonnet MH, et al. **Psychosom Med** 1998 Sep–Oct; 60(5):610–5
Gender, social support, and cardiovascular responses to stress. Glynn LM, et al. **Psychosom Med** 1999 Mar–Apr; 61(2):234–42
Ambulatory blood pressure, heart rate, and neuroendocrine responses in women nurses during work and off work days. Goldstein IB, et al. **Psychosom Med** 1999 May–Jun; 61(3):387–96
Psychosocial factors and heart rate variability in healthy women. Horsten M, et al. **Psychosom Med** 1999 Jan–Feb; 61(1):49–57
Chronic stress and illness in children: the role of allostatic load. Johnston–Brooks CH, et al. **Psychosom Med** 1998 Sep–Oct;60(5):597–603
Longitudinal association of cardiovascular reactivity and blood pressure in Samoan adolescents. Newman JD, et al. **Psychosom Med** 1999 Mar–Apr;61(2):243–9
Fitness and gender–related differences in heart period variability. Rossy LA, et al. **Psychosom Med** 1998 Nov–Dec;60(6):773–81
Cardiac autonomic control buffers blood pressure variability responses to challenge: a psychophysiologic model of coronary artery disease. Sloan RP, et al. **Psychosom Med** 1999 Jan–Feb;61(1):58–68 (106 ref.)
Anxiety and vagal control of heart rate. Watkins LL, et al. **Psychosom Med** 1998 Jul–Aug;60(4):498–502
Power spectral analysis of heart rate variability in psychiatry. Cohen H, et al. **Psychother Psychosom** 1999 Mar–Apr; 68(2):59–66 (55 ref.)
The validity of the Tritrac–R3D activity monitor for the assessment of physical activity: II. Temporal relationships among objective assessments. Welk GJ, et al. **Res Q Exerc Sport** 1998 Dec;69(4):395–9
Daily changes in oxygen saturation and pulse rate associated with particulate air pollution and barometric pressure. Dockery DW, et al. **Res Rep Health Eff Inst** 1999 Jan; (83):1–19; discussion 21–8
Impaired heart rate variability in patients with symptomatic NYHA class II–III hypertrophic cardiomyopathy. Tanabe T. **Rinsho Byori** 1998 Oct;46(10):1030–6
Differences in heart rate variability in the acute phase of first and second attacks of myocardial infarction. Hikita H, et al. **Scand Cardiovasc J** 1998;32(3):157–62
Relationship between physical characteristics and physiological responses during maximal arm cranking in paraplegics. Yamasaki M, et al. **Spinal Cord** 1998 Aug; 36(8):579–83
Autonomic regulation of the circulation during exercise and heat exposure. Inferences from heart rate variability. Brenner IK, et al. **Sports Med** 1998 Aug;26(2):85–99 (59 ref.)
Circadian rhythm of heart rate variability is reversibly abolished in ischemic stroke [letter] Bar–Ilan A, et al. **Stroke** 1998 Nov;29(11):2447
Dynamic behavior of heart rate in ischemic stroke. Korpelainen JT, et al. **Stroke** 1999 May;30(5):1008–13
Physiological reactions to a suicide film: suicide attempters, suicide ideators, and nonsuicidal patients. Doron A, et al. **Suicide Life Threat Behav** 1998 Fall;28(3):309–14
The heart rate–corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Spence S, et al. **Toxicol Sci** 1998 Oct;45(2):247–58
Umbilical arterial blood flow in the mouse embryo during development and following acutely increased heart rate. MacLennan MJ, et al. **Ultrasound Med Biol** 1999 Mar; 25(3):361–70
Arterial baroreflex control during mild–to–moderate nitrous oxide narcosis. Ostlund A, et al. **Undersea Hyperb Med** 1999 Spring;26(1):15–20
Effects of repeated apneas on apneic time and diving response in non–divers. Schagatay E, et al. **Undersea Hyperb Med** 1999 Fall;26(3):143–9
Heart rate variability. Calvert CA. **Vet Clin North Am Small Anim Pract** 1998 Nov; 28(6):1409–27, viii (40 ref.)
Autonomic epilepsy—the influence of epileptic discharges on heart rate and rhythm. Schernthaner C, et al. **Wien Klin Wochenschr** 1999 May 21;111(10):392–401
[Effect of vagi excitation on HRV and the exploration of its mechanism] Li L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):249–52 (Eng. Abstr.) **(Chi)**
[Effect of aerobic training on cardiac autonomic regulation revealed by heart rate variability analysis] Zhang L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):289–94 (Eng. Abstr.) **(Chi)**
[Heart rate and blood pressure variability: analytical methods, physiological significance, and its applications] Zhang LF. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):295–300 (10 ref.) (Eng. Abstr.) **(Chi)**
[Applying correlation dimension of R–R intervals to the analysis of heart rate variability] Liu X, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):54–7 (Eng. Abstr.) **(Chi)**
[Factors of variation of heart rate] Siché JP. **Ann Cardiol Angeiol (Paris)** 1998 Jun;47(6):415–9 (Eng. Abstr.) **(Fre)**
[Prognostic value of study of heart rate variability in chronic cardiac insufficiency] Gibelin P. **Arch Mal Coeur Vaiss** 1998 Dec;91(12 Suppl):15–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[3–dimensional activity analysis with activity sensors for pacemaker therapy] Hoeland K, et al. **Biomed Tech (Berl)** 1998;43 Suppl:368–9 **(Ger)**
[Development of an analytic standard for evaluating heart rate variability in cardiovascular autonomic neuropathy in diabetes: comparison of short–term spectral analysis with Ewing's standard battery of reflex tests as reference method] Howorka K, et al. **Biomed Tech (Berl)** 1998;43 Suppl:568–9 **(Ger)**
[Control algorithm for the "dromotropic" cardiac pacemaker concept] Meine M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:350–1 **(Ger)**
[A technical regulating approach to dromotropic control of closed–loop frequency adjustment] Molina A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:352–3 **(Ger)**
[Analysis of brief blood pressure and heart rate variability] Voss A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:106–7 **(Ger)**
[Symbolic dynamics—an independent method for detecting nonlinear phenomena of heart rate regulation] Wessel N, et al. **Biomed Tech (Berl)** 1998;43 Suppl:510–1 **(Ger)**
[Effect of tissue impedance on the ECG and MCG signal: a phantom study] Winklmaier M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:354–5 **(Ger)**
[Optimization of numerical measurement parameters for ECG–triggered MRI snapshot–FLASH myocardial perfusion studies] Nägele T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):89–93 (Eng. Abstr.) **(Ger)**
[Value of spiro–ergometry and stress echocardiography on optimized programming of the upper frequency limit of dual chamber cardiac pacemakers] Krüger S, et al. **Z Kardiol** 1998 Oct;87(10):817–25 (Eng. Abstr.) **(Ger)**
[Dual sequence method for analysis of spontaneous baroreceptor reflex sensitivity in patients with dilated cardiomyopathy] Malberg H, et al. **Z Kardiol** 1999 May; 88(5):331–7 (Eng. Abstr.) **(Ger)**
[Cardiovascular and metabolic response to dynamic stress echocardiography by patients with coronary heart disease and healthy probands] Meyer T, et al. **Z Kardiol** 1999 Jul; 88(7):473–80 (Eng. Abstr.) **(Ger)**
[Optimized programming of sustained rate duration in patients with implantable cardioverter–defibrillators and diagnosed atrial fibrillation] Wieckhorst A, et al. **Z Kardiol** 1999 Jun;88(6):426–33 (Eng. Abstr.) **(Ger)**
[Cardiovascular neuroregulation and rhythms of the autonomic nervous system: frequency domain analysis] Lino S, et al. **Cardiologia** 1999 Mar;44(3):281–7 (Eng. Abstr.) **(Ita)**
[Variability of heart rate: short and long–term analysis] Lombardi F, et al. **Cardiologia** 1998 Jun;43 Suppl 1:15–9 (20 ref.) **(Ita)**
[New experimental evidence of complex dynamics of heart beat. II. Correlation dimension, Lyapunov's exponents] Pierro C, et al. **Cardiologia** 1998 Aug;43(8):819–24 (Eng. Abstr.) **(Ita)**
[Identification of frequency–dependence in cardiac arrhythmia: methods and implications] Pitzalis MV, et al. **Cardiologia** 1998 Jun;43 Suppl 1:21–4 **(Ita)**
[Dispersion of the QT interval: and index that deserves more widespread clinical use?] Ciolli A, et al. **G Ital Cardiol** 1998 Sep;28(9):1032–7 (46 ref.) **(Ita)**
[Effects of the exercise intensities standardized by anaerobic threshold on EEG and heart rate variability] Sasaki H. **Hokkaido Igaku Zasshi** 1998 Jul;73(4):327–41 (Eng. Abstr.) **(Jpn)**
[Circadian rhythmicity of heart rates in centenarians] Shimizu K, et al. **Nippon Ronen Igakkai Zasshi** 1998 Aug; 35(8):637–42 (Eng. Abstr.) **(Jpn)**
[Assessment of diabetic cardiovascular autonomic neuropathy by heart rate variability and pulse wave velocity] Matsuto T, et al. **Rinsho Byori** 1998 Oct; 46(10):1037–42 (Eng. Abstr.) **(Jpn)**
[Usefulness of heart rate variability for evaluating cardiac autonomic nervous function] Ohtsuka K, et al. **Rinsho Byori** 1998 Oct;46(10):1025–9 (Eng. Abstr.) **(Jpn)**
[The effect of interviewer distance on eyeblinks and heart rates of interviewee] Omori Y, et al. **Shinrigaku Kenkyu** 1998 Dec;69(5):408–13 (Eng. Abstr.) **(Jpn)**
[The effects of media violence on affective, cognitive, and physiological reactions of viewers] Yukawa S, et al. **Shinrigaku Kenkyu** 1998 Jun;69(2):89–96 (Eng. Abstr.) **(Jpn)**

[QT dispersion in patients with acute myocardial infarction] Bancarz A, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):120–3 (Eng. Abstr.) **(Pol)**

[Heart rate response and its variability during different phases of maximal graded exercise] Alonso D de O, et al. **Arq Bras Cardiol** 1998 Dec;71(6):787–92 (Eng. Abstr.) **(Por)**

[Involvement of central and peripheral cholinergic structures in regulation of cerebral electric activity and cardiac function in rabbits during hypoxia] Akopian NS, et al. **Aviakosm Ekolog Med** 1999;33(1):28–31 (Eng. Abstr.) **(Rus)**

[Tachycardia during swallowing and spectral analysis of the heart rate] Khaiutin VM, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):620–4 **(Rus)**

[Dynamics of vagus nerve chronotropic effect during blockage of various M-cholinoreceptors] Osadchii OE, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):252–5 **(Rus)**

[A dynamic analysis of heart rate variability during hyperventilation] Bludov AA, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):66–71 **(Rus)**

[The possibilities of Holter ECG monitoring in studying the rhythm of cardiac activity in pediatrics] Kupriianova OO, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):78–86 **(Rus)**

[The dependence of the characteristics of the heart rate and blood flow on age in healthy subjects and patients with cardiovascular diseases] Zhemaitite D, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):56–65 **(Rus)**

[Clinical and prognostic significance of the degree of delayed ventricular function and vegetative regulation of cardiac rhythm in myocardial infarction patients. Barbarash OL, et al. **Klin Med (Mosk)** 1999;77(2):44–7 (Eng. Abstr.) **(Rus)**

[Cardiac interval measurement attachment to a personal computer] Timoshenko DA, et al. **Med Tekh** 1999 Jul–Aug; (4):15–6 (Eng. Abstr.) **(Rus)**

[Cardiac rhythm in sleeping healthy adolescents as recorded by holter ECG monitoring] Makarov LM, et al. **Ter Arkh** 1999;71(1):19–22 (Eng. Abstr.) **(Rus)**

[Autonomic regulation in patients with panic attacks based on longitudinal study data on the variability of the heart rhythm] Khaspekova NB, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(7):41–4 (Eng. Abstr.) **(Rus)**

[Changes in heart rate variability under informational loading] Danilova NN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):28–38 (Eng. Abstr.) **(Rus)**

[The variability of the heart rhythm and the nature of the feedback as a result of operator activity in man] Kaplan AIa. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar–Apr; 49(2):345–50 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Lack of effects on heart rate and blood pressure in ketamine-anesthetized rats briefly exposed to ultra-wideband electromagnetic pulses. Jauchem JR, et al. **IEEE Trans Biomed Eng** 1999 Jan;46(1):117–20

Light and diurnal cycle affect human heart rate: possible role for the circadian pacemaker. Scheer FA, et al. **J Biol Rhythms** 1999 Jun;14(3):202–12

[Dynamics of the changes in various integral indices of the functional state of the body of white rats during the prolonged action of x-radiation and external heat] Kamyshenko VG, et al. **Radiats Biol Radioecol** 1998 Sep–Oct;38(5):701–5 (Eng. Abstr.) **(Rus)**

HEART RATE, FETAL

Fetal tachydysrhythmia associated with nonimmune hydrops. Ahel V, et al. **Acta Med Croatica** 1999;53(1):41–3

Why are we using electronic fetal monitoring? [editorial; comment] Kripke CC. **Am Fam Physician** 1999 May 1; 59(9):2416, 2421–2. Comment on: Am Fam Physician 1999 May 1;59(9):2487–500.

Interpretation of the electronic fetal heart rate during labor [see comments] Sweha A, et al. **Am Fam Physician** 1999 May 1;59(9):2487–500 (26 ref.). Comment in: Am Fam Physician 1999 May 1;59(9):2416, 2421–2.

Interpretation of intrapartum fetal heart rate tracings [letter; comment] Cibils LA. **Am J Obstet Gynecol** 1998 Oct; 179(4):1099–100. Comment on: Am J Obstet Gynecol 1997 Dec;177(6):1385–90.

Fetal heart rate patterns in postasphyxiated fetal lambs with brain damage. Ikeda T, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1329–37

Two sinusoidal heart rate patterns in fetal lambs undergoing extracorporeal membrane oxygenation. Ikeda T, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):462–8

Fetal seizures causing increased heart rate variability during terminal fetal hypoxia. Westgate JA, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):765–6

Computerized estimation of the baseline fetal heart rate in labour: the low frequency line [letter; comment] Bernardes J, et al. **Br J Obstet Gynaecol** 1998 Oct;105(10):1128–9. Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):714–5. Comment on: Br J Obstet Gynaecol 1997 Oct;104(10):1128–33.

Effects of pulsed ultrasound on sphenoid bone temperature and the heart rate in guinea-pig foetuses. Horder MM, et al. **Early Hum Dev** 1998 Oct;52(3):221–33

Chaotic and periodic heart rate dynamics in uncomplicated intrauterine growth restricted fetuses. Lee JM, et al. **Early Hum Dev** 1998 Dec;53(2):121–8

Noninvasive in utero assessment of PR and QRS intervals from the fetal magnetocardiogram. Leuthold A, et al. **Early Hum Dev** 1999 Apr;54(3):235–43

Gestational age related changes in cardiac dynamics of the fetal baboon. Stark RI, et al. **Early Hum Dev** 1999 Jan; 53(3):219–37

Fetal heart rate variability and complexity in the course of pregnancy. Van Leeuwen P, et al. **Early Hum Dev** 1999 Apr;54(3):259–69

Fetal heart-rate monitoring during maternal hypoglycaemic coma: a case report. Matias A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):223–5

Alteration in the low-frequency domain in power spectral analysis of fetal heart beat fluctuations. Ohta T, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):92–7

Analysis of umbilical artery flow parameters during fetal variable decelerations using computerized Doppler waveforms. Tadmor O, et al. **Fetal Diagn Ther** 1999 Jan–Feb;14(1):2–10

Comparison of unstimulated and stimulated behaviour in human fetuses with congenital abnormalities. Vindla S, et al. **Fetal Diagn Ther** 1999 May–Jun;14(3):156–65

Simplified biophysical profile: an antepartum fetal screening test. Kamel HS, et al. **Gynecol Obstet Invest** 1999; 47(4):223–8

Development and sexual difference in embryonic heart rates in pregnancies resulting from in vitro fertilization. Tezuka N, et al. **Gynecol Obstet Invest** 1998;46(4):217–9

The effect of maternal hypothermia on the fetal heart rate. Aboud E, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):163–4

Objective computerized fetal heart rate analysis. Bernardes J, et al. **Int J Gynaecol Obstet** 1998 Aug;62(2):141–7

Nonlinear analysis of the performance and reliability of wavelet singularity detection based denoising for Doppler ultrasound fetal heart rate signals. Papadimitriou S, et al. **Int J Med Inf** 1999 Jan;53(1):43–60

Case 3--1999. Severe fetal bradycardia in a pregnant woman undergoing hypothermic cardiopulmonary bypass [clinical conference] Kawkabani N, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):346–9

Fetal complication after external cephalic version at term: case report and literature review. Ghidini A, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):190–2 (22 ref.)

Transient synchronous intrapartum late deceleration patterns of concordant twins due to maternal-related etiologies. Sherer DM. **J Matern Fetal Med** 1998 Jul–Aug;7(4):207–9

The effect of uterine rupture on fetal heart rate patterns [see comments] Menihan CA. **J Nurse Midwifery** 1999 Jan–Feb; 44(1):40–6. Comment in: J Nurse Midwifery 1999 Jul–Aug;44(4):422–3.

FHR Terminology [letter; comment] Schifrin BS, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Mar–Apr;28(2):123 . Comment on: J Obstet Gynecol Neonatal Nurs 1998 Mar–Apr;27(2):126.

Pulmonary embolism during labor and the effect on the fetus monitored with oxycardiotocography. Fehervary P, et al. **J Perinat Med** 1998;26(5):404–7

Venous Doppler velocimetry in relationship to central venous pressure and heart rate during hypoxia in the ovine fetus. Gudmundsson S, et al. **J Perinat Med** 1999; 27(2):81–90

Fetal heart rate monitoring casebook. Benign recurrent late decelerations. Gimovsky ML. **J Perinatol** 1998 Sep–Oct; 18(5):404–7

The effect of repeated acute hypoxaemia on fetal cardiovascular development in the sheep. Steyn C, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):295–306

Long-term prognosis of pregnancies complicated by slow embryonic heart rates in the early first trimester. Doubilet PM, et al. **J Ultrasound Med** 1999 Aug;18(8):537–41

Fetal heart rate monitoring certification [letter] Nihill J, et al. **MCN Am J Matern Child Nurs** 1999 Sep–Oct;24(5):266

The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis [letter; comment] Bernardes J. **Obstet Gynecol** 1999 Apr; 93(4):631–2. Comment on: Obstet Gynecol 1998 Nov;92(5):859–64.

Lactate in scalp and cord blood from fetuses with ominous fetal heart rate patterns. Krüger K, et al. **Obstet Gynecol** 1998 Dec;92(6):918–22

Predictive value of electronic fetal monitoring for intrapartum fetal asphyxia with metabolic acidosis. Low JA, et al. **Obstet Gynecol** 1999 Feb;93(2):285–91

MRI does not change fetal cardiotocographic parameters. Poutamo J, et al. **Prenat Diagn** 1998 Nov;18(11):1149–54

Fetal assessment: time to reassess [editorial] Petrikovsky B. **Ultrasound Obstet Gynecol** 1999 May;13(5):297–8

DRUG EFFECTS

The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Rotmensch S, et al. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):493–500

Cardiovascular effects of a mu-selective opioid agonist (tyrosine-D-arginine-phenylalanine-lysine-NH2) in fetal sheep: sites and mechanisms of action. Holsey YS, et al. **Am J Obstet Gynecol** 1999 May;180(5):1127–30

The effects of epidural opioids on fetal heart rate variability when coadministered with 0.25% bupivacaine for labor analgesia. St Amant MS, et al. **Am J Perinatol** 1998 Jun; 15(6):351–6

Effects of 4 hours magnesium sulfate infusion on fetal heart rate variability and reactivity in a goat model. Sameshima H, et al. **Am J Perinatol** 1998;15(9):535–8

Blunted fetal response to vibroacoustic stimulation following chronic exposure to propranolol. Sherer DM, et al. **Am J Perinatol** 1998 Aug;15(8):495–8

The incidence of fetal heart rate changes after intrathecal fentanyl labor analgesia. Palmer CM, et al. **Anesth Analg** 1999 Mar;88(3):577–81

Intrapartum vibratory acoustic stimulation after maternal meperidine administration. Panayotopoulos N, et al. **Clin Exp Obstet Gynecol** 1998;25(4):139–40

Magnesium sulfate, maternal hypothermia, and fetal bradycardia with loss of heart rate variability. Cardosi RJ, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):691–3

Intrathecal fentanyl and fetal bradycardia [letter; comment] Lee BB. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):95. Comment on: Reg Anesth 1997 Jul–Aug;22(4):378–81.

PHYSIOLOGY

Fetal heart rate patterns in term labor vary with sex, gestational age, epidural analgesia, and fetal weight. Dawes NW, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):181–7

The clinical significance of intermittent sinusoidal fetal heart rate. Kang AH, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):151–2

Fetal heart rate characteristics at 25 to 28 weeks' gestation. Guinn DA, et al. **Am J Perinatol** 1998 Aug;15(8):507–10

Characterization and prognostic significance of variable decelerations in the second stage of labor. Spong CY, et al. **Am J Perinatol** 1998 Jun;15(6):369–74

Time-frequency analysis of fetal heartbeat fluctuation using wavelet transform. Kimura Y, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H1993–9

Mechano- and chemoreceptor modulation of renal sympathetic nerve activity at birth in fetal sheep. Segar JL, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1295–301

Significance for fetal outcome of poor prognostic features in fetal heart rate traces with variable decelerations. Ozden S, et al. **Arch Gynecol Obstet** 1999;262(3–4):141–9

Gender does not affect fetal heart rate variation. Oguch O, et al. **Br J Obstet Gynaecol** 1998 Dec;105(12):1312–4

Fetal heart rate variability changes during brief repeated umbilical cord occlusion in near term fetal sheep. Westgate JA, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):664–71

Fetal responses to maternal strength conditioning exercises in late gestation. Avery ND, et al. **Can J Appl Physiol** 1999 Aug;24(4):362–76

Intrapartum fetal assessment. A review. Huddleston JF. **Clin Perinatol** 1999 Sep;26(3):549–68, v (68 ref.)

Heart rate and flow velocity variability as determined from umbilical Doppler velocimetry at 10–20 weeks of gestation. Ursem NT, et al. **Clin Sci (Colch)** 1998 Nov;95(5):539–45

Fetal behavior in diabetic and nondiabetic pregnant women: An exploratory study. Allen CL, et al. **Dev Psychobiol** 1999 Jul;35(1):69–80

Maternal corticotropin-releasing hormone and habituation in the human fetus. Sandman CA, et al. **Dev Psychobiol** 1999 Apr;34(3):163–73

Behavioral state affects heart rate response to low-intensity sound in human fetuses. Groome LJ, et al. **Early Hum Dev** 1999 Feb;54(1):39–54

Diurnal rhythms of fetal and maternal heart rate in the baboon. Stark RI, et al. **Early Hum Dev** 1999 Jul; 55(3):195–209

Transient fetal cerebral dysfunction after road traffic accident. A case report [corrected and republished article originally printed in Eur J Obstet Gynecol Reprod Biol 1998 Mar;77(1):29–31] Nordström L, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):29–32

Neonatal atrial flutter following fetal exposure to vibroacoustic stimulation. Peleg D, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):1–3

Intrauterine resuscitation by rapid urinary bladder instillation in a case of occult prolapse of an excessively long umbilical cord. Runnebaum IB, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):101–2

Computerised analysis of unstimulated and stimulated behaviour in fetuses with intrauterine growth restriction. Vindla S, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):37–45

Early, variable and late decelerations: can a consensus be reached in their identification? Ayres-de-Campos D, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):305–6

Admission test: a predictive test for fetal distress in high risk labour. Kulkarni AA, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):255–9

Physical conditioning effects on fetal heart rate responses to graded maternal exercise. Brenner IK, et al. **Med Sci Sports Exerc** 1999 Jun;31(6):792–9

The Jarisch-Herxheimer reaction and fetal monitoring changes in pregnant women treated for syphilis [see comments] Myles TD, et al. **Obstet Gynecol** 1998 Nov; 92(5):859–64. Comment in: Obstet Gynecol 1999 Apr;93(4):631–2.

Fetal heart rate and umbilical artery velocity variability in pregnancies complicated by insulin-dependent diabetes mellitus. Ursem NT, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):312–6

[Physical diagnostics--auscultation of fetal heart sounds (see comments)] Nijhuis JG, et al. **Ned Tijdschr Geneeskd** 1999

HEART RATE, FETAL

Feb 27;143(9):455–8 (14 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 10;143(15):817–8. **(Dut)**

[Clinical importance of fetal pulse oximetry. II. Comparative predictive values of oximetry and scalp pH. Multicenter study] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May; 28(2):137–44 (Eng. Abstr.) **(Fre)**

[Clinical importance of fetal pulse oximetry. I. Methodological evaluation. Multicenter study. French Study Group on Oximetry of Fetal Pulse] Goffinet F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Feb; 28(1):31–40 (Eng. Abstr.) **(Fre)**

[Fetal sinus bradycardia in the magnetocardiogram as an expression of sympatho-vagal imbalance in the 2nd trimester] Menéndez T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:238–9 **(Ger)**

HEART RUPTURE

DIAGNOSIS

[Ventricular rupture after blunt thoracic trauma] Byhahn C, et al. **Anaesthesiol Reanim** 1999;24(2):47–50 (Eng. Abstr.) **(Ger)**

[Possibilities for the prognosis of cardiac rupture in patients with acute myocardial infarct] Zrazhevskii KN, et al. **Klin Med (Mosk)** 1999;77(6):52–4 **(Rus)**

EPIDEMIOLOGY

Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. Becker RC, et al. **J Am Coll Cardiol** 1999 Feb;33(2):479–87

ETIOLOGY

Isolated fracture of the ventricular septum after blunt chest trauma. Schaffer RB, et al. **Ann Thorac Surg** 1999 Mar; 67(3):843–4

Right ventricular rupture during closed-chest cardiopulmonary resuscitation after pneumonectomy with pericardiotomy: a case report. Kempen PM, et al. **Crit Care Med** 1999 Jul;27(7):1378–9

Coronary sinus rupture secondary to retrograde cardioplegia. Agrawal D, et al. **Indian Heart J** 1998 Sep–Oct;50(5):542–4

Delayed atrial rupture after blunt chest trauma. Hartung O, et al. **J Trauma** 1998 Oct;45(4):833–4

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure [see comments] Heymans S, et al. **Nat Med** 1999 Oct; 5(10):1135–42. Comment in: Nat Med 1999 Oct;5(10):1122–3.

Inflammatory pathways and cardiac repair: the affliction of infarction [news; comment] Knowlton KU, et al. **Nat Med** 1999 Oct;5(10):1122–3. Comment on: Nat Med 1999 Oct;5(10):1135–42.

Papillary muscle rupture complicating inferior myocardial infarction in a young woman with systemic lupus erythematosus and antiphospholipid syndrome. Park CW, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3202–4

[A case of right ventricular rupture due to blunt trauma] Yano H, et al. **Kyobu Geka** 1999 May;52(5):360–3 (Eng. Abstr.) **(Jpn)**

[Possibilities for the prognosis of cardiac rupture in patients with acute myocardial infarct] Zrazhevskii KN, et al. **Klin Med (Mosk)** 1999;77(6):52–4 **(Rus)**

[Double oriface mitral valve: severe mitral regurgitation secondary to chord rupture] Iglesias LF, et al. **Rev Esp Cardiol** 1999 Aug;52(8):632–4 (Eng. Abstr.) **(Spa)**

MORTALITY

Left ventricular rupture after mitral valve replacement. Cheng LC, et al. **J Cardiovasc Surg (Torino)** 1999 Jun; 40(3):339–42

SURGERY

Combined blunt cardiac and pericardial rupture: review of the literature and report of a new diagnostic algorithm. May AK, et al. **Am Surg** 1999 Jun;65(6):568–74 (12 ref.)

Left ventricular free wall rupture following mitral valve replacement. Yoshida K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):336–9 (12 ref.)

Repair of right ventricular rupture complicating mediastinitis. Suen HC, et al. **Ann Thorac Surg** 1998 Dec;66(6):2115–6

[Blunt traumatic rupture of right ventricle and pericardium] Nishikawa T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):781–4 (Eng. Abstr.) **(Jpn)**

[A case report of infective endocarditis with total rupture of the posterior papillary muscle after aortic valve replacement] Sugimoto T, et al. **Kyobu Geka** 1998 Dec; 51(13):1120–2 (Eng. Abstr.) **(Jpn)**

THERAPY

Repair of left ventricular rupture after mitral valve replacement: use of a Teflon patch and glue. de la Fuente A, et al. **Ann Thorac Surg** 1999 Jun;67(6):1802–3

HEART RUPTURE, POST-INFARCTION

Mechanical complication of a myocardial infarction: ventricular septal rupture. Siddiqui S, et al. **J Ark Med Soc** 1999 Sep;96(4):142–4

CHEMICALLY INDUCED

[Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture] Sakai M, et al. **J Cardiol** 1999 Mar;33(3):153–61 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Subacute ventricular free-wall rupture presenting as tamponade without frank hemopericardium. Tate DA, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):417–9

[A case of emergency surgery for acute mitral regurgitation due to complete papillary muscle rupture as complication of acute inferior myocardial infarction] Yanagi H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):1014–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Subacute left ventricular free-wall rupture in early course of acute myocardial infarction. Clinical report of two cases and review of the literature. Varbella F, et al. **G Ital Cardiol** 1999 Feb;29(2):163–70 (55 ref.)

[Fatal ventricular rupture after stent implantation in acute myocardial infarct with subsequent stent thrombosis: discussion of reperfusion injury as the cause] Schröter V, et al. **Z Kardiol** 1999 Jun;88(6):454–8 (14 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Images in cardiology. Acquired interventricular septal defect. Cha R, et al. **Clin Cardiol** 1998 Sep;21(9):685–6

[Mechanical complications due to ischemic damage after an acute myocardial infarct] Brouwer MH, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):129–33 (Eng. Abstr.) **(Dut)**

[Papillary muscle rupture during stress ECG after myocardial infarct] Hanke T, et al. **Z Kardiol** 1999 Mar;88(3):225–8 (Eng. Abstr.) **(Ger)**

[The recurrence of a postinfarct interventricular defect. An alternative approach] Frassani R, et al. **G Ital Cardiol** 1998 Dec;28(12):1409–12 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

The early risk of thrombolytic therapy for acute myocardial infarction: incidence, mechanisms and possible prevention. Verheugt FW. **J Cardiovasc Risk** 1998 Apr;5(2):103–8

SURGERY

Operative results of "repair" of ventricular septal rupture after acute myocardial infraction. Prêtre R, et al. **Am J Cardiol** 1999 Oct 1;84(7):785–8

Left ventricular fibroma masquerading as postinfarction myocardial rupture. Lee KA, et al. **Ann Thorac Surg** 1999 Aug;68(2):580–2 (6 ref.)

[Post-infarction septal rupture. Surgical management and evolution] Prêtre R, et al. **Arch Mal Coeur Vaiss** 1999 Mar; 92(3):309–13 (Eng. Abstr.) **(Fre)**

[Case report of surgical repair of left ventricular free wall rupture using GRF glue and pericardial patch] Tsukui H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep;46(9):898–901 (Eng. Abstr.) **(Jpn)**

[Surgical correction of complete rupture of the anterior papillary muscle complicating acute myocardial infarction] Fukushima Y, et al. **Kyobu Geka** 1998 Nov;51(12):1010–2 (Eng. Abstr.) **(Jpn)**

THERAPY

The right place, the right time [editorial; comment] Heuser RR. **Catheter Cardiovasc Interv** 1999 Apr;46(4):450–1. Comment on: Catheter Cardiovasc Interv 1999 Apr;46(4):446–9.

Catheter-based fixation of the mitral valve after acute papillary muscle rupture: a new technique for temporary hemodynamic stabilization [see comments] Sochman J, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):446–9. Comment in: Catheter Cardiovasc Interv 1999 Apr;46(4):450–1.

Long-term survival of a patient with left ventricular free wall rupture without surgical repair. Mathew TP, et al. **Clin Cardiol** 1999 Mar;22(3):237–8

ULTRASONOGRAPHY

Acute cardiac rupture complicating pre-discharge exercise testing. A case report with complete echocardiographic follow-up. Bodi V, et al. **Int J Cardiol** 1999 Mar 15; 68(3):333–5

Double postinfarction cardiac rupture of left ventricular free wall and papillary muscle documented by transthoracic echocardiography. Ballet-Méchain M, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1084–6

Potential utility of left heart contrast agents in diagnosis of myocardial rupture by 2-dimensional echocardiography. Waggoner AD, et al. **J Am Soc Echocardiogr** 1999 Apr; 12(4):272–4

[Heart rupture in acute myocardial infarct: the advantages of using M-2D color Doppler echocardiography in a coronary intensive therapy unit] Perrone C, et al. **G Ital Cardiol** 1999 Jun;29(6):662–8 (Eng. Abstr.) **(Ita)**

HEART RUPTURE, TRAUMATIC see **HEART INJURIES**

HEART SEPTAL DEFECTS

The mouse with trisomy 16 as a model of human hearts with common atrioventricular junction. Anderson RH, et al. **Cardiovasc Res** 1998 Jul;39(1):155–64 (29 ref.)

Outcome of pregnancy in women with congenital shunt lesions. Zuber M, et al. **Heart** 1999 Mar;81(3):271–5

Left-to-right shunt lesions. Driscoll DJ. **Pediatr Clin North Am** 1999 Apr;46(2):355–68, x (7 ref.)

COMPLICATIONS

Cardiac anomalies associated with extrahepatic portal venous obstruction [letter] Gopanpallikar AM, et al. **Indian Pediatr** 1998 Nov;35(11):1143–4

Multiple systemic emboli complicating the course of a patient with an atrial septal defect, an atrial septal aneurysm and an endocardial right atrial pacemaker lead. Johnson C, et al. **P R Health Sci J** 1998 Sep;17(3):281–4

[Streptococcus uberis endocarditis in an infant with atrioventricular defect (letter)] Bouskraoui M, et al. **Arch Pediatr** 1999 Apr;6(4):481 **(Fre)**

[Surgical removal of right atrial myxoma with severe hypoxemia caused by right to left shunt through persistent foramen ovale] Saito H, et al. **Kyobu Geka** 1998 Dec; 51(13):1135–6 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Images in cardiology. Acquired interventricular septal defect. Cha R, et al. **Clin Cardiol** 1998 Sep;21(9):685–6

EMBRYOLOGY

Mechanisms of deficient cardiac septation in the mouse with trisomy 16. Webb S, et al. **Circ Res** 1999 Apr 30; 84(8):897–905

ETIOLOGY

An isolated ventricular septal defect as a consequence of penetrating injury to the heart. Těšínský L, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):221–3

GENETICS

Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome. Greber-Platzer S, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):395–9

Molecular genetics of congenital heart disease. A problem of faulty septation. [editorial] Schiaffino S, et al. **Circ Res** 1999 Feb 5;84(2):247–9

Localization of the human caveolin-3 gene to the D3S18/D3S4163/D3S4539 locus (3p25), in close proximity to the human oxytocin receptor gene. Identification of the caveolin-3 gene as a candidate for deletion in 3p-syndrome. Sotgia F, et al. **FEBS Lett** 1999 Jun 11;452(3):177–80

PHYSIOPATHOLOGY

Transit time heterogeneity of bolus flow through the heart and lungs in patients with left-to-right intracardiac shunt. Kuikka JT, et al. **Physiol Meas** 1999 May;20(2):207–14

RADIONUCLIDE IMAGING

Transient right-to-left shunt in acute pulmonary embolism. Buffaz PD, et al. **Clin Nucl Med** 1999 Jun;24(6):447–8

Crossed cerebellar diaschisis demonstrated by brain SPECT with Tc-99m MAA in a child with an intracardiac right-to-left shunt. Suga K, et al. **Clin Nucl Med** 1999 Apr; 24(4):282–3

SURGERY

Long term follow-up of atrioventricular valve function after repair of atrioventricular septal defect. Kameyama T, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):101–6

Management of ventricular septal defect: a survey of practice in the United Kingdom. Merrick AF, et al. **Ann Thorac Surg** 1999 Sep;68(3):983–8

Right-sided partial sternotomy for adult congenital heart disease [letter; comment] Wan-Jun L. **Ann Thorac Surg** 1999 Jul;68(1):293–4. Comment on: Ann Thorac Surg 1998 Feb;65(2):569–70.

Congenitally corrected transposition with atrioventricular septal defect. Attie F, et al. **Cardiol Young** 1998 Oct; 8(4):472–8

Atrioventricular septal defect with common valvar orifice and tetralogy of Fallot revisited: making a case for primary repair in infancy. McElhinney DB, et al. **Cardiol Young** 1998 Oct;8(4):455–61

Midterm outcome of mitral valve regurgitation after repair of atrioventricular septal defect. Chen MR, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Jan-Feb;40(1):22–6

Transient thrombocytopenia after cardiac surgery in infants with Down syndrome [letter] Kater AP, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):170–1

[Extracorporeal membrane oxygenation in myocardial failure after pediatric heart surgery] Ramos A, et al. **Rev Esp Anestesiol Reanim** 1998 Dec;45(10):436–40 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Cross sectional echocardiographic assessment of the extent of the atrial septum relative to the atrioventricular junction in atrioventricular septal defect. Falcão S, et al. **Heart** 1999 Feb;81(2):199–205

Methodological parameters influence the detection of right–to–left shunts by contrast transcranial Doppler ultrasonography. Schwarze JJ, et al. **Stroke** 1999 Jun; 30(6):1234–9

HEART SEPTAL DEFECTS, ATRIAL

The role of devices in the closure of atrial septal defects in the oval fossa [editorial; comment] Bjørnstad PG. **Cardiol Young** 1998 Jul;8(3):285–6. Comment on: Cardiol Young 1998 Jul;8(3):295–302. Comment on: Cardiol Young 1998 Jul;8(3):368–78.

Diagnosis and management of entrapped embolus through a patent foramen ovale. Aboyans V, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):624–8 (43 ref.)

A transvenous cardioverted defibrillator lead into the left ventricle via an atrial septal defect [letter; comment] Kaye GC. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2702. Comment on: Pacing Clin Electrophysiol 1998 Jun;21(6):1313–5.

[Viscero–atrial heterotaxia (letter)] Edmar A, et al. **Arch Pediatr** 1999 Feb;6(2):225–6 **(Fre)**

BLOOD

Partial pressure of oxygen is lower in the left upper pulmonary vein than in the right in adults with atrial septal defect: difference in P(O2) between the right and left pulmonary veins. Iga K, et al. **Chest** 1999 Mar; 115(3):679–83

CHEMICALLY INDUCED

Atrioventricular septal defect with separate right and left atrioventricular valvar orifices in a patient with foetal hydantoin syndrome. Grech V, et al. **Cardiol Young** 1999 Jan;9(1):73–4

COMPLICATIONS

Patent foramen ovale and implantable cardioverter defibrillator. Broka SM, et al. **Acta Chir Belg** 1999 May–Jun;99(3):132–4

Preoperative management of pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial septal defect. Atz AM, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1224–8

Fate of moderate and large secundum type atrial septal defect associated with isolated coarctation in infants. Yeager SB, et al. **Am J Cardiol** 1999 Aug 1;84(3):362–3, A9

Congenitally corrected transposition of the great arteries with a patent foramen ovale in an 81–year–old man––a case report. Misumi I, et al. **Angiology** 1999 Jan;50(1):75–9

Coronary artery fistula and atrial septal defect: a case report and brief review of the literature. Hijazi A, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):286–7 (11 ref.)

Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Cujec B, et al. **Can J Cardiol** 1999 Jan;15(1):57–64

Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea [letter; comment] Gossage JR. **Chest** 1998 Dec;114(6):1790. Comment on: Chest 1998 Jan;113(1):91–6.

Maze procedure for atrial fibrillation associated with atrial septal defect. Kobayashi J, et al. **Circulation** 1998 Nov 10; 98(19 Suppl):II399–402

Paradoxical emboli: the relationship between patent foramen ovale, deep vein thrombosis and ischaemic stroke. d'Audiffret A, et al. **Eur J Vasc Endovasc Surg** 1999 Jun; 17(6):468–71 (28 ref.)

Pulmonary capillary haemangiomatosis coexistence with sinus venosus ASD: morphometric analysis and literature review. Slovis BS, et al. **Eur Respir J** 1998 Jul;12(1):240–4 (23 ref.)

Atrial septal defect associated with Albright's hereditary osteodystrophy and other anomalies: a clinical case. Picichè M, et al. **G Ital Cardiol** 1998 Sep;28(9):1012–6

Images in cardiology Acute myocardial infarct from paradoxical embolism in a case of massive pulmonary thromboembolism. Bussani R, et al. **Heart** 1999 Apr; 81(4):430

Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Vogel M, et al. **Heart** 1999 Jul;82(1):30–3

Sinus venosus atrial septal defect with myasthenia gravis––a rare association. Shrivastava S, et al. **Indian Heart J** 1998 May–Jun;50(3):341

Predisposing factors of valve regurgitation in complete atrioventricular septal defect. Suzuki K, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1449–53

Increased prevalence of patent foramen ovale in patients with severe chronic obstructive pulmonary disease. Soliman A, et al. **J Am Soc Echocardiogr** 1999 Feb;12(2):99–105

Atrial tachycardia originating from a single site with exit block mimicking atrial fibrillation eliminated with radiofrequency applications. Mecca AL, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1100–8

Traumatic tricuspid regurgitation complicating endocarditis and right–to–left intracardiac shunt. A case report of successful operation. Liu YB, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):663–5

Coagulation abnormalities in adults with cryptogenic stroke and patent foramen ovale. Chaturvedi S. **J Neurol Sci** 1998 Oct 8;160(2):158–60

Long–term evaluation of treatment for functional tricuspid regurgitation with regurgitant volume: characteristic differences based on primary cardiac lesion. Sugimoto T, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):463–71

Atrial septal defect as an uncommon cardiovascular malformation with Turner's syndrome. Hirose H, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jul;47(7):350–3

Aortic dissection in an elderly patient with atrial septal defect. Terada Y, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Feb;47(2):85–6

Low frequency of clinically silent circulating emboli in patients with mitral valve prolapse or patent foramen ovale detected by bigated transcranial Doppler ultrasound. Droste DW, et al. **Neurol Res** 1998 Sep;20(6):499–503

Complete atrioventricular septal defect and Ebstein's anomaly. Fukuda T, et al. **Pediatr Cardiol** 1999 May–Jun; 20(3):232–5

Intermittent hypoxaemia without orthodeoxia due to right–to–left shunting related to an elongated aorta. Tan KL, et al. **Respirology** 1999 Sep;4(3):291–3

Electrocardiographic diagnosis of patent foramen ovale associated with ischemic stroke [letter] Tembl J, et al. **Stroke** 1998 Dec;29(12):2665–6

A 57–year–old man with a stroke. Fussell K, et al. **Tenn Med** 1999 Jul;92(7):271–2

Congenital tricuspid insufficiency due to a cleft in tricuspid anterior leaflet associated with perimembranous VSD. An unusual case report [letter] Oğuş NT, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):627–8

Risk of decompression sickness with patent foramen ovale [see comments] Bove AA. **Undersea Hyperb Med** 1998 Fall; 25(3):175–8. Comment in: Undersea Hyperb Med 1999 Spring;26(1):49–50.

Comments on risk of decompression sickness with patient foramen ovale [letter; comment] Brown DW. **Undersea Hyperb Med** 1999 Spring;26(1):49–50. Comment on: Undersea Hyperb Med 1998 Fall;25(3):175–8.

[Role of right–to–left atrial shunt in exercise tolerance of patients with Ebstein anomaly] Lupoglazoff JM, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):631–6 (Eng. Abstr.) **(Fre)**

[Misplacement of a transvenous lead from an implantable cardioverter–defibrillator into the left ventricle via a patent foramen ovale] Wieckhorst A, et al. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1172–6 (Eng. Abstr.) **(Ger)**

[Surgical treatment for mitral regurgitation associated with secundum atrial septal defect] Hattori R, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1324–8 (Eng. Abstr.) **(Jpn)**

[A case of cor triatriatum with atrial septal defect in an adult] Kaminishi Y, et al. **Kyobu Geka** 1999 Jun;52(6):492–5 (Eng. Abstr.) **(Jpn)**

[Coronary sinus atrial septal defect, ventricular septal defect and absence of left superior vena cava] Almeida FA, et al. **Arq Bras Cardiol** 1998 Oct;71(4):613–7 (Eng. Abstr.) **(Por)**

[Pulmonary aspergilloma successfully operated on in a patient with the pentalogy of Fallot] Bogdan M, et al. **Pneumoftiziologia** 1998 Jul–Sep;47(3):189–91 (Eng. Abstr.) **(Rum)**

[A complication after lung resection due to a patent foramen ovale] Kuksinskii VE, et al. **Vestn Khir Im I I Grek** 1999; 158(1):65–6 (7 ref.) **(Rus)**

[Myocardial infarct in a young man with angiographically normal coronary arteries and atrial septal defect] Velebit V, et al. **Med Arh** 1999;53(1):33–6 (Eng. Abstr.) **(Scr)**

[Ischemic stroke and auricular septal aneurysm: six cases] Serrano–González C, et al. **Rev Neurol** 1998 Oct; 27(158):658–62 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Pitfalls of undetected patent foramen ovale in off–pump cases. Akhter M, et al. **Ann Thorac Surg** 1999 Feb;67(2):546–8

Prenatal features of ductus arteriosus constriction and restrictive foramen ovale in d–transposition of the great arteries. Maeno YV, et al. **Circulation** 1999 Mar 9; 99(9):1209–14

Division of the right atrium. Mahy IR, et al. **Circulation** 1998 Nov 24;98(21):2352–3

Atrial septal defect in Malta. Grech V. **J Paediatr Child Health** 1999 Apr;35(2):190–5

Electrocardiographic diagnosis of patent foramen ovale associated with ischemic stroke [letter] Tembl J, et al. **Stroke** 1998 Dec;29(12):2665–6

[Right–left intra–atrial shunt in the absence of elevated pressures in the right cardiac cavities] Chaouat A, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3: S205 **(Fre)**

[Atrial fibrillation: a common problem in clinical practice] Vogel M, et al. **Dtsch Med Wochenschr** 1999 Aug 20; 124(33):985 **(Ger)**

[Flow quantification of intracardiac shunt volumes using MR phase contrast technique in the breath holding phase] Kalden P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):378–82 (Eng. Abstr.) **(Ger)**

[Pulmonary embolism associated with a crossed embolism with visualization of the thrombus in transit through the foramen ovale] Pitta ML, et al. **Rev Port Cardiol** 1999 Jul–Aug;18(7–8):769–70 **(Por)**

EPIDEMIOLOGY

Atrial septal defect in Malta. Grech V. **J Paediatr Child Health** 1999 Apr;35(2):190–5

ETIOLOGY

Acquired atrial septal defect as a complication of endocarditis––a case report. Prinz A, et al. **Angiology** 1998 Oct;49(10):865–9

The nature of the superior sinus venosus defect. Li J, et al. **Clin Anat** 1998;11(5):349–52

GENETICS

Atrioventricular canal defect without Down syndrome: a heterogeneous malformation. Digilio MC, et al. **Am J Med Genet** 1999 Jul 16;85(2):140–6 (69 ref.)

Autosomal dominant secundum atrial septal defect with various cardiac and noncardiac defects: a new midline disorder. Mégarbané A, et al. **Am J Med Genet** 1999 Mar 19;83(3):193–200

Holt–Oram syndrome. Brockhoff CJ, et al. **Circulation** 1999 Mar 16;99(10):1395–6

PATHOLOGY

Interventricular communication in complete atrioventricular septal defect. Suzuki K, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1389–93

Lesions produced by radiofrequency ablation in a child. Kantoch MJ, et al. **Cardiol Young** 1998 Oct;8(4):532–3

The structure of the common atrioventricular valve in hearts having isomeric atrial appendages and double inlet ventricle. Uemura H, et al. **J Heart Valve Dis** 1998 Sep; 7(5):580–5

[Aortic subvalvular stenosis associated with interauricular communication] Epelde F, et al. **Rev Esp Cardiol** 1999 Jul; 52(7):521–2 **(Spa)**

PHYSIOPATHOLOGY

Analysis of ventricular septal motion by doppler tissue imaging in atrial septal defect and normal heart. Iwasaki Y, et al. **Am J Cardiol** 1999 Jan 15;83(2):206–10

Use of transesophageal echocardiography for postoperative evaluation of right ventricular function. Ochiai Y, et al. **Ann Thorac Surg** 1999 Jan;67(1):146–52; discussion 153

Heart rate behavior in children with atrial septal defect. Massin MM, et al. **Cardiology** 1998;90(4):269–73

Hypoxemia after prior cardiac surgery due to interatrial shunting and its treatment with a novel transcatheter occlusion device. Wang A, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):452–6

Migraine with aura and right–to–left shunt on transcranial Doppler: a case–control study. Del Sette M, et al. **Cerebrovasc Dis** 1998 Nov–Dec;8(6):327–30

Patent foramen ovale as a potential cause of paradoxical embolism in the postpartum period. Kozelj M, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):55–7

Pulmonary function in children with atrial septal defect before and after heart surgery. Sulc J, et al. **Heart** 1998 Nov;80(5):484–8

Reversal of flow across atrial septal defect during part of atrial flutter wave [letter; comment] Mittal SR, et al. **Indian Heart J** 1998 Sep–Oct;50(5):573. Comment on: Indian Heart J 1997 May–Jun;49(3):337.

Validation of the accuracy of both right and left ventricular outflow volume determinations and semiautomated calculation of shunt volumes through atrial septal defects by digital color Doppler flow mapping in a chronic animal model. Shiota T, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):587–93

Estimation of left ventricular function in right ventricular volume and pressure overload. Detection of early left ventricular dysfunction by Tei index. Kim WH, et al. **Jpn Heart J** 1999 Mar;40(2):145–54

Spontaneous closure of atrial septal defects. Helgason H, et al. **Pediatr Cardiol** 1999 May–Jun;20(3):195–9

Pre– and postoperative exercise testing of the child with atrial septal defect. Matthys D. **Pediatr Cardiol** 1999 Jan–Feb; 20(1):22–5; discussion 26 (29 ref.)

Two–dimensional autoregressive analysis of carotid artery blood flow waveform in children with isolated atrial septal defect. Kojo M, et al. **Pediatr Int** 1999 Jun;41(3):292–8

Intrathoracic pressure changes after Valsalva strain and other maneuvers: implications for divers with patent foramen ovale. Balestra C, et al. **Undersea Hyperb Med** 1998 Fall; 25(3):171–4

[Right–left intra–atrial shunt in the absence of elevated pressures in the right cardiac cavities] Chaouat A, et al.

Rev Mal Respir 1999 Jan;16 Suppl 3: S205 **(Fre)**

[Physical fitness of children after cardiosurgical correction of an atrial septal defect type II] Durmala J, et al. **Przegl Lek** 1998;55(7-8):378-81 (Eng. Abstr.) **(Pol)**

[Evaluation of fragmented potentials in right bundle branch block without structural myocardium abnormalities. Study made by signal-averaged electrocardiogram on time and frequency domain] Ginefra P, et al. **Arq Bras Cardiol** 1998 Nov;71(5):687-94 (Eng. Abstr.) **(Por)**

RADIONUCLIDE IMAGING

Images in clinical medicine. Right-to-left shunt on a lung scan. Moses CA, et al. **N Engl J Med** 1999 Mar 18; 340(11):857

REHABILITATION

[Conventional heart surgery with the fast-track-method: experiences from a pilot study] Berdat P, et al. **Schweiz Med Wochenschr** 1998 Oct 31;128(44):1737-42 (Eng. Abstr.) **(Ger)**

SURGERY

Three-dimensional echocardiographic analysis of valve anatomy as a determinant of mitral regurgitation after surgery for atrioventricular septal defects. Acar P, et al. **Am J Cardiol** 1999 Mar 1;83(5):745-9

Outcome of children with atrial septal defect considered too small for surgical closure. Brassard M, et al. **Am J Cardiol** 1999 Jun 1;83(11):1552-5

Usefulness of intraoperative transesophageal echocardiography in predicting the degree of mitral regurgitation secondary to atrioventricular defect in children. Lee HR, et al. **Am J Cardiol** 1999 Mar 1; 83(5):750-3

The effects of cardiopulmonary bypass on remifentanil kinetics in children undergoing atrial septal defect repair. Davis PJ, et al. **Anesth Analg** 1999 Oct;89(4):904-8

Congenital coronary artery fistula treated surgically in the right atrium and the atrial septum. Tsukamoto S, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):359-62 (12 ref.)

Repair of partial atrioventricular septal defect in children less than five years of age: late results. Agny M, et al. **Ann Thorac Surg** 1999 May;67(5):1412-4

Incidence of atrial flutter/fibrillation in adults with atrial septal defect before and after surgery. Berger F, et al. **Ann Thorac Surg** 1999 Jul;68(1):75-8

Different approaches for minimally invasive closure of atrial septal defects. Cremer JT, et al. **Ann Thorac Surg** 1999 Jun;67(6):1648-52

Surgery for partial atrioventricular septal defect in the adult. Gatzoulis MA, et al. **Ann Thorac Surg** 1999 Feb; 67(2):504-10

Repair of secundum atrial septal defect: limiting the incision without sacrificing exposure. Khan JH, et al. **Ann Thorac Surg** 1998 Oct;66(4):1433-5

Atrioventricular septal defect with tetralogy of Fallot: results of surgical correction. O'Blenes SB, et al. **Ann Thorac Surg** 1998 Dec;66(6):2078-82; discussion 2082-4

Pericardial patch for atrial septal defect closure. Peter S. **Ann Thorac Surg** 1999 Feb;67(2):573-4

The effect of changing attitudes to Down's syndrome in the management of complete atrioventricular septal defects. Amark K, et al. **Arch Dis Child** 1999 Aug;81(2):151-4

Development of an endocardioscope for repair of an atrial septal defect in the beating heart [letter; comment] Poullis M. **ASAIO J** 1999 Jul-Aug;45(4):360-1. Comment on: ASAIO J 1999 Jan-Feb;45(1):90-3.

Development of an endocardioscope for repair of an atrial septal defect in the beating heart [see comments] Sogawa M, et al. **ASAIO J** 1999 Jan-Feb;45(1):90-3. Comment in: ASAIO J 1999 Jul-Aug;45(4):360-1.

The role of devices in the closure of atrial septal defects in the oval fossa [editorial; comment] Bjørnstad PG. **Cardiol Young** 1998 Jul;8(3):285-6. Comment on: Cardiol Young 1998 Jul;8(3):295-302. Comment on: Cardiol Young 1998 Jul;8(3):368-78.

Transcatheter closure of atrial septal defects within the oval fossa: medium-term results in children using the 'ASDOS'-technique. Hausdorf G, et al. **Cardiol Young** 1998 Oct;8(4):462-71

Simultaneous surgical treatment of atrial septal defect and atrial flutter using a simple modification of the atrial incision. Henglein D, et al. **Cardiol Young** 1999 Mar; 9(2):197-9

Lesions produced by radiofrequency ablation in a child. Kantoch MJ, et al. **Cardiol Young** 1998 Oct;8(4):532-3

Impact of dynamic 3D transoesophageal echocardiography in the assessment of atrial septal defects and occlusion by the double-umbrella device (CardioSEAL) [see comments] Maeno YV, et al. **Cardiol Young** 1998 Jul;8(3):368-78. Comment in: Cardiol Young 1998 Jul;8(3):285-6.

Early clinical experience with use of the 'Amplatzer Septal Occluder' device for atrial septal defect [see comments] Wilkinson JL, et al. **Cardiol Young** 1998 Jul;8(3):295-302. Comment in: Cardiol Young 1998 Jul;8(3):285-6.

Multiple atrial septal defects and patent ductus arteriosus: successful outcome using two Amplatzer septal occluders and Gianturco coils. Pedra CA, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):257-9

Video-assisted cardiac surgery: preliminary results in Chang Gung Memorial Hospital. Chu JJ, et al. **Chin Med J (Engl)** 1998 May;111(5):422-7

Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder. Fischer G, et al. **Eur Heart J** 1999 Apr;20(7):541-9

Closure of atrial septal defects via limited right anterolateral thoracotomy as a minimal invasive approach in female patients. Dabritz S, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):18-23

Minimally invasive cardiac surgery for intracardiac congenital lesions. Wu YC, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S154-9

Animal experimental implantation of an atrial septal defect occluder system. Bloch Thomsen A, et al. **Heart** 1998 Dec; 80(6):606-11

Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Chan KC, et al. **Heart** 1999 Sep;82(3):300-6

Percutaneous closure of secundum atrial septal defect with a new self centering device ("angel wings"). Rickers C, et al. **Heart** 1998 Nov;80(5):517-21

Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers. Walsh KP, et al. **Heart** 1999 Mar;81(3):257-61

Minimally invasive atrial septal defects repair. Malhotra R, et al. **Indian Heart J** 1999 Mar-Apr;51(2):193-7

Routine cleft closure in repair of complete atrioventricular septal defects. Rammohan M, et al. **Indian Heart J** 1998 Sep-Oct;50(5):527-30

Closure devices for atrial septal defect: which one to choose? [editorial] Rao PS. **Indian Heart J** 1998 Jul-Aug; 50(4):379-83 (49 ref.)

Chiari network entanglement and herniation into the left atrium by an atrial septal defect occluder device. Cooke JC, et al. **J Am Soc Echocardiogr** 1999 Jul;12(7):601-3

Right parasternal minithoracotomy for repair of atrial septal defect. Kikuchi S, et al. **J Card Surg** 1998 Mar;13(2):133-5

Surgical treatment of atrial septal aneurysm. Wos S, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):139-42

Multifocal embolic strokes following cardiac surgery in a protein C-deficient child. So GM, et al. **J Child Neurol** 1998 Dec;13(12):629-31

Constrictive pericarditis after surgical closure of atrial septal defect in a child. Kim BJ, et al. **J Korean Med Sci** 1998 Dec;13(6):658-61 (15 ref.)

Primary repair is superior to initial palliation in children with atrioventricular septal defect and tetralogy of Fallot. Najm HK, et al. **J Thorac Cardiovasc Surg** 1998 Dec; 116(6):905-13

Anesthesia for multiple sclerosis in a patient undergoing correction of ASD--a case report. al Satli RA, et al. **Middle East J Anesthesiol** 1999 Feb;15(1):91-8

Atrial arrhythmia in atrial septal defect [letter] Conraads V, et al. **N Engl J Med** 1999 Aug 12;341(7):540-1

Atrial arrhythmia after surgical closure of atrial septal defects in adults. Gatzoulis MA, et al. **N Engl J Med** 1999 Mar 18;340(11):839-46

Use of the laryngeal mask airway during repair of atrial septal defect in children. Zerafa M, et al. **Paediatr Anaesth** 1999; 9(3):257-9

Acute inferior cardiac inflow obstruction resulting from inadvertent surgical closure of a prominent Eustachian valve mistaken for an atrial septal defect. Becker A, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):155-7

A case with Weaver syndrome operated for congenital cardiac defect. Sarigül A, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):375-6

Fatal pulmonary embolism after atrial septal defect closure in a paediatric patient. Busch T, et al. **Scand Cardiovasc J** 1999;33(3):187-8

Late postoperative respiratory function in adults after surgical correction of atrial septal defects. Analysis of respiratory dysfunction patterns. Hamano K, et al. **Scand Cardiovasc J** 1998;32(3):135-6

Minimally invasive surgical closure of atrial septal defects via a right anterior thoracotomy. Sim EK, et al. **Singapore Med J** 1999 Apr;40(4):271-2

Transvasal closure of interatrial defects using the Babic double-umbrella occluder system. Pfeiffer D, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):134-40

[Cardiac operation via subaxillary and anterolateral subaxillary thoracotomy with cardiopulmonary bypass] Jia Q, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):237-8 (Eng. Abstr.) **(Chi)**

[Right postero-lateral thoracotomy for open heart surgery in infants and children. Indications and results] Houyel L, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):641-6 (Eng. Abstr.) **(Fre)**

[Percutaneous closure of ostium secundum atrial septal defects using the Amplatz device. Preliminary study on 29 patients] Rey C, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):565-70 (Eng. Abstr.) **(Fre)**

[Computer assisted open heart surgery. First case operated on with success] Carpentier A, et al. **C R Acad Sci III** 1998 May;321(5):437-42 (Eng. Abstr.) **(Fre)**

["Minimally invasive" surgical closure of the patent foramen ovale] Tevaearai HT, et al. **Swiss Surg** 1998;Suppl 2:14-7 (Eng. Abstr.) **(Fre)**

[Diagnosis and surgical treatment of atrial septal defects in adults] Vogel M, et al. **Dtsch Med Wochenschr** 1999 Jan 22;124(3):35-8 (Eng. Abstr.) **(Ger)**

[Successful surgical treatment of atrial septal defect with systemic lupus erythematosis in a 47-year-old female] Okamura T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug; 46(8):730-2 (Eng. Abstr.) **(Jpn)**

[Surgical treatment for perforated aorta caused by mediastinitis after bidirectional Glenn shunt and closure of atrial septal defect--a case report] Takigami K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep;46(9):910-4 (Eng. Abstr.) **(Jpn)**

[Noonan syndrome associated with atrial septal defect, pulmonary stenosis, and completely unroofed coronary sinus without LSVC: a case report] Yoshihara K, et al. **Kyobu Geka** 1999 Feb;52(2):134-7 (Eng. Abstr.) **(Jpn)**

[Physical fitness of children after cardiosurgical correction of an atrial septal defect type II] Durmala J, et al. **Przegl Lek** 1998;55(7-8):378-81 (Eng. Abstr.) **(Pol)**

[Complex implantation of an automatic defibrillator-cardioverter through a left superior vena cava] Castaño Ruiz M, et al. **Rev Esp Cardiol** 1998 Nov; 51(11):908-11 (Eng. Abstr.) **(Spa)**

[Patent foramen ovale as a cause of recurrent cerebral embolism. Closure with minimally invasive surgery] Ortiz de Salazar A, et al. **Rev Esp Cardiol** 1998 Nov;51(11):922-4 (Eng. Abstr.) **(Spa)**

THERAPY

Thrombus formation after transcatheter closure of atrial septal defect. La Rosée K, et al. **Am J Cardiol** 1999 Aug 1;84(3):356-9, A9

Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Sievert H, et al. **Am J Cardiol** 1998 Dec 1;82(11):1405-13

Comparison of the Sideris and Amplatzer septal occlusion devices. Walsh KP, et al. **Am J Cardiol** 1999 Mar 15; 83(6):933-6

Simultaneous transcatheter valvuloplasty and Amplatzer septal occlusion for pulmonary valvar stenosis and secundum atrial septal defect. Yip WC, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):578-81 (11 ref.)

Transcatheter closure of a patent foramen ovale following mitral valve replacement. Skulski R, et al. **Ann Thorac Surg** 1999 Aug;68(2):582-3

Percutaneous closure of atrial septal defects. The role of transesophageal echocardiography. Pedra SR, et al. **Arq Bras Cardiol** 1999 Jan;72(1):59-69 **(Eng, Por)**

Infective endocarditis on an occluder closing an atrial septal defect. Bullock AM, et al. **Cardiol Young** 1999 Jan;9(1):65-7

Transcatheter closure of atrial septal defects under echocardiographic guidance without X-ray: initial experiences. Ewert P, et al. **Cardiol Young** 1999 Mar; 9(2):136-40

Letter to the editor: re Hijazi [letter; comment] Abhaichand RK, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):456. Comment on: Cathet Cardiovasc Diagn 1997 Dec;42(4):388-93.

A new technique for sizing of atrial septal defects [see comments] Gu X, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):51-7. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):58.

New self-expanding patent foramen ovale occlusion device [see comments] Han YM, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):370-6. Comment in: Catheter Cardiovasc Interv 1999 Jul;47(3):377-80.

Measurement of the stretched diameters of atrial septal defects [editorial; comment] Hijazi ZM. **Catheter Cardiovasc Interv** 1999 Jan;46(1):58. Comment on: Catheter Cardiovasc Interv 1999 Jan;46(1):51-7.

Hypoxemia after prior cardiac surgery due to interatrial shunting and its treatment with a novel transcatheter occlusion device. Wang A, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):452-6

Percutaneous patent foramen ovale (PFO) closure: It can be done but should it? [editorial; comment] Windecker S, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):377-80. Comment on: Catheter Cardiovasc Interv 1999 Jul;47(3):370-6.

Closure of atrial septal defects in the cardiac catheterization laboratory: early results using the Amplatzer Septal Occlusion Device. Moore JW, et al. **Del Med J** 1998 Dec; 70(12):513-6

The era of transcatheter closure of atrial septal defects [editorial] Rigby ML. **Heart** 1999 Mar;81(3):227-8

Transcatheter closure of secundum atrial septal defect with atrial septal defect occlusion system (ASDOS): initial experience and short-term follow-up. Kalra GS, et al. **Indian Heart J** 1998 Jul-Aug;50(4):409-13

Transcatheter occlusion of atrial septal defects: an initial experience with the Amplatzer septal occluder. Chan KY, et al. **J Paediatr Child Health** 1998 Aug;34(4):369-73

Transcatheter closure of atrial septal defect guided by on-line transesophageal echocardiography. Chiang CW, et al. **Proc Natl Sci Counc Repub China B** 1998 Oct;22(4):144-9

[Transcatheter closure of atrial septal defect] Zeevi B, et al. **Harefuah** 1998 Oct;135(7-8):271-5, 335 (Eng. Abstr.) **(Heb)**

[Transcatheter closure of atrial septal defects: initial clinical applications] Zimand S, et al. **Harefuah** 1998 Oct; 135(7-8):276-9, 335 (Eng. Abstr.) **(Heb)**

[Percutaneous closure of an interatrial communication with the Amplatzer device. The first case in Mexico] Zabal C,

et al. **Arch Inst Cardiol Mex** 1998 Mar-Apr;68(2):147-52 (20 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Secundum atrial septal defect is a dynamic three-dimensional entity [see comments] Dall'Agata A, et al. **Am Heart J** 1999 Jun;137(6):1075-81. Comment in: Am Heart J 1999 Jun;137(6):1000-1.

Practical application of three-dimensional echocardiography in evaluation of atrial septal defects [editorial; comment] Mizelle KM, et al. **Am Heart J** 1999 Jun;137(6):1000-1. Comment on: Am Heart J 1999 Jun;137(6):1075-81.

Echocardiographic characteristics of successful deployment of the Das AngelWings atrial septal defect closure device: initial multicenter experience in the United States. Banerjee A, et al. **Am J Cardiol** 1999 Apr 15;83(8):1236-41

Incidence and clinical significance of interatrial shunting in patients with atrial septal aneurysm detected by contrast transesophageal echocardiography. Zhao BW, et al. **Angiology** 1999 Sep;50(9):745-53 (39 ref.)

Percutaneous closure of atrial septal defects. The role of transesophageal echocardiography. Pedra SR, et al. **Arq Bras Cardiol** 1999 Jan;72(1):59-69 **(Eng, Por)**

An unusual tethering of the bridging leaflets in atrioventricular septal defect producing a communication from left atrium to right ventricle. Delgado C, et al. **Cardiol Young** 1999 Jan;9(1):84-7

Transcatheter closure of atrial septal defects under echocardiographic guidance without X-ray: initial experiences. Ewert P, et al. **Cardiol Young** 1999 Mar; 9(2):136-40

Impact of dynamic 3D transoesophageal echocardiography in the assessment of atrial septal defects and occlusion by the double-umbrella device (CardioSEAL) [see comments] Maeno YV, et al. **Cardiol Young** 1998 Jul;8(3):368-78. Comment in: Cardiol Young 1998 Jul;8(3):285-6.

Three-dimensional transesophageal echocardiography for secundum atrial septal defects with a large eustachian valve. Maeno YV, et al. **Circulation** 1999 May 25; 99(20):E11

Impending paradoxical embolism: a transophageal echocardiographic image [letter; comment] Cheng TO. **Clin Cardiol** 1999 May;22(5):328-9. Comment on: Clin Cardiol 1999 Jan;22(1):45.

Detection of patent foramen ovale by transcranial Doppler and carotid duplex ultrasonography: a comparison with transoesophageal echocardiography. Nygren AT, et al. **Clin Physiol** 1998 Jul;18(4):327-30

Images in cardiology. Patent foramen ovale. Chatterjee T, et al. **Heart** 1999 May;81(5):538

Chiari network entanglement and herniation into the left atrium by an atrial septal defect occluder device. Cooke JC, et al. **J Am Soc Echocardiogr** 1999 Jul;12(7):601-3

Two-dimensional autoregressive analysis of carotid artery blood flow waveform in children with isolated atrial septal defect. Kojo M, et al. **Pediatr Int** 1999 Jun;41(3):292-8

Contrast transcranial Doppler ultrasound in the detection of right-to-left shunts. Reproducibility, comparison of 2 agents, and distribution of microemboli. Droste DW, et al. **Stroke** 1999 May;30(5):1014-8

Contrast transcranial Doppler ultrasound in the detection of right-to-left shunts: comparison of different procedures and different contrast agents. Droste DW, et al. **Stroke** 1999 Sep;30(9):1827-32

Methodological parameters influence the detection of right-to-left shunts by contrast transcranial Doppler ultrasonography. Schwarze JJ, et al. **Stroke** 1999 Jun; 30(6):1234-9

Arteriovenous fistulas of the placenta in a singleton fetus with large atrial septal defect and anomalous connection of the umbilical veins. Chiappa E, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):132-5

[Surgical evaluation of transthoracic tridimensional echocardiography in the anatomic study of atrial septal defect] Bémurat L, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):573-80 (Eng. Abstr.) **(Fre)**

[Three different types of atrial septal defects in the same family] Cachat F, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):667-9 (Eng. Abstr.) **(Fre)**

[Preoperative diagnosis of a patent foramen ovale: rational use of transthoracic and transesophageal contrast echocardiography] Weihs W, et al. **Anaesthesist** 1998 Oct; 47(10):833-7 (Eng. Abstr.) **(Ger)**

[Patent foramen ovale] Mohr-Kahaly S, et al. **Internist (Berl)** 1999 Feb;40(2):222-3 **(Ger)**

[Detection of patent foramen ovale. Transesophageal echocardiography and transcranial Doppler sonography with ultrasound contrast media are "supplementary, not competing, diagnostic methods"] Heckmann JG, et al. **Med Klin** 1999 Jul 15;94(7):367-70 (Eng. Abstr.) **(Ger)**

[Primary reconstruction of the common truncus arteriosus in infants, using modified pulmonary homograft] Hartyánszky I, et al. **Orv Hetil** 1999 Jun 13;140(24):1361-3 (Eng. Abstr.) **(Hun)**

[The sinus venosus type of interatrial communication: its diagnosis by transesophageal echocardiography] Sousa L, et al. **Rev Port Cardiol** 1999 Feb;18(2):149-53 (Eng. Abstr.) **(Por)**

HEART SEPTAL DEFECTS, VENTRICULAR

Holt-Oram syndrome. Böhm M. **Circulation** 1998 Dec 8; 98(23):2636-7

Small ventricular septal defects in adults. Neumayer U, et al. **Eur Heart J** 1998 Oct;19(10):1573-82

Musculoskeletal abnormalities in velocardiofacial syndrome. Pollard ME, et al. **J Pediatr Orthop** 1999 Sep-Oct; 19(5):607-12

BLOOD

[Changes in serum levels of total amino acids in young children with congenital heart diseases] Ke X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):356-8 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

Atrioventricular septal defect with separate right and left atrioventricular valvar orifices in a patient with foetal hydantoin syndrome. Grech V, et al. **Cardiol Young** 1999 Jan;9(1):73-4

COMPLICATIONS

Simultaneous hypertrophic cardiomyopathy and ventricular septal defect in children. Tikanoja T, et al. **Am J Cardiol** 1999 Aug 15;84(4):485-6

Transposition of the great arteries with anomalous origin of the left coronary artery from the pulmonary artery. Yamagishi M, et al. **Ann Thorac Surg** 1998 Oct;66(4):1416-8

Myocardial infarction complicated by ventricular septal rupture in a patient with polycythemia vera and minimal coronary ectasia. Choy JB, et al. **Can J Cardiol** 1998 Sep; 14(9):1161-4

Sudden death in an adult with a small ventricular septal defect and an aneurysmal membranous septum. Sarubbi B, et al. **Cardiol Young** 1999 Jan;9(1):99-103

Double-outlet right ventricle with non-committed ventricular septal defect. Belli E, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):747-52

Surgical management of transposition of great arteries associated with multiple ventricular septal defects. Belli E, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):14-20

Ventricular outflow tracts after Kawashima intraventricular rerouting for double outlet right ventricle with subpulmonary ventricular septal defect. Kawahira Y, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):26-31

Clinical results of arterial switch operation for double-outlet right ventricle with subpulmonary VSD. Masuda M, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):283-8

Aortic atresia with aortopulmonary window and interrupted aortic arch, simulating common arterial trunk: a case report. Atik E, et al. **Int J Cardiol** 1998 Sep 30;66(2):217-21

Community-acquired methicillin-resistant Staphylococcus aureus right-sided infective endocarditis in a non-addict patient with ventricular septal defect [letter] Villar E, et al. **Intensive Care Med** 1999 Feb;25(2):236-7

Predisposing factors of valve regurgitation in complete atrioventricular septal defect. Suzuki K, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1449-53

Complete atrioventricular septal defect and Ebstein's anomaly. Fukuda T, et al. **Pediatr Cardiol** 1999 May-Jun; 20(3):232-5

Sudden death due to ventricular septal defect. Cohle SD, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):327-32 (29 ref.)

Congenital tricuspid insufficiency due to a cleft in tricuspid anterior leaflet associated with perimembranous VSD. An unusual case report [letter] Oğuş NT, et al. **Turk J Pediatr** 1998 Oct-Dec;40(4):627-8

[The recurrence of a postinfarct interventricular defect. An alternative approach] Frassani R, et al. **G Ital Cardiol** 1998 Dec;28(12):1409-12 (Eng. Abstr.) **(Ita)**

[Aneurysm of the membranous ventricular septum with ventricular septal defect, mitral and tricuspid insufficiency] Tanaka K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):1009-13 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of an infant with pulmonary atresia and ventricular septal defect accompanied by excess pulmonary blood flow for systemic-pulmonary shunt operation] Ataka T, et al. **Masui** 1999 Apr;48(4):372-6 (Eng. Abstr.) **(Jpn)**

[Coronary sinus atrial septal defect, ventricular septal defect and absence of left superior vena cava] Almeida FA, et al. **Arq Bras Cardiol** 1998 Oct;71(4):613-7 (Eng. Abstr.) **(Por)**

[Infectious endocarditis in a child with pulmonary atresia and ventricular septal defect corrected by a valve conduit] Cabrera Duro A, et al. **An Esp Pediatr** 1998 Aug; 49(2):182-4 **(Spa)**

[Subpulmonary obstruction caused by an aneurysm of the membranous ventricular septum. A study of 2 cases] Santos de Soto J, et al. **Rev Esp Cardiol** 1999 May;52(5):351-4 (10 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

High origin of the right coronary artery with congenital heart disease. Ogino H, et al. **Ann Thorac Surg** 1999 Feb; 67(2):558-9

Epidemiology and diagnosis of ventricular septal defect in Malta. Grech V. **Cardiol Young** 1998 Jul;8(3):329-36

Left ventricular septal aneurysm. Dipchand AI, et al. **Circulation** 1998 Oct 20;98(16):1697

MRI of supracristal ventricular septal defects. Bremerich J, et al. **J Comput Assist Tomogr** 1999 Jan-Feb;23(1):13-5

Traumatic ventricular septal defect and mitral incompetence in a 5-year-old child. Nagy Z, et al. **J Trauma** 1999 Apr; 46(4):727-8

Double outlet right ventricle with intact atrial septum and restrictive ventricular septal defect: an analysis of two cases. Cavalini JF, et al. **Pediatr Cardiol** 1998 Nov-Dec; 19(6):490-4

[Development of double-chambered right ventricle after surgical closure of a ventricular septal defect] Massin M. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):579-81 (Eng. Abstr.) **(Fre)**

[Flow quantification of intracardiac shunt volumes using MR phase contrast technique in the breath holding phase] Kalden P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):378-82 (Eng. Abstr.) **(Ger)**

[An anomalous origin of the left coronary artery in the right pulmonary artery with interventricular communication] Cabrera A, et al. **Rev Esp Cardiol** 1999 Apr;52(4):279-80 (8 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Ventricular septal defect: (not) another epidemic? [editorial; comment] Dickinson DF. **Cardiol Young** 1998 Oct; 8(4):423-4. Comment on: Cardiol Young 1998 Oct;8(4):500-5.

Epidemiology and diagnosis of ventricular septal defect in Malta. Grech V. **Cardiol Young** 1998 Jul;8(3):329-36

[Interventricular communication in the neonatal period] Beramendi Calero JR, et al. **An Esp Pediatr** 1998 Sep; 49(3):284-8 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Severe pulmonary contusion with traumatic ventricular septal defect rescued using percutaneous cardiopulmonary support. Hirose Y, et al. **J Trauma** 1999 Mar;46(3):515-8

GENETICS

Mutchinick syndrome in a Japanese girl. Tonoki H, et al. **Am J Med Genet** 1999 Mar 12;83(2):96-9

Clinical relevance of monosomy 22q11.2 in children with pulmonary atresia and ventricular septal defect. Hofbeck M, et al. **Eur J Pediatr** 1999 Apr;158(4):302-7

Abdominal lymphatic dysplasia and 22q11 microdeletion. Mansir T, et al. **Genet Couns** 1999;10(1):67-70

A variant of long QT syndrome manifested as fetal tachycardia and associated with ventricular septal defect. Wu MH, et al. **Heart** 1999 Sep;82(3):386-8

METABOLISM

Total but not resting energy expenditure is increased in infants with ventricular septal defects. Ackerman IL, et al. **Pediatrics** 1998 Nov;102(5):1172-7

[The effects of cardiopulmonary bypass on pulmonary surfactant activity] Xing Q, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Aug; 20(4):225-7 (Eng. Abstr.) **(Chi)**

PATHOLOGY

Interventricular communication in complete atrioventricular septal defect. Suzuki K, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1389-93

Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates [see comments] Du ZD, et al. **Cardiol Young** 1998 Oct;8(4):500-5. Comment in: Cardiol Young 1998 Oct;8(4):423-4.

Left ventricular mechanics after closure of ventricular septal defect: influence of size of the defect and age at surgical repair. Pacileo G, et al. **Cardiol Young** 1998 Jul;8(3):320-8

The structure of the common atrioventricular valve in hearts having isomeric atrial appendages and double inlet ventricle. Uemura H, et al. **J Heart Valve Dis** 1998 Sep; 7(5):580-5

[Congenital aneurysm of the sinus of Valsalva ruptured to right ventricle with a ventricular septal defect and aortic regurgitation] Caballero J, et al. **Rev Esp Cardiol** 1999 Aug; 52(8):635-8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Further evidence suggesting a limited role of digitalis in infants with circulatory congestion secondary to large ventricular septal defect. Seguchi M, et al. **Am J Cardiol** 1999 May 1;83(9):1408-11, A8

Relation between plasma nitrate and mean pulmonary arterial pressure in ventricular septal defect. Takaya J, et al. **Arch Dis Child** 1998 Dec;79(6):498-501

Estimation of oxygen delivery in newborns with a univentricular circulation [letter] Poullis M. **Circulation** 1999 Aug 10;100(6):687-8

Regression of right ventricular pressure in ventricular septal defect in infancy: a longitudinal color-flow Doppler echocardiographic study. Ahunbay G, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):336-42

Pulmonary atresia with ventricular septal defect: a case for central venous pressure and oxygen saturation monitoring.

Weiss BM, et al. **Yale J Biol Med** 1998 Jan–Feb;71(1):15–21

RADIOGRAPHY

Images in cardiovascular medicine. Combined angiography and three-dimensional computed tomography for assessing systemic-to-pulmonary collaterals in pulmonary atresia with ventricular septal defect. Le Bret E, et al. **Circulation** 1998 Dec 22–29;98(25):2930–1

Combination of rare systemic venous anomalies in a child with ventricular septal defect [letter] Saxena A. **Pediatr Cardiol** 1999 Mar–Apr;20(2):170–1

SURGERY

Three-dimensional echocardiographic analysis of valve anatomy as a determinant of mitral regurgitation after surgery for atrioventricular septal defects. Acar P, et al. **Am J Cardiol** 1999 Mar 1;83(5):745–9

Ventricular septal defect and aortic regurgitation: have all the problems been elucidated? Tatsuno K. **Ann Thorac Cardiovasc Surg** 1999 Feb;5(1):3–10 (59 ref.)

Rapid two-stage repair of S,L,L, ventricular septal defect, pulmonary atresia, Ebstein anomaly of the tricuspid valve, and stenotic pulmonary arteries. Abbruzzese PA, et al. **Ann Thorac Surg** 1999 Aug;68(2):571–3

Repair of partial atrioventricular septal defect in children less than five years of age: late results. Agny M, et al. **Ann Thorac Surg** 1999 May;67(5):1412–4

Periventricular closure of ventricular septal defects without cardiopulmonary bypass. Amin Z, et al. **Ann Thorac Surg** 1999 Jul;68(1):149–53; discussion 153–4

Aortic atresia with a ventricular septal defect: modified single-stage neonatal biventricular repair. Black MD, et al. **Ann Thorac Surg** 1999 Mar;67(3):751–5

Surgery for partial atrioventricular septal defect in the adult. Gatzoulis MA, et al. **Ann Thorac Surg** 1999 Feb; 67(2):504–10

Is direct closure dangerous for treatment of doubly committed subarterial ventricular septal defect? Hisatomi K, et al. **Ann Thorac Surg** 1999 Mar;67(3):756–8; discussion 758–9

"Swiss cheese" septal defects: surgical closure using a single patch with intermediate fixings. Macé L, et al. **Ann Thorac Surg** 1999 Jun;67(6):1754–8; discussion 1758–9

Evolving surgical management for ventricular septal defect, pulmonary atresia, and major aortopulmonary collateral arteries. Murthy KS, et al. **Ann Thorac Surg** 1999 Mar; 67(3):760–4

Double patch closure of ventricular septal defect with increased pulmonary vascular resistance. Novick WM, et al. **Ann Thorac Surg** 1998 Nov;66(5):1533–8

Atrioventricular septal defect with tetralogy of Fallot: results of surgical correction. O'Blenes SB, et al. **Ann Thorac Surg** 1998 Dec;66(6):2078–82; discussion 2082–4

Outcome of surgical closure of doubly committed subarterial ventricular septal defect. Sim EK, et al. **Ann Thorac Surg** 1999 Mar;67(3):736–8

Palliative arterial switch for complete transposition with ventricular septal defect. Elizari A, et al. **Cardiol Young** 1999 May;9(3):315–8

Left ventricular mechanics after closure of ventricular septal defect: influence of size of the defect and age at surgical repair. Pacileo G, et al. **Cardiol Young** 1998 Jul;8(3):320–8

Video-assisted cardiac surgery: preliminary results in Chang Gung Memorial Hospital. Chu JJ, et al. **Chin Med J (Engl)** 1998 May;111(5):422–7

New device for closure of muscular ventricular septal defects in a canine model. Amin Z, et al. **Circulation** 1999 Jul 20; 100(3):320–8

Ventricular septal defect patch causing right ventricular inflow tract obstruction. Basaria S, et al. **Circulation** 1999 Jul 13;100(2):e12–3

Median sternotomy single stage complete unifocalization for pulmonary atresia, major aorto-pulmonary collateral arteries and VSD–early experience. Murthy KS, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):21–5

Minimally invasive cardiac surgery for intracardiac congenital lesions. Wu YC, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S154–9

Transcatheter closure of ventricular septal defect using detachable steel coil. Kalra GS, et al. **Heart** 1999 Sep; 82(3):395–6

Transcatheter closure of a mid-muscular ventricular septal defect with an amplatzer VSD occluder device. Tofeig M, et al. **Heart** 1999 Apr;81(4):438–40

Routine cleft closure in repair of complete atrioventricular septal defects. Rammohan M, et al. **Indian Heart J** 1998 Sep–Oct;50(5):527–30

A new strategy for the surgical treatment of aortic coarctation associated with ventricular septal defect in infants using an absorbable pulmonary artery band. Bonnet D, et al. **J Am Coll Cardiol** 1999 Sep;34(3):866–70

Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: initial clinical applications in children. Thanopoulos BD, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1395–9

Arterial switch with internal pulmonary artery banding. A new palliation for TGA and VSD in complex cases. Conte S, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):313–6

Total repair of pulmonary atresia with ventricular septal defect and major aortopulmonary collaterals: an integrated approach. Carotti A, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):914–23

Technique to repair multiple muscular ventricular septal defects [letter; comment] Kapoor L, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):402–4. Comment on: J Thorac Cardiovasc Surg 1998 Apr;115(4):848–56.

Primary repair is superior to initial palliation in children with atrioventricular septal defect and tetralogy of Fallot. Najm HK, et al. **J Thorac Cardiovasc Surg** 1998 Dec; 116(6):905–13

Multiple ventricular septal defects: how and when should they be repaired? Seddio F, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):134–9; discussion 139–40

Progressive pulmonary vascular disease after pulmonary artery banding and total correction in a case of ventricular septal defect and pulmonary hypertension. Yamaki S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 May;47(5):229–33

Ventricular septal defect of the atrioventricular canal type--report of a surgically treated case. Aoyagi S, et al. **Kurume Med J** 1998;45(4):355–9

Anaesthetic management of a patient with erythropoietic protoporphyria for ventricular septal defect closure. Asokumar B, et al. **Paediatr Anaesth** 1999;9(4):356–8

Surgical repair of ventricular septal defect associated with absence of right superior vena cava and persistent left superior vena cava: a case report. Onoe M, et al. **Panminerva Med** 1998 Dec;40(4):334–7

Branch pulmonary artery growth after blalock–taussig shunts in tetralogy of fallot and pulmonary atresia with ventricular septal defect: a retrospective, echocardiographic study. Sabri MR, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):358–63

Surgical repair of postinfarction ventricular septal defect: 10-year experience. Athanassiadi K, et al. **World J Surg** 1999 Jan;23(1):64–7

[Cardiac operation via subaxillary and anterolateral subaxillary thoracotomy with cardiopulmonary bypass] Jia Q, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):237–8 (Eng. Abstr.) **(Chi)**

[Treatment of obstruction of prosthetic conduct by percutaneous implantation of stents] Saliba Z, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):591–6 (Eng. Abstr.) **(Fre)**

[Ventricular septal defect associated with pulmonary hypertension in monozygotic twins--a case report with surgical repair] Kobayashi M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1152–5 (Eng. Abstr.) **(Jpn)**

[Safety and indication of open heart surgery without blood transfusion for congenital cardiac defects in infants] Sakamoto T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec; 46(12):1232–8 (Eng. Abstr.) **(Jpn)**

[A case report of successful mitral valve replacement for congenital mitral stenosis associated with coarctation of the aorta and ventricular septal defect] Noguchi Y, et al. **Kyobu Geka** 1999 Apr;52(4):312–7 (Eng. Abstr.) **(Jpn)**

[Coronary artery bypass grafting and the repair of ventricular septal defect in idiopathic thrombocytopenic purpura] Onoe M, et al. **Kyobu Geka** 1999 Feb;52(2):112–4 (Eng. Abstr.) **(Jpn)**

[Experience with repair of muscular trabecular ventricular septal defects] Sakurai H, et al. **Kyobu Geka** 1999 Jun; 52(6):471–6 (Eng. Abstr.) **(Jpn)**

[Cases of multiple ventricular septal defects] Takiguchi M, et al. **Kyobu Geka** 1998 Sep;51(10):809–12; discussion 813–6 (Eng. Abstr.) **(Jpn)**

[Infectious endocarditis in a child with pulmonary atresia and ventricular septal defect corrected by a valve conduit] Cabrera Duro A, et al. **An Esp Pediatr** 1998 Aug; 49(2):182–4 **(Spa)**

THERAPY

Transcatheter device closure of ventricular septal defects: immediate results and intermediate-term follow-up. Kalra GS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):339–44

Transcatheter closure of ventricular septal defects: are we there yet? [editorial; comment] Hijazi ZM. **Catheter Cardiovasc Interv** 1999 Jan;46(1):49–50. Comment on: Catheter Cardiovasc Interv 1999 Jan;46(1):43–8.

Transcatheter closure of ventricular septal defects using the Rashkind device: initial experience [see comments] Janorkar S, et al. **Catheter Cardiovasc Interv** 1999 Jan; 46(1):43–8. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):49–50.

Severe pulmonary contusion with traumatic ventricular septal defect rescued using percutaneous cardiopulmonary support. Hirose Y, et al. **J Trauma** 1999 Mar;46(3):515–8

ULTRASONOGRAPHY

Three-dimensional echocardiography enhances the assessment of ventricular septal defect. Dall'Agata A, et al. **Am J Cardiol** 1999 Jun 1;83(11):1576–9, A8

Usefulness of intraoperative transesophageal echocardiography in predicting the degree of mitral regurgitation secondary to atrioventricular defect in children. Lee HR, et al. **Am J Cardiol** 1999 Mar 1; 83(5):750–3

Influence of left ventricular cavity size on interventricular shunt timing and outcome in neonates with coarctation of the aorta and ventricular septal defect. Tani LY, et al. **Am J Cardiol** 1999 Sep 15;84(6):750–2, A9

Right bundle branch block: a source of error in the Doppler assessment of right ventricular pressure in patients with a ventricular septal defect. Warren AE, et al. **Can J Cardiol** 1998 Sep;14(9):1165–7

An unusual tethering of the bridging leaflets in atrioventricular septal defect producing a communication from left atrium to right ventricle. Delgado C, et al. **Cardiol Young** 1999 Jan;9(1):84–7

Ventricular septal defect: (not) another epidemic? [editorial; comment] Dickinson DF. **Cardiol Young** 1998 Oct; 8(4):423–4. Comment on: Cardiol Young 1998 Oct;8(4):500–5.

Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates [see comments] Du ZD, et al. **Cardiol Young** 1998 Oct;8(4):500–5. Comment in: Cardiol Young 1998 Oct;8(4):423–4.

Tetralogy of Fallot with flap valve ventricular septal defect producing suprasystemic right ventricular pressure: echocardiographic observations. Kumar PR, et al. **Indian Heart J** 1998 Jul–Aug;50(4):446–50

Corrected transposition with Ebstein-like deformity of systemic tricuspid valve with regurgitation and large ventricular septal defect. Ghosh A. **J Indian Med Assoc** 1998 Mar;96(3):93

Prenatal diagnosis of a coronary fistula in a fetus with pulmonary atresia with intact ventricular septum and trisomy 18. Patel CR, et al. **J Ultrasound Med** 1999 Jun; 18(6):429–31

Regression of right ventricular pressure in ventricular septal defect in infancy: a longitudinal color-flow Doppler echocardiographic study. Ahunbay G, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):336–42

Branch pulmonary artery growth after blalock–taussig shunts in tetralogy of fallot and pulmonary atresia with ventricular septal defect: a retrospective, echocardiographic study. Sabri MR, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):358–63

[Evolution of ventricular septal defects. Relation to echocardiographic anatomy] Chantepie A, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):623–8 (Eng. Abstr.) **(Fre)**

HEART SEPTUM

Atrial septal aneurysm in a patient with pseudoxanthoma elasticum. Bertulezzi G, et al. **Acta Cardiol** 1998;53(4):223–5

Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Kim JJ, et al. **Am J Cardiol** 1999 Apr 15;83(8):1220–3

A needle infixed in the heart. Gallerani M, et al. **Am J Emerg Med** 1998 Nov;16(7):662–3

Balloon mitral valvuloplasty employing double transseptal puncture [see comments] Hildick-Smith DJ, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):33–6. Comment in: Cathet Cardiovasc Diagn 1998 Dec;45(4):471. Comment in: Cathet Cardiovasc Diagn 1999 May;47(1):117.

Single vs double transseptal puncture for balloon mitral valvuloplasty...there is always a better way! [letter; comment] Cheatham JP. **Catheter Cardiovasc Interv** 1999 May;47(1):117. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):33–6.

Rotational atherectomy for left anterior descending artery septal perforator stenosis [see comments] Cohen ID, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):79–82. Comment in: Catheter Cardiovasc Interv 1999 Jan;46(1):83–4.

Pericardium-covered stent for septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Gaspar J, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):73–9

Hemodynamic rounds series II: hemodynamic effects of alcohol-induced septal infarction for hypertrophic obstructive cardiomyopathy. Kern MJ, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):221–8

Rotational atherectomy for the septal perforator: drilling into a deep frontier [editorial; comment] Nobuyoshi M. **Catheter Cardiovasc Interv** 1999 Jan;46(1):83–4. Comment on: Catheter Cardiovasc Interv 1999 Jan;46(1):79–82.

Frequency of atrial septal aneurysms in patients with cerebral ischemic events. Agmon Y, et al. **Circulation** 1999 Apr 20; 99(15):1942–4

Atrial septal aneurysm. Is it a benign finding? Valenzuela LF, et al. **Int J Cardiol** 1999 Apr 30;69(1):101–3

Interatrial septum pacing: a new approach to prevent recurrent atrial fibrillation. Padeletti L, et al. **J Interv Card Electrophysiol** 1999 Mar;3(1):35–43

Outcome after operations for pulmonary atresia with intact ventricular septum. Rychik J, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):924–31

[A giant aneurysm of the interatrial septum simulating cystic masses of the right atrium] Martins S, et al. **Rev Port Cardiol** 1999 Mar;18(3):319–21 **(Por)**

[The role of the interatrial septum in development of supraventricular tachyarrhythmias of vagal origin in dogs] Sharifov OF, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Jul;84(7):561–88 (Eng. Abstr.) **(Rus)**

[The induction of a septal infarct as a therapeutic alternative in hypertrophic obstructive cardiomyopathy: new observations apropos a case] de la Torre Hernández JM, et al. **Rev Esp Cardiol** 1999 May;52(5):339–42 (8 ref.) (Eng. Abstr.) **(Spa)**

[Subpulmonary obstruction caused by an aneurysm of the membranous ventricular septum. A study of 2 cases] Santos de Soto J, et al. **Rev Esp Cardiol** 1999 May;52(5):351–4

(10 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES see HEART SEPTAL DEFECTS

ANATOMY & HISTOLOGY

"Posteroseptal" accessory pathways [letter; comment] Anderson RH, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):422. Comment on: J Cardiovasc Electrophysiol 1998 Oct;9(10):1015–25.

CHEMISTRY

Regional contributions of Kv1.4, Kv4.2, and Kv4.3 to transient outward K+ current in rat ventricle. Wickenden AD, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1599–607

DRUG EFFECTS

Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Faber L, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):462–6

Echocardiography–guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Lakkis NM, et al. **Circulation** 1998 Oct 27;98(17):1750–5

Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Kazmierczak J, et al. **Heart** 1998 Sep;80(3):257–62

Effects of antiarrhythmic drugs on the monophasic action potential of the canine isolated, blood–perfused ventricular septum preparation. Hagihara A, et al. **Heart Vessels** 1998; 13(4):181–8

Complete heart block complicating alcohol septal ablation for hypertrophic cardiomyopathy [letter; comment] Cheng TO. **Tex Heart Inst J** 1999;26(1):100. Comment on: Tex Heart Inst J 1998;25(4):318–9.

Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Seggewiss H, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):94–100

EMBRYOLOGY

HIRA, a DiGeorge syndrome candidate gene, is required for cardiac outflow tract septation. Farrell MJ, et al. **Circ Res** 1999 Feb 5;84(2):127–35

INJURIES

Penetrating trauma to the tricuspid valve and ventricular septum: delayed repair. Doty JR, et al. **Ann Thorac Surg** 1999 Jan;67(1):252–3

Isolated fracture of the ventricular septum after blunt chest trauma. Schaffer RB, et al. **Ann Thorac Surg** 1999 Mar; 67(3):843–4

Old traumatic ventricular septal defect seen on myocardial perfusion imaging. Wadhwa SS, et al. **Clin Nucl Med** 1999 Feb;24(2):135

An isolated ventricular septal defect as a consequence of penetrating injury to the heart. Těšínský L, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):221–3

Posttraumatic aortic valve regurgitation and atrial septum rupture. Tsai FC, et al. **J Trauma** 1999 Sep;47(3):591–3

INNERVATION

Specific electrocardiographic features of manifest coronary vein posteroseptal accessory pathways [see comments] Takahashi A, et al. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1015–25. Comment in: J Cardiovasc Electrophysiol 1999 Mar;10(3):422.

Late complete atrioventricular block complicating radiofrequency catheter ablation of a left posteroseptal accessory pathway. Liu J, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2136–8

Unexpected complete AV block following transcatheter ablation of a left posteroseptal accessory pathway. Seidl K, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2139–42

PATHOLOGY

Echocardiography and excision of lipomatous hypertrophy of the interatrial septum. Oxorn DC, et al. **Ann Thorac Surg** 1999 Mar;67(3):852–4

Evidence of apoptosis induced by myocardial ischemia: A case of ventricular septal rupture following acute myocardial infarction. Toyoda Y, et al. **Cardiology** 1998 Oct;90(2):149–51

Hypoxemia after prior cardiac surgery due to interatrial shunting and its treatment with a novel transcatheter occlusion device. Wang A, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):452–6

Images in cardiovascular medicine. Lipomatous hypertrophy of the atrial septum. Noma M, et al. **Circulation** 1999 Aug 10;100(6):684

Discrete subaortic stenosis: an acquired heart disease. Lampros TD, et al. **Eur J Cardiothorac Surg** 1998 Sep; 14(3):296–303

The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome. Rychik J, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):554–60

Intracardiac yolk sac tumor in an infant girl. Graf M, et al. **Pathol Res Pract** 1999;195(3):193–7

[Lipomatous hypertrophy of the interatrial septum: its assessment with TEE, CT and MRI] Iacovoni A, et al. **G Ital Cardiol** 1998 Nov;28(11):1273–7 (18 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Analysis of ventricular septal motion by doppler tissue imaging in atrial septal defect and normal heart. Iwasaki Y, et al. **Am J Cardiol** 1999 Jan 15;83(2):206–10

Simultaneous multisite mapping of the right and the left atrial septum in the canine intact beating heart. Sun H, et al. **Circulation** 1999 Jul 20;100(3):312–9

Contribution of the interventricular septum to maximal right ventricular function. Klima U, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):250–5

Effect of implantable cardioverter/defibrillator lead placement in the right ventricle on defibrillation energy requirements. A combined experimental and clinical study. Winter J, et al. **Eur J Cardiothorac Surg** 1998 Oct; 14(4):419–25

PHYSIOPATHOLOGY

[Clinical efficacy of non–invasive evaluation of intra– and interatrial conduction in patients with ischemic heart disease] Shabrov AV, et al. **Ter Arkh** 1999;71(1):34–9 (Eng. Abstr.) **(Rus)**

SURGERY

Operative results of "repair" of ventricular septal rupture after acute myocardial infraction. Prêtre R, et al. **Am J Cardiol** 1999 Oct 1;84(7):785–8

Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Rothman A, et al. **Am J Cardiol** 1999 Sep 15;84(6):682–6

Comparison of dual–chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. Ommen SR, et al. **J Am Coll Cardiol** 1999 Jul;34(1):191–6

Morbidity outcome in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac septal myectomy: early–extubation anesthesia versus high–dose opioid anesthesia technique. Cregg N, et al. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):47–52

Technique to repair multiple muscular ventricular septal defects [letter; comment] Kapoor L, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):402–4. Comment on: J Thorac Cardiovasc Surg 1998 Apr;115(4):848–56.

Transluminal percutaneous septal myocardial ablation in a patient with hypertrophic obstructive cardiomyopathy. Tsuchikane E, et al. **Jpn Circ J** 1998 Jul;62(7):537–40

Transeptal approach to ablation of left–sided arrhythmias does not lead to persisting interatrial shunt: a transesophageal echocardiographic study. Fitchet A, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 1):2070–2

[Catheter ablation of atrial flutter. Electrophysiological characterization of posterior and septal isthmus block] Moreira JM, et al. **Arq Bras Cardiol** 1998 Jul;71(1):37–47 (Eng. Abstr.) **(Por)**

[The use of the upper septal approach during the performance of operations on the left atrioventricular valve] Babliak DIe, et al. **Klin Khir** 1998;(11):41–4 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Incidence and clinical significance of interatrial shunting in patients with atrial septal aneurysm detected by contrast transesophageal echocardiography. Zhao BW, et al. **Angiology** 1999 Sep;50(9):745–53 (39 ref.)

Cross sectional echocardiographic assessment of the extent of the atrial septum relative to the atrioventricular junction in atrioventricular septal defect. Falcão S, et al. **Heart** 1999 Feb;81(2):199–205

Intracardiac echocardiography to guide transseptal left heart catheterization for radiofrequency catheter ablation. Daoud EG, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):358–63

[Assessment of localized hypertrophy in the basal part of the interventricular septum in the elderly] Nobuoka S, et al. **Nippon Ronen Igakkai Zasshi** 1998 Sep;35(9):686–90 (Eng. Abstr.) **(Jpn)**

HEART SOUNDS

see related
HEART AUSCULTATION
HEART MURMURS
PHONOCARDIOGRAPHY

The fourth heart sound [letter; comment] Adolph RJ. **Chest** 1999 May;115(5):1480–1. Comment on: Chest 1999 Apr;115(4):1218–9.

The accuracy and interobserver agreement in detecting the 'gallop sounds' by cardiac auscultation [see comments] Lok CE, et al. **Chest** 1998 Nov;114(5):1283–8. Comment in: Chest 1998 Nov;114(5):1235–7. Comment in: Chest 1999 Apr;115(4):1218–9.

Audibility of fourth heart sound [letter; comment] [see comments] Spodick DH. **Chest** 1999 Apr;115(4):1218–9. Comment on: Chest 1998 Nov;114(5):1235–7. Comment on: Chest 1998 Nov;114(5):1283–8. Comment in: Chest 1999 May;115(5):1480–1.

A wavelet–based reduction of heart sound noise from lung sounds. Hadjileontiadis LJ, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):183–90

The third heart sound. Joshi N. **South Med J** 1999 Aug; 92(8):756–61 (46 ref.)

DRUG EFFECTS

The effect of halothane on the amplitude and frequency characteristics of heart sounds in children. Manecke GR Jr, et al. **Anesth Analg** 1999 Feb;88(2):263–7

PHYSIOLOGY

[Physical diagnostics––auscultation of fetal heart sounds (see comments)] Nijhuis JG, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):455–8 (14 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 10;143(15):817–8. **(Dut)**

HEART SURGERY see THORACIC SURGERY

HEART TRANSPLANTATION

Anomalous origin of a coronary artery in a transplanted heart. Bresseleers D, et al. **Acta Cardiol** 1999 Apr;54(2):93–6

Kaposi's sarcoma in a heart transplant patient. Gobitti C, et al. **Acta Oncol** 1998;37(7–8):769–70

Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation. Akinboboye OO, et al. **Am J Cardiol** 1999 Apr 15;83(8):1271–4, A9

David Kempton Cartwright Cooper, MD: a conversation with the editor [interview by William Clifford Roberts] Cooper DK. **Am J Cardiol** 1999 Apr 15;83(8):1253–62

Combining nonpharmacologic therapies for advanced heart failure: the Münster experience with the assist device–defibrillator combination. Deng MC, et al. **Am J Cardiol** 1999 Mar 11;83(5B):158D–160D

Chlamydia pneumoniae infection is frequent but not associated with coronary arteriosclerosis in cardiac transplant recipients. Fang JC, et al. **Am J Cardiol** 1998 Dec 15;82(12):1479–83

Cardiac–allograft vasculopathy and HELP therapy [letter] Lane DM, et al. **Am J Cardiol** 1998 Oct 15;82(8):1000

Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Mahoney P, et al. **Am J Cardiol** 1999 Jun 1;83(11):1544–7

Lung membrane diffusing capacity, heart failure, and heart transplantation. Mettauer B, et al. **Am J Cardiol** 1999 Jan 1;83(1):62–7

The implantable cardioverter defibrillator as a "bridge to transplant": a viable clinical strategy? Schmidinger H. **Am J Cardiol** 1999 Mar 11;83(5B):151D–157D (69 ref.)

Mechanical circulatory support as a bridge to cardiac transplantation: toward the 21st century. Scherr K, et al. **Am J Crit Care** 1999 Sep;8(5):324–37; quiz 338–9 (150 ref.)

Obstetric management in 219 cases of infants with hypoplastic left heart syndrome [letter] Gilles JM, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):226

In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Hölschermann H, et al. **Am J Pathol** 1999 Jan;154(1):211–20

NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2–knockout mice. Koglin J, et al. **Am J Pathol** 1998 Nov;153(5):1371–6

External stimuli in the form of vibratory massage after heart or lung transplantation. Doering TJ, et al. **Am J Phys Med Rehabil** 1999 Mar–Apr;78(2):108–10

The role of cardiac troponin T to predict heart transplant rejection [letter] Anderson JR, et al. **Ann Thorac Surg** 1999 Sep;68(3):1121–2

Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. Copeland JG, et al. **Ann Thorac Surg** 1999 Aug;68(2):756–60

The CardioWest total artificial heart bridge to transplantation: 1993 to 1996 national trial. Copeland JG 3rd, et al. **Ann Thorac Surg** 1998 Nov;66(5):1662–9

Progression of steroid–associated osteoporosis after heart transplantation. Cremer J, et al. **Ann Thorac Surg** 1999 Jan; 67(1):130–3

Bridging from acute to chronic devices. Dembitsky WP. **Ann Thorac Surg** 1999 Aug;68(2):724–8

Pressure delivery of AS–ICAM–1 ODN with LFA–1 mAb reduces reperfusion injury in cardiac allografts. Feeley BT, et al. **Ann Thorac Surg** 1999 Jul;68(1):119–24

Murphy's law in cardiac surgery. Fischer C, et al. **Ann Thorac Surg** 1998 Nov;66(5):1795–7

Rejection with heart failure after pediatric cardiac transplantation. Flippin MJ, et al. **Ann Thorac Surg** 1999 Jul;68(1):176–80

Infection during circulatory support with ventricular assist devices. Holman WL, et al. **Ann Thorac Surg** 1999 Aug; 68(2):711–6

Current results with pediatric heart transplantation. Kanter KR, et al. **Ann Thorac Surg** 1999 Aug;68(2):527–30; discussion 530–1

Thoracic and cardiovascular interventions after orthotopic heart transplantation. Koyanagi T, et al. **Ann Thorac Surg** 1999 May;67(5):1350–4

Preconditioning prevents myocardial stunning after cardiac transplantation. Landymore RW, et al. **Ann Thorac Surg**

1998 Dec;66(6):1953–7
Treatment of infected left ventricular assist device using antibiotic–impregnated beads. McKellar SH, et al. **Ann Thorac Surg** 1999 Feb;67(2):554–5
Bridge to transplantation: the Penn State experience. Mavroidis D, et al. **Ann Thorac Surg** 1999 Aug;68(2):684–7
Permanent ventricular assist device support versus cardiac transplantation. Pennington DG, et al. **Ann Thorac Surg** 1999 Aug;68(2):729–33
Bridge to transplant with the Novacor left ventricular assist system. Robbins RC, et al. **Ann Thorac Surg** 1999 Aug; 68(2):695–7
Cardiac transplantation in a patient with protein S deficiency. Spanier TB, et al. **Ann Thorac Surg** 1999 Sep;68(3):1078–80
Time course and cellular localization of inducible nitric oxide synthases expression during cardiac allograft rejection. Worrall NK, et al. **Ann Thorac Surg** 1999 Mar;67(3):716–22
Correlation between heart rate variability and hypothermic storage in human cardiac transplant recipients. Biernat M, et al. **Ann Transplant** 1998;3(4):37–40
Comparison of intravascular ultrasound and quantitative angiography for evaluation of coronary artery disease in the transplanted heart. Buszman P, et al. **Ann Transplant** 1996;1(2):31–3
Successful full–term pregnancy in a patient three and a half years after a heart transplant. Dziatkowiak A, et al. **Ann Transplant** 1996;1(4):65–6
The incidence of malignancy in heart transplant recipients. Garlicki M, et al. **Ann Transplant** 1998;3(4):41–7
Opportunistic fungal infections in patients treated with heart transplantation––own centre experiences. Konduracka E. **Ann Transplant** 1998;3(3):21–4
Extended donor criteria––a possible way to enhance the number of potential heart donors. Zembala M, et al. **Ann Transplant** 1996;1(1):44–5
Patient survival with renal replacement therapy in heart transplantation patients. Bernardini J, et al. **ASAIO J** 1998 Sep–Oct;44(5):M546–8
Successful experimental multiorgan transplant from non–heart–beating donors using percutaneous cardiopulmonary support. Fukushima N, et al. **ASAIO J** 1998 Sep–Oct;44(5):M525–8
English teenager given heart transplant against her will [news] Dyer C. **BMJ** 1999 Jul 24;319(7204):209
Reduced bone mineral density in men after heart transplantation. Anijar JR, et al. **Braz J Med Biol Res** 1999 Apr;32(4):413–20
Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Veness MJ, et al. **Cancer** 1999 Apr 15;85(8):1758–64 (21 ref.)
Endothelin and heart transplantation. Geny B, et al. **Cardiovasc Res** 1998 Sep;39(3):556–62 (69 ref.)
Circulating adrenomedullin is increased after heart transplantation. Geny B, et al. **Cardiovasc Res** 1999 Mar; 41(3):731–6
Sensitive diagnosis of cardiac allograft rejection by detection of cytokine transcription in situ. Suzuki J, et al. **Cardiovasc Res** 1998 Nov;40(2):307–13
Endothelin–A and –B antagonists protect myocardial and endothelial function after ischemia/reperfusion in a rat heart transplantation model. Szabó G, et al. **Cardiovasc Res** 1998 Sep;39(3):683–90
Heart transplantation for peripartum cardiomyopathy: a report of three cases and a literature review. Aziz TM, et al. **Cardiovasc Surg** 1999 Aug;7(5):565–7
Arresting donor hearts with extracellular–type cardioplegia prevents vasoconstriction induced by UW solution. Tanoue Y, et al. **Cardiovasc Surg** 1998 Dec;6(6):622–8
Repetitive percutaneous transhepatic access for myocardial biopsy in pediatric cardiac transplant recipients. Book WM, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):167–9
Percutaneous revascularization modalities in heart transplant recipients. Topaz O, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):227–37
Heart transplantation after successful donor postpartum pulmonary embolectomy. Aleksic I, et al. **Chest** 1999 Apr; 115(4):1202–3
Ventilatory and diffusion abnormalities in long–term survivors after orthotopic heart transplantation. Ewert R, et al. **Chest** 1999 May;115(5):1305–11
Thrombolysis with resolution of pulmonary hypertension in a heart transplant candidate. Lick S, et al. **Chest** 1999 Mar; 115(3):896–7
Hyperbaric oxygen therapy in deep sternal wound infection after heart transplantation. Petzold T, et al. **Chest** 1999 May;115(5):1455–8
Maximal exercise testing for the selection of heart transplantation candidates: limitation of peak oxygen consumption. Ramos–Barbón D, et al. **Chest** 1999 Feb; 115(2):410–7
Induction of immune tolerance in adult rabbits undergoing heterotopic cardiac transplantation. Yue X, et al. **Chin Med J (Engl)** 1998 May;111(5):387–90
Multivisceral cluster transplantation: a preliminary experience. Petrassi A, et al. **Chir Ital** 1999 Jan–Feb; 51(1):79–86
Upregulation of estrogen receptor–alpha expression in rabbit cardiac allograft. Lou H, et al. **Circ Res** 1998 Nov 2; 83(9):947–51
Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C–11 hydroxyephedrine. Bengel FM, et al. **Circulation** 1999 Apr 13;99(14):1866–71
Atrial reentrant tachycardia after heart transplantation. Hoffmann E, et al. **Circulation** 1999 Jan 19;99(2):326–7
Subunit expression of the cardiac L–type calcium channel is differentially regulated in diastolic heart failure of the cardiac allograft. Hullin R, et al. **Circulation** 1999 Jul 13; 100(2):155–63
FTY720, a new immunosuppressant, promotes long–term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Hwang MW, et al. **Circulation** 1999 Sep 21;100(12):1322–9
Attenuated acute cardiac rejection in NOS2 –/– recipients correlates with reduced apoptosis. Koglin J, et al. **Circulation** 1999 Feb 16;99(6):836–42
Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Masters RG, et al. **Circulation** 1999 Jul 20;100(3):287–91
New method for detection of heart allograft rejection: validation of sensitivity and reliability in a rat heterotopic allograft model. Morgan DC, et al. **Circulation** 1999 Sep 14;100(11):1236–41
Myocardial dysfunction in donor hearts. A possible etiology. Owen VJ, et al. **Circulation** 1999 May 18;99(19):2565–70
Images in Cardiovascular Medicine. Myocardial [18F]fluorodeoxyglucose uptake after heterotopic cardiac transplantation assessed by positron emission tomography. Rechavia E. **Circulation** 1999 Jun 29;99(25):3322
Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound [see comments] Spes CH, et al. **Circulation** 1999 Aug 3;100(5):509–15. Comment in: Circulation 1999 Aug 3;100(5):458–60.
Impact of University of Wisconsin solution on clinical heart transplantation. A comparison with Stanford solution for extended preservation. Stringham JC, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II157–61; discussion II162
Sympathetic rhythmicity in cardiac transplant recipients. van de Borne P, et al. **Circulation** 1999 Mar 30;99(12):1606–10
Allograft vasculopathy: diagnosing the nemesis of heart transplantation [editorial; comment] Young JB. **Circulation** 1999 Aug 3;100(5):458–60. Comment on: Circulation 1999 Aug 3;100(5):509–15.
Endovascular stenting of an unprotected left main coronary artery stenosis in a heart transplant patient. Weston MW, et al. **Clin Cardiol** 1998 Dec;21(12):919–22
Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients [see comments] Cole DE, et al. **Clin Chem** 1998 Nov; 44(11):2307–12. Comment in: Clin Chem 1998 Nov;44(11):2238–9.
Acquired hyperhomocysteinemia in heart transplant recipients [editorial; comment] Jacobsen DW. **Clin Chem** 1998 Nov;44(11):2238–9. Comment on: Clin Chem 1998 Nov;44(11):2307–12.
Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Müller TF, et al. **Clin Chim Acta** 1998 Aug 10;276(1):63–74
Endothelium–smooth muscle interaction in cardiac transplantation. Skarsgard PL, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):836–40
Pneumonia after heart transplantation: a multi–institutional study. Spanish Transplantation Infection Study Group. Cisneros JM, et al. **Clin Infect Dis** 1998 Aug;27(2):324–31
Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clark NM. **Clin Infect Dis** 1999 May;28(5):1169–70
I–131 orthoiodohippurate assessment of renal function after heart transplantation. Kurtek RW, et al. **Clin Nucl Med** 1999 Feb;24(2):117–9
Prolonged stability of brain natriuretic peptide: importance for non–invasive assessment of cardiac function in clinical practice. Buckley MG, et al. **Clin Sci (Colch)** 1998 Sep; 95(3):235–9
Worldwide Transplant Center directory. Heart transplants. **Clin Transpl** 1997;:505–23
The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts. Khajehdehi P, et al. **Clin Transplant** 1999 Apr;13(2):176–80
Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Taylor DO, et al. **Clin Transplant** 1999 Aug;13(4):296–9
Conjunctival epithelial neoplasias in organ transplant patients receiving cyclosporine therapy. Macarez R, et al. **Cornea** 1999 Jul;18(4):495–7
The role of nitric oxide in cardiac transplantation. Cannon PJ. **Coron Artery Dis** 1999 Jul;10(5):309–14 (58 ref.)
Bibliography Current World Literature. Heart transplantation. **Curr Opin Cardiol** 1999 Mar;14(2):B80–8
The role of exercise–based prognosticating algorithms in the selection of patients for heart transplantation. Beniaminovitz A, et al. **Curr Opin Cardiol** 1999 Mar; 14(2):114–20 (28 ref.)
An overview of combined heart and kidney transplantation. Castillo–Lugo JA, et al. **Curr Opin Cardiol** 1999 Mar; 14(2):121–5 (24 ref.)
Noninvasive detection of cardiac transplant rejection using electronic monitoring. Eisen HJ. **Curr Opin Cardiol** 1999 Mar;14(2):151–4 (16 ref.)
Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Gammie JS, et al. **Curr Opin Cardiol** 1999 Mar;14(2):126–32 (52 ref.)
TNF–alpha in acute cardiac transplant rejection. Azzawi M, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):41–9 (66 ref.)
Enteroviral genome in native hearts may influence outcome of patients who undergo cardiac transplantation. Calabrese F, et al. **Diagn Mol Pathol** 1999 Mar;8(1):39–46
Advances in heart transplantation. Winkel E, et al. **Dis Mon** 1999 Mar;45(3):62–87 (58 ref.)
The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi–centre study. El–Banayosy A, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):835–41
Successful heart transplantation in a patient with Ivemark syndrome combined with situs inversus, single atrium and ventricle after total cavo–pulmonary connection. Berdat PA, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):631–4
Orthotopic cardiac transplantation for the failing Fontan circulation. Carey JA, et al. **Eur J Cardiothorac Surg** 1998 Jul;14(1):7–13; discussion 13–4
Clinical experience with heart transplantation in infants. Dapper F, et al. **Eur J Cardiothorac Surg** 1998 Jul;14(1):1–5; discussion 5–6
Absence of toxicity after overdose of ganciclovir in a cardiac transplant recipient [letter] Kostis EB, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):876
Is routine post–operative surveillance for cytomegalovirus infection following heart transplantation necessary? Madden BP, et al. **Eur J Cardiothorac Surg** 1998 Jul; 14(1):15–7; discussion 17–8
Orthotopic transplantation of pig hearts harvested after 30 min of normothermic ischemia: controlled reperfusion with blood cardioplegia containing the Na+–H+–exchange inhibitor HOE 642. Martin J, et al. **Eur J Cardiothorac Surg** 1998 Dec;14(6):607–14
Coronary artery bypass grafting after orthotopic heart transplantation. Musci M, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):163–8
A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Pagano D, et al. **Eur J Cardiothorac Surg** 1996;10(12):1120–6
Assessment of cardiac rejection by MR–imaging and MR–spectroscopy. Walpoth BH, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):426–30
Cardiomyocyte apoptosis and progression of heart failure to transplantation [see comments] Saraste A, et al. **Eur J Clin Invest** 1999 May;29(5):380–6. Comment in: Eur J Clin Invest 1999 May;29(5):369–71.
Three cases of tuberculosis after heart transplantation in Spain. Muñoz RM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):801–6 (15 ref.)
Electron spin resonance analysis of heme–nitrosyl and reduced iron–sulfur centered complexes in allogeneic, heterotopic cardiac transplants: effects of treatment with pyrrolidine dithiocarbamate. Nakanishi AL, et al. **Free Radic Biol Med** 1998 Jul 15;25(2):201–7
Lipid–mediated gene transfer of viral IL–10 prolongs vascularized cardiac allograft survival by inhibiting donor–specific cellular and humoral immune responses. DeBruyne LA, et al. **Gene Ther** 1998 Aug;5(8):1079–87
Role of orthotopic heart transplantation in the management of patients with recurrent ventricular tachyarrhythmias following myocardial infarction. Bourke JP, et al. **Heart** 1998 Nov;80(5):473–8
Home inotrope treatment for intractable heart failure following heart transplantation. Dubrey SW, et al. **Heart** 1999 Aug;82(2):248–51
ECG diagnosis of native heart ventricular tachycardia in a heterotopic heart transplant recipient. Vanderheyden M, et al. **Heart** 1999 Mar;81(3):323–4
Symptom experience associated with maintenance immunosuppression after heart transplantation: patients' appraisal of side effects. Moons P, et al. **Heart Lung** 1998 Sep–Oct;27(5):315–25
Expression of cell division cycle 2 kinase transcription in chronically rejected cardiac allografts of nonhuman primates. Schoenbeck A, et al. **Heart Vessels** 1997; 12(6):275–9
Three cases of severe subfulminant hepatitis in heart–transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Stuyver L, et al. **Hepatology** 1999 Jun;29(6):1876–83
Enhanced natriuretic response to neutral endopeptidase inhibition in heart–transplant recipients. Geny B, et al. **Hypertension** 1999 Apr;33(4):969–74
The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Jones ND, et al. **Int Immunol** 1998 Nov; 10(11):1637–46
Mechanical circulatory support after orthotopic heart transplantation. Tenderich G, et al. **Int J Artif Organs** 1998 Jul;21(7):414–6
Extracellular matrix structure after heart transplantation. Schacherer C, et al. **Int J Cardiol** 1999 Jan;68(1):115–20
About refusal of care in the ICU [letter; comment] Barzaghi N. **Intensive Care Med** 1998 Nov;24(11):1233–4. Comment on: Intensive Care Med 1998 Mar;24(3):204–5. Comment on: Intensive Care Med 1998 Mar;24(3):251–4.

Double-helical CT as a new tool for tracking of allograft atherosclerosis in heart transplant recipients. Shemesh J, et al. **Invest Radiol** 1999 Jul;34(7):485–8

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. Jensen P, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):177–86

Skin cancer in Australian heart transplant recipients. Ong CS, et al. **J Am Acad Dermatol** 1999 Jan;40(1):27–34

Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. Aaronson KD, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1189–95

Coronary stenting in cardiac allograft vasculopathy. Jain SP, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1636–40

Extramediastinal surgical problems in heart transplant recipients. Mueller XM, et al. **J Am Coll Surg** 1999 Oct; 189(4):380–8

Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support. MacGowan GA, et al. **J Card Fail** 1998 Sep;4(3):169–75

The relationship between cardiac function and neuropsychological status among heart transplant candidates. Putzke JD, et al. **J Card Fail** 1998 Dec; 4(4):295–303

Severe and early alteration of action potential during acute cardiac rejection in rats. Babuty D, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1085–93

Congestive heart failure induced by recipient atrial tachycardia conducted to the donor atrium after orthotopic heart transplantation: complete regression after successful radiofrequency ablation. Gasparini M, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):399–404

Serum beta-2-microglobulin (beta-2-M) levels in heart transplant patients (HTP). Grzeszczak W, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):105–7

Analysis of adhesion molecules in myocardial biopsies of cardiac allografts and coronary artery disease with CABG. Lehmkuhl H, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6 Suppl 1):65–70

Pulmonary Rhizopus rhizopodiformis cavitary abscess in a cardiac allograft recipient. Tan HP, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):223–6

A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. Josien R, et al. **J Clin Invest** 1998 Dec 1;102(11):1920–6

Conversion of cardiac and liver transplant recipients from HPLC and FPIA (polyclonal) to an FPIA (monoclonal) technique for measurement of blood cyclosporin A. McBride JH, et al. **J Clin Lab Anal** 1998;12(6):337–42

Posttransplant Kaposi's sarcoma treated with paclitaxel [letter] Wu CJ, et al. **J Clin Oncol** 1998 Oct;16(10):3478–9

Detection of cytomegalovirus in upper gastrointestinal biopsies from heart transplant recipients: comparison of light microscopy, immunocytochemistry, in situ hybridisation, and nested PCR. Muir SW, et al. **J Clin Pathol** 1998 Nov;51(11):807–11

The International Society for Heart and Lung Transplantation 19th annual meeting. San Francisco, California, USA. April 21–24, 1999. Abstracts. **J Heart Lung Transplant** 1999 Jan;18(1):37–105

Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. Allen-Auerbach M, et al. **J Heart Lung Transplant** 1999 Mar;18(3):211–9

RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. Azzawi M, et al. **J Heart Lung Transplant** 1998 Sep;17(9):881–7

Recurrent left-sided heart leiomyosarcoma: should heart transplantation be legitimate? Babatasi G, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1133–8

Adult human cardiomyocytes coexpress vimentin and Ki67 in heart transplant rejection and in dilated cardiomyopathy. Behr TM, et al. **J Heart Lung Transplant** 1998 Aug; 17(8):795–800

Transplantation with older donor hearts for presumed "stable" recipients: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry [published erratum appears in J Heart Lung Transplant 1998 Nov;17(11):1138] [see comments] Bennett LE, et al. **J Heart Lung Transplant** 1998 Sep;17(9):901–5. Comment in: J Heart Lung Transplant 1999 May;18(5):488–91.

Safety of influenza vaccine in heart transplant recipients. Blumberg EA, et al. **J Heart Lung Transplant** 1998 Nov; 17(11):1075–80

Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. Boucek RJ Jr, et al. **J Heart Lung Transplant** 1999 May;18(5):460–9

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies. Cargnoni A, et al. **J Heart Lung Transplant** 1999 May;18(5):478–87

Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. Costanzo MR, et al. **J Heart Lung Transplant** 1998 Aug;17(8):744–53

Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. De Geest S, et al. **J Heart Lung Transplant** 1998 Sep; 17(9):854–63

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? Delgado J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):607–10

Selection and outcome of ventricular assist device patients: the Muenster experience. Deng MC, et al. **J Heart Lung Transplant** 1998 Aug;17(8):817–25

The nitric oxide donor, diethylamine NONOate, enhances preservation of the donor rat heart. Du ZY, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1113–20

Influenza vaccination in heart transplant recipients. Fraund S, et al. **J Heart Lung Transplant** 1999 Mar;18(3):220–5

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenolate mofetil, cyclosporine A, and donor-specific transfusion. Gibson SW, et al. **J Heart Lung Transplant** 1999 Mar;18(3):185–9

Predictors of quality of life in patients at one year after heart transplantation. Grady KL, et al. **J Heart Lung Transplant** 1999 Mar;18(3):202–10

Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients. Kallinowski B, et al. **J Heart Lung Transplant** 1999 Mar;18(3):190–3

The significance of HLA matching in cardiac transplantation. Ketheesan N, et al. **J Heart Lung Transplant** 1999 Mar; 18(3):226–30

Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors. Kevelaitis E, et al. **J Heart Lung Transplant** 1999 Mar;18(3):239–47

Effects of FR167653 on ischemia-reperfusion injury: evaluation through preservation and transplantation in canine hearts. Koyano T, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1247–54

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. Meiser BM, et al. **J Heart Lung Transplant** 1999 Feb;18(2):143–9

Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. Meiser BM, et al. **J Heart Lung Transplant** 1998 Aug;17(8):782–8

Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. Moidl R, et al. **J Heart Lung Transplant** 1999 Mar;18(3):194–201

Long-term hemodynamic benefit of atrial synchronization with A2A2D or A2A2T pacing in sinus node syndrome after orthotopic heart transplantation. Nägele H, et al. **J Heart Lung Transplant** 1998 Sep;17(9):906–12

Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen. Nohria A, et al. **J Heart Lung Transplant** 1998 Sep; 17(9):849–53

Ten-year follow-up after pediatric transplantation. Parisi F, et al. **J Heart Lung Transplant** 1999 Mar;18(3):275–7

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. Parry N, et al. **J Heart Lung Transplant** 1999 May;18(5):441–7

Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus. Pinski SL, et al. **J Heart Lung Transplant** 1999 Apr;18(4):292–6

European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. Reichart B, et al. **J Heart Lung Transplant** 1998 Aug;17(8):775–81

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. Sartori TM, et al. **J Heart Lung Transplant** 1999 Jul;18(7):693–700

Incomplete adherence after pediatric heart and heart-lung transplantation. Serrano-Ikkos E, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1177–83

Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound. Spes CH, et al. **J Heart Lung Transplant** 1999 May;18(5):391–8

Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. Stanek B, et al. **J Heart Lung Transplant** 1999 Apr;18(4):358–66

Cardioprotective effects of Lazaroid U-74389G on ischemia-reperfusion injury in canine hearts. Takahashi T, et al. **J Heart Lung Transplant** 1999 Apr;18(4):285–91

Induction of donor-specific tolerance to cardiac xenografts in utero. Tanaka SA, et al. **J Heart Lung Transplant** 1998 Sep;17(9):888–91

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO, et al. **J Heart Lung Transplant** 1999 Apr;18(4):336–45

Single-field total lymphoid irradiation in the treatment of refractory rejection after heart transplantation. Trachiotis GD, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1045–8

Cardiac troponin T is not a marker of biopsy-proven cellular rejection [letter; comment] [published erratum appears in J Heart Lung Transplant 1999 Jun;18(6):610] Vazquez-Rodriguez JM, et al. **J Heart Lung Transplant** 1999 Feb;18(2):172. Comment on: J Heart Lung Transplant 1998 Apr;17(4):395–8.

Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status? Winkel E, et al. **J Heart Lung Transplant** 1998 Aug;17(8):809–16

Diastolic dysfunction coincides with early mild transplant rejection: in situ measurements in a heterotopic rat heart transplant model. Yoshida S, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1049–56

Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. Zambrana JL, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1213–9

Investigation of the plasma concentrations and circulating forms of BNP and ANP in orthotopic cardiac transplant recipients. Buckley MG, et al. **J Hum Hypertens** 1998 Dec; 12(12):825–6

Role of nitric oxide following cardiac transplantation. Chester AH, et al. **J Hum Hypertens** 1998 Dec;12(12):833–7 (71 ref.)

Hypertension in thoracic transplant recipients. Jenkins GH, et al. **J Hum Hypertens** 1998 Dec;12(12):813–23 (124 ref.)

Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension. Bracht C, et al. **J Hypertens** 1999 Mar;17(3):357–63

Case report: radiofrequency catheter ablation of atrioventricular nodal reentrant tachycardia in a patient with heart transplantation. Zhu DW, et al. **J Interv Card Electrophysiol** 1998 Mar;2(1):87–9

Time-dependent expression of ICAM-1 & VCAM-1 on coronaries of the heterotopically transplanted mouse heart. Lee JR, et al. **J Korean Med Sci** 1999 Jun;14(3):245–52

Abdominal aortic aneurysms in heart transplanted patients. Diciolla F, et al. **J Mal Vasc** 1998 Dec;23(5):358–60

Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially. Petzold DR, et al. **J Med Virol** 1999 May;58(1):1–10

Renography before heart transplantation in patients with cardiomyopathy. Aigner RM, et al. **J Nucl Med** 1998 Dec; 39(12):2153–8

The utility of exercise testing after cardiac transplantation in older patients. Chang AC, et al. **J Surg Res** 1999 Jan; 81(1):48–54

Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate. Schwartz CF, et al. **J Surg Res** 1999 Sep;86(1):24–8

Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. Shapira OM, et al. **J Surg Res** 1999 Jul;85(1):83–7

Pressure volume curves in arrested heterotopic rat heart isografts: role of improved myocardial protection. Starr JP, et al. **J Surg Res** 1999 Sep;86(1):123–9

Myocardial pseudovascular tubes are present in the delayed rejection of pig-to-baboon orthotopic cardiac xenografts [letter; comment] Beranek JT. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1233–4. Comment on: J Thorac Cardiovasc Surg 1998 Jun;115(6):1342–9.

Orthotopic cardiac transplantation after minimally invasive direct coronary artery bypass. Reardon MJ, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):390–1 (9 ref.)

Long-term myocardial preservation: effects of hyperkalemia, sodium channel, and Na/K/2Cl cotransport inhibition on extracellular potassium accumulation during hypothermic storage. Snabaitis AK, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):123–34

Current status of cardiac transplantation. Hunt SA. **JAMA** 1998 Nov 18;280(19):1692–8

Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts. Hachida M, et al. **Jpn Circ J** 1999 Apr;63(4):303–8

Renal hemodynamic effects of L-arginine and sodium nitroprusside in heart transplant recipients. Koller-Strametz J, et al. **Kidney Int** 1999 May;55(5):1871–7

Heart transplantation in the pediatric age-group and for end-stage congenital heart defects [editorial; comment] Shumway SJ. **Mayo Clin Proc** 1998 Oct;73(10):1025–6. Comment on: Mayo Clin Proc 1998 Oct;73(10):923–8.

Cardiac transplantation for end-stage congenital heart defects: the Mayo Clinic experience. Mayo Cardiothoracic Transplant Team [see comments] Speziali G, et al. **Mayo Clin Proc** 1998 Oct;73(10):923–8. Comment in: Mayo Clin Proc 1998 Oct;73(10):1025–6.

Ischemia--reperfusion-induced apoptosis and p53 expression in the course of rat heterotopic heart transplantation. Formigli L, et al. **Microvasc Res** 1998 Nov;56(3):277–81

Skin microvascular distensibility and structural microangiopathy in idiopathic dilated cardiomyopathy and after heart transplantation. Sørensen VB, et al. **Microvasc Res** 1999 Jan;57(1):44–51

Heart transplantation in patients with diuretic resistant heart failure. De Vivo F, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):47–50

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. Barr ML, et al. **N Engl J Med** 1998 Dec 10; 339(24):1744–51

Heme oxygenase: protective gene or Trojan horse [news] Platt JL, et al. **Nat Med** 1998 Dec;4(12):1364–5

Heart transplantation or combined heart/kidney transplantation? Even one renal biopsy may fool you. Haas M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1014–5

Renal insufficiency after heart transplantation: a case-control study. van Gelder T, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2322-6

Cardiac transplantation in a Duchenne muscular dystrophy carrier. Melacini P, et al. **Neuromuscul Disord** 1998 Dec; 8(8):585-90

Dietary amino acids as new and novel agents to enhance allograft survival. Alexander JW, et al. **Nutrition** 1999 Feb; 15(2):130-4

Vasovagal syncope in heart transplant patients during dental surgery. Montebugnoli L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):666-9

Declining need for pacemaker implantation after cardiac transplantation. Parry G, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2350-2

Somatic growth in infant heart transplant recipients [see comments] Chinnock R, et al. **Pediatr Transplant** 1998 Feb; 2(1):30-4. Comment in: Pediatr Transplant 1998 Feb;2(1):3-5.

Changing cyclosporin A formulation: an analysis in paediatric cardiac transplant recipients. Gennery AR, et al. **Pediatr Transplant** 1999 Aug;3(3):215-8

Benign transient hyperphosphatasemia of infancy and early childhood following cardiac transplantation. Gennery AR, et al. **Pediatr Transplant** 1998 Aug;2(3):197-9

Heart transplantation on the first day of life from an anencephalic donor [see comments] Parisi F, et al. **Pediatr Transplant** 1999 May;3(2):150-1. Comment in: Pediatr Transplant 1999 May;3(2):92-4.

15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. Webber SA. **Pediatr Transplant** 1997 Aug;1(1):8-21 (83 ref.)

Participation of coenzyme Q10 in the rejection development of the transplanted heart: a clinical study. Kucharská J, et al. **Physiol Res** 1998;47(6):399-404

New strategy for prolonging the preservation time of hearts for transplantation. Mesáros S, et al. **Physiol Res** 1997; 46(4):251-5

Management of sternal and abdominal wounds in a pediatric heart transplant patient. Low DW, et al. **Plast Reconstr Surg** 1998 Nov;102(6):2100-7

Impact of new UNOS guidelines on donor heart allocation to circulatory assist device patients. Shinn JA. **Prog Cardiovasc Nurs** 1999 Winter;14(1):37-8

Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation. Vento AE, et al. **Res Exp Med (Berl)** 1999 Apr;198(6):299-306

Pulmonary function in chronic heart failure. Changes after heart transplantation. Ulrik CS, et al. **Scand Cardiovasc J** 1999;33(3):131-6

Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Qi Z, et al. **Scand J Immunol** 1998 Oct; 48(4):379-88

Prolonged rat heart allograft survival after treatment with angiotensin converting enzyme inhibitor or a calcium antagonist. Mjörnstedt L, et al. **Scand J Urol Nephrol** 1998 Sep;32(5):341-4

Cardiac transplantation. Spann JC, et al. **Surg Clin North Am** 1998 Oct;78(5):679-90 (30 ref.)

The effect of graft perfusion with warm blood cardioplegia for cadaver heart transplantation. Suehiro K, et al. **Surg Today** 1999;29(9):890-6

The detection of chronic heart graft rejection by 31P NMR spectroscopy. Suzuki K, et al. **Surg Today** 1999;29(2):143-8

Linked pacing after heterotopic heart transplantation with concurrent left ventricular reduction of the native heart. Beyer E, et al. **Tex Heart Inst J** 1998;25(4):299-302

Extracorporeal photochemotherapy: a treatment for organ graft rejection [editorial] Heshmati F, et al. **Ther Apher** 1997 May;1(2):121-5 (25 ref.)

Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Jaeger BR, et al. **Ther Apher** 1999 Aug;3(3):214-8

Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation [published erratum appears in Ther Apher 1997 Nov;1(4):388-9] Robinson JA, et al. **Ther Apher** 1997 May;1(2):147-51

Apheresis in thoracic organ transplantation. Robinson JA. **Ther Apher** 1999 Feb;3(1):34-9

Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Akhlaghi F, et al. **Ther Drug Monit** 1999 Feb;21(1):8-16

Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Dubrey SW, et al. **Ther Drug Monit** 1999 Jun; 21(3):325-6

Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Regazzi MB, et al. **Ther Drug Monit** 1999 Feb; 21(1):2-7

Bridging to cardiac transplantation with the Thoratec Ventricular Assist Device. El-Banayosy A, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:307-10

Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Musci M, et al. **Thorac Cardiovasc Surg** 1998 Oct; 46(5):268-74

Usefulness of the QTc interval in predicting acute allograft rejection. Richartz BM, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):217-21

Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury. Szabó G, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):232-6

WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. Dresske B, et al. **Transpl Immunol** 1998 Dec; 6(4):243-9

Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK, et al. **Transpl Int** 1998;11 Suppl 1:S303-9

Evaluating the donor pool: impact of using hearts from donors over the age of 49 years. Mercer P, et al. **Transpl Int** 1998;11 Suppl 1:S424-9

Intermediate and long-term results after pediatric heart transplantation: incidence and role of pretransplant diagnosis. Parisi F, et al. **Transpl Int** 1998;11 Suppl 1:S493-8

Systematic evaluation of distribution of transgene expression after adenovirus-mediated gene transfer to the transplanted heart. Pellegrini C, et al. **Transpl Int** 1998;11(5):373-7

C-reactive protein in the monitoring of acute rejection after heart transplantation. van Gelder T, et al. **Transpl Int** 1998; 11(5):361-4

Assessment of troponin-T for detection of clinical cardiac rejection. Walpoth BH, et al. **Transpl Int** 1998;11 Suppl 1:S502-7

Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Wreghitt TG, et al. **Transpl Int** 1999;12(4):254-60

Morphometric analyses to predict appropriate donor size for swine-to-human cardiac xenotransplantation. Allan JS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):975-7

Right atrial dilatation: major contributor to increased cardiothoracic ratio in cardiac transplant candidates. Aravot D, et al. **Transplant Proc** 1999 Jun;31(4):1887-8

Prevention of symptomatic infection by herpesvirus in patients after heart transplantation. Arazi HC, et al. **Transplant Proc** 1999 Sep;31(6):2530

Outcome of grafts procured in transplant patients. Arvieux C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):530-2

Importance of the cardiothoracic ratio in the evaluation of cardiac transplant candidates. Berman M, et al. **Transplant Proc** 1999 Jun;31(4):1885-6

Acute parvovirus infection in a heart transplant recipient. Bisognano JD, et al. **Transplant Proc** 1999 Aug; 31(5):2159-60

Surgical extracardiac thoracic complications in heart transplantation. Castells E, et al. **Transplant Proc** 1999 Sep; 31(6):2511-2

Necrotizing soft tissue infection in heart transplantation recipients: two case reports. Chao CS, et al. **Transplant Proc** 1998 Nov;30(7):3347-9

Combined heart and kidney transplantation. Crespo-Leiro MG, et al. **Transplant Proc** 1999 Sep;31(6):2513-4

Predicting outcomes and management of candidates for heart transplantation. Fukushima N, et al. **Transplant Proc** 1999 Aug;31(5):1961-2

Myocardial protection for transplantation. Garlicki M, et al. **Transplant Proc** 1999 Aug;31(5):2079-83

Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter. Gruberg L, et al. **Transplant Proc** 1999 Aug;31(5):2157-8

Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Gullestad L, et al. **Transplant Proc** 1999 Aug;31(5):2163-5

Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):2049-55

Late multiglycosidorum tripterygium treatment ameliorates established graft coronary arteriosclerosis after heart transplantation in the rat. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):2020-4

Mechanisms of exercise response in the denervated heart after transplantation. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):1966-9

Neurologic complications following heart transplantation in the modern era: decreased incidence, but postoperative stroke remains prevalent. Jarquin-Valdivia AA, et al. **Transplant Proc** 1999 Aug;31(5):2161-2

Successful prevention of syphilis transmission from a multiple organ donor with serological evidence of syphilis. Ko WJ, et al. **Transplant Proc** 1998 Nov;30(7):3667-8

Postoperative management following heart transplantation. Kobashigawa JA. **Transplant Proc** 1999 Aug;31(5):2038-46

Usefulness of quantitative cytomegalovirus antigenemia determinations in heart transplantation. Manito N, et al. **Transplant Proc** 1999 Sep;31(6):2526-7

Midterm results of percutaneous transluminal coronary angioplasty in graft coronary artery disease in cardiac transplant patients. Marelli M, et al. **Transplant Proc** 1999 Sep;31(6):2539-41

Lifestyle assessment and heart transplant evaluation. Mozdzierz GJ. **Transplant Proc** 1999 Jun;31(4A):18S

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients. Mullen GM, et al. **Transplant Proc** 1998 Dec;30(8):4110-2

Application of ventricular assist systems for end-stage cardiomyopathy patients as a bridge to heart transplant or recovery. Nakatani T, et al. **Transplant Proc** 1999 Aug; 31(5):2000-1

Management of young potential candidates for heart transplantation. Nakatani T, et al. **Transplant Proc** 1999 Aug;31(5):1963-5

Left ventricular assist systems as a bridge to heart transplantation: the role and the strategy in Japan. Nishimura M, et al. **Transplant Proc** 1999 Aug;31(5):1997-9

Timing of heart transplantation and posttransplant care: overseas experience. Nunoda S, et al. **Transplant Proc** 1999 Aug;31(5):1957-60

Preemptive and prophylactic ganciclovir therapy for CMV infection in heart transplant patients. Paniagua MJ, et al. **Transplant Proc** 1999 Sep;31(6):2528-9

Usefulness of nitric oxide inhalation for management of right ventricular failure after heart transplantation in patients with pretransplant pulmonary hypertension. Paniagua MJ, et al. **Transplant Proc** 1999 Sep;31(6):2505-6

Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Rodríguez JA, et al. **Transplant Proc** 1999 Sep;31(6):2522-3

Bridging to cardiac transplantation: a clinical laboratory for the development of mechanical alternatives to transplantation. Rose EA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):120-2 (16 ref.)

Employment is a misleading indicator for successful outcome after heart transplantation. Sahar G, et al. **Transplant Proc** 1999 Jun;31(4):1905-6

E2F decoy suppresses E-selectin expression in murine cardiac allograft arteriopathy. Suzuki J, et al. **Transplant Proc** 1999 Aug;31(5):2018-9

Ventricular assist as a bridge to heart transplantation. Wang SS, et al. **Transplant Proc** 1998 Nov;30(7):3401-2

Successful use of Phoenix-7 total artificial heart. Wei J, et al. **Transplant Proc** 1998 Nov;30(7):3403-4

Improved graft function using a new myocardial preservation solution: Celsior. Preliminary data from a randomized prospective study. Wieselthaler GM, et al. **Transplant Proc** 1999 Aug;31(5):2067-8

Cytokine induction owing to LVAD support in canine models. Yamagishi T, et al. **Transplant Proc** 1999 Aug; 31(5):1992-3

Effect of 15-deoxyspergualine on coronary arteriosclerosis and platelet-derived growth factor-A mRNA expression in the transplanted heart. Zhang X, et al. **Transplant Proc** 1999 May;31(3):1706-9

Unbound cyclosporine and allograft rejection after heart transplantation. Akhlaghi F, et al. **Transplantation** 1999 Jan 15;67(1):54-9

Bone marrow changes in heart transplant recipients with peripheral cytopenia. Castello A, et al. **Transplantation** 1999 Mar 27;67(6):840-6

Myocardial nuclear factor-kappaB activity and nitric oxide production in rejecting cardiac allografts. Cooper M, et al. **Transplantation** 1998 Oct 15;66(7):838-44

Evidence for heat shock protein immunity in a rat cardiac allograft model of chronic rejection. Duquesnoy RJ, et al. **Transplantation** 1999 Jan 15;67(1):156-64

Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation. Eisen HJ, et al. **Transplantation** 1999 Sep 15;68(5):663-71

Excellent recovery after prolonged heart storage by preservation with coronary oxygen persufflation: orthotopic pig heart transplantations after 14-hr storage. Fischer JH, et al. **Transplantation** 1998 Dec 15; 66(11):1450-9

Microsporidia infection in transplant patients. Gumbo T, et al. **Transplantation** 1999 Feb 15;67(3):482-4 (8 ref.)

Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Hullett DA, et al. **Transplantation** 1998 Oct 15; 66(7):824-8

Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance. Josien R, et al. **Transplantation** 1998 Oct 15;66(7):887-93

Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Knoop C, et al. **Transplantation** 1998 Oct 15;66(7):932-5

Combined heart and kidney transplantation using a single donor: a single center's experience with nine cases. Kocher AA, et al. **Transplantation** 1998 Dec 27;66(12):1760-3

A commentary on a randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients [letter] Korvick JA, et al. **Transplantation** 1999 Sep 15;68(5):708-9

Relationship of HHV8 replication and Kaposi's sarcoma after solid organ transplantation. Mendez JC, et al. **Transplantation** 1999 Apr 27;67(8):1200-1

Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians-National Institutes of Health conference. Miller LW. **Transplantation** 1998 Oct 15;66(7):947-51

Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Oertel SH, et al. **Transplantation** 1999 Mar 15;67(5):765-7

Microchimerism in thymus is associated with up-regulated T helper type 1 cytokine transcription during cardiac allograft rejection in rats. Ota H, et al. **Transplantation** 1999 Jan 15;67(1):165-73

Management of acute right heart failure after combined heart and kidney transplantation: case report. Rego A, et al.

Transplantation 1999 Jan 15;67(1):184–5

FK506 treatment in combination with leflunomide in hamster–to–rat heart and liver xenograft transplantation. Sankary HN, et al. **Transplantation** 1998 Oct 15;66(7):832–7

Extended donor criteria: hemodynamic follow–up of heart transplant recipients receiving a cardiac allograft from donors > or = 60 years of age. Tenderich G, et al. **Transplantation** 1998 Oct 27;66(8):1109–13

Long–term outcome of chronic hepatitis B in heart transplant recipients. Wedemeyer H, et al. **Transplantation** 1998 Nov 27;66(10):1347–53

Xenotransplantation: about baboon hearts and pig livers [letter; comment] van der Kuyl AC, et al. **Trends Microbiol** 1998 Nov;6(11):431–2. Comment on: Trends Microbiol 1998 Oct;6(10):411–5.

Coronary stenting for coronary artery disease in a cardiac transplant recipient. Murdock DK, et al. **WMJ** 1998 Nov; 97(10):30–2

Gastrointestinal disease following heart transplantation. Mueller XM, et al. **World J Surg** 1999 Jul;23(7):650–5; discussion 655–6

Failure of anti–Forssman antibodies to induce rejection of mouse heart xenografts. Wu GD, et al. **Xenotransplantation** 1999 May;6(2):90–7

[ECG anomalies and axis deviations in heart transplant recipients: MRI studies] Ambrosi P, et al. **Ann Cardiol Angeiol (Paris)** 1998 May;47(5):334–9 (Eng. Abstr.) **(Fre)**

[Detection of acute rejection of heart transplantation by Doppler color imaging] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1255–62 (30 ref.) (Eng. Abstr.) **(Fre)**

[Alternative surgical options to heart transplantation] Dreyfus G. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1413–22 (Eng. Abstr.) **(Fre)**

[Ethical aspects of heart transplantation] Tschanz HU, et al. **Schweiz Med Wochenschr** 1998 Aug 29;128(35):1291–7 (33 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic cardiomyopathy––transplantation and bridging with mechanical assist systems] Feindt P, et al. **Z Kardiol** 1998;87 Suppl 2:181–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Coronary vasculopathy after heart transplantation––effect of temporal onset, severity and progression on long–term prognosis] Pethig K, et al. **Z Kardiol** 1999 Jul;88(7):498–506 (Eng. Abstr.) **(Ger)**

[Xenotransplantation of hDAF–transgenic swine hearts] Schmoeckel M, et al. **Zentralbl Chir** 1999;124(7):604–8 (Eng. Abstr.) **(Ger)**

[Cardiovascular autonomic regulation following orthoptic heart transplantation] Török T, et al. **Orv Hetil** 1998 Nov 22;139(47):2833–7 (Eng. Abstr.) **(Hun)**

[Heterotopic heart transplantation in the rat: a preliminary study] Capuano LG, et al. **Ann Ital Chir** 1998 May–Jun; 69(3):351–6 (Eng. Abstr.) **(Ita)**

[Heterotropic heart transplantation in young patients with elevated pulmonary vascular resistance] Gamba A, et al. **G Ital Cardiol** 1999 Aug;29(8):918–24 (Eng. Abstr.) **(Ita)**

[Contraception after heart transplantation] Spina V, et al. **Minerva Ginecol** 1998 Dec;50(12):539–43 (Eng. Abstr.) **(Ita)**

[Heart transplantation] Matsuda H, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1402–10 (15 ref.) **(Jpn)**

[Hemodynamic evaluation and clinical outcome of children with severe dilated cardiomyopathy eligible for heart transplantation] Azeka E, et al. **Arq Bras Cardiol** 1998 Nov; 71(5):661–6 (Eng. Abstr.) **(Por)**

[The detection of cytomegalovirus DNA by the polymerase chain reaction in different biological materials in patients with organ allografts] Vediakov AM, et al. **Klin Lab Diagn** 1998 Nov;(11):19–20, 33–4 (Eng. Abstr.) **(Rus)**

[Preparation for heart transplantation in Slovakia 1994–1997] Fabián J, et al. **Bratisl Lek Listy** 1998 Dec;99(12):635–9 (Eng. Abstr.) **(Slo)**

[Diagnosis and therapy of acute rejection in patients after orthotopic heart transplantation] Schrameková E, et al. **Bratisl Lek Listy** 1998 Dec;99(12):644–6 (Eng. Abstr.) **(Slo)**

[Influence of genetic variation at apoprotein A–1 gene promoter region on plasma lipid levels in heart transplantation patients] González Amieva A, et al. **Med Clin (Barc)** 1998 Sep 26;111(9):321–4 (Eng. Abstr.) **(Spa)**

[The poiymerase chain reaction as a marker of cytomegalovirus infection in heart transplant recipients] Niubò J, et al. **Med Clin (Barc)** 1999 Feb 6;112(4):121–4 (Eng. Abstr.) **(Spa)**

[Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment] Zambrana García JL, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):303–7 (96 ref.) **(Spa)**

[Selection and evaluation of candidate patients for heart transplant] Castro PF, et al. **Rev Esp Cardiol** 1999 Aug; 52(8):604–16 (119 ref.) (Eng. Abstr.) **(Spa)**

[Evaluation of the usefulness of the antimyosin monoclonal antibody (AMA) uptake in the diagnosis of heart transplant (HT) rejection] Bello Arqués P, et al. **Rev Esp Med Nucl** 1999 Jun;18(3):190–6 (Eng. Abstr.) **(Spa)**

[Myocardial perfusion SPET in the detection of coronary artery disease in orthotopic heart transplantation] López Milán D, et al. **Rev Esp Med Nucl** 1998;17(6):419–26 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Disseminated peritoneal plasmacytoma following cardiac transplantation. Chan BK, et al. **Abdom Imaging** 1999 Sep–Oct;24(5):508–10

Coronary arteriopathy after heart transplantation. Kløw NE, et al. **Acta Radiol** 1998 Nov;39(6):656–62

Prediction of human transplantation arteriopathy and coronary events with lung/heart count ratios during intravenous dipyridamole thallium–201 imaging [see comments] Lenihan DJ, et al. **Am Heart J** 1999 May; 137(5):942–8. Comment in: Am Heart J 1999 May;137(5):782–5.

Lung thallium imaging in coronary transplant arteriopathy: "Ce n'est pas un pipe" [editorial; comment] Miller DD. **Am Heart J** 1999 May;137(5):782–5 (25 ref.). Comment on: Am Heart J 1999 May;137(5):942–8.

Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients? Son R, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):358–63

Acute pancreatitis after cardiac transplantation and other cardiac procedures: case–control analysis in 24,631 patients. Herline AJ, et al. **Am Surg** 1999 Sep;65(9):819–25; discussion 826

The spectrum of aortic complications after heart transplantation. Vigano' M, et al. **Ann Thorac Surg** 1999 Jul;68(1):105–11

Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Liu Z, et al. **Atherosclerosis** 1998 Sep; 140(1):1–14 (170 ref.)

Heart allograft vascular disease: an obliterative vascular disease in transplanted hearts. Orbaek Andersen H. **Atherosclerosis** 1999 Feb;142(2):243–63 (333 ref.)

A clinically aggressive, polymorphic, polyclonal posttransplantation lymphoproliferative disorder. Dunphy CH, et al. **Cancer Genet Cytogenet** 1998 Oct 1;106(1):49–53

The continuing challenge of cardiac transplant arteriosclerosis. Weis M, et al. **Cardiologia** 1998 Aug; 43(8):777–87 (132 ref.)

Gene polymorphisms for plasminogen activator inhibitor–1/tissue plasminogen activator and development of allograft coronary artery disease. Benza RL, et al. **Circulation** 1998 Nov 24;98(21):2248–54

Development of transplantation vasculopathy and progression of donor–transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Kapadia SR, et al. **Circulation** 1998 Dec 15;98(24):2672–8

Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Poston RS, et al. **Circulation** 1999 Jul 6;100(1):67–74

Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet–derived growth factor receptor. Sihvola R, et al. **Circulation** 1999 May 4;99(17):2295–301

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo–controlled study. Valantine HA, et al. **Circulation** 1999 Jul 6;100(1):61–6

Incidence and prognostic value of electrocardiographic abnormalities after heart transplantation. Golshayan D, et al. **Clin Cardiol** 1998 Sep;21(9):680–4

High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Glendenning P, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):347–55

Catecholamines and heart function in heart transplant patients: effects of beta1– versus nonselective beta–blockade. Leenen FH, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):522–35

Impact of intravascular ultrasound in understanding transplant coronary artery disease. Kapadia SR, et al. **Curr Opin Cardiol** 1999 Mar;14(2):140–50 (76 ref.)

High and low pulmonary vascular resistance in heart transplant candidates. A 5–year follow–up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Lindelöw B, et al. **Eur Heart J** 1999 Jan;20(2):148–56

Incidence and clinical relevance of coronary calcification detected by electron beam computed tomography in heart transplant recipients. Ludman PF, et al. **Eur Heart J** 1999 Feb;20(4):303–8

Intermediate term results of total lymphoid irradiation for the treatment of non–specific graft dysfunction after heart transplantation. Madden BP, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):663–6

Allograft typical atrial flutter: transesophageal recording in an orthotopic cardiac transplant patient. Avella A, et al. **G Ital Cardiol** 1998 Dec;28(12):1456–7 **(Eng, Ita)**

Donor–to–recipient transmission of bacteria as an unusual cause of mediastinitis in a heart transplant recipient. Burket JS, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):132–3

Clinical relevance of subclinical tricuspid regurgitation after orthotopic cardiac transplantation [letter; comment] Burgess MI, et al. **J Am Soc Echocardiogr** 1999 Feb; 12(2):164. Comment on: J Am Soc Echocardiogr 1998 Jun;11(6):652–9.

Magnesium deficiency and bone loss after cardiac transplantation. Boncimino K, et al. **J Bone Miner Res** 1999 Feb;14(2):295–303

Pericardial tamponade and massive pleural effusion complicating orthotopic heart transplantation. Lee JT, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):377–9

Parvovirus B19 infection in thoracic organ transplant recipients. Calvet A, et al. **J Clin Virol** 1999 Jun; 13(1–2):37–42

Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. Carrier M, et al. **J Heart Lung Transplant** 1999 Jul;18(7):664–7 (9 ref.)

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. Cook RC, et al. **J Heart Lung Transplant** 1999 May;18(5):420–4

Captopril and platelet–activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF–like compounds. Crawford SE, et al. **J Heart Lung Transplant** 1999 May;18(5):470–7

Multiglycosidorum tripterygii, a new immunosuppressant, supresses coronary arteriosclerosis after heart transplantation. Hachida M, et al. **J Heart Lung Transplant** 1999 Mar;18(3):248–54

Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. Shane E, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1089–96

Incidence and outcome of primary Epstein–Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. Zangwill SD, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1161–6

Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus–8. Dotti G, et al. **Leukemia** 1999 May;13(5):664–70 (35 ref.)

A new rat model to study the correlation of cardiac and skeletal muscle allograft rejection. Blanchard J, et al. **Microsurgery** 1998;18(7):406–9

Treatment of end–stage renal failure after heart transplantation. Frimat L, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2905–8

Non–invasive diagnosis of acute heart– or lung–transplant rejection using radiolabeled annexin V. Blankenberg FG, et al. **Pediatr Radiol** 1999 May;29(5):299–305 (53 ref.)

Imaging of cardiac transplantation complications. Knisely BL, et al. **Radiographics** 1999 Mar–Apr;19(2):321–39; discussion 340–1 (41 ref.)

Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Heegaard ED, et al. **Scand J Infect Dis** 1998;30(6):607–10

Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Hammer S, et al. **Transpl Immunol** 1998 Dec;6(4):235–41

Mild chronic anemia following heart transplantation: a syndrome with prognostic relevance? Müller HM, et al. **Transpl Int** 1998;11(6):413–8

Donor–specific CTL frequencies in peripheral blood in relation to graft vascular disease after clinical heart transplantation. van Besouw NM, et al. **Transpl Int** 1998; 11 Suppl 1:S364–6

Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient [letter] Dulai G, et al. **Transplantation** 1999 May 15;67(9):1288–9

Serum cardiac troponin–T concentrations predict development of coronary artery disease in heart transplant patients. Faulk WP, et al. **Transplantation** 1998 Nov 27; 66(10):1335–9

Risks and costs of end–stage renal disease after heart transplantation. Hornberger J, et al. **Transplantation** 1998 Dec 27;66(12):1763–70

Status epilepticus and cardiac transplantation [letter] Rose AG, et al. **Transplantation** 1999 Feb 27;67(4):640–1

Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double–blind trial with calcitriol. Stempfle HU, et al. **Transplantation** 1999 Aug 27;68(4):523–30

Specific expression of Epstein–Barr virus in cutaneous squamous cell carcinomas from heart transplant recipients. Ternesten–Bratel A, et al. **Transplantation** 1998 Dec 15; 66(11):1524–9

Posttransplantation B lymphoblastic leukemia with Burkitt–like features. Tweddle DA, et al. **Transplantation** 1999 May 27;67(10):1379–80

[Intrathoracic occurrence of post–transplantation lymphoproliferation] Jirava D, et al. **Rozhl Chir** 1999 Apr; 78(4):191–5 (Eng. Abstr.) **(Cze)**

[Successful pregnancy after heart transplantation] de Jonge N, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1664–8 (Eng. Abstr.) **(Dut)**

[Hyperlipoproteinemia in patients after heart transplantation] Goncalvesová E, et al. **Bratisl Lek Listy** 1998 Dec; 99(12):640–3 (Eng. Abstr.) **(Slo)**

CLASSIFICATION

The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. Winters GL, et al. **J Heart Lung Transplant** 1998 Aug;17(8):754–60

CONTRAINDICATIONS

[The usefulness of transjugular hepatic biopsy in the evaluation of liver disease in candidates for heart transplantation] Parera A, et al. **Gastroenterol Hepatol** 1999

Feb;22(2):67-71 (Eng. Abstr.) **(Spa)**

ECONOMICS

Effects of modification of the allocation system on ischemia duration and costs of heart transplantation. Transplantation Cooperation UNI-NRW. Petzold T, et al. **Thorac Cardiovasc Surg** 1999 Jun;47(3):153-6

[Political and economic aspects of heart transplantation] Carrel T, et al. **Schweiz Med Wochenschr** 1998 Aug 29; 128(35):1298-304 (Eng. Abstr.) **(Ger)**

HISTORY

America's first human heart transplantation: the concept, the planning, and the furor. Kantrowitz A. **ASAIO J** 1998 Jul-Aug;44(4):244-52

The first lung transplant in man (1963) and the first heart transplant in man (1964). Hardy JD. **Transplant Proc** 1999 Feb-Mar;31(1-2):25-9

Forty years of thoracic transplantation at Stanford. Shumway NE. **Transplant Proc** 1999 Feb-Mar;31(1-2):46

[Ten-year experience with heart transplantation (1987-1997)] Tatou E, et al. **Presse Med** 1999 Sep 11;28(26):1409-13 (Eng. Abstr.) **(Fre)**

[Three hundred years of history: from the first blood transfusion (1667) to the first heart transplantation (1967)] Cosmacini G. **Cardiologia** 1998 Dec;43(12):1383-5 **(Ita)**

IMMUNOLOGY

Advances in immunosuppression for heart transplantation. Kobashigawa JA. **Adv Card Surg** 1998;10:155-74 (46 ref.)

Posttransplantation cytotoxic immunoglobulin G is associated with a high rate of acute allograft dysfunctions in heart transplant recipients. Leprince P, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):586-92

Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: insights from IL-10 knockout mice. Räisänen-Sokolowski A, et al. **Am J Pathol** 1998 Nov; 153(5):1491-500

Interferon-gamma-secreting T-cell populations in rejecting murine cardiac allografts: assessment by flow cytometry. Stinn JL, et al. **Am J Pathol** 1998 Nov;153(5):1383-92

Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation. Exton MS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1710-7

Scintigraphy and immunohistology of antimyosin-Fab during graft rejection. Breuer M, et al. **Angiology** 1999 Jul; 50(7):563-71

Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Abbosh J, et al. **Ann Allergy Asthma Immunol** 1999 May;82(5):473-6

T-cell activation, proliferation, and memory after cardiac transplantation in vivo. Jones ND, et al. **Ann Surg** 1999 Apr;229(4):570-8

Daily noninvasive rejection monitoring improves long-term survival in pediatric heart transplantation. Hetzer R, et al. **Ann Thorac Surg** 1998 Oct;66(4):1343-9

Donor cardiac troponin T: a marker to predict heart transplant rejection. Vijay P, et al. **Ann Thorac Surg** 1998 Dec;66(6):1934-9

Immunologic barriers in pig-to-primate cardiac xenotransplantation. Artrip JH, et al. **Ann Transplant** 1997; 2(1):5-11 (48 ref.)

Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus. Ghobrial R, et al. **Ann Transplant** 1996;1(4):22-9

Protection of heart and rejection of lymphocyte allografts from the same donor in recipients of donor-specific transfusions. Jaskłowska-Englisz M, et al. **Ann Transplant** 1998;3(1):28-33

Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34-40 (61 ref.)

Cyclosporin A decreases lymphocyte migration to the heart allograft through suppression of their L-selectin expression. Maksymowicz M, et al. **Ann Transplant** 1998;3(1):34-6

Activation of donor-specific CTL in a tolerant recipient of cardiac allograft. Petersson E, et al. **Cell Immunol** 1998 Oct 10;189(1):19-24

Heart rate variability as an assessment of acute rejection after heart transplantation. Chou CL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):561-7

Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. Gammie JS, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II163-8; discussion II168-9

Direct antigen presentation and chronic rejection [letter; comment] Hosenpud JD. **Circulation** 1999 May 25; 99(20):2710-11. Comment on: Circulation 1998 Apr 7;97(13):1257-63.

A fatal case of gastric mucormyosis in a heart transplant recipient. Barroso F, et al. **Endoscopy** 1999 Feb;31(2):S2

The influence of antibody and complement removal with a Ig-Therasorb column in a xenogeneic working heart model. Brenner P, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):672-9

Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. McCarthy JF, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):197-200

Analysis of the polymorphism of the tumour necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection. Abdallah AN, et al. **Eur J Immunogenet** 1999 Aug;26(4):249-55

Immunomodulating effects of second-generation calcium channel blockers on experimental heart transplantation. Lapointe N, et al. **Eur Surg Res** 1999;31(3):259-66

Effects of complement suppression on xenograft survival in hyperacute rejection. Mukai S, et al. **Hiroshima J Med Sci** 1999 Mar;48(1):17-24

Effect of IL-4 deletion on cardiac allograft survival in the BALB/c to 129Sv x C57BL/6 strain combination. Mottram P, et al. **Immunol Cell Biol** 1998 Dec;76(6):563-5

The role of anti-endothelial antibodies in the immunopathogenesis of transplant associated coronary artery disease (Review). Collins AD, et al. **Int J Mol Med** 1998 Feb;1(2):439-52 (181 ref.)

Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection [see comments] Ohdan H, et al. **J Clin Invest** 1999 Aug;104(3):281-90. Comment in: J Clin Invest 1999 Aug;104(3):227-8.

Rezulin (troglitazone) greatly increases cyclosporine metabolism [letter] Frantz RP, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1037-8

Treatment of humoral rejection after heart transplantation. Grauhan O, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1184-94

Anti-LFA-1 alpha reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted rats. Harrison PC, et al. **J Heart Lung Transplant** 1999 Apr;18(4):279-84

The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1195-200

Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. Kerman RH, et al. **J Heart Lung Transplant** 1998 Aug;17(8):789-94

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. Pisani BA, et al. **J Heart Lung Transplant** 1999 Jul;18(7):701-6

Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. Walder B, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1004-6

Role of selectin-dependent adhesion in cardiac allograft rejection. Yamazaki S, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1007-16

De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. Fedoseyeva EV, et al. **J Immunol** 1999 Jun 1; 162(11):6836-42

Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4. Hall BM, et al. **J Immunol** 1998 Nov 15; 161(10):5147-56

The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. Judge TA, et al. **J Immunol** 1999 Feb 15;162(4):1947-51

Rejection of cardiac xenografts by CD4+ or CD8+ T cells. Lin Y, et al. **J Immunol** 1999 Jan 15;162(2):1206-14

Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts. Mandelbrot DA, et al. **J Immunol** 1999 Oct 1;163(7):3753-7

Accelerated rejection of Fas ligand-expressing heart grafts. Takeuchi T, et al. **J Immunol** 1999 Jan 1;162(1):518-22

Comparison of detection techniques for cytokine reverse transcriptase polymerase chain reaction; digoxigenin-labeled polymerase chain reaction permits sensitive detection of cytokine mRNA in rat heart allografts. Damoiseaux JG, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):185-93

Donor dendritic cell persistence in organ allograft recipients in the absence of immunosuppression. O'Connell PJ, et al. **J Leukoc Biol** 1999 Aug;66(2):301-5

Peripheral blood allogeneic microchimerism in lung and cardiac allograft recipients. Reinsmoen NL, et al. **J Leukoc Biol** 1999 Aug;66(2):306-9

Intrathymic immunomodulation and the "infectious" tolerance pathway in allograft recipients. Reemtsen BL, et al. **J Surg Res** 1999 Jun 1;84(1):1-7

Anti-TNF antibody modulates cytokine and MHC expression in cardiac allografts. Wei RQ, et al. **J Surg Res** 1999 Feb;81(2):123-8

The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. Vriens PW, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):844-53

Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder. Tsai DE, et al. **Med Oncol** 1998 Dec;15(4):279-81

Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. Antoniou EA, et al. **Microsurgery** 1999; 19(2):98-102

Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Chan SY, et al. **Nat Med** 1999 Oct;5(10):1143-9

Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Hancock WW, et al. **Nat Med** 1998 Dec;4(12):1392-6

Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation [see comments] Harwood JS, et al. **Pediatr Transplant** 1999 May;3(2):100-3. Comment in: Pediatr Transplant 1999 May;3(2):95-9.

Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? [editorial; comment] Webber SA. **Pediatr Transplant** 1999 May; 3(2):95-9. Comment on: Pediatr Transplant 1999 May;3(2):100-3.

Clinical relevance of in vitro propagation of activated lymphocytes from endomyocardial biopsy samples of pediatric heart transplant recipients. Webber SA, et al. **Pediatr Transplant** 1998 Aug;2(3):200-5

A morphological sequential study of mouse-to-rat cardiac xenografts. Bersztel A, et al. **Scand J Immunol** 1998 Nov; 48(5):485-90

Antithymocyte globulin and cyclosporin A are synergistic in an experimental transplantation tolerance model in the rat. Olausson M, et al. **Scand J Immunol** 1999 Jan; 49(1):38-44

Prediction of graft prolongation by mixed lymphocyte culture following anti-CD4 monoclonal antibody treatment among different donor-recipient combinations. Hamano K, et al. **Surg Today** 1999;29(9):868-73

Alpha beta TCR+ T cells play a nonredundant role in the rejection of heart allografts in mice. Exner BG, et al. **Surgery** 1999 Aug;126(2):121-6

Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Schmid C, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):161-2

Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):111-21

Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):122-33

Assessment of peripheral tolerance in anti-CD4 treated C57BL/6 mouse heart transplants recipients. Han WR, et al. **Transpl Immunol** 1999 Mar;7(1):37-44

Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. Khanna A, et al. **Transpl Immunol** 1998 Dec;6(4):225-34

Intrathymic administration of B cells induces prolonged survival of fully allogeneic cardiac grafts without prolonged deletion of donor-specific thymocytes. Niimi M, et al. **Transpl Immunol** 1998 Sep;6(3):177-81

Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Qi Z, et al. **Transpl Immunol** 1998 Jun; 6(2):94-100

Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Suzuki J, et al. **Transpl Immunol** 1999 Mar;7(1):65-72

Kinetics of circulating cytotoxic T lymphocyte precursors that have a high avidity for donor antigens: correlation with the rejection status of the human cardiac allograft. van Emmerik NE, et al. **Transpl Immunol** 1998 Sep; 6(3):153-60

Redundancy of the cytokine network in the development of rejection after clinical heart transplantation. Baan CC, et al. **Transpl Int** 1998;11 Suppl 1:S512-4

Factors relevant for the induction of rejection by indirect recognition in a rat heart allograft model: effect of CTLA4Ig treatment on indirect alloactivation induced by immunization with donor MHC I peptides. Dufter C, et al. **Transpl Int** 1998;11 Suppl 1:S361-3

Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. Horimoto H, et al. **Transpl Int** 1998;11 Suppl 1:S310-2

Circulating interleukin-1 receptor antagonist (IL-1RA) serum levels in patients undergoing orthotopic heart transplantation. Thiele RI, et al. **Transpl Int** 1998; 11(6):443-8

Incidence of side effects of immunosuppressants commonly used in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep;31(6):2519-21

Utility of acoustic densitometry in graft rejection diagnosis in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep;31(6):2544

Induction of long-term heart graft survival in HLA class I transgenic mice by intrathymic injection of HLA class I peptides. Ando Y, et al. **Transplant Proc** 1998 Nov; 30(7):3890-1

Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Antonysamy MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):93

Renal complications after heart transplantation. Bennett WM. **Transplant Proc** 1999 Feb-Mar;31(1-2):88

Three-month survival of HDAFF transgenic pig hearts transplanted into primates. Bhatti FN, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):958

Analysis of T cell repertoire in a concordant hamster-to-rat cardiac xenograft model during accommodation and rejection process. Brouard S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):918-9

Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin

induction. Cantarovich M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):79

Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival. Chang AC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):95

Thymic-independent peripheral tolerance. Chen ZK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):802-3

TAP1 mutant mice reject heart grafts from donors with no MHC disparity. Coelho V, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):900-1

Study of early corticosteroid withdrawal in cardiac transplantation. Delgado D, et al. **Transplant Proc** 1999 Sep;31(6):2524-5

Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. Dresske B, et al. **Transplant Proc** 1999 May;31(3):1561-2

Differences in immunoactivation between heart and liver transplanted patients. Erez E, et al. **Transplant Proc** 1999 Jun;31(4):1883-4

Usefulness of pulsed Doppler tissue imaging for noninvasive detection of cardiac rejection after heart transplantation. Fábregas RI, et al. **Transplant Proc** 1999 Sep;31(6):2545-7

Allopeptide-mediated expression of endothelial Fas-ligand (CD95L) in long-term tolerized heterotopic rat heart grafts. Fändrich F, et al. **Transplant Proc** 1999 May; 31(3):1558-9

Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin. Fastenau DR, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):141-2

Indirect allorecognition is involved in both acute and chronic allograft rejection. Fluck N, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):842-3

Use of cyclosporine MEPC (Neoral) in heart transplant recipients. Fukushima N, et al. **Transplant Proc** 1998 Nov; 30(7):3337-8

Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3815-7

Long-term cardiac allograft survival in mice treated with malononitrilamide 715. Gerauer K, et al. **Transplant Proc** 1998 Dec;30(8):4205-6

In vivo differentiation of alloreactive CD8+ T cells after murine cardiac allograft transplantation. Gilot BJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):130

Photopheresis for recurrent acute rejection in cardiac transplantation. Giunti G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):128-9

The suppression of heart and liver allograft rejection by liver suppressor factor one (LSF-1) and its possible human homologue. Goto S, et al. **Transplant Proc** 1998 Nov; 30(7):3578-9

Adenovirus-mediated gene transfer of CTLA4IG gene results in prolonged survival of heart allograft. Guang-Lin M, et al. **Transplant Proc** 1998 Nov;30(7):2923-4

Inhibitory effect of 15-deoxyspergualin on coronary arteriosclerosis in the transplanted heart. Hachida M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):143-6

Anti-alpha beta-T cell receptor monoclonal antibody induces tolerance without dominant infiltration by Th2 cells into grafts. Hamano K, et al. **Transplant Proc** 1998 Nov; 30(7):3892

Study of immunologic mechanisms in xenogenic transplantation. Han DJ, et al. **Transplant Proc** 1998 Nov; 30(7):3811-2

In vivo cytokine production by allospecific CD8+ transgenic T cells after heart transplantation. Hara M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):91

Donor cells that facilitate tolerance to rat heart allografts after posttransplant total lymphoid irradiation and rabbit anti-thymocyte globulin. Hayamizu K, et al. **Transplant Proc** 1999 May;31(3B Suppl):25S-26S

Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. He G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1239-41

An alternative model to study intrathymic tolerance induction: the neonatal heart-in-ear transplantation model in the rat. Hillebrands JL, et al. **Transplant Proc** 1999 May; 31(3):1563-6

FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. Hoshino Y, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1224-6

Induction of hyporesponsiveness and prolongation of cardiac allograft survival after jejunal administration of donor splenocytes and its abrogation by administration of gadolinium. Ishido N, et al. **Transplant Proc** 1998 Nov; 30(7):3881-2

Can intraoperative inoculation of donor splenocytes via the portal vein prolong allograft survival? Ishido N, et al. **Transplant Proc** 1998 Nov;30(7):3883-4

Coronary arteriosclerosis did not occur in the transplanted hearts of tolerance-induced rats: analysis from platelet-derived growth factor expression. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3871-2

Role of microchimerism on long-term graft survival after donor-specific transfusion in a rat heart transplantation model. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3862-4

Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. Jiang H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1203-5

Apoptosis in rat cardiac allograft rejection. Kageyama Y, et al. **Transplant Proc** 1998 Nov;30(7):2943

Contribution of passenger leukocytes to the induction and maintenance of heart allograft acceptance. Ko S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):158-9

Passenger leukocytes from a heart allograft can induce lethal lymphoid aplasia. Ko S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):139-40

Functional relevance of donor-derived hematopoietic microchimerism only for induction but not for maintenance of allograft acceptance. Ko S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):920-1

Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. Ko WJ, et al. **Transplant Proc** 1998 Nov;30(7):3339-41

CD26/DPP IV-mediated modulation of acute rejection. Korom S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):873

Specific inhibition of CD26/DPP IV enzymatic activity in allograft recipients: effects on humoral immunity. Korom S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):778

Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Koskinen P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):102

When does hyperacute rejection against xenohearts from newborn pigs develop in infantile monkeys? Lee MC, et al. **Transplant Proc** 1998 Nov;30(7):3824-5

Rejection of hamster cardiac xenografts by rat CD4+ or CD8+ T cells. Lin Y, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):959-60

Study of donor-specific antigens in inducing tolerance and enhancing graft survival. Lu YP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):846

Comparison of the immunosuppressive and toxic effects of TII and azathioprine. Lulin M, et al. **Transplant Proc** 1998 Nov;30(7):3517-8

Vascular rejection in cardiac transplantation. McCarthy JF, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):160

Hearts lacking donor-type APCs develop cardiac allograft vasculopathy. McLean AD, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):135

Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Magee JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1194

Inhibition of transplant vasculopathy is associated with attenuated host allo-antibody response. Maggard MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):728-9

A novel effect of cyclosporine A on lymphocyte migration to allograft and recipient lymphoid tissue. Maksymowicz M, et al. **Transplant Proc** 1998 Dec;30(8):4054-6

The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Meiser BM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):84-7

Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Mhoyan A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1189-91

Augmentation of microchimerism with donor bone marrow infusion in hamster-to-rat heart xenograft recipients. Miyata Y, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):694-5

Prolongation of concordant xenograft survival by treatment with FTY720. Miyata Y, et al. **Transplant Proc** 1998 Dec; 30(8):4163-5

Effect of simultaneous infusion of donor bone marrow on hamster-to-rat heart xenograft survival. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3869-70

Comparative efficacy of liposomal FK506 with FK506. Moffatt SD, et al. **Transplant Proc** 1998 Dec;30(8):4066-7

Induction of tolerance to an "untolerizable" strain by double-strain intrathymic inoculation in experimental rat cardiac transplantation. Mohiuddin MM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):838-9

Analysis of donor-specific unresponsiveness to rat allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen. Motoyama K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1237-8

Deficiencies of IL-4 or TNF-alpha receptor-1 do not diminish graft arteriosclerosis in cardiac allografts. Nagano H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):152

Oral administration of alloantigen induces indefinite prolongation of MHC mismatched cardiac allografts. Niimi M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):892

Intrathymic inoculation of donor B cells prolongs cardiac allograft survival by non-deletional mechanisms. Niimi M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):94

A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. Nishimura Y, et al. **Transplant Proc** 1998 Nov;30(7):3850-1

Effect of a new immunosuppressive agent, KF20444, in rat cardiac transplantation. Nomura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1206-7

Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Onodera K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):876-7

Cylexin: a P-selectin inhibitor prolongs heart allograft survival in hypersensitized rat recipients. Park IY, et al. **Transplant Proc** 1998 Nov;30(7):2927-8

Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts. Perez J, et al. **Transplant Proc** 1999 May;31(3):1560

CD4 T cells acutely reject cardiac allografts via direct donor recognition. Pietra B, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):92

Tolerance of rat cardiac allografts does not require donor-type "passenger" antigen presenting cells. Popma SH, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):840-1

Malononitrilamides prevent and suppress allospecific antibody production. Qi Z, et al. **Transplant Proc** 1998 Dec; 30(8):3980

Use of gene therapy for tolerogenic signals. Qin L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):882-3

Serum levels of xenoantibodies in different groups of patients awaiting transplantation. Ramos A, et al. **Transplant Proc** 1999 Sep;31(6):2631-2

Lack of accommodation after long-term survival of hamster xenografts in rats. Ribas Y, et al. **Transplant Proc** 1999 Sep;31(6):2633-4

Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Sánchez V, et al. **Transplant Proc** 1999 Sep;31(6):2515-6

Impact of 70% partial hepatectomy on administration of donor leukocytes in cardiac transplantation in rats. Sato Y, et al. **Transplant Proc** 1998 Nov;30(7):3873-5

Photopheresis after cardiac transplantation induces apoptosis. Schürfeld K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):125-7

Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? Scott JS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):82-3

Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Seydoux C, et al. **Transplant Proc** 1998 Dec;30(8):4037-43

Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Shipkova M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1135-7

Immune nonresponsiveness to cardiac allografts by intrathymic inoculation of donor class I allopeptides is associated with high levels of transcripts for Th2 cytokines in the graft. Shirwan H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):123-4

Simultaneous inoculation of donor lymphocyte subsets with transplantation in a rat cardiac allograft model. Sho M, et al. **Transplant Proc** 1998 Nov;30(7):3876-8

Tolerance in murine cardiac allografts by concurrent infusion of viable donor antigen-bearing cells. Smith XG, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):133-4

Persistent allopeptide reactivity and epitope spreading in chronic rejection. Suciu-Foca N, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):100-1

Indirect allorecognition of donor HLA-DR peptides in chronic rejection of heart allografts. Suciu-Foca N, et al. **Transplant Proc** 1998 Dec;30(8):3999-4000

Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. Terakura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):870-1

Prevention of chronic heart allograft rejection. Valantine-von Kaeppler HA. **Transplant Proc** 1999 Feb-Mar;31(1-2):1288-9 (8 ref.)

Corticosteroid withdrawal after heart transplantation. Vázquez de Prada JA, et al. **Transplant Proc** 1999 Sep; 31(6):2212-4

Cellular immune reaction in hyperacute rejection. Wada S, et al. **Transplant Proc** 1998 Nov;30(7):3818-20

Prolongation of cardiac allograft survival with intracoronary viral interleukin-10 gene transfer. Wang CK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):951-2

Inhibition of acute cardiac allograft rejection in immunoglobulin-deficient mice. Wasowska BA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):136

Cytotoxic T lymphocytes and cytokines in graft vascular disease after clinical heart transplantation. Weimar W, et al. **Transplant Proc** 1998 Dec;30(8):3996-8

Haematopoietic stem cells transduced with a single donor class I major histocompatibility complex gene can induce operational tolerance to fully allogeneic cardiac allografts. Wong W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):886

Characteristics of B lymphocyte and natural killer cell xenotolerance in a concordant hamster-to-athymic rat cardiac xenotransplantation model. Xia GL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):926-7

The effects of heart/kidney versus double heart transplantation on tolerance induction and prevention of cardiac allograft vasculopathy. Yamada K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):108

Differences in cellular mechanisms between heart and skin graft rejection by in vitro and in vivo analyses. Yamamoto T, et al. **Transplant Proc** 1998 Nov;30(7):3854

Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. Yamashita K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1178-9

Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Zheng XX, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):627-8

Tamoxifen prolongs heart allograft survival in cyclosporine-treated female mice. Zou YP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1222-3

Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation. Baan CC, et al. **Transplantation** 1999 Mar 27;67(6):870–6

Prolongation of heart xenograft survival in a hamster–to–rat model after therapy with a rationally designed immunosuppressive peptide. Brouard S, et al. **Transplantation** 1999 Jun 27;67(12):1614–8

The humoral response to xenografts is controlled by a restricted repertoire of immunoglobulin VH genes. Cramer DV, et al. **Transplantation** 1998 Nov 27;66(10):1375–83

Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Dengler TJ, et al. **Transplantation** 1998 Nov 27;66(10):1340–7

Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high–responder rat heart transplantation. Dengler TJ, et al. **Transplantation** 1999 Feb 15;67(3):392–8

Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts. Djamali A, et al. **Transplantation** 1998 Dec 27; 66(12):1793–801

Contribution of CD40–CD154–mediated costimulation to an alloresponse in vivo. Förster E, et al. **Transplantation** 1999 May 15;67(9):1284–7

The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Fredrich R, et al. **Transplantation** 1999 Feb 15;67(3):385–91

Monocyte–derived dendritic cell precursors facilitate tolerance to heart allografts after total lymphoid irradiation. Hayamizu K, et al. **Transplantation** 1998 Nov 27; 66(10):1285–91

Thymus–dependent, anti–CD4–induced tolerance to rat cardiac allografts. Jaques BC, et al. **Transplantation** 1998 Nov 27;66(10):1291–9

Induction of T–independent xenotolerance in a semi–discordant hamster–to–presensitized, nude rat model. Ji P, et al. **Transplantation** 1999 Jul 15;68(1):130–6

Posttransplant therapy using high–dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Jordan SC, et al. **Transplantation** 1998 Sep 27;66(6):800–5

Mouse–to–rabbit xenotransplantation: a new small animal model of hyperacute rejection mediated by the classical complement pathway. Kerr SR, et al. **Transplantation** 1999 Feb 15;67(3):360–5

Immunomodulatory functions of hyaluronate in the LEW–to–F344 model of chronic cardiac allograft rejection. Knoflach A, et al. **Transplantation** 1999 Mar 27; 67(6):909–14

Alloimmune–mediated apoptosis: comparison in mouse models of acute and chronic cardiac rejection. Koglin J, et al. **Transplantation** 1999 Mar 27;67(6):904–9

Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Kozlowski T, et al. **Transplantation** 1999 Jan 15;67(1):18–30

Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Moffatt SD, et al. **Transplantation** 1999 May 15;67(9):1205–8

Redefining peripheral tolerance in the BALB/c to CBA mouse cardiac allograft model: vascular and cytokine analysis after transient CD4 T cell depletion. Mottram PL, et al. **Transplantation** 1998 Dec 15;66(11):1510–8

Donor resting B cells induce indefinite prolongation of fully allogeneic cardiac grafts when delivered with anti–immunoglobulin–D monoclonal antibody: evidence for tolerogenicity of donor resting B cells in vivo. Niimi M, et al. **Transplantation** 1998 Dec 27;66(12):1786–92

T cells are necessary and critical for xenograft rejection in new concordant cardiac xenotransplant model. Obatake M, et al. **Transplantation** 1999 Jun 15;67(11):1480–4

Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Onodera K, et al. **Transplantation** 1999 Jul 27;68(2):288–93

Cytokine regulation of chronic cardiac allograft rejection: evidence against a role for Th1 in the disease process. Piccotti JR, et al. **Transplantation** 1999 Jun 27; 67(12):1548–55

Induction of specific tolerance to allografts in rats by therapy with non–mitogenic, non–depleting anti–CD3 monoclonal antibody: association with TH2 cytokines not anergy. Plain KM, et al. **Transplantation** 1999 Feb 27;67(4):605–13

The role of flow cytometry–detected IgG and IgM anti–donor antibodies in cardiac allograft recipients. Przybylowski P, et al. **Transplantation** 1999 Jan 27; 67(2):258–62

Anti–major histocompatibility complex class II treatment prevents graft rejection in the hamster–to–rat cardiac xenograft [see comments] Saxton NE, et al. **Transplantation** 1999 Jun 27;67(12):1599–606. Comment in: Transplantation 1999 Jun 27;67(12):1515–6.

Efficacy and muscle safety of fluvastatin in cyclosporine–treated cardiac and renal transplant recipients: an exercise provocation test. Schrama YC, et al. **Transplantation** 1998 Nov 15;66(9):1175–81

The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Sheldon S, et al. **Transplantation** 1999 Aug 27;68(4):515–9

Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Shen J, et al. **Transplantation** 1998 Sep 27; 66(6):692–8

Predominant expression of T helper 2 cytokines and altered expression of T helper 1 cytokines in long–term allograft survival induced by intrathymic immune modulation with donor class I major histocompatibility complex peptides. Shirwan H, et al. **Transplantation** 1998 Dec 27; 66(12):1802–9

Inhibition of endothelin–converting enzyme attenuates transplant vasculopathy and rejection in rat cardiac allografts. Simonson MS, et al. **Transplantation** 1999 Jun 27;67(12):1542–7

Protection against allograft rejection with intercellular adhesion molecule–1 antisense oligodeoxynucleotides. Stepkowski SM, et al. **Transplantation** 1998 Sep 27; 66(6):699–707

Injection of mitomycin–C–treated spleen cells induces donor–specific unresponsiveness to cardiac allografts in rats. Tanigawa T, et al. **Transplantation** 1999 Mar 15; 67(5):653–8

Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Vella JP, et al. **Transplantation** 1999 Jun 27; 67(12):1523–32

Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Vu MD, et al. **Transplantation** 1998 Dec 27; 66(12):1575–80

Antagonizing leukotriene B4 receptors delays cardiac allograft rejection in mice. Weringer EJ, et al. **Transplantation** 1999 Mar 27;67(6):808–15

The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model. Yamada K, et al. **Transplantation** 1999 Aug 27;68(4):485–91

Cardiac allograft tolerance induced by intra–arterial infusion of recombinant adenoviral CTLA4Ig. Yang Z, et al. **Transplantation** 1999 Jun 27;67(12):1517–23

Vaccination against tick–borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Dengler TJ, et al. **Vaccine** 1999 Feb 26; 17(7–8):867–74

Intravenous synthetic alphaGal saccharides delay hyperacute rejection following pig–to–baboon heart transplantation. Romano E, et al. **Xenotransplantation** 1999 Feb;6(1):36–42

[Flow cytometry controlled induction therapy with ATG and noninvasive monitoring of rejection—a modern management concept after heart transplantation] Wagner FM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1566–7 (Eng. Abstr.) **(Ger)**

METHODS

Technique for heterotopic pig heart xenotransplantation in primates. Adams DH, et al. **Ann Thorac Surg** 1999 Jul; 68(1):265–8

Effective reduction of a giant left atrium by partial autotransplantation. Lessana A, et al. **Ann Thorac Surg** 1999 Apr;67(4):1164–5

Atrial flap anastomosis: an alternative technique for orthotopic heart transplantation [letter; comment] Sarsam MA. **Ann Thorac Surg** 1998 Nov;66(5):1868–9. Comment on: Ann Thorac Surg 1998 Apr;65(4):1163–4.

Inferior median sternotomy [letter] Bernal JM, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):549–50

Prolonged bleeding after cardiopulmonary bypass with recombinant hirudin in heart transplantation [letter] Kwapisz MM, et al. **Eur J Cardiothorac Surg** 1999 Aug; 16(2):256–7

A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty. Bainbridge AD, et al. **J Heart Lung Transplant** 1999 May;18(5):407–13

Modified technique of abdominal heart transplantation in the rat. Baxter K, et al. **J Heart Lung Transplant** 1998 Nov; 17(11):1057–64

Right ventricular function in orthotopic total atrioventricular heart transplantation. Bittner HB, et al. **J Heart Lung Transplant** 1998 Aug;17(8):826–34

The bicaval anastomosis technique for orthotopic heart transplantation yields better atrial function than the standard technique: an echocardiographic automatic boundary detection study. Traversi E, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1065–74

Heart transplantation for hypoplastic left heart syndrome: modified technique for reducing circulatory arrest time. Vricella LA, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1167–71

Bicaval and standard techniques in orthotopic heart transplantation: medium–term experience in cardiac performance and survival. Aziz T, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):115–22

A propos premières in medicine [letter] Gallino A, et al. **Lancet** 1999 May 22;353(9166):1804

Review of significant microvascular surgical breakthroughs involving the heart and lungs in rats. Chung WS, et al. **Microsurgery** 1999;19(2):71–7 (66 ref.)

Heart transplantation: approaching a new century. Radovancević B, et al. **Tex Heart Inst J** 1999;26(1):60–70 (69 ref.)

Reduction aortoplasty: readaptation technique in great vessel mismatches in heart transplantation. Miralles A, et al. **Transplant Proc** 1999 Sep;31(6):2501–2

Heterotopic heart transplantation for severe pulmonary hypertension. Wang SS, et al. **Transplant Proc** 1998 Nov; 30(7):3408–9

Creation of the "thymoheart" allograft: implantation of autologous thymus into the heart prior to procurement. Lambrigts D, et al. **Transplantation** 1998 Sep 27;66(6):810–4

[Pharmacological testing of the reversibility of increased pulmonary vascular resistance before heart transplantation with prostaglandin I2 (prostacyclin)] Trautnitz M, et al. **Z Kardiol** 1999 Feb;88(2):133–40 (Eng. Abstr.) **(Ger)**

MORTALITY

Paediatric cardiac transplant surgery has improved [letter; comment] Wigfield C, et al. **BMJ** 1999 Apr 3;318(7188):944 . Comment on: BMJ 1998 Oct 3;317(7163):897.

A better long–term outcome in cardiac transplant recipient with a history of previous open heart operations. Chen C, et al. **Chin Med J (Engl)** 1998 Mar;111(3):231–4

Ten year survival after heart transplantation: palliative procedure or successful long term treatment? Fraund S, et al. **Heart** 1999 Jul;82(1):47–51

An analysis of the effect of age on survival after heart transplant. Borkon AM, et al. **J Heart Lung Transplant** 1999 Jul;18(7):668–74

Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmacologic circulatory support. Gronda EG, et al. **J Heart Lung Transplant** 1999 Jul;18(7):654–63

Long–term survival after cardiac retransplantation: a twenty–year single–center experience. John R, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):543–55

Criticism of a hierarchical model using Bayes factors. Albert JH. **Stat Med** 1999 Feb 15;18(3):287–305

Pretransplant risk factors of early mortality after orthotopic heart transplantation. Espinoza C, et al. **Transplant Proc** 1999 Sep;31(6):2507–8

Perioperative mortality risk factors after orthotopic heart transplantation. Espinoza C, et al. **Transplant Proc** 1999 Sep;31(6):2509–10

PATHOLOGY

Histologic findings in the conduction system after cardiac transplantation and correlation with electrocardiographic findings. Calzolari V, et al. **Am J Cardiol** 1999 Sep 15; 84(6):756–9, A9

T cell apoptosis in human heart allografts: association with lack of co–stimulation? Van Hoffen E, et al. **Am J Pathol** 1998 Dec;153(6):1813–24

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Demetris AJ, et al. **Ann Transplant** 1997;2(2):27–44 (288 ref.)

Allograft coronary disease: the role of antigen independent mechanisms in pathogenesis. Miller LW. **Ann Transplant** 1997;2(2):61–4 (53 ref.)

Cellular adhesion molecules changes in myocardium during first year post heart transplant. Zembala M, et al. **Ann Transplant** 1997;2(2):16–9

Relationship of fibrin deposition in microvasculature to outcomes in cardiac transplantation. Labarrere CA. **Curr Opin Cardiol** 1999 Mar;14(2):133–9 (38 ref.)

Pathology of heart transplant. Mindán JP, et al. **Curr Top Pathol** 1999;92:137–65 (112 ref.)

The influence of antibody and complement removal with a Ig–Therasorb column in a xenogeneic working heart model. Brenner P, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):672–9

Volumetric remodeling of the proximal left coronary artery: early versus late after heart transplantation. Pethig K, et al. **J Am Coll Cardiol** 1999 Jul;34(1):197–203

Rescue photochemotherapy for the treatment of acute cardiac rejection in the absence of cyclosporine maintenance therapy [letter] DeNofrio D, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1036–7

Eosinophil activation in cardiac and pulmonary acute allograft rejection [letter] Dosanjh AK, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1038

Prognostic value of myocardial lactate dehydrogenase subunit ratio in heart transplant recipients. Missov E, et al. **J Heart Lung Transplant** 1998 Oct;17(10):959–68

Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin induction. Cantarovich M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):79

Significance of eosinophil infiltration in cardiac rejection. Endoh M, et al. **Transplant Proc** 1998 Nov;30(7):3350

Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Hiemann NE, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):149–51

Effect of low–molecular–weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Hisatomi K. **Transplant Proc** 1998 Dec;30(8):4337–9

Coronary arteriosclerosis did not occur in the transplanted hearts of tolerance–induced rats: analysis from platelet–derived growth factor expression. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3871–2

Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Koskinen P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):102

Effect of FR167653 on ischemia-reperfusion injury of the canine heart: ultrastructural study. Koyano T, et al. **Transplant Proc** 1998 Nov;30(7):3370-1

Vascular rejection in cardiac transplantation. McCarthy JF, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):160

Hearts lacking donor-type APCs develop cardiac allograft vasculopathy. McLean AD, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):135

Inhibition of transplant vasculopathy is associated with attenuated host allo-antibody response. Maggard MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):728-9

Platelet-derived growth factor rather than basic fibroblast growth factor and vascular endothelial cell growth factor is involved in adventitial narrowing causing vascular stenosis in end-stage cardiac allograft vasculopathy. Meliss RR, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):89-90

Idarubicin-anti-CD3 reduces vascular disease in mouse cardiac allografts. Mottram PL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1414-5

Deficiencies of IL-4 or TNF-alpha receptor-1 do not diminish graft arteriosclerosis in cardiac allografts. Nagano H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):152

Ischemic injury in posttransplant endomyocardial biopsies: immunohistochemical study of fibronectin. Panizo A, et al. **Transplant Proc** 1999 Sep;31(6):2550-1

TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model. Richter M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):106-7

Photopheresis after cardiac transplantation induces apoptosis. Schürfeld K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):125-7

Prevention of cardiac allograft arteriopathy by antisense Cdc2 kinase oligonucleotide. Suzuki J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):867-8

The effects of heart/kidney versus double heart transplantation on tolerance induction and prevention of cardiac allograft vasculopathy. Yamada K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):108

Histological evidence of concomitant intramyocardial and epicardial vasculitis in necropsied heart allografts: a possible relationship with graft coronary arteriosclerosis. Higuchi ML, et al. **Transplantation** 1999 Jun 27; 67(12):1569-76

Redefining peripheral tolerance in the BALB/c to CBA mouse cardiac allograft model: vascular and cytokine analysis after transient CD4 T cell depletion. Mottram PL, et al. **Transplantation** 1998 Dec 15;66(11):1510-8

[Quantification of cell proliferation with the proliferation marker MIB-1 in endomyocardial biopsies after heart transplantation. An aid in diagnosis of graft rejection needing treatment?] Gerbaulet S, et al. **Z Kardiol** 1998 Aug; 87(8):613-21 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? Galatius S, et al. **Am Heart J** 1999 Mar; 137(3):549-54

Oxidative metabolism of the transplanted human heart assessed by positron emission tomography using C-11 acetate. Bengel FM, et al. **Am J Cardiol** 1999 May 15; 83(10):1503-5, A8

Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. Kono T, et al. **Am J Cardiol** 1999 Sep 1;84(5):578-82

Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts. Kushwaha SS, et al. **Am J Cardiol** 1998 Dec 1;82(11):1377-81

Measurement of radial bone mineral density in patients after heart transplantation. Garlicki AM, et al. **Ann Transplant** 1996;1(4):32-4

Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Nägele H, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2531-4

Coenzyme Q10 depletion and mitochondrial energy disturbances in rejection development in patients after heart transplantation. Gvozdjáková A, et al. **Biofactors** 1999; 9(2-4):301-6

Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. Schwaiblmair M, et al. **Chest** 1999 Aug; 116(2):332-9

The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity. van Riemsdijk-van Overbeeke IC, et al. **Eur Heart J** 1999 Jun; 20(11):833-40

Association between the degree of platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in the transplanted heart. Hachida M, et al. **Heart Vessels** 1998;13(1):24-9

Effects of muscle electrical stimulation on peak VO2 in cardiac transplant patients. Vaquero AF, et al. **Int J Sports Med** 1998 Jul;19(5):317-22

Chronotropic competence in endurance trained heart transplant recipients: heart rate is not a limiting factor for exercise capacity. Richard R, et al. **J Am Coll Cardiol** 1999 Jan;33(1):192-7

Enhanced brain natriuretic peptide response to peak exercise in heart transplant recipients. Geny B, et al. **J Appl Physiol** 1998 Dec;85(6):2270-6

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analyses. Bernard M, et al. **J Heart Lung Transplant** 1999 Jun;18(6):572-81

A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dtmax. Dambrin C, et al. **J Heart Lung Transplant** 1999 Jun; 18(6):524-31

The role of donor age and ischemic time on survival following orthotopic heart transplantation. Del Rizzo DF, et al. **J Heart Lung Transplant** 1999 Apr;18(4):310-9

Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography. Ducharme A, et al. **J Heart Lung Transplant** 1999 Jun;18(6):510-6

Normal short-term renal response to acute volume expansion in heart transplant recipients: a role for atrial natriuretic peptide? Geny B, et al. **J Heart Lung Transplant** 1998 Nov; 17(11):1081-8

Alteration in diastolic function following cardiac cryopreservation at subzero temperatures. Gutiérrez-Carretero E, et al. **J Heart Lung Transplant** 1999 Apr;18(4):372-5

Heart donation after lightning strike. Lick SD, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1034-5

Successful orthotopic pig heart transplantation from non-heart-beating donors. Martin J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):597-606

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. Penson MG, et al. **J Heart Lung Transplant** 1999 Jul;18(7):707-13

Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation. Raczak G, et al. **J Heart Lung Transplant** 1999 May;18(5):399-406

Evaluation of plasma cyclic GMP assay as a screening test for detection of acute cardiac allograft rejection. Stobierska-Dzierzek B, et al. **J Heart Lung Transplant** 1998 Oct;17(10):969-71

Does University of Wisconsin solution harm the transplanted heart? Stringham JC, et al. **J Heart Lung Transplant** 1999 Jun;18(6):587-96

The significance of atrial monophasic action potentials for monitoring rat cardiac allograft rejection. Tahara K, et al. **J Heart Lung Transplant** 1998 Oct;17(10):954-8

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats. Wada T, et al. **J Heart Lung Transplant** 1999 Jun;18(6):499-509

Out-patient versus in-hospital ambulatory 24-h blood pressure monitoring in heart transplant recipients. Vanhaecke J, et al. **J Hum Hypertens** 1999 Mar; 13(3):199-202

Nonpharmacologic validation of the intrinsic heart rate in cardiac transplant recipients. Strobel JS, et al. **J Interv Card Electrophysiol** 1999 Mar;3(1):15-8

The effect of nutritional and hormonal supplementation on protein synthesis immediately after liver transplantation. Geevarghese SK, et al. **J Surg Res** 1999 Feb;81(2):196-200

Short-term effect of cyclosporine on circulating adrenomedullin after heart transplantation. Geny B, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):391-2

Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. Hassanein WH, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):821-30

Nitroglycerin as a nitric oxide donor accelerates lipid peroxidation but preserves ventricular function in a canine model of orthotopic heart transplantation. Tanoue Y, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):547-56

Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. Kalady MF, et al. **Mol Med** 1998 Sep; 4(9):629-37

The utility of pacemaker evoked T wave amplitude for the noninvasive diagnosis of cardiac allograft rejection. Bainbridge AD, et al. **Pacing Clin Electrophysiol** 1999 Jun; 22(6 Pt 1):942-6

Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience. Bourge R, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2338-44

Intramyocardial electrogram variability in the monitoring of graft rejection after heart transplantation. Grasser B, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2345-9

Exercise response of the recipient atrial remnant after orthotopic cardiac transplantation: implications for recipient atrial triggered pacing. Holt ND, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2331-7

Early benefit of implantable cardioverter defibrillator therapy in patients waiting for cardiac transplantation. Lorga-Filho A, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1747-50

Characteristics of the signal-averaged P wave in orthotopic heart transplant recipients. Volgman AS, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2327-30

Intramyocardial electrograms for non-invasive rejection monitoring: initial experience with an infection-specific parameter. Grasser B, et al. **Transpl Int** 1998;11 Suppl 1:S508-11

Hyaluronidase ameliorates rejection-induced edema. Johnsson C, et al. **Transpl Int** 1999;12(4):235-43

Endothelium-dependent microvascular vasomotion and its correlation with vasoactive mediators early after cardiac transplantation in humans. Wildhirt SM, et al. **Transpl Int** 1998;11 Suppl 1:S519-24

Right bundle branch block as a prognostic factor in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep; 31(6):2548-9

Cardiac transplantation in patients over 60 years of age. Baron O, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):75-8

Cardiac preservation with nitroglycerine and cyclic adenosine monophosphate. Baxter K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1046-7

Analysis of quality of life before and after heart transplantation. Bortman G, et al. **Transplant Proc** 1999 Sep;31(6):2555

Abdominal laparoscopy in follow-up of heterotopic pig heart to baboon xenotransplantation. Crespo FM, et al. **Transplant Proc** 1999 Sep;31(6):2619

Morbidity and mortality among heart transplant patients older and younger than 65 years. Crespo-Leiro MG, et al. **Transplant Proc** 1999 Sep;31(6):2537-8

Coronary artery disease transmitted by donors older than 40 years: prevalence and prognosis. Crespo-Leiro MG, et al. **Transplant Proc** 1999 Sep;31(6):2542-3

Levels of lipoprotein(a) in cardiac transplant recipients. Cristóbal C, et al. **Transplant Proc** 1999 Sep;31(6):2552-3

Growth factors and receptors in allograft arteriosclerosis. Delafontaine P, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):111-4 (41 ref.)

Quantitative analysis of PDGFA, PDGFB, PDGF receptor beta and TGF-beta 1 mRNA in cardiac transplant biopsies. Egan MK, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):131-2

C677T gene mutation in methylenetetrahydrofolate reductase as a risk factor for cardiac allograft vasculopathy. Elstein E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):99

Reversibility of pulmonary hypertension in patients evaluated for orthotopic heart transplantation: importance in the postoperative morbidity and mortality. Espinoza C, et al. **Transplant Proc** 1999 Sep;31(6):2503-4

Immunologic and nonimmunologic risk factors of chronic rejection. Fellström B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1304-5 (20 ref.)

Effects of continuous, long-term therapy with prostaglandin E1 preoperatively on outcome after heart transplantation. Frey B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):80-1

Failure of rapid autonomic augmentation of cardiac performance in transplanted hearts. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3344-6

Successful multiorgan transplants from non-heart-beating donors using percutaneous cardiopulmonary support. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3783-4

Diversity of gene expression following heart transplantation in rats. Han DJ, et al. **Transplant Proc** 1998 Nov; 30(7):3405-6

Implication of monocyte/macrophage infiltration into the graft following heart transplantation in rats. Han DJ, et al. **Transplant Proc** 1998 Nov;30(7):3407

Troponin T serum levels in donors related to troponin T levels in recipients immediately after heart transplantation. Hoki J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):137-8

Quality of life in renal, hepatic, and heart transplant patients. Insensé B, et al. **Transplant Proc** 1999 Sep;31(6):2647-8

Nitric oxide donor induces upregulation of stress proteins in cold ischemic rat hearts. Katori M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1022-3

Cytoprotective role of antioxidant stress protein induced by adenosine A1 receptor antagonist in rat heart ischemic injury. Katori M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1016-7

Discordant xenoheart transplantation with perfluorotributylamine/pluronic F-68 stem emulsion. Kawauchi M, et al. **Transplant Proc** 1998 Nov;30(7):3831-2

Changes in cell cycling and apoptosis contribute to reduced effector cell generation among long-term heart transplant survivors. Kimball PM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):109-10

Expression of heat shock proteins induced by L(+)-glutamine injection and survival of hypothermically stored heart grafts. Kojima R, et al. **Transplant Proc** 1998 Nov;30(7):3746-7

Intestinal metabolism of cyclosporine A in human heart transplant recipients. Lehle K, et al. **Transplant Proc** 1998 Dec;30(8):4044

Cold cardioplegic preservation aggravates alloantibody mediated cardiac dysfunction due to an increase in vascular resistance. Leprince P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):116-7

Recipient pretreatment with mammalian IL-10 prolongs mouse cardiac allograft survival by inhibition of anti-donor T cell responses. Li W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):115

Orthotopic transplantation of pig hearts harvested from non-heart-beating donors. Martin J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):153-4

Donor treatment with mycophenolate mofetil protects against ischemia-reperfusion injury. Paul LC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1026

Development of severe adverse effects after discontinuing

amiodarone therapy in human heart transplant recipients. Preuner JG, et al. **Transplant Proc** 1998 Dec;30(8):3943–4
Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration. Rodriguez JA, et al. **Transplant Proc** 1999 Sep;31(6):2517–8
Antisense Cdc2 kinase oligonucleotide inhibits adhesion molecule expression in cardiac allograft arteriopathy. Suzuki J, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):955–6
Glutamine–induced heme oxygenase–1 protects intestines and hearts from warm ischemic injury. Tamaki T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1018–9
Effect of low molecular weight heparin on graft vascular disease in the rat cardiac allograft model. Teranishi K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):103–5
Operational tolerance of long–surviving cardiac xenografts (LSCX) is related to modification of the graft–in–residence and not to induced tolerance in the recipient: studies in retransplanted LSCX. Thomas F, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):966–7
Myocardial nitric oxide synthase gene–expression and endothelial function in chronic rejection after cardiac transplantation. Wildhirt SM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):96–8
Myocardial preservation in clinical cardiac transplantation. Wildhirt SM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):147–8
Donor brain death affects tempo and intensity of acute rejection of rat chronic allografts. Wilhelm MJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1008–9
Hemodynamic follow–up of cardiac allografts from poisoned donors. Tenderich G, et al. **Transplantation** 1998 Nov 15; 66(9):1163–7
[Blood flow in the isovolumetric relaxation phase in heart transplant patients. Its use in the noninvasive diagnosis of acute rejection] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):731–8 (Eng. Abstr.) **(Fre)**
[Expansion of the initial depolarized tissue zone in cardiac pacemaker stimulation] Leifhelm M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:508–9 **(Ger)**
[Coagulation in heart transplant operations and in operations for applying ventricular assistance devices] Milazzo F, et al. **Minerva Anestesiol** 1999 Jan–Feb;65(1–2 Suppl 1):93–104 (77 ref.) **(Ita)**
[Changes in the diameter of the coronary arteries in heart transplant recipients with angiographically normal vessels during five years] Coma–Canella I, et al. **Rev Esp Cardiol** 1999 Jul;52(7):485–92 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Early post–transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. Dew MA, et al. **J Heart Lung Transplant** 1999 Jun;18(6):549–62
Psychological adjustment after cardiac transplantation. Salmon P, et al. **J Psychosom Res** 1998 Nov;45(5):449–58
Psychological distress in patients awaiting heart transplantation. Zipfel S, et al. **J Psychosom Res** 1998 Nov; 45(5):465–70
Utility of proverb interpretation measures with cardiac transplant candidates. Dugbartey AT. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):883–9
Palpitations and cardiac awareness after heart transplantation. Barsky AJ, et al. **Psychosom Med** 1998 Sep–Oct; 60(5):557–62
Self–report evaluation of health behavior, stress vulnerability, and medical outcome of heart transplant recipients. Harper RG, et al. **Psychosom Med** 1998 Sep–Oct;60(5):563–9
The Millon Behavioral Health Inventory Life Threat Reactivity Scale as a predictor of mortality in patients awaiting heart transplantation. Coffman KL, et al. **Psychosomatics** 1999 Jan–Feb;40(1):44–9
PTSD in heart transplant recipients and their primary family caregivers. Stukas AA Jr, et al. **Psychosomatics** 1999 May–Jun;40(3):212–21
Patients benefit––partners suffer? The impact of heart transplantation on the partner relationship. Bunzel B, et al. **Transpl Int** 1999;12(1):33–41
Analysis of quality of life before and after heart transplantation. Bortman G, et al. **Transplant Proc** 1999 Sep;31(6):2555
Posttransplant quality of life issues: depression–related noncompliance in cardiac transplant patients. Campbell B, et al. **Transplant Proc** 1999 Jun;31(4A):59S–60S
Quality of life in renal, hepatic, and heart transplant patients. Insensé B, et al. **Transplant Proc** 1999 Sep;31(6):2647–8
[Quality of life, depression and coping behavior in patients awaiting heart transplant] Zipfel S, et al. **Psychother Psychosom Med Psychol** 1999 Jun;49(6):187–94 (Eng. Abstr.) **(Ger)**
[Perspectives of patients with terminal renal failure: quality of life and psychological adjustment before and in the first year after heart transplantation] Riedmayr MI, et al. **Z Kardiol** 1998 Oct;87(10):808–16 (Eng. Abstr.) **(Ger)**
[Chronic heart or lung disease and psychosocial stress] Spurkland I, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20; 119(2):209–13 (Eng. Abstr.) **(Nor)**
[Psychological aspects of heart transplantation] Nôtová P. **Bratisl Lek Listy** 1998 Dec;99(12):647–51 (Eng. Abstr.) **(Slo)**

RADIONUCLIDE IMAGING

Oxidative metabolism of the transplanted human heart assessed by positron emission tomography using C–11 acetate. Bengel FM, et al. **Am J Cardiol** 1999 May 15; 83(10):1503–5, A8
Dipyridamole–Tc–99m–tetrofosmin SPECT imaging can identify provokable ischemia in heart transplantation. Vegazo O, et al. **J Nucl Cardiol** 1999 Jul–Aug;6(4):472–3
Sympathetic reinnervation of cardiac allografts evaluated by 123I–MIBG imaging. Estorch M, et al. **J Nucl Med** 1999 Jun;40(6):911–6
Sympathetic reinnervation demonstrated on serial iodine–123–metaiodobenzylguanidine SPECT images after cardiac transplantation. Toba M, et al. **J Nucl Med** 1998 Nov;39(11):1862–4
[Importance of dual isotope myocardial tomoscintigraphy in the detection of coronary disease in the graft among 96 heart transplant recipients] Pouillart F, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):235–41 (Eng. Abstr.) **(Fre)**

REHABILITATION

Cardiorespiratory response of heart transplantation recipients to exercise in the early postoperative period. Chen SY, et al. **J Formos Med Assoc** 1999 Mar;98(3):165–70
Exercise training in patients with CHF and heart transplant recipients. Braith RW. **Med Sci Sports Exerc** 1998 Oct; 30(10 Suppl):S367–78 (58 ref.)
A controlled trial of exercise rehabilitation after heart transplantation [published erratum appears in N Engl J Med 1999 Mar 25;340(12):976] Kobashigawa JA, et al. **N Engl J Med** 1999 Jan 28;340(4):272–7
[Skeletal muscle strength following orthotopic heart transplantation] Quittan M, et al. **Wien Klin Wochenschr** 1999 Jun 18;111(12):476–83 (Eng. Abstr.) **(Ger)**
[The follow–up of the heart transplant patient] Perini G, et al. **G Ital Cardiol** 1998 Dec;28(12):1378–84 (Eng. Abstr.) **(Ita)**

STANDARDS

Heart transplantation selection criteria: attitudes of ethnically diverse medical students. Wilkes MS, et al. **J Clin Ethics** 1998 Summer;9(2):147–55
Age before beauty: the use of "older" donor hearts for cardiac transplantation [comment] Young JB. **J Heart Lung Transplant** 1999 May;18(5):488–91 (13 ref.) . Comment on: J Heart Lung Transplant 1998 Sep;17(9):901–5.
Development of cardiac transplant policy in Germany (part 1) [editorial] Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):1–4

STATISTICS & NUMERICAL DATA

Cardiac transplantation in Kraków. Dziatkowiak A, et al. **Ann Transplant** 1996;1(1):46–50
Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for thoracic organ transplantation. Keck BM, et al. **Clin Transpl** 1997;:29–43
Cardiac transplantation: the University of Florida experience. Schofield RS, et al. **Clin Transpl** 1997;:199–208
Low incidence of transplant coronary artery disease in Chinese heart recipients. Hsu RB, et al. **J Am Coll Cardiol** 1999 May;33(6):1573–7
Variations in cardiac transplantation: comparisons between the United Kingdom and the United States. Anyanwu AC, et al. **J Heart Lung Transplant** 1999 Apr;18(4):297–303
The Registry of the International Society of Heart and Lung Transplantation: Second Official Pediatric Report––1998. Boucek MM, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1141–60
The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report––1999. Hosenpud JD, et al. **J Heart Lung Transplant** 1999 Jul;18(7):611–26
Determinants of waiting time for heart transplants in the United States. Kauffman HM, et al. **J Heart Lung Transplant** 1999 May;18(5):414–9
Thirty years of cardiac transplantation at Stanford university. Robbins RC, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):939–51
Thoracic transplantation in 1998. Conte JV Jr. **Md Med J** 1998 Nov;47(5):235–40 (8 ref.)
Criticism of a hierarchical model using Bayes factors. Albert JH. **Stat Med** 1999 Feb 15;18(3):287–305
Impact of local donor and regionalization on a German transplantation center. UNI NRW. Universities of North Rhine Westfalia. Schmid C, et al. **Transpl Int** 1999; 12(2):141–4
A study of the experience of Spanish Heart Transplant Groups. Almenar L, et al. **Transplant Proc** 1999 Sep; 31(6):2531–3
Review of the current state of thoracic transplantation: a national prospective cohort study. UK Cardiothoracic Transplant Audit Steering Group. Anyanwu AC, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):165
Should recipient risk be a factor in choosing recipients for suboptimal donor hearts: a multi–institutional study. Anyanwu AC, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1399–400
Cardiac transplantation in Taiwan. Chu SH, et al. **Transplant Proc** 1998 Nov;30(7):3387–90
Rehospitalization needs in a cardiac transplantation unit. Cristóbal C, et al. **Transplant Proc** 1999 Sep;31(6):2554
Intrathoracic organ transplantation in Thailand. Ongcharit C, et al. **Transplant Proc** 1998 Nov;30(7):3385–6
Heart transplantation: our experience in 450 cases. Roda JR, et al. **Transplant Proc** 1999 Sep;31(6):2534
Heart transplantation in Catalonia, 1984–1997. Salas T, et al. **Transplant Proc** 1999 Sep;31(6):2535–6
Hemodynamic follow–up of cardiac allografts from poisoned donors. Tenderich G, et al. **Transplantation** 1998 Nov 15; 66(9):1163–7
[Heart transplantation in the Netherlands, an option to be considered for 5 children per year on the average] Raymakers GJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1425–8 (Eng. Abstr.) **(Dut)**
[Status of intensified therapy and regionalized allocation of donor hearts in the management of patients with terminal heart failure] Nägele H, et al. **Z Kardiol** 1998 Sep; 87(9):676–82 (Eng. Abstr.) **(Ger)**
[The National Heart Transplant Registry. The 9th Official Report (1984–1997). The Spanish Heart Transplant Groups. The Section of Heart Transplantation of the Spanish Society of Cardiology] Almenar Bonet L. **Rev Esp Cardiol** 1999 Mar;52(3):153–8 (Eng. Abstr.) **(Spa)**

TRENDS

Musings on intrathoracic transplantation past and future [editorial] Kaye MP. **Ann Transplant** 1997;2(1):12–3
[Present and future of heart transplantation in Japan and the world] Shirakura R, et al. **Nippon Geka Gakkai Zasshi** 1998 Nov;99(11):749–53 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Does use of intravascular ultrasound accelerate arteriopathy in heart transplant recipients? Son R, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):358–63
Dobutamine stress echocardiography: experience in pediatric heart transplant recipients. Pahl E, et al. **J Heart Lung Transplant** 1999 Jul;18(7):725–32

UTILIZATION

Are efforts at expanding the donor pool misdirected? Rayburn BK, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):998–1003 (40 ref.)

VETERINARY

Modified technique for abdominal heterotopic cardiac transplantation in the rabbit. Esper E, et al. **Lab Anim Sci** 1998 Apr;48(2):201–5

HEART VALVE DISEASES

Tricuspid valve disease. Clinical evaluation, physiopathology, and management. Blaustein AS, et al. **Cardiol Clin** 1998 Aug;16(3):551–72, x (168 ref.)
Valvular disease in the elderly. Hinchman DA, et al. **Cardiol Clin** 1999 Feb;17(1):137–58 (130 ref.)
Valvular heart disease in pregnancy. A contemporary perspective. Teerlink JR, et al. **Cardiol Clin** 1998 Aug; 16(3):573–98, x (142 ref.)
Bibliography Current World Literature. Valvular heart disease. **Curr Opin Cardiol** 1999 Mar;14(2):B65–80
Decision analysis for pre–operative interventions in cardiac patients for non–cardiac surgery. Metzler H. **Eur J Anaesthesiol** 1998 Nov;15(6):725–6

BLOOD

[Relation between oxygen saturation of right atrial blood and cardiac index] Xu J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):187 **(Chi)**

CHEMICALLY INDUCED

The clinical dilemma of anorectic drug use and valvular heart disease [editorial; comment] Grayburn PA, et al. **Am J Cardiol** 1999 Aug 1;84(3):324–6, A8. Comment on: Am J Cardiol 1999 Aug 1;84(3):304–8.
Diet–drug debacle [editorial; comment] Parisi AF. **Ann Intern Med** 1998 Dec 1;129(11):903–5. Comment on: Ann Intern Med 1998 Dec 1;129(11):870–4.
Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication [see comments] Wee CC, et al. **Ann Intern Med** 1998 Dec 1;129(11):870–4. Comment in: Ann Intern Med 1998 Dec 1;129(11):903–5.
Dose effect of fenfluramine–phentermine in the production of valvular heart disease [letter] Tovar EA, et al. **Ann Thorac Surg** 1999 Apr;67(4):1213–4
Anorectic therapy and valvular heart disease: a reappraisal [editorial] Silvestry FE, et al. **Eur Heart J** 1999 Jul; 20(13):917–20
Risks of heart–valve abnormalities with appetite suppressants. Baird IM. **Lancet** 1998 Oct 31;352(9138):1403–4
Appetite–suppressant drugs and valvular heart disease [letter] Moyé LA, et al. **N Engl J Med** 1999 Feb 11;340(6):477; discussion 478–80
Appetite–suppressant drugs and valvular heart disease [letter] Myers MD. **N Engl J Med** 1999 Feb 11;340(6):476–7; discussion 478–80
Appetite–suppressant drugs and valvular heart disease [letter]

Paoletti CF. **N Engl J Med** 1999 Feb 11;340(6):477; discussion 478–80

Appetite-suppressant drugs and valvular heart disease [letter] Shapiro S. **N Engl J Med** 1999 Feb 11;340(6):477–8; discussion 478–80

Appetite-suppressant drugs and valvular heart disease [letter] Williamson DF, et al. **N Engl J Med** 1999 Feb 11; 340(6):476; discussion 478–80

Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients [letter] Wadden TA, et al. **Obes Res** 1999 May;7(3):309–10

The fen-phen finale: a study of weight loss and valvular heart disease. Wadden TA, et al. **Obes Res** 1998 Jul;6(4):278–84

[Pulmonary hypertension and heart valve diseases induced by fenfluramine? Hypothesis or certitude? Myth or reality? (editorial)] Godeau P, et al. **Rev Med Interne** 1998 Oct; 19(10):700–3 **(Fre)**

COMPLICATIONS

Risk factors for infective endocarditis [letter; comment] Collignon P. **Ann Intern Med** 1999 Jul 20;131(2):154–5. Comment on: Ann Intern Med 1998 Nov 15;129(10):761–9.

Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study [see comments] Strom BL, et al. **Ann Intern Med** 1998 Nov 15; 129(10):761–9. Comment in: Ann Intern Med 1999 Jul 20;131(2):154; discussion 155. Comment in: Ann Intern Med 1999 Jul 20;131(2):154–5.

Profile for estimating risk of heart failure. Kannel WB, et al. **Arch Intern Med** 1999 Jun 14;159(11):1197–204

Gaucher's disease with valve calcification: possible role of Gaucher cells, bone matrix proteins and integrins. Veinot JP, et al. **Can J Cardiol** 1999 Feb;15(2):211–6

Cardiac papillary fibroelastoma: aA rare cause of ischemic stroke in the young. Giannesini C, et al.
Cerebrovasc Dis 1999 Jan-Feb;9(1):45–9

Hyperlucent lung in a patient with mitral valve disease. Mobeireek AF, et al. **Chest** 1998 Nov;114(5):1469–71

Antithrombotic therapy in valvular heart disease. Salem DN, et al. **Chest** 1998 Nov;114(5 Suppl):590S–601S (142 ref.)

Non-Q-wave infarction and ostial left coronary obstruction due to giant Lambl's excrescences of the aortic valve. Dangas G, et al. **Circulation** 1999 Apr 13;99(14):1919–21

Fibroelastoma and embolic stroke [letter] Veinot JP.
Circulation 1999 May 25;99(20):2709–12

Coagulase-negative staphylococcus endocarditis restricted to the normal pulmonic valve in a patient with end-stage renal disease: case report and review. Hussain KM, et al.
Clin Infect Dis 1998 Dec;27(6):1550–2 (10 ref.)

Incidence and aetiology of heart failure; a population-based study [see comments] Cowie MR, et al. **Eur Heart J** 1999 Mar;20(6):421–8. Comment in: Eur Heart J 1999 Mar;20(6):398–9.

Aortic root disease and valve disease associated with ankylosing spondylitis. Roldan CA, et al.
J Am Coll Cardiol 1998 Nov;32(5):1397–404

Detecting coronary artery stenosis before surgery in patients with valvular heart disease [editorial] Acar J.
J Heart Valve Dis 1999 Mar;8(2):160–1 (8 ref.)

Spontaneous native aortic valve thrombosis. Massetti M, et al. **J Heart Valve Dis** 1999 Mar;8(2):157–9

Rothia dentocariosa endocarditis and aortic root abscess. Ferraz V, et al. **J Infect** 1998 Nov;37(3):292–5 (16 ref.)

Inhaled nitric oxide in patients with pulmonary hypertension due to valvular heart disease and chronic lung disease. Sakane M, et al. **Jpn Circ J** 1998 Dec;62(12):877–82

Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Ribeiro S, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2037–40

Tetralogy of Fallot with absent pulmonary valve. A continuing challenge. Jekel L, et al. **Scand Cardiovasc J** 1998;32(4):213–7

[Mitral papillary fibroelastoma in a HIV infected patient] Paraf F, et al. **Presse Med** 1999 May 15;28(18):962–4 (Eng. Abstr.) **(Fre)**

[Clinical case of the month. Prolapse due to fibro-elastic degeneration. The aging of the mitral valve] Radermecker MA, et al. **Rev Med Liege** 1999 Feb;54(2):76–8 (Eng. Abstr.) **(Fre)**

[Prevention of thrombosis in heart valve diseases] Meyer BJ, et al. **Ther Umsch** 1998 Dec;55(12):756–61 (9 ref.) (Eng. Abstr.) **(Ger)**

[Endocarditis in heart defects--incidence, diagnosis and prevention] Turina J. **Ther Umsch** 1998 Dec;55(12):773–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Role of hypertension in determining valvular diseases in patients with chronic uremia and dialytic treatment] Facchin L, et al. **Cardiologia** 1998 Dec;43(12):1361–6 (Eng. Abstr.) **(Ita)**

[Evaluation of the results of the combined maze procedure for chronic atrial fibrillation with organic heart disease] Arai Y, et al. **Kyobu Geka** 1999 May;52(5):379–83 (Eng. Abstr.) **(Jpn)**

[Pneumonia and panophthalmitis as first signs of pneumococcal endocarditis] Gawryluk D, et al.
Pneumonol Alergol Pol 1998;66(5–6):337–45 (Eng. Abstr.) **(Pol)**

[Analysis of airway function in patients with mitral valve disease in various stages of progression] Hryniewiecki T, et al. **Przegl Lek** 1999;56(4):270–5 (Eng. Abstr.) **(Pol)**

[Progressive subaortic stenosis caused by accessory mitral valve tissue] Aguilar Iñigo C, et al. **Rev Esp Cardiol** 1999 Jun;52(6):438–40 (Eng. Abstr.) **(Spa)**

[Preoperative coronarography in heart valve disease patients. A probability analysis of coronary lesion] Gómez Doblas JJ, et al. **Rev Esp Cardiol** 1998 Sep;51(9):756–61 (Eng. Abstr.) **(Spa)**

[Double orifice mitral valve: severe mitral regurgitation secondary to chord rupture] Iglesias LF, et al.
Rev Esp Cardiol 1999 Aug;52(8):632–4 (Eng. Abstr.) **(Spa)**

CONGENITAL

[A new anatomical approach to congenital valve diseases by three-dimensional echocardiography] Acar P, et al.
Arch Mal Coeur Vaiss 1999 May;92(5):583–90 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Wegener granulomatosis simulating bacterial endocarditis. Anthony DD, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1807–10

ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Bonow RO, et al. **J Heart Valve Dis** 1998 Nov;7(6):672–707

Assessment of valvular heart disease. Why echocardiography is an essential component. Assi ER, et al.
Postgrad Med 1998 Dec;104(6):99–102, 105–6, 109–10 (11 ref.)

Valvular heart disease. Lipton MJ, et al.
Radiol Clin North Am 1999 Mar;37(2):319–39, v–vi (34 ref.)

Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Wisłowska M, et al.
Rheumatol Int 1999;18(5–6):163–9

Plain-film evaluation of valvular heart disease. Romero RC, et al. **Semin Roentgenol** 1999 Jul;34(3):216–27 (30 ref.)

[Diagnosis and major etiologies of infectious endocarditis occurring on native valves] Hofman P. **Ann Pathol** 1999 Jun;19(3):247–52 (54 ref.) **(Fre)**

[Heart valve disease in women in the reproductive age] Zuber M, et al. **Ther Umsch** 1998 Dec;55(12):762–6 (38 ref.) (Eng. Abstr.) **(Ger)**

[Left ventricular papillary fibroelastomas without relation to a heart valve--a report of 2 cases] Hagemeyer J, et al.
Z Kardiol 1998 Nov;87(11):900–5 (Eng. Abstr.) **(Ger)**

[Aortic endocarditis as initial manifestation of Brucella infection (letter)] Hernández-Hernández JL, et al.
An Med Interna 1999 May;16(5):267–8 **(Spa)**

DRUG THERAPY

Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Patron RL, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1754–5

Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Tornos P, et al. **Arch Intern Med** 1999 Mar 8;159(5):473–5

[Intracardiac thrombosis and consecutive thromboembolisms in patients with heart valve diseases: predisposition and concepts for prevention] Piper C, et al. **Z Kardiol** 1998;87 Suppl 4:1–6 (29 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Risk factors for coronary artery stenosis in valvular heart disease. Orlowska-Baranowska E, et al.
J Heart Valve Dis 1998 Sep;7(5):586–9

Low incidence of significant valvar insufficiency following retrograde aortic radiofrequency catheter ablation in young patients. Frias PA, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):181–5

ETIOLOGY

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia.
Kawaguchi A, et al. **Am Heart J** 1999 Mar;137(3):410–8

Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota [see comments] Kimmel SE, et al. **Am J Cardiol** 1999 Aug 1; 84(3):304–8. Comment in: Am J Cardiol 1999 Aug 1;84(3):324–6, A8.

Clinical course, microbiologic profile, and diagnosis of periannular complications in prosthetic valve endocarditis. San Román JA, et al. **Am J Cardiol** 1999 Apr 1;83(7):1075–9

Inverse paradoxical embolism in a patient on chronic hemodialysis with aortic bacterial endocarditis [see comments] Rocha JL, et al. **Am J Kidney Dis** 1999 Aug; 34(2):338–40. Comment in: Am J Kidney Dis 1999 Aug;34(2):362–3.

Cardiac Whipple's disease without digestive symptoms. Elkins C, et al. **Ann Thorac Surg** 1999 Jan;67(1):250–1

Wegener granulomatosis simulating bacterial endocarditis. Anthony DD, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1807–10

Valvular disease associated with systemic illness. Roldan CA.
Cardiol Clin 1998 Aug;16(3):531–50 (75 ref.)

Clinical characteristics of ruptured chordae tendineae in hospitalized patients: primary tear versus infective endocarditis [see comments] Portugese S, et al.
Clin Cardiol 1998 Nov;21(11):813–6. Comment in: Clin Cardiol 1999 Feb;22(2):158.

Perivalvular abscesses in infective endocarditis [editorial; comment] Oakley CM. **Eur Heart J** 1999 Feb;20(3):170–1 . Comment on: Eur Heart J 1999 Feb;20(3):232–41.

The natural history of aortic valve disease after mitral valve surgery [see comments] Vaturi M, et al.
J Am Coll Cardiol 1999 Jun;33(7):2003–8. Comment in: J Am Coll Cardiol 1999 Jun;33(7):2009–15.

Native valve staphylococcal endocarditis: etiology, risk factors and outcome in 53 cases. Hricak V, et al.
J Chemother 1998 Oct;10(5):360–8

Low incidence of significant valvar insufficiency following retrograde aortic radiofrequency catheter ablation in young patients. Frias PA, et al. **J Interv Card Electrophysiol** 1999 Jul;3(2):181–5

Echocardiography in systemic lupus erythematosus [see comments] Kalke S, et al. **Lupus** 1998;7(8):540–4. Comment in: Lupus 1999;8(3):250.

Cardiac sequelae in recurrent cases of Kawasaki disease: a comparison between the initial episode of the disease and a recurrence in the same patients. Nakamura Y, et al.
Pediatrics 1998 Dec;102(6):E66

[Degenerative diseases are in the foreground (interview by Klaus Reinhardt)] Lüscher TF. **Ther Umsch** 1998 Dec; 55(12):735–6 **(Ger)**

[Aortic valvular vegetation in annuloaortic ectasia due to idiopathic cystic medial necrosis: a case report] Fujiyama A, et al. **J Cardiol** 1998 Nov;32(5):331–6 (Eng. Abstr.) **(Jpn)**

[Brain infarct due to non-bacterial thrombotic valvular vegetation associated with primary antiphospholipid antibodies--a case report] Hino H, et al.
Rinsho Shinkeigaku 1998 Oct-Nov;38(10–11):931–5 (Eng. Abstr.) **(Jpn)**

[Medical-surgical management of left heart valve prosthesis dysfunction due to obstruction. Eleven year's experience] Valencia Sánchez JS, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):127–33 (Eng. Abstr.) **(Spa)**

[Abscess of the mitral-aortic confluence and perforation of the mitral valve in a patient with Brucella endocarditis] Castillo Dominguez JC, et al. **Rev Esp Cardiol** 1998 Dec; 51(12):1002–5 (Eng. Abstr.) **(Spa)**

HISTORY

50th Anniversary historical article. Valvular heart disease. Bonow RO. **J Am Coll Cardiol** 1999 Aug;34(2):315–7

IMMUNOLOGY

[HLA-DQA1 genes involved in genetic susceptibility to rheumatic fever and rheumatic heart disease in southern Hans] Gu J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May; 36(5):308–11 (Eng. Abstr.) **(Chi)**

METABOLISM

Acute myocardial beta-adrenergic receptor dysfunction after cardiopulmonary bypass in patients with cardiac valve disease. Duke Heart Center Perioperative Desensitization Group. Gerhardt MA, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II275–81

Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Afek A, et al.
Lupus 1999;8(7):502–7

MICROBIOLOGY

Use of polymerase chain reaction for citrate synthase gene to diagnose Bartonella quintana endocarditis. Patel R, et al. **Am J Clin Pathol** 1999 Jul;112(1):36–40

Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study [see comments] Choussat R, et al. **Eur Heart J** 1999 Feb;20(3):232–41. Comment in: Eur Heart J 1999 Feb;20(3):170–1.

A rare case of aortic valve endocarditis caused by Tropheryma whippelii with left coronary cusp perforation diagnosed by transoesophageal echocardiography and PCR. Mannaerts HF, et al. **Heart** 1999 Feb;81(2):217

Destructive native valve endocarditis caused by Staphylococcus lugdunensis. Burgert SJ, et al.
South Med J 1999 Aug;92(8):812–4 (30 ref.)

[Cardiac abscess in infectious endocarditis. A multicenter study apropos of 233 cases. The Working Group on Valvulopathy of the French Society of Cardiology] Thomas D, et al. **Arch Mal Coeur Vaiss** 1998 Jun; 91(6):745–52 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Calcified papillary fibroelastoma of the tricuspid valve. Paelinck B, et al. **Acta Cardiol** 1998;53(3):165–7

Lipoma of the mitral valve in a child. Vadmal MS, et al.
Ann Clin Lab Sci 1998 Jul-Aug;28(4):242–5

Calcification characteristics of porcine stentless valves in juvenile sheep. Herijgers P, et al.
Eur J Cardiothorac Surg 1999 Feb;15(2):134–42

Acquired heart valve pathology. An update for the millennium. Becker AE. **Herz** 1998 Nov;23(7):415–9

Neoplastic thrombotic endocarditis of the tricuspid valve in a patient with carcinoma of the thyroid. Report of a case.

Bussani R, et al. **Pathol Res Pract** 1999;195(2):121–4
Whipple's disease presenting as sarcoidosis and valvular heart disease. Wolfert AL, et al. **South Med J** 1999 Aug; 92(8):820–5 (33 ref.)
[Degenerative heart valve diseases] Fornes P. **Ann Pathol** 1999 Jun;19(3):178–86 (14 ref.) **(Fre)**

PHYSIOPATHOLOGY

Transesophageal echocardiographic detection of gas embolism and cardiac valvular dysfunction during laparoscopic nephrectomy. Fahy BG, et al. **Anesth Analg** 1999 Mar;88(3):500–4
Influence of functional tricuspid regurgitation on right ventricular function. Sugimoto T, et al. **Ann Thorac Surg** 1998 Dec;66(6):2044–50
Comparison of exercise hemodynamics among nonstented aortic bioprostheses, mechanical valves, and normal native aortic valves. Silberman S, et al. **J Card Surg** 1998 Sep–Oct; 13(5):412–6
Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation. Nitta T, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):521–8

RADIOGRAPHY

Does aortic valve calcium correlate with coronary artery calcium in young power athletes? [letter; comment] Dickerman RD, et al. **Am J Cardiol** 1999 Apr 15;83(8):1300 . Comment on: Am J Cardiol 1998 Oct 15;82(8):996.
Plain-film evaluation of valvular heart disease. Romero RC, et al. **Semin Roentgenol** 1999 Jul;34(3):216–27 (30 ref.)

RADIONUCLIDE IMAGING

Perivalvular abscess complicating infective endocarditis: complementary role of echocardiography and indium-111-labeled leukocytes. Campeau RJ, et al. **Clin Nucl Med** 1998 Sep;23(9):582–4
Assessment of left ventricular function using dobutamine stress echocardiography and myocardial scintigraphy in valvular heart disease. Ozaki N, et al. **Kobe J Med Sci** 1999 Feb;45(1):41–50
[Estimation of pulmonary hypertension in lung and valvular heart diseases by perfusion lung scintigraphy] Fujii T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):458–65 (Eng. Abstr.) **(Jpn)**

SURGERY

Atrial fibrillation early postoperatively following minimally invasive cardiac valvular surgery. Asher CR, et al. **Am J Cardiol** 1999 Sep 15;84(6):744–7, A9
Port Access. Another advance in cardiovascular surgery. Livorsi-Moore J, et al. **Am J Nurs** 1999 Jul;99(7):52–5
Clinical and hemodynamic performance of the Freestyle aortic root bioprosthesis. Cartier PC, et al. **Ann Thorac Surg** 1999 Feb;67(2):345–9; discussion 349–51
Optimizing valve exposure with minimally invasive operations [letter; comment] Castedo E, et al. **Ann Thorac Surg** 1999 Feb;67(2):601. Comment on: Ann Thorac Surg 1996 Nov;62(5):1542–4. Comment on: Ann Thorac Surg 1997 Apr;63(4):1219–20.
Ross procedure for ascending aortic replacement. Elkins RC, et al. **Ann Thorac Surg** 1999 Jun;67(6):1843–5; discussion 1853–6
Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Furnary AP, et al. **Ann Thorac Surg** 1999 Feb;67(2):352–60; discussion 360–2
Aortic allografts and pulmonary autografts for replacement of the aortic valve and aortic root. Kouchoukos NT. **Ann Thorac Surg** 1999 Jun;67(6):1846–8; discussion 1853–6 (13 ref.)
A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. McCarthy PM, et al. **Ann Thorac Surg** 1999 May;67(5):1268–73
Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. McDonald ML, et al. **Ann Thorac Surg** 1999 Feb;67(2):537–9
The anatomical aspects of minimally invasive cardiac valve operations. Reardon MJ, et al. **Ann Thorac Surg** 1999 Jan; 67(1):266–8
The efficacy and safety of aprotinin use in cardiac surgery. Rich JB. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S6–11; discussion S25–8 (20 ref.)
Minimally invasive aortic and mitral valve replacement via hemi-sternotomy. Tam RK, et al. **Aust N Z J Surg** 1998 Nov;68(11):804–5
Canadian contributions to heart valve transplantation for cardiac valve replacement. Heimbecker RO. **Can J Cardiol** 1999 May;15(5):585–6
The role of intraoperative echocardiography in valve surgery. Grimm RA, et al. **Cardiol Clin** 1998 Aug; 16(3):477–89, ix (70 ref.)
Heart valves: which is the best choice? Senthilnathan V, et al. **Cardiovasc Surg** 1999 Jun;7(4):393–7 (37 ref.)
Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery? Talwalkar NG, et al. **Chest** 1999 Jan;115(1):135–9
Excess mortality due to coronary artery disease after valve surgery. Secular trends in valvular regurgitation and effect of internal mammary artery bypass. Tribouilloy CM, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II108–15
Time-course of impairment of respiratory mechanics after cardiac surgery and cardiopulmonary bypass [see comments] Ranieri VM, et al. **Crit Care Med** 1999 Aug; 27(8):1454–60. Comment in: Crit Care Med 1999 Aug;27(8):1653–4.
Acceptance and versatility of the Ross procedure. Oswalt JD. **Curr Opin Cardiol** 1999 Mar;14(2):90–4 (11 ref.)
Myocardial protection in operations requiring more than 2 h of aortic cross-clamping. Bar-El Y, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):271–5
CarboMedics Prosthetic Heart Valve. Craver J. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S3–11; discussion S39–43
Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients. Li G, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):653–7
Minimal access aortic valve surgery. Olin CL, et al. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S32–8; discussion S39–43
Mid-term results after heart valve replacement with the CarboMedics bileaflet prosthesis: experience with 785 implants. Santini F, et al. **G Ital Cardiol** 1999 Jul; 29(7):790–5
Aortic root abscess [editorial] Brecker SJ, et al. **Heart** 1999 Sep;82(3):260–2
Comparison of long term outcome in patients with or without aortic ring abscess treated surgically for aortic valve infective endocarditis. Danchin N, et al. **Heart** 1999 Feb; 81(2):177–81
Fungal endocarditis following cardiac surgery. Verghese S, et al. **Indian Heart J** 1998 Jul–Aug;50(4):418–22
"Prophylactic" valve replacement for mild aortic valve disease at time of surgery for other cardiovascular disease?...No [editorial; comment] Rahimtoola SH. **J Am Coll Cardiol** 1999 Jun;33(7):2009–15 (55 ref.). Comment on: J Am Coll Cardiol 1999 Jun;33(7):2003–8.
Rest and exercise hemodynamics after the Ross procedure: an echocardiographic study. da Costa F, et al. **J Card Surg** 1998 May;13(3):177–85
Aortic valve replacement with stentless porcine bioprostheses. David TE. **J Card Surg** 1998 Sep–Oct; 13(5):344–51 (11 ref.)
Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. Del Rizzo DF, et al. **J Card Surg** 1998 Sep–Oct;13(5):398–407
Medtronic Freestyle aortic root bioprosthesis: Implant techniques. Doty DB, et al. **J Card Surg** 1998 Sep–Oct; 13(5):369–75
Aortic valve replacement with medtronic freestyle bioprosthesis: operative technique and results. Doty JR, et al. **J Card Surg** 1998 May;13(3):208–17
St. Jude SPV versus Medtronic Freestyle: a single institution comparison of two stentless aortic valves. Legare JF, et al. **J Card Surg** 1998 Sep–Oct;13(5):392–7
Aortic valve replacement with the Unique Suture Line Stentless USL porcine valve: A new, simple, and safe stentless valve implantation technique. Navia JA. **J Card Surg** 1998 Sep–Oct;13(5):386–91
The Cryolife-O'Brien stentless aortic porcine xenograft valve. O'Brien MF, et al. **J Card Surg** 1998 Sep–Oct; 13(5):376–85
Invited commentary on the Ross procedure. Oury JH. **J Card Surg** 1998 May;13(3):171–2 (3 ref.)
Options for right ventricular outflow tract reconstruction. Ross DN. **J Card Surg** 1998 May;13(3):186–9 (24 ref.)
Freestyle valve experience: technical considerations and mid-term results. Sintek CF, et al. **J Card Surg** 1998 Sep–Oct;13(5):360–8
Stunned myocardium and cellular damage in patients undergoing valvular cardiac surgery and pretreated with captopril. Ruiz Ros JA, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):203–10
Multiple valve replacement increases the risk of reoperation for structural degeneration of bioprostheses. Caus T, et al. **J Heart Valve Dis** 1999 Jul;8(4):376–83
Early postoperative echocardiographic hemodynamic performance of the On-X prosthetic heart valve: a multicenter study. Chambers J, et al. **J Heart Valve Dis** 1998 Sep;7(5):569–73
Retrograde cardioplegia [editorial] Frater RW. **J Heart Valve Dis** 1999 Mar;8(2):118–9
Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. Goldsmith I, et al. **J Heart Valve Dis** 1998 Sep;7(5):574–9
The Ultracor tilting disc heart valve prosthesis: a seven-year study. Li HH, et al. **J Heart Valve Dis** 1998 Nov; 7(6):647–54
Twelve-year experience with the 19 mm Carpentier-Edwards pericardial aortic valve. Nakajima H, et al. **J Heart Valve Dis** 1998 Sep;7(5):534–9
Conservative surgery for atrioventricular valve myxoma. Roques F, et al. **J Heart Valve Dis** 1999 Jul;8(4):460–2
Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial. Schaff H, et al. **J Heart Valve Dis** 1999 Mar;8(2):131–9
Long-term experience with the omniscience cardiac valve. Teijeira FJ. **J Heart Valve Dis** 1998 Sep;7(5):540–7
The medtronic intact porcine valve: ten-year clinical review. Barratt-Boyes BG, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1005–14
Pulmonary autograft: should it be used in young patients with rheumatic disease? Choudhary SK, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):483–90; discussion 490–1
Atherosclerosis of the ascending aorta is a predictor of renal dysfunction after cardiac operations. Dávila-Román VG, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):111–6
Treatment of impaired coronary blood flow after aortic root replacement with human tissue valves. Dossche KM, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1034–5
Cardiac valve papillary fibroelastoma: surgical excision for revealed or potential embolization. Grinda JM, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):106–10
Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. Peterseim DS, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):890–7
Homograft valve failure in children [letter; comment] Ross DB, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):1044–5. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):111–7.
Tetralogy of Fallot with absent pulmonary valve. A continuing challenge. Jekel L, et al. **Scand Cardiovasc J** 1998;32(4):213–7
The Ross operation: do native aortic, native pulmonary, and homograft pulmonary valve size and form differences influence results? Botha CA, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):192–7
[Chronicle of a defective heart valve prosthesis (see comments)] van der Graaf Y, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1645–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1648–52. **(Dut)**
[Minimally invasive valvular surgery] Le Clerc JL. **Rev Med Brux** 1998 Sep;19(4):A221–3 (Eng. Abstr.) **(Fre)**
[Treatment of the aortic valve and ascending aorta. The significance of reconstructive methods on the aortic root] Graeter T, et al. **Dtsch Med Wochenschr** 1998 Oct 9; 123(41):1195–200 (Eng. Abstr.) **(Ger)**
[Antithrombotic therapy in heart valve diseases pre- and postoperative] Bruhn HD. **Internist (Berl)** 1998 Dec; 39(12):1296 **(Ger)**
[Bj"ork-Shiley heart vales at the Bern University Hospital. Long-term follow-up of 12 to 23 years after mitral and aortic valve replacement in 503 patients] Stuber T, et al. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):355–63 (Eng. Abstr.) **(Ger)**
[Mitral valves from the surgical-echocardiography viewpoint] Egloff L, et al. **Ther Umsch** 1998 Dec; 55(12):746–55 (34 ref.) (Eng. Abstr.) **(Ger)**
[Aortic valve replacement: technique and outcome with artificial heart valves and allografts] Vogt PR, et al. **Ther Umsch** 1998 Dec;55(12):737–45 (37 ref.) (Eng. Abstr.) **(Ger)**
[Molecular mechanisms and indicators of thrombogenesis after heart valve replacement] Scharf RE, et al. **Z Kardiol** 1998;87 Suppl 4:7–19 (46 ref.) (Eng. Abstr.) **(Ger)**
[Minimally invasive interventions in heart surgery] Schüler S, et al. **Zentralbl Chir** 1998;123(10):1118–24 (Eng. Abstr.) **(Ger)**
[Correlation between malfunction of a bioprosthesis and deformation of a valve stent. Comparison of three different vale models] Actis Dato GM, et al. **Minerva Cardioangiol** 1998 Apr;46(4):97–101 (Eng. Abstr.) **(Ita)**
[Postoperative therapy using human atrial natriuretic peptide in cases of valve replacement] Maeda T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1297–304 (Eng. Abstr.) **(Jpn)**
[Surgery for the valvular disease in children] Matano J, et al. **Kyobu Geka** 1999 Apr;52(4):262–8 (Eng. Abstr.) **(Jpn)**
[The surgical treatment of heart defects in active infectious endocarditis] Tsukerman GI, et al. **Ter Arkh** 1998; 70(8):58–60 (Eng. Abstr.) **(Rus)**

THERAPY

Effect of pregnancy on the duration of bovine pericardial bioprostheses [see comments] Salazar E, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):714–20. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):590–1.
Contrast echoes detected during percutaneous mitral balloon commissurotomy with Inoue balloons and their relation to cerebral microembolic signals. Gencbay M, et al. **Angiology** 1998 Nov;49(11):909–14
Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Bonow RO, et al. **Circulation** 1998 Nov 3;98(18):1949–84
ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). **J Am Coll Cardiol** 1998 Nov;32(5):1486–588 (737 ref.)
ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee

on Management of Patients With Valvular Heart Disease). Bonow RO, et al. **J Heart Valve Dis** 1998 Nov;7(6):672–707

[Modern aspects in the management of acquired heart valve lesions] Horstkotte D, et al. **Herz** 1998 Nov;23(7):413–4 (32 ref.) **(Ger)**

ULTRASONOGRAPHY

Mitral annular calcium detected by transthoracic echocardiography is a marker for high prevalence and severity of coronary artery disease in patients undergoing coronary angiography. Adler Y, et al. **Am J Cardiol** 1998 Nov 15;82(10):1183–6

Cyclic variation of thickness in an age-related thick mitral valve observed by transthoracic echocardiography. Mizushige K, et al. **Angiology** 1999 Sep;50(9):735–43

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication [see comments] Wee CC, et al. **Ann Intern Med** 1998 Dec 1;129(11):870–4. Comment in: Ann Intern Med 1998 Dec 1;129(11):903–5.

Stress echocardiography in valvular heart disease. Decena BF 3rd, et al. **Cardiol Clin** 1999 Aug;17(3):555–72, ix (70 ref.)

Longitudinal assessment of valvular heart disease by echocardiography. Chen L, et al. **Curr Opin Cardiol** 1998 Nov;13(6):397–403 (22 ref.)

Thromboembolism floating through 3 cavities. Rizzo S, et al. **G Ital Cardiol** 1998 Jul;28(7):833 **(Eng, Ita)**

Pan-valvular annular calcification in Takayasu's arteritis: report of 3 cases. Ashmeik K, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1166–70

Echocardiographic parameters of the freestyle stentless bioprosthesis in aortic position: the European experience. Baur LH, et al. **J Am Soc Echocardiogr** 1999 Sep; 12(9):729–35

Real-time 3-dimensional volumetric ultrasound imaging of the vena contracta for stenotic valves with the use of echocardiographic contrast imaging: in vitro pulsatile flow studies. Shandas R, et al. **J Am Soc Echocardiogr** 1999 Jul; 12(7):541–50

The stentless quadrileaflet bovine pericardial mitral valve: echocardiographic assessment. Middlemost SJ, et al. **J Heart Valve Dis** 1999 Mar;8(2):180–5

Assessment of left ventricular function using dobutamine stress echocardiography and myocardial scintigraphy in valvular heart disease. Ozaki N, et al. **Kobe J Med Sci** 1999 Feb;45(1):41–50

Morphological evaluation of a regurgitant orifice by 3-D echocardiography: applications in the quantification of valvular regurgitation. Anayiotos AS, et al. **Ultrasound Med Biol** 1999 Feb;25(2):209–23

[Mitral and/or aortic infectious endocarditis. The correlation between transesophageal echocardiography, surgery and pathological anatomy] Espinola Zavaleta N, et al. **Arch Inst Cardiol Mex** 1998 Jul-Aug;68(4):309–14 (Eng. Abstr.), **(Spa)**

VETERINARY

Pathology of mitral valve in regularly slaughtered pigs: an abattoir survey on the occurrence of myxoid degeneration (endocardiosis), fibrosis and valvulitis. Gagna C, et al. **Zentralbl Veterinarmed A** 1998 Sep;45(6–7):383–95

HEART VALVE PROSTHESIS

see related

HEART VALVE PROSTHESIS IMPLANTATION

Management of small aortic roots. Doty JR, et al. **Adv Card Surg** 1998;10:175–96 (32 ref.)

Microbubbles associated with mechanical heart valves: their relationwith serum lactic dehydrogenase levels. Gencbay M, et al. **Am Heart J** 1999 Mar;137(3):463–8

Thrombosis of bileaflet tricuspid valve prosthesis: clinical spectrum and the role of nonsurgical treatment. Shapira Y, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):721–5

Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation. Tarasoutchi F, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):477–85

Hemodynamics and left ventricular mass regression following implantation of the Toronto SPV stentless porcine valve. Bach DS, et al. **Am J Cardiol** 1998 Nov 15;82(10):1214–9

Effects of exercise on Doppler-derived pressure difference, valve resistance, and effective orifice area in different aortic valve prostheses of similar size [see comments] Eriksson MJ, et al. **Am J Cardiol** 1999 Feb 15;83(4):619–22, A10. Comment in: Am J Cardiol 1999 Jun 1;83(11):1593.

Evaluation of the Sorin bicarbon bileaflet valve in 488 patients (519 prostheses). Goldsmith I, et al. **Am J Cardiol** 1999 Apr 1;83(7):1069–74

Usefulness of transthoracic echocardiography in detecting significant prosthetic mitral valve regurgitation. Olmos L, et al. **Am J Cardiol** 1999 Jan 15;83(2):199–205

Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Ozkan M, et al. **Am J Cardiol** 1998 Nov 1;82(9):1066–70

Effect of exercise on bioprosthetic valve hemodynamics [letter; comment] Pibarot P, et al. **Am J Cardiol** 1999 Jun 1;83(11):1593. Comment on: Am J Cardiol 1999 Feb 15;83(4):619–22, A10.

Usefulness of the indexed effective orifice area at rest in predicting an increase in gradient during maximum exercise in patients with a bioprosthesis in the aortic valve position. Pibarot P, et al. **Am J Cardiol** 1999 Feb 15;83(4):542–6

Results of Biocor stentless valve replacement for infective endocarditis of the native aortic valve. Santini F, et al. **Am J Cardiol** 1998 Nov 1;82(9):1136–7, A10

Expeditious diagnosis of primary prosthetic valve failure. Chan L, et al. **Am J Emerg Med** 1999 Mar;17(2):179–81

Small aortic annulus: a functional definition. Ghosh P, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):251–61

Supraannular aortic root enlargement in patients with small aortic annulus: efficacy and safety. Shibata Y, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):262–5

Proceedings of the VII International Symposium for Cardiac Bioprosthesis. Barcelona, Spain, June 13–15, 1997. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S29–266

Leaflet preservation in mitral valve replacement with a tilting-disc valve [letter; comment] Aris A, et al. **Ann Thorac Surg** 1999 Jan;67(1):293–4. Comment on: Ann Thorac Surg 1997 Jul;64(1):271–3.

Long-term results of the Carpentier-Edwards pericardial aortic valve: a 12-year follow-up. Banbury MK, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S73–6

The CarboMedics "Top-Hat" supraannular prosthesis. Bernal JM, et al. **Ann Thorac Surg** 1999 May;67(5):1299–303

Heat treatment mitigates calcification of valvular bioprostheses. Carpentier SM, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S264–6

Clinical and hemodynamic performance of the Freestyle aortic root bioprosthesis. Cartier PC, et al. **Ann Thorac Surg** 1999 Feb;67(2):345–9; discussion 349–51

A surgical method for selecting appropriate size of graft in aortic root remodeling [letter; comment] Choo SJ, et al. **Ann Thorac Surg** 1999 Feb;67(2):599–600. Comment on: Ann Thorac Surg 1995 Aug;60(2 Suppl):S384–90. Comment on: Ann Thorac Surg 1998 Jun;65(6):1795–6.

Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. Cohn LH, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S30–4

The Hancock II bioprosthesis at 12 years. David TE, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S95–8

The Toronto SPV bioprosthesis: clinical and hemodynamic results at 6 years. David TE. **Ann Thorac Surg** 1999 Sep; 68(3 Suppl):S9–13

In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification. Deiwick M, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S206–11

Hemodynamic features of the freestyle aortic bioprosthesis compared with stented bioprosthesis. Dumesnil JG, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S130–3

Treated bovine and autologous pericardium for aortic valve reconstruction. Duran CM, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S166–9

The mosaic bioprosthesis in the aortic position: hemodynamic performance after 2 years. Eichinger WB, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S126–9

As originally published in 1992: The Carpentier-Edwards pericardial aortic valve: intermediate results. Updated in 1998. Frater RW, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2153–4

Determinants of 15-year outcome with 1,119 standard Carpentier-Edwards porcine valves. Glower DD, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S44–8

Early clinical experience with the Tissuemed porcine bioprosthesis. Goldsmith I, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S259–63

Refined alpha aminooleic acid and experimental calcification in bioprostheses [letter; comment] Gott JP, et al. **Ann Thorac Surg** 1998 Nov;66(5):1871. Comment on: Ann Thorac Surg 1997 Jul;64(1):50–8.

Aortic homografts versus mechanical valves in aortic valve replacement in young patients: a retrospective study. Gross C, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S194–7

Aortic valve replacement: is the stentless xenograft an alternative to the homograft? Midterm results. Gross C, et al. **Ann Thorac Surg** 1999 Sep;68(3):919–24

Fluorescence activated cell sorting: a reliable method in tissue engineering of a bioprosthetic heart valve. Hoerstrup SP, et al. **Ann Thorac Surg** 1998 Nov;66(5):1653–7

The stentless Cryolife-O'Brien aortic porcine xenograft: a five-year follow-up. Hvass U, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S134–8

Medtronic intact porcine bioprosthesis: 10 years' experience. Jamieson WR, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S118–21

Carpentier-Edwards supraannular porcine bioprosthesis evaluation over 15 years. Jamieson WR, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S49–52

Carpentier-Edwards standard porcine bioprosthesis: a 21-year experience. Jamieson WR, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S40–3

Carpentier-Edwards standard and supraannular porcine bioprostheses: comparison of technology. Jamieson WR, et al. **Ann Thorac Surg** 1999 Jan;67(1):10–7

Medium-term determinants of left ventricular mass index after stentless aortic valve replacement. Jin XY, et al. **Ann Thorac Surg** 1999 Feb;67(2):411–6

A 20-year experience with the Hancock porcine xenograft in the elderly. Khan SS, et al. **Ann Thorac Surg** 1998 Dec; 66(6 Suppl):S35–9

Stuck valve leaflet detected by intraoperative transesophageal echocardiography. Kumano H, et al. **Ann Thorac Surg** 1999 May;67(5):1484–5

Orientation of tilting disc and bileaflet aortic valve substitutes for optimal hemodynamics. Laas J, et al. **Ann Thorac Surg** 1999 Sep;68(3):1096–9

Aortic valve replacement in the elderly: bioprosthesis or mechanical valve? Logeais Y, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S77–81

Aortic Carpentier-Edwards supraannular porcine bioprosthesis: a 12-year experience. Logeais Y, et al. **Ann Thorac Surg** 1999 Aug;68(2):421–5

Aortic root replacement in adolescents and young adults: composite graft versus homograft or autograft. Luciani GB, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S189–93

Reoperation on stentless aortic xenografts. Luciani GB, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S104–9

Left ventricular mass reduction after aortic valve replacement: homografts, stentless and stented valves. Maselli D, et al. **Ann Thorac Surg** 1999 Apr;67(4):966–71

Evaluation of porcine valves prepared by dye-mediated photooxidation. Moore MA, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S245–8

Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. Neville PH, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S143–7

Valved homograft conduit repair of the right heart in early infancy. Perron J, et al. **Ann Thorac Surg** 1999 Aug; 68(2):542–8

15-year experience with the Carpentier-Edwards pericardial bioprosthesis. Poirer NC, et al. **Ann Thorac Surg** 1998 Dec; 66(6 Suppl):S57–61

Mitroflow pericardial bioprosthesis experience in aortic valve replacement > or =60 years of age. Pomar JL, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S53–6

Tricuspid valve replacement: UK Heart Valve Registry mid-term results comparing mechanical and biological prostheses. Ratnatunga CP, et al. **Ann Thorac Surg** 1998 Dec;66(6):1940–7

Assessment of glutaraldehyde crosslinking efficiency with an amine-specific fluorescent probe. Ricks J, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S240–4

Prosthetic replacement of the tricuspid valve: biological or mechanical? Rizzoli G, et al. **Ann Thorac Surg** 1998 Dec; 66(6 Suppl):S62–7

Multivariate analysis of survival after malfunctioning biological and mechanical prosthesis replacement. Rizzoli G, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S88–94

The Freestyle stentless bioprosthesis for prosthetic valve endocarditis. Sakaguchi T, et al. **Ann Thorac Surg** 1999 Feb;67(2):533–5

Hancock versus stentless bioprosthesis for aortic valve replacement in patients older than 75 years. Santini F, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S99–103

Infrared spectroscopy in the evaluation of the process of calcification of valvular bioprostheses. Shen M, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S236–9

Bioprosthetic replacement after bioprosthesis failure: a hazardous choice? Spampinato N, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S68–72

Medtronic mosaic porcine bioprosthesis satisfactory early clinical performance. Thomson DJ, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S122–5

Long-term clinical experience with the Omnicarbon prosthetic valve. Torregrosa S, et al. **Ann Thorac Surg** 1999 Sep;68(3):881–6

Does glutaraldehyde induce calcification of bioprosthetic tissues? Vincentelli A, et al. **Ann Thorac Surg** 1998 Dec; 66(6 Suppl):S255–8

Porcine stentless valve/bovine pericardial conduit for right ventricle to pulmonary artery. Vrandecic MO, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S179–82

Comparison of different anticalcification treatments for stentless bioprostheses. Walther T, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S249–54

Midterm results of mitral valve repair with homemade annuloplasty rings. Warinsirikul W, et al. **Ann Thorac Surg** 1999 Jul;68(1):63–6

Bioprosthetic heart valves--replacing order with chaos: electron microscopic study. Datta D, et al. **Artif Organs** 1999 Apr;23(4):372–6

Detachable shape-memory sewing ring for heart valves. Jansen J, et al. **Artif Organs** 1992 Jun;16(3):294–7

Improved postfixation treatment of glutaraldehyde fixed porcine aortic valves by monosodium glutamate. Liao K, et al. **Artif Organs** 1992 Jun;16(3):267–72

Bovine pericardium versus porcine aortic valve: comparison of tissue biological properties as prosthetic valves. Liao K, et al. **Artif Organs** 1992 Aug;16(4):361–5

Novel cardiac assist valve with a purge flow in the valve sinus. Affeld K, et al. **ASAIO J** 1998 Sep–Oct;44(5):M642–7

Surface analysis of bileaflet prosthetic heart valve leaflet leading edge. Barmada H, et al. **ASAIO J** 1998 Jul–Aug; 44(4):294–8

Effects of mechanical fatigue on the bending properties of the porcine bioprosthetic heart valve. Gloeckner DC, et al. **ASAIO J** 1999 Jan–Feb;45(1):59–63

Systemic hypertension as a risk factor for complications with an aortic mechanical valve. Natsuaki M, et al. **ASAIO J** 1998 Sep–Oct;44(5):M486–90

Monocusp valve and transannular patch reconstruction of the right ventricular outflow tract: an experimental study. Scavo VA Jr, et al. **ASAIO J** 1998 Sep–Oct;44(5):M480–5

Time-frequency analysis of transient pressure signals for a mechanical heart valve cavitation study. Yu AA, et al. **ASAIO J** 1998 Sep-Oct;44(5):M475-9

Mechanical loading of bovine pericardium accelerates enzymatic degradation. Ellsmere JC, et al. **Biomaterials** 1999 Jun;20(12):1143-50

Biaxial mechanical/structural effects of equibiaxial strain during crosslinking of bovine pericardial xenograft materials. Langdon SE, et al. **Biomaterials** 1999 Jan; 20(2):137-53

Effects of accelerated testing on porcine bioprosthetic heart valve fiber architecture. Sacks MS, et al. **Biomaterials** 1998 Jun;19(11-12):1027-36

Eleven years experience with the Medtronic Hall Valve. Ayala I, et al. **Bol Asoc Med P R** 1998 Jul-Dec; 90(7-12):113-6

Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up. Butler AC, et al. **Br J Haematol** 1998 Dec;103(4):1064-6

Evaluation of prosthetic valve function and associated complications. Barbetseas J, et al. **Cardiol Clin** 1998 Aug; 16(3):505-30 (148 ref.)

Choosing a prosthetic heart valve. Wernly JA, et al. **Cardiol Clin** 1998 Aug;16(3):491-504 (59 ref.)

Aortic valvular replacement in octogenarians. Short-term and mid-term results in 140 patients. Bessou JP, et al. **Cardiovasc Surg** 1999 Apr;7(3):355-62

Hemodynamic rounds series II: hemodynamic evaluation of a stenotic bioprosthetic mitral valve. Azrak E, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):70-5

Is transseptal left heart catheterization for bioprosthetic mitral valve evaluation really necessary? [letter] Zimarino M, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):112-3

Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications [see comments] Tribouilloy CM, et al. **Circulation** 1999 Jan 26;99(3):400-5. Comment in: Circulation 1999 Jan 26;99(3):338-9.

Acute prosthetic mitral valve failure. Fein SA, et al. **Clin Cardiol** 1999 Jan;22(1):46

Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Arnaout MS, et al. **Clin Exp Obstet Gynecol** 1998;25(3):101-4

Actual versus actuarial analysis for cardiac valve complications: the problem of competing risks. Miller CC 3rd, et al. **Curr Opin Cardiol** 1999 Mar;14(2):79-83 (3 ref.)

Surgery of the aortic valve. David TE. **Curr Probl Surg** 1999 Jun;36(6):426-501 (189 ref.)

Mobile echoes on prosthetic valves are not reproducible. Results and clinical implications of a multicentre study. Ionescu AA, et al. **Eur Heart J** 1999 Jan;20(2):140-7

CarboMedics Prosthetic Heart Valve. Craver J. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S3-11; discussion S39-43

Is a prosthetic ring required for mitral repair of mitral insufficiency due to posterior leaflet prolapse? Long-term results in 96 patients submitted to repair with no ring. Eisenmann B, et al. **Eur J Cardiothorac Surg** 1998 Dec; 14(6):584-9

How do you spell 21 mm [letter] Elami A, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):253-4

An alternative repair technique for aortic periprosthetic leakage. Ersoy U, et al. **Eur J Cardiothorac Surg** 1999 Feb; 15(2):204-5

Leaflet escape in Omnicarbon monoleaflet valve. Kornberg A, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):867-9

Stentless or stented aortic valve implants in elderly patients? Van Nooten G, et al. **Eur J Cardiothorac Surg** 1999 Jan; 15(1):31-6

Hemodynamic performance of four mechanical bileaflet prosthetic valves in the mitral position: an echocardiographic study. Reisner SA, et al. **Eur J Ultrasound** 1998 Dec;8(3):193-200

Three-dimensional transesophageal echocardiographic evaluation of large "croissant" thrombus in St. Jude's mitral prosthesis. Greco C, et al. **G Ital Cardiol** 1998 Oct; 28(10):1168 **(Eng, Ita)**

Mid-term results after heart valve replacement with the CarboMedics bileaflet prosthesis: experience with 785 implants. Santini F, et al. **G Ital Cardiol** 1999 Jul; 29(7):790-5

Animal experimental implantation of an atrial septal defect occluder system. Bloch Thomsen A, et al. **Heart** 1998 Dec; 80(6):606-11

Haemodynamic performance of aortic pericardial bioprostheses and bileaflet prostheses at rest and during exercise: implications for the surgical management of patients with small aortic roots. González-Juanatey JR, et al. **Heart** 1999 Aug;82(2):149-55

Images in cardiology: Inoue balloon dilatation of a mitral valve prosthesis. Ludman PF, et al. **Heart** 1999 Mar; 81(3):320

Images in cardiology: A tilting valve. Tio RA, et al. **Heart** 1999 Mar;81(3):251

Thrombosis of mitral valve prosthesis presenting as abdominal pain. Mylonakis E, et al. **Heart Lung** 1999 Mar-Apr;28(2):110-3

Surface modification of polyurethane heart valves: effects on fatigue life and calcification. Bernacca GM, et al. **Int J Artif Organs** 1998 Dec;21(12):814-9

Dynamic obstruction, an unusual complication after aortic valve replacement with a stentless porcine valve. van Roosmalen RP, et al. **Int J Card Imaging** 1999 Jun; 15(3):209-14

Regression of ventricular repolarisation inhomogeneity after aortic bileaflet valve replacement in patients with aortic stenosis. Tsai CH, et al. **Int J Cardiol** 1999 Jul 31; 70(2):141-8

Pregnancy following cardiac valve replacement surgery. Suri V, et al. **Int J Gynaecol Obstet** 1999 Mar;64(3):239-46

Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. Barbetseas J, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1410-7

Echocardiographic parameters of the freestyle stentless bioprosthesis in aortic position: the European experience. Baur LH, et al. **J Am Soc Echocardiogr** 1999 Sep; 12(9):729-35

Application of proximal isovelocity surface area method to determine prosthetic mitral valve area. Degertekin M, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1056-63

Temporal variability of exercise Doppler echocardiography in patients with nonstented aortic bioprostheses. Eriksson MJ, et al. **J Am Soc Echocardiogr** 1999 Jun;12(6):484-91

Morphologic analysis of a strand recovered from a prosthetic mitral valve: No evidence of fibrin. Ionescu AA, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):766-8

Prosthetic valve obstruction with normal disk motion: usefulness of transesophageal echocardiography to define cause. Nakatani S, et al. **J Am Soc Echocardiogr** 1999 Jun; 12(6):537-9

Simultaneous Doppler and catheter transvalvular pressure gradients across St Jude bileaflet mitral valve prosthesis: in vivo study in a chronic animal model with pediatric valve sizes. Solowiejczyk DE, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1145-54

Assessment of pericardium in cardiac bioprostheses. A review. García Páez JM, et al. **J Biomater Appl** 1999 Apr; 13(4):351-88 (150 ref.)

Reduction of calcification by various treatments in cardiac valves. Rao KP, et al. **J Biomater Appl** 1999 Jan; 13(3):238-68 (148 ref.)

A three-dimensional analysis of a fibre-reinforced aortic valve prosthesis. De Hart J, et al. **J Biomech** 1998 Jul; 31(7):629-38

Analysis of 3D transient blood flow passing through an artificial aortic valve by Lattice-Boltzmann methods. Krafczyk M, et al. **J Biomech** 1998 May;31(5):453-62

Steady flow dynamics of prosthetic aortic heart valves: a comparative evaluation with PIV techniques. Lim WL, et al. **J Biomech** 1998 May;31(5):411-21

Inhibition of aortic wall calcification in bioprosthetic heart valves by ethanol pretreatment: biochemical and biophysical mechanisms. Lee CH, et al. **J Biomed Mater Res** 1998 Oct;42(1):30-7

Thermal analysis characterization of aortic tissues for cardiac valve bioprostheses. Samouillan V, et al. **J Biomed Mater Res** 1999 Sep 15;46(4):531-8

Mechanisms of bioprosthetic heart valve failure: fatigue causes collagen denaturation and glycosaminoglycan loss. Vyavahare N, et al. **J Biomed Mater Res** 1999 Jul; 46(1):44-50

Preferred method for insertion of the Toronto Stentless Porcine Valve. Cutrara CA, et al. **J Card Surg** 1998 Sep-Oct;13(5):408-11

Aortic valve replacement with stentless porcine bioprostheses. David TE. **J Card Surg** 1998 Sep-Oct; 13(5):344-51 (11 ref.)

Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. Del Rizzo DF, et al. **J Card Surg** 1998 Sep-Oct;13(5):398-407

Medtronic Freestyle aortic root bioprosthesis: Implant techniques. Doty DB, et al. **J Card Surg** 1998 Sep-Oct; 13(5):369-75

Aortic valve replacement with the Unique Suture Line Stentless USL porcine valve: A new, simple, and safe stentless valve implantation technique. Navia JA. **J Card Surg** 1998 Sep-Oct;13(5):386-91

The Cryolife-O'Brien stentless aortic porcine xenograft valve. O'Brien MF, et al. **J Card Surg** 1998 Sep-Oct; 13(5):376-85

The stentless porcine valve. Pepper JR, et al. **J Card Surg** 1998 Sep-Oct;13(5):352-9 (21 ref.)

Comparison of exercise hemodynamics among nonstented aortic bioprostheses, mechanical valves, and normal native aortic valves. Silberman S, et al. **J Card Surg** 1998 Sep-Oct; 13(5):412-6

Freestyle valve experience: technical considerations and mid-term results. Sintek CF, et al. **J Card Surg** 1998 Sep-Oct;13(5):360-8

Functional hemodynamic assessment of the 21-mm and 23-mm CarboMedics Top Hat aortic prosthetic valve. Strike PC, et al. **J Card Surg** 1998 Mar;13(2):98-103

Prosthetic valve endocarditis leading to valve replacement: a case study. Hubner C. **J Cardiovasc Nurs** 1999 Jan; 13(2):82-96

Absence of severe haemolysis in an adult patient with an aortic mechanical prosthesis and a rare form of sickle cell trait [letter] Agnino A, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):171-2

Early experience with the Sorin bileaflet prosthetic valve. Borman JB, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6 Suppl 1):43-7

Early single centre experience with 192 Sorin Bicarbon valves. Di Salvo C, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):13-5

Results of a 1 to 31 years follow-up after aortic valve replacement in 2327 patients. Feyrer R, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):17-22

Thirty one-year durability of a Starr-Edwards aortic prosthesis. Lazaros GA, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):659-62

Intracranial high-intensity transient signals after homograft or mechanical aortic valve replacement. Lievense AM, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):613-7

Long-term results after aortic valve replacement with the Mitroflow pericardial valve. Reber D, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):23-7

One hundred patients' experience with the Jyros valve. Walesby RK, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6 Suppl 1):37-41

Hemosiderin deposition on the renal cortex by mechanical hemolysis due to malfunctioning prosthetic cardiac valve: report of MR findings in two cases. Lee JW, et al. **J Comput Assist Tomogr** 1999 May-Jun;23(3):445-7

Technique of mitral valve replacement with the Monostrut prosthesis preserving the posterior leaflet. Aris A. **J Heart Valve Dis** 1999 May;8(3):340-2

In vitro studies of gas bubble formation by mechanical heart valves. Biancucci BA, et al. **J Heart Valve Dis** 1999 Mar; 8(2):186-96

Aortic valve replacement for quadricuspid aortic valve incompetence. Bortolotti U, et al. **J Heart Valve Dis** 1998 Sep;7(5):515-7

Morphologic findings in explanted Hancock II porcine bioprostheses [see comments] Butany J, et al. **J Heart Valve Dis** 1999 Jan;8(1):4-15. Comment in: J Heart Valve Dis 1999 Jan;8(1):1-3.

Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review. Carrel TP, et al. **J Heart Valve Dis** 1999 Jul;8(4):392-8

Early postoperative echocardiographic hemodynamic performance of the On-X prosthetic heart valve: a multicenter study. Chambers J, et al. **J Heart Valve Dis** 1998 Sep;7(5):569-73

An in vitro study of the correlation between aortic valve diameter and mitral intertrigonal distance: a simple method to select the correct mitral annuloplasty ring size. Choo SJ, et al. **J Heart Valve Dis** 1998 Sep;7(5):593-7

A new flow model for Doppler ultrasound study of prosthetic heart valves. Durand LG, et al. **J Heart Valve Dis** 1999 Jan;8(1):85-95

Pure pyrolytic carbon: preparation and properties of a new material, On-X carbon for mechanical heart valve prostheses. Ely JL, et al. **J Heart Valve Dis** 1998 Nov; 7(6):626-32

Pressure and flow fields in the hinge region of bileaflet mechanical heart valves. Gao ZB, et al. **J Heart Valve Dis** 1999 Mar;8(2):197-205

In vitro evaluation of the long-body On-X bileaflet heart valve. Hwang NH, et al. **J Heart Valve Dis** 1998 Sep; 7(5):561-8

Polymer heart valves. Hyde JA, et al. **J Heart Valve Dis** 1999 May;8(3):331-9 (59 ref.)

Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical heart valve prosthesis during low-molecular weight heparin therapy. Idir M, et al. **J Heart Valve Dis** 1999 May;8(3):303-4

Medtronic Hall versus St. Jude Medical mechanical aortic valve: downstream turbulences with respect to rotation in pigs. Kleine P, et al. **J Heart Valve Dis** 1998 Sep; 7(5):548-55

Evaluation of a novel bioprosthetic heart valve incorporating anticalcification and antimicrobial technology in a sheep model. Langanki D, et al. **J Heart Valve Dis** 1998 Nov; 7(6):633-8

Eighteen-year follow up after Hancock II bioprosthesis insertion [see comments] Legarra JJ, et al. **J Heart Valve Dis** 1999 Jan;8(1):16-24. Comment in: J Heart Valve Dis 1999 Jan;8(1):1-3.

Thrombolysis is superior to heparin for non-obstructive mitral mechanical valve thrombosis. Lengyel M, et al. **J Heart Valve Dis** 1999 Mar;8(2):167-73

The Ultracor tilting disc heart valve prosthesis: a seven-year study. Li HH, et al. **J Heart Valve Dis** 1998 Nov; 7(6):647-54

The stentless quadrileaflet bovine pericardial mitral valve: echocardiographic assessment. Middlemost SJ, et al. **J Heart Valve Dis** 1999 Mar;8(2):180-5

The stentless quadrileaflet bovine pericardial mitral valve: early clinical results. Middlemost SJ, et al. **J Heart Valve Dis** 1999 Mar;8(2):174-9

Twelve-year experience with the 19 mm Carpentier-Edwards pericardial aortic valve. Nakajima H, et al. **J Heart Valve Dis** 1998 Sep;7(5):534-9

Correlation of valve closing to visualization of single-leg separation in radiographic images of Björk-Shiley convexo-concave heart valves. Powell KA, et al. **J Heart Valve Dis** 1999 Jul;8(4):399-403

High-resolution assessment of velocity fields and shear stresses distal to prosthetic heart valves using high-field magnetic resonance imaging. Ringgaard S, et al. **J Heart Valve Dis** 1999 Jan;8(1):96-103

Fatigue-induced changes in bioprosthetic heart valve

three-dimensional geometry and the relation to tissue damage. Smith DB, et al. **J Heart Valve Dis** 1999 Jan; 8(1):25-33

The Hancock II xenograft: a step forward in bioprosthetic valve longevity? [editorial; comment] Thiene G, et al. **J Heart Valve Dis** 1999 Jan;8(1):1-3. Comment on: J Heart Valve Dis 1999 Jan;8(1):4-15. Comment on: J Heart Valve Dis 1999 Jan;8(1):16-24.

The influence of sizing on the dynamic function of the free-hand implanted porcine aortic homograft: an in vitro study. Thubrikar MJ, et al. **J Heart Valve Dis** 1999 May; 8(3):242-53

Macroscopic aspects of cloth-covered Starr-Edwards prostheses at reoperation: what the precursory valve teaches us. Tsukamoto S, et al. **J Heart Valve Dis** 1998 Sep;7(5):556-60

Distortion of the stentless porcine valve induces accelerated leaflet fibrosis and calcification in juvenile sheep. van Nooten G, et al. **J Heart Valve Dis** 1999 Jan;8(1):34-41

Early results with the Carbo-seal composite valve conduit for aortic root replacement. Vitale N, et al. **J Heart Valve Dis** 1999 Jan;8(1):80-4

Strut fracture mechanisms of the Björk-Shiley convexo-concave heart valve. Wieting DW, et al. **J Heart Valve Dis** 1999 Mar;8(2):206-17

A comparison of the cavitation potential of prosthetic heart valves based on valve closing dynamics. Zapanta CM, et al. **J Heart Valve Dis** 1998 Nov;7(6):655-67

Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. Cannegieter SC, et al. **J Intern Med** 1999 Apr;245(4):369-74 (34 ref.)

Long-term evaluation of orthotopically implanted stentless bioprosthetic aortic valves in juvenile sheep. Ouyang DW, et al. **J Invest Surg** 1998 May-Jun;11(3):175-83

Diamond-like carbon coating and plasma or glow discharge treatment of mechanical heart valves. Tran HS, et al. **J Invest Surg** 1999 May-Jun;12(3):133-40 (50 ref.)

Analysis of regurgitation, mean systolic pressure drop and energy losses for two artificial aortic valves. Sakhacimanesh AA, et al. **J Med Eng Technol** 1999 Mar-Apr;23(2):63-8

High-risk stress myocardial perfusion imaging in a patient with chest pain after aortic valve replacement. Rosenblatt JA. **J Nucl Cardiol** 1999 Mar-Apr;6(2):245-6

The medtronic intact porcine valve: ten-year clinical review. Barratt-Boyes BG, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1005-14

Long-term clinical and hemodynamic evaluation of porcine valved conduits implanted from the right ventricle to the pulmonary artery. Champsaur G, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):793-804

The impact of age, coronary artery disease, and cardiac comorbidity on late survival after bioprosthetic aortic valve replacement. Cohen G, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):273-84

Structural valve deterioration in mitral replacement surgery: comparison of Carpentier-Edwards supra-annular porcine and perimount pericardial bioprostheses. Eric Jamieson WR, et al. **J Thorac Cardiovasc Surg** 1999 Aug; 118(2):297-304

Mitral annular size and shape in sheep with annuloplasty rings. Glasson JR, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):302-9

Multicenter study of stentless valve replacement in the small aortic root. Hvass U, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):267-72

Which manufacturing characteristics are predictors of outlet strut fracture in large sixty-degree Björk-Shiley convexo-concave mitral valves? The Björk-Shiley Study Group. Kallewaard M, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):766-75

Aortic homograft valve functioning for twenty-eight years in the tricuspid position [letter] Kawauchi M, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):384-5

No-React anticalcification tissue treatment results with stentless heart valves in two adolescents. Milo S, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1222-3

The effect of sizing on the in vitro hydrodynamic characteristics and leaflet motion of the Toronto SPV stentless valve. Nagy ZL, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):92-8

Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. Peterseim DS, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):890-7

A novel comparison of stentless versus stented valves in the small aortic root. Rao V, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):431-6; discussion 436-38

Experimental study on modified treatment and endothelialization of bovine pericardial valves. Fu P, et al. **J Tongji Med Univ** 1997;17(3):136-9

Functional evaluation of the bileaflet mechanical valve in the aortic position using dobutamine-stress echocardiography: is a 23-mm prosthetic valve adequately large enough? Tsukamoto M, et al. **Jpn Circ J** 1998 Nov; 62(11):817-23

Rethink on biological aortic valves for the elderly. Treasure T. **Lancet** 1999 Sep 18;354(9183):964-5

Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma [letter; comment] Wijdicks EF, et al. **Neurology** 1999 Feb;52(3):676-7. Comment on: Neurology 1998 May;50(5):1489-91.

Principal stress analysis in LDA measurement of the flow field downstream of 19-mm Sorin Bicarbon heart valve. Barbaro V, et al. **Technol Health Care** 1998 Nov; 6(4):259-70

ON-X bileaflet valve in aortic position--early experience shows an improved hemodynamic profile. Fraund S, et al. **Thorac Cardiovasc Surg** 1998 Oct;46(5):293-7

Experiences with the Toronto SPV bioprosthesis after three years follow-up. Strauch JT, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):19-22

Effectiveness of different anticalcification treatments for stentless aortic bioprostheses. Walther T, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):23-5

[Reoperations on prosthetic heart valves: an analysis of 64 cases] Zhang B, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jun;35(6):367-70 (Eng. Abstr.) **(Chi)**

[Oral anticoagulation therapy in patients with artificial heart valves] **Ugeskr Laeger** 1999 May 31;161(22):3307 **(Dan)**

[Self management of peroral anticoagulant therapy in patients with artificial heart valves] Hasenkam JM, et al. **Ugeskr Laeger** 1998 Nov 16;160(47):6811-5 (Eng. Abstr.) **(Dan)**

[Pathology of heart valve prostheses] Lepidi H. **Ann Pathol** 1999 Jun;19(3):187-94 (32 ref.) **(Fre)**

[Treatment of obstruction of prosthetic conduct by percutaneous implantation of stents] Saliba Z, et al. **Arch Mal Coeur Vaiss** 1999 May;92(5):591-6 (Eng. Abstr.) **(Fre)**

[The pericardium: a heterogeneous tissue. Anatomic and morphometric considerations] Latremouille C, et al. **Morphologie** 1999 Mar;83(260):41-4 (Eng. Abstr.) **(Fre)**

[Propionibacterium acnes infectious endocarditis] Durupt S, et al. **Presse Med** 1998 Nov 21;27(36):1839-41 (21 ref.) (Eng. Abstr.) **(Fre)**

[An in vitro study of hydrodynamic properties of the TRI-Technologies heart valve prosthesis in accordance with prEN 12006-1] Dohmen R, et al. **Biomed Tech (Berl)** 1998;43 Suppl:384-5 **(Ger)**

[Calculation of the flow through a new single cusp valve for heart assist systems] Goubergrits L, et al. **Biomed Tech (Berl)** 1998;43 Suppl:288-9 **(Ger)**

[Labcor-stented porcine heart valve prosthesis in laboratory testing in accordance with prEN 12006-1] Hüsgen P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:386-7 **(Ger)**

[A new heart valve for heart assist systems] Lambertz M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:514-5 **(Ger)**

[Pulsatile flow model of the heart for validating new echocardiography methods for determining regurgitation volume] Mehmel H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:504-5 **(Ger)**

[Evaluation of biomaterial surfaces by detection of mechanical and electrical inhomogeneities using scanning probe microscopy] Röpke C, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:398-9 **(Ger)**

[Effect of pre-existing lipids on calcinosis of swine heart valve bioprostheses. A study of a dynamic in vitro model] Baba HA, et al. **Pathologe** 1998 Nov;19(6):420-4 (Eng. Abstr.) **(Ger)**

[Bj"ork-Shiley heart vales at the Bern University Hospital. Long-term follow-up of 12 to 23 years after mitral and aortic valve replacement in 503 patients] Stuber T, et al. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):355-63 (Eng. Abstr.) **(Ger)**

[Aortic valve replacement in patients over 70: a Doppler echocardiographic study] Sarasso G, et al. **Cardiologia** 1998 Oct;43(10):1067-75 (Eng. Abstr.) **(Ita)**

[High-intensity transcranial Doppler signals in patients wearing heart valve prostheses: a prospective study] D'Alfonso A, et al. **G Ital Cardiol** 1999 Apr;29(4):401-10 (Eng. Abstr.) **(Ita)**

[Thrombosis of aortic valve prostheses: its incidence, morphological aspects and surgical treatment] Ismeno G, et al. **G Ital Cardiol** 1999 Mar;29(3):277-83 (Eng. Abstr.) **(Ita)**

[Correlation between malfunction of a bioprosthesis and deformation of a valve stent. Comparison of three different vale models] Actis Dato GM, et al. **Minerva Cardioangiol** 1998 Apr;46(4):97-101 (Eng. Abstr.) **(Ita)**

[Relative valve area stenosis after replacement of a Starr-Edwards mitral valve (model 6520) for corrected TGA (S, L, L): report of a case] Matsuoka T, et al. **Kyobu Geka** 1998 Dec;51(13):1127-30 (Eng. Abstr.) **(Jpn)**

[New practical sizer for ATS medical open pivot valve] Yaginuma Y, et al. **Kyobu Geka** 1999 May;52(5):376-8 (Eng. Abstr.) **(Jpn)**

[Selection criteria for aortic valve prostheses: mechanical, stented, or stentless valve or homograft?] Koyanagi T, et al. **Nippon Geka Gakkai Zasshi** 1998 Nov;99(11):789-93 (Eng. Abstr.) **(Jpn)**

[Biological prostheses in the tricuspid position. The immediate and follow-up results] Sousa L, et al. **Rev Port Cardiol** 1998 Sep;17(9):697-702 (Eng. Abstr.) **(Por)**

[Experimental study of artificial disk heart valves] Etonov MP, et al. **Med Tekh** 1999 May-Jun;(3):32-7 (Eng. Abstr.) **(Rus)**

[Two-leaflet artificial heart valve with the common turn axis for leaflets] Iurechko VN, et al. **Med Tekh** 1998 Sep-Oct; (5):21-9 (Eng. Abstr.) **(Rus)**

[Physical-mechanical and functional characteristics of xenograft during various methods of stabilization and treatment] Kondratenko ZhE, et al. **Med Tekh** 1998 Jul-Aug;(4):20-3 (Eng. Abstr.) **(Rus)**

[Aortic valve prosthesis implantation from a mini approach] Belov IuV, et al. **Vestn Khir Im I I Grek** 1998;157(3):47-9 (Eng. Abstr.) **(Rus)**

[Rare causes of the dysfunction of mechanical bicuspid heart valves] Novikov VK, et al. **Vestn Khir Im I I Grek** 1998; 157(3):60-4 (36 ref.) (Eng. Abstr.) **(Rus)**

[Medical-surgical management of left heart valve prosthesis dysfunction due to obstruction. Eleven year's experience] Valencia Sánchez JS, et al. **Arch Inst Cardiol Mex** 1999 Mar-Apr;69(2):127-33 (Eng. Abstr.) **(Spa)**

[Late recurrence of endocarditis caused by Coxiella burnetii following prosthetic valve substitution and prolonged antibiotic treatment (letter)] Abril V, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):44-5 **(Spa)**

[Fever and petechiae in a patient with a metallic aortic prosthesis] Pintor E, et al. **Enferm Infecc Microbiol Clin** 1998 Aug-Sep;16(7):341-2 **(Spa)**

[Dehiscence of a composite aortic graft (Bono and Bentall technique) secondary to Acinetobacter endocarditis] Alvarez J, et al. **Rev Esp Cardiol** 1998 Sep;51(9):769-71 (Eng. Abstr.) **(Spa)**

[Pseudoaneurysm of the mitral-aortic fibrosa secondary to the partial detachment of a mechanical aortic prosthesis] Delgado C, et al. **Rev Esp Cardiol** 1999 May;52(5):348-50 (7 ref.) (Eng. Abstr.) **(Spa)**

[The measurement of jet width at its origin in assessing mitral prosthetic regurgitation. The effect of the spatial disposition of the jet] Morillas PJ, et al. **Rev Esp Cardiol** 1999 Jan; 52(1):31-6 (Eng. Abstr.) **(Spa)**

[New system for testing mechanical heart valves. Self-monitoring at home of anti-vitamin K therapy means greater freedom for the patient] Svensson PJ, et al. **Lakartidningen** 1999 May 19;96(20):2478-82 (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Mean velocity and Reynolds stress measurements in the regurgitant jets of tilting disk heart valves in an artificial heart environment. Maymir JC, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):146-56

Personal follow-up of 100 aortic valve replacement patients for 1081 patient years. Varstela E. **Ann Chir Gynaecol** 1998; 87(3):205-12

Early calcific stenosis of the aortic sorin pericarbon valve implanted in the elderly. d'Udekem Y, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S139-42

Valve-related complications in elderly patients with biological and mechanical aortic valves. Milano A, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S82-7

Compression of anomalous circumflex coronary artery by a prosthetic valve ring. Veinot JP, et al. **Ann Thorac Surg** 1998 Dec;66(6):2093-4

A crusty cause of prosthetic valve endocarditis. Zahariadis G, et al. **Can J Cardiol** 1999 Jun;15(6):693-5

Thrombosis of a mitral valve prosthesis resulting from Staphylococcus epidermidis endocarditis. Costa GM, et al. **Cardiologia** 1999 Jul;44(7):675-8 (12 ref.)

Venous microemboli in patients with artificial heart valves. Georgiadis D, et al. **Cerebrovasc Dis** 1999 Jul-Aug; 9(4):238-41

Risks of valve replacements in young women [editorial; comment] Collins JJ. **Circulation** 1999 May 25;99(20):2613 . Comment on: Circulation 1999 May 25;99(20):2669-76.

Long-term survival and valve-related complications in young women with cardiac valve replacements [see comments] North RA, et al. **Circulation** 1999 May 25; 99(20):2669-76. Comment in: Circulation 1999 May 25;99(20):2613.

Endocarditis caused by Aspergillus niger: case report. Vivas C. **Clin Infect Dis** 1998 Nov;27(5):1322-3

Thirty-day mortality and long-term survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry. Edwards MB, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):156-64

Bileaflet mechanical prostheses performance in mitral position. Jamieson WR, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):786-94

Mechanical heart valves: an insight into thrombotic complications. Bharat V. **Indian Heart J** 1999 Jan-Feb; 51(1):59-63

Fungal endocarditis following cardiac surgery. Verghese S, et al. **Indian Heart J** 1998 Jul-Aug;50(4):418-22

In vitro thrombogenicity testing of artificial organs. Paul R, et al. **Int J Artif Organs** 1998 Sep;21(9):548-52

Covert tamponade. Jenkins MG, et al. **J Accid Emerg Med** 1999 Mar;16(2):156

Recurrent prosthetic valve thrombosis: importance of prolonged Doppler echocardiography examination for diagnosis. Rittoo D, et al. **J Am Soc Echocardiogr** 1999 Aug;12(8):686-8

Videoassisted thrombectomy of mechanical prosthetic heart valves. Carrier M, et al. **J Heart Valve Dis** 1999 Jul; 8(4):404-6

In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings. Darouiche RO, et al. **J Heart Valve Dis** 1998 Nov;7(6):639-46

Thrombogenicity of polyethylene oxide-bonded Dacron

sewing ring in a mechanical heart valve. Dewanjee MK, et al. **J Heart Valve Dis** 1999 May;8(3):324–30

Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience. Goldsmith I, et al.
J Heart Valve Dis 1998 Sep;7(5):574–9

Recurrent endocarditis in silver-coated heart valve prosthesis. Kjaergard HK, et al. **J Heart Valve Dis** 1999 Mar;8(2):140–2

Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial. Schaff H, et al. **J Heart Valve Dis** 1999 Mar;8(2):131–9

Leakage flow at mechanical heart valve prostheses: improved washout or increased blood damage? Steegers A, et al.
J Heart Valve Dis 1999 May;8(3):312–23

Long-term experience with the omniscience cardiac valve. Teijeira FJ. **J Heart Valve Dis** 1998 Sep;7(5):540–7

Stent fracture in a Carpentier-Edwards supra-annular porcine bioprosthesis implanted in the mitral position. Hurlé A, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):197–9

Patient recovery after intermittent disc escape and spontaneous recession of a mechanical heart valve [letter] Robicsek F, et al. **J Thorac Cardiovasc Surg** 1999 Mar; 117(3):633–4

Homograft valve failure in children [letter; comment] Ross DB, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):1044–5. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):111–7.

Pentoxifylline treatment for microangiopathic hemolytic anemia caused by mechanical heart valves. Geller S, et al. **Md Med J** 1999 Jul-Aug;48(4):173

Time-frequency analysis of the noise produced by the closing of artificial heart valves: an in vitro study. Masson C, et al. **Med Eng Phys** 1998 Sep;20(6):418–31

Prosthetic-valve endocarditis caused by penicillin-resistant Streptococcus mitis [letter] Levitz RE. **N Engl J Med** 1999 Jun 10;340(23):1843–4

Multifocal brain MRI hypointensities secondary to embolic metal fragments from a mechanical heart valve prosthesis: a possible source of epileptic seizures. Naumann M, et al. **Neurology** 1998 Dec;51(6):1766–7

Microemboli in cerebral circulation and alteration of cognitive abilities in patients with mechanical prosthetic heart valves [letter; comment] Lagos R, et al. **Stroke** 1999 May;30(5):1150. Comment on: Stroke 1998 Sep;29(9):1821–6.

[Lessons from a heart valve prosthesis controversy (comment)] Vandenbroucke JP, et al.
Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1648–52 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1645–8. **(Dut)**

[Chronicle of a defective heart valve prosthesis (see comments)] van der Graaf Y, et al.
Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1645–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1648–52. **(Dut)**

[Severe hemolysis complicated by renal insufficiency in a patient with mitro-aortic bioprostheses and review of the literature] Hammoudi-Bendib N, et al.
Arch Mal Coeur Vaiss 1999 Feb;92(2):269–71 (Eng. Abstr.) **(Fre)**

[Successful thrombolysis on an aortic valve prosthesis by plasminogen tissue activator during pregnancy] Rinaldi JP, et al. **Arch Mal Coeur Vaiss** 1999 Apr;92(4):427–30 (Eng. Abstr.) **(Fre)**

[Heart valve prostheses] Benacerraf S, et al. **Rev Prat** 1999 Feb 15;49(4):419–23 **(Fre)**

[Streptococcus bovis endocarditis. Clinical and microbiological observations and review of the literature] Carfagna P, et al. **Recenti Prog Med** 1998 Nov;89(11):552–8 (Eng. Abstr.) **(Ita)**

[Quantification of mitral prosthesis failure by different methods of evaluation by transesophageal echocardiography] Fischer CH, et al. **Arq Bras Cardiol** 1998 Dec;71(6):741–5 (Eng. Abstr.) **(Por)**

[Prevention of prosthetic heart valve infection] Shevchenko IuL, et al. **Vestn Khir Im I I Grek** 1999;158(3):53–6 (Eng. Abstr.) **(Rus)**

[Transesophageal echocardiography in the study of infected valve prostheses] Crespo Serje L, et al.
Arch Inst Cardiol Mex 1998 Jul-Aug;68(4):315–21 (Eng. Abstr.) **(Spa)**

[Mitral valve prosthetic endocarditis due to Hafnia alvei (letter)] Gallego Page JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):199 (10 ref.) **(Spa)**

[Infectious endocarditis of prosthetic valves due to Staphylococcus capitis: a new case] Dominguez Rodriguez A, et al. **Rev Esp Cardiol** 1999 Apr;52(4):277–8 (7 ref.) (Eng. Abstr.) **(Spa)**

[Hemolytic anemia due to prosthetic mechanical valves (letter)] Rodríguez-Cuartero A, et al. **Sangre (Barc)** 1998 Oct;43(5):468 **(Spa)**

CLASSIFICATION

Heart valves: which is the best choice? Senthilnathan V, et al. **Cardiovasc Surg** 1999 Jun;7(4):393–7 (37 ref.)

Influence of aortic valve replacement, prosthesis type, and size on functional outcome and ventricular mass in patients with aortic stenosis. Bech-Hanssen O, et al.
J Thorac Cardiovasc Surg 1999 Jul;118(1):57–65

HISTORY

Serendipity and the development of heparin and carbon surfaces. Gott VL, et al. **Ann Thorac Surg** 1999 Sep;68(3 Suppl):S19–22

The development of the Starr-Edwards heart valve [letter; comment] Frater RW. **Tex Heart Inst J** 1999;26(1):99. Comment on: Tex Heart Inst J 1998;25(4):282–93.

The development of the Starr-Edwards heart valve [letter; comment] Goldstone J. **Tex Heart Inst J** 1999;26(1):99. Comment on: Tex Heart Inst J 1998;25(4):282–93.

The development of the Starr-Edwards heart valve [see comments] Matthews AM. **Tex Heart Inst J** 1998; 25(4):282–93. Comment in: Tex Heart Inst J 1999;26(1):99.

MICROBIOLOGY

Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia. Munter RG, et al.
Eur J Clin Microbiol Infect Dis 1998 May;17(5):353–6 (18 ref.)

In response to: In vivo efficacy of silver-coated (Sil-zone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis. J Heart Valve Disease; 1998;7:524–530 [letter; comment] Costerton JW. **J Heart Valve Dis** 1999 May;8(3):346–8. Comment on: J Heart Valve Dis 1998 Sep;7(5):524–30.

In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a biofilm-producing bacteria, Staphylococcus epidermidis [see comments] Illingworth BL, et al. **J Heart Valve Dis** 1998 Sep;7(5):524–30. Comment in: J Heart Valve Dis 1999 May;8(3):346–8.

Candida parapsilosis: an unusual organism causing prosthetic heart valve infective endocarditis. Darwazah A, et al.
J Infect 1999 Mar;38(2):130–1

[Lactobacillus acidophilus endocarditis] Penot JP, et al.
Presse Med 1998 Jun 13;27(21):1009–12 (Eng. Abstr.) **(Fre)**

[Endocarditis caused by Moraxella lacunata on the natural and prosthetic valves. An unusual pathogenesis (letter)] Robles M, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul; 16(6):290–1 **(Spa)**

STANDARDS

Does pregnancy affect the durability of valvular bioprostheses? [editorial; comment] Glower DD.
Am Heart J 1999 Apr;137(4 Pt 1):590–1. Comment on: Am Heart J 1999 Apr;137(4 Pt 1):714–20.

Effect of pregnaney on the duration of bovine pericardial bioprostheses [see comments] Salazar E, et al.
Am Heart J 1999 Apr;137(4 Pt 1):714–20. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):590–1.

Orthotropic mechanical properties of chemically treated bovine pericardium. Sacks MS, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):892–902

Inaccurate and misleading valve sizing: a proposed standard for valve size nomenclature. Christakis GT, et al.
Ann Thorac Surg 1998 Oct;66(4):1198–203

Retrieval analysis of mechanical heart valves: impact on design and clinical practice. Cromheecke ME, et al.
Artif Organs 1998 Sep;22(9):794–9

Twenty-year, three-institution evaluation of the Hancock Modified Orifice aortic valve durability. Comparison of actual and actuarial estimates. Mahoney CB, et al.
Circulation 1998 Nov 10;98(19 Suppl):II88–93; discussion II93–4

Inter-laboratory comparisons: approaching a new standard for prosthetic heart valve testing in vitro. VanAuker MD, et al. **J Heart Valve Dis** 1999 Jul;8(4):384–91

Welding metallurgy's putative influence on Björk-Shiley convexo-concave valve outlet strut failures. Wenzel TC, et al. **J Heart Valve Dis** 1999 Mar;8(2):218–31

Biomaterials and cardiovascular devices. Macnair R, et al.
Proc Inst Mech Eng [H] 1998;212(6):465–71 (42 ref.)

[Prosthetic valve replacement in children] Sasahashi N, et al. **Kyobu Geka** 1999 Apr;52(4):269–73 (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Bjork-Shiley convexo-concave valve: is a prophylactic re-replacement justified? Actis Dato GM, et al.
J Cardiovasc Surg (Torino) 1999 Jun;40(3):343–6

Multiple valve replacement increases the risk of reoperation for structural degeneration of bioprostheses. Caus T, et al.
J Heart Valve Dis 1999 Jul;8(4):376–83

Lack of durability of the Mitroflow valve does not affect survival. Houel R, et al. **J Heart Valve Dis** 1999 Jul; 8(4):368–74; discussion 374–5

TRENDS

Future directions in tissue heart valves: impact of recent insights from biology and pathology. Schoen FJ.
J Heart Valve Dis 1999 Jul;8(4):350–8 (95 ref.)

HEART VALVE PROSTHESIS IMPLANTATION

see related

HEART VALVE PROSTHESIS

Nasogastric tube knotting in open heart surgery [letter] Palta S. **Acta Anaesthesiol Scand** 1999 Aug;43(7):790

Bilateral posterior fossa subdural haematomas secondary to anticoagulant therapy. Lagares A, et al.
Acta Neurochir (Wien) 1998;140(10):1097–8

Symptoms, left ventricular function, and timing of valve replacement surgery in patients with aortic regurgitation. Tarasoutchi F, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):477–85

Heart failure after aortic valve replacement for aortic regurgitation: prospective 20-year study. Tornos MP, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):681–7

Evaluation of the Sorin bicarbon bileaflet valve in 488 patients (519 prostheses). Goldsmith I, et al.
Am J Cardiol 1999 Apr 1;83(7):1069–74

Results of Biocor stentless valve replacement for infective endocarditis of the native aortic valve. Santini F, et al.
Am J Cardiol 1998 Nov 1;82(9):1136–7, A10

Transesophageal echocardiographic diagnosis of aortic pseudoaneurysm after combined aortic valve replacement and coronary artery bypass graft surgery [letter] Smith B, et al. **Anesth Analg** 1999 Sep;89(3):802

Early hemodynamic changes following emergency mitral valve replacement for traumatic mitral insufficiency following balloon mitral valvotomy: report of six cases. Tempe DK, et al. **Anesthesiology** 1998 Dec;89(6):1583–5

Replacement of aortic root with valved tubular prosthesis in a ten-year-old child with infective endocarditis--a case report. Demircin M, et al. **Angiology** 1998 Nov;49(11):941–4

Implantation of a mechanical valve within the orifice of a mitral bioprosthesis in a case with severely calcified left atrium--a case report. Sakakibara Y, et al. **Angiology** 1998 Oct;49(10):857–60

Aortic valve replacement in a patient with previous coronary artery bypass grafting. Sugita T, et al.
Ann Thorac Cardiovasc Surg 1998 Oct;4(5):288–9

Cardiac surgery using only autologous blood for a patient with hereditary spherocytosis: a case report. Yamagishi I, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):294–7

Stroke in cardiac surgical patients: determinants and outcome. Almassi GH, et al. **Ann Thorac Surg** 1999 Aug; 68(2):391–7; discussion 397–8

Leaflet preservation in mitral valve replacement with a tilting-disc valve [letter; comment] Aris A, et al.
Ann Thorac Surg 1999 Jan;67(1):293–4. Comment on: Ann Thorac Surg 1997 Jul;64(1):271–3.

An unusual iatrogenic cause of right coronary air embolism. Baker RC, et al. **Ann Thorac Surg** 1999 Aug;68(2):575–6

The CarboMedics "Top-Hat" supraannular prosthesis. Bernal JM, et al. **Ann Thorac Surg** 1999 May;67(5):1299–303

Valve replacement for appetite suppressant-induced valvular heart disease. Biswas SS, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1819–22

"I" ministernotomy for aortic valve replacement. Chang YS, et al. **Ann Thorac Surg** 1999 Jul;68(1):40–5

An unexplained cluster of thrombosed bileaflet mechanical heart valve prostheses [letter; comment] Chaudhuri N, et al. **Ann Thorac Surg** 1999 May;67(5):1542–3. Comment on: Ann Thorac Surg 1998 Nov;66(5):1684–91.

Troponin I and autotransfusion of shed mediastinal blood in redo cardiac operation [letter; comment] Chen LW.
Ann Thorac Surg 1999 Aug;68(2):629–30. Comment on: Ann Thorac Surg 1998 Jun;65(6):1617–20.

Hepatoatrial anastomosis and tricuspid valve replacement in Budd-Chiari syndrome 8. Chiu CK, et al.
Ann Thorac Surg 1998 Nov;66(5):1803–4

601 octogenarians undergoing cardiac surgery: outcome and comparison with younger age groups. Craver JM, et al.
Ann Thorac Surg 1999 Apr;67(4):1104–10

The Toronto SPV bioprosthesis: clinical and hemodynamic results at 6 years. David TE. **Ann Thorac Surg** 1999 Sep; 68(3 Suppl):S9–13

Repair of left ventricular rupture after mitral valve replacement: use of a Teflon patch and glue. de la Fuente A, et al. **Ann Thorac Surg** 1999 Jun;67(6):1802–3

Should a bicuspid aortic valve be replaced in the presence of subvalvar or supravalvar aortic stenosis? Delius RE, et al. **Ann Thorac Surg** 1998 Oct;66(4):1337–42

Small aortic valve prostheses in octogenarians [letter; comment] Ghosh PK. **Ann Thorac Surg** 1999 May; 67(5):1543–4. Comment on: Ann Thorac Surg 1998 Sep;66(3):699–705; discussion 705–6.

Aortic valve replacement after substernal colon interposition. Gillinov AM, et al. **Ann Thorac Surg** 1999 Mar;67(3):838–9

Aortic homografts versus mechanical valves in aortic valve replacement in young patients: a retrospective study. Gross C, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S194–7

Ministernotomy for aortic valve replacement in a patient with osteogenesis imperfecta. Izzat MB, et al.
Ann Thorac Surg 1999 Apr;67(4):1171–3

Carpentier-Edwards supraannular porcine bioprosthesis evaluation over 15 years. Jamieson WR, et al.
Ann Thorac Surg 1998 Dec;66(6 Suppl):S49–52

The relationship of myocardial stroke work to coronary flow velocity immediately after aortic valve replacement. Jin XY, et al. **Ann Thorac Surg** 1999 Mar;67(3):705–10

Early changes in the time course of myocardial contraction after correcting aortic regurgitation. Jin XY, et al.
Ann Thorac Surg 1999 Jan;67(1):139–45

Prosthetic valve replacement in Ebstein's malformation: 30-year follow-up. John S, et al. **Ann Thorac Surg** 1999 Aug;68(2):556–7

A brimmed valved conduit in repair of fibrous skeleton abscess. Kameyama T, et al. **Ann Thorac Surg** 1998 Dec;

66(6):2108–10
Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. Kiziltan HT, et al. **Ann Thorac Surg** 1998 Nov;66(5):1539–45
Orientation of tilting disc and bileaflet aortic valve substitutes for optimal hemodynamics. Laas J, et al. **Ann Thorac Surg** 1999 Sep;68(3):1096–9
Intermediate-term results in pediatric aortic valve replacement. Lupinetti FM, et al. **Ann Thorac Surg** 1999 Aug;68(2):521–5; discussion 525–6
Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. McDonald ML, et al. **Ann Thorac Surg** 1999 Feb;67(2):537–9
Left ventricular mass reduction after aortic valve replacement: homografts, stentless and stented valves. Maselli D, et al. **Ann Thorac Surg** 1999 Apr;67(4):966–71
Effects of mitral valve replacement on regional left ventricular systolic strain. Moon MR, et al. **Ann Thorac Surg** 1999 Sep;68(3):894–902
Prevention of potential complications after minimal access aortic valve replacement [letter; comment] Riess FC, et al. **Ann Thorac Surg** 1998 Nov;66(5):1866. Comment on: Ann Thorac Surg 1996 Aug;62(2):596–7.
Are we implanting half-valves? The role of sinus wall compliance in aortic valve function [letter] Robicsek F, et al. **Ann Thorac Surg** 1999 Feb;67(2):597
Outcome analysis of 245 CarboMedics and St. Jude valves implanted at the same institution [see comments] Rosengart TK, et al. **Ann Thorac Surg** 1998 Nov;66(5):1684–91. Comment in: Ann Thorac Surg 1999 May;67(5):1542–3.
Iatrogenic mammary arteriovenous fistula caused by a sternal wire [letter] Saad RA, et al. **Ann Thorac Surg** 1999 Aug; 68(2):626
Transcatheter closure of a patent foramen ovale following mitral valve replacement. Skulski R, et al. **Ann Thorac Surg** 1999 Aug;68(2):582–3
Long-term clinical experience with the Omnicarbon prosthetic valve. Torregrosa S, et al. **Ann Thorac Surg** 1999 Sep;68(3):881–6
Bileaflet mechanical valve (St. Jude Medical valve) replacement in long-term dialysis patients. Ura M, et al. **Ann Thorac Surg** 1999 Sep;68(3):870–3
Retrieval analysis of mechanical heart valves: impact on design and clinical practice. Cromheecke ME, et al. **Artif Organs** 1998 Sep;22(9):794–9
Anticoagulation after valve replacement: a multicenter retrospective study. Kudo T, et al. **Artif Organs** 1999 Feb; 23(2):199–203
Bovine pericardium versus porcine aortic valve: comparison of tissue biological properties as prosthetic valves. Liao K, et al. **Artif Organs** 1992 Aug;16(4):361–5
Reliability of transthoracic echocardiography in the assessment of aortic valve morphology: pathological correlation in 178 patients. Chan KL, et al. **Can J Cardiol** 1999 Jan;15(1):48–52
Low dose dobutamine echocardiography in the assessment of contractile reserve to predict the outcome of valve replacement for chronic aortic regurgitation. Tam JW, et al. **Can J Cardiol** 1999 Jan;15(1):73–9 (30 ref.)
The risk of cerebrovascular accident in patients with asymptomatic critical carotid artery stenosis who undergo open-heart surgery. Ali IM, et al. **Can J Surg** 1998 Oct; 41(5):374–8
Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: major thromboembolic and hemorrhagic complications. Jamieson WR, et al. **Can J Surg** 1999 Feb; 42(1):27–36
Tricuspid valve disease. Clinical evaluation, physiopathology, and management. Blaustein AS, et al. **Cardiol Clin** 1998 Aug;16(3):551–72, x (168 ref.)
Chronic aortic regurgitation. Role of medical therapy and optimal timing for surgery. Bonow RO. **Cardiol Clin** 1998 Aug;16(3):449–61 (72 ref.)
Clinical assessment and management of mitral stenosis. Bruce CJ, et al. **Cardiol Clin** 1998 Aug;16(3):375–403 (92 ref.)
The role of intraoperative echocardiography in valve surgery. Grimm RA, et al. **Cardiol Clin** 1998 Aug; 16(3):477–89, ix (70 ref.)
Mitral valve repair vs replacement. Current recommendations and long-term results. Lawrie GM. **Cardiol Clin** 1998 Aug;16(3):437–48 (95 ref.)
Aortic stenosis. Clinical evaluation and optimal timing of surgery. Otto CM. **Cardiol Clin** 1998 Aug;16(3):353–73, vii (169 ref.)
Management of mitral regurgitation. Optimal timing for surgery. Quiñones MA. **Cardiol Clin** 1998 Aug; 16(3):421–35, viii (101 ref.)
Management of the patient with aortic root disease and aortic insufficiency. Safi HJ, et al. **Cardiol Clin** 1998 Aug; 16(3):463–75, viii (37 ref.)
Aortic valvular replacement in octogenarians. Short-term and mid-term results in 140 patients. Bessou JP, et al. **Cardiovasc Surg** 1999 Apr;7(3):355–62
Percutaneous balloon mitral valvotomy as a bridge to elective mitral valve replacement [letter; comment] Chow WH, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):102. Comment on: Cathet Cardiovasc Diagn 1998 Feb;43(2):195–7.
Balloon mitral valvuloplasty employing double transseptal puncture [see comments] Hildick-Smith DJ, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):33–6. Comment in: Cathet Cardiovasc Diagn 1998 Dec;45(4):471. Comment in: Cathet Cardiovasc Diagn 1999 May;47(1):117.
Single vs double transseptal puncture for balloon mitral valvuloplasty...there is always a better way! [letter; comment] Cheatham JP. **Catheter Cardiovasc Interv** 1999 May;47(1):117. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):33–6.
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Stein PD, et al. **Chest** 1998 Nov;114(5 Suppl):602S–610S (57 ref.)
Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery? Talwalkar NG, et al. **Chest** 1999 Jan;115(1):135–9
Semirigid or flexible mitral annuloplasty rings do not affect global or basal regional left ventricular systolic function. Green GR, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II128–35; discussion II135–6
Choice of mitral prosthesis in the elderly. An analysis of actual outcome. Grossi EA, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II116–9
Anticoagulation is unnecessary after biological aortic valve replacement. Moinuddeen K, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II195–8; discussion II98–9
Quality of life in patients with bioprostheses and mechanical prostheses. Evaluation of cohorts of patients aged 51 to 65 years at implantation. Perchinsky M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II81–6; discussion II86–7
Valve replacement in chronic aortic regurgitation. True predictors of survival after extended follow-up. Turina J, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II100–6; discussion II106–7
First redo heart valve replacement: a 10-year analysis. Weerasinghe A, et al. **Circulation** 1999 Feb 9;99(5):655–8
Aortic valve replacement in patients older than 85 years: outcomes and the effect on their quality of life. Levin IL, et al. **Coron Artery Dis** 1998;9(6):373–80
Myocardial structure as a determinant of pre- and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis. Lund O, et al. **Eur Heart J** 1998 Jul;19(7):1099–108
Venous gangrene of the lower limbs following aortic valve replacement for native valve endocarditis. Awad WI, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):440–2
Homograft valve insertion for pulmonary regurgitation late after valveless repair of right ventricular outflow tract obstruction. Conte S, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):143–9
Calcification characteristics of porcine stentless valves in juvenile sheep. Herijgers P, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):134–42
Aortic valve replacement in the octogenarians: perioperative outcome and clinical follow-up. Kolh P, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):68–73
Aortic regurgitation in rheumatoid arthritis necessitating aortic valve replacement. Levine AJ, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):213–4
Hemodynamic performance of four mechanical bileaflet prosthetic valves in the mitral position: an echocardiographic study. Reisner SA, et al. **Eur J Ultrasound** 1998 Dec;8(3):193–200
Mid-term results after heart valve replacement with the CarboMedics bileaflet prosthesis: experience with 785 implants. Santini F, et al. **G Ital Cardiol** 1999 Jul; 29(7):790–5
Animal experimental implantation of an atrial septal defect occluder system. Bloch Thomsen A, et al. **Heart** 1998 Dec; 80(6):606–11
To operate or not on elderly patients with aortic stenosis: the decision and its consequences [see comments] Bouma BJ, et al. **Heart** 1999 Aug;82(2):143–8. Comment in: Heart 1999 Aug;82(2):119–20. Comment in: Heart 1999 Aug;82(2):143–8.
Exercise testing to guide surgery in aortic stenosis [editorial] Chambers J. **Heart** 1999 Jul;82(1):7–8
QT dispersion is reduced after valve replacement in patients with aortic stenosis. Darbar D, et al. **Heart** 1999 Jul; 82(1):15–8
Surgery for aortic stenosis in severely symptomatic patients older than 80 years: experience in a single UK centre [see comments] Gilbert T, et al. **Heart** 1999 Aug;82(2):138–42 . Comment in: Heart 1999 Aug;82(2):119–20.
Anticoagulation in pregnant women with mechanical heart valve prostheses. Meschengieser SS, et al. **Heart** 1999 Jul; 82(1):23–6
Prediction of the onset of atrial fibrillation after cardiac surgery using the monophasic action potential. Pichlmaier AM, et al. **Heart** 1998 Nov;80(5):467–72
Main stem subocclusion shortly after aortic valve replacement. Van Langenhove G, et al. **Heart** 1998 Nov; 80(5):530–1
An effective method for improving hemostasis in aortic root replacement with a composite graft. Liu KX, et al. **Heart Vessels** 1998;13(5):237–40
Surgical treatment for annuloaortic ectasia in Takayasu arteritis. Amano J, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S197–202; discussion S203–4
High-dose streptokinase therapy for prosthetic valve thrombosis within 2 weeks of open heart surgery. Bhargava B, et al. **Int J Cardiol** 1998 Sep 30;66(2):143–5
Regression of ventricular repolarisation inhomogeneity after aortic bileaflet valve replacement in patients with aortic stenosis. Tsai CH, et al. **Int J Cardiol** 1999 Jul 31; 70(2):141–8
Pregnancy through a prosthetic heart valve [editorial; comment] Elkayam U. **J Am Coll Cardiol** 1999 May; 33(6):1642–5. Comment on: J Am Coll Cardiol 1999 May;33(6):1637–41.
"Prophylactic" valve replacement for mild aortic valve disease at time of surgery for other cardiovascular disease?...No [editorial; comment] Rahimtoola SH. **J Am Coll Cardiol** 1999 Jun;33(7):2009–15 (55 ref.). Comment on: J Am Coll Cardiol 1999 Jun;33(7):2003–8.
Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves [see comments] Vitale N, et al. **J Am Coll Cardiol** 1999 May;33(6):1637–41. Comment in: J Am Coll Cardiol 1999 May;33(6):1642–5.
The clamshell incision provides adequate exposure for aortic valve replacement and coronary revascularization. Husain SA, et al. **J Card Surg** 1998 Mar;13(2):136–7; discussion 138–9
Repair of a pseudoaneurysm of the ascending aorta after aortic valve replacement. Olearchyk AS. **J Card Surg** 1998 Mar;13(2):143–5
Invited commentary on the Ross procedure. Oury JH. **J Card Surg** 1998 May;13(3):171–2 (3 ref.)
Comparison of clinical outcome between histidine-triptophan-ketoglutalate solution and cold blood cardioplegic solution in mitral valve replacement. Sakata J, et al. **J Card Surg** 1998 Jan;13(1):43–7
Prosthetic valve endocarditis leading to valve replacement: a case study. Hubner C. **J Cardiovasc Nurs** 1999 Jan; 13(2):82–96
Early experience with the Sorin bileaflet prosthetic valve. Borman JB, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6 Suppl 1):43–7
"Band aid" surgery: upper sternal split incision for valve surgery in adults. A modified technique. Connery CP, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):475–7
Early single centre experience with 192 Sorin Bicarbon valves. Di Salvo C, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):13–5
Results of a 1 to 31 years follow-up after aortic valve replacement in 2327 patients. Feyrer R, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):17–22
Mitral valve prolapse. Comparison between valvular repair and replacement in severe mitral regurgitation. Gramaglia B, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):93–9
Aortic stenosis in the elderly: result of aortic valve replacement. Morell VO, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):33–5
One-year experience with the Edwards stentless "Prima" aortic bioprosthesis. Piotrowski JA, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):57–9
Ventricular performance following valve replacement for chronic mitral regurgitation: importance of chordal preservation. Popovic Z, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):183–90
Long-term results after aortic valve replacement with the Mitroflow pericardial valve. Reber D, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):23–7
Mitral valve replacement through a giant left atrial appendage. Rikitake K, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):127–9
Stunned myocardium and cellular damage in patients undergoing valvular cardiac surgery and pretreated with captopril. Ruiz Ros JA, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):203–10
One hundred patients' experience with the Jyros valve. Walesby RK, et al. **J Cardiovasc Surg (Torino)** 1996 Dec; 37(6 Suppl 1):37–41
Results of mechanical prosthetic valve replacement in active valvular endocarditis. Wos S, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):29–32
Successful repair of cardio-Behçet's disease with aortic and mitral regurgitation. Zakaria M, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):803–5
Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. Aramendi JL, et al. **J Heart Valve Dis** 1998 Nov;7(6):610–4
Technique of mitral valve replacement with the Monostrut prosthesis preserving the posterior leaflet. Aris A. **J Heart Valve Dis** 1999 May;8(3):340–2
High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves [see comments] Gencbay M, et al. **J Heart Valve Dis** 1998 Nov; 7(6):601–9. Comment in: J Heart Valve Dis 1998 Nov;7(6):598–600.
Acute aortic endocarditis with annular destruction: assessment of surgical treatment with cryopreserved valvular homografts. Grandmougin D, et al. **J Heart Valve Dis** 1999 May;8(3):234–41
Thromboembolic complications following heart valve replacement: the role of patient-related coagulability [editorial; comment] Horstkotte D, et al. **J Heart Valve Dis** 1998 Nov;7(6):598–600. Comment on: J Heart Valve Dis 1998 Nov;7(6):601–9.
Successful Cox-maze III procedure combined with mitral valve replacement in a massively thrombosed left atrium. Louagie Y, et al. **J Heart Valve Dis** 1999 Jul;8(4):453–6
Effectiveness of continuous warm blood cardioplegia in cardiac valve re-replacement. Nagaoka H, et al. **J Heart Valve Dis** 1999 Mar;8(2):124–30
The quality of life after aortic valve replacement with homografts or prosthetic valves. Podolec P, et al.

J Heart Valve Dis 1999 May;8(3):270–6

Tricuspid regurgitation late after mitral valve replacement: clinical and echocardiographic evaluation. Porter A, et al. **J Heart Valve Dis** 1999 Jan;8(1):57–62

Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial. Schaff H, et al. **J Heart Valve Dis** 1999 Mar;8(2):131–9

Chronic evaluation of orthotopically implanted bileaflet mechanical aortic valves in adult domestic sheep. Salerno CT, et al. **J Invest Surg** 1998 Sep–Oct;11(5):341–7

Association between intraoperative cerebral microembolic signals and postoperative neuropsychological deficit: comparison between patients with cardiac valve replacement and patients with coronary artery bypass grafting. Braekken SK, et al.
J Neurol Neurosurg Psychiatry 1998 Oct;65(4):573–6

"This" is topped again [letter] Flege JB Jr.
J Thorac Cardiovasc Surg 1998 Nov;116(5):884

Multicenter study of stentless valve replacement in the small aortic root. Hvass U, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):267–72

A novel comparison of stentless versus stented valves in the small aortic root. Rao V, et al.
J Thorac Cardiovasc Surg 1999 Mar;117(3):431–6; discussion 436–38

Valve-preserving replacement of the ascending aorta: remodeling versus reimplantation. Schäfers H, et al.
J Thorac Cardiovasc Surg 1998 Dec;116(6):990–6

Surgery for mitral valve disease in the pediatric age group. Yoshimura N, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):99–106

Surgical treatment for Scheie's syndrome (mucopolysaccharidosis type I-S): report of two cases. Minakata K, et al. **Jpn Circ J** 1998 Sep;62(9):700–3

Mitral valve replacement in patients younger than 6 years of age. Katogi T, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Feb;47(2):63–7

Aortic valve replacement in a patient with idiopathic thrombocytopenic purpura. Kumamoto T, et al.
Jpn J Thorac Cardiovasc Surg 1999 Apr;47(4):182–4

Aortic valve replacement after retrosternal gastric tube reconstruction for esophageal cancer. Matsuda H, et al.
Jpn J Thorac Cardiovasc Surg 1999 May;47(5):234–6

Aortic and mitral valve replacement in an 83-year-old female. 3 years follow-up of 16 mm bileaflet valve at the aortic position. Tanemoto K, et al.
Jpn J Thorac Cardiovasc Surg 1998 Sep;46(9):815–20

Acute hemodynamic effects of alternate and combined site pacing in patients after cardiac surgery. Buckingham TA, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):887–93

The significance of oral health and dental treatment for the postoperative outcome of heart valve surgery. Hakeberg M, et al. **Scand Cardiovasc J** 1999;33(1):5–8

Extended survival of a porcine mitral bioprosthesis for 23 years: report of a case. Baba T, et al. **Surg Today** 1999; 29(6):573–4

Repeat tricuspid valve replacement for acquired valvular heart disease: report of a case. Sugimoto T, et al.
Surg Today 1998;28(10):1112–4

Use of the Internet for long-term clinical follow-up. Aucar JA, et al. **Telemed J** 1998 Winter;4(4):371–4

Early massive thrombosis of a mechanical mitral valve. Masiello P, et al. **Tex Heart Inst J** 1998;25(4):303–5

Successful reoperation after Batista partial left ventriculectomy demonstrates patient's hemodynamic recovery. Taşdemir O, et al. **Tex Heart Inst J** 1999; 26(2):132–5

Valve replacement under retrograde warm-blood cardioplegia. Results in 287 patients. Tolis GA, et al.
Tex Heart Inst J 1998;25(3):185–93

ON-X bileaflet valve in aortic position—early experience shows an improved hemodynamic profile. Fraund S, et al.
Thorac Cardiovasc Surg 1998 Oct;46(5):293–7

Reversal of ventricular dilatation after correction of aortic incompetence: mechanical prosthesis compared with biological procedures. Moidl R, et al.
Thorac Cardiovasc Surg 1998 Aug;46(4):188–91

Superior myocardial protection with a new histidine-buffered crystalloid cardioplegic solution in clinical trial. Takeuchi K, et al. **Thorac Cardiovasc Surg** 1999 Jun;47(3):148–52

Replacement of the ascending aorta and aortic valve with a composite graft: operative and long-term results. Tabayashi K, et al. **Tohoku J Exp Med** 1998 Apr; 184(4):257–66

Cardiac surgery in renal transplant recipients. Kobayashi Y, et al. **Transplant Proc** 1998 Nov;30(7):3050–2

[Comparison between intraarterial pulsegraphy and thermodilution method for determination of cardiac output during anesthesia and operation in patients undergoing cardiac valve replacement] Zhou J, et al.
Hunan I Ko Ta Hsueh Hsueh Pao 1997;22(3):256–8 (Eng. Abstr.) **(Chi)**

[Variability of heart rate after heart surgery under extracorporeal circulation: aortocoronary bypass or aortic valve replacement] Bronner F, et al.
Ann Cardiol Angeiol (Paris) 1998 Oct;47(8):549–54 (Eng. Abstr.) **(Fre)**

[Predictive indices of the persistence of left ventricular dilatation after valve replacement for chronic aortic insufficiency. Echocardiographic study] Khatouri A, et al.
Ann Cardiol Angeiol (Paris) 1998 Dec;47(10):716–21 (31 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of the aortic valve and ascending aorta. The significance of reconstructive methods on the aortic root] Graeter T, et al. **Dtsch Med Wochenschr** 1998 Oct 9; 123(41):1195–200 (Eng. Abstr.) **(Ger)**

[Fever, negative blood culture findings and absence of response to antibiotic therapy in a patient after a second aortic valve prosthesis] Miljak T, et al.
Dtsch Med Wochenschr 1998 Oct 16;123(42):1235–8 (Eng. Abstr.) **(Ger)**

[Antithrombotic therapy in heart valve diseases pre- and postoperative] Bruhn HD. **Internist (Berl)** 1998 Dec; 39(12):1296 **(Ger)**

[The abdominal emergency after heart surgery interventions] Wolken D, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:988–90 (Eng. Abstr.) **(Ger)**

[Endocarditis in heart defects--incidence, diagnosis and prevention] Turina J. **Ther Umsch** 1998 Dec;55(12):773–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Aortic valve replacement: technique and outcome with artificial heart valves and allografts] Vogt PR, et al.
Ther Umsch 1998 Dec;55(12):737–45 (37 ref.) (Eng. Abstr.) **(Ger)**

[Optimizing long-term anticoagulation by patient self-management?] Bernardo A. **Z Kardiol** 1998;87 Suppl 4:75–81 (Eng. Abstr.) **(Ger)**

[Value of molecular markers for administration of anticoagulant therapy after heart valve replacement] Dahm M, et al. **Z Kardiol** 1998;87 Suppl 4:42–5 (Eng. Abstr.) **(Ger)**

[Anticoagulation in surgery, after hemorrhagic complications and in pregnancy] Gohlke-Bärwolf C. **Z Kardiol** 1998;87 Suppl 4:56–62 (41 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in patients with heart valve replacement in pregnancy] Harenberg J. **Z Kardiol** 1998;87 Suppl 4:63–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Thrombosis of prosthetic heart valves: diagnosis and management] Horstkotte D, et al. **Z Kardiol** 1998;87 Suppl 4:20–32 (69 ref.) (Eng. Abstr.) **(Ger)**

[Left ventricular remodeling after aortic valve replacement] Rao L, et al. **Z Kardiol** 1999 Apr;88(4):283–9 (Eng. Abstr.) **(Ger)**

[Molecular mechanisms and indicators of thrombogenesis after heart valve replacement] Scharf RE, et al.
Z Kardiol 1998;87 Suppl 4:7–19 (46 ref.) (Eng. Abstr.) **(Ger)**

[Intensity of oral anticoagulant therapy after heart valve replacement] Stenzinger W. **Z Kardiol** 1998;87 Suppl 4:37–41 (12 ref.) (Eng. Abstr.) **(Ger)**

[Aortic valve replacement as an independent predictive factor for later development of aortic dissection] von Kodolitsch Y, et al. **Z Kardiol** 1998 Aug;87(8):604–12 (Eng. Abstr.) **(Ger)**

[Inhibition of thrombocyte aggregation after heart valve replacement] von Schacky C. **Z Kardiol** 1998;87 Suppl 4:46–55 (64 ref.) (Eng. Abstr.) **(Ger)**

[Patient self-monitoring in follow-up of long-term anticoagulant therapy] Zerback R, et al. **Z Kardiol** 1998; 87 Suppl 4:68–74 (Eng. Abstr.) **(Ger)**

[Low cardiac output following open heart surgery and catecholamine therapy] Papp L, et al. **Orv Hetil** 1999 Jan 24;140(4):179–85 (Eng. Abstr.) **(Hun)**

[Painless aortic dissection late after aortic valve replacement, presenting as superior vena cava syndrome] Hayashi Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):724–9 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral valve replacement for three cases of hypertrophic obstructive cardiomyopathy--surgical treatment] Koh Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):747–52 (Eng. Abstr.) **(Jpn)**

[Postoperative therapy using human atrial natriuretic peptide in cases of valve replacement] Maeda T, et al.
Jpn J Thorac Cardiovasc Surg 1998 Dec;46(12):1297–304 (Eng. Abstr.) **(Jpn)**

[Hemodynamic evaluations of patients with small aortic annulus with St. Jude Medical prosthetic heart valve] Shimabukuro T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1285–91 (Eng. Abstr.) **(Jpn)**

[A case of aortic prosthetic valve endocarditis with aortic root aneurysm] Shimomura T, et al.
Jpn J Thorac Cardiovasc Surg 1998 Dec;46(12):1354–7 (Eng. Abstr.) **(Jpn)**

[Surgery for mitral regurgitation in children] Fukushima N, et al. **Kyobu Geka** 1999 Apr;52(4):290–4 (Eng. Abstr.) **(Jpn)**

[A case of mitral valve replacement combined with idiopathic thrombocytopenic purpura (ITP)] Goshima M, et al.
Kyobu Geka 1999 Jul;52(7):573–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Influence of left ventricular wall thickening on myocardial injury in aortic valve replacement] Hosono M, et al.
Kyobu Geka 1998 Dec;51(13):1099–103 (Eng. Abstr.) **(Jpn)**

[Re-do surgery with minimally invasive cardiac surgery (MICS): mitral valve replacement 6 years after open mitral commissurotomy] Imazeki T, et al. **Kyobu Geka** 1998 Sep; 51(10):853–5 (Eng. Abstr.) **(Jpn)**

[A case of mitral valve replacement and left atrial plication for infantile Marfan syndrome with giant left atrium due to mitral valve regurgitation] Kamikubo Y, et al.
Kyobu Geka 1999 Jul;52(7):579–82 (Eng. Abstr.) **(Jpn)**

[A successful case report of a patient who had severe aortic stenosis with cardiac arrest: bridge use of percutaneous cardiopulmonary support system (PCPS)] Kaneda K, et al. **Kyobu Geka** 1999 May;52(5):405–7 (Eng. Abstr.) **(Jpn)**

[Clinical results of mitral valve surgery in children] Masuda M, et al. **Kyobu Geka** 1999 Apr;52(4):301–6 (Eng. Abstr.) **(Jpn)**

[Surgery for the valvular disease in children] Matano J, et al. **Kyobu Geka** 1999 Apr;52(4):262–8 (Eng. Abstr.) **(Jpn)**

[Valve replacement in children] Matsubayashi K, et al.
Kyobu Geka 1999 Apr;52(4):274–80 (Eng. Abstr.) **(Jpn)**

[Relative valve area stenosis after replacement of a Starr-Edwards mitral valve (model 6520) for corrected TGA (S, L, L): report of a case] Matsuoka T, et al.
Kyobu Geka 1998 Dec;51(13):1127–30 (Eng. Abstr.) **(Jpn)**

[A case report of successful mitral valve replacement for congenital mitral stenosis associated with coarctation of the aorta and ventricular septal defect] Noguchi Y, et al.
Kyobu Geka 1999 Apr;52(4):312–7 (Eng. Abstr.) **(Jpn)**

[Valve replacement for congenital mitral stenosis associated with double orifice mitral valve: a case report and a review of Japanese literatures] Ogata T, et al. **Kyobu Geka** 1999 Apr;52(4):307–11 (43 ref.) (Eng. Abstr.) **(Jpn)**

[A case of Bentall's operation for an 11-year-old patient with Marfan syndrome] Ohkado A, et al. **Kyobu Geka** 1999 Mar; 52(3):201–3 (Eng. Abstr.) **(Jpn)**

[Progressive mitral regurgitation which is necessitated the mitral valve replacement after partial left ventriculectomy (Batista procedure): a case report] Ryomoto M, et al.
Kyobu Geka 1999 Sep;52(10):840–3 (Eng. Abstr.) **(Jpn)**

[Prosthetic valve replacement in children] Sasahashi N, et al. **Kyobu Geka** 1999 Apr;52(4):269–73 (Eng. Abstr.) **(Jpn)**

[A case report of infective endocarditis with total rupture of the posterior papillary muscle after aortic valve replacement] Sugimoto T, et al. **Kyobu Geka** 1998 Dec; 51(13):1120–2 (Eng. Abstr.) **(Jpn)**

[Mitral valve replacement under cardiopulmonary bypass which complicated by multiple sclerosis: a case report] Uesugi H, et al. **Kyobu Geka** 1999 Jul;52(7):569–72 (Eng. Abstr.) **(Jpn)**

[Midterm results of bilateral enlargement of the aortic valve ring for valve replacement] Yoshimura N, et al.
Kyobu Geka 1999 Apr;52(4):286–9 (Eng. Abstr.) **(Jpn)**

[Anesthetic management for mitral valve replacement in a patient with mitral stenosis and dilated cardiomyopathy] Kurokawa S, et al. **Masui** 1999 Jun;48(6):639–43 (Eng. Abstr.) **(Jpn)**

[Experiences with biological aortic valve at Ullevål hospital] Nordby T, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):925–7 (Eng. Abstr.) **(Nor)**

[Mitral valve surgery in elderly patients] Antunes MJ.
Rev Port Cardiol 1999 May;18(5):483–8 (11 ref.) (Eng. Abstr.) **(Por)**

[Implantation of mechanical prosthetic valves in the pediatric age group. Review of the last ten years] Castilho T, et al. **Rev Port Cardiol** 1999 May;18(5):491–5 (Eng. Abstr.) **(Por)**

[Operative results after the Cox/maze procedure combined with a mitral valve operation] Fragata JH.
Rev Port Cardiol 1999 Feb;18(2):201–2 **(Por)**

[A pseudoaneurysm of the mitral-aortic intervalvular fibrosis after aortic valve replacement] Sousa L, et al.
Rev Port Cardiol 1999 Feb;18(2):177–8 (Eng. Abstr.) **(Por)**

[Radionuclide study in the diagnosis of infectious foci in heart surgery patients] Shevchenko IuL, et al.
Vestn Khir Im I I Grek 1998;157(5):105–8 (Eng. Abstr.) **(Rus)**

[The superior vena cava syndrome as a manifestation of aortic dissection following aortic valve replacement (letter)] Vericat MC, et al. **An Med Interna** 1999 Jan;16(1):48–9 (10 ref.) **(Spa)**

[Effectiveness of adenosine as a pulmonary vasodilator during weaning from extracorporeal circulation after mitral valve replacement in a patient with severe pulmonary hypertension] Charco Mora P, et al.
Rev Esp Anestesiol Reanim 1999 May;46(5):223–5 (Eng. Abstr.) **(Spa)**

[Fortuitous diagnosis of an undifferentiated large cell carcinoma during cardiac surgery] Abad C, et al.
Rev Esp Cardiol 1999 Jul;52(7):523–5 (Eng. Abstr.) **(Spa)**

[Abscess of the mitral-aortic confluence and perforation of the mitral valve in a patient with Brucella endocarditis] Castillo Dominguez JC, et al. **Rev Esp Cardiol** 1998 Dec; 51(12):1002–5 (Eng. Abstr.) **(Spa)**

[New system for testing mechanical heart valves. Self-monitoring at home of anti-vitamin K therapy means greater freedom for the patient] Svensson PJ, et al.
Lakartidningen 1999 May 19;96(20):2478–82 (Eng. Abstr.) **(Swe)**

[Correction of pseudoaneurysm of the ascending aorta after change of the aortic valve] Olearchyk AS. **Klin Khir** 1999; (7):54–5 **(Ukr)**

ADVERSE EFFECTS

Natural history of early aortic paraprosthetic regurgitation: a five-year follow-up. Rallidis LS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):351–7

The case of the missing fragment: detection and retrieval of a portion of broken valve as it was ejected from the heart. Michelsen LG, et al. **Anesthesiology** 1999 Aug; 91(2):560–2

Personal follow-up of 100 aortic valve replacement patients for 1081 patient years. Varstela E. **Ann Chir Gynaecol** 1998; 87(3):205–12

Left ventricular free wall rupture following mitral valve replacement. Yoshida K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):336–9 (12 ref.)

Risk stratification for cardiac valve replacement. National Cardiac Surgery Database. Database Committee of The Society of Thoracic Surgeons. Jamieson WR, et al. **Ann Thorac Surg** 1999 Apr;67(4):943–51

Stuck valve leaflet detected by intraoperative transesophageal echocardiography. Kumano H, et al. **Ann Thorac Surg** 1999 May;67(5):1484–5

Left ventricular outflow tract obstruction with mitral mechanical prosthesis. Melero JM, et al. **Ann Thorac Surg** 1999 Jul;68(1):255–7

Ochronosis: an unusual finding at aortic valve replacement. Helou J, et al. **Can J Cardiol** 1999 Sep;15(9):1013–5 **(Eng, Fre)**

Actual versus actuarial analysis for cardiac valve complications: the problem of competing risks. Miller CC 3rd, et al. **Curr Opin Cardiol** 1999 Mar;14(2):79–83 (3 ref.)

Localized intraoperative cardiac tamponade. Asham EH, et al. **Eur J Cardiothorac Surg** 1996;10(12):1136–8

How do you spell 21 mm [letter] Elami A, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):253–4

Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk. Rizzoli G, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):74–80

Echocardiography in prosthetic valve disease. Garcia MJ. **Indian Heart J** 1998 May–Jun;50(3):267–76 (72 ref.)

Dynamic obstruction, an unusual complication after aortic valve replacement with a stentless porcine valve. van Roosmalen RP, et al. **Int J Card Imaging** 1999 Jun; 15(3):209–14

Pseudoabscess of the aortic root caused by ectopic seating of an aortic prosthesis. Cohen IS, et al. **J Am Soc Echocardiogr** 1998 Oct;11(10):997–1000

Echocardiographic diagnosis of left ventricular outflow tract obstruction caused by an acquired subaortic membrane after mitral valve replacement. Khoshnevis R, et al. **J Am Soc Echocardiogr** 1999 May;12(5):319–23

Aortic pseudoaneurysm after Bentall procedure. Haddy SM. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):203–6

Papillary muscle rupture after chordal sparing mitral valve replacement. Goldenberg MR, et al. **J Heart Valve Dis** 1998 Sep;7(5):590–2

Aortic complications after aortic valve replacement in patients with dilated ascending aorta and aortic regurgitation. Natsuaki M, et al. **J Heart Valve Dis** 1998 Sep;7(5):504–9

Asymptomatic left ventricular outflow tract obstruction after mitral valve replacement with leaflet preservation. Popovic Z, et al. **J Heart Valve Dis** 1999 Jul;8(4):450–2

Management of brucella endocarditis of a prosthetic valve. Arslan H, et al. **J Infect** 1998 Jul;37(1):70–1

Potential mechanism of left ventricular outflow tract obstruction after mitral ring annuloplasty. Dagum P, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):472–80

Treatment of impaired coronary blood flow after aortic root replacement with human tissue valves. Dossche KM, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1034–5

Posterior aortoventricular bleeding after supra-annular stentless aortic valve replacement. Mediratta N, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1031–2

Homograft valve failure in children [letter; comment] Ross DB, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):1044–5. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):111–7.

Lower extremity hematoma as a complication of warfarinization in patients with artificial heart valves. Sakakibara Y, et al. **Jpn Heart J** 1999 Mar;40(2):239–45

Myocardial infarction caused by compression of anomalous circumflex coronary artery after mitral valve replacement. Speziale G, et al. **Minerva Cardioangiol** 1998 Nov; 46(11):455–6

Aorto-right ventricular fistula: a late complication of aortic valve replacement. Roy D, et al. **Tex Heart Inst J** 1999; 26(2):140–2

[Reoperations on prosthetic heart valves: an analysis of 64 cases] Zhang B, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jun;35(6):367–70 (Eng. Abstr.) **(Chi)**

[Orthopnea: not always of cardiac origin (see comments)] Oranen BI, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):921–4 (32 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jul 3;143(27):1443–4. **(Dut)**

[Iatrogenic left main coronary artery stenosis after aortic and mitral valve replacement] Zakrzewski D, et al. **Pol Arch Med Wewn** 1998 Jul;100(1):63–5 (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

Small aortic annulus: a functional definition. Ghosh P, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):251–61

Supraannular aortic root enlargement in patients with small aortic annulus: efficacy and safety. Shibata Y, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):262–5

Left ventricular mass regression after implantation of St. Jude Medical cardiac valves in small aortic roots. Murakami T, et al. **Artif Organs** 1998 Sep;22(9):740–5

Choosing a prosthetic heart valve. Wernly JA, et al. **Cardiol Clin** 1998 Aug;16(3):491–504 (59 ref.)

Stentless xenograft aortic valves. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):84–9 (17 ref.)

CarboMedics Prosthetic Heart Valve. Craver J. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S3–11; discussion S39–43

Stentless or stented aortic valve implants in elderly patients? Van Nooten G, et al. **Eur J Cardiothorac Surg** 1999 Jan; 15(1):31–6

Aortic valve replacement with stentless porcine bioprostheses. David TE. **J Card Surg** 1998 Sep–Oct; 13(5):344–51 (11 ref.)

Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. Del Rizzo DF, et al. **J Card Surg** 1998 Sep–Oct;13(5):398–407

The Cryolife-O'Brien stentless aortic porcine xenograft valve. O'Brien MF, et al. **J Card Surg** 1998 Sep–Oct; 13(5):376–85

The stentless porcine valve. Pepper JR, et al. **J Card Surg** 1998 Sep–Oct;13(5):352–9 (21 ref.)

Freestyle valve experience: technical considerations and mid-term results. Sintek CF, et al. **J Card Surg** 1998 Sep–Oct;13(5):360–8

Morphologic findings in explanted Hancock II porcine bioprostheses [see comments] Butany J, et al. **J Heart Valve Dis** 1999 Jan;8(1):4–15. Comment in: J Heart Valve Dis 1999 Jan;8(1):1–3.

Eighteen-year follow up after Hancock II bioprosthesis insertion [see comments] Legarra JJ, et al. **J Heart Valve Dis** 1999 Jan;8(1):16–24. Comment in: J Heart Valve Dis 1999 Jan;8(1):1–3.

The stentless quadrileaflet bovine pericardial mitral valve: early clinical results. Middlemost SJ, et al. **J Heart Valve Dis** 1999 Mar;8(2):174–9

Katarcioglu SF, Yamak B, Ulus AT, Tasdemir O, Bayazit K. Mitral valve replacement with St. Jude Medical prosthesis and low-dose anticoagulation in patients aged over 50 years. J. Heart Valve Dis 1998;7:455–459 [letter; comment] Sierra-Quiroga J, et al. **J Heart Valve Dis** 1999 Mar;8(2):232–3. Comment on: J Heart Valve Dis 1998 Jul;7(4):455–9.

The Hancock II xenograft: a step forward in bioprosthetic valve longevity? [editorial; comment] Thiene G, et al. **J Heart Valve Dis** 1999 Jan;8(1):1–3. Comment on: J Heart Valve Dis 1999 Jan;8(1):4–15. Comment on: J Heart Valve Dis 1999 Jan;8(1):16–24.

The medtronic intact porcine valve: ten-year clinical review. Barratt-Boyes BG, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1005–14

Experiences with the Toronto SPV bioprosthesis after three years follow-up. Strauch JT, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):19–22

METHODS

Management of small aortic roots. Doty JR, et al. **Adv Card Surg** 1998;10:175–96 (32 ref.)

Mitral valve replacement through dilated aortic annulus in Marfan's syndrome. Sirbu H, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):107–8

Ministernotomy versus median sternotomy for aortic valve replacement: a prospective, randomized study [see comments] Aris A, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1583–7; discussion 1587–8. Comment in: Ann Thorac Surg 1999 Jun;67(6):1545–6.

Reversed "C" ministernotomy for aortic valve replacement. Aris A. **Ann Thorac Surg** 1999 Jun;67(6):1806–7

A 23-year experience with composite valve graft replacement of the aortic root. Dossche KM, et al. **Ann Thorac Surg** 1999 Apr;67(4):1070–7

Minimally invasive mitral valve surgery: the subxiphoid approach. Karagoz HY, et al. **Ann Thorac Surg** 1999 May; 67(5):1328–32; discussion 1333

Aortic root replacement with the freestyle stentless porcine aortic root bioprosthesis. Kon ND, et al. **Ann Thorac Surg** 1999 Jun;67(6):1609–15; discussion 1615–6

Intravalvular implantation technique for aortic valve replacement in aortitis syndrome. Kotsuka Y, et al. **Ann Thorac Surg** 1999 Jan;67(1):89–92

Implantation of mechanical valves for infective endocarditis [letter; comment] Moro H, et al. **Ann Thorac Surg** 1998 Oct;66(4):1470. Comment on: Ann Thorac Surg 1998 Feb;65(2):359–64.

The "annular sandwich": a simple method of reinforcing a friable mitral valve annulus [letter; comment] Robicsek F. **Ann Thorac Surg** 1999 Jan;67(1):292. Comment on: Ann Thorac Surg 1998 Jun;65(6):1805–6.

Aortic valve replacement using circulatory arrest [letter; comment] Silberman S, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2158–9. Comment on: Ann Thorac Surg 1998 May;65(5):1313–5.

Left atrial wall plication for valve replacement in extensively calcified posterior mitral annulus [letter; comment] Triggiani M, et al. **Ann Thorac Surg** 1998 Dec;66(6):2157–8 . Comment on: Ann Thorac Surg 1997 Feb;63(2):570–1.

Detachable shape-memory sewing ring for heart valves. Jansen J, et al. **Artif Organs** 1992 Jun;16(3):294–7

Surgical treatment for aortic regurgitation caused by non-specific aortitis. Ando M, et al. **Cardiovasc Surg** 1999 Jun;7(4):409–13

Multivalvular surgery for infective endocarditis. Mueller XM, et al. **Cardiovasc Surg** 1999 Jun;7(4):402–8

Comparison of open mitral commissurotomy with mitral valve replacement with or without chordal preservation in patients with mitral stenosis. Glower DD, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II120–3

Acceptance and versatility of the Ross procedure. Oswalt JD. **Curr Opin Cardiol** 1999 Mar;14(2):90–4 (11 ref.)

Mitral valve replacement with preservation of the subvalvular apparatus. Reardon MJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):104–10 (49 ref.)

Aortic valve replacement through a limited bilateral thoracotomy in a patient with a tracheostoma [letter; comment] Abad C. **Eur J Cardiothorac Surg** 1999 Mar; 15(3):376–8. Comment on: Eur J Cardiothorac Surg 1998 Sep;14(3):338–9.

Utility of spiral CT in minimally invasive approach for aortic valve replacement. Ammar R, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S130–3

S-shaped in comparison to L-shaped partial sternotomy for less invasive aortic valve replacement. Autschbach R, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S117–21

Is the femoral cannulation for minimally invasive aortic valve replacement necessary? Cuenca J, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S111–4

Minimally invasive aortic valve replacement. Frazier BL, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S122–5

Cardiopulmonary bypass in sickle cell anaemia without exchange transfusion. Frimpong-Boateng K, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):527–9

New approach for replacement of degenerated mitral bioprostheses. Geha AS, et al. **Eur J Cardiothorac Surg** 1996;10(12):1090–6

Mitral valve operation via Port Access versus median sternotomy. Glower DD, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S143–7

Minimally invasive mitral valve surgery--clinical experiences with a PortAccess system. Gulielmos V, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S148–53

Clinical experiences with minimally invasive mitral valve surgery using a simplified Port Access technique. Gulielmos V, et al. **Eur J Cardiothorac Surg** 1998 Aug; 14(2):141–7

Long-term results of valve replacement using antibiotic-sterilised homografts in the aortic position. Langley SM, et al. **Eur J Cardiothorac Surg** 1996; 10(12):1097–105; discussion 1105–6

Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients. Li G, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):653–7

Minimally invasive aortic valve replacement without sternotomy. Experience with the first 50 cases. Minale C, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S126–9

Minimal access aortic valve surgery. Olin CL, et al. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S32–8; discussion S39–43

Video-assisted tricuspid valve surgery: a new surgical option in endocarditis on pacemaker. Robin J, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):243–5

A new approach to cardiac valve replacement through a small midline incision and inverted L shape partial sternotomy. Rodriguez JE, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S115–6

Lung volume reduction surgery combined with cardiac interventions. Schmid RA, et al. **Eur J Cardiothorac Surg** 1999 May;15(5):585–91

Minimally invasive aortic valve replacement via hemi-sternotomy: a preliminary report. Tam RK, et al. **Eur J Cardiothorac Surg** 1998 Oct;14 Suppl 1:S134–7

Minimally invasive aortic valve replacement through a transverse sternotomy: a word of caution. Bridgewater B, et al. **Heart** 1998 Jun;79(6):605–7

Surgical treatment for aortic regurgitation caused by Takayasu's arteritis Ando M, et al. **J Card Surg** 1998 May; 13(3):202–7

Minimally invasive aortic valve surgery: technical considerations and results with the parasternal approach. Cohn LH. **J Card Surg** 1998 Jul;13(4):302–5

Preferred method for insertion of the Toronto Stentless Porcine Valve. Cutrara CA, et al. **J Card Surg** 1998 Sep–Oct;13(5):408–11

Rest and exercise hemodynamics after the Ross procedure: an echocardiographic study. da Costa F, et al. **J Card Surg** 1998 May;13(3):177–85

Medtronic Freestyle aortic root bioprosthesis: Implant techniques. Doty DB, et al. **J Card Surg** 1998 Sep–Oct; 13(5):369–75

Aortic valve replacement with medtronic freestyle bioprosthesis: operative technique and results. Doty JR, et al. **J Card Surg** 1998 May;13(3):208–17

St. Jude SPV versus Medtronic Freestyle: a single institution comparison of two stentless aortic valves. Legare JF, et al. **J Card Surg** 1998 Sep–Oct;13(5):392–7

Mitral valve replacement in Sickle C disease using intraoperative exchange transfusion. Madan AK, et al. **J Card Surg** 1998 Jan;13(1):48–50

Aortic pulmonary autograft implant: medium-term follow-up with a note on a new right ventricular pulmonary artery conduit. Masetti P, et al. **J Card Surg** 1998 May;13(3):173–6

Aortic valve replacement with the Unique Suture Line Stentless USL porcine valve: A new, simple, and safe

stentless valve implantation technique. Navia JA.
J Card Surg 1998 Sep-Oct;13(5):386-91
Expanding the use of total mitral valve preservation in combination with implantation of the CarboMedics heart valve prosthesis. Aagaard J, et al.
J Cardiovasc Surg (Torino) 1999 Apr;40(2):177-81
Mitral valve surgery through right thoracotomy. Calleja F, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):49-52
Chordal sparing mitral valve replacement [editorial; comment] Frater RW. **J Heart Valve Dis** 1999 Jan;8(1):42-3 . Comment on: J Heart Valve Dis 1999 Jan;8(1):44-6.
Medtronic Hall versus St. Jude Medical mechanical aortic valve: downstream turbulences with respect to rotation in pigs. Kleine P, et al. **J Heart Valve Dis** 1998 Sep; 7(5):548-55
Left ventricular volume reduction for end-stage heart failure: intrapapillary or extrapapillary resection, mitral valve repair or replacement? Lim KH, et al.
J Heart Valve Dis 1998 Sep;7(5):484-7
Mechanical valve replacement in congenital heart disease in children. Lubiszewska B, et al. **J Heart Valve Dis** 1999 Jan;8(1):74-9
Extended vertical transseptal approach versus conventional left atriotomy for mitral valve surgery. Masiello P, et al. **J Heart Valve Dis** 1999 Jul;8(4):440-4
Distortion of the stentless porcine valve induces accelerated leaflet fibrosis and calcification in juvenile sheep. van Nooten G, et al. **J Heart Valve Dis** 1999 Jan;8(1):34-41
Early results with the Carbo-seal composite valve conduit for aortic root replacement. Vitale N, et al.
J Heart Valve Dis 1999 Jan;8(1):80-4
Mitral valve replacement with complete mitral leaflet retention: operative techniques [see comments] Yu Y, et al. **J Heart Valve Dis** 1999 Jan;8(1):44-6. Comment in: J Heart Valve Dis 1999 Jan;8(1):42-3.
Aortic valve surgery in osteogenesis imperfecta: report of two cases and review of the literature. Zegdi R, et al.
J Heart Valve Dis 1998 Sep;7(5):510-4 (30 ref.)
Long-term evaluation of orthotopically implanted stentless bioprosthetic aortic valves in juvenile sheep. Ouyang DW, et al. **J Invest Surg** 1998 May-Jun;11(3):175-83
Double annulus enlargement, Rastan-Manouguian's technique: a case report. Thongcharoen P, et al.
J Med Assoc Thai 1998 Dec;81(12):1034-9
Influence of aortic valve replacement, prosthesis type, and size on functional outcome and ventricular mass in patients with aortic stenosis. Bech-Hanssen O, et al.
J Thorac Cardiovasc Surg 1999 Jul;118(1):57-65
In situ implantation of a prosthetic systemic atrioventricular valve in corrected transposition. Elami A, et al.
J Thorac Cardiovasc Surg 1999 Jan;117(1):190-1
Structural valve deterioration in mitral replacement surgery: comparison of Carpentier-Edwards supra-annular porcine and perimount pericardial bioprostheses. Eric Jamieson WR, et al. **J Thorac Cardiovasc Surg** 1999 Aug; 118(2):297-304
Aortic homograft valve functioning for twenty-eight years in the tricuspid position [letter] Kawauchi M, et al.
J Thorac Cardiovasc Surg 1999 Aug;118(2):384-5
Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. Peterseim DS, et al.
J Thorac Cardiovasc Surg 1999 May;117(5):890-7
Combined surgery for mitral regurgitation associated with extensive annular calcification and left main coronary artery disease. Okamoto H, et al.
Jpn J Thorac Cardiovasc Surg 1998 Sep;46(9):821-4
Early experience of minimally invasive valve surgery. Iedokoro Y, et al. **Nippon Ika Daigaku Zasshi** 1998 Oct; 65(5):413-5
Monocusp valve in right ventricular outflow tract. Fiane AE, et al. **Scand Cardiovasc J** 1999;33(1):33-8
Aortic and mitral valve replacement through a minimally invasive approach. Klokočovnik T. **Tex Heart Inst J** 1998; 25(3):166-9
[Prevention and management of dysfunction of prosthetic heart valves] Körfer R, et al. **Herz** 1998 Nov;23(7):448-52 (6 ref.) (Eng. Abstr.) **(Ger)**
[Diagnosis and indication for aortic valve replacement in asymptomatic and symptomatic patients with aortic regurgitation] Mandinov L, et al. **Herz** 1998 Nov; 23(7):441-7 (18 ref.) (Eng. Abstr.) **(Ger)**
[Aortic valve operations through an upper partial sternotomy] Kiyama H, et al. **Kyobu Geka** 1999 Jul; 52(7):519-24; discussion 525-7 (Eng. Abstr.) **(Jpn)**
[Chylopericardium as a complication of mitral valve replacement] Rowiński A, et al. **Pol Merkuriusz Lek** 1999 Mar;6(33):141-2 (Eng. Abstr.) **(Pol)**
[Aortic valve prosthesis implantation from a mini approach] Belov IuV, et al. **Vestn Khir Im I I Grek** 1998;157(3):47-9 (Eng. Abstr.) **(Rus)**

MORTALITY

Gender differences in patients with severe aortic stenosis: impact on preoperative left ventricular geometry and function, as well as early postoperative morbidity and mortality. Bech-Hanssen O, et al.
Eur J Cardiothorac Surg 1999 Jan;15(1):24-30
Thirty-day mortality and long-term survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry. Edwards MB, et al.
Eur J Cardiothorac Surg 1998 Aug;14(2):156-64
Outcome and risk factors in octogenarians undergoing open-heart surgery. Sahar G, et al. **J Heart Valve Dis** 1999 Mar;8(2):162-6
Aortic disease in Marfan's syndrome [editorial; comment] Devereux RB, et al. **N Engl J Med** 1999 Apr 29; 340(17):1358-9. Comment on: N Engl J Med 1999 Apr 29;340(17):1307-13.
Replacement of the aortic root in patients with Marfan's syndrome [see comments] Gott VL, et al.
N Engl J Med 1999 Apr 29;340(17):1307-13. Comment in: N Engl J Med 1999 Apr 29;340(17):1358-9.
[Quality assessment indicators of cardiac surgeons' work; the validity of mortality rates] Dekker E, et al.
Ned Tijdschr Geneeskd 1998 Jun 13;142(24):1374-9 (Eng. Abstr.) **(Dut)**

NURSING

Telephone monitoring after early discharge for cardiac surgery patients. Savage LS, et al. **Am J Crit Care** 1999 May;8(3):154-9 (14 ref.)

REHABILITATION

Comparison between men and women admitted to an inpatient rehabilitation unit after cardiac surgery. Cristian A, et al. **Arch Phys Med Rehabil** 1999 Feb;80(2):183-5
[Treatment satisfaction in cardiologic rehabilitation and attitude to various forms of rehabilitation] Muthny FA, et al. **Rehabilitation (Stuttg)** 1999 May;38(2):72-8 (Eng. Abstr.) **(Ger)**
[Conventional heart surgery with the fast-track-method: experiences from a pilot study] Berdat P, et al.
Schweiz Med Wochenschr 1998 Oct 31;128(44):1737-42 (Eng. Abstr.) **(Ger)**
[Exercise capacity in children late after aortic valve replacement using the Konno procedure] Shimokawa T, et al. **Kyobu Geka** 1999 Apr;52(4):281-5 (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Actual failure rates: A method of assessing tissue valve reoperation rates. Khan S, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):108-13
Multiple valve replacement increases the risk of reoperation for structural degeneration of bioprostheses. Caus T, et al.
J Heart Valve Dis 1999 Jul;8(4):376-83
Correlations in uncertainty analysis for medical decision making: an application to heart-valve replacement. Chessa AG, et al. **Med Decis Making** 1999 Jul-Sep;19(3):276-86
[Incidence of thromboembolism after heart valve replacement: modifying factors] Burckhardt D, et al.
Z Kardiol 1998;87 Suppl 4:33-6 (11 ref.) (Eng. Abstr.) **(Ger)**
[Report on the structure and performance statistics of the heart catheterization laboratories in Germany. Results of a survey by the Committee of Clinical Cardiology of the German Society of Cardiology--Heart and Cardiovascular research throughout 1997] Gleichmann U, et al.
Z Kardiol 1999 Mar;88(3):234-6 **(Ger)**

TRENDS

Future directions in tissue heart valves: impact of recent insights from biology and pathology. Schoen FJ.
J Heart Valve Dis 1999 Jul;8(4):350-8 (95 ref.)

UTILIZATION

Why do so few older people with aortic stenosis have valve replacement surgery? Abdul-Hamid AR, et al.
Age Ageing 1999 May;28(3):261-4

HEART VALVES

ABNORMALITIES

Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota [see comments] Kimmel SE, et al. **Am J Cardiol** 1999 Aug 1; 84(3):304-8. Comment in: Am J Cardiol 1999 Aug 1;84(3):324-6, A8.
Accessory and anomalous atrioventricular valvar tissue causing outflow tract obstruction: surgical implications of a heterogeneous and complex problem. McElhinney DB, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1741-8
Mechanical valve replacement in congenital heart disease in children. Lubiszewska B, et al. **J Heart Valve Dis** 1999 Jan;8(1):74-9
The structure of the common atrioventricular valve in hearts having isomeric atrial appendages and double inlet ventricle. Uemura H, et al. **J Heart Valve Dis** 1998 Sep; 7(5):580-5

ANATOMY & HISTOLOGY

Laser-induced fluorescence (LIF) recognition of the structural composition of porcine heart valves. Christov AM, et al. **Photochem Photobiol** 1999 Mar;69(3):382-9

CYTOLOGY

Tissue engineering in cardiovascular surgery: MTT, a rapid and reliable quantitative method to assess the optimal human cell seeding on polymeric meshes. Zund G, et al.
Eur J Cardiothorac Surg 1999 Apr;15(4):519-24

EMBRYOLOGY

Development of the atrioventricular valve tension apparatus in the human heart. Oosthoek PW, et al.
Anat Embryol (Berl) 1998 Oct;198(4):317-29
Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Lakkis MM, et al. **Development** 1998 Nov;125(22):4359-67
Bisdiamine inhibits extracellular matrix formation and cell proliferation of atrioventricular mesenchyme from developing chick heart valves. Choy M, et al.
Teratology 1999 Mar;59(3):148-55

ENZYMOLOGY

Tetrazolium reductase activity in human heart valves [letter; comment] Villalba R, et al. **Ann Thorac Surg** 1998 Nov; 66(5):1864-5. Comment on: Ann Thorac Surg 1998 Jan;65(1):24-7.
Viability and enzymatic activity of cryopreserved porcine heart valve. Suh H, et al. **Yonsei Med J** 1999 Apr; 40(2):184-90

METABOLISM

High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Manduteanu I, et al.
Endothelium 1999;6(4):315-24

MICROBIOLOGY

Clinical and morphological characteristics in Streptococcus bovis endocarditis: a comparison with other causative microorganisms in 177 cases. Kupferwasser I, et al.
Heart 1998 Sep;80(3):276-80
Prosthetic ball valve endocarditis due to Gemella species. Ukimura A, et al. **Jpn Circ J** 1998 Aug;62(8):626-8

PATHOLOGY

Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography. Nighoghossian N, et al. **Am Heart J** 1998 Dec; 136(6):1065-9
Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Vogt PR, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):639-44; discussion 644-5
Distortion of the stentless porcine valve induces accelerated leaflet fibrosis and calcification in juvenile sheep. van Nooten G, et al. **J Heart Valve Dis** 1999 Jan;8(1):34-41

PHYSIOLOGY

Effect of storage temperature on cell viability in cryopreserved canine aortic, pulmonic, mitral, and tricuspid valve homografts. Kashima I, et al.
Jpn J Thorac Cardiovasc Surg 1999 Apr;47(4):153-7
Laser-induced fluorescence (LIF) recognition of the structural composition of porcine heart valves. Christov AM, et al. **Photochem Photobiol** 1999 Mar;69(3):382-9
Problems in preservation of allogeneic heart values and vessels. Ohkado A, et al. **Transplant Proc** 1999 Aug; 31(5):2047-8
Viability and enzymatic activity of cryopreserved porcine heart valve. Suh H, et al. **Yonsei Med J** 1999 Apr; 40(2):184-90

PHYSIOPATHOLOGY

Long term follow-up of atrioventricular valve function after repair of atrioventricular septal defect. Kameyama T, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):101-6
Effects of obesity and weight loss on cardiac function and valvular performance. Karason K, et al. **Obes Res** 1998 Nov;6(6):422-9

SURGERY

Analysis of risk factors for development of atrial fibrillation early after cardiac valvular surgery. Asher CR, et al.
Am J Cardiol 1998 Oct 1;82(7):892-5
Comparison of quality of life after coronary and/or valvular cardiac surgery in patients > or =75 years of age with younger patients. Heijmeriks JA, et al. **Am J Cardiol** 1999 Apr 1;83(7):1129-32, A9
Ineffectiveness of burst suppression therapy in mitigating perioperative cerebrovascular dysfunction. Multicenter Study of Perioperative Ischemia (McSPI) Research Group [see comments] Roach GW, et al. **Anesthesiology** 1999 May; 90(5):1255-64. Comment in: Anesthesiology 1999 May;90(5):1243-7.
Improving early and intermediate results of truncus arteriosus repair: a new technique of truncal valve repair. Imamura M, et al. **Ann Thorac Surg** 1999 Apr;67(4):1142-6
Lack of association between factor V Leiden and thromboembolism in patients with prosthetic heart valves. Mammo L, et al. **Blood Coagul Fibrinolysis** 1999 Apr; 10(3):141-4
Decreasing incidence of stroke during valvular surgery. Borger MA, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II137-43

Low systemic vascular resistance state in patients undergoing cardiopulmonary bypass [see comments] Kristof AS, et al. **Crit Care Med** 1999 Jun;27(6):1121-7. Comment in: Crit Care Med 1999 Jun;27(6):1048-50.

Accessory and anomalous atrioventricular valvar tissue causing outflow tract obstruction: surgical implications of a heterogeneous and complex problem. McElhinney DB, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1741-8

Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. Zhou M, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):355-61

Effectiveness of continuous warm blood cardioplegia in cardiac valve re-replacement. Nagaoka H, et al. **J Heart Valve Dis** 1999 Mar;8(2):124-30

Benefits and pitfalls of warm blood cardioplegia in heart valve replacement: systemic protective effects. Yuan SM. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Oct; 14(10):616-24

Inflammatory reactions following homograft insertion in children with congenital heart disease. Atiq M, et al. **Scand Cardiovasc J** 1998;32(5):285-8

TRANSPLANTATION

Canadian contributions to heart valve transplantation for cardiac valve replacement. Heimbecker RO. **Can J Cardiol** 1999 May;15(5):585-6

Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Vogt PR, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):639-44; discussion 644-5

Tissue engineering: a new approach in cardiovascular surgery--seeding of human fibroblasts on resorbable mesh. Hoerstrup SP, et al. **Swiss Surg** 1998;Suppl 2:23-5

ULTRASONOGRAPHY

Course of valvular strands in patients with stroke: cooperative study with transesophageal echocardiography. Nighoghossian N, et al. **Am Heart J** 1998 Dec; 136(6):1065-9

The role of intraoperative echocardiography in valve surgery. Grimm RA, et al. **Cardiol Clin** 1998 Aug; 16(3):477-89, ix (70 ref.)

Eustachian valve endocarditis diagnosed by transoesophageal echocardiography. James PR, et al. **Heart** 1999 Jan;81(1):91

[Segmentation-based movement estimation in ultrasound images] Reise F, et al. **Biomed Tech (Berl)** 1998;43 Suppl:472-3 **(Ger)**

ULTRASTRUCTURE

Bioprosthetic heart valves--replacing order with chaos: electron microscopic study. Datta D, et al. **Artif Organs** 1999 Apr;23(4):372-6

HEART VENTRICLE

see related
VENTRICULAR FUNCTION
VENTRICULAR PRESSURE

Repair of ventricular aneurysm. Dor V. **Adv Card Surg** 1998; 10:25-41

Transmural microcirculatory blood flow distribution in right and left ventricular free walls of rabbits. Matsumoto T, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H183-91

Mobilization of the anterior mitral leaflet for excision of a left ventricular myxoma. Talwalkar NG, et al. **Ann Thorac Surg** 1999 May;67(5):1476-8

Novel ventricular apical cannula: in vitro evaluation using transparent, compliant ventricular casts. Curtis AS, et al. **ASAIO J** 1998 Sep-Oct;44(5):M691-5

Huge false aneurysm of left ventricular posterior wall following resection of an aneurysm of the left ventricular posterior wall [letter] Dubel HP, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):509-10

Relief of right ventricular to pulmonary artery conduit stenosis using a self-expanding stent. Frias PA, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):52-4

Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. Spinale FG, et al. **Circ Res** 1999 Aug 20;85(4):364-76

Influence of thrombolytic therapy on the incidence of left ventricular thrombi after acute anterior myocardial infarction: role of successful reperfusion. Ileri M, et al. **Clin Cardiol** 1999 Jul;22(7):477-80

Pseudoaneurysm of the left ventricle after isolated pericarditis and Staphylococcus aureus septicemia. de Boer HD, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):97-9

Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functional results. Di Mattia DG, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):413-8

Calcified subaortic left ventricular aneurysm causing right pulmonary artery obstruction in a child. Mohan JC, et al. **Int J Cardiol** 1998 Sep 30;66(2):195-7

Totally implantable artificial hearts and left ventricular assist devices: selecting impermeable polycarbonate urethane to manufacture ventricles. Yang M, et al. **J Biomed Mater Res** 1999 Spring;48(1):13-23

Interaction between atrial pacing lead and epicardial ventricular wire resulting in unintended ventricular capture by pacemaker atrial output. Chen PS. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):1031

Regulation of gene expression: how can molecules make the right ventricle distinct from the left? Ross RS. **J Nucl Cardiol** 1998 Nov-Dec;5(6):609-21 (11 ref.)

Left coronary artery-left ventricle fistula with right coronary artery spasm. Komukai K, et al. **Jpn Circ J** 1998 Sep; 62(9):704-6

A case of dislodged atrial screw-in lead with migration to the ventricle 1 year postoperatively. Nakazato Y, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):831-2

Ventricular myxoma presenting as acute visual loss. Abo-Auda WS, et al. **Tenn Med** 1998 Oct;91(10):391-2

Recurrent pseudoaneurysm of the left ventricle with subcutaneous herniation into the chest wall. A case report. Rao MS, et al. **Tex Heart Inst J** 1998;25(4):309-11

Successful thrombolysis in massive pulmonary embolism with right ventricular thrombus. Brodmann M, et al. **Vasa** 1998 Nov;27(4):244-6

[Rupture of a sinus of Valsalva aneurysm into the right ventricle. A case report in the cardiology clinic at the University Hospital Center of Dakar] Diop IB, et al. **Dakar Med** 1996;41(2):91-7 (Eng. Abstr.) **(Fre)**

[Right ventricle-dependent coronary circulation in pulmonary atresia with intact ventricular septum. Absence of origin of the coronary arteries from the aorta] Rivera IR, et al. **Arq Bras Cardiol** 1998 Aug;71(2):143-6 (Eng. Abstr.) **(Por)**

[Removal of a foreign body from the right heart ventricle without diversion of blood circulation] Kuksinskii VE, et al. **Vestn Khir Im I I Grek** 1999;158(3):76 **(Rus)**

ABNORMALITIES

Clinical, echocardiographic, and angiographic profile of patients with double-chambered right ventricle: experience with 48 cases. Singh M, et al. **Angiology** 1999 Mar; 50(3):223-31

The modified Fontan procedure: morphometry and surgical implications. Kiaffas MG, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1746-53

Novel techniques of bidirectional Glenn shunt without cardiopulmonary bypass. Murthy KS, et al. **Ann Thorac Surg** 1999 Jun;67(6):1771-4

Staged surgical approach to neonates with aortic obstruction and single-ventricle physiology. Odim JN, et al. **Ann Thorac Surg** 1999 Sep;68(3):962-7; discussion 968

Technique for repair of single-ventricle hearts with transposition of the great arteries and aortic arch hypoplasia. Thistlewaite PA, et al. **Ann Thorac Surg** 1999 Jan;67(1):260-2

As originally published in 1992: Aortic allografts: reconstruction of right ventricle-pulmonary artery continuity. Updated in 1999. Turley K. **Ann Thorac Surg** 1999 Jul;68(1):289-90

Aortico-right ventricular tunnel. Vargas FJ, et al. **Ann Thorac Surg** 1998 Nov;66(5):1793-5

Monocusp valve and transannular patch reconstruction of the right ventricular outflow tract: an experimental study. Scavo VA Jr, et al. **ASAIO J** 1998 Sep-Oct;44(5):M480-5

Predictive value of pulmonary venous flow patterns in detecting mitral regurgitation and left ventricular abnormalities. Hynes MS, et al. **Can J Cardiol** 1999 Jun; 15(6):665-70 (24 ref.)

Pulmonary arteriovenous fistulas in patients with left isomerism and cardiac malformations [editorial; comment] Amodeo A, et al. **Cardiol Young** 1998 Jul;8(3):283-4. Comment on: Cardiol Young 1998 Jul;8(3):290-4.

An unusual tethering of the bridging leaflets in atrioventricular septal defect producing a communication from left atrium to right ventricle. Delgado C, et al. **Cardiol Young** 1999 Jan;9(1):84-7

Pulmonary and systemic arteriovenous fistulas in patients with left isomerism [see comments] Kawata H, et al. **Cardiol Young** 1998 Jul;8(3):290-4. Comment in: Cardiol Young 1998 Jul;8(3):283-4.

Double-outlet right ventricle with intact ventricular septum in a foetus with trisomy-18. Patel CR, et al. **Cardiol Young** 1999 Jul;9(4):419-22

Isolated left ventricular abnormal trabeculation in adults is associated with neuromuscular disorders. Stöllberger C, et al. **Clin Cardiol** 1999 Feb;22(2):119-23

Isolated congenital left ventricular diverticulum [letter] Bogers AJ. **Eur J Cardiothorac Surg** 1996;10(12):1147

Double chambered right ventricle: delineation by multiplane transoesophageal echocardiography. Sreeram N, et al. **Int J Cardiol** 1998 Oct 30;66(3):309-11

Aortico-right ventricular tunnel. Talwar S, et al. **Int J Cardiol** 1999 Jul 31;70(2):201-5 (11 ref.)

From functional pulmonary atresia to right ventricular restriction. Long term follow up of Uhl's anomaly. Tumbarello R, et al. **Int J Cardiol** 1998 Dec 1;67(2):161-4

The structure of the common atrioventricular valve in hearts having isomeric atrial appendages and double inlet ventricle. Uemura H, et al. **J Heart Valve Dis** 1998 Sep; 7(5):580-5

Familial isolated noncompaction of ventricular myocardium. Matsuda M, et al. **J Hum Genet** 1999;44(2):126-8

Cardiac laterality and ventricular looping in retinoic acid-treated rat embryos. Kim JS, et al. **J Korean Med Sci** 1999 Apr;14(2):138-46

Multiple spontaneously occurring coronary artery-left ventricular communications: a case report. Lipoff JI. **J Ky Med Assoc** 1999 May;97(5):208-10

The nature of the obstructive muscular bundles in double-chambered right ventricle. Alva C, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1180-9

Long-term outcome of infants with single ventricle and total anomalous pulmonary venous connection. Gaynor JW, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):506-13; discussion 513-4

Pulmonary artery growth after systemic-to-pulmonary shunt in children with a univentricular heart and a hypoplastic pulmonary artery bed. Implications for Fontan surgery. Borowski A, et al. **Jpn Heart J** 1998 Sep;39(5):671-80

Isolated noncompaction of the myocardium [letter] Jenni R, et al. **N Engl J Med** 1999 Mar 25;340(12):966-7

Permanent pacing in patients with univentricular heart. Warfield DA, et al. **Pacing Clin Electrophysiol** 1999 Aug; 22(8):1193-201

Doppler echocardiography with extended transesophageal atrial pacing: predicting the efficacy of permanent atrial pacing in the patient with a small left ventricle and sinus node dysfunction. Liske MR, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):218-20

Recent advances in the surgical management of the single ventricle pediatric patient. Tweddell JS, et al. **Pediatr Clin North Am** 1999 Apr;46(2):465-80, xii (52 ref.)

The influence of different strategies on clinical outcome in patients undergoing total cavopulmonary connection. Knez I, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):101-5

[Development of double-chambered right ventricle after surgical closure of a ventricular septal defect] Massin M. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):579-81 (Eng. Abstr.) **(Fre)**

[Single ventricle (cor trilocular biatriatum). A case report] Roos G, et al. **Pathologe** 1998 Nov;19(6):430-5 (27 ref.) (Eng. Abstr.) **(Ger)**

[Adult case of isolated noncompaction of left ventricular myocardium revealed at hospitalization for tuberculous pleuritis] Tanaka N, et al. **J Cardiol** 1999 Mar;33(3):169-74 (Eng. Abstr.) **(Jpn)**

[The role of bidirectional cavopulmonary shunt on selection of Fontan patients] Cho Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1317-23 (Eng. Abstr.) **(Jpn)**

[A successful case report of one and one half ventricle repair for pure pulmonary stenosis in a 4-year-old girl] Kawasaki M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep; 46(9):933-8 (Eng. Abstr.) **(Jpn)**

[Double chambered right ventricle in a 62-year-old female: a surgical case report] Gon S, et al. **Kyobu Geka** 1999 Sep; 52(10):850-2 (Eng. Abstr.) **(Jpn)**

[Absence of right atrioventricular connection. Morphological and clinical presentation when the dominant ventricle is morphologically right] Cavalini JF, et al. **Arq Bras Cardiol** 1998 Dec;71(6):793-6 (Eng. Abstr.) **(Por)**

ANATOMY & HISTOLOGY

Effect of dobutamine on regional left ventricular function measured by tagged magnetic resonance imaging in normal subjects. Scott CH, et al. **Am J Cardiol** 1999 Feb 1; 83(3):412-7

Structure and vascularization of the ventricular myocardium of Piaractus mesopotamicus and Clarias gariepinus (Teleostei). Simões K, et al. **Anat Histol Embryol** 1999 Aug; 28(4):243-6

Physiologic left ventricular cavity dilatation in elite athletes. Pelliccia A, et al. **Ann Intern Med** 1999 Jan 5;130(1):23-31

Ventricular morphology and coronary arterial anatomy in hearts with isometric atrial appendages. Uemura H, et al. **Ann Thorac Surg** 1999 May;67(5):1403-11

An echocardiographic study of right ventricular adaptation to physical exercise in elite male orienteers. Henriksen E, et al. **Clin Physiol** 1998 Nov;18(6):498-503

On the human left ventricular shape. Azhari H, et al. **Comput Biomed Res** 1999 Jun;32(3):264-82

Right ventricular volumes revisited: a simple model and simple formula for echocardiographic determination. Denslow S, et al. **J Am Soc Echocardiogr** 1998 Sep; 11(9):864-73

MR gradient echo volumetric analysis of human cardiac casts: focus on the right ventricle. Jauhiainen T, et al. **J Comput Assist Tomogr** 1998 Nov-Dec;22(6):899-903

Structural association between the carotid artery and the left ventricle in a general population in Northern Italy: the Vobarno study. Muiesan ML, et al. **J Hypertens** 1998 Dec; 16(12 Pt 1):1805-12

The relationship between R amplitude in lead V5 (RV5) and left ventricular mass in the groups of adolescent subjects classified by body composition. Sugita S, et al. **Jpn Circ J** 1998 Dec;62(12):893-9

Ventricular pressure and dimension measurements in mice. Miyamoto MI, et al. **Lab Anim Sci** 1999 Jun;49(3):305-7

Analysis of left ventricular wall motion based on volumetric deformable models and MRI-SPAMM. Park J, et al. **Med Image Anal** 1996 Mar;1(1):53-71

Impact of transvenous lead position on active-can ICD defibrillation: a computer simulation study. Aguel F, et al. **Pacing Clin Electrophysiol** 1999 Jan;22(1 Pt 2):158-64

Koch's triangle in pediatric age: correlation with extra- and intracardiac parameters. Francalanci P, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1576-9

Koch's triangle sized up: anatomical landmarks in perspective of catheter ablation procedures. Inoue S, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1553–8

Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy. Vetter FJ, et al. **Prog Biophys Mol Biol** 1998;69(2–3):157–83 (142 ref.)

CYTOLOGY

Four different components contribute to outward current in rat ventricular myocytes. Himmel HM, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H107–18

Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Carrier RL, et al. **Biotechnol Bioeng** 1999 Sep 5;64(5):580–9

Bay K 8644 increases resting Ca2+ spark frequency in ferret ventricular myocytes independent of Ca influx: contrast with caffeine and ryanodine effects. Satoh H, et al. **Circ Res** 1998 Dec 14–28;83(12):1192–204

Extracellular K+ dependence of inward rectification kinetics in human left ventricular cardiomyocytes. Bailly P, et al. **Circulation** 1998 Dec 15;98(24):2753–9

Effects of ischemia on discontinuous action potential conduction in hybrid pairs of ventricular cells. Wilders R, et al. **Circulation** 1999 Mar 30;99(12):1623–9

Angiotensin II and intracellular calcium of adult cardiac fibroblasts. Brilla CG, et al. **J Mol Cell Cardiol** 1998 Jun; 30(6):1237–46

Cytochalasin D alters kinetics of Ca2+ transient in rat ventricular cardiomyocytes: an effect of altered actin cytoskeleton? Undrovinas AI, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1665–70

Characteristics of two slow inactivation mechanisms and their influence on the sodium channel activity of frog ventricular myocytes. Furue T, et al. **Pflugers Arch** 1998 Oct;436(5):631–8

DRUG EFFECTS

Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Tomoda H. **Am J Cardiol** 1999 Jan 1;83(1):123–5, A9

Effects of age and hypertension on cardiac responses to the alpha1-agonist phenylephrine in humans. White M, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):151–8

Right ventricular size is acutely decreased by inhaled nitric oxide in newborns with pulmonary hypertension. Day RW. **Am J Perinatol** 1998 Jul;15(7):445–51

Post-rest contraction amplitude in myocytes from failing human ventricle. Davia K, et al. **Basic Res Cardiol** 1998; 93 Suppl 1:33–7

Enhancing effects of salicylate on tonic and phasic block of Na+ channels by class 1 antiarrhythmic agents in the ventricular myocytes and the guinea pig papillary muscle. Tanaka Y, et al. **Biochim Biophys Acta** 1999 May 12; 1418(2):320–34

Action potential shortening through the putative beta4-adrenoceptor in ferret ventricle: comparison with beta1- and beta2-adrenoceptor-mediated effects. Lowe MD, et al. **Br J Pharmacol** 1998 Aug;124(7):1341–4

Effects of U-50,488H withdrawal on catecholaminergic neurones of the rat ventricle. Milanés MV, et al. **Br J Pharmacol** 1998 Jul;124(6):1060–4

Different effects of gadolinium on I(KR), I(KS) and I(K1) in guinea-pig isolated ventricular myocytes. Pascarel C, et al. **Br J Pharmacol** 1998 May;124(2):356–60

Taurine modulates I(Kr) but I(Ks) in guinea-pig ventricular cardiomyocytes. Satoh H. **Br J Pharmacol** 1999 Jan; 126(1):87–92

Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Wettwer E, et al. **Br J Pharmacol** 1998 Oct;125(4):659–66

Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol. Matsui K, et al. **Cardiovasc Drugs Ther** 1999 Apr;13(2):105–13

Effects of myosin heavy chain isoform switching on Ca2+-activated tension development in single adult cardiac myocytes. Metzger JM, et al. **Circ Res** 1999 Jun 11;84(11):1310–7

Bay K 8644 increases resting Ca2+ spark frequency in ferret ventricular myocytes independent of Ca influx: contrast with caffeine and ryanodine effects. Satoh H, et al. **Circ Res** 1998 Dec 14–28;83(12):1192–204

Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Kaumann A, et al. **Circulation** 1999 Jan 5–12;99(1):65–72

Effect of phosphorylation on L-type calcium current in ventricular myocytes dialysed with proteolytic enzymes. Dooley PC, et al. **Clin Exp Pharmacol Physiol** 1999 Feb; 26(2):109–16

Propafenone blocks ATP-sensitive K+ channels in rabbit atrial and ventricular cardiomyocytes. Christé G, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):223–32

Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes. Ikeda S, et al. **Eur J Pharmacol** 1998 Sep 18; 357(2–3):243–50

Carbachol inhibition of Ca2+ currents in ventricular cells obtained from neonatal and adult rats. Katsube Y, et al. **Eur J Pharmacol** 1998 Oct 9;358(3):269–75

Na+ channel blocking effects of cibenzoline on guinea-pig ventricular cells. Niwa R, et al. **Eur J Pharmacol** 1998 Jul 10;352(2–3):317–27

Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Novakova M, et al. **Eur J Pharmacol** 1998 Jul 24; 353(2–3):315–27

Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels. Uneyama H, et al. **Eur J Pharmacol** 1999 May 28;373(1):93–100

Role of nitric oxide production in carbachol-induced negative chronotropy in cultured rat ventricular myocytes. Yamamoto S, et al. **Eur J Pharmacol** 1999 Jan 29; 366(1):111–8

Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. Dougherty C, et al. **FASEB J** 1998 Dec;12(15):1785–92

Antiarrhythmic effects of magnesium on rat papillary muscle and guinea pig ventricular myocytes. Aomine M, et al. **Gen Pharmacol** 1999 Jan;32(1):107–14

The offset of beta-adrenoceptor antagonism of the responses of the rat right ventricle to isoprenaline. Doggrell SA, et al. **J Auton Pharmacol** 1998 Oct;18(5):263–9

Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists. Montessuit C, et al. **J Biol Chem** 1999 Mar 26; 274(13):9006–12

Can chemical ablation of ventricular myocardium with ethanol surpass radiofrequency catheter ablation? [editorial; comment] Inoue H. **J Cardiovasc Electrophysiol** 1998 Sep; 9(9):985–7. Comment on: J Cardiovasc Electrophysiol 1998 Sep;9(9):976–84.

Retrograde coronary venous infusion of ethanol for ablation of canine ventricular myocardium [see comments] Wright KN, et al. **J Cardiovasc Electrophysiol** 1998 Sep;9(9):976–84 . Comment in: J Cardiovasc Electrophysiol 1998 Sep;9(9):985–7.

Mechanism of block of cardiac transient outward K+ current (I(to)) by antidepressant drugs. Casis O, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):527–34

Inhibition by fendiline of the transient outward current in rat ventricular cardiomyocytes. Fassbender V, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):905–11

Effects of the calcium sensitizer [+]-EMD 60263 and its enantiomer [-]-EMD 60264 on cardiac ionic currents of guinea pig and rat ventricular myocytes. Himmel HM, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):301–8

Multiple mechanisms are involved in the acute vasodilatory effect of 17beta-estradiol in the isolated perfused rat heart. Hügel S, et al. **J Cardiovasc Pharmacol** 1999 Jun; 33(6):852–8

Effect of bepridil on intracellular calcium concentration and contraction in cultured rat ventricular myocytes. Ozaki H, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):492–9

Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects. Klingbeil AU, et al. **J Hypertens** 1999 Jun;17(6):825–33

Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients. Beltman F, et al. **J Hypertens Suppl** 1998 Oct;16(6):S15–9

Effects of isoproterenol on twitch contraction of wild type and phospholamban-deficient murine ventricular myocardium. Pan BS, et al. **J Mol Cell Cardiol** 1999 Jan; 31(1):159–66

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. Sato S, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1115–28

Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with beta-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle. Sawada H, et al. **J Mol Cell Cardiol** 1999 May; 31(5):1047–62

Cellular basis for the acute inhibitory effects of IL-6 and TNF- alpha on excitation-contraction coupling. Sugishita K, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1457–67

Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. Nishio M, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):293–300

Lack of protective effects of adenosine on the hypoxic and reoxygenated atria and ventricular strips of the rat. Varela A, et al. **J Physiol Biochem** 1999 Mar;55(1):17–23

Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Kimura J, et al. **Jpn J Pharmacol** 1999 Mar;79(3):275–81

YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi. Suzuki M, et al. **Jpn J Pharmacol** 1998 Jul;77(3):177–83

Effects of K+ channel modulators on the relationship between action potential duration and Ca2+ transients in single ventricular myocytes of the guinea pig. Tokuno T, et al. **Jpn J Pharmacol** 1999 Jul;80(3):243–53

Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats. Seki T, et al. **Life Sci** 1999;65(10):1077–86

High affinity regulation of cardiac Cl- and Ca2+ conductances by (13R)-spiroforskolin. Traebert M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Nov; 358(5):538–46

Mid- and long-term similarity of ventricular response to paroxysmal atrial fibrillation: digoxin versus placebo. Hnatkova K, et al. **Pacing Clin Electrophysiol** 1998 Sep; 21(9):1735–40

Steady-state and dynamic behavior of ventricular repolarization and refractoriness in the dog: the effect of multiple cycle length changes and d-sotalol administration. Leerssen HM, et al. **Pacing Clin Electrophysiol** 1998 Sep; 21(9):1766–77

2,3-Butanedione monoxime (BDM) decreases sarcoplasmic reticulum Ca content by stimulating Ca release in isolated rat ventricular myocytes. Adams W, et al. **Pflugers Arch** 1998 Oct;436(5):776–81

Estimation of myofibrillar responsiveness to Ca2+ in isolated rat ventricular myocytes. Hongo K, et al. **Pflugers Arch** 1998 Oct;436(5):639–45

Rapid effects of cytochalasin-D on contraction and intracellular calcium in single rat ventricular myocytes. Howarth FC, et al. **Pflugers Arch** 1998 Oct;436(5):804–6

Calcium influx inhibition: possible mechanism of the negative effect of tetrahydropalmatine on left ventricular pressure in isolated rat heart. Chan P, et al. **Planta Med** 1999 May; 65(4):340–2

Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Müller A, et al. **Planta Med** 1999 May;65(4):335–9

Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91–7

[Effect of renitek--an ACE inhibitor--versus cozaar--an angiotensin I receptors antagonists--on morphofunctional state of left ventricular myocardium in patients with symptomatic cardiac insufficiency] Vizir VA, et al. **Klin Med (Mosk)** 1999;77(3):20–2 (Eng. Abstr.) **(Rus)**

[Effect of metoprolol on ventricular relaxation in experimental myocardial infarction] Meaney-Mendiolea E, et al. **Gac Med Mex** 1998 Nov-Dec;134(6):661–7 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Expression of extracellular matrix components fibronectin and laminin in the human fetal heart. Kim H, et al. **Cell Struct Funct** 1999 Feb;24(1):19–26

Downregulation of atrial markers during cardiac chamber morphogenesis is irreversible in murine embryos. Gruber PJ, et al. **Development** 1998 Nov;125(22):4427–38

Morphological maturation of left ventricle in fetal rats: changes in left ventricular volume, mass, wall thickness, and mitral valvular size. Ito T, et al. **Early Hum Dev** 1998 Nov;53(1):1–7

Ventricular myocardium in control and growth-retarded human fetuses: growth in different tissue compartments and variation with fetal weight, gestational age, and ventricle size. Mayhew TM, et al. **Hum Pathol** 1999 Jun;30(6):655–60

Regulation of chamber-specific gene expression in the developing heart by Irx4. Bao ZZ, et al. **Science** 1999 Feb 19;283(5405):1161–4

Patterning during organogenesis: genetic analysis of cardiac chamber formation. Yelon D, et al. **Semin Cell Dev Biol** 1999 Feb;10(1):93–8 (31 ref.)

ENZYMOLOGY

Cardiac angiotensin-converting enzyme activity in myocardial infarction. Sumida H, et al. **Am J Cardiol** 1999 Oct 1;84(7):774–8

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Wallis RM, et al. **Am J Cardiol** 1999 Mar 4;83(5A):3C–12C

Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Kobayashi N, et al. **Am J Hypertens** 1999 May;12(5):483–91

An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. Mackay K, et al. **J Biol Chem** 1999 Mar 5;274(10):6272–9

Calcium-independent phospholipase A2 in isolated rabbit ventricular myocytes. McHowat J, et al. **Lipids** 1998 Dec; 33(12):1203–12

GROWTH & DEVELOPMENT

Changes in ventricular and muscle volumes of neonates. Ichihashi K, et al. **Pediatr Int** 1999 Feb;41(1):8–12

INJURIES

Reducing the risk of perforation of the right ventricle during Port-Access minimally invasive cardiac procedures [letter; comment] Ortega RA, et al. **Anesthesiology** 1999 Apr; 90(4):1233–4. Comment on: Anesthesiology 1998 Aug;89(2):519–21.

Left ventricular free wall rupture following mitral valve replacement. Yoshida K, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):336–9 (12 ref.)

Repair of left ventricular rupture after mitral valve replacement: use of a Teflon patch and glue. de la Fuente A, et al. **Ann Thorac Surg** 1999 Jun;67(6):1802–3

Penetrating trauma to the tricuspid valve and ventricular

septum: delayed repair. Doty JR, et al. **Ann Thorac Surg** 1999 Jan;67(1):252–3

Successful repair of blunt cardiac rupture involving both ventricles. Duda AM, et al. **Cardiovasc Surg** 1999 Mar; 7(2):263–5

Perforation of the right ventricle by a suction drain. Uppal RS, et al. **Cardiovasc Surg** 1999 Mar;7(2):261–2

Rural thoracotomy that had to be done [letter] Mhaka RJ. **Cent Afr J Med** 1998 Aug;44(8):208–10

Kirschner wire embolization to the heart: an unusual cause of pericardial tamponade. Goodsett JR, et al. **Chest** 1999 Jan;115(1):291–3

Perforation of the right ventricle: a complication of blind placement of a chest tube into the postpneumonectomy space. Kopec SE, et al. **Chest** 1998 Oct;114(4):1213–5

Nail gun penetrating injury of the left ventricle and descending aorta. Wang MJ, et al. **Circulation** 1999 Jul 20; 100(3):e18–9

Cardiac injury from an air gun pellet: a case report. Alaminos Mingorance M, et al. **Eur J Pediatr Surg** 1999 Jun; 9(3):184–5

Erosion of the left ventricle by the epicardial patch of an automatic implantable cardioverter defibrillator. Sutton AG, et al. **Heart** 1999 Jul;82(1):112–3

Left ventricular thrombus after seat-belt-related chest trauma. Hung MJ, et al. **J Trauma** 1999 Sep;47(3):599–601

Pericardial drainage prior to operation contributes to surgical repair of traumatic cardiac injury. Sugimoto S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jan;47(1):31–5

Perforation of the right ventricular free wall by an active fixation transvenous cardioverter defibrillator lead. Shohat-Zabarski R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1118–9

Recovery after prolonged cross-clamping tepid blood cardioplegia: report of a case. Katoh T, et al. **Surg Today** 1998;28(10):1095–7

[Cardiac perforation by a gastric ulcer: an unusual cause of death, after an esophageal and gastric resection of an epidermoid esophageal carcinoma] Luthi F, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):59–62 (Eng. Abstr.) **(Fre)**

[Acute vascular perforation with shunt formation in the right ventricle after percutaneous transluminal coronary angioplasty. Magnetic resonance tomography and Doppler ultrasound detection of shunt flow] Wittlinger T, et al. **Z Kardiol** 1998 Jul;87(7):553–9 (Eng. Abstr.) **(Ger)**

[Blunt traumatic rupture of right ventricle and pericardium] Nishikawa T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Aug;46(8):781–4 (Eng. Abstr.) **(Jpn)**

[A case of right ventricular rupture due to blunt trauma] Yano H, et al. **Kyobu Geka** 1999 May;52(5):360–3 (Eng. Abstr.) **(Jpn)**

[Penetrating gunshot wound of left heart ventricle] Nosov SS, et al. **Khirurgiia (Mosk)** 1998;(12):55 **(Rus)**

[Totally implantable venous systems and cardiac tamponade. Apropos of a case (letter)] Casas Garcia MC, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):48–9 **(Spa)**

INNERVATION

Neuropeptide Y contributes to innervation-dependent increase in I(Ca, L) via ventricular Y2 receptors. Protas L, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H940–6

Intraventricular conduction delay: a prognostic marker in chronic heart failure. Shamim W, et al. **Int J Cardiol** 1999 Jul 31;70(2):171–8

Structure and location of accessory muscular atrioventricular connections [editorial; comment] Anderson RH, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1119–23 (20 ref.). Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1112–8.

Calcium antagonists and sympathetic activity in congestive heart failure. Grassi G, et al. **J Hypertens Suppl** 1998 Oct; 16(6):S9–14 (43 ref.)

Decreasing parasympathetic tone activity and proarrhythmic effect after radiofrequency catheter ablation--differences in ablation site. Jinbo Y, et al. **Jpn Circ J** 1998 Oct; 62(10):733–40

METABOLISM

Expression and function of atrial myosin light chain 1 in the porcine right ventricle of normal and pulmonary hypertensive animals. Morano M, et al. **Adv Exp Med Biol** 1998;453:481–8; discussion 488–9

Oxygen consumption and motility of mechanically unloaded myocardial slices. Takaki M, et al. **Adv Exp Med Biol** 1998; 453:499–506

O(2) cost of contractility but not of mechanical energy increases with temperature in canine left ventricle. Mikane T, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H65–73

The role of Kir2.1 in the genesis of native cardiac inward-rectifier K+ currents during pre- and postnatal development. Nakamura TY, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:434–7

Role of nitric oxide production through M2-cholinergic receptors in cultured rat ventricular myocytes. Yamamoto S, et al. **Biochem Biophys Res Commun** 1998 Oct 29; 251(3):791–5

Stimulation of gene expression in neonatal rat ventricular myocytes by Ras is mediated by Ral guanine nucleotide dissociation stimulator (Ral.GDS) and phosphatidylinositol 3-kinase in addition to Raf. Fuller SJ, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):241–6

Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. Nishiyama A, et al. **Cardiovasc Res** 1998 Nov;40(2):343–51

Passive Ca2+ binding in ventricular myocardium of neonatal and adult rats. Bassani RA, et al. **Cell Calcium** 1998 Jun; 23(6):433–42

Inhibition of Na/Ca exchange by external Ni in guinea-pig ventricular myocytes at 37 degrees C, dialysed internally with cAMP-free and cAMP-containing solutions. Hinde AK, et al. **Cell Calcium** 1999 Apr;25(4):321–31

Sarcomeric myosin heavy chain is degraded by the proteasome. Eble DM, et al. **Cell Tissue Res** 1999 Jun; 296(3):541–8

Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Gwechenberger M, et al. **Circulation** 1999 Feb 2; 99(4):546–51

Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Wang Z, et al. **Circulation** 1998 Dec 1;98(22):2422–8

Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Roebroek AJ, et al. **Development** 1998 Dec;125(24):4863–76

Reversal of mitochondrial Na/Ca exchange during metabolic inhibition in rat cardiomyocytes. Griffiths EJ. **FEBS Lett** 1999 Jun 25;453(3):400–4

Calcium equally increases the internal calcium recirculation fraction before and after beta-blockade in canine left ventricles. Hosogi S, et al. **Heart Vessels** 1997;12(6):280–6

Functional activity of the CFTR Cl- channel in human myocardium. Yajima T, et al. **Heart Vessels** 1997; 12(6):255–61

Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. Griscelli F, et al. **Hum Gene Ther** 1998 Sep 1;9(13):1919–28

ATP synthesis and export in heart left ventricle mitochondria from spontaneously hypertensive rat. Atlante A, et al. **Int J Mol Med** 1998 Apr;1(4):709–16

Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters. Inada T, et al. **J Am Coll Cardiol** 1999 Feb;33(2):565–71

Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. Rohde LE, et al. **J Am Coll Cardiol** 1999 Mar;33(3):835–42

Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras. Chiloeches A, et al. **J Biol Chem** 1999 Jul 9;274(28):19762–70

Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway. Pavoine C, et al. **J Biol Chem** 1999 Jan 8;274(2):628–37

Unitary current analysis of L-type Ca2+ channels in human fetal ventricular myocytes. Chen L, et al. **J Cardiovasc Electrophysiol** 1999 May;10(5):692–700

Heterogeneous loss of connexin43 protein in ischemic dog hearts. Huang XD, et al. **J Cardiovasc Electrophysiol** 1999 Jan;10(1):79–91

Regional variation in cardiac myosin isoforms of female F344 rats during aging. Boluyt MO, et al. **J Gerontol A Biol Sci Med Sci** 1999 Aug;54(8):B313–7

Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. Mujumdar VS, et al. **J Hypertens** 1999 Feb;17(2):261–70

Cytoplasmic sodium, calcium and free energy change of the Na+/Ca2+-exchanger in rat ventricular myocytes. Baartscheer A, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2437–47

Cyclic stretch down-regulates calcium transporter gene expression in neonatal rat ventricular myocytes. Cadre BM, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2247–59

Na(+)influx via Na(+)/H(+)exchange activates protein kinase C isozymes delta and epsilon in cultured neonatal rat cardiac myocytes. Hayasaki-Kajiwara Y, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1559–72

The thrombin receptor elevates intracellular calcium in adult rat ventricular myocytes. Jiang T, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2193–9

Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. Lüss I, et al. **J Mol Cell Cardiol** 1999 Jun;31(6):1299–314

Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. Raju VS, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1581–9

Differential alterations in left and right ventricular G-proteins in congestive heart failure due to myocardial infarction. Sethi R, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2153–63

Cytochalasin D alters kinetics of Ca2+ transient in rat ventricular cardiomyocytes: an effect of altered actin cytoskeleton? Undrovinas AI, et al. **J Mol Cell Cardiol** 1998 Aug;30(8):1665–70

Chamber-related differences in connexin expression in the human heart. Vozzi C, et al. **J Mol Cell Cardiol** 1999 May; 31(5):991–1003

Effects of U50488 and bremazocine on [Ca2+]i and cAMP in naive and tolerant rat ventricular myocytes: evidence of kappa opioid receptor multiplicity in the heart. Zhang WM, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):355–62

Delayed myocardial preconditioning by alpha1-adrenoceptors involves inhibition of apoptosis. Baghelai K, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):980–6

Does retrograde warm blood cardioplegic perfusion provide better protection of ischemic areas than antegrade warm blood cardioplegic perfusion? A magnetic resonance study in pig hearts. Ye J, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):994–1003

A single cell model of myocardial reperfusion injury: changes in intracellular Na+ and Ca2+ concentrations in guinea pig ventricular myocytes. Nakamura T, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):147–57

Left-ventricular expression of interleukin-6 messenger-RNA higher in idiopathic dilated than in ischemic cardiomyopathy. Plenz G, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):213–6

Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91–7

PARASITOLOGY

[Surgical treatment of heart echinococcosis] Ivanov VA, et al. **Khirurgiia (Mosk)** 1999;(1):35–8 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: The Bogalusa Heart Study. Urbina EM, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):122–7

Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Candy GP, et al. **Am J Cardiol** 1999 Mar 1;83(5):740–4

Effect of acute myocardial infarction on the angle between the mitral and aortic valve plane. Harmon KE, et al. **Am J Cardiol** 1999 Aug 1;84(3):342–4, A8

Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Kohara K, et al. **Am J Cardiol** 1999 Feb 1; 83(3):367–70

Influence of left ventricular cavity size on clinical presentation in hypertrophic cardiomyopathy. Manganelli F, et al. **Am J Cardiol** 1999 Feb 15;83(4):547–52

Frequency of echocardiographic improvement in left ventricular cavity size and contractility in idiopathic-dilated cardiomyopathy. Mann-Rouillard V, et al. **Am J Cardiol** 1999 Jan 1;83(1):131–3, A9–10

Dobutamine magnetic resonance imaging with myocardial tagging quantitatively predicts improvement in regional function after revascularization. Sayad DE, et al. **Am J Cardiol** 1998 Nov 1;82(9):1149–51, A10

Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Tomoda H. **Am J Cardiol** 1999 Jan 1;83(1):123–5, A9

Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. Brosnan MJ, et al. **Am J Hypertens** 1999 Jul;12(7):724–31

Genetic heterogeneity of isolated noncompaction of the left ventricular myocardium [letter; comment] Digilio MC, et al. **Am J Med Genet** 1999 Jul 2;85(1):90–1. Comment on: Am J Med Genet 1997 Oct 31;72(3):257–65.

Ventricular noncompaction and distal chromosome 5q deletion. Pauli RM, et al. **Am J Med Genet** 1999 Aug 6; 85(4):419–23

Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture. Pinsky DJ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1189–99

Application of cardiac gated magnetic resonance imaging in murine Chagas' disease. Jelicks LA, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):207–14

Automated measurement of myofiber disarray in transgenic mice with ventricular expression of ras. Karlon WJ, et al. **Anat Rec** 1998 Dec;252(4):612–25

Relation of mass/volume ratio to ECG abnormalities and symptoms in children with aortic stenosis/insufficiency. Atalay S, et al. **Angiology** 1999 Feb;50(2):131–6

Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Liu JE, et al. **Ann Intern Med** 1999 Oct 19;131(8):564–72

Physiologic left ventricular cavity dilatation in elite athletes [letter] Ribeiro I, et al. **Ann Intern Med** 1999 Oct 5; 131(7):546

Left ventricular mass reduction after aortic valve replacement: homografts, stentless and stented valves. Maselli D, et al. **Ann Thorac Surg** 1999 Apr;67(4):966–71

Coronary perfusate composition influences diastolic properties, myocardial water content, and histologic characteristics of the rat left ventricle. Starr JP, et al. **Ann Thorac Surg** 1999 Sep;68(3):925–30

Early redistribution of plasma membrane phosphatidylserine during apoptosis of adult rat ventricular myocytes in vitro. Rücker-Martin C, et al. **Basic Res Cardiol** 1999 Jun; 94(3):171–9

Fibrosis, myocyte degeneration and heart failure in chronic

experimental aortic regurgitation. Liu SK, et al. **Cardiology** 1998 Oct;90(2):101–9

Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance. Brookes C, et al. **Circulation** 1999 Aug 17;100(7):761–7

Midmural fibrosis of left ventricle due to selenium deficiency. Inoko M, et al. **Circulation** 1998 Dec 8;98(23):2638–9

Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Kelley ST, et al. **Circulation** 1999 Jan 5–12;99(1):135–42

Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Perticone F, et al. **Circulation** 1999 Apr 20;99(15):1991–6

Reduced left ventricular dimension and normalized atrial natriuretic hormone level after repair of aortic coarctation in an adult. Pauly DF, et al. **Clin Cardiol** 1999 Mar; 22(3):233–5

Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan. Liu X, et al. **Clin Exp Hypertens** 1999 Jan–Feb;21(1–2):145–56

Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade. Xie Z, et al. **Clin Exp Hypertens** 1999 May;21(4):441–52

Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Gatzka CD, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):514–6

Ventricular myocardium in control and growth-retarded human fetuses: growth in different tissue compartments and variation with fetal weight, gestational age, and ventricle size. Mayhew TM, et al. **Hum Pathol** 1999 Jun;30(6):655–60

Magnetic resonance imaging features of submitral left ventricular aneurysm. Taneja K, et al. **Indian Heart J** 1998 Jul–Aug;50(4):453–5

Kinematic analysis of left ventricular deformation in myocardial infarction using magnetic resonance cardiac tagging. Aelen FW, et al. **Int J Card Imaging** 1999 Jun; 15(3):241–51

Neovascularity related to mural thrombus in endomyocardial fibrosis. Meuwissen M, et al. **Int J Card Imaging** 1999 Jun; 15(3):205–7

MRI of heart morphology. Comparison of nongradient echo sequences with single- and multislice acquisition. Winterer JT, et al. **Invest Radiol** 1999 Aug;34(8):516–22

Left ventricular cavity obliteration during dobutamine stress echocardiography is associated with female sex and left ventricular size and function. Khanal S, et al. **J Am Soc Echocardiogr** 1998 Oct;11(10):957–60

The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. Antzelevitch C, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1124–52 (152 ref.)

Ventricular tachycardia in a patient with cardiac lipoma. Fukushima KK, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1161

Histopathologic effects of radiofrequency catheter ablation in previously infarcted human myocardium. Grubman E, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):336–42

Left ventricular chamber and wall mechanics in the presence of concentric geometry. de Simone G, et al. **J Hypertens** 1999 Jul;17(7):1001–6

Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Pontremoli R, et al. **J Hypertens** 1999 Jul;17(7):993–1000

Impact of arterial elastance as a measure of vascular load on left ventricular geometry in hypertension. Saba PS, et al. **J Hypertens** 1999 Jul;17(7):1007–15

Clinical and morphologic features of hypertrophic cardiomyopathy in elderly patients 85 years or older. Lai ZY, et al. **Jpn Heart J** 1999 Mar;40(2):155–64

Statistical method for characterization of hypertrophic cardiomyopathy by use of morphologic and pathologic measurements in pigs (Sus scrofa domestica). Huang SY, et al. **Lab Anim Sci** 1999 Jun;49(3):276–82

Postmortem analysis of encapsulation around long-term ventricular endocardial pacing leads. Candinas R, et al. **Mayo Clin Proc** 1999 Feb;74(2):120–5

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1999. A 33-year-old man with wide-complex tachycardia and a left ventricular mass [clinical conference] **N Engl J Med** 1999 Oct 14; 341(16):1217–24

Right intraventricular metastasis of squamous cell carcinoma of the uterine cervix: an autopsy case and literature review. Senzaki H, et al. **Pathol Int** 1999 May;49(5):447–52 (33 ref.)

Congenital aneurysm of sinus of valsalva ruptured into right ventricle diagnosed by magnetic resonance imaging. Karaaslan T, et al. **Pediatr Cardiol** 1999 May–Jun; 20(3):212–4

Analysis of right ventricular areas to assess the severity of ascites syndrome in broiler chickens. McGovern RH, et al. **Poult Sci** 1999 Jan;78(1):62–5

Altered levels of mRNA of apoptosis-mediating genes after mid-term mechanical ventricular support in dilative cardiomyopathy--first results of the Halle Assist Induced Recovery Study (HAIR). Milting H, et al. **Thorac Cardiovasc Surg** 1999 Feb;47(1):48–50

PHYSIOLOGY

Dissociation between force and [Ca2+]i during extra systoles in guinea-pig ventricular muscle microinjected with fura-2. Arheden H, et al. **Acta Physiol Scand** 1999 Jan;165(1):1–8

Ventricular pressure-volume area (PVA) accounts for cardiac energy consumption of work production and absorption. Araki J, et al. **Adv Exp Med Biol** 1998; 453:491–7; discussion 497–8 (31 ref.)

Influences of protein kinase A and D-cAMP on actin-myosin interaction and energy consumption of cardiac muscles. Saeki Y, et al. **Adv Exp Med Biol** 1998;453:461–70

Papillary muscle and left ventricle show different contractile and metabolic responses during myocardial stunning. Zuurbier CJ, et al. **Adv Exp Med Biol** 1998;454:519–25

Analysis of ventricular septal motion by doppler tissue imaging in atrial septal defect and normal heart. Iwasaki Y, et al. **Am J Cardiol** 1999 Jan 15;83(2):206–10

Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. Jalil JE, et al. **Am J Hypertens** 1999 Jul;12(7):697–704

Regional assessment of wall curvature and wall stress in left ventricle with magnetic resonance imaging. Balzer P, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H901–10

Estimation of regional left ventricular wall stresses in intact canine hearts. DeAnda A Jr, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 2):H1879–85

Independent effects of preload, afterload, and contractility on left ventricular torsion. Dong SJ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1053–60

What is the role of the AV node if the AV delay occurs before it? [letter; comment] Efimov IR. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1905–6; discussion H1906–9. Comment on: Am J Physiol 1998 Mar;274(3 Pt 2):H829–45.

Four different components contribute to outward current in rat ventricular myocytes. Himmel HM, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H107–18

Energy expenditure by Ba(2+) contracture in rat ventricular slices derives from cross-bridge cycling. Kohzuki H, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H74–9

Neuropeptide Y contributes to innervation-dependent increase in I(Ca, L) via ventricular Y2 receptors. Protas L, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H940–6

Influence of prior Na+ pump activity on pump and Na+/Ca2+ exchange currents in mouse ventricular myocytes. Su Z, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1808–17

Effective epicardial resistance of rabbit ventricles. Baynham TC, et al. **Ann Biomed Eng** 1999 Jan–Feb;27(1):96–102

The force-frequency relationship is dependent on Ca(2+)-influx via L-type- and SR-Ca(2+)-channels in human heart. Reuter H, et al. **Basic Res Cardiol** 1999 Jun; 94(3):159–70

Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation. Hancox JC, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):719–24

Activation of nitric oxide synthase (NOS3) by mechanical activity alters contractile activity in a Ca2+-independent manner in cardiac myocytes: role of troponin I phosphorylation. Kaye DM, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):398–403

Kinetics of rate-dependent shortening of action potential duration in guinea-pig ventricle; effects of IK1 and IKr blockade. Williams BA, et al. **Br J Pharmacol** 1999 Mar; 126(6):1426–36

Regional and temporal nonuniformity of shape and wall movement in the normal left ventricle. Barletta G, et al. **Cardiology** 1998 Dec;90(3):195–201

Electrical heterogeneity in the ventricular wall--and the M cell [editorial; comment] Näbauer M. **Cardiovasc Res** 1998 Nov;40(2):248–50. Comment on: Cardiovasc Res 1998 Nov;40(2):322–31.

Swelling-activated chloride current is persistently activated in ventricular myocytes from dogs with tachycardia-induced congestive heart failure. Clemo HF, et al. **Circ Res** 1999 Feb 5;84(2):157–65

Extracellular K+ dependence of inward rectification kinetics in human left ventricular cardiomyocytes. Bailly P, et al. **Circulation** 1998 Dec 15;98(24):2753–9

Reentrant pathway during ventricular echoes is confined to the atrioventricular node : high-resolution mapping and dissection of the triangle of koch in isolated, perfused canine hearts. Loh P, et al. **Circulation** 1999 Sep 21; 100(12):1346–53

Mechanism of acceleration of functional reentry in the ventricle: effects of ATP-sensitive potassium channel opener. Uchida T, et al. **Circulation** 1999 Feb 9;99(5):704–12

Repolarizing K+ currents ITO1 and IKs are larger in right than left canine ventricular midmyocardium. Volders PG, et al. **Circulation** 1999 Jan 19;99(2):206–10

An echocardiographic study of right ventricular adaptation to physical exercise in elite male orienteers. Henriksen E, et al. **Clin Physiol** 1998 Nov;18(6):498–503

Contribution of the interventricular septum to maximal right ventricular function. Klima U, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):250–5

Effect of implantable cardioverter/defibrillator lead placement in the right ventricle on defibrillation energy requirements. A combined experimental and clinical study. Winter J, et al. **Eur J Cardiothorac Surg** 1998 Oct; 14(4):419–25

Muscarinic regulation of Ca2+ signaling in mammalian atrial and ventricular myocardium. Endoh M. **Eur J Pharmacol** 1999 Jun 30;375(1–3):177–96 (104 ref.)

Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Sarubbi B, et al. **Int J Cardiol** 1998 Sep 30;66(2):157–64

Automatic detection of left ventricular contours from cardiac cine magnetic resonance imaging using fuzzy logic. Lalande A, et al. **Invest Radiol** 1999 Mar;34(3):211–7

Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. Vale PR, et al. **J Am Coll Cardiol** 1999 Jul; 34(1):246–54

Ventricular excitation maps using tissue Doppler acceleration imaging: potential clinical application. Yin LX, et al. **J Am Coll Cardiol** 1999 Mar;33(3):782–7

Automated tracking of left ventricular wall thickening with intracardiac echocardiography. Spencer KT, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1020–6

The controversial M cell. Anyukhovsky EP, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):244–60 (101 ref.)

Virtual electrode effects in transvenous defibrillation-modulation by structure and interface: evidence from bidomain simulations and optical mapping. Entcheva E, et al. **J Cardiovasc Electrophysiol** 1998 Sep; 9(9):949–61

Comparison of standard and irrigated radiofrequency ablation in the canine ventricle. Skrumeda LL, et al. **J Cardiovasc Electrophysiol** 1998 Nov;9(11):1196–205

Multiple components in the unipolar electrogram: a simulation study in a three-dimensional model of ventricular myocardium. Taccardi B, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1062–84

The autonomic control of the transmural dispersion of ventricular repolarization in anesthetized dogs. Takei M, et al. **J Cardiovasc Electrophysiol** 1999 Jul;10(7):981–9

Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. Nuss HB, et al. **J Clin Invest** 1999 Mar;103(6):889–96

Cellular mechanisms for the slow phase of the Frank-Starling response. Bluhm WF, et al. **J Electrocardiol** 1998;31 Suppl:13–22

Modeling defibrillation: effects of fiber curvature. Trayanova N, et al. **J Electrocardiol** 1998;31 Suppl:23–9

Characteristics of current fluctuations originating from activities of inward-rectifier K+ channels in guinea-pig heart cells. Yamada Y, et al. **J Membr Biol** 1999 Jan 15; 167(2):141–9

Inhibition of Na(+)-K+ pump alleviates the shortening of action potential duration caused by metabolic inhibition via blockade of KATP channels in coronary perfused ventricular muscles of guinea-pigs. Abe T, et al. **J Mol Cell Cardiol** 1999 Mar;31(3):533–42

Concentration and elongation of attached cross-bridges as pressure determinants in a ventricular model. Negroni JA, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1509–26

Quantitation of Na/Ca exchanger function in single ventricular myocytes. Su Z, et al. **J Mol Cell Cardiol** 1999 May;31(5):1125–35

Cellular basis for the acute inhibitory effects of IL-6 and TNF- alpha on excitation-contraction coupling. Sugishita K, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1457–67

Complications associated with rapid caffeine application to cardiac myocytes that are not voltage clamped. Zaniboni M, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2229–35

Power output of pericardium-lined skeletal muscle ventricles, left ventricular apex to aorta configuration: up to eight months in circulation. Thomas GA, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1029–42

The influence of changes in loading patterns on left ventricular relaxation in humans. Iketani T, et al. **Jpn Circ J** 1998 Aug;62(8):581–5

Pharmacological evaluation of a new laser blood flowmeter for measuring coronary blood flow, assessed in the canine isolated, blood-perfused ventricular tissue preparation in comparison with an electromagnetic flowmeter. Sugiyama A, et al. **Jpn J Pharmacol** 1999 Jul;80(3):263–6

Linear O2 use-pressure-volume area relation from curved end-systolic pressure-volume relation of the blood-perfused rat left ventricle. Hata Y, et al. **Jpn J Physiol** 1998 Jun;48(3):197–204

Hybrid logistic characterization of isometric twitch force curve of isolated ferret right ventricular papillary muscle. Mizuno J, et al. **Jpn J Physiol** 1999 Apr;49(2):145–58

The protective action of amlodipine on cardiac negative inotropism caused by prolonged incubation in vitro. Bravo G, et al. **Life Sci** 1998;63(21):1849–61

Computer evaluation of left ventricular wall motion by means of shape-based tracking and symbolic description. Baroni M. **Med Eng Phys** 1999 Mar;21(2):73–85

The electrical conductance of a given volume is independent on the shape containing that volume. Valentinuzzi ME. **Med Eng Phys** 1998 Nov;20(8):629–30

Tracking and motion analysis of the left ventricle with deformable superquadrics. Bardinet E, et al. **Med Image Anal** 1996 Jun;1(2):129–49

Lack of correlation between ventricular late potentials and left ventricular mass in top-level male athletes. Biffi A, et al. **Med Sci Sports Exerc** 1999 Mar;31(3):359–61

Complete left ventricular wall motion estimation from cascaded MRI-SPAMM data. Park J, et al. **Medinfo** 1998;

9 Pt 2:1063–5
The relation between the action potential duration, the increase in resting tension, and ATP content during metabolic inhibition in guinea pig ventricular muscles. Hayashi H, et al. **Mol Cell Biochem** 1999 Apr; 194(1–2):193–7
The chick embryo heart as an experimental setup for the assessment of myocardial remodeling induced by pacing. Grobéty M, et al. **Pacing Clin Electrophysiol** 1999 May; 22(5):776–82
The late component of L-type calcium current during guinea-pig cardiac action potentials and its contribution to contraction. Linz KW, et al. **Pflugers Arch** 1998 Oct; 436(5):679–88
Coherence between body surface ECG leads and intracardiac signals increases during the first 10 s of ventricular fibrillation in the human heart. Clayton RH, et al. **Physiol Meas** 1999 May;20(2):159–66
Problems with use of the end systolic pressure–volume slope as an indicator of left ventricular contractility: an alternate method. Krösl P, et al. **Shock** 1998 Oct;10(4):285–91
Beat averaging alternatives for transmitral Doppler flow velocity images. Hall AF, et al. **Ultrasound Med Biol** 1998 Sep;24(7):971–9
[Recording of atrial and ventricular signal averaged ECGs in patients with mitral valve prolapse syndrome] Banasiak W, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):302–5 (Eng. Abstr.) **(Pol)**
[The evaluation of surgical revascularization of the left ventricular systolic function after surgery] Puchała-Borowik M, et al. **Pol Merkuriusz Lek** 1998 Jun; 4(24):298–301 (Eng. Abstr.) **(Pol)**
[The effect of a two-week anti-orthostatic hypokinesia on the cardiac function and on the latter's regulation in monkeys] Korol'kov VI, et al. **Aviakosm Ekolog Med** 1998; 32(3):30–7 (Eng. Abstr.) **(Rus)**
[Complete cava-pulmonary conjunction in surgical treatment of heart abnormalities with a single functionally active ventricle] Dovgan' AM, et al. **Klin Khir** 1999;(1):13–5 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Oxygen consumption and motility of mechanically unloaded myocardial slices. Takaki M, et al. **Adv Exp Med Biol** 1998; 453:499–506
Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. Lauer MS, et al. **Am Heart J** 1999 May;137(5):903–9
Can right-sided atrioventricular sequential pacing provide benefit for selected patients with severe congestive heart failure? Sack S, et al. **Am J Cardiol** 1999 Mar 11; 83(5B):124D–129D
Downregulation of ventricular contractile function during early ischemia is flow but not pressure dependent. He MX, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1520–3
Intracellular chloride activity increases in guinea pig ventricular muscle during simulated ischemia. Lai ZF, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1613–9
Effect of ANG II on pHi, [Ca2+]i, and contraction in rabbit ventricular myocytes from infarcted hearts. Skolnick RL, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1788–97
Ventricular contractility in atrial fibrillation is predictable by mechanical restitution and potentiation. Suzuki S, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1513–9
Techniques for evaluation of right ventricular relaxation rate in horses and effects of inhalant anesthetics with and without intravenous administration of calcium gluconate. Grubb TL, et al. **Am J Vet Res** 1999 Jul;60(7):872–9
Doppler echocardiographic study of left and right ventricular function during dobutamine stress testing in conscious healthy dogs. McEntee K, et al. **Am J Vet Res** 1999 Jul; 60(7):865–71
Left ventricular size and function in patients with noninsulin-dependent diabetes and postinfarction total or subtotal coronary occlusions. Dini FL, et al. **Angiology** 1998 Dec;49(12):967–73
Outflow acceleration assessed by continuous-wave doppler echocardiography in left ventricular hypertrophy: an analysis of 103 consecutive cases. Faber L, et al. **Cardiology** 1998 Dec;90(3):220–6
Effect of sustained stretch on dispersion of ventricular fibrillation intervals in normal rabbit hearts. Burton FL, et al. **Cardiovasc Res** 1998 Aug;39(2):351–9
Electrocardiographic patterns in acute inferior myocardial infarction with and without right ventricle involvement: classification, diagnostic and prognostic value, masking effect. Correale E, et al. **Clin Cardiol** 1999 Jan;22(1):37–44
Gender differences in patients with severe aortic stenosis: impact on preoperative left ventricular geometry and function, as well as early postoperative morbidity and mortality. Bech-Hanssen O, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):24–30
Ventricular repolarization time indexes following anthracycline treatment. Sarubbi B, et al. **Heart Vessels** 1997;12(6):262–6
Competitive pulmonary flow in infancy: the effect of respiration. Henneveld HT, et al. **Int J Cardiol** 1999 Jan; 68(1):9–12
Regression of ventricular repolarisation inhomogeneity after aortic bileaflet valve replacement in patients with aortic stenosis. Tsai CH, et al. **Int J Cardiol** 1999 Jul 31; 70(2):141–8
Diastolic function and insulin resistance in essential hypertension. Zemva A, et al. **Int J Cardiol** 1998 Oct 30; 66(3):293–7
Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. Farshi R, et al. **J Am Coll Cardiol** 1999 Feb;33(2):304–10
Optimization of ventricular pacing: where should we implant the leads? [editorial; comment] Gold MR. **J Am Coll Cardiol** 1999 Feb;33(2):324–6 (21 ref.). Comment on: J Am Coll Cardiol 1999 Feb;33(2):311–6. Comment on: J Am Coll Cardiol 1999 Feb;33(2):317–23.
Angiotensin-converting enzyme (ACE) inhibitors revert abnormal right ventricular filling in patients with restrictive left ventricular disease. Henein MY, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1187–93
Influence of right ventricular stimulation site on left ventricular function in atrial synchronous ventricular pacing [see comments] Schwaab B, et al. **J Am Coll Cardiol** 1999 Feb;33(2):317–23. Comment in: J Am Coll Cardiol 1999 Feb;33(2):324–6.
Optimal right ventricular pacing site in chronically implanted patients: a prospective randomized crossover comparison of apical and outflow tract pacing [see comments] Victor F, et al. **J Am Coll Cardiol** 1999 Feb;33(2):311–6. Comment in: J Am Coll Cardiol 1999 Feb;33(2):324–6.
Real-time strain rate imaging of the left ventricle by ultrasound. Heimdal A, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1013–9
Cardiac dysfunction in murine autoimmune myocarditis. Less H, et al. **J Autoimmun** 1999 May;12(3):209–20
Value of programmed ventricular stimulation in patients with congenital heart disease [see comments] Alexander ME, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1033–44 . Comment in: J Cardiovasc Electrophysiol 1999 Aug;10(8):1045–8.
Acceleration-induced action potential prolongation and early afterdepolarizations. Burashnikov A, et al. **J Cardiovasc Electrophysiol** 1998 Sep;9(9):934–48
Electrical restitution, critical mass, and the riddle of fibrillation [editorial; comment] Gilmour RF Jr, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1087–9 (20 ref.) . Comment on: J Cardiovasc Electrophysiol 1999 Aug;10(8):1077–86.
Reentrant wavefronts in human ventricular tissue. Hwang C, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):419
Short-term rapid ventricular pacing prolongs ventricular refractoriness in patients. Krebs ME, et al. **J Cardiovasc Electrophysiol** 1998 Oct;9(10):1036–42
Noncontact mapping of diseased left ventricles in patients with abnormally activated regions [letter; comment] Meijler FL. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):264 . Comment on: J Cardiovasc Electrophysiol 1998 Sep;9(9):921–33.
Characteristics of sinus rhythm electrograms at sites of ablation of ventricular tachycardia relative to all other sites: a noncontact mapping study of the entire left ventricle [see comments] Schilling RJ, et al. **J Cardiovasc Electrophysiol** 1998 Sep;9(9):921–33. Comment in: J Cardiovasc Electrophysiol 1999 Feb;10(2):264.
Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome [see comments] Shimizu W, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):154–64. Comment in: J Cardiovasc Electrophysiol 1999 Feb;10(2):164–7.
U wave: facts, hypotheses, misconceptions, and misnomers. Surawicz B. **J Cardiovasc Electrophysiol** 1998 Oct; 9(10):1117–28 (35 ref.)
Relation between cellular repolarization characteristics and critical mass for human ventricular fibrillation [see comments] Wu TJ, et al. **J Cardiovasc Electrophysiol** 1999 Aug;10(8):1077–86. Comment in: J Cardiovasc Electrophysiol 1999 Aug;10(8):1087–9.
Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. Zabel M, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1279–84
Influence of right ventricular site of stimulation and infarct location on the inducibility of ventricular tachycardia in patients with coronary artery disease. Harvey M, et al. **J Electrocardiol** 1998 Oct;31(4):278–80
A comparison of simulated QRS isointegral maps resulting from pacing at adjacent sites: implications for the spatial resolution of pace mapping using body surface potentials. Hren R, et al. **J Electrocardiol** 1998;31 Suppl:135–44
Escape capture bigeminy: a manifestation of sinoatrial conduction block. Monir G, et al. **J Electrocardiol** 1999 Jan;32(1):51–5
A simulation study of Torsade de Pointes with M cells. Okazaki O, et al. **J Electrocardiol** 1998;31 Suppl:145–51
Effects of partial left ventriculectomy on left ventricular geometry and wall stress in excised porcine hearts. Green GR, et al. **J Heart Valve Dis** 1998 Sep;7(5):474–83
Left ventricular chamber and wall mechanics in the presence of concentric geometry. de Simone G, et al. **J Hypertens** 1999 Jul;17(7):1001–6
Impact of arterial elastance as a measure of vascular load on left ventricular geometry in hypertension. Saba PS, et al. **J Hypertens** 1999 Jul;17(7):1007–15
Reproducibility of bipolar endocavitary electrogram measurements at sites of radiofrequency energy delivery in patients with the Wolff–Parkinson–White syndrome. de Chillou C, et al. **J Interv Card Electrophysiol** 1998 Dec; 2(4):377–81
On-line assessment of regional ventricular wall motion by transesophageal echocardiography with color kinesis during minimally invasive coronary artery bypass grafting. Kotoh K, et al. **J Thorac Cardiovasc Surg** 1999 May; 117(5):912–7
Efficacy of coronary artery bypass grafting in patients with a dilated left ventricle due to myocardial infarction. Hirata N, et al. **Jpn Circ J** 1998 Aug;62(8):565–70
Heart rate variability before spontaneous episodes of ventricular tachycardia originating from right ventricular outflow tract in patients without organic heart disease. Yoshida A, et al. **Jpn Circ J** 1998 Oct;62(10):745–9
Augmentation of the inotropic response to insulin in diabetic rat hearts. Ren J, et al. **Life Sci** 1999;65(4):369–80
Aortic input impedance and ventriculoarterial coupling following cardioversion/defibrillation. Bauernschmitt R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1047–53
QRS duration widening: reduced synchronization of endocardial activation or transseptal conduction time? Mehdirad AA, et al. **Pacing Clin Electrophysiol** 1998 Aug; 21(8):1589–94
A comparison of ventricular function during high right ventricular septal and apical pacing after his-bundle ablation for refractory atrial fibrillation. Mera F, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1234–9
Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. Simons GR, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2651–63 (74 ref.)
Idiopathic left ventricular tachycardia with block between purkinje potential and ventricular myocardium. Tomokuni A, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1824–7
Resolution of neonatal hypertrophic cardiomyopathy in an infant with an affected mother. Eidem BW, et al. **Pediatr Cardiol** 1999 May–Jun;20(3):208–11
[Infundibulum of the right ventricle: an overlooked site of arrhytmogenic dysplasia?] Proclemer A, et al. **Cardiologia** 1998 Aug;43(8):805–10 (20 ref.) **(Ita)**
[Late ventricular potential as a risk factor for sudden cardiac death in chronically hemodialysed patients] Wierzbicki P. **Pol Merkuriusz Lek** 1998 Nov;5(29):310–2 (25 ref.) (Eng. Abstr.) **(Pol)**
[Slow excitation waves and mechanisms of polymorphic ventricular tachycardia in an experimental model: isolated walls of the right ventricle from rabbit and squirrel] Kukushkin NI, et al. **Biofizika** 1998 Nov–Dec; 43(6):1043–59 (Eng. Abstr.) **(Rus)**
[Clinicofunctional changes of heart in patients with clinically different variants of toxic diphtheria] Anikin VV, et al. **Klin Med (Mosk)** 1998;76(8):35–7 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Low-dose dobutamine testing using contrast left ventriculography in the same session as coronary angiography predicts the improvement of left ventricular function after coronary angioplasty in postinfarction patients. Sanchis J, et al. **Am J Cardiol** 1999 Jan 1; 83(1):15–20
Letter to the editor: re Marques [letter; comment] Kapoor A, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):460. Comment on: Cathet Cardiovasc Diagn 1997 Sep;42(1):34–6.
Accuracy of quantitative ventriculographic analysis at reduced frame rates. Guo A, et al. **Catheter Cardiovasc Interv** 1999 Sep;48(1):18–21; discussion 22–3
Cardiac murmur associated with an abnormal chest x-ray film. Myers RB, et al. **Chest** 1998 Nov;114(5):1459–62
Four-dimensional cardiac image by helical computed tomography. Koyama Y, et al. **Circulation** 1999 Oct 12; 100(15):e61–2
Automatic detection of left ventricular borders on electron beam CT sequential cardiac images using an adaptive algorithm. Herment A, et al. **Comput Med Imaging Graph** 1998 Jul–Aug;22(4):291–9
Ejection fraction by radionuclide ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular Enlargement. Ureña PE, et al. **J Am Coll Cardiol** 1999 Jan; 33(1):180–5
Beneficial effects of mechanical reperfusion therapy on left ventricular remodeling and late outcome following myocardial infarction. Sakakibara M, et al. **Jpn Heart J** 1998 Jul;39(4):419–33
[Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study] Roriz R, et al. **J Radiol** 1999 Jul;80(7):727–32 (Eng. Abstr.) **(Fre)**
[Throat discomfort developing immediately after left ventriculography] Matsushita T, et al. **J Cardiol** 1999 Aug; 34(2):97–9 **(Jpn)**
[Coronary artery bypass grafting for cases which were not amenable to preoperative left ventriculogram] Sakamoto T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):966–70 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Giant pseudoaneurysm of the left ventricle diagnosed by radionuclide ventriculography. Friedensohn A, et al. **Clin Nucl Med** 1998 Sep;23(9):623

Predicting improved function after myocardial revascularization. Di Carli MF. **Curr Opin Cardiol** 1998 Nov;13(6):415–24 (60 ref.)

Automatic analysis of ventricular function by nuclear imaging. Germano G. **Curr Opin Cardiol** 1998 Nov; 13(6):425–9 (41 ref.)

Comparison of pulmonary uptake with transient cavity dilation after exercise thallium-201 perfusion imaging. Hansen CL, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1323–7

SURGERY

Functional evaluation of extracardiac ventriculopulmonary conduits and of the right ventricle with magnetic resonance imaging and velocity mapping. Holmqvist C, et al. **Am J Cardiol** 1999 Mar 15;83(6):926–32

Cardiac observations late after operative transmyocardial laser "revascularization". Summers JH, et al. **Am J Cardiol** 1999 Aug 15;84(4):489–90, A10

Direct neonatal ventriculo-arterial connections (REV): early results and future implications. Black MD, et al. **Ann Thorac Surg** 1999 Apr;67(4):1137–41

Why does partial left ventriculectomy work on dilated cardiomyopathy? [letter; comment] Cui Y. **Ann Thorac Surg** 1999 May;67(5):1541–2. Comment on: Ann Thorac Surg 1998 Nov;66(5):1585–91.

Acute cardiovascular changes of partial left ventriculectomy without mitral valve repair. Dowling RD, et al. **Ann Thorac Surg** 1999 May;67(5):1470–2

Partial left ventriculectomy for idiopathic dilated cardiomyopathy: early results and six-month follow-up. Gradinac S, et al. **Ann Thorac Surg** 1998 Dec;66(6):1963–8

A survey on partial left ventriculectomy in the Asia-Pacific region. Izzat MB, et al. **Ann Thorac Surg** 1999 Feb; 67(2):387–91

Early experience with partial left ventriculectomy in the Asia-Pacific region. Izzat MB, et al. **Ann Thorac Surg** 1999 Jun;67(6):1703–7

Combined Rastelli and atrial switch procedure: a 10-year follow-up. Jacobs ML, et al. **Ann Thorac Surg** 1999 Aug; 68(2):570–1

Left ventricular fibroma masquerading as postinfarction myocardial rupture. Lee KA, et al. **Ann Thorac Surg** 1999 Aug;68(2):580–2 (6 ref.)

Bidirectional Glenn shunt in association with congenital heart repairs: the 1(1/2) ventricular repair. Mavroudis C, et al. **Ann Thorac Surg** 1999 Sep;68(3):976–81; discussion 982

Valved homograft conduit repair of the right heart in early infancy. Perron J, et al. **Ann Thorac Surg** 1999 Aug; 68(2):542–8

Determinants of midterm outcome of partial left ventriculectomy in dilated cardiomyopathy [see comments] Stolf NA, et al. **Ann Thorac Surg** 1998 Nov;66(5):1585–91. Comment in: Ann Thorac Surg 1999 May;67(5):1541–2.

Porcine stentless valve/bovine pericardial conduit for right ventricle to pulmonary artery. Vrandecic MO, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S179–82

Experimental application of microwave tissue coagulation to ventricular myocardium. Watanabe H, et al. **Ann Thorac Surg** 1999 Mar;67(3):666–71

Ventricular radius reduction without resection: a computational analysis. Melvin DB. **ASAIO J** 1999 May-Jun;45(3):160–5

Monocusp valve and transannular patch reconstruction of the right ventricular outflow tract: an experimental study. Scavo VA Jr, et al. **ASAIO J** 1998 Sep–Oct;44(5):M480–5

Retrocaval passage of coronary bypass grafts to the inferior left ventricle wall. Deleuze PH, et al. **Cardiovasc Surg** 1999 Apr;7(3):375–7

Lesion dimensions during temperature-controlled radiofrequency catheter ablation of left ventricular porcine myocardium: impact of ablation site, electrode size, and convective cooling. Høgh Petersen H, et al. **Circulation** 1999 Jan 19;99(2):319–25

Evaluation and management of pulmonary atresia with intact ventricular septum. Bichell DP. **Curr Opin Cardiol** 1999 Jan;14(1):60–6 (62 ref.)

Partial left ventriculectomy--the Batista procedure. Batista R. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S12–9; discussion S39–43 (0 ref.)

Left ventricular assist device as a bridge to partial left ventriculectomy. Frazier OH. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S20–5; discussion S39–43 (13 ref.)

Early and intermediate results of left ventricular reduction surgery. Konertz W, et al. **Eur J Cardiothorac Surg** 1999 Jan;15 Suppl 1:S26–30; discussion S39–43

Sudden cardiac death as a complication of left partial ventriculectomy in patients with end-stage dilated cardiomyopathy [letter] Bestetti RB. **Int J Cardiol** 1998 Dec 1;67(2):183–5

Partial left ventriculectomy: preoperative risk factors for perioperative mortality. Bestetti RB, et al. **Int J Cardiol** 1998 Dec 1;67(2):143–6

Competitive pulmonary flow in infancy: the effect of respiration. Henneveld HT, et al. **Int J Cardiol** 1999 Jan; 68(1):9–12

The current role of left ventricular reduction for treatment of heart failure [editorial; comment] Laks H, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1809–10. Comment on: J Am Coll Cardiol 1998 Dec;32(7):1801–8.

Effects of partial left ventriculectomy on left ventricular performance in patients with nonischemic dilated cardiomyopathy [see comments] Popović Z, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1801–8. Comment in: J Am Coll Cardiol 1998 Dec;32(7):1809–10.

Ventricular reduction therapy: controlled clinical trials overdue [letter] Spodick DH. **J Am Coll Cardiol** 1999 Aug; 34(2):610–1

Partial left ventriculectomy in patients with dialated failing ventricle. Kawaguchi AT, et al. **J Card Surg** 1998 Sep–Oct; 13(5):335–42

Isolated effect of partial left ventriculectomy for dilated cardiomyopathy: a case report. Suma H, et al. **J Cardiol** 1999 May;33(5):273–7

Technical considerations for partial left ventriculectomy (Batista operation). Blanche C, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):829–32

Linear repair versus ventricular reconstruction for treatment of left ventricular aneurysm: a 10-year experience. Vicol C, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):461–7

Results of partial left ventriculectomy in patients with end-stage idiopathic dilated cardiomyopathy. Dowling RD, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1208–12

Partial left ventriculectomy in a two-year-old girl with dilated cardiomyopathy [published erratum appears in J Heart Lung Transplant 1999 Jun;18(6):610] Gradinac S, et al. **J Heart Lung Transplant** 1999 Apr;18(4):381–3

Effects of partial left ventriculectomy on left ventricular geometry and wall stress in excised porcine hearts. Green GR, et al. **J Heart Valve Dis** 1998 Sep;7(5):474–83

Left ventricular volume reduction for end-stage heart failure: intrapapillary or extrapapillary resection, mitral valve repair or replacement? Lim KH, et al. **J Heart Valve Dis** 1998 Sep;7(5):484–7

Bio-battery signal predicts myocardial lesion formation and depth in vitro. He DS, et al. **J Interv Card Electrophysiol** 1999 Mar;3(1):69–77

Partial left ventriculectomy for dilated cardiomyopathy in a newborn [see comments] Berger S, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1017–8. Comment in: J Thorac Cardiovasc Surg 1999 May;117(5):918–9.

Editorial: Partial left ventriculectomy for dilated cardiomyopathy in children [editorial; comment] del Nido PJ. **J Thorac Cardiovasc Surg** 1999 May;117(5):918–9 (9 ref.). Comment on: J Thorac Cardiovasc Surg 1999 Mar;117(3):622–3. Comment on: J Thorac Cardiovasc Surg 1999 May;117(5):1017–8.

Results after partial left ventriculectomy versus heart transplantation for idiopathic cardiomyopathy. Etoch SW, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):952–9

Long-term outcome of infants with single ventricle and total anomalous pulmonary venous connection. Gaynor JW, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):506–13; discussion 513–4

Heart reduction surgery can reconstitute the residual stress-strain state of the left ventricle [letter] Kresh JY, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1084–6

Partial left ventriculectomy in an infant with dilated cardiomyopathy. Yoshii S, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):616–8

Catheter tip orientation affects radiofrequency ablation lesion size in the canine left ventricle. Chugh SS, et al. **Pacing Clin Electrophysiol** 1999 Mar;22(3):413–20

Recent advances in the surgical management of the single ventricle pediatric patient. Tweddell JS, et al. **Pediatr Clin North Am** 1999 Apr;46(2):465–80, xii (52 ref.)

Three ventriculoplasty techniques applied to three left-ventricular pseudoaneurysms in the same patient. Akinci E, et al. **Tex Heart Inst J** 1999;26(1):87–9

Linked pacing after heterotopic heart transplantation with concurrent left ventricular reduction of the native heart. Beyer E, et al. **Tex Heart Inst J** 1998;25(4):299–302

Successful reoperation after Batista partial left ventriculectomy demonstrates patient's hemodynamic recovery. Taşdemir O, et al. **Tex Heart Inst J** 1999; 26(2):132–5

[Hemodynamic effects of maximum laser transmyocardial revascularization] Mueller XM, et al. **Swiss Surg** 1998;Suppl 2:18–22 (Eng. Abstr.) **(Fre)**

[Batista procedure--partial left ventricular volume reduction--new approach to the surgical management of end stage congestive heart failure] Shinfeld A, et al. **Harefuah** 1998 Aug;135(3-4):118–20 (12 ref.) **(Heb)**

[A successful biventricular repair in an adult case with "common ventricle" and isomeric atrial appendages previously undergoing the conventional Glenn procedure] Yoshida M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov; 46(11):1177–81 (Eng. Abstr.) **(Jpn)**

[Double chambered right ventricle in a 62-year-old female: a surgical case report] Gon S, et al. **Kyobu Geka** 1999 Sep; 52(10):850–2 (Eng. Abstr.) **(Jpn)**

[Partial left ventriculectomy] Kawaguchi A, et al. **Kyobu Geka** 1999 Jan;52(1):51–7 (18 ref.) **(Jpn)**

[Progressive mitral regurgitation which is necessitated the mitral valve replacement after partial left ventriculectomy (Batista procedure): a case report] Ryomoto M, et al. **Kyobu Geka** 1999 Sep;52(10):840–3 (Eng. Abstr.) **(Jpn)**

[Anesthetic management of left ventricular reduction surgery (Batista procedure)] Tachibana K, et al. **Masui** 1999 Apr; 48(4):394–8 (Eng. Abstr.) **(Jpn)**

[Partial left ventriculectomy. Forgotten paradigms] Gottschall CA. **Arq Bras Cardiol** 1998 Oct;71(4):625–7 **(Por)**

[Partial left ventriculectomy for end stage dilated cardiomyopathy. Is it an alternative for heart transplantation?] Diaz R, et al. **Rev Med Chil** 1998 Jun; 126(6):661–4 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty. Bainbridge AD, et al. **J Heart Lung Transplant** 1999 May;18(5):407–13

ULTRASONOGRAPHY

Real-time, three-dimensional echocardiography: feasibility of dynamic right ventricular volume measurement with saline contrast. Ota T, et al. **Am Heart J** 1999 May; 137(5):958–66

Comparison of native and contrast-enhanced harmonic echocardiography for visualization of left ventricular endocardial border. Kasprzak JD, et al. **Am J Cardiol** 1999 Jan 15;83(2):211–7

Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Lowes BD, et al. **Am J Cardiol** 1999 Apr 15;83(8):1201–5

Coronary arterial dimension-to-left ventricular mass ratio in idiopathic dilated cardiomyopathy. Mela T, et al. **Am J Cardiol** 1999 Apr 15;83(8):1277–80, A9

Influence of echocardiographic scan plane location and number on the accuracy of three-dimensional left ventricular volume and shape determination. Nguyen TV, et al. **Am J Cardiol** 1999 Jul 15;84(2):208–13

A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure. Himeno E, et al. **Am J Hypertens** 1999 Jul;12(7):682–90

Right ventricular thrombosis early after bidirectional Glenn shunt. Imanaka K, et al. **Ann Thorac Surg** 1999 Aug; 68(2):563–5

Left ventricular aneurysm in the fetus: a diagnosis with a mixed prognosis [editorial; comment] McElhinney DB, et al. **Cardiol Young** 1999 Mar;9(2):123–6 (11 ref.). Comment on: Cardiol Young 1999 Mar;9(2):175–84.

Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use. Dickerman RD, et al. **Cardiology** 1998 Oct;90(2):145–8

The four-chamber view and its sensitivity in detecting congenital heart defects. Fernandez CO, et al. **Cardiology** 1998 Dec;90(3):202–6

Preoperative echocardiographic evaluation of patients referred for lung volume reduction surgery. Bach DS, et al. **Chest** 1998 Oct;114(4):972–80

Doppler estimation of left ventricular filling pressure in sinus tachycardia. A new application of tissue doppler imaging. Nagueh SF, et al. **Circulation** 1998 Oct 20;98(16):1644–50

Early mitral regurgitation after acute myocardial infarction does not contribute to subsequent left ventricular remodeling. Nešković AN, et al. **Clin Cardiol** 1999 Feb; 22(2):91–4

Left ventricular mass regression with amlodipine in elderly hypertensives. Singh NK, et al. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):113–9

Assessment of left ventricular cardiac shape by the use of volumetric curvature analysis from 3D echocardiography. Duann JR, et al. **Comput Med Imaging Graph** 1999 Mar-Apr;23(2):89–101

Three-dimensional echocardiography. Roelandt JR, et al. **Curr Opin Cardiol** 1998 Nov;13(6):386–96 (100 ref.)

An echocardiographic study of right and left ventricular adaptation to physical exercise in elite female orienteers. Henriksen E, et al. **Eur Heart J** 1999 Feb;20(4):309–16

Tracking the left ventricle in echocardiographic images by learning heart dynamics. Malassiotis S, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):282–90

Left ventricular mass index in patients of end stage renal disease (non-diabetic) on regular haemodialysis. Kumar VS, et al. **Indian J Med Sci** 1998 May;52(5):188–90

Harmonic imaging: echocardiographic enhanced contrast intensity and duration. Allen MR, et al. **Int J Card Imaging** 1999 Jun;15(3):215–20

Calculation of left ventricular outflow tract area using three-dimensional echocardiography. Influence on quantification of aortic valve stenosis. Menzel T, et al. **Int J Card Imaging** 1998 Dec;14(6):373–9

Intracardiac echocardiography: computerized detection of left ventricular borders. Sonka M, et al. **Int J Card Imaging** 1998 Dec;14(6):397–411 (20 ref.)

Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death [see comments] Haider AW, et al. **J Am Coll Cardiol** 1998 Nov; 32(5):1454–9. Comment in: J Am Coll Cardiol 1998 Nov;32(5):1460–2. Comment in: J Am Coll Cardiol 1999 Jun;33(7):2089.

Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. Hundley WG, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1426–32

Biventricular repair approach in ducto-dependent neonates with hypoplastic but morphologically normal left ventricle. Serraf A, et al. **J Am Coll Cardiol** 1999 Mar;33(3):827-34

Intracardiac echocardiographic imaging of the left ventricle from the right ventricle: quantitative experimental evaluation. Allan JJ, et al. **J Am Soc Echocardiogr** 1998 Oct;11(10):921-8

Left ventricular apical diastolic collapse: an unusual echocardiographic marker of postoperative cardiac tamponade. Kuvin JT, et al. **J Am Soc Echocardiogr** 1999 Mar;12(3):218-20

A simplified, practical echocardiographic approach for 3-dimensional surfacing and quantitation of the left ventricle: clinical application in patients with abnormally shaped hearts. Mele D, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1001-12

Effect of an acute increase in afterload on left ventricular regional wall motion velocity in healthy subjects. Oki T, et al. **J Am Soc Echocardiogr** 1999 Jun;12(6):476-83

Diastolic flow pattern in the normal left ventricle. Rodevand O, et al. **J Am Soc Echocardiogr** 1999 Jun;12(6):500-7

Reproducibility of pulsed wave tissue Doppler echocardiography. Vinereanu D, et al. **J Am Soc Echocardiogr** 1999 Jun;12(6):492-9

Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography. Whalley GA, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1050-5

Two-dimensional echocardiography with a 15-MHz transducer is a promising alternative for in vivo measurement of left ventricular mass in mice. Youn HJ, et al. **J Am Soc Echocardiogr** 1999 Jan;12(1):70-5

Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines? [see comments] Abergel E, et al. **J Hypertens** 1999 Jun; 17(6):817-24. Comment in: J Hypertens 1999 Jun;17(6):735-6.

Lack of relationship between left ventricular mass and serum cholesterol in hypertensives [letter; comment] Lip GY, et al. **J Hypertens** 1998 Nov;16(11):1703-4. Comment on: J Hypertens 1998 Jul;16(7):1043-7.

Exposure of circumflex branches in the tilted, beating porcine heart: echocardiographic evidence of right ventricular deformation and the effect of right or left heart bypass. Gründeman PF, et al. **J Thorac Cardiovasc Surg** 1999 Aug; 118(2):316-23

Regularization of blood motion fields by modified Navier-Stokes equations. Tura A, et al. **Med Eng Phys** 1999 Jan;21(1):27-36

Images in clinical medicine. Heart in the heart. Schuler J, et al. **N Engl J Med** 1999 Sep 30;341(14):1045

Changes in ventricular and muscle volumes of neonates. Ichihashi K, et al. **Pediatr Int** 1999 Feb;41(1):8-12

Echocardiographic characterization of left ventricular diastolic properties in patients presenting for the maze procedure. Skubas NJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):134-41

Cardiac metastasis of a malignant fibrous histiocytoma occupying the right ventricle and infiltrating the myocardium. Wankmüller H, et al. **Ultraschall Med** 1998 Jun;19(3):139-41

Ultrasonic tissue characterization in predicting residual ischemia and myocardial viability for patients with acute myocardial infarction. Lin LC, et al. **Ultrasound Med Biol** 1998 Oct;24(8):1107-20

The feasibility of using focused ultrasound for transmyocardial revascularization. Smith NB, et al. **Ultrasound Med Biol** 1998 Sep;24(7):1045-54

[Difficulties in distinguishing left ventricular aneurysm from pseudoaneurysm. Case report] Hirnle T, et al. **Pol Arch Med Wewn** 1998 Mar;99(3):228-32 (Eng. Abstr.) **(Pol)**

[The improvement of echocardiographic assessment of the left ventricle by the use of perflenapent and harmonic imaging] Olszewski R, et al. **Pol Merkuriusz Lek** 1998 Sep; 5(27):132-4 (Eng. Abstr.) **(Pol)**

[Acoustic density of tissues: clinical significance in echocardiography] Sedov VP, et al. **Ter Arkh** 1999; 71(4):65-8 (44 ref.) **(Rus)**

[The effect of gender on vasomotor function of the vascular endothelium and cardiovascular remodelling during aging] Bojić M, et al. **Srp Arh Celok Lek** 1999 Mar-Apr; 127(3-4):101-8 (Eng. Abstr.) **(Sec)**

HEART VENTRICLE, ARTIFICIAL see **HEART-ASSIST DEVICES**

HEART VOLUME see **CARDIAC VOLUME**

HEARTBURN

COMPLICATIONS

When does heartburn warrant more concern? [news] Walsh JH. **Gastroenterology** 1999 Aug;117(2):293

DRUG THERAPY

Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Jones R, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):413-9

Low-dose ranitidine for the relief of heartburn. Pappa KA, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):459-65

An evaluation of increasing doses of ranitidine for treatment of heartburn. Pappa KA, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):475-81

Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Richter JE, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):795-804

Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole [see comments] Havelund T, et al. **Am J Gastroenterol** 1999 Jul;94(7):1782-9. Comment in: Am J Gastroenterol 1999 Jul;94(7):1723-4.

Gastroesophageal reflux disease and a HAPPI quality of life [editorial; comment] Johnston BT. **Am J Gastroenterol** 1999 Jul;94(7):1723-4. Comment on: Am J Gastroenterol 1999 Jul;94(7):1782-9.

High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Kahrilas PJ, et al. **Am J Gastroenterol** 1999 Jan;94(1):92-7

Heartburn requiring frequent antacid use may indicate significant illness. Robinson M, et al. **Arch Intern Med** 1998 Nov 23;158(21):2373-6

Pharmaceutical use by U.S. astronauts on space shuttle missions. Putcha L, et al. **Aviat Space Environ Med** 1999 Jul;70(7):705-8

Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Hatlebakk JG, et al. **BMJ** 1999 Aug 28;319(7209):550-3

Antacids vs. antacids plus non-prescription ranitidine for heartburn during pregnancy. Rayburn W, et al. **Int J Gynaecol Obstet** 1999 Jul;66(1):35-7

EPIDEMIOLOGY

Patterns of consultation and treatment for heartburn: findings from a Singaporean community survey. Ho KY, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1029-33

Prevalence of dyspepsia, heartburn, and peptic ulcer disease in veterans. Dominitz JA, et al. **Am J Gastroenterol** 1999 Aug;94(8):2086-93

ETIOLOGY

Esophageal hypersensitivity may be a major cause of heartburn. Rodriguez-Stanley S, et al. **Am J Gastroenterol** 1999 Mar;94(3):628-31

Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Oliveria SA, et al. **Arch Intern Med** 1999 Jul 26; 159(14):1592-8

Gastroesophageal reflux and quality of life. Patient's knowledge, attitudes and perceptions. Jasani K, et al. **Aust Fam Physician** 1999 Jan;28 Suppl 1:S15-8

Heartburn and GERD. **Postgrad Med** 1999 Jun;105(7):233-4

Dyspepsia and heartburn. Ahmad NA, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):703-18, x (106 ref.)

[A common disease: heartburn. Self-medication with low-dose H2-receptor antagonists] **Internist (Berl)** 1998 Nov;39(11 Suppl Selbstmedi):1-4 **(Ger)**

PREVENTION & CONTROL

Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. Bate CM, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):41-7

Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group. Castell D, et al. **Aliment Pharmacol Ther** 1999 Jun; 13(6):787-94

A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Pappa KA, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):467-73

THERAPY

Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Oliveria SA, et al. **Arch Intern Med** 1999 Jul 26; 159(14):1592-8

Burning issues--a guide for patients. Gastrointestinal gas. Bursey RF. **Can J Gastroenterol** 1999 Jun;13(5):378 (0 ref.)

HEARTWATER DISEASE

DIAGNOSIS

Potential value of major antigenic protein 2 for serological diagnosis of heartwater and related ehrlichial infections. Bowie MV, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):209-15

Validation of the indirect MAP1-B enzyme-linked immunosorbent assay for diagnosis of experimental Cowdria ruminantium infection in small ruminants. Mboloi MM, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):66-72

DRUG THERAPY

Treatment of heartwater: potential adverse effects of furosemide administration on certain homeostatic parameters in normal sheep. Shakespeare AS, et al. **J S Afr Vet Assoc** 1998 Dec;69(4):129-36

ECONOMICS

The control of heartwater on large-scale commercial and smallholder farms in Zimbabwe. Chamboko T, et al. **Prev Vet Med** 1999 Apr 9;39(3):191-210

An assessment of the economic impact of heartwater (Cowdria ruminantium infection) and its control in Zimbabwe. Mukhebi AW, et al. **Prev Vet Med** 1999 Apr 9;39(3):173-89

EPIDEMIOLOGY

The distribution of heartwater in the highveld of Zimbabwe, 1980-1997. Peter TF, et al. **Onderstepoort J Vet Res** 1998 Sep;65(3):177-87

Models for heartwater epidemiology: practical implications and suggestions for future research. Yonow T, et al. **Onderstepoort J Vet Res** 1998 Dec;65(4):263-73

IMMUNOLOGY

Susceptibility and carrier status of impala, sable, and tsessebe for Cowdria ruminantium infection (heartwater). Peter TF, et al. **J Parasitol** 1999 Jun;85(3):468-72

MICROBIOLOGY

Electron microscopy of Cowdria-infected macrophages suggests that in the absence of binary fission a mosaic of organisms develops from an amorphous electron dense matrix. Du Plessis JL. **Onderstepoort J Vet Res** 1999 Mar; 66(1):39-46

HEARTWORM DISEASE see **DIROFILARIASIS**

HEAT

consider also terms at THERM-

see related
CALORIMETRY
DESERT CLIMATE
HYPERTHERMIA, INDUCED
REWARMING
TROPICAL CLIMATE

Myocardial metabolism studied during warm blood antero-retrograde reperfusion in ischaemic human hearts. Perseghin G, et al. **Acta Diabetol** 1998 Jul;35(2):67-73

Human body-fluid distribution during exercise in hot, temperate and cool environments. Maw GJ, et al. **Acta Physiol Scand** 1998 Jul;163(3):297-304

Human sudomotor responses to heating and cooling upper-body skin surfaces: cutaneous thermal sensitivity. Patterson MJ, et al. **Acta Physiol Scand** 1998 Jul; 163(3):289-96

Impact of high-temperature food processing on fats and oils. Warner K. **Adv Exp Med Biol** 1999;459:67-77 (25 ref.)

Cholesterol oxidation products. Their occurrence and detection in our foodstuffs. Yan PS. **Adv Exp Med Biol** 1999;459:79-98 (66 ref.)

The effect of dry heat on mite, cat, and dog allergens. Cain G, et al. **Allergy** 1998 Dec;53(12):1213-5

Protein modification by thermal processing. Davis PJ, et al. **Allergy** 1998;53(46 Suppl):102-5 (22 ref.)

Heat treatment modifies the allergenicity of beef and bovine serum albumin. Fiocchi A, et al. **Allergy** 1998 Aug; 53(8):798-802

Relationship of fetal growth to duration of heat stress in an ovine model of placental insufficiency. Galan HL, et al. **Am J Obstet Gynecol** 1999 May;180(5):1278-82

The heat moisture exchange device (HME) in neonatal ventilation. Wilmshurst JM, et al. **Am J Perinatol** 1999; 16(1):13-6

Responses of sympathetic outflow to skin during caloric stimulation in humans. Cui J, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R738-44

Splanchnic tissues undergo hypoxic stress during whole body hyperthermia. Hall DM, et al. **Am J Physiol** 1999 May; 276(5 Pt 1):G1195-203

How dolphins use their blubber to avoid heat stress during encounters with warm water. Heath ME, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1188-94

Regulation of the sympathetic nerve discharge bursting pattern during heat stress. Kenney MJ, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1992-2001

Early and delayed tolerance to simulated ischemia in heat-preconditioned endothelial cells: a role for HSP27. Loktionova SA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2147-58

Heat acclimation increases the basal HSP72 level and alters its production dynamics during heat stress. Maloyan A, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1506-15

Age, splanchnic vasoconstriction, and heat stress during tilting. Minson CT, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R203-12

Heat acclimation induces changes in cardiac mechanical performance: the role of thyroid hormone. Mirit E, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R550-8

Core temperature and sweating onset in humans acclimated to heat given at a fixed daily time. Shido O, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1095-101

Thermoregulatory responses of the inbred heat-tolerant FOK rat to cold. Yahata T, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):R362-7

The thermal effect of monopolar radiofrequency energy on

the properties of joint capsule. An in vivo histologic study using a sheep model. Hecht P, et al. **Am J Sports Med** 1998 Nov-Dec;26(6):808-14

An immunoaffinity procedure for determination of enzyme activity at elevated temperatures. Suresh C, et al. **Anal Biochem** 1998 Nov 15;264(2):286-8

Characteristics of fresh and frozen-thawed red wolf (Canis rufus) spermatozoa. Goodrowe KL, et al. **Anim Reprod Sci** 1998 Oct;53(1-4):299-308

Warmed versus room temperature saline solution for ocular irrigation: a randomized clinical trial. Ernst AA, et al. **Ann Emerg Med** 1998 Dec;32(6):676-9

Heat tolerance. A role for fever? Hales JR, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:188-205 (78 ref.)

Role of KATP channel in heat shock and pharmacological preconditioning. Kukreja RC. **Ann N Y Acad Sci** 1999 Jun 30;874:211-21

Inhibition of myocardial TNF-alpha production by heat shock. A potential mechanism of stress-induced cardioprotection against postischemic dysfunction. Meng X, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:69-82

Heat treatment mitigates calcification of valvular bioprostheses. Carpentier SM, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S264-6

Changes in membrane fatty acid composition of Pediococcus sp. strain NRRL B-2354 in response to growth conditions and its effect on thermal resistance. Annous BA, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2857-62

Visualization and modelling of the thermal inactivation of bacteria in a model food. Bellara SR, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3095-9

Variation in resistance of natural isolates of Escherichia coli O157 to high hydrostatic pressure, mild heat, and other stresses. Benito A, et al. **Appl Environ Microbiol** 1999 Apr; 65(4):1564-9

rRNA stability in heat-killed and UV-irradiated enterotoxigenic Staphylococcus aureus and Escherichia coli O157:H7. McKillip JL, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4264-8

Heat killing of Bacillus subtilis spores in water is not due to oxidative damage. Setlow B, et al. **Appl Environ Microbiol** 1998 Oct;64(10):4109-12

Seasonal variation of sweating responses under identical heat stress. Nakamura Y, et al. **Appl Human Sci** 1998 Sep; 17(5):167-72

Aggregation of human sperm at higher temperature is due to hyperactivation. Keppler EL, et al. **Arch Androl** 1999 Jan-Feb;42(1):35-9

Alkali metal ions protect mitochondrial rhodanese against thermal inactivation. Dionisi HM, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):202-6

Enhancement of cytotoxicity of hydrogen peroxide by hyperthermia in chinese hamster ovary cells: role of antioxidant defenses. Lord-Fontaine S, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):283-95

Revascularization and new bone formation in heat-treated bone grafts. Shimizu K, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):57-61

A thermoresistant strain of feline immunodeficiency virus (FIV) with an altered cytopathic effect and a restricted cell tropism. Alix C, et al. **Arch Virol** 1998;143(11):2093-107

Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Harmon DL, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):208-11

Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation. Azari M, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov; 26(5-6):577-82

Shock-induced hyperalgesia: II. Role of the dorsolateral periaqueductal gray. McLemore S, et al. **Behav Neurosci** 1999 Jun;113(3):539-49

Heat stability of the potato tuber ADP-glucose pyrophosphorylase: role of Cys residue 12 in the small subunit. Ballicora MA, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):782-6

Modulation of the heat-induced activation of mitogen-activated protein (MAP) kinase by quercetin. Nagasaka Y, et al. **Biochem Pharmacol** 1998 Nov 1; 56(9):1151-5

Thermal and pH-induced conformational changes of a beta-sheet protein monitored by infrared spectroscopy. Chehin R, et al. **Biochemistry** 1999 Feb 2;38(5):1525-30

Enthalpy and heat capacity changes for formation of an oligomeric DNA duplex: interpretation in terms of coupled processes of formation and association of single-stranded helices. Holbrook JA, et al. **Biochemistry** 1999 Jun 29; 38(26):8409-22

Adenine base unstacking dominates the observed enthalpy and heat capacity changes for the Escherichia coli SSB tetramer binding to single-stranded oligoadenylates. Kozlov AG, et al. **Biochemistry** 1999 Jun 1;38(22):7388-97

Transition state of the rate-limiting step of heat denaturation of Cry3A delta-endotoxin. Potekhin SA, et al. **Biochemistry** 1999 Mar 30;38(13):4121-7

A chimeric inorganic pyrophosphatase derived from Escherichia coli and Thermus thermophilus has an increased thermostability. Satoh T, et al. **Biochemistry** 1999 Feb 2;38(5):1531-6

Crystal structures of a unique thermal-stable thymidylate synthase from Bacillus subtilis. Stout TJ, et al. **Biochemistry** 1998 Oct 20;37(42):14736-47

Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Abe T, et al. **Biochim Biophys Acta** 1999 Apr 14; 1445(1):123-33

Analysis of thermal stability of soya globulins using monoclonal antibodies. Huang L, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):215-26

Sodium chloride enhances markedly the thermal stability of thermolysin as well as its catalytic activity. Inouye K, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):209-14

Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Welfle K, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):120-31

Different effects of microwave energy and conventional heat on the activity of a thermophilic beta-galactosidase from Bacillus acidocaldarius. La Cara F, et al. **Bioelectromagnetics** 1999;20(3):172-6

Regional brain heating during microwave exposure (2.06 GHz), warm-water immersion, environmental heating and exercise. Walters TJ, et al. **Bioelectromagnetics** 1998; 19(6):341-53

Scrotal heat stress induces altered sperm chromatin structure associated with a decrease in protamine disulfide bonding in the stallion [published erratum appears in Biol Reprod 1999 May;60(5):1271] Love CC, et al. **Biol Reprod** 1999 Mar;60(3):615-20

Atrial natriuretic peptide relation to plasma and heart zinc concentrations of Wistar rats exposed to cold and hot ambients. Vezyraki P, et al. **Biol Trace Elem Res** 1999 Mar; 67(3):215-23

Preparation of high-temperature stabilized beta-tricalcium phosphate by heating deficient hydroxyapatite with Na4P2O7 x 10H2O addition. Lin FH, et al. **Biomaterials** 1998 Jun;19(11-12):1101-7

Kinetics of inactivation of Bacillus subtilis spores by continuous or intermittent ohmic and conventional heating. Cho HY, et al. **Biotechnol Bioeng** 1999 Feb 5;62(3):368-72

Validation of a model describing two-dimensional heat transfer during solid-state fermentation in packed bed bioreactors. Sangsurasak P, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):739-49

Temperature elevation caused by bone cement polymerization during vertebroplasty. Deramond H, et al. **Bone** 1999 Aug;25(2 Suppl):17S-21S

Liability of laryngeal mask airway devices to thermal damage from KTP and Nd:YAG lasers. Keller C, et al. **Br J Anaesth** 1999 Feb;82(2):291-4

Nutritive value of hot water- or cocoa-pod ash solution-treated cocoa bean cake for broiler chicks. Odunsi AA, et al. **Br Poult Sci** 1998 Sep;39(4):519-25

Effects of wheat source, heat treatment and enzyme inclusion on diet metabolisability and broiler performance. Stewart RA, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S42-3

Paradoxical heat sensation in healthy subjects: peripherally conducted by A delta or C fibres? Susser E, et al. **Brain** 1999 Feb;122 (Pt 2):239-46

Synaptophysin immunocytochemistry with thermal intensification: a marker of terminal axonal maturation in the human fetal nervous system. Sarnat HB, et al. **Brain Dev** 1999 Jan;21(1):41-50

Comparison of touch- and laser heat-evoked cortical field potentials in conscious rats. Shaw FZ, et al. **Brain Res** 1999 Apr 10;824(2):183-96

Methods for warming intravenous fluid in small volumes. Schultz JA, et al. **Can J Anaesth** 1998 Nov;45(11):1110-5

Stress tolerance in a yeast lipid mutant: membrane lipids influence tolerance to heat and ethanol independently of heat shock proteins and trehalose. Swan TM, et al. **Can J Microbiol** 1999 Jun;45(6):472-9

Is radiosensitive cell line cross-sensitive to heat?: Effect of heat on two rat yolk sac tumor cell lines with different radiosensitivity. Mitsuhashi N, et al. **Cancer Lett** 1999 Aug 3;142(2):195-200

Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells. Katschinski DM, et al. **Cancer Res** 1999 Jul 15;59(14):3404-10

Analysis of heat generation during rotational atherectomy using different operational techniques. Reisman M, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):453-5

Colonization by diatoms and antirheumatic activity of thermal mud. Tolomio C, et al. **Cell Biochem Funct** 1999 Mar;17(1):29-33

Reduced thermotolerance in aged cells results from a loss of an hsp72-mediated control of JNK signaling pathway. Volloch V, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):265-71

Normative data of quantitative thermal and vibratory thresholds in normal subjects in Taiwan: gender and age effect. Liou JT, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul;62(7):431-7

Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Brandt J, et al. **Clin Chem** 1999 Jan;45(1):47-53

Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI). Brownlee AA, et al. **Clin Exp Immunol** 1999 Jul;117(1):183-9

A new model to assess tcpO2 changes during heat-dependent vasodilation: preliminary observations. Sodi N, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):235-43

Inhibition of the human primary motor area by painful heat stimulation of the skin. Valeriani M, et al. **Clin Neurophysiol** 1999 Aug;110(8):1475-80

Apnoea-associated heart rate changes among preterm and full-term infants exposed to hyperthermia. Tirosh E, et al. **Clin Physiol** 1998 Jul;18(4):331-5

Fluid and electrolyte replacement in soccer. Kirkendall DT. **Clin Sports Med** 1998 Oct;17(4):729-38, vi (23 ref.)

How long should you boil water to make it safe to drink? **Commun Dis Intell** 1998 Sep 3;22(9):191

Heat production and substrate oxidation in rats fed at maintenance level and during fasting. Chwalibog A, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Dec; 121(4):423-9

The effects of elevated summer temperature and sublethal pollutants (ammonia, low pH) on protein turnover in the gill and liver of rainbow trout (Oncorhynchus mykiss) on a limited food ration. Morgan IJ, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 May; 123(1):43-53

Testosterone modifies response to chronic heat exposure in rats. Shvareva N, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):575-8

Do the components of heat and moisture exchanger filters affect their humidifying efficacy and the incidence of nosocomial pneumonia? Thomachot L, et al. **Crit Care Med** 1999 May;27(5):923-8

Induction of a polyubiquitin gene (ubi1) by potato phytoalexins and heat shock in Gibberella pulicaris. Loser K, et al. **Curr Genet** 1998 Dec;34(5):404-9

Effects of low feed intake and hot environment on plasma profiles of glucose, nonesterified fatty acids, insulin, glucagon, and IGF-I in lactating sows. de Bragança MM, et al. **Domest Anim Endocrinol** 1999 Feb;16(2):89-101

Heat influences on plasma insulin and glucagon in response to secretogogues in non-lactating dairy cows. Itoh F, et al. **Domest Anim Endocrinol** 1998 Nov;15(6):499-510

Thermal analysis as a screening technique in preformulation studies of picotamide solid dosage forms. Mura P, et al. **Drug Dev Ind Pharm** 1998 Aug;24(8):747-56

Rheology and filling characteristics of particulate dispersions in polymer melt formulations for liquid fill hard gelatin capsules. Rowley G, et al. **Drug Dev Ind Pharm** 1998 Jul; 24(7):605-11

A standardized method of identification of raw and heat-processed fish by urea isoelectric focusing: a collaborative study. Etienne M, et al. **Electrophoresis** 1999 Jul;20(10):1923-33

Analysis of heat shock-induced monophosphorylation of stathmin in human T lymphoblastic cell line JURKAT by two-dimensional gel electrophoresis. Fujimoto M, et al. **Electrophoresis** 1998 Oct;19(14):2515-20

Subcellular fractionation by organelle electrophoresis: separation of phagosomes containing heat-killed yeast particles. Hasan Z, et al. **Electrophoresis** 1998 Jun; 19(7):1179-84

Single exposure to heat induces stage-specific germ cell apoptosis in rats: role of intratesticular testosterone on stage specificity. Lue YH, et al. **Endocrinology** 1999 Apr; 140(4):1709-17

Heat shock inhibits cytokine-induced nitric oxide synthase expression by rat and human islets. Scarim AL, et al. **Endocrinology** 1998 Dec;139(12):5050-7

Predicting heat worldwide [news] **Environ Health Perspect** 1999 May;107(5):A238-9

Identification of carcinogens in cooking oil fumes. Chiang TA, et al. **Environ Res** 1999 Jul;81(1):18-22

Feline calicivirus as a model system for heat inactivation studies of small round structured viruses in shellfish. Slomka MJ, et al. **Epidemiol Infect** 1998 Oct;121(2):401-7

The neuropathology of hyperthermic seizures in the rat. Jiang W, et al. **Epilepsia** 1999 Jan;40(1):5-19

Benefit of heat acclimation is limited by the evaporative potential when wearing chemical protective clothing. Chang SK, et al. **Ergonomics** 1999 Aug;49(8):1038-50

Human power output during repeated sprint cycle exercise: the influence of thermal stress. Ball D, et al. **Eur J Appl Physiol** 1999 Mar;79(4):360-6

Heterocyclic amine levels in cooked meat and the implication for New Zealanders. Thomson B. **Eur J Cancer Prev** 1999 Jul;8(3):201-6

GH stimulation tests: evaluation of GH responses to heat test versus insulin-tolerance test. Fisker S, et al. **Eur J Endocrinol** 1998 Dec;139(6):605-10

Compritol 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Barthelemy P, et al. **Eur J Pharm Biopharm** 1999 Jan;47(1):87-90

High-temperature effects on antibody response to viral antigen in mice. Yamamoto S, et al. **Exp Anim** 1999 Jan; 48(1):9-14

Recordings of polymodal single c-fiber nociceptive afferents following mechanical and argon-laser heat stimulation of human skin. Olausson B. **Exp Brain Res** 1998 Sep; 122(1):44-54

Recordings of human polymodal single C-fiber afferents following mechanical and argon-laser heat stimulation of inflamed skin. Olausson B. **Exp Brain Res** 1998 Sep; 122(1):55-61

The influence of stimulus temperature rise rate, adapting temperature, and stimulus duration on suprathreshold responses evoked by noxious heat in the glabrous skin of the limb. Comparison of neuronal discharge in the rat spinal

dorsal horn with human sensations. Pertovaara A. **Exp Brain Res** 1999 Jun;126(4):482–94

Synergistic effects of heat and ET-18-OCH3 on membrane expression of hsp70 and lysis of leukemic K562 cells. Botzler C, et al. **Exp Hematol** 1999 Mar;27(3):470–8

Effects of quercetin and sunphenon on responses of cancer cells to heat shock damage. Kudo M, et al. **Exp Mol Pathol** 1999 Apr;66(1):66–75

Effect of temperature on muscle metabolism during submaximal exercise in humans. Starkie RL, et al. **Exp Physiol** 1999 Jul;84(4):775–84

Thermozymes: biotechnology and structure-function relationships. Zeikus JG, et al. **Extremophiles** 1998 Aug; 2(3):179–83 (12 ref.)

Regulation of System A amino acid transport in L6 rat skeletal muscle cells by insulin, chemical and hyperthermic stress. McDowell HE, et al. **FEBS Lett** 1998 Dec 11; 441(1):15–9

Demonstration of thermal dissipation of absorbed quanta during energy-dependent quenching of chlorophyll fluorescence in photosynthetic membranes. Yahyaoui W, et al. **FEBS Lett** 1998 Nov 27;440(1–2):59–63

Increased thermosensitivity associated with topoisomerase I deletion and promoter mutations in Escherichia coli. Qi H, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):141–6

Changes in cell morphology and actin organization during heat shock in Dictyostelium discoideum: does HSP70 play a role in acquired thermotolerance? Xiang W, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):95–107

Survival of cryopreservation and thawing with all blastomeres intact identifies multicell embryos with superior frozen embryo transfer outcome. Burns WN, et al. **Fertil Steril** 1999 Sep;72(3):527–32

Conflicts of thermal adaptation and fever--a cybernetic approach based on physiological experiments. Werner J, et al. **Fiziol Cheloveka** 1998 Jul–Aug;24(4):22–8

Mutagenicity and aromatic amine content of fumes from heated cooking oils produced in Taiwan. Chiang TA, et al. **Food Chem Toxicol** 1999 Feb–Mar;37(2–3):125–34

Toxicity of oxidized fats II: tissue levels of lipid peroxides in rats fed a thermally oxidized corn oil diet. Nwanguma BC, et al. **Food Chem Toxicol** 1999 Apr;37(4):413–6

On the path to the heat shock response: destabilization and formation of partially folded protein intermediates, a consequence of protein thiol modification. Freeman ML, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):737–45 (102 ref.)

Heat stress response and myocardial protection. Joyeux M, et al. **Fundam Clin Pharmacol** 1999;13(1):1–10 (92 ref.)

UV stimulation of chromosomal marker exchange in Sulfolobus acidocaldarius: implications for DNA repair, conjugation and homologous recombination at extremely high temperatures. Schmidt KJ, et al. **Genetics** 1999 Aug; 152(4):1407–15

Demographic evaluation of the fertility of aluminium industry workers: influence of exposure to heat and static magnetic fields. Mur JM, et al. **Hum Reprod** 1998 Jul; 13(7):2016–9

Electromagnetic and thermal analysis for lipid bilayer membranes exposed to RF fields. Eibert TF, et al. **IEEE Trans Biomed Eng** 1999 Aug;46(8):1013–21

Study of the cause of the temperature rise at the muscle-bone interface during ultrasound hyperthermia. Fujii M, et al. **IEEE Trans Biomed Eng** 1999 May;46(5):494–504

Heating of tissue by near-field exposure to a dipole: a model analysis. Riu PJ, et al. **IEEE Trans Biomed Eng** 1999 Aug; 46(8):911–7

Heat mediated quick Coomassie blue protein staining and destaining of SDS-PAGE gels. Kurien BT, et al. **Indian J Biochem Biophys** 1998 Dec;35(6):385–9

Enhancement of thermal effect in virally infected mammalian cells in vitro and its modification by chlorpromazine. Shenoy MA, et al. **Indian J Exp Biol** 1998 Jul;36(7):668–74

Influence of the boundary thermal conditions on the air change efficiency indexes. Di Tommaso RM, et al. **Indoor Air** 1999 Mar;9(1):63–9

Heat-shocked monocytes are resistant to Staphylococcus aureus-induced apoptotic DNA fragmentation due to expression of HSP72. Guzik K, et al. **Infect Immun** 1999 Aug;67(8):4216–22

Neoallergens in heated soybean hull. Codina R, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):120–5

Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity. Katschinski DM, et al. **Int J Cancer** 1999 Jan 5;80(1):104–9

Modelling the overall effect of pH on the apparent heat resistance of Bacillus cereus spores. Couvert O, et al. **Int J Food Microbiol** 1999 Aug 1;49(1–2):57–62

A quantitative approach for studying the effect of heat treatment conditions on resistance and recovery of Bacillus cereus spores. Laurent Y, et al. **Int J Food Microbiol** 1999 May 1;48(2):149–57

Heat resistance of Yersinia enterocolitica grown at different temperatures and heated in different media. Pagán R, et al. **Int J Food Microbiol** 1999 Mar 1;47(1–2):59–66

Production of listeriolysin O by Listeria monocytogenes (Scott A) under heat-shock conditions. Sampathkumar B, et al. **Int J Food Microbiol** 1999 May 1;48(2):131–7

The effect of intermittent heating on some chemical parameters of refined oils used in Egypt. A public health nutrition concern. Tewfik IH, et al. **Int J Food Sci Nutr** 1998 Sep;49(5):339–42

Global climate warming and performance of therapeutic agents in obstetrics and gynecology. Arya SC. **Int J Gynaecol Obstet** 1999 May;65(2):209–10

Spectrofluorometric and microcalorimetric study of the thermal poration relevant to the mechanism of thermohaemolysis. Ivanov IT, et al. **Int J Hyperthermia** 1999 Jan–Feb;15(1):29–43

Damage to DNA purified from the radioresistant prokaryote, Deinococcus radiodurans, by acid heating. Imamura M, et al. **Int J Mol Med** 1999 Apr;3(4):391–5

Physicochemical properties of chitosan-lipid emulsions and their stability during the autoclaving process. Jumaa M, et al. **Int J Pharm** 1999 Jun 25;183(2):175–84

Formation of ondansetron polymorphs. Llácer JM, et al. **Int J Pharm** 1999 Jan 25;177(2):221–9

Heat sensitivity of double-stranded DNA-dependent protein kinase (DNA-PK) activity. Ihara M, et al. **Int J Radiat Biol** 1999 Feb;75(2):253–8

Inhibition of protein kinase C activity promotes heat-induced apoptosis in RIF-1 but not in TR-4 cells. Li JH, et al. **Int J Radiat Biol** 1999 Jul;75(7):903–11

Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Singh DP, et al. **Invest Ophthalmol Vis Sci** 1999 Jun;40(7):1444–51

Acoustic field interaction with a boiling system under terrestrial gravity and microgravity. Sitter JS, et al. **J Acoust Soc Am** 1998 Nov;104(5):2561–9

Hot tumble drying and mite survival in duvets. Mason K, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):499–500

Cardiovascular responses to a hot tub bath. Boone T, et al. **J Altern Complement Med** 1999 Jun;5(3):301–4

Determination of pyrolysis products of smoked methamphetamine mixed with tobacco by tandem mass spectrometry. Lee MR, et al. **J Anal Toxicol** 1999 Jan–Feb; 23(1):41–5

Heat tolerance of Boran and Tuli crossbred steers. Gaughan JB, et al. **J Anim Sci** 1999 Sep;77(9):2398–405

Heat processing changes the protein quality of canned cat foods as measured with a rat bioassay. Hendriks WH, et al. **J Anim Sci** 1999 Mar;77(3):669–76

Heat energy for growing goats and sheep grazing different pastures in the summer. Herselman MJ, et al. **J Anim Sci** 1999 May;77(5):1258–65

Influence of high ambient temperatures on performance of multiparous lactating sows. Quiniou N, et al. **J Anim Sci** 1999 Aug;77(8):2124–34

Comparison of microwave oven and convection oven for acid hydrolysis of dietary fiber polysaccharides. Li BW. **J AOAC Int** 1998 Nov–Dec;81(6):1277–80

Effect of u.v. light irradiation, starvation and heat on Escherichia coli beta-D-galactosidase activity and other potential viability parameters. Fiksdal L, et al. **J Appl Microbiol** 1999 Jul;87(1):62–71

Inactivation of Bacillus subtilis spores by combining ultrasonic waves under pressure and mild heat treatment. Raso J, et al. **J Appl Microbiol** 1998 Nov;85(5):849–54

Immune changes in humans during cold exposure: effects of prior heating and exercise. Brenner IK, et al. **J Appl Physiol** 1999 Aug;87(2):699–710

Effect of increasing central venous pressure during passive heating on skin blood flow. Crandall CG, et al. **J Appl Physiol** 1999 Feb;86(2):605–10

Drink composition, voluntary drinking, and fluid balance in exercising, trained, heat-acclimatized boys. Rivera-Brown AM, et al. **J Appl Physiol** 1999 Jan;86(1):78–84

Enhancement of thermal hyperalgesia by alpha-adrenoceptors in capsaicin-treated skin. Drummond PD. **J Auton Nerv Syst** 1998 Apr 30;69(2–3):96–102

Effect of heat acclimation and heat shock on oscillations of carbamyl-choline-evoked Ca2+ signal in HSY cell line. Kaspler P, et al. **J Basic Clin Physiol Pharmacol** 1999; 10(2):153–61

Lys13 plays a crucial role in the functional adaptation of the thermophilic triose-phosphate isomerase from Bacillus stearothermophilus to high temperatures. Alvarez M, et al. **J Biol Chem** 1999 Jul 2;274(27):19181–7

Recovery of the yeast cell cycle from heat shock-induced G(1) arrest involves a positive regulation of G(1) cyclin expression by the S phase cyclin Clb5. Li X, et al. **J Biol Chem** 1999 Aug 20;274(34):24220–31

DNA-dependent protein kinase protects against heat-induced apoptosis. Nueda A, et al. **J Biol Chem** 1999 May 21;274(21):14988–96

The activation of the rat copper/zinc superoxide dismutase gene by hydrogen peroxide through the hydrogen peroxide-responsive element and by paraquat and heat shock through the same heat shock element. Yoo HY, et al. **J Biol Chem** 1999 Aug 20;274(34):23887–92

Heat-induced changes in the mechanics of a collagenous tissue: isothermal, isotonic shrinkage. Chen SS, et al. **J Biomech Eng** 1998 Jun;120(3):382–8

Heat-induced expression of MHC-linked HSP70 genes in lymphocytes varies at the single-cell level. Dressel R, et al. **J Cell Biochem** 1999 Mar 15;72(4):558–69

Diamide-induced cytotoxicity and thermotolerance in CHO cells. Borrelli MJ, et al. **J Cell Physiol** 1998 Dec; 177(3):483–92

Effects of high pressure and heat treatment on the mineral balance of goats' milk. de la Fuente MA, et al. **J Dairy Res** 1999 Feb;66(1):65–72

Heat-treated whole cottonseed: effect of dietary protein concentration on the performance and amino acid utilization by the mammary gland of dairy cows. Mabjeesh SJ, et al. **J Dairy Res** 1999 Feb;66(1):9–22

Effect of heat treatment on anti-rotavirus activity of bovine colostrum. Mainer G, et al. **J Dairy Res** 1999 Feb; 66(1):131–7

Formation of homocitrulline during heating of milk. Metwalli AA, et al. **J Dairy Res** 1998 Nov;65(4):579–89

Influence of short- and long-term exposure to a hot environment on rumen passage rate and diet digestibility by Friesian heifers. Bernabucci U, et al. **J Dairy Sci** 1999 May;82(5):967–73

Effect of high pressure homogenization on microbial and chemico-physical characteristics of goat cheeses. Guerzoni ME, et al. **J Dairy Sci** 1999 May;82(5):851–62

Effects of controlled heat stress on ovarian function of dairy cattle. 2. Heifers. Wilson SJ, et al. **J Dairy Sci** 1998 Aug; 81(8):2132–8

Effects of controlled heat stress on ovarian function of dairy cattle. 1. Lactating cows. Wilson SJ, et al. **J Dairy Sci** 1998 Aug;81(8):2124–31

Epidermal growth factor as an autocrine modulator of stress response in mammary epithelial cells. Sheffield LG. **J Endocrinol** 1998 Oct;159(1):111–6

Holmium: YAG lithotripsy: photothermal mechanism. Vassar GJ, et al. **J Endourol** 1999 Apr;13(3):181–90

Excess mortality in England and Wales, and in Greater London, during the 1995 heatwave. Rooney C, et al. **J Epidemiol Community Health** 1998 Aug;52(8):482–6

Residual alkaline phosphatase activity in pasteurized milk heated at various temperatures--measurement with the fluorophos and Scharer rapid phosphatase tests. Angelino PD, et al. **J Food Prot** 1999 Jan;62(1):81–5

Thermal resistance of bacterial spores in milk-based beverages supplemented with nisin. Beard BM, et al. **J Food Prot** 1999 May;62(5):484–91

Combined effect of nisin and moderate heat on destruction of Listeria monocytogenes in cold-pack lobster meat. Budu-Amoako E, et al. **J Food Prot** 1999 Jan;62(1):46–50

Decontamination of beef carcass surface tissue by steam vacuuming alone and combined with hot water and lactic acid sprays. Castillo A, et al. **J Food Prot** 1999 Feb; 62(2):146–51

Kinetics of ascorbic acid degradation in green asparagus during heat processing. Esteve MJ, et al. **J Food Prot** 1998 Nov;61(11):1518–21

Alteration in sporulation, enterotoxin production, and protein synthesis by Clostridium perfringens type A following heat shock. Heredia NL, et al. **J Food Prot** 1998 Sep; 61(9):1143–7

Inactivation of Escherichia coli O157:H7 in orange juice using a combination of high pressure and mild heat. Linton M, et al. **J Food Prot** 1999 Mar;62(3):277–9

Effect of shift in growth temperature on tolerance of psychrotrophic and mesophilic strains of Bacillus cereus to heat and sodium chloride. Mahakarnchanakul W, et al. **J Food Prot** 1999 Jan;62(1):57–64

Heat resistance of Bacillus cereus spores: effects of milk constituents and stabilizing additives. Mazas M, et al. **J Food Prot** 1999 Apr;62(4):410–3

Use of capillary tubes and plate heat exchanger to validate U.S. Department of Agriculture pasteurization protocols for elimination of Salmonella enteritidis from liquid egg products. Michalski CB, et al. **J Food Prot** 1999 Feb; 62(2):112–7

Survival of Vibrio cholerae 01 strains in shrimp subjected to freezing and boiling. Nascumento DR, et al. **J Food Prot** 1998 Oct;61(10):1317–20

Thermotolerance of Escherichia coli O157:H7 ATCC 43,894, Escherichia coli B, and an rpoS-deficient mutant of Escherichia coli O157:H7 ATCC 43,895 following exposure to 1.5% acetic acid. Williams NC, et al. **J Food Prot** 1998 Sep;61(9):1184–6

The differentiation of traumatic and heat-related fractures in burned bone. Herrmann NP, et al. **J Forensic Sci** 1999 May;44(3):461–9

Effects of extreme heat on teeth with implications for histologic processing. Myers SL, et al. **J Forensic Sci** 1999 Jul;44(4):805–9

Thermal stability of direct dental esthetic restorative materials at elevated temperatures. Robinson FG, et al. **J Forensic Sci** 1998 Nov;43(6):1163–7

The thermal decomposition of dimethoate. Andreozzi R, et al. **J Hazard Mater** 1999 Feb 15;64(3):283–94

Behaviour of metals under the conditions of roasting MSW incinerator fly ash with chlorinating agents. Chan CC, et al. **J Hazard Mater** 1999 Jan 1;64(1):75–89

Thermogravimetric study of thermal decontamination of soils polluted by hexachlorobenzene, 4-chlorobiphenyl, naphthalene, or n-decane. Risoul V, et al. **J Hazard Mater** 1999 Feb 15;64(3):295–311

Heat inactivation of fetal calf serum is not required for in vitro measurement of lymphocyte functions. Leshem B, et al. **J Immunol Methods** 1999 Mar 4;223(2):249–54

Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. Viard I, et al. **J Invest Dermatol** 1999 Mar;112(3):290–6

Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. Hohmann AG, et al. **J Neurophysiol** 1999 Feb; 81(2):575–83

Role of [Ca2+]i in the ATP-induced heat sensitization

process of rat nociceptive neurons. Kress M, et al. **J Neurophysiol** 1999 Jun;81(6):2612–9

Influence of rewarming conditions after hypothermia in gerbils with transient forebrain ischemia. Nakamura T, et al. **J Neurosurg** 1999 Jul;91(1):114–20

Heating garlic inhibits its ability to suppress 7, 12–dimethylbenz(a)anthracene–induced DNA adduct formation in rat mammary tissue. Song K, et al. **J Nutr** 1999 Mar;129(3):657–61

Thermal balloon endometrial ablator: a preclinical safety and effectiveness study. Banerjee K, et al. **J Obstet Gynaecol Res** 1999 Apr;25(2):143–6

Enhancement of bone apposition to stainless steel cortical screws by surface modification using heat treatment: an experimental study [published erratum appears in J Orthop Trauma 1999 Jan;13(1):69] Tzur I, et al. **J Orthop Trauma** 1998 Sep–Oct;12(7):504–9

Effects of human milk pasteurization and sterilization on available fat content and fatty acid composition. Fidler N, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):317–22

Temperature coefficient of membrane currents induced by noxious heat in sensory neurones in the rat. Vyklický L, et al. **J Physiol (Lond)** 1999 May 15;517 (Pt 1):181–92

Effects of maintaining solstice light and temperature on reproductive activity, coat growth, plasma prolactin and melatonin in goats. Gebbie FE, et al. **J Reprod Fertil** 1999 May;116(1):25–33

Thermal modification of collagen. Wall MS, et al. **J Shoulder Elbow Surg** 1999 Jul–Aug;8(4):339–44

Health hazards due to clenbuterol residues in food [letter] Chan TY. **J Toxicol Clin Toxicol** 1999;37(4):517–9

High–temperature effects on antioxidant systems and toxic product formation in nutritional oils. Durak I, et al. **J Toxicol Environ Health** 1999 Aug 27;57(8):585–9

Experimental test of harmonic contribution to the thermal index for soft tissue. Egerton IB, et al. **J Ultrasound Med** 1999 Jan;18(1):81–6

Bladder welding in rats using controlled temperature CO2 laser system. Lobik L, et al. **J Urol** 1999 May;161(5):1662–5

Canine model of ventricular fibrillation using programmed stimuli and localized myocardial warming or cooling. Tachibana H, et al. **Jpn Heart J** 1999 Mar;40(2):179–88

Effect of functional magnetic particles on radiofrequency capacitive heating. Shinkai M, et al. **Jpn J Cancer Res** 1999 Jun;90(6):699–704

Role of glutathione in the antiulcer effect of hot water extract of black tea (Camellia sinensis). Maity S, et al. **Jpn J Pharmacol** 1998 Nov;78(3):285–92

Higher environmental temperature potentiates cataleptic effect of fentanyl in rats. Vučković S, et al. **Jpn J Pharmacol** 1998 Dec;78(4):523–7

Heat shock treatment decreases the mortality of sepsis in rats. Yang RC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):664–72

Characterization of tissue morphology, angiogenesis, and temperature in the adaptive response of muscle tissue to chronic heating. Seese TM, et al. **Lab Invest** 1998 Dec; 78(12):1553–62

A new cluster headache precipitant: increased body heat [letter] Blau JN, et al. **Lancet** 1999 Sep 18;354(9183):1001–2

Effect of higher pasteurization temperatures, and longer holding times at 72 degrees C, on the inactivation of Mycobacterium paratuberculosis in milk. Grant IR, et al. **Lett Appl Microbiol** 1999 Jun;28(6):461–5

Synergistic effect of heat and sodium lactate on the thermal resistance of Yersinia enterocolitica and Listeria monocytogenes in minced beef. McMahon CM, et al. **Lett Appl Microbiol** 1999 May;28(5):340–4

Survival and biological activity of heat damaged DNA. Masters CI, et al. **Lett Appl Microbiol** 1998 Nov; 27(5):279–82

Resistance of heat–shocked cells of Listeria monocytogenes to mano–sonication and mano–thermo–sonication. Pagán R, et al. **Lett Appl Microbiol** 1999 Jan;28(1):71–5

The study of heat stress in tomato fruits by NMR microimaging. Iwahashi Y, et al. **Magn Reson Imaging** 1999 Jun;17(5):767–72

Human brain activation under controlled thermal stimulation and habituation to noxious heat: an fMRI study. Becerra LR, et al. **Magn Reson Med** 1999 May;41(5):1044–57

Performance of a high–temperature superconducting probe for in vivo microscopy at 2.0 T. Miller JR, et al. **Magn Reson Med** 1999 Jan;41(1):72–9

HSP70 induction may explain the long–lasting resistance to heat of Drosophila melanogaster having lived in hypergravity. Minois N, et al. **Mech Ageing Dev** 1999 Jun 1;109(1):65–77

Intermittent running: muscle metabolism in the heat and effect of hypohydration. Maxwell NS, et al. **Med Sci Sports Exerc** 1999 May;31(5):675–83

Survival and molting incidence after heat and cold shocks in Panstrongylus megistus Burmeister. Garcia SL, et al. **Mem Inst Oswaldo Cruz** 1999 Jan–Feb;94(1):131–7

Microwaves and heat in aldehyde fixation: model experiments with bovine serum albumin. Hopwood D. **Methods** 1998 Jun;15(2):119–22

Mutations in the Schizosaccharomyces pombe heat shock factor that differentially affect responses to heat and cadmium stress. Saltsman KA, et al. **Mol Gen Genet** 1999 Feb;261(1):161–9

The heat shock response in yeast: differential regulations and contributions of the Msn2p/Msn4p and Hsf1p regulons. Boy–Marcotte E, et al. **Mol Microbiol** 1999 Jul; 33(2):274–83

Conversion of a bacterial warm sensor to a cold sensor by methylation of a single residue in the presence of an attractant. Nishiyama SI, et al. **Mol Microbiol** 1999 Apr; 32(2):357–65

Heat sensitivity of sensory fibers in carpal tunnel syndrome [letter] Burke D, et al. **Muscle Nerve** 1999 Jul;22(7):969–70

High–temperature repetitive nerve stimulation in myasthenia gravis. Rutkove SB, et al. **Muscle Nerve** 1998 Nov; 21(11):1414–8

Heat sensitivity of sensory fibers in carpal tunnel syndrome [see comments] Wang AK, et al. **Muscle Nerve** 1999 Jan; 22(1):37–42. Comment in: Muscle Nerve 1999 Jul;22(7):969–70.

A capsaicin–receptor homologue with a high threshold for noxious heat. Caterina MJ, et al. **Nature** 1999 Apr 1; 398(6726):436–41

Heat shock protects synaptic transmission in flight motor circuitry of locusts. Dawson–Scully K, et al. **Neuroreport** 1998 Aug 3;9(11):2589–93

Zinc alleviates thermal hyperalgesia due to partial nerve injury. Liu T, et al. **Neuroreport** 1999 May 14;10(7):1619–23

Zinc alleviates thermal hyperalgesia due to partial nerve injury. Liu T, et al. **Neuroreport** 1999 Feb 25;10(3):645–9

A new human experimental pain model: the heat/capsaicin sensitization model. Petersen KL, et al. **Neuroreport** 1999 May 14;10(7):1511–6

Constitutive and heat–inducible expression of HSP105 in neurons and glial cells in culture. Satoh J, et al. **Neuroreport** 1998 Sep 14;9(13):2977–83

Fibroblasts from Alzheimer's disease donors do not differ from controls in response to heat shock. Arosio B, et al. **Neurosci Lett** 1998 Oct 30;256(1):25–8

Neuroprotection against oxidative stress by serum from heat acclimated rats. Beit–Yannai E, et al. **Neurosci Lett** 1998 Sep 25;254(2):89–92

Brief electrical stimulation of c–fibers in rats produces thermal hyperalgesia lasting weeks. Vatine JJ, et al. **Neurosci Lett** 1998 May 1;246(3):125–8

Intrathecal substance P–induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids. Hua XY, et al. **Neuroscience** 1999 Mar;89(2):525–34

IRIDIUM exposure increases c–fos expression in the mouse brain only at levels which likely result in tissue heating. Morrissey JJ, et al. **Neuroscience** 1999;92(4):1539–46

Noxious heat activates all capsaicin–sensitive and also a sub–population of capsaicin–insensitive dorsal root ganglion neurons. Nagy I, et al. **Neuroscience** 1999; 88(4):995–7

Heat stress, even extreme, does not induce penetration of pyridostigmine into the brain of guinea pigs. Lallement G, et al. **Neurotoxicology** 1998 Dec;19(6):759–66

Dehydromonocrotaline generates sequence–selective N–7 guanine alkylation and heat and alkali stable multiple fragment DNA crosslinks. Pereira TN, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5441–7

Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Hirose K, et al. **Oncology** 1999; 57(2):106–14

Heat–sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor. Nishita T. **Osaka City Med J** 1998 Jun;44(1):73–83

Convective warming blankets improve peroperative heat preservation in congenital heart surgery. Schlünzen L, et al. **Paediatr Anaesth** 1998;8(5):397–401

Psychophysical measures of sensitization to tonic heat discriminate chronic pain patients. Kleinböhl D, et al. **Pain** 1999 May;81(1–2):35–43

C– and A delta–fiber components of heat–evoked cerebral potentials in healthy human subjects. Magerl W, et al. **Pain** 1999 Aug;82(2):127–37

An analysis of the temperature effects of fever on the intra–host population dynamics of Plasmodium falciparum. Gravenor MB, et al. **Parasitology** 1998 Aug;117 (Pt 2):97–105

Impaired induction of heat shock protein implicated in decreased thermotolerance in a temperature–sensitive multinucleated cell line. Cao Y, et al. **Pflugers Arch** 1998 Dec;437(1):15–20

Temperature– and capsaicin–sensitive nerve fibers in brown adipose tissue attenuate thermogenesis in the rat. Osaka T, et al. **Pflugers Arch** 1998 Dec;437(1):36–42

Release kinetics of a controlled–release multiparticulate dosage form prepared using a hot–melt fluid bed coating method. Griffin EN, et al. **Pharm Dev Technol** 1999 Jan; 4(1):117–24

Isothermal and nonisothermal decomposition of thymopentin and its analogs in aqueous solution. Lee ML, et al. **Pharm Res** 1998 Nov;15(11):1702–7

Characterization of the effects of adenosine kinase inhibitors on acute thermal nociception in mice. Kowaluk EA, et al. **Pharmacol Biochem Behav** 1999 May;63(1):83–91

The assessment proposal for long–term and short–term tolerable hygrothermal microclimatic conditions. Jirák Z, et al. **Physiol Res** 1997;46(4):307–17

Reduction of polyphenol and phytic acid content of pearl millet grains by malting and blanching. Archana, et al. **Plant Foods Hum Nutr** 1999;53(2):93–8

Impact of microwave heating on hemagglutinins, trypsin inhibitors and protein quality of selected legume seeds. Hernández–Infante M, et al. **Plant Foods Hum Nutr** 1998; 52(3):199–208

Proximate composition and some functional properties of extrusion cooked soybean and sweet potato blends. Iwe MO, et al. **Plant Foods Hum Nutr** 1999;53(2):121–32

Enhancement of the tolerance of Arabidopsis to high temperatures by genetic engineering of the synthesis of glycinebetaine. Alia, et al. **Plant J** 1998 Oct;16(2):155–61

Aerobic bacteria and solids in a three–tank, two–pass, counterflow scalder. Cason JA, et al. **Poult Sci** 1999 Jan; 78(1):144–7

Effect of acute heat stress on amino acid digestibility in laying hens. Koelkebeck KW, et al. **Poult Sci** 1998 Sep; 77(9):1393–6

The effect of in vitro heat stress on the uptake of neutral red by chicken thrombocytes. Roland GA, et al. **Poult Sci** 1998 Nov;77(11):1661–4

Heat conditioning induces heat shock proteins in broiler chickens and turkey poults. Wang S, et al. **Poult Sci** 1998 Nov;77(11):1636–45

Heat stable and urea resistant alkaline phosphatase in maternal neutrophils from normal and Down syndrome pregnancies. Peleg L, et al. **Prenat Diagn** 1999 Mar; 19(3):224–8

Ion channels gated by heat. Cesare P, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7658–63 (32 ref.)

Protein thermostability above 100 degreesC: a key role for ionic interactions. Vetriani C, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12300–5

Proteins from thermophilic and mesophilic organisms essentially do not differ in packing. Karshikoff A, et al. **Protein Eng** 1998 Oct;11(10):867–72

Thermostable glycerol kinase from a hyperthermophilic archaeon: gene cloning and characterization of the recombinant enzyme. Koga Y, et al. **Protein Eng** 1998 Dec; 11(12):1219–27

Global analysis of the thermal and chemical denaturation of the N–terminal domain of the ribosomal protein L9 in H2O and D2O. Determination of the thermodynamic parameters, deltaH(o), deltaS(o), and deltaC(o)p and evaluation of solvent isotope effects. Kuhlman B, et al. **Protein Sci** 1998 Nov;7(11):2405–12

Sensitization to the cytotoxicity of adriamycin by verapamil and heat in multidrug–resistant Chinese hamster ovary cells. Averill DA, et al. **Radiat Res** 1999 Jun;151(6):694–702

Effect of post–thaw cell rehydration at 4 degrees C on survival of frozen and vitrified IVP–derived bovine embryos. Gutiérrez–Adán A, et al. **Reprod Nutr Dev** 1999 Jul–Aug;39(4):517–20

Nutritional value of the proteins of soybeans roasted at a small–scale unit level in Africa as assessed using growing rats. Ouédraogo CL, et al. **Reprod Nutr Dev** 1999 Mar–Apr; 39(2):201–12

Effects of chronic heat exposure and protein intake on growth performance, nitrogen retention and muscle development in broiler chickens. Temim S, et al. **Reprod Nutr Dev** 1999 Jan–Feb;39(1):145–56

CO2 and heat have different effects on directed ventilation behavior of grasshoppers Melanoplus differentialis. Henderson DR, et al. **Respir Physiol** 1998 Dec; 114(3):297–307

The alteration of nasal resistance before and after local exposure to heated aerosol in perennial allergic rhinitis. Naito K, et al. **Rhinology** 1999 Jun;37(2):66–8

Elongation of oligopeptides in a simulated submarine hydrothermal system. Imai E, et al. **Science** 1999 Feb 5; 283(5403):831–3

Putting risk in its place: methodological considerations for investigating extreme event health risk. Smoyer KE. **Soc Sci Med** 1998 Dec;47(11):1809–24

"Warmth–insensitive fields": evidence of sparse and irregular innervation of human skin by the warmth sense. Green BG, et al. **Somatosens Mot Res** 1998;15(4):269–75

The influence of rate of temperature change and peak stimulus duration on pain intensity and quality. Nielsen J, et al. **Somatosens Mot Res** 1998;15(3):220–9

Autonomic regulation of the circulation during exercise and heat exposure. Inferences from heart rate variability. Brenner IK, et al. **Sports Med** 1998 Aug;26(2):85–99 (59 ref.)

Mechanism of hyperthermia effects on CNS development: rostral gene expression domains remain, despite severe head truncation; and the hindbrain/otocyst relationship is altered. Buckiová D, et al. **Teratology** 1999 Mar; 59(3):139–47

Relationship between the shape and size of radiofrequency induced thermal lesions and hepatic vascularization. Rossi S, et al. **Tumori** 1999 Mar–Apr;85(2):128–32

Ultrasound. Update on thermal bioeffects issues. **Ultrasound Med Biol** 1998;24 Suppl 1:S1–10

Survival of scrapie agent after exposure to sodium dodecyl sulphate and heat. Taylor DM, et al. **Vet Microbiol** 1999 Jun 1;67(1):13–6

Effect of heat on stored red cells during non–flow conditions in a blood–warming device. Eastlund T, et al. **Vox Sang** 1999;76(4):216–9

Resistance of enterococci to heat and chemical agents. Renner P, et al. **Zentralbl Hyg Umweltmed** 1999 Jun; 202(1):41–50

[Appearance of ovomucoid in coagulated egg yolk passing through from soluble fraction of coagulated egg white in boiled egg] Sakai K, et al. **Arerugi** 1998 Nov;47(11):1176–81 (Eng. Abstr.) **(Jpn)**

[Thermoresistance of acid producing psychrotrophic bacteria isolated from milk] Alfenas R de C. **Arch Latinoam Nutr** 1999 Mar;49(1):72–5 (Eng. Abstr.) **(Por)**

[Heat shock pre-conditioning prevents disruption of actin cytoskeleton of endothelial cells due to ATP depletion: the role for heat shock protein HSP27] Loktionova SA, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):237–40 **(Rus)**

[The plasmid carrying the temperature-sensitive mutation in the DNa-methylase gene of the PStI system: effect on host cells at nonpermissive temperature] Danilevich VN, et al. **Genetika** 1999 May;35(5):574–86 (Eng. Abstr.) **(Rus)**

[Frequency of embryonal lethality in various strains of Drosophila melanogaster under conditions of destabilization of microtubule apparatus and as affected by heat shock] Shvartsman PIa, et al. **Genetika** 1999 May; 35(5):712–5 (Eng. Abstr.) **(Rus)**

[New evidence for the induction of mobile genetic element transpositions by severe heat shock] Vasil'eva LA, et al. **Genetika** 1998 Sep;34(9):1243–50 (Eng. Abstr.) **(Rus)**

[Dynamics of changes in integral parameters of muscle tissue heat resistance after preliminary heating at the damaging temperature in various frog species] Mironova AP. **Izv Akad Nauk Ser Biol** 1998 Sep–Oct;(5):602–9 (Eng. Abstr.) **(Rus)**

[Analysis of electromagnetic absorption in biologic objects with industrial high-frequency heating of dielectric materials] Rudakov ML. **Med Tr Prom Ekol** 1999;(6):6–10 (Eng. Abstr.) **(Rus)**

[Dynamics of the changes in various integral indices of the functional state of the body of white rats during the prolonged action of x-radiation and external heat] Kamyshenko VG, et al. **Radiats Biol Radioecol** 1998 Sep–Oct;38(5):701–5 (Eng. Abstr.) **(Rus)**

[Effect of tonicity of the medium on the sensitivity of Escherichia coli bacteria to gamma-quantum 60Co, ultrasound and hyperthermia] Morozov II, et al. **Radiats Biol Radioecol** 1998 Sep–Oct;38(5):657–62 (Eng. Abstr.) **(Rus)**

[Study of the activity of receptors with nonmyelinated fibers during heat exposure of the hairy cat skin] Malysheva GI, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Feb; 85(2):275–82 (Eng. Abstr.) **(Rus)**

[Changes in the concentration of carboxyhemoglobin in the blood under the action of high temperatures] Dobroriz AM. **Sud Med Ekspert** 1999 Mar–Apr;42(2):19–20 (Eng. Abstr.) **(Rus)**

[Dynamics of various integral indices of individual changes of heat-resistance of isolated frog muscles kept in Ringer solution] Mironova AP. **Tsitologiia** 1998;40(10):869–75 (Eng. Abstr.) **(Rus)**

[Features of consequences of osmotic modification at different steps of cell heating] Morozov II, et al. **Tsitologiia** 1999;41(7):605–9 (Eng. Abstr.) **(Rus)**

[Effects of salting, cut type, and initial simmering temperature on protein and fat contents of meat broths: I. Beef] Gotera-Prado Z, et al. **Arch Latinoam Nutr** 1997 Dec; 47(4):362–6 (Eng. Abstr.) **(Spa)**

[Soluble, insoluble and total dietary fiber in raw and cooked legumes] Herrera IM, et al. **Arch Latinoam Nutr** 1998 Jun; 48(2):179–82 (Eng. Abstr.) **(Spa)**

[Heat treatment and dietary fiber effect on protein quality of artichoke and its sub-product] López G, et al. **Arch Latinoam Nutr** 1999 Mar;49(1):49–54 (Eng. Abstr.) **(Spa)**

[Effect of concentration temperature of kiwi fruit pulp on color, chlorophyll and ascorbic acid] Schwartz M, et al. **Arch Latinoam Nutr** 1999 Mar;49(1):44–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

The relation of gestation length to short-term heat stress. Porter KR, et al. **Am J Public Health** 1999 Jul;89(7):1090–2

Free amino acid concentrations in milk: effects of microwave versus conventional heating. Vasson MP, et al. **Amino Acids** 1998;15(4):385–8

Case control study of thermal environment preceding haemorrhagic shock encephalopathy syndrome. Bacon CJ, et al. **Arch Dis Child** 1999 Aug;81(2):155–8

Thermotolerance inhibits various stress-induced apoptosis in NIH3T3 cells. Park JE, et al. **Arch Pharm Res** 1998 Feb; 21(1):46–53

Comparison of responses of men to immersion in circulating water at 40.0 and 41.5 degrees C. Allison TG, et al. **Aviat Space Environ Med** 1998 Sep;69(9):845–50

Particulates from PTFE degradation in terrestrial and microgravity. Srivastava R, et al. **Aviat Space Environ Med** 1999 May;70(5):505–10

Increased temperature: a potentially important side-effect of ultraviolet radiation treatment leading to induction of interstitial collagenase/matrix metalloproteinase-1 [letter] Brenneisen P, et al. **Br J Dermatol** 1998 Sep;139(3):537–9

Thermal injuries in autogenous tissue breast reconstruction. Nahabedian MY, et al. **Br J Plast Surg** 1998 Dec; 51(8):599–602

Delayed presentation of ureteric injury after thermal insult at total hip replacement. Waters E, et al. **Br J Urol** 1998 Oct;82(4):594

Response properties of neurons in the caudate-putamen and globus pallidus to noxious and non-noxious thermal stimulation in anesthetized rats. Chudler EH. **Brain Res** 1998 Nov 23;812(1–2):283–8

Exploding chestnuts [letter; comment] Camp DF. **Burns** 1999 May;25(3):277. Comment on: Burns 1998 Sep;24(6):585–6.

Characteristics of bath-related burns in Japan. Fukunishi K, et al. **Burns** 1999 May;25(3):272–6

Dehydration, rehydration, and exercise in the heat: rehydration strategies for athletic competition. Galloway SD. **Can J Appl Physiol** 1999 Apr;24(2):188–200 (56 ref.)

Exercise in the heat: thermoregulatory limitations to performance in humans and horses. Lindinger MI. **Can J Appl Physiol** 1999 Apr;24(2):152–63 (48 ref.)

Exercise in the heat: limitations to performance and the impact of fluid replacement strategies. Introduction to the symposium. Maughan RJ. **Can J Appl Physiol** 1999 Apr; 24(2):149–51

Sleep and stress in man: an approach through exercise and exposure to extreme environments. Buguet A, et al. **Can J Physiol Pharmacol** 1998 May;76(5):553–61 (81 ref.)

Acute myocardial infarction induced by alternating exposure to heat in a sauna and rapid cooling in cold water. Imai Y, et al. **Cardiology** 1998;90(4):299–301

Apoptosis, the heat shock response, hyperthermia, birth defects, disease and cancer. Where are the common links? Edwards MJ. **Cell Stress Chaperones** 1998 Dec;3(4):213–20 (48 ref.)

Erythema ab igne in a child with atopic eczema [letter] Wilson NJ, et al. **Clin Exp Dermatol** 1999 Jul;24(4):337–8

Advantages of a smaller bodymass in humans when distance-running in warm, humid conditions. Dennis SC, et al. **Eur J Appl Physiol** 1999 Feb;79(3):280–4

Delivery of a constitutively active form of the heat shock factor using a virus vector protects neuronal cells from thermal or ischaemic stress but not from apoptosis. Wagstaff MJ, et al. **Eur J Neurosci** 1998 Nov; 10(11):3343–50

Occupational heat exposure and male fertility: a review. Thonneau P, et al. **Hum Reprod** 1998 Aug;13(8):2122–5 (34 ref.)

Phenomenological evolution equations for heat-induced shrinkage of a collagenous tissue. Chen SS, et al. **IEEE Trans Biomed Eng** 1998 Oct;45(10):1234–40

Relationship of rectal & hippocampal temperature profiles to seizure activity in rats prone & resistant to hot water induced epilepsy. Ullal GR, et al. **Indian J Med Res** 1998 Dec;108:279–84

Tap water scald prevention: it's time for a worldwide effort [editorial; comment] Katcher ML. **Inj Prev** 1998 Sep; 4(3):167–8. Comment on: Inj Prev 1998 Sep;4(3):238–42.

The physics of heat generation during reaming of the medullary cavity. Baumgart F, et al. **Injury** 1998;29 Suppl 2:B11–25

A comparative analysis of heat waves and associated mortality in St. Louis, Missouri--1980 and 1995. Smoyer KE. **Int J Biometeorol** 1998 Aug;42(1):44–50

Localized heat urticaria. Chang A, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):354–6

Effects of environmental management on seasonal decrease in milk production in dairy cattle. Thompson JA, et al. **J Am Vet Med Assoc** 1999 Jan 1;214(1):85–8

Influence of body temperature on the development of fatigue during prolonged exercise in the heat. González-Alonso J, et al. **J Appl Physiol** 1999 Mar;86(3):1032–9

Nitric oxide and cutaneous active vasodilation during heat stress in humans. Kellogg DL Jr, et al. **J Appl Physiol** 1998 Sep;85(3):824–9

Heat acclimation does not alter rat mesenteric artery response to norepinephrine. Looft-Wilson RC, et al. **J Appl Physiol** 1999 Feb;86(2):536–40

Effect of ambient temperature on human skeletal muscle metabolism during fatiguing submaximal exercise. Parkin JM, et al. **J Appl Physiol** 1999 Mar;86(3):902–8

Effects of nitric oxide synthase inhibition on cutaneous vasodilation during body heating in humans. Shastry S, et al. **J Appl Physiol** 1998 Sep;85(3):830–4

The free-convective anomaly. Steadman RG. **J Appl Physiol** 1999 Jul;87(1):54–73

Sodium-free fluid ingestion decreases plasma sodium during exercise in the heat. Vrijens DM, et al. **J Appl Physiol** 1999 Jun;86(6):1847–51

Safe touch temperatures for hot plates. Subramanian B, et al. **J Biomech Eng** 1998 Dec;120(6):727–36

Mortality risks of oesophageal cancer associated with hot tea, alcohol, tobacco and diet in Japan. Kinjo Y, et al. **J Epidemiol** 1998 Oct;8(4):235–43

Analysis of an accident at a solvent recovery plant. Cozzani V, et al. **J Hazard Mater** 1999 Jun 11;67(2):145–61

Force of limb withdrawals elicited by graded noxious heat compared with other behavioral measures of carrageenan-induced hyperalgesia and allodynia. Tabo E, et al. **J Neurosci Methods** 1998 Jun 1;81(1–2):139–49

From the Centers for Disease Control and Prevention. Heat-related illnesses and deaths--Missouri, 1998, and United States, 1979–1996. **JAMA** 1999 Jul 21;282(3):227–8

Measurement of thermal effects on the optical properties of prostate tissue at wavelengths of 1,064 and 633 nm. Nau WH, et al. **Lasers Surg Med** 1999;24(1):38–47

Safety aspects of radiofrequency power deposition in magnetic resonance. Schaefer DJ. **Magn Reson Imaging Clin N Am** 1998 Nov;6(4):775–89 (47 ref.)

Heat shock produces periodic somitic disturbances in the zebrafish embryo. Roy MN, et al. **Mech Dev** 1999 Jul; 85(1–2):27–34

Three-dimensional finite element analysis of thermal shock in a premolar with a composite resin MOD restoration. Fenner DN, et al. **Med Eng Phys** 1998 Jun;20(4):269–75

Heat-related illnesses and deaths--Missouri, 1998, and United States, 1979–1996. **MMWR Morb Mortal Wkly Rep** 1999 Jun 11;48(22):469–73

Noxious thermal stimulation of c-fos activity induced in rat lumbar spinal cord is reduced by AP-5 but not by glycine. Huang W, et al. **Neurosci Lett** 1999 Jan 4;259(1):1–4

The effects of temperature and scopolamine on N-methyl-D-aspartate antagonist-induced neuronal necrosis in the rat. Colbourne F, et al. **Neuroscience** 1999 Apr;90(1):87–94

Behavioral approach to the study of the upper limit of temperature tolerance in rats. Caputa M, et al. **Physiol Behav** 1998 Aug;65(1):183–9

Delayed death after uncomplicated hot tub bathing in dogs and monkeys. Eshel GM, et al. **Resuscitation** 1998 Jun; 37(3):189–95

Global warming and performance of antiepileptic therapeutics [letter] Arya SC. **Seizure** 1999 May;8(3):195–6

Stability study on specimens mailed to a state laboratory and tested with the Gen-Probe PACE 2 assay for chlamydia. Parker EK, et al. **Sex Transm Dis** 1999 Apr;26(4):213–5

Thermal teratology. **Ultraschall Med** 1999 Jun;20(3):125–7 (13 ref.)

Stabilization of two families of critical targets for hyperthermic cell killing and acquired thermotolerance of yeast cells. Obuchi K, et al. **Yeast** 1998 Oct;14(14):1249–55

[Hot water epilepsy: a benign and underestimated form] Ioos C, et al. **Arch Pediatr** 1999 Jul;6(7):755–8 (Eng. Abstr.) **(Fre)**

[Heat-induced symptomatology in human teeth. An in-vitro study] Baldissara P, et al. **Minerva Stomatol** 1998 Sep; 47(9):373–80 (Eng. Abstr.) **(Ita)**

[Metabolic and physiological characteristics of the immediate response of the body to overheating] Andreeva LI, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):19–23 **(Rus)**

[Heat shock modulates xenobiotic cytotoxicity in vivo] Egorova AB, et al. **Biull Eksp Biol Med** 1998 Nov; 126(11):546–7 **(Rus)**

[The viability and thermostability of human lymphocytes with varying resistance to heat exposure] Novikov VS, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):91–6 **(Rus)**

[State of specific functions of women working under conditions of hot microclimate] Kvartovkina LK, et al. **Med Tr Prom Ekol** 1999;(3):30–1 **(Rus)**

DIAGNOSTIC USE

Thermal oral-pharyngeal stimulation and elicitation of swallowing. Bove M, et al. **Acta Otolaryngol (Stockh)** 1998 Sep;118(5):728–31

Radiographic detection of achalasia [letter; comment] Wright FW. **Clin Radiol** 1998 Dec;53(12):933. Comment on: Clin Radiol 1998 May;53(5):372–5.

[Laser Doppler spectral analysis of patients with Raynaud's phenomenon during a standardized thermal test] Léger P. **Ann Dermatol Venereol** 1998 Nov;125 Suppl 2:S28–9 **(Fre)**

THERAPEUTIC USE

Warmed versus room temperature saline solution for ear irrigation: a randomized clinical trial. Ernst AA, et al. **Ann Emerg Med** 1999 Sep;34(3):347–50

Reduction of pain-related behaviors with either cold or heat treatment in an animal model of acute arthritis. Sluka KA, et al. **Arch Phys Med Rehabil** 1999 Mar;80(3):313–7

Design and evaluation of a portable rigid forced-air warming cover for prehospital transport of cold patients. Giesbrecht GG, et al. **Aviat Space Environ Med** 1998 Dec; 69(12):1200–3

Heat-induced membrane damage combined with adriamycin on prostate carcinoma PC-3 cells: correlation of cytotoxicity, permeability and P-glycoprotein or metallothionein expression. Moriyama-Gonda N, et al. **Br J Urol** 1998 Oct;82(4):552–9

Effect of increasing temperature on the properties of four bone cements. Parks ML, et al. **Clin Orthop** 1998 Oct; (355):238–48

Hypothermia and extracorporeal rewarming: the journey toward a less invasive, more accessible methodology [editorial; comment] Josephs JD, et al. **Crit Care Med** 1998 Dec;26(12):1944–5 (9 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2016–20.

Continuous venovenous rewarming: results from a juvenile animal model [see comments] Seigler RS, et al. **Crit Care Med** 1998 Dec;26(12):2016–20. Comment in: Crit Care Med 1998 Dec;26(12):1944–5.

Local thermal stimulation relaxes hypertonic anal sphincter: evidence of somatoanal reflex. Jiang JK, et al. **Dis Colon Rectum** 1999 Sep;42(9):1152–9

Preventing hypothermia: convective and intravenous fluid warming versus convective warming alone. Smith CE, et al. **J Clin Anesth** 1998 Aug;10(5):380–5

Therapeutic modalities in hand surgery. Bissell JH. **J Hand Surg [Am]** 1999 May;24(3):435–48 (166 ref.)

Heat stress pretreatment mitigates postischemic arachidonic acid accumulation in rat heart. van der Vusse GJ, et al. **Mol Cell Biochem** 1998 Aug;185(1-2):205-11

Hot-tub therapy for type 2 diabetes mellitus [letter] Hooper PL. **N Engl J Med** 1999 Sep 16;341(12):924-5

The utility of traditional prehospital interventions in maintaining thermostasis. Watts DD, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):115-22

Transurethral radiofrequency hot balloon thermal therapy in chronic nonbacterial prostatitis. Nickel JC, et al. **Tech Urol** 1998 Sep;4(3):128-30

Mathematical description of combined action of ultrasound and hyperthermia on yeast cells. Petin VG, et al. **Ultrasonics** 1999 Jan;37(1):79-83

[Treatment of subglottic laryngitis (pseudocroup): steroids instead of steam (see comments)] Roorda RJ, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1658-62 (26 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2117. Comment in: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2646-7. **(Dut)**

HEAT COLLAPSE see **HEAT EXHAUSTION**

HEAT CRAMPS see **HEAT STRESS DISORDERS**

HEAT EXHAUSTION

DIAGNOSIS

Use of a handheld, battery-operated chemistry analyzer for evaluation of heat-related symptoms in the backcountry of Grand Canyon National Park: a brief report. Backer HD, et al. **Ann Emerg Med** 1999 Apr;33(4):418-22

PATHOLOGY

[Inhalation heat shock] Wilk E, et al. **Arch Kriminol** 1999 May-Jun;203(5-6):159-69 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The physiological strain index applied to heat-stressed rats. Moran DS, et al. **J Appl Physiol** 1999 Mar;86(3):895-901

HEAT LOSS see **BODY TEMPERATURE REGULATION**

HEAT PRODUCTION see **BODY TEMPERATURE REGULATION**

HEAT PROSTRATION see **HEAT EXHAUSTION**

HEAT-SHOCK PROTEINS

see related
MOLECULAR CHAPERONES

III International Symposium on Heat Shock Proteins: Expression, Immunity and Women's Health. New York, New York, USA. April 10-11, 1999. Proceedings and abstracts. **Infect Dis Obstet Gynecol** 1999;7(1-2):1-123

Mitochondrial Lon of Saccharomyces cerevisiae is a ring-shaped protease with seven flexible subunits. Stahlberg H, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6787-90

Heat shock proteins: facts, thoughts, and dreams. De Maio A. **Shock** 1999 Jan;11(1):1-12 (173 ref.)

[Heat shock proteins: new prospects of myocardial cytoprotection] Shevchenko IuL, et al. **Vestn Ross Akad Med Nauk** 1999;(7):16-20 (53 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Liposomal delivery of heat-shock protein 72 into the heart prevents endotoxin-induced myocardial contractile dysfunction. Meldrum DR, et al. **Surgery** 1999 Aug; 126(2):135-41

ANALYSIS

Heat shock protein 72 expression and microtubule-associated protein 2 disappearance after hypoxia-ischemia in the developing rat brain. Xia XY, et al. **Am J Obstet Gynecol** 1999 May;180(5):1254-62

Cellular localization of the heat shock transcription factors HSF1 and HSF2 in the rat brain during postnatal development and following hyperthermia. Brown IR, et al. **Brain Res** 1999 Mar 13;821(2):333-40

C-Fos, Jun D and HSP72 immunoreactivity, and neuronal injury following lithium-pilocarpine induced status epilepticus in immature and adult rats. Dubé C, et al. **Brain Res Mol Brain Res** 1998 Dec 10;63(1):139-54

Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Kawanishi K, et al. **Cancer** 1999 Apr 15;85(8):1649-57

The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Oesterreich S, et al. **Clin Cancer Res** 1996 Jul;2(7):1199-206

Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Arts HJ, et al. **Int J Cancer** 1999 Jun 21; 84(3):234-8

Induction of DNA fragmentation and HSP72 immunoreactivity by adenovirus-mediated gene transfer in normal gerbil hippocampus and ventricle. Kitagawa H, et al. **J Neurosci Res** 1998 Oct 1;54(1):38-45

Expression of the Na+/myo-inositol cotransporter in the juxtaglomerular region. Yamauchi A, et al. **Kidney Int Suppl** 1998 Sep;67:S183-5

Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Takashi M, et al. **Urol Res** 1998;26(6):395-9

Using heat shock proteins as indicators of the immune function in wistar rats during a secondary Trichinella spiralis infection. Martinez J, et al. **Vet Parasitol** 1999 Sep 1;85(4):269-75

ANTAGONISTS & INHIBITORS

Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice. Yu X, et al. **Brain Res** 1999 Mar 27;823(1-2):213-6

BIOSYNTHESIS

Cold shock proteins CspB and CspC are major stationary-phase-induced proteins in Bacillus subtilis. Graumann PL, et al. **Arch Microbiol** 1999 Jan;171(2):135-8

Overexpression of dnaK/dnaJ and groEL confers freeze tolerance to Escherichia coli. Chow KC, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):502-5

Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Kim D, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):264-8

Tobacco smoke induces coordinate activation of HSF and inhibition of NFkappaB in human monocytes: effects on TNFalpha release. Vayssier M, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):249-56

Localization of a cyclopentenone prostaglandin to the endoplasmic reticulum and induction of BiP mRNA. Takahashi S, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):35-42

Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Abe T, et al. **Biochim Biophys Acta** 1999 Apr 14; 1445(1):123-33

Induction of stress proteins by electromagnetic fields in cultured HL-60 cells. Pipkin JL, et al. **Bioelectromagnetics** 1999 Sep;20(6):347-57

Preischemic blood glucose supply to the brain modulates HSP(72) synthesis and neuronal damage in gerbils. Garnier P, et al. **Brain Res** 1999 Jul 31;836(1-2):245-55

Induction of cerebellar hsp72 in rats learning a two-way active avoidance task. Ambrosini MV, et al. **Brain Res Mol Brain Res** 1999 Jun 18;70(1):164-6

Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Garrido C, et al. **Cancer Res** 1998 Dec 1;58(23):5495-9

Constitutive expression of heat shock proteins Hsp90, Hsc70, Hsp70 and Hsp60 in neural and non-neural tissues of the rat during postnatal development. D'Souza SM, et al. **Cell Stress Chaperones** 1998 Sep;3(3):188-99

Phosphorylation of RNA polymerase II C-terminal domain (CTD): a new control for heat shock gene expression? Dubois MF, et al. **Cell Stress Chaperones** 1998 Sep; 3(3):147-51 (52 ref.)

Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Kato K, et al. **Cell Stress Chaperones** 1998 Sep;3(3):152-60

Transient up-regulation of myotonic dystrophy protein kinase-binding protein, MKBP, and HSP27 in the neonatal myocardium. Shama KM, et al. **Cell Struct Funct** 1999 Feb; 24(1):1-4

Age-related nephropathy in the Fischer 344 rat is associated with overexpression of collagens and collagen-binding heat shock protein 47. Razzaque MS, et al. **Cell Tissue Res** 1998 Sep;293(3):471-8

Characterization of the heat shock response in the gills of sea lampreys and a brook lamprey at different intervals of their life cycles. Wood LA, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):509-18

Heat shock protein (HSP)27: a further refinement in the diagnosis of suspicious fine needle aspirates of breast. Keeling J, et al. **Cytopathology** 1999 Feb;10(1):40-9

Induction of heat shock proteins in response to primary alcohols in Acinetobacter calcoaceticus. Benndorf D, et al. **Electrophoresis** 1999 Apr-May;20(4-5):781-9

Heat shock protein 27 expression in human proximal tubule cells exposed to lethal and sublethal concentrations of CdCl2. Somji S, et al. **Environ Health Perspect** 1999 Jul; 107(7):545-52

Interactive toxicity and stress protein expression by vinylidene chloride and monochloroacetate in precision-cut rat liver slices. Wijeweera J, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1319-23

Induction of ferritin and heat shock proteins by prostaglandin A1 in human monocytes. Evidence for transcriptional and post-transcriptional regulation. Elia G, et al. **Eur J Biochem** 1999 Sep;264(3):736-45

Proteome analysis of heat shock protein expression in Bradyrhizobium japonicum. Münchbach M, et al. **Eur J Biochem** 1999 Aug;264(1):39-48

Delivery of a constitutively active form of the heat shock factor using a virus vector protects neuronal cells from thermal or ischaemic stress but not from apoptosis. Wagstaff MJ, et al. **Eur J Neurosci** 1998 Nov; 10(11):3343-50

Induction of heat shock protein 72 by a nitric oxide donor in guinea-pig gastric mucosal cells. Byrne CR, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):117-22

Sphingosine 1-phosphate regulates heat shock protein 27 induction by a p38 MAP kinase-dependent mechanism in aortic smooth muscle cells. Kozawa O, et al. **Exp Cell Res** 1999 Aug 1;250(2):376-80

Induction of the 27-kDa heat shock protein (Hsp27) in the rat medulla oblongata after vagus nerve injury. Hopkins DA, et al. **Exp Neurol** 1998 Oct;153(2):173-83

Differentiation lineage-specific expression of human heat shock transcription factor 2. Pirkkala L, et al. **FASEB J** 1999 Jun;13(9):1089-98

Dinitrosyl iron complexes with thiol-containing ligands and S-nitroso-D,L-penicillamine as inductors of heat shock protein synthesis in H35 hepatoma cells. Wiegant FA, et al. **FEBS Lett** 1999 Jul 16;455(1-2):179-82

Induction and enhancement of stress proteins in a trichloroethylene-degrading methanotrophic bacterium, Methylocystis sp. M. Uchiyama H, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):125-30

On the path to the heat shock response: destabilization and formation of partially folded protein intermediates, a consequence of protein thiol modification. Freeman ML, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):737-45 (102 ref.)

Life-long dietary restriction modulates the expression of collagens and collagen-binding heat shock protein 47 in aged Fischer 344 rat kidney. Razzaque MS, et al. **Histochem J** 1999 Feb;31(2):123-32

Stimulation of survival capacity in heat shocked cells by subsequent exposure to minute amounts of chemical stressors; role of similarity in hsp-inducing effects. Wiegant FA, et al. **Hum Exp Toxicol** 1999 Jul;18(7):460-70

Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Trieb K, et al. **Hum Pathol** 1998 Oct;29(10):1050-5

Expression of listeriolysin O and ActA by intracellular and extracellular Listeria monocytogenes. Moors MA, et al. **Infect Immun** 1999 Jan;67(1):131-9

A comprehensive analysis of heat shock protein synthesis in human peripheral lymphocytes: the effect of penicillin/streptomycin. Rao DV, et al. **Int J Biochem Cell Biol** 1999 Aug;31(8):861-8

Hyperthermia in the chick embryo: HSP and possible mechanisms of developmental defects. Buckiová D, et al. **Int J Dev Biol** 1998 Jul;42(5):737-40

Production of listeriolysin O by Listeria monocytogenes (Scott A) under heat-shock conditions. Sampathkumar B, et al. **Int J Food Microbiol** 1999 May 1;48(2):131-7

Differential expression of stress proteins in rat myocardium after free wheel or treadmill run training. Noble EG, et al. **J Appl Physiol** 1999 May;86(5):1696-701

Heat-induced synthesis of sigma32 in Escherichia coli: structural and functional dissection of rpoH mRNA secondary structure. Morita M, et al. **J Bacteriol** 1999 Jan; 181(2):401-10

Hsp70 and a 54 kDa protein (Osp54) are induced in salmon (Salmo salar) in response to hyperosmotic stress. Smith TR, et al. **J Exp Zool** 1999 Aug 1;284(3):286-98

Alteration in sporulation, enterotoxin production, and protein synthesis by Clostridium perfringens type A following heat shock. Heredia NL, et al. **J Food Prot** 1998 Sep; 61(9):1143-7

Proinflammatory cytokines regulate myogenic cell proliferation and fusion but have no impact on myotube protein metabolism or stress protein expression. Ji SQ, et al. **J Interferon Cytokine Res** 1998 Oct;18(10):879-88

Increased expression of heat-shock protein 47 is associated with overproduction of type I procollagen in systemic sclerosis skin fibroblasts. Kuroda K, et al. **J Invest Dermatol** 1998 Dec;111(6):1023-8

Endothelial cell hypoxic stress proteins. Graven KK, et al. **J Lab Clin Med** 1998 Dec;132(6):456-63 (29 ref.)

Expression of heat-shock proteins in Streptococcus pyogenes and their immunoreactivity with sera from patients with streptococcal diseases. Lemos JA, et al. **J Med Microbiol** 1998 Aug;47(8):711-5

Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. Strauss M, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2319-25

Expression of heat shock protein after ischemic preconditioning in rabbit hearts. Tanaka M, et al. **Jpn Circ J** 1998 Jul;62(7):512-6

Time course of expression and localization of heat shock protein 72 in the ischemic and reperfused rat heart. Yu H, et al. **Jpn Circ J** 1999 Apr;63(4):278-87

Age-related attenuation in the expression of the major heat shock proteins in human peripheral lymphocytes. Rao DV, et al. **Mech Ageing Dev** 1999 Feb 1;107(1):105-18

Coexpression of collagens and collagen-binding heat shock protein 47 in human diabetic nephropathy and IgA nephropathy. Razzaque MS, et al. **Nephron** 1998 Dec; 80(4):434-43

Cerebral blood flow threshold and regional heterogeneity of heat shock protein 72 induction following transient forebrain ischemia in rats. Goda H, et al. **Neurochem Res** 1999 May;24(5):679-83

Whole body hyperthermia selectively induces heat shock protein 72 in neurons of the rat spinal cord. Xia H, et al.

Neurosci Lett 1998 Dec 24;258(3):151–4

Heat shock protein expression protects against death following exposure to heatstroke in rats. Yang YL, et al. **Neurosci Lett** 1998 Aug 7;252(1):9–12

Expression of Na+/Cl−/betaine and Na+/myo-inositol transporters, aldose reductase and sorbitol dehydrogenase in macula densa cells of the kidney. Burger-Kentischer A, et al. **Pflugers Arch** 1998 Oct;436(5):807–9

Impaired induction of heat shock protein implicated in decreased thermotolerance in a temperature-sensitive multinucleated cell line. Cao Y, et al. **Pflugers Arch** 1998 Dec;437(1):15–20

Heat conditioning induces heat shock proteins in broiler chickens and turkey poults. Wang S, et al. **Poult Sci** 1998 Nov;77(11):1636–45

Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Madersbacher S, et al. **Prostate** 1998 Nov 1;37(3):174–81

Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat-shock response. Rau B, et al. **Radiat Res** 1999 Apr;151(4):479–88

The 16-kDa alpha-crystallin-like protein of Mycobacterium bovis BCG is produced under conditions of oxygen deficiency and is associated with ribosomes. Tabira Y, et al. **Res Microbiol** 1998 Apr;149(4):255–64

Evidence of multi-step regulation of HSP72 expression in experimental sepsis. Chen HW, et al. **Shock** 1999 Jul; 12(1):63–8

Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91–7

Heat shock protein improves cold preserved small bowel grafts. Tarumi K, et al. **Transplant Proc** 1998 Nov; 30(7):3455–8

Correlation between production of listeriolysin O by variants of Listeria monocytogenes and their virulence for rabbits. Waseem M, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):384–8

[A study on expression of the heat shock suppressed gene in distal organs of rats after scalding] Guo XZ, et al. **Sheng Li Hsueh Pao** 1997 Aug;49(4):370–4 (Eng. Abstr.) **(Chi)**

[Heat shock proteins and heart protection] Malyshev IIu, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):604–11 (37 ref.) **(Rus)**

[Protein synthesis in blood lymphocytes of patients with rheumatoid arthritis] Funtikov VA, et al. **Dokl Akad Nauk** 1999 Jan;364(1):126–9 **(Rus)**

[Disruption of heat-shock protein synthesis does not prevent normal development of stress reaction in Drosophila melanogaster] Gryntenko NE, et al. **Dokl Akad Nauk** 1998 Oct;362(6):844–5 **(Rus)**

[Development of thermotolerance in Drosophila melanogaster line l(1) ts403 with a defect in heat shock protein synthesis] Mamon LA, et al. **Genetika** 1998 Jul; 34(7):920–8 (Eng. Abstr.) **(Rus)**

BLOOD

Serological detection of heat shock protein hsp27 in normal and breast cancer patients. Fanelli MA, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Sep;7(9):791–5

Cytotoxic T-cell, delayed type hypersensitive and listeriolysin O responses in experimental bovine listeriosis. Barbuddhe SB, et al. **Vet Microbiol** 1999 Feb 12; 64(4):333–41

CHEMISTRY

Crystallization and preliminary X-ray diffraction studies of perchloric acid soluble protein (PSP) from rat liver. Djinović Carugo K, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):667–8

Molecular cloning and developmental pattern of expression of MSJ-1, a new male germ cell-specific DNAJ homologue. Berruti G, et al. **Adv Exp Med Biol** 1998; 444:145–50; discussion 151 (14 ref.)

Backbone dynamics of the N-terminal domain in E. coli DnaJ determined by 15N- and 13CO-relaxation measurements. Huang K, et al. **Biochemistry** 1999 Aug 10;38(32):10567–77

HspB3, the most deviating of the six known human small heat shock proteins. Boelens WC, et al. **Biochim Biophys Acta** 1998 Nov 10;1388(2):513–6

Analysis of the fatty acid components in a perchloric acid-soluble protein. Sasagawa T, et al. **Biochim Biophys Acta** 1999 Mar 25;1437(3):317–24

Thiol/disulfide exchange between small heat shock protein 25 and glutathione. Zavialov AV, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):123–32

Expression of DjY1, a protein containing a cold shock domain and RG repeat motifs, is targeted to sites of regeneration in planarians. Salvetti A, et al. **Dev Biol** 1998 Sep 15;201(2):217–29

The NMR structure of Escherichia coli ribosomal protein L25 shows homology to general stress proteins and glutaminyl-tRNA synthetases. Stoldt M, et al. **EMBO J** 1998 Nov 2;17(21):6377–84

The mammalian small heat-shock protein Hsp20 forms dimers and is a poor chaperone. van de Klundert FA, et al. **Eur J Biochem** 1998 Dec 15;258(3):1014–21

Western blotting analysis of heat shock proteins of Rickettsiales and other eubacteria. Eremeeva ME, et al. **FEMS Microbiol Lett** 1998 Oct 15;167(2):229–37

Site-directed spin labeling study of subunit interactions in the alpha-crystallin domain of small heat-shock proteins. Comparison of the oligomer symmetry in alphaA-crystallin, HSP 27, and HSP 16.3. Berengian AR, et al. **J Biol Chem** 1999 Mar 5;274(10):6305–14

The dynamics of Hsp25 quaternary structure. Structure and function of different oligomeric species. Ehrnsperger M, et al. **J Biol Chem** 1999 May 21;274(21):14867–74

Marked instability of the sigma(32) heat shock transcription factor at high temperature. Implications for heat shock regulation. Kanemori M, et al. **J Biol Chem** 1999 Jul 30; 274(31):22002–7

The family of cold shock proteins of Bacillus subtilis. Stability and dynamics in vitro and in vivo. Schindler T, et al. **J Biol Chem** 1999 Feb 5;274(6):3407–13

Biochemical characterization of the small heat shock protein IbpB from Escherichia coli. Shearstone JR, et al. **J Biol Chem** 1999 Apr 9;274(15):9937–45

Thermodynamics of the unfolding of the cold-shock protein from Thermotoga maritima. Wassenberg D, et al. **J Mol Biol** 1999 May 28;289(1):187–93

A new use for the 'wing' of the 'winged' helix-turn-helix motif in the HSF-DNA cocrystal. Littlefield O, et al. **Nat Struct Biol** 1999 May;6(5):464–70

3D reconstruction of the ATP-bound form of CCT reveals the asymmetric folding conformation of a type II chaperonin. Llorca O, et al. **Nat Struct Biol** 1999 Jul; 6(7):639–42

Behçet's disease and antibody titers to various heat-shock protein 60s. Tanaka T, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):69–74

Chaperone-mediated protein folding. Fink AL. **Physiol Rev** 1999 Apr;79(2):425–49 (274 ref.)

Structural and functional properties of the hsp16.4-bearing plasmid pER341 in Streptococcus thermophilus. Somkuti GA, et al. **Plasmid** 1998 Jul;40(1):61–72

Mutations in the DnaK chaperone affecting interaction with the DnaJ cochaperone. Gässler CS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15229–34

Interaction of the Hsp70 molecular chaperone, DnaK, with its cochaperone DnaJ. Suh WC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15223–8

Here's the hook: similar substrate binding sites in the chaperone domains of Clp and Lon. Wickner S, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8318–20

GST-Induced dimerization of DNA-binding domains alters characteristics of their interaction with DNA. Niedziela-Majka A, et al. **Protein Expr Purif** 1998 Nov; 14(2):208–20

The influence of C-terminal extension on the structure of the "J-domain" in E. coli DnaJ. Huang K, et al. **Protein Sci** 1999 Jan;8(1):203–14

The Mycobacterium tuberculosis small heat shock protein Hsp16.3 exposes hydrophobic surfaces at mild conditions: conformational flexibility and molecular chaperone activity. Yang H, et al. **Protein Sci** 1999 Jan;8(1):174–9

[Suc-Phe-Leu-Phe-SBzl—a new substrate for functional study of Escherichia coli ATP-dependent Lon-proteinase and its modified forms (letter)] Mel'nikov EE, et al. **Bioorg Khim** 1998 Aug;24(8):638–40 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Kim SH, et al. **Exp Mol Med** 1998 Jun 30;30(2):87–92

Anti-sense inhibition of small-heat-shock-protein (HSP27) expression in MCF-7 mammary-carcinoma cells induces their spontaneous acquisition of a secretory phenotype. Horman S, et al. **Int J Cancer** 1999 Aug 12;82(4):574–82

Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. Amberger A, et al. **Mol Med** 1999 Feb;5(2):117–28

GENETICS

Molecular cloning and developmental pattern of expression of MSJ-1, a new male germ cell-specific DNAJ homologue. Berruti G, et al. **Adv Exp Med Biol** 1998; 444:145–50; discussion 151 (14 ref.)

The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. Ozelius LJ, et al. **Adv Neurol** 1998;78:93–105 (49 ref.)

Influence of bioenergetic stress on heat shock protein gene expression in nucleated red blood cells of fish. Currie S, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R990–6

Heat acclimation increases the basal HSP72 level and alters its production dynamics during heat stress. Maloyan A, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1506–15

Alternate splicing in human Na+-MI cotransporter gene yields differentially regulated transport isoforms. Porcellati F, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1325–37

Stress genes protect brain [editorial; comment] Sharp FR. **Ann Neurol** 1998 Oct;44(4):581–3 (60 ref.). Comment on: Ann Neurol 1998 Oct;44(4):584–91.

Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy [see comments] Yenari MA, et al. **Ann Neurol** 1998 Oct;44(4):584–91. Comment in: Ann Neurol 1998 Oct;44(4):581–3.

Evidence for the interplay between trehalose metabolism and Hsp104 in yeast. Iwahashi H, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4614–7

cDNA sequence and deduced amino acid sequence of a fungal stress protein induced in Rhizopus nigricans by steroids. Crešnar B, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):664–7

Rat Hsp20 confers thermoresistance in a clonal survival assay, but fails to protect coexpressed luciferase in Chinese hamster ovary cells. van de Klundert FAJM, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):164–8

Localization of a cyclopentenone prostaglandin to the endoplasmic reticulum and induction of BiP mRNA. Takahashi S, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):35–42

Opposing effects of tumour necrosis factor alpha and hyperosmolarity on Na+/myo-inositol co-transporter mRNA levels and myo-inositol accumulation by 3T3-L1 adipocytes. Yorek MA, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):317–25

Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. Abe T, et al. **Biochem Pharmacol** 1999 Jul 1; 58(1):69–76

Mutations in the cytosolic DnaJ homologue, YDJ1, delay and compromise the efficient translation of heterologous proteins in yeast. Brodsky JL, et al. **Biochemistry** 1998 Dec 22;37(51):18045–55

Generating controlled reducing environments in aerobic recombinant Escherichia coli fermentations: effects on cell growth, oxygen uptake, heat shock protein expression, and in vivo CAT activity. Gill RT, et al. **Biotechnol Bioeng** 1998 Jul 20;59(2):248–59

Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Soldes OS, et al. **Br J Cancer** 1999 Feb;79(3–4):595–603

Kainic acid-induced seizure upregulates Na(+)/myo-inositol cotransporter mRNA in rat brain. Nonaka M, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):179–86

Effects of transient cerebral ischemia on hsp40 mRNA levels in rat brain. Paschen W, et al. **Brain Res Mol Brain Res** 1998 Apr;55(2):341–4

Anti-oxidants prevent focal rat brain injury as assessed by induction of heat shock proteins (HSP70, HO-1/HSP32, HSP47) following subarachnoid injections of lysed blood. Turner CP, et al. **Brain Res Mol Brain Res** 1999 Feb 19; 65(1):87–102

Stress protein inductions after brain ischemia. Abe K, et al. **Cell Mol Neurobiol** 1998 Dec;18(6):709–19

Modulation of tolerance by mutant heat shock transcription factors. Xia W, et al. **Cell Stress Chaperones** 1999 Mar; 4(1):8–18

Helicobacter pylori heat shock protein A: serologic responses and genetic diversity. Ng EK, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):377–82

Involvement of the Saccharomyces cerevisiae UTH1 gene in the oxidative-stress response. Bandara PD, et al. **Curr Genet** 1998 Oct;34(4):259–68

PaGrg1, a glucose-repressible gene of Podospora anserina that is differentially expressed during lifespan. Kimpel E, et al. **Curr Genet** 1999 Jun;35(5):557–63

Distribution of plasmid-borne stress protein genes in Streptococcus thermophilus and other lactic acid bacteria. Somkuti GA, et al. **Curr Microbiol** 1999 Jan;38(1):43–7

Aging-specific expression of Drosophila hsp22. King V, et al. **Dev Biol** 1999 Mar 1;207(1):107–18

The synthesis of a small heat shock/alpha-crystallin protein in Artemia and its relationship to stress tolerance during development. Liang P, et al. **Dev Biol** 1999 Mar 15; 207(2):445–56

glsA, a Volvox gene required for asymmetric division and germ cell specification, encodes a chaperone-like protein. Miller SM, et al. **Development** 1999 Feb;126(4):649–58

Association of 72-kDa heat shock protein expression with adaptation to aspirin in rat gastric mucosa. Jin M, et al. **Dig Dis Sci** 1999 Jul;44(7):1401–7

Enhanced intestinal expression of heat shock protein 70 in patients with inflammatory bowel diseases. Ludwig D, et al. **Dig Dis Sci** 1999 Jul;44(7):1440–7

Cloning and sequencing of rpoH and identification of ftsE-ftsX in Pseudomonas putida PpG1. Aramaki H, et al. **DNA Res** 1999 Aug 31;6(4):241–5

Expression of the 72-kD heat shock protein is induced by ultraviolet A radiation in a human fibrosarcoma cell line. Trautinger F, et al. **Exp Dermatol** 1999 Jun;8(3):187–92

Characterization of the minimal osmotic response element of the bovine Na+/myo-inositol cotransporter gene [letter] Zhou C, et al. **Exp Eye Res** 1999 Jan;68(1):137–42

The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo. Arias C, et al. **Exp Neurol** 1998 Oct; 153(2):242–54

Enhanced mitochondrial biogenesis is associated with increased expression of the mitochondrial ATP-dependent Lon protease. Luciakova K, et al. **FEBS Lett** 1999 Feb 12;444(2–3):186–8

Cloning of two cold shock genes, cspA and cspG, from the deep-sea psychrophilic bacterium Shewanella violacea strain DSS12. Fujii S, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):123–8

Identification of a new locus in Listeria monocytogenes involved in cellobiose-dependent repression of hly expression. Huillet E, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):265–72

Co-existence of clpB and clpC in the Bacillaceae. Namy O,

et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):297-302
Cloning and expression of the Campylobacter jejuni lon gene detected by RNA arbitrarily primed PCR. Thies FL, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):329-34
A phagemid vector using the E. coli phage shock promoter facilitates phage display of toxic proteins. Beekwilder J, et al. **Gene** 1999 Mar 4;228(1-2):23-31
Drosophila melanogaster is polymorphic for a specific repeated (CATA) sequence in the regulatory region of hsp23. Frydenberg J, et al. **Gene** 1999 Aug 20;236(2):243-50
Genomic structure and chromosomal localization of the mouse Hsf2 gene and promoter sequences. Manuel M, et al. **Gene** 1999 May 17;232(1):115-24
The human genome has only one functional hsp47 gene (CBP2) and a pseudogene (pshsp47). Nagai N, et al. **Gene** 1999 Feb 18;227(2):241-8
Characterization of a maize heat-shock protein 101 gene, HSP101, encoding a ClpB/Hsp100 protein homologue. Nieto-Sotelo J, et al. **Gene** 1999 Apr 16;230(2):187-95
The dnaK/dnaJ operon of Haemophilus ducreyi contains a unique combination of regulatory elements. Parsons LM, et al. **Gene** 1999 Jun 11;233(1-2):109-19
The ClpB protein from Campylobacter jejuni: molecular characterization of the encoding gene and antigenicity of the recombinant protein. Thies FL, et al. **Gene** 1999 Apr 1;230(1):61-7
Sequence analysis and heterologous expression of the groE genes from Thermoanaerobacter sp. R18.G4. Truscott KN, et al. **Gene** 1998 Sep 14;217(1-2):15-23
Translational induction of heat shock transcription factor sigma32: evidence for a built-in RNA thermosensor. Morita MT, et al. **Genes Dev** 1999 Mar 15;13(6):655-65
Genetic mapping of mouse heat shock protein genes Hsc4a to chromosome 11 and Hsc74 to chromosome 18 and two Hsc74 pseudogenes to chromosomes X and 8. Hunt CR, et al. **Genomics** 1999 Mar 15;56(3):358-60
Cloning, expression profile, and genomic organization of the mouse STAP/A170 gene. Okazaki M, et al. **Genomics** 1999 Aug 15;60(1):87-95
A DnaJ-like gene, Hsj2, maps to mouse chromosome 5, at approximately 24 cM from the centromere. Royaux I, et al. **Genomics** 1998 Nov 1;53(3):415
Effect of hexachlorocyclohexane on hsp26 expression in transgenic Drosophila melanogaster. Chowdhuri DK, et al. **Indian J Exp Biol** 1998 Aug;36(8):811-5
Upregulation of a 23 kDa small heat shock protein transcript during pupal diapause in the flesh fly, Sarcophaga, crassipalpis. Yocum GD, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):677-82
A transgenic animal model of osmotic cataract. Part 1: over-expression of bovine Na+/myo-inositol cotransporter in lens fibers. Cammarata PR, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1727-37
The yvyD gene of Bacillus subtilis is under dual control of sigmaB and sigmaH. Drzewiecki K, et al. **J Bacteriol** 1998 Dec;180(24):6674-80
A conserved domain in Escherichia coli Lon protease is involved in substrate discriminator activity. Ebel W, et al. **J Bacteriol** 1999 Apr;181(7):2236-43
Disruption and analysis of the clpB, clpC, and clpE genes in Lactococcus lactis: ClpE, a new Clp family in gram-positive bacteria. Ingmer H, et al. **J Bacteriol** 1999 Apr;181(7):2075-83
The first gene of the Bacillus subtilis clpC operon, ctsR, encodes a negative regulator of its own operon and other class III heat shock genes. Krüger E, et al. **J Bacteriol** 1998 Dec;180(24):6681-8
The unique chaperone operon of Thermotoga maritima: cloning and initial characterization of a functional Hsp70 and small heat shock protein. Michelini ET, et al. **J Bacteriol** 1999 Jul;181(14):4237-44
Heat-induced synthesis of sigma32 in Escherichia coli: structural and functional dissection of rpoH mRNA secondary structure. Morita M, et al. **J Bacteriol** 1999 Jan; 181(2):401-10
Multiple small heat shock proteins in rhizobia. Münchbach M, et al. **J Bacteriol** 1999 Jan;181(1):83-90
CspI, the ninth member of the CspA family of Escherichia coli, is induced upon cold shock. Wang N, et al. **J Bacteriol** 1999 Mar;181(5):1603-9
A novel 66-kDa stress protein, p66, associated with the process of cyst formation of Physarum polycephalum is a Physarum homologue of a yeast actin-interacting protein, AIP1. Matsumoto S, et al. **J Biochem (Tokyo)** 1998 Aug; 124(2):326-31
Bacterial lipopolysaccharide induces expression of the stress response genes hop and H411. Heine H, et al. **J Biol Chem** 1999 Jul 23;274(30):21049-55
Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. Stephanou A, et al. **J Biol Chem** 1999 Jan 15;274(3):1723-8
Protection of neuronal cells from apoptosis by Hsp27 delivered with a herpes simplex virus-based vector. Wagstaff MJ, et al. **J Biol Chem** 1999 Feb 19;274(8):5061-9
Structural organization and promoter analysis of murine heat shock transcription factor-1 gene. Zhang Y, et al. **J Biol Chem** 1998 Dec 4;273(49):32514-21
Regulatory domain of human heat shock transcription factor-2 is not regulated by hemin or heat shock. Zhu Z, et al. **J Cell Biochem** 1999 Apr 1;73(1):56-69
A role for the DnaJ homologue Scj1p in protein folding in the yeast endoplasmic reticulum. Silberstein S, et al. **J Cell Biol** 1998 Nov 16;143(4):921-33
Differential regulation and expression of stress proteins and ferritin in human monocytes. Bornman L, et al. **J Cell Physiol** 1999 Jan;178(1):1-8
Cloning, tissue expression, and chromosomal assignment of human MRJ gene for a member of the DNAJ protein family. Seki N, et al. **J Hum Genet** 1999;44(3):185-9
Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O. Cornell KA, et al. **J Immunol** 1999 Jul 1;163(1):322-9
Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress. Brar BK, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):135-46
Osmotic regulation of the Na+/myo-inositol cotransporter and postinduction normalization. Yorek MA, et al. **Kidney Int** 1999 Jan;55(1):215-24
Influence of osmotic stress on heat shock proteins 25 and 72 in mouse mesangial cells. Müller E, et al. **Kidney Int Suppl** 1998 Sep;67:S162-4
Hypertonicity affects heat shock protein 27 and F-actin localization in Madin-Darby canine kidney cells. Neuhofer W, et al. **Kidney Int Suppl** 1998 Sep;67:S165-7
Expression of the Na+/myo-inositol cotransporter in the juxtaglomerular region. Yamauchi A, et al. **Kidney Int Suppl** 1998 Sep;67:S183-5
PCR differentiation of Escherichia coli from other gram-negative bacteria using primers derived from the nucleotide sequences flanking the gene encoding the universal stress protein. Chen J, et al. **Lett Appl Microbiol** 1998 Dec;27(6):369-71
Cloning and sequencing of the gene encoding universal stress protein from Escherichia coli O157:H7 isolated from Jack-in-a-Box outbreak. Chen J, et al. **Lett Appl Microbiol** 1999 Aug;29(2):103-7
DNA fragmentation and HSP72 gene expression by adenovirus-mediated gene transfer in postischemic gerbil hippocampus and ventricle. Kitagawa H, et al. **Metab Brain Dis** 1998 Sep;13(3):211-23
The type IV Aeromonas pilus (Tap) gene cluster is widely conserved in Aeromonas species. Barnett TC, et al. **Microb Pathog** 1999 Feb;26(2):77-84
Identification and sequencing of the groE operon and flanking genes of Lawsonia intracellularis: use in phylogeny. Dale CJ, et al. **Microbiology** 1998 Aug;144 (Pt 8):2073-84
Stress induction of HSP30, the plasma membrane heat shock protein gene of Saccharomyces cerevisiae, appears not to use known stress-regulated transcription factors. Seymour IJ, et al. **Microbiology** 1999 Jan;145 (Pt 1):231-9
Physiological consequences of mutations in Escherichia coli heat shock dnaK and dnaJ genes. Wolska KI, et al. **Microbios** 1999;97(386):55-67
Effect of acidic pH on heat shock gene expression in Leishmania. Garlapati S, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):95-101
Conservation of genetic linkage between heat shock protein 100 and glycosylphosphatidylinositol-specific phospholipase C in Trypanosoma brucei and Trypanosoma cruzi. Redpath MB, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):113-21
The diversification of plant cytosolic small heat shock proteins preceded the divergence of mosses. Waters ER, et al. **Mol Biol Evol** 1999 Jan;16(1):127-39
Cooperative binding of heat shock factor to the yeast HSP82 promoter in vivo and in vitro [published erratum appears in Mol Cell Biol 1999 May;19(5):3929] Erkine AM, et al. **Mol Cell Biol** 1999 Mar;19(3):1627-39
Comparison of the structure and expression pattern for a low molecular weight heat-shock protein cDNA clone from Nicotiana tabacum. Park SM, et al. **Mol Cells** 1998 Oct 31;8(5):594-9
Increased sensitivity of E. coli to novobiocin, EDTA and the anticalmodulin drug W7 following overproduction of DjlA requires a functional transmembrane domain. Bernard S, et al. **Mol Gen Genet** 1998 Oct;259(6):645-55
Cloning and characterization of the rpoH gene of Rhodobacter capsulatus. Emetz D, et al. **Mol Gen Genet** 1998 Nov;260(2-3):212-7
Mutations in the Schizosaccharomyces pombe heat shock factor that differentially affect responses to heat and cadmium stress. Saltsman KA, et al. **Mol Gen Genet** 1999 Feb;261(1):161-9
The heat shock response in yeast: differential regulations and contributions of the Msn2p/Msn4p and Hsf1p regulons. Boy-Marcotte E, et al. **Mol Microbiol** 1999 Jul; 33(2):274-83
ClpE, a novel type of HSP100 ATPase, is part of the CtsR heat shock regulon of Bacillus subtilis. Derré I, et al. **Mol Microbiol** 1999 May;32(3):581-93
CtsR, a novel regulator of stress and heat shock response, controls clp and molecular chaperone gene expression in gram-positive bacteria. Derré I, et al. **Mol Microbiol** 1999 Jan;31(1):117-31
Effects of metabolic flux on stress response pathways in Lactococcus lactis. Duwat P, et al. **Mol Microbiol** 1999 Feb;31(3):845-58
Genetic and biochemical characterization of mutations affecting the carboxy-terminal domain of the Escherichia coli molecular chaperone DnaJ. Goffin L, et al. **Mol Microbiol** 1998 Oct;30(2):329-40
The ClpB ATPase of Streptomyces albus G belongs to the HspR heat shock regulon. Grandvalet C, et al. **Mol Microbiol** 1999 Jan;31(2):521-32
Evolutionary relationships among photosynthetic prokaryotes (Heliobacterium chlorum, Chloroflexus aurantiacus, cyanobacteria, Chlorobium tepidum and proteobacteria): implications regarding the origin of photosynthesis. Gupta RS, et al. **Mol Microbiol** 1999 Jun; 32(5):893-906
Non-specific, general and multiple stress resistance of growth-restricted Bacillus subtilis cells by the expression of the sigmaB regulon. Hecker M, et al. **Mol Microbiol** 1998 Sep;29(5):1129-36 (55 ref.)
Transcription of rpoH, encoding the Escherichia coli heat-shock regulator sigma32, is negatively controlled by the cAMP-CRP/CytR nucleoprotein complex [see comments] Kallipolitis BH, et al. **Mol Microbiol** 1998 Aug; 29(4):1091-9. Comment in: Mol Microbiol 1999 Jan;31(1):393.
ClpE, a novel member of the HSP100 family, is involved in cell division and virulence of Listeria monocytogenes. Nair S, et al. **Mol Microbiol** 1999 Jan;31(1):185-96
Negative regulation of bacterial heat shock genes. Narberhaus F. **Mol Microbiol** 1999 Jan;31(1):1-8 (45 ref.)
RpoN-dependent transcription of rpoH? [letter; comment] Pallen M. **Mol Microbiol** 1999 Jan;31(1):393. Comment on: Mol Microbiol 1998 Aug;29(4):1091-9.
Levels of DnaK and DnaJ provide tight control of heat shock gene expression and protein repair in Escherichia coli. Tomoyasu T, et al. **Mol Microbiol** 1998 Nov;30(3):567-81
Heat shock proteins, HLA-DR and rheumatoid arthritis [letter; comment] Rich T, et al. **Nat Med** 1998 Nov; 4(11):1210-1. Comment on: Nat Med 1996 Mar;2(3):279-80. Comment on: Nat Med 1996 Mar;2(3):306-10.
Expression of c-fos, junB, c-jun, MKP-1 and hsp72 following traumatic neocortical lesions in rats--relation to spreading depression. Hermann DM, et al. **Neuroscience** 1999 Jan;88(2):599-608
Heterochromatic silencing of Drosophila heat shock genes acts at the level of promoter potentiation. Cryderman DE, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):3364-70
Effect of extracellular pH on the myo-inositol transporter SMIT expressed in Xenopus oocytes. Matskevitch J, et al. **Pflugers Arch** 1998 Nov;436(6):854-7
Inhibition of NaCl-induced heat shock protein 72 expression renders MDCK cells susceptible to high urea concentrations. Neuhofer W, et al. **Pflugers Arch** 1999 Mar; 437(4):611-6
Expression of DnaJ homologs and Hsp70 in the Japanese willow (Salix gilgiana Seemen). Futamura N, et al. **Plant Cell Physiol** 1999 May;40(5):524-31
MsJ1, an alfalfa DnaJ-like gene, is tissue-specific and transcriptionally regulated during cell cycle. Frugis G, et al. **Plant Mol Biol** 1999 Jun;40(3):397-408
Wild and cultivated barleys show differences in the expression pattern of a cold-regulated gene family under different light and temperature conditions. Grossi M, et al. **Plant Mol Biol** 1998 Dec;38(6):1061-9
Molecular characterization of a plant mitochondrial chaperone GrpE. Padidam M, et al. **Plant Mol Biol** 1999 Mar;39(5):871-81
The interaction between cold and light controls the expression of the cold-regulated barley gene cor14b and the accumulation of the corresponding protein. Crosatti C, et al. **Plant Physiol** 1999 Feb;119(2):671-80
Heterologous expression of a plant small heat-shock protein enhances Escherichia coli viability under heat and cold stress. Soto A, et al. **Plant Physiol** 1999 Jun;120(2):521-8
The 70-kDa heat shock cognate protein (Hsc73) gene is enhanced by ovarian hormones in the ventromedial hypothalamus. Krebs CJ, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1686-91
Enhancement of translation by the downstream box does not involve base pairing of mRNA with the penultimate stem sequence of 16S rRNA. O'Connor M, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8973-8
Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. Smith CK, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6678-82
TID1, a human homolog of the Drosophila tumor suppressor l(2)tid, encodes two mitochondrial modulators of apoptosis with opposing functions. Syken J, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8499-504
The regulation of heat shock proteins and their role in systemic lupus erythematosus. Stephanou A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):155-62 (54 ref.)
Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Bernstein H, et al. **Toxicol Lett** 1999 Jul 30;108(1):37-46
TNF-alpha and heat-shock protein gene expression in ischemic-injured liver from fasted and non-fasted rats. Role of donor fasting in the prevention of reperfusion injury following liver transplantation. Nishihara M, et al. **Transpl Int** 1998;11 Suppl 1:S417-20
Nitric oxide donor induces upregulation of stress proteins in cold ischemic rat hearts. Katori M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1022-3
Geranylgeranylacetone induces heat shock protein-73 in rat small intestine. Tsuruma T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):572-3
Does the membrane's physical state control the expression

of heat shock and other genes? Vigh L, et al. **Trends Biochem Sci** 1998 Oct;23(10):369–74 (61 ref.)
[Phylogenetic analysis based on groE shows the closest evolutionary relationship between mitochondria and Rickettsia] Emel'ianov VV, et al. **Genetika** 1999 Jun; 35(6):733–43 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Schwarz MJ, et al. **Am J Psychiatry** 1999 Jul;156(7):1103–4
Interferon-alpha inhibits the emergence of cellular stress response-dependent morbillivirus large plaque variants. Heller M, et al. **Antiviral Res** 1998 Jun;38(3):195–207
Effect of intrathymic administration of mycobacterial heat shock protein 65 and peptide p277 on the development of diabetes in NOD mice: caution required in vaccination studies. Funda DP, et al. **APMIS** 1998 Oct;106(10):1009–16
Production of monoclonal antibodies to Listeria monocytogenes and their application to determine the virulence of isolates from channel catfish. Erdenlig S, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2827–32
Stress protein/peptide complexes derived from autologous tumor tissue as tumor vaccines. Heike M, et al. **Biochem Pharmacol** 1999 Nov 1;58(9):1381–7
Immune responses to inflammation and trauma: a physical training model. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 May;76(5):469–72 (33 ref.)
Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. Colaco CA. **Cell Mol Biol (Noisy-le-grand)** 1998 Sep;44(6):883–90 (40 ref.)
Presence of antibodies to heat stress proteins in workers exposed to benzene and in patients with benzene poisoning. Wu T, et al. **Cell Stress Chaperones** 1998 Sep;3(3):161–7
Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Mayr M, et al. **Circulation** 1999 Mar 30;99(12):1560–6
Helicobacter pylori heat shock protein A: serologic responses and genetic diversity. Ng EK, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):377–82
Stress proteins and immunity mediated by cytotoxic T lymphocytes. Schild H, et al. **Curr Opin Immunol** 1999 Feb; 11(1):109–13 (55 ref.)
HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Uchio E, et al. **Exp Eye Res** 1998 Dec; 67(6):719–27
Antibodies to Chlamydia trachomatis heat shock proteins in women with tubal factor infertility are associated with prior infection by C. trachomatis but not by C. pneumoniae. Persson K, et al. **Hum Reprod** 1999 Aug;14(8):1969–73
Previously undetected Chlamydia trachomatis infection, immunity to heat shock proteins and tubal occlusion in women undergoing in-vitro fertilization. Spandorfer SD, et al. **Hum Reprod** 1999 Jan;14(1):60–4
Antibodies to the chlamydial 60 kilodalton heat shock protein in women with tubal factor infertility. Ault KA, et al. **Infect Dis Obstet Gynecol** 1998;6(4):163–7
Immunity to heat shock proteins and neurological disorders of women. Birnbaum G, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):39–48 (56 ref.)
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Brenner BG, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):80–90 (82 ref.)
Heat shock proteins and protection against ischemic injury. Dillmann WH. **Infect Dis Obstet Gynecol** 1999;7(1–2):55–7 (11 ref.)
Heat shock protein expression and immunity in chlamydial infections. Peeling RW, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):72–9 (50 ref.)
Immunity to heat shock proteins and arthritic disorders. van Eden W. **Infect Dis Obstet Gynecol** 1999;7(1–2):49–54 (23 ref.)
Heat shock proteins and heat shock protein-antibody complexes in placental tissues. Ziegert M, et al. **Infect Dis Obstet Gynecol** 1999;7(4):180–5
Murine gamma delta T lymphocytes elicited during Plasmodium yoelii infection respond to Plasmodium heat shock proteins. Kopacz J, et al. **Infect Immun** 1999 Jan; 67(1):57–63
Induction of protective T cells against Listeria monocytogenes in mice by immunization with a listeriolysin O-negative avirulent strain of bacteria and liposome-encapsulated listeriolysin O. Tanabe Y, et al. **Infect Immun** 1999 Feb;67(2):568–75
Characterization of HDJ-2, a human 40 kD heat shock protein. Davis AR, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1203–21
HLA-DRB1 motifs and heat shock proteins in rheumatoid arthritis. Auger I, et al. **Int Rev Immunol** 1998; 17(5–6):263–71 (23 ref.)
Autoantibodies to small heat shock proteins in glaucoma. Tezel G, et al. **Invest Ophthalmol Vis Sci** 1998 Nov; 39(12):2277–87
T cell affinity maturation by selective expansion during infection. Busch DH, et al. **J Exp Med** 1999 Feb 15; 189(4):701–10
Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O. Cornell KA, et al. **J Immunol** 1999 Jul 1;163(1):322–9
Heat shock protein antibodies in sarcoma patients undergoing 41.8 degrees C whole body hyperthermia. Katschinski DM, et al. **J Immunother** 1999 Jan;22(1):67–70
Stress proteins in fungal diseases. Matthews RC, et al. **Med Mycol** 1998;36 Suppl 1:45–51 (42 ref.)
Role of Toxoplasma gondii HSP70 and Toxoplasma gondii HSP30/bag1 in antibody formation and prophylactic immunity in mice experimentally infected with Toxoplasma gondii. Mun HS, et al. **Microbiol Immunol** 1999;43(5):471–9
Heat shock protein--peptide complexes as immunotherapy for human cancer. Przepiorka D, et al. **Mol Med Today** 1998 Nov;4(11):478–84 (48 ref.)
New therapeutic strategies in juvenile chronic arthritis. Kuis W, et al. **Neth J Med** 1998 Sep;53(3):134–6 (7 ref.)
Behçet's disease and antibody titers to various heat-shock protein 60s. Tanaka T, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):69–74
The small heat shock protein alpha B-crystallin as key autoantigen in multiple sclerosis. Van Noort JM, et al. **Prog Brain Res** 1998;117:435–52 (73 ref.)
The regulation of heat shock proteins and their role in systemic lupus erythematosus. Stephanou A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):155–62 (54 ref.)
Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Ménoret A, et al. **Semin Oncol** 1998 Dec;25(6):654–60 (41 ref.)
Evidence for heat shock protein immunity in a rat cardiac allograft model of chronic rejection. Duquesnoy RJ, et al. **Transplantation** 1999 Jan 15;67(1):156–64
Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Anthony LS, et al. **Vaccine** 1999 Jan 28;17(4):373–83
Kinetics of interferon-gamma production and its comparison with anti-listeriolysin O detection in experimental bovine listeriosis. Barbuddhe SB, et al. **Vet Res Commun** 1998 Dec; 22(8):505–16
The role of heat shock proteins in the immunity theory of atherosclerosis [letter; comment] Tatzber F, et al. **Wien Klin Wochenschr** 1999 May 7;111(9):371–2. Comment on: Wien Klin Wochenschr 1998 May 22;110(10):350–5.
[Circulating antibodies against an epitope of the heat-shock protein 60kDA of chlamydia trachomatis in infertile couples. Relation with surface chlamydia trachomatis anti-antigen antibody and E. coli anti-HSP60 antibody and human anti-HSP60] Witkin SS, et al. **Contracept Fertil Sex** 1998 Nov;26(11):suppl I–VI **(Fre)**
[T lymphocyte immunological response to different antigenic fractions of Mycobacterium bovis in juvenile chronic polyarthritis] González B, et al. **Rev Med Chil** 1999 Apr; 127(4):389–98 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Two-dimensional crystals of reconstituted beta-subunits of the chaperonin TF55 from Sulfolobus shibatae. Koeck PJ, et al. **Biochim Biophys Acta** 1998 Dec 8;1429(1):40–4
Purification and characterization of the 16-kDa heat-shock-responsive protein from the thermophilic cyanobacterium Synechococcus vulcanus, which is an alpha-crystallin-related, small heat shock protein. Roy SK, et al. **Eur J Biochem** 1999 Jun;262(2):406–16
The mammalian small heat-shock protein Hsp20 forms dimers and is a poor chaperone. van de Klundert FA, et al. **Eur J Biochem** 1998 Dec 15;258(3):1014–21
Purification, characterization and immunochemical properties of a novel 60-kDa protein of Vibrio anguillarum strains. Mutharia LM, et al. **FEMS Microbiol Lett** 1998 Nov 1;168(1):111–7
Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. Ishii T, et al. **J Immunol** 1999 Feb 1;162(3):1303–9
A low temperature induced apoplastic protein isolated from Arachis hypogaea. Dave RS, et al. **Phytochemistry** 1998 Dec;49(8):2207–13
The chloroplast small heat shock protein--purification and characterization of pea recombinant protein. Härndahl U, et al. **Protein Expr Purif** 1998 Oct;14(1):87–96
A method for purification of listeriolysin O from a hypersecretor strain of Listeria monocytogenes. Walton CM, et al. **Protein Expr Purif** 1999 Mar;15(2):243–5
Simplified purification of Listeria monocytogenes listeriolysin O and preliminary application in the enzyme-linked immunosorbent assay (ELISA). Traub WH, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):29–42

METABOLISM

Structural insights into the regulation of SOS mutagenesis. Gonzalez M, et al. **Acta Biochim Pol** 1998;45(1):163–72
Heat acclimation increases the basal HSP72 level and alters its production dynamics during heat stress. Maloyan A, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1506–15
Expression of heat shock protein 72 by alveolar macrophages in hypersensitivity pneumonitis. Racine C, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L501–5
Acute exercise can improve cardioprotection without increasing heat shock protein content. Taylor RP, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H1098–102
Rho A regulates sustained smooth muscle contraction through cytoskeletal reorganization of HSP27. Wang P, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1454–62
Heat shock protein expression protects against cerebral ischemia and monoamine overload in rat heatstroke. Yang YL, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1961–7
Change in the localization of heat shock protein 27 (HSP 27) in BG-1 human ovarian cancer cells following treatment by the ether lipid ET-18-OCH3. Fujiwara K, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):181–7
Green fluorescent protein as a noninvasive stress probe in resting Escherichia coli cells. Cha HJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):409–14
Evidence for the interplay between trehalose metabolism and Hsp104 in yeast. Iwahashi H, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4614–7
Evidence for a novel set of small heat-shock proteins that associates with the mitochondria of murine PC12 cells and protects NADH:ubiquinone oxidoreductase from heat and oxidative stress. Downs CA, et al. **Arch Biochem Biophys** 1999 May 15;365(2):344–50
Induction of DNA strand breaks and expression of HSP70 and GRP78 homolog by cadmium in the marine sponge Suberites domuncula. Schröder HC, et al. **Arch Environ Contam Toxicol** 1999 Jan;36(1):47–55
Ultrasound effect on level of stress proteins and arthritic histology in experimental arthritis. Huang MH, et al. **Arch Phys Med Rehabil** 1999 May;80(5):551–6
Overexpression of human homologs of the bacterial DnaJ chaperone in the synovial tissue of patients with rheumatoid arthritis. Kurzik-Dumke U, et al. **Arthritis Rheum** 1999 Feb;42(2):210–20
Involvement of c-Jun NH(2)-terminal kinase pathway in differential regulation of heat shock proteins by anticancer drugs. Kim SH, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):516–22
Proteasome inhibitors induce the association of Alzheimer's amyloid precursor protein with Hsc73. Kouchi Z, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):804–10
Identification of a site of Hsp27 binding with Hsp27 and alpha B-crystallin as indicated by the yeast two-hybrid system. Liu C, et al. **Biochem Biophys Res Commun** 1999 Feb 16; 255(2):256–61
Acute infection of Sindbis virus induces phosphorylation and intracellular translocation of small heat shock protein HSP27 and activation of p38 MAP kinase signaling pathway. Nakatsue T, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):59–64
Translocation of HSP27 to cytoskeleton by repetitive hypoxia-reoxygenation in the rat myoblast cell line, H9c2. Sakamoto K, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):576–9
Characterization of a novel group of basic small heat shock proteins in Xenopus laevis A6 kidney epithelial cells. Ohan NW, et al. **Biochem Cell Biol** 1998;76(4):665–71
Nucleotide binding and hydrolysis properties of Neurospora crassa cytosolic molecular chaperones, Hsp70 and Hsp80, heat-inducible members of the eukaryotic stress-70 and stress-90 families. Ouimet PM, et al. **Biochem Cell Biol** 1999;77(2):89–99
Selectivity of the molecular chaperone-specific immunosuppressive agent 15-deoxyspergualin: modulation of Hsc70 ATPase activity without compromising DnaJ chaperone interactions. Brodsky JL. **Biochem Pharmacol** 1999 Apr 15;57(8):877–80
Regulation of actin dynamics by stress-activated protein kinase 2 (SAPK2)-dependent phosphorylation of heat-shock protein of 27 kDa (Hsp27). Landry J, et al. **Biochem Soc Symp** 1999;64:79–89 (40 ref.)
Endogenous substrates of sphingosine-dependent kinases (SDKs) are chaperone proteins: heat shock proteins, glucose-regulated proteins, protein disulfide isomerase, and calreticulin. Megidish T, et al. **Biochemistry** 1999 Mar 16; 38(11):3369–78
Sequence-specific rates of interaction of target peptides with the molecular chaperones DnaK and DnaJ. Pierpaoli EV, et al. **Biochemistry** 1998 Nov 24;37(47):16741–8
DnaJ dramatically stimulates ATP hydrolysis by DnaK: insight into targeting of Hsp70 proteins to polypeptide substrates. Russell R, et al. **Biochemistry** 1999 Mar 30; 38(13):4165–76
The relationship of p53 and stress proteins in response to bleomycin and retinoic acid in the p53 heterozygous mouse. Pipkin JL, et al. **Biochim Biophys Acta** 1999 Jun 8; 1450(2):164–76
Glucose metabolism in Neurospora is altered by heat shock and by disruption of HSP30. Plesofsky N, et al. **Biochim Biophys Acta** 1999 Feb 4;1449(1):73–82
Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al. **Biochimie** 1998 Aug-Sep;80(8–9):729–37 (49 ref.)
Monitoring of genes that respond to process-related stress in large-scale bioprocesses. Schweder T, et al. **Biotechnol Bioeng** 1999 Oct 20;65(2):151–9
Expression of the small heat shock protein HSP 27 in developing human skin. Jantschitsch C, et al. **Br J Dermatol** 1998 Aug;139(2):247–53
High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy. Takami A, et al. **Br J Haematol** 1999 Aug;106(2):377–84
Infarct size-reducing effect of heat stress and alpha1

adrenoceptors in rats. Joyeux M, et al. **Br J Pharmacol** 1998 Oct;125(4):645–50

Regulation of protein phosphorylation in astrocyte cultures by external calcium ions: specific effects on the phosphorylation of glial fibrillary acidic protein (GFAP), vimentin and heat shock protein 27 (HSP27). Gottfried C, et al. **Brain Res** 1999 Jul 3;833(2):142–9

Presence of molecular chaperones, heat shock cognate (Hsc) 70 and heat shock proteins (Hsp) 40, in the postsynaptic structures of rat brain. Suzuki T, et al. **Brain Res** 1999 Jan 16;816(1):99–110

Stress tolerance in a yeast lipid mutant: membrane lipids influence tolerance to heat and ethanol independently of heat shock proteins and trehalose. Swan TM, et al. **Can J Microbiol** 1999 Jun;45(6):472–9

Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Hsu PL, et al. **Cancer Res** 1998 Dec 1;58(23):5507–13

Chaperone activity with a redox switch. Jakob U, et al. **Cell** 1999 Feb 5;96(3):341–52

Expression and cellular localization of the mRNA for the 25-kDa heat-shock protein in the mouse. Wakayama T, et al. **Cell Biol Int** 1998;22(4):295–304

Small stress protein Hsp27 accumulation during dopamine-mediated differentiation of rat olfactory neurons counteracts apoptosis. Mehlen P, et al. **Cell Death Differ** 1999 Mar;6(3):227–33

Activation of heat shock transcription factor 1 to a DNA binding form during the G(1)phase of the cell cycle. Bruce JL, et al. **Cell Stress Chaperones** 1999 Mar;4(1):36–45

Direct evidence for the intracellular localization of Hsp104 in Saccharomyces cerevisiae by immunoelectron microscopy. Kawai R, et al. **Cell Stress Chaperones** 1999 Mar;4(1):46–53

Hsp and chaperone distribution during endochondral bone development in mouse embryo. Loones MT, et al. **Cell Stress Chaperones** 1998 Dec;3(4):237–44

Expression and localization of collagen-binding stress protein Hsp47 in mouse embryo development: comparison with types I and II collagen. Masuda H, et al. **Cell Stress Chaperones** 1998 Dec;3(4):256–64

Reduced thermotolerance in aged cells results from a loss of an hsp72-mediated control of JNK signaling pathway. Volloch V, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):265–71

Modulation of tolerance by mutant heat shock transcription factors. Xia W, et al. **Cell Stress Chaperones** 1999 Mar; 4(1):8–18

Myocardial protection conferred by electromagnetic fields. DiCarlo AL, et al. **Circulation** 1999 Feb 16;99(6):813–6

Whole-body hyperthermia provides biphasic cardioprotection against ischemia/reperfusion injury in the rat. Yamashita N, et al. **Circulation** 1998 Oct 6; 98(14):1414–21

Expression of the heat shock protein HSP27 in human ovarian cancer. Langdon SP, et al. **Clin Cancer Res** 1995 Dec;1(12):1603–9

Hsp47 binds to the KDEL receptor and cell surface expression is modulated by cytoplasmic and endosomal pH. Sauk JJ, et al. **Connect Tissue Res** 1998;37(1–2):105–19

Expression of stress proteins, adhesion molecules, and interleukin-8 in endothelial cells after preservation and reoxygenation. Eberl T, et al. **Cryobiology** 1999 Mar; 38(2):106–18

Protein chaperones and the heat shock response in Saccharomyces cerevisiae. Morano KA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):197–203 (44 ref.)

An alternatively spliced gene encoding a Y-box protein showing maternal expression and tissue-specific zygotic expression in the ascidian embryo. Wada MR, et al. **Dev Growth Differ** 1998 Dec;40(6):631–40

Direct regulatory interaction of the eyeless protein with an eye-specific enhancer in the sine oculis gene during eye induction in Drosophila. Niimi T, et al. **Development** 1999 May;126(10):2253–60

The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. Meacham GC, et al. **EMBO J** 1999 Mar 15;18(6):1492–505

Heat shock protein HSP 27 is expressed in all types of basal cell carcinoma in low and high risk UV exposure groups. Bayerl C, et al. **Eur J Dermatol** 1999 Jun;9(4):281–4

Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration. Piotrowicz RS, et al. **FASEB J** 1998 Nov;12(14):1481–90

Ubiquitous and cell-specific members of the avian small heat shock protein family. Kawazoe Y, et al. **FEBS Lett** 1999 Jul 23;455(3):271–5

Interaction between the Arabidopsis thaliana heat shock transcription factor HSF1 and the TATA binding protein TBP. Reindl A, et al. **FEBS Lett** 1998 Oct 9;436(3):318–22

The effect of dietary lipid manipulation on murine splenic lymphocytes apoptosis and heat shock protein over expression. Romano Carratelli C, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):19–25

Functional characterisation of the chaperones DnaK, DnaJ, and GrpE from Clostridium acetobutylicum. Rüngeling E, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):119–23

Cloning and expression of the Campylobacter jejuni lon gene detected by RNA arbitrarily primed PCR. Thies FL, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):329–34

Analysis of the heat-shock response displayed by two Chaetomium species originating from different thermal environments. Oberson J, et al. **Fungal Genet Biol** 1999 Apr;26(3):178–89

Ras-mediated signaling pathway regulates the expression of a low-molecular-weight heat-shock protein in fission yeast. Danjoh I, et al. **Gene** 1999 Aug 20;236(2):347–52

Species variation in ATP-dependent protein degradation: protease profiles differ between mycobacteria and protease functions differ between Mycobacterium smegmatis and Escherichia coli. Knipfer N, et al. **Gene** 1999 Apr 29; 231(1–2):95–104

A role for RNA metabolism in inducing the heat shock response. Carlson T, et al. **Gene Expr** 1999;7(4–6):283–91

Lon-mediated proteolysis of the Escherichia coli UmuD mutagenesis protein: in vitro degradation and identification of residues required for proteolysis. Gonzalez M, et al. **Genes Dev** 1998 Dec 15;12(24):3889–99

Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Morimoto RI. **Genes Dev** 1998 Dec 15;12(24):3788–96 (103 ref.)

A study of heat shock protein 27 in endometrial carcinoma. Geisler JP, et al. **Gynecol Oncol** 1999 Mar;72(3):347–50

Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Stenoien DL, et al. **Hum Mol Genet** 1999 May; 8(5):731–41

Heat shock protein expression during gametogenesis and embryogenesis. Neuer A, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):10–6 (43 ref.)

Heat shock proteins in human endometrium throughout the menstrual cycle. Tabibzadeh S, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):5–9 (45 ref.)

Heat shock proteins and regulation of cytokine expression. Xie Y, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):26–30

Characterization of HDJ-2, a human 40 kD heat shock protein. Davis AR, et al. **Int J Biochem Cell Biol** 1998 Nov;30(11):1203–21

Elevated stress protein in transitional cells exposed to urine from interstitial cystitis patients. Ito T, et al. **Int J Urol** 1998 Sep;5(5):444–8

Intracellular interaction of Hsp47 and type I collagen in corneal endothelial cells. Gu X, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):289–95

AlphaB-crystallin selectively targets intermediate filament proteins during thermal stress. Muchowski PJ, et al. **Invest Ophthalmol Vis Sci** 1999 Apr;40(5):951–8

Role of region C in regulation of the heat shock gene-specific sigma factor of Escherichia coli, sigma32. Arsène F, et al. **J Bacteriol** 1999 Jun;181(11):3552–61

The Hsc66-Hsc20 chaperone system in Escherichia coli: chaperone activity and interactions with the DnaK-DnaJ-grpE system. Silberg JJ, et al. **J Bacteriol** 1998 Dec;180(24):6617–24

Efficiency of the pTF-FC2 pas poison-antidote stability system in Escherichia coli is affected by the host strain, and antidote degradation requires the lon protease. Smith ASG, et al. **J Bacteriol** 1998 Oct;180(20):5458–62

Redundant in vivo proteolytic activities of Escherichia coli Lon and the ClpYQ (HslUV) protease. Wu WF, et al. **J Bacteriol** 1999 Jun;181(12):3681–7

HSP47, a collagen-specific molecular chaperone, delays the secretion of type III procollagen transfected in human embryonic kidney cell line 293: a possible role for HSP47 in collagen modification. Hosokawa N, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):654–62

Single-step purification and characterization of MBP (maltose binding protein)-DnaJ fusion protein and its utilization for structure-function analysis. Ishii Y, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):842–7

The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation. Beall A, et al. **J Biol Chem** 1999 Apr 16;274(16):11344–51

Phosphorylation of the small heat shock-related protein, HSP20, in vascular smooth muscles is associated with changes in the macromolecular associations of HSP20. Brophy CM, et al. **J Biol Chem** 1999 Mar 5;274(10):6324–9

Purification of a 38-kDa protein from rabbit reticulocyte lysate which promotes protein renaturation by heat shock protein 70 and its identification as delta-aminolevulinic acid dehydratase and as a putative DnaJ protein. Gross M, et al. **J Biol Chem** 1999 Jan 29;274(5):3125–34

Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. Haché RJ, et al. **J Biol Chem** 1999 Jan 15; 274(3):1432–9

Regulation of protein phosphatase 2A activity by heat shock transcription factor 2. Hong Y, et al. **J Biol Chem** 1999 May 7;274(19):12967–70

Clusterin has chaperone-like activity similar to that of small heat shock proteins. Humphreys DT, et al. **J Biol Chem** 1999 Mar 12;274(11):6875–81

Marked instability of the sigma(32) heat shock transcription factor at high temperature. Implications for heat shock regulation. Kanemori M, et al. **J Biol Chem** 1999 Jul 30; 274(31):22002–7

A new heat shock protein that binds nucleic acids. Korber P, et al. **J Biol Chem** 1999 Jan 1;274(1):249–56

HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. Lambert H, et al. **J Biol Chem** 1999 Apr 2;274(14):9378–85

Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication. Liu JS, et al. **J Biol Chem** 1998 Nov 13;273(46):30704–12

Modulation of human heat shock factor trimerization by the linker domain. Liu PC, et al. **J Biol Chem** 1999 Jun 11; 274(24):17219–25

Protein folding activity of Hsp70 is modified differentially by the hsp40 co-chaperones Sis1 and Ydj1. Lu Z, et al. **J Biol Chem** 1998 Oct 23;273(43):27824–30

Ribonuclease activity of rat liver perchloric acid-soluble protein, a potent inhibitor of protein synthesis. Morishita R, et al. **J Biol Chem** 1999 Jul 16;274(29):20688–92

Loss of Hsp70-Hsp40 chaperone activity causes abnormal nuclear distribution and aberrant microtubule formation in M-phase of Saccharomyces cerevisiae. Oka M, et al. **J Biol Chem** 1998 Nov 6;273(45):29727–37

Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. Pei L. **J Biol Chem** 1999 Jan 29; 274(5):3151–8

The function of HSP72 in suppression of c-Jun N-terminal kinase activation can be dissociated from its role in prevention of protein damage. Yaglom JA, et al. **J Biol Chem** 1999 Jul 16;274(29):20223–8

Binding of the protein disulfide isomerase isoform ERp60 to the nuclear matrix-associated regions of DNA. Ferraro A, et al. **J Cell Biochem** 1999 Mar 15;72(4):528–39

Cell surface colligin/Hsp47 associates with tetraspanin protein CD9 in epidermoid carcinoma cell lines. Hebert C, et al. **J Cell Biochem** 1999 May 1;73(2):248–58

The in vivo association of BiP with newly synthesized proteins is dependent on the rate and stability of folding and not simply on the presence of sequences that can bind to BiP. Hellman R, et al. **J Cell Biol** 1999 Jan 11; 144(1):21–30

Lamin B is a prompt heat shock protein. Dynlacht JR, et al. **J Cell Physiol** 1999 Jan;178(1):28–34

Intermediate filament interactions can be altered by HSP27 and alphaB-crystallin. Perng MD, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2099–112

Dexamethasone protection of rat intestinal epithelial cells against oxidant injury is mediated by induction of heat shock protein 72. Urayama S, et al. **J Clin Invest** 1998 Nov 15;102(10):1860–5

In vivo regulation of MAP kinases in Ratus norvegicus renal papilla by water loading and restriction. Wojtaszek PA, et al. **J Clin Invest** 1998 Nov 15;102(10):1874–81

Thermosensitivity, incidence of apoptosis and accumulations of hsp72 and p53 proteins of murine L cells in wild type status of p53 gene. Hayashi S, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):181–9

Expression of heat shock proteins in mouse skin during wound healing. Laplante AF, et al. **J Histochem Cytochem** 1998 Nov;46(11):1291–301

Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. Arnold-Schild D, et al. **J Immunol** 1999 Apr 1; 162(7):3757–60

Catalysis, commitment and encapsulation during GroE-mediated folding. Beissinger M, et al. **J Mol Biol** 1999 Jun 18;289(4):1075–92

Investigation of the interaction between DnaK and DnaJ by surface plasmon resonance spectroscopy. Mayer MP, et al. **J Mol Biol** 1999 Jun 18;289(4):1131–44

Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress. Brar BK, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):135–46

Mutation of amino acids 246–251 alters nuclear accumulation of human heat shock protein (HSP) 72 with stress, but does not reduce viability. Knowlton AA. **J Mol Cell Cardiol** 1999 Mar;31(3):523–32

Dissociation of heat shock proteins expression with ischemic tolerance by whole body hyperthermia in rat heart. Qian YZ, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1163–72

Whole body heat shock fails to protect mouse heart against ischemia/reperfusion injury: role of 72 kDa heat shock protein and antioxidant enzymes. Xi L, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2213–27

Responses of heat shock proteins hsp27, alphaB-crystallin, and hsp70 in rat brain after kainic acid-induced seizure activity. Kato K, et al. **J Neurochem** 1999 Jul;73(1):229–36

Heat shock protein expression in umbilical artery smooth muscle. Brophy CM, et al. **J Reprod Fertil** 1998 Nov; 114(2):351–5

The small heat shock-related protein-20 is an actin-associated protein. Brophy CM, et al. **J Vasc Surg** 1999 Feb;29(2):326–33

Endothelial-dependent vasodilation is associated with increases in the phosphorylation of a small heat shock protein (HSP20). Jerius H, et al. **J Vasc Surg** 1999 Apr; 29(4):678–84

Identification and transcriptional analysis of new members of the sigmaB regulon in Bacillus subtilis. Petersohn A, et al. **Microbiology** 1999 Apr;145 (Pt 4):869–80

Immunolocalization of collagen and collagen-binding heat shock protein 47 in fibrotic lung diseases. Razzaque MS, et al. **Mod Pathol** 1998 Dec;11(12):1183–8

ERp57 functions as a subunit of specific complexes formed with the ER lectins calreticulin and calnexin. Oliver JD, et al. **Mol Biol Cell** 1999 Aug;10(8):2573–82

Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Carrier F, et al. **Mol Cell Biol** 1999 Mar;19(3):1673-85

Cooperative binding of heat shock factor to the yeast HSP82 promoter in vivo and in vitro [published erratum appears in Mol Cell Biol 1999 May;19(5):3929] Erkine AM, et al. **Mol Cell Biol** 1999 Mar;19(3):1627-39

Interference between proteins Hap46 and Hop/p60, which bind to different domains of the molecular chaperone hsp70/hsc70. Gebauer M, et al. **Mol Cell Biol** 1998 Nov; 18(11):6238-44

Glycogen synthase phosphatase interacts with heat shock factor to activate CUP1 gene transcription in Saccharomyces cerevisiae. Lin JT, et al. **Mol Cell Biol** 1999 May;19(5):3237-45

Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72 [published erratum appears in Mol Cell Biol 1999 Jul;19(7):5235] Meriin AB, et al. **Mol Cell Biol** 1999 Apr;19(4):2547-55

Antagonistic interactions between yeast chaperones Hsp104 and Hsp70 in prion curing. Newnam GP, et al. **Mol Cell Biol** 1999 Feb;19(2):1325-33

CRP.cAMP-dependent transcription activation of the Escherichia coli pts Po promoter by the heat shock RNA polymerase (Esigma32) in vitro. Ryu S. **Mol Cells** 1998 Oct 31;8(5):614-7

Increased sensitivity of E. coli to novobiocin, EDTA and the anticalmodulin drug W7 following overproduction of DjlA requires a functional transmembrane domain. Bernard S, et al. **Mol Gen Genet** 1998 Oct;259(6):645-55

On the mechanism of FtsH-dependent degradation of the sigma 32 transcriptional regulator of Escherichia coli and the role of the Dnak chaperone machine. Biaszczak A, et al. **Mol Microbiol** 1999 Jan;31(1):157-66

ClpE, a novel type of HSP100 ATPase, is part of the CtsR heat shock regulon of Bacillus subtilis. Derré I, et al. **Mol Microbiol** 1999 May;32(3):581-93

ClpP participates in the degradation of misfolded protein in Lactococcus lactis. Frees D, et al. **Mol Microbiol** 1999 Jan; 31(1):79-87

Genetic and biochemical characterization of mutations affecting the carboxy-terminal domain of the Escherichia coli molecular chaperone DnaJ. Goffin L, et al. **Mol Microbiol** 1998 Oct;30(2):329-40

The ClpB ATPase of Streptomyces albus G belongs to the HspR heat shock regulon. Grandvalet C, et al. **Mol Microbiol** 1999 Jan;31(2):521-32

Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Higgins DE, et al. **Mol Microbiol** 1999 Mar;31(6):1631-41

Serine kinase activity of a Bacillus subtilis switch protein is required to transduce environmental stress signals but not to activate its target PP2C phosphatase. Kang CM, et al. **Mol Microbiol** 1998 Oct;30(1):189-96

The contribution of the O-glycosylated protein Pir2p/Hsp150 to the construction of the yeast cell wall in wild-type cells and beta 1,6-glucan-deficient mutants. Kapteyn JC, et al. **Mol Microbiol** 1999 Mar;31(6):1835-44

Listeriolysin O-dependent activation of endothelial cells during infection with Listeria monocytogenes: activation of NF-kappa B and upregulation of adhesion molecules and chemokines. Kayal S, et al. **Mol Microbiol** 1999 Mar; 31(6):1709-22

The XylS-dependent Pm promoter is transcribed in vivo by RNA polymerase with sigma 32 or sigma 38 depending on the growth phase. Marqués S, et al. **Mol Microbiol** 1999 Feb;31(4):1105-13

ClpC regulates the fate of a sporulation initiation sigma factor, sigmaH protein, in Bacillus subtilis at elevated temperatures. Nanamiya H, et al. **Mol Microbiol** 1998 Jul; 29(2):505-13

Sequence-selective interactions with RNA by CspB, CspC and CspE, members of the CspA family of Escherichia coli. Phadtare S, et al. **Mol Microbiol** 1999 Sep; 33(5):1004-14

Hsp47-dependent and -independent intracellular trafficking of type I collagen in corneal endothelial cells. Ko MK, et al. **Mol Vis** 1999 Aug 19;5:17

Induction of heat-shock protein 72 in rat skeletal muscle does not increase tolerance to ischemia-reperfusion injury. Lille S, et al. **Muscle Nerve** 1999 Mar;22(3):390-3

Expression of heat shock protein 27 in chromomycosis. Bayerl C, et al. **Mycoses** 1998 Dec;41(11-12):447-52

Protein unfolding. Trapped in the act [news; comment] Baker TA. **Nature** 1999 Sep 2;401(6748):29-30. Comment on: Nature 1999 Sep 2;401(6748):90-3.

Global unfolding of a substrate protein by the Hsp100 chaperone ClpA [see comments] Weber-Ban EU, et al. **Nature** 1999 Sep 2;401(6748):90-3. Comment in: Nature 1999 Sep 2;401(6748):29-30.

Response to hypertonicity in mesothelial cells: role of Na+/myo-inositol co-transporter. Matsuoka Y, et al. **Nephrol Dial Transplant** 1999 May;14(5):1217-23

Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Lubrich B, et al. **Neuropsychopharmacology** 1999 Oct; 21(4):519-29

Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease. Renkawek K, et al. **Neuroreport** 1999 Aug 2; 10(11):2273-6

Oncogenic potential of Hsp72. Volloch VZ, et al. **Oncogene** 1999 Jun 17;18(24):3648-51

The relationship between rabbit corneal opacity and immunohistochemical expression of heat shock protein 72/73 and c-fos after excimer laser photorefractive keratectomy. Hong JW, et al. **Ophthalmic Res** 1999; 31(3):203-9

Influence of parasitization by Trichinella spiralis on the levels of heat shock proteins in rat liver and muscle. Martinez J, et al. **Parasitology** 1999 Feb;118 (Pt 2):201-9

Shock response induced in rat brain and spleen during primary infection with Trichinella spiralis larvae. Martinez J, et al. **Parasitology** 1999 Jun;118 (Pt 6):605-13

Effect of extracellular pH on the myo-inositol transporter SMIT expressed in Xenopus oocytes. Matskevitch J, et al. **Pflugers Arch** 1998 Nov;436(6):854-7

The heat-shock element is a functional component of the Arabidopsis APX1 gene promoter. Storozhenko S, et al. **Plant Physiol** 1998 Nov;118(3):1005-14

Accumulation of small heat-shock protein homologs in the endoplasmic reticulum of cortical parenchyma cells in mulberry in association with seasonal cold acclimation. Ukaji N, et al. **Plant Physiol** 1999 Jun;120(2):481-90

Minimal and optimal mechanisms for GroE-mediated protein folding [published erratum appears in Proc Natl Acad Sci U S A 1999 May 11;96(10):5890] Ben-Zvi AP, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15275-80

Mitochondrial stress protein recognition of inactivated dehydrogenases during mammalian cell death. Bruschi SA, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13413-8

Mutations in the DnaK chaperone affecting interaction with the DnaJ cochaperone. Gässler CS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15229-34

Differential protease-mediated turnover of H-NS and StpA revealed by a mutation altering protein stability and stationary-phase survival of Escherichia coli. Johansson J, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14; 96(19):10776-81

Mechanism of regulation of hsp70 chaperones by DnaJ cochaperones. Laufen T, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5452-7

Heat-inactivated proteins are rescued by the DnaK.J-GrpE set and ClpB chaperones. Motohashi K, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7184-9

Interaction of the Hsp70 molecular chaperone, DnaK, with its cochaperone DnaJ. Suh WC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15223-8

Substrate sequestration by a proteolytically inactive Lon mutant. Van Melderen L, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6064-71

Heat shock protein interactions with the glucocorticoid receptor. Bertorelli G, et al. **Pulm Pharmacol Ther** 1998 Feb;11(1):7-12 (57 ref.)

Activation of heat-shock transcription factor 1 in heated Chinese hamster ovary cells is dependent on the cell cycle and is inhibited by sodium vanadate. He L, et al. **Radiat Res** 1999 Mar;151(3):283-92

Increased heat shock protein expression after stress in Japanese quail. Hoekstra KA, et al. **Stress** 1998 Dec; 2(4):265-72

Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91-7

Protein phosphorylation in alveolar macrophages after stimulation with heavy metal-coated silica particles. Radloff M, et al. **Toxicol Lett** 1998 Aug;96-97:69-75

[Suppression of stress proteins in endoplasmic reticulum in liver cytosol of rats treated with a highly toxic coplanar PCB] Tasaki K, et al. **Fukuoka Igaku Zasshi** 1999 May; 90(5):251-8 (Eng. Abstr.) **(Jpn)**

[Analysis of the unfolded protein response: an intracellular signaling pathway from the endoplasmic reticulum to the nucleus] Mori K. **Seikagaku** 1998 Jul;70(7):505-15 (42 ref.) **(Jpn)**

[A role of heat-shock proteases in removal of denatured proteins from E. coli cells] Laskowska E, et al. **Postepy Biochem** 1998;44(4):334-44 (126 ref.) **(Pol)**

[A test system based on the lux-regulon from Vibrio fischeri for studying the functional activity of mutant forms of Escherichia coli lon-proteinase] Manukhov IV, et al. **Bioorg Khim** 1999 May;25(5):365-8 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Protection against necrosis but not apoptosis by heat-stress proteins in vascular smooth muscle cells: evidence for distinct modes of cell death. Champagne MJ, et al. **Hypertension** 1999 Mar;33(3):906-13

Depressed responsiveness of peripheral blood mononuclear cells to heat-shock proteins in periodontitis patients. Petit MD, et al. **J Dent Res** 1999 Aug;78(8):1393-400

Chaperonin GroE-facilitated refolding of disulfide-bonded and reduced Taka-amylase A from Aspergillus oryzae. Kawata Y, et al. **Protein Eng** 1998 Dec;11(12):1293-8

PHYSIOLOGY

Protective mechanisms in germ cells: stress proteins in spermatogenesis. Dix DJ, et al. **Adv Exp Med Biol** 1998; 444:137-43; discussion 143-4 (28 ref.)

Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Roigas J, et al. **Adv Exp Med Biol** 1998;451:225-9

Stress-response proteins in cardiovascular disease. Xiao X, et al. **Am J Hum Genet** 1999 Mar;64(3):685-90 (32 ref.)

Specific heat shock proteins protect microtubules during simulated ischemia in cardiac myocytes. Bluhm WF, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2243-9

HSP27 in signal transduction and association with contractile proteins in smooth muscle cells. Ibitayo AI, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G445-54

Early and delayed tolerance to simulated ischemia in heat-preconditioned endothelial cells: a role for HSP27. Loktionova SA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2147-58

Induction of 72-kDa heat shock protein does not produce second window of ischemic preconditioning in rat heart. Qian YZ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H224-34

Phosphorylation events associated with cyclic nucleotide-dependent inhibition of smooth muscle contraction. Woodrum DA, et al. **Am J Physiol** 1999 Sep; 277(3 Pt 2):H931-9

Heat shock proteins as cellular lifeguards. Jäättelä M. **Ann Med** 1999 Aug;31(4):261-71 (135 ref.)

Heat shock proteins and the inflammatory response. Moseley PL. **Ann N Y Acad Sci** 1998 Sep 29;856:206-13 (45 ref.)

Heat shock improves recovery and provides protection against global ischemia after hypothermic storage [see comments] Gowda A, et al. **Ann Thorac Surg** 1998 Dec; 66(6):1991-7. Comment in: Ann Thorac Surg 1999 Aug;68(2):628.

Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Feder ME, et al. **Annu Rev Physiol** 1999;61:243-82 (373 ref.)

Chaperone protein GrpE and the GroEL/GroES complex promote the correct folding of tobacco mosaic virus coat protein for ribonucleocapsid assembly in vivo. Hwang DJ, et al. **Arch Virol** 1998;143(11):2203-14

The role of PKN in the regulation of alphaB-crystallin expression via heat shock transcription factor 1. Kitagawa M, et al. **Biochem Biophys Res Commun** 1998 Nov 27; 252(3):561-5

Heat shock protein stimulates in vitro transcription of nitrogen regulator gene glnL of Escherichia coli. Takahashi T. **Biochem Biophys Res Commun** 1999 May 10; 258(2):341-4

Expression and cellular localization of the mRNA for the 25-kDa heat-shock protein in the mouse. Wakayama T, et al. **Cell Biol Int** 1998;22(4):295-304

International Conference on Heat-Shock Proteins in Immune Response. Farmington, Connecticut, USA. 12-15 October 1998. Abstracts [published erratum appears in Cell Stress Chaperones 1998 Dec;3(4):272] **Cell Stress Chaperones** 1998 Sep;3 Suppl 1:1-28

Stress proteins and apoptosis in prenatal development, cancer and medicine. Anderson RL. **Cell Stress Chaperones** 1998 Dec;3(4):209-12

Heat shock proteins: regulators of stress response and apoptosis. Samali A, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):228-36 (94 ref.)

Heat shock proteins chaperoning life and death. Vayssier M, et al. **Cell Stress Chaperones** 1998 Dec;3(4):221-7 (64 ref.)

Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Zügel U, et al. **Clin Microbiol Rev** 1999 Jan;12(1):19-39 (311 ref.)

Is heat shock protein-72 responsible for nitric oxide's ability to block stress-induced apoptosis? [letter] Cobb JP, et al. **Crit Care Med** 1999 Aug;27(8):1695

Molecular chaperones: small heat shock proteins in the limelight. van den IJssel P, et al. **Curr Biol** 1999 Feb 11; 9(3):R103-5 (13 ref.)

A 16.6-kilodalton protein in the Cyanobacterium synechocystis sp. PCC 6803 plays a role in the heat shock response. Lee S, et al. **Curr Microbiol** 1998 Dec;37(6):403-7

Heat shock proteins in renal injury and recovery. Van Why SK, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):407-12 (49 ref.)

Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Préville X, et al. **Exp Cell Res** 1999 Feb 25;247(1):61-78

Microinjection of an antibody against HSP 72 in keratinocytes to study acute UV injury. Bayerl C, et al. **Exp Dermatol** 1999 Aug;8(4):247-53

The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Yu Z, et al. **Exp Neurol** 1999 Feb; 155(2):302-14

Role of Hsp70 in regulation of stress-kinase JNK: implications in apoptosis and aging. Gabai VL, et al. **FEBS Lett** 1998 Oct 30;438(1-2):1-4 (53 ref.)

The role of DnaK/DnaJ and GroEL/GroES systems in the removal of endogenous proteins aggregated by heat-shock from Escherichia coli cells. Kędzierska S, et al. **FEBS Lett** 1999 Mar 12;446(2-3):331-7

Folding and refolding of thermolabile and thermostable bacterial luciferases: the role of DnaKJ heat-shock proteins. Manukhov IV, et al. **FEBS Lett** 1999 Apr 9; 448(2-3):265-8

Heat-shock protein 72 protects against oxidant-induced injury of barrier function of human colonic epithelial Caco2/bbe cells. Musch MW, et al. **Gastroenterology** 1999 Jul;117(1):115-22

Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes. Martin JL, et al. **Gene Expr** 1999; 7(4–6):349–55

Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. Morano KA, et al. **Gene Expr** 1999;7(4–6):271–82 (92 ref.)

Bacterial senescence: stasis results in increased and differential oxidation of cytoplasmic proteins leading to developmental induction of the heat shock regulon. Dukan S, et al. **Genes Dev** 1998 Nov 1;12(21):3431–41

HSP101 functions as a specific translational regulatory protein whose activity is regulated by nutrient status. Wells DR, et al. **Genes Dev** 1998 Oct 15;12(20):3236–51

Characterization of the Wsc1 protein, a putative receptor in the stress response of Saccharomyces cerevisiae. Lodder AL, et al. **Genetics** 1999 Aug;152(4):1487–99

Surface-associated heat shock proteins of Legionella pneumophila and Helicobacter pylori: roles in pathogenesis and immunity. Hoffman PS, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):58–63 (23 ref.)

Heat-shocked monocytes are resistant to Staphylococcus aureus-induced apoptotic DNA fragmentation due to expression of HSP72. Guzik K, et al. **Infect Immun** 1999 Aug;67(8):4216–22

Role of Listeria monocytogenes exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C in activation of human neutrophils. Sibelius U, et al. **Infect Immun** 1999 Mar;67(3):1125–30

Heat stress proteins and myocardial protection: experimental model or potential clinical tool? Gray CC, et al. **Int J Biochem Cell Biol** 1999 May;31(5):559–73 (95 ref.)

Stress proteins and glycoproteins (Review). Henle KJ, et al. **Int J Mol Med** 1998 Jan;1(1):25–32 (112 ref.)

A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. Hedges JC, et al. **J Biol Chem** 1999 Aug 20;274(34):24211–9

DNA-dependent protein kinase protects against heat-induced apoptosis. Nueda A, et al. **J Biol Chem** 1999 May 21;274(21):14988–96

Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. Rogalla T, et al. **J Biol Chem** 1999 Jul 2;274(27):18947–56

Expression of HSP27 results in increased sensitivity to tumor necrosis factor, etoposide, and H2O2 in an oxidative stress-resistant cell line. Mairesse N, et al. **J Cell Physiol** 1998 Dec;177(4):606–17

In vivo evaluation of hsp27 as an inhibitor of actin polymerization: hsp27 limits actin stress fiber and focal adhesion formation after heat shock. Schneider GB, et al. **J Cell Physiol** 1998 Dec;177(4):575–84

The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. Panjwani N, et al. **J Immunol** 1999 Aug 15;163(4):1936–42

Two distinct mechanisms operate in the reactivation of heat-denatured proteins by the mitochondrial Hsp70/Mdj1p/Yge1p chaperone system. Kubo Y, et al. **J Mol Biol** 1999 Feb 19;286(2):447–64

Neuroprotective role of Na+/myo-inositol cotransporter against veratridine cytotoxicity. Yamashita T, et al. **J Neurochem** 1999 May;72(5):1864–70

Heat shock proteins: a review of the molecular chaperones. Whitley D, et al. **J Vasc Surg** 1999 Apr;29(4):748–51 (10 ref.)

Role of glomerular epithelial cell-derived heat shock protein 47 in experimental lipid nephropathy. Razzaque MS, et al. **Kidney Int Suppl** 1999 Jul;71:S256–9

Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Manzo G. **Med Hypotheses** 1998 Jul;51(1):5–9 (30 ref.)

Mechanisms of autoprotection and the role of stress-proteins in natural defenses, autoprotection, and salutogenesis. Schaefer J, et al. **Med Hypotheses** 1998 Aug;51(2):153–63 (94 ref.)

Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Ballinger CA, et al. **Mol Cell Biol** 1999 Jun;19(6):4535–45

Characterization of Escherichia coli cspE, whose product negatively regulates transcription of cspA, the gene for the major cold shock protein. Bae W, et al. **Mol Microbiol** 1999 Mar;31(5):1429–41

Role of lon and ClpX in the post-translational regulation of a sigma subunit of RNA polymerase required for cellular differentiation in Bacillus subtilis. Liu J, et al. **Mol Microbiol** 1999 Jul;33(2):415–28

Disruption of the Toxoplasma gondii bradyzoite-specific gene BAG1 decreases in vivo cyst formation. Zhang YW, et al. **Mol Microbiol** 1999 Jan;31(2):691–701

Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Morimoto RI, et al. **Nat Biotechnol** 1998 Sep;16(9):833–8 (80 ref.)

DNA protection by stress-induced biocrystallization. Wolf SG, et al. **Nature** 1999 Jul 1;400(6739):83–5

Overexpression of the human 72 kDa heat shock protein in renal tubular cells confers resistance against oxidative injury and cisplatin toxicity. Komatsuda A, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1385–90

Is heat shock protein a potential protective mechanism against ischemia-reperfusion injury? [letter; comment] Lille S, et al. **Plast Reconstr Surg** 1999 Jan;103(1):336–7. Comment on: Plast Reconstr Surg 1998 Mar;101(3):776–84.

Neutrophil heat shock protein expression and activation correlate with increased apoptosis following transmigration through the endothelial barrier. Hennigan SM, et al. **Shock** 1999 Jul;12(1):32–8

Heat-shock protein-73 protects against small intestinal warm ischemia-reperfusion injury in the rat. Tsuruma T, et al. **Surgery** 1999 Apr;125(4):385–95

Efficacy of heat-shock proteins induced by severe fasting to protect rat livers preserved for 72 hours from cold ischemia/reperfusion injury. Takahashi Y, et al. **Transplant Proc** 1998 Nov;30(7):3700–2

Heat-shock protein protection. Sharp FR, et al. **Trends Neurosci** 1999 Mar;22(3):97–9 (70 ref.)

[Heat-shock proteins in the eye (editorial)] Wakakura M. **Nippon Ganka Gakkai Zasshi** 1998 Jul;102(7):409–10 (7 ref.) **(Jpn)**

[Stress proteins: biological function and clinical significance] Matumoto M, et al. **Nippon Ronen Igakkai Zasshi** 1998 Jul; 35(7):521–9 (60 ref.) **(Jpn)**

[Heat shock pre-conditioning prevents disruption of actin cytoskeleton of endothelial cells due to ATP depletion: the role for heat shock protein HSP27] Loktionova SA, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):237–40 **(Rus)**

[Autoinduced myocardial tolerance to ischemia: the role of stress proteins in the mechanisms of its occurrence] Shevchenko IuL, et al. **Fiziol Cheloveka** 1999 Jan–Feb; 25(1):134–9 (49 ref.) **(Rus)**

[Role of heat-shock proteins in cardioprotection of patients operated on for ischemic heart disease] Shevchenko IuL, et al. **Vestn Khir Im I I Grek** 1999;158(3):11–5 (Eng. Abstr.) **(Rus)**

SECRETION

Secretion of stress-related proteins by suspension-cultured Lupinus albus cells. Wojtaszek P, et al. **Acta Biochim Pol** 1998;45(1):281–5

THERAPEUTIC USE

Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. McDaniel LS, et al. **Infect Immun** 1998 Oct; 66(10):4748–54

Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Yedavelli SP, et al. **Int J Mol Med** 1999 Sep; 4(3):243–8

ULTRASTRUCTURE

Two-dimensional crystallization of the chaperonin TF55 from the hyperthermophilic archaeon Sulfolobus solfataricus. Ellis MJ, et al. **J Struct Biol** 1998 Sep; 123(1):30–6

HEAT-SHOCK PROTEINS 10 see **CHAPERONIN 10**

HEAT-SHOCK PROTEINS 60 see **CHAPERONIN 60**

HEAT-SHOCK PROTEINS 70

Heat shock proteins in retinal neurogenesis: identification of the PM1 antigen as the chick Hsc70 and its expression in comparison to that of other chaperones. Morales AV, et al. **Eur J Neurosci** 1998 Oct;10(10):3237–45

Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Kiang JG, et al. **Pharmacol Ther** 1998 Nov; 80(2):183–201 (94 ref.)

ADMINISTRATION & DOSAGE

In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. Breloer M, et al. **J Immunol** 1999 Mar 15;162(6):3141–7

ANALYSIS

Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Kawanishi K, et al. **Cancer** 1999 Apr 15;85(8):1649–57

Localization of DnaK and GroEL in Vibrio cholerae. Jyot J, et al. **FEMS Microbiol Lett** 1999 Mar 15;172(2):165–71

Heat shock proteins HSP70 and HSP60 in Echinococcus granulosus protoscolices. Martinez J, et al. **Folia Parasitol (Praha)** 1999;46(1):76–8

An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Park CS, et al. **Gynecol Oncol** 1999 Jul; 74(1):53–60

Topology and dynamics of the 10 kDa C-terminal domain of DnaK in solution. Bertelsen EB, et al. **Protein Sci** 1999 Feb;8(2):343–54

Baseline levels of Hsp 70, a stress protein and biomarker, in halibut from the Cook Inlet region of Alaska. Scofield E, et al. **Sci Total Environ** 1999 Feb 2;226(1):85–8

Subcellular localization of the HSP70-homolog encoded by beet yellows closterovirus. Medina V, et al. **Virology** 1999 Jul 20;260(1):173–81

ANTAGONISTS & INHIBITORS

Inhibition of Hsp70 ATPase activity and protein renaturation by a novel Hsp70-binding protein. Raynes DA, et al. **J Biol Chem** 1998 Dec 4;273(49):32883–8

[Blockade of heat shock protein synthesis prevents cardioprotective effect of adaptation to physical exertion] Pshennikova MG, et al. **Biull Eksp Biol Med** 1998 Sep; 126(9):299–301 **(Rus)**

BIOSYNTHESIS

Mitochondrial protein and HSP70 signaling after ischemia in hypothermic-adapted hearts augmented with glucose. Ning XH, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R11–7

Tobacco smoke induces both apoptosis and necrosis in mammalian cells: differential effects of HSP70. Vayssier M, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L771–9

Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Wong HR, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L836–41

Balloon angioplasty induces heat shock protein 70 in human blood vessels. Kirby LB, et al. **Ann Vasc Surg** 1999 Sep; 13(5):475–9

Induction of hsp70 by the herbicide oxyfluorfen (Goal) in the Egyptian Nile fish, Oreochromis niloticus. Hassanein HM, et al. **Arch Environ Contam Toxicol** 1999 Jul; 37(1):78–84

Divergent kinetics of hsp70 induction in Oniscus asellus (Isopoda) in response to four environmentally relevant organic chemicals (B[a]P, PCB52, gamma-HCH, PCP): suitability and limits of a biomarker. Köhler H, et al. **Arch Environ Contam Toxicol** 1999 Feb;36(2):179–85

Nitric oxide mediates IL-1beta stimulation of heat shock protein but not IL-1beta inhibition of glutamic acid decarboxylase. Hao W, et al. **Autoimmunity** 1999; 29(2):93–101

Overexpression of dnaK/dnaJ and groEL confers freeze tolerance to Escherichia coli. Chow KC, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):502–5

Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Kim D, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):264–8

The role of c-Myc and heat shock protein 70 in human hepatocarcinoma Hep3B cells during apoptosis induced by prostaglandin A2/Delta12-prostaglandin J2. Ahn SG, et al. **Biochim Biophys Acta** 1998 Nov 19;1448(1):115–25

Characteristic expression of 105-kDa heat shock protein (HSP105) in various tissues of nonstressed and heat-stressed rats. Wakatsuki T, et al. **Biol Pharm Bull** 1998 Sep; 21(9):905–10

Metal chelator NNNNN-tetrakis-(2-pyridymethyl)ethylene diamine inhibits the induction of heat shock protein 70 synthesis by heat in cultured keratinocytes. Parat MO, et al. **Biol Trace Elem Res** 1998 Dec;65(3):261–70

Overexpression of a cytosolic chaperone to improve solubility and secretion of a recombinant IgG protein in insect cells. Ailor E, et al. **Biotechnol Bioeng** 1998 Apr 20–May 5;58(2–3):196–203

Behavioral changes and expression of heat shock protein hsp-70 mRNA, brain-derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid. Hashimoto K, et al. **Brain Res** 1998 Sep 7;804(2):212–23

Is radiosensitive cell line cross-sensitive to heat?: Effect of heat on two rat yolk sac tumor cell lines with different radiosensitivity. Mitsuhashi N, et al. **Cancer Lett** 1999 Aug 3;142(2):195–200

Flow cytometry is a rapid and reliable method for evaluating heat shock protein 70 expression in human monocytes [published erratum appears in Cell Stress Chaperones 1998 Dec;3(4):273] Bachelet M, et al. **Cell Stress Chaperones** 1998 Sep;3(3):168–76

HSP70 expression in granulocytes and lymphocytes of patients with polytrauma: comparison with plasma glutamine. Weingartmann G, et al. **Clin Nutr** 1999 Apr; 18(2):121–4

Effect of different environmental variables on the synthesis of Hsp70 in Raphidocelis subcapitata. Bierkens J, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 May; 120(1):29–34

Impaired inducibility of heat shock protein 70 in peripheral blood lymphocytes of patients with severe sepsis. Schroeder S, et al. **Crit Care Med** 1999 Jun;27(6):1080–4

Studies on heat shock proteins in sea urchin development. Giudice G, et al. **Dev Growth Differ** 1999 Aug;41(4):375–80 (27 ref.)

Superoxide: a major factor for stress protein induction in reoxygenation injury in the intestinal cell line Caco-2. Gebhardt BR, et al. **Digestion** 1999;60(3):238–45

An ex vivo biochemical model to study the antioxidant clinical properties of cosmetic products in human antiaging skin care. Calabrese V, et al. **Drugs Exp Clin Res** 1999; 25(1):43–9

Synergistic effects of heat and ET-18-OCH3 on membrane expression of hsp70 and lysis of leukemic K562 cells. Botzler C, et al. **Exp Hematol** 1999 Mar;27(3):470–8

Overexpression of hsp70i facilitates reactivation of intracellular proteins in neurones and protects them from denaturing stress. Beaucamp N, et al. **FEBS Lett** 1998 Dec 18;441(2):215–9

Human skeletal muscle HSP70 response to training in highly

trained rowers. Liu Y, et al. **J Appl Physiol** 1999 Jan; 86(1):101–4

Suppression of an Hsp70 mutant phenotype in Saccharomyces cerevisiae through loss of function of the chromatin component Sin1p/Spt2p. Baxter BK, et al. **J Bacteriol** 1998 Dec;180(24):6484–92

Heat-induced expression of MHC-linked HSP70 genes in lymphocytes varies at the single-cell level. Dressel R, et al. **J Cell Biochem** 1999 Mar 15;72(4):558–69

Effects of heat shock and hypoxia on protein synthesis in rainbow trout (Oncorhynchus mykiss) cells. Airaksinen S, et al. **J Exp Biol** 1998 Sep;201 (Pt 17):2543–51

Hsp70 and a 54 kDa protein (Osp54) are induced in salmon (Salmo salar) in response to hyperosmotic stress. Smith TR, et al. **J Exp Zool** 1999 Aug 1;284(3):286–98

HSP70 and ER expression in cervical intraepithelial neoplasia and cervical cancer. Kim KK, et al. **J Korean Med Sci** 1998 Aug;13(4):383–8

Expression of the spermatid-specific Hsp70 antigen is conserved in mammals including marsupials. Tsunekawa N, et al. **J Vet Med Sci** 1999 Apr;61(4):381–8

BiP (GRP78) and endoplasmin (GRP94) are induced following rotavirus infection and bind transiently to an endoplasmic reticulum-localized virion component. Xu A, et al. **J Virol** 1998 Dec;72(12):9865–72

Expression of heat shock protein 70 decreases with age in hepatocytes and splenocytes from female rats. Gutsmann-Conrad A, et al. **Mech Ageing Dev** 1999 Mar 15;107(3):255–70

HSP70 induction may explain the long-lasting resistance to heat of Drosophila melanogaster having lived in hypergravity. Minois N, et al. **Mech Ageing Dev** 1999 Jun 1;109(1):65–77

Effect of age and dietary restriction on expression of heat shock protein 70 in rat alveolar macrophages. Moore SA, et al. **Mech Ageing Dev** 1998 Aug 1;104(1):59–73

Induced expression and localization to nuclear-inclusion bodies of hsp70 in varicella-zoster virus-infected human diploid fibroblasts. Ohgitani E, et al. **Microbiol Immunol** 1998;42(11):755–60

Human semen induces interleukin 10 and 70 kDa heat shock protein gene transcription and inhibits interferon-gamma messenger RNA production in peripheral blood mononuclear cells. Jeremias J, et al. **Mol Hum Reprod** 1998 Nov;4(11):1084–8

Inhibition of hsp70-1 and hsp70-3 expression disrupts preimplantation embryogenesis and heightens embryo sensitivity to arsenic. Dix DJ, et al. **Mol Reprod Dev** 1998 Dec;51(4):373–80

Constitutive and heat-inducible expression of HSP105 in neurons and glial cells in culture. Satoh J, et al. **Neuroreport** 1998 Sep 14;9(13):2977–83

Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Kaul SC, et al. **Oncogene** 1998 Aug 20; 17(7):907–11

Hyperthermia, inducing pancreatic heat-shock proteins, fails to prevent cerulein-induced stress kinase activation. Metzler W, et al. **Pancreas** 1999 Aug;19(2):150–7

Overexpression of BiP in tobacco alleviates endoplasmic reticulum stress. Leborgne-Castel N, et al. **Plant Cell** 1999 Mar;11(3):459–70

Analysis of hsp70 mRNA levels in HepG2 cells exposed to various metals differing in toxicity. Steiner E, et al. **Toxicol Lett** 1998 Aug;96–97:169–76

[Distribution of 70kDa heat shock protein in rabbit brains after heat stress and heat stroke] Tan M, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Feb;26(1):38–40 (Eng. Abstr.) **(Chi)**

[The expression of hsp70 and BCL-2 genes in hippocampus of the rats exposed to cerebral ischemia and reperfusion] Lu D, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):224–7 (Eng. Abstr.) **(Chi)**

[The expression of HSP-70 gene in exocrine pancreas of the rats suffering from acute necrotizing pancreatitis] Zhang L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):46–9 (Eng. Abstr.) **(Chi)**

[The protective role of heat shock gene expression on hydrogen peroxide induced pulmonary alveolar macrophages] Wang Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):1–4 (Eng. Abstr.) **(Chi)**

BLOOD

Impaired inducibility of heat shock protein 70 in peripheral blood lymphocytes of patients with severe sepsis. Schroeder S, et al. **Crit Care Med** 1999 Jun;27(6):1080–4

Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. Pockley AG, et al. **Immunol Invest** 1998 Dec;27(6):367–77

Circulating heat shock proteins in women with a history of recurrent vulvovaginitis. Giraldo PC, et al. **Infect Dis Obstet Gynecol** 1999;7(3):128–32

Expression of heat shock protein 70 in leukocytes of patients with sepsis. Martins GA, et al. **Int J Mol Med** 1999 Apr; 3(4):401–4

CHEMISTRY

Structure of a new crystal form of human Hsp70 ATPase domain. Osipiuk J, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):1105–7

Conformational changes of an Hsp70 molecular chaperone induced by nucleotides, polypeptides, and N-ethylmaleimide. Chirico WJ, et al. **Biochemistry** 1998 Sep 29;37(39):13862–70

Mapping the role of active site residues for transducing an ATP-induced conformational change in the bovine 70-kDa heat shock cognate protein. Johnson ER, et al. **Biochemistry** 1999 Aug 17;38(33):10823–30

Peptide-induced conformational changes in the molecular chaperone DnaK. Slepenkov SV, et al. **Biochemistry** 1998 Nov 24;37(47):16749–56

Site-directed mutagenesis of a human brain ecto-apyrase: evidence that the E-type ATPases are related to the actin/heat shock 70/sugar kinase superfamily. Smith TM, et al. **Biochemistry** 1999 Jan 5;38(1):321–8

The hydroxyl of threonine 13 of the bovine 70-kDa heat shock cognate protein is essential for transducing the ATP-induced conformational change. Sousa MC, et al. **Biochemistry** 1998 Nov 3;37(44):15392–9

Characterisation of several Hsp70 interacting proteins from mammalian organelles. Naylor DJ, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):443–50

Molecular cloning of the dnaK locus, and purification and characterization of a DnaK protein from Bacillus brevis HPD31. Tokunaga H, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1–2):65–79

Discontinuous occurrence of the hsp70 (dnaK) gene among Archaea and sequence features of HSP70 suggest a novel outlook on phylogenies inferred from this protein. Gribaldo S, et al. **J Bacteriol** 1999 Jan;181(2):434–43

The chaperoning activity of hsp110. Identification of functional domains by use of targeted deletions. Oh HJ, et al. **J Biol Chem** 1999 May 28;274(22):15712–8

Mutations in the substrate binding domain of the Escherichia coli 70 kDa molecular chaperone, DnaK, which alter substrate affinity or interdomain coupling. Montgomery DL, et al. **J Mol Biol** 1999 Feb 26;286(3):915–32

High-resolution solution structure of the 18 kDa substrate-binding domain of the mammalian chaperone protein Hsc70. Morshauser RC, et al. **J Mol Biol** 1999 Jun 25;289(5):1387–403

Interference between proteins Hap46 and Hop/p60, which bind to different domains of the molecular chaperone hsp70/hsc70. Gebauer M, et al. **Mol Cell Biol** 1998 Nov; 18(11):6238–44

Mutations in the DnaK chaperone affecting interaction with the DnaJ cochaperone. Gässler CS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15229–34

The biochemical properties of the ATPase activity of a 70-kDa heat shock protein (Hsp70) are governed by the C-terminal domains. Lopez-Buesa P, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15253–8

Interaction of the Hsp70 molecular chaperone, DnaK, with its cochaperone DnaJ. Suh WC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15223–8

CLASSIFICATION

Horizontal transfers confuse the prokaryotic phylogeny based on the HSP70 protein family [letter; comment] Philippe H, et al. **Mol Microbiol** 1999 Feb;31(3):1007–10. Comment on: Mol Microbiol 1998 Aug;29(3):695–707.

DIAGNOSTIC USE

Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Nanbu K, et al. **Cancer Detect Prev** 1998;22(6):549–55

DRUG EFFECTS

N-Ethylmaleimide-modified Hsp70 inhibits protein folding. Hermawan A, et al. **Arch Biochem Biophys** 1999 Sep 1; 369(1):157–62

Conformational changes of an Hsp70 molecular chaperone induced by nucleotides, polypeptides, and N-ethylmaleimide. Chirico WJ, et al. **Biochemistry** 1998 Sep 29;37(39):13862–70

GENETICS

Analysis of hsp70 gene polymorphism in allergic asthma. Aron Y, et al. **Allergy** 1999 Feb;54(2):165–70

Heat shock protein 70 and heat shock cognate protein 70 messenger ribonucleic acid induction in the brains, hearts, and livers of neonatal rats after hypoxic stress. Ikeda T, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):457–61

Gene transfer of heat shock protein 70 protects lung grafts from ischemia-reperfusion injury. Hiratsuka M, et al. **Ann Thorac Surg** 1999 May;67(5):1421–7

Analysis of the role of the gene bipA, encoding the major endoplasmic reticulum chaperone protein in the secretion of homologous and heterologous proteins in black Aspergilli. Punt PJ, et al. **Appl Microbiol Biotechnol** 1998 Oct;50(4):447–54

adapt78, a stress-inducible mRNA, is related to the glucose-regulated protein family of genes. Leahy KP, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):67–74

An additional exon of stress-inducible heat shock protein 70 gene (HSP70-1). Shimizu S, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):193–8

Molecular characterization of the first heat shock protein 70 from a reef coral. Tom M, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):103–8

Genomic cloning and promoter analysis of the mouse 105-kDa heat shock protein (HSP105) gene. Yasuda K, et al. **Biochem Biophys Res Commun** 1999 Mar 5; 256(1):75–80

Mutations in the cytosolic DnaJ homologue, YDJ1, delay and compromise the efficient translation of heterologous proteins in yeast. Brodsky JL, et al. **Biochemistry** 1998 Dec 22;37(51):18045–55

Molecular cloning, expression and localization of human 105 kDa heat shock protein, hsp105. Ishihara K, et al. **Biochim Biophys Acta** 1999 Jan 18;1444(1):138–42

Completion of meiosis is not always required for acrosome formation in HSP70-2 null mice. Mori C, et al. **Biol Reprod** 1999 Sep;61(3):813–22

Transient MRI-detected water apparent diffusion coefficient reduction correlates with c-fos mRNA but not hsp70 mRNA induction during focal cerebral ischemia in rats. Mancuso A, et al. **Brain Res** 1999 Aug 21;839(1):7–22

Pixel-based image analysis of HSP70, GADD45 and MAP2 mRNA expression after focal cerebral ischemia: hemodynamic and histological correlates. Schmidt-Kastner R, et al. **Brain Res Mol Brain Res** 1998 Dec 10;63(1):79–97

De-regulation of GRP stress protein expression in human breast cancer cell lines. Gazit G, et al. **Breast Cancer Res Treat** 1999 Mar;54(2):135–46

Expression of the testis-specific HSP70-related gene (hst70 gene) in somatic non-testicular rat tissues revealed by RT-PCR and transgenic mice analysis. Scieglinska D, et al. **Cell Biol Int** 1997 Dec;21(12):813–21

Short-range linkage relationships, genomic organisation and sequence comparisons of a cluster of five HSP70 genes in Fugu rubripes. Lim EH, et al. **Cell Mol Life Sci** 1999 Apr;55(4):668–78

The hsp70 locus of Drosophila auraria (montium subgroup) is single and contains copies in a conserved arrangement. Konstantopoulou I, et al. **Chromosoma** 1998 Dec; 107(8):577–86

Preferential nuclear location of a transgene does not depend on its transcriptional activity during early mouse development. Thompson EM, et al. **Chromosoma** 1998 Nov; 107(5):321–9

Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis. Schroeder S, et al. **Crit Care Med** 1999 Jul; 27(7):1265–70

Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Housby JN, et al. **Cytokine** 1999 May;11(5):347–58

Gene expression and chromatin organization during mouse oocyte growth. Christians E, et al. **Dev Biol** 1999 Mar 1; 207(1):76–85

Constitutive and stress-inducible expression of the endoplasmic reticulum heat shock protein 70 gene family member, immunoglobulin-binding protein (BiP), during Xenopus laevis early development. Miskovic D, et al. **Dev Genet** 1999;25(1):31–9

Developmentally regulated nuclear transport of transcription factors in Drosophila embryos enable the heat shock response. Wang Z, et al. **Development** 1998 Dec; 125(23):4841–50

Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. Jäättelä M, et al. **EMBO J** 1998 Nov 2;17(21):6124–34

Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. Li Q, et al. **EMBO J** 1998 Nov 2;17(21):6300–15

Effects of quercetin and sunphenon on responses of cancer cells to heat shock damage. Kudo M, et al. **Exp Mol Pathol** 1999 Apr;66(1):66–75

Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells. Schliess F, et al. **FASEB J** 1999 Sep; 13(12):1557–64

Requirement of the carboxy-terminal domain of RNA polymerase II for the transcriptional activation of chromosomal c-fos and hsp70A genes. Meininghaus M, et al. **FEBS Lett** 1999 Mar 5;446(1):173–6

Marked differences between avian and mammalian testicular cells in the heat shock induction and polyadenylation of Hsp70 and ubiquitin transcripts. Mezquita B, et al. **FEBS Lett** 1998 Oct 9;436(3):382–6

The product of the mammalian orthologue of the Saccharomyces cerevisiae HBS1 gene is phylogenetically related to eukaryotic release factor 3 (eRF3) but does not carry eRF3-like activity. Wallrapp C, et al. **FEBS Lett** 1998 Dec 4;440(3):387–92

A novel dnaK operon from Porphyromonas gingivalis. Yoshida A, et al. **FEBS Lett** 1999 Mar 12;446(2–3):287–91

Differential stress gene expression during the development of Neurospora crassa and other fungi. Rensing L, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):159–66 (47 ref.)

Regulation of hsp90 and hsp70 genes during antheridiol-induced hyphal branching in the oomycete Achlya ambisexualis. Brunt SA, et al. **Fungal Genet Biol** 1998 Aug;24(3):310–24

Temperature adaptation of house keeping and heat shock gene expression in Neurospora crassa. Mohsenzadeh S, et al. **Fungal Genet Biol** 1998 Oct;25(1):31–43

The dnaK/dnaJ operon of Haemophilus ducreyi contains a unique combination of regulatory elements. Parsons LM, et al. **Gene** 1999 Jun 11;233(1–2):109–19

Transcriptional regulation of the heat shock protein genes by STAT family transcription factors. Stephanou A, et al. **Gene Expr** 1999;7(4–6):311–9 (45 ref.)

Genetic mapping of mouse heat shock protein genes Hsc4a to chromosome 11 and Hsc74 to chromosome 18 and two Hsc74 pseudogenes to chromosomes X and 8. Hunt CR, et al. **Genomics** 1999 Mar 15;56(3):358–60

Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Melcher A, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1431–42

Identification of a 71-kilodalton surface-associated Hsp70 homologue in Coxiella burnetii. Macellaro A, et al. **Infect Immun** 1998 Dec;66(12):5882–8

Cloning and expression of the dnaK gene of Campylobacter jejuni and antigenicity of heat shock protein 70. Thies FL, et al. **Infect Immun** 1999 Mar;67(3):1194–200

Comparative analysis of promoters for transient gene expression in cultured mosquito cells. Zhao YG, et al. **Insect Mol Biol** 1999 Feb;8(1):31–8

Molecular characterisation of a hsp70 gene from the filarial parasite Setaria digitata. Jayasena SM, et al. **Int J Parasitol** 1999 Apr;29(4):581–91

Gene sequence and transcription differences in 70 kDa heat shock protein correlate with murine virulence of Toxoplasma gondii. Lyons RE, et al. **Int J Parasitol** 1998 Jul;28(7):1041–51

Identification of novel 70-kDa heat shock protein-encoding cDNAs from Schistosoma japonicum. Scott JC, et al. **Int J Parasitol** 1999 Mar;29(3):437–44

Discontinuous occurrence of the hsp70 (dnaK) gene among Archaea and sequence features of HSP70 suggest a novel outlook on phylogenies inferred from this protein. Gribaldo S, et al. **J Bacteriol** 1999 Jan;181(2):434–43

SSB, encoding a ribosome-associated chaperone, is coordinately regulated with ribosomal protein genes. Lopez N, et al. **J Bacteriol** 1999 May;181(10):3136–43

The unique chaperone operon of Thermotoga maritima: cloning and initial characterization of a functional Hsp70 and small heat shock protein. Michelini ET, et al. **J Bacteriol** 1999 Jul;181(14):4237–44

Construction and analysis of hybrid Escherichia coli–Bacillus subtilis dnaK genes. Mogk A, et al. **J Bacteriol** 1999 Mar; 181(6):1971–4

A chaperone in the HSP70 family controls production of extracellular fibrils in Myxococcus xanthus. Weimer RM, et al. **J Bacteriol** 1998 Oct;180(20):5357–68

Genomic structure of the spermatid-specific hsp70 homolog gene located in the class III region of the major histocompatibility complex of mouse and man. Ito Y, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):347–53

Differential activation of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinases confers cadmium-induced HSP70 expression in 9L rat brain tumor cells. Hung JJ, et al. **J Biol Chem** 1998 Nov 27; 273(48):31924–31

Metabolic oxidative stress-induced HSP70 gene expression is mediated through SAPK pathway. Role of Bcl-2 and c-Jun NH2-terminal kinase. Lee YJ, et al. **J Biol Chem** 1998 Nov 6;273(45):29857–63

Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. Stephanou A, et al. **J Biol Chem** 1999 Jan 15;274(3):1723–8

Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y. Taira T, et al. **J Biol Chem** 1999 Aug 20;274(34):24270–9

Thermotolerant cells show an attenuated expression of Hsp70 after heat shock. Theodorakis NG, et al. **J Biol Chem** 1999 Apr 23;274(17):12081–6

Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors [published erratum appears in J Biol Chem 1999 Jan 22;274(4):2592] Yoshida H, et al. **J Biol Chem** 1998 Dec 11;273(50):33741–9

A magnetic field-responsive domain in the human HSP70 promoter. Lin H, et al. **J Cell Biochem** 1999 Oct 1; 75(1):170–6

Intron-independent association of splicing factors with active genes. Jolly C, et al. **J Cell Biol** 1999 Jun 14;145(6):1133–43

Differential metal response and regulation of human heavy metal-inducible genes. Murata M, et al. **J Cell Physiol** 1999 Jul;180(1):105–13

Effects of GH, prolactin and cortisol on hepatic heat shock protein 70 expression in a marine teleost Sparus sarba. Deane EE, et al. **J Endocrinol** 1999 Jun;161(3):413–21

Critical analysis of eukaryotic phylogeny: a case study based on the HSP70 family. Germot A, et al. **J Eukaryot Microbiol** 1999 Mar-Apr;46(2):116–24

The HSP70 gene family in Pneumocystis carinii: molecular and phylogenetic characterization of cytoplasmic members. Stedman TT, et al. **J Eukaryot Microbiol** 1998 Nov-Dec; 45(6):589–99

Pressure-induced expression of heat shock protein 70 mRNA in adult rat heart is coupled both to protein kinase A-dependent and protein kinase C-dependent systems. Osaki J, et al. **J Hypertens** 1998 Aug;16(8):1193–200

A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. Gaudin C, et al. **J Immunol** 1999 Feb 1; 162(3):1730–8

Heat shock protein 70 family: multiple sequence comparisons, function, and evolution. Karlin S, et al. **J Mol Evol** 1998 Nov;47(5):565–77

Molecular cloning of a novel member of the HSP110 family of genes, ischemia-responsive protein 94 kDa (irp94), expressed in rat brain after transient forebrain ischemia. Yagita Y, et al. **J Neurochem** 1999 Apr;72(4):1544–51

Control of delivered gene expression in chondrocytes using heat shock protein 70B promoter. Arai Y, et al. **J Rheumatol** 1999 Aug;26(8):1769–74

Expression of foreign gene in mycobacterium regulated by human Mycobacterium tuberculosis heat shock protein 70 promoter. Cheng J, et al. **J Tongji Med Univ** 1997; 17(4):193–9

Activation of the grp78 and grp94 promoters by hepatitis C virus E2 envelope protein. Liberman E, et al. **J Virol** 1999 May;73(5):3718–22

Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. Valk PJ, et al. **J Virol** 1999 May;73(5):3595–602

Heat shock protein 70 overexpression protects LLC-PK1 tubular cells from heat shock but not hypoxia. Turman MA, et al. **Kidney Int** 1999 Jan;55(1):189–97

Differential effects of facial nerve transection on heat shock protein 70 expression in the developing and adult hamster facial nucleus. Newfry GA, et al. **Metab Brain Dis** 1998 Sep;13(3):253–7

Intracellular gene expression. Analysis of RNA from mycobacteria in macrophages using RT-PCR. Butcher PD, et al. **Methods Mol Biol** 1998;101:285–306

The hsp operons are repressed by the hrc37 of the hsp70 operon in Staphylococcus aureus. Kuroda M, et al. **Microbiol Immunol** 1999;43(1):19–27

Physiological consequences of mutations in Escherichia coli heat shock dnaK and dnaJ genes. Wolska KI, et al. **Microbios** 1999;97(386):55–67

Tissue-specific expression of dominant negative mutant Drosophila HSC70 causes developmental defects and lethality. Elefant F, et al. **Mol Biol Cell** 1999 Jul; 10(7):2101–17

DnaK-dependent ribosome biogenesis in Escherichia coli: competition for dominance between the alleles dnaK756 and dnaK+. Sbai M, et al. **Mol Gen Genet** 1998 Nov; 260(2–3):199–206

Differential expression of an hsp70 gene during transition from the mycelial to the infective yeast form of the human pathogenic fungus Paracoccidioides brasiliensis. da Silva SP, et al. **Mol Microbiol** 1999 Feb;31(4):1039–50

Evolutionary relationships among photosynthetic prokaryotes (Heliobacterium chlorum, Chloroflexus aurantiacus, cyanobacteria, Chlorobium tepidum and proteobacteria): implications regarding the origin of photosynthesis. Gupta RS, et al. **Mol Microbiol** 1999 Jun; 32(5):893–906

Post-transcriptional regulation of the Bacillus subtilis dnaK operon. Homuth G, et al. **Mol Microbiol** 1999 Jun; 32(6):1183–97

Horizontal transfers confuse the prokaryotic phylogeny based on the HSP70 protein family [letter; comment] Philippe H, et al. **Mol Microbiol** 1999 Feb;31(3):1007–10. Comment on: Mol Microbiol 1998 Aug;29(3):695–707.

Levels of DnaK and DnaJ provide tight control of heat shock gene expression and protein repair in Escherichia coli. Tomoyasu T, et al. **Mol Microbiol** 1998 Nov;30(3):567–81

dnaK and the heat stress response of Pseudomonas syringae pv. glycinea. Keith LM, et al. **Mol Plant Microbe Interact** 1999 Jul;12(7):563–74

The Hsp70 homolog gene, Hsc70t, is expressed under translational control during mouse spermiogenesis. Tsunekawa N, et al. **Mol Reprod Dev** 1999 Apr; 52(4):383–91

Expression of a non-inactivating K+ channel driven by a rat heat shock promoter increased the resting potential in Aplysia silent neurons. Han JH, et al. **Neurosci Res** 1999 May;34(1):13–9

Specific binding of Drosophila nuclear protein PEP (protein on ecdysone puffs) to hsp70 DNA and RNA. Hamann S, et al. **Nucleic Acids Res** 1998 Sep 15;26(18):4108–15

Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Kaul SC, et al. **Oncogene** 1998 Aug 20; 17(7):907–11

Cloning and analysis of a Trichinella britovi gene encoding a cytoplasmic heat shock protein of 72 kDa. Vayssier M, et al. **Parasitology** 1999 Jul;119 (Pt 1):81–93

TGF-beta1 mediates 70-kDa heat shock protein induction due to ultraviolet irradiation in human skin fibroblasts. Cao Y, et al. **Pflugers Arch** 1999 Aug;438(3):239–44

The Arabidopsis ssi1 mutation restores pathogenesis-related gene expression in npr1 plants and renders defensin gene expression salicylic acid dependent. Shah J, et al. **Plant Cell** 1999 Feb;11(2):191–206

Expression of DnaJ homologs and Hsp70 in the Japanese willow (Salix gilgiana Seemen). Futamura N, et al. **Plant Cell Physiol** 1999 May;40(5):524–31

Coordinate and non-coordinate expression of the stress 70 family and other molecular chaperones at high and low temperature in spinach and tomato. Li QB, et al. **Plant Mol Biol** 1999 Jan;39(1):21–34

Intragenic suppressors of Hsp70 mutants: interplay between the ATPase- and peptide-binding domains. Davis JE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9269–76

Polymorphism of heat-shock protein gene HSP70-2 in Crohn disease: possible genetic marker for two forms of Crohn disease. Esaki M, et al. **Scand J Gastroenterol** 1999 Jul; 34(7):703–7

Expression of heat shock proteins 60 and 70 is a marker of preservation-induced endothelial cell activation. Eberl T, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1034–6

Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Shimizu K, et al. **Virology** 1999 Feb 15;254(2):213–9

[Family of hsp70 stress genes in mammals] Lisowska K, et al. **Postepy Biochem** 1998;44(3):179–92 (197 ref.) **(Pol)**

IMMUNOLOGY

Cellular and antibody responses to the Plasmodium falciparum heat shock protein Pf72/HSP70 during and after acute malaria in individuals from an endemic area of Brazil. de Oliveira-Ferreira J, et al. **Acta Trop** 1999 May 25; 73(1):1–10

Initial development of a small subclass of rat olfactory receptor neurons characterized by antigenicity to HSP 70. Carr VM, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:240–3

Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Hayem G, et al. **Ann Rheum Dis** 1999 May;58(5):291–6

Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Kakeya H, et al. **Clin Exp Immunol** 1999 Mar;115(3):485–90

Assessing the role of anti-hsp70 in cochlear impairment [letter; comment] Billings PB, et al. **Hear Res** 1998 Dec; 126(1–2):210–3. Comment on: Hear Res 1998 Feb;116(1–2):65–70.

Detection of heat shock protein 70 (Hsp70) and anti-Hsp70 antibodies in the serum of normal individuals. Pockley AG, et al. **Immunol Invest** 1998 Dec;27(6):367–77

Analysis of the antigenic properties of the L. infantum Hsp70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis. Quijada L, et al. **Immunol Lett** 1998 Oct;63(3):169–74

Cloning and expression of the dnaK gene of Campylobacter jejuni and antigenicity of heat shock protein 70. Thies FL, et al. **Infect Immun** 1999 Mar;67(3):1194–200

Immunogenicity of recombinant Babesia microti hsp70 homologue in mice. Erol E, et al. **Int J Parasitol** 1999 Feb; 29(2):263–6

Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. Ohguro H, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):82–9

Characteristics of the strong antibody response to mycobacterial Hsp70: a primary, T cell-dependent IgG response with no evidence of natural priming or gamma delta T cell involvement. Bonorino C, et al. **J Immunol** 1998 Nov 15;161(10):5210–6

A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. Gaudin C, et al. **J Immunol** 1999 Feb 1; 162(3):1730–8

Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. Todryk S, et al. **J Immunol** 1999 Aug 1;163(3):1398–408

Recognition of a dominant epitope in bovine heat-shock protein 70 in inner ear disease. Bloch DB, et al. **Laryngoscope** 1999 Apr;109(4):621–5

Macrophages and heat shock proteins. Bachelet M, et al. **Res Immunol** 1998 Sep-Oct;149(7–8):727–32 (40 ref.)

ISOLATION & PURIFICATION

Purification and functional analysis of the DnaK homologue from Prevotella intermedia OMZ 326. Kadri R, et al. **FEMS Microbiol Lett** 1998 Oct 1;167(1):63–8

Expression of 70-kDa heat shock protein in oral lesions: marker of biological stress or pathogenicity. Kaur J, et al. **Oral Oncol** 1998 Nov;34(6):496–501

METABOLISM

Immunoelectron microscopic study of c-Fos, c-Jun and heat shock protein after transient cerebral ischemia in gerbils. Tomimoto H, et al. **Acta Neuropathol (Berl)** 1999 Jan; 97(1):22–30

Vaginal heat shock protein expression in symptom-free women with a history of recurrent vulvovaginitis. Giraldo P, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):524–9

Characterization of the Hsp110/SSE gene family response to hyperosmolality and other stresses. Santos BC, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):F1054–61

Vitamin D receptor interacts with DnaK/heat shock protein 70: identification of DnaK interaction site on vitamin D receptor. Swamy N, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):219–26

Induction of DNA strand breaks and expression of HSP70 and GRP78 homolog by cadmium in the marine sponge Suberites domuncula. Schröder HC, et al. **Arch Environ Contam Toxicol** 1999 Jan;36(1):47–55

Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Nadler SG, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):176–80

Effects of exposure to repetitive pulsed magnetic stimulation on cell proliferation and expression of heat shock protein 70 in normal and malignant cells. Tsurita G, et al.

Biochem Biophys Res Commun 1999 Aug 11;261(3):689–94
Nucleotide binding and hydrolysis properties of Neurospora crassa cytosolic molecular chaperones, Hsp70 and Hsp80, heat-inducible members of the eukaryotic stress-70 and stress-90 families. Ouimet PM, et al. **Biochem Cell Biol** 1999;77(2):89–99
Interaction of mammalian neprilysin with binding protein and calnexin in Schizosaccharomyces pombe. Beaulieu H, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):813–9
Heat stress affects the glucocorticoid receptor interaction with heat shock protein Hsp70 in the rat liver. Cvoro A, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):63–70
BipA affects Ca++ fluxes and phosphorylation of the translocated intimin receptor (Tir/Hp90) in host epithelial cells infected with enteropathogenic E. coli. Farris M, et al. **Biochem Soc Trans** 1998 Aug;26(3):S225
Sequence-specific rates of interaction of target peptides with the molecular chaperones DnaK and DnaJ. Pierpaoli EV, et al. **Biochemistry** 1998 Nov 24;37(47):16741–8
DnaJ dramatically stimulates ATP hydrolysis by DnaK: insight into targeting of Hsp70 proteins to polypeptide substrates. Russell R, et al. **Biochemistry** 1999 Mar 30; 38(13):4165–76
Identification of novel peptide binding proteins in the endoplasmic reticulum: ERp72, calnexin, and grp170. Spee P, et al. **Biochemistry** 1999 Aug 10;38(32):10559–66
Gp96/GRP94 is a putative high density lipoprotein-binding protein in liver. de Crom R, et al.
Biochim Biophys Acta 1999 Mar 25;1437(3):378–92
Phosphorylation of Mycobacterium leprae heat-shock 70 protein at threonine 175 alters its substrate binding characteristics. Peake P, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1–2):387–94
Interferon-gamma is a target for binding and folding by both Escherichia coli chaperone model systems GroEL/GroES and DnaK/DnaJ/GrpE. Vandenbroeck K, et al.
Biochimie 1998 Aug-Sep;80(8–9):729–37 (49 ref.)
ATP-sensitive association of mortalin with the IL-1 receptor type I. Sacht G, et al. **Biofactors** 1999;9(1):49–60
Transient increase in chloride cell number and heat shock protein expression (hsp70) in brown trout (Salmo trutta fario) exposed to sudden temperature elevation [see comments] Schmidt H, et al. **Biol Chem** 1998 Oct; 379(10):1227–33. Comment in: Biol Chem 1998 Oct;379(10):1213–5.
Hepatic concentration of heat shock protein 70 kD (Hsp70) in broilers subjected to different thermal treatments. Givisiez PE, et al. **Br Poult Sci** 1999 May;40(2):292–6
Possible involvement of p38 MAP kinase in HSP70 expression induced by hypoxia in rat primary astrocytes. Uehara T, et al. **Brain Res** 1999 Mar 27;823(1–2):226–30
BiP acts as a molecular ratchet during posttranslational transport of prepro-alpha factor across the ER membrane. Matlack KE, et al. **Cell** 1999 May 28;97(5):553–64
Protein translocation: how Hsp70 pulls it off. Pilon M, et al. **Cell** 1999 Jun 11;97(6):679–82 (19 ref.)
Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains. Teter SA, et al. **Cell** 1999 Jun 11;97(6):755–65
The protein import motor of mitochondria: unfolding and trapping of preproteins are distinct and separable functions of matrix Hsp70. Voisine C, et al. **Cell** 1999 May 28; 97(5):565–74
Phosphorylation of an envelope-associated Hsp70 homolog in amyloplasts isolated from cultured cells of sycamore (Acer pseudoplatanus L.). Checa SK, et al.
Cell Mol Biol (Noisy-le-grand) 1998 Sep;44(6):891–7
The role of hsp70 in protection and repair of luciferase activity in vivo; experimental data and mathematical modelling. Souren JE, et al. **Cell Mol Life Sci** 1999 May; 55(5):799–811
Localization of pNT22 70 kDa heat shock cognate-like protein in the plasma membrane. Hirai I, et al.
Cell Struct Funct 1998 Jun;23(3):153–8
Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Ralhan R, et al. **Clin Cancer Res** 1995 Oct;1(10):1217–22
Heat shock protein (hsp70) in brown trout epidermis after sudden temperature rise. Burkhardt-Holm P, et al.
Comp Biochem Physiol A Mol Integr Physiol 1998 May; 120(1):35–41
Effect of ischemia--reperfusion on heat shock protein 70 and 90 gene expression in rat liver: relation to nutritional status. Gasbarrini A, et al. **Dig Dis Sci** 1998 Dec;43(12):2601–5
BAG-1, a negative regulator of Hsp70 chaperone activity, uncouples nucleotide hydrolysis from substrate release. Bimston D, et al. **EMBO J** 1998 Dec 1;17(23):6871–8
Intranuclear targeted delivery of functional NF-kappaB by 70 kDa heat shock protein. Fujihara SM, et al.
EMBO J 1999 Jan 15;18(2):411–9
Aggregation of hsp70 and hsc70 in vivo is distinct and temperature-dependent and their chaperone function is directly related to non-aggregated forms. Angelidis CE, et al. **Eur J Biochem** 1999 Jan;259(1–2):505–12
Induction of the heat-shock response by antiviral prostaglandins in human cells infected with human immunodeficiency virus type 1. de Marco A, et al.
Eur J Biochem 1998 Sep 1;256(2):334–41
Oligomerization of the 17-kDa peptide-binding domain of the molecular chaperone HSC70. Fouchaq B, et al.
Eur J Biochem 1999 Jan;259(1–2):379–84
Binding of heptapeptides or unfolded proteins to the chimeric C-terminal domains of 70-kDa heat shock cognate protein. Wu SJ, et al. **Eur J Biochem** 1999 Jan;259(1–2):449–55
Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47-D cells: role of [Ca2+]i and protein kinases. Kiang JG, et al.
FASEB J 1998 Nov;12(14):1571–9
Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. Schett G, et al. **FASEB J** 1999 May;13(8):833–42
Influence of polyamines on DNA binding of heat shock and activator protein 1 transcription factors induced by heat shock. Desiderio MA, et al. **FEBS Lett** 1999 Jul 16; 455(1–2):149–53
Functional characterisation of the chaperones DnaK, DnaJ, and GrpE from Clostridium acetobutylicum. Rüngeling E, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):119–23
Interaction of DnaK with native proteins and membrane proteins correlates with their accessible hydrophobicity. de Crouy-Chanel A, et al. **Gene** 1999 Apr 16;230(2):163–70
The archaeal molecular chaperone machine: peculiarities and paradoxes. Macario AJ, et al. **Genetics** 1999 Aug; 152(4):1277–83 (56 ref.)
Differential localization of heat shock proteins 90, 70, 60 and 27 in human decidua and placenta during pregnancy. Shah M, et al. **Histochem J** 1998 Jul;30(7):509–18
Expression of heat shock protein 70 blocks thymic differentiation of T cells in transgenic mice. Lee WH, et al. **Immunology** 1998 Dec;95(4):559–65
Detection of the human 70-kD and 60-kD heat shock proteins in the vagina: relation to microbial flora, vaginal pH, and method of contraception. Giraldo P, et al.
Infect Dis Obstet Gynecol 1999;7(1–2):23–5
Induction of heat shock protein expression in cervical epithelial cells by human semen. Jeremias JC, et al.
Infect Dis Obstet Gynecol 1999;7(1–2):17–22
Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Komesli S, et al. **Int J Immunopharmacol** 1999 May;21(5):349–58
Endotoxin inhibits heat shock protein 70 (HSP70) expression in peripheral blood mononuclear cells of patients with severe sepsis. Schroeder S, et al. **Intensive Care Med** 1999 Jan;25(1):52–7
The Hsc66-Hsc20 chaperone system in Escherichia coli: chaperone activity and interactions with the DnaK-DnaJ-grpE system. Silberg JJ, et al. **J Bacteriol** 1998 Dec;180(24):6617–24
Interaction of Kar2p and Sls1p is required for efficient co-translational translocation of secreted proteins in the yeast Yarrowia lipolytica. Boisramé A, et al.
J Biol Chem 1998 Nov 20;273(47):30903–8
Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. Chen S, et al.
J Biol Chem 1998 Dec 25;273(52):35194–200
Purification of a 38-kDa protein from rabbit reticulocyte lysate which promotes protein renaturation by heat shock protein 70 and its identification as delta-aminolevulinic acid dehydratase and as a putative DnaJ protein. Gross M, et al. **J Biol Chem** 1999 Jan 29;274(5):3125–34
Mammalian Hsp70 and Hsp110 proteins bind to RNA motifs involved in mRNA stability. Henics T, et al.
J Biol Chem 1999 Jun 11;274(24):17318–24
Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication. Liu JS, et al.
J Biol Chem 1998 Nov 13;273(46):30704–12
The yeast Hsp110 family member, Sse1, is an Hsp90 cochaperone. Liu XD, et al. **J Biol Chem** 1999 Sep 17; 274(38):26654–60
Protein folding activity of Hsp70 is modified differentially by the hsp40 co-chaperones Sis1 and Ydj1. Lu Z, et al. **J Biol Chem** 1998 Oct 23;273(43):27824–30
The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity. Melville MW, et al. **J Biol Chem** 1999 Feb 5;274(6):3797–803
Stable association of 70-kDa heat shock protein induces latent multisite specificity of a unisite-specific endonuclease in yeast mitochondria. Mizumura H, et al. **J Biol Chem** 1999 Sep 3;274(36):25682–90
Molecular mechanisms of peptide loading by the tumor rejection antigen/heat shock chaperone gp96 (GRP94). Sastry S, et al. **J Biol Chem** 1999 Apr 23;274(17):12023–35
A nuclear export signal prevents Saccharomyces cerevisiae Hsp70 Ssb1p from stimulating nuclear localization signal-directed nuclear transport. Shulga N, et al.
J Biol Chem 1999 Jun 4;274(23):16501–7
An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. Takayama S, et al.
J Biol Chem 1999 Jan 8;274(2):781–6
Application of magnetic field-induced heat shock protein 70 for presurgical cytoprotection. Han L, et al.
J Cell Biochem 1998 Dec 15;71(4):577–83
Involvement of heat shock elements and basal transcription elements in the differential induction of the 70-kDa heat shock protein and its cognate by cadmium chloride in 9L rat brain tumor cells. Hung JJ, et al. **J Cell Biochem** 1998 Oct 1;71(1):21–35
Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages. Wassenberg JJ, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2167–75
Development and further characterization of a small subclass of rat olfactory receptor neurons that shows immunoreactivity for the HSP70 heat shock protein. Carr VM, et al. **J Comp Neurol** 1999 Feb 15;404(3):375–86
Cytochemical identification of HSP110 during early mouse facial development. Evrard L, et al.
J Craniofac Genet Dev Biol 1999 Jan-Mar;19(1):24–32
Critical analysis of eukaryotic phylogeny: a case study based on the HSP70 family. Germot A, et al.
J Eukaryot Microbiol 1999 Mar-Apr;46(2):116–24
Biphasic translocation of a 70 kDa heat shock protein in human cytomegalovirus-infected cells. Ohgitani E, et al.
J Gen Virol 1999 Jan;80 (Pt 1):63–8
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. Todryk S, et al.
J Immunol 1999 Aug 1;163(3):1398–408
The functional cycle and regulation of the Thermus thermophilus DnaK chaperone system. Klostermeier D, et al. **J Mol Biol** 1999 Apr 2;287(3):511–25
Investigation of the interaction between DnaK and DnaJ by surface plasmon resonance spectroscopy. Mayer MP, et al. **J Mol Biol** 1999 Jun 18;289(4):1131–44
Interaction of mitochondrial presequences with DnaK and mitochondrial hsp70. Zhang XP, et al. **J Mol Biol** 1999 Apr 23;288(1):177–90
Quantification of cardioprotective gene expression in porcine short-term hibernating myocardium. Bartling B, et al.
J Mol Cell Cardiol 1999 Jan;31(1):147–58
A physiologically relevant hyperthermia selectively activates constitutive hsp70 in H9c2 cardiac myoblasts and confers oxidative protection. Su CY, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):845–55
Overexpressed heat shock protein 70 attenuates hypoxic injury in coronary endothelial cells. Suzuki K, et al.
J Mol Cell Cardiol 1998 Jun;30(6):1129–36
Responses of heat shock proteins hsp27, alphaB-crystallin, and hsp70 in rat brain after kainic acid-induced seizure activity. Kato K, et al. **J Neurochem** 1999 Jul;73(1):229–36
Association of the rat liver glucocorticoid receptor with Hsp90 and Hsp70 upon whole body hyperthermic stress. Cvoro A, et al. **J Steroid Biochem Mol Biol** 1998 Nov; 67(4):319–25
Expression of HSP70 in healing wounds of diabetic and nondiabetic mice. McMurtry AL, et al. **J Surg Res** 1999 Sep;86(1):36–41
Thermal preconditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Ito H, et al.
Life Sci 1999;64(9):755–61
Heterogeneous patterns of constitutive and heat shock induced expression of HLA-linked HSP70-1 and HSP70-2 heat shock genes in human melanoma cell lines. Dressel R, et al. **Melanoma Res** 1998 Dec;8(6):482–92
The hsp operons are repressed by the hrc37 of the hsp70 operon in Staphylococcus aureus. Kuroda M, et al.
Microbiol Immunol 1999;43(1):19–27
J proteins catalytically activate Hsp70 molecules to trap a wide range of peptide sequences. Misselwitz B, et al.
Mol Cell 1998 Nov;2(5):593–603
Association of protein kinase CK2 with eukaryotic translation initiation factor eIF-2 and with grp94/endoplasmin. Riera M, et al. **Mol Cell Biochem** 1999 Jan;191(1–2):97–104
Antagonistic interactions between yeast chaperones Hsp104 and Hsp70 in prion curing. Newnam GP, et al.
Mol Cell Biol 1999 Feb;19(2):1325–33
In vivo chaperone activity of heat shock protein 70 and thermotolerance. Nollen EA, et al. **Mol Cell Biol** 1999 Mar; 19(3):2069–79
Immunohistochemical assessment of constitutive and inducible heat-shock protein 70 and ubiquitin in human cerebellum and caudate nucleus. Tytell M, et al.
Mol Chem Neuropathol 1998 Aug-Dec;35(1–3):97–117
Increased heat shock protein-70 in unilateral ureteral obstruction in rats. Lin KC, et al. **Mol Genet Metab** 1998 Dec;65(4):303–10
Ssa1p chaperone interacts with the guanine nucleotide exchange factor of ras Cdc25p and controls the cAMP pathway in Saccharomyces cerevisiae. Geymonat M, et al. **Mol Microbiol** 1998 Nov;30(4):855–64
Different constitutive heat shock protein 70 expression during proliferation and differentiation of rat C6 glioma cells. Helmbrecht K, et al. **Neurochem Res** 1999 Oct; 24(10):1293–9
Heat-shock proteins expression in fish central nervous system and its possible relation with water acidosis resistance. Martin M, et al. **Neurosci Res** 1998 Jun;31(2):97–106
Regional myocardial heat-shock protein (HSP70) concentrations under different blood flow conditions. Loncar R, et al. **Pflugers Arch** 1998 Dec;437(1):98–103
Involvement of heat-shock protein 70 and P53 proteins in attenuation of UVC-induced apoptosis by thermal stress in hepatocellular carcinoma cells. Chen YC, et al.
Photochem Photobiol 1999 Jul;70(1):78–86
A chloroplast-targeted heat shock protein 70 (HSP70) contributes to the photoprotection and repair of photosystem II during and after photoinhibition. Schroda M, et al. **Plant Cell** 1999 Jun;11(6):1165–78
Molecular characterization of DnaK from the halotolerant cyanobacterium Aphanothece halophytica for ATPase, protein folding, and copper binding under various salinity conditions. Hibino T, et al. **Plant Mol Biol** 1999 Jun; 40(3):409–18

Intragenic suppressors of Hsp70 mutants: interplay between the ATPase- and peptide-binding domains. Davis JE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9269-76

Mutations in the DnaK chaperone affecting interaction with the DnaJ cochaperone. Gässler CS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15229-34

Folding in vivo of a newly translated yeast cytosolic enzyme is mediated by the SSA class of cytosolic yeast Hsp70 proteins. Kim S, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12860-5

Mechanism of regulation of hsp70 chaperones by DnaJ cochaperones. Laufen T, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5452-7

The biochemical properties of the ATPase activity of a 70-kDa heat shock protein (Hsp70) are governed by the C-terminal domains. Lopez-Buesa P, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15253-8

Heat-inactivated proteins are rescued by the DnaK.J-GrpE set and ClpB chaperones. Motohashi K, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7184-9

Interaction of the Hsp70 molecular chaperone, DnaK, with its cochaperone DnaJ. Suh WC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15223-8

The hsp70-associating protein Hap46 binds to DNA and stimulates transcription. Zeiner M, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10194-9

Baseline levels of Hsp 70, a stress protein and biomarker, in halibut from the Cook Inlet region of Alaska. Scofield E, et al. **Sci Total Environ** 1999 Feb 2;226(1):85-8

Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Laroia G, et al. **Science** 1999 Apr 16;284(5413):499-502

Heat-shock protein 72/73 and impaired wound healing in diabetic and hypercortisolemic states. Bitar MS, et al. **Surgery** 1999 Jun;125(6):594-601

Characterization of deletion mutations in the carboxy-terminal peptide-binding domain of the Kar2 protein in Saccharomyces cerevisiae. Tokunaga M, et al. **Yeast** 1998 Oct;14(14):1285-95

[Discordance of increase in stress proteins in right and left myocardium of perfused isolated rat heart] Ren H, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):143-7 (Eng. Abstr.) **(Chi)**

[Induction of molecular chaperones HSP70 and HSP90 in rat liver cytosol by a highly toxic coplanar PCB] Fukuda A, et al. **Fukuoka Igaku Zasshi** 1999 May;90(5):259-71 (Eng. Abstr.) **(Jpn)**

[Proteins induction by cysteamine in Escherichia coli cells] Suslov AV, et al. **Radiats Biol Radioecol** 1998 Jul-Aug; 38(4):488-94 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Heat shock proteins 70 and 90 increase calcineurin activity in vitro through calmodulin-dependent and independent mechanisms. Someren JS, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):619-25

In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. Breloer M, et al. **J Immunol** 1999 Mar 15;162(6):3141-7

PHYSIOLOGY

Protective mechanisms in germ cells: stress proteins in spermatogenesis. Dix DJ, et al. **Adv Exp Med Biol** 1998; 444:137-43; discussion 143-4 (28 ref.)

Constitutive hsp70 is essential to mitosis during early cleavage of Paracentrotus lividus embryos: the blockage of constitutive hsp70 impairs mitosis. Sconzo G, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):143-9

Heat shock protein 70 (Hsp70) protects postimplantation murine embryos from the embryolethal effects of hyperthermia. Mirkes PE, et al. **Dev Dyn** 1999 Feb; 214(2):159-70

Heat shock protein 70 (HSP70) prolongs survival in rats exposed to hyperthermia [letter] Frossard JL. **Eur J Clin Invest** 1999 Jun;29(6):561-2

The role of DnaK/DnaJ and GroEL/GroES systems in the removal of endogenous proteins aggregated by heat-shock from Escherichia coli cells. Kędzierska S, et al. **FEBS Lett** 1999 Mar 12;446(2-3):331-7

Folding and refolding of thermolabile and thermostable bacterial luciferases: the role of DnaKJ heat-shock proteins. Manukhov IV, et al. **FEBS Lett** 1999 Apr 9; 448(2-3):265-8

Changes in cell morphology and actin organization during heat shock in Dictyostelium discoideum: does HSP70 play a role in acquired thermotolerance? Xiang W, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):95-107

Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Ethridge RT, et al. **Gastroenterology** 1998 Dec;115(6):1454-63

Role of DnaK in in vitro and in vivo expression of virulence factors of Vibrio cholerae. Chakrabarti S, et al. **Infect Immun** 1999 Mar;67(3):1025-33

Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. Wadhwa R, et al. **J Biol Chem** 1998 Nov 6;273(45):29586-91

The J-related segment of tim44 is essential for cell viability: a mutant Tim44 remains in the mitochondrial import site, but inefficiently recruits mtHsp70 and impairs protein translocation. Merlin A, et al. **J Cell Biol** 1999 May 31; 145(5):961-72

Participation of GRP94-related protein in secretion of pancreatic bile salt-dependent lipase and in its internalization by the intestinal epithelium. Bruneau N, et al. **J Cell Sci** 1998 Sep;111 (Pt 17):2665-79

Two distinct mechanisms operate in the reactivation of heat-denatured proteins by the mitochondrial Hsp70/Mdj1p/Yge1p chaperone system. Kubo Y, et al. **J Mol Biol** 1999 Feb 19;286(2):447-64

2-Deoxy-D-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. Lee J, et al. **J Neurosci Res** 1999 Jul 1;57(1):48-61

Suppression of ceramide-mediated apoptosis by HSP70. Ahn JH, et al. **Mol Cells** 1999 Apr 30;9(2):200-6

On the mechanism of FtsH-dependent degradation of the sigma 32 transcriptional regulator of Escherichia coli and the role of the Dnak chaperone machine. Blaszczak A, et al. **Mol Microbiol** 1999 Jan;31(1):157-66

Trigger factor and DnaK cooperate in folding of newly synthesized proteins. Deuerling E, et al. **Nature** 1999 Aug 12;400(6745):693-6

Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association. Liu H, et al. **Oncogene** 1999 Jun 10;18(23):3461-70

Role of heat shock protein HSP70-2 in spermatogenesis. Eddy EM. **Rev Reprod** 1999 Jan;4(1):23-30 (62 ref.)

[The role of HSP70 and Ca(2+)-pump from the myocardial sarcoplasmic reticulum in cardioprotective effects during adaptation to physical load in rats] Pshennikova MG, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov; 84(11):1214-22 (Eng. Abstr.) **(Rus)**

HEAT-SHOCK PROTEINS 90

ANALYSIS

The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit. Herbertsson H, et al. **Arch Biochem Biophys** 1999 Jul 1;367(1):33-8

Identification of keratins 18, 19 and heat-shock protein 90 beta as candidate substrates of proteolysis during ionizing radiation-induced apoptosis of estrogen-receptor negative breast tumor cells. Prasad S, et al. **Int J Oncol** 1998 Oct; 13(4):757-64

ANTAGONISTS & INHIBITORS

Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. Hartson SD, et al. **Biochemistry** 1999 Mar 23; 38(12):3837-49

Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90. Lele Z, et al. **Dev Biol** 1999 Jun 1;210(1):56-70

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. Roe SM, et al. **J Med Chem** 1999 Jan 28; 42(2):260-6

BIOSYNTHESIS

Stage-specific expression of heat shock protein 90 in murine malaria parasite Plasmodium yoelii. Zhang M, et al. **Exp Parasitol** 1999 Oct;93(2):61-5

CHEMISTRY

20S proteasome, hsp90, p97 fusion protein, PA28 activator copurifying oligomers and ATPase activities. Montel V, et al. **Biochem Mol Biol Int** 1999 Mar;47(3):465-72

Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Meyer BK, et al. **Biochemistry** 1999 Jul 13; 38(28):8907-17

Localization of calponin binding sites in the structure of 90 kDa heat shock protein (Hsp90). Bogatcheva NV, et al. **FEBS Lett** 1999 Sep 3;457(3):369-74

The beta-isoform of heat shock protein hsp-90 is structurally related with human microtubule-interacting protein Mip-90. Cambiazo V, et al. **FEBS Lett** 1999 Sep 3; 457(3):343-7

The charged region of Hsp90 modulates the function of the N-terminal domain. Scheibel T, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1297-302

Hsp90's secrets unfold: new insights from structural and functional studies. Caplan AJ. **Trends Cell Biol** 1999 Jul; 9(7):262-8 (66 ref.)

DIAGNOSTIC USE

Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Nanbu K, et al. **Cancer Detect Prev** 1998;22(6):549-55

GENETICS

Heat-induced expression and chemically induced expression of the Escherichia coli stress protein HtpG are affected by the growth environment. Mason CA, et al. **Appl Environ Microbiol** 1999 Aug;65(8):3433-40

Sequence features and phylogenetic analysis of the stress protein hsp90alpha in chinook salmon (Oncorhynchus tshawytscha), a poikilothermic vertebrate. Palmisano AN, et al. **Biochem Biophys Res Commun** 1999 May 19; 258(3):784-91

Effects of quercetin and sunphenon on responses of cancer cells to heat shock damage. Kudo M, et al. **Exp Mol Pathol** 1999 Apr;66(1):66-75

Regulation of human hsp90alpha gene expression. Zhang SL, et al. **FEBS Lett** 1999 Feb 5;444(1):130-5

Regulation of hsp90 and hsp70 genes during antheridiol-induced hyphal branching in the oomycete Achlya ambisexualis. Brunt SA, et al. **Fungal Genet Biol** 1998 Aug;24(3):310-24

Molecular cloning and characterization of porcine cDNA encoding a 90-kDa heat shock protein and its expression following hyperthermia. Huang H, et al. **Gene** 1999 Jan 21;226(2):307-15

Transcriptional regulation of the heat shock protein genes by STAT family transcription factors. Stephanou A, et al. **Gene Expr** 1999;7(4-6):311-9 (45 ref.)

Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis. Yue L, et al. **Genetics** 1999 Mar;151(3):1065-79

Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. Stephanou A, et al. **J Biol Chem** 1999 Jan 15;274(3):1723-8

Intron-independent association of splicing factors with active genes. Jolly C, et al. **J Cell Biol** 1999 Jun 14;145(6):1133-43

In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. Obermann WM, et al. **J Cell Biol** 1998 Nov 16;143(4):901-10

Is Hsp90 a regulator of evolvability? Wagner GP, et al. **J Exp Zool** 1999 Aug 15;285(2):116-8

CNS1 encodes an essential p60/Sti1 homolog in Saccharomyces cerevisiae that suppresses cyclophilin 40 mutations and interacts with Hsp90. Dolinski KJ, et al. **Mol Cell Biol** 1998 Dec;18(12):7344-52

Genetic interactions between Hsp90 and the Cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe. Muñoz MJ, et al. **Mol Gen Genet** 1999 Mar;261(2):242-50

The Bacillus subtilis htpG gene is not involved in thermal stress management. Versteeg S, et al. **Mol Gen Genet** 1999 Apr;261(3):582-8

Cryptic clues revealed [news; comment] [see comments] Cossins A. **Nature** 1998 Nov 26;396(6709):309-10. Comment on: Nature 1998 Nov 26;396(6709):336-42. Comment in: Nature 1999 May 6;399(6731):30.

Identification of SSF1, CNS1, and HCH1 as multicopy suppressors of a Saccharomyces cerevisiae Hsp90 loss-of-function mutation. Nathan DF, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1409-14

Hsp90 & Co. - a holding for folding. Buchner J. **Trends Biochem Sci** 1999 Apr;24(4):136-41 (57 ref.)

Too late for the midwife toad: stress, variability and Hsp90. McLaren A. **Trends Genet** 1999 May;15(5):169-71 (21 ref.)

IMMUNOLOGY

Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis. Hayem G, et al. **Ann Rheum Dis** 1999 May;58(5):291-6

Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients [letter] Conroy SE, et al. **Eur J Cancer** 1998 May;34(6):942-3

Monomer arrangement in HSP90 dimer as determined by decoration with N and C-terminal region specific antibodies. Maruya M, et al. **J Mol Biol** 1999 Jan 22; 285(3):903-7

ISOLATION & PURIFICATION

High-molecular-weight FK506-binding proteins are components of heat-shock protein 90 heterocomplexes in wheat germ lysate. Reddy RK, et al. **Plant Physiol** 1998 Dec;118(4):1395-401

METABOLISM

Heat-shock protein 90 (hsp90) binds in vitro to tubulin dimer and inhibits microtubule formation. Garnier C, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):414-9

Comparative inhibition by hard and soft metal ions of steroid-binding capacity of renal mineralocorticoid receptor cross-linked to the 90-kDa heat-shock protein heterocomplex. Galigniana MD, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):585-92

Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin. Sugita T, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):587-95

Role of HSP90 in mediating cross-talk between the estrogen receptor and the Ah receptor signal transduction pathways. Caruso JA, et al. **Biochem Pharmacol** 1999 Nov 1; 58(9):1395-403

Isolation of rabbit liver heat shock protein with molecular weight 90 kD (Hsp90) and its interaction with troponin components and calponin. Ma YS, et al. **Biochemistry (Mosc)** 1998 Nov;63(11):1282-9

Expression of hsp90 and cyclin D1 in human breast cancer. Yano M, et al. **Cancer Lett** 1999 Mar 22;137(1):45-51

KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Soga S, et al. **Cancer Res** 1999 Jun 15;59(12):2931-8

Molecular chaperones: the busy life of Hsp90. Mayer MP, et al. **Curr Biol** 1999 May 6;9(9):R322-5 (18 ref.)

Signal transduction: Gyrating protein kinases. Stock J. **Curr Biol** 1999 May 20;9(10):R364–7 (29 ref.)
Effect of ischemia--reperfusion on heat shock protein 70 and 90 gene expression in rat liver: relation to nutritional status. Gasbarrini A, et al. **Dig Dis Sci** 1998 Dec;43(12):2601–5
Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. Loo MA, et al. **EMBO J** 1998 Dec 1; 17(23):6879–87
Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)–domain co–chaperones. Prodromou C, et al. **EMBO J** 1999 Feb 1;18(3):754–62
Delimitation of two regions in the 90–kDa heat shock protein (Hsp90) able to interact with the glucocorticosteroid receptor (GR). Jibard N, et al. **Exp Cell Res** 1999 Mar 15;247(2):461–74
Localization of calponin binding sites in the structure of 90 kDa heat shock protein (Hsp90). Bogatcheva NV, et al. **FEBS Lett** 1999 Sep 3;457(3):369–74
The beta–isoform of heat shock protein hsp–90 is structurally related with human microtubule–interacting protein Mip–90. Cambiazo V, et al. **FEBS Lett** 1999 Sep 3; 457(3):343–7
The role of HSP90 in evolution. Yahara I. **Genes Cells** 1999 Jul;4(7):375–9 (25 ref.)
Functional requirement of p23 and Hsp90 in telomerase complexes. Holt SE, et al. **Genes Dev** 1999 Apr 1; 13(7):817–26
Differential localization of heat shock proteins 90, 70, 60 and 27 in human decidua and placenta during pregnancy. Shah M, et al. **Histochem J** 1998 Jul;30(7):509–18
Neuronal nitric–oxide synthase is regulated by the Hsp90–based chaperone system in vivo. Bender AT, et al. **J Biol Chem** 1999 Jan 15;274(3):1472–8
The common tetratricopeptide repeat acceptor site for steroid receptor–associated immunophilins and hop is located in the dimerization domain of Hsp90. Carrello A, et al. **J Biol Chem** 1999 Jan 29;274(5):2682–9
Heat–induced oligomerization of the molecular chaperone Hsp90. Inhibition by ATP and geldanamycin and activation by transition metal oxyanions. Chadli A, et al. **J Biol Chem** 1999 Feb 12;274(7):4133–9
Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. Chen S, et al. **J Biol Chem** 1998 Dec 25;273(52):35194–200
The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. Grenert JP, et al. **J Biol Chem** 1999 Jun 18; 274(25):17525–33
The assembly of progesterone receptor–hsp90 complexes using purified proteins. Kosano H, et al. **J Biol Chem** 1998 Dec 4;273(49):32973–9
The yeast Hsp110 family member, Sse1, is an Hsp90 cochaperone. Liu XD, et al. **J Biol Chem** 1999 Sep 17; 274(38):26654–60
Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90. Russell LC, et al. **J Biol Chem** 1999 Jul 16; 274(29):20060–3
Only a small portion of the cytoplasmic progesterone receptor is associated with Hsp90 in vivo. Passinen S, et al. **J Cell Biochem** 1999 Sep 1;74(3):458–67
In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. Obermann WM, et al. **J Cell Biol** 1998 Nov 16;143(4):901–10
Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages. Wassenberg JJ, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2167–75
Presence of an aromatase inhibitor, possibly heat shock protein 90, in dominant follicles of cattle. Driancourt MA, et al. **J Reprod Fertil** 1999 Jan;115(1):45–58
Association of the rat liver glucocorticoid receptor with Hsp90 and Hsp70 upon whole body hyperthermic stress. Cvoro A, et al. **J Steroid Biochem Mol Biol** 1998 Nov; 67(4):319–25
Association of MTG8 (ETO/CDR), a leukemia–related protein, with serine/threonine protein kinases and heat shock protein HSP90 in human hematopoietic cell lines. Komori A, et al. **Jpn J Cancer Res** 1999 Jan;90(1):60–8
Hsp90 is required for pheromone signaling in yeast. Louvion JF, et al. **Mol Biol Cell** 1998 Nov;9(11):3071–83
Brassica napus hsp90 can autophosphorylate and phosphorylate other protein substrates. Park M, et al. **Mol Cell Biochem** 1998 Aug;185(1–2):33–8
p50(cdc37) acting in concert with Hsp90 is required for Raf–1 function. Grammatikakis N, et al. **Mol Cell Biol** 1999 Mar; 19(3):1661–72
Role for Hsp90–associated cochaperone p23 in estrogen receptor signal transduction. Knoblauch R, et al. **Mol Cell Biol** 1999 May;19(5):3748–59
Cns1 is an essential protein associated with the hsp90 chaperone complex in Saccharomyces cerevisiae that can restore cyclophilin 40–dependent functions in cpr7Delta cells. Marsh JA, et al. **Mol Cell Biol** 1998 Dec; 18(12):7353–9
Chromatin recycling of glucocorticoid receptors: implications for multiple roles of heat shock protein 90. Liu J, et al. **Mol Endocrinol** 1999 Mar;13(3):355–65
Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones. Schulte TW, et al. **Mol Endocrinol** 1999 Sep;13(9):1435–48
Intracellular localization of HSP73 and HSP90 in rat kidneys with acute lysosomal thesaurismosis. Komatsuda A, et al. **Pathol Int** 1999 Jun;49(6):513–8
Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Byrd CA, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5645–50
The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid–dependent promoter. Kang KI, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1439–44
The charged region of Hsp90 modulates the function of the N–terminal domain. Scheibel T, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1297–302
Maturation of the tyrosine kinase c–src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Xu Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5; 96(1):109–14
Expression of 90–kDa heat shock protein within regenerative tubular cells in a patient with acute oliguric renal failure due to malignant hypertension. Komatsuda A, et al. **Ren Fail** 1999 Jan;21(1):113–7
Hsp90's secrets unfold: new insights from structural and functional studies. Caplan AJ. **Trends Cell Biol** 1999 Jul; 9(7):262–8 (66 ref.)
[Induction of molecular chaperones HSP70 and HSP90 in rat liver cytosol by a highly toxic coplanar PCB] Fukuda A, et al. **Fukuoka Igaku Zasshi** 1999 May;90(5):259–71 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Heat shock proteins 70 and 90 increase calcineurin activity in vitro through calmodulin–dependent and independent mechanisms. Someren JS, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):619–25
Heat shock protein 90–dependent (geldanamycin–inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Galigniana MD, et al. **Mol Endocrinol** 1998 Dec; 12(12):1903–13

PHYSIOLOGY

Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Shah V, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G463–8
HSP90 has neurite–promoting activity in vitro for telencephalic and spinal neurons of chick embryos. Ishimoto T, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):283–7
Reappraisal of the role of heat shock proteins as regulators of steroid receptor activity. Ylikomi T, et al. **Crit Rev Biochem Mol Biol** 1998;33(6):437–66 (196 ref.)
HtpG is essential for the thermal stress management in cyanobacteria. Tanaka N, et al. **FEBS Lett** 1999 Sep 17; 458(2):117–23
Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis. Yue L, et al. **Genetics** 1999 Mar;151(3):1065–79
Is Hsp90 a regulator of evolvability? Wagner GP, et al. **J Exp Zool** 1999 Aug 15;285(2):116–8
Hsp90 as a capacitor for morphological evolution [see comments] Rutherford SL, et al. **Nature** 1998 Nov 26; 396(6709):336–42. Comment in: Nature 1998 Nov 26;396(6709):309–10. Comment in: Nature 1999 May 6;399(6731):30.
Heat shock protein mutes genetic changes [news] Pennisi E. **Science** 1998 Dec 4;282(5395):1796

HEAT-SHOCK REACTION see **HEAT-SHOCK RESPONSE**

HEAT-SHOCK RESPONSE

see related
HEAT-SHOCK PROTEINS

Interferon–alpha inhibits the emergence of cellular stress response–dependent morbillivirus large plaque variants. Heller M, et al. **Antiviral Res** 1998 Jun;38(3):195–207
Trehalose accumulation by tropical yeast strains submitted to stress conditions. Ribeiro MJ, et al. **Antonie Van Leeuwenhoek** 1999 Apr;75(3):245–51
c–fos induction by heat, arsenite, and cadmium is mediated by a heat shock element in its promoter. Ishikawa T, et al. **Biochem Biophys Res Commun** 1999 Jan 27; 254(3):566–71
Heat shock–induced acquisition of thermotolerance at the levels of cell survival and translation in Xenopus A6 kidney epithelial cells. Phang D, et al. **Biochem Cell Biol** 1999; 77(2):141–51
The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3–kinase and not by mitogen–activated protein kinase–activated protein kinase–2. Shaw M, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):241–6
Heat stress affects the glucocorticoid receptor interaction with heat shock protein Hsp70 in the rat liver. Cvoro A, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):63–70
Stress–induced activation of the heat–shock response: cell and molecular biology of heat–shock factors. Cotto JJ, et al. **Biochem Soc Symp** 1999;64:105–18 (55 ref.)
Molecular chaperones and the heat shock response. Sponsored by Cold Spring Harbor Laboratory, 6–10 May 1998. Kaufman RJ. **Biochim Biophys Acta** 1999 Jan 29; 1423(1):R13–27 (27 ref.)
Protein chaperones and the heat shock response in Saccharomyces cerevisiae. Morano KA, et al. **Curr Opin Microbiol** 1998 Apr;1(2):197–203 (44 ref.)
Influence of polyamines on DNA binding of heat shock and activator protein 1 transcription factors induced by heat shock. Desiderio MA, et al. **FEBS Lett** 1999 Jul 16; 455(1–2):149–53
HtpG is essential for the thermal stress management in cyanobacteria. Tanaka N, et al. **FEBS Lett** 1999 Sep 17; 458(2):117–23
Effect of mutations of murine lens alphaB crystallin on transfected neural cell viability and cellular translocation in response to stress. Wiesmann KE, et al. **FEBS Lett** 1998 Oct 30;438(1–2):25–31
Stress tolerance in a yeast sterol auxotroph: role of ergosterol, heat shock proteins and trehalose. Swan TM, et al. **FEMS Microbiol Lett** 1998 Dec 1;169(1):191–7
A role for RNA metabolism in inducing the heat shock response. Carlson T, et al. **Gene Expr** 1999;7(4–6):283–91
Uncoupling of the hnRNP Npl3p from mRNAs during the stress–induced block in mRNA export. Krebber H, et al. **Genes Dev** 1999 Aug 1;13(15):1994–2004
Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Morimoto RI. **Genes Dev** 1998 Dec 15;12(24):3788–96 (103 ref.)
Translational induction of heat shock transcription factor sigma32: evidence for a built–in RNA thermosensor. Morita MT, et al. **Genes Dev** 1999 Mar 15;13(6):655–65
An RNA thermometer. Storz G. **Genes Dev** 1999 Mar 15; 13(6):633–6
Response of preimplantation murine embryos to heat shock as modified by developmental stage and glutathione status. Aréchiga CF, et al. **In Vitro Cell Dev Biol Anim** 1998 Sep; 34(8):655–9
Heat shock proteins and regulation of cytokine expression. Xie Y, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):26–30
A mycobacterial extracytoplasmic sigma factor involved in survival following heat shock and oxidative stress. Fernandes ND, et al. **J Bacteriol** 1999 Jul;181(14):4266–74
Heat shock inhibits radiation–induced activation of NF–kappaB via inhibition of I–kappaB kinase. Curry HA, et al. **J Biol Chem** 1999 Aug 13;274(33):23061–7
Redox factor–1 (Ref–1) mediates the activation of AP–1 in HeLa and NIH 3T3 cells in response to heat shock. Diamond DA, et al. **J Biol Chem** 1999 Jun 11; 274(24):16959–64
Modulation of human heat shock factor trimerization by the linker domain. Liu PC, et al. **J Biol Chem** 1999 Jun 11; 274(24):17219–25
GroEL under heat–shock. Switching from a folding to a storing function. Llorca O, et al. **J Biol Chem** 1998 Dec 4;273(49):32587–94
Thermotolerant cells show an attenuated expression of Hsp70 after heat shock. Theodorakis NG, et al. **J Biol Chem** 1999 Apr 23;274(17):12081–6
Regulatory domain of human heat shock transcription factor–2 is not regulated by hemin or heat shock. Zhu Z, et al. **J Cell Biochem** 1999 Apr 1;73(1):56–69
Feeding is inhibited by sublethal concentrations of toxicants and by heat stress in the nematode Caenorhabditis elegans: relationship to the cellular stress response. Jones D, et al. **J Exp Zool** 1999 Jul 1;284(2):147–57
The effect of the cellular stress response on human T–lymphotropic virus type I envelope protein expression. Andrews JM, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2905–8
Heat shock pretreatment protects pulmonary isografts from subsequent ischemia–reperfusion injury. Hiratsuka M, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1238–46
Dissociation of heat shock proteins expression with ischemic tolerance by whole body hyperthermia in rat heart. Qian YZ, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1163–72
Heat shock stress induces cleavage and activation of PAK2 in apoptotic cells. Chan WH, et al. **J Protein Chem** 1998 Jul;17(5):485–94
Resistance of heat–shocked cells of Listeria monocytogenes to mano–sonication and mano–thermo–sonication. Pagán R, et al. **Lett Appl Microbiol** 1999 Jan;28(1):71–5
Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: contrasting effects of oncogenes and heat stress in a murine marrow–derived cell line. Ahmed N, et al. **Life Sci** 1998; 63(21):1887–903
Heat stress aggravates viral myocarditis in mice. Kanda T, et al. **Life Sci** 1999;64(2):93–101
Expression of the Oenococcus oeni trxA gene is induced by hydrogen peroxide and heat shock. Jobin MP, et al. **Microbiology** 1999 May;145 (Pt 5):1245–51
Intercellular signaling initiated by nitric oxide produced in heat–shocked human glioblastoma cells. Matsumoto H, et al. **Nitric Oxide** 1999;3(2):180–9
Heat shock of HeLa cells inactivates a nuclear protein phosphatase specific for dephosphorylation of the C–terminal domain of RNA polymerase II. Dubois MF, et al. **Nucleic Acids Res** 1999 Mar 1;27(5):1338–44
Heat shock during rat embryo development in vitro results in decreased mitosis and abundant cell death. Breen JG, et al. **Reprod Toxicol** 1999 Jan–Feb;13(1):31–9
Control of mRNA decay by heat shock–ubiquitin–proteasome pathway. Laroia G, et al.

Science 1999 Apr 16;284(5413):499–502

Stress-inducible mechanisms of life-span extension in yeast, eubacteria and metazoans [letter] Braeckman BP, et al. **Trends Microbiol** 1999 Jul;7(7):270–1

[A study on expression of the heat shock suppressed gene in distal organs of rats after scalding] Guo XZ, et al. **Sheng Li Hsueh Pao** 1997 Aug;49(4):370–4 (Eng. Abstr.) **(Chi)**

[Disruption of heat-shock protein synthesis does not prevent normal development of stress reaction in Drosophila melanogaster] Gryntenko NE, et al. **Dokl Akad Nauk** 1998 Oct;362(6):844–5 **(Rus)**

[Disturbances in the Drosophila stress reaction correlate with changes in the heat-shock response] Khlebodarova TM, et al. **Dokl Akad Nauk** 1998 Jul;361(2):284–6 **(Rus)**

[Effect of heat shock on translation in cell culture] Mavletova DA, et al. **Dokl Akad Nauk** 1999 Jan;364(3):410–3 **(Rus)**

[Effect of 2,4-dinitrophenol on stability of a turbidostat yeast culture to heat shock] Kaliuzhin VA. **Mikrobiologiia** 1998 Jul–Aug;67(4):476–82 (Eng. Abstr.) **(Rus)**

[Role of putrescine and potassium transport in regulating the topological state of DNA during adaptation of Escherichia coli to temperature stress] Tkachenko AG, et al. **Mikrobiologiia** 1998 Sep–Oct;67(5):601–6 (Eng. Abstr.) **(Rus)**

[Effect of heat shock on biosynthesis of antibiotics by three strains of Streptomyces] Lu H, et al. **Prikl Biokhim Mikrobiol** 1999 Jan–Feb;35(1):55–9 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Herbimycin-A attenuates ischaemia-reperfusion induced pulmonary neutrophil infiltration. Javadpour M, et al. **Eur J Vasc Endovasc Surg** 1998 Nov;16(5):377–82

Antioxidant-mediated inhibition of the heat shock response leads to apoptosis. Gorman AM, et al. **FEBS Lett** 1999 Feb 19;445(1):98–102

GENETICS

Genetic mapping of the amide response element(s) of the hsr omega locus of Drosophila melanogaster. Lakhotia SC, et al. **Chromosoma** 1998 May;107(2):127–35

Heat-induced degradation of PER and TIM in Drosophila bearing a conditional allele of the heat shock transcription factor gene. Sidote D, et al. **Chronobiol Int** 1999 Jul; 16(4):519–25

Bile salt activation of stress response promoters in Escherichia coli. Bernstein C, et al. **Curr Microbiol** 1999 Aug;39(2):68–72

Altered association of transcriptionally active DNA with the nuclear-matrix after heat shock. Sakkers RJ, et al. **Int J Radiat Biol** 1999 Jul;75(7):875–83

Transcriptional factor mutations reveal regulatory complexities of heat shock and newly identified stress genes in Saccharomyces cerevisiae. Treger JM, et al. **J Biol Chem** 1998 Oct 9;273(41):26875–9

Differential activation of some transcription factors during rat liver ischemia, reperfusion, and heat shock. Tacchini L, et al. **J Cell Physiol** 1999 Aug;180(2):255–62

Heat shock regulation in the ftsH null mutant of Escherichia coli: dissection of stability and activity control mechanisms of sigma32 in vivo. Tatsuta T, et al. **Mol Microbiol** 1998 Nov;30(3):583–93

PHYSIOLOGY

Surgical stress and the heat shock response: in vivo models of stress conditioning. Perdrizet GA, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:320–5

Heat shock improves recovery and provides protection against global ischemia after hypothermic storage [see comments] Gowda A, et al. **Ann Thorac Surg** 1998 Dec; 66(6):1991–7. Comment in: Ann Thorac Surg 1999 Aug;68(2):628.

Fatty acid profile of Escherichia coli during the heat-shock response. Mejia R, et al. **Biochem Mol Biol Int** 1999 May; 47(5):835–44

Enhanced protection of heat shock in myocardial infarction: inhibition of detrimental effect of systemic hyperthermia. Iliodromitis EK, et al. **Cardiovasc Drugs Ther** 1999 May; 13(3):223–31

Heat shock induction of a 65 kDa ATP-binding proteinase in rat C6 glioma cells. Xu CS, et al. **Cell Res** 1999 Jun; 9(2):135–44

Highlights of the 1998 Cold Spring Harbor Meeting: Molecular chaperones and the heat shock response. Bensaude O, et al. **Cell Stress Chaperones** 1999 Mar; 4(1):60–5

Dynamics and regulation of the stress response: meeting report on the stress response and molecular chaperones from Kyoto. Yoshida M, et al. **Cell Stress Chaperones** 1999 Mar;4(1):66–74

Heat-induced degradation of PER and TIM in Drosophila bearing a conditional allele of the heat shock transcription factor gene. Sidote D, et al. **Chronobiol Int** 1999 Jul; 16(4):519–25

Characterization of the heat shock response in the gills of sea lampreys and a brook lamprey at different intervals of their life cycles. Wood LA, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):509–18

A 16.6-kilodalton protein in the Cyanobacterium synechocystis sp. PCC 6803 plays a role in the heat shock response. Lee S, et al. **Curr Microbiol** 1998 Dec;37(6):403–7

Regulation of the heat-shock response. Yura T, et al. **Curr Opin Microbiol** 1999 Apr;2(2):153–8 (66 ref.)

Role of RAS2 in recovery from chronic stress: effect on yeast life span. Shama S, et al. **Exp Cell Res** 1998 Dec 15; 245(2):368–78

Heat stress-induced life span extension in yeast. Shama S, et al. **Exp Cell Res** 1998 Dec 15;245(2):379–88

Lack of heat shock response triggers programmed cell death in a rat histiocytic cell line. Sreedhar AS, et al. **FEBS Lett** 1999 Aug 6;456(2):339–42

Preliminary observations of the cytological structure of the hypothalamo-neurohypophyseal magnocellular neuroendocrine system in field voles after acute thermal stress. Sawicki B, et al. **Folia Histochem Cytobiol** 1999; 37(2):73–4

A genetic analysis of the relationship between life-history variation and heat-shock tolerance in Drosophila buzzatii. Krebs RA, et al. **Heredity** 1999 Jul;83 (Pt 1):46–53

Stimulation of survival capacity in heat shocked cells by subsequent exposure to minute amounts of chemical stressors; role of similarity in hsp-inducing effects. Wiegant FA, et al. **Hum Exp Toxicol** 1999 Jul;18(7):460–70

Altered association of transcriptionally active DNA with the nuclear-matrix after heat shock. Sakkers RJ, et al. **Int J Radiat Biol** 1999 Jul;75(7):875–83

AlphaB-crystallin selectively targets intermediate filament proteins during thermal stress. Muchowski PJ, et al. **Invest Ophthalmol Vis Sci** 1999 Apr;40(5):951–8

Rpb4p is necessary for RNA polymerase II activity at high temperature. Maillet I, et al. **J Biol Chem** 1999 Aug 6; 274(32):22586–90

Conventional and novel PKC isoenzymes modify the heat-induced stress response but are not activated by heat shock. Holmberg CI, et al. **J Cell Sci** 1998 Nov;111 (Pt 22):3357–65

Heat shock provides delayed protection against oxidative injury in cultured human umbilical vein endothelial cells. Gill RR, et al. **J Mol Cell Cardiol** 1998 Dec;30(12):2739–49

Long-term effects of prior heat shock on neuronal potassium currents recorded in a novel insect ganglion slice preparation. Ramirez JM, et al. **J Neurophysiol** 1999 Feb; 81(2):795–802

Heat shock attenuates oxidation and accelerates apoptosis in human neutrophils. Callahan TE, et al. **J Surg Res** 1999 Aug;85(2):317–22

Enhanced measles virus cDNA rescue and gene expression after heat shock. Parks CL, et al. **J Virol** 1999 May; 73(5):3560–6

Cell survival effect of activin against heat shock stress on OVCAR3. Fukuda J, et al. **Life Sci** 1998;63(25):2209–20

Heterogeneous patterns of constitutive and heat shock induced expression of HLA-linked HSP70-1 and HSP70-2 heat shock genes in human melanoma cell lines. Dressel R, et al. **Melanoma Res** 1998 Dec;8(6):482–92

In vivo chaperone activity of heat shock protein 70 and thermotolerance. Nollen EA, et al. **Mol Cell Biol** 1999 Mar; 19(3):2069–79

Multiple independent regulatory pathways control UBI4 expression after heat shock in Saccharomyces cerevisiae. Simon JR, et al. **Mol Microbiol** 1999 Feb;31(3):823–32

Thermotolerance of IVM-derived bovine oocytes and embryos after short-term heat shock. Ju JC, et al. **Mol Reprod Dev** 1999 Jul;53(3):336–40

Thermotolerance in Saccharomyces cerevisiae: the Yin and Yang of trehalose. Singer MA, et al. **Trends Biotechnol** 1998 Nov;16(11):460–8 (71 ref.)

HEAT STRESS DISORDERS

Heat-related illnesses. Khosla R, et al. **Crit Care Clin** 1999 Apr;15(2):251–63 (32 ref.)

Effect of indomethacin on hyperthermia induced by heat stress in broiler chickens. Furlan RL, et al. **Int J Biometeorol** 1998 Dec;42(2):73–6

Quantifying livestock responses for heat stress management: a review. Nienaber JA, et al. **Int J Biometeorol** 1999 Apr; 42(4):183–8 (68 ref.)

Whole body heat shock fails to protect mouse heart against ischemia/reperfusion injury: role of 72 kDa heat shock protein and antioxidant enzymes. Xi L, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2213–27

Optimizing delivery of genetic merit in subtropical climates through advanced reproductive technologies. Singh H. **Poult Sci** 1999 Mar;78(3):453–8

Effects of mild chronic heat exposure on the concentrations of thiobarbituric acid reactive substances, glutathione, and selenium, and glutathione peroxidase activity in the mouse liver. Kasanuma Y, et al. **Tohoku J Exp Med** 1998 Jun; 185(2):79–87

[Antitoxic features of magnesium oxide under combined radiation and thermal injury] Nesterenko VS, et al. **Radiats Biol Radioecol** 1998 Jul–Aug;38(4):591–4 (Eng. Abstr.) **(Rus)**

BLOOD

How significant is magnesium in thermoregulation? Stendig-Lindberg G, et al. **J Basic Clin Physiol Pharmacol** 1998;9(1):73–85

COMPLICATIONS

Features and outcomes of classic heat stroke [letter; comment] Ayus JC, et al. **Ann Intern Med** 1999 Apr 6; 130(7):613; discussion 614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Infarct size-reducing effect of heat stress and alpha1 adrenoceptors in rats. Joyeux M, et al. **Br J Pharmacol** 1998 Oct;125(4):645–50

DIAGNOSIS

Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367–76 (15 ref.)

Wet bulb globe temperature (WBGT)--to what extent is GT essential? Moran DS, et al. **Aviat Space Environ Med** 1999 May;70(5):480–4

Continuous core temperature monitoring of search and rescue divers during extreme conditions [see comments] White LJ, et al. **Prehosp Emerg Care** 1998 Oct–Dec;2(4):280–4. Comment in: Prehosp Emerg Care 1998 Oct–Dec;2(4):330–3.

DRUG THERAPY

[The effect of phenazepam on the pancreatic excretory function in thermal stress] Zakirov EU, et al. **Eksp Klin Farmakol** 1999 Jan–Feb;62(1):31–3 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

The rate and risk of heat-related illness in hospital emergency departments during the 1995 Chicago heat disaster. Rydman RJ, et al. **J Med Syst** 1999 Feb;23(1):41–56

From the Centers for Disease Control and Prevention. Heat-related illnesses and deaths--Missouri, 1998, and United States, 1979–1996. **JAMA** 1999 Jul 21;282(3):227–8

Heat-related illnesses and deaths--Missouri, 1998, and United States, 1979–1996. **MMWR Morb Mortal Wkly Rep** 1999 Jun 11;48(22):469–73

ETIOLOGY

Heat stress and protective clothing: an emerging approach from the United States. Bernard TE. **Ann Occup Hyg** 1999 Jul;43(5):321–7 (22 ref.)

Protective clothing and heat stress: introduction. Crockford GW. **Ann Occup Hyg** 1999 Jul;43(5):287–8

Development of a draft British standard: the assessment of heat strain for workers wearing personal protective equipment. Hanson MA. **Ann Occup Hyg** 1999 Jul; 43(5):309–19 (38 ref.)

Heat balance when wearing protective clothing. Havenith G. **Ann Occup Hyg** 1999 Jul;43(5):289–96 (11 ref.)

Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339–46 (17 ref.). Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

Clothing convective heat exchange--proposal for improved prediction in standards and models [see comments] Holmér I, et al. **Ann Occup Hyg** 1999 Jul;43(5):329–37. Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

The role of performance tests, manikins and test houses in defining clothing characteristics relevant to risk assessment. Holmér I. **Ann Occup Hyg** 1999 Jul;43(5):353–6 (15 ref.)

Heat stress and flame protective clothing in mine rescue brigadesmen: inter- and intraindividual variation of strain. Kampmann B, et al. **Ann Occup Hyg** 1999 Jul;43(5):357–65

The effects of wind and human movement on the heat and vapour transfer properties of clothing [comment] Parsons KC, et al. **Ann Occup Hyg** 1999 Jul;43(5):347–52. Comment on: Ann Occup Hyg 1999 Jul;43(5):329–38. Comment on: Ann Occup Hyg 1999 Jul;43(5):339–46.

International standards for the assessment of the risk of thermal strain on clothed workers in hot environments. Parsons KC. **Ann Occup Hyg** 1999 Jul;43(5):297–308 (28 ref.)

Flight coverall microclimate evaluation using a Japanese type sweating mannequin. Kurihara K, et al. **Aviat Space Environ Med** 1998 Dec;69(12):1174–7

Efficacy of air and liquid cooling during light and heavy exercise while wearing NBC clothing. McLellan TM, et al. **Aviat Space Environ Med** 1999 Aug;70(8):802–11

The free-convective anomaly. Steadman RG. **J Appl Physiol** 1999 Jul;87(1):54–73

Sudden death after typhoid and Japanese encephalitis vaccination in a young male taking pseudoephedrine. Franklin QJ. **Mil Med** 1999 Feb;164(2):157–9

Complications of fluid overload in heat casualty prevention during field training. Reynolds NC Jr, et al. **Mil Med** 1998 Nov;163(11):789–91

Delayed death after uncomplicated hot tub bathing in dogs and monkeys. Eshel GM, et al. **Resuscitation** 1998 Jun; 37(3):189–95

[Effects of water deprivation on rectal and skin temperature and on performance in sustained muscular exercise in a hot climate] Samb A, et al. **Dakar Med** 1996;41(2):109–13 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Cytokine levels in patients with previous heatstroke under

heat stress. Chung NK, et al. **Mil Med** 1999 Apr; 164(4):306–10

METABOLISM

Heat stress produces an early phase of protection against oxidative damage in human muscle. Naito J, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):77–81

Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion. Bell DG, et al. **Aviat Space Environ Med** 1999 Jun;70(6):583–8

Modeling analysis of women litter bearers during heat stress. Santee WR, et al. **Aviat Space Environ Med** 1999 Apr; 70(4):340–5

Heat stress–induced B1 receptor synthesis in the rat: an ex vivo study. Lagneux C, et al. **Br J Pharmacol** 1998 Oct; 125(4):812–6

MORTALITY

A comparative analysis of heat waves and associated mortality in St. Louis, Missouri—1980 and 1995. Smoyer KE. **Int J Biometeorol** 1998 Aug;42(1):44–50

PATHOLOGY

Effect of heat stress on rabbit esophageal epithelium. Tobey NA, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1322–30

PHYSIOPATHOLOGY

Can gender differences during exercise–heat stress be assessed by the physiological strain index? Moran DS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1798–804

Heat balance when wearing protective clothing. Havenith G. **Ann Occup Hyg** 1999 Jul;43(5):289–96 (11 ref.)

Clothing evaporative heat resistance—proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339–46 (17 ref.). Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

Clothing convective heat exchange—proposal for improved prediction in standards and models [see comments] Holmér I, et al. **Ann Occup Hyg** 1999 Jul;43(5):329–37. Comment in: Ann Occup Hyg 1999 Jul;43(5):347–52.

The effects of wind and human movement on the heat and vapour transfer properties of clothing [comment] Parsons KC, et al. **Ann Occup Hyg** 1999 Jul;43(5):347–52. Comment on: Ann Occup Hyg 1999 Jul;43(5):329–38. Comment on: Ann Occup Hyg 1999 Jul;43(5):339–46.

Thermal regulation in the heat during exercise after caffeine and ephedrine ingestion. Bell DG, et al. **Aviat Space Environ Med** 1999 Jun;70(6):583–8

Comparison of short-term aerobic training and high aerobic power on tolerance to uncompensable heat stress. Cheung SS, et al. **Aviat Space Environ Med** 1999 Jul;70(7):637–43

Modeling analysis of women litter bearers during heat stress. Santee WR, et al. **Aviat Space Environ Med** 1999 Apr; 70(4):340–5

Role of radical oxygen species in rat testicular germ cell apoptosis induced by heat stress. Ikeda M, et al. **Biol Reprod** 1999 Aug;61(2):393–9

Effects of dehydration, hypohydration, and hyperhydration on tolerance during uncompensable heat stress. McLellan TM, et al. **Can J Appl Physiol** 1999 Aug;24(4):349–61

Influence of menstrual cycle and oral contraceptives on tolerance to uncompensable heat stress. Tenaglia SA, et al. **Eur J Appl Physiol** 1999 Jul;80(2):76–83

Age and renal prostaglandin inhibition during exercise and heat stress. Farquhar WB, et al. **J Appl Physiol** 1999 Jun; 86(6):1936–43

Low doses of melatonin and diurnal effects on thermoregulation and tolerance to uncompensable heat stress. McLellan TM, et al. **J Appl Physiol** 1999 Jul; 87(1):308–16

The free-convective anomaly. Steadman RG. **J Appl Physiol** 1999 Jul;87(1):54–73

Early and delayed cardioprotection by heat stress is mediated by calcitonin gene-related peptide. Song QJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):477–83

[Selective brain cooling] Corrard F. **Arch Pediatr** 1999 Jan; 6(1):87–92 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Thermal characteristics of clothing ensembles for use in heat stress analysis. Barker DW, et al. **Am Ind Hyg Assoc J** 1999 Jan–Feb;60(1):32–7

Effects of a novel ice-cooling technique on work in protective clothing at 28 degrees C, 23 degrees C, and 18 degrees C WBGTs. Muir IH, et al. **Am Ind Hyg Assoc J** 1999 Jan–Feb;60(1):96–104

Protective clothing and heat stress: introduction. Crockford GW. **Ann Occup Hyg** 1999 Jul;43(5):287–8

Heat stress and flame protective clothing in mine rescue brigadesmen: inter- and intraindividual variation of strain. Kampmann B, et al. **Ann Occup Hyg** 1999 Jul;43(5):357–65

Strategy for evaluation and prevention of risk due to work in thermal environments. Malchaire J, et al. **Ann Occup Hyg** 1999 Jul;43(5):367–76 (15 ref.)

Prediction of workplace wet bulb global temperature. Bernard TE, et al. **Appl Occup Environ Hyg** 1999 Feb; 14(2):126–34

Continuing the search for WBGT clothing adjustment factors. O'Connor DJ, et al. **Appl Occup Environ Hyg** 1999 Feb;14(2):119–25

Comparison of short-term aerobic training and high aerobic power on tolerance to uncompensable heat stress. Cheung SS, et al. **Aviat Space Environ Med** 1999 Jul;70(7):637–43

Efficacy of air and liquid cooling during light and heavy exercise while wearing NBC clothing. McLellan TM, et al. **Aviat Space Environ Med** 1999 Aug;70(8):802–11

Effectiveness of rest pauses and cooling in alleviation of heat stress during simulated fire-fighting activity. Carter JB, et al. **Ergonomics** 1999 Feb;42(2):299–313

Appropriateness of international heat stress standards for use in tropical agricultural environments. McNeill MB, et al. **Ergonomics** 1999 Jun;42(6):779–97

Low doses of melatonin and diurnal effects on thermoregulation and tolerance to uncompensable heat stress. McLellan TM, et al. **J Appl Physiol** 1999 Jul; 87(1):308–16

Fluid replacement recommendations for training in hot weather. Montain SJ, et al. **Mil Med** 1999 Jul;164(7):502–8

Finding the comfort zone. Luther E. **Occup Health Saf** 1999 Mar;68(3):50–2, 54–6

A dangerous misconception. Quiett SC. **Occup Health Saf** 1999 May;68(5):104–6

Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Kiang JG, et al. **Pharmacol Ther** 1998 Nov; 80(2):183–201 (94 ref.)

PSYCHOLOGY

Heat shock disrupts long-term memory consolidation in Caenorhabditis elegans. Beck CD, et al. **Learn Mem** 1995 May–Aug;2(3–4):161–77

THERAPY

[Selective brain cooling] Corrard F. **Arch Pediatr** 1999 Jan; 6(1):87–92 (26 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Cattle deaths spark call for 'black boxes' [news] **Aust Vet J** 1998 Sep;76(9):587

Effect of whole wheat and heat stress on a coccidial infection in broiler chickens. Banfield MJ, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S25–6

Optimum dietary arginine:lysine ratio for broiler chickens is altered during heat stress in association with changes in intestinal uptake and dietary sodium chloride. Brake J, et al. **Br Poult Sci** 1998 Dec;39(5):639–47

Vitamin E can alleviate the depressed egg production of heat-stressed laying hens. Whitehead CC, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S44–6

Nitroblue tetrazolium reduction of neutrophils in heat stressed goats is not influenced by selenium and vitamin E injection. Katamoto H, et al. **J Vet Med Sci** 1998 Nov; 60(11):1243–9

HEAT STRESS SYNDROMES see **HEAT STRESS DISORDERS**

HEAT STROKE

Heatstroke in runners in Oklahoma. Coniglione T. **J Okla State Med Assoc** 1998 Nov;91(8):446–8

COMPLICATIONS

Acute renal failure during heat waves. Semenza JC. **Am J Prev Med** 1999 Jul;17(1):97

Features and outcomes of classic heat stroke [letter; comment] Bouchama A. **Ann Intern Med** 1999 Apr 6; 130(7):613; discussion 614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Cerebral hemorrhage complicating exertional heat stroke. Boersma LV, et al. **Clin Neurol Neurosurg** 1998 Jun; 100(2):112–5

Disseminated zygomycosis due to Rhizopus schipperae after heatstroke. Anstead GM, et al. **J Clin Microbiol** 1999 Aug; 37(8):2656–62

Guillain-Barré syndrome after heat stroke [letter] Pfeiffer G, et al. **J Neurol Neurosurg Psychiatry** 1999 Mar;66(3):408

EPIDEMIOLOGY

Exertional heat stroke: a case series. Epstein Y, et al. **Med Sci Sports Exerc** 1999 Feb;31(2):224–8

ETIOLOGY

Occupational heat exposure. Adelakun A, et al. **Appl Occup Environ Hyg** 1999 Mar;14(3):153–4

Fatal heatstroke in a young woman with previously undiagnosed Hashimoto's thyroiditis. Siegler RW. **J Forensic Sci** 1998 Nov;43(6):1237–40

Heat-related illness. Duthie DJ. **Lancet** 1998 Oct 24; 352(9137):1329–30

IMMUNOLOGY

Elevated serum level of soluble interleukin-2 receptor in heatstroke [letter] Hammami MM, et al. **Intensive Care Med** 1998 Sep;24(9):988

METABOLISM

Explosive increase in Na+ entry to acidified cells at elevated temperature. Evidence for the energy depletion model of heat stroke? Willis JS, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:304–6

Nitric oxide production is enhanced in patients with heat stroke. Alzeer AH, et al. **Intensive Care Med** 1999 Jan; 25(1):58–62

Heatstroke induces c-fos expression in the rat hypothalamus. Tsay HJ, et al. **Neurosci Lett** 1999 Feb 26;262(1):41–4

Heat shock protein expression protects against death following exposure to heatstroke in rats. Yang YL, et al. **Neurosci Lett** 1998 Aug 7;252(1):9–12

[Distribution of 70kDa heat shock protein in rabbit brains after heat stress and heat stroke] Tan M, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Feb;26(1):38–40 (Eng. Abstr.) **(Chi)**

PATHOLOGY

Botryoid neutrophils in unexpected heat stroke [letter] Kitazawa K, et al. **Arch Dis Child** 1999 Aug;81(2):189

PHYSIOPATHOLOGY

Heat shock protein expression protects against cerebral ischemia and monoamine overload in rat heatstroke. Yang YL, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1961–7

PREVENTION & CONTROL

Occupational heat exposure. Adelakun A, et al. **Appl Occup Environ Hyg** 1999 Mar;14(3):153–4

THERAPY

Features and outcomes of classic heat stroke [letter; comment] Graham BS. **Ann Intern Med** 1999 Apr 6; 130(7):613–4; discussion 614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Features and outcomes of classic heat stroke [letter; comment] Slovis CM. **Ann Intern Med** 1999 Apr 6; 130(7):614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Efficacy of blood purification therapy for heat stroke presenting rapid progress of multiple organ dysfunction syndrome: a comparison of five cases. Ikeda Y, et al. **Intensive Care Med** 1999 Mar;25(3):315–8

HEAT WAVES see **INFRARED RAYS**

HEATING

A pilot study of the effect of mechanical ventilation and heat exchange on house-dust mites and Der p 1 in New Zealand homes. Crane J, et al. **Allergy** 1998 Aug;53(8):755–62

Heating oil company responses to inquiries concerning carbon monoxide toxicity. Drescher MJ, et al. **Ann Emerg Med** 1999 Apr;33(4):406–8

Heating of tissues by microwaves: a model analysis. Foster KR, et al. **Bioelectromagnetics** 1998;19(7):420–8

PCDD/F- and PAH-emission from house heating systems. Launhardt T, et al. **Chemosphere** 1998 Oct–Nov; 37(9–12):2013–20

Indoor biofuel air pollution and respiratory health: the role of confounding factors among women in highland Guatemala. Bruce N, et al. **Int J Epidemiol** 1998 Jun; 27(3):454–8

The effect of farrowing crate heat lamp location on sow and pig patterns of lying and pig survival. Hrupka BJ, et al. **J Anim Sci** 1998 Dec;76(12):2995–3002

Survival of Listeria monocytogenes in sea water and effect of exposure on thermal resistance. Bremer PJ, et al. **J Appl Microbiol** 1998 Sep;85(3):545–53

Decontamination of drinking water by direct heating in solar panels. Fjendbo Jørgensen AJ, et al. **J Appl Microbiol** 1998 Sep;85(3):441–7

Synergistic antibacterial action of heat in combination with nisin and magainin II amide. Ueckert JE, et al. **J Appl Microbiol** 1998 Sep;85(3):487–94

ADVERSE EFFECTS

Safety investigation: interaction of infant radiant warmers and bilirubin phototherapy lights in the regulation of temperature of newborn infants. O'Dea TJ, et al. **Biomed Instrum Technol** 1998 Jul–Aug;32(4):355–69

Indoor, outdoor, and regional summer and winter concentrations of PM10, PM2.5, SO4(2)-, H+, NH4+, NO3-, NH3, and nitrous acid in homes with and without kerosene space heaters. Leaderer BP, et al. **Environ Health Perspect** 1999 Mar;107(3):223–31

Cardiovascular catheters and accessories: ex vivo testing of ferromagnetism, heating, and artifacts associated with MRI. Shellock FG, et al. **J Magn Reson Imaging** 1998 Nov–Dec; 8(6):1338–42

Sudden infant death syndrome [letter; comment] Dallas R. **N Z Med J** 1998 Aug 28;111(1072):327–8. Comment on: N Z Med J 1998 Jun 26;111(1068):219–21.

[Methods of risk assessment in transit of chemicals from water to air in disaster situations] Krasovskiĭ GN, et al. **Gig Sanit** 1999 Jul–Aug;(4):58–61 **(Rus)**

INSTRUMENTATION

Oesophageal heat exchanger in the prevention of perioperative hypothermia [letter; comment] Bräuer A, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1232–3.

HEATING

Comment on: Acta Anaesthesiol Scand 1998 Mar;42(3):348–52.
Safety investigation: interaction of infant radiant warmers and bilirubin phototherapy lights in the regulation of temperature of newborn infants. O'Dea TJ, et al. **Biomed Instrum Technol** 1998 Jul–Aug;32(4):355–69

METHODS

Buildings operations and ETS exposure. Spengler JD. **Environ Health Perspect** 1999 May;107 Suppl 2:313–7 (18 ref.)
An ergonomics investigation into human thermal comfort using an automobile seat heated with encapsulated carbonized fabric (ECF). Brooks JE, et al. **Ergonomics** 1999 May;42(5):661–73
Influence of localized auxiliary heating on hand comfort during cold exposure. Brajkovic D, et al. **J Appl Physiol** 1998 Dec;85(6):2054–65
Exposure to air pollution from transitional household fuels in a South African population. Terblanche AP, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:15–22
Efficacy and safety of heat exchanger added to venovenous bypass circuit during orthotopic liver transplantation. Neelakanta G, et al. **Liver Transpl Surg** 1998 Nov; 4(6):506–9

HEAVY CHAIN DISEASE

see related
IMMUNOGLOBULINS, HEAVY-CHAIN

[Heavy chain disease] Mori M. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):464–7 (13 ref.) **(Jpn)**

COMPLICATIONS

Renal and cardiac manifestations of B-cell dyscrasias with nonamyloidotic monoclonal light chain and light and heavy chain deposition diseases. Gallo GR, et al. **Adv Nephrol Necker Hosp** 1998;28:355–82 (51 ref.)
Heavy chain deposition disease: the disease spectrum. Kambham N, et al. **Am J Kidney Dis** 1999 May; 33(5):954–62 (26 ref.)
A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. Witzens M, et al. **Ann Hematol** 1998 Nov;77(5):231–4

ETIOLOGY

[Gamma-heavy chain disease associated with MALT lymphoma of the duodenum] Ieko M, et al. **Rinsho Ketsueki** 1998 Jul;39(7):512–8 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Electrophoretic analyses in a case of monoclonal gamma chain disease. Tissot JD, et al. **Electrophoresis** 1998 Jul; 19(10):1771–3
IgG heavy-chain deposition disease affecting kidney, skin, and skeletal muscle. Rott T, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1825–8

PATHOLOGY

Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. Moulin B, et al. **J Am Soc Nephrol** 1999 Mar;10(3):519–28
IgG heavy-chain deposition disease affecting kidney, skin, and skeletal muscle. Rott T, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1825–8

HEAVY CHAIN DISEASE, IGA TYPE see **IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE**

HEAVY INDUSTRIES see **METALLURGY**

HEAVY IONS

Inhibition in a microgravity environment of the recovery of Escherichia coli cells damaged by heavy ion beams during the NASDA ISS phase I program of NASA Shuttle/Mir mission no. 6. Harada K, et al. **Int J Mol Med** 1998 May;1(5):817–22
Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Ando K, et al. **Int J Radiat Biol** 1999 Apr;75(4):505–12
Carbon beam dosimetry intercomparison at HIMAC. Fukumura A, et al. **Phys Med Biol** 1998 Dec;43(12):3459–63
Initial recombination in a parallel-plate ionization chamber exposed to heavy ions. Kanai T, et al. **Phys Med Biol** 1998 Dec;43(12):3549–58
Heavy-ion radiobiology: new approaches to delineate mechanisms underlying enhanced biological effectiveness. Blakely EA, et al. **Radiat Res** 1998 Nov;150(5 Suppl):S126–45 (264 ref.)
Lethal effect of carbon K-shell photoionizations in Chinese hamster V79 cell nuclei: experimental method and theoretical analysis. Herve du Penhoat MA, et al. **Radiat Res** 1999 Jun;151(6):649–58

ADVERSE EFFECTS

Complex hprt deletion events are recovered after exposure of human lymphoblastoid cells to high-LET carbon and neon ion beams. Kagawa Y, et al. **Mutagenesis** 1999 Mar; 14(2):199–205
DNA double-strand breaks in mammalian cells exposed to gamma-rays and very heavy ions. Fragment-size distributions determined by pulsed-field gel electrophoresis. Kraxenberger F, et al. **Radiat Environ Biophys** 1998 Jul;37(2):107–15
Investigation of lipid peroxidation in liposomes induced by heavy ion irradiation. Ziegler C, et al. **Radiat Environ Biophys** 1998 Jul;37(2):95–100

THERAPEUTIC USE

Cell death induced by high-linear-energy transfer carbon beams in human glioblastoma cell lines. Tsuchida Y, et al. **Brain Tumor Pathol** 1998;15(2):71–6
Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Kanai T, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):201–10

HEAVY METALS see **METALS, HEAVY**

HEAVY WATER see **DEUTERIUM OXIDE**

HEBEPHRENIC SCHIZOPHRENIA see **SCHIZOPHRENIA, DISORGANIZED**

HECK'S DISEASE see **FOCAL EPITHELIAL HYPERPLASIA**

HEDGEHOGS

Hedgehog hives. Fairley JA, et al. **Arch Dermatol** 1999 May; 135(5):561–3
Intestinal lymphosarcoma in captive African hedgehogs. Raymond JT, et al. **J Wildl Dis** 1998 Oct;34(4):801–6
Hedgehog rehabilitation in perspective. Morris PA. **Vet Rec** 1998 Dec 5;143(23):633–6
Paralysis in hedgehogs (Erinaceus europaeus) associated with demyelination. Palmer AC, et al. **Vet Rec** 1998 Nov 14; 143(20):550–2

ANATOMY & HISTOLOGY

Trigeminal projections to thalamus and subthalamus in the hedgehog tenrec. Künzle H. **Neuroscience** 1998 Sep; 86(2):651–61

GENETICS

Genetic differentiation among local populations of the European hedgehog (Erinaceus europaeus) in mosaic habitats. Becher SA, et al. **Mol Ecol** 1998 Nov; 7(11):1599–604
Expression of sonic hedgehog gene in regenerating newt limbs. Imokawa Y, et al. **Wound Repair Regen** 1998 Jul–Aug;6(4):366–70 (22 ref.)

METABOLISM

The role of hedgehog proteins in vertebrate slow and fast skeletal muscle patterning. Hughes SM, et al. **Acta Physiol Scand** 1998 Jul;163(3):S7–10 (39 ref.)
Distribution of acetylcholinesterase and choline acetyltransferase in the main and accessory olfactory bulbs of the hedgehog (Erinaceus europaeus). Crespo C, et al. **J Comp Neurol** 1999 Jan 5;403(1):53–67
Fiber digestion in the African white-bellied hedgehog (Atelerix albiventris): a preliminary evaluation. Graffam WS, et al. **J Nutr** 1998 Dec;128(12 Suppl):2671S–2673S

MICROBIOLOGY

[A molecular epidemiologic investigation of north Asia fever in scenic spots of Beijing suburb] Chen M, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):197–200 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Thalamic territories innervated by cerebellar nuclear afferents in the hedgehog tenrec, Echinops telfairi. Künzle H. **J Comp Neurol** 1998 Dec 21;402(3):313–26
Schwann cell-derived Desert hedgehog controls the development of peripheral nerve sheaths [see comments] Parmantier E, et al. **Neuron** 1999 Aug;23(4):713–24. Comment in: Neuron 1999 Aug;23(4):627–9.
Creating barriers: a new role for Schwann cells and Desert hedgehog [comment] Salzer JL. **Neuron** 1999 Aug; 23(4):627–9. Comment on: Neuron 1999 Aug;23(4):713–24.
Active suppression of interneuron programs within developing motor neurons revealed by analysis of homeodomain factor HB9 [see comments] Thaler J, et al. **Neuron** 1999 Aug;23(4):675–87. Comment in: Neuron 1999 Aug;23(4):626–7.
Unrolling hedgehogs [letter] Scott WA. **Vet Rec** 1999 May 29;144(22):624

HEDONISM see **PHILOSOPHY**

HEEL

see related
ACHILLES TENDON
CALCANEUS
TALUS

Plantar fasciitis and other causes of heel pain. Barrett SJ, et al. **Am Fam Physician** 1999 Apr 15;59(8):2200–6 (19 ref.)
In-shoe pressure measurements with a viscoelastic heel orthosis. Hsi WL, et al. **Arch Phys Med Rehabil** 1999 Jul; 80(7):805–10
Pain-relieving effect of sucrose in newborns during heel prick. Overgaard C, et al. **Biol Neonate** 1999 May; 75(5):279–84
Diagnosing and treating plantar fasciitis: a conservative approach to plantar heel pain. Tisdel CL, et al. **Cleve Clin J Med** 1999 Apr;66(4):231–5 (11 ref.)
The relationship of heel pad elasticity and plantar heel pain. Turgut A, et al. **Clin Orthop** 1999 Mar;(360):191–6
Metastatic breast cancer presenting as heel pain. Groves MJ, et al. **J Am Podiatr Med Assoc** 1998 Aug;88(8):400–5
Management of heel pain syndrome with acetic acid iontophoresis. Japour CJ, et al. **J Am Podiatr Med Assoc** 1999 May;89(5):251–7
Heel pain in children. Diagnosis and treatment. Kim CW, et al. **J Am Podiatr Med Assoc** 1999 Feb;89(2):67–74 (73 ref.)
Infectious causes of heel pain. Kosinski M, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):20–3 (33 ref.)
Enthesitis, arthritis, and heel pain. Lehman TJ. **J Am Podiatr Med Assoc** 1999 Jan;89(1):18–9
Problems and management of the rearfoot in neuromuscular disease. A report of ten cases. Sobel E, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):24–38 (71 ref.)
Orthoses in the treatment of rearfoot problems. Sobel E, et al. **J Am Podiatr Med Assoc** 1999 May;89(5):220–33 (151 ref.)
Long-term follow-up of heel spur surgery. A 10-year retrospective study. Vohra PK, et al. **J Am Podiatr Med Assoc** 1999 Feb;89(2):81–8
Mechanical properties of heel pads reconstructed with flaps. Wang CL, et al. **J Bone Joint Surg Br** 1999 Mar; 81(2):207–11
Percutaneous plantar fasciotomy: a minimally invasive procedure for recalcitrant plantar fasciitis. Benton-Weil W, et al. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):269–72
Entrapment neuropathy: the etiology of intractable chronic heel pain syndrome. Hendrix CL, et al. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):273–9
Heel pain syndrome [letter; comment] Skliar JD. **J Foot Ankle Surg** 1998 Nov–Dec;37(6):548–9. Comment on: J Foot Ankle Surg 1998 Jul–Aug;37(4):267–8.
The heel pain syndrome [editorial] [see comments] Weil LS Sr. **J Foot Ankle Surg** 1998 Jul–Aug;37(4):267–8. Comment in: J Foot Ankle Surg 1998 Nov–Dec;37(6):548–9.
Characterization of the calcaneal fat pad in diabetic and non-diabetic patients using magnetic resonance imaging. Kao PF, et al. **Magn Reson Imaging** 1999 Jul;17(6):851–7
Lateral calcaneal V-Y advancement flap for repair of posterior heel defects. Hayashi A, et al. **Plast Reconstr Surg** 1999 Feb;103(2):577–80
Unusual heel pain in a patient with primary oxalosis treated by liver-kidney transplantation [letter] Javier RM, et al. **Rev Rhum Engl Ed** 1998 Jul–Sep;65(7–9):517–8
[Combined tibio-talar and subtalar arthrodesis by retrograde nail in hindfoot rheumatoid arthritis] Madezo P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(7):646–52 (Eng. Abstr.) **(Fre)**
[Extracorporeal shockwave therapy in heel spur--analysis of the literature] Heller KD. **Z Orthop Ihre Grenzgeb** 1999 Mar–Apr;137(2):Oa13–5 **(Ger)**
[5-years lithotripsy of plantar of plantar heel spur: experiences and results--a follow-up study after 36.9 months] Sistermann R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct;136(5):402–6 (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Architecture of the cancellous bone of the human talus. Pal GP, et al. **Anat Rec** 1998 Oct;252(2):185–93

BLOOD SUPPLY

Combined pedicle and free-tissue transfer to improve functional restoration of the foot: the "backpack principle". Germann G, et al. **J Reconstr Microsurg** 1999 Aug; 15(6):409–13
Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. Berceli SA, et al. **J Vasc Surg** 1999 Sep;30(3):499–508
Heel-skin microvascular blood perfusion responses to sustained pressure loading and unloading. Mayrovitz HN, et al. **Microcirculation** 1998;5(2–3):227–33

INJURIES

Golfer's heel. Baquie P. **Aust Fam Physician** 1998 Aug; 27(8):727–8
Heel replantation. Macionis V. **Br J Plast Surg** 1998 Sep; 51(6):473–5
Spontaneous calcaneal fracture after deep heel burns with diabetes. Matsumura H, et al. **Burns** 1998 Nov;24(7):683–6
Management of pain from heel lance with lidocaine-prilocaine (EMLA) cream: is it safe and efficacious in preterm infants? Stevens B, et al. **J Dev Behav Pediatr** 1999 Aug;20(4):216–21
Radiology case of the month. Painful heel following exercise. Lipoma of the os-calcis. Neitzschman HR. **J La State Med Soc** 1998 Sep;150(9):407–8
[Three kinds of distally based fascial flap containing deep

fascial vessel network on the posterior calf] Zhang Z, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Nov;11(6):356–8 (Eng. Abstr.) **(Chi)**
[Imaging of the ankle and back of the foot in athletes] Tavernier T. **J Radiol** 1999 Jun;80(6 Suppl):658–70 (Eng. Abstr.) **(Fre)**
[Management of Achilles tendon rupture] Thermann H. **Orthopade** 1999 Jan;28(1):82–97 **(Ger)**

INNERVATION

Heel lancing in term new-born infants: an evaluation of pain by frequency domain analysis of heart rate variability. Lindh V, et al. **Pain** 1999 Mar;80(1–2):143–8

PATHOLOGY

Magnetic resonance imaging evaluation of heel pain. Karr JC. **J Am Podiatr Med Assoc** 1999 Jul;89(7):364–7
Imaging of the rearfoot. Yozsa S, et al. **J Am Podiatr Med Assoc** 1999 Jun;89(6):292–301 (52 ref.)
[Radio-anatomy markers and applications of current imaging of the ankle and back of the foot] Morvan G. **J Radiol** 1999 Jun;80(6 Suppl):652–7 (Eng. Abstr.) **(Fre)**
[Two-stage method of surgical flaps as the choice method in the surgery of replacing defects of limb tissues in unusual clinical situations] Galich SP. **Klin Khir** 1998;(8):47–8 **(Rus)**

PHYSIOLOGY

Use of computerized insole sensor system to evaluate the efficacy of a modified ankle-foot orthosis for redistributing heel pressures. Randolph AL, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):801–4
Effect of ankle and knee position on tension in the Achilles tendon. Davis WL Jr, et al. **Foot Ankle Int** 1999 Feb; 20(2):126–31
Natural history of the rearfoot angle: preliminary values in 150 children. Sobel E, et al. **Foot Ankle Int** 1999 Feb; 20(2):119–25
Effect of ankle dorsiflexion range of motion on rearfoot motion during walking. Cornwall MW, et al. **J Am Podiatr Med Assoc** 1999 Jun;89(6):272–7
Reevaluation of the relaxed calcaneal stance position. Reliability and normal values in children and adults. Sobel E, et al. **J Am Podiatr Med Assoc** 1999 May;89(5):258–64

PHYSIOPATHOLOGY

Continuum of reflex excitability in hemiplegia: influence of muscle length and muscular transformation after heel-cord lengthening and immobilization on the pathophysiology of spasticity and clonus. Lin JP, et al. **Dev Med Child Neurol** 1999 Aug;41(8):534–48
A comparative study of the Podotrack, a simple semiquantitative plantar pressure measuring device, and the optical pedobarograph in the assessment of pressures under the diabetic foot. van Schie CH, et al. **Diabet Med** 1999 Feb;16(2):154–9
Clinical correlates of plantar pressure among diabetic veterans. Ahroni JH, et al. **Diabetes Care** 1999 Jun; 22(6):965–72
Total contact casts and removable cast walkers. Mitigation of plantar heel pressure. Armstrong DG, et al. **J Am Podiatr Med Assoc** 1999 Jan;89(1):50–3
[Results of analgetic radiotherapy of inflammation of the calcaneus using 6 MV photons] Heyd R, et al. **Rontgenpraxis** 1999;52(1):26–32 **(Ger)**

RADIOGRAPHY

Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Taal MW, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1917–21

SURGERY

Lateral supramalleolar flap for heel coverage in a patient with Werner's syndrome. Okazaki M, et al. **Ann Plast Surg** 1998 Sep;41(3):307–10
Heel replantation. Macionis V. **Br J Plast Surg** 1998 Sep; 51(6):473–5
Use of the lamina spreader for reduction of the subtalar joint during hindfoot surgery. Oppenheim JR, et al. **Foot Ankle Int** 1999 Aug;20(8):538
Combined pedicle and free-tissue transfer to improve functional restoration of the foot: the "backpack principle". Germann G, et al. **J Reconstr Microsurg** 1999 Aug; 15(6):409–13
Reconstruction of ankle and heel defects by a modified wide-base reverse sural flap. Tu YK, et al. **J Trauma** 1999 Jul;47(1):82–8
[Lower limb stump reconstruction with a functional calcaneo-plantar unit free flap. A series of 16 cases] Malikov S, et al. **Ann Chir Plast Esthet** 1999 Apr; 44(2):163–74 (Eng. Abstr.) **(Fre)**
[Two-stage method of surgical flaps as the choice method in the surgery of replacing defects of limb tissues in unusual clinical situations] Galich SP. **Klin Khir** 1998;(8):47–8 **(Rus)**

ULTRASONOGRAPHY

Prediction of the strength of the elderly proximal femur by bone mineral density and quantitative ultrasound measurements of the heel and tibia. Bouxsein ML, et al. **Bone** 1999 Jul;25(1):49–54
Ultrasonic heel pad thickness measurements: a preliminary study. Rome K, et al. **Br J Radiol** 1998 Nov; 71(851):1149–52
Ultrasonographic assessment of posterior heel pain. Wang CL, et al. **J Formos Med Assoc** 1999 Jan;98(1):56–61
Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Taal MW, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1917–21
Stiffness in discrimination of patients with vertebral fractures. Mikhail MB, et al. **Osteoporos Int** 1999;9(1):24–8
Quantitative heel ultrasound in 3180 women between 45 and 75 years of age: compliance, normal ranges and relationship to fracture history. Thompson P, et al. **Osteoporos Int** 1998; 8(3):211–4
Ultrasound of the plantar aponeurosis (fascia). Gibbon WW, et al. **Skeletal Radiol** 1999 Jan;28(1):21–6

HEERFORDT SYNDROME see **UVEOPAROTID FEVER**

HEINZ BODIES

Heinz bodies interfere with automated reticulocyte counts. Español I, et al. **Haematologica** 1999 Apr;84(4):373–4

HELA CELLS

Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Macville M, et al. **Cancer Res** 1999 Jan 1;59(1):141–50

CHEMISTRY

Molecular characterization of an inwardly rectifying K+ channel from HeLa cells. Klein H, et al. **J Membr Biol** 1999 Jan 1;167(1):43–52
A rapid preparation of extracts for DNA replication in vitro. Wang Y, et al. **Radiat Res** 1999 Jan;151(1):59–62

CYTOLOGY

A society of goal-oriented agents for the analysis of living cells. Boucher A, et al. **Artif Intell Med** 1998 Sep-Oct; 14(1–2):183–99
The induction of apoptosis in HeLa cells by the loss of LBP-p40. Kaneda Y, et al. **Cell Death Differ** 1998 Jan; 5(1):20–8
Distinct roles of profilin in cell morphological changes: microspikes, membrane ruffles, stress fibers, and cytokinesis. Suetsugu S, et al. **FEBS Lett** 1999 Sep 3; 457(3):470–4

DRUG EFFECTS

Thiol and redox reactive agents exert different effects on glutathione metabolism in HeLa cell cultures. Hultberg B, et al. **Clin Chim Acta** 1999 May;283(1–2):21–32
Confluence dependent resistance to photo-activated hypericin in HeLa cells. Delaey EM, et al. **Int J Oncol** 1999 Apr;14(4):759–63
The effect of different solvents on the ATP/ADP content and growth properties of HeLa cells. Forman S, et al. **J Biochem Mol Toxicol** 1999;13(1):11–5
[The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine] Mose S, et al. **Strahlenther Onkol** 1999 Feb;175(2):78–83 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Effect of human seminal fluid on production of messenger ribonucleic acid for metalloproteinase 2 and metalloproteinase 9 in cervical epithelial carcinoma cells. Jeremias J, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):591–5
A drug-responsive and protease-resistant peripheral NADH oxidase complex from the surface of HeLa S cells. del Castillo-Olivares A, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):125–40
Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells. Gromova I, et al. **Biochemistry** 1998 Nov 24;37(47):16645–52
Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A. Kilic F, et al. **FEBS Lett** 1999 Apr 30;450(1–2):61–5
High-level expression of rat class I alcohol dehydrogenase is sufficient for ethanol-induced fat accumulation in transduced HeLa cells. Galli A, et al. **Hepatology** 1999 Apr; 29(4):1164–70
Prereplicative increase of nuclear matrix-bound DNA polymerase-alpha and primase activities in HeLa S3 cells following dilution of long-term cultures. Martelli AM, et al. **J Cell Biochem** 1998 Oct 1;71(1):11–20
Quantitation of RNA polymerase II and its transcription factors in an HeLa cell: little soluble holoenzyme but significant amounts of polymerases attached to the nuclear substructure. Kimura H, et al. **Mol Cell Biol** 1999 Aug; 19(8):5383–92
Rpp14 and Rpp29, two protein subunits of human ribonuclease P. Jarrous N, et al. **RNA** 1999 Feb;5(2):153–7

IMMUNOLOGY

CD 80(B7-1) expression on human tumor cell lines and its costimulatory signals for T cell proliferation and cytokine production. Yan J, et al. **Chin Med J (Engl)** 1998 Mar; 111(3):269–71

METABOLISM

The hCSE1/CAS protein is phosphorylated by HeLa extracts and MEK-1: MEK-1 phosphorylation may modulate the intracellular localization of CAS. Scherf U, et al. **Biochem Biophys Res Commun** 1998 Sep 29; 250(3):623–8
Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells. Wenning LA, et al. **Biotechnol Bioeng** 1998 Feb 20; 57(4):484–96
Role of calreticulin in regulating intracellular Ca2+ storage and capacitative Ca2+ entry in HeLa cells. Llewelyn Roderick H, et al. **Cell Calcium** 1998 Oct;24(4):253–62
Thiol and redox reactive agents exert different effects on glutathione metabolism in HeLa cell cultures. Hultberg B, et al. **Clin Chim Acta** 1999 May;283(1–2):21–32
High-level expression of rat class I alcohol dehydrogenase is sufficient for ethanol-induced fat accumulation in transduced HeLa cells. Galli A, et al. **Hepatology** 1999 Apr; 29(4):1164–70
Expression of the EspB protein of enteropathogenic Escherichia coli within HeLa cells affects stress fibers and cellular morphology. Taylor KA, et al. **Infect Immun** 1999 Jan;67(1):120–5
Immunocytochemical study of endocytotic structures accumulated in HeLa cells transformed with a temperature-sensitive mutant of dynamin. Baba T, et al. **J Histochem Cytochem** 1999 May;47(5):637–48
1H-MRS lipid signal modulation and morphological and ultrastructural changes related to tumor cell proliferation. Rosi A, et al. **Magn Reson Med** 1999 Aug;42(2):248–57
HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Zhang CC, et al. **Mol Endocrinol** 1999 Apr;13(4):632–43

MICROBIOLOGY

Expression of the EspB protein of enteropathogenic Escherichia coli within HeLa cells affects stress fibers and cellular morphology. Taylor KA, et al. **Infect Immun** 1999 Jan;67(1):120–5
Protein kinase C activation and vacuolation in HeLa cells invaded by Mycoplasma penetrans. Borovsky Z, et al. **J Med Microbiol** 1998 Oct;47(10):915–22

PATHOLOGY

1H-MRS lipid signal modulation and morphological and ultrastructural changes related to tumor cell proliferation. Rosi A, et al. **Magn Reson Med** 1999 Aug;42(2):248–57

RADIATION EFFECTS

Delayed DNA damage associated with mitotic catastrophe following X-irradiation of HeLa S3 cells. Ianzini F, et al. **Mutagenesis** 1998 Jul;13(4):337–44
[The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine] Mose S, et al. **Strahlenther Onkol** 1999 Feb;175(2):78–83 (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonically induced alterations of cultured tumour cells. Hrazdira I, et al. **Eur J Ultrasound** 1998 Sep;8(1):43–9

ULTRASTRUCTURE

Immunocytochemical study of endocytotic structures accumulated in HeLa cells transformed with a temperature-sensitive mutant of dynamin. Baba T, et al. **J Histochem Cytochem** 1999 May;47(5):637–48

VIROLOGY

Rhinovirus replication in HeLa cells cultured under conditions of simulated microgravity. Long JP, et al. **Aviat Space Environ Med** 1998 Sep;69(9):851–6
Suppression of tumorigenicity in cervical carcinoma HeLa cells by an episomal form of adeno-associated virus. Wu FY, et al. **Int J Oncol** 1999 Jul;15(1):101–6
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Dunster LM, et al. **Virology** 1999 Sep 1;261(2):309–18

HELIANTHUS

Effect of chicken age on the nutritive value of diets with graded additions of full-fat sunflower seed. Ortiz LT, et al. **Br Poult Sci** 1998 Sep;39(4):530–5
Thiamin-binding protein from sunflower seeds. Watanabe K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Oct;44(5):665–72
Effect of chemical composition of sunflower seed meal on its true metabolizable energy and amino acid digestibility. Villamide MJ, et al. **Poult Sci** 1998 Dec;77(12):1884–92
[Evaluation of rheological and sensorial characteristics of breads prepared with a mix of sunflower protein concentrate and texturized soy protein] Gómez-Juárez C, et al. **Arch Latinoam Nutr** 1998 Jun;48(2):165–8 (Eng. Abstr.) **(Spa)**

HELIANTHUS

ADVERSE EFFECTS

Occupational asthma caused by sunflower-seed dust. Vandenplas O, et al. **Allergy** 1998 Sep;53(9):907–8

CHEMISTRY

Molecular cloning, functional expression, and mutagenesis of cDNA encoding a cysteine proteinase inhibitor from sunflower seeds. Doi-Kawano K, et al. **J Biochem (Tokyo)** 1998 Nov;124(5):911–6

High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. Luckett S, et al. **J Mol Biol** 1999 Jul 9;290(2):525–33

Nutritional evaluation of Zambia indigenous soy bean (Glycine max) and sunflower (Helianthus annus) as protein sources in poultry and pigs diets. Aregheore EM. **Nahrung** 1998 Oct;42(5):298–301

CYTOLOGY

Cloning and immunological characterization of the allergen Hel a 2 (profilin) from sunflower pollen. Asturias JA, et al. **Mol Immunol** 1998 Jun;35(8):469–78

ENZYMOLOGY

The purification and characterization of fatty acid hydroperoxide lyase in sunflower. Itoh A, et al. **Biochim Biophys Acta** 1999 Jan 4;1436(3):531–40

A sphingolipid desaturase from higher plants. Identification of a new cytochrome b5 fusion protein. Sperling P, et al. **J Biol Chem** 1998 Oct 30;273(44):28590–6

GENETICS

Polyadenylation accelerates the degradation of the mitochondrial mRNA associated with cytoplasmic male sterility in sunflower. Gagliardi D, et al. **EMBO J** 1999 Jul 1;18(13):3757–66

Characterization and molecular cloning of the lectin from Helianthus tuberosus. Van Damme EJ, et al. **Eur J Biochem** 1999 Jan;259(1–2):135–42

Hybrid zones and the genetic architecture of a barrier to gene flow between two sunflower species. Rieseberg LH, et al. **Genetics** 1999 Jun;152(2):713–27

Cloning of the fructan biosynthesis pathway of Jerusalem artichoke. van der Meer IM, et al. **Plant J** 1998 Aug; 15(4):489–500

Expression of a dehydrin gene during embryo development and drought stress in ABA-deficient mutants of sunflower (Helianthus annuus L.). Giordani T, et al. **Plant Mol Biol** 1999 Mar;39(4):739–48

Cloning, sequence and characterization of a sunflower (Helianthus annuus L.) pathogen-induced gene showing sequence homology with auxin-induced genes from plants. Mazeyrat F, et al. **Plant Mol Biol** 1998 Nov;38(5):899–903

Seed-specific expression patterns and regulation by ABI3 of an unusual late embryogenesis-abundant gene in sunflower. Prieto-Dapena P, et al. **Plant Mol Biol** 1999 Feb; 39(3):615–27

Characterization of closely related delta-TIP genes encoding aquaporins which are differentially expressed in sunflower roots upon water deprivation through exposure to air. Sarda X, et al. **Plant Mol Biol** 1999 May;40(1):179–91

GROWTH & DEVELOPMENT

Expression of a dehydrin gene during embryo development and drought stress in ABA-deficient mutants of sunflower (Helianthus annuus L.). Giordani T, et al. **Plant Mol Biol** 1999 Mar;39(4):739–48

PHYSIOLOGY

Polyadenylation accelerates the degradation of the mitochondrial mRNA associated with cytoplasmic male sterility in sunflower. Gagliardi D, et al. **EMBO J** 1999 Jul 1;18(13):3757–66

HELICOBACTER

Animal models of Helicobacter gastritis. Eaton KA. **Curr Top Microbiol Immunol** 1999;241:123–54 (155 ref.)

A novel urease-negative Helicobacter species associated with colitis and typhlitis in IL-10-deficient mice. Fox JG, et al. **Infect Immun** 1999 Apr;67(4):1757–62

Helicobacter heilmannii: a spiral shaped organism other than Helicobacter pylori [editorial; comment] Haruma K. **Intern Med** 1999 Mar;38(3):217–8 (13 ref.). Comment on: Intern Med 1999 Mar;38(3):240–3.

Enterohepatic Helicobacters: natural and experimental models. Fox J. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S264–9 (58 ref.)

Healthy cats are commonly colonized with "Helicobacter heilmannii" that is associated with minimal gastritis. Norris CR, et al. **J Clin Microbiol** 1999 Jan;37(1):189–94

Transmission of Helicobacter hepaticus infection to sentinel mice by contaminated bedding. Livingston RS, et al. **Lab Anim Sci** 1998 Jun;48(3):291–3

Impact of Helicobacter hepaticus infection in B6C3F1 mice from twelve National Toxicology Program two-year carcinogenesis studies. Hailey JR, et al. **Toxicol Pathol** 1998 Sep-Oct;26(5):602–11

[Relation between Helicobacter pylori and stomach cancers] Guo F, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr; 36(4):276–8 (20 ref.) **(Chi)**

CLASSIFICATION

Pathology, diagnosis and epidemiology of the rodent Helicobacter infection. Zenner L. **Comp Immunol Microbiol Infect Dis** 1999 Jan;22(1):41–61 (64 ref.)

Discrimination of Helicobacter pullorum and Campylobacter lari by analysis of whole cell fatty acid extracts. Steinbrueckner B, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):209–12

Evaluation of a molecular identification scheme based on 23S rRNA gene polymorphisms for differentiating canine and feline gastric Helicobacter spp. Jalava K, et al. **Lett Appl Microbiol** 1999 Apr;28(4):269–74

Animal reservoirs in the transmission of Helicobacter heilmannii. Results of a questionnaire-based study. Meining A, et al. **Scand J Gastroenterol** 1998 Aug;33(8):795–8

CYTOLOGY

Helicobacter pylori can be induced to assume the morphology of Helicobacter heilmannii. Fawcett PT, et al. **J Clin Microbiol** 1999 Apr;37(4):1045–8

DRUG EFFECTS

Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii. Neiger R, et al. **Am J Vet Res** 1999 Jul;60(7):880–3

GENETICS

A novel method of extracting plasmid DNA from Helicobacter species. De Ungria MC, et al. **Helicobacter** 1998 Dec;3(4):269–77

Fused and overlapping rpoB and rpoC genes in Helicobacters, Campylobacters, and related bacteria. Zakharova N, et al. **J Bacteriol** 1999 Jun;181(12):3857–9

An uncommon Helicobacter isolate from blood: evidence of a group of Helicobacter spp. pathogenic in AIDS patients. Weir SC, et al. **J Clin Microbiol** 1999 Aug;37(8):2729–33

Genetic diversity of canine gastric helicobacters, Helicobacter bizzozeronii and H. salomonis studied by pulsed-field gel electrophoresis. Hänninen ML, et al. **J Med Microbiol** 1999 Apr;48(4):341–7

Cloning and allelic exchange mutagenesis of two flagellin genes of Helicobacter felis. Josenhans C, et al. **Mol Microbiol** 1999 Jul;33(2):350–62

Tracking molecular evolution of photosynthesis by characterization of a major photosynthesis gene cluster from Heliobacillus mobilis. Xiong J, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14851–6

GROWTH & DEVELOPMENT

Mycoplasma contamination of canine gastric biopsy samples and cultures of gastric Helicobacter spp. Hänninen ML, et al. **FEMS Immunol Med Microbiol** 1998 Dec;22(4):335–9

IMMUNOLOGY

Animal models for gastric Helicobacter immunology and vaccine studies. Nedrud JG. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):243–50 (45 ref.)

Mimicry of blood group antigen A by Helicobacter mustelae and H. pylori [letter; comment] Moran AP, et al. **Gastroenterology** 1999 Feb;116(2):504–5. Comment on: Gastroenterology 1998 Apr;114(4):690–6.

Replication-defective adenovirus infection reduces Helicobacter felis colonization in the mouse in a gamma interferon- and interleukin-12-dependent manner. Jiang B, et al. **Infect Immun** 1999 Sep;67(9):4539–44

Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. Roth KA, et al. **J Immunol** 1999 Aug 1;163(3):1490–7

Qualitative and quantitative analysis of the local and systemic antibody response in mice and humans with Helicobacter immunity and infection. Blanchard TG, et al. **J Infect Dis** 1999 Mar;179(3):725–8

Antibodies against Helicobacter felis in sera of cats and dogs. Seidel KE, et al. **Zentralbl Veterinarmed [B]** 1999 Apr; 46(3):181–8

ISOLATION & PURIFICATION

Helicobacter colonization of the biliary tree: commensal, pathogen, or spurious finding? Metz DC. **Am J Gastroenterol** 1998 Oct;93(10):1996–8

The ubiquitous Helicobacter species. Srinivasan R, et al. **Am J Gastroenterol** 1999 Feb;94(2):533–4

Direct analysis and identification of Helicobacter and Campylobacter species by MALDI-TOF mass spectrometry. Winkler MA, et al. **Anal Chem** 1999 Aug 15;71(16):3416–9

Isolation and identification of Helicobacter spp. from canine and feline gastric mucosa. Jalava K, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3998–4006

Helicobacter sp. are not detectable in bile from German patients with biliary disease [letter; comment] Rudi J, et al. **Gastroenterology** 1999 Apr;116(4):1016–7. Comment on: Gastroenterology 1998 Apr;114(4):755–63.

In vivo distribution of Helicobacter felis in the gastric mucus of the mouse: experimental method and results. Schreiber S, et al. **Infect Immun** 1999 Oct;67(10):5151–6

Helicobacter heilmannii associated erosive gastritis [see comments] Yamamoto T, et al. **Intern Med** 1999 Mar; 38(3):240–3. Comment in: Intern Med 1999 Mar;38(3):217–8.

Detection and effects of helicobacters in healthy dogs and dogs with signs of gastritis. Happonen I, et al. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1767–74

Presence of Helicobacter species DNA in Swedish water. Hultén K, et al. **J Appl Microbiol** 1998 Aug;85(2):282–6

Characterization of a culturable "Gastrospirillum hominis" (Helicobacter heilmannii) strain isolated from human gastric mucosa. Andersen LP, et al. **J Clin Microbiol** 1999 Apr;37(4):1069–76

Isolation of Helicobacter canis from a colony of bengal cats with endemic diarrhea. Foley JE, et al. **J Clin Microbiol** 1999 Oct;37(10):3271–5

Septic shock due to Helicobacter fennelliae in a non-human immunodeficiency virus-infected heterosexual patient. Hsueh PR, et al. **J Clin Microbiol** 1999 Jun;37(6):2084–6

Novel intestinal Helicobacter species isolated from cotton-top tamarins (Saguinus oedipus) with chronic colitis. Saunders KE, et al. **J Clin Microbiol** 1999 Jan; 37(1):146–51

Recurrent "Flexispira rappini" bacteremia in an adult patient undergoing hemodialysis: case report. Sorlin P, et al. **J Clin Microbiol** 1999 May;37(5):1319–23

Recurrent bacteremia caused by a "Flexispira"-like organism in a patient with X-linked (Bruton's) agammaglobulinemia. Weir S, et al. **J Clin Microbiol** 1999 Aug;37(8):2439–45

An uncommon Helicobacter isolate from blood: evidence of a group of Helicobacter spp. pathogenic in AIDS patients. Weir SC, et al. **J Clin Microbiol** 1999 Aug;37(8):2729–33

Detection of Helicobacter DNA in bile from bile duct diseases. Roe IH, et al. **J Korean Med Sci** 1999 Apr; 14(2):182–6

Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of scid mice. Shomer NH, et al. **Lab Anim Sci** 1998 Oct;48(5):455–9

Correspondence re: Vartanian RK, Leung JK, Davis JE, Kim YB, Owen DA: A novel alcian yellow-toluidine blue (Leung) stain for Helicobacter species: comparison with standard stains, a cost-effectiveness analysis, and supplemental utilities. Mod Pathol 1998;11:72–8 [letter; comment] Carr NJ, et al. **Mod Pathol** 1998 Aug;11(8):798 . Comment on: Mod Pathol 1998 Jan;11(1):72–8.

Strategy for the detection of Helicobacter species by amplification of 16S rRNA genes and identification of H. felis in a human gastric biopsy. Germani Y, et al. **Res Microbiol** 1997 May;148(4):315–26

Microbiological and histological study of the gastrointestinal tract of germ-free mice infected with Helicobacter trogontum. Moura SB, et al. **Res Microbiol** 1999 Apr; 150(3):205–12

An epizootic of lymphoplasmacytic gastritis attributed to Helicobacter pylori infection in cynomolgus monkeys (Macaca fascicularis). Reindel JF, et al. **Vet Pathol** 1999 Jan;36(1):1–13

Detection of Helicobacter-like bacteria in porcine gastric biopsy samples by amplification of 16S rRNA, ureB, vacA and cagA genes by PCR. Utriainen M, et al. **Vet Res Commun** 1998 Sep;22(6):373–83

[Using polymerase chain reaction to detect Helicobacter heilmannii in gastric biopsy materials] Chen Y, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):241–3 (Eng. Abstr.) **(Chi)**

[Helicobacter heilmannii: anatomo-clinical study of 14 new cases] Foschini MP, et al. **Pathologica** 1999 Feb;91(1):18–24 (Eng. Abstr.) **(Ita)**

PATHOGENICITY

Augmentation of water-immersion stress- induced gastric mucosal lesions in BALB/c mice infected with Helicobacter felis. Matsushima Y, et al. **Digestion** 1999 Jan-Feb;60(1):34–40

The role of gastric Helicobacter and N-methyl-N'-nitro-N-nitrosoguanidine in carcinogenesis of mice. Danon SJ, et al. **Helicobacter** 1998 Dec;3(4):260–8

Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Kullberg MC, et al. **Infect Immun** 1998 Nov; 66(11):5157–66

Ultrastructure of Helicobacter trogontum in culture and in the gastrointestinal tract of gnotobiotic mice. Moura SB, et al. **J Med Microbiol** 1998 Jun;47(6):513–20

Helicobacter heilmannii gastritis: association with acid peptic diseases and comparison with Helicobacter pylori gastritis. Jhala D, et al. **Mod Pathol** 1999 May;12(5):534–8

Helicobacter felis infection in dogs: effect on gastric structure and function. Simpson KW, et al. **Vet Pathol** 1999 May; 36(3):237–48

[Helicobacter heilmannii in the pathology of the stomach and duodenum] Morozov IA. **Arkh Patol** 1999 May-Jun; 61(3):57–60 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Coconnier MH, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4573–80

ULTRASTRUCTURE

Ultrastructure of Helicobacter trogontum in culture and in the gastrointestinal tract of gnotobiotic mice. Moura SB, et al. **J Med Microbiol** 1998 Jun;47(6):513–20

HELICOBACTER INFECTIONS

Gastroduodenal inflammation associated with Helicobacter pylori infection. Diagnostic and therapeutic implications (a review). Fekete B. **Acta Microbiol Immunol Hung** 1998; 45(2):175–94 (121 ref.)

Helicobacter pylori infection in children. Vandenplas Y, et al. **Acta Paediatr** 1998 Nov;87(11):1105–12 (62 ref.)

Helicobacter pylori infection in elderly patients with peptic ulcer [letter] Pilotto A, et al. **Age Ageing** 1999 Jul; 28(4):412–4

Helicobacter pylori as a pathogenic factor in Ménétrier's disease. Badov D, et al. **Am J Gastroenterol** 1998 Oct; 93(10):1976–9

Helicobacter colonization of the biliary tree: commensal, pathogen, or spurious finding? Metz DC. **Am J Gastroenterol** 1998 Oct;93(10):1996–8

Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad [see comments] Richter JE, et al. **Am J Gastroenterol** 1998 Oct;93(10):1800–2 (26 ref.). Comment in: Am J Gastroenterol 1999 May;94(5):1420–1.

Nutritional status of Helicobacter pylori–infected children in Guatemala as compared with uninfected peers. Quiñonez JM, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):395–8

Understanding disease outcome following acquisition of Helicobacter pylori infection during childhood. Day AS, et al. **Can J Gastroenterol** 1999 Apr;13(3):229–34 (75 ref.)

Role of Helicobacter pylori in the pathogenesis of gastric carcinoma and progression of lymphoid nodules to lymphoma. Guindi M. **Can J Gastroenterol** 1999 Apr; 13(3):224–7 (39 ref.)

Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Hunt RH, et al. **Can J Gastroenterol** 1999 Apr;13(3):213–7 (4 ref.)

Pathobiology of Helicobacter pylori infection. Sherman PM, et al. **Can J Gastroenterol** 1999 Apr;13(3):212

From bench to bedside and back--report on the European Helicobacter pylori Study Group Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Thomson AB, et al. **Can J Gastroenterol** 1998 Sep; 12(6):437–46

Helicobacter pylori infection in children. Vandenplas Y. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul–Aug;39(4):223–32 (129 ref.)

Helicobacter pylori and the future: an afterword. Mann NS, et al. **Curr Top Microbiol Immunol** 1999;241:301–8 (51 ref.)

Helicobacter pylori–induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia. Açbay O, et al. **Dig Dis Sci** 1999 Sep;44(9):1837–42

Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Realdi G, et al. **Dig Dis Sci** 1999 Feb;44(2):229–36 (70 ref.)

Development of Helicobacter pylori infection model in BALB/c mice with domestic cagA–positive and –negative strains in Taiwan. Sheu BS, et al. **Dig Dis Sci** 1999 May; 44(5):868–75

Acid-related disorders in the new millennium: European, Japanese and North American perspectives. Freston JW, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10 Suppl 2:S1–40 (120 ref.)

Upper gastrointestinal diseases in the elderly: report of a meeting held at Vicenza, Italy, on 20 March 1998. Pilotto A, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):801–8

Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Fu S, et al. **Gastroenterology** 1999 Jun; 116(6):1319–29

Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis? [letter] Zentilin P, et al. **Gastroenterology** 1999 Feb;116(2):503–4

European Helicobacter pylori Study Group. XIth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Budapest, Hungary, 2–5 September 1998. Abstracts. **Gut** 1998 Sep;43 Suppl 2:A1–128

European Helicobacter pylori Study Group XII International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Helsinki, Finland, 2–4 September 1999. Abstracts. **Gut** 1999 Sep;45 Suppl 3:A1–145

Recurrence of H. pylori infection and dyspeptic symptoms after successful eradication in patients cured of duodenal ulcer disease. Chen TS, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):252–6

Duodenal ulcer and Helicobacter pylori: Presidential Oration, Indian Society of Gastroenterology, 1998. Sharma MP. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):51–3

A conventional beagle dog model for acute and chronic infection with Helicobacter pylori. Rossi G, et al. **Infect Immun** 1999 Jun;67(6):3112–20

Helicobacter heilmannii: a spiral shaped organism other than Helicobacter pylori [editorial; comment] Haruma K. **Intern Med** 1999 Mar;38(3):217–8 (13 ref.). Comment on: Intern Med 1999 Mar;38(3):240–3.

New acquisitions in Helicobacter pylori infection. Introduction. Gasbarrini G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S243 (3 ref.)

Proceedings of the 2nd annual meeting of the Japanese Research Society for Helicobacter pylori Related Gastroduodenal Diseases. Kobe, Japan, April 16–17, 1996. **J Gastroenterol** 1998;33 Suppl 10:1–68

Helicobacter pylori: from art to a science. Hunt RH, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):21–8 (69 ref.)

Helicobacter pylori–positive gastritis in pediatric patients with chronic inflammatory bowel disease. Kolho KL, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):292–5

The rate of Helicobacter pylori infection in children with growth retardation [letter] Sauvé-Martin H, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):354–5

Helicobacter pylori infection in children--an update [news] Wershil BK. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):241

Helicobacter pylori: a review. Ahmed R. **JPMA J Pak Med Assoc** 1998 Aug;48(8):257–8 (29 ref.)

Animal models of Helicobacter infection. Dubois A. **Lab Anim Sci** 1998 Dec;48(6):596–603 (0 ref.)

H. pylori and peptic ulcers still misunderstood. Rapport RS. **N J Med** 1999 Aug;96(8):27–9

Lymphocytic gastritis, Helicobacter pylori, and gastric cancer: is vitamin C the common link? [editorial] Hayat M, et al. **Nutrition** 1999 May;15(5):402–3 (20 ref.)

Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Ganga-Zandzou PS, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):216–21

Scope and consequences of peptic ulcer disease. How important is asymptomatic Helicobacter pylori infection? Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):100–2, 105–8, 110 (38 ref.)

Attitude to Helicobacter pylori infection among Swiss gastroenterologists. Binek J, et al. **Schweiz Med Wochenschr** 1999 Mar 20;129(11):441–5

Proceedings of the Helicobacter pylori Symposium. New Haven, Connecticut, USA. March 1–2, 1997. **Yale J Biol Med** 1998 Mar–Apr;71(2):43–148

[Progresses in the study of gastroenterology in China, 1997] Lu X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):888–90 (0 ref.) **(Chi)**

[Using polymerase chain reaction to detect Helicobacter heilmannii in gastric biopsy materials] Chen Y, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):241–3 (Eng. Abstr.) **(Chi)**

[A consensus on some problems of Helicobacter pylori (draft)] **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):438–9 (0 ref.) **(Chi)**

[Chronic gastritis in Helicobacter heilmannii infection] Dudorkinová D, et al. **Cas Lek Cesk** 1999 May 10; 138(10):316–7 (Eng. Abstr.) **(Cze)**

[Helicobacter pylori, gastritis and stomach tumors (editorial)] Fléjou JF. **Gastroenterol Clin Biol** 1999 Jun–Jul; 23(6–7):737–9 (23 ref.) **(Fre)**

[Gastric malt lymphoma and Helicobacter pylori infection] Eddine MN. **Tunis Med** 1998 Aug–Sep;76(8–9):222–8 **(Fre)**

[Helicobacter pylori. I. Morphology, biochemistry, antigenic profile and correlated diseases] Balli F, et al. **Pediatr Med Chir** 1998 Sep–Oct;20(5):323–8 (49 ref.) (Eng. Abstr.) **(Ita)**

[Effect of Helicobacter pylori eradication from patients with gastritis evaluated by the pathological grading and cell proliferation related factors] Hirabayashi K, et al. **Nippon Rinsho** 1999 Jan;57(1):179–84 (Eng. Abstr.) **(Jpn)**

[Eradication of Helicobacter pylori in Japan] Kamimoto H, et al. **Nippon Rinsho** 1999 Jun;57(6):1435–41 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in endoscopic features and histological findings of H. pylori–related gastritis with a follow-up over a year after eradication of H. pylori] Ohkusa T, et al. **Nippon Rinsho** 1999 Jan;57(1):173–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in the severity of atrophic gastritis after Helicobacter pylori eradication] Satoh K, et al. **Nippon Rinsho** 1999 Jan;57(1):185–90 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Esophagitis, gastritis and duodenitis provoked by cure of Helicobacter pylori infection] Shiotani A, et al. **Nippon Rinsho** 1999 Jan;57(1):191–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori as a new paradigm in the pathogenesis of upper GI diseases] Sugiyama T, et al. **Nippon Rinsho** 1999 Jan;57(1):5–10 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Asia Pacific Consensus Conference on the management of Helicobacter pylori] Terano A. **Nippon Rinsho** 1999 Jan; 57(1):67–71 **(Jpn)**

[Peptic ulcer disease and hemorrhagic gastritis with H. pylori infection] Yamamoto I, et al. **Nippon Rinsho** 1998 Sep; 56(9):2263–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of Helicobacter pylori(Hp) eradication on gastric mucosal pathophysiology in Hp-positive, NSAIDs-induced gastric ulcer] Yanaka A, et al. **Nippon Rinsho** 1999 Jan;57(1):201–7 (48 ref.) (Eng. Abstr.) **(Jpn)**

[The affect of Helicobacter pylori and bile acids as the pathogenesis of gastritis of the remnant stomach after distal partial gastrectomy] Akiyama H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):137–41 (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori and gastric cancer] Asaka M. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):627–33 (35 ref.) **(Jpn)**

[Helicobacter pylori infection and histological types of gastric cancer] Handa Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):634–43 (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori] Nishizono A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):27–9 (13 ref.) **(Jpn)**

[Primary gastritis associated with Helicobacter pylori in children] Kawakami E, et al. **Arq Gastroenterol** 1998 Apr–Jun;35(2):138–42 (Eng. Abstr.) **(Por)**

[Are there "good" H. pylori and "bad" H. pylori?/ Gisbert JP, et al. **Acta Gastroenterol Latinoam** 1998;28(5):341–8 **(Spa)**

BLOOD

Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies. Al-Assi MT, et al. **Am J Gastroenterol** 1999 Sep;94(9):2367–72

The 13C-urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial. Chey WD, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1522–4

Association of Helicobacter pylori infection with elevated serum lipids. Laurila A, et al. **Atherosclerosis** 1999 Jan; 142(1):207–10

Helicobacter pylori infection is not a correlate of plasma fibrinogen in the Australian population. Peach HG, et al. **Clin Lab Haematol** 1999 Feb;21(1):41–3

Plasma free radical activity and antioxidant vitamin levels in dyspeptic patients: correlation with smoking and Helicobacter pylori infection. Phull PS, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):573–8

Comparison of meal-stimulated serum gastrin response in Helicobacter pylori–positive duodenal ulcer and asymptomatic volunteers with and without H. pylori infection. Kamada T, et al. **Helicobacter** 1999 Sep; 4(3):170–7

Gastric inhibitory polypeptide appears less important in mediating acid secretion. Wang YY, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2105–9

Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. Vásconez C, et al. **J Hepatol** 1999 Feb;30(2):260–4

Serological and direct diagnosis of Helicobacter pylori in gastric carcinoma: a case-control study. Queiroz DM, et al. **J Med Microbiol** 1999 May;48(5):501–6

Relationship of CagA to serum gastrin concentrations and antral G, D cell densities in Helicobacter pylori infection. Kim JH, et al. **Yonsei Med J** 1999 Aug;40(4):301–6

Cat owners' risk of acquiring a Helicobacter pylori infection. Ansorg R, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):122–6

CHEMICALLY INDUCED

Non-steroidal anti-inflammatory drug gastropathy and Helicobacter pylori infection. Taha AS. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S23–6 (24 ref.)

[Consequences of Helicobacter pylori infection on the incidence and treatment of gastro-duodenal ulcers in patients taking non-steroidal anti-inflammatory agents] Lamarque D. **Gastroenterol Clin Biol** 1998 Dec; 22(12):1122–4 **(Fre)**

COMPLICATIONS

Non ulcer dyspepsia and Helicobacter pylori. Debongnie JC. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):476–8 (15 ref.)

Indications for HP eradication: gastro-esophageal reflux disease. De Koster E. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):313–5 (22 ref.)

Helicobacter pylori and gastric malignancies. Melange M, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):305–6 (9 ref.)

Association of Helicobacter pylori infection and Parkinson's disease already proposed [letter] Altschuler EL. **Acta Neurol Scand** 1999 Aug;100(2):122

Upper gastrointestinal disease, Helicobacter pylori and recurrent abdominal pain. Roma E, et al. **Acta Paediatr** 1999 Jun;88(6):598–601

Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Pilotto A, et al. **Age Ageing** 1999 Jul;28(4):367–71

Lymphoid hyperplasia of the stomach caused by Helicobacter pylori: upper gastrointestinal findings. Lee EY, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):362–3 (8 ref.)

Panel discussion: breaking the link--clinical options to minimize risk. Blaser MJ, et al. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:19–23

Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Danesh J. **Aliment Pharmacol Ther** 1999 Jul;13(7):851–6 (65 ref.)

Review article: the role of inflammation in the pathogenesis of gastric cancer. Ernst P. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:13–8 (18 ref.)

The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Peters FT, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):921–6

Nocturnal gastric acid breakthrough on proton pump inhibitors [letter] Savarino V, et al.

Aliment Pharmacol Ther 1999 Jul;13(7):977–8

Helicobacter pylori serology in patients with angiographically documented coronary artery disease. Quinn MJ, et al. **Am J Cardiol** 1999 Jun 15;83(12):1664–6, A6

Molecular alterations in early gastric carcinomas. No apparent correlation with Helicobacter pylori status. Blok P, et al. **Am J Clin Pathol** 1999 Feb;111(2):241–7

Epidemiology of peptic ulcer disease in cirrhotic patients: role of Helicobacter pylori infection. Calvet X, et al. **Am J Gastroenterol** 1998 Dec;93(12):2501–7

Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Eslick GD, et al. **Am J Gastroenterol** 1999 Sep;94(9):2373–9

Barrett's metaplasia and Helicobacter pylori infection [letter] Kiltz U, et al. **Am J Gastroenterol** 1999 Jul;94(7):1985–6

Does Helicobacter pylori affect the management of gastroesophageal reflux disease? [editorial; comment] Labenz J. **Am J Gastroenterol** 1999 Apr;94(4):867–9. Comment on: Am J Gastroenterol 1999 Apr;94(4):884–7.

Helicobacter pylori and gastric outlet obstruction [letter; comment] Malik GM, et al. **Am J Gastroenterol** 1998 Oct; 93(10):2004. Comment on: Am J Gastroenterol 1997 Feb;92(2):362–3. Comment on: Am J Gastroenterol 1997 Sep;92(9):1576–7.

Helicobacter pylori and gastric cancer: proving the link. Metz DC. **Am J Gastroenterol** 1999 Mar;94(3):852–3

Symptoms and Helicobacter pylori: any link? The Italian Helicobacter pylori Study Group [letter] Neri M, et al. **Am J Gastroenterol** 1998 Dec;93(12):2633–4

Childhood duodenal ulcer associated with Helicobacter pylori and ABO blood groups [letter; comment] Nijevitch AA, et al. **Am J Gastroenterol** 1999 May;94(5):1424–5. Comment on: Am J Gastroenterol 1996 Jan;91(1):101–4.

Helicobacter pylori and nonulcer dyspepsia: more confusion? Pfau PR, et al. **Am J Gastroenterol** 1999 Sep;94(9):2563–5

Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease [see comments] Schenk BE, et al. **Am J Gastroenterol** 1999 Apr;94(4):884–7. Comment in: Am J Gastroenterol 1999 Apr;94(4):867–9.

Has eradication therapy an effect in Helicobacter-positive patients with chronic urticaria? [letter] Schrutka-Koelbl C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2632–3

Helicobacter pylori infection and gastric juice total phospholipid concentration in patients with bleeding peptic ulcer [letter] Triantafillidis JK, et al. **Am J Gastroenterol** 1998 Dec;93(12):2642–3

Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Wu JC, et al. **Am J Gastroenterol** 1999 Jul;94(7):1790–4

The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Barkin J. **Am J Med** 1998 Nov 2;105(5A):22S–27S (51 ref.)

Helicobacter pylori and gastric cancer. Scheiman JM, et al. **Am J Med** 1999 Feb;106(2):222–6 (55 ref.)

Helicobacter pylori–induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils. Ikeno T, et al. **Am J Pathol** 1999 Mar;154(3):951–60

Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Steinbach G, et al. **Ann Intern Med** 1999 Jul 20;131(2):88–95

Gastric MALT lymphoma: from concept to cure. Isaacson PG. **Ann Oncol** 1999 Jun;10(6):637–45 (96 ref.)

Helicobacter pylori eradication in patients with chronic urticaria [letter] Ozkaya-Bayazit E, et al. **Arch Dermatol** 1998 Sep;134(9):1165–6 (6 ref.)

Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Fendrick AM, et al. **Arch Intern Med** 1999 Jan 25; 159(2):142–8

Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease. Hood HM, et al. **Arch Intern Med** 1999 Jan 25;159(2):149–54

Non-gastrointestinal tract associations of Helicobacter pylori infection. Leontiadis GI, et al. **Arch Intern Med** 1999 May 10;159(9):925–40 (168 ref.)

Symptomatic Helicobacter pylori infection in a neurorehabilitation population. Shem KL, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1297–300

Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease. Oberg S, et al. **Arch Surg** 1999 Jul;134(7):722–6

Helicobacter pylori and peptic ulcer disease: has the emperor got no clothes? [editorial; comment] [see comments] Katelaris PH. **Aust N Z J Med** 1998 Oct;28(5):581–2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1998 Oct;28(5):585–9. Comment in: Aust N Z J Med 1999 Feb;29(1):103. Comment in: Aust N Z J Med 1999 Apr;29(2):271.

Helicobacter pylori infection and duodenal ulceration [letter; comment] [see comments] Pinn G. **Aust N Z J Med** 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1998 Jun;28(3):345. Comment in: Aust N Z J Med 1998 Oct;28(5):581–2. Comment in: Aust N Z J Med 1999 Feb;29(1):103. Comment in: Aust N Z J Med 1999 Apr;29(2):271.

Peptic ulcer disease in the military aviator: a management approach. Lang KA, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1100–3 (15 ref.)

Helicobacter pylori and functional dyspepsia: a real causal link? Pantoflickova D, et al. **Baillieres Clin Gastroenterol** 1998 Sep;12(3):503–32 (141 ref.)

Autoimmune diseases and Helicobacter pylori infection. Gasbarrini A, et al. **Biomed Pharmacother** 1999 Jun; 53(5–6):223–6 (21 ref.)

Commentary: Helicobacter pylori--the story so far. Thomson M. **BMJ** 1999 Aug 28;319(7209):541

Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. Fan XG, et al. **Br J Biomed Sci** 1998 Sep;55(3):176–8

Helicobacter pylori and gastric cancer: time for mega-trials? [editorial] Danesh J. **Br J Cancer** 1999 Jun;80(7):927–9

Are patients at increased risk? [letter; comment] Sloan J. **Can Fam Physician** 1998 Oct;44:2065–6. Comment on: Can Fam Physician 1998 Jul;44:1429–31, 1436–8.

Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Rugge M, et al. **Cancer** 1999 Jun 15; 85(12):2506–11

Development of Helicobacter pylori–induced gastric carcinoma in Mongolian gerbils. Honda S, et al. **Cancer Res** 1998 Oct 1;58(19):4255–9

Helicobacter pylori infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. Shimizu N, et al. **Carcinogenesis** 1999 Apr; 20(4):669–76

Effect of Helicobacter pylori infection on the N-methyl-N'-nitro-N-nitrosoguanidine–induced gastric carcinogenesis in mongolian gerbils. Tokieda M, et al. **Carcinogenesis** 1999 Jul;20(7):1261–6

Hematopoietic cancer and peptic ulcer: a multicenter case–control study. Vineis P, et al. **Carcinogenesis** 1999 Aug;20(8):1459–63

Animal models of Helicobacter gastritis. Eaton KA. **Curr Top Microbiol Immunol** 1999;241:123–54 (155 ref.)

Pediatric Helicobacter pylori infection: clinical manifestations, diagnosis, and therapy. Gold BD. **Curr Top Microbiol Immunol** 1999;241:71–102 (236 ref.)

Chronic gastritis and nonulcer dyspepsia. Kalantar J, et al. **Curr Top Microbiol Immunol** 1999;241:31–45 (94 ref.)

Gastric cancer and lymphoma. Mukhopadhyay P. **Curr Top Microbiol Immunol** 1999;241:57–69 (91 ref.)

The role of Helicobacter pylori infection in duodenal and gastric ulcer. Veldhuyzen van zanten SJ, et al. **Curr Top Microbiol Immunol** 1999;241:47–56 (46 ref.)

Helicobacter pylori as a possible bacterial focus of chronic urticaria. Wustlich S, et al. **Dermatology** 1999;198(2):130–2

No evidence for an association between H. pylori and idiopathic chronic urticaria [letter; comment] Howden CW. **Dig Dis Sci** 1999 Mar;44(3):485–6. Comment on: Dig Dis Sci 1998 Jun;43(6):1226–9.

Halitosis and Helicobacter pylori: a possible relationship. Ierardi E, et al. **Dig Dis Sci** 1998 Dec;43(12):2733–7

Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823–36 (67 ref.)

Helicobacter pylori–associated protein-losing hypertrophic gastropathy with hypercholesterolemia. Kapsoritakis AN, et al. **Dig Dis Sci** 1999 Sep;44(9):1843–7

Helicobacter pylori infection and atrophic gastritis: a nested case–control study in a rural town in Japan. Ozasa K, et al. **Dig Dis Sci** 1999 Feb;44(2):253–6

Helicobacter pylori infection in elderly people: does quantitative serological testing predict gastroduodenal ulcer disease? Tsai CJ. **Dig Dis Sci** 1999 Jan;44(1):96–101

Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Breuer-Katschinski B, et al. **Digestion** 1999;60(3):210–5

Interactions between Helicobacter pylori and gastroesophageal reflux disease. Bowrey DJ, et al. **Dis Esophagus** 1998 Oct;11(4):203–9 (72 ref.)

Helicobacter pylori and gastric cancer. **Drug Ther Bull** 1998 Aug;36(8):57–9 (30 ref.)

Ulcer and gastritis. Anand BS, et al. **Endoscopy** 1999 Feb; 31(2):215–25 (50 ref.)

Antimicrobial treatment for peptic stenosis: a prospective study. Brandimarte G, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):731–4

Helicobacter pylori: a true carcinogen? [editorial] [see comments] Cats A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):447–50. Comment in: Eur J Gastroenterol Hepatol 1999 Mar;11(3):357–9.

Helicobacter pylori and reflux disease. Dent J. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S51–7; discussion S73 (36 ref.)

Topographic distribution of Helicobacter pylori in the resected stomach. Enomoto H, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):473–8

Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Gasbarrini A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):469–72

Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Gasbarrini A, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):713–6

Atrophy, acid suppression and Helicobacter pylori infection: a tale of two studies. Genta RM. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S29–33; discussion S43–5

The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case–control study. Hackelsberger A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):465–8

The effect of eradicating Helicobacter pylori infection on the course of adenomatous and hyperplastic gastric polyps. Ljubicić N, et al. **Eur J Gastroenterol Hepatol** 1999 Jul; 11(7):727–30

Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Spiller RC. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S25–8; discussion S43–5

Is there a link between chronic Helicobacter pylori infection and coronary heart disease? Danesh J. **Eur J Surg Suppl** 1998;(582):27–31 (31 ref.)

Non-gastric effects of H. pylori infection: a literature review with respect to non gastric diseases which might be associated with H. pylori infection. Ekström P. **Eur J Surg Suppl** 1998;(582):32–4 (31 ref.)

Molecular mechanism of human stomach carcinogenesis implicated in Helicobacter pylori infection. Tahara E. **Exp Toxicol Pathol** 1998 Sep;50(4–6):375–8 (21 ref.)

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case–control study. Aalykke C, et al. **Gastroenterology** 1999 Jun; 116(6):1305–9

Helicobacter pylori factors associated with disease [editorial; comment] Cover TL, et al. **Gastroenterology** 1999 Jul; 117(1):257–61 (36 ref.). Comment on: Gastroenterology 1999 Jul;117(1):82–8.

H. pylori and nonulcer dyspepsia: not guilty as charged. Schubert ML. **Gastroenterology** 1999 Jul;117(1):270–2

Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis? [letter] Zentilin P, et al. **Gastroenterology** 1999 Feb;116(2):503–4

Helicobacter pylori and benign gastric outlet obstruction [letter] Yarze JC. **Gastrointest Endosc** 1999 Oct;50(4):598

A case of protein-losing gastropathy caused by acute Helicobacter pylori infection. Yoshikawa I, et al. **Gastrointest Endosc** 1999 Feb;49(2):245–8

Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Blaser MJ. **Gut** 1998 Nov; 43(5):721–7 (101 ref.)

Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study [see comments] Duggan AE, et al. **Gut** 1998 Oct;43(4):494–8. Comment in: Gut 1998 Oct;43(4):451.

Extradigestive manifestations of Helicobacter pylori gastric infection. Gasbarrini A, et al. **Gut** 1999 Jul;45 Suppl 1:I9–I12 (50 ref.)

Helicobacter pylori and dyspepsia: trick or treat? [comment] Jones R. **Gut** 1999 Aug;45(2):164–5. Comment on: Gut 1999 Aug;45(2):186–90.

Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation. McNamara D, et al. **Gut** 1999 Jul;45 Suppl 1:I13–7 (95 ref.)

Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Nardone G, et al. **Gut** 1999 Jun;44(6):789–99

What makes the dyspeptic patient feel ill? A cross sectional survey of functional health status, Helicobacter pylori infection, and psychological distress in dyspeptic patients in general practice. Quartero AO, et al. **Gut** 1999 Jul; 45(1):15–9

How should Helicobacter pylori positive dyspeptic patients be managed? Talley NJ. **Gut** 1999 Jul;45 Suppl 1:I28–31 (39 ref.)

Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report [letter] Grimaz S, et al. **Haematologica** 1999 Mar;84(3):283–4

Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Danesh J, et al. **Heart** 1999 Mar; 81(3):245–7

Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome. Braden B, et al. **Helicobacter** 1998 Sep;3(3):184–7

H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Graham DY, et al. **Helicobacter** 1998 Sep; 3(3):145–51 (51 ref.)

Gastric ulcer formation after the Hanshin-Awaji earthquake: a case study of Helicobacter pylori infection and stress-induced gastric ulcers. Matsushima Y, et al. **Helicobacter** 1999 Jun;4(2):94–9

The effect of H. pylori in perforation of duodenal ulcer. Mihmanli M, et al. **Hepatogastroenterology** 1998 Sep–Oct; 45(23):1610–2

Helicobacter pylori infection in dyspeptic cirrhotic patients. Zullo A, et al. **Hepatogastroenterology** 1999 Jan–Feb; 46(25):395–400

Interobserver agreement in the assessment of gastritis reversibility after Helicobacter pylori eradication. Tepes B, et al. **Histopathology** 1999 Feb;34(2):124–33

Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Schnyder B, et al. **Int Arch Allergy Immunol** 1999 May;119(1):60–3

Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. You WC, et al. **Int J Epidemiol** 1998 Dec;27(6):941–4

Helicobacter pylori infection and ischaemic heart disease. Cammarota G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;

30 Suppl 3:S304–6 (12 ref.)
Helicobacter pylori infection and vascular diseases. Gasbarrini A, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S307–9 (25 ref.)
Helicobacter pylori increases the risk of peptic ulcer bleeding: a case–control study. Labenz J, et al. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):110–5
Helicobacter pylori and non–steroidal anti–inflammatory drugs: ulcers and bleeding ulcers. Russell RI. **Ital J Gastroenterol Hepatol** 1999 Mar;31(2):116–8 (16 ref.)
Refractory exacerbations of hereditary angioedema with associated Helicobacter pylori infection. Rais M, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):713–4
"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study. Archimandritis A, et al. **J Clin Gastroenterol** 1999 Jun;28(4):345–7
Predictive factors for metachronous recurrence of early gastric cancer after endoscopic treatment [see comments] Arima N, et al. **J Clin Gastroenterol** 1999 Jul;29(1):44–7. Comment in: J Clin Gastroenterol 1999 Jul;29(1):5–6.
Duodenal stenosis and Helicobacter pylori [letter; comment] Rinaldi V, et al. **J Clin Gastroenterol** 1999 Jan;28(1):83–4 . Comment on: J Clin Gastroenterol 1995 Dec;21(4):329–30.
Gastric pathology in cholecystectomy patients: role of Helicobacter pylori and bile reflux. Zullo A, et al. **J Clin Gastroenterol** 1998 Dec;27(4):335–8
Septic shock due to Helicobacter fennelliae in a non–human immunodeficiency virus–infected heterosexual patient. Hsueh PR, et al. **J Clin Microbiol** 1999 Jun;37(6):2084–6
Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa–associated lymphoid tissue B–cell lymphoma [published erratum appears in J Clin Oncol 1999 Mar;17(3):1092] Thiede C, et al. **J Clin Oncol** 1998 Dec; 16(12):3822–31
Helicobacter pylori and Epstein–Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non–operated stomach. Baas IO, et al. **J Clin Pathol** 1998 Sep;51(9):662–6
Sudden infant death syndrome, long QT interval, and Helicobacter pylori [letter; comment] Kerr JR. **J Clin Pathol** 1998 Dec;51(12):943–4. Comment on: J Clin Pathol 1998 Jun;51(6):419.
A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. Yang L, et al. **J Controlled Release** 1999 Feb 22;57(3):215–22
Strong correlation between Helicobacter pylori seropositivity and Chlamydia pneumoniae IgG concentrations. Danesh J, et al. **J Epidemiol Community Health** 1998 Dec; 52(12):821–2
Aggressive non–Hodgkin's lymphoma after successful eradication of Helicobacter pylori and regression of gastric lymphoma of mucosa–associated lymphoid tissue. Ohashi S, et al. **J Gastroenterol** 1998 Oct;33(5):724–7
Are there more clinically important complications of Helicobacter pylori infection than peptic ulcer disease? A review of current literature. Unge P. **J Gastroenterol** 1998; 33 Suppl 10:48–52 (47 ref.)
Role of anti–Helicobacter pylori treatment in H. pylori–positive and cytoprotective drugs in H. pylori–negative, non–ulcer dyspepsia: results of a randomized, double–blind, controlled trial in Asian Indians. Dhali GK, et al. **J Gastroenterol Hepatol** 1999 Jun; 14(6):523–8
Treatment of Helicobacter pylori infection to reduce gastric cancer incidence: uncertain benefits of a community based programme in Australia. Forbes GM, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1091–5
Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. Kang JY, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):771–8
Helicobacter pylori–induced lymphonodular hyperplasia: a new cause of gastric outlet obstruction. Misra SP, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1191–4
Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. Blaser MJ. **J Infect Dis** 1999 Jun;179(6):1523–30
Bacterial infections and atherosclerosis. Muhlestein JB. **J Investig Med** 1998 Oct;46(8):396–402 (31 ref.)
High frequency of CagA+ Helicobacter pylori infection in high–grade gastric MALT B–cell lymphomas. Peng H, et al. **J Pathol** 1998 Aug;185(4):409–12
Unexplained refractory iron–deficiency anemia associated with Helicobacter pylori gastric infection in children: further clinical evidence. Barabino A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):116–9
Prevalence of Helicobacter pylori infection detected by serology and 13C–urea breath test in HIV–1 perinatally infected children. Lionetti P, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):301–6
Helicobacter pylori and type 1 diabetes mellitus in children. Salardi S, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):307–9
The relationship between Helicobacter pylori infection and acid–hematuria syndrome in pediatric patients with gastric augmentation–II. Celayir S, et al. **J Pediatr Surg** 1999 Apr; 34(4):532–5
Helicobacter pylori colonization in infants and young children is not necessarily associated with diarrhoea. Rahman MM, et al. **J Trop Pediatr** 1998 Oct;44(5):283–7
Stress and peptic ulcer disease [see comments] Levenstein S, et al. **JAMA** 1999 Jan 6;281(1):10–1. Comment in: JAMA 1999 Jul 21;282(3):237.
Stressful events and peptic ulcer disease [letter; comment] Sovarino R. **JAMA** 1999 Jul 21;282(3):237. Comment on: JAMA 1999 Jan 6;281(1):10–1.
Effect of eradication of Helicobacter pylori on the benign gastric ulcer recurrence––a 24 month follow–up study. Kim N, et al. **Korean J Intern Med** 1999 Jul;14(2):9–14
Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Chen YY, et al. **Mod Pathol** 1998 Oct;11(10):950–6
Clinical course of acute gastric mucosal lesions caused by acute infection with Helicobacter pylori [letter] Moriai T, et al. **N Engl J Med** 1999 Aug 5;341(6):456–7
Bleeding peptic ulcers: audit of eradication treatment for H pylori. Garrigan K, et al. **N Z Med J** 1999 May 28; 112(1088):178–80
Understanding peptic ulcer disease pharmacotherapeutics. Navuluri R, et al. **Nurse Pract** 1999 Mar;24(3):128–32
Index of suspicion. Case 3. Diagnosis: hematemesis resulting from gastritis, duodenal ulcer and hemophilia A. Colli J, et al. **Pediatr Rev** 1998 Dec;19(12):429, 432
Helicobacter pylori infection and insulin requirement among children with type 1 diabetes mellitus. Begue RE, et al. **Pediatrics** 1999 Jun;103(6):e83
Helicobacter pylori and abdominal symptoms [letter; comment] Gilger MA. **Pediatrics** 1999 Jan;103(1):192–3. Comment on: Pediatrics 1998 Apr;101(4 Pt 1):634–7.
Is Helicobacter pylori really the cause of gastroduodenal disease? Weiner H, et al. **QJM** 1998 Oct;91(10):707–11 (50 ref.)
The conflicting relationship between Helicobacter pylori and non–steroidal anti–inflammatory drugs in peptic ulcer bleeding [editorial; comment] Bianchi Porro G, et al. **Scand J Gastroenterol** 1999 Mar;34(3):225–8 (48 ref.). Comment on: Scand J Gastroenterol 1999 Mar;34(3):234–7.
Positive association between Helicobacter pylori infection and food allergy in children. Corrado G, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1135–9
Helicobacter pylori infection and risk of cardia cancer and non–cardia gastric cancer. A nested case–control study. Hansen S, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):353–60
A close relationship between Helicobacter pylori infection and gastric xanthoma. Isomoto H, et al. **Scand J Gastroenterol** 1999 Apr;34(4):346–52
Eradication of Helicobacter pylori infection did not lead to cure of duodenal mucosa–associated lymphoid tissue lymphoma. Kim JS, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):215–8
Nonsteroidal anti–inflammatory drug–associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Voutilainen M, et al. **Scand J Gastroenterol** 1998 Aug; 33(8):811–6
Interaction between Helicobacter pylori and non–steroidal anti–inflammatory drugs in peptic ulcer bleeding [see comments] Wu CY, et al. **Scand J Gastroenterol** 1999 Mar; 34(3):234–7. Comment in: Scand J Gastroenterol 1999 Mar;34(3):225–8.
Is Helicobacter pylori really the cause of gastric cancer? Nyrén O. **Semin Cancer Biol** 1998 Aug;8(4):275–83 (72 ref.)
Helicobacter pylori infection and the risk of myocardial infarction: role of fibrinogen and its genetic control. Zito F, et al. **Thromb Haemost** 1999 Jul;82(1):14–8
Impact of Helicobacter hepaticus infection in B6C3F1 mice from twelve National Toxicology Program two–year carcinogenesis studies. Hailey JR, et al. **Toxicol Pathol** 1998 Sep–Oct;26(5):602–11
Peptic ulcer disease in south Ethiopia is strongly associated with Helicobacter pylori. Henriksen TH, et al. **Trans R Soc Trop Med Hyg** 1999 Mar–Apr;93(2):171–3
Helicobacter pylori in gastric cancer in India. Bhasin DK, et al. **Trop Gastroenterol** 1999 Apr–Jun;20(2):70–2
N–nitroso compounds and Helicobacter pylori in the gastric remnant. Guadagni S, et al. **Tumori** 1999 Mar–Apr; 85(2):108–12
Does Helicobacter pylori infection contribute to gastroesophageal reflux disease? Spechler SJ. **Yale J Biol Med** 1998 Mar–Apr;71(2):143–8 (37 ref.)
Angioedema due to acquired C1–esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Farkas H, et al. **Z Gastroenterol** 1999 Jun;37(6):513–8
[Helicobacter pylori and congestive gastropathy] Dai L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):22–3 (Eng. Abstr.) **(Chi)**
[Relation between Helicobacter pylori infection and ischemic heart disease] Konštacký M. **Cas Lek Cesk** 1998 Aug 24; 137(16):483–5 (48 ref.) (Eng. Abstr.) **(Cze)**
[Treatment of gastroesophageal reflux: should Helicobacter pylori infection be taken into account?] De Korwin JD. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S121–9 (87 ref.) **(Fre)**
[Helicobacter pylori infections in children in the tropical zone. Endoscopic and histological aspects] Ilboudo D, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):855–7 (Eng. Abstr.) **(Fre)**
[Non–ulcerating dyspepsia: role of Helicobacter pylori] Sobhani L. **Presse Med** 1998 Sep 5;27(25):1292–3 **(Fre)**
[Controversies in the treatment of Helicobacter pylori] Van Kemseke C, et al. **Rev Med Liege** 1999 Jul;54(7):570–5 (Eng. Abstr.) **(Fre)**
[Massive duodenal lambliasis and Helicobacter heilmannii gastritis in a diabetic patient (letter)] Grouls V, et al. **Dtsch Med Wochenschr** 1999 May 14;124(19):611 **(Ger)**
[Remission ratio of chronic urticaria––"spontaneous" healing or result of eradication of Helicobacter pylori?] Becker H, et al. **Hautarzt** 1998 Dec;49(12):907–11 (Eng. Abstr.) **(Ger)**
["Helicobacter pylori and gastric cancer" by M. Stolte et al in Pathologe 1998; 19:330–4 (letter; comment)] Dinges HP. **Pathologe** 1999 Mar;20(2):148–9. Comment on: Pathologe 1998 Jul;19(4):330–3. **(Ger)**
[Helicobacter pylori and headache (editorial)] Marko P. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31–32):1261–2 **(Ger)**
[Helicobacter pylori infection in diabetic patients] Kozák R, et al. **Orv Hetil** 1999 May 2;140(18):993–5 (Eng. Abstr.) **(Hun)**
[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection] Petsch B, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):66–8 (Eng. Abstr.) **(Pol)**
[Clinical–endoscopic factors of gastro–duodenal ulcer associated with Helicobacter pylori in elderly and senile patients] Kovalenko LI. **Klin Khir** 1999;(3):7–9 (Eng. Abstr.) **(Rus)**
[The concept of the relationship between the human body and Helicobacter pylori] Tsimmerman IaS, et al. **Klin Med (Mosk)** 1999;77(2):52–6 (20 ref.) **(Rus)**
[The role of the enzymatic antioxidant system and Helicobacter pylori infection in the pathogenesis of peptic ulcer and their effect on treatment efficacy] Esedov EM, et al. **Ter Arkh** 1999;71(2):19–22 (Eng. Abstr.) **(Rus)**
[The relation of Helicobacter pylori with dysplasia and stomach neoplasms in Costa Rica] Miranda M, et al. **Rev Biol Trop** 1998 Sep;46(3):829–32 (Eng. Abstr.) **(Spa)**
[Resolution of a case of gastric outlet obstruction after eradication of Helicobacter pylori (letter)] Diaz Blasco J, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):890–1 **(Spa)**
[Gastroduodenal lesions and non–steroidal anti–inflammatory agents. What role does Helicobacter pylori play in this relationship?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1998 Sep;90(9):655–64 (159 ref.) (Eng. Abstr.) **(Spa)**
[Relation of Helicobacter pylori and the stomach operated on for peptic ulcer] Hurtado–Andrade H. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4):187–97 (90 ref.) (Eng. Abstr.) **(Spa)**
[The influence of Helicobacter pylori on the surgical outcome of duodenal ulcer] Sukhodolia AI. **Klin Khir** 1999;(3):9–10 (Eng. Abstr.) **(Ukr)**
[The enterochromaffin–serotonin system and Helicobacter infection in the mechanisms of the staged development of peptic ulcer] Abrahamovych Ie(O)S, et al. **Lik Sprava** 1998 Dec;(8):73–9 (Eng. Abstr.) **(Ukr)**

DIAGNOSIS

Chronic urticaria and Helicobacter pylori. Valsecchi R, et al. **Acta Derm Venereol** 1998 Nov;78(6):440–2
How (who?) and when to test or retest for H. pylori. Burette A. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):336–43 (64 ref.)
A consensus meeting about HP–related diseases, again? Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep; 61(3):298
Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. Glupczynski Y. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):321–6 (44 ref.)
Urea breath test: a diagnostic tool in the management of Helicobacter pylori–related gastrointestinal diseases. Peeters M. **Acta Gastroenterol Belg** 1998 Jul–Sep; 61(3):332–5 (26 ref.)
Helicobacter pylori––screening prospect. Scaillon M, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):367–75 (86 ref.)
"De–NoI test" for rapid diagnosis of Helicobacter pylori in childhood [letter] Nijevitch AA, et al. **Acta Paediatr** 1999 Feb;88(2):234–5
A multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C–urea breath test for the detection of Helicobacter pylori infection. Cave DR, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):747–52
Is routine histological evaluation an accurate test for Helicobacter pylori infection? MacOni G, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):327–31
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Bravo LE, et al. **Am J Gastroenterol** 1999 Sep; 94(9):2380–3
The impact of delaying gastric emptying by either meal substrate or drug on the [13C]–urea breath test. Casellas F, et al. **Am J Gastroenterol** 1999 Feb;94(2):369–73
The 13C–urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial. Chey WD, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1522–4
A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: a United States, multicenter trial. Chey WD, et al. **Am J Gastroenterol** 1999 Jun;94(6):1512–6
Comparison of [13C]urea blood test to [13C]urea breath test

for the diagnosis of Helicobacter pylori. Cutler AF, et al. **Am J Gastroenterol** 1999 Apr;94(4):959–61

Detection of Helicobacter pylori infection [letter; comment] Dinler G, et al. **Am J Gastroenterol** 1999 Apr;94(4):1118 . Comment on: Am J Gastroenterol 1998 Aug;93(8):1291–6.

Confounding factors in the detection of Helicobacter pylori infection in patients with upper gastrointestinal bleeding [letter; comment] Fantry GT, et al. **Am J Gastroenterol** 1999 May;94(5):1421–2. Comment on: Am J Gastroenterol 1998 Oct;93(10):1914–8.

Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Kulkarni SG, et al. **Am J Gastroenterol** 1999 Feb;94(2):382–6

Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Leodolter A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2100–4

False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood [see comments] Leung WK, et al. **Am J Gastroenterol** 1998 Oct;93(10):1914–8. Comment in: Am J Gastroenterol 1999 May;94(5):1421–2.

Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection. Sadowski D, et al. **Am J Gastroenterol** 1998 Nov;93(11):2119–23

Comparison of isotope ratio mass spectrometry and nondispersive isotope-selective infrared spectroscopy for 13C-urea breath test. Savarino V, et al. **Am J Gastroenterol** 1999 May;94(5):1203–8

Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Zullo A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2214–8

Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Fendrick AM, et al. **Am J Med** 1999 Aug;107(2):133–6

Helicobacter pylori infection and persistent hyperemesis gravidarum. Jacoby EB, et al. **Am J Perinatol** 1999; 16(2):85–8

High seroprevalence of Helicobacter pylori in active bronchiectasis. Tsang KW, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1047–51

Development of a chemiluminescent urease activity assay for Helicobacter pylori infection diagnosis in gastric mucosa biopsies. Roda A, et al. **Anal Biochem** 1998 Nov 1;264(1):47–52

Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease. Hood HM, et al. **Arch Intern Med** 1999 Jan 25;159(2):149–54

The effect of test duration on the sensitivity and specificity of ultra-rapid urease test for the detection of Helicobacter pylori infection. Ho KY, et al. **Aust N Z J Med** 1998 Oct; 28(5):615–9

Helicobacter pylori and peptic ulcer disease [letter; comment] Katelaris PH. **Aust N Z J Med** 1999 Apr;29(2):271. Comment on: Aust N Z J Med 1998 Oct;28(5):581–2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1999 Feb;29(1):103.

Helicobacter pylori and peptic ulcer disease... [letter; comment] [see comments] Mathew J. **Aust N Z J Med** 1999 Feb;29(1):103. Comment on: Aust N Z J Med 1998 Oct;28(5):581–2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment in: Aust N Z J Med 1999 Apr;29(2):271.

Five micro-curie urea breath test for the diagnosis of Helicobacter pylori infection: evaluation in a South-East Asian population. Yu WK, et al. **Aust N Z J Surg** 1999 Jan;69(1):37–40

Serodiagnosis of Helicobacter pylori infection by Cobas Core ELISA in adults from Minas Gerais, Brazil. Rocha GA, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1263–8

Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Mock T, et al. **Clin Biochem** 1999 Feb;32(1):59–63

Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? Ahuja V, et al. **Clin Nucl Med** 1998 Dec; 23(12):815–9

Time-optimized carbon-14 breath test for Helicobacter pylori contamination of the stomach. Caglar M, et al. **Clin Nucl Med** 1999 Sep;24(9):674–7

Association between histological diagnosis of Helicobacter pylori and coronary heart disease: results of a retrospective study. Basili S, et al. **Clin Ter** 1998 Nov-Dec;149(6):413–7

A comparison of six commercial kits for Helicobacter pylori detection. McNulty CA, et al. **Commun Dis Public Health** 1999 Jan;2(1):59–63

Diagnosis of Helicobacter pylori infection. Westblom TU, et al. **Curr Top Microbiol Immunol** 1999;241:215–35 (213 ref.)

Evaluation of three commercial enzyme-linked immunosorbent assay kits for diagnosis of Helicobacter pylori in Chinese patients. Leung WK, et al. **Diagn Microbiol Infect Dis** 1999 May;34(1):13–7

Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients? Werdmuller BF, et al. **Dig Dis Sci** 1998 Oct;43(10):2296–300

Inducible nitric oxide synthase, anti-oxidant enzymes and Helicobacter pylori infection in gastritis and gastric precancerous lesions in humans. Pignatelli B, et al. **Eur J Cancer Prev** 1998 Dec;7(6):439–47

Evaluation of a new serologic test for diagnosis of Helicobacter pylori infection in children. Raymond J, et al. **Eur J Clin Microbiol Infect Dis** 1999 Mar;18(3):192–8

Dyspepsia and Helicobacter pylori: test, treat or investigate? Harris A. **Eur J Gastroenterol Hepatol** 1999 Jun;11 Suppl 1:S31–5

A prospective study of the management of the young Helicobacter pylori negative dyspeptic patient--can gastroscopies be saved in clinical practice? Heaney A, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):953–6

Validation of [13C]urea breath test for Helicobacter pylori using a simple gas chromatograph-mass selective detector. Lee HS, et al. **Eur J Gastroenterol Hepatol** 1998 Jul; 10(7):569–72

Does CagA contribute to ulcer pathogenesis in a developing country, such as Sudan? El-Mahdi AM, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):313–6

Do young dyspeptics require endoscopy any more? Moayyedi P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S59–62; discussion S73

Completeness of vagotomy, Helicobacter pylori colonization and recurrent ulcer 9 and 14 years after operation in duodenal ulcer patients. Peetsalu M, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):305–11

Comparative study of microbiological and histopathological techniques used for the detection of Helicobacter pylori. Muñoz E, et al. **Eur J Histochem** 1998;42(4):297–302

Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Leide-Svegborn S, et al. **Eur J Nucl Med** 1999 Jun; 26(6):573–80

Gastritis and peptic ulcer disease in childhood. Blecker U, et al. **Eur J Pediatr** 1999 Jul;158(7):541–6 (62 ref.)

Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR [published erratum appears in FEMS Microbiol Lett 1999 Apr 1;173(1):275] Sevin E, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):369–72

Sensitivity of urease-based test on diagnosis of Helicobacter pylori in children and the elderly [letter; comment] Drumm B, et al. **Gastroenterology** 1999 Jun;116(6):1506. Comment on: Gastroenterology 1998 Jul;115(1):243–4.

Helicobacter pylori status and endoscopy follow-up of patients having a history of perforated duodenal ulcer. Chu KM, et al. **Gastrointest Endosc** 1999 Jul;50(1):58–62

Helicobacter pylori: drowning in a pool of blood? [editorial; comment] Laine L, et al. **Gastrointest Endosc** 1999 Mar; 49(3 Pt 1):398–402. Comment on: Gastrointest Endosc 1999 Mar;49(3 Pt 1):302–6.

Negative CLOtest pellet can be reused. Lee CL, et al. **Gastrointest Endosc** 1999 Aug;50(2):225–8

Serologic detection of CagA positive Helicobacter pylori strains predicts the presence of peptic ulcer in young dyspeptic patients. Rokkas T, et al. **Gastrointest Endosc** 1999 Oct;50(4):511–5

Unsedated transnasal EGD: an alternative approach to conventional esophagogastroduodenoscopy for documenting Helicobacter pylori eradication [see comments] Saeian K, et al. **Gastrointest Endosc** 1999 Mar; 49(3 Pt 1):297–301. Comment in: Gastrointest Endosc 1999 Mar;49(3 Pt 1):395–8.

Does quantitative serologic testing for Helicobacter pylori predict peptic ulcer disease in cirrhosis? Tsai CJ. **Gastrointest Endosc** 1999 Sep;50(3):381–6

Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers [see comments] Tu TC, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):302–6. Comment in: Gastrointest Endosc 1999 Mar;49(3 Pt 1):398–402.

Clinical trials in Helicobacter pylori infection [letter; comment] Calvet X, et al. **Gut** 1998 Nov;43(5):731–2. Comment on: Gut 1997 Sep;41 Suppl 2:S1–9.

The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients [letter; comment] Pathak C, et al. **Gut** 1999 Apr;44(4):582–3. Comment on: Gut 1997 Mar;40(3):302–6.

The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Savarino V, et al. **Gut** 1999 Jul;45 Suppl 1:I18–22 (53 ref.)

13C urea breath test. Thomas JE. **Gut** 1998 Nov;43 Suppl 3:S7–12

New immunological assays for the diagnosis of Helicobacter pylori infection. Vaira D, et al. **Gut** 1999 Jul;45 Suppl 1:I23–7 (51 ref.)

Pediatric Issues Workshop summary. Gold BD, et al. **Helicobacter** 1998 Dec;3(4):305–9

Performance of a rapid whole blood test for Helicobacter pylori in primary care: a German multicenter study. Hackelsberger A, et al. **Helicobacter** 1998 Sep;3(3):179–83

Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Harris RA, et al. **Helicobacter** 1999 Jun;4(2):69–76

Absence of Helicobacter pylori in dental plaque determined by immunoperoxidase. Savoldi E, et al. **Helicobacter** 1998 Dec;3(4):283–7

Helicobacter pylori stool antigen (HpSA) test--a simple, accurate and non-invasive test for detection of Helicobacter pylori infection. Chang MC, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):299–302

Helicobacter pylori and gastroesophageal reflux disease: friends or foes? Gisbert JP, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1023–9 (70 ref.)

Quantitative result of 13C urea breath test at 15 minutes may correlate with the bacterial density of H. pylori in the stomach. Sheu BS, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2057–62

Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. El-Zimaity HM, et al. **Hum Pathol** 1999 Jan;30(1):72–7

Helicobacter pylori infection in recurrent abdominal pain. Bansal D, et al. **Indian Pediatr** 1998 Apr;35(4):329–35

Effect of ranitidine and metronidazole on IgG activity of patients with Helicobacter pylori infection [letter] Konorev MR. **Int J Antimicrob Agents** 1998 Aug;10(3):249–50

Rapid serological diagnosis of Helicobacter pylori: a need for caution and re-evaluation. Heaney A, et al. **Ir J Med Sci** 1998 Jul-Sep;167(3):152–4

HpSA: assessment of a new non-invasive diagnostic assay for Helicobacter pylori infection in an Irish population. McNamara D, et al. **Ir J Med Sci** 1999 Apr-Jun; 168(2):111–3

Diagnosis of Helicobacter pylori infection: non-invasive diagnostic tests. Bazzoli F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S313–4 (6 ref.)

Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Calabrese C, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):359–65

Diagnosis of Helicobacter pylori: invasive methods. Pajares-Garcia JM. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S320–3 (10 ref.)

Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies. Perri F, et al. **Ital J Gastroenterol Hepatol** 1999 May; 31(4):290–4

Usefulness of brushing urease test for diagnosis of Helicobacter pylori infection. Trevisani L, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):599–601

Review article: non-invasive methods for the diagnosis of Helicobacter pylori infection. Zagari RM, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):408–15 (77 ref.)

Diagnosis of Helicobacter pylori gastritis in children using the 13C urea breath test. Eltumi M, et al. **J Clin Gastroenterol** 1999 Apr;28(3):238–40

[13C]-urea breath test for assessment of cure of Helicobacter pylori infection at 1 month after treatment. Miwa H, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S150–3

A comparison of new rapid urease tests for detection of Helicobacter pylori: test characteristics and factors affecting positivity and time to positivity. Niv Y, et al. **J Clin Gastroenterol** 1998 Dec;27(4):327–30

Performance characteristics of an enzyme-linked immunosorbent assay for determining salivary immunoglobulin G response to Helicobacter pylori. De Pascalis R, et al. **J Clin Microbiol** 1999 Feb;37(2):430–2

Detection of Helicobacter pylori DNA in fecal samples from infected individuals. Gramley WA, et al. **J Clin Microbiol** 1999 Jul;37(7):2236–40

Evaluation of commercially available Helicobacter pylori serology kits: a review. Laheij RJ, et al. **J Clin Microbiol** 1998 Oct;36(10):2803–9 (91 ref.)

Comparison of two rapid whole-blood tests for Helicobacter pylori infection in Chinese patients. Leung WK, et al. **J Clin Microbiol** 1998 Nov;36(11):3441–2

Comparison of five PCR methods for detection of Helicobacter pylori DNA in gastric tissues. Lu JJ, et al. **J Clin Microbiol** 1999 Mar;37(3):772–4

Usefulness of Leifson staining method in diagnosis of Helicobacter pylori infection. Piccolomini R, et al. **J Clin Microbiol** 1999 Jan;37(1):199–201

Testing for Helicobacter pylori in primary care: trouble in store? Foy R, et al. **J Epidemiol Community Health** 1998 May;52(5):305–9 (78 ref.)

Diagnosis of Helicobacter pylori in Britain. Duggan A, et al. **J Gastroenterol** 1998;33 Suppl 10:31–5

Clinical studies of 13C-urea breath test in Japan. Kato M, et al. **J Gastroenterol** 1998;33 Suppl 10:36–9 (22 ref.)

Ten minute 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Kato M, et al. **J Gastroenterol** 1998,33 Suppl 10:40–3

Serologic detection of Helicobacter pylori infection with cagA-positive strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis. Miehlke S, et al. **J Gastroenterol** 1998;33 Suppl 10:18–21

What is the optimum strategy for managing dyspepsia? Moayyedi P. **J Gastroenterol** 1998;33 Suppl 10:44–7 (35 ref.)

Evaluation of a new immunochromatographic test for Helicobacter pylori IgG antibodies in elderly symptomatic patients [see comments] Shirin H, et al. **J Gastroenterol** 1999 Feb;34(1):7–10. Comment in: J Gastroenterol 1999 Feb;34(1):145–6.

Pitfalls in serological testing for Helicobacter pylori infection in the elderly [editorial; comment] Sugiyama T, et al. **J Gastroenterol** 1999 Feb;34(1):145–6 (7 ref.). Comment on: J Gastroenterol 1999 Feb;34(1):7–10.

Usefulness of the [13C]-urea breath test for detection of Helicobacter pylori infection in fasting patients. Miwa H, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1039–43

[14C]-urea breath test to confirm eradication of Helicobacter

pylori. Sharma BC, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):309–12

Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. Tanahashi T, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):732–7

Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. Kim SY, et al. **J Immunoassay** 1998 Nov;19(4):251–70

PCR-based diagnosis of Helicobacter pylori infection in Polish children and adults. Gzyl A, et al. **J Med Microbiol** 1999 Apr;48(4):349–56

General population screening for infection with Helicobacter pylori: a realistic option? Stone MA, et al. **J Med Screen** 1998;5(3):162–6

Procedure guideline for carbon-14-urea breath test. Society of Nuclear Medicine. Balon H, et al. **J Nucl Med** 1998 Nov;39(11):2012–4

Detection of Helicobacter pylori infection in children with a standardized and simplified 13C-urea breath test. Cadranel S, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep; 27(3):275–80

Evaluation of serology, 13C-urea breath test, and polymerase chain reaction of stool samples to detect Helicobacter pylori in Bangladeshi children. Casswall TH, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):31–6

Serodiagnosis of Helicobacter pylori in pediatric patients [editorial; comment] Czinn SJ. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):132–4 (20 ref.) . Comment on: J Pediatr Gastroenterol Nutr 1999 Feb;28(2):157–61.

Accuracy of the [13C]-urea breath test in diagnosing Helicobacter pylori gastritis in pediatric patients. Delvin EE, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):59–62

Evaluation of enzyme-linked immunosorbent assay for the diagnosis of Helicobacter pylori infection in children from different age groups with and without duodenal ulcer [see comments] de Oliveira AM, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):157–61. Comment in: J Pediatr Gastroenterol Nutr 1999 Feb;28(2):132–4.

Reverse transcription-polymerase chain reaction in the diagnosis of Helicobacter pylori infection in Finnish children. Oksanen K, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):252–6

Helicobacter pylori infection may undergo spontaneous eradication in children: a 2-year follow-up study. Perri F, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):181–3

Helicobacter pylori and nonulcer dyspepsia in childhood: clinical pattern, diagnostic techniques, and bacterial strains. Rutigliano V, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):296–300

Prevalence of Helicobacter pylori antibodies in endoscopy personnel and non-medical volunteers of Karachi. Abbas Z, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):201–3

CLO antibody assay--can it be an alternate to endoscopy and biopsy? Mehdi I, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):203–5

Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Solnick JV, et al. **Lab Anim Sci** 1999 Apr;49(2):197–201

Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Vaira D, et al. **Lancet** 1999 Jul 3;354(9172):30–3

Application of Bead-ELISA method to detect Helicobacter pylori VacA. Nagata H, et al. **Microb Pathog** 1999 Feb; 26(2):103–10

Utilization of proteinase K-treated cells as lipopolysaccharide antigens for the serodiagnosis of Helicobacter pylori infections. Amano K, et al. **Microbiol Immunol** 1998; 42(7):509–14

Serology and urea breath test in the diagnosis of H. pylori infection. Hawtin PR. **Mol Biotechnol** 1999 Feb;11(1):85–92

Symptom clusters cannot be used in distinguishing Helicobacter pylori positive or negative patients with functional dyspepsia [see comments] Werdmuller BF, et al. **Neth J Med** 1998 Oct;53(4):164–7. Comment in: Neth J Med 1998 Oct;53(4):147–52.

13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? [letter] Hart GC, et al. **Nucl Med Commun** 1999 May;20(5):495–6

Accuracy and clinical utility of the mini-dose 14C-urea breath test in the evaluation of Helicobacter pylori infection. Jensen G, et al. **Nucl Med Commun** 1998 Aug; 19(8):771–5

13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? [letter] Millar AM, et al. **Nucl Med Commun** 1999 Jul;20(7):686

13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? [editorial] Rodrigues M, et al. **Nucl Med Commun** 1998 Nov;19(11):1021–2

Interpreting the 13C-urea breath test among a large population of young children from a developing country. Thomas JE, et al. **Pediatr Res** 1999 Aug;46(2):147–51

Helicobacter pylori and hypergastrinemia in children with recurrent abdominal pain. Günel E, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):40–2

Debate over testing for H pylori [letter] Rashidi A. **Postgrad Med** 1999 Sep;106(3):33

Evaluation of the one-minute ultra-rapid urease test for diagnosing Helicobacter pylori. Misra SP, et al. **Postgrad Med J** 1999 Mar;75(881):154–6

Non-invasive testing for Helicobacter pylori. Stone MA. **Postgrad Med J** 1999 Feb;75(880):74–7

Strategy for the detection of Helicobacter species by amplification of 16S rRNA genes and identification of H. felis in a human gastric biopsy. Germani Y, et al. **Res Microbiol** 1997 May;148(4):315–26

Helicobacter pylori test-and-treat' strategy for dyspeptic patients. Gisbert JP, et al. **Scand J Gastroenterol** 1999 Jul; 34(7):644–52 (120 ref.)

A novel tablet-based 13C urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy. Hamlet A, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):367–74

Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Lerang F, et al. **Scand J Gastroenterol** 1998 Jul;33(7):710–5

Validation and value of an enzyme-linked immunosorbent assay for Helicobacter pylori in primary care. Lewin-van den Broek NT, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):391–5

A systematic overview of the use of diary cards, quality-of-life questionnaires, and psychometric tests in treatment trials of Helicobacter pylori-positive and -negative non-ulcer dyspepsia. Sandha GS, et al. **Scand J Gastroenterol** 1999 Mar;34(3):244–9

Detection of Helicobacter pylori in faeces with a new enzyme immunoassay method: preliminary results [letter] Trevisani L, et al. **Scand J Gastroenterol** 1998 Aug;33(8):893–4

Detection of Helicobacter pylori gene by means of immunomagnetic separation-based polymerase chain reaction in feces. Watanabe T, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1140–3

A home made rapid urease test in the diagnosis of Helicobacter pylori infection. Chiu WY, et al. **Singapore Med J** 1999 Apr;40(4):243–5

Normal limits of 14C-urea breath test. Kaul A, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):110–3

Association between serum pepsinogen A and C levels, serum gastrin concentrations and Helicobacter pylori antibodies. Kullich W, et al. **Wien Med Wochenschr** 1999;149(7):157–61

Accuracy and economics of Helicobacter pylori diagnosis. Cutler AF. **Yale J Biol Med** 1998 Mar-Apr;71(2):75–9 (14 ref.)

Helicobacter pylori and smoking: two additive risk factors for organic dyspepsia. Halter F, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):91–9 (35 ref.)

Realities of diagnosing Helicobacter pylori infection in clinical practice: a case for non-invasive indirect methodologies. Metz DC, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):81–90

Nondispersive infrared spectrometry for 13CO2/12CO2-measurements: a clinically feasible analyzer for stable isotope breath tests in gastroenterology. Braden B, et al. **Z Gastroenterol** 1999 Jun;37(6):477–81

[Laser-assisted 13C-urea breath test; a new noninvasive detection method for Helicobacter pylori infection] van der Hulst RW, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):400–4 (Eng. Abstr.) **(Dut)**

[The 13C-urea breath test in Helicobacter pylori gastric infection in children] Kalach N, et al. **Arch Pediatr** 1998 Dec;5(12):1359–65 (42 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of Helicobacter pylori infection is still a timely issue (editorial; comment)] Mégraud F. **Gastroenterol Clin Biol** 1998 Apr;22(4):405–6. Comment on: Gastroenterol Clin Biol 1998 Apr;22(4):407–12. **(Fre)**

[Non-ulcerating dyspepsia: role of Helicobacter pylori] Sobhani L. **Presse Med** 1998 Sep 5;27(25):1292–3 **(Fre)**

[Helicobacter pylori screening in a general practice] Hollenz M, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):171–5 (Eng. Abstr.) **(Ger)**

[The 13C urea breath test] Schwörer H, et al. **Internist (Berl)** 1998 Nov;39(11):1188 **(Ger)**

[Prevention of stomach carcinoma by Helicobacter pylori eradication. Invitation to participate in the PRISMA Study] Bayerdörffer E, et al. **Z Gastroenterol** 1999 May; 37(5):XXI-XXV **(Ger)**

[An unusual course of low-malignancy non-Hodgkin lymphoma of the stomach] De Mas CR, et al. **Z Gastroenterol** 1998 Jul;36(7):567–9 (Eng. Abstr.) **(Ger)**

[Gastric MALT lymphoma, clinical features] Udvardy M. **Orv Hetil** 1999 Feb 7;140(6):291–4 (Eng. Abstr.) **(Hun)**

[Investigation about usefulness of serum antibody of Helicobacter pylori and serum pepsinogen I/II ratio as a marker of the judgment after eradication therapy] Fujisawa T, et al. **Nippon Rinsho** 1999 Jan;57(1):101–6 (Eng. Abstr.) **(Jpn)**

[Possible availability of rapid urease tests for diagnosis of Helicobacter pylori eradication: comparative study with culture and histology] Murata H, et al. **Nippon Rinsho** 1999 Jan;57(1):97–100 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The 13C-urea breath test efficacy in determining Helicobacter pylori eradication] Toyama J, et al. **Nippon Rinsho** 1999 Jan;57(1):93–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[PCR-monitoring of gastric juice obtained with the capsuled string for the evaluation of H. pylori eradication] Yoshida H, et al. **Nippon Rinsho** 1999 Jan;57(1):107–10 (Eng. Abstr.) **(Jpn)**

[Usefulness of Helicobacter pylori stool antigen (HpSA) assay for detection of Helicobacter pylori infection] Ohkura R, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec; 95(12):1397 **(Jpn)**

[Semi-quantitative detection of Helicobacter pylori using immunohistochemical staining] Shirahase H, et al. **Rinsho Byori** 1998 Dec;46(12):1258–63 (Eng. Abstr.) **(Jpn)**

[13C-urea breath test as diagnostic method in Helicobacter pylori infection] Dahlberg M, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3762–5 (Eng. Abstr.) **(Nor)**

[Contemporary approaches to diagnosis and treatment of chronic duodenitis among flying personnel] Preobrazhenskii VN, et al. **Aviakosm Ekolog Med** 1998; 32(3):70–3 (Eng. Abstr.) **(Rus)**

[Helicobacter pylori in patients with complicated peptic ulcer] Gonchar MG, et al. **Khirurgiia (Mosk)** 1999;(6):25–6 (Eng. Abstr.) **(Rus)**

[Evaluation of a fast urease test for detection of Helicobacter pylori (editorial)] Besasso H. **Acta Gastroenterol Latinoam** 1999;29(1):37–8 **(Spa)**

[Evaluation of a fast urease test for the detection of Helicobacter pylori] Blanco D, et al. **Acta Gastroenterol Latinoam** 1999;29(1):17–20 (Eng. Abstr.) **(Spa)**

[A comparative analysis of diagnostic methods for Helicobacter pylori infection in children] Parejo Carranza R, et al. **An Esp Pediatr** 1998 Sep;49(3):257–63 (Eng. Abstr.) **(Spa)**

[Use of the polymerase chain reaction (PCR) for the diagnosis of Helicobacter pylori infection in pediatric patients] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):395–9 (Eng. Abstr.) **(Spa)**

[Typification of strains of Helicobacter pylori by the detection of the cagA gene and subtypes of the vacA gene] Gómez J, et al. **Enferm Infecc Microbiol Clin** 1999 Apr; 17(4):171–5 (Eng. Abstr.) **(Spa)**

[Evaluation of a western blot technique (Helicoblot 2.0) fpr the detection of specific Heliocobacter pylori antigens in children) López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul;16(6):275–9 (Eng. Abstr.) **(Spa)**

[Evaluation of a simple rapid polymerase chain reaction (PCR) technique for the diagnosis of Helicobacter pylori infection in childhood] Muñoz C, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):119–25 (Eng. Abstr.) **(Spa)**

[The evaluation of a new immunoenzyme analysis for the detection of Helicobacter pylori infection in stool samples] Calvet X, et al. **Gastroenterol Hepatol** 1999 Jun-Jul; 22(6):270–2 (Eng. Abstr.) **(Spa)**

[The attitude of primary health care physicians in the metropolitan area of Barcelona about the diagnosis and treatment of Helicobacter pylori infection in gastroduodenal diseases] Martínez-Sánchez G, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):473–8 (Eng. Abstr.) **(Spa)**

[Should H. pylori infection in duodenal ulcer be confirmed before administering eradicating treatment? (editorial)] Gisbert JP, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):134–7 (68 ref.) **(Spa)**

[Leukocytoclastic vasculitis associated with Helicobacter pylori infection (letter)] Herranz P, et al. **Rev Clin Esp** 1998 Nov;198(11):779 (8 ref.) **(Spa)**

[The breath test with labeled urea for the diagnosis of Helicobacter pylori infection] Pérez Páramo M, et al. **Rev Esp Med Nucl** 1998;17(6):455–67 (53 ref.) **(Spa)**

[Breath tests as a noninvasive diagnostic method in Helicobacter pylori infection] Di Silvio M, et al. **Rev Gastroenterol Mex** 1998 Jul-Sep;63(3):135–42 (Eng. Abstr.) **(Spa)**

[Time for a national consensus on the diagnosis of peptic ulcer (letter)] Sjövall H. **Lakartidningen** 1999 Aug 11; 96(32-33):3404 **(Swe)**

[Morphological changes in the stomach and duodenum in ulcer disease with Helicobacter infection] Honchar MH, et al. **Klin Khir** 1998;(12):5–6 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

Consensus for the management of Helicobacter pylori infection in children: still searching for a paradigm. Cadranel S, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):316–20 (53 ref.)

The search for optimal Helicobacter pylori eradication regimen: a mid 1997 update. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):344–7 (30 ref.)

Pharmacoeconomics in HP-related diseases: more questions than answers. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):352–6 (49 ref.)

Who? When to treat? Gastritis, particular histological lesions, NSAID therapy and extradigestive diseases. Deprez P. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):307–12 (83 ref.)

Short-term side effects during H. pylori eradication therapy. Dumonceau JM. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):348–9 (11 ref.)

Antimicrobial resistance in Helicobacter pylori: a global overview. Glupczynski Y. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):357–66 (85 ref.)

Adverse events of HP eradication: long-term negative consequences of HP eradication. Koster ED. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):350–1 (10 ref.)

Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Včev A, et al.

Acta Med Croatica 1998;52(4–5):209–14

Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. Tirén U, et al. **Acta Paediatr** 1999 Feb; 88(2):166–8

Helicobacter pylori and gastro–oesophageal reflux disease [letter] Attwood S. **Aliment Pharmacol Ther** 1999 Aug; 13(8):1132–4

Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Bortolotti M, et al. **Aliment Pharmacol Ther** 1998 Oct; 12(10):1021–5

Two–week dual vs. one–week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Calvet X, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):781–6

Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. Cestari R.
Aliment Pharmacol Ther 1998 Oct;12(10):991–6

Does eradication of Helicobacter pylori impair healing of nonsteroidal anti–inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Chan FK, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1201–5

Low– versus high–dose azithromycin triple therapy for Helicobacter pylori infection. Chey WD, et al.
Aliment Pharmacol Ther 1998 Dec;12(12):1263–7 (16 ref.)

Two–day 'weekend' lansoprazole–quadruple therapy for Helicobacter pylori infection. de Boer WA, et al.
Aliment Pharmacol Ther 1998 Jan;12(1):77–81

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1–week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Ducóns JA, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):775–80

Review article: factors influencing antibiotic transfer across the gastric mucosa. Goddard AF.
Aliment Pharmacol Ther 1998 Dec;12(12):1175–84 (69 ref.)

Ranitidine bismuth citrate, tetracycline, clarithromycin twice–a–day triple therapy for clarithromycin susceptible Helicobacter pylori infection. Graham DY, et al.
Aliment Pharmacol Ther 1999 Feb;13(2):169–72

Comparison of two 3–day Helicobacter pylori eradication regimens with a standard 1–week regimen. Grimley CE, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):869–73

Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori—a randomized, controlled trial. Gschwantler M, et al. **Aliment Pharmacol Ther** 1999 Aug; 13(8):1063–9

High Helicobacter pylori eradication rate with a 1–week regimen containing ranitidine bismuth citrate. Gudjonsson H, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1113–9

Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Harris AW, et al. **Aliment Pharmacol Ther** 1998 Aug;12(8):741–5

Efficacy of a 1–week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. Hoffman JS, et al.
Aliment Pharmacol Ther 1999 Apr;13(4):503–6

A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates. Houben MH, et al.
Aliment Pharmacol Ther 1999 Aug;13(8):1047–55 (50 ref.)

Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole–resistant or –susceptible Helicobacter pylori strains. Houben MH, et al.
Aliment Pharmacol Ther 1999 Jul;13(7):883–9

Clarithromycin–based triple therapies [letter; comment] Huang J, et al. **Aliment Pharmacol Ther** 1999 Mar; 13(3):437–9. Comment on: Aliment Pharmacol Ther 1998 Sep;12(9):823–37.

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta–analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Huang J, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):719–29

Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Kashimura H, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):483–7

Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Knigge K, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):323–6

Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost–effectiveness analysis. Laheij RJ, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1249–56

Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta–analysis. Laheij RJ, et al.
Aliment Pharmacol Ther 1999 Jul;13(7):857–64

Low rate of emergence of clarithromycin–resistant Helicobacter pylori with amoxycillin co–therapy. Laine L, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):887–92

Treatment options for Helicobacter pylori infection when proton pump inhibitor–based triple therapy fails in clinical practice. Lee JM, et al. **Aliment Pharmacol Ther** 1999 Apr; 13(4):489–96

Furazolidone–containing short–term triple therapies are effective in the treatment of Helicobacter pylori infection. Liu WZ, et al. **Aliment Pharmacol Ther** 1999 Mar; 13(3):317–22

Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co–therapy with amoxycillin and clarithromycin. Louw JA, et al.
Aliment Pharmacol Ther 1998 Sep;12(9):881–5

The GU–MACH study: the effect of 1–week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Malfertheiner P, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):703–12

Changes in Helicobacter pylori–induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Meining A, et al. **Aliment Pharmacol Ther** 1998 Aug;12(8):735–40

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection–comparison with omeprazole and lansoprazole. Miwa H, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):741–6

Prospective evaluation of ranitidine bismuth citrate–based triple therapy for the treatment of Helicobacter pylori infection. Mönkemüller KE, et al.
Aliment Pharmacol Ther 1999 May;13(5):661–5

The optimal antibiotic combination in a 5–day Helicobacter pylori eradication regimen. Neville PM, et al.
Aliment Pharmacol Ther 1999 Apr;13(4):497–501

A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Okada M, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):769–74

Novel therapies for Helicobacter pylori infection. Opekun AR, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):35–42

Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. Paré P, et al.
Aliment Pharmacol Ther 1999 Aug;13(8):1071–8

Short–term low–dose pantoprazole–based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. Pazzi P, et al. **Aliment Pharmacol Ther** 1998 Aug; 12(8):731–4

Review article: one–week clarithromycin triple therapy regimens for eradication of Helicobacter pylori [see comments] Pipkin GA, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):823–37 (213 ref.). Comment in: Aliment Pharmacol Ther 1999 Mar;13(3):437–9.

Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole—an open pilot study. Pohle T, et al. **Aliment Pharmacol Ther** 1998 Dec; 12(12):1273–8

H2–antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study. Prach AT, et al.
Aliment Pharmacol Ther 1998 Sep;12(9):873–80

Helicobacter pylori eradication with proton pump inhibitor–based triple therapies and re–treatment with ranitidine bismuth citrate–based triple therapy. Rinaldi V, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):163–8

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. Savarino V, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):43–7

Head–to–head comparison of 1–week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Savarino V, et al.
Aliment Pharmacol Ther 1999 May;13(5):643–9

Short–term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. Sieg A, et al. **Aliment Pharmacol Ther** 1999 Jul; 13(7):865–8

Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Spadaccini A, et al. **Aliment Pharmacol Ther** 1998 Oct;12(10):997–1001

One–week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC–MACH study. Sung JJ, et al.
Aliment Pharmacol Ther 1999 Aug;13(8):1079–84

One–week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori–related duodenal ulcer. Sung JJ, et al.
Aliment Pharmacol Ther 1998 Aug;12(8):725–30

The effect of Helicobacter pylori eradication on gastro–oesophageal reflux. Tefera S, et al.
Aliment Pharmacol Ther 1999 Jul;13(7):915–20

Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease. Trevisani L, et al.
Aliment Pharmacol Ther 1998 Dec;12(12):1269–72

The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Van der Wouden EJ, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):297–302

Failure of a 1–day high–dose quadruple therapy for cure of Helicobacter pylori infection. Wermeille J, et al.
Aliment Pharmacol Ther 1999 Feb;13(2):173–7

Triple therapy for Helicobacter pylori eradication is more effective than long–term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long–term follow–up study. Wong BC, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):303–9

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. Xiao SD, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):311–5

The DU–MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Zanten SJ, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):289–95

Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole–based one–week modified triple therapy versus two–week dual therapy. The International Pantoprazole HP Study Group. Adamek RJ, et al. **Am J Gastroenterol** 1998 Oct;93(10):1919–24

A second–line anti–Helicobacter pylori therapy in patients with previously failed treatment [letter] Ali' A, et al.
Am J Gastroenterol 1999 Aug;94(8):2321–3

Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Bravo LE, et al. **Am J Gastroenterol** 1999 Sep; 94(9):2380–3

Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study. Henry A, et al. **Am J Gastroenterol** 1999 Mar;94(3):811–5

Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies [letter] Higuchi K, et al. **Am J Gastroenterol** 1999 May; 94(5):1419–20

Remission of Ménétrier's disease after a prolonged period with therapeutic eradication of Helicobacter pylori. Kaneko T, et al. **Am J Gastroenterol** 1999 Jan;94(1):272–3

One–week ranitidine bismuth citrate versus colloidal bismuth subcitrate–based anti–Helicobacter triple therapy: a prospective randomized controlled trial. Kung NN, et al.
Am J Gastroenterol 1999 Mar;94(3):721–4

Once–daily therapy for H. pylori infection: a randomized comparison of four regimens. Laine L, et al.
Am J Gastroenterol 1999 Apr;94(4):962–6

Twice–daily, 10–day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double–blind, United States trials. Laine L, et al. **Am J Gastroenterol** 1998 Nov;93(11):2106–12

Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Marchildon P, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2105–8

Hyperplastic gastric polyps: medical management is feasible. Metz DC. **Am J Gastroenterol** 1999 Jul;94(7):1977–8

Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. Murata H, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2102–5

Do we all treat functional dyspepsia with Helicobacter pylori eradication? [letter; comment] Prónai L, et al.
Am J Gastroenterol 1999 Feb;94(2):543. Comment on: Am J Gastroenterol 1998 Apr;93(4):553–61.

Has eradication therapy an effect in Helicobacter–positive patients with chronic urticaria? [letter] Schrutka–Koelbl C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2632–3

Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. Smoot DT, et al. **Am J Gastroenterol** 1999 Apr;94(4):955–8

The effect of antibiotic therapy on bleeding from duodenal ulcer. Sonnenberg A, et al. **Am J Gastroenterol** 1999 Apr; 94(4):950–4

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Stack WA, et al. **Am J Gastroenterol** 1998 Oct;93(10):1909–13

Body–fundic mucopeptic cells expansion after Helicobacter pylori eradication [letter] Testino G.
Am J Gastroenterol 1998 Dec;93(12):2636–8

Treatment of the "ineradicable" Helicobacter pylori infection [letter] Tucci A, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1713–5

Ten–day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Vakil N, et al. **Am J Gastroenterol** 1999 May; 94(5):1197–9

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole–containing anti–Helicobacter pylori regimens: a meta–analysis. van der Wouden EJ, et al. **Am J Gastroenterol** 1999 Jul;94(7):1751–9

Helicobacter pylori: rational management options. Peura D. **Am J Med** 1998 Nov;105(5):424–30 (43 ref.)

In a world of black and white, Helicobacter pylori is gray [editorial] Blaser MJ. **Ann Intern Med** 1999 Apr 20; 130(8):695–7

Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ohkusa T, et al. **Ann Intern Med** 1998 Nov 1; 129(9):712–5

Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Jenks PJ, et al.
Antimicrob Agents Chemother 1999 Apr;43(4):777–81

Gastric penetration of amoxicillin in a human Helicobacter pylori–infected xenograft model. Lozniewski A, et al.
Antimicrob Agents Chemother 1999 Aug;43(8):1909–13

Effect of treatment of Helicobacter pylori infection on rosacea. Bamford JT, et al. **Arch Dermatol** 1999 Jun;

135(6):659–63

Helicobacter pylori eradication in patients with chronic urticaria [letter] Ozkaya-Bayazit E, et al. **Arch Dermatol** 1998 Sep;134(9):1165–6 (6 ref.)

Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Behrens R, et al. **Arch Dis Child** 1999 Jul;81(1):68–70

Effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease. Goggin N, et al. **Arch Dis Child** 1998 Dec;79(6):502–5

Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Fennerty MB, et al. **Arch Intern Med** 1999 Jul 26;159(14):1562–6

Treating Helicobacter pylori [letter; comment] Howden CW, et al. **Arch Intern Med** 1998 Nov 23;158(21):2396–8. Comment on: Arch Intern Med 1998 Apr 27;158(8):842–51.

Three treatment schemes with colloidal bismuth subcitrate (Q-ULCER) in peptic ulcer with Helicobacter pylori. Suárez MS, et al. **Arch Med Res** 1999 Jan-Feb;30(1):55–9

Perforated duodenal ulcer: an alternative therapeutic plan. Donovan AJ, et al. **Arch Surg** 1998 Nov;133(11):1166–71 (34 ref.)

Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pyroli. Katayama H, et al. **Biol Pharm Bull** 1999 Jan;22(1):55–60

Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents [published erratum appears in Bioorg Med Chem Lett 1998 Oct 20;8(20):2937] Sakurai N, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2185–90

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Talley NJ, et al. **BMJ** 1999 Mar 27;318(7187):833–7

Helicobacter pylori in South America. Castro L de P, et al. **Can J Gastroenterol** 1998 Oct;12(7):509–12 (32 ref.)

Treatment of Helicobacter pylori in patients with upper abdominal pain syndromes. Freeman H. **Can J Gastroenterol** 1999 May;13(4):299–300

Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Torgano G, et al. **Circulation** 1999 Mar 30;99(12):1555–9

Treatment of Helicobacter pylori in nonulcer dyspepsia: should we or shouldn't we? Falk GW. **Cleve Clin J Med** 1999 Jul-Aug;66(7):398–9, 402–4 (12 ref.)

Serological assessment of the early response to eradication therapy using an immunodominant outer membrane protein of Helicobacter pylori. Nishizono A, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):856–61

Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. Enroth H, et al. **Clin Infect Dis** 1999 Jun;28(6):1305–7

Reactive arthritis induced by Clostridium difficile enteritis as a complication of Helicobacter pylori eradication. Söderlin MK, et al. **Clin Rheumatol** 1999;18(4):337–8

Antibiotic treatment of Helicobacter pylori infection. Unge P. **Curr Top Microbiol Immunol** 1999;241:261–300 (441 ref.)

Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments. Catalano F, et al. **Dig Dis Sci** 1999 May;44(5):863–7

Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dial EJ, et al. **Dig Dis Sci** 1998 Dec;43(12):2750–6

Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. Keto Y, et al. **Dig Dis Sci** 1999 Feb; 44(2):257–65

Resolution of gastritis induced by Helicobacter pylori 4–5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. Abdul Aal GM, et al. **Digestion** 1999;60(3):286–97

One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. Dajani AI, et al. **Digestion** 1999;60(3):298–304

Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. Miehlke S, et al. **Digestion** 1998 Nov-Dec;59(6):646–50

Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment. Raderer M, et al. **Digestion** 1999 Jul-Aug;60(4):358–62

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Langtry HD, et al. **Drugs** 1998 Sep;56(3):447–86 (126 ref.)

Endoscopic ultrasonography images of gastric mucosa-associated lymphoid tissue type (MALT) lymphoma after Helicobacter pylori eradication. Fujiwara Y, et al. **Endoscopy** 1999 Feb;31(2):S3

Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options? [editorial] Hazell SL. **Eur J Clin Microbiol Infect Dis** 1999 Feb; 18(2):83–6

Treatment of Helicobacter pylori: where are we now? What are the key questions? Axon A. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S3–7; discussion S23–4

Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Bayerdörffer E, et al. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S19–22; discussion S23–4

What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? Bazzoli F, et al. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S39–42; discussion S43–5

My approach to Helicobacter pylori eradication. Bazzoli F. **Eur J Gastroenterol Hepatol** 1999 Jun;11 Suppl 1:S37–41

Antimicrobial treatment for peptic stenosis: a prospective study. Brandimarte G, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):731–4

Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Cammarota G, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):247–50

Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. de Boer WA. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):697–700 (40 ref.)

Should we go further and screen and treat? Forman D. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S69–71; discussion S73

Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Gasbarrini A, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):713–6

Atrophy, acid suppression and Helicobacter pylori infection: a tale of two studies. Genta RM. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S29–33; discussion S43–5

Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Gisbert JP, et al. **Eur J Gastroenterol Hepatol** 1999 Feb;11(2):189–200

Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Gschwantler M, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):579–82

Is Helicobacter pylori eradication useful in patients taking NSAIDs? Hawkey CJ. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S47–50; discussion S73

The Maastricht recommendations and their impact on general practice. Malfertheiner P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S63–7; discussion S73

Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Mégraud F. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S35–7; discussion S43–5

Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Roghani HS, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):709–12

Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Spiller RC. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S25–8; discussion S43–5

The OAC and OMC options. Unge P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S9–17; discussion S23–4

The case for treatment of dyspeptic patients infected with H. pylori. Hunt RH, et al. **Eur J Surg Suppl** 1998;(582):6–10

H. pylori infection in non-ulcer patients--to treat or not to treat. The case against treatment. McCarthy DM. **Eur J Surg Suppl** 1998;(582):11–5

Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies. Unge P. **Eur J Surg Suppl** 1998;(582):16–26

Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population. López-Brea M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):183–8

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status [see comments] Gillen D, et al. **Gastroenterology** 1999 Feb;116(2):239–47. Comment in: Gastroenterology 1999 Feb;116(2):479–83.

Antibiotic resistance in Helicobacter pylori: implications for therapy. Graham DY. **Gastroenterology** 1998 Nov; 115(5):1272–7 (36 ref.)

Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibodies [letter] Isaacson PG, et al. **Gastroenterology** 1999 Sep;117(3):750–1

Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion [editorial; comment] Kuipers EJ, et al. **Gastroenterology** 1999 Feb; 116(2):479–83 (35 ref.). Comment on: Gastroenterology 1999 Feb;116(2):239–47. Comment on: Gastroenterology 1999 Feb;116(2):248–53.

The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies [see comments] Lind T, et al. **Gastroenterology** 1999 Feb; 116(2):248–53. Comment in: Gastroenterology 1999 Feb;116(2):479–83.

Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Lundell L, et al. **Gastroenterology** 1999 Aug;117(2):319–26

PPI-based triple therapy in the eradication of H. pylori infection [letter] Savarino V, et al. **Gastroenterology** 1999 Sep;117(3):746–7

Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication [letter; comment] Bateson MC. **Gut** 1998 Oct;43(4):586. Comment on: Gut 1998 Feb;42(2):166–9.

A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic [see comments] Heaney A, et al. **Gut** 1999 Aug;45(2):186–90. Comment in: Gut 1999 Aug;45(2):164–5.

Treatment after failure: the problem of "non-responders". Huang JQ, et al. **Gut** 1999 Jul;45 Suppl 1:I40–4 (47 ref.)

Helicobacter pylori resists arrest [comment] Owen RJ. **Gut** 1999 Apr;44(4):447–8. Comment on: Gut 1999 Apr;44(4):463–7.

How should Helicobacter pylori infected children be managed? Rowland M, et al. **Gut** 1999 Jul;45 Suppl 1:I36–9 (47 ref.)

Helicobacter pylori-reflections for the next millennium. Tytgat GN. **Gut** 1999 Jul;45 Suppl 1:I45–7 (15 ref.)

Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics. Adamek RJ, et al. **Helicobacter** 1998 Sep;3(3):206–11

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Bazzoli F, et al. **Helicobacter** 1998 Sep; 3(3):195–201

Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. Catalano F, et al. **Helicobacter** 1999 Sep;4(3):178–84

Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Choe YH, et al. **Helicobacter** 1999 Jun;4(2):135–9

Pediatric Issues Workshop summary. Gold BD, et al. **Helicobacter** 1998 Dec;3(4):305–9

Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Kamada T, et al. **Helicobacter** 1999 Sep;4(3):204–10

Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Kato S, et al. **Helicobacter** 1998 Dec;3(4):278–82

Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. Korman MG, et al. **Helicobacter** 1998 Sep;3(3):202–5

Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Lanza FL, et al. **Helicobacter** 1998 Sep;3(3):212–21

Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. Nie Y, et al. **Helicobacter** 1999 Jun;4(2):128–34

Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Realdi G, et al. **Helicobacter** 1999 Jun;4(2):106–12

Can proton pump inhibitors be used as bactericidal drugs in Helicobacter pylori-positive patients? [letter] Saito N, et al. **Helicobacter** 1999 Sep;4(3):211–2

Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Schwartz HI, et al. **Helicobacter** 1999 Jun;4(2):121–7

Eradication of Helicobacter pylori in routine clinical practice: doubts and uncertainties. Cammarota G, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):312–5

Beneficial effects of Helicobacter pylori eradication on migraine. Gasbarrini A, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):765–70

Eradiction of H. pylori results in regression of B-cell low grade gastric MALToma with evident B-symptoms. Huang GC, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2464–7

Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Ihan A, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1740–5

The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Kyzekova J, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2048–56

A three-day octreotide-containing helicobacter pylori eradication therapy for cure of peptic ulcers. Ladas SD, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):761–4

Acid suppression with ranitidine plus oral triple therapy improves ulcer healing but not Helicobacter pylori eradication. Magalhaes AF, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2161–4

Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. Parente F, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):990–3

Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients. Pilotto A, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):245–51

Helicobacter pylori of the remnant stomach and its eradication. Rino Y, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2069–73

Cardiac biopsy of stomach may improve the detection of H. pylori after dual therapy. Sheu BS, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):543–8

A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication. Tepes B, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1746–50

Rethinking our approach to dyspepsia [editorial] Johnson MF. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):13–4, 17, 21

The role of azithromycin in the treatment of Helicobacter pylori infection – a retrospective report. Dohmen W, et al. **Infection** 1998 Jul–Aug;26(4):256–62

Determination of azithromycin in gastric biopsy samples. Krichhoff RM, et al. **Int J Clin Pharmacol Ther** 1999 Jul; 37(7):361–4

Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series [see comments] Battaglia G, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):370–4 . Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):375–7.

Helicobacter pylori eradication failure--'salvage' therapies needed [comment] Borody TJ. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):375–7. Comment on: Ital J Gastroenterol Hepatol 1998 Aug;30(4):370–4.

Recovery after Helicobacter pylori eradication: how long does it take? [comment] Correa P. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):9. Comment on: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):4–8.

Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication [letter] Delle Cave M, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):265

Eradication of Helicobacter pylori: why does it fail? Deltenre M, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S326–8 (14 ref.)

New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. Gasbarrini G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S244–7 (20 ref.)

Economic evaluations in medicine: still more questions than answers? Grossi E. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):347–50

Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association [letter] Lombardo L, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):266–7

Novel therapeutic approaches to the management of Helicobacter pylori infection. Montague S, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S334–8 (35 ref.)

Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Monteiro L, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S329–33 (24 ref.)

Therapeutic news on Helicobacter pylori from Budapest and Wien. Ricci C, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):648–62

Histological and functional recovery in patients with multifocal atrophic gastritis after eradication of Helicobacter pylori infection [see comments] Savarino V, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):4–8 . Comment in: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):9.

How can we improve on the efficacy of Helicobacter pylori treatment? [editorial] Spiller RC. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):351–4

Pre-treatment with misoprostol increases the efficacy of omeprazole plus amoxycillin to cure Helicobacter pylori infection. A pilot study [letter] Tursi A, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):449–50

Helicobacter pylori eradication treatment reduces the severity of rosacea. Utaş S, et al. **J Am Acad Dermatol** 1999 Mar;40(3):433–5

The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. Moshkowitz M, et al. **J Am Geriatr Soc** 1999 Jun;47(6):720–2

The value of different detection methods of Helicobacter pylori during treatment. Adamsson I, et al. **J Clin Gastroenterol** 1998 Sep;27(2):138–42

Helicobacter pylori eradication: comparison of three treatment regimens in India. Bhasin DK, et al. **J Clin Gastroenterol** 1999 Jun;28(4):348–51

Does acid suppression by antacids and H2 receptor antagonists increase the incidence of atrophic gastritis in patients with or without H. pylori gastritis? Carter M, et al. **J Clin Gastroenterol** 1999 Sep;29(2):183–7

Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. Dattilo M, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S163–9 (55 ref.)

After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. Gürel S, et al. **J Clin Gastroenterol** 1999 Apr;28(3):241–4

Long-term effect of Helicobacter pylori eradication on gastric metaplasia in patients with duodenal ulcer. Kim N, et al. **J Clin Gastroenterol** 1998 Oct;27(3):246–52

Eradication of Helicobacter pylori, improvement of gastritis, and the normalization of the hyperproliferative state of gastric mucosa did not prevent a case of gastric cancer [letter] Maconi G, et al. **J Clin Gastroenterol** 1999 Mar; 28(2):178–9

Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. Mera R, et al. **J Clin Gastroenterol** 1999 Jul;29(1):51–5

Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. Sakaki N, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S187–91

Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection. Shimoyama T, et al. **J Clin Gastroenterol** 1998 Dec;27(4):348–50

Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. Suzuki J, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S159–62

Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone. Suzuki M, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S183–6

Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori. Siu LK, et al. **J Clin Microbiol** 1998 Oct;36(10):3048–50

Treatment of Helicobacter pylori infection in functional dyspepsia. Grimm KJ. **J Fam Pract** 1999 Jul;48(7):496–7

Treating Helicobacter pylori infection in nonulcer dyspepsia. Lord RW Jr. **J Fam Pract** 1999 Mar;48(3):172–3

One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. Lee CL, et al. **J Formos Med Assoc** 1998 Nov; 97(11):733–7

Eradication therapies for Helicobacter pylori. Borody TJ, et al. **J Gastroenterol** 1998;33 Suppl 10:53–6 (10 ref.)

Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. Moayyedi P, et al. **J Gastroenterol** 1998;33 Suppl 10:62–5

A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. Okada M, et al. **J Gastroenterol** 1998 Oct;33(5):640–5

Eradication therapy of Helicobacter pylori. A review. Report from a workshop organized by the Swedish and Norwegian Medical Products Agencies, September 1995. Unge P. **J Gastroenterol** 1998;33 Suppl 10:57–61

Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. Chen W, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):322–7

Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians. Dhali GK, et al. **J Gastroenterol Hepatol** 1999 Jun; 14(6):523–8

Follow up after successful eradication of Helicobacter pylori: symptoms and reinfection. Fraser AG, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):555–9

Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. Miwa H, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):317–21

Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. Pilotto A, et al. **J Gastroenterol Hepatol** 1999 May;14(5):468–75

Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy. Saita H, et al. **J Gastroenterol Hepatol** 1998 Jul; 13(7):725–31

Eradication of Helicobacter pylori. Kundu AK. **J Indian Med Assoc** 1998 Nov;96(11):349–50 (11 ref.)

Contact granulomas [letter] Hynes B. **J Otolaryngol** 1998 Oct; 27(5):310

One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. Casswall TH, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):415–8

Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori. Huang FC, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):76–80

Helicobacter pylori reinfection rates in children after eradication therapy. Kato S, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):543–6

Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy. Schultz-Süchting F, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):341–2

The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers. Sasakii M, et al. **J Pharm Pharmacol** 1999 Jul;51(7):825–30

Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. Shah S, et al. **J Pharm Pharmacol** 1999 Jun; 51(6):667–72

A study of Helicobacterium pylori and prevention and treatment of chronic atrophic gastritis. Zhang L, et al. **J Tradit Chin Med** 1997 Mar;17(1):3–9

The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail. Shuter J, et al. **J Urban Health** 1998 Dec;75(4):896–902

Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Chan FK, et al. **Lancet** 1998 Dec 19–26;352(9145):2016; discussion 2017. Comment on: Lancet 1998 Sep 26;352(9133):1016–21.

Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Savarino V, et al. **Lancet** 1998 Dec 19–26;352(9145):2016–7 . Comment on: Lancet 1998 Sep 26;352(9133):1016–21.

Antibiotic resistance in Helicobacter pylori [letter] Teare L, et al. **Lancet** 1999 Jan 16;353(9148):242

Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Pasta DJ, et al. **Med Decis Making** 1999 Jul–Sep;19(3):353–63

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group [see comments] Blum AL, et al. **N Engl J Med** 1998 Dec 24;339(26):1875–81. Comment in: N Engl J Med 1998 Dec 24;339(26):1928–30. Comment in: ACP J Club 1999 May–Jun;130(3):64–5. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1508–9; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1509; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1509–11.

Helicobacter pylori and nonulcer dyspepsia [editorial; comment] [see comments] Friedman LS. **N Engl J Med** 1998 Dec 24;339(26):1928–30. Comment on: N Engl J Med 1998 Dec 24;339(26):1869–74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875–71. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1509–11.

Helicobacter pylori and nonulcer dyspepsia [letter; comment] Lieber CS. **N Engl J Med** 1999 May 13;340(19):1508; discussion 1509–11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869–74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875–81. Comment on: N Engl J Med 1998 Dec 24;339(26):1928–30.

Helicobacter pylori and nonulcer dyspepsia [letter; comment] Logan RF, et al. **N Engl J Med** 1999 May 13;340(19):1509; discussion 1509–11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869–74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875–81.

Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia [see comments] McColl K, et al. **N Engl J Med** 1998 Dec 24; 339(26):1869–74. Comment in: N Engl J Med 1998 Dec 24;339(26):1928–30. Comment in: ACP J Club 1999 May–Jun;130(3):65. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1508–9; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1509; discussion 1509–11. Comment in: N Engl J Med 1999 May 13;340(19):1509–11.

Helicobacter pylori and nonulcer dyspepsia [letter; comment] Püspök A, et al. **N Engl J Med** 1999 May 13;340(19):1508–9; discussion 1509–11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869–74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875–81.

Helicobacter pylori and nonulcer dyspepsia [letter; comment] Scott BB. **N Engl J Med** 1999 May 13;340(19):1509–11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869–74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875–81. Comment on: N Engl J Med 1998 Dec 24;339(26):1928–30.

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Talley NJ, et al. **N Engl J Med** 1999 Oct 7;341(15):1106–11

Functional dyspepsia has a good prognosis irrespective of H. pylori status. Long-term follow-up of symptoms after anti H. pylori treatment. Werdmuller BF, et al. **Neth J Med** 1999 Aug;55(2):64–70

Understanding peptic ulcer disease pharmacotherapeutics. Navuluri R, et al. **Nurse Pract** 1999 Mar;24(3):128–32

An evaluative system for the response of antibacterial therapy: based on the morphological change of Helicobacter pylori and mucosal inflammation. Wen M, et al. **Pathol Int** 1999 Apr;49(4):332–7

Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after Helicobacter pylori eradication. Kato S, et al. **Pediatrics** 1999 Aug;104(2):e22

Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Buring SM, et al. **Pharmacotherapy** 1999 Mar;19(3):324–32

New treatment for peptic ulcer disease. **Postgrad Med** 1999 Mar;105(3):239–40

Practical advice on eradicating Helicobacter pylori infection. Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):137–40, 145–8 (22 ref.)

Helicobacter pylori test-and-treat' strategy for dyspeptic patients. Gisbert JP, et al. **Scand J Gastroenterol** 1999 Jul; 34(7):644–52 (120 ref.)

Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. Gisbert JP, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1144–51

National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. Juul KV, et al. **Scand J Gastroenterol** 1998 Sep;33(9):928–32

Intragastric pH and Helicobacter pylori treatment with proton pump inhibitors combined with amoxycillin [letter; comment] Kleveland PM, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1230. Comment on: Scand J Gastroenterol 1998 Jan;33(1):39–43.

The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Wada T, et al. **Scand J Gastroenterol** 1999 Mar;34(3):238–43

Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole.

Stolte M, et al. **Virchows Arch** 1999 Jan;434(1):91–4

Eradication of Helicobacter pylori infection in the management of patients with dyspepsia and non-ulcer dyspepsia. Huang JQ, et al. **Yale J Biol Med** 1998 Mar–Apr; 71(2):125–33 (61 ref.)

Helicobacter pylori: therapeutic targets. Louw JA, et al. **Yale J Biol Med** 1998 Mar–Apr;71(2):113–7 (22 ref.)

Helicobacter pylori and non-steroidal anti-inflammatory drugs: does infection affect the outcome of NSAID therapy? McCarthy DM. **Yale J Biol Med** 1998 Mar–Apr; 71(2):101–11 (45 ref.)

Treatment of H. pylori infection: the reality. Vakil N. **Yale J Biol Med** 1998 Mar–Apr;71(2):119–24 (30 ref.)

Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. Kirstein FW, et al. **Z Gastroenterol** 1998 Sep;36(9):803–9

Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. Stolte M, et al. **Z Gastroenterol** 1998 Aug;36(8):641–3

[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers] Huang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):488–91 (20 ref.) **(Chi)**

[Intensifying the study of the proper treatment of digestive ulceration (editorial)] Yao X. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):221–2 **(Chi)**

[Effect of H. pylori eradication regimes on the proliferation index of gastric mucosa] Hep A, et al. **Vnitr Lek** 1998 Aug; 44(8):447–50 (Eng. Abstr.) **(Cze)**

[Non-ulcus dyspepsia--eradication of Helicobacter pylori] Schaffalitzky de Muckadell OB. **Ugeskr Laeger** 1999 Mar 29;161(13):1933 **(Dan)**

[Treatment of Helicobacter pylori infections] van der Hulst RW, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):395–400 (37 ref.) (Eng. Abstr.) **(Dut)**

[Treatment of gastroesophageal reflux: should Helicobacter pylori infection be taken into account?] De Korwin JD. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S121–9 (87 ref.) **(Fre)**

[Consequences of Helicobacter pylori infection on the incidence and treatment of gastro-duodenal ulcers in patients taking non-steroidal anti-inflammatory agents] Lamarque D. **Gastroenterol Clin Biol** 1998 Dec; 22(12):1122–4 **(Fre)**

[Modified triple therapies for Helicobacter pylori eradication] Nguyen HN, et al. **Dtsch Med Wochenschr** 1999 Mar 5; 124(9):271 **(Ger)**

[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole] Müller P, et al. **Fortschr Med** 1998 Oct 10;116(28):31–2 **(Ger)**

[Remission ratio of chronic urticaria--"spontaneous" healing or result of eradication of Helicobacter pylori?] Becker H, et al. **Hautarzt** 1998 Dec;49(12):907–11 (Eng. Abstr.) **(Ger)**

[Helicobacter eradication and ulcer hemorrhage] Frieling T. **Internist (Berl)** 1998 Oct;39(10):1070 **(Ger)**

[Symptomatic improvement of patients with nonulcer dyspepsia after Helicobacter pylori eradication] Zwimpfer J. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31-32):1291 **(Ger)**

[Meta-analysis of determining the pathogen eradicating efficacy of various therapeutic regimens in Helicobacter pylori infection] Dobrucali A, et al. **Wien Med Wochenschr** 1998;148(20):464–8 (Eng. Abstr.) **(Ger)**

[Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?] Labenz J, et al. **Z Gastroenterol** 1999 Jul;37(7):649–52 **(Ger)**

[Eradication of Helicobacter pylori in peptic ulcer patients] Buzás GM, et al. **Orv Hetil** 1999 Jan 17;140(3):121–4 (32 ref.) (Eng. Abstr.) **(Hun)**

[Eradication of Helicobacter pylori: utopia or reality? (editorial)] Stella S. G **Chir** 1998 Nov–Dec; 19(11–12):429–32 **(Ita)**

[Peptic ulcer, functional dyspepsia, Helicobacter pylori: a 1998 stock-taking on the topic of their correlation and therapeutic strategies] Dobrilla G. **Recenti Prog Med** 1999 Jun;90(6):347–54 (75 ref.) (Eng. Abstr.) **(Ita)**

[Treatment of infections of the current interest. 1) Helicobacter pylori infection] Shimoyama T, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2263–7 (6 ref.) **(Jpn)**

[Characteristics of anti-microbial agents and its clinical choice for H. pylori treatment] Aoyama N, et al. **Nippon Rinsho** 1999 Jan;57(1):43–52 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease] Habu Y, et al. **Nippon Rinsho** 1999 Jan;57(1):135–9 (Eng. Abstr.) **(Jpn)**

[The treatment strategy of H. pylori infection and the new triple therapy] Hoshiya S, et al. **Nippon Rinsho** 1999 Jan; 57(1):121–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Increased acid secretion after Helicobacter pylori eradication is the important risk factor of acute duodenitis and reflux esophagitis] Iijima K, et al. **Nippon Rinsho** 1999 Jan;57(1):196–200 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy] Iwasaki A. **Nippon Rinsho** 1999 Jan;57(1):127–33 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication] Kanayama S. **Nippon Rinsho** 1999 Jan;57(1):153–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A preventive and therapeutic measures for upper gastrointestinal disorders occurred after successful eradication of Helicobacter pylori] Kaneko T, et al. **Nippon Rinsho** 1999 Jan;57(1):208–11 (Eng. Abstr.) **(Jpn)**

[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections] Kihira K, et al. **Nippon Rinsho** 1999 Jan;57(1):148–52 (Eng. Abstr.) **(Jpn)**

[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer] Nakagawa M, et al. **Nippon Rinsho** 1999 Jan;57(1):144–7 (Eng. Abstr.) **(Jpn)**

[Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori] Sakurai K, et al. **Nippon Rinsho** 1999 Jan;57(1):72–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment] Sekine H, et al. **Nippon Rinsho** 1999 Jan;57(1):116–20 (Eng. Abstr.) **(Jpn)**

[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer] Shirai T, et al. **Nippon Rinsho** 1999 Jan;57(1):140–3 **(Jpn)**

[Long-term endoscopic follow-up for peptic ulcer patients after eradication of H. pylori; comparison with the maintainance therapy by H2-blocker] Shirai T, et al. **Nippon Rinsho** 1999 Jan;57(1):157–61 (Eng. Abstr.) **(Jpn)**

[In a view of international consensus conference for the treatment of H. pylori infection] Watanabe K, et al. **Nippon Rinsho** 1999 Jan;57(1):61–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[The role and significance of acid suppressive drugs in the eradication of H. pylori] Yakabi K, et al. **Nippon Rinsho** 1999 Jan;57(1):53–60 (29 ref.) (Eng. Abstr.) **(Jpn)**

[History of the treatment of Helicobacter pylori and clinical efficacy] Yamamoto I, et al. **Nippon Rinsho** 1999 Jan; 57(1):32–42 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Erosive duodenitis after eradication therapy for Helicobacter pylori] Goto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):14–20 (Eng. Abstr.) **(Jpn)**

[Treatment of Helicobacter pylori infection] Lygren I, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4511–4 (Eng. Abstr.) **(Nor)**

[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection] Petsch B, et al. **Pol Merkuriusz Lek** 1998 Aug;5(26):66–8 (Eng. Abstr.) **(Pol)**

[Contemporary approaches to diagnosis and treatment of chronic duodenitis among flying personnel] Preobrazhenskii VN, et al. **Aviakosm Ekolog Med** 1998; 32(3):70–3 (Eng. Abstr.) **(Rus)**

[Modern policy of anti-helicobacter therapy of ulcer disease] Ryss ES. **Klin Med (Mosk)** 1998;76(10):7–11 (10 ref.) **(Rus)**

[The treatment characteristics of patients with peptic ulcer infected with Helicobacter pylori] Kharchenko NV. **Lik Sprava** 1999 Mar;(2):70–4 (Eng. Abstr.) **(Rus)**

[The comparative efficacy of different drug regimens in the treatment of peptic ulcer] Tkach SM. **Lik Sprava** 1998 Aug; (6):45–7 (Eng. Abstr.) **(Rus)**

[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children] Lykova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):76–81 (Eng. Abstr.) **(Rus)**

[Cost-effectiveness of the eradication of Helicobacter pylori in the treatment of duodenal ulcer (editorial; comment)] Dominguez Muñoz JE. **An Med Interna** 1998 Oct; 15(10):513–4. Comment on: An Med Interna 1998 Oct;15(10):515–22. **(Spa)**

[Cost-effectiveness analysis of the eradication of Helicobacter pylori as treatment for duodenal ulcer (see comments)] Fernández Muñoz J, et al. **An Med Interna** 1998 Oct;15(10):515–22 (Eng. Abstr.). Comment in: An Med Interna 1998 Oct;15(10):513–4. **(Spa)**

[Evidence-based management of gastroduodenal ulcer] Rodriguez Téllez M, et al. **An Med Interna** 1998 Oct; 15(10):548–53 (64 ref.) **(Spa)**

[Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care] Baena Diez JM, et al. **Aten Primaria** 1998 Nov 30;22(9):547–51 (Eng. Abstr.) **(Spa)**

[Eradicating treatment against Helicobacter pylori (letter)] Barrera Linares F, et al. **Aten Primaria** 1998 Oct 31; 22(7):469–70, 472 **(Spa)**

[Helicobacter pylori (letter)] García Bernabé C. **Aten Primaria** 1998 Dec;22(10):669 **(Spa)**

[Helicobacter pylori: 6-day triple therapy in duodenal ulcer. Study Group of Helicobacter pylori (GEHPY) (letter)] Mascort JJ, et al. **Aten Primaria** 1998 Dec;22(10):668–9 **(Spa)**

[Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity] Garrido A, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):471–3 (Eng. Abstr.) **(Spa)**

[Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer] García-Romero E, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):1–6 (Eng. Abstr.) **(Spa)**

[Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule] Martín Mir ML, et al. **Gastroenterol Hepatol** 1998 Nov;21(9):432–6 (Eng. Abstr.) **(Spa)**

[The attitude of primary health care physicians in the metropolitan area of Barcelona about the diagnosis and treatment of Helicobacter pylori infection in gastroduodenal diseases] Martínez-Sánchez G, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):473–8 (Eng. Abstr.) **(Spa)**

[Triple treatment for the eradication of Helicobacter pylori infection (letter; comment)] Calvet X, et al. **Med Clin (Barc)** 1998 Dec 5;111(19):759. Comment on: Med Clin (Barc) 1998 Jan 17;110(1):1–5. **(Spa)**

[The attitude in a failure to eradicate Helicobacter pylori: surrender or fight? (editorial)] Gisbert JP. **Med Clin (Barc)** 1998 Dec 12;111(20):778–82 (72 ref.) **(Spa)**

[Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments] Gisbert JP, et al. **Med Clin (Barc)** 1999 Mar 20;112(10):365–7 (Eng. Abstr.) **(Spa)**

[Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size (letter; comment)] Baena Diez JM, et al. **Rev Clin Esp** 1999 Jun; 199(6):407. Comment on: Rev Clin Esp 1998 Oct;198(10):655–9. **(Spa)**

[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient? (see comments)] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):655–9 (37 ref.) (Eng. Abstr.). Comment in: Rev Clin Esp 1999 Jun;199(6):407. **(Spa)**

[Role of pantoprazole in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):678–83 (50 ref.) **(Spa)**

[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy] Gisbert JP. **Rev Esp Enferm Dig** 1999 Feb;91(2):133–43 (111 ref.) (Eng. Abstr.) **(Spa)**

[Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori (letter)] González Carro P, et al. **Rev Esp Enferm Dig** 1998 Aug;90(8):594–5 **(Spa)**

[Characteristics of Helicobacter pylori infection in children: therapeutic implications] Martínez Gómez J. **Rev Esp Quimioter** 1998 Dec;11(4):316–21 (62 ref.) **(Spa)**

[Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer] Dehesa M, et al. **Rev Gastroenterol Mex** 1998 Apr–Jun;63(2):66–71 (Eng. Abstr.) **(Spa)**

[Efficacy of quadruple therapy in the eradication of Helicobacter pylori and prevention of recurrent duodenal ulcer] Ocaña Andrade E, et al. **Rev Gastroenterol Mex** 1998 Oct–Dec;63(4):182–6 (Eng. Abstr.) **(Spa)**

[Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial] Rodriguez Hernández H, et al. **Rev Gastroenterol Mex** 1998 Jan–Mar; 63(1):21–7 (Eng. Abstr.) **(Spa)**

[Helicobacter pylori illustrates a paradigmatic shift's breakthrough] Hjalt CA, et al. **Lakartidningen** 1999 Jun 30;96(26–27):3177–9 **(Swe)**

[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance] Nilsson F, et al. **Lakartidningen** 1999 Feb 3;96(5):460–3 (12 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Breuer T, et al. **Am J Gastroenterol** 1999 Mar;94(3):725–9

Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Fendrick AM, et al. **Am J Med** 1999 Aug;107(2):133–6

Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Fendrick AM, et al. **Arch Intern Med** 1999 Jan 25; 159(2):142–8

Economic perspectives in the management of Helicobacter pylori infections. Sonnenberg A, et al. **Curr Top Microbiol Immunol** 1999;241:237–60 (52 ref.)

Economic evaluations in medicine: still more questions than answers? Grossi E. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):347–50

ENZYMOLOGY

Helicobacter pylori infection induces telomerase activity in

premalignant lesions [letter] Kameshima H, et al. **Am J Gastroenterol** 1999 Feb;94(2):547–8

Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. McCarthy CJ, et al. **Am J Gastroenterol** 1999 May; 94(5):1218–23

Gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide: down-regulation of nitric oxide synthase-2 and caspase-3 by sulglycotide. Slomiany BL, et al. **Biochem Biophys Res Commun** 1999 Jul 22; 261(1):15–20

Phospholipases A2 in gastric juice of Helicobacter pylori--positive and negative individuals. Huhtinen HT, et al. **Clin Chem Lab Med** 1999 Jan;37(1):61–4

Tryosine kinase and ornithine decarboxylase activation in children with Helicobactor pylori gastritis. Elitsur Y, et al. **Life Sci** 1999;65(13):1373–80

Influences of Helicobacter pylori on serum pepsinogen concentrations in dialysis patients. Tamura H, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):113–7

Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Sawaoka H, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Nov; 59(5):313–6

H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori. Furuta T, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):384–90

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Sagar M, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1034–8

EPIDEMIOLOGY

Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Tindberg Y, et al. **Acta Paediatr** 1999 Jun;88(6):631–5

The prevalence and related symptomatology of Helicobacter pylori in children with recurrent abdominal pain. Wewer V, et al. **Acta Paediatr** 1998 Aug;87(8):830–5

Helicobacter pylori serology in elderly people: a 21-year cohort comparison in 70-year-olds and a 20-year longitudinal population study in 70-90-year-olds. Gause-Nilsson I, et al. **Age Ageing** 1998 Jul;27(4):433–6

Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Danesh J. **Aliment Pharmacol Ther** 1999 Jul;13(7):851–6 (65 ref.)

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. O'Connor HJ. **Aliment Pharmacol Ther** 1999 Feb; 13(2):117–27 (108 ref.)

Inverse graded relation between alcohol consumption and active infection with Helicobacter pylori. Brenner H, et al. **Am J Epidemiol** 1999 Mar 15;149(6):571–6

Age distribution of Helicobacter pylori seroprevalence among young children in a United States/Mexico border community: evidence for transitory infection [see comments] Redlinger T, et al. **Am J Epidemiol** 1999 Aug 1;150(3):225–30. Comment in: Am J Epidemiol 1999 Aug 1;150(3):231–2.

Invited commentary: dynamics of Helicobacter pylori infection in childhood [comment] Taylor DN. **Am J Epidemiol** 1999 Aug 1;150(3):231–2; discussion 233–4 . Comment on: Am J Epidemiol 1999 Aug 1;150(3):225–30.

Colorectal adenomateous polyps and Helicobacter pylori infection [letter] Aydin A, et al. **Am J Gastroenterol** 1999 Apr;94(4):1121–2

Migraine in children and Helicobacter pylori [letter] Caselli M, et al. **Am J Gastroenterol** 1999 Apr;94(4):1116–8

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Ciociola AA, et al. **Am J Gastroenterol** 1999 Jul;94(7):1834–40

H. pylori-CagA serum antibody and RAP in children [letter; comment] Elitsur Y. **Am J Gastroenterol** 1999 Feb;94(2):539 . Comment on: Am J Gastroenterol 1998 Aug;93(8):1264–70.

Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Eslick GD, et al. **Am J Gastroenterol** 1999 Sep;94(9):2373–9

Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Fujisawa T, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2094–9

Point prevalence of peptic ulcer and gastric histology in healthy Indians with Helicobacter pylori infection [letter; comment] Malik GM, et al. **Am J Gastroenterol** 1998 Oct; 93(10):2002–3. Comment on: Am J Gastroenterol 1997 Sep;92(9):1487–91.

The ubiquitous Helicobacter species. Srinivasan R, et al. **Am J Gastroenterol** 1999 Feb;94(2):533–4

Seroprevalence of Helicobacter pylori among Egyptian newborns and their mothers: a preliminary report. Bassily S, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):37–40

Risk of Helicobacter pylori infection among long-term residents in developing countries. Becker SI, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):267–70

Prospective study of the incidence of diarrheal disease and Helicobacter pylori infection among children in an orphanage in Thailand. Isenbarger DW, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):796–800

Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Leal-Herrera Y, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):587–92

Seroprevalence of Helicobacter pylori in a longitudinal study of New Zealanders at ages 11 and 21 [see comments] Fawcett JP, et al. **Aust N Z J Med** 1998 Oct;28(5):585–9 . Comment in: Aust N Z J Med 1998 Oct;28(5):581–2.

Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort. Yuan JM, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jul;8(7):621–4

Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community. Malaty HM, et al. **Clin Infect Dis** 1999 Feb;28(2):279–82

Helicobacter pylori infection is not a correlate of plasma fibrinogen in the Australian population. Peach HG, et al. **Clin Lab Haematol** 1999 Feb;21(1):41–3

Helicobacter pylori and critical illness: a passive bystander or cause of disease? [editorial; comment] Hawker FH. **Crit Care Med** 1999 Jul;27(7):1385–6. Comment on: Crit Care Med 1999 Jul;27(7):1276–80.

Helicobacter pylori infection in intensive care: increased prevalence and a new nosocomial infection [see comments] Robertson MS, et al. **Crit Care Med** 1999 Jul;27(7):1276–80 . Comment in: Crit Care Med 1999 Jul;27(7):1385–6.

The epidemiology of Helicobacter pylori. Mitchell HM. **Curr Top Microbiol Immunol** 1999;241:11–30 (122 ref.)

Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Bernstein CN, et al. **Dig Dis Sci** 1999 Apr;44(4):668–74

High prevalence of Helicobacter pylori infection in shepherds. Dore MP, et al. **Dig Dis Sci** 1999 Jun; 44(6):1161–4

Alcohol consumption and Helicobacter pylori infection: results from the German National Health and Nutrition Survey [see comments] Brenner H, et al. **Epidemiology** 1999 May;10(3):214–8. Comment in: Epidemiology 1999 May;10(3):207–9.

Prevalence of Helicobacter pylori infection in two Spanish regions with different incidence of gastric cancer. Senra-Varela A, et al. **Eur J Epidemiol** 1998 Jul;14(5):491–4

Prevalence of Helicobacter pylori infection in medical professionals in Spain. Monés J, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):239–42

Results of Helicobacter pylori screening and eradication in a multi-ethnic community in central England. Stone MA, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):957–62

Is there a link between the variation in gastric cancer mortality and differences in Helicobacter pylori prevalence in different regions of France? Broutet N, et al. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6-7):754–60

Seroprevalence of immunoglobulin G antibodies against Helicobacter pylori among endoscopy personnel in Japan [see comments] Nishikawa J, et al. **Gastrointest Endosc** 1998 Sep;48(3):237–43. Comment in: Gastrointest Endosc 1998 Sep;48(3):317–8.

Co-screening for primary biliary cirrhosis and coeliac disease. Helicobacter pylori: the African enigma [letter] Segal I, et al. **Gut** 1998 Aug;43(2):300–1

Prevalence of CagA, VacA antibodies in symptomatic and asymptomatic children with Helicobacter pylori infection. Elitsur Y, et al. **Helicobacter** 1999 Jun;4(2):100–5

Differences among Helicobacter pylori strains isolated from three different populations and demonstrated by restriction enzyme analysis of an internal fragment of the conserved gene hpaA. Evans DG, et al. **Helicobacter** 1999 Jun; 4(2):82–8

CagA and VacA: virulence factors of Helicobacter pylori in Thai patients with gastroduodenal diseases. Mahachai V, et al. **Helicobacter** 1999 Sep;4(3):143–7

Seroprevalence of Helicobacter pylori and length of stay in a nursing home. Regev A, et al. **Helicobacter** 1999 Jun; 4(2):89–93

Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Varanasi RV, et al. **Helicobacter** 1998 Sep;3(3):188–94

The role of Helicobacter pylori in primary gastric MALT lymphoma. Bouzourene H, et al. **Histopathology** 1999 Feb; 34(2):118–23

Seroepidemiology of Helicobacter pylori infection in an urban, upper class population in Chennai. Alaganantham TP, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):66–8

Role of Helicobacter pylori in peptic ulcer in patients with hepatic cirrhosis [letter] Ghoshal UC, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):90

Incidence of Helicobacter pylori infection in a cohort of Italian military students. Biselli R, et al. **Infection** 1999 May-Jun;27(3):187–91

Infection with CagA+ Helicobacter pylori strains as a possible predictor of risk in the development of gastric adenocarcinoma in Mexico. Torres J, et al. **Int J Cancer** 1998 Oct 29;78(3):298–300

Iron-deficiency anemia in Nunavik: pregnancy and infancy. Hodgins S, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:135–40

A role for Helicobacter pylori in the gastrointestinal complaints of eating disorder patients? Hill KK, et al. **Int J Eat Disord** 1999 Jan;25(1):109–12

Prevalence of duodenal bulb gastric metaplasia and Helicobacter pylori in patients with duodenal ulcer and normal duodenum [letter] Doğan UB, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):429

Confounding factors in observational and intervention studies. Feldman RA. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S248–53 (12 ref.)

Food allergy and Helicobacter pylori infection. Figura N, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):186–91

Helicobacter pylori eradication treatment reduces the severity of rosacea. Utaş S, et al. **J Am Acad Dermatol** 1999 Mar;40(3):433–5

"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study. Archimandritis A, et al. **J Clin Gastroenterol** 1999 Jun;28(4):345–7

Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. Kim N, et al. **J Clin Gastroenterol** 1998 Dec;27(4):321–6

No difference in seroprevalences of Helicobacter pylori infection between patients with pulmonary tuberculosis and those without. Sanaka M, et al. **J Clin Gastroenterol** 1998 Dec;27(4):331–4

Helicobacter pylori in Meckel's diverticulum with heterotopic gastric mucosa in a population with relatively high H. pylori prevalence rate. Chan GS, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):313–6

Helicobacter pylori: evidence for spouse-to-spouse transmission. Singh V, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):519–22

Differential Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South China. China Gastric Cancer Study Group. Wong BC, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):120–5

High prevalence of cagA-positive strains in Helicobacter pylori-infected, healthy, young Chinese adults. Yang H, et al. **J Gastroenterol Hepatol** 1999 May;14(5):476–80

Helicobacter antibodies in Finnish centenarians. Rehnberg-Laiho L, et al. **J Gerontol A Biol Sci Med Sci** 1999 Aug;54(8):M400–3

Seroprevalence of Helicobacter pylori infection in an Asymptomatic Turkish population. Us D, et al. **J Infect** 1998 Sep;37(2):148–50

Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. Blaser MJ. **J Infect Dis** 1999 Jun;179(6):1523–30

A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. Torres J, et al. **J Infect Dis** 1998 Oct;178(4):1089–94

Helicobacter pylori infection in a large company [letter; comment] Ziem G. **J Occup Environ Med** 1999 Jun; 41(6):415–6. Comment on: J Occup Environ Med 1998 Jul;40(7):586–94.

Helicobacter pylori infection and cytotoxic antigen associated gene "A" status in short children. Cacciari E, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr; 12(2):197–201

Helicobacter pylori infection in children with celiac disease: prevalence and clinicopathologic features. Luzza F, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):143–6

Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Lin CW, et al. **Jpn J Med Sci Biol** 1998 Nov;51(1):13–23

US prevalence of Helicobacter pylori may plummet in next century [news] Bhattacharya I. **Lancet** 1999 May 29; 353(9167):1859

Epidemiology could yield new ways to manage H. pylori infection [news] Logan R. **Lancet** 1999 Sep 18; 354(9183):1006

Seroprevalence of Helicobacter pylori in the adult population of Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. Collett JA, et al. **N Z Med J** 1999 Aug 13;112(1093):292–5

Helicobacter pylori and Giardia lamblia infections in hemodialysis patients [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1803–4

Epidemiology of Helicobacter pylori in chronic haemodialysis patients using the new RIBA H. pylori SIA. Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):1929–33

Pets are not a risk factor for Helicobacter pylori infection in young children: results of a population-based study in Southern Germany. Bode G, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):909–12

Persisting Helicobacter antibodies in Finnish children and adolescents between two and twenty years of age. Rehnberg-Laiho L, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9):796–9

Helicobacter pylori infection in postoperative patients with biliary atresia. A benign colonization? Kubota M, et al. **Pediatr Surg Int** 1999;15(3-4):210–3

Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. Gisbert JP, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1144–51

Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Henriksson AE, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1030–3

Helicobacter pylori and intestinal metaplasia with its subtypes in the gastric antrum in a Saudi population. Al-Knawy B, et al. **Scand J Gastroenterol** 1999 Jun;34(6):562–5

Risk factors for infection with Helicobacter pylori--a study of children in rural Ethiopia. Lindkvist P, et al. **Scand J Infect Dis** 1998;30(4):371–6

Helicobacter pylori infection in infants and children of Bangladesh. Bardhan PK, et al.

Schweiz Rundsch Med Prax 1998 Dec 24;87(51-52):1814-6

Seroconversion for Helicobacter pylori in adults from Brazil. de Oliveira AM, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):261-3

Risk factors for duodenal ulcer in north India. Jain A, et al. **Trop Gastroenterol** 1999 Jan-Mar;20(1):36-9

Helicobacter pylori and smoking: two additive risk factors for organic dyspepsia. Halter F, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):91-9 (35 ref.)

Helicobacter pylori, peptic ulcer and gastric cancer in China. Lam SK, et al. **Yale J Biol Med** 1998 Jan-Feb;71(1):1-6 (43 ref.)

Helicobacter pylori: the Middle East scenario. Novis BH, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):135-41 (30 ref.)

[Prevalence of Helicobacter pylori(Hp) infection in the department of gastroenterology staff members in Nanjing] Lu YK, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Apr; 18(2):70-2 (Eng. Abstr.) **(Chi)**

[Seroprevalence of Helicobacter pylori infection among Yi and Han nationalities in Yunxian County, Yunnan Province] Zhou ZF, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Feb; 18(1):18-21 (Eng. Abstr.) **(Chi)**

[Studies on infection of Helicobacter pylori and their subtypes cagA+ and hspA+ in population living in the areas with high and low incidence of gastric cancer] Zhang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar; 32(2):67-9 (Eng. Abstr.) **(Chi)**

[Prevalence of Helicobacter pylori infection in the Czech Republic--the South Moravia Region] Ditě P, et al.
Vnitr Lek 1998 Mar;44(3):132-4 (Eng. Abstr.) **(Cze)**

[Helicobacter pylori and upper digestive disease at the Main Hospital of Dakar. Study apropos of 105 consecutive endoscopies] Mbaye PS, et al. **Dakar Med** 1995; 40(2):187-91 (Eng. Abstr.) **(Fre)**

[Possibilities of epidemiologic studies within the scope of school entrance examinations exemplified by Ulm Helicobacter pylori studies] Gonser T, et al.
Gesundheitswesen 1998 Aug;60 Suppl 1:S24-9 (Eng. Abstr.) **(Ger)**

[Prevalence of Helicobacter pylori infection in asymptomatic 5-7-year-old children of St. Gallen canton] Boltshauser S, et al. **Schweiz Med Wochenschr** 1999 Apr 17; 129(15):579-84 (Eng. Abstr.) **(Ger)**

[Behavior of Helicobacter pylori in 3d and 4th age-bracket patients] Daturi R, et al. **Minerva Chir** 1999 Jun;54(6):411-4 (Eng. Abstr.) **(Ita)**

[Epidemiological study for infection with H. pylori in Japan compared with that in USA, Europe and Asian Pacific area] Shimoyama T, et al. **Nippon Rinsho** 1999 Jan; 57(1):11-6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Frequency of Helicobacter pylori infection depending on morphological changes in gastric mucosa in patients over 65 years of age] Poniewierka E, et al.
Pol Merkuriusz Lek 1998 Apr;4(22):193-5 (Eng. Abstr.) **(Pol)**

[Incidence of primary gastric lymphoma and H. pylori infection in the central zone of Asturias] Vallina E, et al.
An Med Interna 1999 Apr;16(4):175-7 (Eng. Abstr.) **(Spa)**

[Reinfection by Helicobacter pylori after its eradication: irrational fear? (editorial)] Gisbert JP. **Med Clin (Barc)** 1998 Oct 3;111(10):380-4 **(Spa)**

[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence] Gisbert JP, et al.
Med Clin (Barc) 1999 Feb 13;112(5):161-5 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Helicobacter pylori in the Canadian arctic: seroprevalence and detection in community water samples. McKeown I, et al. **Am J Gastroenterol** 1999 Jul;94(7):1823-9

Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Katelaris PH, et al. **Aust N Z J Med** 1998 Oct;28(5):633-8

Determinants of ethnic or geographical differences in infectivity and transmissibility of Helicobacter pylori. Fallone CA. **Can J Gastroenterol** 1999 Apr;13(3):251-5 (57 ref.)

Helicobacter pylori in a Chukotka Native male population. Reshetnikov OV, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:293-5

Helicobacter pylori infection and atrophic gastritis in middle-aged Japanese residents of São Paulo and Lima. Tsugane S, et al. **Int J Epidemiol** 1999 Jun;28(3):577-82

Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. Fraser AG, et al. **J Gastroenterol Hepatol** 1998 Jun; 13(6):560-5

Seroprevalence of Helicobacter pylori infection in Malaysian children: evidence for ethnic differences in childhood. Boey CC, et al. **J Paediatr Child Health** 1999 Apr;35(2):151-2

[Helicobacter pylori and peptic ulcer in the population of Khakasiia] Tsukanov VV, et al. **Ter Arkh** 1999;71(2):17-9 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Tindberg Y, et al. **Acta Paediatr** 1999 Jun;88(6):631-5

Co-twin study of the effect of environment and dietary elements on acquisition of Helicobacter pylori infection. Malaty HM, et al. **Am J Epidemiol** 1998 Oct 15; 148(8):793-7

The inflammatory response in CD1 mice shortly after infection with a CagA+/VacA+ Helicobacter pylori strain. van Doorn NE, et al. **Clin Exp Immunol** 1999 Mar; 115(3):421-7

Parental smoking and infection with Helicobacter pylori among preschool children in southern Germany. Brenner H, et al. **Epidemiology** 1998 Sep;9(5):545-9

Low rates of Helicobacter pylori reinfection in children. Rowland M, et al. **Gastroenterology** 1999 Aug; 117(2):336-41

Host determinants of Helicobacter pylori infection and its clinical outcome. Nguyen TN, et al. **Helicobacter** 1999 Sep; 4(3):185-97 (115 ref.)

Dental plaque as reservoir, and determinants of pathogenic potential of Helicobacter pylori: the controversy remains [editorial; comment] Mazumder DN, et al.
Indian J Gastroenterol 1998 Oct-Dec;17(4):123-5. Comment on: Indian J Gastroenterol 1998 Oct-Dec;17(4):126-8. Comment on: Indian J Gastroenterol 1998 Oct-Dec;17(4):138-40.

Establishment of BALB/c mice model infected with Helicobacter pylori. Jin DZ, et al.
Korean J Intern Med 1999 Jul;14(2):55-63

Seroprevalence of Helicobacter pylori in the adult population of Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. Collett JA, et al.
N Z Med J 1999 Aug 13;112(1093):292-5

[Pathophysiology of Helicobacter pylori infections] van der Ende A, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):392-5 (31 ref.) (Eng. Abstr.) **(Dut)**

[Reductionism once again. The example of Helicobacter pylori (editorial)] Weiner H.
Psychother Psychosom Med Psychol 1998 Nov;48(11):425-9 (49 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Ihrig M, et al.
Am J Pathol 1999 Aug;155(2):571-82

Expression of bcl-2 in autoimmune and Helicobacter pylori-associated atrophic gastritis. Maor-Kendler Y, et al. **Dig Dis Sci** 1999 Apr;44(4):680-5

Helicobacter pylori infection and polymorphisms in the tumor necrosis factor region. Kunstmann E, et al.
Electrophoresis 1999 Jun;20(8):1756-61

Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Meining AG, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):717-20

Clinical outcome after infection with Helicobacter pylori does not appear to be reliably predicted by the presence of any of the genes of the cag pathogenicity island. Jenks PJ, et al. **Gut** 1998 Dec;43(6):752-8

Host, heredity and helicobacter [comment] Nedrud JG, et al. **Gut** 1999 Sep;45(3):323-4. Comment on: Gut 1999 Sep;45(3):335-40.

A genetic basis for atrophy: dominant non-responsiveness and helicobacter induced gastritis in F(1) hybrid mice [see comments] Sutton P, et al. **Gut** 1999 Sep;45(3):335-40. Comment in: Gut 1999 Sep;45(3):323-4.

Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Pappo J, et al. **Infect Immun** 1999 Jan; 67(1):337-41

C3 phenotypes and peptic ulcer: association of C3 with peptic ulcer but no association of C3 with Helicobacter pylori [letter; comment] Archimandritis A, et al.
Scand J Gastroenterol 1999 Feb;34(2):219-20. Comment on: Scand J Gastroenterol 1997 Jan;32(1):16-21.

Relationship of CagA to serum gastrin concentrations and antral G, D cell densities in Helicobacter pylori infection. Kim JH, et al. **Yonsei Med J** 1999 Aug;40(4):301-6

[Fas/Fas ligand mRNA are expressed in Helicobacter pylori infected mucosa] Meyer F, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:1150-2 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Barratt J, et al. **Am J Kidney Dis** 1999 Jun;33(6):1049-57

Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Leal-Herrera Y, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):587-92

Immunomodulation of helicobacter infection. Croitoru K.
Can J Gastroenterol 1999 Apr;13(3):237-41 (62 ref.)

Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Blanchard TG, et al. **Cell Immunol** 1999 Jan 10;191(1):74-80

Polymorphonuclear oxidative burst after Helicobacter pylori water extract stimulation is not influenced by the cytotoxic genotype but indicates infection and gastritis grade. Basso D, et al. **Clin Chem Lab Med** 1999 Mar;37(3):223-9

Production of IL-12 in gastritis relates to infection with Helicobacter pylori. Bauditz J, et al. **Clin Exp Immunol** 1999 Aug;117(2):316-23

Host response and vaccine development to Helicobacter pylori infection. Blanchard TG, et al.
Curr Top Microbiol Immunol 1999;241:181-213 (155 ref.)

Gastric mucosal interleukin-8 and IL-8 antibody concentrations related to prevailing Helicobacter pylori infections. A Danish-Albanian study. Nielsen OH, et al.
Dan Med Bull 1999 Jun;46(3):249-52

Increased gastric production of platelet-activating factor, leukotriene-B4, and tumor necrosis factor-alpha in children with Helicobacter pylori infection. Hüseyinov A, et al.
Dig Dis Sci 1999 Apr;44(4):675-9

Effects of inflammatory cytokines induced by Helicobacter pylori infection on aminopyrine accumulation in parietal cells isolated from guinea pigs. Tani N, et al.
Dig Dis Sci 1999 Apr;44(4):686-90

Decreased Helicobacter pylori-specific gastric secretory IgA antibodies in infected patients. Birkholz S, et al.
Digestion 1998 Nov-Dec;59(6):638-45

Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Lamarque D, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):721-6

Impact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study. Kist M, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):239-42

IgG antibodies to Lewis type 2 antigens in serum of H. pylori-infected and noninfected blood donors of different Lewis(a,b) blood-group phenotype. Kurtenkov O, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):227-32

Changes in the mucosal expression of interleukin 15 in Helicobacter pylori-associated gastritis. Luzza F, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):233-8

Lack of a relationship between Lewis antigen expression and cagA, CagA, vacA and VacA status of Irish Helicobacter pylori isolates. Marshall DG, et al.
FEMS Immunol Med Microbiol 1999 May;24(1):79-90

Animal models for gastric Helicobacter immunology and vaccine studies. Nedrud JG.
FEMS Immunol Med Microbiol 1999 Jun;24(2):243-50 (45 ref.)

Mucosal vaccination: "all politics are local". Lencer WI.
Gastroenterology 1999 Feb;116(2):497-9

Mimicry of blood group antigen A by Helicobacter mustelae and H. pylori [letter; comment] Moran AP, et al.
Gastroenterology 1999 Feb;116(2):504-5. Comment on: Gastroenterology 1998 Apr;114(4):690-6.

Systemic and local immune responses against Helicobacter pylori urease in patients with chronic gastritis: distinct IgA and IgG productive sites. Futagami S, et al. **Gut** 1998 Aug; 43(2):168-75

Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Kawahara Y, et al.
Gut 1999 Jul;45(1):20-3

Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Zevering Y, et al. **Gut** 1999 Sep;45(3):465-74 (146 ref.)

Autoimmune reactions in type A and H. pylori gastritis [letter; comment] Dixon MF. **Helicobacter** 1998 Sep; 3(3):222. Comment on: Helicobacter 1998 Mar;3(1):39-44.

Third International Workshop on Pathogenesis and Host Response in Helicobacter Infections. Taylor DE.
Helicobacter 1998 Dec;3(4):303-4

Antigenic mimicry between Helicobacter pylori and gastric mucosa: failure to implicate heat-shock protein Hsp60 using immunoelectron microscopy. Taylor DE, et al.
Helicobacter 1999 Sep;4(3):148-53

Antibodies to Cag A protein are not predictive of serious gastroduodenal disease in Indian patients [see comments] Kumar S, et al. **Indian J Gastroenterol** 1998 Oct-Dec; 17(4):126-8. Comment in: Indian J Gastroenterol 1998 Oct-Dec;17(4):123-5.

Increased susceptibility to Helicobacter pylori infection in pregnancy. Lanciers S, et al. **Infect Dis Obstet Gynecol** 1999;7(4):195-8

Role of local cytokines in increased gastric expression of the secretory component in Helicobacter pylori infection. Ahlstedt I, et al. **Infect Immun** 1999 Sep;67(9):4921-5

Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication. Ando T, et al. **Infect Immun** 1998 Oct;66(10):4742-7

Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice. Eaton KA, et al.
Infect Immun 1999 Sep;67(9):4594-602

Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, et al. **Infect Immun** 1999 May;67(5):2531-9

Proinflammatory activation of neutrophils and monocytes by Helicobacter pylori in patients with different clinical presentations. Hansen PS, et al. **Infect Immun** 1999 Jun; 67(6):3171-4

Local cytokine response in Helicobacter pylori-infected subjects. Lindholm C, et al. **Infect Immun** 1998 Dec;

66(12):5964–71

Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Pappo J, et al. **Infect Immun** 1999 Jan; 67(1):337–41

Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Sommer F, et al. **Infect Immun** 1998 Nov; 66(11):5543–6

Helicobacter pylori-associated gastritis in mice is host and strain specific. van Doorn NE, et al. **Infect Immun** 1999 Jun;67(6):3040–6

Autoantibodies reacting with gastric antigens in Helicobacter pylori associated body gastritis of dyspeptic children. Ierardi E, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):478–80

Helicobacter pylori infection and autoimmune processes: an emerging field of study. Sorrentino D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S310–2 (15 ref.)

Mucosal macrophage inflammatory protein-1alpha levels are increased in Helicobacter pylori infection. Ando T, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S144–9

Serological discrimination of dogs infected with gastric Helicobacter spp. and uninfected dogs. Strauss-Ayali D, et al. **J Clin Microbiol** 1999 May;37(5):1280–7

Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer. Yamaoka Y, et al. **J Clin Pathol** 1999 Mar;52(3):215–8

Chemokine expression in Helicobacter pylori-infected gastric mucosa. Shimada T, et al. **J Gastroenterol** 1998 Oct; 33(5):613–7 (48 ref.)

Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. Roth KA, et al. **J Immunol** 1999 Aug 1;163(3):1490–7

Qualitative and quantitative analysis of the local and systemic antibody response in mice and humans with Helicobacter immunity and infection. Blanchard TG, et al. **J Infect Dis** 1999 Mar;179(3):725–8

Local cellular immune response in the acute phase of gastritis in mice induced chemically and by Helicobacter pylori. van Doorn NE, et al. **J Med Microbiol** 1998 Oct; 47(10):863–70

Helicobacter pylori in childhood: new insights into the immunopathogenesis of gastric disease and implications for managing infection in children. Ernst PB, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):462–73 (117 ref.)

The prevalence of antibody to CagA in children is not a marker for specific disease. Mitchell HM, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):71–5

Immune response to a recombinant fragment of the CagA protein of Helicobacter pylori in blood donors and patients with gastric cancer: relation to ABO(H) blood group phenotype, stage of the disease and tumor morphology. Klaamas K, et al. **Med Microbiol Immunol (Berl)** 1999 May; 187(4):227–32

Are autoantibodies against Lewis antigens involved in the pathogenesis of Helicobacter pylori-induced peptic ulcers? Kamiya K, et al. **Microbiol Immunol** 1999;43(5):403–8

Heat shock protein 60 (HSP60) immunoreactivity in gastric epithelium associated with Helicobacter pylori infection: a pitfall in immunohistochemically interpreting HSP60-mediated autoimmune responses [letter] Kamoshida S, et al. **Pathol Int** 1999 Jan;49(1):88–90

Decrease of antigastric autoantibodies in Helicobacter pylori gastritis after cure of infection. Faller G, et al. **Pathol Res Pract** 1999;195(4):243–6

Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins. Kim JS, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1249–55

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Novak MJ, et al. **Vaccine** 1999 May 14;17(19):2384–91

Structure, function and localization of Helicobacter pylori urease. Dunn BE, et al. **Yale J Biol Med** 1998 Mar-Apr; 71(2):63–73 (67 ref.)

[Incidence of increased serum Helicobacter pylori IgG antibodies in children with and without chronic abdominal pain] Blümel P, et al. **Klin Padiatr** 1998 Sep-Oct; 210(5):366–9 (Eng. Abstr.) **(Ger)**

[Immune response to an H. pylori infection in the stomach] Wakatsuki Y. **Nippon Rinsho** 1999 Jan;57(1):23–31 (47 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Relation between vacA subtypes, cytotoxin activity, and disease in Helicobacter pylori-infected patients from The Netherlands. Pan ZJ, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1517–21

Decreased gastroduodenal mucosal concentration of transforming growth factor-alpha in Helicobacter pylori-infected dyspeptic patients [letter] Persico M, et al. **Am J Gastroenterol** 1998 Dec;93(12):2643–4

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Furuta T, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1027–30

Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model. Lozniewski A, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1909–13

Enhanced expression of inducible nitric oxide synthase and nitrotyrosine in gastric mucosa of gastric cancer patients. Goto T, et al. **Clin Cancer Res** 1999 Jun;5(6):1411–5

Gastric mucosal interleukin-8 and IL-8 antibody concentrations related to prevailing Helicobacter pylori infections. A Danish-Albanian study. Nielsen OH, et al. **Dan Med Bull** 1999 Jun;46(3):249–52

Attenuation of hydrophobic phospholipid barrier is an early event in Helicobacter felis-induced gastritis in mice. Lichtenberger LM, et al. **Dig Dis Sci** 1999 Jan;44(1):108–15

Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion [editorial; comment] Kuipers EJ, et al. **Gastroenterology** 1999 Feb; 116(2):479–83 (35 ref.). Comment on: Gastroenterology 1999 Feb;116(2):239–47. Comment on: Gastroenterology 1999 Feb;116(2):248–53.

Helicobacter pylori-dependent ceramide production may mediate increased interleukin 8 expression in human gastric cancer cell lines. Masamune A, et al. **Gastroenterology** 1999 Jun;116(6):1330–41

The histamine H3 receptor agonist N alpha-methylhistamine produced by Helicobacter pylori does not alter somatostatin release from cultured rabbit fundic D-cells. Beales IL, et al. **Gut** 1998 Aug;43(2):176–81

Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole [see comments] Gillen D, et al. **Gut** 1999 Apr;44(4):468–75. Comment in: Gut 1999 Apr;44(4):448–9.

Omeprazole: Helicobacter pylori makes thee greater yet [comment] Pantoflickova D, et al. **Gut** 1999 Apr; 44(4):448–9. Comment on: Gut 1999 Apr;44(4):468–75.

Regulation of tumour necrosis factor (TNF) induced apoptosis by soluble TNF receptors in Helicobacter pylori infection [see comments] Shibata J, et al. **Gut** 1999 Jul; 45(1):24–31. Comment in: Gut 1999 Jul;45(1):5–7.

A key cytokine unlocks the door [comment] Shirin H, et al. **Gut** 1999 Jul;45(1):5–6. Comment on: Gut 1999 Jul;45(1):24–31.

The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. Zhang ZW, et al. **Gut** 1998 Sep;43(3):322–6

Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter-associated gastritis. Sasaki M, et al. **Histopathology** 1998 Dec; 33(6):554–60

Relation of gastric juice vitamin C levels with H. pylori infection [letter] Bhatnagar M, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):129–30

Signaling pathway and pepsinogen secretion in Helicobacter pylori-infected human gastric adenocarcinoma. Chan EC, et al. **Int J Mol Med** 1999 Apr;3(4):421–5

The effect of Helicobacter pylori eradication on maximal acid secretion in duodenal ulcer patients; findings and mechanisms [comment] Calam J. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):368–9. Comment on: Ital J Gastroenterol Hepatol 1998 Aug;30(4):363–7.

Basal and pentagastrin stimulated acid secretion in duodenal ulcer subjects before and after Helicobacter pylori eradication: a 12-month follow-up study [see comments] Louw JA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):363–7. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):368–9.

Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. Shimoyama T, et al. **J Clin Pathol** 1998 Oct; 51(10):765–70

Enhanced mucosal expression of interleukin-6 mRNA but not of interleukin-8 mRNA at the margin of gastric ulcer in Helicobacter pylori-positive gastritis. Furukawa K, et al. **J Gastroenterol** 1998 Oct;33(5):625–33

Gastrin release and gastric acid secretion in the rat infected with either Helicobacter felis or Helicobacter heilmannii. Danon SJ, et al. **J Gastroenterol Hepatol** 1998 Jan; 13(1):95–103

p53 expression in gastric mucosa with Helicobacter pylori infection. Kodama M, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):215–9

Mucosal macrophage inflammatory protein-1alpha activity in Helicobacter pylori infection. Kusugami K, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):20–6

Effect of Helicobacter pylori infection on gastric mucosal phospholipid contents and their fatty acid composition. Wakabayashi H, et al. **J Gastroenterol Hepatol** 1998 Jun; 13(6):566–71

Gastric secretion and ulcer healing in mouse stomach infected with cytotoxin expressing strain of Helicobacter pylori. Brzozowski T, et al. **J Physiol Pharmacol** 1998 Sep; 49(3):387–403

Effect of Helicobacter pylori infection on antral gastrin and somatostatin cells and on serum gastrin concentrations. Park SM, et al. **Korean J Intern Med** 1999 Jan;14(1):15–20

Plasmogastric passage of urea and ammonia in children with Helicobacter pylori infection [letter] Nijevitch AA, et al. **Pediatr Int** 1999 Aug;41(4):447–8

Effect of cytokines on acid secretion and gastrin secretion in Helicobacter pylori infection and aspirin-induced gastritis [letter; comment] Beales IL. **Scand J Gastroenterol** 1998 Nov;33(11):1230–2. Comment on: Scand J Gastroenterol 1998 Apr;33(4):346–56.

Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Konturek PC, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):375–83

Gastroduodenal mucosal vitamin-C levels in Helicobacter pylori infection. Phull PS, et al. **Scand J Gastroenterol** 1999 Apr;34(4):361–6

Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Ota H, et al. **Virchows Arch** 1998 Nov;433(5):419–26

[Levels of vitamins A, E and C in serum and gastric juice in relation to gastric mucosa and occurrence of Helicobacter pylori] Hep A, et al. **Vnitr Lek** 1998 Jul; 44(7):396–9 (Eng. Abstr.) **(Cze)**

MICROBIOLOGY

Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Charlett A, et al. **Acta Neurol Scand** 1999 Jan;99(1):26–35

The physiology and metabolism of the human gastric pathogen Helicobacter pylori. Kelly DJ. **Adv Microb Physiol** 1998;40:137–89 (164 ref.)

Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. Gschwantler M, et al. **Aliment Pharmacol Ther** 1999 Aug; 13(8):1063–9

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Houben MH, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1047–55 (50 ref.)

Helicobacter pylori-positive peptic ulcer patients do not adapt to aspirin. Konturek JW, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):857–64

The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Zanten SJ, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):289–95

Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Aiba Y, et al. **Am J Gastroenterol** 1998 Nov;93(11):2097–101

The interrelationship between Helicobacter pylori vacuolating cytotoxin and gastric carcinoma. de Figueiredo Soares T, et al. **Am J Gastroenterol** 1998 Oct;93(10):1841–7

Molecular relationships of Helicobacter pylori strains in a family with gastroduodenal disease. Miehlke S, et al. **Am J Gastroenterol** 1999 Feb;94(2):364–8

Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. Murata H, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2102–5

Effect of treatment of Helicobacter pylori infection on rosacea. Bamford JT, et al. **Arch Dermatol** 1999 Jun; 135(6):659–63

Mechanisms of Helicobacter pylori infection: bacterial factors. McGee DJ, et al. **Curr Top Microbiol Immunol** 1999;241:155–80 (178 ref.)

Detection and characterization of Helicobacter pylori from patients with gastroduodenal diseases. Busolo F, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):531–6

One stomach--one strain: does Helicobacter pylori strain variation influence disease outcome? Enroth H, et al. **Dig Dis Sci** 1999 Jan;44(1):102–7

Helicobacter pylori in the oral cavity reflects handling of contaminants but not gastric infection. Doré-Davin C, et al. **Digestion** 1999;60(3):196–202

Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Michetti P, et al. **Digestion** 1999; 60(3):203–9

Relationship of Helicobacter pylori CagA(+) status to gastric juice vitamin C levels. Rokkas T, et al. **Eur J Clin Invest** 1999 Jan;29(1):56–62

Lack of correlation between vacuolating cytotoxin activity, cagA gene in Helicobacter pylori, and peptic ulcer disease in children. Loeb M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):653–6

Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Wolle K, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):519–21

Detection and typing of the virulence determinants cagA and vacA of Helicobacter pylori directly from biopsy DNA: are in vitro strains representative of in vivo strains? Gunn MC, et al. **Eur J Gastroenterol Hepatol** 1998 Aug; 10(8):683–7

The effect of Helicobacter pylori on neutrophil chemotaxis is independent of cagA. Akyön Y, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):209–13

cagA gene and vacA alleles in Spanish Helicobacter pylori clinical isolates from patients of different ages. Alarcón T, et al. **FEMS Immunol Med Microbiol** 1999 Jun; 24(2):215–9

13C-urea breath test results in pigs challenged with Helicobacter pylori or other urease producing bacteria. Enroth H, et al. **FEMS Immunol Med Microbiol** 1999 Mar; 23(3):253–7

Helicobacter pylori detection in human biopsies: a competitive PCR assay with internal control reveals false results. Thoreson AC, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):201–8

Urease-positive, acid-sensitive mutants of Helicobacter pylori: urease-independent acid resistance involved in growth at low pH. Bijlsma JJ, et al. **FEMS Microbiol Lett** 1998 Oct 15;167(2):309–13

Production of monoclonal antibodies neutralizing vacuolation of cultured cells by Helicobacter pylori cytotoxin. Yamaguchi H, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):277–82

Host specificity of Helicobacter pylori strains and host responses in experimentally challenged nonhuman primates. Dubois A, et al. **Gastroenterology** 1999 Jan;116(1):90–6

Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Hamlet A, et al. **Gastroenterology** 1999 Feb;116(2):259–68

Endoscopic urease sensor system for detecting Helicobacter pylori on gastric mucosa. Sato T, et al. **Gastrointest Endosc** 1999 Jan;49(1):32–8

Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications. Axon AT. **Gut** 1999 Jul;45 Suppl 1:I1–4 (28 ref.)

Helicobacter pylori induced apoptosis. Shirin H, et al. **Gut** 1998 Nov;43(5):592–4 (34 ref.)

Genotypes of Helicobacter pylori in Lithuanian families. Chalkauskas H, et al. **Helicobacter** 1998 Dec;3(4):296–302

The role of gastric Helicobacter and N-methyl-N'-nitro-N-nitrosoguanidine in carcinogenesis of mice. Danon SJ, et al. **Helicobacter** 1998 Dec;3(4):260–8

Heterogeneity of protein profiles of Helicobacter pylori isolated from individual patients. Kitamoto N, et al. **Helicobacter** 1998 Sep;3(3):152–62

Experimental infection in cats with a cagA+ human isolate of Helicobacter pylori. Perkins SE, et al. **Helicobacter** 1998 Dec;3(4):225–35

Detection of coccoid Helicobacter pylori: light microscopical immunogold silver enhancing stain. Saito N, et al. **Helicobacter** 1998 Sep;3(3):170–3

Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Trautmann M, et al. **Helicobacter** 1999 Jun;4(2):113–20

Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Yamaoka Y, et al. **Helicobacter** 1998 Dec;3(4):241–53

Heavy bacterial loads of H. pylori may precipitate duodenal ulcer bleeding but not bleeding severity. Bor-Shyang S, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2165–70

Helicobacter pylori-seronegative gastric carcinoma: a subset of gastric carcinoma with distinct clinicopathologic features. Wu MS, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2432–6

Dental plaque: an unlikely reservoir of Helicobacter pylori [see comments] Kamat AH, et al. **Indian J Gastroenterol** 1998 Oct-Dec;17(4):138–40. Comment in: Indian J Gastroenterol 1998 Oct-Dec;17(4):123–5. Comment in: Indian J Gastroenterol 1999 Jan-Mar;18(1):43.

Surface-associated heat shock proteins of Legionella pneumophila and Helicobacter pylori: roles in pathogenesis and immunity. Hoffman PS, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):58–63 (23 ref.)

In vivo distribution of Helicobacter felis in the gastric mucus of the mouse: experimental method and results. Schreiber S, et al. **Infect Immun** 1999 Oct;67(10):5151–6

Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains. Wirth HP, et al. **Infect Immun** 1998 Oct;66(10):4856–66

Antibiotic resistance problems with Helicobacter pylori. Alarcón T, et al. **Int J Antimicrob Agents** 1999 Jun; 12(1):19–26 (93 ref.)

Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Osato MS, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):341–7

Helicobacter heilmannii associated erosive gastritis [see comments] Yamamoto T, et al. **Intern Med** 1999 Mar; 38(3):240–3. Comment in: Intern Med 1999 Mar;38(3):217–8.

Experimental model of Helicobacter pylori infection. Del Giudice G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S261–3 (15 ref.)

New acquisitions in Helicobacter pylori characteristics. Figura N, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S254–8 (61 ref.)

Helicobacter pylori and lymphoproliferative disorders. Fischbach W. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S299–303 (39 ref.)

Enterohepatic Helicobacters: natural and experimental models. Fox J. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S264–9 (58 ref.)

Helicobacter pylori and gastric cancer. McNamara D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S294–8 (49 ref.)

Gastro-oesophageal reflux and Helicobacter pylori. Pace F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S289–93 (36 ref.)

Helicobacter pylori infection and dyspepsia. Quina MG. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S286–8 (25 ref.)

Natural course of Helicobacter pylori gastric infection. Sipponen P. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S270–2 (22 ref.)

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. Debets-Ossenkopp YJ, et al. **J Antimicrob Chemother** 1999 Apr;43(4):511–5

Gastric epithelial cells stimulate Helicobacter pylori growth. Nakajima N, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S138–40

cagA and vacA status of Spanish Helicobacter pylori clinical isolates [letter; comment] Domingo D, et al. **J Clin Microbiol** 1999 Jun;37(6):2113–4. Comment on: J Clin Microbiol 1998 Apr;36(4):944–8.

PCR-based restriction pattern typing of the vacA gene provides evidence for a homogeneous group among Helicobacter pylori strains associated with peptic ulcer disease. Donati M, et al. **J Clin Microbiol** 1999 Apr; 37(4):912–5

Helicobacter pylori infection in indigenous families of Central America: serostatus and oral and fingernail carriage. Dowsett SA, et al. **J Clin Microbiol** 1999 Aug; 37(8):2456–60

Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori-associated gastric diseases. Evans DG, et al. **J Clin Microbiol** 1998 Nov;36(11):3435–7

Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? Han SR, et al. **J Clin Microbiol** 1999 Aug;37(8):2740–1

DNA fingerprinting of single colonies of Helicobacter pylori from gastric cancer patients suggests infection with a single predominant strain. Miehlke S, et al. **J Clin Microbiol** 1999 Jan;37(1):245–7

Distinct variants of Helicobacter pylori cagA are associated with vacA subtypes. van Doorn LJ, et al. **J Clin Microbiol** 1999 Jul;37(7):2306–11

Analysis of vacA, cagA, and IS605 genotypes and those determined by PCR amplification of DNA between repetitive sequences of Helicobacter pylori strains isolated from patients with nonulcer dyspepsia or mucosa-associated lymphoid tissue lymphoma. van Doorn NE, et al. **J Clin Microbiol** 1999 Jul;37(7):2348–9

Recurrent bacteremia caused by a "Flexispira"-like organism in a patient with X-linked (Bruton's) agammaglobulinemia. Weir S, et al. **J Clin Microbiol** 1999 Aug;37(8):2439–45

An uncommon Helicobacter isolate from blood: evidence of a group of Helicobacter spp. pathogenic in AIDS patients. Weir SC, et al. **J Clin Microbiol** 1999 Aug;37(8):2729–33

The significance of cagA and vacA subtypes of Helicobacter pylori in the pathogenesis of inflammation and peptic ulceration. Gunn MC, et al. **J Clin Pathol** 1998 Oct; 51(10):761–4

Toxigenicity of Helicobacter pylori isolates possessing cagA gene and vacuolating cytotoxin. Kodama K, et al. **J Gastroentorol** 1998;33 Suppl 10:14–7

Characteristics of Helicobacter pylori strains isolated from patients with different gastric diseases. Kurihara N, et al. **J Gastroenterol** 1998;33 Suppl 10:10–3

Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer. Futami H, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):114–9

Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites. Xia HH, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1044–9

Rapid and easy detection of Helicobacter pylori by in situ hybridization. Park CS, et al. **J Korean Med Sci** 1999 Feb; 14(1):15–20

Severe gastritis in guinea-pigs infected with Helicobacter pylori. Sturegård E, et al. **J Med Microbiol** 1998 Dec; 47(12):1123–9

Identification of Helicobacter in gastric biopsies by PCR based on 16S rDNA sequences: a matter of little significance for the prediction of H. pylori-associated gastritis? Tiveljung A, et al. **J Med Microbiol** 1998 Aug; 47(8):695–704

Seroprevalence of Helicobacter pylori infection in Malaysian children: evidence for ethnic differences in childhood. Boey CC, et al. **J Paediatr Child Health** 1999 Apr;35(2):151–2

Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Lin CW, et al. **Jpn J Med Sci Biol** 1998 Nov;51(1):13–23

Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. Owen RJ, et al. **Microb Drug Resist** 1999 Summer;5(2):141–6

Helicobacter pylori--a conundrum of genetic diversity. Marshall DG, et al. **Microbiology** 1998 Nov;144 (Pt 11):2925–39 (160 ref.)

Improving the success of culturing Helicobacter pylori from gastric biopsies. Hua J, et al. **Microbios** 1998;96(384):95–101

Characterization of clinical isolates of Helicobacter pylori in Singapore. Hua J, et al. **Microbios** 1998;94(378):71–81

Helicobacter heilmannii gastritis: association with acid peptic diseases and comparison with Helicobacter pylori gastritis. Jhala D, et al. **Mod Pathol** 1999 May;12(5):534–8

Emergence of recombinant strains of Helicobacter pylori during human infection. Kersulyte D, et al. **Mol Microbiol** 1999 Jan;31(1):31–43

Helicobacter pylori-like dyspepsia: fact or myth? [editorial; comment] Adang RP. **Neth J Med** 1998 Oct;53(4):147–52 (95 ref.). Comment on: Neth J Med 1998 Oct;53(4):164–7.

An evaluative system for the response of antibacterial therapy: based on the morphological change of Helicobacter pylori and mucosal inflammation. Wen M, et al. **Pathol Int** 1999 Apr;49(4):332–7

Helicobacter pylori transmission between a boy with duodenal ulcer and his father. Shimizu T, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):655–6

Microbiological and histological study of the gastrointestinal tract of germ-free mice infected with Helicobacter trogontum. Moura SB, et al. **Res Microbiol** 1999 Apr; 150(3):205–12

Helicobacter pylori virulence and genetic geography. Covacci A, et al. **Science** 1999 May 21;284(5418):1328–33 (57 ref.)

Host-bacterial interactions and the pathogenesis of Helicobacter pylori infection. Dorrell N, et al. **Trends Microbiol** 1998 Oct;6(10):379–82

Pathobiology of Helicobacter pylori infection. Cave DR, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):43–51 (55 ref.)

Helicobacter pylori and apoptosis. Moss SF. **Yale J Biol Med** 1998 Mar-Apr;71(2):53–61 (32 ref.)

Dietary factors influence the recovery rates of Helicobacter pylori in a BALB/cA mouse model. Wang X, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):195–205

[Investigation of relationship between primary gastric malignant lymphoma and Helicobacter pylori infection] Yi Z, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):442–5 (Eng. Abstr.) **(Chi)**

[Detection and differentiation of Helicobacter pylori from gastric biopsy and saliva by PCR-SSCP] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):446–9 (Eng. Abstr.) **(Chi)**

[Comparison of quantifying Helicobacter pylori gastric infection by culture, histology and C13 urea breath test (see comments)] Auroux J, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):407–12 (Eng. Abstr.) . Comment in: Gastroenterol Clin Biol 1998 Apr;22(4):405–6. **(Fre)**

[Molecular analysis of the progression of Helicobacter pylori-associated chronic gastritis toward mucosa-associated lymphoid tissue (MALT) lymphoma] Martin A. **Gastroenterol Clin Biol** 1998 Oct;22(10):843–4 **(Fre)**

[Low-grade gastric MALT lymphoma and helicobacter heilmannii (Gastrospirillum hominis] Regimbeau C, et al. **Gastroenterol Clin Biol** 1998 Aug-Sep;22(8–9):720–3 (Eng. Abstr.) **(Fre)**

[Helicobacter heilmannii, another agent responsible for acute gastritis in the human (letter)] Mennecier D, et al. **Presse Med** 1998 Sep 26;27(28):1436 **(Fre)**

[Helocobacter heilmannii (Gastrospirillum hominis)-associated gastritis: first reported cases in Hungary] Tiszlavicz L, et al. **Orv Hetil** 1999 Apr 18; 140(16):887–90 (30 ref.) (Eng. Abstr.) **(Hun)**

[Effect of Helicobacter pylori infection on the apoptotic and cell proliferative processes of the gastric mucosa] Törgyekes E, et al. **Orv Hetil** 1999 Apr 4;140(14):755–60 (Eng. Abstr.) **(Hun)**

[Helicobacter heilmannii: anatomo-clinical study of 14 new cases] Foschini MP, et al. **Pathologica** 1999 Feb;91(1):18–24 (Eng. Abstr.) **(Ita)**

[The appropriate time for the assessment of Helicobacter pylori eradication] Ishizuka J, et al. **Nippon Rinsho** 1999 Jan;57(1):111–5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Antibiotic-resistant H. pylori strains in the last ten years in Japan] Murakami K, et al. **Nippon Rinsho** 1999 Jan; 57(1):81–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Bezoars and gigantic stomach ulcers associated with helicobacter pylori] Khutiev TsS, et al. **Khirurgiia (Mosk)** 1999;(3):28–31 (Eng. Abstr.) **(Rus)**

[On the role of Helicobacter pylori in the pathogenesis of ulcers] Krylov AA. **Klin Med (Mosk)** 1998;76(11):68–9 **(Rus)**

[Helicobacter pylori and stomach cancer] Butov IuL, et al. **Lik Sprava** 1998 Jun;(4):69–71 (Eng. Abstr.) **(Rus)**

[The possibility of Helicobacter pylori being present in the resting state in the gastric mucosa of peptic acid patients after treatment] Loginov AS, et al. **Ter Arkh** 1999; 71(2):13–6 (Eng. Abstr.) **(Rus)**

[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40–3 (22 ref.) **(Spa)**

PATHOLOGY

Histological detection of Helicobacter pylori. De Prez C. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):327–9 (25 ref.)

Detection of Helicobacter pylori infection by biopsy urease test. Ramdani B, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):330–1 (11 ref.)

Characteristics of Helicobacter pylori-negative and -positive peptic ulcer disease. Kemppainen H, et al. **Age Ageing** 1998 Jul;27(4):427–31

Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing. Konturek PC, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):333–46

Review article: exploring the link between Helicobacter pylori and gastric cancer. Kuipers EJ. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:3–11 (27 ref.)

Gastric cellular turnover and the development of atrophy after 31 years of follow-up: a case-control study. Moss SF, et al. **Am J Gastroenterol** 1999 Aug;94(8):2109–14

Body-fundic mucopeptic cells expansion after Helicobacter pylori eradication [letter] Testino G. **Am J Gastroenterol** 1998 Dec;93(12):2636–8

Endoscopic biopsy pathology of Helicobacter pylori gastritis.

Comparison of bacterial detection by immunohistochemistry and Genta stain. Toulaymat M, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):778–81

Apoptosis in Helicobacter pylori-associated gastric and duodenal ulcer disease is mediated via the Fas antigen pathway. Houghton J, et al. **Dig Dis Sci** 1999 Mar; 44(3):465–78

Reactions from rat gastric mucosa during one year of Helicobacter pylori infection. Li H, et al. **Dig Dis Sci** 1999 Jan;44(1):116–24

Relationship of Helicobacter pylori CagA status to gastric cell proliferation and apoptosis. Rokkas T, et al. **Dig Dis Sci** 1999 Mar;44(3):487–93

Augmentation of water-immersion stress- induced gastric mucosal lesions in BALB/c mice infected with Helicobacter felis. Matsushima Y, et al. **Digestion** 1999 Jan–Feb;60(1):34–40

'Carditis': an objective histological marker for pathologic gastroesophageal reflux disease. Csendes A, et al. **Dis Esophagus** 1998 Apr;11(2):101–5

Evaluation of antral biopsies used in the rapid urease test for Helicobacter pylori culture. Hyde DK, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):73–5

Helicobacter pylori, pre-neoplastic changes, gastric cancer: a point of view [letter; comment] Testino G, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):357–9. Comment on: Eur J Gastroenterol Hepatol 1998 Jun;10(6):447–50.

Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Coyle WJ, et al. **Gastrointest Endosc** 1998 Sep;48(3):327–8

Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer. Kohda K, et al. **Gut** 1999 Apr;44(4):456–62

Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier thickness is not compromised. Newton JL, et al. **Gut** 1998 Oct;43(4):470–5

Third International Workshop on Pathogenesis and Host Response in Helicobacter Infections. Taylor DE. **Helicobacter** 1998 Dec;3(4):303–4

Relationship between Helicobacter pylori infection, histological gastritis, and functional dyspepsia. Glasbrenner B, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2238–43

The importance of increasing the number of gastric biopsies in the diagnosis of Helicobacter pylori. Gur G, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2219–23

Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection. Tseng GY, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1000–4

Helicobacter pylori infection and age on the development of intestinal metaplasia--a multiple logistic regression analysis. Wang CC, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2234–7

SCID/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis. Li X, et al. **Infect Immun** 1998 Nov; 66(11):5477–84

Human embryonic gastric xenografts in nude mice: a new model of Helicobacter pylori infection. Lozniewski A, et al. **Infect Immun** 1999 Apr;67(4):1798–805

Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Sawai N, et al. **Infect Immun** 1999 Jan;67(1):279–85

Atrophy and atrophic gastritis: one step beyond the Sydney system. Genta RM. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S273–5 (12 ref.)

Atrophy, metaplasia and dysplasia: are they reversible? Genta RM. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S324–5 (15 ref.)

Prevalence of gastric metaplasia in the duodenal bulb and distribution of Helicobacter pylori in the gastric mucosa. A clinical and histopathological study in 96 consecutive patients. Jonkers D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):481–3

Polyamine profile in human gastric mucosa infected by Helicobacter pylori. Linsalata M, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):484–9

Pathologic changes in the glandular stomach and duodenum in an H. pylori-infected Mongolian gerbil model. Sawada Y, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S141–3

Helicobacter pylori infection in the remnant stomach after gastrectomy: with special reference to the difference between Billroth I and II anastomoses. Tomtitchong P, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S154–8

Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. Rudi J, et al. **J Clin Invest** 1998 Oct 15; 102(8):1506–14

Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori. Siu LK, et al. **J Clin Microbiol** 1998 Oct;36(10):3048–50

Pathological changes in glandular stomach of Helicobacter pylori-infected Mongolian gerbil model. Sawada Y, et al. **J Gastroenterol** 1998;33 Suppl 10:22–5

Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. Fraser AG, et al. **J Gastroenterol Hepatol** 1998 Jun; 13(6):560–5

Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. Roth KA, et al. **J Immunol** 1999 Aug 1;163(3):1490–7

Role of mast cells as a trigger of inflammation in Helicobacter pylori infection. Yamamoto J, et al. **J Physiol Pharmacol** 1999 Mar;50(1):17–23

Experimentally induced infection with Helicobacter pylori in squirrel monkeys (Saimiri spp.): clinical, microbiological, and histopathologic findings. Stadtländer CT, et al. **Lab Anim Sci** 1998 Jun;48(3):303–9

Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Schmidt PH, et al. **Lab Invest** 1999 Jun;79(6):639–46

Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Stolte M. **Lancet** 1998 Dec 19–26;352(9145):2016; discussion 2017. Comment on: Lancet 1998 Sep 26;352(9133):1016–21.

Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Loffeld RJ. **Neth J Med** 1999 Mar;54(3):96–100

Gastric foveolar immature cells (mucopeptic cells) expansion in body-fundic advanced intestinal type gastric cancer in patients with chronic non-atrophic ("superficial") gastritis: Helicobacter pylori role. Testino G. **Panminerva Med** 1998 Sep;40(3):179–82

Gastric inflammation is enhanced in children with CagA-positive Helicobacter pylori infection. Kolho KL, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):337–41

Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Peek RM Jr, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):531–44

Helicobacter pylori infection and progression of gastric atrophy and intestinal metaplasia [letter] Furuta T, et al. **Scand J Gastroenterol** 1998 Sep;33(9):1005

Role of aging in the expression of Helicobacter pylori gastritis in the antrum, corpus, and cardia. Hackelsberger A, et al. **Scand J Gastroenterol** 1999 Feb;34(2):138–43

Gastric carcinoma risk index in patients infected with Helicobacter pylori [letter; comment] Stachura J. **Virchows Arch** 1998 Dec;433(6):583–5. Comment on: Virchows Arch 1998 Apr;432(4):311–4.

Helicobacter pylori and apoptosis. Moss SF. **Yale J Biol Med** 1998 Mar–Apr;71(2):53–61 (32 ref.)

Simultaneous MALT-type lymphoma and early adenocarcinoma of the stomach associated with Helicobacter pylori gastritis. Müller S, et al. **Z Gastroenterol** 1999 Feb;37(2):153–7

Helicobacter pylori induces apoptosis in mucosal lymphocytes in patients with gastritis. Reinacher-Schick A, et al. **Z Gastroenterol** 1998 Dec;36(12):1021–6

Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controls. Schilling D, et al. **Z Gastroenterol** 1999 Feb;37(2):127–32

[Effect of Helicobacter pylori on gastric epithelial apoptosis] Dong Q, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov; 36(11):751–3 (Eng. Abstr.) **(Chi)**

[Gastric epithelial proliferation and apoptosis in Helicobacter pylori infection (editorial)] Xiao S, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):219–20 **(Chi)**

[Mas cells in the stomach--what is their role in Helicobacter pylori gastritis?] Schmidt-Choudhury A, et al. **Z Gastroenterol** 1998 Nov;36(11):1013–5 **(Ger)**

[Effect of the eradication of Helicobacter pylori on peptic ulcer healing] Harase I, et al. **Nippon Rinsho** 1999 Jan; 57(1):162–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers] Imaizumi H, et al. **Nippon Rinsho** 1999 Jan;57(1):167–72 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic and histological changes in the mucosa of the gastric stump in Helicobacter pylori infection] Inshakov LN, et al. **Vestn Khir Im I I Grek** 1999;158(2):13–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Hawkey CJ. **Aliment Pharmacol Ther** 1999 Jun; 13(6):695–702 (62 ref.)

Helicobacter pylori-positive peptic ulcer patients do not adapt to aspirin. Konturek JW, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):857–64

Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing. Konturek PC, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):333–46

Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Martinek J, et al. **Aliment Pharmacol Ther** 1999 Jan; 13(1):27–34

Helicobacter pylori, GERD, NSAIDs, and cancer: where we really stand [letter; comment] Graham DY. **Am J Gastroenterol** 1999 May;94(5):1420–1. Comment on: Am J Gastroenterol 1998 Oct;93(10):1800–2.

Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Perri F, et al. **Am J Gastroenterol** 1998 Nov;93(11):2082–8

Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Walker MM, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:96–111 (105 ref.)

Effect of processed and non-processed coffee samples on gastric potential difference. Study with healthy male Helicobacter pylori-positive and Helicobacter pylori-negative volunteers. Ehrlich A, et al. **Arzneimittelforschung** 1999 Jul;49(7):626–30

Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Shelton MJ, et al. **Clin Infect Dis** 1998 Oct;27(4):739–45

The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Gentile S, et al. **Diabetes Res Clin Pract** 1998 Oct;42(1):41–8

Proximal and distal gastric distension in normal subjects and H. pylori-positive and -negative dyspeptic patients and correlation with symptoms. Marzio L, et al. **Dig Dis Sci** 1998 Dec;43(12):2757–63

Water extracts of Helicobacter pylori delay healing of chronic gastric ulcers in rats: role of cytokines and gastrin-somatostatin link. Brzozowski T, et al. **Digestion** 1999 Jan–Feb;60(1):22–33

Helicobacter pylori and somatostatin cells [comment] Calam J. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):281–3. Comment on: Eur J Gastroenterol Hepatol 1998 Apr;10(4):289–91.

Lack of correlation between self-reported symptoms of dyspepsia and infection with Helicobacter pylori, in a general population sample. Stone MA, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):301–4

Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans [see comments] Tham TC, et al. **Eur J Gastroenterol Hepatol** 1998 Apr; 10(4):289–91. Comment in: Eur J Gastroenterol Hepatol 1998 Apr;10(4):281–3.

Helicobacter pylori associated gastric pathology in patients with type II diabetes mellitus and its relationship with gastric emptying: the Ankara study. Güvener N, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):172–6

Helicobacter pylori-associated gastric pro- and antioxidant formation in Mongolian gerbils. Suzuki H, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):679–84

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Holtmann G, et al. **Gastroenterology** 1999 Jul;117(1):11–6

Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Hackelsberger A, et al. **Gut** 1998 Oct;43(4):465–9

Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Thumshirn M, et al. **Gut** 1999 Jan;44(1):55–64

Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. Graham DY, et al. **Helicobacter** 1998 Sep;3(3):174–8

Effect of adequate alcohol intake, with or without cigarette smoking, on the risk of Helicobacter pylori infection. Tursi A, et al. **Hepatogastroenterology** 1998 Sep–Oct; 45(23):1892–5

Vitamin C, Helicobacter pylori infection and gastric carcinogenesis. Reed PI. **Int J Vitam Nutr Res** 1999 May; 69(3):220–7 (71 ref.)

Spontaneous remission of hypertrophic lymphocytic gastritis associated with hypoproteinemia. Amenomori M, et al. **Intern Med** 1998 Dec;37(12):1019–22

A virulence factor of Helicobacter pylori: role of heat shock protein in mucosal inflammation after H. pylori infection. Kamiya S, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S35–9

Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. Yamaoka Y, et al. **J Clin Microbiol** 1999 Jul; 37(7):2274–9

Follow up after successful eradication of Helicobacter pylori: symptoms and reinfection. Fraser AG, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):555–9

Delayed healing of chronic gastric ulcer after Helicobacter pylori infection in mice. Makino M, et al. **J Pharm Pharmacol** 1998 Aug;50(8):943–8

The hemodynamic changes of gastroduodenal regional blood flow after Helicobacter pylori eradication in patients with duodenal ulcer scar. Wu DC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jan; 15(1):19–25

Gastric inflammation is enhanced in children with CagA-positive Helicobacter pylori infection. Kolho KL, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):337–41

Helicobacter pylori colonization in early life. Thomas JE, et al. **Pediatr Res** 1999 Feb;45(2):218–23

Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients. Agnihotri N, et al. **Scand J Gastroenterol** 1998 Jul;33(7):704–9

Extracts of Helicobacter pylori reduce gastric mucosal blood flow through a VacA- and CagA-independent pathway in rats. Atuma C, et al. **Scand J Gastroenterol** 1998 Dec; 33(12):1256–61

Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Manes G, et al. **Scand J Gastroenterol** 1999 Jul;34(7):658–62

Treatment with proton pump inhibitors induces tolerance to

histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Qvigstad G, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1244–8

[Role of cytokines in the pathogenesis of gastrointestinal diseases associated with Helicobacter pylori infection] Imanishi J, et al. **C R Seances Soc Biol Fil** 1998;192(5):991–6 (Eng. Abstr.) **(Fre)**

[Helicobacter pylori and gastric acid secretion] Konturek JW, et al. **Z Gastroenterol** 1999 Feb;37(2):187–94 (56 ref.) (Eng. Abstr.) **(Ger)**

[Effect of Helicobacter pylori on gastric emptying in non-ulcer dyspepsia—evaluation of Helicobacter pylori by 13C-urea breath test] Abe K. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):273–9 (Eng. Abstr.) **(Jpn)**

[The expression of chemokines and the dynamics of inflammatory cell infiltration before and after H. pylori eradication] Kikuchi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):933–40 (Eng. Abstr.) **(Jpn)**

[The interrelationship of gallbladder contractile function, the morphological status of the mucosa of the gastroduodenal area and its Helicobactor pylori colonization in patients with duodenal peptic ulcer] Klimanskaia NV, et al. **Lik Sprava** 1998 Dec;(8):79–83 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Eradication of Helicobacter pylori in functional dyspepsia. Study had several weaknesses [letter] McColl KE, et al. **BMJ** 1999 Aug 14;319(7207):451; discussion 451–2

Does imbibing alcohol protect against enteric pathogens? [editorial; comment] Klontz KC. **Epidemiology** 1999 May; 10(3):207–9 (27 ref.). Comment on: Epidemiology 1999 May;10(3):214–8.

Should we go further and screen and treat? Forman D. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S69–71; discussion S73

Vaccines. Lee A. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S75–9 (41 ref.)

Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein. Dunkley ML, et al. **FEMS Immunol Med Microbiol** 1999 Jun; 24(2):221–5

Working towards a Helicobacter pylori vaccine [editorial; comment] Czinn SJ, et al. **Gastroenterology** 1999 Apr; 116(4):990–3. Comment on: Gastroenterology 1999 Apr;116(4):804–12.

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults [see comments] Michetti P, et al. **Gastroenterology** 1999 Apr;116(4):804–12 . Comment in: Gastroenterology 1999 Apr;116(4):990–94.

Helicobacter pylori eradication: not enough grounds for recommendation [letter; comment] Prasad AV. **Indian J Gastroenterol** 1998 Oct–Dec;17(4):158–9. Comment on: Indian J Gastroenterol 1997 Nov;16 Suppl 1:S29–33. Comment on: Indian J Gastroenterol 1998 Jul–Sep;17(3):115–6.

Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, et al. **Infect Immun** 1999 May;67(5):2531–9

Development of a vaccine against Helicobacter pylori infection. Michetti P. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S339–41 (12 ref.)

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. Ermak TH, et al. **J Exp Med** 1998 Dec 21; 188(12):2277–88

Oral immunization against Helicobacter pylori—a future concept. Michetti P. **J Gastroenterol** 1998;33 Suppl 10:66–8 (36 ref.)

Treatment of Helicobacter pylori infection to reduce gastric cancer incidence: uncertain benefits of a community based programme in Australia. Forbes GM, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1091–5

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. Lam SK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):1–12 (74 ref.)

Seasonal behaviour of healed duodenal ulcer. Gupta AK, et al. **J Indian Med Assoc** 1998 Apr;96(4):106–8

Vaccination of gnotobiotic piglets against Helicobacter pylori. Eaton KA, et al. **J Infect Dis** 1998 Nov; 178(5):1399–405

Inhibitory effect of rose oil products on Helicobacter pylori growth in vitro: preliminary report [letter] Boyanova L, et al. **J Med Microbiol** 1999 Jul;48(7):705–6

Prospects for therapeutic Helicobacter pylori vaccines [editorial] Rijpkema SG. **J Med Microbiol** 1999 Jan; 48(1):1–3 (27 ref.)

Managing intrafamilial dissemination of Helicobacter pylori gastric infection improves eradication rate in children [letter] Kalach N, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):356

Virulence factors of Helicobacter pylori: implications for vaccine development. Suerbaum S, et al. **Mol Med Today** 1999 Jan;5(1):32–9 (54 ref.)

What happens to Helicobacter pylori after vagotomy and drainage? Jones VS, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):50–2

The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases. Gómez-Duarte OG, et al. **Vaccine** 1999 Mar 26;17(13–14):1667–73 (81 ref.)

Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection. Myers GA, et al. **Vaccine** 1999 Mar 17; 17(11–12):1394–403

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Novak MJ, et al. **Vaccine** 1999 May 14;17(19):2384–91

[Helicobacter pylori and stomach carcinoma. Is a preventive intervention study of value? (see comments)] Stolte M, et al. **Pathologe** 1998 Jul;19(4):330–3 (28 ref.). Comment in: Pathologe 1999 Mar;20(2):148–9. **(Ger)**

[Prevention of gastric cancer: Helicobacter—eradication and immunization] Koop H. **Schweiz Rundsch Med Prax** 1998 Sep 16;87(38):1233–5 (6 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Relationship between enterogastric reflux estimated by scintigraphy and the presence of Helicobacter pylori. Artiko VM, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1234–7

SURGERY

Evaluation of carotid arterial plaques after endarterectomy for Helicobacter pylori infection. Malnick SD, et al. **Am J Cardiol** 1999 Jun 1;83(11):1586–7, A8

THERAPY

Belgian consensus guidelines for the management of Helicobacter pylori related upper gastrointestinal diseases. Brussels, 6–7 February 1998. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):298–375 (0 ref.)

Gastro-duodenal ulcers. Who? When to treat? Colemont L. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):303–4 (11 ref.)

The 1998 national Belgian consensus meeting on HP-related diseases: an extensive summary. The HP Belgian contact group organized in CHU Brugmann, Brussels. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):299–302 (7 ref.)

Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies. Al-Assi MT, et al. **Am J Gastroenterol** 1999 Sep;94(9):2367–72

Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Graham DY, et al. **Am J Gastroenterol** 1999 May;94(5):1200–2

Increase in apoptosis and decrease in ornithine decarboxylase activity of the gastric mucosa in patients with atrophic gastritis and gastric ulcer after successful eradication of Helicobacter pylori. Hirasawa R, et al. **Am J Gastroenterol** 1999 Sep;94(9):2398–402

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Howden CW, et al. **Am J Gastroenterol** 1998 Dec;93(12):2330–8

Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Coconnier MH, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4573–80

A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Peitz U, et al. **Drugs** 1999 Jun;57(6):905–20 (226 ref.)

Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Jarosz M, et al. **Eur J Cancer Prev** 1998 Dec; 7(6):449–54

Guidance for trials in Helicobacter pylori infection [letter; comment] Gomollón F. **Gut** 1998 Nov;43(5):731. Comment on: Gut 1997 Sep;41 Suppl 2:S1–9.

Facts and fables in management of Helicobacter pylori [editorial; comment] Barbezat GO. **Med J Aust** 1999 Apr 19;170(8):348–9. Comment on: Med J Aust 1999 Apr 19;170(8):354–7.

Australian doctors' beliefs and practice regarding Helicobacter pylori [see comments] Mollison LC, et al. **Med J Aust** 1999 Apr 19;170(8):354–7. Comment in: Med J Aust 1999 Apr 19;170(8):348–9.

Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Oberhuber G, et al. **Pathol Res Pract** 1998;194(9):609–13

Therapeutic and clinical regimens against Helicobacter pylori infections in humans: an overview. Vyas SP, et al. **Pharmazie** 1999 Jun;54(6):399–408 (96 ref.)

Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice. Guy B, et al. **Vaccine** 1999 Mar 5;17(9–10):1130–5

[MALT stomach lymphoma: is there a standardized therapy?] Fischbach W. **Z Gastroenterol** 1998 Dec;36(12):1099–102 **(Ger)**

[Therapy of Helicobacter pylori infection using Lactobacillus acidophilus] Mrda Z, et al. **Med Pregl** 1998 Jul–Aug; 51(7–8):343–5 (Eng. Abstr.) **(Scr)**

TRANSMISSION

Dietary risk factors associated with the transmission of Helicobacter pylori in Lima, Peru. Begue RE, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):637–40

Helicobacter pylori: an occupational hazard for anaesthetists [letter; comment] Pittman J, et al. **Anaesthesia** 1999 Apr; 54(4):398. Comment on: Anaesthesia 1998 Feb;53(2):209–10.

Is Helicobacter pylori infection an occupational hazard for anesthesiologists? Shelley KH, et al. **Anesth Analg** 1998 Oct;87(4):973–4

Evidence for an oral-faecal transmission of Helicobacter pylori infection in an experimental murine model. Cellini L, et al. **APMIS** 1999 May;107(5):477–84

Familial clustering of Helicobacter pylori infection: population based study. Dominici P, et al. **BMJ** 1999 Aug 28;319(7209):537–40

Determinants of ethnic or geographical differences in infectivity and transmissibility of Helicobacter pylori. Fallone CA. **Can J Gastroenterol** 1999 Apr;13(3):251–5 (57 ref.)

Use of chopsticks for eating and Helicobacter pylori infection. Leung WK, et al. **Dig Dis Sci** 1999 Jun; 44(6):1173–6

Active infection with Helicobacter pylori in healthy couples. Brenner H, et al. **Epidemiol Infect** 1999 Feb;122(1):91–5

Endoscopy personnel and the transmission of Helicobacter pylori infection [editorial; comment] Kugathasan S, et al. **Gastrointest Endosc** 1998 Sep;48(3):317–8. Comment on: Gastrointest Endosc 1998 Sep;48(3):237–43.

Endoscopy personnel and Helicobacter pylori infection [letter] Luzza F, et al. **Gastrointest Endosc** 1999 Aug; 50(2):304–5

Seroprevalence of immunoglobulin G antibodies against Helicobacter pylori among endoscopy personnel in Japan [see comments] Nishikawa J, et al. **Gastrointest Endosc** 1998 Sep;48(3):237–43. Comment in: Gastrointest Endosc 1998 Sep;48(3):317–8.

Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer. Ma JL, et al. **Int J Epidemiol** 1998 Aug;27(4):570–3

Routes of transmission of Helicobacter pylori infection. Vaira D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S279–85 (74 ref.)

Helicobacter pylori antibody profile in household members of children with H. pylori infection. Elitsur Y, et al. **J Clin Gastroenterol** 1999 Sep;29(2):178–82

Helicobacter pylori: evidence for spouse-to-spouse transmission. Singh V, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):519–22

Helicobacter pylori and endoscopy. Williams CL. **J Hosp Infect** 1999 Apr;41(4):263–8 (56 ref.)

Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. Rothenbacher D, et al. **J Infect Dis** 1999 Feb; 179(2):398–402

Managing intrafamilial dissemination of Helicobacter pylori gastric infection improves eradication rate in children [letter] Kalach N, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):356

Transmission of Helicobacter hepaticus infection to sentinel mice by contaminated bedding. Livingston RS, et al. **Lab Anim Sci** 1998 Jun;48(3):291–3

Helicobacter pylori transmission between a boy with duodenal ulcer and his father. Shimizu T, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):655–6

Animal reservoirs in the transmission of Helicobacter heilmannii. Results of a questionnaire-based study. Meining A, et al. **Scand J Gastroenterol** 1998 Aug;33(8):795–8

Risk factors for infection with Helicobacter pylori—a study of children in rural Ethiopia. Lindkvist P, et al. **Scand J Infect Dis** 1998;30(4):371–6

[Prevalence of Helicobacter pylori(Hp) infection in the department of gastroenterology staff members in Nanjing] Lu YK, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):70–2 (Eng. Abstr.) **(Chi)**

VETERINARY

Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs. Cornetta AM, et al. **Am J Vet Res** 1998 Nov;59(11):1364–9

Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii. Neiger R, et al. **Am J Vet Res** 1999 Jul;60(7):880–3

Pathology, diagnosis and epidemiology of the rodent Helicobacter infection. Zenner L. **Comp Immunol Microbiol Infect Dis** 1999 Jan;22(1):41–61 (64 ref.)

Detection and effects of helicobacters in healthy dogs and dogs with signs of gastritis. Happonen I, et al. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1767–74

Novel intestinal Helicobacter species isolated from cotton-top tamarins (Saguinus oedipus) with chronic colitis. Saunders KE, et al. **J Clin Microbiol** 1999 Jan; 37(1):146–51

Genetic diversity of canine gastric helicobacters, Helicobacter bizzozeronii and H. salomonis studied by pulsed-field gel electrophoresis. Hänninen ML, et al. **J Med Microbiol** 1999 Apr;48(4):341–7

Enterohepatic lesions in SCID mice infected with Helicobacter bilis. Franklin CL, et al. **Lab Anim Sci** 1998 Aug;48(4):334–9

Helicobacter bilis/Helicobacter rodentium co-infection associated with diarrhea in a colony of scid mice. Shomer NH, et al. **Lab Anim Sci** 1998 Oct;48(5):455–9

HELICOBACTER INFECTIONS

Evaluation of a molecular identification scheme based on 23S rRNA gene polymorphisms for differentiating canine and feline gastric Helicobacter spp. Jalava K, et al. **Lett Appl Microbiol** 1999 Apr;28(4):269–74

Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Lee CK, et al. **Vaccine** 1999 Mar 17;17(11–12):1493–505

Gastric Helicobacter infection in dogs. Strauss-Ayali D, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):397–414, vi (98 ref.)

An epizootic of lymphoplasmacytic gastritis attributed to Helicobacter pylori infection in cynomolgus monkeys (Macaca fascicularis). Reindel JF, et al. **Vet Pathol** 1999 Jan;36(1):1–13

Helicobacter felis infection in dogs: effect on gastric structure and function. Simpson KW, et al. **Vet Pathol** 1999 May; 36(3):237–48

Detection of Helicobacter-like bacteria in porcine gastric biopsy samples by amplification of 16S rRNA, ureB, vacA and cagA genes by PCR. Utriainen M, et al. **Vet Res Commun** 1998 Sep;22(6):373–83

Antibodies against Helicobacter felis in sera of cats and dogs. Seidel KE, et al. **Zentralbl Veterinarmed [B]** 1999 Apr; 46(3):181–8

HELICOBACTER PYLORI

Chronic urticaria and Helicobacter pylori. Valsecchi R, et al. **Acta Derm Venereol** 1998 Nov;78(6):440–2

Belgian consensus guidelines for the management of Helicobacter pylori related upper gastrointestinal diseases. Brussels, 6–7 February 1998. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):298–375 (0 ref.)

Non ulcer dyspepsia and Helicobacter pylori. Debongnie JC. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):476–8 (15 ref.)

Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Včev A, et al. **Acta Med Croatica** 1998;52(4–5):209–14

Gastroduodenal inflammation associated with Helicobacter pylori infection. Diagnostic and therapeutic implications (a review). Fekete B. **Acta Microbiol Immunol Hung** 1998; 45(2):175–94 (121 ref.)

Association of Helicobacter pylori infection and Parkinson's disease already proposed [letter] Altschuler EL. **Acta Neurol Scand** 1999 Aug;100(2):122

Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Charlett A, et al. **Acta Neurol Scand** 1999 Jan;99(1):26–35

"De-Nol test" for rapid diagnosis of Helicobacter pylori in childhood [letter] Nijevitch AA, et al. **Acta Paediatr** 1999 Feb;88(2):234–5

Helicobacter pylori infection in children. Vandenplas Y, et al. **Acta Paediatr** 1998 Nov;87(11):1105–12 (62 ref.)

Characteristics of Helicobacter pylori-negative and -positive peptic ulcer disease. Kemppainen H, et al. **Age Ageing** 1998 Jul;27(4):427–31

Helicobacter pylori infection in elderly patients with peptic ulcer [letter] Pilotto A, et al. **Age Ageing** 1999 Jul; 28(4):412–4

Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Pilotto A, et al. **Age Ageing** 1999 Jul;28(4):367–71

Lymphoid hyperplasia of the stomach caused by Helicobacter pylori: upper gastrointestinal findings. Lee EY, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):362–3 (8 ref.)

Helicobacter pylori and gastro-oesophageal reflux disease [letter] Attwood S. **Aliment Pharmacol Ther** 1999 Aug; 13(8):1132–4

Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Bortolotti M, et al. **Aliment Pharmacol Ther** 1998 Oct; 12(10):1021–5

Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. Calvet X, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):781–6

A multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C-urea breath test for the detection of Helicobacter pylori infection. Cave DR, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):747–52

Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group. Cestari R. **Aliment Pharmacol Ther** 1998 Oct;12(10):991–6

Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection. Chey WD, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1263–7 (16 ref.)

Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Danesh J. **Aliment Pharmacol Ther** 1999 Jul;13(7):851–6 (65 ref.)

Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. Graham DY, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):169–72

Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. Grimley CE, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):869–73

Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. Gschwantler M, et al. **Aliment Pharmacol Ther** 1999 Aug; 13(8):1063–9

High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. Gudjonsson H, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1113–9

Clarithromycin-based triple therapies [letter; comment] Huang J, et al. **Aliment Pharmacol Ther** 1999 Mar; 13(3):437–9. Comment on: Aliment Pharmacol Ther 1998 Sep;12(9):823–37.

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Huang J, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):719–29

Helicobacter pylori-positive peptic ulcer patients do not adapt to aspirin. Konturek JW, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):857–64

Mouse model of Helicobacter pylori infection: studies of gastric function and ulcer healing. Konturek PC, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):333–46

Review article: exploring the link between Helicobacter pylori and gastric cancer. Kuipers EJ. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:3–11 (27 ref.)

Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis. Laheij RJ, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):857–64

Is routine histological evaluation an accurate test for Helicobacter pylori infection? MacOni G, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):327–31

The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Malfertheiner P, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):703–12

Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Martinek J, et al. **Aliment Pharmacol Ther** 1999 Jan; 13(1):27–34

Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Meining A, et al. **Aliment Pharmacol Ther** 1998 Aug;12(8):735–40

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Miwa H, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):741–6

Novel therapies for Helicobacter pylori infection. Opekun AR, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):35–42

Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. Paré P, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1071–8

The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Peters FT, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):921–6

Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study. Pohle T, et al. **Aliment Pharmacol Ther** 1998 Dec; 12(12):1273–8

Nocturnal gastric acid breakthrough on proton pump inhibitors [letter] Savarino V, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):977–8

Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. Savarino V, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):43–7

Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. Sieg A, et al. **Aliment Pharmacol Ther** 1999 Jul; 13(7):865–8

Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Spadaccini A, et al. **Aliment Pharmacol Ther** 1998 Oct;12(10):997–1001

One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Sung JJ, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1079–84

The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Tefera S, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):915–20

Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease. Trevisani L, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1269–72

Failure of a 1-day high-dose quadruple therapy for cure of Helicobacter pylori infection. Wermeille J, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):173–7

Evaluation of carotid arterial plaques after endarterectomy for Helicobacter pylori infection. Malnick SD, et al. **Am J Cardiol** 1999 Jun 1;83(11):1586–7, A8

Helicobacter pylori serology in patients with angiographically documented coronary artery disease. Quinn MJ, et al. **Am J Cardiol** 1999 Jun 15;83(12):1664–6, A6

Molecular alterations in early gastric carcinomas. No apparent correlation with Helicobacter pylori status. Blok P, et al. **Am J Clin Pathol** 1999 Feb;111(2):241–7

Inverse graded relation between alcohol consumption and active infection with Helicobacter pylori. Brenner H, et al. **Am J Epidemiol** 1999 Mar 15;149(6):571–6

Co-twin study of the effect of environment and dietary elements on acquisition of Helicobacter pylori infection. Malaty HM, et al. **Am J Epidemiol** 1998 Oct 15; 148(8):793–7

Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Adamek RJ, et al. **Am J Gastroenterol** 1998 Oct;93(10):1919–24

Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies. Al-Assi MT, et al. **Am J Gastroenterol** 1999 Sep;94(9):2367–72

Colorectal adenomateous polyps and Helicobacter pylori infection [letter] Aydin A, et al. **Am J Gastroenterol** 1999 Apr;94(4):1121–2

Helicobacter pylori as a pathogenic factor in Ménétrier's disease. Badov D, et al. **Am J Gastroenterol** 1998 Oct; 93(10):1976–9

Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Bravo LE, et al. **Am J Gastroenterol** 1999 Sep; 94(9):2380–3

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Breuer T, et al. **Am J Gastroenterol** 1999 Mar;94(3):725–9

Epidemiology of peptic ulcer disease in cirrhotic patients: role of Helicobacter pylori infection. Calvet X, et al. **Am J Gastroenterol** 1998 Dec;93(12):2501–7

Migraine in children and Helicobacter pylori [letter] Caselli M, et al. **Am J Gastroenterol** 1999 Apr;94(4):1116–8

The 13C-urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial. Chey WD, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1522–4

Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Ciociola AA, et al. **Am J Gastroenterol** 1999 Jul;94(7):1834–40

Comparison of [13C]urea blood test to [13C]urea breath test for the diagnosis of Helicobacter pylori. Cutler AF, et al. **Am J Gastroenterol** 1999 Apr;94(4):959–61

Detection of Helicobacter pylori infection [letter; comment] Dinler G, et al. **Am J Gastroenterol** 1999 Apr;94(4):1118 . Comment on: Am J Gastroenterol 1998 Aug;93(8):1291–6.

Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Eslick GD, et al. **Am J Gastroenterol** 1999 Sep;94(9):2373–9

Confounding factors in the detection of Helicobacter pylori infection in patients with upper gastrointestinal bleeding [letter; comment] Fantry GT, et al. **Am J Gastroenterol** 1999 May;94(5):1421–2. Comment on: Am J Gastroenterol 1998 Oct;93(10):1914–8.

Helicobacter pylori, GERD, NSAIDs, and cancer: where we really stand [letter; comment] Graham DY. **Am J Gastroenterol** 1999 May;94(5):1420–1. Comment on: Am J Gastroenterol 1998 Oct;93(10):1800–2.

Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Graham DY, et al. **Am J Gastroenterol** 1999 May;94(5):1200–2

Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study. Henry A, et al. **Am J Gastroenterol** 1999 Mar;94(3):811–5

Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies [letter] Higuchi K, et al. **Am J Gastroenterol** 1999 May; 94(5):1419–20

Increase in apoptosis and decrease in ornithine decarboxylase activity of the gastric mucosa in patients with atrophic gastritis and gastric ulcer after successful eradication of Helicobacter pylori. Hirasawa R, et al. **Am J Gastroenterol** 1999 Sep;94(9):2398–402

Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Howden CW, et al. **Am J Gastroenterol** 1998 Dec;93(12):2330–8

Helicobacter pylori infection induces telomerase activity in premalignant lesions [letter] Kameshima H, et al. **Am J Gastroenterol** 1999 Feb;94(2):547–8

Remission of Ménétrier's disease after a prolonged period with therapeutic eradication of Helicobacter pylori. Kaneko T, et al. **Am J Gastroenterol** 1999 Jan;94(1):272–3

Barrett's metaplasia and Helicobacter pylori infection [letter] Kiltz U, et al. **Am J Gastroenterol** 1999 Jul;94(7):1985–6

One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial. Kung NN, et al. **Am J Gastroenterol** 1999 Mar;94(3):721–4

Does Helicobacter pylori affect the management of gastroesophageal reflux disease? [editorial; comment] Labenz J. **Am J Gastroenterol** 1999 Apr;94(4):867–9. Comment on: Am J Gastroenterol 1999 Apr;94(4):884–7.

Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. Laine L, et al. **Am J Gastroenterol** 1999 Apr;94(4):962–6

Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three

multicenter, double-blind, United States trials. Laine L, et al. **Am J Gastroenterol** 1998 Nov;93(11):2106-12
Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Leodolter A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2100-4
Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. McCarthy CJ, et al. **Am J Gastroenterol** 1999 May; 94(5):1218-23
Helicobacter pylori in the Canadian arctic: seroprevalence and detection in community water samples. McKeown I, et al. **Am J Gastroenterol** 1999 Jul;94(7):1823-9
Point prevalence of peptic ulcer and gastric histology in healthy Indians with Helicobacter pylori infection [letter; comment] Malik GM, et al. **Am J Gastroenterol** 1998 Oct; 93(10):2002-3. Comment on: Am J Gastroenterol 1997 Sep;92(9):1487-91.
Helicobacter pylori and gastric outlet obstruction [letter; comment] Malik GM, et al. **Am J Gastroenterol** 1998 Oct; 93(10):2004. Comment on: Am J Gastroenterol 1997 Feb;92(2):362-3. Comment on: Am J Gastroenterol 1997 Sep;92(9):1576-7.
Hyperplastic gastric polyps: medical management is feasible. Metz DC. **Am J Gastroenterol** 1999 Jul;94(7):1977-8
Helicobacter pylori and gastric cancer: proving the link. Metz DC. **Am J Gastroenterol** 1999 Mar;94(3):852-3
Gastric cellular turnover and the development of atrophy after 31 years of follow-up: a case-control study. Moss SF, et al. **Am J Gastroenterol** 1999 Aug;94(8):2109-14
Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. Murata H, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2102-5
Symptoms and Helicobacter pylori: any link? The Italian Helicobacter pylori Study Group [letter] Neri M, et al. **Am J Gastroenterol** 1998 Dec;93(12):2633-4
Childhood duodenal ulcer associated with Helicobacter pylori and ABO blood groups [letter; comment] Nijevitch AA, et al. **Am J Gastroenterol** 1999 May;94(5):1424-5. Comment on: Am J Gastroenterol 1996 Jan;91(1):101-4.
Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Perri F, et al. **Am J Gastroenterol** 1998 Nov;93(11):2082-8
Decreased gastroduodenal mucosal concentration of transforming growth factor-alpha in Helicobacter pylori-infected dyspeptic patients [letter] Persico M, et al. **Am J Gastroenterol** 1998 Dec;93(12):2643-4
Helicobacter pylori and nonulcer dyspepsia: more confusion? Pfau PR, et al. **Am J Gastroenterol** 1999 Sep;94(9):2563-5
Do we all treat functional dyspepsia with Helicobacter pylori eradication? [letter; comment] Prónai L, et al. **Am J Gastroenterol** 1999 Feb;94(2):543. Comment on: Am J Gastroenterol 1998 Apr;93(4):553-61.
Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad [see comments] Richter JE, et al. **Am J Gastroenterol** 1998 Oct;93(10):1800-2 (26 ref.). Comment in: Am J Gastroenterol 1999 May;94(5):1420-1.
Comparison of isotope ratio mass spectrometry and nondispersive isotope-selective infrared spectroscopy for 13C-urea breath test. Savarino V, et al. **Am J Gastroenterol** 1999 May;94(5):1203-8
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease [see comments] Schenk BE, et al. **Am J Gastroenterol** 1999 Apr;94(4):884-7. Comment in: Am J Gastroenterol 1999 Apr;94(4):867-9.
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. Smoot DT, et al. **Am J Gastroenterol** 1999 Apr;94(4):955-8
The effect of antibiotic therapy on bleeding from duodenal ulcer. Sonnenberg A, et al. **Am J Gastroenterol** 1999 Apr; 94(4):950-4
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Stack WA, et al. **Am J Gastroenterol** 1998 Oct;93(10):1909-13
Body-fundic mucopeptic cells expansion after Helicobacter pylori eradication [letter] Testino G. **Am J Gastroenterol** 1998 Dec;93(12):2636-8
Helicobacter pylori infection and gastric juice total phospholipid concentration in patients with bleeding peptic ulcer [letter] Triantafillidis JK, et al. **Am J Gastroenterol** 1998 Dec;93(12):2642-3
Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Vakil N, et al. **Am J Gastroenterol** 1999 May; 94(5):1197-9
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. van der Wouden EJ, et al. **Am J Gastroenterol** 1999 Jul;94(7):1751-9
Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Wu JC, et al. **Am J Gastroenterol** 1999 Jul;94(7):1790-4
Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Zullo A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2214-8
The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Barkin J. **Am J Med** 1998 Nov 2;105(5A):22S-27S (51 ref.)
Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Fendrick AM, et al. **Am J Med** 1999 Aug;107(2):133-6
Helicobacter pylori: rational management options. Peura D. **Am J Med** 1998 Nov;105(5):424-30 (43 ref.)
Helicobacter pylori and gastric cancer. Scheiman JM, et al. **Am J Med** 1999 Feb;106(2):222-6 (55 ref.)
Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils. Ikeno T, et al. **Am J Pathol** 1999 Mar;154(3):951-60
Helicobacter pylori infection and persistent hyperemesis gravidarum. Jacoby EB, et al. **Am J Perinatol** 1999; 16(2):85-8
Persistence of Helicobacter pylori VacA toxin and vacuolating potential in cultured gastric epithelial cells. Sommi P, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G681-8
Dietary risk factors associated with the transmission of Helicobacter pylori in Lima, Peru. Begue RE, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):637-40
Prospective study of the incidence of diarrheal disease and Helicobacter pylori infection among children in an orphanage in Thailand. Isenbarger DW, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):796-800
Nutritional status of Helicobacter pylori-infected children in Guatemala as compared with uninfected peers. Quiñonez JM, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):395-8
Helicobacter pylori: an occupational hazard for anaesthetists [letter; comment] Pittman J, et al. **Anaesthesia** 1999 Apr; 54(4):398. Comment on: Anaesthesia 1998 Feb;53(2):209-10.
Development of a chemiluminescent urease activity assay for Helicobacter pylori infection diagnosis in gastric mucosa biopsies. Roda A, et al. **Anal Biochem** 1998 Nov 1;264(1):47-52
Is Helicobacter pylori infection an occupational hazard for anesthesiologists? Shelley KH, et al. **Anesth Analg** 1998 Oct;87(4):973-4
In a world of black and white, Helicobacter pylori is gray [editorial] Blaser MJ. **Ann Intern Med** 1999 Apr 20; 130(8):695-7
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Furuta T, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1027-30
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ohkusa T, et al. **Ann Intern Med** 1998 Nov 1; 129(9):712-5
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Steinbach G, et al. **Ann Intern Med** 1999 Jul 20;131(2):88-95
Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Walker MM, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:96-111 (105 ref.)
Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model. Lozniewski A, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1909-13
Evidence for an oral-faecal transmission of Helicobacter pylori infection in an experimental murine model. Cellini L, et al. **APMIS** 1999 May;107(5):477-84
Effect of treatment of Helicobacter pylori infection on rosacea. Bamford JT, et al. **Arch Dermatol** 1999 Jun; 135(6):659-63
Helicobacter pylori eradication in patients with chronic urticaria [letter] Ozkaya-Bayazit E, et al. **Arch Dermatol** 1998 Sep;134(9):1165-6 (6 ref.)
Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Behrens R, et al. **Arch Dis Child** 1999 Jul;81(1):68-70
Effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease. Goggin N, et al. **Arch Dis Child** 1998 Dec;79(6):502-5
Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Fendrick AM, et al. **Arch Intern Med** 1999 Jan 25; 159(2):142-8
Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Fennerty MB, et al. **Arch Intern Med** 1999 Jul 26;159(14):1562-6
Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease. Hood HM, et al. **Arch Intern Med** 1999 Jan 25;159(2):149-54
Treating Helicobacter pylori [letter; comment] Howden CW, et al. **Arch Intern Med** 1998 Nov 23;158(21):2396-8. Comment on: Arch Intern Med 1998 Apr 27;158(8):842-51.
Non-gastrointestinal tract associations of Helicobacter pylori infection. Leontiadis GI, et al. **Arch Intern Med** 1999 May 10;159(9):925-40 (168 ref.)
Symptomatic Helicobacter pylori infection in a neurorehabilitation population. Shem KL, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1297-300
Perforated duodenal ulcer: an alternative therapeutic plan. Donovan AJ, et al. **Arch Surg** 1998 Nov;133(11):1166-71 (34 ref.)
Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease. Oberg S, et al. **Arch Surg** 1999 Jul;134(7):722-6
Effect of processed and non-processed coffee samples on gastric potential difference. Study with healthy male Helicobacter pylori-positive and Helicobacter pylori-negative volunteers. Ehrlich A, et al. **Arzneimittelforschung** 1999 Jul;49(7):626-30
Association of Helicobacter pylori infection with elevated serum lipids. Laurila A, et al. **Atherosclerosis** 1999 Jan; 142(1):207-10
Helicobacter pylori and peptic ulcer disease [letter; comment] Katelaris PH. **Aust N Z J Med** 1999 Apr;29(2):271. Comment on: Aust N Z J Med 1998 Oct;28(5):581-2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1999 Feb;29(1):103.
Helicobacter pylori and peptic ulcer disease: has the emperor got no clothes? [editorial; comment] [see comments] Katelaris PH. **Aust N Z J Med** 1998 Oct;28(5):581-2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1998 Oct;28(5):585-9. Comment in: Aust N Z J Med 1999 Feb;29(1):103. Comment in: Aust N Z J Med 1999 Apr;29(2):271.
Helicobacter pylori and peptic ulcer disease... [letter; comment] [see comments] Mathew J. **Aust N Z J Med** 1999 Feb;29(1):103. Comment on: Aust N Z J Med 1998 Oct;28(5):581-2. Comment on: Aust N Z J Med 1998 Oct;28(5):662. Comment in: Aust N Z J Med 1999 Apr;29(2):271.
Helicobacter pylori infection and duodenal ulceration [letter; comment] [see comments] Pinn G. **Aust N Z J Med** 1998 Oct;28(5):662. Comment on: Aust N Z J Med 1998 Jun;28(3):345. Comment in: Aust N Z J Med 1998 Oct;28(5):581-2. Comment in: Aust N Z J Med 1999 Feb;29(1):103. Comment in: Aust N Z J Med 1999 Apr;29(2):271.
Five micro-curie urea breath test for the diagnosis of Helicobacter pylori infection: evaluation in a South-East Asian population. Yu WK, et al. **Aust N Z J Surg** 1999 Jan;69(1):37-40
Peptic ulcer disease in the military aviator: a management approach. Lang KA, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1100-3 (15 ref.)
Helicobacter pylori and functional dyspepsia: a real causal link? Pantoflickova D, et al. **Baillieres Clin Gastroenterol** 1998 Sep;12(3):503-32 (141 ref.)
Gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide: down-regulation of nitric oxide synthase-2 and caspase-3 by sulglycotide. Slomiany BL, et al. **Biochem Biophys Res Commun** 1999 Jul 22; 261(1):15-20
Autoimmune diseases and Helicobacter pylori infection. Gasbarrini A, et al. **Biomed Pharmacother** 1999 Jun; 53(5-6):223-6 (21 ref.)
Familial clustering of Helicobacter pylori infection: population based study. Dominici P, et al. **BMJ** 1999 Aug 28;319(7209):537-40
Eradication of Helicobacter pylori in functional dyspepsia. Study had several weaknesses [letter] McColl KE, et al. **BMJ** 1999 Aug 14;319(7207):451; discussion 451-2
Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Talley NJ, et al. **BMJ** 1999 Mar 27;318(7187):833-7
Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. Fan XG, et al. **Br J Biomed Sci** 1998 Sep;55(3):176-8
Helicobacter pylori and gastric cancer: time for mega-trials? [editorial] Danesh J. **Br J Cancer** 1999 Jun;80(7):927-9
Are patients at increased risk? [letter; comment] Sloan J. **Can Fam Physician** 1998 Oct;44:2065-6. Comment on: Can Fam Physician 1998 Jul;44:1429-31, 1436-8.
Helicobacter pylori in South America. Castro L de P, et al. **Can J Gastroenterol** 1998 Oct;12(7):509-12 (32 ref.)
Immunomodulation of helicobacter infection. Croitoru K. **Can J Gastroenterol** 1999 Apr;13(3):237-41 (62 ref.)
Understanding disease outcome following acquisition of Helicobacter pylori infection during childhood. Day AS, et al. **Can J Gastroenterol** 1999 Apr;13(3):229-34 (75 ref.)
Determinants of ethnic or geographical differences in infectivity and transmissibility of Helicobacter pylori. Fallone CA. **Can J Gastroenterol** 1999 Apr;13(3):251-5 (57 ref.)
Role of Helicobacter pylori in the pathogenesis of gastric carcinoma and progression of lymphoid nodules to lymphoma. Guindi M. **Can J Gastroenterol** 1999 Apr; 13(3):224-7 (39 ref.)
Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Hunt RH, et al. **Can J Gastroenterol** 1999 Apr;13(3):213-7 (4 ref.)
Pathobiology of Helicobacter pylori infection. Sherman PM, et al. **Can J Gastroenterol** 1999 Apr;13(3):212
From bench to bedside and back--report on the European Helicobacter pylori Study Group Xth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Thomson AB, et al. **Can J Gastroenterol** 1998 Sep; 12(6):437-46
Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort. Yuan JM, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jul;8(7):621-4
Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Honda S, et al. **Cancer Res** 1998 Oct 1;58(19):4255-9
Hematopoietic cancer and peptic ulcer: a multicenter

case-control study. Vineis P, et al. **Carcinogenesis** 1999 Aug;20(8):1459-63

Helicobacter pylori infection in children. Vandenplas Y. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul-Aug;39(4):223-32 (129 ref.)

Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Torgano G, et al. **Circulation** 1999 Mar 30;99(12):1555-9

Treatment of Helicobacter pylori in nonulcer dyspepsia: should we or shouldn't we? Falk GW. **Cleve Clin J Med** 1999 Jul-Aug;66(7):398-9, 402-4 (12 ref.)

Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Mock T, et al. **Clin Biochem** 1999 Feb;32(1):59-63

Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community. Malaty HM, et al. **Clin Infect Dis** 1999 Feb;28(2):279-82

Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Shelton MJ, et al. **Clin Infect Dis** 1998 Oct;27(4):739-45

Helicobacter pylori infection is not a correlate of plasma fibrinogen in the Australian population. Peach HG, et al. **Clin Lab Haematol** 1999 Feb;21(1):41-3

Time-optimized carbon-14 breath test for Helicobacter pylori contamination of the stomach. Caglar M, et al. **Clin Nucl Med** 1999 Sep;24(9):674-7

Association between histological diagnosis of Helicobacter pylori and coronary heart disease: results of a retrospective study. Basili S, et al. **Clin Ter** 1998 Nov-Dec;149(6):413-7

Helicobacter pylori and critical illness: a passive bystander or cause of disease? [editorial; comment] Hawker FH. **Crit Care Med** 1999 Jul;27(7):1385-6. Comment on: Crit Care Med 1999 Jul;27(7):1276-80.

Helicobacter pylori infection in intensive care: increased prevalence and a new nosocomial infection [see comments] Robertson MS, et al. **Crit Care Med** 1999 Jul;27(7):1276-80. Comment in: Crit Care Med 1999 Jul;27(7):1385-6.

Pediatric Helicobacter pylori infection: clinical manifestations, diagnosis, and therapy. Gold BD. **Curr Top Microbiol Immunol** 1999;241:71-102 (236 ref.)

Helicobacter pylori and the future: an afterword. Mann NS, et al. **Curr Top Microbiol Immunol** 1999;241:301-8 (51 ref.)

Microbiology of Helicobacter pylori. Marais A, et al. **Curr Top Microbiol Immunol** 1999;241:103-22 (97 ref.)

The epidemiology of Helicobacter pylori. Mitchell HM. **Curr Top Microbiol Immunol** 1999;241:11-30 (122 ref.)

Gastric cancer and lymphoma. Mukhopadhyay P. **Curr Top Microbiol Immunol** 1999;241:57-69 (91 ref.)

Economic perspectives in the management of Helicobacter pylori infections. Sonnenberg A, et al. **Curr Top Microbiol Immunol** 1999;241:237-60 (52 ref.)

Antibiotic treatment of Helicobacter pylori infection. Unge P. **Curr Top Microbiol Immunol** 1999;241:261-300 (441 ref.)

The role of Helicobacter pylori infection in duodenal and gastric ulcer. Veldhuyzen van zanten SJ, et al. **Curr Top Microbiol Immunol** 1999;241:47-56 (46 ref.)

Diagnosis of Helicobacter pylori infection. Westblom TU, et al. **Curr Top Microbiol Immunol** 1999;241:215-35 (213 ref.)

Gastric mucosal interleukin-8 and IL-8 antibody concentrations related to prevailing Helicobacter pylori infections. A Danish-Albanian study. Nielsen OH, et al. **Dan Med Bull** 1999 Jun;46(3):249-52

Helicobacter pylori as a possible bacterial focus of chronic urticaria. Wustlich S, et al. **Dermatology** 1999;198(2):130-2

The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Gentile S, et al. **Diabetes Res Clin Pract** 1998 Oct;42(1):41-8

Helicobacter pylori-induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia. Açbay O, et al. **Dig Dis Sci** 1999 Sep;44(9):1837-42

Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments. Catalano F, et al. **Dig Dis Sci** 1999 May;44(5):863-7

High prevalence of Helicobacter pylori infection in shepherds. Dore MP, et al. **Dig Dis Sci** 1999 Jun;44(6):1161-4

Apoptosis in Helicobacter pylori-associated gastric and duodenal ulcer disease is mediated via the Fas antigen pathway. Houghton J, et al. **Dig Dis Sci** 1999 Mar;44(3):465-78

No evidence for an association between H. pylori and idiopathic chronic urticaria [letter; comment] Howden CW. **Dig Dis Sci** 1999 Mar;44(3):485-6. Comment on: Dig Dis Sci 1998 Jun;43(6):1226-9.

Increased gastric production of platelet-activating factor, leukotriene-B4, and tumor necrosis factor-alpha in children with Helicobacter pylori infection. Hüseyinov A, et al. **Dig Dis Sci** 1999 Apr;44(4):675-9

Halitosis and Helicobacter pylori: a possible relationship. Ierardi E, et al. **Dig Dis Sci** 1998 Dec;43(12):2733-7

Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823-36 (67 ref.)

Helicobacter pylori-associated protein-losing hypertrophic gastropathy with hypercholesterolemia. Kapsoritakis AN, et al. **Dig Dis Sci** 1999 Sep;44(9):1843-7

Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. Keto Y, et al. **Dig Dis Sci** 1999 Feb;44(2):257-65

Reactions from rat gastric mucosa during one year of Helicobacter pylori infection. Li H, et al. **Dig Dis Sci** 1999 Jan;44(1):116-24

Expression of bcl-2 in autoimmune and Helicobacter pylori-associated atrophic gastritis. Maor-Kendler Y, et al. **Dig Dis Sci** 1999 Apr;44(4):680-5

Proximal and distal gastric distension in normal subjects and H. pylori-positive and -negative dyspeptic patients and correlation with symptoms. Marzio L, et al. **Dig Dis Sci** 1998 Dec;43(12):2757-63

Helicobacter pylori infection and atrophic gastritis: a nested case-control study in a rural town in Japan. Ozasa K, et al. **Dig Dis Sci** 1999 Feb;44(2):253-6

Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Realdi G, et al. **Dig Dis Sci** 1999 Feb;44(2):229-36 (70 ref.)

Effects of cytokines, without and with Helicobacter pylori components, on mucus secretion by cultured gastric epithelial cells. Takahashi S, et al. **Dig Dis Sci** 1998 Oct;43(10):2301-8

Effects of inflammatory cytokines induced by Helicobacter pylori infection on aminopyrine accumulation in parietal cells isolated from guinea pigs. Tani N, et al. **Dig Dis Sci** 1999 Apr;44(4):686-90

Interactions between Helicobacter pylori and gastroesophageal reflux disease. Bowrey DJ, et al. **Dis Esophagus** 1998 Oct;11(4):203-9 (72 ref.)

Helicobacter pylori and gastric cancer. **Drug Ther Bull** 1998 Aug;36(8):57-9 (30 ref.)

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Langtry HD, et al. **Drugs** 1998 Sep;56(3):447-86 (126 ref.)

A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Peitz U, et al. **Drugs** 1999 Jun;57(6):905-20 (226 ref.)

Ulcer and gastritis. Anand BS, et al. **Endoscopy** 1999 Feb;31(2):215-25 (50 ref.)

Endoscopic ultrasonography images of gastric mucosa-associated lymphoid tissue type (MALT) lymphoma after Helicobacter pylori eradication. Fujiwara Y, et al. **Endoscopy** 1999 Feb;31(2):S3

Active infection with Helicobacter pylori in healthy couples. Brenner H, et al. **Epidemiol Infect** 1999 Feb;122(1):91-5

Alcohol consumption and Helicobacter pylori infection: results from the German National Health and Nutrition Survey [see comments] Brenner H, et al. **Epidemiology** 1999 May;10(3):214-8. Comment in: Epidemiology 1999 May;10(3):207-9.

Does imbibing alcohol protect against enteric pathogens? [editorial; comment] Klontz KC. **Epidemiology** 1999 May;10(3):207-9 (27 ref.). Comment on: Epidemiology 1999 May;10(3):214-8.

Inducible nitric oxide synthase, anti-oxidant enzymes and Helicobacter pylori infection in gastritis and gastric precancerous lesions in humans. Pignatelli B, et al. **Eur J Cancer Prev** 1998 Dec;7(6):439-47

Prevalence of Helicobacter pylori infection in two Spanish regions with different incidence of gastric cancer. Senra-Varela A, et al. **Eur J Epidemiol** 1998 Jul;14(5):491-4

Treatment of Helicobacter pylori: where are we now? What are the key questions? Axon A. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S3-7; discussion S23-4

Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. Bayerdörffer E, et al. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S19-22; discussion S23-4

My approach to Helicobacter pylori eradication. Bazzoli F. **Eur J Gastroenterol Hepatol** 1999 Jun;11 Suppl 1:S37-41

Antimicrobial treatment for peptic stenosis: a prospective study. Brandimarte G, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):731-4

Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Cammarota G, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):247-50

Helicobacter pylori: a true carcinogen? [editorial] [see comments] Cats A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):447-50. Comment in: Eur J Gastroenterol Hepatol 1999 Mar;11(3):357-9.

Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. de Boer WA. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):697-700 (40 ref.)

Helicobacter pylori and reflux disease. Dent J. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S51-7; discussion S73 (36 ref.)

Topographic distribution of Helicobacter pylori in the resected stomach. Enomoto H, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):473-8

Should we go further and screen and treat? Forman D. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S69-71; discussion S73

Acid-related disorders in the new millennium: European, Japanese and North American perspectives. Freston JW, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10 Suppl 2:S1-40 (120 ref.)

Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Gasbarrini A, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):713-6

Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Gasbarrini A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):469-72

Atrophy, acid suppression and Helicobacter pylori infection: a tale of two studies. Genta RM. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S29-33; discussion S43-5

Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Gisbert JP, et al. **Eur J Gastroenterol Hepatol** 1999 Feb;11(2):189-200

Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Gschwantler M, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):579-82

Detection and typing of the virulence determinants cagA and vacA of Helicobacter pylori directly from biopsy DNA: are in vitro strains representative of in vivo strains? Gunn MC, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):683-7

The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Hackelsberger A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):465-8

Is Helicobacter pylori eradication useful in patients taking NSAIDs? Hawkey CJ. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S47-50; discussion S73

The effect of eradicating Helicobacter pylori infection on the course of adenomatous and hyperplastic gastric polyps. Ljubicić N, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):727-30

The Maastricht recommendations and their impact on general practice. Malfertheiner P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S63-7; discussion S73

Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Meining AG, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):717-20

Do young dyspeptics require endoscopy any more? Moayyedi P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S59-62; discussion S73

Prevalence of Helicobacter pylori infection in medical professionals in Spain. Monés J, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):239-42

Plasma free radical activity and antioxidant vitamin levels in dyspeptic patients: correlation with smoking and Helicobacter pylori infection. Phull PS, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):573-8

Upper gastrointestinal diseases in the elderly: report of a meeting held at Vicenza, Italy, on 20 March 1998. Pilotto A, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):801-8

Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Roghani HS, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):709-12

Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Spiller RC. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S25-8; discussion S43-5

Lack of correlation between self-reported symptoms of dyspepsia and infection with Helicobacter pylori, in a general population sample. Stone MA, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):301-4

Results of Helicobacter pylori screening and eradication in a multi-ethnic community in central England. Stone MA, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):957-62

Helicobacter pylori, pre-neoplastic changes, gastric cancer: a point of view [letter; comment] Testino G, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):357-9. Comment on: Eur J Gastroenterol Hepatol 1998 Jun;10(6):447-50.

Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans [see comments] Tham TC, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):289-91. Comment in: Eur J Gastroenterol Hepatol 1998 Apr;10(4):281-3.

The OAC and OMC options. Unge P. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S9-17; discussion S23-4

Is there a link between chronic Helicobacter pylori infection and coronary heart disease? Danesh J. **Eur J Surg Suppl** 1998;(582):27-31 (31 ref.)

Non-gastric effects of H. pylori infection: a literature review with respect to non gastric diseases which might be associated with H. pylori infection. Ekström P. **Eur J Surg Suppl** 1998;(582):32-4 (31 ref.)

The case for treatment of dyspeptic patients infected with H. pylori. Hunt RH, et al. **Eur J Surg Suppl** 1998;(582):6-10

H. pylori infection in non-ulcer patients--to treat or not to treat. The case against treatment. McCarthy DM. **Eur J Surg Suppl** 1998;(582):11-5

Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies. Unge P. **Eur J Surg Suppl** 1998;(582):16-26

Helicobacter pylori associated gastric pathology in patients with type II diabetes mellitus and its relationship with gastric emptying: the Ankara study. Güvener N, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):172-6

Molecular mechanism of human stomach carcinogenesis implicated in Helicobacter pylori infection. Tahara E. **Exp Toxicol Pathol** 1998 Sep;50(4-6):375-8 (21 ref.)

TPA and butyrate increase cell sensitivity to the vacuolating

toxin of Helicobacter pylori. de Bernard M, et al. **FEBS Lett** 1998 Oct 2;436(2):218–22

Expression of functional Na+/H+ antiporters of Helicobacter pylori in antiporter-deficient Escherichia coli mutants. Inoue H, et al. **FEBS Lett** 1999 Jan 22;443(1):11–6

Is there a link between the variation in gastric cancer mortality and differences in Helicobacter pylori prevalence in different regions of France? Broutet N, et al. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6-7):754–60

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Aalykke C, et al. **Gastroenterology** 1999 Jun; 116(6):1305–9

Sensitivity of urease-based test on diagnosis of Helicobacter pylori in children and the elderly [letter; comment] Drumm B, et al. **Gastroenterology** 1999 Jun;116(6):1506. Comment on: Gastroenterology 1998 Jul;115(1):243–4.

Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Fu S, et al. **Gastroenterology** 1999 Jun; 116(6):1319–29

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status [see comments] Gillen D, et al. **Gastroenterology** 1999 Feb;116(2):239–47. Comment in: Gastroenterology 1999 Feb;116(2):479–83.

Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Hamlet A, et al. **Gastroenterology** 1999 Feb;116(2):259–68

Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Holtmann G, et al. **Gastroenterology** 1999 Jul;117(1):11–6

Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibodies [letter] Isaacson PG, et al. **Gastroenterology** 1999 Sep;117(3):750–1

Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion [editorial; comment] Kuipers EJ, et al. **Gastroenterology** 1999 Feb; 116(2):479–83 (35 ref.). Comment on: Gastroenterology 1999 Feb;116(2):239–47. Comment on: Gastroenterology 1999 Feb;116(2):248–53.

Mucosal vaccination: "all politics are local". Lencer WI. **Gastroenterology** 1999 Feb;116(2):497–9

Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Lundell L, et al. **Gastroenterology** 1999 Aug;117(2):319–26

Helicobacter pylori-dependent ceramide production may mediate increased interleukin 8 expression in human gastric cancer cell lines. Masamune A, et al. **Gastroenterology** 1999 Jun;116(6):1330–41

Low rates of Helicobacter pylori reinfection in children. Rowland M, et al. **Gastroenterology** 1999 Aug; 117(2):336–41

PPI-based triple therapy in the eradication of H. pylori infection [letter] Savarino V, et al. **Gastroenterology** 1999 Sep;117(3):746–7

H. pylori and nonulcer dyspepsia: not guilty as charged. Schubert ML. **Gastroenterology** 1999 Jul;117(1):270–2

Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Taha AS, et al. **Gastroenterology** 1999 Feb;116(2):254–8

Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study. The Eurogst Study Group. Webb PM, et al. **Gastroenterology** 1999 Feb;116(2):269–76

Helicobacter pylori status and endoscopy follow-up of patients having a history of perforated duodenal ulcer. Chu KM, et al. **Gastrointest Endosc** 1999 Jul;50(1):58–62

Helicobacter pylori: drowning in a pool of blood? [editorial; comment] Laine L, et al. **Gastrointest Endosc** 1999 Mar; 49(3 Pt 1):398–402. Comment on: Gastrointest Endosc 1999 Mar;49(3 Pt 1):302–6.

Endoscopy personnel and Helicobacter pylori infection [letter] Luzza F, et al. **Gastrointest Endosc** 1999 Aug; 50(2):304–5

Unsedated transnasal EGD: an alternative approach to conventional esophagogastroduodenoscopy for documenting Helicobacter pylori eradication [see comments] Saeian K, et al. **Gastrointest Endosc** 1999 Mar; 49(3 Pt 1):297–301. Comment in: Gastrointest Endosc 1999 Mar;49(3 Pt 1):395–8.

Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers [see comments] Tu TC, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):302–6. Comment in: Gastrointest Endosc 1999 Mar;49(3 Pt 1):398–402.

Helicobacter pylori and benign gastric outlet obstruction [letter] Yarze JC. **Gastrointest Endosc** 1999 Oct;50(4):598

European Helicobacter pylori Study Group XII International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Helsinki, Finland, 2-4 September 1999. Abstracts. **Gut** 1999 Sep;45 Suppl 3:A1–145

European Helicobacter pylori Study Group. XIth International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Budapest, Hungary, 2-5 September 1998. Abstracts. **Gut** 1998 Sep;43 Suppl 2:A1–128

Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication [letter; comment] Bateson MC. **Gut** 1998 Oct;43(4):586. Comment on: Gut 1998 Feb;42(2):166–9.

Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Blaser MJ. **Gut** 1998 Nov; 43(5):721–7 (101 ref.)

Clinical trials in Helicobacter pylori infection [letter; comment] Calvet X, et al. **Gut** 1998 Nov;43(5):731–2. Comment on: Gut 1997 Sep;41 Suppl 2:S1–9.

Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study [see comments] Duggan AE, et al. **Gut** 1998 Oct;43(4):494–8. Comment in: Gut 1998 Oct;43(4):451.

Systemic and local immune responses against Helicobacter pylori urease in patients with chronic gastritis: distinct IgA and IgG productive sites. Futagami S, et al. **Gut** 1998 Aug; 43(2):168–75

Extradigestive manifestations of Helicobacter pylori gastric infection. Gasbarrini A, et al. **Gut** 1999 Jul;45 Suppl 1:I9–I12 (50 ref.)

Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole [see comments] Gillen D, et al. **Gut** 1999 Apr;44(4):468–75. Comment in: Gut 1999 Apr;44(4):448–9.

Guidance for trials in Helicobacter pylori infection [letter; comment] Gomollón F. **Gut** 1998 Nov;43(5):731. Comment on: Gut 1997 Sep;41 Suppl 2:S1–9.

Age and Helicobacter pylori decrease gastric mucosal surface hydrophobicity independently. Hackelsberger A, et al. **Gut** 1998 Oct;43(4):465–9

A prospective randomised trial of a "test and treat" policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic [see comments] Heaney A, et al. **Gut** 1999 Aug;45(2):186–90. Comment in: Gut 1999 Aug;45(2):164–5.

Treatment after failure: the problem of "non-responders". Huang JQ, et al. **Gut** 1999 Jul;45 Suppl 1:I40–4 (47 ref.)

Helicobacter pylori and dyspepsia: trick or treat? [comment] Jones R. **Gut** 1999 Aug;45(2):164–5. Comment on: Gut 1999 Aug;45(2):186–90.

Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation. McNamara D, et al. **Gut** 1999 Jul;45 Suppl 1:I13–7 (95 ref.)

Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Nardone G, et al. **Gut** 1999 Jun;44(6):789–99

The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients [letter; comment] Pathak C, et al. **Gut** 1999 Apr;44(4):582–3. Comment on: Gut 1997 Mar;40(3):302–6.

What makes the dyspeptic patient feel ill? A cross sectional survey of functional health status, Helicobacter pylori infection, and psychological distress in dyspeptic patients in general practice. Quartero AO, et al. **Gut** 1999 Jul; 45(1):15–9

How should Helicobacter pylori infected children be managed? Rowland M, et al. **Gut** 1999 Jul;45 Suppl 1:I36–9 (47 ref.)

The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Savarino V, et al. **Gut** 1999 Jul;45 Suppl 1:I18–22 (53 ref.)

Co-screening for primary biliary cirrhosis and coeliac disease. Helicobacter pylori: the African enigma [letter] Segal I, et al. **Gut** 1998 Aug;43(2):300–1

Regulation of tumour necrosis factor (TNF) induced apoptosis by soluble TNF receptors in Helicobacter pylori infection [see comments] Shibata J, et al. **Gut** 1999 Jul; 45(1):24–31. Comment in: Gut 1999 Jul;45(1):5–7.

A key cytokine unlocks the door [comment] Shirin H, et al. **Gut** 1999 Jul;45(1):5–6. Comment on: Gut 1999 Jul;45(1):24–31.

How should Helicobacter pylori positive dyspeptic patients be managed? Talley NJ. **Gut** 1999 Jul;45 Suppl 1:I28–31 (39 ref.)

13C urea breath test. Thomas JE. **Gut** 1998 Nov;43 Suppl 3:S7–12

Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Thumshirn M, et al. **Gut** 1999 Jan;44(1):55–64

Helicobacter pylori-reflections for the next millennium. Tytgat GN. **Gut** 1999 Jul;45 Suppl 1:I45–7 (15 ref.)

New immunological assays for the diagnosis of Helicobacter pylori infection. Vaira D, et al. **Gut** 1999 Jul;45 Suppl 1:I23–7 (51 ref.)

Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Danesh J, et al. **Heart** 1999 Mar; 81(3):245–7

Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics. Adamek RJ, et al. **Helicobacter** 1998 Sep;3(3):206–11

Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. Bazzoli F, et al. **Helicobacter** 1998 Sep; 3(3):195–201

Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome. Braden B, et al. **Helicobacter** 1998 Sep;3(3):184–7

Autoimmune reactions in type A and H. pylori gastritis [letter; comment] Dixon MF. **Helicobacter** 1998 Sep; 3(3):222. Comment on: Helicobacter 1998 Mar;3(1):39–44.

Pediatric Issues Workshop summary. Gold BD, et al. **Helicobacter** 1998 Dec;3(4):305–9

Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Kamada T, et al. **Helicobacter** 1999 Sep;4(3):204–10

Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. Korman MG, et al. **Helicobacter** 1998 Sep;3(3):202–5

Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Lanza FL, et al. **Helicobacter** 1998 Sep;3(3):212–21

Gastric ulcer formation after the Hanshin-Awaji earthquake: a case study of Helicobacter pylori infection and stress-induced gastric ulcers. Matsushima Y, et al. **Helicobacter** 1999 Jun;4(2):94–9

Host determinants of Helicobacter pylori infection and its clinical outcome. Nguyen TN, et al. **Helicobacter** 1999 Sep; 4(3):185–97 (115 ref.)

A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Satoh K, et al. **Helicobacter** 1998 Dec;3(4):236–40

Absence of Helicobacter pylori in dental plaque determined by immunoperoxidase. Savoldi E, et al. **Helicobacter** 1998 Dec;3(4):283–7

Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Varanasi RV, et al. **Helicobacter** 1998 Sep;3(3):188–94

Relationship between enterogastric reflux estimated by scintigraphy and the presence of Helicobacter pylori. Artiko VM, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1234–7

Eradication of Helicobacter pylori in routine clinical practice: doubts and uncertainties. Cammarota G, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):312–5

Recurrence of H. pylori infection and dyspeptic symptoms after successful eradication in patients cured of duodenal ulcer disease. Chen TS, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):252–6

Helicobacter pylori and gastroesophageal reflux disease: friends or foes? Gisbert JP, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1023–9 (70 ref.)

Relationship between Helicobacter pylori infection, histological gastritis, and functional dyspepsia. Glasbrenner B, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2238–43

The importance of increasing the number of gastric biopsies in the diagnosis of Helicobacter pylori. Gur G, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2219–23

The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Kyzekova J, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2048–56

A three-day octreotide-containing helicobacter pylori eradication therapy for cure of peptic ulcers. Ladas SD, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):761–4

The effect of H. pylori in perforation of duodenal ulcer. Mihmanli M, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1610–2

Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. Parente F, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):990–3

Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients. Pilotto A, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):245–51

Helicobacter pylori of the remnant stomach and its eradication. Rino Y, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2069–73

Quantitative result of 13C urea breath test at 15 minutes may correlate with the bacterial density of H. pylori in the stomach. Sheu BS, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2057–62

A four-year follow-up of duodenal ulcer patients after Helicobacter pylori eradication. Tepes B, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1746–50

Effect of non-steroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection. Tseng GY, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1000–4

Effect of adequate alcohol intake, with or without cigarette smoking, on the risk of Helicobacter pylori infection. Tursi A, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1892–5

Helicobacter pylori infection and age on the development of intestinal metaplasia--a multiple logistic regression analysis. Wang CC, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2234–7

Gastric inhibitory polypeptide appears less important in mediating acid secretion. Wang YY, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2105–9

Helicobacter pylori infection in dyspeptic cirrhotic patients. Zullo A, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):395–400

Interobserver agreement in the assessment of gastritis reversibility after Helicobacter pylori eradication. Tepes B, et al. **Histopathology** 1999 Feb;34(2):124–33

Rethinking our approach to dyspepsia [editorial] Johnson MF. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):13–4, 17, 21

Le lymphome imaginaire [letter; comment] Torlakovic E.

Hum Pathol 1999 May;30(5):594–5. Comment on: Hum Pathol 1997 Feb;28(2):166–73. Comment on: Hum Pathol 1998 Aug;29(8):769–70. Comment on: Hum Pathol 1998 Aug;29(8):784–90.

Seroepidemiology of Helicobacter pylori infection in an urban, upper class population in Chennai. Alaganantham TP, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):66–8

Relation of gastric juice vitamin C levels with H. pylori infection [letter] Bhatnagar M, et al.
Indian J Gastroenterol 1999 Jul–Sep;18(3):129–30

Role of Helicobacter pylori in peptic ulcer in patients with hepatic cirrhosis [letter] Ghoshal UC, et al.
Indian J Gastroenterol 1999 Apr–Jun;18(2):90

Helicobacter pylori eradication: not enough grounds for recommendation [letter; comment] Prasad AV.
Indian J Gastroenterol 1998 Oct–Dec;17(4):158–9. Comment on: Indian J Gastroenterol 1997 Nov;16 Suppl 1:S29–33. Comment on: Indian J Gastroenterol 1998 Jul–Sep;17(3):115–6.

Duodenal ulcer and Helicobacter pylori: Presidential Oration, Indian Society of Gastroenterology, 1998. Sharma MP. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):51–3

Local cytokine response in Helicobacter pylori–infected subjects. Lindholm C, et al. **Infect Immun** 1998 Dec; 66(12):5964–71

Human embryonic gastric xenografts in nude mice: a new model of Helicobacter pylori infection. Lozniewski A, et al. **Infect Immun** 1999 Apr;67(4):1798–805

Helicobacter pylori alters exogenous antigen absorption and processing in a digestive tract epithelial cell line model. Matysiak-Budnik T, et al. **Infect Immun** 1998 Dec; 66(12):5785–91

A conventional beagle dog model for acute and chronic infection with Helicobacter pylori. Rossi G, et al.
Infect Immun 1999 Jun;67(6):3112–20

The role of azithromycin in the treatment of Helicobacter pylori infection – a retrospective report. Dohmen W, et al. **Infection** 1998 Jul–Aug;26(4):256–62

Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Schnyder B, et al.
Int Arch Allergy Immunol 1999 May;119(1):60–3

Effect of ranitidine and metronidazole on IgG activity of patients with Helicobacter pylori infection [letter] Konorev MR. **Int J Antimicrob Agents** 1998 Aug;10(3):249–50

Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Peek RM Jr, et al.
Int J Cancer 1999 Aug 12;82(4):520–4

Infection with CagA+ Helicobacter pylori strains as a possible predictor of risk in the development of gastric adenocarcinoma in Mexico. Torres J, et al.
Int J Cancer 1998 Oct 29;78(3):298–300

A role for Helicobacter pylori in the gastrointestinal complaints of eating disorder patients? Hill KK, et al.
Int J Eat Disord 1999 Jan;25(1):109–12

Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer. Ma JL, et al. **Int J Epidemiol** 1998 Aug;27(4):570–3

Helicobacter pylori infection and atrophic gastritis in middle-aged Japanese residents of São Paulo and Lima. Tsugane S, et al. **Int J Epidemiol** 1999 Jun;28(3):577–82

Helicobacter pylori infection, garlic intake and precancerous lesions in a Chinese population at low risk of gastric cancer. You WC, et al. **Int J Epidemiol** 1998 Dec;27(6):941–4

Vitamin C, Helicobacter pylori infection and gastric carcinogenesis. Reed PI. **Int J Vitam Nutr Res** 1999 May; 69(3):220–7 (71 ref.)

Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series [see comments] Battaglia G, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):370–4 . Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):375–7.

Helicobacter pylori eradication failure--'salvage' therapies needed [comment] Borody TJ.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):375–7. Comment on: Ital J Gastroenterol Hepatol 1998 Aug;30(4):370–4.

Correlation between endoscopic features of gastric antrum, histology and Helicobacter pylori infection in adults. Calabrese C, et al. **Ital J Gastroenterol Hepatol** 1999 Jun–Jul;31(5):359–65

The effect of Helicobacter pylori eradication on maximal acid secretion in duodenal ulcer patients; findings and mechanisms [comment] Calam J.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):368–9. Comment on: Ital J Gastroenterol Hepatol 1998 Aug;30(4):363–7.

Helicobacter pylori infection and ischaemic heart disease. Cammarota G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S304–6 (12 ref.)

Prevalence of duodenal bulb gastric metaplasia and Helicobacter pylori in patients with duodenal ulcer and normal duodenum [letter] Doğan UB, et al.
Ital J Gastroenterol Hepatol 1999 Jun–Jul;31(5):429

New acquisitions in Helicobacter pylori characteristics. Figura N, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S254–8 (61 ref.)

Helicobacter pylori and lymphoproliferative disorders. Fischbach W. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S299–303 (39 ref.)

Helicobacter pylori infection and vascular diseases. Gasbarrini A, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S307–9 (25 ref.)

New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report. Gasbarrini G, et al.
Ital J Gastroenterol Hepatol 1998 Oct;30 Suppl 3:S244–7 (20 ref.)

Economic evaluations in medicine: still more questions than answers? Grossi E. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):347–50

Helicobacter pylori increases the risk of peptic ulcer bleeding: a case–control study. Labenz J, et al.
Ital J Gastroenterol Hepatol 1999 Mar;31(2):110–5

Basal and pentagastrin stimulated acid secretion in duodenal ulcer subjects before and after Helicobacter pylori eradication: a 12-month follow-up study [see comments] Louw JA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):363–7. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):368–9.

Helicobacter pylori and gastric cancer. McNamara D, et al.
Ital J Gastroenterol Hepatol 1998 Oct;30 Suppl 3:S294–8 (49 ref.)

Therapeutic news on Helicobacter pylori from Budapest and Wien. Ricci C, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):648–62

Helicobacter pylori and non-steroidal anti-inflammatory drugs: ulcers and bleeding ulcers. Russell RI.
Ital J Gastroenterol Hepatol 1999 Mar;31(2):116–8 (16 ref.)

Helicobacter pylori infection and autoimmune processes: an emerging field of study. Sorrentino D, et al.
Ital J Gastroenterol Hepatol 1998 Oct;30 Suppl 3:S310–2 (15 ref.)

How can we improve on the efficacy of Helicobacter pylori treatment? [editorial] Spiller RC.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):351–4

Pre-treatment with misoprostol increases the efficacy of omeprazole plus amoxycillin to cure Helicobacter pylori infection. A pilot study [letter] Tursi A, et al.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):449–50

Routes of transmission of Helicobacter pylori infection. Vaira D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S279–85 (74 ref.)

Review article: non-invasive methods for the diagnosis of Helicobacter pylori infection. Zagari RM, et al.
Ital J Gastroenterol Hepatol 1999 Jun–Jul;31(5):408–15 (77 ref.)

Refractory exacerbations of hereditary angioedema with associated Helicobacter pylori infection. Rais M, et al.
J Allergy Clin Immunol 1999 Apr;103(4):713–4

The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori–positive older patients with dyspepsia. Moshkowitz M, et al. **J Am Geriatr Soc** 1999 Jun;47(6):720–2

Mucosal macrophage inflammatory protein-1alpha levels are increased in Helicobacter pylori infection. Ando T, et al.
J Clin Gastroenterol 1998;27 Suppl 1:S144–9

Does acid suppression by antacids and H2 receptor antagonists increase the incidence of atrophic gastritis in patients with or without H. pylori gastritis? Carter M, et al. **J Clin Gastroenterol** 1999 Sep;29(2):183–7

Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. Dattilo M, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S163–9 (55 ref.)

Eradication of Helicobacter pylori, improvement of gastritis, and the normalization of the hyperproliferative state of gastric mucosa did not prevent a case of gastric cancer [letter] Maconi G, et al. **J Clin Gastroenterol** 1999 Mar; 28(2):178–9

Eradication of Helicobacter pylori infection with proton pump–based triple therapy in patients in whom bismuth–based triple therapy failed. Mera R, et al.
J Clin Gastroenterol 1999 Jul;29(1):51–5

[13C]–urea breath test for assessment of cure of Helicobacter pylori infection at 1 month after treatment. Miwa H, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S150–3

Duodenal stenosis and Helicobacter pylori [letter; comment] Rinaldi V, et al. **J Clin Gastroenterol** 1999 Jan;28(1):83–4 . Comment on: J Clin Gastroenterol 1995 Dec;21(4):329–30.

Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. Sakaki N, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S187–91

Pathologic changes in the glandular stomach and duodenum in an H. pylori–infected Mongolian gerbil model. Sawada Y, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S141–3

Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. Suzuki J, et al.
J Clin Gastroenterol 1998;27 Suppl 1:S159–62

Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone. Suzuki M, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S183–6

Helicobacter pylori infection in the remnant stomach after gastrectomy: with special reference to the difference between Billroth I and II anastomoses. Tomtitchong P, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S154–8

Evaluation of commercially available Helicobacter pylori serology kits: a review. Laheij RJ, et al.
J Clin Microbiol 1998 Oct;36(10):2803–9 (91 ref.)

DNA fingerprinting of single colonies of Helicobacter pylori from gastric cancer patients suggests infection with a single predominant strain. Miehlke S, et al. **J Clin Microbiol** 1999 Jan;37(1):245–7

Usefulness of Leifson staining method in diagnosis of Helicobacter pylori infection. Piccolomini R, et al.
J Clin Microbiol 1999 Jan;37(1):199–201

Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. Yamaoka Y, et al. **J Clin Microbiol** 1999 Jul; 37(7):2274–9

Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma [published erratum appears in J Clin Oncol 1999 Mar;17(3):1092] Thiede C, et al. **J Clin Oncol** 1998 Dec; 16(12):3822–31

Helicobacter pylori and Epstein–Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach. Baas IO, et al. **J Clin Pathol** 1998 Sep;51(9):662–6

Sudden infant death syndrome, long QT interval, and Helicobacter pylori [letter; comment] Kerr JR.
J Clin Pathol 1998 Dec;51(12):943–4. Comment on: J Clin Pathol 1998 Jun;51(6):419.

Strong correlation between Heiicobacter pylori seropositivity and Chlamydia pneumoniae IgG concentrations. Danesh J, et al. **J Epidemiol Community Health** 1998 Dec; 52(12):821–2

Treatment of Helicobacter pylori infection in functional dyspepsia. Grimm KJ. **J Fam Pract** 1999 Jul;48(7):496–7

Treating Helicobacter pylori infection in nonulcer dyspepsia. Lord RW Jr. **J Fam Pract** 1999 Mar;48(3):172–3

One-week low-dose triple therapy is effective in treating Helicobacter pylori–infected patients with bleeding peptic ulcers. Lee CL, et al. **J Formos Med Assoc** 1998 Nov; 97(11):733–7

Proceedings of the 2nd annual meeting of the Japanese Research Society for Helicobacter pylori Related Gastroduodenal Diseases. Kobe, Japan, April 16–17, 1996.
J Gastroenterol 1998;33 Suppl 10:1–68

Eradication therapies for Helicobacter pylori. Borody TJ, et al. **J Gastroenterol** 1998;33 Suppl 10:53–6 (10 ref.)

Ten minute 13C–urea breath test for the diagnosis of Helicobacter pylori infection. Kato M, et al.
J Gastroenterol 1998;33 Suppl 10:40–3

Clinical studies of 13C–urea breath test in Japan. Kato M, et al. **J Gastroenterol** 1998;33 Suppl 10:36–9 (22 ref.)

Aggressive non-Hodgkin's lymphoma after successful eradication of Helicobacter pylori and regression of gastric lymphoma of mucosa-associated lymphoid tissue. Ohashi S, et al. **J Gastroenterol** 1998 Oct;33(5):724–7

Pathological changes in glandular stomach of Helicobacter pylori–infected Mongolian gerbil model. Sawada Y, et al.
J Gastroenterol 1998;33 Suppl 10:22–5

Chemokine expression in Helicobacter pylori–infected gastric mucosa. Shimada T, et al. **J Gastroenterol** 1998 Oct; 33(5):613–7 (48 ref.)

Are there more clinically important complications of Helicobacter pylori infection than peptic ulcer disease? A review of current literature. Unge P. **J Gastroenterol** 1998; 33 Suppl 10:48–52 (47 ref.)

Eradication therapy of Helicobacter pylori. A review. Report from a workshop organized by the Swedish and Norwegian Medical Products Agencies, September 1995. Unge P.
J Gastroenterol 1998;33 Suppl 10:57–61

Treatment of Helicobacter pylori infection to reduce gastric cancer incidence: uncertain benefits of a community based programme in Australia. Forbes GM, et al.
J Gastroenterol Hepatol 1998 Nov;13(11):1091–5

Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. Fraser AG, et al. **J Gastroenterol Hepatol** 1998 Jun; 13(6):560–5

Follow up after successful eradication of Helicobacter pylori: symptoms and reinfection. Fraser AG, et al.
J Gastroenterol Hepatol 1998 Jun;13(6):555–9

Helicobacter pylori: from art to a science. Hunt RH, et al.
J Gastroenterol Hepatol 1998 Jan;13(1):21–8 (69 ref.)

Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. Kang JY, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):771–8

p53 expression in gastric mucosa with Helicobacter pylori infection. Kodama M, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):215–9

Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. Lam SK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):1–12 (74 ref.)

Helicobacter pylori–induced lymphonodular hyperplasia: a new cause of gastric outlet obstruction. Misra SP, et al.
J Gastroenterol Hepatol 1998 Dec;13(12):1191–4

Efficacy of 1 week omeprazole or lansoprazole–amoxycillin–clarithromycin therapy for Helicobacter pylori infection in the Japanese population. Miwa H, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):317–21

Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy. Saita H, et al. **J Gastroenterol Hepatol** 1998 Jul; 13(7):725–31

[14C]–urea breath test to confirm eradication of Helicobacter pylori. Sharma BC, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):309–12

Analysis of the 13C–urea breath test for detection of Helicobacter pylori infection based on the kinetics of

delta-13CO2 using laser spectroscopy. Tanahashi T, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):732-7
Effect of Helicobacter pylori infection on gastric mucosal phospholipid contents and their fatty acid composition. Wakabayashi H, et al. **J Gastroenterol Hepatol** 1998 Jun; 13(6):566-71
Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. Vásconez C, et al. **J Hepatol** 1999 Feb;30(2):260-4
Helicobacter pylori and endoscopy. Williams CL. **J Hosp Infect** 1999 Apr;41(4):263-8 (56 ref.)
Seasonal behaviour of healed duodenal ulcer. Gupta AK, et al. **J Indian Med Assoc** 1998 Apr;96(4):106-8
Qualitative and quantitative analysis of the local and systemic antibody response in mice and humans with Helicobacter immunity and infection. Blanchard TG, et al. **J Infect Dis** 1999 Mar;179(3):725-8
Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. Blaser MJ. **J Infect Dis** 1999 Jun;179(6):1523-30
A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. Torres J, et al. **J Infect Dis** 1998 Oct;178(4):1089-94
Bacterial infections and atherosclerosis. Muhlestein JB. **J Investig Med** 1998 Oct;46(8):396-402 (31 ref.)
Severe gastritis in guinea-pigs infected with Helicobacter pylori. Sturegård E, et al. **J Med Microbiol** 1998 Dec; 47(12):1123-9
Local cellular immune response in the acute phase of gastritis in mice induced chemically and by Helicobacter pylori. van Doorn NE, et al. **J Med Microbiol** 1998 Oct; 47(10):863-70
General population screening for infection with Helicobacter pylori: a realistic option? Stone MA, et al. **J Med Screen** 1998;5(3):162-6
3D imaging of the 58 kDa cell binding subunit of the Helicobacter pylori cytotoxin. Reyrat JM, et al. **J Mol Biol** 1999 Jul 9;290(2):459-70
Procedure guideline for carbon-14-urea breath test. Society of Nuclear Medicine. Balon H, et al. **J Nucl Med** 1998 Nov;39(11):2012-4
Contact granulomas [letter] Hynes B. **J Otolaryngol** 1998 Oct; 27(5):310
Unexplained refractory iron-deficiency anemia associated with Helicobacter pylori gastric infection in children: further clinical evidence. Barabino A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):116-9
Detection of Helicobacter pylori infection in children with a standardized and simplified 13C-urea breath test. Cadranel S, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep; 27(3):275-80
One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. Casswall TH, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):415-8
Evaluation of enzyme-linked immunosorbent assay for the diagnosis of Helicobacter pylori infection in children from different age groups with and without duodenal ulcer [see comments] de Oliveira AM, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):157-61. Comment in: J Pediatr Gastroenterol Nutr 1999 Feb;28(2):132-4.
Helicobacter pylori in childhood: new insights into the immunopathogenesis of gastric disease and implications for managing infection in children. Ernst PB, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):462-73 (117 ref.)
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori. Huang FC, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):76-80
Managing intrafamilial dissemination of Helicobacter pylori gastric infection improves eradication rate in children [letter] Kalach N, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):356
Helicobacter pylori reinfection rates in children after eradication therapy. Kato S, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):543-6
Helicobacter pylori infection in children with celiac disease: prevalence and clinicopathologic features. Luzza F, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):143-6
Helicobacter pylori infection may undergo spontaneous eradication in children: a 2-year follow-up study. Perri F, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):181-3
Helicobacter pylori and nonulcer dyspepsia in childhood: clinical pattern, diagnostic techniques, and bacterial strains. Rutigliano V, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):296-300
Helicobacter pylori and type 1 diabetes mellitus in children. Salardi S, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):307-9
The rate of Helicobacter pylori infection in children with growth retardation [letter] Sauvé-Martin H, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):354-5
Helicobacter pylori infection in children--an update [news] Wershil BK. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):241
The relationship between Helicobacter pylori infection and acid-hematuria syndrome in pediatric patients with gastric augmentation-II. Celayir S, et al. **J Pediatr Surg** 1999 Apr; 34(4):532-5
Delayed healing of chronic gastric ulcer after Helicobacter pylori infection in mice. Makino M, et al. **J Pharm Pharmacol** 1998 Aug;50(8):943-8
Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. Shah S, et al. **J Pharm Pharmacol** 1999 Jun; 51(6):667-72
Gastric secretion and ulcer healing in mouse stomach infected with cytotoxin expressing strain of Helicobacter pylori. Brzozowski T, et al. **J Physiol Pharmacol** 1998 Sep; 49(3):387-403
A study of Helicobacterium pylori and prevention and treatment of chronic atrophic gastritis. Zhang L, et al. **J Tradit Chin Med** 1997 Mar;17(1):3-9
Helicobacter pylori colonization in infants and young children is not necessarily associated with diarrhoea. Rahman MM, et al. **J Trop Pediatr** 1998 Oct;44(5):283-7
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail. Shuter J, et al. **J Urban Health** 1998 Dec;75(4):896-902
Stress and peptic ulcer disease [see comments] Levenstein S, et al. **JAMA** 1999 Jan 6;281(1):10-1. Comment in: JAMA 1999 Jul 21;282(3):237.
Stressful events and peptic ulcer disease [letter; comment] Sovarino R. **JAMA** 1999 Jul 21;282(3):237. Comment on: JAMA 1999 Jan 6;281(1):10-1.
Helicobacter pylori: a review. Ahmed R. **JPMA J Pak Med Assoc** 1998 Aug;48(8):257-8 (29 ref.)
The hemodynamic changes of gastroduodenal regional blood flow after Helicobacter pylori eradication in patients with duodenal ulcer scar. Wu DC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jan; 15(1):19-25
Establishment of BALB/c mice model infected with Helicobacter pylori. Jin DZ, et al. **Korean J Intern Med** 1999 Jul;14(2):55-63
Effect of eradication of Helicobacter pylori on the benign gastric ulcer recurrence--a 24 month follow-up study. Kim N, et al. **Korean J Intern Med** 1999 Jul;14(2):9-14
Effect of Helicobacter pylori infection on antral gastrin and somatostatin cells and on serum gastrin concentrations. Park SM, et al. **Korean J Intern Med** 1999 Jan;14(1):15-20
Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Solnick JV, et al. **Lab Anim Sci** 1999 Apr;49(2):197-201
Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Schmidt PH, et al. **Lab Invest** 1999 Jun;79(6):639-46
US prevalence of Helicobacter pylori may plummet in next century [news] Bhattacharya I. **Lancet** 1999 May 29; 353(9167):1859
Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Chan FK, et al. **Lancet** 1998 Dec 19-26;352(9145):2016; discussion 2017. Comment on: Lancet 1998 Sep 26;352(9133):1016-21.
Epidemiology could yield new ways to manage H. pylori infection [news] Logan R. **Lancet** 1999 Sep 18; 354(9183):1006
Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Savarino V, et al. **Lancet** 1998 Dec 19-26;352(9145):2016-7 . Comment on: Lancet 1998 Sep 26;352(9133):1016-21.
Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs [letter; comment] Stolte M. **Lancet** 1998 Dec 19-26;352(9145):2016; discussion 2017. Comment on: Lancet 1998 Sep 26;352(9133):1016-21.
Tryosine kinase and ornithine decarboxylase activation in children with Helicobactor pylori gastritis. Elitsur Y, et al. **Life Sci** 1999;65(13):1373-80
Facts and fables in management of Helicobacter pylori [editorial; comment] Barbezat GO. **Med J Aust** 1999 Apr 19;170(8):348-9. Comment on: Med J Aust 1999 Apr 19;170(8):354-7.
Australian doctors' beliefs and practice regarding Helicobacter pylori [see comments] Mollison LC, et al. **Med J Aust** 1999 Apr 19;170(8):354-7. Comment in: Med J Aust 1999 Apr 19;170(8):348-9.
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group [see comments] Blum AL, et al. **N Engl J Med** 1998 Dec 24;339(26):1875-81. Comment in: N Engl J Med 1998 Dec 24;339(26):1928-30. Comment in: ACP J Club 1999 May-Jun;130(3):64-5. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1508-9; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1509; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1509-11.
Helicobacter pylori and nonulcer dyspepsia [editorial; comment] [see comments] Friedman LS. **N Engl J Med** 1998 Dec 24;339(26):1928-30. Comment on: N Engl J Med 1998 Dec 24;339(26):1869-74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875-71. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1509-11.
Helicobacter pylori and nonulcer dyspepsia [letter; comment] Lieber CS. **N Engl J Med** 1999 May 13;340(19):1508; discussion 1509-11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869-74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875-81. Comment on: N Engl J Med 1998 Dec 24;339(26):1928-30.
Helicobacter pylori and nonulcer dyspepsia [letter; comment] Logan RF, et al. **N Engl J Med** 1999 May 13;340(19):1509; discussion 1509-11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869-74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875-81.
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia [see comments] McColl K, et al. **N Engl J Med** 1998 Dec 24; 339(26):1869-74. Comment in: N Engl J Med 1998 Dec 24;339(26):1928-30. Comment in: ACP J Club 1999 May-Jun;130(3):65. Comment in: N Engl J Med 1999 May 13;340(19):1508; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1508-9; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1509; discussion 1509-11. Comment in: N Engl J Med 1999 May 13;340(19):1509-11.
Clinical course of acute gastric mucosal lesions caused by acute infection with Helicobacter pylori [letter] Moriai T, et al. **N Engl J Med** 1999 Aug 5;341(6):456-7
Helicobacter pylori and nonulcer dyspepsia [letter; comment] Püspök A, et al. **N Engl J Med** 1999 May 13;340(19):1508-9; discussion 1509-11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869-74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875-81.
Helicobacter pylori and nonulcer dyspepsia [letter; comment] Scott BB. **N Engl J Med** 1999 May 13;340(19):1509-11. Comment on: N Engl J Med 1998 Dec 24;339(26):1869-74. Comment on: N Engl J Med 1998 Dec 24;339(26):1875-81. Comment on: N Engl J Med 1998 Dec 24;339(26):1928-30.
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Talley NJ, et al. **N Engl J Med** 1999 Oct 7;341(15):1106-11
H. pylori and peptic ulcers still misunderstood. Rapport RS. **N J Med** 1999 Aug;96(8):27-9
Seroprevalence of Helicobacter pylori in the adult population of Christchurch: risk factors and relationship to dyspeptic symptoms and iron studies. Collett JA, et al. **N Z Med J** 1999 Aug 13;112(1093):292-5
Bleeding peptic ulcers: audit of eradication treatment for H pylori. Garrigan K, et al. **N Z Med J** 1999 May 28; 112(1088):178-80
Helicobacter pylori and Giardia lamblia infections in hemodialysis patients [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1803-4
Epidemiology of Helicobacter pylori in chronic haemodialysis patients using the new RIBA H. pylori SIA. Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):1929-33
Influences of Helicobacter pylori on serum pepsinogen concentrations in dialysis patients. Tamura H, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):113-7
Diagnostic value of endoscopic signs of gastritis: with special emphasis to nodular antritis. Loffeld RJ. **Neth J Med** 1999 Mar;54(3):96-100
13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? [letter] Hart GC, et al. **Nucl Med Commun** 1999 May;20(5):495-6
Accuracy and clinical utility of the mini-dose 14C-urea breath test in the evaluation of Helicobacter pylori infection. Jensen G, et al. **Nucl Med Commun** 1998 Aug; 19(8):771-5
13C-urea versus 14C-urea breath test: is there still a need for 14C-urea? [editorial] Rodrigues M, et al. **Nucl Med Commun** 1998 Nov;19(11):1021-2
Understanding peptic ulcer disease pharmacotherapeutics. Navuluri R, et al. **Nurse Pract** 1999 Mar;24(3):128-32
Lymphocytic gastritis, Helicobacter pylori, and gastric cancer: is vitamin C the common link? [editorial] Hayat M, et al. **Nutrition** 1999 May;15(5):402-3 (20 ref.)
Gastric foveolar immature cells (mucopeptic cells) expansion in body-fundic advanced intestinal type gastric cancer in patients with chronic non-atrophic ("superficial") gastritis: Helicobacter pylori role. Testino G. **Panminerva Med** 1998 Sep;40(3):179-82
Decrease of antigastric autoantibodies in Helicobacter pylori gastritis after cure of infection. Faller G, et al. **Pathol Res Pract** 1999;195(4):243-6
Gastric inflammation is enhanced in children with CagA-positive Helicobacter pylori infection. Kolho KL, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):337-41
Plasmogastric passage of urea and ammonia in children with Helicobacter pylori infection [letter] Nijevitch AA, et al. **Pediatr Int** 1999 Aug;41(4):447-8
Interpreting the 13C-urea breath test among a large population of young children from a developing country. Thomas JE, et al. **Pediatr Res** 1999 Aug;46(2):147-51
Helicobacter pylori colonization in early life. Thomas JE, et al. **Pediatr Res** 1999 Feb;45(2):218-23
Index of suspicion. Case 3. Diagnosis: hematemesis resulting from gastritis, duodenal ulcer and hemophilia A. Colli J, et al. **Pediatr Rev** 1998 Dec;19(12):429, 432
Helicobacter pylori and hypergastrinemia in children with recurrent abdominal pain. Günel E, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):40-2
Helicobacter pylori infection in postoperative patients with biliary atresia. A benign colonization? Kubota M, et al. **Pediatr Surg Int** 1999;15(3-4):210-3
Helicobacter pylori infection and insulin requirement among children with type 1 diabetes mellitus. Begue RE, et al. **Pediatrics** 1999 Jun;103(6):e83
Natural outcome of Helicobacter pylori infection in

asymptomatic children: a two-year follow-up study. Ganga-Zandzou PS, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):216-21

Helicobacter pylori and abdominal symptoms [letter; comment] Gilger MA. **Pediatrics** 1999 Jan;103(1):192-3. Comment on: Pediatrics 1998 Apr;101(4 Pt 1):634-7.

Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Buring SM, et al. **Pharmacotherapy** 1999 Mar;19(3):324-32

Therapeutic and clinical regimens against Helicobacter pylori infections in humans: an overview. Vyas SP, et al. **Pharmazie** 1999 Jun;54(6):399-408 (96 ref.)

New treatment for peptic ulcer disease. **Postgrad Med** 1999 Mar;105(3):239-40

Practical advice on eradicating Helicobacter pylori infection. Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):137-40, 145-8 (22 ref.)

Scope and consequences of peptic ulcer disease. How important is asymptomatic Helicobacter pylori infection? Graham DY, et al. **Postgrad Med** 1999 Mar;105(3):100-2, 105-8, 110 (38 ref.)

Debate over testing for H pylori [letter] Rashidi A. **Postgrad Med** 1999 Sep;106(3):33

Evaluation of the one-minute ultra-rapid urease test for diagnosing Helicobacter pylori. Misra SP, et al. **Postgrad Med J** 1999 Mar;75(881):154-6

Non-invasive testing for Helicobacter pylori. Stone MA. **Postgrad Med J** 1999 Feb;75(880):74-7

Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Sawaoka H, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Nov; 59(5):313-6

Is Helicobacter pylori really the cause of gastroduodenal disease? Weiner H, et al. **QJM** 1998 Oct;91(10):707-11 (50 ref.)

C3 phenotypes and peptic ulcer: association of C3 with peptic ulcer but no association of C3 with Helicobacter pylori [letter; comment] Archimandritis A, et al. **Scand J Gastroenterol** 1999 Feb;34(2):219-20. Comment on: Scand J Gastroenterol 1997 Jan;32(1):16-21.

Effect of cytokines on acid secretion and gastrin secretion in Helicobacter pylori infection and aspirin-induced gastritis [letter; comment] Beales IL. **Scand J Gastroenterol** 1998 Nov;33(11):1230-2. Comment on: Scand J Gastroenterol 1998 Apr;33(4):346-56.

The conflicting relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding [editorial; comment] Bianchi Porro G, et al. **Scand J Gastroenterol** 1999 Mar;34(3):225-8 (48 ref.). Comment on: Scand J Gastroenterol 1999 Mar;34(3):234-7.

H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori. Furuta T, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):384-90

Helicobacter pylori infection and progression of gastric atrophy and intestinal metaplasia [letter] Furuta T, et al. **Scand J Gastroenterol** 1998 Sep;33(9):1005

Helicobacter pylori test-and-treat' strategy for dyspeptic patients. Gisbert JP, et al. **Scand J Gastroenterol** 1999 Jul; 34(7):644-52 (120 ref.)

Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Hansen S, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):353-60

Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Henriksson AE, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1030-3

National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. Juul KV, et al. **Scand J Gastroenterol** 1998 Sep;33(9):928-32

Eradication of Helicobacter pylori infection did not lead to cure of duodenal mucosa-associated lymphoid tissue lymphoma. Kim JS, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):215-8

Intragastric pH and Helicobacter pylori treatment with proton pump inhibitors combined with amoxycillin [letter; comment] Kleveland PM, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1230. Comment on: Scand J Gastroenterol 1998 Jan;33(1):39-43.

Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Konturek PC, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):375-83

Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Manes G, et al. **Scand J Gastroenterol** 1999 Jul;34(7):658-62

Gastroduodenal mucosal vitamin-C levels in Helicobacter pylori infection. Phull PS, et al. **Scand J Gastroenterol** 1999 Apr;34(4):361-6

Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Qvigstad G, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1244-8

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Sagar M, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1034-8

A systematic overview of the use of diary cards, quality-of-life questionnaires, and psychometric tests in treatment trials of Helicobacter pylori-positive and -negative non-ulcer dyspepsia. Sandha GS, et al. **Scand J Gastroenterol** 1999 Mar;34(3):244-9

Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide. Slomiany BL, et al. **Scand J Gastroenterol** 1998 Sep;33(9):916-22

Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Voutilainen M, et al. **Scand J Gastroenterol** 1998 Aug; 33(8):811-6

The therapeutic effect of bovine lactoferrin in the host infected with Helicobacter pylori. Wada T, et al. **Scand J Gastroenterol** 1999 Mar;34(3):238-43

Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding [see comments] Wu CY, et al. **Scand J Gastroenterol** 1999 Mar; 34(3):234-7. Comment in: Scand J Gastroenterol 1999 Mar;34(3):225-8.

Risk factors for infection with Helicobacter pylori--a study of children in rural Ethiopia. Lindkvist P, et al. **Scand J Infect Dis** 1998;30(4):371-6

Attitude to Helicobacter pylori infection among Swiss gastroenterologists. Binek J, et al. **Schweiz Med Wochenschr** 1999 Mar 20;129(11):441-5

Helicobacter pylori infection in infants and children of Bangladesh. Bardhan PK, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51-52):1814-6

Is Helicobacter pylori really the cause of gastric cancer? Nyrén O. **Semin Cancer Biol** 1998 Aug;8(4):275-83 (72 ref.)

Cell vacuolization induced by Helicobacter pylori VacA toxin: cell line sensitivity and quantitative estimation. de Bernard M, et al. **Toxicol Lett** 1998 Oct 15;99(2):109-15

Peptic ulcer disease in south Ethiopia is strongly associated with Helicobacter pylori. Henriksen TH, et al. **Trans R Soc Trop Med Hyg** 1999 Mar-Apr;93(2):171-3

N-nitroso compounds and Helicobacter pylori in the gastric remnant. Guadagni S, et al. **Tumori** 1999 Mar-Apr; 85(2):108-12

An epizootic of lymphoplasmacytic gastritis attributed to Helicobacter pylori infection in cynomolgus monkeys (Macaca fascicularis). Reindel JF, et al. **Vet Pathol** 1999 Jan;36(1):1-13

Gastric carcinoma risk index in patients infected with Helicobacter pylori [letter; comment] Stachura J. **Virchows Arch** 1998 Dec;433(6):583-5. Comment on: Virchows Arch 1998 Apr;432(4):311-4.

Proceedings of the Helicobacter pylori Symposium. New Haven, Connecticut, USA. March 1-2, 1997. **Yale J Biol Med** 1998 Mar-Apr;71(2):43-148

Eradication of Helicobacter pylori infection in the management of patients with dyspepsia and non-ulcer dyspepsia. Huang JQ, et al. **Yale J Biol Med** 1998 Mar-Apr; 71(2):125-33 (61 ref.)

Helicobacter pylori, peptic ulcer and gastric cancer in China. Lam SK, et al. **Yale J Biol Med** 1998 Jan-Feb;71(1):1-6 (43 ref.)

Helicobacter pylori: therapeutic targets. Louw JA, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):113-7 (22 ref.)

Helicobacter pylori: the Middle East scenario. Novis BH, et al. **Yale J Biol Med** 1998 Mar-Apr;71(2):135-41 (30 ref.)

Treatment of H. pylori infection: the reality. Vakil N. **Yale J Biol Med** 1998 Mar-Apr;71(2):119-24 (30 ref.)

Relationship of CagA to serum gastrin concentrations and antral G, D cell densities in Helicobacter pylori infection. Kim JH, et al. **Yonsei Med J** 1999 Aug;40(4):301-6

Nondispersive infrared spectrometry for 13CO2/12CO2-measurements: a clinically feasible analyzer for stable isotope breath tests in gastroenterology. Braden B, et al. **Z Gastroenterol** 1999 Jun;37(6):477-81

Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection. Farkas H, et al. **Z Gastroenterol** 1999 Jun;37(6):513-8

Simultaneous MALT-type lymphoma and early adenocarcinoma of the stomach associated with Helicobacter pylori gastritis. Müller S, et al. **Z Gastroenterol** 1999 Feb;37(2):153-7

Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controls. Schilling D, et al. **Z Gastroenterol** 1999 Feb;37(2):127-32

Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. Stolte M, et al. **Z Gastroenterol** 1998 Aug;36(8):641-3

[Progresses in the study of gastroenterology in China, 1997] Lu X. **Chung Hua I Hsueh Tsa Chih** 1997 Dec; 77(12):888-90 (0 ref.) **(Chi)**

[Helicobacter pylori and congestive gastropathy] Dai L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):22-3 (Eng. Abstr.) **(Chi)**

[Prevalence of Helicobacter pylori(Hp) infection in the department of gastroenterology staff members in Nanjing] Lu YK, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):70-2 (Eng. Abstr.) **(Chi)**

[Seroprevalence of Helicobacter pylori infection among Yi and Han nationalities in Yunxian County, Yunnan Province] Zhou ZF, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Feb; 18(1):18-21 (Eng. Abstr.) **(Chi)**

[A consensus on some problems of Helicobacter pylori (draft)] **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):438-9 (0 ref.) **(Chi)**

[Effect of Helicobacter pylori on gastric epithelial apoptosis] Dong Q, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov; 36(11):751-3 (Eng. Abstr.) **(Chi)**

[Relation between Helicobacter pylori and stomach cancers] Guo F, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr; 36(4):276-8 (20 ref.) **(Chi)**

[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers] Huang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):488-91 (20 ref.) **(Chi)**

[Gastric epithelial proliferation and apoptosis in Helicobacter pylori infection (editorial)] Xiao S, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):219-20 **(Chi)**

[Intensifying the study of the proper treatment of digestive ulceration (editorial)] Yao X. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):221-2 **(Chi)**

[Studies on infection of Helicobacter pylori and their subtypes cagA+ and hspA+ in population living in the areas with high and low incidence of gastric cancer] Zhang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar; 32(2):67-9 (Eng. Abstr.) **(Chi)**

[Relation between Helicobacter pylori infection and ischemic heart disease] Konštacký M. **Cas Lek Cesk** 1998 Aug 24; 137(16):483-5 (48 ref.) (Eng. Abstr.) **(Cze)**

[Prevalence of Helicobacter pylori infection in the Czech Republic--the South Moravia Region] Ditě P, et al. **Vnitr Lek** 1998 Mar;44(3):132-4 (Eng. Abstr.) **(Cze)**

[Levels of vitamins A, E and C in serum and gastric juice in relation to gastric mucosa and occurrence of Helicobacter pylori] Hep A, et al. **Vnitr Lek** 1998 Jul; 44(7):396-9 (Eng. Abstr.) **(Cze)**

[Effect of H. pylori eradication regimes on the proliferation index of gastric mucosa] Hep A, et al. **Vnitr Lek** 1998 Aug; 44(8):447-50 (Eng. Abstr.) **(Cze)**

[Non-ulcus dyspepsia--eradication of Helicobacter pylori] Schaffalitzky de Muckadell OB. **Ugeskr Laeger** 1999 Mar 29;161(13):1933 **(Dan)**

[The 13C-urea breath test in Helicobacter pylori gastric infection in children] Kalach N, et al. **Arch Pediatr** 1998 Dec;5(12):1359-65 (42 ref.) (Eng. Abstr.) **(Fre)**

[Role of cytokines in the pathogenesis of gastrointestinal diseases associated with Helicobacter pylori infection] Imanishi J, et al. **C R Seances Soc Biol Fil** 1998;192(5):991-6 (Eng. Abstr.) **(Fre)**

[Treatment of gastroesophageal reflux: should Helicobacter pylori infection be taken into account?] De Korwin JD. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S121-9 (87 ref.) **(Fre)**

[Helicobacter pylori, gastritis and stomach tumors (editorial)] Fléjou JF. **Gastroenterol Clin Biol** 1999 Jun-Jul; 23(6-7):737-9 (23 ref.) **(Fre)**

[Helicobacter pylori infections in children in the tropical zone. Endoscopic and histological aspects] Iloudo D, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):855-7 (Eng. Abstr.) **(Fre)**

[Consequences of Helicobacter pylori infection on the incidence and treatment of gastro-duodenal ulcers in patients taking non-steroidal anti-inflammatory agents] Lamarque D. **Gastroenterol Clin Biol** 1998 Dec; 22(12):1122-4 **(Fre)**

[Diagnosis of Helicobacter pylori infection is still a timely issue (editorial; comment)] Mégraud F. **Gastroenterol Clin Biol** 1998 Apr;22(4):405-6. Comment on: Gastroenterol Clin Biol 1998 Apr;22(4):407-12. **(Fre)**

[Non-ulcerating dyspepsia: role of Helicobacter pylori] Sobhani I. **Presse Med** 1998 Sep 5;27(25):1292-3 **(Fre)**

[Controversies in the treatment of Helicobacter pylori] Van Kemseke C, et al. **Rev Med Liege** 1999 Jul;54(7):570-5 (Eng. Abstr.) **(Fre)**

[Helicobacter pylori screening in a general practice] Hollenz M, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):171-5 (Eng. Abstr.) **(Ger)**

[Modified triple therapies for Helicobacter pylori eradication] Nguyen HN, et al. **Dtsch Med Wochenschr** 1999 Mar 5; 124(9):271 **(Ger)**

[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole] Müller P, et al. **Fortschr Med** 1998 Oct 10;116(28):31-2 **(Ger)**

[Possibilities of epidemiologic studies within the scope of school entrance examinations exemplified by Ulm Helicobacter pylori studies] Gonser T, et al. **Gesundheitswesen** 1998 Aug;60 Suppl 1:S24-9 (Eng. Abstr.) **(Ger)**

[Helicobacter eradication and ulcer hemorrhage] Frieling T. **Internist (Berl)** 1998 Oct;39(10):1070 **(Ger)**

["Helicobacter pylori and gastric cancer" by M. Stolte et al in Pathologe 1998; 19:330-4 (letter; comment)] Dinges HP. **Pathologe** 1999 Mar;20(2):148-9. Comment on: Pathologe 1998 Jul;19(4):330-3. **(Ger)**

[Helicobacter pylori and stomach carcinoma. Is a preventive intervention study of value? (see comments)] Stolte M, et al. **Pathologe** 1998 Jul;19(4):330-3 (28 ref.). Comment in: Pathologe 1999 Mar;20(2):148-9. **(Ger)**

[Reductionism once again. The example of Helicobacter pylori (editorial)] Weiner H. **Psychother Psychosom Med Psychol** 1998 Nov;48(11):425-9

(49 ref.) (Eng. Abstr.) **(Ger)**

[Prevalence of Helicobacter pylori infection in asymptomatic 5-7-year-old children of St. Gallen canton] Boltshauser S, et al. **Schweiz Med Wochenschr** 1999 Apr 17; 129(15):579-84 (Eng. Abstr.) **(Ger)**

[Symptomatic improvement of patients with nonulcer dyspepsia after Helicobacter pylori eradication] Zwimpfer J. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31-32):1291 **(Ger)**

[Prevention of stomach carcinoma by Helicobacter pylori eradication. Invitation to participate in the PRISMA Study] Bayerdörffer E, et al. **Z Gastroenterol** 1999 May; 37(5):XXI-XXV **(Ger)**

[MALT stomach lymphoma: is there a standardized therapy?] Fischbach W. **Z Gastroenterol** 1998 Dec;36(12):1099-102 **(Ger)**

[Helicobacter pylori and gastric acid secretion] Konturek JW, et al. **Z Gastroenterol** 1999 Feb;37(2):187-94 (56 ref.) (Eng. Abstr.) **(Ger)**

[Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?] Labenz J, et al. **Z Gastroenterol** 1999 Jul;37(7):649-52 **(Ger)**

[Mas cells in the stomach--what is their role in Helicobacter pylori gastritis?] Schmidt-Choudhury A, et al. **Z Gastroenterol** 1998 Nov;36(11):1013-5 **(Ger)**

[Effect of Helicobacter pylori infection on the apoptotic and cell proliferative processes of the gastric mucosa] Törgyekes E, et al. **Orv Hetil** 1999 Apr 4;140(14):755-60 (Eng. Abstr.) **(Hun)**

[Helicobacter pylori. I. Morphology, biochemistry, antigenic profile and correlated diseases] Balli F, et al. **Pediatr Med Chir** 1998 Sep-Oct;20(5):323-8 (49 ref.) (Eng. Abstr.) **(Ita)**

[Peptic ulcer, functional dyspepsia, Helicobacter pylori: a 1998 stock-taking on the topic of their correlation and therapeutic strategies] Dobrilla G. **Recenti Prog Med** 1999 Jun;90(6):347-54 (75 ref.) (Eng. Abstr.) **(Ita)**

[Treatment of infections of the current interest. I) Helicobacter pylori infection] Shimoyama T, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2263-7 (6 ref.) **(Jpn)**

[Effect of the eradication of Helicobacter pylori on peptic ulcer healing] Harase I, et al. **Nippon Rinsho** 1999 Jan; 57(1):162-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of Helicobacter pylori eradication from patients with gastritis evaluated by the pathological grading and cell proliferation related factors] Hirabayashi K, et al. **Nippon Rinsho** 1999 Jan;57(1):179-84 (Eng. Abstr.) **(Jpn)**

[The treatment strategy of H. pylori infection and the new triple therapy] Hoshiya S, et al. **Nippon Rinsho** 1999 Jan; 57(1):121-6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Increased acid secretion after Helicobacter pylori eradication is the important risk factor of acute duodenitis and reflux esophagitis] Iijima K, et al. **Nippon Rinsho** 1999 Jan;57(1):196-200 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers] Imaizumi H, et al. **Nippon Rinsho** 1999 Jan;57(1):167-72 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Eradication of Helicobacter pylori in Japan] Kamimoto H, et al. **Nippon Rinsho** 1999 Jun;57(6):1435-41 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication] Kanayama S. **Nippon Rinsho** 1999 Jan;57(1):153-6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[A preventive and therapeutic measures for upper gastrointestinal disorders occurred after successful eradication of Helicobacter pylori] Kaneko T, et al. **Nippon Rinsho** 1999 Jan;57(1):208-11 (Eng. Abstr.) **(Jpn)**

[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections] Kihira K, et al. **Nippon Rinsho** 1999 Jan;57(1):148-52 (Eng. Abstr.) **(Jpn)**

[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer] Nakagawa M, et al. **Nippon Rinsho** 1999 Jan;57(1):144-7 (Eng. Abstr.) **(Jpn)**

[Changes in endoscopic features and histological findings of H. pylori-related gastritis with a follow-up over a year after eradication of H. pylori] Ohkusa T, et al. **Nippon Rinsho** 1999 Jan;57(1):173-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in the severity of atrophic gastritis after Helicobacter pylori eradication] Satoh K, et al. **Nippon Rinsho** 1999 Jan;57(1):185-90 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Epidemiological study for infection with H. pylori in Japan compared with that in USA, Europe and Asian Pacific area] Shimoyama T, et al. **Nippon Rinsho** 1999 Jan; 57(1):11-6 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Esophagitis, gastritis and duodenitis provoked by cure of Helicobacter pylori infection] Shiotani A, et al. **Nippon Rinsho** 1999 Jan;57(1):191-5 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Long-term endoscopic follow-up for peptic ulcer patients after eradication of H. pylori; comparison with the maintainance therapy by H2-blocker] Shirai T, et al. **Nippon Rinsho** 1999 Jan;57(1):157-61 (Eng. Abstr.) **(Jpn)**

[Asia Pacific Consensus Conference on the management of Helicobacter pylori] Terano A. **Nippon Rinsho** 1999 Jan; 57(1):67-71 **(Jpn)**

[In a view of international consensus conference for the treatment of H. pylori infection] Watanabe K, et al. **Nippon Rinsho** 1999 Jan;57(1):61-6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[History of the treatment of Helicobacter pylori and clinical efficacy] Yamamoto I, et al. **Nippon Rinsho** 1999 Jan; 57(1):32-42 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Peptic ulcer disease and hemorrhagic gastritis with H. pylori infection] Yamamoto I, et al. **Nippon Rinsho** 1998 Sep; 56(9):2263-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of Helicobacter pylori(Hp) eradication on gastric mucosal pathophysiology in Hp-positive, NSAIDs-induced gastric ulcer] Yanaka A, et al. **Nippon Rinsho** 1999 Jan;57(1):201-7 (48 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of Helicobacter pylori on gastric emptying in non-ulcer dyspepsia--evaluation of Helicobacter pylori by 13C-urea breath test] Abe K. **Nippon Shokakibyo Gakkai Zasshi** 1999 Mar;96(3):273-9 (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori and gastric cancer] Asaka M. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):627-33 (35 ref.) **(Jpn)**

[Helicobacter pylori infection and histological types of gastric cancer] Handa Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):634-43 (Eng. Abstr.) **(Jpn)**

[The expression of chemokines and the dynamics of inflammatory cell infiltration before and after H. pylori eradication] Kikuchi T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):933-40 (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori] Nishizono A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):27-9 (13 ref.) **(Jpn)**

[13C-urea breath test as diagnostic method in Helicobacter pylori infection] Dahlberg M, et al. **Tidsskr Nor Laegeforen** 1998 Oct 10;118(24):3762-5 (Eng. Abstr.) **(Nor)**

[Treatment of Helicobacter pylori infection] Lygren I, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4511-4 (Eng. Abstr.) **(Nor)**

[Helicobacter pylori in patients with complicated peptic ulcer] Gonchar MG, et al. **Khirurgiia (Mosk)** 1999;(6):25-6 (Eng. Abstr.) **(Rus)**

[On the role of Helicobacter pylori in the pathogenesis of ulcers] Krylov AA. **Klin Med (Mosk)** 1998;76(11):68-9 **(Rus)**

[The treatment characteristics of patients with peptic ulcer infected with Helicobacter pylori] Kharchenko NV. **Lik Sprava** 1999 Mar;(2):70-4 (Eng. Abstr.) **(Rus)**

[The interrelationship of gallbladder contractile function, the morphological status of the mucosa of the gastroduodenal area and its Helicobactor pylori colonization in patients with duodenal peptic ulcer] Klimanskaia NV, et al. **Lik Sprava** 1998 Dec;(8):79-83 (Eng. Abstr.) **(Rus)**

[The comparative efficacy of different drug regimens in the treatment of peptic ulcer] Tkach SM. **Lik Sprava** 1998 Aug; (6):45-7 (Eng. Abstr.) **(Rus)**

[The role of the enzymatic antioxidant system and Helicobacter pylori infection in the pathogenesis of peptic ulcer and their effect on treatment efficacy] Esedov EM, et al. **Ter Arkh** 1999;71(2):19-22 (Eng. Abstr.) **(Rus)**

[Helicobacter pylori and peptic ulcer in the population of Khakasiia] Tsukanov VV, et al. **Ter Arkh** 1999;71(2):17-9 (Eng. Abstr.) **(Rus)**

[Endoscopic and histological changes in the mucosa of the gastric stump in Helicobacter pylori infection] Inshakov LN, et al. **Vestn Khir Im I I Grek** 1999;158(2):13-6 (Eng. Abstr.) **(Rus)**

[Combined antibacterial and probiotic therapy of Helicobacter-associated diseases in children] Lykova EA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):76-81 (Eng. Abstr.) **(Rus)**

[Therapy of Helicobacter pylori infection using Lactobacillus acidophilus] Mrda Z, et al. **Med Pregl** 1998 Jul-Aug; 51(7-8):343-5 (Eng. Abstr.) **(Scr)**

[Evaluation of a fast urease test for detection of Helicobacter pylori (editorial)] Besasso H. **Acta Gastroenterol Latinoam** 1999;29(1):37-8 **(Spa)**

[Evaluation of a fast urease test for the detection of Helicobacter pylori] Blanco D, et al. **Acta Gastroenterol Latinoam** 1999;29(1):17-20 (Eng. Abstr.) **(Spa)**

[Are there "good" H. pylori and "bad" H. pylori?/ Gisbert JP, et al. **Acta Gastroenterol Latinoam** 1998;28(5):341-8 **(Spa)**

[A comparative analysis of diagnostic methods for Helicobacter pylori infection in children] Parejo Carranza R, et al. **An Esp Pediatr** 1998 Sep;49(3):257-63 (Eng. Abstr.) **(Spa)**

[Cost-effectiveness of the eradication of Helicobacter pylori in the treatment of duodenal ulcer (editorial; comment)] Dominguez Muñoz JE. **An Med Interna** 1998 Oct; 15(10):513-4. Comment on: An Med Interna 1998 Oct;15(10):515-22. **(Spa)**

[Cost-effectiveness analysis of the eradication of Helicobacter pylori as treatment for duodenal ulcer (see comments)] Fernández Muñoz J, et al. **An Med Interna** 1998 Oct;15(10):515-22 (Eng. Abstr.). Comment in: An Med Interna 1998 Oct;15(10):513-4. **(Spa)**

[Evidence-based management of gastroduodenal ulcer] Rodriguez Téllez M, et al. **An Med Interna** 1998 Oct; 15(10):548-53 (64 ref.) **(Spa)**

[Incidence of primary gastric lymphoma and H. pylori infection in the central zone of Asturias] Vallina E, et al. **An Med Interna** 1999 Apr;16(4):175-7 (Eng. Abstr.) **(Spa)**

[Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care] Baena Diez JM, et al. **Aten Primaria** 1998 Nov 30;22(9):547-51 (Eng. Abstr.) **(Spa)**

[Eradicating treatment against Helicobacter pylori (letter)] Barrera Linares F, et al. **Aten Primaria** 1998 Oct 31; 22(7):469-70, 472 **(Spa)**

[Helicobacter pylori (letter)] García Bernabé C. **Aten Primaria** 1998 Dec;22(10):669 **(Spa)**

[Helicobacter pylori: 6-day triple therapy in duodenal ulcer. Study Group of Helicobacter pylori (GEHPY) (letter)] Mascort JJ, et al. **Aten Primaria** 1998 Dec;22(10):668-9 **(Spa)**

[Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity] Garrido A, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):471-3 (Eng. Abstr.) **(Spa)**

[Evaluation of a simple rapid polymerase chain reaction (PCR) technique for the diagnosis of Helicobacter pylori infection in childhood] Muñoz C, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):119-25 (Eng. Abstr.) **(Spa)**

[Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer] García-Romero E, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):1-6 (Eng. Abstr.) **(Spa)**

[Triple treatment for the eradication of Helicobacter pylori infection (letter; comment)] Calvet X, et al. **Med Clin (Barc)** 1998 Dec 5;111(19):759. Comment on: Med Clin (Barc) 1998 Jan 17;110(1):1-5. **(Spa)**

[Reinfection by Helicobacter pylori after its eradication: irrational fear? (editorial)] Gisbert JP. **Med Clin (Barc)** 1998 Oct 3;111(10):380-4 **(Spa)**

[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration? (letter)] Gisbert JP, et al. **Med Clin (Barc)** 1998 Nov 28;111(18):716 **(Spa)**

[The attitude in a failure to eradicate Helicobacter pylori: surrender or fight? (editorial)] Gisbert JP. **Med Clin (Barc)** 1998 Dec 12;111(20):778-82 (72 ref.) **(Spa)**

[Should H. pylori infection in duodenal ulcer be confirmed before administering eradicating treatment? (editorial)] Gisbert JP, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):134-7 (68 ref.) **(Spa)**

[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence] Gisbert JP, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):161-5 (Eng. Abstr.) **(Spa)**

[Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size (letter; comment)] Baena Diez JM, et al. **Rev Clin Esp** 1999 Jun; 199(6):407. Comment on: Rev Clin Esp 1998 Oct;198(10):655-9. **(Spa)**

[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient? (see comments)] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):655-9 (37 ref.) (Eng. Abstr.). Comment in: Rev Clin Esp 1999 Jun;199(6):407. **(Spa)**

[Role of pantoprazole in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1998 Oct;198(10):678-83 (50 ref.) **(Spa)**

[Leukocytoclastic vasculitis associated with Helicobacter pylori infection (letter)] Herranz P, et al. **Rev Clin Esp** 1998 Nov;198(11):779 (8 ref.) **(Spa)**

[Microorganisms in vascular pathology and myocardial ischemia] López-Sendón J, et al. **Rev Clin Esp** 1998 Sep; 198 Suppl 1:40-3 (22 ref.) **(Spa)**

[Resolution of a case of gastric outlet obstruction after eradication of Helicobacter pylori (letter)] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):890-1 **(Spa)**

[Gastroduodenal lesions and non-steroidal anti-inflammatory agents. What role does Helicobacter pylori play in this relationship?] Gisbert JP, et al. **Rev Esp Enferm Dig** 1998 Sep;90(9):655-64 (159 ref.) (Eng. Abstr.) **(Spa)**

[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy] Gisbert JP. **Rev Esp Enferm Dig** 1999 Feb;91(2):133-43 (111 ref.) (Eng. Abstr.) **(Spa)**

[Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori (letter)] González Carro P, et al. **Rev Esp Enferm Dig** 1998 Aug;90(8):594-5 **(Spa)**

[Characteristics of Helicobacter pylori infection in children: therapeutic implications] Martínez Gómez J. **Rev Esp Quimioter** 1998 Dec;11(4):316-21 (62 ref.) **(Spa)**

[Comparison of 2 schedules based on pantoprazole for

eradication of Helicobacter pylori in patients with active duodenal ulcer] Dehesa M, et al.
Rev Gastroenterol Mex 1998 Apr-Jun;63(2):66-71 (Eng. Abstr.) **(Spa)**

[Breath tests as a noninvasive diagnostic method in Helicobacter pylori infection] Di Silvio M, et al.
Rev Gastroenterol Mex 1998 Jul-Sep;63(3):135-42 (Eng. Abstr.) **(Spa)**

[Relation of Helicobacter pylori and the stomach operated on for peptic ulcer] Hurtado-Andrade H.
Rev Gastroenterol Mex 1998 Oct-Dec;63(4):187-97 (90 ref.) (Eng. Abstr.) **(Spa)**

[Efficacy of quadruple therapy in the eradication of Helicobacter pylori and prevention of recurrent duodenal ulcer] Ocaña Andrade E, et al. **Rev Gastroenterol Mex** 1998 Oct-Dec;63(4):182-6 (Eng. Abstr.) **(Spa)**

[Eradication of Helicobacter pylori in peptic ulcer and chronic gastritis. A randomized clinical trial] Rodriguez Hernández H, et al. **Rev Gastroenterol Mex** 1998 Jan-Mar; 63(1):21-7 (Eng. Abstr.) **(Spa)**

[Helicobacter pylori illustrates a paradigmatic shift's breakthrough] Hjalt CA, et al. **Lakartidningen** 1999 Jun 30;96(26-27):3177-9 **(Swe)**

[Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin] Wreiber K, et al. **Lakartidningen** 1999 Feb 10;96(6):582-4 (8 ref.) (Eng. Abstr.) **(Swe)**

[Morphological changes in the stomach and duodenum in ulcer disease with Helicobacter infection] Honchar MH, et al. **Klin Khir** 1998;(12):5-6 (Eng. Abstr.) **(Ukr)**

[The enterochromaffin-serotonin system and Helicobacter infection in the mechanisms of the staged development of peptic ulcer] Abrahamovych Ie(O)S, et al. **Lik Sprava** 1998 Dec;(8):73-9 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

Analysis of 3- and 6-linked sialic acids in mixtures of gangliosides using blotting to polyvinylidene difluoride membranes, binding assays, and various mass spectrometry techniques with application to recognition by Helicobacter pylori. Johansson L, et al. **Anal Biochem** 1998 Dec 15; 265(2):260-8

Helicobacter pylori water extract induces interleukin-8 production by gastric epithelial cells. Kassai K, et al.
Dig Dis Sci 1999 Feb;44(2):237-42

Relationship of Helicobacter pylori CagA(+) status to gastric juice vitamin C levels. Rokkas T, et al.
Eur J Clin Invest 1999 Jan;29(1):56-62

VacA from Helicobacter pylori: a hexameric chloride channel. Iwamoto H, et al. **FEBS Lett** 1999 Apr 30; 450(1-2):101-4

Phenotypic changes of Helicobacter pylori components during an experimental infection in mice. Janvier B, et al.
FEMS Immunol Med Microbiol 1999 May;24(1):27-33

Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Dore MP, et al.
Helicobacter 1999 Sep;4(3):154-61

Heterogeneity of protein profiles of Helicobacter pylori isolated from individual patients. Kitamoto N, et al.
Helicobacter 1998 Sep;3(3):152-62

Antibacterial peptide from H. pylori [letter] Pütsep K, et al. **Nature** 1999 Apr 22;398(6729):671-2

Helicobacter pylori fatty acid cis 9,10-methyleneoctadecanoic acid increases [Ca2+]i, activates protein kinase C and stimulates acid secretion in parietal cells. Beil W, et al.
Prostaglandins Leukot Essent Fatty Acids 1998 Aug; 59(2):119-25

Fingerprinting of Helicobacter pylori strains by matrix-assisted laser desorption/ionization mass spectrometric analysis. Nilsson CL.
Rapid Commun Mass Spectrom 1999;13(11):1067-71

CLASSIFICATION

Molecular methods for typing of Helicobacter pylori and their applications. Colding H, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):193-9 (53 ref.)

Differences among Helicobacter pylori strains isolated from three different populations and demonstrated by restriction enzyme analysis of an internal fragment of the conserved gene hpaA. Evans DG, et al. **Helicobacter** 1999 Jun; 4(2):82-8

HP0333, a member of the dprA family, is involved in natural transformation in Helicobacter pylori. Ando T, et al.
J Bacteriol 1999 Sep;181(18):5572-80

PCR-based restriction pattern typing of the vacA gene provides evidence for a homogeneous group among Helicobacter pylori strains associated with peptic ulcer disease. Donati M, et al. **J Clin Microbiol** 1999 Apr; 37(4):912-5

Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. Hynes SO, et al. **J Clin Microbiol** 1999 Jun;37(6):1994-8

Colonization of Mexican patients by multiple Helicobacter pylori strains with different vacA and cagA genotypes. Morales-Espinosa R, et al. **J Clin Microbiol** 1999 Sep; 37(9):3001-4

Development of a scheme for genotyping Helicobacter pylori based on allelic variation in urease subunit genes. Owen RJ, et al. **J Clin Microbiol** 1998 Dec;36(12):3710-2

Distinct variants of Helicobacter pylori cagA are associated with vacA subtypes. van Doorn LJ, et al.
J Clin Microbiol 1999 Jul;37(7):2306-11

Identification by PCR of Helicobacter pylori in subgingival plaque of adult periodontitis patients. Riggio MP, et al.
J Med Microbiol 1999 Mar;48(3):317-22

Characterization of clinical isolates of Helicobacter pylori in Singapore. Hua J, et al. **Microbios** 1998;94(378):71-81

[Typing of H. pylori strains isolated from patients with gastric diseases] Chen JJ, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Dec; 18(6):338-40 (Eng. Abstr.) **(Chi)**

CYTOLOGY

Inhibitory effect of somatostatin on Helicobacter pylori proliferation in vitro. Yamashita K, et al.
Gastroenterology 1998 Nov;115(5):1123-30

The morphological transition of Helicobacter pylori cells from spiral to coccoid is preceded by a substantial modification of the cell wall. Costa K, et al.
J Bacteriol 1999 Jun;181(12):3710-5

Helicobacter pylori can be induced to assume the morphology of Helicobacter heilmannii. Fawcett PT, et al. **J Clin Microbiol** 1999 Apr;37(4):1045-8

An evaluative system for the response of antibacterial therapy: based on the morphological change of Helicobacter pylori and mucosal inflammation. Wen M, et al. **Pathol Int** 1999 Apr;49(4):332-7

DRUG EFFECTS

The search for optimal Helicobacter pylori eradication regimen: a mid 1997 update. Deltenre M, et al.
Acta Gastroenterol Belg 1998 Jul-Sep;61(3):344-7 (30 ref.)

Short-term side effects during H. pylori eradication therapy. Dumonceau JM. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):348-9 (11 ref.)

Antimicrobial resistance in Helicobacter pylori: a global overview. Glupczynski Y. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):357-66 (85 ref.)

Adverse events of HP eradication: long-term negative consequences of HP eradication. Koster ED.
Acta Gastroenterol Belg 1998 Jul-Sep;61(3):350-1 (10 ref.)

Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Catalano F, et al.
Aliment Pharmacol Ther 1998 Jan;12(1):59-62

Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection. de Boer WA, et al.
Aliment Pharmacol Ther 1998 Jan;12(1):77-81

Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. Dobrilla G, et al.
Aliment Pharmacol Ther 1998 Jan;12(1):63-8

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Ducóns JA, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):775-80

Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. Goddard AF, et al. **Aliment Pharmacol Ther** 1999 May;13(5):637-42

Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. Harris AW, et al. **Aliment Pharmacol Ther** 1998 Aug;12(8):741-5

Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Haruma K, et al.
Aliment Pharmacol Ther 1999 Feb;13(2):155-62

Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. Houben MH, et al.
Aliment Pharmacol Ther 1999 Jul;13(7):883-9

A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Houben MH, et al.
Aliment Pharmacol Ther 1999 Aug;13(8):1047-55 (50 ref.)

Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days. Knigge K, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):323-6

Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. Laine L, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):887-92

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Liu WZ, et al. **Aliment Pharmacol Ther** 1999 Mar; 13(3):317-22

Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. Louw JA, et al.
Aliment Pharmacol Ther 1998 Sep;12(9):881-5

Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection. Mönkemüller KE, et al.
Aliment Pharmacol Ther 1999 May;13(5):661-5

A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Okada M, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):769-74

Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Olafsson S, et al.
Aliment Pharmacol Ther 1999 May;13(5):651-9

Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis. Ottlecz A, et al.
Aliment Pharmacol Ther 1999 Jul;13(7):875-81

The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. Pilotto A, et al. **Aliment Pharmacol Ther** 1999 May;13(5):667-73

Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori [see comments] Pipkin GA, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):823-37 (213 ref.). Comment in: Aliment Pharmacol Ther 1999 Mar;13(3):437-9.

H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study. Prach AT, et al.
Aliment Pharmacol Ther 1998 Sep;12(9):873-80

Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients. Przytulski K, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):69-75

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Rinaldi V, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):163-8

Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori. Savarino V, et al.
Aliment Pharmacol Ther 1999 May;13(5):643-9

The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Van der Wouden EJ, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):297-302

Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Wong BC, et al. **Aliment Pharmacol Ther** 1999 Mar;13(3):303-9

Effects of ranitidine bismuth citrate on Helicobacter pylori motility, morphology and survival. Worku ML, et al.
Aliment Pharmacol Ther 1999 Jun;13(6):753-60

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. Xiao SD, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):311-5

The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Zanten SJ, et al.
Aliment Pharmacol Ther 1999 Mar;13(3):289-95

Effects of garlic compounds diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Chung JG, et al. **Am J Chin Med** 1998;26(3-4):353-64

A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment [letter] Ali' A, et al.
Am J Gastroenterol 1999 Aug;94(8):2321-3

In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Akada JK, et al.
Antimicrob Agents Chemother 1999 May;43(5):1072-6

Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Debets-Ossenkopp YJ, et al.
Antimicrob Agents Chemother 1998 Oct;42(10):2749-51

Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Dore MP, et al.
Antimicrob Agents Chemother 1999 Jul;43(7):1803-4

Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Garcia-Arata MI, et al.
Antimicrob Agents Chemother 1999 Feb;43(2):374-6

Activities of beta-lactams and macrolides against Helicobacter pylori. Hassan IJ, et al.
Antimicrob Agents Chemother 1999 Jun;43(6):1387-92

Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Heep M, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1497-9

In vitro and in vivo activities of tea catechins against Helicobacter pylori. Mabe K, et al.
Antimicrob Agents Chemother 1999 Jul;43(7):1788-91

Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Mégraud F, et al. **Antimicrob Agents Chemother** 1998 Nov; 42(11):2836-40

Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Nagahara N, et al.
Antimicrob Agents Chemother 1998 Oct;42(10):2492-4

In vitro inhibition of the growth of Helicobacter pylori by oil-macerated garlic constituents [letter] Ohta R, et al.
Antimicrob Agents Chemother 1999 Jul;43(7):1811-2

Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing. van der Wouden EJ, et al.
Antimicrob Agents Chemother 1999 Jun;43(6):1484-6

Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. van Doorn LJ, et al.
Antimicrob Agents Chemother 1999 Jul;43(7):1779-82

Three treatment schemes with colloidal bismuth subcitrate

(Q-ULCER) in peptic ulcer with Helicobacter pylori. Suárez MS, et al. **Arch Med Res** 1999 Jan-Feb;30(1):55-9

Inhibitory action of YJA20379, a new proton pump inhibitor on Helicobacter pylori growth and urease. Woo TW, et al. **Arch Pharm Res** 1998 Feb;21(1):6-11

Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Katelaris PH, et al. **Aust N Z J Med** 1998 Oct;28(5):633-8

Anti-Helicobacter pylori activity of herbal medicines. Bae EA, et al. **Biol Pharm Bull** 1998 Sep;21(9):990-2

Anti-Helicobacter pylori activity of the metabolites of poncirin from Poncirus trifoliata by human intestinal bacteria. Kim DH, et al. **Biol Pharm Bull** 1999 Apr; 22(4):422-4

Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles. Katsura Y, et al. **Bioorg Med Chem Lett** 1998 Jun 2;8(11):1307-12

In vitro susceptibility of Helicobacter pylori to trifluoromethyl ketones. Kawase M, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):193-4

A highly stereoselective synthesis of plaunotol and its thiourea derivatives as potent antibacterial agents against Helicobacter pylori. Kogen H, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1347-50

Microanalysis of a selective potent anti-Helicobacter pylori compound in a Brazilian medicinal plant, Myroxylon peruiferum and the activity of analogues. Ohsaki A, et al. **Bioorg Med Chem Lett** 1999 Apr 19;9(8):1109-12

Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents [published erratum appears in Bioorg Med Chem Lett 1998 Oct 20;8(20):2937] Sakurai N, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2185-90

Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. Yoshida Y, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1897-902

Metronidazole sensitivity testing of Helicobacter pylori: the importance of media. Taylor KJ, et al. **Br J Biomed Sci** 1998 Jun;55(2):118-22

Treatment of Helicobacter pylori in patients with upper abdominal pain syndromes. Freeman H. **Can J Gastroenterol** 1999 May;13(4):299-300

Antibiotic resistance mechanisms of Helicobacter pylori. Hoffman PS. **Can J Gastroenterol** 1999 Apr;13(3):243-9 (41 ref.)

Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Iovene MR, et al. **Chemotherapy** 1999 Jan-Feb;45(1):8-14

Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. Yamamoto Y, et al. **Chemotherapy** 1999 Jul-Aug; 45(4):303-12

Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. Enroth H, et al. **Clin Infect Dis** 1999 Jun;28(6):1305-7

Reactive arthritis induced by Clostridium difficile enteritis as a complication of Helicobacter pylori eradication. Söderlin MK, et al. **Clin Rheumatol** 1999;18(4):337-8

Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. Boyanova L, et al. **Diagn Microbiol Infect Dis** 1999 Aug;34(4):309-13

The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori. Coudron PE, et al. **Diagn Microbiol Infect Dis** 1998 Sep; 32(1):39-44

Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dial EJ, et al. **Dig Dis Sci** 1998 Dec;43(12):2750-6

Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity. Sandha GS, et al. **Dig Dis Sci** 1998 Dec; 43(12):2727-32

Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Jarosz M, et al. **Eur J Cancer Prev** 1998 Dec; 7(6):449-54

Growth characteristics and influence of antibiotics on rough/smooth phenotypic variants of Helicobacter pylori. Bertram-Drogatz PA, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):490-5

Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options? [editorial] Hazell SL. **Eur J Clin Microbiol Infect Dis** 1999 Feb; 18(2):83-6

Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Wolle K, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):519-21

Helicobacter pylori clearance and serum gastrin and pepsinogen I concentrations in omeprazole treatment of duodenal ulcer patients. Lee CT, et al. **Eur J Clin Pharmacol** 1999 Jan;54(11):817-20

What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? Bazzoli F, et al. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S39-42; discussion S43-5

Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. Mégraud F. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S35-7; discussion S43-5

Susceptibility in vitro of Helicobacter pylori to cetylpyridinium chloride. Bereswill S, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):189-92

Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population. López-Brea M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):183-8

Effect on cell surface hydrophobicity and susceptibility of Helicobacter pylori to medicinal plant extracts. Annuk H, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):41-5

Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR [published erratum appears in FEMS Microbiol Lett 1999 Apr 1;173(1):275] Sevin E, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):369-72

The effects of vitamin E on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Chung JG. **Food Chem Toxicol** 1999 Jun; 37(6):655-61

Regression of MALT lymphoma of the rectum after anti-H. pylori therapy in a patient negative for H. pylori [letter] Inoue F, et al. **Gastroenterology** 1999 Aug;117(2):514-5

The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies [see comments] Lind T, et al. **Gastroenterology** 1999 Feb; 116(2):248-53. Comment in: Gastroenterology 1999 Feb;116(2):479-83.

Inhibitory effect of somatostatin on Helicobacter pylori proliferation in vitro. Yamashita K, et al. **Gastroenterology** 1998 Nov;115(5):1123-30

Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens [see comments] Marais A, et al. **Gut** 1999 Apr;44(4):463-7. Comment in: Gut 1999 Apr;44(4):447-8.

Helicobacter pylori resists arrest [comment] Owen RJ. **Gut** 1999 Apr;44(4):447-8. Comment on: Gut 1999 Apr;44(4):463-7.

Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Dore MP, et al. **Helicobacter** 1999 Sep;4(3):154-61

Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Kato S, et al. **Helicobacter** 1998 Dec;3(4):278-82

Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions. Mobley HL, et al. **Helicobacter** 1999 Sep;4(3):162-9

Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. Nie Y, et al. **Helicobacter** 1999 Jun;4(2):128-34

Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Realdi G, et al. **Helicobacter** 1999 Jun;4(2):106-12

Can proton pump inhibitors be used as bactericidal drugs in Helicobacter pylori-positive patients? [letter] Saito N, et al. **Helicobacter** 1999 Sep;4(3):211-2

Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Schwartz HI, et al. **Helicobacter** 1999 Jun;4(2):121-7

Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Trautmann M, et al. **Helicobacter** 1999 Jun;4(2):113-20

Diminished interferon-gamma production in gastric mucosa T lymphocytes after H. pylori eradication in duodenal ulcer patients. Ihan A, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1740-5

Acid suppression with ranitidine plus oral triple therapy improves ulcer healing but not Helicobacter pylori eradication. Magalhaes AF, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2161-4

Helicobacter pylori containing only cytoplasmic urease is susceptible to acid. Krishnamurthy P, et al. **Infect Immun** 1998 Nov;66(11):5060-6

Antibiotic resistance problems with Helicobacter pylori. Alarcón T, et al. **Int J Antimicrob Agents** 1999 Jun; 12(1):19-26 (93 ref.)

Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. Fera MT, et al. **Int J Antimicrob Agents** 1998 Nov;10(4):285-9

Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Osato MS, et al. **Int J Antimicrob Agents** 1999 Aug;12(4):341-7

Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication [letter] Delle Cave M, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):265

Eradication of Helicobacter pylori: why does it fail? Deltenre M, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S326-8 (14 ref.)

Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association [letter] Lombardo L, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):266-7

Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Monteiro L, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S329-33 (24 ref.)

In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori. Coudron PE, et al. **J Antimicrob Chemother** 1998 Nov;42(5):657-60

Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. Debets-Ossenkopp YJ, et al. **J Antimicrob Chemother** 1999 Apr;43(4):511-5

Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637. Hassan IJ, et al. **J Antimicrob Chemother** 1998 Nov;42(5):661-3

The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori. Jenks PJ, et al. **J Antimicrob Chemother** 1999 Jun;43(6):753-8

Antibacterial effect of garlic and omeprazole on Helicobacter pylori. Jonkers D, et al. **J Antimicrob Chemother** 1999 Jun; 43(6):837-9

Interactions of plaunotol with bacterial membranes. Koga T, et al. **J Antimicrob Chemother** 1998 Aug;42(2):133-40

Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates. López-Brea M, et al. **J Antimicrob Chemother** 1998 Sep;42(3):309-14

In-vitro synergy of paromomycin with metronidazole alone or metronidazole plus hydroxymetronidazole against Helicobacter pylori. Meyer JM, et al. **J Antimicrob Chemother** 1999 Mar;43(3):403-6

Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. Stratton CW, et al. **J Antimicrob Chemother** 1999 May;43(5):659-66

Effects of three different fish oil formulations on Helicobacter pylori growth and viability: in vitro study. Drago L, et al. **J Chemother** 1999 Jun;11(3):207-10

The value of different detection methods of Helicobacter pylori during treatment. Adamsson I, et al. **J Clin Gastroenterol** 1998 Sep;27(2):138-42

After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. Gürel S, et al. **J Clin Gastroenterol** 1999 Apr;28(3):241-4

Long-term effect of Helicobacter pylori eradication on gastric metaplasia in patients with duodenal ulcer. Kim N, et al. **J Clin Gastroenterol** 1998 Oct;27(3):246-52

Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection. Shimoyama T, et al. **J Clin Gastroenterol** 1998 Dec;27(4):348-50

Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. Chaves S, et al. **J Clin Microbiol** 1999 May;37(5):1628-31

Stable and unstable amoxicillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? Han SR, et al. **J Clin Microbiol** 1999 Aug;37(8):2740-1

Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. Pina M, et al. **J Clin Microbiol** 1998 Nov; 36(11):3285-90

Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. Moayyedi P, et al. **J Gastroenterol** 1998;33 Suppl 10:62-5

A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. Okada M, et al. **J Gastroenterol** 1998 Oct;33(5):640-5

Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. Chen W, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):322-7

Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites. Xia HH, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1044-9

Evaluation of microbicidal activity of a new disinfectant: Sterilox 2500 against Clostridium difficile spores, Helicobacter pylori, vancomycin resistant Enterococcus species, Candida albicans and several Mycobacterium species. Shetty N, et al. **J Hosp Infect** 1999 Feb;41(2):101-5

Antibacterial tests of bismuth(III)-quinolone (ciprofloxacin, cf) compounds against Helicobacter pylori and some other bacteria. Crystal structure of (cfH2)2[Bi2Cl10].4H2O. Turel I, et al. **J Inorg Biochem** 1998 Aug;71(1-2):53-60

Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. Katsura Y, et al. **J Med Chem** 1999 Jul 29;42(15):2920-6

Comparison of the effects of anaerobic and micro-aerophilic incubation on resistance of Helicobacter pylori to metronidazole. Abdi YM, et al. **J Med Microbiol** 1999 Apr; 48(4):407-10

Inhibitory effect of rose oil products on Helicobacter pylori growth in vitro: preliminary report [letter] Boyanova L, et al. **J Med Microbiol** 1999 Jul;48(7):705-6

The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers. Sasakii M, et al. **J Pharm Pharmacol** 1999 Jul;51(7):825-30

Antibiotic resistance in Helicobacter pylori [letter; comment] Guslandi M. **Lancet** 1999 Jan 16;353(9148):241-2. Comment on: Lancet 1998 Nov 14;352(9140):1595.

Antibiotic resistance in Helicobacter pylori [letter] Teare L, et al. **Lancet** 1999 Jan 16;353(9148):242

Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Pasta DJ, et al. **Med Decis Making** 1999 Jul-Sep;19(3):353-63

Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. Owen RJ, et al. **Microb Drug Resist** 1999 Summer;5(2):141-6

Significance of anaerobic preincubation of Helicobacter pylori for measuring metronidazole susceptibility by the Etest. Chida-Sakata N, et al. **Microbiol Immunol** 1999; 43(5):397-401

Mastic gum kills Helicobacter pylori [letter] Huwez FU, et al. **N Engl J Med** 1998 Dec 24;339(26):1946

An evaluative system for the response of antibacterial therapy: based on the morphological change of Helicobacter pylori and mucosal inflammation. Wen M, et al. **Pathol Int** 1999 Apr;49(4):332-7

In vitro anti-Helicobacter pylori activity of some flavonoids and their metabolites [letter] Bae EA, et al. **Planta Med** 1999 Jun;65(5):442-3

Organobismuth compounds: activity against Helicobacter pylori. Dahlgren A, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):135-7

Effect of an aluminum hydroxide-magnesium hydroxide combination drug on adhesion, IL-8 inducibility, and expression of HSP60 by Helicobacter pylori. Kamiya S, et al. **Scand J Gastroenterol** 1999 Jul;34(7):663-70

Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole. Stolte M, et al. **Virchows Arch** 1999 Jan;434(1):91-4

Helicobacter pylori and non-steroidal anti-inflammatory drugs: does infection affect the outcome of NSAID therapy? McCarthy DM. **Yale J Biol Med** 1998 Mar-Apr; 71(2):101-11 (45 ref.)

Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. Kirstein FW, et al. **Z Gastroenterol** 1998 Sep;36(9):803-9

[Eradication of Helicobacter pylori does not significantly improve dyspepsia] Bergmann JF. **Presse Med** 1999 Mar 27;28(12):634 **(Fre)**

[Meta-analysis of determining the pathogen eradicating efficacy of various therapeutic regimens in Helicobacter pylori infection] Dobrucali A, et al. **Wien Med Wochenschr** 1998;148(20):464-8 (Eng. Abstr.) **(Ger)**

[Eradication of Helicobacter pylori in peptic ulcer patients] Buzás GM, et al. **Orv Hetil** 1999 Jan 17;140(3):121-4 (32 ref.) (Eng. Abstr.) **(Hun)**

[Gastric MALT lymphoma, clinical features] Udvardy M. **Orv Hetil** 1999 Feb 7;140(6):291-4 (Eng. Abstr.) **(Hun)**

[A mechanism of clarithromycin resistance in Helicobacter pylori] Saika T, et al. **Kansenshogaku Zasshi** 1998 Sep; 72(9):918-23 (Eng. Abstr.) **(Jpn)**

[Evaluation of CO2 condition for antibiotic susceptibility test of Helicobacter pylori on microdilution broth] Udagawa H, et al. **Kansenshogaku Zasshi** 1999 Jun;73(6):565-9 (Eng. Abstr.) **(Jpn)**

[Characteristics of anti-microbial agents and its clinical choice for H. pylori treatment] Aoyama N, et al. **Nippon Rinsho** 1999 Jan;57(1):43-52 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test] Fukazawa K, et al. **Nippon Rinsho** 1999 Jan;57(1):76-80 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Antibiotic-resistant H. pylori strains in the last ten years in Japan] Murakami K, et al. **Nippon Rinsho** 1999 Jan; 57(1):81-6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori] Sakurai K, et al. **Nippon Rinsho** 1999 Jan;57(1):72-5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[The role and significance of acid suppressive drugs in the eradication of H. pylori] Yakabi K, et al. **Nippon Rinsho** 1999 Jan;57(1):53-60 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population] Rosário M, et al. **Acta Med Port** 1998 Dec; 11(12):1069-72 (Eng. Abstr.) **(Por)**

[Modern policy of anti-helicobacter therapy of ulcer disease] Ryss ES. **Klin Med (Mosk)** 1998;76(10):7-11 (10 ref.) **(Rus)**

[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance] Nilsson F, et al. **Lakartidningen** 1999 Feb 3;96(5):460-3 (12 ref.) (Eng. Abstr.) **(Swe)**

ENZYMOLOGY

Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis. Ottlecz A, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):875-81

Effects of garlic compounds diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Chung JG, et al. **Am J Chin Med** 1998;26(3-4):353-64

Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Leal-Herrera Y, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):587-92

In situ characterization of Helicobacter pylori arginase. Mendz GL, et al. **Biochim Biophys Acta** 1998 Nov 10; 1388(2):465-77

Arylamine N-acetyltransferase: a possible promoter in Helicobacter pylori-related gastric carcinogenesis. Hung CF, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr; 62(4):203-8

Detection of Helicobacter pylori organisms by Hp-fast in children. Elitsur Y, et al. **Dig Dis Sci** 1999 Jun; 44(6):1169-72

New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Houimel M, et al. **Eur J Biochem** 1999 Jun;262(3):774-80

The tricarboxylic acid cycle of Helicobacter pylori. Pitson SM, et al. **Eur J Biochem** 1999 Feb;260(1):258-67

13C-urea breath test results in pigs challenged with Helicobacter pylori or other urease producing bacteria. Enroth H, et al. **FEMS Immunol Med Microbiol** 1999 Mar; 23(3):253-7

Protein kinase activity in Helicobacter pylori. Grangeasse C, et al. **FEMS Microbiol Lett** 1999 Jul 15;176(2):327-32

Negative CLOtest pellet can be reused. Lee CL, et al. **Gastrointest Endosc** 1999 Aug;50(2):225-8

Endoscopic urease sensor system for detecting Helicobacter pylori on gastric mucosa. Sato T, et al. **Gastrointest Endosc** 1999 Jan;49(1):32-8

Helicobacter pylori containing only cytoplasmic urease is susceptible to acid. Krishnamurthy P, et al. **Infect Immun** 1998 Nov;66(11):5060-6

Characterization of a cb-type cytochrome c oxidase from Helicobacter pylori. Tsukita S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):194-201

Recombinant Helicobacter pylori urease activates primary mucosal macrophages. Harris PR, et al. **J Infect Dis** 1998 Nov;178(5):1516-20

Helicobacter pylori urease significantly reduces opsonization by human complement. Rokita E, et al. **J Infect Dis** 1998 Nov;178(5):1521-5

Potential role of two Helicobacter pylori relaxases in DNA transfer? [letter] Backert S, et al. **Mol Microbiol** 1998 Nov; 30(3):673-4

Essential role of Helicobacter pylori gamma-glutamyltranspeptidase for the colonization of the gastric mucosa of mice. Chevalier C, et al. **Mol Microbiol** 1999 Mar;31(5):1359-72

Helicobacter pylori with separate beta- and beta'-subunits of RNA polymerase is viable and can colonize conventional mice. Raudonikiene A, et al. **Mol Microbiol** 1999 Apr; 32(1):131-8

Decreased sensitivity of the ultrarapid urease test for diagnosing Helicobacter pylori in patients with chronic renal failure. Misra V, et al. **Pathology** 1999 Feb;31(1):44-6

A home made rapid urease test in the diagnosis of Helicobacter pylori infection. Chiu WY, et al. **Singapore Med J** 1999 Apr;40(4):243-5

Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Lee CK, et al. **Vaccine** 1999 Mar 17;17(11-12):1493-505

Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection. Myers GA, et al. **Vaccine** 1999 Mar 17; 17(11-12):1394-403

[HpyNI--a novel restriction endonuclease isolated from the pathogenic microorganism Helicobacter pylori] Repin VE, et al. **Mol Gen Mikrobiol Virusol** 1998;(3):37-8 (Eng. Abstr.) **(Rus)**

GENETICS

Genotypes of Helicobacter pylori obtained from gastric ulcer patients taking or not taking NSAIDs. Li L, et al. **Am J Gastroenterol** 1999 Jun;94(6):1502-7

Molecular relationships of Helicobacter pylori strains in a family with gastroduodenal disease. Miehlke S, et al. **Am J Gastroenterol** 1999 Feb;94(2):364-8

Helicobacter pylori biomarkers [news] **Anal Chem** 1999 Aug 1;71(15):512A

Helicobacter pylori and its genome: lessons from the treasure map. Taylor DE. **Can J Gastroenterol** 1999 Apr; 13(3):218-23 (39 ref.)

Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Rugge M, et al. **Cancer** 1999 Jun 15; 85(12):2506-11

Helicobacter pylori heat shock protein A: serologic responses and genetic diversity. Ng EK, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):377-82

Helicobacter pylori: molecular evolution of a bacterial quasi-species. Covacci A, et al. **Curr Opin Microbiol** 1998 Feb;1(1):96-102 (53 ref.)

Development of Helicobacter pylori infection model in BALB/c mice with domestic cagA-positive and -negative strains in Taiwan. Sheu BS, et al. **Dig Dis Sci** 1999 May; 44(5):868-75

Rapid genomic diversification of Helicobacter pylori. Vos M, et al. **Electrophoresis** 1999 Jun;20(7):1476-85

Detection of Helicobacter pylori cagA gene by polymerase chain reaction in faecal samples. Russo F, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):251-6

cagA gene and vacA alleles in Spanish Helicobacter pylori clinical isolates from patients of different ages. Alarcón T, et al. **FEMS Immunol Med Microbiol** 1999 Jun; 24(2):215-9

Lack of a relationship between Lewis antigen expression and cagA, CagA, vacA and VacA status of Irish Helicobacter pylori isolates. Marshall DG, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):79-90

Non-random fragmentation of ribosomal RNA in Helicobacter pylori during conversion to the coccoid form. Monstein HJ, et al. **FEMS Immunol Med Microbiol** 1998 Nov;22(3):217-24

Single-step PCR amplification and enzyme restriction analysis of the entire Helicobacter pylori cytotoxin vacA gene for genetic variability studies. Perales G, et al. **FEMS Microbiol Lett** 1999 Sep 1;178(1):55-62

Regulation of the transcription of genes encoding different virulence factors in Helicobacter pylori by free iron. Szczebara F, et al. **FEMS Microbiol Lett** 1999 Jun 15; 175(2):165-70

GLP-2 cloning may lead to therapy for intestinal deficiency diseases [news] Gordon D. **Gastroenterology** 1999 Apr; 116(4):786

Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Yamaoka Y, et al. **Gastroenterology** 1999 Aug; 117(2):342-9

Novel sequence organization and insertion specificity of IS605 and IS606: chimaeric transposable elements of Helicobacter pylori. Kersulyte D, et al. **Gene** 1998 Nov 26;223(1-2):175-86

Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. Basso D, et al. **Gut** 1998 Aug; 43(2):182-6

Clinical outcome after infection with Helicobacter pylori does not appear to be reliably predicted by the presence of any of the genes of the cag pathogenicity island. Jenks PJ, et al. **Gut** 1998 Dec;43(6):752-8

Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Maeda S, et al. **Gut** 1998 Sep; 43(3):317-21

Genotypes of Helicobacter pylori in Lithuanian families. Chalkauskas H, et al. **Helicobacter** 1998 Dec;3(4):296-302

RFLP and RAPD analysis of in vivo genetic interactions between strains of Helicobacter pylori. Danon SJ, et al. **Helicobacter** 1998 Dec;3(4):254-9

H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Graham DY, et al. **Helicobacter** 1998 Sep; 3(3):145-51 (51 ref.)

Experimental infection in cats with a cagA+ human isolate of Helicobacter pylori. Perkins SE, et al. **Helicobacter** 1998 Dec;3(4):225-35

Third International Workshop on Pathogenesis and Host Response in Helicobacter Infections. Taylor DE. **Helicobacter** 1998 Dec;3(4):303-4

Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Yamaoka Y, et al. **Helicobacter** 1998 Dec;3(4):241-53

Identification of virulence genes of Helicobacter pylori by random insertion mutagenesis. Bijlsma JJ, et al. **Infect Immun** 1999 May;67(5):2433-40

Isolation of recombinant protective Helicobacter pylori antigens. Hocking D, et al. **Infect Immun** 1999 Sep; 67(9):4713-9

Multiple genes in the left half of the cag pathogenicity island of Helicobacter pylori are required for tyrosine kinase-dependent transcription of interleukin-8 in gastric epithelial cells. Li SD, et al. **Infect Immun** 1999 Aug; 67(8):3893-9

Molecular characterization of a flagellar export locus of Helicobacter pylori. Porwollik S, et al. **Infect Immun** 1999 May;67(5):2060-70

Cloning and characterization of a novel membrane-associated antigenic protein of Helicobacter pylori. Yoshida M, et al. **Infect Immun** 1999 Jan; 67(1):286-93

HP0333, a member of the dprA family, is involved in natural transformation in Helicobacter pylori. Ando T, et al. **J Bacteriol** 1999 Sep;181(18):5572-80

Mutational analysis of the vacA promoter provides insight into gene transcription in Helicobacter pylori. Forsyth MH, et al. **J Bacteriol** 1999 Apr;181(7):2261-6

Identification of a novel penicillin-binding protein from Helicobacter pylori. Krishnamurthy P, et al. **J Bacteriol** 1999 Aug;181(16):5107-10

Isolation of Helicobacter pylori genes that modulate urease activity. McGee DJ, et al. **J Bacteriol** 1999 Apr; 181(8):2477-84

Helicobacter pylori: a eubacterium lacking the stringent response. Scoarughi GL, et al. **J Bacteriol** 1999 Jan; 181(2):552-5

Rapid PCR detection of Helicobacter pylori-associated virulence and resistance genes directly from gastric biopsy material. Björkholm B, et al. **J Clin Microbiol** 1998 Dec; 36(12):3689-90

cagA and vacA status of Spanish Helicobacter pylori clinical isolates [letter; comment] Domingo D, et al. **J Clin Microbiol** 1999 Jun;37(6):2113-4. Comment on: J Clin Microbiol 1998 Apr;36(4):944-8.

PCR-based restriction pattern typing of the vacA gene provides evidence for a homogeneous group among Helicobacter pylori strains associated with peptic ulcer

disease. Donati M, et al. **J Clin Microbiol** 1999 Apr; 37(4):912–5

Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori–associated gastric diseases. Evans DG, et al. **J Clin Microbiol** 1998 Nov;36(11):3435–7

Allelic diversity of the Helicobacter pylori vacuolating cytotoxin gene in South Africa: rarity of the vacA s1a genotype and natural occurrence of an s2/m1 allele. Letley DP, et al. **J Clin Microbiol** 1999 Apr;37(4):1203–5

Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. Pina M, et al. **J Clin Microbiol** 1998 Nov; 36(11):3285–90

Distinct variants of Helicobacter pylori cagA are associated with vacA subtypes. van Doorn LJ, et al. **J Clin Microbiol** 1999 Jul;37(7):2306–11

Analysis of vacA, cagA, and IS605 genotypes and those determined by PCR amplification of DNA between repetitive sequences of Helicobacter pylori strains isolated from patients with nonulcer dyspepsia or mucosa–associated lymphoid tissue lymphoma. van Doorn NE, et al. **J Clin Microbiol** 1999 Jul;37(7):2348–9

Helicobacter pylori non–cytotoxic genotype enhances mucosal gastrin and mast cell tryptase. Basso D, et al. **J Clin Pathol** 1999 Mar;52(3):210–4

Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. Shimoyama T, et al. **J Clin Pathol** 1998 Oct; 51(10):765–70

High prevalence of cagA–positive strains in Helicobacter pylori–infected, healthy, young Chinese adults. Yang H, et al. **J Gastroenterol Hepatol** 1999 May;14(5):476–80

Full–length sequence analysis of the vacA gene from cytotoxic and noncytotoxic Helicobacter pylori. Ito Y, et al. **J Infect Dis** 1998 Nov;178(5):1391–8

Phenotypic diversity in Lewis expression of Helicobacter pylori isolates from the same host. Wirth HP, et al. **J Lab Clin Med** 1999 May;133(5):488–500

PCR–based diagnosis of Helicobacter pylori infection in Polish children and adults. Gzyl A, et al. **J Med Microbiol** 1999 Apr;48(4):349–56

Identification by PCR of Helicobacter pylori in subgingival plaque of adult periodontitis patients. Riggio MP, et al. **J Med Microbiol** 1999 Mar;48(3):317–22

High frequency of CagA+ Helicobacter pylori infection in high–grade gastric MALT B–cell lymphomas. Peng H, et al. **J Pathol** 1998 Aug;185(4):409–12

Reverse transcription–polymerase chain reaction in the diagnosis of Helicobacter pylori infection in Finnish children. Oksanen K, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):252–6

Stable amoxicillin resistance in Helicobacter pylori [letter] [see comments] [published erratum appears in Lancet 1999 Jan 9;353(9147):154] van Zwet AA, et al. **Lancet** 1998 Nov 14;352(9140):1595. Comment in: Lancet 1999 Jan 16;353(9148):241–2.

Structural, functional and mutational analysis of the pfr gene encoding a ferritin from Helicobacter pylori. Bereswill S, et al. **Microbiology** 1998 Sep;144 (Pt 9):2505–16

A novel tRNA–associated locus (trl) from Helicobacter pylori is co–transcribed with tRNA(Gly) and reveals genetic diversity. Dundon WG, et al. **Microbiology** 1999 Jun;145 (Pt 6):1289–98

Helicobacter pylori—a conundrum of genetic diversity. Marshall DG, et al. **Microbiology** 1998 Nov;144 (Pt 11):2925–39 (160 ref.)

Multiple haem–utilization loci in Helicobacter pylori. Worst DJ, et al. **Microbiology** 1999 Mar;145 (Pt 3):681–8

Coccoid forms of Helicobacter pylori can be viable. Ren Z, et al. **Microbios** 1999;97(388):153–63

Variations in the gene for vacuolating toxin, vacA, in Japanese isolates of Helicobacter pylori. Ueda T, et al. **Microbios** 1999;97(388):165–78

Recombination and clonal groupings within Helicobacter pylori from different geographical regions. Achtman M, et al. **Mol Microbiol** 1999 May;32(3):459–70

Functional analysis of the Helicobacter pylori principal sigma subunit of RNA polymerase reveals that the spacer region is important for efficient transcription. Beier D, et al. **Mol Microbiol** 1998 Oct;30(1):121–34

Emergence of recombinant strains of Helicobacter pylori during human infection. Kersulyte D, et al. **Mol Microbiol** 1999 Jan;31(1):31–43

Acid–induced expression of an LPS–associated gene in Helicobacter pylori. McGowan CC, et al. **Mol Microbiol** 1998 Oct;30(1):19–31

Molecular genetic basis for the variable expression of Lewis Y antigen in Helicobacter pylori: analysis of the alpha (1,2) fucosyltransferase gene. Wang G, et al. **Mol Microbiol** 1999 Feb;31(4):1265–74

Genomic–sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori [published erratum appears in Nature 1999 Feb 25;397(6721):719] Alm RA, et al. **Nature** 1999 Jan 14;397(6715):176–80

Helicobacter pylori transmission between a boy with duodenal ulcer and his father. Shimizu T, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):655–6

Molecular characterization and interstrain variability of pHPS1, a plasmid isolated from the Sydney strain (SS1) of Helicobacter pylori. De Ungria MC, et al. **Plasmid** 1999 Mar;41(2):97–109

Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome. Peek RM Jr, et al. **Proc Assoc Am Physicians** 1998 Nov–Dec;110(6):531–44

PCR–based subtractive hybridization and differences in gene content among strains of Helicobacter pylori. Akopyants NS, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):13108–13

Sequence anomalies in the Cag7 gene of the Helicobacter pylori pathogenicity island. Liu G, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7011–6

Free recombination within Helicobacter pylori. Suerbaum S, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12619–24

The Helicobacter pylori genome: from sequence analysis to structural and functional predictions. Pawlowski K, et al. **Proteins** 1999 Jul 1;36(1):20–30

Vacuolating toxin gene polymorphism among Helicobacter pylori clinical isolates and its association with m1, m2, or chimeric vacA middle types. Yang JC, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1152–7

Helicobacter pylori virulence and genetic geography. Covacci A, et al. **Science** 1999 May 21;284(5418):1328–33 (57 ref.)

Inferring the direction of evolutionary changes of genomic base composition. Bellgard MI, et al. **Trends Genet** 1999 Jul;15(7):254–6

Host–bacterial interactions and the pathogenesis of Helicobacter pylori infection. Dorrell N, et al. **Trends Microbiol** 1998 Oct;6(10):379–82

Evolution of Helicobacter pylori: the role of recombination. Suerbaum S, et al. **Trends Microbiol** 1999 May;7(5):182–4 (21 ref.)

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Novak MJ, et al. **Vaccine** 1999 May 14;17(19):2384–91

[Studies on microbial genome] Lu D. **Wei Sheng Wu Hsueh Pao** 1997 Aug;37(4):323–5 (5 ref.) **(Chi)**

[Fas/Fas ligand mRNA are expressed in Helicobacter pylori infected mucosa] Meyer F, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1150–2 (Eng. Abstr.) **(Ger)**

[Detection of Helicobacter pylori 23S rRNA gene mutation associated with clarithromycin resistance and its clinical applicability] Maeda S, et al. **Nippon Rinsho** 1999 Jan; 57(1):87–92 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Typification of strains of Helicobacter pylori by the detection of the cagA gene and subtypes of the vacA gene] Gómez J, et al. **Enferm Infecc Microbiol Clin** 1999 Apr; 17(4):171–5 (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Lactic acid–mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Aiba Y, et al. **Am J Gastroenterol** 1998 Nov;93(11):2097–101

Disinfection of biopsy forceps and culture of Helicobacter pylori from gastric mucosal biopsies [letter; comment] Graham DY, et al. **Am J Gastroenterol** 1999 May; 94(5):1422–3. Comment on: Am J Gastroenterol 1998 Sep;93(9):1450–2.

Multiplex sequence analysis demonstrates the competitive growth advantage of the A–to–G mutants of clarithromycin–resistant Helicobacter pylori. Wang G, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):683–5

Inhibitory action of YJA20379, a new proton pump inhibitor on Helicobacter pylori growth and urease. Woo TW, et al. **Arch Pharm Res** 1998 Feb;21(1):6–11

Comparison of preservation mixtures for Helicobacter pylori. Liaw SJ, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Dec;31(4):261–3

Optimized conditions for growth and fermentation of Helicobacter pylori. Wang JT, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Sep;31(3):146–50

Osmotic effect of honey on growth and viability of Helicobacter pylori. Osato MS, et al. **Dig Dis Sci** 1999 Mar; 44(3):462–4

Effect of whey–based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Michetti P, et al. **Digestion** 1999; 60(3):203–9

Completeness of vagotomy, Helicobacter pylori colonization and recurrent ulcer 9 and 14 years after operation in duodenal ulcer patients. Peetsalu M, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):305–11

Susceptibility in vitro of Helicobacter pylori to cetylpyridinium chloride. Bereswill S, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):189–92

Non–random fragmentation of ribosomal RNA in Helicobacter pylori during conversion to the coccoid form. Monstein HJ, et al. **FEMS Immunol Med Microbiol** 1998 Nov;22(3):217–24

Urease–positive, acid–sensitive mutants of Helicobacter pylori: urease–independent acid resistance involved in growth at low pH. Bijlsma JJ, et al. **FEMS Microbiol Lett** 1998 Oct 15;167(2):309–13

The effect of oxygen on the growth and cell morphology of Helicobacter pylori. Donelli G, et al. **FEMS Microbiol Lett** 1998 Nov 1;168(1):9–15

Colony formation by Helicobacter pylori after long–term incubation under anaerobic conditions. Yamaguchi H, et al. **FEMS Microbiol Lett** 1999 Jun 1;175(1):107–11

Efficacy of conventional endoscopic disinfection and sterilization methods against Helicobacter pylori contamination. Cronmiller JR, et al. **Helicobacter** 1999 Sep; 4(3):198–203

Diversity in protein synthesis and viability of Helicobacter pylori coccoid forms in response to various stimuli. Mizoguchi H, et al. **Infect Immun** 1998 Nov;66(11):5555–60

Gastric epithelial cells stimulate Helicobacter pylori growth. Nakajima N, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S138–40

Evaluation of the AnaeroPack Campylo system for growth of microaerophilic bacteria. Van Horn K, et al. **J Clin Microbiol** 1999 Jul;37(7):2376–7

Survival of Helicobacter pylori in milk and tap water. Fan XG, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1096–8

flaA mRNA transcription level correlates with Helicobacter pylori colonisation efficiency in gnotobiotic piglets. Mankoski R, et al. **J Med Microbiol** 1999 Apr;48(4):395–9

The maintenance of viability and spiral morphology of Helicobacter pylori in mineral water [letter] Sato F, et al. **J Med Microbiol** 1999 Oct;48(10):971

Biofilm formation by Helicobacter pylori. Stark RM, et al. **Lett Appl Microbiol** 1999 Feb;28(2):121–6

Improving the success of culturing Helicobacter pylori from gastric biopsies. Hua J, et al. **Microbios** 1998;96(384):95–101

Unchanged characteristics of Helicobacter pylori during its morphological conversion. Zheng PY, et al. **Microbios** 1999;98(389):51–64

Dietary factors influence the recovery rates of Helicobacter pylori in a BALB/cA mouse model. Wang X, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):195–205

[Resuscitation from the viable but nonculturable state of Helicobacter pylori] Kurokawa M, et al. **Kansenshogaku Zasshi** 1999 Jan;73(1):15–9 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The prevalence and related symptomatology of Helicobacter pylori in children with recurrent abdominal pain. Wewer V, et al. **Acta Paediatr** 1998 Aug;87(8):830–5

Helicobacter pylori serology in elderly people: a 21–year cohort comparison in 70–year–olds and a 20–year longitudinal population study in 70–90–year–olds. Gause–Nilsson I, et al. **Age Ageing** 1998 Jul;27(4):433–6

A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: a United States, multicenter trial. Chey WD, et al. **Am J Gastroenterol** 1999 Jun;94(6):1512–6

H. pylori–CagA serum antibody and RAP in children [letter; comment] Elitsur Y. **Am J Gastroenterol** 1999 Feb;94(2):539 . Comment on: Am J Gastroenterol 1998 Aug;93(8):1264–70.

Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Fujisawa T, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2094–9

Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Marchildon P, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2105–8

Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection. Sadowski D, et al. **Am J Gastroenterol** 1998 Nov;93(11):2119–23

Decrease in serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin [letter] Sanaka M, et al. **Am J Gastroenterol** 1999 Jul;94(7):1983–4

Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Barratt J, et al. **Am J Kidney Dis** 1999 Jun;33(6):1049–57

Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ridker PM, et al. **Ann Intern Med** 1999 Oct 19; 131(8):573–7

Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain–Barré syndrome. Chiba S, et al. **Ann Neurol** 1998 Oct;44(4):686–8

Seroprevalence of Helicobacter pylori in a longitudinal study of New Zealanders at ages 11 and 21 [see comments] Fawcett JP, et al. **Aust N Z J Med** 1998 Oct;28(5):585–9 . Comment in: Aust N Z J Med 1998 Oct;28(5):581–2.

Helicobacter pylori seropositivity in patients with severe neurologic impairment. Kimura A, et al. **Brain Dev** 1999 Mar;21(2):113–7

Antibody–independent protective mucosal immunity to gastric helicobacter infection in mice. Blanchard TG, et al. **Cell Immunol** 1999 Jan 10;191(1):74–80

Polymorphonuclear oxidative burst after Helicobacter pylori water extract stimulation is not influenced by the cytotoxic genotype but indicates infection and gastritis grade. Basso D, et al. **Clin Chem Lab Med** 1999 Mar;37(3):223–9

Serological assessment of the early response to eradication therapy using an immunodominant outer membrane protein of Helicobacter pylori. Nishizono A, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):856–61

Detection of anti–VacA antibody responses in serum and gastric juice samples using type s1/m1 and s2/m2

Helicobacter pylori VacA antigens. Perez-Perez GI, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):489-93

Serum antibody responses to Helicobacter pylori and the cagA marker in patients with mucosa-associated lymphoid tissue lymphoma. Taupin A, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):633-8

Production of IL-12 in gastritis relates to infection with Helicobacter pylori. Bauditz J, et al. **Clin Exp Immunol** 1999 Aug;117(2):316-23

Relationship between mucosal levels of Helicobacter pylori-specific IgA, interleukin-8 and gastric inflammation. Zhang QB, et al. **Clin Sci (Colch)** 1999 Apr;96(4):409-14

Host response and vaccine development to Helicobacter pylori infection. Blanchard TG, et al. **Curr Top Microbiol Immunol** 1999;241:181-213 (155 ref.)

Evaluation of three commercial enzyme-linked immunosorbent assay kits for diagnosis of Helicobacter pylori in Chinese patients. Leung WK, et al. **Diagn Microbiol Infect Dis** 1999 May;34(1):13-7

Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Bernstein CN, et al. **Dig Dis Sci** 1999 Apr;44(4):668-74

Anti-CagA reactivity in Helicobacter pylori-negative subjects: a comparison of three different methods. Fusconi M, et al. **Dig Dis Sci** 1999 Aug;44(8):1691-5

Clinical significance of Helicobacter pylori seropositivity and seronegativity in asymptomatic blood donors. Menegatti M, et al. **Dig Dis Sci** 1998 Nov;43(11):2542-8

Helicobacter pylori infection in elderly people: does quantitative serological testing predict gastroduodenal ulcer disease? Tsai CJ. **Dig Dis Sci** 1999 Jan;44(1):96-101

Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients? Werdmuller BF, et al. **Dig Dis Sci** 1998 Oct;43(10):2296-300

Decreased Helicobacter pylori-specific gastric secretory IgA antibodies in infected patients. Birkholz S, et al. **Digestion** 1998 Nov-Dec;59(6):638-45

Evaluation of a new serologic test for diagnosis of Helicobacter pylori infection in children. Raymond J, et al. **Eur J Clin Microbiol Infect Dis** 1999 Mar;18(3):192-8

Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Lamarque D, et al. **Eur J Gastroenterol Hepatol** 1999 Jul;11(7):721-6

Vaccines. Lee A. **Eur J Gastroenterol Hepatol** 1999 Aug;11 Suppl 2:S75-9 (41 ref.)

Serum antibodies to H+,K+-ATPase, serum pepsinogen A and Helicobacter pylori in relation to gastric mucosa morphology in patients with low or low-normal concentrations of serum cobalamins. Lindgren A, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):583-8

Does CagA contribute to ulcer pathogenesis in a developing country, such as Sudan? El-Mahdi AM, et al. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):313-6

HLA-DQA1 alleles and the presence of Helicobacter pylori antibodies. Karhukorpi J, et al. **Eur J Immunogenet** 1999 Feb;26(1):15-7

Helicobacter pylori lipopolysaccharide enhances the expression of NADPH oxidase components in cultured guinea pig gastric mucosal cells. Teshima S, et al. **FEBS Lett** 1999 Jun 11;452(3):243-6

The effect of Helicobacter pylori on neutrophil chemotaxis is independent of cagA. Akyön Y, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):209-13

Impact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study. Kist M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):239-42

Changes in the mucosal expression of interleukin 15 in Helicobacter pylori-associated gastritis. Luzza F, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):233-8

Lack of a relationship between Lewis antigen expression and cagA, CagA, vacA and VacA status of Irish Helicobacter pylori isolates. Marshall DG, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):79-90

Production of monoclonal antibodies neutralizing vacuolation of cultured cells by Helicobacter pylori cytotoxin. Yamaguchi H, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):277-82

Working towards a Helicobacter pylori vaccine [editorial; comment] Czinn SJ, et al. **Gastroenterology** 1999 Apr; 116(4):990-3. Comment on: Gastroenterology 1999 Apr;116(4):804-12.

Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults [see comments] Michetti P, et al. **Gastroenterology** 1999 Apr;116(4):804-12. Comment in: Gastroenterology 1999 Apr;116(4):990-94.

Mimicry of blood group antigen A by Helicobacter mustelae and H. pylori [letter; comment] Moran AP, et al. **Gastroenterology** 1999 Feb;116(2):504-5. Comment on: Gastroenterology 1998 Apr;114(4):690-6.

Lack of correlation between Lewis antigen expression by Helicobacter pylori and gastric epithelial cells in infected patients. Taylor DE, et al. **Gastroenterology** 1998 Nov; 115(5):1113-22

CagA status and gastric cancer unreliable serological tests produce unreliable data [letter] Yamaoka Y, et al. **Gastroenterology** 1999 Sep;117(3):745

Seroprevalence of immunoglobulin G antibodies against Helicobacter pylori among endoscopy personnel in Japan [see comments] Nishikawa J, et al. **Gastrointest Endosc** 1998 Sep;48(3):237-43. Comment in: Gastrointest Endosc 1998 Sep;48(3):317-8.

Does quantitative serologic testing for Helicobacter pylori predict peptic ulcer disease in cirrhosis? Tsai CJ. **Gastrointest Endosc** 1999 Sep;50(3):381-6

Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Kawahara Y, et al. **Gut** 1999 Jul;45(1):20-3

Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Zevering Y, et al. **Gut** 1999 Sep;45(3):465-74 (146 ref.)

The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. Zhang ZW, et al. **Gut** 1998 Sep;43(3):322-6

Prevalence of CagA, VacA antibodies in symptomatic and asymptomatic children with Helicobacter pylori infection. Elitsur Y, et al. **Helicobacter** 1999 Jun;4(2):100-5

Highly sensitive urine-based enzyme-linked immunosorbent assay for detection of antibody to Helicobacter pylori. Katsuragi K, et al. **Helicobacter** 1998 Dec;3(4):289-95

Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by "proteome" technologies. McAtee CP, et al. **Helicobacter** 1998 Sep;3(3):163-9

CagA and VacA: virulence factors of Helicobacter pylori in Thai patients with gastroduodenal diseases. Mahachai V, et al. **Helicobacter** 1999 Sep;4(3):143-7

Seroprevalence of Helicobacter pylori and length of stay in a nursing home. Regev A, et al. **Helicobacter** 1999 Jun; 4(2):89-93

Antigenic mimicry between Helicobacter pylori and gastric mucosa: failure to implicate heat-shock protein Hsp60 using immunoelectron microscopy. Taylor DE, et al. **Helicobacter** 1999 Sep;4(3):148-53

Third International Workshop on Pathogenesis and Host Response in Helicobacter Infections. Taylor DE. **Helicobacter** 1998 Dec;3(4):303-4

Helicobacter pylori stool antigen (HpSA) test--a simple, accurate and non-invasive test for detection of Helicobacter pylori Infection. Chang MC, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):299-302

Helicobacter pylori-seronegative gastric carcinoma: a subset of gastric carcinoma with distinct clinicopathologic features. Wu MS, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2432-6

Antibodies to Cag A protein are not predictive of serious gastroduodenal disease in Indian patients [see comments] Kumar S, et al. **Indian J Gastroenterol** 1998 Oct-Dec; 17(4):126-8. Comment in: Indian J Gastroenterol 1998 Oct-Dec;17(4):123-5.

Role of local cytokines in increased gastric expression of the secretory component in Helicobacter pylori infection. Ahlstedt I, et al. **Infect Immun** 1999 Sep;67(9):4921-5

Helicobacter pylori lipopolysaccharide binds to CD14 and stimulates release of interleukin-8, epithelial neutrophil-activating peptide 78, and monocyte chemotactic protein 1 by human monocytes. Bliss CM Jr, et al. **Infect Immun** 1998 Nov;66(11):5357-63

Deletion of the major proteolytic site of the Helicobacter pylori cytotoxin does not influence toxin activity but favors assembly of the toxin into hexameric structures. Burroni D, et al. **Infect Immun** 1998 Nov;66(11):5547-50

Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice. Eaton KA, et al. **Infect Immun** 1999 Sep;67(9):4594-602

Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, et al. **Infect Immun** 1999 May;67(5):2531-9

Proinflammatory activation of neutrophils and monocytes by Helicobacter pylori in patients with different clinical presentations. Hansen PS, et al. **Infect Immun** 1999 Jun; 67(6):3171-4

Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Pappo J, et al. **Infect Immun** 1999 Jan; 67(1):337-41

Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Sawai N, et al. **Infect Immun** 1999 Jan;67(1):279-85

Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Sommer F, et al. **Infect Immun** 1998 Nov; 66(11):5543-6

Helicobacter pylori-associated gastritis in mice is host and strain specific. van Doorn NE, et al. **Infect Immun** 1999 Jun;67(6):3040-6

Cloning and characterization of a novel membrane-associated antigenic protein of Helicobacter pylori. Yoshida M, et al. **Infect Immun** 1999 Jan; 67(1):286-93

Incidence of Helicobacter pylori infection in a cohort of Italian military students. Biselli R, et al. **Infection** 1999 May-Jun;27(3):187-91

Experimental model of Helicobacter pylori infection. Del Giudice G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S261-3 (15 ref.)

Autoantibodies reacting with gastric antigens in Helicobacter pylori associated body gastritis of dyspeptic children. Ierardi E, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):478-80

Development of a vaccine against Helicobacter pylori infection. Michetti P. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S339-41 (12 ref.)

Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies. Perri F, et al. **Ital J Gastroenterol Hepatol** 1999 May; 31(4):290-4

Helicobacter pylori LPS: molecular mimicry with the host and role in autoimmunity. Vandenbroucke-Grauls CM, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S259-60 (15 ref.)

Characterization of a Helicobacter pylori vaccine candidate by proteome techniques. McAtee CP, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 4;714(2):325-33

Helicobacter pylori antibody profile in household members of children with H. pylori infection. Elitsur Y, et al. **J Clin Gastroenterol** 1999 Sep;29(2):178-82

Performance characteristics of an enzyme-linked immunosorbent assay for determining salivary immunoglobulin G response to Helicobacter pylori. De Pascalis R, et al. **J Clin Microbiol** 1999 Feb;37(2):430-2

Serological discrimination of dogs infected with gastric Helicobacter spp. and uninfected dogs. Strauss-Ayali D, et al. **J Clin Microbiol** 1999 May;37(5):1280-7

Detection of Helicobacter pylori antibodies in a pediatric population: comparison of three commercially available serological tests and one in-house enzyme immunoassay. Sunnerstam B, et al. **J Clin Microbiol** 1999 Oct; 37(10):3328-31

Comparison of four serological tests to determine the CagA or VacA status of Helicobacter pylori strains. Yamaoka Y, et al. **J Clin Microbiol** 1998 Nov;36(11):3433-4

Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer. Yamaoka Y, et al. **J Clin Pathol** 1999 Mar;52(3):215-8

Oral immunization against Helicobacter pylori--a future concept. Michetti P. **J Gastroenterol** 1998;33 Suppl 10:66-8 (36 ref.)

Serologic detection of Helicobacter pylori infection with cagA-positive strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis. Miehlke S, et al. **J Gastroenterol** 1998;33 Suppl 10:18-21

Evaluation of a new immunochromatographic test for Helicobacter pylori IgG antibodies in elderly symptomatic patients [see comments] Shirin H, et al. **J Gastroenterol** 1999 Feb;34(1):7-10. Comment in: J Gastroenterol 1999 Feb;34(1):145-6.

Pitfalls in serological testing for Helicobacter pylori infection in the elderly [editorial; comment] Sugiyama T, et al. **J Gastroenterol** 1999 Feb;34(1):145-6 (7 ref.). Comment on: J Gastroenterol 1999 Feb;34(1):7-10.

Differential Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South China. China Gastric Cancer Study Group. Wong BC, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):120-5

Helicobacter antibodies in Finnish centenarians. Rehnberg-Laiho L, et al. **J Gerontol A Biol Sci Med Sci** 1999 Aug;54(8):M400-3

Seroprevalence of Helicobacter pylori infection in an Asymptomatic Turkish population. Us D, et al. **J Infect** 1998 Sep;37(2):148-50

Vaccination of gnotobiotic piglets against Helicobacter pylori. Eaton KA, et al. **J Infect Dis** 1998 Nov; 178(5):1399-405

Establishment and characterisation of a monoclonal antibody to inhibit adhesion of Helicobacter pylori to gastric epithelial cells. Osaki T, et al. **J Med Microbiol** 1998 Jun; 47(6):505-12

Prospects for therapeutic Helicobacter pylori vaccines [editorial] Rijpkema SG. **J Med Microbiol** 1999 Jan; 48(1):1-3 (27 ref.)

Serodiagnosis of Helicobacter pylori in pediatric patients [editorial; comment] Czinn SJ. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):132-4 (20 ref.) . Comment on: J Pediatr Gastroenterol Nutr 1999 Feb;28(2):157-61.

On/off antigenic variation in Helicobacter pylori: a clue to understanding immune evasion in the host. Jones NL, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):233-4

Prevalence of Helicobacter pylori infection detected by serology and 13C-urea breath test in HIV-1 perinatally infected children. Lionetti P, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):301-6

Testing for serum IgG antibodies to Helicobacter pylori cytotoxin-associated protein detects children with higher grades of gastric inflammation. Luzza F, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):302-7

The prevalence of antibody to CagA in children is not a marker for specific disease. Mitchell HM, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):71-5

Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren's syndrome. Aragona P, et al. **J Rheumatol** 1999 Jun;26(6):1306-11

Prevalence of Helicobacter pylori antibodies in endoscopy personnel and non-medical volunteers of Karachi. Abbas Z, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):201-3

CLO antibody assay--can it be an alternate to endoscopy and biopsy? Mehdi I, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):203-5

Changes in the evolution of the antigenic profiles and morphology during coccoid conversion of Helicobacter pylori. Roe IH, et al. **Korean J Intern Med** 1999 Jan; 14(1):9-14

Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Vaira D, et al. **Lancet** 1999 Jul 3;354(9172):30-3

Immune response to a recombinant fragment of the CagA protein of Helicobacter pylori in blood donors and patients with gastric cancer: relation to ABO(H) blood group phenotype, stage of the disease and tumor morphology. Klaamas K, et al. **Med Microbiol Immunol (Berl)** 1999 May; 187(4):227-32

Utilization of proteinase K-treated cells as lipopolysaccharide antigens for the serodiagnosis of Helicobacter pylori infections. Amano K, et al. **Microbiol Immunol** 1998; 42(7):509-14

Are autoantibodies against Lewis antigens involved in the pathogenesis of Helicobacter pylori-induced peptic ulcers? Kamiya K, et al. **Microbiol Immunol** 1999;43(5):403-8

Virulence factors of Helicobacter pylori: implications for vaccine development. Suerbaum S, et al. **Mol Med Today** 1999 Jan;5(1):32-9 (54 ref.)

Persisting Helicobacter antibodies in Finnish children and adolescents between two and twenty years of age. Rehnberg-Laiho L, et al. **Pediatr Infect Dis J** 1998 Sep; 17(9):796-9

Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after Helicobacter pylori eradication. Kato S, et al. **Pediatrics** 1999 Aug;104(2):e22

Seroconversion for Helicobacter pylori in adults from Brazil. de Oliveira AM, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):261-3

The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases. Gómez-Duarte OG, et al. **Vaccine** 1999 Mar 26;17(13-14):1667-73 (81 ref.)

Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. Kim SY, et al. **Vaccine** 1999 Feb 12;17(6):607-16

Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Novak MJ, et al. **Vaccine** 1999 May 14;17(19):2384-91

Association between serum pepsinogen A and C levels, serum gastrin concentrations and Helicobacter pylori antibodies. Kullich W, et al. **Wien Med Wochenschr** 1999;149(7):157-61

Cat owners' risk of acquiring a Helicobacter pylori infection. Ansorg R, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):122-6

[Progress in the study of Helicobacter pylori vaccines] Pan Q. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):492-3 (7 ref.) **(Chi)**

[Incidence of increased serum Helicobacter pylori IgG antibodies in children with and without chronic abdominal pain] Blümel P, et al. **Klin Padiatr** 1998 Sep-Oct; 210(5):366-9 (Eng. Abstr.) **(Ger)**

[Behavior of Helicobacter pylori in 3d and 4th age-bracket patients] Daturi R, et al. **Minerva Chir** 1999 Jun;54(6):411-4 (Eng. Abstr.) **(Ita)**

[Investigation about usefulness of serum antibody of Helicobacter pylori and serum pepsinogen I/II ratio as a marker of the judgment after eradication therapy] Fujisawa T, et al. **Nippon Rinsho** 1999 Jan;57(1):101-6 (Eng. Abstr.) **(Jpn)**

[Immune response to an H. pylori infection in the stomach] Wakatsuki Y. **Nippon Rinsho** 1999 Jan;57(1):23-31 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of Helicobacter pylori stool antigen (HpSA) assay for detection of Helicobacter pylori infection] Ohkura R, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec; 95(12):1397 **(Jpn)**

[Changes in antibody titer and positivity of Helicobacter pylori in severely disabled children] Miyashiro H, et al. **No To Hattatsu** 1998 Nov;30(6):555 **(Jpn)**

[Evaluation of a western blot technique (Helicoblot 2.0) fpr the detection of specific Heliocobacter pylori antigens in children) López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul;16(6):275-9 (Eng. Abstr.) **(Spa)**

[The evaluation of a new immunoenzyme analysis for the detection of Helicobacter pylori infection in stool samples] Calvet X, et al. **Gastroenterol Hepatol** 1999 Jun-Jul; 22(6):270-2 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

How (who?) and when to test or retest for H. pylori. Burette A. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):336-43 (64 ref.)

Consensus for the management of Helicobacter pylori infection in children: still searching for a paradigm. Cadranel S, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):316-20 (53 ref.)

Gastro-duodenal ulcers. Who? When to treat? Colemont L. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):303-4 (11 ref.)

Indications for HP eradication: gastro-esophageal reflux disease. De Koster E. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):313-5 (22 ref.)

Pharmacoeconomics in HP-related diseases: more questions than answers. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):352-6 (49 ref.)

The 1998 national Belgian consensus meeting on HP-related diseases: an extensive summary. The HP Belgian contact group organized in CHU Brugmann, Brussels. Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):299-302 (7 ref.)

A consensus meeting about HP-related diseases, again? Deltenre M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):298

Histological detection of Helicobacter pylori. De Prez C. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):327-9 (25 ref.)

Who? When to treat? Gastritis, particular histological lesions, NSAID therapy and extradigestive diseases. Deprez P. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):307-12 (83 ref.)

Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. Glupczynski Y. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):321-6 (44 ref.)

Helicobacter pylori and gastric malignancies. Melange M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):305-6 (9 ref.)

Urea breath test: a diagnostic tool in the management of Helicobacter pylori-related gastrointestinal diseases. Peeters M. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):332-5 (26 ref.)

Detection of Helicobacter pylori infection by biopsy urease test. Ramdani B, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):330-1 (11 ref.)

Helicobacter pylori--screening prospect. Scaillon M, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):367-75 (86 ref.)

Upper gastrointestinal disease, Helicobacter pylori and recurrent abdominal pain. Roma E, et al. **Acta Paediatr** 1999 Jun;88(6):598-601

Clinical symptoms and social factors in a cohort of children spontaneously clearing Helicobacter pylori infection. Tindberg Y, et al. **Acta Paediatr** 1999 Jun;88(6):631-5

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. O'Connor HJ. **Aliment Pharmacol Ther** 1999 Feb; 13(2):117-27 (108 ref.)

The impact of delaying gastric emptying by either meal substrate or drug on the [13C]-urea breath test. Casellas F, et al. **Am J Gastroenterol** 1999 Feb;94(2):369-73

The interrelationship between Helicobacter pylori vacuolating cytotoxin and gastric carcinoma. de Figueiredo Soares T, et al. **Am J Gastroenterol** 1998 Oct;93(10):1841-7

Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Kulkarni SG, et al. **Am J Gastroenterol** 1999 Feb;94(2):382-6

False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood [see comments] Leung WK, et al. **Am J Gastroenterol** 1998 Oct;93(10):1914-8. Comment in: Am J Gastroenterol 1999 May;94(5):1421-2.

Genotypes of Helicobacter pylori obtained from gastric ulcer patients taking or not taking NSAIDs. Li L, et al. **Am J Gastroenterol** 1999 Jun;94(6):1502-7

Correlation of histology, CLO, dental plaque, and saliva in patients undergoing upper GI endoscopy [letter] Qureshi H, et al. **Am J Gastroenterol** 1999 Mar;94(3):861-2

Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Trevisani L, et al. **Am J Gastroenterol** 1999 Jul;94(7):1830-3

Low seroprevalence of Helicobacter pylori in patients with leukemia [letter] Matsukawa Y, et al. **Am J Hematol** 1999 Mar;60(3):253

High seroprevalence of Helicobacter pylori in active bronchiectasis. Tsang KW, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1047-51

Seroprevalence of Helicobacter pylori among Egyptian newborns and their mothers: a preliminary report. Bassily S, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):37-40

The epidemic of cocaine-related juxtapyloric perforations: with a comment on the importance of testing for Helicobacter pylori. Feliciano DV, et al. **Ann Surg** 1999 Jun;229(6):801-4; discussion 804-6

Lack of association between aphthous ulcers and Helicobacter pylori [letter] Chapman MS, et al. **Arch Dermatol** 1998 Dec;134(12):1634-5

Endoscopic biopsy pathology of Helicobacter pylori gastritis. Comparison of bacterial detection by immunohistochemistry and Genta stain. Toulaymat M, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):778-81

The effect of test duration on the sensitivity and specificity of ultra-rapid urease test for the detection of Helicobacter pylori infection. Ho KY, et al. **Aust N Z J Med** 1998 Oct; 28(5):615-9

Serodiagnosis of Helicobacter pylori infection by Cobas Core ELISA in adults from Minas Gerais, Brazil. Rocha GA, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1263-8

Phospholipases A2 in gastric juice of Helicobacter pylori--positive and negative individuals. Huhtinen HT, et al. **Clin Chem Lab Med** 1999 Jan;37(1):61-4

Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? Ahuja V, et al. **Clin Nucl Med** 1998 Dec; 23(12):815-9

Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Yildiz A, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):13-6

A comparison of six commercial kits for Helicobacter pylori detection. McNulty CA, et al. **Commun Dis Public Health** 1999 Jan;2(1):59-63

The discovery of Campylobacter-like organisms. McNulty CA. **Curr Top Microbiol Immunol** 1999;241:1-9

Detection and characterization of Helicobacter pylori from patients with gastroduodenal diseases. Busolo F, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):531-6

One stomach--one strain: does Helicobacter pylori strain variation influence disease outcome? Enroth H, et al. **Dig Dis Sci** 1999 Jan;44(1):102-7

Use of chopsticks for eating and Helicobacter pylori infection. Leung WK, et al. **Dig Dis Sci** 1999 Jun; 44(6):1173-6

Relationship between persistence of Helicobacter pylori and dysplasia, intestinal metaplasia, atrophy, inflammation, and cell proliferation following partial gastrectomy. Safatle-Ribeiro AV, et al. **Dig Dis Sci** 1999 Feb; 44(2):243-52

Examination of tissue distribution of Helicobacter pylori within columnar-lined esophagus. Sharma VK, et al. **Dig Dis Sci** 1999 Jun;44(6):1165-8

Helicobacter pylori in dental plaque: a comparison of different PCR primer sets. Song Q, et al. **Dig Dis Sci** 1999 Mar;44(3):479-84

Helicobacter pylori in the oral cavity reflects handling of contaminants but not gastric infection. Doré-Davin C, et al. **Digestion** 1999;60(3):196-202

Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment. Raderer M, et al. **Digestion** 1999 Jul-Aug;60(4):358-62

'Carditis': an objective histological marker for pathologic gastroesophageal reflux disease. Csendes A, et al. **Dis Esophagus** 1998 Apr;11(2):101-5

Helicobacter pylori infection and polymorphisms in the tumor necrosis factor region. Kunstmann E, et al. **Electrophoresis** 1999 Jun;20(8):1756-61

Chromogranin A-, somatostatin- and serotonin- containing endocrine cells in the corporal gastric mucosa of patients with Helicobacter pylori associated chronic gastritis. Tzaneva M, et al. **Endocr Regul** 1999 Jun;33(2):79-82

Evaluation of antral biopsies used in the rapid urease test for Helicobacter pylori culture. Hyde DK, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):73-5

Screening dyspeptic patients for Helicobacter pylori prior to endoscopy: laboratory or near-patient testing? Asante MA, et al. **Eur J Gastroenterol Hepatol** 1998 Oct; 10(10):843-6

Dyspepsia and Helicobacter pylori: test, treat or investigate? Harris A. **Eur J Gastroenterol Hepatol** 1999 Jun;11 Suppl 1:S31-5

Validation of [13C]urea breath test for Helicobacter pylori using a simple gas chromatograph-mass selective detector. Lee HS, et al. **Eur J Gastroenterol Hepatol** 1998 Jul; 10(7):569-72

Comparative study of microbiological and histopathological techniques used for the detection of Helicobacter pylori. Muñoz E, et al. **Eur J Histochem** 1998;42(4):297-302

Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test. Leide-Svegborn S, et al. **Eur J Nucl Med** 1999 Jun; 26(6):573-80

Gastritis and peptic ulcer disease in childhood. Blecker U, et al. **Eur J Pediatr** 1999 Jul;158(7):541-6 (62 ref.)

The effect of Helicobacter pylori on neutrophil chemotaxis is independent of cagA. Akyön Y, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):209-13

13C-urea breath test results in pigs challenged with Helicobacter pylori or other urease producing bacteria. Enroth H, et al. **FEMS Immunol Med Microbiol** 1999 Mar; 23(3):253-7

Helicobacter pylori detection in human biopsies: a competitive PCR assay with internal control reveals false results. Thoreson AC, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):201-8

Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR [published erratum appears in FEMS Microbiol Lett 1999 Apr 1;173(1):275] Sevin E, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):369-72

Geographic distribution of vacA allelic types of Helicobacter pylori. Van Doorn LJ, et al. **Gastroenterology** 1999 Apr; 116(4):823-30

Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Coyle WJ, et al. **Gastrointest Endosc** 1998 Sep;48(3):327-8

Endoscopy personnel and the transmission of Helicobacter pylori infection [editorial; comment] Kugathasan S, et al. **Gastrointest Endosc** 1998 Sep;48(3):317-8. Comment on: Gastrointest Endosc 1998 Sep;48(3):237-43.

Serologic detection of CagA positive Helicobacter pylori strains predicts the presence of peptic ulcer in young dyspeptic patients. Rokkas T, et al. **Gastrointest Endosc** 1999 Oct;50(4):511-5

A case of protein-losing gastropathy caused by acute Helicobacter pylori infection. Yoshikawa I, et al. **Gastrointest Endosc** 1999 Feb;49(2):245-8

How should Helicobacter pylori negative patients be managed? Stanghellini V, et al. **Gut** 1999 Jul;45 Suppl 1:I32-5 (46 ref.)

Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. Graham DY, et al. **Helicobacter** 1998 Sep;3(3):174-8

Performance of a rapid whole blood test for Helicobacter pylori in primary care: a German multicenter study. Hackelsberger A, et al. **Helicobacter** 1998 Sep;3(3):179-83

Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Harris RA, et al. **Helicobacter** 1999 Jun;4(2):69–76

Comparison of meal-stimulated serum gastrin response in Helicobacter pylori-positive duodenal ulcer and asymptomatic volunteers with and without H. pylori infection. Kamada T, et al. **Helicobacter** 1999 Sep; 4(3):170–7

Detection of coccoid Helicobacter pylori: light microscopical immunogold silver enhancing stain. Saito N, et al. **Helicobacter** 1998 Sep;3(3):170–3

Heavy bacterial loads of H. pylori may precipitate duodenal ulcer bleeding but not bleeding severity. Bor-Shyang S, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2165–70

Cardiac biopsy of stomach may improve the detection of H. pylori after dual therapy. Sheu BS, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):543–8

Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. El-Zimaity HM, et al. **Hum Pathol** 1999 Jan;30(1):72–7

Are H. pylori really absent in dental plaque? [letter; comment] Aggarwal R. **Indian J Gastroenterol** 1999 Jan–Mar;18(1):43. Comment on: Indian J Gastroenterol 1998 Oct–Dec;17(4):138–40.

Dental plaque: an unlikely reservoir of Helicobacter pylori [see comments] Kamat AH, et al. **Indian J Gastroenterol** 1998 Oct–Dec;17(4):138–40. Comment in: Indian J Gastroenterol 1998 Oct–Dec;17(4):123–5. Comment in: Indian J Gastroenterol 1999 Jan–Mar;18(1):43.

Dental plaque as reservoir, and determinants of pathogenic potential of Helicobacter pylori: the controversy remains [editorial; comment] Mazumder DN, et al. **Indian J Gastroenterol** 1998 Oct–Dec;17(4):123–5. Comment on: Indian J Gastroenterol 1998 Oct–Dec;17(4):126–8. Comment on: Indian J Gastroenterol 1998 Oct–Dec;17(4):138–40.

Helicobacter pylori infection in recurrent abdominal pain. Bansal D, et al. **Indian Pediatr** 1998 Apr;35(4):329–35

Biopsy forceps as a source of bacterial contamination leading to overgrowth of Helicobacter pylori culture medium with Pseudomonas aeruginosa [letter] Cooper CL, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):300–1

Increased susceptibility to Helicobacter pylori infection in pregnancy. Lanciers S, et al. **Infect Dis Obstet Gynecol** 1999;7(4):195–8

Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Hensel F, et al. **Int J Cancer** 1999 Apr 12;81(2):229–35

Helicobacter pylori in a Chukotka Native male population. Reshetnikov OV, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:293–5

Spontaneous remission of hypertrophic lymphocytic gastritis associated with hypoproteinemia. Amenomori M, et al. **Intern Med** 1998 Dec;37(12):1019–22

Rapid serological diagnosis of Helicobacter pylori: a need for caution and re-evaluation. Heaney A, et al. **Ir J Med Sci** 1998 Jul–Sep;167(3):152–4

HpSA: assessment of a new non-invasive diagnostic assay for Helicobacter pylori infection in an Irish population. McNamara D, et al. **Ir J Med Sci** 1999 Apr–Jun; 168(2):111–3

Diagnosis of Helicobacter pylori infection: non-invasive diagnostic tests. Bazzoli F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S313–4 (6 ref.)

Food allergy and Helicobacter pylori infection. Figura N, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):186–91

Prevalence of gastric metaplasia in the duodenal bulb and distribution of Helicobacter pylori in the gastric mucosa. A clinical and histopathological study in 96 consecutive patients. Jonkers D, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):481–3

Polyamine profile in human gastric mucosa infected by Helicobacter pylori. Linsalata M, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):484–9

Diagnosis of Helicobacter pylori: invasive methods. Pajares-Garcia JM. **Ital J Gastroenterol Hepatol** 1998 Oct; 30 Suppl 3:S320–3 (10 ref.)

Non-steroidal anti-inflammatory drug gastropathy and Helicobacter pylori infection. Taha AS. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S23–6 (24 ref.)

Usefulness of brushing urease test for diagnosis of Helicobacter pylori infection. Trevisani L, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):599–601

"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study. Archimandritis A, et al. **J Clin Gastroenterol** 1999 Jun;28(4):345–7

Predictive factors for metachronous recurrence of early gastric cancer after endoscopic treatment [see comments] Arima N, et al. **J Clin Gastroenterol** 1999 Jul;29(1):44–7. Comment in: J Clin Gastroenterol 1999 Jul;29(1):5–6.

Helicobacter pylori eradication: comparison of three treatment regimens in India. Bhasin DK, et al. **J Clin Gastroenterol** 1999 Jun;28(4):348–51

Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. Kim N, et al. **J Clin Gastroenterol** 1998 Dec;27(4):321–6

A comparison of new rapid urease tests for detection of Helicobacter pylori: test characteristics and factors affecting positivity and time to positivity. Niv Y, et al. **J Clin Gastroenterol** 1998 Dec;27(4):327–30

No difference in seroprevalences of Helicobacter pylori infection between patients with pulmonary tuberculosis and those without. Sanaka M, et al. **J Clin Gastroenterol** 1998 Dec;27(4):331–4

Gastric pathology in cholecystectomy patients: role of Helicobacter pylori and bile reflux. Zullo A, et al. **J Clin Gastroenterol** 1998 Dec;27(4):335–8

Is Helicobacter pylori a factor in coronary atherosclerosis? Danesh J, et al. **J Clin Microbiol** 1999 May;37(5):1651

Performance characteristics of an enzyme-linked immunosorbent assay for determining salivary immunoglobulin G response to Helicobacter pylori. De Pascalis R, et al. **J Clin Microbiol** 1999 Feb;37(2):430–2

Helicobacter pylori infection in indigenous families of Central America: serostatus and oral and fingernail carriage. Dowsett SA, et al. **J Clin Microbiol** 1999 Aug; 37(8):2456–60

Helicobacter pylori cagA status and s and m alleles of vacA in isolates from individuals with a variety of H. pylori-associated gastric diseases. Evans DG, et al. **J Clin Microbiol** 1998 Nov;36(11):3435–7

Detection of Helicobacter pylori DNA in fecal samples from infected individuals. Gramley WA, et al. **J Clin Microbiol** 1999 Jul;37(7):2236–40

Differentiation of Helicobacter pylori isolates based on lectin binding of cell extracts in an agglutination assay. Hynes SO, et al. **J Clin Microbiol** 1999 Jun;37(6):1994–8

Comparison of two rapid whole-blood tests for Helicobacter pylori infection in Chinese patients. Leung WK, et al. **J Clin Microbiol** 1998 Nov;36(11):3441–2

Comparison of five PCR methods for detection of Helicobacter pylori DNA in gastric tissues. Lu JJ, et al. **J Clin Microbiol** 1999 Mar;37(3):772–4

Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori. Siu LK, et al. **J Clin Microbiol** 1998 Oct;36(10):3048–50

Testing for Helicobacter pylori in primary care: trouble in store? Foy R, et al. **J Epidemiol Community Health** 1998 May;52(5):305–9 (78 ref.)

Diagnosis of Helicobacter pylori in Britain. Duggan A, et al. **J Gastroenterol** 1998;33 Suppl 10:31–5

Enhanced mucosal expression of interleukin-6 mRNA but not of interleukin-8 mRNA at the margin of gastric ulcer in Helicobacter pylori-positive gastritis. Furukawa K, et al. **J Gastroenterol** 1998 Oct;33(5):625–33

Helicobacter pylori in Meckel's diverticulum with heterotopic gastric mucosa in a population with relatively high H. pylori prevalence rate. Chan GS, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):313–6

Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer. Futami H, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):114–9

Usefulness of the [13C]-urea breath test for detection of Helicobacter pylori infection in fasting patients. Miwa H, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1039–43

Helicobacter pylori: evidence for spouse-to-spouse transmission. Singh V, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):519–22

High prevalence of cagA-positive strains in Helicobacter pylori-infected, healthy, young Chinese adults. Yang H, et al. **J Gastroenterol Hepatol** 1999 May;14(5):476–80

Eradication of Helicobacter pylori. Kundu AK. **J Indian Med Assoc** 1998 Nov;96(11):349–50 (11 ref.)

Absence of Helicobacter pylori in oral mucosal lesions. Singh K, et al. **J Indian Med Assoc** 1998 Jun;96(6):177–8

Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. Rothenbacher D, et al. **J Infect Dis** 1999 Feb; 179(2):398–402

Rapid and easy detection of Helicobacter pylori by in situ hybridization. Park CS, et al. **J Korean Med Sci** 1999 Feb; 14(1):15–20

Serological and direct diagnosis of Helicobacter pylori in gastric carcinoma: a case-control study. Queiroz DM, et al. **J Med Microbiol** 1999 May;48(5):501–6

Identification of Helicobacter in gastric biopsies by PCR based on 16S rDNA sequences: a matter of little significance for the prediction of H. pylori-associated gastritis? Tiveljung A, et al. **J Med Microbiol** 1998 Aug; 47(8):695–704

Detection of Helicobacter pylori in oral aphthous ulcers. Birek C, et al. **J Oral Pathol Med** 1999 May;28(5):197–203

Seroprevalence of Helicobacter pylori infection in Malaysian children: evidence for ethnic differences in childhood. Boey CC, et al. **J Paediatr Child Health** 1999 Apr;35(2):151–2

Evaluation of serology, 13C-urea breath test, and polymerase chain reaction of stool samples to detect Helicobacter pylori in Bangladeshi children. Casswall TH, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):31–6

Accuracy of the [13C]-urea breath test in diagnosing Helicobacter pylori gastritis in pediatric patients. Delvin EE, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):59–62

Helicobacter pylori-positive gastritis in pediatric patients with chronic inflammatory bowel disease. Kolho KL, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):292–5

Reverse transcription-polymerase chain reaction in the diagnosis of Helicobacter pylori infection in Finnish children. Oksanen K, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):252–6

Helicobacter pylori risk associated with sibship size and family history of gastric diseases in Japanese adults. Kikuchi S, et al. **Jpn J Cancer Res** 1998 Nov;89(11):1109–12

Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Lin CW, et al. **Jpn J Med Sci Biol** 1998 Nov;51(1):13–23

Helicobacter pylori in sheep milk [letter] Dore MP, et al. **Lancet** 1999 Jul 10;354(9173):132

Application of Bead-ELISA method to detect Helicobacter pylori VacA. Nagata H, et al. **Microb Pathog** 1999 Feb; 26(2):103–10

Gastroesophageal reflux disease versus Helicobacter pylori infection as the cause of gastric carditis. Chen YY, et al. **Mod Pathol** 1998 Oct;11(10):950–6

An easy and quick stain for the demonstration of Helicobacter pylori [letter] Ramos CV. **Mod Pathol** 1998 Sep;11(9):914

Helicobacter pylori-like dyspepsia: fact or myth? [editorial; comment] Adang RP. **Neth J Med** 1998 Oct;53(4):147–52 (95 ref.). Comment on: Neth J Med 1998 Oct;53(4):164–7.

Symptom clusters cannot be used in distinguishing Helicobacter pylori positive or negative patients with functional dyspepsia [see comments] Werdmuller BF, et al. **Neth J Med** 1998 Oct;53(4):164–7. Comment in: Neth J Med 1998 Oct;53(4):147–52.

Functional dyspepsia has a good prognosis irrespective of H. pylori status. Long-term follow-up of symptoms after anti H. pylori treatment. Werdmuller BF, et al. **Neth J Med** 1999 Aug;55(2):64–70

Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Oberhuber G, et al. **Pathol Res Pract** 1998;194(9):609–13

Decreased sensitivity of the ultrarapid urease test for diagnosing Helicobacter pylori in patients with chronic renal failure. Misra V, et al. **Pathology** 1999 Feb;31(1):44–6

Helicobacter pylori transmission between a boy with duodenal ulcer and his father. Shimizu T, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):655–6

Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients. Agnihotri N, et al. **Scand J Gastroenterol** 1998 Jul;33(7):704–9

Positive association between Helicobacter pylori infection and food allergy in children. Corrado G, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1135–9

Recurrence of Helicobacter pylori infection after eradication: incidence and variables influencing it. Gisbert JP, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1144–51

Role of aging in the expression of Helicobacter pylori gastritis in the antrum, corpus, and cardia. Hackelsberger A, et al. **Scand J Gastroenterol** 1999 Feb;34(2):138–43

A novel tablet-based 13C urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy. Hamlet A, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):367–74

A close relationship between Helicobacter pylori infection and gastric xanthoma. Isomoto H, et al. **Scand J Gastroenterol** 1999 Apr;34(4):346–52

Helicobacter pylori and intestinal metaplasia with its subtypes in the gastric antrum in a Saudi population. Al-Knawy B, et al. **Scand J Gastroenterol** 1999 Jun;34(6):562–5

Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Lerang F, et al. **Scand J Gastroenterol** 1998 Jul;33(7):710–5

Validation and value of an enzyme-linked immunosorbent assay for Helicobacter pylori in primary care. Lewin-van den Broek NT, et al. **Scand J Gastroenterol** 1999 Apr; 34(4):391–5

Detection of Helicobacter pylori in faeces with a new enzyme immunoassay method: preliminary results [letter] Trevisani L, et al. **Scand J Gastroenterol** 1998 Aug;33(8):893–4

Detection of Helicobacter pylori gene by means of immunomagnetic separation-based polymerase chain reaction in feces. Watanabe T, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1140–3

Peptic ulcer disease: another emerging infection. Moore WL Jr. **Tenn Med** 1998 Dec;91(12):466–7

Helicobacter pylori infection and the risk of myocardial infarction: role of fibrinogen and its genetic control. Zito F, et al. **Thromb Haemost** 1999 Jul;82(1):14–8

Helicobacter pylori in gastric cancer in India. Bhasin DK, et al. **Trop Gastroenterol** 1999 Apr–Jun;20(2):70–2

Risk factors for duodenal ulcer in north India. Jain A, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):36–9

What happens to Helicobacter pylori after vagotomy and drainage? Jones VS, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):50–2

Normal limits of 14C-urea breath test. Kaul A, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):110–3

Gastric Helicobacter infection in dogs. Strauss-Ayali D, et al. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):397–414, vi (98 ref.)

Accuracy and economics of Helicobacter pylori diagnosis. Cutler AF. **Yale J Biol Med** 1998 Mar–Apr;71(2):75–9 (14 ref.)

Helicobacter pylori and smoking: two additive risk factors for organic dyspepsia. Halter F, et al. **Yale J Biol Med** 1998 Mar–Apr;71(2):91–9 (35 ref.)

Realities of diagnosing Helicobacter pylori infection in clinical practice: a case for non-invasive indirect methodologies. Metz DC, et al. **Yale J Biol Med** 1998

Mar-Apr;71(2):81-90
[Investigation of relationship between primary gastric malignant lymphoma and Helicobacter pylori infection] Yi Z, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):442-5 (Eng. Abstr.) **(Chi)**
[Detection and differentiation of Helicobacter pylori from gastric biopsy and saliva by PCR-SSCP] Zhang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):446-9 (Eng. Abstr.) **(Chi)**
[The significance of Helicobacter pylori in medical science] Tytgat GN. **Verh K Acad Geneeskd Belg** 1998;60(6):521-32; discussion 532-3 (39 ref.) (Eng. Abstr.) **(Dut)**
[Primary gastric MALT lymphoma in children. Report of 2 cases] Mezlini A, et al. **Arch Anat Cytol Pathol** 1999; 47(1):38-43 (Eng. Abstr.) **(Fre)**
[Comparison of quantifying Helicobacter pylori gastric infection by culture, histology and C13 urea breath test (see comments)] Auroux J, et al.
Gastroenterol Clin Biol 1998 Apr;22(4):407-12 (Eng. Abstr.)
. Comment in: Gastroenterol Clin Biol 1998 Apr;22(4):405-6. **(Fre)**
[Molecular analysis of the progression of Helicobacter pylori-associated chronic gastritis toward mucosa-associated lymphoid tissue (MALT) lymphoma] Martin A. **Gastroenterol Clin Biol** 1998 Oct;22(10):843-4 **(Fre)**
[Remission ratio of chronic urticaria--"spontaneous" healing or result of eradication of Helicobacter pylori?] Becker H, et al. **Hautarzt** 1998 Dec;49(12):907-11 (Eng. Abstr.) **(Ger)**
[Helicobacter pylori infection in diabetic patients] Kozák R, et al. **Orv Hetil** 1999 May 2;140(18):993-5 (Eng. Abstr.) **(Hun)**
[Detection of Helicobacter pylori in tissue samples of stomach cancer] Palatka K, et al. **Orv Hetil** 1999 Sep 5; 140(36):1985-9 (Eng. Abstr.) **(Hun)**
[Occurrence of Helicobacter pylori in patients with gastroesophageal tumors] Szilvás A, et al. **Orv Hetil** 1999 May 9;140(19):1049-52 (52 ref.) (Eng. Abstr.) **(Hun)**
[Dyspepsia and Helicobacter pylori] Carella AM, et al. **Clin Ter** 1999 Jan-Feb;150(1):67-76 (125 ref.) (Eng. Abstr.) **(Ita)**
[Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease] Habu Y, et al. **Nippon Rinsho** 1999 Jan;57(1):135-9 (Eng. Abstr.) **(Jpn)**
[The appropriate time for the assessment of Helicobacter pylori eradication] Ishizuka J, et al. **Nippon Rinsho** 1999 Jan;57(1):111-5 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy] Iwasaki A. **Nippon Rinsho** 1999 Jan;57(1):127-33 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Possible availability of rapid urease tests for diagnosis of Helicobacter pylori eradication: comparative study with culture and histology] Murata H, et al. **Nippon Rinsho** 1999 Jan;57(1):97-100 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment] Sekine H, et al. **Nippon Rinsho** 1999 Jan;57(1):116-20 (Eng. Abstr.) **(Jpn)**
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer] Shirai T, et al. **Nippon Rinsho** 1999 Jan;57(1):140-3 **(Jpn)**
[The 13C-urea breath test efficacy in determining Helicobacter pylori eradication] Toyama J, et al. **Nippon Rinsho** 1999 Jan;57(1):93-6 (17 ref.) (Eng. Abstr.) **(Jpn)**
[PCR-monitoring of gastric juice obtained with the capsuled string for the evaluation of H. pylori eradication] Yoshida H, et al. **Nippon Rinsho** 1999 Jan;57(1):107-10 (Eng. Abstr.) **(Jpn)**
[Erosive duodenitis after eradication therapy for Helicobacter pylori] Goto T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):14-20 (Eng. Abstr.) **(Jpn)**
[Semi-quantitative detection of Helicobacter pylori using immunohistochemical staining] Shirahase H, et al. **Rinsho Byori** 1998 Dec;46(12):1258-63 (Eng. Abstr.) **(Jpn)**
[Primary gastritis associated with Helicobacter pylori in children] Kawakami E, et al. **Arq Gastroenterol** 1998 Apr-Jun;35(2):138-42 (Eng. Abstr.) **(Por)**
[Bezoars and gigantic stomach ulcers associated with helicobacter pylori] Khutiev TsS, et al. **Khirurgiia (Mosk)** 1999;(3):28-31 (Eng. Abstr.) **(Rus)**
[Clinical-endoscopic factors of gastro-duodenal ulcer associated with Helicobacter pylori in elderly and senile patients] Kovalenko LI. **Klin Khir** 1999;(3):7-9 (Eng. Abstr.) **(Rus)**
[Helicobacter pylori and stomach cancer] Butov IuL, et al. **Lik Sprava** 1998 Jun;(4):69-71 (Eng. Abstr.) **(Rus)**
[The possibility of Helicobacter pylori being present in the resting state in the gastric mucosa of peptic acid patients after treatment] Loginov AS, et al. **Ter Arkh** 1999; 71(2):13-6 (Eng. Abstr.) **(Rus)**
[Helicobacter pylori detection by polymerase chain reaction in gastric juice and its correlation with the histology (Giemsa)] Monti J, et al. **Acta Gastroenterol Latinoam** 1998; 28(5):335-6 (Eng. Abstr.) **(Spa)**
[Dental plaque in Helicobacter pylori infection] Santamaría MJ, et al. **An Esp Pediatr** 1999 Mar;50(3):244-6 (Eng. Abstr.) **(Spa)**
[Use of the polymerase chain reaction (PCR) for the diagnosis of Helicobacter pylori infection in pediatric patients] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):395-9 (Eng. Abstr.) **(Spa)**
[Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments] Gisbert JP, et al. **Med Clin (Barc)** 1999 Mar 20;112(10):365-7 (Eng. Abstr.) **(Spa)**
[Isolation of Helicobacter pylori from dental plaque] Mattana CM, et al. **Rev Argent Microbiol** 1998 Apr-Jun;30(2):93-5 (Eng. Abstr.) **(Spa)**
[The relation of Helicobacter pylori with dysplasia and stomach neoplasms in Costa Rica] Miranda M, et al. **Rev Biol Trop** 1998 Sep;46(3):829-32 (Eng. Abstr.) **(Spa)**
[The influence of Helicobacter pylori on the surgical outcome of duodenal ulcer] Sukhodolia AI. **Klin Khir** 1999;(3):9-10 (Eng. Abstr.) **(Ukr)**

METABOLISM

Epitope dissection of receptor-active gangliosides with affinity for Helicobacter pylori and influenza virus. Miller-Podraza H, et al. **Acta Biochim Pol** 1998; 45(2):439-49
Properties and function of the P type ion pumps cloned from Helicobacter pylori. Melchers K, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:123-35
The physiology and metabolism of the human gastric pathogen Helicobacter pylori. Kelly DJ. **Adv Microb Physiol** 1998;40:137-89 (164 ref.)
Relation between vacA subtypes, cytotoxin activity, and disease in Helicobacter pylori-infected patients from The Netherlands. Pan ZJ, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1517-21
Direct determination of Helicobacter pylori vacA genotypes and cagA gene in gastric biopsies and relationship to gastrointestinal diseases. Rudi J, et al. **Am J Gastroenterol** 1999 Jun;94(6):1525-31
Involvement of endothelin-1 in up-regulation of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. Slomiany BL, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):17-20
Characterization of the C-terminal domain of Helicobacter pylori vacuolating toxin and its relationship with extracellular toxin production. Wang HJ, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):397-402
Cancer-associated strains of Helicobacter pylori stimulate DNA synthesis in IEC-6 cells. Bark J, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):837-41
The origin of cecropins; implications from synthetic peptides derived from ribosomal protein L1. Pütsep K, et al. **FEBS Lett** 1999 May 28;451(3):249-52
Characterization of the respiratory chain of Helicobacter pylori. Chen M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):169-74
pH-dependent binding of Helicobacter pylori to pig gastric mucins. Nordman H, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):175-81
Production of monoclonal antibodies neutralizing vacuolation of cultured cells by Helicobacter pylori cytotoxin. Yamaguchi H, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):277-82
Selective binding by Helicobacter pylori of leucocyte gangliosides with 3-linked sialic acid, as identified by a new approach of linkage analysis. Johansson L, et al. **Glycoconj J** 1998 Jul;15(7):713-21
The histamine H3 receptor agonist N alpha-methylhistamine produced by Helicobacter pylori does not alter somatostatin release from cultured rabbit fundic D-cells. Beales IL, et al. **Gut** 1998 Aug;43(2):176-81
Omeprazole: Helicobacter pylori makes thee greater yet [comment] Pantoflickova D, et al. **Gut** 1999 Apr; 44(4):448-9. Comment on: Gut 1999 Apr;44(4):468-75.
Surface-associated heat shock proteins of Legionella pneumophila and Helicobacter pylori: roles in pathogenesis and immunity. Hoffman PS, et al. **Infect Dis Obstet Gynecol** 1999;7(1-2):58-63 (23 ref.)
Diversity in protein synthesis and viability of Helicobacter pylori coccoid forms in response to various stimuli. Mizoguchi H, et al. **Infect Immun** 1998 Nov;66(11):5555-60
Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874. Pantzar M, et al. **Infect Immun** 1998 Oct;66(10):4976-80
Kinetics and mechanisms of extracellular protein release by Helicobacter pylori. Schraw W, et al. **Infect Immun** 1999 Oct;67(10):5247-52
Helicobacter pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Zullo A, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):405-9
A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori. Burns BP, et al. **J Bacteriol** 1998 Nov;180(21):5574-9
Helicobacter pylori: a eubacterium lacking the stringent response. Scoarughi GL, et al. **J Bacteriol** 1999 Jan; 181(2):552-5
Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. Suzuki M, et al. **J Gastroenterol Hepatol** 1999 Jan; 14(1):27-31
Enterotoxic effect of the vacuolating toxin produced by Helicobacter pylori in Caco-2 cells. Guarino A, et al. **J Infect Dis** 1998 Nov;178(5):1373-8
Helicobacter pylori interactions with human gastric mucin studied with a resonant mirror biosensor. Hirmo S, et al. **J Microbiol Methods** 1999 Aug;37(2):177-82
Role of mast cells as a trigger of inflammation in Helicobacter pylori infection. Yamamoto J, et al. **J Physiol Pharmacol** 1999 Mar;50(1):17-23
In vitro cytotoxic effects of vacuolating cytotoxin produced by clinical isolates of Helicobacter pylori. Kodama K, et al. **Kansenshogaku Zasshi** 1998 Oct;72(10):1027-34
Vacuolating cytotoxin purified from Helicobacter pylori causes mitochondrial damage in human gastric cells. Kimura M, et al. **Microb Pathog** 1999 Jan;26(1):45-52
Helicobacter pylori attaches to NeuAc alpha 2,3Gal beta 1,4 glycoconjugates produced in the stomach of transgenic mice lacking parietal cells. Syder AJ, et al. **Mol Cell** 1999 Mar;3(3):263-74
Inhibitory effect of vacuolating toxin of Helicobacter pylori on enzyme secretion from rat pancreatic acini. Hori Y, et al. **Pancreas** 1999 Apr;18(3):324-7
Structure, function and localization of Helicobacter pylori urease. Dunn BE, et al. **Yale J Biol Med** 1998 Mar-Apr; 71(2):63-73 (67 ref.)
Does Helicobacter pylori infection contribute to gastroesophageal reflux disease? Spechler SJ. **Yale J Biol Med** 1998 Mar-Apr;71(2):143-8 (37 ref.)
[Laser-assisted 13C-urea breath test; a new noninvasive detection method for Helicobacter pylori infection] van der Hulst RW, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):400-4 (Eng. Abstr.) **(Dut)**

PATHOGENICITY

Panel discussion: breaking the link--clinical options to minimize risk. Blaser MJ, et al. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:19-23
Review article: the role of inflammation in the pathogenesis of gastric cancer. Ernst P. **Aliment Pharmacol Ther** 1999 Mar;13 Suppl 1:13-8 (18 ref.)
Gastric MALT lymphoma: from concept to cure. Isaacson PG. **Ann Oncol** 1999 Jun;10(6):637-45 (96 ref.)
Induction of caspase-3 and nitric oxide synthase-2 during gastric mucosal inflammatory reaction to Helicobacter pylori lipopolysaccharide. Slomiany BL, et al. **Biochem Mol Biol Int** 1998 Dec;46(5):1063-70
Helicobacter pylori vacuolating toxin forms anion-selective channels in planar lipid bilayers: possible implications for the mechanism of cellular vacuolation. Tombola F, et al. **Biophys J** 1999 Mar;76(3):1401-9
Commentary: Helicobacter pylori--the story so far. Thomson M. **BMJ** 1999 Aug 28;319(7209):541
Helicobacter pylori infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. Shimizu N, et al. **Carcinogenesis** 1999 Apr; 20(4):669-76
Effect of Helicobacter pylori infection on the N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in mongolian gerbils. Tokieda M, et al. **Carcinogenesis** 1999 Jul;20(7):1261-6
The inflammatory response in CD1 mice shortly after infection with a CagA+/VacA+ Helicobacter pylori strain. van Doorn NE, et al. **Clin Exp Immunol** 1999 Mar; 115(3):421-7
Helicobacter pylori: molecular evolution of a bacterial quasi-species. Covacci A, et al. **Curr Opin Microbiol** 1998 Feb;1(1):96-102 (53 ref.)
Mechanisms of Helicobacter pylori infection: bacterial factors. McGee DJ, et al. **Curr Top Microbiol Immunol** 1999;241:155-80 (178 ref.)
Interleukin-8 production in primary cultures of human gastric epithelial cells induced by Helicobacter pylori. Ogura K, et al. **Dig Dis Sci** 1998 Dec;43(12):2738-43
Relationship of Helicobacter pylori CagA status to gastric cell proliferation and apoptosis. Rokkas T, et al. **Dig Dis Sci** 1999 Mar;44(3):487-93
Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Breuer-Katschinski B, et al. **Digestion** 1999;60(3):210-5
Water extracts of Helicobacter pylori delay healing of chronic gastric ulcers in rats: role of cytokines and gastrin-somatostatin link. Brzozowski T, et al. **Digestion** 1999 Jan-Feb;60(1):22-33
Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. La Corte R, et al. **Drug Saf** 1999 Jun;20(6):527-43 (103 ref.)
Helicobacter pylori and somatostatin cells [comment] Calam J. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):281-3. Comment on: Eur J Gastroenterol Hepatol 1998 Apr;10(4):289-91.
Molecular and cellular activities of Helicobacter pylori pathogenic factors. Montecucco C, et al. **FEBS Lett** 1999 Jun 4;452(1-2):16-21 (60 ref.)
Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population. López-Brea M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):183-8
Functional analysis of the roles of FliQ and FlhB in flagellar expression in Helicobacter pylori. Foynes S, et al. **FEMS Microbiol Lett** 1999 May 1;174(1):33-9
Regulation of the transcription of genes encoding different virulence factors in Helicobacter pylori by free iron.

Szczebara F, et al. **FEMS Microbiol Lett** 1999 Jun 15; 175(2):165–70

Host specificity of Helicobacter pylori strains and host responses in experimentally challenged nonhuman primates. Dubois A, et al. **Gastroenterology** 1999 Jan;116(1):90–6

The gastric transitional zones: neglected links between gastroduodenal pathology and helicobacter ecology. Van Zanten SJ, et al. **Gastroenterology** 1999 May;116(5):1217–29 (164 ref.)

Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications. Axon AT. **Gut** 1999 Jul;45 Suppl 1:I1–4 (28 ref.)

Host, heredity and helicobacter [comment] Nedrud JG, et al. **Gut** 1999 Sep;45(3):323–4. Comment on: Gut 1999 Sep;45(3):335–40.

Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier thickness is not compromised. Newton JL, et al. **Gut** 1998 Oct;43(4):470–5

Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report [letter] Grimaz S, et al. **Haematologica** 1999 Mar;84(3):283–4

Invasiveness of Helicobacter pylori into human gastric mucosa. Ko GH, et al. **Helicobacter** 1999 Jun;4(2):77–81

Experimental infection in cats with a cagA+ human isolate of Helicobacter pylori. Perkins SE, et al. **Helicobacter** 1998 Dec;3(4):225–35

Relationship of vacA genotypes of Helicobacter pylori to cagA status, cytotoxin production, and clinical outcome. Yamaoka Y, et al. **Helicobacter** 1998 Dec;3(4):241–53

Beneficial effects of Helicobacter pylori eradication on migraine. Gasbarrini A, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):765–70

The role of Helicobacter pylori in primary gastric MALT lymphoma. Bouzourene H, et al. **Histopathology** 1999 Feb; 34(2):118–23

Phase variation in Helicobacter pylori lipopolysaccharide due to changes in the lengths of poly(C) tracts in alpha3-fucosyltransferase genes. Appelmelk BJ, et al. **Infect Immun** 1999 Oct;67(10):5361–6

Identification of virulence genes of Helicobacter pylori by random insertion mutagenesis. Bijlsma JJ, et al. **Infect Immun** 1999 May;67(5):2433–40

Identification of the Helicobacter pylori VacA toxin domain active in the cell cytosol. de Bernard M, et al. **Infect Immun** 1998 Dec;66(12):6014–6

Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression. Jones NL, et al. **Infect Immun** 1999 Aug;67(8):4237–42

Experimental infection of Mongolian gerbils with wild-type and mutant Helicobacter pylori strains. Wirth HP, et al. **Infect Immun** 1998 Oct;66(10):4856–66

New acquisitions in Helicobacter pylori infection. Introduction. Gasbarrini G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S243 (3 ref.)

Gastro-oesophageal reflux and Helicobacter pylori. Pace F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S289–93 (36 ref.)

Helicobacter pylori infection and dyspepsia. Quina MG. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S286–8 (25 ref.)

Natural course of Helicobacter pylori gastric infection. Sipponen P. **Ital J Gastroenterol Hepatol** 1998 Oct;30 Suppl 3:S270–2 (22 ref.)

A virulence factor of Helicobacter pylori: role of heat shock protein in mucosal inflammation after H. pylori infection. Kamiya S, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S35–9

Simple and accurate PCR-based system for typing vacuolating cytotoxin alleles of Helicobacter pylori. Atherton JC, et al. **J Clin Microbiol** 1999 Sep;37(9):2979–82

The significance of cagA and vacA subtypes of Helicobacter pylori in the pathogenesis of inflammation and peptic ulceration. Gunn MC, et al. **J Clin Pathol** 1998 Oct; 51(10):761–4

Toxigenicity of Helicobacter pylori isolates possessing cagA gene and vacuolating cytotoxin. Kodama K, et al. **J Gastroenterol** 1998;33 Suppl 10:14–7

Establishment and characterisation of a monoclonal antibody to inhibit adhesion of Helicobacter pylori to gastric epithelial cells. Osaki T, et al. **J Med Microbiol** 1998 Jun; 47(6):505–12

Induction of secretion of interleukin-8 from human gastric epithelial cells by heat-shock protein 60 homologue of Helicobacter pylori. Yamaguchi H, et al. **J Med Microbiol** 1999 Oct;48(10):927–33

Helicobacter pylori infection in a large company [letter; comment] Ziem G. **J Occup Environ Med** 1999 Jun; 41(6):415–6. Comment on: J Occup Environ Med 1998 Jul;40(7):586–94.

Detection of Helicobacter pylori in oral aphthous ulcers. Birek C, et al. **J Oral Pathol Med** 1999 May;28(5):197–203

Animal models of Helicobacter infection. Dubois A. **Lab Anim Sci** 1998 Dec;48(6):596–603 (0 ref.)

Experimentally induced infection with Helicobacter pylori in squirrel monkeys (Saimiri spp.): clinical, microbiological, and histopathologic findings. Stadtländer CT, et al. **Lab Anim Sci** 1998 Jun;48(3):303–9

Virulence factors of Helicobacter pylori: implications for vaccine development. Suerbaum S, et al. **Mol Med Today** 1999 Jan;5(1):32–9 (54 ref.)

Essential role of Helicobacter pylori gamma-glutamyltranspeptidase for the colonization of the gastric mucosa of mice. Chevalier C, et al. **Mol Microbiol** 1999 Mar;31(5):1359–72

Helicobacter pylori with separate beta- and beta'-subunits of RNA polymerase is viable and can colonize conventional mice. Raudonikiene A, et al. **Mol Microbiol** 1999 Apr; 32(1):131–8

Dynamics of Helicobacter pylori colonization in relation to the host response. Blaser MJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8359–64

Extracts of Helicobacter pylori reduce gastric mucosal blood flow through a VacA- and CagA-independent pathway in rats. Atuma C, et al. **Scand J Gastroenterol** 1998 Dec; 33(12):1256–61

Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins. Kim JS, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1249–55

Infection with Helicobacter pylori expressing the cagA gene is not associated with an increased risk of developing peptic ulcer diseases in Korean patients. Park SM, et al. **Scand J Gastroenterol** 1998 Sep;33(9):923–7

Helicobacter pylori virulence and genetic geography. Covacci A, et al. **Science** 1999 May 21;284(5418):1328–33 (57 ref.)

Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Ota H, et al. **Virchows Arch** 1998 Nov;433(5):419–26

Pathobiology of Helicobacter pylori infection. Cave DR, et al. **Yale J Biol Med** 1998 Mar–Apr;71(2):43–51 (55 ref.)

Structure, function and localization of Helicobacter pylori urease. Dunn BE, et al. **Yale J Biol Med** 1998 Mar–Apr; 71(2):63–73 (67 ref.)

Helicobacter pylori and apoptosis. Moss SF. **Yale J Biol Med** 1998 Mar–Apr;71(2):53–61 (32 ref.)

Helicobacter pylori induces apoptosis in mucosal lymphocytes in patients with gastritis. Reinacher-Schick A, et al. **Z Gastroenterol** 1998 Dec;36(12):1021–6

[Pathophysiology of Helicobacter pylori infections] van der Ende A, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20; 143(8):392–5 (31 ref.) (Eng. Abstr.) **(Dut)**

[Gastric malt lymphoma and Helicobacter pylori infection] Eddine MN. **Tunis Med** 1998 Aug–Sep;76(8–9):222–8 **(Fre)**

[Helicobacter pylori and headache (editorial)] Marko P. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31–32):1261–2 **(Ger)**

[Eradication of Helicobacter pylori: utopia or reality? (editorial)] Stella S. G **Chir** 1998 Nov–Dec; 19(11–12):429–32 **(Ita)**

[High prevalence of VacA, CagA protein expression and presence of cag pathogenicity island in Japanese Helicobacter pylori isolates] Omata M, et al. **Nippon Rinsho** 1999 Jan;57(1):17–22 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori as a new paradigm in the pathogenesis of upper GI diseases] Sugiyama T, et al. **Nippon Rinsho** 1999 Jan;57(1):5–10 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The affect of Helicobacter pylori and bile acids as the pathogenesis of gastritis of the remnant stomach after distal partial gastrectomy] Akiyama H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):137–41 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases. Annibale B, et al. **Aliment Pharmacol Ther** 1998 Aug; 12(8):779–88

Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Chan FK, et al. **Aliment Pharmacol Ther** 1998 Dec;12(12):1201–5

Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Hawkey CJ. **Aliment Pharmacol Ther** 1999 Jun; 13(6):695–702 (62 ref.)

The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. van Herwaarden MA, et al. **Aliment Pharmacol Ther** 1999 Jun; 13(6):731–40

Effects of Helicobacter pylori on proliferation of gastric epithelial cells in vitro. Smoot DT, et al. **Am J Gastroenterol** 1999 Jun;94(6):1508–11

Helicobacter pylori inhibits the G1 to S transition in AGS gastric epithelial cells. Shirin H, et al. **Cancer Res** 1999 May 15;59(10):2277–81

Influence of Helicobacter pylori on gastric secretion and gastrin release in normal Chinese subjects. Tseng GY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr; 62(4):217–22

Bovine milk inhibits both adhesion of Helicobacter pylori to sulfatide and Helicobacter pylori-induced vacuolation of vero cells. Hata Y, et al. **Dig Dis Sci** 1999 Aug; 44(8):1696–702

Lack of correlation between vacuolating cytotoxin activity, cagA gene in Helicobacter pylori, and peptic ulcer disease in children. Loeb M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Sep;17(9):653–6

Phenotypic changes of Helicobacter pylori components during an experimental infection in mice. Janvier B, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):27–33

Effect on cell surface hydrophobicity and susceptibility of Helicobacter pylori to medicinal plant extracts. Annuk H, et al. **FEMS Microbiol Lett** 1999 Mar 1;172(1):41–5

Helicobacter pylori-associated gastric pro- and antioxidant formation in Mongolian gerbils. Suzuki H, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):679–84

Rebound hypersecretion after omeprazole [letter; comment] Friedel DM, et al. **Gastroenterology** 1999 Aug;117(2):513–4 . Comment on: Gastroenterology 1999 Feb;116(2):239–47.

Antibiotic resistance in Helicobacter pylori: implications for therapy. Graham DY. **Gastroenterology** 1998 Nov; 115(5):1272–7 (36 ref.)

Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Mégraud F. **Gastroenterology** 1998 Nov;115(5):1278–82 (33 ref.)

Signal transduction-mediated adherence and entry of Helicobacter pylori into cultured cells. Su B, et al. **Gastroenterology** 1999 Sep;117(3):595–604

Fingerprinting of large oligosaccharides linked to ceramide by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: highly heterogeneous polyglycosylceramides of human erythrocytes with receptor activity for Helicobacter pylori. Karlsson H, et al. **Glycobiology** 1999 Aug;9(8):765–78

Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer. Kohda K, et al. **Gut** 1999 Apr;44(4):456–62

Helicobacter pylori induced apoptosis. Shirin H, et al. **Gut** 1998 Nov;43(5):592–4 (34 ref.)

Urease plays an important role in the chemotactic motility of Helicobacter pylori in a viscous environment. Nakamura H, et al. **Infect Immun** 1998 Oct;66(10):4832–7

Motility of Helicobacter pylori is coordinately regulated by the transcriptional activator FlgR, an NtrC homolog. Spohn G, et al. **J Bacteriol** 1999 Jan;181(2):593–9

Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. Romano M, et al. **J Biol Chem** 1998 Oct 30;273(44):28560–3

Sulphomucins favour adhesion of Helicobacter pylori to metaplastic gastric mucosa. Bravo JC, et al. **J Clin Pathol** 1999 Feb;52(2):137–40

Characteristics of Helicobacter pylori strains isolated from patients with different gastric diseases. Kurihara N, et al. **J Gastroenterol** 1998;33 Suppl 10:10–3

Helicobacter pylori infection affects gastric ulcer healing in Japanese monkeys. Okui M, et al. **J Gastroenterol** 1998;33 Suppl 10:26–30

Relationship between expression of HSP60, urease activity, production of vacuolating toxin, and adherence activity of Helicobacter pylori. Yamaguchi H, et al. **J Gastroenterol** 1998;33 Suppl 10:6–9

Chemotaxis of Helicobacter pylori: a urease-independent response. Yoshiyama H, et al. **J Gastroenterol** 1998;33 Suppl 10:1–5

Type I Helicobacter pylori shows Lewis(b)-independent adherence to gastric cells requiring de novo protein synthesis in both host and bacteria. Su B, et al. **J Infect Dis** 1998 Nov;178(5):1379–90

Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue. Odenbreit S, et al. **Mol Microbiol** 1999 Mar;31(5):1537–48

Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori. Peck B, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):3325–33

The vacuolating toxin from Helicobacter pylori forms hexameric pores in lipid bilayers at low pH. Czajkowsky DM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2001–6

Does NADH play a central role in energy metabolism in Helicobacter pylori? Finel M. **Trends Biochem Sci** 1998 Nov;23(11):412–3 (19 ref.)

Adherence of Helicobacter pylori to areas of type II intestinal metaplasia in Korean gastric mucosa. Jang TJ, et al. **Yonsei Med J** 1999 Aug;40(4):392–5

Adhesion of Helicobacter pylori to yeast cells. Ansorg R, et al. **Zentralbl Bakteriol** 1998 Dec;288(4):501–8

Haemolytic activity of Helicobacter pylori against human and animal erythrocytes. von Recklinghausen U, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):207–15

[The concept of the relationship between the human body and Helicobacter pylori] Tsimmerman IaS, et al. **Klin Med (Mosk)** 1999;77(2):52–6 (20 ref.) **(Rus)**

ULTRASTRUCTURE

Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. Stratton CW, et al. **J Antimicrob Chemother** 1999 May;43(5):659–66

Changes in the evolution of the antigenic profiles and morphology during coccoid conversion of Helicobacter pylori. Roe IH, et al. **Korean J Intern Med** 1999 Jan; 14(1):9–14

HELICOPTER AMBULANCES see **AIR AMBULANCES**

HELICOPTERS see **AIRCRAFT**

HELIGMOSOMOIDES POLYGYRUS see **NEMATOSPIROIDES DUBIUS**

HELIOTHERAPY

Increased levels of enkephalin following natural sunlight

(combined with salt water bathing at the Dead Sea) and ultraviolet A irradiation. Nissen JB, et al. **Br J Dermatol** 1998 Dec;139(6):1012–9

High mountain climatotherapy. Tsankov NK. **Clin Dermatol** 1998 Nov–Dec;16(6):699–707 (38 ref.)

Why do mothers still sun their infants? Harrison SL, et al. **J Paediatr Child Health** 1999 Jun;35(3):296–9

["Ozone holes"--ultraviolet radiation--heliotherapy] Slutskaia GF, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep–Oct;(5):50–1 (19 ref.) **(Rus)**

ADVERSE EFFECTS

Are we really dying for a tan? Ness AR, et al. **BMJ** 1999 Jul 10;319(7202):114–6

Beach holiday sunburn: the sunscreen paradox and gender differences. McCarthy EM, et al. **Cutis** 1999 Jul;64(1):37–42

Sunbathing and sunbed use related to self-image in a randomized sample of Swedish adolescents. Brandberg Y, et al. **Eur J Cancer Prev** 1998 Aug;7(4):321–9

Acceptance by Swedish users of a multimedia program for primary and secondary prevention of malignant melanoma. Lindholm LH, et al. **J Cancer Educ** 1998 Winter; 13(4):207–12

Phenotypic markers, sunlight-related factors and sunscreen use in patients with cutaneous melanoma: an Austrian case-control study. Wolf P, et al. **Melanoma Res** 1998 Aug; 8(4):370–8

PSYCHOLOGY

Sun-safety behavior among elementary school children: the role of knowledge, social norms, and parental involvement. Donavan DT, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):831–6

UTILIZATION

A population-based survey on the use of artificial tanning devices in the Province of Québec, Canada. Rhainds M, et al. **J Am Acad Dermatol** 1999 Apr;40(4):572–6

HELIOTROPE see **VALERIAN**

HELIOTROPISM see **PHOTOTROPISM**

HELIUM

Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Tassaux D, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):22–32

Use of heliox-driven nebulizer therapy in the treatment of acute asthma. Henderson SO, et al. **Ann Emerg Med** 1999 Feb;33(2):141–6

Experiment of nitrox saturation diving with trimix excursion. Shi ZY. **Appl Human Sci** 1998 Nov;17(6):249–52

Evoked potentials and decompression [letter; comment] Hamilton RW. **Aviat Space Environ Med** 1999 Feb; 70(2):193. Comment on: Aviat Space Environ Med 1998 Jun;69(6):545–50.

Evaluation of heliox saturated diving on the basis of selected haemostatic parameters. Olszański R. **Bull Inst Marit Trop Med Gdynia** 1998;49(1–4):117–21

The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Hess DR, et al. **Chest** 1999 Jan;115(1):184–9

The impact of laparoscopy with carbon dioxide versus helium on immunologic function and tumor growth in a rat model. Jacobi CA, et al. **Dig Surg** 1998;15(2):110–6

Impact of laparoscopy with carbon dioxide versus helium on local and systemic inflammation in an animal model of peritonitis. Jacobi CA, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):305–12

NMR imaging of thermally polarized helium-3 gas. Kober F, et al. **J Magn Reson** 1999 Jun;138(2):308–12

Effect of helium-oxygen on delivery of albuterol in a pediatric, volume-cycled, ventilated lung model. Habib DM, et al. **Pharmacotherapy** 1999 Feb;19(2):143–9

ADMINISTRATION & DOSAGE

In vitro inhibition of tumour growth in a helium-rich environment: implications for laparoscopic surgery. Neuhaus SJ, et al. **Aust N Z J Surg** 1999 Jan;69(1):52–5

Evaluation of a Pitot type spirometer in helium/oxygen mixtures. Søndergaard S, et al. **J Clin Monit Comput** 1998 Aug;14(6):425–31

High-frequency jet ventilation using a helium-oxygen mixture. Tobias JD, et al. **Paediatr Anaesth** 1999;9(5):451–5

Effects of respiratory gas composition on transthoracic impedance. Deakin CD, et al. **Resuscitation** 1998 Sep; 38(3):193–5

ADVERSE EFFECTS

Helium vapour injury: a case report. Kumar P, et al. **Burns** 1999 May;25(3):265–8

DIAGNOSTIC USE

Effect of nitric oxide, perfluorocarbon, and heliox on minute volume measurement and ventilator volumes delivered. Devabhaktuni VG, et al. **Crit Care Med** 1999 Aug; 27(8):1603–7

Low-temperature polarized helium-3 for MRI applications. Kober F, et al. **Magn Reson Med** 1999 Jun;41(6):1084–7

Functional MR microscopy of the lung using hyperpolarized 3He. Viallon M, et al. **Magn Reson Med** 1999 Apr; 41(4):787–92

Lung air spaces: MR imaging evaluation with hyperpolarized 3He gas. de Lange EE, et al. **Radiology** 1999 Mar; 210(3):851–7

Cystic fibrosis: combined hyperpolarized 3He–enhanced and conventional proton MR imaging in the lung--preliminary observations. Donnelly LF, et al. **Radiology** 1999 Sep; 212(3):885–9

[Magnetic resonance tomography with inhalation of polarized noble gases: new perspectives in functional imaging diagnosis of emphysema] Kauczor HU, et al. **Pneumologie** 1998 Oct;52(10):563–7 (22 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Intrapulmonary gas mixing and the sloping alveolar plateau in COPD patients with macroscopic emphysema. Wilschut FA, et al. **Eur Respir J** 1999 Jul;14(1):166–71

PHARMACOKINETICS

Exchange rates of gases across the tympanic membrane in rhesus monkeys. Doyle WJ, et al. **Acta Otolaryngol (Stockh)** 1998 Jul;118(4):567–73

PHARMACOLOGY

Helium and sulfur hexafluoride bolus washin in short-term microgravity. Dutrieue B, et al. **J Appl Physiol** 1999 May; 86(5):1594–602

Relationship between T-wave amplitude and oxygen pulse in guinea pigs in hyperbaric helium and hydrogen. Kayar SR, et al. **J Appl Physiol** 1998 Sep;85(3):798–806

Analgesia in selectively bred mice exposed to cold in helium/oxygen atmosphere. Sadowski B, et al. **Physiol Behav** 1999 Mar;66(1):145–51

THERAPEUTIC USE

The effect of heliox on croup: a pilot study. Terregino CA, et al. **Acad Emerg Med** 1998 Nov;5(11):1130–3

Ventilatory and cardiovascular responses to inspired He–O2 during exercise in chronic obstructive pulmonary disease. Oelberg DA, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1876–82

Does heliox decrease the need for intubation in acute bronchiolitis? [editorial; comment] Barnes SD. **Crit Care Med** 1998 Oct;26(10):1633–5 (18 ref.). Comment on: Crit Care Med 1998 Oct;26(10):1731–6.

Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis [see comments] Hollman G, et al. **Crit Care Med** 1998 Oct;26(10):1731–6. Comment in: Crit Care Med 1998 Oct;26(10):1633–5.

Re: Viscosity of helium [letter] Smith SW. **J Emerg Med** 1999 Jul–Aug;17(4):745

HELIX (SNAILS)

[The bronchorelaxant effect of helicidine, a Helix pomatia extract, interferes with prostaglandin E2] Pons F, et al. **Pathol Biol (Paris)** 1999 Jan;47(1):73–80 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Topographic organization of serotonergic and dopaminergic neurons in the cerebral ganglia and their peripheral projection patterns in the head areas of the snail Helix pomatia. Hernádi L, et al. **J Comp Neurol** 1999 Aug 23; 411(2):274–87

DRUG EFFECTS

[The action of the neurotoxins 5,6-dihydroxytryptamine and p-chlorophenylalanine on the electrical activity parameters of the command neurons during long-term sensitization and learning in the snail] Gainutdinov KhL, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):48–58 (Eng. Abstr.) **(Rus)**

[The modulating action of serotonin on single calcium channels in the neurons of the snail Helix pomatia] Luk'ianets' OO, et al. **Fiziol Zh** 1998;44(5–6):27–34 (Eng. Abstr.) **(Ukr)**

ENZYMOLOGY

A two-component affinity chromatography purification of Helix pomatia arylsulfatase by tyrosine vanadate. Skorey KI, et al. **Protein Expr Purif** 1999 Mar;15(2):178–87

METABOLISM

[Mathematical model of the dual action of G protein on the Ca2+ current in identified neurons of the snail Helix aspersa] Pastor-Gómez J. **Rev Neurol** 1999 Apr 16–30; 28(8):745–51 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Intracellular Mg2+ regulation in voltage-clamped Helix aspersa neurones measured with mag-fura-2 and Mg(2+)-sensitive microelectrodes. Kennedy HJ. **Exp Physiol** 1998 Jul;83(4):449–60

Nitric oxide-containing neurons in the nervous ganglia of Helix aspersa during rest and activity: immunocytochemical and enzyme histochemical detection. Pisu MB, et al. **J Comp Neurol** 1999 Jun 28;409(2):274–84

Two modulatory inputs exert reciprocal reinforcing effects on synaptic input of premotor interneurons for withdrawal in terrestrial snails. Maksimova OA, et al. **Learn Mem** 1999 Mar–Apr;6(2):168–76

Effects of serotonin levels on postsynaptically induced potentiation of snail neuron responses. Malyshev AYu, et al. **Neurosci Behav Physiol** 1998 Sep–Oct;28(5):556–63

Neuronal mechanisms of site-specific nociceptive sensitization in the common snail. Nikitin VP, et al. **Neurosci Behav Physiol** 1999 Mar–Apr;29(2):167–73

Serotonin imitates several of the neuronal effects of nociceptive sensitization in the common snail. Shevelkin AV, et al. **Neurosci Behav Physiol** 1998 Sep–Oct; 28(5):547–55

Heptanol exerts epileptiform effects in identified neurons of the buccal ganglia of Helix pomatia. Tarner IH, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):73–6

Pharmacological actions of essential (zinc, copper) and toxic metal ions (lead, mercury) on neurons and neuronal synapses of the snail, Helix pomatia L. Erdélyi L, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):565–9

[The activation of the transcription factors of the CRE and AP-1 families correlates with the development of plasticity in Helix] Grinkevich LN, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov–Dec; 48(6):1037–42 (Eng. Abstr.) **(Rus)**

HELIX-LOOP-HELIX MOTIFS

Daily cycle of bHLH-PAS proteins, Ah receptor and Arnt, in multiple tissues of female Sprague-Dawley rats. Richardson VM, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):225–31

Dissection of the de novo designed peptide alpha t alpha: stability and properties of the intact molecule and its constituent helices. Fezoui Y, et al. **Biochemistry** 1999 Mar 2;38(9):2796–804

Characterization of the DNA binding properties of the bHLH domain of Deadpan to single and tandem sites. Winston RL, et al. **Biochemistry** 1999 Apr 20;38(16):5138–46

Strep-tag II for one-step affinity purification of active bHLHzip domain of human c-Myc. Zwicker N, et al. **Biotechniques** 1999 Aug;27(2):368–75

The leukemic oncogene tal-2 is expressed in the developing mouse brain. Mori S, et al. **Brain Res Mol Brain Res** 1999 Feb 5;64(2):199–210

Winged helix hepatocyte nuclear factor 3 and POU-domain protein brn-2/N-oct-3 bind overlapping sites on the neuronal promoter of human aromatic L-amino acid decarboxylase gene. Raynal JF, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):227–37

Expression of the microphthalmia-associated basic helix-loop-helix leucine zipper transcription factor Mi in avian neuroretina cells induces a pigmented phenotype. Planque N, et al. **Cell Growth Differ** 1999 Jul;10(7):525–36

Repetitive use of a phosphate-binding module in DNA polymerase beta, Oct-1 POU domain and phage repressors. Yura K, et al. **Cell Mol Life Sci** 1999 Mar;55(3):472–86

A beta-sheet peptide inhibitor of E47 dimerization and DNA binding. Ghosh I, et al. **Chem Biol** 1998 Aug;5(8):439–45

Evolutionary conservation of MyoD function and differential utilization of E proteins. Zhang JM, et al. **Dev Biol** 1999 Apr 15;208(2):465–72

Alternative splicing and embryonic expression of the Xenopus mad4 bHLH gene. Newman CS, et al. **Dev Dyn** 1999 Jun;215(2):170–8

epicardin: A novel basic helix-loop-helix transcription factor gene expressed in epicardium, branchial arch myoblasts, and mesenchyme of developing lung, gut, kidney, and gonads. Robb L, et al. **Dev Dyn** 1998 Sep;213(1):105–13

Mash1 regulates neurogenesis in the ventral telencephalon. Casarosa S, et al. **Development** 1999 Feb;126(3):525–34

Ectopic expression of individual E(spl) genes has differential effects on different cell fate decisions and underscores the biphasic requirement for notch activity in wing margin establishment in Drosophila. Ligoxygakis P, et al. **Development** 1999 May;126(10):2205–14

Early specification of sensory neuron fate revealed by expression and function of neurogenins in the chick embryo. Perez SE, et al. **Development** 1999 Apr; 126(8):1715–28

Transcription factors Mash-1 and Prox-1 delineate early steps in differentiation of neural stem cells in the developing central nervous system. Torii Ma, et al. **Development** 1999 Feb;126(3):443–56

A class of neuroD-related basic helix-loop-helix transcription factors expressed in developing central nervous system in zebrafish. Liao J, et al. **DNA Cell Biol** 1999 Apr;18(4):333–44

Id helix-loop-helix proteins inhibit nucleoprotein complex formation by the TCF ETS-domain transcription factors. Yates PR, et al. **EMBO J** 1999 Feb 15;18(4):968–76

A distal regulatory region of the insulin-like growth factor binding protein-2 (IGFBP-2) gene interacts with the basic helix-loop-helix transcription factor, AP-4. Badinga L, et al. **Endocrine** 1998 Jun;8(3):281–9

Mutations within or upstream of the basic helix-loop-helix domain of the TWIST gene are specific to Saethre-Chotzen syndrome. El Ghouzzi V, et al. **Eur J Hum Genet** 1999

Jan;7(1):27-33
Id4 expression induces apoptosis in astrocytic cultures and is down-regulated by activation of the cAMP-dependent signal transduction pathway. Andres-Barquin PJ, et al. **Exp Cell Res** 1999 Mar 15;247(2):347-55
The helix-loop-helix transcription factors Id1 and Id3 have a functional role in control of cell division in human normal and neoplastic chondrocytes. Asp J, et al. **FEBS Lett** 1998 Oct 30;438(1-2):85-90
Negative cooperativity between juxtaposed E-box and cAMP/TPA responsive elements in the cholecystokinin gene promoter. Rourke IJ, et al. **FEBS Lett** 1999 Apr 1; 448(1):15-8
Site-selective control of the reactivity of surface-exposed histidine residues in designed four-helix-bundle catalysts. Broo KS, et al. **Fold Des** 1998;3(4):303-12
The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas. Krapp A, et al. **Genes Dev** 1998 Dec 1;12(23):3752-63
Molecular consequences of Ds insertion into and excision from the helix-loop-helix domain of the maize R gene. Liu Y, et al. **Genetics** 1998 Dec;150(4):1639-48
Human bHLH transcription factor gene myogenin (MYOG): genomic sequence and negative mutation analysis in patients with severe congenital myopathies. Tseng BS, et al. **Genomics** 1999 May 1;57(3):419-23
The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction. Kraichely DM, et al. **J Biol Chem** 1999 May 14;274(20):14352-8
Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. Ribeiro A, et al. **J Biol Chem** 1999 Jan 15;274(3):1216-25
Altered expression levels of SEF-2 and p112 in the rat hippocampus after transient cerebral ischemia: identification by mRNA differential display. Wigle D, et al. **J Cereb Blood Flow Metab** 1999 Apr;19(4):435-42
Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. Hayek B, et al. **J Immunol** 1998 Dec 15; 161(12):7031-9
Regulation of hippocampal neuronal differentiation by the basic helix-loop-helix transcription factors HES-1 and MASH-1. Castella P, et al. **J Neurosci Res** 1999 May 1; 56(3):229-40
Expression of the bHLH gene NSCL-1 suggests a role in regulating cerebellar granule cell growth and differentiation. Uittenbogaard M, et al. **J Neurosci Res** 1999 Sep 15;57(6):770-81
Hey genes: a novel subfamily of hairy- and Enhancer of split related genes specifically expressed during mouse embryogenesis. Leimeister C, et al. **Mech Dev** 1999 Jul; 85(1-2):173-7
Circadian regulation of a Drosophila homolog of the mammalian Clock gene: PER and TIM function as positive regulators. Bae K, et al. **Mol Cell Biol** 1998 Oct; 18(10):6142-51
Myogenic basic helix-loop-helix proteins and Sp1 interact as components of a multiprotein transcriptional complex required for activity of the human cardiac alpha-actin promoter. Biesiada E, et al. **Mol Cell Biol** 1999 Apr; 19(4):2577-84
Upstream stimulatory factor regulates major histocompatibility complex class I gene expression: the U2DeltaE4 splice variant abrogates E-box activity. Howcroft TK, et al. **Mol Cell Biol** 1999 Jul;19(7):4788-97
Target specificities of Drosophila enhancer of split basic helix-loop-helix proteins. Jennings BH, et al. **Mol Cell Biol** 1999 Jul;19(7):4600-10
Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein Arnt. Lees MJ, et al. **Mol Cell Biol** 1999 Aug;19(8):5811-22
Requirements for chromatin modulation and transcription activation by the Pho4 acidic activation domain. McAndrew PC, et al. **Mol Cell Biol** 1998 Oct; 18(10):5818-27
The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. Sharma A, et al. **Mol Cell Biol** 1999 Jan;19(1):704-13
Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins. Tian G, et al. **Mol Cell Biol** 1999 Apr;19(4):2946-57
Basic helix-loop-helix proteins can act at the E-box within the serum response element of the c-fos promoter to influence hormone-induced promoter activation in Sertoli cells. Chaudhary J, et al. **Mol Endocrinol** 1999 May; 13(5):774-86
Upstream stimulatory factors mediate estrogen receptor activation of the cathepsin D promoter. Xing W, et al. **Mol Endocrinol** 1998 Sep;12(9):1310-21
Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Yokota Y, et al. **Nature** 1999 Feb 25;397(6721):702-6
Identification of a novel transcriptional activity of mammalian Id proteins. Bounpheng MA, et al. **Nucleic Acids Res** 1999 Apr 1;27(7):1740-6
Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Ferrier R, et al. **Oncogene** 1999 Jan 28;18(4):995-1005
The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Lüscher B, et al. **Oncogene** 1999 May 13;18(19):2955-66 (110 ref.)
A bHLH transcription factor mediates organ, region and flower type specific signals on dihydroflavonol-4-reductase (dfr) gene expression in the inflorescence of Gerbera hybrida (Asteraceae). Elomaa P, et al. **Plant J** 1998 Oct;16(1):93-9
Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Alani RM, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9637-41
poc1: an Arabidopsis mutant perturbed in phytochrome signaling because of a T DNA insertion in the promoter of PIF3, a gene encoding a phytochrome-interacting bHLH protein. Halliday KJ, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5832-7
[Structure/function of EF-hand proteins: the molecular switch for intracellular Ca2+ signaling] Taoka M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1640-51 (55 ref.) **(Jpn)**

GENETICS

Phosphorylation and spatiotemporal distribution of KW8 (NDRF/NeuroD2), a NeuroD family basic helix-loop-helix protein. Kume H, et al. **Brain Res Mol Brain Res** 1998 Sep 18;60(1):107-14
Structure and regulation of the human NeuroD (BETA2/BHF1) gene. Miyachi T, et al. **Brain Res Mol Brain Res** 1999 Jun 8;69(2):223-31
Overexpression of NeuroD in PC12 cells alters morphology and enhances expression of the adenylate kinase isozyme 1 gene. Noma T, et al. **Brain Res Mol Brain Res** 1999 Apr 6;67(1):53-63
Id gene expression as a key mediator of tumor cell biology. Israel MA, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1726s-1730s
The roles of intrinsic and extrinsic cues and bHLH genes in the determination of retinal cell fates. Cepko CL. **Curr Opin Neurobiol** 1999 Feb;9(1):37-46 (55 ref.)
Cloning of TCFL5 encoding a novel human basic helix-loop-helix motif protein that is specifically expressed in primary spermatocytes at the pachytene stage. Maruyama O, et al. **Cytogenet Cell Genet** 1998;82(1-2):41-5
Expression of zebrafish bHLH genes ngn1 and nrd defines distinct stages of neural differentiation. Korzh V, et al. **Dev Dyn** 1998 Sep;213(1):92-104
Misexpression of a bHLH gene, cNSCL1, results in abnormal brain development. Li CM, et al. **Dev Dyn** 1999 Jul; 215(3):238-47
Distinct expression patterns of different enhancer of split bHLH genes during embryogenesis of Drosophila melanogaster. Wech I, et al. **Dev Genes Evol** 1999 Jun; 209(6):370-5
Sequence and expression analysis of Nhlh1: a basic helix-loop-helix gene implicated in neurogenesis. Murdoch JN, et al. **Dev Genet** 1999;24(1-2):165-77
No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France. Dupont S, et al. **Diabetologia** 1999 Apr;42(4):480-4
Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Prochownik EV, et al. **Genes Chromosomes Cancer** 1998 Aug;22(4):295-304
The bHLH gene Hes1 is essential for expansion of early T cell precursors. Tomita K, et al. **Genes Dev** 1999 May 1; 13(9):1203-10
Cloning and characterization of the murine genes for bHLH-ZIP transcription factors TFEC and TFEB reveal a common gene organization for all MiT subfamily members. Rehli M, et al. **Genomics** 1999 Feb 15; 56(1):111-20
Id1, Id2, and Id3 gene expression in neural cells during development. Tzeng SF, et al. **Glia** 1998 Dec;24(4):372-81
Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism. Tanaka K, et al. **J Biol Chem** 1998 Oct 2;273(40):25922-8
Positional dependence, cliques, and predictive motifs in the bHLH protein domain. Atchley WR, et al. **J Mol Evol** 1999 May;48(5):501-16
Isolation, expression and regulation of a zebrafish paraxis homologue. Shanmugalingam S, et al. **Mech Dev** 1998 Nov; 78(1-2):85-9
A conserved motif present in a class of helix-loop-helix proteins activates transcription by direct recruitment of the SAGA complex. Massari ME, et al. **Mol Cell** 1999 Jul; 4(1):63-73
Targeting the microphthalmia basic helix-loop-helix-leucine zipper transcription factor to a subset of E-box elements in vitro and in vivo. Aksan I, et al. **Mol Cell Biol** 1998 Dec;18(12):6930-8
Is the genetic basis of DiGeorge syndrome in HAND? [news] Baldini A. **Nat Genet** 1999 Mar;21(3):246-7
Expression of basic helix-loop-helix/PAS genes in the mouse suprachiasmatic nucleus. Shearman LP, et al. **Neuroscience** 1999 Mar;89(2):387-97
MyoR: a muscle-restricted basic helix-loop-helix transcription factor that antagonizes the actions of MyoD. Lu J, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19; 96(2):552-7
HAND proteins: molecular mediators of cardiac development and congenital heart disease. Srivastava D. **Trends Cardiovasc Med** 1999 Jan-Feb;9(1-2):11-8 (42 ref.)

IMMUNOLOGY

Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. O'Riordan M, et al. **Immunity** 1999 Jul;11(1):21-31
Positive and negative regulation of V(D)J recombination by the E2A proteins. Bain G, et al. **J Exp Med** 1999 Jan 18; 189(2):289-300

PHYSIOLOGY

Differential activation of the SMalphaA promoter in smooth vs. skeletal muscle cells by bHLH factors. Johnson AD, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1420-31
Expression of the basic helix-loop-helix protein REBalpha in rat testicular Sertoli cells. Chaudhary J, et al. **Biol Reprod** 1999 May;60(5):1244-50
PIF3, a phytochrome-interacting factor necessary for normal photoinduced signal transduction, is a novel basic helix-loop-helix protein. Ni M, et al. **Cell** 1998 Nov 25; 95(5):657-67
Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro. Näär AM, et al. **Genes Dev** 1998 Oct 1; 12(19):3020-31
Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRalphadelta enhancers. Bernard M, et al. **Int Immunol** 1998 Oct;10(10):1539-49
Identification of DERMO-1 as a member of helix-loop-helix type transcription factors expressed in osteoblastic cells. Tamura M, et al. **J Cell Biochem** 1999 Feb 1;72(2):167-76
PAS domains: internal sensors of oxygen, redox potential, and light. Taylor BL, et al. **Microbiol Mol Biol Rev** 1999 Jun;63(2):479-506 (269 ref.)
Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Chervinsky DS, et al. **Mol Cell Biol** 1999 Jul;19(7):5025-35
PER and TIM inhibit the DNA binding activity of a Drosophila CLOCK-CYC/dBMAL1 heterodimer without disrupting formation of the heterodimer: a basis for circadian transcription. Lee C, et al. **Mol Cell Biol** 1999 Aug;19(8):5316-25

HELIX (SNAILS)

ANATOMY & HISTOLOGY

Morphological and electrophysiological features of F76 and D1 neurones of the sub-oesophageal ganglia of Helix aspersa in vitro and in culture. Janahmadi M, et al. **Anat Embryol (Berl)** 1999 Jun;199(6):563-72

HELIX-TURN-HELIX MOTIFS

Tetracycline-chelated Mg2+ ion initiates helix unwinding in Tet repressor induction. Orth P, et al. **Biochemistry** 1999 Jan 5;38(1):191-8
Modeling helix-turn-helix protein-induced DNA bending with knowledge-based distance restraints. Tzou WS, et al. **Biophys J** 1999 Sep;77(3):1191-205
Dynamic DNA contacts observed in the NMR structure of winged helix protein-DNA complex. Jin C, et al. **J Mol Biol** 1999 Jun 18;289(4):683-90
Pogo transposase contains a putative helix-turn-helix DNA binding domain that recognises a 12 bp sequence within the terminal inverted repeats. Wang H, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):455-61

GENETICS

Towards functional characterisation of the members of the R2R3-MYB gene family from Arabidopsis thaliana. Kranz HD, et al. **Plant J** 1998 Oct;16(2):263-76

PHYSIOLOGY

A new use for the 'wing' of the 'winged' helix-turn-helix motif in the HSF-DNA cocrystal. Littlefield O, et al. **Nat Struct Biol** 1999 May;6(5):464-70

HELLP SYNDROME

They should have reviewed the obstetric literature [letter] Goodlin RC. **Am J Obstet Gynecol** 1999 Jul;181(1):230-1
HELLP syndrome. Egerman RS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):381-9 (37 ref.)
Persistant pre-eclampsia post partum with elevated liver enzymes and hemolytic uremic syndrome. Mahalati K, et al. **J Clin Apheresis** 1999;14(2):69-78
[The HELLP syndrome] Váchová D, et al. **Cas Lek Cesk** 1998 Nov 16;137(22):675-8 (29 ref.) (Eng. Abstr.) **(Cze)**
[HELLP syndrome is a life-threatening pregnancy complication. A specific coagulation factor therapy is now possible] Zetterberg E, et al. **Lakartidningen** 1999 Mar 3; 96(9):1025-30 **(Swe)**

BLOOD

Plasma endothelin and big endothelin levels in women with severe preeclampsia or HELLP-syndrome. Bussen S, et

al. **Arch Gynecol Obstet** 1999;262(3–4):113–9

Association of a decrease in antithrombin III activity with a perinatal elevation in aspartate aminotransferase in women with twin pregnancies: relevance to the HELLP syndrome. Minakami H, et al. **J Hepatol** 1999 Apr; 30(4):603–11

Triplet pregnancy complicated by a gradual decline in antithrombin-III activity and HELLP syndrome: a case report. Izumi A, et al. **J Obstet Gynaecol Res** 1998 Aug; 24(4):275–9

Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Knapen MF, et al. **Obstet Gynecol** 1998 Dec;92(6):1012–5

CLASSIFICATION

The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Martin JN Jr, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1373–84

COMPLICATIONS

HELLP syndrome with antepartum pulmonary edema--a case report. Chang HC, et al. **Acta Anaesthesiol Sin** 1999 Mar;37(1):41–4

Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Abramovici D, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):221–5

Liver function following pregnancy complicated by the HELLP syndrome. Knapen MF, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1208–10

Acute onset of blindness during labor: report of a case of transient cortical blindness in association with HELLP syndrome. Ebert AD, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):111–3

Massive liver haemorrhage and rupture caused by HELLP-syndrome treated by collagen fleeces coated with fibrin glue. Cerwenka H, et al. **Eur J Surg** 1998 Sep; 164(9):709–11

Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323–8 (37 ref.)

Liver rupture postpartum associated with preeclampsia and HELLP syndrome. Risseeuw JJ, et al. **J Matern Fetal Med** 1999 Jan–Feb;8(1):32–5

Prognosis of children born to mothers with HELLP-syndrome. Kändler C, et al. **J Perinat Med** 1998; 26(6):486–90

HELLP syndrome [letter; comment] Buist NR, et al. **JAMA** 1999 Feb 24;281(8):704–5. Comment on: JAMA 1998 Aug 12;280(6):559–62.

Dexamethasone-facilitated postponement of delivery of an extremely preterm pregnancy complicated by the syndrome of hemolysis, elevated liver enzymes, and low platelets. O'Boyle JD, et al. **Mil Med** 1999 Apr;164(4):316–8

Acute pancreatitis and deep vein thrombosis associated with HELLP syndrome. Paternoster DM, et al. **Minerva Ginecol** 1999 Jan–Feb;51(1–2):31–3

Postpartum renal failure: a complex case with probable coexistence of hemolysis, elevated liver enzymes, low platelet count, and hemolytic uremic syndrome. Kahra K, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):698–700

[Labor complications of the HELLP syndrome without any predictive factors] Debette M, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):264–7 (Eng. Abstr.) **(Fre)**

[Acute renal insufficiency in HELLP syndrome] Martínez de Ita AL, et al. **Ginecol Obstet Mex** 1998 Nov;66:462–8 (Eng. Abstr.) **(Spa)**

[Brain stem involvement in eclampsia and HELLP syndrome] Gutiérrez-García JM, et al. **Rev Neurol** 1999 Jun 16–30; 28(12):1162–6 (Eng. Abstr.) **(Spa)**

[HELLP syndrome associated with familial protein S deficiency (letter)] Raya Sánchez JM, et al. **Sangre (Barc)** 1999 Feb;44(1):85–6 **(Spa)**

DIAGNOSIS

HELLP syndrome: recognition and perinatal management. Padden MO. **Am Fam Physician** 1999 Sep 1;60(3):829–36, 839 (35 ref.)

31P magnetic resonance spectroscopy of the liver in HELLP syndrome. Magee LA, et al. **Br J Obstet Gynaecol** 1999 Jun;106(6):582–8

A 32-year-old pregnant woman with malaise, headache, nausea, right upper quadrant abdominal pain, and facial swelling. Levine S. **Chest** 1999 Jun;115(6):1729–30

HELLP! A cry for laboratory assistance: a comprehensive review of the HELLP syndrome highlighting the role of the laboratory. Jones SL. **Hematopathol Mol Hematol** 1998; 11(3–4):147–71 (112 ref.)

HELLP syndrome: mechanisms and management. Ellison J, et al. **Hosp Med** 1999 Apr;60(4):243–9 (38 ref.)

HELLP syndrome: undiagnosed in a case of impending rupture of uterus. A case report. Khan-Ghori SN, et al. **Middle East J Anesthesiol** 1998 Oct;14(6):459–67

[Neonatal lupus erythematosus and maternal HELLP syndrome: is there a pathogenetic link?] Freyschmidt-Paul P, et al. **Hautarzt** 1998 Aug;49(8):662–5 (Eng. Abstr.) **(Ger)**

[Discordant growth of multiple fetuses in combination of HELLP syndrome and single umbilical artery in a triplet fetus] Fritz K, et al. **Z Geburtshilfe Neonatol** 1998 Nov–Dec;202(6):251–4 (Eng. Abstr.) **(Ger)**

[The HELLP syndrome: a potentially severe complication of pre-eclampsia in the immediate puerperium (letter)] Martínez Díaz de Argandoña C, et al. **Rev Clin Esp** 1999 Apr;199(4):255–6 (10 ref.) **(Spa)**

[HELLP syndrome. Analysis of 2 cases] Rivera A, et al. **Rev Esp Enferm Dig** 1998 Sep;90(9):665–7 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Tompkins MJ, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):304–9

ETIOLOGY

A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. Ibdah JA, et al. **N Engl J Med** 1999 Jun 3;340(22):1723–31

GENETICS

Concordance for pre-eclampsia in monozygous twins. Lachmeijer AM, et al. **Br J Obstet Gynaecol** 1998 Dec; 105(12):1315–7

MORTALITY

Pre-eclampsia and the HELLP syndrome still cause maternal mortality in The Netherlands and other developed countries; can we reduce it? Onrust S, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):41–6

PHYSIOPATHOLOGY

Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Abramovici D, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):221–5

[HELLP syndrome] Emonts P, et al. **Rev Med Liege** 1999 May;54(5):444–7 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

HELLP syndrome [letter; comment] Minakami H, et al. **JAMA** 1999 Feb 24;281(8):703–4; discussion 704–5. Comment on: JAMA 1998 Aug 12;280(6):559–62.

SURGERY

[Anuria after delivery] Mohaupt MG. **Ther Umsch** 1998 Sep; 55(9):579–82 (Eng. Abstr.) **(Ger)**

THERAPY

HELLP syndrome: recognition and perinatal management. Padden MO. **Am Fam Physician** 1999 Sep 1;60(3):829–36, 839 (35 ref.)

Twelve steps to optimal management of HELLP syndrome. Magann EF, et al. **Clin Obstet Gynecol** 1999 Sep; 42(3):532–50 (20 ref.)

Is conservative treatment of HELLP syndrome safe? Tsatsaris V, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):139–41

Continuous renal replacement therapy in patients with HELLP syndrome. Piccinni P, et al. **Minerva Anestesiol** 1999 Jun;65(6):433–6 (38 ref.)

[HELLP syndrome. Case report] Dybkowska K, et al. **Ginekol Pol** 1998 Jul;69(7):607–9 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Imaging of subcapsular hepatic and renal hematomas in pregnancy complicated by preeclampsia and the HELLP syndrome. Chan AD, et al. **J Clin Ultrasound** 1999 Jan; 27(1):35–40 (28 ref.)

HELMETS see **HEAD PROTECTIVE DEVICES**

HELMINTH ANTIBODIES see **ANTIBODIES, HELMINTH**

HELMINTH ANTIGENS see **ANTIGENS, HELMINTH**

HELMINTH DNA see **DNA, HELMINTH**

HELMINTH GENES see **GENES, HELMINTH**

HELMINTH PROTEINS

ANALYSIS

Actin and major sperm protein in spermatozoa of a nematode, Graphidium strigosum (Strongylida: Trichostrongylidae). Mansir A, et al. **Folia Parasitol (Praha)** 1999;46(1):47–51

The primary sex determination signal of Caenorhabditis elegans. Carmi I, et al. **Genetics** 1999 Jul;152(3):999–1015

Immunolocalisation of the glutathione S-transferases, GST-26 and GST-28, within adult Schistosoma japonicum. Gobert GN, et al. **Int J Parasitol** 1998 Sep;28(9):1437–43

An experimental, NADPH-diaphorase histochemical and immunocytochemical study of Mesocestoides vogae tetrathyridia. Terenina NB, et al. **Int J Parasitol** 1999 May; 29(5):787–93

Characterization of MALS/Velis-1, -2, and -3: a family of mammalian LIN-7 homologs enriched at brain synapses in association with the postsynaptic density-95/NMDA receptor postsynaptic complex. Jo K, et al. **J Neurosci** 1999 Jun 1;19(11):4189–99

Preparing 2-D protein extracts from Caenorhabditis elegans. Zwilling R. **Methods Mol Biol** 1999;112:43–8 (6 ref.)

Immunolocalization of schistosome proteins. Gobert GN. **Microsc Res Tech** 1998 Aug 1;42(3):176–85 (70 ref.)

The peroxidoxin 2 protein of the human parasite Onchocerca volvulus: recombinant expression, immunolocalization, and demonstration of homologous molecules in other species. Zipfel PF, et al. **Parasitol Res** 1998 Aug;84(8):623–31

ANTAGONISTS & INHIBITORS

Caenorhabditis elegans EGL-1 disrupts the interaction of CED-9 with CED-4 and promotes CED-3 activation. del Peso L, et al. **J Biol Chem** 1998 Dec 11;273(50):33495–500

MGBG analogues as potent inhibitors of S-adenosylmethionine decarboxylase of Onchocerca volvulus. Da'dara AA, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1–2):13–9

BIOSYNTHESIS

Expression of spliceosome-associated protein 49 is required for early embryogenesis in Caenorhabditis elegans. Fujita M, et al. **Biochem Biophys Res Commun** 1998 Dec 9; 253(1):80–4

CHEMISTRY

Purification and crystallization of a novel membrane-anchored protein: the Schistosoma haematobium serpin. Huang W, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):350–2

Sequence-divergent units of the ABA-1 polyprotein array of the nematode Ascaris suum have similar fatty-acid- and retinol-binding properties but different binding-site environments. Moore J, et al. **Biochem J** 1999 May 15;340 (Pt 1):337–43

The folding and structural integrity of the first LIN-12 module of human Notch1 are calcium-dependent. Aster JC, et al. **Biochemistry** 1999 Apr 13;38(15):4736–42

Ascaridia galli fatty acid-binding protein, a member of the nematode polyprotein allergens family. Timanova A, et al. **Eur J Biochem** 1999 Apr;261(2):569–76

Acanthocheilonema viteae: characterization of a molt-associated excretory/secretory 18-kDa protein. Pogonka T, et al. **Exp Parasitol** 1999 Oct;93(2):73–81

Haemonchus contortus: sequence heterogeneity of internucleotide binding domains from P-glycoproteins. Sangster NC, et al. **Exp Parasitol** 1999 Mar;91(3):250–7

Modelling a 3D structure for EgDf1 from Echinococcus granulosus: putative epitopes, phosphorylation motifs and ligand. Paulino M, et al. **J Comput Aided Mol Des** 1998 Jul;12(4):351–60

Solution structure of the motile major sperm protein (MSP) of Ascaris suum - evidence for two manganese binding sites and the possible role of divalent cations in filament formation. Haaf A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1611–24

Characterization of a hemoglobin-like protein from adult Haemonchus contortus. Fetterer RH, et al. **J Parasitol** 1999 Apr;85(2):295–300

Molecular cloning and characterization of the polypeptide backbone of Schistosoma mansoni circulating cathodic antigen. Abdeen HH, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1–2):149–59

Molecular characterization of a calcium-binding protein from the filarial parasite Dirofilaria immitis. Tsuji N, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1–2):69–79

The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis [see comments] [published erratum appears in Nature 1999 Jul 1;400(6739):89] Imai Y, et al. **Nature** 1999 Apr 29; 398(6730):777–85. Comment in: Nature 1999 Apr 29;398(6730):756–7.

Evidence for functional and physical association between Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. Wu G, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15787–91

Comparison of the complete protein sets of worm and yeast: orthology and divergence. Chervitz SA, et al. **Science** 1998 Dec 11;282(5396):2022–8 (44 ref.)

Zinc fingers in Caenorhabditis elegans: finding families and probing pathways [see comments] Clarke ND, et al. **Science** 1998 Dec 11;282(5396):2018–22 (39 ref.). Comment in: Science 1998 Dec 11;282(5396):1972–4.

DIAGNOSTIC USE

Use of synthetic peptides derived from adult worm proteins of Schistosoma mansoni, in the diagnosis of schistosomiasis. Noya O, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:157–8

Diagnostic glycoproteins of Taenia solium cysts share homologous 14- and 18-kDa subunits. Greene RM, et al. **Mol Biochem Parasitol** 1999 Apr 30;99(2):257–61

HELMINTH PROTEINS

GENETICS

Cloning of the SmSPO-1 gene preferentially expressed in sporocyst during the life cycle of the parasitic helminth Schistosoma mansoni1. Ram D, et al. **Biochim Biophys Acta** 1999 Mar 30;1453(3):412-6

Identity of the F52F12.1 gene product in Caenorhabditis elegans as an organic cation transporter. Wu X, et al. **Biochim Biophys Acta** 1999 Apr 14;1418(1):239-44

The TRA-1A sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene [see comments] Conradt B, et al. **Cell** 1999 Aug 6;98(3):317-27. Comment in: Cell 1999 Aug 6;98(3):277-80.

Control of spindle orientation in Drosophila by the Par-3-related PDZ-domain protein Bazooka. Kuchinke U, et al. **Curr Biol** 1998 Dec 17-31;8(25):1357-65

Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Burdon T, et al. **Dev Biol** 1999 Jun 1;210(1):30-43

Patterning of Caenorhabditis elegans posterior structures by the Abdominal-B homolog, egl-5. Ferreira HB, et al. **Dev Biol** 1999 Mar 1;207(1):215-28

The Caenorhabditis elegans gene ncc-1 encodes a cdc2-related kinase required for M phase in meiotic and mitotic cell divisions, but not for S phase. Boxem M, et al. **Development** 1999 May;126(10):2227-39

egl-27 generates anteroposterior patterns of cell fusion in C. elegans by regulating Hox gene expression and Hox protein function. Ch'ng Q, et al. **Development** 1999 Aug; 126(15):3303-12

COG-2, a sox domain protein necessary for establishing a functional vulval-uterine connection in Caenorhabditis elegans. Hanna-Rose W, et al. **Development** 1999 Jan; 126(1):169-79

EGL-27 is similar to a metastasis-associated factor and controls cell polarity and cell migration in C. elegans. Herman MA, et al. **Development** 1999 Feb;126(5):1055-64

PAR-6 is a conserved PDZ domain-containing protein that colocalizes with PAR-3 in Caenorhabditis elegans embryos. Hung TJ, et al. **Development** 1999 Jan; 126(1):127-35

UNC-84 localizes to the nuclear envelope and is required for nuclear migration and anchoring during C. elegans development. Malone CJ, et al. **Development** 1999 Jun; 126(14):3171-81

A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al. **Development** 1999 Jan;126(1):37-49

Caenorhabditis elegans lin-25: cellular focus, protein expression and requirement for sur-2 during induction of vulval fates. Nilsson L, et al. **Development** 1998 Dec; 125(23):4809-19

The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning. Solari F, et al. **Development** 1999 Jun; 126(11):2483-94

her1, a zebrafish pair-rule like gene, acts downstream of notch signalling to control somite development. Takke C, et al. **Development** 1999 Jul;126(13):3005-14

The C. elegans gene lin-36 acts cell autonomously in the lin-35 Rb pathway. Thomas JH, et al. **Development** 1999 Aug;126(15):3449-59

CLK-1 controls respiration, behavior and aging in the nematode Caenorhabditis elegans. Felkai S, et al. **EMBO J** 1999 Apr 1;18(7):1783-92

Repression by the 3' UTR of fem-3, a sex-determining gene, relies on a ubiquitous mog-dependent control in Caenorhabditis elegans. Gallegos M, et al. **EMBO J** 1998 Nov 2;17(21):6337-47

The STAR protein, GLD-1, is a translational regulator of sexual identity in Caenorhabditis elegans. Jan E, et al. **EMBO J** 1999 Jan 4;18(1):258-69

Functional identification of a fatty acid delta5 desaturase gene from Caenorhabditis elegans. Michaelson LV, et al. **FEBS Lett** 1998 Nov 20;439(3):215-8

Characterization of cDNAs encoding a new family of tetraspanins from schistosomes--the Sj25 family. Fan J, et al. **Gene** 1998 Sep 28;219(1-2):1-8

Caenorhabditis elegans ZC376.5 encodes a tRNA (m2/2G(26))dimethyltransferance in which (246)arginine is important for the enzyme activity. Liu J, et al. **Gene** 1999 Jan 8;226(1):73-81

A highly conserved nematode protein folding operon in Caenorhabditis elegans and Caenorhabditis briggsae. Page AP. **Gene** 1999 Apr 16;230(2):267-75

Molecular cloning of hSLP-1, a novel human brain-specific member of the band 7/MEC-2 family similar to Caenorhabditis elegans UNC-24. Seidel G, et al. **Gene** 1998 Dec 28;225(1-2):23-9

The Caenorhabditis elegans gene ham-2 links Hox patterning to migration of the HSN motor neuron. Baum PD, et al. **Genes Dev** 1999 Feb 15;13(4):472-83

A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Cox DN, et al. **Genes Dev** 1998 Dec 1;12(23):3715-27

Synapsis and chiasma formation in Caenorhabditis elegans require HIM-3, a meiotic chromosome core component that functions in chromosome segregation. Zetka MC, et al. **Genes Dev** 1999 Sep 1;13(17):2258-70

smg-7 is required for mRNA surveillance in Caenorhabditis elegans. Cali BM, et al. **Genetics** 1999 Feb;151(2):605-16

Genetic and molecular characterization of the caenorhabditis elegans gene, mel-26, a postmeiotic negative regulator of mei-1, a meiotic-specific spindle component. Dow MR, et al. **Genetics** 1998 Sep;150(1):119-28

Evidence for multiple promoter elements orchestrating male-specific regulation of the her-1 gene in Caenorhabditis elegans. Li W, et al. **Genetics** 1999 May; 152(1):237-48

Complexity of developmental control: analysis of embryonic cell lineage specification in Caenorhabditis elegans using pes-1 as an early marker. Molin L, et al. **Genetics** 1999 Jan;151(1):131-41

Homologs of the Caenorhabditis elegans masculinizing gene her-1 in C. briggsae and the filarial parasite Brugia malayi. Streit A, et al. **Genetics** 1999 Aug;152(4):1573-84

Functional genomics in Caenorhabditis elegans: An approach involving comparisons of sequences from related nematodes. Thacker C, et al. **Genome Res** 1999 Apr; 9(4):348-59

Cloning and mapping of the UNC5C gene to human chromosome 4q21-q23. Ackerman SL, et al. **Genomics** 1998 Sep 1;52(2):205-8

Developmental expression of a Fasciola hepatica sequence homologous to ABC transporters. Reed MB, et al. **Int J Parasitol** 1998 Sep;28(9):1375-81

Identification of an evolutionarily conserved heterotrimeric protein complex involved in protein targeting. Borg JP, et al. **J Biol Chem** 1998 Nov 27;273(48):31633-6

Cadmium-regulated genes from the nematode Caenorhabditis elegans. Identification and cloning of new cadmium-responsive genes by differential display. Liao VH, et al. **J Biol Chem** 1998 Nov 27;273(48):31962-70

Human homolog of Caenorhabditis elegans sqv-3 gene is galactosyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. Okajima T, et al. **J Biol Chem** 1999 Aug 13;274(33):22915-8

Transcription, biochemistry and localization of nematode annexins. Daigle SN, et al. **J Cell Sci** 1999 Jun;112 (Pt 12):1901-13

Protein carbonyl accumulation in aging dauer formation-defective (daf) mutants of Caenorhabditis elegans. Yasuda K, et al. **J Gerontol A Biol Sci Med Sci** 1999 Feb;54(2):B47-51; discussion B52-3

Complete cDNA sequence and genomic organization of a human pancreas-specific gene homologous to Caenorhabditis elegans sel-1. Harada Y, et al. **J Hum Genet** 1999;44(5):330-6

Sequence conservation of repeat 3 region of the gene coding for the 15 kDa polyprotein within human and simian Loa loa. Toure FS, et al. **J Med Primatol** 1999 Apr;28(2):57-61

A mariner-like transposable element in the insect parasite nematode Heterorhabditis bacteriophora. Grenier E, et al. **J Mol Evol** 1999 Mar;48(3):328-36

Identification of a TRAF (TNF receptor-associated factor) gene in Caenorhabditis elegans. Wajant H, et al. **J Mol Evol** 1998 Dec;47(6):656-62

Cloning of the oxidative stress-responsive genes in Caenorhabditis elegans. Yanase S, et al. **J Radiat Res (Tokyo)** 1999 Mar;40(1):39-47

Cloning and characterization of Sel-1l, a murine homolog of the C. elegans sel-1 gene. Donoviel DB, et al. **Mech Dev** 1998 Nov;78(1-2):203-7

Characterization of platyhelminth POU domain genes: ubiquitous and specific anterior nerve cell expression of different epitopes of GtPOU-1. Muñoz-Mármol AM, et al. **Mech Dev** 1998 Aug;76(1-2):127-40

Stu-7/air-2 is a C. elegans aurora homologue essential for chromosome segregation during embryonic and post-embryonic development. Woollard A, et al. **Mech Dev** 1999 Apr;82(1-2):95-108

Transcription levels of two actin genes (SmAct and SmAct2), cytochrome C oxidase subunit II (SmCOXII), triosephosphate isomerase (TPI), and a putative translation regulatory protein EIF-5 during the first seven days of in vitro development of Schistosoma mansoni schistosomula. Oliveira G, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:215-7

Molecular cloning and characterization of the polypeptide backbone of Schistosoma mansoni circulating cathodic antigen. Abdeen HH, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1-2):149-59

Ancylostoma secreted protein 1 (ASP-1) homologues in human hookworms. Bin Z, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):143-9

Characterization of the genomic locus expressing the ERM-like protein of Echinococcus multilocularis. Brehm K, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):147-52

Cloning and localisation of an avermectin receptor-related subunit from Haemonchus contortus. Delany NS, et al. **Mol Biochem Parasitol** 1998 Nov 30;97(1-2):177-87

Molecular cloning of the 22-24 kDa excretory-secretory 22U protein of Dirofilaria immitis and other filarial nematode parasites. Frank GR, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):297-302

Ancylostoma secreted protein 2: cloning and characterization of a second member of a family of nematode secreted proteins from Ancylostoma caninum. Hawdon JM, et al. **Mol Biochem Parasitol** 1999 Apr 30;99(2):149-65

cut-1-like genes are present in the filarial nematodes, Brugia pahangi and Brugia malayi, and, as in other nematodes, code for components of the cuticle. Lewis E, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1-2):173-83

Hgm1, a novel male-specific gene from Heterodera glycines identified by differential mRNA display. Llado RR, et al. **Mol Biochem Parasitol** 1998 Sep 1;95(1):45-52

Molecular characterization of a calponin-like protein from Schistosoma japonicum. Yang W, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):225-37

UNC-11, a Caenorhabditis elegans AP180 homologue, regulates the size and protein composition of synaptic vesicles. Nonet ML, et al. **Mol Biol Cell** 1999 Jul; 10(7):2343-60

Basolateral localization of the Caenorhabditis elegans epidermal growth factor receptor in epithelial cells by the PDZ protein LIN-10. Whitfield CW, et al. **Mol Biol Cell** 1999 Jun;10(6):2087-100

Substitution bias, rapid saturation, and the use of mtDNA for nematode systematics. Blouin MS, et al. **Mol Biol Evol** 1998 Dec;15(12):1719-27

The Caenorhabditis elegans sex determination gene mog-1 encodes a member of the DEAH-Box protein family. Puoti A, et al. **Mol Cell Biol** 1999 Mar;19(3):2189-97

mRNA surveillance mitigates genetic dominance in Caenorhabditis elegans. Cali BM, et al. **Mol Gen Genet** 1998 Nov;260(2-3):176-84

Lethal mutations defining 112 complementation groups in a 4.5 Mb sequenced region of Caenorhabditis elegans chromosome III. Stewart HI, et al. **Mol Gen Genet** 1998 Nov;260(2-3):280-8

A secretory cellulose-binding protein cDNA cloned from the root-knot nematode (Meloidogyne incognita). Ding X, et al. **Mol Plant Microbe Interact** 1998 Oct;11(10):952-9

The complete family of genes encoding G proteins of Caenorhabditis elegans. Jansen G, et al. **Nat Genet** 1999 Apr;21(4):414-9

The nuclear hormone receptor SEX-1 is an X-chromosome signal that determines nematode sex [see comments] Carmi I, et al. **Nature** 1998 Nov 12;396(6707):168-73. Comment in: Nature 1998 Nov 12;396(6707):115, 117.

Developmental genetics. Too much sex is bad for males [news; comment] Swain A, et al. **Nature** 1998 Nov 12; 396(6707):115, 117. Comment on: Nature 1998 Nov 12;396(6707):168-73.

Isolation and characterization of mammalian homologues of Caenorhabditis elegans lin-7: localization at cell-cell junctions. Irie M, et al. **Oncogene** 1999 May 6;18(18):2811-7

Identification of a differentially expressed Echinococcus multilocularis protein Em6 potentially related to antigen 5 of Echinococcus granulosus. Siles-Lucas M, et al. **Parasite Immunol** 1998 Oct;20(10):473-81

Identification, characterization and expression of Toxocara canis nematode polyprotein allergen TBA-1. Yahiro S, et al. **Parasite Immunol** 1998 Aug;20(8):351-7

Schistosoma japonicum myosin: cloning, expression and vaccination studies with the homologue of the S. mansoni myosin fragment IrV-5. Zhang Y, et al. **Parasite Immunol** 1998 Dec;20(12):583-94

Neurosecretory control of aging in Caenorhabditis elegans. Ailion M, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22; 96(13):7394-7

Reverse genetic analysis of Caenorhabditis elegans presenilins reveals redundant but unequal roles for sel-12 and hop-1 in Notch-pathway signaling. Westlund B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2497-502

Recombinant expression of a galectin from the sheep gastrointestinal parasite Teladorsagia circumcincta: its use in isolating galectin-glycoconjugates. Greenhalgh CJ, et al. **Protein Expr Purif** 1999 Jun;16(1):152-9

Insertional RNA editing in metazoan mitochondria: the cytochrome b gene in the nematode Teratocephalus lirellus [letter] Vanfleteren JR, et al. **RNA** 1999 May;5(5):622-4

U2AF35 is encoded by an essential gene clustered in an operon with RRM/cyclophilin in Caenorhabditis elegans. Zorio DA, et al. **RNA** 1999 Apr;5(4):487-94

IMMUNOLOGY

Failure of highly immunogenic filarial proteins to provide host-protective immunity. Peralta ME, et al. **Exp Parasitol** 1999 Apr;91(4):334-40

Natural immunity to Ascaris lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. McSharry C, et al. **Infect Immun** 1999 Feb;67(2):484-9

Use of a pre-selected epitope of cathepsin-L1 in a highly specific peptide-based immunoassay for the diagnosis of Fasciola hepatica infections in cattle. Cornelissen JB, et al. **Int J Parasitol** 1999 May;29(5):685-96

The vaccine efficacy of native paramyosin (Sj-97) against Chinese Schistosoma japonicum. McManus DP, et al. **Int J Parasitol** 1998 Nov;28(11):1739-42

Immuno-cross-reactivity of CUT-1 and cuticlin epitopes between ascaris lumbricoides, Caenorhabditis elegans, and Heterorhabditis. Favre R, et al. **J Struct Biol** 1998 Sep; 123(1):1-7

Identification of a differentially expressed Echinococcus multilocularis protein Em6 potentially related to antigen 5 of Echinococcus granulosus. Siles-Lucas M, et al. **Parasite Immunol** 1998 Oct;20(10):473-81

Schistosoma japonicum myosin: cloning, expression and vaccination studies with the homologue of the S. mansoni myosin fragment IrV-5. Zhang Y, et al. **Parasite Immunol** 1998 Dec;20(12):583-94

Schistosomal granuloma modulation. II. Specific immunogenic carbohydrates can modulate schistosome-egg-antigen-induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan; 85(1):14–8

Schistosomal granuloma modulation. I. Schistosoma mansoni worm antigens CAA and CCA prime egg-antigen-induced hepatic granuloma formation. Jacobs W, et al. **Parasitol Res** 1999 Jan;85(1):7–13

Identification and characterization of excreted-secreted products and surface coat antigens of animal and plant-parasitic nematodes. Lopez de Mendoza ME, et al. **Parasitology** 1999 Apr;118 (Pt 4):397–405

A fatty acid binding protein from Fasciola hepatica induced protection in C57/BL mice from challenge infection with Schistosoma bovis. Abán JL, et al. **Vet Parasitol** 1999 Jun 15;83(2):107–21

ISOLATION & PURIFICATION

Purification and crystallization of a novel membrane-anchored protein: the Schistosoma haematobium serpin. Huang W, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):350–2

Protective immunity induced in mice by F8.1 and F8.2 antigens purified from Schistosoma mansoni eggs. Ferreira CC, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:185–9

Identification of a peroxidoxin protein (OvPXN-2) of the human parasitic nematode Onchocerca volvulus by sequential protein fractionation. Schrum S, et al. **Mol Biochem Parasitol** 1998 Jul 1;94(1):131–5

Characterization by enzyme electrophoresis of specimens of the genus Helicometra (Trematoda, Opecoelidae) from fish caught off the coast of northwest Spain. Paniagua E, et al. **Parasite** 1999 Mar;6(1):89–91

METABOLISM

Characterization of a novel Ras-binding protein Ce-FLI-1 comprising leucine-rich repeats and gelsolin-like domains. Goshima M, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):111–6

Oligomerized Ced-4 kills budding yeast through a caspase-independent mechanism. Tao W, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):799–805

Synthesis and biological activity of anthelmintic thiadiazoles using an AF-2 receptor binding assay. Lee BH, et al. **Bioorg Med Chem Lett** 1999 Jun 21;9(12):1727–32

The TRA-1A sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene [see comments] Conradt B, et al. **Cell** 1999 Aug 6;98(3):317–27. Comment in: Cell 1999 Aug 6;98(3):277–80.

Sex, cell death, and the genome of C. elegans [comment] Hodgkin J. **Cell** 1999 Aug 6;98(3):277–80 (16 ref.). Comment on: Cell 1999 Aug 6;98(3):317–27.

A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion [see comments] Hong K, et al. **Cell** 1999 Jun 25;97(7):927–41. Comment in: Cell 1999 Jun 25;97(7):821–4.

WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in C. elegans. Rocheleau CE, et al. **Cell** 1999 Jun 11;97(6):717–26

Purification and biochemical characterization of actin from Caenorhabditis elegans: its difference from rabbit muscle actin in the interaction with nematode ADF/cofilin. Ono S. **Cell Motil Cytoskeleton** 1999;43(2):128–36

Apparent uncoupling of energy production and consumption in long-lived Clk mutants of Caenorhabditis elegans. Braeckman BP, et al. **Curr Biol** 1999 May 6;9(9):493–6

Reciprocal EGF signaling back to the uterus from the induced C. elegans vulva coordinates morphogenesis of epithelia. Chang C, et al. **Curr Biol** 1999 Mar 11;9(5):237–46

Receptor tyrosine phosphatases: the worm clears the picture. Zinn K. **Curr Biol** 1998 Oct 8;8(20):R725–6 (9 ref.)

The timing of lin-4 RNA accumulation controls the timing of postembryonic developmental events in Caenorhabditis elegans. Feinbaum R, et al. **Dev Biol** 1999 Jun 1; 210(1):87–95

The C. elegans homeodomain gene unc-42 regulates chemosensory and glutamate receptor expression. Baran R, et al. **Development** 1999 May;126(10):2241–51

Regulation of touch receptor differentiation by the Caenorhabditis elegans mec-3 and unc-86 genes. Duggan A, et al. **Development** 1998 Oct;125(20):4107–19

COG-2, a sox domain protein necessary for establishing a functional vulval-uterine connection in Caenorhabditis elegans. Hanna-Rose W, et al. **Development** 1999 Jan; 126(1):169–79

PAR-6 is a conserved PDZ domain-containing protein that colocalizes with PAR-3 in Caenorhabditis elegans embryos. Hung TJ, et al. **Development** 1999 Jan; 126(1):127–35

Effects of SEL-12 presenilin on LIN-12 localization and function in Caenorhabditis elegans. Levitan D, et al. **Development** 1998 Sep;125(18):3599–606

UNC-84 localizes to the nuclear envelope and is required for nuclear migration and anchoring during C. elegans development. Malone CJ, et al. **Development** 1999 Jun; 126(14):3171–81

A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al. **Development** 1999 Jan;126(1):37–49

Atypical protein kinase C cooperates with PAR-3 to establish embryonic polarity in Caenorhabditis elegans. Tabuse Y, et al. **Development** 1998 Sep;125(18):3607–14

C. elegans MAC-1, an essential member of the AAA family of ATPases, can bind CED-4 and prevent cell death. Wu D, et al. **Development** 1999 May;126(9):2021–31

Similarity of DNA binding and transcriptional regulation by Caenorhabditis elegans MAB-3 and Drosophila melanogaster DSX suggests conservation of sex determining mechanisms. Yi W, et al. **Development** 1999 Feb;126(5):873–81

Expression and characterization of human PDEdelta and its Caenorhabditis elegans ortholog CEdelta. Li N, et al. **FEBS Lett** 1998 Dec 4;440(3):454–7

Antagonism between G(o)alpha and G(q)alpha in Caenorhabditis elegans: the RGS protein EAT-16 is necessary for G(o)alpha signaling and regulates G(q)alpha activity. Hajdu-Cronin YM, et al. **Genes Dev** 1999 Jul 15; 13(14):1780–93

Negative regulation of male development in Caenorhabditis elegans by a protein-protein interaction between TRA-2A and FEM-3. Mehra A, et al. **Genes Dev** 1999 Jun 1; 13(11):1453–63

A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Paradis S, et al. **Genes Dev** 1999 Jun 1;13(11):1438–52

Wnt pathway components orient a mitotic spindle in the early Caenorhabditis elegans embryo without requiring gene transcription in the responding cell. Schlesinger A, et al. **Genes Dev** 1999 Aug 1;13(15):2028–38

Cysteine conjugate beta-lyase activity in three species of parasitic helminth. Adcock HJ, et al. **Int J Parasitol** 1999 Apr;29(4):543–8

Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. Bertin J, et al. **J Biol Chem** 1999 May 7;274(19):12955–8

The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phosphatase, PTP-1B. Moeslein FM, et al. **J Biol Chem** 1999 Sep 17;274(38):26697–704

A conserved LIM protein that affects muscular adherens junction integrity and mechanosensory function in Caenorhabditis elegans. Hobert O, et al. **J Cell Biol** 1999 Jan 11;144(1):45–57

Localized depolymerization of the major sperm protein cytoskeleton correlates with the forward movement of the cell body in the amoeboid movement of nematode sperm. Italiano JE Jr, et al. **J Cell Biol** 1999 Sep 6;146(5):1087–96

An atypical PKC directly associates and colocalizes at the epithelial tight junction with ASIP, a mammalian homologue of Caenorhabditis elegans polarity protein PAR-3. Izumi Y, et al. **J Cell Biol** 1998 Oct 5;143(1):95–106

p24 proteins and quality control of LIN-12 and GLP-1 trafficking in Caenorhabditis elegans. Wen C, et al. **J Cell Biol** 1999 Jun 14;145(6):1165–75

Innexin-3 forms connexin-like intercellular channels. Landesman Y, et al. **J Cell Sci** 1999 Jul;112 (Pt 14):2391–6

Solution structure of the motile major sperm protein (MSP) of Ascaris suum – evidence for two manganese binding sites and the possible role of divalent cations in filament formation. Haaf A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1611–24

Regulation of the UNC-18–Caenorhabditis elegans syntaxin complex by UNC-13. Sassa T, et al. **J Neurosci** 1999 Jun 15;19(12):4772–7

Characterization of platyhelminth POU domain genes: ubiquitous and specific anterior nerve cell expression of different epitopes of GtPOU-1. Muñoz-Mármol AM, et al. **Mech Dev** 1998 Aug;76(1–2):127–40

Regulated nuclear entry of the C. elegans Pax-6 transcription factor. Zhang Y, et al. **Mech Dev** 1998 Nov;78(1–2):179–87

Characterization of the Ras homologue of Schistosoma mansoni. Osman A, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):27–41

Identification of NF-AT-like transcription factor in Schistosoma mansoni: its possible involvement in the antiparasitic action of cyclosporin A. Serra EC, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1–2):33–41

UNC-11, a Caenorhabditis elegans AP180 homologue, regulates the size and protein composition of synaptic vesicles. Nonet ML, et al. **Mol Biol Cell** 1999 Jul; 10(7):2343–60

Basolateral localization of the Caenorhabditis elegans epidermal growth factor receptor in epithelial cells by the PDZ protein LIN-10. Whitfield CW, et al. **Mol Biol Cell** 1999 Jun;10(6):2087–100

E1B 19,000-molecular-weight protein interacts with and inhibits CED-4-dependent, FLICE-mediated apoptosis. Han J, et al. **Mol Cell Biol** 1998 Oct;18(10):6052–62

The SKN-1 amino-terminal arm is a DNA specificity segment. Kophengnavong T, et al. **Mol Cell Biol** 1999 Apr; 19(4):3039–50

Selected elements of herpes simplex virus accessory factor HCF are highly conserved in Caenorhabditis elegans. Liu Y, et al. **Mol Cell Biol** 1999 Jan;19(1):909–15

SMG-2 is a phosphorylated protein required for mRNA surveillance in Caenorhabditis elegans and related to Upf1p of yeast. Page MF, et al. **Mol Cell Biol** 1999 Sep; 19(9):5943–51

Ultrastructural localization of an Echinococcus granulosus laminin-binding protein. Jones MK, et al. **Parasitology** 1999 Mar;118 (Pt 3):319–25

Effects of an Onchocerca-derived cysteine protease inhibitor on microfilariae in their simuliid vector. Kläger SL, et al. **Parasitology** 1999 Mar;118 (Pt 3):305–10

Myophilin of Echinococcus granulosus: isoforms and phosphorylation by protein kinase C. Martin RM, et al. **Parasitology** 1997 Aug;115 (Pt 2):205–11

The suppressive excretory-secretory product of Trichobilharzia ocellata: a possible factor for determining compatibility in parasite-host interactions. Núñez PE, et al. **Parasitology** 1997 Aug;115 (Pt 2):193–203

Molecular and functional characterization and tissue localization of 2 glucose transporter homologues (TGTP1 and TGTP2) from the tapeworm Taenia solium. Rodríguez-Contreras D, et al. **Parasitology** 1998 Dec;117 (Pt 6):579–88

Proapoptotic activity of Caenorhabditis elegans CED-4 protein in Drosophila: implicated mechanisms for caspase activation. Kanuka H, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):145–50

Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Yu ZK, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11324–9

Genetics of RAS signaling in C. elegans. Sternberg PW, et al. **Trends Genet** 1998 Nov;14(11):466–72 (83 ref.)

PHARMACOLOGY

Apoptosis induced by filarial parasitic sheath protein in HEp 2 cell lines blocked by ectopic expression of bcl 2. Krishnamoorthy B, et al. **Cell Biol Int** 1998;22(7–8):483–92

Effects of the excretory/secretory products of Trichostrongylus colubriformis on the growth of different cell lines. Huby F, et al. **Int J Parasitol** 1999 May; 29(5):697–702

Induction of signalling anergy via the T-cell receptor in cultured Jurkat T cells by pre-exposure to a filarial nematode secreted product. Harnett MM, et al. **Parasite Immunol** 1998 Nov;20(11):551–63

PHYSIOLOGY

Expression of spliceosome-associated protein 49 is required for early embryogenesis in Caenorhabditis elegans. Fujita M, et al. **Biochem Biophys Res Commun** 1998 Dec 9; 253(1):80–4

Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Fraser AG, et al. **Curr Biol** 1999 Mar 25;9(6):292–301

Life extension and stress resistance in Caenorhabditis elegans modulated by the tkr-1 gene. Murakami S, et al. **Curr Biol** 1998 Sep 24;8(19):1091–4

Regulation of dauer larva development in Caenorhabditis elegans by daf-18, a homologue of the tumour suppressor PTEN. Rouault JP, et al. **Curr Biol** 1999 Mar 25; 9(6):329–32

The LIN-29 transcription factor is required for proper morphogenesis of the Caenorhabditis elegans male tail. Euling S, et al. **Dev Biol** 1999 Feb 15;206(2):142–56

The Caenorhabditis elegans mel-11 myosin phosphatase regulatory subunit affects tissue contraction in the somatic gonad and the embryonic epidermis and genetically interacts with the Rac signaling pathway. Wissmann A, et al. **Dev Biol** 1999 May 1;209(1):111–27

Cell cycle-dependent sequencing of cell fate decisions in Caenorhabditis elegans vulva precursor cells. Ambros V. **Development** 1999 May;126(9):1947–56

CLK-1 controls respiration, behavior and aging in the nematode Caenorhabditis elegans. Felkai S, et al. **EMBO J** 1999 Apr 1;18(7):1783–92

The STAR protein, GLD-1, is a translational regulator of sexual identity in Caenorhabditis elegans. Jan E, et al. **EMBO J** 1999 Jan 4;18(1):258–69

The levels of the RoRNP-associated Y RNA are dependent upon the presence of ROP-1, the Caenorhabditis elegans Ro60 protein. Labbé JC, et al. **Genetics** 1999 Jan; 151(1):143–50

Characterisation of Fasciola hepatica cytochrome c peroxidase as an enzyme with potential antioxidant activity in vitro. Campos EG, et al. **Int J Parasitol** 1999 May; 29(5):655–62

The nonmuscle myosin regulatory light chain gene mlc-4 is required for cytokinesis, anterior-posterior polarity, and body morphology during Caenorhabditis elegans embryogenesis. Shelton CA, et al. **J Cell Biol** 1999 Jul 26; 146(2):439–51

p24 proteins and quality control of LIN-12 and GLP-1 trafficking in Caenorhabditis elegans. Wen C, et al. **J Cell Biol** 1999 Jun 14;145(6):1165–75

Role of netrin UNC-6 in patterning the longitudinal nerves of Caenorhabditis elegans. Ren XC, et al. **J Neurobiol** 1999 Apr;39(1):107–18

Coordinated transcriptional regulation of the unc-25 glutamic acid decarboxylase and the unc-47 GABA vesicular transporter by the Caenorhabditis elegans UNC-30 homeodomain protein. Eastman C, et al. **J Neurosci** 1999 Aug 1;19(15):6225–34

Stu-7/air-2 is a C. elegans aurora homologue essential for chromosome segregation during embryonic and post-embryonic development. Woollard A, et al. **Mech Dev** 1999 Apr;82(1–2):95–108

The C. elegans PTEN homolog, DAF-18, acts in the insulin

HELMINTH PROTEINS

receptor-like metabolic signaling pathway. Ogg S, et al. **Mol Cell** 1998 Dec;2(6):887-93

Control of organ shape by a secreted metalloprotease in the nematode Caenorhabditis elegans. Blelloch R, et al. **Nature** 1999 Jun 10;399(6736):586-90

The nuclear hormone receptor SEX-1 is an X-chromosome signal that determines nematode sex [see comments] Carmi I, et al. **Nature** 1998 Nov 12;396(6707):168-73. Comment in: Nature 1998 Nov 12;396(6707):115, 117.

TRA-1 regulates the cellular distribution of the tra-2 mRNA in C. elegans. Graves LE, et al. **Nature** 1999 Jun 24; 399(6738):802-5

Developmental genetics. Too much sex is bad for males [news; comment] Swain A, et al. **Nature** 1998 Nov 12; 396(6707):115, 117. Comment on: Nature 1998 Nov 12;396(6707):168-73.

A cytosolic catalase is needed to extend adult lifespan in C. elegans daf-C and clk-1 mutants. Taub J, et al. **Nature** 1999 May 13;399(6732):162-6

Regulation of apoptosis by a Caenorhabditis elegans BNIP3 homolog. Yasuda M, et al. **Oncogene** 1998 Nov 12; 17(19):2525-30

The PTEN tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Mihaylova VT, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7427-32

Reverse genetic analysis of Caenorhabditis elegans presenilins reveals redundant but unequal roles for sel-12 and hop-1 in Notch-pathway signaling. Westlund B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2497-502

Evidence for functional and physical association between Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. Wu G, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15787-91

Molecular and functional characterization of a recombinant protein of Trichuris trichiura. Drake LJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Aug 22;265(1405):1559-65

Dosage compensation proteins targeted to X chromosomes by a determinant of hermaphrodite fate [see comments] Dawes HE, et al. **Science** 1999 Jun 11;284(5421):1800-4. Comment in: Science 1999 Jun 11;284(5421):1787-9.

Sex and repression [comment] Kuroda MI, et al. **Science** 1999 Jun 11;284(5421):1787-8. Comment on: Science 1999 Jun 11;284(5421):1800-4.

Notch/LIN-12 signaling: transduction by regulated protein slicing. Kimble J, et al. **Trends Biochem Sci** 1998 Sep; 23(9):353-7 (48 ref.)

SECRETION

CuZn superoxide dismutase activities from Fasciola hepatica. Piacenza L, et al. **Parasitology** 1998 Dec;117 (Pt 6):555-62

THERAPEUTIC USE

Immunization with an affinity purified protein extract from the adult parasite protects lambs against infection with Haemonchus contortus. Knox DP, et al. **Parasite Immunol** 1999 Apr;21(4):201-10

URINE

Schistosoma mansoni: the circulating cathodic antigen forms an abundant product of 41/42 kDa in the urine of infected patients. Abdeen HH, et al. **Exp Parasitol** 1998 Nov; 90(3):286-9

HELMINTH RNA see **RNA, HELMINTH**

HELMINTH STRUCTURAL GENES see **GENES, STRUCTURAL, HELMINTH**

HELMINTHIASIS

see related

ANTHELMINTICS

[Diagnosis and management of parasitic hypereosinophilia] Ranque S, et al. **Presse Med** 1998 Feb 28;27(8):370-5 (18 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary parasitoses. General aspects] L'Her P, et al. **Rev Pneumol Clin** 1998 Dec;54(6):321-8 (36 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Eosinophilia in the returning traveler. Wolfe MS. **Med Clin North Am** 1999 Jul;83(4):1019-32, vii (52 ref.)

Complications of worm infestation--serious, costly, predictable and preventable. Fincham JE, et al. **S Afr Med J** 1998 Aug;88(8):952-3

Intestinal amoebiasis, giardiasis and geohelminthiases: their association with other intestinal parasites and reported intestinal symptoms. Utzinger J, et al. **Trans R Soc Trop Med Hyg** 1999 Mar-Apr;93(2):137-41

CONGENITAL

[Parasitic infections in pregnancy and congenital parasitoses. II. Helminth infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 May-Jun;203(3):128-33 (32 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Familial eosinophilia: contribution of parasitology to its diagnosis] Petithory JC. **Bull Acad Natl Med** 1998; 182(9):1823-35; discussion 1836-8 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Olds GR, et al. **J Infect Dis** 1999 Apr;179(4):996-1003

Helminthic infection and anthropometric indicators in children from a tropical slum: Ascaris reinfection after anthelmintic treatment. Hagel I, et al. **J Trop Pediatr** 1999 Aug;45(4):215-20

[Anthelmintics (published erratum appears in Ned Tijdschr Geneeskd 1998 Aug 1;142(31):1800)] Kager PA. **Ned Tijdschr Geneeskd** 1998 Jun 13;142(24):1364-8 (24 ref.) (Eng. Abstr.) **(Dut)**

ECONOMICS

[The socioeconomic efficiency of preventing mass helminthiases] Lebedeva MN, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):23-6 **(Rus)**

EPIDEMIOLOGY

Intestinal worms impair child health in the Philippines [news] Easton A. **BMJ** 1999 Jan 23;318(7178):214

Association of polymorphisms in the beta2-adrenoreceptor gene with higher levels of parasitic infection. Ramsay CE, et al. **Hum Genet** 1999 Mar;104(3):269-74

How much human helminthiasis is there in the world? [comment] Crompton DW. **J Parasitol** 1999 Jun; 85(3):397-403 (75 ref.). Comment on: J Parasitol 1999 Jun;85(3):392-6.

Soil-transmitted helminthic infection and its effect on nutritional status of adolescent schoolgirls of low socioeconomic status in Sri Lanka. Atukorala TM, et al. **J Trop Pediatr** 1999 Feb;45(1):18-22

Malaria, schistosomiasis, and intestinal helminths in relation to microdams in Tigray, northern Ethiopia. Alemayehu T, et al. **Parassitologia** 1998 Sep;40(3):259-67

Different patterns of intestinal helminth infection among young workers in urban and rural areas of Alexandria Governorate, Egypt. Curtale F, et al. **Parassitologia** 1998 Sep;40(3):251-4

Comparisons of schistosome and geohelminth infection prevalences in school-aged children from selected areas of Africa: implications for rapid assessment and combined control. Brooker S, et al. **Trans R Soc Trop Med Hyg** 1999 Mar-Apr;93(2):125-6

[Parasitic diseases and fecal hazards: diseases due to helminths] Nozais JP. **Bull Soc Pathol Exot** 1998;91(5 Pt 1-2):416-22 (53 ref.) (Eng. Abstr.) **(Fre)**

[Current status of imported parasitic diseases in Japan] Otomo H. **Rinsho Byori** 1998 Nov;Suppl 108:152-9 (5 ref.) **(Jpn)**

[The epizootic situation in regions of the North in Russia and the risk of human infection with biohelminthiases] Bessonov AS, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep; (3):19-23 **(Rus)**

[An analysis of cartographic models of the nosogeographic ranges of mass biohelminthiases in Russia applicable to the missions of the federal targetted program Children of the North] Darchenkova NN, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):33-8 **(Rus)**

[Serological methods in assessing the incidence of tissue helminth lesions in children under the extreme natural conditions of the North] Poletaeva OG, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):29-32 **(Rus)**

[The effect of the technogenic pollution of the natural environment on the prevalence of parasitic diseases in the Republic of Byelarus] Skripova LV. **Med Parazitol (Mosk)** 1999 Jan-Mar;(1):6-8 (Eng. Abstr.) **(Rus)**

[Prevalence of intestinal helminthiasis in 100 municipalities in Venezuela (1989-1992)] Morales GA, et al. **Rev Soc Bras Med Trop** 1999 May-Jun;32(3):263-70 (Eng. Abstr.) **(Spa)**

HISTORY

This wormy world. 1947 [classical article] [see comments] Stoll NR. **J Parasitol** 1999 Jun;85(3):392-6. Comment in: J Parasitol 1999 Jun;85(3):397-403.

IMMUNOLOGY

Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection. Kalinkovich A, et al. **Clin Exp Immunol** 1998 Dec; 114(3):414-21

Interleukin-12 and the host response to parasitic helminths; the paradoxical effect on protective immunity and immunopathology. Mountford AP, et al. **Parasite Immunol** 1998 Nov;20(11):509-17 (70 ref.)

PARASITOLOGY

Proteinases and associated genes of parasitic helminths. Tort J, et al. **Adv Parasitol** 1999;43:161-266 (300 ref.)

First paleoparasitological analysis of a midden in the Aleutian Islands (Alaska): results and limits. Bouchet F, et al. **J Parasitol** 1999 Apr;85(2):369-72

PHYSIOPATHOLOGY

Effect of intestinal helminth infection on some nutritional parameters among rural villagers in Nepal. Rai SK, et al. **Kobe J Med Sci** 1998 Apr;44(2):91-8

PREVENTION & CONTROL

Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Beach MJ, et al. **Am J Trop Med Hyg** 1999 Mar;60(3):479-86

How much human helminthiasis is there in the world? [comment] Crompton DW. **J Parasitol** 1999 Jun; 85(3):397-403 (75 ref.). Comment on: J Parasitol 1999 Jun;85(3):392-6.

An analysis of individual, household, and environmental risk factors for intestinal helminth infection among children in Qena Governorate, Upper Egypt. Curtale F, et al. **J Trop Pediatr** 1999 Feb;45(1):14-7

Helminth control as an entry point for health-promoting schools in KwaZulu-Natal. Taylor M, et al. **S Afr Med J** 1999 Mar;89(3):273-9

A school-based schistosomiasis and intestinal helminthiasis control programme in Nigeria: acceptability to community members. Nwaorgu OC, et al. **Trop Med Int Health** 1998 Oct;3(10):842-9

[The socioeconomic efficiency of preventing mass helminthiases] Lebedeva MN, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):23-6 **(Rus)**

[Mass health-promotion measures among children's contingents in helminthiasis foci in the populated territories of the North in Khabarovsk Territory] Liberova RN, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):46-8 **(Rus)**

[Experience in the eradication of helminthiases in Khanty-Mansi District] Vorob'ev EV, et al. **Med Parazitol (Mosk)** 1998 Jul-Sep;(3):51-4 **(Rus)**

RADIOGRAPHY

CT features of intraperitoneal manifestations of parasitic infestation. Rha SE, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1289-92

THERAPY

Can we deworm this wormy world? Bundy DA, et al. **Br Med Bull** 1998;54(2):421-32 (43 ref.)

TRANSMISSION

Cockroaches can vector human disease [letter; comment] Marty AM. **Int J Dermatol** 1998 Aug;37(8):639-40. Comment on: Int J Dermatol 1997 Feb;36(2):90-6.

VETERINARY see **HELMINTHIASIS, ANIMAL**

HELMINTHIASIS, ANIMAL

Proceedings of the 2nd International Conference Novel Approaches to the Control of the Helminth Parasites of Livestock. Baton Rouge, Louisiana, USA. 22-26 March 1998. **Int J Parasitol** 1999 Jan;29(1):1-198

CLASSIFICATION

[Helminth species of goats in Germany] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11-12):427-31 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Concerns about recommending over-the-counter drugs to treat helminthiasis [letter; comment] Gagnon C. **Can Vet J** 1999 Jun;40(6):379-80. Comment on: Can Vet J 1999 Feb;40(2):95. **(Eng, Fre)**

Frontiers in anthelmintic pharmacology. Geary TG, et al. **Vet Parasitol** 1999 Aug 1;84(3-4):275-95 (98 ref.)

Efficacy of closantel plus albendazole liquid suspension against natural infection of gastrointestinal parasites in camels. Al-Qudah KM, et al. **Vet Parasitol** 1999 Mar 31; 82(2):173-8

EPIDEMIOLOGY

A survey of helminth parasites of cats from Saskatoon. Pomroy WE. **Can Vet J** 1999 May;40(5):339-40

The role of epidemiological knowledge and grazing management for helminth control in small ruminants. Barger IA. **Int J Parasitol** 1999 Jan;29(1):41-7; discussion 49-50 (24 ref.)

Helminth infections in Apodemus sylvaticus in southern England: interactive effects of host age, sex and year on the prevalence and abundance of infections. Behnke JM, et al. **J Helminthol** 1999 Mar;73(1):31-44

Ecological studies of helminth parasites of the largemouth bass, Micropterus salmoides, from Lake Naivasha and the Oloidien Bay, Kenya. Aloo PA. **Onderstepoort J Vet Res** 1999 Jun;66(2):73-9

A survey to identify the important macroparasites of rock partridge (Alectoris graeca saxatilis) in Trentino, Italy. Rizzoli A, et al. **Parassitologia** 1997 Dec;39(4):331-4

Tsetse challenge, trypanosome and helminth infection in relation to productivity of village Ndama cattle in Senegal. Fall A, et al. **Vet Parasitol** 1999 Mar 1;81(3):235-47

Habitat related differences in helminth parasites of red foxes in the Ebro valley. Gortázar C, et al. **Vet Parasitol** 1998

Dec 15;80(1):75–81
Helminth levels of working donkeys kept under different management systems in the Moretele 1 district of the North-West Province, South Africa. Wells D, et al. **Vet Parasitol** 1998 Jun 15;77(2–3):163–77
Fluke and roundworm infestations could be 'major problems' this winter [news] **Vet Rec** 1999 Jan 9;144(2):32–4
[The epizootic situation in regions of the North in Russia and the risk of human infection with biohelminthiases] Bessonov AS, et al. **Med Parazitol (Mosk)** 1998 Jul–Sep; (3):19–23 **(Rus)**

ETIOLOGY

Versternema struthionis in ostriches: is there an association with peritonitis? [letter] Bekker A. **J S Afr Vet Assoc** 1998 Dec;69(4):118–9

IMMUNOLOGY

Progress and expectations for helminth vaccines. Meeusen EN, et al. **Adv Vet Med** 1999;41:241–56 (41 ref.)
The effects of pollutants on the immune response of fish: implications for helminth parasites. Hoole D. **Parassitologia** 1997 Sep;39(3):219–25 (58 ref.)
Parasite infection and Japanese cedar pollinosis in monkeys. Kobayashi C, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):93–100
The susceptibility of Djallonké and Djallonké-Sahelian crossbred sheep to Trypanosoma congolense and helminth infection under different diet levels. Goossens B, et al. **Vet Parasitol** 1999 Aug 16;85(1):25–41
Immunology of helminth infections, with special reference to immunopathology. Meeusen EN. **Vet Parasitol** 1999 Aug 1;84(3–4):259–73 (58 ref.)

PARASITOLOGY

Pomphorhynchus laevis: the intestinal acanthocephalan as a lead sink for its fish host, chub (Leuciscus cephalus). Sures B, et al. **Exp Parasitol** 1999 Oct;93(2):66–72
Helminth parasites of the rare endemic catfish, Liobagrus reini, in Japan. Moravec F, et al. **Folia Parasitol (Praha)** 1998;45(4):283–94
Is there a fixed number of niches for endoparasites of fish? Rohde K. **Int J Parasitol** 1998 Dec;28(12):1861–5
Anthelmintic resistance: past, present and future. Sangster NC. **Int J Parasitol** 1999 Jan;29(1):115–24; discussion 137–8 (56 ref.)
Site selection by intestinal helminths of the Virginia opossum (Didelphis virginiana). Ellis RD, et al. **J Parasitol** 1999 Feb;85(1):1–5
Helminths of six species of Anolis lizards (Polychrotidae) from Hispaniola, West Indies. Goldberg SR, et al. **J Parasitol** 1998 Dec;84(6):1291–5
Gastrointestinal helminths of four gekkonid lizards, Gehyra mutilata, Gehyra oceanica, Hemidactylus frenatus and Lepidodactylus lugubris from the Mariana Islands, Micronesia. Goldberg SR, et al. **J Parasitol** 1998 Dec; 84(6):1295–8
Metazoan parasites and other symbionts of cetaceans in the Caribbean. Mignucci-Giannoni AA, et al. **J Parasitol** 1998 Oct;84(5):939–46
Helminths of white-bellied opossum from Brazil. Quintão e Silva M da G, et al. **J Wildl Dis** 1999 Apr;35(2):371–4
Richness and diversity of parasite communities in European eels Anguilla anguilla of the River Rhine, Germany, with special reference to helminth parasites. Sures B, et al. **Parasitology** 1999 Sep;119 (Pt 3):323–30
Biodiversity of parasites in freshwater environment in relation to pollution. Gelnar M, et al. **Parassitologia** 1997 Sep; 39(3):189–99
A multidisciplinary approach using several biomarkers, including a parasite, as indicators of pollution: a case history from a paper mill in Newfoundland. Khan RA, et al. **Parassitologia** 1997 Sep;39(3):183–8
Helminths from a stranded manatee in the Dominican Republic. Mignucci-Giannoni AA, et al. **Vet Parasitol** 1999 Feb 1;81(1):69–71

PHYSIOPATHOLOGY

Impact of abomasal nematodes on roe deer and chamois body condition in an alpine environment. Zaffaroni E, et al. **Parassitologia** 1997 Dec;39(4):313–7

PREVENTION & CONTROL

Irradiated vaccines for helminth control in livestock. Bain RK. **Int J Parasitol** 1999 Jan;29(1):185–91 (36 ref.)
The role of epidemiological knowledge and grazing management for helminth control in small ruminants. Barger IA. **Int J Parasitol** 1999 Jan;29(1):41–7; discussion 49–50 (24 ref.)
Prospects for vaccines of helminth parasites of grazing ruminants. Smith WD. **Int J Parasitol** 1999 Jan;29(1):17–24 (54 ref.)
The role of parasite epidemiology in the management of grazing cattle. Stromberg BE, et al. **Int J Parasitol** 1999 Jan;29(1):33–9; discussion 49–50 (49 ref.)
Integrated and biological control of parasites in organic and conventional production systems. Thamsborg SM, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):169–86 (67 ref.)

HELMINTHOSPORIUM

KM-01, a brassinolide inhibitor, its production, isolation and structure from two fungi Drechslera avenae and Pycnoporus coccineus. Kim SK, et al. **Bioorg Med Chem** 1998 Nov;6(11):1975–82

VIROLOGY

Assembly of the Hv190S totivirus capsid is independent of posttranslational modification of the capsid protein. Soldevila AI, et al. **Virology** 1998 Nov 25;251(2):327–33

HELMINTHS

Proceedings of the 2nd International Conference Novel Approaches to the Control of the Helminth Parasites of Livestock. Baton Rouge, Louisiana, USA. 22–26 March 1998. **Int J Parasitol** 1999 Jan;29(1):1–198

CHEMISTRY

Histochemical characteristics of Gyrodactylus derjavini parasitizing the fins of rainbow trout (Oncorhynchus mykiss). Buchmann K. **Folia Parasitol (Praha)** 1998; 45(4):312–8

CLASSIFICATION

Helminth parasites of the rare endemic catfish, Liobagrus reini, in Japan. Moravec F, et al. **Folia Parasitol (Praha)** 1998;45(4):283–94
Gastrointestinal helminths of four gekkonid lizards, Gehyra mutilata, Gehyra oceanica, Hemidactylus frenatus and Lepidodactylus lugubris from the Mariana Islands, Micronesia. Goldberg SR, et al. **J Parasitol** 1998 Dec; 84(6):1295–8
Helminths of six species of Anolis lizards (Polychrotidae) from Hispaniola, West Indies. Goldberg SR, et al. **J Parasitol** 1998 Dec;84(6):1291–5
Metazoan parasites and other symbionts of cetaceans in the Caribbean. Mignucci-Giannoni AA, et al. **J Parasitol** 1998 Oct;84(5):939–46
Helminths of white-bellied opossum from Brazil. Quintão e Silva M da G, et al. **J Wildl Dis** 1999 Apr;35(2):371–4
Habitat related differences in helminth parasites of red foxes in the Ebro valley. Gortázar C, et al. **Vet Parasitol** 1998 Dec 15;80(1):75–81
[Helminth species of goats in Germany] Rehbein S, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov–Dec; 111(11–12):427–31 (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Mechanism-based screening: discovery of the next generation of anthelmintics depends upon more basic research. Geary TG, et al. **Int J Parasitol** 1999 Jan;29(1):105–12; discussion 113–4 (40 ref.)
Anthelmintic resistance: past, present and future. Sangster NC. **Int J Parasitol** 1999 Jan;29(1):115–24; discussion 137–8 (56 ref.)
Anthelmintic activity of the latex of Ficus species. de Amorin A, et al. **J Ethnopharmacol** 1999 Mar;64(3):255–8
Anthelmintic resistance and the control of worms [editorial] Coles GC. **J Med Microbiol** 1999 Apr;48(4):323–5
Frontiers in anthelmintic pharmacology. Geary TG, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):275–95 (98 ref.)

ENZYMOLOGY

Cytochrome P450 in parasitic protozoa and helminths. Barrett J. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1–3):181–3 (30 ref.)

GENETICS

Proteinases and associated genes of parasitic helminths. Tort J, et al. **Adv Parasitol** 1999;43:161–266 (300 ref.)
Parasitic helminth genomics. Filarial Genome Project. Blaxter M, et al. **Parasitology** 1999;118 Suppl:S39–51 (70 ref.)
Helminth genome analysis: the current status of the filarial and schistosome genome projects. Filarial Genome Project. Schistosome Genome Project. Williams SA, et al. **Parasitology** 1999;118 Suppl:S19–38 (80 ref.)

GROWTH & DEVELOPMENT

The life cycle of a horsehair worm, Gordius robustus (Nematomorpha: Gordioidea). Hanelt B, et al. **J Parasitol** 1999 Feb;85(1):139–41
Integrated and biological control of parasites in organic and conventional production systems. Thamsborg SM, et al. **Vet Parasitol** 1999 Aug 1;84(3–4):169–86 (67 ref.)

IMMUNOLOGY

Irradiated vaccines for helminth control in livestock. Bain RK. **Int J Parasitol** 1999 Jan;29(1):185–91 (36 ref.)
Interleukin-12 and the host response to parasitic helminths; the paradoxical effect on protective immunity and immunopathology. Mountford AP, et al. **Parasite Immunol** 1998 Nov;20(11):509–17 (70 ref.)
The effects of pollutants on the immune response of fish: implications for helminth parasites. Hoole D. **Parassitologia** 1997 Sep;39(3):219–25 (58 ref.)
The susceptibility of Djallonké and Djallonké-Sahelian crossbred sheep to Trypanosoma congolense and helminth infection under different diet levels. Goossens B, et al. **Vet Parasitol** 1999 Aug 16;85(1):25–41
Immunology of helminth infections, with special reference to immunopathology. Meeusen EN. **Vet Parasitol** 1999 Aug 1;84(3–4):259–73 (58 ref.)

ISOLATION & PURIFICATION

Helminth fauna of the Iberian lynx, Lynx pardinus. Torres J, et al. **J Helminthol** 1998 Sep;72(3):221–6
First paleoparasitological analysis of a midden in the Aleutian Islands (Alaska): results and limits. Bouchet F, et al. **J Parasitol** 1999 Apr;85(2):369–72
Richness and diversity of parasite communities in European eels Anguilla anguilla of the River Rhine, Germany, with special reference to helminth parasites. Sures B, et al. **Parasitology** 1999 Sep;119 (Pt 3):323–30
Viewpoint: the neglect of stool microscopy for intestinal parasites and possible solutions. Parija SC, et al. **Trop Med Int Health** 1999 Jul;4(7):522–4

METABOLISM

Sphingomyelin synthesis in helminths: a minireview. Bankov I, et al. **Folia Parasitol (Praha)** 1998;45(4):257–60 (19 ref.)

PARASITOLOGY

Helminths and bot fly larvae of wild ungulates on a game ranch in central province, Zambia. Zieger U, et al. **Onderstepoort J Vet Res** 1998 Jun;65(2):137–41

PHYSIOLOGY

Progress and expectations for helminth vaccines. Meeusen EN, et al. **Adv Vet Med** 1999;41:241–56 (41 ref.)
The role of epidemiological knowledge and grazing management for helminth control in small ruminants. Barger IA. **Int J Parasitol** 1999 Jan;29(1):41–7; discussion 49–50 (24 ref.)
The role of parasite epidemiology in the management of grazing cattle. Stromberg BE, et al. **Int J Parasitol** 1999 Jan;29(1):33–9; discussion 49–50 (49 ref.)
Helminth infections in Apodemus sylvaticus in southern England: interactive effects of host age, sex and year on the prevalence and abundance of infections. Behnke JM, et al. **J Helminthol** 1999 Mar;73(1):31–44
Site selection by intestinal helminths of the Virginia opossum (Didelphis virginiana). Ellis RD, et al. **J Parasitol** 1999 Feb;85(1):1–5

HELOGALE see **MONGOOSES**

HELPER CELLS see **T-LYMPHOCYTES, HELPER-INDUCER**

HELPER-INDUCER T-LYMPHOCYTES see **T-LYMPHOCYTES, HELPER-INDUCER**

HELPER VIRUSES

see related
SATELLITE VIRUSES

Tamplicon-7, a novel T-lymphotropic vector derived from human herpesvirus 7. Romi H, et al. **J Virol** 1999 Aug; 73(8):7001–7
A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. Von Seggern DJ, et al. **J Virol** 1999 Feb;73(2):1601–8

CLASSIFICATION

Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. Bantel-Schaal U, et al. **J Virol** 1999 Feb;73(2):939–47

GENETICS

Rescue of IBV D-RNA by heterologous helper virus strains. Stirrups K, et al. **Adv Exp Med Biol** 1998;440:259–64
Biology and structure of plant satellite viruses activated by icosahedral helper viruses. Scholthof KB, et al. **Curr Top Microbiol Immunol** 1999;239:123–43 (59 ref.)
New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Fallaux FJ, et al. **Hum Gene Ther** 1998 Sep 1;9(13):1909–17
High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Morral N, et al. **Hum Gene Ther** 1998 Dec 10;9(18):2709–16
Helper-free foamy virus vectors. Trobridge GD, et al. **Hum Gene Ther** 1998 Nov 20;9(17):2517–25
Expanded-capacity adenoviral vectors--the helper-dependent vectors. Morsy MA, et al. **Mol Med Today** 1999 Jan;5(1):18–24 (40 ref.)
Features of the autonomous function of the translational enhancer domain of satellite tobacco necrosis virus. Meulewaeter F, et al. **RNA** 1998 Nov;4(11):1347–56

ISOLATION & PURIFICATION

Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and

HELPER VIRUSES

wild-type viruses. Clark KR, et al. **Hum Gene Ther** 1999 Apr 10;10(6):1031-9

METABOLISM

The E protein of satellite phage P4 acts as an anti-repressor by binding to the C protein of helper phage P2. Liu T, et al. **Mol Microbiol** 1998 Dec;30(5):1041-50

PHYSIOLOGY

Induction of B-cell lymphoma in BALB/c nude mice with an ecotropic, B-tropic helper virus present in the murine AIDS virus stock. Tayar L, et al. **J Virol** 1999 Feb; 73(2):1640-4

Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Ongrádi J, et al. **Pathol Oncol Res** 1998;4(3):191-9

Deletion of internal sequences results in tobacco mosaic virus defective RNAs that accumulate to high levels without interfering with replication of the helper virus. Lewandowski DJ, et al. **Virology** 1998 Nov 25; 251(2):427-37

HELPING BEHAVIOR

Lifesavers and Samaritans: emergency use of cellular (mobile) phones in Australia. Chapman S, et al. **Accid Anal Prev** 1998 Nov;30(6):815-9

Codependency in male and female helping professionals. Martsolf DS, et al. **Arch Psychiatr Nurs** 1999 Apr; 13(2):97-103

The helping process in couples during recovery from heart attack: a single case study. Pistrang N, et al. **Br J Med Psychol** 1999 Jun;72 (Pt 2):227-37

Patterns and predictors of formal and informal care among elderly persons living in board and care homes. Hopp FP. **Gerontologist** 1999 Apr;39(2):167-76

The effects of family conflict resolution and decision making on the provision of help for an elder with Alzheimer's disease. Lieberman MA, et al. **Gerontologist** 1999 Apr; 39(2):159-66

Implicit and self-attributed dependency strivings: differential relationships to laboratory and field measures of help seeking. Bornstein RF. **J Pers Soc Psychol** 1998 Sep; 75(3):778-87

Prosocial self-schemas, self-awareness, and children's prosocial behavior. Froming WJ, et al. **J Pers Soc Psychol** 1998 Sep;75(3):766-77

The influence of perceived responsibility and personality characteristics on the emotional and behavioral reactions to people with AIDS. Steins G, et al. **J Soc Psychol** 1999 Aug;139(4):487-95

Abortion affiliation, urban size, and geographic bias of responses to lost letters. Bridges FS, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):1107-12

College students' perceptions of helpful responses to bereaved persons: effects of sex of bereaved persons and cause of death. Knight KH, et al. **Psychol Rep** 1998 Oct; 83(2):627-36

An attribution-emotion model of helping behavior. Yamauchi H, et al. **Psychol Rep** 1999 Jun;84(3 Pt 2):1073-4

Community health workers: examining the Helper Therapy principle. Roman LA, et al. **Public Health Nurs** 1999 Apr; 16(2):87-95

Determinants of reluctance to perform CPR among residents and applicants: the impact of experience on helping behavior. Brenner BE, et al. **Resuscitation** 1997 Nov; 35(3):203-11

HELPLESSNESS, LEARNED

Stress, learned helplessness, and brain interleukin-1 beta. Maier SF, et al. **Adv Exp Med Biol** 1999;461:235-49 (63 ref.)

Decrease in stress-induced c-Fos-like immunoreactivity in the lateral septal nucleus of learned helpless rats. Steciuk M, et al. **Brain Res** 1999 Mar 20;822(1-2):256-9

Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Tejedor-Real P, et al. **Eur J Pharmacol** 1998 Jul 31; 354(1):1-7

The quota system in burn rehabilitation. Ehde DM, et al. **J Burn Care Rehabil** 1998 Sep-Oct;19(5):436-40

The effect of depression in an animal model on 5'-ectonucleotidase, antibody production, and tissue ascorbate stores. Blake-Mortimer JS, et al. **J Gen Psychol** 1998 Apr;125(2):129-46

An experimental examination of learned helplessness in older adolescents and young adults with long-standing asthma. Chaney JM, et al. **J Pediatr Psychol** 1999 Jun;24(3):259-70

Serotonin and learned helplessness: a regional study of 5-HT1A, 5-HT2A receptors and the serotonin transport site in rat brain. Wu J, et al. **J Psychiatr Res** 1999 Jan-Feb; 33(1):17-22

Learned helplessness: a survey of cognitive, motivational and perceptual-motor consequences in motor tasks. Germigon C, et al. **J Sports Sci** 1999 May;17(5):403-12

Forced exercise blocks learned helplessness in the cockroach (Periplaneta americana). Brown GE, et al. **Psychol Rep** 1999 Feb;84(1):155-6

Suicidality and helplessness. Ozment JM, et al. **Psychol Rep** 1998 Oct;83(2):718

The depression system: preliminary studies. Richardson DE, et al. **Stereotact Funct Neurosurg** 1997;68(1-4 Pt 1):221-5

[Creation of a line of "depressed" mice from a selection of breeders exhibiting a behavioral helplessness] Vaugeois JM, et al. **C R Seances Soc Biol Fil** 1998;192(6):1149-61 (Eng. Abstr.) **(Fre)**

[Effect of buspirone on the development of acquired helplessness] Toloknov AV, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):286-8 **(Rus)**

[The characteristics of the development of learned helplessness in rats selected for the excitability threshold of their nervous systems] Ordian NE. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov-Dec; 48(6):1058-64 (Eng. Abstr.) **(Rus)**

HELSINKI DECLARATION

Declaration of Helsinki--nothing to declare? [editorial] [see comments] **Lancet** 1999 Apr 17;353(9161):1285. Comment in: Lancet 1999 May 29;353(9167):1888. Comment in: Lancet 1999 Jul 24;354(9175):343.

Declaration of Helsinki [letter; comment] Human D. **Lancet** 1999 May 29;353(9167):1888. Comment on: Lancet 1999 Apr 17;353(9161):1285.

WMA postpones decision to revise Declaration of Helsinki. World Medical Association [news] Ramsay S. **Lancet** 1999 Sep 11;354(9182):928

Helsinki Declaration and Thailand [letter; comment] Suwanjandee J, et al. **Lancet** 1999 Jul 24;354(9175):343. Comment on: Lancet 1999 Apr 17;353(9161):1285.

Proposed revisions to the Declaration of Helsinki--will they weaken the ethical principles underlying human research? Brennan TA. **N Engl J Med** 1999 Aug 12;341(7):527-31

The need to revise the Declaration of Helsinki. Levine RJ. **N Engl J Med** 1999 Aug 12;341(7):531-4

Research ethics-no easy fix ahead [news] Brown P. **Nat Med** 1999 Oct;5(10):1094

Proposed revisions to the Declaration of Helsinki. Paving the way for globalization in research. Lurie P, et al. **West J Med** 1999 Jul;171(1):6

[Incorrect information about suggested changes in the Helsinki declaration (letter)] Milton A. **Lakartidningen** 1999 May 12;96(19):2335 **(Swe)**

[Confusing proposal for revisions in the Helsinki declaration (letter)] Tännsjö T. **Lakartidningen** 1999 May 5;96(18):2196, 2198 **(Swe)**

HEMACHATUS see **COBRA**

HEMADSORPTION

Identification of complement activators and elucidation of the fate of complement activation products during extracorporeal plasma purification therapy. Fadul JE, et al. **J Clin Apheresis** 1998;13(4):167-73

[The "Fractionated Plasma Separation and Adsorption system" (FPSA), a new membrane absorption-assisted adjunctive extracorporeal blood purification system for liver failure] Strobl W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:168-9 **(Ger)**

HEMADSORPTION VIRUS 1 see **PARAINFLUENZA VIRUS 3, HUMAN**

HEMADSORPTION VIRUS 2 see **PARAINFLUENZA VIRUS 1, HUMAN**

HEMAGGLUTINATING VIRUS OF JAPAN see **PARAMYXOVIRUS**

HEMAGGLUTINATION

The classification, recognition and significance of polyagglutination in transfusion medicine. Horn KD. **Blood Rev** 1999 Mar;13(1):36-44 (50 ref.)

Transmission electron microscopy studies of Moraxella (Branhamella) catarrhalis. Fitzgerald M, et al. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):57-66

Characterization of the relationship between polysaccharide intercellular adhesin and hemagglutination in Staphylococcus epidermidis. Fey PD, et al. **J Infect Dis** 1999 Jun;179(6):1561-4

The hemagglutinating action of Vibrio vulnificus metalloprotease. Miyoshi S, et al. **Microbiol Immunol** 1999; 43(1):79-82

Haemagglutination and haemolysis by oral Fusobacterium nucleatum. Gaetti-Jardim Júnior E, et al. **New Microbiol** 1999 Jan;22(1):63-7

Blood transfusion in premature or young infants with polyagglutination and activation of the T antigen [published erratum appears in Vox Sang 1999;76(3):191] Engelfriet CP, et al. **Vox Sang** 1999;76(2):128-32

DRUG EFFECTS

Chemical modification studies on the glucose/mannose specific lectins from field and lablab beans. Nadimpalli SK. **Biochem Mol Biol Int** 1999 May;47(5):825-34

Salicylate inhibits fimbriae mediated HEp-2 cell adherence of and haemagglutination by enteroaggregative Escherichia coli. Kang G, et al. **FEMS Microbiol Lett** 1998 Sep 15; 166(2):257-65

A comparative study on the purification of the Amaranthus leucocarpus syn. hypocondriacus lectin. Hernández P, et al. **Prep Biochem Biotechnol** 1999 Aug;29(3):219-34

Primary structure and biological activity of snake venom lectin (APL) from Agkistrodon p. piscivorus (Eastern cottonmouth). Komori Y, et al. **Toxicon** 1999 Jul; 37(7):1053-64

IMMUNOLOGY

A protein (M9) associated with monoclonal antibody-mediated agglutination of Mycoplasma gallisepticum is a member of the pMGA family. Liu L, et al. **Infect Immun** 1998 Nov;66(11):5570-5

HEMAGGLUTINATION INHIBITION TESTS

METHODS

Preliminary studies on the use of solid-phase immunosorbent techniques for the rapid detection of Wesselsbron virus (WSLV) IgM by haemagglutination-inhibition. Baba SS, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jan; 22(1):71-9

VETERINARY

Evaluation of the hemagglutination-inhibition assay using a baculovirus-expressed hemagglutinin-neuraminidase protein for detection of Newcastle disease virus antibodies. Heckert RA, et al. **J Vet Diagn Invest** 1999 Jan;11(1):99-102

HEMAGGLUTINATION TESTS

Trypanosomosis agglutination card test for Trypanosoma brucei rhodesiense sleeping sickness. Akol MN, et al. **East Afr Med J** 1999 Jan;76(1):38-41

Treponemal specific tests for the serodiagnosis of syphilis. Syphilis and HIV Study Group. Augenbraun M, et al. **Sex Transm Dis** 1998 Nov;25(10):549-52

Sequence and specificity analysis of recombinant human Fab anti-Rh D isolated by phage display. Miescher S, et al. **Vox Sang** 1998;75(4):278-87

METHODS

Improvement of the indirect hemagglutination test for the detection of antibodies to Streptococcus pyogenes. Rubinsky-Elefant G, et al. **Braz J Med Biol Res** 1998 Aug; 31(8):1081-9

Quantitation of tetanus and diphtheria antitoxins in mouse sera by indirect haemagglutination. Maheshwari SC, et al. **J Commun Dis** 1998 Mar;30(1):23-8

Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. Rimmelzwaan GF, et al. **J Virol Methods** 1998 Sep; 74(1):57-66

Evaluation of the gel system for ABO grouping and D typing. Langston MM, et al. **Transfusion** 1999 Mar;39(3):300-5

Use of IgM monoclonal reagents licensed for tube tests in column agglutination technology. Morelati F, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1037-40

VETERINARY

Antibody response to sheep erythrocytes in Indian native vis-à-vis imported breeds of chickens. Kundu A, et al. **Br Poult Sci** 1999 Mar;40(1):40-3

Correlation between ability of Ornithobacterium rhinotracheale to agglutinate red blood cells and susceptibility to fosfomycin. Fitzgerald SL, et al. **Onderstepoort J Vet Res** 1998 Dec;65(4):317-20

Comparison of ELISA and 2-META assays used in serological diagnosis of infection with Actinobacillus pleuropneumoniae serotypes 2 and 4-7 in breeding pigs in Croatia. Habrun B, et al. **Prev Vet Med** 1998 Sep 1; 36(3):179-86

HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Pöltl-Frank F, et al. **Clin Exp Immunol** 1999 Sep; 117(3):496-503

[Influenza viruses and their receptor sugar recognition] Suzuki Y. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2559-66 (33 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice. Bercovici N, et al. **Eur J Immunol** 1999 Jan;29(1):345-54

Polymeric nanoparticles as delivery system for influenza virus glycoproteins. Lemoine D, et al. **J Controlled Release** 1998 Jun;54(1):15-27

Intradermal DNA immunization by using jet-injectors in mice and monkeys. Haensler J, et al. **Vaccine** 1999 Feb 26;17(7-8):628-38

ANALYSIS

M protein correlates with the receptor-binding specificity of haemagglutinin protein of reassortant influenza A (H1N1) virus. Tong N, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2425-34

BIOSYNTHESIS

Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. Morgan DJ, et al. **J Immunol** 1999 Jul 15; 163(2):723-7

CHEMISTRY

Identification of a novel HA conformational change inhibitor of human influenza virus. Yoshimoto J, et al. **Arch Virol** 1999;144(5):865-78

Membrane destabilizing activity of influenza virus hemagglutinin-based synthetic peptide: implications of critical glycine residue in fusion peptide. Matsumoto T. **Biophys Chem** 1999 Jun 7;79(2):153-62

A mechanism of protein-mediated fusion: coupling between refolding of the influenza hemagglutinin and lipid rearrangements. Kozlov MM, et al. **Biophys J** 1998 Sep; 75(3):1384-96

Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Chen J, et al. **Cell** 1998 Oct 30; 95(3):409-17

Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. Ferguson PL, et al. **J Biol Chem** 1999 Jun 4;274(23):16269-78

Influence of the amino acid differences between the hemagglutinin HA1 domains of influenza virus H1N1 strains on their reaction with antibody. Drescher J, et al. **J Med Virol** 1999 Apr;57(4):397-404

The ectodomain of HA2 of influenza virus promotes rapid pH dependent membrane fusion. Epand RF, et al. **J Mol Biol** 1999 Feb 19;286(2):489-503

Conformational intermediates and fusion activity of influenza virus hemagglutinin. Korte T, et al. **J Virol** 1999 Jun; 73(6):4567-74

Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Melikyan GB, et al. **Mol Biol Cell** 1999 Jun;10(6):1821-36

A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Fleury D, et al. **Nat Struct Biol** 1999 Jun;6(6):530-4

N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. Chen J, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8967-72

pH-induced conformational changes of membrane-bound influenza hemagglutinin and its effect on target lipid bilayers. Gray C, et al. **Protein Sci** 1998 Nov;7(11):2359-73

Domain-structure of cytoplasmic border region is main determinant for palmitoylation of influenza virus hemagglutinin (H7). Ponimaskin E, et al. **Virology** 1998 Sep 30;249(2):325-35

Changes in H3 influenza A virus receptor specificity during replication in humans. Ryan-Poirier K, et al. **Virus Res** 1998 Aug;56(2):169-76

GENETICS

A novel amino acid substitution at the receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated from 6 cases with acute encephalopathy during the 1997-1998 season in Tokyo. Mori SI, et al. **Arch Virol** 1999; 144(1):147-55

T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Marzo AL, et al. **Cancer Res** 1999 Mar 1;59(5):1071-9

Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: separation of attachment and fusion functions on different molecules. Patterson SM, et al. **Gene Ther** 1999 Apr;6(4):694-702

Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hatziioannou T, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1533-44

Hierarchy of sorting signals in chimeras of intestinal lactase-phlorizin hydrolase and the influenza virus hemagglutinin. Jacob R, et al. **J Biol Chem** 1999 Mar 19; 274(12):8061-7

Genetic characterization of the hemagglutinin of two strains of influenza B virus co-circulated in Taiwan. Chan CH, et al. **J Med Virol** 1999 Oct;59(2):208-14

Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. Lindstrom SE, et al. **J Virol** 1999 May;73(5):4413-26

Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. McCullers JA, et al. **J Virol** 1999 Sep;73(9):7343-8

Phylogenetic analysis of H7 avian influenza viruses isolated from the live bird markets of the Northeast United States. Suarez DL, et al. **J Virol** 1999 May;73(5):3567-73

Antigenic and genetic analyses of H5 influenza viruses isolated from ducks in Asia. Imai M, et al. **Jpn J Vet Res** 1999 Feb;46(4):171-7

A specific point mutant at position 1 of the influenza hemagglutinin fusion peptide displays a hemifusion phenotype. Qiao H, et al. **Mol Biol Cell** 1999 Aug; 10(8):2759-69

The 1918 'Spanish' flu: pearls from swine? [news] [see comments] Shortridge KF. **Nat Med** 1999 Apr;5(4):384-5 . Comment in: Nat Med 1999 Jun;5(6):592.

Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene [see comments] Reid AH, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1651-6. Comment in: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1164-6.

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164-6 (31 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651-6.

Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Lunn DP, et al. **Vaccine** 1999 May 4;17(18):2245-58

Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Bender C, et al. **Virology** 1999 Feb 1;254(1):115-23

Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Xu X, et al. **Virology** 1999 Aug 15;261(1):15-9

IMMUNOLOGY

Recombinant vaccinia viruses expressing an immunodominant epitope of HIV-1 envelope protein within an influenza hemagglutinin cassette predominantly prime epitope-specific CD8(+) CTL. Chiba M, et al. **Arch Virol** 1999;144(8):1469-85

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Webster A, et al. **Clin Pharmacokinet** 1999;36 Suppl 1:51-8

Effect of CpG methylation on isotype and magnitude of antibody responses to influenza hemagglutinin-expressing plasmid. Feltquate DM, et al. **DNA Cell Biol** 1999 Sep; 18(9):663-70

Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. Sha Z, et al. **Immunobiology** 1999 Feb; 200(1):21-30

Expression of antibody interferes with disulfide bond formation and intracellular transport of antigen in the secretory pathway. Pelkmans L, et al. **J Biol Chem** 1999 May 14;274(20):14495-9

Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. Operschall E, et al. **J Clin Virol** 1999 Jun;13(1-2):17-27

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Li S, et al. **J Infect Dis** 1999 May;179(5):1132-8

Influence of the amino acid differences between the hemagglutinin HA1 domains of influenza virus H1N1 strains on their reaction with antibody. Drescher J, et al. **J Med Virol** 1999 Apr;57(4):397-404

Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. Glück U, et al. **J Virol** 1999 Sep;73(9):7780-6

DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Kodihalli S, et al. **J Virol** 1999 Mar;73(3):2094-8

Attenuated vesicular stomatitis viruses as vaccine vectors. Roberts A, et al. **J Virol** 1999 May;73(5):3723-32

Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. Tamura M, et al. **J Virol** 1998 Nov;72(11):9404-6

Ontogeny of T cell tolerance to peripherally expressed antigens. Morgan DJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3854-8

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Babai I, et al. **Vaccine** 1999 Mar 5; 17(9-10):1223-38

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Babai I, et al. **Vaccine** 1999 Mar 5;17(9-10):1239-50

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z, et al. **Vaccine** 1999 Feb 26;17(7-8):653-9

Intradermal DNA immunization by using jet-injectors in mice and monkeys. Haensler J, et al. **Vaccine** 1999 Feb 26;17(7-8):628-38

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE. **Vaccine** 1999 Apr 9;17(15-16):2073-80

Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Lunn DP, et al. **Vaccine** 1999 May 4;17(18):2245-58

Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Zurbriggen R, et al. **Vaccine** 1999 Mar 17; 17(11-12):1301-5

Induction of antibody response by DNA immunization of newborn baboons against influenza virus. Bot A, et al. **Viral Immunol** 1999;12(2):91-6

Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Pertmer TM, et al. **Virology** 1999 May 10; 257(2):406-14

METABOLISM

A polar octapeptide fused to the N-terminal fusion peptide solubilizes the influenza virus HA2 subunit ectodomain. Chen J, et al. **Biochemistry** 1998 Sep 29;37(39):13643-9

Influenza hemagglutinin mediated fusion of membranes containing poly(ethylene-glycol) grafted lipids: new insights into the fusion mechanism. Chams V, et al. **FEBS Lett** 1999 Apr 1;448(1):28-32

The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin-Darby canine kidney cells. Puertollano R, et al. **J Cell Biol** 1999 Apr 5;145(1):141-51

pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion. Cianci C, et al. **J Virol** 1999 Mar; 73(3):1785-94

The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Matrosovich M, et al. **J Virol** 1999 Feb;73(2):1146-55

Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Melikyan GB, et al. **Mol Biol Cell** 1999 Jun;10(6):1821-36

pH-induced conformational changes of membrane-bound influenza hemagglutinin and its effect on target lipid bilayers. Gray C, et al. **Protein Sci** 1998 Nov;7(11):2359-73

Turnover of thrombomodulin at the cell surface occurs at a similar rate to receptors that are not actively internalized. Chu M, et al. **Thromb Haemost** 1998 Jul;80(1):119-27

Membrane fusion by surrogate receptor-bound influenza haemagglutinin. Millar BM, et al. **Virology** 1999 May 10; 257(2):415-23

Domain-structure of cytoplasmic border region is main determinant for palmitoylation of influenza virus hemagglutinin (H7). Ponimaskin E, et al. **Virology** 1998 Sep 30;249(2):325-35

PHARMACOLOGY

Influenza virus hemagglutinin stimulates the protein kinase C activity of human polymorphonuclear leucocytes. Arora DJ, et al. **Arch Virol** 1998;143(10):2029-37

Membrane destabilizing activity of influenza virus hemagglutinin-based synthetic peptide: implications of critical glycine residue in fusion peptide. Matsumoto T. **Biophys Chem** 1999 Jun 7;79(2):153-62

PHYSIOLOGY

Tension of membranes expressing the hemagglutinin of influenza virus inhibits fusion. Markosyan RM, et al. **Biophys J** 1999 Aug;77(2):943-52

Effects of spontaneous bilayer curvature on influenza virus-mediated fusion pores. Razinkov VI, et al. **J Gen Physiol** 1998 Oct;112(4):409-22

Understanding influenza virus pathogenicity. Garten W, et al. **Trends Microbiol** 1999 Mar;7(3):99-100 (16 ref.)

Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Steinhauer DA. **Virology** 1999 May 25; 258(1):1-20 (240 ref.)

ULTRASTRUCTURE

Picture story. Fight the flu. **Nat Struct Biol** 1998 Dec; 5(12):1032

HEMAGGLUTININ-NEURAMINIDASE GLYCOPROTEIN see **HN PROTEIN**

HEMAGGLUTININS

Galectins: a key intersection between glycobiology and immunology. Rabinovich GA, et al. **Braz J Med Biol Res** 1999 Apr;32(4):383-93 (81 ref.)

Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Cotter PA, et al. **Infect Immun** 1998 Dec;66(12):5921-9

The hemagglutination-positive phenotype of Mycoplasma synoviae induces experimental infectious synovitis in chickens more frequently than does the hemagglutination-negative phenotype. Narat M, et al. **Infect Immun** 1998 Dec;66(12):6004-9

ANALYSIS

Transmission electron microscopy studies of Moraxella (Branhamella) catarrhalis. Fitzgerald M, et al. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):57-66

Expression of galectin-1 in the mouse olfactory system. Tenne-Brown J, et al. **Int J Dev Biol** 1998 Sep;42(6):791-9

HEMAGGLUTININS

Impact of microwave heating on hemagglutinins, trypsin inhibitors and protein quality of selected legume seeds. Hernández-Infante M, et al. **Plant Foods Hum Nutr** 1998; 52(3):199–208

Postoperative increase of hemagglutinin titer in ABO-compatible incompatible living related liver transplantation. Suzuki T, et al. **Transplant Proc** 1998 Nov; 30(7):3513–4

BIOSYNTHESIS

A parallel association between differentiation and induction of galectin-1, and inhibition of galectin-3 by retinoic acid in mouse embryonal carcinoma F9 cells. Lu Y, et al. **Biol Chem** 1998 Nov;379(11):1323–31

galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Cindolo L, et al. **Int J Cancer** 1999 Feb 19;84(1):39–43

Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Ellerhorst J, et al. **Int J Oncol** 1999 Feb;14(2):217–24

Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Ellerhorst J, et al. **Int J Oncol** 1999 Feb;14(2):225–32

BLOOD

Antibody screening: elimination of another piece of the test [editorial; comment] Issitt PD. **Transfusion** 1999 Mar; 39(3):229–30. Comment on: Transfusion 1999 Mar;39(3):295–7.

Revisiting the issue: can the reading for serologic reactivity following 37 degrees C incubation be omitted? [see comments] Judd WJ, et al. **Transfusion** 1999 Mar; 39(3):295–9. Comment in: Transfusion 1999 Mar;39(3):229–30.

Evaluation of the gel system for ABO grouping and D typing. Langston MM, et al. **Transfusion** 1999 Mar;39(3):300–5

CHEMISTRY

Preliminary crystallographic studies of a protease resistant botulinum neurotoxin associated protein Hn-33. Hadfield AT, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun; 55 (Pt 6):1237–9

Production, crystallization and diffraction to atomic resolution of an antibody Fv specific for the blood-group A oligosaccharide antigen. Patenaude SI, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(2 (Pt 6)):1456–9

Identification of a carbohydrate-binding site in Physarum haemagglutinin I. Morita M, et al. **Biochem Mol Biol Int** 1998 Oct;46(2):233–40

The characterization of Mycoplasma synoviae EF-Tu protein and proteins involved in hemadherence and their N-terminal amino acid sequences. Benčina D, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):85–94

Variable carbohydrate modifications to the catalytic chains of the RgpA and RgpB proteases of Porphyromonas gingivalis W50. Curtis MA, et al. **Infect Immun** 1999 Aug; 67(8):3816–23

Haemophilus ducreyi secretes a filamentous hemagglutinin-like protein. Ward CK, et al. **J Bacteriol** 1998 Nov;180(22):6013–22

Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. Sharma SK, et al. **J Nat Toxins** 1998 Oct;7(3):239–53

Molecular properties of a hemagglutinin purified from type A Clostridium botulinum. Sharma SK, et al. **J Protein Chem** 1999 Jan;18(1):29–38

Evidence that a globular conformation is not compatible with FhaC-mediated secretion of the Bordetella pertussis filamentous haemagglutinin. Guedin S, et al. **Mol Microbiol** 1998 Aug;29(3):763–74

DIAGNOSTIC USE

Detection of inflammation- and neoplasia-associated alterations in human large intestine using plant/invertebrate lectins, galectin-1 and neoglycoproteins. Brinck U, et al. **Acta Anat (Basel)** 1998;161(1–4):219–33 (90 ref.)

GENETICS

Identification and cloning of rat galectin-2: expression is predominantly in epithelial cells of the stomach. Oka T, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):195–201

Molecular characterization of the hemagglutinin gene and oral immunization with a waterfowl-origin avian influenza virus. Crawford JM, et al. **Avian Dis** 1998 Jul-Sep; 42(3):486–96

Cloning of a galactose-binding lectin from the venom of Trimeresurus stejnegeri. Xu Q, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):733–7

Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. Lu Y, et al. **Biochim Biophys Acta** 1999 Jan 18;1444(1):85–91

Control of galectin gene expression. Chiariotti L, et al. **Biochimie** 1999 Apr;81(4):381–8 (66 ref.)

Vectors for inducible expression of dual epitope-tagged proteins in insect cells. Braun H, et al. **Biotechniques** 1999 Jun;26(6):1038–40, 1042

Amino acid sequence of the D-galactose binding lectin II from the sponge Axinella polypoides (Schmidt) and identification of the carbohydrate binding site in lectin II and related lectin I. Buck F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):153–60

Differences among Helicobacter pylori strains isolated from three different populations and demonstrated by restriction enzyme analysis of an internal fragment of the conserved gene hpaA. Evans DG, et al. **Helicobacter** 1999 Jun; 4(2):82–8

Molecular mechanism for the spontaneous generation of pigmentless Porphyromonas gingivalis mutants. Chen W, et al. **Infect Immun** 1999 Sep;67(9):4926–30

The number of direct repeats in hagA is variable among Porphyromonas gingivalis strains. Kozarov E, et al. **Infect Immun** 1998 Oct;66(10):4721–5

Transposition of the endogenous insertion sequence element IS1126 modulates gingipain expression in Porphyromonas gingivalis. Simpson W, et al. **Infect Immun** 1999 Oct; 67(10):5012–20

Genetic and transcriptional analyses of the Vibrio cholerae mannose-sensitive hemagglutinin type 4 pilus gene locus. Marsh JW, et al. **J Bacteriol** 1999 Feb;181(4):1110–7

Haemophilus ducreyi secretes a filamentous hemagglutinin-like protein. Ward CK, et al. **J Bacteriol** 1998 Nov;180(22):6013–22

GRIFIN, a novel lens-specific protein related to the galectin family. Ogden AT, et al. **J Biol Chem** 1998 Oct 30; 273(44):28889–96

Genotypes of canine distemper virus determined by analysis of the hemagglutinin genes of recent isolates from dogs in Japan. Mochizuki M, et al. **J Clin Microbiol** 1999 Sep; 37(9):2936–42

Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. Rabinovich GA, et al. **J Exp Med** 1999 Aug 2;190(3):385–98

Galectins from sheep gastrointestinal nematode parasites are highly conserved. Greenhalgh CJ, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):285–9

The organization of a galectin gene from Teladorsagia circumcincta. Greenhalgh CJ, et al. **Mol Biochem Parasitol** 1999 Jun 25;101(1–2):199–206

hpaA mutants of Xanthomonas campestris pv. vesicatoria are affected in pathogenicity but retain the ability to induce host-specific hypersensitive reaction. Huguet E, et al. **Mol Microbiol** 1998 Sep;29(6):1379–90

Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Menozzi FD, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12625–30

Recombinant expression of a galectin from the sheep gastrointestinal parasite Teladorsagia circumcincta: its use in isolating galectin-glycoconjugates. Greenhalgh CJ, et al. **Protein Expr Purif** 1999 Jun;16(1):152–9

Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Boursaux-Eude C, et al. **Vaccine** 1999 Jun 4;17(20–21):2651–60

[Comparison of the synonymous and non-synonymous substitution rates in various regions of the neuraminidase and hemagglutinin genes of the influenza A virus] Makarova KS, et al. **Genetika** 1998 Aug;34(8):1040–4 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Serum IgG antibody response to pertussis toxin in persons for whom pertussis vaccination failed depends upon the number of antigens in the vaccine [editorial; comment] Cherry JD. **Clin Infect Dis** 1999 Mar;28(3):560–1. Comment on: Clin Infect Dis 1999 Mar;28(3):552–9.

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis [see comments] Trollfors B, et al. **Clin Infect Dis** 1999 Mar;28(3):552–9. Comment in: Clin Infect Dis 1999 Mar;28(3):560–1.

C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Vasta GR, et al. **Dev Comp Immunol** 1999 Jun-Jul;23(4–5):401–20 (103 ref.)

Identification of immunodominant epitopes in the filamentous hemagglutinin of Bordetella pertussis. Piatti G. **FEMS Immunol Med Microbiol** 1999 Mar;23(3):235–41

Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Katz J, et al. **Infect Immun** 1999 Sep;67(9):4352–9

Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Li Z, et al. **Infect Immun** 1999 Sep;67(9):4780–6

Antigenic analysis of Bordetella pertussis filamentous hemagglutinin with phage display libraries and rabbit anti-filamentous hemagglutinin polyclonal antibodies. Wilson DR, et al. **Infect Immun** 1998 Oct;66(10):4884–94

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Jabbal-Gill I, et al. **Vaccine** 1998 Dec; 16(20):2039–46

Cold-induced augmentation of I blood group antigen interactions with galactophilic lectins. Sudakevitz D, et al. **Zentralbl Bakteriol** 1999 Apr;289(2):147–54

ISOLATION & PURIFICATION

Purification and cell attachment activity of a D-galactose-binding lectin from the skin of sea hare, Aplysia kurodai. Ozeki Y. **Biochem Mol Biol Int** 1998 Aug; 45(5):989–95

Purification of a mannose/glucose-specific hemagglutinin/lectin from a Vibrio cholerae O1 strain. Sasmal D, et al. **FEMS Immunol Med Microbiol** 1999 Mar; 23(3):221–7

Identification of a fimbriae-associated haemagglutinin from Prevotella intermedia. Leung K, et al. **Microb Pathog** 1999 Mar;26(3):139–48

Location of haemagglutinin in bacterial cells of Fusobacterium necrophorum subsp. necrophorum. Kanoe M, et al. **Microbios** 1998;96(383):33–8

Isolation and partial characterisation of galactose-specific lectins from African yam beans, Sphenostyles stenocarpa Harms. Machuka JS, et al. **Phytochemistry** 1999 Jul; 51(6):721–8

METABOLISM

Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance? Fritz P, et al. **Acta Histochem** 1999 Jul;101(3):239–53

Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. François C, et al. **Am J Clin Pathol** 1999 Aug;112(2):194–203

Conjugation of plasmid DNAs with lactose via diazocoupling enhances resistance to restriction enzymes and acquires binding affinity to galactose-specific lectin. Akasaka T, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):323–8

Rapid and efficient inactivation of IL-6 gingipains, lysine- and arginine-specific proteinases from Porphyromonas gingivalis. Banbula A, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):598–602

Purification and cell attachment activity of a D-galactose-binding lectin from the skin of sea hare, Aplysia kurodai. Ozeki Y. **Biochem Mol Biol Int** 1998 Aug; 45(5):989–95

Activation of protein C by arginine-specific cysteine proteinases (gingipains-R) from Porphyromonas gingivalis. Hosotaki K, et al. **Biol Chem** 1999 Jan;380(1):75–80

Fusion of macrophages on an implant surface is associated with down-regulated expression of ligands for galectin-1 and -3 in the rat. Smetana K Jr, et al. **Biomaterials** 1998 Oct;19(19):1799–805

Sequential changes in anti-GAL-1 staining of the rat organ of Corti following amikacin exposure. Bartolomé MV, et al. **Brain Res** 1999 Mar 20;822(1–2):43–51

Role of gingipains R in the pathogenesis of Porphyromonas gingivalis-mediated periodontal disease. Genco CA, et al. **Clin Infect Dis** 1999 Mar;28(3):456–65 (67 ref.)

Amino acid sequence of the D-galactose binding lectin II from the sponge Axinella polypoides (Schmidt) and identification of the carbohydrate binding site in lectin II and related lectin I. Buck F, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):153–60

Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. Chen JM, et al. **FEBS Lett** 1998 Dec 28;441(3):361–5

Purification and characterization of an Aeromonas caviae metalloprotease that is related to the Vibrio cholerae hemagglutinin/protease. Toma C, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):237–42

Enzymatic synthesis of natural and 13C enriched linear poly-N-acetyllactosamines as ligands for galectin-1. Di Virgilio S, et al. **Glycobiology** 1999 Apr;9(4):353–64

Binding of synthetic sulfated ligands by human splenic galectin 1, a beta-galactoside-binding lectin. Allen HJ, et al. **Glycoconj J** 1998 Jul;15(7):691–5

Correspondence of gradual developmental increases of expression of galectin-reactive glycoconjugates with alterations of the total contents of the two differentially regulated galectins in chicken intestine and liver as indication for overlapping functions. Lips KS, et al. **Histol Histopathol** 1999 Jul;14(3):743–60

Sertoli cell expression of galectin-1 and -3 and accessible binding sites in normal human testis and Sertoli cell only-syndrome. Wollina U, et al. **Histol Histopathol** 1999 Jul;14(3):779–84

Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. Walzel H, et al. **Immunol Lett** 1999 Apr 15;67(3):193–202

Inhibitory effects of protamines on proteolytic and adhesive activities of Porphyromonas gingivalis. Kontani M, et al. **Infect Immun** 1999 Sep;67(9):4917–20

Effect of temperature on growth, hemagglutination, and protease activity of Porphyromonas gingivalis. Percival RS, et al. **Infect Immun** 1999 Apr;67(4):1917–21

Characterization of the avian pathogenic Escherichia coli hemagglutinin Tsh, a member of the immunoglobulin A protease-type family of autotransporters. Stathopoulos C, et al. **Infect Immun** 1999 Feb;67(2):772–81

Modulation of major histocompatibility complex protein expression by human gamma interferon mediated by cysteine proteinase-adhesin polyproteins of Porphyromonas gingivalis. Yun PL, et al. **Infect Immun** 1999 Jun;67(6):2986–95

Porphyrin-mediated binding to hemoglobin by the HA2

domain of cysteine proteinases (gingipains) and hemagglutinins from the periodontal pathogen Porphyromonas gingivalis. DeCarlo AA, et al. **J Bacteriol** 1999 Jun;181(12):3784–91

Hemoglobinase activity of the lysine gingipain protease (Kgp) of Porphyromonas gingivalis W83. Lewis JP, et al. **J Bacteriol** 1999 Aug;181(16):4905–13

Arg-gingipain acts as a major processing enzyme for various cell surface proteins in Porphyromonas gingivalis. Kadowaki T, et al. **J Biol Chem** 1998 Oct 30; 273(44):29072–6

Determination and characterization of the hemagglutinin-associated short motifs found in Porphyromonas gingivalis multiple gene products. Shibata Y, et al. **J Biol Chem** 1999 Feb 19;274(8):5012–20

Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. André S, et al. **J Cancer Res Clin Oncol** 1999 Aug-Sep;125(8–9):461–74

In vitro influence of lectins and neoglycoconjugates on the growth of three human sarcoma cell lines. Remmelink M, et al. **J Cancer Res Clin Oncol** 1999;125(5):275–85

Developmental association of the beta-galactoside-binding protein galectin-1 with the nuclear matrix of rat calvarial osteoblasts. Choi JY, et al. **J Cell Sci** 1998 Oct;111 (Pt 20):3035–43

Two domains of rat galectin-4 bind to distinct structures of the intercellular borders of colorectal epithelia. Wasano K, et al. **J Histochem Cytochem** 1999 Jan;47(1):75–82

Evidence that a globular conformation is not compatible with FhaC-mediated secretion of the Bordetella pertussis filamentous haemagglutinin. Guédin S, et al. **Mol Microbiol** 1998 Aug;29(3):763–74

PHARMACOLOGY

Negative cell cycle control of human T cells by beta-galactoside binding protein (beta GBP): induction of programmed cell death in leukaemic cells. Novelli F, et al. **J Cell Physiol** 1999 Jan;178(1):102–8

Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. Vespa GN, et al. **J Immunol** 1999 Jan 15; 162(2):799–806

Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components of extracellular matrix. Moiseeva EP, et al. **J Vasc Res** 1999 Jan-Feb; 36(1):47–58

PHYSIOLOGY

The filamentous hemagglutinin of Bordetella parapertussis is the major adhesin in the phase-dependent interaction with NCI-H292 human lung epithelial cells. van den Akker WM. **Biochem Biophys Res Commun** 1998 Nov 9; 252(1):128–33

Endogenous galectins and effect of galectin hapten inhibitors on the differentiation of the chick mesonephros. Murphy KM, et al. **Dev Dyn** 1999 Jul;215(3):248–63

Modulation of interleukin-8 activity by gingipains from Porphyromonas gingivalis: implications for pathogenicity of periodontal disease. Mikolajczyk-Pawlinska J, et al. **FEBS Lett** 1998 Dec 4;440(3):282–6

Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis. Li X, et al. **Infect Immun** 1999 Jun;67(6):2822–33

Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Rupp ME, et al. **Infect Immun** 1999 May;67(5):2627–32

Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Rupp ME, et al. **Infect Immun** 1999 May; 67(5):2656–9

A role for the mannose-sensitive hemagglutinin in biofilm formation by Vibrio cholerae El Tor. Watnick PI, et al. **J Bacteriol** 1999 Jun;181(11):3606–9

Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. Pace KE, et al. **J Immunol** 1999 Oct 1; 163(7):3801–11

[Galectins and apoptosis] Hirabayashi J, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2442–9 (37 ref.) **(Jpn)**

HEMAGGLUTININS, PLANT see **LECTINS**

HEMAGGLUTININS, VIRAL

ANALYSIS

Characterization of haemagglutinin-esterase protein (HE) of murine corona virus DVIM by monoclonal antibodies. Kasai H, et al. **Arch Virol** 1998;143(10):1941–8

BIOSYNTHESIS

Using a defective-interfering RNA system to express the HE protein of mouse hepatitis virus for studying viral pathogenesis. Zhang X, et al. **Adv Exp Med Biol** 1998; 440:521–8

CHEMISTRY

X-ray crystallographic determination of the structure of the influenza C virus haemagglutinin-esterase-fusion glycoprotein. Zhang X, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):945–61

Identification of a novel HA conformational change inhibitor of human influenza virus. Yoshimoto J, et al. **Arch Virol** 1999;144(5):865–78

The cytoplasmic tail of the influenza C virus glycoprotein HEF negatively affects transport to the cell surface. Oeffner F, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):363–9

Structural intermediates in influenza haemagglutinin-mediated fusion. Chernomordik LV, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):33–42 (53 ref.)

The paramyxovirus fusion protein forms an extremely stable core trimer: structural parallels to influenza virus haemagglutinin and HIV-1 gp41. Lamb RA, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):11–9

Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Rosenthal PB, et al. **Nature** 1998 Nov 5;396(6706):92–6

Structural and functional studies of the measles virus hemagglutinin: identification of a novel site required for CD46 interaction. Patterson JB, et al. **Virology** 1999 Mar 30;256(1):142–51

Primary structures of hemagglutinin-esterase and spike glycoproteins of murine coronavirus DVIM. Morita E, et al. **Virus Genes** 1998;17(2):123–8

DRUG EFFECTS

Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. Plotch SJ, et al. **J Virol** 1999 Jan; 73(1):140–51

GENETICS

New genetic group of measles virus isolated in the People's Republic of China. Xu W, et al. **Virus Res** 1998 Apr; 54(2):147–56

IMMUNOLOGY

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Saelens X, et al. **Eur J Biochem** 1999 Feb;260(1):166–75

Evaluation of hemagglutinin protein-specific immunoglobulin M for diagnosis of measles by an enzyme-linked immunosorbent assay based on recombinant protein produced in a high-efficiency mammalian expression system. Bouche FB, et al. **J Clin Microbiol** 1998 Dec;36(12):3509–13

A simplified immunoassay based on measles virus recombinant hemagglutinin protein for testing the immune status of vaccinees. Bouche F, et al. **J Virol Methods** 1998 Sep;74(1):77–87

Enhanced antigenicity of a four-contact-residue epitope of the measles virus hemagglutinin protein by phage display libraries: evidence of a helical structure in the putative active site. Deroo S, et al. **Mol Immunol** 1998 Jun; 35(8):435–43

Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Crawford J, et al. **Vaccine** 1999 May 4;17(18):2265–74

A novel immunization method to induce cytotoxic T-lymphocyte responses (CTL) against plasmid-encoded herpes simplex virus type-1 glycoprotein D. Cruz PE, et al. **Vaccine** 1999 Mar 5;17(9–10):1091–9

Location of a linear epitope recognized by monoclonal antibody S16 on the hemagglutinin-esterase glycoprotein of influenza C virus. Muraki Y, et al. **Virus Res** 1999 May; 61(1):53–61

[A common antigenic epitope in influenza A virus (H1, H2, H5, H6) hemagglutinin] Smirnov IuA, et al. **Vopr Virusol** 1999 May-Jun;44(3):111–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Coronavirus envelope glycoprotein assembly complexes. Nguyen VP, et al. **Adv Exp Med Biol** 1998;440:361–5

The cytoplasmic tail of the influenza C virus glycoprotein HEF negatively affects transport to the cell surface. Oeffner F, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):363–9

Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. Klausegger A, et al. **J Virol** 1999 May;73(5):3737–43

The hemagglutinin-esterase of mouse hepatitis virus strain S is a sialate-4-O-acetylesterase. Regl G, et al. **J Virol** 1999 Jun;73(6):4721–7

Induction of interferon-alpha by glycoprotein D of herpes simplex virus: a possible role of chemokine receptors. Ankel H, et al. **Virology** 1998 Nov 25;251(2):317–26

Use of site-specific mutagenesis and monoclonal antibodies to map regions of CD46 that interact with measles virus H protein. Hsu EC, et al. **Virology** 1999 Jun 5;258(2):314–26

Structural and functional studies of the measles virus hemagglutinin: identification of a novel site required for CD46 interaction. Patterson JB, et al. **Virology** 1999 Mar 30;256(1):142–51

The isolation of the ectodomain of the alphavirus E1 protein as a soluble hemagglutinin and its crystallization. Wengler G, et al. **Virology** 1999 May 10;257(2):472–82

Processing of N-linked oligosaccharides on the measles virus glycoproteins: importance for antigenicity and for production of infectious virus particles. Bolt G, et al. **Virus Res** 1999 May;61(1):43–51

[Functional activity of hemagglutinins from Hantaan viruses strains and use of hemagglutinating antigens for serodiagnosis hemorrhagic fever with kidney syndrome] Kushnareva TV, et al. **Vopr Virusol** 1999 Jul-Aug; 44(4):186–90 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

[The effect of influenza virus hemagglutinin on erythrocytes and thrombocytes] Zhilinskaia IN, et al. **Izv Akad Nauk Ser Biol** 1999 May-Jun;(3):355–8 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The H gene of rodent brain-adapted measles virus confers neurovirulence to the Edmonston vaccine strain. Duprex WP, et al. **J Virol** 1999 Aug;73(8):6916–22

A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism. Johnston IC, et al. **J Virol** 1999 Aug;73(8):6903–15

Cell surface expression of biologically active influenza C virus HEF glycoprotein expressed from cDNA. Pekosz A, et al. **J Virol** 1999 Oct;73(10):8808–12

The influenza haemagglutinin-induced fusion cascade: effects of target membrane permeability changes. Blumenthal R, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):43–7

[How can the carbohydrate moiety of influenza virus HA contribute to the initiation of viral infection?] Ohuchi M, et al. **Uirusu** 1998 Jun;48(1):1–8 (26 ref.) **(Jpn)**

[Differences in properties and structure of hemagglutinins from influenza virus variants, adapted to lungs of mice and beta-inhibitors from murine serum] Shilov AA, et al. **Dokl Akad Nauk** 1999 Mar;365(3):406–8 **(Rus)**

HEMANGIOBLASTOMA

Hemangioblastoma of the L-5 nerve root. Case illustration. Chazono M, et al. **J Neurosurg** 1999 Jan;90(1 Suppl):160

BLOOD SUPPLY

An intracranial aneurysm on the feeding artery of a cerebellar hemangioblastoma. Case report. Guzman R, et al. **J Neurosurg** 1999 Jul;91(1):136–8

COMPLICATIONS

Postpartum cerebellar herniation in von Hippel-Lindau syndrome. Othmane IS, et al. **Am J Ophthalmol** 1999 Sep; 128(3):387–9

Syringomyelia in myotonic dystrophy due to spinal hemangioblastoma. Mascalchi M, et al. **Surg Neurol** 1998 Nov;50(5):446–8

[Analysis of spinal cord hemangioblastoma in von Hippel-Lindau disease] Nakashima H, et al. **No Shinkei Geka** 1999 Jun;27(6):533–40 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Metastatic brain adenocarcinoma masquerading as recurrent haemangioblastoma. Rosenthal G, et al. **Acta Neurochir (Wien)** 1998;140(11):1207–8

Hemangioblastoma of the filum terminale: MR imaging. Arbelaez A, et al. **AJR Am J Roentgenol** 1999 Sep; 173(3):857–8

Cerebellar hemangioblastoma. de Jonge JC, et al. **J Belge Radiol** 1998 Oct;81(5):236

Syringomyelia, hemangioblastomas, and Chiari I malformation. Case illustration. Lonser RR, et al. **J Neurosurg** 1999 Jan;90(1):169

Cerebellar hemangioblastoma as a late manifestation of sporadic von Hippel-Lindau disease. Kume H, et al. **J Urol** 1999 Mar;161(3):911–2

Hemangioblastoma mimicking tentorial meningioma: preoperative embolization of the meningeal arterial blood supply--case report. Tsugu H, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):45–8

DRUG THERAPY

Intratumoral ethanol injection [letter] Okada Y, et al. **J Neurosurg** 1999 Sep;91(3):521–3

Interferon for tufted angioma [letter; comment] Wollina U. **Pediatr Dermatol** 1999 Jul-Aug;16(4):338. Comment on: Pediatr Dermatol 1998 Nov-Dec;15(6):482.

ETIOLOGY

Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Webster AR, et al. **Arch Ophthalmol** 1999 Mar;

117(3):371-8
Hepatic hemangioblastoma: an unusual presentation of von Hippel-Lindau disease. Hayasaka K, et al. **J Comput Assist Tomogr** 1999 Jul-Aug;23(4):565-6

GENETICS

Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, et al. **Blood** 1998 Nov 1;92(9):3388-93
Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Olschwang S, et al. **Hum Mutat** 1998;12(6):424-30
The two-stage mutation model in retinal hemangioblastoma. Chang JH, et al. **Ophthalmic Genet** 1998 Sep;19(3):123-30
[Von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management] Richard S, et al. **Neurochirurgie** 1998 Nov; 44(4):258-66 (59 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Expression of vascular endothelial growth factor in cerebellar hemangioblastomas does not correlate with tumor angiogenesis. Vaquero J, et al. **Cancer Lett** 1998 Oct 23; 132(1-2):213-7
Vascular permeability factor expression in cerebellar hemangioblastomas: correlation with tumor-associated cysts. Vaquero J, et al. **J Neurooncol** 1999 Jan;41(1):3-7

PATHOLOGY

Contralateral recurrent cerebellar hemangioblastoma--a case report. Chang DS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Aug; 14(8):514-8
Peripheral nerve hemangioblastoma. Giannini C, et al. **Mod Pathol** 1998 Oct;11(10):999-1004
15-year-old male with neck pain [clinical conference] Huhn SL, et al. **Pediatr Neurosurg** 1998 Sep;29(3):154-9
Sellar-sphenoid sinus hemangioblastoma: case report. Kachhara R, et al. **Surg Neurol** 1998 Nov;50(5):461-3; discussion 463-4

RADIOGRAPHY

Sellar-sphenoid sinus hemangioblastoma: case report. Kachhara R, et al. **Surg Neurol** 1998 Nov;50(5):461-3; discussion 463-4

SURGERY

Surgical management of intramedullary hemangioblastoma of the spinal cord. Cristante L, et al. **Acta Neurochir (Wien)** 1999;141(4):333-9; discussion 339-40
Multiple cerebellar haemangioblastomas symptomatic during pregnancy [letter] Turgut M, et al. **Br J Neurosurg** 1999 Feb;13(1):93
Successful removal of a hemangioblastoma from the medulla oblongata: case report. Lu K, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):503-8
Intramedullary hemangioblastoma of the medulla oblongata--two case reports and review of the literature. Fukushima T, et al. **Neurol Med Chir (Tokyo)** 1998 Aug; 38(8):489-98 (31 ref.)
Hemangioblastoma mimicking tentorial meningioma: preoperative embolization of the meningeal arterial blood supply--case report. Tsugu H, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):45-8
Hemangioblastoma of the filum terminale: case report. Tibbs RE Jr, et al. **Neurosurgery** 1999 Jan;44(1):221-3
Gamma knife radiosurgery for hemangioblastomas. Pan L, et al. **Stereotact Funct Neurosurg** 1998 Oct;70 Suppl 1:179-86
Extradural spinal hemangioblastomas: report of two cases. Tronnier V, et al. **Zentralbl Neurochir** 1999;60(2):86-92

THERAPY

Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Logan TF, et al. **Clin Exp Immunol** 1998 Dec;114(3):347-54
Treatment of tufted angioma with interferon alfa: role of bFGF [letter] [see comments] Robenzadeh A, et al. **Pediatr Dermatol** 1998 Nov-Dec;15(6):482. Comment in: Pediatr Dermatol 1999 Jul-Aug;16(4):338.

HEMANGIOENDOTHELIOMA

Cardiac hemangioendothelioma. Hongquan Y, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):655-8 (10 ref.)

CLASSIFICATION

[Hemangioendotheliomas--evolution of a concept of a heterogeneous group of vascular neoplasms] Mentzel T. **Verh Dtsch Ges Pathol** 1998;82:99-111 (27 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Infantile hemangioendothelioma of the thymus with massive pleural effusion and Kasabach--Merritt syndrome: histopathological, flow cytometrical analysis of the tumor. Hiraiwa H, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):604-7
Sudden death with malignant hemangioendothelioma originating in the pericardium--a case report. Yoshida A, et al. **Angiology** 1999 Jul;50(7):607-11
Critical obstruction of the right ventricular outflow tract by a primary hemangioendothelioma in a seven month old. Robinson HA, et al. **Cardiol Young** 1999 Mar;9(2):185-8
Kaposiform hemangioendothelioma with associated Kasabach-Merritt phenomenon. The Hemophilia Growth and Development Study. Arnaout MK, et al. **J Pediatr** 1998 Dec;133(6):788

DIAGNOSIS

Hemangioendothelioma of the adrenal gland in a 4-month-old male infant. Soboleski D, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):235-7
Hemangioendothelioma of the spleen: imaging findings at color Doppler, US, and CT. Ferrozzi F, et al. **Clin Imaging** 1999 Mar-Apr;23(2):111-4
12000 miles for parental reassurance [letter] van Delft F, et al. **Lancet** 1998 Oct 3;352(9134):1122
Endovascular papillary angioendothelioma (Dabska tumor) of bone. McCarthy EF, et al. **Skeletal Radiol** 1999 Feb; 28(2):100-3
[Case for diagnosis. Masson tumor] Vieira-Mota AJ, et al. **Ann Dermatol Venereol** 1999 May;126(5):443-4 **(Fre)**
[Value of imaging in early diagnosis of peripheral vein tumors] Louail B, et al. **J Radiol** 1998 Nov;79(11):1387-91 (Eng. Abstr.) **(Fre)**
[Costal epithelioid hemangioendothelioma. A case report (letter)] Nicolau Pastrie F, et al. **Arch Bronconeumol** 1998 Oct;34(9):467 **(Spa)**

DRUG THERAPY

In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. Wang C, et al. **J Invest Dermatol** 1999 May; 112(5):775-81
Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D. Hu B, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):567-9

GENETICS

Hemangioendothelioma of bone in a patient with a constitutional supernumerary marker. Rogatto SR, et al. **Cancer Genet Cytogenet** 1999 Apr;110(1):23-7

METABOLISM

Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Khalidi HS, et al. **Mod Pathol** 1998 Oct;11(10):983-8

PATHOLOGY

Infantile hemangioendothelioma of the thymus with massive pleural effusion and Kasabach--Merritt syndrome: histopathological, flow cytometrical analysis of the tumor. Hiraiwa H, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):604-7
Reactive angioendotheliomatosis in an infant. Brazzelli V, et al. **Am J Dermatopathol** 1999 Feb;21(1):42-5
Papillary intralymphatic angioendothelioma (PILA): a report of twelve cases of a distinctive vascular tumor with phenotypic features of lymphatic vessels. Fanburg-Smith JC, et al. **Am J Surg Pathol** 1999 Sep;23(9):1004-10
Intravascular papillary endothelial hyperplasia with presumed bilateral orbital varices. Shields JA, et al. **Arch Ophthalmol** 1999 Sep;117(9):1247-9
Cutaneous necrosis by cold agglutinins associated with glomeruloid reactive angioendotheliomatosis. Porras-Luque JI, et al. **Br J Dermatol** 1998 Dec; 139(6):1068-72
Malignant vascular tumors in young patients. Lezama-del Valle P, et al. **Cancer** 1998 Oct 15;83(8):1634-9
A case of epithelioid haemangioendothelioma (EHE) of the lung with bronchial brushing cytology. Kumar RP, et al. **Cytopathology** 1999 Apr;10(2):132-6
Recurrent intracranial Masson's vegetant intravascular hemangioendothelioma. Case report and review of the literature. Avellino AM, et al. **J Neurosurg** 1999 Aug; 91(2):308-12 (20 ref.)
Hemangioma of spinal nerve root. Roncaroli F, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):175-80
Regarding "Primary aortic intimal sarcoma of the endothelial cell type with long-term survival" [letter] Seelig MH, et al. **J Vasc Surg** 1998 Oct;28(4):756
Infantile hemangioendothelioma of the liver. Amonkar P, et al. **Med Pediatr Oncol** 1999 May;32(5):392-4
Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene. Mühlner U, et al. **Oncogene** 1999 Jul 22;18(29):4200-10
Endovascular papillary angioendothelioma (Dabska tumor) [letter; comment] Fukunaga M. **Pathol Int** 1998 Oct; 48(10):840-1. Comment on: Pathol Int 1998 Feb;48(2):164-7.
Juvenile hemangioma (infantile hemangioendothelioma) of the parotid gland associated with cytomegalovirus infection. Horie Y, et al. **Pathol Int** 1999 Jul;49(7):668-71
Malignant hemangioendothelioma of the small intestine: report of a case. Yoshida R, et al. **Surg Today** 1999; 29(5):439-42 (15 ref.)
[Diagnostic case. Angiotrophic lymphoma with T-cell immunophenotype (letter)] Marquart-Elbaz C, et al. **Ann Dermatol Venereol** 1998 May;125(5):345-6 **(Fre)**
[Hemangioendotheliomas--evolution of a concept of a heterogeneous group of vascular neoplasms] Mentzel T. **Verh Dtsch Ges Pathol** 1998;82:99-111 (27 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Maffucci syndrome: a false venous malformation? A case with hemangioendothelioma with fusiform cells] Enjolras O, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):512-5 (Eng. Abstr.) **(Fre)**
[The clinical picture, diagnosis and treatment of benign vascular tumors of the spine] Slyn'ko EI. **Klin Khir** 1998; (9-10):37-40 (Eng. Abstr.) **(Rus)**

SECONDARY

Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report. Shokunbi WA, et al. **Afr J Med Med Sci** 1996 Sep;25(3):293-6
Malignant hemangioendothelioma presenting as multifocal intraskeletal lesions during pregnancy. A case report. Ilasi JA, et al. **J Reprod Med** 1999 Jan;44(1):49-52

SURGERY

[Malignant hemangioendothelioma of the thyroid gland: new results on pathogenesis, therapy and prognosis] Rhomberg W, et al. **Wien Klin Wochenschr** 1998 Jul 31; 110(13-14):479-84 (Eng. Abstr.) **(Ger)**

THERAPY

Hepatic hemangioendothelioma: clinical experience and management strategy. Daller JA, et al. **J Pediatr Surg** 1999 Jan;34(1):98-105; discussion 105-6
[Interventional therapy for hemangioendothelioma of the liver in a newborn infant using a central venous approach] Peuster M, et al. **Z Kardiol** 1998 Oct;87(10):832-6 (Eng. Abstr.) **(Ger)**

HEMANGIOENDOTHELIOMA, EPITHELIOID

COMPLICATIONS

Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. Traverse JH, et al. **Circulation** 1999 Aug 3;100(5):564-5

CONGENITAL

Congenital hemihypertrophy and epithelioid haemangioendothelioma in a 10-year-old boy: a case report. Miller JH, et al. **Pediatr Radiol** 1999 Aug; 29(8):613-6

DIAGNOSIS

Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. Traverse JH, et al. **Circulation** 1999 Aug 3;100(5):564-5
Epithelioid haemangioendothelioma of the lung: a high malignancy case. Paciocco G, et al. **Monaldi Arch Chest Dis** 1999 Jun;54(3):231-3
Epithelioid hemangioendothelioma of the lower extremity. Ignacio EA, et al. **Radiographics** 1999 Mar-Apr;19(2):531-7
Epithelioid hemangioendothelioma of the greater omentum: report of a case. Ratan S, et al. **Surg Today** 1999; 29(9):919-21
[A young oligosymptomatic woman] Poza A, et al. **Rev Clin Esp** 1999 Apr;199(4):251-2 (12 ref.) **(Spa)**

DRUG THERAPY

Aggressive form of pleural epithelioid haemangioendothelioma: complete response after chemotherapy. Pinet C, et al. **Eur Respir J** 1999 Jul; 14(1):237-8

PATHOLOGY

Epithelioid hemangioendothelioma. Pälsson B. **Acta Oncol** 1999;38(5):659-61
Epithelioid hemangioendothelioma presenting in the skin: a clinicopathologic study of eight cases. Quante M, et al. **Am J Dermatopathol** 1998 Dec;20(6):541-6 (33 ref.)
Hobnail hemangioma: a pseudomalignant vascular lesion with a reappraisal of targetoid hemosiderotic hemangioma. Guillou L, et al. **Am J Surg Pathol** 1999 Jan;23(1):97-105
Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Makhlouf HR, et al. **Cancer** 1999 Feb 1;85(3):562-82
Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Kitaichi M, et al. **Eur Respir J** 1998 Jul;12(1):89-96 (33 ref.)
Intraosseous epithelioid hemangioendothelioma of the mandible: a case report with an immunohistochemical study. Hamakawa H, et al. **J Oral Pathol Med** 1999 May; 28(5):233-7
Epithelioid hemangioendothelioma with marked liver deformity and secondary Budd-Chiari syndrome: pathological and radiological correlation. Hayashi Y, et al. **Pathol Int** 1999 Jun;49(6):547-52

RADIOGRAPHY

Metastatic pulmonary epithelioid hemangioendothelioma with peculiar radiographic features. Nagata N, et al. **Respiration** 1999;66(1):78–80

SECONDARY

Epithelioid hemangioendothelioma with solitary bone location associated to multiple lung and liver lesions. A case report. Dechambre SD, et al. **Acta Radiol** 1999 Mar; 40(2):217–9

Epithelioid hemangioendothelioma, multiple focal nodular hyperplasias, and cavernous hemangiomas of the liver. Bralet MP, et al. **Arch Pathol Lab Med** 1999 Sep; 123(9):846–9

[Clinical case of the month. Multiple pulmonary nodules. Epithelioid hemangioendothelioma] Vandenheede M, et al. **Rev Med Liege** 1998 Aug;53(8):454–8 (Eng. Abstr.) **(Fre)**

[Case report of epithelioid hemangioendothelioma of the frontal region metastatic to the parotid gland] Schneider B, et al. **Laryngorhinootologie** 1998 Dec;77(12):728–31 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Liver transplantation for epithelioid hemangioendothelioma. Hung CF, et al. **Transplant Proc** 1998 Nov;30(7):3307–9

VETERINARY

Epithelioid haemangioendothelioma of the lung in a dog. Machida N, et al. **J Comp Pathol** 1998 Oct;119(3):317–22

HEMANGIOMA

Intracortical hemangioma of bone. Report of two cases and review of the literature. López-Barea F, et al. **J Bone Joint Surg Am** 1998 Nov;80(11):1673–8 (22 ref.)

Hemangiomas in children. Drolet BA, et al. **N Engl J Med** 1999 Jul 15;341(3):173–81 (73 ref.)

New clinical observations in hemangiomas. Blei F. **Semin Cutan Med Surg** 1999 Sep;18(3):187–94 (106 ref.)

Vascular anomalies of the mediastinum. Fishman SJ. **Semin Pediatr Surg** 1999 May;8(2):92–8 (21 ref.)

Vertebral hemangiomas: diagnosis, management, natural history and clinicopathological correlates in 86 patients. Pastushyn AI, et al. **Surg Neurol** 1998 Dec;50(6):535–47

[Sclerosing tufted angioma. Apropos of 4 cases involving lower limbs] Catteau B, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):682–7 (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Atypical hepatic hemangiomas with intense arterial enhancement and early fading. Martí-Bonmatí L, et al. **Abdom Imaging** 1999 Mar–Apr;24(2):147–52

Upper posterior mediastinal tumor supplied by an atrial branch of the left circumflex artery. Ilia R, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):467–8

CHEMICALLY INDUCED

Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis [letter] De Felipe I, et al. **Arch Dermatol** 1998 Nov;134(11):1487–8

Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas [letter] Firooz A, et al. **J Am Acad Dermatol** 1999 Apr;40(4):646–7

Eruptive cherry angiomas and irritant symptoms after one acute exposure to the glycol ether solvent 2-butoxyethanol. Raymond LW, et al. **J Occup Environ Med** 1998 Dec; 40(12):1059–64

COMPLICATIONS

Hydrops foetalis caused by hepatic haemangioma. Albano G, et al. **Acta Paediatr** 1998 Dec;87(12):1307–9

Venous infarction from a venous angioma occurring after thrombosis of a drainage vein. Lai PH, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1698–9

Familial idiopathic myelofibrosis and multiple hemangiomas. Bonduel M, et al. **Am J Hematol** 1998 Oct;59(2):175–7

Unexplained haemoglobinuria may have been haematuria [letter] Mortensen S. **BMJ** 1999 Jan 16;318(7177):192

Verruciform xanthoma arising in an arteriovenous haemangioma [letter] Kishimoto S, et al. **Br J Dermatol** 1998 Sep;139(3):546–8

Distortion of subcapsular hepatic hemangioma by hepatic cirrhosis. de Caralt TM, et al. **Can Assoc Radiol J** 1999 Apr;50(2):137–8

Temporal bone hemangioma as a cause of facial paralysis. Palacios E, et al. **Ear Nose Throat J** 1999 Feb;78(2):84

Acute spinal cord compression due to intraspinal bleeding from a vertebral hemangioma: two case-reports. Castel E, et al. **Eur Spine J** 1999;8(3):244–8

A unique cause of unconscious urinary incontinence. Bellina J, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(1):36–8

Localized soft tissue angiomatosis with subsequent development of angiolymphoid hyperplasia with eosinophilia. Misago N, et al. **J Dermatol** 1999 Jan; 26(1):48–55

Complex right hemisphere developmental venous anomaly associated with multiple facial hemangiomas. Case report. Aagaard BD, et al. **J Neurosurg** 1999 Apr;90(4):766–9

Successful treatment of obstructive sleep apnea with use of nasal continuous positive airway pressure in three patients with mucosal hemangiomas of the oral cavity. Kimura K, et al. **Mayo Clin Proc** 1999 Feb;74(2):155–8

Temporal lobe epilepsy associated with cerebral venous angioma--case report. Fujii M, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):413–6

Cavernous angioma associated with venous angioma--two case reports. Kuroiwa T, et al. **Neurol Med Chir (Tokyo)** 1998 Oct;38(10):648–53

Coloboma of the lens, optic nerve hypoplasia, and orbital hemangioma--a possible developmental field defect. Fard AK, et al. **Ophthalmic Genet** 1998 Dec;19(4):209–12

Surface hemangiomas presenting as bone lesions. Weiner SD, et al. **Orthopedics** 1999 May;22(5):539–41

Phakomatosis pigmentovascularis: A new case with renal angiomas and some considerations about the classification. Di Landro A, et al. **Pediatr Dermatol** 1999 Jan–Feb; 16(1):25–30

Progressive neurological symptoms in a diabetic patient. al-Mahroos S, et al. **Postgrad Med J** 1998 Nov; 74(877):699–700

Debulking of a gastrointestinal hemangioma alleviates coagulopathy associated with Kasabach-Merritt syndrome. Mahmoud NN, et al. **Surgery** 1999 Feb;125(2):236–8

Pathophysiology and treatment of fetal anemia due to placental chorioangioma. Haak MC, et al. **Ultrasound Obstet Gynecol** 1999 Jul;14(1):68–70

Acute onset of coagulopathy in a patient with Kasabach-Merritt syndrome following transurethral resection of bladder tumor. Shoji N, et al. **Urol Int** 1998; 61(2):115–8

[Kasabach-Merritt syndrome on a congenital tufted angioma] Enjolras O, et al. **Ann Dermatol Venereol** 1998 Apr; 125(4):257–60 (Eng. Abstr.) **(Fre)**

[Multiple hepatic tumors] Marie I, et al. **Rev Med Interne** 1998 Jul;19(7):516–7 **(Fre)**

[Compressive vertebral angiomas: a case report] Ben Hamouda I, et al. **Tunis Med** 1999 Apr;77(4):236–41 (Eng. Abstr.) **(Fre)**

[Gastric polypoid angioma: a rare cause of bleeding in the elderly. Report of a case and review of the literature] Pelizzari E, et al. **Minerva Chir** 1998 May;53(5):405–10 (18 ref.) (Eng. Abstr.) **(Ita)**

[Hydrops fetalis correlated with voluminous chorioangioma of the placenta] Berzioli M, et al. **Pediatr Med Chir** 1999 Jan–Feb;21(1):37–8 (Eng. Abstr.) **(Ita)**

[Primary racemose hemangioma of bronchial artery] Sukoh N, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):67–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[A case of cerebellar hematoma due to venous angioma presenting trigeminal dysfunction] Hayashida O, et al. **No Shinkei Geka** 1999 Mar;27(3):233–6 (Eng. Abstr.) **(Jpn)**

[Treatment of Kasabach Merritt syndrome] Lanau Arilla MP, et al. **Sangre (Barc)** 1998 Jun;43(3):218–22 (35 ref.) **(Spa)**

CONGENITAL

Resection of a large right atrial hemangioma in a neonate after prenatal diagnosis. Eckstein FS, et al. **Ann Thorac Surg** 1999 Sep;68(3):1074–5

Caudal appendage in a full-term infant. Svatek M, et al. **Curr Opin Pediatr** 1998 Dec;10(6):635–9

Cutaneous angiosarcoma arising on the radiation site of a congenital facial hemangioma [letter] Cabo H, et al. **Int J Dermatol** 1998 Aug;37(8):638–9

Images in clinical medicine. Congenital hemangioma. Bonifazi E, et al. **N Engl J Med** 1999 Apr 8;340(14):1080

[Kasabach-Merritt syndrome on a congenital tufted angioma] Enjolras O, et al. **Ann Dermatol Venereol** 1998 Apr; 125(4):257–60 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Littoral cell angioma of the spleen: US and MR imaging findings. Oliver-Goldaracena JM, et al. **Abdom Imaging** 1998 Nov–Dec;23(6):636–9

Chemotherapy-treated liver metastases mimicking hemangiomas on MR images. Semelka RC, et al. **Abdom Imaging** 1999 Jul–Aug;24(4):378–82

The importance of arthroscopy in diagnosing synovial haemangioma of the knee joint. Farkas C, et al. **Acta Chir Hung** 1998;37(1–2):17–22 (22 ref.)

Diffuse neonatal haemangiomatosis: new views on diagnostic criteria and prognosis. Lopriore E, et al. **Acta Paediatr** 1999 Jan;88(1):93–7

Diaphragmatic haemangioma. A case report. Kaniklides C, et al. **Acta Radiol** 1999 May;40(3):329–32

Lumbar extradural hemangiomas: report of three cases. Rovira A, et al. **AJNR Am J Neuroradiol** 1999 Jan; 20(1):27–31

Choroidal hemangioma: MR findings and differentiation from uveal melanoma. Stroszczynski C, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1441–7

Hemangioma of the rib: a rare diagnosis. Clements RH, et al. **Am Surg** 1998 Nov;64(11):1027–9

Ureteric haemangioma masquerading as multiple transitional cell tumours. Khastgir J, et al. **BJU Int** 1999 Mar; 83(4):518–9

Distortion of subcapsular hepatic hemangioma by hepatic cirrhosis. de Caralt TM, et al. **Can Assoc Radiol J** 1999 Apr;50(2):137–8

Musculoskeletal case 5. Hemangioma of bone. Hodge JC. **Can J Surg** 1999 Aug;42(4):252, 267–8

Not by blood alone: diagnosis of hemangiomas by fine-needle aspiration. Layfield LJ, et al. **Diagn Cytopathol** 1998 Oct; 19(4):250–4

Temporal bone hemangioma as a cause of facial paralysis. Palacios E, et al. **Ear Nose Throat J** 1999 Feb;78(2):84

Tufted angioma. Wilmer A, et al. **Eur J Dermatol** 1999 Jan–Feb;9(1):51–3

Anaemia, thrombocytopenia and coagulopathy due to occult diffuse infantile haemangiomatosis of spleen and pancreas. Schulz AS, et al. **Eur J Pediatr** 1999 May;158(5):379–83

Mediastinal and diffuse pulmonary haemangiolymphangioma. Wittram C, et al. **Eur J Radiol** 1999 Feb;29(2):164–7

Transforming growth factor-beta1 in hemangioma of the ovary. Loverro G, et al. **Gynecol Obstet Invest** 1998; 46(3):210–3

Vascular hamartoma of the left ventricle. Miche E, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):479–82

MRI of breast hemangioma. Vuorela AL. **J Comput Assist Tomogr** 1998 Nov–Dec;22(6):1009–10

A rare case of intramuscular haemangioma in a six-year-old boy--a diagnostic dilemma. Chatrath P, et al. **J Laryngol Otol** 1998 Dec;112(12):1181–2

Intramuscular haemangioma of head and neck region. Chaudhary N, et al. **J Laryngol Otol** 1998 Dec; 112(12):1199–201

Differentiation of hepatic malignancies from hemangiomas and cysts by T2 relaxation times: early experience with multiply refocused four-echo imaging at 1.5 T. Olcott EW, et al. **J Magn Reson Imaging** 1999 Jan;9(1):81–6

Intramuscular hemangioma: a benign tumor masquerading as malignant soft tissue tumor. Report of two cases. Verna C, et al. **J Okla State Med Assoc** 1999 Jan;92(1):21–3

Head and neck vascular anomalies of childhood. Robertson RL, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):115–32 (59 ref.)

Sacral haemangioma as a cause of coccydynia. Lath R, et al. **Neuroradiology** 1998 Aug;40(8):524–6

Head and neck haemangiomas: contrast-enhanced three-dimensional MR angiography. Tetsumura A, et al. **Neuroradiology** 1999 Feb;41(2):140–3

Multiple orbital intraosseous hemangiomas. Kiratli H, et al. **Ophthal Plast Reconstr Surg** 1998 Sep;14(5):345–8

Congenital malformation of the iris's major arterial circle simulating an angioma. Isola VM, et al. **Ophthalmologica** 1998;212(6):422–3

Vascular lesion of the masseter presenting with phlebolith. Hessel AC, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):545–8

Hemangioma of the intratemporal vestibular nerve. Raney R, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):946–7

Uveal melanoma, choroidal hemangioma, and simulating lesions. Role of MR imaging. Mafee MF. **Radiol Clin North Am** 1998 Nov;36(6):1083–99, x (67 ref.)

An unusual filling defect in the ureter. Biyani CS, et al. **Urol Int** 1998;61(2):124–5

Early homogeneously enhancing hemangioma versus hepatocellular carcinoma: differentiation using quantitative analysis of multiphasic dynamic magnetic resonance imaging. Jeong MG, et al. **Yonsei Med J** 1999 Jun; 40(3):248–55

[Importance of bFGF ("basic fibroblast growth factor") for diagnosis and treatment of hemangiomas] Dosquet C, et al. **Ann Dermatol Venereol** 1998 May;125(5):313–6 (Eng. Abstr.) **(Fre)**

[Angiomatous and cerulodermic macules: early cutaneous signs of neurofibromatosis type I] Vabres P, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):593–4 (Eng. Abstr.) **(Fre)**

[Littoral cell angioma: a rare vascular splenic tumor] Parrens M, et al. **Ann Pathol** 1998 Dec;18(6):484–7 (Eng. Abstr.) **(Fre)**

[Hemangioma and superficial arteriovenous malformations] Brevière GM, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):649–58 (Eng. Abstr.) **(Fre)**

[Symptomatic venous angioma. Report of a case] Herbreteau O, et al. **J Neuroradiol** 1999 Jun;26(2):126–31 (Eng. Abstr.) **(Fre)**

[Febrile hepatomegaly and anemia] Algayres JP, et al. **Rev Med Interne** 1999;20 Suppl 2:308s–310s **(Fre)**

[Mandibular arteriovenous angioma and the circumstances of discovery: fissuration syndrome] Pouyat X, et al. **Rev Stomatol Chir Maxillofac** 1999 Apr;100(1):38–42 (Eng. Abstr.) **(Fre)**

[Compressive vertebral angiomas: a case report] Ben Hamouda I, et al. **Tunis Med** 1999 Apr;77(4):236–41 (Eng. Abstr.) **(Fre)**

[Littoral-cell angioma--a rare differential diagnosis on splenic tumors] Sauer J, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):624–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Benign liver tumors: diagnosis and therapy--a review] Nufer M, et al. **Schweiz Med Wochenschr** 1999 Sep 4; 129(35):1257–64 (16 ref.) (Eng. Abstr.) **(Ger)**

[Hemangioma of the frontal bone] Niijima K. **No To Shinkei** 1999 Jul;51(7):646–7 **(Jpn)**

[Intramuscular epithelioid hemangioma of the parapharyngeal space] Santaolalla Montoya F, et al. **Acta Otorrinolaringol Esp** 1999 Mar;50(2):167–71 (Eng. Abstr.) **(Spa)**

[Familial cerebral cavernomatosis associated with cutaneous

angiomas] García-Moreno JM, et al. **Rev Neurol** 1998 Sep; 27(157):484-90 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Alcohol ablation of symptomatic vertebral hemangiomas [see comments] Goyal M, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul;20(6):1091-6. Comment in: AJNR Am J Neuroradiol 1999 Jun-Jul;20(6):959-60.

Intralesional injection of absolute alcohol into vertebral hemangiomas: a new treatment option? [editorial; comment] Munk PL, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul; 20(6):959-60. Comment on: AJNR Am J Neuroradiol 1999 Jun-Jul;20(6):1091-6.

Caution with regard to the efficacy of interferon alfa-2b in the treatment of giant hemangiomas [letter; comment] Léauté-Labrèze C, et al. **Arch Dermatol** 1998 Oct; 134(10):1297-8. Comment on: Arch Dermatol 1997 Dec;133(12):1567-71. Comment on: Arch Dermatol 1997 Dec;133(12):1593-5.

Interferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication [letter] Wörle H, et al. **Eur J Pediatr** 1999 Apr;158(4):344.

Neurotoxicity of interferon alfa in children treated for hemangiomas [letter; comment] Enjolras O. **J Am Acad Dermatol** 1998 Dec;39(6):1037-8. Comment on: J Am Acad Dermatol 1997 Dec;37(6):1019-21.

Perineal hemangioma, anorectal malformation, and genital anomaly: a new association? Bouchard S, et al. **J Pediatr Surg** 1999 Jul;34(7):1133-5

In vitro and in vivo photosensitizing capabilities of 5-ALA versus photofrin in vascular endothelial cells. Chang CJ, et al. **Lasers Surg Med** 1999;24(3):178-86

Megadose methylprednisolone for Kasabach-Merritt syndrome [letter; comment] Ozsoylu S. **Pediatr Hematol Oncol** 1999 Jul-Aug;16(4):373-4. Comment on: Pediatr Hematol Oncol 1998 Jul-Aug;15(4):295-305.

Conservative treatment of hemangiomas in infancy and childhood with interferon-alpha 2a. Tryfonas GI, et al. **Pediatr Surg Int** 1998 Oct;13(8):590-3

The rebound effect in the treatment of complex hemangioma with interferon alpha 2A. Anger J, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1826-8

Brown-Sequard syndrome after management of vertebral hemangioma with intralesional alcohol. A case report. Niemeyer T, et al. **Spine** 1999 Sep 1;24(17):1845-7

[Intralesional corticoid therapy and orbital-palpebral hemangiomas] Lacour JP. **Ann Dermatol Venereol** 1998 Oct;125(10):754-8 **(Fre)**

[Steroid therapy of hemangioma in children] Schiavon G, et al. **Minerva Pediatr** 1998 Apr;50(4):105-9 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Diffuse and circumscribed choroidal hemangiomas in a patient with Sturge-Weber syndrome. Scott IU, et al. **Arch Ophthalmol** 1999 Mar;117(3):406-7

Guidelines of care: hemangiomas of infancy [letter; comment] Haimowitz JE. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):662. Comment on: J Am Acad Dermatol 1997 Oct;37(4):631-7.

GENETICS

Genetic mapping of a novel familial form of infantile hemangioma. Walter JW, et al. **Am J Med Genet** 1999 Jan 1;82(1):77-83

Physicians should inquire about vascular lesions in family members of children with hemangiomas and vascular malformations [letter; comment] Lanigan SW, et al. **Arch Dermatol** 1999 Feb;135(2):209. Comment on: Arch Dermatol 1998 Jun;134(6):718-22.

Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Kobayashi T, et al. **Cancer Res** 1999 Mar 15; 59(6):1206-11

Morphologic and genetic analysis of retinal angioma associated with massive gliosis in a patient with von Hippel-Lindau disease. Vortmeyer AO, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun;237(6):513-7

A clinical and molecular genetic analysis of solitary ocular angioma. Webster AR, et al. **Ophthalmology** 1999 Mar; 106(3):623-9

Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Chang J, et al. **Plast Reconstr Surg** 1999 Jan;103(1):1-9; discussion 10

p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Duddy SK, et al. **Toxicol Appl Pharmacol** 1999 Apr 15; 156(2):106-12

METABOLISM

Changes in matrix composition during the growth and regression of human hemangiomas. Jang YC, et al. **J Surg Res** 1998 Nov;80(1):9-15

MICROBIOLOGY

[Infection and angiomatous cutaneous lesions] Janier M. **J Mal Vasc** 1999 May;24(2):135-8 (14 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Tumor of the right shoulder in a newborn. Bossed hemangioma with telangiectasia and peripheral pallor. Patrizi A, et al. **Arch Dermatol** 1998 Sep;134(9):1146, 1148-9

Atypical cellular chorangioma. Mesia AF, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):536-8

Renal haemangioma presenting as an abdominal mass in a neonate. Zaidi SZ, et al. **Br J Urol** 1998 Nov;82(5):763-4

Hemangioma of the urinary bladder. Cheng L, et al. **Cancer** 1999 Aug 1;86(3):498-504 (41 ref.)

Hemorrhagic epithelioid and spindle cell hemangioma: a newly recognized, unique vascular tumor of bone. Keel SB, et al. **Cancer** 1999 May 1;85(9):1966-72

Immunoultrastructural expression of intercellular adhesion molecule-1 in endothelial cell vesiculotubular structures and vesiculovacuolar organelles in blood-brain barrier development and injury. Lossinsky AS, et al. **Cell Tissue Res** 1999 Jan;295(1):77-88

Not by blood alone: diagnosis of hemangiomas by fine-needle aspiration. Layfield LJ, et al. **Diagn Cytopathol** 1998 Oct; 19(4):250-4

Guess what! Targetoid hemosiderotic hemangioma. Ly S, et al. **Eur J Dermatol** 1998 Dec;8(8):583; discussion 584-5

Phenotype of mast cells in the congenital malformations of human cerebrovascular system. Maślińska D, et al. **Folia Neuropathol** 1998;36(4):251-2

Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Sgonc R, et al. **Int Arch Allergy Immunol** 1998 Nov;117(3):209-14

An infant with multiple hemangiomas showing favorable prognosis. Altunay IK, et al. **Int J Dermatol** 1999 Mar; 38(3):211-3

An autopsy case of systemic hemangiomatosis with honeycomb-like liver and focal splenic sarcomatoid changes. Tsukagoshi H, et al. **Intern Med** 1998 Oct; 37(10):847-52

Targetoid hemosiderotic hemangioma- a dynamic vascular tumor: report of 3 cases with episodic and cyclic changes and comparison with solitary angiokeratomas. Carlson JA, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):215-24 (51 ref.)

Hobnail hemangioma ("targetoid hemosiderotic hemangioma"): clinicopathologic and immunohistochemical analysis of 62 cases. Mentzel T, et al. **J Cutan Pathol** 1999 Jul;26(6):279-86

Phacomatosis pigmentovascularis type IIb associated with Sturge-Weber syndrome and pyogenic granuloma. Hagiwara K, et al. **J Dermatol** 1998 Nov;25(11):721-9 (26 ref.)

Targetoid hemosiderotic hemangioma [letter] Avci O, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):186-7

Cutaneous angiomyolipoma: report of two cases with emphasis on HMB-45 utility. Büyükbabani N, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):151-4

Changes in matrix composition during the growth and regression of human hemangiomas. Jang YC, et al. **J Surg Res** 1998 Nov;80(1):9-15

Increased apoptosis coincides with onset of involution in infantile hemangioma. Razon MJ, et al. **Microcirculation** 1998;5(2-3):189-95

A case of intraplacental choriocarcinoma associated with placental hemangioma. Aonahata M, et al. **Pathol Int** 1998 Nov;48(11):897-901 (21 ref.)

Vascular tumors and vascular malformations: are we at the dawn of a better knowledge? Enjolras O. **Pediatr Dermatol** 1999 May-Jun;16(3):238-41 (24 ref.)

Recent trends in chorangiomas, especially those of multiple and recurrent chorangiomas. Benirschke K. **Pediatr Dev Pathol** 1999 May-Jun;2(3):264-9 (33 ref.)

Deep soft tissue hemangiomas [letter; comment] Munk PL, et al. **Skeletal Radiol** 1999 Jan;28(1):57-8. Comment on: Skeletal Radiol 1998 Apr;27(4):205-10.

Littoral cell angioma of the spleen: an additional report of four cases with emphasis on the association with visceral organ cancers. Bisceglia M, et al. **Tumori** 1998 Sep-Oct; 84(5):595-9 (21 ref.)

[A nodule of the left temporal artery] Poilpre M, et al. **Ann Pathol** 1999 Mar;19(1):53-4 **(Fre)**

[Echo-guided fine-needle biopsy for the diagnosis of hepatic angioma. A report on 114 cases] Caldironi MW, et al. **Minerva Chir** 1998 Jun;53(6):505-9 (Eng. Abstr.) **(Ita)**

[Hemangiomyolipoma of the vastus lateralis. A case report] Di Girolamo M, et al. **Radiol Med (Torino)** 1998 Dec; 96(6):618-20 **(Ita)**

[Diagnostic problems in vertebral body hemangioma] Bobek J, et al. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):465-73 (Eng. Abstr.) **(Pol)**

[Racemose arteriovenous angioma (malformation) of the brain] Matsko DE, et al. **Arkh Patol** 1999 Jan-Feb; 61(1):30-5 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Sgonc R, et al. **Int Arch Allergy Immunol** 1998 Nov;117(3):209-14

Progressive development of diffuse liver hemangiomatosis. Lehmann FS, et al. **J Hepatol** 1999 May;30(5):951-4

Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Chang J, et al. **Plast Reconstr Surg** 1999 Jan;103(1):1-9; discussion 10

[Angiomas and major tissue dysplasias. Pathogenic origins and management] Hamel-Teillac D. **Arch Pediatr** 1999;6 Suppl 2:299s-302s (22 ref.) **(Fre)**

PREVENTION & CONTROL

A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Liekens S, et al. **Cancer Res** 1999 May 15; 59(10):2376-83

RADIOGRAPHY

Littoral cell angioma of the spleen. Grantham M, et al. **Abdom Imaging** 1998 Nov-Dec;23(6):633-5

Hepatic hemangioma: contrast-enhancement pattern during the arterial and portal venous phases of spiral CT. Yun EJ, et al. **Abdom Imaging** 1999 May-Jun;24(3):262-6

High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. Dufour B, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1321-4

Littoral cell angioma of the spleen. Ring DH, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1138-9

Gastric hemangioma associated with phleboliths: CT appearance. Sharma S, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):859-60

A case of perirenal hemangioma mimicking renal cell carcinoma. Okuno T, et al. **Int J Urol** 1999 Feb;6(2):104-6

Surface hemangiomas presenting as bone lesions. Weiner SD, et al. **Orthopedics** 1999 May;22(5):539-41

[Percutaneous vertebroplasty of the cervico-thoracic junction using an anterior route. Technique and results. Report of nine cases] Dufresne AC, et al. **J Neuroradiol** 1998 Jul;25(2):123-8 (Eng. Abstr.) **(Fre)**

[Angioma of the dome of the skull] Chagnon S, et al. **J Radiol** 1998 Dec;79(12):1532-3 **(Fre)**

[Pulmonary sclerosing hemangioma with specific CT findings] Matsuyama W, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jun;36(6):564-7 (Eng. Abstr.) **(Jpn)**

[Diagnostic problems in vertebral body hemangioma] Bobek J, et al. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):465-73 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Tc-99m RBC SPECT demonstrating vertebral hemangioma. Choi YY, et al. **Clin Nucl Med** 1998 Sep;23(9):632-4

Unusual Tc-99m MDP bone scan imaging in a case of skull angioma. Tondeur M, et al. **Clin Nucl Med** 1999 May; 24(5):362

Effect of dual and triple energy window scatter correction methods on image quality in liver scintigraphy. Perisinakis K, et al. **Nuklearmedizin** 1998;37(7):239-44

Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Jensen RT, et al. **Yale J Biol Med** 1997 Sep-Dec; 70(5-6):481-500

[Scintigraphic studies in abdominal vascular diseases] Estorch Cabrera M. **Rev Esp Med Nucl** 1998;17(5):372-9 **(Spa)**

RADIOTHERAPY

Proton beam therapy for posterior pole circumscribed choroidal haemangioma. Lee V, et al. **Eye** 1998;12 (Pt 6):925-8

Cutaneous angiosarcoma arising on the radiation site of a congenital facial hemangioma [letter] Cabo H, et al. **Int J Dermatol** 1998 Aug;37(8):638-9

Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Lundell M, et al. **Radiat Res** 1999 May;151(5):626-32

Individualized phantom based on CT slices and auxological data (ICTA) for dose estimations following radiotherapy for skin haemangioma in childhood. Ligot L, et al. **Radiother Oncol** 1998 Dec;49(3):279-85

[Results of radiotherapy for vertebral hemangioma] Brackrock S, et al. **Strahlenther Onkol** 1999 Aug; 175(8):405-8 (Eng. Abstr.) **(Ger)**

SURGERY

Retroperitoneal venous hemangioma. Igarashi J, et al. **Am J Gastroenterol** 1998 Nov;93(11):2292-3

Anaesthetic implications of Maffucci's syndrome. Chan SK, et al. **Anaesth Intensive Care** 1998 Oct;26(5):586-9

The sliding door flap for repair of vermilion defects [see comments] Iwahira Y, et al. **Ann Plast Surg** 1998 Sep; 41(3):300-3. Comment in: Ann Plast Surg 1999 Aug;43(2):221.

Resection of a large right atrial hemangioma in a neonate after prenatal diagnosis. Eckstein FS, et al. **Ann Thorac Surg** 1999 Sep;68(3):1074-5

Intralesional photocoagulation of vascular anomalies of the tongue. Chang CJ, et al. **Br J Plast Surg** 1999 Apr; 52(3):178-81

Controversies in neurosurgery: microsurgery versus radiosurgery for arteriovenous malformations--the case for microsurgery. Barrow DL. **Clin Neurosurg** 1999;45:13-7 (14 ref.)

Radiosurgery versus surgery for arteriovenous malformations: the case for radiosurgery. Friedman WA.

Clin Neurosurg 1999;45:18–20 (16 ref.)
Controversies in neurosurgery: microsurgery versus radiosurgery for arteriovenous malformations—introduction. Nanda A. **Clin Neurosurg** 1999;45:11–2
Calgary home to country's first comprehensive vascular birthmark clinic. Sibbald B. **CMAJ** 1999 Mar 23;160(6):898
Treatment of oral vascular anomalies by transfixion technique. Vázquez-Doval FJ, et al. **Dermatol Surg** 1998 Oct;24(10):1087–91
Surgical removal of subglottic hemangiomas in children. Van Den Abbeele T, et al. **Laryngoscope** 1999 Aug; 109(8):1281–6
Surgery of angiomas in the brainstem with a stress on the presence of telangiectasia. Fukui M, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:250–4
Treatment strategies and results in spinal vascular malformations. Huffmann BC, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:231–7
Anterior approach to intramedullary hemangioblastoma: case report. Iwasaki Y, et al. **Neurosurgery** 1999 Mar;44(3):655–7
Removal of orbital apex hemangioma using new transorbital craniotomy through suprabrow approach. Maus M, et al. **Ophthal Plast Reconstr Surg** 1999 May;15(3):166–70
Intraosseus zygomatic hemangioma. Konior RJ, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):122–5
Cryosurgery for hemangiomas [letter; comment] Cremer H. **Pediatr Dermatol** 1998 Sep–Oct;15(5):410–1. Comment on: Pediatr Dermatol 1997 May–Jun;14(3):173–9.
Special compression sutures: a new surgical technique to achieve a quick decrease in shunt volume caused by diffuse hemangiomatosis of the liver. Rokitansky AM, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):119–21
Intralesional photocoagulation of periorbital hemangiomas. Achauer BM, et al. **Plast Reconstr Surg** 1999 Jan; 103(1):11–6; discussion 17–9
Debulking of a gastrointestinal hemangioma alleviates coagulopathy associated with Kasabach–Merritt syndrome. Mahmoud NN, et al. **Surgery** 1999 Feb;125(2):236–8
[Role of surgery in the treatment of hemangiomas. A retrospective study apropos of 29 surgically treated children] Degardin N, et al. **Ann Chir Plast Esthet** 1998 Dec;43(6):649–58 (Eng. Abstr.) **(Fre)**
[Vascular "tumors" and the rules of their surgical management] Enjolras O, et al. **Ann Chir Plast Esthet** 1998 Aug;43(4):455–89 (Eng. Abstr.) **(Fre)**
[Early excision of hemangiomas of the face: an new technic using ultrasonics] Diner PA, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):605–7 **(Fre)**
–Neonatal Kasabach–Merritt syndrome healed by complete surgical excision of the angioma– Velin P, et al. **Arch Pediatr** 1998 Mar;5(3):295–7 (Eng. Abstr.) **(Fre)**
[Endonasal, microsurgical approach to the retrobulbar region exemplified by intraconal hemangioma] Mir-Salim PA, et al. **HNO** 1999 Mar;47(3):192–5 (Eng. Abstr.) **(Ger)**
[A case of racemose hemangioma of the right bronchial artery and intercostal to pulmonary arterial anastomosis] Tanaka K, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):1028–31 (Eng. Abstr.) **(Jpn)**
[Surface-induced mild hypothermia anesthesia for hepatectomy in a patient with a giant hemangioma of the liver (Kasabach–Merritt syndrome)] Wake M, et al. **Masui** 1998 Nov;47(11):1344–9 (Eng. Abstr.) **(Jpn)**
[Hemangioma on a pedicle on the mesentery of the transverse colon found during an appendectomy] Meshcheriakov VI, et al. **Vestn Khir Im I I Grek** 1998;157(4):110 **(Rus)**

THERAPY

Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma. Rapizzi E, et al. **Am J Ophthalmol** 1999 Apr;127(4):481–2
Circumscribed choroidal hemangioma managed by transpupillary thermotherapy. Othmane IS, et al. **Arch Ophthalmol** 1999 Jan;117(1):136–7
An update on the treatment of hemangiomas in children with interferon alfa-2a. Greinwald JH Jr, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):21–7
Cutaneous hemangioma of the penis successfully treated with sclerotherapy and ligation. Tsujii T, et al. **Int J Urol** 1998 Jul;5(4):396–7
Subglottic haemangioma: controversies in management. Walker P, et al. **J Paediatr Child Health** 1999 Aug; 35(4):392–5
Alcohol injection: a new method of treating placental chorioangiomas [letter] Nicolini U, et al. **Lancet** 1999 May 15;353(9165):1674–5
Complications of angioma surgery—personal experience in 191 patients with cerebral angiomas. Hassler W, et al. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:238–44 (32 ref.)
[Clinical application of highly selected embolotherapy via external carotid artery in craniofacial diseases] Wang X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):517–20 (Eng. Abstr.) **(Chi)**
[Angiomas and major tissue dysplasias. Pathogenic origins and management] Hamel-Teillac D. **Arch Pediatr** 1999;6 Suppl 2:299s–302s (22 ref.) **(Fre)**
[Dearterialization of the liver as a treatment method in hemangiomas] Bprisov AE, et al. **Vestn Khir Im I I Grek** 1999;158(2):17–21 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Imaging of neonatal hemangiomas, two cases. Auriemma A, et al. **Eur J Ultrasound** 1999 May;9(2):161–5
Echo-enhancing sonography of a large-vessel hemangioma of the neck. Chou YH, et al. **J Clin Ultrasound** 1999 Oct; 27(8):465–8
A case of large placental chorioangioma with non-immunological hydrops fetalis. Makino Y, et al. **J Perinat Med** 1999;27(2):128–31
Ultrasonographic diagnosis of hemangiomas of soft tissue. Kang B, et al. **J Tongji Med Univ** 1997;17(3):168–71
Ultrasonographic appearances of fetal hepatic hemangioma. Chuileannain FN, et al. **J Ultrasound Med** 1999 May; 18(5):379–81
Focal aneurysmal dilatation of subchorionic vessels simulating chorioangioma. Reinhart RD, et al. **Ultrasound Obstet Gynecol** 1999 Feb;13(2):147–9
In utero diagnosis of cardiac hemangioma. Tseng JJ, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):363–5
[Placental chorioangioma: three cases] Chanoufi MB, et al. **Tunis Med** 1999 Apr;77(4):229–32 (Eng. Abstr.) **(Fre)**

VETERINARY

Renal haemangioma in a dog. Eddlestone S, et al. **J Small Anim Pract** 1999 Mar;40(3):132–5

HEMANGIOMA, CAPILLARY

Left ventricular hemangioma. Manasse E, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):864–6
[Kasabach–Merrit syndrome] Suzuki S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):513–6 (14 ref.) **(Jpn)**

COMPLICATIONS

Capillary haemangiomas in association with morning glory disc anomaly. Holmström G, et al. **Acta Ophthalmol Scand** 1998 Oct;76(5):613–6
Postpartum cerebellar herniation in von Hippel-Lindau syndrome. Othmane IS, et al. **Am J Ophthalmol** 1999 Sep; 128(3):387–9
Pulmonary capillary haemangiomatosis coexistence with sinus venosus ASD: morphometric analysis and literature review. Slovis BS, et al. **Eur Respir J** 1998 Jul;12(1):240–4 (23 ref.)
Cutaneomeningospinal angiomatosis (Cobb syndrome) with tethered cord. Brant AJ, et al. **Pediatr Neurosurg** 1999 Feb; 30(2):93–5
[Palpebral capillary hemangioma and amblyopia. Apropos of 2 cases] Cheour M, et al. **Rev Stomatol Chir Maxillofac** 1998 Nov;99(4):214–6 (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital capillary hemangioma and its therapeutic approach in infants: a case report. Hassan E, et al. **J Dermatol** 1998 Oct;25(10):673–6
[Prevention of amblyopia in acute eyelid closure—a new method for keeping the optical axis open by insertion of a small tube] Esser J. **Klin Monatsbl Augenheilkd** 1998 Jul; 213(1):55–9 (Eng. Abstr.) **(Ger)**
[Extensive cavernous capillary hemangioma of the right atrium in a newborn infant] Bosk A, et al. **Z Geburtshilfe Neonatol** 1999 May–Jun;203(3):120–2 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Magnetic resonance imaging features of a nerve root capillary hemangioma of the spinal cord: case report. Zander DR, et al. **Can Assoc Radiol J** 1998 Dec;49(6):398–400
Pulmonary capillary hemangiomatosis in an asymptomatic elderly patient. Cioffi U, et al. **Int Surg** 1999 Apr–Jun; 84(2):168–70
Intravascular capillary hemangioma presenting as a solid renal mass. Hull GW 3rd, et al. **J Urol** 1999 Sep;162(3 Pt 1):784–5
A lymph nodal capillary-cavernous hemangioma. Dellachà A, et al. **Lymphology** 1999 Sep;32(3):123–5
Intracranial contrast-enhancing masses in infants with capillary haemangioma of the head and neck: intracranial capillary haemangioma? Tortori-Donati P, et al. **Neuroradiology** 1999 May;41(5):369–75
Diffuse neonatal hemangiomatosis with extensive involvement of the brain and cervical spinal cord. Balaci E, et al. **Pediatr Radiol** 1999 Jun;29(6):441–3
Diagnostic and therapeutic challenges. Schatz H, et al. **Retina** 1999;19(1):69–74

EPIDEMIOLOGY

Middle ear capillary hemangioma in an infant. Payman RN, et al. **Am J Otolaryngol** 1999 Jan–Feb;20(1):59–63 (16 ref.)

ETIOLOGY

Pulmonary capillary hemangiomatosis as cause of pulmonary hypertension in a young woman with systemic lupus erythematosus [letter] Fernández-Alonso J, et al. **J Rheumatol** 1999 Jan;26(1):231–3

GENETICS

VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Chan CC, et al. **Arch Ophthalmol** 1999 May;117(5):625–30
[Retinal capillary angioma. Clinical and molecular genetic studies] Kreusel KM, et al. **Ophthalmologe** 1999 Feb; 96(2):71–6 (Eng. Abstr.) **(Ger)**

METABOLISM

ICAM-3 and E-selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas. Verkarre V, et al. **J Cutan Pathol** 1999 Jan; 26(1):17–24

MICROBIOLOGY

Bartonella henselae infection associated with peripapillary angioma, branch retinal artery occlusion, and severe vision loss. Gray AV, et al. **Am J Ophthalmol** 1999 Feb; 127(2):223–4

PATHOLOGY

Eccrine angiomatous hamartoma: report of seven cases. Cebreiro C, et al. **Clin Exp Dermatol** 1998 Nov;23(6):267–70
Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Bielenberg DR, et al. **Int J Oncol** 1999 Mar;14(3):401–8
A palatal haemangioma in a child. Lale AM, et al. **J Laryngol Otol** 1998 Jul;112(7):677–8
Hemangioma of spinal nerve root. Roncaroli F, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):175–80
Intravascular Kaposi's-like spindle cell proliferation of the capsular vessels of follicular-derived thyroid carcinomas. Baloch ZW, et al. **Mod Pathol** 1998 Oct;11(10):995–8
PHACE: a neurocutaneous syndrome with important ophthalmologic implications: case report and literature review. Coats DK, et al. **Ophthalmology** 1999 Sep; 106(9):1739–41 (10 ref.)
Prepartum mixed type cavernous-capillary hemangioma arising in nevus flammeus. Rumelt S, et al. **Ophthalmology** 1999 Jun;106(6):1219–22
Posterior mediastinal capillary hemangioma with extradural extension resembling neuroblastoma. Herman TE, et al. **Pediatr Radiol** 1999 Jul;29(7):517–9
Histopathology of a vasoproliferative tumor of the ocular fundus. Smeets MH, et al. **Retina** 1998;18(5):470–2

RADIOGRAPHY

Posterior mediastinal capillary hemangioma with extradural extension resembling neuroblastoma. Herman TE, et al. **Pediatr Radiol** 1999 Jul;29(7):517–9
[The clinical picture, diagnosis and treatment of benign vascular tumors of the spine] Slyn'ko EI. **Klin Khir** 1998; (9–10):37–40 (Eng. Abstr.) **(Rus)**

RADIOTHERAPY

Treatment of cutaneous hemangiomas with low-dose soft x-ray. Chang B, et al. **Chin Med J (Engl)** 1997 Nov; 110(11):893–4

SURGERY

Lobular capillary hemangioma of the cauda equina. Case report. Holtzman RN, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):239–41
Laser treatment of hemangiomas of the larynx and trachea. Cholewa D, et al. **Lasers Surg Med** 1998;23(4):221–32
Treatment of cutaneous hemangiomas in preterm neonatal twins with the flashlamp-pumped pulsed dye laser [letter] Lask GP. **Lasers Surg Med** 1999;24(1):1–2
[Therapy evaluation in dermatology by comparative color measurements] Meffert B, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:82–3 **(Ger)**

THERAPY

Management of subglottic haemangioma. Bailey CM, et al. **J Laryngol Otol** 1998 Aug;112(8):765–8
[Review on the treatment of superficial hemangioma] Wang S, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):19–22 (24 ref.) **(Chi)**

HEMANGIOMA, CAVERNOUS

Cavernous haemangiomas of the spinal cord. A review of 117 cases. Zevgaridis D, et al. **Acta Neurochir (Wien)** 1999; 141(3):237–45 (55 ref.)
Cavernous hemangioma of the skull in a neonate. Yoshida D, et al. **Childs Nerv Syst** 1999 Jul;15(6–7):351–3
Cerebral cavernous malformations: serial magnetic resonance imaging findings in patients with and without gamma knife surgery. Yoon PH, et al. **Neurol Med Chir (Tokyo)** 1998; 38 Suppl:255–61
[A case report of cavernous hemangioma of the left atrial epicardium] Hara T, et al. **Kyobu Geka** 1998 Nov; 51(12):1027–9 (Eng. Abstr.) **(Jpn)**
[Adult laryngeal hemangioma] Berkeš B, et al. **Med Pregl** 1998 Nov–Dec;51(11–12):547–50 (Eng. Abstr.) **(Scr)**

HEMANGIOMA, CAVERNOUS

BLOOD SUPPLY

Hepatic hemangioma with arterioportal shunts. Naganuma H, et al. **Abdom Imaging** 1999 Jan-Feb;24(1):42-6

COMPLICATIONS

Superficial siderosis of the CNS associated with multiple cavernous malformations. Hsu WC, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1245-8

Isolated inferior rectus paresis secondary to a mesencephalic cavernous angioma. Harrison AR, et al. **Am J Ophthalmol** 1999 May;127(5):617-9

Cavernous angioma presenting with hemidystonia. Akbostanci MC, et al. **Clin Neurol Neurosurg** 1998 Sep; 100(3):234-7 (16 ref.)

Color Doppler image of central retinal artery of eyes with an intraconal mass. Mendivil A, et al. **Curr Eye Res** 1999 Feb;18(2):104-9

Mediastinal germ cell tumor complicated by visceral hemangiomatosis. Sekine I, et al. **Intern Med** 1998 Dec; 37(12):1042-5

Massive subependymal hemorrhage caused by an occult vascular malformation--two case reports. Kobata H, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):302-7

Cavernous angioma associated with venous angioma--two case reports. Kuroiwa T, et al. **Neurol Med Chir (Tokyo)** 1998 Oct;38(10):648-53

Gastric haemangioma: a rare cause of gastrointestinal bleeding. Schlecht I, et al. **Pediatr Radiol** 1999 Jan;29(1):63

Giant ossified cavernous hemangioma of an extremity associated with an equinovarus deformity. Wang YC, et al. **Skeletal Radiol** 1998 Sep;27(9):522-4

Cavernous angioma of the conus medullaris as a cause of paraplegia. Hernández D, et al. **Spinal Cord** 1999 Jan; 37(1):65-7

Complete paraplegia due to multiple intracerebral and spinal cavernomas. Parsch D, et al. **Spinal Cord** 1999 Jan; 37(1):62-4

Hemobilia caused by a giant benign hemangioma of the liver: report of a case. Mikami T, et al. **Surg Today** 1998; 28(9):948-52

[Automated perimetry analysis of optic nerve compression caused by orbital tumors and tumor-like lesions] Wei R, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Jan;33(1):33-5 (Eng. Abstr.) **(Chi)**

[Cavernous hemangioma of the rectum--a rare cause of peranal hemorrhage] Freudenberg S, et al. **Chirurg** 1998 Jul;69(7):780-2 (Eng. Abstr.) **(Ger)**

[De novo formation of a cavernoma in association with a preformed venous malformation during immunosuppressive treatment] Brunken M, et al. **Zentralbl Neurochir** 1999; 60(2):81-5 (Eng. Abstr.) **(Ger)**

[Intestinal hemorrhage for 21 years in a case of blue nevus syndrome] Ramírez Mateos C, et al. **Rev Gastroenterol Mex** 1998 Jan-Mar;63(1):37-40 (Eng. Abstr.) **(Spa)**

CONGENITAL

[Extensive cavernous capillary hemangioma of the right atrium in a newborn infant] Bosk A, et al. **Z Geburtshilfe Neonatol** 1999 May-Jun;203(3):120-2 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Fluid-fluid levels in giant cavernous hemangioma of the liver: CT and MRI demonstration. Obata S, et al. **Abdom Imaging** 1998 Nov-Dec;23(6):600-2

MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. Lee BC, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1239-42

Lumbar extradural hemangiomas: report of three cases. Rovira A, et al. **AJNR Am J Neuroradiol** 1999 Jan; 20(1):27-31

Lesson of the week: cavernous haemangioma mimicking multiple sclerosis. Cader MZ, et al. **BMJ** 1999 Jun 12; 318(7198):1604-5

Pedunculated hepatic hemangioma identified on Tc-99m DTPA-HSA scintigraphy. Nishiyama Y, et al. **Clin Nucl Med** 1999 Feb;24(2):133-4

A case of esophageal cancer with cavernous hemangioma: endoscopic and endosonographic assessment. Kusumi F, et al. **Endoscopy** 1999 Jun;31(5):S36

Diffuse cavernous haemangioma of the rectum. Tanaka N, et al. **Eur J Surg** 1999 Mar;165(3):280-3 (18 ref.)

Inflammatory pseudotumor of the spleen associated with a cavernous hemangioma diagnosed at intra-operative cytology: report of a case and review of literature. Nasir A, et al. **In Vivo** 1999 Jan-Feb;13(1):87-92 (40 ref.)

Cavernous hemangioma of the intracranial optic pathways: CT and MRI. Arrué P, et al. **J Comput Assist Tomogr** 1999 May-Jun;23(3):357-61

Solitary primary haemangioma of thyroid. Pendse AK, et al. **J Indian Med Assoc** 1998 Jun;96(6):190

Pharyngo-oesophageal haemangioma with a positive cough impulse. Hollis LJ, et al. **J Laryngol Otol** 1999 Feb; 113(2):172-3

Lhermitte's sign in cavernous angioma of the cervical spinal cord [letter] Murphy DK, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):954-5

Homonymous hemianopsia due to a dural cavernous hemangioma. Lee AG, et al. **J Neuroophthalmol** 1998 Dec; 18(4):250-4

Cavernous hemangiomas of the orbit: MR imaging. Thorn-Kany M, et al. **J Neuroradiol** 1999 Jun;26(2):79-86

Growing patterns of cavernous angioma in the fourth ventricle. Case report. Moro M, et al. **J Neurosurg Sci** 1998 Dec;42(4):221-5

A case of solitary cavernous hemangioma of the small intestine with recurrent clinical anemic attacks in childhood. Sakaguchi M, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):342-3

Intracranial cystic cavernous angioma: a case report. Lai PH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):593-8 (25 ref.)

A lymph nodal capillary-cavernous hemangioma. Dellachà A, et al. **Lymphology** 1999 Sep;32(3):123-5

Differentiation of hepatic cavernous hemangioma from metastases by rare sequence MR imaging. Jafari F, et al. **Magn Reson Imaging** 1999 Jun;17(5):669-77

Rubral tremor associated with cavernous angioma of the midbrain. Leung GK, et al. **Mov Disord** 1999 Jan; 14(1):191-3

Images in clinical medicine. Synovial hemangioma. Macdonald D, et al. **N Engl J Med** 1999 Jul 29;341(5):336

Stereotactic radiosurgery for cavernous sinus cavernous hemangioma--case report. Iwai Y, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):288-90

Massive subependymal hemorrhage caused by an occult vascular malformation--two case reports. Kobata H, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):302-7

Cavernous angioma of the VIIIth cranial nerve. A case report. Ferrante L, et al. **Neurosurg Rev** 1998;21(4):270-6 (21 ref.)

Orbital and cerebral cavernomas: comparison of clinical, neuroimaging, and neuropathological features. Hejazi N, et al. **Neurosurg Rev** 1999;22(1):28-33

A comparison of the clinical profile of cavernous malformations with and without associated venous malformations. Abdulrauf SI, et al. **Neurosurgery** 1999 Jan; 44(1):41-6; discussion 46-7

Cavernous angioma: a cryptic CT and MRI presentation. Schemmer DC, et al. **Pediatr Radiol** 1999 Feb;29(2):146

Familial cavernous angiomas masquerading as multiple sclerosis. Dougan CF, et al. **Postgrad Med J** 1998 Aug; 74(874):489-91

Giant ossified cavernous hemangioma of an extremity associated with an equinovarus deformity. Wang YC, et al. **Skeletal Radiol** 1998 Sep;27(9):522-4

Cavernous angiomas of the brain stem. Intra-axial anatomical pitfalls and surgical strategies. Cantore G, et al. **Surg Neurol** 1999 Jul;52(1):84-93; discussion 93-4

Images in clinical urology. Venous cavernous hemangioma of the testis. Frank RG, et al. **Urology** 1998 Oct; 52(4):709-10

Giant cavernous hemangioma of the scalp. Tüzün Y, et al. **Zentralbl Neurochir** 1998;59(4):274-7

["Therapy refractory" exophthalmos. Orbital hemangioma] Offergeld C, et al. **HNO** 1999 Jul;47(7):654-5 **(Ger)**

[Cavernous hemangioma of the rectum--a rare differential per anal hemorrhage diagnosis] Kroesen AJ, et al. **Z Gastroenterol** 1999 Mar;37(3):229-34 (Eng. Abstr.) **(Ger)**

[An unusual cause of adrenal mass in a patient with operable non-small-cell pulmonary carcinoma (letter)] Alcázar J, et al. **Arch Bronconeumol** 1998 Nov;34(10):513-4 **(Spa)**

[A renal cortical hemangioma simulating a carcinoma] Medina Pérez M, et al. **Arch Esp Urol** 1999 Jun;52(5):520-2 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Anticipation in familial cavernous angioma: ascertainment bias or genetic cause [see comments] Siegel AM, et al. **Acta Neurol Scand** 1998 Dec;98(6):372-6 (16 ref.). Comment in: Acta Neurol Scand 1998 Dec;98(6):369-71.

Ovarian cavernous hemangioma in an 8-year-old girl. Mirilas P, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):116-8 (15 ref.)

ETIOLOGY

[Cavernoma of the portal vein in Beh,cet's syndrome] Kchir MM, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):530-2 **(Fre)**

GENETICS

Anticipation in familial cavernous angioma: ascertainment bias or genetic cause [see comments] Siegel AM, et al. **Acta Neurol Scand** 1998 Dec;98(6):372-6 (16 ref.). Comment in: Acta Neurol Scand 1998 Dec;98(6):369-71.

Familial cavernous angioma: an unknown, known disease [editorial; comment] Siegel AM. **Acta Neurol Scand** 1998 Dec;98(6):369-71 (8 ref.). Comment on: Acta Neurol Scand 1998 Dec;98(6):372-6.

An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. Labauge P, et al. **Ann Neurol** 1999 Feb;45(2):250-4

Genetic heterogeneity and absence of founder effect in a series of 36 French cerebral cavernous angiomas families. Laberge S, et al. **Eur J Hum Genet** 1999 May-Jun; 7(4):499-504

Cavernous haemangioma of retina and skin [letter] Backhouse O, et al. **Eye** 1998;12 (Pt 6):1027-8

Cavernomas in the central nervous system and the relevance of multiple intracranial lesions in the familial form of this disease [letter] Stacey RJ, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):117

Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families. Société Française de Neurochirurgie. Labauge P, et al. **Lancet** 1998 Dec 12; 352(9144):1892-7

Anticipation in familial cavernous angioma: a study of 52 families from International Familial Cavernous Angioma Study. IFCAS Group [letter] Siegel AM, et al. **Lancet** 1998 Nov 21;352(9141):1676-7

Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Laberge-le Couteulx S, et al. **Nat Genet** 1999 Oct;23(2):189-93

[Familial cerebral cavernomatosis associated with cutaneous angiomas] García-Moreno JM, et al. **Rev Neurol** 1998 Sep; 27(157):484-90 (Eng. Abstr.) **(Spa)**

PATHOLOGY

Noonan syndrome and cavernous hemangioma of the brain. Tanaka Y, et al. **Am J Med Genet** 1999 Jan 29;82(3):212-4

Epithelioid hemangioendothelioma, multiple focal nodular hyperplasias, and cavernous hemangiomas of the liver. Bralet MP, et al. **Arch Pathol Lab Med** 1999 Sep; 123(9):846-9

Presumed calcified retinal cavernous hemangioma. Almasswary MA, et al. **Can J Ophthalmol** 1999 Aug; 34(5):294-5

Ossified and de novo cavernous malformations in the same patient. Rosahl SK, et al. **Clin Neurol Neurosurg** 1998 Jun; 100(2):138-43

Dural cavernous haemangioma with bony infiltration. Rushton AW, et al. **Clin Radiol** 1999 Jun;54(6):406-8

Diffuse cavernous hemangioma of the rectum and sigmoid colon. Demircan O, et al. **Dig Surg** 1998;15(6):713-5

Giant cavernous hemangioma of the esophagus: endoscopic and echo-endoscopic appearance. Maluf-Filho F, et al. **Endoscopy** 1999 May;31(4):S32

Cavernous haemangioma of the submandibular salivary gland. El-Hakim IE, et al. **Int J Oral Maxillofac Surg** 1999 Feb;28(1):58-9

Cavernous haemangioma in the infraorbital nerve canal--an unusual expansion in the maxillary sinus. Walch C, et al. **J Laryngol Otol** 1998 Sep;112(9):872-4 (10 ref.)

Retrograde temporal order amnesia resulting from damage to the fornix. Yasuno F, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):102-5

Cavernous hemangioma presenting as a renal hilar mass. Haas CA, et al. **J Urol** 1998 Dec;160(6 Pt 1):2139-40

Cerebral cavernous malformations: serial magnetic resonance imaging findings in patients with and without gamma knife surgery. Yoon PH, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:255-61

Intraventricular cavernomas: three cases and review of the literature. Reyns N, et al. **Neurosurgery** 1999 Mar; 44(3):648-54; discussion 654-5 (45 ref.)

Prepartum mixed type cavernous-capillary hemangioma arising in nevus flammeus. Rumelt S, et al. **Ophthalmology** 1999 Jun;106(6):1219-22

Conus medullaris hematomyelia associated with an intradural-extramedullary cavernous angioma. Mastronardi L, et al. **Spinal Cord** 1999 Jan;37(1):68-70

Cavernous angiomas of the cauda equina: case report and review of the literature. Duke BJ, et al. **Surg Neurol** 1998 Nov;50(5):442-5 (20 ref.)

Giant penile cavernous hemangioma with intrapelvic extension. Froehner M, et al. **Urology** 1999 Feb;53(2):414-5

[Clinicopathological study on 3,160 cases of liver tumors] Cong W, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Apr;26(2):70-3 (Eng. Abstr.) **(Chi)**

[Sinusoidal hemangioma] Enjolras O, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):575-80 (Eng. Abstr.) **(Fre)**

[Bone neogenesis in a rare space-occupying lesion of the inner ear canal] Relic A, et al. **HNO** 1999 Jun;47(6):563-8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Cavernous hemangioma of the umbilical cord] Nawroth F, et al. **Zentralbl Gynakol** 1998;120(9):458-61 (17 ref.) (Eng. Abstr.) **(Ger)**

[Cavernous angiomatosis of the central nervous system starting in the medulla. A case report] Tessa C, et al. **Radiol Med (Torino)** 1998 Nov;96(5):521-2 **(Ita)**

[Cavernous hemangioma of the scrotum: a case report] Awakura Y, et al. **Hinyokika Kiyo** 1998 Oct;44(10):751-3 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Subcutaneous sinusoid cavernous hemangioma of the outer ear. Review of literature] García-Purriños FJ, et al. **Acta Otorrinolaringol Esp** 1998 Oct;49(7):576-8 (18 ref.) (Eng. Abstr.) **(Spa)**

[Cavernous hemangioma of the tympanic membrane. Otoscopic image] Ramírez Anguiano J, et al. **Rev Invest Clin** 1999 Jan-Feb;51(1):39-42 (8 ref.) (Eng. Abstr.) **(Spa)**

[Familial cerebral cavernomatosis associated with cutaneous angiomas] García-Moreno JM, et al. **Rev Neurol** 1998 Sep; 27(157):484-90 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Supratentorial cavernous haemangiomas and epilepsy: a review of the literature and case series. Moran NF, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):561-8 (74

ref.)
Orbital and cerebral cavernomas: comparison of clinical, neuroimaging, and neuropathological features. Hejazi N, et al. **Neurosurg Rev** 1999;22(1):28–33

RADIOGRAPHY

Atypical CT findings of orbital cavernous hemangioma. Gerstle RJ, et al. **AJR Am J Roentgenol** 1999 Jan; 172(1):249–50
Role of computed tomography in diagnosis of diffuse cavernous hemangioma of the rectum [letter; comment] Sharma S, et al. **Am J Gastroenterol** 1999 Jul;94(7):1986–7 . Comment on: Am J Gastroenterol 1998 Aug;93(8):1357–9.
Quiz case 1. Cavernous hemangioma of the hypopharynx. Thorp MA, et al. **Arch Otolaryngol Head Neck Surg** 1999 Sep;125(9):1036, 1038
Diffuse cavernous hemangioma of the rectosigmoid colon: imaging findings. Djouhri H, et al.
J Comput Assist Tomogr 1998 Nov–Dec;22(6):851–5
Images in hepatology. Giant cavernous hemangioma. Baron A, et al. **J Hepatol** 1998 Aug;29(2):316
Intraventricular cavernomas: three cases and review of the literature. Reyns N, et al. **Neurosurgery** 1999 Mar; 44(3):648–54; discussion 654–5 (45 ref.)
Radiologic and surgical aspects of pure spinal epidural cavernous angiomas. Report on 5 cases and review of the literature. Talacchi A, et al. **Surg Neurol** 1999 Aug; 52(2):198–203 (43 ref.)
[The clinical picture, diagnosis and treatment of benign vascular tumors of the spine] Slyn'ko EI. **Klin Khir** 1998; (9–10):37–40 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

Incidental detection of bilateral kidney calyces in Tc–99m phytate liver and spleen scan. Kao CH. **Clin Nucl Med** 1999 Sep;24(9):720–1
Focal liver uptake of Tc–99m mebrofenin in a patient with cavernous hemangioma. Oussama N, et al.
Clin Nucl Med 1998 Jul;23(7):475–7
Pedunculated giant liver hemangioma mimicking a hypervascular gastric tumor on Tc–99m RBC SPECT. Tsai CC, et al. **Clin Nucl Med** 1999 Feb;24(2):132–3
Marked uptake of TI–201 in intracranial extracerebral cavernous hemangioma. Wang XM, et al.
Clin Nucl Med 1999 Sep;24(9):718–20
Tc–99m labeled red blood cells scintigraphy: a diagnostic method for orbital cavernous hemangioma. Gdal–On M, et al. **Eur J Ophthalmol** 1999 Apr–Jun;9(2):125–9
[Utility of the hepatic grammagraphy with red blood cells marked with 99mTC in the differential diagnosis between cavernous hemangioma and hepatocarcinoma: based on one clinical case] Delgado Garcia M, et al.
Rev Esp Med Nucl 1999;18(2):104–8 (Eng. Abstr.) **(Spa)**
[Diagnosis of giant cavernous hemangioma using Tc 99m labeled erythrocytes] Guede C, et al.
Rev Esp Med Nucl 1998;17(5):368–9 **(Spa)**

RADIOTHERAPY

Treatment of cutaneous hemangiomas with low–dose soft x–ray. Chang B, et al. **Chin Med J (Engl)** 1997 Nov; 110(11):893–4

SURGERY

Intraoperative direct electrical stimulation of the lamina quadrigemina in a case of a deep tectal cavernoma. Duffau H, et al. **Acta Neurochir (Wien)** 1998;140(12):1309–12
Localization and characterization of intracerebral cavernous angiomas by intra–operative high–resolution colour–duplex–sonography. Woydt M, et al.
Acta Neurochir (Wien) 1999;141(2):143–51; discussion 152
Transnasal endoscopic removal of an orbital cavernoma. Herman P, et al. **Ann Otol Rhinol Laryngol** 1999 Feb; 108(2):147–50
Cavernous hemangioma of the liver: anatomic resection vs. enucleation. Gedaly R, et al. **Arch Surg** 1999 Apr; 134(4):407–11
The case for aggressive resection. Sekhar LN, et al.
Clin Neurosurg 1999;45:263–78 (18 ref.)
Risk factors associated with intra–operative blood loss in hepatectomized patients with giant cavernous hemangioma of the liver. Hanazaki K, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1089–93
Hepatic resection for cavernous hemangiomas of the liver. Asahara T, et al. **Hiroshima J Med Sci** 1998 Dec; 47(4):145–9
Laparoscopy–assisted hepatectomy for a large tumor of the liver. Asahara T, et al. **Hiroshima J Med Sci** 1998 Dec; 47(4):163–6
Efficacy of induced hypotension in the surgical treatment of large cavernous sinus cavernomas. Ohata K, et al.
J Neurosurg 1999 Apr;90(4):702–8
Laser treatment of hemangiomas of the larynx and trachea. Cholewa D, et al. **Lasers Surg Med** 1998;23(4):221–32
Minimally invasive stereotactically–guided extirpation of brain stem cavernoma with the aid of electrophysiological methods. Cedzich C, et al. **Minim Invasive Neurosurg** 1999 Mar;42(1):41–3
Surgery of angiomas in the brainstem with a stress on the presence of telangiectasia. Fukui M, et al.
Neurol Med Chir (Tokyo) 1998;38 Suppl:250–4
Stereotactic radiosurgery for cavernous sinus cavernous hemangioma––case report. Iwai Y, et al.
Neurol Med Chir (Tokyo) 1999 Apr;39(4):288–90
Cavernous angioma of the optic chiasm––case report. Iwai Y, et al. **Neurol Med Chir (Tokyo)** 1999 Aug;39(8):617–20
Intracranial cavernomas: indications for and results of surgery. Mehdorn HM, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:245–9
Intracranial cavernomas: indications for and results of surgery. Mehdorn HM, et al. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:245–9
Lesionectomy in surgical treatment of epilepsy. Bidziński J, et al. **Neurol Neurochir Pol** 1998;32 Suppl 2:69–79 **(Eng, Pol)**
The surgical management of cerebral cavernous angiomas. Chaskis C, et al. **Neurol Res** 1998 Oct;20(7):597–606
Radical excision of intramedullary cavernous angiomas [see comments] Cristante L, et al. **Neurosurgery** 1998 Sep; 43(3):424–30; discussion 430–1. Comment in: Neurosurgery 1999 Feb;44(2):428.
Patients with spinal cord cavernous malformations are at an increased risk for multiple neuraxis cavernous malformations. Vishteh AG, et al. **Neurosurgery** 1999 Jul; 45(1):30–2; discussion 33
Radical excision of intramedullary cavernous angiomas [letter; comment] Vishteh AG, et al. **Neurosurgery** 1999 Feb;44(2):428. Comment on: Neurosurgery 1998 Sep;43(3):424–30; discussion 430–1.
Deep transorbital approach to the apex and cavernous sinus. Goldberg RA, et al. **Ophthal Plast Reconstr Surg** 1998 Sep; 14(5):336–41
Surgical outcome of transconjunctival cryosurgical extraction of orbital cavernous hemangioma. Gdal–On M, et al. **Ophthalmic Surg Lasers** 1998 Dec;29(12):969–73
Brain glucose metabolism with [18F]–fluorodeoxyglucose and positron emission tomography before and after surgical resection of epileptogenic cavernous angiomas. Gogoleva SM, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):225–8
Cavernous angiomas of the brain stem. Intra–axial anatomical pitfalls and surgical strategies. Cantore G, et al.
Surg Neurol 1999 Jul;52(1):84–93; discussion 93–4
Intramedullary cavernous angioma. Resection by oblique corpectomy. Fontaine D, et al. **Surg Neurol** 1999 Apr; 51(4):435–41; discussion 441–2 (33 ref.)
Radiologic and surgical aspects of pure spinal epidural cavernous angiomas. Report on 5 cases and review of the literature. Talacchi A, et al. **Surg Neurol** 1999 Aug; 52(2):198–203 (43 ref.)
[Therapy evaluation in dermatology by comparative color measurements] Meffert B, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:82–3 **(Ger)**
[Surgical treatment of giant hemangiomas of the liver] Schilling MK, et al. **Swiss Surg** 1999;5(3):133–5 (Eng. Abstr.) **(Ger)**
[Surgical removal of adrenal hemangioma after five years of follow–up: a case report] Makiyama K, et al.
Hinyokika Kiyo 1998 Aug;44(8):579–81 (Eng. Abstr.) **(Jpn)**
[Cardiac hemangioma of the right ventricle––report of a case] Harada H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Jul; 46(7):629–33 (16 ref.) (Eng. Abstr.) **(Jpn)**
[A case of recurrent esophageal cavernous hemangioma increasing rapidly after surgery] Urakami T, et al.
Jpn J Thorac Cardiovasc Surg 1998 Nov;46(11):1206–10 (Eng. Abstr.) **(Jpn)**
[A case of mediastinal cavernous hemangioma resected through thoracoscope] Yamazaki A, et al. **Kyobu Geka** 1998 Nov;51(12):1051–3 (Eng. Abstr.) **(Jpn)**
[Surgical removal of large cavernous angioma in the pontomedullary junction: a case report] Sugawara A, et al. **No Shinkei Geka** 1999 Apr;27(4):371–5 (Eng. Abstr.) **(Jpn)**
[Hemostasis of the gallbladder bed by using muscle flap with vascular pedicle] Makhovskiĭ VZ, et al.
Khirurgiia (Mosk) 1998;(11):64–5 **(Rus)**

THERAPY

Colonic cavernous hemangioma [letter; comment] Levitt RE. **Gastrointest Endosc** 1998 Sep;48(3):337. Comment on: Gastrointest Endosc 1998 Mar;47(3):307–8.
[Study on intravascular pressure change during sclerotherapy for cavernous hemangiomas (CHs)] Ouyang T, et al.
Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih 1997 May;13(3):171–4 (Eng. Abstr.) **(Chi)**
[Review on the treatment of superficial hemangioma] Wang S, et al.
Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih 1998 Jan;12(1):19–22 (24 ref.) **(Chi)**
[Treatment of lingual angiocavernoma by selective arteriocatheterization with urea injection] Lu X, et al.
Lin Chuang Erh Pi Yen Hou Ko Tsa Chih 1997 Oct; 11(10):451–3 (Eng. Abstr.) **(Chi)**
[Arterial embolization in treatment of hepatic cavernous hemangioma] Granov AM, et al. **Khirurgiia (Mosk)** 1999; (4):13–7 (Eng. Abstr.) **(Rus)**
[Personal experience in embolization of liver hemangiomas] Ješić R, et al. **Srp Arh Celok Lek** 1998 Sep–Oct; 126(9–10):349–54 (Eng. Abstr.) **(Scc)**
[Blue nevus syndrome: endoscopic treatment by sclerosis and banding ligation] Sala Felis T, et al.
Gastroenterol Hepatol 1999 Mar;22(3):136–8 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Successful abdominal delivery in a woman with sonographic diagnosis of diffuse cavernous hemangioma of the uterus. Sütterlin MW, et al. **Am J Perinatol** 1998 Jul;15(7):423–5
Duplex Doppler sonography of small (<3 cm diameter) liver tumours: intralesional arterial flow does not exclude cavernous haemangioma. Wachsberg RH, et al.
Clin Radiol 1999 Feb;54(2):103–6
Giant cavernous hemangioma of the esophagus: endoscopic and echo–endoscopic appearance. Maluf–Filho F, et al.
Endoscopy 1999 May;31(4):S32
Doppler sonographic enhancement of hepatic hemangiomas and hepatocellular carcinomas after perflenapent emulsion: preliminary study. Lopez–Ben R, et al.
J Ultrasound Med 1999 Feb;18(2):109–16

HEMANGIOMA, HISTIOCYTOID see **HEMANGIOMA**

HEMANGIOMA, INTRAMUSCULAR see **HEMANGIOMA**

HEMANGIOMA, LOBULAR CAPILLARY see **GRANULOMA, PYOGENIC**

HEMANGIOPERICYTOMA

Congenital nasal hemangiopericytoma: intrauterine, intraoperative, and histologic findings. Götte K, et al.
Ann Otol Rhinol Laryngol 1999 Jun;108(6):589–93
Intraventricular hemangiopericytoma [letter; comment] McDonald JV. **J Neurosurg** 1999 Jul;91(1):167. Comment on: J Neurosurg 1999 Feb;90(2):359–62.

COMPLICATIONS

Oncogenic osteomalacia secondary to a hemangiopericytoma of the hip: case report. Baronofsky SI, et al.
Can Assoc Radiol J 1999 Feb;50(1):26–8
Treatment of hemangiopericytoma–induced hypoglycemia with growth hormone and corticosteroids [letter] Gullo D, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1758–9
Progressive proptosis in a neonate. O'Driscoll DA, et al.
Postgrad Med J 1998 Sep;74(875):559–61
Oncogenic osteomalacia presenting as bilateral stress fractures of the tibia. Ohashi K, et al. **Skeletal Radiol** 1999 Jan;28(1):46–8
Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May–Jun;85(3):199–204 (41 ref.)

DIAGNOSIS

Hemangiopericytoma and temporal bone. Magliulo G, et al.
An Otorrinolaringol Ibero Am 1999;26(1):67–74
Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Fukumoto S, et al. **Bone** 1999 Sep;25(3):375–7
MR appearance of pelvic hemangiopericytoma. Kehagias D, et al. **Eur Radiol** 1999;9(1):163–5
Primary liver hemangiopericytoma associated with hypoglycemia: report of a second case. Campion JP, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1944–8
Hemangiopericytoma of the parapharyngeal space. Llorente JL, et al. **Otolaryngol Head Neck Surg** 1999 Apr; 120(4):531–3
Combined malignant hemangiopericytoma and deep venous thrombosis. A case report. Campanella N, et al. **Tumori** 1999 May–Jun;85(3):199–204 (41 ref.)
[Intraabdominal hemangiopericytoma. Diagnosed during surgery for suspected acute appendicitis] Gad D, et al.
Ugeskr Laeger 1999 Aug 9;161(32):4519 (Eng. Abstr.) **(Dan)**
[Intra–abdominal hemangiopericytoma: an unexpected finging during laparotomy] Borgmann U, et al.
Zentralbl Gynakol 1999;121(3):153–5 (Eng. Abstr.) **(Ger)**
[A case of retroperitoneal hemangiopericytoma] Kura N, et al. **Hinyokika Kiyo** 1999 Jan;45(1):45–8 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Hemangiopericytoma of the head and neck. Carew JF, et al. **Laryngoscope** 1999 Sep;109(9):1409–11

ETIOLOGY

Exposure to polymeric materials in vascular soft–tissue sarcomas. Rhomberg W.
Int Arch Occup Environ Health 1998 Jul;71(5):343–7

METABOLISM

Tumor expression studies indicate that HEM–1 is unlikely to be the active factor in oncogenic osteomalacia. Nelson AE, et al. **Bone** 1998 Dec;23(6):549–53

PATHOLOGY

Polypoid dermal hemangiopericytoma: a case report. Pollock AM, et al. **Am J Dermatopathol** 1998 Oct;20(5):506–8
Primary hemangiopericytoma of the superior mediastinum: a case report. Hayashi A, et al.
Ann Thorac Cardiovasc Surg 1998 Oct;4(5):283–5

HEMANGIOPERICYTOMA

Hemangiopericytoma of the nose: a case for both internal and external localization. Melato M, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):717-21

Hemangiopericytoma of the lacrimal sac. Charles NC, et al. **Arch Ophthalmol** 1998 Dec;116(12):1677-80 (17 ref.)

Fine-needle aspiration cytology of hemangiopericytoma: A report of five cases. Chhieng D, et al. **Cancer** 1999 Aug 25;87(4):190-5

Intranasal hemangiopericytoma. Boey HP, et al. **Ear Nose Throat J** 1998 Dec;77(12):944-5

Subcutaneous haemangiopericytoma. Singla SL, et al. **J Indian Med Assoc** 1998 Mar;96(3):97

Nasal haemangiopericytoma: report of two cases with literature review. Marianowski R, et al. **J Laryngol Otol** 1999 Mar;113(3):199-206 (51 ref.)

Hemangiopericytoma of the third ventricle. Case report [see comments] Abrahams JM, et al. **J Neurosurg** 1999 Feb; 90(2):359-62. Comment in: J Neurosurg 1999 Jul;91(1):167.

Hemangiopericytoma arising at the site of a dural graft 13 years after total removal of a benign meningioma--case report. Hirose Y, et al. **Neurol Med Chir (Tokyo)** 1998 Nov; 38(11):733-7

Myofibroblastoma of the breast with hemangiopericytoma-like pattern and pleomorphic lipoma-like areas. Report of a case with diagnostic and histogenetic considerations. Magro G, et al. **Pathol Res Pract** 1999;195(4):257-62

Solitary fibrous tumor of the meninges: two new cases and review of the literature. Brunori A, et al. **Surg Neurol** 1999 Jun;51(6):636-40 (34 ref.)

Primary malignant hemangiopericytoma of the breast: report of a case. Kanazawa N, et al. **Surg Today** 1999;29(9):939-44 (22 ref.)

[Pelvic hemangiopericytoma in pregnancy. Report of a case] Petignat P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Nov;27(7):721-4 (Eng. Abstr.) **(Fre)**

[Clinical and histopathological features of hemangiopericytoma-like tumor of the nasal cavity] Iguchi Y, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Sep; 101(9):1082-7 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Hemangiopericytoma ischiorectal. Report of a case. Espinosa A, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):577-81

RADIONUCLIDE IMAGING

Positron emission tomography in a case of intracranial hemangiopericytoma. Kracht LW, et al. **J Comput Assist Tomogr** 1999 May-Jun;23(3):365-8

SECONDARY

Aspiration biopsy cytology of malignant hemangiopericytoma metastatic to the lungs. Cytomorphologic and immunocytochemical study of a case. Saleh HA, et al. **Acta Cytol** 1997 Jul-Aug;41(4 Suppl):1265-8

Hepatic and pulmonary metastases from a meningeal hemangiopericytoma and severe hypoglycemia due to abnormal secretion of insulin-like growth factor: a case report. Grunenberger F, et al. **Cancer** 1999 May 15; 85(10):2245-8

Metastatic meningeal hemangiopericytoma of thoracic spine. Nonaka M, et al. **Clin Neurol Neurosurg** 1998 Sep; 100(3):228-30

Recurrence in meningeal hemangiopericytomas. Hara M, et al. **Surg Neurol** 1998 Dec;50(6):586-91

[Meningeal hemangiopericytoma with liver metastasis] Davies C, et al. **HNO** 1999 Mar;47(3):183-7 (Eng. Abstr.) **(Ger)**

[Unusual course of hemangiopericytoma] Dempke W, et al. **Med Klin** 1998 Dec 15;93(12):726-8 (Eng. Abstr.) **(Ger)**

SURGERY

Hemangiopericytoma of the third ventricle. Case report [see comments] Abrahams JM, et al. **J Neurosurg** 1999 Feb; 90(2):359-62. Comment in: J Neurosurg 1999 Jul;91(1):167.

Free flap reconstruction after near-total glossectomy in the child. Sajjadian A, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):614-6

Liver transplantation for metastatic hemangiopericytoma associated with hypoglycemia. Adams J, et al. **Transplantation** 1999 Feb 15;67(3):488-9

[Renal hemangiopericytoma. Anatomo-pathologic and clinico-therapeutic considerations. A case report] Fornaro R, et al. **G Chir** 1999 Jan-Feb;20(1-2):20-4 (Eng. Abstr.) **(Ita)**

[Two cases of an intracranial large hemangiopericytoma associated with brain swelling in the early operative stage] Suyama D, et al. **No Shinkei Geka** 1999 May;27(5):453-7 (Eng. Abstr.) **(Jpn)**

VETERINARY

Cytogenetic, ras, and p53: studies in cases of canine neoplasms (hemangiopericytoma, mastocytoma, histiocytoma, chloroma). Mayr B, et al. **J Hered** 1999 Jan-Feb;90(1):124-8

Haemangiopericytoma in a calf. Mitarai Y, et al. **Res Vet Sci** 1998 Nov-Dec;65(3):265-7

HEMANGIOSARCOMA

Angiosarcoma of the chest wall. Maziak DE, et al. **Ann Thorac Surg** 1999 Mar;67(3):839-41

Primary angiosarcomas of the chest wall and pleura. Alexiou C, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):523-6 (13 ref.)

Primary angiosarcoma of bone in Paget's disease. Boulanger V, et al. **Eur J Surg Oncol** 1998 Dec;24(6):611-3

Angiosarcoma of the aorta: report of a case and review of the literature. Seelig MH, et al. **J Vasc Surg** 1998 Oct; 28(4):732-7

Angiosarcoma of the bladder: a review. Engel JD, et al. **Urology** 1998 Nov;52(5):778-84 (19 ref.)

BLOOD

Vascular endothelial growth factor in angiosarcoma. Fujimoto M, et al. **Anticancer Res** 1998 Sep-Oct; 18(5B):3725-9

BLOOD SUPPLY

The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. Arbiser JL, et al. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):925-9

CHEMICALLY INDUCED

Primary hepatic angiosarcoma: report of a case involving environmental arsenic exposure. Tsai MH, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):469-74

Critical genes as early warning signs: example of vinyl chloride. Marion MJ. **Toxicol Lett** 1998 Dec 28; 102-103:603-7

[Chance ultrasonographic findings in a former chemical industry employee] Morakkabati N, et al. **Radiologe** 1998 Dec;38(12):1083-5 **(Ger)**

CHEMISTRY

Primary renal angiosarcoma: a case report with immunohistochemical, ultrastructural, and cytogenetic features and review of the literature. Cerilli LA, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):929-35 (8 ref.)

COMPLICATIONS

Splenic hemangiosarcoma with massive calcification. Kinoshita T, et al. **Abdom Imaging** 1999 Mar-Apr; 24(2):185-7

Ruptured primary splenic angiosarcoma into the colon. Presentation as anal bleeding. Jiménez-Heffernan JA, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):248-51

Coincidental acute myeloblastic leukemia in a patient with renal angiosarcoma. Aydogdu I, et al. **Haematologia (Budap)** 1999;29(4):313-7

Stewart-Treves syndrome in a patient with elephantiasis. Hallel-Halevy D, et al. **J Am Acad Dermatol** 1999 Aug; 41(2 Pt 2):349-50

Cutaneous angiosarcoma with thrombocytopenia. Satoh T, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):872-6

Splenic angiosarcoma--an unusual cause of bleeding gastrointestinal tract. Chung YF, et al. **Singapore Med J** 1999 Feb;40(2):106-8

[Angiosarcoma of the liver as a cause of massive hemoperitoneum] Slováček R, et al. **Rozhl Chir** 1999 Mar; 78(3):99-101 (Eng. Abstr.) **(Cze)**

DIAGNOSIS

Angiosarcoma of the breast mimicking radiation dermatitis arising after lumpectomy and breast irradiation: a case report. Deutsch M, et al. **Am J Clin Oncol** 1998 Dec; 21(6):608-9

Primary cardiac angiosarcoma with right coronary artery-to-pericardial fistula--a case report. Reising C, et al. **Angiology** 1999 Sep;50(9):777-80

Cardiac angiosarcoma: early diagnosis. A case report. Cucchi G, et al. **G Ital Cardiol** 1999 May;29(5):555-7 (20 ref.)

Primary right atrial angiosarcoma mimicking acute pericarditis, pulmonary embolism, and tricuspid stenosis. Ananthasubramaniam K, et al. **Heart** 1999 May;81(5):556-8

Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. Wu C, et al. **J Clin Oncol** 1998 Dec; 16(12):3913-5

Multimodality demonstration of primary splenic angiosarcoma. Aytaç S, et al. **J Clin Ultrasound** 1999 Feb; 27(2):92-5

Primary spheno-orbital angiosarcoma: case report and review of the literature. Lopes M, et al. **Neurosurgery** 1999 Feb;44(2):405-7; discussion 407-8 (39 ref.)

CT and MR findings of splenic angiosarcoma. Imaoka I, et al. **Radiat Med** 1999 Jan-Feb;17(1):67-70

Angiosarcomas associated with bone infarcts. Abdelwahab IF, et al. **Skeletal Radiol** 1998 Oct;27(10):546-51 (17 ref.)

[Primary renal epithelioid angiosarcoma with transitional cell carcinoma in renal pelvis] Li N, et al. **Chung Hua Wai Ko Tsa Chih** 1997 May;35(5):294-5 (5 ref.) (Eng. Abstr.) **(Chi)**

[Cutaneous angiosarcoma] Couwenberg SM, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1584 **(Dut)**

[Angiosarcoma of the thoracic wall revealed by hemothorax] Boulay V, et al. **Rev Pneumol Clin** 1998 Oct;54(5):259-62 (Eng. Abstr.) **(Fre)**

[Angiosarcoma of the nasal septum] Karapantzos I, et al. **Laryngorhinootologie** 1998 Sep;77(9):513-6 (Eng. Abstr.) **(Ger)**

[Angiosarcoma of the kidney. Case report and review of the literature] Matter LE, et al. **Urologe A** 1999 Jan;38(1):65-8 (19 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Therapeutic efficacy of interferon alfa-2a and 13-cis-retinoic acid in recurrent angiosarcoma of the head. Spieth K, et al. **Arch Dermatol** 1999 Sep;135(9):1035-7

Treatment of a malignant enterocutaneous fistula with octreotide acetate. Ayache S, et al. **Cancer Invest** 1999; 17(5):320-1

Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Lankester KJ, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):208-10

The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. Arbiser JL, et al. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):925-9

[Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report] Rhomberg W, et al. **Strahlenther Onkol** 1999 Mar;175(3):102-4 (17 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The risk of angiosarcoma following primary breast cancer. Cozen W, et al. **Br J Cancer** 1999 Oct;81(3):532-6

Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Marchal C, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):113-9 (48 ref.)

ETIOLOGY

Angiosarcoma. A rare secondary malignancy after breast cancer treatment. Autio P, et al. **Eur J Dermatol** 1999 Mar; 9(2):118-21 (26 ref.)

Angiosarcoma of the breast following radiation therapy. Williams EV, et al. **Eur J Surg Oncol** 1999 Apr;25(2):221-2 (18 ref.)

Exposure to polymeric materials in vascular soft-tissue sarcomas. Rhomberg W. **Int Arch Occup Environ Health** 1998 Jul;71(5):343-7

Intra-abdominal angiosarcomatosis after radiotherapy. Suzuki F, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):289-92

GENETICS

The akt kinase: molecular determinants of oncogenicity. Aoki M, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8; 95(25):14950-5

p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Duddy SK, et al. **Toxicol Appl Pharmacol** 1999 Apr 15; 156(2):106-12

METABOLISM

Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Breiteneder-Geleff S, et al. **Am J Pathol** 1999 Feb;154(2):385-94

MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Zietz C, et al. **Am J Pathol** 1998 Nov;153(5):1425-33

Expression of basic fibroblast growth factor and its receptor in angiosarcoma. Yamamoto T, et al. **J Am Acad Dermatol** 1999 Jul;41(1):127-9

PATHOLOGY

Cytomorphologic features of angiosarcoma on fine needle aspiration biopsy. Liu K, et al. **Acta Cytol** 1999 May-Jun; 43(3):407-15

Angiosarcoma of the lower leg in chronic lymphoedema [letter] Simonetti V, et al. **Acta Derm Venereol** 1999 May; 79(3):251-2

Pathologic quiz case. Abboud E, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):157-8

Cardiac angiosarcoma: an unusual presentation with cutaneous metastases. Pomper GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):273-6

Haemangiosarcoma of the breast, metastatic to the ciliary body and iris [letter] Sach J, et al. **Br J Ophthalmol** 1998 Jun;82(6):709-11

Gliosarcoma with angiosarcomatous features: a case report. Shintaku M, et al. **Brain Tumor Pathol** 1998;15(2):101-5

Malignant vascular tumors in young patients. Lezama-del Valle P, et al. **Cancer** 1998 Oct 15;83(8):1634-9

Primary angiosarcoma of the bladder: cytomorphology and differential diagnosis. Schindler S, et al. **Cytopathology** 1999 Apr;10(2):137-43

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105-10 (35 ref.)

Intimal sarcoma of the thoracic aorta: a case report. le Rochais JP, et al. **Eur J Vasc Endovasc Surg** 1999 Aug; 18(2):181-2

Primary angiosarcoma of the ovary: a case report and review of the literature. Platt JS, et al. **Gynecol Oncol** 1999 Jun; 73(3):443–6 (19 ref.)

Intraneural angiosarcoma and angiosarcoma arising in benign and malignant peripheral nerve sheath tumours: clinicopathological and immunohistochemical analysis of four cases. Mentzel T, et al. **Histopathology** 1999 Aug; 35(2):114–20

Radiation-associated angiosarcoma involving the parotid gland [letter] Pérez del Rio MJ, et al. **Histopathology** 1998 Dec;33(6):586–7

Establishment of a human hemangiosarcoma cell line (ISO–HAS). Masuzawa M, et al. **Int J Cancer** 1999 Apr 12;81(2):305–8

Cutaneous angiosarcoma arising on the radiation site of a congenital facial hemangioma [letter] Cabo H, et al. **Int J Dermatol** 1998 Aug;37(8):638–9

Primary cardiac angiosarcoma of the right atrium undiagnosed by transvenous endocardial tumor biopsy. Nitta R, et al. **Intern Med** 1998 Dec;37(12):1023–6

Vaginal epithelioid angiosarcoma. McAdam JA, et al. **J Clin Pathol** 1998 Dec;51(12):928–30

34-year-old man with history of progressive orthopnea and exertional dyspnea: a clinicopathological correlation conference from the University of Oklahoma College of Medicine. Tardibono G, et al. **J Okla State Med Assoc** 1999 Jan;92(1):24–35

Angiosarcoma of the tongue: report of a case with immunohistochemical findings. Tabata M, et al. **J Oral Pathol Med** 1999 Feb;28(2):92–5 (24 ref.)

Primary ovarian angiosarcoma: a case report and literature review. Furihata M, et al. **Pathol Int** 1998 Dec; 48(12):967–73 (28 ref.)

Pseudovascular squamous cell carcinoma of the uterine cervix: a lesion that may simulate an angiosarcoma. Horie Y, et al. **Pathol Int** 1999 Feb;49(2):170–4

Mediastinal mature teratoma with coexistence of angiosarcoma, granulocytic sarcoma and a hematopoietic region in the tumor: a rare case of association between hematological malignancy and mediastinal germ cell tumor. Saito A, et al. **Pathol Int** 1998 Sep;48(9):749–53

Case report: spontaneous hemangiosarcoma in the pancreas of a Fischer rat. Katsuta O, et al. **Toxicol Pathol** 1999 Jul–Aug;27(4):463–7

Angiosarcoma of the testis. Masera A, et al. **Virchows Arch** 1999 Apr;434(4):351–3

[Angiosarcoma of the outer ear. A case report] Ferrer Baixauli F, et al. **Acta Otorrinolaringol Esp** 1999 May; 50(4):311–4 (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Lankester KJ, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):208–10

Angiosarcoma of the head and neck managed by a combination of multiple biopsies to determine tumor margin and radiation therapy. Report of three cases and review of the literature. Bullen R, et al. **Dermatol Surg** 1998 Oct; 24(10):1105–10 (35 ref.)

[Angiosarcoma of the right atrium: local control via low radiation doses and razoxane. A case report] Rhomberg W, et al. **Strahlenther Onkol** 1999 Mar;175(3):102–4 (17 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Cardiac angiosarcoma: an unusual presentation with cutaneous metastases. Pomper GJ, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):273–6

Metastatic cardiac angiosarcoma of the cervical spine. Case report. Shapiro S, et al. **Spine** 1999 Jun 1;24(11):1156–8

[Relapsing pneumothorax secondary to thin-walled cavitary pulmonary metastasis from angiosarcoma of the scalp] Kobayashi T, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Dec;36(12):1058–61 (Eng. Abstr.) **(Jpn)**

SURGERY

Primary cardiac angiosarcoma with superior vena caval syndrome: review of surgical resection and interventional management of venous inflow obstruction. Uchita S, et al. **Can J Cardiol** 1998 Oct;14(10):1283–5

Multifocal angiosarcoma of the scalp: a case report and review of the literature. Kacker A, et al. **Ear Nose Throat J** 1999 Apr;78(4):302–5 (14 ref.)

[The observation of angiosarcoma of the greater omentum] Karabanov GN. **Klin Khir** 1998;(5):47 **(Rus)**

ULTRASONOGRAPHY

[Multi-plane transesophageal echocardiography in cardiac angiosarcoma. Apropos of a case] Rojas M, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91(10):1289–93 (Eng. Abstr.) **(Fre)**

[Chance ultrasonographic findings in a former chemical industry employee] Morakkabati N, et al. **Radiologe** 1998 Dec;38(12):1083–5 **(Ger)**

VETERINARY

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Vail DM, et al. **Clin Cancer Res** 1995 Oct;1(10):1165–70

Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma. Kraje AC, et al. **J Am Vet Med Assoc** 1999 Mar 1; 214(5):670–2

What is your diagnosis? Primary splenic tumor and suppurative peritonitis due to gallbladder rupture. Ramirez O 3rd, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):625–6

Cardiac tumors in dogs: 1982–1995. Ware WA, et al. **J Vet Intern Med** 1999 Mar–Apr;13(2):95–103

Low-intensity laser light-induced closure of a chronic wound in a dog. Lucroy MD, et al. **Vet Surg** 1999 Jul–Aug; 28(4):292–5

VIROLOGY

Absence of Kaposi's sarcoma-associated virus (human herpesvirus-8) sequences in angiosarcoma. Lasota J, et al. **Virchows Arch** 1999 Jan;434(1):51–6

HEMARTHROSIS

DIAGNOSIS

Expanding portal haematomata as a complication of knee arthroscopies in persons with haemophilia. Heim M, et al. **Haemophilia** 1999 May;5(3):213–5

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Magnetic resonance imaging in acute knee haemarthrosis. Mukerjee A. **J Accid Emerg Med** 1999 May;16(3):216–7

An acutely painful elbow as a first presentation of von Willebrand's disease. Poncia HD, et al. **J Accid Emerg Med** 1999 Mar;16(2):153–4

[Diagnostic imaging of hemophilic osteoarthropathy] Erlemann R, et al. **Orthopade** 1999 Apr;28(4):329–40 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Hemarthrosis and tourniquet use [letter; comment] Miller GK. **Am J Knee Surg** 1998 Summer;11(3):151. Comment on: Am J Knee Surg 1998 Spring;11(2):95–100.

Radiation therapy in pseudotumour haemarthrosis. Lal P, et al. **Australas Radiol** 1998 Nov;42(4):344–6

Common orthopaedic problems in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:53–60 (16 ref.)

Hemarthrosis of the ankle revealing an aneurysm of the anterior tibial artery [letter] Billey T, et al. **Rev Rhum Engl Ed** 1999 May;66(5):297–8

IMMUNOLOGY

An unusual haemarthrosis in an HIV-seronegative haemophilia A patient. Ménart C, et al. **Haemophilia** 1998 Sep;4(5):752–4

PHYSIOPATHOLOGY

Common orthopaedic problems in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:53–60 (16 ref.)

PREVENTION & CONTROL

Hemarthrosis and tourniquet use [letter; comment] Miller GK. **Am J Knee Surg** 1998 Summer;11(3):151. Comment on: Am J Knee Surg 1998 Spring;11(2):95–100.

Anatomic and radioanatomic study of the lateral genicular arteries: application to prevention of postoperative hemarthrosis after arthroscopic lateral retinacular release. Vialle R, et al. **Surg Radiol Anat** 1999;21(1):49–53

[Joint preserving operations and endoprosthetic joint substitutions in hemophiliacs. Indications and long term results] Hovy L. **Orthopade** 1999 Apr;28(4):356–65 (29 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of joint damage in hemophilic children with early prophylaxis] Kreuz W, et al. **Orthopade** 1999 Apr; 28(4):341–6 (Eng. Abstr.) **(Ger)**

[Conservative management of hemophilic arthropathy] Müller S, et al. **Orthopade** 1999 Apr;28(4):347–55 (Eng. Abstr.) **(Ger)**

[Pathology of synovitis and hemophilic arthropathy] Roosendaal G, et al. **Orthopade** 1999 Apr;28(4):323–8 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radiation therapy in pseudotumour haemarthrosis. Lal P, et al. **Australas Radiol** 1998 Nov;42(4):344–6

SURGERY

A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis. Molho P, et al. **Haemophilia** 1999 Mar; 5(2):115–23

HEMATEMESIS

ETIOLOGY

Orbital hemorrhage as a complication of gastroscopy. Tóth E, et al. **Endoscopy** 1998 Oct;30(8):S89

Hematemesis due to prolapse gastropathy: an emetogenic injury. Byfield F, et al. **Gastrointest Endosc** 1998 Nov; 48(5):527–9 (10 ref.)

Recurrent GI hemorrhage following the use of silk sutures [letter] Gur G, et al. **Gastrointest Endosc** 1999 Sep; 50(3):456–7

Castleman's disease: a rare cause of hematemesis. Zamir A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):112–5

Index of suspicion. Case 3. Diagnosis: hematemesis resulting from gastritis, duodenal ulcer and hemophilia A. Colli J, et al. **Pediatr Rev** 1998 Dec;19(12):429, 432

[Hematemesis and respiratory airway obstruction due to leeches (letter)] Iraqi MR, et al. **Arch Pediatr** 1999 Apr; 6(4):479–80 **(Fre)**

[Biliary ileus preceded by hematemesis: role of the tomodensitometry assessment (letter)] Ngo MD, et al. **Gastroenterol Clin Biol** 1998 May;22(5):558–9 **(Fre)**

[Hematemesis and cholestasis] Schwab D, et al. **Med Klin** 1998 Oct 15;93(10):629 **(Ger)**

[Hematemesis and bilateral vision loss. Acute methanol poisoning] Winter M, et al. **Ophthalmologe** 1999 Jun; 96(6):408–9 **(Ger)**

[Efficiency of electro-hydrothermal coagulation in the management of non-variceal upper gastrointestinal bleeding] Patai A, et al. **Orv Hetil** 1998 Sep 27; 139(39):2299–304 (36 ref.) (Eng. Abstr.) **(Hun)**

PSYCHOLOGY

Variceal haemorrhage and post-traumatic stress disorder. O'Carroll RE, et al. **Br J Clin Psychol** 1999 Jun;38 (Pt 2):203–8

THERAPY

Practical advice on treating haematemesis. Conlong PJ. **Hosp Med** 1998 Nov;59(11):851–5 (17 ref.)

HEMATIN see **HEMIN**

HEMATINICS

ADMINISTRATION & DOSAGE

Adding zinc to prenatal iron and folate supplements improves maternal and neonatal zinc status in a Peruvian population. Caulfield LE, et al. **Am J Clin Nutr** 1999 Jun;69(6):1257–63

Iron and folate supplementation: an effective intervention in adolescent females [editorial] Picciano MF. **Am J Clin Nutr** 1999 Jun;69(6):1069–70

Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project. Bailie GR, et al. **Am J Kidney Dis** 1999 Jun;33(6):1187–9

Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Goodkin DA, et al. **Clin Nephrol** 1999 Jun;51(6):367–72

Dietary folate intake in US adults: findings from the third National Health and Nutrition Examination Survey. Ford ES, et al. **Ethn Dis** 1998 Autumn;8(3):299–305

Periconceptional folic acid in The Netherlands in 1995. Socioeconomic differences. de Walle HE, et al. **J Epidemiol Community Health** 1998 Dec;52(12):826–7

Folic acid supplementation prevents deficient blood [letter; comment] Doube A. **J Rheumatol** 1998 Dec;25(12):2473. Comment on: J Rheumatol 1998 Mar;25(3):441–6.

Oral vitamin B12 for B12 deficiency [letter] Cobcroft R, et al. **Med J Aust** 1999 May 3;170(9):451

Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Hergesell O, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):863–7

Dietary reference intakes for folate: the debut of dietary folate equivalents. Bailey LB. **Nutr Rev** 1998 Oct; 56(10):294–9 (58 ref.)

Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Sloand JA, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):522–7

[Folate consumption in the preconception period of Sicilian pregnant women and their knowledge about the prevention of neural tube defect by folate supplementation] Pepe F, et al. **Minerva Ginecol** 1999 May;51(5):177–81 (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans [see comments] Faich G, et al. **Am J Kidney Dis** 1999 Mar;33(3):464–70 (20 ref.). Comment in: Am J Kidney Dis 1999 Mar;33(3):595.

Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery. de Andrade JR, et al. **Orthopedics** 1999 Jan;22(1 Suppl):s113–8

CHEMISTRY

Stability of iron dextran (DexFerrum) in peritoneal dialysis bags. Manley HJ, et al. **Perit Dial Int** 1998 Sep–Oct; 18(5):538–40

ECONOMICS

Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood. Driver PS.

HEMATINICS

Am J Health Syst Pharm 1998 Dec 15;55(24 Suppl 4):S12-6
Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Meadowcroft AM, et al. **Am J Health Syst Pharm** 1998 Sep 15;55(18):1898-902
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis [see comments] Ortega A, et al. **Cancer** 1998 Dec 15;83(12):2588-96. Comment in: Cancer 1998 Dec 15;83(12):2427-9.

METABOLISM

10-Formyl-dihydrofolic acid is bioactive in human leukemia cells. Baggott JE, et al. **J Nutr** 1999 Jul;129(7):1315-8

PHARMACOLOGY

Short time effect of Chemiron (a combination iron preparation), single iron, and different magnesium salts on plasma. Magnesium concentration during early pregnancy in Nigerian women. A preliminary report. Ajayi GO, et al. **Clin Exp Obstet Gynecol** 1998;25(1-2):64-6
Effect of trans-retinoic acid and folic acid on apoptosis in human gastric cancer cell lines MKN-45 and MKN-28. Fang JY, et al. **J Gastroenterol** 1998 Oct;33(5):656-61
Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. van Guldener C, et al. **J Intern Med** 1999 Feb;245(2):175-83
Genetic selection and folate intake during pregnancy [letter] [see comments] Muñoz-Moran E, et al. **Lancet** 1998 Oct 3;352(9134):1120-1. Comment in: Lancet 1998 Nov 28;352(9142):1784-5.

THERAPEUTIC USE

Folic acid in the treatment of acute watery diarrhoea in children: a double-blind, randomized, controlled trial. Ashraf H, et al. **Acta Paediatr** 1998 Nov;87(11):1113-5
School-administered weekly iron-folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls. Tee ES, et al. **Am J Clin Nutr** 1999 Jun;69(6):1249-56
Intravenous iron supplementation in end-stage renal disease patients [editorial; comment] [see comments] Matzke GR. **Am J Kidney Dis** 1999 Mar;33(3):595-7. Comment on: Am J Kidney Dis 1999 Mar;33(3):464-70. Comment on: Am J Kidney Dis 1999 Mar;33(3):471-82. Comment in: Am J Kidney Dis 1999 Aug;34(2):401-2.
Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond [editorial; comment] Mittman N. **Am J Kidney Dis** 1999 Jul;34(1):173-6. Comment on: Am J Kidney Dis 1999 Jul;34(1):21-8. Comment on: Am J Kidney Dis 1999 Jul;34(1):29-35.
Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial [see comments] Nissenson AR, et al. **Am J Kidney Dis** 1999 Mar;33(3):471-82. Comment in: Am J Kidney Dis 1999 Mar;33(3):495.
Drug and environmental factors associated with adverse pregnancy outcomes. Part III: Folic acid: pharmacology, therapeutic recommendations, and economics. Lewis DP, et al. **Ann Pharmacother** 1998 Oct;32(10):1087-95 (119 ref.)
Transfusion-free surgery is a treatment plan for all patients. Trovarelli T, et al. **AORN J** 1998 Nov;68(5):773-8, 780-4
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Thatcher N, et al. **Br J Cancer** 1999 May;80(3-4):396-402
Preventing neural tube defects. Survey of preconceptional use of folic acid. Neimanis IM, et al. **Can Fam Physician** 1999 Jul;45:1717-22
Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Verhaar MC, et al. **Circulation** 1999 Jul 27;100(4):335-8
The effect of combined iron therapy (Chemiron) and single iron therapy on the dexamethasone-estriol reaction test for placenta insufficiency during normal pregnancy. Ajayi GO, et al. **Clin Exp Obstet Gynecol** 1999;26(1):27-30
Epoetin alfa. A bloodless approach for the treatment of perioperative anemia. Faris PM, et al. **Clin Orthop** 1998 Dec;(357):60-7 (37 ref.)
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Demetri GD, et al. **J Clin Oncol** 1998 Oct;16(10):3412-25
Effective utilization of erythropoietin with intravenous iron therapy. Bhandari S, et al. **J Clin Pharm Ther** 1998 Feb; 23(1):73-8
Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Aarsand AK, et al. **J Intern Med** 1998 Aug;244(2):169-74
Elevated serum levels of methylmalonic acid and homocysteine in elderly people. A population-based intervention study. Björkegren K, et al. **J Intern Med** 1999 Sep;246(3):317-24
Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients [letter] Chang JM, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1045-7
The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin [editorial; comment] Macdougall IC. **Nephrol Dial Transplant** 1999 Aug; 14(8):1836-41 (28 ref.). Comment on: Nephrol Dial Transplant 1999 Aug;14(8):1912-6. Comment on: Nephrol Dial Transplant 1999 Aug;14(8):2047-9.
Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Adamson JW, et al. **Oncology** 1999;56(1):46-53 (47 ref.)
An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Stowell CP, et al. **Orthopedics** 1999 Jan;22(1 Suppl):s105-12
Cardiovascular function before and after iron therapy by echocardiography in patients with iron deficiency anemia. Hayashi R, et al. **Pediatr Int** 1999 Feb;41(1):13-7
Treatment of hyperhomocysteinemia in children on dialysis by folic acid. Schröder CH, et al. **Pediatr Nephrol** 1999 Sep;13(7):583-5
Impact of epoetin alfa in chemotherapy-associated anemia. Jilani SM, et al. **Semin Oncol** 1998 Oct;25(5):571-6 (37 ref.)
[Iron supplementation in preterm infants treated with erythropoietin] Picaud JC, et al. **Arch Pediatr** 1999 Jun; 6(6):657-64 (57 ref.) (Eng. Abstr.) **(Fre)**
[Epoietin alfa in lung cancer] Ardizzoni A, et al. **Tumori** 1998 Nov-Dec;84(6 Suppl 1):S20-6 (35 ref.) (Eng. Abstr.) **(Ita)**
[Blood transfusion in oncologic surgery: the role of recombinant human erythropoietin (rHuEPO)] Mercuriali F, et al. **Tumori** 1998 Nov-Dec;84(6 Suppl 1):S3-14 (109 ref.) (Eng. Abstr.) **(Ita)**
[Epoetin alfa in radiotherapy] Trodella L, et al. **Tumori** 1998 Nov-Dec;84(6 Suppl 1):S15-9 (44 ref.) (Eng. Abstr.) **(Ita)**

HEMATOCELE

COMPLICATIONS

[Quid? Gallbladder hemorrhage with intraperitoneal rupture] Noël JB, et al. **J Radiol** 1999 Jul;80(7):741-3 **(Fre)**

ETIOLOGY

Unilateral traumatic hematocele--an unusual presentation of bilateral testicular rupture. Talic RF. **Scand J Urol Nephrol** 1999 Apr;33(2):131-2

RADIOGRAPHY

[Quid? Gallbladder hemorrhage with intraperitoneal rupture] Noël JB, et al. **J Radiol** 1999 Jul;80(7):741-3 **(Fre)**

HEMATOCHEZIA see **GASTROINTESTINAL HEMORRHAGE**

HEMATOCOLPOS

COMPLICATIONS

Hematocolpos as an easily overlooked diagnosis. Schneider K, et al. **Curr Opin Pediatr** 1999 Jun;11(3):249-52
[Surgical treatment in a case of partial vaginal obliteration coexisting with hematometra, hematocolpos and other congenital defects] Goluda M, et al. **Ginekol Pol** 1999 May; 70(5):292-4 (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Robinow syndrome, vaginal atresia, hematocolpos, and extra middle finger. Balci S, et al. **Am J Med Genet** 1998 Aug 27;79(1):27-9

SURGERY

[Surgical treatment in a case of partial vaginal obliteration coexisting with hematometra, hematocolpos and other congenital defects] Goluda M, et al. **Ginekol Pol** 1999 May; 70(5):292-4 (Eng. Abstr.) **(Pol)**

HEMATOCRIT

Optical measurement of hematocrit and other biological constituents in renal therapy. Steuer RR, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):217-24 (27 ref.)
Hemoconcentration as an early risk factor for necrotizing pancreatitis. Baillargeon JD, et al. **Am J Gastroenterol** 1998 Nov;93(11):2130-4
Effect of hematocrit on blood pressure via hyperviscosity. Cinar Y, et al. **Am J Hypertens** 1999 Jul;12(7):739-43
What crit? [editorial; comment] Bolton WK. **Am J Kidney Dis** 1999 Jun;33(6):1177-9. Comment on: Am J Kidney Dis 1999 Jun;33(6):1122-30.
Optimal hematocrit in patients on dialysis therapy. Nissenson AR. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S142-6
Normalizing hematocrit in dialysis patients improves brain function [see comments] Pickett JL, et al. **Am J Kidney Dis** 1999 Jun;33(6):1122-30. Comment in: Am J Kidney Dis 1999 Jun;33(6):1177-9.
The effect of hematocrit on cerebral blood flow velocity in neonates and infants undergoing deep hypothermic cardiopulmonary bypass. Gruber EM, et al. **Anesth Analg** 1999 Aug;89(2):322-7
Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Quaknine-Orlando B, et al. **Anesthesiology** 1999 May;90(5):1454-61
O2-Hb reaction kinetics and the Fåhraeus effect during stagnant, hypoxic, and anemic supply deficit. Ye GF, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):60-75
Hematocrit and stroke in black Africans under tropical climate and meteorological influence. Longo-Mbenza B, et al. **Ann Med Interne (Paris)** 1999 Apr;150(3):171-7
Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit [see comments] Steen RG, et al. **Ann Neurol** 1999 Mar;45(3):279-86. Comment in: Ann Neurol 1999 Mar;45(3):277-8.
Measurement of blood hematocrit inside the magnetically suspended centrifugal pump using an optical technique: application to assessment of pump flow. Kaiwa T, et al. **Artif Organs** 1999 Jun;23(6):490-5
Minimum hematocrit at differing cardiopulmonary bypass temperatures in dogs. Cook DJ, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II170-4; discussion II175
The effect of 61 days of combined iron (Chemiron) and single iron therapy on haemoglobin, packed cell volume, platelets and reticulocytes during pregnancy. Preliminary report. Ajayi GO, et al. **Clin Exp Obstet Gynecol** 1998;25(3):107-11
A comparative study of the haemorheology of various breeds of dog. Bodey AR, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(4):291-8
Erythrocyte elongation index measured on a Rheodyn SSD laser diffractometer. Influence of the hematocrit. Martinez M, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):255-7
Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Goodkin DA, et al. **Clin Nephrol** 1999 Jun;51(6):367-72
Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Escolar G, et al. **Haematologica** 1999 Jul;84(7):614-9
Safe and effective regulation of hematocrit by gene gun administration of an erythropoietin-encoding DNA plasmid. Klinman DM, et al. **Hum Gene Ther** 1999 Mar 1;10(4):659-65
Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Fábregues F, et al. **Hum Reprod** 1998 Sep;13(9):2406-10
Hematocrit correlates with blood pressure in young male office workers. Nishikido N, et al. **Ind Health** 1999 Jan; 37(1):76-81
Hemodynamic properties of the hemopump HP14. Lachat M, et al. **Int J Artif Organs** 1999 Mar;22(3):155-9
Hematocrit level and associated mortality in hemodialysis patients. Ma JZ, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):610-9
Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. Metry G, et al. **J Am Soc Nephrol** 1999 Apr;10(4):854-63
Hematocrit levels and hospitalization risks in hemodialysis patients. Xia H, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1309-16
The measurement of venous haematocrit in patients with polycythaemia vera. Andréasson B, et al. **J Intern Med** 1999 Sep;246(3):293-7
High hematocrit value is a risk factor for myocardial infarction [letter; comment] Cheng TO. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):199-200. Comment on: J Thorac Cardiovasc Surg 1998 Sep;116(3):460-7.
Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Berns JS, et al. **Kidney Int** 1999 Jul;56(1):253-60
Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). Kronenberg F, et al. **Kidney Int** 1998 Oct;54(4):1385-9
Packed-cell volume in athletes [letter] Dugué B, et al. **Lancet** 1998 Oct 24;352(9137):1387-8
Complications of acute anaemia: caused by low packed-cell volume or by transfusion? Sandham JD. **Lancet** 1999 Sep 11;354(9182):883-4
Packed-cell volume and haemoglobin in elite athletes [letter; comment] Tikkanen HO. **Lancet** 1999 Jan 23; 353(9149):327-8. Comment on: Lancet 1998 Aug 8;352(9126):451. Comment on: Lancet 1998 Nov 28;352(9142):1758.
Hematocrits of triathletes: is monitoring useful? O'Toole ML, et al. **Med Sci Sports Exerc** 1999 Mar;31(3):372-7
Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] González F. **N Engl J Med** 1998 Dec 31;339(27):2023-4. Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.
Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] Sklar AH, et al. **N Engl J Med** 1998 Dec 31;339(27):2023; discussion 2023-4 . Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.
Transfusion medicine [letter; comment] Valeri CR, et al. **N Engl J Med** 1999 Jul 8;341(2):124-5; discussion 126-7. Comment on: N Engl J Med 1999 Feb 11;340(6):438-47. Comment on: N Engl J Med 1999 Feb 18;340(7):525-33.
The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Bellizzi V, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2210-5
The Normal Haematocrit Trial in dialysis patients with cardiac disease [letter] Besarab A, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2043-4

Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? [editorial] Collins AJ, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1627–9 (27 ref.)
The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry [news] Locatelli F, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1642–4
The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Macdougall IC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3030–3 (18 ref.)
Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true'-functional haematocrit? [letter] Vlassopoulos D, et al. **Nephrol Dial Transplant** 1999 May;14(5):1340–1
Hemoglobin and red cell indices correlated with serum ferritin concentration in late pregnancy. Tam KF, et al. **Obstet Gynecol** 1999 Mar;93(3):427–31
Effects of ginseng extract on various haematological parameters during aerobic exercise in the rat [letter] Ferrando A, et al. **Planta Med** 1999 Apr;65(3):288–90
Mode of inheritance of unselected traits in lines of chickens selected for high or low antibody response to sheep red blood cells. 2. Heterophils, lymphocytes, and hematocrits. Yang A, et al. **Poult Sci** 1998 Aug;77(8):1081–4
Haematological indices at fetal blood sampling in monochorionic pregnancies complicated by feto-fetal transfusion syndrome. Denbow M, et al. **Prenat Diagn** 1998 Sep;18(9):941–6
Variations in white blood count, thromboxane B2 levels and hematocrit in chronic venous hypertension. Guimarães PC, et al. **Rev Paul Med** 1998 May-Jun;116(3):1721–6
A decrease in regional cerebral blood volume and hematocrit in crossed cerebellar diaschisis. Yamauchi H, et al. **Stroke** 1999 Jul;30(7):1429–31
Where does preoperative erythropoietin therapy count? A mathematical perspective. Brecher ME, et al. **Transfusion** 1999 Apr;39(4):392–5
Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis. Tsang WK, et al. **Transplant Proc** 1998 Nov;30(7):3072–3
[What is the right hematocrit in patients with chronic renal failure?] Deray G. **Presse Med** 1999 Feb 6;28(5):234–5 **(Fre)**
[Hematocrit in professional cyclists and in sedentary men (letter)] Varet B. **Presse Med** 1999 Jul 3–10;28(24):1294 **(Fre)**
[Myeloproliferative syndrome of the polycythemia vera type] Lorz B. **Schweiz Rundsch Med Prax** 1998 Dec 10; 87(50):1763–5 **(Ger)**
[The association of hematocrit with blood pressure and left ventricular mass in subjects over 55] González Quijada S, et al. **Rev Clin Esp** 1999 Apr;199(4):202–7 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Evaluation in volunteers of the VIA V-ABG automated bedside blood gas, chemistry, and hematocrit monitor. Bailey PL, et al. **J Clin Monit Comput** 1998 Jul;14(5):339–46
[The separator that separated cream from milk was an inspiration for the first hematocrit centrifuge] Thorén L. **Lakartidningen** 1998 Nov 4;95(45):5015 **(Swe)**

VETERINARY

Evaluation of automated methods of measuring hemoglobin and hematocrit in horses. Sorrell-Raschi LA, et al. **Am J Vet Res** 1998 Dec;59(12):1519–22
Hematocrit values in weight-selected and relaxed lines of White Rock chickens. Price SE, et al. **Poult Sci** 1998 Oct; 77(10):1478–80

HEMATO-ENCEPHALIC BARRIER see **BLOOD-BRAIN BARRIER**

HEMATOLOGIC AGENTS

Characterization of liposomes carrying von Willebrand factor-binding domain of platelet glycoprotein Ibalpha: a potential substitute for platelet transfusion. Kitaguchi T, et al. **Biochem Biophys Res Commun** 1999 Aug 11; 261(3):784–9

ADVERSE EFFECTS

Hydroxyurea-induced skin disease mimicking the baboon syndrome [letter] Chowdhury MM, et al. **Clin Exp Dermatol** 1999 Jul;24(4):336–7

CHEMISTRY

[The application of the endotoxin test for globulin and other blood products] Fujiwara H, et al. **Yakugaku Zasshi** 1999 Jun;119(6):451–5 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Invertebrate compounds acting on the hemostatic mechanism [see comments] Arocha-Piñango CL, et al. **Blood Coagul Fibrinolysis** 1999 Mar;10(2):43–68 (229 ref.) . Comment in: Blood Coagul Fibrinolysis 1999 Jun;10(4):213.
Kinetics of beneficial effect of pentoxifylline on persistent forms of arterial hypertension. Mchedlishvili G, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(4):285–90
Evaluation of pentoxifylline in the prevention of haze after photorefractive keratectomy in the rabbit. Francesconi CM, et al. **J Refract Surg** 1998 Sep-Oct;14(5):567–70
[Effects of lithium on the proliferation of murine high proliferative potential colony-forming cells and granulocyte macrophage colony forming unit in vitro] Xia T, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):264–7 (Eng. Abstr.) **(Chi)**
[Effect of pentoxifylline preparations and photohemotherapy with blue light on the blood viscosity] Karandashov VI, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):579–80 **(Rus)**

THERAPEUTIC USE

Improvement with disodium cromoglycate of neutrophil phagocytosis and respiratory burst activity in a patient with hyperimmunoglobulin E syndrome. Kojima K, et al. **Allergy** 1998 Nov;53(11):1101–3
Modulation of intravariceal pressure with pentoxifylline: a possible new approach in the treatment of portal hypertension. Eleftheriadis E, et al. **Am J Gastroenterol** 1998 Dec;93(12):2431–5
Kinetics of beneficial effect of pentoxifylline on persistent forms of arterial hypertension. Mchedlishvili G, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(4):285–90
Pharmacological approaches to the prevention of restenosis after coronary angioplasty. Hamon M, et al. **Drugs Aging** 1998 Oct;13(4):291–301 (100 ref.)
Topically applied pentoxifylline has no effect on allergic patch responses. Brehler R, et al. **J Am Acad Dermatol** 1998 Dec;39(6):1017–21
Pentoxifylline treatment for microangiopathic hemolytic anemia caused by mechanical heart valves. Geller S, et al. **Md Med J** 1999 Jul-Aug;48(4):173
Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Navarro JF, et al. **Scand J Urol Nephrol** 1999 Apr;33(2):121–5
[In vitro and clinical effect of pentoxifylline on natural killer cell activity] Nagy Z, et al. **Orv Hetil** 1998 Oct 11; 139(41):2441–5 (Eng. Abstr.) **(Hun)**

HEMATOLOGIC DISEASES

43rd Annual meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung). Mannheim, Germany, February 24–27, 1999. Abstracts. **Ann Hematol** 1999;78 Suppl 1:A1–100
Periodic hematological disorders [letter; comment] Morley A. **Blood** 1999 Jun 1;93(11):4023–4. Comment on: Blood 1998 Oct 15;92(8):2629–40.
Recent advances in haematology. Provan D, et al. **BMJ** 1999 Apr 10;318(7189):991–4 (29 ref.)
28th Annual meeting of the International Society for Experimental Hematology. Monte Carlo, Principality of Monaco, July 10–14, 1999. Abstracts. **Exp Hematol** 1999 Jul;27(7 Suppl 1):37–149
36th Congress of the Italian Society of Hematology. Catania-Naxos Taormina, Italy. October 2–5, 1997. Abstracts. **Haematologica** 1998 Sep;83(9 Suppl):1–67, i–vii
CD95 (APO-1/Fas) in hematopoietic diseases. Debatin KM. **Results Probl Cell Differ** 1998;24:157–74 (130 ref.)
[The 40th congress of the Japanese Society of Clinical Hematology. Kanazawa City, Japan. November 11–13, 1998. Abstracts] **Rinsho Ketsueki** 1998 Oct;39(10):723–1078 **(Jpn)**
[The 41st congress of the Japanese Society of Clinical Hematology. Akita City, Japan. October 13–15, 1999. Abstracts] **Rinsho Ketsueki** 1999 Sep;40(9):707–1049 **(Jpn)**

BLOOD

Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Harrison P, et al. **Blood Coagul Fibrinolysis** 1999 Jan;10(1):25–31
Importance of basophilia in haematopoietic disorders. Shibata K, et al. **Haematologia (Budap)** 1998;29(3):241–53
Prediction of blood cyclosporine concentrations in non-obese and obese hematologic patients with multidrug resistance using total, lean and different adipose factor dosing body weights [letter] Wu G, et al. **Haematologica** 1999 May; 84(5):476–7
Reactivity of platelets from healthy individuals and from patients with hematologic diseases following incubation with pegylated recombinant human megakaryocyte growth and development factor in vitro. Matzdorff AC, et al. **Haemostasis** 1998 Jan-Feb;28(1):37–44
Characterization of native human thrombopoietin in the blood of normal individuals and of patients with haematologic disorders. Matsumoto A, et al. **Thromb Haemost** 1999 Jul;82(1):24–9

CHEMICALLY INDUCED

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Black AJ, et al. **Ann Intern Med** 1998 Nov 1;129(9):716–8
Haematological monitoring with clozapine therapy in India [letter] [see comments] Tharyan P. **Br J Psychiatry** 1998 Jun;172:540. Comment in: Br J Psychiatry 1996 Oct;169(4):483–8.
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Zalcberg J, et al. **Eur J Cancer** 1998 Nov; 34(12):1871–5
Lack of evidence for systemic toxicity following topical chloramphenicol use. Walker S, et al. **Eye** 1998;12 (Pt 5):875–9 (38 ref.)
Socio-medical intervention in occupational health: benzenism in Brazil. Augusto LG, et al. **Int J Occup Environ Health** 1999 Jan-Mar;5(1):20–5
Evaluation of exposure to ethylene glycol monoethyl ether acetates and their possible haematological effects on shipyard painters. Kim Y, et al. **Occup Environ Med** 1999 Jun;56(6):378–82
Antiepileptics and blood dyscrasias: a cohort study. Blackburn SC, et al. **Pharmacotherapy** 1998 Nov-Dec; 18(6):1277–83
Hematologic side effects of psychotropics. Oyesanmi O, et al. **Psychosomatics** 1999 Sep-Oct;40(5):414–21 (52 ref.)
The use of hematological effects in the development of minimal risk levels. Abadin HG, et al. **Regul Toxicol Pharmacol** 1998 Aug;28(1):61–6 (34 ref.)
Human natural tumor necrosis factor alpha induces multiple endocrine and hematologic disorders in rats. Kakinuma C, et al. **Toxicol Pathol** 1999 Jul-Aug;27(4):402–11

COMPLICATIONS

Haematologic features of the human immunodeficiency virus (HIV) infection in adult Zimbabweans. Adewuyi JO, et al. **Cent Afr J Med** 1999 Feb;45(2):26–30
Rheumatologic features of hematologic disorders. Ehrenfeld M, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):62–7 (42 ref.)
Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Borgna-Pignatti C, et al. **Haematologica** 1998 Sep;83(9):788–90
Immunohistochemical study on transforming growth factor-beta1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis. Arai H, et al. **Hum Pathol** 1999 Apr;30(4):474–6
Can a single antibiotic policy for the empirical treatment of febrile neutropenic patients be used for all categories of haematology/oncology patient in the same institution? [letter] O'Connell B, et al. **J Antimicrob Chemother** 1998 Nov;42(5):677–8
Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. Maertens J, et al. **J Clin Microbiol** 1999 Oct;37(10):3223–8
Intraepithelial haemorrhage of the oesophagus: a terminal event in haematological disorders. Shimizu M, et al. **J Clin Pathol** 1998 Nov;51(11):838–41
Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Mebis J, et al. **Leukemia** 1998 Oct;12(10):1627–9
Low incidence of candidaemia among neutropenic patients treated for haematological diseases. Chryssanthou E, et al. **Scand J Infect Dis** 1998;30(5):489–93
[Clinical effects of combination therapy with cefozopran and tobramycin for severe infections in patients with hematologic diseases] Toyama K, et al. **Jpn J Antibiot** 1999 Feb;52(2):153–61 (Eng. Abstr.) **(Jpn)**
[Mycobacterial infection in patients with hematologic disorders] Morii T, et al. **Nippon Rinsho** 1998 Dec; 56(12):3209–11 (18 ref.) (Eng. Abstr.) **(Jpn)**
[The characteristics of the oral health promotion of patients with hematological diseases] Popov SA, et al. **Stomatologiia (Mosk)** 1999;78(4):14–6 (Eng. Abstr.) **(Rus)**
[Clinical manifestations, diagnosis and course of Pneumocystis carinii pneumonia in patients with hematologic diseases] Galstian GM, et al. **Ter Arkh** 1999; 71(7):33–9 (Eng. Abstr.) **(Rus)**
[Impact of disorders in blood rheology on progress of glaucoma in patients with stable normalized intraocular pressure] Egorov VV, et al. **Vestn Oftalmol** 1999 Jan-Feb; 115(1):5–7 (Eng. Abstr.) **(Rus)**
[outbreak of invasive pulmonary mycosis in neutropenic hematologic patients in relation to remodelling construction work] Gaspar C, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):113–8 (Eng. Abstr.) **(Spa)**

CONGENITAL

Intrauterine fetal diagnosis for hematologic and other congenital disorders. Kramer K, et al. **Clin Lab Med** 1999 Mar;19(1):239–53, vii–viii (98 ref.)

DIAGNOSIS

Endomitotic index of megakaryocytes measured by flow cytometry helps to diagnose hematological disorders with abnormal platelet counts. Baatout S, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3347–53
British Society for Haematology slide session annual scientific meeting of BSH, Glasgow, 1998. **Clin Lab Haematol** 1999 Apr;21(2):149–53
Intrauterine fetal diagnosis for hematologic and other congenital disorders. Kramer K, et al. **Clin Lab Med** 1999

Mar;19(1):239–53, vii–viii (98 ref.)
Is the practice of haematology evidence based? III. Evidence based diagnostic testing [editorial] [see comments] Galloway MJ, et al. **J Clin Pathol** 1998 Jul;51(7):489–91 . Comment in: J Clin Pathol 1998 Dec;51(12):944.
Presenting features and value of diagnostic procedures in leptomeningeal metastases. van Oostenbrugge RJ, et al. **Neurology** 1999 Jul 22;53(2):382–5
[The diagnostic and prognostic stakes in hematologic diseases (editorial)] Reyes F. **Ann Pathol** 1998 Oct;18(4):251–2 **(Fre)**
[Decision tree in hematologic diseases: for a rationalization of histologic, phenotypic and genotypic diagnosis] Xerri L, et al. **Ann Pathol** 1998 Oct;18(4):343–60 (138 ref.) **(Fre)**
[Eye diseases in hematologic illnesses] Lang GE, et al. **Ophthalmologe** 1998 Sep;95(9):658–69 (18 ref.) **(Ger)**
[New clinical tests that physicians should know for diagnosis of hematologic diseases] Maruyama I. **Nippon Naika Gakkai Zasshi** 1998 Oct 10;87(10):2016–22 (7 ref.) **(Jpn)**

DRUG THERAPY

Severe and common side-effects of amphotericin B lipid complex (Abelcet) [letter] Ringdén O, et al. **Bone Marrow Transplant** 1998 Oct;22(7):733–4
Utilization of natural products for treatment of blood diseases. Miles DH, et al. **Curr Med Chem** 1998 Dec; 5(6):421–40 (65 ref.)
Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Schaison G, et al. **Eur J Pediatr** 1998 Dec;157(12):955–66 (76 ref.)
[The role of glycopeptides in hematology] Tourniaire B. **Presse Med** 1999 Apr 10;28(14):764–5 **(Fre)**

ENZYMOLOGY

[Arginase activity in plasma and erythrocytes in children with hematologic diseases] Blaković G, et al. **Srp Arh Celok Lek** 1998 May-Jun;126(5–6):153–6 (Eng. Abstr.) **(Sec)**

EPIDEMIOLOGY

[Aging of the population and incidence of primary acquired hemopathies in the Autonomous Community of Aragón] Giraldo Castellano P, et al. **Rev Esp Salud Publica** 1998 Nov–Dec;72(6):559–70 (71 ref.) (Eng. Abstr.) **(Spa)**
[Which are the true incidence rates of primary hematological disorders acquired in our population?] Franco-García E, et al. **Sangre (Barc)** 1998 Oct;43(5):356–64 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Hematologic abnormalities associated with influenza A infection: a report of 3 cases. Rice J, et al. **Am J Med Sci** 1998 Dec;316(6):401–3
Short report: hematologic changes in acute, imported Plasmodium falciparum malaria. Richards MW, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):859
Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment. Mitsuyasu R. **Clin Infect Dis** 1999 Jul;29(1):35–43 (77 ref.)
Hematologic complications of heparin-induced thrombocytopenia. Raible MD. **Semin Thromb Hemost** 1999;25 Suppl 1:17–21 (60 ref.)
[HIT'91: Precision and acute maximal side effects of radiotherapy of craniospinal axis. Concerning the contribution by R.D. Kortmann et al., Strahlenther Onkol 1999;175:162–9 (No.4) (letter)] Weiss E, et al. **Strahlenther Onkol** 1999 May;175(5):245–6 **(Ger)**
[Hematological manifestations] Kumakura S, et al. **Nippon Rinsho** 1999 Feb;57(2):413–8 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Hematological problems in patients with bronchial cancer] Wołowiec D, et al. **Pol Arch Med Wewn** 1998 Apr; 99(4):331–5 (Eng. Abstr.) **(Pol)**

GENETICS

Exclusion of linkage of Shwachman–Diamond syndrome to chromosome regions 6q and 12q implicated by a de novo translocation. Goobie S, et al. **Am J Med Genet** 1999 Jul 16;85(2):171–4
Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Hinson DD, et al. **Am J Med Genet** 1998 Aug 6;78(5):408–12
Advances in molecular hematopathology: T-cell receptor gamma and bcl-2 genes [see comments] Greiner TC. **Am J Pathol** 1999 Jan;154(1):7–9 (28 ref.). Comment in: Am J Pathol 1999 Jan;154(1):67–75. Comment in: Am J Pathol 1999 Jan;154(1):97–103.
Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Goyal RK, et al. **Ann Med** 1999 Jun;31(3):208–16 (75 ref.)
Dehydrated hereditary stomatocytosis is not linked to the hIK1 locus, a Gardos channel candidate, on chromosome 19q13.2 [letter] Gallagher PG, et al. **Blood** 1999 Mar 15; 93(6):2134–5
Adeno-associated virus vectors and hematology. Russell DW, et al. **Blood** 1999 Aug 1;94(3):864–74 (130 ref.)
Trisomy 6 as a primary karyotypic aberration in hematologic disorders. Mohamed AN, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):152–5 (27 ref.)
Molecular biology of hematological disorders. Niho Y. **Intern Med** 1999 Feb;38(2):77–8
Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. Ginzberg H, et al. **J Pediatr** 1999 Jul;135(1):81–8
[Hereditary abnormalities of phagocytic cells] Seger R. **Arch Pediatr** 1999;6 Suppl 2:420s–422s **(Fre)**
[Molecular biology of hematologic diseases] Niho Y. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1633–46 (56 ref.) **(Jpn)**

IMMUNOLOGY

Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? Raptis A, et al. **Br J Haematol** 1998 Sep; 102(5):1354–8
Legionella sp pneumonia in patients with hematologic diseases. A study of 10 episodes from a series of 67 cases of pneumonia [letter] Fernández-Avilés F, et al. **Haematologica** 1999 May;84(5):474–5
[Hereditary abnormalities of phagocytic cells] Seger R. **Arch Pediatr** 1999;6 Suppl 2:420s–422s **(Fre)**

METABOLISM

Nerve growth factor: a survey of activity on immune and hematopoietic cells. Simone MD, et al. **Hematol Oncol** 1999 Mar;17(1):1–10 (59 ref.)

MICROBIOLOGY

Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. Siegrist HH, et al. **J Antimicrob Chemother** 1999 Jun;43 Suppl C:51–4

PATHOLOGY

Immunohistochemical assessment of human bone marrow macrophages in hematologic disorders. Sadahira Y, et al. **Pathol Int** 1999 Jul;49(7):626–32

PHYSIOPATHOLOGY

Erythropoietin receptor and hematological disease. McMullin MF, et al. **Am J Hematol** 1999 Jan;60(1):55–60 (71 ref.)
Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models [see comments] Haurie C, et al. **Blood** 1998 Oct 15;92(8):2629–40 (206 ref.). Comment in: Blood 1999 Jun 1;93(11):4023–4.
[Cellular adhesion molecules in hematologic disease] Geissmann F, et al. **Ann Pathol** 1998 Oct;18(4):253–60 (45 ref.) **(Fre)**

PREVENTION & CONTROL

Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Fujita A, et al. **Oncology** 1999;56(4):301–7
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. Lauria R, et al. **Oncology** 1999; 56(4):267–73

PSYCHOLOGY

[Examining the quality of life in patients with proliferative diseases of the hemopoietic system] Wichary R, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):513–8 (32 ref.) **(Pol)**

SURGERY

Early postoperative complications of splenectomy for hematologic disease. Arnoletti JP, et al. **Am J Clin Oncol** 1999 Apr;22(2):114–8
Laparoscopic splenectomy: outcome and efficacy in 103 consecutive patients. Katkhouda N, et al. **Ann Surg** 1998 Oct;228(4):568–78 (49 ref.)
Splenectomy in hematology. Current practice and new perspectives. Baccarani U, et al. **Haematologica** 1999 May; 84(5):431–6 (43 ref.)
Laparoscopic splenectomy for hematological disorders. Our experience in adult and pediatric patients. Caprotti R, et al. **Int Surg** 1998 Oct–Dec;83(4):303–7
Splenectomy complications in hematological diseases. Ruiz-Argüelles GJ, et al. **Rev Invest Clin** 1998 Jul–Aug; 50(4):347–50
Present status of laparoscopic splenectomy for hematologic diseases: certitudes and unresolved issues. Gigot JF, et al. **Semin Laparosc Surg** 1998 Sep;5(3):147–67 (184 ref.)
Laparoscopic splenectomy. Rescorla FJ. **Semin Pediatr Surg** 1998 Nov;7(4):207–12 (28 ref.)
Laparoscopic splenectomy. Glasgow RE, et al. **World J Surg** 1999 Apr;23(4):384–8 (25 ref.)
[Laparoscopic splenectomy for hematological diseases; results in 28 patients] den Hoed PT, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1222–5 (Eng. Abstr.) **(Dut)**
[Laparoscopic splenectomy--surgical and hematological results in the first 35 consecutive patients] Meyer G, et al. **Zentralbl Chir** 1998;123(11):1297–302 (Eng. Abstr.) **(Ger)**

THERAPY

Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Cohen A, et al. **Blood** 1999 Jun 15; 93(12):4109–15
Adeno-associated virus vectors and hematology. Russell DW, et al. **Blood** 1999 Aug 1;94(3):864–74 (130 ref.)
Indications for therapeutic platelet transfusions. Hunt BJ. **Blood Rev** 1998 Dec;12(4):227–33 (65 ref.)
European results of unrelated cord blood transplants. Eurocord group. Gluckman E, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S87–91
Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Kanda Y, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):751–4
Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Mahmoud H, et al. **Bone Marrow Transplant** 1999 Aug;24(4):355–8
Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants. Ortega M, et al. **Bone Marrow Transplant** 1999 Jul;24(1):81–7
Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant group. Rocha V, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S59–62
Neuropsychological outcome of children undergoing bone marrow transplantation. Simms S, et al. **Bone Marrow Transplant** 1998 Jul;22(2):181–4
Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT. Urbano-Ispizua A, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S71–4
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Zander AR, et al. **Bone Marrow Transplant** 1999 May;23(9):889–93
Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Stasi R, et al. **Br J Haematol** 1999 Apr; 105(1):141–8
HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. McGuirk JP, et al. **Cancer J Sci Am** 1998 Sep–Oct; 4(5):278–86 (134 ref.)
Complications of sickle cell anemia in adults: guidelines for effective management. Ballas SK. **Cleve Clin J Med** 1999 Jan;66(1):48–58 (37 ref.)
Recent developments in gene therapy for oncology and hematology. Roskrow MA, et al. **Crit Rev Oncol Hematol** 1998 Sep;28(3):139–51 (89 ref.)
Hematology and oncology [editorial; comment] Newburger PE. **Curr Opin Pediatr** 1999 Feb;11(1):31–2. Comment on: Curr Opin Pediatr 1999 Feb;11(1):33–8. Comment on: Curr Opin Pediatr 1999 Feb;11(1):39–46. Comment on: Curr Opin Pediatr 1999 Feb;11(1):47–55. Comment on: Curr Opin Pediatr 1999 Feb;11(1):56–64.
Mucormycosis and hemopoietic transplants [letter] Peñalver FJ, et al. **Haematologica** 1998 Oct;83(10):950–1
The potential application of ribozymes for the treatment of hematological disorders. James HA. **J Leukoc Biol** 1999 Sep;66(3):361–8 (125 ref.)
The future of placental-blood transplantation [editorial; comment] Parkman R. **N Engl J Med** 1998 Nov 26; 339(22):1628–9. Comment on: N Engl J Med 1998 Nov 26;339(22):1565–77.
Pediatric oncology and hematology in Birmingham, England. Mann JR, et al. **Pediatr Hematol Oncol** 1999 Jan–Feb; 16(1):3–7
Pediatric hematology and oncology in Children's Hospital of Nancy, France. Contribution to the organization of clinical oncology. Sommelet D. **Pediatr Hematol Oncol** 1998 Sep–Oct;15(5):385–92
Nurse practitioner support for transfusion in patients with haematological disorders in hospital and at home. Craig JI, et al. **Transfus Med** 1999 Mar;9(1):31–6
[Comparison of infectious complications of long-term and short-term central venous catheterization] Guiguet M, et al. **Presse Med** 1999 Sep 4;28(25):1347–51 (Eng. Abstr.) **(Fre)**
[Hematology: large steps followed by a time of small steps] Fehr J. **Schweiz Med Wochenschr** 1998 Dec 26; 128(51–52):2034–7 (6 ref.) **(Ger)**
[25 years allogenic bone marrow transplantation in Basel: 1973–1998] Passweg JR, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1568–74 (Eng. Abstr.) **(Ger)**
[The fetus as patient: intrauterine fetal stem cell transplantation] Pschera H. **Zentralbl Gynakol** 1998; 120(10):481–7 (50 ref.) (Eng. Abstr.) **(Ger)**
[Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings] Morimoto T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):631–9 (Eng. Abstr.) **(Jpn)**
[Allogeneic peripheral blood stem cell transplantation in 30 patients with hematologic disorders] Sawada H, et al. **Rinsho Ketsueki** 1998 Nov;39(11):1085–91 (Eng. Abstr.) **(Jpn)**
[Dental care for patients with hematological diseases] Agadzhanian AA, et al. **Stomatologiia (Mosk)** 1998; 77(4):42–8 (Eng. Abstr.) **(Rus)**

[Use of apheresis procedures in the treatment of patients with hemobiologic disorders] Balint B, et al. **Vojnosanit Pregl** 1999 Jan-Feb;56(1):45-55 (66 ref.) **(Sec)**

VETERINARY

Administration of diminazene aceturate or imidocarb dipropionate for treatment of cytauxzoonosis in cats. Greene CE, et al. **J Am Vet Med Assoc** 1999 Aug 15; 215(4):497-500, 482

VIROLOGY

Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study. Cummins D, et al. **Clin Lab Haematol** 1998 Oct;20(5):285-7

Human herpesvirus 8 in hematologic diseases. Mikala G, et al. **Pathol Oncol Res** 1999;5(1):73-9 (42 ref.)

Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Lundqvist A, et al. **Scand J Infect Dis** 1999;31(2):119-22

HEMATOLOGIC MALIGNANCIES see **HEMATOLOGIC NEOPLASMS**

HEMATOLOGIC NEOPLASMS

see related
LEUKEMIA
LYMPHOMA

40th annual meeting of the American Society of Hematology. Taylor N. **Bull Cancer** 1999 Feb;86(2):228-30

Current world literature. Hematologic malignancies. **Curr Opin Hematol** 1998 Jul;5(4):B89-158

Recent publications in hematologic oncology. **Hematol Oncol** 1999 Mar;17(1):39-44

Recent publications in hematological oncology. **Hematol Oncol** 1998 Dec;16(4):169-74

Recent publications in hematological oncology. **Hematol Oncol** 1998 Sep;16(3):125-30

Recent publications in hematological oncology. **Hematol Oncol** 1998 Jun;16(2):79-84

Cryopreservation of gametes in young patients with cancer. Schover LR, et al. **J Pediatr Hematol Oncol** 1998 Sep-Oct; 20(5):426-8 (19 ref.)

Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Meirow D. **Leuk Lymphoma** 1999 Mar; 33(1-2):65-76 (69 ref.)

Guidelines for the characterization and publication of human malignant hematopoietic cell lines. Drexler HG, et al. **Leukemia** 1999 Jun;13(6):835-42

International Society of Paediatric Oncology, American Society of Pediatric Hematology/Oncology joint meeting and International Society of Paediatric Surgical Oncology 31st meeting. Montreal, Canada, September 13-18, 1999. Abstracts. **Med Pediatr Oncol** 1999 Sep;33(3):141-353

BLOOD

Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Huet S, et al. **Cytometry** 1998 Dec 15; 34(6):248-56

The "G-CSF test": the response to a single dose of granulocyte colony-stimulating factor predicts mobilization of hemopoietic progenitors in patients with hematologic malignancies. Mijovic A, et al. **Exp Hematol** 1999 Jul;27(7):1204-9

The value of serum soluble transferrin receptor (sTfR) determination in hematological malignancies. Takubo T, et al. **Haematologia (Budap)** 1998;29(3):259-60

Electrolyte monitoring in patients undergoing peripheral blood stem cell collection. Perseghin P, et al. **J Clin Apheresis** 1999;14(1):14-7

Differential effects of IL-2 incubation on hematopoietic potential of autologous bone marrow and mobilized PBSC from patients with hematologic malignancies. Areman EM, et al. **J Hematother** 1999 Feb;8(1):39-44

[Coagulation system in patients with blood malignancies treated with estrogens in the course of cytostatic therapy] Ignashina EV, et al. **Ter Arkh** 1998;70(10):46-8 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Lymphopoietic cancer and other major causes of death among petrochemical researchers: an update. Lewis RJ, et al. **Occup Med (Lond)** 1999 Feb;49(2):71-7

CHEMISTRY

Flow cytometric quantification of cyclin E in human cell lines and hematopoietic malignancies. Erlanson M, et al. **Cytometry** 1998 Jul 1;32(3):214-22

CLASSIFICATION

The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13-39 (490 ref.)

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Jaffe ES, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S8-12

COMPLICATIONS

Possible relationship between neurocysticercosis and hematological malignancies. Herrera LA, et al. **Arch Med Res** 1999 Mar-Apr;30(2):154-8

Diagnosis and prevention of fungal infection in the immunocompromized patient. Richardson MD, et al. **Blood Rev** 1998 Dec;12(4):241-54 (114 ref.)

A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology [published erratum appears in Br J Haematol 1998 Dec;103(4):1215] Clark AD, et al. **Br J Haematol** 1998 Oct; 103(1):198-204

Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit? Böhme A, et al. **Chemotherapy** 1999 May-Jun;45(3):224-32 (58 ref.)

Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Böhme A, et al. **Chemotherapy** 1999 Sep-Oct;45(5):315-24 (62 ref.)

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov-Dec;44(6):427-35 (23 ref.)

Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia. Martino R, et al. **Chemotherapy** 1999 May-Jun;45(3):205-12

Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Menichetti F, et al. **Clin Infect Dis** 1999 Feb;28(2):250-5

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Viscoli C, et al. **Clin Infect Dis** 1999 May;28(5):1071-9

Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. Takatsuka H, et al. **Drugs Exp Clin Res** 1999; 25(4):193-200

Emergence and infectious complications of ciprofloxacin-resistant Escherichia coli in haematological cancer patients. van Kraaij MG, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):591-2

Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Pagano L, et al. **Eur J Haematol** 1999 Aug;63(2):77-85

Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Ewig S, et al. **Eur Respir J** 1998 Jul;12(1):116-22

A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours. Davies JM. **Infection** 1998 Nov-Dec;26(6):389-95 (54 ref.)

Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. Yoshida M, et al. **Int J Hematol** 1999 Feb; 69(2):81-8

Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Todeschini G, et al. **Int J Infect Dis** 1998-99 Winter;3(2):99-104

Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial. Engervall P, et al. **J Chemother** 1999 Aug;11(4):278-86

PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. Morace G, et al. **J Clin Microbiol** 1999 Jun; 37(6):1871-5

Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. Wisplinghoff H, et al. **J Clin Microbiol** 1999 Jun;37(6):1876-80

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. Denning DW, et al. **J Infect** 1998 Sep; 37(2):173-80

Which type of underlying disease facilitates cytomegalovirus infection? Comparison of benign disease, hematopoietic malignancy, and post-bone-marrow or renal transplantation status by using the first standardized objective PCR test for cytomegalovirus detection. Hiyoshi M, et al. **Kansenshogaku Zasshi** 1999 Feb;73(2):144-8

Fungal infection due to Fusarium (spp) in children with refractory hematologic malignancies. Mangini C, et al. **Med Pediatr Oncol** 1999 Feb;32(2):149-50

Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. Helweg-Larsen J, et al. **QJM** 1998 Dec;91(12):813-20

Lactate dehydrogenase isoenzyme analysis for the diagnosis of pleural effusion in haemato-oncological patients. Lossos IS, et al. **Respir Med** 1999 May;93(5):338-41

Intensive care for patients with medical complications of haematological malignancy: is it worth it? Hinds CJ, et al. **Schweiz Med Wochenschr** 1998 Sep 26;128(39):1467-73 (20 ref.)

[Rare pulmonary mycoses in patients with hematologic diseases] Breton P, et al. **Rev Pneumol Clin** 1998 Oct; 54(5):253-7 (Eng. Abstr.) **(Fre)**

[Mycoses and their treatment in malignant hemopathies] Martino P, et al. **Recenti Prog Med** 1999 Mar;90(3):160-8 (59 ref.) (Eng. Abstr.) **(Ita)**

[Clinical study of itraconazole for systemic fungal infections complicated with hematological malignancies--multicenter cooperative study. West-Japan Systemic Fungal Infection Study Group] Shiku H, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1208-18 (Eng. Abstr.) **(Jpn)**

[Complicated gastrointestinal bleeding of neoplastic diseases of the hematopoietic system] Yoshida T. **Nippon Rinsho** 1998 Sep;56(9):2405-10 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Malignancy-associated hemophagocytic syndrome] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):355-7 (17 ref.) **(Jpn)**

[Heptral potentialities in the treatment of hepatic damage in children with malignant blood disease] Reizis AR, et al. **Ter Arkh** 1998;70(10):48-51 (Eng. Abstr.) **(Rus)**

[Pneumonias in patients with malignant hemopathies. Their etiology, response to treatment and prognostic factors in 69 patients (88 episodes)] Fernández Avilés F, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):321-5 (Eng. Abstr.) **(Spa)**

[incidence of intestinal parasites in pediatric patients with hematologic neoplasms from 1 to 15 years of age] Martínez Pérez A, et al. **Rev Alerg Mex** 1999 Jan-Feb;46(1):26-9 (Eng. Abstr.) **(Spa)**

[Infectious and non-infectious complications of tunneled central catheters in hematologic patients] Albo López C, et al. **Sangre (Barc)** 1999 Jun;44(3):176-81 (Eng. Abstr.) **(Spa)**

[Complications associated with central venous catheters in patient with hematologic neoplasms or hematopoietic transplants] Gutiérrez AM, et al. **Sangre (Barc)** 1999 Jun; 44(3):171-5 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Belgian consensus recommendations for flow cytometric immunophenotyping. The Belgian Association for Cytometry/Belgische Vereniging voor Cytometrie/Association Belge de Cytométrie. Van Bockstaele DR, et al. **Acta Clin Belg** 1999 Apr;54(2):88-98

Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Orfao A, et al. **Clin Chem** 1999 Oct;45(10):1708-17 (150 ref.)

Multicentric quality control trial for CD34+ cells evaluation in peripheral blood and leukapheresis collections from patients with hematological malignancies. Regione Piemonte Study Group. Omedè P, et al. **Eur J Histochem** 1997;41 Suppl 2:35-6

Magnetic resonance imaging of the bone marrow in hematological malignancies. Vande Berg BC, et al. **Eur Radiol** 1998;8(8):1335-44 (94 ref.)

Antibody panel in diagnosis of lymphoid neoplasms [letter; comment] [see comments] Vassallo J, et al. **J Clin Pathol** 1998 Aug;51(8):638-9. Comment on: J Clin Pathol 1997 Jun;50(6):521-4. Comment in: J Clin Pathol 1999 Jan;52(1):79.

The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Kornblau SM. **Leukemia** 1998 Sep;12 Suppl 1:S41-6 (61 ref.)

[Eye diseases in hematologic illnesses] Lang GE, et al. **Ophthalmologe** 1998 Sep;95(9):658-69 (18 ref.) **(Ger)**

[Immunocytochemistry techniques for the diagnosis of hematologic neoplasms] Diaz de Domingo NB, et al. **Medicina (B Aires)** 1999;59(1):11-6 (Eng. Abstr.) **(Spa)**

[Recommendations for performing cytogenetic studies in hematological malignancies] Solé F, et al. **Sangre (Barc)** 1999 Feb;44(1):73-5 **(Spa)**

DRUG THERAPY

Serum leptin levels during cancer chemotherapy [letter] Usuki K, et al. **Ann Hematol** 1998 Oct;77(4):191-2

Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Chklovskaia E, et al. **Blood** 1999 Apr 15; 93(8):2595-604

TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Tomasson MH, et al. **Blood** 1999 Mar 1;93(5):1707-14

Persistence and clinical outcome of hepatitis G virus infection in pediatric bone marrow transplant recipients and children treated for hematological malignancy. Yamada-Osaki M, et al. **Blood** 1999 Jan 15;93(2):721-7

A comparative study of administration methods of granisetron injection used to treat nausea/vomiting induced by cancer chemotherapy without cisplatin in tumors of hematopoietic organs. Keihanshin Study Group of Hematological Malignancies. Tatsumi N, et al. **Cancer Chemother Pharmacol** 1999;43(5):379-84

Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells.

Erben U, et al. **Cancer Res** 1999 Jun 15;59(12):2924–30
Prognostic factors in clinical cancer trials. Estey E. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2591–3 (15 ref.)
Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Karthaus M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):501–4
Viral findings during febrile episodes after cytotoxic chemotherapy in patients with hematological malignancies. Rintala EM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):593–4
Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Kanda Y, et al. **Hematol Oncol** 1998 Mar;16(1):33–7
Modelling and simulation of chemotherapy of haematological and gynaecological cancers. Nani FK, et al. **IMA J Math Appl Med Biol** 1999 Mar;16(1):39–91
The role of apoptosis in hematologic malignancies and modulation of apoptosis as a new therapeutic approach. Kliche KO, et al. **J Cancer Res Clin Oncol** 1999; 125(3–4):226–31 (28 ref.)
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. Gandhi V, et al. **J Clin Oncol** 1998 Nov;16(11):3607–15
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction. Kantarjian H. **Semin Hematol** 1998 Jul;35(3 Suppl 4):1–2
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. List AF. **Semin Oncol** 1999 Apr;26(2 Suppl 7):61–5 (30 ref.)
[Chinese herbal drugs: sheng-bai-kuai in the treatment of leukopenia caused by chemotherapy] Tan D, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):547–9 **(Chi)**
[Warning signs preceding the development of septic shock in patients with neutropenia treated for hematologic malignancies] Kubešová H, et al. **Cas Lek Cesk** 1999 Mar 1;138(5):147–51 (Eng. Abstr.) **(Cze)**
[Pseudomonas aeruginosa septicemia in onco-hematology. Report of 22 cases] Laatiri MA, et al. **Tunis Med** 1998 Aug–Sep;76(8–9):229–33 **(Fre)**
[Antibiotic therapy in leukopenia] Böhme A, et al. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1120–5 (43 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration] Karthaus M, et al. **Wien Med Wochenschr** 1998;148(21):481–7 (Eng. Abstr.) **(Ger)**
[Oral antitumor drugs for hematological malignancies] Ohnishi K. **Gan To Kagaku Ryoho** 1999 Feb;26(3):295–300 (14 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Time trends in incidence of haematological malignancies and related conditions. Cartwright RA, et al. **Br J Haematol** 1999 Aug;106(2):281–95 (56 ref.)
Incidence of haematological malignancies in French Polynesia between 1990 and 1995. Roda L, et al. **Leuk Res** 1999 Apr;23(4):349–55

ETIOLOGY

Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. Miligi L, et al. **Am J Ind Med** 1999 Jul;36(1):60–9
Possible carcinogenic effects of X-rays in a transgenerational study with CBA mice. Mohr U, et al. **Carcinogenesis** 1999 Feb;20(2):325–32

GENETICS

Familial aggregation of nonhematological malignancies in relatives of patients with hematological neoplasms. Shpilberg O, et al. **Acta Haematol** 1999 Mar;101(1):21–4
Analysis of the Smad5 gene in hematological malignancies [letter] Ikezoe T, et al. **Am J Hematol** 1999 Mar;60(3):249
Genetic alterations in the retinoblastoma protein-related p107 gene in human hematologic malignancies. Takimoto H, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):264–8
Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Fioretos T, et al. **Blood** 1999 Jul 1;94(1):225–32
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Tomasson MH, et al. **Blood** 1999 Mar 1;93(5):1707–14
Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Tsujimura T, et al. **Blood** 1999 Feb 15;93(4):1319–29
Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Wickremasinghe RG, et al. **Blood** 1999 Jun 1; 93(11):3587–600 (189 ref.)
The impact of the new fish technologies on the cytogenetics of haematological malignancies. Kearney L. **Br J Haematol** 1999 Mar;104(4):648–58 (72 ref.)
Clonality determined by fluorescence in situ hybridization of single-cell aberrations in hematopoietic neoplasias [letter] Gebhart T, et al. **Cancer Genet Cytogenet** 1999 Sep; 113(2):193–4
11q13 is a cytogenetically promiscuous site in hematologic malignancies. Wong KF. **Cancer Genet Cytogenet** 1999 Aug;113(1):93–5
Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Ricciardone MD, et al. **Cancer Res** 1999 Jan 15;59(2):290–3
Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Lemos MC, et al. **Carcinogenesis** 1999 Jul;20(7):1225–9
Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia. Ohyashiki JH, et al. **Clin Cancer Res** 1996 Sep;2(9):1583–9
A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. Mauritzson N, et al. **Eur J Haematol** 1999 Feb;62(2):95–102
Cytogenetic polyclonality in hematologic malignancies. Johansson B, et al. **Genes Chromosomes Cancer** 1999 Mar; 24(3):222–9
Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Miyagawa K, et al. **Genes Chromosomes Cancer** 1999 Jun;25(2):176–83
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Dahia PL, et al. **Hum Mol Genet** 1999 Feb;8(2):185–93
Analysis of the Smad3 gene in hematological malignancies [letter] Ikezoe T, et al. **Int J Hematol** 1998 Dec;68(4):457–8
Centric and pericentric chromosome rearrangements in hematopoietic malignancies. Berger R, et al. **Leukemia** 1999 May;13(5):671–8 (84 ref.)
Selective usage of D-type cyclins in lymphoid malignancies. Suzuki R, et al. **Leukemia** 1999 Sep;13(9):1335–42
Reversible tumorigenesis by MYC in hematopoietic lineages. Felsher DW, et al. **Mol Cell** 1999 Aug;4(2):199–207
[Promiscuous genes and chromosomal rearrangements of hematopoietic malignancies] Berger R. **Ann Genet** 1999; 42(1):21–32 (105 ref.) (Eng. Abstr.) **(Fre)**
[Cytogenetics of malignant hemopathies: update] Lai JL, et al. **Bull Cancer** 1999 Jan;86(1):23–8 (31 ref.) **(Fre)**
[Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies] Quesnel B. **Bull Cancer** 1998 Sep;85(9):747–54 (43 ref.) (Eng. Abstr.) **(Fre)**
[p53 and hematologic malignancies] Preudhomme C, et al. **Pathol Biol (Paris)** 1997 Dec;45(10):898–908 (128 ref.) (Eng. Abstr.) **(Fre)**
[Changes in the long arm of chromosome 3 (3q) in malignant myeloid hemopathies. A study of 10 cases] Sancho JM, et al. **Med Clin (Barc)** 1999 Apr 17;112(13):499–502 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Krammer PH, et al. **Adv Cancer Res** 1998;75:251–73 (114 ref.)
Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Kaufmann O, et al. **Am J Clin Pathol** 1999 Jan;111(1):117–22
Peripheral blood T cells generated after allogeneic bone marrow transplantation: lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro. Abrogation of the apoptotic phenotype coincides with the recovery of normal naive/primed T-cell profiles. Hebib NC, et al. **Blood** 1999 Sep 1;94(5):1803–13
Immune reconstitution following allogeneic peripheral blood stem cell transplants. Shenoy S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):335–46
Platelet-bound immunoglobulins before and after platelet transfusion: measurement of in vivo binding. Levin MD, et al. **Br J Haematol** 1999 Feb;104(2):397–402
Cytokine deregulation in hematological malignancies: clinical and biological implications. Kurzrock R. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2581–4 (31 ref.)
Quality control of flow cytometric immunophenotyping of haematological malignancies. Gratama JW, et al. **Clin Lab Haematol** 1999 Jun;21(3):155–60 (23 ref.)
Advances in immunotherapy of hematologic malignancies. Maloney DG. **Curr Opin Hematol** 1998 Jul;5(4):237–43 (39 ref.)
Serum IL-10 and IL-13 concentrations in patients with haematological malignancies. Denizot Y, et al. **Cytokine** 1999 Aug;11(8):634–5
Flow cytometric identification of myeloid disorders by asynchronous expression of the CD14 and CD66 antigens. Hansen I, et al. **Eur J Haematol** 1998 Nov;61(5):339–46
Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z, et al. **J Exp Clin Cancer Res** 1998 Sep;17(3):251–8
Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Brydak LB, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):369–74
CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytoiytic activity and enhanced tendency to apoptosis. Van den Hove LE, et al. **Leukemia** 1998 Oct;12(10):1573–82
Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Osman Y, et al. **Oncol Rep** 1999 Sep-Oct;6(5):1057–63
A cluster of suspected Pneumocystis carinii Pneumonia following intensive chemotherapy in a Belfast haematology unit. Ong YL, et al. **Ulster Med J** 1998 Nov;67(2):104–9
[The criteria of disorders in body antitumor resistance in subjects with dyshemopoiesis] Komissarenko VG, et al. **Lik Sprava** 1998 Oct-Nov;(7):74–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation. Gruber A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):169–72
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Bellamy WT, et al. **Cancer Res** 1999 Feb 1;59(3):728–33
The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Børset M, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):249–56 (60 ref.)
Expression of membrane-associated macrophage colony-stimulating factor (M-CSF) in Hodgkin's disease and other hematologic malignancies. Zheng GG, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):339–44
hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Dominguez A, et al. **Oncogene** 1998 Oct 29;17(17):2187–93

MICROBIOLOGY

Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. Kerr KG, et al. **Support Care Cancer** 1999 Jan;7(1):28–30

MORTALITY

Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group. Carli PM, et al. **Eur J Cancer** 1998 Dec;34(14 Spec No):2253–63
Lymphatic and haematopoietic cancer mortality in a population attending school adjacent to styrene-butadiene facilities, 1963–1993. Loughlin JE, et al. **J Epidemiol Community Health** 1999 May;53(5):283–7

PATHOLOGY

Proceedings of the 4th Slide Workshop of the Society of Hematopathology. Extranodal hematopoietic/lymphoid disorders. Pittsburgh, Pennsylvania, USA. September 1997. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S7–150
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Aboul-Nasr R, et al. **Am J Clin Pathol** 1999 Jun;111(6):753–8
Extranodal hematopoietic/lymphoid disorders. An introduction. Burke JS. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S40–5
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. Frizzera G, et al. **Am J Clin Pathol** 1999 Jan;111(1 Suppl 1):S13–39 (490 ref.)
Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Wickremasinghe RG, et al. **Blood** 1999 Jun 1; 93(11):3587–600 (189 ref.)
The role of apoptosis in hematologic malignancies and modulation of apoptosis as a new therapeutic approach. Kliche KO, et al. **J Cancer Res Clin Oncol** 1999; 125(3–4):226–31 (28 ref.)
Cell cycle dependency of 67gallium uptake and cytotoxicity in human cell lines of hematological malignancies. Van Leeuwen-Stok EA, et al. **Leuk Lymphoma** 1998 Nov; 31(5–6):533–44
Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Blalock WL, et al. **Leukemia** 1999 Aug;13(8):1109–66 (871 ref.)
Reversible tumorigenesis by MYC in hematopoietic lineages. Felsher DW, et al. **Mol Cell** 1999 Aug;4(2):199–207
Mediastinal mature teratoma with coexistence of angiosarcoma, granulocytic sarcoma and a hematopoietic region in the tumor: a rare case of association between hematological malignancy and mediastinal germ cell tumor. Saito A, et al. **Pathol Int** 1998 Sep;48(9):749–53
[Angiogenesis in malignant blood diseases] Ellegaard J, et al. **Ugeskr Laeger** 1999 Jun 28;161(26):4012 **(Dan)**
[Importance of tumor banks in hemo-lymphatic pathology] Delsol G, et al. **Ann Pathol** 1998;18(5 Suppl):27–32 (25 ref.) **(Fre)**

PHYSIOPATHOLOGY

Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Chklovskaia E, et al. **Blood** 1999 Apr 15; 93(8):2595–604
Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation. Gruber A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):169–72
A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological

malignancies: karyotypic features in relation to morphology, age and gender. Mauritzson N, et al. **Eur J Haematol** 1999 Feb;62(2):95–102

The hypothalamus–pituitary–gonad axis and testicular function in male patients after treatment for haematological malignancies [letter; comment] Fernández-Fernández FJ, et al. **J Intern Med** 1999 Jul;246(1):122–3. Comment on: J Intern Med 1998 Nov;244(5):411–6.

The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Kornblau SM. **Leukemia** 1998 Sep;12 Suppl 1:S41–6 (61 ref.)

RADIONUCLIDE IMAGING

The present role of bone marrow scintigraphy [editorial] Cremerius U, et al. **Eur J Nucl Med** 1999 Mar;26(3):191–3 (34 ref.)

SURGERY

Laparoscopic splenectomy for hematologic malignancies. Schlachta CM, et al. **Surg Endosc** 1999 Sep;13(9):865–8

[An approach to operative treatment for acute abdomen complicated by malignant hemopathy] Min B, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):97–101 (Eng. Abstr.) **(Chi)**

THERAPY

Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Lichtman SM, et al. **Am J Hematol** 1999 Aug;61(4):262–4

The quality of medical evidence in hematology–oncology [see comments] Djulbegovic B, et al. **Am J Med** 1999 Feb; 106(2):198–205. Comment in: Am J Med 1999 Feb;106(2):263–4.

Immunotherapy with recombinant human interleukin 2 in patients with hematological malignancies after bone marrow or peripheral blood stem cell transplantation. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):223–7 (40 ref.)

Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft–versus–host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Beelen DW, et al. **Blood** 1999 May 15;93(10):3267–75

Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Dumont-Girard F, et al. **Blood** 1998 Dec 1; 92(11):4464–71

Peripheral blood T cells generated after allogeneic bone marrow transplantation: lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro. Abrogation of the apoptotic phenotype coincides with the recovery of normal naive/primed T-cell profiles. Hebib NC, et al. **Blood** 1999 Sep 1;94(5):1803–13

A randomized trial of granulocyte colony–stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bence-Bruckler I, et al. **Bone Marrow Transplant** 1998 Nov;22(10):965–9

Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Blaise D, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1153–8

Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells. Burt RK, et al. **Bone Marrow Transplant** 1999 Feb;23(4):381–6

High incidence of adeno- and polyomavirus-induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Childs R, et al. **Bone Marrow Transplant** 1998 Nov;22(9):889–93

Delaying treatment with granulocyte colony–stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Ciernik IF, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):147–51

A retrospective Dutch study comparing T cell–depleted allogeneic blood stem cell transplantation vs T cell–depleted allogeneic bone marrow transplantation. Cornelissen JJ, et al. **Bone Marrow Transplant** 1998 Jun; 21 Suppl 3:S66–70

Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases. Dazzi C, et al. **Bone Marrow Transplant** 1999 Mar;23(6):529–32

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Gandhi MK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):9–13

Pulmonary enterovirus infections in stem cell transplant recipients. González Y, et al. **Bone Marrow Transplant** 1999 Mar;23(5):511–3

Veno–occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Hasegawa S, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1191–7

Prevention of graft–versus–host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, et al. **Bone Marrow Transplant** 1999 Mar;23(5):443–50

Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies. Iestra JA, et al. **Bone Marrow Transplant** 1999 May;23(9):933–9

Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Lowenthal RM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):763–70

Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Mahmoud H, et al. **Bone Marrow Transplant** 1999 Aug;24(4):355–8

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. Martínez E, et al. **Bone Marrow Transplant** 1999 Jan;23(1):41–4

The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Millar BC, et al. **Bone Marrow Transplant** 1998 Sep;22(5):469–75

Allogeneic BMT for haematological disorders: single centre experience of University Hospital Bratislava. Mistrík M, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S67–70

CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft–versus–host disease prophylaxis in high-risk hematologic malignancies. O'Donnell PV, et al. **Bone Marrow Transplant** 1998 Nov;22(10):947–55

Hepatic veno–occlusive disease after stem cell transplantation in Japan [letter] Oh H, et al. **Bone Marrow Transplant** 1999 Jul;24(2):223–4

Follow–up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants. Ortega M, et al. **Bone Marrow Transplant** 1999 Jul;24(1):81–7

Spleen sizing by ultrasound scan and risk of pneumococcal infection in patients with chronic GVHD: preliminary observations. Picardi M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):173–7

Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies. Rabitsch W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S49–52

Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse. Serrano J, et al. **Bone Marrow Transplant** 1999 Mar; 23(5):475–82

Introduction: current issues in high-dose chemotherapy and stem cell support. Shea TC. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S1–5 (62 ref.)

Immune reconstitution following allogeneic peripheral blood stem cell transplants. Shenoy S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):335–46

Chronic graft–versus–host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Spanish Group of Allo-PBT. Solano C, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1129–35

Iron overload in bone marrow transplant recipients. Strasser SI, et al. **Bone Marrow Transplant** 1998 Jul;22(2):167–73

HLA-identical sibling peripheral blood cell transplants. The Australian experience and preliminary results of a randomised study. Szer J, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S57–8

A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Välimäki MJ, et al. **Bone Marrow Transplant** 1999 Feb;23(4):355–61

A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Vigorito AC, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1145–51

Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco–hematological malignancies with a high risk of relapse. Vivancos P, et al. **Bone Marrow Transplant** 1999 Jan;23(2):169–72

Red cell fragmentation (schistocytosis) after bone marrow transplantation. Zomas A, et al. **Bone Marrow Transplant** 1998 Oct;22(8):777–80

A prospective molecular study of chimaerism in patients with haematological malignancies receiving unrelated cord blood or bone marrow transplants: detection of mixed chimaerism predicts graft failure with or without early autologous reconstitution in cord blood recipients. Cimino G, et al. **Br J Haematol** 1999 Mar;104(4):770–7

Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation [see comments] Hénon P, et al. **Br J Haematol** 1998 Nov;103(2):568–81. Comment in: Br J Haematol 1999 Mar;104(3):643–4.

Cellular immunotherapy in haematological malignancies. Reid CD. **Br J Haematol** 1999 Apr;105 Suppl 1:7–10 (31 ref.)

Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Voso MT, et al. **Br J Haematol** 1999 Feb; 104(2):382–91

Bibliography. Current world literature. Hematologic malignancies. **Curr Opin Hematol** 1999 Jul;6(4):B51–106

Hematologic malignancies [editorial] Bernstein I. **Curr Opin Hematol** 1999 Jul;6(4):199–200

Supportive care in hematological malignancies: hematopoietic growth factors, infections, transfusion therapy. Fetscher S, et al. **Curr Opin Hematol** 1999 Jul; 6(4):262–73 (80 ref.)

Supportive care in hematologic malignancies [published erratum appears in Curr Opin Hematol 1999 Jan;6(1):59] Fetscher S, et al. **Curr Opin Hematol** 1998 Jul;5(4):271–86 (91 ref.)

Advances in immunotherapy of hematologic malignancies. Maloney DG. **Curr Opin Hematol** 1998 Jul;5(4):237–43 (39 ref.)

Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. Maloney DG. **Curr Opin Hematol** 1999 Jul;6(4):222–8 (46 ref.)

Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions. Sandler SG. **Haematologia (Budap)** 1998;29(1):1–11 (46 ref.)

Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Carella AM, et al. **Haematologica** 1998 Oct;83(10):904–9

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor. Dresse MF, et al. **Haematologica** 1999 Jul;84(7):637–42

Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies. AIEOP–BMT Group (Italian Association for Pediatric Hematology and Oncology–Bone Marrow Transplant Group) [letter] Miniero R, et al. **Haematologica** 1999 Jul;84(7):657–60

Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B, et al. **Haematologica** 1999 Apr;84(4):342–9

Monoclonal antibody–based therapies for hematologic malignancies. Multani PS, et al. **J Clin Oncol** 1998 Nov; 16(11):3691–710 (217 ref.)

Changing approaches to transplant conditioning for hematologic malignancy editorial Kelemen E. **J Hematother** 1999 Jun;8(3):231–2

Use of collagen for standardization of PBSC graft quality evaluation: a multicenter comparative analysis of commercial collagen–based and methylcellulose–based colony–forming unit (CFU) assay kits. Mossuz P, et al. **J Hematother** 1998 Aug;7(4):351–9

A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. Stainer CJ, et al. **J Hematother** 1998 Aug;7(4):375–83

The hypothalamus–pituitary–gonad axis and testicular function in male patients after treatment for haematological malignancies [letter; comment] Fernández-Fernández FJ, et al. **J Intern Med** 1999 Jul;246(1):122–3. Comment on: J Intern Med 1998 Nov;244(5):411–6.

The hypothalamus–pituitary–gonad axis and testicular function in male patients after treatment for haematological malignancies [see comments] Kauppila M, et al. **J Intern Med** 1998 Nov;244(5):411–6. Comment in: J Intern Med 1999 Jul;246(1):122–3.

Early infections after autologous transplantation for haematological malignancies. Schiødt I, et al. **Med Oncol** 1998 Jul;15(2):103–8

Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Osman Y, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1057–63

Roundtable discussion: Incorporating bone marrow transplantation into NCCN guidelines. Vaughan WP, et al. **Oncology (Huntingt)** 1998 Nov;12(11A):390–2

Neuropsychological functioning after treatment for hematological malignancies in childhood, including autologous bone marrow transplantation. Arvidson J, et al. **Pediatr Hematol Oncol** 1999 Jan–Feb;16(1):9–21

Respiratory function in children undergoing bone marrow transplantation. Leneveu H, et al. **Pediatr Pulmonol** 1999 Jul;28(1):31–8

Assessment of quality of life during intensive chemotherapy or bone marrow transplantation. Zittoun R, et al. **Psychooncology** 1999 Jan–Feb;8(1):64–73

Lethal pulmonary toxicity after autologous bone marrow transplantation/peripheral blood stem cell transplantation for hematological malignancies. Lohr F, et al. **Radiother Oncol** 1998 Jul;48(1):45–51

Transplantation in childhood hematologic malignancies with closely matched family donors in Hong Kong. Yuen PM, et al. **Transplant Proc** 1998 Nov;30(7):3481–3

Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH, et al. **Vox Sang** 1998;74 Suppl 2:483–7 (36 ref.)

[Emergency in pediatric hematologic oncology. French Group for the Study of Cancers and Leukemias of the Child (CFECLE)] Leverger G, et al. **Arch Pediatr** 1999;6 Suppl 2:459s–460s **(Fre)**

[Total body irradiation: techniques, dosimetry, and complications] Belkacémi Y, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):162–73 (86 ref.) (Eng. Abstr.) **(Fre)**

[Hematology] Hermine O. **Rev Med Interne** 1999 Jan;

20(1):74–80 (18 ref.) **(Fre)**

[Interferons: Clinical applications in hematology] Ben Rhomdhane N, et al. **Tunis Med** 1998 Dec;76(12):427–36 (98 ref.) **(Fre)**

[Management of hematologic systemic diseases and rare tumor entities with manifestations in the oromaxillofacial area] Petrasch S. **Mund Kiefer Gesichtschir** 1998 Jul; 2(4):172–80 (74 ref.) (Eng. Abstr.) **(Ger)**

[Hematology: large steps followed by a time of small steps] Fehr J. **Schweiz Med Wochenschr** 1998 Dec 26; 128(51–52):2034–7 (6 ref.) **(Ger)**

[25 years allogenic bone marrow transplantation in Basel: 1973–1998] Passweg JR, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1568–74 (Eng. Abstr.) **(Ger)**

[A trial of using allogeneic bone marrow transplantation in children with different hematologic neoplastic diseases] Zubarovskaia LS, et al. **Ter Arkh** 1998;70(7):60–3 (Eng. Abstr.) **(Rus)**

[Antineoplastic agents and biologic response modifiers in oncologic hematology] Cabrera Marin JR, et al. **Rev Clin Esp** 1999 Apr;199 Suppl 1:3–13 (17 ref.) **(Spa)**

VIROLOGY

Persistence and clinical outcome of hepatitis G virus infection in pediatric bone marrow transplant recipients and children treated for hematological malignancy. Yamada-Osaki M, et al. **Blood** 1999 Jan 15;93(2):721–7

Identification of a novel GB type C virus/hepatitis G virus subtype in patients with hematologic malignancies. López-Alcorocho JM, et al. **J Med Virol** 1999 Jan; 57(1):80–4

Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential. Pavlova BG, et al. **J Med Virol** 1999 Apr; 57(4):361–6

HEMATOLOGIC TESTS

Point-of-care blood testing: more than simply changing venue [editorial; comment] Shapiro BA. **Chest** 1999 Apr; 115(4):917–8. Comment on: Chest 1999 Apr;115(4):1140–54.

The ethics of blood testing as an element of doping control in sport. Browne A, et al. **Med Sci Sports Exerc** 1999 Apr; 31(4):497–501

Seasonal variation in haematological parameters in male and female Tinca tinca. Collazos ME, et al. **Mol Cell Biochem** 1998 Jun;183(1–2):165–8

[Are the procedures in hematology always rational? Considerations] Churý Z. **Vnitr Lek** 1998 May;44(5):294–6 (Eng. Abstr.) **(Cze)**

[A feature of hematological findings in myelodysplastic syndromes] Bando S, et al. **Rinsho Byori** 1998 Aug; 46(8):790–5 (Eng. Abstr.) **(Jpn)**

[Hemogram in differential diagnosis of infectious diseases] Bogomolov BP. **Klin Med (Mosk)** 1998;76(12):25–9 (0 ref.) **(Rus)**

ECONOMICS

Near-patient testing for serum cholesterol: attitudes of general practitioners and patients, appropriateness, and costs [letter; comment] Janus ED, et al. **Med J Aust** 1999 Feb 15;170(4):187–8. Comment on: Med J Aust 1998 Jun 15;168(12):605–9.

INSTRUMENTATION

Effects of hypertriglyceridemia on platelet counts in automated hematologic analysis [letter] Kabutomori O, et al. **Ann Intern Med** 1999 Mar 2;130(5):452

Measurement of red blood cell aggregation in a "plate-plate" shearing system by analysis of light transmission. Baskurt OK, et al. **Clin Hemorheol Microcirc** 1998 Dec;19(4):307–14

Erythrocyte elongation index measured on a Rheodyn SSD laser diffractometer. Influence of the hematocrit. Martinez M, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):255–7

Treatment of superficial pseudomonal infection with citric acid [letter] Dealler S. **J Hosp Infect** 1999 Apr;41(4):340

Prevalence of myeloperoxidase deficiency: population studies using Bayer-Technicon automated hematology. Kutter D. **J Mol Med** 1998 Sep;76(10):669–75 (8 ref.)

Sample suitability for the detection of minor white cell populations (microchimerism) by polymerase chain reaction. Reed W, et al. **Transfusion** 1998 Nov-Dec; 38(11–12):1041–5

METHODS

Evaluation of a new reagent for preserving fresh blood samples and its potential usefulness for internal quality controls of multichannel hematology analyzers. Springer W, et al. **Am J Clin Pathol** 1999 Mar;111(3):387–96

Folate measurements in patients on regular hemodialysis treatment. Bamonti-Catena F, et al. **Am J Kidney Dis** 1999 Mar;33(3):492–7

Laboratory diagnosis of von Willebrand disease. Veyradier A, et al. **Int J Clin Lab Res** 1998;28(4):201–10 (33 ref.)

Prognostic score for Hodgkin's disease [letter; comment] Watine J. **N Engl J Med** 1999 Apr 22;340(16):1289–90. Comment on: N Engl J Med 1998 Nov 19;339(21):1506–14.

[Establishing the presence of blood in stains for material evidence by using the luminescent blood test] Sidorov VL, et al. **Sud Med Ekspert** 1998 Nov-Dec;41(6):20–3 (Eng. Abstr.) **(Rus)**

STANDARDS

Immunohematological reference ranges for adult Ethiopians. Tsegaye A, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):410–4

Reference intervals for haematological parameters in urban school children and adolescents [letter] Flegar-Meštrić Z, et al. **Clin Lab Haematol** 1999 Feb;21(1):72–4

Analysis of the practice guidelines of the Dutch College of General Practitioners with respect to the use of blood tests. van Wijk MA, et al. **J Am Med Inform Assoc** 1999 Jul-Aug; 6(4):322–31

Pediatric blood volumes: a one-page reference guide. Smiley J, et al. **J Pediatr Oncol Nurs** 1998 Oct;15(4):223–8

STATISTICS & NUMERICAL DATA

Influence of valproate monotherapy on platelet activation and hematologic values. Zeller JA, et al. **Epilepsia** 1999 Feb;40(2):186–9

[Integral hematological indices in assessing body immunological reactivity in patients with ophthalmic pathology] Mustafina ZhG, et al. **Klin Lab Diagn** 1999 May; (5):47–9 **(Rus)**

UTILIZATION

Pre-operative blood tests in children undergoing plastic surgery. Ansermino JM, et al. **Ann R Coll Surg Engl** 1999 May;81(3):175–8

Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? de Moerloose P, et al. **Semin Thromb Hemost** 1998;24(4):321–7 (57 ref.)

VETERINARY

Normal haematological and serum biochemical values of Eurasian otters (Lutra lutra) from a Scottish rehabilitation centre. Lewis JC, et al. **Vet Rec** 1998 Dec 19–26; 143(25):676–9

[The hematologic analyzer Vet ABC: evaluation of its use for dogs and cats] van Leeuwen MW, et al. **Tijdschr Diergeneeskd** 1999 May 15;124(10):306–9 (Eng. Abstr.) **(Dut)**

HEMATOLOGY

see related

HEMATOLOGIC DISEASES

Bilaterally cleft lip, limb defects, and haematological manifestations: Roberts syndrome versus TAR syndrome. Urban M, et al. **Am J Med Genet** 1998 Sep 23;79(3):155–60 (30 ref.)

Annual Congress of the German and Austrian Societies of Hematology and Oncology. Frankfurt, October 25–28, 1998. Abstracts. **Ann Hematol** 1998;77 Suppl 2:S1–243

American Society of Hematology 40th annual meeting. Miami Beach, Florida, USA. December 4–8, 1998. Part 1 of 2. Abstracts. **Blood** 1998 Nov 15;92(10 Su 1 Pt 1):1a–841a

American Society of Hematology 40th annual meeting. Miami Beach, Florida, USA. December 4–8, 1998. Part 2 of 2. Abstracts. **Blood** 1998 Nov 15;92(10 Su 1 Pt 2):1b–387b

Web access to the American Society of Hematology slide bank [letter] Afrin LB. **Blood** 1999 Apr 1;93(7):2425–6

"Stochastic" –40 years of use and abuse [letter] Blackett N, et al. **Blood** 1999 May 1;93(9):3148–9

Current use and outcome of blood and marrow transplantation in childhood according to the Italian Registry. Pession A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S25–7

40th annual meeting of the American Society of Hematology. Taylor N. **Bull Cancer** 1999 Feb;86(2):228–30

Consensus and accuracy in haematology laboratories of developing countries: the Jordanian experience. Bilto YY. **Clin Lab Haematol** 1999 Feb;21(1):11–5

An audit of waiting times in a haematology clinic before and after the introduction of point-of-care testing. Galloway MJ, et al. **Clin Lab Haematol** 1999 Jun; 21(3):201–5

28th Annual meeting of the International Society for Experimental Hematology. Monte Carlo, Principality of Monaco, July 10–14, 1999. Abstracts. **Exp Hematol** 1999 Jul;27(7 Suppl 1):37–149

36th Congress of the Italian Society of Hematology. Catania-Naxos Taormina, Italy. October 2–5, 1997. Abstracts. **Haematologica** 1998 Sep;83(9 Suppl):1–67, i–vii

The state of the journal: 1998 achievements and future objectives [editorial] Cazzola M, et al. **Haematologica** 1998 Dec;83(12):1057–8

Pediatric oncology and hematology in Birmingham, England. Mann JR, et al. **Pediatr Hematol Oncol** 1999 Jan-Feb; 16(1):3–7

[Antibiotic therapy of febrile neutropenic patients: prospective study at a hematologic department] Limat S, et al. **Presse Med** 1999 Apr 10;28(14):729–33 (Eng. Abstr.) **(Fre)**

[The 40th congress of the Japanese Society of Clinical Hematology. Kanazawa City, Japan. November 11–13, 1998. Abstracts] **Rinsho Ketsueki** 1998 Oct;39(10):723–1078 **(Jpn)**

[The 41st congress of the Japanese Society of Clinical Hematology. Akita City, Japan. October 13–15, 1999. Abstracts] **Rinsho Ketsueki** 1999 Sep;40(9):707–1049 **(Jpn)**

EDUCATION

Validation of training and competency of apheresis specialists: organizational guidelines for therapeutic apheresis facilities. **J Clin Apheresis** 1998;13(4):174–89

[No motivation, no time, no money—does oncologic graduate and continuing education still have a future? Presentation at the 50th Scientific Session of the Society of Pediatric Oncology and Hematology within the scope of the KOK and PSAPOH general session] Voss H. **Klin Padiatr** 1998 Jul-Aug;210(4):301–3 (Eng. Abstr.) **(Ger)**

[HemoSurf—an interactive hematology atlas on the world wide web] Woermann U, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1605–7 (Eng. Abstr.) **(Ger)**

HISTORY

History of hematology at the Charles University, Faculty of Medicine and Faculty Hospital in Hradec Králové. Chrobák L, et al. **Acta Medica (Hradec Kralove)** 1998; 41(3):145–53

NHLBI at 50: reflections on a half-century of research on the heart, lungs, and blood. National Heart, Lung, and Blood Institute [interview by Charles Marwick] Lenfant C. **JAMA** 1998 Dec 23–30;280(24):2062–4

Silhouette. Professor Ya-mei Hu. Tsuchida Y, et al. **Med Pediatr Oncol** 1999 Feb;32(2):139–40

From Karl Landsteiner to human xenotransplantation. Samuelsson B. **Vox Sang** 1998;74 Suppl 2:65–8

[The discovery of blood platelets] Caen J. **Rev Prat** 1999 Mar 15;49(6):581–2 **(Fre)**

[Russian hematological school] Vorob'ev AI, et al. **Ter Arkh** 1998;70(9):19–22 **(Rus)**

[The separator that separated cream from milk was an inspiration for the first hematocrit centrifuge] Thorén L. **Lakartidningen** 1998 Nov 4;95(45):5015 **(Swe)**

INSTRUMENTATION

Determination of hematopoietic stem cells in peripheral blood by an automated hematology analyzer (SE-9000). Takekawa K, et al. **Acta Haematol** 1998 Dec;100(3):130–6

Quantification of apoptosis by the Abbott CD4000 hematology analyzer. Mentz F, et al. **Hematol Cell Ther** 1998 Oct;40(5):183–8

Evaluation of a new automated instrument for pretransfusion testing. Morelati F, et al. **Transfusion** 1998 Oct; 38(10):959–65

METHODS

Clinical analyzers. Advances in automated cell counting. Kickler TS. **Anal Chem** 1999 Jun 15;71(12):363R–365R (11 ref.)

Comparative cell morphology in the peripheral blood film from exotic and native animals. Canfield PJ. **Aust Vet J** 1998 Dec;76(12):793–800

Is the practice of haematology evidence based? III. Evidence based diagnostic testing [editorial] [see comments] Galloway MJ, et al. **J Clin Pathol** 1998 Jul;51(7):489–91 . Comment in: J Clin Pathol 1998 Dec;51(12):944.

[Telemedicine and telepathology in hematology] Flandrin G. **Bull Acad Natl Med** 1998;182(5):1037–42; discussion 1042–4 (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Decentralised anticoagulant care [letter; comment] Fitzmaurice DA, et al. **J Clin Pathol** 1998 Sep;51(9):711–2 . Comment on: J Clin Pathol 1998 Feb;51(2):89–90.

STANDARDS

Guidelines for the clinical use of blood cell separators. Joint Working Party of the Transfusion and Clinical Haematology Task Forces of the British Committee for Standards in Haematology. **Clin Lab Haematol** 1998 Oct; 20(5):265–78

Impact of unified procedures as implemented in the Canadian Quality Assurance Program for T lymphocyte subset enumeration. Participating Flow Cytometry Laboratories of the Canadian Clinical Trials Network for HIV/AIDS Therapies. Bergeron M, et al. **Cytometry** 1998 Oct 1; 33(2):146–55

Is the practice of haematology evidence based? [letter; comment] Cavill I. **J Clin Pathol** 1998 Dec;51(12):944. Comment on: J Clin Pathol 1998 May;51(5):345–6. Comment on: J Clin Pathol 1998 Jun;51(6):417–9. Comment on: J Clin Pathol 1998 Jul;51(7):489–91.

[Criteria and algorithms for the computerized validation of the hematology laboratory] Aulesa C, et al. **Sangre (Barc)** 1998 Oct;43(5):451–60 **(Spa)**

[Clinical impact of standardization in hematology. A vision through time] Outeiriño J, et al. **Sangre (Barc)** 1998 Jun; 43(3):255–6 (7 ref.) **(Spa)**

TRENDS

Haematology. Important steps forward. Montserrat E, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV13 (5 ref.)

[Hematology and internal medicine oncology] Engert A, et al. **Internist (Berl)** 1999 Apr;40(4):356–68 (51 ref.) **(Ger)**

HEMATOMA

BLOOD

A large bruise. Standen G, et al. **Lancet** 1999 Jun 5; 353(9168):1934

[Subcutaneous hematomas, reduced Quick value. Factor VII deficiency] Osterwalder P, et al. **Schweiz Rundsch Med Prax** 1998 Jul 22;87(29–30):958–60 **(Ger)**

CHEMICALLY INDUCED

Massive subfascial hematoma after alteplase therapy for acute myocardial infarction. Khanlou H, et al. **Am J Med Sci** 1999 Jan;317(1):53–4

Uvula hematoma: an unusual complication of streptokinase. Gill P, et al. **Anesth Analg** 1999 Aug;89(2):307–8

Retroperitoneal haematoma and small bowel intramural haematoma caused by warfarin and miconazole interaction [letter] Marco M, et al. **Int J Oral Maxillofac Surg** 1998 Dec;27(6):485

Lower extremity hematoma as a complication of warfarinization in patients with artificial heart valves. Sakakibara Y, et al. **Jpn Heart J** 1999 Mar;40(2):239–45

Large hepatic hematoma and intraabdominal hemorrhage associated with abuse of anabolic steroids [letter] Schumacher J, et al. **N Engl J Med** 1999 Apr 8; 340(14):1123–4

Sedimentation level in acute intracerebral hematoma in a patient receiving anticoagulation therapy: an autopsy study. Ichikawa K, et al. **Neuroradiology** 1998 Jun;40(6):380–2

Dissecting intramural haematoma of the oesophagus exacerbated by heparin therapy [letter] Cullen SN, et al. **QJM** 1999 Feb;92(2):123–4

Low-molecular weight heparin, spinal hematomas, and the FDA: what's wrong with this picture? [editorial] Landow L, et al. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):8–10

Acute renal failure due to retroperitoneal haematoma: a question of warfarin dispensation. Waring WS, et al. **Scott Med J** 1999 Feb;44(1):16

[Ureteral hematoma complicating anticoagulant treatment] Belliol E, et al. **J Radiol** 1998 Jan;79(1):49–51 (Eng. Abstr.) **(Fre)**

[Parietal abdominal hematoma after combined acenocoumarol and roxithromycin treatment (letter)] Chassany O, et al. **Presse Med** 1998 Jun 20;27(22):1103 **(Fre)**

[Exasperating hematomas] Carli P, et al. **Rev Med Interne** 1999;20 Suppl 2:267s–268s **(Fre)**

[Intracerebral hemorrhage following amphetamine use] Janik P, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1539–46 (Eng. Abstr.) **(Pol)**

[Retroperitoneal hematoma and femoral compression neuropathy—a complication of anticoagulation therapy after myocardial infarct] Kristian P, et al. **Vnitr Lek** 1998 Jun;44(6):366–9 (Eng. Abstr.) **(Slo)**

[Upper airway obstruction as a complication of acenocoumarol treatment] Garcia Callejo FJ, et al. **Sangre (Barc)** 1998 Jun;43(3):223–6 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Intramural haematoma of the duodenum: a rare cause of duodenal obstruction. de Bree E, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):485–7

Life-threatening airway obstruction caused by a retropharyngeal haematoma. Senthuran S, et al. **Anaesthesia** 1999 Jul;54(7):674–8

A case of amnestic syndrome caused by a subcortical haematoma in the right occipital lobe. Masuo O, et al. **Brain Inj** 1999 Mar;13(3):213–6

Femoral neuropathy following anticoagulant therapy: a case report and discussion [editorial] Ahuja R, et al. **Conn Med** 1999 Feb;63(2):69–71

Delayed focal neurological deficit secondary to a cervico-thoracic spinal cord epidural haematoma. Newey ML, et al. **Eur Spine J** 1999;8(4):332–3

Small bowel obstruction resulting from mesenteric hematoma caused by spontaneous rupture of a jejunal branch artery. Weinstock LB, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):537–40

Post-traumatic multilobated pseudoaneurysm of the left ventricle secondary to dissecting intramyocardial haematoma of the posterior wall: obstructive and fenestrated communication demonstrated by colour Doppler imaging. Mohan JC, et al. **Indian Heart J** 1998 Sep–Oct;50(5):539–41

Unusual cause of a raised right hemidiaphragm. Inyang V. **J Accid Emerg Med** 1998 Nov;15(6):433

Retropharyngeal haematoma causing acute airway obstruction—first presentation of metastatic carcinoma. Draper MR, et al. **J Laryngol Otol** 1999 Mar;113(3):258–9

Bilateral ureteral obstruction and renal failure caused by massive retroperitoneal hematoma: is there a pelvic compartment syndrome analogous to abdominal compartment syndrome? Hessmann M, et al. **J Orthop Trauma** 1998 Nov–Dec;12(8):553–7

Stridor due to laryngeal haematoma. Roblin G, et al. **J R Soc Med** 1998 Nov;91(11):593

Sternal fracture with mediastinal hematoma: delayed cardiopulmonary sequelae. Crestanello JA, et al. **J Trauma** 1999 Jul;47(1):161–4

Spontaneous abdominal hematoma in dermatomyositis. Orrell RW, et al. **Muscle Nerve** 1998 Dec;21(12):1800–3

Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Tanaka A, et al. **Stroke** 1999 Aug;30(8):1637–42

Obstructive Ileus caused by blood clot after emergency total gastrectomy in a patient with hemophilia A: report of a case. Onda M, et al. **Surg Today** 1998;28(12):1266–9

[Deep venous thrombosis secondary to hematoma of the psoas muscle in a patient receiving anticoagulants (letter)] Marti J, et al. **An Med Interna** 1999 Aug;16(8):434 **(Spa)**

DIAGNOSIS

Intramural haematoma of the duodenum: a rare cause of duodenal obstruction. de Bree E, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):485–7

Haematoma of the piriformis muscle simulating a giant presacral tumour: unusual case of lumbosacral radiculopathy. Katati MJ, et al. **Acta Neurochir (Wien)** 1998;140(4):403–4

MR imaging of experimentally induced intracranial hemorrhage in rabbits during the first 6 hours. Gustafsson O, et al. **Acta Radiol** 1999 Jul;40(4):360–8

Rectus sheath haematoma in elderly patients: a diagnostic challenge. Bene J, et al. **Age Ageing** 1998 Jul;27(4):512–4

Spontaneous bilateral arytenoid hematoma in a patient on warfarin. Jandreau SW, et al. **Am J Emerg Med** 1998 Nov; 16(7):674–6

Spontaneous intramural hematoma of the esophagus. Hiller N, et al. **Am J Gastroenterol** 1999 Aug;94(8):2282–4

Extraskeletal Ewing's sarcoma mimicking traumatic hematoma. Ogose A, et al. **Arch Orthop Trauma Surg** 1998; 118(3):172–3

A case of amnestic syndrome caused by a subcortical haematoma in the right occipital lobe. Masuo O, et al. **Brain Inj** 1999 Mar;13(3):213–6

Delayed splenic rupture in an amateur hockey player. Flik K, et al. **Clin J Sport Med** 1998 Oct;8(4):309–10

Spontaneous cervical hematoma: a report of two cases. DiFrancesco RC, et al. **Ear Nose Throat J** 1999 Mar; 78(3):168, 171, 175

Aortic dissection limited to the ascending aorta mimicking intramural hematoma. Berdat PA, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):108–9

Haemophilia A: two cases showing unusual features at birth. Le Pommelet C, et al. **Haemophilia** 1998 Mar;4(2):122–5

Spontaneous isolated lesser sac hematoma in a patient with hemophilia. Prasad S, et al. **Indian J Gastroenterol** 1999 Jan–Mar;18(1):38–9

Spontaneous calf hematoma: a report of two cases diagnosed with MRI. Hoffman RD, et al. **Iowa Orthop J** 1998; 18:142–5

Persistent "haematoma". Clancy MJ. **J Accid Emerg Med** 1999 Jul;16(4):303

Aortic intramural hematoma presenting as angina. Haddy SM, et al. **J Clin Anesth** 1998 Nov;10(7):603–5

Dynamic T1-weighted spin-echo MR imaging: the role of digital subtraction in the demonstration of enhancing brain lesions. Melhem ER, et al. **J Magn Reson Imaging** 1999 Apr;9(4):503–8

Intradural nerve root hematoma in the lumbar spine. Case illustration. Başkaya MK, et al. **J Neurosurg** 1999 Oct;91(2 Suppl):242

Lower extremity hematoma as a complication of warfarinization in patients with artificial heart valves. Sakakibara Y, et al. **Jpn Heart J** 1999 Mar;40(2):239–45

Active intrahepatic gadolinium extravasation following TIPS. Hasegawa S, et al. **Magn Reson Imaging** 1998 Sep; 16(7):851–3

Magnetic resonance imaging of postpartum pelvic hematomas: early experience in diagnosis and treatment planning. Jain KA, et al. **Magn Reson Imaging** 1999 Sep; 17(7):973–7

Mentzel T, Goodland JR, Smith MA, Fletcher CDM: Ancient hematoma: a unifying concept for a post-traumatic lesion mimicking an aggressive soft tissue neoplasm. Mod Pathol 1997;10:334–340 [letter; comment] Finn LS. **Mod Pathol** 1998 Aug;11(8):799–800. Comment on: Mod Pathol 1997 Apr;10(4):334–40.

MR angiography in internal carotid artery dissection: improvement of diagnosis by selective demonstration of the intramural haematoma. Kirsch E, et al. **Neuroradiology** 1998 Nov;40(11):704–9

Spontaneous pelvic hematoma simulating neoplasm: case report and literature review. Chia SH, et al. **Oncol Rep** 1999 Jan–Feb;6(1):189–91

Spontaneous pericardial hematoma in an infant. Cordes D, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):380–1

Dissecting intramural haematoma of the oesophagus. McIntyre AS, et al. **QJM** 1998 Oct;91(10):701–5

Adrenal adenoma and hematoma mimicking a collision tumor at MR imaging. Khati NJ, et al. **Radiographics** 1999 Jan–Feb;19(1):235–9

Orbital subperiosteal hematoma, cholesterol granuloma, and infection. Evaluation with MR imaging and CT. Dobben GD, et al. **Radiol Clin North Am** 1998 Nov;36(6):1185–200

What is your diagnosis? Multiple unilateral nodular pulmonary lesions in a lung transplant recipient. Diagnosis: focal intrapulmonary hemorrhage following transbronchial lung biopsy. Laube I, et al. **Respiration** 1999;66(1):91–2

Predictors of hematoma growth? [letter] Cheung RT. **Stroke** 1998 Nov;29(11):2442–3

Chronic progressive hematomyelia: case reports and review of the literature. Matsumura A, et al. **Surg Neurol** 1999 May;51(5):559–63 (27 ref.)

Giant hydronephrosis—a diagnostic dilemma. Mountney J, et al. **Urol Int** 1998;61(2):121–3

Subepithelial pelvic hematoma of the kidney clinically mimicking cancer: report of six cases and review of the literature. Iczkowski KA, et al. **Urology** 1999 Feb; 53(2):276–9 (12 ref.)

[Hematomyelia complicating a spinal dural arteriovenous fistula. Report of a case] Mascalchi M, et al. **J Neuroradiol** 1998 Jul;25(2):140–3 (Eng. Abstr.) **(Fre)**

[Encapsulated hematoma of the sigmoid mesocolon. Apropos of an unusual case in Niger] Théry Y, et al. **J Radiol** 1999 Mar;80(3):312–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Pheochromocytoma revealed by cerebral hematomas. Significance of the abolition of a cutaneous abdominal reflex ipsilateral to the adrenal tumor] Alla P, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):55–7 (Eng. Abstr.) **(Fre)**

[Subperiostal hematoma of the orbit and epidural hematoma in patients with skull-brain trauma] Winnekendonk G, et al. **Radiologe** 1998 Nov;38(11):954–7 (Eng. Abstr.) **(Ger)**

[Acute rupture of a solitary angiomyolipoma in the upper pol of the right kidney with extensive perirenal hematoma] Wolfensberger UE, et al. **Schweiz Rundsch Med Prax** 1998 Nov 4;87(45):1509–11 **(Ger)**

[Diagnosis of an intramyocardial hematoma via MRI after a traumatic myocardial infarct] Wittlinger T, et al. **Z Kardiol** 1999 Feb;88(2):147–53 (Eng. Abstr.) **(Ger)**

[Idiopathic adrenal hemorrhage: a case report] Sakamoto T, et al. **Hinyokika Kiyo** 1998 Nov;44(11):805–7 (Eng. Abstr.) **(Jpn)**

[Chronic encapsulated intracerebral hematoma] Dulić S. **Vojnosanit Pregl** 1998 Nov–Dec;55(6):653–6 (Eng. Abstr.) **(Scc)**

[Spontaneous retroperitoneal hematoma: our experience] Machuca Santa Cruz J, et al. **Actas Urol Esp** 1999 Jan; 23(1):43–50 (Eng. Abstr.) **(Spa)**

[Submucosa esophageal hematoma (letter)] Cervantes González JL, et al. **An Med Interna** 1998 Sep;15(9):506 **(Spa)**

[Purely bulbar hematomas] Jato M, et al. **Rev Neurol** 1998 Oct;27(158):667–71 (19 ref.) (Eng. Abstr.) **(Spa)**

[Intraparenchymal hematomas: specific features in children] Marzo-Sola ME, et al. **Rev Neurol** 1998 Apr;26(152):561–3 (Eng. Abstr.) **(Spa)**

[Pontine hematoma secondary to aneurysm of the PICA (letter; comment)] Ramírez-Moreno JM, et al. **Rev Neurol** 1998 Dec;27(160):1071. Comment on: Rev Neurol 1996 Aug;24(132):984–6. **(Spa)**

DRUG THERAPY

Spinal epidural haematoma in haemophilia A with inhibitors—efficacy of recombinant factor VIIa concentrate. Leach M, et al. **Haemophilia** 1999 May; 5(3):209–12

Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma [letter; comment] Wijdicks EF, et al. **Neurology** 1999 Feb;52(3):676–7. Comment on: Neurology 1998 May;50(5):1489–91.

[Effects of "qing kai ling" injection on experimental cerebral hematoma in rabbits] Li KL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb; 17(2):91–3 (Eng. Abstr.) **(Chi)**

[Fibrinolysis of intraventricular hematoma with rt-PA] Schwarz S, et al. **Nervenarzt** 1999 Feb;70(2):123–30 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Nine cases of nontraumatic spinal epidural hematoma. Hejazi N, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):718–23; discussion 723–4 (18 ref.)

Predictors of hematoma growth? [letter] Cheung RT. **Stroke** 1998 Nov;29(11):2442–3

ETIOLOGY

Chronic expanding hematoma of the spleen caused by angiomyolipoma in a patient with tuberous sclerosis. Asayama Y, et al. **Abdom Imaging** 1998 Sep–Oct; 23(5):527–30

Epiglottic hematoma secondary to endotracheal intubation. Cheng KS, et al. **Acta Anaesthesiol Sin** 1999 Mar; 37(1):49–52

Thyroid gland hematoma after blunt cervical trauma. Blaivas M, et al. **Am J Emerg Med** 1999 Jul;17(4):348–50

Intraduodenal hematoma complicating intestinal biopsy: case reports and review of the literature. Guzman C, et al. **Am J Gastroenterol** 1998 Dec;93(12):2547–50 (29 ref.)

Epidural placement in a patient with undiagnosed acquired haemophilia from factor VIII inhibitor. Christie-Taylor GA, et al. **Anaesthesia** 1999 Apr;54(4):367–71

Spontaneous retroperitoneal hematoma from rupture of an aneurysm of the ovarian artery following delivery. Guillem P, et al. **Ann Vasc Surg** 1999 Jul;13(4):445–8 (9 ref.)

Orbital hematoma following minor trauma due to platelet aggregation abnormality. Khan MA, et al.

Arch Ophthalmol 1998 Oct;116(10):1402–3

Cystic hematoma formation following use of a biodegradable arrow for meniscal repair. Hechtman KS, et al. **Arthroscopy** 1999 Mar;15(2):207–10

Intramural duodenal haematoma following endoscopic biopsy in a bone marrow transplant patient [letter] Worynski A, et al. **Aust N Z J Med** 1998 Dec;28(6):843–4

Periurethral haematomas in a child following urethral dilation for dysfunctional voiding [letter; comment] Lyon RP, et al. **BJU Int** 1999 Feb;83(3):364. Comment on: Br J Urol 1998 Jun;81(6):920–1.

The end of the heparin pump? Epidural haematoma may occur after epidural and spinal regional anaesthesia [letter] Callander CC. **BMJ** 1999 Aug 28;319(7209):576

Bilateral frontal extradural haematomas caused by rupture of the superior sagittal sinus: case report. Kett-White R, et al. **Br J Neurosurg** 1999 Feb;13(1):77–8

Head injuries in the elderly [editorial] Maurice-Williams RS. **Br J Neurosurg** 1999 Feb;13(1):5–8

Multiple postoperative intracerebral haematomas remote from the site of craniotomy. Rapanà A, et al. **Br J Neurosurg** 1998 Aug;12(4):364–8 (32 ref.)

Aorto-oesophageal fistula presenting as a submucosal oesophageal haematoma. Maher MM, et al. **Br J Radiol** 1998 Sep;71(849):972–4

Risk factors for post-carotid endarterectomy hematoma formation. Self DD, et al. **Can J Anaesth** 1999 Jul; 46(7):635–40

The effect of early ambulation on hematoma formation and vascular complications following 7 French diagnostic cardiac catheterization. Singh N, et al. **Can J Cardiol** 1998 Oct;14(10):1223–7

Subcapsular hemorrhage of adult Wilms' tumor. Erdağ N, et al. **Clin Imaging** 1999 Jan-Feb;23(1):44–6

Gastric wall haematoma as a complication of percutaneous endoscopic gastrostomy insertion. Jowett S, et al. **Endoscopy** 1999 Aug;31(6):S48

Hematometra and extended vaginal haematoma after laser conization. A case report. Giannacopoulos K, et al. **Eur J Gynaecol Oncol** 1998;19(6):569–70

Intramural hematoma of stomach after splenectomy for idiopathic thrombocytopenic purpura [letter] Kami M, et al. **Haematologica** 1999 Jul;84(7):669–71

Expanding portal haematomata as a complication of knee arthroscopies in persons with haemophilia. Heim M, et al. **Haemophilia** 1999 May;5(3):213–5

Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate. Leach M, et al. **Haemophilia** 1999 May; 5(3):209–12

Central venous cannulation in patients with liver disease and coagulopathy--a prospective audit. Fisher NC, et al. **Intensive Care Med** 1999 May;25(5):481–5

Endovascular management of axillary artery trauma. Martinez R, et al. **J Cardiovasc Surg (Torino)** 1999 Jun; 40(3):413–5

Spontaneous intramural hematoma localized in the proximal esophagus: truly "spontaneous"? Sanaka M, et al. **J Clin Gastroenterol** 1998 Oct;27(3):265–6

Low molecular weight heparin and epidurals [news] Crews JC. **J Clin Monit Comput** 1998 Dec;14(7–8):507–9

Early postoperative rise in defibrillation threshold associated with hematoma formation with unipolar defibrillation system. Yazmajian DY, et al. **J Interv Card Electrophysiol** 1997 Sep;1(2):135–7

Upper airway obstruction by retropharyngeal hematoma after cervical spine trauma: report of a case treated with percutaneous dilational tracheostomy. Mazzon D, et al. **J Neurosurg Anesthesiol** 1998 Oct;10(4):237–40

Extradural haematoma complicating lumbar puncture following a craniotomy. A case report. Mohanty A, et al. **J Neurosurg Sci** 1998 Dec;42(4):233–7

Vascular complications following laparoscopy: two unusual cases. Ou CS. **J Soc Laparoendosc Surg** 1997 Apr-Jun; 1(2):159–61

Complications of lumbar puncture with injection of hydrosoluble material. Hoeffel C, et al. **J Spinal Disord** 1999 Apr;12(2):168–71

Ruptured lumbar artery pseudoaneurysm: a diagnostic dilemma in retroperitoneal hemorrhage after abdominal trauma [see comments] Kalangos A, et al. **J Trauma** 1998 Oct;45(4):829–32 (13 ref.). Comment in: J Trauma 1999 Mar;46(3):531–2.

Traumatic retropharyngeal hematoma: case report. Tsai KJ, et al. **J Trauma** 1999 Apr;46(4):715–6

Simultaneous bilateral perirenal hematomas developing spontaneously in a patient with polyarteritis nodosa. Yonou H, et al. **J Urol** 1999 Aug;162(2):483 (3 ref.)

Intrapericardial organized hematoma. A rare complication after open heart surgery. Kagaya S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jun;47(6):291–4

Safe cycling [letter; comment] Nehoda H, et al. **Lancet** 1999 Apr 3;353(9159):1192. Comment on: Lancet 1998 Jan 31;351(9099):342.

Fatal hematoma during treatment with adjusted-dose subcutaneous heparin therapy [letter] Gabel A, et al. **N Engl J Med** 1999 Jan 7;340(1):61–2

Handlebar accidents [letter] Adams JD. **N Z Med J** 1998 Nov 13;111(1077):440

Autosomal dominant polycystic kidney disease presenting with prolonged macrohaematuria and perinephric haematoma [letter] Sirvent AE, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2422–3

Traumatic epidural hematoma of the cervical spine: magnetic resonance imaging diagnosis and spontaneous resolution: case report. Lefranc F, et al. **Neurosurgery** 1999 Feb; 44(2):408–10; discussion 410–1

A case with subcapsular hematoma of the liver following laparoscopic cholecystectomy. Obara K, et al. **Nippon Ika Daigaku Zasshi** 1998 Dec;65(6):478–80

Endocapsular hematoma: report of a case following glaucoma surgery in a pseudophakic eye. Mandal AK, et al. **Ophthalmic Surg Lasers** 1999 May;30(5):389–93 (22 ref.)

Two faces of orbital hematoma in intranasal (endoscopic) sinus surgery. Stankiewicz JA, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):841–7

A case of intramedullary haematoma associated with congenital alpha2-plasmin inhibitor deficiency. Devaussuzenet VMP, et al. **Pediatr Radiol** 1998 Dec; 28(12):978–80

Rectus sheath hematoma/abscess following acute peritoneal dialysis [letter] Thiruventhiran T, et al. **Perit Dial Int** 1999 Jan-Feb;19(1):88

Axillary block complicated by hematoma and radial nerve injury. Ben-David B, et al. **Reg Anesth Pain Med** 1999 May-Jun;24(3):264–6

Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Urmey WF, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6 Suppl 2):146–51 (16 ref.)

A fatal complication of the Seldings technique for cannulation of the femoral vein [letter] Reynolds FE, et al. **Resuscitation** 1998 Dec;39(3):219

Renal hematoma as a complication of extracorporeal shock wave lithotripsy. Collado Serra A, et al. **Scand J Urol Nephrol** 1999 Jun;33(3):171–5

Intrahepatic subcapsular hematoma. A rare postoperative complication of laparoscopic cholecystectomy. Pietra N, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):304–7

[Post-traumatic hematoma of the esophagus] Rozec B, et al. **Ann Fr Anesth Reanim** 1998;17(9):1160–3 (Eng. Abstr.) **(Fre)**

[Adrenal hematoma may mask renal vein thrombosis (letter)] Mourani C, et al. **Arch Pediatr** 1998 Jan;5(1):92 **(Fre)**

[Retroplacental hematoma at the Dakar University Hospital Center] Diallo D, et al. **Dakar Med** 1997;42(1):59–62 (19 ref.) (Eng. Abstr.) **(Fre)**

[Post-traumatic hematoma of the duodenum (letter; comment)] Hoeffel JC, et al. **J Radiol** 1998 Sep;79(9):897–8 . Comment on: J Radiol 1997 Jan;78(1):61–4. **(Fre)**

[Acute adrenal insufficiency due to bilateral adrenal hematoma following severe thrombopenia induced by low-molecular-weight heparin] Caubet O, et al. **Presse Med** 1999 May 22-29;28(19):1010–2 (Eng. Abstr.) **(Fre)**

[Bilateral spontaneous perirenal hematoma: an unusual complication of polyarteritis nodosa] Launay D, et al. **Rev Med Interne** 1998 Sep;19(9):666–9 (Eng. Abstr.) **(Fre)**

[Gastric and duodenal intramural hematoma: report of two cases] Dibuz M, et al. **Orv Hetil** 1998 Dec 6;139(49):2963 (39 ref.) (Eng. Abstr.) **(Hun)**

[Intrapulmonary hematoma surrounding the stapled line after video-assisted thoracoscopic bullectomy for spontaneous pneumothorax] Horio H, et al. **Kyobu Geka** 1999 Jun; 52(6):477–80 (Eng. Abstr.) **(Jpn)**

[Giant retroperitoneal hematoma in a patient with von Recklinghausen's disease] Shimizu T, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Oct;89(10):846–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case of idiopathic iliopsoas hematoma associated with liver cirrhosis] Kamura M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov;95(11):1266–9 **(Jpn)**

[Severe stenosis of the internal carotid artery and intracerebral hematoma associated with neurofibromatosis type 1: a case report] Fujimoto K, et al. **No Shinkei Geka** 1999 Jan;27(1):61–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

[A case of cerebellar hematoma due to venous angioma presenting trigeminal dysfunction] Hayashida O, et al. **No Shinkei Geka** 1999 Mar;27(3):233–6 (Eng. Abstr.) **(Jpn)**

[A case of multiple intracranial hematomas due to head trauma] Ikeda K. **No To Shinkei** 1998 Oct;50(10):954–5 **(Jpn)**

[Letter concerning the paper by Stefan Bayassi and Stefan Kopczyński: "Traumatic intracranial hematomas: analysis of 54 cases" published in Neurol. Neurosurg. Pol., 1997, 31, 4, 727... (letter)] Kwiatkowski S. **Neurol Neurochir Pol** 1998 Mar-Apr;32(2):445–6 **(Pol)**

[Arterial hypertension due to perirenal hematoma after renal percutaneous biopsy] Wanic-Kossowska M. **Pol Arch Med Wewn** 1998 Nov;100(5):454–7 (Eng. Abstr.) **(Pol)**

[Spontaneous ruptures of the kidney and retroperitoneal hematomas in hemorrhagic fever with renal syndrome] Zagidullin IM, et al. **Urol Nefrol (Mosk)** 1998 Nov-Dec; (6):50–3 (56 ref.) **(Rus)**

[Wunderlich's syndrome in a patient on hemodialysis with acquired cystic kidney disease. A report of a new case] Peña Porta JM, et al. **Actas Urol Esp** 1999 Jan;23(1):76–8 (11 ref.) (Eng. Abstr.) **(Spa)**

[Intraparenchymal cerebral hematoma following the insertion of a catheter for monitoring intracranial pressure (letter)] Aguilar-Aguilar G, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):45–6 **(Spa)**

[Epidural hematoma after removal of an epidural catheter] Blasi A, et al. **Rev Esp Anestesiol Reanim** 1998 Aug-Sep; 45(7):294–7 (Eng. Abstr.) **(Spa)**

[Infectious and non-infectious complications of tunneled central catheters in hematologic patients] Albo López C, et al. **Sangre (Barc)** 1999 Jun;44(3):176–81 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Primarily infected cephalhematoma and osteomyelitis in a newborn. Miedema CJ, et al. **Eur J Med Res** 1999 Jan 26;4(1):8–10

Cerebral vasculitis associated with chronic mucocutaneous candidiasis. Grouhi M, et al. **J Pediatr** 1998 Oct; 133(4):571–4

Hepatic subcapsular hematomas in fetuses and neonatal infants. Singer DB, et al. **Pediatr Dev Pathol** 1999 May-Jun; 2(3):215–20

Infection of a traumatic pelvic hematoma with Mycoplasma hominis. Burke DS, et al. **Sex Transm Dis** 1978 Apr-Jun; 5(2):65–7

PATHOLOGY

Papillary endothelial hyperplasia presenting as a chest wall neoplasm. Duarte IG, et al. **Ann Thorac Surg** 1999 Jan; 67(1):238–40

Hemophilic pseudotumor of the soft tissue of the hand: a case report. Hopkins JD, et al. **J Okla State Med Assoc** 1999 May;92(5):227–30

Low-intensity laser therapy for benign fibrotic lumps in the breast following reduction mammaplasty. Nussbaum EL. **Phys Ther** 1999 Jul;79(7):691–8

PHYSIOPATHOLOGY

Comparison of cerebral blood flow and injury following intracerebral and subdural hematoma in the rat. Patel TR, et al. **Brain Res** 1999 May 22;829(1-2):125–33

Correction for partial volume effects in regional blood flow measurements adjacent to hematomas in humans with intracerebral hemorrhage: implementation and validation. Videen TO, et al. **J Comput Assist Tomogr** 1999 Mar-Apr; 23(2):248–56

Effects of hematoma on the short-term fate of experimental microvenous autografts. Bayramiçli M, et al. **J Reconstr Microsurg** 1998 Nov;14(8):575–86

Predicting neurologic deterioration in patients with cerebellar hematomas. St. Louis EK, et al. **Neurology** 1998 Nov;51(5):1364–9

PREVENTION & CONTROL

Epidural catheter removal before unanticipated anticoagulation: the pharmacy fail-safe [letter] Keegan MT, et al. **Anesthesiology** 1999 Jul;91(1):328

Safe cycling [letter; comment] Nehoda H, et al. **Lancet** 1999 Apr 3;353(9159):1192. Comment on: Lancet 1998 Jan 31;351(9099):342.

Galea-cranium suture method for prevention of the subcutaneous fluid collection--technical note. Kato T, et al. **Neurol Med Chir (Tokyo)** 1999 May;39(5):384–6

Anatomic guidelines for the prevention of abdominal wall hematoma induced by trocar placement. Balzer KM, et al. **Surg Radiol Anat** 1999;21(2):87–9

RADIOGRAPHY

Displacement of extrapleural fat with extrapleural hematoma [letter; comment] Gilkeson RC, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):243–4. Comment on: AJR Am J Roentgenol 1997 Sep;169(3):687–9.

Hematoma in a low-grade medullary astrocytoma: report of an unusual case and literature review. van Ouwerkerk WJ, et al. **Childs Nerv Syst** 1998 Dec;14(12):742–6 (64 ref.)

Unilateral traumatic adrenal haematoma presenting as pheochromocytoma. Khan A, et al. **Eur J Radiol** 1998 Sep; 28(2):133–5

Radiology case of the month. Enlarging thigh mass. McCarthy K, et al. **J La State Med Soc** 1999 Mar; 151(3):121–2

Prognostic value of early computerized tomography scanning following craniotomy for traumatic hematoma. Lubillo S, et al. **J Neurosurg** 1999 Oct;91(4):581–7

Special exhibit for the SCVIR Annual Meeting Film Panel Session: diagnosis and discussion of cases 5–8. Society of Cardiovascular & Interventional Radiology. Case 5. Traumatic hepatic arterial injury with probable avulsion of the left hepatic artery origin. Hematoma within the porta hepatis. LaBerge JM, et al. **J Vasc Interv Radiol** 1999 May; 10(5):653–57

Predicting neurologic deterioration in patients with cerebellar hematomas. St. Louis EK, et al. **Neurology** 1998 Nov;51(5):1364–9

Large chronic cephalohematoma without calcification. Firlik KS, et al. **Pediatr Neurosurg** 1999 Jan;30(1):39–42

Clinical indicators of intracranial injury in head-injured infants. Greenes DS, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):861–7

Images in medicine. Retroperitoneal haematoma. Ahmed M, et al. **Postgrad Med J** 1998 Jul;74(873):415

Spontaneous perirenal haematoma. Godbole HC, et al. **Postgrad Med J** 1998 Dec;74(878):767–8

Clinics in diagnostic imaging (38). Post-ESWL perinephric haematoma. Chong KW, et al. **Singapore Med J** 1999 Jun; 40(6):430–3

The radiological findings in chronic expanding hematoma. Aoki T, et al. **Skeletal Radiol** 1999 Jul;28(7):396–401

[Pseudoaneurysm of the lingual artery after tonsillectomy. A rare complication] Menauer F, et al. **Laryngorhinootologie** 1999 Jul;78(7):405–7 (Eng. Abstr.) **(Ger)**

[A case of spontaneous submucosal hematoma of the esophagus] Matsui T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1008–12 (16 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

In-111-labeled leukocyte infection imaging: false-positive results caused by wound dressing and hematoma. Rajendran JG, et al. **Clin Nucl Med** 1999 Feb;24(2):126–7

Localization of a bone imaging agent in a calcified hematoma. Shih WJ, et al. **J Nucl Med Technol** 1999 Mar;27(1):45–7

SURGERY

Acute postoperative neck hematoma. Roy SP. **Am J Emerg Med** 1999 May;17(3):308–9

Percutaneous drainage of subcapsular splenic hematoma: an experimental model in dogs. Sofer M, et al. **Am Surg** 1998 Dec;64(12):1212–4

Spontaneous spinal epidural hematoma [letter; comment] Cirek B, et al. **Arch Phys Med Rehabil** 1999 Jan;80(1):125 . Comment on: Arch Phys Med Rehabil 1998 Apr;79(4):460–3.

Intraparenchymal and intrasylvian haematomas secondary to ruptured middle cerebral artery aneurysms: prognostic factors and therapeutic considerations. Yoshimoto Y, et al. **Br J Neurosurg** 1999 Feb;13(1):18–24

Transient cerebellar mutism after evacuation of a spontaneous vermian haematoma. Sinha AK, et al. **Childs Nerv Syst** 1998 Sep;14(9):460–2

An infantile intraosseous hematoma of the skull. Report of a case and review of the literature. Yücesoy K, et al. **Childs Nerv Syst** 1999 Jan;15(1):69–72 (13 ref.)

Strategy, technology, and techniques of surgical treatment of supratentorial intracerebral hematomas. Peresedov VV. **Comput Aided Surg** 1999;4(1):51–63; discussion 50

Traumatic aortic rupture and retroperitoneal haematoma--treatment including combined operative and endovascular approach. Lindblad B, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):451–5 (6 ref.)

Intramural duodenal hematoma of pancreatic origin. Bellens L, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):930–2

Laparoscopic evacuation of a subcapsular renal hematoma causing symptomatic hypertension. Graham CW, et al. **J Endourol** 1998 Dec;12(6):551–3

Laparoscopic drainage of an intramural duodenal hematoma. Maemura T, et al. **J Gastroenterol** 1999 Feb;34(1):119–22

Surgical options of hypertensive intracerebral hematoma: stereotactic endoscopic removal versus stereotactic catheter drainage. Kim MH, et al. **J Korean Med Sci** 1998 Oct;13(5):533–40

Prognostic value of early computerized tomography scanning following craniotomy for traumatic hematoma. Lubillo S, et al. **J Neurosurg** 1999 Oct;91(4):581–7

Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. Wagner KR, et al. **J Neurosurg** 1999 Mar;90(3):491–8

Surgical outcome of traumatic intracranial hematoma at a regional hospital in Taiwan. Wu JJ, et al. **J Trauma** 1999 Jul;47(1):39–43

Surgical treatment for intracerebral hemorrhage (STICH): a single-center, randomized clinical trial. Morgenstern LB, et al. **Neurology** 1998 Nov;51(5):1359–63

Transcollicular approach to intrinsic tectal lesions. Kaku Y, et al. **Neurosurgery** 1999 Feb;44(2):338–43; discussion 343–4

[Primary clinical experience of neuroendoscopy: report of 19 cases] Yang X, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):234–6 (Eng. Abstr.) **(Chi)**

[Minimally invasive treatment of traumatic cerebral hematoma. Further experience with stereotaxic evacuation] Fadrus P, et al. **Rozhl Chir** 1998 Oct;77(10):441–4 (Eng. Abstr.) **(Cze)**

[Severe pancreaticoduodenal trauma: review of a series of 30 patients] Jurczak F, et al. **Ann Chir** 1999;53(4):267–72 (Eng. Abstr.) **(Fre)**

[Bilobar liver hematoma and spontaneous rupture after cesarean section] Knoop M, et al. **Chirurg** 1999 Feb; 70(2):214–6 (Eng. Abstr.) **(Ger)**

[Usefulness of aspiration surgery for elderly patients with hypertensive cerebellar hemorrhage] Takanashi Y, et al. **No To Shinkei** 1998 Aug;50(8):751–4 (Eng. Abstr.) **(Jpn)**

THERAPY

Treatment of a urinoma and a post-traumatic pseudoaneurysm using selective arterial embolization. Pinto IT, et al. **Cardiovasc Intervent Radiol** 1998 Nov–Dec; 21(6):506–8

Life-threatening spontaneous psoas haematoma treated by transcatheter arterial embolization. Qanadli SD, et al. **Eur Radiol** 1999;9(6):1231–4

Subcapsular hematoma as a complication of acute pyelonephritis: a case report. Kim HJ, et al. **J Korean Med Sci** 1998 Oct;13(5):551–3

Posterior fossa epidural hematomas: observations on a series of 73 cases. Bozbuğa M, et al. **Neurosurg Rev** 1999; 22(1):34–40

Spontaneous splenic rupture in infectious mononucleosis: conservative management with gradual percutaneous drainage of a subcapsular hematoma. Schwarz M, et al. **Pediatr Surg Int** 1999;15(2):139–40

[Splenic hematoma during infectious mononucleosis: non-operative treatment (letter)] Lambotte O, et al. **Presse Med** 1998 Feb 7;27(5):209 **(Fre)**

[Nonoperative management of major blunt renal lacerations with urinary extravasation: report of two cases] Sekiguchi Y, et al. **Hinyokika Kiyo** 1998 Dec;44(12):875–8 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Transesophageal echocardiographic Doppler findings in patients with penetrating aortic ulcers. Atar S, et al. **Am J Cardiol** 1999 Jan 1;83(1):133–5, A10

Cephalhematoma and caput succedaneum: do they always occur in labor? Petrikovsky BM, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):906–8

Ultrasound in the diagnosis and management of fluid collection complications following abdominoplasty. Mohammad JA, et al. **Ann Plast Surg** 1998 Nov; 41(5):498–502

Ultrasound detection of vault haematoma following vaginal hysterectomy [letter; comment] Tincello DG. **Br J Obstet Gynaecol** 1998 Dec;105(12):1336–7. Comment on: Br J Obstet Gynaecol 1998 Feb;105(2):211–5.

Sonographically diagnosed pelvic hematomas and postcesarean febrile morbidity. Gemer O, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):7–9

Persistent subchorionic hematoma with clinical symptoms until delivery. Seki H, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):123–8

Intramyocardial hematoma causing cardiac tamponade after repair of Ebstein malformation: erroneous echocardiographic diagnosis as intracavitary thrombus. Momenah TS, et al. **J Am Soc Echocardiogr** 1998 Nov; 11(11):1087–9

An abnormal transesophageal echocardiography finding after retrograde cardioplegia. Kinkoph RJ 2nd, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):498–9

Imaging of subcapsular hepatic and renal hematomas in pregnancy complicated by preeclampsia and the HELLP syndrome. Chan AD, et al. **J Clin Ultrasound** 1999 Jan; 27(1):35–40 (28 ref.)

Sonographic diagnosis of mesenteric hematoma. Chao HC, et al. **J Clin Ultrasound** 1999 Jun;27(5):284–6

Sonographic diagnosis of intramural duodenal hematomas. Lorente-Ramos RM, et al. **J Clin Ultrasound** 1999 May; 27(4):213–6

[Spontaneous hematoma of the abdominal wall: diagnostic error of abruptio placentae] Brühwiler H, et al. **Z Geburtshilfe Neonatol** 1999 May–Jun;203(3):126–7 (Eng. Abstr.) **(Ger)**

VETERINARY

Benign masses in the pericardium of two dogs. Simpson DJ, et al. **Aust Vet J** 1999 Apr;77(4):225–9

Laparoscopic diagnosis of subcapsular splenic hematoma in a horse. Mehl ML, et al. **J Am Vet Med Assoc** 1998 Oct 15;213(8):1171–3, 1133

Neodymium:yttrium-aluminum-garnet laser-assisted excision of progressive ethmoid hematomas in horses: 20 cases (1986–1996). Rothaug PG, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1037–41

Diagnosis of a haematoma in the uterine broad ligament associated with a dystocia in a cow using ultrasonography. Cockcroft PD. **Vet Rec** 1999 Jun 12;144(24):675–6

VIROLOGY

[Splenic hematoma during infectious mononucleosis: non-operative treatment (letter)] Lambotte O, et al. **Presse Med** 1998 Feb 7;27(5):209 **(Fre)**

HEMATOMA, EPIDURAL

Five patients with a spontaneous spinal epidural hematoma (SSEH) [letter] Groen RJ. **Spine** 1999 Jul 15; 24(14):1499–500

CHEMICALLY INDUCED

Spontaneous spinal epidural hematoma associated with thrombolysis and anticoagulation therapy: report of three cases. Van Schaeybroeck P, et al. **Clin Neurol Neurosurg** 1998 Dec;100(4):283–7

Delayed severe airway obstruction due to hematoma following stellate ganglion block. Mishio M, et al. **Reg Anesth Pain Med** 1998 Sep–Oct;23(5):516–9

Spinal epidural hematoma following MI [letter; comment] Groen RJ. **Surg Neurol** 1999 Mar;51(3):349–50. Comment on: Surg Neurol 1998 May;49(5):520–2; discussion 523.

COMPLICATIONS

A pain in the back! Jan W, et al. **Br J Radiol** 1999 Jan; 72(853):99–100

Epileptic falling spells after epidural haematoma in adult Down's syndrome. Yoshida M, et al. **Brain Inj** 1999 Mar; 13(3):205–11

Association between spinal extradural and cerebral arteriovenous malformations appearing as acute paraplegia after epidural hemorrhage [letter] Bozzao A, et al. **Eur Radiol** 1999;9(5):1007–8

Spinal epidural hematoma and high thromboembolic risk: between Scylla and Charybdis. Phuong LK, et al. **Mayo Clin Proc** 1999 Feb;74(2):147–9

Spinal epidural haematoma in a patient with haemophilia-B. Meena AK, et al. **Spinal Cord** 1998 Sep;36(9):658–60

Spontaneous spinal epidural hematoma with spinal cord compression complicating plasma cell myeloma. A case report. Hayem G, et al. **Spine** 1998 Nov 15;23(22):2432–5

[A case of systemic lupus erythematosus associated with spinal epidural hematoma] Satoh S, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug;21(4):166–71 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Acute spontaneous spinal epidural hematomas. Fukui MB, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1365–72

Stroke vignette. Epidural hematoma and hemorrhagic infarction mimicking a left temporal meningioma. Schwartz A, et al. **Cerebrovasc Dis** 1999 Jul–Aug;9(4):251–2

Chronic lumbar epidural hematoma in a patient who had spondylolysis at the third lumbar vertebra. Report of a rare case involving a seventeen-year-old adolescent. Nagata K, et al. **J Bone Joint Surg Am** 1998 Oct;80(10):1515–20

MRI of acute spinal epidural hematomas. Sklar EM, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):238–43

Retroclival epidural hematoma secondary to decompressive craniectomy in cerebellar infarction: MR demonstration. Calli C, et al. **J Neuroradiol** 1998 Oct;25(3):229–32

Spontaneous chronic spinal epidural hematoma of the lumbar spine. Riffaud L, et al. **J Neuroradiol** 1999 Mar;26(1 Suppl):64–7

Epidural hematoma in infants: a different entity? Beni-Adani L, et al. **J Trauma** 1999 Feb;46(2):306–11

Factors influencing the functional outcome of patients with acute epidural hematomas: analysis of 200 patients undergoing surgery. Lee EJ, et al. **J Trauma** 1998 Nov; 45(5):946–52

Abrupt exacerbation of acute subdural hematoma mimicking benign acute epidural hematoma on computed tomography--case report. Kato K, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):33–5

Postcontrast magnetic resonance imaging to predict progression of traumatic epidural and subdural hematomas in the acute stage [letter] Kanat A, et al. **Neurosurgery** 1999 Mar;44(3):685–6

Acute nontraumatic spinal epidural hematomas. An important differential diagnosis in spinal emergencies. Alexiadou-Rudolf C, et al. **Spine** 1998 Aug 15; 23(16):1810–3

[Extradural hematoma in the posterior fossa without fracture in a neonate] Piyaraly S, et al. **Arch Pediatr** 1998 Feb; 5(2):204–5 **(Fre)**

[Acute spinal epidural hematoma--comments on MRI diagnosis using fluid-attenuated inversion recovery sequence (FLAIR)] Textor HJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):231–2 **(Ger)**

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

[Right sensory-motor syndrome as the presentation of a spontaneous cervico-thoracic epidural hematoma] Castro M, et al. **Rev Neurol** 1998 Oct;27(158):591–4 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Acute epidural haematoma in a patient with Paget's disease of the skull. Strojnik T. **Acta Neurochir (Wien)** 1998; 140(8):835–6

Epidural haematoma following anticoagulant treatment in a patient with an indwelling epidural catheter [letter; comment] Checketts MR, et al. **Anaesthesia** 1999 Jan; 54(1):87–8. Comment on: Anaesthesia 1998 Jul;53(7):691–5.

Spinal haematoma following epidural anaesthesia in a patient with eclampsia. Yuen TS, et al. **Anaesthesia** 1999 Apr; 54(4):350–4

Epidural hematoma after ventriculoperitoneal shunt surgery. Report of two cases. Pereira CU, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):629–32

Spinal epidural hematoma complicating active systemic lupus erythematosus. Goker B, et al. **Arthritis Rheum** 1999 Mar; 42(3):577–8

Epidural haematoma after removal of an epidural catheter in a patient receiving high-dose enoxaparin [see comments] Yin B, et al. **Br J Anaesth** 1999 Feb;82(2):288–90. Comment in: Br J Anaesth 1999 Feb;82(2):164–7.

Epidural hematoma following epidural catheter placement in a patient with chronic renal failure. Basta M, et al. **Can J Anaesth** 1999 Mar;46(3):271–4

Spinal epidural hematoma caused by extradural arteriovenous

malformation: a case report and review of the literature. Saeheng S, et al. **J Med Assoc Thai** 1999 May;82(5):520–7 (80 ref.)

Resolution of extensive spinal epidural haematoma with conservative treatment [letter] Kumar R, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):949–50

Extradural hematomas in children. Maggi G, et al. **J Neurosurg Sci** 1998 Jun;42(2):95–9

Epidural haematoma and stroller-associated injury [letter; comment] Donald TG. **J Paediatr Child Health** 1998 Aug; 34(4):402. Comment on: J Paediatr Child Health 1997 Oct;33(5):446–7.

A case of unpaired anterior cerebral artery occlusion producing akinetic mutism [letter] Oomman A, et al. **Neurol India** 1999 Jun;47(2):157–8

Spontaneous spinal extradural haematoma [letter] Tewari MK, et al. **Neurol India** 1999 Jun;47(2):159

Spontaneous spinal epidural hematoma in children. Patel H, et al. **Pediatr Neurol** 1998 Oct;19(4):302–7 (38 ref.)

Bilateral epidural hematoma in a pyknodysostotic child. Cirak B, et al. **Pediatr Neurosurg** 1999 Jan;30(1):33–4

Delayed severe airway obstruction due to hematoma following stellate ganglion block. Mishio M, et al. **Reg Anesth Pain Med** 1998 Sep–Oct;23(5):516–9

Small cell lung carcinoma causing epidural hematoma: case report. Simmons NE, et al. **Surg Neurol** 1999 Jan;51(1):56–9

[Combined chronic subdural and acute epidural hematoma secondary to metastatic hepatocellular cancer: case report] Endo M, et al. **No Shinkei Geka** 1999 Apr;27(4):331–4 (Eng. Abstr.) **(Jpn)**

[Spontaneous epidural hematoma. Report of two cases] Hamamoto O, et al. **Arq Neuropsiquiatr** 1998 Sep; 56(3A):453–6 (Eng. Abstr.) **(Por)**

[Spontaneous epidural spinal hematoma: report of 2 cases and review of the literature] Horcajadas A, et al. **Neurologia** 1998 Oct;13(8):401–4 (26 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Spinal epidural haematoma in haemophilia A. Schmitz A, et al. **Haemophilia** 1998 Jan;4(1):51–5

PATHOLOGY

Resolution of extensive spinal epidural haematoma with conservative treatment [letter] Kumar R, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):949–50

[Spontaneous epidural spinal hematoma] Casado I, et al. **Neurologia** 1998 Oct;13(8):400 **(Spa)**

PHYSIOPATHOLOGY

Brain eigenfrequency shifting as a sensitive index of cerebral compliance in an experimental model of epidural hematoma in the rabbit: preliminary study [see comments] Douzinas EE, et al. **Crit Care Med** 1999 May;27(5):978–84. Comment in: Crit Care Med 1999 May;27(5):869–70.

Does it leak in or does it leak out. Concerning the article by Malek et al., Pediatr Neurosurg 1997;26:160–165 [letter] Akagami R, et al. **Pediatr Neurosurg** 1999 Feb;30(2):109–10

RADIOGRAPHY

The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. van den Brink WA, et al. **Acta Neurochir (Wien)** 1999;141(5):509–14

Conservative management of epidural hematomas: is it safe and is it cost-effective? [comment] Shah MV. **AJNR Am J Neuroradiol** 1999 Jan;20(1):115–6. Comment on: AJNR Am J Neuroradiol 1999 Jan;20(1):107–13.

Follow-up of conservatively managed epidural hematomas: implications for timing of repeat CT [see comments] Sullivan TP, et al. **AJNR Am J Neuroradiol** 1999 Jan; 20(1):107–13. Comment in: AJNR Am J Neuroradiol 1999 Jan;20(1):115–6.

SURGERY

Is the size of an epidural haematoma related to outcome? Paterniti S, et al. **Acta Neurochir (Wien)** 1998;140(9):953–5

Factors influencing the functional outcome of patients with acute epidural hematomas: analysis of 200 patients undergoing surgery. Lee EJ, et al. **J Trauma** 1998 Nov; 45(5):946–52

Decompressive surgery for "pure" epidural hematomas: does neurosurgical expertise improve the outcome? Wester K. **Neurosurgery** 1999 Mar;44(3):495–500; discussion 500–2

Bilateral epidural hematoma in a pyknodysostotic child. Cirak B, et al. **Pediatr Neurosurg** 1999 Jan;30(1):33–4

Small cell lung carcinoma causing epidural hematoma: case report. Simmons NE, et al. **Surg Neurol** 1999 Jan;51(1):56–9

[The initial treatment and the site of care in brain injury] Helén P, et al. **Duodecim** 1995;111(21):1993–8 (19 ref.) **(Fin)**

[What are the indications for neurosurgery in the early stage of head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):58–71 (31 ref.) **(Fre)**

[Prepontine epidural hemorrhage] Müller JU, et al. **Zentralbl Neurochir** 1998;59(3):185–8 (8 ref.) (Eng. Abstr.) **(Ger)**

[Successful emergency operation for subdural hematoma and acute epidural hematoma in a patient with acute promyelocytic leukemia] Yamaji S, et al. **Rinsho Ketsueki** 1999 Jul;40(7):606–9 (Eng. Abstr.) **(Jpn)**

THERAPY

Conservative management of epidural hematomas: is it safe and is it cost-effective? [comment] Shah MV. **AJNR Am J Neuroradiol** 1999 Jan;20(1):115–6. Comment on: AJNR Am J Neuroradiol 1999 Jan;20(1):107–13.

Follow-up of conservatively managed epidural hematomas: implications for timing of repeat CT [see comments] Sullivan TP, et al. **AJNR Am J Neuroradiol** 1999 Jan; 20(1):107–13. Comment in: AJNR Am J Neuroradiol 1999 Jan;20(1):115–6.

Magnetic resonance imaging-monitored conservative management of traumatic spinal epidural hematomas. Report of four cases. La Rosa G, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):128–32

Asymptomatic or minimally symptomatic traumatic epidural haematomas: comparison of the results of surgical and conservative management related to SPECT and neuropsychological tests. Preliminary results. Cayli S, et al. **Neurosurg Rev** 1998;21(4):226–31

Loss prevention case of the month. Patient care is a collaborative effort. Avery JK. **Tenn Med** 1998 Oct; 91(10):388–9

HEMATOMA, SUBDURAL

BLOOD

Serum protein exudation in chronic subdural haematomas: a mechanism for haematoma enlargement? Fujisawa H, et al. **Acta Neurochir (Wien)** 1998;140(2):161–5; discussion 165–6

Increased concentration of vascular endothelial growth factor (VEGF) in chronic subdural hematoma [letter] Suzuki K, et al. **J Trauma** 1999 Mar;46(3):532–3

[The relationship between coagulation time and bilateral occurrence in chronic subdural hematoma] Oyama H, et al. **No To Shinkei** 1999 Apr;51(4):325–30 (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Bilateral posterior fossa subdural haematomas secondary to anticoagulant therapy. Lagares A, et al. **Acta Neurochir (Wien)** 1998;140(10):1097–8

Chronic subdural haematoma: a possible relationship with tamoxifen. Missori P, et al. **Clin Neurol Neurosurg** 1998 Dec;100(4):268–70

Early vitamin K deficiency bleeding after maternal phenobarbital intake: management of massive intracranial haemorrhage by minimal surgical intervention. Renzulli P, et al. **Eur J Pediatr** 1998 Aug;157(8):663–5

Subdural hematoma mimicking a transient ischemic attack due to antihypertensive medication. Mishriki YY. **South Med J** 1999 Sep;92(9):905–6

COMPLICATIONS

Meningioma associated with chronic subdural hematoma. Scarrow AM, et al. **Acta Neurochir (Wien)** 1998; 140(12):1317–8

Chronic subdural haematomas and Parkinsonian syndromes. Wiest RG, et al. **Acta Neurochir (Wien)** 1999;141(7):753–7; discussion 757–8 (32 ref.)

Case of the month: education of the pathologist. Autopsy Committee of the College of American Pathologists. Hanzlick R, et al. **Arch Intern Med** 1999 May 10; 159(9):907–8

Gerstmann's syndrome associated with chronic subdural haematoma: a case report. Maeshima S, et al. **Brain Inj** 1998 Aug;12(8):697–701

Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat. Doppenberg EM, et al. **J Neurotrauma** 1999 Feb; 16(2):123–33

Subdural empyema caused by hematogenous dissemination from an abscess in thigh to a preexisting chronic subdural hematoma--case report. Kawamoto S, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):743–5

Subdural haematoma in a child with glutaric aciduria type I. Köhler M, et al. **Pediatr Radiol** 1998 Aug;28(8):582

[Subperiosteal hematoma of the orbit associated with a frontal extradural hematoma] Bourdon EL, et al. **J Fr Ophtalmol** 1999 Jun–Jul;22(6):659–61 (Eng. Abstr.) **(Fre)**

[A case of Salmonella subdural empyema developed in chronic subdural hematoma] Kan M, et al. **No Shinkei Geka** 1998 Oct;26(10):903–7 (Eng. Abstr.) **(Jpn)**

[MRI of the impending cerebral herniation caused by chronic subdural hematoma] Fujita K. **No To Shinkei** 1999 Jul; 51(7):648–9 **(Jpn)**

[Kernohan notch] Takehara S, et al. **No To Shinkei** 1998 Aug;50(8):774–5 **(Jpn)**

DIAGNOSIS

Bilateral ICP monitoring: its importance in detecting the severity of secondary insults. Chambers IR, et al. **Acta Neurochir Suppl (Wien)** 1998;71:42–3

Slow-onset subdural hematoma, evolving into paraplegia, after attempted spinal anesthesia--a case report. Cabitza P, et al. **Acta Orthop Scand** 1998 Dec;69(6):650–2

Calcified chronic subdural hematoma: case report. Yan HJ, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):521–5

Meningioma recurrence at a different site masquerading as a subdural hematoma. Case report. Timothy J, et al. **J Neurosurg** 1999 Sep;91(3):496–8

Angiographically occult dural arteriovenous malformation in the anterior cranial fossa--case report. Hattori T, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):291–3

Abrupt exacerbation of acute subdural hematoma mimicking benign acute epidural hematoma on computed tomography--case report. Kato K, et al. **Neurol Med Chir (Tokyo)** 1999 Jan;39(1):33–5

Characteristics of symptomatic chronic subdural haematomas on high-field MRI. Kaminogo M, et al. **Neuroradiology** 1999 Feb;41(2):109–16

Chronic spinal subdural haematoma associated with intracranial subdural haematoma: CT and MRI. Tillich M, et al. **Neuroradiology** 1999 Feb;41(2):137–9

Postcontrast magnetic resonance imaging to predict progression of traumatic epidural and subdural hematomas in the acute stage [letter] Kanat A, et al. **Neurosurgery** 1999 Mar;44(3):685–6

Subdural hematoma mimicking a transient ischemic attack due to antihypertensive medication. Mishriki YY. **South Med J** 1999 Sep;92(9):905–6

Geometry and subdural hematoma volume [letter; comment] Kasner SE. **Stroke** 1999 Jan;30(1):188. Comment on: Stroke 1998 Sep;29(9):1799–801.

[Acute severe headache: a subarachnoidal hemorrhage?] Linn FH, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13; 143(11):545–50 (17 ref.) (Eng. Abstr.) **(Dut)**

[Intermittent paraparesis as manifestation of a bilateral chronic subdural hematoma] Schaller B, et al. **Schweiz Med Wochenschr** 1999 Jul 27;129(29–30):1067–72 (Eng. Abstr.) **(Ger)**

[MRI of the impending cerebral herniation caused by chronic subdural hematoma] Fujita K. **No To Shinkei** 1999 Jul; 51(7):648–9 **(Jpn)**

[Acute hematoma between the dura and the external membrane of hematoma capsule of after the removal of bilateral chronic subdural hematomas by trepanation. Case report] Dreczka J, et al. **Neurol Neurochir Pol** 1998 Jul–Sep;32(4):979–85 (Eng. Abstr.) **(Pol)**

[Chronic subdural hematoma of the posterior cranial fossa] Kachkov IA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):30–1 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Local coagulofibrinolysis in the postsurgical recovery of patients with chronic subdural haematoma. Matsumoto M, et al. **Acta Neurochir (Wien)** 1999;141(2):177–81

EPIDEMIOLOGY

Subdural haemorrhages in infants: population based study [see comments] Jayawant S, et al. **BMJ** 1998 Dec 5; 317(7172):1558–61. Comment in: BMJ 1998 Dec 5;317(7172):1538–9.

Chronic and subacute subdural hematoma in the adult population. The Puerto Rico experience. De Jesús O, et al. **P R Health Sci J** 1998 Sep;17(3):227–33

ETIOLOGY

Intracystic hemorrhage of the middle fossa arachnoid cyst and subdural hematoma caused by ruptured middle cerebral artery aneurysm. Huang D, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1284–6

Chronic subdural haematoma following caesarean section under spinal anaesthesia. Akpek EA, et al. **Anaesth Intensive Care** 1999 Apr;27(2):206–8

Subdural haemorrhages in infants. Almost all are due to abuse but abuse is often not recognised [editorial; comment] [published erratum appears in BMJ 1999 Jan 9;318(7176):74] Lloyd B. **BMJ** 1998 Dec 5;317(7172):1538–9. Comment on: BMJ 1998 Dec 5;317(7172):1538–9.

Recurrent subdural haematoma as the primary and sole manifestation of chronic lymphocytic leukaemia. Bromberg JE, et al. **Br J Neurosurg** 1998 Aug;12(4):373–6

Chronic subdural haematoma, an unusual injury from playing basketball. Keller TM, et al. **Br J Sports Med** 1998 Dec; 32(4):338–9

Origin of chronic subdural haematoma and relation to traumatic subdural lesions. Lee KS, et al. **Brain Inj** 1998 Nov;12(11):901–10 (96 ref.)

Subdural hematomas in children under 2 years. Accidental or inflicted? A 10-year experience. Tzioumi D, et al. **Child Abuse Negl** 1998 Nov;22(11):1105–12

Moyamoya disease causes acute subdural hematomas and sudden death: a case report. Shen WC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):619–23

Cerebral herniation through a subdural membrane defect following non-accidental injury. Ceccherini AF, et al. **Clin Radiol** 1999 Aug;54(8):550–2

Intracranial subdural haematoma complicates accidental dural tap during labour. Sköldefors EK, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;81(1):119–21

Severe factor V deficiency presenting as subdural haematoma in the newborn [letter] Ehrenforth S, et al. **Eur J Pediatr** 1998 Dec;157(12):1032

Extradural haematoma--a preventable cause of death. Caird J, et al. **Ir Med J** 1999 Mar;92(2):270–1

Spontaneous spinal subdural hematoma in a young adult with hemophilia. Friday RY, et al. **J Natl Med Assoc** 1999 May; 91(5):289–94

Subdural hematoma from a Type I spinal arteriovenous malformation. Case report. Han PP, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):255–7

Three-dimensional finite element analysis of subdural hematoma. Huang HM, et al. **J Trauma** 1999 Sep; 47(3):538–44

Spinal subdural hematoma: a rare complication of lumbar puncture. Case report and review of the literature. Egede LE, et al. **Md Med J** 1999 Jan–Feb;48(1):15–7 (15 ref.)

Heading injury precipitating subdural hematoma associated with arachnoid cysts—two case reports. Kawanishi A, et al. **Neurol Med Chir (Tokyo)** 1999 Mar;39(3):231–3

Lumbar spinal subdural hematoma following craniotomy—case report. Shimizu S, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):299–301

Acute posttraumatic subdural hematomas: "intradural" computed tomographic appearance as a favorable prognostic factor [letter; comment] Kanat A. **Neurosurgery** 1998 Sep;43(3):649–50. Comment on: Neurosurgery 1998 Jan;42(1):51–5.

Spinal subdural hematoma after resection of an acoustic neuroma. Marx SV, et al. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):540–2

Meningioma associated with acute subdural hematoma—case report. Sunada I, et al. **Radiat Med** 1998 Nov–Dec; 16(6):483–6

Acute subdural hematoma and pachymeningitis carcinomatosa: case report. Caputi F, et al. **Rev Neurol (Paris)** 1999 May;155(5):383–5 (10 ref.)

Falx meningioma presenting as acute subdural hematoma: case report. Okuno S, et al. **Surg Neurol** 1999 Aug; 52(2):180–4

[Intracranial subdural hematoma during spinal anesthesia] Petrognani R, et al. **Med Trop (Mars)** 1998;58(3):271–2 (Eng. Abstr.) **(Fre)**

[Bilateral intracranial subdural hematoma following lumbar puncture: report of a case] Lavie F, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):703–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Combined chronic subdural and acute epidural hematoma secondary to metastatic hepatocellular cancer: case report] Endo M, et al. **No Shinkei Geka** 1999 Apr;27(4):331–4 (Eng. Abstr.) **(Jpn)**

[Acute encephalopathy and a pericerebral fluid collection in the battered child syndrome] Abenia Usón P, et al. **An Esp Pediatr** 1999 Jun;50(6):610–2 (15 ref.) **(Spa)**

MORTALITY

[The epidemiological characteristics of fatal subdural hematomas in forensic medical practice] Pigolkin IuI, et al. **Sud Med Ekspert** 1999 Mar–Apr;42(2):12–4 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Intralaminar dural haematoma developing in the contralateral convexity after temporal lobectomy [letter] Chung CK, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):248–9

Detection of ultra-early brain damage after acute subdural hematoma in the rat by magnetic resonance imaging. Tsuchida E, et al. **J Neurotrauma** 1999 Jul;16(7):595–602

Ethanol level differential between postmortem blood and subdural hematoma. Riggs JE, et al. **Mil Med** 1998 Oct; 163(10):722–4

Quantitative kinetic analysis of blood vessels in the outer membranes of chronic subdural hematomas. Mori K, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):697–702; discussion 702–3

Compression of the midbrain. Chalela J, et al. **Neurology** 1999 Jul 22;53(2):423

Serial magnetic resonance imaging findings for a spontaneously resolving spinal subdural hematoma: case report [letter; comment] Chung CK. **Neurosurgery** 1998 Dec;43(6):1495. Comment on: Neurosurgery 1998 Feb;42(2):398–400; discussion 400–1.

Geometry and subdural hematoma volume [letter; comment] Kasner SE. **Stroke** 1999 Jan;30(1):188. Comment on: Stroke 1998 Sep;29(9):1799–801.

[Histological study of vascular structure between the dura mater and the outer membrane in chronic subdural hematoma in an adult] Tanaka T, et al. **No Shinkei Geka** 1999 May;27(5):431–6 (Eng. Abstr.) **(Jpn)**

[The morphological characteristics of chronic subdural hematomas] Pigolkin IuI, et al. **Sud Med Ekspert** 1999 Jan–Feb;42(1):11–4 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Comparison of cerebral blood flow and injury following intracerebral and subdural hematoma in the rat. Patel TR, et al. **Brain Res** 1999 May 22;829(1–2):125–33

Favorable recovery from bilateral loss of somatosensory evoked potentials. Schwarz S, et al. **Crit Care Med** 1999 Jan;27(1):182–7

[Spontaneous resolution of idiopathic spinal subdural hematoma: case report] Tamano Y, et al. **No Shinkei Geka** 1998 Nov;26(11):1013–8 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. van den Brink WA, et al. **Acta Neurochir (Wien)** 1999;141(5):509–14

Computed tomography characteristics suggestive of spontaneous resolution of chronic subdural hematoma. Horikoshi T, et al. **Neurol Med Chir (Tokyo)** 1998 Sep; 38(9):527–32; discussion 532–3

Acute posttraumatic subdural hematomas: "intradural" computed tomographic appearance as a favorable prognostic factor [letter; comment] Kanat A. **Neurosurgery** 1998 Sep;43(3):649–50. Comment on: Neurosurgery 1998 Jan;42(1):51–5.

Subdural haematoma in a child with glutaric aciduria type I. Köhler M, et al. **Pediatr Radiol** 1998 Aug;28(8):582

Sudden right-sided hemiparesis in a middle-aged woman. Mehta JS, et al. **Postgrad Med J** 1998 Oct;74(876):627–8

[Falls of an old woman: chronic subdural hematoma] Permal S, et al. **Rev Med Interne** 1999 Apr;20(4):369–70 **(Fre)**

[Extravasation of contrast media in acute subdural hematoma during three-dimensional CT angiography: a case report] Kinoshita Y, et al. **No Shinkei Geka** 1999 Feb;27(2):157–61 (Eng. Abstr.) **(Jpn)**

[A resolving sign of acute subdural hematoma: from report of two cases] Suzuki Y, et al. **No Shinkei Geka** 1998 Nov; 26(11):1025–9 (Eng. Abstr.) **(Jpn)**

SURGERY

A new forceps for the safe and easier insertion of subdural catheter: technical note. Birbilis T, et al. **Acta Neurochir (Wien)** 1998;140(7):721–2

Burr hole evacuation of chronic subdural haematomas followed by continuous inflow and outflow irrigation. Hennig R, et al. **Acta Neurochir (Wien)** 1999;141(2):171–6

Subdural haematomas in the elderly: experience with treatment by trephine craniotomy and not closing the dura or replacing the bone plate. Beatty RA. **Br J Neurosurg** 1999 Feb;13(1):60–4

Nontraumatic acute spinal subdural hematoma: report of five cases and review of the literature. Domenicucci M, et al. **J Neurosurg** 1999 Jul;91(1 Suppl):65–73 (87 ref.)

A fatal acute subdural hematoma occurring after evacuation of "contralateral" chronic subdural hematoma. Turgut M, et al. **J Neurosurg Sci** 1998 Mar;42(1):61–3

Experience with an ultrasonic aspirator in neuroendoscopy. Oka K, et al. **Minim Invasive Neurosurg** 1999 Mar; 42(1):32–4

Bilateral chronic subdural hematomas resulting in unilateral oculomotor nerve paresis and brain stem symptoms after operation—case report. Okuchi K, et al. **Neurol Med Chir (Tokyo)** 1999 May;39(5):367–71

New device to treat chronic subdural hematoma—hollow screw. Emonds N, et al. **Neurol Res** 1999 Jan;21(1):77–8

Recurrence factors for chronic subdural hematomas after burr-hole craniostomy and closed system drainage. Matsumoto K, et al. **Neurol Res** 1999 Apr;21(3):277–80

Successful treatment of traumatic acute posterior fossa subdural hematoma: report of two cases. Hećimović I, et al. **Surg Neurol** 1999 Mar;51(3):247–51

[The initial treatment and the site of care in brain injury] Helén P, et al. **Duodecim** 1995;111(21):1993–8 (19 ref.) **(Fin)**

[What are the indications for neurosurgery in the early stage of head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):58–71 (31 ref.) **(Fre)**

[Chronic subdural hematoma in patients over 80 years of age] Bourgeois P, et al. **Neurochirurgie** 1999 May; 45(2):124–8 (Eng. Abstr.) **(Fre)**

[Chronic subdural hematoma in utero. Case report with literature review] Diaz A, et al. **Neurochirurgie** 1998 Apr; 44(2):124–6 (Eng. Abstr.) **(Fre)**

[Chronic bilateral subdural hematomas] Penchet G, et al. **Neurochirurgie** 1998 Nov;44(4):247–52 (Eng. Abstr.) **(Fre)**

[Use of Ommaya CSF reservoir for refractory chronic subdural hematoma] Sato M, et al. **No Shinkei Geka** 1999 Apr;27(4):323–8 (Eng. Abstr.) **(Jpn)**

[Successful emergency operation for subdural hematoma and acute epidural hematoma in a patient with acute promyelocytic leukemia] Yamaji S, et al. **Rinsho Ketsueki** 1999 Jul;40(7):606–9 (Eng. Abstr.) **(Jpn)**

[Acute hematoma between the dura and the external membrane of hematoma capsule of after the removal of bilateral chronic subdural hematomas by trepanation. Case report] Dreczka J, et al. **Neurol Neurochir Pol** 1998 Jul–Sep;32(4):979–85 (Eng. Abstr.) **(Pol)**

THERAPY

Surgery or conservative treatment in children with traumatic intracerebral haematoma. Mandera M, et al. **Childs Nerv Syst** 1999 May;15(5):267–9; discussion 270

[Treatment of chronic subdural hematoma with a closed drainage system] Beneš J, et al. **Rozhl Chir** 1999 Apr; 78(4):158–62 (Eng. Abstr.) **(Cze)**

VIROLOGY

Fever, mucocutaneous haemorrhage, and severe headache during an epidemic of haemorrhagic fever. Dey AB, et al. **Postgrad Med J** 1998 Jul;74(873):433–5

HEMATOMETRA

COMPLICATIONS

[Surgical treatment in a case of partial vaginal obliteration coexisting with hematometra, hematocolpos and other congenital defects] Goluda M, et al. **Ginekol Pol** 1999 May; 70(5):292–4 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Hematometra and extended vaginal haematoma after laser conization. A case report. Giannacopoulos K, et al. **Eur J Gynaecol Oncol** 1998;19(6):569–70

Resectoscopic treatment of uterus didelphys with unilateral imperforate vagina complicated by hematocolpos and hematometra: case report. Cicinelli E, et al. **Fertil Steril** 1999 Sep;72(3):553–5

SURGERY

[Surgical treatment in a case of partial vaginal obliteration coexisting with hematometra, hematocolpos and other congenital defects] Goluda M, et al. **Ginekol Pol** 1999 May; 70(5):292–4 (Eng. Abstr.) **(Pol)**

THERAPY

Transcervical metallic stents for drainage of uterine collections. Gooding JM, et al. **J Vasc Interv Radiol** 1999 May;10(5):629–33

HEMATOPOIESIS

(R)evolutionary considerations in hematopoietic development. Cooper DD, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:83–93 (60 ref.)

Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells. Medin JA, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:233–40; discussion 240–2

Hematopoietic commitment during embryogenesis. Robertson S, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:9–15; discussion 15–6 (37 ref.)

Retroviral-fibronectin interactions in transduction of mammalian cells. Williams DA. **Ann N Y Acad Sci** 1999 Apr 30;872:109–13; discussion 113–4 (15 ref.)

Human red cells from pre (hepato splenic-late fetal) and postnatal (bone marrow-adult's) stages of haemopoiesis: Na+/Li+ exchange kinetic. Taborda D, et al. **Arch Physiol Biochem** 1998 Apr;106(2):81–7

Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. Stunnenberg HG, et al. **Biochim Biophys Acta** 1999 Jan 29;1423(1):F15–33 (159 ref.)

Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Ailles LE, et al. **Blood** 1999 Sep 1;94(5):1761–72

Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 [see comments] Aoki Y, et al. **Blood** 1999 Jun 15;93(12):4034–43 . Comment in: Blood 1999 Jun 15;93(12):4031–3.

CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. Arai A, et al. **Blood** 1999 Jun 1;93(11):3713–22

Lineage-restricted expression of protein kinase C isoforms in hematopoiesis. Bassini A, et al. **Blood** 1999 Feb 15; 93(4):1178–88

Altered hematopoiesis in murine sickle cell disease. Blouin MJ, et al. **Blood** 1999 Aug 15;94(4):1451–9

Long-term contribution to the myeloid compartment by lineage-committed stem cells. Chen CC, et al. **Blood** 1998 Nov 1;92(9):3210–7

Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Gupta P, et al. **Blood** 1998 Dec 15; 92(12):4641–51

The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Haddad E, et al. **Blood** 1999 Jul 15;94(2):509–18

Does recombinant human granulocyte colony-stimulating factor really prime marrow stem cells in mice and humans? [letter; comment] Johnsen HE. **Blood** 1999 Jun 15; 93(12):4446–9. Comment on: Blood 1998 Nov 1;92(9):3489–90.

The mouse GATA-2 gene is expressed in the para-aortic splanchnopleura and aorta-gonads and mesonephros region. Minegishi N, et al. **Blood** 1999 Jun 15; 93(12):4196–207

Periodic hematological disorders [letter; comment] Morley A. **Blood** 1999 Jun 1;93(11):4023–4. Comment on: Blood 1998 Oct 15;92(8):2629–40.

Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Persons DA, et al. **Blood** 1999 Jan 15;93(2):488–99

The myeloid-lymphoid initiating cell (ML-IC) assay assesses the fate of multipotent human progenitors in vitro. Punzel M, et al. **Blood** 1999 Jun 1;93(11):3750–6

Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Rivière C, et al. **Blood** 1999 Mar 1;93(5):1511–23

Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on

megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Sakamaki S, et al. **Blood** 1999 Sep 15;94(6):1961–70

Neutrophilic cell production by combination of stem cell factor and thrombopoietin from CD34(+) cord blood cells in long-term serum-deprived liquid culture. Sawai N, et al. **Blood** 1999 Jan 15;93(2):509–18

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Somlo G, et al. **Blood** 1999 May 1; 93(9):2798–806

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Szilvassy SJ, et al. **Blood** 1999 Mar 1;93(5):1557–66

Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Taniguchi T, et al. **Blood** 1999 Jun 15; 93(12):4167–78

Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Amigo ML, et al. **Bone Marrow Transplant** 1999 Aug;24(3):289–93

Circadian and seasonal variations of hematopoiesis in cord blood. Baudoux E, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S12

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. del Cañizo C, et al. **Bone Marrow Transplant** 1999 May;23(9):901–5

The number of particular hematopoietic progenitors cells and the haematopoietic recovery following Allo PBSCT. Knopińska-Posłuszny W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S92–5

Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Lowenthal RM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):763–70

Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Pecora AL. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S7–12 (33 ref.)

Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells. Schwartz GN, et al. **Bone Marrow Transplant** 1998 Sep;22(5):457–68

Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Peters UR, et al. **Cancer Res** 1999 Sep 1;59(17):4233–6

Effects of in utero alcohol exposure on B cell development in neonatal spleen and bone marrow. Moscatello KM, et al. **Cell Immunol** 1999 Feb 1;191(2):124–30

Hematopoietic reconstruction: new approaches. Moore MA. **Clin Cancer Res** 1995 Jan;1(1):3–9 (61 ref.)

Serum leptin level: possible association with haematopoiesis in adolescents, independent of body mass index and serum insulin. Hirose H, et al. **Clin Sci (Colch)** 1998 Jun; 94(6):633–6

Developmental hematopoiesis. Morales-Alcelay S, et al. **Crit Rev Immunol** 1998;18(6):485–501 (160 ref.)

Stimulation of hematopoiesis in vivo by stem cell factor. Andrews RG, et al. **Curr Opin Hematol** 1994 May; 1(3):187–96 (123 ref.)

Development of the definitive hematopoietic hierarchy in the mouse. Medvinsky AL, et al. **Dev Comp Immunol** 1998 May–Jun;22(3):289–301 (84 ref.)

Early hematopoiesis and developing lymphoid organs in the zebrafish. Willett CE, et al. **Dev Dyn** 1999 Apr; 214(4):323–36

Emergence of intraembryonic hematopoietic precursors in the pre-liver human embryo. Tavian M, et al. **Development** 1999 Feb;126(4):793–803

Direct evidence for an increase in thrombopoiesis after liver transplantation. Stiegler G, et al. **Eur J Clin Invest** 1998 Sep;28(9):755–9

Effects of hTNFalpha expression in T cells on haematopoiesis in transgenic mice. Glosli H, et al. **Eur J Haematol** 1999 Jul;63(1):50–60

HIV influence on hematopoiesis at the initial stage of infection. Spada C, et al. **Eur J Haematol** 1998 Oct; 61(4):255–60

Acquisition of CD24 expression by Lin-CD43+B220(low)ckit(hi) cells coincides with commitment to the B cell lineage. Hunte BE, et al. **Eur J Immunol** 1998 Nov;28(11):3850–6

Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Galotto M, et al. **Exp Hematol** 1999 Sep;27(9):1460–6

CD44 isoforms in normal and leukemic hematopoiesis. Ghaffari S, et al. **Exp Hematol** 1999 Jun;27(6):978–93 (184 ref.)

Hematopoietic dynamics in grey collies. Haurie C, et al. **Exp Hematol** 1999 Jul;27(7):1139–48

SZF1: a novel KRAB-zinc finger gene expressed in CD34+ stem/progenitor cells. Liu C, et al. **Exp Hematol** 1999 Feb; 27(2):313–25

Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses. Omori F, et al. **Exp Hematol** 1999 Feb;27(2):242–9

Ectopic overexpression of c-mpl by retroviral-mediated gene transfer suppressed megakaryopoiesis but enhanced erythropoiesis in mice. Yan XQ, et al. **Exp Hematol** 1999 Sep;27(9):1409–17

Self-renewal, maturation, and differentiation of the rat myelomonocytic hematopoietic stem cell. Lucas T, et al. **FASEB J** 1999 Feb;13(2):263–72

Human immunodeficiency virus and the hematopoietic repertoire: implications for gene therapy. Panoskaltsis N, et al. **Front Biosci** 1999 May 1;4:D457–67 (110 ref.)

A role for G-CSF receptor signaling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. Semerad CL, et al. **Immunity** 1999 Aug; 11(2):153–61

Lymphocyte development in fish and amphibians. Hansen JD, et al. **Immunol Rev** 1998 Dec;166:199–220 (159 ref.)

CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review). Yamanaka R, et al. **Int J Mol Med** 1998 Jan;1(1):213–21 (106 ref.)

Differential effects of IL-2 incubation on hematopoietic potential of autologous bone marrow and mobilized PBSC from patients with hematologic malignancies. Areman EM, et al. **J Hematother** 1999 Feb;8(1):39–44

Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. Ishida T, et al. **J Immunol** 1998 Nov 1;161(9):4842–51

Emergence of T cell progenitors without B cell or myeloid differentiation potential at the earliest stage of hematopoiesis in the murine fetal liver. Kawamoto H, et al. **J Immunol** 1999 Mar 1;162(5):2725–31

Senescent BALB/c mice exhibit decreased expression of lambda5 surrogate light chains and reduced development within the pre-B cell compartment. Sherwood EM, et al. **J Immunol** 1998 Nov 1;161(9):4472–5

Effects of fibroblast-mediated interleukin 3 and interleukin 6 gene therapy on hematopoiesis in mice treated with 5-fluorouracil. Cao X, et al. **J Mol Med** 1998 Oct; 76(11):782–9

Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Eaves C, et al. **Leuk Res** 1998 Dec; 22(12):1085–96 (86 ref.)

Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Qu CK, et al. **Mol Cell Biol** 1998 Oct; 18(10):6075–82

CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control. Zhang W, et al. **Oncogene** 1999 Sep 2;18(35):4899–907

Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Watts TL, et al. **Pediatr Res** 1999 Jul;46(1):28–32

Effects of cord blood transfer on the hematopoietic recovery following sublethal irradiation in MRL lpr/lpr mice. Czarneski J, et al. **Proc Soc Exp Biol Med** 1999 Feb; 220(2):79–87

CD95 (APO-1/Fas) in hematopoietic diseases. Debatin KM. **Results Probl Cell Differ** 1998;24:157–74 (130 ref.)

KDR receptor: a key marker defining hematopoietic stem cells. Ziegler BL, et al. **Science** 1999 Sep 3;285(5433):1553–8

Is donor-derived long-term and multilineage hematopoiesis established after liver transplantation? Taniguchi H, et al. **Transplant Proc** 1998 Nov;30(7):3865–6

Bone marrow changes in heart transplant recipients with peripheral cytopenia. Castello A, et al. **Transplantation** 1999 Mar 27;67(6):840–6

In vivo disturbance of hematopoiesis in mice persistently infected with murine cytomegalovirus: impairment of stromal cell function. Mori T, et al. **Virology** 1999 Jan 20; 253(2):145–54

Blood cell precursors in context. Composition of the bone marrow microenvironment that supports B lymphopoiesis. Kincade PW, et al. **Vox Sang** 1998;74 Suppl 2:265–8 (19 ref.)

[Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation] Mayer J, et al. **Cas Lek Cesk** 1999 Mar 15;138(6):170–7 (Eng. Abstr.) **(Cze)**

[Affiliation between endothelial and intra-embryonic hematopoietic stem cells] Jaffredo T, et al. **J Soc Biol** 1999; 193(2):165–70 (Eng. Abstr.) **(Fre)**

[Manipulation of angiopoietc/hematopoietic potentials in the avian embryo] Pardanaud L, et al. **J Soc Biol** 1999; 193(2):171–9 (Eng. Abstr.) **(Fre)**

[Thrombopoietin: current and future status] Teramura M, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):421–8 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Rapid recovery of hemopoiesis and alleviation of symptoms similar to peri-engraftment syndrome after donor leukocyte infusion] Azuma T, et al. **Rinsho Ketsueki** 1999 Jan; 40(1):59–62 (Eng. Abstr.) **(Jpn)**

[Hemopoiesis in chronic myelomonocytic leukemia] Lugovskaia SA, et al. **Klin Lab Diagn** 1998 Oct;(10):8–11 (Eng. Abstr.) **(Rus)**

[An analysis of the correlations in the indices of the hemopoietic, biochemical and immunological characteristics in patients with acute myelo- and lymphoblastic leukemias] Pesotskaia LA. **Lik Sprava** 1999 Mar;(2):53–6 (Eng. Abstr.) **(Rus)**

[Experimental research on the cellular interactions during hemopoiesis] Michurina TV, et al. **Ontogenez** 1999 Jan–Feb;30(1):3–25 (90 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient. Bradley RR, et al. **Am J Kidney Dis** 1999 Aug;34(2):349–54

Interleukin-6 may play an important role in thrombopoiesis: a case of leukemic transformation from myelodysplastic syndrome [letter] Ota T, et al. **Ann Hematol** 1998 Nov; 77(5):243–4

Post-chemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4+ cell proliferation. Sara E, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):471–6

Increase of hematopoietic responses by triple or single helical conformer of an antitumor (1-->3)-beta-D-glucan preparation, Sonifilan, in cyclophosphamide-induced leukopenic mice. Tsuzuki A, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):104–10

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Gabrilovich D, et al. **Blood** 1998 Dec 1;92(11):4150–66

Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. Huber TL, et al. **Blood** 1998 Dec 1;92(11):4128–37

Synergistic activation of mitogen-activated protein kinase by cyclic AMP and myeloid growth factors opposes cyclic AMP's growth-inhibitory effects. Lee AW. **Blood** 1999 Jan 15;93(2):537–53

Interleukin-4 synergizes with Raf-1 to promote long-term proliferation and activation of c-jun N-terminal kinase. Levings MK, et al. **Blood** 1999 Jun 1;93(11):3694–702

Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Berger C, et al. **Bone Marrow Transplant** 1999 May; 23(10):983–90

Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Sietsma H, et al. **Cancer Res** 1998 Nov 1; 58(21):4840–4

Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Liu FJ, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1168–72

Selenium effects on gallium arsenide induced biochemical and immunotoxicological changes in rats. Flora SJ, et al. **Chem Biol Interact** 1999 Aug 30;122(1):1–13

Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. Anderson JE, et al. **Curr Opin Hematol** 1994 May;1(3):203–9 (43 ref.)

Hematologic effects of interleukin-1 and interleukin-6. Ruscetti FW. **Curr Opin Hematol** 1994 May;1(3):210–5 (37 ref.)

The cloning and expression of the cDNA for ovine stem cell factor (kit-ligand) and characterization of its in vitro haematopoietic activity. McInnes CJ, et al. **Cytokine** 1999 Apr;11(4):249–56

Blood cell induction in Xenopus animal cap explants: effects of fibroblast growth factor, bone morphogenetic proteins, and activin. Miyanaga Y, et al. **Dev Genes Evol** 1999 Feb; 209(2):69–76

The in vivo effect of liposomes on hematopoiesis. Jovcic G, et al. **Drug Dev Ind Pharm** 1999 Apr;25(4):517–21

The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect. Boyko VN, et al. **Drugs Exp Clin Res** 1998; 24(5–6):335–7

Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Ishimi Y, et al. **Endocrinology** 1999 Apr; 140(4):1893–900

In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. Comte L, et al. **Eur J Clin Invest** 1998 Oct; 28(10):856–63

All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. Visani G, et al. **Eur J Haematol** 1999 Sep;63(3):149–53

Megakaryocytopoiesis induced by PEG-rHu megakaryocyte growth and development factor (MGDF). Fattorossi A, et al. **Eur J Histochem** 1997;41 Suppl 2:13–4

In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure. Biljanović-Paunović L, et al. **Eur J Med Res** 1998 Dec 16;3(12):564–70

Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Bowen S, et al. **Exp Hematol** 1999 Mar;27(3):425–32

Modulation of histidine decarboxylase activity and cytokine synthesis in human leukemic cell lines: relationship with basophilic and/or megakaryocytic differentiation. Dy M, et al. **Exp Hematol** 1999 Aug;27(8):1295–305

Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic, and cyclical neutropenic patients before and during treatment with G-CSF. Haurie C, et al. **Exp Hematol** 1999 Mar;27(3):401–9

IL-1beta mediates diethyldithiocarbamate-induced

granulocyte colony-stimulating factor production and hematopoiesis. Kennedy SM, et al. **Exp Hematol** 1999 Feb; 27(2):210–6

Estrone potentiates myeloid cell differentiation: a role for 17 beta-hydroxysteroid dehydrogenase in modulating hemopoiesis. Mountford JC, et al. **Exp Hematol** 1999 Mar; 27(3):451–60

In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Patchen ML, et al. **Exp Hematol** 1998 Dec; 26(13):1247–54

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Platanias LC, et al. **Exp Hematol** 1999 Aug; 27(8):1315–21

Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Reykdal S, et al. **Exp Hematol** 1999 Mar;27(3):441–50

In vitro and in vivo effects of KT6352, a derivative of indolocarbazole compounds, on murine megakaryocytopoiesis. Shiotsu Y, et al. **Exp Hematol** 1998 Dec;26(13):1195–201

Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Woody MA, et al. **Exp Hematol** 1999 May; 27(5):811–6

Stimulatory effects of neopterin on hematopoiesis in vitro are mediated by activation of stromal cell function. Aizawa S, et al. **Hematol Oncol** 1998 Jun;16(2):57–67

Study of erythrocytes, hemoglobin levels, and menstrual cycle characteristics of women exposed to aromatic hydrocarbons. Georgieva T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S16–8

Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Mouthon MA, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1; 43(4):867–75

Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. Bhatia M, et al. **J Exp Med** 1999 Apr 5;189(7):1139–48

The haematopoietic effects of growth hormone and insulin-like growth factor-I. Merchav S. **J Pediatr Endocrinol Metab** 1998 Nov-Dec;11(6):677–85 (97 ref.)

Radioprotective effects of sodium tungstate on hematopoietic injury by exposure to 60Co gamma-rays in Wistar rats. Sato K, et al. **J Radiat Res (Tokyo)** 1999 Jun;40(2):101–13

Interferon-gamma and human megakaryopoiesis. Tsuji K, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):107–13 (44 ref.)

Do lipoxygenases modulate normal or aberrant lympho-hematopoiesis? [published erratum appears in Leuk Res 1999 May;23(5):519] Anderson KM, et al. **Leuk Res** 1999 Jan;23(1):51–6 (50 ref.)

Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis. Dräger AM, et al. **Leukemia** 1999 Jan; 13(1):62–9

A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group. Ossenkoppele GJ, et al. **Leukemia** 1999 Aug;13(8):1207–13

In vivo and in vitro effects of cytokines and the hemoregulatory peptide dimer (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 on G alpha16-positive hematopoiesis. Pfeilstöcker M, et al. **Leukemia** 1999 Apr; 13(4):590–4

Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Schwertschlag US, et al. **Leukemia** 1999 Sep;13(9):1307–15 (98 ref.)

The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). De Schoenmakere G, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1770–5

Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Adamson JW, et al. **Oncology** 1999;56(1):46–53 (47 ref.)

Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Koumakis G, et al. **Oncology** 1999;56(1):28–35

Thrombopoietin: biology and potential clinical applications. Prow D, et al. **Oncology (Huntingt)** 1998 Nov; 12(11):1597–604, 1607–8; discussion 1611–4 (78 ref.)

Hematoregulators. A case history of a novel hematoregulatory peptide, SK&F 107647. Bhatnagar PK, et al. **Pharm Biotechnol** 1998;11:367–91 (128 ref.)

Comparative pharmacology of zinc mesoporphyrin and tin mesoporphyrin: toxic actions of zinc mesoporphyrin on hematopoiesis and progenitor cell mobilization. Lutton JD, et al. **Pharmacology** 1999 Jan;58(1):44–50

Pharmacologic effects of the red blood cell substitutes cross-linked and non-cross-linked hemoglobins on hematopoiesis in rabbits. Lutton JD, et al. **Pharmacology** 1999 Jun;58(6):319–24

Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine act additively to enhance the hemopoietic spleen colony formation in irradiated mice. Hofer M, et al. **Physiol Res** 1999;48(1):37–42

Protective effect of swerchirin on hematopoiesis in 60Co-irradiated mice. Ya BQ, et al. **Phytomedicine** 1999 May;6(2):85–8

Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis. Kinoshita T, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7265–70

Differential activation of functionally distinct STAT5 proteins by IL-5 and GM-CSF during eosinophil and neutrophil differentiation from human CD34+ hematopoietic stem cells. Caldenhoven E, et al. **Stem Cells** 1998;16(6):397–403

[Preliminary studies on the efficacy and mechanism of interleukin-3 in the treatment of myelosuppression in mice] Chen J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):134–7 (Eng. Abstr.) **(Chi)**

[Cytostatic-induced cell death in hypoplasia of the hematopoietic tissue] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):39–42 **(Rus)**

[The blood-simulating properties of a recombinant colony-stimulating factor and glycyram during cytostatic myelosuppression] Dygai AM, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):34–7 (Eng. Abstr.) **(Rus)**

GENETICS

Clinical outcome in three patients with myelodysplastic syndrome showing polyclonal hematopoiesis. Karasawa M, et al. **Acta Haematol** 1999 Mar;101(1):46–9

Spi-1/PU.1 proto-oncogene induces opposite effects on monocytic and erythroid differentiation of K562 cells. Delgado MD, et al. **Biochem Biophys Res Commun** 1998 Nov 18;252(2):383–91

Expression of a gene trap reporter construct in a subset of cells in embryonic sites of hematopoiesis: evidence for alternative rRNA production in hematopoietic cells. Wagner DS, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):674–81

The SCL gene: from case report to critical hematopoietic regulator. Begley CG, et al. **Blood** 1999 May 1; 93(9):2760–70 (141 ref.)

Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Crooks GM, et al. **Blood** 1999 Jul 15; 94(2):519–28

A regulatory role for Fcgamma receptors CD16 and CD32 in the development of murine B cells. de Andres B, et al. **Blood** 1998 Oct 15;92(8):2823–9

Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Haneline LS, et al. **Blood** 1999 Jul 1;94(1):1–8

Definitive but not primitive hematopoiesis is impaired in jumonji mutant mice. Kitajima K, et al. **Blood** 1999 Jan 1;93(1):87–95

Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Oike Y, et al. **Blood** 1999 May 1; 93(9):2771–9

Loss of c-kit accompanies B-lineage commitment and acquisition of CD45R by most murine B-lymphocyte precursors. Payne KJ, et al. **Blood** 1999 Jul 15;94(2):713–23

Role of members of the Wnt gene family in human hematopoiesis. Van Den Berg DJ, et al. **Blood** 1998 Nov 1;92(9):3189–202

C/EBPepsilon directly interacts with the DNA binding domain of c-myb and cooperatively activates transcription of myeloid promoters. Verbeek W, et al. **Blood** 1999 May 15;93(10):3327–37

Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Wickremasinghe RG, et al. **Blood** 1999 Jun 1; 93(11):3587–600 (189 ref.)

Def-2, -3, -6 and -8, novel mouse genes differentially expressed in the haemopoietic system. Hotfilder M, et al. **Br J Haematol** 1999 Aug;106(2):335–44

Intersections between blood cell development and leukemia genes. Orkin SH, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1784s–1787s; discussion 1788s

Hematopoietic deficiencies and core binding factor expression in murine Ts16, an animal model for Down syndrome. Gjertson C, et al. **Clin Immunol** 1999 Apr; 91(1):50–60

Gene trap screening using negative selection: identification of two tandem, differentially expressed loci with potential hematopoietic function. Cannon JP, et al. **Dev Genet** 1999; 25(1):49–63

Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. North T, et al. **Development** 1999 Jun;126(11):2563–75

Cell-autonomous and non-autonomous requirements for the zebrafish gene cloche in hematopoiesis. Parker L, et al. **Development** 1999 Jun;126(12):2643–51

Expression of the LIM-homeobox gene LH2 generates immortalized steel factor-dependent multipotent hematopoietic precursors. Pinto do O P, et al. **EMBO J** 1998 Oct 1;17(19):5744–56

Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development. Zhou Y, et al. **EMBO J** 1998 Nov 16;17(22):6689–700

Retroviral transduction of enriched hematopoietic stem cells allows lifelong Bcl-2 expression in multiple lineages but does not perturb hematopoiesis. Innes KM, et al. **Exp Hematol** 1999 Jan;27(1):75–87

A homolog of the fungal nuclear migration gene nudC is involved in normal and malignant human hematopoiesis. Miller BA, et al. **Exp Hematol** 1999 Apr;27(4):742–50

Partial block in B lymphocyte development at the transition into the pre-B cell receptor stage in Vpre-B1-deficient mice. Mårtensson A, et al. **Int Immunol** 1999 Mar; 11(3):453–60

Homeobox genes in normal hematopoiesis and leukemogenesis. Chiba S. **Int J Hematol** 1998 Dec; 68(4):343–53 (82 ref.)

The core binding factor (CBF) alpha interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFbeta-SMMHC are both required to slow cell proliferation. Cao W, et al. **J Biol Chem** 1998 Nov 20; 273(47):31534–40

Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice. D'Andrea RJ, et al. **J Clin Invest** 1998 Dec 1;102(11):1951–60

Hematopoietic progenitor cell abnormalities in Hoxc-8 null mutant mice. Shimamoto T, et al. **J Exp Zool** 1999 Feb 1;283(2):186–93

Homeobox genes and hematopoiesis: an emerging picture for genomic therapy. Rich IN. **J Hematother** 1998 Dec; 7(6):515–20 (35 ref.)

The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. Moritz DR, et al. **J Immunol** 1998 Nov 1;161(9):4866–74

A mouse carrying genetic defect in the choice between T and B lymphocytes. Tokoro Y, et al. **J Immunol** 1998 Nov 1;161(9):4591–8

Regulation of mouse CD72 gene expression during B lymphocyte development. Ying H, et al. **J Immunol** 1998 Nov 1;161(9):4760–7

Cell lineage specificity in G-CSF receptor gene methylation. Felgner J, et al. **Leukemia** 1999 Apr;13(4):530–4

Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Metcalf D, et al. **Leukemia** 1999 Jun; 13(6):926–34

A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Liu LQ, et al. **Mol Cell Biol** 1999 Apr;19(4):3029–38

Pro-B-cell-specific transcription and proapoptotic function of protein kinase Ceta. Morrow TA, et al. **Mol Cell Biol** 1999 Aug;19(8):5608–18

The zebrafish and haematopoietic justice [news; comment] Amemiya CT. **Nat Genet** 1998 Nov;20(3):222–3. Comment on: Nat Genet 1998 Nov;20(3):239–43. Comment on: Nat Genet 1998 Nov;20(3):244–50.

Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis. Labbaye C, et al. **Oncogene** 1999 Jun 10;18(23):3529–40

AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Okada H, et al. **Oncogene** 1998 Nov 5; 17(18):2287–93

Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia. Peters UR, et al. **Oncogene** 1999 Jan 7;18(1):79–85

Transformation of hematopoietic cells by the Ski oncoprotein involves repression of retinoic acid receptor signaling. Dahl R, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15; 95(19):11187–92

Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Tamayo P, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2907–12

Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Zhang P, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8705–10

The molecular control of hematopoiesis: progress and problems with gene manipulation. Metcalf D. **Stem Cells** 1998;16(5):314–21 (58 ref.)

[The clinical significance of MDR-1 gene expression in the hemopoietic cells of patients with acute leukemias in different phases of the disease] Bykova TV, et al. **Ter Arkh** 1998;70(7):11–4 (Eng. Abstr.) **(Rus)**

[Genetic origin of malignant hematopoiesis well defined] Bernell P, et al. **Lakartidningen** 1998 Nov 25;95(48):5493–4, 5497–8 (15 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGY

MHC class II and negative regulators of hematopoiesis. Deeg HJ, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):285–91 (46 ref.)

A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantation. Blazar BR, et al. **Blood** 1998 Dec 1; 92(11):4453–63

Activation of gp130 signaling in vivo by the IL-6 super-agonist K-7/D-6 accelerates repopulation of lymphoid organs after irradiation. Frasca D, et al. **Eur J Immunol** 1999 Jan;29(1):300–10

A regulatory role for Fc gamma receptors (CD16 and CD32) in hematopoiesis. de Andres B, et al. **Immunol Lett** 1999 May 3;68(1):109–13

Hemopoietic mechanisms in allergic airway inflammation. Denburg JA, et al. **Int Arch Allergy Immunol** 1998 Nov; 117(3):155–9 (55 ref.)

IL-17 stimulates granulopoiesis in mice: use of an alternate,

novel gene therapy-derived method for in vivo evaluation of cytokines. Schwarzenberger P, et al. **J Immunol** 1998 Dec 1;161(11):6383-9

CD44H participates in the intrahepatic growth of murine colon 26 adenocarcinoma cells. Ogoshi T, et al. **Jpn J Cancer Res** 1998 Nov;89(11):1160-8

CD34high+ CD38(low/-) cells generated in a xenogenic coculture system are capable of both long-term hematopoiesis and multiple differentiation. Tsuji T, et al. **Leukemia** 1999 Sep;13(9):1409-19

Haematopathology of 'Sjögren-mice': histopathological changes in spleens after semiallogeneic cell transfer. Ussing AP, et al. **Scand J Immunol** 1999 Jun;49(6):641-8

[Reactions of the immune and hematopoietic systems to antigens during cytostatic disease] Masnaia NV, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):576-8 **(Rus)**

[The criteria of disorders in body antitumor resistance in subjects with dyshemopoiesis] Komissarenko VG, et al. **Lik Sprava** 1998 Oct-Nov;(7):74-9 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cytokines in hematopoiesis: specificity and redundancy in receptor function. Socolovsky M, et al. **Adv Protein Chem** 1998;52:141-98 (254 ref.)

Lineage-related susceptibility of human hemopoietic cell lines to apoptosis. Mariani AR, et al. **Anat Rec** 1999 Jan; 254(1):1-6

Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production. Goyal RK, et al. **Ann Med** 1999 Jun;31(3):208-16 (75 ref.)

Embryonic beginnings of definitive hematopoietic stem cells. Dzierzak E. **Ann N Y Acad Sci** 1999 Apr 30;872:256-62; discussion 262-4 (27 ref.)

Thrombopoietin and hematopoietic stem cell development. Kaushansky K. **Ann N Y Acad Sci** 1999 Apr 30;872:314-9 (38 ref.)

Stem cells, pre-progenitor cells and lineage-committed cells: are our dogmas correct? Metcalf D. **Ann N Y Acad Sci** 1999 Apr 30;872:289-303; discussion 303-4 (33 ref.)

Hemangioblast development and regulation. Choi K. **Biochem Cell Biol** 1998;76(6):947-56 (104 ref.)

Bisecting GlcNAc structure is implicated in suppression of stroma-dependent haemopoiesis in transgenic mice expressing N-acetylglucosaminyltransferase III. Yoshimura M, et al. **Biochem J** 1998 May 1;331 (Pt 3):733-42

Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Begley CG, et al. **Blood** 1999 Mar 1; 93(5):1443-7 (59 ref.)

Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Carlesso N, et al. **Blood** 1999 Feb 1;93(3):838-48

Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Chklovskaia E, et al. **Blood** 1999 Apr 15; 93(8):2595-604

Src-related protein tyrosine kinases in hematopoiesis. Corey SJ, et al. **Blood** 1999 Jan 1;93(1):1-14 (163 ref.)

Expression of macrophage inflammatory protein-1 receptors in human CD34(+) hematopoietic cells and their modulation by tumor necrosis factor-alpha and interferon-gamma. Dürig J, et al. **Blood** 1998 Nov 1; 92(9):3073-81

A critical role for PU.1 in homing and long-term engraftment by hematopoietic stem cells in the bone marrow. Fisher RC, et al. **Blood** 1999 Aug 15;94(4):1283-90

Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. Huber TL, et al. **Blood** 1998 Dec 1;92(11):4128-37

The presence of novel amino acids in the cytoplasmic domain of stem cell factor results in hematopoietic defects in Steel(17H) mice. Kapur R, et al. **Blood** 1999 Sep 15; 94(6):1915-25

Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Khaldoyanidi S, et al. **Blood** 1999 Aug 1;94(3):940-9

Catecholaminergic regulation of hematopoiesis in mice [letter; comment] Maestroni GJ. **Blood** 1998 Oct 15; 92(8):2971; discussion 2972-3. Comment on: Blood 1998 Feb 15;91(4):1280-7.

Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Milner LA, et al. **Blood** 1999 Apr 15;93(8):2431-48 (189 ref.)

Neural regulation of bone marrow [letter; comment] Miyan JA, et al. **Blood** 1998 Oct 15;92(8):2971-3. Comment on: Blood 1998 Feb 15;91(4):1280-7.

Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Peters M, et al. **Blood** 1998 Nov 15;92(10):3495-504 (85 ref.)

A secreted proform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells. Sköld S, et al. **Blood** 1999 Feb 1;93(3):849-56

Adhesion receptors as regulators of the hematopoietic process [comment] Verfaillie CM. **Blood** 1998 Oct 15; 92(8):2609-12 (60 ref.). Comment on: Blood 1998 Oct 15;92(8):2613-28.

C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Wang X, et al. **Blood** 1999 Jul 15; 94(2):560-71

Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice. Yang FC, et al. **Blood** 1999 Aug 1;94(3):950-8

The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis [see comments] Zannettino AC, et al. **Blood** 1998 Oct 15; 92(8):2613-28. Comment in: Blood 1998 Oct 15;92(8):2609-12.

Oncoprotein v-Myb and retinoic acid receptor alpha are mutual antagonists. Zemanová K, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):239-50

Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Fruehauf S, et al. **Br J Haematol** 1999 Jun; 105(3):786-94

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Gersuk GM, et al. **Br J Haematol** 1998 Oct; 103(1):176-88

Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Marley SB, et al. **Br J Haematol** 1999 Jul;106(1):162-6

Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation. Mielcarek M, et al. **Br J Haematol** 1999 May;105(2):361-5

Dyserythropoiesis and severe anaemia associated with malaria correlate with deficient interleukin-12 production. Mohan K, et al. **Br J Haematol** 1998 Dec;103(4):942-9

Spleen stromal cells support haemopoiesis and in vitro growth of dendritic cells from bone marrow. Ni K, et al. **Br J Haematol** 1999 Apr;105(1):58-67

Telomeres and haemopoiesis. Wynn RF, et al. **Br J Haematol** 1998 Dec;103(3):591-3

Core-binding factor: a central player in hematopoiesis and leukemia. Speck NA, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1789s-1793s (47 ref.)

Cell interaction molecules utilized in bone marrow. Kincade PW, et al. **Cell Adhes Commun** 1998;6(2-3):211-5 (34 ref.)

The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Oikawa T, et al. **Cell Death Differ** 1999 Jul; 6(7):599-608 (161 ref.)

Regulation of B and T cell development by anterior pituitary hormones. Foster M, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1076-82 (55 ref.)

Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Liu FJ, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1168-72

Effect of sublethal liver injury on doxorubicin metabolism. August DA, et al. **Clin Cancer Res** 1995 Mar;1(3):351-8

Hematologic values and appearances in the healthy fetus, neonate, and child. Geaghan SM. **Clin Lab Med** 1999 Mar; 19(1):1-37, v (101 ref.)

Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Alexander WS, et al. **Curr Biol** 1999 Jun 3;9(11):605-8

A transcription factor party during blood cell differentiation. Sieweke MH, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):545-51 (58 ref.)

Role of endothelium in the control of mouse yolk sac stem cell differentiation. Auerbach R, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):333-8 (14 ref.)

Hematopoietic induction and respecification of A-P identity by visceral endoderm signaling in the mouse embryo. Belaoussoff M, et al. **Development** 1998 Dec; 125(24):5009-18

Thrombopoietin and its receptor. Wendling F, et al. **Eur Cytokine Netw** 1998 Sep;9(3):221-31 (139 ref.)

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Parcharidou A, et al. **Eur J Haematol** 1999 Jan;62(1):19-26

Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Broxmeyer HE, et al. **Exp Hematol** 1999 Jul;27(7):1113-23 (147 ref.)

Comparative studies of different stromal cell microenvironments in support of human B-cell development. Kurosaka D, et al. **Exp Hematol** 1999 Aug; 27(8):1271-81

Endogenous hematopoietic reconstitution induced by human umbilical cord blood cells in immunocompromised mice: implications for adoptive therapy. Rameshwar P, et al. **Exp Hematol** 1999 Jan;27(1):176-85

Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Roy V, et al. **Exp Hematol** 1999 Feb;27(2):302-12

Expression of p15INK4B in normal hematopoiesis. Teofili L, et al. **Exp Hematol** 1998 Nov;26(12):1133-9

Erythropoietin and platelet production. Beguin Y. **Haematologica** 1999 Jun;84(6):541-7 (101 ref.)

Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery. del Cañizo MC, et al. **Haematologica** 1999 Jun;84(6):511-6

Thrombopoietin: its role from early hematopoiesis to platelet production. Wendling F. **Haematologica** 1999 Feb; 84(2):158-66 (138 ref.)

Hematopoietic support and cytokine expression of murine-stable hepatocyte cell lines (MMH). Aiuti A, et al. **Hepatology** 1998 Dec;28(6):1645-54

Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Takakura N, et al. **Immunity** 1998 Nov;9(5):677-86

Cell-cell signalling in the regulation of blood cell formation and function. Metcalf D. **Immunol Cell Biol** 1998 Oct; 76(5):441-7

Multiple gamma c-dependent cytokines regulate T-cell development. Malek TR, et al. **Immunol Today** 1999 Feb; 20(2):71-6 (55 ref.)

Overexpression of Bcl-2 does not rescue impaired B lymphopoiesis in IL-7 receptor-deficient mice but can enhance survival of mature B cells. Maraskovsky E, et al. **Int Immunol** 1998 Sep;10(9):1367-75

Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Nishimura M, et al. **Int J Hematol** 1998 Aug; 68(2):203-11

Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). Dao MA, et al. **Int J Mol Med** 1998 Jan;1(1):257-64 (50 ref.)

Commitment to the B lymphoid lineage occurs before DH-JH recombination. Allman D, et al. **J Exp Med** 1999 Feb 15;189(4):735-40

Stem cell emergence and hemopoietic activity are incompatible in mouse intraembryonic sites. Godin I, et al. **J Exp Med** 1999 Jul 5;190(1):43-52

Human red cells from prenatal hemopoiesis. Sodium/lithium exchange symmetry. Mújica G, et al. **J Physiol Biochem** 1998 Jun;54(2):85-90

Biology of CD34+CD38- cells in lymphohematopoiesis. Novelli EM, et al. **Leuk Lymphoma** 1998 Oct; 31(3-4):285-93 (80 ref.)

The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Valk PJ, et al. **Leuk Lymphoma** 1998 Dec; 32(1-2):29-43 (108 ref.)

Role of umbilical vein endothelial cells in hematopoiesis. Yamaguchi H, et al. **Leuk Lymphoma** 1998 Sep;31(1-2):61-9 (62 ref.)

Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Avraham H, et al. **Methods** 1999 Mar;17(3):250-64 (131 ref.)

Vascular and blood gene expression. Parker LH, et al. **Methods Cell Biol** 1999;59:313-36 (75 ref.)

A role for leptin in hemopoieses? Gainsford T, et al. **Mol Biotechnol** 1999 Apr;11(2):149-58 (91 ref.)

Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages. Liu Q, et al. **Mol Cell Biol** 1999 Sep;19(9):6229-39

CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. de Wynter EA, et al. **Stem Cells** 1998; 16(6):387-96

The role of blood stem cells in hematopoietic cell renewal. Fliedner TM. **Stem Cells** 1998;16(6):361-74

The molecular control of hematopoiesis: progress and problems with gene manipulation. Metcalf D. **Stem Cells** 1998;16(5):314-21 (58 ref.)

Blood transfusions downregulate hematopoiesis and subsequently downregulate the immune response. Grzelak I, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1104-14

Stem cell biology for the transfusionist. Lansdorp PM. **Vox Sang** 1998;74 Suppl 2:91-4 (32 ref.)

[Pathogenic gene linkage analysis and hemopoietic characteristics in a kindred with sideroblastic anemia] Zhu P, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Feb 10;16(1):22-5 (Eng. Abstr.) **(Chi)**

[Interactions of cytokines with their receptors in the regulation of hematopoiesis, clinical and diagnostic applications] Koubek K, et al. **Sb Lek** 1998;99(1):33-51 (54 ref.) (Eng. Abstr.) **(Cze)**

[Chemokines and the regulation of hematopoiesis] Maurer AM, et al. **C R Seances Soc Biol Fil** 1998;192(5):917-23 (26 ref.) (Eng. Abstr.) **(Fre)**

[Thrombopoietin and megakaryocyte differentiation] Vainchenker W, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1575-81 (36 ref.) (Eng. Abstr.) **(Fre)**

[Dynamic theory of hematopoiesis] Gol'dberg ED, et al. **Biull Eksp Biol Med** 1999 May;127(5):484-94 (126 ref.) **(Rus)**

[Mechanisms of hemopoiesis cytostatic damage and regeneration] Gol'dberg ED, et al. **Vestn Ross Akad Med Nauk** 1998;(10):6-10 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Activation of gp130 signaling in vivo by the IL-6 super-agonist K-7/D-6 accelerates repopulation of lymphoid organs after irradiation. Frasca D, et al. **Eur J Immunol** 1999 Jan;29(1):300-10

Radiation-induced genomic instability in haemopoietic cells. Wright EG. **Int J Radiat Biol** 1998 Dec;74(6):681-7 (49 ref.)
Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Mouthon MA, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1; 43(4):867-75
Radioprotective effects of sodium tungstate on hematopoietic injury by exposure to 60Co gamma-rays in Wistar rats. Sato K, et al. **J Radiat Res (Tokyo)** 1999 Jun;40(2):101-13
Preferential liver irradiation enhances hematopoiesis through a thrombopoietin-independent mechanism. Mouthon MA, et al. **Radiat Res** 1999 Oct;152(4):390-7
Haematological toxicity of cranio-spinal irradiation. Jefferies S, et al. **Radiother Oncol** 1998 Jul;48(1):23-7
[Methodical approaches for establishing the values of spatial non-uniformity radiation coefficients for generalized dose calculation to evaluate immediate radiobiological effects] Shafirkin AV. **Aviakosm Ekolog Med** 1999;33(1):50-6 (36 ref.) (Eng. Abstr.) **(Rus)**
[Bone marrow hematopoiesis in those who worked in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station with a history of acute radiation sickness (based on myelogram data)] Klimenko SV. **Lik Sprava** 1999 Jan-Feb;(1):25-7 (Eng. Abstr.) **(Rus)**

HEMATOPOIESIS, EXTRAMEDULLARY

Focal intrahepatic extramedullary hematopoiesis: color Doppler US and CT findings. Aytaç S, et al. **Abdom Imaging** 1999 Jul-Aug;24(4):366-8
Fluorescence in situ hybridization and surface markers of fine needle aspiration specimen confirm extramedullary myeloblastoma in a patient with chronic myeloid leukemia. Karthaus M, et al. **Acta Haematol** 1998;100(2):91-3
Neuroradiology case of the day. Spinal cord compression caused by extramedullary hematopoiesis. Rowe DW, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):806, 810-2
Massive ascites caused by peritoneal extramedullary hematopoiesis as the initial manifestation of myelofibrosis. Hung SC, et al. **Am J Med Sci** 1999 Sep;318(3):198-200
Extramedullary hematopoiesis mimicking metastatic lung carcinoma. Hsu FI, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1411-3
Cutaneous extramedullary haematopoiesis associated with blast crisis in myelofibrosis [letter] Pagerols X, et al. **Clin Exp Dermatol** 1998 Nov;23(6):296-7
Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Abdel-Dayem HM, et al. **Clin Nucl Med** 1999 May;24(5):319-22
Extramedullary hematopoiesis related to Paget's disease. Relea A, et al. **Eur Radiol** 1999;9(2):205-7
Spinal cord compression secondary to extramedullary hematopoiesis in thalassemia intermedia. Coşkun E, et al. **Eur Spine J** 1998;7(6):501-4
Extramedullary haemopoiesis in the cervix [letter] Pandey U, et al. **Histopathology** 1999 Jun;34(6):556-7
Spinal cord compression due to extramedullary hematopoiesis in beta-thalassemia intermedia. Munn RK, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):607-9
Mediastinal extramedullary hematopoiesis. Roger T. **J Belge Radiol** 1998 Oct;81(5):248
A case of cutaneous extramedullary hematopoiesis in myelofibrosis with a preponderance of eosinophilic precursor cells. Kwon KS, et al. **J Dermatol** 1999 Jun; 26(6):379-84
Fine-needle aspiration cytology of retroperitoneal extramedullary hematopoiesis: a case report. Jan YJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Oct; 14(10):659-63
Intrathoracic extramedullary haematopoiesis complicated by massive haemothorax in alpha-thalassaemia. Chu KA, et al. **Thorax** 1999 May;54(5):466-8
[Extramedullary hematopoiesis. Unusual presentation as a posterior mediastinal mass (letter)] Fernández Vázquez E, et al. **Arch Bronconeumol** 1998 Oct;34(9):470 **(Spa)**
[Spinal cord compression secondary to epidural extramedullary hematopoiesis in thalassemia: a clinical case and review of literature] Martínez-Rodrigo MA, et al. **Rev Neurol** 1998 Dec;27(160):998-1004 (61 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia--the occurrence of retinoic acid syndrome is a risk factor. Ko BS, et al. **Leukemia** 1999 Sep;13(9):1406-8
Hepatic extramedullary granulopoiesis after treatment with liver-stimulatory xenobiotics, in lpr mice. Sarraf CE, et al. **Ultrastruct Pathol** 1998 Nov-Dec;22(6):443-8

GENETICS

Excessive extramedullary hematopoiesis in Cbfa1-deficient mice with a congenital lack of bone marrow. Deguchi K, et al. **Biochem Biophys Res Commun** 1999 Feb 16; 255(2):352-9

IMMUNOLOGY

Extramedullar B lymphopoiesis in liver schistosomal granulomas: presence of the early stages and inhibition of the full B cell differentiation. Rossi MI, et al. **Int Immunol** 1999 Apr;11(4):509-18
Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. Sparwasser T, et al. **J Immunol** 1999 Feb 15;162(4):2368-74

PHYSIOLOGY

Pseudo-Gaucher cells in peritoneal fluid: an uncommon manifestation of extramedullary hematopoiesis. Lang E, et al. **Diagn Cytopathol** 1999 Jun;20(6):379-81
Extramedullary paraspinal hematopoiesis in thalassemia: CT and MRI evaluation. Tsitouridis J, et al. **Eur J Radiol** 1999 Apr;30(1):33-8
Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Bárcena A, et al. **Exp Hematol** 1999 Sep;27(9):1428-39
Interstitial pneumonitis due to extramedullary haematopoiesis (EMH) in agnogenic myeloid metaplasia [letter] Coyne JD, et al. **Histopathology** 1999 Mar;34(3):275-6
Intrathymic non-lymphatic hematopoiesis during mammalian ontogenesis. Bodey B, et al. **In Vivo** 1998 Nov-Dec; 12(6):599-618 (236 ref.)
[Hematopoietic microenvironment transfer units and inducible progenitors of hematopoietic stroma in the bone marrow of thymectomized mice] Todria TV. **Biull Eksp Biol Med** 1999 Feb;127(2):186-9 **(Rus)**

RADIATION EFFECTS

Spinal cord compression in beta-thalassemia: follow-up after radiotherapy. da Fonseca SF, et al. **Rev Paul Med** 1998 Nov-Dec;116(6):1879-81

HEMATOPOIESIS, MEDULLARY see **HEMATOPOIESIS**

HEMATOPOIETIC AGENTS see **HEMATINICS**

HEMATOPOIETIC CELL GROWTH FACTORS

see related
RECEPTORS, COLONY-STIMULATING FACTOR

Bibliography. Current world literature. Hematopoietic growth factors. **Curr Opin Hematol** 1999 May;6(3):B33-49
Hematopoietic growth factors. **Curr Opin Hematol** 1994 May; 1(3):B51-80

BLOOD

Measurement and clinical significance of circulating hematopoietic growth factor levels. Cebon J, et al. **Curr Opin Hematol** 1994 May;1(3):228-34 (34 ref.)
Hematopoietic growth factor levels in term and preterm infants. Rondini G, et al. **Curr Opin Hematol** 1999 May; 6(3):192-7 (59 ref.)
The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors. Weisbach V, et al. **Transfusion** 1999 Aug;39(8):889-94

METABOLISM

Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1. DiGiuseppe JA, et al. **In Vivo** 1999 Jan-Feb;13(1):1-6
Clozapine induced agranulocytosis: hypothesis on immune-mediated pathogenesis and the role of haematopoietic growth factors [letter] Faber HJ, et al. **Neth J Med** 1999 Aug;55(2):86-7

PHARMACOLOGY

Hematopoietic growth factors signal through the formation of reactive oxygen species. Sattler M, et al. **Blood** 1999 May 1;93(9):2928-35
The potential impact of platelet growth factors in transfusion medicine. McCullough J. **Curr Opin Hematol** 1998 Nov; 5(6):386-90 (42 ref.)
In aplastic anemia progenitor cells have a reduced sensitivity to the effects of growth factors. Novitzky N, et al. **Eur J Haematol** 1999 Sep;63(3):141-8
Platelet growth factors: potential impact on transfusion medicine. Kuter DJ, et al. **Transfusion** 1999 Mar; 39(3):321-32 (60 ref.)
[Hematopoietic growth factors induce proliferation of non-hematopoietic tumor cells] López-Marure R, et al. **Rev Invest Clin** 1998 Sep-Oct;50(5):413-8 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Hematopoietic growth factors. Commentary. Dale DC. **Curr Opin Hematol** 1994 May;1(3):177-9 (15 ref.)
Role of hematopoietic growth factors in non-neutropenic infections and sepsis. Held TK, et al. **Curr Opin Hematol** 1999 May;6(3):176-83 (46 ref.)
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Mellstedt H, et al. **Curr Opin Hematol** 1999 May;6(3):169-75 (61 ref.)
Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line. Andrew DJ, et al. **Immunopharmacology** 1999 Jan;41(1):1-10
All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Miyauchi J. **Leuk Lymphoma** 1999 Apr;33(3-4):267-80 (138 ref.)

THERAPEUTIC USE

Transplantation of peripheral blood stem cells mobilized by haematopoietic growth factors in childhood. Locatelli F, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S51-5 (44 ref.)
Isolation and transduction of CD34+ cells from small quantities of peripheral blood from HIV-1-infected patients not treated with hemopoietic growth factors. Adams GB, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):1-8
The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. D'Hondt L, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):105-9
Clozapine-induced agranulocytosis: haematopoietic growth factors indicated? [letter; comment] van Melick EJ, et al. **Neth J Med** 1999 Jan;54(1):31. Comment on: Neth J Med 1998 Jan;52(1):26-9.
Alloimmune neonatal neutropenia treated with rHuG-CSF. Ruggiero A, et al. **Pediatr Med Chir** 1999 Jan-Feb; 21(1):27-8
Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes. Hast R, et al. **Pol Arch Med Wewn** 1998 Feb;99(2):144-9
Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. Terakura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):870-1
[Importance of recombinant proteins in the adjuvant treatment of cancer] Cheron JM. **Ann Pharm Fr** 1998; 56(6):241-3 (Eng. Abstr.) **(Fre)**
[Analysis of hematopoietic growth factor prescriptions in 19 french cancer centers] Gautié L, et al. **Bull Cancer** 1998 Dec;85(12):1043-8 (Eng. Abstr.) **(Fre)**

HEMATOPOIETIC GROWTH FACTORS RECEPTORS see **RECEPTORS, COLONY-STIMULATING FACTOR**

HEMATOPOIETIC NEOPLASMS see **HEMATOLOGIC NEOPLASMS**

HEMATOPOIETIC STEM CELL MOBILIZATION

see related
BLOOD COMPONENT REMOVAL
HEMATOPOIETIC STEM CELL TRANSPLANTATION

Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Bertolini F, et al. **Ann Oncol** 1998 Aug;9(8):913-6
Administration of daniplestim and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in nonhuman primates. Fleming WH, et al. **Biol Blood Marrow Transplant** 1999; 5(1):8-14
Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Haut PR, et al. **Biol Blood Marrow Transplant** 1998;4(1):38-42
Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Leung W, et al. **Biol Blood Marrow Transplant** 1999;5(2):69-76
Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. Roecklein BA, et al. **Biol Blood Marrow Transplant** 1998;4(2):61-8
Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. Brandt JE, et al. **Blood** 1999 Jul 1;94(1):106-13
Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Carella AM, et al. **Blood** 1999 Mar 1;93(5):1534-9
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Facon T, et al. **Blood** 1999 Aug 15;94(4):1218-25
Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Franklin WA, et al. **Blood** 1999 Jul 1;94(1):340-7
Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Gothot

A, et al. **Blood** 1998 Oct 15;92(8):2641–9

Randomized trial of autologous filgrastim–primed bone marrow transplantation versus filgrastim–mobilized peripheral blood stem cell transplantation in lymphoma patients [letter; comment] [see comments] Gyger M, et al. **Blood** 1998 Nov 1;92(9):3489–90. Comment on: Blood 1997 Jul 1;90(1):36–42. Comment in: Blood 1999 Jun 15;93(12):4446–9.

The soluble interleukin–6 (IL–6) receptor/IL–6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(–/low) cells capable of repopulating severe combined immunodeficiency mice. Kollet O, et al. **Blood** 1999 Aug 1;94(3):923–31

Long–term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Shih CC, et al. **Blood** 1999 Sep 1;94(5):1623–36

Osteoclast–mediated bone resorption is stimulated during short–term administration of granulocyte colony–stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Takamatsu Y, et al. **Blood** 1998 Nov 1;92(9):3465–73

Endogenous interleukin–8 (IL–8) surge in granulocyte colony–stimulating factor–induced peripheral blood stem cell mobilization. Watanabe T, et al. **Blood** 1999 Feb 15; 93(4):1157–63

Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Abonour R, et al. **Bone Marrow Transplant** 1998 Nov;22(10):957–63

Autotransplantation in chronic myeloid leukemia [letter; comment] Aguado MJ, et al. **Bone Marrow Transplant** 1998 Oct;22(8):831. Comment on: Bone Marrow Transplant 1998 Mar;21(5):455–60.

Cord blood banking: volume reduction of cord blood units using a semi–automated closed system. Armitage S, et al. **Bone Marrow Transplant** 1999 Mar;23(5):505–9

Modulation of VLA–4 and L–selectin expression on normal CD34+ cells during mobilization with G–CSF. Bellucci R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):1–8

Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Benet I, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1101–7

Mobilisation of healthy donors with lenograstim and transplantation of HLA–genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Blaise D, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1153–8

A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Burtness BA, et al. **Bone Marrow Transplant** 1999 Feb;23(4):311–5

A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium–treated patient with acute myeloid leukaemia [letter] Canales MA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):305

Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP–doxorubicin–vinorelbine–cyclophosphamide–fluorouracil) and granulocyte colony–stimulating factor in breast cancer. Charrier S, et al. **Bone Marrow Transplant** 1998 Nov;22(9):845–51

Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing. Cilloni D, et al. **Bone Marrow Transplant** 1999 Mar;23(5):497–503

Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Clark RE, et al. **Bone Marrow Transplant** 1998 Nov;22(9):859–63

Use of G–CSF to mobilise PBSC in normal healthy donors--an international survey. Cleaver SA, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S29–31

Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Couban S, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1199–205

Circulating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield [letter; comment] D'Arena G, et al. **Bone Marrow Transplant** 1998 Jul;22(2):215–6. Comment on: Bone Marrow Transplant 1997 Oct;20(7):587–91.

Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases. Dazzi C, et al. **Bone Marrow Transplant** 1999 Mar;23(6):529–32

Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long–term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Dreger P, et al. **Bone Marrow Transplant** 1999 Jul;24(2):153–61

Clinical and economic comparison of lenograstim–primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Faucher C, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S92–8

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Gandhi MK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):9–13

Lymphoma cell contamination of PBSC: a murine model. Gidáli J, et al. **Bone Marrow Transplant** 1999 Sep; 24(6):617–20

Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G–CSF and stem cell factor (SCF) as compared to G–CSF alone. Hartung G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S16–20

Recombinant human granulocyte and granulocyte–macrophage colony–stimulating factor (G–CSF and GM–CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):625–30

Peripheral blood stem cell mobilization with granulocyte colony–stimulating factor and a harvesting procedure in pediatric donors. Kawano Y, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S32–4

Anaphylactoid reaction to granulocyte colony–stimulating factor used in mobilization of peripheral blood stem cell [letter] Keung YK, et al. **Bone Marrow Transplant** 1999 Jan;23(2):200–1

An eight–fold ex vivo expansion of long–term culture–initiating cells from umbilical cord blood in stirred suspension cultures. Kögler G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S48–53

Stem cell mobilization with G–CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N, et al. **Bone Marrow Transplant** 1999 Jan;23(2):125–9

Biological characterization of CD34+ cells mobilized into peripheral blood. Lemoli RM, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S47–50

Granulocyte colony–stimulating factor (G–CSF) dose–dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G–CSF. Lie AK, et al. **Bone Marrow Transplant** 1998 Nov;22(9):853–7

Transplantation of peripheral blood stem cells mobilized by haematopoietic growth factors in childhood. Locatelli F, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S51–5 (44 ref.)

Factors influencing haemopoietic recovery following chemotherapy–mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10–year single institution experience. Lowenthal RM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):763–70

G–CSF–mobilized PBSCT in children with AML in first complete remission [letter; comment] Madero L, et al. **Bone Marrow Transplant** 1999 May;23(9):975–6. Comment on: Bone Marrow Transplant 1998 Feb;21(4):375–82.

Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post–PBPC transplant. Maharaj D, et al. **Bone Marrow Transplant** 1999 Mar;23(6):539–48

Effects of short–term administration of G–CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Martínez C, et al. **Bone Marrow Transplant** 1999 Jan;23(1):15–9

Ifosfamide and etoposide–based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J, et al. **Bone Marrow Transplant** 1999 Mar;23(5):413–9

Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non–glycosylated rhG–CSF [letter] Miclea J, et al. **Bone Marrow Transplant** 1999 Aug;24(4):441–3

The importance of CD34+/CD33– cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Millar BC, et al. **Bone Marrow Transplant** 1998 Sep;22(5):469–75

Poor stem cell mobilizers--variation in response to G–CSF dose escalation [letter] Morris T, et al. **Bone Marrow Transplant** 1999 Aug;24(4):448–9

Effects of long–term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Mugishima H, et al. **Bone Marrow Transplant** 1999 Feb;23(4):395–6

CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. Olivero S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):387–94

Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. Ordemann R, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S25–8

Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Pecora AL. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S7–12 (33 ref.)

Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases. European Group for Blood and Marrow Transplantation. Peters C, et al. **Bone Marrow Transplant** 1998 Sep; 22(5):431–7

G–CSF–primed peripheral blood progenitor cells (PBPC) support in high–risk Ewing sarcoma of childhood. Prete A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S21–3

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti–tumor activity in patients with metastatic breast cancer. Prince HM, et al. **Bone Marrow Transplant** 1999 Mar;23(5):427–35

Expansion of cord blood progenitor cells. Querol S, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S77–80

Alloantigen presenting capacity, T cell alloreactivity and NK function of G–CSF–mobilized peripheral blood cells. Rondelli D, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):631–7

Stem cell mobilisation in lymphoproliferative diseases. Russell NH, et al. **Bone Marrow Transplant** 1998 Nov; 22(10):935–40 (41 ref.)

PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Scimè R, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1159–65

Introduction: current issues in high–dose chemotherapy and stem cell support. Shea TC. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S1–5 (62 ref.)

The utilization of cytokines in stem cell mobilization strategies. Shpall EJ. **Bone Marrow Transplant** 1999 May; 23 Suppl 2:S13–9 (37 ref.)

Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Singh RK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):53–62

Superior autologous blood stem cell mobilization from dose–intensive cyclophosphamide, etoposide, cisplatin plus G–CSF than from less intensive chemotherapy regimens. Stewart DA, et al. **Bone Marrow Transplant** 1999 Jan; 23(2):111–7

Management strategies for the hard–to–mobilize patient. Stiff PJ. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S29–33 (22 ref.)

Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection [letter] Tchirkov A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):229–30

Single leukapheresis products collected from healthy donors after the administration of granulocyte colony–stimulating factor contain ten–fold higher numbers of long–term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Theilgaard–Mönch K, et al. **Bone Marrow Transplant** 1999 Feb;23(3):243–9

Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo–PBT. Urbano–Ispizua A, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S71–4

Detection of contaminating tumor cells by RT–PCR in breast cancer patients [letter] Vannucchi AM, et al. **Bone Marrow Transplant** 1999 Jul;24(2):228–9

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Waples JM, et al. **Bone Marrow Transplant** 1999 May;23(9):867–73

Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY. Weaver CH, et al. **Bone Marrow Transplant** 1999 Mar; 23(5):421–5

Granulocyte colony–stimulating factor (G–CSF) transiently suppresses mitogen–stimulated T–cell proliferative response. Reyes E, et al. **Br J Cancer** 1999 Apr; 80(1–2):229–35

Fludarabine–containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Visani G, et al. **Br J Haematol** 1999 Jun;105(3):775–9

Efficacy of the mobilization of peripheral blood stem cells by granulocyte colony–stimulating factor in pediatric donors. Kawano Y, et al. **Cancer Res** 1999 Jul 15; 59(14):3321–4

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim–mobilized CD34–positive progenitor cells. Shapiro F, et al. **Clin Cancer Res** 1997 Sep;3(9):1571–8

Factors influencing platelet recovery after autologous transplantation of G–CSF–mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Hassan HT, et al. **Clin Lab Haematol** 1999 Feb;21(1):21–7

Granulocyte colony–stimulating factor–mobilized granulocyte concentrate transfusions. Price TH. **Curr Opin Hematol** 1998 Nov;5(6):391–5 (34 ref.)

Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin–8. Pruijt JF, et al. **Curr Opin Hematol** 1999 May;6(3):152–8

Study on the measurement of the percentage of viable cells in frozen peripheral blood stem cell harvesting samples by an automated hematology analyzer [letter] Aoyama Y, et al. **Eur J Haematol** 1998 Nov;61(5):356–7

Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. Knudsen LM, et al. **Eur J Haematol** 1998 Oct;61(4):229–34

Granulocyte colony–stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA. Horwitz ME, et al. **Exp Hematol** 1999 Jul;27(7):1160–7

Mobilization of peripheral blood progenitor cells for human immunodeficiency virus–infected individuals. Law P, et al. **Exp Hematol** 1999 Jan;27(1):147–54

Granulocyte colony–stimulating factor–mobilized peripheral blood stem cells in beta–thalassemia patients: kinetics of mobilization and composition of apheresis product. Li K, et al. **Exp Hematol** 1999 Mar;27(3):526–32

The "G–CSF test": the response to a single dose of

granulocyte colony-stimulating factor predicts mobilization of hemopoietic progenitors in patients with hematologic malignancies. Mijovic A, et al. **Exp Hematol** 1999 Jul;27(7):1204–9

Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Pierelli L, et al. **Exp Hematol** 1999 Mar;27(3):416–24

Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits. Pless M, et al. **Exp Hematol** 1999 Jan;27(1):155–61

Cord blood is better than bone marrow for generating megakaryocytic progenitor cells. Tao H, et al. **Exp Hematol** 1999 Feb;27(2):293–301

Regulation of the proliferative potential of cord blood long-term culture-initiating cells (LTC-IC) by different stromal cell lines: implications for LTC-IC measurement. Nadali G, et al. **Haematologica** 1998 Dec;83(12):1059–65

Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B, et al. **Haematologica** 1999 Apr;84(4):342–9

Leukocyte recovery from umbilical cord blood by poligeline. Perutelli P, et al. **Hematol Cell Ther** 1999 Feb;41(1):1–3

Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement. Viret F, et al. **Hematol Cell Ther** 1999 Feb;41(1):5–11

Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. Buzzi M, et al. **J Chemother** 1999 Aug;11(4):293–300

Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells. Bojko P, et al. **J Clin Apheresis** 1999;14(2):57–62

Selection of appropriate venous access for the collection of peripheral blood progenitor cells by experienced apheresis nurses. McDiarmid S, et al. **J Clin Apheresis** 1999; 14(2):51–6

Mobilization of peripheral blood stem cells in children using G-CSF after carboplatin containing myelosuppressive chemotherapy. Rauck AM, et al. **J Clin Apheresis** 1998; 13(4):146–54

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. Basser RL, et al. **J Clin Oncol** 1999 Jan;17(1):82–92

Infection of apheresis cells by parvovirus B19. Hemauer A, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):627–30

Hematotherapy Literature Watch. **J Hematother** 1999 Apr; 8(2):223–8

Differential effects of IL-2 incubation on hematopoietic potential of autologous bone marrow and mobilized PBSC from patients with hematologic malignancies. Areman EM, et al. **J Hematother** 1999 Feb;8(1):39–44

Factors influencing mobilization and engraftment in patients with metastatic breast cancer undergoing PBSC transplantation. de Magalhaes-Silverman M, et al. **J Hematother** 1999 Apr;8(2):167–72

Peripheral blood stem cell mobilization for high-dose chemotherapy. Demirer T, et al. **J Hematother** 1999 Apr; 8(2):103–13 (103 ref.)

G-CSF-mobilized leukapheresis products: cellular characteristics and clinical performance in allografting. Dlubek D, et al. **J Hematother** 1999 Apr;8(2):157–66

Fetal cord blood as an alternative source of hematopoietic progenitor cells: immunophenotype, maternal cell contamination, and ex vivo expansion. Engel H, et al. **J Hematother** 1999 Apr;8(2):141–55

Expanding mobilized progenitors for hematotherapy [editorial; comment] English D. **J Hematother** 1999 Apr; 8(2):91–2. Comment on: J Hematother 1999 Apr;8(2):93–102.

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. Gazitt Y, et al. **J Hematother** 1999 Apr;8(2):173–83

The relation between the number of PBSC and number of leukapheresis in children. Kajiume T, et al. **J Hematother** 1999 Apr;8(2):185–8

Minimization of CD34+ cell enumeration variability using the ProCOUNT standardized methodology. McNiece I, et al. **J Hematother** 1998 Dec;7(6):499–504

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. Schumm M, et al. **J Hematother** 1999 Apr;8(2):209–18

Ex vivo expansion of hematopoietic stem and progenitor cells: are we there yet? [see comments] Srour EF, et al. **J Hematother** 1999 Apr;8(2):93–102 (99 ref.). Comment in: J Hematother 1999 Apr;8(2):91–2.

The effect of overnight storage of leukapheresis stem cell products on cell viability, recovery, and cost. Sugrue MW, et al. **J Hematother** 1998 Oct;7(5):431–6

IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: monocyte inhibition. Ageitos AG, et al. **J Immunother** 1998 Nov;21(6):409–17

Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. Varney ML, et al. **J Interferon Cytokine Res** 1999 Apr; 19(4):351–60

Mini-ICE protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia [letter] Carella AM. **Leuk Lymphoma** 1998 Oct;31(3-4):437–8

Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Morton J, et al. **Leuk Res** 1999 Feb;23(2):177–83

Efficient detection and selection of immature rhesus monkey and human CD34+ hematopoietic cells expressing the enhanced green fluorescent protein (EGFP). Bierhuizen MF, et al. **Leukemia** 1999 Apr;13(4):605–13

The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Moos M, et al. **Leukemia** 1998 Dec;12(12):1971–6

Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer. Krüger W, et al. **Med Oncol** 1999 Apr;16(1):17–22

Feasibility and safety of peripheral blood stem cell collection in children with poor-prognosis solid tumors: a single center experience. Dolgopolov I, et al. **Pediatr Hematol Oncol** 1999 Jul-Aug;16(4):291–8

Peripheral blood stem cell transplantation in young children: experience with harvesting, mobilization and engraftment. Kletzel M, et al. **Pediatr Transplant** 1998 Aug;2(3):191–6

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Tarella C, et al. **Stem Cells** 1999; 17(1):55–61

Cytapheresis--the next 25 years: stem cell therapy [editorial] Isbister JP. **Ther Apher** 1997 May;1(2):112–6 (13 ref.)

Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Anderlini P, et al. **Transfusion** 1999 Jun;39(6):555–60

Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor [letter] Vij R, et al. **Transfusion** 1999 May;39(5):542–3

[Ex-vivo expansion of hematopoietic stem cells: study in the primate model] Norol F, et al. **Hematol Cell Ther** 1999 Apr;41(2):75–7 **(Fre)**

ADVERSE EFFECTS

Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Kasper C, et al. **Ann Hematol** 1999 Feb;78(2):91–2

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Ageitos AG, et al. **Bone Marrow Transplant** 1999 Jan; 23(1):63–9

Blood stem cell procurement: donor safety issues. Anderlini P, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S35–9 (62 ref.)

A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. LeBlanc R, et al. **Bone Marrow Transplant** 1999 May;23(10):991–6

Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination. Söhngen D, et al. **Bone Marrow Transplant** 1998 Dec; 22(11):1087–90

Bacterial decontamination of blood stem cell apheresis products. Gagnon JA, et al. **J Clin Apheresis** 1998; 13(3):103–7

Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization. Kobbe G, et al. **Oncol Rep** 1999 Sep-Oct;6(5):1151–2

ECONOMICS

The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Le Corroller AG, et al. **Anticancer Drugs** 1998 Nov;9(10):917–24 (39 ref.)

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Glaspy JA. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S21–7 (29 ref.)

Optimization of peripheral blood stem cell collection by leukopheresis. Interaction between economic and clinical assessment of an innovation. Le Corroller AG, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):161–72

INSTRUMENTATION

CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices. McNiece IK, et al. **J Hematother** 1998 Oct;7(5):457–61

METHODS

Biology of IL-8-induced stem cell mobilization. Fibbe WE, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:71–82 (39 ref.)

Amphotropic retrovirus transduction of hematopoietic stem cells. Orlic D, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:115–23; discussion 123–4

Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Neipp M, et al. **Blood** 1998 Nov 1;92(9):3177–88

A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Shpall EJ, et al. **Blood** 1999 Apr 15;93(8):2491–501

Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries. Clarke E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):117–24

Cell culture bags allow a large extent of ex vivo expansion of LTC-IC and functional mature cells which can subsequently be frozen: interest for a large-scale clinical applications. Giarratana MC, et al. **Bone Marrow Transplant** 1998 Oct;22(7):707–15

Conclusions of a national multicenter intercomparative study of in vitro cultures of human hematopoietic progenitors. Lamana M, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):373–80

Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Leuner S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):699–706

Characterization of peripheral blood progenitor cells mobilized by nartograstim (N-terminal replaced granulocyte colony-stimulating factor) in normal volunteers. Maruyama K, et al. **Bone Marrow Transplant** 1998 Aug;22(4):313–20

Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Reiser M, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1223–8

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Siegert W, et al. **Bone Marrow Transplant** 1998 Sep;22(6):579–83

A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Snowden JA, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1035–41

Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Waller CF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):19–24

Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Wiesneth M, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S21–4

Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA. Bellos F, et al. **Br J Haematol** 1998 Dec; 103(4):1192–7

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Ketterer N, et al. **Br J Haematol** 1998 Oct; 103(1):235–42

Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Roberts MM, et al. **Br J Haematol** 1999 Mar;104(4):778–84

Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Tichelli A, et al. **Br J Haematol** 1999 Jul;106(1):152–8

Mobilization of primitive haemopoietic progenitor cells and stem cells with long-term repopulating ability into peripheral blood in mice by pegylated recombinant human megakaryocyte growth and development factor. Torii Y, et al. **Br J Haematol** 1998 Dec;103(4):1172–80

A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes. van den Oudenrijn S, et al. **Br J Haematol** 1999 Aug;106(2):553–63

Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Waller CF, et al. **Br J Haematol** 1998 Oct;103(1):227–34

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma [letter; comment] Pedrazzoli P, et al. **Cancer** 1999 May 15;85(10):2295–6. Comment on: Cancer 1998 Mar 1;82(5):867–73.

Umbilical cord blood banking for unrelated transplantation: evaluation of cell separation and storage methods. Regidor C, et al. **Exp Hematol** 1999 Feb;27(2):380–5

Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization: comparative studies in a murine model. Verma UN, et al. **Exp Hematol** 1999 Mar;27(3):553–60

Short-term, serum-free, static culture of cord blood-derived CD34+ cells: effects of FLT3-L and MIP-1alpha on in vitro expansion of hematopoietic progenitor cells. Capmany G, et al. **Haematologica** 1999 Aug;84(8):675–82

New technology and changing parameters of leukapheresis for blood cell transplantation [letter] Granzow K, et al. **Haematologica** 1999 Aug;84(8):752

The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with

poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell technology. Chabannon C, et al. **Hematol Cell Ther** 1999 Apr;41(2):78-81

Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. McNiece I, et al. **Hematol Cell Ther** 1999 Apr;41(2):82-6

Femoral vascular access for large-volume collection of peripheral blood progenitor cells. Shariatmadar S, et al. **J Clin Apheresis** 1998;13(3):99-102

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Zimmerman TM, et al. **J Clin Apheresis** 1999;14(1):31-4

Continuous monitoring of hematocrit values during apheresis for allogeneic peripheral blood stem cell collection. Kajiume T, et al. **J Hematother** 1998 Dec;7(6):493-7

Clinical scale expansion of cryopreserved small volume whole bone marrow aspirates produces sufficient cells for clinical use. Lundell BI, et al. **J Hematother** 1999 Apr; 8(2):115-27

CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices. McNiece IK, et al. **J Hematother** 1998 Oct;7(5):457-61

Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. Paquette RL, et al. **J Hematother** 1998 Dec;7(6):481-91

Use of merocyanine 540 for the isolation of quiescent, primitive human bone marrow hematopoietic progenitor cells. Pyatt RE, et al. **J Hematother** 1999 Apr;8(2):189-98

Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent [letter] Serke S, et al. **J Hematother** 1998 Aug; 7(4):315-8

Concurrent partial body radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. Sharp JG, et al. **J Hematother** 1998 Aug;7(4):343-9

A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. Stainer CJ, et al. **J Hematother** 1998 Aug;7(4):375-83

The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. D'Hondt L, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):105-9

Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Petit J, et al. **Leuk Lymphoma** 1999 Jun; 34(1-2):119-27

In vitro and in vivo expansion of stem cell populations. Wagemaker G. **Vox Sang** 1998;74 Suppl 2:463-6 (51 ref.)

[Peripheral blood stem cell transplantation--practices of mobilization and harvest] Sugio Y, et al. **Rinsho Byori** 1999 May;Suppl 110:63-9 (Eng. Abstr.) **(Jpn)**

HEMATOPOIETIC STEM CELL TRANSPLANTATION

see related
HEMATOPOIETIC STEM CELL MOBILIZATION

Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Exner BG, et al. **Acta Haematol** 1999;101(2):78-81 (30 ref.)

Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Panizo C, et al. **Acta Haematol** 1999;101(4):193-6

Gene marking and gene therapy in multiple myeloma. Gahrton G, et al. **Adv Exp Med Biol** 1998;451:493-7 (15 ref.)

Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes. Schwartzberg LS, et al. **Am J Clin Oncol** 1999 Apr;22(2):136-42

Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support. Schwartzberg LS, et al. **Am J Clin Oncol** 1999 Apr;22(2):162-7

Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers. Schwartzberg LS, et al. **Am J Clin Oncol** 1998 Oct;21(5):523-31

The feasibility of using blood bank-stored (4 degrees C) cord blood, unmatched for HLA for marrow transplantation. Ende N, et al. **Am J Clin Pathol** 1999 Jun;111(6):773-81

Autopsy findings in umbilical cord blood transplant recipients. Nuckols JD. **Am J Clin Pathol** 1999 Sep; 112(3):335-42

Relationships between aminoglycoside and vancomycin pharmacokinetics in patients with hematopoietic stem-cell transplants. Leader WG, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):161-4

Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Ketterer N, et al. **Am J Med** 1999 Feb;106(2):191-7

Transplantation of CD34 human cells into mice with severe combined immunodeficiency results in functional T cells 4 weeks after transplantation. Polcaro J, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):80-6

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ferrara F, et al. **Ann Hematol** 1999 Aug;78(8):380-4

High-dose therapy and stem cell transplantation in follicular lymphoma. Friedberg JW, et al. **Ann Hematol** 1999 May; 78(5):203-11 (62 ref.)

Successful salvage treatment for relapse after autologous stem cell transplantation in a patient with Hodgkin's disease--a case report. Kaiser U, et al. **Ann Hematol** 1999 Jan; 78(1):33-5

Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Kasper C, et al. **Ann Hematol** 1999 Feb;78(2):91-2

Technical aspects and performance in collecting peripheral blood progenitor cells. Moog R, et al. **Ann Hematol** 1998 Oct;77(4):143-7 (46 ref.)

Effect of high-dose melphalan and peripheral blood stem cell transplantation on renal function in patients with multiple myeloma and renal insufficiency: a case report and review of the literature. Reiter E, et al. **Ann Hematol** 1999 Apr;78(4):189-91 (14 ref.)

High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis. McColl G, et al. **Ann Intern Med** 1999 Oct 5;131(7):507-9

Characterization of purified and ex vivo manipulated human hematopoietic progenitor and stem cells in xenograft recipients. Bock TA, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:200-7; discussion 207-10 (42 ref.)

Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Brugger W, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:363-71 (22 ref.)

Absence of CD34 on some human SCID-repopulating cells. Dick JE. **Ann N Y Acad Sci** 1999 Apr 30;872:211-7; discussion 217-9 (30 ref.)

Stem cell gene therapy for the beta-chain hemoglobinopathies. Problems and progress. Emery DW, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:94-107; discussion 107-8 (64 ref.)

Transplantation of megadoses of purified haploidentical stem cells. Handgretinger R, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:351-61; discussion 361-2

Homing of long-term and short-term engrafting cells in vivo. Lanzkron SM, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:48-54; discussion 54-6

Organogenesis by desired metaplasia of autogenous stem cells. Matapurkar BG, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:263-7

Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells. Medin JA, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:233-40; discussion 240-2

Further characterization of CD34-low/negative mouse hematopoietic stem cells. Nakauchi H, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:57-66; discussion 66-70

Lymphohematopoietic stem cell engraftment. Quesenberry PJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:40-5; discussion 45-7 (19 ref.)

The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Reisner Y, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:336-48; discussion 348-50 (37 ref.)

The Placental/Umbilical Cord Blood Program of the New York Blood Center. A progress report. Rubinstein P, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:328-34; discussion 334-5

Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells. Slavin S, et al. **Ann N Y Acad Sci** 1998 Dec 30;862:37-44

Engraftment and multilineage expression of human bone marrow CD34- cells in vivo. Zanjani ED, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:220-31; discussion 231-2

Lyon Consensus Conference on high-dose therapy in diffuse large-cell lymphoma [news] **Ann Oncol** 1998 Jul;9(7):685-6

Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Bertolini F, et al. **Ann Oncol** 1998 Aug;9(8):913-6

A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany [letter] Diehl V, et al. **Ann Oncol** 1999 May;10(5):609

High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre [see comments] Foran JM, et al. **Ann Oncol** 1998 Aug;9(8):865-9. Comment in: Ann Oncol 1998 Aug;9(8):803-5.

The high-dose sequential (Milan) chemotherapy/PBSC transplantation regimen for patients with lymphoma is not cardiotoxic. Ghielmini M, et al. **Ann Oncol** 1999 May; 10(5):533-7

The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission. Goldstone AH. **Ann Oncol** 1998;9 Suppl 5:S83-5 (3 ref.)

High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Pavletic ZS, et al. **Ann Oncol** 1998 Sep;9(9):1023-6

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. Prince HM, et al. **Ann Oncol** 1999 Apr;10(4):479-81

Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Przepiorka D, et al. **Ann Oncol** 1999 May;10(5):527-32

Stem cell transplant at home: glimpse of the future [editorial; comment] Reed E, et al. **Ann Oncol** 1999 May;10(5):493-4 . Comment on: Ann Oncol 1999 May;10(5):511-7.

Minimal residual disease in autologous hematopoietic harvests from breast cancer patients. Spyridonidis A, et al. **Ann Oncol** 1998 Aug;9(8):821-6 (72 ref.)

Cost comparison between PAV and ICE treatment with peripheral blood progenitor cells (PBPC) reinfusion in small-cell lung cancer (SCLC) [letter] Wasserfallen JB, et al. **Ann Oncol** 1999 Feb;10(2):243-4

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies [see comments] Westermann AM, et al. **Ann Oncol** 1999 May;10(5):511-7 . Comment in: Ann Oncol 1999 May;10(5):493-4.

Tolerance induction for islet transplantation. Exner BG, et al. **Ann Transplant** 1997;2(3):77-80 (68 ref.)

High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution. Bertucci F, et al. **Anticancer Res** 1999 Mar-Apr; 19(2B):1455-61

High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Bessho A, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):693-8

Immunotherapy with recombinant human interleukin 2 in patients with hematological malignancies after bone marrow or peripheral blood stem cell transplantation. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):223-7 (40 ref.)

An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Volk EE, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):508-13 (62 ref.)

A preliminary definition of the term "cure" as applied to systemic lupus erythematosus. Euler HH. **Arthritis Rheum** 1999 Jul;42(7):1552

Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Martini A, et al. **Arthritis Rheum** 1999 Apr; 42(4):807-11

Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Schachna L, et al. **Arthritis Rheum** 1998 Dec;41(12):2271-2

A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: a phase II study. Gingrich RD, et al. **Biol Blood Marrow Transplant** 1999; 5(2):86-93

Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Haut PR, et al. **Biol Blood Marrow Transplant** 1998;4(1):38-42

Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Leung W, et al. **Biol Blood Marrow Transplant** 1999;5(2):69-76

A human-murine chimera model for in utero human hematopoietic stem cell transplantation. Leung W, et al. **Biol Blood Marrow Transplant** 1999;5(1):1-7

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Margolin KA, et al. **Biol Blood Marrow Transplant** 1999;5(1):36-45

Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Shpall EJ, et al. **Biol Blood Marrow Transplant** 1998;4(2):84-92 (57 ref.)

A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Ustün C, et al. **Biol Blood Marrow Transplant** 1999;5(1):28-35

A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Vredenburgh JJ, et al. **Biol Blood Marrow Transplant** 1998;4(3):134-41

Serum-free ex vivo expansion of CD34(+) hematopoietic progenitor cells. Möbest D, et al. **Biotechnol Bioeng** 1998 Nov 5;60(3):341-7

Choosing the source of stem cells for allogeneic transplantation: no longer a peripheral issue [comment] Appelbaum FR. **Blood** 1999 Jul 15;94(2):381-3. Comment on: Blood 1999 Jul 15;94(2):384-9.

In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Battaile KP, et al. **Blood** 1999 Sep 15;94(6):2151-8

Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results

in a graft capable of rescuing lethally irradiated baboons. Brandt JE, et al. **Blood** 1999 Jul 1;94(1):106–13

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Burt RK, et al. **Blood** 1998 Nov 15;92(10):3505–14

Comparative analysis of autografting in chronic myelogenous leukemia: effect of priming regimen and marrow or blood origin of stem cells [letter; comment] Carella A. **Blood** 1999 Mar 15;93(6):2136–8. Comment on: Blood 1998 Sep 1;92(5):1820–31.

Autografting with philadelphia chromosome–negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Carella AM, et al. **Blood** 1999 Mar 1;93(5):1534–9

Human growth factor–enhanced regeneration of transplantable human hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient mice. Cashman JD, et al. **Blood** 1999 Jan 15;93(2):481–7

Long-term contribution to the myeloid compartment by lineage–committed stem cells. Chen CC, et al. **Blood** 1998 Nov 1;92(9):3210–7

The risk of residual molecular and cytogenetic disease in patients with Philadelphia–chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow [see comments] Elmaagacli AH, et al. **Blood** 1999 Jul 15;94(2):384–9. Comment in: Blood 1999 Jul 15;94(2):381–3.

Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Facon T, et al. **Blood** 1999 Aug 15;94(4):1218–25

Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Fearnley DB, et al. **Blood** 1999 Jan 15;93(2):728–36

High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Fermand JP, et al. **Blood** 1998 Nov 1; 92(9):3131–6

Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Franklin WA, et al. **Blood** 1999 Jul 1;94(1):340–7

Behavior and therapeutic efficacy of beta-glucuronidase–positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Freeman BJ, et al. **Blood** 1999 Sep 15;94(6):2142–50

Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo–expanded human CD34(+) cord blood cells. G enechea G, et al. **Blood** 1999 Feb 1;93(3):1097–105

Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization. Gokmen E, et al. **Blood** 1998 Oct 15;92(8):2802–14

Cell cycle–related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Gothot A, et al. **Blood** 1998 Oct 15;92(8):2641–9

Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Guardiola P, et al. **Blood** 1999 May 1;93(9):2831–8

Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients [letter; comment] [see comments] Gyger M, et al. **Blood** 1998 Nov 1;92(9):3489–90. Comment on: Blood 1997 Jul 1;90(1):36–42. Comment in: Blood 1999 Jun 15;93(12):4446–9.

The common marmoset as a target preclinical primate model for cytokine and gene therapy studies. Hibino H, et al. **Blood** 1999 May 1;93(9):2839–48

Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Holyoake T, et al. **Blood** 1999 Sep 15;94(6):2056–64

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Kawano Y, et al. **Blood** 1998 Nov 1;92(9):3123–30

Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT [see comments] Kawano Y, et al. **Blood** 1998 Dec 1;92(11):4040–6. Comment in: Blood 1999 May 15;93(10):3565–6.

A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1–infected children. Kohn DB, et al. **Blood** 1999 Jul 1;94(1):368–71

The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. Kollet O, et al. **Blood** 1999 Aug 1;94(3):923–31

Hematopoietic stem cell tracking in vivo: a comparison of short-term and long-term repopulating cells. Lanzkron SM, et al. **Blood** 1999 Mar 15;93(6):1916–21

Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Locatelli F, et al. **Blood** 1999 Jun 1;93(11):3662–71

Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Lutzko C, et al. **Blood** 1999 Mar 15;93(6):1895–905

Engraftment of ex vivo–expanded cord blood cells in NOD/SCID mice: what is the clinical relevance? [letter; comment] McNiece IK. **Blood** 1999 Jun 15;93(12):4445–6 Comment on: Blood 1999 Feb 1;93(3):1097–105.

Idiotype vaccination in human myeloma: generation of tumor–specific immune responses after high-dose chemotherapy. Massaia M, et al. **Blood** 1999 Jul 15; 94(2):673–83

Engraftment of MDR1 and NeoR gene–transduced hematopoietic cells after breast cancer chemotherapy. Moscow JA, et al. **Blood** 1999 Jul 1;94(1):52–61

Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? [letter; comment] Ojeda E, et al. **Blood** 1999 May 15;93(10):3565–6 . Comment on: Blood 1998 Dec 1;92(11):4040–6.

Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Palumbo A, et al. **Blood** 1999 Aug 15; 94(4):1248–53

Granulocyte colony–stimulating factor–mobilized allogeneic stem cell transplantation maintains graft–versus–leukemia effects through a perforin-dependent pathway while preventing graft–versus–host disease. Pan L, et al. **Blood** 1999 Jun 15;93(12):4071–8

Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self–renewal of repopulating stem cells. Piacibello W, et al. **Blood** 1999 Jun 1;93(11):3736–49

Risk factors for acute graft–versus–host disease after allogeneic blood stem cell transplantation. Przepiorka D, et al. **Blood** 1999 Aug 15;94(4):1465–70

One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Rebel VI, et al. **Blood** 1999 Apr 1;93(7):2217–24

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Reichardt VL, et al. **Blood** 1999 Apr 1;93(7):2411–9

Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Ringdén O, et al. **Blood** 1999 Jul 15;94(2):455–64

Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Ruggeri L, et al. **Blood** 1999 Jul 1;94(1):333–9

High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions. Schilz AJ, et al. **Blood** 1998 Nov 1;92(9):3163–71

Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Shih CC, et al. **Blood** 1999 Sep 1;94(5):1623–36

A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Shpall EJ, et al. **Blood** 1999 Apr 15;93(8):2491–501

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Szilvassy SJ, et al. **Blood** 1999 Mar 1;93(5):1557–66

Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. van Hennik PB, et al. **Blood** 1998 Dec 1;92(11):4013–22

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Vescio R, et al. **Blood** 1999 Mar 15;93(6):1858–68

Proceedings of the 3rd Central European Transplant Conference. Wroclaw, Poland, December 15–17, 1997. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S1–122

EUROCORD. Proceedings of the 2nd Eurocord Transplant Concerted Action Workshop. Annecy, France, May 8–10, 1997. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S1–88

25th Annual meeting of the European Group for Blood and Marrow Transplantation and 15th meeting of the Nurses Group. Hamburg, March 21–24, 1999. Abstracts. **Bone Marrow Transplant** 1999 Mar;23 Suppl 1:S1–286

3rd Stem Cell Workshop. High dose therapy and transplantation of haemopoietic stem cells. Bad Saarow, Germany, 25–27 April 1997. Abstracts. **Bone Marrow Transplant** 1998 Aug;22 Suppl 2:S1–40

4th International Symposium on High-dose Chemotherapy and Stem Cell Transplantation in Solid Tumors. Berlin, Germany, 18–19 April 1998. Abstracts. **Bone Marrow Transplant** 1998 Nov;22 Suppl 3:S1–115

4th International Stem Cell Workshop: High dose therapy and transplantation of haemopoietic stem cells and Round Table discussion of experts in stem cell transplantation: Indications and novel approaches in allogeneic and autologous blood cell transplantation. Bad Saarow/Berlin, Germany, April 29–May 1, 1999. Abstracts. **Bone Marrow Transplant** 1999 May;23 Suppl 3:S1–41

Peripheral Blood Stem Cells Transplantation in Children. Padua, Italy, September 19, 1997. Proceedings. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S1–55

PBPC as an alternative cell therapy for post-transplant relapse in CML [letter] Abecasis MM, et al. **Bone Marrow Transplant** 1998 Sep;22(6):613–4

Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Abonour R, et al. **Bone Marrow Transplant** 1998 Nov;22(10):957–63

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Ageitos AG, et al. **Bone Marrow Transplant** 1999 Jan; 23(1):63–9

Autotransplantation in chronic myeloid leukemia [letter; comment] Aguado MJ, et al. **Bone Marrow Transplant** 1998 Oct;22(8):831. Comment on: Bone Marrow Transplant 1998 Mar;21(5):455–60.

Massive myelomatous ascites responsive to VAD chemotherapy and autologous stem cell transplantation. Alegre A, et al. **Bone Marrow Transplant** 1999 Aug; 24(3):343–4

Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Alessandrino EP, et al. **Bone Marrow Transplant** 1999 Mar;23(6):607–12

Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Amigo ML, et al. **Bone Marrow Transplant** 1999 Aug;24(3):289–93

Blood stem cell procurement: donor safety issues. Anderlini P, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S35–9 (62 ref.)

Umbilical cord blood transplant from HLA-mismatched unrelated donor in high-risk leukemia. Arcese W, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S85–6

Cord blood banking in London: the first 1000 collections. Armitage S, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):139–45

Unrelated donor stem cell transplantation after autologous transplantation: experience of a single center. Aschan J, et al. **Bone Marrow Transplant** 1999 Aug;24(3):279–82

Mismatched T cell–depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia. Aversa F, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S29–32

Haemopoietic cell transplantation activity and results: a single institution experience. Barta A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S60–2

Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient [letter; comment] Başlar Z, et al. **Bone Marrow Transplant** 1998 Aug;22(4):404–5. Comment on: Bone Marrow Transplant 1997 Jul;20(2):179–80.

Successful cryopreservation of purified autologous CD34+ cells: influence of freezing parameters on cell recovery and engraftment. Beaujean F, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1091–6

Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts. Behringer D, et al. **Bone Marrow Transplant** 1999 Aug;24(3):295–302

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bellucci R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):1–8

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bence-Bruckler I, et al. **Bone Marrow Transplant** 1998 Nov;22(10):965–9

Discrepancy of clinical, radiographic and histopathologic findings in two children with chronic pulmonary graft-versus-host disease after HLA-identical sibling stem cell transplantation. Benesch M, et al. **Bone Marrow Transplant** 1998 Oct;22(8):809–12

Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Benet I, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1101–7

Control of stem cell proliferation and differentiation to achieve stable gene transfer and expression. Bertolini F, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S75–6

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bewick M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):377–84

Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study. Blaise D, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1153–8

Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. EBMT Working Party on Chronic Leukemias. Boiron JM, et al. **Bone Marrow Transplant** 1999 Aug;24(3):259–64

Stable mixed chimerism without relapse after related

allogeneic umbilical cord blood transplantation in a child with severe aplastic anemia. Boiron JM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):819–21

Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bolwell B, et al. **Bone Marrow Transplant** 1998 Sep; 22(6):547–51

Successful related umbilical cord blood transplantation for graft failure following T cell–depleted non–identical bone marrow transplantation in a child with major histocompatibility complex class II deficiency. Bonduel M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):437–40

Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bonnet D, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):203–9

Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood stem cells. Burt RK, et al. **Bone Marrow Transplant** 1999 Feb;23(4):381–6

A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Burtness BA, et al. **Bone Marrow Transplant** 1999 Feb;23(4):311–5

Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL, et al. **Bone Marrow Transplant** 1998 Sep;22(6):541–5

Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Byrne JL, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):639–43

Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity. Chan KW, et al. **Bone Marrow Transplant** 1999 Apr;23(8):849–51

Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis. Chan KW, et al. **Bone Marrow Transplant** 1998 Aug;22(3):301–2

Peripheral blood CD34+ cell count reliably predicts autograft yield. Chapple P, et al. **Bone Marrow Transplant** 1998 Jul;22(2):125–30

Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Chockalingam A, et al. **Bone Marrow Transplant** 1999 May;23(10):1093–4

Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Clark RE, et al. **Bone Marrow Transplant** 1998 Nov;22(9):859–63

Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M: effect on CD34+ cells and progenitor cell recoveries. Clarke E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):117–24

Use of G-CSF to mobilise PBSC in normal healthy donors--an international survey. Cleaver SA, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S29–31

Immunological and functional differences between cord and peripheral blood. Cohen SB, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S9–12

A retrospective Dutch study comparing T cell–depleted allogeneic blood stem cell transplantation vs T cell–depleted allogeneic bone marrow transplantation. Cornelissen JJ, et al. **Bone Marrow Transplant** 1998 Jun; 21 Suppl 3:S66–70

Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Couban S, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1199–205

Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases. Dazzi C, et al. **Bone Marrow Transplant** 1999 Mar;23(6):529–32

FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Deane M, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1137–43

Changes in L-selectin expression on CD34-positive cells upon cryopreservation of peripheral blood stem cell transplants. De Boer F, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1103–10

Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity. de la Serna J, et al. **Bone Marrow Transplant** 1999 Jan;23(1):95–7

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. del Cañizo C, et al. **Bone Marrow Transplant** 1999 May;23(9):901–5

Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation. Demirer T, et al. **Bone Marrow Transplant** 1999 Aug;24(3):335–7

Umbilical cord blood as a good alternative to bone marrow for allogeneic cell transplantation in children with hemoblastosis. Diaz de Heredia C, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S80–2

Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Dreger P, et al. **Bone Marrow Transplant** 1999 Jul;24(2):153–61

Hematopoietic stem cell transplantation for infantile osteopetrosis. Eapen M, et al. **Bone Marrow Transplant** 1998 Nov;22(10):941–6

Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Fanin R, et al. **Bone Marrow Transplant** 1999 Mar; 23(5):437–42

Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Faucher C, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S92–8

Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours. Fischmeister G, et al. **Bone Marrow Transplant** 1999 Aug; 24(4):405–9

Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Freeman M, et al. **Bone Marrow Transplant** 1999 Sep;24(6):679–84

A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Gandhi M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):369–75

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Gandhi MK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):9–13

Lymphoma cell contamination of PBSC: a murine model. Gidáli J, et al. **Bone Marrow Transplant** 1999 Sep; 24(6):617–20

Immunotherapeutic aspects of allogeneic peripheral progenitor cells. Glass B, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S3–8

European results of unrelated cord blood transplants. Eurocord group. Gluckman E, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S87–91

Cord blood banking and transplant in Europe. Eurocord. Gluckman E, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S68–74

High-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in children with high-risk NHL and ALL–preliminary results. Gorczyńska E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S107–9

Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Gratwohl A, et al. **Bone Marrow Transplant** 1999 Aug;24(3):231–45

Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation. Gruber A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):169–72

Relapsed chronic myeloid leukemia in accelerated phase 10 years after allogeneic bone marrow transplantation: full chimera reconversion with donor peripheral blood stem cells infusion. Guimarães A, et al. **Bone Marrow Transplant** 1998 Sep;22(6):595–7

Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Hägglund H, et al. **Bone Marrow Transplant** 1998 Jul;22(2):131–6

NETCORD: a cord blood allocation network. Hakenberg P, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S17–8

Allogeneic peripheral blood stem cell transplantation for standard-risk leukemia. A multicenter pilot study: Japanese experience. Japan Blood Cell Transplantation Study Group. Harada M, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S54–6

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Hartmann O, et al. **Bone Marrow Transplant** 1999 Apr;23(8):789–95

Superior antileukemic activity of murine peripheral blood progenitor cell (PBPC) grafts mobilized by G-CSF and stem cell factor (SCF) as compared to G-CSF alone. Hartung G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S16–20

Effective T cell regeneration following high-dose chemotherapy rescued with CD34+ cell enriched peripheral blood progenitor cells in children. Heitger A, et al. **Bone Marrow Transplant** 1999 Feb;23(4):347–53

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):625–30

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Holmberg LA, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):651–9

Allogeneic peripheral blood stem cell transplantation in a Wiskott-Aldrich syndrome patient [letter] Hongeng S, et al. **Bone Marrow Transplant** 1999 Aug;24(4):445–6

Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Bone Marrow Transplant** 1999 Jul;24(2):119–21

Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Imashuku S, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):569–72

Colostrum and severe gut GVHD [letter] Inoue M, et al. **Bone Marrow Transplant** 1998 Aug;22(4):402–3

Umbilical cord blood (UCB) transplant from unrelated mismatched donor in patients with high risk (HR) leukemia. Iori AP, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S75

Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Jacquy C, et al. **Bone Marrow Transplant** 1999 Apr;23(7):681–6

Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Jansen J, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1251–6

Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications. Jindra P, et al. **Bone Marrow Transplant** 1999 Jul;24(2):215–7

Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Katsanis E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):185–91

Peripheral blood stem cell mobilization with granulocyte colony-stimulating factor and a harvesting procedure in pediatric donors. Kawano Y, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S32–4

Extramedullary T lymphoblastic transformation of chronic myeloid leukaemia occurring after double allogeneic transplantation. Kell J, et al. **Bone Marrow Transplant** 1998 Oct;22(8):813–6

Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Kiel K, et al. **Bone Marrow Transplant** 1999 May;23(10):1019–27

The number of particular hematopoietic progenitors cells and the haematopoietic recovery following Allo PBSCT. Knopińska-Posłuszny W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S92–5

An eight-fold ex vivo expansion of long-term culture-initiating cells from umbilical cord blood in stirred suspension cultures. Kögler G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S48–53

Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Koh MB, et al. **Bone Marrow Transplant** 1999 May; 23(10):1071–9

Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B. Krüger WH, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S10–3

Use of selected CD34+ cells in the treatment of relapsed Hodgkin's lymphoma (letter). Lakota J. **Bone Marrow Transplant** 1999 Sep;24(6):697–9

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Lancet JE, et al. **Bone Marrow Transplant** 1998 Aug;22(3):265–71

Clinical scale isolation of highly purified peripheral CD34+ progenitors for autologous and allogeneic transplantation in children. Lang P, et al. **Bone Marrow Transplant** 1999 Sep;24(6):583–9

Unrelated mismatched cord blood transplantation in patients with hematological malignancies: a single institution experience. Laporte JP, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S76–7

Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Lee J, et al. **Bone Marrow Transplant** 1999 Aug;24(4):411–5

Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Lee SM, et al. **Bone Marrow Transplant** 1999 Aug;24(3):271–7

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Lemoli RM, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):235–41

Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Leung W, et al. **Bone Marrow Transplant** 1998 Nov;22(10):971–9

Busulphan level and early mortality in thalassaemia patients after BMT. Li CK, et al. **Bone Marrow Transplant** 1999 Feb;23(4):307–10

Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Lie AK, et al. **Bone Marrow Transplant** 1998 Nov;22(9):853–7

Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow. Liu J, et al. **Bone Marrow Transplant** 1999 Aug;24(3):247–52

Immunization of transplant recipients [editorial; comment] Ljungman P. **Bone Marrow Transplant** 1999 Apr; 23(7):635–6. Comment on: Bone Marrow Transplant 1999 Apr;23(7):637–46.

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Ljungman P, et al. **Bone Marrow Transplant** 1998 Sep; 22(5):445–8

Cord blood transplantation for children with acute leukemia. Eurocord Transplant Group. Locatelli F, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S63–5

Transplantation of peripheral blood stem cells mobilized by haematopoietic growth factors in childhood. Locatelli F, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S51–5 (44 ref.)

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):317–22

Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Lowenthal RM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):763–70

Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Lucidarme N, et al. **Bone Marrow Transplant** 1998 Sep; 22(6):535–40

Autotransplants in men with breast cancer. ABMTR Breast Cancer Working Committee. Autologous Blood and Marrow Transplant Registry. McCarthy P, et al. **Bone Marrow Transplant** 1999 Aug;24(4):365–8

G-CSF dosage and scheduling following autologous PBSC transplantation [letter; comment] McQuaker IG, et al. **Bone Marrow Transplant** 1998 Nov;22(10):1027–8. Comment on: Bone Marrow Transplant 1998 May;21(10):1005–10.

G-CSF-mobilized PBSCT in children with AML in first complete remission [letter; comment] Madero L, et al. **Bone Marrow Transplant** 1999 May;23(9):975–6. Comment on: Bone Marrow Transplant 1998 Feb;21(4):375–82.

Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant. Maharaj D, et al. **Bone Marrow Transplant** 1999 Mar;23(6):539–48

Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Mahmoud H, et al. **Bone Marrow Transplant** 1999 Aug;24(4):355–8

Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Majolino I, et al. **Bone Marrow Transplant** 1998 Sep;22(5):449–55

Formation of fibrin clots in cryopreserved stem cell bags during thawing procedure: lack of impact on engraftment in autologous stem cell transplantation [letter] Mandanas RA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):303–4

Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura. Marmont AM, et al. **Bone Marrow Transplant** 1998 Oct;22(8):827–8

Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic purpura. Marmont AM. **Bone Marrow Transplant** 1999 Jun; 23(12):1215–6 (26 ref.)

Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent. Marolleau JP, et al. **Bone Marrow Transplant** 1999 Apr;23(8):819–26

CDC group IV c-2 bacteremia in stem cell transplant recipients [letter; comment] Martino R, et al. **Bone Marrow Transplant** 1998 Aug;22(4):401–2. Comment on: Bone Marrow Transplant 1997 Dec;20(11):1005–6.

Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Martino R, et al. **Bone Marrow Transplant** 1999 Aug;24(3):283–7

Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Mazza P, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1273–8

Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Meehan KR, et al. **Bone Marrow Transplant** 1999 Apr;23(7):667–73

The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Millar BC, et al. **Bone Marrow Transplant** 1998 Sep;22(5):469–75

Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Milpied N, et al. **Bone Marrow Transplant** 1999 Mar;23(6):629–30

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Milpied N, et al. **Bone Marrow Transplant** 1998 Oct;22(7):645–50

Allogeneic transplantation of peripheral blood progenitor cells in children: experience of two pediatric centers. Miniero R, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S33–6

Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Miniero R, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S37–40

Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Miniero R, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S78–9

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Moreau P, et al. **Bone Marrow Transplant** 1999 May;23(10):1003–6

Poor stem cell mobilizers--variation in response to G-CSF dose escalation [letter] Morris T, et al. **Bone Marrow Transplant** 1999 Aug;24(4):448–9

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Moskowitz CH, et al. **Bone Marrow Transplant** 1999 Mar;23(6):561–7

Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. Müller S, et al. **Bone Marrow Transplant** 1999 Sep;24(6):575–81

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor (CD34+) cell transplantation. Musso M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):207–9

Immunological reconstitution after cord blood transplantation for an adult patient. Nagayama H, et al. **Bone Marrow Transplant** 1999 Jul;24(2):211–3

Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Nagler A, et al. **Bone Marrow Transplant** 1999 Aug;24(3):339–42

Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation. Nakane M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):219–21

Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Nawa Y, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1321–2

Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APBSCT) for cutaneous CD30-negative large T cell lymphoma. Nishio M, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1211–4

Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy. Nowak R, et al. **Bone Marrow Transplant** 1999 May;23(9):895–900

Multifocal reversible epithelial dysplasia mimicking carcinoma in situ after conditioning therapy with busulfan and cyclophosphamide [letter] Obermann E, et al. **Bone Marrow Transplant** 1999 Aug;24(4):446–7

CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. O'Donnell PV, et al. **Bone Marrow Transplant** 1998 Nov;22(10):947–55

A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Ojeda E, et al. **Bone Marrow Transplant** 1999 Sep;24(6):601–7

Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. Ordemann R, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S25–8

High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Papadopoulos KP, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):661–7

Double allogeneic peripheral stem cell transplants for patients at high risk of relapse. Passweg JR, et al. **Bone Marrow Transplant** 1998 Aug;22(4):321–4

Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura. Patriarca F, et al. **Bone Marrow Transplant** 1999 Aug;24(4):433–5

Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Pecora AL. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S7–12 (33 ref.)

Autologous stem cell transplantation for high-risk pediatric solid tumors. Perer.tesis J, et al. **Bone Marrow Transplant** 1999 Sep;24(6):609–15

Transplantation activities and treatment strategies in paediatric stem cell transplantation centres: a report from the EBMT Working Party on Paediatric Diseases. European Group for Blood and Marrow Transplantation. Peters C, et al. **Bone Marrow Transplant** 1998 Sep; 22(5):431–7

Peripheral blood stem cell collection and transplantation in paediatric malignancies: a monocentric experience. Petris MG, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S13–5

Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Piccirillo N, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1245–50

Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Pigneux A, et al. **Bone Marrow Transplant** 1999 Aug;24(3):265–70

Contribution of maternal and neonatal factors to the evaluation of umbilical cord blood [letter] Prat I, et al. **Bone Marrow Transplant** 1999 Apr;23(8):853–5

Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells. Preijers FW, et al. **Bone Marrow Transplant** 1999 May;23(10):1061–70

G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. Prete A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S21–3

Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Przepiorka D, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1291–5

Expansion of cord blood progenitor cells. Querol S, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S77–80

Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies. Rabitsch W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S49–52

Autologous stem cell transplantation for relapsed and primary refractory myeloma. Rajkumar SV, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1267–72

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Rajkumar SV, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1261–6

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Reece DE, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1131–8

Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Reiser M, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1223–8

Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Reiter E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S86–8

Autologous stem cell transplantation for malignant lymphomas. Reményi P, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S104–6

Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. Ringdén O, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S81–4

Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant group. Rocha V, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S59–62

Autologous PBPCT in a patient with lymphoma and Sjögren's syndrome: complete remission of lymphoma without control of the autoimmune disease. Rösler W, et al. **Bone Marrow Transplant** 1998 Jul;22(2):211–3

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. Rossbach HC, et al. **Bone Marrow Transplant** 1999 Jan;23(1):91–3

Stem cell mobilisation in lymphoproliferative diseases. Russell NH, et al. **Bone Marrow Transplant** 1998 Nov; 22(10):935–40 (41 ref.)

Multiple risk factors for high-dose chemotherapy [letter] Sarrá J, et al. **Bone Marrow Transplant** 1998 Nov;22(9):933

Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation. Schimmer AD, et al. **Bone Marrow Transplant** 1998 Sep; 22(5):491–4

Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Schuler US, et al. **Bone Marrow Transplant** 1998 Aug;22(3):241–4

Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis. Schwinger W, et al. **Bone Marrow Transplant** 1998 Aug;22(4):393–6

PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia. Scimè R, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1159–65

Hematopoietic cell transplantation: activity and results of the BMT Unit K.Dłuski Hosp./Inst.Immun. & Exp.Therapy, Wrocław, Poland. Sędzimirska M, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S57–9

Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Seropian S, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):599–605

Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent

high-dose chemotherapy with autologous stem cell support. Sezer O, et al. **Bone Marrow Transplant** 1999 May; 23(9):967–9

Introduction: current issues in high-dose chemotherapy and stem cell support. Shea TC. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S1–5 (62 ref.)

Immune reconstitution following allogeneic peripheral blood stem cell transplants. Shenoy S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):335–46

Optimal timing for processing and cryopreservation of umbilical cord haematopoietic stem cells for clinical transplantation. Shlebak AA, et al. **Bone Marrow Transplant** 1999 Jan;23(2):131–6

The utilization of cytokines in stem cell mobilization strategies. Shpall EJ. **Bone Marrow Transplant** 1999 May; 23 Suppl 2:S13–9 (37 ref.)

Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. Sica S, et al. **Bone Marrow Transplant** 1998 Oct;22(8):823–5

High-dose chemotherapy for salvage treatment of germ cell tumors: Charité, Virchow Klinikum, Berlin. Siegert W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S7–9

Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Siegert W, et al. **Bone Marrow Transplant** 1998 Sep;22(6):579–83

High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Simpson DR, et al. **Bone Marrow Transplant** 1998 Aug;22(3):259–64

Reimmunization after blood or marrow stem cell transplantation [see comments] Singhal S, et al. **Bone Marrow Transplant** 1999 Apr;23(7):637–46 (87 ref.). Comment in: Bone Marrow Transplant 1999 Apr;23(7):635–6.

Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. Singhal S, et al. **Bone Marrow Transplant** 1999 May;23(9):875–9

A quality system for placental blood banking. Sirchia G, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S43–7 (18 ref.)

A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Snowden JA, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1035–41

Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT. Solano C, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1129–35

Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Stewart DA, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1237–43

Management strategies for the hard-to-mobilize patient. Stiff PJ. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S29–33 (22 ref.)

HLA-identical sibling peripheral blood cell transplants. The Australian experience and preliminary results of a randomised study. Szer J, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S57–8

Transplantation with peripheral blood stem cells, manipulated or unmanipulated, for the treatment of high-risk childhood leukemia. Takaue Y, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S1–6 (15 ref.)

Successful engraftment of unrelated cord blood stem cells for familial erythrophagocytic lymphohistiocytosis. Kinki Cord Blood Bank. Tanaka Y, et al. **Bone Marrow Transplant** 1998 Sep;22(5):511–3

Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection [letter] Tchirkov A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):229–30

Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Testoni N, et al. **Bone Marrow Transplant** 1998 Dec; 22(11):1065–70

Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. Theilgaard-Mönch K, et al. **Bone Marrow Transplant** 1999 Feb;23(3):243–9

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Thiede C, et al. **Bone Marrow Transplant** 1999 May;23(10):1055–60

Successful human umbilical cord blood stem cell transplantation without conditioning in severe combined immune deficiency. Toren A, et al. **Bone Marrow Transplant** 1999 Feb;23(4):405–8

Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Tsukasaki K, et al. **Bone Marrow Transplant** 1999 Jan;23(1):87–9

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Urbano-Ispizua A, et al. **Bone Marrow Transplant** 1998 Sep;22(6):519–25

Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT. Urbano-Ispizua A, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S71–4

Bone Marrow Donors Worldwide and cord blood stem cell transplantation. van Rood JJ, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S19–21

An HLA matched donor! An HLA matched donor? What do you mean by: HLA matched donor? van Rood JJ, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S83

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? Vellenga E, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1279–82

A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Vigorito AC, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1145–51

Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD [letter] Viret F, et al. **Bone Marrow Transplant** 1999 Jul;24(2):225–7

Transplantation of allogeneic peripheral blood progenitor cells--a single centre experience. Vitek A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S73–6

Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Vivancos P, et al. **Bone Marrow Transplant** 1999 Jan;23(2):169–72

Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma. von Neuhoff N, et al. **Bone Marrow Transplant** 1998 Jul;22(2):161–6

Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. Wakui M, et al. **Bone Marrow Transplant** 1999 Mar;23(6):573–8

Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Wandt H, et al. **Bone Marrow Transplant** 1999 Apr; 23(8):763–70

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Waples JM, et al. **Bone Marrow Transplant** 1999 May;23(9):867–73

Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Weaver CH, et al. **Bone Marrow Transplant** 1998 Aug;22(3):245–51

Transplantation of unrelated cord blood cells. Weinreb S, et al. **Bone Marrow Transplant** 1998 Jul;22(2):193–6

Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Wiesneth M, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S21–4

Disseminated retinoblastoma successfully treated with myeloablative chemotherapy--implication for molecular detection of minimal residual disease. Yamane S, et al. **Bone Marrow Transplant** 1999 May;23(9):971–4

Facilitated engraftment by intramedullary administered enriched allogeneic CD34+ cells? Yano M, et al. **Bone Marrow Transplant** 1999 Apr;23(8):847–8

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN, et al. **Br J Cancer** 1999 Oct;81(3):476–83

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Hohaus S, et al. **Br J Cancer** 1999 Mar;79(9–10):1500–7

Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Reyes E, et al. **Br J Cancer** 1999 Apr; 80(1–2):229–35

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Viens P, et al. **Br J Cancer** 1999 Oct; 81(3):449–56

Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Carella AM, et al. **Br J Haematol** 1998 Nov;103(2):565–7

Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. MacMillan ML, et al. **Br J Haematol** 1998 Nov;103(2):552–8

In utero transplantation of human fetal haemopoietic cells in NOD/SCID mice. Turner CW, et al. **Br J Haematol** 1998 Nov;103(2):326–34

Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Arun B, et al. **Cancer** 1999 Jan 1;85(1):93–9

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma [letter; comment] Pedrazzoli P, et al. **Cancer** 1999 May 15;85(10):2295–6. Comment on: Cancer 1998 Mar 1;82(5):867–73.

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. Shinozuka T, et al. **Cancer** 1999 Apr 1;85(7):1555–64

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma. Zimmerman TM, et al. **Cancer** 1998 Oct 15;83(8):1540–5

Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up. Ito Y, et al. **Cancer Chemother Pharmacol** 1999;43(1):8–12

HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. McGuirk JP, et al. **Cancer J Sci Am** 1998 Sep-Oct; 4(5):278–86 (134 ref.)

Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Singh RK, et al. **Cancer Res** 1999 Jul 1;59(13):3107–11

Bone marrow and stem cell transplantation for multiple myeloma. Vesole DH. **Cancer Treat Res** 1999;99:171–94 (89 ref.)

High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Rahman ZU, et al. **Cancer Treat Rev** 1998 Aug;24(4):249–63 (145 ref.)

Reconstruction of the hematopoietic system after stem cell transplantation. Gordon MY, et al. **Cell Transplant** 1998 Jul-Aug;7(4):339–44 (23 ref.)

Fifteen years' review of advanced childhood neuroblastoma from a single institution in Hong Kong. Leung CK. **Chin Med J (Engl)** 1998 May;111(5):466–9

Autologous peripheral blood stem cell transplantation using simplified procedures for collection and freezing. Hwang WL, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Aug; 62(8):529–35

Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Alpert LC, et al. **Clin Cancer Res** 1997 May;3(5):661–7

Advances in therapy of multiple myeloma: lessons from acute leukemia. Barlogie B. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2605–13 (81 ref.)

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Basser RL, et al. **Clin Cancer Res** 1995 Jul;1(7):715–21

Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Choi D, et al. **Clin Cancer Res** 1998 Nov; 4(11):2709–16

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients [see comments] Cowan KH, et al. **Clin Cancer Res** 1999 Jul;5(7):1619–28. Comment in: Clin Cancer Res 1999 Jul;5(7):1607–9.

High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer. deMagalhaes-Silverman M, et al. **Clin Cancer Res** 1997 Feb;3(2):193–7

Hematopoietic supportive care. Hester J. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2666–70 (27 ref.)

Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Lister J, et al. **Clin Cancer Res** 1995 Jun;1(6):607–14

Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Mohr M, et al. **Clin Cancer Res** 1999 May;5(5):1035–40

Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Nieto Y, et al. **Clin Cancer Res** 1999 Jul;5(7):1731–7

Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Rahman Z, et al. **Clin Cancer Res** 1998 Nov;4(11):2717–21

Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Tricot G, et al. **Clin Cancer Res** 1996 Jun;2(6):947–52

Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Vahdat L, et al. **Clin Cancer Res** 1995 Nov;1(11):1267–73

Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. Hassan HT, et al. **Clin Lab Haematol** 1999 Feb;21(1):21–7

Clinical use of marrow osteoprogenitor cells to stimulate osteogenesis. Connolly JF. **Clin Orthop** 1998 Oct;(355 Suppl):S257–66 (69 ref.)

Worldwide Transplant Center directory. Peripheral blood stem cell transplants. **Clin Transpl** 1997;:497–503
High-dose treatment of multiple myeloma. Gahrton G, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):173–80 (67 ref.)
From autoimmunity to stem cell transplantation. Gratwohl A, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):159–72 (115 ref.)
Current world literature. Hematologic malignancies. **Curr Opin Hematol** 1998 Jul;5(4):B89–158
Hematopoietic stem cell transplantation in chronic myeloid leukemia. Apperley JF. **Curr Opin Hematol** 1998 Nov; 5(6):445–53 (67 ref.)
Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia. Boogaerts MA. **Curr Opin Hematol** 1998 Nov;5(6):465–71 (38 ref.)
Hematopoietic stem cell therapy of autoimmune diseases. Burt RK, et al. **Curr Opin Hematol** 1998 Nov;5(6):472–7 (58 ref.)
Hematopoietic stem cell transplantation [editorial] Goldman J. **Curr Opin Hematol** 1998 Nov;5(6):417–8
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Khouri IF, et al. **Curr Opin Hematol** 1998 Nov;5(6):454–9 (29 ref.)
Hematopoietic stem cell transplantation for severe aplastic anemia. Margolis DA, et al. **Curr Opin Hematol** 1998 Nov; 5(6):441–4 (12 ref.)
"Suicide" gene for the control of graft-versus-host disease. Tiberghien P. **Curr Opin Hematol** 1998 Nov;5(6):478–82 (31 ref.)
High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinoma. McAfee SL, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):17–21 (20 ref.)
Adoptive immunotherapy after hematopoietic stem cell transplantation. Burt RK, et al. **Curr Opin Oncol** 1998 Nov; 10(6):525–32 (115 ref.)
Bibliography. Current world literature. Clinical therapeutics. **Curr Opin Rheumatol** 1999 May;11(3):B69–90
Hematopoietic stem cell transplantation in rheumatic diseases. Snowden JA, et al. **Curr Opin Rheumatol** 1999 May; 11(3):167–72 (43 ref.)
Bone-marrow and blood stem-cell transplantation. Atkinson K. **Curr Top Pathol** 1999;92:107–36
Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors. Zimmerman TM, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):257–64 (87 ref.)
Cell analysis for hematopoietic stem/progenitor cell transplantation. Law P, et al. **Cytometry** 1999 Apr 15; 38(2):47–52 (76 ref.)
The sources and uses of hematopoietic stem cells keep increasing. Trigg ME. **Del Med J** 1998 Sep;70(9):387–92
Comparison of rhG--CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours. Knudsen LM, et al. **Eur J Haematol** 1998 Oct;61(4):229–34
Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. Nakao S, et al. **Eur J Haematol** 1999 Apr;62(4):265–70
A comparative study of CD34+ cells, CD34+ subsets, colony forming cells and cobblestone area forming cells in cord blood and bone marrow allografts. Theilgaard-Mönch K, et al. **Eur J Haematol** 1999 Mar; 62(3):174–83
In utero hematopoietic stem cell transfer: current status and future strategies. Surbek DV, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jul;85(1):109–15 (55 ref.)
Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Bachier CR, et al. **Exp Hematol** 1999 Apr;27(4):615–23
Pattern of localization of primitive hematopoietic cells in vivo using a novel mouse model. Bolante-Cervantes R, et al. **Exp Hematol** 1999 Aug;27(8):1346–52
Detection of cytomegalovirus proteins by flow cytometry in the blood of patients undergoing hematopoietic stem cell transplantation. Detrick B, et al. **Exp Hematol** 1999 Mar;27(3):569–75
Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Holyoake TL, et al. **Exp Hematol** 1999 Sep; 27(9):1418–27
Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals. Law P, et al. **Exp Hematol** 1999 Jan;27(1):147–54
Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study. Mapara MY, et al. **Exp Hematol** 1999 Jan;27(1):169–75
Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Martinez C, et al. **Exp Hematol** 1999 Mar;27(3):561–8
Umbilical cord blood banking for unrelated transplantation: evaluation of cell separation and storage methods. Regidor C, et al. **Exp Hematol** 1999 Feb;27(2):380–5
Use of gene marking technologies in oncology. Brenner M. **Forum (Genova)** 1998 Oct-Dec;8(4):342–53 (67 ref.)
Stem cell transplantation in myelodysplastic syndromes. de Witte T. **Forum (Genova)** 1999 Jan-Mar;9(1):75–81 (53 ref.)
Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells. Bunnell BA, et al. **Gene Ther** 1999 Jan;6(1):48–56
Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice. Eliopoulos N, et al. **Gene Ther** 1998 Nov;5(11):1545–51
FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Hildinger M, et al. **Gene Ther** 1998 Nov;5(11):1575–9
Abrogation of TGF-beta activity during retroviral transduction improves murine hematopoietic progenitor and repopulating cell gene transfer efficiency. Yu J, et al. **Gene Ther** 1998 Sep;5(9):1265–71
Failure of high-dose chemotherapy with peripheral blood stem cell support for refractory placental site trophoblastic tumor. Aoki Y, et al. **Gynecol Obstet Invest** 1999; 47(3):214–6
Resistant graft failure overcome with allogenic peripheral blood plus bone marrow stem cells. Arslan O, et al. **Haematologia (Budap)** 1998;29(1):47–50
Pulmonary multinodular relapse of non-Hodgkin's lymphoma [letter] Arguiñano JM, et al. **Haematologica** 1998 Aug;83(8):759–60
Short-term, serum-free, static culture of cord blood-derived CD34+ cells: effects of FLT3-L and MIP-1alpha on in vitro expansion of hematopoietic progenitor cells. Capmany G, et al. **Haematologica** 1999 Aug;84(8):675–82
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Carella AM, et al. **Haematologica** 1998 Oct;83(10):904–9
Phenotypic changes in neutrophils after rhG-CSF administration in non-Hodgkin's lymphoma patients undergoing PBSC transplantation or conventional chemotherapy [letter] Carulli G, et al. **Haematologica** 1999 Mar;84(3):281–3
Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery. del Cañizo MC, et al. **Haematologica** 1999 Jun;84(6):511–6
HLA-C and HLA-DQB1 compatibility in unrelated cord blood transplants. Elia L, et al. **Haematologica** 1999 Jun; 84(6):530–4
WWW accessible system for national/regional registries of clinical results of cord blood transplants: a tool to facilitate cooperative clinical research. Fernández MN, et al. **Haematologica** 1998 Dec;83(12):1099–103
New technology and changing parameters of leukapheresis for blood cell transplantation [letter] Granzow K, et al. **Haematologica** 1999 Aug;84(8):752
The contribution of autologous transplant in lymphoma [editorial] Kessinger A, et al. **Haematologica** 1999 Jul; 84(7):577–9
Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience. López R, et al. **Haematologica** 1999 Apr;84(4):350–5
Stem cell transplantation for severe autoimmune diseases: progress and problems. Marmont AM. **Haematologica** 1998 Aug;83(8):733–43 (148 ref.)
Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. Martinelli G, et al. **Haematologica** 1999 May; 84(5):397–404
Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter [editorial] Martino R, et al. **Haematologica** 1998 Oct;83(10):865–7 (13 ref.)
Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital. Mazza P, et al. **Haematologica** 1999 Feb;84(2):142–9
Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Meldgaard Knudsen L, et al. **Haematologica** 1999 Jun;84(6):517–24
Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia [letter] Meloni G, et al. **Haematologica** 1999 Jul; 84(7):665–7
Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies. AIEOP-BMT Group (Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant Group) [letter] Miniero R, et al. **Haematologica** 1999 Jul;84(7):657–60
Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer [see comments] Pedrazzoli P, et al. **Haematologica** 1998 Aug; 83(8):718–23. Comment in: Haematologica 1998 Aug;83(8):673–5.
Placental/umbilical cord blood transplantation. Sirchia G, et al. **Haematologica** 1999 Aug;84(8):738–47 (75 ref.)
Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience. Watanabe T, et al. **Haematologica** 1999 Feb;84(2):167–76 (140 ref.)
Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Zikos P, et al. **Haematologica** 1998 Oct; 83(10):896–903
Proceedings of the 10th Cell Therapy Workshop. Paris, France, 31 March-1 April 1999. **Hematol Cell Ther** 1999 Apr;41(2):51–86
The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell technology. Chabannon C, et al. **Hematol Cell Ther** 1999 Apr;41(2):78–81
Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. McNiece I, et al. **Hematol Cell Ther** 1999 Apr;41(2):82–6
Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement. Viret F, et al. **Hematol Cell Ther** 1999 Feb;41(1):5–11
Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia. Arslan O, et al. **Hematol Oncol** 1998 Dec;16(4):155–62
Circulating CD34+ counts and apheresis planning. Auer RL, et al. **Hematol Oncol** 1998 Jun;16(2):69–75
Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Lutzko C, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1521–32
Cord blood banking [letter] **Indian J Med Sci** 1998 Nov; 52(11):522–3
Unrelated umbilical cord-blood stem cell transplantation: a report from Kanagawa Cord Blood Bank, Japan. Nishihira H, et al. **Int J Hematol** 1998 Aug;68(2):193–202
Successful treatment of relapsed T-cell non-Hodgkin's lymphoma with allogeneic peripheral blood stem cell transplantation with double conditioning. Oji Y, et al. **Int J Hematol** 1999 Jun;69(4):263–7
Bone marrow, peripheral blood and cord blood stem cell transplantation in children: ten years' experience at Siriraj Hospital. Suvatte V, et al. **Int J Hematol** 1998 Dec; 68(4):411–9
The role of accessory cells in allogeneic peripheral blood stem cell transplantation. Tanaka J, et al. **Int J Hematol** 1999 Feb;69(2):70–4 (50 ref.)
Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment (Review). Ikehara S. **Int J Mol Med** 1998 Jan;1(1):5–16 (68 ref.)
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study. Czyzewski EA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):569–77
Allogeneic peripheral blood stem cell transplantation as an alternative to allogeneic bone marrow transplantation [editorial; comment] Harada M. **Intern Med** 1998 Dec; 37(12):1001–2 (9 ref.). Comment on: Intern Med 1998 Dec;37(12):1050–4.
Allogeneic peripheral blood stem cell transplantation for the treatment of refractory follicular lymphoma [see comments] Masuda R, et al. **Intern Med** 1998 Dec;37(12):1050–4. Comment in: Intern Med 1998 Dec;37(12):1001–2.
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. Huober J, et al. **J Cancer Res Clin Oncol** 1998;124(12):690–4
Changes of immunological markers after autologous peripheral blood stem cell transplantation. Katsura K, et al. **J Cancer Res Clin Oncol** 1998;124(11):633–40
Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. Buzzi M, et al. **J Chemother** 1999 Aug;11(4):293–300
Kinetic study of CD34+ cells during peripheral blood stem cell collections. Bojko P, et al. **J Clin Apheresis** 1999; 14(1):18–25
Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells. Bojko P, et al. **J Clin Apheresis** 1999;14(2):57–62
Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. Champlin R, et al. **J Clin Apheresis** 1999;14(1):45–9
Bacterial decontamination of blood stem cell apheresis products. Gagnon JA, et al. **J Clin Apheresis** 1998; 13(3):103–7
Electrolyte monitoring in patients undergoing peripheral blood stem cell collection. Perseghin P, et al. **J Clin Apheresis** 1999;14(1):14–7
Shorter turn-around-time and improved patient care in peripheral blood progenitor cell collection procedures. Ratcliffe N, et al. **J Clin Apheresis** 1999;14(1):35–41
Femoral vascular access for large-volume collection of peripheral blood progenitor cells. Shariatmadar S, et al. **J Clin Apheresis** 1998;13(3):99–102
Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Zimmerman TM, et al. **J Clin Apheresis** 1999;14(1):31–4
Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation [letter] Beck R, et al. **J Clin Microbiol** 1999 Oct; 37(10):3430–1
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's

disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. André M, et al. **J Clin Oncol** 1999 Jan;17(1):222–9

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. Baker KS, et al. **J Clin Oncol** 1999 Mar; 17(3):825–31

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. Basser RL, et al. **J Clin Oncol** 1999 Jan;17(1):82–92

Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. Brown RA, et al. **J Clin Oncol** 1999 Mar;17(3):806–12

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Corradini P, et al. **J Clin Oncol** 1999 Jan;17(1):208–15

Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. Heussel CP, et al. **J Clin Oncol** 1999 Mar;17(3):796–805

Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study. Hjermstad MJ, et al. **J Clin Oncol** 1999 Feb;17(2):706–18

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Khouri IF, et al. **J Clin Oncol** 1998 Dec;16(12):3803–9

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Lazarus HM, et al. **J Clin Oncol** 1999 Feb;17(2):534–45

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Liu SY, et al. **J Clin Oncol** 1998 Oct; 16(10):3270–8

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. Pein F, et al. **J Clin Oncol** 1998 Oct; 16(10):3295–301

Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. Rajkumar SV, et al. **J Clin Oncol** 1999 May;17(5):1551–7

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. Shipp MA, et al. **J Clin Oncol** 1999 Jan;17(1):423–9 (32 ref.)

Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. Hsu C, et al. **J Formos Med Assoc** 1999 Mar;98(3):157–64

Hematotherapy Literature Watch. **J Hematother** 1999 Apr; 8(2):223–8

Effects of long-term storage at -90 degrees C of bone marrow and PBPC on cell recovery, viability, and clonogenic potential. Ayello J, et al. **J Hematother** 1998 Aug;7(4):385–90

Factors influencing mobilization and engraftment in patients with metastatic breast cancer undergoing PBSC transplantation. de Magalhaes-Silverman M, et al. **J Hematother** 1999 Apr;8(2):167–72

Peripheral blood stem cell mobilization for high-dose chemotherapy. Demirer T, et al. **J Hematother** 1999 Apr; 8(2):103–13 (103 ref.)

Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation. Díaz MA, et al. **J Hematother** 1998 Aug;7(4):367–73

G-CSF-mobilized leukapheresis products: cellular characteristics and clinical performance in allografting. Dlubek D, et al. **J Hematother** 1999 Apr;8(2):157–66

Expanding mobilized progenitors for hematotherapy [editorial; comment] English D. **J Hematother** 1999 Apr; 8(2):91–2. Comment on: J Hematother 1999 Apr;8(2):93–102.

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. Gazitt Y, et al. **J Hematother** 1999 Apr;8(2):173–83

Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I. Hubel A, et al. **J Hematother** 1998 Dec;7(6):505–14

Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. Johnsen HE, et al. **J Hematother** 1999 Feb; 8(1):15–28

The relation between the number of PBSC and number of leukaphereses in children. Kajiume T, et al. **J Hematother** 1999 Apr;8(2):185–8

Continuous monitoring of hematocrit values during apheresis for allogeneic peripheral blood stem cell collection. Kajiume T, et al. **J Hematother** 1998 Dec;7(6):493–7

Clinical scale expansion of cryopreserved small volume whole bone marrow aspirates produces sufficient cells for clinical use. Lundell BI, et al. **J Hematother** 1999 Apr; 8(2):115–27

Minimization of CD34+ cell enumeration variability using the ProCOUNT standardized methodology. McNiece I, et al. **J Hematother** 1998 Dec;7(6):499–504

CD34+ cell selection from frozen cord blood products using the Isolex 300i and CliniMACS CD34 selection devices. McNiece IK, et al. **J Hematother** 1998 Oct;7(5):457–61

Use of collagen for standardization of PBSC graft quality evaluation: a multicenter comparative analysis of commercial collagen-based and methylcellulose-based colony-forming unit (CFU) assay kits. Mossuz P, et al. **J Hematother** 1998 Aug;7(4):351–9

Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. Paquette RL, et al. **J Hematother** 1998 Dec;7(6):481–91

Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support. Saito S, et al. **J Hematother** 1999 Jun; 8(3):291–7

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. Schumm M, et al. **J Hematother** 1999 Apr;8(2):209–18

Ex vivo expansion of hematopoietic stem and progenitor cells: are we there yet? [see comments] Srour EF, et al. **J Hematother** 1999 Apr;8(2):93–102 (99 ref.). Comment in: J Hematother 1999 Apr;8(2):91–2.

The effect of overnight storage of leukapheresis stem cell products on cell viability, recovery, and cost. Sugrue MW, et al. **J Hematother** 1998 Oct;7(5):431–6

Comparison of T-cell-depleted BMT and PBPCT with respect to chimerism, graft rejection, and leukemic relapse. Wiesneth M, et al. **J Hematother** 1999 Jun;8(3):269–74

Development of intraepithelial T lymphocytes in the intestine of irradiated SCID mice by adult liver hematopoietic stem cells from normal mice. Yamagiwa S, et al. **J Hepatol** 1999 Apr;30(4):681–8

Simple determination of donor/host origin and donor leukocyte subsets in rat-mouse chimeras. Balázs M, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):117–21

Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. Or R, et al. **J Immunother** 1998 Nov; 21(6):447–53

A novel immunodeficient mouse model--RAG2 x common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. Mazurier F, et al. **J Interferon Cytokine Res** 1999 May;19(5):533–41

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. Schultze JL, et al. **J Mol Med** 1999 Feb;77(2):259–65 (34 ref.)

Current status in intrauterine fetal stem cell therapy. Pschera H. **J Obstet Gynaecol Res** 1998 Dec;24(6):419–24

Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia [see comments] Aker M, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):237–9. Comment in: J Pediatr Hematol Oncol 1999 May-Jun;21(3):175–6.

Reduction of toxicity of marrow transplantation in children with Fanconi anemia [comment] Harris RE. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):175–6. Comment on: J Pediatr Hematol Oncol 1999 May-Jun;21(3):237–9.

Sibling HLA-matched cord blood transplant for beta-thalassemia: report of two cases, expression of fetal hemoglobin, and review of the literature. Lau YL, et al. **J Pediatr Hematol Oncol** 1998 Sep-Oct;20(5):477–81

Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. Odunusi E, et al. **J Pediatr Orthop** 1999 Mar-Apr;19(2):270–4

Postnatal booster injections increase engraftment after in utero stem cell transplantation. Milner R, et al. **J Surg Res** 1999 May 1;83(1):44–7

Cure of beta-thalassaemia major by umbilical cord blood transplantation--a case report of Malaysia's first cord blood transplantation. Chan LL, et al. **J Trop Pediatr** 1999 Aug; 45(4):243–5

Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. Amado RG, et al. **J Virol** 1999 Aug;73(8):6361–9

Bone marrow/stem cells: no edge in breast cancer [news] Stephenson J. **JAMA** 1999 May 5;281(17):1576–8

Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor [letter] Falzetti F, et al. **Lancet** 1999 Feb 13;353(9152):555

Haemopoietic stem-cell transplantation for juvenile chronic arthritis [letter; comment] Kami M, et al. **Lancet** 1999 May 29;353(9167):1885. Comment on: Lancet 1999 Feb 13;353(9152):550–3.

T-cell-depleted stem-cell transplantation for rheumatoid arthritis [letter; comment] Munro R, et al. **Lancet** 1998 Nov 14;352(9140):1628–9. Comment on: Lancet 1998 Sep 12;352(9131):881.

High-dose chemotherapy and stem-cell support in breast cancer [letter; comment] Pedrazzoli P, et al. **Lancet** 1998 Oct 10;352(9135):1220. Comment on: Lancet 1998 Aug 15;352(9127):501–2. Comment on: Lancet 1998 Aug 15;352(9127):515–21.

Haemopoietic stem-cell transplantation for juvenile chronic arthritis [letter; comment] Quartier P, et al. **Lancet** 1999 May 29;353(9167):1885–6. Comment on: Lancet 1999 Feb 13;353(9152):550–3.

Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis [see comments] Wulffraat N, et al. **Lancet** 1999 Feb 13; 353(9152):550–3. Comment in: Lancet 1999 May 29;353(9167):1885. Comment in: Lancet 1999 May 29;353(9167):1885–6.

Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Bachier CR, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):279–88

Mini-ICE protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia [letter] Carella AM. **Leuk Lymphoma** 1998 Oct;31(3–4):437–8

Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Delain M, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):305–13

High-dose chemotherapy with peripheral blood stem cell rescue in blastoid natural killer cell lymphoma. Mukai HY, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):583–8

Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Oddou S, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):187–94

High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow. Santini G, et al. **Leuk Lymphoma** 1999 Apr; 33(3–4):321–30

Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. Schiller G, et al. **Leuk Lymphoma** 1999 May;33(5–6):475–84

Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Soussain C, et al. **Leuk Lymphoma** 1999 May;33(5–6):543–50

A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressive non-Hodgkin's lymphoma. Tarumi T, et al. **Leuk Lymphoma** 1999 Jul; 34(3–4):361–71

Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Varadi G, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):185–90

Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Morton J, et al. **Leuk Res** 1999 Feb;23(2):177–83

Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report on 42 patients. Bouabdallah R, et al. **Leukemia** 1999 Jun;13(6):950–6

Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Byrne JL, et al. **Leukemia** 1999 May;13(5):786–91

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Eder M, et al. **Leukemia** 1999 Sep;13(9):1383–9

Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases [letter] Leleu X, et al. **Leukemia** 1999 Feb;13(2):307–9

The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases. Plantier-Colcher I, et al. **Leukemia** 1999 Feb;13(2):282–8

Stem cell engraftment and cell cycle phenotype. Quesenberry P, et al. **Leukemia** 1999 Apr;13 Suppl 1:S92–3

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Rajkumar SV, et al. **Leukemia** 1999 Mar; 13(3):469–72

Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Reichle A, et al. **Leukemia** 1999 Aug; 13(8):1227–34

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Sutton L, et al. **Leukemia** 1998 Nov; 12(11):1699–707

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Tarella C, et al. **Leukemia** 1999 Sep;13(9):1456–62

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes. Wattel E, et al. **Leukemia** 1999 Apr;13(4):524–9

Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Fouillard L, et al. **Lupus** 1999;8(4):320–3

Intense immunosuppression and stem cell transplantation or rescue for severe systemic lupus erythematosus [editorial]] Marmont AM. **Lupus** 1999;8(4):256–7

Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Musso M, et al. **Lupus** 1998;7(7):492–4

Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities. Toren A, et al. **Med Oncol** 1998 Jul;15(2):113–8

Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. Jakacki RI, et al. **Med Pediatr Oncol** 1998 Dec;31(6):483–90

Large-volume leukapheresis procedure for peripheral blood progenitor cell collection in children weighing 15 kg or less: efficacy and safety evaluation. Kanold J, et al. **Med Pediatr Oncol** 1999 Jan;32(1):7–10

Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia. Pirich L, et al. **Med Pediatr Oncol** 1999 Jan;32(1):1–6

High-dose chemotherapy followed by peripheral blood stem cell rescue for metastatic rhabdomyosarcoma: the experience at Chicago Children's Memorial Hospital. Walterhouse DO, et al. **Med Pediatr Oncol** 1999 Feb; 32(2):88–92

Why do in utero stem cell transplants sometimes fail? Jones DR. **Mol Med Today** 1999 Jul;5(7):288–91

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Bolan CD, et al. **N Engl J Med** 1999 Mar 11;340(10):810; discussion 811–2. Comment on: N Engl J Med 1998 Oct 22;339(17):1186–93.

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency [see comments] Buckley RH, et al. **N Engl J Med** 1999 Feb 18; 340(7):508–16. Comment in: N Engl J Med 1999 Feb 18;340(7):559–61. Comment in: N Engl J Med 1999 Jul 22;341(4):291–2.

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Eiermann TH. **N Engl J Med** 1999 Mar 11;340(10):809; discussion 810–1. Comment on: N Engl J Med 1998 Oct 22;339(17):1177–85.

Cord-blood transplants [letter; comment] Fernández MN, et al. **N Engl J Med** 1999 Apr 22;340(16):1287–8. Comment on: N Engl J Med 1998 Nov 26;339(22):1565–77.

Thirty years of bone marrow transplantation for severe combined immunodeficiency [editorial; comment] Fischer A. **N Engl J Med** 1999 Feb 18;340(7):559–61. Comment on: N Engl J Med 1999 Feb 18;340(7):508–16.

Treatment of severe combined immunodeficiency [letter; comment] Flake AW, et al. **N Engl J Med** 1999 Jul 22; 341(4):291–2. Comment on: N Engl J Med 1999 Feb 18;340(7):508–16.

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Machida U, et al. **N Engl J Med** 1999 Mar 11;340(10):810; discussion 811–2. Comment on: N Engl J Med 1998 Oct 22;339(17):1186–93.

The future of placental-blood transplantation [editorial; comment] Parkman R. **N Engl J Med** 1998 Nov 26; 339(22):1628–9. Comment on: N Engl J Med 1998 Nov 26;339(22):1565–77.

Outcomes among 562 recipients of placental-blood transplants from unrelated donors [see comments] Rubinstein P, et al. **N Engl J Med** 1998 Nov 26; 339(22):1565–77. Comment in: N Engl J Med 1998 Nov 26;339(22):1628–9. Comment in: N Engl J Med 1999 Apr 22;340(16):1287–8.

In vivo selection of retrovirally transduced hematopoietic stem cells. Allay JA, et al. **Nat Med** 1998 Oct;4(10):1136–43

Human embryonic stem cells: the future is now [news] Keller G, et al. **Nat Med** 1999 Feb;5(2):151–2

T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Kohn DB, et al. **Nat Med** 1998 Jul;4(7):775–80

Dystrophin expression in the mdx mouse restored by stem cell transplantation. Gussoni E, et al. **Nature** 1999 Sep 23; 401(6751):390–4

Autologous stem cell therapy for treatment of severe inflammatory autoimmune diseases. van Bekkum DW. **Neth J Med** 1998 Sep;53(3):130–3 (18 ref.)

Apheresis unit preparation for patients receiving peripheral blood stem cells. Madlener D. **Oncol Nurs Forum** 1998 Sep; 25(8):1311

Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization. Kobbe G, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1151–2

Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Osman Y, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1057–63

Hematopoietic stem cell transplantation: a new therapy for autoimmune disease. Burt RK, et al. **Oncologist** 1999; 4(1):77–83 (56 ref.)

Clinical utility in maximizing CD34+ cell count in stem cell grafts. Burt RK. **Oncologist** 1999;4(3):265–8

Chronic myelogenous leukemia: update on biology and treatment. Faderl S, et al. **Oncology (Huntingt)** 1999 Feb; 13(2):169–80; discussion 181, 184 (75 ref.)

Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma. Stiff PJ. **Oncology (Huntingt)** 1998 Oct;12(10 Suppl 8):56–62 (43 ref.)

Peripheral blood stem cell transplantation for non-Hodgkin's lymphoma in complete remission. Yamane T, et al. **Osaka City Med J** 1998 Dec;44(2):219–23

Prolonged hematopoietic chimerism in normal mice transplanted in utero with human hematopoietic stem cells. Pixley JS, et al. **Pathobiology** 1998;66(5):230–9

The role of autologous stem cell transplantation in the management of multiple myeloma. Fermand JP, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):199–202 (15 ref.)

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3–15 (84 ref.)

Successful unrelated umbilical cord blood transplantation in a child with Omenn's syndrome. Benito A, et al. **Pediatr Hematol Oncol** 1999 Jul–Aug;16(4):361–6

Autologous peripheral blood stem cell transplantation in childhood tumors [editorial] Kalmanti M, et al. **Pediatr Hematol Oncol** 1999 Jul–Aug;16(4):277–81

Double haploidentical transplantation of hematopoietic progenitor cells in a boy with myelodysplastic syndrome. Toporski J, et al. **Pediatr Hematol Oncol** 1999 May–Jun; 16(3):257–61

Peripheral blood stem cell transplantation in young children: experience with harvesting, mobilization and engraftment. Kletzel M, et al. **Pediatr Transplant** 1998 Aug;2(3):191–6

Mobilization of peripheral blood progenitor cells using 16 versus 10 mg/kg/d G-CSF in children with malignancies. Kurekci AE, et al. **Pediatr Transplant** 1998 May;2(2):160–4

Cancers after stem cell transplantation in children: a cost of cure? Ship AM, et al. **Pediatr Transplant** 1997 Nov; 1(2):104–10 (38 ref.)

Chimerism after allogeneic hematopoietic cell transplantation: time for a paradigm shift? [editorial] Yeager AM. **Pediatr Transplant** 1998 Aug;2(3):179–81

Cord blood banking for potential future transplantation: subject review. American Academy of Pediatrics. Work Group on Cord Blood Banking. **Pediatrics** 1999 Jul;104(1 Pt 1):116–8

CARE-PARTNER: a computerized knowledge-support system for stem-cell post-transplant long-term follow-up on the World-Wide-Web. Bichindaritz I, et al. **Proc AMIA Symp** 1998;:386–90

Effects of cord blood transfer on the hematopoietic recovery following sublethal irradiation in MRL lpr/lpr mice. Czarneski J, et al. **Proc Soc Exp Biol Med** 1999 Feb; 220(2):79–87

Lethal pulmonary toxicity after autologous bone marrow transplantation/peripheral blood stem cell transplantation for hematological malignancies. Lohr F, et al. **Radiother Oncol** 1998 Jul;48(1):45–51

The role of T-cell depletion of autografts for autoimmune diseases. Bierings M. **Rheumatology (Oxford)** 1999 Aug; 38(8):755–6

Autologous stem cell transplantation: an alternative for refractory juvenile chronic arthritis. Kuis W, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):737–8

Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Martini A, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):773

Risk taking in patients with rheumatoid arthritis: are the risks of haemopoietic stem cell transplantation acceptable? Snowden JA, et al. **Rheumatology (Oxford)** 1999 Apr; 38(4):321–4

Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Traynor A, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):767–72

Haematological stem cell transplantation in the treatment of severe autoimmune diseases: first experiences from an international project. Tyndall A. **Rheumatology (Oxford)** 1999 Aug;38(8):774–6

Addendum: proposed guidelines for autologous stem cell transplantation in juvenile chronic arthritis. Paediatric Rheumatology Workshop. Wulffraat NM, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):775–8

Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis? Wulffraat NM, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):764–6

Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Miyoshi H, et al. **Science** 1999 Jan 29;283(5402):682–6

Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Peled A, et al. **Science** 1999 Feb 5;283(5403):845–8

Hematopoietic stem cell transplantation for primary lymphoid immunodeficiencies. Kapoor N, et al. **Semin Hematol** 1998 Oct;35(4):346–53 (50 ref.)

Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):66–71 (32 ref.)

Dose-intensive therapy for adult acute lymphoblastic leukemia. Finiewicz KJ, et al. **Semin Oncol** 1999 Feb; 26(1):6–20 (68 ref.)

Should autologous or allogeneic stem-cell therapy be a part of consolidation therapy for all cases of adult acute myelogenous leukemia? Garcia-Manero G, et al. **Semin Oncol** 1999 Feb;26(1):xvi–xvii, xxi–xxii

High-dose chemotherapy in ovarian carcinoma. Herrin VE, et al. **Semin Oncol** 1999 Feb;26(1):99–105 (35 ref.)

High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Kyle RA. **Semin Oncol** 1999 Feb; 26(1):74–83 (53 ref.)

Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Marshall NA, et al. **Semin Oncol** 1999 Feb;26(1):67–73 (41 ref.)

High-dose therapy and transplantation in non-Hodgkin's lymphoma. Morrison VA, et al. **Semin Oncol** 1999 Feb; 26(1):84–98 (120 ref.)

High-dose chemotherapy with autologous stem-cell support for germ cell tumors: a critical review. Sobecks RM, et al. **Semin Oncol** 1999 Feb;26(1):106–18 (86 ref.)

Progenitor cell transplantation for chronic myelogenous leukemia. Szatrowski TP. **Semin Oncol** 1999 Feb;26(1):62–6 (27 ref.)

Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived. Waselenko JK, et al. **Semin Oncol** 1999 Feb;26(1):48–61 (105 ref.)

Introduction: dose-intensive therapy for adult malignancies. Weiss RB. **Semin Oncol** 1999 Feb;26(1):1–5 (21 ref.)

The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation. Haire WD. **Semin Thromb Hemost** 1999;25(2):223–37 (93 ref.)

The characteristics of umbilical cord blood (UCB) and UCB transplantation. Kasai M, et al. **Semin Thromb Hemost** 1998; 24(5):491–5

Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours. Leong SS, et al. **Singapore Med J** 1998 Sep; 39(9):396–8

Bone marrow as multidimensional orbit oscillator after autologous bone marrow transplantation. Hajek D, et al. **Stem Cells** 1999;17(1):25–30

Autologous stem cell transplantation for treatment of autoimmune diseases. van Bekkum DW. **Stem Cells** 1999; 17(3):172–8 (40 ref.)

The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Wagemaker G, et al. **Stem Cells** 1998;16(6):375–86 (97 ref.)

The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Barbounis V, et al. **Support Care Cancer** 1999 Mar;7(2):79–83

Cytapheresis—the next 25 years: stem cell therapy [editorial] Isbister JP. **Ther Apher** 1997 May;1(2):112–6 (13 ref.)

Safe and efficient peripheral blood stem cell collection in the smallest of children. Kanold J, et al. **Ther Apher** 1998 Feb;2(1):49–57

Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: a case report. Üstün C, et al. **Ther Apher** 1999 Aug;3(3):275–7

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Slattery JT, et al. **Ther Drug Monit** 1998 Oct;20(5):543–9 (21 ref.)

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Hurley CK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):394–406 (88 ref.)

Evaluation and eligibility of HLA-identical sibling donors for stem cell/bone marrow donation. Morrison AE, et al. **Transfus Med** 1998 Sep;8(3):215–20

Practical placental blood banking. Rebulla P, et al. **Transfus Med Rev** 1999 Jul;13(3):205–26 (156 ref.)

Intra-apheresis recruitment of blood progenitor cells in children. Abe T, et al. **Transfusion** 1998 Oct;38(10):944–50

Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Anderlini P, et al. **Transfusion** 1999 Jun;39(6):555–60

Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Lane TA, et al. **Transfusion** 1999 Jan;39(1):39–47

Peripheral blood progenitor cell collections in children [letter; comment] Moog R, et al. **Transfusion** 1999 Mar; 39(3):334–5. Comment on: Transfusion 1998 Jan;38(1):70–4.

Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Salmon JP, et al. **Transfusion** 1999 Aug;39(8):824–7

Tolerance induction by megadose stem cell transplants: synergism between SCA-1+ Lin- cells and nonalloreactive T cells. Bachar-Lustig E, et al. **Transplant Proc** 1998 Dec;30(8):4007–8

Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Basara N, et al. **Transplant Proc** 1998 Dec;30(8):4087–9

Reversal of diabetes in the rat by injection of hematopoietic stem cells infected with recombinant adeno-associated virus containing the preproinsulin II gene. Bochan MR, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):690–1

Extension of graft survival with pulsed administration of donor dendritic cells. Gozzo J, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1196

Pediatric hematopoietic stem cell transplantation in Taiwan. Lin KH. **Transplant Proc** 1998 Nov;30(7):3477–80

Immune recovery after bone marrow and peripheral blood stem cells transplantation. Marin GH, et al.

Transplant Proc 1999 Sep;31(6):2582-4

Deletion of donor-reactive cells followed by stem cell transplantation in recipients treated with total lymphoid-irradiation as a means for induction of transplantation tolerance to organ allografts and xenografts. Slavin S, et al. **Transplant Proc** 1998 Dec;30(8):4021-2

Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Storb R, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):677-8

Engraftment of murine embryonic stem cells in neonatal rats. Sun J, et al. **Transplant Proc** 1998 Nov;30(7):2935-7

Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Sykes M, et al. **Transplant Proc** 1998 Dec; 30(8):4020

Is donor-derived long-term and multilineage hematopoiesis established after liver transplantation? Taniguchi H, et al. **Transplant Proc** 1998 Nov;30(7):3865-6

Haematopoietic stem cells transduced with a single donor class I major histocompatibility complex gene can induce operational tolerance to fully allogeneic cardiac allografts. Wong W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):886

Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Yoshikawa M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):898-9

Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Yoshikawa M, et al. **Transplant Proc** 1999 Aug;31(5):1939

Transplantation in childhood hematologic malignancies with closely matched family donors in Hong Kong. Yuen PM, et al. **Transplant Proc** 1998 Nov;30(7):3481-3

Preserved long-term repopulation and differentiation properties of hematopoietic grafts subjected to ex vivo expansion with stem cell factor and interleukin 11. Albella B, et al. **Transplantation** 1999 May 27;67(10):1348-57

Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Bornhäuser M, et al. **Transplantation** 1999 Jul 15;68(1):87-8

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bornhäuser M, et al. **Transplantation** 1999 Feb 27;67(4):499-504

The xenotransplantation of goat and human hematopoietic cells to sheep fetuses. Colas G, et al. **Transplantation** 1999 Apr 15;67(7):984-90

Comparisons of alloreactive potential of clinical hematopoietic grafts. Leung W, et al. **Transplantation** 1999 Sep 15;68(5):628-35

Peripheral blood stem cells from unrelated donors for allogeneic transplantation [letter; comment] Russell NH, et al. **Transplantation** 1999 Jan 27;67(2):339. Comment on: Transplantation 1998 Jul 15;66(1):142-3.

Stem-cell gene therapy: problems and solutions. The 2nd Conference on Stem Cell Gene Therapy: Biology and Technology, Rosario Resort, Orcas Island, WA, USA, 31 March-2 June 1998. Bodine DM. **Trends Genet** 1998 Sep; 14(9):346-7

Use of cord blood progenitor cells as an alternative for bone marrow transplantation. Engelfriet CP, et al. **Vox Sang** 1998;75(2):156-72

Cord blood banking and transplant in Europe. Eurocord. Gluckman E, et al. **Vox Sang** 1998;74 Suppl 2:95-101 (13 ref.)

Autologous platelet collection and storage to support thrombocytopenia in patients undergoing high-dose chemotherapy and circulating progenitor cell transplantation for high-risk breast cancer. Torretta L, et al. **Vox Sang** 1998;75(3):224-9

Transplantation of related and unrelated umbilical cord blood stem cells in Austria. Austrian Working Party for Stem Cell Transplantation. Austrian Society of Hematology and Oncology [see comments] Schwinger W, et al. **Wien Klin Wochenschr** 1999 May 7;111(9):348-53. Comment in: Wien Klin Wochenschr 1999 May 7;111(9):335-8.

[Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation] Mayer J, et al. **Cas Lek Cesk** 1999 Mar 15;138(6):170-7 (Eng. Abstr.) **(Cze)**

[Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group] Adam Z, et al. **Vnitr Lek** 1998 Jul;44(7):400-8 (Eng. Abstr.) **(Cze)**

[Autologous transplantation of peripheral stem cells in treatment of recurrent multiple myeloma] Krejčí M, et al. **Vnitr Lek** 1998 Dec;44(12):698-701 (Eng. Abstr.) **(Cze)**

[Hematopoietic stem cell transplantation in sickle cell anemia] Cornu G, et al. **Arch Pediatr** 1999;6 Suppl 2:345s-347s **(Fre)**

[High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996] Fléchon A, et al. **Bull Cancer** 1999 Apr;86(4):391-9 (Eng. Abstr.) **(Fre)**

[Biological basis of total body irradiation] Dubray B, et al. **Cancer Radiother** 1999 Mar-Apr;3(2):154-61 (Eng. Abstr.) **(Fre)**

[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04] Lotz JP, et al. **Hematol Cell Ther** 1999 Apr;41(2):71-4 (Eng. Abstr.) **(Fre)**

[Ex-vivo expansion of hematopoietic stem cells: study in the primate model] Norol F, et al. **Hematol Cell Ther** 1999 Apr;41(2):75-7 **(Fre)**

[Human Herpesvirus 6: general information and infections in organ transplantations and hematopoietic stem cell grafts] Fontan J, et al. **Presse Med** 1999 Jan 23;28(3):149-56 (60 ref.) (Eng. Abstr.) **(Fre)**

[Erythrocyte transfusion practices after allogeneic hematopoietic stem cell transplantation] Lapierre V, et al. **Transfus Clin Biol** 1999 Apr;6(2):148-52 (Eng. Abstr.) **(Fre)**

[Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology] Maschmeyer G, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124 Suppl 1:S9-13 **(Ger)**

[Stem cell reserve after autologous blood stem cell transplantation] Mayer F, et al. **Internist (Berl)** 1999 Mar; 40(3):323-5 **(Ger)**

[High dose therapy with stem cell transplantation] Wörmann B. **Internist (Berl)** 1998 Nov;39(11):1115-22 (36 ref.) **(Ger)**

[High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study] Fleischhack G, et al. **Klin Padiatr** 1998 Jul-Aug;210(4):248-55 (Eng. Abstr.) **(Ger)**

[Bone marrow and stem cell transplantation in multiple sclerosis?] Haase CG, et al. **Nervenarzt** 1999 Feb; 70(2):178-81 (23 ref.) **(Ger)**

[MR tomography of the bone marrow changes after high-dosage chemotherapy and autologous peripheral stem-cell transplantation] Pereira PL, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):251-7 (Eng. Abstr.) **(Ger)**

[Establishing an umbilical cord blood bank for unrelated allogenic stem cell transplantation] Tichelli A, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1598-601 (Eng. Abstr.) **(Ger)**

[Stem cell therapy in autoimmune diseases] Hasler P, et al. **Schweiz Rundsch Med Prax** 1999 Mar 11;88(11):476-7 (9 ref.) **(Ger)**

[Stem cell supported high dose chemotherapy (HDCT) in primary treatment of advanced ovarian carcinoma] Möbus V, et al. **Schweiz Rundsch Med Prax** 1999 Mar 18; 88(12):507-12 (20 ref.) (Eng. Abstr.) **(Ger)**

[A randomized phase-II study of high-dosage chemotherapy with stem-cell transplantation in women with operable infraclavicular metastatic breast carcinoma] Grabenbauer GG. **Strahlenther Onkol** 1999 Feb;175(2):85-6 **(Ger)**

[Therapeutic spectrum of blood stem cell transplantation (editorial; comment)] Hinterberger W. **Wien Klin Wochenschr** 1999 May 7;111(9):335-8. Comment on: Wien Klin Wochenschr 1999 May 7;111(9):348-a53. **(Ger)**

[Quality of life and cytokines in oncological therapy] Leitgeb C. **Wien Med Wochenschr** 1998;148(18):424-6 (19 ref.) (Eng. Abstr.) **(Ger)**

[High dosage chemotherapy and peripheral blood stem cell transplantation in breast carcinoma] Jentsch-Ullrich K, et al. **Zentralbl Chir** 1998;123 Suppl 5:162-4 (8 ref.) (Eng. Abstr.) **(Ger)**

[The fetus as patient: intrauterine fetal stem cell transplantation] Pschera H. **Zentralbl Gynakol** 1998; 120(10):481-7 (50 ref.) (Eng. Abstr.) **(Ger)**

[Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for adult acute myelogenous leukemia] Uchida N, et al. **Fukuoka Igaku Zasshi** 1999 Jun; 90(6):295-9 (Eng. Abstr.) **(Jpn)**

[Stem cell transplantation in multiple myeloma] Fukuda S, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1407-14 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Hematopoietic stem cell transplantation for treatment of acute leukemia] Harada M. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1387-95 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Hematopoietic stem cell transplantation in childhood leukemias] Kawano Y, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1415-23 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Chronic myelogenous leukemia and blood stem cell transplantation] Masaoka T. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1396-400 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Hematopoietic stem cell transplantation for malignant lymphoma] Morishima Y. **Gan To Kagaku Ryoho** 1999 Sep; 26(10):1401-6 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous peripheral blood stem cell transplantation for malignant lymphoma] Morishima Y. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2217-22 (20 ref.) (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy and hematopoietic stem cell transplant in the treatment of advanced neuroblastoma] Mugishima H. **Gan To Kagaku Ryoho** 1999 Jul; 26(8):1056-67 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Differences in therapeutic strategies for adult leukemia and lymphoma between Japan and western countries] Sakamaki H. **Gan To Kagaku Ryoho** 1999 Jan;26(1):41-8 (37 ref.) (Eng. Abstr.) **(Jpn)**

[CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer] Suwata J, et al. **Gan To Kagaku Ryoho** 1999 Jan;26(1):83-8 (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas] Yonemoto T, et al. **Gan To Kagaku Ryoho** 1999 Sep;26(10):1431-5 (Eng. Abstr.) **(Jpn)**

[A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor] Muraki O, et al. **Hinyokika Kiyo** 1998 Oct;44(10):743-5 (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy followed by peripheral blood stem cell transplantation in advanced extragonadal germ cell tumor--a case report] Matsuura H, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Apr;90(4):521-5 (Eng. Abstr.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 1. Acute leukemia] Ikeda K, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1464-9 (6 ref.) **(Jpn)**

[Future development in hematopoietic stem cell transplantation. Discussion] Ikeda Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1532-46 **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 3. Aplastic anemia and myelodysplastic syndrome] Sakamaki H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1477-82 (8 ref.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 5. Solid tumor] Shimazaki C, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1488-94 (13 ref.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 2. Chronic myelogenous leukemia] Takahashi S. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1470-6 (13 ref.) **(Jpn)**

[Indication and results of hematopoietic stem cell transplantation. 4. Malignant lymphoma and multiple myeloma] Tanosaki R. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1483-7 (4 ref.) **(Jpn)**

[PBSCT and GVHD] Hino M, et al. **Rinsho Byori** 1999 May; Suppl 110:92-8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Cord blood transplantation for adults] Kai S. **Rinsho Byori** 1999 May;Suppl 110:48-53 (Eng. Abstr.) **(Jpn)**

[Peripheral blood stem cell transplantation--practices of mobilization and harvest] Sugio Y, et al. **Rinsho Byori** 1999 May;Suppl 110:63-9 (Eng. Abstr.) **(Jpn)**

[Tests for donors of cord blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1999 May;Suppl 110:113-23 (Eng. Abstr.) **(Jpn)**

[Role of the government for development of umbilical cord blood bank system in Japan] Yamamoto N. **Rinsho Byori** 1999 May;Suppl 110:1-6 (Eng. Abstr.) **(Jpn)**

[Syngeneic peripheral blood stem cell transplantation for chronic myelogenous leukemia associated with Klinefelter's syndrome] Fujii H, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):218-23 (15 ref.) (Eng. Abstr.) **(Jpn)**

[CD34-positive cell selection using an Isolex 300 system in patients with solid tumors and its application for autologous peripheral blood stem cell transplantation] Kaneko H, et al. **Rinsho Ketsueki** 1998 Sep;39(9):652-7 (Eng. Abstr.) **(Jpn)**

[Analysis of T-cell repertoire after allogeneic peripheral blood stem cell transplantation] Kondo Y, et al. **Rinsho Ketsueki** 1999 Jun;40(6):464-8 **(Jpn)**

[Autoimmune thrombocytopenia following syngeneic peripheral blood stem cell transplantation] Nishio M, et al. **Rinsho Ketsueki** 1998 Aug;39(8):580-5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Allogeneic peripheral blood stem cell transplantation in an elderly patient with myelodysplatic syndrome with myelofibrosis] Sawada H, et al. **Rinsho Ketsueki** 1999 Jan; 40(1):28-33 (Eng. Abstr.) **(Jpn)**

[Allogeneic peripheral blood stem cell transplantation in 30 patients with hematologic disorders] Sawada H, et al. **Rinsho Ketsueki** 1998 Nov;39(11):1085-91 (Eng. Abstr.) **(Jpn)**

[A trial for peripheral blood stem cell harvest by combination of G-CSF with ABVD regimen in the management of Hodgkin's disease] Suzuki A, et al. **Rinsho Ketsueki** 1999 Jan;40(1):16-21 (Eng. Abstr.) **(Jpn)**

[Treatment for adult hemophagocytic syndrome] Takami Y. **Rinsho Ketsueki** 1999 Feb;40(2):108-11 **(Jpn)**

[High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination] Uno H, et al. **Rinsho Ketsueki** 1999 Jul;40(7):556-62 (Eng. Abstr.) **(Jpn)**

[Extramedullary relapse in the external auditory canal in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and autologous peripheral blood stem cell transplantation] Yagita M, et al. **Rinsho Ketsueki** 1998 Sep;39(9):709-15 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Successful treatment with high dose chemotherapy

following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement] Yamao H, et al. **Rinsho Ketsueki** 1998 Nov; 39(11):1121–6 (Eng. Abstr.) **(Jpn)**

[Transplantation of haemopoietic precursor cells in myelodysplastic syndromes] Hellmann A. **Pol Arch Med Wewn** 1998 Feb;99(2):150–4 **(Pol)**

[The transplantation of hemopoietic cells in patients with solid tumors] Mikhaĭlova NB, et al. **Ter Arkh** 1998; 70(7):63–7 (Eng. Abstr.) **(Rus)**

[The role of high-dose chemotherapy with hemopoietic stem cell transplantation in the treatment of breast cancer with unfavorable prognosis] Ptushkin VV, et al. **Vopr Onkol** 1998;44(4):422–6 (16 ref.) (Eng. Abstr.) **(Rus)**

[Hematopoietic stem cells--biology and therapeutic use] Balint B, et al. **Vojnosanit Pregl** 1998 Nov–Dec; 55(6):627–39 (112 ref.) **(Scc)**

[Fever, general malaise, adenopathies and hepatosplenomegaly in a 17-year-old woman after an allogeneic transplant of peripheral blood hematopoietic progenitors for chronic myeloid leukemia (clinical conference)] Conde E, et al. **Med Clin (Barc)** 1999 Jan 30; 112(3):106–14 **(Spa)**

[The autologous transplantation of hematopoietic precursors on an outpatient basis: an analysis of its feasibility at the Hospital Clínic de Barcelona] Rives S, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):201–4 (Eng. Abstr.) **(Spa)**

[Bases of bone marrow transplantation: modalities and indications] García Laraña J. **Rev Clin Esp** 1999 Apr;199 Suppl 1:14–21 (26 ref.) **(Spa)**

[Complications associated with central venous catheters in patient with hematologic neoplasms or hematopoietic transplants] Gutiérrez AM, et al. **Sangre (Barc)** 1999 Jun; 44(3):171–5 (Eng. Abstr.) **(Spa)**

[Umbilical cord blood from unrelated donor. An alternative to bone marrow transplantation] Békássy A, et al. **Lakartidningen** 1999 Mar 24;96(12):1437–40, 1443–4 (Eng. Abstr.) **(Swe)**

[Hemopoietic cells from human embryonic liver in the treatment of HIV/AIDS] Pylypchak OM. **Lik Sprava** 1998 Dec;(8):116–8 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Post-traumatic stress symptoms in patients undergoing autologous stem cell transplantation. Wettergren L, et al. **Acta Oncol** 1999;38(4):475–80

The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. Shulman HM, et al. **Am J Clin Pathol** 1999 Oct;112(4):513–23

Clinical toxicity of cryopreserved circulating progenitor cells infusion. Zambelli A, et al. **Anticancer Res** 1998 Nov–Dec; 18(6B):4705–8

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Boeckh M, et al. **Biol Blood Marrow Transplant** 1998;4(1):13–9

A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Haire WD, et al. **Biol Blood Marrow Transplant** 1998;4(3):142–50

Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. Tzung SP, et al. **Biol Blood Marrow Transplant** 1998; 4(1):43–8

Fungal infections after bone marrow transplant. Wingard JR. **Biol Blood Marrow Transplant** 1999;5(2):55–68 (171 ref.)

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Carreras E, et al. **Blood** 1998 Nov 15;92(10):3599–604

High risk of chronic graft-versus-host disease in unmanipulated allogeneic peripheral blood stem cell transplantation [letter; comment] Kalayoğlu-Beşişik S, et al. **Blood** 1998 Oct 15;92(8):2973–5. Comment on: Blood 1997 Dec 15;90(12):4705–9.

A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Przepiorka D, et al. **Blood** 1998 Dec 1;92(11):4066–71

Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease [letter; comment] Sica S, et al. **Blood** 1999 May 1;93(9):3154. Comment on: Blood 1998 Dec 15;92(12):4568–72.

Cirrhosis of the liver in long-term marrow transplant survivors. Strasser SI, et al. **Blood** 1999 May 15; 93(10):3259–66

Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Strasser SI, et al. **Blood** 1999 Feb 15;93(4):1127–36 (129 ref.)

Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Alessandrino P, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):533–7

Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Amigo ML, et al. **Bone Marrow Transplant** 1999 May;23(10):997–1002

Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease. Berisso GA, et al. **Bone Marrow Transplant** 1999 May;23(10):1091–2

Prolonged isolated thrombocytopenia after hematopoietic stem cell transplantation: morphologic correlation. Bielski M, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1071–6

Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bilgrami S, et al. **Bone Marrow Transplant** 1999 May;23(10):1039–42

Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bilgrami S, et al. **Bone Marrow Transplant** 1999 Jul;24(1):69–73

Concurrent Pneumocystis carinii and cytomegalovirus pneumonia after autologous peripheral blood stem cell transplantation. Chuu WM, et al. **Bone Marrow Transplant** 1999 May;23(10):1087–9

Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. de Arriba F, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):621–4

Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine. Dovat S, et al. **Bone Marrow Transplant** 1999 Aug;24(3):321–3

Lymphomatoid granulomatosis following autologous stem cell transplantation. Fassas A, et al. **Bone Marrow Transplant** 1999 Jan;23(1):79–81

Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Feingold JM, et al. **Bone Marrow Transplant** 1998 Aug;22(3):297–300

Pulmonary enterovirus infections in stem cell transplant recipients. González Y, et al. **Bone Marrow Transplant** 1999 Mar;23(5):511–3

An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous peripheral blood stem cell (PBSC) transplantation in a child. González-Vicent M, et al. **Bone Marrow Transplant** 1999 Apr;23(7):735–6

Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation. Gordon B, et al. **Bone Marrow Transplant** 1998 Nov;22(10):999–1003

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251–8 (42 ref.)

Neurological complications after stem cell transplantation in childhood. Iguchi A, et al. **Bone Marrow Transplant** 1999 Sep;24(6):647–52

Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Ishikawa F, et al. **Bone Marrow Transplant** 1998 Oct;22(7):729–31

Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Jacobson P, et al. **Bone Marrow Transplant** 1998 Aug;22(3):217–25 (129 ref.)

Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. Ketterer N, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1309–15

Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children. Kondo M, et al. **Bone Marrow Transplant** 1998 Nov;22(10):995–8

Early infections in patients undergoing bone marrow or blood stem cell transplantation--a 7 year single centre investigation of 409 cases. Krüger W, et al. **Bone Marrow Transplant** 1999 Mar;23(6):589–97

Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Manteiga R, et al. **Bone Marrow Transplant** 1998 Nov;22(9):899–904

Noninvasive mechanical ventilation in a patient with respiratory failure after hematopoietic progenitor transplantation. Marin D, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1123–4

Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Moretti S, et al. **Bone Marrow Transplant** 1998 Jul;22(2):175–80

Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Murakami CS, et al. **Bone Marrow Transplant** 1999 May;23(9):921–7

Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting. Naughton M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):197–9

Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Nieto Y, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1323–4

Hepatic veno-occlusive disease after stem cell transplantation in Japan [letter] Oh H, et al. **Bone Marrow Transplant** 1999 Jul;24(2):223–4

A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Peniket AJ, et al. **Bone Marrow Transplant** 1998 Aug; 22(3):307–9

Plasmodium vivax causing pancytopenia after allogeneic blood stem cell transplantation in CML [published erratum appears in Bone Marrow Transplant 1999 Jun;23(11):1213] Raina V, et al. **Bone Marrow Transplant** 1998 Jul; 22(2):205–6

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Salazar R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):27–33

Acute quadriplegic myopathy following autologous peripheral blood stem cell transplantation for breast cancer. Samuelsson J, et al. **Bone Marrow Transplant** 1999 Apr; 23(8):835–7

Using at least 5x10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Scheid C, et al. **Bone Marrow Transplant** 1999 Jun; 23(11):1177–81

Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis. Schulenburg A, et al. **Bone Marrow Transplant** 1998 Aug;22(3):293–5

A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. Scott MA, et al. **Bone Marrow Transplant** 1998 Aug; 22(3):273–6

Non-invasive ventilatory support in the management of respiratory failure after autologous peripheral blood stem cell transplantation [letter] Sica S, et al. **Bone Marrow Transplant** 1999 Mar;23(5):527

Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Sobecks RM, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1161–5

Crescentic glomerulonephritis developing 3 months after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Takeuchi M, et al. **Bone Marrow Transplant** 1998 Oct;22(7):725–7

Transplantation of allogeneic CD34-selected peripheral stem cells does not prevent transmission of hepatitis C virus from an infected donor. Tomás JF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):109–12

Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Trotman J, et al. **Bone Marrow Transplant** 1999 Apr;23(8):797–801

Safety aspects of cord blood banking. Warwick RM, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S40–2 (13 ref.)

Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Wiesmann A, et al. **Bone Marrow Transplant** 1998 Sep; 22(6):565–9

Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Quaranta S, et al. **Clin Immunol** 1999 Apr;91(1):106–16

Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Nguyen Q, et al. **Clin Infect Dis** 1999 Mar;28(3):618–23

Mucormycosis of petrous bone in an allogeneic stem cell transplant recipient. Oo MM, et al. **Clin Infect Dis** 1998 Dec;27(6):1546–7

Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Ribaud P, et al. **Clin Infect Dis** '999 Mar;28(3):690–1

Diagnosis and treatment of cytomegalovirus infection. Hebart H, et al. **Curr Opin Hematol** 1998 Nov;5(6):483–7 (41 ref.)

Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Aguilar LK, et al. **Curr Opin Oncol** 1999 Mar;11(2):96–101 (57 ref.)

Clinical relevance of acute pancreatitis in allogeneic hemopoietic stem cell (bone marrow or peripheral blood) transplants. Salomone T, et al. **Dig Dis Sci** 1999 Jun; 44(6):1124–7

Antibodies reactive with neutrophils following allogeneic haematopoietic stem cell transplantation. Tazzari PL, et al. **Eur J Haematol** 1999 Jan;62(1):57–62

Neurological complications after autologous stem cell transplantation. Guerrero A, et al. **Eur Neurol** 1999 Jan; 41(1):48–50

How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation. Scheding S, et al. **Exp Hematol** 1999 May;27(5):956–65

Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Ponec RJ, et al. **Gastrointest Endosc** 1999 May;49(5):612–21

IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Ferrà C, et al. **Haematologica** 1998 Dec;83(12):1082–7

Mucormycosis and hemopoietic transplants [letter] Peñalver FJ, et al. **Haematologica** 1998 Oct;83(10):950–1

Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. Nakamura H, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S457–61

Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. Ebeling PR, et al. **J Bone Miner Res** 1999 Mar;14(3):342–50

Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. Iwen PC, et al. **J Clin Microbiol** 1998 Dec; 36(12):3713–7

Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous

transplantation in patients with metastatic breast cancer. Cooper BW, et al. **J Clin Oncol** 1998 Nov;16(11):3509–17

Graft versus host disease in autologous stem cell transplantation. Marin GH, et al. **J Exp Clin Cancer Res** 1999 Jun;18(2):201–8

Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study. Hann DM, et al. **J Pain Symptom Manage** 1999 May;17(5):311–9

Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation [letter] [see comments] Brand RE, et al. **Lancet** 1998 Dec 19–26;352(9145):1985. Comment in: Lancet 1999 Mar 6;353(9155):846.

Late effects of transplantation. Gerard Socie, for the Late Effects Working Party of the European Group for Blood and Marrow Transplantation [letter] McCann S, et al. **Lancet** 1999 Aug 28;354(9180):778

Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation [letter; comment] Nordesjö-Haglund G, et al. **Lancet** 1999 Mar 6; 353(9155):846. Comment on: Lancet 1998 Dec 19–26;352(9145):1985.

Effects of peripheral stem-cell or bone-marrow reinfusion on peripheral serotonin metabolism [letter] Wymenga AN, et al. **Lancet** 1999 Jan 23;353(9149):293–4

Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Richardson P, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):267–77 (86 ref.)

The risk of secondary leukemias following autologous stem cell transplantation [comment] Bishop MR. **Leuk Res** 1999 Mar;23(3):281–2. Comment on: Leuk Res 1999 Mar;23(3):291–7.

Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation [see comments] Lambertenghi Deliliers G, et al. **Leuk Res** 1999 Mar; 23(3):291–7. Comment in: Leuk Res 1999 Mar;23(3):281–2.

Early infections after autologous transplantation for haematological malignancies. Schiødt I, et al. **Med Oncol** 1998 Jul;15(2):103–8

Pain and distress in adults and children undergoing peripheral blood stem cell or bone marrow transplant. Pederson C, et al. **Oncol Nurs Forum** 1999 Apr;26(3):575–82

Ocular findings in allogeneic stem cell transplantation without total body irradiation. Kerty E, et al. **Ophthalmology** 1999 Jul;106(7):1334–8

Pulmonary Langerhans' cell histiocytosis following autologous haemopoietic progenitor cell transplantation. Soler N, et al. **Respir Med** 1998 Oct;92(10):1253–5

Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. Niethammer D, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):747–50

Transfusion-related acute lung injury (TRALI) following autologous stem cell transplant for relapsed acute myeloid leukaemia: a case report and review of the literature [see comments] Leach M, et al. **Transfus Med** 1998 Dec; 8(4):333–7 (26 ref.). Comment in: Transfus Med 1999 Jun;9(2):175.

[Recommendations for the diagnosis and therapy of cytomegalovirus infection after stem-cell transplantation. The Research Alliance on the Complications of Organ Transplantation due to Herpes Viruses] Einsele H, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):501–6 (39 ref.) **(Ger)**

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 1. Infections] Gondo H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1495–501 (11 ref.) **(Jpn)**

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 2. Graft-versus-host disease (GVHD)] Morishita Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1502–9 (5 ref.) **(Jpn)**

[Infantile T cell acute lymphoblastic leukemia complicated by thrombotic microangiopathy and human herpes virus 6 infection after allogeneic peripheral blood stem cell transplantation using CD34-positive cells] Hasegawa D, et al. **Rinsho Ketsueki** 1999 Jul;40(7):574–80 (Eng. Abstr.) **(Jpn)**

[Adverse reactions to autologous peripheral blood stem cell transplantation in patients over 65 years old] Kodama K, et al. **Rinsho Ketsueki** 1999 Jan;40(1):55–8 (Eng. Abstr.) **(Jpn)**

[Engraftment syndrome in hematopoietic stem cell transplantation] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):595–600 (23 ref.) **(Jpn)**

[Thrombotic microangiopathy in hematopoietic stem cell transplantation] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):611–8 (19 ref.) **(Jpn)**

[Acute renal failure in the allogeneic transplantation of hemopoietic progenitors. The clinical characteristics in a series of 92 patients] Gruss E, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):774–5 (Eng. Abstr.) **(Spa)**

CONTRAINDICATIONS

Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. Ustün C, et al. **J Hepatol** 1999 Aug;31(2):202–9

ECONOMICS

The economic evaluation of hematopoietic growth factors in high-dose chemotherapy. Le Corroller AG, et al. **Anticancer Drugs** 1998 Nov;9(10):917–24 (39 ref.)

A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Barosi G, et al. **Bone Marrow Transplant** 1999 Apr;23(7):719–25

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Glaspy JA. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S21–7 (29 ref.)

HISTORY

A history of haemopoietic cell transplantation. Thomas ED. **Br J Haematol** 1999 May;105(2):330–9 (118 ref.)

Autologous bone marrow transplants to hematopoietic stem cell support with peripheral blood stem cells: a historical perspective. Buckner CD. **J Hematother** 1999 Jun; 8(3):233–6

INSTRUMENTATION

[Peripheral blood stem cell transplantation as an interdisciplinary challenge--theory and practice] Cassens U, et al. **Zentralbl Gynakol** 1998;120(8):367–72 (26 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

US Congress debates stem cell research [news] Ciment J. **BMJ** 1999 Jan 23;318(7178):215

Eurocord position on ethical and legal issues involved in cord blood transplantation. Fernandez MN. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S84–5

Scientists react to government indecision [news] Brown P. **Nat Med** 1999 Aug;5(8):855–6

METHODS

Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). Cortelazzo S, et al. **Ann Oncol** 1999 Apr;10(4):427–32

Umbilical cord blood transplantation. Will AM. **Arch Dis Child** 1999 Jan;80(1):3–6 (26 ref.)

Total therapy with tandem transplants for newly diagnosed multiple myeloma. Barlogie B, et al. **Blood** 1999 Jan 1; 93(1):55–65

Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Dao MA, et al. **Blood** 1998 Dec 15;92(12):4612–21

Graft-versus-host disease and graft-versus-leukemia effect in mice grafted with peripheral newborn blood. de La Selle V, et al. **Blood** 1998 Nov 15;92(10):3968–75

Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device. Biffi R, et al. **Bone Marrow Transplant** 1999 Jul;24(1):89–93

LDH elevation after autologous stem cell transplantation. Bolwell B, et al. **Bone Marrow Transplant** 1999 Jul; 24(1):53–5

Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia. Clark RE, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1303–8

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):221–6

Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia. Kögler G, et al. **Bone Marrow Transplant** 1999 Aug; 24(4):397–403

Conclusions of a national multicenter intercomparative study of in vitro cultures of human hematopoietic progenitors. Lamana M, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):373–80

Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants. Ortega M, et al. **Bone Marrow Transplant** 1999 Jul;24(1):81–7

Central venous catheters inserted percutaneously via the femoral vein can be used long-term in recipients of allogeneic peripheral blood stem cell transplants [letter] Rabitsch W, et al. **Bone Marrow Transplant** 1999 Jul; 24(1):115–6

Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Singhal S, et al. **Bone Marrow Transplant** 1999 Jul;24(1):13–7

Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Waller CF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):19–24

Toxicity of single daily dose gentamicin in stem cell transplantation. Warkentin D, et al. **Bone Marrow Transplant** 1999 Jul;24(1):57–61

The safety and usefulness of routine bronchoscopy before stem cell transplantation and during neutropenia. Whittle AT, et al. **Bone Marrow Transplant** 1999 Jul;24(1):63–7

Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Anderlini P, et al. **Br J Haematol** 1999 Jul;106(1):154–61

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Bladé J, et al. **Br J Haematol** 1998 Sep;102(5):1115–23

Syngeneic stem cell transplantation for HIV-related lymphoma. Campbell P, et al. **Br J Haematol** 1999 Jun; 105(3):795–8

Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Comenzo RL, et al. **Br J Haematol** 1999 Mar;104(3):553–9

Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Diviné M, et al. **Br J Haematol** 1999 May;105(2):349–60

CD34+CD38-HLA-DR- correlate more closely than CD34+CD38- with engraftment post-PBSC transplantation [letter; comment] Drake M, et al. **Br J Haematol** 1999 Mar;104(3):643–4. Comment on: Br J Haematol 1998 Nov;103(2):568–81.

Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia. Dreger P, et al. **Br J Haematol** 1999 Jul;106(1):115–8

Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Guikema JE, et al. **Br J Haematol** 1999 Mar;104(4):748–54

CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Gupta D, et al. **Br J Haematol** 1999 Jan;104(1):166–77

Haemopoietic stem cell transplantation from unrelated donors. Heslop HE. **Br J Haematol** 1999 Apr;105(1):2–6 (41 ref.)

Content of long-term culture-initiating cells, clonogenic progenitors and CD34 cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma. Kasper C, et al. **Br J Haematol** 1999 Feb;104(2):374–81

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Maeda Y, et al. **Br J Haematol** 1999 Apr; 105(1):295–302

Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation. Mielcarek M, et al. **Br J Haematol** 1999 May;105(2):361–5

A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Murata M, et al. **Br J Haematol** 1999 Jun; 105(3):799–802

Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis. Perry AR, et al. **Br J Haematol** 1999 Apr;105(1):280–7

Expansion of megakaryocyte progenitors from human umbilical cord blood using a new two-step separation procedure. Pick M, et al. **Br J Haematol** 1998 Dec; 103(3):639–50

Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Rottenburger C, et al. **Br J Haematol** 1999 Aug; 106(2):545–52

Developments in allogeneic peripheral blood progenitor cell transplantation. Russell NH, et al. **Br J Haematol** 1998 Dec; 103(3):594–600 (59 ref.)

The impact of antenatal and perinatal variables on cord blood haemopoietic stem/progenitor cell yield available for transplantation. Shlebak AA, et al. **Br J Haematol** 1998 Dec;103(4):1167–71

Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells. Singer IO, et al. **Br J Haematol** 1998 Sep;102(5):1359–62

Composition and function of peripheral blood stem and progenitor cell harvests from patients with severe active rheumatoid arthritis. Snowden JA, et al. **Br J Haematol** 1998 Dec;103(3):601–9

A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission. Stahel RA, et al. **Br J Haematol** 1999 Mar;104(4):763–9

Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma. Thunberg U, et al. **Br J Haematol** 1999 Mar;104(3):546–52

Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Tichelli A, et al. **Br J Haematol** 1999 Jul;106(1):152–8

Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Voso MT, et al. **Br J Haematol** 1999 Feb; 104(2):382–91

Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Waller CF, et al. **Br J Haematol** 1998 Oct;103(1):227–34

Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Marini FC, et al. **Clin Cancer Res** 1999 Jun;5(6):1557-68

Quantity and origin of transplanted autologous blood cells are independent factors associated with speed of postransplant hematological reconstitution. Rogulj D, et al. **Croat Med J** 1999 Sep;40(3):404-8

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. Glück S, et al. **Eur J Cancer** 1998 Jun;34(7):1008-14

Stem cell directed gene therapy. Engel BC, et al. **Front Biosci** 1999 May 1;4:e26-33 (82 ref.)

Ex vivo expansion of hematopoietic cells and their clinical use. Aglietta M, et al. **Haematologica** 1998 Sep;83(9):824-48 (215 ref.)

Autologous blood stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong disease-free survival. de la Rubia J, et al. **Haematologica** 1999 Feb;84(2):125-32

Controlled-rate versus uncontrolled-rate cryopreservation of peripheral blood progenitor cells: a prospective multicenter study. Group for Cryobiology and Biology of Bone Marrow Transplantation (CBTMO), Spain. Perez-Oteyza J, et al. **Haematologica** 1998 Nov; 83(11):1001-5

Bone marrow and peripheral blood stem cell transplantation for malignancy. Johnson PW, et al. **Health Technol Assess** 1998;2(8):1-187 (209 ref.)

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Hum Immunol** 1999 Apr;60(4):347-60

Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). Dao MA, et al. **Int J Mol Med** 1998 Jan;1(1):257-64 (50 ref.)

Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program. Wilke R, et al. **J Clin Apheresis** 1999;14(1):26-30

A controlled comparison of two different clinical grade devices for CD34+ cell selection of autologous blood stem cell grafts. Björkstrand B, et al. **J Hematother** 1999 Feb; 8(1):75-80

A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections. Stainer CJ, et al. **J Hematother** 1998 Aug;7(4):375-83

Transfusion of fetal cord blood cells: an improved method of hematopoietic stem cell transplantation? Craven CM, et al. **J Reprod Immunol** 1999 Jan;42(1):59-77 (50 ref.)

Umbilical cord transplantation. Wagner JE. **Leukemia** 1998 Sep;12 Suppl 1:S30-2

Adult acute myeloid leukaemia: update on treatment. Bishop JF. **Med J Aust** 1999 Jan 4;170(1):39-43 (36 ref.)

Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Herrmann RP, et al. **Oncol Nurs Forum** 1998 Sep;25(8):1427-32

Guidelines for the collection, processing, storage and of administration of hemopoietic stem and progenitor cells for transplantation. Report of the Working Party on Hemopoietic Stem Cell Processing, Hematology Discipline Advisory Committee, the Royal College of Pathologists of Australasia [published erratum appears in Pathology 1999 Feb;31(1):following 75] To LB, et al. **Pathology** 1998 Aug;30(3):276-85

Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation [editorial; comment] Peters C, et al. **Pediatr Transplant** 1998 Nov;2(4):250-3 (20 ref.). Comment on: Pediatr Transplant 1998 Nov;2(4):299-304.

The depletion of T cells from haematopoietic stem cell transplants. Slaper-Cortenbach IC, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):751-4

Rationale for high-dose cyclophosphamide and medium-dose total body irradiation in the conditioning of children with progressive systemic and polyarticular juvenile chronic arthritis before autologous stem cell transplantation. Vossen JM, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):762-3

High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma. Sanna P, et al. **Schweiz Med Wochenschr** 1998 Oct 3; 128(40):1500-7

Prenatal cellular transplantation. Albanese CT, et al. **Semin Pediatr Surg** 1999 Aug;8(3):101-8 (71 ref.)

Issues in peripheral blood stem cell transplantation [editorial] Lim HL, et al. **Singapore Med J** 1998 Sep;39(9):388-9

Isolation of hematopoietic stem cells from heparinized cadaveric multiple organ donors: potential clinical implications. Marlicz W, et al. **Transplant Proc** 1999 Aug; 31(5):2099-101

Ex vivo expansion of human hematopoietic stem cells: implications for the modern blood bank. Hoffman R, et al. **Vox Sang** 1998;74 Suppl 2:259-64 (48 ref.)

Ex vivo expansion of cord blood progenitors. Piacibello W, et al. **Vox Sang** 1998;74 Suppl 2:457-62 (41 ref.)

Analysis of CD34-expressing cells in clinical practice. Serke S, et al. **Vox Sang** 1998;74 Suppl 2:469-75 (15 ref.)

In vitro and in vivo expansion of stem cell populations. Wagemaker G. **Vox Sang** 1998;74 Suppl 2:463-6 (51 ref.)

[High-dose chemotherapy with stem cell support for solid tumors in adults] Rodenhuis S, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):731-8 (32 ref.) (Eng. Abstr.) **(Dut)**

[Intensive therapy in non-Hodgkins lymphoma. Indications and modalities] Albin N, et al. **Presse Med** 1998 Jun 6; 27(20):977-85 (71 ref.) (Eng. Abstr.) **(Fre)**

[Development in cord blood transplantation] Kai S, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1516-21 (5 ref.) **(Jpn)**

[Current status of hematopoietic stem cell transplantation] Kodera Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1457-63 (5 ref.) **(Jpn)**

[Clinical results of cord blood transplantation] Kato S. **Rinsho Byori** 1999 May;Suppl 110:41-7 (Eng. Abstr.) **(Jpn)**

[Ex vivo and in vivo purging for PBSCT] Moriyama Y. **Rinsho Byori** 1999 May;Suppl 110:79-84 (Eng. Abstr.) **(Jpn)**

[Preservation, thawing and infusion of hematopoietic stem cells] Nakamura H, et al. **Rinsho Byori** 1999 May;Suppl 110:70-8 (Eng. Abstr.) **(Jpn)**

[Detection of hematopoietic stem cells by flow cytometry, hematology analyzer or in vitro culture method] Saigo K, et al. **Rinsho Byori** 1999 May;Suppl 110:124-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Allogeneic peripheral blood stem cell transplantation] Yamane T, et al. **Rinsho Byori** 1999 May;Suppl 110:85-91 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Indications and limitations of purified CD34-positive cell transplantation] Kawano Y, et al. **Rinsho Ketsueki** 1999 Jun;40(6):459-63 **(Jpn)**

[Transplant of hematopoietic stem cells from cord blood] Madero L. **An Esp Pediatr** 1999 Feb;50(2):119-25 **(Spa)**

MORTALITY

Predictive value of left ventricular ejection fraction in stem cell transplantation. Zangari M, et al. **Bone Marrow Transplant** 1999 May;23(9):917-20

Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. Goldberg SL, et al. **J Clin Oncol** 1998 Dec;16(12):3796-802

PSYCHOLOGY

Psychosocial adjustment of pediatric patients after allogeneic stem cell transplantation. Felder-Puig R, et al. **Bone Marrow Transplant** 1999 Jul;24(1):75-80

Psychosocial aspects of haematopoietic stem cell donation for allogeneic transplantation: how family donors cope with this experience. Munzenberger N, et al. **Psychooncology** 1999 Jan-Feb;8(1):55-63

[Psychological problems and treatment possibilities in intensive care medicine exemplified by bone marrow transplantation] Schulz-Kindermann F, et al. **Psychother Psychosom Med Psychol** 1998 Sep-Oct; 48(9-10):390-7 (55 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Shipp MA, et al. **Ann Oncol** 1999 Jan;10(1):13-9 (33 ref.)

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Hum Immunol** 1999 Apr;60(4):347-60

Cord Blood Transplantation Study Standard Operating Procedures: an evolving document will improve cord blood unit quality [editorial; comment] Broxmeyer HE. **J Hematother** 1998 Dec;7(6):479-80. Comment on: J Hematother 1998 Dec;7(6):521-61.

Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures [see comments] Fraser JK, et al. **J Hematother** 1998 Dec;7(6):521-61 (25 ref.). Comment in: J Hematother 1998 Dec;7(6):479-80.

STATISTICS & NUMERICAL DATA

Hematopoetic progenitor cells transplantation in Poland: structure and clinical practice. Lange A, et al. **Ann Transplant** 1996;1(1):63-6

Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT). Gratwohl A, et al. **Bone Marrow Transplant** 1998 Aug;22(3):227-40

World transplant records--1997. **Clin Transpl** 1997;:385-434

Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Glick HA, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):419-30

Bayesian optimal design in population models for haematologic data. Palmer JL, et al. **Stat Med** 1998 Jul 30;17(14):1613-22

Hemopoietic progenitor cell transplantation in Catalonia, 1988-1997. Amado ML, et al. **Transplant Proc** 1999 Sep; 31(6):2577-8

[Nationwide survey of allogeneic peripheral blood stem cell transplantation in Japan] Takenaka K, et al. **Rinsho Ketsueki** 1999 Jun;40(6):451-4 **(Jpn)**

TRENDS

Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT). Gratwohl A, et al. **Bone Marrow Transplant** 1998 Aug;22(3):227-40

Buzz, hype...foundation [editorial] Collins NH. **J Hematother** 1998 Oct;7(5):401

Progress in cell therapy in Japan 1999 [editorial] Takaue Y, et al. **Jpn J Clin Oncol** 1999 Mar;29(3):117-8

What is in store after stem-cell transplantation? Leiper AD. **Lancet** 1999 May 8;353(9164):1544-5 (12 ref.)

Stem cell transplantation--a treatment for severe rheumatic diseases?--A review. Jantunen EJ, et al. **Scand J Rheumatol** 1999;28(2):69-74 (47 ref.)

[25 years allogenic bone marrow transplantation in Basel: 1973-1998] Passweg JR, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1568-74 (Eng. Abstr.) **(Ger)**

[Expectation of cell therapy in the 21st century] Asano S. **Rinsho Byori** 1999 May;Suppl 110:7-10 (Eng. Abstr.) **(Jpn)**

[Future development of cord blood transplantation] Hara H. **Rinsho Byori** 1999 May;Suppl 110:134-8 (Eng. Abstr.) **(Jpn)**

UTILIZATION

Current use and outcome of blood and marrow transplantation in childhood according to the Italian Registry. Pession A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S25-7

Changes in platelet demand in association with the spread of autologous peripheral blood progenitor cell transplantation. Ueda Y, et al. **Ther Apher** 1998 Nov; 2(4):283-7

HEMATOPOIETIC STEM CELLS

see related

COLONY-FORMING UNITS ASSAY

Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome. Richards M, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F215-7

Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-)CD14(-) and a CD34(-)CD14(+) dendritic cell precursor. Arrighi JF, et al. **Blood** 1999 Apr 1;93(7):2244-52

Comparative analysis of autografting in chronic myelogenous leukemia: effect of priming regimen and marrow or blood origin of stem cells [letter; comment] Carella A. **Blood** 1999 Mar 15;93(6):2136-8. Comment on: Blood 1998 Sep 1;92(5):1820-31.

Periodic hematological disorders [letter; comment] Morley A. **Blood** 1999 Jun 1;93(11):4023-4. Comment on: Blood 1998 Oct 15;92(8):2629-40.

Successful cryopreservation of purified autologous CD34+ cells: influence of freezing parameters on cell recovery and engraftment. Beaujean F, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1091-6

Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing. Cilloni D, et al. **Bone Marrow Transplant** 1999 Mar;23(5):497-503

Monitoring of CD34+ cells during leukapheresis allows a single, successful collection of hemopoietic progenitors in patients with low numbers of circulating stem cells. de Fabritiis P, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1229-36

Multicentre European study comparing selection techniques for the isolation of CD34+ cells. de Wynter EA, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1191-6

Cell culture bags allow a large extent of ex vivo expansion of LTC-IC and functional mature cells which can subsequently be frozen: interest for a large-scale clinical applications. Giarratana MC, et al. **Bone Marrow Transplant** 1998 Oct;22(7):707-15

Ex vivo expansion of bone marrow from breast cancer patients: reduction in tumor cell content through passive purging. Lundell BI, et al. **Bone Marrow Transplant** 1998 Jul;22(2):153-9

Formation of fibrin clots in cryopreserved stem cell bags during thawing procedure: lack of impact on engraftment in autologous stem cell transplantation [letter] Mandanas RA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):303-4

Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Mugishima H, et al. **Bone Marrow Transplant** 1999 Feb;23(4):395-6

5% Me2SO is sufficient to preserve stem cells derived from cord blood. Richter E, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S16

An improved micro-method for obtaining chromosome preparations from individual haemopoietic colonies. Kadhim MA, et al. **Br J Haematol** 1999 Jun;105(3):673-5

Human neonatal blood: stem cell content, kinetics of CD34+ cell decline and ex vivo expansion capacity. Li K, et al. **Br J Haematol** 1999 Jan;104(1):178-85

Factors affecting progenitor cell yields using three tandem leukaphereses in previously treated malignancies. Lin JS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Dec; 61(12):700-7

Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Mohr M, et al. **Clin Cancer Res** 1999 May;5(5):1035-40

Developmental hematopoiesis. Morales-Alcelay S, et al. **Crit Rev Immunol** 1998;18(6):485-501 (160 ref.)

Hematopoiesis: progenitors and their genetic program. Dieterlen-Lièvre F. **Curr Biol** 1998 Oct 8;8(20):R727-30 (13 ref.)

Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. Matsumura I, et al. **EMBO J** 1999 Mar 1;18(5):1367-77

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Schwaller J, et al. **EMBO J** 1998 Sep 15;17(18):5321-33

Study on the measurement of the percentage of viable cells in frozen peripheral blood stem cell harvesting samples by an automated hematology analyzer [letter] Aoyama Y, et al. **Eur J Haematol** 1998 Nov;61(5):356-7

Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis. Colović MD, et al. **Eur J Haematol** 1999 Mar; 62(3):155-9

SZF1: a novel KRAB-zinc finger gene expressed in CD34+ stem/progenitor cells. Liu C, et al. **Exp Hematol** 1999 Feb; 27(2):313-25

Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. off Diaz MA, et al. **Haematologica** 1999 Jan;84(1):32-5

Preleukapheresis peripheral blood CD34+ cells predict progenitor cell collection yield and the necessary number of procedures to undergo [letter] Osma MM, et al. **Haematologica** 1999 Mar;84(3):280-1

Controlled-rate versus uncontrolled-rate cryopreservation of peripheral blood progenitor cells: a prospective multicenter study. Group for Cryobiology and Biology of Bone Marrow Transplantation (CBTMO), Spain. Perez-Oteyza J, et al. **Haematologica** 1998 Nov; 83(11):1001-5

Placental/umbilical cord blood transplantation. Sirchia G, et al. **Haematologica** 1999 Aug;84(8):738-47 (75 ref.)

Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Denburg JA. **Immunol Today** 1999 Mar;20(3):111-3

Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide. Chabannon C, et al. **Int J Oncol** 1999 Sep;15(3):511-8

Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. Hernigou P, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):349-55

Hematotherapy Literature Watch. **J Hematother** 1999 Apr; 8(2):223-8

Fetal cord blood as an alternative source of hematopoietic progenitor cells: immunophenotype, maternal cell contamination, and ex vivo expansion. Engel H, et al. **J Hematother** 1999 Apr;8(2):141-55

The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. Fontão-Wendel R, et al. **J Hematother** 1999 Jun; 8(3):255-62

Comparative evaluation of procedures with a Baxter CS-3000 cell separator for collecting peripheral blood cells from children. Makimoto A, et al. **J Hematother** 1999 Jun; 8(3):305-10

Myb-transformed hematopoietic cells as a model for monocyte differentiation into dendritic cells and macrophages. Banyer JL, et al. **J Leukoc Biol** 1999 Aug; 66(2):217-23 (82 ref.)

Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Persons DA, et al. **Nat Med** 1998 Oct;4(10):1201-5

ETO-2, a new member of the ETO-family of nuclear proteins. Davis JN, et al. **Oncogene** 1999 Feb 11; 18(6):1375-83

Optimizing conditions for gene transfer into human hematopoietic cells. Moore MA, et al. **Prog Exp Tumor Res** 1999;36:20-49 (138 ref.)

Basic principles of gene transfer in hematopoietic stem cells. Sadelain M, et al. **Prog Exp Tumor Res** 1999;36:1-19 (116 ref.)

Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Miyoshi H, et al. **Science** 1999 Jan 29;283(5402):682-6

Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Balzarotti M, et al. **Semin Oncol** 1999 Apr;26(2 Suppl 7):66-71 (32 ref.)

Prologue to characteristics and potentials of blood stem cells, Stem Cells volume 16, supplement 1. Fliedner TM. **Stem Cells** 1998;16(6):357-60 (16 ref.)

Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels. Köhler T, et al. **Stem Cells** 1999;17(1):19-24

Safe and efficient peripheral blood stem cell collection in the smallest of children. Kanold J, et al. **Ther Apher** 1998 Feb;2(1):49-57

Collection of two peripheral blood stem cell concentrates from healthy donors. Stroncek DF, et al. **Transfus Med** 1999 Mar;9(1):37-50

Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Froberg MK, et al. **Transfusion** 1999 Apr;39(4):410-4

Long-term storage at -80 degrees C of hematopoietic progenitor cells with 5-percent dimethyl sulfoxide as the sole cryoprotectant. Galmés A, et al. **Transfusion** 1999 Jan; 39(1):70-3

Collection of allogeneic peripheral blood progenitor cells by two protocols on an apheresis system. Schreiner T, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1051-5

Kinetics of peripheral blood stem cell harvests during a single apheresis. Smolowicz AG, et al. **Transfusion** 1999 Apr; 39(4):403-9

CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies. Johnsen HE, et al. **Vox Sang** 1998; 74 Suppl 2:477-82

[Technique of gene transfer into hematopoietic stem cells] Hanasono Y, et al. **Hum Cell** 1998 Dec;11(4):247-50 (12 ref.) **(Jpn)**

[Gene transfer to hematopoietic stem cells and its clinical application] Ozawa K. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1526-31 (5 ref.) **(Jpn)**

[Gene transfer into hematopoietic stem cells] Kume A, et al. **Nippon Seirigaku Zasshi** 1999;61(1):23-9 (14 ref.) **(Jpn)**

[Standardization of hemopoietic colony assay reagents] Ueda M, et al. **Rinsho Ketsueki** 1998 Sep;39(9):625-30 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Taniguchi T, et al. **Blood** 1999 Jun 15; 93(12):4167-78

Cell adhesion molecules in cord blood hematopoietic progenitors. Timeus F, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S61-2

Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy. de Pauw ES, et al. **Cytometry** 1998 Jul 1; 32(3):163-9

Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry--time to let go! [see comments] Keeney M, et al. **Cytometry** 1998 Dec 15;34(6):280-3. Comment in: Cytometry 1999 Apr 15;38(2):78-80.

Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Menéndez P, et al. **Cytometry** 1998 Dec 15;34(6):264-71

Reduced expression of hemopoietic cytokine receptors on cord blood progenitor cells in neonates at risk for atopy. Upham JW, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):370-5

Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. Nicholls SE, et al. **J Immunol** 1999 May 15;162(10):6191-9

Selection of BCR/ABL-negative stem cells from marrow or blood of patients with chronic myeloid leukemia. Guyotat D, et al. **Leukemia** 1999 Jul;13(7):991-8

CLASSIFICATION

A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Gandhi M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):369-75

Extensive phenotypic analysis of CD34 subsets in successive collections of mobilized peripheral blood progenitors. Perey L, et al. **Br J Haematol** 1998 Dec;103(3):618-29

Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors. Pierelli L, et al. **Br J Haematol** 1998 Sep; 102(5):1139-50

Age-related changes of immunophenotypically immature lymphocytes in normal human peripheral blood. Calado RT, et al. **Cytometry** 1999 Jun 15;38(3):133-7

CYTOLOGY

A human myeloid cell line producing stem cell growth factor, KPB-M15, secretes another growth factor active on murine hematopoietic progenitor cells. Hiraoka A, et al. **Acta Haematol** 1998;100(4):174-80

Simple indicators for determining the timing of efficient collection of autologous peripheral blood stem cells in children with malignancies. Sato A, et al. **Acta Haematol** 1999;101(3):163-4

Determination of hematopoietic stem cells in peripheral blood by an automated hematology analyzer (SE-9000). Takekawa K, et al. **Acta Haematol** 1998 Dec;100(3):130-6

Deficient proliferation of myeloid, erythroid, and multipotent progenitor cells in long-term marrow cultures from patients with aplastic anemia treated with immunosuppressive therapy. Gómez-Morales E, et al. **Am J Hematol** 1998 Oct;59(2):149-55

Hematopoietic differentiation activity of a recombinant human interleukin-6 (IL-6) isoform resulting from alternatively spliced deletion of the second exon. Kestler DP, et al. **Am J Hematol** 1999 Jul;61(3):169-77

Placing the newborn on the maternal abdomen after delivery increases the volume and CD34 cell content in the umbilical cord blood collected: an old maneuver with new applications. Grisaru D, et al. **Am J Obstet Gynecol** 1999 May;180(5):1240-3

Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second- and third-trimester human fetal cord blood hematopoietic stem cells (progenitor cells). Surbek DV, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1228-33

G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: comparison of efficacy and tolerability. Fischmeister G, et al. **Ann Hematol** 1999 Mar;78(3):117-23

Comparison of different methods for separation and ex vivo expansion of cord blood progenitor cells. Schwinger W, et al. **Ann Hematol** 1999 Aug;78(8):364-70

Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Broxmeyer HE, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:142-62; discussion 163 (57 ref.)

Asymmetric cell divisions in hematopoietic stem cells. Brümmendorf TH, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:265-72; discussion 272-3

Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Bunting KD, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:125-40; discussion 140-1

(R)evolutionary considerations in hematopoietic development. Cooper DD, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:83-93 (60 ref.)

Absence of CD34 on some human SCID-repopulating cells. Dick JE. **Ann N Y Acad Sci** 1999 Apr 30;872:211-7; discussion 217-9 (30 ref.)

Embryonic beginnings of definitive hematopoietic stem cells. Dzierzak E. **Ann N Y Acad Sci** 1999 Apr 30;872:256-62; discussion 262-4 (27 ref.)

Introduction to stem cell biology in vitro. Threshold to the future. Eaves C, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:1-8 (34 ref.)

Biology of IL-8-induced stem cell mobilization. Fibbe WE, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:71-82 (39 ref.)

Thrombopoietin and hematopoietic stem cell development. Kaushansky K. **Ann N Y Acad Sci** 1999 Apr 30;872:314-9 (38 ref.)

Homing of long-term and short-term engrafting cells in vivo. Lanzkron SM, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:48-54; discussion 54-6

Searching for stem cell regulatory molecules. Some general thoughts and possible approaches. Lemischka I. **Ann N Y Acad Sci** 1999 Apr 30;872:274-87; discussion 287-8 (81 ref.)

A human factor-dependent cell line simulates cobblestone formation under human bone marrow stromal cells in vitro. Mantel CR, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:399-401

Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells. Medin JA, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:233-40; discussion 240-2

Stem cells, pre-progenitor cells and lineage-committed cells: are our dogmas correct? Metcalf D. **Ann N Y Acad Sci** 1999 Apr 30;872:289-303; discussion 303-4 (33 ref.)

Further characterization of CD34-low/negative mouse hematopoietic stem cells. Nakauchi H, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:57-66; discussion 66-70

Humoral regulation of hematopoietic stem cells. Ogawa M, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:17-23; discussion 23-4 (17 ref.)

Amphotropic retrovirus transduction of hematopoietic stem cells. Orlic D, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:115-23; discussion 123-4

Hematopoietic stem/progenitor cell mobilization. A continuing quest for etiologic mechanisms. Papayannopoulou T. **Ann N Y Acad Sci** 1999 Apr 30; 872:187-97; discussion 197-9 (45 ref.)

The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Reisner Y, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:336-48; discussion 348-50 (37 ref.)

Hematopoietic commitment during embryogenesis. Robertson S, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:9-15; discussion 15-6 (37 ref.)

Stromal inhibition of myeloid differentiation. A possible role for hJagged1. Tanaka J, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:171-2; discussion 172-5

Engraftment and multilineage expression of human bone marrow CD34- cells in vivo. Zanjani ED, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:220-31; discussion 231-2

Reconstitution of lymphoid tissue after vascularized bone marrow transplantation. Lukomska B, et al.

Ann Transplant 1996;1(1):67–9
In vivo and in vitro studies on the toxicity of Hoechst 33342 (Ho342). Implications for employing Ho342 for the isolation of haematopoietic stem cells. Machaliński B, et al. **Ann Transplant** 1998;3(3):5–13
Comparison of the different strategies for cryopreserving and storage of the bone marrow CD34+ cells. Possibility of unprogrammed rate freezing and storage at –80 degrees C mechanical freezer. Ratajczak J, et al. **Ann Transplant** 1996;1(4):35–8
Rapid cell isolation by magnetic flow sorting for applications in tissue engineering. Zborowski M, et al. **ASAIO J** 1999 May–Jun;45(3):127–30
Frequencies of cytotoxic T lymphocyte precursor estimate in three different populations. Haque K, et al. **Asian Pac J Allergy Immunol** 1999 Jun;17(2):93–9
Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation. Wimmer K, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):691–6
Activation of phospholipase A2 during differentiation of human haemopoietic progenitor cells. Roberts PJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):S233
Effects of low-level 50 Hz magnetic fields on the level of host defense and on spleen colony formation. Korneva HA, et al. **Bioelectromagnetics** 1999;20(1):57–63
The hemangioblast--an elusive cell captured in culture. Robb L, et al. **Bioessays** 1998 Aug;20(8):611–4 (37 ref.)
Tissue culture surface characteristics influence the expansion of human bone marrow cells. Koller MR, et al. **Biomaterials** 1998 Nov;19(21):1963–72
Serum-free ex vivo expansion of CD34(+) hematopoietic progenitor cells. Möbest D, et al. **Biotechnol Bioeng** 1998 Nov 5;60(3):341–7
Transport in a grooved perfusion flat-bed bioreactor for cell therapy applications. Horner M, et al. **Biotechnol Prog** 1998 Sep–Oct;14(5):689–98
Stromal cell CD9 regulates differentiation of hematopoietic stem/progenitor cells. Aoyama K, et al. **Blood** 1999 Apr 15;93(8):2586–94
CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. Arai A, et al. **Blood** 1999 Jun 1;93(11):3713–22
In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia. Battaile KP, et al. **Blood** 1999 Sep 15;94(6):2151–8
Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells. Bergh G, et al. **Blood** 1999 Sep 15; 94(6):1971–8
"Stochastic" –40 years of use and abuse [letter] Blackett N, et al. **Blood** 1999 May 1;93(9):3148–9
The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Canque B, et al. **Blood** 1999 Jun 1;93(11):3866–75
Human growth factor-enhanced regeneration of transplantable human hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient mice. Cashman JD, et al. **Blood** 1999 Jan 15;93(2):481–7
Long-term contribution to the myeloid compartment by lineage-committed stem cells. Chen CC, et al. **Blood** 1998 Nov 1;92(9):3210–7
Dynamic changes in mouse hematopoietic stem cell numbers during aging. de Haan G, et al. **Blood** 1999 May 15; 93(10):3294–301
Functional and molecular analysis of hematopoietic progenitors derived from the aorta-gonad-mesonephros region of the mouse embryo. Delassus S, et al. **Blood** 1999 Sep 1;94(5):1495–503
Heparan sulfate proteoglycan expression is induced during early erythroid differentiation of multipotent hematopoietic stem cells. Drzeniek Z, et al. **Blood** 1999 May 1; 93(9):2884–97
Activation of granulocyte-macrophage colony-stimulating factor and interleukin-3 receptor subunits in a multipotential hematopoietic progenitor cell line leads to differential effects on development. Evans CA, et al. **Blood** 1999 Sep 1;94(5):1504–14
In vitro reconstitution of human B-cell ontogeny: from CD34(+) multipotent progenitors to Ig-secreting cells. Fluckiger AC, et al. **Blood** 1998 Dec 15;92(12):4509–20
Rapid differentiation of a rare subset of adult human lin(–)CD34(–)CD38(–) cells stimulated by multiple growth factors in vitro. Fujisaki T, et al. **Blood** 1999 Sep 15; 94(6):1926–32
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Gabrilovich D, et al. **Blood** 1998 Dec 1;92(11):4150–66
Influence of cytokines on the growth kinetics and immunophenotype of daughter cells resulting from the first division of single CD34(+)Thy-1(+)lin– cells. Goff JP, et al. **Blood** 1998 Dec 1;92(11):4098–107
Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Gothot A, et al. **Blood** 1998 Oct 15;92(8):2641–9
In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-mesonephros region. Hamaguchi I, et al. **Blood** 1999 Mar 1;93(5):1549–56
Differentiation in culture of murine primitive lymphohematopoietic progenitors toward T-cell lineage. Hirayama F, et al. **Blood** 1999 Jun 15;93(12):4187–95
Optimal proliferation of a hematopoietic progenitor cell line requires either costimulation with stem cell factor or increase of receptor expression that can be replaced by overexpression of Bcl-2. Huang HM, et al. **Blood** 1999 Apr 15;93(8):2569–77
Does recombinant human granulocyte colony-stimulating factor really prime marrow stem cells in mice and humans? [letter; comment] Johnsen HE. **Blood** 1999 Jun 15; 93(12):4446–9. Comment on: Blood 1998 Nov 1;92(9):3489–90.
Characterization of mast cell-committed progenitors present in human umbilical cord blood. Kempuraj D, et al. **Blood** 1999 May 15;93(10):3338–46
Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Koski GK, et al. **Blood** 1999 Aug 15; 94(4):1359–71
Molecular identity of hematopoietic precursor cells emerging in the human embryo. Labastie MC, et al. **Blood** 1998 Nov 15;92(10):3624–35
Hematopoietic stem cell tracking in vivo: a comparison of short-term and long-term repopulating cells. Lanzkron SM, et al. **Blood** 1999 Mar 15;93(6):1916–21
Single adult human CD34(+)/Lin–/CD38(–) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Miller JS, et al. **Blood** 1999 Jan 1;93(1):96–106
Expression of alpha4-integrin defines the earliest precursor of hematopoietic cell lineage diverged from endothelial cells. Ogawa M, et al. **Blood** 1999 Feb 15;93(4):1168–77
Prolonged expression of c-fos suppresses cell cycle entry of dormant hematopoietic stem cells. Okada S, et al. **Blood** 1999 Feb 1;93(3):816–25
The myeloid-lymphoid initiating cell (ML-IC) assay assesses the fate of multipotent human progenitors in vitro. Punzel M, et al. **Blood** 1999 Jun 1;93(11):3750–6
An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Pyatt DW, et al. **Blood** 1999 May 15;93(10):3302–8
One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Rebel VI, et al. **Blood** 1999 Apr 1;93(7):2217–24
Enhanced myeloid progenitor cell cycling and apoptosis in mice lacking the chemokine receptor, CCR2. Reid S, et al. **Blood** 1999 Mar 1;93(5):1524–33
Thrombopoietin augments stem cell factor-dependent growth of human mast cells from bone marrow multipotential hematopoietic progenitors. Sawai N, et al. **Blood** 1999 Jun 1;93(11):3703–12
High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions. Schilz AJ, et al. **Blood** 1998 Nov 1;92(9):3163–71
Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Shih CC, et al. **Blood** 1999 Sep 1;94(5):1623–36
D3: a gene induced during myeloid cell differentiation of Linlo c-Kit+ Sca-1(+) progenitor cells. Weiler SR, et al. **Blood** 1999 Jan 15;93(2):527–36
Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells. Yaroslavskiy B, et al. **Blood** 1999 May 1;93(9):2907–17
Transforming growth factor-beta1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway. Zhang Y, et al. **Blood** 1999 Feb 15;93(4):1208–20
Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Zhou P, et al. **Blood** 1998 Nov 1; 92(9):3226–39
Involvement of H-ras in erythroid differentiation of TF1 and human umbilical cord blood CD34 cells. Ge Y, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):124–36; discussion 137
Association of porous hydroxyapatite and bone marrow cells for bone regeneration. Anselme K, et al. **Bone** 1999 Aug; 25(2 Suppl):51S–54S
Stem cell enumeration in cord blood vs bone marrow and peripheral blood. Bertolini F, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S57
Control of stem cell proliferation and differentiation to achieve stable gene transfer and expression. Bertolini F, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S75–6
Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow. Blazsek I, et al. **Bone Marrow Transplant** 1999 Apr;23(7):647–57
Immunological and functional differences between cord and peripheral blood. Cohen SB, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S9–12
Peripheral blood stem cell collection from G-CSF-stimulated unrelated donors for second transplant. Dini G, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S41–5 (33 ref.)
Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors [letter] González M, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):631–2
A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. Hensel N, et al. **Bone Marrow Transplant** 1999 Jan;23(1):71–8
Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period. Katayama Y, et al. **Bone Marrow Transplant** 1999 Apr;23(7):659–65
The number of particular hematopoietic progenitors cells and the haematopoietic recovery following Allo PBSCT. Knopińska-Posłuszny W, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S92–5
Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Leuner S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):699–706
Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Mahmoud H, et al. **Bone Marrow Transplant** 1999 Aug;24(4):355–8
Collection of peripheral blood stem cells in pediatric patients: a concise review on technical aspects. Marson P, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S7–11 (28 ref.)
Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF [letter] Miclea J, et al. **Bone Marrow Transplant** 1999 Aug;24(4):441–3
Comparison of repopulating ability of hematopoietic progenitor cells isolated from human umbilical cord blood or bone marrow cells in NOD/SCID mice. Noort WA, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S58–60
Peripheral blood stem cell collection and transplantation in paediatric malignancies: a monocentric experience. Petris MG, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S13–5
Expansion of cord blood progenitor cells. Querol S, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S77–80
Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells. Schwartz GN, et al. **Bone Marrow Transplant** 1998 Sep;22(5):457–68
Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Wiesneth M, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S21–4
Expansion and differentiation of haemopoietic progenitor cells on endothelialized hydroxyapatite under static conditions. Conrad V, et al. **Br J Haematol** 1999 Apr; 105(1):40–9
Flt3LP3nduces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. De Felice L, et al. **Br J Haematol** 1999 Jul;106(1):133–41
Recruitment of primitive peripheral blood cells: synergism of interleukin 12 with interleukin 6 and stem cell factor. Grafte-Faure S, et al. **Br J Haematol** 1999 Apr;105(1):33–9
The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. Hjertson M, et al. **Br J Haematol** 1999 Mar;104(3):516–22
Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-beta1. Mahmud N, et al. **Br J Haematol** 1999 May; 105(2):470–7
Implication of expression of GDNF/Ret signalling components in differentiation of bone marrow haemopoietic cells. Nakayama S, et al. **Br J Haematol** 1999 Apr;105(1):50–7
Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Ratajczak MZ, et al. **Br J Haematol** 1998 Dec;103(4):969–79
Identification of human T-lymphoid progenitor cells in CD34+ CD38low and CD34+ CD38+ subsets of human cord blood and bone marrow cells using NOD-SCID fetal thymus organ cultures. Robin C, et al. **Br J Haematol** 1999 Mar;104(4):809–19
The impact of antenatal and perinatal variables on cord blood haemopoietic stem/progenitor cell yield available for transplantation. Shlebak AA, et al. **Br J Haematol** 1998 Dec;103(4):1167–71
Mobilization of primitive haemopoietic progenitor cells and stem cells with long-term repopulating ability into peripheral blood in mice by pegylated recombinant human megakaryocyte growth and development factor. Torii Y, et al. **Br J Haematol** 1998 Dec;103(4):1172–80
The role of osteoblast density and endogenous interleukin-6 production in osteoclast formation from the hemopoietic stem cell line FDCP-MIX C2GM in coculture with primary osteoblasts. de Grooth R, et al. **Calcif Tissue Int** 1998 Jul;63(1):57–62
Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Fujii S, et al. **Cancer Res** 1999 May 1; 59(9):2150–8
Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic

drugs by inducing MCL1 acting as an antiapoptotic factor. Katoh O, et al. **Cancer Res** 1998 Dec 1;58(23):5565-9

Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Socolovsky M, et al. **Cell** 1999 Jul 23; 98(2):181-91

Regulation of the apoptotic response to radiation damage in B cell development. Nishii K, et al. **Cell Death Differ** 1998 Jan;5(1):77-86

Nucleolar segregation during apoptosis of haemopoietic stem cell line FDCP-Mix. Reipert S, et al. **Cell Death Differ** 1999 Apr;6(4):334-41

The fraction of cells in G1 with bound retinoblastoma protein increases with the duration of the cell cycle. Jonassen TS, et al. **Cell Prolif** 1994 Feb;27(2):95-104

Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Perry SS, et al. **Cell Transplant** 1999 Jul-Aug;8(4):339-44

Effects of different subtypes of histamine receptors on proliferation and differentiation of murine colony forming unit granulocyte-macrophage and colony forming unit megakaryocyte. Tan M, et al. **Chin Med J (Engl)** 1998 Feb; 111(2):132-5

Hematopoietic reconstruction: new approaches. Moore MA. **Clin Cancer Res** 1995 Jan;1(1):3-9 (61 ref.)

Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Yu J, et al. **Clin Cancer Res** 1997 Mar;3(3):433-8

Surface phenotype analysis of CD16+ monocytes from leukapheresis collections for peripheral blood progenitors. Tanaka M, et al. **Clin Exp Immunol** 1999 Apr;116(1):57-61

The effect of superoxide dismutase on the recovery of human bone marrow hemopoietic stem cells stored at 4 degreesC. Ma EP, et al. **Cryobiology** 1998 Dec;37(4):372-5

Role of cytokines and extracellular matrix in the regulation of haemopoietic stem cells. Whetton AD, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):721-6 (44 ref.)

Progress in the development of systems for in vitro expansion of human hematopoietic stem cells. Hoffman R. **Curr Opin Hematol** 1999 May;6(3):184-91 (69 ref.)

Thrombopoietin stimulation of hematopoietic stem/progenitor cells. Long MW. **Curr Opin Hematol** 1999 May;6(3):159-63 (52 ref.)

Cell analysis for hematopoietic stem/progenitor cell transplantation. Law P, et al. **Cytometry** 1999 Apr 15; 38(2):47-52 (76 ref.)

Role of endothelium in the control of mouse yolk sac stem cell differentiation. Auerbach R, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):333-8 (14 ref.)

Renewal of thymocyte progenitors and emigration of thymocytes during avian development. Dunon D, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):279-87

A linkage between dendritic cell and T-cell development in the mouse thymus: the capacity of sequential T-cell precursors to form dendritic cells in culture. Lucas K, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):339-49

Development of the definitive hematopoietic hierarchy in the mouse. Medvinsky AL, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):289-301 (84 ref.)

Detailed characterization of the human aorta-gonad-mesonephros region reveals morphological polarity resembling a hematopoietic stromal layer. Marshall CJ, et al. **Dev Dyn** 1999 Jun;215(2):139-47

Self-renewal and differentiation of a basic fibroblast growth factor-dependent multipotent hematopoietic cell line derived from embryonic stem cells. Anzai H, et al. **Dev Growth Differ** 1999 Feb;41(1):51-8

Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. Jaffredo T, et al. **Development** 1998 Nov;125(22):4575-83

Mona, a novel hematopoietic-specific adaptor interacting with the macrophage colony-stimulating factor receptor, is implicated in monocyte/macrophage development. Bourette RP, et al. **EMBO J** 1998 Dec 15;17(24):7273-81

Expression of the LIM-homeobox gene LH2 generates immortalized steel factor-dependent multipotent hematopoietic precursors. Pinto do O P, et al. **EMBO J** 1998 Oct 1;17(19):5744-56

Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. Mbalaviele G, et al. **Endocrinology** 1999 Aug; 140(8):3736-43

Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Wani MR, et al. **Endocrinology** 1999 Apr;140(4):1927-35

Detection of breast cancer cells using the magnetic cell separation (MACS) system: implications for stem cell purging. Garau D, et al. **Eur J Histochem** 1997;41 Suppl 2:17-8

Proliferative status and antigenic profile of CD34+ peripheral blood progenitors mobilized by chemotherapy and G-CSF. Rumi C, et al. **Eur J Histochem** 1997;41 Suppl 2:47-8

Studies on the phenotype of migrant thymic stem cells. Suniara RK, et al. **Eur J Immunol** 1999 Jan;29(1):75-80

Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Bachier CR, et al. **Exp Hematol** 1999 Apr;27(4):615-23

Extended culture of multipotent hematopoietic progenitors without cytokine augmentation in a novel three-dimensional device. Bagley J, et al. **Exp Hematol** 1999 Mar;27(3):496-504

Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Barcena A, et al. **Exp Hematol** 1999 Sep;27(9):1428-39

Development and aging of primitive hematopoietic stem cells in BALB/cBy mice. Chen J, et al. **Exp Hematol** 1999 May; 27(5):928-35

A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures. Chute JP, et al. **Exp Hematol** 1999 Feb;27(2):370-9

The influence of interleukin (IL)-4 and IL-13 on human dendritic cell differentiation from CD34+ progenitor cells: the importance of the source of serum [letter; comment] Di Nicola M, et al. **Exp Hematol** 1999 Feb;27(2):386-7. Comment on: Exp Hematol 1998 Jan;26(1):63-72.

Functional activity of murine CD34+ and CD34- hematopoietic stem cell populations. Donnelly DS, et al. **Exp Hematol** 1999 May;27(5):788-96

Characterization and retroviral transduction of an early human lymphomyeloid precursor assayed in nonswitched long-term culture on murine stroma. Gan OI, et al. **Exp Hematol** 1999 Jun;27(6):1097-106

Differential effects of CD4+ and CD8+ cells on lymphocyte development from human cord blood cells in murine fetal thymus explants. Globerson A, et al. **Exp Hematol** 1999 Feb;27(2):282-92

Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Holyoake TL, et al. **Exp Hematol** 1999 Sep; 27(9):1418-27

Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system. Kawada H, et al. **Exp Hematol** 1999 May;27(5):904-15

Intrinsic potential of phenotypically defined human hemopoietic stem cells to self-renew in short-term in vitro cultures. Knaan-Shanzer S, et al. **Exp Hematol** 1999 Sep; 27(9):1440-50

Direct contact between CD34+lin- cells and stroma induces a soluble activity that specifically increases primitive hematopoietic cell production. Koller MR, et al. **Exp Hematol** 1999 Apr;27(4):734-41

Cytoskeleton and integrin-mediated adhesion signaling in human CD34+ hemopoietic progenitor cells. Lévesque JP, et al. **Exp Hematol** 1999 Apr;27(4):579-86 (60 ref.)

Expression of murine CD34 by fetal liver NK cell progenitors. Lu J, et al. **Exp Hematol** 1999 Feb;27(2):272-81

Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Murray LJ, et al. **Exp Hematol** 1999 Jun;27(6):1019-28

Administration of Flk2/Flt3 ligand induces expansion of human high-proliferative potential colony-forming cells in the SCID-hu mouse. Namikawa R, et al. **Exp Hematol** 1999 Jun;27(6):1029-37

A novel growth-factor-dependent myeloid cell line derived from mouse bone marrow cells contains progenitors endowed with high proliferative potential. Revol V, et al. **Exp Hematol** 1999 Jan;27(1):88-98

Adhesion of hematopoietic progenitor cells to human bone marrow or umbilical vein derived endothelial cell lines: a comparison. Rood PM, et al. **Exp Hematol** 1999 Aug; 27(8):1306-14

Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Rösel M, et al. **Exp Hematol** 1999 Apr;27(4):698-711

Problems raised by the in vitro generation of dendritic cells for use in immunotherapy [letter] Rosenzwajg M, et al. **Exp Hematol** 1999 Feb;27(2):387-8

Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Roy V, et al. **Exp Hematol** 1999 Feb;27(2):302-12

Cord blood is better than bone marrow for generating megakaryocytic progenitor cells. Tao H, et al. **Exp Hematol** 1999 Feb;27(2):293-301

Distinct actions of interleukin-9 and interleukin-4 on a hematopoietic stem cell line, EMLC1. Wang XY, et al. **Exp Hematol** 1999 Jan;27(1):139-46

Changes in signal transduction downstream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells. Wheadon H, et al. **Exp Hematol** 1999 Jun; 27(6):1077-86

Marrow engraftment of hematopoietic stem and progenitor cells is independent of Galphai-coupled chemokine receptors. Wiesmann A, et al. **Exp Hematol** 1999 May; 27(5):946-55

Umbilical cord blood from preterm human fetuses is rich in committed and primitive hematopoietic progenitors with high proliferative and self-renewal capacity. Wyrsch A, et al. **Exp Hematol** 1999 Aug;27(8):1338-45

A novel stromal cell-dependent hematopoietic cell line established from temperature-sensitive SV40 T-antigen transgenic mice. Yanai N, et al. **Exp Hematol** 1999 Jun; 27(6):1087-96

CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo. Young JC, et al. **Exp Hematol** 1999 Jun;27(6):994-1003

Expression of interferon-gamma by stromal cells inhibits murine long-term repopulating hematopoietic stem cell activity. Yu JM, et al. **Exp Hematol** 1999 May; 27(5):895-903

Genetic analysis of hemopoietic cell cycling in mice suggests its involvement in organismal life span. De Haan G, et al. **FASEB J** 1999 Apr;13(6):707-13

Self-renewal, maturation, and differentiation of the rat myelomonocytic hematopoietic stem cell. Lucas T, et al. **FASEB J** 1999 Feb;13(2):263-72

Differentiation lineage-specific expression of human heat shock transcription factor 2. Pirkkala L, et al. **FASEB J** 1999 Jun;13(9):1089-98

Gene transfer into human umbilical cord blood-derived CD34+ cells by particle-mediated gene transfer. Verma S, et al. **Gene Ther** 1998 May;5(5):692-9

Short-term, serum-free, static culture of cord blood-derived CD34+ cells: effects of FLT3-L and MIP-1alpha on in vitro expansion of hematopoietic progenitor cells. Capmany G, et al. **Haematologica** 1999 Aug;84(8):675-82

Expression of the nlsLacz gene in dendritic cells derived from retrovirally transduced peripheral blood CD34+ cells. Chischportich C, et al. **Haematologica** 1999 Mar; 84(3):195-203

Regulation of the proliferative potential of cord blood long-term culture-initiating cells (LTC-IC) by different stromal cell lines: implications for LTC-IC measurement. Nadali G, et al. **Haematologica** 1998 Dec;83(12):1059-65

Circulating hematopoietic progenitors are not altered in patients with post-transplant erythrocytosis [letter] Smalcelj R, et al. **Haematologica** 1998 Oct;83(10):948-9

In vitro evidence for the presence of hematopoietic stem cells in the adult human liver. Crosbie OM, et al. **Hepatology** 1999 Apr;29(4):1193-8

Induction of apoptosis in CD34+ cells by sera from patients with aplastic anemia. Liu H, et al. **Hiroshima J Med Sci** 1999 Jun;48(2):57-63

Cell cycle regulation of hematopoietic stem cells. Furukawa Y. **Hum Cell** 1998 Jun;11(2):81-92 (57 ref.)

A clonal culture assay for human cord blood lymphohematopoietic progenitors. Yoshikawa Y, et al. **Hum Immunol** 1999 Jan;60(1):75-82

Identification of a fetal hematopoietic precursor with B cell, T cell, and macrophage potential. Lacaud G, et al. **Immunity** 1998 Dec;9(6):827-38

Role of interleukin-7 in T-cell development from hematopoietic stem cells. Akashi K, et al. **Immunol Rev** 1998 Oct;165:13-28 (137 ref.)

Cell fate in the immune system: decisions, decisions, decisions. Bluestone JA. **Immunol Rev** 1998 Oct;165:5-12 (9 ref.)

Crucial function of the pre-T-cell receptor (TCR) in TCR beta selection, TCR beta allelic exclusion and alpha beta versus gamma delta lineage commitment. von Boehmer H, et al. **Immunol Rev** 1998 Oct;165:111-9 (56 ref.)

Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line. Andrew DJ, et al. **Immunopharmacology** 1999 Jan;41(1):1-10

Improved soft-agar colony assay in a fluid processing apparatus. Forsman AD, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan;35(1):55-60

Lymphoid development from hematopoietic stem cells. Akashi K, et al. **Int J Hematol** 1999 Jun;69(4):217-26 (90 ref.)

Replating potential of colony-forming units of granulocytes/macrophages (CFU-GM) expanded ex vivo by stem cell factor, interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor, erythropoietin with or without thrombopoietin. Katayama Y, et al. **Int J Hematol** 1998 Aug;68(2):157-68

Hematopoietic stem cell gene therapy: a current overview. Kume A, et al. **Int J Hematol** 1999 Jun;69(4):227-33 (45 ref.)

The proliferative status of haematopoietic progenitor cells in the developing murine liver and adult bone marrow. Blair A, et al. **J Anat** 1998 Oct;193 (Pt 3):443-7

Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. Rausch O, et al. **J Biol Chem** 1999 Feb 12;274(7):4096-105

Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. Townsend KJ, et al. **J Biol Chem** 1999 Jan 15;274(3):1801-13

The box-1 region of the leukemia inhibitory factor receptor alpha-chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation. Zhang Y, et al. **J Biol Chem** 1998 Dec 18;273(51):34370-83

Retroviral transfer of antisense sequences results in reduction of C-Abl and induction of apoptosis in hemopoietic cells. Daniel R, et al. **J Biomed Sci** 1998 Sep-Oct;5(5):383-94

Isolation and characterization of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody. Oyajobi BO, et al. **J Bone Miner Res** 1999 Mar;14(3):351-61

Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with

downregulation of Mcl-1 expression. Myklebust JH, et al. **J Cell Physiol** 1999 Jul;180(1):71-80

Expression of two inward rectifier potassium channels is essential for differentiation of primitive human hematopoietic progenitor cells. Shirihai O, et al. **J Cell Physiol** 1998 Nov;177(2):197-205

In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells. Tanaka-Douzono M, et al. **J Cell Physiol** 1999 Feb; 178(2):267-73

Quantification of residual dimethyl sulfoxide in supernatants of haematopoietic stem cells by capillary zone electrophoresis. Houzé P, et al. **J Chromatogr B Biomed Sci Appl** 1999 May 14;728(1):75-83

Kinetic study of CD34+ cells during peripheral blood stem cell collections. Bojko P, et al. **J Clin Apheresis** 1999; 14(1):18-25

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. Zimmerman TM, et al. **J Clin Apheresis** 1999;14(1):31-4

Detection of small numbers of immature cells in the blood of healthy subjects. Oertel J, et al. **J Clin Pathol** 1998 Dec; 51(12):886-90

Commitment to the B lymphoid lineage occurs before DH-JH recombination. Allman D, et al. **J Exp Med** 1999 Feb 15;189(4):735-40

The transcription factor early growth response 1 (Egr-1) advances differentiation of pre-B and immature B cells. Dinkel A, et al. **J Exp Med** 1998 Dec 21;188(12):2215-24

Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. Rufer N, et al. **J Exp Med** 1999 Jul 19; 190(2):157-67

A controlled comparison of two different clinical grade devices for CD34+ cell selection of autologous blood stem cell grafts. Björkstrand B, et al. **J Hematother** 1999 Feb; 8(1):75-80

Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests. Bornhäuser M, et al. **J Hematother** 1998 Oct; 7(5):425-30

Reproducible scoring of CFU-GM and BFU-E grown in collagen-based semisolid medium after a short (3 h) training. Dobo I, et al. **J Hematother** 1999 Feb;8(1):45-51

Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the third workshop. Nordic Stem Cell Laboratory Group. Johnsen HE, et al. **J Hematother** 1999 Feb; 8(1):15-28

Ex vivo generation of dendritic cells from CD34+ cells in gas-permeable containers under serum-free conditions. Kowalkowski KL, et al. **J Hematother** 1998 Oct; 7(5):403-11

Minimization of CD34+ cell enumeration variability using the ProCOUNT standardized methodology. McNiece I, et al. **J Hematother** 1998 Dec;7(6):499-504

Neutrophil precursor generation: effects of culture conditions. Martinson JA, et al. **J Hematother** 1998 Oct; 7(5):463-71

Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. Dong Q, et al. **J Immunol** 1999 Mar 15;162(6):3220-30

Differential regulation of 4E-BP1 and 4E-BP2, two repressors of translation initiation, during human myeloid cell differentiation. Grolleau A, et al. **J Immunol** 1999 Mar 15;162(6):3491-7

Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hemopoietic cells. Hinton HJ, et al. **J Immunol** 1999 Jun 15;162(12):7002-9

Regulation of cell survival during B lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone marrow of mice with altered expression of IL-7 and recombinase-activating gene-2. Lu L, et al. **J Immunol** 1999 Feb 15;162(4):1931-40

Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. St. Louis DC, et al. **J Immunol** 1999 Mar 15;162(6):3237-48

Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. Williams NS, et al. **J Immunol** 1999 Sep 1;163(5):2648-56

Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. Sutton RE, et al. **J Virol** 1999 May; 73(5):3649-60

A proposal regarding the mechanism which underlies lineage choice during hematopoietic differentiation. Preisler HD, et al. **Leuk Res** 1999 Aug;23(8):685-94

Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Tsuboi A, et al. **Leuk Res** 1999 May;23(5):499-505

Efficient detection and selection of immature rhesus monkey and human CD34+ hematopoietic cells expressing the enhanced green fluorescent protein (EGFP). Bierhuizen MF, et al. **Leukemia** 1999 Apr;13(4):605-13

Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia. Corsetti MT, et al. **Leukemia** 1999 Jul;13(7):999-1008

Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis. Dräger AM, et al. **Leukemia** 1999 Jan; 13(1):62-9

Cell division tracking and expansion of hematopoietic long-term repopulating cells [editorial] Oostendorp RA, et al. **Leukemia** 1999 Apr;13(4):499-501

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells. Paloczi K. **Leukemia** 1999 Apr;13 Suppl 1:S87-9 (36 ref.)

Does long-term culture favor normal clonogenic cells from interferon-treated patients with chronic myelogenous leukemia? Pasternak G, et al. **Leukemia** 1999 Apr;13 Suppl 1:S55-64 (60 ref.)

The type of stromal feeder used in limiting dilution assays influences frequency and maintenance assessment of human long-term culture initiating cells. Punzel M, et al. **Leukemia** 1999 Jan;13(1):92-7

Stem cell engraftment and cell cycle phenotype. Quesenberry P, et al. **Leukemia** 1999 Apr;13 Suppl 1:S92-3

Purification of hematopoietic stem cells for further biological study. Thomas TE, et al. **Methods** 1999 Mar;17(3):202-18

Reversible tumorigenesis by MYC in hematopoietic lineages. Felsher DW, et al. **Mol Cell** 1999 Aug;4(2):199-207

Two distinct interleukin-3-mediated signal pathways, Ras-NF1L3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes. Kuribara R, et al. **Mol Cell Biol** 1999 Apr;19(4):2754-62

Pro-B-cell-specific transcription and proapoptotic function of protein kinase Ceta. Morrow TA, et al. **Mol Cell Biol** 1999 Aug;19(8):5608-18

Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate. Domen J, et al. **Mol Med Today** 1999 May;5(5):201-8 (52 ref.)

"Turning brain into blood"--clinical applications of stem-cell research in neurobiology and hematology. Moore MA. **N Engl J Med** 1999 Aug 19;341(8):605-7 (8 ref.)

Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. Carè A, et al. **Oncogene** 1999 Mar 18; 18(11):1993-2001

Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2. Kohzaki H, et al. **Oncogene** 1999 Jul 15;18(28):4055-62

Regulation of myeloid cell growth by distinct effectors of Ras. Matsuguchi T, et al. **Oncogene** 1998 Nov 26; 17(21):2701-9

Involvement of the adapter protein CRKL in integrin-mediated adhesion. Uemura N, et al. **Oncogene** 1999 Jun 3;18(22):3343-53

HOX11 interacts with CTF1 and mediates hematopoietic precursor cell immortalization. Zhang N, et al. **Oncogene** 1999 Apr 1;18(13):2273-9

Murine schistosomiasis mansoni: experimental analysis of bone marrow and peripheral myelopoiesis. Dutra HS, et al. **Parasitol Res** 1998 Aug;84(8):668-75

Analysis and characterization of hematopoietic progenitor cells from fetal bone marrow, adult bone marrow, peripheral blood, and cord blood. Wu AG, et al. **Pediatr Res** 1999 Aug;46(2):163-9

In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Cheshier SH, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3120-5

Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Dao MA, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13006-11

Hepatic differentiation induced by oncostatin M attenuates fetal liver hematopoiesis. Kinoshita T, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7265-70

Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Krämer A, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2087-92

Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Storms RW, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9118-23

Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. Yagi M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8126-31

In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors. Sorrentino BP, et al. **Prog Exp Tumor Res** 1999;36:143-61 (47 ref.)

Lipid and glycolipid mediators in CD95-induced apoptotic signaling. Malisan F, et al. **Results Probl Cell Differ** 1999; 23:65-76 (59 ref.)

The depletion of T cells from haematopoietic stem cell transplants. Slaper-Cortenbach IC, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):751-4

Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo [see comments] Bjornson CR, et al. **Science** 1999 Jan 22;283(5401):534-7. Comment in: Science 1999 Jan 22;283(5401):471.

Brain stem cells show their potential [news; comment] Strauss E. **Science** 1999 Jan 22;283(5401):471. Comment on: Science 1999 Jan 22;283(5401):534-7.

KDR receptor: a key marker defining hematopoietic stem cells. Ziegler BL, et al. **Science** 1999 Sep 3;285(5433):1553-8

Differences between bone marrow and lung endothelial cells. Imai K, et al. **Semin Thromb Hemost** 1998;24(3):275-7

The characteristics of umbilical cord blood (UCB) and UCB transplantation. Kasai M, et al. **Semin Thromb Hemost** 1998; 24(5):491-5

CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. de Wynter EA, et al. **Stem Cells** 1998; 16(6):387-96

Direct measurement of CD34+ blood stem cell absolute counts by flow cytometry. Fukuda J, et al. **Stem Cells** 1998; 16(4):294-300

Mature accessory cells influence long-term growth of human hematopoietic progenitors on a murine stromal cell feeder layer. Mazini L, et al. **Stem Cells** 1998;16(6):404-12

Toward standardization of CD34+ cell enumeration: an international study. Biomedial Excellence for Safer Transfusion Working Party. Dzik W, et al. **Transfusion** 1999 Aug;39(8):856-63

The timing of granulocyte-colony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Lefrère F, et al. **Transfusion** 1999 Jun;39(6):561-4

A direct method for the calculation of alloreactive CD4+ T cell precursor frequency. Noorchashm H, et al. **Transplantation** 1999 May 15;67(9):1281-4

Intrapatient comparison of an intermittent and a continuous flow cell separator for the collection of progenitor and stem cells from the blood. Beretta F, et al. **Vox Sang** 1998; 75(2):149-53

The CD34 molecule and hematopoietic progenitor cell studies--a challenge in clinical medicine. Egeland T. **Vox Sang** 1998;74 Suppl 2:467-8 (13 ref.)

Ex vivo expansion of human hematopoietic stem cells: implications for the modern blood bank. Hoffman R, et al. **Vox Sang** 1998;74 Suppl 2:259-64 (48 ref.)

Blood cell precursors in context. Composition of the bone marrow microenvironment that supports B lymphopoiesis. Kincade PW, et al. **Vox Sang** 1998;74 Suppl 2:265-8 (19 ref.)

Stem cell biology for the transfusionist. Lansdorp PM. **Vox Sang** 1998;74 Suppl 2:91-4 (32 ref.)

Harvesting of peripheral blood progenitor cells with different programmes of discontinuous flow systems. Moog R, et al. **Vox Sang** 1999;76(1):50-4

Ex vivo expansion of cord blood progenitors. Piacibello W, et al. **Vox Sang** 1998;74 Suppl 2:457-62 (41 ref.)

Analysis of CD34-expressing cells in clinical practice. Serke S, et al. **Vox Sang** 1998;74 Suppl 2:469-75 (15 ref.)

In vitro and in vivo expansion of stem cell populations. Wagemaker G. **Vox Sang** 1998;74 Suppl 2:463-6 (51 ref.)

[In vitro expansion of human umbilical cord blood hematopiotic cells and its subpopulation] Cao XS, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):422-4 (Eng. Abstr.) **(Chi)**

[The protective effect of SOD on injury of bone marrow hematopoietic progenitor cells of mice under 4 degrees C storage] Liu X, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):319-21 (Eng. Abstr.) **(Chi)**

[Optimum choice for the cultivation of CFU-GM in media buffered with HEPES] Jiang D, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):99-101 (Eng. Abstr.) **(Chi)**

[Studies on characteristics of proliferation and differentiation of hematopoietic stem cells in mice] Liu CR, et al. **Sheng Li Hsueh Pao** 1997 Jun;49(3):255-60 (Eng. Abstr.) **(Chi)**

[Optical measuring methods for monitoring and evaluation of experimental cell and tissue cultures in undisturbed and flowing media] Röhlecke U, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:450-1 **(Ger)**

[Detection of hematopoietic stem cells by flow cytometry, hematology analyzer or in vitro culture method] Saigo K, et al. **Rinsho Byori** 1999 May;Suppl 110:124-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The role of NF-E2 related transcription factors in hematopoiesis] Itou E. **Rinsho Ketsueki** 1999 Apr; 40(4):280-3 (9 ref.) **(Jpn)**

[New approaches of differentiation-inducing therapy for leukemia] Kosugi H, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):480-3 (14 ref.) **(Jpn)**

[A trial for peripheral blood stem cell harvest by combination of G-CSF with ABVD regimen in the management of Hodgkin's disease] Suzuki A, et al. **Rinsho Ketsueki** 1999 Jan;40(1):16-21 (Eng. Abstr.) **(Jpn)**

[The molecular mechanism of hematopoietic stem cell development in the AGM region] Takakura N. **Rinsho Ketsueki** 1999 Apr;40(4):262-7 (15 ref.) **(Jpn)**

[Hematopoietic stem cells and stromal cells in AGM region of mouse embryo] Tuji K. **Rinsho Ketsueki** 1999 Apr; 40(4):268-71 (7 ref.) **(Jpn)**

[Synergistic function of TAL1 and LMO in hematopoietic differentiation and T cell tumorigenesis] Ono Y. **Seikagaku** 1999 Apr;71(4):269-73 (18 ref.) **(Jpn)**

[Clonal succession in the hemopoietic system: number of the primitive stem hemopoietic cells and clone life span] Drize NI, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):419-23 **(Rus)**

[Hematopoietic microenvironment transfer units and inducible progenitors of hematopoietic stroma in the bone marrow of thymectomized mice] Todria TV. **Biull Eksp Biol Med** 1999 Feb;127(2):186–9 **(Rus)**

[CD3+4–8–thymocytes produce a chemotactic factor for stem elements of the bone marrow] Anfalova TV, et al. **Dokl Akad Nauk** 1998 Sep;362(2):274–6 **(Rus)**

[Experimental research on the cellular interactions during hemopoiesis] Michurina TV, et al. **Ontogenez** 1999 Jan–Feb;30(1):3–25 (90 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia--A possible role of high endogenous IL-2 in their suppression. Nissen C, et al. **Acta Haematol** 1999;101(4):165–72

Impaired response of granulocyte-committed progenitor cells to stem cell factor and granulocyte colony-stimulating factor in human cyclic neutropenia. Takami A, et al. **Ann Hematol** 1999 Apr;78(4):197–9

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743). Ghielmini M, et al. **Ann Oncol** 1998 Sep;9(9):989–93

Effects of docetaxel on the in vitro growth of human myeloid progenitors. Botta M, et al. **Anticancer Res** 1999 May–Jun; 19(3A):1855–8

In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors. Pannacciulli I, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):409–12

Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Repetto L, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):879–84

Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):113–8

An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Volk EE, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):508–13 (62 ref.)

Ex vivo expansion of immature 4-hydroperoxycyclophosphamide-resistant progenitor cells from G-CSF-mobilized peripheral blood. Roecklein BA, et al. **Biol Blood Marrow Transplant** 1998;4(2):61–8

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources [corrected and republished article originally printed in Biotherapy 1998;10(4):295–8] Eridani S, et al. **Biotherapy** 1998; 11(4):291–6

Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-)CD14(-) and a CD34(-)CD14(+) dendritic cell precursor. Arrighi JF, et al. **Blood** 1999 Apr 1;93(7):2244–52

Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34(+)CD38(low/neg) human bone marrow cells. Bennaceur-Griscelli A, et al. **Blood** 1999 Jul 15; 94(2):529–38

Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Dao MA, et al. **Blood** 1998 Dec 15;92(12):4612–21

Expression of macrophage inflammatory protein-1 receptors in human CD34(+) hematopoietic cells and their modulation by tumor necrosis factor-alpha and interferon-gamma. Dürig J, et al. **Blood** 1998 Nov 1; 92(9):3073–81

Influence of cytokines on the growth kinetics and immunophenotype of daughter cells resulting from the first division of single CD34(+)Thy-1(+)lin- cells. Goff JP, et al. **Blood** 1998 Dec 1;92(11):4098–107

Interleukin-6 directly modulates stem cell factor-dependent development of human mast cells derived from CD34(+) cord blood cells. Kinoshita T, et al. **Blood** 1999 Jul 15; 94(2):496–508

Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential. Neipp M, et al. **Blood** 1998 Nov 1;92(9):3177–88

All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Purton LE, et al. **Blood** 1999 Jul 15;94(2):483–95

Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Seymour JF, et al. **Blood** 1998 Oct 15;92(8):2657–67

C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Wang X, et al. **Blood** 1999 Jul 15; 94(2):560–71

Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Yu H, et al. **Blood** 1998 Nov 15; 92(10):3647–57

Analysis of surface markers on CD34+ cells, isolated from cord blood and G-CSF primed peripheral blood. Barbosa IL, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S56

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bellucci R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):1–8

A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia [letter] Canales MA, et al. **Bone Marrow Transplant** 1999 Feb;23(3):305

Flt3L enhances the early stem cell compartment after ex vivo amplification of umbilical cord blood CD34+ cells. De Felice L, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S66–7

Clinical application of in vitro expansion of cord blood. Denning-Kendall PA, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S63–5

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. Martinez C, et al. **Bone Marrow Transplant** 1999 Jan;23(1):15–9

Characterization of peripheral blood progenitor cells mobilized by nartograstim (N-terminal replaced granulocyte colony-stimulating factor) in normal volunteers. Maruyama K, et al. **Bone Marrow Transplant** 1998 Aug;22(4):313–20

Comparative study of the in vitro behavior of cord blood subpopulations after short-term cytokine exposure. Rice A, et al. **Bone Marrow Transplant** 1999 Feb;23(3):211–20

Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. Klein JL, et al. **Br J Cancer** 1999 Apr;80(1-2):87–95

In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue. Pierelli L, et al. **Br J Cancer** 1998 Oct;78(8):1024–9

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors. Thijsen SF, et al. **Br J Cancer** 1999 Mar;79(9-10):1406–12

Pre-treatment of peripheral blood progenitor cells with macrophage inflammatory protein-1alpha induces prolonged survival of early progenitor cells over 6 weeks of long-term culture. Egger D, et al. **Br J Haematol** 1998 Dec;103(4):1181–3

Human long-term culture initiating cells are sensitive to benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and protected after mutant (G156A) methylguanine methyltransferase gene transfer. Koç ON, et al. **Cancer Gene Ther** 1999 Jul-Aug;6(4):340–8

Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. Erben U, et al. **Cancer Res** 1999 Jun 15;59(12):2924–30

Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Katoh O, et al. **Cancer Res** 1998 Dec 1;58(23):5565–9

Lead and catechol hematotoxicity in vitro using human and murine hematopoietic progenitor cells. Van Den Heuvel RL, et al. **Cell Biol Toxicol** 1999 Apr;15(2):101–10

Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Perry SS, et al. **Cell Transplant** 1999 Jul-Aug;8(4):339–44

Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia. McGuinness SM, et al. **Chem Biol Interact** 1999 Aug 1;121(3):253–65

Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Allay JA, et al. **Clin Cancer Res** 1996 Aug;2(8):1353–9

Potent antileukemic activity of the novel agents norsegoline and dibezine. Einat M, et al. **Clin Cancer Res** 1995 Aug; 1(8):823–9

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. Shapiro F, et al. **Clin Cancer Res** 1997 Sep;3(9):1571–8

In vitro antineoplastic activity of a novel lanthionine-containing peptide. Zheng H, et al. **Clin Cancer Res** 1997 Aug;3(8):1323–30

The effect of superoxide dismutase on the recovery of human bone marrow hemopoietic stem cells stored at 4 degreesC. Ma EP, et al. **Cryobiology** 1998 Dec;37(4):372–5

Modulation of haematopoietic progenitor development by FLT-3 ligand. Banu N, et al. **Cytokine** 1999 Sep; 11(9):679–88

Phototoxicity of the fluorescent membrane dyes PKH2 and PKH26 on the human hematopoietic KG1a progenitor cell line. Oh DJ, et al. **Cytometry** 1999 Aug 1;36(4):312–8

In aplastic anemia progenitor cells have a reduced sensitivity to the effects of growth factors. Novitzky N, et al. **Eur J Haematol** 1999 Sep;63(3):141–8

Synergistic effects of heat and ET-18-OCH3 on membrane expression of hsp70 and lysis of leukemic K562 cells. Botzler C, et al. **Exp Hematol** 1999 Mar;27(3):470–8

Modulation of histidine decarboxylase activity and cytokine synthesis in human leukemic cell lines: relationship with basophilic and/or megakaryocytic differentiation. Dy M, et al. **Exp Hematol** 1999 Aug;27(8):1295–305

Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Hofmann WK, et al. **Exp Hematol** 1999 Mar;27(3):395–400

Granulocyte colony-stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA. Horwitz ME, et al. **Exp Hematol** 1999 Jul;27(7):1160–7

Marrow sensitization to 5-fluorouracil using the ligands for Flt-3 and c-Kit. Jin L, et al. **Exp Hematol** 1999 Mar; 27(3):520–5

Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells. Josefsen D, et al. **Exp Hematol** 1999 Apr;27(4):642–53

Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Josefsen D, et al. **Exp Hematol** 1999 Sep;27(9):1451–9

Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product. Li K, et al. **Exp Hematol** 1999 Mar;27(3):526–32

Estrone potentiates myeloid cell differentiation: a role for 17 beta-hydroxysteroid dehydrogenase in modulating hemopoiesis. Mountford JC, et al. **Exp Hematol** 1999 Mar; 27(3):451–60

Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15. Pierelli L, et al. **Exp Hematol** 1999 Mar;27(3):416–24

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Platanias LC, et al. **Exp Hematol** 1999 Aug; 27(8):1315–21

Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Reykdal S, et al. **Exp Hematol** 1999 Mar;27(3):441–50

In vivo testing of Enterogenin for a mutagenic activity of bone marrow hemopoietic tissue of mice. Drakopoylos D, et al. **Folia Med (Plovdiv)** 1999;41(1):153–6

Long term hematopoietic damage after chemotherapy and cytokine. Gardner RV. **Front Biosci** 1999 Jul 15;4:e47–57 (113 ref.)

In vitro effect of clozapine on hemopoietic progenitor cells. Deliliers GL, et al. **Haematologica** 1998 Oct;83(10):882–9

In vitro growth and quantification of early (CD33-/CD38-) myeloid progenitor cells: stem cell factor requirement and effects of previous chemotherapy. Ferrero D, et al. **Haematologica** 1999 May;84(5):390–6

Recombinant adeno-associated virus-mediated expression of O6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity. Longhurst SJ, et al. **Hum Gene Ther** 1999 Jan 20;10(2):301–10

Soluble bone marrow stroma factors improve the efficiency of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells. Schiedlmeier B, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1443–52

Effects of in vivo administration of adamantylamide dipeptide on bone marrow granulocyte-macrophage hemopoietic progenitor cells (GM-CFC) and on ability of serum of the treated mice to stimulate GM-CFC colony formation in vitro: comparison with muramyl dipeptide and glucan. Vacek A, et al. **Immunopharmacol Immunotoxicol** 1999 Feb; 21(1):1–14

Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line. Andrew DJ, et al. **Immunopharmacology** 1999 Jan;41(1):1–10

The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo. Aidoudi S, et al. **Int J Hematol** 1998 Aug; 68(2):145–55

Growth and differentiation of bone marrow hematopoietic cells in mice bearing Ehrlich ascite tumor and treated with Dicyclopentadienildichlorotitanium (IV). Valadares MC, et al. **Int J Immunopharmacol** 1998 Oct;20(10):573–81

Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Fujimura S, et al. **Int J Oncol** 1998 Dec;13(6):1263–7

Distinctive actions of interleukin-13 and interleukin-4 on growth of hematopoietic progenitors. Sugawara T, et al. **Int J Oncol** 1999 Mar;14(3):471–7

In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells. Tanaka-Douzono M, et al. **J Cell Physiol** 1999 Feb; 178(2):267–73

Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. Bhatia M, et al. **J Exp Med** 1999 Apr 5;189(7):1139–48

Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. Kim CH, et al. **J Exp Med** 1999 Sep 6; 190(5):681–90

Concurrent partial body-radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. Sharp JG, et al. **J Hematother** 1998 Aug;7(4):343–9

Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency

virus-infected patients. Dam Nielsen S, et al. **J Infect Dis** 1998 Nov;178(5):1299-305

SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation. Kim CH, et al. **J Leukoc Biol** 1999 Sep;66(3):455-61

Study on the protective effects of compound blood-activating soup on bone marrow hematopoietic cells in acute radiation injured mice. Liu W, et al. **J Tongji Med Univ** 1997;17(4):225-8

Study on oxygen supply and protection of bone marrow in acute radiation injured mice. Sun H, et al. **J Tongji Med Univ** 1997;17(4):229-31, 243

Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Bhatia R, et al. **Leukemia** 1998 Nov;12(11):1708-17

Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. List AF, et al. **Leukemia** 1998 Oct;12(10):1596-602

Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures. Ploemacher RE, et al. **Leukemia** 1999 Mar;13(3):428-37

Developmentally regulated responsiveness to transforming growth factor-beta is correlated with functional differences between human adult and fetal primitive hematopoietic progenitor cells. Weekx SF, et al. **Leukemia** 1999 Aug; 13(8):1266-72

Growth inhibition of leukemic cells by (-)-epigallocatechin gallate, the main constituent of green tea. Otsuka T, et al. **Life Sci** 1998;63(16):1397-403

Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Pessina A, et al. **Life Sci** 1999; 65(5):513-23

The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors. Paukovits JB, et al. **Mol Pharmacol** 1999 Oct;56(4):665-74

IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Dumon S, et al. **Oncogene** 1999 Jul 22;18(29):4191-9

Mobilization of peripheral blood progenitor cells using 16 versus 10 mg/kg/d G-CSF in children with malignancies. Kurekci AE, et al. **Pediatr Transplant** 1998 May;2(2):160-4

Acute effects of prechemotherapy filgrastim administration on late hematopoietic progenitor cells. Higa GM. **Pharmacotherapy** 1998 Nov-Dec;18(6):1249-54

Enhancement of haemopoietic spleen colony formation by drugs elevating extracellular adenosine: effects of repeated in vivo treatment. Hofer M, et al. **Physiol Res** 1997; 46(4):285-90

cDNA cloning of FRIL, a lectin from Dolichos lablab, that preserves hematopoietic progenitors in suspension culture. Colucci G, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19; 96(2):646-50

Transfer of the MDR-1 gene into hematopoietic cells. Bank A, et al. **Prog Exp Tumor Res** 1999;36:50-64

O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Davis BM, et al. **Prog Exp Tumor Res** 1999;36:65-81 (69 ref.)

Effect of interleukin 10 on the hematopoietic progenitor cells from patients with aplastic anemia. Asano Y, et al. **Stem Cells** 1999;17(3):147-51

In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation. Gaudron S, et al. **Stem Cells** 1999;17(2):100-6

Cotinine (a metabolite of nicotine) suppresses the growth of hematopoietic progenitor cells at the concentration range equivalent to its serum levels in smokers [letter] Takahashi M, et al. **Stem Cells** 1999;17(2):125-6

Improved progenitor assay standardization using peripheral blood progenitor cells from a donor treated with granulocyte-colony-stimulating factor. Burger SR, et al. **Transfusion** 1999 May;39(5):451-6

In vitro effect of ketone bodies, glucocorticosteroids and bovine pregnancy-associated glycoprotein on cultures of bone marrow progenitor cells of cows and calves. Hoeben D, et al. **Vet Immunol Immunopathol** 1999 May; 68(2-4):229-40

The effect of diclofenac Na (Voltarol) on the haematopoietic cells of bone marrow in sheep. Naeini AT, et al. **Vet Res Commun** 1998 Sep;22(6):401-3

Effect of pig-specific cytokines on mobilization of hematopoietic progenitor cells in pigs and on pig bone marrow engraftment in baboons. Kozlowski T, et al. **Xenotransplantation** 1999 Feb;6(1):17-27

[Clinical observation on aplastic anemia treated by Spatholobus suberectus Composita] Su EY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr; 17(4):213-5 (Eng. Abstr.) **(Chi)**

[Preliminary studies on the efficacy and mechanism of interleukin-3 in the treatment of myelosuppression in mice] Chen J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):134-7 (Eng. Abstr.) **(Chi)**

[The protective effect of SOD on injury of bone marrow hematopoietic progenitor cells of mice under 4 degrees C storage] Liu X, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):319-21 (Eng. Abstr.) **(Chi)**

[Effects of lithium on the proliferation of murine high proliferative potential colony-forming cells and granulocyte macrophage colony forming unit in vitro] Xia T, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):264-7 (Eng. Abstr.) **(Chi)**

[In vitro growth characteristics of rIL3 stimulated megakaryocytic progenitor cells (CFU-MK) of fetal liver] Ma DC, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):215-20 (Eng. Abstr.) **(Chi)**

[Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles] Gibaud S, et al. **Ann Pharm Fr** 1999 Jul;57(4):324-31 (Eng. Abstr.) **(Fre)**

[The effect of erythropoietin (rh-EPO) om in vitro proliferation of granulocyte/monocyte-determined stem cells in bone marrow and peripheral blood] Neumann U, et al. **Med Klin** 1999 Mar 15;94(3):133-6 (Eng. Abstr.) **(Ger)**

[Recovery of the colony-forming activity of of stem hemopoietic and blood cells of mice after 1-beta-D-arabinofuranosylcytosine administration] Kozlov VA, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):83-5 **(Rus)**

[The induction of the migration of bone marrow stem elements to the periphery by the cytokines of cortisone-resistant thymocytes] Anfalova TV, et al. **Ontogenez** 1999 May-Jun;30(3):188-91 (Eng. Abstr.) **(Rus)**

[Effect of mussels hydrolysate MIGI-K on the adaptive response od bone marrow hematopoietic stem cells in mice] Parkhomenko IM, et al. **Radiats Biol Radioecol** 1999 Mar-Jun;39(2-3):310-2 (Eng. Abstr.) **(Rus)**

[Mechanisms of hemopoiesis cytostatic damage and regeneration] Gol'dberg ED, et al. **Vestn Ross Akad Med Nauk** 1998;(10):6-10 (Eng. Abstr.) **(Rus)**

[Stem cell factor (SCF) supports granulocyte progenitor survival in mouse bone marrow cultures] Cáceres-Cortés JR, et al. **Rev Invest Clin** 1999 Mar-Apr;51(2):107-16 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Peripheral CD34+ progenitor cells express CD26 and contain increased dipeptidyl peptidase IV activity. Ruiz P, et al. **Acta Haematol** 1998;100(2):110-2

Characterization and partial purification of CD34+ progenitor cell ecto-phosphatidic acid phosphohydrolase. Harvey KA, et al. **Biochem Mol Biol Int** 1999 Jan; 47(1):9-23

Activation of phospholipase A2 during differentiation of human haemopoietic progenitor cells. Roberts PJ, et al. **Biochem Soc Trans** 1998 Aug;26(3):S233

Lineage-restricted expression of protein kinase C isoforms in hematopoiesis. Bassini A, et al. **Blood** 1999 Feb 15; 93(4):1178-88

Fluorescence-based selection of gene-corrected hematopoietic stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved stem cell gene transfer procedures. Erlich S, et al. **Blood** 1999 Jan 1;93(1):80-6

Protein kinase C-theta (PKCtheta) distribution analysis in hematopoietic cells: proliferating T cells exhibit high proportions of PKCtheta in the particulate fraction. Meller N, et al. **Cell Immunol** 1999 May 1;193(2):185-93

Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Reese JS, et al. **Clin Cancer Res** 1999 Jan;5(1):163-9

Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Yu J, et al. **Clin Cancer Res** 1997 Mar;3(3):433-8

Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Takenaka T, et al. **Exp Hematol** 1999 Jul;27(7):1149-59

Successful transfer of ADA gene in vitro into human peripheral blood CD34+ cells by transfecting EBV-based episomal vectors. Satoh E, et al. **FEBS Lett** 1998 Dec 11; 441(1):39-42

Isolation and characterization of NUC70, a cytoplasmic, hematopoietic apoptotic endonuclease. Urbano A, et al. **J Biol Chem** 1998 Dec 25;273(52):34820-7

IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells. Ahmad F, et al. **J Immunol** 1999 Apr 15; 162(8):4864-75

Cytokine-induced protein kinase B activation and Bad phosphorylation do not correlate with cell survival of hemopoietic cells. Hinton HJ, et al. **J Immunol** 1999 Jun 15;162(12):7002-9

Phosphatidylinositol 3'-kinase, but not S6-kinase, is required for insulin-like growth factor-I and IL-4 to maintain expression of Bcl-2 and promote survival of myeloid progenitors. Minshall C, et al. **J Immunol** 1999 Apr 15; 162(8):4542-9

Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment. Maze R, et al. **J Pharmacol Exp Ther** 1999 Sep; 290(3):1467-74

A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation. Birkenkamp KU, et al. **Leukemia** 1999 Jul;13(7):1037-45

Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Storms RW, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9118-23

IMMUNOLOGY

Peripheral CD34+ progenitor cells express CD26 and contain increased dipeptidyl peptidase IV activity. Ruiz P, et al. **Acta Haematol** 1998;100(2):110-2

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. Adams GB, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):551-9

CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Martín-Henao GA, et al. **Am J Hematol** 1999 Jul;61(3):178-86

Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second- and third-trimester human fetal cord blood hematopoietic stem cells (progenitor cells). Surbek DV, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1228-33

The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Viardot A, et al. **Ann Hematol** 1998 Nov;77(5):193-7

Expression of novel surface antigens on early hematopoietic cells. Bühring HJ, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:25-38; discussion 38-9

Humoral regulation of hematopoietic stem cells. Ogawa M, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:17-23; discussion 23-4 (17 ref.)

Lymphohematopoietic stem cell engraftment. Quesenberry PJ, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:40-5; discussion 45-7 (19 ref.)

Expression and functional analysis of a hemopoietic progenitor antigen, NJ-1 (114/A10), in the megakaryocytic lineage. Duan Y, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):401-6

c-Kit and CD38 are expressed by long-term reconstituting hematopoietic cells present in the murine yolk sac. Dagher RN, et al. **Biol Blood Marrow Transplant** 1998;4(2):69-74

Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Shpall EJ, et al. **Biol Blood Marrow Transplant** 1998;4(2):84-92 (57 ref.)

Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Aiuti A, et al. **Blood** 1999 Jul 1;94(1):62-73

Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Brown MP, et al. **Blood** 1999 Sep 15;94(6):1906-14

CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Cignetti A, et al. **Blood** 1999 Sep 15;94(6):2048-55

Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells [letter] Horn PA, et al. **Blood** 1999 Feb 15;93(4):1435-7

Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Lee B, et al. **Blood** 1999 Feb 15;93(4):1145-56

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Mutis T, et al. **Blood** 1999 Apr 1;93(7):2336-41

In vivo T-lymphocyte tolerance in the absence of thymic clonal deletion mediated by hematopoietic cells. van Meerwijk JP, et al. **Blood** 1999 Jun 1;93(11):3856-62

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Vescio R, et al. **Blood** 1999 Mar 15;93(6):1858-68

Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Watanabe T, et al. **Blood** 1999 Feb 15; 93(4):1157-63

Cytofluorimetric analysis of CD34 cells. Basso G, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S17-20 (19 ref.)

Immunological and functional differences between cord and peripheral blood. Cohen SB, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S9-12

Changes in L-selectin expression on CD34-positive cells upon cryopreservation of peripheral blood stem cell transplants. De Boer F, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1103-10

Adhesion molecules on peripheral blood-derived CD34+ cells: effects of cryopreservation and short-term ex vivo incubation with serum and cytokines. Koenigsmann MP, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1077-85

Biological characterization of CD34+ cells mobilized into peripheral blood. Lemoli RM, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 5:S47-50

Functional aspects of cord blood lymphocytes response to

polyclonal and allogeneic activation. Paiva A, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S31–4

Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Perfetti V, et al. **Bone Marrow Transplant** 1999 Feb;23(4):323–7

Alloantigen presenting capacity, T cell alloreactivity and NK function of G–CSF–mobilized peripheral blood cells. Rondelli D, et al. **Bone Marrow Transplant** 1998 Oct; 22(7):631–7

The cytotoxicity of mafosfamide on G–CSF mobilized hematopoietic progenitors is reduced by SH groups of albumin––implications for further purging strategies. Schlenke P, et al. **Bone Marrow Transplant** 1999 Jan; 23(2):157–61

Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Singh RK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):53–62

Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Stewart DA, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1237–43

Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection [letter] Tchirkov A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):229–30

Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? Raptis A, et al. **Br J Haematol** 1998 Sep; 102(5):1354–8

Dual control by divalent cations and mitogenic cytokines of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity expressed by human hemopoietic cells. Takamatsu Y, et al. **Cell Adhes Commun** 1998 Jul;5(5):349–66

The impact of variation in the number of CD8(+) T-cell precursors on the outcome of virus infection. Ehl S, et al. **Cell Immunol** 1998 Oct 10;189(1):67–73

Cloning thymic precursor cells: demonstration that individual pro–T1 cells have dual T–NK potential and individual pro–T2 cells have dual alphabeta–gammadelta T cell potential. Lee CK, et al. **Cell Immunol** 1999 Feb 1; 191(2):139–44

Isolation and characterization of macaque dendritic cells from CD34(+) bone marrow progenitors. Pinchuk LM, et al. **Cell Immunol** 1999 Aug 25;196(1):34–40

Dendritic cell–based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell–depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Choi D, et al. **Clin Cancer Res** 1998 Nov; 4(11):2709–16

Novel phenotype associated with in vivo activated CTL precursors. Oughton JA, et al. **Clin Immunol** 1999 Mar; 90(3):323–33

T cell precursors in man and mice. Blom B, et al. **Crit Rev Immunol** 1998;18(4):371–88 (155 ref.)

An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. Martinez A, et al. **Cytometry** 1999 Apr 15;38(2):70–5

Antigenic profiles of endothelial and hemopoietic lineages in murine intraembryonic hemogenic sites. Garcia–Porrero JA, et al. **Dev Comp Immunol** 1998 May–Jun;22(3):303–19

The avian transcription factor c–Rel is expressed in lymphocyte precursor cells and antigen–presenting cells during thymus development. Huguet C, et al. **Dev Immunol** 1998;5(4):247–61

Thymic stromal–cell abnormalities and dysregulated T–cell development in IL–2–deficient mice. Reya T, et al. **Dev Immunol** 1998;5(4):287–302

Multicentric quality control trial for CD34+ cells evaluation in peripheral blood and leukapheresis collections from patients with hematological malignancies. Regione Piemonte Study Group. Omedè P, et al. **Eur J Histochem** 1997;41 Suppl 2:35–6

Intrathymic deletion of MHC class I–restricted cytotoxic T cell precursors by constitutive cross–presentation of exogenous antigen. Merkenschlager M, et al. **Eur J Immunol** 1999 May;29(5):1477–86

Studies on the phenotype of migrant thymic stem cells. Suniara RK, et al. **Eur J Immunol** 1999 Jan;29(1):75–80

CD44 isoforms in normal and leukemic hematopoiesis. Ghaffari S, et al. **Exp Hematol** 1999 Jun;27(6):978–93 (184 ref.)

The real CD34+ events: simplicity versus accuracy and flexibility [letter; comment] Gratama JW, et al. **Exp Hematol** 1999 Jun;27(6):975–7 (18 ref.). Comment on: Exp Hematol 1998 Jan;26(1):73–8. Comment on: Exp Hematol 1998 Jul;26(7):550–1.

Candidate hematopoietic stem cells from fetal tissues, umbilical cord blood vs. adult bone marrow and mobilized peripheral blood. Huang S, et al. **Exp Hematol** 1998 Nov; 26(12):1162–71

Identification of a peptide directed against the anti–CD34 antibody, 9C5, by phage display and its use in hematopoietic stem cell selection. Tseng–Law J, et al. **Exp Hematol** 1999 May;27(5):936–45

Upstream elements bestow T–cell and haemopoietic progenitor–specific activity on the granzyme B promoter. Johnson BA, et al. **Gene** 1999 Jun 24;234(1):101–7

Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Meldgaard Knudsen L, et al. **Haematologica** 1999 Jun;84(6):517–24

Ex vivo expansion CD34+/AC133+–selected autologous peripheral blood progenitor cells (PBPC) in high–risk breast cancer patients receiving intensive chemotherapy. Vávrová J, et al. **Hematol Cell Ther** 1999 Jun;41(3):105–12

Long–term genetic modification of rhesus monkey hematopoietic cells following transplantation of adenoassociated virus vector–transduced CD34+ cells. Schimmenti S, et al. **Hum Gene Ther** 1998 Dec 10; 9(18):2727–34

Gene transfer into fetal baboon hematopoietic progenitor cells. Winkler A, et al. **Hum Gene Ther** 1999 Mar 1; 10(4):667–77

The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Ma Q, et al. **Immunity** 1999 Apr;10(4):463–71

The molecular characterization of the fetal stem cell marker AA4. Petrenko O, et al. **Immunity** 1999 Jun;10(6):691–700

Comparison of restimulation methods to elicit SIV specific cytotoxic T–lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursors. Kakimoto WM, et al. **Immunol Lett** 1999 Mar;66(1–3):135–40

Reconstitution of immune systems in RAG2–/– mice by transfer with interleukin–12–induced splenic hematopoietic progenitor cells. Yahata T, et al. **Immunol Lett** 1998 Jul; 62(3):165–70

Enrichment of c–kit+ Lin– haemopoietic progenitor cells that commit themselves to extrathymic T cells in in vitro culture of appendix mononuclear cells. Koya T, et al. **Immunology** 1999 Mar;96(3):447–56

Effects of in vivo administration of adamantylamide dipeptide on bone marrow granulocyte–macrophage hemopoietic progenitor cells (GM–CFC) and on ability of serum of the treated mice to stimulate GM–CFC colony formation in vitro: comparison with muramyl dipeptide and glucan. Vacek A, et al. **Immunopharmacol Immunotoxicol** 1999 Feb; 21(1):1–14

Characterization of prethymic progenitors within the chicken embryo. Lampisuo M, et al. **Int Immunol** 1999 Jan; 11(1):63–9

Partial block in B lymphocyte development at the transition into the pre–B cell receptor stage in Vpre–B1–deficient mice. Mårtensson A, et al. **Int Immunol** 1999 Mar; 11(3):453–60

Large volume leukapheresis for collecting hemopoietic progenitors: role of CD 34+ precount in predicting successful collection. Menichella G, et al. **Int J Artif Organs** 1999 May;22(5):334–41

Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)–2. Ozerol I, et al. **Int J Immunopharmacol** 1999 Aug; 21(8):509–21

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Young MR, et al. **Int J Immunopharmacol** 1999 Apr;21(4):241–52 (35 ref.)

Isolation and transduction of CD34+ cells from small quantities of peripheral blood from HIV–1–infected patients not treated with hemopoietic growth factors. Adams GB, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):1–8

The origins of basophils and eosinophils in allergic inflammation. Denburg JA. **J Allergy Clin Immunol** 1998 Nov;102(5):S74–6

Expression of MUC–1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. Brugger W, et al. **J Clin Oncol** 1999 May; 17(5):1535–44

Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z, et al. **J Exp Clin Cancer Res** 1998 Sep;17(3):251–8

The common cytokine receptor gamma chain and the pre–T cell receptor provide independent but critically overlapping signals in early alpha/beta T cell development. Di Santo JP, et al. **J Exp Med** 1999 Feb 1;189(3):563–74

Interleukin 7 receptor control of T cell receptor gamma gene rearrangement: role of receptor–associated chains and locus accessibility. Durum SK, et al. **J Exp Med** 1998 Dec 21; 188(12):2233–41

CD34(+) hematopoietic stem cells exert accessory function in lipopolysaccharide–induced T cell stimulation and CD80 expression on monocytes. Mattern T, et al. **J Exp Med** 1999 Feb 15;189(4):693–700

Identification of lymphomyeloid primitive progenitor cells in fresh human cord blood and in the marrow of nonobese diabetic–severe combined immunodeficient (NOD–SCID) mice transplanted with human CD34(+) cord blood cells. Robin C, et al. **J Exp Med** 1999 May 17;189(10):1601–10

Isolation from human fetal liver of cells co–expressing CD34 haematopoietic stem cell and CAM 5.2 pancytokeratin markers. Lemmer ER, et al. **J Hepatol** 1998 Sep;29(3):450–4

SLP–76 expression is restricted to hemopoietic cells of monocyte, granulocyte, and T lymphocyte lineage and is regulated during T cell maturation and activation. Clements JL, et al. **J Immunol** 1998 Oct 15;161(8):3880–9

Presence of progenitors restricted to T, B, or myeloid lineage, but absence of multipotent stem cells, in the murine fetal thymus. Kawamoto H, et al. **J Immunol** 1998 Oct 15; 161(8):3799–802

Protection from radiation–induced colitis requires MHC class II antigen expression by cells of hemopoietic origin. Marguerat S, et al. **J Immunol** 1999 Oct 1;163(7):4033–40

Enhanced autoimmune arthritis in IFN–gamma receptor–deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac–1+ myeloid cells. Matthys P, et al. **J Immunol** 1999 Sep 15; 163(6):3503–10

Transfer of primitive stem/progenitor bone marrow cells from LT alpha–/– donors to wild–type hosts: implications for the generation of architectural events in lymphoid B cell domains. Mebius RE, et al. **J Immunol** 1998 Oct 15; 161(8):3836–43

Peripheral blood–derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. Ruiz ME, et al. **J Immunol** 1998 Oct 15;161(8):4169–76

Syndecan–4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes. Yamashita Y, et al. **J Immunol** 1999 May 15;162(10):5940–8

Separate precursor cells for macrophages and microglia in mouse brain: immunophenotypic and immunoregulatory properties of the progeny. Walker WS. **J Neuroimmunol** 1999 Feb 1;94(1–2):127–33

Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7–directed cytotoxic T–lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. Doan T, et al. **J Virol** 1999 Jul;73(7):6166–70

Gastrointestinal epithelium is an early extrathymic site for increased prevalence of CD34(+) progenitor cells in contrast to the thymus during primary simian immunodeficiency virus infection. Mattapallil JJ, et al. **J Virol** 1999 May;73(5):4518–23

Defunct hematopoietic progenitor growth and heterogeneous immunological phenotypes in acquired aplastic anemia of childhood: identification of subsets with decreased hematopoietic progenitors and increased IL15 or IL10 production. Dirksen U, et al. **Klin Padiatr** 1998 Jul–Aug; 210(4):167–72

Biology of CD34+CD38– cells in lymphohematopoiesis. Novelli EM, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):285–93 (80 ref.)

CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Tien HF, et al. **Leuk Lymphoma** 1998 Sep;31(1–2):93–8 (43 ref.)

Philadelphia chromosome–positive cells are equally distributed in AC133+ and AC133– fractions of CD34+ peripheral blood progenitor cells from patients with CML [letter] Waller CF, et al. **Leukemia** 1999 Sep;13(9):1466–7

Anti–CD34+ Fabs generated against hematopoietic stem cells in HIV–derived combinatorial immunoglobulin library suggest antigen–selected autoantibodies. Rubinstein DB, et al. **Mol Immunol** 1998 Oct;35(14–15):955–64

Differential expression of the murine Ly–6A/E antigen homolog of human squamous cell carcinoma antigen E48 during malignant transformation and tumor progression of squamous cell carcinoma line Pam 212. Kato T, et al. **Otolaryngol Head Neck Surg** 1998 Oct;119(4):408–11

L–selectin expression enhances clonogenesis of CD34+ cord blood progenitors. Koenig JM, et al. **Pediatr Res** 1999 Jun; 45(6):867–70

Formation of coding joints in V(D)J recombination–inducible severe combined immune deficient pre–B cell lines. Chang Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):191–6

Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Engels FH, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10332–7

Influence of intestinal microflora on murine bone marrow and spleen macrophage precursors. Nicaise P, et al. **Scand J Immunol** 1998 Dec;48(6):585–91

Peripheral blood platelets express VEGF–C and VEGF which are released during platelet activation. Wartiovaara U, et al. **Thromb Haemost** 1998 Jul;80(1):171–5

Comparison of volumetric capillary cytometry with standard flow cytometry for routine enumeration of CD34+ cells. Cabezudo E, et al. **Transfusion** 1999 Aug;39(8):864–72

Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high–dose chemotherapy and autotransplantation. Cancelas JA, et al. **Transfusion** 1998 Nov–Dec;38(11–12):1063–70

Toward standardization of CD34+ cell enumeration: an international study. Biomedial Excellence for Safer Transfusion Working Party. Dzik W, et al. **Transfusion** 1999 Aug;39(8):856–63

Factors affecting the efficiency of collection of CD34–positive peripheral blood cells by a blood cell separator. Ford CD, et al. **Transfusion** 1998 Nov–Dec; 38(11–12):1046–50

Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system. Ravagnani F, et al. **Transfusion** 1999 Jan;39(1):48–55

The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Yu J, et al. **Transfusion** 1999 May;39(5):442–50

Kinetics of circulating cytotoxic T lymphocyte precursors that have a high avidity for donor antigens: correlation with the rejection status of the human cardiac allograft. van Emmerik NE, et al. **Transpl Immunol** 1998 Sep; 6(3):153–60

Hematopoietic chimerism and tolerance of T cells, B cells,

and NK cells. Sykes M, et al. **Transplant Proc** 1998 Dec; 30(8):4020

A direct method for the calculation of alloreactive CD4+ T cell precursor frequency. Noorchashm H, et al. **Transplantation** 1999 May 15;67(9):1281-4

METABOLISM

Retroviral-mediated transfer and expression of the common gamma chain into human hematopoietic progenitors. Candotti F, et al. **Acta Haematol** 1999;101(2):106-10

The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Viardot A, et al. **Ann Hematol** 1998 Nov;77(5):193-7

A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells. Kume A, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):9-12

Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin. Ota J, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):779-86

p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Zhang S, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):440-5

Transmembrane 4 superfamily protein CD151 (PETA-3) associates with beta 1 and alpha IIb beta 3 integrins in haemopoietic cell lines and modulates cell-cell adhesion. Fitter S, et al. **Biochem J** 1999 Feb 15;338 (Pt 1):61-70

Transcriptional activation of vesicular monoamine transporter 2 in the pre-B cell line Ea3.123. Watson F, et al. **Biochem J** 1999 Jan 15;337 (Pt 2):193-9

Stirred culture of peripheral and cord blood hematopoietic cells offers advantages over traditional static systems for clinically relevant applications. Collins PC, et al. **Biotechnol Bioeng** 1998 Sep 5;59(5):534-43

AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors [letter] Bühring HJ, et al. **Blood** 1999 Jul 15; 94(2):832-3

Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors. Chatterjee S, et al. **Blood** 1999 Mar 15;93(6):1882-94

HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Cortés F, et al. **Blood** 1999 Feb 1;93(3):826-37

Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Crooks GM, et al. **Blood** 1999 Jul 15; 94(2):519-28

Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Du C, et al. **Blood** 1999 Jul 15;94(2):793-802

Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Dworzak MN, et al. **Blood** 1998 Nov 1;92(9):3203-9

Fluorescence-based selection of gene-corrected hematopoietic stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved stem cell gene transfer procedures. Erlich S, et al. **Blood** 1999 Jan 1;93(1):80-6

Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Gupta P, et al. **Blood** 1998 Dec 15; 92(12):4641-51

Downregulation of c-kit (stem cell factor receptor) in transformed hematopoietic precursor cells by stroma cells. Heberlein C, et al. **Blood** 1999 Jan 15;93(2):554-63

p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Mantel C, et al. **Blood** 1999 Feb 15; 93(4):1390-8

Positive and negative cis-acting elements are required for hematopoietic expression of zebrafish GATA-1. Meng A, et al. **Blood** 1999 Jan 15;93(2):500-8

Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta 2-integrin LFA-1. Pruijt JF, et al. **Blood** 1999 Jan 1; 93(1):107-12

Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Reddy JA, et al. **Blood** 1999 Jun 1;93(11):3940-8

Ceramide and cyclic adenosine monophosphate (cAMP) induce cAMP response element binding protein phosphorylation via distinct signaling pathways while having opposite effects on myeloid cell survival. Scheid MP, et al. **Blood** 1999 Jan 1;93(1):217-25

Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Stanford WL, et al. **Blood** 1998 Dec 15; 92(12):4622-31

Expression of p53, Bcl-2, and Bax in Cd34+ cells recovering after chemotherapy [letter] Toefili L, et al. **Blood** 1998 Dec 15;92(12):4880-1

Role of members of the Wnt gene family in human hematopoiesis. Van Den Berg DJ, et al. **Blood** 1998 Nov 1;92(9):3189-202

A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Wisniewski D, et al. **Blood** 1999 Apr 15;93(8):2707-20

Tyrosine phosphorylation of Shc proteins in normal CD34+ progenitor cells and leukemic cells [letter] Yang J, et al. **Blood** 1999 Jul 1;94(1):373-4

Cyclin A1 expression in leukemia and normal hematopoietic cells. Yang R, et al. **Blood** 1999 Mar 15;93(6):2067-74

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bellucci R, et al. **Bone Marrow Transplant** 1999 Jan;23(1):1-8

Early progenitor cells from human mobilized peripheral blood express low levels of the flt3 receptor, but exhibit various biological responses to flt3-L. Aurran-Schleinitz T, et al. **Br J Haematol** 1999 Aug;106(2):357-67

Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside. Braess J, et al. **Br J Haematol** 1999 May;105(2):388-93

HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. Gibellini D, et al. **Br J Haematol** 1999 Jan;104(1):81-6

Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor. Roberts MM, et al. **Br J Haematol** 1999 Mar;104(4):778-84

Beta-galactosidase marker genes to tag and track human hematopoietic cells. Bagnis C, et al. **Cancer Gene Ther** 1999 Jan-Feb;6(1):3-13 (172 ref.)

Characterization of a novel receptor that maps near the natural killer gene complex: demonstration of carbohydrate binding and expression in hematopoietic cells. Fernandes MJ, et al. **Cancer Res** 1999 Jun 1;59(11):2709-17

Expression of the cell adhesion molecule E-cadherin by the human bone marrow stromal cells and its probable role in CD34(+) stem cell adhesion. Turel KR, et al. **Cell Biol Int** 1998;22(9-10):641-8

Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodulating properties. Whetsell M, et al. **Cell Immunol** 1999 Mar 15; 192(2):159-66

The fraction of cells in G1 with bound retinoblastoma protein increases with the duration of the cell cycle. Jonassen TS, et al. **Cell Prolif** 1994 Feb;27(2):95-104

Procedure for the quantitation of Gadd45 expression levels in clonal hematopoietic progenitor cells by competitive polymerase chain reaction. Santucci MA, et al. **Clin Biochem** 1999 Feb;32(1):1-8

Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Ward M, et al. **Clin Cancer Res** 1996 May;2(5):873-6

Cryobiophysical characteristics of genetically modified hematopoietic progenitor cells. Hubel A, et al. **Cryobiology** 1999 Mar;38(2):140-53

Threshold of pre-T-cell-receptor surface expression is associated with alphabeta T-cell lineage commitment. Bruno L, et al. **Curr Biol** 1999 Jun 3;9(11):559-68

Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors. Zimmerman TM, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):257-64 (87 ref.)

Disruption of alpha beta but not of gamma delta T cell development by overexpression of the helix-loop-helix protein Id3 in committed T cell progenitors. Blom B, et al. **EMBO J** 1999 May 17;18(10):2793-802

Low frequency of myeloid progenitor cells in chronic idiopathic neutropenia of adults may be related to increased production of TGF-beta1 by bone marrow stromal cells. Papadaki HA, et al. **Eur J Haematol** 1999 Sep;63(3):154-62

Expression and functional role of urokinase-type plasminogen activator receptor (UPA-R; CD87) in normal and acute leukemia cells. Castagnari B, et al. **Eur J Histochem** 1997;41 Suppl 2:109-10

Proliferative status and antigenic profile of CD34+ peripheral blood progenitors mobilized by chemotherapy and G-CSF. Rumi C, et al. **Eur J Histochem** 1997;41 Suppl 2:47-8

Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status. Becker PS, et al. **Exp Hematol** 1999 Mar; 27(3):533-41

A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures. Chute JP, et al. **Exp Hematol** 1999 Feb;27(2):370-9

Expression of homing-associated cell adhesion molecule (H-CAM/CD44) on human CD34+ hematopoietic progenitor cells. Deguchi T, et al. **Exp Hematol** 1999 Mar; 27(3):542-52

Retroviral vector-mediated gene transfer into umbilical cord blood CD34brCD38-CD33- cells. Gentry T, et al. **Exp Hematol** 1999 Aug;27(8):1244-54

Retroviral transduction of enriched hematopoietic stem cells allows lifelong Bcl-2 expression in multiple lineages but does not perturb hematopoiesis. Innes KM, et al. **Exp Hematol** 1999 Jan;27(1):75-87

Primitive human hematopoietic progenitor cells express receptors for granulocyte-macrophage colony-stimulating factor. Lund-Johansen F, et al. **Exp Hematol** 1999 Apr; 27(4):762-72

CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Murray LJ, et al. **Exp Hematol** 1999 Aug;27(8):1282-94

IL-3-induced coexpression of histidine decarboxylase, IL-4 and IL-6 mRNA by murine basophil precursors. Schneider E, et al. **Exp Hematol** 1999 Jun;27(6):1010-8

Expression of Flt3 and c-kit during growth and maturation of human CD34+CD38- cells. Xiao M, et al. **Exp Hematol** 1999 May;27(5):916-27

Prenatal development of hematopoietic and hormone-producing cells in the chicken adenohypophysis. Allaerts W, et al. **Gen Comp Endocrinol** 1999 May; 114(2):213-24

Identification of sequence-tagged transcripts differentially expressed within the human hematopoietic hierarchy. Claudio JO, et al. **Genomics** 1998 May 15;50(1):44-52

Retroviral gene transfer into human hematopoietic cells: an in vitro kinetic study. Briones J, et al. **Haematologica** 1999 Jun;84(6):483-8

Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. Byk T, et al. **Hum Gene Ther** 1998 Nov 20;9(17):2493-502

Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia. Machiels JP, et al. **Hum Gene Ther** 1999 Mar 20; 10(5):801-11

No discrepancy between in vivo gene marking efficiency assessed in peripheral blood populations compared with bone marrow progenitors or CD34+ cells. Sellers SE, et al. **Hum Gene Ther** 1999 Mar 1;10(4):633-40

Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery. Ye ZQ, et al. **Hum Gene Ther** 1998 Oct 10;9(15):2197-205

Characterization of TEK receptor tyrosine kinase and its ligands, Angiopoietins, in human hematopoietic progenitor cells. Sato A, et al. **Int Immunol** 1998 Aug;10(8):1217-27

A relationship between 5-lipoxygenase-activating protein and bcl-xL expression in murine pro-B lymphocytic FL5.12 cells. Datta K, et al. **J Biol Chem** 1998 Oct 23; 273(43):28163-9

Regulation of AML2/CBFA3 in hematopoietic cells through the retinoic acid receptor alpha-dependent signaling pathway. Le XF, et al. **J Biol Chem** 1999 Jul 30; 274(31):21651-8

Alternate promoters and developmental modulation of expression of the chicken GATA-2 gene in hematopoietic progenitor cells. Nony P, et al. **J Biol Chem** 1998 Dec 4;273(49):32910-9

Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling. Cho RL, et al. **J Cell Biochem** 1999 Apr 1;73(1):79-89

High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells. Fortunel N, et al. **J Cell Sci** 1998 Jul;111 (Pt 13):1867-75

Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Nath D, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):579-87

TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy. Gautam SC, et al. **J Hematother** 1999 Jun;8(3):237-45

Regulation of NK1.1 expression during lineage commitment of progenitor thymocytes. Carlyle JR, et al. **J Immunol** 1998 Dec 15;161(12):6544-51

Early IL-4 induction in bone marrow lymphoid precursor cells by mycobacterial lipoarabinomannan. Collins HL, et al. **J Immunol** 1998 Nov 15;161(10):5546-54

Differential regulation of 4E-BP1 and 4E-BP2, two repressors of translation initiation, during human myeloid cell differentiation. Grolleau A, et al. **J Immunol** 1999 Mar 15;162(6):3491-7

Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells is a phenotypic alteration for committed lymphoid progenitors. Ishii T, et al. **J Immunol** 1999 Oct 1;163(7):3612-20

Protection from radiation-induced colitis requires MHC class II antigen expression by cells of hemopoietic origin. Marguerat S, et al. **J Immunol** 1999 Oct 1;163(7):4033-40

Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. Todryk S, et al. **J Immunol** 1999 Aug 1;163(3):1398-408

The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. Dawson MJ, et al. **J Leukoc Biol** 1998 Oct;64(4):546-54

Stem cell maneuvers target bone marrow toxicity [news] Randal J. **J Natl Cancer Inst** 1999 Sep 15;91(18):1530-2

Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. Häfer R, et al. **J Neuroimmunol** 1999 May 3;96(2):201-6

Retrovirus receptor mRNA expression correlates with gene

transfer efficiency in pluripotent hematopoietic stem cells. Orlic D, et al. **Leukemia** 1999 Apr;13 Suppl 1:S52-4

Preparation and analysis of cDNA from a small number of hematopoietic cells. Liu M, et al. **Methods Enzymol** 1999; 303:45-55

The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation. Nagler A, et al. **Mol Biotechnol** 1999 Apr;11(2):181-94

A targeted kappa immunoglobulin gene containing a deletion of the nuclear matrix association region exhibits spontaneous hyper-recombination in pre-B cells. Hale MA, et al. **Mol Immunol** 1998 Jul;35(10):609-20

Stem cell transformations proliferate [news] Brower V. **Nat Biotechnol** 1999 Mar;17(3):215

Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Adams JM, et al. **Oncogene** 1999 Sep 20;18(38):5268-77 (127 ref.)

Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. Reed MF, et al. **Oncogene** 1998 Dec 10; 17(23):2961-71

Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Clay TM, et al. **Pathol Oncol Res** 1999;5(1):3-15 (84 ref.)

L-selectin expression enhances clonogenesis of CD34+ cord blood progenitors. Koenig JM, et al. **Pediatr Res** 1999 Jun; 45(6):867-70

In childhood acute lymphoblastic leukemia the hypophosphorylated retinoblastoma protein, p110RB, is diminished, as compared with normal CD34+ peripheral blood progenitor cells. Leibundgut K, et al. **Pediatr Res** 1999 May;45(5 Pt 1):692-6

Distinct biological effects of macrophage inflammatory protein-1alpha and stroma-derived factor-1alpha on CD34+ hemopoietic cells. Dürig J, et al. **Stem Cells** 1999; 17(2):62-71

Thrombopoietin combined with early-acting growth factors effectively expands human hematopoietic progenitor cells in vitro. Hunnestad JA, et al. **Stem Cells** 1999;17(1):31-8

Stimulation of adult human bone marrow by factors secreted by fetal liver hematopoietic cells: in vitro evaluation using semisolid clonal assay system. Kale VP, et al. **Stem Cells** 1999;17(2):107-16

Cell-surface antigen expression in early and term gestation fetal hematopoietic progenitor cells. Opie TM, et al. **Stem Cells** 1998;16(5):343-8

Recombinant adeno-associated virus-based vectors provide short-term rather than long-term transduction of primitive hematopoietic stem cells. van Os R, et al. **Stem Cells** 1999; 17(2):117-20

The Notch/Jagged pathway inhibits proliferation of human hematopoietic progenitors in vitro. Walker L, et al. **Stem Cells** 1999;17(3):162-71

A chimeric aryl hydrocarbon receptor knockout mouse model indicates that aryl hydrocarbon receptor activation in hematopoietic cells contributes to the hepatic lesions induced by 2,3,7, 8-tetrachlorodibenzo-p-dioxin. Thurmond TS, et al. **Toxicol Appl Pharmacol** 1999 Jul 1; 158(1):33-40

[Myelodysplastic syndrome--disease of the hemopoietic stem cell] Kuliczkowski K. **Pol Arch Med Wewn** 1998 Feb; 99(2):104-9 **(Pol)**

MICROBIOLOGY

Routine cultures of bone marrow and peripheral stem cell harvests: clinical impact, cost analysis, and review. Nasser RM, et al. **Clin Infect Dis** 1998 Oct;27(4):886-8

PATHOLOGY

CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Martin-Henao GA, et al. **Am J Hematol** 1999 Jul;61(3):178-86

Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. Leung W, et al. **Biol Blood Marrow Transplant** 1999;5(2):69-76

Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Abruzzese E, et al. **Blood** 1999 Sep 1;94(5):1814-9

Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. Brandt JE, et al. **Blood** 1999 Jul 1;94(1):106-13

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Carella AM, et al. **Blood** 1999 Mar 1;93(5):1534-9

Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. Chelucci C, et al. **Blood** 1999 Sep 1; 94(5):1590-600

BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Delforge M, et al. **Blood** 1999 Jan 1;93(1):284-92

Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Haneline LS, et al. **Blood** 1999 Jul 1;94(1):1-8

Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Jego G, et al. **Blood** 1999 Jul 15;94(2):701-12

New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. Nafa K, et al. **Blood** 1998 Nov 1;92(9):3422-7

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Szilvassy SJ, et al. **Blood** 1999 Mar 1;93(5):1557-66

Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Westervelt P, et al. **Blood** 1999 Apr 1;93(7):2143-8 (26 ref.)

The proteasome regulates caspase-dependent and caspase-independent protease cascades during apoptosis of MO7e hematopoietic progenitor cells. Wu LW, et al. **Blood Cells Mol Dis** 1999 Feb;25(1):20-9

Peripheral blood CD34+ cell count reliably predicts autograft yield. Chapple P, et al. **Bone Marrow Transplant** 1998 Jul;22(2):125-30

Circulating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield [letter; comment] D'Arena G, et al. **Bone Marrow Transplant** 1998 Jul;22(2):215-6. Comment on: Bone Marrow Transplant 1997 Oct;20(7):587-91.

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Gandhi MK, et al. **Bone Marrow Transplant** 1999 Jan;23(1):9-13

Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells. Hoppe B, et al. **Bone Marrow Transplant** 1999 Apr;23(8):809-17

Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. Kleinman MB, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1297-301

Conclusions of a national multicenter intercomparative study of in vitro cultures of human hematopoietic progenitors. Lamana M, et al. **Bone Marrow Transplant** 1999 Feb; 23(4):373-80

Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Leung W, et al. **Bone Marrow Transplant** 1998 Nov;22(10):971-9

CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. Olivero S, et al. **Bone Marrow Transplant** 1999 Feb;23(4):387-94

Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. Selleri C, et al. **Bone Marrow Transplant** 1999 May;23(10):1029-37

The utilization of cytokines in stem cell mobilization strategies. Shpall EJ. **Bone Marrow Transplant** 1999 May; 23 Suppl 2:S13-9 (37 ref.)

Management strategies for the hard-to-mobilize patient. Stiff PJ. **Bone Marrow Transplant** 1999 May;23 Suppl 2:S29-33 (22 ref.)

Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection [letter] Tchirkov A, et al. **Bone Marrow Transplant** 1999 Jul;24(2):229-30

Detection of contaminating tumor cells by RT-PCR in breast cancer patients [letter] Vannucchi AM, et al. **Bone Marrow Transplant** 1999 Jul;24(2):228-9

Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Waples JM, et al. **Bone Marrow Transplant** 1999 May;23(9):867-73

Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. Frassoni F, et al. **Br J Haematol** 1999 Mar;104(3):538-45

Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Fruehauf S, et al. **Br J Haematol** 1999 Jun; 105(3):786-94

In vitro evaluation of the haemopoietic defect of CD34+ cells from patients with acute myeloid leukaemia in first remission. Herman P, et al. **Br J Haematol** 1999 Jul; 106(1):142-51

Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Marley SB, et al. **Br J Haematol** 1999 Jul;106(1):162-6

Use of the haemopoietic progenitor cell count of the Sysmex SE-9500 to refine apheresis timing of peripheral blood stem cells. Pollard Y, et al. **Br J Haematol** 1999 Aug; 106(2):538-44

Quantitative and qualitative alterations of long-term culture-initiating cells in patients with acute leukaemia in complete remission. Yao M, et al. **Br J Haematol** 1998 Oct; 103(1):124-8

Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia. McGuinness SM, et al. **Chem Biol Interact** 1999 Aug 1;121(3):253-65

Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Tyer CL, et al. **Clin Cancer Res** 1996 Jan;2(1):81-6

Presence of circulating abnormal CD34+ progenitors in adult Langerhans cell histiocytosis. Misery L, et al. **Clin Exp Immunol** 1999 Jul;117(1):177-82

In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. Shih LY, et al. **Eur J Clin Invest** 1998 Jul; 28(7):569-76

Flt-3 ligand does not induce the growth of peripheral blood granulocyte-macrophage colony-forming cells in myeloproliferative disorders. Siitonen T, et al. **Eur J Haematol** 1999 Feb;62(2):103-8

Hematopoietic stem cells and aging. Globerson A. **Exp Gerontol** 1999 Apr;34(2):137-46 (49 ref.)

Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Bhatia R, et al. **Exp Hematol** 1999 Sep;27(9):1384-96

Hematopoietic dynamics in grey collies. Haurie C, et al. **Exp Hematol** 1999 Jul;27(7):1139-48

Long-term bone marrow cultures in Diamond-Blackfan anemia reveal a defect of both granulomacrophage and erythroid progenitors. Santucci MA, et al. **Exp Hematol** 1999 Jan;27(1):9-18

Long term hematopoietic damage after chemotherapy and cytokine. Gardner RV. **Front Biosci** 1999 Jul 15;4:e47-57 (113 ref.)

Potential clinical implications of early diagnosis of chronic myeloid leukemia [editorial; comment] **Haematologica** 1999 Apr;84(4):289-90. Comment on: Haematologica 1999 Apr;84(4):324-7.

In vitro effect of clozapine on hemopoietic progenitor cells. Deliliers GL, et al. **Haematologica** 1998 Oct;83(10):882-9

Acute myeloblastic leukemia with trilineage myelodysplasia and CD34+ blast cells with abnormal chromatin clumping [letter] Gil S, et al. **Haematologica** 1998 Aug;83(8):750-1

Fanconi's anemia cells are relatively resistant to H2O2-induced damage. Notaro R, et al. **Haematologica** 1998 Oct;83(10):868-74

Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B, et al. **Haematologica** 1999 Apr;84(4):342-9

Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Naume B, et al. **Int J Cancer** 1998 Nov 23; 78(5):556-60

Effects of Chlorella vulgaris on bone marrow progenitor cells of mice infected with Listeria monocytogenes. Dantas DC, et al. **Int J Immunopharmacol** 1999 Aug;21(8):499-508

Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. Ross TS, et al. **J Biol Chem** 1999 Aug 6; 274(32):22328-36

Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. Gabriele L, et al. **J Exp Med** 1999 Aug 2;190(3):411-22

Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium. Lefebvre P, et al. **J Hematother** 1999 Apr;8(2):199-208

Use of merocyanine 540 for the isolation of quiescent, primitive human bone marrow hematopoietic progenitor cells. Pyatt RE, et al. **J Hematother** 1999 Apr;8(2):189-98

Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. Schumm M, et al. **J Hematother** 1999 Apr;8(2):209-18

Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent [letter] Serke S, et al. **J Hematother** 1998 Aug; 7(4):315-8

CD44 and adhesion of normal and leukemic CD34+ cells to bone marrow stroma. Bendall LJ, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):427-39 (99 ref.)

Human cytomegalovirus infection of human hematopoietic progenitor cells. Maciejewski JP, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):1-13 (74 ref.)

All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. Miyauchi J. **Leuk Lymphoma** 1999 Apr;33(3-4):267-80 (138 ref.)

Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Flores-Figueroa E, et al. **Leuk Res** 1999 Apr;23(4):385-94

Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia [see comments] Suzuki R, et al. **Leuk Res** 1999 Jul;23(7):615-24 (50 ref.). Comment in: Leuk Res 1999 Jul;23(7):675-6.

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Blalock WL, et al. **Leukemia** 1999 Aug;13(8):1109-66 (871 ref.)

Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Reichle A, et al. **Leukemia** 1999 Aug; 13(8):1227-34

Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia. Span LF, et al. **Leukemia** 1998 Nov;12(11):1685-95

Clonality analysis of refractory anemia with ring sideroblasts: simultaneous study of clonality and cytochemistry of bone marrow progenitors. Suzuki H, et al. **Leukemia** 1999 Jan; 13(1):130-4

In vitro development of haemopoietic progenitors in myelodysplastic syndromes (MDS) [letter; comment] Tauro S, et al. **Leukemia** 1999 Mar;13(3):494-5. Comment on: Leukemia 1998 Jun;12(6):882-6.

Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Verstegen MM, et al. **Leukemia** 1999 Apr;13(4):618-28

In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction. Wittebol S, et al. **Leukemia** 1998 Nov;12(11):1782-8

Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Sawa A, et al. **Nat Med** 1999 Oct; 5(10):1194-8

Hematogones as an internal control in flow cytometric analysis of suspected acute lymphoblastic leukemia. Vargas SO, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):371-6

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Araten DJ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5209-14

Hematopoietic cytokine levels and in vitro colony formation assay in fetal anemia. Yamada H, et al. **Semin Thromb Hemost** 1998;24(5):485-90

[Abnormalities of hematopoietic stem cells in autoimmune diseases] Qiu Z, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):352-4 (20 ref.) **(Chi)**

[Ex-vivo expansion of hematopoietic stem cells: study in the primate model] Norol F, et al. **Hematol Cell Ther** 1999 Apr;41(2):75-7 **(Fre)**

[Kinetics of hematopoietic clones in sublethally irradiated mice] Ol'shanskaia IuV, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):693-6 **(Rus)**

[Growth-inhibiting activity of bone marrow cells during CCl4-induced liver cirrhosis] Zubakhin AA, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):645-7 **(Rus)**

[Leukemias--diseases of haemopoietic organs stroma (hypothesis)] Morozova VT. **Klin Lab Diagn** 1999 Jun; (6):3-13 (29 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Hemopoietic progenitors and cytokines in allergic inflammation. Denburg JA. **Allergy** 1998;53(45 Suppl):22-6 (53 ref.)

Mixed hematopoietic chimerism induces donor-specific tolerance for lung allografts in rodents. Pham SM, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):199-205

Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Broxmeyer HE, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:142-62; discussion 163 (57 ref.)

Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. Bunting KD, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:125-40; discussion 140-1

(R)evolutionary considerations in hematopoietic development. Cooper DD, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:83-93 (60 ref.)

Embryonic beginnings of definitive hematopoietic stem cells. Dzierzak E. **Ann N Y Acad Sci** 1999 Apr 30;872:256-62; discussion 262-4 (27 ref.)

Introduction to stem cell biology in vitro. Threshold to the future. Eaves C, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:1-8 (34 ref.)

Thrombopoietin and hematopoietic stem cell development. Kaushansky K. **Ann N Y Acad Sci** 1999 Apr 30;872:314-9 (38 ref.)

Thrombopoietin and interleukin-3 are chemotactic and chemokinetic chemoattractants for a factor-dependent hematopoietic progenitor cell line. Kim CH, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:395-8

Searching for stem cell regulatory molecules. Some general thoughts and possible approaches. Lemischka I. **Ann N Y Acad Sci** 1999 Apr 30;872:274-87; discussion 287-8 (81 ref.)

A human factor-dependent cell line simulates cobblestone formation under human bone marrow stromal cells in vitro. Mantel CR, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:399-401

Stem cells, pre-progenitor cells and lineage-committed cells: are our dogmas correct? Metcalf D. **Ann N Y Acad Sci** 1999 Apr 30;872:289-303; discussion 303-4 (33 ref.)

Regulation of transendothelial migration of hematopoietic progenitor cells. Möhle R, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:176-85; discussion 185-6 (35 ref.)

Amphotropic retrovirus transduction of hematopoietic stem cells. Orlic D, et al. **Ann N Y Acad Sci** 1999 Apr 30; 872:115-23; discussion 123-4

Isolation of stem cell-specific cDNAs from hematopoietic stem cell populations. Orlic D, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:243-54; discussion 254-5

Hematopoietic stem/progenitor cell mobilization. A continuing quest for etiologic mechanisms. Papayannopoulou T. **Ann N Y Acad Sci** 1999 Apr 30; 872:187-97; discussion 197-9 (45 ref.)

Hematopoietic commitment during embryogenesis. Robertson S, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:9-15; discussion 15-6 (37 ref.)

Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Storb R, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:372-5; discussion 375-6

Retroviral-fibronectin interactions in transduction of mammalian cells. Williams DA. **Ann N Y Acad Sci** 1999 Apr 30;872:109-13; discussion 113-4 (15 ref.)

Effects of several cytokine combinations on retrovirus-mediated human MDR1 gene transfer into bone marrow hematopoietic cells. Zhou S, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:391-4

Syngeneic and allogeneic blood transfusions produce hematopoietic and immune effects. Grzelak I, et al. **Ann Transplant** 1996;1(2):5-10

Effect of hypoxia on the hematopoietic and immune modulator preprotachykinin-I. Quinlan DP Jr, et al. **Arch Surg** 1998 Dec;133(12):1328-34

Migration of exogenous immature hematopoietic cells into adult mouse brain parenchyma under GFP-expressing bone marrow chimera. Ono K, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):610-4

Expression of a gene trap reporter construct in a subset of cells in embryonic sites of hematopoiesis: evidence for alternative rRNA production in hematopoietic cells. Wagner DS, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):674-81

Hemangioblast development and regulation. Choi K. **Biochem Cell Biol** 1998;76(6):947-56 (104 ref.)

Segregation of the embryonic vascular and hemopoietic systems. Eichmann A, et al. **Biochem Cell Biol** 1998; 76(6):939-46 (87 ref.)

Commitment and differentiation of stem cells to the osteoclast lineage. Hayashi S, et al. **Biochem Cell Biol** 1998; 76(6):911-22 (136 ref.)

Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line. Bauer G, et al. **Biol Blood Marrow Transplant** 1998;4(3):119-27

Osteogenic differentiation of cultured marrow stromal stem cells on surface of microporous hydroxyapatite based mica composite and macroporous synthetic hydroxyapatite. Nordström E, et al. **Biomed Mater Eng** 1999;9(1):21-6

Concentration-dependent internalization of a cytokine/cytokine receptor complex in human hematopoietic cells. Zandstra PW, et al. **Biotechnol Bioeng** 1999 May 20;63(4):493-501

Modulation of integrin function in hematopoietic progenitor cells by CD43 engagement: possible involvement of protein tyrosine kinase and phospholipase C-gamma. Anzai N, et al. **Blood** 1999 May 15;93(10):3317-26

Stromal cell CD9 regulates differentiation of hematopoietic stem/progenitor cells. Aoyama K, et al. **Blood** 1999 Apr 15;93(8):2586-94

CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. Arai A, et al. **Blood** 1999 Jun 1;93(11):3713-22

Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Begley CG, et al. **Blood** 1999 Mar 1; 93(5):1443-7 (59 ref.)

Heparan sulfate proteoglycan expression is induced during early erythroid differentiation of multipotent hematopoietic stem cells. Drzeniek Z, et al. **Blood** 1999 May 1; 93(9):2884-97

Activation of granulocyte-macrophage colony-stimulating factor and interleukin-3 receptor subunits in a multipotential hematopoietic progenitor cell line leads to differential effects on development. Evans CA, et al. **Blood** 1999 Sep 1;94(5):1504-14

Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Falanga A, et al. **Blood** 1999 Apr 15;93(8):2506-14

Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors. Fichelson S, et al. **Blood** 1999 Sep 1;94(5):1601-13

A critical role for PU.1 in homing and long-term engraftment by hematopoietic stem cells in the bone marrow. Fisher RC, et al. **Blood** 1999 Aug 15;94(4):1283-90

Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Grande A, et al. **Blood** 1999 May 15;93(10):3276-85

c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors. Hegde SP, et al. **Blood** 1999 Sep 1;94(5):1578-89

Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. Henkel GW, et al. **Blood** 1999 May 1;93(9):2849-58

Optimal proliferation of a hematopoietic progenitor cell line requires either costimulation with stem cell factor or increase of receptor expression that can be replaced by overexpression of Bcl-2. Huang HM, et al. **Blood** 1999 Apr 15;93(8):2569-77

Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Imai K, et al. **Blood** 1999 Jan 1;93(1):149-56

Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Janowska-Wieczorek A, et al. **Blood** 1999 May 15; 93(10):3379-90

The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. Kollet O, et al. **Blood** 1999 Aug 1;94(3):923-31

Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Lecoq-Lafon C, et al. **Blood** 1999 Apr 15;93(8):2578-85

The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Lopez M, et al. **Blood** 1998 Dec 15;92(12):4602-11

The nuclear topography of ABL, BCR, PML, and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Neves H, et al. **Blood** 1999 Feb 15;93(4):1197-207

Glycoprotein IIb-IIIa is expressed on avian multilineage hematopoietic progenitor cells. Ody C, et al. **Blood** 1999 May 1;93(9):2898-906

Chemotactic response toward chemokines and its regulation by transforming growth factor-beta1 of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells. Ogata M, et al. **Blood** 1999 May 15;93(10):3225-32

Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Ogilvy S, et al. **Blood** 1999 Sep 15;94(6):1855-63

Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Pilarski LM, et al. **Blood** 1999 May 1; 93(9):2918-27

Enhanced retroviral transduction of 5-fluorouracil-resistant human bone marrow (stem) cells using a genetically modified packaging cell line. Povey J, et al. **Blood** 1998 Dec 1;92(11):4080-9

An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Pyatt DW, et al. **Blood** 1999 May 15;93(10):3302-8

Primitive myeloid cells express high levels of phospholipase A(2) activity in the absence of leukotriene release: selective regulation by stem cell factor involving the MAP kinase pathway. Roberts PJ, et al. **Blood** 1999 Aug 15; 94(4):1261-72

Functional analysis of mature hematopoietic cells from mice lacking the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Scott CL, et al. **Blood** 1998 Dec 1;92(11):4119-27

H-Ras is involved in the inside-out signaling pathway of interleukin-3-induced integrin activation. Shibayama H, et al. **Blood** 1999 Mar 1;93(5):1540-8

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Somlo G, et al. **Blood** 1999 May 1; 93(9):2798-806

Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD34(+) blood progenitor cells. Spyridonidis A, et al. **Blood** 1999 Jan 15;93(2):746-55

Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. Sui X, et al. **Blood** 1999 Apr 15;93(8):2525-32

A common signaling pathway via Syk and Lyn tyrosine kinases generated from capping of the sialomucins CD34 and CD43 in immature hematopoietic cells. Tada J, et al. **Blood** 1999 Jun 1;93(11):3723-35

Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. van Hennik PB, et al. **Blood** 1998 Dec 1;92(11):4013-22

Hematopoietic cells from -spectrin-deficient mice are sufficient to induce thrombotic events in hematopoietically ablated recipients. Wandersee NJ, et al. **Blood** 1998 Dec 15;92(12):4856-63

Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells. Yaroslavskiy B, et al. **Blood** 1999 May 1;93(9):2907-17

The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis [see comments] Zannettino AC, et al. **Blood** 1998 Oct 15; 92(8):2613-28. Comment in: Blood 1998 Oct 15;92(8):2609-12.

Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Haynes DR, et al. **Bone** 1999 Sep;25(3):269-78

Control of stem cell proliferation and differentiation to achieve stable gene transfer and expression. Bertolini F, et al. **Bone Marrow Transplant** 1998 Jun;21 Suppl 3:S75-6

Culturing human umbilical cord blood: a comparison of mononuclear vs CD34+ selected cells. Fietz T, et al.

Bone Marrow Transplant 1999 Jun;23(11):1109–15

SDF-1 suppresses cytokine-induced adhesion of human haemopoietic progenitor cells to immobilized fibronectin. Gotoh A, et al. **Br J Haematol** 1999 Jul;106(1):171–4

Expansion of megakaryocyte progenitors from human umbilical cord blood using a new two-step separation procedure. Pick M, et al. **Br J Haematol** 1998 Dec; 103(3):639–50

Composition and function of peripheral blood stem and progenitor cell harvests from patients with severe active rheumatoid arthritis. Snowden JA, et al. **Br J Haematol** 1998 Dec;103(3):601–9

Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Mackensen A, et al. **Cancer Immunol Immunother** 1999 May-Jun;48(2–3):118–22

CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. Kim CH, et al. **Cell Immunol** 1999 May 1; 193(2):226–35

Reconstruction of the hematopoietic system after stem cell transplantation. Gordon MY, et al. **Cell Transplant** 1998 Jul-Aug;7(4):339–44 (23 ref.)

Hematopoietic reconstruction: new approaches. Moore MA. **Clin Cancer Res** 1995 Jan;1(1):3–9 (61 ref.)

Interaction between haemopoietic regulation and airway inflammation. O'Byrne PM, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:27–32 (33 ref.)

From autoimmunity to stem cell transplantation. Gratwohl A, et al. **Crit Rev Oncol Hematol** 1999 Apr;30(2):159–72 (115 ref.)

Recent progress in gene transfer into hematopoietic stem cells. Lutzko C, et al. **Crit Rev Oncol Hematol** 1999 Apr; 30(2):143–58 (199 ref.)

Recent progress in identifying genes regulating hematopoietic stem cell function and fate. Jordan CT, et al. **Curr Opin Cell Biol** 1998 Dec;10(6):716–20 (45 ref.)

A transcription factor party during blood cell differentiation. Sieweke MH, et al. **Curr Opin Genet Dev** 1998 Oct; 8(5):545–51 (58 ref.)

Regulation and function of hematopoietic stem cells. Moore MA, et al. **Curr Opin Hematol** 1994 May;1(3):180–6 (58 ref.)

Expansion of stem and progenitor cells. Ziegler BL, et al. **Curr Opin Hematol** 1998 Nov;5(6):434–40 (48 ref.)

Differentiation of hemangioblasts from embryonic mesothelial cells? A model on the origin of the vertebrate cardiovascular system. Muñoz-Chápuli R, et al. **Differentiation** 1999 Mar;64(3):133–41

Efficient and persistent expression of beta-glucuronidase gene in CD34+ cells from human umbilical cord blood by retroviral vector. Ohashi T, et al. **Eur J Haematol** 1998 Oct;61(4):235–9

Finite lifespans of T cell clones derived from CD34+ human haematopoietic stem cells in vitro. Pawelec G, et al. **Exp Gerontol** 1999 Jan;34(1):69–77

Targeted transfection of the IL-3 gene into primary human hematopoietic progenitor cells through the c-kit receptor. Chapel A, et al. **Exp Hematol** 1999 Feb;27(2):250–8

Candidate hematopoietic stem cells from fetal tissues, umbilical cord blood vs. adult bone marrow and mobilized peripheral blood. Huang S, et al. **Exp Hematol** 1998 Nov; 26(12):1162–71

Retroviral transduction of enriched hematopoietic stem cells allows lifelong Bcl-2 expression in multiple lineages but does not perturb hematopoiesis. Innes KM, et al. **Exp Hematol** 1999 Jan;27(1):75–87

Comparative studies of different stromal cell microenvironments in support of human B-cell development. Kurosaka D, et al. **Exp Hematol** 1999 Aug; 27(8):1271–81

Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses. Omori F, et al. **Exp Hematol** 1999 Feb;27(2):242–9

Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Roy V, et al. **Exp Hematol** 1999 Feb;27(2):302–12

Distinct actions of interleukin-9 and interleukin-4 on a hematopoietic stem cell line, EMLC1. Wang XY, et al. **Exp Hematol** 1999 Jan;27(1):139–46

The new biotech world order. Cahill LS. **Hastings Cent Rep** 1999 Mar-Apr;29(2):45–8 (9 ref.)

Property, progeny, and patents. Knowles LP. **Hastings Cent Rep** 1999 Mar-Apr;29(2):38–40

What's in the dish? McGee G, et al. **Hastings Cent Rep** 1999 Mar-Apr;29(2):36–8

Research with human embryonic stem cells: ethical considerations. By Geron Ethics Advisory Board. Mendiola MM, et al. **Hastings Cent Rep** 1999 Mar-Apr; 29(2):31–6 (26 ref.)

Human primordial stem cells. Okarma TB. **Hastings Cent Rep** 1999 Mar-Apr;29(2):30

Private ethics boards and public debate. Tauer CA. **Hastings Cent Rep** 1999 Mar-Apr;29(2):43–5

Foresight, insight, oversight. White GB. **Hastings Cent Rep** 1999 Mar-Apr;29(2):41–2

Nerve growth factor: a survey of activity on immune and hematopoietic cells. Simone MD, et al. **Hematol Oncol** 1999 Mar;17(1):1–10 (59 ref.)

Functional characterization of a novel hematopoietic stem cell and its place in the c-Kit maturation pathway in bone marrow cell development. Ortiz M, et al. **Immunity** 1999 Feb;10(2):173–82

Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Roberts AW, et al. **Immunity** 1999 Feb;10(2):183–96

A role for G-CSF receptor signaling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. Semerad CL, et al. **Immunity** 1999 Aug; 11(2):153–61

Increased resistance to apoptosis by bone marrow CD34(+)progenitor cells from tumor-bearing mice. Young MR, et al. **Int J Cancer** 1999 Aug 12;82(4):609–15

Embryonic stem cells and transgenic mice in the study of hematopoiesis. Orkin SH. **Int J Dev Biol** 1998;42(7 Spec No):927–34 (45 ref.)

Cytokine signaling for proliferation, survival, and death in hematopoietic cells. Miyajima A, et al. **Int J Hematol** 1999 Apr;69(3):137–46 (107 ref.)

The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Mundle S, et al. **Int J Hematol** 1999 Apr;69(3):152–9

Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. Baxter GT, et al. **J Biol Chem** 1999 Apr 2; 274(14):9539–47

Divergent regulation of 1,25-dihydroxyvitamin D3 on human bone marrow osteoclastogenesis and myelopoiesis. Qi DY, et al. **J Cell Biochem** 1999 Mar 1;72(3):387–95

Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. Shalhoub V, et al. **J Cell Biochem** 1999 Feb 1;72(2):251–61

Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. Conget PA, et al. **J Cell Physiol** 1999 Oct;181(1):67–73

Stem cell emergence and hemopoietic activity are incompatible in mouse intraembryonic sites. Godin I, et al. **J Exp Med** 1999 Jul 5;190(1):43–52

Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. Kim CH, et al. **J Exp Med** 1999 Sep 6; 190(5):681–90

Identification of a late stage of small noncycling pTalpha-pre-T cells as immediate precursors of T cell receptor alpha/beta+ thymocytes. Trigueros C, et al. **J Exp Med** 1998 Oct 19;188(8):1401–12

Hematopoietic progenitor cell abnormalities in Hoxc-8 null mutant mice. Shimamoto T, et al. **J Exp Zool** 1999 Feb 1;283(2):186–93

Differential effects of IL-2 incubation on hematopoietic potential of autologous bone marrow and mobilized PBSC from patients with hematologic malignancies. Areman EM, et al. **J Hematother** 1999 Feb;8(1):39–44

Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I. Hubel A, et al. **J Hematother** 1998 Dec;7(6):505–14

A novel role for HEB downstream or parallel to the pre-TCR signaling pathway during alpha beta thymopoiesis. Barndt R, et al. **J Immunol** 1999 Sep 15; 163(6):3331–43

Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1. Dong Q, et al. **J Immunol** 1999 Mar 15;162(6):3220–30

Emergence of T cell progenitors without B cell or myeloid differentiation potential at the earliest stage of hematopoiesis in the murine fetal liver. Kawamoto H, et al. **J Immunol** 1999 Mar 1;162(5):2725–31

Chemokine receptors and the molecular basis for human immunodeficiency virus type 1 entry into peripheral hematopoietic stem cells and their progeny. Zhao SF, et al. **J Infect Dis** 1998 Dec;178(6):1623–34

A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Narabayashi M, et al. **Jpn J Clin Oncol** 1999 Jun; 29(6):285–90

Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Aizawa S, et al. **Leuk Res** 1999 Mar;23(3):239–46

Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Eaves C, et al. **Leuk Res** 1998 Dec; 22(12):1085–96 (86 ref.)

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Blalock WL, et al. **Leukemia** 1999 Aug;13(8):1109–66 (871 ref.)

A method for identifying differentially expressed genes in rare populations of primary human hematopoietic cells. Hung HL, et al. **Leukemia** 1999 Feb;13(2):295–7

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. McCubrey JA, et al. **Leukemia** 1998 Dec;12(12):1903–29

Developmentally regulated responsiveness to transforming growth factor-beta is correlated with functional differences between human adult and fetal primitive hematopoietic progenitor cells. Weekx SF, et al. **Leukemia** 1999 Aug; 13(8):1266–72

Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Pessina A, et al. **Life Sci** 1999; 65(5):513–23

Monitoring antisense oligodeoxynucleotide activity in hematopoietic cells. Sokol DL, et al. **Methods** 1999 Mar; 17(3):219–30 (112 ref.)

Purification of hematopoietic stem cells for further biological study. Thomas TE, et al. **Methods** 1999 Mar;17(3):202–18

The fascinating life of hematopoietic stem cells [news] Sharkis S, et al. **Nat Med** 1998 Oct;4(10):1118–9

Hematopoietic cell differentiation antigens (CD system 1997). Cancer research relevance. Chorváth B, et al. **Neoplasma** 1998;45(5):273–6 (20 ref.)

Analysis and characterization of hematopoietic progenitor cells from fetal bone marrow, adult bone marrow, peripheral blood, and cord blood. Wu AG, et al. **Pediatr Res** 1999 Aug;46(2):163–9

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Araten DJ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5209–14

Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Case SS, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):2988–93

Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. Cho SK, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9797–802

Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Dao MA, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13006–11

Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow [see comments] Frenette PS, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14423–8. Comment in: Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15155–7.

Conditional requirement for the Flk-1 receptor in the in vitro generation of early hematopoietic cells. Hidaka M, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7370–5

Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Krämer A, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2087–92

Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Pruijt JF, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10863–8

Stem cell homing: rolling, crawling, and nesting [comment] Quesenberry PJ, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15155–7 (54 ref.). Comment on: Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14423–8.

In vitro hematopoietic and endothelial potential of flk-1(-/-) embryonic stem cells and embryos. Schuh AC, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2159–64

Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Wilcox DA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17; 96(17):9654–9

Class I MHC molecules on hematopoietic cells can support intrathymic positive selection of T cell receptor transgenic T cells. Zerrahn J, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11470–5

Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Peled A, et al. **Science** 1999 Feb 5;283(5403):845–8

The role of blood stem cells in hematopoietic cell renewal. Fliedner TM. **Stem Cells** 1998;16(6):361–74

c-kit<low Pluripotent hemopoietic stem cells form CFU-S on day 16. Lian Z, et al. **Stem Cells** 1999;17(1):39–44

Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells. Möbest D, et al. **Stem Cells** 1999;17(3):152–61

Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Storb R, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):677–8

Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Lee WC, et al. **Transplantation** 1998 Dec 27;66(12):1810–7

Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. Sakamoto T, et al. **Transplantation** 1999 Mar 27; 67(6):833–40

Homing and mobilization in the stem cell niche. Whetton AD, et al. **Trends Cell Biol** 1999 Jun;9(6):233–8 (42 ref.)

[Receptors and development of endothelial and hematopoietic cells] Eichmann A, et al. **J Soc Biol** 1999; 193(2):155–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Affiliation between endothelial and intra-embryonic

hematopoietic stem cells] Jaffredo T, et al. **J Soc Biol** 1999; 193(2):165–70 (Eng. Abstr.) **(Fre)**

[Manipulation of angiopoietc/hematopoietic potentials in the avian embryo] Pardanaud L, et al. **J Soc Biol** 1999; 193(2):171–9 (Eng. Abstr.) **(Fre)**

[Characteristics of hematopoietic stem cells] Kanakura Y. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1451–6 (5 ref.) **(Jpn)**

[Reactions of granulocytic hematopoietic stem cells during experimental neurosis-inducing situations] Dygai AM, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):628–31 **(Rus)**

[Mechanisms of hemopoiesis cytostatic damage and regeneration] Gol'dberg ED, et al. **Vestn Ross Akad Med Nauk** 1998;(10):6–10 (Eng. Abstr.) **(Rus)**

[Hematopoietic stem cells--biology and therapeutic use] Balint B, et al. **Vojnosanit Pregl** 1998 Nov-Dec; 55(6):627–39 (112 ref.) **(Scc)**

[Biology of hematopoietic stem cells] Zambrano-Ramírez IR, et al. **Rev Invest Clin** 1999 Jan-Feb;51(1):53–68 (91 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta 2-integrin LFA-1. Pruijt JF, et al. **Blood** 1999 Jan 1; 93(1):107–12

Haemopoietic reconstitution after sublethal irradiation: comparison of the effects of different haemopoietic cytokines on murine lymphocytes and bone marrow cells. Frasca D, et al. **Br J Haematol** 1999 Aug;106(2):317–24

Chromosomal instability in haemopoietic cells of the foetus, mother and offspring after in utero irradiation of the CBA/Ca mouse. Rosemann M, et al. **Int J Radiat Biol** 1999 May;75(5):601–7

Concurrent partial body radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. Sharp JG, et al. **J Hematother** 1998 Aug;7(4):343–9

RADIONUCLIDE IMAGING

Pattern of localization of primitive hematopoietic cells in vivo using a novel mouse model. Bolante-Cervantes R, et al. **Exp Hematol** 1999 Aug;27(8):1346–52

TRANSPLANTATION see HEMATOPOIETIC STEM CELL TRANSPLANTATION

ULTRASTRUCTURE

Two new pseudopod morphologies displayed by the human hematopoietic KG1a progenitor cell line and by primary human CD34(+) cells. Francis K, et al. **Blood** 1998 Nov 15;92(10):3616–23

p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Mantel C, et al. **Blood** 1999 Feb 15; 93(4):1390–8

The nuclear topography of ABL, BCR, PML, and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Neves H, et al. **Blood** 1999 Feb 15;93(4):1197–207

Ultrastructure of primitive hematopoietic stem cells isolated using probes of functional status. Radley JM, et al. **Exp Hematol** 1999 Feb;27(2):365–9

Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Engel H, et al. **Leukemia** 1999 Apr; 13(4):568–77

Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission. Feuring-Buske M, et al. **Leukemia** 1999 Mar;13(3):386–92

VIROLOGY

Up-regulation of amphotrophic retroviral receptor expression in human peripheral blood CD34+ cells. Kaubisch A, et al. **Am J Hematol** 1999 Aug;61(4):243–53

Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Aiuti A, et al. **Blood** 1999 Jul 1;94(1):62–73

Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. Chelucci C, et al. **Blood** 1999 Sep 1; 94(5):1590–600

Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Lee B, et al. **Blood** 1999 Feb 15;93(4):1145–56

Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Sansonno D, et al. **Blood** 1998 Nov 1;92(9):3328–37

Latent infection and reactivation of human herpesvirus 6 in two novel myeloid cell lines. Yasukawa M, et al. **Blood** 1999 Feb 1;93(3):991–9

Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients. Cull GM, et al. **Bone Marrow Transplant** 1999 Apr;23(8):759–61

Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. Introna M, et al. **Br J Haematol** 1998 Nov;103(2):449–61

Human immunodeficiency virus and the hematopoietic repertoire: implications for gene therapy. Panoskaltsis N, et al. **Front Biosci** 1999 May 1;4:D457–67 (110 ref.)

Infection of apheresis cells by parvovirus B19. Hemauer A, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):627–30

Transduction of CD34+ cells by a vesicular stomach virus protein G (VSV-G) pseudotyped HIV-1 vector. Stable gene expression in progeny cells, including dendritic cells. Li X, et al. **J Hum Virol** 1998 Jul-Aug;1(5):346–52

Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. Ruiz ME, et al. **J Immunol** 1998 Oct 15;161(8):4169–76

Chemokine receptors and the molecular basis for human immunodeficiency virus type 1 entry into peripheral hematopoietic stem cells and their progeny. Zhao SF, et al. **J Infect Dis** 1998 Dec;178(6):1623–34

Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. Luppi M, et al. **J Virol** 1999 Jan; 73(1):754–9

Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. Shen H, et al. **J Virol** 1999 Jan;73(1):728–37

Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. Sutton RE, et al. **J Virol** 1999 May; 73(5):3649–60

Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Bachier CR, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):279–88

Human cytomegalovirus infection of human hematopoietic progenitor cells. Maciejewski JP, et al. **Leuk Lymphoma** 1999 Mar;33(1–2):1–13 (74 ref.)

p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Unnikrishnan I, et al. **Mol Cell Biol** 1999 Jul;19(7):4825–31

Interferon-beta-induced human immunodeficiency virus resistance in CD34(+) human hematopoietic progenitor cells: correlation with a down-regulation of CCR-5 expression. Cremer I, et al. **Virology** 1999 Jan 20; 253(2):241–9

HEMATOPOIETIC SYSTEM

CYTOLOGY

Lineage-related susceptibility of human hemopoietic cell lines to apoptosis. Mariani AR, et al. **Anat Rec** 1999 Jan; 254(1):1–6

Insulin receptor substrate 4 supports insulin- and interleukin 4-stimulated proliferation of hematopoietic cells. Fantin VR, et al. **Biochem Biophys Res Commun** 1999 Jul 14; 260(3):718–23

Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Georgescu MM, et al. **Mol Cell Biol** 1999 Feb;19(2):1171–81

DRUG EFFECTS

Acute 2,4-D poisoning in tench (Tinca tinca L.): lesions in the hematopoietic portion of the kidney. Gómez L, et al. **Arch Environ Contam Toxicol** 1998 Oct;35(3):479–83

Co-administration of toluene and xylene antagonized the testicular toxicity but not the hematopoietic toxicity caused by ethylene glycol monoethyl ether in Sprague-Dawley rats. Yu IJ, et al. **Toxicol Lett** 1999 Sep 20;109(1–2):11–20

T-2 toxin-induced apoptosis in hematopoietic tissues of mice. Shinozuka J, et al. **Toxicol Pathol** 1998 Sep-Oct; 26(5):674–81

Systemic and histopathologic changes in Beagle dogs after chronic daily oral administration of synthetic (ethinyl estradiol) or natural (estradiol) estrogens, with special reference to the kidney and thyroid. Zayed I, et al. **Toxicol Pathol** 1998 Nov-Dec;26(6):730–41

[The effect of platinum-containing cytostatic preparations on the immune and hematopoietic systems] Masnaia NV, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):53–5 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Molecular identity of hematopoietic precursor cells emerging in the human embryo. Labastie MC, et al. **Blood** 1998 Nov 15;92(10):3624–35

Elucidating the origins of the vascular system: a fate map of the vascular endothelial and red blood cell lineages in Xenopus laevis. Mills KR, et al. **Dev Biol** 1999 May 15; 209(2):352–68

Cellular and molecular events that govern the development of the hematopoietic and immune system in the embryo [editorial] Dieterlen-Lièvre F, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):249–52

Induction and early development of the hematopoietic and immune systems in Xenopus. Turpen JB. **Dev Comp Immunol** 1998 May-Jun;22(3):265–78 (71 ref.)

Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Bárcena A, et al. **Exp Hematol** 1999 Sep;27(9):1428–39

Development of the hematopoietic system in the mouse. Keller G, et al. **Exp Hematol** 1999 May;27(5):777–87 (106 ref.)

ENZYMOLOGY

Production and characterization of an antibody specific for a novel protein serine/threonine kinase, MPK38, highly expressed in hematopoietic cells. Yang Y, et al. **Appl Biochem Biotechnol** 1999 Apr;80(1):13–22

Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Yoshida H, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):321–32 (56 ref.)

IMMUNOLOGY

MUC1 expression in hematopoietic tissues. Dent GA, et al. **Am J Clin Pathol** 1999 Jun;111(6):741–7

Coordinated host defense through an integration of the neural, immune and haemopoietic systems. Miyan JA, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):297–304 (20 ref.)

METABOLISM

HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues. Cortés F, et al. **Blood** 1999 Feb 1;93(3):826–37

Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Georgescu MM, et al. **Mol Cell Biol** 1999 Feb;19(2):1171–81

PATHOLOGY

T-2 toxin-induced apoptosis in hematopoietic tissues of mice. Shinozuka J, et al. **Toxicol Pathol** 1998 Sep-Oct; 26(5):674–81

[Functional characteristics of hematopoietic and stromal cells in various forms of myelodysplastic syndrome] Gerasimova LP, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):14–8 **(Rus)**

PHYSIOLOGY

Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects. Skoda RC. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1–4):741–72 (163 ref.)

RADIATION EFFECTS

Effect of gamma radiation on the foetal haemopoietic system in the mouse. Uma Devi P, et al. **Int J Radiat Biol** 1998 Nov;74(5):639–46

HEMATOPOIETINS see **HEMATOPOIETIC CELL GROWTH FACTORS**

HEMATOPORPHYRIN D see **HEMATOPORPHYRIN DERIVATIVE**

HEMATOPORPHYRIN DERIVATIVE

see related

HEMATOPORPHYRIN PHOTORADIATION

Damage to tumour and brain by interstitial photodynamic therapy in the 9L rat tumour model comparing intravenous and intratumoral administration of the photosensitiser. Hebeda KM, et al. **Acta Neurochir (Wien)** 1998; 140(5):495–501

ANALYSIS

Determination of endogenous porphyrins and the maximal HpD tumor/normal skin ratio in SKH-1 hairless mice by light induced fluorescence spectroscopy. Bossu E, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):109–17

METABOLISM

DNA-drug interaction measurements using surface plasmon resonance. Bischoff G, et al. **J Biomol Struct Dyn** 1998 Oct;16(2):187–203

PHARMACOLOGY

Determination of endogenous porphyrins and the maximal HpD tumor/normal skin ratio in SKH-1 hairless mice by light induced fluorescence spectroscopy. Bossu E, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):109–17

Delayed hyperresistance of endothelial cells to photodynamic inactivation after contact with hemin. Lin F, et al. **Photochem Photobiol** 1998 Aug;68(2):211–7

[Studies on purging leukemic cells by photosensitizer PSD-007 laser photoradiation in vitro] Liang X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):199–202 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Changes of skin perfusion after photodynamic therapy for port wine stain. Jiang L, et al. **Chin Med J (Engl)** 1998 Feb;111(2):136–8

HEMATOPORPHYRIN PHOTORADIATION

Damage to tumour and brain by interstitial photodynamic therapy in the 9L rat tumour model comparing intravenous and intratumoral administration of the photosensitiser. Hebeda KM, et al. **Acta Neurochir (Wien)** 1998; 140(5):495–501

Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Moskal TL, et al. **Ann Thorac Surg** 1998 Oct;66(4):1128–33

Feasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. Moore JV, et al. **Eur J Nucl Med** 1998 Sep;25(9):1248–54

Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients [see comments] Overholt BF, et al. **Gastrointest Endosc** 1999 Jan;49(1):1–7. Comment in: Gastrointest Endosc 1999 Jan;49(1):122–5.

Photodynamic therapy. A shining light. McGrath K, et al. **N C Med J** 1999 Jul–Aug;60(4):237–9

[Studies on purging leukemic cells by photosensitizer PSD-007 laser photoradiation in vitro] Liang X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):199–202 (Eng. Abstr.) **(Chi)**

ADVERSE EFFECTS

Chemical modification of normal tissue damage induced by photodynamic therapy. Sigdestad CP, et al. **Br J Cancer Suppl** 1996 Jul;27:S89–92

HEMATOPORPHYRINS

Carotenohematoporphyrins as tumor-imaging dyes. Synthesis and in vitro photophysical characterization. Tatman D, et al. **Photochem Photobiol** 1998 Oct; 68(4):459–66

PHARMACOKINETICS

Induction of superficial bladder tumors in the female Fischer 344 rats with AY-27 tumor cells for the study of diffusion and localization of hemoglobin derived components (hematoporphyrin derivative) in view of photochemotherapy. Bisson JF, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jan; 27(1):77–84

Fluorescence spectroscopic and histochemical analysis using hematoporphyrin as a microenvironmental probe for atherosclerotic change in the human aorta. Machida M, et al. **Lab Invest** 1999 Jun;79(6):733–45

PHARMACOLOGY

Photodynamic action of porphyrin on Ca2+ influx in endoplasmic reticulum: a comparison with mitochondria. Ricchelli F, et al. **Biochem J** 1999 Feb 15;338 (Pt 1):221–7

Hyperthermic sensitization by hematoporphyrin on glioma cells. Saito A, et al. **Int J Hyperthermia** 1998 Sep–Oct; 14(5):503–11

Examination of antibacterial activity of the photoactivated arginine haematoporphyrin derivative. Lasocki K, et al. **Pharmacol Res** 1999 Mar;39(3):181–4

THERAPEUTIC USE

Irradiation of amelanotic melanoma cells with 532 nm high peak power pulsed laser radiation in the presence of the photothermal sensitizer Cu(II)-hematoporphyrin: a new approach to cell photoinactivation. Soncin M, et al. **Photochem Photobiol** 1999 Jun;69(6):708–12

HEMATOSIDE see **G(M3) GANGLIOSIDE**

HEMATOXYLIN

The H&E technique: old mistress apologue [editorial] Rosai J. **Pathologica** 1998 Dec;90(6):739–42

Use of hematoxylin stain to enhance evaluation of heart malformations in the fetal rat. Eggers J, et al. **Teratology** 1999 Mar;59(3):173–5

[Use of electromagnetic field in the preparation of some histological stains] Ial'tsev AV, et al. **Klin Lab Diagn** 1999 Mar;(3):45–6 **(Rus)**

HEMATURIA

CHEMICALLY INDUCED

Carboplatin-related hematuria and acute renal failure. Agraharkar M, et al. **Am J Kidney Dis** 1998 Nov;32(5):E5

Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Auer BL, et al. **Eur J Clin Invest** 1998 Sep;28(9):695–700

Effects of intermittent vomitoxin exposure on body weight, immunoglobulin levels and haematuria in the B6C3F1 mouse. Banotai C, et al. **Food Chem Toxicol** 1999 Apr; 37(4):343–50

Presence of mucosal change in the urinary bladder in nonhematuric patients with long-term exposure and/or accumulating high-dose cyclophosphamide. Possible significance of follow-up cystoscopy on preventing development of cyclophosphamide-induced hemorrhagic cystitis. Kimura M, et al. **Urol Int** 1998 Oct;61(1):8–11

[Ureteral hematoma complicating anticoagulant treatment] Belliol E, et al. **J Radiol** 1998 Jan;79(1):49–51 (Eng. Abstr.) **(Fre)**

[Hemorrhagic cystitis after high dose chemotherapy. An interdisciplinary problem] Sommerkamp H. **Urologe A** 1998 Sep;37(5):516–21 (59 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Acute renal failure in an adult patient with Henoch-Schoenlein purpura after episode of macroscopic hematuria. Michail S, et al. **Ren Fail** 1999 Jan;21(1):107–11

[Blind ureter diagnosed through hematuria] Menéndez López V, et al. **Actas Urol Esp** 1998 Jul–Aug;22(7):624–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Re: Haematuria in the diagnosis of urinary calculi. SBS Ooi, NW Kour, Amahadev. Ann Acad Med Singapore 1998; 27:210–4 [letter; comment] Lin R. **Ann Acad Med Singapore** 1998 Jul;27(4):606. Comment on: Ann Acad Med Singapore 1998 Mar;27(2):210–4.

Comparison of reagent strip (dipstick) and microscopic haematuria in urological out-patients. Gleeson MJ, et al. **Br J Urol** 1993 Nov;72(5 Pt 1):594–6

Screening school children for albuminuria, proteinuria and occult blood with dipsticks. Pugia MJ, et al. **Clin Chem Lab Med** 1999 Feb;37(2):149–57

Diagnostic approach to a child with hematuria. Vijayakumar M, et al. **Indian Pediatr** 1998 Jun;35(6):525–32 (14 ref.)

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Miyanaga N, et al. **Int J Urol** 1999 Apr; 6(4):173–7

Ureteropyeloscopy in the diagnosis of patients with upper tract hematuria: an initial clinical study. Yazaki T, et al. **Int J Urol** 1999 May;6(5):219–25

Renal tuberculosis presenting as lateralizing hematuria diagnosis by ureteronephroscopy and selective upper tract urine culture. Chan SW, et al. **J Endourol** 1998 Aug; 12(4):363–4

Reexamining the value of hematuria testing in patients with acute flank pain. Bove P, et al. **J Urol** 1999 Sep;162(3 Pt 1):685–7

Fluid intake and bladder cancer [letter] Goldstein MR. **N Engl J Med** 1999 Sep 9;341(11):847–8

Exercise induced macroscopic haematuria: run for a diagnosis? Ubels FL, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2030–1

Differential diagnosis between glomerular and nonglomerular hematuria by automated urinary flow cytometer. Kitasato University Kidney Center criteria. Hyodo T, et al. **Nephron** 1999;82(4):312–23

Evaluating adult hematuria. Fickenscher L. **Nurse Pract** 1999 Sep;24(9):58–65 (18 ref.)

Frequency of microscopic hematuria in acute poststreptococcal glomerulonephritis [letter] Bircan Z, et al. **Pediatr Nephrol** 1999 Apr;13(3):269–70

Could this be loin pain hematuria syndrome? Gusmano RG. **Pediatr Nephrol** 1998 Nov;12(9):800

Isolated microscopic hematuria--is it a disease state? [letter; comment] Stark H. **Pediatr Nephrol** 1999 Jun;13(5):468. Comment on: Pediatr Nephrol 1998 Jun;12(5):386–91.

Haematuria clinic--a preliminary audit and considerations for a one-stop assessment centre. Tan PK, et al. **Singapore Med J** 1998 Nov;39(11):501–3

Evaluation of asymptomatic microscopic hematuria. Grossfeld GD, et al. **Urol Clin North Am** 1998 Nov; 25(4):661–76 (72 ref.)

[Values of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part I. Establishing individual norms for glomerular hematuria] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):277–9 (16 ref.) (Eng. Abstr.) **(Pol)**

[Value of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part II: Analysis of factors modifying morphology of erythrocytes in urine sediment] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):280–4 (Eng. Abstr.) **(Pol)**

[The value of urine sediment cytomorphology in the ambulatory differential diagnosis of hematuria] Obroniecka I, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):285–7 (Eng. Abstr.) **(Pol)**

[The diagnostic importance of erythrocyte dysmorphism in the study of hematuria] Daniel MI, et al. **Acta Med Port** 1998 Dec;11(12):1101–5 (22 ref.) (Eng. Abstr.) **(Por)**

[Hematuria] Milheiro A, et al. **Acta Med Port** 1999 Jan–Mar; 12(1–3):13–7 (Eng. Abstr.) **(Por)**

DRUG THERAPY

Urine circulating soluble egg antigen in relation to egg counts, hematuria, and urinary tract pathology before and after treatment in children infected with Schistosoma haematobium in Kenya. Kahama AI, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):215–9

Re: The treatment of gross hematuria secondary to prostatic bleeding with finasteride [letter; comment] Sorrentino F, et al. **J Urol** 1998 Dec;160(6 Pt 1):2164. Comment on: J Urol 1998 Apr;159(4):1232–3.

Formalin treatment of refractory hemorrhagic cystitis in systemic lupus erythematosus. Fu LW, et al. **Pediatr Nephrol** 1998 Nov;12(9):788–9

EPIDEMIOLOGY

[Hematuria in pediatric clinical practice] Khoory BJ, et al. **Minerva Pediatr** 1999 Jan–Feb;51(1–2):11–8 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Evaluation of asymptomatic microscopic hematuria in adults. Thaller TR, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1143–52, 1154 (28 ref.)

Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607–12 (27 ref.)

A 12-year-old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Gross hematuria of uncommon origin: the nutcracker syndrome. Russo D, et al. **Am J Kidney Dis** 1998 Sep; 32(3):E3

Hematuria from arteriovesical fistula: unusual presentation of ruptured iliac artery aneurysm. Goff CD, et al. **Am Surg** 1999 May;65(5):421–2

Traumatic hematuria in patients with polycystic kidney disease. Klein AJ, et al. **Am Surg** 1999 May;65(5):464–6 (25 ref.)

Haematuria and clot retention after transurethral resection of the prostate: a pilot study [letter; comment] Charles A. **BJU Int** 1999 Apr;83(6):737–8. Comment on: Br J Urol 1998 Nov;82(5):624–7.

Haematuria and clot retention after transurethral resection of the prostate: a pilot study [letter; comment] Foley SJ, et al. **BJU Int** 1999 Apr;83(6):738. Comment on: BJU Int 1998 Nov;82(5):624–7.

Preputial calculi. Nagata D, et al. **BJU Int** 1999 Jun; 83(9):1076–7

Unexplained haemoglobinuria may have been haematuria [letter] Mortensen S. **BMJ** 1999 Jan 16;318(7177):192

Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children. Kondo M, et al. **Bone Marrow Transplant** 1998 Nov;22(10):995–8

Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Trotman J, et al. **Bone Marrow Transplant** 1999 Apr;23(8):797–801

Re: Effectiveness of haematuria clinics. J. P. Britton. Br. J. Urol., 71, 247–252, 1993 [letter] Bdesha AS, et al. **Br J Urol** 1993 Nov;72(5 Pt 1):671

Haematuria and clot retention after transurethral resection of the prostate: a pilot study [see comments] Olapade-Olaopa EO, et al. **Br J Urol** 1998 Nov;82(5):624–7 . Comment in: BJU Int 1999 Apr;83(6):737–8. Comment in: BJU Int 1999 Apr;83(6):738.

Haematuria as the presenting symptom: experience from a tertiary referral centre in Sri Lanka. Goonewardena SA, et al. **Ceylon Med J** 1998 Sep;43(3):156–8

Retroaortic left renal vein with renal vein hypertension causing hematuria. Gibo M, et al. **Clin Imaging** 1998 Nov–Dec;22(6):422–4

Level of red blood cells in the urinary sediment reflects the degree of renal activity in Wegener's granulomatosis [see comments] Fujita T, et al. **Clin Nephrol** 1998 Nov; 50(5):284–8. Comment in: Clin Nephrol 1999 Jun;51(6):388–9.

Long-term outcome of adult patients with minimal urinary abnormalities and normal renal function. Shu KH, et al. **Clin Nephrol** 1999 Jul;52(1):5–9

The effect of exercise intensity on hematuria in healthy male runners. McInnis MD, et al. **Eur J Appl Physiol** 1998 Dec; 79(1):99–105

An unusual case of haematuria treated by endoluminal repair. Asham EH, et al. **Eur J Vasc Endovasc Surg** 1999 Jan; 17(1):89–90

Diagnostic approach to a child with hematuria. Vijayakumar M, et al. **Indian Pediatr** 1998 Jun;35(6):525–32 (14 ref.)

Placenta percreta invading the bladder causing exsanguinating hemorrhage. Kotwal SV, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999;10(4):260–1

Inflammatory pseudotumour of the bladder: a rare cause of haematuria. Ranê AM, et al. **Int Urol Nephrol** 1998; 30(5):561–4

Hematuria associated with sickle cell trait during pregnancy. Videlefsky A, et al. **J Am Board Fam Pract** 1998 Jul–Aug; 11(4):321–3

Haematuria. Mukherjee B. **J Indian Med Assoc** 1998 Apr; 96(4):121–2 (0 ref.)

Hematuria associated with low-volume cell saver in pediatric orthopaedics. Keverline JP, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):594–7

The value of comparative volumetric analysis of urinary and blood erythrocytes to localize the source of hematuria. Angulo JC, et al. **J Urol** 1999 Jul;162(1):119–26

Reexamining the value of hematuria testing in patients with acute flank pain. Bove P, et al. **J Urol** 1999 Sep;162(3 Pt 1):685–7

Macroscopic hematuria as an initial manifestation of carcinoma of the colon. Rub R, et al. **J Urol** 1999 Mar; 161(3):922

Hematuria: an unusual presentation for mucocele of the appendix. Case report and review of the literature. Oliphant UJ, et al. **JSLS** 1999 Jan–Mar;3(1):71–4 (4 ref.)

An unusual cause of haematuria. Macdonald A.

N Z Med J 1999 Mar 12;112(1083):78
The Sudanese immigrant with recurrent gross haematuria--diagnosis at a glance by examination of the urine sediment. Colucci P, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2247-9
Renal papillary necrosis in a marathon runner [letter] Ducloux D, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):247-8
The patient with macrohaematuria and flank pain after renal biopsy. Haas-Wöhrle A, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1876
The lady with a history of blood transfusion who developed palpable purpura and microhaematuria. Höhler T, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2035-7
Unexplained haematuria. Koene RA. **Nephrol Dial Transplant** 1999 Aug;14(8):2025-7
Autosomal dominant polycystic kidney disease presenting with prolonged macrohaematuria and perinephric haematoma [letter] Sirvent AE, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2422-3
Exercise induced macroscopic haematuria: run for a diagnosis? Ubels FL, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2030-1
Life-threatening hematuria from an arteriovenous fistula complicating an open renal biopsy. Tarif N, et al. **Nephron** 1998 Sep;80(1):66-70 (30 ref.)
Evaluating adult hematuria. Fickenscher L. **Nurse Pract** 1999 Sep;24(9):58-65 (18 ref.)
Spontaneous resolution of hemolysis after partial coil occlusion of ductus arteriosus. Lee C, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):371-2
Frequency of microscopic hematuria in acute poststreptococcal glomerulonephritis [letter] Bircan Z, et al. **Pediatr Nephrol** 1999 Apr;13(3):269-70
Index of Suspicion. Case 1. Rhabdomyolysis. Amin S. **Pediatr Rev** 1998 Oct;19(10):333-4
Renal medullary carcinoma in an adolescent with sickle cell trait. Warren KE, et al. **Pediatrics** 1999 Feb;103(2):E22 (8 ref.)
Toothpick migration into bladder presents as abdominal pain and hematuria. Alagiri M, et al. **Urology** 1998 Dec; 52(6):1130-1
Hematuria and death secondary to aortoureteric fistula. Holmes M, et al. **Urology** 1998 Oct;52(4):720-2
Day case hematuria diagnostic service: use of ultrasonography and flexible cystoscopy. Yip SK, et al. **Urology** 1998 Nov;52(5):762-6
[Effort-induced macroscopic hematuria revealing segmental and congenital absence of inferior vena cava] Vedrine L, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):524-6 (Eng. Abstr.) **(Fre)**
[Pathological horseshoe kidney. 30 case reports] Benchekroun A, et al. **Ann Urol (Paris)** 1998;32(5):279-82 (Eng. Abstr.) **(Fre)**
[Hematuria revealing primary hyperparathyroidism in a child] Ichay L, et al. **Arch Pediatr** 1999 Feb;6(2):182-5 (Eng. Abstr.) **(Fre)**
[Nephroblastoma presenting with massive hematuria may require emergency surgery] Lo Piccolo MS, et al. **Pediatr Med Chir** 1998 Sep-Oct;20(5):337-9 (Eng. Abstr.) **(Ita)**
[Value of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part II: Analysis of factors modifying morphology of erythrocytes in urine sediment] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):280-4 (Eng. Abstr.) **(Pol)**
[Values of phase-contrast microscopy in the etiological diagnosis of hematuria in adults. Part I. Establishing individual norms for glomerular hematuria] Obroniecka I. **Pol Merkuriusz Lek** 1998 Nov;5(29):277-9 (16 ref.) (Eng. Abstr.) **(Pol)**
[Uretero-iliac fistula] Herranz Amo F, et al. **Arch Esp Urol** 1998 Oct;51(8):818-20 (Eng. Abstr.) **(Spa)**

GENETICS

Evidence for genetic heterogeneity in benign familial hematuria. Piccini M, et al. **Am J Nephrol** 1999;19(4):464-7

IMMUNOLOGY

Evaluation of urinary IL-1alpha and IL-1beta in gravid females and patients with bacterial cystitis and microscopic hematuria. Candela JV, et al. **Urol Res** 1998;26(3):175-80

METABOLISM

Recurrent calcium stones in Gordon's syndrome. Stratton JD, et al. **Br J Urol** 1998 Dec;82(6):925

MICROBIOLOGY

The relationship between Helicobacter pylori infection and acid-hematuria syndrome in pediatric patients with gastric augmentation-II. Celayir S, et al. **J Pediatr Surg** 1999 Apr; 34(4):532-5

PATHOLOGY

A 46-year-old woman with nephrotic syndrome and persistent microscopic hematuria. Milord R, et al. **Am J Kidney Dis** 1998 Dec;32(6):1098-105 (51 ref.)
Thin glomerular basement membranes in patients with hematuria and minimal change disease. Marquez B, et al. **Ultrastruct Pathol** 1999 May-Jun;23(3):149-56

RADIOGRAPHY

Radiology case of the month. Painless microhematuria. Bladder tumor. Neitzschman HR 3rd, et al. **J La State Med Soc** 1998 Aug;150(8):345-6

SURGERY

Renal auto-transplantation with interposed PTFE arterial graft: not necessarily a cure for loin pain/haematuria syndrome. Blacklock AR, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):134
Tonsillectomy for asymptomatic isolated hematuria [letter] Kaneko K, et al. **Nephron** 1999 Jan;81(1):113-4

THERAPY

Encephalopathy after bladder irrigation with alum: case report and literature review. Phelps KR, et al. **Am J Med Sci** 1999 Sep;318(3):181-5 (37 ref.)

ULTRASONOGRAPHY

Acute renal failure with macrohaematuria--don't be fooled by large hyperechogenic kidneys. Ruiz JC, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1858-9

URINE

Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria. Paoluzzi M, et al. **Arch Ital Urol Androl** 1999 Feb;71(1):13-8
Computer-assisted light microscopy in evaluating urinary red blood cell morphology [letter; comment] Oktenli G, et al. **Clin Nephrol** 1999 Feb;51(2):130-1. Comment on: Clin Nephrol 1997 Apr;47(4):271-2.
The Sudanese immigrant with recurrent gross haematuria--diagnosis at a glance by examination of the urine sediment. Colucci P, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2247-9
Unexplained haematuria. Koene RA. **Nephrol Dial Transplant** 1999 Aug;14(8):2025-7
Induction of transient proteinuria, hematuria, and glucosuria by ethanol consumption in Japanese alcoholics. Ito S, et al. **Nephron** 1999;82(3):246-53

VETERINARY

Haematuria in a geriatric cat. Beatty JA, et al. **Aust Vet J** 1999 Mar;77(3):160, 166-7
Recurrent urethral obstruction secondary to idiopathic renal hematuria in a puppy. Hawthorne JC, et al. **J Am Anim Hosp Assoc** 1998 Nov-Dec;34(6):511-4
Renal haemangioma in a dog. Eddlestone S, et al. **J Small Anim Pract** 1999 Mar;40(3):132-5
Primary immune-mediated thrombocytopenia in a cat. Tasker S, et al. **J Small Anim Pract** 1999 Mar;40(3):127-31

VIROLOGY

Primary BK virus (BKV) infection due to possible BKV transmission during bone marrow transplantation is not the major cause of hemorrhagic cystitis in transplanted children. Bogdanovic G, et al. **Pediatr Transplant** 1998 Nov;2(4):288-93

HEME

Evaluation of iron bioavailability in infant weaning foods fortified with haem concentrate. Martinez C, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):419-24

ADMINISTRATION & DOSAGE

Heme arginate therapy for beta thalassemia: in vitro versus in vivo effects. Rund D, et al. **Acta Haematol** 1998; 100(2):82-4

ANALOGS & DERIVATIVES

Energy-dependent redox state of heme a + a3 and copper of cytochrome oxidase in perfused rat brain in situ. Matsunaga A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1022-30
The role of Saccharomyces cerevisiae Met1p and Met8p in sirohaem and cobalamin biosynthesis. Raux E, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):701-8
Consideration of a phlorin structure for haem P-460 of hydroxylamine oxidoreductase and its implications regarding reaction mechanism. Arciero DM, et al. **Biochem Soc Trans** 1998 Aug;26(3):385-9 (41 ref.)
Electrochemical and ultraviolet/visible/infrared spectroscopic analysis of heme a and a3 redox reactions in the cytochrome c oxidase from Paracoccus denitrificans: separation of heme a and a3 contributions and assignment of vibrational modes. Hellwig P, et al. **Biochemistry** 1999 Feb 9;38(6):1685-94
Molecular oxygen oxidizes the porphyrin ring of the ferric alpha-hydroxyheme in heme oxygenase in the absence of reducing equivalent. Migita CT, et al. **Biochim Biophys Acta** 1999 Jul 13;1432(2):203-13
Cooperative coupling and role of heme a in the proton pump of heme-copper oxidases. Papa S, et al. **Biochimie** 1998 Oct;80(10):821-36 (62 ref.)
Lactoferrin inhibits Bacillus cereus growth and heme analogs recover its growth. Sato N, et al. **Biol Pharm Bull** 1999 Feb;22(2):197-9
Cloning of Bacillus stearothermophilus ctaA and heme A synthesis with the CtaA protein produced in Escherichia coli. Sakamoto J, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):96-103
Effects of nitric oxide on the eosinophil survival in vitro. A role for nitrosyl-heme. Beauvais F, et al. **FEBS Lett** 1999 Jan 22;443(1):37-40
A cooperative model for protonmotive heme-copper oxidases. The role of heme a in the proton pump of cytochrome c oxidase. Papa S, et al. **FEBS Lett** 1998 Nov 13;439(1-2):1-8
The heme prosthetic group of lactoperoxidase. Structural characteristics of heme 1 and heme 1-peptides. Rae TD, et al. **J Biol Chem** 1998 Oct 23;273(43):27968-77
Ferric alpha-hydroxyheme bound to heme oxygenase can be converted to verdoheme by dioxygen in the absence of added reducing equivalents. Sakamoto H, et al. **J Biol Chem** 1999 Jun 25;274(26):18196-200
Photoreactivation of the cytochrome oxidase complex with cyanide: the reaction of heme a3 photoreduction. Konev SV, et al. **Membr Cell Biol** 1998;12(5):743-54
[Mechanisms of actovegin effect on the central nervous system during postischemic period] Boiarinov GA, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):395-8 **(Rus)**
[The metabolic effects of the neurotropic action of actovegin during hypoxia] Boiarinov GA, et al. **Eksp Klin Farmakol** 1999 Mar-Apr;62(2):61-3 (33 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

A colorimetric assay for heme in biological samples using 96-well plates. Pandey AV, et al. **Anal Biochem** 1999 Mar 1;268(1):159-61
Extended heme promiscuity in the cyanobacterial cytochrome c oxidase: characterization of native complexes containing hemes A, O, and D, respectively. Fromwald S, et al. **Arch Biochem Biophys** 1999 Jul 1;367(1):122-8
Observations on the zinc protoporphyrin/heme ratio in whole blood. Labbé RF, et al. **Clin Chem** 1999 Jan; 45(1):146-8
Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency. Rettmer RL, et al. **Pediatrics** 1999 Sep; 104(3):e37

BIOSYNTHESIS

Altered activity of heme biosynthesis pathway enzymes in individuals chronically exposed to arsenic in Mexico. Hernández-Zavala A, et al. **Arch Toxicol** 1999 Mar; 73(2):90-5
Common chelatase design in the branched tetrapyrrole pathways of heme and anaerobic cobalamin synthesis. Schubert HL, et al. **Biochemistry** 1999 Aug 17; 38(33):10660-9
A missing metabolic pathway in the cattle tick Boophilus microplus. Braz GR, et al. **Curr Biol** 1999 Jul 1;9(13):703-6
Cytotoxic and porphyrinogenic effects of diphenyl ethers in cultured rat hepatocytes: chlornitrofen (CNP), CNP-amino, chlomethoxyfen and bifenox. Jinno H, et al. **Food Chem Toxicol** 1999 Jan;37(1):69-74
Neisseria gonorrhoeae heme biosynthetic mutants utilize heme and hemoglobin as a heme source but fail to grow within epithelial cells. Turner PC, et al. **Infect Immun** 1998 Nov;66(11):5215-23
Conditional stability of the HemA protein (glutamyl-tRNA reductase) regulates heme biosynthesis in Salmonella typhimurium. Wang L, et al. **J Bacteriol** 1999 Feb; 181(4):1211-9
Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria. Lange H, et al. **J Biol Chem** 1999 Jul 2;274(27):18989-96
Porphyrias. Scarlett YV, et al. **J Clin Gastroenterol** 1998 Oct; 27(3):192-8 (16 ref.)
Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells. Kauppinen R, et al. **Mol Genet Metab** 1998 Sep;65(1):10-7
Pharmacologic effects of the red blood cell substitutes cross-linked and non-cross-linked hemoglobins on hematopoiesis in rabbits. Lutton JD, et al. **Pharmacology** 1999 Jun;58(6):319-24
The genetic bases of the porphyrias. Frank J, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):297-309 (100 ref.)
Variegate porphyria: past, present and future. Frank J, et al. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):310-20 (73 ref.)
Arsenite alters heme synthesis in long-term cultures of adult rat hepatocytes. Aguilar-González MG, et al. **Toxicol Sci** 1999 Jun;49(2):281-9

CHEMISTRY

Crystallization and preliminary X-ray diffraction studies on the water soluble form of rat heme oxygenase-1 in complex with heme. Omata Y, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1017-9
Cellular applications of a sensitive and selective fiber-optic

nitric oxide biosensor based on a dye-labeled heme domain of soluble guanylate cyclase. Barker SL, et al. **Anal Chem** 1999 Jun 1;71(11):2071-5

Effect of modified hemes on the spectral properties and activity of manganese peroxidase. Reading NS, et al. **Arch Biochem Biophys** 1998 Nov 15;359(2):291-6

Substitution of the sixth axial ligand of Rhodobacter capsulatus cytochrome c1 heme yields novel cytochrome c1 variants with unusual properties. Darrouzet E, et al. **Biochemistry** 1999 Jun 22;38(25):7908-17

Dynamics of protein-bound water in the heme domain of P450BM3 studied by high-pressure spectroscopy: comparison with P450cam and P450 2B4. Davydov DR, et al. **Biochemistry** 1999 Jan 12;38(2):751-61

Solution 1H NMR investigation of the heme cavity and substrate binding site in cyanide-inhibited horseradish peroxidase. de Ropp JS, et al. **Biochemistry** 1999 Jan 19; 38(3):1077-86

Probing the heme axial ligation in the CO-sensing CooA protein with magnetic circular dichroism spectroscopy. Dhawan IK, et al. **Biochemistry** 1999 Sep 28; 38(39):12805-13

The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds. Doussiere J, et al. **Biochemistry** 1999 Mar 23;38(12):3694-703

Heme protein dynamics revealed by geminate nitric oxide recombination in mutants of iron and cobalt myoglobin. Kholodenko Y, et al. **Biochemistry** 1999 May 4; 38(18):5918-24

Discrete species of activated oxygen yield different cytochrome P450 heme adducts from aldehydes. Kuo CL, et al. **Biochemistry** 1999 Aug 10;38(32):10511-8

Distinct structures and environments for the three hemes of the cytochrome bc1 complex from Rhodospirillum rubrum. A resonance Raman study using B-band excitations. Le Moigne C, et al. **Biochemistry** 1999 Jan 19;38(3):1066-76

Heme speciation in alkaline ferric FixL and possible tyrosine involvement in the signal transduction pathway for regulation of nitrogen fixation. Lukat-Rodgers GS, et al. **Biochemistry** 1998 Sep 29;37(39):13543-52

The structural origin of nonplanar heme distortions in tetraheme ferricytochromes c3. Ma JG, et al. **Biochemistry** 1998 Sep 8;37(36):12431-42

UV resonance Raman studies of alpha-nitrosyl hemoglobin derivatives: relation between the alpha 1-beta 2 subunit interface interactions and the Fe-histidine bonding of alpha heme. Nagatomo S, et al. **Biochemistry** 1999 Jul 27; 38(30):9659-66

Assignment of the heme axial ligand(s) for the ferric myoglobin (H93G) and heme oxygenase (H25A) cavity mutants as oxygen donors using magnetic circular dichroism. Pond AE, et al. **Biochemistry** 1999 Jun 8; 38(23):7601-8

Role of unusual amino acid residues in the proximal and distal heme regions of a plant P450, CYP73A1. Schalk M, et al. **Biochemistry** 1999 May 11;38(19):6093-103

Resonance raman characterization of the heme domain of soluble guanylate cyclase. Schelvis JP, et al. **Biochemistry** 1998 Nov 17;37(46):16289-97

Functionalized de novo designed proteins: mechanism of proton coupling to oxidation/reduction in heme protein maquettes. Shifman JM, et al. **Biochemistry** 1998 Nov 24; 37(47):16815-27

Engineering cytochrome c peroxidase into cytochrome P450: a proximal effect on heme-thiolate ligation. Sigman JA, et al. **Biochemistry** 1999 Aug 24;38(34):11122-9

Characterization of the heme and pyridoxal phosphate cofactors of human cystathionine beta-synthase reveals nonequivalent active sites [published erratum appears in Biochemistry 1999 Jun 1;38(22):7406] Taoka S, et al. **Biochemistry** 1999 Mar 2;38(9):2738-44

Proton NMR investigation of the heme active site structure of an engineered cytochrome c peroxidase that mimics manganese peroxidase. Wang X, et al. **Biochemistry** 1999 Jul 13;38(28):9146-57

Structural changes in the heme proximal pocket induced by nitric oxide binding to soluble guanylate cyclase. Zhao Y, et al. **Biochemistry** 1998 Sep 8;37(36):12458-64

Aromatic amino acids in the Rieske iron-sulfur protein do not form an obligatory conduit for electron transfer from the iron-sulfur cluster to the heme of cytochrome c1 in the cytochrome bc1 complex. Snyder CH, et al. **Biochim Biophys Acta** 1999 Mar 9;1410(3):237-47

1H-NMR investigation of the influence of the heme orientation on functional properties of myoglobin. Yamamoto Y, et al. **Biochim Biophys Acta** 1998 Nov 10; 1388(2):349-62

Studies on the heme and H2-uptake reaction from Azotobacter vinelandii bacterial ferritin. Huang HQ, et al. **Bioelectrochem Bioenerg** 1999 Feb;48(1):87-93

Time resolved emissions in the picosecond range of single tryptophan recombinant myoglobins reveal the presence of long range heme protein interactions. Gryczynski Z, et al. **Biophys Chem** 1998 Sep 14;74(3):187-96

The quantum mixed-spin heme state of barley peroxidase: A paradigm for class III peroxidases. Howes BD, et al. **Biophys J** 1999 Jul;77(1):478-92

Fe-heme conformations in ferric myoglobin. Longa SD, et al. **Biophys J** 1998 Dec;75(6):3154-62

A study of vibrational relaxation of B-state carbon monoxide in the heme pocket of photolyzed carboxymyoglobin. Sagnella DE, et al. **Biophys J** 1999 Jul;77(1):70-84

Resonance Raman spectroscopic study of the caa3 oxidase from Thermus thermophilus. Gerscher S, et al. **Biospectroscopy** 1998;4(6):365-77

Orientation of the heme vinyl groups in the hydrogen sulfide-binding hemoglobin I from Lucina pectinata. Silfa E, et al. **Biospectroscopy** 1998;4(5):311-26

Understanding heme cavity structure of peroxidases: comparison of electronic absorption and resonance Raman spectra with crystallographic results. Smulevich G. **Biospectroscopy** 1998;4(5 Suppl):S3-17 (101 ref.)

Characterization of the Asp94 and Glu242 mutants in myeloperoxidase, the residues linking the heme group via ester bonds. Kooter IM, et al. **Eur J Biochem** 1999 Aug; 264(1):211-7

Kinetic approach to the interaction of sodium n-dodecyl sulphate with heme enzymes. Gebicka L. **Int J Biol Macromol** 1999 Jan;24(1):69-74

Internal electron transfer between hemes and Cu(II) bound at cysteine beta93 promotes methemoglobin reduction by carbon monoxide. Bonaventura C, et al. **J Biol Chem** 1999 Feb 26;274(9):5499-507

Chlamydomonas chloroplast ferrous hemoglobin. Heme pocket structure and reactions with ligands. Couture M, et al. **J Biol Chem** 1999 Mar 12;274(11):6898-910

Hydroxide rather than histidine is coordinated to the heme in five-coordinate ferric Scapharca inaequivalvis hemoglobin. Das TK, et al. **J Biol Chem** 1999 Jan 29; 274(5):2916-9

The heme environment in barley hemoglobin. Das TK, et al. **J Biol Chem** 1999 Feb 12;274(7):4207-12

Modulation of the remote heme site geometry of recombinant mouse neuronal nitric-oxide synthase by the N-terminal hook region. Iwasaki T, et al. **J Biol Chem** 1999 Mar 19; 274(12):7705-13

Biochemical evidence for heme linkage through esters with Asp-93 and Glu-241 in human eosinophil peroxidase. The ester with Asp-93 is only partially formed in vivo. Oxvig C, et al. **J Biol Chem** 1999 Jun 11;274(24):16953-8

Structural and functional roles of heme binding module in globin proteins: identification of the segment regulating the heme binding structure. Inaba K, et al. **J Mol Biol** 1998; 283(1):311-27

Structural organization in peptide fragments of cytochrome c by heme binding. Kang X, et al. **J Mol Biol** 1999 Jan 15;285(2):463-8

Optical characterization of heme a + a3 and copper of cytochrome oxidase in blood-free perfused rat brain. Nomura Y, et al. **J Neurosci Methods** 1998 Aug 1; 82(2):135-44

Heme packing motifs revealed by the crystal structure of the tetra-heme cytochrome c554 from Nitrosomonas europaea. Iverson TM, et al. **Nat Struct Biol** 1998 Nov; 5(11):1005-12

A test of the relationship between sequence and structure in proteins: excision of the heme binding site in apocytochrome b5. Constans AJ, et al. **Protein Sci** 1998 Sep;7(9):1983-93

DEFICIENCY

Evidence for and consequences of chronic heme deficiency in Belgrade rat reticulocytes. Garrick MD, et al. **Biochim Biophys Acta** 1999 Mar 8;1449(2):125-36

ISOLATION & PURIFICATION

Protoheme extraction from plant tissue. Stillman LC, et al. **Anal Biochem** 1978 Nov;91(1):166-72

METABOLISM

Class I heme peroxidases: characterization of soybean ascorbate peroxidase. Jones DK, et al. **Arch Biochem Biophys** 1998 Dec 15;360(2):173-8

Metmyoglobin/azide: the effect of heme-linked ionizations on the rate of complex formation. Lin J, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):148-58

Human serum albumin-bound synthetic hemes as an oxygen carrier: determination of equilibrium constants for heme binding to host albumin. Komatsu T, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov; 26(5-6):519-27

Presence and formation of heme and occurrence of certain heme proteins in the filarial parasite Setaria digitata. Kumar RA, et al. **Biochem Biophys Res Commun** 1998 Dec 9; 253(1):49-52

Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Loria P, et al. **Biochem J** 1999 Apr 15;339 (Pt 2):363-70

Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Ginsburg H, et al. **Biochem Pharmacol** 1998 Nov 15;56(10):1305-13

The membrane-integral domain of succinate:quinone oxidoreductases--a secretive haem-containing domain. Hederstedt L. **Biochem Soc Trans** 1998 Aug;26(3):408-13 (33 ref.)

Yeast iso-1-cytochrome c met80X mutants: the pKa of the spin state transition as a probe for haem pocket flexibility. Silkstone G, et al. **Biochem Soc Trans** 1998 Nov;26(4):S348

Regeneration of the ferrous heme of soluble guanylate cyclase from the nitric oxide complex: acceleration by thiols and oxyhemoglobin. Brandish PE, et al. **Biochemistry** 1998 Dec 1;37(48):16898-907

Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. He K, et al. **Biochemistry** 1998 Dec 15;37(50):17448-57

Interaction site for high-potential iron-sulfur protein on the tetraheme cytochrome subunit bound to the photosynthetic reaction center of Rubrivivax gelatinosus. Osyczka A, et al. **Biochemistry** 1999 Mar 9;38(10):2861-5

Identification of two important heme site residues (cysteine 75 and histidine 77) in CooA, the CO-sensing transcription factor of Rhodospirillum rubrum. Shelver D, et al. **Biochemistry** 1999 Mar 2;38(9):2669-78

Structural changes in the heme proximal pocket induced by nitric oxide binding to soluble guanylate cyclase. Zhao Y, et al. **Biochemistry** 1998 Sep 8;37(36):12458-64

The ferric-reducing activity of duodenal brush-border membrane vesicles is associated with a b-type haem. Pountney DJ, et al. **Biometals** 1999 Mar;12(1):53-62

The participation of the hemes of flavocytochrome b245 in the electron transfer process in NADPH oxidase [letter; comment] Cross A. **Blood** 1999 Jun 15;93(12):4449. Comment on: Blood 1999 Mar 1;93(5):1464-76.

No significant effects of sodium aurothiomalate on haem metabolism and mixed function oxygenase activity in patients with rheumatoid arthritis. Herrick AL, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):461-2

Changes in protein synthesis as a consequence of heme depletion in Escherichia coli. Rompf A, et al. **Curr Microbiol** 1998 Oct;37(4):226-30

Heme-mediated oxygen activation in biology: cytochrome c oxidase and nitric oxide synthase. Poulos TL, et al. **Curr Opin Chem Biol** 1999 Apr;3(2):131-7 (41 ref.)

Heme-based sensors in biological systems. Rodgers KR. **Curr Opin Chem Biol** 1999 Apr;3(2):158-67 (85 ref.)

Proton translocation by bacteriorhodopsin and heme-copper oxidases. Wikström M. **Curr Opin Struct Biol** 1998 Aug; 8(4):480-8 (68 ref.)

A unique tertiary amine N-oxide reduction system composed of quinone reductase and heme in rat liver preparations. Kitamura S, et al. **Drug Metab Dispos** 1999 Jan;27(1):92-7

Nonsynergic effect of ethanol and lead on heme metabolism in rats. Santos JL, et al. **Ecotoxicol Environ Saf** 1999 May; 43(1):98-102

NMR studies of the C-terminal secretion signal of the haem-binding protein, HasA. Izadi-Pruneyre N, et al. **Eur J Biochem** 1999 Apr;261(2):562-8

Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. Lyoumi S, et al. **Eur J Biochem** 1999 Apr;261(1):190-6

Recombinant bovine lactoperoxidase as a tool to study the heme environment in mammalian peroxidases. Watanabe S, et al. **FEBS Lett** 1998 Dec 28;441(3):476-9

Identification of iron-regulated outer membrane proteins in uropathogenic Proteus mirabilis and its relationship with heme uptake. Piccini CD, et al. **FEMS Microbiol Lett** 1998 Sep 15;166(2):243-8

The CcmE protein from Escherichia coli is a haem-binding protein. Reid E, et al. **FEMS Microbiol Lett** 1998 Sep 15; 166(2):369-75

Heme and apoprotein modification of cytochrome P450 2B4 during its oxidative inactivation in monooxygenase reconstituted system. Karuzina II, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):620-32

Cyclooxygenase dependent release of heme from microsomal hemeproteins correlates with induction of heme oxygenase 1 transcription in human fibroblasts. Kvam E, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):511-7

Retinoic acid in association with tin-metalloporphyrins influences heme metabolism in vivo in rats. Chandra R, et al. **Int J Vitam Nutr Res** 1999 Jan;69(1):16-22

Use of heme-protein complexes by the Yersinia enterocolitica HemR receptor: histidine residues are essential for receptor function. Bracken CS, et al. **J Bacteriol** 1999 Oct; 181(19):6063-72

Comparison of the heme iron utilization systems of pathogenic Vibrios. O'Malley SM, et al. **J Bacteriol** 1999 Jun;181(11):3594-8

A mutant HemA protein with positive charge close to the N terminus is stabilized against heme-regulated proteolysis in Salmonella typhimurium. Wang L, et al. **J Bacteriol** 1999 Oct;181(19):6033-41

Redox-controlled ligand exchange of the heme in the CO-sensing transcriptional activator CooA. Aono S, et al. **J Biol Chem** 1998 Oct 2;273(40):25757-64

Effects of Asp-369 and Arg-372 mutations on heme environment and function in human endothelial nitric-oxide synthase. Chen PF, et al. **J Biol Chem** 1998 Dec 18;273(51):34164-70

Heme degradation as catalyzed by a recombinant bacterial heme oxygenase (Hmu O) from Corynebacterium diphtheriae. Chu GC, et al. **J Biol Chem** 1999 Jul 23; 274(30):21319-25

Cellular protection mechanisms against extracellular heme. heme-hemopexin, but not free heme, activates the N-terminal c-jun kinase. Eskew JD, et al. **J Biol Chem** 1999 Jan 8;274(2):638-48

Role of heme in intracellular trafficking of thyroperoxidase and involvement of H2O2 generated at the apical surface of thyroid cells in autocatalytic covalent heme binding. Fayadat L, et al. **J Biol Chem** 1999 Apr 9;274(15):10533-8

Pseudo-native motifs in the noncovalent heme-apocytochrome c complex. Evidence from antibody

binding studies by enzyme-linked immunosorbent assay and microcalorimetry. Goldberg ME, et al. **J Biol Chem** 1999 Jun 4;274(23):16052-61

The yeast heme-responsive transcriptional activator Hap1 is a preexisting dimer in the absence of heme. Hon T, et al. **J Biol Chem** 1999 Aug 6;274(32):22770-4

EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase. Makino R, et al. **J Biol Chem** 1999 Mar 19;274(12):7714-23

Identification of enzymes responsible for the metabolism of heme in human platelets. Nowell SA, et al. **J Biol Chem** 1998 Dec 11;273(50):33342-6

Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. Pandey AV, et al. **J Biol Chem** 1999 Jul 2;274(27):19383-8

A common mechanism for blockade of heme polymerization by antimalarial quinolines. Sullivan DJ Jr, et al. **J Biol Chem** 1998 Nov 20;273(47):31103-7

Molecular characterization of a newly identified heme-binding protein induced during differentiation of urine erythroleukemia cells. Taketani S, et al. **J Biol Chem** 1998 Nov 20;273(47):31388-94

Rapid kinetics of tyrosyl radical formation and heme redox state changes in prostaglandin H synthase-1 and -2. Tsai AI, et al. **J Biol Chem** 1999 Jul 30;274(31):21695-700

Effect of the heme/heme oxygenase pathway on the relationship between salt consumption and blood pressure. dos Santos EA, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1965-9

Role of interleukin-1beta in the modulations of cytochrome P450 and heme metabolism in rat liver. Kudo S, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):601-7

Heme-binding by Drosophila retinoid- and fatty acid-binding glycoprotein (RFABG), a member of the proapolipophorin gene family. Duncan T, et al. **J Lipid Res** 1999 Jul;40(7):1222-8

Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. Wagener FA, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):416-23

Transmembrane topology of the two FhuB domains representing the hydrophobic components of bacterial ABC transporters involved in the uptake of siderophores, haem and vitamin B12. Groeger W, et al. **Microbiology** 1998 Oct;144 (Pt 10):2759-69

Multiple haem-utilization loci in Helicobacter pylori. Worst DJ, et al. **Microbiology** 1999 Mar;145 (Pt 3):681-8

Dual role for Hsc70 in the biogenesis and regulation of the heme-regulated kinase of the alpha subunit of eukaryotic translation initiation factor 2. Uma S, et al. **Mol Cell Biol** 1999 Sep;19(9):5861-71

Vibrio cholerae iron transport: haem transport genes are linked to one of two sets of tonB, exbB, exbD genes. Occhino DA, et al. **Mol Microbiol** 1998 Sep;29(6):1493-507

Colorless green ideas... [news; comment] Tobin M, et al. **Nat Biotechnol** 1999 Apr;17(4):333-4. Comment on: Nat Biotechnol 1999 Apr;17(4):379-84.

The crystal structure of HasA, a hemophore secreted by Serratia marcescens. Arnoux P, et al. **Nat Struct Biol** 1999 Jun;6(6):516-20

Crystal structure of human heme oxygenase-1. Schuller DJ, et al. **Nat Struct Biol** 1999 Sep;6(9):860-7

Haem detoxification by an insect [letter] Oliveira MF, et al. **Nature** 1999 Aug 5;400(6744):517-8

Structure of a biological oxygen sensor: a new mechanism for heme-driven signal transduction. Gong W, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15177-82

Heme transfer to the heme chaperone CcmE during cytochrome c maturation requires the CcmC protein, which may function independently of the ABC-transporter CcmAB. Schulz H, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6462-7

Structure of a cytochrome P450-redox partner electron-transfer complex. Sevrioukova IF, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1863-8

Effect of stabilising amino acids on the digestive absorption of heme and non-heme iron. Vaghefi N, et al. **Reprod Nutr Dev** 1998 Sep-Oct;38(5):559-66

Heme oxygenase inhibits nitric oxide synthase by degrading heme: a negative feedback regulation mechanism for nitric oxide production. Turcanu V, et al. **Transplant Proc** 1998 Dec;30(8):4184-5

[Photodissociation of oxygenated forms of native hemoglobin HbA and its isolated alpha- and beta-subunits, and kinetics of rebinding of molecular oxygen] Dzhagarov BM, et al. **Dokl Akad Nauk** 1999 May;366(1):121-4 **(Rus)**

PHARMACOLOGY

Heme arginate therapy for beta thalassemia: in vitro versus in vivo effects. Rund D, et al. **Acta Haematol** 1998; 100(2):82-4

Proteolytic degradation of heme-modified hepatic cytochromes P450: A role for phosphorylation, ubiquitination, and the 26S proteasome? Korsmeyer KK, et al. **Arch Biochem Biophys** 1999 May 1;365(1):31-44

PHYSIOLOGY

Heme initiates changes in the expression of a wide array of genes during the early erythroid differentiation stage. Zhu Y, et al. **Biochem Biophys Res Commun** 1999 Apr 29; 258(1):87-93

A novel endogenous antimalarial: Fe(II)-protoporphyrin IX alpha (heme) inhibits hematin polymerization to beta-hematin (malaria pigment) and kills malaria parasites. Monti D, et al. **Biochemistry** 1999 Jul 13;38(28):8858-63

Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Johnson RA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):1-14 (57 ref.)

Role of heme in intracellular trafficking of thyroperoxidase and involvement of H2O2 generated at the apical surface of thyroid cells in autocatalytic covalent heme binding. Fayadat L, et al. **J Biol Chem** 1999 Apr 9;274(15):10533-8

A new class of repression modules is critical for heme regulation of the yeast transcriptional activator Hap1. Hach A, et al. **Mol Cell Biol** 1999 Jun;19(6):4324-33

Chemoreceptor discharges and cytochrome redox changes of the rat carotid body: role of heme ligands. Lahiri S, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9427-32

THERAPEUTIC USE

The value of intravenous heme-albumin and plasmapheresis in reducing postoperative complications of orthotopic liver transplantation for erythropoietic protoporphyria. Reichheld JH, et al. **Transplantation** 1999 Mar 27; 67(6):922-8

HEME OXYGENASE (DECYCLIZING)

ANALYSIS

Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Nishie A, et al. **Clin Cancer Res** 1999 May;5(5):1107-13

Co-localization of carbon monoxide and nitric oxide synthesizing enzymes in the human urethral sphincter. Ho KM, et al. **J Urol** 1999 Jun;161(6):1968-72

Heme oxygenase activity determination by high-performance liquid chromatography. Ryter S, et al. **Methods Enzymol** 1999;300:322-36

ANTAGONISTS & INHIBITORS

Mechanism of inhibition of VIP-induced LES relaxation by heme oxygenase inhibitor zinc protoporphyrin IX. Rattan S, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G138-45

Effect of heme oxygenase inhibitors on soluble guanylyl cyclase activity. Serfass L, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):8-16

Modification by heme oxygenase inhibitor, tin protoporphyrin, of cellular differentiation of human myeloid leukemia K562 cell line. Koiso Y, et al. **Biol Pharm Bull** 1999 Apr;22(4):439-40

Role of carbon monoxide in L-glutamate-induced cardiovascular responses in nucleus tractus solitarius of conscious rats. Silva CC, et al. **Brain Res** 1999 Apr 10; 824(2):147-52

The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Tozer GM, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):849-53

Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. Mancuso C, et al. **J Neuroimmunol** 1999 Oct 29; 99(2):189-94

New approach to prevention of kernicterus. Cooke RW. **Lancet** 1999 May 29;353(9167):1814-5

Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase- deficient newborns [letter] Kaplan M, et al. **Pediatrics** 1999 Feb;103(2):536-7

Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Martinez JC, et al. **Pediatrics** 1999 Jan; 103(1):1-5

Zinc protoporphyrin/heme ratio for diagnosis of preanemic iron deficiency. Rettmer RL, et al. **Pediatrics** 1999 Sep; 104(3):e37

Heme oxygenase inhibitors transiently increase serum ferritin concentrations without altering other acute-phase reactants in man. Berglund L, et al. **Pharmacology** 1999 Jul;59(1):51-6

BIOSYNTHESIS

Hemoxygenase and nitric oxide synthase do not maintain human uterine quiescence during pregnancy. Barber A, et al. **Am J Pathol** 1999 Sep;155(3):831-40

Heme oxygenase-1 induction in skeletal muscle cells: hemin and sodium nitroprusside are regulators in vitro. Vesely MJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1087-94

Balloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injured rat carotid artery. Aizawa T, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):302-7

Human lymphocyte heme oxygenase 1 as a response biomarker to inorganic arsenic. Menzel DB, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):653-6

Induction of heme oxygenase-1 in the rat brain by kainic acid-mediated excitotoxicity: the dissociation of mRNA and protein expression in hippocampus. Nakaso K, et al. **Biochem Biophys Res Commun** 1999 May 27;259(1):91-6

Induction of heme oxygenase-1 as a response in sensing the signals evoked by distinct nitric oxide donors. Hara E, et al. **Biochem Pharmacol** 1999 Jul 15;58(2):227-36

Coordinate up-regulation of CYP1A1 and heme oxygenase-1 (HO-1) expression and modulation of delta-aminolevulinic acid synthase and tryptophan pyrrolase activities in pyridine-treated rats [published erratum appears in Biochem Pharmacol 1999 Oct 15;58(8):1379] Iba MM, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):723-34

Heme oxygenase isozymes in bone: induction of HO-1 mRNA following physiological levels of mechanical loading in vivo. Rawlinson SC, et al. **Bone** 1998 Nov; 23(5):433-6

Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Doi K, et al. **Br J Cancer** 1999 Aug;80(12):1945-54

Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Sammut IA, et al. **Br J Pharmacol** 1998 Dec; 125(7):1437-44

Oxidative stress response induced in rat primary hepatocyte monolayers by mechanical removal of adherent cells. Pillar TM, et al. **Cell Tissue Res** 1999 Feb;295(2):363-7

Induction of haem oxygenase contributes to the synthesis of pro-inflammatory cytokines in re-oxygenated rat macrophages: role of cGMP. Tamion F, et al. **Cytokine** 1999 May;11(5):326-33

Transcriptional regulation of the heme oxygenase 1 gene by pyrrolidine dithiocarbamate. Hartsfield CL, et al. **FASEB J** 1998 Dec;12(15):1675-82

Iron overload upregulates haem oxygenase 1 in the lung more rapidly than in other tissues. Anning PB, et al. **FEBS Lett** 1999 Mar 19;447(1):111-4

Fibre type specificity of haem oxygenase-1 induction in rat skeletal muscle. Vesely MJ, et al. **FEBS Lett** 1999 Sep 17; 458(2):257-60

A chromatographic assay for heme oxygenase activity in cultured human cells: application to artificial heme oxygenase overexpression. Ryter S, et al. **Free Radic Biol Med** 1998 Apr;24(6):959-71

Involvement of the tyrosine phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium arsenite, and cadmium chloride. Masuya Y, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):628-33

Carbon monoxide stimulates the apical 70-pS K+ channel of the rat thick ascending limb. Liu H, et al. **J Clin Invest** 1999 Apr;103(7):963-70

Heme oxygenase-1 gene induction as an intrinsic regulation against delayed cerebral vasospasm in rats. Suzuki H, et al. **J Clin Invest** 1999 Jul;104(1):59-66

Induction of metallothionein and heme oxygenase in rats after inhalation of endotoxin. Hur T, et al. **J Toxicol Environ Health** 1999 Feb 12;56(3):183-203

Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats. Seki T, et al. **Life Sci** 1999;65(10):1077-86

Hemozoin stability and dormant induction of heme oxygenase in hemozoin-fed human monocytes. Schwarzer E, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):61-72

Expression of heme oxygenase-1 mediated by non-NMDA and metabotropic receptors in glial cells: possible involvement of reactive oxygen species production and protein kinase C activation. Matsuoka Y, et al. **Neuropharmacology** 1999 Jun;38(6):825-34

Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Kitamura Y, et al. **Neurosci Lett** 1999 Mar 5;262(2):129-32

Heme oxygenase induction mediates the photoimmunoprotective activity of UVA radiation in the mouse. Reeve VE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9317-21

Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32). Woo J, et al. **Transpl Immunol** 1998 Jun;6(2):84-93

Cytoprotective role of antioxidant stress protein induced by adenosine A1 receptor antagonist in rat heart ischemic injury. Katori M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1016-7

BLOOD

Expression of the antioxidant stress protein heme oxygenase-1 (HO-1) in human leukocytes. Niess AM, et al. **Free Radic Biol Med** 1999 Jan;26(1-2):184-92

CHEMISTRY

Crystallization and preliminary X-ray diffraction studies on the water soluble form of rat heme oxygenase-1 in complex with heme. Omata Y, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1017-9

Assignment of the heme axial ligand(s) for the ferric myoglobin (H93G) and heme oxygenase (H25A) cavity mutants as oxygen donors using magnetic circular dichroism. Pond AE, et al. **Biochemistry** 1999 Jun 8; 38(23):7601-8

Molecular oxygen oxidizes the porphyrin ring of the ferric alpha-hydroxyheme in heme oxygenase in the absence of reducing equivalent. Migita CT, et al. **Biochim Biophys Acta** 1999 Jul 13;1432(2):203-13

Crystallization and preliminary X-ray diffraction analysis of a recombinant bacterial heme oxygenase (Hmu O) from

Corynebacterium diphtheriae. Chu GC, et al. **J Struct Biol** 1999 Jun 15;126(2):171–4
Crystal structure of human heme oxygenase-1. Schuller DJ, et al. **Nat Struct Biol** 1999 Sep;6(9):860–7
Crystallization of recombinant human heme oxygenase-1. Schuller DJ, et al. **Protein Sci** 1998 Aug;7(8):1836–8

DEFICIENCY

Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. Yachie A, et al. **J Clin Invest** 1999 Jan;103(1):129–35

GENETICS

TNF-alpha and IL-1alpha induce heme oxygenase-1 via protein kinase C, Ca2+, and phospholipase A2 in endothelial cells. Terry CM, et al. **Am J Physiol** 1999 May; 276(5 Pt 2):H1493–501
Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Yang L, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):L127–33
Iron regulates hyperoxia-dependent human heme oxygenase 1 gene expression in pulmonary endothelial cells. Fogg S, et al. **Am J Respir Cell Mol Biol** 1999 Apr;20(4):797–804
Pineal nitric oxide synthase, but not heme oxygenase, mRNA is suppressed by continuous exposure to light. Jacobs RA, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):264–72
Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats [see comments] Lyoumi S, et al. **Crit Care Med** 1998 Oct;26(10):1683–9. Comment in: Crit Care Med 1998 Oct;26(10):1630–1.
Heme oxygenase-1 gene expression as a stress index to ocular irritation. Braunstein SG, et al. **Curr Eye Res** 1999 Aug; 19(2):115–22
Developmental changes of gene expression in heme metabolic enzymes in rat placenta. Ihara N, et al. **FEBS Lett** 1998 Nov 13;439(1–2):163–7
Modulation of the UVA activation of haem oxygenase, collagenase and cyclooxygenase gene expression by epigallocatechin in human skin cells. Soriani M, et al. **FEBS Lett** 1998 Nov 20;439(3):253–7
Cyclooxygenase dependent release of heme from microsomal hemeproteins correlates with induction of heme oxygenase 1 transcription in human fibroblasts. Kvam E, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):511–7
The identification and expression of heme oxygenase-2 alternative transcripts in the mouse. Gibbs L, et al. **Gene** 1998 Oct 23;221(2):171–7
Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Fernandez M, et al. **Hepatology** 1999 Jun;29(6):1672–9
Retinal pigment epithelial cell-based gene therapy against hemoglobin toxicity. Abraham NG, et al. **Int J Mol Med** 1998 Apr;1(4):657–63
Linoleyl hydroperoxide transcriptionally upregulates heme oxygenase-1 gene expression in human renal epithelial and aortic endothelial cells. Agarwal A, et al. **J Am Soc Nephrol** 1998 Nov;9(11):1990–7
Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. Alam J, et al. **J Biol Chem** 1999 Sep 10;274(37):26071–8
Upregulation of human heme oxygenase gene expression by Ets-family proteins. Deramaudt BM, et al. **J Cell Biochem** 1999 Mar 1;72(3):311–21
Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. Otterbein LE, et al. **J Clin Invest** 1999 Apr; 103(7):1047–54
Nitric oxide mediates the lipopolysaccharide dependent upregulation of the heme oxygenase-1 gene expression in cultured rat Kupffer cells. Immenschuh S, et al. **J Hepatol** 1999 Jan;30(1):61–9
Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. Panahian N, et al. **J Neurochem** 1999 Mar; 72(3):1187–203
Suppression of heme oxygenase-1 mRNA expression by interferon-gamma in human glioblastoma cells. Takahashi K, et al. **J Neurochem** 1999 Jun;72(6):2356–61
The expression of heme oxygenase-1 gene responded to oxidative stress produced by phorone, a glutathione depletor, in the rat liver; the relevance to activation of c-jun n-terminal kinase. Oguro T, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):773–8
Nitric oxide induces heme oxygenase-1 gene expression in mesangial cells. Datta PK, et al. **Kidney Int** 1999 May; 55(5):1734–9
Quantitation of heme oxygenase (HO-1) copies in human tissues by competitive RT/PCR. Abraham NG. **Methods Mol Biol** 1998;108:199–209
Enhanced expression and localization of heme oxygenase-1 during recovery phase of porcine stunned myocardium. Sharma HS, et al. **Mol Cell Biochem** 1999 Jun; 196(1–2):133–9
Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Hancock WW, et al. **Nat Med** 1998 Dec;4(12):1392–6
Heme oxygenase: protective gene or Trojan horse [news] Platt JL, et al. **Nat Med** 1998 Dec;4(12):1364–5
The Arabidopsis photomorphogenic mutant hy1 is deficient in phytochrome chromophore biosynthesis as a result of a mutation in a plastid heme oxygenase. Muramoto T, et al. **Plant Cell** 1999 Mar;11(3):335–48

IMMUNOLOGY

Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous [editorial; comment] Deutschman CS. **Crit Care Med** 1998 Oct;26(10):1630–1 (22 ref.). Comment on: Crit Care Med 1998 Oct;26(10):1683–9.
Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats [see comments] Lyoumi S, et al. **Crit Care Med** 1998 Oct;26(10):1683–9. Comment in: Crit Care Med 1998 Oct;26(10):1630–1.
Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32). Woo J, et al. **Transpl Immunol** 1998 Jun;6(2):84–93

METABOLISM

P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson's disease. Riedl AG, et al. **Adv Neurol** 1999;80:271–86 (170 ref.)
Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Frank RN, et al. **Am J Ophthalmol** 1999 Jun; 127(6):694–709
Carbon monoxide provides protection against hyperoxic lung injury. Otterbein LE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L688–94
Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. Suttner DM, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L443–51
Determination of heme oxygenase activity in murine macrophages for studying oxidative stress inhibitors. Turcanu V, et al. **Anal Biochem** 1998 Oct 15;263(2):251–3
Peroxynitrite induces haem oxygenase-1 in vascular endothelial cells: a link to apoptosis. Foresti R, et al. **Biochem J** 1999 May 1;339 (Pt 3):729–36
Replacement of the proximal histidine iron ligand by a cysteine or tyrosine converts heme oxygenase to an oxidase. Liu Y, et al. **Biochemistry** 1999 Mar 23;38(12):3733–43
Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Morgan D, et al. **Brain Res** 1998 Oct 12;808(1):110–2
Heme oxygenase-1 expression in oral squamous cell carcinoma as involved in lymph node metastasis. Tsuji MH, et al. **Cancer Lett** 1999 Apr 26;138(1–2):53–9
Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide? Siow RC, et al. **Cardiovasc Res** 1999 Feb;41(2):385–94 (110 ref.)
Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. Henningsson R, et al. **Diabetes** 1999 Jan;48(1):66–76
Interaction of heme oxygenase-2 with nitric oxide donors. Is the oxygenase an intracellular 'sink' for NO? Ding Y, et al. **Eur J Biochem** 1999 Sep;264(3):854–61
Acute phencyclidine neurotoxicity in rat forebrain: induction of haem oxygenase-1 and attenuation by the antioxidant dimethylthiourea. Rajdev S, et al. **Eur J Neurosci** 1998 Dec;10(12):3840–52
Carbon monoxide-mediated alterations in paracellular permeability and vesicular transport in acetaminophen-treated perfused rat liver. Mori M, et al. **Hepatology** 1999 Jul;30(1):160–8
Expression of antioxidant protective proteins in the rat retina during prenatal and postnatal development. Chen W, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):744–51
Heme degradation as catalyzed by a recombinant bacterial heme oxygenase (Hmu O) from Corynebacterium diphtheriae. Chu GC, et al. **J Biol Chem** 1999 Jul 23; 274(30):21319–25
Identification of enzymes responsible for the metabolism of heme in human platelets. Nowell SA, et al. **J Biol Chem** 1998 Dec 11;273(50):33342–6
Ferric alpha-hydroxyheme bound to heme oxygenase can be converted to verdoheme by dioxygen in the absence of added reducing equivalents. Sakamoto H, et al. **J Biol Chem** 1999 Jun 25;274(26):18196–200
Effect of the heme/heme oxygenase pathway on the relationship between salt consumption and blood pressure. dos Santos EA, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1965–9
Chamber-specific regulation of heme oxygenase-1 (heat shock protein 32) in right-sided congestive heart failure. Raju VS, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1581–9
Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. Le WD, et al. **J Neurosci Res** 1999 Jun 15;56(6):652–8
Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. Wagener FA, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):416–23
Induction of heme oxygenase-1 with hemoglobin depresses vasoreactivity in rat aorta. Gaine SP, et al. **J Vasc Res** 1999 Mar-Apr;36(2):114–9
Decrease in hepatic CYP2C11 mRNA and increase in heme oxygenase activity after intracerebroventricular injection of bacterial endotoxin. Shimamoto Y, et al. **J Vet Med Sci** 1999 Jun;61(6):609–13
Crystal structure of human heme oxygenase-1. Schuller DJ, et al. **Nat Struct Biol** 1999 Sep;6(9):860–7
Pharmacologic effects of the red blood cell substitutes cross-linked and non-cross-linked hemoglobins on hematopoiesis in rabbits. Lutton JD, et al. **Pharmacology** 1999 Jun;58(6):319–24
Heme oxygenase and nitric oxide synthase in the placenta of the guinea-pig during gestation. Odrcich MJ, et al. **Placenta** 1998 Sep;19(7):509–16
The Arabidopsis thaliana HY1 locus, required for phytochrome-chromophore biosynthesis, encodes a protein related to heme oxygenases. Davis SJ, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6541–6
Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Doré S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2445–50
Carbon monoxide, a cyclic GMP-related messenger, involved in hypoxic bronchodilation in vivo. Cardell LO, et al. **Pulm Pharmacol Ther** 1998;11(4):309–15
Nitric oxide synthase inhibition by haem oxygenase decreases macrophage nitric-oxide-dependent cytotoxicity: a negative feedback mechanism for the regulation of nitric oxide production. Turcanu V, et al. **Res Immunol** 1998 Sep-Oct;149(7–8):741–4
Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Horváth I, et al. **Thorax** 1998 Aug;53(8):668–72
Induction of stress proteins in rat cardiac myocytes by antimony. Snawder JE, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):91–7
Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Magee JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1194
Glutamine-induced heme oxygenase-1 protects intestines and hearts from warm ischemic injury. Tamaki T, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1018–9
Heme oxygenase inhibits nitric oxide synthase by degrading heme: a negative feedback regulation mechanism for nitric oxide production. Turcanu V, et al. **Transplant Proc** 1998 Dec;30(8):4184–5

PHARMACOLOGY

Protective effects of heme oxygenase-1 against oxidant-induced injury in the cultured human tracheal epithelium. Yamada N, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):428–35

PHYSIOLOGY

Carbon monoxide: from toxin to endogenous modulator of cardiovascular functions. Johnson RA, et al. **Braz J Med Biol Res** 1999 Jan;32(1):1–14 (57 ref.)
Protective effects of heme oxygenase-1 in acute lung injury. Otterbein LE, et al. **Chest** 1999 Jul;116(1 Suppl):61S–63S
Upregulation of human heme oxygenase gene expression by Ets-family proteins. Deramaudt BM, et al. **J Cell Biochem** 1999 Mar 1;72(3):311–21
Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. Yet SF, et al. **J Clin Invest** 1999 Apr;103(8):R23–9
Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. Schipper HM, et al. **J Neurochem** 1999 May;72(5):1802–11
Heme oxygenase: protective gene or Trojan horse [news] Platt JL, et al. **Nat Med** 1998 Dec;4(12):1364–5

HEME SYNTHETASE see **FERROCHELATASE**

HEMEPROTEINS

Characterization of acute reversible systemic hypertension in a model of heme protein-induced renal injury. Warden DH, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F58–65
[Lipid peroxidation induced by hemoproteins in terms of forensic medicine] Iwase H. **Nippon Hoigaku Zasshi** 1998 Oct;52(5):306–10 (34 ref.) **(Jpn)**

ANALYSIS

Chemiluminescence detection of heme proteins separated by capillary isoelectric focusing. Hashimoto M, et al. **J Chromatogr A** 1999 Aug 13;852(2):597–601
Splenic and hepatic hemozoin in mice after malaria parasite clearance. Levesque MA, et al. **J Parasitol** 1999 Jun; 85(3):570–3
Laveran remembered: malaria haemozoin in leucocytes [letter] Lawrence C. **Lancet** 1999 May 29;353(9167):1852

CHEMISTRY

Dynamic light-scattering and preliminary crystallographic studies of the sensor domain of the haem-based oxygen sensor FixL from Rhizobium meliloti. Miyatake H, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1215–8
Use of evolutionary factor analysis in the spectroelectrochemistry of Escherichia coli sulfite reductase hemoprotein and a Mo/Fe/S cluster. Keesey RL,

et al. **Anal Chem** 1999 May 1;71(9):1744–52
Identification of the veratryl alcohol binding site in lignin peroxidase by site-directed mutagenesis. Ambert-Balay K, et al. **Biochem Biophys Res Commun** 1998 Oct 9; 251(1):283–6
Reversible and irreversible hemichrome generation by the oxygenation of nitrosylmyoglobin. Arnold EV, et al. **Biochemistry** 1999 Apr 13;38(15):4750–6
Binding of pyridoxal 5'-phosphate to the heme protein human cystathionine beta-synthase. Kery V, et al. **Biochemistry** 1999 Mar 2;38(9):2716–24
Heme speciation in alkaline ferric FixL and possible tyrosine involvement in the signal transduction pathway for regulation of nitrogen fixation. Lukat-Rodgers GS, et al. **Biochemistry** 1998 Sep 29;37(39):13543–52
Resonance Raman evidence for a novel charge relay activation mechanism of the CO-dependent heme protein transcription factor CooA. Vogel KM, et al. **Biochemistry** 1999 Mar 2;38(9):2679–87
Cytochrome c" from the obligate methylotroph Methylophilus methylotrophus, an unexpected homolog of sphaeroides heme protein from the phototroph Rhodobacter sphaeroides. Klarskov K, et al. **Biochim Biophys Acta** 1999 May 26;1412(1):47–55
Determination of zero-field splitting and evidence for the presence of charge-transfer transitions in the Soret region of high-spin ferric hemoproteins obtained from an analysis of low-temperature magnetic circular dichroism. Oganesyan VS, et al. **Biochim Biophys Acta** 1998 Dec 8; 1429(1):163–75
Effect of redox state on unfolding energetics of heme proteins. Wittung-Stafshede P. **Biochim Biophys Acta** 1999 Jul 13;1432(2):401–5
Spectroelectrochemistry of heme proteins: effects of active-site heterogeneity on Nernst plots. Taboy CH, et al. **Bioelectrochem Bioenerg** 1999 Feb;48(1):79–86
Pentacoordinate hemin derivatives in sodium dodecyl sulfate micelles: model systems for the assignment of the fifth ligand in ferric heme proteins. Boffi A, et al. **Biophys J** 1999 Aug;77(2):1143–9
13C- and 57Fe-NMR studies of the Fe–C–O unit of heme proteins and synthetic model compounds in solution: comparison with IR vibrational frequencies and X-ray structural data. Kalodimos CG, et al. **Biospectroscopy** 1998; 4(5 Suppl):S57–69
800 MHz 1H NMR solution structure refinement of oxidized cytochrome c7 from Desulfuromonas acetoxidans. Assfalg M, et al. **Eur J Biochem** 1998 Sep 1;256(2):261–70
Heme-regulated eIF-2alpha kinase purifies as a hemoprotein. Chefalo PJ, et al. **Eur J Biochem** 1998 Dec 1;258(2):820–30
Active site topology of artificial peroxidase-like hemoproteins based on antibodies constructed from a specifically designed ortho-carboxy-substituted tetraarylporphyrin. De Lauzon S, et al. **Eur J Biochem** 1998 Oct 1;257(1):121–30
A cooperative model for protonmotive heme-copper oxidases. The role of heme a in the proton pump of cytochrome c oxidase. Papa S, et al. **FEBS Lett** 1998 Nov 13;439(1-2):1–8
Redox-controlled ligand exchange of the heme in the CO-sensing transcriptional activator CooA. Aono S, et al. **J Biol Chem** 1998 Oct 2;273(40):25757–64
The heme environment in barley hemoglobin. Das TK, et al. **J Biol Chem** 1999 Feb 12;274(7):4207–12
Iron coordination structures of oxygen sensor FixL characterized by Fe K-edge extended x-ray absorption fine structure and resonance raman spectroscopy. Miyatake H, et al. **J Biol Chem** 1999 Aug 13;274(33):23176–84
The heme prosthetic group of lactoperoxidase. Structural characteristics of heme 1 and heme 1-peptides. Rae TD, et al. **J Biol Chem** 1998 Oct 23;273(43):27968–77
Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain. No evidence for a non-heme metal requirement for catalysis. Rodriguez-Crespo I, et al. **J Biol Chem** 1999 Jul 30; 274(31):21617–24
Characterization of a new hemoprotein in the yeast Saccharomyces cerevisiae. Sartori G, et al. **J Biol Chem** 1999 Feb 19;274(8):5032–7
Hemepeptide models for hemoproteins: the behavior of N-acetylmicroperoxidase-11 in aqueous solution. Marques HM, et al. **J Inorg Biochem** 1999 Jul 15;75(4):281–91
Crystallographic characterization of a stress-induced multifunctional protein, rat HBP-23. Hirotsu S, et al. **J Struct Biol** 1999 Jun 1;126(1):80–3
Photoacoustic calorimetry of proteins. McLean MA, et al. **Methods Enzymol** 1998;295:316–30
Peroxynitrite reaction with heme proteins. Mehl M, et al. **Nitric Oxide** 1999;3(2):142–52
Structure of a biological oxygen sensor: a new mechanism for heme-driven signal transduction. Gong W, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15177–82
Applications of electron paramagnetic resonance spectroscopy to study interactions of iron proteins in cells with nitric oxide. Cammack R, et al. **Spectrochim Acta A Mol Biomol Spectrosc** 1998 Dec; 54A(14):2393–402
The crystal structure of nitrophorin 4 at 1.5 A resolution: transport of nitric oxide by a lipocalin-based heme protein. Andersen JF, et al. **Structure** 1998 Oct 15;6(10):1315–27

DRUG EFFECTS

Occupation of the cytochrome P450 substrate pocket by diverse compounds at general anesthesia concentrations. LaBella FS, et al. **Eur J Pharmacol** 1998 Oct 2; 358(2):177–85

GENETICS

Occurrence of satA and vgb genes in streptogramin-resistant Enterococcus faecium isolates of animal and human origins in the Netherlands [letter] Jensen LB, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3330–1
Identification of the veratryl alcohol binding site in lignin peroxidase by site-directed mutagenesis. Ambert-Balay K, et al. **Biochem Biophys Res Commun** 1998 Oct 9; 251(1):283–6
Recognition of target DNA and transcription activation by the CO-sensing transcriptional activator CooA. Aono S, et al. **Biochem Biophys Res Commun** 1999 Aug 2; 261(2):270–5
Response of the NAD(P)H-oxidising flavohaemoglobin (Hmp) to prolonged oxidative stress and implications for its physiological role in Escherichia coli. Anjum MF, et al. **FEMS Microbiol Lett** 1998 Sep 15;166(2):219–23
Up-regulation of heme-binding protein 23 (HBP23) gene expression by lipopolysaccharide is mediated via a nitric oxide-dependent signaling pathway in rat Kupffer cells. Immenschuh S, et al. **Hepatology** 1999 Jul;30(1):118–27
Regulation of hmp gene transcription in Mycobacterium tuberculosis: effects of oxygen limitation and nitrosative and oxidative stress. Hu Y, et al. **J Bacteriol** 1999 Jun; 181(11):3486–93
Regulation of the Salmonella typhimurium flavohemoglobin gene. A new pathway for bacterial gene expression in response to nitric oxide [published erratum appears in J Biol Chem 1999 Feb 5;274(6):3918] Crawford MJ, et al. **J Biol Chem** 1998 Dec 18;273(51):34028–32
Molecular characterization of a newly identified heme-binding protein induced during differentiation of urine erythroleukemia cells. Taketani S, et al. **J Biol Chem** 1998 Nov 20;273(47):31388–94
Purification and cloning of the salivary nitrophorin from the hemipteran Cimex lectularius. Valenzuela JG, et al. **J Exp Biol** 1998 Sep;201 (Pt 18):2659–64
A novel mechanism for upregulation of the Escherichia coli K-12 hmp (flavohaemoglobin) gene by the 'NO releaser', S-nitrosoglutathione: nitrosation of homocysteine and modulation of MetR binding to the glyA-hmp intergenic region. Membrillo-Hernández J, et al. **Mol Microbiol** 1998 Aug;29(4):1101–12

ISOLATION & PURIFICATION

Salivary heme proteins distinguish Rhodnius prolixus from Rhodnius robustus (Hemiptera: Reduviidae: Triatominae). Soares RP, et al. **Acta Trop** 1998 Nov 30;71(3):285–91
Purification and cloning of the salivary nitrophorin from the hemipteran Cimex lectularius. Valenzuela JG, et al. **J Exp Biol** 1998 Sep;201 (Pt 18):2659–64

METABOLISM

Formation of long-lived radicals on proteins by radical transfer from heme enzymes--a common process? Ostdal H, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):105–12
Uptake of Rhodnius heme-binding protein (RHBP) by the ovary of Rhodnius prolixus. Machado EA, et al. **Arch Insect Biochem Physiol** 1998;39(4):133–43
Recognition of target DNA and transcription activation by the CO-sensing transcriptional activator CooA. Aono S, et al. **Biochem Biophys Res Commun** 1999 Aug 2; 261(2):270–5
Presence and formation of heme and occurrence of certain heme proteins in the filarial parasite Setaria digitata. Kumar RA, et al. **Biochem Biophys Res Commun** 1998 Dec 9; 253(1):49–52
Imidazole is a sensitive probe of steric hindrance in the distal pockets of oxygen-binding heme proteins. Mansy SS, et al. **Biochemistry** 1998 Sep 8;37(36):12452–7
Identification of two important heme site residues (cysteine 75 and histidine 77) in CooA, the CO-sensing transcription factor of Rhodospirillum rubrum. Shelver D, et al. **Biochemistry** 1999 Mar 2;38(9):2669–78
Rational design of a functional metalloenzyme: introduction of a site for manganese binding and oxidation into a heme peroxidase. Wilcox SK, et al. **Biochemistry** 1998 Dec 1; 37(48):16853–62
Nitric oxide and iron proteins. Cooper CE. **Biochim Biophys Acta** 1999 May 5;1411(2-3):290–309 (136 ref.)
Kinetic analysis on nitric oxide binding of recombinant Prolixin-S, a nitric oxide transport protein from the bloodsucking bug, Rhodnius prolixus. Kaneko Y, et al. **Biochim Biophys Acta** 1999 May 18;1431(2):492–9
Interactions of nitric oxide with hemoproteins: roles of nitric oxide in mitochondria. Henry Y, et al. **Cell Mol Life Sci** 1999 Jul;55(8-9):1003–14 (131 ref.)
Biological sensors: More than one way to sense oxygen. Pellequer JL, et al. **Curr Biol** 1999 Jun 3;9(11):R416–8 (12 ref.)
Phospholipid bound to the flavohemoprotein from Alcaligenes eutrophus. Ollesch G, et al. **Eur J Biochem** 1999 Jun;262(2):396–405
Studies of the reactivity of artificial peroxidase-like hemoproteins based on antibodies elicited against a specifically designed ortho-carboxy substituted tetraarylporphyrin. de Lauzon S, et al. **FEBS Lett** 1999 Jan 25;443(2):229–34
Anoxic function for the Escherichia coli flavohaemoglobin (Hmp): reversible binding of nitric oxide and reduction to nitrous oxide. Kim SO, et al. **FEBS Lett** 1999 Feb 26; 445(2-3):389–94
Response of the NAD(P)H-oxidising flavohaemoglobin (Hmp) to prolonged oxidative stress and implications for its physiological role in Escherichia coli. Anjum MF, et al. **FEMS Microbiol Lett** 1998 Sep 15;166(2):219–23
The CcmE protein from Escherichia coli is a haem-binding protein. Reid E, et al. **FEMS Microbiol Lett** 1998 Sep 15; 166(2):369–75
Calcium is required for quasi-lipoxygenase activity of hemoproteins. Iwase H, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):943–52
Cyclooxygenase dependent release of heme from microsomal hemeproteins correlates with induction of heme oxygenase 1 transcription in human fibroblasts. Kvam E, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):511–7
Endocytosis by the corneal endothelium. I. Regulation of binding and transport of hemeproteins and peroxidase-conjugated lectins across the tissue. Gordon SR, et al. **Histochem Cell Biol** 1998 Sep;110(3):251–62
Molecular characterization of the hemin uptake locus (hmu) from Yersinia pestis and analysis of hmu mutants for hemin and hemoprotein utilization. Thompson JM, et al. **Infect Immun** 1999 Aug;67(8):3879–92
The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a "Nitric oxide Releaser," and paraquat and is essential for transcriptional responses to oxidative stress. Membrillo-Hernández J, et al. **J Biol Chem** 1999 Jan 8;274(2):748–54
Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain. No evidence for a non-heme metal requirement for catalysis. Rodriguez-Crespo I, et al. **J Biol Chem** 1999 Jul 30; 274(31):21617–24
A common mechanism for blockade of heme polymerization by antimalarial quinolines. Sullivan DJ Jr, et al. **J Biol Chem** 1998 Nov 20;273(47):31103–7
Molecular characterization of a newly identified heme-binding protein induced during differentiation of urine erythroleukemia cells. Taketani S, et al. **J Biol Chem** 1998 Nov 20;273(47):31388–94
Novel nitric oxide-liberating heme proteins from the saliva of bloodsucking insects. Walker FA, et al. **Met Ions Biol Syst** 1999;36:621–63 (189 ref.)
Hemozoin stability and dormant induction of heme oxygenase in hemozoin-fed human monocytes. Schwarzer E, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):61–72
Structure of a biological oxygen sensor: a new mechanism for heme-driven signal transduction. Gong W, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15177–82
Nitrosative stress: metabolic pathway involving the flavohemoglobin. Hausladen A, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14100–5
Heme transfer to the heme chaperone CcmE during cytochrome c maturation requires the CcmC protein, which may function independently of the ABC-transporter CcmAB. Schulz H, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6462–7
Redox-dependent binding of CO to heme protein controls P(O2)-sensitive chemoreceptor discharge of the rat carotid body. Lahiri S, et al. **Respir Physiol** 1999 Apr 1; 115(2):169–77
The crystal structure of nitrophorin 4 at 1.5 A resolution: transport of nitric oxide by a lipocalin-based heme protein. Andersen JF, et al. **Structure** 1998 Oct 15;6(10):1315–27

PHARMACOLOGY

Neutrophils and monocytes from subjects with the Mediterranean G6PD variant: effect of Plasmodium falciparum hemozoin on G6PD activity, oxidative burst and cytokine production. Mordmüller B, et al. **Eur Cytokine Netw** 1998 Sep;9(3):239–45

RADIATION EFFECTS

The photodynamic and non-photodynamic actions of porphyrins. Afonso SG, et al. **Braz J Med Biol Res** 1999 Mar;32(3):255–66 (56 ref.)

HEMERALOPIA see **VISION DISORDERS**

HEMERYTHRIN

ANALOGS & DERIVATIVES

Identification of a gene for a rubrerythrin/nigerythrin-like protein in Spirillum volutans by using amino acid sequence data from mass spectrometry and NH2-terminal sequencing. Alban PS, et al. **J Appl Microbiol** 1998 Nov; 85(5):875–82

CHEMISTRY

EPR properties of mixed-valent mu-oxo and mu-hydroxo dinuclear iron complexes produced by radiolytic reduction at 77 K. Davydov RM, et al. **J Biol Inorg Chem** 1999 Jun;

4(3):292–301

HEMI-FONTAN PROCEDURE see **FONTAN PROCEDURE**

HEMIANOPSIA

COMPLICATIONS

Monocular band atrophy [letter] Lee AG. **J Neuroophthalmol** 1999 Sep;19(3):217

[Headaches, vomiting and left homonymous lateral hemianopsia in a 25-year-old man] Mas JL, et al. **Rev Neurol (Paris)** 1999 Feb;155(2):158–64 **(Fre)**

DIAGNOSIS

The ophthalmology of internal carotid artery dissection. Kerty E. **Acta Ophthalmol Scand** 1999 Aug;77(4):418–21

The association of visual field deficits and visuo-spatial neglect in acute right-hemisphere stroke patients. Cassidy TP, et al. **Age Ageing** 1999 May;28(3):257–60

Traumatic cataract presenting with unilateral nasal hemianopsia. Karp CL, et al. **J Cataract Refract Surg** 1999 Sep;25(9):1302–3

To see better to the left when looking more to the right: effects of gaze direction and frames of spatial coordinates in unilateral neglect. Vuilleumier P, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):75–82

Line bisection in hemianopia [letter; comment] Mark VW. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):122–3. Comment on: J Neurol Neurosurg Psychiatry 1998 May;64(5):660–2.

When fighting makes you see black holes instead of stars. Kosmorsky G, et al. **J Neuroophthalmol** 1998 Dec; 18(4):255–7

Usefulness of visual field norms [letter] Williams TD. **Ophthalmologica** 1999;213(4):276

ETIOLOGY

Macular preservation with bilateral visual field defect caused by embolic occlusion of the posterior cerebral arteries [letter] Silani V, et al. **J Neurol** 1999 Jan;246(1):55–7

When the left brain is not right the right brain may be left: report of personal experience of occipital hemianopia. Cole M. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):169–73

Hemianopsia related to dissection of the internal carotid artery. Bourcier-Bareil F, et al. **J Neuroophthalmol** 1999 Jun;19(2):136–9

Homonymous hemianopsia due to a dural cavernous hemangioma. Lee AG, et al. **J Neuroophthalmol** 1998 Dec; 18(4):250–4

Cerebral metastasis presenting with altitudinal field defect. Newsom RS, et al. **J Neuroophthalmol** 1999 Mar;19(1):10–1

Patterns of hysterical hemianopia. Keane JR. **Neurology** 1998 Oct;51(4):1230–1

[Bilateral homonymous hemianopsia with atrial fibrillation] Yamaji K, et al. **Nippon Ronen Igakkai Zasshi** 1998 Sep; 35(9):691–4 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Retinal nerve fiber layer thickness within the area of apparently normal visual field in normal-tension glaucoma with hemifield defect. Reyes RD, et al. **J Glaucoma** 1998 Oct;7(5):329–35

PHYSIOPATHOLOGY

Functional hemianopias on Humphrey visual field analysis. Assi A, et al. **Acta Ophthalmol Scand** 1998 Oct;76(5):620–2

Visual perception of motion, luminance and colour in a human hemianope. Morland AB, et al. **Brain** 1999 Jun;122 (Pt 6):1183–98

'Saccadic strategies in children with hemianopia' [letter; comment] Coats DK, et al. **Dev Med Child Neurol** 1999 Jun;41(6):429–30. Comment on: Dev Med Child Neurol 1998 Sep;40(9):626–30.

Spectral sensitivity in hemianopic macaque monkeys. Cowey A, et al. **Eur J Neurosci** 1999 Jun;11(6):2114–20

Visual search and visual target detection in patients with infarctions of the left or right posterior or the right middle brain artery. Hildebrandt H, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):94–107

When the left brain is not right the right brain may be left: report of personal experience of occipital hemianopia. Cole M. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):169–73

Activation of the remaining hemisphere following stimulation of the blind hemifield in hemispherectomized subjects. Bittar RG, et al. **Neuroimage** 1999 Sep;10(3 Pt 1):339–46

Spatial representation in the normal visual field: a study of hemifield line bisection. Nielsen KE, et al. **Neuropsychologia** 1999 Mar;37(3):267–77

Dissociation between recency and span: neuropsychological and experimental evidence. Della Sala S, et al. **Neuropsychology** 1998 Oct;12(4):533–45

Investigating form and colour perception in blindsight using an interference task. Danckert J, et al. **Neuroreport** 1998 Sep 14;9(13):2919–25

PSYCHOLOGY

Visual search and visual target detection in patients with infarctions of the left or right posterior or the right middle brain artery. Hildebrandt H, et al. **J Clin Exp Neuropsychol** 1999 Feb;21(1):94–107

Patterns of hysterical hemianopia. Keane JR. **Neurology** 1998 Oct;51(4):1230–1

REHABILITATION

Functional disability and rehabilitation outcome in right hemisphere damaged patients with and without unilateral spatial neglect. Katz N, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):379–84

HEMIBODY IRRADIATION

see related
WHOLE-BODY IRRADIATION

Concurrent partial body radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. Sharp JG, et al. **J Hematother** 1998 Aug;7(4):343–9

HEMICRANIA see **MIGRAINE**

HEMIFACIAL MICROSOMIA see **FACIAL ASYMMETRY**

HEMIFACIAL SPASM

COMPLICATIONS

Hemifacial spasm associated with Marfan's syndrome: a case report. Nagatani T, et al. **Neurosurg Rev** 1998;21(2–3):152–4

Unilateral glaucomatous damage in a patient with hemifacial spasm. Killer HE, et al. **Ophthalmologica** 1999;213(4):273–5

[Cochleovestibular disorders associated with hemifacial spasm: an outcome after microvascular decompression of the facial nerve] Thai Van H, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Feb;115(1):9–18 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Prediction of vertebral artery compression in patients with hemifacial spasm using oblique sagittal MR imaging. Nagaseki Y, et al. **Acta Neurochir (Wien)** 1998; 140(6):565–71

Vascular loop and hemifacial spasm. Palacios E, et al. **Ear Nose Throat J** 1999 Jul;78(7):470

DRUG THERAPY

Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias. Mauriello JA Jr, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):627–31

Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm. Chang LB, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jan;62(1):1–5

Gabapentin as treatment for hemifacial spasm. Bandini F, et al. **Eur Neurol** 1999 Jul;42(1):49–51

Hemifacial spasm: clinical findings and treatment. Wang A, et al. **Muscle Nerve** 1998 Dec;21(12):1740–7

Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Tan AK. **Singapore Med J** 1998 Sep;39(9):403–5

[Hemifacial spasm and its treatment with botulinum toxin] Gouider-Khouja N, et al. **Tunis Med** 1999 Jan;77(1):41–4 **(Fre)**

[Long-term treatment with botulinum toxin: dosage, treatment schedules and costs] Schnider P, et al. **Wien Klin Wochenschr** 1999 Jan 29;111(2):59–65 (Eng. Abstr.) **(Ger)**

[Treatment of hemifacial spasm with type A botulinum toxin (AGN 191622): a dose finding study and the evaluation of clinical effect with electromyography] Mezaki T, et al. **No To Shinkei** 1999 May;51(5):427–32 (Eng. Abstr.) **(Jpn)**

[Facial hemispasm: modern views on the etiology, pathogenesis and treatment. Personal experience with botulinum A toxin treatment] Sławek J, et al. **Neurol Neurochir Pol** 1998 Mar-Apr;32(2):277–84 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Atypical hemifacial spasm. Ryu H, et al. **Acta Neurochir (Wien)** 1998;140(11):1173–6

Vascular loop and hemifacial spasm. Palacios E, et al. **Ear Nose Throat J** 1999 Jul;78(7):470

Hemifacial spasm in Parkinson's disease. Miwa H, et al. **Mov Disord** 1999 Mar;14(2):358–9

Transient hemifacial spasm associated with subarachnoid brainstem cysticercosis: a case report. Revuelta Gutierrez R, et al. **Neurosurg Rev** 1998;21(2–3):167–70

Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Kobata H, et al. **Neurosurgery** 1998 Dec; 43(6):1351–61; discussion 1361–2 (109 ref.)

Endovascular treatment of hemifacial spasm associated with a cerebral arteriovenous malformation using transvenous embolization: case report. Konan AV, et al. **Neurosurgery** 1999 Mar;44(3):663–6

[Facial hemispasm: modern views on the etiology, pathogenesis and treatment. Personal experience with botulinum A toxin treatment] Sławek J, et al. **Neurol Neurochir Pol** 1998 Mar-Apr;32(2):277–84 (Eng. Abstr.) **(Pol)**

GENETICS

Familial trigeminal neuralgia and contralateral hemifacial spasm. Duff JM, et al. **Neurology** 1999 Jul 13;53(1):216–8

PATHOLOGY

Delineation of small nerves and blood vessels with three-dimensional fast spin-echo MR imaging: comparison of presurgical and surgical findings in patients with hemifacial spasm. Mitsuoka H, et al. **AJNR Am J Neuroradiol** 1998 Nov-Dec;19(10):1823–9

Hemifacial spasm [letter; comment] Jannetta PJ, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):255–6. Comment on: J Neurol Neurosurg Psychiatry 1998 May;64(5):687.

Perforating branches from offending arteries in hemifacial spasm: anatomical correlation with vertebrobasilar configuration. Nagatani T, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):73–7

PHYSIOPATHOLOGY

Prediction of vertebral artery compression in patients with hemifacial spasm using oblique sagittal MR imaging. Nagaseki Y, et al. **Acta Neurochir (Wien)** 1998; 140(6):565–71

Hemifacial spasm due to posterior fossa tumors: the impact of tumor location on electrophysiological findings. Glocker FX, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):104–11

Comment on Kojima et al. Long latency responses to magnetic stimulation in patients with hemifacial spasm [letter] Oge AE. **Clin Neurophysiol** 1999 Jul;110(7):1321–2

Bilateral hemifacial spasm: a report of five cases and a literature review. Tan EK, et al. **Mov Disord** 1999 Mar; 14(2):345–9 (24 ref.)

Hemifacial spasm: clinical findings and treatment. Wang A, et al. **Muscle Nerve** 1998 Dec;21(12):1740–7

SURGERY

Postoperative oblique sagittal MR imaging of microvascular decompression for hemifacial spasm. Nagaseki Y, et al. **Acta Neurochir (Wien)** 1999;141(7):737–42

Delineation of small nerves and blood vessels with three-dimensional fast spin-echo MR imaging: comparison of presurgical and surgical findings in patients with hemifacial spasm. Mitsuoka H, et al. **AJNR Am J Neuroradiol** 1998 Nov-Dec;19(10):1823–9

Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias. Mauriello JA Jr, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):627–31

Relationship between cochleovestibular disorders in hemifacial spasm and neurovascular compression. Van HT, et al. **Laryngoscope** 1999 May;109(5):741–7

Posterior fossa reexploration for persistent or recurrent trigeminal neuralgia or hemifacial spasm: surgical findings and therapeutic implications. Kureshi SA, et al. **Neurosurgery** 1998 Nov;43(5):1111–7

Microvascular decompression for the treatment of hemifacial spasm. Retrospective study of a consecutive series of 75 operated patients--electrophysiologic and anatomical surgical analysis. Acevedo JC, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):260–5

Delayed facial weakness after microvascular decompression of cranial nerve VII. Lovely TJ, et al. **Surg Neurol** 1998 Nov;50(5):449–52

[Cochleovestibular disorders associated with hemifacial spasm: an outcome after microvascular decompression of the facial nerve] Thai Van H, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Feb;115(1):9–18 (Eng. Abstr.) **(Fre)**

THERAPY

Endovascular treatment of hemifacial spasm associated with a cerebral arteriovenous malformation using transvenous embolization: case report. Konan AV, et al. **Neurosurgery** 1999 Mar;44(3):663–6

HEMIMELIA see **ECTROMELIA**

HEMIN

ADMINISTRATION & DOSAGE

Balloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injured rat carotid artery. Aizawa T, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):302–7

ANALYSIS

A mutation that improves soluble recombinant hemoglobin accumulation in Escherichia coli in heme excess. Weickert MJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):640–7

ANTAGONISTS & INHIBITORS

A novel endogenous antimalarial: Fe(II)-protoporphyrin IX

alpha (heme) inhibits hematin polymerization to beta-hematin (malaria pigment) and kills malaria parasites. Monti D, et al. **Biochemistry** 1999 Jul 13;38(28):8858-63

CHEMISTRY

Kinetics of hemin distribution in plasma reveals its role in lipoprotein oxidation. Miller YI, et al. **Biochim Biophys Acta** 1999 Jul 7;1454(2):153-64

Pentacoordinate hemin derivatives in sodium dodecyl sulfate micelles: model systems for the assignment of the fifth ligand in ferric heme proteins. Boffi A, et al. **Biophys J** 1999 Aug;77(2):1143-9

Characterisation of synthetic beta-haematin and effects of the antimalarial drugs quinidine, halofantrine, desbutylhalofantrine and mefloquine on its formation. Egan TJ, et al. **J Inorg Biochem** 1999 Jan-Feb;73(1-2):101-7

METABOLISM

8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Vennerstrom JL, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):598-602

Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Famin O, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):59-68

Deferoxamine: stimulation of hematin polymerization and antagonism of its inhibition by chloroquine Vippagunta SR, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):817-24

Involvement of lipids in ferriprotoporphyrin IX polymerization in malaria. Fitch CD, et al. **Biochim Biophys Acta** 1999 May 31;1454(1):31-7

Inhibition of nuclear envelope reconstitution in Xenopus interphase egg extract by hemin. Nishiyama R, et al. **Cell Struct Funct** 1998 Oct;23(5):291-301

DNA-enhanced peroxidase activity of a DNA-aptamer-hemin complex. Travascio P, et al. **Chem Biol** 1998 Sep;5(9):505-17

Molecular characterization of the hemin uptake locus (hmu) from Yersinia pestis and analysis of hmu mutants for hemin and hemoprotein utilization. Thompson JM, et al. **Infect Immun** 1999 Aug;67(8):3879-92

Identification of a two-component signal transduction system from Corynebacterium diphtheriae that activates gene expression in response to the presence of heme and hemoglobin. Schmitt MP. **J Bacteriol** 1999 Sep; 181(17):5330-40

Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. Bray PG, et al. **J Cell Biol** 1999 Apr 19;145(2):363-76

Effect of environmental haemin upon the physiology and biochemistry of Prevotella intermedia R78. Stubbs S, et al. **Lett Appl Microbiol** 1999 Jul;29(1):31-6

The haemin storage (Hms+) phenotype of Yersinia pestis is not essential for the pathogenesis of bubonic plague in mammals. Lillard JW Jr, et al. **Microbiology** 1999 Jan;145 (Pt 1):197-209

Role of glutathione in the detoxification of ferriprotoporphyrin IX in chloroquine resistant Plasmodium berghei. Platel DF, et al. **Mol Biochem Parasitol** 1999 Jan 25;98(2):215-23

The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Zhang J, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):129-41

PHARMACOLOGY

Heme oxygenase-1 induction in skeletal muscle cells: hemin and sodium nitroprusside are regulators in vitro. Vesely MJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1087-94

The possible role of hematin and Mössbauer effect in the inhibition of osteosarcoma cell proliferation. Ortalli I, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4127-30

Interaction of macrophage-migration-inhibitory factor with haematin. Pennock JL, et al. **Biochem J** 1998 May 1;331 (Pt 3):905-8

Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. McHale CM, et al. **Br J Haematol** 1999 Mar; 104(4):829-37

Heme-regulated eIF-2alpha kinase purifies as a hemoprotein. Chefalo PJ, et al. **Eur J Biochem** 1998 Dec 1;258(2):820-30

Hemin and carbon monoxide modulate the immunological response of human basophils. Mirabella C, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):259-60

Involvement of the tyrosine phosphorylation pathway in induction of human heme oxygenase-1 by hemin, sodium arsenite, and cadmium chloride. Masuya Y, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):628-33

Urate synthesis in the blood-sucking insect rhodnius prolixus. Stimulation by hemin is mediated by protein kinase C. Graça-Souza AV, et al. **J Biol Chem** 1999 Apr 2; 274(14):9673-6

[The effects of hematin and Mössbauer gamma radiation in cellular inactivation] Ortalli I. **Acta Biomed Ateneo Parmense** 1998;69(1-2):27-35 (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

MAP kinase-independent induction of proto-oncogene c-fos mRNA by hemin in human cells. Masuya Y, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):289-95

Regulatory domain of human heat shock transcription factor-2 is not regulated by hemin or heat shock. Zhu Z, et al. **J Cell Biochem** 1999 Apr 1;73(1):56-69

THERAPEUTIC USE

[Effect of hemin in treating hemorrhagic anemia and toxicity] You KS, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May; 17(3):284-6 (Eng. Abstr.) **(Chi)**

[Porphyric crisis: experience of 30 episodes] Morales Ortega X, et al. **Medicina (B Aires)** 1999;59(1):23-7 (Eng. Abstr.) **(Spa)**

HEMIPARESIS see **HEMIPLEGIA**

HEMIPELVECTOMY

Extended hemipelvectomy in a Jehovah's Witness with erythropoietin support. Meyers MO, et al. **Am Surg** 1998 Nov;64(11):1074-6

Alveolar soft part sarcoma involving the ilium. A case report. Durkin RC, et al. **Clin Orthop** 1999 Feb;(359):197-202 (21 ref.)

Traumatic hemipelvectomy before body image has developed. Cho KJ, et al. **Yonsei Med J** 1999 Feb; 40(1):80-3

ECONOMICS

Cost analysis of three different surgical procedures for treatment of a pelvic tumour. Bruns J, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):359-63

METHODS

Internal hemipelvectomy with intraoperative and external beam radiotherapy in the limb-sparing treatment of a pelvic girdle chondrosarcoma. Hoekstra HJ, et al. **Arch Orthop Trauma Surg** 1998;117(6-7):408-10

Modified hemipelvectomy. Cáceres E, et al. **J Surg Oncol** 1999 May;71(1):66-7; discussion 67-8

[Mutilating complex trauma of the pelvis] Rieger H, et al. **Chirurg** 1998 Nov;69(11):1275-9 (19 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Total hip disarticulation prosthesis with suction socket: report of two cases. Zaffer SM, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):160-2

HEMIPLEGIA

Continuum of reflex excitability in hemiplegia: influence of muscle length and muscular transformation after heel-cord lengthening and immobilization on the pathophysiology of spasticity and clonus. Lin JP, et al. **Dev Med Child Neurol** 1999 Aug;41(8):534-48

CHEMICALLY INDUCED

Transient hemiparesis with topiramate. Stephen LJ, et al. **BMJ** 1999 Mar 27;318(7187):845

Hemiplegia following general anaesthesia: an unusual presentation of migraine. Thurlow JA. **Eur J Anaesthesiol** 1998 Sep;15(5):610-2

Hemiplegia as a complication of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin [letter] Tsiouris J, et al. **J Pediatr** 1998 Nov;133(5):717

COMPLICATIONS

Hemiplegia and contralateral upper limb claudication--a case of dual disability from pseudoaneurysm of the brachiocephalic artery: a brief report. Harvey RL. **Am J Phys Med Rehabil** 1999 Jan-Feb;78(1):56-9

Evaluation and treatment of shoulder subluxation in hemiplegia: relationship between subluxation and pain. Ikai T, et al. **Am J Phys Med Rehabil** 1998 Sep-Oct;77(5):421-6

Bone mineral density of metatarsus in hemiplegic subjects. Iwamoto J, et al. **Am J Phys Med Rehabil** 1999 May-Jun; 78(3):202-7

Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Meythaler JM, et al. **Am J Phys Med Rehabil** 1999 May-Jun;78(3):247-54

Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D. Sato Y, et al. **Am J Phys Med Rehabil** 1999 Sep-Oct;78(5):457-63

Task-dependent weakness at the elbow in patients with hemiparesis. Beer RF, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):766-72

Muscle strength changes as measured by dynamometry following functional rehabilitation in individuals with spinal cord injury. Drolet M, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):791-800

The impact of hemiparalysis on the expression of osteoarthritis. Segal R, et al. **Arthritis Rheum** 1998 Dec; 41(12):2249-56

Fingertip forces during object manipulation in children with hemiplegic cerebral palsy. I: anticipatory scaling. Gordon AM, et al. **Dev Med Child Neurol** 1999 Mar;41(3):166-75

Fingertip forces during object manipulation in children with hemiplegic cerebral palsy. II: bilateral coordination. Gordon AM, et al. **Dev Med Child Neurol** 1999 Mar; 41(3):176-85

Global aphasia without hemiparesis: language profiles and lesion distribution. Hanlon RE, et al. **J Neurol Neurosurg Psychiatry** 1999 Mar;66(3):365-9

Hemiosteoporosis after severe stroke, independent of changes in body composition and weight. Ramnemark A, et al. **Stroke** 1999 Apr;30(4):755-60

[Treatment of spastic equinovarus foot in the hemiplegic adult by retrograde fixation of the peroneus brevis tendon onto the anterior tibialis tendon] Curvale G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):286-92 (Eng. Abstr.) **(Fre)**

[Ataxic hemiparesis with cerebellar dysarthria due to an opercular lesion] Marié RM, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):28-34 (Eng. Abstr.) **(Fre)**

CONGENITAL

A particular type of epilepsy in children with congenital hemiparesis associated with unilateral polymicrogyria. Caraballo R, et al. **Epilepsia** 1999 Jul;40(7):865-71

Congenital hemiplegia in children at school age: assessment of hand function in the non-hemiplegic hand and correlation with MRI. Mercuri E, et al. **Neuropediatrics** 1999 Feb;30(1):8-13

DIAGNOSIS

The association of visual field deficits and visuo-spatial neglect in acute right-hemisphere stroke patients. Cassidy TP, et al. **Age Ageing** 1999 May;28(3):257-60

MR and CT imaging in the Dyke-Davidoff-Masson syndrome. Report of three cases and contribution to pathogenesis and differential diagnosis. Aguiar PH, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):803-7

Quantification of force abnormalities during passive and active-assisted upper-limb reaching movements in post-stroke hemiparesis. Lum PS, et al. **IEEE Trans Biomed Eng** 1999 Jun;46(6):652-62

Nonlateralized attentional deficits: an important component behind persisting visuospatial neglect? Samuelsson H, et al. **J Clin Exp Neuropsychol** 1998 Feb;20(1):73-88

To see better to the left when looking more to the right: effects of gaze direction and frames of spatial coordinates in unilateral neglect. Vuilleumier P, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):75-82

Alternating hemiplegia of childhood or Hashimoto's encephalopathy? [letter] Balestri P, et al. **J Neurol Neurosurg Psychiatry** 1999 Apr;66(4):548-9

Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Krauss JK, et al. **Mov Disord** 1999 May;14(3):497-501

Anisotropy of water diffusion in corona radiata and cerebral peduncle in patients with hemiparesis. Wieshmann UC, et al. **Neuroimage** 1999 Aug;10(2):225-30

[MRI, SPECT and MRS findings in a case of acute hemiplegia syndrome with a marked hemispheric brain edema] Higuchi T, et al. **No To Hattatsu** 1998 Sep; 30(5):403-9 (Eng. Abstr.) **(Jpn)**

[Neuroimaging findings of hemiconvulsions, hemiplegia, epilepsy (HHE) syndrome] Oe H, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):485-8 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Vitamin K deficiency and osteopenia in disuse-affected limbs of vitamin D-deficient elderly stroke patients. Sato Y, et al. **Am J Phys Med Rehabil** 1999 Jul-Aug;78(4):317-22

Clinical trial of electrical acupuncture on hemiplegic stroke patients. Wong AM, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):117-22

A man with hemiparesis. Molan M. **Aust Fam Physician** 1999 Jun;28(6):602-4

Outcome after treatment of neurological decompression illness is predicted by a published clinical scoring system. Pitkin AD, et al. **Aviat Space Environ Med** 1999 May; 70(5):517-21

Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Sato Y, et al. **Bone** 1998 Sep;23(3):291-6

Ictal hemiparesis. Dale RC, et al. **Dev Med Child Neurol** 1999 May;41(5):344-7

Transient hypoglycemic hemiparesis in children with IDDM [letter] Spallino L, et al. **Diabetes Care** 1998 Sep; 21(9):1567-8

Hemiplegia hypoglycaemia syndrome. Vanpee D, et al. **Eur J Emerg Med** 1999 Jun;6(2):157-9

Metabolic stroke in isolated 3-methylcrotonyl-CoA carboxylase deficiency. Steen C, et al. **Eur J Pediatr** 1999 Sep;158(9):730-3

Weber's syndrome secondary to subarachnoid hemorrhage. Ilsen PF, et al. **J Am Optom Assoc** 1998 Dec;69(12):766-74

Idiopathic CSF rhinorrhoea presenting with tension pneumocephalus and hemiparesis. Hogg RP, et al. **J Laryngol Otol** 1998 Jul;112(7):654-6 (24 ref.)

Magnetic resonance angiography of primary varicella vasculitis: report of two cases. Kramer LA, et al. **J Magn Reson Imaging** 1999 Mar;9(3):491-6 (15 ref.)

Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Krauss JK, et al. **Mov Disord** 1999 May;14(3):497-501

Bilateral chronic subdural hematomas resulting in unilateral oculomotor nerve paresis and brain stem symptoms after operation--case report. Okuchi K, et al. **Neurol Med Chir (Tokyo)** 1999 May;39(5):367-71

Associated exploratory-motor and perceptual-sensory neglect without hemiparesis. Kumral E, et al. **Neurology** 1999 Jan 1;52(1):199-202

Neurological deficit following spinal anaesthesia: MRI and CT evidence of spinal cord gas embolism. Tedeschi E, et al. **Neuroradiology** 1999 Apr;41(4):275-8

Motor organization after early middle cerebral artery stroke: a PET study. Müller RA, et al. **Pediatr Neurol** 1998 Oct; 19(4):294-8

Early prognostic indicators of outcome in infants with neonatal cerebral infarction: a clinical, electroencephalogram, and magnetic resonance imaging study. Mercuri E, et al. **Pediatrics** 1999 Jan;103(1):39-46

Sudden right-sided hemiparesis in a middle-aged woman. Mehta JS, et al. **Postgrad Med J** 1998 Oct;74(876):627-8

Hemiparesis following influenza vaccination. Selvaraj N, et al. **Postgrad Med J** 1998 Oct;74(876):633-5

Neurologic compromise after an isolated laminar fracture of the cervical spine. Makan P. **Spine** 1999 Jun 1;24(11):1144-6

Ataxic hemiparesis: critical appraisal of a lacunar syndrome [see comments] Gorman MJ, et al. **Stroke** 1998 Dec; 29(12):2549-55. Comment in: Stroke 1999 Jul;30(7):1492-3.

Prevention of shoulder subluxation after stroke with electrical stimulation. Linn SL, et al. **Stroke** 1999 May; 30(5):963-8

Electrical stimulation of wrist extensors in poststroke hemiplegia. Powell J, et al. **Stroke** 1999 Jul;30(7):1384-9

Delayed thrombus propagation after parent artery clipping for giant fusiform aneurysms of the circle of Willis. Miyamoto S, et al. **Surg Neurol** 1999 Jan;51(1):89-93

Alternating transient dense hemiplegia due to episodes of hypoglycemia. Wattoo MA, et al. **West J Med** 1999 Mar; 170(3):170-1

[Ataxic hemiparesis due to lacunar infarct] Besson G, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):209-12 (Eng. Abstr.) **(Fre)**

[A case of brain abscess accompanied with sudden-onset hemiplegia as initial manifestation] Okubo K, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1232-5 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Ipsilateral central-type facial palsy and contralateral hemiparesis associated with unilateral medial medullary infarction: a case report] Yamana T, et al. **Rinsho Shinkeigaku** 1998 Aug;38(8):750-3 (Eng. Abstr.) **(Jpn)**

[Assessment of blink reflex in hemiparetic patients after stroke] Filipowska J, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1405-14 (Eng. Abstr.) **(Pol)**

["Repty" scales of strokes. Functional index "Repty" for the evaluation of ADL in hemiplegic patients after cerebral stroke. Part II] Opara J, et al. **Neurol Neurochir Pol** 1998 Jul-Sep;32(4):803-12 (Eng. Abstr.) **(Pol)**

[Progressive hemiplegia and complete paralysis of the third cranial nerve as a clinical sign of a hemi-lateral mesencephalic-pontine bulbar infarct (letter; comment)] Amorin M, et al. **Rev Neurol** 1998 Dec;27(160):1066. Comment on: Rev Neurol 1998 Apr;26(152):660. **(Spa)**

GENETICS

Coincidence of familial hemiplegic migraine and hemicrania continua? A case report. Evers S, et al. **Cephalalgia** 1999 Jun;19(5):533-5

Familial hemiplegic migraine with cerebellar ataxia and paroxysmal psychosis. Spranger M, et al. **Eur Neurol** 1999; 41(3):150-2

A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia [see comments] Battistini S, et al. **Neurology** 1999 Jul 13;53(1):38-43. Comment in: Neurology 1999 Jul 13;53(1):3-4.

Genetic heterogeneity in Italian families with familial hemiplegic migraine [see comments] Carrera P, et al. **Neurology** 1999 Jul 13;53(1):26-33. Comment in: Neurology 1999 Jul 13;53(1):3-4.

A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia [see comments] Jen J, et al. **Neurology** 1999 Jul 13;53(1):34-7. Comment in: Neurology 1999 Jul 13;53(1):3-4.

CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others [editorial; comment] Tournier-Lasserve E. **Neurology** 1999 Jul 13;53(1):3-4 (14 ref.). Comment on: Neurology 1999 Jul 13;53(1):26-33. Comment on: Neurology 1999 Jul 13;53(1):34-7. Comment on: Neurology 1999 Jul 13;53(1):38-43.

PATHOLOGY

Three-dimensional anisotropy contrast (3DAC) magnetic resonance imaging of the human brain: application to assess Wallerian degeneration. Igarashi H, et al. **Intern Med** 1998 Aug;37(8):662-8

Diffusion weighted MRI demonstrates abnormal pyramidal tract in hemiparesis. Wieshmann UC, et al. **J Neurol Neurosurg Psychiatry** 1999 Jun;66(6):797-8

Ataxic hemiparesis: an old debate for Lacune aficionados [letter; comment] Moulin T, et al. **Stroke** 1999 Jul; 30(7):1492-3. Comment on: Stroke 1998 Dec;29(12):2549-55.

PHYSIOPATHOLOGY

Wheelchair propulsion: descriptive comparison of hemiplegic and two-hand patterns during selected activities. Kirby RL, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr; 78(2):131-5

Physical performance and cardiovascular and metabolic adaptation of elite female wheelchair basketball players in wheelchair ergometry and in competition. Schmid A, et al. **Am J Phys Med Rehabil** 1998 Nov-Dec;77(6):527-33

Relationship between stride length and walking rate in gait training for hemiparetic stroke patients. Suzuki K, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):147-52

Hemiplegic gait of stroke patients: the effect of using a cane. Kuan TS, et al. **Arch Phys Med Rehabil** 1999 Jul; 80(7):777-84

Correlation of spasticity with hyperactive stretch reflexes and motor dysfunction in hemiplegia. Lin FM, et al. **Arch Phys Med Rehabil** 1999 May;80(5):526-30

Impaired grip-lift synergy in children with unilateral brain lesions. Forssberg H, et al. **Brain** 1999 Jun;122 (Pt 6):1157-68

The use of one-arm crank ergometry in the prediction of upper body aerobic capacity. Birkett WA, et al. **Clin Rehabil** 1998 Aug;12(4):319-27

Freezing episodes in hemiparetic stroke: results of a pilot survey. Bussin JL, et al. **Clin Rehabil** 1999 Jun;13(3):207-10

Trunk kinematics in hemiplegic gait and the effect of walking aids. Tyson SF. **Clin Rehabil** 1999 Aug;13(4):295-300

'Improved hand function remains after upper-limb tendon transfer and muscle release in children with hemiplegia' [letter; comment] Sköld A, et al. **Dev Med Child Neurol** 1999 Apr;41(4):284-5. Comment on: Dev Med Child Neurol 1998 Sep;40(9):612-21.

Immediate effects of therapeutic facilitation on the gait of hemiparetic patients as compared with walking with and without a cane. Hesse S, et al. **Electroencephalogr Clin Neurophysiol** 1998 Dec; 106(6):515-22

Initial motor unit recruitment in patients with spastic hemiplegia. Frascarelli M, et al. **Electromyogr Clin Neurophysiol** 1998 Jul-Aug;38(5):267-71

Unusual late responses in a patient with an Arnold-Chiari malformation. Kutukcu Y, et al. **Electromyogr Clin Neurophysiol** 1999 Jun;39(4):213-6

Recruitment and sequencing of different degrees of freedom during pointing movements involving the trunk in healthy and hemiparetic subjects. Archambault P, et al. **Exp Brain Res** 1999 May;126(1):55-67

Quantification of force abnormalities during passive and active-assisted upper-limb reaching movements in post-stroke hemiparesis. Lum PS, et al. **IEEE Trans Biomed Eng** 1999 Jun;46(6):652-62

Activation of selected trunk muscles during symmetric functional activities in poststroke hemiparetic and hemiplegic patients. Dickstein R, et al. **J Neurol Neurosurg Psychiatry** 1999 Feb;66(2):218-21

Sensory alien hand syndrome [letter] Persaud RS. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):130-1

Different mechanisms of bone metabolism between patients with stroke and with spinal cord injury [letter; comment] Davie MW, et al. **J Neurol Sci** 1999 Feb 1;163(1):99-101 . Comment on: J Neurol Sci 1998 Apr 1;156(2):205-10.

Functional consequences of mutations in the human alpha1A calcium channel subunit linked to familial hemiplegic migraine. Hans M, et al. **J Neurosci** 1999 Mar 1; 19(5):1610-9

Functional recovery from cortical hemiplegia in the rat: effects of a callosotomy. Zepeda A, et al. **J Neurotrauma** 1999 Mar;16(3):267-71

Comparison of a stiff and a spring-type ankle-foot orthosis to improve gait in spastic hemiplegic children. Brunner R, et al. **J Pediatr Orthop** 1998 Nov-Dec;18(6):719-26

Reorganization of flexion reflexes in the upper extremity of hemiparetic subjects. Dewald JP, et al. **Muscle Nerve** 1999 Sep;22(9):1209-21

Acquired and isolated asymmetrical palatal palsy. Cuvellier JC, et al. **Neuropediatrics** 1998 Dec;29(6):324-5

Possible mechanisms of anosognosia: a defect in self-awareness. Heilman KM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1903-9 (34 ref.)

Quantization of continuous arm movements in humans with brain injury. Krebs HI, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4645-9

A clinical guide to assess the role of lower limb extensor overactivity in hemiplegic gait disorders. Yelnik A, et al. **Stroke** 1999 Mar;30(3):580-5

PREVENTION & CONTROL

Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. Sheng H, et al. **Neuroscience** 1999 Jan;88(1):185-91

Prevention of shoulder subluxation after stroke with electrical stimulation. Linn SL, et al. **Stroke** 1999 May; 30(5):963-8

PSYCHOLOGY

Peer problems of 9- to 11-year-old children with hemiplegia in mainstream schools. Can these be predicted? Yude C, et al. **Dev Med Child Neurol** 1999 Jan;41(1):4-8

Relations between biased tonicity of the body and vertical judgement in poststroke hemiplegic persons. Ishikura K. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):952-6

Possible mechanisms of anosognosia: a defect in self-awareness. Heilman KM, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Nov 29; 353(1377):1903-9 (34 ref.)

RADIOGRAPHY

Motor organization after early middle cerebral artery stroke: a PET study. Müller RA, et al. **Pediatr Neurol** 1998 Oct; 19(4):294-8

RADIONUCLIDE IMAGING

Cerebral blood flow changes in pseudomigraine with pleocytosis analyzed by single photon emission computed tomography. A spreading depression mechanism? Fuentes B, et al. **Cephalalgia** 1998 Oct;18(8):570-3; discussion 531

Reorganization of sensory and motor systems in hemiplegic stroke patients. A positron emission tomography study. Nelles G, et al. **Stroke** 1999 Aug;30(8):1510-6

REHABILITATION

Changes in the quality of life of hemiplegic stroke patients with time: a preliminary report. Béthoux F, et al. **Am J Phys Med Rehabil** 1999 Jan-Feb;78(1):19-23

Comparison of discomfort associated with surface and percutaneous intramuscular electrical stimulation for persons with chronic hemiplegia. Chae J, et al. **Am J Phys Med Rehabil** 1998 Nov-Dec;77(6):516-22

Spastic paretic stiff-legged gait: biomechanics of the unaffected limb. Kerrigan DC, et al. **Am J Phys Med Rehabil** 1999 Jul-Aug;78(4):354-60

Relationship between stride length and walking rate in gait training for hemiparetic stroke patients. Suzuki K, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):147-52

Clinical trial of electrical acupuncture on hemiplegic stroke patients. Wong AM, et al. **Am J Phys Med Rehabil** 1999 Mar-Apr;78(2):117-22

Shoulder pain and dysfunction in hemiplegia: effects of functional electrical stimulation. Chantraine A, et al. **Arch Phys Med Rehabil** 1999 Mar;80(3):328-31

Treadmill walking with partial body weight support versus floor walking in hemiparetic subjects. Hesse S, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):421-7

Functional disability and rehabilitation outcome in right hemisphere damaged patients with and without unilateral spatial neglect. Katz N, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):379-84

Hemiplegic gait of stroke patients: the effect of using a cane. Kuan TS, et al. **Arch Phys Med Rehabil** 1999 Jul; 80(7):777-84

Resistance to passive shoulder external rotation in persons with hemiplegia: evaluation of an assessment system. Mngoma NF, et al. **Arch Phys Med Rehabil** 1999 May; 80(5):531-5

Determinants and predictors of the maximum walking speed during computer-assisted gait training in hemiparetic stroke patients. Suzuki K, et al. **Arch Phys Med Rehabil** 1999 Feb; 80(2):179-82

Chronic conversion disorders [letter; comment] Teasell R, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1482-3. Comment on: Arch Phys Med Rehabil 1998 Jun;79(6):709-14.

Bridging activity as a mode of stress testing for persons with hemiplegia. Tsuji T, et al. **Arch Phys Med Rehabil** 1999 Sep;80(9):1060-4

Development of an advanced mechanised gait trainer, controlling movement of the centre of mass, for restoring gait in non-ambulant subjects. Hesse S, et al. **Biomed Tech (Berl)** 1999 Jul-Aug;44(7-8):194-201

The use of one-arm crank ergometry in the prediction of upper body aerobic capacity. Birkett WA, et al. **Clin Rehabil** 1998 Aug;12(4):319-27

Description of a new motor re-education programme for the paretic lower limb aimed at improving the mobility of stroke patients. Mercier C, et al. **Clin Rehabil** 1999 Jun; 13(3):199-206

Effect of severity of arm impairment on response to additional physiotherapy early after stroke. Parry RH, et al. **Clin Rehabil** 1999 Jun;13(3):187-98

The support taken through walking aids during hemiplegic gait. Tyson SF. **Clin Rehabil** 1998 Oct;12(5):395-401

The long-term outcome of arm function after stroke: results of a follow-up study. Broeks JG, et al. **Disabil Rehabil** 1999 Aug;21(8):357-64

The effect of wrist angle on electrically evoked hand opening in patients with spastic hemiplegia. Cameron T, et al. **IEEE Trans Rehabil Eng** 1999 Mar;7(1):109-11

Guidance-based quantification of arm impairment following brain injury: a pilot study. Reinkensmeyer DJ, et al. **IEEE Trans Rehabil Eng** 1999 Mar;7(1):1-11

Rehabilitation of hemiparesis after stroke with a mirror [letter] Altschuler EL, et al. **Lancet** 1999 Jun 12; 353(9169):2035-6

Balance retraining in a hemiparetic patient using center of gravity biofeedback: a single-case study. Simmons RW, et al. **Percept Mot Skills** 1998 Oct;87(2):603-9

Non-velocity-related effects of a rigid double-stopped ankle-foot orthosis on gait and lower limb muscle activity of hemiparetic subjects with an equinovarus deformity. Hesse S, et al. **Stroke** 1999 Sep;30(9):1855-61

Electrical stimulation of wrist extensors in poststroke hemiplegia. Powell J, et al. **Stroke** 1999 Jul;30(7):1384–9

SURGERY

'Improved hand function remains after upper-limb tendon transfer and muscle release in children with hemiplegia' [letter; comment] Sköld A, et al.
Dev Med Child Neurol 1999 Apr;41(4):284–5. Comment on: Dev Med Child Neurol 1998 Sep;40(9):612–21.
[The development of gait in the hemiplegic patient after selective tibial neurotomy] Caillet F, et al.
Neurochirurgie 1998 Sep;44(3):183–91 (Eng. Abstr.) **(Fre)**

THERAPY

Functional recovery in hemiplegic cerebral palsy: ipsilateral electromyographic responses to focal transcranial magnetic stimulation. Nezu A, et al. **Brain Dev** 1999 Apr;21(3):162–5
Treatment of apoplectic hemiplegia by digital acupoint pressure--a report of 42 cases. Chen R.
J Tradit Chin Med 1997 Sep;17(3):198–202
Acupuncture methods for hemiplegic spasm. Guo Z, et al.
J Tradit Chin Med 1997 Dec;17(4):284–8
The ways and methods for improving the therapeutic effect of acupuncture in treatment of apoplectic hemiplegia. Lu S. **J Tradit Chin Med** 1997 Jun;17(2):83–91
Experience in the point-selection for electro-acupuncture. Zheng Q. **J Tradit Chin Med** 1998 Dec;18(4):277–81

HEMIPTERA

Poly(A) mRNA is attached to insect ovarian microtubules in vivo in a nucleotide-sensitive manner. Stephen S, et al.
Cell Motil Cytoskeleton 1999;43(2):159–66
Subcellular effects and localization of binding sites of phytohemagglutinin in the potato leafhopper, Empoasca fabae (Insecta: Homoptera: Cicadellidae). Habibi J, et al.
Cell Tissue Res 1998 Dec;294(3):561–71
Lethocerus americanus, the "toe biter". Huntley A.
Dermatol Online J 1998 Oct;4(1):6
Beauveria bassiana (Hyphomycetes) as a possible agent for biological control of Chagas disease vectors. Luz C, et al.
J Med Entomol 1998 Nov;35(6):977–9

ANATOMY & HISTOLOGY

The ovaries of scale insects (Hemiptera, Coccinea). Morphology and phylogenetic conclusions. Szklarzewicz T. **Folia Histochem Cytobiol** 1998;36(4):157–65 (57 ref.)

CHEMISTRY

Structure of the insect troponin complex. Wendt T, et al.
J Mol Biol 1999 Jan 29;285(4):1845–56
[Separation and preparation of indole alkaloids in Lycorma delicatula White. by HPLC] Xue G, et al.
Chung Kuo Chung Yao Tsa Chih 1996 Sep;21(9):554–5, 576 (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

Occurrence of digestive cysteine proteases in Perillus bioculatus, a natural predator of the Colorado potato beetle. Overney S, et al.
Comp Biochem Physiol B Biochem Mol Biol 1998 May;120(1):191–5

GENETICS

Two hexameric cyanoprotein subunits from an insect, Riptortus clavatus. Sequence, phylogeny and developmental and juvenile hormone regulation. Miura K, et al. **Eur J Biochem** 1998 Dec 15;258(3):929–40
The relationship between DNA methylation and chromosome imprinting in the coccid Planococcus citri. Bongiorni S, et al. **Genetics** 1999 Apr;151(4):1471–8
Molecular-based approach to the differentiation of mealybug (Hemiptera: Pseudococcidae) species. Beuning LL, et al.
J Econ Entomol 1999 Apr;92(2):463–72

METABOLISM

Selenium bioaccumulation by the water boatman Trichocorixa reticulata (Guerin-Meneville). Thomas BV, et al. **Arch Environ Contam Toxicol** 1999 Apr;36(3):295–300
Phosphorylation of microtubule-associated proteins from the ovaries of hemipteran insects by MPF and MAP kinase: possible roles in the regulation of microtubules during oogenesis. Lane JD, et al. **Arch Insect Biochem Physiol** 1998;39(2):81–90
The relationship between DNA methylation and chromosome imprinting in the coccid Planococcus citri. Bongiorni S, et al. **Genetics** 1999 Apr;151(4):1471–8

PHYSIOLOGY

Molecular basis for thermoprotection in Bemisia: structural differences between whitefly ketose reductase and other medium-chain dehydrogenases/reductases. Wolfe GR, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):113–20

ULTRASTRUCTURE

Spermiogenesis in phytophagous bug (Hemiptera, Pentatomidae): an ultrastructural study. Fernandes AP, et al. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):485–93

VIROLOGY

Tissue tropism related to vector competence of Frankliniella occidentalis for tomato spotted wilt tospovirus. Nagata T, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):507–15
Lettuce infectious yellows virus: in vitro acquisition analysis using partially purified virions and the whitefly Bemisia tabaci. Tian T, et al. **J Gen Virol** 1999 May;80 (Pt 5):1111–7
Identification of genes directly and indirectly involved in the insect transmission of African cassava mosaic geminivirus by Bemisia tabaci. Liu S, et al. **Virus Genes** 1999;18(1):5–11

HEMLOCK

Biochemistry of hemlock (Conium maculatum L.) alkaloids and their acute and chronic toxicity in livestock. A review. López TA, et al. **Toxicon** 1999 Jun;37(6):841–65 (96 ref.)
[Socrates and hemlock (editorial)] Kotsias BA.
Medicina (B Aires) 1999;59(2):211–4 **(Spa)**

TOXICITY

Lupines, poison-hemlock and Nicotiana spp: toxicity and teratogenicity in livestock. Panter KE, et al.
J Nat Toxins 1999 Feb;8(1):117–34 (88 ref.)

HEMOBILIA

COMPLICATIONS

Hemobilia causing acute biliary pancreatitis after percutaneous liver biopsy. Kim HJ, et al. **Endoscopy** 1999 Mar;31(3):S18–9
Acute cholecystitis secondary to hemobilia. Lee SL, et al.
J Laparoendosc Adv Surg Tech A 1999 Aug;9(4):347–9
[Hemobilia of gallbladder origin manifesting as malignant hypertension (letter)] Seguin P, et al. **Presse Med** 1998 May 23–30;27(19):913 **(Fre)**

DIAGNOSIS

A rare case of haemobilia. Sarkar C, et al.
J Indian Med Assoc 1998 Jun;96(6):186–7
Haemobilia mimicking acute cholecystitis following percutaneous renal biopsy. Lee MC, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2118–20

DRUG THERAPY

Local application of a potent vasoconstrictor during ERCP for the acute management of hemobilia [letter] Wettstein AR, et al. **Am J Gastroenterol** 1998 Dec;93(12):2644–5

ETIOLOGY

Multiple visceral aneurysms presenting with haemobilia. Yeung YP, et al. **Aust N Z J Surg** 1999 Jul;69(7):545–6
Hepatic artery pseudoaneurysm with hemobilia following angioplasty after liver transplantation. Narumi S, et al.
Clin Transplant 1998 Dec;12(6):508–10
Pancreatic pseudocyst with fistula to the common bile duct presenting with gastrointestinal bleeding. Raimondo M, et al. **Dig Dis Sci** 1998 Dec;43(12):2622–6 (16 ref.)
Spontaneous hemobilia in a hemophiliac treated by factor VIII replacement and nasobiliary drainage. Sreenivas DV, et al. **Dig Dis Sci** 1998 Dec;43(12):2606–9
Hemobilia in advanced pancreatic cancer with portal vein obstruction and a metal endobiliary stent: a case report. Cvetkovski B, et al. **Gastrointest Endosc** 1999 Sep; 50(3):420–2
Carcinoma gall bladder presenting as hemobilia. John A, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):88–9
Posttraumatic intra-gallbladder hemorrhage in a patient with liver cirrhosis. Nishiwaki M, et al. **J Gastroenterol** 1999 Apr;34(2):282–5 (21 ref.)
A rare case of haemobilia. Sarkar C, et al.
J Indian Med Assoc 1998 Jun;96(6):186–7
Posttraumatic hemobilia complicated by obstructive jaundice. Butler KL, et al. **J Trauma** 1999 Sep;47(3):582–4
Haemobilia mimicking acute cholecystitis following percutaneous renal biopsy. Lee MC, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2118–20
Hemobilia caused by a giant benign hemangioma of the liver: report of a case. Mikami T, et al. **Surg Today** 1998; 28(9):948–52
[Angioleiomyoma of the gallbladder: a rare cause of hemobilia in a patient on dialysis] Aschl G, et al.
Dtsch Med Wochenschr 1999 Jan 8;124(1–2):13–6 (Eng. Abstr.) **(Ger)**
[Gastrointestinal hemorrhage in hepatocellular carcinoma] Wettstein AR, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1627 **(Ger)**
[Hemobilia in acute cholecystitis] Akpetrov IA, et al.
Khirurgiia (Mosk) 1998;(7):60 **(Rus)**
[Observation of x-ray surgical occlusion of the patient's own liver artery in a patient with post-traumatic hemobilia] Zaitsev VT, et al. **Klin Khir** 1998;(7):54 **(Rus)**

RADIOGRAPHY

Local application of a potent vasoconstrictor during ERCP for the acute management of hemobilia [letter] Wettstein AR, et al. **Am J Gastroenterol** 1998 Dec;93(12):2644–5
Hepatic artery angiography and embolization for hemobilia following laparoscopic cholecystectomy. Nicholson T, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):20–4

THERAPY

Hepatic artery angiography and embolization for hemobilia following laparoscopic cholecystectomy. Nicholson T, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):20–4
Hemobilia caused by a pseudoaneurysm of the hepatic artery diagnosed by EUS. Cattan P, et al. **Gastrointest Endosc** 1999 Feb;49(2):252–5
Hemobilia in advanced pancreatic cancer with portal vein obstruction and a metal endobiliary stent: a case report. Cvetkovski B, et al. **Gastrointest Endosc** 1999 Sep; 50(3):420–2

ULTRASONOGRAPHY

Hemobilia caused by a pseudoaneurysm of the hepatic artery diagnosed by EUS. Cattan P, et al. **Gastrointest Endosc** 1999 Feb;49(2):252–5

HEMOCHROMATOSIS

Juvenile haemochromatosis. Camaschella C.
Baillieres Clin Gastroenterol 1998 Jun;12(2):227–35 (47 ref.)
Haemochromatosis. Crawford DH, et al.
Baillieres Clin Gastroenterol 1998 Jun;12(2):209–25 (71 ref.)

BLOOD

Interpretation of iron studies in adolescent haemochromatosis. Catterson PR, et al.
Clin Lab Haematol 1999 Apr;21(2):129–31
Long-term survival in a patient with AIDS and hereditary haemochromatosis [letter] Nielsen P, et al.
Eur J Haematol 1999 Sep;63(3):202–4
Hemochromatosis probands as blood donors [see comments] Barton JC, et al. **Transfusion** 1999 Jun;39(6):578–85. Comment in: Transfusion 1999 Jun;39(6):549–50. Comment in: Transfusion 1999 Jun;39(6):551–4.
Blood from patients with hereditary hemochromatosis--a wasted resource [comment] Jeffrey G, et al. **Transfusion** 1999 Jun;39(6):549–50. Comment on: Transfusion 1999 Jun;39(6):578–85. Comment on: Transfusion 1999 Jun;39(6):651–6.
A survey of phlebotomy among persons with hemochromatosis [see comments] McDonnell SM, et al. **Transfusion** 1999 Jun;39(6):651–6. Comment in: Transfusion 1999 Jun;39(6):549–50. Comment in: Transfusion 1999 Jun;39(6):551–4.
Hemochromatosis and blood donors: a perspective [comment] Sacher RA. **Transfusion** 1999 Jun;39(6):551–4. Comment on: Transfusion 1999 Jun;39(6):578–85. Comment on: Transfusion 1999 Jun;39(6):651–6.
[Pathogenetic aspects of hemolysis and changes of blood rheology in hereditary hemochromatosis] Ershova LI, et al. **Ter Arkh** 1998;70(11):74–6 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder [letter] Cazzola M, et al. **Blood** 1998 Oct 15; 92(8):2979–81

COMPLICATIONS

Diagnosis of hemochromatosis [letter] Kalantar-Zadeh K, et al. **Ann Intern Med** 1999 Aug 17;131(4):311
Ejaculatory failure and hypogonadotrophic hypogonadism caused by haemochromatosis. Stopforth HB, et al.
BJU Int 1999 Apr;83(6):728
Haemochromatosis and exercise related joint pains. McCurdie I, et al. **BMJ** 1999 Feb 13;318(7181):449–51
Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Beris P, et al.
Br J Haematol 1999 Jan;104(1):97–9
HCV and C282Y: a sinister synergism? Russo M, et al.
Gastroenterology 1999 Feb;116(2):494–5
HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload [letter] Remacha AF, et al. **Haematologica** 1999 Mar;84(3):284–5
Iron overload in porphyria cutanea tarda. Sampietro M, et al. **Haematologica** 1999 Mar;84(3):248–53 (65 ref.)
Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.). Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.
Ferumoxide-enhanced MRI of sideronecrosis superimposed on genetic hemochromatosis. Aizenstein RI, et al.
J Comput Assist Tomogr 1999 Jan–Feb;23(1):90–3
Effect of venesection on bone mineral density in an eugonadal woman with haemochromatosis. Hibbert EJ, et al.
J Gastroenterol Hepatol 1999 Feb;14(2):176–8
Haemochromatosis and the liver. Niederau C, et al.
J Hepatol 1999;30 Suppl 1:6–11 (22 ref.)
Magnetic resonance imaging of the pituitary gland in patients with secondary hypogonadism due to transfusional hemochromatosis. Sparacia G, et al. **MAGMA** 1999 May; 8(2):87–90
Hemochromatosis and male infertility. Oehninger S, et al.
Obstet Gynecol 1998 Oct;92(4 Pt 2):652–3
Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report.

HEMOCHROMATOSIS

Köhler HH, et al. **Pathol Res Pract** 1999;195(7):509–13

Early diagnosis of hepatocellular carcinoma in haemochromatosis influences surgical management. Pleass H, et al. **Scott Med J** 1998 Aug;43(4):114–5

[Osteoarticular hemochromatosis] Zeevaert B, et al. **Rev Med Liege** 1999 Mar;54(3):169–74 (Eng. Abstr.) **(Fre)**

[The articular damage of hemochromatosis. A little known aspect] Biasi D, et al. **Recenti Prog Med** 1999 Apr; 90(4):226–30 (22 ref.) (Eng. Abstr.) **(Ita)**

[Hemochromatosis--a rare cause of hypogonadism] Rishaug U, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20; 119(19):2818–9 (Eng. Abstr.) **(Nor)**

[Multicentric hepatocarcinoma in a patient with hemochromatosis: apropos of a case (letter)] Minguez Garcia P, et al. **An Med Interna** 1998 Oct;15(10):565–6 **(Spa)**

CONGENITAL

Neonatal hemochromatosis, renal tubular dysgenesis, and hypocalvaria in a neonate. Johal JS, et al. **Pediatr Dev Pathol** 1998 Sep–Oct;1(5):433–7

[Neonatal hemochromatosis. Report of 3 autopsy cases] Rodriguez Velasco A, et al. **Rev Invest Clin** 1999 Mar–Apr; 51(2):81–7 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis [letter] Somerville MJ, et al. **Am J Hum Genet** 1999 Sep;65(3):924–6

A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. McDonnell SM, et al. **Am J Med** 1999 Jun;106(6):619–24

Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. McDonnell SM, et al. **Am J Med** 1999 Jul;107(1):30–7

Screening for hemochromatosis. A public health perspective. Cogswell ME, et al. **Am J Prev Med** 1999 Feb;16(2):134–40 (73 ref.)

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674–7

Diagnosis of hemochromatosis [letter] Kalantar-Zadeh K, et al. **Ann Intern Med** 1999 Aug 17;131(4):311

Strategies to increase detection of hemochromatosis. McDonnell SM, et al. **Ann Intern Med** 1998 Dec 1; 129(11):987–92 (65 ref.)

Screening for hemochromatosis in primary care settings. McDonnell SM, et al. **Ann Intern Med** 1998 Dec 1; 129(11):962–70 (48 ref.)

Diagnosis of hemochromatosis. Powell LW, et al. **Ann Intern Med** 1998 Dec 1;129(11):925–31 (41 ref.)

Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Pascoe A, et al. **Gut** 1999 Aug;45(2):301–5

Population screening for hemochromatosis. Adams PC. **Hepatology** 1999 Apr;29(4):1324–7 (43 ref.)

Screening for hemochromatosis can prevent serious disease [letter] Marino GG. **J Am Osteopath Assoc** 1999 May; 99(5):240–1

Utility of genotyping in diagnosis of genetic haemochromatosis [editorial; comment] Crawford DH, et al. **J Gastroenterol Hepatol** 1999 May;14(5):401–2. Comment on: J Gastroenterol Hepatol 1999 May;14(5):427–30.

Genotyping as a diagnostic aid in genetic haemochromatosis [see comments] Rossi E, et al. **J Gastroenterol Hepatol** 1999 May;14(5):427–30. Comment in: J Gastroenterol Hepatol 1999 May;14(5):401–2.

Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. George DK, et al. **J Hepatol** 1999 Jul;31(1):47–52

Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. Himmelmann A, et al. **J Lab Clin Med** 1999 Mar; 133(3):229–36 (51 ref.)

Histiocytic-phagocytic infiltrates in the liver of an infant: a case clinically simulating perinatal hemochromatosis. Senger C, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug; 29(2):215–20

Hereditary haemochromatosis: diagnosis and management in the gene era. Olynyk JK. **Liver** 1999 Apr;19(2):73–80 (81 ref.)

Update on hereditary hemochromatosis and the HFE gene. Brandhagen DJ, et al. **Mayo Clin Proc** 1999 Sep; 74(9):917–21 (25 ref.)

Hepatocellular carcinoma: association with increased iron deposition in the cirrhotic liver at MR imaging. Ito K, et al. **Radiology** 1999 Jul;212(1):235–40

Predominant ankle arthropathy in hereditary haemochromatosis [letter] Jacki SH, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):378–9

High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary haemochromatosis in South Africa. de Villiers JN, et al. **S Afr Med J** 1999 Mar;89(3):279–82

Molecular diagnosis of hereditary haemochromatosis--identify an affected person and save a family [editorial] Milani MY, et al. **S Afr Med J** 1999 Mar;89(3):263–4

Evaluation and interpretation of iron in the liver. Turlin B, et al. **Semin Diagn Pathol** 1998 Nov;15(4):237–45 (63 ref.)

[Picture of the month] Hansen TM, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4417 **(Dan)**

[Diagnosis and treatment of primary hemochromatosis] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1404–8 (57 ref.) (Eng. Abstr.) **(Dut)**

[Molecular genetic diagnosis in hemochromatosis] Gehrke SG, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):431–4 (19 ref.) **(Ger)**

[Diagnosis of hereditary hemochromatosis with molecular analysis of DNA in patients with anti-HCV positive liver cirrhosis. Clinical case] Carella AM, et al. **Minerva Med** 1998 Sep;89(9):323–7 (Eng. Abstr.) **(Ita)**

[Imaging tests for the diagnosis of metabolic diseases] Martí-Bonmatí L. **Gastroenterol Hepatol** 1999 Feb;22 Suppl 1:25–6 **(Spa)**

[Hereditary hemochromatosis: biochemical and genetic diagnosis (published erratum appears in Gastroenterol Hepatol 1999 Mar;22(3):156)] Quintero E. **Gastroenterol Hepatol** 1999 Feb;22 Suppl 1:1–5 **(Spa)**

[Inaccurate diagnosis presumption of haemochromatosis in a patient with alpha-1-antitrypsin deficiency (letter)] Aniés Omiste C, et al. **Rev Esp Enferm Dig** 1999 Apr;91(4):310–1 **(Spa)**

DRUG THERAPY

Hemochromatosis and vitamin C [letter] Herbert V. **Ann Intern Med** 1999 Sep 21;131(6):475–6

EPIDEMIOLOGY

A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. McDonnell SM, et al. **Am J Med** 1999 Jun;106(6):619–24

Prevalence of the C282Y mutation in Brittany: penetrance of genetic hemochromatosis? Jouanolle AM, et al. **Ann Genet** 1998;41(4):195–8

Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Cogswell ME, et al. **Ann Intern Med** 1998 Dec 1;129(11):971–9 (80 ref.)

Prevalence of elevated serum transferrin saturation in adults in the United States. Looker AC, et al. **Ann Intern Med** 1998 Dec 1;129(11):940–5

Prevalence of hereditary hemochromatosis in 16031 primary care patients. Phatak PD, et al. **Ann Intern Med** 1998 Dec 1;129(11):954–61

Public health surveillance for hereditary hemochromatosis. Wetterhall SF, et al. **Ann Intern Med** 1998 Dec 1; 129(11):980–6 (58 ref.)

High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis [see comments] De Filippi F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):529–33. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):467–9.

Hemochromatosis probands as blood donors [see comments] Barton JC, et al. **Transfusion** 1999 Jun;39(6):578–85. Comment in: Transfusion 1999 Jun;39(6):549–50. Comment in: Transfusion 1999 Jun;39(6):551–4.

ETIOLOGY

Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Lichtman SM, et al. **Am J Hematol** 1999 Aug;61(4):262–4

Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis. Parizhskaya M, et al. **Pediatr Dev Pathol** 1999 Jul–Aug;2(4):360–6

GENETICS

"Secondary hemochromatosis" [letter] Vanhaeverbeek M. **Acta Clin Belg** 1999 Jun;54(3):172–4 **(Eng, Fre)**

New knowledge of genetic pathogenesis of hemochromatosis and Wilson's disease. Bacon BR, et al. **Adv Intern Med** 1999;44:91–116 (77 ref.)

Putative hemochromatosis gene mutations and alcoholic liver disease with iron overload in Japan. Sohda T, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):21S–23S

Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping [see comments] Adams PC, et al. **Am J Gastroenterol** 1999 Jun;94(6):1593–600. Comment in: Am J Gastroenterol 1999 Jun;94(6):1430–3.

Magnetic resonance iron-free nodules in genetic hemochromatosis. Guyader D, et al. **Am J Gastroenterol** 1999 Apr;94(4):1083–6

Screening for hemochromatosis: phenotyping or genotyping or both? [editorial; comment] Tavill AS. **Am J Gastroenterol** 1999 Jun;94(6):1430–3 (24 ref.). Comment on: Am J Gastroenterol 1999 Jun;94(6):1593–600.

Absence of C282Y and H63D mutations of the hemochromatosis gene in Japanese patients with sideroblastic anemia [letter] Furuyama K, et al. **Am J Hematol** 1999 Aug;61(4):276

Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Mendez M, et al. **Am J Hum Genet** 1998 Nov;63(5):1363–75

Juvenile hemochromatosis locus maps to chromosome 1q. Roetto A, et al. **Am J Hum Genet** 1999 May;64(5):1388–93

An HFE intronic variant promotes misdiagnosis of hereditary hemochromatosis [letter] Somerville MJ, et al. **Am J Hum Genet** 1999 Sep;65(3):924–6

Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. McDonnell SM, et al. **Am J Med** 1999 Jul;107(1):30–7

Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes. Bernard PS, et al. **Am J Pathol** 1998 Oct;153(4):1055–61

Screening for hemochromatosis. A public health perspective. Cogswell ME, et al. **Am J Prev Med** 1999 Feb;16(2):134–40 (73 ref.)

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674–7

Hereditary hemochromatosis. Walker EM Jr, et al. **Ann Clin Lab Sci** 1998 Sep–Oct;28(5):300–12

Prevalence of the C282Y mutation in Brittany: penetrance of genetic hemochromatosis? Jouanolle AM, et al. **Ann Genet** 1998;41(4):195–8

HFE genotype in patients with hemochromatosis and other liver diseases [see comments] Bacon BR, et al. **Ann Intern Med** 1999 Jun 15;130(12):953–62. Comment in: Ann Intern Med 1999 Jun 15;130(12):1018–9.

Research priorities in hereditary hemochromatosis. Brittenham GM, et al. **Ann Intern Med** 1998 Dec 1; 129(11):993–6

Population screening for hemochromatosis: the evolving role of genetic analysis [editorial] Davis JG. **Ann Intern Med** 1998 Dec 1;129(11):905–8

Introduction to supplement on Iron Overload, Public Health, and Genetics. Franks AL, et al. **Ann Intern Med** 1998 Dec 1;129(11):923–4

Will the real hemochromatosis please stand up? [editorial; comment] Franks AL, et al. **Ann Intern Med** 1999 Jun 15; 130(12):1018–9. Comment on: Ann Intern Med 1999 Jun 15;130(12):953–62.

Prevalence of hereditary hemochromatosis in 16031 primary care patients. Phatak PD, et al. **Ann Intern Med** 1998 Dec 1;129(11):954–61

Public health surveillance for hereditary hemochromatosis. Wetterhall SF, et al. **Ann Intern Med** 1998 Dec 1; 129(11):980–6 (58 ref.)

Genetics of hemochromatosis. Cullen LM, et al. **Annu Rev Med** 1999;50:87–98 (55 ref.)

Frequencies in the Japanese population of HFE gene mutations. Sohda T, et al. **Biochem Genet** 1999 Feb; 37(1-2):63–8

Identification and characterization of the human HCG V gene product as a novel inhibitor of protein phosphatase-1. Zhang J, et al. **Biochemistry** 1998 Nov 24;37(47):16728–34

Rapid genetic screening for hemochromatosis using automated SSCP-based capillary electrophoresis (SSCP-CE). Bosserhoff AK, et al. **Biotechniques** 1999 Jun; 26(6):1106–10

Coinheritance of alleles associated with hemochromatosis and hereditary hyperferritinemia-cataract syndrome [letter] Barton JC, et al. **Blood** 1998 Dec 1;92(11):4480

Nontransfusional iron overload in thalassemia intermedia: role of the hemochromatosis allele [letter] Cappellini MD, et al. **Blood** 1998 Dec 1;92(11):4479–80

Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Cotter PD, et al. **Blood** 1999 Mar 1; 93(5):1757–69

No association between factor V Leiden and C282Y mutation in the hereditary hemochromatosis gene [letter; comment] Le Maréchal C, et al. **Blood** 1999 Jun 1;93(11):4024–5. Comment on: Blood 1998 Aug 15;92(4):1461–2.

C282Y hemochromatosis mutation does not contribute to hypercoagulability in a factor V Leiden population referred to venous thrombosis [letter; comment] Lellouche F, et al. **Blood** 1999 Mar 15;93(6):2135–6. Comment on: Blood 1998 Aug 15;92(4):1461–2.

The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Levy JE, et al. **Blood** 1999 Jul 1;94(1):9–11

HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Mura C, et al. **Blood** 1999 Apr 15; 93(8):2502–5

The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms. Lee PL, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):199–215

Celtic origin of the C282Y mutation of hemochromatosis. Lucotte G. **Blood Cells Mol Dis** 1998 Dec;24(4):433–8

Frequency of the C282Y mutation of hemochromatosis in five French populations. Mercier G, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):165–6

Hemochromatosis in Ireland and HFE. Ryan E, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):428–32

Transferrin receptor mutation analysis in hereditary hemochromatosis patients. Tsuchihashi Z, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):317–21

Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled [editorial] Haddow JE, et al. **BMJ** 1999 Aug 28;319(7209):531–2

Hereditary haemochromatosis should be more widely known about [letter] Rosenberg W, et al. **BMJ** 1999 May 29; 318(7196):1486–7

The common haemochromatosis mutation does not increase the risk of thrombosis in patients with factor V Leiden [letter] Banypersad S, et al. **Br J Haematol** 1999 Jun; 105(3):842–3

The haemochromatosis mutations do not modify the clinical picture of thalassaemia major in patients regularly transfused and chelated. Borgna-Pignatti C, et al. **Br J Haematol** 1998 Dec;103(3):813–6

Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation. Brown K, et al. **Br J Haematol** 1999 Apr; 105(1):95–7

Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Franco RF, et al. **Br J Haematol** 1998 Sep;102(5):1172–5

Is there a link between African iron overload and the described mutations of the hereditary haemochromatosis gene? McNamara L, et al. **Br J Haematol** 1998 Sep; 102(5):1176–8

Haemochromatosis mutations in North-East Scotland. Miedzybrodzka Z, et al. **Br J Haematol** 1999 Aug; 106(2):385–7

Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Nielsen P, et al. **Br J Haematol** 1998 Dec;103(3):842–5

Pathogenesis and management of haemochromatosis. Worwood M. **Br J Haematol** 1999 Apr;105 Suppl 1:16–8 (24 ref.)

Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Nair J, et al. **Cancer Epidemiol Biomarkers Prev** 1998 May; 7(5):435–40

Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women [see comments] Roest M, et al. **Circulation** 1999 Sep 21; 100(12):1268–73. Comment in: Circulation 1999 Sep 21;100(12):1260–3.

Iron and the genetics of cardiovascular disease [editorial; comment] Sullivan JL. **Circulation** 1999 Sep 21; 100(12):1260–3. Comment on: Circulation 1999 Sep 21;100(12):1268–73. Comment on: Circulation 1999 Sep 21;100(12):1274–9.

Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see comments] Tuomainen TP, et al. **Circulation** 1999 Sep 21; 100(12):1274–9. Comment in: Circulation 1999 Sep 21;100(12):1260–3.

Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Datz C, et al. **Clin Chem** 1998 Dec;44(12):2429–32

Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Mangasser-Stephan K, et al. **Clin Chem** 1999 Oct; 45(10):1875–8

Simple multiplex PCR for the simultaneous detection of the C282Y and H63D hemochromatosis (HFE) gene mutations. Stott MK, et al. **Clin Chem** 1999 Mar;45(3):426–8

Hemochromatosis: genetics helps to define a multifactorial disease. Burke W, et al. **Clin Genet** 1998 Jul;54(1):1–9 (70 ref.)

Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Kwan T, et al. **Clin Invest Med** 1998 Dec;21(6):251–7

Haemochromatosis: an inherited metal and toxicity syndrome. Cox TM, et al. **Curr Opin Genet Dev** 1998 Jun; 8(3):274–81 (61 ref.)

Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM [letter] Dubois-Laforgue D, et al. **Diabetes Care** 1998 Aug;21(8):1371–2

C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes [letter] Fernandez-Real JM, et al. **Diabetes Care** 1999 Mar;22(3):525–6

Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in Type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Florkowski CM, et al. **Diabetes Res Clin Pract** 1999 Mar; 43(3):199–203

Hereditary haemochromatosis mutations (HFE) in patients with Type II diabetes mellitus [letter] Braun J, et al. **Diabetologia** 1998 Aug;41(8):983–4

A 6p22 reference map of leukocyte DNA: exclusion of rearrangement in four cases of atypical haemochromatosis. Wallace DF, et al. **Eur J Hum Genet** 1998 Sep-Oct; 6(5):523–6

Molecular medicine and hemochromatosis: at the crossroads. Bacon BR, et al. **Gastroenterology** 1999 Jan;116(1):193–207

The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Kazemi-Shirazi L, et al. **Gastroenterology** 1999 Jan; 116(1):127–34

Hemochromatosis mutation in hepatitis C: histopathology [letter; comment] Knöll A, et al. **Gastroenterology** 1998 Nov;115(5):1307–9. Comment on: Gastroenterology 1998 Feb;114(2):311–8.

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Moirand R, et al. **Gastroenterology** 1999 Feb;116(2):372–7

HCV and C282Y: a sinister synergism? Russo M, et al. **Gastroenterology** 1999 Feb;116(2):494–5

p53 mutations in british patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Vautier G, et al. **Gastroenterology** 1999 Jul;117(1):154–60

A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Wallace DF, et al. **Gastroenterology** 1999 Jun; 116(6):1409–12

Cloning, sequencing and characterization of the rat hereditary hemochromatosis promoter: comparison of the human, mouse and rat HFE promoter regions. Sánchez M, et al. **Gene** 1998 Dec 28;225(1-2):77–87

Mutation analysis of the HLA-H gene in French hemochromatosis patients, and genetic counseling in families. Mercier G, et al. **Genet Couns** 1998;9(3):181–6

Is the hemochromatosis gene a modifier locus for cystic fibrosis? Rohlfs EM, et al. **Genet Test** 1998;2(1):85–8

The significance of haemochromatosis gene mutations in the general population: implications for screening. Burt MJ, et al. **Gut** 1998 Dec;43(6):830–6

H63D is an haemochromatosis associated allele [letter; comment] Fairbanks VF, et al. **Gut** 1998 Sep;43(3):441–2 . Comment on: Gut 1997 Dec;41(6):841–4. Comment on: Gut 1997 Dec;41(6):855–6.

Colorectal cancer and HFE gene mutations [letter] Altés A, et al. **Haematologica** 1999 May;84(5):479–80

Variation in the phenotypic expression of C282Y hemochromatosis in an Italian family [letter] Bosio S, et al. **Haematologica** 1999 Feb;84(2):184–5

Isolated hyperferritinemia with normal transferrin saturation and dysmetabolism, in the absence of the two known mutations in the HFE gene of hereditary hemochromatosis [letter] [see comments] Orlandi E, et al. **Haematologica** 1999 Feb;84(2):181–2. Comment in: Haematologica 1999 Feb;84(2):97–8.

The dysmetabolic iron overload syndrome is clinically and genetically distinct from HFE-related genetic hemochromatosis [letter] [see comments] Rovati A, et al. **Haematologica** 1999 Feb;84(2):182–3. Comment in: Haematologica 1999 Feb;84(2):97–8.

Population screening for hemochromatosis. Adams PC. **Hepatology** 1999 Apr;29(4):1324–7 (43 ref.)

Prevalence of the C282Y mutation of the hemochromatosis gene in liver transplant recipients and donors. Alanen KW, et al. **Hepatology** 1999 Sep;30(3):665–9

Inherited HFE-unrelated hemochromatosis in Italian families. Camaschella C, et al. **Hepatology** 1999 May; 29(5):1563–4

Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis [letter; comment] Hézode C, et al. **Hepatology** 1999 Apr;29(4):1338. Comment on: Hepatology 1998 Jun;27(6):1695–9.

Hemochromatosis: a "simple" genetic trait. Press RD. **Hosp Pract (Off Ed)** 1999 Aug 15;34(8):55–8, 61–2, 68 passim

A rapid automated SSCP multiplex capillary electrophoresis protocol that detects the two common mutations implicated in hereditary hemochromatosis (HH). Wenz HM, et al. **Hum Genet** 1999 Jan;104(1):29–35

Polymorphisms in the HFE gene. Douabin V, et al. **Hum Hered** 1999 Jan;49(1):21–6

Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. de Villiers JN, et al. **Hum Mol Genet** 1999 Aug;8(8):1517–22

A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Merryweather-Clarke AT, et al. **Hum Mutat** 1999; 13(2):154–9

Alternate splice variants of the hemochromatosis gene Hfe. Rhodes DA, et al. **Immunogenetics** 1999 Apr;49(4):357–9

Utility of genotyping in diagnosis of genetic haemochromatosis [editorial; comment] Crawford DH, et al. **J Gastroenterol Hepatol** 1999 May;14(5):401–2. Comment on: J Gastroenterol Hepatol 1999 May;14(5):427–30.

The haemochromatosis gene: a co-factor for chronic liver diseases? George DK, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):745–9 (50 ref.)

Genotyping as a diagnostic aid in genetic haemochromatosis [see comments] Rossi E, et al. **J Gastroenterol Hepatol** 1999 May;14(5):427–30. Comment in: J Gastroenterol Hepatol 1999 May;14(5):401–2.

A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. Brissot P, et al. **J Hepatol** 1999 Apr;30(4):588–93

End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. Cotler SJ, et al. **J Hepatol** 1998 Aug;29(2):257–62

Hemochromatosis 1998: is one gene enough? Pietrangelo A. **J Hepatol** 1998 Sep;29(3):502–9 (66 ref.)

Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. Pratiwi R, et al. **J Hepatol** 1999 Jul;31(1):39–46

Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. Sánchez M, et al. **J Hepatol** 1998 Nov;29(5):725–8

Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. Himmelmann A, et al. **J Lab Clin Med** 1999 Mar; 133(3):229–36 (51 ref.)

Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver injury. Niemelä O, et al. **J Lab Clin Med** 1999 May;133(5):451–60

Frequency of the HFE C282Y and H63D mutations in distinct ethnic groups living in Spain [letter; comment] Baiget M, et al. **J Med Genet** 1998 Aug;35(8):701. Comment on: J Med Genet 1997 Apr;34(4):275–8.

Non-C282Y familial iron overload: evidence for locus heterogeneity in haemochromatosis. Pinson S, et al. **J Med Genet** 1998 Nov;35(11):954–6

High frequency of the haemochromatosis C282Y mutation in Hungary could argue against a Celtic origin of the mutation [letter; comment] Tordai A, et al. **J Med Genet** 1998 Oct;35(10):878–9. Comment on: J Med Genet 1997 Apr;34(4):275–8.

Atypical haemochromatosis: phenotypic spectrum and beta2-microglobulin candidate gene analysis. Walker AP, et al. **J Med Genet** 1999 Jul;36(7):537–41

Familial perinatal hemochromatosis: a disease that causes recurrent non-immune hydrops. Kassem E, et al. **J Perinat Med** 1999;27(2):122–7

Haemochromatosis and control of intestinal iron absorption [comment] Anderson GJ, et al. **Lancet** 1999 Jun 19; 353(9170):2089–90. Comment on: Lancet 1999 Jun 19;353(9170):2120–3.

Transfusion with blood from people with HFE gene mutations [letter] Ania BJ, et al. **Lancet** 1999 Jul 31; 354(9176):430

Interaction between haemochromatosis and transferrin receptor genes in multiple myeloma [letter] Van Landeghem GF, et al. **Lancet** 1998 Oct 17;352(9136):1285–6

Haemochromatosis gene C282Y homozygotes in an elderly male population [letter] Willis G, et al. **Lancet** 1999 Jul 17;354(9174):221–2

Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis [see comments] Zoller H, et al. **Lancet** 1999 Jun 19; 353(9170):2120–3. Comment in: Lancet 1999 Jun 19;353(9170):2089–90.

Prevalence of hemochromatosis related HFE gene mutations in patients with acute myeloid leukemia [letter] Gimferrer E, et al. **Leuk Res** 1999 Jun;23(6):597–8

Hereditary hemochromatosis in liver transplantation. Fiel MI, et al. **Liver Transpl Surg** 1999 Jan;5(1):50–6

Update on hereditary hemochromatosis and the HFE gene. Brandhagen DJ, et al. **Mayo Clin Proc** 1999 Sep; 74(9):917–21 (25 ref.)

A PCR-SSP method for detecting the His63Asp mutation in the HFE gene associated with hereditary haemochromatosis. Smillie D. **Mol Pathol** 1998 Aug; 51(4):232–3

A population-based study of the clinical expression of the hemochromatosis gene [see comments] Olynyk JK, et al. **N Engl J Med** 1999 Sep 2;341(10):718–24. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.

Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene [see comments] Pietrangelo A, et al. **N Engl J Med** 1999 Sep 2; 341(10):725–32. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.

Clinical implications of the hemochromatosis gene [editorial; comment] Tavill AS. **N Engl J Med** 1999 Sep 2; 341(10):755–7. Comment on: N Engl J Med 1999 Sep 2;341(10):718–24. Comment on: N Engl J Med 1999 Sep 2;341(10):725–32.

Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis [letter] Jeffrey GP, et al. **Nat Genet** 1999 Aug;22(4):325–6

Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)

Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Salter-Cid L, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5434–9

Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. Kelly AL, et al. **QJM** 1998 Sep;91(9):607–18

High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary haemochromatosis in South Africa. de Villiers JN, et al. **S Afr Med J** 1999 Mar;89(3):279–82

Molecular diagnosis of hereditary haemochromatosis--identify an affected person and save a family [editorial] Milani MY, et al. **S Afr Med J** 1999 Mar;89(3):263–4

Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis [letter] Frenzer A, et al. **Scand J Gastroenterol** 1998 Dec; 33(12):1324

Haemochromatosis: pathological or beneficial. Worwood M. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1925–35 (85 ref.)

High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population--implications for haemochromatosis. Murphy S, et al. **Tissue Antigens** 1998 Nov;52(5):484–8

Determination of gene frequencies for two common

haemochromatosis mutations in the Danish population by a novel polymerase chain reaction with sequence-specific primers. Steffensen R, et al. **Tissue Antigens** 1998 Sep; 52(3):230–5

Iron overload: molecular clues to its cause. Kühn LC. **Trends Biochem Sci** 1999 May;24(5):164–6 (24 ref.)

Rapid detection of genetic mutations associated with haemochromatosis. Guttridge MG, et al. **Vox Sang** 1998; 75(3):253–6

[Is there a link between secondary hemochromatosis and genetics? Apropos of 2 cases] Paris I, et al. **Acta Clin Belg** 1999 Jan–Feb;54(1):26–9 (Eng. Abstr.) **(Fre)**

[Genetic hemochromatosis] Jouanolle AM, et al. **Ann Biol Clin (Paris)** 1998 Jul;56 Spec No:31–5 (22 ref.) **(Fre)**

[Genetic screening of hemochromatosis (editorial)] Brissot P. **Rev Med Interne** 1998 Mar;19(3):165–7 (15 ref.) **(Fre)**

[The hemochromatosis gene (HFE). Molecular analysis--diagnostic applications] Ferec C, et al. **Transfus Clin Biol** 1998 Aug;5(4):283–9 (Eng. Abstr.) **(Fre)**

[Hemochromatosis and Wilson disease] Herrmann T, et al. **Internist (Berl)** 1999 May;40(5):513–21 (44 ref.) **(Ger)**

[Molecular biology analysis: hereditary hemochromatosis, Wilson disease, alpha 1-antitrypsin deficiency and Dubin-Johnson syndrome] Arnold C. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1390–6 (28 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of hereditary hemochromatosis with molecular analysis of DNA in patients with anti-HCV positive liver cirrhosis. Clinical case] Carella AM, et al. **Minerva Med** 1998 Sep;89(9):323–7 (Eng. Abstr.) **(Ita)**

[Interpretation of genetic test results in hemochromatosis] Boman H. **Tidsskr Nor Laegeforen** 1998 Oct 20; 118(25):3984 **(Nor)**

[Pathogenetic aspects of hemolysis and changes of blood rheology in hereditary hemochromatosis] Ershova LI, et al. **Ter Arkh** 1998;70(11):74–6 (Eng. Abstr.) **(Rus)**

[The prevalence of the Cys282Tyr mutation in the hemochromatosis gene in Cantabria in patients diagnosed with hereditary hemochromatosis] Fábrega E, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):451–3 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Gamma delta intraepithelial lymphocytes drive tumor necrosis factor-alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis. Ten Elshof AE, et al. **Immunol Rev** 1999 Feb;167:223–32

METABOLISM

Elevated parathyroid hormone 44–68 and osteoarticular changes in patients with genetic hemochromatosis. Pawlotsky Y, et al. **Arthritis Rheum** 1999 Apr;42(4):799–806

Relation between iron stores and non-insulin dependent diabetes in men: case-control study. Salonen JT, et al. **BMJ** 1998 Sep 12;317(7160):727

Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Bastin JM, et al. **Br J Haematol** 1998 Dec;103(4):931–41

Molecular medicine and hemochromatosis: at the crossroads. Bacon BR, et al. **Gastroenterology** 1999 Jan;116(1):193–207

Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Kaltwasser JP, et al. **Gut** 1998 Nov;43(5):699–704

Gamma delta intraepithelial lymphocytes drive tumor necrosis factor-alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis. Ten Elshof AE, et al. **Immunol Rev** 1999 Feb;167:223–32

Influence of iron overload on manganese, zinc, and copper concentration in rat tissues in vivo: study of liver, spleen, and brain. Vayenas DV, et al. **Int J Clin Lab Res** 1998; 28(3):183–6

Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations. Vergani A, et al. **Ital J Gastroenterol Hepatol** 1999 Jun–Jul; 31(5):395–400

Expression of SFT (stimulator of Fe transport) is enhanced by iron chelation in HeLa cells and by hemochromatosis in liver. Yu J, et al. **J Biol Chem** 1998 Dec 25; 273(52):34675–8

Cellular expression and regulation of iron transport and storage proteins in genetic haemochromatosis. Basclain KA, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):624–34

Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. Fletcher LM, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):202–14 (157 ref.)

The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary haemochromatosis. Lebrón JA, et al. **J Mol Biol** 1999 Jun 18;289(4):1109–18

Haemochromatosis and control of intestinal iron absorption [comment] Anderson GJ, et al. **Lancet** 1999 Jun 19; 353(9170):2089–90. Comment on: Lancet 1999 Jun 19;353(9170):2120–3.

Beeturia and iron absorption [letter] Sotos JG. **Lancet** 1999 Sep 18;354(9183):1032

Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis [see comments] Zoller H, et al. **Lancet** 1999 Jun 19; 353(9170):2120–3. Comment in: Lancet 1999 Jun 19;353(9170):2089–90.

Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Fleming RE, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3143–8

MORTALITY

Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Yang Q, et al. **Ann Intern Med** 1998 Dec 1; 129(11):946–53

PATHOLOGY

Magnetic resonance iron-free nodules in genetic hemochromatosis. Guyader D, et al. **Am J Gastroenterol** 1999 Apr;94(4):1083–6

Oval cell numbers in human chronic liver diseases are directly related to disease severity. Lowes KN, et al. **Am J Pathol** 1999 Feb;154(2):537–41

Corneal findings in hemochromatosis [letter] Lazzaro DR, et al. **Arch Ophthalmol** 1998 Nov;116(11):1531–2

Effects of dietary iron overload on progression in chemical hepatocarcinogenesis. Stål P, et al. **Liver** 1999 Aug; 19(4):326–34

Skin fragility and abnormal liver function tests. Chitturi S, et al. **Postgrad Med J** 1999 Jul;75(885):435–6

Predominant ankle arthropathy in hereditary haemochromatosis [letter] Jacki SH, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):378–9

PHYSIOPATHOLOGY

Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis. Hempenius LM, et al. **J Endocrinol Invest** 1999 May;22(5):369–76

[Diabetes mellitus in hemochromatosis] Niederau C. **Z Gastroenterol** 1999 Jun;Suppl 1:22–32 (53 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Should we genetically test everyone for haemochromatosis? Allen K, et al. **J Med Ethics** 1999 Apr;25(2):209–14

[Genetic screening of hemochromatosis (editorial)] Brissot P. **Rev Med Interne** 1998 Mar;19(3):165–7 (15 ref.) **(Fre)**

SURGERY

Liver transplantation for metabolic liver diseases. Khanna A, et al. **Surg Clin North Am** 1999 Feb;79(1):153–62, ix (61 ref.)

THERAPY

Management of hemochromatosis. Hemochromatosis Management Working Group. Barton JC, et al. **Ann Intern Med** 1998 Dec 1;129(11):932–9 (86 ref.)

Clinical management of iron overload. Tung BY, et al. **Gastroenterol Clin North Am** 1998 Sep;27(3):637–54 (86 ref.)

Hereditary haemochromatosis: diagnosis and management in the gene era. Olynyk JK. **Liver** 1999 Apr;19(2):73–80 (81 ref.)

[Diagnosis and treatment of primary hemochromatosis] Swinkels DW, et al. **Ned Tijdschr Geneeskd** 1999 Jul 3; 143(27):1404–8 (57 ref.) (Eng. Abstr.) **(Dut)**

[The use of therapeutic plasmapheresis in the combined therapy of a female patient with idiopathic hemochromatosis] Krivosheev AB, et al. **Anesteziol Reanimatol** 1998 Jul–Aug;(4):50–2 (10 ref.) (Eng. Abstr.) **(Rus)**

URINE

Quantitative determination of 8-hydroxy-2'-deoxyguanosine in human urine by isotope dilution mass spectrometry: normal levels in hemochromatosis. Holmberg I, et al. **Free Radic Biol Med** 1999 Jan;26(1–2):129–35

Orange urine. Lord RC. **Postgrad Med J** 1999 Feb; 75(880):109–10

HEMOCOAGULASE see **REPTILASE**

HEMOCUPREIN see **SUPEROXIDE DISMUTASE**

HEMOCYANIN

ANALOGS & DERIVATIVES

Abalone (Haliotis tuberculata) hemocyanin type 1 (HtH1). Organization of the approximately 400 kDa subunit, and amino acid sequence of its functional units f, g and h. Keller H, et al. **Eur J Biochem** 1999 Aug;264(1):27–38

ANALYSIS

Production and characterization of a bivalent single chain Fv/alkaline phosphatase conjugate specific for the hemocyanin of the scorpion Androctonus australis. Mousli M, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):348–60

CHEMISTRY

Subunits composition and allosteric control in Carcinus aestuarii hemocyanin. Dainese E, et al. **Eur J Biochem** 1998 Sep 1;256(2):350–8

Tarantula hemocyanin shows phenoloxidase activity. Decker H, et al. **J Biol Chem** 1998 Oct 2;273(40):25889–92

Intramolecular localization of the functional units of Sepia officinalis hemocyanin by immunoelectron microscopy. Lamy J, et al. **J Mol Biol** 1998 Dec 11;284(4):1051–74

GENETICS

Subunit composition and N-terminal analysis of arthropod hemocyanins. Stoeva S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):69–75

Identification, molecular cloning, and phylogenetic analysis of a non-respiratory pseudo-hemocyanin of Homarus americanus. Burmester T. **J Biol Chem** 1999 May 7; 274(19):13217–22

IMMUNOLOGY

Optimization and immunological characterization of a photochemically coupled lysergic acid diethylamide (LSD) immunogen. Kerrigan S, et al. **Bioconjug Chem** 1998 Sep–Oct;9(5):596–603

Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Adluri S, et al. **Br J Cancer** 1999 Apr;79(11–12):1806–12

In-vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma. Wen YJ, et al. **Br J Haematol** 1998 Dec;103(3):663–8

Detection of adducts of bromobenzene 3,4-oxide with rat liver microsomal protein sulfhydryl groups using specific antibodies. Rombach EM, et al. **Chem Res Toxicol** 1999 Feb;12(2):159–63

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Yao TJ, et al. **Clin Cancer Res** 1999 Jan;5(1):77–81

Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Douce G, et al. **Infect Immun** 1999 Sep;67(9):4400–6

Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. Kantele A, et al. **J Immunol** 1999 May 1;162(9):5173–7

An improved method for the production of antibodies to lipophilic carboxylic hapten using small amount of hapten-carrier conjugate. Pauillac S, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):105–14

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. Sandmaier BM, et al. **J Immunother** 1999 Jan;22(1):54–66

Cross reacting antibodies against keyhole limpet haemocyanin may interfere with the diagnostics of acute schistosomiasis. Thors C, et al. **Parasite Immunol** 1998 Oct; 20(10):489–96

Periodate-sensitive immunological cross-reactivity between keyhole limpet haemocyanin (KLH) and serodiagnostic Schistosoma mansoni egg antigens. Hamilton JV, et al. **Parasitology** 1999 Jan;118 (Pt 1):83–9

METABOLISM

The enzymatic properties of Octopus vulgaris hemocyanin: o-diphenol oxidase activity. Salvato B, et al. **Biochemistry** 1998 Oct 6;37(40):14065–77

Controlled cleavage of KLH1 and KLH2 by the V8 protease from Staphylococcus aureus reassociation, electrophoretic and transmission electron microscopy study of peptide fragments. Gebauer W, et al. **Eur J Biochem** 1999 May; 262(1):166–75

Lipid binding capacity of spider hemocyanin. Cunningham M, et al. **J Exp Zool** 1999 Sep 1;284(4):368–73

Quantum mechanical analysis of oxygenated and deoxygenated states of hemocyanin: theoretical clues for a plausible allosteric model of oxygen binding. Fariselli P, et al. **Protein Sci** 1999 Jul;8(7):1546–50

THERAPEUTIC USE

Dendritic cell immuno-therapy in disseminated parathyroid carcinoma [letter; comment] Schott M, et al. **Lancet** 1999 Apr 3;353(9159):1188–9. Comment on: Lancet 1999 Jan 30;353(9150):370–3.

Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy. Jurincic-Winkler C, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):409–15

ULTRASTRUCTURE

Intramolecular localization of the functional units of Sepia officinalis hemocyanin by immunoelectron microscopy. Lamy J, et al. **J Mol Biol** 1998 Dec 11;284(4):1051–74

HEMOCYTES

CHEMISTRY

Presence of IL-1- and TNF-like molecules in Galleria mellonella (Lepidoptera) haemocytes and in an insect cell line Fromestigmene acraea (Lepidoptera). Wittwer D, et al. **Cytokine** 1999 Sep;11(9):637-42

Purification and characterization of a cysteine-rich 11.5-kDa antibacterial protein from the granular haemocytes of the shore crab, Carcinus maenas. Relf JM, et al. **Eur J Biochem** 1999 Sep;264(2):350-7

Presence of immunoreactive corticotropin-releasing hormone and cortisol molecules in invertebrate haemocytes and lower and higher vertebrate thymus. Ottaviani E, et al. **Histochem J** 1998 Feb;30(2):61-7

Horseshoe crab hemocyte-derived antimicrobial polypeptides, tachystatins, with sequence similarity to spider neurotoxins. Osaki T, et al. **J Biol Chem** 1999 Sep 10;274(37):26172-8

CYTOLOGY

Plasmatocyte spreading peptide does not induce Microplitis demolitor polydnavirus-infected plasmatocytes to spread on foreign surfaces. Strand MR, et al. **Arch Insect Biochem Physiol** 1999;40(1):41-52

DRUG EFFECTS

Interactions of signaling pathways in ACTH (1-24)-induced cell shape changes in invertebrate immunocytes. Sassi D, et al. **Peptides** 1998;19(6):1105-10

ENZYMOLOGY

Prophenoloxidase from brown shrimp (Penaeus californiensis) hemocytes. Gollas-Galván T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):77-82

Ascidian phenoloxidase: its release from hemocytes, isolation, characterization and physiological roles. Hata S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):769-76

Four serine proteinases expressed in Manduca sexta haemocytes. Jiang H, et al. **Insect Mol Biol** 1999 Feb; 8(1):39-53

A hemocyte-like cell line established from the malaria vector Anopheles gambiae expresses six prophenoloxidase genes. Müller HM, et al. **J Biol Chem** 1999 Apr 23; 274(17):11727-35

Stimulation of NO synthase activity in the immune-competent lepidopteran Estigmene acraea hemocyte line. Weiske J, et al. **Nitric Oxide** 1999; 3(2):123-31

IMMUNOLOGY

Comparative study on the effect of cyclic nucleotides related to the function of Biomphalaria glabrata hemocytes and human granulocytes. Bezerra FS, et al. **Acta Trop** 1999 Apr 30;72(3):275-80

Factors influencing in vitro killing of bacteria by hemocytes of the eastern oyster (Crassostrea virginica). Genthner FJ, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3015-20

The suppressive excretory-secretory product of Trichobilharzia ocellata: a possible factor for determining compatibility in parasite-host interactions. Núñez PE, et al. **Parasitology** 1997 Aug;115 (Pt 2):193-203

Presence of Dirofilaria repens and an insect immunocyte (plasmatocyte) in a human subcutaneous nodule, induced by a mosquito bite. Pampiglione S, et al. **Parassitologia** 1998 Sep;40(3):343-6

METABOLISM

Acidification of the phagosome in Crassostrea virginica hemocytes following engulfment of zymosan. Beaven AE, et al. **Biol Bull** 1999 Feb;196(1):26-33

Morphine coupling to invertebrate immunocyte nitric oxide release is dependent on intracellular calcium transients. Nieto-Fernandez FE, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jul; 123(3):295-9

Cadmium turnover in the hemocytes of Mercenaria mercenaria (L.) in relation to hemocyte turnover. McIntosh LM, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 May;123(1):61-6

PDGF and TGF-beta induce cell shape changes in invertebrate immunocytes via specific cell surface receptors. Kletsas D, et al. **Eur J Cell Biol** 1998 Apr; 75(4):362-6

The lipopolysaccharide-binding protein participating in hemocyte nodule formation in the silkworm Bombyx mori is a novel member of the C-type lectin superfamily with two different tandem carbohydrate-recognition domains. Koizumi N, et al. **FEBS Lett** 1999 Jan 25;443(2):139-43

A cell-surface superoxide dismutase is a binding protein for peroxinectin, a cell-adhesive peroxidase in crayfish. Johansson MW, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):917-25

PARASITOLOGY

Effect of Biomphalaria straminea plasma in the phagocytosis of Biomphalaria glabrata hemolymph cells. Malagueño E, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:301-2

PHYSIOLOGY

Analysis of the Drosophila host defense in domino mutant larvae, which are devoid of hemocytes. Braun A, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14337-42

VIROLOGY

Concomitant primary infection of the midgut epithelial cells and the hemocytes of Trichoplusia ni by Autographa californica nucleopolyhedrovirus. Barrett JW, et al. **Tissue Cell** 1998 Dec;30(6):602-16

HEMODIAFILTRATION

Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Brunet S, et al. **Am J Kidney Dis** 1999 Sep;34(3):486-92

Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration. Meyer MM, et al. **Am J Kidney Dis** 1999 Apr;33(4):790-5

Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor [see comments] Ozkahya M, et al. **Am J Kidney Dis** 1999 Aug; 34(2):218-21. Comment in: Am J Kidney Dis 1999 Aug;34(2):359-61.

Continuous venovenous hemodiafiltration in the treatment of acute hyperammonemia. Braun MC, et al. **Am J Nephrol** 1998;18(6):531-3

The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients. Sato T, et al. **Artif Organs** 1999 Feb;23(2):143-5

Intensive tandem cryofiltration apheresis and hemodialysis to treat a patient with severe calciphylaxis, cryoglobulinemia, and end-stage renal disease. Siami GA, et al. **ASAIO J** 1999 May-Jun;45(3):229-33

Ineffectiveness of dialysis in transthyretin (TTR) clearance in familial amyloid polyneuropathy type I, in spite of lower stability of the TTR Met30 variant. Beirão I, et al. **Clin Nephrol** 1999 Jan;51(1):45-9

Peculiar blood volume profile during hemodiafiltration therapy: of benefit to the hemodynamic stability in patients? [letter] Kawabata M, et al. **Clin Nephrol** 1998 Nov; 50(5):333-4

The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. van der Sande FM, et al. **Clin Nephrol** 1998 Nov;50(5):301-8

Hemofiltration and left ventricular function in sepsis: mechanisms and clinical implications [editorial; comment] Dhainaut JF, et al. **Crit Care Med** 1999 Mar;27(3):473-4 (13 ref.). Comment on: Crit Care Med 1999 Mar;27(3):588-96.

Elimination of meropenem by continuous hemo(dia) filtration: an in vitro one-compartment model. Schroeder TH, et al. **Int J Artif Organs** 1999 May;22(5):307-12

Monocyte activation and humoral immune response to endotoxins in patients receiving on-line hemodiafiltration therapy. Weber C, et al. **Int J Artif Organs** 1998 Jun; 21(6):335-40

Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Hu ZJ, et al. **Intensive Care Med** 1999 May; 25(5):524-7

Contrast medium-removing effect of hemofiltration and hemodiafiltration. Okahisa T, et al. **J Med Invest** 1998 Aug; 45(1-4):87-93

Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Locatelli F, et al. **Kidney Int** 1999 Jan;55(1):286-93

Enhancement of convective transport by internal filtration in a modified experimental hemodialyzer: technical note. Ronco C, et al. **Kidney Int** 1998 Sep;54(3):979-85

Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Camici M, et al. **Minerva Med** 1998 Nov-Dec;89(11-12):405-9

Plasma or whole blood concentrations of trace elements in patients treated by haemodiafiltration with on-line prepared substitution fluid. Bonforte G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:29-33

Thermal energy balance and body temperature: comparison between isolated ultrafiltration and haemodialysis at different dialysate temperatures. Keijman JM, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2196-200

Does intensive perioperative dialysis improve the results of coronary artery bypass grafting in haemodialysed patients? Okada H, et al. **Nephrol Dial Transplant** 1999 Mar; 14(3):771-5

Clinical perspectives of on-line haemodiafiltration. Pizzarelli F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:34-7 (46 ref.)

Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Schettler V, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2588-93

Trace elements and micropollutant anions in the dialysis and reinfusion fluid prepared on-line for haemodiafiltration. Surian M, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:24-8

Treatment of hirudin overdosage in a patient with chronic renal failure [letter] Bauersachs RM, et al. **Thromb Haemost** 1999 Feb;81(2):323-4

[Paired filtration dialysis--evaluation of effectiveness of the method] Eiselt J, et al. **Vnitr Lek** 1998 Jun;44(6):320-5 (Eng. Abstr.) **(Cze)**

ADVERSE EFFECTS

Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. Panichi V, et al. **ASAIO J** 1998 Sep-Oct;44(5):M415-7

Cytokine production in haemodiafiltration: a multicentre study. Panichi V, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1737-44

INSTRUMENTATION

Duocart biofiltration: a new method of hemodialysis. Mercadal L, et al. **ASAIO J** 1999 May-Jun;45(3):151-6

Efficiency parameters and treatment adequacy of hemodialysis and hemodiafiltration using polymethylmethacrylate membranes. Di Filippo S, et al. **Contrib Nephrol** 1999;125:86-95

Continuous hemodialfiltration using PMMA membrane: clinical efficacy and its mechanisms. Moriyama K, et al. **Contrib Nephrol** 1999;125:222-32 (21 ref.)

On-line haemodiafiltration: state of the art. Canaud B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:3-11 (55 ref.)

Regulatory issues for on-line haemodiafiltration. Pirovano D. **Nephrol Dial Transplant** 1998;13 Suppl 5:21-3; discussion 39

METHODS

On-line hemodiafiltration: technique and therapy. Ledebo I. **Adv Ren Replace Ther** 1999 Apr;6(2):195-208 (59 ref.)

Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Falkenhagen D, et al. **Artif Organs** 1999 Jan;23(1):81-6

Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? Awad SS, et al. **ASAIO J** 1999 Jan-Feb;45(1):47-9

Duocart biofiltration: a new method of hemodialysis. Mercadal L, et al. **ASAIO J** 1999 May-Jun;45(3):151-6

Improved cardiovascular variables during acetate free biofiltration. Schrander-v.d. Meer AM, et al. **Clin Nephrol** 1999 May;51(5):304-9

Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome [see comments] Kellum JA, et al. **Crit Care Med** 1998 Dec;26(12):1995-2000. Comment in: Crit Care Med 1998 Dec;26(12):1940-2.

On-line hemodiafiltration with pre- and postdilution: impact on the acid-base status. Ahrenholz P, et al. **Int J Artif Organs** 1998 Jun;21(6):321-7

Changing acute renal failure treatment from intermittent hemodialysis to continuous hemofiltration: impact on azotemic control. Bellomo R, et al. **Int J Artif Organs** 1999 Mar;22(3):145-50

The concept of sorbent in hemodialysis [editorial] La Greca G, et al. **Int J Artif Organs** 1998 Jun;21(6):303-8

Change from conventional haemodiafiltration to on-line haemodiafiltration. Maduell F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1202-7

Hemodiafiltration for vancomycin overdose in a neonate with end-stage renal failure. Goebel J, et al. **Pediatr Nephrol** 1999 Jun;13(5):423-5

STANDARDS

Water quality for on-line haemodiafiltration. Cappelli G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:12-6 (34 ref.)

TRENDS

On-line haemodiafiltration: state of the art. Canaud B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 5:3-11 (55 ref.)

Ultrafiltration and convective-based dialysis modalities: new trends and applications for renal replacement therapy in ESRD patients. Canaud B, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:98-105 (57 ref.)

HEMODIALYSIS

see related

KIDNEY, ARTIFICIAL

Acute renal failure requiring haemodialysis after high doses percutaneous acetic acid injection for hepatocellular carcinoma. Van Hoof M, et al. **Acta Gastroenterol Belg** 1999 Jan-Mar;62(1):49-51

Neurohumoral responses to a single haemodialysis in chronic renal patients. Uusimaa P, et al. **Acta Physiol Scand** 1999 Jan;165(1):25-31

Thoracic CT findings in long-term hemodialysis patients. Coşkun M, et al. **Acta Radiol** 1999 Mar;40(2):181-6

Sodium management in dialysis by conductivity. Bosetto A, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):243-54 (10 ref.)

Physical functioning and exercise capacity in patients on dialysis. Johansen KL. **Adv Ren Replace Ther** 1999 Apr;

6(2):141–8 (42 ref.)
Cardiac output and central blood volume during hemodialysis: methodology. Krivitski NM, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):225–32
Hemodynamic monitoring during hemodialysis. Leypoldt JK, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):233–42 (68 ref.)
Biofeedback systems architecture. Paolini F, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):255–64 (23 ref.)
Urea sensors--a world of possibilities. Sternby J. **Adv Ren Replace Ther** 1999 Jul;6(3):265–72 (26 ref.)
Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure [letter] Guardiola JM, et al. **AIDS** 1998 Jul 30;12(11):1395
Resource requirements for interventional radiologic management of long-term ambulatory hemodialysis patients. Jaques PF, et al. **AJR Am J Roentgenol** 1999 Oct; 173(4):1017–21
Reversibility of peritoneal calcification in a dialysis patient maintained on hemodialysis and total parenteral nutrition. Najem ES, et al. **AJR Am J Roentgenol** 1999 Jan; 172(1):247–8
Cost comparison of radiologic versus surgical placement of long-term hemodialysis catheters. Noh HM, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):673–5
Using helical CT to evaluate renal cell carcinoma in patients undergoing hemodialysis: value of early enhanced images. Takebayashi S, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):429–33
An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161–4 (46 ref.)
Effects of physical training on heart rate variability in patients on hemodialysis. Deligiannis A, et al. **Am J Cardiol** 1999 Jul 15;84(2):197–202
ED hemodialysis for treatment of renal failure emergencies. Sacchetti A, et al. **Am J Emerg Med** 1999 May;17(3):305–7
Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Glicklich D, et al. **Am J Gastroenterol** 1999 Jan; 94(1):159–63
Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood. Driver PS. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S12–6
Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients. de Lima JJ, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):204–8
Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Zazgornik J, et al. **Am J Hypertens** 1998 Nov; 11(11 Pt 1):1364–70
Proceedings of the workshop on nutritional support in dialysis with a focus on the role of intradialytic parenteral nutrition. December 3, 1997. **Am J Kidney Dis** 1999 Jan; 33(1):170–222
Strategies for influencing outcomes in pre-ESRD and ESRD patients: a special conference. 1998. Proceedings. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S1–193
Monitoring interposition graft venous pressures at higher blood-flow rates improves sensitivity in predicting graft failure. Agarwal R, et al. **Am J Kidney Dis** 1999 Aug; 34(2):212–7
Role of home blood pressure monitoring in hemodialysis patients. Agarwal R. **Am J Kidney Dis** 1999 Apr; 33(4):682–7
Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Amin NB, et al. **Am J Kidney Dis** 1999 Aug;34(2):222–7
A study of parenteral iron regimens in hemodialysis patients [see comments] Besarab A, et al. **Am J Kidney Dis** 1999 Jul;34(1):21–8. Comment in: Am J Kidney Dis 1999 Jul;34(1):173–6.
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Bleyer AJ, et al. **Am J Kidney Dis** 1999 Apr;33(4):694–701
Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Boaz M, et al. **Am J Kidney Dis** 1999 Sep;34(3):438–44
Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients. Borrego MJ, et al. **Am J Kidney Dis** 1999 Sep;34(3):456–63
Hematopoietic effect of Radix angelicae sinensis in a hemodialysis patient. Bradley RR, et al. **Am J Kidney Dis** 1999 Aug;34(2):349–54
Cerebral embolism after mechanical thrombolysis of a clotted hemodialysis access [see comments] Briefel GR, et al. **Am J Kidney Dis** 1999 Aug;34(2):341–3. Comment in: Am J Kidney Dis 1999 Aug;34(2):361–3.
Effect of hemodialysis on serum progesterone level in pregnant women. Brost BC, et al. **Am J Kidney Dis** 1999 May;33(5):917–9
Effect of hemodialysis on the pharmacokinetics of 19-nor-1alpha,25-dihydroxyvitamin D2. Cato A 3rd, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S55–60
Blood pressure control in dialysis patients: importance of the lag phenomenon. Charra B, et al. **Am J Kidney Dis** 1998 Nov;32(5):720–4 (28 ref.)
Outcome of nutritional status and body composition of uremic patients on a very low protein diet. Chauveau P, et al. **Am J Kidney Dis** 1999 Sep;34(3):500–7
Higher levels of antioxidant defenses in enalapril-treated versus non-enalapril-treated hemodialysis patients. de Cavanagh EM, et al. **Am J Kidney Dis** 1999 Sep; 34(3):445–55
Diagnosis of iron deficiency in chronic renal failure. Fernández-Rodríguez AM, et al. **Am J Kidney Dis** 1999 Sep;34(3):508–13
Iron treatment: impact of safety issues. Fishbane S. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S152–6
Intradialytic parenteral nutrition treatment [letter] Foulks CJ. **Am J Kidney Dis** 1999 Jun;33(6):1202
Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. Frankenfield DL, et al. **Am J Kidney Dis** 1999 Mar;33(3):584–91
Natural logarithmic estimates of Kt/V in the pediatric hemodialysis population. Goldstein SL, et al. **Am J Kidney Dis** 1999 Mar;33(3):518–22
Evaluation and prediction of urea rebound and equilibrated Kt/V in the pediatric hemodialysis population. Goldstein SL, et al. **Am J Kidney Dis** 1999 Jul;34(1):49–54
Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Gunnell J, et al. **Am J Kidney Dis** 1999 Jan;33(1):63–72
Proposed clinical trials in the evaluation of intradialytic parenteral nutrition. Hakim RM. **Am J Kidney Dis** 1999 Jan;33(1):217–20
Influence of the dialysis membrane on outcome of ESRD patients. Hakim RM. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S71–5
Hemodynamic stability during dialysis and cardiovascular disease in end-stage renal disease patients. Henrich WL. **Am J Kidney Dis** 1999 Jun;33(6):XLIX–LII (7 ref.)
Failure of advance care planning to elicit patients' preferences for withdrawal from dialysis. Holley JL, et al. **Am J Kidney Dis** 1999 Apr;33(4):688–93
Interferon-alpha in chronic hepatitis C infection in dialysis patients. Huraib S, et al. **Am J Kidney Dis** 1998 Dec;32(6):1036–40
Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Johannsson G, et al. **Am J Kidney Dis** 1999 Apr; 33(4):709–17
Successful treatment of valproic acid overdose with hemodialysis. Johnson LZ, et al. **Am J Kidney Dis** 1999 Apr;33(4):786–9
Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Kakuta T, et al. **Am J Kidney Dis** 1999 Jun;33(6):1091–9
Subcutaneous erythropoietin therapy: efficacy and economic implications. Kaufman JS. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S147–51
Transplantation, not dialysis, corrects azotemia-dependent priming of the neutrophil oxidative burst. Klein JB, et al. **Am J Kidney Dis** 1999 Mar;33(3):483–91
Low calorie intake in dialysis patients: an alternative explanation [letter; comment] Kloppenburg WD, et al. **Am J Kidney Dis** 1999 Jun;33(6):1202–4. Comment on: Am J Kidney Dis 1998 Dec;32(6):1019–22.
Dietary protein and energy requirements in ESRD patients. Kopple JD. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S97–104
Obstacles to achieving adequate dialysis dose: compliance, education, transportation, and reimbursement. Latham CE. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S93–5
Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Llach F, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S48–54
Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Lowrie EG. **Am J Kidney Dis** 1998 Dec; 32(6 Suppl 4):S105–12
Effect of intradialytic parenteral nutrition on delivered Kt/V. McCann L, et al. **Am J Kidney Dis** 1999 Jun;33(6):1131–5
L-carnitine use in hemodialyzed patients [letter; comment] Mantovani LG, et al. **Am J Kidney Dis** 1999 Aug; 34(2):400–1. Comment on: Am J Kidney Dis 1995 Nov;26(5):757–64. Comment on: Am J Kidney Dis 1998 Aug;32(2):258–64. Comment on: Am J Kidney Dis 1998 Aug;32(2):265–72.
Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Meier-Kriesche HU, et al. **Am J Kidney Dis** 1999 Apr;33(4):e8
Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Navarro JF, et al. **Am J Kidney Dis** 1999 Jul;34(1):43–8
To be or not to be: the decision to withdraw or be withdrawn from dialysis. Neff MS. **Am J Kidney Dis** 1999 Mar; 33(3):601–3; discussion 603–6
Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Park CW, et al. **Am J Kidney Dis** 1999 Jan;33(1):73–81
Does blood flow accurately predict thrombosis or failure of hemodialysis synthetic grafts? A meta-analysis. Paulson WD, et al. **Am J Kidney Dis** 1999 Sep;34(3):478–85
Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts. Petronis JD, et al. **Am J Kidney Dis** 1999 Aug;34(2):207–11
Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Propst T, et al. **Am J Kidney Dis** 1998 Dec;32(6):1041–5
Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients [see comments] Rahman M, et al. **Am J Kidney Dis** 1999 Mar;33(3):498–506. Comment in: Am J Kidney Dis 1999 Mar;33(3):492–4.
Intradialytic serial vascular access flow measurements. Rehman SU, et al. **Am J Kidney Dis** 1999 Sep;34(3):471–7
Inverse paradoxical embolism in a patient on chronic hemodialysis with aortic bacterial endocarditis [see comments] Rocha JL, et al. **Am J Kidney Dis** 1999 Aug; 34(2):338–40. Comment in: Am J Kidney Dis 1999 Aug;34(2):362–3.
Hypertension in the hemodialysis population? High time for answers [editorial; comment] [see comments] Salem M. **Am J Kidney Dis** 1999 Mar;33(3):592–4. Comment on: Am J Kidney Dis 1999 Mar;33(3):498–506. Comment on: Am J Kidney Dis 1999 Mar;33(3):507–17. Comment in: Am J Kidney Dis 1999 Aug;34(2):400.
Blood volume regulation during hemodialysis. Santoro A, et al. **Am J Kidney Dis** 1998 Nov;32(5):739–48
Indices of activity of the nitric oxide system in hemodialysis patients. Schmidt RJ, et al. **Am J Kidney Dis** 1999 Aug; 34(2):228–34
Identification of factors responsible for postdialysis fatigue. Sklar A, et al. **Am J Kidney Dis** 1999 Sep;34(3):464–70
Ambulatory blood pressure monitoring and interdialytic weight gain in children receiving chronic hemodialysis. Sorof JM, et al. **Am J Kidney Dis** 1999 Apr;33(4):667–74
Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Stopper H, et al. **Am J Kidney Dis** 1999 Sep;34(3):433–7
Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Swartz RD, et al. **Am J Kidney Dis** 1999 Sep;34(3):424–32
Attention and mental processing speed in hemodialysis patients. Umans JG, et al. **Am J Kidney Dis** 1998 Nov; 32(5):749–51
Association of acidosis and nutritional parameters in hemodialysis patients. Uribarri J, et al. **Am J Kidney Dis** 1999 Sep;34(3):493–9
Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Vanholder R, et al. **Am J Kidney Dis** 1999 May;33(5):934–40
Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Vardinon N, et al. **Am J Kidney Dis** 1999 Jul;34(1):146–9
Bilateral ophthalmoplegia and exophthalmos complicating central hemodialysis catheter placement. Varelas PN, et al. **Am J Kidney Dis** 1999 May;33(5):966–9
Optimal care of the pediatric end-stage renal disease patient on dialysis. Warady BA, et al. **Am J Kidney Dis** 1999 Mar; 33(3):567–83 (104 ref.)
Prevalence of preterminal pulmonary thromboembolism among patients on maintenance hemodialysis treatment before and after introduction of recombinant erythropoietin. Wiesholzer M, et al. **Am J Kidney Dis** 1999 Apr;33(4):702–8
Telecommunications and the dialysis patient. Winchester JF. **Am J Kidney Dis** 1999 Jul;34(1):XXXVI–XXXVIII
Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis. Wright MJ, et al. **Am J Kidney Dis** 1999 Jul;34(1):36–42
Dialysis dose, membrane type, and anemia control. Young EW. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S157–60
Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. Ahmed A, et al. **Am J Nephrol** 1999;19(4):505–8
Cimetidine-induced climacteric symptoms in a young man maintained on chronic hemodialysis. Bastani B, et al. **Am J Nephrol** 1998;18(6):538–40
The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Bay WH, et al. **Am J Nephrol** 1998;18(5):379–83
Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients. Charytan C, et al. **Am J Nephrol** 1998; 18(6):498–503
Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Elisaf M, et al. **Am J Nephrol** 1998;18(5):416–21
Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Fabrizi F, et al. **Am J Nephrol** 1999;19(3):383–8
Urea reduction ratio and urea kinetic modeling: a mathematical analysis of changing dialysis parameters. Kessler E, et al. **Am J Nephrol** 1998;18(6):471–7
Clinical findings and outcomes of intra-hemodialysis cardiopulmonary resuscitation. Lai M, et al. **Am J Nephrol** 1999;19(4):468–73
Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Lemmilä S,

et al. **Am J Nephrol** 1998;18(5):404–10
Protein intake seems to respond to increases in Kt/V despite baseline Kt/V greater than 1.2. Marcus RG, et al. **Am J Nephrol** 1999;19(4):500–4
Current status of renal replacement therapy for acute renal failure. A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. Mehta RL, et al. **Am J Nephrol** 1999;19(3):377–82
A new treatment forInterdialytic hyperkalemia – the use of fosinopril sodium. Mousa D, et al. **Am J Nephrol** 1999; 19(3):395–9
Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Nitta K, et al. **Am J Nephrol** 1998;18(5):411–5
Delivered dialysis dose is suboptimal in hospitalized patients. Obialo CI, et al. **Am J Nephrol** 1998;18(6):525–30
QRS amplitude and volume changes during hemodialysis. Ojanen S, et al. **Am J Nephrol** 1999;19(3):423–7
Abnormal adhesion of T cells to extracellular matrix proteins in hemodialysis patients [letter] Paczek L, et al. **Am J Nephrol** 1998;18(5):469–70
Improvement of myocardial fatty acid metabolism through L-carnitine administration to chronic hemodialysis patients. Sakurabayashi T, et al. **Am J Nephrol** 1999;19(4):480–4
Efficacy of percutaneous transluminal coronary angioplasty for patients on hemodialysis. Comparison with those not on dialysis. Sanai T, et al. **Am J Nephrol** 1999;19(1):38–44
Tuberculosis in active dialysis patients in Jeddah. Shohaib SA, et al. **Am J Nephrol** 1999;19(1):34–7
Study of effect of optimization of dialysis and protein intake on neuromuscular function in patients under maintenance hemodialysis treatment. Sobh MA, et al. **Am J Nephrol** 1998;18(5):399–403
Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Spence JD, et al. **Am J Nephrol** 1999;19(3):405–10
Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements. Teruel JL, et al. **Am J Nephrol** 1999;19(3):428–32
Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis. Yang C, et al. **Am J Nephrol** 1998; 18(5):384–90
The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Malone RS, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1580–4
Elevated basilic vein arteriovenous fistula. Humphries AL Jr, et al. **Am J Surg** 1999 Jun;177(6):489–91
Treatment of malarial acute renal failure by hemodialysis. Wilairatana P, et al. **Am J Trop Med Hyg** 1999 Feb; 60(2):233–7
Abdominal surgery in chronic hemodialysis patients. Wind P, et al. **Am Surg** 1999 Apr;65(4):347–51
Influence of acetate and bicarbonate dialysate on blood short- and long-chain acyl carnitine in adult pyelonephritis patients. Alhomida AS. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):48–55
Emergency department hemodialysis in a case of severe ethylene glycol poisoning. Johnson B, et al. **Ann Emerg Med** 1999 Jan;33(1):108–10
Life-threatening diphenhydramine overdose treated with charcoal hemoperfusion and hemodialysis. Mullins ME, et al. **Ann Emerg Med** 1999 Jan;33(1):104–7
Pharmacokinetic study of busulfan in an AML patient treated with regular hemodialysis [letter] Masauzi N, et al. **Ann Hematol** 1998 Dec;77(6):293–4
Dialysis patients' preferences for family-based advance care planning. Hines SC, et al. **Ann Intern Med** 1999 May 18; 130(10):825–8
Study of the relation between fluid distribution change in tissue and impedance change during hemodialysis by frequency characteristics of the flowing blood. Sakamoto K, et al. **Ann N Y Acad Sci** 1999 Apr 20;873:77–88
High anion gap metabolic acidosis associated with aminocaproic acid. Budris WA, et al. **Ann Pharmacother** 1999 Mar;33(3):308–11
Cardiovascular operations in patients with dialysis-dependent renal failure. Frenken M, et al. **Ann Thorac Surg** 1999 Sep; 68(3):887–93
Bileaflet mechanical valve (St. Jude Medical valve) replacement in long-term dialysis patients. Ura M, et al. **Ann Thorac Surg** 1999 Sep;68(3):870–3
Evaluation of expanded polytetrafluoroethylene arteriovenous access grafts onto which microvessel-derived cells were transplanted to "improve" graft performance: preliminary results. Schmidt SP, et al. **Ann Vasc Surg** 1998 Sep;12(5):405–11
Dialysis or transplantation: fitting the treatment to the patient. Berkoben M, et al. **Annu Rev Med** 1999;50:193–205 (21 ref.)
Circulating levels of inhibin in hemodialysis males. Sasagawa I, et al. **Arch Androl** 1998 Nov-Dec;41(3):167–71
Dialysis or plasmapheresis for acute renal failure due to Africanized honeybee stings [letter; comment] Beccari M. **Arch Intern Med** 1999 Jun 14;159(11):1255–6. Comment on: Arch Intern Med 1998 Apr 27;158(8):925–7.
Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. Berry GT, et al. **Arch Neurol** 1999 Apr;56(4):481–4
Single dose recombinant human erythropoietin reduces transforming growth factor beta in patients on chronic haemodialysis. Logofetov A, et al. **Arch Physiol Biochem** 1998 Oct;106(4):265–8
Histochemical study of the skeletal muscle in children with chronic renal failure in dialysis treatment. do Prado LB, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):381–7
Interactions between platelets and leukocytes during hemodialysis. Bonomini M, et al. **Artif Organs** 1999 Jan; 23(1):23–8 (52 ref.)
Towards long-term dialysis: a personal view. Davison AM. **Artif Organs** 1999 Jan;23(1):6–9
Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Fujimori A, et al. **Artif Organs** 1998 Dec;22(12):1014–7
KT/V and protein catabolic rate determination from serial urea measurement in the dialysate effluent stream. Garred LJ, et al. **Artif Organs** 1992 Jun;16(3):248–55
Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Gawaz MP, et al. **Artif Organs** 1999 Jan; 23(1):29–36
Evaluation of urea kinetics utilizing stable isotope urea and pharmacokinetic modeling. Kaplan B, et al. **Artif Organs** 1999 Jan;23(1):44–50
Is ionic dialysance a valid parameter for quantification of dialysis efficiency? Mercadal L, et al. **Artif Organs** 1998 Dec;22(12):1005–9
Survival of patients on chronic hemodialysis: single center experience. Polenakovik M, et al. **Artif Organs** 1999 Jan; 23(1):61–4
Hyperbaric oxygenation, plasma exchange, and hemodialysis for treatment of acute liver failure in a 3-year-old child. Ponikvar R, et al. **Artif Organs** 1998 Nov;22(11):952–7
Serum and intracellular detection of cytokines in patients undergoing chronic hemodialysis. Roccatello D, et al. **Artif Organs** 1992 Apr;16(2):131–40
A newly developed on-line monitoring system for the determination of serum electrolytes and urea during hemodialysis. Yanai M, et al. **Artif Organs** 1998 Dec; 22(12):1010–3
Development of a new cellulose triacetate membrane with a microgradient porous structure for hemodialysis. Akizawa T, et al. **ASAIO J** 1998 Sep-Oct;44(5):M584–6
First clinical experience with a new concentrate system for dialysis with dry sodium chloride. Alquist M, et al. **ASAIO J** 1998 Sep-Oct;44(5):M592–5
Patient survival with renal replacement therapy in heart transplantation patients. Bernardini J, et al. **ASAIO J** 1998 Sep-Oct;44(5):M546–8
Dialysis kinetics of homocysteine and reactive oxygen species. Biasioli S, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M423–32
Synthetically modified cellulose (SMC): a cellulosic hemodialysis membrane with minimized complement activation. Bowry SK, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M579–83
Retention of limulus amoebocyte lysate reactive bacterial products by polysulfone dialyzers is affected by the type of disinfectant. Cappelli G, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M587–91
Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion. Cohen D, et al. **ASAIO J** 1998 Sep-Oct;44(5):M596–7
Predialysis urea concentration is sufficient to characterize hemodialysis adequacy. De Wachter DS, et al. **ASAIO J** 1998 Sep-Oct;44(5):M670–6
Measurement of blood access flow rate during hemodialysis from conductivity dialysance. Gotch FA, et al. **ASAIO J** 1999 May-Jun;45(3):139–46
Initiation of dialysis is not delayed in whites with progressive renal failure. Iofel Y, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M598–600
Estimation of hemodialysis access blood flow rates by a urea method is a poor predictor of access outcome. Lindsay RM, et al. **ASAIO J** 1998 Nov-Dec;44(6):818–22
Cardiac troponin I in patients receiving renal replacement therapy. Morton AR, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M433–5
The relationship between cardiac output and access flow during hemodialysis. Pandeya S, et al. **ASAIO J** 1999 May-Jun;45(3):135–8
Estimates of interdialytic sodium and water intake based on the balance principle: differences between nondiabetic and diabetic subjects on hemodialysis. Ramdeen G, et al. **ASAIO J** 1998 Nov-Dec;44(6):812–7
Exercise and extracorporeal blood cooling during hemodialysis. Rosales LM, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M574–8
Longitudinal evaluation of a renal Kt/V(urea) of 2.0 as a threshold for initiation of dialysis. Saran R, et al. **ASAIO J** 1998 Sep-Oct;44(5):M677–81
Bioincompatibility of dialyzer membranes may have a negative impact on outcome of acute renal failure, independent of the dose of dialysis delivered: a retrospective multicenter analysis. Schiffl H, et al. **ASAIO J** 1998 Sep-Oct;44(5):M418–22
Effectiveness of low dose urokinase on dialysis catheter thrombolysis. Seddon PA, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M559–61
Prediction of dry weight through changes in blood volume and plasma cyclic 3',5'-guanosine monophosphate in patients under maintenance hemodialysis. Wann GL, et al. **ASAIO J** 1998 Sep-Oct;44(5):M569–73
Validation of changes in extracellular volume measured during hemodialysis using a segmental bioimpedance technique. Zhu F, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M541–5
HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Hasselwander O, et al. **Atherosclerosis** 1999 Mar;143(1):125–33
Phagocyte-induced oxidative stress in patients with haemodialysis treatment and organ transplantation. Lojek A, et al. **Biofactors** 1998;8(1–2):165–8
Perspectives on dialysis therapy. Zickler P. **Biomed Instrum Technol** 1998 Nov-Dec;32(6):627–30
Reduced blood bcl-2 protein concentration in patients on hemodialysis. Buemi M, et al. **Blood Purif** 1998;16(6):312–6
Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Chen MF, et al. **Blood Purif** 1998;16(5):290–300
Modulation of neutrophil apoptosis by uremic plasma during hemodialysis. Jaber BL, et al. **Blood Purif** 1998;16(6):325–35
Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Massimetti C, et al. **Blood Purif** 1998;16(6):317–24
Effects of hemodialysis on circulating adrenomedullin concentrations in patients with end-stage renal disease. Toepfer M, et al. **Blood Purif** 1998;16(5):269–74
A new method of measuring blood pressure excluding Korotkoff sounds 4 and 5 in the dialysis unit [letter] Yang YM, et al. **Blood Purif** 1998;16(6):349–50
Trace elements in hemodialysis and continuous ambulatory peritoneal dialysis patients. Zima T, et al. **Blood Purif** 1998; 16(5):253–60
Plasma catecholamines, neuropeptide Y and leucine-enkephalin in uremic patients before and after dialysis during rest and handgrip. Klin M, et al. **Boll Chim Farm** 1998 Sep;137(8):306–13
Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Perry JJ, et al. **Bone Marrow Transplant** 1999 Apr;23(8):839–42
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Pfister M, et al. **Br J Clin Pharmacol** 1999 Jun;47(6):645–51
Effect of plasma colloid osmotic pressure on intraocular pressure during haemodialysis. Tokuyama T, et al. **Br J Ophthalmol** 1998 Jul;82(7):751–3
Validation of self-reported transfusion histories in renal dialysis patients. Sandhu JS, et al. **Can J Public Health** 1999 May-Jun;90(3):201–4
Specificity of cardiac troponin I and creatine kinase-MB isoenzyme in asymptomatic long-term hemodialysis patients and effect of hemodialysis on these cardiac markers. Tun A, et al. **Cardiology** 1998;90(4):280–5
Re: Stent placement at the venous anastomosis of a dialysis graft: be cost-effective and demanding with regard to the result [letter; comment] Turmel-Rodrigues LA. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):442. Comment on: Cardiovasc Intervent Radiol 1998 Mar-Apr;21(2):176–8.
Cause and treatment of symptomatic steals following the insertion of haemodialysis shunts [letter] Dodds SR. **Cardiovasc Surg** 1998 Dec;6(6):657–9
A comparison of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in patients on hemodialysis. Simsir SA, et al. **Cardiovasc Surg** 1998 Oct;6(5):500–5
Short- and long-term outcomes after percutaneous transluminal coronary angioplasty in chronic hemodialysis patients. Hang CL, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):430–3
The leukointegrin alpha d/beta 2 (alpha d/CD18): specific changes in surface expression in patients on hemodialysis. Rabb H, et al. **Cell Adhes Commun** 1998 Jun;6(1):13–20
Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients. Takayama F, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1101–9
Ischemic bowel disease in chronic dialysis patients. Hung KH, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar; 22(1):82–7
The significance of syphilis serology tests on long-term hemodialysis patients. Lee CT, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):447–52
Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Reiner E, et al. **Chem Biol Interact** 1999 May 14;119–120:405–11
Automatic system for the assay of guanidino compounds to assess uremic status and effect of hemodialysis. Nohara Y, et al. **Chem Pharm Bull (Tokyo)** 1998 Nov;46(11):1844–5
Is serum transferrin receptor a sensitive marker of iron repletion in patients with iron-deficiency anemia and hemodialysis patients? Hou CC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr; 62(4):189–94
Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Galli F, et al. **Clin Chem** 1999 Oct; 45(10):1781–8
Hyperkalemia risks in hemodialysed patients consuming fluoride-rich water. Nicolay A, et al. **Clin Chim Acta** 1999

Mar;281(1-2):29-36
Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Schwabe RF, et al. **Clin Exp Immunol** 1999 Jul;117(1):153-8
Uteroplacental and fetoplacental blood flow in a patient with renal anemia. Reister F, et al. **Clin Hemorheol Microcirc** 1998 Sep;19(1):33-7
Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Ahuja TS, et al. **Clin Nephrol** 1999 Jan;51(1):40-4
Regression of massive tumoral calcinosis of the ischium in a dialysis patient after treatment with reduced calcium dialysate and i.v. administration. Apostolou T, et al. **Clin Nephrol** 1998 Oct;50(4):247-51
Ineffectiveness of dialysis in transthyretin (TTR) clearance in familial amyloid polyneuropathy type I, in spite of lower stability of the TTR Met30 variant. Beirão I, et al. **Clin Nephrol** 1999 Jan;51(1):45-9
Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Cruz DN, et al. **Clin Nephrol** 1998 Aug;50(2):101-7
Maintenance hemodialysis in patients with HIV-associated nephropathy. Dave MB, et al. **Clin Nephrol** 1998 Dec; 50(6):367-74
Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. Ferraris J, et al. **Clin Nephrol** 1998 Sep;50(3):172-7
Study on nutritional status of maintenance hemodialysis patients. Ge YQ, et al. **Clin Nephrol** 1998 Nov;50(5):309-14
Insertion of internal jugular temporary hemodialysis cannulae by direct ultrasound guidance--a prospective comparison of experienced and inexperienced operators. Geddes CC, et al. **Clin Nephrol** 1998 Nov;50(5):320-5
Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Goodkin DA, et al. **Clin Nephrol** 1999 Jun;51(6):367-72
The dependency of calcium set point on basal plasma calcium in dialysis patients: a better explanation for the discrepancies regarding its link with PTH secretion than methodological differences. Hardy-Yverneau P, et al. **Clin Nephrol** 1998 Oct;50(4):236-46
Hepatocellular carcinoma among hemodialysis patients infected with hepatitis C virus--early evolution and rapid progression [letter] Hayashi H, et al. **Clin Nephrol** 1999 May;51(5):321-3
Successful combined therapy of nifedipine and diltiazem for severe hypertension in a maintenance hemodialysis patient [letter] Ikeda Y, et al. **Clin Nephrol** 1999 Feb;51(2):127-8
The pattern of intracellular free amino acids in granulocytes from hemodialysis patients change to an oral protein supplement (granulocyte amino acids after protein in HD patients). Ivarsen P, et al. **Clin Nephrol** 1999 Aug; 52(2):110-8
Specialized chronic care for dialysis patients--a five-year study. Jassal SV, et al. **Clin Nephrol** 1998 Aug;50(2):84-9
Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. Jensen PB, et al. **Clin Nephrol** 1999 Aug;52(2):103-9
The effect on blood pressure of an acute fall in ionized calcium during hemodialysis. A randomized study in two patients. Kaye M, et al. **Clin Nephrol** 1998 Dec;50(6):361-6
Importance of bone aluminum status in renal insufficiency and removal after kidney transplantation with low serum aluminum values [letter; comment] Kisters K, et al. **Clin Nephrol** 1999 Mar;51(3):191-3. Comment on: Clin Nephrol 1998 Aug;50(2):69-76.
Intravenous single dose of erythropoietin (rHuEPO) does not influence plasma leptin concentration in hemodialyzed patients with chronic renal failure (CRF) [letter] Kokot F, et al. **Clin Nephrol** 1999 Jun;51(6):389-91
Effect of H2-blockers on serum calcium and phosphorus in hemodialysis patients on calcium carbonate therapy [letter] Kushihata S, et al. **Clin Nephrol** 1998 Sep;50(3):198-9
Risk factors of renal failure progression two years prior to dialysis. Mazouz H, et al. **Clin Nephrol** 1999 Jun; 51(6):355-66
Prevalence of hypertension in a hemodialysis population. Mittal SK, et al. **Clin Nephrol** 1999 Feb;51(2):77-82
On the toxicity of valproic-acid. Moreiras Plaza M, et al. **Clin Nephrol** 1999 Mar;51(3):187-9
Measurement of serum leptin in patients with chronic renal failure on hemodialysis. Nishikawa M, et al. **Clin Nephrol** 1999 May;51(5):296-303
Calcaneal bone ultrasonometry in patients with renal failure treated with dialysis [letter] Patel S, et al. **Clin Nephrol** 1999 Jun;51(6):387-8
Long-term persistence of hepatitis C viremia in hemodialysis patients [letter; comment] Piazza V, et al. **Clin Nephrol** 1999 Feb;51(2):129-30. Comment on: Clin Nephrol 1996 Apr;45(4):257-60.
Hypoalbuminemia accelerates erythrocyte membrane lipid peroxidation in chronic hemodialysis patients. Soejima A, et al. **Clin Nephrol** 1999 Feb;51(2):92-7
Efficacy of oral immunotherapy on respiratory infections in hemodialysis patients: a double-blind, placebo-controlled study. Tielemans C, et al. **Clin Nephrol** 1999 Mar; 51(3):153-60
A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Valeri A, et al. **Clin Nephrol** 1999 Feb;51(2):116-21
Low serum aluminum values in dialysis patients with increased bone aluminum levels [see comments] van Landeghem GF, et al. **Clin Nephrol** 1998 Aug;50(2):69-76 . Comment in: Clin Nephrol 1999 Mar;51(3):191-3.
Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Wilkes BM, et al. **Clin Nephrol** 1998 Dec;50(6):381-6
Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Brody SR, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):21-8
Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Goldenberg MM. **Clin Ther** 1999 Mar;21(3):432-41 (27 ref.)
Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Yildiz A, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):13-6
Dialysis patients with tuberculosis [letter; comment] FitzGerald JM, et al. **CMAJ** 1999 Sep 7;161(5):489. Comment on: CMAJ 1999 Jun 1;160(11):1557-63.
Body size, not sex, is responsible for differences in type of dialysis [see comments] Florakas C, et al. **CMAJ** 1999 Mar 23;160(6):818-9. Comment in: CMAJ 1999 Mar 23;160(6):828-9.
Sex or body size? Selection of dialysis type revisited [editorial; comment] Levin A. **CMAJ** 1999 Mar 23; 160(6):828-9 (10 ref.). Comment on: CMAJ 1999 Mar 23;160(6):818-9.
Features of uremic neuropathy in long-term dialysis. Jurčić D, et al. **Coll Antropol** 1998 Jun;22(1):119-25
Platelet and leucocyte behaviour during haemodialysis. Hoenich NA. **Contrib Nephrol** 1999;125:120-32 (36 ref.)
Coronary artery disease in dialysis patients. Wizemann V. **Contrib Nephrol** 1998;124:1-9; discussion 9-17 (52 ref.)
Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Benci A, et al. **Curr Med Res Opin** 1998;14(3):141-4
Haemodialysis and peritoneal dialysis: metabolic alterations and nutritional status [see comments] Cano N. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):329-33 (65 ref.). Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):313-4.
Dialysis and transplantation. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):711-30
Hemofiltration and double high flux dialysis: risks and benefits. Bosch JP, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):643-7 (16 ref.)
Peripheral motor and sensory nerve conduction studies in haemodialysis patients. A study of 54 patients. Van den Neucker K, et al. **Electromyogr Clin Neurophysiol** 1998 Dec;38(8):467-74
Facial nerve stimulation by a cochlear implant in a hemodialysis patient with bone of low mineral density. Iwasaki S, et al. **Eur Arch Otorhinolaryngol** 1998; 255(7):352-4
Immediate and long-term results of coronary revascularization in patients undergoing chronic hemodialysis. Castelli P, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):51-4
Risk factors of hepatitis C virus infection in patients on hemodialysis: a multivariate analysis based on a dialysis register in Central Italy. Di Lallo D, et al. **Eur J Epidemiol** 1999 Jan;15(1):11-4
Colonic pseudo-obstruction due to beta2-microglobulin amyloidosis after long-term haemodialysis. Bruno MJ, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):717-20
A possible side-effect of human erythropoietin therapy: thrombosis of peripheral arterial reconstruction. Mingoli A. **Eur J Vasc Endovasc Surg** 1999 Sep;18(3):273-4
Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium. Dimitrakov D, et al. **Folia Med (Plovdiv)** 1998;40(4):48-53
Antioxidant status and dialysis: plasma and saliva antioxidant activity in patients with fluctuating urate levels. Meucci E, et al. **Free Radic Res** 1998 Nov;29(5):367-76
Ethical issues involved in dialysis for the elderly. Bhatnagar V, et al. **Geriatr Nephrol Urol** 1998;8(2):111-4
Health-related quality of life (HRQOL) in end stage renal disease (ESRD) patients over 65 years. Rebollo P, et al. **Geriatr Nephrol Urol** 1998;8(2):85-94
Endometrial response to unopposed estrogens remains unaltered in patients with chronic renal failure receiving hemodialysis. Ergeneli MH, et al. **Gynecol Obstet Invest** 1999;47(1):26-8
Vancomycin-resistant enterococci in hemodialysis patients is related to intravenous vancomycin use [letter] Fishbane S, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):461-2
Central venous catheters as a source of hemodialysis-related bacteremia. Taylor GD, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):643-6
Changes in neutrophil surface phenotype during hemodialysis. Skubitz KM, et al. **Inflammation** 1998 Dec; 22(6):559-72
Staged basilic vein transposition for dialysis angioaccess. El Mallah S. **Int Angiol** 1998 Jun;17(2):65-8
Hemodialysis as a treatment of severe ethanol poisoning. Atassi WA, et al. **Int J Artif Organs** 1999 Jan;22(1):18-20
Levels of sustainable aerobic workload in dialysis patients. Capodaglio EM, et al. **Int J Artif Organs** 1998 Jul; 21(7):391-7
Pregnancy in chronic dialysis: a review and analysis of the literature. Chan WS, et al. **Int J Artif Organs** 1998 May; 21(5):259-68 (82 ref.)
Model-based dialysis adequacy prediction by continuous dialysate urea monitoring. Chiari L, et al. **Int J Artif Organs** 1998 Sep;21(9):526-34
Endoscopy as a tool for diagnosing and treating gastrointestinal angiodysplasia in haemodialysis patients. Di Liberato L, et al. **Int J Artif Organs** 1999 Jul;22(7):488-91
Acute tubulo-interstitial nephritis requiring dialysis associated with intermittent rifampicin use: case report. Gallieni M, et al. **Int J Artif Organs** 1999 Jul;22(7):477-81
Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin [editorial] Gallieni M. **Int J Artif Organs** 1998 Nov;21(11):681-6
Vitamin C and E as antioxidants in hemodialysis patients. Hegbrant J, et al. **Int J Artif Organs** 1999 Feb;22(2):69-73 (70 ref.)
Daily dialysis in hemodialysis patients with pericardial effusion: where are the data? [editorial] Ifudu O. **Int J Artif Organs** 1999 Jul;22(7):469-70
Effects of dialysis membranes on the kinetics of tumor necrosis factor-alpha production by peripheral mononuclear cells in chronic hemodialysis patients. Kushihata S, et al. **Int J Artif Organs** 1998 Jul;21(7):384-90
Factors influencing arteriovenous fistula dysfunction in Japanese patients on chronic hemodialysis. Masaki T, et al. **Int J Artif Organs** 1999 Jan;22(1):14-7
Mass balance index: an index for adequacy of dialysis and nutrition. Raj DS, et al. **Int J Artif Organs** 1998 Jun; 21(6):328-34
Fever in dialysis patients with recently rejected renal allografts. Sever MS, et al. **Int J Artif Organs** 1998 Jul; 21(7):403-7
The role of platelet-activating factor in the haemoincompatibility of haemodialytic treatments [editorial] Tetta C, et al. **Int J Artif Organs** 1998 Nov; 21(11):693-8
Effects of zinc supplementation on the immune system and on antibody response to multivalent influenza vaccine in hemodialysis patients. Türk S, et al. **Int J Artif Organs** 1998 May;21(5):274-8
Interdialytic weight gain: role of salt and water intake [editorial; comment] Tzamaloukas AH, et al. **Int J Artif Organs** 1999 Feb;22(2):64-8. Comment on: Int J Artif Organs 1988 May;11(3):161-8.
Mathematical modeling of solute kinetics and body fluid changes during profiled hemodialysis. Ursino M, et al. **Int J Artif Organs** 1999 Feb;22(2):94-107
Tissue factor and tissue factor pathway inhibitor in hemodialysis patients. Yorioka N, et al. **Int J Artif Organs** 1998 Nov;21(11):699-701
Risk of tuberculosis in dialysis patients: a population-based study. Chia S, et al. **Int J Tuberc Lung Dis** 1998 Dec; 2(12):989-91
Nephrogenic adenoma of the bladder in a chronic hemodialysis patient. Ashida S, et al. **Int J Urol** 1999 Apr; 6(4):208-10
Surgical treatment for biliary lithiasis in patients associated with chronic renal failure on hemodialysis. Nozoe T, et al. **Int Surg** 1998 Apr-Jun;83(2):115-8
Use of vascular closure staples in vascular access for dialysis, kidney and pancreas transplantation. Papalois VE, et al. **Int Surg** 1998 Apr-Jun;83(2):177-80
Red cell lipid peroxidation and antioxidant system in haemodialysed patients: influence of recombinant human erythropoietin (r-HuEPO) treatment. Boran M, et al. **Int Urol Nephrol** 1998;30(4):507-12
Bladder cancer in a patient on long-term haemodialysis. Hadatsuki H, et al. **Int Urol Nephrol** 1998;30(5):565-8
The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients. Tonbul HZ, et al. **Int Urol Nephrol** 1998;30(5):645-51
Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Kuwabara S, et al. **Intern Med** 1999 Jun;38(6):472-5
Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Nakao T, et al. **Intern Med** 1998 Oct;37(10):826-30
Mechanical thrombectomy in hemodialysis access shunts using a 5F pigtail rotation catheter. In vitro and in vivo investigations. Wildberger J, et al. **Invest Radiol** 1999 Jul; 34(7):489-95
Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. Aweeka FT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):350-7
Predialysis education helps patients choose dialysis modality and increases disease-specific knowledge. Klang B, et al. **J Adv Nurs** 1999 Apr;29(4):869-76
A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. Roppolo LP, et al. **J Am Coll Cardiol** 1999 Aug;34(2):448-54
Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis. Martino MA, et al. **J Am Coll Surg** 1998 Dec;187(6):616-9
Molecular detection and prevalence investigation of HGV infection among older patients undergoing chronic

hemodialysis [letter] Bianchi D, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1040–1

Dialysis modality and delayed graft function after cadaveric renal transplantation. Bleyer AJ, et al. **J Am Soc Nephrol** 1999 Jan;10(1):154–9

Clinical practice guidelines for initiation of dialysis. Canadian Society of Nephrology. Churchill DN, et al. **J Am Soc Nephrol** 1999 Jun;10 Suppl 13:S289–91

Clinical practice guidelines for the delivery of hemodialysis. Canadian Society pf Nephrology. Deziel C, et al. **J Am Soc Nephrol** 1999 Jun;10 Suppl 13:S306–10

Clinical practice guidelines for vascular access. Canadian Society pf Nephrology. Ethier JH, et al. **J Am Soc Nephrol** 1999 Jun;10 Suppl 13:S297–305

Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. Girndt M, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1689–96

QT dispersion in patients with end-stage renal failure and during hemodialysis. Lorincz I, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1297–302

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Martin KJ, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1427–32

QT dispersion before and after hemodialysis. Morris ST, et al. **J Am Soc Nephrol** 1999 Jan;10(1):160–3

Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. Quaschning T, et al. **J Am Soc Nephrol** 1999 Feb;10(2):332–41

Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. Rosenkranz AR, et al. **J Am Soc Nephrol** 1999 Jan;10(1):128–35

Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. Rostaing L, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2344–8

Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. Shemin D, et al. **J Am Soc Nephrol** 1999 May;10(5):1095–9

Whole body Kt/V from dialysate urea measurements during hemodialysis. Sternby J. **J Am Soc Nephrol** 1998 Nov; 9(11):2118–23

Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients. Suliman ME, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1287–96

Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. Takahashi N, et al. **J Am Soc Nephrol** 1999 May;10(5):1090–4

Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. Vonesh EF, et al. **J Am Soc Nephrol** 1999 Feb;10(2):354–65

Total hip arthroplasty in patients on long-term renal dialysis. Sakalkale DP, et al. **J Arthroplasty** 1999 Aug;14(5):571–5

Hip arthroplasty in chronic dialysis patients. Toomey HE, et al. **J Arthroplasty** 1998 Sep;13(6):647–52

Oxygen consumption in hemodialysis patients undergoing cardiopulmonary bypass. Karzai W, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):415–7

Surgical treatment of "steal syndrome" induced by arteriovenous grafts for hemodialysis. Stierli P, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):441–3

Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. Indridason OS, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3860–6

The effects of dose, nutrition, and age on hexarelin-induced anterior pituitary hormone secretion in adult patients on maintenance hemodialysis. Jenkins RC, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1220–5

Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. Garinis G, et al. **J Clin Lab Anal** 1999;13(3):122–5

Primary Shewanella alga septicemia in a patient on hemodialysis. Iwata M, et al. **J Clin Microbiol** 1999 Jun; 37(6):2104–5

Benign nodular calcification and calciphylaxis in a haemodialysed patient. Strumia R, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):69–71

Screening for gastroenterological malignancies in new and maintenance dialysis patients. Ito T, et al. **J Gastroenterol** 1999 Feb;34(1):35–40

Transmission of and liver injury by TT virus in patients on maintenance hemodialysis [see comments] Oguchi T, et al. **J Gastroenterol** 1999 Apr;34(2):234–40. Comment in: J Gastroenterol 1999 Apr;34(2):292–3.

Superinfection of TT virus and hepatitis C virus among chronic haemodialysis patients. Ikeuchi T, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):796–800

Acute hepatitis C among renal failure patients on chronic haemodialysis. Okuda K, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):62–7

Reduced production of nitric oxide during haemodialysis. Sumino H, et al. **J Hum Hypertens** 1999 Jul;13(7):437–42

Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. Radovic M, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):369–73

Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. Lee YK, et al. **J Korean Med Sci** 1999 Apr; 14(2):193–8

GB virus C/hepatitis G virus infection in hemodialysis patients: determination of seroprevalence by a four-antigen recombinant immunoblot assay. Schröter M, et al. **J Med Virol** 1999 Mar;57(3):230–4

HIV infection in dialysis centers in Italy: a nationwide multicenter study. Barbiano di Belgiojoso G, et al. **J Nephrol** 1998 Sep-Oct;11(5):249–54

Henoch-Schönlein purpura in a chronic hemodialysis patient. Esposito C, et al. **J Nephrol** 1999 May-Jun;12(3):197–200

The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure. Günal AI, et al. **J Nephrol** 1999 Jan-Feb;12(1):38–40

The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. Locatelli F, et al. **J Nephrol** 1999 Mar-Apr;12(2):85–8

Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. Malatino LS, et al. **J Nephrol** 1999 Jul-Aug;12(4):256–60

Carotid intima-media thickness and ACE-gene polymorphism in hemodialysis patients. Nergizoğlu G, et al. **J Nephrol** 1999 Jul-Aug;12(4):261–5

Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. Ronco C, et al. **J Nephrol** 1999 May-Jun;12(3):173–8

The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. Sasagawa T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Dec;44(6):809–18

Menstrual disorders in patients undergoing chronic hemodialysis. Kawashima R, et al. **J Obstet Gynaecol Res** 1998 Oct;24(5):367–73

Analysis of synovial fluid components of hydrarthrosis in long-term hemodialysis patients. Shiota E, et al. **J Orthop Sci** 1999;4(3):171–5

Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. Tom A, et al. **J Pediatr** 1999 Apr;134(4):464–71

Hemodialysis prognostic nutrition index as a predictor for morbidity and mortality in hemodialysis patients and its correlation to adequacy of dialysis. Council on Renal Nutrition National Research Question Collaborative Study Group. Beto JA, et al. **J Ren Nutr** 1999 Jan;9(1):2–8

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. Burrowes JD, et al. **J Ren Nutr** 1999 Apr; 9(2):89–94

Treating fluid noncompliance in the hemodialysis population using unit wide contests. Bushman MC. **J Ren Nutr** 1999 Jan;9(1):35–7

The effects of exercise during hemodialysis on physical performance and nutrition assessment. Cappy CS, et al. **J Ren Nutr** 1999 Apr;9(2):63–70

Epidemiologic cohort studies of critical nutritional issues in the care of the dialysis patient: report of the epidemiology work group. McClellan W, et al. **J Ren Nutr** 1999 Jul; 9(3):133–7 (49 ref.)

Quality of life implications of inadequate protein nutrition among hemodialysis patients. Ohri-Vachaspati P, et al. **J Ren Nutr** 1999 Jan;9(1):9–13

A cross-sectional study comparing the nutritional status of peritoneal dialysis and hemodialysis patients in Korea. Park YK, et al. **J Ren Nutr** 1999 Jul;9(3):149–56

Response to intradialytic parenteral nutrition. Saunders S, et al. **J Ren Nutr** 1999 Jan;9(1):32–4

Barriers to adequate protein nutrition among hemodialysis patients. Sehgal AR, et al. **J Ren Nutr** 1998 Oct;8(4):179–87

Validation of 24-hour dietary recall: a study in hemodialysis patients. Sharma M, et al. **J Ren Nutr** 1998 Oct;8(4):199–202

A dietary survey in Indian hemodialysis patients. Sharma M, et al. **J Ren Nutr** 1999 Jan;9(1):21–5

The effect of a self-monitoring tool on self-efficacy, health beliefs, and adherence in patients receiving hemodialysis. Tanner JL, et al. **J Ren Nutr** 1998 Oct;8(4):203–11

Reported pica behavior in a sample of incident dialysis patients. Ward P, et al. **J Ren Nutr** 1999 Jan;9(1):14–20

Body composition, treatment time, and outcome in hemodialysis patients. Williams AJ, et al. **J Ren Nutr** 1999 Jul;9(3):157–62

Effectiveness of nutrition interventions in the management of malnourished patients treated with maintenance dialysis. Wolfson M. **J Ren Nutr** 1999 Jul;9(3):126–8 (15 ref.)

Hemodialysis following butoxyethanol ingestion. Burkhart KK, et al. **J Toxicol Clin Toxicol** 1998;36(7):723–5

Glycolate kinetics and hemodialysis clearance in ethylene glycol poisoning. META Study Group. Moreau CL, et al. **J Toxicol Clin Toxicol** 1998;36(7):659–66

Volumetric measurements of the brachial and carotid arteries in dialysis grafts: is there evidence of a subclavian-carotid artery steal syndrome? Eicke BM, et al. **J Ultrasound Med** 1998 Dec;17(12):759–63

Use of a simple compression dressing to obtain hemostasis after pharmacologic thrombolysis of dialysis grafts. Barzel E. **J Vasc Interv Radiol** 1999 Sep;10(8):1039–42

Puncture-induced deformity of a metallic stent within a dialysis access graft causing thrombotic failure: case report and description of salvage. Lane JD, et al. **J Vasc Interv Radiol** 1998 Sep-Oct;9(5):837–9

Modified use of the arrow-trerotola percutaneous thrombolytic device for the treatment of thrombosed hemodialysis access grafts. Lazzaro CR, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1025–31

Endovascular interventional MR: balloon angioplasty in a hemodialysis access flow phantom [corrected] [published erratum appears in J Vasc Interv Radiol 1998 Nov-Dec;9(6):1024] Smits HF, et al. **J Vasc Interv Radiol** 1998 Sep-Oct;9(5):840–5

Thromboaspiration to treat inadvertent arterial emboli during dialysis graft declotting [letter; comment] Turmel-Rodrigues LA, et al. **J Vasc Interv Radiol** 1998 Sep-Oct;9(5):849–50. Comment on: J Vasc Interv Radiol 1998 Jan-Feb;9(1 Pt 1):141–3.

Thrombosed dialysis grafts: percutaneous mechanical declotting using a central venous approach [see comments] Zaetta JM, et al. **J Vasc Interv Radiol** 1998 Sep-Oct; 9(5):833–6. Comment in: J Vasc Interv Radiol 1999 Mar;10(3):375–6.

Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. Curi MA, et al. **J Vasc Surg** 1999 Apr;29(4):608–16

Management of dialysis access-associated steal syndrome: use of intraoperative duplex ultrasound scanning for optimal flow reduction. Shemesh D, et al. **J Vasc Surg** 1999 Jul; 30(1):193–5

Significance of antibodies to the recombinant E2 protein of hepatitis G virus in haemodialysis patients. Schulte-Frohlinde E, et al. **J Viral Hepat** 1998 Sep; 5(5):341–4

Prevalence of GBV-C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. El-Zayadi AR, et al. **J Virol Methods** 1999 Jun; 80(1):53–8

An international study of patient compliance with hemodialysis. Bleyer AJ, et al. **JAMA** 1999 Apr 7; 281(13):1211–3

Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial [see comments] Johansen KL, et al. **JAMA** 1999 Apr 14; 281(14):1275–81. Comment in: JAMA 1999 Apr 14;281(14):1326–7.

Intradialytic parenteral nutrition in malnourished hemodialysis patients: a prospective long-term study. Mortelmans AK, et al. **JPEN J Parenter Enteral Nutr** 1999 Mar-Apr;23(2):90–5

Evaluation of the effect of haemodialysis on cardiac dysfunction in patients of chronic renal failure. Yazdani I, et al. **JPMA J Pak Med Assoc** 1998 Aug;48(8):230–2

Reduced size of liquefaction necrosis of mitral annular calcification in chronic renal failure by using low calcium concentration hemodialysis. Koito H, et al. **Jpn Circ J** 1999 Jun;63(6):490–2

Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients. Wu SG, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Feb; 15(2):62–8

Causes of coronary heart disease in patients on renal replacement therapy. Wanner C, et al. **Kidney Blood Press Res** 1998;21(2-4):287–9 (16 ref.)

Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Attman PO, et al. **Kidney Int** 1999 Apr;55(4):1536–42

Interleukin-1 receptor antagonist synthesis by peripheral blood mononuclear cells in hemodialysis patients. Balakrishnan VS, et al. **Kidney Int** 1998 Dec;54(6):2106–12

Malnutrition and dialysis [letter; comment] Baltzan MA Sr, et al. **Kidney Int** 1998 Sep;54(3):999. Comment on: Kidney Int 1998 Mar;53(3):773–82.

Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Berns JS, et al. **Kidney Int** 1999 Jul;56(1):253–60

Factors determining the percentage of hypochromic red blood cells in hemodialysis patients. Bovy C, et al. **Kidney Int** 1999 Sep;56(3):1113–9

Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996. Cotter DJ, et al. **Kidney Int** 1998 Dec;54(6):2129–39

Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. de Francisco AL, et al. **Kidney Int** 1998 Dec;54(6):2140–5

Measurement of the delivery of dialysis in acute renal failure. Evanson JA, et al. **Kidney Int** 1999 Apr;55(4):1501–8

Role of cytokines in the response to erythropoietin in hemodialysis patients. Goicoechea M, et al. **Kidney Int** 1998 Oct;54(4):1337–43

Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Gupta A, et al. **Kidney Int** 1999 May;55(5):1891–8

Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Ikizler TA, et al. **Kidney Int** 1999 May; 55(5):1945–51

Quest for postdialysis urea rebound-equilibrated Kt/V with only intradialytic urea samples. Jean G, et al. **Kidney Int** 1999 Sep;56(3):1149–53

Effects of sodium nitroprusside on hemodialysis-induced platelet activation. Jilma B, et al. **Kidney Int** 1999 Feb; 55(2):686–91

Moderately high serum ferritin concentration is not a sign

of iron overload in dialysis patients [letter] Kalantar-Zadeh K, et al. **Kidney Int** 1999 Aug;56(2):758-9

Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Locatelli F, et al. **Kidney Int** 1999 Jan;55(1):286-93

Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patients. Mallamaci F, et al. **Kidney Int** 1998 Nov;54(5):1697-703

Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Miller PE, et al. **Kidney Int** 1999 Jul;56(1):275-80

Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Moustapha A, et al. **Kidney Int** 1999 Apr;55(4):1470-5

Dynamic tests of parathyroid hormone secretion using hemodialysis and calcium infusion cannot be compared. Moysés RM, et al. **Kidney Int** 1999 Aug;56(2):659-65

Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Nguyen-Khoa T, et al. **Kidney Int** 1999 Aug;56(2):747-53

Use of iohexol to quantify hemodialysis delivered and residual renal function: technical note. Sacamay TE, et al. **Kidney Int** 1998 Sep;54(3):986-91

Vascular access for hemodialysis [clinical conference] Schwab SJ, et al. **Kidney Int** 1999 May;55(5):2078-90

RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Slatopolsky EA, et al. **Kidney Int** 1999 Jan;55(1):299-307

Erythrocyte voltage-dependent calcium influx is reduced in hemodialyzed patients. Soldati L, et al. **Kidney Int** 1999 Jul;56(1):190-7

Chronic renal replacement therapy in children: which index is best for adequacy? Verrina E, et al. **Kidney Int** 1998 Nov;54(5):1690-6

Ultrafiltration method for measuring vascular access flow rates during hemodialysis. Yarar D, et al. **Kidney Int** 1999 Sep;56(3):1129-35

Sum of segmental bioimpedance analysis during ultrafiltration and hemodialysis reduces sensitivity to changes in body position. Zhu F, et al. **Kidney Int** 1999 Aug;56(2):692-9

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Zimmermann J, et al. **Kidney Int** 1999 Feb;55(2):648-58

Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients. Goto T, et al. **Kidney Int Suppl** 1999 Jul;71:S213-5

Apolipoprotein E phenotypes in hemodialysis patients. Imura T, et al. **Kidney Int Suppl** 1999 Jul;71:S245-7

Cardiovascular response to hemodialysis: the effects of uremia and dialysate buffer. Jaraba M, et al. **Kidney Int Suppl** 1998 Dec;68:S86-91

A common mutation of cholesteryl ester transfer protein gene in dialysis patients. Kimura H, et al. **Kidney Int Suppl** 1999 Jul;71:S186-9

Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kimura K, et al. **Kidney Int Suppl** 1999 Jul;71:S238-41

Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Koda Y, et al. **Kidney Int Suppl** 1999 Jul;71:S251-3

Abnormalities in lipoprotein metabolism in hemodialysis patients. Köniğer M, et al. **Kidney Int Suppl** 1999 Jul; 71:S248-50

Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Lopez-Gomez JM, et al. **Kidney Int Suppl** 1998 Dec;68:S92-8 (74 ref.)

Effect of simvastatin on the lipid profile of hemodialysis patients. Nishikawa O, et al. **Kidney Int Suppl** 1999 Jul; 71:S219-21

Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Ohashi H, et al. **Kidney Int Suppl** 1999 Jul;71:S242-4

Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Oi K, et al. **Kidney Int Suppl** 1999 Jul;71:S227-8

Serum lipids status in patients with diabetic uremia on 10 years of maintenance hemodialysis. Sakurai T, et al. **Kidney Int Suppl** 1999 Jul;71:S216-8

Phosphotyrosine of macrophage by low-density lipoproteins from hemodialysis patients. Sonobe M, et al. **Kidney Int Suppl** 1999 Jul;71:S254-5

Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Wanner C, et al. **Kidney Int Suppl** 1999 Jul;71:S222-6

Heart failure [letter; comment] Andrews PA. **Lancet** 1998 Oct 10;352(9135):1228. Comment on: Lancet 1998 Aug;352 Suppl 1:SI1-2.

Aboriginal people trade land claim for dialysis [news] Loff B, et al. **Lancet** 1998 Oct 31;352(9138):1451

Haemodialysis. Mallick NP, et al. **Lancet** 1999 Feb 27; 353(9154):737-42 (30 ref.)

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy [see comments] Ruggenenti P, et al. **Lancet** 1998 Oct 17; 352(9136):1252-6. Comment in: Lancet 1998 Dec 19-26;352(9145):2020-1; discussion 2021-2. Comment in: Lancet 1998 Dec 19-26;352(9145):2021-2.

The effect of n-3 fatty acids on leukotriene formation from neutrophils in patients on hemodialysis. Løssl K, et al. **Lipids** 1999;34 Suppl:S185

A practical approach to the management of patients with chronic renal failure [published erratum appears in Mayo Clin Proc 1999 May;74(5):538] McCarthy JT. **Mayo Clin Proc** 1999 Mar;74(3):269-73 (10 ref.)

Whole body urea kinetics. Sternby J. **Med Biol Eng Comput** 1998 Nov;36(6):734-9

Estimation of parameters in a two-pool urea kinetic model for hemodialysis [letter; comment] Cappello A, et al. **Med Eng Phys** 1998 Jun;20(4):315-8. Comment on: Med Eng Phys 1997 Jan;19(1):69-76.

Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: relation to apolipoprotein(a) size polymorphism. Arnadottir M, et al. **Metabolism** 1999 Mar;48(3):342-6

Hypertension in dialysis patients. Bellinghieri G, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):84-9 (32 ref.)

Left ventricular hypertrophy in daily dialysis. Buoncristiani U, et al. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):90-4

Cardiovascular mortality and morbidity in dialysis patients. Eknoyan G. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):100-4 (38 ref.)

Past, present and future of end-stage renal disease therapy in the United States. Uribarri J. **Mt Sinai J Med** 1999 Jan; 66(1):14-9 (39 ref.)

The care of patients undergoing hemodialysis [letter; comment] Fournier A, et al. **N Engl J Med** 1999 Mar 4; 340(9):736; discussion 736-7. Comment on: N Engl J Med 1998 Oct 8;339(15):1054-62.

Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] González F. **N Engl J Med** 1998 Dec 31;339(27):2023-4. Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.

The care of patients undergoing hemodialysis [letter; comment] Knoll G, et al. **N Engl J Med** 1999 Mar 4; 340(9):736-7. Comment on: N Engl J Med 1998 Oct 8;339(15):1054-62.

The care of patients undergoing hemodialysis [letter; comment] Korosi A, et al. **N Engl J Med** 1999 Mar 4; 340(9):735-6; discussion 736-7. Comment on: N Engl J Med 1998 Oct 8;339(15):1054-62.

Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin [letter; comment] Sklar AH, et al. **N Engl J Med** 1998 Dec 31;339(27):2023; discussion 2023-4 . Comment on: N Engl J Med 1998 Aug 27;339(9):584-90.

C-reactive protein and atherosclerosis in dialysis patients [letter] **Nephrol Dial Transplant** 1998 Oct;13(10):2710-1

Dialysis without heparin in a patient with combined hereditary deficit in coagulation factor V and protein C. Absy M. **Nephrol Dial Transplant** 1999 Mar;14(3):748-9

Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Aisenpreis U, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:5-6

Successful endovascular repair of a subclavian artery pseudoaneurysm. Akgün S, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2219-21

Pharmacokinetics of clodronate in haemodialysis patients. Ala-Houhala I, et al. **Nephrol Dial Transplant** 1999 Mar; 14(3):699-705

Serum thrombopoietin levels in haemodialysis patients: involvement of arteriovenous fistula. Altun B, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2173-7

Nutritional status of haemodialysis patients: a French national cooperative study. French Study Group for Nutrition in Dialysis. Aparicio M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1679-86

Influence of haemodialysis on plasma total homocysteine concentration. Arnadottir M, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):142-6

Optimization of haemodialysis frequency and duration. A computer simulation study. Arrigo G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:31-4

Low levels of dehydroascorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by haemodialysis. Bakaev VV, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1472-4

Antithrombotic measures for indwelling intravenous haemodialysis catheters--Columbus' egg yet to be found [editorial] Barendregt JN, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1834-5 (8 ref.)

Monitoring dialysis efficacy by comparing delivered and predicted Kt/V. Beige J, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):683-7

Lessons from 494 permanent accesses in 348 haemodialysis patients older than 65 years of age: 29 years of experience. Berardinelli L, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:73-7

Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients [letter] Bhandari S, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3276-7

Nutritional status in type 2 diabetic patients requiring haemodialysis. Biesenbach G, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):655-8

Daily-dialysis programme: indications and results. Bonomini V, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2774-7; discussion 2777-8

Management of vascular access for dialysis: an Italian survey [news] Bonucchi D, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2116-8

Vascular access for haemodialysis: from surgical procedure to an integrated therapeutic approach. Bonucchi D, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:78-81

Helicobacter pylori and Giardia lamblia infections in hemodialysis patients [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1803-4

Permanent twin catheter: a vascular access option of choice for haemodialysis in elderly patients. Canaud B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:82-8

Dialock: a new vascular access device for extracorporeal renal replacement therapy. Preliminary clinical results. Canaud B, et al. **Nephrol Dial Transplant** 1999 Mar; 14(3):692-8

Atheroembolic disease associated with the use of low-molecular-weight heparin during haemodialysis [letter] Carron PL, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):520-1

Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients [letter] Chang JM, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1045-7

Abysmal prognosis of patients with type 2 diabetes entering dialysis [see comments] Chantrel F, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):129-36. Comment in: Nephrol Dial Transplant 1999 Jan;14(1):30-1.

The Janus-faced aspect of 'dry weight'. Chazot C, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):121-4

The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients [letter] [see comments] Chew CG, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2047-9. Comment in: Nephrol Dial Transplant 1999 Aug;14(8):1836-41.

Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Coen G, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2294-302

Gastrostomy buttons for nutritional support on chronic dialysis. Coleman JE, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2041-6

Urea kinetic modelling--are any of the 'bedside' Kt/V formulae reliable enough? Covic A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3138-46

Hepatitis virus infection in haemodialysis patients from Moldavia. Covic A, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):40-5

Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Cullen P, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):659-65

Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood-borne viruses [letter] Dalekos GN, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):255-6

The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). De Schoenmakere G, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1770-5

Ultrasonic videodensitometric analysis of myocardium in end-stage renal disease treated with haemodialysis. Di Bello V, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2184-91

Kt/V or solute removal index: problems in measuring and interpreting the results. Di Filippo S, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2199-202 (18 ref.)

Daily variations of protein intake in haemodialysed patients [letter; comment] Di Iorio B, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2977-8. Comment on: Nephrol Dial Transplant 1998 Mar;13(3):674-8.

Hypertension in haemodialysis patients: who cares? [editorial; comment] Dorhout Mees EJ. **Nephrol Dial Transplant** 1999 Jan;14(1):28-30. Comment on: Nephrol Dial Transplant 1999 Jan;14(1):125-8.

The use of an ethanol- and phosphate-enriched dialysate to maintain stable serum ethanol levels during haemodialysis for methanol intoxication. Dorval M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1774-7

The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients [see comments] Ertürk S, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1912-6. Comment in: Nephrol Dial Transplant 1999 Aug;14(8):1836-41.

Spurious hepatitis B surface antigen detection in adult haemodialysis patients following vaccination [letter; comment] Esparza N, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):794. Comment on: Nephrol Dial Transplant 1998 Jul;13(7):1897-8.

Haemodialysis vascular access and fistula surveillance methods in The Netherlands. Ezzahiri R, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2110-5

Epidemiology of Helicobacter pylori in chronic haemodialysis patients using the new RIBA H. pylori SIA. Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):1929-33

Pulmonary migration of a vascular stent [letter] Fernández-Juárez G, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):250-1

Nephroquiz for the beginner: A swollen face in a girl on haemodialysis. Diagnosis: renal osteodystrophy. Fisher D,

et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1797–8
Chloramine-induced haemolysis presenting as erythropoietin resistance. Fluck S, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1687–91
Immunophenotyping and LDL receptor activity analysis in monocytes/macrophages during low- and high-flux haemodialysis. Forster PB, et al.
Nephrol Dial Transplant 1999;14 Suppl 4:49–51
Haemodialysis for French diabetic patients [editorial; comment] Friedman EA. **Nephrol Dial Transplant** 1999 Jan; 14(1):30–1. Comment on: Nephrol Dial Transplant 1999 Jan;14(1):129–36.
Methadone is poorly removed by haemodialysis [letter] Furlan V, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):254–5
High prevalence of hepatitis G virus (HGV) infections in dialysis staff. Gärtner BC, et al.
Nephrol Dial Transplant 1999 Feb;14(2):406–8
Nandrolone decanoate may be an adjuvant therapy to augment haemoglobin response today? [letter] Gascón A, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2257–8
The elderly haemodialysis patient with abdominal symptoms and hypovolemic shock--splenic rupture secondary to splenic infarction in a patient with severe atherosclerosis [letter] Gascón A, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):1044–5
Pregnancy during dialysis: case report and management guidelines [see comments] Giatras I, et al.
Nephrol Dial Transplant 1998 Dec;13(12):3266–72 (36 ref.) . Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3005–7.
Relationships between volume status and blood pressure in haemodialysis patients--the long and the short of it? [letter; comment] Goldsmith DJ. **Nephrol Dial Transplant** 1998 Aug;13(8):2164–6. Comment on: Nephrol Dial Transplant 1997 Nov;12(11):2308–11.
Molecular aspects of endotoxins relevant to their biological functions. Haeffner-Cavaillon N, et al.
Nephrol Dial Transplant 1999 Apr;14(4):853–60 (47 ref.)
Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Hayano J, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1480–8
Continuous veno-venous haemofiltration versus continuous veno-venous haemodialysis in severe lithium
self-poisoning: a toxicokinetics study in an intensive care unit [letter] Hazouard E, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1605–6
Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Henle T, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1968–75
Reactivation of multisystemic sarcoidosis after immunosuppression withdrawal in a transplanted patient returning to chronic dialysis [letter] Herrero JC, et al.
Nephrol Dial Transplant 1998 Dec;13(12):3280–1
Prolonged use of intradialysis parenteral nutrition in elderly malnourished chronic haemodialysis patients. Hiroshige K, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2081–7
Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities. House AA, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1763–9
High prevalence of GB virus-C infection in haemodialysis patients [letter] Huang CC, et al.
Nephrol Dial Transplant 1999 Jul;14(7):1802–3
Serum ferritin level required for adequate response to recombinant human erythropoietin in haemodialysis patients with hepatitis C virus infection [letter] Hung KY, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2709–10
Haemodialysis dose is independent of type of surgically-created vascular access. Ifudu O, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2311–6
Prevalence of central autonomic neuropathy in elderly dialysis patients. Jassal SV, et al.
Nephrol Dial Transplant 1998 Jul;13(7):1702–8
Phlegmonous gastritis in a haemodialysis patient with secondary amyloidosis. Joko T, et al.
Nephrol Dial Transplant 1999 Jan;14(1):196–8
Outcome and complications of temporary haemodialysis catheters. Kairaitis LK, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1710–4
Near infra-red interactance for nutritional assessment of dialysis patients. Kalantar-Zadeh K, et al.
Nephrol Dial Transplant 1999 Jan;14(1):169–75
A modified quantitative subjective global assessment of nutrition for dialysis patients. Kalantar-Zadeh K, et al.
Nephrol Dial Transplant 1999 Jul;14(7):1732–8
Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Kang DH, et al.
Nephrol Dial Transplant 1998 Nov;13(11):2877–83
Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients? Karkoszka H, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2077–80
Fluid state and blood pressure control in patients treated with long and short haemodialysis. Katzarski KS, et al.
Nephrol Dial Transplant 1999 Feb;14(2):369–75
Is prophylactic haemodialysis recommended to remove contrast medium immediately after angiography? [letter; comment] Kimura G, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):249. Comment on: Nephrol Dial Transplant 1998 Feb;13(2):358–62.
Relating protein intake to nutritional status in haemodialysis patients: how to normalize the protein equivalent of total nitrogen appearance (PNA)? Kloppenburg WD, et al.
Nephrol Dial Transplant 1999 Sep;14(9):2165–72
A primer on the av fistula--Achilles' heel, but also Cinderella of haemodialysis. Konner K. **Nephrol Dial Transplant** 1999 Sep;14(9):2094–8 (6 ref.)
Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Kooistra MP, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2853–60
Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Kunz K, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1934–42
Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment [letter] Kuypers D, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):2050–1
International nephrological assistance to Kosovo refugees. European Branch of the Task Force. Lameire N.
Nephrol Dial Transplant 1999 Aug;14(8):1845
Haemodialysis for French diabetic patients [letter] Laurent G, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2044–5
Changes in adrenomedullin plasma concentrations during haemodialysis in patients with chronic renal failure [letter] Letizia C, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):519–20
Haemodialysis for severe hyperammonaemic coma complicating urinary diversions. Lévesque R, et al.
Nephrol Dial Transplant 1999 Feb;14(2):458–61
How should anaemia be managed in pre-dialysis patients? Levin A. **Nephrol Dial Transplant** 1999;14 Suppl 2:66–74 (51 ref.)
Duration of dialysis sessions--was Hegel right? Locatelli F, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):560–3
How long can dialysis be postponed by low protein diet and ACE inhibitors? [editorial] Locatelli F, et al.
Nephrol Dial Transplant 1999 Jun;14(6):1360–4
The dialysis patient with persisting elevation of bone alkaline phosphatase after parathyroidectomy. Lorho R, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2394–6
Increased cardiac troponin T and endothelin-1 concentrations in dialysis patients may indicate heart disease. Löwbeer C, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1948–55
Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. McMahon LP, et al.
Nephrol Dial Transplant 1999 May;14(5):1182–7
Tissue factor pathway inhibitor and tissue factor in HD and CAPD [letter] Małyszko J, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2424–6
Dialysis with increased frequency of sessions (Lecce dialysis). Mastrangelo F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:139–47
Peripheral deletion of gammadelta T cells in haemodialysis patients. Matsumoto Y, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2861–6
The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Matuszkiewicz-Rowińska J, et al.
Nephrol Dial Transplant 1999 May;14(5):1238–43
Development of a walking test for the assessment of functional capacity in non-anaemic maintenance dialysis patients. Mercer TH, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2023–6
Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Merkus MP, et al.
Nephrol Dial Transplant 1999 May;14(5):1163–70
Penile necrosis in a haemodialysis patient: a rare manifestation of cholesterol crystal embolism. Mondragon P, et al.
Nephrol Dial Transplant 1998 Dec;13(12):3233–5
Contact from Poland and Lithuania to Copenhagen: paving the road from charity to research. Nielsen B.
Nephrol Dial Transplant 1999 Jul;14(7):1632–3
Hyperkalaemic muscle paresis--side-effect of prostaglandin inhibition in a haemodialysis patient. Nielsen EH.
Nephrol Dial Transplant 1999 Feb;14(2):480–2
Daytime hypertension, sleep apnea and metabolic alkalosis in a haemodialysis patient--the result of sodium bicarbonate abuse. Okada H, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):452–4
Intensive perioperative dialysis can improve the hospital mortality of haemodialysis patients undergoing cardiac surgery [letter] Okada H, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2713–4
Positive skin reaction test in haemodialysis patients allergic to nafamostat mesilate [letter] Okada H, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2166–7
Does intensive perioperative dialysis improve the results of coronary artery bypass grafting in haemodialysed patients? Okada H, et al. **Nephrol Dial Transplant** 1999 Mar; 14(3):771–5
Importance of dry-weight assessment in well-being, appetite, nutritional status, and anaemia correction in haemodialysis patients [letter] Ortega Marcos O, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2424
The effect of alpha interferon therapy and short-interval intradermal administration on response to hepatitis B vaccine in haemodialysis patients [letter] Ozener C, et al.
Nephrol Dial Transplant 1999 May;14(5):1339–40
Baclofen neurotoxicity in chronic haemodialysis patients with hiccups [letter] Peces R, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1896–7
Bone mineral density by quantitative digital radiography in patients with end-stage renal failure beginning replacement hemodialysis treatment and after one year of treatment [letter] Pecovnik Balon B, et al.
Nephrol Dial Transplant 1998 Jul;13(7):1899
Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. Prata MM, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2345–7
Anti-HCV seropositivity among haemodialysis patients of Iranian origin [letter] Rais-Jalali G, et al.
Nephrol Dial Transplant 1999 Aug;14(8):2055–6
Haemodialysis for end-stage renal disease in Southern India--a perspective from a tertiary referral care centre [news] Rao M, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2494–500
Behaviour of potassium removal in different dialytic schedules. Redaelli B, et al. **Nephrol Dial Transplant** 1998; 13 Suppl 6:35–8
No effect of vitamin K1 supplementation on biochemical bone markers in haemodialysis patients [letter] Reichel H.
Nephrol Dial Transplant 1999 Jan;14(1):249–50
Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Ribeiro S, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2037–40
Spurious hepatitis B surface antigen detection in a haemodialysis patient [letter] [see comments] Riley S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1897–8. Comment in: Nephrol Dial Transplant 1999 Mar;14(3):794.
The elderly dialysis patient: management of the hospital stay. Röhrich B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:69–72
Effect of dialyser biocompatibility on recovery from acute renal failure after cadaver renal transplantation. Romão JE Jr, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):709–12
The haemodialysis system: basic mechanisms of water and solute transport in extracorporeal renal replacement therapies. Ronco C, et al. **Nephrol Dial Transplant** 1998; 13 Suppl 6:3–9 (9 ref.)
A single dose of dalteparin effectively prevents clotting during haemodialysis. Sagedal S, et al.
Nephrol Dial Transplant 1999 Aug;14(8):1943–7
HCV infection in haemodialysis and CAPD patients [letter] Sayiner AA, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):256–7
Dialysis in neonates with inborn errors of metabolism. Schaefer F, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):910–8
Validation of haemodialysis recirculation and access blood flow measured by thermodilution. Schneditz D, et al.
Nephrol Dial Transplant 1999 Feb;14(2):376–83
Recirculation, a seemingly simple concept [editorial] Schneditz D. **Nephrol Dial Transplant** 1998 Sep; 13(9):2191–3 (12 ref.)
Indwelling devices for vascular access in haemodialysis [letter] Shaldon S. **Nephrol Dial Transplant** 1999 Sep; 14(9):2258–9
Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population. Shibuya A, et al.
Nephrol Dial Transplant 1998 Aug;13(8):2033–6
The haemodialysis patient who developed acute respiratory distress syndrome after a trip to a hot spring spa. Shimizu Y, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):455–7
Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Sommerburg O, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2583–7
Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Song IS, et al.
Nephrol Dial Transplant 1999 Jan;14(1):137–41
Decrease in serum pentosidine levels of ESRD patients during polysulfone haemodialysis [letter] Stein G, et al.
Nephrol Dial Transplant 1999 Jun;14(6):1606–8
The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Stolear JC, et al.
Nephrol Dial Transplant 1999 Aug;14(8):1961–7
Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Taal MW, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1917–21
Malonyldialdehyde content of cell membranes is the most important marker of oxidative stress in haemodialysis patients [letter; comment] Taccone-Gallucci M, et al.
Nephrol Dial Transplant 1998 Oct;13(10):2711–2. Comment on: Nephrol Dial Transplant 1997 Nov;12(11):2312–7.
Influences of Helicobacter pylori on serum pepsinogen concentrations in dialysis patients. Tamura H, et al.
Nephrol Dial Transplant 1999 Jan;14(1):113–7
Pregnancy in women receiving renal dialysis or transplantation in Japan: a nationwide survey. Toma H, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1511–6
LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism [letter] Tsunoda S, et al.
Nephrol Dial Transplant 1999 Apr;14(4):1041–2
Cefonicid 'restores' the depressed activities of polymorphonuclear cells from chronic haemodialysis patients and renal transplant recipients in vitro. Tullio V, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2017–22

Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation [letter] Túri S, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):252–3

Unmasking of thyrotoxicosis after initiation of regular haemodialysis treatment? [letter] Utas C, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2423

Haemodialysis access graft with shunting through an iatrogenic fistula—the diagnostic role of magnetic resonance flow measurement. van Kempen BP, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):444–6

Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'? [letter] Vlassopoulos D, et al. **Nephrol Dial Transplant** 1999 May;14(5):1340–1

Quality of water used for haemodialysis: bacteriological and chemical parameters. Vorbeck-Meister I, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):666–75

Trichosporon beigelii fungaemia in a patient with haemodialysis. Wang HY, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2017–8

Again: segmentary necrosis of the ascending colon (SNAC) in a chronic haemodialysis patient [letter] Weber T, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1901–2

Acute effects of haemodialysis on cutaneous microcirculation in patients with peripheral arterial occlusive disease. Weiss T, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2317–21

Folate supplementation in the dialysis patient—fragmentary evidence and tentative recommendations [editorial] Westhuyzen J. **Nephrol Dial Transplant** 1998 Nov; 13(11):2748–50

Dialysis schedule-related fluid state and cardiovascular effects. Wizemann V, et al. **Nephrol Dial Transplant** 1998; 13 Suppl 6:91–3 (19 ref.)

Cefepime-related neurotoxicity in a haemodialysis patient [letter] Wong KM, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2265–6

Membrane compatibility and clearance of hepatitis C virus in chronic dialysis patients [letter] Adorati M, et al. **Nephron** 1999;82(4):358

Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India [letter] Agarwal SK, et al. **Nephron** 1999;81(4):448

Transmission of hepatitis C virus infection to spouses of patients undergoing chronic hemodialysis [letter] Akarsu E, et al. **Nephron** 1999;82(4):359–60

Hyperphosphatemia: a serious limiting factor preventing the possible benefit from intravenous calcitriol therapy [letter] Arik N, et al. **Nephron** 1999;82(1):77–8

Prevalence of hepatitis E virus antibody in hemodialysis patients [letter] Arinsoy T, et al. **Nephron** 1998 Sep;80(1):85

Influence of aminosteril on serum parathyroid hormone levels in hemodialysis patients [letter] Boran M, et al. **Nephron** 1999;82(1):75–6

The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Boran M, et al. **Nephron** 1999;82(1):22–6

HCV Infection: Six years after' in a dialysis unit [letter; comment] Brugnano R, et al. **Nephron** 1999 Feb;81(2):244–5 . Comment on: Nephron 1992;61(3):263–5.

Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. Campo N, et al. **Nephron** 1999;82(1):17–21

Effects of conventional heparin and low-molecular-weight heparin treatment on lipid metabolism during a single hemodialysis session [letter] Camsari T, et al. **Nephron** 1999; 82(3):286–8

Volatile alkanes and increased concentrations of isoprene in exhaled air during hemodialysis. Capodicasa E, et al. **Nephron** 1999;82(4):331–7

Effects of heparin and enoxaparin on lipids and oxidant system during a single hemodialysis session [letter] Cavdar C, et al. **Nephron** 1999;82(1):81–3

Postdialysis serum albumin is more rational than predialysis value [letter] Chen YC, et al. **Nephron** 1999;82(3):284–5

Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Fabrizi F, et al. **Nephron** 1998 Dec;80(4):428–33

Gastroduodenal bleeding after discontinuation of H2-receptor antagonists in hemodialysis patients [letter] Fiorini F, et al. **Nephron** 1998 Sep;80(1):118

Platelet-leukocyte activation during hemodialysis detected with a monoclonal antibody to leukocyte integrin CD11b. Hernández MR, et al. **Nephron** 1998 Oct;80(2):197–203

Hemodialysis neutropenia correlates with a decreased filterability and an increase in the number of cytoplasmic actin filaments in peripheral blood neutrophils, which is preceded by a decrease in the number of surface expression of L-selectin. Iijima S, et al. **Nephron** 1999;82(3):214–20

Does PTH influence leptin concentration in haemodialysed uraemic patients? [letter] Kokot F, et al. **Nephron** 1999; 82(4):372–3

Vitamin D3 withdrawal in hemodialysis patients with adynamic bone disease [letter] Kondo M, et al. **Nephron** 1998 Sep;80(1):89

Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Kristal B, et al. **Nephron** 1999;81(4):406–13

Intravenous low-dose iron administration in hemodialysis patients treated with erythropoietin [letter] Kurihara I, et al. **Nephron** 1998 Nov;80(3):369–70

Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Nephron** 1998 Dec;80(4):380–400 (115 ref.)

Calcified carcinoma of the stomach in a hemodialysis patient [letter] Matsumura M, et al. **Nephron** 1999;82(1):84

Serum leptin concentrations in patients on hemodialysis. Nakazono H, et al. **Nephron** 1998 Sep;80(1):35–40

Optimal tuberculosis screening of hemodialysis patients [letter] Narsipur SS, et al. **Nephron** 1999;82(4):356

Free magnesium in patients on regular dialysis treatment [letter] Paskalev E, et al. **Nephron** 1999;81(3):356–7

Plasma alpha-lipoic acid and total glutathione levels in patients on maintenance hemodialysis [letter] Reddi AS, et al. **Nephron** 1999;82(4):357

Plasma carnitine levels in patients undergoing hemodialysis [letter] Reddi AS, et al. **Nephron** 1998 Sep;80(1):87–8

Sympathetic skin response in hemodialysis patients: correlation with nerve conduction studies and adequacy of dialysis. Robles NR, et al. **Nephron** 1999;82(1):12–6

Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Roxborough HE, et al. **Nephron** 1999;81(3):278–83

Pentanucleotide repeat and size polymorphisms in the apolipoprotein(a) gene are associated with the lipoprotein(a) concentration in chronic hemodialysis patients. Tanaka M, et al. **Nephron** 1999;81(4):414–20

Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Uchihara M, et al. **Nephron** 1998 Sep;80(1):51–6

Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Yildiz A, et al. **Nephron** 1998 Sep;80(1):57–60

Relationship between erythropoietin administration and the endothelial nitric oxide synthase gene polymorphism in patients with hemodialysis [letter] Yokoyama K, et al. **Nephron** 1999;82(4):354–5

The effect of hemodialysis on hearing using pure-tone audiometry and distortion-product otoacoustic emissions. Ozturan O, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec;60(6):306–13

Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Russo CR, et al. **Osteoporos Int** 1998;8(5):443–8

Comparison of two methods for predicting equilibrated Kt/V (eKt/V) using true eKt/V value. Marsenić O, et al. **Pediatr Nephrol** 1999 Jun;13(5):418–22

Treatment of hyperhomocysteinemia in children on dialysis by folic acid. Schröder CH, et al. **Pediatr Nephrol** 1999 Sep;13(7):583–5

Intravenous iron treatment of renal anemia in children on hemodialysis. Tenbrock K, et al. **Pediatr Nephrol** 1999 Sep; 13(7):580–2

Continuum and integration of pre-dialysis care and dialysis modalities. Agrawal A, et al. **Perit Dial Int** 1999;19 Suppl 2:S276–80

Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Kim SB, et al. **Perit Dial Int** 1999;19 Suppl 2:S144–9 (59 ref.)

Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Lin CC, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):516–21

CAPD in patients with failure of hemodialysis vascular access. Makil D, et al. **Perit Dial Int** 1998 Sep–Oct; 18(5):534–6

Comparison of nutritional status between peritoneal dialysis and hemodialysis patients. Park YK. **Perit Dial Int** 1999; 19 Suppl 2:S523–6

Early-start dialysis in diabetic nephropathy. Walker RJ. **Perit Dial Int** 1999;19 Suppl 2:S219–21

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Kovacs SJ, et al. **Pharmacotherapy** 1999 May; 19(5):612–9

Translumbar placement of inferior vena caval catheters: a solution for challenging hemodialysis access. Rajan DK, et al. **Radiographics** 1998 Sep–Oct;18(5):1155–67; discussion 1167–70

Venous anastomosis of hemodialysis grafts [letter; comment] Funaki B, et al. **Radiology** 1999 May;211(2):586. Comment on: Radiology 1998 Nov;209(2):365–70.

Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Haage P, et al. **Radiology** 1999 Jul;212(1):175–80

Hemodialysis access fistula creation: preoperative assessment with MR venography and comparison with conventional venography. Menegazzo D, et al. **Radiology** 1998 Dec; 209(3):723–8

Patency of Wallstents placed across the venous anastomosis of hemodialysis grafts after percutaneous recanalization [see comments] Patel RI, et al. **Radiology** 1998 Nov; 209(2):365–70. Comment in: Radiology 1999 May;211(2):586.

Brachytherapy for the prevention of stenosis in a canine hemodialysis graft model: preliminary observations. Trerotola SO, et al. **Radiology** 1999 Sep;212(3):748–54

Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism. Vlassopoulos D, et al. **Ren Fail** 1999 Mar;21(2):199–207

No relation of tuberculin reactivity with quantitative analysis of peripheral blood lymphocyte subsets in haemodialysis patients. Yildiz A, et al. **Respir Med** 1999 Feb;93(2):119–22

Hepatitis B virus infection profile in central Brazilian hemodialysis population. Teles SA, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):281–6

Seasonal variation of blood pressure in maintenance hemodialysis. de Castro MC, et al. **Rev Paul Med** 1998 Jul–Aug;116(4):1774–7

Short- and long-term uses of calcium acetate do not change hair and serum zinc concentrations in hemodialysis patients. Hwang SJ, et al. **Scand J Clin Lab Invest** 1999 Apr; 59(2):83–7

Oxygen and 2,3 biphosphoglycerate (2,3-BPG) during haemodialysis. Nielsen AL, et al. **Scand J Clin Lab Invest** 1998 Oct;58(6):459–67

Gastric dysrhythmia in uremic patients on maintenance hemodialysis. Ko CW, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1047–51

Hepatitis G virus infection in haemodialysis patients and its relationship with hepatitis C virus RNA positivity. Hizel N, et al. **Scand J Infect Dis** 1998;30(5):451–4

Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Gröntoft KC, et al. **Scand J Urol Nephrol** 1998 Jul;32(4):276–83

The cellular clearance theory does not explain the post-dialytic small molecule rebound. Heaf JG, et al. **Scand J Urol Nephrol** 1998 Sep;32(5):350–5

Dialysis and related therapies. Conger J. **Semin Nephrol** 1998 Sep;18(5):533–40 (65 ref.)

Principles of dialysis: special issues in women. Gipson D, et al. **Semin Nephrol** 1999 Mar;19(2):140–7 (78 ref.)

Prognostic value of intraoperative blood flow measurements in vascular access surgery. Johnson CP, et al. **Surgery** 1998 Oct;124(4):729–37; discussion 737–8

Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin [editorial] Gejyo F, et al. **Ther Apher** 1997 May;1(2):126–8

Autologous blood donation preceding coronary artery bypass graft operation in a hemodialysis patient. Shinoda T, et al. **Ther Apher** 1998 Nov;2(4):311–3

Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Franssen EJ, et al. **Ther Drug Monit** 1999 Jun;21(3):289–92

Analysis of the effects of recipient age and pretransplant hemodialysis period on cadaveric kidney transplant outcome using non-heart-beating donors. Shiroki R, et al. **Transplant Proc** 1999 Aug;31(5):1970–2

Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Pescovitz MD, et al. **Transplantation** 1998 Oct 27;66(8):1104–7

Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Djavan B, et al. **Urology** 1999 Jun;53(6):1169–74

Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. Krüger S, et al. **Vaccine** 1999 Mar 5;17(9–10):1145–50

Does HCV screening of blood donors affect transmission of hepatitis G virus in dialysed patients? [letter] Gérard C, et al. **Vox Sang** 1998;75(1):77

[Assessment of nutrition in dialysis patients and chronic uremic patients] Liu H, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):727–30 (Eng. Abstr.) **(Chi)**

[The peripheral blood levels of TNF alpha and PLA2 activities in dialysis and non-dialysis patients with uremia] Duan S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(1):78–80 (Eng. Abstr.) **(Chi)**

[A study on the relationship between plasma level of ET-1 and cGRP and blood pressure in hemodialysis patients] Zhou Q, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(4):335–7 (Eng. Abstr.) **(Chi)**

[Renal anemia and the effect of long-term dialysis] Opatrná S, et al. **Cas Lek Cesk** 1999 Feb 22;138(4):107–10 (44 ref.) (Eng. Abstr.) **(Cze)**

[Problems with trace elements in hemodialysis. Evaluation of serum levels] Senft V, et al. **Cas Lek Cesk** 1999 Apr 19;138(8):245–8 (Eng. Abstr.) **(Cze)**

[Vitreoretinal surgery in diabetic patients in a dialysis program] Synek S. **Cesk Slov Oftalmol** 1999 Jul;55(4):203–5 (Eng. Abstr.) **(Cze)**

[Aneurysm as a complication of arteriovenous anastomoses for hemodialysis] Bachleda P, et al. **Rozhl Chir** 1998 Dec; 77(12):541–4 (Eng. Abstr.) **(Cze)**

[Inflammatory (infectious) complications in arteriovenous fistulae for hemodialysis] Bachleda P, et al. **Rozhl Chir** 1999 Feb;78(2):50–4 (Eng. Abstr.) **(Cze)**

[Massive paraquat poisoning. Favorable course after treatment with n-acetylcysteine and early hemodialysis] Drault JN, et al. **Ann Fr Anesth Reanim** 1999 May; 18(5):534–7 (Eng. Abstr.) **(Fre)**

[Tuberculosis among hemodialysis patients in Dakar, apropos of 2 cases] Diouf B, et al. **Dakar Med** 1998;43(1):129–31 (Eng. Abstr.) **(Fre)**

[Echocardiographic data from chronic dialysis patients in Dakar] Kane A, et al. **Dakar Med** 1997;42(1):25–9 (Eng. Abstr.) **(Fre)**

[Treatment of abdominal aortic aneurysms in chronic hemodialysis] Lacombe M. **J Mal Vasc** 1998 Dec; 23(5):349–53 (Eng. Abstr.) **(Fre)**

[Fistulas in chronic hemodialysis (editorial)] Krause D. **J Radiol** 1998 Mar;79(3):207–8 **(Fre)**

[Percutaneous recanalization of proximal venous thromboses in chronic hemodialysis patients] Vautier-Rodary R, et al. **J Radiol** 1998 Mar;79(3):253–7 (Eng. Abstr.) **(Fre)**

[Management of malnutrition in chronic hemodialysis] Cano N, et al. **Nephrologie** 1998;19(6):353–7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Incidence of atherosclerotic cardiovascular events in patients with chronic uremia: epidemiologic studies in Ile-de-France] Jungers P, et al. **Nephrologie** 1998; 19(8):489–94 (Eng. Abstr.) **(Fre)**

[Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis (see comments)] Kacso I, et al. **Nephrologie** 1999;20(1):19–28 (46 ref.) (Eng. Abstr.) . Comment in: Nephrologie 1999 ;20(1):3–7. **(Fre)**

[Prevalence of HIV infection in dialysis patients: results of a national multicenter study] Poignet JL, et al. **Nephrologie** 1999;20(3):159–63 (Eng. Abstr.) **(Fre)**

[Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis] Séchet A, et al. **Nephrologie** 1999; 20(4):209–12 (Eng. Abstr.) **(Fre)**

[Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis] Séchet A, et al. **Nephrologie** 1999;20(4):213–6 (Eng. Abstr.) **(Fre)**

[Hemodialysis of the elderly patient: consider the coronary arteries (letter; comment)] Jan F, et al. **Presse Med** 1998 Jun 13;27(21):1014. Comment on: Presse Med 1998 Apr 25;27(16):748–52. **(Fre)**

[Chemotherapy of small cell bronchogenic carcinoma in a patient on hemodialysis for chronic renal failure. Apropos of a case] Guillou B, et al. **Rev Pneumol Clin** 1998 Sep; 54(4):215–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Measuring bioimpedance in dialysis patients for determining the amount of water in individual fluid compartments of the body] Seeger A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:534–5 **(Ger)**

[Dialysis shunt surgery] Scheideler K. **Chirurg** 1998 Aug; 69(8):893–902 **(Ger)**

[Angioleiomyoma of the gallbladder: a rare cause of hemobilia in a patient on dialysis] Aschl G, et al. **Dtsch Med Wochenschr** 1999 Jan 8;124(1–2):13–6 (Eng. Abstr.) **(Ger)**

[Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease] Floege J, et al. **Internist (Berl)** 1999 Jan; 40(1):64–9 (27 ref.) **(Ger)**

[Chronic hemodialysis--a contraindication for thrombolytic therapy?] Schnieder W, et al. **Internist (Berl)** 1998 Oct; 39(10):1069 **(Ger)**

[Pharmacokinetics and dosage of fluconazole in continuous hemofiltration (CAVH, CVVH) and hemodialysis (CAVHD, CVVHD)] Pittrow L, et al. **Mycoses** 1998;41 Suppl 2:86–8 (Eng. Abstr.) **(Ger)**

[Acquired cystic kidney disease in patients on long-term dialysis: a retrospective study of 125 autopsies. Part 2: tumors] Segerer S, et al. **Pathologe** 1998 Sep;19(5):368–72 (Eng. Abstr.) **(Ger)**

[Acquired, cystic kidney disease in chronic dialysis patients: a retrospective study of 125 autopsies. 1: Cysts] Segerer S, et al. **Pathologe** 1998 Jul;19(4):292–8 (Eng. Abstr.) **(Ger)**

[Radiologic diagnosis of the kidneys in dialysis patients] Bahner ML, et al. **Radiologe** 1999 May;39(5):398–403 (Eng. Abstr.) **(Ger)**

[Treatment of anemia in chronic renal failure (predialysis)] Ruedin P. **Schweiz Rundsch Med Prax** 1999 Jan 28; 88(5):173–7 (35 ref.) (Eng. Abstr.) **(Ger)**

[Long-term HIV infection and dialysis dependent renal failure in analgesic nephropathy] Müller V, et al. **Ther Umsch** 1998 Sep;55(9):555–7 (Eng. Abstr.) **(Ger)**

[Reconstruction of mediastinal veins in same side dialysis shunt] Haug M, et al. **Zentralbl Chir** 1999;124(1):2–6 (Eng. Abstr.) **(Ger)**

[Changes in body fluid compartments estimated by multifrequency bioelectric impedance analysis in patients treated by hemodialysis] Pátri L, et al. **Orv Hetil** 1999 Jun 20;140(25):1407–10 (Eng. Abstr.) **(Hun)**

[Hepatitis G virus infection in hemodialyzed children and adults following kidney transplantation] Szabó A, et al. **Orv Hetil** 1999 Jul 18;140(29):1619–23 (Eng. Abstr.) **(Hun)**

[Role of hypertension in determining valvular diseases in patients with chronic uremia and dialytic treatment] Facchin L, et al. **Cardiologia** 1998 Dec;43(12):1361–6 (Eng. Abstr.) **(Ita)**

[Evaluation of urea recirculation and dialysis efficiency of central venous jugular catheters when the venous lumen is used as an arterial lumen] Dionisio P, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):61–5 (Eng. Abstr.) **(Ita)**

[Chronic pain during dialysis. Pharmacologic therapy and its costs] Fortina F, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):85–7 (Eng. Abstr.) **(Ita)**

[Role of magnetic resonance in hemodialysis patients with amyloid shoulder arthropathy] Della Sala SW, et al. **Radiol Med (Torino)** 1998 Oct;96(4):300–9 (Eng. Abstr.) **(Ita)**

[Causes and risks of hyperlipidemia during dialysis and after renal transplantation] Verzola A, et al. **Recenti Prog Med** 1998 Nov;89(11):590–7 (51 ref.) (Eng. Abstr.) **(Ita)**

[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis] Nishioka Y, et al. **Gan To Kagaku Ryoho** 1999 Mar; 26(4):527–30 (Eng. Abstr.) **(Jpn)**

[Synchronous multifocal development of invasive transitional cell carcinoma of the urinary tract in a patient with renal failure receiving long-term hemodialysis: a case report] Kanatani I, et al. **Hinyokika Kiyo** 1998 Nov;44(11):821–4 (Eng. Abstr.) **(Jpn)**

[Coronary artery bypass graft surgery in dialysis patient] Sawada Y, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct; 46(10):983–6 (Eng. Abstr.) **(Jpn)**

[A case report of pleural empyema treated by video-assisted thoracoscopic surgery in an elder patient receiving hemodialysis] Inoue N, et al. **Kyobu Geka** 1999 Feb; 52(2):168–71 (Eng. Abstr.) **(Jpn)**

[A case of solitary metastatic lung tumor from follicular carcinoma of the thyroid in hemodialysis patient] Naito A, et al. **Kyobu Geka** 1999 Aug;52(9):787–9 (Eng. Abstr.) **(Jpn)**

[Emergency coronary artery bypass grafting in dialysis patients] Tanaka H, et al. **Kyobu Geka** 1999 Jul;52(8 Suppl):683–7 (Eng. Abstr.) **(Jpn)**

[Current states and future prospects of kidney failure] Kuromawa K. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1231–3 **(Jpn)**

[A case of unruptured cerebral aneurysm treated by intra-aneurysmal embolization during outpatient hemodialysis for chronic renal failure] Nakajima T, et al. **No Shinkei Geka** 1999 Mar;27(3):255–9 (Eng. Abstr.) **(Jpn)**

[Plasma macrophage colony-stimulating factor level and changes of monocyte subpopulations in chronic renal failure patients treated with hemodialysis] Satoh T, et al. **Rinsho Byori** 1999 Apr;47(4):359–64 (Eng. Abstr.) **(Jpn)**

[Natural killer cell count in hemodialysis patients] Liszka M, et al. **Pol Arch Med Wewn** 1998 Jul;100(1):9–18 (Eng. Abstr.) **(Pol)**

[Metastasis of kidney clear cell carcinoma to the thyroid cell in patients on renal replacement therapy] Barczyński M, et al. **Przegl Lek** 1998;55(11):623–5 (Eng. Abstr.) **(Pol)**

[Water purification for hemodialysis] Eventov VL, et al. **Med Tekh** 1999 Mar–Apr;(2):21–5 (Eng. Abstr.) **(Rus)**

[Interferon system status in hemodialysis patients infected with hepatitis B and C viruses] Priimiagi LS, et al. **Vopr Virusol** 1999 Jul–Aug;44(4):167–9 (Eng. Abstr.) **(Rus)**

[Does uremic pruritus in hemodialyzed patients disappear only with replacement therapy?] Jakić M. **Lijec Vjesn** 1999 Apr–May;121(4–5):118–22 (Eng. Abstr.) **(Scr)**

[Echocardiographic changes in patients with chronic renal insufficiency on hemodialysis] Resić H, et al. **Med Arh** 1999;53(1):21–3 (Eng. Abstr.) **(Scr)**

[Hepatitis B immunization in hemodialysis patients] Skladaný L, et al. **Vnitr Lek** 1998 Sep;44(9):535–7 (Eng. Abstr.) **(Slo)**

[HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study] Cañero-Velasco MC, et al. **Acta Gastroenterol Latinoam** 1998;28(3):265–8 (Eng. Abstr.) **(Spa)**

[Wunderlich's syndrome in a patient on hemodialysis with acquired cystic kidney disease. A report of a new case] Peña Porta JM, et al. **Actas Urol Esp** 1999 Jan;23(1):76–8 (11 ref.) (Eng. Abstr.) **(Spa)**

[Kidney revascularization and function recovery in patients in dialysis] Bracco A, et al. **Medicina (B Aires)** 1998; 58(6):747–54 (754 ref.) (Eng. Abstr.) **(Spa)**

[Septic pulmonary embolism in patients on chronic hemodialysis with Staphylococcus aureus bacteremia] Bello Martínez E, et al. **Rev Clin Esp** 1999 Feb;199(2):55–8 (Eng. Abstr.) **(Spa)**

[Renal failure secondary to diabetic nephropathy. A review of the characteristics of the diabetic patients who started dialysis in Catalonia in 1994] González MT, et al. **Rev Clin Esp** 1999 Jan;199(1):8–12 (Eng. Abstr.) **(Spa)**

[Transient blood surface antigens of hepatitis B in patients on hemodialysis] Santana Rodriguez OE, et al. **Rev Clin Esp** 1999 Apr;199(4):198–201 (Eng. Abstr.) **(Spa)**

[Lipoprotein(a) and lipids in chronic renal insufficiency and kidney transplant] Ochoa-Sosa CA, et al. **Rev Invest Clin** 1998 Jul–Aug;50(4):301–6 (Eng. Abstr.) **(Spa)**

[Necessity to administer 131I in a patient with papillary thyroid carcinoma undergoing chronic hemodialysis (letter)] Novik V, et al. **Rev Med Chil** 1998 Jul;126(7):874–5 **(Spa)**

ADVERSE EFFECTS

Prevalence of hepatitis G virus in a haemodialysis unit. Lamproye A, et al. **Acta Gastroenterol Belg** 1999 Jan–Mar; 62(1):13–5

Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Sandhu J, et al. **Am J Epidemiol** 1999 Jul 1;150(1):58–66

Hepatitis G virus infection in hemodialysis patients: fact or fancy? [letter; comment] Macedo G, et al. **Am J Gastroenterol** 1999 May;94(5):1423–4. Comment on: Am J Gastroenterol 1997 Nov;92(11):1986–91.

Risk factors for vertebral fractures in renal osteodystrophy. Atsumi K, et al. **Am J Kidney Dis** 1999 Feb;33(2):287–93

Folate measurements in patients on regular hemodialysis treatment. Bamonti-Catena F, et al. **Am J Kidney Dis** 1999 Mar;33(3):492–7

Protein-energy malnutrition in dialysis patients. Bistrian BR, et al. **Am J Kidney Dis** 1999 Jan;33(1):172–5 (37 ref.)

Fatal cervical spondyloarthropathy in a hemodialysis patient with systemic deposition of beta2-microglobulin amyloid. Danesh FR, et al. **Am J Kidney Dis** 1999 Mar;33(3):563–6 (17 ref.)

A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. Emili S, et al. **Am J Kidney Dis** 1999 Jun;33(6):1107–14

Fatal cardiac beta2-microglobulin amyloidosis in patients on long-term hemodialysis. Kawano M, et al. **Am J Kidney Dis** 1998 Mar;31(3):E4

Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Kopple JD. **Am J Kidney Dis** 1999 Jan;33(1):180–5 (53 ref.)

Hypertension in the dialysis patient [editorial; comment] CO Mailloux LU. **Am J Kidney Dis** 1999 Aug;34(2):359–61. Comment on: Am J Kidney Dis 1999 Aug;34(2):218–21.

Intravenous iron supplementation in end-stage renal disease patients [editorial; comment] [see comments] Matzke GR. **Am J Kidney Dis** 1999 Mar;33(3):595–7. Comment on: Am J Kidney Dis 1999 Mar;33(3):464–70. Comment on: Am J Kidney Dis 1999 Mar;33(3):471–82. Comment in: Am J Kidney Dis 1999 Aug;34(2):401–2.

Neocytolysis: from outer space to the dialysis unit [editorial; comment] Means RT Jr. **Am J Kidney Dis** 1999 Jan; 33(1):140–1. Comment on: Am J Kidney Dis 1999 Jan;33(1):59–62.

Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Miller ER, et al. **Am J Kidney Dis** 1999 Feb;33(2):356–60

Pseudotumor cerebri: an unusual complication of brachiocephalic vein thrombosis associated with hemodialysis catheters. Molina JC, et al. **Am J Kidney Dis** 1998 May;31(5):E3

Optimal hematocrit in patients on dialysis therapy. Nissenson AR. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S142–6

Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial [see comments] Nissenson AR, et al. **Am J Kidney Dis** 1999 Mar;33(3):471–82. Comment in: Am J Kidney Dis 1999 Mar;33(3):495.

Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Odamaki M, et al. **Am J Kidney Dis** 1999 Feb;33(2):361–8

Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor [see comments] Ozkahya M, et al. **Am J Kidney Dis** 1999 Aug; 34(2):218–21. Comment in: Am J Kidney Dis 1999 Aug;34(2):359–61.

Reducing the risk of hemodialysis access [editorial; comment] Schwab SJ. **Am J Kidney Dis** 1999 Aug;34(2):362–3. Comment on: Am J Kidney Dis 1999 Aug;34(2):338–40. Comment on: Am J Kidney Dis 1999 Aug;34(2):341–3.

Effectiveness of nutrition interventions in the pre-ESRD and the ESRD population. Wolfson M. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S126–30

Factors influencing serum albumin in dialysis patients. Yeun JY, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S118–25

Hypertension in the hemodialysis population [letter] Zager P. **Am J Kidney Dis** 1999 Aug;34(2):400

Porphyria cutanea tarda, hepatitis C infection, and iron overload in a patient on hemodialysis [letter; comment] Albitar S, et al. **Am J Med** 1999 Feb;106(2):266–7. Comment on: Am J Med 1997 Aug;103(2):163–4.

Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Kang ES, et al. **Am J Med Sci** 1999 Jan;317(1):9–21

Pathogenesis and management of dialysis-related amyloid bone disease. Nangaku M, et al. **Am J Med Sci** 1999 Jun; 317(6):410–5 (61 ref.)

Intradialytic dobutamine therapy in maintenance hemodialysis patients with persistent hypotension. Anand U, et al. **Am J Nephrol** 1999;19(4):459–63

Dialysis-associated renal cystic disease resembling autosomal dominant polycystic kidney disease: a report of two cases. Bakir AA, et al. **Am J Nephrol** 1999;19(4):519–22

A cluster of bloodstream infections and pyrogenic reactions among hemodialysis patients traced to dialysis machine waste-handling option units. Jochimsen EM, et al. **Am J Nephrol** 1998;18(6):485–9

Venous thoracic outlet syndrome simulating subclavian stenosis in a hemodialysis patient. Williams ME. **Am J Nephrol** 1998;18(6):562–4

Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Abdulkarim AS, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):571–6

Intravenous infusion ascitic fluid during hemodialysis: a study of 108 treatments in 13 uremic cases. Liu J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):153–62

Hemodialysis-induced hypophosphatemia in a normophosphatemic patient dialyzed for ethylene glycol poisoning: treatment with phosphorus-enriched hemodialysis. Chow MT, et al. **Artif Organs** 1998 Oct; 22(10):905–7

Acetate hemodialysis does not increase the frequency of arrhythmia in hemodialysis patients. Kayatas M, et al. **Artif Organs** 1998 Sep;22(9):781–4

Hepatitis C virus infection in dialysis: a continuing problem. Pereira BJ. **Artif Organs** 1999 Jan;23(1):51–60 (87 ref.)

HEMODIALYSIS

Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Yu AW, et al. **Artif Organs** 1992 Aug;16(4):414–6

Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. House AA, et al. **ASAIO J** 1999 Jan–Feb;45(1):94–7

Venous stenosis and thrombosis associated with the use of internal jugular vein catheters for hemodialysis. Jassal SV, et al. **ASAIO J** 1999 Jul–Aug;45(4):356–9

Intervention based on monthly monitoring decreases hemodialysis access thrombosis. Sands JJ, et al. **ASAIO J** 1999 May–Jun;45(3):147–50

Predictive value of access blood flow in detecting access thrombosis. Wang E, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M555–8

Relative underestimation of fluid removal during hemodialysis hypotension measured by whole body bioimpedance. Zaluska WT, et al. **ASAIO J** 1998 Nov–Dec; 44(6):823–7

Symptomatic acute raised IOP following hemodialysis in a patient with end stage renal failure [letter] Choong YF, et al. **Br J Ophthalmol** 1998 Nov;82(11):1342

Al and Si: their speciation, distribution, and toxicity. van Landeghem GF, et al. **Clin Biochem** 1998 Jul;31(5):385–97 (135 ref.)

Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. Straumann E, et al. **Clin Cardiol** 1998 Sep; 21(9):672–8

Polymorphonuclear granulocyte stimulation by cellulose-based hemodialysis membranes. Körmöczi GF, et al. **Clin Chem Lab Med** 1999 Mar;37(3):351–5 (60 ref.)

Occult hypoglycemia caused by hemodialysis. Jackson MA, et al. **Clin Nephrol** 1999 Apr;51(4):242–7

Patients with analgetic nephropathy on chronic hemodialysis have a high incidence of severe secondary hyperparathyroidism. Pecovnik Balon B, et al. **Clin Nephrol** 1998 Dec;50(6):347–51

Impaired sympathetic response before intradialytic hypotension: a study based on spectral analysis of heart rate and pressure variability. Pelosi G, et al. **Clin Sci (Colch)** 1999 Jan;96(1):23–31

Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Contrib Nephrol** 1998;124:166–89; discussion 190–201 (115 ref.)

Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane (BK-F). Yamada S, et al. **Contrib Nephrol** 1999;125:159–72

Haemodialysis catheter bacteraemia: evolving strategies. O'Riordan E, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):639–42 (24 ref.)

Amyloid arthropathy of the hip joint: MR demonstration of presumed amyloid lesions in 152 patients with long-term hemodialysis. Otake S, et al. **Eur Radiol** 1998;8(8):1352–6

Effect of oxygen on breathing irregularities during haemodialysis in patients with chronic uraemia. Yap JC, et al. **Eur Respir J** 1998 Aug;12(2):420–5

Effects of age, gender and hyperparathyroidism on lean body mass in hemodialysis patients. Trovato GM, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar–Apr;2(2):89–95

Prevalence of hepatitis C virus antibody in patients on chronic hemodialysis. Nomiyama K, et al. **Fukuoka Igaku Zasshi** 1998 Aug;89(8):232–7

Surgical treatments for orthopaedic complications in long-term haemodialysis patients--a review of 546 cases over the last 8 years. Shiota E, et al. **Fukuoka Igaku Zasshi** 1998 Sep;89(9):261–76

Dialysis-related amyloidosis: an important cause of gastrointestinal symptoms in patients with end-stage renal disease. Mogyorosi A, et al. **Gastroenterology** 1999 Jan; 116(1):217–20

Undetected venous line needle dislodgment during hemodialysis. **Health Devices** 1998 Nov;27(11):404–6

Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events. George J, et al. **Hum Antibodies** 1999;9(2):125–31

Correlations between bone histopathology and serum biochemistry in uremic patients on chronic hemodialysis. Canavese C, et al. **Int J Artif Organs** 1998 Aug;21(8):443–50

Dialysis-induced hypotension [editorial] Copley JB, et al. **Int J Artif Organs** 1998 Aug;21(8):440–2

Hemodialysis-related bioincompatibility and adhesion molecules [editorial] Dhondt A, et al. **Int J Artif Organs** 1998 Sep;21(9):501–5

Adequacy of hemodialysis and cause-specific morbidity [letter] Djordjević V, et al. **Int J Artif Organs** 1999 May; 22(5):347–8

Adequacy of dialysis revisited [editorial] Dorhout Mees EJ. **Int J Artif Organs** 1999 Jan;22(1):8–10

Anemia and blood pressure correction obtained by daily hemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients [letter] Fagugli RM, et al. **Int J Artif Organs** 1998 Jul;21(7):429–31

Functional iron deficiency and inadequate dialysis: is there a connection? [editorial] Ifudu O. **Int J Artif Organs** 1999 Mar;22(3):128–30 (21 ref.)

Dialysis hypotension [editorial] Leunissen KM. **Int J Artif Organs** 1998 Dec;21(12):771–3

Cerebral edema after hemodialysis: the "reverse urea effect" lives [editorial] Silver SM. **Int J Artif Organs** 1998 May; 21(5):247–50

Intradialytic hypotension in relation to pre-existent autonomic dysfunction in hemodialysis patients. Straver B, et al. **Int J Artif Organs** 1998 Dec;21(12):794–801

Symptoms in hemodialysis patients and their relationship with biochemical and demographic parameters. Virga G, et al. **Int J Artif Organs** 1998 Dec;21(12):788–93

Dialysis hypotension and splanchnic circulation [editorial] Yu AW, et al. **Int J Artif Organs** 1998 Dec;21(12):774–7

Worsening of left ventricular diastolic function during long-term correction of anemia with erythropoietin in chronic hemodialysis patients--an assessment by radionuclide ventriculography at rest and exercise. Topuzović N. **Int J Card Imaging** 1999 Jun;15(3):233–9

Exposure of hemodialysis patients to di-2-ethylhexyl phthalate. Faouzi MA, et al. **Int J Pharm** 1999 Mar 25; 180(1):113–21

Current problems of hepatitis C virus infection in hemodialysis patients [editorial; comment] Kiyosawa K. **Intern Med** 1999 Aug;38(8):615–6. Comment on: Intern Med 1999 Aug;38(8):626–31.

Prevalence and characterization of hepatitis C virus in hemodialysis patients [see comments] Morikawa T, et al. **Intern Med** 1999 Aug;38(8):626–31. Comment in: Intern Med 1999 Aug;38(8):615–6.

Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. LeSar CJ, et al. **J Am Coll Surg** 1999 Jul;189(1):73–9; discussion 79–81

Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. Beathard GA. **J Am Soc Nephrol** 1999 May;10(5):1045–9

Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. Graham KA, et al. **J Am Soc Nephrol** 1997 Apr;8(4):627–31

Correction of acidosis in hemodialysis decreases whole-body protein degradation. Graham KA, et al. **J Am Soc Nephrol** 1997 Apr;8(4):632–7

Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. Hernández D, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1507–10

A cholesteryl ester transfer protein gene mutation and vascular disease in dialysis patients. Kimura H, et al. **J Am Soc Nephrol** 1999 Feb;10(2):294–9

The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. Kronenberg F, et al. **J Am Soc Nephrol** 1999 May; 10(5):1027–36

Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. Metry G, et al. **J Am Soc Nephrol** 1999 Apr;10(4):854–63

Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. Ottosson-Seeberger A, et al. **J Am Soc Nephrol** 1999 May;10(5):1037–44

Radiological case of the month. Dialysis related amyloid arthropathy. Nokes SR, et al. **J Ark Med Soc** 1999 May; 95(12):544–5

Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. Ziouzenkova O, et al. **J Biol Chem** 1999 Jul 2;274(27):18916–24

TT virus infection in French hemodialysis patients: study of prevalence and risk factors. Gallian P, et al. **J Clin Microbiol** 1999 Aug;37(8):2538–42

Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. Le Pogam S, et al. **J Clin Microbiol** 1998 Oct;36(10):3040–3

Recurrent "Flexispira rappini" bacteremia in an adult patient undergoing hemodialysis: case report. Sorlin P, et al. **J Clin Microbiol** 1999 May;37(5):1319–23

Prospective follow-up study of hepatitis C virus infection in patients undergoing maintenance haemodialysis: comparison among haemodialysis units. Kobayashi M, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):604–9

Prevalence of transmitted transfusion virus (TTV) in populations at different risk for hepatitis virus: hemodialysis, chronic hepatitis C and cryptogenetic hepatitis patients [letter] Halfon P, et al. **J Hepatol** 1999 Mar;30(3):552

Detection of HGV in serum and peripheral blood mononuclear cells of maintenance haemodialysis patients. Basaras M, et al. **J Hosp Infect** 1999 Jun;42(2):155–9

Reduction of Staphylococcus aureus nasal carriage and infection in dialysis patients. Herwaldt LA. **J Hosp Infect** 1998 Sep;40 Suppl B:S13–23 (38 ref.)

GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. Kao JH, et al. **J Infect Dis** 1999 Jul;180(1):191–4

Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. van Guldener C, et al. **J Intern Med** 1999 Feb;245(2):175–83

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient. Burrowes JD, et al. **J Ren Nutr** 1999 Apr; 9(2):89–94

Energy supplementation in chronic hemodialysis patients with moderate and severe malnutrition. Milano MC, et al. **J Ren Nutr** 1998 Oct;8(4):212–7

Clinical outcome of calcitriol therapy and patient education program on hyperparathyroidism. Poole R, et al. **J Ren Nutr** 1999 Apr;9(2):95–8

Renal dietitians' perspective: identification, prevalence, and intervention for malnutrition in dialysis patients in Texas. Tai TW, et al. **J Ren Nutr** 1998 Oct;8(4):188–98

Uremic tumoral calcinosis in patients receiving longterm hemodialysis therapy. Cofan F, et al. **J Rheumatol** 1999 Feb;26(2):379–85

Surgical removal of pseudotumoral calcified bursitis of the shoulder in a patient with hemodialysis. Mestdagh H, et al. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):437–9

Hemodialysis graft mechanical thrombolysis with use of the Amplatz Thrombectomy Device: histopathologic evaluation of extracted myointimal tissue. Cooper SG, et al. **J Vasc Interv Radiol** 1999 Mar;10(3):285–8

Percutaneous mechanical declotting of dialysis grafts using a central approach: a summation of risks not acceptable in 1998 [letter; comment] Turmel-Rodrigues L. **J Vasc Interv Radiol** 1999 Mar;10(3):375–6. Comment on: J Vasc Interv Radiol 1998 Sep–Oct;9(5):833–6.

Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option. El-Sabrout RA, et al. **J Vasc Surg** 1999 Mar;29(3):472–8

Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Boaz M, et al. **Kidney Int** 1999 Sep; 56(3):1078–83

Graft flow as a predictor of thrombosis in hemodialysis grafts. Bosman PJ, et al. **Kidney Int** 1998 Nov;54(5):1726–30

GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in hemodialysis patients. Cabrerizo M, et al. **Kidney Int** 1999 Sep;56(3):1120–8

Hypertension/hypotension in dialysis [letter; comment] Charra B, et al. **Kidney Int** 1999 Mar;55(3):1128. Comment on: Kidney Int 1998 Aug;54(2):561–9.

Long-term evolution of cardiomyopathy in dialysis patients. Foley RN, et al. **Kidney Int** 1998 Nov;54(5):1720–5

Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis. Garcia-Garcia M, et al. **Kidney Int** 1999 Mar;55(3):899–906

Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Ghazali A, et al. **Kidney Int** 1999 Jun; 55(6):2169–77

Hemodialysis access failure: a call to action. Hakim R, et al. **Kidney Int** 1998 Oct;54(4):1029–40 (103 ref.)

Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Jadoul M, et al. **Kidney Int** 1998 Sep;54(3):956–9

Human herpesvirus-8 infection in hemodialysis patients from northern Italy [letter] Luppi M, et al. **Kidney Int** 1999 Jan; 55(1):340

Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Manns BJ, et al. **Kidney Int** 1999 Jan;55(1):315–20

Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Marr KA, et al. **Kidney Int** 1998 Nov;54(5):1684–9

N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Motomiya Y, et al. **Kidney Int** 1998 Oct; 54(4):1357–66

Hemodialysis with high-calcium dialysate impairs cardiac relaxation. Näppi SE, et al. **Kidney Int** 1999 Mar; 55(3):1091–6

Change in access blood flow over time predicts vascular access thrombosis. Neyra NR, et al. **Kidney Int** 1998 Nov; 54(5):1714–9

Septicemia in dialysis patients: incidence, risk factors, and prognosis. Powe NR, et al. **Kidney Int** 1999 Mar; 55(3):1081–90

Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Renaux JL, et al. **Kidney Int** 1999 Mar;55(3):1097–103

Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Rodriguez M, et al. **Kidney Int** 1999 Jul;56(1):306–17

CO2 and gadopentetate dimeglumine as alternative contrast agents for malfunctioning dialysis grafts and fistulas. Spinosa DJ, et al. **Kidney Int** 1998 Sep;54(3):945–50

Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Tarng DC, et al. **Kidney Int** 1999 Jun; 55(6):2477–86

Beneficial effects of iron therapy in renal failure patients on hemodialysis. Fishbane S, et al. **Kidney Int Suppl** 1999 Mar; 69:S67–70 (34 ref.)

Anemia and carnitine supplementation in hemodialyzed patients. Kletzmayr J, et al. **Kidney Int Suppl** 1999 Mar; 69:S93–106

Evaluation of the Losartan in Hemodialysis (ELHE) Study. Saracho R, et al. **Kidney Int Suppl** 1998 Dec;68:S125–9

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study [see comments] Maisonneuve P, et al. **Lancet** 1999 Jul 10;354(9173):93–9. Comment in: Lancet 1999 Jul 10;354(9173):90–1.

Cancer risk in patients on dialysis [comment] Newstead CG. **Lancet** 1999 Jul 10;354(9173):90–1. Comment on: Lancet 1999 Jul 10;354(9173):93–9.

Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miyata T, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):114–7 (21 ref.)

The management of hypotension in dialyzed patients. Zucchelli P, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):105–8 (20 ref.)

Levonorgestrel-releasing intrauterine device for the treatment of menometrorrhagia in a woman on hemodialysis [letter] Fedele L, et al. **N Engl J Med** 1999 Aug 12;341(7):541

Isolation of HCV patient is efficient in reducing the annual incidence of HCV infection, but is it really necessary? [letter] Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 May;14(5):1337-9

Audit on the degree of application of universal precautions in a haemodialysis unit. Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1001-3

Standard precautions in haemodialysis--the gap between theory and practice [editorial] Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):823-5

The irritable patient [see comments] Argilés A, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2481-3. Comment in: Nephrol Dial Transplant 1998 Oct;13(10):2483-4.

Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit [letter] Balkovetz DF, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2979-80

Early destructive spondyloarthropathy from combined beta2-microglobulin and transthyretin Met30 amyloidosis in a dialysed patient. Beirão I, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3223-5

Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study. Birck R, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1475-9

How to identify the haemodialysis access at risk of thrombosis? Are flow measurements the answer? [editorial] Blankestijn PJ, et al. **Nephrol Dial Transplant** 1999 May; 14(5):1068-71 (29 ref.)

Errors in dialysis--the lessons to learn [comment] Bommer J. **Nephrol Dial Transplant** 1998 Oct;13(10):2483-4 (0 ref.) . Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2480-1. Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2481-3.

Preliminary survey of the occurrence of anaphylactoid reactions during haemodialysis [letter] Bright RA, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):799-800

IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. Brunet P, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1745-51

Which level of cytokine production is critical in haemodialysis? Cappelli G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:55-60 (66 ref.)

Lupus profundus (panniculitis) in a chronic haemodialysis patient. Chen MT, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):966-8

Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Dalekos GN, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1804-6

Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. Dhondt A, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1752-8

Hepatitis C virus in the haemodialysis units: novel insights by new techniques? [editorial] Fabrizi F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1072-5 (26 ref.)

Cryptosporidiosis in a haemodialysis patient with depressed CD4+ T cell count: successful treatment with azithromycin. Gascón A, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2932-3

Cytokines and bioincompatibility [editorial] Gesualdo L, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1622-6 (37 ref.)

Echinocytosis induced by haemodialysis. Hasler CR, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3132-7

Dialysis-related amyloidosis: importance of biocompatibility and age. Jadoul M. **Nephrol Dial Transplant** 1998;13 Suppl 7:61-4 (31 ref.)

Haemopericardium associated with disruption of a clot using a flexible J-guide-wire in a haemodialysis catheter [letter] Jean G. **Nephrol Dial Transplant** 1998 Jul;13(7):1898

Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Jones CH, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2873-6

Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. Jungers P, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):898-902

Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Katsoulidou A, et al. **Nephrol Dial Transplant** 1999 May;14(5):1188-94

Two cases of psoas abscess with discitis by methicillin-resistant Staphylococcus aureus as a complication of femoral-vein catheterization for haemodialysis. Kikuchi S, et al. **Nephrol Dial Transplant** 1999 May;14(5):1279-81

Back pain and Staphylococcal bacteraemia in haemodialysed patients--beware! Korzets A, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):483-6

Gender-specific differences in dialysis quality (Kt/V): 'big men' are at risk of inadequate haemodialysis treatment. Kuhlmann MK, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):147-53

Recurrent infections in haemodialysis patients--do not forget selective immunoglobulin A deficiency. Kuo MC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3220-2

Intradialytic hypotension: new insights into the mechanism of vasovagal syncope [editorial] Ligtenberg G, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2745-7

Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Lindholm B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:66-73 (86 ref.)

Is there a female predominance in popliteal cysts in long-term haemodialysis patients? [letter] Maruyama H, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1900-1

The patient developing chest pain at the onset of haemodialysis sessions--it is not always angina pectoris. Modi KS, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):221-3

Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: a prospective study. Movilli E, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1719-22

Tuberculosis of the skull in a patient on maintenance haemodialysis. Nergizoglu G, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2019-21

Persisting aluminium-related bone disease after cadaveric renal transplantation. Nicholas JC, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):202-4

Dialysis catheter-related septicaemia--focus on Staphylococcus aureus septicaemia. Nielsen J, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2847-52

Expression of VLA-4 on peripheral mononuclear cells in patients on chronic haemodialysis with carpal tunnel syndrome. Ogino M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3126-31

Hypervolemia in dialysis patients--Doppler echocardiography studies. Ozerkan F, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2151-3

Silicon and aluminium interactions in haemodialysis patients. Parry R, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1759-62

Dialysis hypotension: do we see light at the end of the tunnel? Passauer J, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3024-9 (35 ref.)

Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. Roe SD, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3226-9

Life-threatening hyperkalaemia during a haemodialysis session: an avoidable risk [see comments] Romagnoni M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2480-1. Comment in: Nephrol Dial Transplant 1998 Oct;13(10):2483-4.

The dialysed patient who turned blind during a haemodialysis session. Sabeel A, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2957-8

Iron supplementation in haemodialysis--practical clinical guidelines. Silva J, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2572-7

Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Sirrs S, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):738-43

Sites of stenosis in AV fistulae for haemodialysis access. Sivanesan S, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):118-20

White coat hypertension in haemodialysis: the role of nurses' dresses. Stragier A. **Nephrol Dial Transplant** 1999 Apr; 14(4):861-2

Risk factors for reduced bone density in haemodialysis patients. Taal MW, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1922-8

Back pain out of the blue in a haemodialysis patient. Tanaka N, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1792-4

A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Tarng DC, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2867-72

Tolosa-Hunt syndrome in uraemic patients undergoing maintenance haemodialysis. Tatsumi H, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2370-2

Bilateral symmetric retinal detachment and multiple retinal pigment epithelial detachments during haemodialysis. Troiano P, et al. **Nephrol Dial Transplant** 1998 Aug; 13(8):2135-7

Severe osteoarthropathy associated with diffuse soft-tissue calcifications in a long-term haemodialysis patient. Zingraff J, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2149-50

Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Ureña P, et al. **Nephrologie** 1999; 20(4):217-25

Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism [letter] Boran M, et al. **Nephron** 1998 Sep;80(1):119-20

Uremic pruritus: an unresolved problem in hemodialysis patients [letter] Goicoechea M, et al. **Nephron** 1999; 82(1):73-4

Q-T interval dispersion and its arrhythmogenic potential in hemodialyzed patients: methodological aspects [letter] Gussak HM, et al. **Nephron** 1999;82(3):278

Increased aortic calcification index in hemodialysis patients [letter] Kabaya T, et al. **Nephron** 1999;81(3):354-5

Hemodialysis-related nodulocystic acne treated with isotretinoin. Lin J, et al. **Nephron** 1999 Feb;81(2):146-50

Hepatitis G virus infection among patients undergoing hemodialysis [letter] Mas MR, et al. **Nephron** 1998 Oct; 80(2):247-8

Assessment of occlusion of the vascular access in patients on chronic hemodialysis: comparison of physical examination with continuous-wave Doppler ultrasound. STOP Investigators. Shunt Thrombotic Occlusion Prevention with Picotamide. Migliacci R, et al. **Nephron** 1999;82(1):7-11

Clostridium perfringens: an unusual pathogen infecting arteriovenous shunts for dialysis [letter] Oliveras A, et al. **Nephron** 1998 Dec;80(4):479

Hypertension as an etiopathological factor in the development of cerebral atrophy in hemodialyzed patients. Savazzi GM, et al. **Nephron** 1999 Jan;81(1):17-24

Intravenous iron and anaemia in haemodialysis patients [letter; comment] Shaldon S. **Nephron** 1998 Dec;80(4):485 . Comment on: Nephron 1998;79(3):299-305.

Effect of a hemodialysis session on plasma levels of endothelin-1 in hypertensive and normotensive subjects with end-stage renal failure. Surdacki A, et al. **Nephron** 1999 Jan;81(1):31-6

The advanced glycation endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: comparison with idiopathic carpal tunnel syndrome. Takahashi M, et al. **Nephron** 1998 Dec;80(4):444-9

Transforming growth factor-beta1 may be involved in shunt obstruction in patients on chronic hemodialysis. Taniguchi Y, et al. **Nephron** 1999 Jan;81(1):102-5

Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Ligtenberg G. **Neth J Med** 1999 Jul; 55(1):13-8 (36 ref.)

Sleep complaints and sleep disordered breathing in hemodialysis patients. Venmans BJ, et al. **Neth J Med** 1999 May;54(5):207-12

111In-labelled platelets for assessment of thrombogenicity of new haemodialysis vascular access. Neumann I, et al. **Nucl Med Commun** 1999 May;20(5):445-51

Serum beta2-microglobulin and immunoglobulin levels in young hemodialysis patients. Dixit MP, et al. **Pediatr Nephrol** 1999 Feb;13(2):139-42

Transferrin saturation in pediatric hemodialysis [letter] Seguias LF, et al. **Pediatr Nephrol** 1998 Sep;12(7):618

Low prevalence of hypercalcemia in Korean dialysis patients: possible role of dietary phosphate intake. Park MS, et al. **Perit Dial Int** 1999 May-Jun;19(3):270-3

Beta2-microglobulin and renal bone disease. Wada T, et al. **Perit Dial Int** 1999;19 Suppl 2:S413-6 (21 ref.)

Changes of arterial arachidonic acid metabolites in hypertensive patients during haemodialysis. Keskil ZA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Jun; 58(6):395-7

Mania associated with dialysis. A literature review and new patient report. Wilson R. **Psychosomatics** 1998 Nov-Dec; 39(6):543-6 (22 ref.)

The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings. Duarte ME, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1790-7

Poor value of surveillance cultures for prediction of septicaemia caused by coagulase-negative staphylococci in patients undergoing haemodialysis with central venous catheters. Nielsen J, et al. **Scand J Infect Dis** 1998; 30(6):569-72

Pathologic features of spinal disorders in patients treated with long-term hemodialysis. Ito M, et al. **Spine** 1998 Oct 1; 23(19):2127-33

Parathyroid carcinoma in a patient receiving long-term hemodialysis [letter; comment] Takami H, et al. **Surgery** 1999 Feb;125(2):239-40. Comment on: Surgery 1996 Nov;120(5):897-901.

New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion [editorial] Furuyoshi S, et al. **Ther Apher** 1998 Feb;2(1):13-7 (18 ref.)

Renal cell carcinoma of native kidneys in renal transplant recipients. Ishikawa N, et al. **Transplant Proc** 1998 Nov; 30(7):3156-8

Hepatitis E virus: relevance in blood donors and other risk groups. Mateos ML, et al. **Vox Sang** 1998;75(4):267-9

[Progress in the diagnosis and therapy of dialysis related amyloidosis] Hou F, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):135-7 (6 ref.) **(Chi)**

[Hepatitis C virus infection among long-term hemodialysis patients] Lu A, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun;36(6):402-5 (Eng. Abstr.) **(Chi)**

[Cardiovascular diseases in dialysis patients] Kooman JP, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1084-7 (21 ref.) (Eng. Abstr.) **(Dut)**

[Epidemic of cardiovascular diseases in patients undergoing chronic hemodialysis; closer attention needs to be paid to volume expansion] Mees EJ. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1079-83 (Eng. Abstr.) **(Dut)**

[Arterial perfusion disorders of the hand in 9 patients with arteriovenous fistula for hemodialysis] Tordoir JH, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1093-8 (Eng. Abstr.) **(Dut)**

[Acute pancreatitis complicating acute dialytic hemolysis] Richieri JP, et al. **Gastroenterol Clin Biol** 1999 Mar; 23(3):408-9 **(Fre)**

[Prolonged post-anesthesia recovery in

hemodialysis-induced hypothyroidism] Nibler R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):810–2 (Eng. Abstr.) **(Ger)**

[A long-term organic brain syndrome and brain stem symptoms in an undiagnosed dialysis-associated encephalopathy] Reusche E, et al. **Dtsch Med Wochenschr** 1999 Feb 19;124(7):176–81 (21 ref.) (Eng. Abstr.) **(Ger)**

[Effect of hemodialysis on QT dispersion in chronic uremia] Lőrincz I, et al. **Orv Hetil** 1999 Jan 3;140(1):15–9 (Eng. Abstr.) **(Hun)**

[Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis] Cice G, et al. **Cardiologia** 1999 Mar;44(3):289–94 (Eng. Abstr.) **(Ita)**

[Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients] Biamino E, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):53–5 (Eng. Abstr.) **(Ita)**

[Radiological study of destructive spondyloarthropathy in patients receiving a long-term of hemodialysis] Nakamura M. **Fukuoka Igaku Zasshi** 1999 Feb;90(2):59–66 (Eng. Abstr.) **(Jpn)**

[A clinical study of dialysis-related osteoarthropathy in long-term hemodialysis patients] Maruyama S. **Nippon Jinzo Gakkai Shi** 1998 Nov;40(8):573–86 (Eng. Abstr.) **(Jpn)**

[Usefulness of magnetic resonance imaging of the wrist for the early diagnosis of dialysis-related amyloidosis] Mochizuki T, et al. **Nippon Jinzo Gakkai Shi** 1999 Jan; 41(1):14–20 (Eng. Abstr.) **(Jpn)**

[Long-term hemodialysis for advanced-stage chronic kidney failure and their complications] Maeda K. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1311–6 (5 ref.) **(Jpn)**

[Detection of TT virus in hemodialysis patients] Hino K, et al. **Nippon Rinsho** 1999 Jun;57(6):1413–6 (Eng. Abstr.) **(Jpn)**

[Detection of TT virus (TTV) in Japanese hemodialysis (HD) patients] Tanaka H, et al. **Nippon Rinsho** 1999 Jun; 57(6):1410–2 (Eng. Abstr.) **(Jpn)**

[The prevalence of TTV infection and the route of TTV transmission in hemodialysis patients--compared with HCV infection] Utsunomiya S, et al. **Nippon Rinsho** 1999 Jun;57(6):1417–20 (Eng. Abstr.) **(Jpn)**

[Homeostasis of antioxidant status in hemodialysis patients] Saionji K, et al. **Rinsho Byori** 1999 May;47(5):461–6 (Eng. Abstr.) **(Jpn)**

[Dialysis-related amyloidosis] Kitajima W. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):515–7 (11 ref.) **(Jpn)**

[Uremic neuropathy--II. Is pruritus in dialyzed patients related to neuropathy?] Jędras M, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):462–9 (Eng. Abstr.) **(Pol)**

[Levels of L-carnitine in serum of patients with chronic renal failure treated by hemodialysis (HD)] Wanic-Kossowska M, et al. **Pol Arch Med Wewn** 1998 Apr;99(4):314–22 (Eng. Abstr.) **(Pol)**

[Influence of alphacalcidole on selected markers of the bone turnover in hemodialysed patients with secondary hyperparathyroidism] Nowak Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):288–91 (Eng. Abstr.) **(Pol)**

[Low doses of recombinant erythropoietin in the treatment of renal anemia in patients on chronic hemodialysis and ambulatory peritoneal dialysis] Lashutin SV, et al. **Ter Arkh** 1999;71(6):61–3 (Eng. Abstr.) **(Rus)**

[Amyloid tumor in a patient on a regular hemodialysis program] Kovačević Z, et al. **Vojnosanit Pregl** 1999 Mar-Apr;56(2):213–6 (Eng. Abstr.) **(Scc)**

[Effect of hemodialysis on functional parameters of the left ventricle] Nuhbegović S, et al. **Med Arh** 1999;53(1):19–20 (Eng. Abstr.) **(Scr)**

[EEG pattern indicative of dialysis encephalopathy] Dobato JL, et al. **Neurologia** 1999 Jan;14(1):35 **(Spa)**

[Idiopathic ascites associated with hemodialysis. Case report and literature review] González-Michaca L, et al. **Rev Invest Clin** 1999 Jan-Feb;51(1):49–52 (16 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Rationing dialysis in the United States: possible implications of capitated systems. Glover JJ, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):341–9

Japanese government saves hemodialysis patients' lives [editorial; comment] Nosé Y. **Artif Organs** 1998 Oct; 22(10):815. Comment on: Artif Organs 1998 Apr;22(4):271–2.

Cost effectiveness of artificial organ therapies. Mussivand T, et al. **ASAIO J** 1998 Jul-Aug;44(4):253–8

Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: a prospective study that compares Impra versus Gore-tex grafts. Hurlbert SN, et al. **Cardiovasc Surg** 1998 Dec;6(6):652–6

Cost functions for dialysis facilities and the quality of dialysis [editorial; comment] Escarce JJ, et al. **Health Serv Res** 1999 Feb;33(6):1563–6. Comment on: Health Serv Res 1999 Feb;33(6):1567–92.

Practice patterns, case mix, Medicare payment policy, and dialysis facility costs [see comments] Hirth RA, et al. **Health Serv Res** 1999 Feb;33(6):1567–92. Comment in: Health Serv Res 1999 Feb;33(6):1563–6.

Managing capital and administrative (indirect) costs to achieve strategic objectives: the dialysis clinic versus the outpatient clinic. West DA, et al. **J Health Care Finance** 1998 Winter;25(2):20–34 (20 ref.)

For-profit versus not-for-profit dialysis care for children with end stage renal disease. Furth SL, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):519–24

Hemodialysis and CAPD--are they comparable? Nolph KD. **Przegl Lek** 1998;55 Suppl 1:35–6

Medical cost difference between renal transplantation and hemodialysis. Hu RH, et al. **Transplant Proc** 1998 Nov; 30(7):3617–20

Cost effectiveness analysis of alternative treatments of end-stage renal disease: Philippine experience. Naidas OD, et al. **Transplant Proc** 1998 Nov;30(7):3116

[Cost analysis of dialysis treatment at the Odense University Hospital and the Sønderborg Hospital] Maschoreck TR, et al. **Ugeskr Laeger** 1998 Dec 14;160(51):7418–24 (Eng. Abstr.) **(Dan)**

[The cost of dialysis and kidney transplantation in the economically developed countries] Denisov VK. **Klin Khir** 1998;(9-10):74–6 (11 ref.) **(Rus)**

HISTORY

The early years of chronic dialysis: The Seattle contribution. Blagg CR. **Am J Nephrol** 1999;19(2):350–4

Artificial dialysis membranes: from concept to large scale production. Vienken J, et al. **Am J Nephrol** 1999; 19(2):355–62

Hemodialysis 1912–1945: no medical technology: before its time: part I. Fagette P. **ASAIO J** 1999 Jul-Aug; 45(4):238–49

Hemodialysis in military casualties. 1955 [classical article] Teschan PE. **ASAIO J** 1998 Jul-Aug;44(4):260–2; discussion 259

Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. 1966 [classical article] Brescia MJ, et al. **J Am Soc Nephrol** 1999 Jan;10(1):193–9

Profound neutropenia during the early phase of hemodialysis. 1968 [classical article] Kaplow LS, et al. **J Am Soc Nephrol** 1999 Feb;10(2):425–8

Prophylactic hemodialysis in the treatment of acute renal failure. Annals of Internal Medicine, 53:992–1016, 1960 [classical article] Teschan PE, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2384–97

The use of the artificial kidney in the treatment of uremia. 1952 [classical article] Merrill JP. **J Urban Health** 1998 Dec;75(4):911–8; discussion 919–21 (9 ref.)

'Dry weight' in dialysis: the history of a concept. Charra B. **Nephrol Dial Transplant** 1998 Jul;13(7):1882–5

[The development of artificial kidney--from sausage casing to capillary fibers] Hofmann B. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1100–3 (Eng. Abstr.) **(Nor)**

INSTRUMENTATION

Biocompatibility of dialysis membrane. Kes P. **Acta Med Croatica** 1999;53(1):29–40 (60 ref.)

Clearance of iopromide during haemodialysis with high- and low-flux membranes. Matzkies FK, et al. **Acta Radiol** 1999 Mar;40(2):220–3

Efficacy of percutaneous fibrin sheath stripping in restoring patency of tunneled hemodialysis catheters. Brady PS, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1023–7

Exchange of poorly functioning tunneled permanent hemodialysis catheters. Garofalo RS, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):155–8

Experience with tunneled femoral hemodialysis catheters. Zaleski GX, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):493–6

Reuse of dialyzers and clinical outcomes: fact or fiction. Agodoa LY, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S88–92

Relationship of dialysis membrane and cause-specific mortality. Bloembergen WE, et al. **Am J Kidney Dis** 1999 Jan;33(1):1–10

Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Leypoldt JK, et al. **Am J Kidney Dis** 1999 Feb;33(2):349–55

Severe access recirculation secondary to free flow between the lumens of a dual-lumen dialysis catheter. Sarnak MJ, et al. **Am J Kidney Dis** 1999 Jun;33(6):1168–70

Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. Scott MK, et al. **Am J Kidney Dis** 1999 Jan;33(1):87–96

Percutaneous cuffed catheter insertion by nephrologists. Choudhury D, et al. **Am J Nephrol** 1999;19(1):51–4

The impact of a community-wide vascular access program on the management of graft thromboses in a dialysis population of 495 patients. Cull DL, et al. **Am J Surg** 1999 Aug;178(2):113–6

Brachial neuropathy after hemodialysis shunt placement under axillary blockade. Hebl JR, et al. **Anesth Analg** 1999 Oct;89(4):1025–6

A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Cinat ME, et al. **Ann Vasc Surg** 1999 Mar;13(2):191–8

Cellulose carbamates and derivatives as hemocompatible membrane materials for hemodialysis. Diamantoglou M, et al. **Artif Organs** 1999 Jan;23(1):15–22

Development of a new approach to vascular access. Megerman J, et al. **Artif Organs** 1999 Jan;23(1):10–4

The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis. Opatrný K Jr, et al. **Artif Organs** 1998 Oct;22(10):816–20

Dialysate pressure isobars in a hollow-fiber dialyzer determined from magnetic resonance imaging and numerical simulation of dialysate flow. Osuga T, et al. **Artif Organs** 1998 Oct;22(10):907–9

The cleaning and disinfecting of hemodialysis equipment using electrolyzed strong acid aqueous solution. Tanaka N, et al. **Artif Organs** 1999 Apr;23(4):303–9

Effect of hemodialysis on the hypersulfatemia of chronic renal failure. Kirschbaum B. **ASAIO J** 1998 Jul-Aug; 44(4):314–8

New access device for hemodialysis. Levin NW, et al. **ASAIO J** 1998 Sep-Oct;44(5):M529–31

Comparison of blood flow rates and hydraulic resistance between the Mahurkar catheter, the Tesio twin catheter, and the Ash Split Cath. Mankus RA, et al. **ASAIO J** 1998 Sep-Oct;44(5):M532–4

Protein-membrane interactions during hemodialysis: effects on solute transport. Morti SM, et al. **ASAIO J** 1998 Jul-Aug;44(4):319–26

New needle for two needle hemodialysis. Zarate AR. **ASAIO J** 1998 Sep-Oct;44(5):M549–54

Ex vivo factors affecting contact phase activation in negatively charged medical devices [letter; comment] Renaux JL, et al. **Blood** 1999 Mar 15;93(6):2129–30. Comment on: Blood 1998 Jul 15;92(2):616–22.

Analysis of the influence of the infusion site on dialyser clearances measured in an in vitro system mimicking haemodialysis and haemodiafiltration. Ficheux A, et al. **Blood Purif** 1999;17(1):10–8

New polyether sulfone dialyzers attenuate passage of cytokine-inducing substances from pseudomonas aeruginosa contaminated dialysate. Jaber BL, et al. **Blood Purif** 1998;16(4):210–9

A prospective study of central venous hemodialysis catheter colonization and peripheral bacteremia. Dittmer ID, et al. **Clin Nephrol** 1999 Jan;51(1):34–9

Myocardial abscess: an unusual complication of long-term hemodialysis line presence [letter] Witham M, et al. **Clin Nephrol** 1999 Mar;51(3):193–4

Clinical experience with PMMA membrane. Albertazzi A, et al. **Contrib Nephrol** 1999;125:213–21

Nitric oxide production with PMMA membrane. Amore A, et al. **Contrib Nephrol** 1999;125:182–96 (72 ref.)

Long-term clinical experience with PMMA membrane. Aoike I. **Contrib Nephrol** 1999;125:205–12

Hydraulic and flow dynamic characteristics of PMMA dialyzers. Brendolan A, et al. **Contrib Nephrol** 1999; 125:41–52

Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes. Buoncristiani U, et al. **Contrib Nephrol** 1999;125:133–58 (72 ref.)

Beta-2-microglobulin removal by hemodialysis with polymethylmethacrylate membranes. Campistol JM, et al. **Contrib Nephrol** 1999;125:76–85 (42 ref.)

Pyrogen transfer across PMMA membranes. Cappelli G, et al. **Contrib Nephrol** 1999;125:233–9 (41 ref.)

Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA. Coli L, et al. **Contrib Nephrol** 1999;125:111–9

Effects of PMMA membrane on hepatocyte growth factor release. Dal Canton A. **Contrib Nephrol** 1999;125:197–204 (21 ref.)

High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results. David S, et al. **Contrib Nephrol** 1999;125:96–110

Efficiency parameters and treatment adequacy of hemodialysis and hemodiafiltration using polymethylmethacrylate membranes. Di Filippo S, et al. **Contrib Nephrol** 1999;125:86–95

Structural and functional characteristics of currently available PMMA dialyzers. Ghezzi PM, et al. **Contrib Nephrol** 1999;125:25–40 (18 ref.)

Behaviour of clearances and diffusive permeability during hemodialysis with PMMA dialyzers: clinical study. Ghezzi PM, et al. **Contrib Nephrol** 1999;125:53–64

Anemia of hemodialysis patients: evaluation of the effect of BK-F polymethylmethacrylate membrane. Locatelli F, et al. **Contrib Nephrol** 1999;125:173–81

Biocompatibility of PMMA membranes in acute and chronic patients with renal failure. Manzoni C, et al. **Contrib Nephrol** 1999;125:65–75 (28 ref.)

Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. Ueda J, et al. **Eur J Radiol** 1999 Jul;31(1):76–80

Undetected venous line needle dislodgment during hemodialysis. **Health Devices** 1998 Nov;27(11):404–6

Effects of dialysis membrane nature on intradialytic phagocytizing activity. Coli L, et al. **Int J Artif Organs** 1999 Feb;22(2):74–80

Push-pull sorbent-based pheresis treatment in an experimental canine endotoxemia model: preliminary report. Peter AT, et al. **Int J Artif Organs** 1999 Mar; 22(3):177–88

Use of permanent dual lumen catheters for long-term haemodialysis. Akoh JA. **Int Surg** 1999 Apr-Jun; 84(2):171–5

Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients. Kimak E, et al. **Int Urol Nephrol** 1998;30(6):789–98

Permeability of gadolinium-DTPA through two types of hemodialysis membrane. Ueda J, et al. **Invest Radiol** 1998 Oct;33(10):734–7

Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. Beathard GA. **J Am Soc Nephrol** 1999 May;10(5):1045–9

Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. Cheung AK, et al. **J Am Soc Nephrol** 1999 Jan; 10(1):117–27

Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989–1993 [see comments] Collins AJ, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2108–17. Comment in: J Am Soc Nephrol 1998 Nov;9(11):2153–6.

Dialyzer reuse and the treatment of patients with end-stage renal disease by hemodialysis [editorial; comment] Kimmel PL, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2153–6 (32 ref.). Comment on: J Am Soc Nephrol 1998 Nov;9(11):2108–17.

Assessment of hemodialysis access performance by color-flow Doppler ultrasound. Sands JJ, et al. **J Biomater Appl** 1999 Jan;13(3):224–37 (15 ref.)

Improvement of blood compatibility on cellulose hemodialysis membrane: IV. Phospholipid polymer bonded to the membrane surface. Ishihara K, et al. **J Biomater Sci Polym Ed** 1999;10(3):271–82

Association of dialyzer reuse with hospitalization and survival rates among U.S. hemodialysis patients: do comorbidities matter? Feldman HI, et al. **J Clin Epidemiol** 1999 Mar;52(3):209–17

Outcome following haemodialysis catheter-related Staphylococcus aureus bacteraemia. Peacock SJ, et al. **J Hosp Infect** 1999 Mar;41(3):223–8

Two cases of Enterococcus faecalis bacteremia associated with a hemodialysis machine [letter] Olver WJ, et al. **J Infect Dis** 1999 May;179(5):1312

Volume flow measurement in hemodialysis shunts using time-domain correlation. Basseau F, et al. **J Ultrasound Med** 1999 Mar;18(3):177–83

Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access. Standards of Practice Committee of the Society of Cardiovascular & Interventional Radiology. Aruny JE, et al. **J Vasc Interv Radiol** 1999 Apr;10(4):491–8

Dialysis graft declotting with very low dose urokinase: is it feasible to use "less and wait?" Duszak R Jr, et al. **J Vasc Interv Radiol** 1999 Feb;10(2 Pt 1):123–8

Surgery versus percutaneous treatment of thrombosed dialysis access grafts: is there a best method? [comment] Gelbfish GA. **J Vasc Interv Radiol** 1998 Nov-Dec; 9(6):875–7. Comment on: J Vasc Interv Radiol 1997 May-Jun;8(3):313–27.

Initial performance of Tesio hemodialysis catheters. Hassell DD 3rd, et al. **J Vasc Interv Radiol** 1999 May;10(5):553–8

The apex-puncture technique for mechanical thrombolysis of loop hemodialysis grafts. Hathaway PB, et al. **J Vasc Interv Radiol** 1999 Jun;10(6):775–9

Ultrasound guidance to gain access for the "lyse and wait" technique [letter] Mahon BR. **J Vasc Interv Radiol** 1999 Jun;10(6):833

Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study. Martin LG, et al. **J Vasc Interv Radiol** 1999 Apr; 10(4):389–96

Forearm loop, upper arm straight, and brachial-internal jugular vein dialysis grafts: a comparison study of graft survival utilizing a combined percutaneous endovascular and surgical maintenance approach. Savader SJ, et al. **J Vasc Interv Radiol** 1999 May;10(5):537–45

Replacement of tunneled central venous dialysis catheter in the inferior vena cava [letter] Shenoy SS, et al. **J Vasc Interv Radiol** 1999 Jun;10(6):832–3

Randomized comparison of high-flow versus conventional hemodialysis catheters. Trerotola SO, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1032–8

Endovascular stent placement for angioplasty-induced venous rupture related to the treatment of hemodialysis grafts. Welber A, et al. **J Vasc Interv Radiol** 1999 May; 10(5):547–51

Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. Zaleski GX, et al. **J Vasc Interv Radiol** 1999 Feb;10(2 Pt 1):129–36

Regarding "Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option" [letter] Nghiem DD. **J Vasc Surg** 1999 Sep;30(3):582–4

From the Centers for Disease Control and Prevention. Multistate outbreak of hemolysis in hemodialysis patients--Nebraska and Maryland, 1998. **JAMA** 1998 Oct 21;280(15):1299–300

In vivo measurement of hemodialyzer fiber bundle volume: theory and validation. Krivitski NM, et al. **Kidney Int** 1998 Nov;54(5):1751–8

Initial results of a new access device for hemodialysis technical note. Levin NW, et al. **Kidney Int** 1998 Nov; 54(5):1739–45

Enhancement of convective transport by internal filtration in a modified experimental hemodialyzer: technical note. Ronco C, et al. **Kidney Int** 1998 Sep;54(3):979–85

The hemodialysis catheter conundrum: hate living with them, but can't live without them. Schwab SJ, et al. **Kidney Int** 1999 Jul;56(1):1–17 (71 ref.)

Removal of digoxin and doxorubicin by multidrug resistance protein-overexpressed cell culture in hollow fiber. Tsuruoka S, et al. **Kidney Int** 1999 Jul;56(1):154–63

Endoluminal brushing of blocked indwelling haemodialysis catheters [letter; comment] Bel'eed K, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):241. Comment on: Nephrol Dial Transplant 1997 Sep;12(9):2040.

Arachidonic acid metabolites as biocompatibility parameters for cellulosic membranes [letter] Boran M, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1804–5

Successful prolonged use of an intracardiac catheter for dialysis. Chavanon O, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2015–6

Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Girndt M, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):676–82

Haemopericardium associated with disruption of a clot using a flexible J-guide-wire in a haemodialysis catheter [letter] Jean G. **Nephrol Dial Transplant** 1998 Jul;13(7):1898

Percutaneous fibrin sleeve stripping of failing haemodialysis catheters. Johnstone RD, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):688–91

Long-term experience with an ultrapure individual dialysis fluid with a batch type machine [see comments] Kleophas W, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3118–25 . Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3010–2.

i-STAT hand-held point-of-care analyzer for dialysis units. Gault MH, et al. **Nephron** 1998 Nov;80(3):344–8

Evidence of hepatitis C virus passage across dialysis membrane. Valtuille R, et al. **Nephron** 1998 Oct;80(2):194–6

111In-labelled platelets for assessment of thrombogenicity of new haemodialysis vascular access. Neumann I, et al. **Nucl Med Commun** 1999 May;20(5):445–51

Survival and complications of cuffed catheters in children on chronic hemodialysis. Sharma A, et al. **Pediatr Nephrol** 1999 Apr;13(3):245–8

Transhepatic insertion of vascular dialysis catheters in children: a safe, life-prolonging procedure. Bergey EA, et al. **Pediatr Radiol** 1999 Jan;29(1):42–5

Hemodialysis membrane biocompatibility--does it matter? Jacobson SH. **Scand J Urol Nephrol** 1999 Apr;33(2):83–8 (26 ref.)

Internal jugular vein haemodialysis catheter-induced right atrium endocarditis--case report and review of the literature. Tarng DC, et al. **Scand J Urol Nephrol** 1998 Dec;32(6):411–4 (17 ref.)

[Planning strategies for individual patient optimization of the dialysis process] Hutten H, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:166–7 **(Ger)**

[Microsphere based detoxification system. A new blood purification method: technical safety aspects] Vogt G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:170–1 **(Ger)**

[Dialysis approach for hemo- and peritoneal dialysis] Brunkhorst R, et al. **Internist (Berl)** 1999 Jan;40(1):13–21 (21 ref.) **(Ger)**

[Bacterial contamination in a dialysis unit] Fabiani M, et al. **Ann Ig** 1999 Mar-Apr;11(2):107–16 (Eng. Abstr.) **(Ita)**

[Equipment for hemodialysis using biologically active dialyzing solutions] Grinval'd VM, et al. **Med Tekh** 1999 Jan-Feb;(1):21–2 (Eng. Abstr.) **(Rus)**

[Functional role' of hemodialysis equipment in the bioengineering system of artificial purification] Grinval'd VM. **Med Tekh** 1999 Mar-Apr;(2):9–14 (Eng. Abstr.) **(Rus)**

METHODS

Collaborative management of hemodialysis access complications. Holloway MS, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):350–2

BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients. Tagliabue J, et al. **Am J Clin Pathol** 1999 Sep;112(3):366–70

Salvage of the nonfunctioning arteriovenous fistula [see comments] Beathard GA, et al. **Am J Kidney Dis** 1999 May;33(5):910–6. Comment in: Am J Kidney Dis 1999 May;33(5):977–9.

Successful treatment of severe hyponatremia in a patient with renal failure using continuous venovenous hemodialysis. Bender FH. **Am J Kidney Dis** 1998 Nov;32(5):829–31

A glimmer of hope: increasing the construction and maturation of autologous arteriovenous fistulas [editorial; comment] Besarab A, et al. **Am J Kidney Dis** 1999 May; 33(5):977–9. Comment on: Am J Kidney Dis 1999 May;33(5):904–9. Comment on: Am J Kidney Dis 1999 May;33(5):910–6.

Pediatric experience with intradialytic parenteral nutrition and supplemental tube feeding. Brewer ED. **Am J Kidney Dis** 1999 Jan;33(1):205–7 (20 ref.)

High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Coyne DW, et al. **Am J Kidney Dis** 1998 Dec;32(6):1031–5

Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose. Depner T, et al. **Am J Kidney Dis** 1999 Jan;33(1):142–9 (26 ref.)

Prescribed versus delivered dialysis in acute renal failure patients [see comments] Evanson JA, et al. **Am J Kidney Dis** 1998 Nov;32(5):731–8. Comment in: Am J Kidney Dis 1998 Nov;32(5):832–3.

An evidence-based evaluation of intradialytic parenteral nutrition [see comments] Foulks CJ. **Am J Kidney Dis** 1999 Jan;33(1):186–92 (56 ref.). Comment in: Am J Kidney Dis 1999 Jun;33(6):1202.

Time on dialysis [see comments] Levin NW. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S83–5. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Dialysis is not dialysis is not dialysis! Acute dialysis is different and needs help! [editorial; comment] Paganini EP. **Am J Kidney Dis** 1998 Nov;32(5):832–3. Comment on: Am J Kidney Dis 1998 Nov;32(5):731–8.

Ringer's lactate: an inexpensive and effective dialysate for continuous renal replacement therapy [letter] Perazella MA, et al. **Am J Kidney Dis** 1999 Mar;33(3):614–5

Normalizing hematocrit in dialysis patients improves brain function [see comments] Pickett JL, et al. **Am J Kidney Dis** 1999 Jun;33(6):1122–30. Comment in: Am J Kidney Dis 1999 Jun;33(6):1177–9.

Daily hemodialysis: why the renewed interest? [see comments] Pierratos A. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S76–82. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Brachiocephalic jump graft fistula: an alternative for dialysis use of elbow crease veins [see comments] Polo JR, et al. **Am J Kidney Dis** 1999 May;33(5):904–9. Comment in: Am J Kidney Dis 1999 May;33(5):977–9.

An innovative approach to temporary hemodialysis vascular access. Ross JL, et al. **Am J Kidney Dis** 1999 Apr; 33(4):718–21

A consensus report on the dose of dialysis: quantity and time [comment] Schulman G. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S86–7. Comment on: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S34–8. Comment on: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S39–43. Comment on: Am J Kidney Dis 1998 Dec;32(6 Suppl 4)::S63–70. Comment on: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S76–82. Comment on: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S83–5.

All currently used measurements of recirculation in blood access by chemical methods are flawed due to intradialytic disequilibrium or recirculation at low flow. Twardowski ZJ, et al. **Am J Kidney Dis** 1998 Dec;32(6):1046–58

Effect of dialysate temperature on energy balance during hemodialysis: quantification of extracorporeal energy transfer. van der Sande FM, et al. **Am J Kidney Dis** 1999 Jun;33(6):1115–21

Preliminary prospective randomized experience with vascular clips in the creation of arteriovenous fistulae for hemodialysis. Schild AF, et al. **Am J Surg** 1999 Jul; 178(1):33–7

Continuous renal replacement therapy: continuous blood purification in the intensive care unit. Bellomo R, et al. **Ann Acad Med Singapore** 1998 May;27(3):426–9 (28 ref.)

Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Buturović J, et al. **Artif Organs** 1998 Nov;22(11):945–7

Clinical use of profiled hemodialysis. Coli L, et al. **Artif Organs** 1998 Sep;22(9):724–30

Bacteria and endotoxin removal from bicarbonate dialysis fluids for use in conventional, high-efficiency, and high-flux hemodialysis. Oliver JC, et al. **Artif Organs** 1992 Apr;16(2):141–5

Prediction of anticoagulation during hemodialysis by population kinetics and an artificial neural network. Smith BP, et al. **Artif Organs** 1998 Sep;22(9):731–9

Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Stange J, et al. **Artif Organs** 1999 Apr;23(4):319–30

Clinical application of vascular closure staple clips for blood access surgery. Haruguchi H, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M562–4

In vitro clotting technique for hemodialysis circuits. Summerton JA, et al. **ASAIO J** 1999 Jan-Feb;45(1):109–12

A new sterile bicarbonate dialysis solution for use during cardiopulmonary bypass. Tobe SW, et al. **ASAIO J** 1999 May-Jun;45(3):157–9

Is post-dialysis urea rebound significant with long slow hemodialysis? Jean G, et al. **Blood Purif** 1998;16(4):187–96

Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Luik AJ, et al. **Blood Purif** 1998;16(4):197–209

Outcome of primary radiocephalic fistula for haemodialysis [see comments] Golledge J, et al. **Br J Surg** 1999 Feb; 86(2):211–6. Comment in: Br J Surg 1999 Jul;86(7):966.

Outcome of primary radiocephalic fistula for haemodialysis [letter] Sharma D, et al. **Br J Surg** 1999 Jul;86(7):966

Temporary vascular access for first dialysis is common, undesirable and usually avoidable. Chesser AM, et al. **Clin Nephrol** 1999 Apr;51(4):228–32

Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient. Higgins RM, et al. **Clin Nephrol** 1998 Sep; 50(3):178–83 (11 ref.)

Large-pore hemodialysis in acute endotoxin shock [see comments] Kline JA, et al. **Crit Care Med** 1999 Mar; 27(3):588–96. Comment in: Crit Care Med 1999 Mar;27(3):473–4.

Enterococcus hirae septicemia in a patient with end-stage

renal disease undergoing hemodialysis. Gilad J, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):576–7

The morbidity of secondary vascular access. A lifetime of intervention. Ruddle AC, et al. **Eur J Vasc Endovasc Surg** 1999 Jul;18(1):30–4

Changing acute renal failure treatment from intermittent hemodialysis to continuous hemofiltration: impact on azotemic control. Bellomo R, et al. **Int J Artif Organs** 1999 Mar;22(3):145–50

Evidence of profiled hemodialysis efficacy in the treatment of intradialytic hypotension. Coli L, et al. **Int J Artif Organs** 1998 Jul;21(7):398–402

Conductivity: on-line monitoring of dialysis adequacy. Del Vecchio L, et al. **Int J Artif Organs** 1998 Sep;21(9):521–5

Chronic hemodialysis: Kt/V or solute removal index to evaluate the effective delivered dose? Di Filippo S, et al. **Int J Artif Organs** 1998 Sep;21(9):509–14

Continuous renal replacement therapy or hemodialysis for acute renal failure? [editorial] Dillon JJ. **Int J Artif Organs** 1999 Mar;22(3):125–7 (12 ref.)

Adequacy of dialysis revisited [editorial] Dorhout Mees EJ. **Int J Artif Organs** 1999 Jan;22(1):8–10

On-line monitoring of the intravascular volume during haemodialysis by continuous refractometry. Kuhlmann U, et al. **Int J Artif Organs** 1999;22(4):205–9

Do shorter hemodialyses increase the risk of death? [editorial] Shinzato T, et al. **Int J Artif Organs** 1999;22(4):199–201

ABR differences before and after dialyses. Niedzielska G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):27–9

Failing arteriovenous hemodialysis fistulas: assessment with magnetic resonance angiography. Laissy JP, et al. **Invest Radiol** 1999 Mar;34(3):218–24

Bypass grafts for hemoaccess [letter; comment] Tellis VA. **J Am Coll Surg** 1998 Nov;187(5):569. Comment on: J Am Coll Surg 1998 Jul;187(1):106–7.

Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. Clark WR, et al. **J Am Soc Nephrol** 1999 Mar;10(3):601–9

Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. Fanti P, et al. **J Am Soc Nephrol** 1999 Apr;10(4):864–71

Effect of intravenous saline, albumin, or hydroxyethylstarch on blood volume during combined ultrafiltration and hemodialysis. van der Sande FM, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1303–8

Effective utilization of erythropoietin with intravenous iron therapy. Bhandari S, et al. **J Clin Pharm Ther** 1998 Feb; 23(1):73–8

Hemodialysis catheter placement directly into occluded central vein segments: a technical note. Horton MG, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1059–62

Supervised atenolol therapy in the management of hemodialysis hypertension. Agarwal R. **Kidney Int** 1999 Apr;55(4):1528–35

Imprecision of the hemodialysis dose when measured directly from urea removal. Hemodialysis Study Group. Depner TA, et al. **Kidney Int** 1999 Feb;55(2):635–47

The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Lowrie EG, et al. **Kidney Int** 1999 Aug;56(2):729–37

Removal of digoxin and doxorubicin by multidrug resistance protein-overexpressed cell culture in hollow fiber. Tsuruoka S, et al. **Kidney Int** 1999 Jul;56(1):154–63

Clinical and biochemical correlates of starting "daily" hemodialysis. Woods JD, et al. **Kidney Int** 1999 Jun; 55(6):2467–76

Optimizing outcomes in hemodialysis [editorial; comment] Nissenson AR. **Mayo Clin Proc** 1998 Nov;73(11):1123–4. Comment on: Mayo Clin Proc 1998 Nov;73(11):1035–45.

Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: a pilot study [see comments] O'Sullivan DA, et al. **Mayo Clin Proc** 1998 Nov;73(11):1035–45. Comment in: Mayo Clin Proc 1998 Nov;73(11):1123–4.

Fifteen years of clinical experience with daily haemodialysis. Buoncristiani U. **Nephrol Dial Transplant** 1998;13 Suppl 6:148–51

Axillo-axillary arteriovenous fistula as a suitable surgical alternative for chronic haemodialysis access. Debing E, et al. **Nephrol Dial Transplant** 1999 May;14(5):1252–3

The effect of long, slow haemodialysis on patient survival. Innes A, et al. **Nephrol Dial Transplant** 1999 Apr; 14(4):919–22

The results of an 8 h thrice weekly haemodialysis schedule. Laurent G, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:125–31

Progress in dialysis technology--clinical benefit vs increased complexity and risk. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 7 June 1998, Rimini. Ledebo I, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2101–5 (20 ref.)

On-line monitoring and convective treatment modalities: short-term advantages. Locatelli F, et al. **Nephrol Dial Transplant** 1999;14 Suppl 3:92–7 (20 ref.)

Quantification of dialysis unphysiology. Lopot F, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:74–8 (10 ref.)

Vascular steal syndrome and ischaemic monomelic neuropathy: two variants of upper limb ischaemia after haemodialysis vascular access surgery [editorial] Miles AM. **Nephrol Dial Transplant** 1999 Feb;14(2):297–300 (26 ref.)

Lymph leakage following subclavian vein catheterization. Modi GK, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):447–8

Vascular access for haemodialysis--an epidemiological study of the Catalan Renal Registry. Rodriguez JA, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1651–7

Placement of an internal jugular dialysis catheter into the superior intercostal vein. Sarnak MJ, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2028–9

Characterizing flow distributions in AV fistulae for haemodialysis access. Sivanesan S, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3108–10

Measurement of vascular access recirculation unaffected by cardiopulmonary recirculation: evaluation of an ultrasound method. Alloatti S, et al. **Nephron** 1999 Jan;81(1):25–30

Role of bedside autoanalyzers in independent dialysis facilities [letter] Goicoechea M, et al. **Nephron** 1998 Dec; 80(4):480

Prolonged cannulation of the femoral vein is a safe method of temporary vascular access for hemodialysis [letter] Weyde W, et al. **Nephron** 1998 Sep;80(1):86

Hemodialysis for end-stage renal disease in children weighing less than 10 kg. Al-Hermi BE, et al. **Pediatr Nephrol** 1999 Jun;13(5):401–3

Hemodialysis catheter placement and recirculation in treatment of hyperammonemia. Vats A, et al. **Pediatr Nephrol** 1998 Sep;12(7):592–5

Microsurgery in angioacces gaining for chronic dialysis is a benefit for the patient and a valuable teaching instrument [letter; comment] Luchian S, et al. **Plast Reconstr Surg** 1998 Dec;102(7):2521–2. Comment on: Plast Reconstr Surg 1997 Sep;100(3):809–10.

Endovascular brachytherapy in arteriovenous grafts for haemodialysis does not prevent development of stenosis [letter] El Sharouni SY, et al. **Radiother Oncol** 1998 Nov; 49(2):199–200

Acute renal failure--which treatment modality is the best? Papadimitriou M, et al. **Ren Fail** 1998 Sep;20(5):651–61 (36 ref.)

Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Schelling JR, et al. **Ren Fail** 1998 Jul;20(4):635–44 (32 ref.)

Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Seige M, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1371–5

Cryopreserved femoral arterial allografts for vascular access in hemodialysis. Takamoto S, et al. **Transplant Proc** 1998 Nov;30(7):3917–9

[Telescopic adhesive anastomosis of small blood vessel applied in formation of arteriovenous fistula for hemodialysis] Shen G, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):121–3 (Eng. Abstr.) **(Chi)**

[Adequate dialysis treatment in hemodialysis and peritoneal dialysis patients] Felten H, et al. **Internist (Berl)** 1999 Jan; 40(1):22–36 (80 ref.) **(Ger)**

[Temporary dialysis access in patients with acute renal failure. Protocols of the dialysis centers in the Piedmont and Valled'Aosta] Cardelli R, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):57–60 (Eng. Abstr.) **(Ita)**

[Clearance of gadolinium contrast agent by hemodialysis: in vitro and clinical studies] Katagiri K, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Nov; 58(13):739–44 (Eng. Abstr.) **(Jpn)**

[Effects of hemodialysis membrane on serum lipid profile of maintenance hemodialysis patients] Tanaka H, et al. **Nippon Jinzo Gakkai Shi** 1999 Jan;41(1):1–7 (Eng. Abstr.) **(Jpn)**

[Vitamin D receptor gene polymorphism and the rate of bone loss of the femur neck and lumbar spine in hemodialized patients with chronic renal failure] Karkoszka H, et al. **Pol Merkuriusz Lek** 1998 Oct;5(28):199–202 (Eng. Abstr.) **(Pol)**

[The usefulness of echocardiography in prospective heart function evaluation in children on maintenance haemodialysis] Szczepanska M, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):128–31 (Eng. Abstr.) **(Pol)**

[Successful aorto-coronary bypass in the care of unstable heart ischemia in the course of irreversible renal failure treated by repeated hemodialyses] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):292–4 (11 ref.) (Eng. Abstr.) **(Pol)**

MORTALITY

Primary associates of mortality among dialysis patients: trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Lowrie EG, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S16–31

Status of hemodialysis adequacy in the United States: does it account for improved patient survival?[see comments] Owen WF. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S39–43. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Trends in treatment and survival for hemodialysis patients in the United States [see comments] Port FK, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S34–8. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients [see comments] Port FK, et al. **Am J Kidney Dis** 1999 Mar; 33(3):507–17. Comment in: Am J Kidney Dis 1999 Mar;33(3):592–4. Comment in: Am J Kidney Dis 1999 Aug;34(2):400.

Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Mesler DE, et al. **Am J Med** 1999 Mar;106(3):300–6

Dialysis, time and death: comparisons of two consecutive decades among patients treated at the same Brazilian dialysis center. De-Lima JJ, et al. **Braz J Med Biol Res** 1999 Mar;32(3):289–95

Morbidity and mortality on maintenance haemodialysis. Locatelli F, et al. **Contrib Nephrol** 1998;124:166–89; discussion 190–201 (115 ref.)

How much better can we predict dialysis patient survival using clinical data? Mesler DE, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):365–75

Hematocrit level and associated mortality in hemodialysis patients. Ma JZ, et al. **J Am Soc Nephrol** 1999 Mar; 10(3):610–9

Association of dialyzer reuse with hospitalization and survival rates among U.S. hemodialysis patients: do comorbidities matter? Feldman HI, et al. **J Clin Epidemiol** 1999 Mar;52(3):209–17

Sudden and cardiac death rates in hemodialysis patients. Bleyer AJ, et al. **Kidney Int** 1999 Apr;55(4):1553–9

Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients [see comments] Fleischmann E, et al. **Kidney Int** 1999 Apr;55(4):1560–7. Comment in: Kidney Int 1999 Apr;55(4):1580–1.

Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kopple JD, et al. **Kidney Int** 1999 Sep;56(3):1136–48

Total body nitrogen predicts long-term mortality in haemodialysis patients--a single-centre experience. Arora P, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1731–6

Hypertension in the haemodialysis population: any relationship to 2-years survival? [see comments] Salem MM. **Nephrol Dial Transplant** 1999 Jan;14(1):125–8. Comment in: Nephrol Dial Transplant 1999 Jan;14(1):28–30.

Nursing application: results aid in identifying focus of patient teaching [see comments] Bernardini J. **Perit Dial Int** 1998 Sep-Oct;18(5):557. Comment in: Perit Dial Int 1998 Sep-Oct;18(5):478–84.

Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? [see comments] Schaubel DE, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):478–84. Comment in: Perit Dial Int 1998 Sep-Oct;18(5):557.

Hemodialysis and CAPD--are they comparable? Nolph KD. **Przegl Lek** 1998;55 Suppl 1:35–6

Baseline variables associated with early death and extended survival on dialysis. De Lima JJ, et al. **Ren Fail** 1998 Jul; 20(4):581–7

[Cardiovascular diseases in dialysis patients] Kooman JP, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1084–7 (21 ref.) (Eng. Abstr.) **(Dut)**

[Epidemic of cardiovascular diseases in patients undergoing chronic hemodialysis; closer attention needs to be paid to volume expansion] Mees EJ. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1079–83 (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

Experience and opinion of a dialysis patient regarding nutrition. Lundin AP. **Am J Kidney Dis** 1999 Jan; 33(1):221–2

An investigation of factors associated with fluid adherence among hemodialysis patients: a self-efficacy theory based approach. Brady BA, et al. **Ann Behav Med** 1998 Fall; 19(4):339–43

A comparison of attributions, health beliefs, and negative emotions as predictors of fluid adherence in renal dialysis patients: a prospective analysis. Friend R, et al. **Ann Behav Med** 1998 Fall;19(4):344–7

Social support and conscientiousness in hemodialysis adherence. Moran PJ, et al. **Ann Behav Med** 1998 Fall; 19(4):333–8

Compliance in hemodialysis patients: unanticipated monitoring of biochemical indices. Arici M, et al. **Blood Purif** 1998;16(5):275–80

The features of psychological problems and their significance in patients on hemodialysis--with reference to social and somatic factors. Tanaka K, et al. **Clin Nephrol** 1999 Mar; 51(3):161–76

Hemodialysis morbidity and mortality: links to patient non-compliance. Bander SJ, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):649–53 (30 ref.)

A comparison of the quality of life reported by elderly whites and elderly blacks on dialysis. Kutner NG, et al. **Geriatr Nephrol Urol** 1998;8(2):77–83

Opinions of elderly people on treatment for end-stage renal disease. Ahmed S, et al. **Gerontology** 1999 May-Jun; 45(3):156–9

Improving adjustment to chronic illness through strategic self-presentation: an experimental study on a renal dialysis unit. Leake R, et al. **Health Psychol** 1999 Jan;18(1):54–62

Assessing adherence to dietary recommendations for hemodialysis patients: the Renal Adherence Attitudes Questionnaire (RAAQ) and the Renal Adherence Behaviour Questionnaire (RABQ). Rushe H, et al. **J Psychosom Res** 1998 Aug;45(2):149–57

Quality of life over time in dialysis: the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Merkus MP, et al. **Kidney Int** 1999 Aug;56(2):720–8

Use of focus groups to identify concerns about dialysis. Choice Study. Bass EB, et al. **Med Decis Making** 1999 Jul–Sep;19(3):287–95

Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Mingardi G, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1503–10

White coat hypertension in haemodialysis: the role of nurses' dresses. Stragier A. **Nephrol Dial Transplant** 1999 Apr; 14(4):861–2

Application of the Zung self-rating depression scale to patients before and after introduction to haemodialysis. Miura H, et al. **Psychiatry Clin Neurosci** 1999 Jun; 53(3):381–5

A schizophrenic patient's attempt to resume dialysis following renal transplantation. Krahn LE, et al. **Psychosomatics** 1998 Sep–Oct;39(5):470–3

[New patients on dialysis: their biopsychosocial profile (letter)] Rios Zambudio A, et al. **Aten Primaria** 1998 Sep 30;22(5):321–3 **(Spa)**

STANDARDS

Practical guide to measuring adequacy of dialysis. Blake PG. **Adv Ren Replace Ther** 1999 Jan;6(1):80–4 (12 ref.)

The impact of the Dialysis Outcomes Quality Initiative Guidelines on the care of the pediatric end-stage renal disease patient. Jabs K, et al. **Adv Ren Replace Ther** 1999 Jan;6(1):97–106

Timely initiation of dialysis: a urea kinetic approach. Keshaviah PR, et al. **Am J Kidney Dis** 1999 Feb;33(2):344–8

Recommended criteria for initiating and discontinuing intradialytic parenteral nutrition therapy. Lazarus JM. **Am J Kidney Dis** 1999 Jan;33(1):211–6

Cost functions for dialysis facilities and the quality of dialysis [editorial; comment] Escarce JJ, et al. **Health Serv Res** 1999 Feb;33(6):1563–6. Comment on: Health Serv Res 1999 Feb;33(6):1567–92.

Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses [letter; comment] Lverla R, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):156–7. Comment on: Infect Control Hosp Epidemiol 1998 Jul;19(7):508–10.

Dialysis outcome quality initiative (DOQI) guideline for hemodialysis adequacy. Di Giulio S, et al. **Int J Artif Organs** 1998 Nov;21(11):757–61

Hemodialysis adequacy in six dialysis centers in Serbia [letter] Djordjević V, et al. **Int J Artif Organs** 1999 Feb; 22(2):118–9

Target practice [editorial] Will EJ. **Int J Artif Organs** 1998 Aug;21(8):433–6

Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. Arora P, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1281–6

Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. Cheung AK, et al. **J Am Soc Nephrol** 1999 Jan; 10(1):117–27

Low dialysate [K+] decreases efficiency of hemodialysis and increases urea rebound. Dolson GM, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2124–8

Assessment of dry weight in hemodialysis: an overview. Jaeger JQ, et al. **J Am Soc Nephrol** 1999 Feb;10(2):392–403 (101 ref.)

Clinical practice guidelines in end-stage renal disease: a strategy for implementation. Kliger AS, et al. **J Am Soc Nephrol** 1999 Apr;10(4):872–7 (18 ref.)

Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. McClellan WM, et al. **J Am Soc Nephrol** 1998 Oct; 9(10):1940–7

Dose of hemodialysis and survival: differences by race and sex. Owen WF Jr, et al. **JAMA** 1998 Nov 25;280(20):1764–8

NKF-DOQI guidelines--will they change the treatment of dialysis patients in Germany? National Kidney Foundation. Dialyses Outcomes Quality Initiative. Molzahn M. **Kidney Blood Press Res** 1998;21(2–4):286

Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient. Kloppenburg WD, et al. **Kidney Int** 1999 May;55(5):1961–9

The care of patients undergoing hemodialysis [letter; comment] Andrews PA. **N Engl J Med** 1999 Mar 4; 340(9):735; discussion 736–7. Comment on: N Engl J Med 1998 Oct 8;339(15):1054–62.

Audit on the degree of application of universal precautions in a haemodialysis unit. Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1001–3

Audit of quality of hospital haemodialysis in Scotland. The Scottish Renal Registry [letter; comment] Junor BJ. **Nephrol Dial Transplant** 1998 Sep;13(9):2426–7. Comment on: Nephrol Dial Transplant 1997 Jan;12(1):29–32.

Gender-specific differences in dialysis quality (Kt/V): 'big men' are at risk of inadequate haemodialysis treatment. Kuhlmann MK, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):147–53

Critical interpretation of adequacy parameters in peritoneal dialysis and hemodialysis. Henderson LW. **Perit Dial Int** 1999;19 Suppl 2:S38–44

STATISTICS & NUMERICAL DATA

"Springing back" advance care planning in dialysis. **Am J Kidney Dis** 1999 May;33(5):980–91

Nosocomial transmission of HCV in hemodialysis centres. Patti AM, et al. **Ann Ig** 1998 May–Jun;10(3):147–54

Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. Chandna SM, et al. **BMJ** 1999 Jan 23; 318(7178):217–23

Anti-HEV in dialysis and renal transplant patients in an endemic region in Chile [letter] Ibarra H, et al. **Clin Nephrol** 1998 Oct;50(4):267–8

Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Ojo AO, et al. **Kidney Int** 1999 May;55(5):1952–60

Coronary artery diameter and left ventricular function in patients on maintenance hemodialysis treatment: comparison between diabetic and nondiabetic patients. Hatada K, et al. **Nephron** 1998 Nov;80(3):269–73

Chronic dialysis in children and adolescents. The 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Lerner GR, et al. **Pediatr Nephrol** 1999 Jun;13(5):404–17

Dialysis therapy in the region of central and eastern Europe. Rutkowski B. **Przegl Lek** 1998;55 Suppl 1:32–4 (11 ref.) **(Eng, Pol)**

The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients. Barton EN, et al. **West Indian Med J** 1998 Sep;47(3):105–7

Renal replacement by regular haemodialysis therapy and renal transplantation in Barbados: 1979 to 1997. Nicholson GD, et al. **West Indian Med J** 1998 Jun;47(2):54–8

[Current status of treatment for chronic renal insufficiency in Morocco] Bourquia A. **Nephrologie** 1999;20(2):75–80 (Eng. Abstr.) **(Fre)**

[Survival of patients starting dialysis at an advanced age in the Piedmont] Giachino G, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):67–70 (Eng. Abstr.) **(Ita)**

[Dialysis in the elderly. Indications for and efficacy of hemodialysis] Manes M, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):75–8 (Eng. Abstr.) **(Ita)**

TRENDS

Dialysis: a 5-year perspective. Henderson LW. **Adv Ren Replace Ther** 1998 Oct;5(4):333–40

Daily hemodialysis: dialysis for the next century. Kjellstrand C, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):267–74 (34 ref.)

Hemodialysis trends in time, 1989 to 1998, independent of dose and outcome [see comments] Charra B, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S63–70. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Trends in treatment and survival for hemodialysis patients in the United States [see comments] Port FK, et al. **Am J Kidney Dis** 1998 Dec;32(6 Suppl 4):S34–8. Comment in: Am J Kidney Dis 1998 Dec;32(6 Suppl 4):S86–7.

Hemodialysis vascular access: entering a new ara. Schwab SJ. **Am J Kidney Dis** 1999 Sep;34(3):xxxviii–xi

The concept of sorbent in hemodialysis [editorial] La Greca G, et al. **Int J Artif Organs** 1998 Jun;21(6):303–8

Progress in dialysis technology--clinical benefit vs increased complexity and risk. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 7 June 1998, Rimini. Ledebo I, et al. **Nephrol Dial Transplant** 1999 Sep; 14(9):2101–5 (20 ref.)

Home haemodialysis in the 1990s [see comments] Mackenzie P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1944–8 (17 ref.). Comment in: Nephrol Dial Transplant 1999 Jan;14(1):251–2. Comment in: Nephrol Dial Transplant 1999 Apr;14(4):1031–2.

Pediatric dialysis and renal transplantation in Kuwait over the past 11 years. El-Reshaid K, et al. **Pediatr Nephrol** 1999 Apr;13(3):259–64

UTILIZATION

Is there a rationale for rationing chronic dialysis? Two points need clarification [letter] Ahmad R. **BMJ** 1999 Jun 12; 318(7198):1619; discussion 1620

Is there a rationale for rationing chronic dialysis? Question is difficult to address on basis of retrospective studies [letter; comment] Caskey FJ, et al. **BMJ** 1999 Jun 12; 318(7198):1619–20. Comment on: BMJ 1999 Jan 23;318(7178):217–23.

Is there a rationale for rationing chronic dialysis? Study's objectives were not achieved [letter; comment] Farrant T. **BMJ** 1999 Jun 12;318(7198):1619; discussion 1620. Comment on: BMJ 1999 Jan 23;318(7178):217–23.

Pediatric dialysis and renal transplantation in Kuwait over the past 11 years. El-Reshaid K, et al. **Pediatr Nephrol** 1999 Apr;13(3):259–64

Attitudes of Canadian nephrologists toward dialysis modality selection. Jung B, et al. **Perit Dial Int** 1999 May–Jun; 19(3):263–8

The referral pattern of end-stage renal disease patients and the initiation of dialysis: a European perspective. Van Biesen W, et al. **Perit Dial Int** 1999;19 Suppl 2:S273–5

HEMODIALYSIS, HOME

Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies. Sloand JA, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):522–7

[Intensive nocturnal hemodialysis, a choice for survival in renal failure without hope for a graft (news)] Deschênes G. **Arch Pediatr** 1998 Nov;5(11):1215 **(Fre)**

[Current status and management of home dialysis programs] Saito A. **Nippon Naika Gakkai Zasshi** 1999 Aug 10; 88(8):1541–7 (11 ref.) **(Jpn)**

METHODS

Telematics application for home hemodialysis [letter] Agroyannis B, et al. **Kidney Int** 1999 Jan;55(1):338

PSYCHOLOGY

Home haemodialysis--beware the psychological impact on the helper and/or family [letter; comment] Bernheim J, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1031–2. Comment on: Nephrol Dial Transplant 1998 Aug;13(8):1944–8.

TRENDS

Can telemedicine contribute to the expansion of home haemodialysis? [letter; comment] Agroyannis B, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):251–2. Comment on: Nephrol Dial Transplant 1998 Aug;13(8):1944–8.

UTILIZATION

The decline of home hemodialysis: how and why? [editorial] Féraud P, et al. **Nephron** 1999;81(3):249–55

HEMODIALYSIS SOLUTIONS

Bacteriology of hemodialysis fluids: are current methodologies meaningful? Harding GB, et al. **Artif Organs** 1992 Oct;16(5):448–56

Bacteria and endotoxin removal from bicarbonate dialysis fluids for use in conventional, high-efficiency, and high-flux hemodialysis. Oliver JC, et al. **Artif Organs** 1992 Apr;16(2):141–5

[Dialysate and biocompatibility in hemodialysis] Berland Y. **Nephrologie** 1998;19(6):329–34 (27 ref.) (Eng. Abstr.) **(Fre)**

[Equipment for hemodialysis using biologically active dialyzing solutions] Grinval'd VM, et al. **Med Tekh** 1999 Jan–Feb;(1):21–2 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose. Depner T, et al. **Am J Kidney Dis** 1999 Jan;33(1):142–9 (26 ref.)

Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? Awad SS, et al. **ASAIO J** 1999 Jan–Feb;45(1):47–9

Regression of massive tumoral calcinosis of the ischium in a dialysis patient after treatment with reduced calcium dialysate and i.v. administration. Apostolou T, et al. **Clin Nephrol** 1998 Oct;50(4):247–51

CHEMISTRY

Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. Scott MK, et al. **Am J Kidney Dis** 1999 Jan;33(1):87–96

KT/V and protein catabolic rate determination from serial urea measurement in the dialysate effluent stream. Garred LJ, et al. **Artif Organs** 1992 Jun;16(3):248–55

Preparation of ethanol-enriched, bicarbonate-based hemodialysates. Noghnogh AA, et al. **Artif Organs** 1999 Feb;23(2):208–9

Dialysate pressure isobars in a hollow-fiber dialyzer determined from magnetic resonance imaging and numerical simulation of dialysate flow. Osuga T, et al. **Artif Organs** 1998 Oct;22(10):907–9

Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Yu AW, et al. **Artif Organs** 1992 Aug;16(4):414–6

Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis. Emelife-Obi C, et al. **Clin Nephrol** 1998 Aug; 50(2):131–3

Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. Clark WR, et al. **J Am Soc Nephrol** 1999 Mar;10(3):601–9

Fluorimetric determination of aluminum traces in hemodialysis solutions using Mordant Red 19. Raggi MA, et al. **J Anal Toxicol** 1999 Mar–Apr;23(2):94–8

PHARMACOLOGY

Effects of sodium acetate on rat bone-nodule formation and mineralization in vitro. Visconti LA, et al. **Arch Oral Biol** 1998 Sep;43(9):729–33

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307–9 (30 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Hemodialysis-induced hypophosphatemia in a normophosphatemic patient dialyzed for ethylene glycol

HEMODIALYSIS SOLUTIONS

poisoning: treatment with phosphorus-enriched hemodialysis. Chow MT, et al. **Artif Organs** 1998 Oct; 22(10):905-7

[Alternative dialysis solutions in continuous ambulatory peritoneal dialysis] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):307-9 (30 ref.) (Eng. Abstr.) **(Pol)**

HEMODIALYSIS UNITS, HOSPITAL

Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies [letter] Caramelo C, et al. **Clin Nephrol** 1999 Jan;51(1):59-60

Specialized chronic care for dialysis patients--a five-year study. Jassal SV, et al. **Clin Nephrol** 1998 Aug;50(2):84-9

Hepatitis C virus seroconversion and genotype prevalence in patients and staff on chronic hemodialysis. Zamir D, et al. **J Clin Gastroenterol** 1999 Jan;28(1):23-8

Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. Le Pogam S, et al. **J Clin Microbiol** 1998 Oct;36(10):3040-3

Endotoxin concentration in treated water of all hemodialysis units in Greece and inquisition of influencing factors. Arvanitidou M, et al. **J Nephrol** 1999 Jan-Feb;12(1):32-7

Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. Pouria S, et al. **Lancet** 1998 Jul 4; 352(9121):21-6

Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Katsoulidou A, et al. **Nephrol Dial Transplant** 1999 May;14(5):1188-94

Blood-borne virus infections in dialysis units--a review. Wreghitt TG. **Rev Med Virol** 1999 Apr-Jun;9(2):101-9 (115 ref.)

Locations for renal services--patient satisfaction surveys. Willis CE, et al. **Ulster Med J** 1998 Nov;67(2):110-4

[Bacterial contamination in a dialysis unit] Fabiani M, et al. **Ann Ig** 1999 Mar-Apr;11(2):107-16 (Eng. Abstr.) **(Ita)**

ECONOMICS

Comparative cost-analysis of two different chronic care facilities for end-stage renal disease patients. Jassal SV, et al. **Geriatr Nephrol Urol** 1998;8(2):69-76

Practice patterns, case mix, Medicare payment policy, and dialysis facility costs [see comments] Hirth RA, et al. **Health Serv Res** 1999 Feb;33(6):1567-92. Comment in: Health Serv Res 1999 Feb;33(6):1563-6.

[Cost analysis of dialysis treatment at the Odense University Hospital and the Sønderborg Hospital] Maschoreck TR, et al. **Ugeskr Laeger** 1998 Dec 14;160(51):7418-24 (Eng. Abstr.) **(Dan)**

MANPOWER

Role of physician assistants in dialysis units and nephrology [see comments] Anderson JE, et al. **Am J Kidney Dis** 1999 Apr;33(4):647-51. Comment in: Am J Kidney Dis 1999 Apr;33(4):796-7. Comment in: Am J Kidney Dis 1999 Apr;33(4):798-800.

Reducing staff turnover: a case study of dialysis facilities. Tai TW, et al. **Health Care Manage Rev** 1998 Fall; 23(4):21-42

ORGANIZATION & ADMINISTRATION

Dollars for dialysis. The height of helping out. Castrey M. **Hosp Health Netw** 1998 Nov 20;72(22):46

HCV Infection: Six years after' in a dialysis unit [letter; comment] Brugnano R, et al. **Nephron** 1999 Feb;81(2):244-5 . Comment on: Nephron 1992;61(3):263-5.

[Epidemic of cardiovascular diseases in patients undergoing chronic hemodialysis; closer attention needs to be paid to volume expansion] Mees EJ. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1079-83 (Eng. Abstr.) **(Dut)**

STANDARDS

Nutritional status: a continuous quality improvement approach. Blondin J, et al. **Am J Kidney Dis** 1999 Jan; 33(1):198-202

Hemodialysis adequacy in Network 5: disparity between states and the role of center effects. Fink JC, et al. **Am J Kidney Dis** 1999 Jan;33(1):97-104

Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. Arora P, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1281-6

Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units. Mizuno M, et al. **J Clin Microbiol** 1998 Oct;36(10):2926-31

[Nosocomial transmission of hepatitis C virus in a Dutch dialysis center] Schneeberger PM, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):801-6 (Eng. Abstr.) **(Dut)**

STATISTICS & NUMERICAL DATA

XI. Annual facility survey of providers of ESRD therapy. **Am J Kidney Dis** 1999 Aug;34(2 Suppl 1):S140-3

Association of dialyzer reuse with hospitalization and survival rates among U.S. hemodialysis patients: do comorbidities matter? Feldman HI, et al. **J Clin Epidemiol** 1999 Mar;52(3):209-17

UTILIZATION

The provision of renal replacement therapy for adults in England and Wales: recent trends and future directions. Roderick PJ, et al. **QJM** 1998 Aug;91(8):581-7

HEMODILUTION

Hemodilution mediates changes in renal hemodynamics after acute volume expansion in rats. Franchini KG. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1670-6

Microvascular responses to hemodilution with Hb vesicles as red blood cell substitutes: influence of O2 affinity. Sakai H, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H553-62

Hemodilution, cerebral O2 delivery, and cerebral blood flow: a study using hyperbaric oxygenation. Tomiyama Y, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1190-6

Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. Tsai AG, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2170-80

Uncompensated blood loss is not tolerated during acute normovolemic hemodilution in anesthetized pigs [see comments] Schou H, et al. **Anesth Analg** 1998 Oct; 87(4):786-94. Comment in: Anesth Analg 1999 Aug;89(2):532-3.

Retinal artery air embolism in dogs: fluorescein angiographic evaluation of effects of hypotension and hemodilution. Soga K, et al. **Anesth Analg** 1999 May;88(5):1004-10

Normovolemic hemodilution and acute hemorrhage [letter; comment] Van der Linden P, et al. **Anesth Analg** 1999 Aug; 89(2):532-3. Comment on: Anesth Analg 1998 Oct;87(4):786-94.

Acute severe hemodilution to a hemoglobin of 1.3 g/dl tolerated in the presence of mild hypothermia [letter] Koehntop DE, et al. **Anesthesiology** 1999 Jun;90(6):1798-9

A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Monk TG, et al. **Anesthesiology** 1999 Jul;91(1):24-33

Decrease in red blood cell deformability caused by hypothermia, hemodilution, and mechanical stress: factors related to cardiopulmonary bypass. Kameneva MV, et al. **ASAIO J** 1999 Jul-Aug;45(4):307-10

Acute normovolaemic haemodilution vs controlled hypotension for reducing the use of allogeneic blood in patients undergoing radical prostatectomy [see comments] Boldt J, et al. **Br J Anaesth** 1999 Feb;82(2):170-4. Comment in: Br J Anaesth 1999 Feb;82(2):161-3.

Hyperoxaemia in extreme haemodilution. Habler O, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:79-82 (29 ref.)

Consequences of acute normovolaemic haemodilution on haemostasis during major orthopaedic surgery. Hobisch-Hagen P, et al. **Br J Anaesth** 1999 Apr;82(4):503-9

Intraoperative conservation of red cell mass: controlled hypotension or haemodilution--not necessarily mutually exclusive? [editorial; comment] Levack ID, et al. **Br J Anaesth** 1999 Feb;82(2):161-3. Comment on: Br J Anaesth 1999 Feb;82(2):170-4.

Cerebral response to haemodilution during cardiopulmonary bypass in dogs: the role of nitric oxide synthase. Plöchl W, et al. **Br J Anaesth** 1999 Feb;82(2):237-43

Monitoring normovolaemic haemodilution. Trouwborst A, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:73-8 (70 ref.)

Cerebral blood flow velocity during isovolemic hemodilution and subsequent autologous blood retransfusion. Mühling J, et al. **Can J Anaesth** 1999 Jun;46(6):550-7

Effects of isovolumetric hemodilution treatment and superoxide dismutase on ischemic reperfused hearts in rabbit. Li X, et al. **Clin Hemorheol Microcirc** 1998 Jul; 18(2-3):157-63

Global blood management in orthopaedic surgery. Sculco TP. **Clin Orthop** 1998 Dec;(357):43-9 (31 ref.)

Pseudocholinesterase-activity reduction during cardiopulmonary bypass: the role of dilutional processes and pharmacological agents. Rump AF, et al. **Gen Pharmacol** 1999 Jan;32(1):65-9

Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. Caron A, et al. **J Appl Physiol** 1999 Feb;86(2):541-8

Mechanisms of improvement in pulmonary gas exchange during isovolemic hemodilution. Deem S, et al. **J Appl Physiol** 1999 Jul;87(1):132-41

Effect of hemodilution on RBC velocity, supply rate, and hematocrit in the cerebral capillary network. Hudetz AG, et al. **J Appl Physiol** 1999 Aug;87(2):505-9

Effect of acute normovolemic hemodilution on distribution of blood flow and tissue oxygenation in dog skeletal muscle. Hutter J, et al. **J Appl Physiol** 1999 Mar;86(3):860-6

Effects of acute normovolemic hemodilution on T2*-weighted images of rat brain. Lin W, et al. **Magn Reson Med** 1998 Dec;40(6):857-64

Transfusion medicine. Second of two parts--blood conservation [see comments] Goodnough LT, et al. **N Engl J Med** 1999 Feb 18;340(7):525-33 (79 ref.). Comment in: N Engl J Med 1999 Jul 8;341(2):124-5; discussion 126-7. Comment in: N Engl J Med 1999 Jul 8;341(2):125; discussion 126-7. Comment in: N Engl J Med 1999 Jul 8;341(2):125-6; discussion 126-7. Comment in: N Engl J Med 1999 Jul 8;341(2):126-7.

A minimal priming technique that allows for a higher circulating hemoglobin on cardiopulmonary bypass. Cromer MJ, et al. **Perfusion** 1998 Sep;13(5):311-3

Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Borst MM, et al. **Respiration** 1999;66(3):225-32

Cerebral blood flow during hemodilution and hypoxia in rats : role of ATP-sensitive potassium channels. Tomiyama Y, et al. **Stroke** 1999 Sep;30(9):1942-7; discussion 1947-8

Circulating immunoreactive thrombopoietin increases rapidly after normovolemic hemodilution [letter] Hobisch-Hagen P, et al. **Thromb Haemost** 1998 Oct;80(4):718-9

[Effect of administration of recombinant human erythropoietin in acute normovolemic hemodilution on transfusion needs during total hip prosthesis implantation] Beris P, et al. **Schweiz Med Wochenschr** 1998 Oct 17; 128(42):1582-6 (Eng. Abstr.) **(Fre)**

[Changes in blood coagulation in treatment with hydroxyethyl starch] Sefrin P, et al. **Anaesthesiol Reanim** 1998;23(6):149-56 (Eng. Abstr.) **(Ger)**

[A method for outcome control of hemodilution therapy in fetal growth retardation] Kahn N, et al. **Biomed Tech (Berl)** 1998;43 Suppl:150-2 **(Ger)**

[Effects of nitric oxide synthase inhibitor on skin blood flow responses to acute isovolemic hemodilution during halothane and isoflurane anesthesia] Hirose Y, et al. **Masui** 1998 Aug;47(8):918-24 (Eng. Abstr.) **(Jpn)**

[Therapeutic effects of prolonged normovolemic hemodilution in patients with Raynaud's disease] Mamurov VA. **Khirurgiia (Mosk)** 1998;(12):22-3 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Extreme, progressive isovolemic hemodilution with 5% human albumin, PentaLyte, or Hextend does not cause hepatic ischemia or histologic injury in rabbits. Nielsen VG, et al. **Anesthesiology** 1999 May;90(5):1428-35

METHODS

Reduced transfusion requirements during major hepatic resection with use of intraoperative isovolemic hemodilution. Johnson LB, et al. **Am J Surg** 1998 Dec; 176(6):608-11

The effects of in vitro hemodilution with gelatin, hydroxyethyl starch, and lactated Ringer's solution on markers of coagulation: an analysis using SONOCLOT. Konrad C, et al. **Anesth Analg** 1999 Mar;88(3):483-8

Effect of 20% in vitro haemodilution with warmed buffered salt solution and cerebrospinal fluid on coagulation. Ruttmann TG, et al. **Br J Anaesth** 1999 Jan;82(1):110-1

Critical haemoglobin concentration in anaesthetized dogs: comparison of two plasma substitutes [published erratum appears in Br J Anaesth 1999 Apr;82(4):658] Van der Linden P, et al. **Br J Anaesth** 1998 Oct;81(4):556-62

Early clinical experience with a newly formulated hydroxyethyl starch--Hextend [letter] Woolf RL, et al. **Br J Anaesth** 1999 Feb;82(2):299-300

Acute normovolemic hemodilution. Monk TG, et al. **Clin Orthop** 1998 Dec;(357):74-81 (37 ref.)

Subarachnoid hemorrhage in rats: effect of singular or sustained hemodilution with alpha-alpha diaspirin crosslinked hemoglobin on cerebral hyperperfusion. Cole DJ, et al. **Crit Care Med** 1999 May;27(5):972-7

Con: the use of modified ultrafiltration during pediatric cardiovascular surgery is not a benefit. Ramamoorthy C, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):483-5 (24 ref.)

Acute normovolemic hemodilution (ANH) in surgery of the thoraco-abdominal aorta. A cohort study to evaluate coagulation parameters and blood products utilization. Cinà CS, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):37-43

Differential effects of serial hemodilution with hydroxyethyl starch, albumin, and 0.9% saline on whole blood coagulation. Tobias MD, et al. **J Clin Anesth** 1998 Aug; 10(5):366-71

Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Copley LA, et al. **Spine** 1999 Feb 1;24(3):219-22; discussion 223-4

HEMODYNAMICS

Haemodynamic and metabolic changes induced by repeated episodes of hypoxia in pigs. Licker M, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):957-65

Fetal Doppler hemodynamic changes in spontaneous versus prostaglandin E1-induced active labor. Chen WH, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):599-604

A correlation of intravital microscopically assessed NADH fluorescence, tissue oxygenation, and organ function during shock and resuscitation of the rat liver. Vollmar B, et al. **Adv Exp Med Biol** 1998;454:95-101

Hemodynamic monitoring during hemodialysis. Leypoldt JK, et al. **Adv Ren Replace Ther** 1999 Jul;6(3):233-42 (68 ref.)

Hemodynamic abnormalities in patients with coronary artery disease and their relationship to intermittent ischemic episodes. Goldschlager N, et al. **Am Heart J** 1970 Nov; 80(5):610-8

Hemodynamic effects of new intra-aortic balloon counterpulsation timing methods in patients: a multicenter evaluation. Kern MJ, et al. **Am Heart J** 1999 Jun; 137(6):1129-36

Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Reindl I, et

al. **Am Heart J** 1998 Nov;136(5):778–85

Cardiovascular responses to exercise in children and adolescents with myocardial dysfunction. Rowland T, et al. **Am Heart J** 1999 Jan;137(1):126–33

Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Zeng C, et al. **Am Heart J** 1998 Nov;136(5):852–8

Effect of low altitude (Dead Sea location) on exercise performance and wall motion in patients with coronary artery disease. Abinader EG, et al. **Am J Cardiol** 1999 Jan 15;83(2):250–1, A5

Hemodynamics and left ventricular mass regression following implantation of the Toronto SPV stentless porcine valve. Bach DS, et al. **Am J Cardiol** 1998 Nov 15;82(10):1214–9

Noninvasive assessment of hemodynamic subsets in patients with acute myocardial infarction using digital color Doppler velocity profile integration and pulmonary venous flow analysis. Hozumi T, et al. **Am J Cardiol** 1999 Apr 1;83(7):1027–32

Antecedent angina pectoris as a predictor of better functional and clinical outcomes in patients with an inferior wall acute myocardial infarction. Inoue K, et al. **Am J Cardiol** 1999 Jan 15;83(2):159–63

Effect of cardiac pacing on peripheral and cerebral hemodynamics in patients with carotid sinus syndrome. Leftheriotis G, et al. **Am J Cardiol** 1999 Mar 15;83(6):974–7, A10

Hemodynamic and cardiorespiratory function following internal atrial defibrillation for chronic atrial fibrillation. Schimpf R, et al. **Am J Cardiol** 1999 Jun 15;83(12):1633–7

Noninvasive assessment of hemodynamic characteristics in an episode of sustained narrow-complex tachycardia. Alsabrook G, et al. **Am J Crit Care** 1999 Jul;8(4):243–5

Hemodynamic patterns of women with chronic hypertension during pregnancy. Fukushima T. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1584–92

Neuronal cell bodies in paraventricular nucleus affect renal hemodynamics and excretion via the renal nerves. Haselton JR, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1334–42

Role of central circulatory factors in the fat-free mass-maximal aerobic capacity relation across age. Hunt BE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1178–82

Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Iaccarino G, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1298–306

Hemodynamic model for analysis of Doppler ultrasound indexes of umbilical blood flow. Kleiner-Assaf A, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2204–14

Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Pemberton CJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1200–8

Insulin action on heart and skeletal muscle glucose uptake in weight lifters and endurance athletes. Takala TO, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E706–11

Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Botney MD. **Am J Respir Crit Care Med** 1999 Feb;159(2):361–4 (35 ref.)

Clinical use of respiratory changes in arterial pulse pressure to monitor the hemodynamic effects of PEEP. Michard F, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):935–9

The cardiorespiratory effects of laparoscopic procedures in infants. Bozkurt P, et al. **Anaesthesia** 1999 Sep;54(9):831–4

Metabolic and hemodynamic changes during recovery and tracheal extubation in neurosurgical patients: immediate versus delayed recovery. Bruder N, et al. **Anesth Analg** 1999 Sep;89(3):674–8

The effects of the lateral position on cardiopulmonary function during laparoscopic urological surgery. Fujise K, et al. **Anesth Analg** 1998 Oct;87(4):925–30

Cardiovascular autonomic dysfunction and hemodynamic response to anesthetic induction in patients with coronary artery disease and diabetes mellitus. Keyl C, et al. **Anesth Analg** 1999 May;88(5):985–91

The relationship among carbon dioxide pneumoperitoneum, vasopressin release, and hemodynamic changes. Mann C, et al. **Anesth Analg** 1999 Aug;89(2):278–83

Hemodynamic and catecholamine stress responses to insertion of the Combitube, laryngeal mask airway or tracheal intubation. Oczenski W, et al. **Anesth Analg** 1999 Jun;88(6):1389–94

Hemodynamic and catecholamine responses to a laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Pretorius M, et al. **Anesth Analg** 1998 Dec; 87(6):1268–70

Transient hyperdynamic response associated with controlled hypocapneic hyperventilation during sevoflurane-nitrous oxide mask induction in adults. Vakkuri AP, et al. **Anesth Analg** 1999 Jun;88(6):1384–8

Simulation of arterial hemodynamics after partial prosthetic replacement of the aorta. Bauernschmitt R, et al. **Ann Thorac Surg** 1999 Mar;67(3):676–82

The Toronto SPV bioprosthesis: clinical and hemodynamic results at 6 years. David TE. **Ann Thorac Surg** 1999 Sep; 68(3 Suppl):S9–13

Cardiovascular effects of induced hypothermia after lung transplantation. Eriksson LT, et al. **Ann Thorac Surg** 1999 Mar;67(3):804–9

Orientation of tilting disc and bileaflet aortic valve substitutes for optimal hemodynamics. Laas J, et al. **Ann Thorac Surg** 1999 Sep;68(3):1096–9

Hyperdynamic circulation of arteriovenous fistula preconditions the heart and limits infarct size. Mahgoub MA, et al. **Ann Thorac Surg** 1999 Jul;68(1):22–8

Hemodynamic effects of carbon dioxide insufflation under single-lung ventilation during thoracoscopy. Ohtsuka T, et al. **Ann Thorac Surg** 1999 Jul;68(1):29–32; discussion 32–3

Myocardial metabolism and hemodynamics during coronary surgery without cardiopulmonary bypass. Penttilä HJ, et al. **Ann Thorac Surg** 1999 Mar;67(3):683–8

The aortic outflow and root: a tale of dynamism and crosstalk. Yacoub MH, et al. **Ann Thorac Surg** 1999 Sep; 68(3 Suppl):S37–43

The effect of clinical and biochemical donor parameters on pancreatic islet isolation yield from cadaveric organ donors. Fiedor P, et al. **Ann Transplant** 1996;1(1):59–62

The effect of endocrine disturbances on hemodynamic stability of brain dead organ donors. I. Thyroid function. Szostek M, et al. **Ann Transplant** 1996;1(2):27–30

Extended donor criteria--a possible way to enhance the number of potential heart donors. Zembala M, et al. **Ann Transplant** 1996;1(1):44–5

Fluctuations of tumor markers in heart failure patients pre and post heart transplantation. Nägele H, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2531–4

Haemodynamic effects of altering arterial oxygen saturation in preterm infants with respiratory failure. Skinner JR, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F81–7

The pivotal role of adrenomedullin in producing hyperdynamic circulation during the early stage of sepsis. Wang P, et al. **Arch Surg** 1998 Dec;133(12):1298–304

Rotary blood pump flow spontaneously increases during exercise under constant pump speed: results of a chronic study. Akimoto T, et al. **Artif Organs** 1999 Aug; 23(8):797–801

Improvement of the hydrodynamic response of a ventricular assist device: a false auricle solution. Antoranz JC, et al. **Artif Organs** 1992 Jun;16(3):301–5

Hemodynamic and mechanical performance of arterial grafts assessed by numerical simulation: a design oriented study. Cavalcanti S, et al. **Artif Organs** 1999 Feb;23(2):175–85

Hemodynamic evaluation of a new left ventricular assist device: an integrated cardioassist catheter as a pulsatile left ventricle-femoral artery bypass. Ide H, et al. **Artif Organs** 1992 Jun;16(3):286–90

Techniques for optimization of pulsatile ventricular assist device support. Mills TC, et al. **Artif Organs** 1992 Apr; 16(2):218–21

A future prediction type artificial heart system. Yambe T, et al. **Artif Organs** 1999 Mar;23(3):268–73

Vascular determinants of univentricular support. Kresh JY, et al. **ASAIO J** 1998 Sep-Oct;44(5):M330–5

Development of a flow feedback pulse duplicator system with rhesus monkey arterial input impedance characteristics. Schaub JD, et al. **ASAIO J** 1999 Jul-Aug;45(4):334–8

Effects of hemodynamics on thromboembolism in coronary stents and prototype flow cells in vitro. Sukavaneshvar S, et al. **ASAIO J** 1998 Sep-Oct;44(5):M388–92

Steady state hemodynamic and energetic characterization of the Penn State/3M Health Care Total Artificial Heart. Weiss WJ, et al. **ASAIO J** 1999 May-Jun;45(3):189–93

Continuous monitoring of autonomic nerve information for the control of an artificial heart. Yambe T, et al. **ASAIO J** 1998 Sep-Oct;44(5):M696–9

Numeric modeling of the cardiovascular system with a left ventricular assist device. Zhou J, et al. **ASAIO J** 1999 Jan-Feb;45(1):83–9

A prospective randomized trial evaluating the haemodynamic role of incompetent calf perforating veins. Fitridge RA, et al. **Aust N Z J Surg** 1999 Mar;69(3):214–6

Predicting outcome after cardiac surgery: comparison of global haemodynamic and tonometric variables. Bams JL, et al. **Br J Anaesth** 1999 Jan;82(1):33–7

Effects of lightwand (Trachlight) compared with direct laryngoscopy on circulatory responses to tracheal intubation. Hirabayashi Y, et al. **Br J Anaesth** 1998 Aug; 81(2):253–5

Haemodynamic changes after tracheal intubation in cigarette smokers compared with non-smokers. Laxton CH, et al. **Br J Anaesth** 1999 Mar;82(3):442–3

Haemodynamic and electroencephalographic response to insertion of a cuffed oropharyngeal airway: comparison with the laryngeal mask airway. Versichelen L, et al. **Br J Anaesth** 1998 Sep;81(3):393–7

The effect of compression therapy on venous haemodynamics in pregnant women. Büchtemann AS, et al. **Br J Obstet Gynaecol** 1999 Jun;106(6):563–9

Hemodynamic effects of medical antishock trousers during mechanical ventilation. Fellahi JL, et al. **Can J Anaesth** 1999 May;46(5 Pt 1):423–8

Possible sources of right-to-left shunting in patients following a total cavopulmonary connection. Buheitel G, et al. **Cardiol Young** 1998 Jul;8(3):358–63

Elevation of atrial natriuretic peptide prohormone. Hemodynamic background of the elevation of N-terminal natriuretic peptide prohormone in children with congenital heart disease. Holmström H, et al. **Cardiol Young** 1999 Mar; 9(2):141–9

24-hour leg and forearm haemodynamics in transected spinal cord subjects. Casiglia E, et al. **Cardiovasc Res** 1999 Jan; 41(1):312–6

Temporal effects of prolonged hypoxaemia and reoxygenation on systemic, pulmonary and mesenteric perfusions in newborn piglets. Cheung PY, et al. **Cardiovasc Res** 1998 Aug;39(2):451–8

Deleterious hemodynamic effects of thrombotic/embolic materials on the distal myocardial vasculature [editorial; comment] Folts JD. **Cardiovasc Res** 1999 Apr;42(1):6–8. Comment on: Cardiovasc Res 1999 Apr;42(1):193–200.

Hemodynamics of cardiac tamponade in a patient with AIDS-related non-Hodgkin's lymphoma. Azrak EC, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):287–91

Multicenter study of noninvasive monitoring systems as alternatives to invasive monitoring of acutely ill emergency patients [see comments] Shoemaker WC, et al. **Chest** 1998 Dec;114(6):1643–52. Comment in: Chest 1998 Dec;114(6):1511–3.

Plasma concentrations of interferon-alpha in patients with liver cirrhosis: relationship to systemic and portal hemodynamics. Wang YY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr; 62(4):195–202

Sequencing analysis of hepatitis C virus mixed genotype in a hemodialysis patients. Lee HF, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Nov;28(4):280–90

Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Auricchio A, et al. **Circulation** 1999 Jun 15;99(23):2993–3001

Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Condorelli G, et al. **Circulation** 1999 Jun 15; 99(23):3071–8

Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Furlan R, et al. **Circulation** 1998 Nov 17;98(20):2154–9

Chronic orthostatic intolerance: part of a spectrum of dysfunction in orthostatic cardiovascular homeostasis? [editorial] Narkiewicz K, et al. **Circulation** 1998 Nov 17; 98(20):2105–7

Blood flow dynamics in heart failure. Shoemaker JK, et al. **Circulation** 1999 Jun 15;99(23):3002–8

Maximizing the hemodynamic benefit of enhanced external counterpulsation. Suresh K, et al. **Clin Cardiol** 1998 Sep; 21(9):649–53

Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise. Friedl W, et al. **Clin Chim Acta** 1999 Mar; 281(1-2):121–6

Heterogeneous haemodynamics in acromegaly: evidence of endothelial dysfunction? [comment] Evans LM, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):711–2. Comment on: Clin Endocrinol (Oxf) 1998 Dec;49(6):725–31.

Hemorheological parameters in coronary artery disease. Kesmarky G, et al. **Clin Hemorheol Microcirc** 1998 Jul; 18(4):245–51

Deep venous thrombosis: a prospective 3-month follow-up using duplex scanning and strain-gauge plethysmography. Janssen MC, et al. **Clin Sci (Colch)** 1998 Jun;94(6):651–6

A graphic orientated data analysis system for hemodynamic research. Hu WC, et al. **Comput Methods Programs Biomed** 1999 Jun;59(3):197–214

Pathogenesis of acute renal failure: new aspects. Bock HA. **Contrib Nephrol** 1998;124:43–55; discussion 55–63 (92 ref.)

Pleural effusions and hypoxemia [editorial; comment] Dobyns EL. **Crit Care Med** 1999 Mar;27(3):472. Comment on: Crit Care Med 1999 Mar;27(3):583–7.

Redox status of cytochrome a,a3: a noninvasive indicator of dysoxia in regional hypoxic or ischemic hypoxia [see comments] Guery BP, et al. **Crit Care Med** 1999 Mar; 27(3):576–82. Comment in: Crit Care Med 1999 Mar;27(3):469–71.

Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome [see comments] Jolliet P, et al. **Crit Care Med** 1998 Dec;26(12):1977–85. Comment in: Crit Care Med 1998 Dec;26(12):1934–5.

Large-pore hemodialysis in acute endotoxin shock [see comments] Kline JA, et al. **Crit Care Med** 1999 Mar; 27(3):588–96. Comment in: Crit Care Med 1999 Mar;27(3):473–4.

Hemodynamic effects of fluid loading in acute massive pulmonary embolism [see comments] Mercat A, et al. **Crit Care Med** 1999 Mar;27(3):540–4. Comment in: Crit Care Med 1999 Mar;27(3):461–3.

Prognostic value of blood lactate, base deficit, and oxygen-derived variables in an LD50 model of penetrating trauma. Moomey CB Jr, et al. **Crit Care Med** 1999 Jan; 27(1):154–61

Gas exchange and hemodynamics in experimental pleural effusion [see comments] Nishida O, et al. **Crit Care Med** 1999 Mar;27(3):583–7. Comment in: Crit Care Med 1999 Mar;27(3):472.

Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Rogiers P, et al. **Crit Care Med** 1999 Sep;27(9):1848–55

Circulation and hemodynamics. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):133–51

Cardiovascular effects of oesophageal dilation under general anaesthesia. Jakobsen CH, et al. **Dan Med Bull** 1999 Jun;

46(3):252-4
Critical perspectives [comment] Allison GT, et al. **Disabil Rehabil** 1999 Mar;21(3):133; discussion 137-8. Comment on: Disabil Rehabil 1998 Feb;20(2):41-8.
Methodological perspectives [comment] Newham DJ. **Disabil Rehabil** 1999 Mar;21(3):134-6; discussion 137-8. Comment on: Disabil Rehabil 1998 Feb;20(2):41-8.
Cardiorespiratory variables and sensation during stimulation of the left vagus in patients with epilepsy. Banzett RB, et al. **Epilepsy Res** 1999 May;35(1):1-11
Hemodynamic monitoring prior to and at the time of death in status epilepticus. Boggs JG, et al. **Epilepsy Res** 1998 Aug;31(3):199-209
Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy. Kalsi KK, et al. **Eur J Clin Invest** 1999 Jun;29(6):469-77
Echocardiographic features of primary, secondary and familial amyloidosis. Moyssakis I, et al. **Eur J Clin Invest** 1999 Jun;29(6):484-9
Effects of half the tidal volume during cardiopulmonary resuscitation on acid-base balance and haemodynamics in pigs. Winkler M, et al. **Eur J Emerg Med** 1998 Jun; 5(2):201-6
The influence of the mode of emergency ambulance transportation on the emergency patient's outcome. Witzel K, et al. **Eur J Emerg Med** 1999 Jun;6(2):115-8
Hemodynamic performance of four mechanical bileaflet prosthetic valves in the mitral position: an echocardiographic study. Reisner SA, et al. **Eur J Ultrasound** 1998 Dec;8(3):193-200
The effect of 'non-critical' (<50%) stenosis on vein graft longitudinal resistance and impedance. Moawad J, et al. **Eur J Vasc Endovasc Surg** 1999 Jun;17(6):517-20
Cerebral hemodynamics after traumatic brain injury of immature brain. Armstead WM. **Exp Toxicol Pathol** 1999 Feb;51(2):137-42 (48 ref.)
Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Dalloz F, et al. **Free Radic Biol Med** 1999 Apr; 26(7-8):785-800
Hemodynamic basis of blood pressure variability in normotensive and spontaneously hypertensive rats. Janssen BJ. **Fundam Clin Pharmacol** 1998;12 Suppl 1:11s-16s
Clinical events after TIPS: correlation with hemodynamic findings [letter; comment] Ter Borg PC, et al. **Gastroenterology** 1998 Dec;115(6):1607. Comment on: Gastroenterology 1998 Jun;114(6):1296-303.
Effect of upper gastrointestinal endoscopy on circulation in the elderly. Shimamoto C, et al. **Gerontology** 1999 Jul-Aug; 45(4):200-5
Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Huonker M, et al. **Gut** 1999 May;44(5):743-8
Ventricular dilatation in the absence of ACE inhibitors: influence of haemodynamic and neurohormonal variables following myocardial infarction. Walsh JT, et al. **Heart** 1999 Jan;81(1):33-9
The hemodynamic impact of diffuse myocardial ischemic lesions: an animal experimental model based on intracoronary microembolization. Terp K, et al. **Heart Vessels** 1998;13(3):132-41
Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal. Henriksen JH, et al. **Hepatology** 1999 Jun;29(6):1818-24
Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Henrion J, et al. **Hepatology** 1999 Feb;29(2):427-33
The effect of mechanically enhancing portal venous inflow on hepatic oxygenation, microcirculation, and function in a rabbit model with extensive hepatic fibrosis. Jiao LR, et al. **Hepatology** 1999 Jul;30(1):46-52
Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Piscaglia F, et al. **Hepatology** 1999 Jul;30(1):58-64
Correlation of endothelial vimentin content with hemodynamic parameters. Schnittler HJ, et al. **Histochem Cell Biol** 1998 Aug;110(2):161-7
The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Anderson KM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):402-7
Evaluation of common carotid hemodynamic forces. Relations with wall thickening. Carallo C, et al. **Hypertension** 1999 Aug;34(2):217-21
Early continuous noninvasive haemodynamic monitoring after severe blunt trauma. Velmahos GC, et al. **Injury** 1999 Apr;30(3):209-14
The enabler cannula pump: a novel circulatory support system. Nishimura Y, et al. **Int J Artif Organs** 1999 May; 22(5):317-23
Cardiovascular flow patterns: what should we make of them? [comment] Saloner D. **Int J Card Imaging** 1999 Apr; 15(2):97-8. Comment on: Int J Card Imaging 1999 Apr;15(2):99-103.
Integration of haemodynamic and electrocardiographic waveform data with DICOM images. Solomon HP. **Int J Card Imaging** 1998 Oct;14(5):301-6 (11 ref.)
Immediate effects of hepatic denervation on hepatic hemodynamics in dogs. Ito Y, et al. **Int Surg** 1998 Jan-Mar; 83(1):48-52
Statistical pattern detection in univariate time series of intensive care on-line monitoring data. Imhoff M, et al. **Intensive Care Med** 1998 Dec;24(12):1305-14
Hemodynamic profile in severe ARDS [letter; comment] Jardin F. **Intensive Care Med** 1999 Feb;25(2):246-7. Comment on: Intensive Care Med 1998 Oct;24(10):1018-28.
Improvement in oxygenation by prone position and nitric oxide in patients with acute respiratory distress syndrome. Martinez M, et al. **Intensive Care Med** 1999 Jan;25(1):29-36
Noninvasive pressure support ventilation (NIPSV) with face mask in patients with acute cardiogenic pulmonary edema (ACPE) [see comments] Rusterholtz T, et al. **Intensive Care Med** 1999 Jan;25(1):21-8. Comment in: Intensive Care Med 1999 Jan;25(1):1-2.
Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study [published erratum appears in Intensive Care Med 1999 Feb;25(2):247] [see comments] Squara P, et al. **Intensive Care Med** 1998 Oct; 24(10):1018-28. Comment in: Intensive Care Med 1999 Feb;25(2):246-7.
Cardiorespiratory, tissue oxygen and hepatic NADH responses to graded hypoxia. Stidwill RP, et al. **Intensive Care Med** 1998 Nov;24(11):1209-16
Spontaneous variability of arterial oxygenation in critically ill mechanically ventilated patients. Tsai YH, et al. **Intensive Care Med** 1999 Jan;25(1):37-43
Haemodynamics and fluid retention in liver disease. Henriksen JH, et al. **Ital J Gastroenterol Hepatol** 1998 Jun; 30(3):320-32 (147 ref.)
Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. Ritz E, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1798-804
Magnitude and time course of hemodynamic responses to Mueller maneuvers in patients with congestive heart failure. Hall MJ, et al. **J Appl Physiol** 1998 Oct;85(4):1476-84
Effect of prolonged, heavy exercise on pulmonary gas exchange in athletes. Hopkins SR, et al. **J Appl Physiol** 1998 Oct;85(4):1523-32
Leg mass and lower body negative pressure tolerance in men and women. Lawler LA, et al. **J Appl Physiol** 1998 Oct; 85(4):1471-5
Role of L-selectin in physiological manifestations after burn and smoke inhalation injury in sheep. Sakurai H, et al. **J Appl Physiol** 1999 Apr;86(4):1151-9
Enhanced peripheral chemoreflex function in conscious rabbits with pacing-induced heart failure. Sun SY, et al. **J Appl Physiol** 1999 Apr;86(4):1264-72
Compensatory alveolar growth normalizes gas-exchange function in immature dogs after pneumonectomy. Takeda S, et al. **J Appl Physiol** 1999 Apr;86(4):1301-10
Effect of urokinase on disseminated intravascular coagulation. Vasquez Y, et al. **J Appl Physiol** 1998 Oct; 85(4):1421-8
Postnatal hemodynamic changes in very-low-birthweight infants. Yanowitz TD, et al. **J Appl Physiol** 1999 Jul; 87(1):370-80
Cholesterol concentrations and cardiovascular reactivity to stress in African American college volunteers. Clark VR, et al. **J Behav Med** 1998 Oct;21(5):505-15
Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. Doyle MP, et al. **J Biol Chem** 1999 Jan 22;274(4):2583-91
Numerical study on the effect of steady axial flow development in the human aorta on local shear stresses in abdominal aortic branches. Shipkowitz T, et al. **J Biomech** 1998 Nov;31(11):995-1007
Performance analysis of a cardiac assist device in counterpulsation. Chesler NC, et al. **J Biomech Eng** 1998 Aug;120(4):437-45
Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. Kronenberg MW, et al. **J Card Fail** 1998 Sep;4(3):159-67
Hemodynamic changes and neurohumoral regulation during development of congestive heart failure in a model of epinephrine-induced cardiomyopathy in conscious rabbits. Muders F, et al. **J Card Fail** 1999 Jun;5(2):109-16
Clinical and hemodynamic comparison of the Medtronic Freestyle and Toronto SPV stentless valves. Del Rizzo DF, et al. **J Card Surg** 1998 Sep-Oct;13(5):398-407
Endovascular aortic repair is associated with greater hemodynamic stability compared with open aortic reconstruction. Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):42-6
Comparative analysis of systemic and coronary hemodynamics during sevoflurane- and isoflurane-induced hypotension in dogs. Tomiyasu S, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):741-7
Transcutaneous renal function monitor: precision during unsteady hemodynamics. Bauman LA, et al. **J Clin Monit Comput** 1998 May;14(4):275-82
Role of neurosympathetic pathways in the vascular response to sepsis. Magder S, et al. **J Crit Care** 1998 Dec; 13(4):169-76
Comparison between intrathoracic blood volume and cardiac filling pressures in the early phase of hemodynamic instability of patients with sepsis or septic shock. Sakka SG, et al. **J Crit Care** 1999 Jun;14(2):78-83
Blood flow rate in normal and tumor-bearing rats in conscious state, under urethane anesthesia, and during systemic hypothermia. Sakaeda T, et al. **J Drug Target** 1998;6(4):261-72
Prolonged bleeding time in experimental cirrhosis: role of nitric oxide [see comments] Albornoz L, et al. **J Hepatol** 1999 Mar;30(3):456-60. Comment in: J Hepatol 1999 Mar;30(3):532-5.
Should measurements of hemodynamics in portal hypertension be dynamic? [editorial; comment] Cales P. **J Hepatol** 1998 Nov;29(5):829-31. Comment on: J Hepatol 1998 Nov;29(5):772-8.
Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. Elizalde JI, et al. **J Hepatol** 1998 Nov;29(5):789-95
Hepatopulmonary syndrome associated with cardiorespiratory disease. Martinez G, et al. **J Hepatol** 1999 May;30(5):882-9
Haemodynamic responses to obstructive sleep apnoeas in premenopausal women. Edwards N, et al. **J Hypertens** 1999 May;17(5):603-10
Hemodynamic concomitants of glycemia in diabetes mellitus: working hypothesis. Hon EH. **J Matern Fetal Med** 1999 May-Jun;8(3):107-13
Development of a flow simulator to study haemodynamic behaviour of natural and artificial blood vessels under physiologic flow conditions. Charara J, et al. **J Med Eng Technol** 1999 May-Jun;23(3):83-95
Analysis of regurgitation, mean systolic pressure drop and energy losses for two artificial aortic valves. Sakhacimanesh AA, et al. **J Med Eng Technol** 1999 Mar-Apr;23(2):63-8
2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor. Wolkowicz PE, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1405-12
Effects of hindlimb temperature on sciatic nerve laser Doppler vascular conductance in control and streptozotocin-diabetic rats. Dines KC, et al. **J Neurol Sci** 1999 Feb 1;163(1):17-24
Hemodynamic characterization of intracranial pressure plateau waves in head-injury patients. Czosnyka M, et al. **J Neurosurg** 1999 Jul;91(1):11-9
Computer simulation of intracranial pressure changes during induction of anesthesia: comparison of thiopental, propofol, and etomidate. Bekker AY, et al. **J Neurosurg Anesthesiol** 1999 Apr;11(2):69-80
Hemodynamic observations in a newborn with Parkes-Weber syndrome. Berger TM, et al. **J Pediatr** 1999 Apr;134(4):513
Effect of chronic mitral valve damage on activity of pulmonary rapidly adapting receptors in the rabbit. Gunawardena S, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):79-88
Metabolic and cardiovascular responses during work on a high ropes course. Watts PB, et al. **J Sports Med Phys Fitness** 1999 Mar;39(1):37-41
Soluble tumor necrosis factor receptor prevents post-pump syndrome. Carney DE, et al. **J Surg Res** 1999 May 15; 83(2):113-21
Hepato-splanchnic blood flow and oxygen extraction capabilities during experimental tamponade: effects of endotoxin. Zhang H, et al. **J Surg Res** 1999 Feb; 81(2):129-38
Fourier analysis of the intra-aortic balloon pump [letter] Grossi EA. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):568
Effect and clinical value of splanchnic nerve block of hemodynamics in ACST. Zheng Q, et al. **J Tongji Med Univ** 1997;17(3):182-6
Physiologic responses to primary blast. Guy RJ, et al. **J Trauma** 1998 Dec;45(6):983-7
Esophageal Doppler ultrasound monitor versus pulmonary artery catheter in the hemodynamic management of critically ill surgical patients. Madan AK, et al. **J Trauma** 1999 Apr;46(4):607-11; discussion 611-2
Vascular tone in patients with hemorrhagic shock. Miyagatani Y, et al. **J Trauma** 1999 Aug;47(2):282-7
Determinants of myocardial performance after blunt chest trauma. Moomey CB Jr, et al. **J Trauma** 1998 Dec; 45(6):988-96
Continuous measurement of gut pH with near-infrared spectroscopy during hemorrhagic shock. Puyana JC, et al. **J Trauma** 1999 Jan;46(1):9-15
Liver laceration in the hemodynamically unstable post-cardiac massage patient: early recognition and management--case report. Rosen J, et al. **J Trauma** 1999 Aug;47(2):408-9
Effects of local cooling on microvascular hemodynamics and leukocyte adhesion in the striated muscle of hamsters. Thorlacius H, et al. **J Trauma** 1998 Oct;45(4):715-9
Study of cavernosal arterial anatomy using color and power Doppler sonography: impact on hemodynamic parameter measurement. Chiou RK, et al. **J Urol** 1999 Aug; 162(2):358-60
A comparative study between hypothermic and normothermic cardiopulmonary bypass in open heart surgery in dogs--effects on systemic hemodynamics. Shibazaki A, et al. **J Vet Med Sci** 1999 Apr;61(4):331-6
Hemodynamic factors and symptomatic carotid artery occlusion [letter] Kario K, et al. **JAMA** 1999 Feb 3; 281(5):420
Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. Kishida H, et al. **Jpn Heart J** 1999 Jan;40(1):31-44
Oxygen utilization and hemodynamic response during exercise in children after Fontan procedure. Miyairi T, et al. **Jpn Heart J** 1998 Sep;39(5):659-69
Hemodynamic response to anesthesia in pregnant and

nonpregnant ICR mice. Furukawa S, et al. **Lab Anim Sci** 1998 Aug;48(4):357–63

Evaluation of dual-tip micromanometers during 21-day implantation in goats. Reister CA, et al. **Med Eng Phys** 1998 Sep;20(6):410–7

Cardiovascular responses to facial cooling are age and fitness dependent. Petrella RJ, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1163–8

Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Kooistra MP, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2853–60

Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Marchais SJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2178–83

Renal perfusion and nephronal structure [letter] Futrakul P, et al. **Nephron** 1999;82(1):79–80

Left ventricular function at rest and during bicycle exercise in normal subjects: assessment by ECG-gated myocardial perfusion SPET with 99Tcm-tetrofosmin. Kumita S, et al. **Nucl Med Commun** 1999 May;20(5):427–32

Ocular volume change per minute with ocular pneumoplethysmography. Gee W, et al. **Ophthalmic Res** 1999;31(5):351–7

Distensible venous malformations of the orbit: clinical and hemodynamic features and a new technique of management. Lacey B, et al. **Ophthalmology** 1999 Jun; 106(6):1197–209

CABG and ICD for all patients with hemodynamically significant ventricular arrhythmia and significant coronary artery disease? Do we know enough to decide--or to design a randomized trial? [editorial; comment] Bergfeldt L. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1129–31 (9 ref.). Comment on: Pacing Clin Electrophysiol 1999 Aug;22(8):1132–9.

Left-to-right shunt lesions. Driscoll DJ. **Pediatr Clin North Am** 1999 Apr;46(2):355–68, x (7 ref.)

Influence of age and low afterload on the stress-velocity relation of the left ventricle. De Wolf D, et al. **Pediatr Res** 1998 Oct;44(4):600–6

Acute intrauterine pulmonary hypertension impairs endothelium-dependent vasodilation in the ovine fetus. Storme L, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):575–81

Cardiovascular morbidity in obstructive sleep apnea. Weiss JW, et al. **Prog Cardiovasc Dis** 1999 Mar-Apr;41(5):367–76 (68 ref.)

Cardiovascular and endocrine changes during sexual arousal and orgasm [editorial; comment] Bancroft J. **Psychosom Med** 1999 May-Jun;61(3):290–1. Comment on: Psychosom Med 1999 May-Jun;61(3):280–9.

Cardiovascular and endocrine alterations after masturbation-induced orgasm in women [see comments] Exton MS, et al. **Psychosom Med** 1999 May-Jun; 61(3):280–9. Comment in: Psychosom Med 1999 May-Jun;61(3):290–1.

Improved haemodynamics and restoration of spontaneous circulation with constant aortic occlusion during experimental cardiopulmonary resuscitation. Gedeborg R, et al. **Resuscitation** 1999 Apr-May;40(3):171–80

Plasma noradrenaline and neuropeptide-Y may not be of primary importance in the pathophysiology of cardiac involvement in systemic sclerosis. Kazzam E, et al. **Scand J Rheumatol** 1999;28(4):238–43

Cardiovascular aspects of experimental meningococcal sepsis in young and older awake piglets: age-related differences. Hazelzet JA, et al. **Shock** 1999 Aug;12(2):145–54

Mediator-dependent secondary injury after unilateral blunt thoracic trauma. Melton SM, et al. **Shock** 1999 Jun; 11(6):396–402

Interleukin-1 mediates hemodynamic dysfunction and release of eicosanoids and tumor necrosis factor during graded bacteremia. Santos MC, et al. **Shock** 1999 Jun;11(6):423–8

Hemodynamic consequences of high- and low-pressure capnoperitoneum during laparoscopic cholecystectomy. Dexter SP, et al. **Surg Endosc** 1999 Apr;13(4):376–81

Pneumoperitoneum risk prognosis and correction of venous circulation disturbances in laparoscopic surgery. A pilot study. Emeljanov SI, et al. **Surg Endosc** 1998 Oct; 12(10):1224–31

To cut is not always to cure [letter] Shayani V. **Surg Endosc** 1999 Apr;13(4):427–8

Prehospital stabilization of pelvic dislocations: a new strap belt to provide temporary hemodynamic stabilization. Vermeulen B, et al. **Swiss Surg** 1999;5(2):43–6

Continuous, less invasive, hemodynamic monitoring in intensive care after cardiac surgery. Gödje O, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):242–9

Is there a cirrhotic myocardiopathy in patients proposed for liver transplantation? Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2368

Influence of surgical technique on postreperfusion syndrome during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2380–1

Effect of reperfusion on right ventriculoarterial coupling in liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2384–5

Hemodynamic profile in cirrhotic patients undergoing liver retransplantation due to chronic rejection. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2371

Cardiac evaluation of patients with familial amyloidotic polyneuropathy proposed for liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2372

Hemodynamic consequences of portal and lateral clamping of the inferior vena cava during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2413–4

Need for inotropic and/or vasopressor drugs during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep; 31(6):2402–3

Need for venovenous bypass in patients with familial amyloidotic polyneuropathy treated with liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep; 31(6):2394–5

Preservation with a retrograde second flushing of Eurocollins in clinical lung transplantation. Alvarez A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1088–90

Use of a newly developed ultrasound contrast medium for color Doppler evaluation in kidney transplantation. Ferraresso M, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1354–6

Failure of rapid autonomic augmentation of cardiac performance in transplanted hearts. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3344–6

Portal hemodynamics in living-related liver transplantation: quantitative measurement by Doppler ultrasound. Huang TL, et al. **Transplant Proc** 1998 Nov;30(7):3186–7

Hemodynamic alterations during liver xenotransplantation from pig to baboon. Ramirez P, et al. **Transplant Proc** 1999 Sep;31(6):2625–6

Myocardial preservation in clinical cardiac transplantation. Wildhirt SM, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):147–8

Hemodynamic follow-up of cardiac allografts from poisoned donors. Tenderich G, et al. **Transplantation** 1998 Nov 15; 66(9):1163–7

In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Vallhonrat H, et al. **Transplantation** 1999 Jan 27;67(2):253–8

A spatial approach to transcriptional profiling: mechanotransduction and the focal origin of atherosclerosis. Davies PF, et al. **Trends Biotechnol** 1999 Sep;17(9):347–51 (29 ref.)

The effect of hemodynamics, vessel wall compliance and hematocrit on ultrasonic Doppler power: an in vitro study. Missaridis TX, et al. **Ultrasound Med Biol** 1999 May; 25(4):549–59

Baroreceptor-heart rate reflex sensitivity enhancement after urinary bladder distention in essential hypertensives. Bardelli M, et al. **Urol Res** 1999 Apr;27(2):153–6

Influence of brain death and cardiac preservation on systolic and diastolic function and coronary circulation in the cross-circulated canine heart. Szabó G, et al. **World J Surg** 1999 Jan;23(1):36–43

[Hemodynamic response to exercise in patients with chronic obstructive pulmonary disease (COPD)] Liu Z, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Jun; 20(3):157–60 (Eng. Abstr.) **(Chi)**

[Clinical efficacy of prolonged therapy with NO on patients with pulmonary hypertension] He JG, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):762–4 (Eng. Abstr.) **(Chi)**

[Portal-systemic shunting and hemodynamics of prehepatic portal hypertensive rat models] Zhou YB, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):244–7 (Eng. Abstr.) **(Chi)**

[Effects of inhalation of nitric oxide on hemodynamics, blood gas and oxygen transport function in chronic obstructive pulmonary disease] Dai A, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):305, 325, 332 **(Chi)**

[Morpho-functional characteristics of vascular endothelial cells affected by hemodynamic factors] Lai X, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):87–91 (20 ref.) (Eng. Abstr.) **(Chi)**

[An in vitro study of hydrodynamic properties of the TRI-Technologies heart valve prosthesis in accordance with prEN 12006-1] Dohmen R, et al. **Biomed Tech (Berl)** 1998;43 Suppl:384–5 **(Ger)**

[Labcor-stented porcine heart valve prosthesis in laboratory testing in accordance with prEN 12006-1] Hüsgen P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:386–7 **(Ger)**

[Hemodynamic indications for DDD mode pacing therapy] Kowalski M, et al. **Dtsch Med Wochenschr** 1999 May 28; 124(21):647–9 (Eng. Abstr.) **(Ger)**

[Intrarenal doppler flow analysis in patients with kidney transplantation and stable transplant function] Restrepo-Schäfer IK, et al. **Ultraschall Med** 1999 Jun; 20(3):87–92 (Eng. Abstr.) **(Ger)**

[The hemodynamics laboratory without cine film. A comparison between the production costs of 35-mm film and the recordable compact disk (see comments)] Danzi GB, et al. **G Ital Cardiol** 1998 Aug;28(8):887–92 (Eng. Abstr.). Comment in: G Ital Cardiol 1998 Nov;28(11):1324–5; discussion 1326–7. Comment in: G Ital Cardiol 1998 Nov;28(11):1325; discussion 1326–7. **(Ita)**

[Hemodynamics laboratories without cine film (letter; comment)] Diligenti LM, et al. **G Ital Cardiol** 1998 Nov; 28(11):1325; discussion 1326–7. Comment on: G Ital Cardiol 1998 Aug;28(8):887–92. **(Ita)**

[Hemodynamics laboratories without cine film (letter; comment)] Morocutti G. **G Ital Cardiol** 1998 Nov; 28(11):1324–5; discussion 1326–7. Comment on: G Ital Cardiol 1998 Aug;28(8):887–92. **(Ita)**

[Volumetric hemodynamic monitoring] Pittoni G, et al. **Minerva Anestesiol** 1999 Jun;65(6):357–61 (20 ref.) **(Ita)**

[Does mixed venous desaturation during a bed bath indicate cardiopulmonary decompensation in postoperative cardiac patients?] Hayashida M, et al. **Masui** 1998 Aug;47(8):933–8 (Eng. Abstr.) **(Jpn)**

[Correlation between intraoperative hemodynamic instability and postoperative renal dysfunction] Oka T, et al. **Masui** 1999 Jan;48(1):2–8 (Eng. Abstr.) **(Jpn)**

[Correlation between intraoperative hemodynamic variability and postoperative arrhythmias in patients with pulmonary surgery] Oka T, et al. **Masui** 1999 Feb;48(2):118–23 (Eng. Abstr.) **(Jpn)**

[Non-invasive continuous hemodynamic measurement during operation for a child with coarctation of aorta] Taguchi A, et al. **Masui** 1999 Mar;48(3):304–8 (Eng. Abstr.) **(Jpn)**

[Hemodynamics and oxygen transport in patients with surgical sepsis during hemofiltration] Bobrinskaia IG, et al. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):58–62 (Eng. Abstr.) **(Rus)**

[Electroacupuncture effect on the systemic hemodynamics in animals with postinfarct cardiosclerosis] Belkina LM, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):29–34 **(Rus)**

[Effect of training to antiorthostatic hypokinesia on parameters of the central hemodynamics in rats] Bychkova EIu, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):289–93 **(Rus)**

[Central hemodynamics in rats with various resistivity to acute hemorrhage] Kovalenko NIa, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):384–8 **(Rus)**

[Thromboembolic complications, venous hemodynamics and lower extremities in laparoscopic operations] Starkov IuG, et al. **Khirurgiia (Mosk)** 1999;(8):63–7 (68 ref.) **(Rus)**

[Central and regional hepatic hemodynamics in patients with ischemic heart disease and concomitant chronic persistent hepatitis] Akimova LG. **Lik Sprava** 1998 Jun;(4):67–9 (Eng. Abstr.) **(Rus)**

[The central hemodynamic characteristics of patients with postinfarct cardiosclerosis and heart failure] Koshlia EV. **Lik Sprava** 1999 Jan-Feb;(1):39–41 (Eng. Abstr.) **(Rus)**

[Central hemodynamics as dependent on the method of bicycle exercise in sanatorium patients who have had a myocardial infarct] Efremushkin GG, et al. **Ter Arkh** 1998; 70(8):37–41 (Eng. Abstr.) **(Rus)**

[The central hemodynamics in children during operations on the organs of the upper urinary tracts] Vezirov MS, et al. **Urol Nefrol (Mosk)** 1998 Sep-Oct;(5):43–6 (Eng. Abstr.) **(Rus)**

[The clinical assessment of central hemodynamics in patients over 70 undergoing the surgical treatment of calculous cholecystitis] Miroshnikov BI, et al. **Vestn Khir Im I I Grek** 1998;157(4):42–5 (Eng. Abstr.) **(Rus)**

[Pathogenesis of systemic hemodynamic disorders and choice of optimal obstetrical strategy in pregnant patients with gestosis] Strizhakov AN, et al. **Vestn Ross Akad Med Nauk** 1999;(1):51–7 (Eng. Abstr.) **(Rus)**

[The hemodynamics and physical work capacity of divers after prolonged deep-water immersions] Novikov VS, et al. **Voen Med Zh** 1999 Feb;320(2):69–71 **(Rus)**

[The action of a low-frequency alternating magnetic field on the indices of hemodynamics and temperature homeostasis in women] Gerasimov IG, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep-Oct;(5):30–2 (Eng. Abstr.) **(Rus)**

[Hemodynamic changes in liver cirrhosis] Szántová M, et al. **Bratisl Lek Listy** 1999 Jan;100(1):41–8 (33 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Influence of dopexamine hydrochloride on haemodynamics and regulators of circulation in patients undergoing major abdominal surgery. Boldt J, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):941–7

Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery. Colson P, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1114–9

Comparison of the haemodynamic actions of desflurane/N2O and isoflurane/N2O anaesthesia in vascular surgical patients. Zubicki A, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1057–62

Comparison of hemodynamics and recovery of sevoflurane and isoflurane anesthesia in Chinese adult patients. Chen TL, et al. **Acta Anaesthesiol Sin** 1998 Mar;36(1):31–6

Effects of dobutamine, norepinephrine and epinephrine on intramucosal pH and hemodynamics of dogs during endotoxic shock. Hayes JK, et al. **Acta Anaesthesiol Sin** 1998 Sep;36(3):113–26

Combination of bupivacaine scalp circuit infiltration with general anesthesia to control the hemodynamic response in craniotomy patients. Shiau JM, et al. **Acta Anaesthesiol Sin** 1998 Dec;36(4):215–20

Effect of Kampo formulations (traditional Chinese medicine) on circulatory parameters. Xu FH, et al. **Acupunct Electrother Res** 1999;24(1):11–28

Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition. Naitoh M, et al. **Adv Exp Med Biol** 1998;449:445–6

Acute hemodynamic effects of ethanol in conscious spontaneously hypertensive and normotensive rats. El-Mas MM, et al. **Alcohol Clin Exp Res** 1999 Feb;23(2):285–92

HEMODYNAMICS

Long-term haemodynamic effects of octreotide on postprandial splanchnic hyperemia in humans: a placebo-controlled echo-doppler study. Ludwig D, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1119–29

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure [see comments] Giustina A, et al. **Am Heart J** 1999 Jun;137(6):1035–43. Comment in: Am Heart J 1999 Jun;137(6):989–91.

Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Guazzi M, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):460–7

Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure [see comments] Hatzizacharias A, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):241–6. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):191–2.

Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. Kukin ML, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):261–8

Effect of vesnarinone on cardiac function in patients with severe congestive heart failure [see comments] Scherrer-Crosbie M, et al. **Am Heart J** 1998 Nov; 136(5):769–77. Comment in: Am Heart J 1998 Nov;136(5):753–8.

Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism [see comments] Tebbe U, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):39–44. Comment in: Am Heart J 1999 Jul;138(1 Pt 1):1–2.

Hemodynamic and electrophysiologic effects of acute chocolate ingestion in young adults. Baron AM, et al. **Am J Cardiol** 1999 Aug 1;84(3):370–3, A10

Efficacy of bretylium tosylate for ventricular tachycardia. Chandrasekaran S, et al. **Am J Cardiol** 1999 Jan 1; 83(1):115–7, A9

Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Dickstein K, et al. **Am J Cardiol** 1999 Jun 15;83(12):1638–44

Dobutamine-induced changes in pulmonary artery pressure in patients with congestive heart failure and their relation to abnormalities of lung diffusing capacity. Faggiano P, et al. **Am J Cardiol** 1998 Nov 15;82(10):1296–8, A10

Effects of sildenafil citrate on human hemodynamics. Jackson G, et al. **Am J Cardiol** 1999 Mar 4;83(5A):13C–20C

Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. Krombach RS, et al. **Am J Cardiol** 1999 Aug 19;84(4A):3L–15L

Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis. Lin HC, et al. **Am J Gastroenterol** 1999 Apr;94(4):1012–7

Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals. Olsen ME, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):209–16

Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Swislocki AL, et al. **Am J Hypertens** 1999 Jun;12(6):581–9

Effects of age and hypertension on cardiac responses to the alpha1-agonist phenylephrine in humans. White M, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):151–8

Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Broere A, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F870–7

Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50). Eichelbrönner O, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H290–8

Role of cholinergic receptors and cholinesterase activity in hemodynamic responses to cocaine in conscious rats. Knuepfer MM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R103–12

Hemodynamic and renal effects of U-46619, a TXA2/PGH2 analog, in late-pregnant rats. Kriston T, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R831–7

Species-dependent hemodynamic effects of adenosine A3-receptor agonists IB-MECA and Cl-IB-MECA. Lasley RD, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2076–84

Concentration-dependent effects of bradykinin on leukocyte recruitment and venular hemodynamics in rat mesentery. Shigematsu S, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H152–60

Rapid tachyphylaxis to hemodynamic effects of PACAP-27 after inhibition of nitric oxide synthesis. Whalen EJ, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2117–26

Pentoxifylline prevents the transition from the hyperdynamic to hypodynamic response during sepsis. Yang S, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1036–44

The effects of retroperitoneal carbon dioxide insufflation on hemodynamics and arterial carbon dioxide. Baird JE, et al. **Am J Surg** 1999 Feb;177(2):164–6

Cardiorespiratory effects of a tiletamine/zolazepam-ketamine-detomidine combination in horses. Muir WW 3rd, et al. **Am J Vet Res** 1999 Jun; 60(6):770–4

Induction of anaesthesia with sevoflurane, preprogrammed propofol infusion or combined sevoflurane/propofol for laryngeal mask insertion: cardiovascular, movement and EEG bispectral index responses. Blake DW, et al. **Anaesth Intensive Care** 1998 Aug;26(4):360–5

Clonidine and cardiac surgery: haemodynamic and metabolic effects, myocardial ischaemia and recovery. Myles PS, et al. **Anaesth Intensive Care** 1999 Apr;27(2):137–47

The cardiovascular, coagulation and haematological effects of tiger snake (Notechis scutatus) venom. Tibballs J. **Anaesth Intensive Care** 1998 Oct;26(5):529–35

The cardiovascular, coagulation and haematological effects of tiger snake (Notechis scutatus) prothrombin activator and investigation of release of vasoactive substances. Tibballs J. **Anaesth Intensive Care** 1998 Oct;26(5):536–47

Smokers and haemodynamic responses to desflurane. Fitz-Henry J, et al. **Anaesthesia** 1999 Aug;54(8):800–3

The use of neuromuscular blocking agents in noncardiac surgery after dynamic cardiomyoplasty. Timmerman J, et al. **Anaesthesia** 1999 Sep;54(9):879–82

The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Levy JH, et al. **Anesth Analg** 1999 Aug; 89(2):290–5

The combined effects of sevoflurane and remifentanil on central respiratory activity and nociceptive cardiovascular responses in anesthetized rabbits. Ma D, et al. **Anesth Analg** 1999 Aug;89(2):453–61

Desflurane and isoflurane produce similar alterations in systemic and pulmonary hemodynamics and arterial oxygenation in patients undergoing one-lung ventilation during thoracotomy. Pagel PS, et al. **Anesth Analg** 1998 Oct;87(4):800–7

The effect of magnesium sulphate on hemodynamics and its efficacy in attenuating the response to endotracheal intubation in patients with coronary artery disease. Puri GD, et al. **Anesth Analg** 1998 Oct;87(4):808–11

A comparative study of hemodynamic and T-wave criteria for detecting intravascular injection of the test dose (epinephrine) in sevoflurane-anesthetized adults. Tanaka M, et al. **Anesth Analg** 1999 Jul;89(1):32–6

Small-dose inhaled nitric oxide attenuates hemodynamic changes after pulmonary air embolism in dogs. Tanus-Santos JE, et al. **Anesth Analg** 1999 May; 88(5):1025–9

The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat. Yoon MH, et al. **Anesth Analg** 1999 Aug;89(2):434–9

Analgesic and hemodynamic effects of intrathecal clonidine as the sole analgesic agent during first stage of labor: a dose-response study. Chiari A, et al. **Anesthesiology** 1999 Aug;91(2):388–96

Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. Hettrick DA, et al. **Anesthesiology** 1998 Nov;89(5):1166–73

Hemodynamic and metabolic manifestations of acute endotoxin infusion in pigs with and without the malignant hyperthermia mutation. Musley SK, et al. **Anesthesiology** 1999 Sep;91(3):833–8

Effects of xenon on hemodynamic responses to skin incision in humans. Nakata Y, et al. **Anesthesiology** 1999 Feb; 90(2):406–10

Anesthetic doses of sevoflurane to block cardiovascular responses to incision when administered with xenon or nitrous oxide. Nakata Y, et al. **Anesthesiology** 1999 Aug; 91(2):369–73

Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

Microcirculatory response to halothane and isoflurane anesthesia. Kusza K, et al. **Ann Plast Surg** 1999 Jul; 43(1):57–66

Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Chaney MA, et al. **Ann Thorac Surg** 1999 Apr;67(4):1006–11

Effect of brimonidine tartrate on ocular hemodynamic measurements. Lachkar Y, et al. **Arch Ophthalmol** 1998 Dec;116(12):1591–4

Nitric oxide inhalation as a chemical assist for circulation in patients after cardiovascular surgery. Kumon K, et al. **Artif Organs** 1999 Feb;23(2):169–74

Effects of AL 107, a novel semisynthetic cardiac glycoside, on the cardiovascular system in anaesthetized beagle dogs with pentobarbital-induced cardiac insufficiency. Kögel B, et al. **Arzneimittelforschung** 1999 Aug;49(8):679–84

Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 3rd communication: stereoselectivity of the enantiomers in cardiovascular effects. Sugawara H, et al. **Arzneimittelforschung** 1999 May; 49(5):412–9

Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs. Yoshimura A, et al. **Arzneimittelforschung** 1999 May; 49(5):407–11

Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during--6 degrees of head down tilt. Rosene JM, et al. **Aviat Space Environ Med** 1999 Jan; 70(1):15–21

Attenuation of myocardial stunning by the AT1 receptor antagonist candesartan. Dörge H, et al. **Basic Res Cardiol** 1999 Jun;94(3):208–14

Coenzyme Q10 treatment in serious heart failure. Munkholm H, et al. **Biofactors** 1999;9(2–4):285–9

Endothelin ET(B) receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats. Hashimoto N, et al. **Biol Pharm Bull** 1998 Aug; 21(8):800–4

Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Barabino GA, et al. **Blood** 1999 Feb 15;93(4):1422–9

Effects of propranolol on cardiovascular and neurohumoral actions of alcohol in hypertensive patients [see comments] Kawano Y, et al. **Blood Press** 1999;8(1):37–42. Comment in: Blood Press 1999 ;8(1):3–4.

Relationship between the circulating and vascular renin-angiotensin system and the vasodilating effect of captopril in human hypertension. Virdis A, et al. **Blood Press** 1999;8(2):85–93

Cardiovascular effects of novel imidazoline congeners. Shukla S, et al. **Boll Chim Farm** 1998 Jul-Aug; 137(7):229–32

Comparison of the myocardial effects of desflurane and isoflurane in healthy patients: assessment by continuous oesophageal aortic blood flow echo-Doppler. Gueugniaud PY, et al. **Br J Anaesth** 1998 Dec;81(6):844–9

Identification of causal relations between haemodynamic variables, auditory evoked potentials and isoflurane by means of fuzzy logic. Jensen EW, et al. **Br J Anaesth** 1999 Jan;82(1):25–32

Haemodynamic stability and ketamine-alfentanil anaesthetic induction. Katz RI, et al. **Br J Anaesth** 1998 Nov; 81(5):702–6

Effect of remifentanil on the auditory evoked response and haemodynamic changes after intubation and surgical incision. McGregor RR, et al. **Br J Anaesth** 1998 Nov; 81(5):785–6

Atropine premedication and the cardiovascular response to electroconvulsive therapy. Mayur PM, et al. **Br J Anaesth** 1998 Sep;81(3):466–7

Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. O'Hare R, et al. **Br J Anaesth** 1999 Feb;82(2):283–5

Haemodynamic effects of propofol vs thiopental in infants: an echocardiographic study. Wodey E, et al. **Br J Anaesth** 1999 Apr;82(4):516–20

Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Cheung BM, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):179–87

Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Pfister M, et al. **Br J Clin Pharmacol** 1999 Jun;47(6):645–51

Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers. Schäfers RF, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):59–66

The haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans? Swan L, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):189–94

Effects of tocolytic treatment with ritodrine on cardiovascular autonomic regulation. Vesalainen RK, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):238–43

Influence of CGRP (8–37), but not adrenomedullin (22–52), on the haemodynamic responses to lipopolysaccharide in conscious rats. Gardiner SM, et al. **Br J Pharmacol** 1999 Aug;127(7):1611–8

The influence of antibodies to TNF-alpha and IL-1beta on haemodynamic responses to the cytokines, and to lipopolysaccharide, in conscious rats. Gardiner SM, et al. **Br J Pharmacol** 1998 Dec;125(7):1543–50

Haemodynamic effects of a selective adenosine A2A receptor agonist, CGS 21680, in chronic heart failure in anaesthetized rats. Nekooeian AA, et al. **Br J Pharmacol** 1998 Oct;125(4):651–8

Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. Oldner A, et al. **Br J Pharmacol** 1999 Aug;127(8):1793–804

Cardiovascular effects of intravenous administration of clonidine in conscious cats. Ally A. **Brain Res** 1998 Nov 9;810(1–2):153–60

Heparin and protamine interaction [editorial] Blaise G. **Can J Anaesth** 1998 Dec;45(12):1144–7 **(Eng, Fre)**

Calcium channel blockers attenuate cardiovascular responses to tracheal extubation in hypertensive patients. Fujii Y, et al. **Can J Anaesth** 1998 Jul;45(7):655–9

Comparison of the hemodynamic effects of sevoflurane anesthesia induction and maintenance vs TIVA in CABG surgery. Gravel NR, et al. **Can J Anaesth** 1999 Mar; 46(3):240–6

Comparison of the cardiovascular effects of cisatracurium and vecuronium in patients with coronary artery disease. Reich DL, et al. **Can J Anaesth** 1998 Aug;45(8):794–7

Reduced efficacy of simulated epidural test doses in sevoflurane-anesthetized adults. Takahashi S, et al. **Can J Anaesth** 1999 May;46(5 Pt 1):433–8

Haemodynamic and catecholamine responses to calcitonin gene-related peptide during volatile anaesthesia. Takeda S, et al. **Can J Anaesth** 1998 Nov;45(11):1116–22

Hypotensive mechanism of [Leu13]motilin in dogs in vivo and in vitro. Iwai T, et al. **Can J Physiol Pharmacol** 1998 Dec;76(12):1103–9

Anesthetic potency and cardiopulmonary effects of sevoflurane in goats: comparison with isoflurane and halothane. Hikasa Y, et al. **Can J Vet Res** 1998 Oct; 62(4):299–306

Verapamil therapy in infants with hypertrophic cardiomyopathy. Moran AM, et al. **Cardiol Young** 1998 Jul;8(3):310–9

Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Anand I, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):291–9

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Mitsunami K, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):469–74

Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment. Muller CA, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):449–55

Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs. Choussat R, et al. **Cardiovasc Res** 1998 Sep;39(3):580–8

Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. Cowburn PJ, et al. **Cardiovasc Res** 1998 Sep;39(3):563–70

Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Marano G, et al. **Cardiovasc Res** 1999 Apr;42(1):201–5

Effect of bolus epinephrine on systemic hemodynamics in canine anaphylactic shock. Mink SN, et al. **Cardiovasc Res** 1998 Dec;40(3):546–56

Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Mulder P, et al. **Cardiovasc Res** 1998 Sep;39(3):600–8

Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Ohnishi M, et al. **Cardiovasc Res** 1998 Sep; 39(3):617–24

Increased aortic blood pressure contributes to potentiated dobutamine inotropic responses after systemic NO synthase inhibition in sheep. Penny DJ, et al. **Cardiovasc Res** 1998 Nov;40(2):282–9

Cardiovascular response to the injection of acetylcholine into the anterior cingulate region of the medial prefrontal cortex of unanesthetized rats. Crippa GE, et al. **Cereb Cortex** 1999 Jun;9(4):362–5

Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Atwood JE, et al. **Chest** 1999 Apr; 115(4):1175–80

Dobutamine in severe scorpion envenomation: effects on standard hemodynamics, right ventricular performance, and tissue oxygenation. Elatrous S, et al. **Chest** 1999 Sep; 116(3):748–53

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Baruch L, et al. **Circulation** 1999 May 25;99(20):2658–64

L-Arginine normalizes coronary vasomotion in long-term smokers. Campisi R, et al. **Circulation** 1999 Feb 2; 99(4):491–7

Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Fabre JE, et al. **Circulation** 1999 Jun 15;99(23):3043–9

Recombinant growth hormone therapy in patients with ischemic cardiomyopathy : effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Genth-Zotz S, et al. **Circulation** 1999 Jan 5–12; 99(1):18–21

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Goodfield NE, et al. **Circulation** 1999 Jun 15;99(23):2983–5

Mobilization of antioxidant vitamin pools and hemodynamic function after myocardial infarction. Palace VP, et al. **Circulation** 1999 Jan 5–12;99(1):121–6

Chronic amlodipine treatment during the development of heart failure. Spinale FG, et al. **Circulation** 1998 Oct 20; 98(16):1666–74

Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Szebeni J, et al. **Circulation** 1999 May 4;99(17):2302–9

Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Wada A, et al. **Circulation** 1999 Feb 2;99(4):570–7

Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Wenzel RR, et al. **Circulation** 1998 Nov 24; 98(21):2235–40

Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Yamauchi-Kohno R, et al. **Circulation** 1999 Apr 27;99(16):2171–6

Renal and metabolic effects of L-arginine infusion in kidney transplant recipients. Zhang XZ, et al. **Clin Nephrol** 1999 Jul;52(1):37–43

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Angst MS, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):499–510

Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. Leenen FH, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):522–35

Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Muir DF, et al. **Clin Pharmacol Ther** 1999 Jul;66(1):85–90

Chronic infusions of brain natriuretic peptide in conscious sheep: bioactivity at low physiological levels. Charles CJ, et al. **Clin Sci (Colch)** 1998 Dec;95(6):701–8

Influences of carvedilol treatment on the effects of acetylcholine on regional haemodynamics in the spontaneously hypertensive rat. Granstam SO, et al. **Clin Sci (Colch)** 1998 Sep;95(3):303–9

Effect of long-term octreotide and isosorbide dinitrate on haemodynamics in rats with portal vein stenosis. Lin HC, et al. **Clin Sci (Colch)** 1998 Jun;94(6):645–50

Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. Wong F, et al. **Clin Sci (Colch)** 1999 May;96(5):467–74

Aldosterone blunts the baroreflex response in man [see comments] Yee KM, et al. **Clin Sci (Colch)** 1998 Dec; 95(6):687–92. Comment in: Clin Sci (Colch) 1998 Dec;95(6):647–8.

Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. **Crit Care Med** 1999 Mar;27(3):639–60 (197 ref.)

Selective inhibition of inducible nitric oxide synthase: effects on hemodynamics and regional blood flow in healthy and septic sheep. Booke M, et al. **Crit Care Med** 1999 Jan; 27(1):162–7

Optimizing liquid ventilation as a lung protection strategy for neonatal cardiopulmonary bypass: full functional residual capacity dosing is more effective than half functional residual capacity dosing [see comments] Cannon ML, et al. **Crit Care Med** 1999 Jun;27(6):1140–6. Comment in: Crit Care Med 1999 Jun;27(6):1052–3.

The hemodynamic effects of dobutamine infusion in the chronically instrumented newborn piglet [see comments] Cheung PY, et al. **Crit Care Med** 1999 Mar;27(3):558–64 . Comment in: Crit Care Med 1999 Mar;27(3):466–7.

Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Giebler R, et al. **Crit Care Med** 1999 Mar;27(3):597–604

Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients [see comments] Martin C, et al. **Crit Care Med** 1999 Sep;27(9):1708–13. Comment in: Crit Care Med 1999 Sep;27(9):2022–3.

The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects [see comments] Mathur VS, et al. **Crit Care Med** 1999 Sep;27(9):1832–7. Comment in: Crit Care Med 1999 Sep;27(9):2044–5.

Acadesine during fluid resuscitation from shock and abdominal sepsis [see comments] Melton SM, et al. **Crit Care Med** 1999 Mar;27(3):565–75 (46 ref.). Comment in: Crit Care Med 1999 Mar;27(3):468–9.

Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Mitaka C, et al. **Crit Care Med** 1999 Jan;27(1):146–53

Effects of adrenergic-receptor blockade and ligation of spleen vessels on the hemodynamics of dogs injected with scorpion venom [see comments] Tarasiuk A, et al. **Crit Care Med** 1999 Feb;27(2):365–72. Comment in: Crit Care Med 1999 Feb;27(2):250.

Hypertonic saline without or with dextran-70 in the treatment of experimental acute myocardial ischemia and reperfusion [see comments] Waagstein LM, et al. **Crit Care Med** 1999 Mar;27(3):605–16. Comment in: Crit Care Med 1999 Mar;27(3):475–6.

E. Coli bacteremia-induced changes in the skeletal muscle microcirculation vary with anesthetics. Lüebbe AS, et al. **Croat Med J** 1998 Dec;39(4):392–400

Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Shimoyama M, et al. **Diabetes** 1999 Mar;48(3):609–15

Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Yakubu-Madus FE, et al. **Diabetes** 1999 May; 48(5):1093–100

Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. Fabbri A, et al. **Dig Dis Sci** 1999 Feb;44(2):377–84

Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Sàbat M, et al. **Dig Dis Sci** 1998 Oct;43(10):2184–9

Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects. Chu KM, et al. **Drug Metab Dispos** 1999 Jun;27(6):701–9

Cardiovascular effects of hyperbaric oxygen with and without addition of carbon dioxide. Bergo GW, et al. **Eur J Appl Physiol** 1999 Sep;80(4):264–75

Tolerance to ACE inhibitors after cardiac surgery. Manché A, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):55–60

Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Fridman K, et al. **Eur J Clin Pharmacol** 1998 Sep;54(7):497–501

Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea. Heitmann J, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9–10):691–6

Haemodynamic and renal effects of felodipine in young and elderly subjects. Lernfelt B, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):595–601

No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers. Mores N, et al. **Eur J Clin Pharmacol** 1999 Jun;55(4):251–4

Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-1 in normal adults. Bisi G, et al. **Eur J Endocrinol** 1999 Apr; 140(4):322–7

Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Krowicki ZK, et al. **Eur J Pharmacol** 1999 Apr 29;371(2–3):187–96

The attenuated effect of ATP-sensitive K+ channel opener pinacidil on renal haemodynamics in spontaneously hypertensive rats. Mimuro T, et al. **Eur J Pharmacol** 1998 Oct 2;358(2):153–60

Cardiovascular effects of verapamil enantiomer combinations in conscious dogs. Pagel PS, et al. **Eur J Pharmacol** 1998 May 8;348(2–3):213–21

Cardiovascular effects of noradrenaline in hypovolemic haemorrhage: role of inducible nitric oxide synthase. Tabrizchi R. **Eur J Pharmacol** 1998 Nov 20; 361(2–3):227–34

Acute hemodynamic and renal effects of adrenomedullin in rats with aortocaval shunt. Willenbrock R, et al. **Eur J Pharmacol** 1999 Mar 19;369(2):195–203

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Yatsu T, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):239–46

The haemodynamic effects of iodinated water soluble radiographic contrast media: a review. Morcos SK, et al. **Eur J Radiol** 1998 Nov;29(1):31–46 (184 ref.)

The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair. Barry MC, et al. **Eur J Vasc Endovasc Surg** 1998 Oct;16(4):311–9

CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Jerabek I, et al. **Eur Neuropsychopharmacol** 1999 Jan;9(1–2):149–55

Cardiorespiratory efficacy of thrombolytic therapy in acute massive pulmonary embolism: identification of predictive factors. Michard F, et al. **Eur Respir J** 1999 Mar; 13(3):610–5

Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH. de Mey C. **Eur Urol** 1998;34 Suppl 2:18–28; discusion 47 (87 ref.)

Hemodynamic effect of the nitroxide superoxide dismutase mimics. Hahn SM, et al. **Free Radic Biol Med** 1999 Sep; 27(5–6):529–35

Peripheral cardiovascular actions of SR 58611 A, a beta 3-adrenoceptor agonist, in the dog: lack of central effect. Montastruc JL, et al. **Fundam Clin Pharmacol** 1999; 13(2):180–6

Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Poo JL, et al. **Gastroenterology** 1999 Jan;116(1):161–7

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease. Myreng Y, et al. **Heart** 1999 Sep;82(3):333–5

Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model. Usui T, et al. **Heart Vessels** 1998;13(2):49–57

Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Angeli P, et al. **Hepatology** 1998 Oct;28(4):937–43

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Angeli P, et al. **Hepatology** 1999 Jun;29(6):1690–7

Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Bañares R, et al. **Hepatology** 1999 Jul;30(1):79–83

Stimulation of the renin-angiotensin system by endothelin subtype A receptor blockade in conscious dogs. Berthold H, et al. **Hypertension** 1999 Jun;33(6):1420–4

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Brodsky S, et al. **Hypertension** 1998 Oct;32(4):746–52

Bradykinin stimulates tissue plasminogen activator release in human vasculature. Brown NJ, et al. **Hypertension** 1999 Jun;33(6):1431–5

Low calorie diet enhances renal, hemodynamic, and humoral

effects of exogenous atrial natriuretic peptide in obese hypertensives. Dessi-Fulgheri P, et al. **Hypertension** 1999 Feb;33(2):658–62

Raised cerebrovascular resistance in idiopathic orthostatic intolerance: evidence for sympathetic vasoconstriction. Jordan J, et al. **Hypertension** 1998 Oct;32(4):699–704

Cardiovascular effects of nociceptin in unanesthetized mice [published erratum appears in Hypertension 1999 May;33(5):1250] Madeddu P, et al. **Hypertension** 1999 Mar; 33(3):914–9

Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Pasquié JL, et al. **Hypertension** 1999 Mar;33(3):830–4

Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Sakata K, et al. **Hypertension** 1999 Jun; 33(6):1447–52

Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Strachan FE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):581–5

Peripheral hemodynamics evaluated by acceleration plethysmography in workers exposed to lead. Aiba Y, et al. **Ind Health** 1999 Jan;37(1):3–8

Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy. Hennersdorf MG, et al. **Int J Cardiol** 1999 Mar 15;68(3):289–95

Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers. Kähönen M, et al. **Int J Clin Pharmacol Ther** 1998 Sep;36(9):483–9

Gas exchange and pulmonary haemodynamic responses to fat emulsions in acute respiratory distress syndrome. Masclans JR, et al. **Intensive Care Med** 1998 Sep; 24(9):918–23

Long chain versus medium chain lipids in patients with ARDS: effects on pulmonary haemodynamics and gas exchange. Smirniotis V, et al. **Intensive Care Med** 1998 Oct;24(10):1029–33

Absence of cardiovascular adverse effects of sertraline in children and adolescents. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1999 May;38(5):573–7

Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. Havranek EP, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1174–81

Systemic effects and side effects of interstitial techniques used in liver tissue. Brunken C, et al. **J Am Coll Surg** 1999 Jun; 188(6):636–42

Effect of dobutamine stress on left ventricular systolic and diastolic functions in patients with moderate to severe left ventricular dysfunction. Daggubati RB, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):787–91

The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat. Champion HC, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S95–7

Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. Ottosson-Seeberger A, et al. **J Am Soc Nephrol** 1999 May;10(5):1037–44

Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. Caron A, et al. **J Appl Physiol** 1999 Feb;86(2):541–8

In vivo demonstration of alpha-adrenoceptor-mediated positive inotropy in pithed rats: evidence that noradrenaline does not stimulate myocardial alpha-adrenoceptors. Broadley KJ, et al. **J Auton Pharmacol** 1999 Feb; 19(1):55–63

Effects of phentolamine on tissue perfusion in pediatric cardiac surgery. Köner O, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):191–7

A novel alpha 2-adrenoceptor antagonist attenuates the early, but preserves the late cardiovascular effects of intravenous dexmedetomidine in conscious dogs. Pagel PS, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):429–34

Calcium chloride minimizes the hemodynamic effects of propofol in patients undergoing coronary artery bypass grafting. Tritapepe L, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):150–3

Effects of a bolus injection of adenosine triphosphate on atrioventricular conduction and hemodynamics in patients undergoing coronary artery bypass grafting. Watanabe S, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):181–5

Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure. Carville C, et al. **J Cardiovasc Pharmacol** 1998 Oct; 32(4):562–70

Enalapril improves arterial elastic properties in rats with myocardial infarction. Driss AB, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):102–7

Effects of the vasopressin V1 agonist [Phe2,Ile3,Orn8]] vasopressin on regional kidney perfusion and renal excretory function in anesthetized rabbits. Evans RG, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):571–81

Influence of FR 167653, an inhibitor of TNF-alpha and IL-1, on the cardiovascular responses to chronic infusion of lipopolysaccharide in conscious rats. Gardiner SM, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):64–9

Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. Herzer WA, et al. **J Cardiovasc Pharmacol** 1998 Nov; 32(5):769–76

Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. Hood S, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):89–94

Effect of ketanserin on central haemodynamics and coronary circulation. Hood S, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):983–7

Acadesine increases blood flow in the collateralized heart during exercise. Ishibashi Y, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):552–61

Combined effects of caffeine and alcohol on hemodynamics and coronary artery blood flow in dogs. Jain AC, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):49–55

Hemodynamic and hormonal responses to nicorandil in a canine model of acute ischemic heart failure: a comparison with cromakalim and nitroglycerin. Kamijo T, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):93–101

Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. Kieback AG, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):629–36

Long-term administration of atrial natriuretic peptide in patients with acute heart failure. Kitashiro S, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):948–52

Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. Milone SD, et al. **J Cardiovasc Pharmacol** 1999 May; 33(5):685–90

Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. Sugiyama A, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):70–7

Regional blood flow responses to acute ANG II infusion: effects of nitric oxide synthase inhibition. Symons JD, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):116–23

Comparative effects of oral clonidine and intravenous esmolol in attenuating the hemodynamic response to epinephrine injection. Campagni MA, et al. **J Clin Anesth** 1999 May;11(3):208–15

Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. Mildh LH, et al. **J Clin Anesth** 1999 Jun;11(4):310–6

Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study. Taylor AA, et al. **J Clin Pharmacol** 1999 May;39(5):471–9

Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. Andresen M, et al. **J Crit Care** 1998 Dec;13(4):164–8

IL-1ra administration does not improve cardiac function in patients with severe sepsis. Vincent JL, et al. **J Crit Care** 1999 Jun;14(2):69–72

Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Bisi G, et al. **J Endocrinol Invest** 1999 Apr;22(4):266–72

Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension [see comments] Chu CJ, et al. **J Hepatol** 1999 Jun;30(6):1105–11 . Comment in: J Hepatol 1999 Jun;30(6):1160–2.

Improvement in liver fibrosis, functionality and hemodynamics in CCl4-cirrhotic rats after injection of the Liver Growth Factor. Diaz-Gil JJ, et al. **J Hepatol** 1999 Jun;30(6):1065–72

Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. Hansen EF, et al. **J Hepatol** 1999 Mar;30(3):503–10

Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. Stanley AJ, et al. **J Hepatol** 1999 Mar;30(3):479–84

Haemodynamic and sympathetic effects of inhibition of nitric oxide synthase by systemic infusion of N(G)-monomethyl-L-arginine into humans are dose dependent. Lepori M, et al. **J Hypertens** 1998 Apr; 16(4):519–23

Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. Rhéaume C, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2085–9

Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. Susic D, et al. **J Hypertens** 1999 Aug;17(8):1209–15

The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions. Brittsan AG, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1725–37

Captopril treatment improves the sarcoplasmic reticular Ca(2+) transport in heart failure due to myocardial infarction. Shao Q, et al. **J Mol Cell Cardiol** 1999 Sep; 31(9):1663–72

Vasomotor response to CO2 and L-Arginine in patients with severe internal carotid artery stenosis; pre- and post-surgical evaluation with transcranial Doppler. Micieli G, et al. **J Neurol Sci** 1999 Mar 1;163(2):153–8

Effects of two calculated plasma sufentanil concentrations on the hemodynamic and bispectral index responses to Mayfield head holder application. Hans P, et al. **J Neurosurg Anesthesiol** 1999 Apr;11(2):81–5

The effect of magnesium sulfate on cerebral blood flow velocity, cardiovascular variables, and arterial carbon dioxide tension in awake sheep. Ludbrook GL, et al. **J Neurosurg Anesthesiol** 1999 Apr;11(2):96–101

Compensated shock and dopamine [letter; comment] Evans N, et al. **J Pediatr** 1999 Jul;135(1):135–6. Comment on: J Pediatr 1998 Dec;133(6):728–34.

Different contributions of the endothelin ET(A) receptor to hypertension induced by acute or chronic inhibition of nitric oxide synthesis. Hashimoto N, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1051–8

Clonidine evokes vasodepressor responses via alpha2-adrenergic receptors in gigantocellular reticular formation. Aicher SA, et al. **J Pharmacol Exp Ther** 1999 May;289(2):688–94

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Catella-Lawson F, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):735–41

Cardiopulmonary effects of the alpha2-adrenoceptor agonists medetomidine and ST-91 in anesthetized sheep. Celly CS, et al. **J Pharmacol Exp Ther** 1999 May;289(2):712–20

Central administration of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. Kapusta DR, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):173–80

O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. Lieberthal W, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1278–87

Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions. Locker GJ, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):43–50

Adrenoceptors mediating the cardiovascular and metabolic effects of alpha-methylnoradrenaline in humans. Schäfers RF, et al. **J Pharmacol Exp Ther** 1999 May;289(2):918–25

Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs. Tanahashi M, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1533–8

Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. van Schaick EA, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):21–30

Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and In vivo bladder instability in rat. Wojdan A, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1410–8

A pharmacological validation of radiotelemetry in conscious, freely moving rats. Deveney AM, et al. **J Pharmacol Toxicol Methods** 1998 Aug;40(2):71–9

The effect of nitrendipine on renal haemodynamics and tubular reabsorption and its neural control in anaesthetised rats with chronic renal failure. Manitius J, et al. **J Physiol Pharmacol** 1999 Mar;50(1):89–98

Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. Kovacich JC, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):154–62

A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. Mullis-Jansson SL, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1128–34

Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. Yuan TH, et al. **J Toxicol Clin Toxicol** 1999;37(4):463–74

The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. Soltero RG, et al. **J Trauma** 1999 Feb;46(2):286–91

Doppler sonography is a useful tool to assess the hemodynamic changes caused by ANG-II [letter; comment] Hirai M. **J Ultrasound Med** 1999 Apr;18(4):324 . Comment on: J Ultrasound Med 1998 Jun;17(6):357–68.

Haemodynamic effects of ATP in dogs during hypoxia-induced pulmonary hypertension. Driessen B, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):213–9

Endocrine and metabolic responses to plasma volume expansion during halothane anesthesia in ponies. Taylor PM. **J Vet Pharmacol Ther** 1998 Dec;21(6):485–90

Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Wimmer A, et al. **Jpn Heart J** 1999 May;40(3):321–34

The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats. Fujita H, et al. **Jpn J Pharmacol** 1998 Oct;78(2):229–32

The effects of preperitoneal carbon dioxide insufflation on cardiopulmonary function in pigs. Blaney MW, et al. **JSLS** 1999 Jan-Mar;3(1):49–55

Midazolam-fentanyl-isoflurane anaesthesia is suitable for haemodynamic and fluid balance studies in pigs. Husby P, et al. **Lab Anim** 1998 Jul;32(3):316–23

Prospects for therapy of nitrate tolerance [see comments] Glasser SP. **Lancet** 1999 May 8;353(9164):1545–6 (8 ref.) . Comment in: Lancet 1999 Jul 24;354(9175):338–9.

Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Hermann HP, et al. **Lancet** 1999 Apr 17;353(9161):1321–3

Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety. Molina PE, et al. **Life Sci** 1999;65(11):1175–82

Effects of 4-(4-bromophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride on acute gastric lesions, acid secretion in rats and on some hemodynamic parameters in cats. Atanassova R, et al.

Methods Find Exp Clin Pharmacol 1999 Jan-Feb; 21(1):39-46

Block distribution and cardiovascular effects of unilateral spinal anaesthesia by 0.5% hyperbaric bupivacaine. A clinical comparison with bilateral spinal block. Casati A, et al. **Minerva Anestesiol** 1998 Jul-Aug;64(7-8):307-12

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Hemmelder MH, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):98-104

Hemodynamic effects of recombinant human erythropoietin [editorial] Buemi M, et al. **Nephron** 1999 Jan;81(1):1-4 (21 ref.)

Effect of N-methyl-D-aspartate receptor blockade on the control of cerebral O2 supply/consumption balance during hypoxia in newborn pigs. Williams JA, et al. **Neurochem Res** 1998 Sep;23(9):1139-45

Cardiovascular effects produced by nitric oxide-related drugs in the caudal ventrolateral medulla. Lage RC, et al. **Neuroreport** 1999 Mar 17;10(4):731-5

Systemic NO synthase inhibition blunts the chronotropic, but not the inotropic response to isoprenaline in man. Schmetterer L, et al. **Nitric Oxide** 1999 Jun;3(3):209-15

Haemodynamic improvement in a child with meningococcal sepsis following methylprednisolone: restoration of beta-adrenergic receptor responsiveness? O'Brien K, et al. **Paediatr Anaesth** 1998;8(5):419-20

Adverse hemodynamic effects observed with inhaled nitric oxide after surgical repair of total anomalous pulmonary venous return. Rosales AM, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):224-6

Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Meadow W, et al. **Pediatr Res** 1998 Aug;44(2):181-6

Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Beck JR, et al. **Perfusion** 1999 Jan;14(1):37-42

The influence of lidocaine and verapamil on haemodynamic parameters after intravenous administration of midazolam in rabbits. Wiktorowska A, et al. **Pharmacol Res** 1999 Jun; 39(6):421-9

Acute hemodynamic effects of tetramethylpyrazine and tetrandrine on cirrhotic rats. Huang YT, et al. **Planta Med** 1999 Mar;65(2):130-4

Changes in the gastrointestinal tract, cardiovascular function and some drug metabolizing processes in rats and guinea-pigs intoxicated with aflatoxin B1. Stětinová V, et al. **Pol J Pharmacol** 1998 Mar-Apr;50(2):135-41

Cardiac output in four-, five-, and six-week-old broilers, and hemodynamic responses to intravenous injections of epinephrine. Wideman RF Jr. **Poult Sci** 1999 Mar; 78(3):392-403

Prophylactic octreotide reduces the severity of histopathologic changes and hemodynamic shock in early taurodeoxycholate-induced experimental pancreatitis. Chen CC, et al. **Proc Natl Sci Counc Repub China B** 1999 Jan;23(1):1-6

Impedance cardiography-derived hemodynamic responses during baroreceptor testing with amyl nitrite and phenylephrine: a validity and reliability study. Nelesen RA, et al. **Psychophysiology** 1999 Jan;36(1):105-8

Atrial natriuretic peptide as a preload depressor in acute renal failure secondary to congestive heart failure. Seta K, et al. **Ren Fail** 1998 Sep;20(5):717-23

Pituitary-adrenocortical effects of methoxamine infusion on halothane anaesthetised ponies. Brodbelt DC, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):119-23

Hemodynamic effects of 8-day DL-028 and octreotide administration in rats with portal hypertension. Huang YT, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1303-9

L-arginine and endothelin receptor antagonist bosentan counteract hemodynamic effects of modified hemoglobin. Fischer SR, et al. **Shock** 1999 Apr;11(4):283-90

CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS. Molina PE, et al. **Shock** 1998 Nov; 10(5):329-34

Hemodynamic and metabolic responses to repeated hemorrhage and resuscitation with hypertonic saline dextran in conscious swine. O'Benar JD, et al. **Shock** 1998 Sep;10(3):223-8

Central and regional hemodynamics during uncontrolled bleeding using hypertonic saline dextran for resuscitation. Riddez L, et al. **Shock** 1998 Sep;10(3):176-81

3-Aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock. Szabó A, et al. **Shock** 1998 Nov;10(5):347-53

The effects of a new ultra-short-acting beta-adrenergic blocker, ONO-1101, on cardiac function during and after cardiopulmonary bypass. Ahmet I, et al. **Surg Today** 1999; 29(3):248-54

The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation. Akasaka S, et al. **Surg Today** 1999;29(8):747-54

Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Eriksson M, et al. **Thromb Haemost** 1998 Dec;80(6):1022-6

Cardiovascular effects of acute and chronic cocaine administration in pregnant and nonpregnant rabbits. Sutliff RL, et al. **Toxicol Appl Pharmacol** 1999 Aug 1; 158(3):278-87

Value of sequential big endothelin plasma concentrations to predict rapid worsening of chronic heart failure. Stanek B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):155-7

Effect of lazaroid U-74389G on lung ischemia-reperfusion injury. Takeyoshi I, et al. **Transplant Proc** 1998 Nov; 30(7):3364-5

Effects of adenosine on dopamine-induced hepatic impairment in the dog model. Tanaka H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):445-6

Hemodynamic effects of medetomidine in the dog: a dose titration study. Pypendop BH, et al. **Vet Surg** 1998 Nov-Dec;27(6):612-22

Effects of subarachnoid xylazine and medetomidine on haemodynamics and ECG in goats. Kinjavdekar P, et al. **Zentralbl Veterinarmed A** 1999 Jul;46(5):271-5

[The effect of spinal analgesia on the hemodynamic indices in cesarean section] Dukanov M, et al. **Akush Ginekol (Sofiia)** 1998;37(2):11-5 (Eng. Abstr.) **(Bul)**

[Effects of ligustrazine on hemodynamics in chronic pulmonary heart disease patients] Wei DG, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Dec; 16(12):730-2 **(Chi)**

[Effects of captopril on the myocardial performances and hemodynamics after cardiac arrest] Guo X, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Jun; 19(3):212-6 (Eng. Abstr.) **(Chi)**

[Prevention of arterial hypotension during spinal anesthesia using intramuscular ephedrine in older people] Di Roio C, et al. **Ann Fr Anesth Reanim** 1997;16(5):483-7 (Eng. Abstr.) **(Fre)**

[Effect of local anesthetics on hemodynamic effects during Mayfield skull clamp fixation in neurosurgery using total intravenous anesthesia] Schaffranietz L, et al. **Anaesthesiol Reanim** 1999;24(2):51-4 (Eng. Abstr.) **(Ger)**

[Circulatory function and oxygenation during hemihepatectomy. Dopamine versus dopexamine] Höltje M, et al. **Anaesthesist** 1999 Apr;48(4):224-30 (Eng. Abstr.) **(Ger)**

[Hemodynamic effects of a ventriculo-cisternal perfusion of bupivacaine] Schäfer MK, et al. **Anaesthesist** 1999 Apr; 48(4):218-23 (Eng. Abstr.) **(Ger)**

[Remifentanil in gynecologic laparoscopy. A comparison of consciousness and circulatory effects of a combination with desflurane and propofol] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):552-6 (Eng. Abstr.) **(Ger)**

[Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease] Bickel C, et al. **Med Klin** 1999 Feb 15;94(2):67-73 (Eng. Abstr.) **(Ger)**

[Pharmacological stress echocardiography--a new non-invasive follow-up examination of intermittent ventilation] Herth F, et al. **Med Klin** 1999 Apr;94(1 Spec No):32-4 (Eng. Abstr.) **(Ger)**

[New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)] Kapl D, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):317-21 (26 ref.) (Eng. Abstr.) **(Ger)**

[Sevoflurane (SEVOrane) as an inhalation anesthetic in dogs in comparison with halothane and isoflurane] Tacke S, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Nov; 26(6):369-77 (Eng. Abstr.) **(Ger)**

[Hemodynamic effects of a single intravenous administration of prostaglandin E1 in a patient sample with chronic NYHA-stage II/III heart failure] Schrader N, et al. **Z Kardiol** 1998 Sep;87(9):683-90 (Eng. Abstr.) **(Ger)**

[The hemodynamic effects of the in-vivo administration of insulin-like growth-factor I] Gaspari A, et al. **Minerva Chir** 1998 Sep;53(9):691-9 (Eng. Abstr.) **(Ita)**

[Variations in hemodynamic parameters in patients under general anesthesia undergoing submucosal infiltration with a mixture of local anesthetic and adrenaline] Santoro V, et al. **Minerva Stomatol** 1998 Dec;47(12):649-53 (Eng. Abstr.) **(Ita)**

[Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting] Marui A, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1112-6 (Eng. Abstr.) **(Jpn)**

[Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog] Fujishima K, et al. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):371-80 (Eng. Abstr.) **(Jpn)**

[Use of serotonin adipinate in combined therapy of hemodynamic disorders in acute poisoning by psychopharmacological preparations] Il'iashenko KK, et al. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):36-8 (Eng. Abstr.) **(Rus)**

[The pharmacological correction of hemodynamics during the simulation of the early period of adaptation to weightlessness] Shashko VS, et al. **Aviakosm Ekolog Med** 1999;33(3):3-8 (Eng. Abstr.) **(Rus)**

[Effect of the gamma-aminobutyric acid derivative, TZ-50-2, on the systemic and cardiac hemodynamics, and the size of myocardial necrosis area] Galenko-Iaroshevskii PA, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):662-5 **(Rus)**

[Synthesis and hemodynamic effects of the new inhibitor of endothelin converting enzyme] Pozdnev VF, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):526-9 **(Rus)**

[Taurine administration for prevention of changes in the systemic hemodynamics] Sapronov NS, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):282-4 **(Rus)**

[Effect of various doses of high molecular weight polyethylene oxide and polyacrylamide on hemodynamics of anesthesized rats] Grigorian SS, et al. **Dokl Akad Nauk** 1998 Dec;363(4):565-6 **(Rus)**

[Cardio-hemodynamic effects of domestic adrenergic beta-antagonist proxodolol in hypertension in patients with pacemaker] Iskenderov BG, et al. **Klin Med (Mosk)** 1999; 77(4):29-31 (Eng. Abstr.) **(Rus)**

[The effect of diltiazem on the systemic hemodynamics of patients with heart failure due to ischemic heart disease] Koshlia EV. **Lik Sprava** 1998 Dec;(8):97-9 (Eng. Abstr.) **(Rus)**

[Changes in parameters of the systemic hemodynamics during combined action of humoral stimuli exerting various effects on arterial pressure] Evlakhov VI, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Sep;84(9):845-52 (Eng. Abstr.) **(Rus)**

[Effects of fenigidin treatment regimen on the state of peripheral hemodynamics of patients with stable effort angina pectoris and postinfarction cardiosclerosis] Boev SS. **Ter Arkh** 1998;70(12):17-9 (Eng. Abstr.) **(Rus)**

[Adalat effects on clinical course of coronary heart disease, peripheral circulation and myocardial perfusion in patients with stenosing coronary atherosclerosis] Garganeeva AA, et al. **Ter Arkh** 1998;70(9):61-3 (Eng. Abstr.) **(Rus)**

[Effect of local hypotensive therapy on ocular hemodynamics in patients with primary open-angle glaucoma] Bakshinskii PP. **Vestn Oftalmol** 1999 Jan-Feb;115(1):8-10 (Eng. Abstr.) **(Rus)**

[Cardiovascular effects of induction doses of the intravenous anesthetics, propofol, etomidate and thiopentone] Djordjević B, et al. **Vojnosanit Pregl** 1999 Jan-Feb; 56(1):15-9 (Eng. Abstr.) **(Scc)**

[Nitric oxide as a regulator of hemodynamic changes in pregnancy] Genoveva Durán-Reyes MO, et al. **Ginecol Obstet Mex** 1999 Jan;67:29-36 (35 ref.) (Eng. Abstr.) **(Spa)**

[Inhalation administration of nitric oxide during selective pulmonary ventilation decreases the intrapulmonary shunt] del Barrio E, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul; 46(6):247-51 (Eng. Abstr.) **(Spa)**

[Cardiocirculatory effects of intravenous anesthetic induction in an experimental model of acute hypovolemia] Errando CL, et al. **Rev Esp Anestesiol Reanim** 1998 Oct;45(8):333-9 (Eng. Abstr.) **(Spa)**

[Effect of etomidate and thiopental on the onset of rocuronium action] Muñoz Letelier H, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul;46(6):252-5 (Eng. Abstr.) **(Spa)**

[Evaluation of the hemodynamic effects of tumor necrosis factor alpha factor in rats with portal hypertension using the radioactive microsphere technique] Pérez-Páramo M, et al. **Rev Esp Med Nucl** 1998;17(4):294-301 (Eng. Abstr.) **(Spa)**

[The effect of membrane channel agonists and antagonists on hemodynamics and vascular tonus] Shevchuk VH, et al. **Fiziol Zh** 1999;45(1-2):35-9 (Eng. Abstr.) **(Ukr)**

[The hemodynamic status of patients with ischemic heart disease under long-term treatment with calcium antagonists] Bychko MV. **Lik Sprava** 1999 Apr-May; (3):62-5 **(Ukr)**

[The effect of kavinton and korglycon on the central and cerebral hemodynamics of patients with an ischemic stroke in stenoses and occlusions of the major cerebral arteries] Ishchenko MM, et al. **Lik Sprava** 1998 Aug;(6):120-4 (Eng. Abstr.) **(Ukr)**

GENETICS

Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Kojda G, et al. **Cardiovasc Res** 1999 Apr;42(1):206-13

Parental hyperdynamic circulation predicts insulin resistance in offspring: The Tecumseh Offspring Study. Palatini P, et al. **Hypertension** 1999 Mar;33(3):769-74

PHYSIOLOGY

The pathophysiology of the acute compartment syndrome. Tollens T, et al. **Acta Chir Belg** 1998 Aug;98(4):171-5 (11 ref.)

Cerebral hemodynamic changes during sustained hypocapnia in severe head injury: can hyperventilation cause cerebral ischemia? Ausina A, et al. **Acta Neurochir Suppl (Wien)** 1998;71:1-4

Multimodal hemodynamic neuromonitoring--quality and consequences for therapy of severely head injured patients. Meixensberger J, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:260-2

Morphological and hemodynamic evaluations by means of transcranial power Doppler imaging in patients with severe head injury. Shiogai T, et al. **Acta Neurochir Suppl (Wien)** 1998;71:94-100

Intellectual functions and regional cerebral haemodynamics after extensive omental transplantation spread over both frontal lobes in childhood moyamoya disease. Ohtaki M, et al. **Acta Neurochir (Wien)** 1998;140(10):1043-53; discussion 1052-3

Effect of cerebral ischaemia on the cerebrovascular and

cardiovascular response to haemorrhage. Rise IR, et al. **Acta Neurochir (Wien)** 1998;140(7):699–705; discussion 705–6

Cerebral infarct following carotid endarterectomy. Frequency, clinical and hemodynamic significance evaluated by MRI and TCD. Enevoldsen EM, et al. **Acta Neurol Scand** 1999 Aug;100(2):106–10

Haemodynamic influence and endothelin-1 plasma concentrations by selective or non-selective endothelin receptor antagonists in the pig in vivo. Holm P, et al. **Acta Physiol Scand** 1999 Feb;165(2):163–8

Hemodynamic effects of middle cerebral artery stenosis and occlusion. Derdeyn CP, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1463–9

Small rosarylike infarctions in the centrum ovale suggest hemodynamic failure. Krapf H, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1479–84

M-mode analysis of mitral annulus motion for detection of pseudonormalization of the mitral inflow pattern. Bruch C, et al. **Am J Cardiol** 1999 Sep 15;84(6):692–7

Reproducibility of cardiopulmonary exercise testing in elderly patients with congestive heart failure. Marburger CT, et al. **Am J Cardiol** 1998 Oct 1;82(7):905–9

Influence of left ventricular cavity size on interventricular shunt timing and outcome in neonates with coarctation of the aorta and ventricular septal defect. Tani LY, et al. **Am J Cardiol** 1999 Sep 15;84(6):750–2, A9

Systemic hemodynamic changes in mansonic schistosomiasis with portal hypertension treated by azygoportal disconnection and splenectomy. de Cleva R, et al. **Am J Gastroenterol** 1999 Jun;94(6):1632–7

Serial changes in cardiovascular and renal function of rabbits ingesting a high-fat, high-calorie diet. Antic V, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):826–9

Altered sympathetic and vagal modulations of the cardiovascular system in patients with pheochromocytoma: their relations to orthostatic hypotension. Munakata M, et al. **Am J Hypertens** 1999 Jun;12(6):572–80

Hemodynamic stability during dialysis and cardiovascular disease in end-stage renal disease patients. Henrich WL. **Am J Kidney Dis** 1999 Jun;33(6):XLIX–LII (7 ref.)

Vascular endothelium, hemodynamic forces, and atherogenesis [comment] Gimbrone MA Jr. **Am J Pathol** 1999 Jul;155(1):1–5 (38 ref.). Comment on: Am J Pathol 1999 Jul;155(1):85–92.

Dissociation between regional dysfunction and beta-adrenergic receptor signaling in heart failure. Anzai T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1267–73

Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. Audoly LP, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H924–30

Hemodynamic and hormonal responses to hemorrhage in conscious rabbits at mid- and late gestation. Brooks VL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1082–90

Effect of treadmill exercise on transmural distribution of blood flow in hypertrophied left ventricle. Duncker DJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1274–82

Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50). Eichelbrönner O, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H290–8

Responses of muscle sympathetic nerve activity to lower body positive pressure. Fu Q, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1254–9

Role of angiotensin II in modulating the hemodynamic effects of nitric oxide synthesis inhibition. Hernández I, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R104–11

C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats. Klinger JR, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L645–52

Evidence for increased cardiac compliance during exposure to simulated microgravity. Koenig SC, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1343–52

NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. Liu P, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2191–8

Effects of sustained flow reduction on postnatal intestinal circulation. Nowicki PT. **Am J Physiol** 1998 Oct;275(4 Pt 1):G758–68

Mutual information discloses relationship between hemodynamic variables in artificial heart-implanted dogs. Osaka M, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1419–33

Hemodynamics of gastric microcirculation in rats. Peti-Peterdi J, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1404–10

Sensitivity of canine intrinsic cardiac neurons to H2O2 and hydroxyl radical. Thompson GW, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1434–40

Right heart catheterization in acute lung injury: an observational study. Marinelli WA, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):69–76

Cardiopulmonary effects of the laparoscopic pneumoperitoneum in a porcine model of adult respiratory distress syndrome. Greif WM, et al. **Am J Surg** 1999 Mar;177(3):216–21

Anesthesia of horses with a combination of detomidine, zolazepam, tiletamine, and isoflurane immediately after strenuous treadmill exercise. Rankin DC, et al. **Am J Vet Res** 1999 Jun;60(6):743–8

Hemodynamic effects of thyroidectomy in sedentary horses. Vischer CM, et al. **Am J Vet Res** 1999 Jan;60(1):14–21

The hemodynamic effects of pneumoperitoneum during laparoscopic surgery in healthy infants: assessment by continuous esophageal aortic blood flow echo Doppler [letter; comment] de Waal EE. **Anesth Analg** 1999 Feb;88(2):468–9. Comment on: Anesth Analg 1998 Feb;86(2):290–3.

Hemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Joris JL, et al. **Anesth Analg** 1999 Jan;88(1):16–21

Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery [see comments] Reich DL, et al. **Anesth Analg** 1999 Oct;89(4):814–22. Comment in: Anesth Analg 1999 Oct;89(4):811–3.

Early hemodynamic changes following emergency mitral valve replacement for traumatic mitral insufficiency following balloon mitral valvotomy: report of six cases. Tempe DK, et al. **Anesthesiology** 1998 Dec;89(6):1583–5

Rapid changes in the coagulant proteins on saphenous vein endothelium in response to arterial flow. Golledge J, et al. **Angiology** 1999 Sep;50(9):693–701

Accuracy of computational hemodynamics in complex arterial geometries reconstructed from magnetic resonance imaging. Moore JA, et al. **Ann Biomed Eng** 1999 Jan–Feb;27(1):32–41

Desflurane anesthesia inhibits fever in humans. Negishi C, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:286–8

Microcirculatory hemodynamics during the acute phase of free vascularized muscle allograft rejection. Siemionow M, et al. **Ann Plast Surg** 1998 Sep;41(3):275–82

Abnormal autonomic cardiovascular control in ankylosing spondylitis. Toussirot E, et al. **Ann Rheum Dis** 1999 Aug;58(8):481–7

Clinical and hemodynamic performance of the Freestyle aortic root bioprosthesis. Cartier PC, et al. **Ann Thorac Surg** 1999 Feb;67(2):345–9; discussion 349–51

Hemodynamic features of the freestyle aortic bioprosthesis compared with stented bioprosthesis. Dumesnil JG, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S130–3

The mosaic bioprosthesis in the aortic position: hemodynamic performance after 2 years. Eichinger WB, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S126–9

Left ventricular assist system as a bridge to myocardial recovery. Frazier OH, et al. **Ann Thorac Surg** 1999 Aug;68(2):734–41

Monitoring of venous hemodynamics in patients with cerebral venous thrombosis by transcranial Doppler ultrasound. Valdueza JM, et al. **Arch Neurol** 1999 Feb;56(2):229–34

Effects of PEEP on systemic venous capacitance. Lambermont B, et al. **Arch Physiol Biochem** 1998 Aug;105(4):373–8

Structural, functional, and hemodynamic changes of the common carotid artery with age in male subjects. Schmidt-Trucksäss A, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):1091–7

Hemodynamics and mitochondrial energy metabolism in right heart hypertrophy after acute hypoxic stress. Thürich T, et al. **Arzneimittelforschung** 1999 Mar;49(3):212–20

Female exposure to high G: echocardiographic evaluation for chronic changes in cardiac function. Albery WB, et al. **Aviat Space Environ Med** 1998 Sep;69(9):857–61

A Simulink model for the human circulatory system. Wabel P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:314–5

Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Luik AJ, et al. **Blood Purif** 1998;16(4):197–209

Effect of graft reperfusion on haemodynamics and gas exchange during liver transplantation. Walsh TS, et al. **Br J Anaesth** 1998 Sep;81(3):311–6

"Living high and training low" can improve sea level performance in endurance athletes. Stray-Gundersen J, et al. **Br J Sports Med** 1999 Jun;33(3):150–1

Personality and tonic cardiovascular, neuroendocrine, and immune parameters. Miller GE, et al. **Brain Behav Immun** 1999 Jun;13(2):109–23

Cerebral oxygenation and hemodynamics during hyperventilation and sleep in patients with Rett syndrome. Murakami Y, et al. **Brain Dev** 1998 Dec;20(8):574–8

Collateral hemodynamics after middle cerebral artery occlusion in Wistar and Fischer-344 rats. Herz RC, et al. **Brain Res** 1998 May 18;793(1–2):289–96

Spinal block levels and cardiovascular changes during post-Cesarean transport. Bandi E, et al. **Can J Anaesth** 1999 Aug;46(8):736–40

Transfer function analysis of the circulation in patients undergoing sevoflurane anesthesia. Fujiwara Y, et al. **Can J Anaesth** 1999 Sep;46(9):820–6

Gender differences in cardiovascular and catecholamine responses to cold-air exposure at rest. Pettit SE, et al. **Can J Appl Physiol** 1999 Apr;24(2):131–47

Respiratory, cardiovascular, and metabolic adjustments to hypoxemia during sleep in piglets. Côté A, et al. **Can J Physiol Pharmacol** 1998 Jul–Aug;76(7–8):747–55

Cause and treatment of symptomatic steals following the insertion of haemodialysis shunts [letter] Dodds SR. **Cardiovasc Surg** 1998 Dec;6(6):657–9

Hemodynamic rounds series II: hemodynamic evaluation of a stenotic bioprosthetic mitral valve. Azrak E, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):70–5

Hemodynamic rounds series II: hemodynamics of dual-chamber pacing and valsalva maneuver in a patient with hypertrophic obstructive cardiomyopathy. Kern MJ, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):438–42

Hemodynamic rounds series II: hemodynamics of constrictive physiology: influence of respiratory dynamics on ventricular pressures. Higano ST, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):473–86

Catheter-based fixation of the mitral valve after acute papillary muscle rupture: a new technique for temporary hemodynamic stabilization [see comments] Sochman J, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):446–9. Comment in: Catheter Cardiovasc Interv 1999 Apr;46(4):450–1.

Effects of subcortical cerebrovascular lesions on cortical hemodynamic parameters assessed by perfusion magnetic resonance imaging. Nighoghossian N, et al. **Cerebrovasc Dis** 1999 May–Jun;9(3):136–41

Superior predictor of the hemodynamic response to fluid challenge in critically ill patients [letter; comment] Cheatham ML, et al. **Chest** 1998 Oct;114(4):1226–7. Comment on: Chest 1998 Apr;113(4):1048–54.

Intraoperative fluid management--what and how much? Rosenthal MH. **Chest** 1999 May;115(5 Suppl):106S–112S (32 ref.)

Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. Hickey MJ, et al. **Circ Res** 1998 Nov 30;83(11):1124–31

Hemodynamic effects of direct biventricular compression studied in isovolumic and ejecting isolated canine hearts. Artrip JH, et al. **Circulation** 1999 Apr 27;99(16):2177–84

Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. Brookes CI, et al. **Circulation** 1998 Oct 27;98(17):1762–8

Hemodynamic effects of basal and stimulated release of endogenous nitric oxide in isolated human lungs. Cremona G, et al. **Circulation** 1999 Sep 21;100(12):1316–21

Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. Xi L, et al. **Circulation** 1999 Apr 27;99(16):2157–63

Peculiar blood volume profile during hemodiafiltration therapy: of benefit to the hemodynamic stability in patients? [letter] Kawabata M, et al. **Clin Nephrol** 1998 Nov;50(5):333–4

The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. van der Sande FM, et al. **Clin Nephrol** 1998 Nov;50(5):301–8

Reproducibility of the alterations in circulation and cerebral oxygenation from supine rest to head-up tilt. Houtman S, et al. **Clin Physiol** 1999 Mar;19(2):169–77

Cardiovascular response during head-up tilt in chronic fatigue syndrome. LaManca JJ, et al. **Clin Physiol** 1999 Mar;19(2):111–20

Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. Edwards CM, et al. **Clin Sci (Colch)** 1999 Jun;96(6):577–88

Cardiovascular control and plasma catecholamines during rest and mental stress: effects of posture. Tulen JH, et al. **Clin Sci (Colch)** 1999 Jun;96(6):567–76

Death in a hobble restraint [letter; comment] Röggla G, et al. **CMAJ** 1999 Jul 13;161(1):21. Comment on: CMAJ 1998 Jun 16;158(12):1603–7.

A software package for non-invasive, real-time beat-to-beat monitoring of stroke volume, blood pressure, total peripheral resistance and for assessment of autonomic function. Gratze G, et al. **Comput Biol Med** 1998 Mar;28(2):121–42

The combination of magnetic resonance angiography and computational fluid dynamics: a critical review. Long Q, et al. **Crit Rev Biomed Eng** 1998;26(4):227–74 (125 ref.)

Noninvasive evaluation of hemodynamics by Doppler echocardiography. Nagueh SF. **Curr Opin Cardiol** 1999 May;14(3):217–24 (43 ref.)

Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Rattigan S, et al. **Diabetes** 1999 Mar;48(3):564–9

Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection. Deplano A, et al. **Dig Dis Sci** 1999 Jan;44(1):155–62

Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Genesca J, et al. **Dig Dis Sci** 1999 Feb;44(2):372–6

Apoptosis induced by lack of hemodynamic forces is a general endothelial feature even occuring in immortalized cell lines. Kaiser D, et al. **Endothelium** 1999;6(4):325–34

Cerebral hemodynamic response to generalized spike-wave discharges. Diehl B, et al. **Epilepsia** 1998 Dec;39(12):1284–9

Metabolic and cardioventilatory responses during a graded exercise test before and 24 h after a triathlon. Le Gallais D, et al. **Eur J Appl Physiol** 1999 Jan;79(2):176–81

Influence of intact left atrial appendage on hemodynamic parameters of isolated guinea pig heart. Massoudy P, et al. **Eur J Med Res** 1998 Oct 14;3(10):470–4

Dynamics of fetal circulatory responses to hypoxia and asphyxia. Jensen A, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jun;84(2):155–72 (136 ref.)

Haemodynamic consequences of phototherapy in term

infants. Benders MJ, et al. **Eur J Pediatr** 1999 Apr; 158(4):323–8

Central haemodynamics in experimental acute pancreatitis. Kinnala PJ, et al. **Eur J Surg** 1999 Jun;165(6):598–603

New insights into perforator vein incompetence. Labropoulos N, et al. **Eur J Vasc Endovasc Surg** 1999 Sep;18(3):228–34

Primary superficial vein reflux with competent saphenous trunk. Labropoulos N, et al. **Eur J Vasc Endovasc Surg** 1999 Sep;18(3):201–6

Blood flow in distal end-to-side anastomoses with PTFE and a venous patch: results of an in vitro flow visualisation study. Noori N, et al. **Eur J Vasc Endovasc Surg** 1999 Sep; 18(3):191–200

Cardiovascular and catecholamine responses during endovascular and conventional abdominal aortic aneurysm repair. Thompson JP, et al. **Eur J Vasc Endovasc Surg** 1999 Apr;17(4):326–33

Axial flow fields in cuffed end-to-side anastomoses: effect of angle and disease progression. Wijesinghe LD, et al. **Eur J Vasc Endovasc Surg** 1999 Sep;18(3):240–4

CT of hemodynamically unstable abdominal trauma. Petridis A, et al. **Eur Radiol** 1999;9(2):250–5

The haemodynamic response to exercise in chronic obstructive pulmonary disease: assessment by impedance cardiography. Bogaard HJ, et al. **Eur Respir J** 1998 Aug; 12(2):374–9

Central hemodynamic changes in experimental muscle crush injury in pigs. Rawlins M, et al. **Eur Surg Res** 1999; 31(1):9–18

Effects of selective nitric oxide synthase inhibition in hyperdynamic endotoxemia in dogs. Wolfárd A, et al. **Eur Surg Res** 1999;31(4):314–23

Cardiovascular function and brain metabolites in normal weight and intrauterine growth restricted newborn piglets--effect of mild hypoxia. Bauer R, et al. **Exp Toxicol Pathol** 1998 Sep;50(4–6):294–300

The influence of simultaneous intra-aortic balloon pumping and mechanical ventilation on hemodynamic parameters--numerical simulation. Darowski M, et al. **Front Med Biol Eng** 1999;9(2):155–74

Rheologic analysis of gastric mucosal hemodynamics in patients with cirrhosis. Masuko E, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):371–9

The pathophysiology of advanced heart failure. Baig MK, et al. **Heart Lung** 1999 Mar-Apr;28(2):87–101 (164 ref.)

Psychophysiological manifestations of anxiety in patients undergoing electrophysiology studies. Cupples SA, et al. **Heart Lung** 1998 Nov-Dec;27(6):374–86

The effects of nitric oxide on shock caused by temporary hepatic inflow occlusion in pigs. Saito A, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):436–42

Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Lotterer E, et al. **Hepatology** 1999 Mar;29(3):632–9

Event-related fMRI and the hemodynamic response. Buckner RL. **Hum Brain Mapp** 1998;6(5–6):373–7

Convergent approaches to electrophysiological and hemodynamic investigations of memory. Rugg MD. **Hum Brain Mapp** 1998;6(5–6):394–8 (10 ref.)

Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. Alexander BT, et al. **Hypertension** 1999 Jan;33(1 Pt 2):435–9

beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Gratze G, et al. **Hypertension** 1999 Jun; 33(6):1425–30

Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension. Higashi Y, et al. **Hypertension** 1999 Jan;33(1 Pt 2):591–7

Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Susic D, et al. **Hypertension** 1999 Jan;33(1 Pt 2):451–5

Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Zhuo J, et al. **Hypertension** 1999 Jan;33(1 Pt 2):347–53

Cardiac nociception induced rectal response: relation with haemodynamic changes. Koley J, et al. **Indian J Physiol Pharmacol** 1998 Apr;42(2):259–65

Hemodynamic properties of the hemopump HP14. Lachat M, et al. **Int J Artif Organs** 1999 Mar;22(3):155–9

Haemodynamic changes in patients undergoing high-risk PTCA under protection of transfemoral heart- lung machine support with centrifugal pumps. Waldenberger FR, et al. **Int J Artif Organs** 1998 Dec;21(12):809–13

Balloon mitral valvuloplasty: comparison of haemodynamic and echocardiographic assessment of mitral stenosis at different heart rates in the catheterisation laboratory. Harcombe AA, et al. **Int J Cardiol** 1999 Mar 15;68(3):253–9

Central adiposity and hemodynamic functioning at rest and during stress in adolescents [published erratum appears in Int J Obes Relat Metab Disorder 1999 Feb;23(2):220] Barnes VA, et al. **Int J Obes Relat Metab Disord** 1998 Nov;22(11):1079–83

Self presentation and cardiovascular reactivity. Hartley TR, et al. **Int J Psychophysiol** 1999 Apr;32(1):75–88

Cardiovascular and metabolic responses during 30 minutes of treadmill exercise shortly after consuming a small, high-carbohydrate meal. Diboll DC, et al. **Int J Sports Med** 1999 Aug;20(6):384–9

Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Tilton RG, et al. **Invest Ophthalmol Vis Sci** 1999 Mar; 40(3):689–96

Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction [see comments] Cowburn PJ, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):932–8. Comment in: J Am Coll Cardiol 1999 Mar 15;33(4):939–42.

Three-dimensional color Doppler: a clinical study in patients with mitral regurgitation. De Simone R, et al. **J Am Coll Cardiol** 1999 May;33(6):1646–54

Hemodynamic changes induced by laparoscopy and their endocrine correlates: effects of clonidine. Joris JL, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1389–96

Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. Metra M, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):943–50

Renin-angiotensin system dependence of renal hemodynamics in mice. Traynor TR, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S184–8

Baroreceptor-mediated compensation for hemodynamic effects of positive end-expiratory pressure. Blevins SS, et al. **J Appl Physiol** 1999 Jan;86(1):285–93

Mechanisms of acute cardiovascular response to periodic apneas in sedated pigs. Chen L, et al. **J Appl Physiol** 1999 Apr;86(4):1236–46

Role of muscular factors in cardiorespiratory responses to static exercise: contribution of reflex mechanisms. Iellamo F, et al. **J Appl Physiol** 1999 Jan;86(1):174–80

Impaired capillary hemodynamics in skeletal muscle of rats in chronic heart failure. Kindig CA, et al. **J Appl Physiol** 1999 Aug;87(2):652–60

Patterned cardiovascular responses to sleep and nonrespiratory arousals in a porcine model. Launois SH, et al. **J Appl Physiol** 1998 Oct;85(4):1285–91

Dynamics of lung collapse and recruitment during prolonged breathing in porcine lung injury. Neumann P, et al. **J Appl Physiol** 1998 Oct;85(4):1533–43

Cardiovascular and Valsalva responses during parabolic flight. Schlegel TT, et al. **J Appl Physiol** 1998 Nov; 85(5):1957–65

Effects of vagotomy on cardiovascular response to periodic apneas in sedated pigs. Slamowitz D, et al. **J Appl Physiol** 1999 Jun;86(6):1890–6

Reductions in cardiac output in hypoxic young pigs: systemic and regional perfusion and oxygen metabolism. Stonestreet BS, et al. **J Appl Physiol** 1998 Sep;85(3):874–82

Postpneumonectomy alveolar growth does not normalize hemodynamic and mechanical function. Takeda SI, et al. **J Appl Physiol** 1999 Aug;87(2):491–7

Effect of rilmenidine on the cadiovascular responses to stress in the conscious rabbit. Burke SL, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):177–86

Cardiovascular changes following acute and chronic chemical lesions of the dorsal periaqueductal gray in conscious rats. Sampaio KN, et al. **J Auton Nerv Syst** 1999 May 28;76(2–3):99–107

In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. Rizzo V, et al. **J Biol Chem** 1998 Dec 25;273(52):34724–9

Pulmonary artery hemodynamics with varying degrees of valvular stenosis: an in vitro study. Sung HW, et al. **J Biomech** 1998 Dec;31(12):1153–61

Effects of disturbed flow on endothelial cells. Chiu JJ, et al. **J Biomech Eng** 1998 Feb;120(1):2–8

A constitutive law for mitral valve tissue. May-Newman K, et al. **J Biomech Eng** 1998 Feb;120(1):38–47

Cross-sectional deformation of the aorta as measured with magnetic resonance imaging. Moreno MR, et al. **J Biomech Eng** 1998 Feb;120(1):18–21

Venous haemodynamics after total knee arthroplasty: evaluation of active dorsal to plantar flexion and several mechanical compression devices. Westrich GH, et al. **J Bone Joint Surg Br** 1998 Nov;80(6):1057–66

Hemodynamic monitoring during left atriofemoral bypass for resection of a postductal aortic isthmus stenosis: current role of intraoperative transesophageal echocardiography. Martin K, et al. **J Cardiothorac Vasc Anesth** 1999 Apr; 13(2):207–9

Transesophageal echocardiographic area and Doppler flow velocity measurements: comparison with hemodynamic changes in coronary artery bypass surgery. Schmidlin D, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):143–9

Effect of short- and long-term heart failure on small artery morphology and endothelial function in the rat. Buus NH, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):34–40

Systemic and regional hemodynamics assessment in rats with fluorescent microspheres. Gervais M, et al. **J Cardiovasc Pharmacol** 1999 Mar;33(3):425–32

Delayed hypovolemic hypotension exacerbates the hemodynamic and histopathologic consequences of thromboembolic stroke in rats. Dietrich WD, et al. **J Cereb Blood Flow Metab** 1999 Aug;19(8):918–26

Transfer function analysis of cerebral hemodynamics in patients with carotid stenosis. Hu HH, et al. **J Cereb Blood Flow Metab** 1999 Apr;19(4):460–5

Hemodynamic changes during a new procedure for regional chemotherapy involving occlusion of the thoracic aorta and inferior vena cava. Berkenstadt H, et al. **J Clin Anesth** 1998 Dec;10(8):636–40

Transesophageal echocardiographic assessment of right heart hemodynamics during high-frequency jet ventilation. Ihra G, et al. **J Clin Anesth** 1999 Feb;11(1):32–8

Preoperative pulse wave velocity fails to predict hemodynamic responses to anesthesia and to surgical stimulation. Nakata Y, et al. **J Clin Anesth** 1999 Jun; 11(4):285–9

Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. Thomas DW, et al. **J Clin Invest** 1998 Dec 1;102(11):1994–2001

Physiologic measures of emotion. Bauer RM. **J Clin Neurophysiol** 1998 Sep;15(5):388–96 (62 ref.)

Activation of neuropeptide FF neurons in the brainstem nucleus tractus solitarius following cardiovascular challenge and opiate withdrawal. Jhamandas JH, et al. **J Comp Neurol** 1998 Dec 14;402(2):210–21

Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. Böger RH. **J Endocrinol Invest** 1999;22(5 Suppl):75–81 (42 ref.)

Effect of anaemia on haemodynamics in patients with cirrhosis. Lee WC, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):370–5

Reasons for intracranial hypertension and hemodynamic instability during acute elevations of intra-abdominal pressure: observations in a large animal model. Rosenthal RJ, et al. **J Gastrointest Surg** 1998 Sep-Oct;2(5):415–25

Brain death-induced alterations in myocardial workload and high-energy phosphates: a phosphorus 31 magnetic resonance spectroscopy study in the cat. Brandon Bravo Bruinsma GJ, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):984–90

Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography. Ducharme A, et al. **J Heart Lung Transplant** 1999 Jun;18(6):510–6

Long-term hemodynamic benefit of atrial synchronization with A2A2D or A2A2T pacing in sinus node syndrome after orthotopic heart transplantation. Nägele H, et al. **J Heart Lung Transplant** 1998 Sep;17(9):906–12

Effect of graded hypoxia on hepatic tissue oxygenation measured by near infrared spectroscopy. El-Desoky AE, et al. **J Hepatol** 1999 Jul;31(1):71–6

Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. Fort J, et al. **J Hepatol** 1998 Aug;29(2):263–70

Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. Gentilini P, et al. **J Hepatol** 1999 Apr; 30(4):632–8

The haemodynamic response to hyperinsulinaemia in hypertensive subjects. Lind L, et al. **J Hum Hypertens** 1999 Jan;13(1):41–5

Cardiovascular regulation during insulin infusion into the carotid or vertebral artery in dogs. Hildebrandt DA, et al. **J Hypertens** 1999 Feb;17(2):251–60

Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats. Hu L, et al. **J Hypertens** 1998 Sep;16(9):1285–98

Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. Wilkinson IB, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2079–84

Mechanism of progression of renal disease: current hemodynamic concepts. Johnston CI, et al. **J Hypertens Suppl** 1998 Sep;16(4):S3–7 (20 ref.)

Bioenergetic, functional and morphological consequences of postinfarct cardiac remodeling in the rat. Omerovic E, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1685–95

Dimensional and hemodynamic differences between native and transplanted kidneys, evaluated by color Doppler ultrasonography. Rivolta R, et al. **J Nephrol** 1999 May-Jun; 12(3):179–83

Continuous haemodynamic monitoring in an unusual case of swallow induced syncope. Deguchi K, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):220–2

Recollection and familiarity in recognition memory: an event-related functional magnetic resonance imaging study. Henson RN, et al. **J Neurosci** 1999 May 15; 19(10):3962–72

A simple relationship between radiological arteriovenous malformation hemodynamics and clinical presentation: a prospective, blinded analysis of 31 cases. Norris JS, et al. **J Neurosurg** 1999 Apr;90(4):673–9

The erythrocyte-perfused "working heart" model: hemodynamic and metabolic performance in comparison to crystalloid perfused hearts. Podesser BK, et al. **J Pharmacol Toxicol Methods** 1999 Feb;41(1):9–15

Adrenergic and vasopressinergic contributions to the cardiovascular response to acute hypoxaemia in the llama fetus. Giussani DA, et al. **J Physiol (Lond)** 1999 Feb 15; 515 (Pt 1):233–41

The influence of endurance training on the transient haemodynamic response to orthostatic manoeuvre. Cybulski G, et al. **J Physiol Pharmacol** 1999 Jun; 50(2):275–86

Intraoperative hemodynamic assessment of gastroepiploic artery and saphenous vein bypass grafts: a comparative study. Louagie YA, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):330–8

Effect of alcohol intoxication on hemodynamic physiology and outcome in patients with traumatic cardiac tamponade. Hewitt PM, et al. **J Trauma** 1999 Aug;47(2):346–51

Impact of different hemodynamic criteria for stent placement

after suboptimal iliac angioplasty. Dutch Iliac Stent Trial Study Group. Kamphuis AG, et al. **J Vasc Interv Radiol** 1999 Jun;10(6):741–6

Leukocyte margination in alveolar capillaries: interrelationship with functional capillary geometry and microhemodynamics. Kuebler WM, et al. **J Vasc Res** 1999 Jul–Aug;36(4):282–8

Hemodynamically significant early recurrent carotid stenosis: an often self-limiting and self-reversing condition. Samson RH, et al. **J Vasc Surg** 1999 Sep;30(3):446–52

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. Nappo F, et al. **JAMA** 1999 Jun 9;281(22):2113–8

Comparisons between hemodynamics, during and after bathing, and prognosis in patients with myocardial infarction. Sorimachi M, et al. **Jpn Circ J** 1999 Jul; 63(7):527–32

Temporal relationships between hormonal and hemodynamic changes in early human pregnancy [published erratum appears in Kidney Int 1999 Mar;55(3):1185] Chapman AB, et al. **Kidney Int** 1998 Dec;54(6):2056–63

Haemodynamic analysis of efficacy of compression hosiery in elderly fallers with orthostatic hypotension [letter] Henry R, et al. **Lancet** 1999 Jul 3;354(9172):45–6

Utilizing hemodynamic delay and dispersion to detect fMRI signal change without auditory interference: the behavior interleaved gradients technique. Eden GF, et al. **Magn Reson Med** 1999 Jan;41(1):13–20

Effects of acceleration, jerk, and field inhomogeneities on vessel positions in magnetic resonance angiography. Stefansic JD, et al. **Magn Reson Med** 1998 Aug; 40(2):261–71

Pulse wave attenuation measurement by linear and nonlinear methods in nonlinearly elastic tubes. Bertram CD, et al. **Med Eng Phys** 1999 Apr;21(3):155–66

Viscoelasticity modulates resonance in the terminal aortic circulation. Burattini R, et al. **Med Eng Phys** 1999 Apr; 21(3):175–85

Effect of gender differences and estrogen replacement therapy on vascular reactivity. Perregaux D, et al. **Metabolism** 1999 Feb;48(2):227–32

Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. De Vries P, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr;359(4):331–8

Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. Reichert LJ, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):91–7

The variability of human, BOLD hemodynamic responses. Aguirre GK, et al. **Neuroimage** 1998 Nov;8(4):360–9

The effect of normal aging on the coupling of neural activity to the bold hemodynamic response. D'Esposito M, et al. **Neuroimage** 1999 Jul;10(1):6–14

Characterizing evoked hemodynamics with fMRI. Friston KJ, et al. **Neuroimage** 1995 Jun;2(2):157–65

Characterizing dynamic brain responses with fMRI: a multivariate approach. Friston KJ, et al. **Neuroimage** 1995 Jun;2(2):166–72

Hemodynamic evaluation of the effect of percutaneous transluminal angioplasty for atherosclerotic disease of the vertebrobasilar arterial system. Touho H, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38(9):548–55; discussion 555–6

Hemodynamic and metabolic changes following cerebral revascularization in patients with cerebral occlusive diseases. Kobayashi H, et al. **Neurol Res** 1999 Mar; 21(2):153–60

Simulation of therapeutic parent artery occlusion for basilar head aneurysms. Hemodynamic effect of occlusion sites and diameters of collateral arteries. Nagasawa S, et al. **Neurol Res** 1999 Mar;21(2):180–4

Strain differences in Fos expression following airpuff startle in Spontaneously Hypertensive and Wistar Kyoto rats. Palmer AA, et al. **Neuroscience** 1999 Mar;89(3):965–78

Effects of size and shape (aspect ratio) on the hemodynamics of saccular aneurysms: a possible index for surgical treatment of intracranial aneurysms. Ujiie H, et al. **Neurosurgery** 1999 Jul;45(1):119–29; discussion 129–30

Impedance cardiography for noninvasive measurement of cardiovascular hemodynamics. McFetridge J, et al. **Nurs Res** 1999 Mar–Apr;48(2):109–13

Aortic input impedance and ventriculoarterial coupling following cardioversion/defibrillation. Bauernschmitt R, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1047–53

Acute hemodynamic effects of alternate and combined site pacing in patients after cardiac surgery. Buckingham TA, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):887–93

Importance of the site of ventricular tachycardia origin on left ventricular hemodynamics in humans. Kolettis TM, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):871–9

Hemodynamic effect of rapid atrial pacing in fetal lambs. Shiraishi H, et al. **Pacing Clin Electrophysiol** 1999 Feb; 22(2):320–5

The effect of DDD pacing on ergospirometric parameters and neurohormonal activity in patients with hypertrophic obstructive cardiomyopathy. Simantirakis EN, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2269–72

Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing. Ylitalo K, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1064–70

Normative cardiovascular responses to exercise in children. Braden DS, et al. **Pediatr Cardiol** 1999 Jan–Feb;20(1):4–10; discussion 11 (64 ref.)

A comparison of the hemodynamic and respiratory effects of surfactant instillation during interrupted ventilation versus noninterrupted ventilation in rabbits with severe respiratory failure. Dijk PH, et al. **Pediatr Res** 1999 Feb; 45(2):235–40

Nebulization of sodium nitroprusside in lung-lavaged newborn piglets. Yu XQ, et al. **Pediatr Res** 1999 Feb; 45(2):255–9

Characterization of cardiorespiratory responses to electrical stimulation of the globus pallidus in cat. Angyán L, et al. **Physiol Behav** 1999 Mar;66(1):53–8

Separation of haemodynamic flow waves measured by MR into forward and backward propagating components. Kaandorp DW, et al. **Physiol Meas** 1999 May;20(2):187–99

Regional haemodynamic differences between normotensive and spontaneously hypertensive rats—a microsphere study. Granstam SO, et al. **Physiol Res** 1998;47(1):9–15

Stress and strain as regulators of myocardial growth. Omens JH. **Prog Biophys Mol Biol** 1998;69(2–3):559–72

Blunted cardiovascular and catecholamine stress reactivity in women with bulimia nervosa. Koo-Loeb JH, et al. **Psychiatry Res** 1998 Jul 27;80(1):13–27

Dominance, gender, and cardiovascular reactivity during social interaction. Newton TL, et al. **Psychophysiology** 1999 Mar;36(2):245–52

Combining electrophysiological and hemodynamic measures of the auditory oddball. Opitz B, et al. **Psychophysiology** 1999 Jan;36(1):142–7

Endothelial function and hemodynamic responses during mental stress. Sherwood A, et al. **Psychosom Med** 1999 May–Jun;61(3):365–70

Cardiovascular effects of alcohol. Friedman HS. **Recent Dev Alcohol** 1998;14:135–66 (214 ref.)

Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Melo LG, et al. **Regul Pept** 1999 Feb 5;79(2–3):109–15

Ventilatory, cardiovascular and metabolic responses to hypoxia and hypercapnia in the armadillo. Boggs DF, et al. **Respir Physiol** 1998 Aug;113(2):101–9

Cardiovascular and respiratory reflexes: the tropical fish, traira (Hoplias malabaricus) O2 chemoresponses. Sundin LI, et al. **Respir Physiol** 1999 Aug 3;116(2–3):181–99

Hemodynamic effects of bilevel nasal positive airway pressure ventilation in patients with heart failure. Philip-Joët FF, et al. **Respiration** 1999;66(2):136–43

Benefit of in-phase chest wall vibration on the pulmonary hemodynamics in patients with chronic obstructive pulmonary disease. Nakayama H, et al. **Respirology** 1998 Dec;3(4):235–40

Efficacy of chest compression-only BLS CPR in the presence of an occluded airway. Kern KB, et al. **Resuscitation** 1998 Dec;39(3):179–88

Improved haemodynamics with increased compression-decompression rates during ACD-CPR in pigs. Sunde K, et al. **Resuscitation** 1998 Dec;39(3):197–205

Hemodynamic indexes in newborns using the arteriovenous oxygen content difference. Tapia-Rombo CA, et al. **Rev Invest Clin** 1998 May–Jun;50(3):191–6

Normal relationships between cardiovascular variables in active orthostatism and clinostatism in postural change. Bettencourt MJ, et al. **Rev Port Cardiol** 1998 Nov; 17(11):875–9

Effects of exaggerated lithotomy position on ventilation and hemodynamics during radical perineal prostatectomy. Ryniak S, et al. **Scand J Urol Nephrol** 1998 May;32(3):200–3

MRI for physiology and function in congenital heart disease: functional assessment of the heart preoperatively and postoperatively. Fogel MA, et al. **Semin Roentgenol** 1998 Jul;33(3):239–51 (71 ref.)

MRI for physiology and function: technical advances in MRI of congenital heart disease. Haselgrove JC, et al. **Semin Roentgenol** 1998 Jul;33(3):293–301 (20 ref.)

Congenital heart disease: measuring physiology with MRI. Reddy GP, et al. **Semin Roentgenol** 1998 Jul;33(3):228–38 (39 ref.)

Arterial hemodynamics and wall mechanics. Vorp DA, et al. **Semin Vasc Surg** 1998 Sep;11(3):169–80 (95 ref.)

The role of endothelin-1 in circulatory changes during hypodynamic sepsis in the rat. László Szalay, József Kaszaki, Sándor Nagy, and Mihály Boros. Shock 10(2):123–128, 1998 [letter; comment] Doherty JC, et al. **Shock** 1999 Feb;11(2):149–50. Comment on: Shock 1998 Aug;10(2):123–8.

The role of endothelin-1 in circulatory changes during hypodynamic sepsis in the rat [see comments] Szalay L, et al. **Shock** 1998 Aug;10(2):123–8. Comment in: Shock 1999 Feb;11(2):149–50.

Exercise stress testing. An overview of current guidelines. Lear SA, et al. **Sports Med** 1999 May;27(5):285–312 (91 ref.)

Physiology of perfusion as it relates to the optic nerve head. Orgül S, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S17–26 (144 ref.)

Phenylephrine treatment of the postreperfusion syndrome in liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2373–4

Hemodynamic consequences of oxidative stress following reperfusion during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2375–6

Characterization of hepatic microcirculatory impairment induced during portal-venous infusion of endothelin-1 by thermal diffusion technology. Kraus T, et al. **Transplant Proc** 1998 Nov;30(7):3743–5

Impaired vascular responsiveness to nitric oxide in renal transplant recipients. Morris ST, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):304–5

Effect of intraportal infusion of adenosine on hepatic blood flow and injury after ischemia and reperfusion of canine liver. Sakata C, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1027–8

Impaired hepatic mitochondrial function reserve in brain-dead pigs. Sato T, et al. **Transplant Proc** 1998 Dec; 30(8):4351–5

Assessment of left ventricular filling in normally grown fetuses, growth-restricted fetuses and fetuses of diabetic mothers. Tsyvian P, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):33–8

Physiologic monitoring of circulatory dysfunction in patients with severe head injuries. Velmahos GC, et al. **World J Surg** 1999 Jan;23(1):54–8

[Hemodynamics in young people after staying at altitude over 5000 meters for 1 year] Wang W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):28 **(Chi)**

[Simple transposition of great vessels. Physiopathology, current management] David N. **Arch Pediatr** 1998;5 Suppl 2:111s–113s **(Fre)**

[Value of nitric oxide (NO) in neonatal right ventricular dysfunction (letter)] Saygili A, et al. **Arch Pediatr** 1998 Jan;5(1):93–4 **(Fre)**

[Hemodynamic monitoring using esophageal Doppler ultrasonography during laparoscopic cholecystectomy] Mann C, et al. **Can J Anaesth** 1999 Jan;46(1):15–20 (Eng. Abstr.) **(Fre)**

[Hemodynamic effects of maximum laser transmyocardial revascularization] Mueller XM, et al. **Swiss Surg** 1998;Suppl 2:18–22 (Eng. Abstr.) **(Fre)**

[Separating elastic, flow and velocity work and work of smooth musculature of the peripheral arterial pulse of the human] Bendel U, et al. **Biomed Tech (Berl)** 1998;43 Suppl:316–7 **(Ger)**

[Coupling cardiovascular models for analysis of frequency-adaptive cardiac pacemaker systems] Böhringer D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:318–9 **(Ger)**

[Calculation of the flow through a new single cusp valve for heart assist systems] Goubergrits L, et al. **Biomed Tech (Berl)** 1998;43 Suppl:288–9 **(Ger)**

[Determining hemodynamic status using intramyocardial electrocardiograms] Hutten H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:88–9 **(Ger)**

[Flow dynamics of an over-dimensional end-to-side anastomosis in a circulatory model with numerical flow simulation] Krüger U, et al. **Biomed Tech (Berl)** 1998;43 Suppl:312–3 **(Ger)**

[Modeling of the baroreceptor reflex in a pulsatile model] Schulz S, et al. **Biomed Tech (Berl)** 1998;43 Suppl:310–1 **(Ger)**

[Signal analysis of the hemodynamics of extracorporeal circulation for the evaluation of patient status] Schwarzhaupt A, et al. **Biomed Tech (Berl)** 1999 May; 44(5):120–8 (11 ref.) (Eng. Abstr.) **(Ger)**

[Validation of a robot for determination of regional perfusion with fluorescent microspheres] Thein E, et al. **Biomed Tech (Berl)** 1998;43 Suppl:536–7 **(Ger)**

[Hemodynamic-kinetic controlled extracorporeal circulation in heart surgery] Waldhans S, et al. **Biomed Tech (Berl)** 1998 Dec;43(12):367–70 (Eng. Abstr.) **(Ger)**

[Hemodynamically-induced transitory ischemic attacks. A differential focal motor seizures diagnosis?] Niehaus L, et al. **Nervenarzt** 1998 Oct;69(10):901–4 (Eng. Abstr.) **(Ger)**

[Retinal hemodynamics in patients with normal pressure glaucoma. Quantification with digital laser scanning fluorescein angiography] Arend O, et al. **Ophthalmologe** 1999 Jan;96(1):24–9 (Eng. Abstr.) **(Ger)**

[Effect of GLP-1 and amylin on lung circulation, the bronchial system and systemic circulation in isolated ex vivo organ cultures of the rat] Golpon H. **Pneumologie** 1998 Aug;52(8):439 **(Ger)**

[Flow quantification of intracardiac shunt volumes using MR phase contrast technique in the breath holding phase] Kalden P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):378–82 (Eng. Abstr.) **(Ger)**

[Cardiac MRI for determining functional left ventricular parameters] Miller S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):47–53 (Eng. Abstr.) **(Ger)**

[The supratrochlear artery as an indicator of cerebral hemodynamics in carotid occlusion] Krapf H, et al. **Ultraschall Med** 1998 Jun;19(3):114–9 (Eng. Abstr.) **(Ger)**

[Hemodynamic and left ventricular parameters in dobutamine stress echocardiography in diagnosis of coronary heart disease] Wankmüller H, et al. **Ultraschall Med** 1998 Aug; 19(4):174–80 (Eng. Abstr.) **(Ger)**

[Prospective 12-year follow-up study of clinical and hemodynamic sequelae of deep venous thromboses in patients with low risk (Zurich Study)] Franzeck UK, et al. **Wien Med Wochenschr** 1999;149(2–4):78–84 (Eng. Abstr.) **(Ger)**

[Risk of invasive diagnosis with retrograde catheterization of the left ventricle in patients with acquired aortic valve stenosis] Bartsch B, et al. **Z Kardiol** 1999 Apr;88(4):255–60

(Eng. Abstr.) **(Ger)**
[The significance of physical activity on the physiological stress reaction] Dickhuth HH, et al. **Z Kardiol** 1999 May; 88(5):305–14 (78 ref.) (Eng. Abstr.) **(Ger)**
[Effect of defibrillation on hemodynamics during cardioverter defibrillator implantation] Hayashi K. **J Cardiol** 1999 Jul;34(1):25–34 (Eng. Abstr.) **(Jpn)**
[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report] Soeki T, et al. **J Cardiol** 1999 Jun;33(6):339–45 (Eng. Abstr.) **(Jpn)**
[Pulmonary hemodynamic and gas exchange effects of various oxygen concentrations in patients with severe pulmonary hypertension primarily affecting the pulmonary vasculature] Sato K, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):449–57 (Eng. Abstr.) **(Jpn)**
[Changes in atrial natriuretic peptide and pulmonary hemodynamics induced by exercise in patients with chronic pulmonary emphysema] Takeda A, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):607–12 (Eng. Abstr.) **(Jpn)**
[Hemodynamics of prepapillary vascular loop in hemi-central retinal vein occlusion] Takahashi K. **Nippon Ganka Gakkai Zasshi** 1999 May;103(5):404–8 (Eng. Abstr.) **(Jpn)**
[Studies on pulmonary and systemic hemodynamic changes after transjugular intrahepatic portosystemic shunt (TIPS)] Wagatsuma Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec;95(12):1350–6 (Eng. Abstr.) **(Jpn)**
[The indices of urinary tribulin activity as an indicator of psychological traits and of hemodynamic status] Volchegorskii IA, et al. **Fiziol Cheloveka** 1998 Jul–Aug; 24(4):126–9 **(Rus)**
[The systemic and organ hemodynamics during combined use of stimuli with various strength and orientation] Tkachenko BI. **Ross Fiziol Zh Im I M Sechenova** 1998 Sep;84(9):833–44 **(Rus)**
[Laws of typological interactions of clino- and antiorthostatic systemic and cerebral circulation in children] Gavrikov KV, et al. **Vestn Ross Akad Med Nauk** 1999;(7):32–6 (Eng. Abstr.) **(Rus)**
[Hemodynamic changes during laparoscopic surgery. Preliminary study] de Agustin JC, et al. **Cir Pediatr** 1999 Jan;12(1):30–2 (Eng. Abstr.) **(Spa)**
[Hemodynamics and oxygenation in experimental lung lobe transplantation] Greco R, et al. **Cir Pediatr** 1999 Jan; 12(1):16–21 (Eng. Abstr.) **(Spa)**
[The effect of local vibration on central and cerebral hemodynamics] Sova SH. **Lik Sprava** 1999 Apr–May; (3):68–71 (Eng. Abstr.) **(Ukr)**

RADIATION EFFECTS

[The effect of ultraviolet irradiation of the blood on lung–heart hemodynamics in patients with ischemic heart disease and concomitant chronic obstructive bronchitis] Shut' SV. **Lik Sprava** 1999 Jan–Feb;(1):70–3 (Eng. Abstr.) **(Ukr)**

HEMOFILTRATION

Interleukin-6 (IL-6) is not removed from plasma during experimental haemofiltration [letter] Hansen TG, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1129
Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Brunet S, et al. **Am J Kidney Dis** 1999 Sep;34(3):486–92
Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Swartz RD, et al. **Am J Kidney Dis** 1999 Sep;34(3):424–32
Hemofiltration in parallel to the venovenous bypass circuit for oliguric hypervolemia during liver transplantation. Tobias MD, et al. **Anesthesiology** 1999 Mar;90(3):909–11
Propafenone disposition during continuous venovenous hemofiltration. Seto W, et al. **Ann Pharmacother** 1999 Sep; 33(9):957–9
Extended use of hemofiltration and high perfusion flow rate in cardiopulmonary bypass improves perioperative fluid balance in neonates and infants. Sakurai H, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):94–100
Antithrombogenicity of polyacrylonitrile-polyethyleneoxide hollow fiber membrane developed for designing an antithrombogenic continuous ultrafiltration system. Arakawa M, et al. **Artif Organs** 1992 Apr;16(2):146–50
Pharmacokinetics and dosage adjustment of antibiotics during continuous extracorporeal lung assistance and hemofiltration. Kroh UF, et al. **Artif Organs** 1992 Oct; 16(5):457–60
Effect of ultrafiltration during cardiopulmonary bypass for pediatric cardiac surgery. Watanabe T, et al. **Artif Organs** 1998 Dec;22(12):1052–5
Assessment of efficiency using on-line urea kinetic modeling in hemodiafiltration. Navino C, et al. **ASAIO J** 1998 Sep–Oct;44(5):M565–8
Assessment of acetate free continuous veno–venous hemofiltration in acute renal failure. Wynckel A, et al. **ASAIO J** 1998 Sep–Oct;44(5):M606–9
The filterability of leukocytes in undiluted blood. Cook AM, et al. **Biorheology** 1998 Mar–Apr;35(2):119–30
The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. van der Sande FM, et al. **Clin Nephrol** 1998 Nov;50(5):301–8
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Tegeder I, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):50–7
Hemofiltration for SIRS: bloodletting, twentieth century style? [editorial; comment] Rodby RA. **Crit Care Med** 1998 Dec;26(12):1940–2 (10 ref.). Comment on: Crit Care Med 1998 Dec;26(12):1995–2000.
Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. Rogiers P, et al. **Crit Care Med** 1999 Sep;27(9):1848–55
Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration [see comments] Story DA, et al. **Crit Care Med** 1999 Jan;27(1):220–3. Comment in: Crit Care Med 1999 Jan;27(1):36.
Hemofiltration and double high flux dialysis: risks and benefits. Bosch JP, et al. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):643–7 (16 ref.)
Modified ultrafiltration improves global left ventricular systolic function after open-heart surgery in infants and children. Chaturvedi RR, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):742–6
Presence of factor-VII and -XIII activity in ultrafiltrate during hemofiltration. Guth HJ, et al. **Int J Artif Organs** 1999 Jul;22(7):482–7
The benefits of daily hemofiltration in the management of anuria in patients with severe heart failure (NYHA IV). Iorio L, et al. **Int J Artif Organs** 1998 Aug;21(8):457–9
Daily hemofiltration in severe heart failure [editorial] Iorio L. **Int J Artif Organs** 1998 Dec;21(12):778–80
Endothelial dysfunction in critically ill patients: the effect of haemofiltration. Cardigan R, et al. **Intensive Care Med** 1998 Dec;24(12):1264–71
Efficacy of blood purification therapy for heat stroke presenting rapid progress of multiple organ dysfunction syndrome: a comparison of five cases. Ikeda Y, et al. **Intensive Care Med** 1999 Mar;25(3):315–8
Case 4—1999. Myocardial function improvement after hemofiltration in a septic patient [clinical conference] Oppenheim-Eden A, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):484–9
Intraoperative continuous hemofiltration for metabolic management in acute aortoiliac occlusion. van der Hoven B, et al. **J Clin Anesth** 1998 Nov;10(7):599–602
Contrast medium-removing effect of hemofiltration and hemodiafiltration. Okahisa T, et al. **J Med Invest** 1998 Aug; 45(1–4):87–93
Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. Ronco C, et al. **J Nephrol** 1999 May–Jun;12(3):173–8
Effects of long-term hemofiltration on circulating mediators and superoxide production during continuous endotoxin administration. Ishihara S, et al. **J Trauma** 1999 May; 46(5):894–9
Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Locatelli F, et al. **Kidney Int** 1999 Jan;55(1):286–93
A mechanistic model of plasma filtration. Fernandez CA, et al. **Med Eng Phys** 1998 Jul;20(5):383–92
Daily hemofiltration in severe heart failure. Iorio L, et al. **Miner Electrolyte Metab** 1999 Jan–Apr;25(1–2):39–42
Hemofiltration during cardiopulmonary bypass. Journois D. **Minerva Anestesiol** 1999 Jun;65(6):427–32 (19 ref.)
Immunomodulation in sepsis: the role of hemofiltration. Kellum JA. **Minerva Anestesiol** 1999 Jun;65(6):410–8 (58 ref.)
Continuous renal replacement therapy in patients with HELLP syndrome. Piccinni P, et al. **Minerva Anestesiol** 1999 Jun;65(6):433–6 (38 ref.)
Present and future options in continuous renal replacement therapies of sepsis and MOF. Tetta C, et al. **Minerva Anestesiol** 1999 Jun;65(6):419–26 (63 ref.)
Results from ethical international surveys on the management of the continuous renal replacement therapy. Zamperetti N, et al. **Minerva Anestesiol** 1999 Jun;65(6):437–9 (7 ref.)
In vivo and in vitro neurotoxic action of plasma ultrafiltrate from uraemic patients. Cantaro S, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2288–93
Efficacy of extracorporeal ultrafiltration of ascitic fluid as a treatment of refractory ascites. Daimon S, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2617–23
Sodium transport with different dialysis ultrafiltration schedules using a bio-feedback module (BFB). Di Giulio S, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:39–42
Continuous veno–venous haemofiltration versus continuous veno–venous haemodialysis in severe lithium self-poisoning: a toxicokinetics study in an intensive care unit [letter] Hazouard E, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1605–6
Thermal energy balance and body temperature: comparison between isolated ultrafiltration and haemodialysis at different dialysate temperatures. Keijman JM, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2196–200
Ultrafiltration behaviour with different dialysis schedules. Santoro A, et al. **Nephrol Dial Transplant** 1998;13 Suppl 6:55–61 (26 ref.)
Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration. Wong KY, et al. **Pediatr Nephrol** 1998 Sep;12(7):589–91
Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Schelling JR, et al. **Ren Fail** 1998 Jul;20(4):635–44 (32 ref.)
Effect of haemofiltration on pathological fibrinolysis due to severe sepsis: a case report. Perouansky M, et al. **Resuscitation** 1999 Jan;40(1):53–6
Techsighting. Test tube kidneys. Sikorski R, et al. **Science** 1999 Jun 18;284(5422):1952
Extracorporeal rheopheresis in the treatment of acute ischemic stroke: A randomized pilot study. Berrouschot J, et al. **Stroke** 1999 Apr;30(4):787–92
[Clinical and respiratory function follow-up of 39 infants treated with neonatal respiratory extracorporeal assistance] Koskas M, et al. **Arch Pediatr** 1999 Mar;6(3):263–70 (Eng. Abstr.) **(Fre)**
[Pharmacokinetics of anti-infective agents in continuous hemofiltration] Jaumain H, et al. **Presse Med** 1998 Oct 10; 27(30):1536–44 (27 ref.) (Eng. Abstr.) **(Fre)**
[Modification of vision by change in rheologic parameters in senile macular degeneration through membrane differential filtration—initial results of a randomized study] Widder RA, et al. **Klin Monatsbl Augenheilkd** 1999 Jul; 215(1):43–8; discussion 48–9 (Eng. Abstr.) **(Ger)**
[Plasma separation combined with CVVHF in septic and SIRS patients] Schmidt J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1080–2 (Eng. Abstr.) **(Ger)**
[Pharmacokinetics and dosage of fluconazole in continuous hemofiltration (CAVH, CVVH) and hemodialysis (CAVHD, CVVHD)] Pittrow L, et al. **Mycoses** 1998;41 Suppl 2:86–8 (Eng. Abstr.) **(Ger)**
[Intra- and extravascular volumes in congestive heart failure and their redistribution following extracorporeal ultrafiltration] Marenzi G, et al. **Cardiologia** 1998 Nov; 43(11):1193–200 (Eng. Abstr.) **(Ita)**
[Liver protection and liver transplantation from a living donor for the treatment of acute hepatic failure] Inaba S. **Masui** 1998 Dec;47 Suppl:S235–9 **(Jpn)**
[Severe Legionella micdadei pneumonia effectively treated with hemofiltration therapy] Matsubara S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):886–90 (Eng. Abstr.) **(Jpn)**
[Acute blood purification] Hirasawa H, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1317–22 (5 ref.) **(Jpn)**
[Hemodynamics and oxygen transport in patients with surgical sepsis during hemofiltration] Bobrinskaia IG, et al. **Anesteziol Reanimatol** 1998 Nov–Dec;(6):58–62 (Eng. Abstr.) **(Rus)**
[Complement system during hemofiltration in patients with multiple organ failure] Iakovleva II, et al. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):23–6 (Eng. Abstr.) **(Rus)**
[Continuous arteriovenous hemofiltration in the newborn infant] Castillo Salinas F, et al. **An Esp Pediatr** 1999 Mar; 50(3):279–84 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

To replace or not to replace vitamins and minerals in CVVH: This is the question [editorial; comment] Bistrian BR. **Crit Care Med** 1999 Jan;27(1):36. Comment on: Crit Care Med 1999 Jan;27(1):220–3.
Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Cardigan RA, et al. **Kidney Int** 1999 Apr;55(4):1568–74
Atrial flutter? An electrocardiographic artifact caused by the COBE PRISMA system [letter] Biswas A, et al. **Pediatr Nephrol** 1998 Aug;12(6):524

INSTRUMENTATION

Thermal energy balance during in vitro continuous veno-venous hemofiltration. Manns M, et al. **ASAIO J** 1998 Sep–Oct;44(5):M601–5
Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Bouman CS, et al. **Blood Purif** 1998;16(5):261–8
Analysis of the influence of the infusion site on dialyser clearances measured in an in vitro system mimicking haemodialysis and haemodiafiltration. Ficheux A, et al. **Blood Purif** 1999;17(1):10–8
Biocompatibility evaluation of polyamide hemofiltration. Panichi V, et al. **Int J Artif Organs** 1998 Jul;21(7):408–13
Cytokine removal during continuous hemofiltration in septic patients. De Vriese AS, et al. **J Am Soc Nephrol** 1999 Apr; 10(4):846–53
Cellulose triacetate: another membrane for continuous renal replacement therapy. Ronco C, et al. **J Nephrol** 1999 Jul–Aug;12(4):241–7
A novel leucocyte-depleting filter for use in continuous venovenous haemofiltration: preliminary in vitro studies. Gant VA, et al. **Perfusion** 1998 Nov;13(6):437–46

METHODS

Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs. Yekebas EF, et al. **Ann Surg** 1999 Apr;229(4):514–22

HEMOFILTRATION

A simple technique to perform combined ultrafiltration. Portela FA, et al. **Ann Thorac Surg** 1999 Mar;67(3):859–61

Systemic inflammatory response syndrome treatment by powdered sorbent pheresis: the BioLogic-Detoxification Plasma Filtration System. Levy H, et al. **ASAIO J** 1998 Sep–Oct;44(5):M659–65

Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal. Zhang Y, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M368–73

Use of polyester leukocyte elimination filters in blood filterability research. Lindmark K, et al. **Biorheology** 1998 Mar–Apr;35(2):131–40

Determination of the content of nonfilterable cells in erythrocyte suspensions as a function of the medium osmolality. Lisovskaya IL, et al. **Biorheology** 1998 Mar–Apr;35(2):141–53

High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Nagashima M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II378–84

Hypothermia and extracorporeal rewarming: the journey toward a less invasive, more accessible methodology [editorial; comment] Josephs JD, et al. **Crit Care Med** 1998 Dec;26(12):1944–5 (9 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2016–20.

Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome [see comments] Kellum JA, et al. **Crit Care Med** 1998 Dec;26(12):1995–2000. Comment in: Crit Care Med 1998 Dec;26(12):1940–2.

Continuous venovenous rewarming: results from a juvenile animal model [see comments] Seigler RS, et al. **Crit Care Med** 1998 Dec;26(12):2016–20. Comment in: Crit Care Med 1998 Dec;26(12):1944–5.

Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration. Hammer JH, et al. **Eur J Haematol** 1999 Jul;63(1):29–34

Pro: the use of modified ultrafiltration during pediatric cardiac surgery is a benefit. Montenegro LM, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):480–2 (14 ref.)

Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting. Tassani P, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):285–91

Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome. Phillips GJ, et al. **J Clin Pharm Ther** 1998 Oct;23(5):353–9

Massive pulmonary haemorrhage caused by leptospirosis successfully treated with nitric oxide inhalation and haemofiltration. Borer A, et al. **J Infect** 1999 Jan;38(1):42–5

Venovenous modified ultrafiltration after cardiopulmonary bypass in children: a prospective randomized study. Hennein HA, et al. **J Thorac Cardiovasc Surg** 1999 Mar; 117(3):496–505

Reopro removal during cardiopulmonary bypass using a hemoconcentrator. Poullis M, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1032–4

Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Palsson R, et al. **Kidney Int** 1999 May; 55(5):1991–7

Continuous venovenous haemofiltration in hyperammonaemic coma of an adult with non-diagnosed partial ornithine transcarbamylase deficiency. Chang MY, et al. **Nephrol Dial Transplant** 1999 May;14(5):1282–4

Modified ultrafiltration in paediatric cardiopulmonary bypass. Wang W, et al. **Perfusion** 1998 Sep;13(5):304–10

The effective removal of proinflammatory cytokines by continuous hemofiltration with a polymethylmethacrylate membrane following severe burn injury: report of three cases. Nakae H, et al. **Surg Today** 1999;29(8):762–5

Blood purification for critical care medicine: endotoxin adsorption. Kodama M, et al. **Ther Apher** 1997 Aug; 1(3):224–7

Cryofiltration apheresis in the treatment of cryoprecipitate induced diseases. Siami FS, et al. **Ther Apher** 1997 Feb; 1(1):58–62

Cryofiltration apheresis for major ABO-incompatible kidney transplantation. Tamaki T, et al. **Ther Apher** 1998 Nov; 2(4):308–10

[Treatment of iliac vein thrombosis by use of filter placed in the inferior cava vein in a female patient after reoperation of meningioma of the smaller section of the sphenoid bone] Gościński I, et al. **Neurol Neurochir Pol** 1998 May–Jun; 32(3):689–97 (Eng. Abstr.) **(Pol)**

STANDARDS

Theoretical comparison of filtration by the renal glomerulus and artificial membranes. Tsuji M, et al. **ASAIO J** 1999 Jan–Feb;45(1):98–103

TRENDS

Hemofiltration in children [editorial] Saborio P, et al. **Int J Artif Organs** 1998 Jul;21(7):371–7

HEMOFILTRATION, CONTINUOUS ARTERIOVENOUS see **HEMOFILTRATION**

HEMOGLOBIN A

ADMINISTRATION & DOSAGE

Cerebral blood flow during hypoxic hypoxia with plasma-based hemoglobin at reduced hematocrit. Ulatowski JA, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2): H1933–42

ANALOGS & DERIVATIVES

Carbamylated hemoglobin interference in glycohemoglobin assays [letter; comment] Weykamp CW, et al. **Clin Chem** 1999 Mar;45(3):438–40. Comment on: Clin Chem 1997 Apr;43(4):644–8.

ANALYSIS

Clinical radiobiology of glottic T1 squamous cell carcinoma. Skladowski K, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1;43(1):101–6

A flow-cytometric equivalent of the Kleihauer test. Nelson M, et al. **Vox Sang** 1998;75(3):234–41

BIOSYNTHESIS

Shift from fetal to adult hemoglobin production in a preterm infant after exchange transfusion: a quantitative approach. Refsum HE, et al. **Pediatr Hematol Oncol** 1998 Sep–Oct; 15(5):431–5

CHEMISTRY

Kinetics of oxygen binding to hemoglobin A. Gibson QH. **Biochemistry** 1999 Apr 20;38(16):5191–9

Probing the diphosphoglycerate binding pocket of HbA and HbPresbyterian (beta 108Asn --> Lys). Gottfried DS, et al. **Biochemistry** 1999 Aug 31;38(35):11307–15

Quaternary structure sensitive tyrosine residues in human hemoglobin: UV resonance raman studies of mutants at alpha140, beta35, and beta145 tyrosine. Nagai M, et al. **Biochemistry** 1999 Jan 26;38(4):1243–51

Effects of substitutions of lysine and aspartic acid for asparagine at beta 108 and of tryptophan for valine at alpha 96 on the structural and functional properties of human normal adult hemoglobin: roles of alpha 1 beta 1 and alpha 1 beta 2 subunit interfaces in the cooperative oxygenation process. Tsai CH, et al. **Biochemistry** 1999 Jul 6; 38(27):8751–61

Functional comparison of specifically cross-linked hemoglobins biased toward the R and T states. Johnson MB, et al. **Biophys J** 1998 Dec;75(6):3078–84

Effects of S-nitrosation on oxygen binding by normal and sickle cell hemoglobin. Bonaventura C, et al. **J Biol Chem** 1999 Aug 27;274(35):24742–8

The N-terminal sequence affects distant helix interactions in hemoglobin. Implications for mutant proteins from studies on recombinant hemoglobin felix. Dumoulin A, et al. **J Biol Chem** 1998 Dec 25;273(52):35032–8

Chemistry of the "molecular trap" of protease-catalyzed splicing reaction of complementary segments of alpha-subunit of hemoglobin A. Sahni G, et al. **J Protein Chem** 1998 Oct;17(7):669–78

DRUG EFFECTS

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Demetri GD, et al. **J Clin Oncol** 1998 Oct;16(10):3412–25

Stabilization of the T-state of ferrous human adult and fetal hemoglobin by Ln(III) complexes: a thermodynamic study. Aime S, et al. **J Inorg Biochem** 1998 Aug;71(1–2):37–43

Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. Ostman J, et al. **J Intern Med** 1998 Aug; 244(2):95–107

METABOLISM

Oxidative stress causes intracellular reversible S-thiolation of chicken hemoglobin under diamide and xanthine oxidase treatment. Dafré AL, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):291–6

Kinetics of oxygen binding to hemoglobin A. Gibson QH. **Biochemistry** 1999 Apr 20;38(16):5191–9

Probing the diphosphoglycerate binding pocket of HbA and HbPresbyterian (beta 108Asn --> Lys). Gottfried DS, et al. **Biochemistry** 1999 Aug 31;38(35):11307–15

Oxidative stress in beta-thalassemia: hemoglobin alpha-chains activate peroxidation of low density lipoproteins. Altamentova SM, et al. **Biofactors** 1998; 8(1–2):169–72

Functional comparison of specifically cross-linked hemoglobins biased toward the R and T states. Johnson MB, et al. **Biophys J** 1998 Dec;75(6):3078–84

Influence of haemoglobin concentration after extracorporeal circulation on mortality and morbidity in patients undergoing cardiac surgery. Hardy JF, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:38–45

Critical haemoglobin concentration in anaesthetized dogs: comparison of two plasma substitutes [published erratum appears in Br J Anaesth 1999 Apr;82(4):658] Van der Linden P, et al. **Br J Anaesth** 1998 Oct;81(4):556–62

The more you look the more you find: problems of biases inherent in non-randomized studies [letter; comment] Bryant P. **Br J Gen Pract** 1998 Sep;48(434):1614. Comment on: Br J Gen Pract 1998 May;48(430):1237–40.

Differential development of fetal and adult haemoglobin profiles in colony culture: isolation of fetal nucleated red cells by two-colour fluorescence labelling. Bohmer RM, et al. **Br J Haematol** 1998 Nov;103(2):351–60

Coupling of the oxygen-linked interaction energy for inositol hexakisphosphate and bezafibrate binding to human HbA0. Coletta M, et al. **J Biol Chem** 1999 Mar 12;274(11):6865–74

[Photodissociation of oxygenated forms of native hemoglobin HbA and its isolated alpha- and beta-subunits, and kinetics of rebinding of molecular oxygen] Dzhagarov BM, et al. **Doki Akad Nauk** 1999 May;366(1):121–4 **(Rus)**

PHYSIOLOGY

The effect of hemoglobin A and S on the volume- and pH-dependence of K-Cl cotransport in human erythrocyte ghosts. Vitoux D, et al. **J Membr Biol** 1999 Feb 1; 167(3):233–40

Physiological effects of modified hemoglobin as an oxygen-carrying macromolecule. Nosé Y. **Keio J Med** 1999 Mar;48(1):38–43 (18 ref.)

HEMOGLOBIN A, GLYCOSYLATED

[GHbA1c and peoples democracy (letter)] Koivisto V. **Duodecim** 1995;111(24):2430 **(Fin)**

ANALYSIS

Establishing trimester- and ethnic group-related reference ranges for fructosamine and HbA1c in non-diabetic pregnant women. Hartland AJ, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):235–7

Measurement of HbA1c by high-performance liquid chromatography in patients with renal failure. Holbrook I. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):238–9

Measurement of glycated haemoglobin by boronate-affinity high-pressure liquid chromatography. Stirk H, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):233–4

Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Khuu HM, et al. **Arch Pathol Lab Med** 1999 Sep;123(9):763–7

Dapsone at onset of diabetes lowers glycated hemoglobin and delays death in NOD mice. Peterson CM, et al. **Autoimmunity** 1998;28(3):157–61

High dose inhaled corticosteroids and dose dependent loss of diabetic control. Faul JL, et al. **BMJ** 1998 Nov 28; 317(7171):1491

Glycosylated haemoglobin and hypertension arising in pregnancy. Roberts RN, et al. **Br J Obstet Gynaecol** 1998 Oct;105(10):1122–4

Comparison of hemoglobin A1C results by two different methods on patients with structural hemoglobin variants. Blakney GB, et al. **Clin Biochem** 1998 Nov;31(8):619–26

Chronic lymphocytic leukemia cells may interfere in a glycated hemoglobin assay based on fluorescence quenching. Daae LN, et al. **Clin Chem** 1999 Apr;45(4):569

Multicenter evaluation of Tosoh glycohemoglobin analyzer. Gibb I, et al. **Clin Chem** 1999 Oct;45(10):1833–41

Correction: evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer [letter; comment] Nisbet JA, et al. **Clin Chem** 1999 Jan;45(1):154. Comment on: Clin Chem 1997 Jun;43(6 Pt 1):968–75.

Glycohemoglobin results in samples with hemoglobin C or S trait: a comparison of four test systems. Roberts WL, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):906–9

Carbamylated hemoglobin interference in glycohemoglobin assays [letter; comment] Weykamp CW, et al. **Clin Chem** 1999 Mar;45(3):438–40. Comment on: Clin Chem 1997 Apr;43(4):644–8.

Influence of hyperglycemia on early embryonal growth in IDDM pregnant women. Ivanišević M, et al. **Coll Antropol** 1999 Jun;23(1):183–8

Hyperglycemia in hummingbirds and its consequences for hemoglobin glycation. Beuchat CA, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):409–16

Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. Neuhaus IM, et al. **Compr Psychiatry** 1999 May–Jun;40(3):234–7

Episodic hyperglycaemia in pregnant women with well-controlled Type 1 diabetes mellitus: a major potential factor underlying macrosomia [see comments] Kyne-Grzebalski D, et al. **Diabet Med** 1999 Aug; 16(8):702–6. Comment in: Diabet Med 1999 Aug;16(8):621–2.

How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Bouma M, et al. **Diabetes Care** 1999 Jun; 22(6):904–7

Should age and sex be taken into account in the determination of HbA1c reference range? [letter] Carrera T, et al. **Diabetes Care** 1998 Dec;21(12):2193–4

The burden of chronic hyperglycemia. Clark CM Jr. **Diabetes Care** 1998 Dec;21 Suppl 3:C32–4

Risk for metabolic control problems in minority youth with diabetes. Delamater AM, et al. **Diabetes Care** 1999 May; 22(5):700–5

Assessing the utility of glycated hemoglobin [letter; comment] Eberhardt MS, et al. **Diabetes Care** 1998 Sep; 21(9):1578–9. Comment on: Diabetes Care 1998 Feb;21(2):261–4.

Poor metabolic control decreases the growth velocity of diabetic children [letter; comment] Gunczler P, et al. **Diabetes Care** 1999 Jun;22(6):1012. Comment on: Diabetes Care 1998 Aug;21(8):1226–9.

Heterozygous hemoglobin Hamadan affects HbA1c assay [letter] Gunton JE, et al. **Diabetes Care** 1999 Jan;22(1):177

Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Hofmann MA, et al. **Diabetes Care** 1998 Aug;21(8):1310–6

Abnormally decreased HbA1c can be assessed with erythrocyte creatine in patients with a shortened erythrocyte age. Jiao Y, et al. **Diabetes Care** 1998 Oct; 21(10):1732–5

Significant improvement in HbA1c in a morbidly obese type 2 diabetic patient after gastric bypass surgery despite relatively small weight loss [letter] Khateeb NI, et al. **Diabetes Care** 1999 Apr;22(4):651

Supplement to the use of a paired value of fasting plasma glucose and glycated hemoglobin in predicting the likelihood of having diabetes [letter] Ko GT, et al. **Diabetes Care** 1998 Nov;21(11):2032–3

Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects [see comments] Ko GT, et al. **Diabetes Care** 1998 Aug;21(8):1221–5. Comment in: Diabetes Care 1998 Aug;21(8):1215–6.

Comparison of percent total GHb with percent HbA1c in people with and without known diabetes. Nuttall FQ. **Diabetes Care** 1998 Sep;21(9):1475–80

Glycemic control and CAD risk: a heretical thought [letter] Orchard TJ. **Diabetes Care** 1999 Jul;22(7):1220

Glycosylated hemoglobin levels and new diagnostic criteria [letter] Raj D, et al. **Diabetes Care** 1998 Dec;21(12):2198–9

Use of HbA1c in screening for diabetes [letter; comment] Roubicek M, et al. **Diabetes Care** 1998 Sep;21(9):1577–8; discussion 1578–9. Comment on: Diabetes Care 1998 Feb;21(2):261–4.

HbA1c determination in patients with hemoglobinopathies [letter] Schnedl WJ, et al. **Diabetes Care** 1999 Feb; 22(2):368–9

Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. van der Does FE, et al. **Diabetes Care** 1998 Dec;21(12):2085–93

HBA1C measurement with the portable DCA 2000 device [letter] Papoz L, et al. **Diabetes Metab** 1998 Sep;24(4):368–9

Arterial hypertension and glycemia in non-diabetic subjects: is there an association independent of obesity? Kroke A, et al. **Diabetes Metab Res Rev** 1999 Mar-Apr;15(2):99–105

Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Hammes HP, et al. **Diabetologia** 1999 May;42(5):603–7

Diagnostic utility of glycosylated hemoglobin concentrations in the cat. Hoenig M, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):11–7

Is glycosylated haemoglobin a marker of fertility? A follow-up study of first-pregnancy planners. Hjollund NH, et al. **Hum Reprod** 1999 Jun;14(6):1478–82

A patient with a hemoglobin variant (Hb JLome) unexpectedly detected by HPLC for glycated hemoglobin (Hb A1c). Oshima Y, et al. **Int J Hematol** 1998 Oct; 68(3):317–21

Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Nakao T, et al. **Intern Med** 1998 Oct;37(10):826–30

Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. Elliott DA, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1794–8

Immunoturbidimetric assay of glycated hemoglobin. Metus P, et al. **J Clin Lab Anal** 1999;13(1):5–8

Is having a regular provider of diabetes care related to intensity of care and glycemic control? [see comments] O'Connor PJ, et al. **J Fam Pract** 1998 Oct;47(4):290–7. Comment in: J Fam Pract 1999 Apr;48(4):305.

Postmortem diagnosis of unsuspected diabetes mellitus established by determination of decedent's hemoglobin A1c level. Khuu HM, et al. **J Forensic Sci** 1999 May;44(3):643–6

Glycated haemoglobin in various pathological conditions: investigations based on a new, fully automated method. Haberer B, et al. **J Small Anim Pract** 1998 Nov;39(11):510–7

Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria [see comments] [published erratum appears in JAMA 1999 Jun 16;281(23):2187] Davidson MB, et al. **JAMA** 1999 Apr 7;281(13):1203–10. Comment in: JAMA 1998 Apr 7;281(13):1222–4.

Self-reported diabetes and distribution of HbA1c in a population-based sample in Victoria [letter; comment] McCarty CA, et al. **Med J Aust** 1999 Mar 1;170(5):238–9 . Comment on: Med J Aust 1995 Aug 7;163(3):129–32.

Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Tarim O, et al. **Pediatr Int** 1999 Aug; 41(4):357–62

Association between diabetes control and visits to a multidisciplinary pediatric diabetes clinic. Kaufman FR, et al. **Pediatrics** 1999 May;103(5 Pt 1):948–51

Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction. Chowdhury TA, et al. **Postgrad Med J** 1998 Aug;74(874):480–1

Age does not influence levels of HbA1c in normal subject. Wiener K, et al. **QJM** 1999 Mar;92(3):169–73

Accuracy of conversion formulae for estimation of glycohaemoglobin. Camargo JL, et al. **Scand J Clin Lab Invest** 1998 Oct;58(6):521–8

Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Smulders RA, et al. **Thromb Haemost** 1998 Jul;80(1):52–7

[What's new about hemoglobin A1C? Groupe de travail Standardisation des dosages d'hémoglobin glyquée de la Socieété française de biologie clinique] Gillery P. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):455–7 **(Fre)**

[Glycated hemoglobins: the time for standardization has arrived (editorial)] Gillery P, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):249–51 **(Fre)**

[More than diabetics? (editorial)] Trivin F. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):385–6 **(Fre)**

HBA1c: clinical and biological agreement for standardization of assay methods. Report by the experts of ALFEDIAM (Association de Langue Française pour lÉtude du Diabète et des Maladies Métabolique) and SFBC (Société Française de Biologie Clinique)] Gillery P, et al. **Diabetes Metab** 1999 Sep;25(3):283–7 (Eng. Abstr.) **(Fre)**

[Which HbA1c to look at?] Marre M. **Journ Annu Diabetol Hotel Dieu** 1998;:249–56 (26 ref.) **(Fre)**

[Rapid hemoglobin A1c determination (a new possibility in diabetes care)] Jermendy G, et al. **Orv Hetil** 1999 May 30;140(22):1251–4 (Eng. Abstr.) **(Hun)**

[The blood sugar levels after hypothermic cardiopulmonary bypass in diabetic patients: their relation to preoperative values of hemoglobin-A1c and medication] Kihara M, et al. **Masui** 1999 Feb;48(2):172–5 (Eng. Abstr.) **(Jpn)**

[Vascular risk factors in non-insulin-dependent diabetes mellitus. Correlation between albuminuria and glycosylated hemoglobin] Zancada Diaz de Entre-Sotos F, et al. **An Med Interna** 1999 Apr;16(4):181–5 (Eng. Abstr.) **(Spa)**

[The usefulness of basal blood glucose and glycosylated hemoglobin for the detection of abnormal glucose tolerance in the relatives of patients with type-2 diabetes mellitus] Costa A, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):241–4 (Eng. Abstr.) **(Spa)**

[Comparative study of glycosylated hemoglobin with oral glucose tolerance test in a selected population] Viñes GB, et al. **Medicina (B Aires)** 1998;58(6):728–32 (Eng. Abstr.) **(Spa)**

[Comparative study of the analyzers L-9100 (Merck-Hitachi) and HA-8121 (Menarini) for the determination of glycosylated hemoglobin] Quetglas P, et al. **Sangre (Barc)** 1998 Oct;43(5):439–42 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Novel inhibitors of advanced glycation endproducts. Rahbar S, et al. **Biochem Biophys Res Commun** 1999 Sep 7; 262(3):651–6

The evidence for insulin lispro [letter; comment] Grossman LD. **CMAJ** 1999 Jun 1;160(11):1551–2. Comment on: CMAJ 1998 Feb 24;158(4):506–11. Comment on: CMAJ 1998 Dec 1;159(11):1353–5.

Day-to-day consistency in amount and source of carbohydrate associated with improved blood glucose control in type 1 diabetes. Wolever TM, et al. **J Am Coll Nutr** 1999 Jun;18(3):242–7

ISOLATION & PURIFICATION

Practical aspects of managing diabetes in adolescents. Mortensen HB. **Acta Paediatr Suppl** 1998 Oct;425:72–6 (27 ref.)

METABOLISM

The effects of first-trimester diabetes control on the incidence of macrosomia. Rey E, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):202–6

Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. Hudson PR, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):451–9

Mean corpuscular volume is not a reliable marker of red cell age in case of anisocytosis. Kocsis A, et al. **Ann Hematol** 1998 Oct;77(4):149–51

Glycated hemoglobin as a physiological measure of stress and its relations to some psychological stress indicators. Schuck P. **Behav Med** 1998 Summer;24(2):89–94

Levels of lipid peroxidation product and glycated hemoglobin A1c in the erythrocytes of diabetic patients. Inouye M, et al. **Clin Chim Acta** 1998 Aug 28;276(2):163–72

Link between glycation and lipoxidation in red blood cells in diabetes. Inouye M, et al. **Clin Chim Acta** 1999 Jul; 285(1-2):35–44

A new rapid method to detect inhibition of Amadori product generated by delta-gluconolactone. Rahbar S, et al. **Clin Chim Acta** 1999 Sep;287(1-2):123–30

Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control. Turk Z, et al. **Clin Chim Acta** 1998 Oct;277(2):159–70

Are European standard deviation targets for haemoglobin A1c too strict? Kilpatrick ES, et al. **Diabet Med** 1998 Nov; 15(11):920–3

Long-term glycaemic control directly correlates with glomerular filtration rate in early Type 1 diabetes mellitus before the onset of microalbuminuria. Soper CP, et al. **Diabet Med** 1998 Dec;15(12):1010–4

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Ciofetta M, et al. **Diabetes Care** 1999 May;22(5):795–800

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30–60% of energy from carbohydrate [see comments] Wolever TM, et al. **Diabetes Care** 1998 Oct;21(10):1612–8. Comment in: Diabetes Care 1999 Jul;22(7):1227.

Ability of patients with type 1 diabetes mellitus to predict changes in HbA1c levels. Jorde R. **Diabetes Metab** 1999 Sep;25(3):241–5

An inverse correlation between serum leptin levels and hemoglobin A1c in patients with non-insulin dependent diabetes mellitus. Moriya M, et al. **Diabetes Res Clin Pract** 1999 Mar;43(3):187–91

Association between HbA1c and HDL-cholesterol independent of fasting triglycerides in a Caucasian population: evidence for enhanced cholesterol ester transfer induced by in vivo glycation [letter; comment] Bakker SJ, et al. **Diabetologia** 1998 Oct;41(10):1249–50. Comment on: Diabetologia 1997 Sep;40(9):1085–93.

Relation of fibre intake to HbA1c and the prevalence of severe ketoacidosis and severe hypoglycaemia. EURODIAB IDDM Complications Study Group. Buyken AE, et al. **Diabetologia** 1998 Aug;41(8):882–90

Relationship between glycosylated hemoglobin and the prevalence of proteinuria in Japanese men. Hashimoto Y, et al. **Intern Med** 1999 Jan;38(1):6–11

The frequency and severity of retinopathy are related to HbA1c values after, but not at, the diagnosis of NIDDM. Henricsson M, et al. **J Intern Med** 1998 Aug;244(2):149–54

Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. de Groot M, et al. **J Psychosom Res** 1999 May;46(5):425–35

Type 1 diabetes mellitus in early childhood: glycemic control and associated risk of hypoglycemic reactions [see comments] Lteif AN, et al. **Mayo Clin Proc** 1999 Mar; 74(3):211–6. Comment in: Mayo Clin Proc 1999 Mar;74(3):309–11.

Glycated hemoglobin and lipid peroxidation in erythrocytes of diabetic patients. Inouye M, et al. **Metabolism** 1999 Feb; 48(2):205–9

No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Ligtenberg PC, et al. **Neth J Med** 1999 Aug;55(2):59–63

Economic evaluation of alternative indicators for screening for diabetes mellitus. Shirasaya K, et al. **Prev Med** 1999 Aug;29(2):79–86

["Good" blood glucose values, "bad" HbA1c] Osterwalder P, et al. **Schweiz Rundsch Med Prax** 1998 Sep 23; 87(39):1260–2 **(Ger)**

PHARMACOLOGY

Effect of glycosylated hemoglobin on endothelium-dependent relaxation of omental arteries from pregnant women. Vedernikov Y, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):1047–50

HEMOGLOBIN A(1) see HEMOGLOBIN A, GLYCOSYLATED

HEMOGLOBIN A2

ANALYSIS

Evaluation of a capillary electrophoresis method for routine determination of hemoglobins A2 and F. Cotton F, et al. **Clin Chem** 1999 Feb;45(2):237–43

Interference of hemoglobin D in hemoglobin A(2) measurement by cation-exchange HPLC [letter] Cotton F, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1317–8

Hb A2 in subjects with Hb D [letter; comment] [see comments] Dash S. **Clin Chem** 1998 Nov;44(11):2381–2. Comment on: Clin Chem 1997 Oct;43(10):1850–6. Comment in: Clin Chem 1999 Aug;45(8 Pt 1):1317–8.

Comparison of FPLC with cellulose acetate electrophoresis for the diagnosis of beta-thalassaemia trait. Desai SN, et al. **Indian J Med Res** 1998 Oct;108:145–8

Haematological parameters and HbA2 levels in beta-thalassaemia trait with coincident iron deficiency. Madan N, et al. **Indian J Pathol Microbiol** 1998 Jul; 41(3):309–13

Influence of iron deficiency anaemia on haemoglobin A2 levels: possible consequences for beta-thalassaemia screening. Harthoorn-Lasthuizen EJ, et al. **Scand J Clin Lab Invest** 1999 Feb;59(1):65–70

HEMOGLOBIN A2

GENETICS

Phenotypic expression of hemoglobin A2 in beta-thalassemia trait with iron deficiency. Madan N, et al. **Ann Hematol** 1998 Sep;77(3):93-6

METABOLISM

Haemoglobin A2 concentration in glucose-6-phosphate-dehydrogenase-deficient patients. Al-Jawadi O, et al. **Acta Haematol** 1998;100(2):99-100

HEMOGLOBIN C

ANALYSIS

Blood transfusion-acquired hemoglobin C. Suarez AA, et al. **Arch Pathol Lab Med** 1999 Jul;123(7):642-3

Glycohemoglobin results in samples with hemoglobin C or S trait: a comparison of four test systems. Roberts WL, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):906-9

CHEMISTRY

Solution-active structural alterations in liganded hemoglobins C (beta6 Glu --> Lys) and S (beta6 Glu --> Val). Hirsch RE, et al. **J Biol Chem** 1999 May 14; 274(20):13777-82

GENETICS

Hemoglobins in Togolese newborns: Hb S, Hb C, Hb Bart's, and alpha-globin gene status. Segbena AY, et al. **Am J Hematol** 1998 Nov;59(3):208-13

HEMOGLOBIN C DISEASE

COMPLICATIONS

[Vitreo-retinal complications of hemoglobinopathy SC] Ndiaye PA, et al. **Dakar Med** 1998;43(1):21-4 (Eng. Abstr.) **(Fre)**

HEMOGLOBIN E

GENETICS

Phenotypic variability of Filipino beta(o)-thalassemia/HbE patients in Indonesia. Setianingsih I, et al. **Am J Hematol** 1999 Sep;62(1):7-12

Influence of hemoglobin E trait on the severity of Falciparum malaria. Hutagalung R, et al. **J Infect Dis** 1999 Jan; 179(1):283-6

Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. Eichhorn RF, et al. **J Intern Med** 1999 Jan;245(1):103-6

METABOLISM

Serum levels of tumor necrosis factor-alpha, interleukin-1, and interferon-gamma in beta(o)-thalassemia/HbE and their clinical significance. Wanachiwanawin W, et al. **J Interferon Cytokine Res** 1999 Feb;19(2):105-11

HEMOGLOBIN, ERYTHROCYTE, MEAN CELL see **ERYTHROCYTE INDICES**

HEMOGLOBIN F see **FETAL HEMOGLOBIN**

HEMOGLOBIN F DISEASE see **BETA-THALASSEMIA**

HEMOGLOBIN H

ANALYSIS

Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease. Papassotiriou I, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):539-44

HEMOGLOBIN H DISEASE see **ALPHA-THALASSEMIA**

HEMOGLOBIN J

ANALYSIS

A patient with a hemoglobin variant (Hb JLome) unexpectedly detected by HPLC for glycated hemoglobin (Hb A1c). Oshima Y, et al. **Int J Hematol** 1998 Oct; 68(3):317-21

GENETICS

Posttranslational deamidation of proteins: the case of hemoglobin J Sardegna [alpha50(CD8)His-->Asn-->Asp]. Paleari R, et al. **Clin Chem** 1999 Jan;45(1):21-8

HEMOGLOBIN M

GENETICS

Identification of the molecular genetic defect of patients with methemoglobin M-Kankakee (M-Iwate), alpha87 (F8) His --> Tyr: evidence for an electrostatic model of alphaM hemoglobin assembly. Ameri A, et al. **Blood** 1999 Sep 1; 94(5):1825-6

HEMOGLOBIN S see **HEMOGLOBIN, SICKLE**

HEMOGLOBIN S DISEASE see **ANEMIA, SICKLE CELL**

HEMOGLOBIN SC DISEASE

Mitral valve replacement in Sickle C disease using intraoperative exchange transfusion. Madan AK, et al. **J Card Surg** 1998 Jan;13(1):48-50

BLOOD

Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. van der Dijs FP, et al. **Am J Hematol** 1998 Nov;59(3):192-8

Plasma homocysteine levels and folate status in children with sickle cell anemia [see comments] Rodriguez-Cortes HM, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):219-23 . Comment in: J Pediatr Hematol Oncol 1999 May-Jun;21(3):176-8.

COMPLICATIONS

Infections and immunizations of children with sickle cell disease. Overturf GD. **Adv Pediatr Infect Dis** 1999; 14:191-218 (90 ref.)

Hemoglobin SC and multiple myeloma [letter] Nicoleau A, et al. **Am J Hematol** 1999 Mar;60(3):250-1

Trans-scleral diode laser photocoagulation in proliferative sickle cell retinopathy. Seiberth V. **Ophthalmology** 1999 Sep;106(9):1828-9

Transient left ventricular dysfunction in childhood sickle cell disease. Johnson WH Jr, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):221-3

[Autologous transfusion and hemoglobin SC disease] Lecam B, et al. **Ann Fr Anesth Reanim** 1999 Feb;18(2):233-6 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Spontaneous labyrinthine hemorrhage in sickle cell disease. Whitehead RE, et al. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1437-40

Accuracy of pulse oximetry in sickle cell disease. Ortiz FO, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):447-51

Hemoglobin SC disease presenting as acute chest syndrome with ventilation-perfusion mismatches. Noto H. **Respiration** 1999;66(1):73-7

PATHOLOGY

Morphological features of the human umbilical vein in normal, sickle cell trait, and sickle cell disease pregnancies. Decastel M, et al. **Hum Pathol** 1999 Jan;30(1):13-20

Pulmonary bone marrow embolism in sickle cell disease. Eckardt P, et al. **South Med J** 1999 Feb;92(2):245-7

PHYSIOPATHOLOGY

Hemoglobin SC disease and proliferative retinopathy. Carraro MC, et al. **Haematologica** 1998 Oct;83(10):944-5

Platelet-erythrocyte adhesion in sickle cell disease. Wun T, et al. **J Investig Med** 1999 Mar;47(3):121-7

PSYCHOLOGY

Comparison of attitudes about communication in children and adolescents with sickle cell disease. Fuller J, et al. **Percept Mot Skills** 1998 Oct;87(2):634

THERAPY

Role of nutritional supplement in sickle cell disease [comment] Wang WC. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):176-8. Comment on: J Pediatr Hematol Oncol 1999 May-Jun;21(3):219-23.

HEMOGLOBIN, SICKLE

Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Zimmerman SA, et al. **Am J Hematol** 1999 Apr;60(4):279-84 (27 ref.)

Osmotic fragility of normal and sickle haemoglobin containing red blood cells [letter] Dash BP, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):267-9

ANALYSIS

Glycohemoglobin results in samples with hemoglobin C or S trait: a comparison of four test systems. Roberts WL, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):906-9

Red blood cell indices, cation content, and membrane cation transports. de Franceschi L, et al. **Hemoglobin** 1998 Sep-Nov;22(5-6):493-500

CHEMISTRY

A biochemical and biophysical characterization of recombinant mutants of fetal hemoglobin and their interaction with sickle cell hemoglobin. Larson SC, et al. **Biochemistry** 1999 Jul 20;38(29):9549-55

The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Kim-Shapiro DB, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):381-7

Temperature and domain size dependence of sickle cell hemoglobin polymer melting in high concentration phosphate buffer. Louderback JG, et al. **Biophys Chem** 1999 Jul 19;80(1):21-30

Sickle hemoglobin polymer melting in high concentration phosphate buffer. Louderback JG, et al. **Biophys J** 1999 Apr;76(4):2216-22

Mutational analysis of sickle haemoglobin (Hb) gelation. Li X, et al. **Biotechnol Appl Biochem** 1999 Apr;29 (Pt 2):165-84

Red blood cell indices, cation content, and membrane cation transports. de Franceschi L, et al. **Hemoglobin** 1998 Sep-Nov;22(5-6):493-500

Effects of S-nitrosation on oxygen binding by normal and sickle cell hemoglobin. Bonaventura C, et al. **J Biol Chem** 1999 Aug 27;274(35):24742-8

Polymer structure and solubility of deoxyhemoglobin S in the presence of high concentrations of volume-excluding 70-kDa dextran. Effects of non-s hemoglobins and inhibitors. Bookchin RM, et al. **J Biol Chem** 1999 Mar 5; 274(10):6689-97

Crystal structure of deoxy-human hemoglobin beta6 Glu --> Trp. Implications for the structure and formation of the sickle cell fiber. Harrington DJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32690-6

Solution-active structural alterations in liganded hemoglobins C (beta6 Glu --> Lys) and S (beta6 Glu --> Val). Hirsch RE, et al. **J Biol Chem** 1999 May 14; 274(20):13777-82

GENETICS

Hemoglobins in Togolese newborns: Hb S, Hb C, Hb Bart's, and alpha-globin gene status. Segbena AY, et al. **Am J Hematol** 1998 Nov;59(3):208-13

HbS-oman heterozygote: a new dominant sickle syndrome. Nagel RL, et al. **Blood** 1998 Dec 1;92(11):4375-82

Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia. Alami R, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):110-9

Haemorheological changes and fibrinolytic activity in adult asthmatic patients with sickle cell trait (HbAS). Famodu AA. **Clin Hemorheol Microcirc** 1998 Sep;19(1):1-5

Severe Hb S-beta+ thalassemia caused by IVS-I splice site mutations. Li J, et al. **Hemoglobin** 1998 Jul;22(4):383-6

Repairing the sickle cell mutation. I. Specific covalent binding of a photoreactive third strand to the mutated base pair. Broitman S, et al. **J Biol Chem** 1999 Jul 30; 274(31):21763-8

In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. Embury SH, et al. **J Clin Invest** 1999 Mar;103(6):915-20

Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. Eichhorn RF, et al. **J Intern Med** 1999 Jan;245(1):103-6

Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb betas-globin yeast artificial chromosome: A mouse model of sickle cell anemia. Chang JC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14886-90

[Splenic infarct in heterozygote sickle cell trait (Hb AS)] von Känel R, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1614-7 (Eng. Abstr.) **(Ger)**

METABOLISM

A biochemical and biophysical characterization of recombinant mutants of fetal hemoglobin and their interaction with sickle cell hemoglobin. Larson SC, et al. **Biochemistry** 1999 Jul 20;38(29):9549-55

Trimodal distribution of HbS levels in sickle heterozygotes--an useful predictor of the alpha-genotype for population screening. Mukherjee MB, et al. **Indian J Med Res** 1998 Dec;108:285-90

PHYSIOLOGY

The effect of hemoglobin A and S on the volume- and pH-dependence of K-Cl cotransport in human erythrocyte ghosts. Vitoux D, et al. **J Membr Biol** 1999 Feb 1; 167(3):233-40

HEMOGLOBIN SUBSTITUTES see **BLOOD SUBSTITUTES**

HEMOGLOBINOMETRY

Evaluation of acetaldehyde-modified hemoglobin and other markers of chronic heavy alcohol use: effects of gender and hemoglobin concentration. Hazelett SE, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1813-9

[Perioperative monitoring of hemoglobin fractions in homozygous sickle cell disease] Frietsch T, et al. **Anaesthesist** 1999 Apr;48(4):231-5 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Accuracy of bedside haemoglobin measurement [letter] Chen PP. **Anaesthesia** 1998 Sep;53(9):932

HaemoCue for haemoglobin monitoring [letter; comment] Luger TJ, et al. **Anaesthesia** 1998 Nov;53(11):1136. Comment on: Anaesthesia 1998 Apr;53(4):349-52.

Accuracy of methemoglobin measurements: comparison of six different commercial devices and one manual method. Dötsch J, et al. **Crit Care Med** 1999 Jun;27(6):1191–4

METHODS

Diagnosing anaemia in pregnancy in rural clinics: assessing the potential of the Haemoglobin Colour Scale. van den Broek NR, et al. **Bull World Health Organ** 1999;77(1):15–21

Determination of Hb F levels: the routine methods. Préhu C, et al. **Hemoglobin** 1998 Sep–Nov;22(5–6):459–67

Inexpensive and reliable haemoglobin colour scale [letter] Topley E. **J Clin Pathol** 1998 Nov;51(11):878

Hemoglobin determination in blood donors [letter] Vuk T, et al. **Vox Sang** 1998;75(1):73

HEMOGLOBINOPATHIES

[A center for hemoglobin diseases in the county of Copenhagen] Birgens H, et al. **Ugeskr Laeger** 1999 Jan 25; 161(4):445–6 **(Dan)**

[Hemoglobinopathy in Japan: detection and analysis] Harano T. **Rinsho Byori** 1999 Mar;47(3):215–23 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of abnormal Hb on red cell membranes] Ideguchi H. **Rinsho Byori** 1999 Mar;47(3):232–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The origin of molecular disease: functional abnormalities and consequent clinical symptoms caused by single amino acid substitutions] Imai K. **Rinsho Byori** 1999 Mar;47(3):238–43 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

HbA1c determination in patients with hemoglobinopathies [letter] Schnedl WJ, et al. **Diabetes Care** 1999 Feb; 22(2):368–9

Serum vitamin A and E in pregnant women with hemoglobinopathies. Phuapradit W, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):173–6

[Reticulocytes parameters in some hemolysis syndromes: preliminary results obtained with the Coulter Gen.S system] Fourcade C, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb;57(1):85–9 **(Fre)**

COMPLICATIONS

Healing of chronic leg ulcers in the hemoglobinopathies with perilesional injections of granulocyte–macrophage colony–stimulating factor [letter] Voskaridou E, et al. **Blood** 1999 May 15;93(10):3568–9

Pituitary deficiency and lack of gonads in an XY pseudohermaphrodite with beta 39/lepore haemoglobinopathy. Saviano A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:997–9

Partial splenectomy in children under 4 years of age with hemoglobinopathy. Idowu O, et al. **J Pediatr Surg** 1998 Aug;33(8):1251–3

Association of Hb–D trait with nephrotic syndrome: a fact or coincidence? Jamal A, et al. **JPMA J Pak Med Assoc** 1999 Feb;49(2):44–5

DIAGNOSIS

Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Zimmerman SA, et al. **Am J Hematol** 1999 Apr;60(4):279–84 (27 ref.)

Hemoglobinopathy screening in pregnancy: comparison of two protocols. Chasen ST, et al. **Am J Perinatol** 1999; 16(4):175–80

Costing model for neonatal screening and diagnosis of haemoglobinopathies. Cronin EK, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F161–7

Ethnicity study and non–selective screening for haemoglobinopathies in the antenatal population of central Manchester. Kadkhodaei Elyaderani M, et al. **Clin Lab Haematol** 1998 Aug;20(4):207–11

HbA1c determination in patients with hemoglobinopathies [letter] Schnedl WJ, et al. **Diabetes Care** 1999 Feb; 22(2):368–9

Screening for hemoglobinopathies in neonates in Argentina [letter] Noguera NI, et al. **Haematologica** 1999 May; 84(5):468–70

Newborn screening for haemoglobinopathies: the Brussels experience. Gulbis B, et al. **J Med Screen** 1999;6(1):11–5

[Hemoglobin Sydney––alpha beta 2 67 (E11) Val–Ala and hemoglobin Olomouc alpha 2 beta 2 86 (F 2) Ala–Asp in Czech families. DNA sequence analysis for a more accurate diagnosis of hemoglobinopathies] Indrák K, et al. **Vnitr Lek** 1998 Jun;44(6):347–9 (Eng. Abstr.) **(Cze)**

[Screening for hemoglobinopathy (letter)] Birgens HS, et al. **Ugeskr Laeger** 1999 Feb 22;161(8):1137–8 **(Dan)**

[Genetic carrier screening for hemoglobinopathies: the situation in the Netherlands compared with England (see comments)] van Rhee MA, et al. **Ned Tijdschr Geneeskd** 1998 May 2;142(18):996–7 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):326–7. **(Dut)**

[Heterozygote detection for hemoglobinopathies: situation in the Netherlands as compared to the British (letter; comment)] Wierenga KJ, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):326–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):996–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):1019–22. **(Dut)**

[Evaluation of high performance liquid chromatography modular system for the diagnosis of hemoglobinopathies] Lusina D, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec; 56(6):734–9 **(Fre)**

[Diagnosis of thalassemias and hemoglobinopathies by HPLC (high performance liquid chromatography): study of 627 patients] Sabo G, et al. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1196–200 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Pouillart PR. **Life Sci** 1998;63(20):1739–60 (225 ref.)

EPIDEMIOLOGY

Evaluation of cation–exchange HPLC compared with isoelectric focusing for neonatal hemoglobinopathy screening. Campbell M, et al. **Clin Chem** 1999 Jul; 45(7):969–75

[Prevalence of hemoglobin abnormalities in Kebili (Tunisian South)] Mseddi S, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):29–36 (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Ethnicity study and non–selective screening for haemoglobinopathies in the antenatal population of central Manchester. Kadkhodaei Elyaderani M, et al. **Clin Lab Haematol** 1998 Aug;20(4):207–11

[Genetic carrier screening for hemoglobinopathies in the Netherlands is not opportune (see comments)] Schulpen TW, et al. **Ned Tijdschr Geneeskd** 1998 May 2; 142(18):1019–22 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Feb 6;143(6):326–7. **(Dut)**

[Hemoglobinopathies in students at the Russian University of the Friendship of Peoples] Troitskaia OV, et al. **Klin Lab Diagn** 1999 May;(5):19–24, 41–6 (51 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The 11th conference on hemoglobin switching. Orcas Island, Washington, USA. October 2–6, 1998. Abstracts. **Blood Cells Mol Dis** 1998 Dec;24(4):462–521

HbOThrace trait, HbOThrace hemoglobinopathy and HbOThrace/Hb beta zero hemoglobinopathy: a retrospective study of 118 cases. Vassiliadou D, et al. **Folia Med (Plovdiv)** 1998;40(3B Suppl 3):46–50

Molecular diagnosis and characterization of Hb Zürich [beta63(E7)His––>Arg]] carriers in a Kentucky family. Aguinaga MP, et al. **Hemoglobin** 1998 Sep–Nov; 22(5–6):509–15

Hb Köln [beta98(FG5)Val––>Met]: the first case found in a Chinese family. Chang JG, et al. **Hemoglobin** 1998 Sep–Nov;22(5–6):535–6

Hb Tende [beta124(H2)Pro––>Leu]: a new variant with a moderate increase in oxygen affinity. Wajcman H, et al. **Hemoglobin** 1998 Sep–Nov;22(5–6):517–23

[Murine models of hemoglobinopathies] Beuzard Y. **Pathol Biol (Paris)** 1998 Feb;46(2):118–9 **(Fre)**

METABOLISM

Hemoglobinopathies affecting maternal–fetal oxygen gradient during pregnancy: molecular, biochemical and clinical studies. Bard H, et al. **Am J Perinatol** 1998 Jun;15(6):389–93

THERAPY

Stem cell gene therapy for the beta–chain hemoglobinopathies. Problems and progress. Emery DW, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:94–107; discussion 107–8 (64 ref.)

Gene therapy: repairing haemoglobin disorders with ribozymes. Weatherall DJ. **Curr Biol** 1998 Sep 24; 8(19):R696–8 (13 ref.)

Why do in utero stem cell transplants sometimes fail? Jones DR. **Mol Med Today** 1999 Jul;5(7):288–91

Prenatal cellular transplantation. Albanese CT, et al. **Semin Pediatr Surg** 1999 Aug;8(3):101–8 (71 ref.)

HEMOGLOBINS

see related

IRON CHELATING AGENTS

Exercise–induced hemoconcentration in heart failure due to dilated cardiomyopathy. Agostoni P, et al. **Am J Cardiol** 1999 Jan 15;83(2):278–80, A6

Resuscitation of the injured patient with polymerized stroma–free hemoglobin does not produce systemic or pulmonary hypertension. Johnson JL, et al. **Am J Surg** 1998 Dec;176(6):612–7

Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation. Azari M, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov; 26(5–6):577–82

Evaluation of methemoglobin formation during the storage of various hemoglobin solutions. Moore GL, et al. **Artif Organs** 1992 Oct;16(5):513–8

Modified hemoglobin blood substitutes: present status and future perspectives. Chang TM. **Biotechnol Annu Rev** 1998; 4:75–112 (163 ref.)

WHO haemoglobin colour scale is modern version of what was used previously [letter] Lewis SM. **BMJ** 1998 Oct 3; 317(7163):949

Severe pyruvate kinase deficiency anemia. A case report. Ghidini A, et al. **J Reprod Med** 1998 Aug;43(8):713–5

Altitude training at 2690m does not increase total haemoglobin mass or sea level VO2max in world champion track cyclists [published erratum appears in J Sci Med Sport 1998 Dec;1(4):202] Gore CJ, et al. **J Sci Med Sport** 1998 Sep;1(3):156–70

Effect of hemoglobin on radiotherapy response in children with medulloblastoma: should patients with a low hemoglobin be transfused? Chow E, et al. **Med Pediatr Oncol** 1999 May;32(5):395–7

Transfusions in critically ill patients [editorial; comment] Ely EW, et al. **N Engl J Med** 1999 Feb 11;340(6):467–8. Comment on: N Engl J Med 1999 Feb 11;340(6):409–17.

Blood transfusions in critical care [letter; comment] Pilla MA. **N Engl J Med** 1999 Jul 8;341(2):123; discussion 124. Comment on: N Engl J Med 1999 Feb 11;340(6):409–17.

Hemoglobin–based blood substitutes: oxygen carriers, pressor agents, or oxidants? Alayash AI. **Nat Biotechnol** 1999 Jun; 17(6):545–9 (53 ref.)

Correct assembly of human normal adult hemoglobin when expressed in transgenic swine: chemical, conformational and functional equivalence with the human–derived protein. Manjula BN, et al. **Protein Eng** 1998 Jul; 11(7):583–8

[Measurement of haptoglobin by immunonephelometry using Immage (Beckmann): pay attention to interference by hemoglobin (letter)] Zerbani A, et al. **Ann Biol Clin (Paris)** 1999 Jul–Aug;57(4):490 **(Fre)**

[Red cell substitutes: perfluorocarbon emulsions and hemoglobin solutions] Rémy B, et al. **Ann Fr Anesth Reanim** 1999 Feb;18(2):211–24 (76 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Microvascular responses to hemodilution with Hb vesicles as red blood cell substitutes: influence of O2 affinity. Sakai H, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H553–62

Hemodynamic changes induced by liposomes and liposome–encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti–C5a antibody. Szebeni J, et al. **Circulation** 1999 May 4;99(17):2302–9

Effects of free and liposome–encapsulated hemoglobin on choroidal vascular plexus blood flow, using the rabbit eye as a model system. Flower R, et al. **Eur J Ophthalmol** 1999 Apr–Jun;9(2):103–14

Effect of diaspirin cross–linked hemoglobin on endothelin–1 and blood pressure in acute ischemic stroke in man. Saxena R, et al. **J Hypertens** 1998 Oct;16(10):1459–65

Controlled safety study of a hemoglobin–based oxygen carrier, DCLHb, in acute ischemic stroke. Saxena R, et al. **Stroke** 1999 May;30(5):993–6

ADVERSE EFFECTS

Deciphering the dark side of free hemoglobin in sepsis [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):685–6 (10 ref.). Comment on: Crit Care Med 1999 Apr;27(4):771–8.

ANALYSIS

A comparison of the monitors INVOS 3100 and NIRO 500 in detecting changes in cerebral oxygenation. Grubhofer G, et al. **Acta Anaesthesiol Scand** 1999 Apr;43(4):470–5

Relation between hemoglobin discordance and adverse outcome in monochorionic twins. Honma Y, et al. **Acta Obstet Gynecol Scand** 1999 Mar;78(3):207–11

Heterogeneity (DVT) depth determination using phase shift and time constant values from NIR–TRS spectra. Hemelt MW, et al. **Adv Exp Med Biol** 1998;454:671–9

Anaemia is an independent predictive marker for clinical prognosis in HIV–infected patients from across Europe. EuroSIDA study group. Mocroft A, et al. **AIDS** 1999 May 28;13(8):943–50

Precision, accuracy, and reliability of hemoglobin assessment with use of capillary blood. Morris SS, et al. **Am J Clin Nutr** 1999 Jun;69(6):1243–8

School–administered weekly iron–folate supplements improve hemoglobin and ferritin concentrations in Malaysian adolescent girls. Tee ES, et al. **Am J Clin Nutr** 1999 Jun;69(6):1249–56

Accuracy of measurements of hemoglobin and potassium in blood samples from peripheral catheters. Fincher RK, et al. **Am J Crit Care** 1998 Nov;7(6):439–43

Variations in regional cerebral blood volume in neonates associated with nursery care events. Gagnon RE, et al. **Am J Perinatol** 1999;16(1):7–11

Percent of oxygen saturation of arterial hemoglobin among Bolivian Aymara at 3,900–4,000 m. Beall CM, et al. **Am J Phys Anthropol** 1999 Jan;108(1):41–51

Evaluation of automated methods of measuring hemoglobin and hematocrit in horses. Sorrell–Raschi LA, et al. **Am J Vet Res** 1998 Dec;59(12):1519–22

High–performance liquid chromatography in clinical analysis. Anderson DJ. **Anal Chem** 1999 Jun 15; 71(12):314R–327R (379 ref.)

Characterization of hemoglobin variants by MALDI–TOF

MS using a polyurethane membrane as the sample support. McComb ME, et al. **Anal Chem** 1998 Dec 15;70(24):5142–9

Acute severe hemodilution to a hemoglobin of 1.3 g/dl tolerated in the presence of mild hypothermia [letter] Koehntop DE, et al. **Anesthesiology** 1999 Jun;90(6):1798–9

Changes in the functional properties of bovine hemoglobin induced by covalent modification with polyethylene glycol. Shorr RG, et al.
Artif Cells Blood Substit Immobil Biotechnol 1999 May; 27(3):185–202

In situ control of cardiotomy suction reduces blood trauma. Tevaearai HT, et al. **ASAIO J** 1998 Sep–Oct;44(5):M380–3

Spectrophotometric quantitative analysis of the main hemoglobin derivatives. Adamov SA, et al.
Biochemistry (Mosc) 1998 Oct;63(10):1160–3

Relationship between levels of leptin and hemoglobin in Japanese men [letter] Togo M, et al. **Blood** 1999 Jun 15; 93(12):4444–5

Preoperative packed cell volume necessary for patients undergoing elective surgery. Spence RK. **Br J Anaesth** 1998 Dec;81 Suppl 1:50–5 (46 ref.)

Seasonal effect on airborne pyrene, urinary 1-hydroxypyrene, and benzo(a)pyrene diol epoxide-hemoglobin adducts in the general population. Pastorelli R, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jun;8(6):561–5

HPLC detection of fetal blood in meconium: improved sensitivity compared with qualitative methods. Chen D, et al. **Clin Chem** 1998 Nov;44(11):2277–80

Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Datz C, et al. **Clin Chem** 1998 Dec;44(12):2429–32

Distribution of hemoglobin F, A, S, C, E, and D quantities in 4 million newborn screening specimens. Eastman JW, et al. **Clin Chem** 1999 May;45(5):683–5

Simplified interpretative format for assessing test interference: studies with hemoglobin-based oxygen carrier solutions. Kazmierczak SC, et al. **Clin Chem** 1998 Nov; 44(11):2347–52

Lyophilized bovine hemoglobin as a possible reference material for the determination of hemoglobin derivatives in human blood. Maas BH, et al. **Clin Chem** 1998 Nov; 44(11):2331–9

Multiple regression analysis of interference effects from a hemoglobin-based oxygen carrier solution. Kazmierczak SC, et al. **Clin Chem Lab Med** 1999 Apr;37(4):453–64

Spectrophotometric determination of trace amounts of hemoglobin using the oxidative decomposition reaction of a copper(II)-phthalocyanine complex. Takahata K, et al. **Clin Chim Acta** 1999 May;283(1–2):129–38

Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Tseng A, et al. **Clin Infect Dis** 1998 Oct;27(4):908–9

Use of intraosseous blood to assess blood chemistries and hemoglobin during cardiopulmonary resuscitation with drug infusions [see comments] Johnson L, et al.
Crit Care Med 1999 Jun;27(6):1147–52. Comment in: Crit Care Med 1999 Jun;27(6):1053–4.

Comparison of percent total GHb with percent HbA1c in people with and without known diabetes. Nuttall FQ.
Diabetes Care 1998 Sep;21(9):1475–80

Maternal haemoglobin and premature child delivery. Arafa M, et al. **East Mediterr Health J** 1998 Dec;4(3):480–6

Skin-prick blood samples are reliable for estimating Hb mass with the CO-dilution technique. Ashenden MJ, et al.
Eur J Appl Physiol 1999 May;79(6):535–7

Does the hemoglobin concentration in fetal blood interfere with the accuracy of fetal reflection pulse oximetry? Arikan GM, et al. **Fetal Diagn Ther** 1998 Jul–Aug;13(4):236–40

Hemoglobin levels and platelet counts after iron therapy in iron deficiency anemia. Cid J, et al. **Haematologica** 1998 Aug;83(8):749

Hematologic response in type I Gaucher's disease after enzyme replacement therapy [letter] Parco S, et al.
Haematologica 1999 Apr;84(4):376–7

Capillary zone electrophoresis: an additional technique for the identification of hemoglobin variants. Lin C, et al.
Hemoglobin 1999 May;23(2):97–109

Effects of iron supplementation on total body hemoglobin during endurance training at moderate altitude. Friedmann B, et al. **Int J Sports Med** 1999 Feb;20(2):78–85

Separation and detection of the alpha- and beta-chains of hemoglobin of a single intact red blood cells using capillary electrophoresis/electrospray ionization time-of-flight mass spectrometry. Cao P, et al. **J Am Soc Mass Spectrom** 1999 Feb;10(2):184–6

The clinical relevance of hemoglobin, platelet, and serotonin changes in sequestered and circulating blood during cardiopulmonary bypass. McNulty SE, et al.
J Cardiothorac Vasc Anesth 1998 Aug;12(4):402–7

Chemical and pharmacological evaluation of different ayurvedic preparations of iron. Pandit S, et al.
J Ethnopharmacol 1999 May;65(2):149–56

World Health Organization hemoglobin cut-off points for the detection of anemia are valid for an Indonesian population. Khusun H, et al. **J Nutr** 1999 Sep; 129(9):1669–74

Glycated haemoglobin in various pathological conditions: investigations based on a new, fully automated method. Haberer B, et al. **J Small Anim Pract** 1998 Nov;39(11):510–7

Hemoglobin near-infrared spectroscopy and surface EMG study in muscle ischaemia and fatiguing isometric contraction. Alfonsi E, et al.
J Sports Med Phys Fitness 1999 Jun;39(2):83–92

Novel techniques for in vivo hemolysis studies in guinea pigs. Tjatur Rasa FS, et al. **J Vet Med Sci** 1999 Feb;61(2):125–8

Reticulocyte hemoglobin content to diagnose iron deficiency in children [see comments] Brugnara C, et al. **JAMA** 1999 Jun 16;281(23):2225–30. Comment in: JAMA 1999 Jun 16;281(23):2247–8.

The definition of anemia in older persons. Izaks GJ, et al.
JAMA 1999 May 12;281(18):1714–7

Early occurrence of respiratory muscle deoxygenation assessed by near-infrared spectroscopy during leg exercise in patients with chronic heart failure. Terakado S, et al.
Jpn Circ J 1999 Feb;63(2):97–103

Packed-cell volume and haemoglobin in elite athletes [letter; comment] Tikkanen HO. **Lancet** 1999 Jan 23; 353(9149):327–8. Comment on: Lancet 1998 Aug 8;352(9126):451. Comment on: Lancet 1998 Nov 28;352(9142):1758.

Changes in blood hemoglobin concentration of middle-aged healthy men. Vlassov VV. **Mil Med** 1999 Apr;164(4):311–5

Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Glover RE, et al. **Mol Pharmacol** 1999 Jun;55(6):1006–10

Blood transfusions in critical care [letter; comment] Gemma M, et al. **N Engl J Med** 1999 Jul 8;341(2):123; discussion 124. Comment on: N Engl J Med 1999 Feb 11;340(6):409–17.

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group [see comments] Hébert PC, et al. **N Engl J Med** 1999 Feb 11;340(6):409–17. Comment in: N Engl J Med 1999 Feb 11;340(6):467–8. Comment in: N Engl J Med 1999 Jul 8;341(2):123; discussion 124. Comment in: N Engl J Med 1999 Jul 8;341(2):123–4. Comment in: ACP J Club 1999 Jul–Aug;131(1):9.

Hypochromic red cells and reticulocyte haemglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Cullen P, et al.
Nephrol Dial Transplant 1999 Mar;14(3):659–65

Nandrolone decanoate may be an adjuvant therapy to augment haemoglobin response today? [letter] Gascón A, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2257–8

Normalization of haemoglobin: why not? Jacobs C.
Nephrol Dial Transplant 1999;14 Suppl 2:75–9 (11 ref.)

Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Jones CH, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2873–6

Reevaluation of the Griess method for determining NO/NO2- in aqueous and protein-containing samples. Schulz K, et al. **Nitric Oxide** 1999 Jun;3(3):225–34

MRI measurements of cerebral deoxyhaemoglobin concentration [dHb]--correlation with near infrared spectroscopy (NIRS). Punwani S, et al. **NMR Biomed** 1998 Oct;11(6):281–9

Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Knapen MF, et al.
Obstet Gynecol 1998 Dec;92(6):1012–5

Hemoglobin and red cell indices correlated with serum ferritin concentration in late pregnancy. Tam KF, et al.
Obstet Gynecol 1999 Mar;93(3):427–31

The influence of a clear layer on near-infrared spectrophotometry measurements using a liquid neonatal head phantom. Wolf M, et al. **Phys Med Biol** 1999 Jul; 44(7):1743–53

Hemoglobin and myoglobin content in muscles of broiler chickens. Kranen RW, et al. **Poult Sci** 1999 Mar; 78(3):467–76

Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Canaday DJ, et al.
Radiat Oncol Investig 1999;7(1):42–8

Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Dunst J, et al. **Strahlenther Onkol** 1999 Mar;175(3):93–6

The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Frommhold H, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:31–4

Greater increase in cytokine concentration after salvage with filtered whole blood than with washed red cells, but no difference in postoperative hemoglobin recovery. Avall A, et al. **Transfusion** 1999 Mar;39(3):271–6

The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria. Camacho LH, et al. **Trop Med Int Health** 1999 Jul;4(7):471–5

Hemoglobin determination in blood donors [letter] Vuk T, et al. **Vox Sang** 1998;75(1):73

[Capillary free zone electrophoresis of globin chains] Liao Y, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Jun;16(3):180–4 (Eng. Abstr.) **(Chi)**

[Significance of the hemoglobin level in tumor therapy. Satellite Symposium. 9 November 1998]
Dtsch Med Wochenschr 1999 Mar;124(13 Suppl):1–12 **(Ger)**

[On hemoglobin, venesection, statins and mortality (letter)] Welander F. **Tidsskr Nor Laegeforen** 1999 Apr 30; 119(11):1648–9 **(Nor)**

[Biochemical status and iron intake in a population of pregnant women of Buenos Aires, Argentina] Martin de Portela ML, et al. **Medicina (B Aires)** 1998;58(2):194–6 (Eng. Abstr.) **(Spa)**

[A survey of non-approved blood donors in Ume]. Every seventh donor was not rejected, low Hb level was the most common cause] Axelsson CG, et al. **Lakartidningen** 1998 Dec 9;95(50):5776–8 **(Swe)**

BIOSYNTHESIS

A mutation that improves soluble recombinant hemoglobin accumulation in Escherichia coli in heme excess. Weickert MJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):640–7

Transcription factor CP2 is crucial in hemoglobin synthesis during erythroid terminal differentiation in vitro. Chae JH, et al. **Biochem Biophys Res Commun** 1999 Sep 24; 263(2):580–3

Construction of Escherichia coli-Streptomyces shuttle expression vectors for gene expression in Streptomyces. Yang R, et al. **Chin J Biotechnol** 1998;14(1):1–8

Proteolytic degradation of hemoglobin by endogenous lysosomal proteases gives rise to bioactive peptides: hemorphins. Fruitier I, et al. **FEBS Lett** 1999 Mar 19; 447(1):81–6

Phytase improves iron bioavailability for hemoglobin synthesis in young pigs. Stahl CH, et al. **J Anim Sci** 1999 Aug;77(8):2135–42

Heterogeneity and differential expression under hypoxia of two-domain hemoglobin chains in the water flea, Daphnia magna. Kimura S, et al. **J Biol Chem** 1999 Apr 9; 274(15):10649–53

Hemoglobin induction in mouse macrophages. Liu L, et al.
Proc Natl Acad Sci U S A 1999 Jun 8;96(12):6643–7

Immunocytochemical mapping of the hemoglobin biosynthesis site in amphibian erythroid cells. Cianciarullo AM, et al. **Tissue Cell** 1999 Jun;31(3):342–8

CHEMISTRY

Structures of the deoxy and CO forms of haemoglobin from Dasyatis akajei, a cartilaginous fish. Chong KT, et al.
Acta Crystallogr D Biol Crystallogr 1999 Jul;55 (Pt 7):1291–300

Crystallization of the haptoglobin–hemoglobin complex. Przybylska M, et al.
Acta Crystallogr D Biol Crystallogr 1999 Apr;55 (Pt 4):883–4

Human carboxyhemoglobin at 2.2 A resolution: structure and solvent comparisons of R-state, R2-state and T-state hemoglobins. Vásquez GB, et al.
Acta Crystallogr D Biol Crystallogr 1998 May 1;54 (Pt 3):355–66

Assessing the relative stabilities of engineered hemoglobins using electrospray mass spectrometry. Apostol I.
Anal Biochem 1999 Jul 15;272(1):8–18

Electrospray ionization mass spectrometric analysis of blood for differentiation of species. Espinoza EO, et al.
Anal Biochem 1999 Mar 15;268(2):252–61

A rapid method for hemoglobin chain recombination. Lee TC. **Anal Biochem** 1978 Dec;91(2):646–50

Carbamylation of cysteine: a potential artifact in peptide mapping of hemoglobins in the presence of urea. Lippincott J, et al. **Anal Biochem** 1999 Feb 1;267(1):57–64

Toward a simple, expedient, and complete analysis of human hemoglobin by MALDI-TOFMS. Houston CT, et al.
Anal Chem 1999 Aug 15;71(16):3397–404

Heroin-induced deoxygenation of cerebral hemoglobin: monitoring by means of near-infrared spectroscopy [letter] Hock C, et al. **Ann Neurol** 1999 Jan;45(1):134–5

Hemoglobin oxygenation of venous-perfused forearm flaps. Wolff KD, et al. **Ann Plast Surg** 1998 Dec;41(6):646–52; discussion 652–3

Hexagonal bilayer structuring activity of linker chains of an annelid giant hemoglobin from the polychaete Perinereis aibuhitensis. Gotoh T, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):75–84

PE-PEG/LEH can reduce its interactions with plasma expanders indexed through viscosity measurements. Chung TW, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 May;27(3):215–27

Oxygen releasing from cellular hemoglobin. Kawai N, et al.
Artif Cells Blood Substit Immobil Biotechnol 1998 Nov; 26(5–6):507–17

Effects of the pH-controlled hemoglobin vesicles by CO2 gas. Park S, et al.
Artif Cells Blood Substit Immobil Biotechnol 1998 Nov; 26(5–6):497–506

Changes in the functional properties of bovine hemoglobin induced by covalent modification with polyethylene glycol. Shorr RG, et al.
Artif Cells Blood Substit Immobil Biotechnol 1999 May; 27(3):185–202

Properties of hemoglobin and dextran-hemoglobin rightshifted by oxidized inositol tetrakisphosphate. Xue H, et al. **Artif Organs** 1992 Aug;16(4):427–31

Autoxidation of pyridoxalated hemoglobin polyoxyethylene conjugate. Talarico T, et al.
Biochem Biophys Res Commun 1998 Sep 18;250(2):354–8

Circe's haemoglobins, pig–human hybrids: functional characterization and structural considerations. Sanna MT, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):211–6

Stabilization of the T-state of human hemoglobin by

proflavine, an antiseptic drug. Ascenzi P, et al. **Biochem Mol Biol Int** 1999 Jun;47(6):991-5

Reactions of cross-linked ferric haemoglobins with hydrogen peroxide. Dunne J, et al. **Biochem Soc Trans** 1998 Nov; 26(4):S320

Crystal structure of the S-nitroso form of liganded human hemoglobin. Chan NL, et al. **Biochemistry** 1998 Nov 24; 37(47):16459-64

Novel allosteric conformation of human HB revealed by the hydration and anion effects on O(2) binding. Colombo MF, et al. **Biochemistry** 1999 Sep 7;38(36):11741-8

UV resonance Raman spectra reveal a structural basis for diminished proton and CO2 binding to alpha,alpha-cross-linked hemoglobin. Dick LA, et al. **Biochemistry** 1999 May 18;38(20):6406-10

Ligand-linked changes at the subunit interfaces in Scapharca hemoglobins probed through the sulfhydryl infrared absorption. Guarrera L, et al. **Biochemistry** 1999 Aug 3; 38(31):10079-83

Structural and functional properties of human hemoglobins reassembled after synthesis in Escherichia coli. Hui HL, et al. **Biochemistry** 1999 Jan 19;38(3):1040-9

Anionic binding site and 2,3-DPG effect in bovine hemoglobin. Marta M, et al. **Biochemistry** 1998 Oct 6; 37(40):14024-9

UV resonance Raman studies of alpha-nitrosyl hemoglobin derivatives: relation between the alpha 1-beta 2 subunit interface interactions and the Fe-histidine bonding of alpha heme. Nagatomo S, et al. **Biochemistry** 1999 Jul 27; 38(30):9659-66

A cyanobacterial hemoglobin with unusual ligand binding kinetics and stability properties. Thorsteinsson MV, et al. **Biochemistry** 1999 Feb 16;38(7):2117-26

Spectrophotometric quantitative analysis of the main hemoglobin derivatives. Adamov SA, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1160-3

Resonance energy transfer study of hemoglobin and cytochrome c complexes with lipids. Gorbenko GP. **Biochim Biophys Acta** 1998 Nov 2;1409(1):12-24

A re-evaluation of the molecular mass of earthworm extracellular hemoglobin from meniscus depletion sedimentation equilibrium. Nature of the 10 S dissociation species. Tsfadia Y, et al. **Biochim Biophys Acta** 1999 Aug 17;1433(1-2):217-28

NMR study of the sites of human hemoglobin acetylated by aspirin. Xu AS, et al. **Biochim Biophys Acta** 1999 Jul 13;1432(2):333-49

Direct electron transfer for hemoglobin in biomembrane-like dimyristoyl phosphatidylcholine films on pyrolytic graphite electrodes. Yang J, et al. **Bioelectrochem Bioenerg** 1999 Feb; 48(1):117-27

Hemoglobin-oxygen-carbon monoxide equilibria with the MWC model. Senozan NM, et al. **Biophys Chem** 1998 Nov 16;75(2):141-50

The apparently symmetrical hexagonal bilayer hemoglobin from Lumbricus terrestris has a large dipole moment. Takashima S, et al. **Biophys Chem** 1999 Mar 8;77(1):27-35

Metal complexes as allosteric effectors of human hemoglobin: an NMR study of the interaction of the gadolinium(III) bis(m-boroxyphenylamide)diethylenetriaminepentaacetic acid complex with human oxygenated and deoxygenated hemoglobin. Aime S, et al. **Biophys J** 1999 May; 76(5):2735-43

Augmented water binding and low cellular water content in erythrocytes of camel and camelids. Bogner P, et al. **Biophys J** 1998 Dec;75(6):3085-91

Heterotropic effectors exert more significant strain on monoligated than on unligated hemoglobin. Coletta M, et al. **Biophys J** 1999 Mar;76(3):1532-6

Structural and dynamic properties of the homodimeric hemoglobin from Scapharca inaequivalvis Thr-72-->Ile mutant: molecular dynamics simulation, low temperature visible absorption spectroscopy, and resonance Raman spectroscopy studies. Falconi M, et al. **Biophys J** 1998 Nov; 75(5):2489-503

Cysteines beta93 and beta112 as probes of conformational and functional events at the human hemoglobin subunit interfaces. Vásquez GB, et al. **Biophys J** 1999 Jan;76(1 Pt 1):88-97

The synthesis and screening of a combinatorial peptide library for affinity ligands for glycosylated haemoglobin. Chen B, et al. **Biosens Bioelectron** 1998 Oct 1; 13(7-8):779-85

Solvent effect on kinetics of appearance of haemorphins in the course of peptic hydrolysis of bovine haemoglobin. Lignot B, et al. **Biotechnol Appl Biochem** 1999 Feb;29 (Pt 1):25-30

Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation. Heller MC, et al. **Biotechnol Bioeng** 1999 Apr 20;63(2):166-74

Cerebral oximetry by near infrared spectroscopy measures cerebral haemoglobin oxygen saturation and the balance between supply and demand, not cerebral blood flow [letter] Nemoto EM. **Br J Neurosurg** 1999 Feb;13(1):93-5

Identifying the conformational state of bi-liganded haemoglobin. Marden MC, et al. **Cell Mol Life Sci** 1998 Dec;54(12):1365-84 (99 ref.)

A new assay for albumin and hemoglobin adducts of 1,2- and 1,4-benzoquinones. Waidyanatha S, et al. **Chem Biol Interact** 1998 Sep 4;115(2):117-39

Characterization of the reactivity, regioselectivity, and stereoselectivity of the reactions of butadiene monoxide with valinamide and the N-terminal valine of mouse and rat hemoglobin. Moll TS, et al. **Chem Res Toxicol** 1999 Aug;12(8):679-89

Heterogeneous motions within human apohemoglobin. Haouz A, et al. **Eur J Biochem** 1999 Aug;264(1):250-7

The artificial alpha1beta1-contact mutant hemoglobin, Hb Phe-35beta, shows only small functional abnormalities. Nakatsukasa T, et al. **FEBS Lett** 1998 Dec 11;441(1):93-6

Probing the reactivity of nucleophile residues in human 2,3-diphosphoglycerate/deoxy-hemoglobin complex by aspecific chemical modifications. Scaloni A, et al. **FEBS Lett** 1999 Jun 11;452(3):190-4

Damage to hemoglobin by radiation-generated serum albumin radicals. Puchala M, et al. **Free Radic Biol Med** 1999 May;26(9-10):1284-91

Affinity reagents for cross-linking hemoglobin: bis(phenoxycarbonylethyl)phosphinic acid (BPCEP) and bis(3-nitrophenoxycarbonylethyl)phosphinic acid (BNCEP). Peri SP, et al. **Hemoglobin** 1999 Feb;23(1):1-20

Low temperature photolysis of denatured nitrosyl hemoproteins. Alves OC, et al. **Int J Biol Macromol** 1998 Oct;23(3):157-64

Effects of S-nitrosation on oxygen binding by normal and sickle cell hemoglobin. Bonaventura C, et al. **J Biol Chem** 1999 Aug 27;274(35):24742-8

Chlamydomonas chloroplast ferrous hemoglobin. Heme pocket structure and reactions with ligands. Couture M, et al. **J Biol Chem** 1999 Mar 12;274(11):6898-910

Hydroxide rather than histidine is coordinated to the heme in five-coordinate ferric Scapharca inaequivalvis hemoglobin. Das TK, et al. **J Biol Chem** 1999 Jan 29; 274(5):2916-9

Structural, functional, and genetic characterization of Gastrophilus hemoglobin. Dewilde S, et al. **J Biol Chem** 1998 Dec 4;273(49):32467-74

Crystal structure of deoxy-human hemoglobin beta6 Glu --> Trp. Implications for the structure and formation of the sickle cell fiber. Harrington DJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32690-6

Determinants of Ascaris hemoglobin octamer formation. Minning DM, et al. **J Biol Chem** 1998 Dec 4; 273(49):32644-9

Biochemical characterization of human S-nitrosohemoglobin. Effects on oxygen binding and transnitrosation. Patel RP, et al. **J Biol Chem** 1999 May 28;274(22):15487-92

Immobilized human hemoglobin, a versatile matrix for analytical and biotechnological applications. Chiancone E, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 11; 715(1):81-4 (18 ref.)

Hydrogen ion titrations of the anodic and cathodic haemoglobin components of the European eel Anguilla anguilla. Brauner CJ, et al. **J Exp Biol** 1998 Sep;201 (Pt 17):2507-14

Anticooperative ligand binding properties of recombinant ferric Vitreoscilla homodimeric hemoglobin: a thermodynamic, kinetic and X-ray crystallographic study. Bolognesi M, et al. **J Mol Biol** 1999 Aug 20;291(3):637-50

Energetic components of the allosteric machinery in hemoglobin measured by hydrogen exchange. Englander JJ, et al. **J Mol Biol** 1998 Dec 18;284(5):1695-706

Signal transmission between subunits in the hemoglobin T-state. Englander JJ, et al. **J Mol Biol** 1998 Dec 18; 284(5):1707-16

Asymmetric (deoxy dimer/azido-met dimer) hemoglobin hybrids dissociate within seconds. Kiger L, et al. **J Mol Biol** 1999 Aug 6;291(1):227-36

Crystal structure of Trematomus newnesi haemoglobin re-opens the root effect question. Mazzarella L, et al. **J Mol Biol** 1999 Apr 16;287(5):897-906

Modulation of ligand binding in engineered human hemoglobin distal pocket. Miele AE, et al. **J Mol Biol** 1999 Jul 9;290(2):515-24

Functional analysis of hemoglobin molecules locked in doubly liganded conformations. Shibayama N. **J Mol Biol** 1999 Jan 29;285(4):1383-8

Three-dimensional reconstruction of Lumbricus terrestris hemoglobin at 22 A resolution: intramolecular localization of the globin and linker chains. Taveau JC, et al. **J Mol Biol** 1999 Jun 25;289(5):1343-59

Conformational stability of lyophilized PEGylated proteins in a phase-separating system. Heller MC, et al. **J Pharm Sci** 1999 Jan;88(1):58-64

Acute and long-term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications. Kerwin BA, et al. **J Pharm Sci** 1999 Jan;88(1):79-88

Subunit interacting surfaces of human hemoglobin in solution: localization of the alpha-beta subunit interacting surfaces on the alpha-chain by a comprehensive synthetic strategy. Yoshioka N, et al. **J Protein Chem** 1999 Feb;18(2):179-85

Study of the Bohr effect in hemoglobin intermediates. Benazzi L, et al. **Methods Enzymol** 1998;295:208-27

Daphnia pulex didomain hemoglobin: structure and evolution of polymeric hemoglobins and their coding genes. Dewilde S, et al. **Mol Biol Evol** 1999 Sep;16(9):1208-18

Is cooperative oxygen binding by hemoglobin really understood? Eaton WA, et al. **Nat Struct Biol** 1999 Apr; 6(4):351-8 (45 ref.)

Short-lived intermediates in hemoglobin/O2 systems. Czerlinski G, et al. **Physiol Chem Phys Med NMR** 1998; 30(1):25-48

A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. Couture M, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11223-8

Structural changes in hemoglobin during adsorption to solid surfaces: effects of pH, ionic strength, and ligand binding. Höök F, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12271-6

Protein fluctuations are sensed by stimulated infrared echoes of the vibrations of carbon monoxide and azide probes. Lim M, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15315-20

Hemoglobins from deep-sea hydrothermal vent scaleworms of the genus Branchipolynoe: a new type of quaternary structure. Hourdez S, et al. **Proteins** 1999 Mar 1; 34(4):427-34

Characterization and functional properties of the extracellular coelomic hemoglobins from the deep-sea, hydrothermal vent scaleworm Branchipolynoe symmytilida. Hourdez S, et al. **Proteins** 1999 Mar 1;34(4):435-42

Structural analysis and quantitative evaluation of the modifications produced in human hemoglobin by methyl bromide using mass spectrometry and Edman degradation. Mamone G, et al. **Rapid Commun Mass Spectrom** 1998; 12(22):1783-92

The second space experiment of protein crystallization with domestic facilities. Wang Y, et al. **Sci China C Life Sci** 1996 Oct;39(5):458-64

Fourier transform Raman approach to structural correlation in hemoglobin derivatives. Venkatesh B, et al. **Spectrochim Acta A Mol Biomol Spectrosc** 1999 Jul; 55A(7-8):1691-7

The 2.7 A crystal structure of deoxygenated hemoglobin from the sea lamprey (Petromyzon marinus): structural basis for a lowered oxygen affinity and Bohr effect. Heaslet HA, et al. **Structure Fold Des** 1999 May;7(5):517-26

Future prospects for artificial blood. Chang TM. **Trends Biotechnol** 1999 Feb;17(2):61-7 (89 ref.)

Modified hemoglobin-based blood substitutes: crosslinked, recombinant and encapsulated hemoglobin. Chang TM. **Vox Sang** 1998;74 Suppl 2:233-41 (32 ref.)

[Current state of the art and perspectives on hemoglobin solutions (editorial)] Schulte am Esch J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):695-6 **(Ger)**

[Localization of pyridoxal-5-phosphate, covalently bound with human hemoglobin. Spectrofluorimetric studies] Zavodnik IB, et al. **Biofizika** 1999 May-Jun;44(3):412-20 (Eng. Abstr.) **(Rus)**

[Physico-chemical characteristics and functional properties of membrane-bound hemoglobin] Val'ovka TI, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):59-63 (Eng. Abstr.) **(Ukr)**

DEFICIENCY

The hemoglobin-deficit mouse: cure of the anemia following bone marrow transplantation with normal marrow. Simon-Stoos KL, et al. **Exp Hematol** 1999 Jan;27(1):162-8

Effect of the Cu T380 IUD on hemoglobin and iron stores in Egyptian women. Sadek SS, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):69-70

The contribution of hookworm and other parasitic infections to haemoglobin and iron status among children and adults in western Kenya. Olsen A, et al. **Trans R Soc Trop Med Hyg** 1998 Nov-Dec;92(6):643-9

DRUG EFFECTS

Evaluation of acetaldehyde-modified hemoglobin and other markers of chronic heavy alcohol use: effects of gender and hemoglobin concentration. Hazelett SE, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1813-9

Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50). Eichelbrönner O, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H290-8

Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat. Sarraf-Yazdi S, et al. **Brain Res** 1999 May 1; 826(2):172-80

Absence of hemoprotein-associated free radical events following oxidant challenge of crosslinked hemoglobin-superoxide dismutase catalase. D'Agnillo F, et al. **Free Radic Biol Med** 1998 Apr;24(6):906-12

Biomonitoring of exposure to ethylene oxide and propylene oxide by determination of hemoglobin adducts: correlations between airborne exposure and adduct levels. Boogaard PJ, et al. **Int Arch Occup Environ Health** 1999 May; 72(3):142-50

Zinc and IGF-I concentrations in pregnant women with anemia before and after supplementation with iron and/or zinc. Nishiyama S, et al. **J Am Coll Nutr** 1999 Jun; 18(3):261-7

Toxic oxidative denaturation of hemoglobin [editorial; comment] Kerremans AL. **Neth J Med** 1999 Jul;55(1):1-3 . Comment on: Neth J Med 1999 Jul;55(1):19-22.

RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice. Rockwell S, et al. **Radiat Oncol Investig** 1998;6(5):199-208

[The effect of food additives containing polyunsaturated fatty acids on intraerythrocyte metabolism and hemoglobin

oxygen affinity in volleyball players during exposure to intensive physical loading] Popichev MI, et al. **Fiziol Cheloveka** 1999 Jan-Feb;25(1):140-2 **(Rus)**

[The effect of biological food supplements containing polyunsaturated fatty acids on the erythrocyte enzyme activity and on the hemoglobin oxygen affinity in volleyball players exposed to intensive physical loading] Popichev MI, et al. **Vopr Pitan** 1999;68(3):7-8 (Eng. Abstr.) **(Rus)**

[Effects of dehydroepiandrosterone on blood cells of the rat] Rojas J, et al. **Acta Cient Venez** 1998;49(1):25-30 (Eng. Abstr.) **(Spa)**

GENETICS

A nonsymbiotic hemoglobin gene is expressed during somatic embryogenesis in Cichorium. Hendriks T, et al. **Biochim Biophys Acta** 1998 Nov 26;1443(1-2):193-7

Synthesis and excretion of alpha-amylase in vgb+ and vgb- recombinant Escherichia coli: a comparative study. Tari C, et al. **Biotechnol Bioeng** 1998 Sep 20;59(6):673-8

Metabolic engineering of Serratia marcescens with the bacterial hemoglobin gene: alterations in fermentation pathways. Wei ML, et al. **Biotechnol Bioeng** 1998 Sep 5; 59(5):640-6

Genetic engineering of Serratia marcescens with bacterial hemoglobin gene: effects on growth, oxygen utilization, and cell size. Wei ML, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):477-83

Production of alpha-amylase in fed-batch cultures of vgb+ and vgb- recombinant Escherichia coli: some observations. Enayati N, et al. **Biotechnol Prog** 1999 Jul-Aug;15(4):640-5

Expression of Vitreoscilla hemoglobin in Escherichia coli enhances ribosome and tRNA levels: a flow field-flow fractionation study. Nilsson M, et al. **Biotechnol Prog** 1999 Mar-Apr;15(2):158-63

The 11th conference on hemoglobin switching. Orcas Island, Washington, USA. October 2-6, 1998. Abstracts. **Blood Cells Mol Dis** 1998 Dec;24(4):462-521

Hemoglobin switching and its clinical implications. Blau CA, et al. **Curr Opin Hematol** 1994 Mar;1(2):136-42 (66 ref.)

Regulation of embryonic/fetal globin genes by nuclear hormone receptors: a novel perspective on hemoglobin switching. Filipe A, et al. **EMBO J** 1999 Feb 1;18(3):687-97

The exon/intron organization of the globin gene of Scapharca inaequivalvis homodimeric hemoglobin: unusual intron homology with other bivalve mollusc globin genes. Piro MC, et al. **Gene** 1998 Oct 9;221(1):45-9

Two hemoglobin variants with an alteration of the oxygen-linked chloride binding: Hb Antananarivo [alpha1(NA1)Val-->Gly] and Hb Barbizon [beta144(HC1)Lys-->Met]. Kister J, et al. **Hemoglobin** 1999 Feb;23(1):21-32

Testing a biochemical model of human genetic resistance to falciparum malaria by the analysis of variation at protein and microsatellite loci. Destro-Bisol G, et al. **Hum Biol** 1999 Jun;71(3):315-32

Some atypical and rare sickle cell gene haplotypes in populations of Andhra Pradesh, India. Niranjan Y, et al. **Hum Biol** 1999 Jun;71(3):333-40

Additive effects of beta chain mutations in low oxygen affinity hemoglobin betaF41Y,K66T. Baudin-Creuza V, et al. **J Biol Chem** 1999 Sep 3;274(36):25550-4

Heterogeneity and differential expression under hypoxia of two-domain hemoglobin chains in the water flea, Daphnia magna. Kimura S, et al. **J Biol Chem** 1999 Apr 9; 274(15):10649-53

Phylogenetic analysis of reptilian hemoglobins: trees, rates, and divergences. Gorr TA, et al. **J Mol Evol** 1998 Oct; 47(4):471-85

Ancient and recent intron stability in the Artemia hemoglobin gene. Matthews CM, et al. **J Mol Evol** 1998 Dec; 47(6):763-71

The myoglobin and the hemoglobin of Biomphalaria glabrata, an evidence of gene duplications. Arndt MH, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:171-2

Genetic engineering of an industrial strain of Saccharopolyspora erythraea for stable expression of the Vitreoscilla haemoglobin gene (vhb). Brünker P, et al. **Microbiology** 1998 Sep;144 (Pt 9):2441-8

Daphnia pulex didomain hemoglobin: structure and evolution of polymeric hemoglobins and their coding genes. Dewilde S, et al. **Mol Biol Evol** 1999 Sep;16(9):1208-18

Conserved elements containing NF-E2 and tandem GATA binding sites are required for erythroid-specific chromatin structure reorganization within the human beta-globin locus control region. Pomerantz O, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5684-91

Use of somatic cell fusion to reprogram globin genes. Broyles RH. **Semin Cell Dev Biol** 1999 Jun;10(3):259-65 (35 ref.)

HISTORY

First molecular explanation of disease [see comments] Smith T. **Nat Struct Biol** 1999 Apr;6(4):307. Comment in: Nat Struct Biol 1999 Apr;6(4):293-4.

Hemoglobin is an honorary enzyme. Brunori M. **Trends Biochem Sci** 1999 Apr;24(4):158-61

IMMUNOLOGY

A novel epitope (pentapeptide) in the human hemoglobin beta chain. Endo M, et al. **Hemoglobin** 1998 Jul; 22(4):321-31

TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. Grakoui A, et al. **J Immunol** 1999 Feb 15;162(4):1923-30

The study of self-tolerance using murine haemoglobin as a model self antigen. Williams CB, et al. **Novartis Found Symp** 1998;215:41-6; discussion 46-53 (23 ref.)

ISOLATION & PURIFICATION

A rapid method for hemoglobin chain recombination. Lee TC. **Anal Biochem** 1978 Dec;91(2):646-50

Continuous separation of serum proteins using a stirred cell charged with carboxylated and sulfonated microspheres. Lee JH, et al. **Biomed Chromatogr** 1998 Nov-Dec; 12(6):330-4

Antimicrobial activity of a bovine hemoglobin fragment in the tick Boophilus microplus. Fogaça AC, et al. **J Biol Chem** 1999 Sep 3;274(36):25330-4

Protein variant separations by cation-exchange chromatography on tentacle-type polymeric stationary phases. Weitzhandler M, et al. **J Chromatogr A** 1998 Dec 18;828(1-2):365-72

The myoglobin and the hemoglobin of Biomphalaria glabrata, an evidence of gene duplications. Arndt MH, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:171-2

[A method for atraumatic erythrocyte plasma removal to obtain membranes capable of performing the hemostatic function of thrombocytes] Grigor'ev GI. **Klin Lab Diagn** 1999 Jul;(7):18-21 (Eng. Abstr.) **(Rus)**

METABOLISM

Rhythmical variations of haemoglobin oxygenation in cutaneous capillaries. Stücker M, et al. **Acta Derm Venereol** 1998 Nov;78(6):408-11

NIRS: dose dependency of local changes of cerebral HbO2 and Hb with pCO2 in parietal cortex. Benni PB, et al. **Acta Neurochir Suppl (Wien)** 1998;71:258-9

Reflectance measurement of heart muscle oxygenation. Barlow CH, et al. **Adv Exp Med Biol** 1998;454:487-500

Use of oxygen-15-labeled molecular oxygen for oxygen delivery studies of blood and blood substitutes. Goins B, et al. **Adv Exp Med Biol** 1998;454:643-52

Spectroscopic investigation of reflectance changes in the barrel cortex following whisker stimulation. Mayhew J, et al. **Adv Exp Med Biol** 1998;454:139-48

RSR13, a synthetic allosteric modifier of hemoglobin, enhances recovery of stunned myocardium in dogs. Pagel PS, et al. **Adv Exp Med Biol** 1998;454:527-31

Effect of RSR13 on temperature-dependent changes in hemoglobin oxygen affinity of human whole blood. Steffen RP. **Adv Exp Med Biol** 1998;454:653-61

Comparison of absolute cerebral haemoglobin concentration in neonates measured directly and by the oxygen swing method both based on near infrared spectrophotometry. Wolf M, et al. **Adv Exp Med Biol** 1998;454:125-9

Relation of hemoglobin measured at different times in pregnancy to preterm birth and low birth weight in Shanghai, China. Zhou LM, et al. **Am J Epidemiol** 1998 Nov 15;148(10):998-1006

Hemoglobin diffusion across a venous wall: an experimental study. Skopp G, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):372-6

Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Levin A, et al. **Am J Kidney Dis** 1999 Jul;34(1):125-34

Oxygen binding and its allosteric control in hemoglobin of the pulmonate snail, Biomphalaria glabrata. Bugge J, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R347-56

Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50). Eichelbrönner O, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H290-8

Novel assessment of acute lung injury by in vivo near-infrared spectroscopy. Shibata S, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):317-23

Nitric oxide, malaria, and anemia: inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children. Anstey NM, et al. **Am J Trop Med Hyg** 1999 Aug; 61(2):249-52

Critical hemoglobin desaturation can be delayed by apneic diffusion oxygenation [letter; comment] Baraka A, et al. **Anesthesiology** 1999 Jan;90(1):332-3. Comment on: Anesthesiology 1997 Oct;87(4):979-82. Comment on: Anesthesiology 1998 Jun;88(6):1686-8.

O2-Hb reaction kinetics and the Fähraeus effect during stagnant, hypoxic, and anemic supply deficit. Ye GF, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):60-75

Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols. Mungthin M, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2973-7

Nuclear magnetic resonance and oxygen affinity study of cesium binding in human erythrocytes. Lin W, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):78-88

Haemoglobin and ferritin concentrations in children aged 12 and 18 months. ALSPAC Children in Focus Study Team. Sherriff A, et al. **Arch Dis Child** 1999 Feb;80(2):153-7

Biomonitoring of aromatic amines V: acetylation and deacetylation in the metabolic activation of aromatic amines as determined by haemoglobin binding. Zwirner-Baier I, et al. **Arch Toxicol** 1998 Jul-Aug; 72(8):499-504

The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models. Conover CD, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):93-107

Effects of the pH-controlled hemoglobin vesicles by CO2 gas. Park S, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov; 26(5-6):497-506

Circe's haemoglobins, pig-human hybrids: functional characterization and structural considerations. Sanna MT, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):211-6

Structural and functional properties of human hemoglobins reassembled after synthesis in Escherichia coli. Hui HL, et al. **Biochemistry** 1999 Jan 19;38(3):1040-9

CO binding and valency exchange in asymmetric Hb hybrids. Kiger L, et al. **Biochemistry** 1998 Oct 13;37(41):14643-50

A cyanobacterial hemoglobin with unusual ligand binding kinetics and stability properties. Thorsteinsson MV, et al. **Biochemistry** 1999 Feb 16;38(7):2117-26

Nitric oxide and hemoglobin interactions in the vasculature. Kosaka H. **Biochim Biophys Acta** 1999 May 5; 1411(2-3):370-7 (43 ref.)

CO2 reactivity of the cerebral hemoglobin concentration in healthy term newborns measured by near infrared spectrophotometry. Dietz V, et al. **Biol Neonate** 1999; 75(2):85-90

Augmented water binding and low cellular water content in erythrocytes of camel and camelids. Bogner P, et al. **Biophys J** 1998 Dec;75(6):3085-91

Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Port RE, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):461-6

Haemoglobin, blood volume, cardiac function, and aerobic power. Gledhill N, et al. **Can J Appl Physiol** 1999 Feb; 24(1):54-65 (45 ref.)

4-Hydroxy-1-(3-pyridyl)-1-butanone-hemoglobin adducts as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. Atawodi SE, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Sep; 7(9):817-21

Adducts with haemoglobin and with DNA in epichlorohydrin-exposed rats. Landin HH, et al. **Chem Biol Interact** 1999 Jan 1;117(1):49-64

The effect of 61 days of combined iron (Chemiron) and single iron therapy on haemoglobin, packed cell volume, platelets and reticulocytes during pregnancy. Preliminary report. Ajayi GO, et al. **Clin Exp Obstet Gynecol** 1998;25(3):107-11

Effects of contraceptives on hemoglobin and ferritin. Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. **Contraception** 1998 Nov;58(5):262-73

Nitric oxide metabolites in decompensated liver cirrhosis. Barak N, et al. **Dig Dis Sci** 1999 Jul;44(7):1338-41

Toxic effect of nickel on hemoglobin concentration of Limnodrilus hoffmeisteri in spiked sediments of trout farms. Martinez-Tabche L, et al. **Ecotoxicol Environ Saf** 1999 Feb; 42(2):143-9

Lead in plasma and whole blood from lead-exposed children. Bergdahl IA, et al. **Environ Res** 1999 Jan;80(1):25-33

Frontal brain activation during the Wisconsin Card Sorting Test assessed with two-channel near-infrared spectroscopy. Fallgatter AJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1998;248(5):245-9

Proteolytic degradation of hemoglobin by endogenous lysosomal proteases gives rise to bioactive peptides: hemorphins. Fruitier I, et al. **FEBS Lett** 1999 Mar 19; 447(1):81-6

Evaluation of the hemoglobin-binding activity of Actinobacillus pleuropneumoniae using fluorescein-labeled pig hemoglobin and flow cytometry. Archambault M, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):17-25

Absence of hemoprotein-associated free radical events following oxidant challenge of crosslinked hemoglobin-superoxide dismutase catalase. D'Agnillo F, et al. **Free Radic Biol Med** 1998 Apr;24(6):906-12

Autocatalytic oxidation of hemoglobin by nitrite: a possible mechanism. Lissi E. **Free Radic Biol Med** 1998 Jun; 24(9):1535-6 (7 ref.)

Smoking, hemoglobin concentration and pregnancy-induced hypertension. Rasmussen S, et al. **Gynecol Obstet Invest** 1998;46(4):225-31

Hemoglobin levels correlate with serum soluble CD23 and TNF-Rs concentrations in patients with rheumatoid arthritis. Vaiopoulos G, et al. **Haematologia (Budap)** 1998; 29(2):89-99

Immunohistochemical localization of haemoglobin binding sites in the distal tubule of the rat kidney. Gburek J, et al. **Histochem J** 1998 Jun;30(6):421-4

High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Kersh GJ, et al. **Immunity** 1998 Dec;9(6):817-26

Recombinant expression and localization of Schistosoma mansoni cathepsin L1 support its role in the degradation of host hemoglobin. Brady CP, et al. **Infect Immun** 1999 Jan;67(1):368-74

hgpB, a gene encoding a second Haemophilus influenzae hemoglobin- and hemoglobin-haptoglobin-binding protein. Ren Z, et al. **Infect Immun** 1998 Oct;66(10):4733–41

Neisseria gonorrhoeae heme biosynthetic mutants utilize heme and hemoglobin as a heme source but fail to grow within epithelial cells. Turner PC, et al. **Infect Immun** 1998 Nov;66(11):5215–23

Oxidative stress resulting from hemolysis and formation of catalytically active hemoglobin: protective strategies. Ziouzenkova O, et al. **Int J Clin Pharmacol Ther** 1999 Mar; 37(3):125–32

The comparison of mixed distribution analysis with a three-criteria model as a method for estimating the prevalence of iron deficiency anaemia in Costa Rican children aged 12–23 months. Cohen JH, et al. **Int J Epidemiol** 1999 Feb;28(1):82–9

Intensive indoor versus outdoor swine production systems: genotype and supplemental iron effects on blood hemoglobin and selected immune measures in young pigs. Kleinbeck SN, et al. **J Anim Sci** 1999 Sep;77(9):2384–90

Effects of hyperchloremia on blood oxygen binding in healthy calves. Cambier C, et al. **J Appl Physiol** 1998 Oct; 85(4):1267–72

Experimental and theoretical comparison of NIR spectroscopy measurements of cerebral hemoglobin changes. Firbank M, et al. **J Appl Physiol** 1998 Nov; 85(5):1915–21

Splenic contraction-induced reversible increase in hemoglobin concentration in intermittent hypoxia. Kuwahira I, et al. **J Appl Physiol** 1999 Jan;86(1):181–7

Efficacy of recombinant human Hb by 31P-NMR during isovolemic total exchange transfusion. Sillerud LO, et al. **J Appl Physiol** 1999 Mar;86(3):887–94

Hemoglobin and the brain: a piece of the autism puzzle? [letter] Simon N. **J Autism Dev Disord** 1998 Dec; 28(6):579–80

Porphyrin-mediated binding to hemoglobin by the HA2 domain of cysteine proteinases (gingipains) and hemagglutinins from the periodontal pathogen Porphyromonas gingivalis. DeCarlo AA, et al. **J Bacteriol** 1999 Jun;181(12):3784–91

Transport of intact porphyrin by HpuAB, the hemoglobin-haptoglobin utilization system of Neisseria meningitidis. Lewis LA, et al. **J Bacteriol** 1998 Nov; 180(22):6043–7

Role of CCAA nucleotide repeats in regulation of hemoglobin and hemoglobin-haptoglobin binding protein genes of Haemophilus influenzae. Ren Z, et al. **J Bacteriol** 1999 Sep;181(18):5865–70

HmbR, a hemoglobin-binding outer membrane protein of Neisseria meningitidis, undergoes phase variation. Richardson AR, et al. **J Bacteriol** 1999 Apr;181(7):2067–74

Identification of a two-component signal transduction system from Corynebacterium diphtheriae that activates gene expression in response to the presence of heme and hemoglobin. Schmitt MP. **J Bacteriol** 1999 Sep; 181(17):5330–40

Additive effects of beta chain mutations in low oxygen affinity hemoglobin betaF41Y,K66T. Baudin-Creuza V, et al. **J Biol Chem** 1999 Sep 3;274(36):25550–4

ATP-induced tetramerization and cooperativity in hemoglobin of lower vertebrates. Bonafe CF, et al. **J Biol Chem** 1999 Jan 15;274(3):1196–8

Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. Pandey AV, et al. **J Biol Chem** 1999 Jul 2;274(27):19383–8

CO ligation intermediates and the mechanism of hemoglobin cooperativity. Perrella M, et al. **J Biol Chem** 1999 Jan 29; 274(5):2605–8

Hemoglobin endocytosis in Leishmania is mediated through a 46-kDa protein located in the flagellar pocket. Sengupta S, et al. **J Biol Chem** 1999 Jan 29;274(5):2758–65

The hemoglobins of the antarctic fishes Atedidraco orianae and Pogonophryne scotti. Amino acid sequence, lack of cooperativity, and ligand binding properties. Tamburrini M, et al. **J Biol Chem** 1998 Dec 4;273(49):32452–9

Acetylation of human hemoglobin by methyl acetylphosphate. Evidence of broad regio-selectivity revealed by NMR studies. Xu AS, et al. **J Biol Chem** 1999 Sep 17;274(38):26629–32

Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. Ziouzenkova O, et al. **J Biol Chem** 1999 Jul 2;274(27):18916–24

Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": a clinical biologist's point of view [letter; comment] Watine J. **J Cancer Res Clin Oncol** 1998;124(10):581–3. Comment on: J Cancer Res Clin Oncol 1997;123(5):259–66.

Reliability of continuous jugular venous bulb hemoglobin oxygen saturation during cardiac surgery. Anastasiou E, et al. **J Cardiothorac Vasc Anesth** 1999 Jun;13(3):276–9

Effect of mild hypothermia during cardiopulmonary bypass on erythrocytic hemoglobin oxygen delivery. Leone BJ, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):393–6

Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. Bray PG, et al. **J Cell Biol** 1999 Apr 19;145(2):363–76

Analysis of optical signals evoked by peripheral nerve stimulation in rat somatosensory cortex: dynamic changes in hemoglobin concentration and oxygenation. Nemoto M, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):246–59

Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity. Weiss RG, et al. **J Clin Invest** 1999 Mar;103(5):739–46

Interaction between haemoglobin and synthetic peptides of the N-terminal cytoplasmic fragment of trout band 3 (AE1) protein. Jensen FB, et al. **J Exp Biol** 1998 Oct;201 (Pt 19):2685–90

Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. Elizalde JI, et al. **J Hepatol** 1998 Nov;29(5):789–95

Plasmodium falciparum infection: influence on hemoglobin levels in alpha-thalassemia and microcytosis. Mockenhaupt FP, et al. **J Infect Dis** 1999 Sep;180(3):925–8

The bidirectional effect of vanadyl ion on the oxygen affinity of human hemoglobin. Xue D, et al. **J Inorg Biochem** 1998 Aug;71(1-2):79–85

Permeability characteristics of hemoglobin derivatives across cultured endothelial cell monolayers. Nakai K, et al. **J Lab Clin Med** 1998 Oct;132(4):313–9

In vivo correlation between blood T2* and oxygen saturation. Li D, et al. **J Magn Reson Imaging** 1998 Nov-Dec;8(6):1236–9

Identification and quantitation of N-(carboxymethyl)valine adduct in hemoglobin by gas chromatography/mass spectrometry. Cai J, et al. **J Mass Spectrom** 1999 May; 34(5):537–43

Anticooperative ligand binding properties of recombinant ferric Vitreoscilla homodimeric hemoglobin: a thermodynamic, kinetic and X-ray crystallographic study. Bolognesi M, et al. **J Mol Biol** 1999 Aug 20;291(3):637–50

Signal transmission between subunits in the hemoglobin T-state. Englander JJ, et al. **J Mol Biol** 1998 Dec 18; 284(5):1707–16

The role of linkers in the reassembly of the 3.6 MDa hexagonal bilayer hemoglobin from Lumbricus terrestris. Kuchumov AR, et al. **J Mol Biol** 1999 Jun 25; 289(5):1361–74

Crystal structure of Trematomus newnesi haemoglobin re-opens the root effect question. Mazzarella L, et al. **J Mol Biol** 1999 Apr 16;287(5):897–906

Modulation of ligand binding in engineered human hemoglobin distal pocket. Miele AE, et al. **J Mol Biol** 1999 Jul 9;290(2):515–24

Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin: structural basis for altered allosteric activity. Pardanani A, et al. **J Mol Biol** 1998 Dec 4;284(3):729–39

Erythrocytes and delayed brain edema formation following intracerebral hemorrhage in rats. Xi G, et al. **J Neurosurg** 1998 Dec;89(6):991–6

Hemoglobin/O2 systems: using short-lived intermediates for mechanistic discrimination. Czerlinski G, et al. **J Theor Biol** 1999 Jul 7;199(1):25–44

Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits. Uchida K, et al. **Jpn J Physiol** 1998 Dec; 48(6):439–44

Degradations of human immunoglobulins and hemoglobin by a 60 kDa cysteine proteinase of Trichomonas vaginalis. Min DY, et al. **Korean J Parasitol** 1998 Dec;36(4):261–8

In vitro and in vivo studies of 1H NMR visibility to detect deoxyhemoglobin and deoxymyoglobin signals in myocardium. Chen W, et al. **Magn Reson Med** 1999 Jul; 42(1):1–5

Evidence of muscle BOLD effect revealed by simultaneous interleaved gradient-echo NMRI and myoglobin NMRS during leg ischemia. Lebon V, et al. **Magn Reson Med** 1998 Oct;40(4):551–8

Effect of carbogen breathing on the physiological profile of human glioma xenografts. van der Sanden BP, et al. **Magn Reson Med** 1999 Sep;42(3):490–9

Upper gastrointestinal bleeding: an ammoniagenic and catabolic event due to the total absence of isoleucine in the haemoglobin molecule. Olde Damink SW, et al. **Med Hypotheses** 1999 Jun;52(6):515–9 (37 ref.)

Biochemical characterization of cathepsin D from adult Schistosoma mansoni worms. Cesari IM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:165–8

Study of the Bohr effect in hemoglobin intermediates. Benazzi L, et al. **Methods Enzymol** 1998;295:208–27

Analysis of spectra from multiwavelength oxygen-binding studies of mixed metal hybrid hemoglobins. Klinger AL, et al. **Methods Enzymol** 1998;295:190–207

Concerted nitric oxide/oxygen delivery by hemoglobin. McMahon TJ, et al. **Methods Enzymol** 1999;301:99–114

Intracapillary haemoglobin oxygenation and interstitial pO2 in venous flaps: an experimental study in rats. Wolff KD, et al. **Microsurgery** 1998;18(5):324–30

Dynamic changes in intracapillary hemoglobin oxygenation in human skin following various temperature changes. Kakihana Y, et al. **Microvasc Res** 1998 Sep;56(2):104–12

Prediction of microcirculatory oxygen transport by erythrocyte/hemoglobin solution mixtures. Page TC, et al. **Microvasc Res** 1998 Sep;56(2):113–26

Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Lewis LA, et al. **Mol Microbiol** 1999 Jun;32(5):977–89

Is cooperative oxygen binding by hemoglobin really understood? Eaton WA, et al. **Nat Struct Biol** 1999 Apr; 6(4):351–8 (45 ref.)

Response of mean reticulocyte haemoglobin content to intravenous iron therapy in haemodialysis patients [letter] Bhandari S, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3276–7

Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. McMahon LP, et al. **Nephrol Dial Transplant** 1999 May;14(5):1182–7

The predictive power of baseline hemoglobin for transfusion risk in surgery patients. Faris PM, et al. **Orthopedics** 1999 Jan;22(1 Suppl):s135–40

Anti-oxidant effect of flavonoids on hemoglobin glycosylation. Asgary S, et al. **Pharm Acta Helv** 1999 Feb; 73(5):223–6

Short-lived intermediates in hemoglobin/O2 systems. Czerlinski G, et al. **Physiol Chem Phys Med NMR** 1998; 30(1):25–48

Cutaneous hemoglobin oxygenation of different free flap donor sites. Wolff KD, et al. **Plast Reconstr Surg** 1998 Oct; 102(5):1537–43

Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. Al-Abed Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2385–90

Physiological reactions of nitric oxide and hemoglobin: a radical rethink. Gross SS, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9967–9 (49 ref.)

Steady-state fluorescence and circular dichroism of trout hemoglobins I and IV interacting with tributyltin. Zolese G, et al. **Proteins** 1999 Mar 1;34(4):443–52

alpha-Tocopherol enhances the peroxidase activity of hemoglobin on phospholipid hydroperoxide. Bao Y, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):325–30

Bicarbonate binding to hemoglobin links oxygen and carbon dioxide transport in hagfish. Fago A, et al. **Respir Physiol** 1999 May 3;115(3):309–15

Hypophysectomy, high tumor necrosis factor levels, and hemoglobinemia in lethal endotoxemic shock. Bloom O, et al. **Shock** 1998 Dec;10(6):395–400

The causes and prognostic significance of low hemoglobin levels in tumor patients. Manegold C. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:17–9 (13 ref.)

Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:13–6 (35 ref.)

The affinity of hemoglobin for oxygen: its control and in vivo significance. Miller LD, et al. **Surgery** 1970 Jul; 68(1):187–94; discussion 194–5

Regional differences of cerebral hemoglobin concentration in preterm infants measured by near infrared spectrophotometry. Keel M, et al. **Technol Health Care** 1999;7(1):63–73

Human hemoglobin adducts following exposure to hexahydrophthalic anhydride and methylhexahydrophthalic anhydride. Lindh CH, et al. **Toxicol Appl Pharmacol** 1998 Dec;153(2):152–60

Plasma and blood lead in humans: capacity-limited binding to delta-aminolevulinic acid dehydratase and other lead-binding components. Bergdahl IA, et al. **Toxicol Sci** 1998 Dec;46(2):247–53

Changes in hemoglobin levels after renal transplantation. Kahng K, et al. **Transplant Proc** 1998 Nov;30(7):3023–4

The metabolic effects of native and transgenic hemoglobins on plants. Bülow L, et al. **Trends Biotechnol** 1999 Jan; 17(1):21–4 (49 ref.)

Extracorporeal shock waves act by shock wave-gas bubble interaction. Delius M, et al. **Ultrasound Med Biol** 1998 Sep; 24(7):1055–9

Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: reduced need for blood transfusions in patients undergoing colorectal surgery--prospective double-blind placebo-controlled study. Qvist N, et al. **World J Surg** 1999 Jan;23(1):30–5

Haemoglobin binding of a musk xylene metabolite in man. Riedel J, et al. **Xenobiotica** 1999 Jun;29(6):573–82

[Erythrocyte, plasma and substitute hemoglobins facing physiological oxidizing and reducing agents] Faivre-Fiorina B, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct; 56(5):545–56 (32 ref.) (Eng. Abstr.) **(Fre)**

[Techniques for automatic recording of the oxygen equilibrium curve: precision determination of gaseous ligand binding (1)] Imai K. **Tanpakushitsu Kakusan Koso** 1999 Apr;44(5):706–13 (19 ref.) **(Jpn)**

[The slope of hemoglobin-oxygen equilibrium curve: implications hidden in the sigmoid curve] Kobayashi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2110–9 (20 ref.) **(Jpn)**

PHARMACOKINETICS

Presence of hemoglobin inside aortic endothelial cells after cell-free hemoglobin administration in guinea pigs. Faivre-Fiorina B, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H766–70

Filtration of diaspirin crosslinked hemoglobin into lung and soft tissue lymph. Conhaim RL, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1204–12

Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. Phillips

WT, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):665–70

PHARMACOLOGY

Effect of cross-linked hemoglobin transfusion on endothelial-dependent dilation in cat pial arterioles. Asano Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1313–21

Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Baldwin AL. **Am J Physiol** 1999 Aug;277(2 Pt 2):H650–9

Plasma volume expansion with solutions of hemoglobin, albumin, and Ringer lactate in sheep. Fischer SR, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2194–203

Effect of diaspirin cross-linked hemoglobin on normal and postischemic microcirculation of the rat pancreas. von Dobschuetz E, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1507–14

Hemoglobin protects from streptococcal cell wall-induced arthritis. McCartney-Francis NL, et al. **Arthritis Rheum** 1999 Jun;42(6):1119–27

Enhanced mitosis in cultured protoplasts: beneficial effects of oxygenated perfluorocarbon and haemoglobin. Anthony P, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov;26(5–6):449–54

Haemoglobin (Erythrogen)-enhanced post-thaw growth of cryopreserved cells. Azhakanandam K, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):163–9

The effects of stroma-free and dextran-conjugated hemoglobin on hemodynamics and carotid blood flow in hemorrhaged guinea pigs. Caron A, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jan; 27(1):49–64

Effects of liposome-encapsulated hemoglobin on phorbol ester-induced superoxide production and expression of costimulatory molecules by monocytes in vitro. Fujihara M, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov;26(5–6):487–95

Physiologic responses of cross-linked hemoglobin in endotoxin-treated rats. Goff JM, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jan; 27(1):11–21

Inflammatory cytokine production in whole blood modified by liposome-encapsulated hemoglobin. Niwa K, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov; 26(5–6):559–70

Inhaled nitric oxide attenuates increased pulmonary artery pressure following diaspirin crosslinked hemoglobin (DCLHb) administration. Sefton W, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 May; 27(3):203–13

Complement-mediated acute effects of liposome-encapsulated hemoglobin. Szebeni J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Jan; 27(1):23–41 (64 ref.)

Hemolink-induced effects on intestinal motor function and attenuation of these effects by selected agents. Wong LT, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1998 Nov;26(5–6):529–48

Effects of pyridoxalated hemoglobin polyoxyethylene conjugate on diameter of rat mesenteric arterioles in situ. Matsumura H, et al. **Artif Organs** 1992 Oct;16(5):461–7

Mechanism of the acute pressor effect and bradycardia elicited by diaspirin crosslinked hemoglobin in anesthetized rats. Moisan S, et al. **Can J Physiol Pharmacol** 1998 Apr; 76(4):434–42

Nimodipine inhibits the pressor activity of diaspirin-crosslinked hemoglobin (DCLHb) in the rat. Rioux F, et al. **Can J Physiol Pharmacol** 1998 Oct–Nov; 76(10–11):983–8

Differentially increased IL-6 mRNA expression in liver and spleen following injection of liposome-encapsulated haemoglobin. Zhu XL, et al. **Cytokine** 1999 Sep; 11(9):696–703

Reduced nitric oxide reactivity of a new recombinant human hemoglobin attenuates gastric dysmotility. Hartman JC, et al. **Eur J Pharmacol** 1998 Dec 18;363(2–3):175–8

Ferritin and hemoglobin in pituitary gland extracts are mitogenic for rat mammary epithelial cells in culture [letter] Wilkinson MC, et al. **In Vitro Cell Dev Biol Anim** 1998 Jul–Aug;34(7):518–9

Cardiovascular and hemorheological effects of three modified human hemoglobin solutions in hemodiluted rabbits. Caron A, et al. **J Appl Physiol** 1999 Feb;86(2):541–8

Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats. Fitzgerald SM, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):206–11

Pharmacology of hemoglobin therapeutics. Gulati A, et al. **J Lab Clin Med** 1999 Feb;133(2):112–9 (57 ref.)

Endothelin plays a role in contractions of isolated pig pulmonary vessels induced by diaspirin cross-linked hemoglobin. Ledvina MA, et al. **J Lab Clin Med** 1999 May; 133(5):478–87

A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor. Moeller I, et al. **J Neurochem** 1999 Jul; 73(1):301–8

O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. Lieberthal W, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1278–87

Induction of heme oxygenase-1 with hemoglobin depresses vasoreactivity in rat aorta. Gaine SP, et al. **J Vasc Res** 1999 Mar–Apr;36(2):114–9

Histology and ultrastructure of liver and kidney following blood exchange with ultrapurified, polymerised bovine hemoglobin in comparison with hydroxyethyl starch. Lipfert B, et al. **Lab Invest** 1999 May;79(5):573–82

Vasoactive properties of synthetic blood substitutes. de Figueiredo LF. **Medicina (B Aires)** 1998;58(4):403–10 (74 ref.)

Administration of polymerized bovine hemoglobin improves survival in a rat model of traumatic shock. Hayward R, et al. **Methods Find Exp Clin Pharmacol** 1999 Jul–Aug; 21(6):427–33

Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Garreau I, et al. **Peptides** 1998; 19(8):1339–48

Pharmacologic effects of the red blood cell substitutes cross-linked and non-cross-linked hemoglobins on hematopoiesis in rabbits. Lutton JD, et al. **Pharmacology** 1999 Jun;58(6):319–24

L-arginine and endothelin receptor antagonist bosentan counteract hemodynamic effects of modified hemoglobin. Fischer SR, et al. **Shock** 1999 Apr;11(4):283–90

PHYSIOLOGY

Clinical implications of hemoglobin as a nitric oxide carrier. Veeramachaneni NK, et al. **Arch Surg** 1999 Apr; 134(4):434–7 (44 ref.)

Embryonic globins of the marsupial the Tammar Wallaby (Macropus eugenii): bird like and mammal like. Holland RA, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):740–4

Low-temperature sensitivity and enhanced Bohr effect in red deer (Cervus elaphus) haemoglobin: a molecular adaptive strategy to life at high altitude and low temperature. Pellegrini M, et al. **Eur J Biochem** 1999 Mar; 260(3):667–71

Functional differentiation in trematode hemoglobin isoforms. Rashid AK, et al. **Eur J Biochem** 1999 Mar;260(3):717–25

Novel mechanism by which hemoglobin induces constriction of cerebral arteries. Vollrath B, et al. **Eur J Pharmacol** 1998 Nov 20;361(2–3):311–9

Rectal temperature and prostaglandin E2 increase in cerebrospinal fluid of conscious rabbits after intracerebroventricular injection of hemoglobin. Frosini M, et al. **Exp Brain Res** 1999 May;126(2):252–8

Humoral regulation of hemoglobin transition from larval to adult types in a salamander, Hynobius retardatus. Satoh SJ, et al. **Gen Comp Endocrinol** 1999 May;114(2):225–34

Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. Doyle MP, et al. **J Biol Chem** 1999 Jan 22;274(4):2583–91

Role of NO and endothelin in hemoglobin-induced pulmonary vasoconstriction. Heller A, et al. **Shock** 1998 Dec;10(6):401–6

Remote contributions to subunit interactions: lessons from adult and fetal hemoglobins. Manning JM, et al. **Trends Biochem Sci** 1999 Jun;24(6):211–2 (16 ref.)

[Cellular engineering: crash tests with human erythrocytes reveal hidden properties of cellular proteins] Artmann GM, et al. **Biomed Tech (Berl)** 1998;43 Suppl:446–7 **(Ger)**

[Nitric oxide and hemoglobin] Yonetani T. **Nippon Yakurigaku Zasshi** 1998 Sep;112(3):155–60 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The role of hemoglobin on the regulation of electrokinetic characteristics and volume of erythrocytes] Bashirova RM, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):49–51 **(Rus)**

RADIATION EFFECTS

Damage to hemoglobin by radiation-generated serum albumin radicals. Puchała M, et al. **Free Radic Biol Med** 1999 May;26(9–10):1284–91

Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, et al. **Strahlenther Onkol** 1998 Dec;174 Suppl 4:13–6 (35 ref.)

STANDARDS

Lyophilized bovine hemoglobin as a possible reference material for the determination of hemoglobin derivatives in human blood. Maas BH, et al. **Clin Chem** 1998 Nov; 44(11):2331–9

Regression-based reference limits: determination of sufficient sample size. Virtanen A, et al. **Clin Chem** 1998 Nov; 44(11):2353–8

Future prospects for artificial blood. Chang TM. **Trends Biotechnol** 1999 Feb;17(2):61–7 (89 ref.)

THERAPEUTIC USE

Decreased lactic acidosis and anemia after transfusion of o-raffinose cross-linked and polymerized hemoglobin in severe murine malaria. Freilich D, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):322–8

Hemoglobin-based oxygen carriers: development and clinical potential. Ketcham EM, et al. **Ann Emerg Med** 1999 Mar; 33(3):326–37 (96 ref.)

Comparison of resuscitation with diaspirin crosslinked hemoglobin (DCLHb) vs fresh blood in a rat burn shock model. Soltero RG, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):135–52

Haemoglobin therapy in clinical practice: use and characteristics of DCLHb. Baron JF. **Br J Anaesth** 1998 Dec;81 Suppl 1:34–7 (24 ref.)

Subarachnoid hemorrhage in rats: effect of singular or sustained hemodilution with alpha-alpha diaspirin crosslinked hemoglobin on cerebral hypoperfusion. Cole DJ, et al. **Crit Care Med** 1999 May;27(5):972–7

Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice [see comments] Su D, et al. **Crit Care Med** 1999 Apr; 27(4):771–8. Comment in: Crit Care Med 1999 Apr;27(4):685–6.

Low-volume resuscitation with a hemoglobin-based oxygen carrier after hemorrhage improves gut microvascular oxygenation in swine. van Iterson M, et al. **J Lab Clin Med** 1998 Nov;132(5):421–31

The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats. Soltero RG, et al. **J Trauma** 1999 Feb;46(2):286–91

Effect of liposome-encapsulated hemoglobin, neo red cells, on hemorrhagic shock. Usuba A, et al. **Surg Today** 1998; 28(10):1027–35

Potential effect of hemoglobin solutions on blood components [letter; comment] Menu P, et al. **Transfusion** 1999 Feb; 39(2):226–7. Comment on: Transfusion 1997 Nov–Dec;37(11–12):1149–55.

[Failure to prove the effectiveness of hemoglobin solutions as oxygen carrier in the paper of Horn et al. Anaesthesist (1998) 47:116–123 (letter)] Zander R. **Anaesthesist** 1998 Dec;47(12):998–1003 **(Ger)**

[Hemoglobin solutions: volume replacement or oxygen therapy?] Standl T. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):699–714 (152 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Toxic effect of hemoglobin on spinal cord neurons in culture. Regan RF, et al. **J Neurotrauma** 1998 Aug;15(8):645–53

In vitro erythrophagocytosis by renal tubular cells and tubular toxicity by haemoglobin and iron. Sheerin NS, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1391–7

URINE see HEMOGLOBINURIA

HEMOGLOBINS, ABNORMAL

Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Zimmerman SA, et al. **Am J Hematol** 1999 Apr;60(4):279–84 (27 ref.)

Homozygous alpha-thalassaemia and hypospadias--common aetiology or incidental association? Long-term survival of Hb Bart's hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Dame C, et al. **Eur J Pediatr** 1999 Mar;158(3):217–20

Hb Oita [alpha45(CE3)His-->Pro]: a new silent hemoglobin variant [published erratum appears in Hemoglobin 1998 Sep-Nov;22(5–6):539–40] Hamaguchi K, et al. **Hemoglobin** 1998 Jul;22(4):347–54

A new hemoglobin variant found during Hb A1c measurement: Hb Hokusetsu [beta52(D3)Asp-->Gly]. Nakanishi T, et al. **Hemoglobin** 1998 Jul;22(4):355–71

Pituitary deficiency and lack of gonads in an XY pseudohermaphrodite with beta 39/lepore haemoglobinopathy. Saviano A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:997–9

Characterization of hemoglobin Hotel Dieu in a Puerto Rican adolescent. Cadilla CL, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct;20(5):506–10

Association of Hb-D trait with nephrotic syndrome: a fact or coincidence? Jamal A, et al. **JPMA J Pak Med Assoc** 1999 Feb;49(2):44–5

[Hemoglobinopathy in Japan: detection and analysis] Harano T. **Rinsho Byori** 1999 Mar;47(3):215–23 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of abnormal Hb on red cell membranes] Ideguchi H. **Rinsho Byori** 1999 Mar;47(3):232–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The origin of molecular disease: functional abnormalities and consequent clinical symptoms caused by single amino acid substitutions] Imai K. **Rinsho Byori** 1999 Mar;47(3):238–43 (18 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Comparison of hemoglobin A1C results by two different methods on patients with structural hemoglobin variants. Blakney GB, et al. **Clin Biochem** 1998 Nov;31(8):619–26

Interference of hemoglobin D in hemoglobin A(2) measurement by cation-exchange HPLC [letter] Cotton F, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1317–8

Hb A2 in subjects with Hb D [letter; comment] [see comments] Dash S. **Clin Chem** 1998 Nov;44(11):2381–2. Comment on: Clin Chem 1997 Oct;43(10):1850–6. Comment in: Clin Chem 1999 Aug;45(8 Pt 1):1317–8.

Capillary zone electrophoresis for the diagnosis of congenital hemoglobinopathies. Mario N, et al. **Clin Chem** 1999 Feb; 45(2):285–8

Predictive value of cord blood hematological indices and hemoglobin Barts for the detection of heterozygous alpha-thalassemia-2 in an African-Caribbean population. van der Dijs FP, et al. **Clin Chem** 1999 Sep;45(9):1495–500

Hb Köln [beta98(FG5)Val-->Met]: the first case found in a Chinese family. Chang JG, et al. **Hemoglobin** 1998

Sep-Nov;22(5-6):535-6

Hb Hammersmith [beta 42(CD1) Phe-->Ser]: occurrence as a de novo mutation in black monozygotic twins with multiple congenital anomalies. Tuohy AM, et al. **J Pediatr Hematol Oncol** 1998 Nov-Dec;20(6):563-6

[A new approach for the characterization of aberrant hemoglobins: the applications of current advanced mass spectrometric techniques (nanoESIMS, MS3)] Nakanishi T. **Rinsho Byori** 1999 Mar;47(3):224-31 (Eng. Abstr.) **(Jpn)**

[Chemical analysis of clinical materials using mass spectrometry] Shimizu A, et al. **Rinsho Byori** 1999 Feb; Suppl 109:116-25 (16 ref.) **(Jpn)**

BIOSYNTHESIS

Successful hydroxyurea treatment of a patient with SD hemoglobinopathy [letter] Udden MM, et al. **Am J Hematol** 1999 Jan;60(1):84-5

CHEMISTRY

Probing the diphosphoglycerate binding pocket of HbA and HbPresbyterian (beta 108Asn --> Lys). Gottfried DS, et al. **Biochemistry** 1999 Aug 31;38(35):11307-15

New light on allostery: dynamic resonance Raman spectroscopy of hemoglobin kempsey. Hu X, et al. **Biochemistry** 1999 Mar 23;38(12):3462-7

The conformational and dynamic basis for ligand binding reactivity in hemoglobin Ypsilanti (beta 99 asp-->Tyr): origin of the quaternary enhancement effect. Huang J, et al. **Biochemistry** 1999 Apr 6;38(14):4514-25

Cyanide binding to Lucina pectinata hemoglobin I and to sperm whale myoglobin: an x-ray crystallographic study. Bolognesi M, et al. **Biophys J** 1999 Aug;77(2):1093-9

Orientation of the heme vinyl groups in the hydrogen sulfide-binding hemoglobin I from Lucina pectinata. Silfa E, et al. **Biospectroscopy** 1998;4(5):311-26

Altered ligand rebinding kinetics due to distal-side effects in hemoglobin chico (Lysbeta66(E10) --> thr). Bonaventura C, et al. **J Biol Chem** 1999 Mar 26; 274(13):8686-93

The structural and functional analysis of the hemoglobin D component from chicken. Knapp JE, et al. **J Biol Chem** 1999 Mar 5;274(10):6411-20

GENETICS

Hb Iraq-Halabja beta10 (A7) Ala-->Val (GCC-->GTC): a new beta-chain silent variant in a family with multiple Hb disorders. Deutsch S, et al. **Am J Hematol** 1999 Jul; 61(3):187-93

Hemoglobins in Togolese newborns: Hb S, Hb C, Hb Bart's, and alpha-globin gene status. Segbena AY, et al. **Am J Hematol** 1998 Nov;59(3):208-13

HbS-oman heterozygote: a new dominant sickle syndrome. Nagel RL, et al. **Blood** 1998 Dec 1;92(11):4375-82

Hb Nancy and Hb Osler: two distinct genetic variants with identical clinical and hemoglobin phenotype. Préhu C, et al. **C R Acad Sci III** 1998 May;321(5):373-6

Heterozygous hemoglobin Hamadan affects HbA1c assay [letter] Gunton JE, et al. **Diabetes Care** 1999 Jan;22(1):177

Homozygous alpha-thalassaemia and hypospadias--common aetiology or incidental association? Long-term survival of Hb Bart's hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Dame C, et al. **Eur J Pediatr** 1999 Mar;158(3):217-20

HbOThrace trait, HbOThrace hemoglobinopathy and HbOThrace/Hb beta zero hemoglobinopathy: a retrospective study of 118 cases. Vassiliadou D, et al. **Folia Med (Plovdiv)** 1998;40(3B Suppl 3):46-50

Molecular diagnosis and characterization of Hb Zürich [beta63(E7)His-->Arg]] carriers in a Kentucky family. Aguinaga MP, et al. **Hemoglobin** 1998 Sep-Nov; 22(5-6):509-15

The association of Hb Khartoum [beta124(H2)Pro-->Arg] with gamma+-thalassemia is responsible for hemolytic disease in the newborn of a Sudanese family. Bayoumi RA, et al. **Hemoglobin** 1999 Feb;23(1):33-45

Characterization and locus assignment of two alpha-globin variants present in the Maltese population: Hb St. Luke's [alpha95(G2)Pro-->Arg] and Hb Setif [alpha94(G1)Asp-->Tyr]. Bezzina Wettinger S, et al. **Hemoglobin** 1999 May;23(2):145-57

Hb Rainier [beta145(HC2)Tyr-->Cys] in Italy. Characterization of the amino acid substitution and the DNA mutation. Carbone V, et al. **Hemoglobin** 1999 May; 23(2):111-24

Hb Siriraj: a G-->A substitution at codon 7 of the beta-globin chain creates an MboII cutting site. Chang JG, et al. **Hemoglobin** 1999 May;23(2):197-9

Hb Köln [beta98(FG5)Val-->Met]: the first case found in a Chinese family. Chang JG, et al. **Hemoglobin** 1998 Sep-Nov;22(5-6):535-6

Hb Schlierbach or beta108(G10)Asn-->Ile: a new variant with low oxygen affinity detected in a Swiss family. Frischknecht H, et al. **Hemoglobin** 1999 Feb;23(1):83-7

Haplotype analysis of two new, independent cases of Hb Osu-Christiansborg. Giordano PC, et al. **Hemoglobin** 1999 May;23(2):193-5

Hb Rio Claro [beta34(B16)Val-->Met]: a novel electrophoretically silent variant found in association with Hb Hasharon [alpha47(CE5)Asp-->His] and alpha-thalassemia-2(-alpha3.7). Grignoli CR, et al. **Hemoglobin** 1999 May;23(2):177-82

Hb Brent [beta117(G19)His-->Asn]: a new hemoglobin variant found during routine antenatal screening. Henthorn JS, et al. **Hemoglobin** 1999 Feb;23(1):89-93

Hb Chile [beta28(B10)Leu-->Met]: an unstable hemoglobin associated with chronic methemoglobinemia and sulfonamide or methylene blue-induced hemolytic anemia. Hojas-Bernal R, et al. **Hemoglobin** 1999 May;23(2):125-34

A new beta chain variant, Hb Vienna or beta77(EF1)His-->Gln. Hopmeier P, et al. **Hemoglobin** 1998 Jul;22(4):391-5

Identification of Hb J-Buda [alpha61(E10)Lys-->Asn] in a Thai female. Itchayanan D, et al. **Hemoglobin** 1999 May; 23(2):183-6

Hb G-Coushatta [beta22(B4)Glu-->Ala] in Thailand. Itchayanan D, et al. **Hemoglobin** 1999 Feb;23(1):69-72

Two hemoglobin variants with an alteration of the oxygen-linked chloride binding: Hb Antananarivo [alpha1(NA1)Val-->Gly] and Hb Barbizon [beta144(HC1)Lys-->Met]. Kister J, et al. **Hemoglobin** 1999 Feb;23(1):21-32

Characterization of Hb Djelfa [beta98(FG5)Val-->Ala]] by DNA sequencing in a French Caucasian family. Lacan P, et al. **Hemoglobin** 1999 Feb;23(1):73-7

Genetic studies suggest a multicentric origin for Hb G-Coushatta [beta22(B4)Glu-->Ala]. Li J, et al. **Hemoglobin** 1999 Feb;23(1):57-67

Sheep Hb I variant, or beta13(A10)Gly-->Ser, in breeds from Corsica: detection by gene sequencing. Serreri E, et al. **Hemoglobin** 1998 Sep-Nov;22(5-6):525-8

Hb Brockton [beta138(H16)Ala-->Pro] observed in a Chinese boy. Tsoi WC, et al. **Hemoglobin** 1998 Jul; 22(4):397-400

Hb Nijkerk: a new mutation at codons 138/139 of the beta-globin gene inducing severe hemolytic anemia in a Dutch girl. van den Berg HM, et al. **Hemoglobin** 1999 May; 23(2):135-44

Hemoglobin Phnom Penh [alpha117Phe(H1)-Ile-alpha118Thr(H2)]; evidence for a hotspot for insertion of residues in the third exon of the alpha1-globin gene. Wajcman H, et al. **Hum Mutat** 1998; Suppl 1:S20-2

Hemoglobin Agenogi [beta 90 (F6) Glu-->Lys] found in Piedmont. Case report. Scimè-Degani V, et al. **Panminerva Med** 1998 Sep;40(3):250-3

Molecular exclusion of haemoglobin SD disease by prenatal diagnosis. Fodor FH, et al. **Prenat Diagn** 1999 Jan; 19(1):58-60

[Hemoglobin Sydney--alpha beta 2 67 (E11) Val-Ala and hemoglobin Olomouc alpha 2 beta 2 86 (F 2) Ala-Asp in Czech families. DNA sequence analysis for a more accurate diagnosis of hemoglobinopathies] Indrák K, et al. **Vnitr Lek** 1998 Jun;44(6):347-9 (Eng. Abstr.) **(Cze)**

[Haplotypes of the beta-globulin locus in Czechs and Slovaks with beta-thalassemia and structurally variant hemoglobins (published erratum appears in Vnitr Lek 1999 Jan;45(1):45)] Kynčlová E, et al. **Vnitr Lek** 1998 Sep;44(9):518-23 (Eng. Abstr.) **(Cze)**

METABOLISM

Probing the diphosphoglycerate binding pocket of HbA and HbPresbyterian (beta 108Asn --> Lys). Gottfried DS, et al. **Biochemistry** 1999 Aug 31;38(35):11307-15

The conformational and dynamic basis for ligand binding reactivity in hemoglobin Ypsilanti (beta 99 asp-->Tyr): origin of the quaternary enhancement effect. Huang J, et al. **Biochemistry** 1999 Apr 6;38(14):4514-25

Cyanide binding to Lucina pectinata hemoglobin I and to sperm whale myoglobin: an x-ray crystallographic study. Bolognesi M, et al. **Biophys J** 1999 Aug;77(2):1093-9

Orientation of the heme vinyl groups in the hydrogen sulfide-binding hemoglobin I from Lucina pectinata. Silfa E, et al. **Biospectroscopy** 1998;4(5):311-26

Partitioning of oxygen and carbon monoxide in the three human embryonic hemoglobins. Hofmann OM, et al. **Hemoglobin** 1998 Jul;22(4):313-9

Hb Tende [beta124(H2)Pro-->Leu]: a new variant with a moderate increase in oxygen affinity. Wajcman H, et al. **Hemoglobin** 1998 Sep-Nov;22(5-6):517-23

Steady-state fluorescence and circular dichroism of trout hemoglobins I and IV interacting with tributyltin. Zolese G, et al. **Proteins** 1999 Mar 1;34(4):443-52

PHYSIOLOGY

Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly. Hohl RJ, et al. **Am J Hematol** 1998 Nov;59(3):181-4

HEMOGLOBINURIA

Orange urine. Lord RC. **Postgrad Med J** 1999 Feb; 75(880):109-10

CHEMICALLY INDUCED

Purification, properties, and amino acid sequence of a hemoglobinuria-inducing phospholipase A(2), MiPLA-1, from Micropechis ikaheka venom. Gao R, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):181-92

ETIOLOGY

Unexplained haemoglobinuria may have been haematuria [letter] Mortensen S. **BMJ** 1999 Jan 16;318(7177):192

GENETICS

Phenotypic variability of Filipino beta(o)-thalassemia/HbE patients in Indonesia. Setianingsih I, et al. **Am J Hematol** 1999 Sep;62(1):7-12

VETERINARY

Cullen's sign and haemoglobinuria as presenting signs of retroperitoneal haemorrhage in a dog. Schermerhorn T, et al. **J Small Anim Pract** 1998 Oct;39(10):490-4

Parturient haemoglobinuria in buffaloes--a review. Pirzada WH, et al. **Trop Anim Health Prod** 1998 Aug;30(4):209-15 (31 ref.)

Lowered antioxidant status of red blood cells in post-parturient haemoglobinuria of buffaloes. Chugh SK, et al. **Vet Res Commun** 1998 Sep;22(6):385-8

HEMOGLOBINURIA, PAROXYSMAL

[Paroxysmal nocturnal hemoglobinuria in pregnancy] Lange JG, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2308-11 (Eng. Abstr.) **(Dut)**

BLOOD

Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Hugel B, et al. **Blood** 1999 May 15; 93(10):3451-6

Correction of the PNH defect by GPI-anchored protein transfer. Sloand EM, et al. **Blood** 1998 Dec 1; 92(11):4439-45

Complement-induced procoagulant alteration of red blood cell membranes with microvesicle formation in paroxysmal nocturnal haemoglobinuria (PNH): implication for thrombogenesis in PNH. Ninomiya H, et al. **Br J Haematol** 1999 Jul;106(1):224-31

Paroxysmal nocturnal haemoglobinuria: the disease and a hypothesis for a new treatment. Jarva H, et al. **Scand J Immunol** 1999 Feb;49(2):119-25 (78 ref.)

[Detection of PNH clones using flow cytometry in aplastic anemia and paroxysmal nocturnal hemoglobinuria] Forés R, et al. **Sangre (Barc)** 1999 Jun;44(3):199-203 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Clonal variation, autoimmunity, and neoplasia: an ecology lesson from paroxysmal nocturnal hemoglobinuria [editorial; comment] Benz EJ Jr. **Ann Intern Med** 1999 Sep 21;131(6):467-8. Comment on: Ann Intern Med 1999 Sep 21;131(6):401-8.

Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes [see comments] Dunn DE, et al. **Ann Intern Med** 1999 Sep 21;131(6):401-8. Comment in: Ann Intern Med 1999 Sep 21;131(6):467-8.

Acute reversible renal failure in a patient with paroxysmal nocturnal hemoglobinuria. Mooraki A, et al. **Clin Nephrol** 1998 Oct;50(4):255-7

Leukemia arising out of paroxysmal nocturnal hemoglobinuria. Harris JW, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):401-26 (189 ref.)

Renal transplantation for end-stage renal disease due to paroxysmal nocturnal haemoglobinuria. Vanwalleghem J, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3250-2

DIAGNOSIS

Portal vein thrombosis in paroxysmal nocturnal haemoglobinuria. Tomizuka H, et al. **Acta Haematol** 1999; 101(3):149-52 (20 ref.)

Paroxysmal cold haemoglobinuria of childhood: a review of the management and unusual presenting features of six cases. Wynn RF, et al. **Clin Lab Haematol** 1998 Dec; 20(6):373-5

Paroxysmal nocturnal haemoglobinuria mimicking Crohn's disease. Sivakumaran S, et al. **Gut** 1999 Jun;44(6):889

Hemosiderin deposition on the renal cortex by mechanical hemolysis due to malfunctioning prosthetic cardiac valve: report of MR findings in two cases. Lee JW, et al. **J Comput Assist Tomogr** 1999 May-Jun;23(3):445-7

[Case of paroxysmal nocturnal hemoglobinuria diagnosed by the analysis of leukocyte glycosylphosphatidylinositol protein] Hanabusa N, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1557-9 **(Jpn)**

[The Budd-Chiari syndrome coinciding with a hemolytic crisis in a patient with paroxysmal nocturnal hemoglobinuria (letter)] Jiménez Marco M, et al. **Rev Clin Esp** 1999 Jan;199(1):50-1 (9 ref.) **(Spa)**

DRUG THERAPY

Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Brodsky RA, et al. **Blood** 1999 Mar 1;93(5):1749-56

[Current status and prospect of research on the treatment of paroxysmal nocturnal hemoglobinuria with integrated traditional Chinese and Western medicine] Ji Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun;

17(6):381-3 (18 ref.) **(Chi)**

ETIOLOGY

Paroxysmal cold haemoglobinuria caused by non-Hodgkin's lymphoma. Sivakumaran M, et al. **Br J Haematol** 1999 Apr; 105(1):278-9

Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. Nishimura J, et al. **Hematopathol Mol Hematol** 1998; 11(3-4):119-46 (180 ref.)

GENETICS

Paroxysmal nocturnal hemoglobinuria: analysis of the effects of mutant PIG-A on gene expression. Kanai N, et al. **Am J Hematol** 1999 Aug;61(4):221-31 (40 ref.)

New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. Nafa K, et al. **Blood** 1998 Nov 1;92(9):3422-7

Hypermethylation of p15(INK4B) gene in a patient with acute myelogenous leukemia evolved from paroxysmal nocturnal hemoglobinuria [letter] Uchida T, et al. **Blood** 1998 Oct 15;92(8):2981-3

The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Nafa K, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):370-84

Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria. Purow DB, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):81-91

Genotypic, immunophenotypic and clinical features of Thai patients with paroxysmal nocturnal haemoglobinuria. Pramoonjago P, et al. **Br J Haematol** 1999 May; 105(2):497-504

Thrombosis in heritable hemolytic disorders. Barker JE, et al. **Curr Opin Hematol** 1999 Mar;6(2):71-5 (48 ref.)

Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. Nishimura J, et al. **Hematopathol Mol Hematol** 1998; 11(3-4):119-46 (180 ref.)

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Araten DJ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5209-14

IMMUNOLOGY

Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype. Shichishima T, et al. **Br J Haematol** 1999 Feb; 104(2):303-6

Autoimmune haemolytic anaemia with a paroxysmal nocturnal haemoglobinuria-like defect [letter] Zupańska B, et al. **Eur J Haematol** 1999 May;62(5):346-9

METABOLISM

Paroxysmal nocturnal haemoglobinuria. MRI of renal cortical haemosiderosis in two patients, including one renal transplant. Verswijvel G, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1586-9

PATHOLOGY

Paroxysmal nocturnal hemoglobinuria and complement-mediated erythrocyte damage. Parker CJ. **Curr Opin Hematol** 1994 Mar;1(2):151-6 (37 ref.)

Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Araten DJ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5209-14

PHYSIOPATHOLOGY

Clonal evolution of aplastic anaemia to myelodysplasia/acute myeloid leukaemia and paroxysmal nocturnal haemoglobinuria. Tooze JA, et al. **Leuk Lymphoma** 1999 Apr;33(3-4):231-41 (104 ref.)

THERAPY

Identical twin marrow transplantation for venous thrombosis in paroxysmal nocturnal hemoglobinuria; long-term complete remission as assessed by flow cytometry. Doukas MA, et al. **Bone Marrow Transplant** 1998 Oct;22(7):717-21

Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Bemba M, et al. **Br J Haematol** 1999 May; 105(2):366-8

Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Saso R, et al. **Br J Haematol** 1999 Feb; 104(2):392-6

Paroxysmal cold haemoglobinuria of childhood: a review of the management and unusual presenting features of six cases. Wynn RF, et al. **Clin Lab Haematol** 1998 Dec; 20(6):373-5

Paroxysmal nocturnal haemoglobinuria: the disease and a hypothesis for a new treatment. Jarva H, et al. **Scand J Immunol** 1999 Feb;49(2):119-25 (78 ref.)

[Effective treatment combining antithymocyte globulin, cyclosporin A, and granulocyte colony-stimulating factor for atypical paroxysmal nocturnal hemoglobinuria accompanied by bone marrow hypoplasia] Noji H, et al. **Rinsho Ketsueki** 1999 Mar;40(3):240-3 (Eng. Abstr.) **(Jpn)**

URINE

The irreplaceable image: Paroxysmal nocturnal hemoglobinuria. Shahab N, et al. **Haematologica** 1999 Jun; 84(6):558

HEMOLYMPH

CHEMISTRY

Acaloleptins A: inducible antibacterial peptides from larvae of the beetle, Acalolepta luxuriosa. Imamura M, et al. **Arch Insect Biochem Physiol** 1999;40(2):88-98

Isolation and partial characterization of chromoprotein from the larval hemolymph of the Japanese oak silkworm (Antheraea yamamai). Saito H, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):625-30

Sialic acid in hemolymph and affinity purified lectins from two marine bivalves. Tunkijjanukij S, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):705-13

The hemolymph clottable proteins of tiger shrimp, Penaeus monodon, and related species. Yeh MS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Oct; 121(2):169-76

Catechol conjugation with hemolymph proteins and their incorporation into the cuticle of the American cockroach, Periplaneta americana. Bailey WD, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):139-45

Presence of IL-1- and TNF-like molecules in Galleria mellonella (Lepidoptera) haemocytes and in an insect cell line Fromestigmene acraea (Lepidoptera). Wittwer D, et al. **Cytokine** 1999 Sep;11(9):637-42

Functional and structural diversities of C-reactive proteins present in horseshoe crab hemolymph plasma. Iwaki D, et al. **Eur J Biochem** 1999 Sep;264(2):314-26

A novel lipoprotein from the hemolymph of the cochineal insect, Dactylopius confusus. Ziegler R, et al. **Eur J Biochem** 1999 Apr;261(1):285-90

A newly established ELISA showing the effect of the androgenic gland on secondary-vitellogenic-specific protein in the hemolymph of the crayfish Cherax quadricarinatus. Sagi A, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):37-45

Mytilus edulis hemolymph contain prodynorphin. Stefano GB, et al. **Immunol Lett** 1998 Aug;63(1):33-9

C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. Shrive AK, et al. **J Mol Biol** 1999 Jul 30; 290(5):997-1008

CYTOLOGY

Effect of Biomphalaria straminea plasma in the phagocytosis of Biomphalaria glabrata hemolymph cells. Malagueño E, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:301-2

DRUG EFFECTS

Endogenous morphine levels increase in molluscan neural and immune tissues after physical trauma. Sonetti D, et al. **Brain Res** 1999 Jul 24;835(2):137-47

Mytilus edulis hemolymph contains pro-opiomelanocortin: LPS and morphine stimulate differential processing. Stefano GB, et al. **Brain Res Mol Brain Res** 1999 Jan 8; 63(2):340-50

ENZYMOLOGY

Primary structure and properties of the cathepsin G/chymotrypsin inhibitor from the larval hemolymph of Apis mellifera. Bania J, et al. **Eur J Biochem** 1999 Jun; 262(3):680-7

Cooperation of dopachrome conversion factor with phenoloxidase in the eumelanin pathway in haemolymph of Locusta migratoria (Insecta). Cherqui A, et al. **Insect Biochem Mol Biol** 1998 Nov;28(11):839-48

Molecular cloning and characterization of hemolymph 3-dehydroecdysone 3beta-reductase from the cotton leafworm, Spodoptera littoralis. A new member of the third superfamily of oxidoreductases. Chen JH, et al. **J Biol Chem** 1999 Apr 9;274(15):10551-6

Haemolymph and fat body metallo-protease associated with Enterobacter cloacae infection in the bloodsucking insect, Rhodnius prolixus. Feder D, et al. **Mem Inst Oswaldo Cruz** 1998 Nov-Dec;93(6):823-6

METABOLISM

Evidence that hemolymph glucose in Aplysia californica is regulated but does not affect feeding behavior. Horn CC, et al. **Behav Neurosci** 1998 Oct;112(5):1258-65

Specific binding of human interferon-gamma to particulates from hemolymph and protocerebrum of tobacco hornworm (Manduca sexta) larvae. Parker MS, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):155-63

Purification and properties of a small lipid-binding protein from the hemolymph of Triatoma infestans. Rimoldi OJ, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan;122(1):97-104

Lipid binding capacity of spider hemocyanin. Cunningham M, et al. **J Exp Zool** 1999 Sep 1;284(4):368-73

Hemolymph and tissue-bound peptidase-resistant analogs of the insect allatostatins. Nachman RJ, et al. **Peptides** 1999; 20(1):23-9

PARASITOLOGY

Studies on a haemolymph lectin isolated from Rhodnius prolixus and its interaction with Trypanosoma rangeli. Mello CB, et al. **Exp Parasitol** 1999 Apr;91(4):289-96

PHYSIOLOGY

Respecified larval proleg and body wall muscles circulate hemolymph in developing wings of Manduca sexta pupae. Lubischer JL, et al. **J Exp Biol** 1999 Apr;202 (Pt 7):787-96

Levels of serotonin in the hemolymph of Aplysia are modulated by light/dark cycles and sensitization training. Levenson J, et al. **J Neurosci** 1999 Sep 15;19(18):8094-103

HEMOLYSIN FACTORS

GENETICS

Regulation of the Enterococcus faecalis pAD1-related sex pheromone response: analyses of traD expression and its role in controlling conjugation functions. do Carmo de Freire Bastos M, et al. **Mol Microbiol** 1998 Oct; 30(2):381-92

HEMOLYSINS

Differential regulation of enteric and systemic salmonellosis by slyA. Watson PR, et al. **Infect Immun** 1999 Sep; 67(9):4950-4

ANALYSIS

Frequency of alpha- and beta-haemolysin in Staphylococcus aureus of bovine and human origin. A comparison between pheno- and genotype and variation in phenotypic expression. Aarestrup FM, et al. **APMIS** 1999 Apr; 107(4):425-30

[Analysis of Vibrio cholerae hemolysins using monolayer continuous cell cultures] Telesmanich NR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec; (6):30-2 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Characteristics of induction of virulence factor expression by activated charcoal in Listeria monocytogenes. Ermolaeva S, et al. **FEMS Microbiol Lett** 1999 May 1; 174(1):137-41

Hyperproduction of alpha-hemolysin in a sigB mutant is associated with elevated SarA expression in Staphylococcus aureus. Cheung AL, et al. **Infect Immun** 1999 Mar;67(3):1331-7

Expression of listeriolysin O and ActA by intracellular and extracellular Listeria monocytogenes. Moors MA, et al. **Infect Immun** 1999 Jan;67(1):131-9

Hemolysin as a virulence factor for systemic infection with isolates of Mycobacterium avium complex. Maslow JN, et al. **J Clin Microbiol** 1999 Feb;37(2):445-6

Detection of total and hemolysin-producing Vibrio parahaemolyticus in shellfish using multiplex PCR amplification of tl, tdh and trh. Bej AK, et al. **J Microbiol Methods** 1999 Jun;36(3):215-25

Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Blanco M, et al. **Res Microbiol** 1997 Dec;148(9):745-55

Correlation between production of listeriolysin O by variants of Listeria monocytogenes and their virulence for rabbits. Waseem M, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):384-8

Prevalence of the fimbrial antigens F18 and K88 and of enterotoxins and verotoxins among Escherichia coli isolated from weaned pigs. Wittig W, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):95-104

[Inhibition effect of hypoxia on humoral immunity of rats] Bai HB, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):167-72 (Eng. Abstr.) **(Chi)**

[Effect of subinhibitory concentrations of antibiotics on the production of enterohemolysin by enterohemorrhagic Escherichia coli O157:H7] Zhang HM, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):255-6 **(Jpn)**

BLOOD

Unsatisfactory detection of an in vivo haemolytic anti-vel by the gel test. Neppert J, et al. **Vox Sang** 1998;75(1):70-1

CHEMISTRY

Crystallization of the alpha-hemolysin heptamer solubilized in decyldimethyl- and decyldiethylphosphine oxide. Song L, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Mar 1; 54 (Pt 2):276-8

HlyC, the internal protein acyltransferase that activates hemolysin toxin: the role of conserved tyrosine and arginine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis. Trent MS, et al. **Biochemistry** 1999 Jul 6;38(27):8831-8

The staphylococcal alpha-toxin pore has a flexible conformation. Vécsey-Semjén B, et al. **Biochemistry** 1999 Apr 6;38(14):4296-302

The amphipathic helix concept: length effects on ideally

amphipathic LiKj(i=2j) peptides to acquire optimal hemolytic activity. Castano S, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1-2):161-75

Structure, orientation and affinity for interfaces and lipids of ideally amphipathic lytic LiKj(i=2j) peptides. Castano S, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1-2):176-94

Two forms of Vibrio cholerae O1 El Tor hemolysin derived from identical precursor protein. Ikigai H, et al. **Biochim Biophys Acta** 1999 Jan 8;1415(2):297-305

Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates. Lackey CA, et al. **Bioconjug Chem** 1999 May-Jun;10(3):401-5

Localization and environment of tryptophans in soluble and membrane-bound states of a pore-forming toxin from Staphylococcus aureus. Raja SM, et al. **Biophys J** 1999 Mar;76(3):1469-79

The cytotoxic enterotoxin of Aeromonas hydrophila is aerolysin [letter; comment] Buckley JT, et al. **Infect Immun** 1999 Jan;67(1):466-7. Comment on: Infect Immun 1997 Oct;65(10):4299-308. Comment on: Infect Immun 1998 Aug;66(8):3501-9.

Importance of the carboxyl terminus in the folding and function of alpha-hemolysin of Staphylococcus aureus. Sangha N, et al. **J Biol Chem** 1999 Apr 2;274(14):9193-9

NMR structural characterization of cecropin A(1-8) - magainin 2(1-12) and cecropin A (1-8) - melittin (1-12) hybrid peptides. Oh D, et al. **J Pept Res** 1999 May; 53(5):578-89

Kinetics and mechanism of St I modification by peroxyl radicals. Campos AM, et al. **J Protein Chem** 1999 Apr; 18(3):297-306

Secretion of hemolysin of Aeromonas sobria as protoxin and contribution of the propeptide region removed from the protoxin to the proteolytic stability of the toxin. Nomura T, et al. **Microbiol Immunol** 1999;43(1):29-38

Heptameric structures of two alpha-hemolysin mutants imaged with in situ atomic force microscopy. Malghani MS, et al. **Microsc Res Tech** 1999 Mar 1;44(5):353-6

Insertion of Escherichia coli alpha-haemolysin in lipid bilayers as a non-transmembrane integral protein: prediction and experiment. Soloaga A, et al. **Mol Microbiol** 1999 Feb;31(4):1013-24

A functional protein pore with a "retro" transmembrane domain. Cheley S, et al. **Protein Sci** 1999 Jun;8(6):1257-67

DRUG EFFECTS

Modification of sticholysin II hemolytic activity by free radicals. Pazos IF, et al. **Toxicon** 1998 Oct;36(10):1383-93

GENETICS

Polymerase chain reaction techniques for differentiating cytotoxic and noncytotoxic Pasteurella trehalosi from Rocky Mountain bighorn sheep. Green AL, et al. **Am J Vet Res** 1999 May;60(5):583-8

Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Ohlsen K, et al. **Antimicrob Agents Chemother** 1998 Nov; 42(11):2817-23

Detection of shiga-like toxin (stx1 and stx2), intimin (eaeA), and enterohemorrhagic Escherichia coli (EHEC) hemolysin (EHEC hlyA) genes in animal feces by multiplex PCR. Fagan PK, et al. **Appl Environ Microbiol** 1999 Feb; 65(2):868-72

HlyC, the internal protein acyltransferase that activates hemolysin toxin: role of conserved histidine, serine, and cysteine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis. Trent MS, et al. **Biochemistry** 1999 Mar 16;38(11):3433-9

HlyC, the internal protein acyltransferase that activates hemolysin toxin: roles of various conserved residues in enzymatic activity as probed by site-directed mutagenesis. Trent MS, et al. **Biochemistry** 1999 Jul 20;38(29):9541-8

Genetically engineered metal ion binding sites on the outside of a Channel's transmembrane beta-barrel. Kasianowicz JJ, et al. **Biophys J** 1999 Feb;76(2):837-45

Virulence markers in Shiga toxin-producing Escherichia coli isolated from cattle. Sandhu KS, et al. **Can J Vet Res** 1999 Jul;63(3):177-84

Regulation of the Escherichia coli sheA gene and characterization of its encoded hemolytic activity. Fernández SV, et al. **FEMS Microbiol Lett** 1998 Nov 1; 168(1):85-90

Distribution of two hemolytic toxin genes in clinical and environmental isolates of Aeromonas spp.: correlation with virulence in a suckling mouse model. Heuzenroeder MW, et al. **FEMS Microbiol Lett** 1999 May 1;174(1):131-6

Characterisation of the gene encoding suilysin from Streptococcus suis and expression in field strains. Segers RP, et al. **FEMS Microbiol Lett** 1998 Oct 15;167(2):255-61

Identification, cloning, and expression of the CAMP factor gene (cfa) of group A streptococci. Gase K, et al. **Infect Immun** 1999 Sep;67(9):4725-31

Pathogenicity of an enterotoxigenic Escherichia coli hemolysin (hlyA) mutant in gnotobiotic piglets. Moxley RA, et al. **Infect Immun** 1998 Oct;66(10):5031-5

Identification of genetic determinants for the hemolytic activity of Streptococcus agalactiae by ISS1 transposition. Spellerberg B, et al. **J Bacteriol** 1999 May;181(10):3212-9

Cloning and characterization of the gene encoding Pasteurella haemolytica FnrP, a regulator of the Escherichia coli silent hemolysin sheA. Uhlich GA, et al. **J Bacteriol** 1999 Jun;181(12):3845-8

Actinobacillus actinomycetemcomitans in Chinese adults. Serotype distribution and analysis of the leukotoxin gene promoter locus. Mombelli A, et al. **J Clin Periodontol** 1999 Aug;26(8):505-10

Detection of tdh and trh genes in a urea-hydrolysing environmental isolate of Vibrio parahaemolyticus from the Andamans. Ghosh AR, et al. **J Diarrhoeal Dis Res** 1998 Jun;16(2):87-90

Detection of total and hemolysin-producing Vibrio parahaemolyticus in shellfish using multiplex PCR amplification of tl, tdh and trh. Bej AK, et al. **J Microbiol Methods** 1999 Jun;36(3):215-25

Evaluation of alkaline phosphatase- and digoxigenin-labelled probes for detection of the thermolabile hemolysin (tlh) gene of Vibrio parahaemolyticus. McCarthy SA, et al. **Lett Appl Microbiol** 1999 Jan;28(1):66-70

TTG as the initiation codon of Salmonella slyA, a gene required for survival within macrophages. Kawakami T, et al. **Microbiol Immunol** 1999;43(4):351-7

A novel protein of Erysipelothrix rhusiopathiae that confers haemolytic activity on Escherichia coli. Makino S, et al. **Microbiology** 1999 Jun;145 (Pt 6):1369-74

Manifestation of the Kanagawa phenomenon, the virulence-associated phenotype, of Vibrio parahaemolyticus depends on a particular single base change in the promoter of the thermostable direct haemolysin gene. Okuda J, et al. **Mol Microbiol** 1998 Nov; 30(3):499-511

Molecular analysis of the cytolytic protein ClyA (SheA) from Escherichia coli. Oscarsson J, et al. **Mol Microbiol** 1999 Jun;32(6):1226-38

Identification of a new Escherichia coli She haemolysin homolog in avian E. coli. Reingold J, et al. **Vet Microbiol** 1999 Apr 1;66(2):125-34

IMMUNOLOGY

Production of monoclonal antibodies to Listeria monocytogenes and their application to determine the virulence of isolates from channel catfish. Erdenlig S, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2827-32

Prevalence of, antibody response to, and immunity induced by Haemophilus ducreyi hemolysin. Dutro SM, et al. **Infect Immun** 1999 Jul;67(7):3317-28

Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Tiwana H, et al. **Infect Immun** 1999 Jun;67(6):2769-75

Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E. coli heat-labile enterotoxin B subunit. Bagdasarian MM, et al. **Vaccine** 1999 Feb 5;17(5):441-7

Anti-haemolysin IgG1 to IgG2 ratios correlate with haemolysin neutralization titres and lung lesion scores in Actinobacillus pleuropneumoniae infected pigs. Furesz SE, et al. **Vaccine** 1998 Dec;16(20):1971-5

Kinetics of interferon-gamma production and its comparison with anti-listeriolysin O detection in experimental bovine listeriosis. Barbuddhe SB, et al. **Vet Res Commun** 1998 Dec; 22(8):505-16

[The isolation of monoclonal antibodies to the hemolysin of noncholerigenic vibrios] Telesmanich NR. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):19-22 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Crystallization of the alpha-hemolysin heptamer solubilized in decyldimethyl- and decyldiethylphosphine oxide. Song L, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Mar 1; 54 (Pt 2):276-8

Purification and characterization of hemolysin from Porphyromonas gingivalis A7436. Deshpande RG, et al. **FEMS Microbiol Lett** 1999 Jul 15;176(2):387-94

Simplified purification of Listeria monocytogenes listeriolysin O and preliminary application in the enzyme-linked immunosorbent assay (ELISA). Traub WH, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):29-42

METABOLISM

The Serratia marcescens hemolysin is secreted but not activated by stable protoplast-type L-forms of Proteus mirabilis. Sieben S, et al. **Arch Microbiol** 1998 Oct; 170(4):236-42

The fusion protein of peste des petits ruminants virus is a hemolysin. Devireddy LR, et al. **Arch Virol** 1999; 144(6):1241-7

HlyC, the internal protein acyltransferase that activates hemolysin toxin: roles of various conserved residues in enzymatic activity as probed by site-directed mutagenesis. Trent MS, et al. **Biochemistry** 1999 Jul 20;38(29):9541-8

HlyC, the internal protein acyltransferase that activates hemolysin toxin: role of conserved histidine, serine, and cysteine residues in enzymatic activity as probed by chemical modification and site-directed mutagenesis. Trent MS, et al. **Biochemistry** 1999 Mar 16;38(11):3433-9

Bacillus thuringiensis insecticidal Cry1Aa toxin binds to a highly conserved region of aminopeptidase N in the host insect leading to its evolutionary success. Nakanishi K, et al. **Biochim Biophys Acta** 1999 Jun 15;1432(1):57-63

Water transport by the bacterial channel alpha-hemolysin. Paula S, et al. **Biochim Biophys Acta** 1999 Apr 14; 1418(1):117-26

Binding of Asp-hemolysin from Aspergillus fumigatus to oxidized low density lipoprotein. Kudo Y, et al. **Biol Pharm Bull** 1999 May;22(5):549-50

Further study on the two pivotal parts of Hlg2 for the full hemolytic activity of staphylococcal gamma-hemolysin. Yokota K, et al. **Biosci Biotechnol Biochem** 1998 Sep; 62(9):1745-50

Substrate-induced assembly of a contiguous channel for protein export from E.coli: reversible bridging of an inner-membrane translocase to an outer membrane exit pore. Thanabalu T, et al. **EMBO J** 1998 Nov 16; 17(22):6487-96

The erythrocyte receptor for Fusobacterium necrophorum hemolysin: phosphatidylcholine as a possible candidate. Amoako KK, et al. **FEMS Microbiol Lett** 1998 Nov 1; 168(1):65-70

Oxidized low density lipoprotein inhibits the hemolytic activity of Asp-hemolysin from Aspergillus fumigatus. Fukuchi Y, et al. **FEMS Microbiol Lett** 1998 Oct 15; 167(2):275-80

Analysis of receptor for Vibrio cholerae El tor hemolysin with a monoclonal antibody that recognizes glycophorin B of human erythrocyte membrane. Zhang D, et al. **Infect Immun** 1999 Oct;67(10):5332-7

The pore-forming toxin proaerolysin is activated by furin. Abrami L, et al. **J Biol Chem** 1998 Dec 4;273(49):32656-61

C-terminal amino acid residues are required for the folding and cholesterol binding property of perfringolysin O, a pore-forming cytolysin. Shimada Y, et al. **J Biol Chem** 1999 Jun 25;274(26):18536-42

Kinetics and mechanism of St I modification by peroxyl radicals. Campos AM, et al. **J Protein Chem** 1999 Apr; 18(3):297-306

Secretion of hemolysin of Aeromonas sobria as protoxin and contribution of the propeptide region removed from the protoxin to the proteolytic stability of the toxin. Nomura T, et al. **Microbiol Immunol** 1999;43(1):29-38

Antibody analysis of the localisation, expression and stability of HlyD, the MFP component of the E. coli haemolysin translocator. Pimenta AL, et al. **Mol Gen Genet** 1999 Feb; 261(1):122-32

Characterization of the C-terminal domain essential for toxic activity of adenylate cyclase toxin. Bejerano M, et al. **Mol Microbiol** 1999 Jan;31(1):381-92

The haemolysin-secreting ShlB protein of the outer membrane of Serratia marcescens: determination of surface-exposed residues and formation of ion-permeable pores by ShlB mutants in artificial lipid bilayer membranes. Könninger UW, et al. **Mol Microbiol** 1999 Jun; 32(6):1212-25

Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12. Ludwig A, et al. **Mol Microbiol** 1999 Jan;31(2):557-67

The Escherichia coli haemolysin secretion apparatus: a potential universal antigen delivery system in gram-negative bacterial vaccine carriers [letter] Spreng S, et al. **Mol Microbiol** 1999 Mar;31(5):1596-8

PHARMACOLOGY

The interaction of Staphylococcus aureus bi-component gamma-hemolysins and leucocidins with cells and lipid membranes. Ferreras M, et al. **Biochim Biophys Acta** 1998 Nov 11;1414(1-2):108-26

Activation of particulate guanylyl cyclase by Vibrio vulnificus hemolysin. Kook H, et al. **Eur J Pharmacol** 1999 Jan 22;365(2-3):267-72

A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. Helmerhorst EJ, et al. **FEBS Lett** 1999 Apr 23;449(2-3):105-10

Hemolysin of Aeromonas sobria stimulates production of cyclic AMP by cultured cells. Fujii Y, et al. **FEMS Microbiol Lett** 1999 Jul 1;176(1):67-72

Biological activities of prymnesin-2 isolated from a red tide alga Prymnesium parvum. Igarashi T, et al. **Nat Toxins** 1998;6(1):35-41

Occurrence of hemolytic activity in the skin secretion of the caecilian siphonops paulensis. Schwartz EN, et al. **Nat Toxins** 1998;6(5):179-82

PHYSIOLOGY

E. coli alpha-hemolysin: a membrane-active protein toxin. Goñi FM, et al. **Braz J Med Biol Res** 1998 Aug; 31(8):1019-34 (113 ref.)

An Arcanobacterium (Actinomyces) pyogenes mutant deficient in production of the pore-forming cytolysin pyolysin has reduced virulence. Jost BH, et al. **Infect Immun** 1999 Apr;67(4):1723-8

Role of Listeria monocytogenes exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C in activation of human neutrophils. Sibelius U, et al. **Infect Immun** 1999 Mar;67(3):1125-30

TOXICITY

Localization and environment of tryptophans in soluble and membrane-bound states of a pore-forming toxin from Staphylococcus aureus. Raja SM, et al. **Biophys J** 1999 Mar;76(3):1469-79

Target cell specificity of the Pasteurella haemolytica leukotoxin is unaffected by the nature of the fatty-acyl

HEMOLYSINS

group used to activate the toxin in vitro. Hormozi K, et al. **FEMS Microbiol Lett** 1998 Dec 1;169(1):139–45

Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model. Callegan MC, et al. **Infect Immun** 1999 Jul; 67(7):3357–66

Vibrio parahaemolyticus thermostable direct hemolysin modulates cytoskeletal organization and calcium homeostasis in intestinal cultured cells. Fabbri A, et al. **Infect Immun** 1999 Mar;67(3):1139–48

Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Harvill ET, et al. **Infect Immun** 1999 Mar;67(3):1493–500

Cytotoxic action of Serratia marcescens hemolysin on human epithelial cells. Hertle R, et al. **Infect Immun** 1999 Feb; 67(2):817–25

Alpha-toxin damages the air-blood barrier of the lung in a rat model of Staphylococcus aureus-induced pneumonia. McElroy MC, et al. **Infect Immun** 1999 Oct;67(10):5541–4

Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis. Nilsson IM, et al. **Infect Immun** 1999 Mar;67(3):1045–9

Target cell range of Haemophilus ducreyi hemolysin and its involvement in invasion of human epithelial cells. Wood GE, et al. **Infect Immun** 1999 Aug;67(8):3740–9

Purification and characterization of enterotoxin produced by Aeromonas sobria. Fujii Y, et al. **Microbiol Immunol** 1998; 42(10):703–14

Group B streptococcal beta-hemolysin promotes injury of lung microvascular endothelial cells. Gibson RL, et al. **Pediatr Res** 1999 May;45(5 Pt 1):626–34

Staphyloccal alpha toxin. Palmer M. **Soc Appl Bacteriol Symp Ser** 1998;27:125S–126S (1 ref.)

HEMOLYSIS

see related
ANEMIA, HEMOLYTIC
OSMOTIC FRAGILITY

Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. McManigal S, et al. **Am J Clin Pathol** 1999 Feb; 111(2):202–6

Intravascular hemolysis in aluminium phosphide poisoning. Aggarwal P, et al. **Am J Emerg Med** 1999 Sep;17(5):488–9

Undetectable plasma L-arginine level before visible hemolysis in thrombotic thrombocytopenic purpura [letter] Waugh WH, et al. **Am J Hematol** 1999 Jul;61(3):216

Neocytolysis: from outer space to the dialysis unit [editorial; comment] Means RT Jr. **Am J Kidney Dis** 1999 Jan; 33(1):140–1. Comment on: Am J Kidney Dis 1999 Jan;33(1):59–62.

Neocytolysis contributes to the anemia of renal disease [see comments] Rice L, et al. **Am J Kidney Dis** 1999 Jan; 33(1):59–62. Comment in: Am J Kidney Dis 1999 Jan;33(1):140–1.

Blanking-out effects of haemolysis on Boehringer Mannheim creatine kinase (total and MB isoenzyme) assays [letter] Parry DM. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):785–7

Prevention of hemolysis in rapidly frozen erythrocytes by using a laser pulse. Fowler AJ, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:245–52

Experimental study on hemolysis in centrifugal blood pumps: improvement of flow visualization method. Ahmed S, et al. **Artif Organs** 1999 Jun;23(6):542–6

A preliminary study of microcapsule suspension for hemolysis evaluation of artificial organs. Maruyama O, et al. **Artif Organs** 1999 Mar;23(3):274–9

Development of design methods for a centrifugal blood pump with a fluid dynamic approach: results in hemolysis tests. Masuzawa T, et al. **Artif Organs** 1999 Aug;23(8):757–61

Flow visualization study to improve hemocompatibility of a centrifugal blood pump. Nishida M, et al. **Artif Organs** 1999 Aug;23(8):697–703

Effects of temperature and pH on the osmotic fragility of erythrocytes of yaks. Sarkar M, et al. **Aust Vet J** 1999 Mar; 77(3):188–9

Effect of dose-rate and dose fractionation on radiation-induced hemolysis of human erythrocytes. Koziczak R, et al. **Biochem Mol Biol Int** 1999 May; 47(5):865–72

The amphipathic helix concept: length effects on ideally amphipathic LiKj(i=2j) peptides to acquire optimal hemolytic activity. Castano S, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1-2):161–75

Low pH-induced hemolysis of erythrocytes is related to the entry of the acid into cytosole and oxidative stress on cellular membranes. Ivanov IT. **Biochim Biophys Acta** 1999 Jan 8;1415(2):349–60

Mechanism of interference by hemolysis in immunoassays and requirements for sample quality [letter] Wenk RE. **Clin Chem** 1998 Dec;44(12):2554

Differential resistance to calcium-induced bilirubin-dependent hemolysis in mammalian erythrocytes. Ali MK, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Jan;122(1):109–13

Isolation and haemolytic activity of Aeromonas species from domestic dogs and cats. Ghenghesh KS, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jul;22(3):175–9

Modification of CytoRich Red fixative system for use on bloody Pap and fine-needle aspiration smears. Weidmann J, et al. **Diagn Cytopathol** 1999 Feb;20(2):95–8

Regulation of the Escherichia coli sheA gene and characterization of its encoded hemolytic activity. Fernández SV, et al. **FEMS Microbiol Lett** 1998 Nov 1; 168(1):85–90

Massive hemolysis in Clostridium perfringens infection [letter] Alvarez A, et al. **Haematologica** 1999 Jun; 84(6):571–3

Haemolysis following implantation of duct occlusion coils. Uzun O, et al. **Heart** 1999 Feb;81(2):160–1

Type III secretion-dependent hemolytic activity of enteropathogenic Escherichia coli. Warawa J, et al. **Infect Immun** 1999 Oct;67(10):5538–40

Acute rhabdomyolysis and intravascular hemolysis following extensive wasp stings. Chao SC, et al. **Int J Dermatol** 1999 Feb;38(2):135–7

Spectrofluorometric and microcalorimetric study of the thermal poration relevant to the mechanism of thermohaemolysis. Ivanov IT, et al. **Int J Hyperthermia** 1999 Jan-Feb;15(1):29–43

A discussion on the threshold limit for hemolysis related to Reynolds shear stress. Grigioni M, et al. **J Biomech** 1999 Oct;32(10):1107–12

Absence of severe haemolysis in an adult patient with an aortic mechanical prosthesis and a rare form of sickle cell trait [letter] Agnino A, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):171–2

Hemosiderin deposition on the renal cortex by mechanical hemolysis due to malfunctioning prosthetic cardiac valve: report of MR findings in two cases. Lee JW, et al. **J Comput Assist Tomogr** 1999 May-Jun;23(3):445–7

Leakage flow at mechanical heart valve prostheses: improved washout or increased blood damage? Steegers A, et al. **J Heart Valve Dis** 1999 May;8(3):312–23

Novel techniques for in vivo hemolysis studies in guinea pigs. Tjatur Rasa FS, et al. **J Vet Med Sci** 1999 Feb;61(2):125–8

The hemolytic activity of bracken extracts in guinea pigs. Tjatur Rasa FS, et al. **J Vet Med Sci** 1999 Feb;61(2):129–33

From the Centers for Disease Control and Prevention. Multistate outbreak of hemolysis in hemodialysis patients--Nebraska and Maryland, 1998. **JAMA** 1998 Oct 21;280(15):1299–300

From the Centers for Disease Control and Prevention. Hemolysis associated with 25% human albumin diluted with sterile water--United States, 1994–1998. **JAMA** 1999 Mar 24-31;281(12):1076–7

Outbreak of Coca-Cola-related illness in Belgium: a true association [letter] Pouthier D. **Lancet** 1999 Aug 21; 354(9179):681–2

Short note: heterogeneous response of red blood cells to colloidal silica as a criterion for study of their membrane alterations: flow cytometric approach. Gerashchenko BI. **Med Hypotheses** 1998 Oct;51(4):355–7

A novel protein of Erysipelothrix rhusiopathiae that confers haemolytic activity on Escherichia coli. Makino S, et al. **Microbiology** 1999 Jun;145 (Pt 6):1369–74

Characterization of a haemolytic factor from Candida albicans. Watanabe T, et al. **Microbiology** 1999 Mar;145 (Pt 3):689–94

Hemolysis associated with 25% human albumin diluted with sterile water--United States, 1994–1998. **MMWR Morb Mortal Wkly Rep** 1999 Mar 5;48(8):157–9

A Plasmodium falciparum hemolytic activity. Roggwiller E, et al. **Mol Biochem Parasitol** 1998 Aug 1;94(2):303–7

Metformin-induced hemolysis with jaundice [letter; comment] Lin KD, et al. **N Engl J Med** 1998 Dec 17; 339(25):1860–1. Comment on: N Engl J Med 1996 Feb 29;334(9):574–9.

Occurrence of hemolytic activity in the skin secretion of the caecilian siphonops paulensis. Schwartz EN, et al. **Nat Toxins** 1998;6(5):179–82

Does uraemia potentiate bacteraemia-associated haemolysis in patients receiving erythropoietin? [letter] Ifudu O, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):517–9

Haemagglutination and haemolysis by oral Fusobacterium nucleatum. Gaetti-Jardim Júnior E, et al. **New Microbiol** 1999 Jan;22(1):63–7

Spontaneous resolution of hemolysis after partial coil occlusion of ductus arteriosus. Lee C, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):371–2

Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, nonocclusive roller pumps and centrifugal pumps. Hansbro SD, et al. **Perfusion** 1999 Jan;14(1):3–10

Hemolysate-mediated renal vasoconstriction and hypersensitization. Burke TJ, et al. **Ren Fail** 1999 Jan; 21(1):23–33

Monitoring erythrocyte free radical resistance in neonatal blood microsamples using a peroxyl radical-mediated haemolysis test. Boda V, et al. **Scand J Clin Lab Invest** 1998 Jul;58(4):317–22

Hemolysis and acute renal failure due to the administration of albumin diluted in sterile water [letter] Pierce LR, et al. **Transfusion** 1999 Jan;39(1):110–1

Inhibition of complement-mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin. Kojima T, et al. **Transplantation** 1999 Feb 27;67(4):637–8

Sonolysis of Albunex-supplemented, 40% hematocrit human erythrocytes by pulsed 1-MHz ultrasound: pulse number, pulse duration and exposure vessel rotation dependence. Brayman AA, et al. **Ultrasound Med Biol** 1999 Feb; 25(2):307–14

Effect of high-intensity focused ultrasound on whole blood with and without microbubble contrast agent. Poliachik SL, et al. **Ultrasound Med Biol** 1999 Jul;25(6):991–8

Effects of haemolysis, lipaemia and bilirubinaemia on an enzyme-linked immunosorbent assay for cortisol and free thyroxine in serum samples from dogs. Lucena R, et al. **Vet J** 1998 Sep;156(2):127–31

[The renal function protection of prostaglandin E1 from hemolysis caused by cardiopulmonary bypass] Yang G, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):695–7 (Eng. Abstr.) **(Chi)**

[Acute pancreatitis complicating acute dialytic hemolysis] Richieri JP, et al. **Gastroenterol Clin Biol** 1999 Mar; 23(3):408–9 **(Fre)**

[Comparison of selective screening of verotoxin-producing Escherichia coli (VTEC) isolation depending on O-serotyping and hemolysis from faeces of healthy persons] Kozaki A, et al. **Kansenshogaku Zasshi** 1998 Aug; 72(8):853–4 **(Jpn)**

[Hemolytic activity of Klebsiella pneumoniae and Klebsiella oxytoca] Szramka B, et al. **Med Dosw Mikrobiol** 1998; 50(3-4):207–13 (Eng. Abstr.) **(Pol)**

[A method for atraumatic erythrocyte plasma removal to obtain membranes capable of performing the hemostatic function of thrombocytes] Grigor'ev GI. **Klin Lab Diagn** 1999 Jul;(7):18–21 (Eng. Abstr.) **(Rus)**

[Acute renal failure, intravascular hemodialysis and toxic hepatitis caused by repeated use of rifampicin (case report)] Sefer S, et al. **Lijec Vjesn** 1999 Apr-May;121(4-5):126–8 (Eng. Abstr.) **(Scr)**

[New findings on the physiopathology of acute hemolytic transfusion reactions] Rakić S. **Med Pregl** 1999 Jan-Feb; 52(1-2):19–24 (21 ref.) (Eng. Abstr.) **(Scr)**

[Intravascular hemolysis following percutaneous occlusion of the ductus arteriosus] Pérez Rodriguez MJ, et al. **Rev Esp Cardiol** 1999 Jun;52(6):449–50 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and complement-dependent hemolysis. Tambourgi DV, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):366–73

Ca2+ enhancement of hemolysis induced by the topical anesthetic oxethazaine in vitro. Yasuno R, et al. **Biol Pharm Bull** 1998 Dec;21(12):1294–9

Erythrocyte hemolysis and shape changes induced by new lysine-derivate surfactants. Vives MA, et al. **Chem Biol Interact** 1999 Mar 1;118(1):1–18

Hemolytic activity of copper sulfate as influenced by epinephrine and chelating thiols. Aaseth J, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May;19(3):203–6

Cyclodextrin inclusion complexes of miconazole and econazole--isolation, toxicity on human cells, and confirmation of a new interpretation of the drug supersaturation phenomenon. Pedersen M, et al. **Drug Dev Ind Pharm** 1999 Apr;25(4):463–70

Effect of resveratrol and some other natural compounds on tyrosine kinase activity and on cytolysis. Palmieri L, et al. **Drugs Exp Clin Res** 1999;25(2-3):79–85

Oxidized low density lipoprotein inhibits the hemolytic activity of Asp-hemolysin from Aspergillus fumigatus. Fukuchi Y, et al. **FEMS Microbiol Lett** 1998 Oct 15; 167(2):275–80

Mechanisms of anionic detergent-induced hemolysis. Chernitsky E, et al. **Gen Physiol Biophys** 1998 Sep; 17(3):265–70

Oxidative stress resulting from hemolysis and formation of catalytically active hemoglobin: protective strategies. Ziouzenkova O, et al. **Int J Clin Pharmacol Ther** 1999 Mar; 37(3):125–32

Toxicity of gamma irradiated liposomes. 1. In vitro interactions with blood components. Stensrud G, et al. **Int J Pharm** 1999 Feb 1;178(1):33–46

Binding and lysing of blood clots using MRX-408. Wu Y, et al. **Invest Radiol** 1998 Dec;33(12):880–5

Synthesis of 1-monoglycerides having C11-20 branched chain fatty acids and their hemolysis effects. Ping X, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):345–7

Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. Kondejewski LH, et al. **J Biol Chem** 1999 May 7;274(19):13181–92

Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. Yu BG, et al. **J Controlled Release** 1998 Apr 30;53(1-3):131–6

Addition and omission analogs of the 13-residue antibacterial and hemolytic peptide PKLLKTFLSKWIG: structural preferences, model membrane binding and biological activities. Bikshapathy E, et al. **J Pept Res** 1999 Jan; 53(1):47–55

Effects of chemical modification of cysteines 201 and 317 of band 3 on hemolytic properties of human erythrocytes under hydrostatic pressure. Yamaguchi T, et al. **Jpn J Physiol** 1998 Jun;48(3):205–10

Effects of Ca2+ on erythrocyte membrane skeleton-bound phosphofructokinase, ATP levels, and hemolysis. Assouline-Cohen M, et al. **Mol Genet Metab** 1999 Jan; 66(1):56–61

Chloramine-induced haemolysis presenting as erythropoietin resistance. Fluck S, et al. **Nephrol Dial Transplant** 1999

Jul;14(7):1687-91

Photohemolysis sensitized by the furocoumarin imperatorin and its oxyfunctionalized derivatives. Potapenko AYa, et al. **Photochem Photobiol** 1999 Apr;69(4):410-20

Amelioration by glucose-6-phosphate and NADP of potato glycoalkaloid inhibition in cell, enzyme and liposome assays. Roddick JG, et al. **Phytochemistry** 1999 May; 51(1):23-7

Haemolytic and antifungal activities of saponins or anti-ATPase and antiviral activities of cardiac glycosides. Takechi M, et al. **Planta Med** 1999 Aug;65(6):585-6

L-Sorbose but not D-tagatose induces hemolysis of dog erythrocytes in vitro. Bär A, et al.
Regul Toxicol Pharmacol 1999 Apr;29(2 Pt 2):S43-5

Erythroid accelerating factor detected in serum from rats with drug induced hemolysis. Kasai M, et al.
Tohoku J Exp Med 1998 Dec;186(4):279-89

Wollastonite fibers in vitro generate reactive oxygen species able to lyse erythrocytes and activate the complement alternate pathway. Governa M, et al. **Toxicol Sci** 1998 Jul; 44(1):32-8

Pharmacological effects of the leaf-nosed viper snake (Eristocophis macmahoni) venom and its HPLC fractions. Ali SA, et al. **Toxicon** 1999 Aug;37(8):1095-107

Biological properties of a venom extract from the sea anemone, Bunodosoma cavernata. Eno AE, et al.
Toxicon 1998 Dec;36(12):2013-20

Three toxins with phospholipase activity isolated from the yellow-legged hornet (Vespa verutina) venom. Ho CL, et al. **Toxicon** 1999 Jul;37(7):1015-24

Decreased hemolysis and lipid peroxidation in blood during storage in the presence of nicotinic acid. Arun P, et al. **Vox Sang** 1999;76(4):220-5

[Parameters of hemolysis by sodium dodecyl sulfate as an indicator of the structural states of erythrocyte membranes] Chernitskil EA, et al. **Biofizika** 1999 Jan-Feb;44(1):66-9 (Eng. Abstr.) **(Rus)**

[Membranotropic effect of 2-(chloroethoxy)-para-N-dimethylaminophenylphosphinylacetic acid hydrazide (Kapakh)] Semina IG, et al. **Biull Eksp Biol Med** 1998 Aug; 126(8):175-7 **(Rus)**

[Determination of glucose-6-phosphate dehydrogenase deficiency to prevent possible drug-induced hemolysis] Hadad Meléndez P, et al. **Rev Cubana Med Trop** 1991; 43(3):205 **(Spa)**

GENETICS

Thrombosis in heritable hemolytic disorders. Barker JE, et al. **Curr Opin Hematol** 1999 Mar;6(2):71-5 (48 ref.)

Hb Brockton [beta138(H16)Ala-->Pro] observed in a Chinese boy. Tsoi WC, et al. **Hemoglobin** 1998 Jul; 22(4):397-400

Identification of genetic determinants for the hemolytic activity of Streptococcus agalactiae by ISS1 transposition. Spellerberg B, et al. **J Bacteriol** 1999 May;181(10):3212-9

IMMUNOLOGY

Delayed haemolytic transfusion reaction due to anti-M antibody. Sancho JM, et al. **Br J Haematol** 1998 Oct; 103(1):268-9

In vitro and in vivo responses of murine granulocytes to human complement-derived, haemolytically inactive C5b67 (iC5b67). Wang C, et al. **Clin Exp Immunol** 1999 Aug;117(2):261-8

Calcium-independent haemolysis via the lectin pathway of complement activation in the guinea-pig and other species*. Zhang Y, et al. **Immunology** 1999 Aug; 97(4):686-92

A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood. Yamane K, et al.
Immunopharmacol Immunotoxicol 1998 Nov;20(4):531-9

Inhibition of human and mouse complement-dependent hemolytic activity by mouse fibronectin. Hitsumoto Y, et al. **Immunopharmacology** 1999 May;42(1-3):203-8

Lysis via the lectin pathway of complement activation: minireview and lectin pathway enhancement of endotoxin-initiated hemolysis. Zhang Y, et al.
Immunopharmacology 1999 May;42(1-3):81-90 (22 ref.)

IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. Wagner E, et al. **J Immunol** 1999 Sep 15;163(6):3549-58

Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. Kalyanaraman M, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):70-3 (16 ref.)

Severe delayed hemolytic transfusion reaction secondary to anti-At(a). Cash KL, et al. **Transfusion** 1999 Aug; 39(8):834-7

Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Salmon JP, et al. **Transfusion** 1999 Aug;39(8):824-7

[Gastrointestinal cancer-associated antigen (GICA) and intravascular hemolysis. Report of 2 cases and review of the literature] Bianconcini G, et al. **Minerva Med** 1999 Mar; 90(3):73-9 (98 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Scaling of hemolysis in needles and catheters. Sharp MK, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):788-97

Mechanism of free radical-induced hemolysis of human erythrocytes: comparison of calculated rate constants for hemolysis with experimental rate constants. Sato Y, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):61-9

Calreticulin, a component of the endoplasmic reticulum and of cytotoxic lymphocyte granules, regulates perforin-mediated lysis in the hemolytic model system. Fraser SA, et al. **Biochem Cell Biol** 1998;76(5):881-7

Lesson of the week: incompatible plasma transfusions and haemolysis in children. Duguid JK, et al. **BMJ** 1999 Jan 16;318(7177):176-7

Changes in haematological parameters and iron metabolism associated with a 1600 kilometre ultramarathon. Fallon KE, et al. **Br J Sports Med** 1999 Feb;33(1):27-31; discussion 32

Correlation of cytokine elaboration with mononuclear cell adhesion to platelet storage bag plastic polymers: a pilot study. ElKattan I, et al. **Clin Diagn Lab Immunol** 1999 Jul; 6(4):509-13

Lactate determination in exercise testing using an electrochemical analyser: with or without blood lysis? Thin AG, et al. **Eur J Appl Physiol** 1999 Jan;79(2):155-9

Hemolysis caused by CMV infection in a pregnant woman with silent elliptocytosis. Horiguchi-Yamada J, et al.
Int J Hematol 1998 Oct;68(3):311-5

Repetitive cell 'jumps' during hypotonic lysis of erythrocytes observed with a simple flow chamber. Zade-Oppen AM. **J Microsc** 1998 Oct;192 (Pt 1):54-62

Immediate early gene expression in vascular smooth-muscle cells synergistically induced by hemolysate components. Wang X, et al. **J Neurosurg** 1999 Jun;90(6):1083-90

Mitogen-activated protein kinase mediation of hemolysate-induced contraction in rabbit basilar artery. Zubkov AY, et al. **J Neurosurg** 1999 Jun;90(6):1091-7

Modification of red cell membrane lipids by hypochlorous acid and haemolysis by preformed lipid chlorohydrins. Carr AC, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):263-71

A hemolytic factor from Haemonchus contortus alters erythrocyte morphology. Fetterer RH, et al.
Vet Parasitol 1998 Dec 15;80(1):37-45

[Comparative studies of hemolysis in blood pumps of various designs] van der Hoeven JG, et al. **Biomed Tech (Berl)** 1998;43 Suppl:332-4 **(Ger)**

[Diagnosis of hemolysis and differential hemolytic anemia diagnosis] Schrezenmeier H, et al. **Internist (Berl)** 1998 Dec; 39(12):W1273-89 (7 ref.) **(Ger)**

[Pathogenetic aspects of hemolysis and changes of blood rheology in hereditary hemochromatosis] Ershova LI, et al. **Ter Arkh** 1998;70(11):74-6 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Photohemolysis sensitized by the furocoumarin imperatorin and its oxyfunctionalized derivatives. Potapenko AYa, et al. **Photochem Photobiol** 1999 Apr;69(4):410-20

Effect of high linear energy transfer radiation on biological membranes. Choudhary D, et al.
Radiat Environ Biophys 1998 Oct;37(3):177-85

HEMOLYTIC DISEASE OF NEWBORN see **ERYTHROBLASTOSIS, FETAL**

HEMOLYTIC PLAQUE TECHNIQUE

[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test] Meyer F, et al. **Transfus Clin Biol** 1999 Jul;6(4):221-6 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

[Technical test of the AlaSat system] Lavigne JP, et al.
Ann Biol Clin (Paris) 1998 Sep-Oct;56(5):590-2 **(Fre)**

HEMOLYTIC TITRATION ASSAY see **COMPLEMENT HEMOLYTIC ACTIVITY ASSAY**

HEMOLYTIC-UREMIC SYNDROME

The haemolytic-uraemic syndrome in childhood. van de Kar NC, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):497-507 (62 ref.)

Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Trachtman H, et al.
Curr Opin Pediatr 1999 Apr;11(2):162-8 (51 ref.)

Haemolytic uraemic syndrome: a review. McLigeyo SO.
East Afr Med J 1999 Mar;76(3):148-53 (53 ref.)

Persistant pre-eclampsia post partum with elevated liver enzymes and hemolytic uremic syndrome. Mahalati K, et al. **J Clin Apheresis** 1999;14(2):69-78

A case of hemolytic uremic syndrome associated with emphysematous cholecystitis and a liver abscess. Yoshida K, et al. **Tohoku J Exp Med** 1998 Jun;185(2):147-55

BLOOD

Erythrocyte P1 group antigen expression in VTEC-associated hemolytic uremic syndrome. Ashida A, et al. **Clin Nephrol** 1999 Feb;51(2):73-6

Hemolytic uremic syndrome in children: platelet aggregation and membrane glycoproteins. Sassetti B, et al.
J Pediatr Hematol Oncol 1999 Mar-Apr;21(2):123-8

Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome. Van Geet C, et al.
Kidney Int 1998 Oct;54(4):1324-30

Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Warwicker P, et al.
Nephrol Dial Transplant 1999 May;14(5):1229-33

Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome. Ray PE, et al. **Pediatr Nephrol** 1999 Sep; 13(7):586-93

Coagulation changes associated with the hemolytic uremic syndrome. Gordjani N, et al. **Semin Thromb Hemost** 1998; 24(6):577-82 (85 ref.)

CHEMICALLY INDUCED

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. Leach JW, et al. **Am J Hematol** 1999 Aug;61(4):268-70

Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Flombaum CD, et al.
Am J Kidney Dis 1999 Mar;33(3):555-62

Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Glynne P, et al.
Am J Kidney Dis 1999 Jan;33(1):133-7 (22 ref.)

Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Taylor FB Jr, et al. **Am J Pathol** 1999 Apr; 154(4):1285-99

Hemolytic-uremic syndrome caused by gemcitabine [letter; comment] Nackaerts K, et al. **Ann Oncol** 1998 Dec; 9(12):1355 (4 ref.). Comment on: Ann Oncol 1998 Dec;9(12):1265-7.

Cyclosporin neurotoxicity after chemotherapy. Case had features of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome [letter] Pratt G, et al.
BMJ 1999 Jul 3;319(7201):54; discussion 54-5

Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Serke S, et al. **Br J Cancer** 1999 Mar;79(9-10):1519-21

Hemolytic-uremic syndrome induced by pentostatin in a patient with cutaneous T-cell lymphoma [letter] Antunes I, et al. **Dermatology** 1999;198(2):179-80

Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. Walder B, et al.
J Heart Lung Transplant 1998 Oct;17(10):1004-6

A laboratory model of toxin-induced hemolytic uremic syndrome. Taylor CM, et al. **Kidney Int** 1999 Apr; 55(4):1367-74

Uneventful re-treatment with cyclosporin in two cases of cyclosporin-induced haemolytic uraemic syndrome. Guella A, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1864-5

Cyclosporin-induced haemolytic-uraemic syndrome presenting as primary graft dysfunction. Kohli HS, et al.
Nephrol Dial Transplant 1998 Nov;13(11):2940-2

Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumour. Mathur RV, et al.
Nephrol Dial Transplant 1999 Jul;14(7):1786-8

Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. Schmidt RH, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):979-83

Hemolytic-uremic syndrome during therapy with estramustine phosphate for advanced prostatic cancer. Tassinari D, et al. **Oncology** 1999;56(2):112-3

Was antithymocyte globulin the cause of hemolytic uremic syndrome? Proesmans W. **Pediatr Nephrol** 1998 Oct; 12(8):698-9

Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. Morris-Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S98-9

CLASSIFICATION

Recalling Barnard and Kibel's hypothesis on hemolytic uremic syndrome [letter] Kaplan BS. **Pediatr Nephrol** 1999 Jun;13(5):466-7

COMPLICATIONS

Neuropsychological sequelae of haemolytic uraemic syndrome. Investigators of the HUS Cognitive Study. Schlieper A, et al. **Arch Dis Child** 1999 Mar;80(3):214-20

Colonic stenosis after hemolytic-uremic syndrome. Sebbag H, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):119-20

Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Sutor GC, et al. **Infection** 1999 Jan-Feb; 27(1):12-5 (45 ref.)

Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Ishida Y, et al.
Intern Med 1998 Aug;37(8):694-9

Neuropsychological sequelae of haemolytic uraemic syndrome. Accardo PJ. **J Pediatr** 1999 Sep;135(3):398

Recurrent ventricular tachycardia complicating atypical haemolytic-uraemic syndrome [letter] Prakash J, et al.
Nephrol Dial Transplant 1998 Sep;13(9):2419-20

Coincidence of haemolytic uraemic syndrome and

c-ANCA-associated rapidly progressive glomerulonephritis. Stefanidis I, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1818–21

Postpartum renal failure: a complex case with probable coexistence of hemolysis, elevated liver enzymes, low platelet count, and hemolytic uremic syndrome. Kahra K, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):698–700

Pleural effusion complicating acute peritoneal dialysis in hemolytic uremic syndrome. Butani L, et al. **Pediatr Nephrol** 1998 Nov;12(9):772–4

Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Jha V, et al. **Ren Fail** 1998 Nov;20(6):845–50

Progressive subretinal fibrosis in a child following hemolytic uremic syndrome [published erratum appears in Retina 1999;19(3):259–60] Krott R, et al. **Retina** 1999;19(1):77–9

[Cardiac involvement during classic hemolytic uremic syndrome] Eckart P, et al. **Arch Pediatr** 1999 Apr; 6(4):430–3 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Clinical aspects of the hemolytic uremic syndrome. Chen CH, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep–Oct;39(5):319–23

Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)

Anemia and renal failure after acute onset of diarrhea. Archer TP, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):142–5

Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: diagnosis and management. George JN, et al. **J Clin Apheresis** 1998;13(3):120–5 (33 ref.)

von Willebrand factor–cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [letter; comment] Sarkodee-Adoo C, et al. **N Engl J Med** 1999 Apr 29;340(17):1368; discussion 1369 . Comment on: N Engl J Med 1998 Nov 26;339(22):1578–84.

Diagnosis and therapeutic guidelines for hemolytic uremic syndrome associated with enterohemorrhagic Escherichia coli infection. Japanese Pediatric Nephrology Association. **Pediatr Int** 1999 Aug;41(4):449–51

Clinical quiz. Dubin-Johnson syndrome or Rotor syndrome. Teh CP, et al. **Pediatr Nephrol** 1999 Sep;13(7):627–8

Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Jha V, et al. **Ren Fail** 1998 Nov;20(6):845–50

[What is your diagnosis? Hemolytic uremic-syndrome (diarrhea associated form with evidence of shiga toxin)] Schlapbach SZ. **Schweiz Rundsch Med Prax** 1999 Apr 1; 88(14):599–600 **(Ger)**

[Evaluation of thrombomodulin and tumor necrosis factor-alpha levels in patients with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection] Yamamoto T, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):60–4 (Eng. Abstr.) **(Jpn)**

[The hemolytic-uremic syndrome] Rodrigues PA, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):217–22 (19 ref.) (Eng. Abstr.) **(Por)**

[Uremic hemolytic syndrome. Analysis of 43 cases] Mencia Bartolomé S, et al. **An Esp Pediatr** 1999 May;50(5):467–70 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Fung MC, et al. **Cancer** 1999 May 1;85(9):2023–32

Haemolytic–uraemic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil [letter] McGregor DO, et al. **Nephron** 1998 Nov;80(3):365–6

Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Shiomi M, et al. **Pediatr Int** 1999 Apr;41(2):228–32

ENZYMOLOGY

von Willebrand factor–cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [see comments] Furlan M, et al. **N Engl J Med** 1998 Nov 26;339(22):1578–84. Comment in: N Engl J Med 1998 Nov 26;339(22):1629–31. Comment in: N Engl J Med 1999 Apr 29;340(17):1368; discussion 1369. Comment in: N Engl J Med 1999 Apr 29;340(17):1368–9.

Moschcowitz, multimers, and metalloprotease [editorial; comment] Moake JL. **N Engl J Med** 1998 Nov 26; 339(22):1629–31. Comment on: N Engl J Med 1998 Nov 26;339(22):1578–84. Comment on: N Engl J Med 1998 Nov 26;339(22):1585–94.

EPIDEMIOLOGY

An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Cody SH, et al. **Ann Intern Med** 1999 Feb 2;130(3):202–9

A large outbreak of hemolytic uremic syndrome caused by an unusual sorbitol-fermenting strain of Escherichia coli O157:H–. Ammon A, et al. **J Infect Dis** 1999 May; 179(5):1274–7

ETIOLOGY

Hemolytic uremic syndrome due to Capnocytophaga canimorsus bacteremia after a dog bite. Tobé TJ, et al. **Am J Kidney Dis** 1999 Jun;33(6):e5

Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Paquette RL, et al. **Bone Marrow Transplant** 1998 Aug;22(4):351–7

Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Ravandi-Kashani F, et al. **Cancer** 1999 Jun 15;85(12):2583–8

Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS, et al. **Clin Exp Immunol** 1999 Jun;116(3):462–7

Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Starr M, et al. **Clin Infect Dis** 1998 Aug;27(2):310–5 (47 ref.)

Antimotility agents and E. coli infection [letter] Tarr PI, et al. **CMAJ** 1999 Apr 6;160(7):984, 986

Escherichia coli O157 incident associated with a farm open to members of the public. Milne LM, et al. **Commun Dis Public Health** 1999 Jan;2(1):22–6

Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Labrune P, et al. **Eur J Pediatr** 1999 Sep;158(9):734–9

Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of hemolytic uremic syndrome with glomerular disease. Morita S, et al. **Intern Med** 1999 Jun;38(6):495–9 (27 ref.)

Epidemiology, pathogenesis and therapeutic modalities in hemolytic-uremic syndrome. Zimmerhackl LB. **Kidney Blood Press Res** 1998;21(2–4):290–2 (12 ref.)

von Willebrand factor–cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [letter; comment] Warwicker P, et al. **N Engl J Med** 1999 Apr 29;340(17):1368–9. Comment on: N Engl J Med 1998 Nov 26;339(22):1578–84. Comment on: N Engl J Med 1998 Nov 26;339(22):1585–94.

Relapse of atypical haemolytic uraemic syndrome after kidney transplantation: role of ATG and failure of mycophenolate mofetil as rescue therapy. Davin JC, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):984–7

Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation--is tacrolimus the answer? [editorial] Grupp C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1629–31 (28 ref.)

Bilateral renal parenchymal malakoplakia presenting as haemolytic–uraemic syndrome. Hong JJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2206–9

Haemolytic–uraemic syndrome following a scorpion sting. Mocan H, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2639–40

An unusual complication of pregnancy. Ong AC, et al. **Nephrol Dial Transplant** 1999 May;14(5):1324–6

Haemolytic–uraemic syndrome in a heroin addict. Peces R, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3197–9

No common final pathogenetic pathway in haemolytic uraemic syndromes. Taylor CM, et al. **Nephrol Dial Transplant** 1999 May;14(5):1100–2 (13 ref.)

Factor H--US? [editorial] Warwicker P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1921–3 (39 ref.)

Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C [letter] Ubara Y, et al. **Nephron** 1998 Sep;80(1):107–8

Hemolytic-uremic syndrome caused by Escherichia coli O157:H7 after perforated appendix. Volinsky JB, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):846–7

Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Fukushima H, et al. **Pediatr Int** 1999 Apr;41(2):213–7

Factors influencing the development of hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli infection: from a questionnaire survey to in vitro experiment. Honda T. **Pediatr Int** 1999 Apr;41(2):209–12

Risk factors for the development of Escherichia coli O157:H7 associated with hemolytic uremic syndrome. Kawamura N, et al. **Pediatr Int** 1999 Apr;41(2):218–22

The hemolytic uremic syndrome as a complication of adriamycin nephropathy. Viero RM, et al. **Ren Fail** 1998 Jul;20(4):565–71

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Gordon LI, et al. **Semin Thromb Hemost** 1999;25(2):217–21 (82 ref.)

Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Franz M, et al. **Transplantation** 1998 Nov 15; 66(9):1258–62

[Acute bacterial gastroenteritis and hemolytic-uremic syndrome] Paerregaard A. **Ugeskr Laeger** 1999 May 10; 161(19):2799–801 **(Dan)**

[Enterohemorrhagic Escherichia coli O157 infection in an elderly patient with secondary hemolytic uremic syndrome who developed recurrent acute exacerbation of chronic cholecystitis] Izumi Y, et al. **Nippon Ronen Igakkai Zasshi** 1998 Jul;35(7):559–65 (Eng. Abstr.) **(Jpn)**

[HUS caused by enterohemorrhagic E. coli] Honda M. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):547–51 (10 ref.) **(Jpn)**

[Thrombotic microangiopathy in hematopoietic stem cell transplantation] Miwa A. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):611–8 (19 ref.) **(Jpn)**

GENETICS

Familial hemolytic-uremic syndrome in three generations. Petermann A, et al. **Am J Kidney Dis** 1998 Dec; 32(6):1063–7 (45 ref.)

Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Noris M, et al. **J Am Soc Nephrol** 1999 Feb; 10(2):281–93

Human complement factor H deficiency associated with hemolytic uremic syndrome. Rougier N, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2318–26

Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Warwicker P, et al. **Nephrol Dial Transplant** 1999 May;14(5):1229–33

Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Ohali M, et al. **Pediatr Nephrol** 1998 Oct;12(8):619–24

Familial, atypical hemolytic-uremic syndrome in a premature infant. Wilson BJ, et al. **Pediatr Nephrol** 1998 Nov; 12(9):782–4

[Familial hemolytic and uremic syndrome (letter)] Mourani C, et al. **Arch Pediatr** 1999 Mar;6(3):336–7 **(Fre)**

IMMUNOLOGY

Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS, et al. **Clin Exp Immunol** 1999 Jun;116(3):462–7

Profiles of circulating inflammatory- and anti-inflammatory cytokines in patients with hemolytic uremic syndrome due to E. coli O157 infection. Murata A, et al. **Cytokine** 1998 Jul;10(7):544–8

Translocated intimin receptors (Tir) of Shiga-toxigenic Escherichia coli isolates belonging to serogroups O26, O111, and O157 react with sera from patients with hemolytic-uremic syndrome and exhibit marked sequence heterogeneity. Paton AW, et al. **Infect Immun** 1998 Nov; 66(11):5580–6

Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Galbusera M, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1234–41

Antibodies to Shiga toxin in the serum of children with Shigella-associated haemolytic uraemic syndrome. Azim T, et al. **J Med Microbiol** 1999 Jan;48(1):11–6

Postpartum hemolytic-uremic syndrome associated with lupus anticoagulant. A case report. Gherman RB, et al. **J Reprod Med** 1999 May;44(5):471–4

A laboratory model of toxin-induced hemolytic uremic syndrome. Taylor CM, et al. **Kidney Int** 1999 Apr; 55(4):1367–74

METABOLISM

Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Mitra D, et al. **Am J Hematol** 1998 Dec; 59(4):279–87

Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Galbusera M, et al. **Blood** 1999 Jul 15; 94(2):610–20

The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Uchida H, et al. **Pediatr Res** 1999 Jan;45(1):133–7

MICROBIOLOGY

Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Besser RE, et al. **Annu Rev Med** 1999;50:355–67 (62 ref.)

Survival of Escherichia coli 0157 in a soil protozoan: implications for disease. Barker J, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):291–5

Molecular characterization of a Shiga toxigenic Escherichia coli O113:H21 strain lacking eae responsible for a cluster of cases of hemolytic-uremic syndrome. Paton AW, et al. **J Clin Microbiol** 1999 Oct;37(10):3357–61

Clonal diversity of Chilean isolates of enterohemorrhagic Escherichia coli from patients with hemolytic-uremic syndrome, asymptomatic subjects, animal reservoirs, and food products. Rios M, et al. **J Clin Microbiol** 1999 Mar; 37(3):778–81

Haemolytic–uraemic syndrome in an adult male with Aeromonas hydrophila enterocolitis. Fang JS, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):439–40

Campylobacter jejuni and hemolytic-uremic syndrome [letter] Sillero M, et al. **Nephron** 1999;82(4):363–4

Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome. Proulx F, et al. **Pediatr Infect Dis J** 1998 Oct; 17(10):899–904

Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection: experience of an outbreak in Sakai City, 1996. Yoshioka K, et al. **Pediatr Int** 1999 Apr;41(2):223–7

Haemolytic-uraemic syndrome caused by vero toxin-producing Escherichia coli serotype Rough: K-: H49. Keskimäki M, et al. **Scand J Infect Dis** 1999; 31(2):141–4

MORTALITY

Haemolytic uraemic syndrome in childhood: an experience of 7 years at the Aga Khan University. Ibrahim SH, et al. **JPMA J Pak Med Assoc** 1998 Apr;48(4):100–3

PATHOLOGY

De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Waiser J, et al. **Am J Kidney Dis** 1999 Sep;34(3):556–9

Pathologic distinctions among the thrombotic microangiopathies [letter; comment] Laurence J, et al. **Clin Nephrol** 1998 Dec;50(6):393. Comment on: Clin Nephrol 1998 Mar;49(3):193–7.

Thrombotic microangiopathy: a challenge with uncertain outcome. Kulzer P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2154–60 (29 ref.)

[Hemorrhagic colitis and hemolytic uremic syndrome caused by Escherichia coli O157:H7] Attar A, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):288–90 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Pathophysiology and management of thrombotic microangiopathies. Ruggenenti P, et al. **J Nephrol** 1998 Nov–Dec;11(6):300–10 (58 ref.)

Thrombotic microangiopathy: a challenge with uncertain outcome. Kulzer P, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2154–60 (29 ref.)

Markers of endothelial cell activation and injury in childhood haemolytic uraemic syndrome. Nevard CH, et al. **Pediatr Nephrol** 1999 Aug;13(6):487–92

Renal function in Inuit survivors of epidemic hemolytic-uremic syndrome. Ogborn MR, et al. **Pediatr Nephrol** 1998 Aug;12(6):485–8

PREVENTION & CONTROL

Haemolytic uraemic syndrome and E coli 0157 [editorial] Fitzpatrick M. **BMJ** 1999 Mar 13;318(7185):684–5

Strategy to prevent the progression of enterohemorrhagic Escherichia coli O157 infection to hemolytic uremic syndrome. Takeda T. **Jpn J Med Sci Biol** 1998;51 Suppl:S124–8

SURGERY

Haemolytic-uraemic syndrome--the experience in Argentina [editorial] Repetto HA. **Nephrol Dial Transplant** 1999 Mar; 14(3):548–50

THERAPY

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor (CD34+) cell transplantation. Musso M, et al. **Bone Marrow Transplant** 1999 Jul;24(2):207–9

Diagnosis and management of thrombotic microangiopathies during pregnancy. Esplin MS, et al. **Clin Obstet Gynecol** 1999 Jun;42(2):360–7 (32 ref.)

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. George JN, et al. **J Clin Apheresis** 1998;13(3):120–5 (33 ref.)

Epidemiology, pathogenesis and therapeutic modalities in hemolytic-uremic syndrome. Zimmerhackl LB. **Kidney Blood Press Res** 1998;21(2–4):290–2 (12 ref.)

Relapse of atypical haemolytic uraemic syndrome after kidney transplantation: role of ATG and failure of mycophenolate mofetil as rescue therapy. Davin JC, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):984–7

Diagnosis and therapeutic guidelines for hemolytic uremic syndrome associated with enterohemorrhagic Escherichia coli infection. Japanese Pediatric Nephrology Association. **Pediatr Int** 1999 Aug;41(4):449–51

Pleural effusion complicating acute peritoneal dialysis in hemolytic uremic syndrome. Butani L, et al. **Pediatr Nephrol** 1998 Nov;12(9):772–4

Clinical outcome in three patients with postpartum hemolytic uremic syndrome treated with frequent plasma exchange. Shemin D, et al. **Ther Apher** 1998 Feb;2(1):43–8

VETERINARY

Possible hemolytic uremic syndrome in three cats after renal transplantation and cyclosporine therapy. Aronson LR, et al. **Vet Surg** 1999 May-Jun;28(3):135–40

HEMOPERFUSION

Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Nakamura T, et al. **Am J Med Sci** 1998 Dec; 316(6):355–60

Life-threatening diphenhydramine overdose treated with charcoal hemoperfusion and hemodialysis. Mullins ME, et al. **Ann Emerg Med** 1999 Jan;33(1):104–7

Efficacy of nafamostat mesilate as a regional anticoagulant in experimental direct hemoperfusion and in plasma exchange on humans. Abe H, et al. **Artif Organs** 1992 Apr; 16(2):206–8

Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure. Hughes RD, et al. **Artif Organs** 1998 Oct;22(10):854–8

Efficacy of a bioreactor filled with porcine hepatocytes immobilized on nonwoven fabric for ex vivo direct hemoperfusion treatment of liver failure in pigs. Naruse K, et al. **Artif Organs** 1998 Dec;22(12):1031–7

Lixelle adsorbent to remove inflammatory cytokines. Tsuchida K, et al. **Artif Organs** 1998 Dec;22(12):1064–7

Changes in plasma erythropoietin and interleukin-6 concentrations in patients with septic shock after hemoperfusion with polymyxin B-immobilized fiber. Nakamura T, et al. **Intensive Care Med** 1998 Dec; 24(12):1272–6

Changes in phenytoin concentrations in blood and cerebrospinal fluid caused by direct hemoperfusion in a patient intoxicated with phenytoin. Kanayama Y, et al. **Ther Apher** 1998 Feb;2(1):74–7

Bilirubin adsorbent column for plasma perfusion. Takenaka Y. **Ther Apher** 1998 May;2(2):129–33 (25 ref.)

Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Franssen EJ, et al. **Ther Drug Monit** 1999 Jun;21(3):289–92

Early cellular rejection of pig kidney perfused with manipulated human blood to avoid hyperacute rejection. Vega A, et al. **Transplant Proc** 1999 Sep;31(6):2643–4

[Plasma separation and bilirubin adsorption therapy in excessive hyperbilirubinemia after liver transplantation] Ott R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1563–5 (Eng. Abstr.) **(Ger)**

[Detoxication therapy of patients with acute diffuse peritonitis] Tashev KhR, et al. **Khirurgiia (Mosk)** 1999; (3):37–9 (Eng. Abstr.) **(Rus)**

[Impact of ozonized sorbent hemocarboperfusion on kallikrein-kinin system in patients with progressive pulmonary tuberculosis] Belianin II, et al. **Probl Tuberk** 1999;(1):59–61 (Eng. Abstr.) **(Rus)**

[The joint use of hemosorption and plasmapheresis in the combined treatment of rheumatoid arthritis patients] Trusov VV, et al. **Ter Arkh** 1999;71(5):22–5 (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Tani T, et al. **Artif Organs** 1998 Dec; 22(12):1038–44

Clinical evaluation of setting pump occlusion by the dynamic method: effect on flow. Mongero LB, et al. **Perfusion** 1998 Sep;13(5):360–8

New adsorption column (Lixelle) to eliminate beta2-microglobulin for direct hemoperfusion [editorial] Furuyoshi S, et al. **Ther Apher** 1998 Feb;2(1):13–7 (18 ref.)

Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application [editorial] Shoji H, et al. **Ther Apher** 1998 Feb;2(1):3–12 (58 ref.)

[Microsphere based detoxification system. A new blood purification method: technical safety aspects] Vogt G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:170–1 **(Ger)**

METHODS

Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. Ebihara I, et al. **Am J Kidney Dis** 1998 Dec;32(6):953–61

Hemoperfusion with polymyxin B-immobilized fiber attenuates the increased plasma levels of thrombomodulin and von Willebrand factor from patients with septic shock. Nakamura T, et al. **Blood Purif** 1998;16(4):179–86

Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. Gaubitz M, et al. **J Autoimmun** 1998 Oct;11(5):495–501

Effect of charcoal hemoperfusion on clearance of cibenzoline succinate (cifenline) poisoning. Aoyama N, et al. **J Toxicol Clin Toxicol** 1999;37(4):505–8

Clinical evaluation of setting pump occlusion by the dynamic method: effect on flow. Mongero LB, et al. **Perfusion** 1998 Sep;13(5):360–8

Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Bosch T, et al. **Ther Apher** 1999 Aug;3(3):209–13

Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus [editorial] Kutsuki H, et al. **Ther Apher** 1998 Feb;2(1):18–24 (23 ref.)

In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment. Mitteregger R, et al. **Ther Apher** 1999 Aug;3(3):257–63

Extracorporeal adsorption of endotoxin. Staubach KH, et al. **Ther Apher** 1997 Feb;1(1):67–74

[Electrochemically regulated hemosorption detoxification] Gol'din MM, et al. **Anesteziol Reanimatol** 1998 Nov–Dec; (6):12–5 (Eng. Abstr.) **(Rus)**

[The clinico-immunological parallels of hemosorption using different sorbents in the treatment of bronchial asthma patients] Tkachenko Iula. **Lik Sprava** 1998 Jul–Aug; (5):113–5 (Eng. Abstr.) **(Rus)**

[The role of the extracorporeal detoxication in prophylaxis and treatment of respiratory disorders in patients with acute ileus] Kutsyk IuB. **Klin Khir** 1998;(6):4–6 (Eng. Abstr.) **(Ukr)**

[Study of sorption properties of organosilanes to be used as the basis for hemosorbents and diagnostic enzyme and immunosensors] Starodub VM. **Ukr Biokhim Zh** 1998 May-Jun;70(3):56–63 (Eng. Abstr.) **(Ukr)**

HEMOPERICARDIUM see **PERICARDIAL EFFUSION**

HEMOPERITONEUM

BLOOD

Haemoperitoneum in a patient with cryoglobulinaemia: a form of peritoneal purpura? [letter] Morey A, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2167–8

CHEMICALLY INDUCED

Large hepatic hematoma and intraabdominal hemorrhage associated with abuse of anabolic steroids [letter] Schumacher J, et al. **N Engl J Med** 1999 Apr 8; 340(14):1123–4

CLASSIFICATION

Haemoperitoneum in a patient with cryoglobulinaemia: a form of peritoneal purpura? [letter] Morey A, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2167–8

CONGENITAL

A neonate with haemorrhagic ascites. Pillay T, et al. **Lancet** 1999 Sep 11;354(9182):914

DIAGNOSIS

Sonographic detection of echogenic fluid and correlation with culdocentesis in the evaluation of ectopic pregnancy [letter; comment] Wachsberg RH. **AJR Am J Roentgenol** 1999 Jan;172(1):244–5. Comment on: AJR Am J Roentgenol 1998 May;170(5):1299–302.

[Encapsulated hematoma of the sigmoid mesocolon. Apropos of an unusual case in Niger] Théry Y, et al. **J Radiol** 1999 Mar;80(3):312–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[The application of laparocentesis and peritoneal lavage and the analysis of hemo-peritoneal volume in the diagnosis of closed abdominal wound] Tishchenko VV. **Klin Khir** 1999;(1):11–2 (2 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive [letter; comment] Ghosh K, et al. **Haemophilia** 1998 Sep;4(5):767–8. Comment on: Haemophilia 1998 Jan;4(1):60–2.

Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease [see comments] Gomez A, et al. **Haemophilia** 1998 Jan;4(1):60–2 . Comment in: Haemophilia 1998 Sep;4(5):767–8.

ETIOLOGY

Ovarian cyst rupture causing hemoperitoneum: imaging features and the potential for misdiagnosis. Hertzberg BS, et al. **Abdom Imaging** 1999 May-Jun;24(3):304–8

Third trimester intra uterine death following spontaneous hemoperitoneum. Megevand E, et al. **Acta Obstet Gynecol Scand** 1999 Jan;78(1):72–3

Massive spontaneous hemoperitoneum of unknown etiology: a case report. Suber WJ Jr, et al. **Am Surg** 1998 Dec; 64(12):1177–8

Acute haemoperitoneum caused by intra-abdominal testicular germ cell tumour: a rare presentation of peritonitis. Feldbaum DM, et al. **Br J Urol** 1998 Oct; 82(4):603–4

Intestinal leiomyosarcoma as the cause of severe hemoperitoneum. Reina AJ, et al. **Dig Surg** 1998; 15(1):69–71

Metastases from a regressed malignant melanoma as a cause of haemoperitoneum. Wong LS, et al. **Eur J Surg Oncol** 1999 Apr;25(2):227

Hemoperitoneum caused by spontaneous rupture of a true splenic cyst. Lam CM, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1884–6

Spontaneous uterine rupture with fatal hemoperitoneum due to placenta accreta percreta: a case report and review of the literature. deRoux SJ, et al. **Int J Gynecol Pathol** 1999 Jan;18(1):82–6

Delayed massive intraperitoneal hemorrhage after pancreatoduodenectomy. Yoshida T, et al. **Int Surg** 1998 Apr–Jun;83(2):131–5

Hemoperitoneum due to spontaneous rupture of an aneurysm of the left gastroepiploic artery. Borioni R, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):63–4

Massive hemoperitoneum from endometriosis of the fallopian

HEMOPERITONEUM

tube. A case report. Harmanli OH, et al. **J Reprod Med** 1998 Aug;43(8):716–8

Ruptured lumbar artery pseudoaneurysm: a diagnostic dilemma in retroperitoneal hemorrhage after abdominal trauma [letter; comment] Silberzweig JE. **J Trauma** 1999 Mar;46(3):531–2. Comment on: J Trauma 1998 Oct;45(4):829–32.

Massive haemoperitoneum due to rupture of splenic infarct during CAPD. Kanagasundaram NS, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2380–1

Hemoperitoneum as the sole indicator of abdominal visceral injuries: a potential limitation of screening abdominal US for trauma. Shanmuganathan K, et al. **Radiology** 1999 Aug; 212(2):423–30

A fatal complication of the Seldings technique for cannulation of the femoral vein [letter] Reynolds FE, et al. **Resuscitation** 1998 Dec;39(3):219

Massive intraperitoneal hemorrhage and hypovolemic shock due to rupture of a coronary vessel of a uterine leiomyoma: a report of two cases. Akahira J, et al. **Tohoku J Exp Med** 1998 Jul;185(3):217–22

[Angiosarcoma of the liver as a cause of massive hemoperitoneum] Slováček R, et al. **Rozhl Chir** 1999 Mar; 78(3):99–101 (Eng. Abstr.) **(Cze)**

[Hemoperitoneum due to spontaneous splenic rupture: a rare complication of primary cytomegalovirus infection (letter)] Bellaïche G, et al. **Gastroenterol Clin Biol** 1998 Jan; 22(1):107–8 **(Fre)**

[Duodenal hematoma, acute pancreatitis, and hemoperitoneum after endoscopic hemostasis for duodenal ulcer] Pauwels M, et al. **Gastroenterol Clin Biol** 1998 Apr; 22(4):462–4 (Eng. Abstr.) **(Fre)**

[Liver metastases of a choriocarcinoma: a rare cause of hemoperitoneum (letter)] Roumilhac D, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):275–6 **(Fre)**

[Quid? Gallbladder hemorrhage with intraperitoneal rupture] Noël JB, et al. **J Radiol** 1999 Jul;80(7):741–3 **(Fre)**

[Hemoperitoneum--how to proceed?] Stähelin B, et al. **Schweiz Rundsch Med Prax** 1999 Feb 25;88(9):379–82 (Eng. Abstr.) **(Ger)**

[Vascular complications during laparoscopy. An analysis of a personal case] Esposito C, et al. **Minerva Chir** 1999 Mar; 54(3):163–5 (9 ref.) (Eng. Abstr.) **(Ita)**

[Spontaneous hemorrhage in liver neoplasms. Experience at an institution] González-Ojeda A, et al. **Rev Gastroenterol Mex** 1998 Jul–Sep;63(3):126–30 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Ruptured lumbar artery pseudoaneurysm: a diagnostic dilemma in retroperitoneal hemorrhage after abdominal trauma [letter; comment] Silberzweig JE. **J Trauma** 1999 Mar;46(3):531–2. Comment on: J Trauma 1998 Oct;45(4):829–32.

[Hemoperitoneum as the form of presentation of hepatocellular carcinoma. The contribution of computed tomography to the diagnosis] da Fonseca CR, et al. **Acta Med Port** 1999 Apr–Jun;12(4–6):223–6 (15 ref.) (Eng. Abstr.) **(Por)**

SURGERY

Massive spontaneous hemoperitoneum of unknown etiology: a case report. Suber WJ Jr, et al. **Am Surg** 1998 Dec; 64(12):1177–8

Emergency liver resection for ruptured hepatocellular carcinoma complicating cirrhosis. Chiappa A, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1145–50

THERAPY

Expectant management of haemoperitoneum. Bose SM, et al. **Injury** 1999 May;30(4):269–73

ULTRASONOGRAPHY

Ultrasound for the detection of intraperitoneal fluid: the role of Trendelenburg positioning. Abrams BJ, et al. **Am J Emerg Med** 1999 Mar;17(2):117–20

Early detection of hemoperitoneum by ultrasound examination of the right upper quadrant: a multicenter study. Rozycki GS, et al. **J Trauma** 1998 Nov;45(5):878–83

Focused abdominal sonogram for trauma: the learning curve of nonradiologist clinicians in detecting hemoperitoneum. Shackford SR, et al. **J Trauma** 1999 Apr;46(4):553–62; discussion 562–4 (40 ref.)

Ultrasonography in the evaluation of hemoperitoneum in war casualties. Miletić D, et al. **Mil Med** 1999 Aug;164(8):600–2

Hemoperitoneum as the sole indicator of abdominal visceral injuries: a potential limitation of screening abdominal US for trauma. Shanmuganathan K, et al. **Radiology** 1999 Aug; 212(2):423–30

HEMOPEXIN

CHEMISTRY

Identification of the TIMP-2 binding site on the gelatinase A hemopexin C-domain by site-directed mutagenesis and the yeast two-hybrid system. Overall CM, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:747–53

Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. Cheung PK, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1700–8

GENETICS

Regulation of hemopexin synthesis in degenerating and regenerating rat sciatic nerve. Madore N, et al. **J Neurochem** 1999 Feb;72(2):708–15

METABOLISM

Differential changes in alpha2-macroglobulin and hemopexin in brain and liver in response to acute inflammation. Saso L, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):839–44

Cellular protection mechanisms against extracellular heme. heme-hemopexin, but not free heme, activates the N-terminal c-jun kinase. Eskew JD, et al. **J Biol Chem** 1999 Jan 8;274(2):638–48

Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. Overall CM, et al. **J Biol Chem** 1999 Feb 12;274(7):4421–9

HEMOPHAGOCYTIC SYNDROME, INFECTION-ASSOCIATED see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

HEMOPHILIA see **HEMOPHILIA A**

HEMOPHILIA A

see related

HEMARTHROSIS

Acquired hemophilia due to factor VIII inhibitors in 34 patients. Bossi P, et al. **Am J Med** 1998 Nov;105(5):400–8 (87 ref.)

XXIII International Congress of the World Federation of Hemophilia. The Hague, The Netherlands, 17–21 May 1998. Abstracts. **Haemophilia** 1998 May;4(3):155–330

Unsolved problems in haemophilia. Aledort LM. **Haemophilia** 1998 Jul;4(4):341–5

Rehabilitation in haemophilia--options in the developing world. Battistella LR. **Haemophilia** 1998 Jul;4(4):486–90 (12 ref.)

Factor concentrates for haemophilia in the developing world. Bird A, et al. **Haemophilia** 1998 Jul;4(4):481–5 (9 ref.)

Immune tolerance: a synopsis of the international experience. Di Michele DM. **Haemophilia** 1998 Jul;4(4):568–73 (28 ref.)

Management of pregnancy in carriers of haemophilia. Giangrande PL. **Haemophilia** 1998 Nov;4(6):779–84 (23 ref.)

Factor VIII inhibitors in mild and moderate-severity haemophilia A. Hay CR. **Haemophilia** 1998 Jul;4(4):558–63 (32 ref.)

Management of haemophilia in the developing world. Srivastava A, et al. **Haemophilia** 1998 Jul;4(4):474–80 (19 ref.)

Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Szucs TD, et al. **Haemophilia** 1998 Jul;4(4):498–501

Carrier testing and prenatal diagnosis of haemophilia--utilisation and psychological consequences. Tedgård U. **Haemophilia** 1998 Jul;4(4):365–9 (29 ref.)

Haemophilia and advanced fibrin sealant technologies. Tock B, et al. **Haemophilia** 1998 Jul;4(4):449–55 (30 ref.)

The genetic basis of inhibitor development in haemophilia A. Tuddenham EG, et al. **Haemophilia** 1998 Jul;4(4):543–5

[Hemophilia. Diagnosis, genetics, complications] Négrier C, et al. **Rev Prat** 1998 Mar 15;48(6):657–9 (4 ref.) **(Fre)**

[Female hemophilia (female hemophiliacs)] Sakuragawa N. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):471–3 (20 ref.) **(Jpn)**

[Hemophilia A] Tanaka A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):423–6 (10 ref.) **(Jpn)**

BLOOD

Why do inhibitors arise in patients with haemophilia A? Hay CR. **Br J Haematol** 1999 Jun;105(3):584–90 (56 ref.)

Comparability of absolute/percent CD4+ T-lymphocytes completed locally and centrally. Hemophilia Growth and Development Study. Donfield SM, et al. **Control Clin Trials** 1998 Oct;19(5):451–60

Inhibitor development and substitution therapy in a developing country: Turkey. Kavakli K, et al. **Haemophilia** 1998 Mar;4(2):104–8

Using Gaussian-like input rate function in the two-compartment model. Formulation and application to analysis of didanosine plasma concentration in two Japanese hemophiliacs. Tatsunami S, et al. **Int J Clin Pharmacol Res** 1998;18(3):129–35

Interleukin-2 restores natural killer activity inhibited by sera from HIV+ hemophilic patients. Vulcano M, et al. **Medicina (B Aires)** 1999;59(2):162–6

Plasma platelet-activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand's disease [letter] Kavakli K, et al. **Thromb Haemost** 1999 Apr;81(4):665–6

Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil [letter] Rieger A, et al. **Thromb Haemost** 1999 Mar;81(3):475–6

CHEMICALLY INDUCED

Acquired hemophilia secondary to factor VIII inhibitors after pregnancy. Dhôte R, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):300–2

COMPLICATIONS

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia. Francis JD, et al. **Acta Anaesthesiol Scand** 1999 Sep;43(8):870–3

Decline of anti-DP107 antibody associated with clinical progression [letter] Hattori T, et al. **AIDS** 1998 Aug 20; 12(12):1557–9

Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Kupfer B, et al. **AIDS** 1999 Jun 18;13(9):1025–8

Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Sabin CA, et al. **AIDS** 1998 Jul 30; 12(11):1347–52

Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. Touloumi G, et al. **AIDS** 1998 Sep 10;12(13):1691–7

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection. Zamarchi R, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):337–44

Epidural placement in a patient with undiagnosed acquired haemophilia from factor VIII inhibitor. Christie-Taylor GA, et al. **Anaesthesia** 1999 Apr;54(4):367–71

Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: a measure of current immune suppression. Multicenter Hemophilia Cohort Study. Engels EA, et al. **Ann Intern Med** 1999 Aug 17;131(4):256–64

Femoral head osteonecrosis in a child with hemophilia. Kilcoyne RF, et al. **Arthritis Rheum** 1999 Jul;42(7):1550–1

Radiation therapy in pseudotumour haemarthrosis. Lal P, et al. **Australas Radiol** 1998 Nov;42(4):344–6

Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis. Avanogmacr;lu A, et al. **BJU Int** 1999 Jan;83(1):91–4

Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome [letter] Ragni MV, et al. **Blood** 1999 Feb 1;93(3):1113–4

Major surgery seems not to influence HIV disease progression in haemophilia patients. Astermark J, et al. **Br J Haematol** 1998 Oct;103(1):10–4

Development of autoantibodies and factor VIII inhibitor in an HIV-infected haemophiliac following treatment with combination anti-retroviral therapy [letter] Evans GD, et al. **Br J Haematol** 1998 Sep;102(5):1382–3

Hepatitis in haemophilia. Giangrande PL. **Br J Haematol** 1998 Oct;103(1):1–9 (105 ref.)

Central venous catheter-associated thrombosis in severe haemophilia. Vidler V, et al. **Br J Haematol** 1999 Mar; 104(3):461–4

CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. Daniel V, et al. **Clin Exp Immunol** 1999 Mar;115(3):477–84

Enhanced IFN-gamma production in vitro by CD8+ T cells in hemophiliacs with AIDS as demonstrated on the single-cell level. Pae Y, et al. **Clin Immunol** 1999 Jul; 92(1):111–7

Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. Nitu IC, et al. **Clin Lab Haematol** 1999 Apr; 21(2):139–41

Delayed splenic rupture in a haemophiliac. Thomas DW, et al. **Clin Lab Haematol** 1999 Jun;21(3):215–7

Knee arthroplasty in hemophilic arthropathy. Thomason HC 3rd, et al. **Clin Orthop** 1999 Mar;(360):169–73

Splenic rupture in a newborn with hemophilia A: case report and review of the literature. Johnson-Robbins LA, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):117–9 (15 ref.)

Spontaneous hemobilia in a hemophiliac treated by factor VIII replacement and nasobiliary drainage. Sreenivas DV, et al. **Dig Dis Sci** 1998 Dec;43(12):2606–9

Maintenance of musculoskeletal function in people with haemophilia. Battistella LR. **Haemophilia** 1998;4 Suppl 2:26–32 (35 ref.)

Muscle rehabilitation in haemophilia. Beeton K, et al. **Haemophilia** 1998 Jul;4(4):532–7 (33 ref.)

Proprioceptive training in haemophilia. Buzzard BM. **Haemophilia** 1998 Jul;4(4):528–31 (14 ref.)

Physiotherapy for the prevention of articular contraction in haemophilia. Buzzard BM. **Haemophilia** 1999 Mar;5 Suppl 1:10–5 (29 ref.)

Haemophilic synovitis: is rifampicin an alternative? Caviglia H, et al. **Haemophilia** 1998 Jul;4(4):514–7 (54 ref.)

Extensor supracondylar femoral osteotomy as treatment for flexed haemophilic knee. Caviglia HA, et al. **Haemophilia** 1999 Mar;5 Suppl 1:28–32

Therapy for chronic hepatitis B and C infection in haemophilia. Dusheiko GM. **Haemophilia** 1998 Jul; 4(4):577–86 (65 ref.)

Treatment of acute and chronic synovitis by non-surgical

means. Fernandez-Palazzi F. **Haemophilia** 1998 Jul; 4(4):518-23 (21 ref.)

Non-operative treatment of flexion contracture of the knee in haemophilia. Fernandez-Palazzi F, et al. **Haemophilia** 1999 Mar;5 Suppl 1:20-4

Assessment and treatment of liver disease in Japanese haemophilia patients. Fukuda Y, et al. **Haemophilia** 1998 Jul;4(4):595-600 (45 ref.)

Management of fixed flexion contracture of the elbow in haemophilia. Gilbert MS, et al. **Haemophilia** 1999 Mar;5 Suppl 1:39-42

Excision of a haemophilic pseudotumour of the ilium, complicated by fistulation. Heeg M, et al. **Haemophilia** 1998 Mar;4(2):132-5

Physiotherapy for the treatment of articular contractures in haemophilia. Heijnen L, et al. **Haemophilia** 1999 Mar;5 Suppl 1:16-9

Functional kinesiology in haemophilia, an area yet to be explored. Heijnen L, et al. **Haemophilia** 1998 Jul;4(4):524-7

Expanding portal haematomata as a complication of knee arthroscopies in persons with haemophilia. Heim M, et al. **Haemophilia** 1999 May;5(3):213-5

The role of orthoses in the management of elbow joints in persons with haemophilia. Heim M, et al. **Haemophilia** 1999 Mar;5 Suppl 1:43-5

The management of a person with haemophilia who has a fixed flexed hip and intractable pain. Heim M, et al. **Haemophilia** 1998 Nov;4(6):842-4

Circumcision and haemophilia: a perspective. Kavakli K, et al. **Haemophilia** 1998 Jan;4(1):1-3 (25 ref.)

Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Laursen AL, et al. **Haemophilia** 1998 Jan; 4(1):25-32

Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate. Leach M, et al. **Haemophilia** 1999 May; 5(3):209-12

Does avascular necrosis cause collapse of the dome of the talus in severe haemophilia? MacNicol MF, et al. **Haemophilia** 1999 Mar;5(2):139-42

Does protease inhibitor treatment induce increased bleeding tendency in haemophilia? [letter] Mandalaki T, et al. **Haemophilia** 1998 Sep;4(5):766-7

Nasopharyngeal angiofibroma in a patient with haemophilia A: a bleeding tumour in a bleeding-prone patient. Oztürk MA, et al. **Haemophilia** 1999 May;5(3):207-8

Knowledge of HIV/AIDS and emotional adjustment in a cohort of men with haemophilia and HIV infection: final report. Pasqual Marsettin E, et al. **Haemophilia** 1998 Nov; 4(6):820-5

Clinical characteristics and blood product usage in AIDS-associated lymphoma in haemophiliacs: a case-control study. Ragni MV, et al. **Haemophilia** 1998 Nov;4(6):826-35

Progression of HIV in haemophilia. Ragni MV. **Haemophilia** 1998 Jul;4(4):601-9 (63 ref.)

Management of equinus contractures of the ankle in haemophilia. Ribbans WJ, et al. **Haemophilia** 1999 Mar;5 Suppl 1:46-52 (22 ref.)

Therapeutic options in the management of articular contractures in haemophiliacs. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:5-9 (9 ref.)

Correction of fixed contractures during total knee arthroplasty in haemophiliacs. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:33-8

Common orthopaedic problems in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1999 Mar;5 Suppl 1:53-60 (16 ref.)

Joint replacement for a spontaneously ankylosed hip in a haemophilic patient. Rodriguez-Merchan EC, et al. **Haemophilia** 1999 Jan;5(1):69-72

Hamstring release and posterior capsulotomy for fixed knee flexion contracture in haemophiliacs. Wallny T, et al. **Haemophilia** 1999 Mar;5 Suppl 1:25-7

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Arkin S, et al. **Haemostasis** 1998 Mar-Apr;28(2):93-8

Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Wenzel T, et al. **Haemostasis** 1998 Mar-Apr;28(2):106-10

Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand's syndrome. Braden B, et al. **Helicobacter** 1998 Sep;3(3):184-7

Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Roosendaal G, et al. **Histopathology** 1999 Feb;34(2):144-53

Spontaneous isolated lesser sac hematoma in a patient with hemophilia. Prasad S, et al. **Indian J Gastroenterol** 1999 Jan-Mar;18(1):38-9

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study. Daar ES, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):317-25

HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. Mahoney EM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):333-7

Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men [letter; comment] Sabin CA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):546-8. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1998 Mar 1;17(3):209-13.

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. Eyster ME, et al. **J Infect Dis** 1999 May;179(5):1062-9

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. Lesens O, et al. **J Infect Dis** 1999 May;179(5):1254-8

Hemophiliacs bone pseudotumors. Boonjunwetwat D, et al. **J Med Assoc Thai** 1999 Jan;82(1):89-95

Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Devereux H, et al. **J Med Virol** 1998 Dec;56(4):316-20

Spontaneous spinal subdural hematoma in a young adult with hemophilia. Friday RY, et al. **J Natl Med Assoc** 1999 May; 91(5):289-94

Dealing with a hemophilia-A patient undergoing cerebral aneurysm surgery. Dönmez A, et al. **J Neurosurg Anesthesiol** 1999 Jul;11(3):214-5

Hemophilic pseudotumor of the soft tissue of the hand: a case report. Hopkins JD, et al. **J Okla State Med Assoc** 1999 May;92(5):227-30

Hemophilia morbidity, cognitive functioning, and academic achievement. Usner DW, et al. **J Pediatr** 1998 Dec; 133(6):782-7

Factor concentrate prophylaxis for neonates with hemophilia [comment] Buchanan GR. **J Pediatr Hematol Oncol** 1999 Jul-Aug;21(4):254-6. Comment on: J Pediatr Hematol Oncol 1999 Jul-Aug;21(4):289-95.

Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature [see comments] Kulkarni R, et al. **J Pediatr Hematol Oncol** 1999 Jul-Aug; 21(4):289-95 (41 ref.). Comment in: J Pediatr Hematol Oncol 1999 Jul-Aug;21(4):254-6.

Brachial plexus palsy presenting as an initial manifestation of hemophilia in a middle-aged man. Ogawa K, et al. **J Shoulder Elbow Surg** 1998 Sep-Oct;7(5):546-8

Advanced testicular germ cell tumor in a hemophilic patient with human immunodeficiency virus infection. Kageyama Y, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):567-70

Successful surgical removal of a large arteriovenous malformation in a patient with hemophilia: case report. Nakau H, et al. **Neurosurgery** 1998 Dec;43(6):1459-61; discussion 1461-2

Neurologic complications of cancer, sickle cell disease, and hemophilia. Zuckerman GB, et al. **Pediatr Ann** 1998 Oct; 27(10):640-50 (53 ref.)

Facial nerve palsy in an infant with hemophilia A. Ray M, et al. **Pediatr Hematol Oncol** 1999 Jan-Feb;16(1):71-4

Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection. Hagerty SL, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):929-30

Index of suspicion. Case 3. Diagnosis: hematemesis resulting from gastritis, duodenal ulcer and hemophilia A. Colli J, et al. **Pediatr Rev** 1998 Dec;19(12):429, 432

Characteristics of septic arthritis in human immunodeficiency virus-infected haemophiliacs versus other risk groups. Barzilai A, et al. **Rheumatology (Oxford)** 1999 Feb; 38(2):139-42

Hepatitis C virus-infected, HCV-RNA-negative patients with bleeding disorders--relationship to age, HIV and treatment. Schulman S, et al. **Scand J Infect Dis** 1998; 30(5):455-8

Obstructive Ileus caused by blood clot after emergency total gastrectomy in a patient with hemophilia A: report of a case. Onda M, et al. **Surg Today** 1998;28(12):1266-9

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, et al. **Thromb Haemost** 1998 Dec; 80(6):912-8

Retrospective neuropathological review of prion disease in UK haemophilic patients. Lee CA, et al. **Thromb Haemost** 1998 Dec;80(6):909-11

Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Brambilla A, et al. **Virology** 1999 Jul 5;259(2):349-68

[Knee replacement arthroplasty in hemophilia: results, complications and predictive elements of their occurrence] Vastel L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):458-65 (Eng. Abstr.) **(Fre)**

[Diagnostic imaging of hemophilic osteoarthropathy] Erlemann R, et al. **Orthopade** 1999 Apr;28(4):329-40 (Eng. Abstr.) **(Ger)**

[Joint preserving operations and endoprosthetic joint substitutions in hemophiliacs. Indications and long term results] Hovy L. **Orthopade** 1999 Apr;28(4):356-65 (29 ref.) (Eng. Abstr.) **(Ger)**

[Hemophilia in orthopedics--severe complications can be avoided (editorial)] Kerschbaumer F. **Orthopade** 1999 Apr; 28(4):315 **(Ger)**

[Prevention of joint damage in hemophilic children with early prophylaxis] Kreuz W, et al. **Orthopade** 1999 Apr; 28(4):341-6 (Eng. Abstr.) **(Ger)**

[Conservative management of hemophilic arthropathy] Müller S, et al. **Orthopade** 1999 Apr;28(4):347-55 (Eng. Abstr.) **(Ger)**

[Pathology of synovitis and hemophilic arthropathy] Roosendaal G, et al. **Orthopade** 1999 Apr;28(4):323-8 (Eng. Abstr.) **(Ger)**

[Diagnosis and management of coagulation disorders in orthopedic surgery] Scharrer I. **Orthopade** 1999 Apr; 28(4):316-22 (Eng. Abstr.) **(Ger)**

[TT virus (TTV) in Japanese haemophiliacs] Yokozaki S, et al. **Nippon Rinsho** 1999 Jun;57(6):1427-32 (Eng. Abstr.) **(Jpn)**

[Congenital combined deficiency of factor V and factor VIII] Takamatsu J. **Ryoikibetsu Shokogun Shiriza** 1998;(21 Pt 2):437-8 (3 ref.) **(Jpn)**

[Two-stage spleen rupture in child with hemophilia] Krivosheina EL, et al. **Khirurgiia (Mosk)** 1999;(3):62 **(Rus)**

[The use of sorbent "Sillard" in comprehensive treatment of patients with hemophilia and purulent-inflammatory complications] Sukhovii MV, et al. **Klin Khir** 1999;(2):28-30 (Eng. Abstr.) **(Rus)**

[The characteristics of the causative agents of suppurative-inflammatory complications in hemophiliacs] Fedorovskaia EA, et al. **Mikrobiol Z** 1998 Jul-Aug; 60(4):88-92 (Eng. Abstr.) **(Rus)**

[Characteristics of kidney lesions in patients with hemophilia] Fedorov DV, et al. **Urol Nefrol (Mosk)** 1998 Nov-Dec; (6):9-12 (Eng. Abstr.) **(Rus)**

[Magnetic resonance Imaging in the diagnosis of hemophilic lesions of joints] Briukhanov AV, et al. **Vestn Rentgenol Radiol** 1998 Sep-Oct;(5):25-9 (Eng. Abstr.) **(Rus)**

[Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor] Huliková M, et al. **Vnitr Lek** 1998 Sep;44(9):547-50 (Eng. Abstr.) **(Slo)**

DIAGNOSIS

Acquired haemophilia A: errors in the diagnosis. Kazmi MA, et al. **Blood Coagul Fibrinolysis** 1998 Oct;9(7):623-8

Recognition of hemophilia A in an elderly patient. Cáceres W, et al. **Bol Asoc Med P R** 1998 Apr-Jun;90(4-6):85-7

A rapid prenatal diagnosis of hemophilia A by DNA analysis on crude chorionic villus biopsy [letter] Acquila M, et al. **Haematologica** 1999 Apr;84(4):382-3

Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme. Jennings I, et al. **Haemophilia** 1998 Sep; 4(5):739-46

Haemophilia A: two cases showing unusual features at birth. Le Pommelet C, et al. **Haemophilia** 1998 Mar;4(2):122-5

Prenatal diagnosis of haemophilia. Ljung RC. **Haemophilia** 1999 Mar;5(2):84-7 (17 ref.)

Hemophilia. A new approach to an old disease. DiMichele D, et al. **Hematol Oncol Clin North Am** 1998 Dec; 12(6):1315-44 (158 ref.)

Molecular diagnostics of 15 hemophilia A patients: characterization of eight novel mutations in the factor VIII gene, two of which result in exon skipping. Tavassoli K, et al. **Hum Mutat** 1998;12(5):301-3

Cases of male babies with easy bruising of skin. Lokeshwar MR. **Indian Pediatr** 1998 Apr;35(4):400

Facial nerve palsy in an infant with hemophilia A. Ray M, et al. **Pediatr Hematol Oncol** 1999 Jan-Feb;16(1):71-4

Long-term psychological effects of carrier testing and prenatal diagnosis of haemophilia: comparison with a control group. Tedgård U, et al. **Prenat Diagn** 1999 May; 19(5):411-7

[Factor VIII inhibitor appearing in women during delivery] Kucharski W, et al. **Ginekol Pol** 1997 Sep;68(9):402-6 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Papadaki HA, et al. **Ann Hematol** 1998 Sep;77(3):123-5

Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience. Campbell PJ, et al. **Aust N Z J Med** 1998 Aug;28(4):440-5

Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Hoffman M, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S61-5 (13 ref.)

Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs. Négrier C, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S135-41

Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Nicolaisen EM. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S119-23

Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. Petrini P, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S143-6

Clinical experience with activated factor VII: focus on safety aspects. Roberts HR. **Blood Coagul Fibrinolysis** 1998 Mar; 9 Suppl 1:S115-8

Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections. Scaraggi FA, et al. **Blood Coagul Fibrinolysis** 1999 Jan;10(1):33–8

Experiences with continuous infusion of recombinant activated factor VII. Schulman S, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S97–101

Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Stewart AJ, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S93–5

Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates. Zanon E, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):117–20

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Santagostino E, et al. **Br J Haematol** 1999 Jan;104(1):22–6

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Brackmann HH, et al. **Eur J Haematol Suppl** 1998;63:18–23 (15 ref.)

Pharmaco-economic aspects of inhibitor treatment. Goudemand J. **Eur J Haematol Suppl** 1998;63:24–7

Approaches towards successful home treatment in patients with inhibitors. Ingerslev J, et al. **Eur J Haematol Suppl** 1998;63:11–4

Early treatment with recombinant factor VIIa results in greater efficacy with less product. Lusher JM. **Eur J Haematol Suppl** 1998;63:7–10

Inhibitors occur more frequently in African-American and Latino haemophiliacs [letter] Aledort LM, et al. **Haemophilia** 1998 Jan;4(1):68

Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Aznar JA, et al. **Haemophilia** 1998 Jan;4(1):21–4

Guidelines on treatment of haemophilia in Sweden. Berntorp E. **Haemophilia** 1998 Jul;4(4):425–6

Witnessing medical history: an interview with Dr Rosemary Biggs [interview by Christine Lee and Charles Rizza] Biggs R. **Haemophilia** 1998 Sep;4(5):769–77

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Brackmann HH, et al. **Haemophilia** 1999 May;5(3):203–6

Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Deitcher SR, et al. **Haemophilia** 1999 Mar;5(2):88–95

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Freiburghaus C, et al. **Haemophilia** 1998 Jan;4(1):16–20

Tolerance induction using the Malmö treatment model 1982–1995. Freiburghaus C, et al. **Haemophilia** 1999 Jan; 5(1):32–9

Management of a premature infant with moderate haemophilia A using recombinant factor VIII. Gale RF, et al. **Haemophilia** 1998 Nov;4(6):850–3

Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE). Gringeri A. **Haemophilia** 1998 Jul;4(4):423–4

Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A. Hay JW, et al. **Haemophilia** 1999 May;5(3):191–202

Development of a factor VIII inhibitor in a newborn haemophiliac. Haya S, et al. **Haemophilia** 1998 Sep; 4(5):755–6

Total knee and hip arthroplasty in haemophilic patients. Heeg M, et al. **Haemophilia** 1998 Sep;4(5):747–51

Clotting factor concentrates and immune function in haemophilic patients. Hoots K, et al. **Haemophilia** 1998 Sep; 4(5):704–13 (85 ref.)

Can we improve on nature? "Super molecules" of factor VIII. Kaufman RJ, et al. **Haemophilia** 1998 Jul;4(4):370–9 (96 ref.)

Postoperative use of rFVIIa by continuous infusion in a haemophilic boy. Lorenzo JI, et al. **Haemophilia** 1999 Mar; 5(2):135–8

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Lusher JM, et al. **Haemophilia** 1998 Nov; 4(6):790–8

In vivo recovery with products of very high purity--assay discrepancies. Lusher JM, et al. **Haemophilia** 1998 Jul; 4(4):641–5

Treatment protocols in The Netherlands. Mauser-Bunschoten EP, et al. **Haemophilia** 1998 Jul; 4(4):428–30

Novel delivery systems for coagulation proteins. Miekka SI, et al. **Haemophilia** 1998 Jul;4(4):436–42

Clinical characteristics and blood product usage in AIDS-associated lymphoma in haemophiliacs: a case-control study. Ragni MV, et al. **Haemophilia** 1998 Nov;4(6):826–35

Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery. Rochat C, et al. **Haemophilia** 1999 May;5(3):181–6

The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Scandella D, et al. **Haemophilia** 1998 Jul;4(4):546–51

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Scharrer I, et al. **Haemophilia** 1999 May; 5(3):145–54 (61 ref.)

Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Schulman S. **Haemophilia** 1998 Jul;4(4):564–7 (13 ref.)

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Seremetis S, et al. **Haemophilia** 1999 Jan;5(1):9–16

A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates. Shen MC, et al. **Haemophilia** 1998 Jan; 4(1):33–40

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Stanworth SJ, et al. **Haemophilia** 1998 Mar;4(2):109–14

Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada. Teitel JM, et al. **Haemophilia** 1998 Sep;4(5):731–8

National haemophilia treatment protocols: Canada. Teitel JM. **Haemophilia** 1998 Jul;4(4):422–3

Continuous infusion therapy in haemophilia. Varon D, et al. **Haemophilia** 1998 Jul;4(4):431–5 (28 ref.)

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Mauser-Bunschoten EP, et al. **Neth J Med** 1998 Dec;53(6):249–55

Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Laub R, et al. **Thromb Haemost** 1999 Jan;81(1):39–44

Human parvovirus B19 infection in persons with haemophilia [letter; comment] Prowse C, et al. **Thromb Haemost** 1998 Aug;80(2):351. Comment on: Thromb Haemost 1997 Nov;78(5):1352–6.

Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Smith MP, et al. **Thromb Haemost** 1999 Jan;81(1):35–8

Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? [letter; comment] Yee TT, et al. **Thromb Haemost** 1999 May;81(5):852. Comment on: Thromb Haemost 1998 Dec;80(6):1036–7.

[Acquired factor VIII deficiency treated with cyclosporine] Leinøe EB, et al. **Ugeskr Laeger** 1999 Aug 23; 161(34):4762–3 (Eng. Abstr.) **(Dan)**

[The use of sorbent "Sillard" in comprehensive treatment of patients with hemophilia and purulent-inflammatory complications] Sukhovii MV, et al. **Klin Khir** 1999;(2):28–30 (Eng. Abstr.) **(Rus)**

ECONOMICS

Pharmaco-economic aspects of inhibitor treatment. Goudemand J. **Eur J Haematol Suppl** 1998;63:24–7

Economic aspects of haemophilia care. Aldedort LM, et al. **Haemophilia** 1999 May;5(3):216–9

Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A. Hay JW, et al. **Haemophilia** 1999 May;5(3):191–202

US bill aids HIV-1-infected haemophiliacs [news] Rovner J. **Lancet** 1998 Nov 14;352(9140):1610

EPIDEMIOLOGY

Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Soucie JM, et al. **Am J Hematol** 1998 Dec;59(4):288–94

Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964–97. Yee TT, et al. **Br J Haematol** 1999 Mar;104(4):909–14

Secular trends in the prevalence of HIV infection among a population of males with hemophilia, 1988–1997: the Oklahoma Hemophilia Surveillance System. Cowan LD, et al. **J Okla State Med Assoc** 1999 Sep;92(9):462–7

Dealing with a bleeding nuisance: a study of haemophilia care in New Zealand. Park J, et al. **N Z Med J** 1999 May 14;112(1087):155–8

High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Mauser-Bunschoten EP, et al. **Vox Sang** 1998;74(4):225–7

ETIOLOGY

Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Pipe SW, et al. **Blood** 1999 Jan 1;93(1):176–83

The natural history of HIV disease in haemophilia. Lee CA. **Blood Rev** 1998 Sep;12(3):135–44 (60 ref.)

A case of unpaired anterior cerebral artery occlusion producing akinetic mutism [letter] Oomman A, et al. **Neurol India** 1999 Jun;47(2):157–8

Recurrent adenocarcinoma of prostate presenting as acquired haemophilia A [letter] Sati HI, et al. **Thromb Haemost** 1998 Dec;80(6):1034

GENETICS

Subcycling-PCR for multiplex long-distance amplification of regions with high and low GC content: application to the inversion hotspot in the factor VIII gene. Liu Q, et al. **Biotechniques** 1998 Dec;25(6):1022–8

Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Neerman-Arbez M, et al. **Blood** 1999 Apr 1;93(7):2253–60

ERGIC-53 gene structure and mutation analysis in 19 combined factors V and VIII deficiency families. Nichols WC, et al. **Blood** 1999 Apr 1;93(7):2261–6

A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins. Liu M, et al. **Br J Haematol** 1998 Dec;103(4):1051–60

Rapid and non-isotopic detection of intron 18 polymorphism of the factor VIII gene. Soares RP, et al. **Clin Chim Acta** 1999 Sep;287(1–2):157–61

How do carriers of hemophilia and their spouses experience prenatal diagnosis by chorionic villus sampling? Tedgård U, et al. **Clin Genet** 1999 Jan;55(1):26–33

An unexpected cause for combined deficiency of coagulation factors V and VIII. Wellington C. **Clin Genet** 1998 Jul; 54(1):22–3

Inversions of the factor VIII gene in Slovenian patients with severe haemophilia A [letter] Strmecki L, et al. **Eur J Haematol** 1999 Jul;63(1):64–6

A rapid prenatal diagnosis of hemophilia A by DNA analysis on crude chorionic villus biopsy [letter] Acquila M, et al. **Haematologica** 1999 Apr;84(4):382–3

Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. Andrews JL, et al. **Haemophilia** 1999 May; 5(3):160–8

Molecular genetics of coagulation factor VIII gene and haemophilia A. Antonarakis SE. **Haemophilia** 1998;4 Suppl 2:1–11 (68 ref.)

Haemophilia A gene therapy. Connelly S, et al. **Haemophilia** 1998 Jul;4(4):380–8 (97 ref.)

Combined factors V and VIII deficiency--the solution. Ginsburg D, et al. **Haemophilia** 1998 Jul;4(4):677–82

Advances in carrier detection in haemophilia. Goodeve AC. **Haemophilia** 1998 Jul;4(4):358–64 (44 ref.)

Linkage analysis in haemophilia A: simultaneous genotyping of two polymorphisms of the human factor VIII gene using induced heteroduplex formation. Howarth A, et al. **Haemophilia** 1998 Nov;4(6):812–9

Factor VIII gene inversions and an XbaI polymorphism: nonradioactive detection and clinical usage. Liu ML, et al. **Haemophilia** 1999 Jan;5(1):26–31

Intron 22 inversions in the Turkish haemophilia A patients: prevalence and haplotype analysis. El-Maarri O, et al. **Haemophilia** 1999 May;5(3):169–73

Counselling about diagnosis and inheritance of genetic bleeding disorders: haemophilia A and B. Miller R. **Haemophilia** 1999 Mar;5(2):77–83

Genetic services available for counselling and prenatal diagnosis of haemophilia. Peake I. **Haemophilia** 1998;4 Suppl 2:24–5

The molecular basis of haemophilia A. Peake I. **Haemophilia** 1998 Jul;4(4):346–9 (21 ref.)

Molecular characterization of haemophilia A & B in Indians. Shetty S, et al. **Haemophilia** 1998 Nov;4(6):802–5

A deletion/insertion leading to the generation of a direct repeat as a result of slipped mispairing and intragenic recombination in the factor VIII gene. Tavassoli K, et al. **Hum Genet** 1999 May;104(5):435–7

Screen of 55 Slovenian haemophilia A patients: identification of 2 novel mutations (S-1R and IVS23+1G-->A) and discussion of mutation spectrum. Mutation in brief no. 241. Online. Strmecki L, et al. **Hum Mutat** 1999;13(5):413

Identification of four novel mutations in the factor VIII gene: three missense mutations (E1875G, G2088S, I2185T) and a 2-bp deletion (1780delTC). Tavassoli K, et al. **Hum Mutat** 1998;Suppl 1:S260–2

Independent occurrence of the novel Arg2163 to His mutation in the factor VIII gene in three unrelated families with haemophila A with different phenotypes. Mutations in brief no. 126. Online. Theophilus BD, et al. **Hum Mutat** 1998;11(4):334

Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-infected and uninfected hemophilia patients. Kantor R, et al. **J Hum Virol** 1998 May-Jun; 1(4):299–301

Haemophilia A carrier detection in the Free State and Northern Cape [letter] Vosloo WM, et al. **S Afr Med J** 1999 Jun;89(6):625–6

Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution. van den Brink EN, et al. **Thromb Haemost** 1999 May;81(5):723–6

Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch. Haemophilia Centres. Waseem NH, et al. **Thromb Haemost** 1999 Jun;81(6):900–5

Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. Scheiflinger F, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):172–80 (117 ref.)

[Analysis of inversion in intron 22 of the factor F VIII:C

gene in patients with hemophilia A in the Slovak population] Poláková H, et al. **Bratisl Lek Listy** 1998 Oct; 99(10):538–42 (Eng. Abstr.) **(Slo)**

[Obstetric treatment of hemophilia carriers] Aguilar C, et al. **Sangre (Barc)** 1998 Oct;43(5):399–405 (71 ref.) **(Spa)**

[Analysis of Bcl I polymorphism of factor VIII gene in the molecular diagnosis of female hemophilia A carriers in families from northwestern Venezuela] Borjas-Fajardo L, et al. **Sangre (Barc)** 1999 Feb;44(1):19–23 (Eng. Abstr.) **(Spa)**

[No genetic counseling prior to the marriage of the future Czar] Bergentz UH. **Lakartidningen** 1998 Nov 18; 95(47):5348–9 **(Swe)**

HISTORY

The history of haemophilia in the royal families of Europe. Stevens RF. **Br J Haematol** 1999 Apr;105(1):25–32

Orthopaedic surgery in haemophilia--The Tel Hashomer experience: a tribute to Professor Henri Horoszowski. Heim M. **Haemophilia** 1998 Jul;4(4):viii–x

Commentary to Erik von Willebrand's original paper from 1926 'Hereditär pseudohemofili' [comment] Nilsson IM. **Haemophilia** 1999 May;5(3):220–1. Comment on: Haemophilia 1999 May;5(3):223–31; discussion 222.

Hereditary pseudohaemophilia [classical article][see comments] Von Willebrand EA. **Haemophilia** 1999 May; 5(3):223–31; discussion 222. Comment in: Haemophilia 1999 May;5(3):220–21.

Hemophilia: a story of success--disaster and the perseverance of the human spirit, Part 2. Dubin CS. **J Assoc Nurses AIDS Care** 1999 Jul–Aug;10(4):88–92

IMMUNOLOGY

Decline of anti-DP107 antibody associated with clinical progression [letter] Hattori T, et al. **AIDS** 1998 Aug 20; 12(12):1557–9

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Peerlinck K, et al. **Blood** 1999 Apr 1;93(7):2267–73

Acquired haemophilia A: errors in the diagnosis. Kazmi MA, et al. **Blood Coagul Fibrinolysis** 1998 Oct;9(7):623–8

Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates. Zanon E, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):117–20

Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients. Chia WK, et al. **Br J Haematol** 1998 Dec;103(4):1014–22

Functional lymphocyte immunophenotypes observed in thalassaemia and haemophilia patients receiving current blood product preparations. Hodge G, et al. **Br J Haematol** 1999 Jun;105(3):817–25

CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. Daniel V, et al. **Clin Exp Immunol** 1999 Mar;115(3):477–84

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Brackmann HH, et al. **Eur J Haematol Suppl** 1998;63:18–23 (15 ref.)

Optimal care of inhibitor patients during surgery. Vermylen J, et al. **Eur J Haematol Suppl** 1998;63:15–7

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Brackmann HH, et al. **Haemophilia** 1999 May;5(3):203–6

Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies. Girma JP, et al. **Haemophilia** 1998 Mar; 4(2):98–103

Factor VIII immunogenicity. Jacquemin MG, et al. **Haemophilia** 1998 Jul;4(4):552–7 (37 ref.)

An unusual haemarthrosis in an HIV-seronegative haemophilia A patient. Ménart C, et al. **Haemophilia** 1998 Sep;4(5):752–4

Increased CD4-positive monocytes in HIV-infected haemophilic patients. Riera N, et al. **Haemophilia** 1998 Sep; 4(5):725–30

The natural history of the immune response to exogenous factor VIII in severe haemophilia A. Scandella D, et al. **Haemophilia** 1998 Jul;4(4):546–51

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Scharrer I, et al. **Haemophilia** 1999 May; 5(3):145–54 (61 ref.)

Spinal epidural haematoma in haemophilia A. Schmitz A, et al. **Haemophilia** 1998 Jan;4(1):51–5

Human immunodeficiency virus infection in haemophiliacs in Taiwan: the importance of CD4 lymphocyte count in the progression to acquired immunodeficiency syndrome. Shen MC, et al. **Haemophilia** 1998 Mar;4(2):115–21

Analysis of clinical AIDS-free interval after CD4+ cell counts fall below 200 x 10(6) L-1 in Japanese haemophiliacs infected with HIV-1. Tatsunami S, et al. **Haemophilia** 1998 Jan;4(1):41–6

Fatal liver failure in haemophiliacs with HIV-induced immunodeficiency: observation of six patients. Toyoda H, et al. **Haemophilia** 1999 Mar;5(2):109–14

How do some haemophiliacs develop inhibitors? Vermylen J. **Haemophilia** 1998 Jul;4(4):538–42 (29 ref.)

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Daniel V, et al. **Immunol Lett** 1999 Aug 3;69(2):283–9

Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. Kuwabara I, et al. **J Immunol Methods** 1999 Apr 22; 224(1-2):89–99

Long-term prophylaxis and immune parameters in haemophilia [letter] Kavakli K, et al. **J Trop Pediatr** 1999 Apr;45(2):122–3

Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Lacroix-Desmazes S, et al. **Nat Med** 1999 Sep;5(9):1044–7

Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Gilles JG, et al. **Thromb Haemost** 1999 Jul;82(1):40–5

Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Laub R, et al. **Thromb Haemost** 1999 Jan;81(1):39–44

Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil [letter] Rieger A, et al. **Thromb Haemost** 1999 Mar;81(3):475–6

French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Rothschild C, et al. **Thromb Haemost** 1998 Nov;80(5):779–83

Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Smith MP, et al. **Thromb Haemost** 1999 Jan;81(1):35–8

Inhibitor development in a multitransfused patient with severe haemophilia A [letter] van den Berg HM, et al. **Thromb Haemost** 1999 Jul;82(1):151–2

Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution. van den Brink EN, et al. **Thromb Haemost** 1999 May;81(5):723–6

Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Ohta H, et al. **Tissue Antigens** 1999 Jul; 54(1):91–7

[Recombinant factor VIIa (eptacog alfa): a new therapeutic option for patients with severe bleeding disorder due to inhibitory antibodies against a coagulation factor] Turkstra F, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1464–7 (Eng. Abstr.) **(Dut)**

[The young hemophiliac, inhibitors and immune tolerance] Rothschild C. **Transfus Clin Biol** 1999 Jun;6(3):191–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Hemophilia A with inhibitor] Takahashi I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):498–501 (16 ref.) **(Jpn)**

METABOLISM

From the ER to the golgi: insights from the study of combined factors V and VIII deficiency. Nichols WC, et al. **Am J Hum Genet** 1999 Jun;64(6):1493–8 (38 ref.)

Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Pipe SW, et al. **Blood** 1999 Jan 1;93(1):176–83

Enhanced IFN-gamma production in vitro by CD8+ T cells in hemophiliacs with AIDS as demonstrated on the single-cell level. Pae Y, et al. **Clin Immunol** 1999 Jul; 92(1):111–7

Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. Scheiflinger F, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):172–80 (117 ref.)

MICROBIOLOGY

[The characteristics of the causative agents of suppurative-inflammatory complications in hemophiliacs] Fedorovskaia EA, et al. **Mikrobiol Z** 1998 Jul–Aug; 60(4):88–92 (Eng. Abstr.) **(Rus)**

MORTALITY

Causes of death in Canadians with haemophilia 1980–1995. Association of Hemophilia Clinic Directors of Canada. Walker IR, et al. **Haemophilia** 1998 Sep;4(5):714–20

PATHOLOGY

The destructive capabilities of the synovium in the haemophilic joint. Rodriguez-Merchan EC. **Haemophilia** 1998 Jul;4(4):506–10

Synovium in haemophilic arthropathy. Roosendaal G, et al. **Haemophilia** 1998 Jul;4(4):502–5 (23 ref.)

Magnetic resonance imaging in hemophilic children: value of gradient echo and contrast-enhanced imaging. Rand T, et al. **Magn Reson Imaging** 1999 Feb;17(2):199–205

PHYSIOPATHOLOGY

Control of the synovium in haemophilia. Eickhoff HH, et al. **Haemophilia** 1998 Jul;4(4):511–3 (23 ref.)

Haemophilia and the mysterious spleen: the story of a hate-love relationship. Ingram GI. **Haemophilia** 1998 Jan; 4(1):69–74 (76 ref.)

Quality of life during menstruation in patients with inherited bleeding disorders. Kadir RA, et al. **Haemophilia** 1998 Nov; 4(6):836–41

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Kreuz W, et al. **Haemophilia** 1998 Jul;4(4):413–7

The destructive capabilities of the synovium in the haemophilic joint. Rodriguez-Merchan EC. **Haemophilia** 1998 Jul;4(4):506–10

PREVENTION & CONTROL

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Funk M, et al. **Ann Hematol** 1998 Oct;77(4):171–4

A prospective clinical trial of implantable central venous access in children with haemophilia. Santagostino E, et al. **Br J Haematol** 1998 Sep;102(5):1224–8

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Kreuz W, et al. **Haemophilia** 1998 Jul;4(4):413–7

Prophylactic treatment in Sweden--overtreatment or optimal model? Ljung RC. **Haemophilia** 1998 Jul;4(4):409–12 (22 ref.)

PSYCHOLOGY

Close relationships and safer sex among HIV-infected men with haemophilia. Norman LR, et al. **AIDS Care** 1998 Jun; 10(3):339–54

Reproductive choices of haemophilia carriers. Tedgård U, et al. **Br J Haematol** 1999 Aug;106(2):421–6

Knowledge of HIV/AIDS and emotional adjustment in a cohort of men with haemophilia and HIV infection: final report. Pasqual Marsettin E, et al. **Haemophilia** 1998 Nov; 4(6):820–5

Psychological aspects and coping of parents with a haemophilic child: a quantitative approach. Saviolo-Negrin N, et al. **Haemophilia** 1999 Jan;5(1):63–8

Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Wenzel T, et al. **Haemostasis** 1998 Mar-Apr;28(2):106–10

Carrier testing of children for two X linked diseases in a family based setting: a retrospective long term psychosocial evaluation. Järvinen O, et al. **J Med Genet** 1999 Aug; 36(8):615–20

Long-term psychological effects of carrier testing and prenatal diagnosis of haemophilia: comparison with a control group. Tedgård U, et al. **Prenat Diagn** 1999 May; 19(5):411–7

RADIOGRAPHY

Contrast venography in young haemophiliacs with implantable central venous access devices. Medeiros D, et al. **Haemophilia** 1998 Jan;4(1):10–5

SURGERY

Surgery in haemophilia: experience from a centre in India. Ghosh K, et al. **Haemophilia** 1998 Mar;4(2):94–7

The surgical treatment of a haemophilic pseudotumour in an extremity: a report of three cases with pathological fractures. Ishiguro N, et al. **Haemophilia** 1998 Mar; 4(2):126–31

The role of fibrin tissue adhesives in surgery of haemophilia patients. Martinowitz U, et al. **Haemophilia** 1998 Jul; 4(4):443–8 (46 ref.)

A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis. Molho P, et al. **Haemophilia** 1999 Mar; 5(2):115–23

Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia. Srivastava A, et al. **Haemophilia** 1998 Nov;4(6):799–801

Obstructive Ileus caused by blood clot after emergency total gastrectomy in a patient with hemophilia A: report of a case. Onda M, et al. **Surg Today** 1998;28(12):1266–9

THERAPY

Port-A-Cath usage in children with haemophilia: experience of 53 cases. Ljung R, et al. **Acta Paediatr** 1998 Oct; 87(10):1051–4

GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates. Woelfle J, et al. **Arch Dis Child** 1999 May;80(5):429–32

Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Gnatenko DV, et al. **Br J Haematol** 1999 Jan;104(1):27–36

Acquired hemophilia A: report of two cases. Chen YC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Sep; 61(9):538–44

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Hsu HC, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul; 62(7):450–4

Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Martin PG, et al. **Clin Lab Haematol** 1999 Apr;21(2):125–8

Gene therapy for hemophilia: hopes and hurdles. Chuah MK, et al. **Crit Rev Oncol Hematol** 1998 Sep;28(3):153–71 (124 ref.)

Problems and prospects in gene therapy for hemophilia. Herzog RW, et al. **Curr Opin Hematol** 1998 Sep;5(5):321–6

HEMOPHILIA A

(49 ref.)

Haemophilia care in developing countries. A report of a joint WHO/World Federation of Hemophilia meeting. Geneva, Switzerland, 16-17 June 1997. **Haemophilia** 1998;4 Suppl 2:v, 1-66

WHO/WFH recommendations, June 1997. Hemophilia care in developing countries. **Haemophilia** 1998;4 Suppl 2:64-6

Economic aspects of haemophilia care. Aldedort LM, et al. **Haemophilia** 1999 May;5(3):216-9

Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. Andrews JL, et al. **Haemophilia** 1999 May; 5(3):160-8

Cryoprecipitate and the plastic blood-bag system: provision of adequate replacement therapy for routine treatment of haemophilia. 1967 [classical article] Bennett E, et al. **Haemophilia** 1998 Mar;4(2):139-42

The Malmö-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts. Berntorp E, et al. **Haemophilia** 1998 Mar;4(2):79-82

Emotional reactions of haemophilia health care providers. Brown LK, et al. **Haemophilia** 1999 Mar;5(2):127-31

Meeting the needs of haemophilic children in developing countries. Chuansumrit A. **Haemophilia** 1998;4 Suppl 2:19-23

Haemophilia A gene therapy. Connelly S, et al. **Haemophilia** 1998 Jul;4(4):380-8 (97 ref.)

Prions and haemophilia: assessment of risk. Evatt BL. **Haemophilia** 1998 Jul;4(4):628-33 (42 ref.)

Public health and international health-care development for persons with haemophilia: operation improvement and operation access. Evatt BL. **Haemophilia** 1998;4 Suppl 2:54-8

Gene therapy for haemophilia: how far have we come? Fields PA, et al. **Haemophilia** 1998 Sep;4(5):699-703

Additional data on the morbidity of central venous access devices in patients with haemophilia [letter] Geraghty S, et al. **Haemophilia** 1998 Jan;4(1):66

Towards achieving global haemophilia care--World Federation of Hemophilia programmes. Lee CA. **Haemophilia** 1998 Jul;4(4):463-73 (10 ref.)

World Federation of Hemophilia developing world programmes. Lee CA. **Haemophilia** 1998;4 Suppl 2:59-63

Haemophilia care within the United Kingdom. Ludlam CA. **Haemophilia** 1998 Jul;4(4):427-8

Acute renal failure complicating high-dose intravenous immunoglobulin therapy for acquired haemophilia. McColl MD, et al. **Haemophilia** 1999 Mar;5(2):124-6

Haemophilia treatment protocols around the world: towards a consensus. Mannucci PM. **Haemophilia** 1998 Jul;4(4):421

Medical care for haemophilia. Nuss R, et al. **Haemophilia** 1998 Nov;4(6):806-11

The transfer of technology from the developed to the developing world. Rickard KA. **Haemophilia** 1998;4 Suppl 2:46-53

Intraoperative transmission of blood-borne disease in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1998 Mar;4(2):75-8 (15 ref.)

Delivery of haemophilia care in the developing world. Srivastava A. **Haemophilia** 1998;4 Suppl 2:33-40 (43 ref.)

The emerging needs of persons living with haemophilia and HIV/AIDS in British Columbia. Taylor G. **Haemophilia** 1999 Jan;5(1):1-8 (16 ref.)

Hemophilia. A new approach to an old disease. DiMichele D, et al. **Hematol Oncol Clin North Am** 1998 Dec; 12(6):1315-44 (158 ref.)

The non-surgical treatments of hepatocellular carcinomas in a patient with severe hemophilia A. Toyoda H, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1156-9

Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648. Chiang GG, et al. **Hum Gene Ther** 1999 Jan 1;10(1):61-76

Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. Miners AH, et al. **J Intern Med** 1998 Dec;244(6):515-22

Factor concentrate prophylaxis for neonates with hemophilia [comment] Buchanan GR. **J Pediatr Hematol Oncol** 1999 Jul-Aug;21(4):254-6. Comment on: J Pediatr Hematol Oncol 1999 Jul-Aug;21(4):289-95.

Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. Matsui H, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb; 21(1):74-6

New therapeutic products and difficult decisions [letter; comment] Schweiger M. **J Public Health Med** 1999 Mar; 21(1):115-6. Comment on: J Public Health Med 1998 Jun;20(2):137-8.

Haemophilia: does the future lie in replacement therapy or auto-supply? [letter; comment] Tuddenham E. **J R Soc Med** 1998 Sep;91(9):506. Comment on: J R Soc Med 1998 Jul;91(7):399.

Long-term prophylaxis and immune parameters in haemophilia [letter] Kavakli K, et al. **J Trop Pediatr** 1999 Apr;45(2):122-3

Gene therapy for the hemophilias [comment] Kay MA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9973-5 (44 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10379-84.

Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice [see comments] VandenDriessche T, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10379-84. Comment in: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):9973-5.

Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? [letter; comment] [see comments] Baglin T, et al. **Thromb Haemost** 1998 Dec; 80(6):1036-7. Comment on: Thromb Haemost 1998 Apr;79(4):762-6. Comment in: Thromb Haemost 1999 May;81(5):852.

Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Connelly S, et al. **Thromb Haemost** 1999 Feb;81(2):234-9

Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Qian J, et al. **Thromb Haemost** 1999 Feb;81(2):240-4

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Shapiro AD, et al. **Thromb Haemost** 1998 Nov;80(5):773-8

Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy [letter] Toepfer M, et al. **Thromb Haemost** 1998 Dec;80(6):1035-6

Progression to AIDS in relation to clinical factors and clotting product consumption. A 14-year follow-up of a cohort of 52 Dutch HIV-1-infected haemophilic patients. Roosendaal G, et al. **Vox Sang** 1998;75(4):261-6

[Gene therapy for hemophilia: feasible in principle but not yet clinically applicable] van der Eb MM, et al. **Ned Tijdschr Geneeskd** 1998 Apr 11;142(15):840-4 (38 ref.) (Eng. Abstr.) **(Dut)**

[Emergency management of hemophiliac patients with suspected hemorrhage. National Agency of Accreditation and Evaluation in Health (ANAES)] **Presse Med** 1999 Mar 20;28(11):591-5 **(Fre)**

[Apropos of emergency management of hemophiliac patients with suspected hemorrhage (interview)] Sultan Y. **Presse Med** 1999 Mar 20;28(11):595-6 **(Fre)**

[Recombinant activated factor VII: a new treatment for hemophilia] Goudemand J. **Transfus Clin Biol** 1998 Aug; 5(4):260-5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Centralized care is the basis of care programs for hemophilia patients] Berntorp E, et al. **Lakartidningen** 1999 Apr 14; 96(15):1849-52 (Eng. Abstr.) **(Swe)**

VIROLOGY

V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection [letter] Vallejo A, et al. **AIDS** 1999 Mar 11; 13(4):532-4

Genetic characterization of the V3 loop sequences of 21 HIV type 1 Spanish isolates from hemophilia patients. Ortiz M, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1487-90

Multiple infection of TT virus (TTV) with different genotypes in Japanese hemophiliacs. Takayama S, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):208-11

UK inquiry should establish why contaminated blood products were given to people with haemophilia [letter] Pappenheim K. **BMJ** 1999 Jul 3;319(7201):52-3

Prevalence and persistence of a novel DNA TT virus (TTV) infection in Japanese haemophiliacs. Takayama S, et al. **Br J Haematol** 1999 Mar;104(3):626-9

Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II (HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results. Carneiro-Proietti AB, et al. **Haemophilia** 1998 Jan; 4(1):47-50

Health status and satisfaction of asymptomatic HIV-positive haemophiliacs in Kyushu, Japan. Tanaka S, et al. **Haemophilia** 1999 Jan;5(1):56-62

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean island. Césaire R, et al. **J Med Virol** 1999 Oct;59(2):160-3

Transfusion transmitted virus [letter; comment] Sumazaki R, et al. **Lancet** 1998 Oct 17;352(9136):1308-9; discussion 1310-1. Comment on: Lancet 1998 Jul 18;352(9123):191-5.

GB virus C/hepatitis G virus isolates in Japanese haemophiliacs and their origins. Toyoda H, et al. **Thromb Haemost** 1998 Aug;80(2):242-5

[Detection and genotype analysis of GB virus C/hepatitis G virus (GBV-C/HGV) in the sera of Japanese patients with hemophilia A] Okamoto Y, et al. **Rinsho Byori** 1999 Jun;47(6):571-5 (Eng. Abstr.) **(Jpn)**

HEMOPHILIA B

Management of haemophilia B patients with inhibitors and anaphylaxis. Warrier I. **Haemophilia** 1998 Jul;4(4):574-6 (8 ref.)

[Hemophilia B] Asano A, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):427-9 (15 ref.) **(Jpn)**

[Female hemophilia (female hemophiliacs)] Sakuragawa N. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):471-3 (20 ref.) **(Jpn)**

BLOOD

Inhibitor development and substitution therapy in a developing country: Turkey. Kavakli K, et al. **Haemophilia** 1998 Mar;4(2):104-8

COMPLICATIONS

Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis. Avanogmacr;lu A, et al. **BJU Int** 1999 Jan;83(1):91-4

Acute liver failure induced by alcohol and paracetamol in an HCV-infected haemophiliac. Leach M, et al. **Br J Haematol** 1998 Dec;103(3):891-3

Therapy for chronic hepatitis B and C infection in haemophilia. Dusheiko GM. **Haemophilia** 1998 Jul; 4(4):577-86 (65 ref.)

Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Arkin S, et al. **Haemostasis** 1998 Mar-Apr;28(2):93-8

Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Wenzel T, et al. **Haemostasis** 1998 Mar-Apr;28(2):106-10

Spinal epidural haematoma in a patient with haemophilia-B. Meena AK, et al. **Spinal Cord** 1998 Sep;36(9):658-60

Orthotopic liver transplantation for hepatitis C infection: the best Christmas present? Johnston SD, et al. **Ulster Med J** 1998 Nov;67(2):134-6

[Joint preserving operations and endoprosthetic joint substitutions in hemophiliacs. Indications and long term results] Hovy L. **Orthopade** 1999 Apr;28(4):356-65 (29 ref.) (Eng. Abstr.) **(Ger)**

[Prevention of joint damage in hemophilic children with early prophylaxis] Kreuz W, et al. **Orthopade** 1999 Apr; 28(4):341-6 (Eng. Abstr.) **(Ger)**

[Conservative management of hemophilic arthropathy] Müller S, et al. **Orthopade** 1999 Apr;28(4):347-55 (Eng. Abstr.) **(Ger)**

[Diagnosis and management of coagulation disorders in orthopedic surgery] Scharrer I. **Orthopade** 1999 Apr; 28(4):316-22 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Educational symposium: DNA diagnosis of malignancies; strategies and applications of PCR-mediated DNA diagnosis in a case of hemophilia B] Kojima T. **Rinsho Byori** 1998 Sep;46(9):861-8 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs. Négrier C, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S135-41

Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Nicolaisen EM. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S119-23

Tolerance induction using the Malmö treatment model 1982-1995. Freiburghaus C, et al. **Haemophilia** 1999 Jan; 5(1):32-9

Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement. Liebman HA, et al. **Haemophilia** 1999 May;5(3):174-80

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Lusher JM, et al. **Haemophilia** 1998 Nov; 4(6):790-8

Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Schulman S, et al. **Haemophilia** 1999 Mar;5(2):96-100

Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Tengborn L, et al. **Haemophilia** 1998 Jan;4(1):56-9

Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Thorland EC, et al. **Haemophilia** 1999 Mar; 5(2):101-5

Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. Mauser-Bunschoten EP, et al. **Neth J Med** 1998 Dec;53(6):249-55

A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Goudemand J, et al. **Thromb Haemost** 1998 Dec;80(6):919-24

[Antifibrinolytics as a treatment for severe factor XI deficiency in laryngeal surgery (letter)] Medina Pérez A, et al. **Sangre (Barc)** 1999 Jun;44(3):246-7 **(Spa)**

EPIDEMIOLOGY

Secular trends in the prevalence of HIV infection among a population of males with hemophilia, 1988-1997: the Oklahoma Hemophilia Surveillance System. Cowan LD, et al. **J Okla State Med Assoc** 1999 Sep;92(9):462-7

ETIOLOGY

[Hemophilia B with inhibitor] Takahashi I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):502–5 (8 ref.) **(Jpn)**

GENETICS

A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. Hinks JL, et al. **Br J Haematol** 1999 Mar;104(4):915–8

Haemophilia B Brandenberg-type promoter mutation. Heit JA, et al. **Haemophilia** 1999 Jan;5(1):73–5

Hepatic gene therapy for haemophilia B. Kay MA. **Haemophilia** 1998 Jul;4(4):389–92 (20 ref.)

The molecular basis of haemophilia B. Lillicrap D. **Haemophilia** 1998 Jul;4(4):350–7 (71 ref.)

Counselling about diagnosis and inheritance of genetic bleeding disorders: haemophilia A and B. Miller R. **Haemophilia** 1999 Mar;5(2):77–83

Molecular characterization of haemophilia A & B in Indians. Shetty S, et al. **Haemophilia** 1998 Nov;4(6):802–5

Five novel factor IX mutations in unrelated hemophilia B patients. David D, et al. **Hum Mutat** 1998;Suppl 1:S301–3

Deep intronic mutations are rarely a cause of hemophilia B [letter] Feng J, et al. **Hum Mutat** 1999;14(3):267–8

IMMUNOLOGY

Development of anaphylactic shock in haemophilia B patients with inhibitors. Warrier I, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S125–8

Human immunodeficiency virus infection in haemophiliacs in Taiwan: the importance of CD4 lymphocyte count in the progression to acquired immunodeficiency syndrome. Shen MC, et al. **Haemophilia** 1998 Mar;4(2):115–21

Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Tengborn L, et al. **Haemophilia** 1998 Nov;4(6):854–9

Change of antigenic and neutralizing specificity in substitutional epitope peptides of hemophilia B inhibitor. Takahashi I, et al. **Peptides** 1998;19(7):1129–36

PHYSIOPATHOLOGY

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Kreuz W, et al. **Haemophilia** 1998 Jul;4(4):413–7

PREVENTION & CONTROL

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Funk M, et al. **Ann Hematol** 1998 Oct;77(4):171–4

Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Carlsson M, et al. **Haemophilia** 1998 Mar;4(2):83–8

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Kreuz W, et al. **Haemophilia** 1998 Jul;4(4):413–7

SURGERY

Tympanoplasty in a patient with hemophilia B. Fujita N, et al. **Auris Nasus Larynx** 1999 Apr;26(2):195–9

THERAPY

The rhesus macaque as an animal model for hemophilia B gene therapy. Lozier JN, et al. **Blood** 1999 Mar 15; 93(6):1875–81

Hepatic gene therapy for haemophilia B. Kay MA. **Haemophilia** 1998 Jul;4(4):389–92 (20 ref.)

Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hortelano G, et al. **Hum Gene Ther** 1999 May 20;10(8):1281–8

Case 1--1999. Elective and emergency cardiac surgery on a patient with hemophilia B [clinical conference] Donahue BS, et al. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):92–7

Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. Miners AH, et al. **J Intern Med** 1998 Dec;244(6):515–22

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector [see comments] Herzog RW, et al. **Nat Med** 1999 Jan;5(1):56–63. Comment in: Nat Med 1999 Jan;5(1):21–2.

AAVant-garde gene therapy [news; comment] Linden RM, et al. **Nat Med** 1999 Jan;5(1):21–2. Comment on: Nat Med 1999 Jan;5(1):56–63. Comment on: Nat Med 1999 Jan;5(1):64–70.

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors [see comments] Snyder RO, et al. **Nat Med** 1999 Jan;5(1):64–70 . Comment in: Nat Med 1999 Jan;5(1):21–2.

Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Dharnidharka VR, et al. **Pediatr Nephrol** 1998 Oct;12(8):654–7

Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Wang L, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3906–10

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Shapiro AD, et al. **Thromb Haemost** 1998 Nov;80(5):773–8

Progression to AIDS in relation to clinical factors and clotting product consumption. A 14-year follow-up of a cohort of 52 Dutch HIV-1-infected haemophilic patients. Roosendaal G, et al. **Vox Sang** 1998;75(4):261–6

[Treatment of hemophilia B with 15 nm filtered factor IX-LFB] Derlon A. **Presse Med** 1998 Apr 18;27(15):740–1 **(Fre)**

[Centralized care is the basis of care programs for hemophilia patients] Berntorp E, et al. **Lakartidningen** 1999 Apr 14; 96(15):1849–52 (Eng. Abstr.) **(Swe)**

VIROLOGY

Prevalence and persistence of a novel DNA TT virus (TTV) infection in Japanese haemophiliacs. Takayama S, et al. **Br J Haematol** 1999 Mar;104(3):626–9

Health status and satisfaction of asymptomatic HIV-positive haemophiliacs in Kyushu, Japan. Tanaka S, et al. **Haemophilia** 1999 Jan;5(1):56–62

HEMOPHILIA C see **FACTOR XI DEFICIENCY**

HEMOPHILIA, VASCULAR see **VON WILLEBRAND DISEASE**

HEMOPHILUS see **HAEMOPHILUS**

HEMOPHILUS INFECTIONS see **HAEMOPHILUS INFECTIONS**

HEMOPHTHALMOS see **EYE HEMORRHAGE**

HEMOPNEUMOTHORAX

DIAGNOSIS

Accuracy of auscultation in the detection of haemopneumothorax. Chen SC, et al. **Eur J Surg** 1998 Sep; 164(9):643–5

ETIOLOGY

[A case of spontaneous hemopneumothorax occurred after thoracic drainage] Baba M, et al. **Kyobu Geka** 1998 Oct; 51(11):970–3 (Eng. Abstr.) **(Jpn)**

SURGERY

[Video-assisted thoracoscopic surgery in spontaneous hemopneumothorax] Horio H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):987–91 (Eng. Abstr.) **(Jpn)**

[Two cases of spontaneous hemopeumothorax] Baba K, et al. **Kyobu Geka** 1998 Oct;51(11):974–7 (Eng. Abstr.) **(Jpn)**

HEMOPTYSIS

CHEMICALLY INDUCED

Amiodarone-associated hemoptysis. Ravishankar R, et al. **Am J Med Sci** 1998 Dec;316(6):390–2

Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome. Nicolls MR, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1302–5

Hemoptysis due to MDI therapy in a patient with permanent tracheostomy: treatment with mask AeroChamber. Newhouse MT. **Chest** 1999 Jan;115(1):279–82

COMPLICATIONS

Fever, hemoptysis and pneumonia in a twelve-year-old girl. Shetty AK, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):849; 852–3

DIAGNOSIS

Role of bronchoscopy in massive hemoptysis. Dweik RA, et al. **Clin Chest Med** 1999 Mar;20(1):89–105 (78 ref.)

Factitious hemoptysis [letter] Ozden A, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Apr;38(4):356–7

Munchausen's syndrome. A case of factitious hemoptysis. Saed G, et al. **Panminerva Med** 1999 Mar;41(1):62–7 (23 ref.)

[Hemoptysis: diagnostic direction] Tazi A. **Rev Prat** 1998 Jun 1;48(11):1239–42 (0 ref.) **(Fre)**

[Hemoptysis and pulmonary infiltrates in a 22-year-old woman (clinical conference)] Juan Pastor A, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):349–55 **(Spa)**

[Hemoptysis and a positive Mantoux in a 28-year-old man] Mariblanca Sánchez M, et al. **Rev Clin Esp** 1999 Jan; 199(1):41–2 **(Spa)**

[Hemoptysis in a male ex-smoker. Hemoptysis in relation to the aspiration of a foreign body (a metal bracelet)] Núñez Orantos MJ, et al. **Rev Clin Esp** 1999 May;199(5):327–8 **(Spa)**

ETIOLOGY

Cholangiocarcinoma presenting as lung mass with hemoptysis. Leaw SJ, et al. **Abdom Imaging** 1999 Jul–Aug; 24(4):407–9

Unusual presentation of hemoptysis in a 78-year-old with previous Nissen fundoplication. Bavry AA, et al. **Am Surg** 1998 Dec;64(12):1223–5 (18 ref.)

The higher risk of bleeding in lung transplant recipients from bronchoscopy is independent of traditional bleeding risks: results of a prospective cohort study. Diette GB, et al. **Chest** 1999 Feb;115(2):397–402

Positive antineutrophil cytoplasmic antibodies-associated vasculitis presenting with hemoptysis and a mediastinal mass. Fidder HH, et al. **Chest** 1999 May;115(5):1473–5

Multiple cavitating nodules in a patient with hemoptysis. Meghjee S, et al. **Chest** 1999 Apr;115(4):1184–7

Hemoptysis and dyspnea in a 67-year-old man with a normal chest radiograph. Velez Jo ET, et al. **Chest** 1999 Sep; 116(3):803–7

Unilateral pulmonary artery agenesis with presentation of hemoptysis: a case report. Lin YM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep;62(9):644–7

Pulmonary hydatid cyst as a cause of recurrent haemoptysis and responding to treatment with albendazole. Aderaye G. **Ethiop Med J** 1998 Jul;36(3):193–7

Haemoptysis after breath-hold diving. Boussuges A, et al. **Eur Respir J** 1999 Mar;13(3):697–9

Haemoptysis associated with pulmonary varices: demonstration using computed tomographic angiography. Ferretti GR, et al. **Eur Respir J** 1998 Oct;12(4):989–92

Late massive haemoptyses from bronchopulmonary collaterals in infarcted segments following pulmonary embolism. Thomas CS, et al. **Eur Respir J** 1999 Feb; 13(2):463–4

Catamenial hemoptysis--a case report. Tandon S. **Indian J Med Sci** 1998 Oct;52(10):450–2

Chronic haemoptysis as delayed complication of ventricular aneurysmectomy. Kovac JD, et al. **Int J Cardiol** 1999 Jun 1;69(3):299–303

Delayed massive hemoptysis after expandable bronchial stent placement. Urschel JD. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):155–8

Hughes-Stovin syndrome: a case report and review of the literature. Riantawan P, et al. **J Med Assoc Thai** 1999 Mar; 82(3):312–6 (7 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099–104 (13 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1999. A 77-year-old man with hemoptysis and cardiovascular disease [clinical conference] **N Engl J Med** 1999 May 20;340(20):1571–9

Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Gupta KL, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3258–60

Occult aspiration of a chicken wishbone as a cause of hemoptysis. Mercado JA, et al. **P R Health Sci J** 1999 Mar;18(1):71–3

Fatal pulmonary haemorrhage during anaesthesia for bronchial artery embolization in cystic fibrosis. McDougall RJ, et al. **Paediatr Anaesth** 1999;9(4):345–8

Moderate hemoptysis of unknown etiology. Sheikh S, et al. **Pediatr Pulmonol** 1999 May;27(5):351–5

Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor? Langendijk JA, et al. **Radiother Oncol** 1998 Nov;49(2):175–83

Gastroesophageal reflux presented with haemoptysis and carinal erythematous lesion resembling in situ carcinoma. Bouros D, et al. **Respir Med** 1998 Oct;92(10):1251–2

Cause, treatment and outcome of patients with life-threatening haemoptysis. Stebbings AE, et al. **Singapore Med J** 1999 Feb;40(2):67–9

[Hemoptysis with intralobar pulmonary sequestration] Wessels J, et al. **Ugeskr Laeger** 1998 Nov 23;160(48):6982–3 (Eng. Abstr.) **(Dan)**

[Management of hemoptysis in invasive pulmonary aspergillosis] Dohen-Bécue F, et al. **Rev Mal Respir** 1998 Dec;15(6):791–6 (Eng. Abstr.) **(Fre)**

[A case of febrile hemoptysis] Hamidfar R, et al. **Rev Mal Respir** 1999 Jun;16(3):398–9 **(Fre)**

[Hemoptysis in pneumonia] Tanguy B, et al. **Rev Mal Respir** 1998 Dec;15(6):811–2 **(Fre)**

[A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)] Cailleux N, et al. **Rev Med Interne** 1998 Jun;19(6):434–7 (Eng. Abstr.) **(Fre)**

[A rare cause of hemoptysis] Chouabe S, et al. **Rev Pneumol Clin** 1999 Mar;55(1):35–7 (Eng. Abstr.) **(Fre)**

[Duration of anamnesis in patients with hemoptysis] Salajka F. **Acta Med Austriaca** 1999;26(1):17–9 (Eng. Abstr.) **(Ger)**

[Vasculo-Behcet's disease with fatal massive hemoptysis] Sekine K, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Feb; 37(2):135–9 (Eng. Abstr.) **(Jpn)**

[Primary racemose hemangioma of bronchial artery] Sukoh N, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):67–71 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Giant cyst of the left lung complicated by mediastinal hernia and hemoptysis] Opanasenko NS, et al. **Klin Khir** 1999; (3):50–1 **(Rus)**

[Pulmonary hemorrhage in patients with tuberculosis (lecture)] Rzhavskov IuV. **Probl Tuberk** 1999;(1):65–9 **(Rus)**

[Massive hemoptysis as a rare complication in a patient with cystic fibrosis] Nagorni-Obradović Lj, et al.

Srp Arh Celok Lek 1998 Nov-Dec;126(11-12):512-5 (Eng. Abstr.) **(Scc)**

[Impact of gender and influence of tobacco on the etiology of patients with hemoptysis] Haro M, et al. **An Med Interna** 1999 May;16(5):239-43 (Eng. Abstr.) **(Spa)**

[Hemoptysis and bronchiolitis obliterans organizing pneumonia (letter)] Haro M, et al. **Arch Bronconeumol** 1998 Sep;34(8):410 **(Spa)**

[Pseudo-hemoptysis due to Serratia marcescens, an etiology to remember (letter)] Hurtado Ayuso JE, et al. **Arch Bronconeumol** 1999 Apr;35(4):194-5 **(Spa)**

PATHOLOGY

[An 86-year-old man with a constitutional syndrome, hemoptysis, abdominal pain and renal failure (clinical conference)] **Rev Clin Esp** 1999 Apr;199(4):239-46 **(Spa)**

PHYSIOPATHOLOGY

[Duration of anamnesis in patients with hemoptysis] Salajka F. **Acta Med Austriaca** 1999;26(1):17-9 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Internal mammary artery embolization for hemoptysis. Hashimoto M, et al. **Acta Radiol** 1999 Mar;40(2):187-90

THERAPY

Management of exsanguinating hemoptysis during cardiopulmonary bypass. Smythe WR, et al. **Ann Thorac Surg** 1999 May;67(5):1288-91

Referred pain to the ipsilateral forehead and orbit: An unusual phenomenon during bronchial artery embolization. Ramakantan R, et al. **Cardiovasc Intervent Radiol** 1999 Jul-Aug;22(4):275-7

Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis [see comments] Mal H, et al. **Chest** 1999 Apr;115(4):996-1001 . Comment in: Chest 1999 Apr;115(4):912-5.

Bronchial artery embolotherapy for control of acute hemoptysis: analysis of outcome [editorial; comment] White RI Jr. **Chest** 1999 Apr;115(4):912-5. Comment on: Chest 1999 Apr;115(4):996-1001.

Role of bronchoscopy in massive hemoptysis. Dweik RA, et al. **Clin Chest Med** 1999 Mar;20(1):89-105 (78 ref.)

Massive hemoptysis secondary to bronchial collaterals: treatment with use of TIPS and embolization. Mansilla AV, et al. **J Vasc Interv Radiol** 1999 Mar;10(3):372-4

Transient cortical blindness: a complication of bronchial artery embolization. Liu SF, et al. **Respir Med** 1998 Jul; 92(7):983-6

Cause, treatment and outcome of patients with life-threatening haemoptysis. Stebbings AE, et al. **Singapore Med J** 1999 Feb;40(2):67-9

[Bronchial embolization in the treatment of hemoptysis] Bustamante M, et al. **Arch Bronconeumol** 1998 Nov; 34(10):479-83 (Eng. Abstr.) **(Spa)**

HEMORHEOLOGY

Vector analysis of the hemodynamics of atherogenesis in the human thoracic aorta using MR velocity mapping. Suzuki J, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1285-90

Shear stress-induced nitric oxide antagonizes adenosine effects on intestinal metabolism. Han C, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1227-34

Arterial vasomotion: effect of flow and evidence of nonlinear dynamics. Stergiopulos N, et al. **Am J Physiol** 1998 Jun; 274(6 Pt 2):H1858-64

Shear-induced platelet activation and platelet-neutrophil aggregate formation by equine platelets. Weiss DJ, et al. **Am J Vet Res** 1998 Oct;59(10):1243-6

A computational analysis of FXa generation by TF:FVIIa on the surface of rat vascular smooth muscle cells. Hall CL, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):28-36

Pulsatile flow in tubes of elliptic cross sections. Haslam M, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):780-7

Mean velocity and Reynolds stress measurements in the regurgitant jets of tilting disk heart valves in an artificial heart environment. Maymir JC, et al. **Ann Biomed Eng** 1998 Jan-Feb;26(1):146-56

Scaling of hemolysis in needles and catheters. Sharp MK, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):788-97

Comparison between three- and four-element Windkessel models to characterize vascular properties of pulmonary circulation. Lambermont B, et al. **Arch Physiol Biochem** 1997 Dec;105(7):625-32

Blood flow in a continuous flow ventricular assist device. Allaire PE, et al. **Artif Organs** 1999 Aug;23(8):769-73

Relation between non-uniform hemodynamics and sites of altered permeability and lesion growth at the rabbit aorto-celiac junction. Buchanan JR Jr, et al. **Atherosclerosis** 1999 Mar;143(1):27-40

Influence of hypercholesterolemia and endothelin-3 pre-treatment on the effects of shear forces on platelet aggregation and cyclic GMP content. Gagnet C, et al. **Atherosclerosis** 1999 Mar;143(1):91-7

Association between secondary flow in models of the aorto-celiac junction and subendothelial macrophages in the normal rabbit. Malinauskas RA, et al. **Atherosclerosis** 1998 Sep;140(1):121-34

Effects of lipids and lipoproteins on thrombosis and rheology. Rosenson RS, et al. **Atherosclerosis** 1998 Oct;140(2):271-80 (135 ref.)

The filterability of leukocytes in undiluted blood. Cook AM, et al. **Biorheology** 1998 Mar-Apr;35(2):119-30

Effect of nonaxisymmetric hematocrit distribution on non-Newtonian blood flow in small tubes. Das B, et al. **Biorheology** 1998 Jan-Feb;35(1):69-87

Electrostatic repulsion among erythrocytes in tube flow, demonstrated by the thickness of marginal cell-free layer. Suzuki Y, et al. **Biorheology** 1998 Mar-Apr;35(2):155-70

Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Fredrickson BJ, et al. **Blood** 1998 Nov 15;92(10):3684-93

Haemorheological changes in sickle cell disease: measurement and significance. Famodu AA, et al. **Br J Biomed Sci** 1998 Dec;55(4):265-7

Early hemorheologic aspects of overtraining in elite athletes. Aissa Benhaddad A, et al. **Clin Hemorheol Microcirc** 1999; 20(2):117-25

The role of spleen in suppressing the rheological alterations in circulating blood. Baskurt OK. **Clin Hemorheol Microcirc** 1999;20(3):181-8

Relationships among body composition, hemorheology and exercise performance in rugbymen. Bouix D, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):245-54

The triphasic effects of exercise on blood rheology: which relevance to physiology and pathophysiology? Brun JF, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):89-104 (164 ref.)

Haemorheological profile in subjects with nonvalvular atrial fibrillation. Caimi G, et al. **Clin Hemorheol Microcirc** 1999; 20(2):85-90

Essential hypertension: leukocyte rheology and polymorphonuclear cytosolic Ca2+ content at baseline and after activation. Caimi G, et al. **Clin Hemorheol Microcirc** 1998 Dec;19(4):281-9

Methods for studying leukocyte filterability in undiluted blood from intermittent claudicants. Cook AM, et al. **Clin Hemorheol Microcirc** 1998 Dec;19(4):271-80

Hemorheological changes during venous stasis as result of tourniquet application [letter] Forconi S. **Clin Hemorheol Microcirc** 1999;20(3):197-9

Haemorheological consequences of hyperglycaemic spike in healthy volunteers and insulin-dependent diabetics. Khodabandehlou T, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):105-14

Early rheological and microcirculatory changes in children with type I diabetes mellitus. Koscielny J, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):139-50

Disturbed blood flow structuring as critical factor of hemorheological disorders in microcirculation. Mchedlishvili G. **Clin Hemorheol Microcirc** 1998 Dec; 19(4):315-25 (63 ref.)

Hemorheological alterations and hypercoagulable state in deep vein thrombosis. Mira Y, et al. **Clin Hemorheol Microcirc** 1998 Dec;19(4):265-70

Exercise-induced growth hormone secretion and hemorheology during exercise in elite athletes. Peyreigne C, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):169-76

Hemorheology of growth hormone-deficient adults. Peyreigne C, et al. **Clin Hemorheol Microcirc** 1999; 20(3):167-74

Haemorheology and the inflammatory process. Rampling MW. **Clin Hemorheol Microcirc** 1998 Oct;19(2):129-32 (24 ref.)

Sodium fluorescein influence on the hemorheological profile of non-insulin dependent diabetes mellitus patients. Sargento L, et al. **Clin Hemorheol Microcirc** 1999; 20(2):77-84

A modified Casson equation to characterize blood rheology for hypertension. Shi YD, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):115-27

Hemorheology and vascular endothelial cells. Stoltz JF, et al. **Clin Hemorheol Microcirc** 1999;20(2):127-39

Hemorheological changes in children with polygenic hypercholesterolemia. Vayá A, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):259-62

Effect of acute hypoxia and hypoxic acclimation on hemorheological behavior in rats with frostbite. Zengren Y, et al. **Clin Hemorheol Microcirc** 1999;20(3):189-95

Biomechanical behavior of the arterial wall and its numerical characterization. Holzapfel GA, et al. **Comput Biol Med** 1998 Jul;28(4):377-92

Computational analysis of platelet adhesion and aggregation under stagnation point flow conditions. Reininger CB, et al. **Comput Biol Med** 1999 Jan;29(1):1-18

Fluid shear stress activation of IkappaB kinase is integrin-dependent. Bhullar IS, et al. **J Biol Chem** 1998 Nov 13;273(46):30544-9

Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. Chen KD, et al. **J Biol Chem** 1999 Jun 25;274(26):18393-400

Flow waveform effects on end-to-side anastomotic flow patterns. Ethier CR, et al. **J Biomech** 1998 Jul;31(7):609-17

The influence of the non-Newtonian properties of blood on the flow in large arteries: steady flow in a carotid bifurcation model. Gijsen FJ, et al. **J Biomech** 1999 Jun; 32(6):601-8

Alteration of mean wall shear stress near an oscillating stagnation point. Hazel AL, et al. **J Biomech Eng** 1998 Apr;120(2):227-37

Confocal imaging of flows in artificial venular bifurcations. Hitt DL, et al. **J Biomech Eng** 1999 Apr;121(2):170-7

An evaluation of pseudoelastic descriptors used in arterial mechanics. Humphrey JD. **J Biomech Eng** 1999 Apr; 121(2):259-62

Numerical analysis of the deformation of an adherent drop under shear flow. Kan HC, et al. **J Biomech Eng** 1999 Apr; 121(2):160-9

Development of wall surface tangent DPIV measurement techniques for arterial branch models. Karn EL, et al. **J Biomech Eng** 1998 Dec;120(6):784-7

Finite element analysis of the lift on a slightly deformable and freely rotating and translating cylinder in two-dimensional channel flow. Zhao Y, et al. **J Biomech Eng** 1999 Apr;121(2):148-52

Haemorheological disturbances and possibility of their correction in cerebrovascular diseases. Forconi S, et al. **J Mal Vasc** 1999 May;24(2):110-6 (79 ref.)

A basis of echinocytosis and stomatocytosis in the disc-sphere transformations of the erythrocyte. Wong P. **J Theor Biol** 1999 Feb 7;196(3):343-61

Analytical relationship between arterial input impedance and the three-element Windkessel series resistance. Gnudi G. **Med Biol Eng Comput** 1998 Jul;36(4):480-4

Passive deformability of mature, immature, and active neutrophils in healthy and septicemic neonates. Linderkamp O, et al. **Pediatr Res** 1998 Dec;44(6):946-50

The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 1: A review of models for arterial wall behaviour. Zhao SZ, et al. **Proc Inst Mech Eng [H]** 1998;212(4):229-40 (73 ref.)

The numerical analysis of fluid-solid interactions for blood flow in arterial structures. Part 2: Development of coupled fluid-solid algorithms. Zhao SZ, et al. **Proc Inst Mech Eng [H]** 1998;212(4):241-52 (42 ref.)

Vascular hemostasis in flowing blood in children. Van Cott EM, et al. **Semin Thromb Hemost** 1998;24(6):583-90 (70 ref.)

Arterial hemodynamics and wall mechanics. Vorp DA, et al. **Semin Vasc Surg** 1998 Sep;11(3):169-80 (95 ref.)

Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Redmond EM, et al. **Thromb Haemost** 1999 Feb;81(2):293-300

Effects of blood donation on the physical fitness and hemorheology of healthy elderly donors. Janetzko K, et al. **Vox Sang** 1998;75(1):7-11

[Study on a new rheological equation of state for blood] Zeng D, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):1-3 (Eng. Abstr.) **(Chi)**

[Hemorheology and vascular endothelial cells] Stoltz JF, et al. **J Mal Vasc** 1999 May;24(2):99-109 (68 ref.) (Eng. Abstr.) **(Fre)**

[Hemorheology and autotransfusion] Clivillé X. **Sangre (Barc)** 1998 Aug;43(4):321-2 (39 ref.) **(Spa)**

DRUG EFFECTS

Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia. Otto C, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):473-8

The beneficial effects of omega-3 and omega-6 essential fatty acid supplementation on red blood cell rheology. Ho M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul; 61(1):13-7

HISTORY

In memoriam. George Pearman Fulton, Jr. (1914-1998). Shepro D. **Microvasc Res** 1998 May;55(3):186-8

INSTRUMENTATION

Hydrodynamics of micropipette aspiration. Drury JL, et al. **Biophys J** 1999 Jan;76(1 Pt 1):110-28

Newly developed initial-flow cell filtrometer and the comparison with viscometry and ektacytometry on erythrocyte deformability. Peng J, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(2-3):117-24

A new simple cone-plate viscometer for hemorheology. Wang X, et al. **Clin Hemorheol Microcirc** 1998 Sep; 19(1):25-31

Rectification on the inertial effects for co-axial cylinders rheometer. Zhang JB, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):229-34

METHODS

Use of polyester leukocyte elimination filters in blood filterability research. Lindmark K, et al. **Biorheology** 1998 Mar-Apr;35(2):131-40

Determination of the content of nonfilterable cells in erythrocyte suspensions as a function of the medium osmolality. Lisovskaya IL, et al. **Biorheology** 1998 Mar-Apr;35(2):141-53

STANDARDS

Chronic animal health assessment during axial ventricular assistance: importance of hemorheologic parameters. Kameneva MV, et al. **ASAIO J** 1999 May-Jun;45(3):183-8

Red blood cell aggregability in blood. Criteria for scoring

the techniques. Mchedlishvili G.
Clin Hemorheol Microcirc 1998 Oct;19(2):161–2

HEMORRHAGE

Bleedout efficiency, carcass damage, and rigor mortis development following electrical stunning or carbon dioxide stunning on a shackle line. Kang IS, et al.
Poult Sci 1999 Jan;78(1):139–43

The thrombophilic state in acute promyelocytic leukemia. Tallman MS. **Semin Thromb Hemost** 1999;25(2):209–15 (72 ref.)

[Bleeding from the otorhinolaryngeal (ORL) area] Reiss M, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):246–8 **(Ger)**

[Adrenal hemorrhagic cysts: apropos of a clinical case and review of the literature] Forte A, et al. **Ann Ital Chir** 1998 May–Jun;69(3):365–9 (Eng. Abstr.) **(Ita)**

[Hemorrhagic cystitis (adenovirus infection)] Yagisawa T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):149–51 (14 ref.) **(Jpn)**

[Acute massive hemorrhage and disseminated intravascular coagulation (editorial)] Vorob'ev AI, et al. **Ter Arkh** 1999; 71(7):5–12 (21 ref.) **(Rus)**

[Spontaneous renal hemorrhage. Report of 8 cases] Gómez Jiménez J, et al. **Actas Urol Esp** 1998 Sep;22(8):677–80 (Eng. Abstr.) **(Spa)**

BLOOD

Bleeding in a patient with lupus anticoagulant without associated hemostatic abnormalities. Wynn SS, et al.
Am J Hematol 1998 Nov;59(3):258–9

Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency. Ingerslev J, et al.
Blood Coagul Fibrinolysis 1998 Mar;9 Suppl 1:S129–34

High predictive value of red cell volume measurement using carboxy-haemoglobin in a rabbit model of haemorrhage. Obata H, et al. **Br J Anaesth** 1998 Dec;81(6):940–4

Clinical significance of lupus anticoagulants in children. Male C, et al. **J Pediatr** 1999 Feb;134(2):199–205

[Dynamics of lipid peroxidation and antioxidant system in patients with severe combined trauma] Andreev AA, et al. **Vopr Med Khim** 1998 Sep–Oct;44(5):485–93 (Eng. Abstr.) **(Rus)**

[Lipid peroxidation during enteral correction of experimental blood loss] Matveev SB, et al. **Vopr Med Khim** 1999 Mar–Apr;45(2):140–4 (Eng. Abstr.) **(Rus)**

[The phenomenon of endotoxicosis in patients with profuse hemorrhages studied by a bioassay method using an isolated preparation of the portal vein from a white rat] Ivashkevych HA, et al. **Fiziol Zh** 1999;45(3):74–8 (Eng. Abstr.) **(Ukr)**

CHEMICALLY INDUCED

Outcomes of anticoagulated trauma patients. Ferrera PC, et al. **Am J Emerg Med** 1999 Mar;17(2):154–6

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)

Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Meyer G, et al.
Am J Med 1998 Dec;105(6):472–7

Effects of nonsteroidal anti-inflammatory therapy on platelets. Schafer AI. **Am J Med** 1999 May 31; 106(5B):25S–36S (120 ref.)

Sublingual administration of all-trans-retinoic acid to a comatose patient with acute promyelocytic leukemia [letter] Kueh YK, et al. **Ann Pharmacother** 1999 Apr; 33(4):503–5

Commonly used medicinal herbs [letter] Eliason BC.
Arch Fam Med 1999 Sep–Oct;8(5):376

Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery [letter; comment] Ghosh A. **Arch Intern Med** 1999 Jul 26;159(14):1622–3. Comment on: Arch Intern Med 1999 Jan 25;159(2):137–41.

Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Gulløv AL, et al.
Arch Intern Med 1999 Jun 28;159(12):1322–8

Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Kuijer PM, et al.
Arch Intern Med 1999 Mar 8;159(5):457–60

Anticoagulation after valve replacement: a multicenter retrospective study. Kudo T, et al. **Artif Organs** 1999 Feb; 23(2):199–203

Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Panneerselvam S, et al.
Br J Haematol 1998 Nov;103(2):422–4

Spontaneous anticoagulant-induced testicular haemorrhage mimicking a testicular tumour [letter; comment] Costa ML, et al. **Br J Urol** 1998 Nov;82(5):775. Comment on: Br J Urol 1998 May;81(5):777.

Platypnea-orthodeoxia syndrome: etiology, differential diagnosis, and management [editorial; comment] Cheng TO. **Catheter Cardiovasc Interv** 1999 May;47(1):64–6. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):61–3.

Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone [see comments] Iskander S, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):61–3. Comment in: Catheter Cardiovasc Interv 1999 May;47(1):64–6.

A stuck pig—even on warfarin—doesn't always bleed [editorial; comment] Kitchens CS. **Chest** 1999 Jun; 115(6):1492–3 (6 ref.). Comment on: Chest 1999 Jun;115(6):1667–71.

Hemorrhagic complications of anticoagulant treatment. Levine MN, et al. **Chest** 1998 Nov;114(5 Suppl):511S–523S (138 ref.)

Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Madan M, et al.
Curr Opin Hematol 1999 Sep;6(5):334–41 (25 ref.)

Pulmonary haemorrhage in infants with gestational age of less than 30 weeks [letter] De Carolis MP, et al.
Eur J Pediatr 1998 Dec;157(12):1037–8

Hemorrhagic panesophagitis after acute organophosphorus poisoning. Koga H, et al. **Gastrointest Endosc** 1999 May; 49(5):642–3 (13 ref.)

Does protease inhibitor treatment induce increased bleeding tendency in haemophilia? [letter] Mandalaki T, et al.
Haemophilia 1998 Sep;4(5):766–7

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Stanworth SJ, et al.
Haemophilia 1998 Mar;4(2):109–14

Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. Houde JP, et al.
J Arthroplasty 1999 Apr;14(3):372–4

Determining the risk of bleeding in warfarin therapy. Ebell MH. **J Fam Pract** 1999 Jun;48(6):413

Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. Boysen G.
J Intern Med 1999 Sep;246(3):239–45 (16 ref.)

Extensive spontaneous retroperitoneal hemorrhage: an unusual complication of heparin anticoagulation during pregnancy. Sherer DM, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):196–9

Partial amino acid sequence and biological characterization of elegatoxin, hemorrhagic toxin from Trimeresurus elegans (Sakishimahabu) venom. Nikai T, et al.
J Nat Toxins 1999 Jun;8(2):189–202

Protein toxins produced by pathogenic vibrios. Shinoda S.
J Nat Toxins 1999 Jun;8(2):259–69 (78 ref.)

Cyclophosphamide induced hemorrhagic cystitis. Walker RD. **J Urol** 1999 Jun;161(6):1747

Thromboprophylaxis for atrial fibrillation [letter; comment] Dalton RG. **Lancet** 1999 Feb 27;353(9154):756. Comment on: Lancet 1999 Jan 2;353(9146):4–6. Comment on: Lancet 1999 May 8;353(9164):1620–1.

Thromboprophylaxis for atrial fibrillation [letter; comment] Lip GY. **Lancet** 1999 May 8;353(9164):1620–1. Comment on: Lancet 1999 Feb 27;353(9154):756.

Successful management of a child with asparaginase-induced hemorrhagic pancreatitis [letter] Lamelas RG, et al.
Med Pediatr Oncol 1999 Apr;32(4):316

Enoxaparin in neurosurgical patients [letter; comment] Connolly ES, et al. **N Engl J Med** 1998 Nov 26; 339(22):1639–40. Comment on: N Engl J Med 1998 Jul 9;339(2):80–5.

Abciximab and alveolar hemorrhage [letter; comment] Khanlou H, et al. **N Engl J Med** 1998 Dec 17; 339(25):1861–3. Comment on: N Engl J Med 1994 Apr 7;330(14):956–61. Comment on: N Engl J Med 1997 Jun 12;336(24):1689–96.

Haemorrhagic activity of neotropical rattlesnake (Crotalus vegrandis Klauber, 1941) venom. Rodriguez-Acosta A, et al. **Nat Toxins** 1998;6(1):15–8

Spontaneous retromammary haemorrhage during warfarin therapy. Routledge PA, et al. **Postgrad Med J** 1998 Jun; 74(872):347–8

The overdosed patient and bleedings with oral anticoagulation. Pindur G, et al. **Semin Thromb Hemost** 1999;25(1):85–8

Analysis and occurrence of adverse events with oral anticoagulant therapy. Schenk JF, et al.
Semin Thromb Hemost 1999;25(1):65–71

Complications of subcutaneous low-dose heparin therapy in neurosurgical patients. Wen DY, et al. **Surg Neurol** 1998 Dec;50(6):521–5

Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism [letter] Prandoni P, et al. **Thromb Haemost** 1999 Jul;82(1):158–9

Delayed acute toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD), after oral administration, Obeys Haber's rule of inhalation toxicology. Rozman KK. **Toxicol Sci** 1999 May;49(1):102–9

Altered hemostasis in male rats following administration of the ACAT inhibitor SKF-99085. Sellers T, et al.
Toxicol Sci 1998 Nov;46(1):151–4

Characterization of the local tissue damage induced by LHF-II, a metalloproteinase with weak hemorrhagic activity isolated from Lachesis muta muta snake venom. Rucavado A, et al. **Toxicon** 1999 Sep;37(9):1297–312

[Hemorrhage and thrombocytopenia caused by selective serotonin uptake inhibitors (SSRI)] Gram LF.
Ugeskr Laeger 1999 May 3;161(18):2697–8 **(Dan)**

[Hemorrhagic complications of antivitamin K. Report of 75 hospitalized patients] Constans J, et al. **J Mal Vasc** 1999 Jun;24(3):202–7 (Eng. Abstr.) **(Fre)**

[Anticoagulation in surgery, after hemorrhagic complications and in pregnancy] Gohlke-Bärwolf C. **Z Kardiol** 1998;87 Suppl 4:56–62 (41 ref.) (Eng. Abstr.) **(Ger)**

[Hemorrhagic complications of spinal and epidural analgesia (letter; comment)] Andreassen G.
Tidsskr Nor Laegeforen 1999 Jan 30;119(3):409–10. Comment on: Tidsskr Nor Laegeforen 1998 Jan 20;118(2):210–1. **(Nor)**

[The risk of hemorrhage in long-term use of aspirin and triflusal] Alvarez Sabin J, et al. **Rev Neurol** 1998 Dec; 27(160):951–5 (43 ref.) (Eng. Abstr.) **(Spa)**

[Hemorrhagic and edema-forming activity and histologic changes in the mouse footpad induced by venoms from Argentinian Bothrops and Crotalus genuses] Acosta de Pérez OC, et al. **Toxicon** 1998 Aug;36(8):1165–72 (Eng. Abstr.) **(Spa)**

[Survey of complications following treatment with anticoagulants. A computerized search for hemorrhagic complications completes manual reporting] Taghavi A, et al. **Lakartidningen** 1999 Aug 11;96(32–33):3421–4 **(Swe)**

COMPLICATIONS

Typical presentation of intramural aortic haemorrhage (IAH) with evidence of intimal tear at MRI and angiography. Radermecker MA, et al. **Acta Chir Belg** 1999 Feb; 99(1):44–6

Correction of hemorrhage-induced anemia with intra-amniotic iron in the ovine fetus. Brace RA, et al.
Am J Obstet Gynecol 1999 Jan;180(1 Pt 1):214–20

Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage. Talmor D, et al. **Anesth Analg** 1999 Oct;89(4):950–6

Dehydroepiandrosterone: an inexpensive steroid hormone that decreases the mortality due to sepsis following trauma-induced hemorrhage. Angele MK, et al.
Arch Surg 1998 Dec;133(12):1281–8

Mechanism of adrenal insufficiency following trauma and severe hemorrhage: role of hepatic 11beta-hydroxysteroid dehydrogenase. Wang P, et al. **Arch Surg** 1999 Apr; 134(4):394–401

Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Schnabel A, et al. **Eur Respir J** 1999 Jul;14(1):118–24

Issues of thrombosis and hemorrhagic events in patients with cancer. Frenkel EP, et al. **In Vivo** 1998 Nov–Dec; 12(6):625–8 (35 ref.)

Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323–8 (37 ref.)

Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995. Trevejo RT, et al.
J Infect Dis 1998 Nov;178(5):1457–63

Altered vasoconstrictor and dilator responses after a "two-hit" model of sequential hemorrhage and bacteremia. Price SA, et al. **J Surg Res** 1999 Jan;81(1):59–64

Bradycardia and hypotension associated with severe hemorrhage are reversed by morphine given centrally or peripherally in anesthetized rats. Ohnishi M, et al.
J Trauma 1998 Dec;45(6):1024–30

Re: The treatment of gross hematuria secondary to prostatic bleeding with finasteride [letter; comment] Sorrentino F, et al. **J Urol** 1998 Dec;160(6 Pt 1):2164. Comment on: J Urol 1998 Apr;159(4):1232–3.

Arteriovenous fistula of the thyroid gland associated with spontaneous bleeding from a flow-induced aneurysm of the inferior thyroid artery. Klingler PJ, et al.
Mayo Clin Proc 1999 May;74(5):485–8

Acute renal failure in Henoch-Schönlein purpura due to interstitial haemorrhage of the kidney. Costa de Beauregard MA, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2355–7

Pulmonary haemorrhage in a patient with idiopathic membranous nephropathy. Dienstl A, et al.
Nephrol Dial Transplant 1998 Jul;13(7):1815–7

A case of familial Mediterranean fever and polyarteritis nodosa complicated by spontaneous bilateral perirenal and subcapsular splenic haemorrhage [letter] Basaranoglu M, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):794–6

[Sheehan's syndrome: a recurrent obstetrical complication] Conreux F, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):430–5 (Eng. Abstr.) **(Fre)**

[Clinical results of surgical repair for thoracic aortic aneurysms: intraoperative blood loss and morbidity] Utoh J, et al. **Kyobu Geka** 1999 Aug;52(9):717–20; discussion 721–3 (Eng. Abstr.) **(Jpn)**

[Idiopathic interstitial pneumonia exacerbated by alveolar hemorrhage] Ashitani J, et al.
Nihon Kokyuki Gakkai Zasshi 1998 May;36(5):459–63 (Eng. Abstr.) **(Jpn)**

[Atypical case of retroperitoneal paraganglioma parasympaticum coexisting with recurrent bleeding from upper gastrointestinal tract] Witek R, et al.
Pol Merkuriusz Lek 1998 Apr;4(22):210–1 (Eng. Abstr.) **(Pol)**

[Hemorrhagic renal cysts—diagnostic and therapeutic approach] Marković N, et al. **Vojnosanit Pregl** 1998 Sep–Oct;55(5 Suppl):37–41 **(Scc)**

[Rectal hemorrhage as a first sign of renal cell adenocarcinoma] Ramírez Fabián M, et al.
Actas Urol Esp 1998 Jul–Aug;22(7):599–601 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MR imaging of a hemorrhagic and granulomatous cyst of

the ligamentum flavum with pathologic correlation. Mahallati H, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul; 20(6):1166–8

Spontaneous labyrinthine hemorrhage in sickle cell disease. Whitehead RE, et al. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1437–40

Methemoglobin suppression in T2–weighted pulse sequences: an adjunctive technique in MR imaging of hemorrhagic tumors. Chan JH, et al. **AJR Am J Roentgenol** 1999 Jul; 173(1):13–4

Emergency! Splenic injury. Abdominal assessment signs confirm acute bleeding. Salavec LM. **Am J Nurs** 1999 Sep; 99(9):32

Correlation of magnetic resonance imaging and intraoperative punctate bleeding to assess the vascularity of scaphoid nonunion. Günal I, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):285–7

Mycotoxins and pulmonary hemorrhage [letter; comment] Sudakin DL. **Arch Pediatr Adolesc Med** 1999 Feb; 153(2):205–6. Comment on: Arch Pediatr Adolesc Med 1998 Aug;152(8):757–62.

A case of coliform haemorrhagic cystitis presenting as a tumour of the bladder. Sangra MS, et al. **BJU Int** 1999 May;83(7):871–2

Mycobacterium tuberculosis infection masquerading as diffuse alveolar hemorrhage after autologous stem cell transplant. Keung YK, et al. **Bone Marrow Transplant** 1999 Apr;23(7):737–8

Pulmonary hemorrhage: imaging with a new magnetic resonance blood pool agent in conjunction with breathheld three–dimensional magnetic resonance angiography. Weishaupt D, et al. **Cardiovasc Intervent Radiol** 1999 Jul–Aug;22(4):321–5

A macrosomic newborn with a cystic adrenal mass. Zenker M, et al. **Eur J Pediatr** 1999 Mar;158(3):261–3

Acute generalized, widespread bleeding. Diagnosis and management. Rocha E, et al. **Haematologica** 1998 Nov; 83(11):1024–37 (194 ref.)

Haemophilia A: two cases showing unusual features at birth. Le Pommelet C, et al. **Haemophilia** 1998 Mar;4(2):122–5

Pseudosepsis secondary to bilateral adrenal hemorrhage. Gabbay DS, et al. **Heart Lung** 1998 Sep–Oct;27(5):348–51

Self–inflicted vaginal bleeding [letter] Levavi H, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):337–8

Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: four cases and a review. Sheikh RA, et al. **J Clin Gastroenterol** 1999 Jun;28(4):323–8 (37 ref.)

Spontaneous tonsillar hemorrhage: an underdiagnosed condition. Dawlatly EE, et al. **J Otolaryngol** 1998 Oct; 27(5):270–4

Posttraumatic hypertension secondary to adrenal hemorrhage mimicking pheochromocytoma: case report. Schmidt J, et al. **J Trauma** 1999 May;46(5):973–5

Acute and subacute liver–related hemorrhage: MRI findings. Balci NC, et al. **Magn Reson Imaging** 1999 Feb;17(2):207–11

Acute hemorrhage in chronic pancreatitis: diagnosis and treatment options including superselective microcoil embolization. Reber PU, et al. **Pancreas** 1999 May; 18(4):399–402

Acute hemorrhagic edema of childhood present at birth [letter; comment] Cunningham BB, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):68. Comment on: Pediatr Dermatol 1998 Mar–Apr;15(2):91–6.

Blood loss estimation by out–of–hospital emergency care providers. Moscati R, et al. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):239–42

Imaging of nontraumatic hemorrhage of the adrenal gland. Kawashima A, et al. **Radiographics** 1999 Jul–Aug; 19(4):949–63 (63 ref.)

Power spectral analysis of arterial and central venous pressure signals during graded hemorrhage in anesthetized rats. Shyr MH, et al. **Shock** 1999 Mar;11(3):187–92

Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Boberg KM, et al. **Thromb Haemost** 1999 Mar;81(3):378–81

[Diagnosis and monitoring of hemorrhage due to viper envenomation in the African savanna] Chippaux JP, et al. **Bull Soc Pathol Exot** 1999 May;92(2):109–13 (Eng. Abstr.) **(Fre)**

[Acute tumor of the lower eyelid caused by spontaneous hemorrhage of an occult vascular anomaly] Rohrbach JM, et al. **Klin Monatsbl Augenheilkd** 1998 Sep;213(3):186–7 (Eng. Abstr.) **(Ger)**

[Intramural hemorrhage of the thoracic aorta] Dieckmann C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):370–7 (Eng. Abstr.) **(Ger)**

[Leptospirosis (Weil's syndrome) with renal failure, severe jaundice, disseminated hemorrhages and xanthopsia] Fuchs W, et al. **Schweiz Med Wochenschr** 1999 Jun 5; 129(22):847–50 (Eng. Abstr.) **(Ger)**

[Intramural hemorrhage of the thoracic aorta: diagnosis, therapy and prognosis of 209 in vivo diagnosed cases] von Kodolitsch Y, et al. **Z Kardiol** 1998 Oct;87(10):797–807 (71 ref.) (Eng. Abstr.) **(Ger)**

[MPO–ANCA related diffuse alveolar hemorrhage] Ohnishi H, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Dec; 36(12):1017–22 (Eng. Abstr.) **(Jpn)**

[Rapid diagnosis in sero–hemorrhagic pleurisy] Smarandache M, et al. **Pneumoftiziologia** 1998 Jul–Sep;47(3):203–4 **(Rum)**

[Laparoscopic semeiotics: the diagnostic significance of a hemorrhagic exudate] Mishchenko NV. **Klin Khir** 1998; (9–10):51–2 (Eng. Abstr.) **(Rus)**

[Acute postoperative pancreatitis and hypertension of the pancreatic vascular system during hemorrhage in the course of the experiment] Uzhva VP. **Klin Khir** 1999; (5):42–4 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

L–Arginine restores splenocyte functions after trauma and hemorrhage potentially by improving splenic blood flow. Angele MK, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):C145–51

Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Lusher JM. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S111–4

Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. Petrini P, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S143–6

Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukaemia and acquired FVII deficiency [letter] White B, et al. **Br J Haematol** 1999 Jul;106(1):254–5

Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia [see comments] Heller S, et al. **Crit Care Med** 1999 Apr;27(4):756–63. Comment in: Crit Care Med 1999 Apr;27(4):681–3.

The effect of sympatholytics on uncontrolled hemorrhage [see comments] Rudé MJ, et al. **Crit Care Med** 1999 Sep; 27(9):1856–61. Comment in: Crit Care Med 1999 Sep;27(9):2045–6.

Dehydroepiandrosterone restores immune function following trauma–haemorrhage by a direct effect on T lymphocytes. Catania RA, et al. **Cytokine** 1999 Jun;11(6):443–50

Approaches towards successful home treatment in patients with inhibitors. Ingerslev J, et al. **Eur J Haematol Suppl** 1998;63:11–4

Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease [see comments] Gomez A, et al. **Haemophilia** 1998 Jan;4(1):60–2 . Comment in: Haemophilia 1998 Sep;4(5):767–8.

A randomized, double–blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Lusher JM, et al. **Haemophilia** 1998 Nov; 4(6):790–8

The use of fibrin glue as an operative sealant in dental extraction in bleeding disorder patients. Suwannuraks M, et al. **Haemophilia** 1999 Mar;5(2):106–8

Protective effect of anti–P–selectin monoclonal antibody in lipopolysaccharide–induced lung hemorrhage. Ohnishi M, et al. **Inflammation** 1999 Oct;23(5):461–9

The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin–dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit. Bernat A, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):573–9

Effect of a specific synthetic inhibitor of neutrophil elastase (ONO–5046) on the course of acute hemorrhagic pancreatitis in dogs. Imamura M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):422–8

Bactericidal/permeability–increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. Demetriades D, et al. **J Trauma** 1999 Apr;46(4):667–76; discussion 676–7

A prospective randomized double–blind trial of fibrin glue for pain and bleeding after tonsillectomy. Stoeckli SJ, et al. **Laryngoscope** 1999 Apr;109(4):652–5

Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia [letter] Blanche P, et al. **Leukemia** 1999 Aug; 13(8):1294

Does parenteral oestrogen therapy flare up disease activity in patients with systemic lupus erythematosus complicated by haemorrhagic cystitis? [letter] Yang LY, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):372–3

Prevention of the hemorrhagic hypotension–induced hepatic arterial vasoconstriction by L–arginine and naloxone. Benyó Z, et al. **Shock** 1999 May;11(5):342–6

Hemodynamic and metabolic responses to repeated hemorrhage and resuscitation with hypertonic saline dextran in conscious swine. O'Benar JD, et al. **Shock** 1998 Sep;10(3):223–8

Central and regional hemodynamics during uncontrolled bleeding using hypertonic saline dextran for resuscitation. Riddez L, et al. **Shock** 1998 Sep;10(3):176–81

Development of an anti–bleeding agent for recombinant hirudin induced skin bleeding in the pig. Dickneite G, et al. **Thromb Haemost** 1998 Jul;80(1):192–8

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, et al. **Thromb Haemost** 1998 Dec; 80(6):912–8

Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII [letter] Meijer K, et al. **Thromb Haemost** 1998 Jul;80(1):204–5

Recombinant factor VIIa in severe uremic bleeding [letter] Révész T, et al. **Thromb Haemost** 1998 Aug;80(2):353

DX–9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Tanabe K, et al. **Thromb Haemost** 1999 May;81(5):828–34

Neutralization of edema, hemorrhage and myonecrosis induced by North American crotalid venoms in simulated first–aid treatments. Evans J, et al. **Toxicon** 1999 Apr; 37(4):633–50

[Clinical observation on effect of xiaoyu zhixue tablet on 104 patients with idiopathic multifocal bleeding and platelet aggregation defect] Shen D, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 May; 17(5):280–2 (Eng. Abstr.) **(Chi)**

[Recombinant factor VIIa (eptacog alfa): a new therapeutic option for patients with severe bleeding disorder due to inhibitory antibodies against a coagulation factor] Turkstra F, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1464–7 (Eng. Abstr.) **(Dut)**

[A new treatment for hemorrhagic complications associated with severe liver disease?] Gruel Y, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul;22(6–7):652–4 **(Fre)**

[Intravesical instillation of Maalox for the treatment of bladder hemorrhage due to prostate cancer invasion: report of two cases] Hongo F, et al. **Hinyokika Kiyo** 1999 May; 45(5):367–9 (Eng. Abstr.) **(Jpn)**

ECONOMICS

The economic impact of esophageal variceal hemorrhage: cost–effectiveness implications of endoscopic therapy. Gralnek IM, et al. **Hepatology** 1999 Jan;29(1):44–50

ENZYMOLOGY

Alpha 2–adrenoceptor activation may trigger the increased production of endothelium–derived nitric oxide in skeletal muscle during acute haemorrhage. Ekelund U, et al. **Acta Physiol Scand** 1998 Nov;164(3):285–92

Snake venom hemorrhagins. Hati R, et al. **Crit Rev Toxicol** 1999 Jan;29(1):1–19 (142 ref.)

Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Pérez JC, et al. **Toxicon** 1999 May;37(5):703–28 (116 ref.)

EPIDEMIOLOGY

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Sundlof DW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1569–71, A7

Percutaneous renal biopsy in the 1990s: safety, value, and implications for early hospital discharge. Khajehdehi P, et al. **Am J Kidney Dis** 1999 Jul;34(1):92–7

Vitamin K deficiency bleeding in Thailand: a 32–year history. Chuansumrit A, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):649–54

[The risk of hemorrhage in long–term use of aspirin and triflusal] Alvarez Sabin J, et al. **Rev Neurol** 1998 Dec; 27(160):951–5 (43 ref.) (Eng. Abstr.) **(Spa)**

[Hemorrhagic complications from anticoagulant treatment: analysis of predictive risk factors] Vázquez Ruiz de Castroviejo E, et al. **Sangre (Barc)** 1999 Jun;44(3):216–21 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Hemorrhage from recanalized umbilical vein in a patient with cirrhosis. Lewis CP, et al. **Am J Gastroenterol** 1999 Jan; 94(1):280

Retroperitoneal hemorrhage after diagnostic colonoscopy: an unusual complication [letter] Yoshimura H, et al. **Am J Gastroenterol** 1999 Jul;94(7):1992–3

Bleeding in a patient with lupus anticoagulant without associated hemostatic abnormalities. Wynn SS, et al. **Am J Hematol** 1998 Nov;59(3):258–9

A 12–year–old girl with pulmonary hemorrhage, skin lesions, and hematuria. Paueksakon P, et al. **Am J Kidney Dis** 1999 Feb;33(2):404–9 (13 ref.)

Vitamin K deficiency with hemorrhage after kidney and combined kidney–pancreas transplantation. Prasad GV, et al. **Am J Kidney Dis** 1999 May;33(5):963–5

Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Quaknine–Orlando B, et al. **Anesthesiology** 1999 May;90(5):1454–61

Haemorrhagic complications of pancreatitis: presentation, diagnosis and management. Ammori BJ, et al. **Ann R Coll Surg Engl** 1998 Sep;80(5):316–25

Unavoidable outcomes vs misadventures. Autopsy Committee of the College of American Pathologists. Davis A, et al. **Arch Intern Med** 1999 Apr 12;159(7):646–7

The adenovirus that causes hemorrhagic disease of black–tailed deer is closely related to bovine adenovirus–3. Lapointe JM, et al. **Arch Virol** 1999;144(2):393–6

Severe pulmonary hemorrhage in the premature newborn infant: analysis of presurfactant and surfactant eras. Braun KR, et al. **Biol Neonate** 1999;75(1):18–30

Vaginal bleeding as a presentation of metastatic renal cell carcinoma. Abraham R, et al. **BJU Int** 1999 Aug; 84(3):384–5

High incidence of adeno– and polyomavirus–induced hemorrhagic cystitis in bone marrow allotransplantation

for hematological malignancy following T cell depletion and cyclosporine. Childs R, et al. **Bone Marrow Transplant** 1998 Nov;22(9):889–93

Risk factors for severe hemorrhagic cystitis following BMT. Seber A, et al. **Bone Marrow Transplant** 1999 Jan; 23(1):35–40

Sub-aponeurotic haemorrhage: a rare but life-threatening neonatal complication associated with ventouse delivery. Fortune PM, et al. **Br J Obstet Gynaecol** 1999 Aug; 106(8):868–70

Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: major thromboembolic and hemorrhagic complications. Jamieson WR, et al. **Can J Surg** 1999 Feb; 42(1):27–36

Pulmonary hemorrhage in factor V deficiency (letter). Satoh H, et al. **Can Respir J** 1999 Jul–Aug;6(4):320

Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosis: a clinicopathologic report of four cases. Würthner JU, et al. **Cancer** 1999 Jan 15; 85(2):368–74

Delayed esophageal hemorrhage caused by a metal stent: treatment with embolization. Kos X, et al. **Cardiovasc Intervent Radiol** 1998 Sep–Oct;21(5):428–30

Severe envenomation by a "pet" vine snake. Muguti GI, et al. **Cent Afr J Med** 1998 Sep;44(9):232–4

Negative pressure pulmonary hemorrhage. Schwartz DR, et al. **Chest** 1999 Apr;115(4):1194–7

Metastatic hepatocellular carcinoma presenting as hemocholecyst with perforation: a case report. Chang KM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):613–8

Onychomatricoma: an unusual cause of nail bleeding [letter] Raison-Peyron N, et al. **Clin Exp Dermatol** 1998 May; 23(3):138

Severe pulmonary hemorrhage in patients with serious group A streptococcal infections: report of two cases. Ooe K, et al. **Clin Infect Dis** 1999 Jun;28(6):1317–9

Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis. Stanback J, et al. **Contraception** 1998 Dec; 58(6):357–60

Bleeding and thrombosis in myeloproliferative disorders. Landolfi R. **Curr Opin Hematol** 1998 Sep;5(5):327–31 (33 ref.)

Hemorrhagic necrosis due to peliosis hepatis: imaging findings and pathological correlation. Vignaux O, et al. **Eur Radiol** 1999;9(3):454–6

Bronchoscopy with transbronchial biopsies: measurement of bleeding volume and evaluation of the predictive value of coagulation tests. Bjørtuft O, et al. **Eur Respir J** 1998 Nov; 12(5):1025–7

Exsanguination from impact head trauma; the explanation for the "empty heart" sign. Contostavlos DL. **Forensic Sci Int** 1998 Aug 12;95(3):201–12

A woman who bled after a decade of dyspnoea. Robertson NJ, et al. **Gut** 1999 Aug;45(2):310

Bleeding problems in factor XI deficient women. Bolton-Maggs PH. **Haemophilia** 1999 May;5(3):155–9 (28 ref.)

Acute hemorrhage into the peritoneal cavity--a complication of chronic pancreatitis with pseudocyst: a case report from clinical practice. Skok P, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):518–21

Peliosis of spleen presenting as splenic rupture with haemoperitoneum--a case report. Rege JD, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):465–7

Life-threatening bleeding in a case of autoantibody-induced factor VII deficiency. Okajima K, et al. **Int J Hematol** 1999 Feb;69(2):129–32

Bilateral haemorrhagic tuberculous pleuritis in an 81-year-old female [letter] Papamichalopoulos A, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):456

Central venous cannulation in patients with liver disease and coagulopathy--a prospective audit. Fisher NC, et al. **Intensive Care Med** 1999 May;25(5):481–5

Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus-related mixed cryoglobulinemia. Gómez-Tello V, et al. **Intensive Care Med** 1999 Mar; 25(3):319–22

Arterial bleeding after biliary drainage catheter placement: diagnosis and treatment. Maleux G, et al. **J Belge Radiol** 1998 Aug;81(4):176–7

Bleeding from a pulmonary artery catheter temperature connection port. Kodavatiganti R, et al. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):75–7

Effect of pressure distribution of shockwave on renal hemorrhage after extracorporeal shockwave lithotripsy: comparison of EDAP LT-01 and Siemens Lithostar. Momose A, et al. **J Endourol** 1999 Apr;13(3):165–71

Peliosis hepatis with initial presentation as acute hepatic failure and intraperitoneal hemorrhage in children. Jacquemin E, et al. **J Hepatol** 1999 Jun;30(6):1146–50

Massive pulmonary haemorrhage caused by leptospirosis successfully treated with nitric oxide inhalation and haemofiltration. Borer A, et al. **J Infect** 1999 Jan;38(1):42–5

An aneurysm of the petrous internal carotid artery. Reece PH, et al. **J Laryngol Otol** 1999 Jan;113(1):55–7

Spontaneous tonsillar hemorrhage: an underdiagnosed condition. Dawlatly EE, et al. **J Otolaryngol** 1998 Oct; 27(5):270–4

Palliative management of bleeding events in advanced cancer patients. Gagnon B, et al. **J Palliat Care** 1998 Winter; 14(4):50–4

Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature [see comments] Kulkarni R, et al. **J Pediatr Hematol Oncol** 1999 Jul–Aug; 21(4):289–95 (41 ref.). Comment in: J Pediatr Hematol Oncol 1999 Jul–Aug;21(4):254–6.

Delayed hemorrhage after nonoperative management of blunt hepatic trauma in children: a rare but significant event. Shilyansky J, et al. **J Pediatr Surg** 1999 Jan;34(1):60–4

Central venous line disconnections with associated blood loss. Savage M, et al. **J Qual Clin Pract** 1998 Sep;18(3):213–5

Nipple discharge in a teenager. Mudan SS, et al. **J R Soc Med** 1998 Sep;91(9):490–1

Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment. Gertner E. **J Rheumatol** 1999 Apr;26(4):805–7

Successful simultaneously stapled lobectomy for a stab wound to the lung with massive hemorrhage: case report. Kaseda S, et al. **J Trauma** 1999 Jun;46(6):1140–1

Renal cell carcinoma presenting as vaginal bleeding. Bouyounes BT, et al. **J Urol** 1998 Nov;160(5):1797

Drainage vein of left renal cell carcinoma communicating with inferior mesenteric vein. Inoue Y, et al. **J Urol** 1999 May;161(5):1562

Massive prostatic bleeding after transurethral resection of the prostate in a patient with a congenital pelvic arteriovenous malformation. Touyama H, et al. **J Urol** 1998 Nov;160(5):1803 (3 ref.)

A case study and national database report of progressive systemic sclerosis and associated conditions. Phillips D, et al. **J Womens Health** 1998 Nov;7(9):1099–104 (13 ref.)

Trigeminal neurinoma presenting as intratumoral hemorrhage--case report. Lieu AS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Mar; 14(3):181–5 (15 ref.)

Deaths related to liposuction [letter] Talmor M, et al. **N Engl J Med** 1999 Sep 23;341(13):1001; discussion 1002–3

Renal papillary necrosis in a marathon runner [letter] Ducloux D, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):247–8

Bleeding after renal biopsy resulting from a persisting left cardinal vein. Meola M, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):185–6

Traumatic epidural hematoma of the cervical spine: magnetic resonance imaging diagnosis and spontaneous resolution: case report. Lefranc F, et al. **Neurosurgery** 1999 Feb; 44(2):408–10; discussion 410–1

Masked bleeding posttonsillectomy with ondansetron [letter] Courtman SP, et al. **Paediatr Anaesth** 1999;9(5):467

Henoch-Schönlein purpura and pulmonary hemorrhage: a report and literature review. Vats KR, et al. **Pediatr Nephrol** 1999 Aug;13(6):530–4 (23 ref.)

Imaging of nontraumatic hemorrhage of the adrenal gland. Kawashima A, et al. **Radiographics** 1999 Jul–Aug; 19(4):949–63 (63 ref.)

Neuraxial bleeding: fibrinolytics/thrombolytics. Rosenquist RW, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6 Suppl 2):152–6

Massive pulmonary hemorrhage due to cytomegalovirus infection in a Japanese patient with alpha-1-antitrypsin-deficient emphysema. Tsushima K, et al. **Respiration** 1999;66(4):373–6

Spontaneous subcapsular or perirenal haemorrhage caused by renal tumours. A urological emergency. Hellström PA, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):17–23

Vitamin K deficiency bleeding in Thailand: a 32-year history. Chuansumrit A, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):649–54

Evolving magnetic resonance spinal cord trauma in child: from hemorrhage to intradural arachnoid cyst. Fobe JL, et al. **Spinal Cord** 1998 Dec;36(12):864–6

Retroperitoneal hemorrhage after cardiac catheterization causing a diagnostic dilemma. Goenka P, et al. **Tenn Med** 1998 Dec;91(12):461–2

Intrapleural streptokinase [letter] Porter J, et al. **Thorax** 1998 Aug;53(8):720

Fatal haemorrhage from Dieulafoy's disease of the bronchus. van der Werf TS, et al. **Thorax** 1999 Feb;54(2):184–5

Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Boberg KM, et al. **Thromb Haemost** 1999 Mar;81(3):378–81

Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Nevo S, et al. **Transplantation** 1999 Mar 15; 67(5):681–9

Acoustic cavitation and capillary bleeding. **Ultraschall Med** 1999 Jun;20(3):124–5 (10 ref.)

[Spontaneous rupture of the kidney with perirenal hemorrhage in undiagnosed polyarteritis nodosa] Johansen M, et al. **Ugeskr Laeger** 1999 May 3;161(18):2680–1 (Eng. Abstr.) **(Dan)**

[Double hemorrhagic complication of endo-urologic drainage in single kidney] Slaba S, et al. **Ann Urol (Paris)** 1999;33(1):15–8 (Eng. Abstr.) **(Fre)**

[A new treatment for hemorrhagic complications associated with severe liver disease?] Gruel Y, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul;22(6–7):652–4 **(Fre)**

[Validity of a test for diagnosis and monitoring of hemorrhagic syndrome after viper envenomation in sub-saharan Africa] Chippaux JP, et al. **Med Trop (Mars)** 1998;58(4):369–71 (Eng. Abstr.) **(Fre)**

[Hemorrhagic mandibular metastasis of renal origin: usefulness of therapeutic embolization] Guyot L, et al. **Presse Med** 1999 Jun 5;28(20):1066–8 (Eng. Abstr.) **(Fre)**

[Hemorrhagic complications during percutaneous nephrolithotomy. Retrospective studies of 772 cases] Gremmo E, et al. **Prog Urol** 1999 Jun;9(3):460–3 (Eng. Abstr.) **(Fre)**

[Systematic evaluation of hemostasis before a bronchoscopy--against] Febvre M. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S69–70 **(Fre)**

[Systematic evaluation of hemostasis before a bronchoscopy--for] L'Huillier JP. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S68–9 **(Fre)**

[Hemorrhage during the first pregnancy trimester. Diagnostic assessment] Dreyfus M, et al. **Rev Prat** 1998 Oct 15; 48(16):1831–3 **(Fre)**

[Horizontal deceleration trauma with diffuse decollement bleeding--a casuistry] Denz C, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Feb; 34(2):105–9 (Eng. Abstr.) **(Ger)**

[Death due to liver hemorrhage after infarct lysis] La Rosee K, et al. **Dtsch Med Wochenschr** 1999 Jun 11;124(23):746–7 **(Ger)**

[The bleeding risk of arterial puncture during anticoagulation] Schieber M, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):441 **(Ger)**

[Variations in the course of the internal carotid artery: possible risks in so-called standard operations in the area of the pharynx] Schumacher WA, et al. **Laryngorhinootologie** 1998 Sep;77(9):517–20 (Eng. Abstr.) **(Ger)**

[Diagnostic and therapeutic problems of sponaneous retroperitoneal hematoma] Temes G, et al. **Orv Hetil** 1998 Oct 4;139(40):2369–71 (Eng. Abstr.) **(Hun)**

[Massive mediastinal bleeding due to spontaneous rupture of the vertebral artery in von Recklinghausen disease] Magara T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep; 46(9):906–9 (Eng. Abstr.) **(Jpn)**

[The maximum safe dosage of the low molecular weight hydroxyethyl starch, HESPANDAR (HES), estimated from HES induced changes in coagulation parameters and clinical bleeding] Saito Y, et al. **Masui** 1999 Mar; 48(3):238–43 (Eng. Abstr.) **(Jpn)**

[Perihilar interstitial bleeding due to thoracic endometriosis] Hoshino H, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul; 36(7):647–51 (Eng. Abstr.) **(Jpn)**

[Case of cystic hemorrhage probably due to rupture of pseudoaneurysm of the gallbladder (letter] Suzuki M. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1165 **(Jpn)**

[Bleeding due to vitamin K deficiency] Ootsuka H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):525–8 (10 ref.) **(Jpn)**

[Hemorrhagic complications in spinal and epidural analgesia (letter)] Andreassen G. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):83–4 **(Nor)**

[Massive hemorrhage into the cavity of giant common bile duct cyst after transcutaneous transhepatic cholangiostomy] Vishnevskii VA, et al. **Khirurgiia (Mosk)** 1998;(11):59–61 **(Rus)**

[The incidence of the perforative bleeding ulcer of the duodenum in a combination with pancreatic necrosis] Krivoruchko IA, et al. **Klin Khir** 1998;(8):48–9 **(Rus)**

[Aspects of excision of the perforative duodenal ulcer complicated by penetration and stenosis] Veligotskii NN, et al. **Klin Khir** 1998;(8):4–7 (Eng. Abstr.) **(Rus)**

[The meaning of duodenostasis in the intestinal phase gastric secretion disorders in bleeding duodenal ulcer] Zaitsev VT, et al. **Klin Khir** 1999;(3):5–6 (Eng. Abstr.) **(Rus)**

[Odontogenic total mediastinitis complicated by an arrosive hemorrhage from the major vessels of the neck] Vol'fovskii VZ, et al. **Vestn Khir Im I I Grek** 1998;157(3):82–3 **(Rus)**

[Acute lung injury as initial manifestation of diffuse alveolar hemorrhage] Fernández Fabrellas E, et al. **An Med Interna** 1999 Jun;16(6):281–4 (Eng. Abstr.) **(Spa)**

[Hemorrhagic prostatic cyst following ultrasound guided biopsy. A case report] Herranz Amo F, et al. **Arch Esp Urol** 1999 May;52(4):379–80 (Eng. Abstr.) **(Spa)**

[39-year-old male with rectal bleeding, prominent formations in the colon and perforation after colonoscopy] Sans M, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):70–6 **(Spa)**

[Clinical-statistical prognosis of gastroduodenal erosion and ulcer incidence after surgical treatment of inflammatory disease of hepato-biliary tract] Koval' AI, et al. **Klin Khir** 1998;(8):10–2 (Eng. Abstr.) **(Ukr)**

GENETICS

Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Santoro SA. **Blood** 1999 Jun 1;93(11):3575–7 (32 ref.)

Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Poort SR, et al. **Blood Coagul Fibrinolysis** 1998 Nov;9(8):761–4

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [see comments] Aithal GP, et al.

Lancet 1999 Feb 27;353(9154):717–9. Comment in: Lancet 1999 Feb 27;353(9154):688–9. Comment in: Lancet 1999 Jun 5;353(9168):1972–3.

Genetic control of anticoagulation [comment] Mannucci PM. **Lancet** 1999 Feb 27;353(9154):688–9. Comment on: Lancet 1999 Feb 27;353(9154):717–9.

IMMUNOLOGY

Does uninjured skin release proinflammatory cytokines following trauma and hemorrhage? Catania RA, et al. **Arch Surg** 1999 Apr;134(4):368–73; discussion 373–4

Neutrophil apoptosis in the lung after hemorrhage or endotoxemia: apoptosis and migration are independent of IL-1beta. Parsey MV, et al. **Clin Immunol** 1999 May; 91(2):219–25

Autoantibodies to coagulation factors and bleeding disorders. Ahmed AE. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):313–9 (20 ref.)

Peliosis of the spleen: an immune-complex disease? Gugger M, et al. **Histopathology** 1998 Oct;33(4):387–9

Sublethal hemorrhage blunts the inflammatory cytokine response to endotoxin in a rat model. Zervos EE, et al. **J Trauma** 1999 Jan;46(1):145–9

Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia [letter] Blanche P, et al. **Leukemia** 1999 Aug; 13(8):1294

[ANCA-associated lung hemorrhage] Díaz Alcázar F, et al. **Rev Clin Esp** 1999 Mar;199(3):147–9 (14 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Sex steroids regulate pro- and anti-inflammatory cytokine release by macrophages after trauma-hemorrhage. Angele MK, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):C35–42

Proteasome participates in the alteration of signal transduction in T and B lymphocytes following trauma-hemorrhage. Samy TS, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):92–104

Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-kappa B, and cyclic AMP response element binding protein. Shenkar R, et al. **J Immunol** 1999 Jul 15; 163(2):954–62

Expression of brain-derived neurotrophic factor in catecholaminergic neurons of the rat lower brainstem after colchicine treatment or hemorrhage. Cho HJ, et al. **Neuroscience** 1999;92(3):901–9

Trauma-hemorrhage delays wound healing potentially by increasing pro-inflammatory cytokines at the wound site. Angele MK, et al. **Surgery** 1999 Aug;126(2):279–85

[Oxygen free radical on interleukin-1 activity of hemorrhage/resuscitation rat] Shi H, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):601–3 (Eng. Abstr.) **(Chi)**

[Effects of hypertonic lactated Ringer's solution on hepatic ATP and L/P ratio in rats subjected to acute hemorrhage] Ikeya K, et al. **Masui** 1998 Dec;47(12):1422–6 (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Hemorrhage exacerbates bacterial translocation at low levels of intra-abdominal pressure. Gargiulo NJ 3rd, et al. **Arch Surg** 1998 Dec;133(12):1351–5

Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia [see comments] Heller S, et al. **Crit Care Med** 1999 Apr;27(4):756–63. Comment in: Crit Care Med 1999 Apr;27(4):681–3.

Adrenal hemorrhage associated with Klebsiella oxytoca bacteremia. Hori K, et al. **Intern Med** 1998 Nov; 37(11):990–4

NURSING

Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. SANDBAG Nursing Coordinators. Standards of Angioplasty Nursing Techniques to Diminish Bleeding Around the Groin. Juran NB, et al. **Am J Crit Care** 1999 Sep;8(5):303–13

PATHOLOGY

Problems in the interpretation of hemorrhage into neck musculature in cases of drowning. Carter N, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):223–5

Recurrent oral blood blisters. Domínguez JD, et al. **Arch Dermatol** 1999 May;135(5):593–4, 596–7

Bullous and hemorrhagic lesions. Gomez-Calcerrada MR, et al. **Arch Dermatol** 1999 Jan;135(1):81–6

Coagulative necrosis: the forgotten way to die. Jones GR. **Biochem Soc Trans** 1998 Nov;26(4):S321

Neutrophil apoptosis in the lung after hemorrhage or endotoxemia: apoptosis and migration are independent of interleukin-1beta. Parsey MV, et al. **Chest** 1999 Jul;116(1 Suppl):67S–68S

Pheochromocytoma arising from an accessory adrenal gland in a patient with multiple endocrine neoplasia type 2A: transient development of clinical manifestations after hemorrhagic necrosis. Katai M, et al. **Endocr J** 1998 Jun; 45(3):329–34

Haemorrhages in the posterior cricoarytenoid muscles--an unspecific autopsy finding. Keil W, et al. **Forensic Sci Int** 1998 Aug 12;95(3):225–30

Macromorphology and histology of intramuscular hemorrhages in cases of drowning. Püschel K, et al. **Int J Legal Med** 1999;112(2):101–6

Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. Clements JL, et al. **J Clin Invest** 1999 Jan;103(1):19–25

Intraepithelial haemorrhage of the oesophagus: a terminal event in haematological disorders. Shimizu M, et al. **J Clin Pathol** 1998 Nov;51(11):838–41

Conus medullaris hematomyelia associated with an intradural-extramedullary cavernous angioma. Mastronardi L, et al. **Spinal Cord** 1999 Jan;37(1):68–70

Adrenal hemorrhage diagnosed by ultrasonically-guided biopsy. Ochiai A, et al. **Urol Int** 1998;61(4):257–60

[Intranodal hemorrhagic spindle cell tumor] Grantcharov TP, et al. **Ugeskr Laeger** 1998 Dec 7;160(50):7273–4 (Eng. Abstr.) **(Dan)**

[DNA-endonucleolysis in cell nuclei of brain and liver in patients dying from hemorrhage and after resuscitation: general patterns and differences] Kozhura VL, et al. **Patol Fiziol Eksp Ter** 1999 Apr-Jun;(2):5–7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats. Ang KK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1552–8

Hemodynamic and hormonal responses to hemorrhage in conscious rabbits at mid- and late gestation. Brooks VL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1082–90

Regional conductance changes during hemorrhage in pregnant and nonpregnant conscious rabbits. Brooks VL, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R675–81

Role of nitric oxide in regulation of renal sympathetic nerve activity during hemorrhage in conscious rats. Fujisawa Y, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H8–14

Role of central AT1 and V1 receptors in cardiovascular adaptation to hemorrhage in SD and renin TGR rats. Paczwa P, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1918–26

Arterial baroreceptors control blood pressure and vasopressin responses to hemorrhage in conscious dogs. Thrasher TN, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1843–57

Uncompensated blood loss is not tolerated during acute normovolemic hemodilution in anesthetized pigs [see comments] Schou H, et al. **Anesth Analg** 1998 Oct; 87(4):786–94. Comment in: Anesth Analg 1999 Aug;89(2):532–3.

Normovolemic hemodilution and acute hemorrhage [letter; comment] Van der Linden P, et al. **Anesth Analg** 1999 Aug; 89(2):532–3. Comment on: Anesth Analg 1998 Oct;87(4):786–94.

The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide on renal tissue injury of rats exposed to hemorrhagic ischemia and retransfusion: a possible interaction mechanism among mast cells and tissue histamine. Erden SH, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:570–81

Differential recruitment of hypothalamic neuroendocrine and ventrolateral medulla catecholamine cells by non-hypotensive and hypotensive hemorrhages. Buller KM, et al. **Brain Res** 1999 Jul 10;834(1-2):42–54

Differential time- and dose-related effects of haemorrhage on tyrosine hydroxylase and neuropeptide Y mRNA expression in medullary catecholamine neurons. Chan RK, et al. **Eur J Neurosci** 1998 Dec;10(12):3747–58

Early hemodynamic changes during uncontrolled intra-abdominal bleeding. Riddez L, et al. **Eur Surg Res** 1999;31(1):19–25

Acid-base disturbance during hemorrhage in rats: significant role of strong inorganic ions. Alfaro V, et al. **J Appl Physiol** 1999 May;86(5):1617–25

Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. Winslow RM, et al. **J Appl Physiol** 1998 Sep;85(3):993–1003

Haemorrhage increases the pressor effect of angiotensin-(1-7) but not of angiotensin II at the rat rostral ventrolateral medulla. Lima DX, et al. **J Hypertens** 1999 Aug;17(8):1145–52

Effects of thalamic hemorrhage on cortical hemodynamic parameters assessed by perfusion MR imaging: preliminary report. Berthezène Y, et al. **J Neurol Sci** 1998 Apr 15; 157(1):67–72

Preserved arterial flow secures hepatic oxygenation during haemorrhage in the pig. Rasmussen A, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):539–48

Induction of tolerance to hemorrhagic or endotoxic shock involves activation of NF-kappaB. Kramer AA, et al. **J Surg Res** 1999 May 15;83(2):89–94

Thermal filament continuous thermodilution cardiac output delayed response limits its value during acute hemodynamic instability. Poli de Figueiredo LF, et al. **J Trauma** 1999 Aug;47(2):288–93

Effect of L-arginine on adrenal and renal blood flows during hemorrhage in cats. Benyó Z, et al. **Kidney Int Suppl** 1998 Sep;67:S221–3

The effect of sennosides on bacterial translocation and survival in a model of acute hemorrhagic pancreatitis. Chen X, et al. **Pancreas** 1999 Jan;18(1):39–46

Quantification of blood volume by electrical impedance tomography using a tissue-equivalent phantom. Sadleir R, et al. **Physiol Meas** 1998 Nov;19(4):501–16

Bleeding induced interleukin-6 decreases blood loss via activation of coagulation. Katsuyama I, et al. **Shock** 1999 Feb;11(2):87–92

[Hemorrhage exerts different effects on variabilities of heart rate and blood pressure in dogs] Kawase M, et al. **Masui** 1998 Aug;47(8):925–32 (Eng. Abstr.) **(Jpn)**

[Effects of pentobarbital on coronary and cerebral circulation and metabolism in dogs subjected to hemorrhage] Matsumoto Y, et al. **Masui** 1999 Apr;48(4):356–61 (Eng. Abstr.) **(Jpn)**

[Individual resistance of the cardiovascular system to acute hemorrhage] Kovalenko NIa, et al. **Anesteziol Reanimatol** 1999 Jan-Feb;(1):51–4 (Eng. Abstr.) **(Rus)**

[Central hemodynamics in rats with various resistivity to acute hemorrhage] Kovalenko NIa, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):384–8 **(Rus)**

[Effect of mesodiencephalic modulation on the spike electric activity of the rat small intestine during massive hemorrhage] Tropskaia NS, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):377–9 **(Rus)**

[Hemocoagulation while dying of blood loss and restoration to life after clinical death] Iakovleva NE, et al. **Patol Fiziol Eksp Ter** 1999 Apr-Jun;(2):26–8 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

A novel vascular sealing device for closure of percutaneous arterial access sites. Silber S, et al. **Am J Cardiol** 1999 Apr 15;83(8):1248–52

Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. SANDBAG Nursing Coordinators. Standards of Angioplasty Nursing Techniques to Diminish Bleeding Around the Groin. Juran NB, et al. **Am J Crit Care** 1999 Sep;8(5):303–13

Prevention of first variceal bleed: an appraisal of current therapies. Shahi HM, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2348–58 (95 ref.)

Prolonged bleeding from epidural catheterisation reconsidered [letter] Cohen S, et al. **Anaesthesia** 1999 Jul; 54(7):719

The vitamin K debacle: cut the Gordian knot but first do no harm. Tripp JH, et al. **Arch Dis Child** 1998 Oct; 79(4):295–7

Delivery system for targeted thrombolysis without the risk of hemorrhage. Byun Y, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M638–41

Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Federici AB, et al. **Blood** 1998 Oct 15;92(8):2707–11

Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Nitu IC, et al. **Clin Lab Haematol** 1998 Dec;20(6):363–7

Prophylactic platelet transfusion in acute leukemia: which threshold should be used [editorial; comment] Finazzi G. **Haematologica** 1998 Nov;83(11):961–2. Comment on: Haematologica 1998 Nov;83(11):998–1000.

Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Navarro JT, et al. **Haematologica** 1998 Nov;83(11):998–1000

Haemophilia and advanced fibrin sealant technologies. Tock B, et al. **Haemophilia** 1998 Jul;4(4):449–55 (30 ref.)

The effect of pressure bandaging on complications and comfort in patients undergoing coronary angiography: a multicenter randomized trial. Botti M, et al. **Heart Lung** 1998 Nov-Dec;27(6):360–73

Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonist. Bernat A, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):897–904

Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. Cannegieter SC, et al. **J Intern Med** 1999 Apr;245(4):369–74 (34 ref.)

Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. Miners AH, et al. **J Intern Med** 1998 Dec;244(6):515–22

Effect of dry fibrin sealant dressings versus gauze packing on blood loss in grade V liver injuries in resuscitated swine. Holcomb JB, et al. **J Trauma** 1999 Jan;46(1):49–57

Use of fibrin sealant to reduce bleeding after needle liver biopsy in an anticoagulated canine model: work in progress. Falstrom JK, et al. **J Vasc Interv Radiol** 1999 Apr; 10(4):457–62

Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Palsson R, et al. **Kidney Int** 1999 May; 55(5):1991–7

Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits [see comments] Levi M, et al. **Nat Med** 1999 Jan;5(1):107–11. Comment in: Nat Med 1999 Jan;5(1):17–8.

No indication for APTT screening in patients on oral anticoagulant therapy. van der Meer FJ, et al. **Thromb Haemost** 1999 Mar;81(3):364–6

[Systematic evaluation of hemostasis before a

bronchoscopy--against] Febvre M. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S69-70 **(Fre)**

[Systematic evaluation of hemostasis before a bronchoscopy--for] L'Huillier JP. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S68-9 **(Fre)**

[Extracorporeal shock wave lithotripsy in patients with coagulopathies: report of three cases] Onishi T, et al. **Hinyokika Kiyo** 1998 Sep;44(9):657-60 (Eng. Abstr.) **(Jpn)**

[Usefulness of cryoapplication for bleeding after needle biopsy during fiberoptic bronchoscopy] Ziora D, et al. **Pneumonol Alergol Pol** 1997;65(11-12):749-53 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

CT assessment of abdominal hemorrhage in coagulopathic patients: impact on clinical management. Nazarian LN, et al. **Abdom Imaging** 1999 May-Jun;24(3):246-9

Renal hemorrhage in polyarteritis nodosa: diagnosis and management. Chandrakantan A, et al. **Am J Kidney Dis** 1999 Jun;33(6):e8

Congenital bilateral cystic neuroblastoma with liver metastases and massive intracystic haemorrhage. Lee SY, et al. **Br J Radiol** 1998 Nov;71(851):1205-7

Management of bleeding pseudoaneurysms in patients with pancreatitis. de Perrot M, et al. **Br J Surg** 1999 Jan; 86(1):29-32

Intestinal and peritoneal bleeding: detection with an intravascular contrast agent and fast three-dimensional MR imaging--preliminary experience from an experimental study. Hilfiker PR, et al. **Radiology** 1998 Dec;209(3):769-74

Unenhanced CT of abdominal and pelvic hemorrhage. Katz DS, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):94-107 (56 ref.)

Retroperitoneal hemorrhage after cardiac catheterization causing a diagnostic dilemma. Goenka P, et al. **Tenn Med** 1998 Dec;91(12):461-2

[Aneurysmal hemorrhage as a complication of paracentesis] Delank KW, et al. **HNO** 1998 Aug;46(8):762-5 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Neonatal adrenal haemorrhage at bone scintigraphy: a case report. Jacobsson H, et al. **Pediatr Radiol** 1998 Nov; 28(11):896-8 (5 ref.)

SURGERY

Physiological predictors of death in exsanguinating trauma patients undergoing conventional trauma surgery. Krishna G, et al. **Aust N Z J Surg** 1998 Dec;68(12):826-9

Percutaneous arterial closure in severely scarred groins: a technical note. Winter K, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):315-7

Varicosities, hemorrhages and vocal fold masses. Sataloff RT, et al. **Ear Nose Throat J** 1998 Oct;77(10):808

Massive liver haemorrhage and rupture caused by HELLP-syndrome treated by collagen fleeces coated with fibrin glue. Cerwenka H, et al. **Eur J Surg** 1998 Sep; 164(9):709-11

Lymphangiectasia haemorrhagica conjunctivae. Lochhead J, et al. **Eye** 1998;12 (Pt 4):627-9

Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Garcia-Villarreal L, et al. **Hepatology** 1999 Jan;29(1):27-32

Reoperations for bleeding portal hypertension. Surgical rescue of surgical failures. Mercado MA, et al. **HPB Surg** 1999;11(3):151-5

Access to the traumatized vertebral artery: an unusual approach. Lloyd RV, et al. **J Laryngol Otol** 1999 Jan; 113(1):76-8

Successful simultaneously stapled lobectomy for a stab wound to the lung with massive hemorrhage: case report. Kaseda S, et al. **J Trauma** 1999 Jun;46(6):1140-1

Subcapsular hemorrhage of the liver in a very-low-birth-weight neonate: survival after decompression laparotomy. Kosumi T, et al. **Pediatr Surg Int** 1999;15(3-4):270-1 (15 ref.)

Computer simulation of hypothermia during "damage control" laparotomy. Hirshberg A, et al. **World J Surg** 1999 Sep;23(9):960-5

[Life-threatening hemorrhage in the thoracic region] Capov I, et al. **Bratisl Lek Listy** 1998 Dec;99(12):668-9 **(Cze)**

[Treatment of 8 patients with an acute hemorrhage in a hepatocellular adenoma at the Academic Medical Center, Amsterdam] Croes EA, et al. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2463-8 (Eng. Abstr.) **(Dut)**

[Hemostasis of the gallbladder bed by using muscle flap with vascular pedicle] Makhovskii VZ, et al. **Khirurgiia (Mosk)** 1998;(11):64-5 **(Rus)**

[The arrest of an arrosive hemorrhage from the brachiocephalic trunk into the tracheobronchial tree resulting from a tracheal ulcer due to an endoprosthesis] Parshin VD, et al. **Khirurgiia (Mosk)** 1998;(8):51-4 **(Rus)**

[Treatment of splenic hemorrhage by intervention on the splenic artery] Durdik S, et al. **Bratisl Lek Listy** 1998 Dec; 99(12):686-7 **(Slo)**

[A transsternal method for stopping pulmonary hemorrhage in patients with superior-lobe destructive pulmonary tuberculosis] Savenkov IuF. **Lik Sprava** 1998 Aug;(6):113-4 (Eng. Abstr.) **(Ukr)**

THERAPY

Klebsiella pneumoniae panophthalmitis: a possible complication of endoscopic variceal injection sclerotherapy. Hung HC, et al. **Am J Gastroenterol** 1998 Dec;93(12):2603-4

Prone ventilation [letter] Sartain J, et al. **Anaesth Intensive Care** 1999 Aug;27(4):424

ABIOMED BVS 5000 system: repair of venous cannulation site for excessive bleeding. Krause TJ. **Ann Thorac Surg** 1998 Nov;66(5):1817

Pulmonary hemorrhage: clinical course and outcomes among very low-birth-weight infants. Tomaszewska M, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):715-21

Diagnosis and treatment of patients refractory to platelet transfusions. Contreras M. **Blood Rev** 1998 Dec; 12(4):215-21 (69 ref.)

Hyperbaric oxygen in the treatment of refractory haemorrhagic cystitis. Hughes AJ, et al. **Bone Marrow Transplant** 1998 Sep;22(6):585-6

Delayed esophageal hemorrhage caused by a metal stent: treatment with embolization. Kos X, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):428-30

Management of bleeding with uremia and liver disease. DeLoughery TG. **Curr Opin Hematol** 1999 Sep;6(5):329-33 (32 ref.)

Stent-graft treatment of iatrogenic iliac artery perforations: report of three cases. Nyman U, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):259-63 (18 ref.)

Non-operative management of arterial liver hemorrhages. Görich J, et al. **Eur Radiol** 1999;9(1):85-8

Urological treatment and clinical course of BK polyomavirus-associated hemorrhagic cystitis in children after bone marrow transplantation. Vögeli TA, et al. **Eur Urol** 1999 Sep;36(3):252-7

The management of a person with haemophilia who has a fixed flexed hip and intractable pain. Heim M, et al. **Haemophilia** 1998 Nov;4(6):842-4

Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Garcia-Villarreal L, et al. **Hepatology** 1999 Jan;29(1):27-32

Arterial injury complicating femoral shaft fracture: control of primary and secondary profunda femoral bleeding by transcatheter embolisation. Owers KL, et al. **Injury** 1999 May;30(4):305-8

Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. Winslow RM, et al. **J Appl Physiol** 1998 Sep;85(3):993-1003

Massive pulmonary hemorrhage in newborn infants successfully treated with high frequency oscillatory ventilation. Ko SY, et al. **J Korean Med Sci** 1998 Oct; 13(5):495-9

Palliative management of bleeding events in advanced cancer patients. Gagnon B, et al. **J Palliat Care** 1998 Winter; 14(4):50-4

Decreased alpha-adrenergic response in the intestinal microcirculation after "two-hit" hemorrhage/resuscitation and bacteremia. Spain DA, et al. **J Surg Res** 1999 Jun 15; 84(2):180-5

Prehospital blood transfusion in prolonged evacuation. Barkana Y, et al. **J Trauma** 1999 Jan;46(1):176-80

Fibrin glue terminates massive bleeding after complex hepatic injury. Cohn SM, et al. **J Trauma** 1998 Oct;45(4):666-72

Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries. Holcomb JB, et al. **J Trauma** 1999 Aug;47(2):233-40; discussion 240-2

Balloon tamponade for bleeding control in penetrating liver injuries [letter; comment] Losanoff J, et al. **J Trauma** 1998 Dec;45(6):1103-4. Comment on: J Trauma 1998 Mar;44(3):538-9.

Control of splenic bleeding by using high intensity ultrasound. Vaezy S, et al. **J Trauma** 1999 Sep;47(3):521-5

Hyperbaric oxygen therapy for pediatric hemorrhagic cystitis. Furness PD 3rd, et al. **J Urol** 1999 May; 161(5):1596-7

Complete renal embolization as an alternative to nephrectomy. Hom D, et al. **J Urol** 1999 Jan;161(1):24-7

Massive hemorrhage: treatment with forced wire manipulation. Görich J, et al. **J Vasc Interv Radiol** 1999 Apr;10(4):435-8

Developments in blood management: the potential therapeutic role for epoetin alfa in orthopedic trauma. Mears DC, et al. **Orthopedics** 1999 Jan;22(1 Suppl):s151-4

Acute hemorrhage in chronic pancreatitis: diagnosis and treatment options including superselective microcoil embolization. Reber PU, et al. **Pancreas** 1999 May; 18(4):399-402

Internal iliac artery embolisation for intractable bladder haemorrhage in the peri-operative phase. Gujral S, et al. **Postgrad Med J** 1999 Mar;75(881):167-8

Labetalol-induced hypotension decreases blood loss during uncontrolled hemorrhage. Gurevich B, et al. **Resuscitation** 1998 Jul;38(1):25-32

Hemostasis of punctured blood vessels using high-intensity focused ultrasound. Vaezy S, et al. **Ultrasound Med Biol** 1998 Jul;24(6):903-10

Replacement of massive blood loss. Hiippala S. **Vox Sang** 1998;74 Suppl 2:399-407 (67 ref.)

Management of peripartum hemorrhage. Skye DV. **WMJ** 1998 Dec;97(11):43-6 (3 ref.)

[Embolization treatment of a traumatic adrenal hemorrhage] Tixedor N, et al. **J Radiol** 1999 Jul;80(7):733-5 (Eng. Abstr.) **(Fre)**

[Klebsiella oxytoca septicemia following platelet transfusion] Boyeldieu D, et al. **Pathol Biol (Paris)** 1999 May; 47(5):405-7 (Eng. Abstr.) **(Fre)**

[The percutaneous transarterial embolization therapy of traumatic kidney hemorrhages] Krämer SC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):297-301 (Eng. Abstr.) **(Ger)**

[Temporary balloon occlusion as therapy of uncontrollable arterial hemorrhage in multiple trauma patients] Rieger J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):80-3 (Eng. Abstr.) **(Ger)**

[A coated stent as alternative therapy for stopping a tumor-induced arrosive hemorrhage] Steudel A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):324-6 (10 ref.) **(Ger)**

[Percutaneous transcatheter embolization in a case of post-traumatic adrenal hemorrhage] Ettorre GC, et al. **Radiol Med (Torino)** 1998 Nov;96(5):531-3 **(Ita)**

[Arterial embolization: present role of an old method of interventional radiology in the treatment of hemorrhages] Florio F, et al. **Radiol Med (Torino)** 1999 Mar;97(3):107-15 (28 ref.) **(Ita)**

[Low-volume infusion therapy with hyperosmolar sodium chloride solutions in the treatment of acute massive blood loss] Tsybuliak GN, et al. **Vestn Khir Im I I Grek** 1999; 158(2):73-6 (31 ref.) **(Rus)**

ULTRASONOGRAPHY

Different remodeling of descending thoracic aorta after acute event in aortic intramural hemorrhage versus aortic dissection. Song JK, et al. **Am J Cardiol** 1999 Mar 15; 83(6):937-41

Detection of retroperitoneal hemorrhage by transesophageal echocardiography during cardiac surgery. Yamaura K, et al. **Can J Anaesth** 1999 Feb;46(2):169-72

Prenatal sonographic detection of adrenal hemorrhage confirmed by postnatal surgery. Fang SB, et al. **J Clin Ultrasound** 1999 May;27(4):206-9

Use of transvaginal color Doppler ultrasound in the diagnosis of ovarian bleeding: a report of 10 cases. Emoto M, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):247-50

Prenatal sonographic appearance of hemorrhagic cerebellar infarction. Ranzini AC, et al. **J Ultrasound Med** 1998 Nov; 17(11):725-7

The correlation of ultrasonic carotid plaque morphology and carotid plaque hemorrhage: clinical implications. AbuRahma AF, et al. **Surgery** 1998 Oct;124(4):721-6; discussion 726-8

Prenatal diagnosis of fetal adrenal masses: differentiation between hemorrhage and solid tumor by color Doppler sonography. Schwärzler P, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):351-5

VETERINARY

Effects of extrathoracic airway obstruction on intrathoracic pressure and pulmonary artery pressure in exercising horses. Hackett RP, et al. **Am J Vet Res** 1999 Apr; 60(4):485-94

Effect of timing and route of administration of furosemide on pulmonary hemorrhage and pulmonary arterial pressure in exercising thoroughbred racehorses. Lester G, et al. **Am J Vet Res** 1999 Jan;60(1):22-8

Effect of acute haemorrhage on QRS amplitude of the lead II canine electrocardiogram. Della Torre PK, et al. **Aust Vet J** 1999 May;77(5):298-300

First identification of infectious salmon anaemia virus in North America with haemorrhagic kidney syndrome. Lovely JE, et al. **Dis Aquat Organ** 1999 Jan 29;35(2):145-8

What is your diagnosis? Rodenticide poisoning in a dog. McGuire NC, et al. **J Am Vet Med Assoc** 1999 Apr 15; 214(8):1157-8

Generalised amyloidosis in two Siamese cats: spontaneous liver haemorrhage and chronic renal failure. Godfrey DR, et al. **J Small Anim Pract** 1998 Sep;39(9):442-7

Cullen's sign and haemoglobinuria as presenting signs of retroperitoneal haemorrhage in a dog. Schermerhorn T, et al. **J Small Anim Pract** 1998 Oct;39(10):490-4

Review of furosemide in horse racing: its effects and regulation. Soma LR, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):228-40 (103 ref.)

Effects of citrated whole blood transfusion in response to hemorrhage. Blumenthal SR, et al. **Lab Anim Sci** 1999 Aug; 49(4):411-7

The effect of current frequency during waterbath stunning on the physical recovery and rate and extent of bleed out in turkeys. Mouchonière M, et al. **Poult Sci** 1999 Mar; 78(3):485-9

Pathological investigations on guillemots (Uria aalge) stranded on the Belgian coast during the winter of 1993-94. Jauniaux T, et al. **Vet Rec** 1998 Oct 3;143(14):387-90

VIROLOGY

Haemorrhagic varicella: a malignant variant of chicken pox. Olasode OA, et al. **Cent Afr J Med** 1998 Aug;44(8):205-6

Lesions and transmission of experimental adenovirus hemorrhagic disease in black-tailed deer fawns. Woods

HEMORRHAGE

LW, et al. **Vet Pathol** 1999 Mar;36(2):100–10

HEMORRHAGE, BILIARY TRACT see **HEMOBILIA**

HEMORRHAGE, CEREBRAL see **CEREBRAL HEMORRHAGE**

HEMORRHAGE, CHOROID see **CHOROID HEMORRHAGE**

HEMORRHAGE, EYE see **EYE HEMORRHAGE**

HEMORRHAGE, FETOMATERNAL see **FETOMATERNAL TRANSFUSION**

HEMORRHAGE, GASTROINTESTINAL see **GASTROINTESTINAL HEMORRHAGE**

HEMORRHAGE, GINGIVAL see **GINGIVAL HEMORRHAGE**

HEMORRHAGE, ORAL see **ORAL HEMORRHAGE**

HEMORRHAGE, PEPTIC ULCER see **PEPTIC ULCER HEMORRHAGE**

HEMORRHAGE, POSTOPERATIVE see **POSTOPERATIVE HEMORRHAGE**

HEMORRHAGE, POSTPARTUM see **POSTPARTUM HEMORRHAGE**

HEMORRHAGE, RETINAL see **RETINAL HEMORRHAGE**

HEMORRHAGE, RETROBULBAR see **RETROBULBAR HEMORRHAGE**

HEMORRHAGE, SUBARACHNOID see **SUBARACHNOID HEMORRHAGE**

HEMORRHAGE, SURGICAL see **BLOOD LOSS, SURGICAL**

HEMORRHAGE, UTERINE see **UTERINE HEMORRHAGE**

HEMORRHAGE, VITREOUS see **VITREOUS HEMORRHAGE**

HEMORRHAGIC BACTEREMIA

VETERINARY

Haemorrhagic septicaemia by Aeromonas salmonicida subsp. salmonicida in a black-tip reef shark (Carcharhinus melanopterus). Briones V, et al. **Zentralbl Veterinarmed [B]** 1998 Sep;45(7):443–5

HEMORRHAGIC DIATHESIS see **HEMORRHAGIC DISORDERS**

HEMORRHAGIC DISEASE OF NEWBORN

Vitamin K deficiency bleeding (VKDB) in infancy. ISTH Pediatric/Perinatal Subcommittee. International Society on Thrombosis and Haemostasis. Sutor AH, et al. **Thromb Haemost** 1999 Mar;81(3):456–61 (65 ref.)

COMPLICATIONS

[Duodenal perforation, pericarditis and pneumothorax in newborn] Gumerov AA, et al. **Khirurgiia (Mosk)** 1999; (2):57 **(Rus)**

DIAGNOSIS

Late-form hemorrhagic disease of the newborn: a fatal case report with illustration of investigations that may assist in avoiding the mistaken diagnosis of child abuse. Rutty GN, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):48–51

PREVENTION & CONTROL

Prevention of vitamin K deficiency bleeding in newborns. Zipursky A. **Br J Haematol** 1999 Mar;104(3):430–7 (58 ref.)

Case report: fatal hemorrhagic disease in a newborn despite vitamin K prophylaxis. Morrice LM, et al. **Can Fam Physician** 1998 Sep;44:1893–4, 1896

HEMORRHAGIC DISEASE VIRUS, EPIZOOTIC

Experimental infection of calves with epizootic hemorrhagic disease virus. Abdy MJ, et al. **Am J Vet Res** 1999 May; 60(5):621–6

IMMUNOLOGY

Characterisation of monoclonal antibodies to epizootic hemorrhagic disease virus of deer (EHDV) and bluetongue virus by immunisation of mice with EHDV recombinant VP7 antigen. Zhou E, et al. **Res Vet Sci** 1999 Jun; 66(3):247–52

Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus. Martínez-Torrecuadrada JL, et al. **Virology** 1999 May 10;257(2):449–59

ISOLATION & PURIFICATION

Preliminary description of a polymerase chain reaction test for bluetongue and epizootic hemorrhagic disease viral RNA in bovine semen. Wilson WC. **J Vet Diagn Invest** 1999 Jul;11(4):377–9

HEMORRHAGIC DISEASE VIRUS, RABBIT

Hepatic lesions in young rabbits experimentally infected with rabbit haemorrhagic disease virus. Mikami O, et al. **Res Vet Sci** 1999 Jun;66(3):237–42

GENETICS

Sequence analysis of rabbit haemorrhagic disease virus (RHDV) in Australia: alterations after its release. Asgari S, et al. **Arch Virol** 1999;144(1):135–45

Pathogenic, antigenic and molecular properties of rabbit haemorrhagic disease virus (RHDV) isolated from vaccinated rabbits: detection and characterization of antigenic variants. Schirrmeier H, et al. **Arch Virol** 1999; 144(4):719–35

A further step in the evolution of rabbit hemorrhagic disease virus: the appearance of the first consistent antigenic variant. Capucci L, et al. **Virus Res** 1998 Nov; 58(1-2):115–26

IMMUNOLOGY

Pathogenic, antigenic and molecular properties of rabbit haemorrhagic disease virus (RHDV) isolated from vaccinated rabbits: detection and characterization of antigenic variants. Schirrmeier H, et al. **Arch Virol** 1999; 144(4):719–35

Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. Castañón S, et al. **J Virol** 1999 May;73(5):4452–5

Control of rabbit viral haemorrhagic disease in Benin by vaccination. Kpodekon M, et al. **Vet Rec** 1998 Dec 19–26; 143(25):693–4

ISOLATION & PURIFICATION

A cross-sectional study of risk factors affecting the outcome of rabbit haemorrhagic disease virus releases in New South Wales. Lugton IW. **Aust Vet J** 1999 May;77(5):322–8

Serology of rabbit haemorrhagic disease virus in wild rabbits before and after release of the virus in New Zealand. O'Keefe JS, et al. **Vet Microbiol** 1999 Mar 31;66(1):29–40

Evaluation of three tests for the detection of rabbit haemorrhagic disease virus in wild rabbits. Motha MX, et al. **Vet Rec** 1998 Dec 5;143(23):627–9

Field evidence for mechanical transmission of rabbit haemorrhagic disease virus (RHDV) by flies (Diptera:Calliphoridae) among wild rabbits in Australia. Asgari S, et al. **Virus Res** 1998 Apr;54(2):123–32

PATHOGENICITY

Viral haemorrhagic disease of rabbits and human health. Carman JA, et al. **Epidemiol Infect** 1998 Oct;121(2):409–18

Rabbit haemorrhagic disease in Saudi Arabia. Abu Elzein EM, et al. **Vet Rec** 1999 Apr 24;144(17):480–1

PHYSIOLOGY

Macrophage tropism of rabbit hemorrhagic disease virus is associated with vascular pathology. Ramiro-Ibáñez F, et al. **Virus Res** 1999 Mar;60(1):21–8

HEMORRHAGIC DISEASE VIRUS, SIMIAN see **ARTERIVIRUS**

HEMORRHAGIC DISORDERS

see related
VASCULAR HEMOSTATIC DISORDERS

Acquired haemophilia. Hay CR. **Baillieres Clin Haematol** 1998 Jun;11(2):287–303 (82 ref.)

Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Van Os EC, et al. **Gastrointest Endosc** 1999 Oct;50(4):536–43 (27 ref.)

Department of Health & report. The Tennessee State Hemophilia Program. Moffatt LS. **Tenn Med** 1998 Oct; 91(10):398–9

[Plasminogen activator inhibitor deficiency] Mimuro J. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):494–7 (9 ref.) **(Jpn)**

[Acquired inhibitor to coagulation factor V] Takahashi I. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):506–8 (10 ref.) **(Jpn)**

BLOOD

Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Manoharan A, et al. **Br J Haematol** 1999 Jun;105(3):618–25

Protein Z in healthy human individuals and in patients with a bleeding tendency. Ravi S, et al. **Br J Haematol** 1998 Sep;102(5):1219–23

Bleeding tendency of unknown origin and protein Z levels. Gamba G, et al. **Thromb Res** 1998 Jun 15;90(6):291–5

[Therapy refractory idiopathic thrombocytopenia. Contraindication for dental surgery interventions] Schramm A, et al. **Mund Kiefer Gesichtschir** 1999 Jan; 3(1):43–5 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

CT assessment of abdominal hemorrhage in coagulopathic patients: impact on clinical management. Nazarian LN, et al. **Abdom Imaging** 1999 May-Jun;24(3):246–9

Severe bleeding diathesis in a premature baby with extensive hepatic necrosis due to portal vein thrombosis of prenatal onset [letter] Ries M, et al. **Ann Hematol** 1999 Jul; 78(7):339–40

Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. Kuo RL, et al. **Urology** 1998 Oct; 52(4):609–13

[Hemophilic pseudotumor] Sakuragawa N. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):474–5 (15 ref.) **(Jpn)**

DIAGNOSIS

Laboratory diagnosis of hereditary bleeding disorders: external quality assessment. Preston FE. **Haemophilia** 1998; 4 Suppl 2:12–8

[Hemostaseology--rational diagnosis] Spannagl M, et al. **Internist (Berl)** 1999 Jun;40(6):657–65; quiz 665 (5 ref.) **(Ger)**

[Rational hemostatic screening] Maurin N. **Med Klin** 1999 Mar 15;94(3):165–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[The concomitant presence of prohemorrhagic and thrombophilic changes in coagulation factor V: a severe defect of coagulant activity and homozygote resistance to activated protein C (see comments)] Rossi V, et al. **Ann Ital Med Int** 1999 Apr-Jun;14(2):127–9 (10 ref.) (Eng. Abstr.). Comment in: Ann Ital Med Int 1999 Apr-Jun;14(2):71–3. **(Ita)**

[Acquired coagulation factor VIII inhibitor in a non-hemophiliac patient (letter)] Polo Romero FJ, et al. **Rev Clin Esp** 1999 Feb;199(2):114–5 **(Spa)**

ETIOLOGY

The role of von Willebrand factor in the hemostatic defect of acute promyelocytic leukemia. Federici AB, et al. **Leuk Lymphoma** 1998 Nov;31(5–6):491–9 (41 ref.)

A Glanzmann thrombasthenia-like phenotype caused by a defect in inside-out signaling through the integrin alpha(IIb)beta3. Tomiyama Y, et al. **Thromb Haemost** 1998 Nov;80(5):735–42

[Congenital deficiency of alpha 2-plasmin inhibitor] Yoshinaga H, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):488–90 (10 ref.) **(Jpn)**

[Alveolar rhabdomyosarcoma with massive infiltration of the bone marrow as its initial manifestation] Pérez del Río MJ, et al. **Sangre (Barc)** 1998 Jun;43(3):236–9 (Eng. Abstr.) **(Spa)**

GENETICS

Gly319 --> arg substitution in the dysfunctional prothrombin Segovia. Akhavan S, et al. **Br J Haematol** 1999 Jun;105(3):667–9

Symptoms of inherited factor V deficiency in 35 Iranian patients. Lak M, et al. **Br J Haematol** 1998 Dec; 103(4):1067–9

Genetic deficiency of factor VII and hemorrhagic diathesis. A case report and literature review. Iannello S, et al. **Panminerva Med** 1998 Sep;40(3):226–38 (144 ref.)

PHYSIOPATHOLOGY

Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Kadir RA, et al. **Haemophilia** 1999 Jan;5(1):40–8

Good correlation between clinical bleeding tendencies and bleeding pattern from the bleeding time incision. Tamai Y, et al. **Thromb Res** 1999 Jul 15;95(2):131–4

PREVENTION & CONTROL

Oral vitamin K1 prophylaxis for newborns with a new mixed-micellar preparation of phylloquinone: 3 years experience in Switzerland. Schubiger G, et al. **Eur J Pediatr** 1999 Jul;158(7):599–602

THERAPY

Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council. **S Afr Med J** 1998 Oct;88(10):1344–7

VIROLOGY

Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders. Ahmed MM, et al. **Haemophilia** 1999 Jan;5(1):49–55

HEMORRHAGIC FEVER, AMERICAN

DIAGNOSIS

Clinical case definitions for Argentine hemorrhagic fever. Harrison LH, et al. **Clin Infect Dis** 1999 May;28(5):1091–4

ENZYMOLOGY

Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Marta RF, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):85–9

IMMUNOLOGY

Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Marta RF, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):85–9

VIROLOGY

Sequence analysis of the small RNA segment of guinea pig-passaged Pichinde virus variants. Zhang L, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):220–5

HEMORRHAGIC FEVER, ARGENTINIAN see **HEMORRHAGIC FEVER, AMERICAN**

HEMORRHAGIC FEVER, BOLIVIAN see **HEMORRHAGIC FEVER, AMERICAN**

HEMORRHAGIC FEVER, CRIMEAN

[Crimean-Congo hemorrhagic fever] Kurata T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):94–6 (6 ref.) **(Jpn)**

DIAGNOSIS

[Laboratory diagnosis of viral infections. 8. Viral hemorrhagic fever] Morikawa S. **Rinsho Byori** 1998 Nov; Suppl 108:105–10 (9 ref.) **(Jpn)**

TRANSMISSION

Outbreak of Crimean-Congo haemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Altaf A, et al. **Trop Med Int Health** 1998 Nov;3(11):878–82

[Experimental transmission of Crimean-Congo hemorrhagic fever virus by Rhipicephalus evertsi evertsi (Acarina:Ixodidae)] Faye O, et al. **Bull Soc Pathol Exot** 1999 Jul;92(3):143–7 (Eng. Abstr.) **(Fre)**

[Experimental transmission of Crimean-Congo hemorrhagic fever virus: role of 3 vector species in the maintenance and transmission cycles in Senegal] Faye O, et al. **Parasite** 1999 Mar;6(1):27–32 (Eng. Abstr.) **(Fre)**

VETERINARY

Experimental infection of ostriches with Crimean-Congo haemorrhagic fever virus. Swanepoel R, et al. **Epidemiol Infect** 1998 Oct;121(2):427–32

VIROLOGY

Biological and clinical responses of west African sheep to Crimean-Congo haemorrhagic fever virus experimental infection. Gonzalez JP, et al. **Res Virol** 1998 Nov-Dec; 149(6):445–55

HEMORRHAGIC FEVER, DENGUE see **DENGUE HEMORRHAGIC FEVER**

HEMORRHAGIC FEVER, EBOLA

An introduction to Ebola: the virus and the disease. Peters CJ, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:ix–xvi (101 ref.)

[Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects] Hirabayashi Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):85–9 (28 ref.) **(Jpn)**

COMPLICATIONS

Isolated case of Ebola hemorrhagic fever with mucormycosis complications, Kinshasa, Democratic Republic of the Congo. Kalongi Y, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S15–7

Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. Kibadi K, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S13–4

Ebola hemorrhagic fever and pregnancy. Mupapa K, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S11–2

DIAGNOSIS

Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. Prehaud C, et al. **J Gen Virol** 1998 Nov; 79 (Pt 11):2565–72

ELISA for the detection of antibodies to Ebola viruses. Ksiazek TG, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S192–8

Long-term disease surveillance in Bandundu region, Democratic Republic of the Congo: a model for early detection and prevention of Ebola hemorrhagic fever. Lloyd ES, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S274–80

Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. Muyembe-Tamfum JJ, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S259–62

A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. Zaki SR, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S36–47

[Laboratory diagnosis of viral infections. 8. Viral hemorrhagic fever] Morikawa S. **Rinsho Byori** 1998 Nov; Suppl 108:105–10 (9 ref.) **(Jpn)**

DRUG THERAPY

Sicarius (six-eyed crab spider): a homeopathic treatment for Ebola haemorrhagic fever and disseminated intravascular coagulation? Richardson-Boedler C. **Br Homeopath J** 1999 Jan;88(1):24–7 (23 ref.)

Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. Harcourt BH, et al. **J Virol** 1999 Apr;73(4):3491–6

EPIDEMIOLOGY

Leptospirosis and Ebola virus infection in five gold-panning villages in northeastern Gabon. Bertherat E, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):610–5

Ebola virus outbreaks in the Ivory Coast and Liberia, 1994–1995. Le Guenno B, et al. **Curr Top Microbiol Immunol** 1999;235:77–84

Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. Busico KM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S102–7

Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. Bwaka MA, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S1–7

Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. Dowell SF, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S87–91

Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. Georges AJ, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S65–75

Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. Guimard Y, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S268–73

Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the Congo. Heymann DL, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S283–6

Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981–1985. Jezek Z, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S60–4

Gleanings from the harvest: suggestions for priority actions against Ebola virus epidemics. Johnson KM. **J Infect Dis** 1999 Feb;179 Suppl 1:S287–8

Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. Kerstiëns B, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S263–7

The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. Khan AS, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S76–86

Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. Kibadi K, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S13–4

Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. Leirs H, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S155–63

Long-term disease surveillance in Bandundu region, Democratic Republic of the Congo: a model for early detection and prevention of Ebola hemorrhagic fever. Lloyd ES, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S274–80

Ebola outbreak in Kikwit, Democratic Republic of the Congo: discovery and control measures. Muyembe-Tamfum JJ, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S259–62

Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. Ndambi R, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S8–10

Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. Reiter P, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S148–54

Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. Rodriguez LL, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S170–6

Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. Roels TH, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S92–7

Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. Rowe AK, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S28–35

Serologic survey among hospital and health center workers during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo, 1995. Tomori O, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S98–101

Surviving Ebola virus infection [news; comment] Nabel GJ. **Nat Med** 1999 Apr;5(4):373–4. Comment on: Nat Med 1999 Apr;5(4):423–6.

Characteristics of Filoviridae: Marburg and Ebola viruses. Beer B, et al. **Naturwissenschaften** 1999 Jan;86(1):8–17 (88 ref.)

Ebola: the virus and the disease. **Wkly Epidemiol Rec** 1999 Mar 26;74(12):89 **(Eng, Fre)**

[Study of the reasons for spread of communicable diseases] Wei CY. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr;18(2):102–5 (8 ref.) **(Chi)**

ETIOLOGY

Risk for Ebola virus infection in Côte d'Ivoire [letter] Kunii O, et al. **Emerg Infect Dis** 1999 Mar-Apr;5(2):312–3

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. Bray M, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S248–58

Pathogenesis of experimental Ebola virus infection in guinea pigs. Connolly BM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S203–17

An analysis of features of pathogenesis in two animal models of Ebola virus infection. Ryabchikova EI, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S199–202

GENETICS

Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. Harcourt BH, et al. **J Virol** 1999 Apr;73(4):3491–6

IMMUNOLOGY

Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. Busico KM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S102–7

ELISA for the detection of antibodies to Ebola viruses. Ksiazek TG, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S192–8

Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. Ksiazek TG, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S177–87

Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. Rowe AK, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S28–35

Serologic survey among hospital and health center workers during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo, 1995. Tomori O, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S98–101

Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. Villinger F, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S188–91

Ebola virus can be effectively neutralized by antibody produced in natural human infection. Maruyama T, et al. **J Virol** 1999 Jul;73(7):6024–30

Surviving Ebola virus infection [news; comment] Nabel GJ. **Nat Med** 1999 Apr;5(4):373–4. Comment on: Nat Med 1999 Apr;5(4):423–6.

[Effects of repeated administration of Ebola virus preparations on dynamics of immunologic parameters] Chepurnov AA, et al. **Biull Eksp Biol Med** 1999 Jan; 127(1):81–5 **(Rus)**

[Dynamics of immunologic indicators in guinea pigs upon administering various preparations of the Ebola virus] Dadaeva AA, et al. **Vopr Virusol** 1998 Jul-Aug;43(4):163–9 (Eng. Abstr.) **(Rus)**

MORTALITY

Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. Sadek RF, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S24–7

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients [see comments] Baize S, et al. **Nat Med** 1999 Apr;5(4):423–6. Comment in: Nat Med 1999 Apr;5(4):373–4.

PHYSIOPATHOLOGY

Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Schnittler HJ, et al. **Clin Infect Dis** 1998 Aug;27(2):404–6

Pathophysiology of Ebola haemorrhagic fever [letter; comment] Clark IA, et al. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):469. Comment on: Trans R Soc Trop Med Hyg 1998 Jan-Feb;92(1):1–2.

HEMORRHAGIC FEVER, EBOLA

PREVENTION & CONTROL

US policy for disease control among imported nonhuman primates. DeMarcus TA, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S281–2

Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the Congo. Heymann DL, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S283–6

Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. Kerstiëns B, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S263–7

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. Kudoyarova-Zubavichene NM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S218–23

[Surveillance and control of some emerging zoonoses] Yu ES. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Feb; 18(1):47–9 (5 ref.) **(Chi)**

PSYCHOLOGY

Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. De Roo A, et al. **Trop Med Int Health** 1998 Nov;3(11):883–5

THERAPY

Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. Guimard Y, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S268–73

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. Jahrling PB, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S224–34

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. Kudoyarova-Zubavichene NM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S218–23

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. Mupapa K, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S18–23

TRANSMISSION

Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. Dowell SF, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S87–91

Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. Leirs H, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S155–63

Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. Reiter P, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S148–54

Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. Roels TH, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S92–7

[Ebola virus: what the practitioner needs to know] Georges AJ, et al. **Med Trop (Mars)** 1998;58(2):177–86 (104 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

US policy for disease control among imported nonhuman primates. DeMarcus TA, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S281–2

Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. Formenty P, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S120–6

Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. Miranda ME, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S115–9

Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. Wyers M, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S54–9

VIROLOGY

Emerging viral infections. Khabbaz RF. **Adv Pediatr Infect Dis** 1999;14:1–27 (111 ref.)

Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. Formenty P, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S48–53

Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. Ksiazek TG, et al. **J Infect Dis** 1999 Feb; 179 Suppl 1:S177–87

Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. Rodriguez LL, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S170–6

Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. Sanchez A, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S164–9

Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. Ito H, et al. **J Virol** 1999 Oct; 73(10):8907–12

HEMORRHAGIC FEVER, EPIDEMIC see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC FEVER, KOREAN see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC FEVER RENAL SYNDROME VIRUS see **HANTAAN VIRUS**

HEMORRHAGIC FEVER VIRUS, ARGENTINIAN see **JUNIN VIRUS**

HEMORRHAGIC FEVER VIRUS, CRIMEAN see **HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO**

HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO

[Experimental transmission of Crimean-Congo hemorrhagic fever virus by Rhipicephalus evertsi evertsi (Acarina:Ixodidae)] Faye O, et al. **Bull Soc Pathol Exot** 1999 Jul;92(3):143–7 (Eng. Abstr.) **(Fre)**

[Crimean-Congo hemorrhagic fever] Kurata T. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):94–6 (6 ref.) **(Jpn)**

PATHOGENICITY

Experimental infection of ostriches with Crimean-Congo haemorrhagic fever virus. Swanepoel R, et al. **Epidemiol Infect** 1998 Oct;121(2):427–32

PHYSIOLOGY

Biological and clinical responses of west African sheep to Crimean-Congo haemorrhagic fever virus experimental infection. Gonzalez JP, et al. **Res Virol** 1998 Nov-Dec; 149(6):445–55

[Experimental transmission of Crimean-Congo hemorrhagic fever virus: role of 3 vector species in the maintenance and transmission cycles in Senegal] Faye O, et al. **Parasite** 1999 Mar;6(1):27–32 (Eng. Abstr.) **(Fre)**

HEMORRHAGIC FEVER VIRUS, EPIDEMIC see **HANTAAN VIRUS**

HEMORRHAGIC FEVER VIRUS, KOREAN see **HANTAAN VIRUS**

HEMORRHAGIC FEVER VIRUS, OMSK see **ENCEPHALITIS VIRUSES, TICK-BORNE**

HEMORRHAGIC FEVER WITH RENAL SYNDROME

Hantavirus nephropathy in a child [letter] Eboriadou M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1040–1

[Hemorrhagic fever with renal syndrome] Penalba C. **Rev Prat** 1998 Jan 1;48(1):9–12 (20 ref.) **(Fre)**

BLOOD

[Effects of sodium ethamsylate on anticoagulant and anti-aggregation activity of vascular endothelium in hemorrhagic fever patients with renal syndrome] Davidovich IM, et al. **Ter Arkh** 1999;71(6):49–53 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Hemorrhagic fever (Puumala virus infection) with ocular involvement. Kontkanen M, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Sep;236(9):713–6

Isolated abducens nerve palsy as a complication of haemorrhagic fever with renal syndrome. Lee EY, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2113–4

[Hemophagocytic syndrome and hemorrhagic fever with renal syndrome (letter)] Baty V, et al. **Presse Med** 1998 Oct 17;27(31):1577 **(Fre)**

[Spontaneous ruptures of the kidney and retroperitoneal hematomas in hemorrhagic fever with renal syndrome] Zagidullin IM, et al. **Urol Nefrol (Mosk)** 1998 Nov-Dec; (6):50–3 (56 ref.) **(Rus)**

[Combination of bilateral otitis media chronica purulence and hemorrhagic fever with renal syndrome] Bobrov VM. **Vestn Otorinolaringol** 1999;(4):45–6 **(Rus)**

DIAGNOSIS

[The clinical picture of hemorrhagic fever with renal syndrome in the children of Udmurtia] Ermolaeva Ilu. **Med Parazitol (Mosk)** 1999 Jan-Mar;(1):59–60 **(Rus)**

[Functional activity of hemagglutinins from Hantaan viruses strains and use of hemagglutinating antigens for serodiagnosis hemorrhagic fever with kidney syndrome] Kushnareva TV, et al. **Vopr Virusol** 1999 Jul-Aug; 44(4):186–90 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Sibold C, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):409–11

A major outbreak of hemorrhagic fever with renal syndrome in the Samara region, European Russia [letter] Alexeyev OA, et al. **Infection** 1998 Sep-Oct;26(5):322

Hantavirus infection--haemorrhagic fever in the Balkans--potential nephrological hazards in the Kosovo war [editorial] Bugert JJ, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1843–4 (17 ref.)

[Urgent epidemiological problems in hemorrhagic fever with renal syndrome] Wu XK. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Oct; 18(5):303–5 (14 ref.) **(Chi)**

[Epidemiologic and experimental studies on epidemic haemorrhagic fever virus in pigs] Yang Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Aug; 19(4):218–20 (Eng. Abstr.) **(Chi)**

[Serotyping of hemorrhagic fever with renal syndrome in Hubei province] Fang Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):272–4 (Eng. Abstr.) **(Chi)**

ETIOLOGY

[New aspects of the pathogenesis of hantavirus infections. A systemic disease with general vascular changes] Linderholm M, et al. **Lakartidningen** 1999 Apr 28; 96(17):2083–6 (20 ref.) **(Swe)**

IMMUNOLOGY

Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Peters CJ, et al. **Annu Rev Med** 1999;50:531–45 (69 ref.)

Role of peripheral blood mononuclear cell (PBMC) phenotype changes in the pathogenesis of haemorrhagic fever with renal syndrome (HFRS). Markotić A, et al. **Clin Exp Immunol** 1999 Feb;115(2):329–34

Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. Van Epps HL, et al. **J Virol** 1999 Jul;73(7):5301–8

Expression of ICAM-1 on the Hantaan virus-infected human umbilical vein endothelial cells. Song JS, et al. **Korean J Intern Med** 1999 Jul;14(2):47–54

Hantavirus seropositivity in Israeli patients with renal failure. George J, et al. **Viral Immunol** 1998;11(2):103–8

[Immune mechanisms in pathogenesis of hemorrhagic fever with renal syndrome (review)] Alekseev OA, et al. **Ter Arkh** 1998;70(11):39–42 (61 ref.) **(Rus)**

METABOLISM

Metabolic acidosis and urinary acidification defect during the course of hemorrhagic fever with renal syndrome. Han JS, et al. **J Korean Med Sci** 1998 Aug;13(4):389–94

PREVENTION & CONTROL

DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Hooper JW, et al. **Virology** 1999 Mar 15; 255(2):269–78

[The experience of winter field deratization in a focus of hemorrhagic fever with renal syndrome] Matrosov AN, et al. **Gig Sanit** 1999 Mar-Apr;(2):57–9 **(Rus)**

THERAPY

[The therapeutic effect of purified human leucocytic interferon-alpha on hemorrhagic fever with renal syndrome] Bai J, et al. **Chung Hua Nei Ko Tsa Chih** 1997; 36(2):90–3 (Eng. Abstr.) **(Chi)**

TRANSMISSION

[Progress in the study of communicable diseases in China, 1997] Luo K, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):893–5 (0 ref.) **(Chi)**

VETERINARY

[Epidemiologic and experimental studies on epidemic haemorrhagic fever virus in pigs] Yang Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Aug; 19(4):218–20 (Eng. Abstr.) **(Chi)**

[Studies on epidemic hemorrhagic fever among rats in Jianghan Plian, Hubei Province, China] Li S, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):137–9 (Eng. Abstr.) **(Chi)**

VIROLOGY

Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. Gavrilovskaya IN, et al. **J Virol** 1999 May;73(5):3951–9

Polymerase chain reaction detection of Puumala virus RNA in formaldehyde-fixed biopsy material. Heiske A, et al. **Kidney Int** 1999 May;55(5):2062–9

[Acute hantavirus infection caused by a genetically newly identified viral strain. Severe and complicated course of hemorrhagic fever with renal syndrome (nephropathia epidemica)] Lauer B, et al. **Med Klin** 1999 Jan 15; 94(1):39–44 (Eng. Abstr.) **(Ger)**

HEMORRHAGIC FEVERS, VIRAL

COMPLICATIONS

Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic tests for Plasmodium falciparum. Loutfy MR, et al. **J Infect Dis** 1998 Dec; 178(6):1852–5

DIAGNOSIS

Suspected viral haemorrhagic fever: rapid tests help to exclude dangerous infections.
Commun Dis Rep CDR Wkly 1999 Jan 1;9(1):1, 4

Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections. Mayers DL.
Dermatol Clin 1999 Jan;17(1):29–40, vii–viii (69 ref.)

'Unexplained death' from malaria tropica mistaken for viral haemorrhagic fever [letter] Heyman P, et al.
Trop Med Int Health 1999 Jul;4(7):525

EPIDEMIOLOGY

Filoviral haemorrhagic fevers. Khan AS, et al.
Br Med Bull 1998;54(3):675–92 (86 ref.)

Viral haemorrhagic fever/Marburg, Democratic Republic of the Congo. **Wkly Epidemiol Rec** 1999 May 21;74(20):157–8 **(Eng, Fre)**

[Venezuelan hemorrhagic fever: eight years of observation] Salas RA, et al. **Acta Cient Venez** 1998;49 Suppl 1:46–51 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Management of a Sabiá virus-infected patients in a US hospital. Armstrong LR, et al.
Infect Control Hosp Epidemiol 1999 Mar;20(3):176–82

Viral haemorrhagic fever guidelines [letter; comment] Gaya H, et al. **J Hosp Infect** 1998 Dec;40(4):325. Comment on: J Hosp Infect 1998 Jul;39(3):169–72.

Viral haemorrhagic fever guidelines [letter; comment] Orr KE, et al. **J Hosp Infect** 1998 Dec;40(4):325–6. Comment on: J Hosp Infect 1998 Jul;39(3):169–72.

THERAPY

Exotic virus infections of military significance. Hemorrhagic fever viruses and pox virus infections. Mayers DL.
Dermatol Clin 1999 Jan;17(1):29–40, vii–viii (69 ref.)

TRANSMISSION

Zoonoses and haemorrhagic fever. Mahy BW.
Dev Biol Stand 1998;93:31–6 (9 ref.)

VIROLOGY

Characterisation of an echovirus type 11' (prime) epidemic strain causing haemorrhagic syndrome in newborn babies in Hungary. el-Sageyer MM, et al. **Acta Virol** 1998 Jun; 42(3):157–66

HEMORRHAGIC NEPHROSO-NEPHRITIS see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC NEPHROSO-NEPHRITIS VIRUS see **HANTAAN VIRUS**

HEMORRHAGIC THROMBOCYTHEMIA see **THROMBOCYTHEMIA, HEMORRHAGIC**

HEMORRHOIDS

COMPLICATIONS

Local thermal stimulation relaxes hypertonic anal sphincter: evidence of somatoanal reflex. Jiang JK, et al.
Dis Colon Rectum 1999 Sep;42(9):1152–9

DIAGNOSIS

Evaluation of hemorrhoids with the retroflexed fiberoptic colonoscope [letter] Fernández-Bermejo M, et al.
Gastrointest Endosc 1999 Aug;50(2):305–6

A new method of evaluating hemorrhoids with the retroflexed fiberoptic colonoscope. Sadahiro S, et al.
Gastrointest Endosc 1998 Sep;48(3):272–5

Hemorrhoids: what the dermatologist should know. Orkin BA, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):449–56 (14 ref.)

Hemorrhoids. Hussain JN. **Prim Care** 1999 Mar;26(1):35–51 (23 ref.)

[Hemorrhoidal disease] Geile D.
Schweiz Rundsch Med Prax 1998 Nov 26;87(48):1643–4 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Biochemical sphincterotomy is effective treatment for haemorrhoids and associated conditions: an audit. Mathur D, et al. **Biochem Soc Trans** 1998 Nov;26(4):S326

ECONOMICS

[The financing of topical antihemorrhoidal agents by drawing on Social Security (letter)] Palop Larrea V, et al.
Aten Primaria 1999 May 15;23(8):504–5 **(Spa)**

ETIOLOGY

Associations between hemorrhoids and other diagnoses. Delcò F, et al. **Dis Colon Rectum** 1998 Dec;41(12):1534–41; discussion 1541–2

[Is there a correlation between dietary habits and hemorrhoidal disease?] Sielezneff I, et al. **Presse Med** 1998 Mar 21;27(11):513–7 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Anal manometric findings before and after hemorrhoidectomy: a preliminary report. Chen HH.
Chang Keng I Hsueh Tsa Chih 1999 Mar;22(1):25–30

[Can hemorrhoids facilitate the transit of allergens from feces into the blood circulation?] Neef M, et al.
Dtsch Med Wochenschr 1999 Jun 4;124(22):711 **(Ger)**

SURGERY

Anal endosonography in patients with anorectal symptoms after haemorrhoidectomy. Abbasakoor F, et al.
Br J Surg 1998 Nov;85(11):1522–4

Randomized trial of open versus closed day-case haemorrhoidectomy. Carapeti EA, et al. **Br J Surg** 1999 May;86(5):612–3

Day-case haemorrhoidectomy. Hunt L, et al. **Br J Surg** 1999 Feb;86(2):255–8

Anal manometric findings before and after hemorrhoidectomy: a preliminary report. Chen HH.
Chang Keng I Hsueh Tsa Chih 1999 Mar;22(1):25–30

Effect of transcutaneous electrical nerve stimulation for pain relief on patients undergoing hemorrhoidectomy: prospective, randomized, controlled trial. Chiu JH, et al.
Dis Colon Rectum 1999 Feb;42(2):180–5

Limited hemorrhoidectomy: results and long-term follow-up. Hayssen TK, et al. **Dis Colon Rectum** 1999 Jul; 42(7):909–14; discussion 914–5

Local injection of bupivacaine after rubber band ligation of hemorrhoids: prospective, randomized study. Hooker GD, et al. **Dis Colon Rectum** 1999 Feb;42(2):174–9

Prospective, randomized trial comparing pain and complications between diathermy and scissors for closed hemorrhoidectomy. Ibrahim S, et al. **Dis Colon Rectum** 1998 Nov;41(11):1418–20

New rubber-band loader to facilitate use of hemorrhoid ligator. Kosugi M, et al. **Dis Colon Rectum** 1998 Oct; 41(10):1328–9

Triple rubber band ligation for hemorrhoids: prospective, randomized trial of use of local anesthetic injection. Law WL, et al. **Dis Colon Rectum** 1999 Mar;42(3):363–6

Prospective study of healing time after hemorrhoidectomy: influence of HIV infection, acquired immunodeficiency syndrome, and anal wound infection. Morandi E, et al.
Dis Colon Rectum 1999 Sep;42(9):1140–4

Disposable device and a minimally invasive technique for rubber band ligation of hemorrhoids. O'Regan PJ.
Dis Colon Rectum 1999 May;42(5):683–5

Urinary retention after anorectal operations [letter; comment] Pescatori M. **Dis Colon Rectum** 1999 Jul;42(7):964. Comment on: Dis Colon Rectum 1998 Jun;41(6):696–704.

Endoscopic hemorrhoidal band removal [letter] Trowers EA, et al. **Gastrointest Endosc** 1999 May;49(5):672

Circular hemorrhoidectomy in advanced hemorrhoidal disease. Boccasanta P, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):969–72

Rubber band ligation of hemorrhoids: relapse as a function of time. Savioz D, et al. **Int J Colorectal Dis** 1998; 13(4):154–6

Bupivacaine local injection in anorectal surgery. Hussein MK, et al. **Int Surg** 1998 Jan-Mar;83(1):56–7

A prospective randomized study of calcium alginate (Sorbsan) versus standard gauze packing following haemorrhoidectomy. Ingram M, et al.
J R Coll Surg Edinb 1998 Oct;43(5):308–9

[Rubberband ligation of hemorrhoids: symptoms almost gone after 6 weeks, but many patients need retreatment in the long run] Konings M, et al. **Ned Tijdschr Geneeskd** 1999 Jun 12;143(24):1265–8 (Eng. Abstr.) **(Dut)**

[Treatment of stage III and IV hemorrhoids by the Longo technique] Gravié JF. **Ann Chir** 1999;53(3):245–7 **(Fre)**

[Early postoperative morbidity after hemorrhoidectomy using the Milligan-Morgan technic. A retrospective studies of 1,134 cases] Sielezneff I, et al. **J Chir (Paris)** 1997 Nov; 134(5–6):243–47 (Eng. Abstr.) **(Fre)**

[Mechanical hemorrhoidectomy using circular staples: warning to colleagues] Marti MC. **Swiss Surg** 1999; 5(3):151–2; discussion 152–4 **(Fre, Ger)**

[Stapler hemorrhoidectomy--a new alternative to conventional methods] Gastinger I. **Zentralbl Chir** 1999; 124(7):676 **(Ger)**

[Stapler hemorrhoidectomy. A new alternative to conventional methods] Kohlstadt CM, et al.
Zentralbl Chir 1999;124(3):238–43 (Eng. Abstr.) **(Ger)**

[Common variable immunodeficiency associated with autoimmune thrombocytopenia: anesthetic management] Fernández-Liesa JI, et al. **Rev Esp Anestesiol Reanim** 1998 Dec;45(10):433–5 (Eng. Abstr.) **(Spa)**

[Infrared photocoagulation in the treatment of hemorrhoids] Charúa Guindic L, et al. **Rev Gastroenterol Mex** 1998 Jul-Sep;63(3):131–4 (Eng. Abstr.) **(Spa)**

[Combined hemorrhoids in early childhood] Bartosh AM, et al. **Klin Khir** 1998;(6):49–50 **(Ukr)**

[Results of hemoroidectomy with the use of staplers] Harvrylenko SP. **Klin Khir** 1998;(6):9–10 (Eng. Abstr.) **(Ukr)**

THERAPY

Eight-year experience in treatment of hemorrhoidal disease. Nagy A, et al. **Acta Chir Hung** 1998;37(1–2):71–6 (17 ref.)

Life-threatening retroperitoneal sepsis after hemorrhoid injection sclerotherapy: report of a case. Barwell J, et al.
Dis Colon Rectum 1999 Mar;42(3):421–3

Necrotizing fasciitis after injection sclerotherapy for hemorrhoids: report of a case. Kaman L, et al.
Dis Colon Rectum 1999 Mar;42(3):419–20

Nonoperative management of hemorrhoids: evolution of the office management of hemorrhoids. Salvati EP.
Dis Colon Rectum 1999 Aug;42(8):989–93

Internal hemorrhoids coexisting with chronic anal fissure: new nonsurgical modalities. Madaliński M, et al.
Endoscopy 1998 Oct;30(8):S96

Patient satisfaction and symptom relief after anal dilatation. Oliver DW, et al. **Int J Colorectal Dis** 1998;13(5–6):228–31

Hemorrhoids. Hussain JN. **Prim Care** 1999 Mar;26(1):35–51 (23 ref.)

[Hemorrhoid disease] Hudziak H. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B155–63 (52 ref.) **(Fre)**

[Hemorrhoids--a commonplace affliction. Adequate drugs and application forms bring therapeutic success] Kressenstein S. **Fortschr Med** 1998 Aug 20;116(22–23):42–3 **(Ger)**

[Choice of hemorrhoids treatment] Vorob'ev GI, et al.
Khirurgiia (Mosk) 1999;(8):50–5 (43 ref.) **(Rus)**

[Interventional radiology for chronic hemorrhoids complicated by hemorrhage] Galkin EV, et al.
Vestn Rentgenol Radiol 1998 Sep-Oct;(5):21–4 (Eng. Abstr.) **(Rus)**

[Current concepts in the treatment of hemorrhoids] Muñoz-Juárez M, et al. **Rev Gastroenterol Mex** 1998 Jul-Sep;63(3):163–8 (45 ref.) (Eng. Abstr.) **(Spa)**

HEMOSIDERIN

see related
SIDEROSIS

ANALYSIS

Carbon and hemosiderin-laden macrophages in sputum of traffic policeman exposed to air pollution. Giovagnoli MR, et al. **Arch Environ Health** 1999 Jul-Aug;54(4):284–90

Mild or subclinical intravascular haemolysis subsequent to transcatheter occlusion of the patent arterial duct. Jamjureeruk V, et al. **Cardiol Young** 1999 Jan;9(1):58–62

METABOLISM

[Reference values of hemosiderin-laden alveolar macrophages in bronchoalveolar lavage in children] Ahrens P, et al. **Pneumologie** 1999 May;53(5):262–5 (Eng. Abstr.) **(Ger)**

HEMOSIDEROSIS

Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Milman N, et al.
Respir Med 1998 Jul;92(7):902–7 (50 ref.)

BLOOD

Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis. Cantinieaux B, et al. **J Lab Clin Med** 1999 Apr;133(4):353–61

COMPLICATIONS

Preclinical cardiac dysfunction in transfusion-dependent children and young adults detected with low-dose dobutamine stress echocardiography. Suarez WA, et al.
J Am Soc Echocardiogr 1998 Oct;11(10):948–56

[Cochlear prosthesis implantation in superficial leptomeningeal hemosiderosis] Haferkamp C, et al.
HNO 1999 Jul;47(7):642–6 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Idiopathic pulmonary hemosiderosis. Cohen S.
Am J Med Sci 1999 Jan;317(1):67–74

Idiopathic pulmonary haemosiderosis in an adult. Carbone R, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):530–2

Paroxysmal nocturnal haemoglobinuria. MRI of renal cortical haemosiderosis in two patients, including one renal transplant. Verswijvel G, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1586–9

Evaluation and interpretation of iron in the liver. Turlin B, et al. **Semin Diagn Pathol** 1998 Nov;15(4):237–45 (63 ref.)

[Marked hemosiderosis in myelodysplastic syndrome] Klinz C. **Dtsch Med Wochenschr** 1999 Jan 29;124(4):79–82 (Eng. Abstr.) **(Ger)**

[Pulmonary hemosiderosis and gastroesophageal reflux in an infant] Weimer B, et al. **Pneumologie** 1998 Jul;52(7):412–6 (Eng. Abstr.) **(Ger)**

[Leptomeningeal hemosiderosis and spinal intradural arachnoid cyst] Oelerich M, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1998 Oct;169(4):444–6 **(Ger)**

HEMOSIDEROSIS

DRUG THERAPY

Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979–1994): prolonged survival with low-dose corticosteroid therapy. Kiper N, et al. **Pediatr Pulmonol** 1999 Mar;27(3):180–4

[Case of superficial hemosiderosis of the central nervous system treated with trientine] Arnaud A, et al. **Rev Neurol (Paris)** 1998 Apr;154(3):243–5 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Corneal changes associated with intrastromal corneal ring segments. Fink AM, et al. **Arch Ophthalmol** 1999 Feb; 117(2):282

[A case of hereditary ceruloplasmin deficiency with hemosiderosis] Nakane S, et al. **Rinsho Shinkeigaku** 1999 Feb-Mar;39(2-3):347–51 (Eng. Abstr.) **(Jpn)**

GENETICS

Assignment of the locus for a new lethal neonatal metabolic syndrome to 2q33–37. Visapää I, et al. **Am J Hum Genet** 1998 Nov;63(5):1396–403

[Cerebral hemosiderosis related to hereditary ceruloplasmin deficiency. Clinical familial case study] Servan J, et al. **Rev Neurol (Paris)** 1998 Feb;154(2):158–62 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Immunological aspects of a child with idiopathic pulmonary hemosiderosis and celiac disease] Ploier R, et al. **Klin Padiatr** 1998 Nov-Dec;210(6):409–12 (Eng. Abstr.) **(Ger)**

METABOLISM

Effects of experimental hemosiderosis on pancreatic tissue iron content and structure. Pelot D, et al. **Dig Dis Sci** 1998 Nov;43(11):2411–4

MICROBIOLOGY

Study of toxin production by isolates of Stachybotrys chartarum and Memnoniella echinata isolated during a study of pulmonary hemosiderosis in infants. Jarvis BB, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3620–5

Isolation of Stachybotrys from the lung of a child with pulmonary hemosiderosis. Elidemir O, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):964–6

MORTALITY

Prognosis in pediatric idiopathic pulmonary hemosiderosis. Saeed MM, et al. **Chest** 1999 Sep;116(3):721–5

PATHOLOGY

Chronic peripheral separation of placenta. The significance of diffuse chorioamnionic hemosiderosis. Redline RW, et al. **Am J Clin Pathol** 1999 Jun;111(6):804–10

Hobnail hemangioma: a pseudomalignant vascular lesion with a reappraisal of targetoid hemosiderotic hemangioma. Guillou L, et al. **Am J Surg Pathol** 1999 Jan;23(1):97–105

Effects of experimental hemosiderosis on pancreatic tissue iron content and structure. Pelot D, et al. **Dig Dis Sci** 1998 Nov;43(11):2411–4

Guess what! Targetoid hemosiderotic hemangioma. Ly S, et al. **Eur J Dermatol** 1998 Dec;8(8):583; discussion 584–5

Hobnail hemangioma ("targetoid hemosiderotic hemangioma"): clinicopathologic and immunohistochemical analysis of 62 cases. Mentzel T, et al. **J Cutan Pathol** 1999 Jul;26(6):279–86

Targetoid hemosiderotic hemangioma [letter] Avci O, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):186–7

MR findings in pituitary haemosiderosis. Ambrosetto P, et al. **Pediatr Radiol** 1998 May;28(5):288–9

[Magnetic resonance findings in a case of multiple adenomatous hyperplastic lesions in hemosiderin-containing liver] Blandino A, et al. **Radiol Med (Torino)** 1998 Sep;96(3):260–3 **(Ita)**

HEMOSORPTION see **HEMOPERFUSION**

HEMOSTASIS

Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Cherng YG, et al. **Acta Anaesthesiol Sin** 1998 Dec;36(4):179–86

Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Sakkinen PA, et al. **Am J Epidemiol** 1999 Feb 1;149(3):261–7

Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Wada H, et al. **Am J Hematol** 1999 Apr;60(4):273–8

Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Andersen LF, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):283–9

Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Miyashita T, et al. **Anesth Analg** 1998 Dec; 87(6):1228–33

Valve system performance [letter; comment] Moore MJ. **Anesthesiology** 1999 Apr;90(4):1230–1. Comment on: Anesthesiology 1998 May;88(5):1404–6.

Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Mariani MA, et al. **Ann Thorac Surg** 1999 May;67(5):1370–5

Influence of different autotransfusion devices on the quality of salvaged blood. Reents W, et al. **Ann Thorac Surg** 1999 Jul;68(1):58–62

Hematological problems during the use of cardiac assist devices: clinical experiences in Japan. Tanaka K, et al. **Artif Organs** 1992 Apr;16(2):182–8

The effects of structurally defined triglycerides of differing fatty acid composition on postprandial haemostasis in young, healthy men. Hunter KA, et al. **Atherosclerosis** 1999 Jan;142(1):151–8

Postprandial lipaemia and haemostatic factors. Miller GJ. **Atherosclerosis** 1998 Dec;141 Suppl 1:S47–51 (30 ref.)

British Society for Haemostasis and Thrombosis. 16–18 September 1998. London, UK. Programme and abstracts. **Blood Coagul Fibrinolysis** 1998 Nov;9(8):765–86

Haemostatic factors and risk of coronary heart disease [letter] De Lorenzo F, et al. **Blood Coagul Fibrinolysis** 1999 Mar; 10(2):113–4

Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Harrison P, et al. **Blood Coagul Fibrinolysis** 1999 Jan;10(1):25–31

Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia? He S, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):127–32

Use of snake venom fractions in the coagulation laboratory. Marsh NA. **Blood Coagul Fibrinolysis** 1998 Jul;9(5):395–404 (119 ref.)

Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Lee JH, et al. **Bone Marrow Transplant** 1998 Nov; 22(9):883–8

Consequences of acute normovolaemic haemodilution on haemostasis during major orthopaedic surgery. Hobisch-Hagen P, et al. **Br J Anaesth** 1999 Apr;82(4):503–9

Evaluation of the effect of storage at -70 degrees C for six months on hemostatic function testing in dogs. Bateman SW, et al. **Can J Vet Res** 1999 Jul;63(3):216–20

Hemostatic changes in patients with liver cirrhosis. Ho CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jun; 62(6):376–82

Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Folsom AR, et al. **Circulation** 1999 Aug 17;100(7):736–42

Thrombogenic factors and recurrent coronary events. Moss AJ, et al. **Circulation** 1999 May 18;99(19):2517–22

Hemorheological changes during venous stasis as result of tourniquet application [letter] Forconi S. **Clin Hemorheol Microcirc** 1999;20(3):197–9

Bibliography. Current world literature. Hemostasis and thrombosis. **Curr Opin Hematol** 1999 Sep;6(5):B107–42

Bibliography. Current world literature. Hemostasis and thrombosis. **Curr Opin Hematol** 1998 Sep;5(5):B159–85

Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Duncan BB, et al. **Diabetes Care** 1999 May;22(5):767–72

Study of hemostasis in pediatric patients with portal vein thrombosis [letter] Seixas CA, et al. **Haematologica** 1998 Oct;83(10):955–6

Thrombelastographic patterns during cryotherapy for recurrent hepatocellular carcinoma. Ng KF. **Hepatogastroenterology** 1999 Jan-Feb;46(25):448–52

Adhesion-dependent signalling and the initiation of haemostasis and thrombosis. Andrews RK, et al. **Histol Histopathol** 1998 Jul;13(3):837–44 (70 ref.)

Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. Borries M, et al. **J Am Coll Cardiol** 1999 Aug;34(2):486–93

Relationship between hemostatic factors and known cardiovascular disease correlates in two suburban populations in Taiwan. Pan WH, et al. **J Formos Med Assoc** 1999 Aug;98(8):543–9

Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study [see comments] Junker R, et al. **J Hypertens** 1998 Jul;16(7):917–23. Comment in: J Hypertens 1998 Jul;16(7):913–6.

Comparison of two topical collagen-based hemostatic sponges during cardiothoracic procedures. Zwischenberger JB, et al. **J Invest Surg** 1999 Mar-Apr;12(2):101–6

Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. Shinohara H, et al. **Jpn Heart J** 1998 Nov; 39(6):721–30

Vascular-bed--specific hemostasis and hypercoagulable states. Rosenberg RD, et al. **N Engl J Med** 1999 May 20; 340(20):1555–64 (79 ref.)

Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation [see comments] Enjyoji K, et al. **Nat Med** 1999 Sep;5(9):1010–7 . Comment in: Nat Med 1999 Sep;5(9):987–8.

Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis [news; comment] Zimmermann H. **Nat Med** 1999 Sep;5(9):987–8. Comment on: Nat Med 1999 Sep;5(9):1010–7.

The decidua regulates hemostasis in human endometrium. Lockwood CJ, et al. **Semin Reprod Endocrinol** 1999; 17(1):45–51 (48 ref.)

Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics. Dati F, et al. **Semin Thromb Hemost** 1998;24(5):443–8 (42 ref.)

Platelet hemostatic capacity (PHC) and fibrinolytic inhibitors during pregnancy. Suzuki S, et al. **Semin Thromb Hemost** 1998;24(5):449–51

Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Wada H, et al. **Semin Thromb Hemost** 1998;24(3):293–7

The emerging impact of phage display technology in thrombosis and haemostasis. Arza B, et al. **Thromb Haemost** 1998 Sep;80(3):354–65 (159 ref.)

Acute haemostasis activation after scuba diving [letter] Gris JC, et al. **Thromb Haemost** 1998 Oct;80(4):721–2

Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Lowe GD, et al. **Thromb Haemost** 1999 Jun;81(6):879–86

Contribution of erythrocytes to thrombin generation in whole blood. Peyrou V, et al. **Thromb Haemost** 1999 Mar; 81(3):400–6

A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy. Sattar N, et al. **Thromb Haemost** 1999 Jan;81(1):71–5

XVth National Congress of the Italian Society on Haemostasis and Thrombosis (SISET). Naples, Italy, September 10–13, 1998. Abstracts. **Thromb Res** 1998 Aug 1;91(3 Suppl 1):S1–149

The influence of a vegetarian diet on haemostatic risk factors for cardiovascular disease in Africans. Famodu AA, et al. **Thromb Res** 1999 Jul 1;95(1):31–6

Applications of a hollow fiber device to monitor hemostasis. Gabriel DA, et al. **Thromb Res** 1998 Dec 15;92(6 Suppl 2):S59–65

The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury. Li CK, et al. **Thromb Res** 1998 Dec 15;92(6 Suppl 2):S67–77

Is it sufficient for hemostatic abnormalities alone to explain atherosclerotic change in coronary arteries? [letter] Matsuo T, et al. **Thromb Res** 1999 Apr 15;94(2):135–6

Mechanical factors affecting hemostasis and thrombosis. Turitto VT, et al. **Thromb Res** 1998 Dec 15;92(6 Suppl 2):S25–31 (37 ref.)

Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Kaliciński P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):378–9

Microbes, hemostasis and vascular biology. Lottenberg R, et al. **Trends Microbiol** 1998 Nov;6(11):428–9

Evaluation of secondary haemostasis in canine leishmaniasis. Moreno P. **Vet Rec** 1999 Feb 13;144(7):169–71

[Hemostasis and levels of cytoadhesion molecules in gestational diabetes] Bendl J, et al. **Ceska Gynekol** 1999 Apr;64(2):83–6 (Eng. Abstr.) **(Cze)**

[Hemostasis and human immunodeficiency virus (HIV) infection] Toulon P. **Ann Biol Clin (Paris)** 1998 Mar-Apr; 56(2):153–60 (46 ref.) (Eng. Abstr.) **(Fre)**

[Hemostasis and transfusion aspects of blood and plasma product safety] Seyfert UT, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):488–92 (7 ref.) **(Ger)**

[Hemostatic abnormalities in ischemic stroke] Misz M, et al. **Orv Hetil** 1998 Oct 18;139(42):2503–7 (4 ref.) (Eng. Abstr.) **(Hun)**

[Hemostasis for the anesthesiologist in surgery and intensive care. Milano, Italy, 11–12 February 1999. Proceedings] **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):1–104 **(Ita)**

[Some parameters of hemostasis and fibrinolysis in diabetic patients] Telejko B, et al. **Pol Arch Med Wewn** 1998 Aug; 100(2):133–8 (Eng. Abstr.) **(Pol)**

[State of the hemostasis and fibrinolysis systems in cesarean section under combined ketamine anesthesia] Kairov GT, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):33–5 (Eng. Abstr.) **(Rus)**

[Abnormal structure of blood cells and related hemostasis reactions during persistence of mycoplasma infection in humans] Chernova OA, et al. **Dokl Akad Nauk** 1999 Apr; 365(6):842–5 **(Rus)**

[A method for atraumatic erythrocyte plasma removal to obtain membranes capable of performing the hemostatic function of thrombocytes] Grigor'ev GI. **Klin Lab Diagn** 1999 Jul;(7):18–21 (Eng. Abstr.) **(Rus)**

[Novel method for calculation of hemostatic potential and its clinical applications. 2] Roitman EV, et al. **Klin Lab Diagn** 1999 Apr;(4):36–9 (Eng. Abstr.) **(Rus)**

[The pathology of hemostasis] Makarov VA. **Patol Fiziol Eksp Ter** 1998 Oct-Dec;(4):40–8 (27 ref.) **(Rus)**

[The evaluation of hemostatic disorders in patients with systemic lupus erythematosus] Arshinov AV, et al. **Ter Arkh** 1999;71(5):38–40 (Eng. Abstr.) **(Rus)**

[Hemostatic changes in acute disorders of the cerebral circulation] Shirokov EA. **Voen Med Zh** 1999 Apr; 320(4):56–60 (22 ref.) **(Rus)**

[Platelet function (letter)] Rolović Z. **Srp Arh Celok Lek** 1999 May-Jun;127(5-6):222-3 **(Scc)**

[Ten new lessons in hemostasis] Obradović S, et al. **Vojnosanit Pregl** 1998 Nov-Dec;55(6):641-8 (64 ref.) **(Scc)**

[The effect of the lysosomal function of circulating neutrophils on hemostasis and on the morphological changes in the internal organs in the disseminated intravascular coagulation syndrome] Koval' SB, et al. **Fiziol Zh** 1999;45(3):61-8 (Eng. Abstr.) **(Ukr)**

[The function of the hemostatic system in patients with a duodenal ulcer combined with chronic pancreatitis] Dzvonkovs'ka VV, et al. **Lik Sprava** 1999 Mar;(2):50-3 (Eng. Abstr.) **(Ukr)**

[The effect of reflexotherapy on the hemostatic system of patients with glomerulonephritis] Holub TI. **Lik Sprava** 1999 Apr-May;(3):157-61 (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

Effects of ketorolac and dextran-70 alone and in combination on haemostasis. Power I, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):982-6

Molecular mechanisms underlying alcohol-induced cardioprotection: contribution of hemostatic components. Introduction to the symposium. Zakhari S. **Alcohol Clin Exp Res** 1999 Jun;23(6):1108-10

Effects of oral contraceptives on hemostasis and thrombosis. Rosing J, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S375-82 (28 ref.)

The effects of sevoflurane on cerebral blood flow autoregulation in rats. Lu H, et al. **Anesth Analg** 1998 Oct; 87(4):854-8

Invertebrate compounds acting on the hemostatic mechanism [see comments] Arocha-Piñango CL, et al. **Blood Coagul Fibrinolysis** 1999 Mar;10(2):43-68 (229 ref.) . Comment in: Blood Coagul Fibrinolysis 1999 Jun;10(4):213.

Invertebrate compounds acting on the hemostatic mechanism: new information [letter; comment] Arocha-Piñango CL. **Blood Coagul Fibrinolysis** 1999 Jun; 10(4):213. Comment on: Blood Coagul Fibrinolysis 1999 Mar;10(2):43-68.

The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Hahn L, et al. **Blood Coagul Fibrinolysis** 1999 Mar;10(2):81-6

A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. LeBlanc R, et al. **Bone Marrow Transplant** 1999 May;23(10):991-6

Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Sonksen JR, et al. **Br J Anaesth** 1999 Mar;82(3):360-5

Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Egberg N, et al. **Contraception** 1998 Aug; 58(2):93-8

The effect of nimesulide versus placebo on hemostasis in healthy voluateers. Marbet GA, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):383-7

Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters. Glusa E, et al. **Haemostasis** 1998 Jan-Feb;28(1):45-56

Aspirin and heparin prevent hepatic blood stasis and thrombosis induced by the toxic glycoprotein Bolesatine in mice. Ennamany R, et al. **Hum Exp Toxicol** 1998 Nov; 17(11):620-4

Effects of progestins on cardiovascular diseases: the haemostatic system [see comments] Winkler UH. **Hum Reprod Update** 1999 May-Jun;5(3):200-4 (51 ref.). Comment in: Hum Reprod Update 1999 May-Jun;5(3):189-90.

Anticoagulative effect of nitric oxide inhalation in ARDS. Ferrer R, et al. **Intensive Care Med** 1998 Aug;24(8):837-8

Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat. Lavelle SM, et al. **Ir J Med Sci** 1998 Oct-Dec;167(4):216-20

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile [see comments] Dangas G, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1294-304. Comment in: J Am Coll Cardiol 1999 Apr;33(5):1305-7.

Antiplasmin correlates to arterial reactivity in a healthy population of 35-year-old men and women. Johansson J, et al. **J Intern Med** 1999 Jan;245(1):21-9

Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage. Niemi T, et al. **J Neurosurg Anesthesiol** 1999 Jul;11(3):188-94

A prospective study on the effects of reformulated 2-rod Norplant implant on haemostasis after five years of use. Koh SC, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):177-83

The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. Klokkevold PR, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):49-52

NO effect on hemostasis [letter; comment] Cheung PY, et al. **J Pediatr** 1999 Mar;134(3):383-4. Comment on: J Pediatr 1998 Apr;132(4):731-4.

Treatment of heartwater: potential adverse effects of furosemide administration on certain homeostatic parameters in normal sheep. Shakespeare AS, et al. **J S Afr Vet Assoc** 1998 Dec;69(4):129-36

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Schultze AE, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):271-346 (381 ref.)

Strategy for balancing anticoagulation and hemostasis in aortocoronary bypass surgery: blood conservation and graft patency. Hashimoto K, et al. **Jpn Circ J** 1999 Mar; 63(3):165-9

Hemostasis, platelet functions, serotonin and serum lipids during omega-3 fatty acid treatment in patients with glomerulonephritis [letter] Malyszko JS, et al. **Nephron** 1998 Sep;80(1):94-6

Resistance to activated protein C in women using oral contraceptives. Spannagl M, et al. **Semin Thromb Hemost** 1998;24(5):423-30

Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Bloemenkamp KW, et al. **Thromb Haemost** 1998 Sep;80(3):382-7

Altered hemostasis in male rats following administration of the ACAT inhibitor SKF-99085. Sellers T, et al. **Toxicol Sci** 1998 Nov;46(1):151-4

[Pharmacotherapeutic choices for correction of disorders of primary hemostasis] Levi M, et al. **Ned Tijdschr Geneeskd** 1999 Feb 13;143(7):347-51 (42 ref.) (Eng. Abstr.) **(Dut)**

[Effects on vasomotor tone and hemostatic function of radiologic contrast media used during invasive cardiological procedures] De Caterina R, et al. **G Ital Cardiol** 1999 Sep;29(9):1047-52 (40 ref.) (Eng. Abstr.) **(Ita)**

[Effects of the water and ethanol extracts from the root bark of the peony Paconia lutea on the hemostatic blood parameters] Pastorova VE, et al. **Biull Eksp Biol Med** 1999 May;127(5):533-5 **(Rus)**

[Vitamins and trace elements in abnormal hemostasis] Khoksi DK. **Klin Med (Mosk)** 1998;76(8):15-8 (29 ref.) **(Rus)**

[The effect of a peptide erythrocyte extract on the hemostatic reactions of animals under measured gamma irradiation] Zviahol's'ka IM. **Fiziol Zh** 1999;45(3):87-91 (Eng. Abstr.) **(Ukr)**

[The effect of heparin on the functioning of the hemostasis system in patients with insulin-dependent diabetes mellitus in severe forms of diabetic foot] Garbaruchuk OI, et al. **Ukr Biokhim Zh** 1998 Sep-Oct;70(5):111-6 (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

Pro-/anti-coagulants and oxygen transport in tissue. Kang KA. **Adv Exp Med Biol** 1998;454:667-70 (16 ref.)

Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Aronson D, et al. **Am J Cardiol** 1999 Aug 15;84(4):449-53

Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Boaz M, et al. **Am J Kidney Dis** 1999 Sep;34(3):438-44

Hemostatic effects of smoking and oral contraceptive use. Fruzzetti F. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 2):S369-74

Hormone replacement therapy, inflammation, and hemostasis in elderly women. Cushman M, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):893-9

Socioeconomic status and determinants of hemostatic function in healthy women. Wamala SP, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):485-92

Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Falanga A, et al. **Blood** 1999 Apr 15;93(8):2506-14

Some thoughts about localization and expression of tissue factor. Nemerson Y, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S45-7 (10 ref.)

Modulation of haemostatic function and prevention of experimental thrombosis by red wine in rats: a role for increased nitric oxide production. Wollny T, et al. **Br J Pharmacol** 1999 Jun;127(3):747-55

A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Sestito A, et al. **Cardiologia** 1999 Jul;44(7):661-5

Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Freedman JE, et al. **Circ Res** 1999 Jun 25;84(12):1416-21

The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Male C, et al. **Clin Lab Med** 1999 Mar;19(1):39-69 (150 ref.)

Searching for simple outcome markers in sepsis: an effort in futility? [editorial; comment] Boucher BA, et al. **Crit Care Med** 1999 Jul;27(7):1390-1. Comment on: Crit Care Med 1999 Jul;27(7):1303-8.

Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha [see comments] Martínez MA, et al. **Crit Care Med** 1999 Jul;27(7):1303-8. Comment in: Crit Care Med 1999 Jul;27(7):1390-1.

Primary haemostasis: sticky fingers cement the relationship. Clemetson KJ. **Curr Biol** 1999 Feb 11;9(3):R110-2 (9 ref.)

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Freiburghaus C, et al. **Haemophilia** 1998 Jan;4(1):16-20

The pathogenesis of vascular thrombosis and its impact in microvascular surgery. Esclamado RM, et al. **Head Neck** 1999 Jul;21(4):355-62

Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Papatheodoridis GV, et al. **Hepatology** 1999 Apr; 29(4):1085-90

Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Coumans AB, et al. **Hum Reprod** 1999 Jan;14(1):211-4

Platelet receptors for the complement component C1q: implications for hemostasis and thrombosis. Peerschke EI, et al. **Immunobiology** 1998 Aug;199(2):239-49 (47 ref.)

The renin-angiotensin system and vascular fibrinolytic balance. Agirbasli M, et al. **Int J Clin Pract Suppl** 1998 May;94:20-5 (35 ref.)

Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. Li YH, et al. **J Am Coll Cardiol** 1999 May;33(6):1543-8

A study on hemostasis parameters in the neurosurgery of cerebral aneurysms. Carelli EF, et al. **J Neurosurg Sci** 1998 Sep;42(3):131-6

Analysis of hemostasis in the zebrafish. Jagadeeswaran P, et al. **Methods Cell Biol** 1999;59:337-57 (55 ref.)

Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients. Kim SB, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2053-8

Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease. Trifiletti A, et al. **Panminerva Med** 1999 Mar; 41(1):15-7

Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Rand ML, et al. **Semin Thromb Hemost** 1998;24(6):523-9 (38 ref.)

Vascular hemostasis in flowing blood in children. Van Cott EM, et al. **Semin Thromb Hemost** 1998;24(6):583-90 (70 ref.)

Changes in hemostasis after laparoscopic cholecystectomy. Martínez-Ramos C, et al. **Surg Endosc** 1999 May; 13(5):476-9

Cloning and characterization of a cDNA encoding murine coagulation factor X. Liang Z, et al. **Thromb Haemost** 1998 Jul;80(1):87-91

Development and practical use of the new quantitative bleeding time test apparatus. Tamai Y, et al. **Thromb Haemost** 1998 Jul;80(1):181-5

Hemostasis in the mouse (Mus musculus): a review. Tsakiris DA, et al. **Thromb Haemost** 1999 Feb;81(2):177-88 (187 ref.)

Relative influence of age and thrombotic history on hemostatic parameters. Javorschi S, et al. **Thromb Res** 1998 Sep 1;91(5):241-8

Snake venoms and the hemostatic system. Markland FS. **Toxicon** 1998 Dec;36(12):1749-800 (254 ref.)

The hemostatic effect of packed red cell transfusion in patients with anemia. Ho CH. **Transfusion** 1998 Nov-Dec; 38(11-12):1011-4

Comparison of haemostatic parameters in arterial and venous blood from patients with peripheral arterial occlusive disease. Woller T, et al. **Vasa** 1999 Feb;28(1):10-4

[The role of thrombotic and hemostatic mechanisms in the initial phases of atherosclerosis] Drouet L, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:41-51 (42 ref.) (Eng. Abstr.) **(Fre)**

[Polytrauma and hemostatic anomalies] Guay J, et al. **Can J Anaesth** 1998 Jul;45(7):683-91 (Eng. Abstr.) **(Fre)**

[The discovery of blood platelets] Caen J. **Rev Prat** 1999 Mar 15;49(6):581-2 **(Fre)**

[Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment] Conard J. **Therapie** 1999 May-Jun;54(3):363-7 (35 ref.) (Eng. Abstr.) **(Fre)**

[General classification of hemostasis] Baudo F, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):1-5 (24 ref.) **(Ita)**

[Hemostasis and coagulation during major liver surgery and during orthotopic liver transplant] De Gasperi A. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):77-91 (43 ref.) **(Ita)**

[The role of thrombin in hemostasis] Olas B, et al. **Postepy Hig Med Dosw** 1998;52(5):471-87 (85 ref.) (Eng. Abstr.) **(Pol)**

[The role of tissue factor and its inhibitor in hemostasis] Naumnik B, et al. **Przegl Lek** 1998;55(2):68-73 (36 ref.) (Eng. Abstr.) **(Pol)**

[The effect of progressive incremental exercise on some parameters of hemostasis] Przybylowski J, et al. **Wiad Lek** 1998;51(5-6):260-4 (Eng. Abstr.) **(Pol)**

[Reaction of the system of hemostasis to additional respiratory resistance] Bialovskii IuIu. et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):40-3 **(Rus)**

[Mathematical models in hemostasis physiology] Barynin IuA, et al. **Izv Akad Nauk Ser Biol** 1999 Jan-Feb;(1):59-66 (7 ref.) (Eng. Abstr.) **(Rus)**

[Hemostatic potential of the blood: from concept to estimation. 1] Roitman EV, et al. **Klin Lab Diagn** 1999 Mar; (3):18-21 **(Rus)**

[The effect of contrast baths on the hemostatic function of patients with ischemic heart disease] Sorokina EI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 May-Jun; (3):26-8 (Eng. Abstr.) **(Rus)**

[A new model of hemostasis] Galajda P, et al. **Vnitr Lek** 1998 Nov;44(11):671-4 (Eng. Abstr.) **(Slo)**

HEMOSTASIS

[Physical activity and arteriosclerosis. The effects of physical activity on lipid oxidation, hemostasis and endothelial function] Codina O, et al. **Med Clin (Barc)** 1999 Apr 17; 112(13):508–15 (133 ref.) **(Spa)**

[Status of the system of hemostasis in patients with non-insulin-dependent and insulin-dependent diabetes mellitus without clinical manifestation of vessel pathology] Harbarchuk OI. **Ukr Biokhim Zh** 1998 Jul–Aug;70(4):134–9 (Eng. Abstr.) **(Ukr)**

RADIATION EFFECTS

[The effect of a peptide erythrocyte extract on the hemostatic reactions of animals under measured gamma irradiation] Zviahol's'ka IM. **Fiziol Zh** 1999;45(3):87–91 (Eng. Abstr.) **(Ukr)**

HEMOSTASIS, ENDOSCOPIC

Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials [see comments] Gralnek IM, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2047–56. Comment in: Am J Gastroenterol 1998 Nov;93(11):2009–11.

Bleeding ulcer: inject or clip? Nagasu N, et al. **Am J Gastroenterol** 1998 Oct;93(10):1998

Ethanolamine injection for sclerotherapy of angiodysplasia of the colon. Bemvenuti GA, et al. **Endoscopy** 1998 Aug; 30(6):564–9

Effect of programmed endoscopic follow-up examinations on the rebleeding rate of gastric or duodenal peptic ulcers treated by injection therapy: a prospective, randomized controlled trial [see comments] Messmann H, et al. **Endoscopy** 1998 Sep;30(7):583–9. Comment in: Endoscopy 1998 Sep;30(7):650–2.

Fibrin sealing in peptic ulcer bleeding: the fate of the clot. Pescatore P, et al. **Endoscopy** 1998 Aug;30(6):519–23

Second thoughts about second-look endoscopy for ulcer bleeding? [editorial; comment] Saeed ZA. **Endoscopy** 1998 Sep;30(7):650–2. Comment on: Endoscopy 1998 Sep;30(7):583–9.

Endoscopic hemostasis in exulceratio simplex-Dieulafoy's disease hemorrhage: a review of 25 cases. Skok P. **Endoscopy** 1998 Sep;30(7):590–4

Endoscopic ligation for bleeding rectal varices in a child with primary extrahepatic portal hypertension. Uno Y, et al. **Endoscopy** 1998 Nov;30(9):S107–8

Endoscopic ligation for non-esophageal variceal upper gastrointestinal hemorrhage. Wong RM, et al. **Endoscopy** 1998 Nov;30(9):774–7

Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Coraggio F, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):673–6

The role of endoscopic therapy in the management of variceal hemorrhage. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec; 48(6):697–8

Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers. Chung IK, et al. **Gastrointest Endosc** 1999 Jan;49(1):13–8

Endoscopic management of hemorrhage from a duodenal diverticulum. Dalal AA, et al. **Gastrointest Endosc** 1998 Oct;48(4):418–20

Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. de la Peña J, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):417–23

Clinical usefulness of 3% hydrogen peroxide in acute upper GI bleeding: a pilot study. Kalloo AN, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):518–21

Endoscopic injection and polypectomy for bleeding Brunner's gland hamartoma [letter] Mukherjee S, et al. **Gastrointest Endosc** 1999 Oct;50(4):597–8

Massive bleeding of esophageal ulcer: treatment by endoscopic ligation. Yoshimura K, et al. **Gastrointest Endosc** 1999 Oct;50(4):581–2

Comparison of adrenaline injection and bipolar electrocoagulation for the arrest of peptic ulcer bleeding. Lin HJ, et al. **Gut** 1999 May;44(5):715–9

Sclerotherapy or banding for oesophageal varices? Sung JJ. **HPB Surg** 1998;11(2):131–3

Experimental studies of injection agents for peptic ulcer bleeding endoscopic control. Pundzius J, et al. **Int Surg** 1998 Oct–Dec;83(4):280–2

The successful use of telemedicine in acute variceal hemorrhage [letter] Ahmed A, et al. **J Clin Gastroenterol** 1999 Sep;29(2):212–3

Influence of endoscopic variceal ligation on oesophageal motility. Chen SM, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):231–5

Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. De BK, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):220–4

Oesophageal motility and gastro-oesophageal reflux: effect of variceal eradication by endoscopic sclerotherapy. Ghoshal UC, et al. **J Gastroenterol Hepatol** 1998 Oct; 13(10):1033–8

Evaluation of endoscopic variceal ligation in prophylactic therapy for bleeding of oesophageal varices: a prospective, controlled trial compared with endoscopic injection sclerotherapy. Gotoh Y, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):241–4

Endoscopic variceal ligation is a sufficient procedure for the treatment of oesophageal varices in patients with hepatitis C liver cirrhosis: comparison with injection sclerotherapy. Hata Y, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):236–40

Clinical evaluation of endoscopic injection sclerotherapy using n-butyl-2-cyanoacrylate for gastric variceal bleeding. Ogawa K, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):245–50

Management of severe ulcer rebleeding [editorial; comment] Jensen DM. **N Engl J Med** 1999 Mar 11;340(10):799–801 . Comment on: N Engl J Med 1999 Mar 11;340(10):751–6.

Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers [see comments] Lau JY, et al. **N Engl J Med** 1999 Mar 11;340(10):751–6. Comment in: N Engl J Med 1999 Mar 11;340(10):799–801. Comment in: N Engl J Med 1999 Aug 5;341(6):455–6.

Endoscopic retreatment or surgery for severe ulcer rebleeding [letter; comment] Schein M. **N Engl J Med** 1999 Aug 5;341(6):455–6. Comment on: N Engl J Med 1999 Mar 11;340(10):751–6.

A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. Svoboda P, et al. **Surg Endosc** 1999 Jun;13(6):580–4

[The endoscopic diagnosis and therapy as well as the long-term course of Dieulafoy ulcer hemorrhage] Schilling D, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124(14):419–23 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Severe bleeding following endoscopic variceal ligation: should EVL be avoided in Child C patients? Van Vlierberghe H, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):175–7

Early massive bleeding after endoscopic ligation for junctional varices. Savoye G, et al. **Endoscopy** 1998 Nov; 30(9):S101

ECONOMICS

The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Gralnek IM, et al. **Hepatology** 1999 Jan;29(1):44–50

Cost analysis for the prevention of variceal rebleeding: a comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients. Meddi P, et al. **Hepatology** 1999 Apr;29(4):1074–7

INSTRUMENTATION

In vitro evaluation of integrity and sterilization of single-use argon beam plasma coagulation probes. Roach SK, et al. **Am J Gastroenterol** 1999 Jan;94(1):139–43

Endoscopic band ligation device for bleeding gastric angiodysplasia [letter] Jo Y, et al. **Gastrointest Endosc** 1999 Oct;50(4):599

Randomized controlled studies of injection Gold Probes compared with monotherapies for hemostasis of bleeding canine gastric ulcers. Jutabha R, et al. **Gastrointest Endosc** 1998 Dec;48(6):598–605

How secure are the arteries occluded by a newly developed ultrasonically activated device? Kanehira E, et al. **Surg Endosc** 1999 Apr;13(4):340–2

METHODS

Endoscopic hemostasis in sphincterotomy-induced hemorrhage: its efficacy and safety. Kim HJ, et al. **Endoscopy** 1999 Aug;31(6):431–6

Endoscopic hemostasis in acute diverticular bleeding. Prakash C, et al. **Endoscopy** 1999 Aug;31(6):460–3

Gastric variceal ligation: a new technique. Shiha G, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):437–41

Use of endoscopic band ligation in the treatment of ongoing rectal bleeding. Vandervoort J, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):392–4

Esophageal variceal ligation by reloading with inexpensive hemorrhoidal O-ring--is an overtube necessary? Wong SY, et al. **J Clin Gastroenterol** 1999 Sep;29(2):158–60

[Case records from Nippon Medical School. Emergency endoscopy and endoscopic treatment to hemorrhagic peptic ulcer (clinical conference)] Matsuhisa T, et al. **Nippon Ika Daigaku Zasshi** 1999 Jun;66(3):199–202 **(Jpn)**

[Endoscopic hemostasis for esophagogastric bleeding: technical assessment and recent advances] Murashima N. **Nippon Rinsho** 1998 Sep;56(9):2276–80 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Ligation with bands in the treatment of hemorrhagic esophageal varices] Llach J, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):413–7 (54 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Endoscopic practice for upper gastrointestinal hemorrhage: differences between major teaching and community-based hospitals. Cooper GS, et al. **Gastrointest Endosc** 1998 Oct; 48(4):348–53

HEMOSTASIS, SURGICAL

The efficacy and safety of aprotinin use in cardiac surgery. Rich JB. **Ann Thorac Surg** 1998 Nov;66(5 Suppl):S6–11; discussion S25–8 (20 ref.)

Tympanoplasty in a patient with hemophilia B. Fujita N, et al. **Auris Nasus Larynx** 1999 Apr;26(2):195–9

Perioperative reliability of an on-site prothrombin time assay under different haemostatic conditions. Zalunardo MP, et al. **Br J Anaesth** 1998 Oct;81(4):533–6

Control of intraoperative bleeding with hydrostatic pressure during endoscopic surgery. Wang KC, et al. **Childs Nerv Syst** 1998 Jun;14(6):280–4

Does bismuth subgallate have haemostatic effects in tonsillectomy? Sørensen WT, et al. **Clin Otolaryngol** 1999 Feb;24(1):72–4

A novel application of the infrared coagulator in hair transplantation. Significant reduction of width of the donor site wound [see comments] Warmuth IP, et al. **Dermatol Surg** 1998 Oct;24(10):1079–82. Comment in: Dermatol Surg 1999 Jan;25(1):78.

Immediate and late bleeding after endoscopic sphincterotomy [letter; comment] Mosca S, et al. **Endoscopy** 1999 Mar; 31(3):278–9. Comment on: Endoscopy 1998 Jan;30(1):37–9.

Fibrinogen-impregnated collagen as a combined haemostatic agent and antibiotic delivery system in a porcine model of splenic trauma. Parker SJ, et al. **Eur J Surg** 1999 Jun; 165(6):609–14

Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia. Srivastava A, et al. **Haemophilia** 1998 Nov;4(6):799–801

An effective method for improving hemostasis in aortic root replacement with a composite graft. Liu KX, et al. **Heart Vessels** 1998;13(5):237–40

Application of cryoprecipitate as a hematostatic glue. Shiono N, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):609–12

Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. Khuri SF, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):172–83; discussion 183–4

Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Despotis GJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):84–104 (208 ref.)

Per anal suturing of a bleeding ulcer to achieve successful hemostasis of massive hemorrhage associated with ulcerative colitis: report of two cases. Yokoyama T, et al. **Surg Today** 1998;28(11):1179–81

[New approaches to tissue management in minimal invasive pediatric surgery] Carbon RT, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1175–8 (Eng. Abstr.) **(Ger)**

[Hemostatic effect of a novel sheeted fibrin adhesive agent, TO-193, on experimental incision models] Ueda N, et al. **Nippon Yakurigaku Zasshi** 1999 Mar;113(3):177–84 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Tourniquet release for hemostasis increases bleeding. A randomized study of 77 knee replacements. Jorn LP, et al. **Acta Orthop Scand** 1999 Jun;70(3):265–7

Surgical hemostasis after tourniquet release does not reduce blood loss in knee replacement. A prospective randomized study of 81 patients. Widman J, et al. **Acta Orthop Scand** 1999 Jun;70(3):268–70

Septal branch right ventricular fistula: a complication in coronary artery snaring. Tanemoto K, et al. **Ann Thorac Surg** 1999 Jul;68(1):246–8

Prolonged lactic acidosis after extended hepatectomy under in situ hypothermic perfusion. Davidson BR, et al. **Liver Transpl Surg** 1999 Mar;5(2):151–2

[Fatal gas embolism during corrective surgery for scoliosis using the posterior approach] López LM, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul;46(6):267–70 (Eng. Abstr.) **(Spa)**

HISTORY

Kurt Semm and the fight against skepticism: endoscopic hemostasis, laparoscopic appendectomy, and Semm's impact on the "laparoscopic revolution". Litynski GS. **J Soc Laparoendosc Surg** 1998 Jul–Sep;2(3):309–13 (27 ref.)

INSTRUMENTATION

Sutureless repair of major intracranial vessels with the Sundt clip-graft: technical note. Lanzino G, et al. **Acta Neurochir (Wien)** 1998;140(5):491–3

A "tacky" situation [letter] Yarze JC. **Am J Gastroenterol** 1999 Jul;94(7):1984–5

As originally published in 1996: Endothelial effects of hemostatic devices for continuous cardioplegia or minimally invasive operations. Updated in 1999. Chavanon O, et al. **Ann Thorac Surg** 1999 Sep;68(3):1118–20

Vascular clamp for hemostasis and stabilization during minimally invasive direct coronary artery bypass. Goh K, et al. **Ann Thorac Surg** 1999 Aug;68(2):585–6

The Shaw hemostatic scalpel in parotid surgery [letter; comment] Eisele DW. **Arch Otolaryngol Head Neck Surg** 1999 Jan;125(1):119.

Comment on: Arch Otolaryngol Head Neck Surg 1998 Mar;124(3):296–8.

Use of the Perclose device in the brachial artery after coronary intervention. Kulick DL, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):111–2

New techniques using the ultrasonic scalpel in laparoscopic hysterectomy. Kauko M. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):303–5

First clinical evaluation of a new concept for puncture-site occlusion in interventional cardiology and angioplasty. Illi OE, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):220–3

Endoclip: closing the surgical gap [editorial; comment] Devereaux CE, et al. **Gastrointest Endosc** 1999 Sep; 50(3):440–2. Comment on: Gastrointest Endosc 1999 Sep;50(3):405–7. Comment on: Gastrointest Endosc 1999 Sep;50(3):407–10. Comment on: Gastrointest Endosc 1999 Sep;50(3):410–4. Comment on: Gastrointest Endosc 1999 Sep;50(3):431–3.

Hemostasis of colonic diverticular bleeding with hemoclips under endoscopic control: report of a case. Rino Y, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1733–5

Simplified hepatic resection utilizing absorbable polyglycolic acid–based tape and other ligature apparatus. Suzuki M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):292–6

Suture? Staple? Electrosurgery? How to decide what is best for you [see comments] Carter JE. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):171–4 (17 ref.) . Comment in: J Soc Laparoendosc Surg 1997 Jul–Sep;1(3):293.

Hemostatic control with flexible compression tape used during partial nephrectomy and organ salvage. Selikowitz SM, et al. **J Urol** 1999 Aug;162(2):458–9

Preliminary results with a new vascular basket occluder in swine. Kónya A, et al. **J Vasc Interv Radiol** 1999 Sep; 10(8):1043–9

Hemostasis with the ultrasonically activated scalpel. Effective substitute for electrocautery in surgical patients with pacemakers. Strate T, et al. **Surg Endosc** 1999 Jul; 13(7):727

Laparoscopic cholecystectomy using ultrasonically activated coagulating shears. Tsimoyiannis EC, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):421–4

The efficiency of absorbable clips in minimally invasive surgery. Tan TM, et al. **Surg Today** 1999;29(8):828–31

[PTLA (percutaneous transluminal laser angioplasty) recanalization of femoral artery stenoses/occlusions after Angio-Seal administration] Steinkamp HJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):105–8 (Eng. Abstr.) **(Ger)**

[Distal femoro-popliteal bypass using Esmarch regional ischemia. Is evaluation of the method adequate? An opposing comment (letter)] Rimpler H, et al. **Vasa** 1999 Feb;28(1):65–6 **(Ger)**

[An ultrasonic scalpel for laparoscopic gynecologic surgery] Stanojević D, et al. **Srp Arh Celok Lek** 1998 May–Jun; 126(5–6):214–6 (Eng. Abstr.) **(Scc)**

METHODS

Tourniquet release for hemostasis increases bleeding. A randomized study of 77 knee replacements. Jorn LP, et al. **Acta Orthop Scand** 1999 Jun;70(3):265–7

Surgical hemostasis after tourniquet release does not reduce blood loss in knee replacement. A prospective randomized study of 81 patients. Widman J, et al. **Acta Orthop Scand** 1999 Jun;70(3):268–70

The effects of dilute epinephrine saline irrigation on the need for tourniquet use in routine arthroscopic knee surgery. Olszewski AD, et al. **Am J Sports Med** 1999 May–Jun; 27(3):354–6

Repair of left ventricular rupture after mitral valve replacement: use of a Teflon patch and glue. de la Fuente A, et al. **Ann Thorac Surg** 1999 Jun;67(6):1802–3

Funnel graft to innominate vein to control epicardial bleeding. Mehta ID, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1413–4

A simplified method of stabilization and hemostasis for minimally invasive coronary artery bypass. Mueller XM, et al. **Ann Thorac Surg** 1999 Jun;67(6):1811–2

Point of Tehcnique. Bloodless circumcision. Fearne C. **BJU Int** 1999 Apr;83(6):717

Acute normovolaemic haemodilution vs controlled hypotension for reducing the use of allogeneic blood in patients undergoing radical prostatectomy [see comments] Boldt J, et al. **Br J Anaesth** 1999 Feb;82(2):170–4. Comment in: Br J Anaesth 1999 Feb;82(2):161–3.

Intraoperative conservation of red cell mass: controlled hypotension or haemodilution—not necessarily mutually exclusive? [editorial; comment] Levack ID, et al. **Br J Anaesth** 1999 Feb;82(2):161–3. Comment on: Br J Anaesth 1999 Feb;82(2):170–4.

Blood transfusion for caesarean section [letter; comment] McDonald JM, et al. **Br J Anaesth** 1998 Nov;81(5):825–6 . Comment on: Br J Anaesth 1998 Feb;80(2):195–8.

Cardiac bypass haemostasis: putting blood through the mill. Bevan DH. **Br J Haematol** 1999 Feb;104(2):208–19 (145 ref.)

Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). Chamberlin JR, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):143–7; discussion 148

Massive liver haemorrhage and rupture caused by HELLP-syndrome treated by collagen fleeces coated with fibrin glue. Cerwenka H, et al. **Eur J Surg** 1998 Sep; 164(9):709–11

Can we evaluate the pressure of perihepatic packing? Results of a study on dogs. Gadzijev EM, et al. **Injury** 1999 Jan; 30(1):35–41

Intermittent clamping of suction drains in total hip replacement reduces postoperative blood loss: a randomized, controlled trial. Brueggemann PM, et al. **J Arthroplasty** 1999 Jun;14(4):470–2

Reduction of hemorrhage after knee arthroplasty using cryo–based fibrin sealant. Curtin WA, et al. **J Arthroplasty** 1999 Jun;14(4):481–7

Simplified hepatic resection utilizing absorbable polyglycolic acid–based tape and other ligature apparatus. Suzuki M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):292–6

Comparison of coagulation modalities in surgery. Lantis JC II, et al. **J Laparoendosc Adv Surg Tech A** 1998 Dec; 8(6):381–94

Efficacy of dural tenting sutures. Winston KR. **J Neurosurg** 1999 Aug;91(2):180–4

Influence of ligation of the internal iliac veins on the venous plexuses around the sacrum. Hata M, et al. **J Orthop Sci** 1998;3(5):264–71

Best options for cutting and hemostasis during laparoscopic surgery [letter; comment] Fowler DL. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):293. Comment on: J Soc Laparoendosc Surg 1997 Apr–Jun;1(2):171–4.

Multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds. Greenhalgh DG, et al. **J Trauma** 1999 Mar; 46(3):433–40

Use of high–intensity focused ultrasound to control bleeding. Vaezy S, et al. **J Vasc Surg** 1999 Mar;29(3):533–42

Dental extractions in patients maintained on continued oral anticoagulant: comparison of local hemostatic modalities. Blinder D, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):137–40

1:50,000 epinephrine [letter; comment] Collini FJ. **Plast Reconstr Surg** 1999 Apr;103(4):1328–9. Comment on: Plast Reconstr Surg 1998 Sep;102(3):917.

Laparoscopic splenectomy: optimal vascular control using the lateral approach and ultrasonic dissection. Gossot D, et al. **Surg Endosc** 1999 Jan;13(1):21–5

Conservative laparoscopy in the treatment of posttraumatic splenic laceration using microfiber hemostatic collagen: three case histories. Orcalli F, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):445–8

Liver resection using total vascular exclusion. Evans PM, et al. **Surgery** 1998 Oct;124(4):807–13; discussion 814–5

Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Shapiro AD, et al. **Thromb Haemost** 1998 Nov;80(5):773–8

Use of perihepatic packing in the management of intraoperative hemorrhage in liver transplantation. Rodriguez-Montalvo C, et al. **Transplant Proc** 1999 Sep; 31(6):2398–9

[Effect of compression with aerosolized fibrin sealant on surgical hemostasis] Matsui Y, et al. **Kyobu Geka** 1999 Mar; 52(3):211–5 (Eng. Abstr.) **(Jpn)**

[The arrest of an arrosive hemorrhage from the brachiocephalic trunk into the tracheobronchial tree resulting from a tracheal ulcer due to an endoprosthesis] Parshin VD, et al. **Khirurgiia (Mosk)** 1998;(8):51–4 **(Rus)**

Noval radiosurgical technique of cuts and hemostasis in otorhinolaryngology] Pogosov VS, et al. **Vestn Otorinolaringol** 1999;(4):40–1 (6 ref.) (Eng. Abstr.) **(Rus)**

[Other strategies to reduce the use of blood and blood products] Martín Vega C. **Sangre (Barc)** 1998 Aug; 43(4):339–41 (8 ref.) **(Spa)**

[Aortic compression in atonic bleeding after parturition (letter)] Westin B. **Lakartidningen** 1999 Jun 23;96(25):3057 **(Swe)**

[Methods for the surgical arrest of hemorrhage from esophageal varices in liver cirrhosis in the decompensation stage] Rusyn VI, et al. **Klin Khir** 1998;(9–10):83–4 **(Ukr)**

[A transsternal method for stopping pulmonary hemorrhage in patients with superior–lobe destructive pulmonary tuberculosis] Savenkov IuF. **Lik Sprava** 1998 Aug;(6):113–4 (Eng. Abstr.) **(Ukr)**

HEMOSTATIC TECHNIQUES

Management of arterial puncture site after catheterization procedures: evaluating a suture–mediated closure device. Gerckens U, et al. **Am J Cardiol** 1999 Jun 15;83(12):1658–63

Bleeding ulcer: inject or clip? Nagasu N, et al. **Am J Gastroenterol** 1998 Oct;93(10):1998

Shunt control of bleeding after homograft replacement of the ascending aorta. Mancini MC, et al. **Ann Thorac Surg** 1999 Apr;67(4):1162–3

Percutaneous microcrystalline chitosan application for sealing arterial puncture sites. Hoekstra A, et al. **Biomaterials** 1998 Aug;19(16):1467–71

Temporary occlusion of the bladder by sutures for intractable bleeding. Nauth-Misir RR, et al. **Br J Urol** 1993 Nov;72(5 Pt 1):668–9

Vasoseal hemostasis following coronary interventions with Abciximab. Lunney L, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):405–6

Hemostasis using high intensity focused ultrasound. Vaezy S, et al. **Eur J Ultrasound** 1999 Mar;9(1):79–87 (23 ref.)

Non–surgical treatment of variceal bleeding. Fleig WE. **Hepatogastroenterology** 1999 Mar–Apr;46(26):746–52 (37 ref.)

Endoscopic therapy for upper gastrointestinal hemorrhage: a state of the art. Simoens M, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):737–45 (114 ref.)

Alcohol isn't for kids: endoscopic hemostasis of bleeding peptic ulcers in pediatric patients [letter; comment] Kay MH, et al. **J Pediatr** 1998 Dec;133(6):802–3. Comment on: J Pediatr 1997 Dec;131(6):934–6.

Control of splenic bleeding by using high intensity ultrasound. Vaezy S, et al. **J Trauma** 1999 Sep;47(3):521–5

Use of a simple compression dressing to obtain hemostasis after pharmacologic thrombolysis of dialysis grafts. Barzel E. **J Vasc Interv Radiol** 1999 Sep;10(8):1039–42

Massive hemorrhage: treatment with forced wire manipulation. Görich J, et al. **J Vasc Interv Radiol** 1999 Apr;10(4):435–8

Histological changes in the rat common carotid artery induced by aneurysmal wrapping and coating materials. Herrera O, et al. **Neurol Med Chir (Tokyo)** 1999 Feb; 39(2):134–9; discussion 139–40

Internal balloon compression: a method to achieve hemostasis when removing an inadvertently placed pacemaker lead from the subclavian artery. Oude Ophuis AJ, et al. **Pacing Clin Electrophysiol** 1998 Dec;21(12):2673–6

Nasal packing in rhinoplasty and septorhinoplasty: it is wiser to avoid [letter] Yavuzer R, et al. **Plast Reconstr Surg** 1999 Mar;103(3):1081–2

Hemostasis of punctured vessels using Doppler–guided high–intensity ultrasound. Martin RW, et al. **Ultrasound Med Biol** 1999 Jul;25(6):985–90

Hemostasis of punctured blood vessels using high–intensity focused ultrasound. Vaezy S, et al. **Ultrasound Med Biol** 1998 Jul;24(6):903–10

[Secondary ulcer perforation after endoscopic hemostasis with fibrin glue] Wenk H, et al. **Chirurg** 1998 Aug; 69(8):880–2 (Eng. Abstr.) **(Ger)**

[Balloon tamponade in penetrating liver lesions. Technical note] Pellegrino A, et al. **Minerva Chir** 1999 May; 54(5):363–6 (Eng. Abstr.) **(Ita)**

[Hemostasis of the gallbladder bed by using muscle flap with vascular pedicle] Makhovskiĭ VZ, et al. **Khirurgiia (Mosk)** 1998;(11):64–5 **(Rus)**

[The bleeding ulcer of the duodenum: the procedure in unreliable hemostasis] Ratner GL, et al. **Khirurgiia (Mosk)** 1999;(6):23–4 (Eng. Abstr.) **(Rus)**

[Treatment of splenic hemorrhage by intervention on the splenic artery] Durdik S, et al. **Bratisl Lek Listy** 1998 Dec; 99(12):686–7 **(Slo)**

[Elastic band ligation in secondary prevention of esophageal varices hemorrhage] Hrušovský S, et al. **Bratisl Lek Listy** 1999 May;100(5):252–5 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Fatal pulmonary embolism during limb exanguination [letter] Boogaerts JG. **Can J Anaesth** 1998 Oct;45(10):1031–2

[Accidental intracerebral penetration of a nasal hemostatic probe] Adam JC, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):436–9 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

A novel vascular sealing device for closure of percutaneous arterial access sites. Silber S, et al. **Am J Cardiol** 1999 Apr 15;83(8):1248–52

A sprayable hemostat containing fibrillar collagen, bovine thrombin, and autologous plasma. Prior JJ, et al. **Ann Thorac Surg** 1999 Aug;68(2):479–85

Percutaneous vascular closure: plugs, stitches, and glue [editorial; comment] Feldman T. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):89. Comment on: Cathet Cardiovasc Diagn 1998 Sep;45(1):82–8; discussion 90–1.

Novel vascular sealing device for closure of percutaneous vascular access sites [see comments] Gershony G, et al. **Cathet Cardiovasc Diagn** 1998 Sep;45(1):82–8; discussion 90–1. Comment in: Cathet Cardiovasc Diagn 1998 Sep;45(1):89.

Day case angiography of anticoagulated patients using the Angio–Seal haemostatic puncture closure device [letter; comment] Crowe PM. **Clin Radiol** 1999 May;54(5):340–1 . Comment on: Clin Radiol 1999 Jan;54(1):51–5.

The use of the angio–seal haemostatic puncture closure device in high risk patients [see comments] O'Sullivan GJ, et al. **Clin Radiol** 1999 Jan;54(1):51–5. Comment in: Clin Radiol 1999 May;54(5):340–1.

Aspiration of gauze pressure–pack following a dental extraction: a case report. Villasenor A. **Pediatr Dent** 1999 Mar–Apr;21(2):135–6 (6 ref.)

Suture–mediated percutaneous closure of antegrade femoral arterial access sites in patients who have received full anticoagulation therapy. Duda SH, et al. **Radiology** 1999 Jan;210(1):47–52

Femoral artery haemostasis with a pneumatic compression

HEMOSTATIC TECHNIQUES

device versus a clamp after coronary angiography. Janerot-Sjöberg B, et al. **Scand Cardiovasc J** 1998; 32(5):281-4

[A hemostatic tourniquet] Azarskii IN, et al. **Klin Khir** 1998; (9-10):82 **(Rus)**

HEMOSTATICS

see related

VASOCONSTRICTOR AGENTS

Fibrinogen-impregnated collagen as a combined haemostatic agent and antibiotic delivery system in a porcine model of splenic trauma. Parker SJ, et al. **Eur J Surg** 1999 Jun; 165(6):609-14

Hemostatic agents and their safety. Levy JH. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4 Suppl 1):6-11; discussion 36-7

Histological changes in the rat common carotid artery induced by aneurysmal wrapping and coating materials. Herrera O, et al. **Neurol Med Chir (Tokyo)** 1999 Feb; 39(2):134-9; discussion 139-40

Hemostatic factors in hypertriglyceridemic men: effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate. Orth M, et al. **Thromb Res** 1999 Jun 15;94(6):341-51

[Hemostatic and structural effects of the lyophilized cellulose sponge] Mello LR, et al. **Arq Neuropsiquiatr** 1998 Sep; 56(3B):613-20 (Eng. Abstr.) **(Por)**

[Use of fibrin glue prepared from recycled cryoprecipitate in experimental liver surgery] Balint B, et al. **Vojnosanit Pregl** 1998 Sep-Oct;55(5):501-7 (Eng. Abstr.) **(Scc)**

ADMINISTRATION & DOSAGE

Vascular and interventional case of the day. Pancreatic head pseudoaneurysm treated with percutaneous thrombin injection. Luchs SG, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):830, 833-4

Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass. Ray MJ, et al. **Ann Thorac Surg** 1999 Sep;68(3):940-5

Absorption and elimination of alpha-thrombin and tranexamic acid after fibrin sealant application on resected livers in rabbits. Nur I, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):533-7

Treatment of an iatrogenic femoral artery pseudoaneurysm with percutaneous duplex-guided injection of thrombin. Lennox AF, et al. **Circulation** 1999 Aug 10;100(6):e39-41

Does bismuth subgallate have haemostatic effects in tonsillectomy? Sørensen WT, et al. **Clin Otolaryngol** 1999 Feb;24(1):72-4

A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Kasper SM, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):669-75

Longer treatment with vasoactive drugs to prevent early variceal rebleeding in cirrhosis. de Franchis R. **Eur J Gastroenterol Hepatol** 1998 Dec;10(12):1041-4 (32 ref.)

First clinical evaluation of a new concept for puncture-site occlusion in interventional cardiology and angioplasty. Illi OE, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):220-3

A comparative study of the effects of thrombin and electrodesiccation used for haemostasis on inflammation and adhesion formation. Yarali H, et al. **Hum Reprod** 1998 Jun;13(6):1493-5

Reducing perioperative blood loss in patients undergoing total hip arthroplasty. D'Ambrosio A, et al. **Int J Artif Organs** 1999 Jan;22(1):47-51

Treatment of von Willebrand disease. Mannucci PM. **Int J Clin Lab Res** 1998;28(4):211-4 (33 ref.)

Dilute ornitin vasopressin and a myoma drill for laparoscopic myomectomy. Rossetti A, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):189-93

Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin [see comments] Basora M, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):382-7. Comment in: J Cardiothorac Vasc Anesth 1999 Aug;13(4):379-81.

Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy [see comments] Wendel HP, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):388-92. Comment in: J Cardiothorac Vasc Anesth 1999 Aug;13(4):379-81.

O/W lipid emulsions for parenteral drug delivery. IV. Changes in the pharmacokinetics and pharmacodynamics of a highly lipophilic drug, menatetrenone. Sakaeda T, et al. **J Drug Target** 1998;6(3):183-9

Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. Escorsell A, et al. **J Hepatol** 1998 Nov;29(5):779-88

Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. Braat EA, et al. **J Lab Clin Med** 1999 Aug;134(2):161-7

A prospective randomized study of calcium alginate (Sorbsan) versus standard gauze packing following haemorrhoidectomy. Ingram M, et al. **J R Coll Surg Edinb** 1998 Oct;43(5):308-9

Regarding "Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms" [letter; comment] Lennox A, et al. **J Vasc Surg** 1998 Dec;28(6):1120-1. Comment on: J Vasc Surg 1998 Jun;27(6):1032-8.

Strategy for balancing anticoagulation and hemostasis in aortocoronary bypass surgery: blood conservation and graft patency. Hashimoto K, et al. **Jpn Circ J** 1999 Mar; 63(3):165-9

Retrospective analysis of effect of low-dose aprotinin priming on allogeneic blood transfusion in repeated cardiac operations. Miyashita T, et al. **Perfusion** 1999 May; 14(3):189-94

Effects of aprotinin during cardiopulmonary bypass in patients treated with acetylsalicylic acid. Ivert T, et al. **Scand Cardiovasc J** 1998;32(5):289-95

A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent. Cole DJ, et al. **Surgery** 1999 Sep; 126(3):510-7

Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Lubetsky A, et al. **Thromb Haemost** 1999 Mar;81(3):396-9

[Aprotinin and recombinant human erythropoietin reduce the need for homologous blood transfusion in cardiac surgery] Osaka M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep; 46(9):846-53 (Eng. Abstr.) **(Jpn)**

[Lipid peroxidation during enteral correction of experimental blood loss] Matveev SB, et al. **Vopr Med Khim** 1999 Mar-Apr;45(2):140-4 (Eng. Abstr.) **(Rus)**

[The treatment of rectorrhagia secondary to postradiation proctitis with 4% formalin] Coyoli-García O, et al. **Ginecol Obstet Mex** 1999 Jul;67:341-5 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia. Francis JD, et al. **Acta Anaesthesiol Scand** 1999 Sep;43(8):870-3

Severe anaphylactic reaction after primary exposure to aprotinin. Cohen DM, et al. **Ann Thorac Surg** 1999 Mar; 67(3):837-8

Hemostatic agents and their safety. Levy JH. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4 Suppl 1):6-11; discussion 36-7

Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. Alderman EL, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):716-30

Aprotinin and vein graft occlusion--the controversy continues [editorial] Westaby S, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):731-3

Ruptured de novo aneurysm induced by ethyl 2-cyanoacrylate: case report. Tokuda Y, et al. **Neurosurgery** 1998 Sep;43(3):626-8

ANALYSIS

In vitro evaluation of the haemostatic value of the LFB-von Willebrand factor concentrate. Mazurier C. **Haemophilia** 1998;4 Suppl 3:40-3

CLASSIFICATION

Inventory of exogenous hemostatic factors derived form arthropods. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Subcommittee of the International Society on Thrombosis and Haemostasis. Arocha-Piñango CL, et al. **Thromb Haemost** 1999 Apr; 81(4):647-56 (125 ref.)

IMMUNOLOGY

Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease [letter] Schlag G, et al. **J Thorac Cardiovasc Surg** 1998 Dec; 116(6):1082-3

METABOLISM

Vitamin K-supplemented snacks containing olestra: implication for patients taking warfarin [letter] Harrell CC, et al. **JAMA** 1999 Sep 22-29;282(12):1133-4

Human endothelial cells do not exert heparin like accelerating effects on thrombin-antithrombin-complex formation. Ruzicka K, et al. **Life Sci** 1998;63(17):1493-503

Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Gori AM, et al. **Thromb Haemost** 1999 Apr;81(4):589-93

PHARMACOKINETICS

The duration of antidiuretic response of two desmopressin nasal sprays. Eller N, et al. **Int J Clin Pharmacol Ther** 1998 Sep;36(9):494-500

O/W lipid emulsions for parenteral drug delivery. IV. Changes in the pharmacokinetics and pharmacodynamics of a highly lipophilic drug, menatetrenone. Sakaeda T, et al. **J Drug Target** 1998;6(3):183-9

Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. Callréus T, et al. **Pharmacol Toxicol** 1998 Dec; 83(6):259-62

[The effect of the microenvironment of the liver tissues on the dynamic resorption of hemostatic resorbable materials and of adhesive compositions] Savitskaia IM. **Klin Khir** 1999;(6):35-7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Effects of ketorolac and dextran-70 alone and in combination on haemostasis. Power I, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):982-6

The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man. Kubba AK, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1077-82

The blood sparing effect of aprotinin should be revisited [letter; comment] Lentschener C, et al. **Anesthesiology** 1998 Dec;89(6):1598-600. Comment on: Anesthesiology 1998 Jan;88(1):50-7.

Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. Khan MM, et al. **Ann Thorac Surg** 1999 Aug;68(2):473-8

A sprayable hemostat containing fibrillar collagen, bovine thrombin, and autologous plasma. Prior JJ, et al. **Ann Thorac Surg** 1999 Aug;68(2):479-85

Effect of desmopressin on plasma factor VIII and von Willebrand factor concentrations in Greyhounds. Sato I, et al. **Aust Vet J** 1998 Dec;76(12):809-12

Hemostatic capability of rapidly curable glues from gelatin, poly(L-glutamic acid), and carbodiimide. Otani Y, et al. **Biomaterials** 1998 Nov;19(22):2091-8

Erythropoietin- and stem cell factor-induced DNA synthesis in normal human erythroid progenitor cells requires activation of protein kinase Calpha and is strongly inhibited by thrombin. Haslauer M, et al. **Blood** 1999 Jul 1; 94(1):114-26

High-dose aprotinin with gentamicin-vancomycin antibiotic prophylaxis increases blood concentrations of creatinine and cystatin C in patients undergoing coronary artery bypass grafting. Mercieri M, et al. **Br J Anaesth** 1999 Apr; 82(4):531-6

Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation. Chiang HS, et al. **Br J Cancer** 1998 Nov;78(9):1121-7

Reversal of the anticoagulant effects of warfarin by vitamin K1 [editorial; comment] Hirsh J. **Chest** 1998 Dec; 114(6):1505-8. Comment on: Chest 1998 Dec;114(6):1546-50.

Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged [see comments] Wentzien TH, et al. **Chest** 1998 Dec; 114(6):1546-50. Comment in: Chest 1998 Dec;114(6):1505-8.

Synergism of procoagulation effect of thrombin-like enzymes from Dienagkistrodon acutus and Agkistrodon halys snake venoms. Wei WL, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):527-31

Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Seasholtz TM, et al. **Circ Res** 1999 May 28;84(10):1186-93

The effect of arginine vasopressin, lysine vasopressin or oxytocin on ADP or arginine vasopressin-induced Ca2+ increase in human platelets. Pedersen OS, et al. **Clin Physiol** 1999 Jul;19(4):305-10

Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Peters DC, et al. **Drugs** 1999 Feb;57(2):233-60 (124 ref.)

Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Brunet J, et al. **Eur J Pharmacol** 1998 Oct 9;358(3):213-20

Mechanism of endothelium-dependent relaxation induced by thrombin in the pig coronary artery. Mizuno O, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):67-77

The effect of met-enkephalin and aprotinin on heterophil (neutrophil) granulocyte phagocytosis and chemotaxis. Godlewski A, et al. **Folia Histochem Cytobiol** 1999; 37(2):119-20

Does desmopressin reduce bleeding in liver surgery? An experimental study on pigs. Walther C, et al. **In Vivo** 1999 Jan-Feb;13(1):83-5

The role of tissue factor in the pathogenesis of thrombosis and atherosclerosis. Asada Y, et al. **J Atheroscler Thromb** 1998;4(3):135-9 (38 ref.)

Aprotinin versus epsilon-aminocaproic acid for aortic surgery using deep hypothermic circulatory arrest. Eaton MP, et al. **J Cardiothorac Vasc Anesth** 1998 Oct; 12(5):548-52

Complement activation during major surgery: the effect of extracorporeal circuits and high-dose aprotinin. Segal H, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):542-7

Aprotinin has direct platelet protective properties: fact or fiction? [editorial; comment] Shore-Lesserson L. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):379-81. Comment on: J Cardiothorac Vasc Anesth 1999 Aug;13(4):382-7. Comment on: J Cardiothorac Vasc Anesth 1999 Aug;13(4):388-92.

The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. Klokkevold PR, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):49-52

In vitro effects of calcium dobesilate on the responsiveness of spontaneously diabetic rat aorta. Sanz M, et al. **Jpn J Pharmacol** 1998 Nov;78(3):391-4

Agonist-stimulated calcium entry in primary cultures of

human cerebral microvascular endothelial cells. Li L, et al. **Microvasc Res** 1999 May;57(3):211–26

Endothelium-derived hyperpolarizing factor, but not nitric oxide or prostacyclin release, is resistant to menadione-induced oxidative stress in the bovine coronary artery. Kaw S, et al.
Naunyn Schmiedebergs Arch Pharmacol 1999 Feb; 359(2):133–9

Hemodynamic effects of 8-day DL-028 and octreotide administration in rats with portal hypertension. Huang YT, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1303–9

Thrombin receptor occupancy modulates aggregation efficiency and platelet surface expression of vWF and thrombospondin at low thrombin concentrations. Kasirer-Friede A, et al. **Thromb Haemost** 1999 Jun; 81(6):967–75

Ethanol inhibits thrombin-induced secretion of the contents of human platelet dense and alpha-granules and lysosomes. Nguyen A, et al. **Thromb Haemost** 1998 Oct;80(4):662–7

Antiplatelet and antithrombotic effects of a combination of ticlopidine and ginkgo biloba ext (EGb 761). Kim YS, et al. **Thromb Res** 1998 Jul 1;91(1):33–8

Suppression of protein kinase C is associated with inhibition of PYK2 tyrosine phosphorylation and enhancement of PYK2 interaction with Src in thrombin-activated platelets. Ohmori T, et al. **Thromb Res** 1999 Mar 15;93(6):291–8

[Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time] Wen Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):304–6 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Thrombin injection for the repair of brachial artery pseudoaneurysms. Sheiman RG, et al.
AJR Am J Roentgenol 1999 Oct;173(4):1029–30

Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Lentschener C, et al. **Anesth Analg** 1999 Sep;89(3):590–7

Aprotinin in deep hypothermic circulatory arrest. Smith CR, et al. **Ann Thorac Surg** 1999 Jul;68(1):278–86 (66 ref.)

Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Wippermann CF, et al.
Ann Thorac Surg 1999 Jan;67(1):173–6

Adenotonsillectomy in children with von Willebrand disease. Allen GC, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):547–51

Percutaneous microcrystalline chitosan application for sealing arterial puncture sites. Hoekstra A, et al.
Biomaterials 1998 Aug;19(16):1467–71

Safer circumcision in patients with haemophilia: the use of fibrin glue for local haemostasis. Avanogmacr;lu A, et al. **BJU Int** 1999 Jan;83(1):91–4

Recombinant activated factor VII as a universal haemostatic agent. Hedner U. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S147–52 (45 ref.)

Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Sato Y, et al. **Bone** 1998 Sep;23(3):291–6

Aprotinin therapy and disseminated intravascular coagulation after hip replacement [letter; comment] Higgins DJ, et al. **Br J Anaesth** 1998 Dec;81(6):995–6. Comment on: Br J Anaesth 1998 Jun;80(6):853–5.

Case report: fatal hemorrhagic disease in a newborn despite vitamin K prophylaxis. Morrice LM, et al.
Can Fam Physician 1998 Sep;44:1893–4, 1896

Pharmacotherapy of acute non-variceal bleeding [editorial; comment] Gostout CJ. **Dig Dis** 1998 Sep-Oct;16(5):263–5 . Comment on: Dig Dis 1998 Jul-Aug;16(4):214–24.

Thrombin is effective in arresting bleeding from gastric variceal hemorrhage. Przemioslo RT, et al. **Dig Dis Sci** 1999 Apr;44(4):778–81

A comparison between endoscopic injection of bleeding esophageal varices using ethanolamine oleate and fibrin glue sealant in patients with bilharzial liver fibrosis [letter] Naga MI, et al. **Endoscopy** 1999 Jun;31(5):405

Aprotinin counterbalances an increased risk of peri-operative hemorrhage in CABG patients pre-treated with Aspirin. Klein M, et al. **Eur J Cardiothorac Surg** 1998 Oct; 14(4):360–6

Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Coraggio F, et al.
Eur J Gastroenterol Hepatol 1998 Aug;10(8):673–6

Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Kouroumalis EA, et al.
Eur J Gastroenterol Hepatol 1998 Jun;10(6):509–12

A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of variceal haemorrhage. Lee JG. **Gastrointest Endosc** 1998 Oct;48(4):442–4

Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Tamás P, et al. **Gynecol Obstet Invest** 1999;47(3):210–3

Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Deitcher SR, et al. **Haemophilia** 1999 Mar;5(2):88–95

Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor. Montoro JB, et al. **Haemophilia** 1998 Sep; 4(5):762–5

The use of fibrin glue as an operative sealant in dental extraction in bleeding disorder patients. Suwannuraks M, et al. **Haemophilia** 1999 Mar;5(2):106–8

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. D'Amico G, et al.
Hepatology 1998 Nov;28(5):1206–14

Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? Tassani P, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):165–72

Effect of different barriers of oxidized regenerated cellulose (ORC) on cecal and sidewall adhesions in the presence and absence of bleeding. Wiseman DM, et al.
J Invest Surg 1999 May-Jun;12(3):141–6

Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. Scheule AM, et al.
J Thorac Cardiovasc Surg 1999 Aug;118(2):348–53

Fibrin glue terminates massive bleeding after complex hepatic injury. Cohn SM, et al. **J Trauma** 1998 Oct;45(4):666–72

Hemostatic efficacy of a fibrin sealant dressing in an animal model of kidney injury. Jackson MR, et al. **J Trauma** 1998 Oct;45(4):662–5

Use of fibrin sealant to reduce bleeding after needle liver biopsy in an anticoagulated canine model: work in progress. Falstrom JK, et al. **J Vasc Interv Radiol** 1999 Apr; 10(4):457–62

Hemostatic efficacy of fibrin sealant (human) on expanded poly-tetrafluoroethylene carotid patch angioplasty: a randomized clinical trial. Jackson MR, et al.
J Vasc Surg 1999 Sep;30(3):461–6

Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Despotis GJ, et al. **Lancet** 1999 Jul 10;354(9173):106–10

Vitamin K2 therapy for a patient with myelodysplastic syndrome [letter] Yaguchi M, et al. **Leukemia** 1999 Jan; 13(1):144–5

Uterine artery embolization in a hemorrhaging postoperative myomectomy patient [editorial] Schifano MJ, et al.
Obstet Gynecol Surv 1999 Jan;54(1):1–3; discussion 3–4

Efficacy of fibrin sealant in patients on various levels of oral anticoagulant undergoing oral surgery. Bodner L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):421–4

Desmopressin (DDAVP) in bleeding disorders of childhood. Sutor AH. **Semin Thromb Hemost** 1998;24(6):555–66 (114 ref.)

Effects of deamino-8-D-arginin vasopressin on blood loss and coagulation factors in scoliosis surgery. A double-blind randomized clinical trial. Alanay A, et al. **Spine** 1999 May 1;24(9):877–82

Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS, and sepsis. Boeken U, et al. **Thorac Cardiovasc Surg** 1998 Dec; 46(6):348–51

Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Casonato A, et al. **Thromb Haemost** 1999 Feb;81(2):224–8

Plasma platelet-activating factor (PAF) levels and desmopressin response in children with hemophilia A and von Willebrand's disease [letter] Kavakli K, et al.
Thromb Haemost 1999 Apr;81(4):665–6

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, et al. **Thromb Haemost** 1998 Dec; 80(6):912–8

[Clinical observation on effect of xiaoyu zhixue tablet on 104 patients with idiopathic multifocal bleeding and platelet aggregation defect] Shen D, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1997 May; 17(5):280–2 (Eng. Abstr.) **(Chi)**

[Study of controlling acute hemorrhage from esophageal varices using adhesion technique of traditional Chinese medicine] Zhao J, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1997 Dec; 17(12):724–5 (Eng. Abstr.) **(Chi)**

[The plasma levels of endothelin in diabetic retinopathy and their changes after treatment with doxium] Zhong H, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):56–8 (Eng. Abstr.) **(Chi)**

[Pharmacotherapeutic choices for correction of disorders of primary hemostasis] Levi M, et al.
Ned Tijdschr Geneeskd 1999 Feb 13;143(7):347–51 (42 ref.) (Eng. Abstr.) **(Dut)**

[Hemostatic effect of a novel sheeted fibrin adhesive agent, TO-193, on experimental incision models] Ueda N, et al.
Nippon Yakurigaku Zasshi 1999 Mar;113(3):177–84 (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of early bleedings after open-heart surgery] Shevchenko IuL, et al. **Khirurgiia (Mosk)** 1999; (8):28–36 (59 ref.) (Eng. Abstr.) **(Rus)**

[Effects of sodium ethamsylate on anticoagulant and anti-aggregation activity of vascular endothelium in hemorrhagic fever patients with renal syndrome] Davidovich IM, et al. **Ter Arkh** 1999;71(6):49–53 (Eng. Abstr.) **(Rus)**

[2-Component silicone compounds in the emergency surgery of gastrointestinal hemorrhages] Naumov EV, et al.
Vestn Khir Im I I Grek 1998;157(3):26–9 (Eng. Abstr.) **(Rus)**

[Use of nonopiate agents for anesthesia in ENT patients at high surgical-anesthesiological risk] Kulian SM, et al.
Vestn Otorinolaringol 1998;(6):15–20 (Eng. Abstr.) **(Rus)**

[Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases (see comments)] César JM, et al. **Med Clin (Barc)** 1998 Nov 14;111(16):601–3 (Eng. Abstr.). Comment in: Med Clin (Barc) 1998 Nov 14;111(16):616–8. **(Spa)**

HEMOTHORAX

DIAGNOSIS

[CA 125 in the department of internal medicine--a marker of ovarian tumor, thoracic fluid or ascites?] Kasalický P, et al. **Vnitr Lek** 1998 Aug;44(8):478–80 (Eng. Abstr.) **(Cze)**

DRUG THERAPY

[Current value of intrapleural fibrinolysis in the treatment of exudative fibrinous pleural effusions in pleural empyema and hemothorax] Kemper P, et al. **Pneumologie** 1999 Aug; 53(8):373–84 (96 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Pleural complications in the intensive care unit. Strange C. **Clin Chest Med** 1999 Jun;20(2):317–27 (84 ref.)

ETIOLOGY

Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. Quinn MW, et al. **Chest** 1999 Jul; 116(1):257–60

Isolated pericardial rupture with left-sided haematothorax after blunt chest trauma. Verkroost MW, et al.
Eur J Cardiothorac Surg 1998 Nov;14(5):517–9

Rupture of aortic aneurysm with right-sided haemothorax. Baharloo F, et al. **Eur Respir J** 1999 Feb;13(2):465–7

Haemoptysis after breath-hold diving. Boussuges A, et al. **Eur Respir J** 1999 Mar;13(3):697–9

Spontaneous hemothorax secondary to immature teratoma of the mediastinum. Shiota S, et al. **Intern Med** 1999 Sep; 38(9):726–8

An unusual complication of anterior spinal instrumentation: hemothorax contralateral to the side of the incision. A case report. Hsieh PH, et al. **J Bone Joint Surg Am** 1999 Jul; 81(7):998–1001

Tension hemothorax caused by inadvertent insertion of an introducer/dilator into the vertebral artery [letter] Irita K, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):241–2

Solitary cellular schwannoma presenting with haemothorax. Lee MH, et al. **J R Soc Med** 1998 Nov;91(11):596–7

Delayed hemothorax after blunt thoracic trauma: an uncommon entity with significant morbidity. Simon BJ, et al. **J Trauma** 1998 Oct;45(4):673–6

Spontaneous haemothorax: a cause of sudden death in von Recklinghausen's disease. Griffiths AP, et al.
Postgrad Med J 1998 Nov;74(877):679–81

Bilateral hemothorax revealing mediastinal parathyroid adenoma. Santelmo N, et al. **Respiration** 1999;66(2):176–8

Mediastinal perforation and contralateral hemothorax by a chest tube. Rashid MA, et al. **Thorac Cardiovasc Surg** 1998 Dec;46(6):375–6

Intrathoracic extramedullary haematopoiesis complicated by massive haemothorax in alpha-thalassaemia. Chu KA, et al. **Thorax** 1999 May;54(5):466–8

[Unusual diagnosis of post-traumatic hemothorax] Afif H, et al. **Rev Mal Respir** 1999 Feb;16(1):104–6 **(Fre)**

[Angiosarcoma of the thoracic wall revealed by hemothorax] Boulay V, et al. **Rev Pneumol Clin** 1998 Oct;54(5):259–62 (Eng. Abstr.) **(Fre)**

[An error in the catheterization of the subclavian vein in the presence of total pneumothorax] Pivovarov GN.
Klin Khir 1998;(9–10):79 **(Rus)**

[Hemothorax secondary to extracorporal lithotripsy (letter)] León Atance P, et al. **Arch Bronconeumol** 1998 Oct; 34(9):469–70 **(Spa)**

RADIOGRAPHY

The diagnostic problem associated with blunt traumatic azygous vein injury: delayed appearance of right haemothorax after blunt chest trauma. Sugimoto K, et al. **Injury** 1998 Jun;29(5):380–2 (11 ref.)

Predicting the need for thoracoscopic evacuation of residual traumatic hemothorax: chest radiograph is insufficient. Velmahos GC, et al. **J Trauma** 1999 Jan;46(1):65–70

SURGERY

A prospective evaluation of video-assisted thoracic surgery for persistent air leak due to trauma. Schermer CR, et al. **Am J Surg** 1999 Jun;177(6):480–4

Successful treatment of exsanguinating aortic injury from a fractured rib. Kern JA, et al. **Am Surg** 1998 Dec; 64(12):1158–60

Reexpansion pulmonary edema with acute hypovolemia [letter] Cinnella G, et al. **Intensive Care Med** 1998 Oct; 24(10):1117

A case of ruptured descending thoracic aortic aneurysm into the right pleural cavity: importance of preoperative drainage of the right pleural cavity. Akiyama K, et al.
J Cardiovasc Surg (Torino) 1998 Dec;39(6):869–71

HEMOTHORAX

THERAPY

Embolization therapy as an alternative to thoracotomy in vascular injuries of the chest wall. Carrillo EH, et al. **Am Surg** 1998 Dec;64(12):1142–8

[Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor] Huliková M, et al. **Vnitr Lek** 1998 Sep;44(9):547–50 (Eng. Abstr.) **(Slo)**

VETERINARY

Hemothorax in 2 horses. Perkins G, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):375–8

HEMOTOXINS see **HEMOLYSINS**

HEMP see **CANNABIS**

HEMPAS see **ANEMIA, DYSERYTHROPOIETIC, CONGENITAL**

HENDERSON–JONES SYNDROME see **CHONDROMATOSIS, SYNOVIAL**

HENOCH PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

HENOCH–SCHOENLEIN PURPURA see **PURPURA, SCHOENLEIN–HENOCH**

HEPADNAVIRIDAE

ENZYMOLOGY

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Seifer M, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3200–8

GENETICS

A new group of hepadnaviruses naturally infecting orangutans (Pongo pygmaeus). Warren KS, et al. **J Virol** 1999 Sep;73(9):7860–5

IMMUNOLOGY

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Rollier C, et al. **Gastroenterology** 1999 Mar;116(3):658–65

ISOLATION & PURIFICATION

[Detection of TTV DNA in liver tissue of patients with non A–G hepatitis] Xu D, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):96–7 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Structure and function of the encapsidation signal of hepadnaviridae. Kramvis A, et al. **J Viral Hepat** 1998 Nov; 5(6):357–67 (90 ref.)

HEPADNAVIRIDAE INFECTIONS

Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Michalak TI, et al. **Hepatology** 1999 Mar;29(3):928–38

DRUG THERAPY

Treatment of duck hepatitis B virus by antisense poly-2'-O-(2,4-dinitrophenyl)-oligoribonucleotides. Xin W, et al. **Antisense Nucleic Acid Drug Dev** 1998 Dec; 8(6):459–68

The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Hantz O, et al. **Antiviral Res** 1999 Jan;40(3):179–87

Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Soni PN, et al. **Hepatology** 1998 Nov;28(5):1402–10

IMMUNOLOGY

Cellular immune response of ducks to duck hepatitis B virus infection. Vickery K, et al. **J Med Virol** 1999 May; 58(1):19–25

PATHOLOGY

Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus. Lenhoff RJ, et al. **Hepatology** 1999 Feb;29(2):563–71

PREVENTION & CONTROL

Inactivation of duck hepatitis B virus by a hydrogen peroxide gas plasma sterilization system: laboratory and 'in use' testing. Vickery K, et al. **J Hosp Infect** 1999 Apr; 41(4):317–22

VETERINARY

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Rollier C, et al. **Gastroenterology** 1999 Mar;116(3):658–65

A new group of hepadnaviruses naturally infecting orangutans (Pongo pygmaeus). Warren KS, et al. **J Virol** 1999 Sep;73(9):7860–5

VIROLOGY

Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. Sunyach C, et al. **J Virol** 1999 Apr;73(4):2569–75

Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. Yang W, et al. **J Virol** 1998 Nov; 72(11):8710–7

Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. Zhang YY, et al. **J Virol** 1999 May;73(5):3616–22

Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Lenhoff RJ, et al. **Virology** 1998 Nov 10;251(1):85–95

HEPARAN SULFATE see **HEPARITIN SULFATE**

HEPARAN SULFATE PROTEOGLYCAN

Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Summerford C, et al. **Nat Med** 1999 May;5(5):587–8

BIOSYNTHESIS

Basement membrane heparan sulfate proteoglycan (perlecan) synthesized by ACC3, adenoid cystic carcinoma cells of human salivary gland origin. Kimura S, et al. **J Biochem (Tokyo)** 1999 Feb;125(2):406–13

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. Kleeff J, et al. **J Clin Invest** 1998 Nov 1;102(9):1662–73

Chondroitin sulphate and heparan sulfate proteoglycan are sequentially expressed in the uterine extracellular matrix during early pregnancy in the rat. Slater M, et al. **Matrix Biol** 1999 Apr;18(2):125–31

Lead inhibits the core protein synthesis of a large heparan sulfate proteoglycan perlecan by proliferating vascular endothelial cells in culture. Fujiwara Y, et al. **Toxicology** 1999 Apr 15;133(2–3):159–69

CHEMISTRY

The emerging roles of cell surface heparan sulfate proteoglycans [comment] David G, et al. **Matrix Biol** 1998 Nov;17(7):461–3 (12 ref.). Comment on: Matrix Biol 1998 Nov;17(7):473–6. Comment on: Matrix Biol 1998 Nov;17(7):477–84. Comment on: Matrix Biol 1998 Nov;17(7):485–94.

Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Groffen AJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2119–29 (115 ref.)

GENETICS

Heparan sulfate proteoglycan expression is induced during early erythroid differentiation of multipotent hematopoietic stem cells. Drzeniek Z, et al. **Blood** 1999 May 1; 93(9):2884–97

Glypican 3 and glypican 4 are juxtaposed in Xq26.1. Huber R, et al. **Gene** 1998 Dec 28;225(1–2):9–16

Mouse K-glypican gene, gpc4, maps to chromosome X. Matsuki Y, et al. **Genomics** 1998 Dec 1;54(2):358–9

GPC6, a novel member of the glypican gene family, encodes a product structurally related to GPC4 and is colocalized with GPC5 on human chromosome 13. Paine-Saunders S, et al. **Genomics** 1999 May 1;57(3):455–8

Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans. Veugelers M, et al. **J Biol Chem** 1999 Sep 17;274(38):26968–77

Regulated expression and subcellular localization of syndecan heparan sulfate proteoglycans and the syndecan-binding protein CASK/LIN-2 during rat brain development. Hsueh YP, et al. **J Neurosci** 1999 Sep 1;19(17):7415–25

IMMUNOLOGY

Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barré syndrome and other demyelinating polyneuropathies. Pestronk A, et al. **J Neuroimmunol** 1998 Nov 2;91(1–2):204–9

METABOLISM

Binding of beta-VLDL to heparan sulfate proteoglycans requires lipoprotein lipase, whereas ApoE only modulates binding affinity. de Beer F, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):633–7

Physicochemical binding properties of the proteoglycan receptor for serum lipoproteins. Siegel G, et al. **Atherosclerosis** 1999 May;144(1):59–67

Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products. Tumova S, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):471–81

Chromatin clearance in C57Bl/10 mice: interaction with heparan sulphate proteoglycans and receptors on Kupffer cells. Du Clos TW, et al. **Clin Exp Immunol** 1999 Aug; 117(2):403–11

Molecular interactions of the syndecan core proteins. Rapraeger AC, et al. **Curr Opin Cell Biol** 1998 Oct; 10(5):620–8 (63 ref.)

Alterations in both heparan sulfate proteoglycans and mitogenic activity of fibroblast growth factor-2 are triggered by inhibitors of proliferation in normal and breast cancer epithelial cells. Lambrecht V, et al. **Exp Cell Res** 1998 Dec 15;245(2):239–44

Response to "Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia" [letter] Whiteway AJ, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1553–7

Sodium chlorate induces undersulfation of cellular proteoglycans and increases in FSH-stimulated estradiol production in immature rat Sertoli cells. Phamantu NT, et al. **J Androl** 1999 Mar–Apr;20(2):241–50

Identification and characterization of ligands for L-selectin in the kidney. III. Characterization of L-selectin reactive heparan sulfate proteoglycans. Watanabe N, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):826–31

Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding following elastase-induced injury. Buczek-Thomas JA, et al. **J Biol Chem** 1999 Aug 27; 274(35):25167–72

Mammalian homologues of the Drosophila slit protein are ligands of the heparan sulfate proteoglycan glypican-1 in brain. Liang Y, et al. **J Biol Chem** 1999 Jun 18; 274(25):17885–92

Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex. McKeehan WL, et al. **J Biol Chem** 1999 Jul 30;274(31):21511–4

Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. Mahley RW, et al. **J Lipid Res** 1999 Jan; 40(1):1–16 (126 ref.)

Proteoglycan receptor binding by Neisseria gonorrhoeae MS11 is determined by the HV-1 region of OpaA. Grant CC, et al. **Mol Microbiol** 1999 Apr;32(2):233–42

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 [see comments] Qing K, et al. **Nat Med** 1999 Jan;5(1):71–7. Comment in: Nat Med 1999 May;5(5):467–8.

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection [see comments] Summerford C, et al. **Nat Med** 1999 Jan;5(1):78–82. Comment in: Nat Med 1999 May;5(5):467–8.

PHYSIOLOGY

Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. LaRochelle WJ, et al. **Biochemistry** 1999 Feb 9; 38(6):1765–71

Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis. Borghesi LA, et al. **Blood** 1999 Jan 1;93(1):140–8

Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Damiens E, et al. **Eur J Cell Biol** 1998 Dec;77(4):344–51

Evidence that glypican is a receptor mediating beta-amyloid neurotoxicity in PC12 cells. Schulz JG, et al. **Eur J Neurosci** 1998 Jun;10(6):2085–93

The emerging roles of cell surface heparan sulfate proteoglycans [comment] David G, et al. **Matrix Biol** 1998 Nov;17(7):461–3 (12 ref.). Comment on: Matrix Biol 1998 Nov;17(7):473–6. Comment on: Matrix Biol 1998 Nov;17(7):477–84. Comment on: Matrix Biol 1998 Nov;17(7):485–94.

In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Colin S, et al. **Mol Pharmacol** 1999 Jan;55(1):74–82

Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Groffen AJ, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2119–29 (115 ref.)

HEPARIN

Miss-'n-mix and mimics. **Acta Anaesthesiol Belg** 1998; 49(3):221–2

Thromboplastins, heparin, and polybrene [letter; comment] Carroll WE. **Am J Clin Pathol** 1999 Apr;111(4):565. Comment on: Am J Clin Pathol 1996 Oct;106(4):556. Comment on: Am J Clin Pathol 1998 Jun;109(6):764–8.

The risks of heparin-neutralizing substances [letter; comment] Tripodi A. **Am J Clin Pathol** 1999 Apr; 111(4):566. Comment on: Am J Clin Pathol 1998 Jun;109(6):764–8.

The effects of heparin coating of oxygenator fibers on platelet adhesion and protein adsorption. Niimi Y, et al. **Anesth Analg** 1999 Sep;89(3):573–9

Serendipity and the development of heparin and carbon surfaces. Gott VL, et al. **Ann Thorac Surg** 1999 Sep;68(3 Suppl):S19–22

Decreased incidence of arterial thrombosis using heparin-bonded intraaortic balloons. Lazar HL, et al. **Ann Thorac Surg** 1999 Feb;67(2):446–9

Thrombogenicity of deflated intraaortic balloon: impact of heparin coating. Mueller XM, et al. **Artif Organs** 1999 Feb; 23(2):195–8

A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Plötz FB, et al. **Artif Organs** 1992 Aug;16(4):366–70

Nitric oxide gas infusion to the oxygenator enhances the biocompatibility of heparin coated extracorporeal bypass circuits. Hayashi Y, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M456–61

Comparative studies of glycoprotein Ib in heparin coated and nonheparin coated extracorporeal circulation circuits. Hioki I, et al. **ASAIO J** 1998 Sep–Oct;44(5):M397–400

Synthesis and characterization of heparinized polyurethanes using plasma glow discharge. Bae JS, et al. **Biomaterials** 1999 Mar;20(6):529–37

Characterization of transient platelet contacts on a polyvinyl alcohol hydrogel by video microscopy. Godo MN, et al. **Biomaterials** 1999 Jun;20(12):1117–26

Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation. Blezer R, et al. **Blood Coagul Fibrinolysis** 1998 Jul;9(5):435–40

Coating of extracorporeal circuit with heparin does not prevent sequestration of propofol in vitro. Hammarén E, et al. **Br J Anaesth** 1999 Jan;82(1):38–40

Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Reiner E, et al. **Chem Biol Interact** 1999 May 14;119–120:405–11

Is heparin daily flushing useful to decrease the incidence of catheter-related infections? [letter] Martinón-Torres F, et al. **Chest** 1998 Nov;114(5):1498–9

Improvement of patency rate in heparin-coated small synthetic vascular grafts. Walpoth BH, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II319–23; discussion II324

High concentrations of lithium heparin decrease measured serum sodium in some analyzers [letter] Vuillaume I, et al. **Clin Chem** 1999 Oct;45(10):1880–1

Application of heparin to chiral separations of antihistamines by capillary electrophoresis. Jin Y, et al. **Electrophoresis** 1998 Sep;19(12):2119–23

Transfusion after coronary artery bypass surgery: the impact of heparin-bonded circuits. Mahoney CB, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):206–10

Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences. Wimmer-Greinecker G, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):211–7

Ex vivo testing of heparin-coated extracorporeal circuits: bovine experiments. Weerwind PW, et al. **Int J Artif Organs** 1998 May;21(5):291–8

Heparin-coated circuits: a new perspective--the boundary layer [letter] Poullis M. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):508–9

Heparin-surface-modified intraocular lenses in pediatric cataract surgery: prospective randomized study. Basti S, et al. **J Cataract Refract Surg** 1999 Jun;25(6):782–7

Contaminated lithium heparin bottles as a source of pseudobacteraemia due to Pseudomonas fluorescens. Namnyak S, et al. **J Hosp Infect** 1999 Jan;41(1):23–8

Contaminated lithium heparin bottles as a source of pseudobacteraemia [letter] Whyte A, et al. **J Hosp Infect** 1999 Aug;42(4):342–3

Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action. Opanashuk LA, et al. **J Neurosci** 1999 Jan 1;19(1):133–46

Temporary shunt system with a heparin-coated inner surface for interruption of cerebral circulation: experiments in primates. Tenjin H, et al. **Neurosurgery** 1998 Aug; 43(2):312–5; discussion 315–6

Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces. Wendel HP, et al. **Perfusion** 1999 Jan;14(1):21–8

Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Harig F, et al. **Thorac Cardiovasc Surg** 1999 Apr;47(2):111–8

Adherence and proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate. Bos GW, et al. **Tissue Eng** 1998 Fall;4(3):267–79

[Does heparin coating improve the biocompatibility poly(D,L)lactide?] Heidemann W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:434–5 **(Ger)**

[Use of heparin-coated "Jo Stent M" in patients with ischemic heart disease: first results] Savchenko AP, et al. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):4–8 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina. Mombelli G, et al. **Am Heart J** 1998 Dec; 136(6):1106–13

Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Zabel KM, et al. **Am Heart J** 1998 Nov; 136(5):868–76

Establishing an institution-specific therapeutic range for heparin. Volles DF, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):2002–6

Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis. Wright MJ, et al. **Am J Kidney Dis** 1999 Jul;34(1):36–42

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Wallis DE, et al. **Am J Med** 1999 Jun;106(6):629–35

Current clinical concepts in perioperative anticoagulation. Hewitt RL, et al. **Am Surg** 1999 Mar;65(3):270–3 (15 ref.)

The effect of low-dose heparin on hypercoagulability following abdominal aortic surgery. Gibbs NM, et al. **Anaesth Intensive Care** 1998 Oct;26(5):503–8

Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement. Sharrock NE, et al. **Anesthesiology** 1999 Apr;90(4):981–7

Subcutaneous heparin for deep venous thrombosis [letter; comment] Alatri A, et al. **Ann Intern Med** 1999 Jun 15; 130(12):1027. Comment on: Ann Intern Med 1998 Aug 15;129(4):299–302.

Retrograde intra-arterial infusion of prostaglandin E1 and heparin for the no-reflow phenomenon after oromandibular reconstruction with a free fibular flap. Hataya Y, et al. **Ann Plast Surg** 1999 Jan;42(1):92–5

Assessment of heparin anticoagulation: comparison of two commercially available methods. Flom-Halvorsen HI, et al. **Ann Thorac Surg** 1999 Apr;67(4):1012–6; discussion 1016–7

Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ranucci M, et al. **Ann Thorac Surg** 1999 Apr;67(4):994–1000

Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment [see comments] Chamorro A, et al. **Arch Neurol** 1999 Sep;56(9):1098–102 . Comment in: Arch Neurol 1999 Sep;56(9):1104–8.

Weight-based heparin dosing is more effective in the treatment of postoperative deep vein thrombosis. Linke LC, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):208–11

Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Buturović J, et al. **Artif Organs** 1998 Nov;22(11):945–7

A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits. Chan AK, et al. **Blood Coagul Fibrinolysis** 1998 Oct;9(7):587–95

The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin [editorial] Grubb NR, et al. **BMJ** 1998 Dec 5; 317(7172):1540–2

Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin [letter; comment] Laifer SA, et al. **Br J Obstet Gynaecol** 1999 Jun; 106(6):614–5. Comment on: Br J Obstet Gynaecol 1998 Jul;105(7):795–7.

Experimental study of the effect of intraperitoneal heparin on tumour implantation following laparoscopy. Neuhaus SJ, et al. **Br J Surg** 1999 Mar;86(3):400–4

The use of low-dose heparin is safe in carotid endarterectomy and avoids the use of protamine sulfate. Paty PS, et al. **Cardiovasc Surg** 1999 Jan;7(1):39–43

Sustained local delivery of heparin to the rabbit arterial wall with an electroporation catheter. Dev NB, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):337–45

Local intramural heparin delivery during primary angioplasty for acute myocardial infarction: results of the Local PAMI Pilot Study. Esente P, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):237–42

Effects of local heparin administration on coronary thrombin activity during percutaneous transluminal coronary angioplasty. Laskey WK, et al. **Catheter Cardiovasc Interv** 1999 Sep;48(1):84–8

Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Brucker AB, et al. **Cerebrovasc Dis** 1998 Nov–Dec; 8(6):331–7

High-dose heparin impairs nitric oxide pathway and vasomotion in rats. Bachetti T, et al. **Circulation** 1999 Jun 8;99(22):2861–3

Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers. Cannon CP, et al. **Circulation** 1999 Feb 16; 99(6):751–6

Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Newby KH, et al. **Circulation** 1998 Dec 8;98(23):2567–73

Weight-based heparin dosing: clinical response and resource utilization. Lackie CL, et al. **Clin Ther** 1998 Jul–Aug; 20(4):699–710

Confirmation that heparin is an alternative means of promoting early reperfusion. Braga JC, et al. **Coron Artery Dis** 1998;9(6):335–8

The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease [see comments] Linder R, et al. **Eur Heart J** 1999 Apr; 20(7):506–18. Comment in: Eur Heart J 1999 Apr;20(7):479–80.

Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Marchetti M, et al. **Haematologica** 1999 Aug;84(8):726–9

Thromboprophylaxis in the cancer patient. Kakkar AK, et al. **Haemostasis** 1998;28 Suppl 3:61–5 (17 ref.)

Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. Réganon E, et al. **Haemostasis** 1998 Mar–Apr;28(2):99–105

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17–21 (15 ref.)

New perspectives for treatment of pulmonary embolism. Simonneau G. **Haemostasis** 1998;28 Suppl 3:95–9 (9 ref.)

Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Prisco D, et al. **Int J Clin Lab Res** 1998;28(3):170–3

Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. Rabah M, et al. **J Am Coll Cardiol** 1999 Aug;34(2):461–7

The venous ACT after heparin--how much discard? [letter] Chauhan S, et al. **J Cardiothorac Vasc Anesth** 1998 Dec; 12(6):721–2

Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass. Shore-Lesserson L. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6):705–9

Platelet protection in coronary artery surgery: benefits of heparin-coated circuits and high-dose aprotinin therapy [see comments] Wendel HP, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):388–92. Comment in: J Cardiothorac Vasc Anesth 1999 Aug;13(4):379–81.

Con: heparin-bonded cardiopulmonary bypass circuits do not represent a desirable and cost-effective advance in cardiopulmonary bypass technology. Woolf RL, et al. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6):710–2

Do anticoagulation with heparin and protamine reversal alter thrombogenicity of coated and noncoated pulmonary artery catheters? Youngberg JA, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):405–9

The activation of platelet function, coagulation, and fibrinolysis during radiofrequency catheter ablation in heparinized patients. Anfinsen OG, et al. **J Cardiovasc Electrophysiol** 1999 Apr;10(4):503–12

Perivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injury. Teomim D, et al. **J Controlled Release** 1999 Jun 28;60(1):129–42

Endemic nosocomial gram-negative bacteraemias resulting from contamination of intravenous heparin infusions. Playford EG, et al. **J Hosp Infect** 1999 May;42(1):21–6

The effect of chitosan (poly-N-acetyl glucosamine) on lingual hemostasis in heparinized rabbits. Klokkevold PR, et al. **J Oral Maxillofac Surg** 1999 Jan;57(1):49–52

Intravenous bolus infusion of heparin for circulatory insufficiency after finger replantation. Noguchi M, et al. **J Reconstr Microsurg** 1999 May;15(4):245–53

Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. Videm V, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):794–802

Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. Videm V, et al. **J Thorac Cardiovasc Surg** 1999 Apr; 117(4):803–9

A model for collaboration in quality improvement projects: implementing a weight-based heparin dosing nomogram across an integrated health care delivery system. Berry BB, et al. **Jt Comm J Qual Improv** 1998 Sep;24(9):459–69

Black-white differences in postprandial triglyceride response and postheparin lipoprotein lipase and hepatic triglyceride lipase among young men. Friday KE, et al. **Metabolism** 1999 Jun;48(6):749–54

A multistate Kalman filter for neonatal clotting time prediction and early detection of coagulation disturbances. de Haan AF, et al. **Methods Inf Med** 1999 Jun;38(2):113–8

Puerperal cerebral venous thrombosis: therapeutic benefit of low dose heparin. Nagaraja D, et al. **Neurol India** 1999 Mar;47(1):43–6

Intravenous heparin for acute stroke: what can we learn from the megatrials? Swanson RA. **Neurology** 1999 Jun 10; 52(9):1746–50 (27 ref.)

Heparin injection into the adult rat hippocampus induces seizures in the absence of macroscopic abnormalities. Mudher AK, et al. **Neuroscience** 1999 Mar;89(2):329–33

Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Macdonald RL, et al. **Neurosurgery** 1999 Aug; 45(2):245–51; discussion 251–2

Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Rosborough TK. **Pharmacotherapy** 1999 Jun;19(6):760–6

In unfractionated heparin dosing, the combination of patient age and estimated plasma volume predicts initial antifactor Xa activity better than patient weight alone. Rosborough TK. **Pharmacotherapy** 1998 Nov–Dec;18(6):1217–23

Prophylaxis of deep vein thrombosis in total hip replacement: which heparin and what duration? [editorial; comment] Chaouat A, et al. **Respiration** 1998;65(5):345–6. Comment on: Respiration 1998 ;65(5):369–74.

HEPARIN

Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement [see comments] Manganelli D, et al. **Respiration** 1998;65(5):369–74. Comment in: Respiration 1998 ;65(5):345–6.

Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Gori AM, et al. **Thromb Haemost** 1999 Apr;81(4):589–93

Low-dose heparin pretreatment is not able to prevent clotting activation during coronary angiography. Capanni M, et al. **Thromb Res** 1998 Aug 1;91(3):151–3

Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Hansen JB, et al. **Thromb Res** 1998 Aug 15;91(4):177–81

Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. Karlsson H, et al. **Thromb Res** 1998 Jun 1;90(5):223–8

Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction. Takazoe K, et al. **Thromb Res** 1999 Jul 1;95(1):37–47

Anticoagulation with prostaglandins during extracorporeal circulation. Kozek-Langenecker SA. **Wien Klin Wochenschr** 1999 Feb 26;111(4):129–40 (124 ref.)

[Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia] **Chirurg** 1998 Nov;69(11 Suppl Massnahme):1–4 **(Ger)**

[How much does rinsing with heparin influence the analysis of coagulations parameters when bloodletting from one arterial access (letter)] Janssens U. **Dtsch Med Wochenschr** 1999 Apr 1;124(13):405–6 **(Ger)**

[Prevention of embolisms] Balleisen L. **Internist (Berl)** 1998 Oct;39(10):1078–9 **(Ger)**

[New methods for effective prevention of thromboembolism in surgical medicine exemplified by trauma surgery] Chylarecki C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1200–4 (Eng. Abstr.) **(Ger)**

[Anticoagulation control during neuroradiological interventions with ACT (activated clotting time)] Berlis A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Apr;170(4):378–83 (Eng. Abstr.) **(Ger)**

[Standard heparin versus low-molecular-weight heparin] Lockner D. **Wien Med Wochenschr** 1999;149(2–4):37–8 (Eng. Abstr.) **(Ger)**

[Experiences with loco-regional fibrinolytic therapy of deep venous thrombosis with defined drainage management] Unkel B, et al. **Zentralbl Chir** 1999;124(1):18–23 (Eng. Abstr.) **(Ger)**

[New screening method for coagulation abnormality including AT III deficiency during CABG] Nakamura K, et al. **Kyobu Geka** 1999 Jul;52(7):554–8 (Eng. Abstr.) **(Jpn)**

[Heparin-protamine-protocol] Nomoto S. **Nippon Geka Hokan** 1997 May 1;66(2):49–50 **(Jpn)**

[Two cases of intractable ulcerative colitis with successful heparin treatment] Miyake Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1027–31 **(Jpn)**

[Heparin inhalations combined with intravenous laser exposure of blood in patients with diabetic retinopathy] Balashova LM, et al. **Vestn Oftalmol** 1999 Jan–Feb; 115(1):16–8 (Eng. Abstr.) **(Rus)**

[Heparin inhalations and laser exposure of blood in treatment of patients with open-angle glaucoma] Balashova LM, et al. **Vestn Oftalmol** 1998 Nov–Dec;114(6):6–9 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Bilateral posterior fossa subdural haematomas secondary to anticoagulant therapy. Lagares A, et al. **Acta Neurochir (Wien)** 1998;140(10):1097–8

Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Harenberg J, et al. **Allergy** 1999 May;54(5):473–7

Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Pouplard C, et al. **Am J Clin Pathol** 1999 May;111(5):700–6

Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Tomer A, et al. **Am J Hematol** 1999 May;61(1):53–61

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Warkentin TE, et al. **Am J Hematol** 1999 Sep;62(1):44–8 (36 ref.)

Management of heparin-induced thrombocytopenia during continuous renal replacement therapy. Davenport A. **Am J Kidney Dis** 1998 Oct;32(4):E3

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Wallis DE, et al. **Am J Med** 1999 Jun;106(6):629–35

Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Ling E, et al. **Anesthesiology** 1998 Dec;89(6):1567–9

A case report of heparin resistance due to acquired antithrombin III deficiency. Leong CK, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):877–9

Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Petty GW, et al. **Ann Intern Med** 1999 Jan 5;130(1):14–22

Acquired hemophilia secondary to factor VIII inhibitors after pregnancy. Dhôte R, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):300–2

Heparin-induced thrombocytopenia in coronary bypass surgery. Arnoletti JP, et al. **Ann Thorac Surg** 1999 Aug; 68(2):576–8

Immediate vein graft thrombectomy for acute occlusion after coronary artery bypass grafting. Saltman AE, et al. **Ann Thorac Surg** 1999 Jun;67(6):1775–6

Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran). Saxon BR, et al. **Ann Thorac Surg** 1999 Sep;68(3):1076–8

Heparin-induced thrombocytopenia: a ten-year retrospective. Warkentin TE. **Annu Rev Med** 1999; 50:129–47 (59 ref.)

Priapism as a complication of heparin therapy. De Siati M, et al. **Arch Ital Urol Androl** 1999 Jun;71(3):201–2

Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. Amiral J, et al. **Baillieres Clin Haematol** 1998 Jun;11(2):447–60 (73 ref.)

Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. Greinacher A. **Baillieres Clin Haematol** 1998 Jun;11(2):461–74 (74 ref.)

A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Shaughnessy SG, et al. **Blood** 1999 Feb 15;93(4):1231–6

Heparin-induced thrombocytopenia. Kaplan KL, et al. **Blood Rev** 1999 Mar;13(1):1–7 (75 ref.)

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Huhle G, et al. **Br J Haematol** 1999 Jul;106(1):195–201

Heparin and protamine interaction [editorial] Blaise G. **Can J Anaesth** 1998 Dec;45(12):1144–7 **(Eng, Fre)**

Treatment of May–Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607–13 (29 ref.)

Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Hale LP, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):318–22

Multiple coronary artery graft occlusion in a fatal case of heparin-induced thrombocytopenia. Burke AP, et al. **Chest** 1998 Nov;114(5):1492–5

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Tardy-Poncet B, et al. **Chest** 1999 Jun; 115(6):1616–20

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Greinacher A, et al. **Circulation** 1999 Aug 10;100(6):587–93

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Greinacher A, et al. **Circulation** 1999 Jan 5–12;99(1):73–80

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Pouplard C, et al. **Circulation** 1999 May 18;99(19):2530–6

Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Sloan MA, et al. **Circulation** 1998 Oct 6;98(14):1376–82

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Song X, et al. **Circulation** 1999 Oct 5;100(14):1528–32

Heparin-induced thrombocytopenia and thrombosis. Arepally G, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):237–47 (94 ref.)

Femoral neuropathy following anticoagulant therapy: a case report and discussion [editorial] Ahuja R, et al. **Conn Med** 1999 Feb;63(2):69–71

Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis [see comments] Knight CJ, et al. **Eur Heart J** 1998 Aug;19(8):1239–48. Comment in: Eur Heart J 1998 Aug;19(8):1130–1.

Clinical manifestation of heparin-induced thrombocytopenia type II. Koster A, et al. **Eur J Cardiothorac Surg** 1999 Jun;15(6):874–5

Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II. Wang LC, et al. **Eur J Clin Invest** 1999 Mar;29(3):232–7

The use of heparin in patients in whom a pulmonary embolism is suspected after total hip arthroplasty. Lawton RL, et al. **J Bone Joint Surg Am** 1999 Aug;81(8):1063–72

Heparin-induced vascular occlusion in vasculosurgical patients. An evaluation of the disease in 13 cases. Buerger T, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):237–42

High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. Winder A, et al. **J Clin Immunol** 1998 Sep;18(5):330–4

Low molecular weight heparin and epidurals [news] Crews JC. **J Clin Monit Comput** 1998 Dec;14(7–8):507–9

Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). Wang L, et al. **J Immunol Methods** 1999 Jan 1; 222(1–2):93–9

Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. Kadidal VV, et al. **J Intern Med** 1999 Sep;246(3):325–9 (22 ref.)

Extensive spontaneous retroperitoneal hemorrhage: an unusual complication of heparin anticoagulation during pregnancy. Sherer DM, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):196–9

Pancreatic pseudocyst: heparin-induced haemorrhage through the ampulla of Vater. Hong D, et al. **J R Coll Surg Edinb** 1999 Aug;44(4):271–3 (30 ref.)

Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia. Bauer M, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):191–2

Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. Januzzi JL Jr, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):259–64 (28 ref.)

Pharmacologic levels of heparin do not destabilize neonatal parenteral nutrition. Silvers KM, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep–Oct;22(5):311–4

Neurological complications in heparin-induced thrombocytopenia [letter] Pohl C, et al. **Lancet** 1999 May 15;353(9165):1678–9

Fatal hematoma during treatment with adjusted-dose subcutaneous heparin therapy [letter] Gabel A, et al. **N Engl J Med** 1999 Jan 7;340(1):61–2

Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. Roe SD, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3226–9

Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Steuer S, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:45–7

Serial magnetic resonance imaging findings for a spontaneously resolving spinal subdural hematoma: case report [letter; comment] Chung CK. **Neurosurgery** 1998 Dec;43(6):1495. Comment on: Neurosurgery 1998 Feb;42(2):398–400; discussion 400–1.

Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II. Janssens U, et al. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 1):678–81

Newer strategies for the treatment of heparin-induced thrombocytopenia. Warkentin TE, et al. **Pharmacotherapy** 1999 Feb;19(2):181–95 (84 ref.)

Recognition, diagnosis, and management of heparin-induced thrombocytopenia and thrombosis. Smoot EC, et al. **Plast Reconstr Surg** 1999 Feb;103(2):559–65

Ex vivo evaluation of a Taylor-Couette flow, immobilized heparinase I device for clinical application. Ameer GA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2350–5

Dissecting intramural haematoma of the oesophagus exacerbated by heparin therapy [letter] Cullen SN, et al. **QJM** 1999 Feb;92(2):123–4

Antigens involved in heparin-induced thrombocytopenia. Amiral J. **Semin Hematol** 1999 Jan;36(1 Suppl 1):7–11 (29 ref.)

Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Blakeman B. **Semin Hematol** 1999 Jan;36(1 Suppl 1):37–41 (14 ref.)

A mouse model for heparin-induced thrombocytopenia. Blank M, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 1):12–6

Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Chong BH, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):3–8; discussion 35–6 (26 ref.)

Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes. Cohen M. **Semin Hematol** 1999 Jan;36(1 Suppl 1):33–6 (14 ref.)

The clinical management of heparin-induced thrombocytopenia. Kelton JG. **Semin Hematol** 1999 Jan; 36(1 Suppl 1):17–21 (12 ref.)

New treatment options for heparin-induced thrombocytopenia. Ortel TL, et al. **Semin Hematol** 1998 Oct;35(4 Suppl 5):26–34; discussion 35–6 (29 ref.)

Heparin-induced thrombocytopenia. Ortel TL. **Semin Hematol** 1998 Oct;35(4 Suppl 5):1–2 (18 ref.)

Plasmapheresis in the management of heparin-induced thrombocytopenia. Robinson JA, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 1):29–32

Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Walenga JM, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 1):22–8

Limitations of conventional treatment options for heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):17–25; discussion 35–6 (27 ref.)

Clinical presentation of heparin-induced thrombocytopenia. Warkentin TE. **Semin Hematol** 1998 Oct;35(4 Suppl 5):9–16; discussion 35–6 (30 ref.)

Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed J, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:37–42 (24 ref.)

Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Haas S, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:67–75

Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Izban KF, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:51–6

Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia. Kwaan HC, et al.

Semin Thromb Hemost 1999;25 Suppl 1:23–7

Use of argatroban during percutaneous coronary interventions in patients with heparin–induced thrombocytopenia. Matthai WH Jr.
Semin Thromb Hemost 1999;25 Suppl 1:57–60

Heparin–induced thrombocytopenia in France, 1980–1998. Nguyen P, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:9–15

Hematologic complications of heparin–induced thrombocytopenia. Raible MD. **Semin Thromb Hemost** 1999;25 Suppl 1:17–21 (60 ref.)

Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Walenga JM, et al. **Semin Thromb Hemost** 1999;25 Suppl 1:77–81

Laboratory tests for the diagnosis of heparin–induced thrombocytopenia. Walenga JM, et al.
Semin Thromb Hemost 1999;25 Suppl 1:43–9

Failure of current strategies in the prevention of thrombosis in patients with heparin–induced thrombocytopenia: a clinician's perspective. Wallis DE, et al.
Semin Thromb Hemost 1999;25 Suppl 1:3–7

Complications of subcutaneous low–dose heparin therapy in neurosurgical patients. Wen DY, et al. **Surg Neurol** 1998 Dec;50(6):521–5

First workshop for detection of heparin–induced antibodies: validation of the heparin–induced platelet–activation test (HIPA) in comparison with a PF4/heparin ELISA. Eichler P, et al. **Thromb Haemost** 1999 Apr;81(4):625–9

Effect of SR121566A, a potent GP IIb–IIIa antagonist, on the HIT serum/heparin–induced platelet mediated activation of human endothelial cells. Herbert JM, et al. **Thromb Haemost** 1998 Aug;80(2):326–31

In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin–induced thrombocytopenia. Mak KH, et al.
Thromb Haemost 1998 Dec;80(6):989–93

[Heparin–induced thrombocytopenia] Novotný J, et al. **Vnitr Lek** 1998 May;44(5):282–7 (31 ref.) (Eng. Abstr.) **(Cze)**

[Heparin induced thrombocytopenia associated with thrombosis] Lepilleur B, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):740–2 **(Fre)**

[Heparin–induced thrombopenia: significance and difficulties of precise identification of the immunologic mechanism] Samama MM, et al. **Bull Acad Natl Med** 1998; 182(7):1517–33; discussion 1534–6 (Eng. Abstr.) **(Fre)**

[Refludan. First line of treatment for type II heparin–induced thrombopenia] Camez A. **Presse Med** 1998 Jun;27 Suppl 2:28–30 (Eng. Abstr.) **(Fre)**

[Heparin–induced thrombopenia. Clinical manifestations and physiopathology] Gruel Y. **Presse Med** 1998 Jun;27 Suppl 2:7–12 (37 ref.) (Eng. Abstr.) **(Fre)**

[Hirudin for heparin–induced thrombopenia: a new step forward (editorial)] Lecompte T. **Presse Med** 1998 Jun;27 Suppl 2:3–4 **(Fre)**

[Biological diagnosis and surveillance of heparin–induced thrombopenia] Nguyên P. **Presse Med** 1998 Jun;27 Suppl 2:13–7 (18 ref.) (Eng. Abstr.) **(Fre)**

[Management of a suspicion of heparin–induced thrombopenia] Samama CM. **Presse Med** 1998 Jun;27 Suppl 2:18–21 (10 ref.) (Eng. Abstr.) **(Fre)**

[Refludan: pharmacologic surveillance study] Winicki J. **Presse Med** 1998 Jun;27 Suppl 2:31–2 **(Fre)**

[Heparin osteoporosis: a case report (letter)] Gil H, et al. **Rev Med Interne** 1998 Jul;19(7):520–2 **(Fre)**

[Heparin–induced thrombopenias: new treatments (editorial; comment)] Lecompte T, et al. **Rev Med Interne** 1998 Nov; 19(11):783–6 (15 ref.). Comment on: Rev Med Interne 1998 Nov;19(11):819–22. **(Fre)**

[Heparin–induced thrombopenia: rapid regression of thrombopenia and thrombosis after plasma exchange. Case report (see comments)] Poullin P, et al.
Rev Med Interne 1998 Nov;19(11):819–22 (Eng. Abstr.). Comment in: Rev Med Interne 1998 Nov;19(11):783–6. **(Fre)**

[Clinical experiences with Danaparoid sodium. Measures to be taken in heparin–induced thrombocytopenia]
Anaesthesist 1998 Nov;47(11 Suppl Massnahmen):1–4 **(Ger)**

[Heparin–induced coagulation disturbance from mechanical autotransfusion] Vorweg M, et al. **Anaesthesist** 1998 Dec; 47(12):979–81 (Eng. Abstr.) **(Ger)**

[Atypical heparin–induced thrombocytopenia (HIT)—"heparin allergy" with thrombocytosis] Folwaczny EK, et al. **Chirurg** 1999 May;70(5):588–93; discussion 593–4 (Eng. Abstr.) **(Ger)**

[Successful lysis therapy of inferior vena cava and iliofemoral venous thrombosis in heparin–induced thrombocytopenia type II (letter; comment)] Fischer KG.
Dtsch Med Wochenschr 1999 Jan 8;124(1–2):32–3. Comment on: Dtsch Med Wochenschr 1997 Aug 1;122(31–32):965–8. **(Ger)**

[Heparin–induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation] Madei W, et al. **Dtsch Med Wochenschr** 1999 Apr 23; 124(16):487–90 (16 ref.) (Eng. Abstr.) **(Ger)**

[Current treatment concepts in heparin–induced thrombocytopenia] Ranze O, et al.
Dtsch Med Wochenschr 1999 Jul 16;124(28–29):865–73 (67 ref.) **(Ger)**

[Heparin–induced thrombocytopenia type II. Intra– and postoperative lepirudin treatment in acute ischemia of the extremities (see comments)] Schmidt O, et al.
Dtsch Med Wochenschr 1998 Oct 9;123(41):1207–10 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1999 Jan 22;124(3):67. **(Ger)**

[Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives] Jappe U, et al. **Hautarzt** 1999 Jun;50(6):406–11 (49 ref.) (Eng. Abstr.) **(Ger)**

[Difficulties in the detection of heparin–induced thrombocytopenia type II] Goyen M, et al.
Schweiz Rundsch Med Prax 1999 Mar 11;88(11):485–90 (Eng. Abstr.) **(Ger)**

[Heparin–induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA—treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA] Laubenthal FC, et al. **Z Kardiol** 1999 Feb;88(2):141–6 (Eng. Abstr.) **(Ger)**

[Heparin–induced thrombocytopenia. Case report] Krenzien J, et al. **Zentralbl Chir** 1999;124(3):230–3 (Eng. Abstr.) **(Ger)**

[Incidence of thromboembolic complications in cesarean sections and heparin prophylaxis] Corosu R, et al.
Minerva Ginecol 1999 May;51(5):173–6 (Eng. Abstr.) **(Ita)**

[Heparin–induced thrombocytopenia] Koide M, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):307–10 (15 ref.) **(Jpn)**

[Clinical significance and problems of treatment of patients with heparin–induced thrombocytopenia] Barkagan ZS.
Ter Arkh 1999;71(7):72–6 **(Rus)**

[The thrombocytopenia syndrome caused by heparin] Gorišek B, et al. **Lijec Vjesn** 1998 Jun;120(6):157–9 (Eng. Abstr.) **(Scr)**

[Heparin–associated autoimmune thrombopenia (letter; comment)] Salvador Osuna C, et al. **An Med Interna** 1999 Apr;16(4):212. Comment on: An Med Interna 1998 Jun;15(6):339–40. **(Spa)**

[Giant intracavitary thrombi secondary to a heparin–induced thrombocytopenia–thrombosis syndrome] Fernández Ratero JA, et al. **Rev Esp Cardiol** 1999 Apr;52(4):269–72 (8 ref.) (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Mast cell granule heparin proteoglycan induces lacunae in confluent endothelial cell monolayers. Lagunoff D, et al.
Am J Pathol 1999 May;154(5):1591–600

Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20–kDa glycosaminoglycan chains. Graham LD, et al.
Biochem Biophys Res Commun 1999 Mar 24;256(3):542–8

An IKLLI–containing peptide derived from the laminin alpha1 chain mediating heparin–binding, cell adhesion, neurite outgrowth and proliferation, represents a binding site for integrin alpha3beta1 and heparan sulphate proteoglycan. Tashiro K, et al. **Biochem J** 1999 May 15; 340 (Pt 1):119–26

Mechanism by which heparin proteoglycan modulates mast cell chymase activity. Pejler G, et al. **Biochemistry** 1999 Sep 14;38(37):12187–95

In vitro evaluation of synthetic heparin–like conjugates comprising different thrombin binding domains. Basten JE, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1201–6

Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
Dreef–Tromp CM, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2081–6

New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Petitou M, et al. **Bioorg Med Chem Lett** 1999 Apr 19;9(8):1155–60

Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics. Petitou M, et al. **Bioorg Med Chem Lett** 1999 Apr 19; 9(8):1161–6

Heparin proteoglycans released from rat serosal mast cells inhibit proliferation of rat aortic smooth muscle cells in culture. Wang Y, et al. **Circ Res** 1999 Jan 8–22;84(1):74–83

Vasoflux, a new anticoagulant with a novel mechanism of action. Weitz JI, et al. **Circulation** 1999 Feb 9;99(5):682–9

N–Acetylheparin pretreatment reduces infarct size in the rabbit. Park JL, et al. **Pharmacology** 1999 Mar;58(3):120–31

ANALYSIS

Determination of heparin in aqueous solutions. Demoré B, et al. **J Clin Pharm Ther** 1998 Oct;23(5):381–4

Assessing heparin neutralization following cardiac surgery: sensitivity of thrombin time–based assays versus protamine titration methods. LaDuca FM, et al. **Perfusion** 1999 May; 14(3):181–7

ANTAGONISTS & INHIBITORS see HEPARIN ANTAGONISTS

BIOSYNTHESIS

Heparin is a unique marker of progenitors in the glial cell lineage. Stringer SE, et al. **J Biol Chem** 1999 Sep 3; 274(36):25455–60

Abnormal mast cells in mice deficient in a heparin–synthesizing enzyme [see comments] Forsberg E, et al. **Nature** 1999 Aug 19;400(6746):773–6. Comment in: Nature 1999 Aug 19;400(6746):714–5.

BLOOD

Bedside activated partial thromboplastin time monitoring: just a matter of time? [editorial; comment] Patel VB, et al. **Am Heart J** 1999 Jan;137(1):8–11. Comment on: Am Heart J 1999 Jan;137(1):59–71.

Assay for endogenous heparin in plasma of livestock using a synthetic chromogenic substrate. Ledwożyw A, et al. **Arch Vet Pol** 1993;33(3–4):269–73

Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device. Tao W, et al. **ASAIO J** 1999 Jan–Feb;45(1):50–2

Surface plasmon resonance sensor for heparin measurements in blood plasma. Gaus K, et al. **Biosens Bioelectron** 1998 Dec 1;13(12):1307–15

Investigation of a whole blood fluidized bed Taylor–Couette flow device for enzymatic heparin neutralization. Ameer GA, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):602–8

Monitoring the effects of heparin: evaluation of a new portable device. Cavanagh SP, et al. **Cardiovasc Surg** 1998 Oct;6(5):496–9

HEPTEST: a suitable method for monitoring heparin during pregnancy. Campbell PJ, et al. **Clin Lab Haematol** 1999 Jun;21(3):193–9

Performance characteristics of a new synthetic APTT reagent. Ts'ao C, et al. **Clin Lab Haematol** 1998 Oct; 20(5):307–13

Problems with monitoring heparin anticoagulation [editorial] Bussey HI. **Pharmacotherapy** 1999 Jan;19(1):2–5

Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. Taylor CT, et al. **Pharmacotherapy** 1999 Apr;19(4):383–7

[Heparin–like factors in pregnancy. Report of a clinical case] Cassese E, et al. **Minerva Ginecol** 1998 Oct;50(10):435–40 (Eng. Abstr.) **(Ita)**

[A new test for monitoring heparin therapy] Camici M, et al. **Minerva Med** 1998 Sep;89(9):345–9 (Eng. Abstr.) **(Ita)**

CHEMICAL SYNTHESIS

Synthesis of a 3–deoxy–L–iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence. Lei PS, et al.
Bioorg Med Chem 1998 Aug;6(8):1337–46

New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Petitou M, et al. **Bioorg Med Chem Lett** 1999 Apr 19;9(8):1155–60

Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition. Duchaussoy P, et al. **Carbohydr Res** 1999 Apr 30; 317(1–4):85–99

Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Lee Y, et al. **Thromb Res** 1998 Nov 15; 92(4):149–56

CHEMISTRY

Purification, crystallization and preliminary crystallographic studies of a two fibronectin type–III domain segment from chicken tenascin encompassing the heparin– and contactin–binding regions. Bisig D, et al.
Acta Crystallogr D Biol Crystallogr 1999 May;55(5):1069–73

Stability of antibiotics used for antibiotic–lock treatment of infections of implantable venous devices (ports). Anthony TU, et al. **Antimicrob Agents Chemother** 1999 Aug; 43(8):2074–6

Assay for endogenous heparin in plasma of livestock using a synthetic chromogenic substrate. Ledwożyw A, et al. **Arch Vet Pol** 1993;33(3–4):269–73

A new heparin–bonded dense membrane lung combined with minimal systemic heparinization prolonged extracorporeal lung assist in goats. Okamoto T, et al. **Artif Organs** 1998 Oct;22(10):864–72

Biocompatibility of heparin and low–molecular mass heparin in a new implantable medication pump. Schmid MG, et al. **Arzneimittelforschung** 1998 Sep;48(9):910–3

Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device. Tao W, et al. **ASAIO J** 1999 Jan–Feb;45(1):50–2

Sequence analysis of heparan sulphate and heparin oligosaccharides. Vivès RR, et al. **Biochem J** 1999 May 1;339 (Pt 3):767–73

Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry. Hileman RE, et al. **Biochemistry** 1998 Oct 27; 37(43):15231–7

Structural analysis of the heparin–binding site of the NC1 domain of collagen XIV by CD and NMR. Montserret R, et al. **Biochemistry** 1999 May 18;38(20):6479–88

Quantitative characterization of the binding of histamine by heparin. Rabenstein DL, et al. **Biochemistry** 1998 Oct 6; 37(40):14121–7

Structural studies of octasaccharides derived from the low–sulfated repeating disaccharide region and octasaccharide serines derived from the protein linkage region of porcine intestinal heparin. Yamada S, et al.
Biochemistry 1999 Jan 12;38(2):838–47

Novel regio– and stereoselective O–6–desulfation of the glucosamine moiety of heparin with N–methylpyrrolidinone–water or

N,N-dimethylformamide-water mixtures. Baumann H, et al. **Carbohydr Res** 1998 Jun;308(3-4):381-8
Conversion of N-sulfated glucosamine to N-sulfated mannosamine in an unsaturated heparin disaccharide by non-enzymatic, base-catalyzed C-2 epimerization during enzymatic oligosaccharide preparation. Yamada S, et al. **Carbohydr Res** 1998 Jul;309(3):261-8
Diversity does make a difference: fibroblast growth factor-heparin interactions. Faham S, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):578-86 (47 ref.)
Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. Hricovini M, et al. **Eur J Biochem** 1999 May;261(3):789-801
Structural features in heparin that interact with VEGF165 and modulate its biological activity. Ono K, et al. **Glycobiology** 1999 Jul;9(7):705-11
Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro. Stone AL, et al. **Glycoconj J** 1998 Jul;15(7):697-712
Metachromatic activity of beta-cyclodextrin sulfates as heparin mimics. Baumann R, et al. **Int J Biol Macromol** 1999 Jan;24(1):15-8
Fructose 1,6-bisphosphate aldolase is a heparin-binding protein. Ta TV, et al. **J Biochem (Tokyo)** 1999 Mar; 125(3):554-9
Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes. Characterization of novel anticoagulants. Monagle P, et al. **J Biol Chem** 1998 Dec 11;273(50):33566-71
Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). Passirani C, et al. **J Biomater Sci Polym Ed** 1999;10(1):47-62
Heparin elution of transcription factors from DNA-Sepharose columns. Gadgil H, et al. **J Chromatogr A** 1999 Jul 2;848(1-2):131-8
Effect of eluent composition on retention behavior of anions in ion chromatography on anion-exchangers modified with heparin. Safni, et al. **J Chromatogr A** 1999 Jul 30; 850(1-2):65-72
Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. Rhomberg AJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12232-7
Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Venkataraman G, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1892-7
A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding [published erratum appears in Structure Fold Des 1999 Aug 15;7(8):R198] Huhtala MT, et al. **Structure Fold Des** 1999 Jun 15;7(6):699-709
Ethylenediaminetetraacetic acid (EDTA) in heparin. Coyne E, et al. **Thromb Res** 1998 Jun 1;90(5):245-6

CONTRAINDICATIONS

Fortnightly review: anticoagulation in heart disease. Hardman SM, et al. **BMJ** 1999 Jan 23;318(7178):238-44 (43 ref.)

DIAGNOSTIC USE

The heparin-glutathione test: an alternative to the hypo-osmotic swelling test to select viable sperm for intracytoplasmic sperm injection. Vendrell FJ, et al. **Fertil Steril** 1998 Dec;70(6):1156-61

ECONOMICS

Pharmacoeconomic impact of a weight-based heparin protocol. Bowden C, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S29-32
Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Etchells E, et al. **Arch Intern Med** 1999 Jun 14; 159(11):1221-8
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis [see comments] Rodger M, et al. **CMAJ** 1998 Oct 20; 159(8):931-8. Comment in: ACP J Club 1999 Mar-Apr;130(2):53.
The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Hull RD, et al. **Haemostasis** 1998; 28 Suppl 3:8-16
The cost-effectiveness of low-molecular-weight heparin vs unfractionated heparin in general and orthopaedic surgery: an analysis for the German healthcare system. Szucs TD, et al. **Pharmacol Res** 1999 Jul;40(1):83-9

GENETICS

A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Turnbull JE, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2698-703

HISTORY

Heparin. Davies MK, et al. **Heart** 1998 Aug;80(2):120

IMMUNOLOGY

Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Ziporen L, et al. **Blood** 1998 Nov 1;92(9):3250-9
Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Pouplard C, et al. **Circulation** 1999 May 18;99(19):2530-6
The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. Calaitges JG, et al. **J Vasc Surg** 1999 May;29(5):779-85; discussion 785-6
Detection of PF4-heparin auto-antibodies by ELISA [letter] Woodhams BJ, et al. **Thromb Haemost** 1999 Jul;82(1):157-8
[Heparin-induced thrombopenia: significance and difficulties of precise identification of the immunologic mechanism] Samama MM, et al. **Bull Acad Natl Med** 1998; 182(7):1517-33; discussion 1534-6 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal. Zhang Y, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M368-73
Investigation of a whole blood fluidized bed Taylor-Couette flow device for enzymatic heparin neutralization. Ameer GA, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):602-8
[Isolation of heparin and chondroitin sulfate from animal tissue by an ion exchange method] Ivankin AN, et al. **Prikl Biokhim Mikrobiol** 1998 Nov-Dec;34(6):692-7 (Eng. Abstr.) **(Rus)**

METABOLISM

Phosphorylation of yeast ribosomal proteins by CK1 and CK2 in the presence of heparin. Wojda I, et al. **Acta Biochim Pol** 1999;46(1):211-5
Purification, crystallization and preliminary crystallographic studies of a two fibronectin type-III domain segment from chicken tenascin encompassing the heparin- and contactin-binding regions. Bisig D, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):1069-73
Arterial heparin deposition: role of diffusion, convection, and extravascular space. Lovich MA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2236-42
Use of affinity capillary electrophoresis for the study of protein and drug interactions. Liu J, et al. **Analyst** 1998 Jul;123(7):1455-9
Heparin binding and augmentation of C1 inhibitor activity. Caldwell EE, et al. **Arch Biochem Biophys** 1999 Jan 15; 361(2):215-22
Human selenium-dependent thioredoxin reductase from HeLa cells: properties of forms with differing heparin affinities. Gorlatov SN, et al. **Arch Biochem Biophys** 1999 Sep 1;369(1):133-42
Degradation of acharan sulfate and heparin by Bacteroides stercoris HJ-15, a human intestinal bacterium. Kim DH, et al. **Arch Pharm Res** 1998 Oct;21(5):576-80
Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Nissen NN, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):637-42
An IKLLI-containing peptide derived from the laminin alpha1 chain mediating heparin-binding, cell adhesion, neurite outgrowth and proliferation, represents a binding site for integrin alpha3beta1 and heparan sulphate proteoglycan. Tashiro K, et al. **Biochem J** 1999 May 15; 340 (Pt 1):119-26
Purification of heparin-binding protein HBp17 and identification of HBp17 heparin binding site. Wang XC, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):81-7
The role of heparin in the complex formation between fibroblast growth factor 2 and its high affinity receptor: comparative modelling and biochemical studies. Pellegrini L, et al. **Biochem Soc Trans** 1998 Aug;26(3):545-9
The role of Arg46 and Arg47 of antithrombin in heparin binding. Arocas V, et al. **Biochemistry** 1999 Aug 3; 38(31):10196-204
Vascular endothelial growth factor VEGF-like heparin-binding protein from the venom of Vipera aspis aspis (Aspic viper). Komori Y, et al. **Biochemistry** 1999 Sep 7;38(36):11796-803
Structural analysis of the heparin-binding site of the NC1 domain of collagen XIV by CD and NMR. Montserret R, et al. **Biochemistry** 1999 May 18;38(20):6479-88
Site-directed mutagenesis and molecular modeling identify a crucial amino acid in specifying the heparin affinity of FGF-1. Patrie KM, et al. **Biochemistry** 1999 Jul 20; 38(29):9264-72
Quantitative characterization of the binding of histamine by heparin. Rabenstein DL, et al. **Biochemistry** 1998 Oct 6; 37(40):14121-7
Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site. Shuvaev VV, et al. **Biochim Biophys Acta** 1999 Aug 30;1454(3):296-308
Changes in the heparin affinity of extracellular-superoxide dismutase in patients with coronary artery atherosclerosis. Adachi T, et al. **Biol Pharm Bull** 1998 Oct;21(10):1090-3
Regional heparinization via simultaneous separation and reaction in a novel Taylor-Couette flow device. Ameer GA, et al. **Biotechnol Bioeng** 1999 Jun 5;63(5):618-24
Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis. Patel MK, et al. **Br J Pharmacol** 1999 May;127(2):361-8
Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. de Nigris F, et al. **Cancer Res** 1998 Oct 15; 58(20):4745-51
Simpler technique for measuring oxidative susceptibility by heparin affinity column isolation of lipoproteins. Kaplan IV, et al. **Clin Chim Acta** 1999 May;283(1-2):89-103
Diversity does make a difference: fibroblast growth factor-heparin interactions. Faham S, et al. **Curr Opin Struct Biol** 1998 Oct;8(5):578-86 (47 ref.)
Capillary affinity chromatography and affinity capillary electrophoresis of heparin binding proteins. Wu X, et al. **Electrophoresis** 1998 Nov;19(15):2650-3
Crystal structure of a heparin- and integrin-binding segment of human fibronectin. Sharma A, et al. **EMBO J** 1999 Mar 15;18(6):1468-79
Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. Talts JF, et al. **EMBO J** 1999 Feb 15;18(4):863-70
Heparin-binding property of human prolactin: a novel aspect of prolactin biology. Khurana S, et al. **Endocrinology** 1999 Feb;140(2):1026-9
Selectivity of von Willebrand factor triplet bands towards heparin binding supports structural model. Fischer BE, et al. **Eur J Haematol** 1999 Mar;62(3):169-73
Functional changes in the conformation of thrombospondin-1 during complexation with fibronectin or heparin. Dardik R, et al. **Exp Cell Res** 1999 May 1; 248(2):407-14
Characterisation of the conformational and quaternary structure-dependent heparin-binding region of bovine seminal plasma protein PDC-109. Calvete JJ, et al. **FEBS Lett** 1999 Feb 12;444(2-3):260-4
Interaction of heparin with annexin V. Capila I, et al. **FEBS Lett** 1999 Mar 12;446(2-3):327-30
Interaction of soluble and surface-bound heparin binding growth-associated molecule with heparin. Fath M, et al. **FEBS Lett** 1999 Jul 2;454(1-2):105-8
Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. Goedert M, et al. **FEBS Lett** 1999 May 7;450(3):306-11
Heparin binding to cobra basic phospholipase A2 depends on heparin chain length and amino acid specificity. Lin YH, et al. **FEBS Lett** 1999 Jun 25;453(3):395-9
Heparin down-regulates the phorbol ester-induced protein kinase C gene expression in human endothelial cells: enzyme-mediated autoregulation of protein kinase C-alpha and -delta genes. Pintus G, et al. **FEBS Lett** 1999 Apr 23;449(2-3):135-40
Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Miyazaki Y, et al. **Gastroenterology** 1999 Jan;116(1):78-89
Studies on interactions between metmyoglobin and heparin. Fedunová D, et al. **Gen Physiol Biophys** 1998 Jun; 17(2):117-31
Structural features in heparin that interact with VEGF165 and modulate its biological activity. Ono K, et al. **Glycobiology** 1999 Jul;9(7):705-11
Heparin-binding EGF-like growth factor mRNA is upregulated in the peri-infarct region of the remnant kidney model: in vitro evidence suggests a regulatory role in myofibroblast transformation. Kirkland G, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1464-73
The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. Ancsin JB, et al. **J Biol Chem** 1999 Mar 12;274(11):7172-81
Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. Becker DL, et al. **J Biol Chem** 1999 Mar 5;274(10):6226-33
Orientation of heparin-binding sites in native vitronectin. Analyses of ligand binding to the primary glycosaminoglycan-binding site indicate that putative secondary sites are not functional. Gibson AD, et al. **J Biol Chem** 1999 Mar 5;274(10):6432-42
The NH2-terminal region of apolipoprotein B is sufficient for lipoprotein association with glycosaminoglycans. Goldberg IJ, et al. **J Biol Chem** 1998 Dec 25; 273(52):35355-61
Subdomain chimeras of hepatic lipase and lipoprotein lipase. Localization of heparin and cofactor binding. Hill JS, et al. **J Biol Chem** 1998 Nov 20;273(47):30979-84
Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin. Hocking DC, et al. **J Biol Chem** 1999 Sep 17;274(38):27257-64
The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. Joyce JG, et al. **J Biol Chem** 1999 Feb 26; 274(9):5810-22
A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. Maeda N, et al. **J Biol Chem** 1999 Apr 30;274(18):12474-9
Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially

folded state and implications for heparin-induced thrombocytopenia. Mikhailov D, et al. **J Biol Chem** 1999 Sep 3;274(36):25317-29

Cooperative role for activated alpha4 beta1 integrin and chondroitin sulfate proteoglycans in cell adhesion to the heparin III domain of fibronectin. Identification of a novel heparin and cell binding sequence in repeat III5. Moyano JV, et al. **J Biol Chem** 1999 Jan 1;274(1):135-42

Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin. Panetti TS, et al. **J Biol Chem** 1999 Jan 1;274(1):430-7

Oxidation of methionine residues in antithrombin. Effects on biological activity and heparin binding. Van Patten SM, et al. **J Biol Chem** 1999 Apr 9;274(15):10268-76

Glycosaminoglycans mediate the coacervation of human tropoelastin through dominant charge interactions involving lysine side chains. Wu WJ, et al. **J Biol Chem** 1999 Jul 30;274(31):21719-24

Characterization of a heparin binding site on the heavy chain of factor XI. Zhao M, et al. **J Biol Chem** 1998 Nov 20; 273(47):31153-9

Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. Ogura K, et al. **J Biomol NMR** 1999 Jan;13(1):11-24

Identification of a heparin binding site and the biological activities of the laminin alpha1 chain carboxy-terminal globular domain. Yoshida I, et al. **J Cell Physiol** 1999 Apr; 179(1):18-28

The gene for heparin-binding epidermal growth factor-like growth factor is stress-inducible: its role in cerebral ischemia. Kawahara N, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):307-20

Properties of a heparin-binding peptide derived from bovine lactoferrin. Shimazaki K, et al. **J Dairy Sci** 1998 Nov; 81(11):2841-9

IL-12 is a heparin-binding cytokine. Hasan M, et al. **J Immunol** 1999 Jan 15;162(2):1064-70

Heparin in plasma samples causes nonspecific binding to histones on Western blots. Alcantara FF, et al. **J Immunol Methods** 1999 Jun 24;226(1-2):11-8

Analysis of heparin, alpha-dystroglycan and sulfatide binding to the G domain of the laminin alpha1 chain by site-directed mutagenesis. Andac Z, et al. **J Mol Biol** 1999 Mar 26;287(2):253-64

Analysis of heparin-binding sites in human lipoprotein lipase using synthetic peptides. Beg OU, et al. **J Protein Chem** 1998 Nov;17(8):807-15

Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. Shigeta O, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):354-60

Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. Feldman SA, et al. **J Virol** 1999 Aug;73(8):6610-7

Human endothelial cells do not exert heparin like accelerating effects on thrombin-antithrombin-complex formation. Ruzicka K, et al. **Life Sci** 1998;63(17):1493-503

Identification and characterization of a heparin binding site within the NC1 domain of chicken collagen XIV. Giry-Lozinguez C, et al. **Matrix Biol** 1998 Jun;17(2):145-9

Identification of heparin as a ligand for the A-domain of Plasmodium falciparum thrombospondin-related adhesion protein. McCormick CJ, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):111-24

Fibronectin regulates assembly of actin filaments and focal contacts in cultured cells via the heparin-binding site in repeat III13. Bloom L, et al. **Mol Biol Cell** 1999 May; 10(5):1521-36

Association of myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Daphna EM, et al. **Mol Cell Biochem** 1998 Jun;183(1-2):55-61

Binding of heparin to platelet membrane glycoprotein Ib: functional effects [letter] Jandrot-Perrus M, et al. **Thromb Haemost** 1999 Feb;81(2):316-7

On the control of the plasma contact activation system on human endothelium: comparisons with heparin surface. Sánchez J, et al. **Thromb Res** 1999 Jan 1;93(1):27-34

[Recognition of heparin-like domain by midkine and its significance] Muramatsu T. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2288-94 (60 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. Ishida M, et al. **Arzneimittelforschung** 1998 Aug;48(8):818-21

New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Petitou M, et al. **Bioorg Med Chem Lett** 1999 Apr 19;9(8):1155-60

The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. Enghild JJ, et al. **J Biol Chem** 1999 May 21; 274(21):14818-22

[The effects of heparin on intrauterine arteries of the human non-pregnant uterus: II. The analysis of the route of action] Litorowicz A, et al. **Ginekol Pol** 1998 Oct;69(10):740-5 (Eng. Abstr.) **(Pol)**

[The effects of heparin on intrauterine arteries of the human non-pregnant uterus: I. The action of clinically administered heparin] Litorowicz A, et al. **Ginekol Pol** 1998 Oct;69(10):734-9 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Risk of clot formation in femoral arterial sheaths maintained overnight for neuroangiographic procedures. Koenigsberg RA, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):297-9

Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Erduran E, et al. **Am J Hematol** 1999 Jun;61(2):90-3

Heparin inhibits lung branching morphogenesis: potential role of smooth muscle cells in cleft formation. Roman J, et al. **Am J Med Sci** 1998 Dec;316(6):368-78

Mesangial cell proliferation in long-term streptozotocin-induced diabetes mellitus in the rat and the renoprotective activity of heparin. Gambaro G, et al. **Am J Nephrol** 1999;19(4):530-4

Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1. Kozek-Langenecker SA, et al. **Anesth Analg** 1998 Nov;87(5):985-8

Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Mochizuki T, et al. **Anesth Analg** 1998 Oct;87(4):781-5

The direct effects of heparin and protamine on canine tracheal smooth muscle tone. Yamakage M, et al. **Anesth Analg** 1999 Jun;88(6):1232-8

Effects of medium containing heparin and theophylline on capacitation and metabolic enzyme activities of ejaculated spermatozoa from dogs with asthenozoospermia. Kawakami E, et al. **Anim Reprod Sci** 1999 Jan 29; 54(4):251-9

Heparin and fragments modulate the expression of collagen-degrading enzymes (matrix metalloproteinases 1 and 2) by human gingival fibroblasts. Hornebeck W, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:625-8

Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. Heinzelmann M, et al. **Ann Surg** 1999 Apr;229(4):542-50

Heparin preserves nitric oxide activity in coronary endothelium during ischemia-reperfusion injury. Kouretas PC, et al. **Ann Thorac Surg** 1998 Oct;66(4):1210-5

Reducing inflammatory reactions by heparin-coated circuit [letter; comment] Wan S, et al. **Ann Thorac Surg** 1998 Nov; 66(5):1868. Comment on: Ann Thorac Surg 1997 Dec;64(6):1790-4.

Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model. Bossavy JP, et al. **Ann Vasc Surg** 1999 Jul;13(4):393-401

Heparin binding and augmentation of C1 inhibitor activity. Caldwell EE, et al. **Arch Biochem Biophys** 1999 Jan 15; 361(2):215-22

Heparin modulates migration of human peripheral blood mononuclear cells and neutrophils. Zak-Nejmark T, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(4):245-9

Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphonuclear cells. Beltrán AE, et al. **Arch Med Res** 1999 Mar-Apr;30(2):116-9

Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Bossavy JP, et al. **Arterioscler Thromb Vasc Biol** 1999 May; 19(5):1348-53

Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin. Hakala JK, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1276-83

Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Lupu C, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2251-62

Effect of cardiopulmonary bypass and heparin on plasma levels of Lp(a) and Apo(a) fragments. Mooser V, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):1060-5

Morphometric analysis of heparin coated versus standard intra-aortic balloons. Mueller XM, et al. **ASAIO J** 1998 Sep-Oct;44(5):M401-4

Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Watanabe H, et al. **Atherosclerosis** 1999 Jul;145(1):45-50

The effect of heparin and pentosan polysulfate on the thermal stability of yeast alcohol dehydrogenase. Pauliková H, et al. **Biochem Mol Biol Int** 1998 Dec;46(5):887-94

Influence of heparin(s) on the interleukin-1-beta-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Gogly B, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1447-54

Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Boudier C, et al. **Biochemistry** 1999 Jun 29;38(26):8451-7

Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Gupta K, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):63-73

Heparin influence on alpha-staphylotoxin formed channel. Krasilnikov OV, et al. **Biochim Biophys Acta** 1999 Feb 4; 1417(1):167-82

Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan. Mauray S, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):184-94

Kinetic study of the inhibition of CK2 by heparin fragments of different length. O'Farrell F, et al. **Biochim Biophys Acta** 1999 Aug 17;1433(1-2):68-75

Changes in the heparin affinity of extracellular-superoxide dismutase in patients with coronary artery atherosclerosis. Adachi T, et al. **Biol Pharm Bull** 1998 Oct;21(10):1090-3

Heparin-selenocystamine conjugate with selenol groups. Saito Y, et al. **Biol Pharm Bull** 1998 Aug;21(8):805-.

Heparin and high-density lipoprotein mediate bovine sperm capacitation by different mechanisms. Lane M, et al. **Biol Reprod** 1999 Jan;60(1):169-75

In vitro evaluation of synthetic heparin-like conjugates comprising different thrombin binding domains. Basten JE, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1201-6

Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers. Dreef-Tromp CM, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2081-6

Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Bacsi S, et al. **Blood** 1999 Jul 1;94(1):208-15

Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Gerotziafas GT, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):571-80

The anticoagulant effect of antithrombin/heparin complex. A new screening test to detect a thrombophilic tendency? [letter] Makris PE, et al. **Blood Coagul Fibrinolysis** 1998 Oct;9(7):665-6

Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Seidel C, et al. **Br J Haematol** 1999 Jun;105(3):641-7

Inhibition of serum and transforming growth factor beta (TGF-beta1)-induced DNA synthesis in confluent airway smooth muscle by heparin. Okona-Mensah KB, et al. **Br J Pharmacol** 1998 Oct;125(4):599-606

Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis. Patel MK, et al. **Br J Pharmacol** 1999 May;127(2):361-8

Actions of heparin that may affect the malignant process. Engelberg H. **Cancer** 1999 Jan 15;85(2):257-72 (243 ref.)

Healing effects of heparin on acetic acid-induced gastric ulcers in rats. Li Y, et al. **Chin Med J (Engl)** 1998 Jan; 111(1):12-6

Effects of heparin on growth factor-induced mitogenic and proliferative responses of rat pulmonary artery smooth muscle cells. Wang HL, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):397-400

Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor [letter; comment] Cella G, et al. **Circulation** 1999 Jun 29;99(25):3323. Comment on: Circulation 1998 Jan 27;97(3):251-6.

Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin. De Candia E, et al. **Circulation** 1999 Jun 29;99(25):3308-14

Effects of chronic heparin administration on coronary vascular adaptation to hypertension and ventricular hypertrophy in sheep. Flanagan MF, et al. **Circulation** 1999 Aug 31;100(9):981-7

PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Hart CE, et al. **Circulation** 1999 Feb 2; 99(4):564-9

Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Lazar HL, et al. **Circulation** 1999 Sep 28;100(13):1438-42

Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Peter K, et al. **Circulation** 1999 Oct 5;100(14):1533-9

Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis. San Antonio JD, et al. **Connect Tissue Res** 1998;37(1-2):87-103 (96 ref.)

Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Boden G, et al. **Diabetes** 1999 Mar;48(3):577-83

Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin. Brecher AS, et al. **Dig Dis Sci** 1999 Jul;44(7):1349-55

Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Theoharides TC, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):87S-93S

Two distinct forms of human mast cell chymase--differences in affinity for heparin and in distribution in skin, heart, and other tissues. McEuen AR, et al. **Eur J Biochem** 1998 Sep 1;256(2):461-70

Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Giraux JL, et al. **Eur J Cell Biol** 1998 Dec;77(4):352-9

Antithrombin increases pulmonary endothelins: inhibition by heparin and Ca2+ channel antagonism. Stangl K, et al. **Eur J Pharmacol** 1999 Apr 1;370(1):57-61

Change of plasma lipoproteins by heparin-released lipoprotein lipase. Yang JY, et al. **Exp Mol Med** 1999 Jun 30;31(2):60-4

Inhibition of enzymes of drug metabolism in rat liver by ultrasound and correction by heparin. Legonkova LF, et al. **Exp Toxicol Pathol** 1999 Jul;51(4-5):360-2

Spin-trapping agent alpha-phenyl N-tert-butylnitrone binds to trypsin and enhances heparin-induced inhibition of amidolytic activity and structural degradation of the enzyme. Finotti P, et al. **FEBS Lett** 1999 Jun 18; 453(1-2):159-63

Heparin potentiates in vivo neutrophil migration induced by IL-8. Dias-Baruffi M, et al. **Glycoconj J** 1998 May; 15(5):523-6

Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro. Stone AL, et al. **Glycoconj J** 1998 Jul;15(7):697-712

Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation. Denk PO, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr; 237(4):342-7

Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity. Ranganath LR, et al. **Horm Metab Res** 1999 Apr;31(4):262-6

Aspirin and heparin prevent hepatic blood stasis and thrombosis induced by the toxic glycoprotein Bolesatine in mice. Ennamany R, et al. **Hum Exp Toxicol** 1998 Nov; 17(11):620-4

Heparin potentiates collateral growth but not growth of intramyocardial endarteries in dogs with repeated coronary occlusion. Fujita M, et al. **Int J Cardiol** 1999 Jul 31; 70(2):165-70

Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat. Lavelle SM, et al. **Ir J Med Sci** 1998 Oct-Dec;167(4):216-20

Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. Fagiolo U, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1143-7

The correlation of sperm chromatin decondensation following in vitro exposure to heparin and sperm penetration rates. Carrell DT, et al. **J Assist Reprod Genet** 1998 Oct;15(9):560-4

Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex. Berry L, et al. **J Biol Chem** 1998 Dec 25;273(52):34730-6

Heparin-induced conformational change in microtubule-associated protein Tau as detected by chemical cross-linking and phosphopeptide mapping. Paudel HK, et al. **J Biol Chem** 1999 Mar 19;274(12):8029-38

Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. Gibbs NM, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):536-41

Effect of heparin-bonded pulmonary artery catheters on the activated coagulation time. McNulty SE, et al. **J Cardiothorac Vasc Anesth** 1998 Oct;12(5):533-5

Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. Modi NB, et al. **J Cardiovasc Pharmacol** 1998 Sep; 32(3):397-405

Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. Mishra-Gorur K, et al. **J Cell Physiol** 1999 Feb; 178(2):205-15

Effects of heparin on polymerase chain reaction for blood white cells. Yokota M, et al. **J Clin Lab Anal** 1999; 13(3):133-40

Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity. Brecher AS, et al. **J Investig Med** 1999 Jan;47(1):76-80

Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro. Zsigmond E, et al. **J Lipid Res** 1998 Sep; 39(9):1852-61

Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. Kouretas PC, et al. **J Mol Cell Cardiol** 1998 Dec; 30(12):2669-82

Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. Matsumori A, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2145-9

The preventive effect of heparin on stricture formation after caustic esophageal burns. Bingöl-Kologlu M, et al. **J Pediatr Surg** 1999 Feb;34(2):291-4

Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. Kilgore KS, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1041-7

Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. Uriuda Y, et al. **J Pharmacol Toxicol Methods** 1998 Mar;39(2):81-9

Heparin increases protein S levels in cultured endothelial cells by causing a block in degradation. Dougherty CS, et al. **J Vasc Res** 1998 Nov-Dec;35(6):437-48

Heparin fails to inhibit the proliferation of human vascular smooth muscle cells in the presence of human serum. Underwood PA, et al. **J Vasc Res** 1998 Nov-Dec; 35(6):449-60

Modulation of vascular cell growth kinetics by local cytokine delivery from fibrin glue suspensions. Shireman PK, et al. **J Vasc Surg** 1999 May;29(5):852-61; discussion 862

Inhibition of glomerular cell apoptosis by heparin. Ishikawa Y, et al. **Kidney Int** 1999 Sep;56(3):954-63

Pulmonary embolism [letter; comment] Marlar RA, et al. **N Engl J Med** 1998 Nov 19;339(21):1556-7. Comment on: N Engl J Med 1998 Jul 9;339(2):93-104.

Enhanced interstitial expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Ando Y, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1408-17

Altered vascular reactivity following partial nephrectomy in the rat: a possible mechanism of the blood-pressure-lowering effect of heparin. Benchetrit S, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):64-9

Effect of heparin on mesangial cell growth and gene expression of matrix proteins. Wang ZQ, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3052-7

Effects of heparin and enoxaparin on lipids and oxidant system during a single hemodialysis session [letter] Cavdar C, et al. **Nephron** 1999;82(1):81-3

Heparin modulates adenine nucleotide hydrolysis by synaptosomes from cerebral cortex. Schetinger MR, et al. **Neurochem Int** 1998 Sep;33(3):243-9

The effect of collagen, interleukin-1 alpha and glicosaminoglycan on the neovascularization of central nervous system. Tuna M, et al. **Neurol Res** 1998 Sep; 20(6):513-25

Effects of systemic heparinization on the thrombogenicity of hydrophilic and nonhydrophilic catheters in a swine model. Kallmes DF, et al. **Neuroradiology** 1998 Aug; 40(8):530-5

Heparin inhibits induction of nitric oxide synthase by cytokines in rat brain microvascular endothelial cells. Bonmann E, et al. **Neurosci Lett** 1998 Sep 4;253(2):95-8

Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Baufreton C, et al. **Perfusion** 1998 Nov;13(6):419-27

Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Lovich MA, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11111-6

Downregulation of class II antigen expression by FGF-heparin complexes is due primarily to heparin effect. Hackshaw KV, et al. **Res Commun Mol Pathol Pharmacol** 1998 Aug; 101(2):99-114 (45 ref.)

The influence of epsilon-aminocaproic acid derivatives on the anticoagulant activity of heparin. Midura-Nowaczek K, et al. **Rocz Akad Med Bialymst** 1998;43:228-31

Immobilised heparin accelerates the healing of human wounds in vivo. Kratz G, et al. **Scand J Plast Reconstr Surg Hand Surg** 1998 Dec; 32(4):381-5

Dracula's wish. Peters R, et al. **Science** 1999 May 21; 284(5418):1294

Continuous heparinization and circulating adhesion molecules in the critically ill. Boldt J, et al. **Shock** 1999 Jan;11(1):13-8

Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model. Call DR, et al. **Shock** 1998 Sep;10(3):192-7

Low molecular weight heparin alters porcine neutrophil responses to platelet-activating factor. Kruse-Elliott KT, et al. **Shock** 1998 Sep;10(3):198-202

Differential effects of heparin on the early and late phases of hepatic ischemia and reperfusion injury in the pig. Liu W, et al. **Shock** 1999 Aug;12(2):134-8

Heparin modulates the single channel kinetics of reconstituted AMPA receptors from rat brain. Sinnarajah S, et al. **Synapse** 1999 Mar 1;31(3):203-9

The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Bhandari M, et al. **Thromb Haemost** 1998 Sep;80(3):413-7

Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors. Gandossi E, et al. **Thromb Haemost** 1998 Nov; 80(5):840-4

Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Giraux JL, et al. **Thromb Haemost** 1998 Oct;80(4):692-5

Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors [letter] Hézard N, et al. **Thromb Haemost** 1998 Nov;80(5):865-6

A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass. Hioki I, et al. **Thromb Haemost** 1998 Sep;80(3):437-42

Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Keularts IM, et al. **Thromb Haemost** 1998 Sep;80(3):370-1

Heparin regulates ICAM-1 expression in human endothelial cells: an example of non-cytokine-mediated endothelial activation. Miller SJ, et al. **Thromb Haemost** 1998 Sep; 80(3):481-7

Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor. Shen L, et al. **Thromb Haemost** 1999 Jul;82(1):72-9

Effects of heparin and related sulfated polysaccharides on tissue factor expression induced by mitogenic and non-mitogenic factors in human vascular smooth muscle cells. Xuereb JM, et al. **Thromb Haemost** 1999 Jan; 81(1):151-6

Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Beythien C, et al. **Thromb Res** 1999 Apr 15; 94(2):79-86

Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Jacobsen EM, et al. **Thromb Res** 1999 May 15;94(4):213-20

Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells. Orbe J, et al. **Thromb Res** 1999 May 1;94(3):137-45

Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis. Silver PJ, et al. **Thromb Res** 1998 Aug 1;91(3):143-50

Ability of wedelolactone, heparin, and para-bromophenacyl bromide to antagonize the myotoxic effects of two crotaline venoms and their PLA2 myotoxins. Melo PA, et al. **Toxicon** 1999 Jan;37(1):199-215

Improved lung microvascular permeability by heparin infusion in rabbit lungs from non-heart-beating donors. Matsuda E, et al. **Transplant Proc** 1998 Nov;30(7):3354-7

Heparin attenuates norepinephrine-induced venoconstriction. Hawari FI, et al. **Vasc Med** 1998;3(2):95-100

[Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time] Wen Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):304-6 (Eng. Abstr.) **(Chi)**

[Effect of heparin on airway goblet cell secretion in sensitized guinea pigs] Nakata J, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):845-50 (Eng. Abstr.) **(Jpn)**

[New properties of heparin-serotonin complex] Kondashevskaia MV, et al. **Biull Eksp Biol Med** 1998 Oct; 126(10):425-7 **(Rus)**

[Heparin-piracetam complex and its effect on blood and blood circulation] Kondashevskaia MV, et al. **Izv Akad Nauk Ser Biol** 1998 Nov-Dec;(6):758-61 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor. Hsu YR, et al. **Biochemistry** 1999 Feb 23;38(8):2523-34

Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Horiuchi A, et al. **Mol Hum Reprod** 1999 Feb;5(2):139-45

Heparin is essential for the storage of specific granule proteases in mast cells [see comments] Humphries DE, et al. **Nature** 1999 Aug 19;400(6746):769-72. Comment in: Nature 1999 Aug 19;400(6746):714-5.

Mast-cell heparin demystified [news; comment] Zehnder JL, et al. **Nature** 1999 Aug 19;400(6746):714-5. Comment on: Nature 1999 Aug 19;400(6746):769-72. Comment on: Nature 1999 Aug 19;400(6746):773-6.

SECRETION

[Hormonal regulation of heparin secretion by rat mast cells during stress] Shapiro FB, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May-Jun; 84(5-6):469-73 (Eng. Abstr.) **(Rus)**

STANDARDS

[Sodium heparin and calcium heparin: units in which their potency should be expressed in Argentina] Oliva LM, et al. **Sangre (Barc)** 1998 Jun;43(3):257-9 **(Spa)**

THERAPEUTIC USE

Heparin-mediated extracorporeal LDL/fibrinogen precipitation--H.E.L.P.--in coronary and cerebral ischemia. Jaeger BR, et al. **Acta Neurochir Suppl (Wien)** 1999;73:81-4 (28 ref.)

Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Tyrrell DJ, et al. **Adv Pharmacol** 1999;46:151-208 (349 ref.)

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators [see comments] Becker RC, et al. **Am Heart J** 1999 Jan;137(1):59-71. Comment in: Am Heart J 1999 Jan;137(1):8-11.

A new regimen for heparin use in acute coronary syndromes. Hochman JS, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):313-8

Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. Kleiman NS, et al. **Am Heart J** 1999 Jan; 137(1):12-23

Electrophysiologic procedures and activation of the hemostatic system. Michelucci A, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):128-32

Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention [see comments] Ragosta M, et al. **Am Heart J** 1999 Feb;137(2):250-7. Comment in: Am Heart J 1999 Feb;137(2):190-2.

The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation. Anand SS.

Am J Cardiol 1999 Sep 2;84(5A):13M–19M

A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Bittl JA, et al. **Am J Cardiol** 1998 Oct 22;82(8B):43P–49P

Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Bittl JA, et al. **Am J Cardiol** 1998 Oct 22; 82(8B):50P–56P

Implications of the Organization to Assess Strategies for Ischemic Syndromes–2 (OASIS–2) study and the results in the context of other trials. Fox KA. **Am J Cardiol** 1999 Sep 2;84(5A):26M–31M (18 ref.)

Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Konstantinides S, et al. **Am J Cardiol** 1998 Oct 15;82(8):966–70

Heparin dosing in patients undergoing coronary intervention. Popma JJ, et al. **Am J Cardiol** 1998 Oct 22;82(8B):19P–24P (58 ref.)

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO–2) trial. White HD. **Am J Cardiol** 1998 Oct 22; 82(8B):57P–62P

Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C–based chemotherapy: the role of adjunctive heparin. Sadoff L, et al. **Am J Clin Oncol** 1999 Apr;22(2):187–90

Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Folwaczny C, et al. **Am J Gastroenterol** 1999 Jun;94(6):1551–5

Meta-analysis of streptokinase and heparin in deep vein thrombosis. Ng CM, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):1995–2001

Unfractionated heparin in acute coronary syndromes: has its time come and gone? Trujillo TC, et al. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2402–9 (61 ref.)

Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Italian CAP Study Group. Antonicelli R, et al. **Am J Med** 1999 Sep;107(3):234–9

Puerperal septic pelvic thrombophlebitis: incidence and response to heparin therapy. Brown CE, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):143–8

Heparin plus aspirin as a "single" therapy for recurrent spontaneous abortion associated with both allo- and autoimmunity. Cadavid A, et al. **Am J Reprod Immunol** 1999 Apr;41(4):271–8

The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Sher G, et al. **Am J Reprod Immunol** 1998 Aug;40(2):74–82

Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Abubakar K, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1620–5

Management of deep vein thrombosis of the lower extremity in pregnancy: a challenging dilemma. Aburahma AF, et al. **Am Surg** 1999 Feb;65(2):164–7

The effects of minidose heparin and low molecular weight heparin on peritonitis in the rat. Vela AR, et al. **Am Surg** 1999 May;65(5):473–7

Heparin resistance, antithrombin III treatment, and activated clotting time values [letter; comment] Kanbak M. **Anesth Analg** 1998 Nov;87(5):1215. Comment on: Anesth Analg 1997 Sep;85(3):498–506.

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis [see comments] Gould MK, et al. **Ann Intern Med** 1999 May 18; 130(10):789–99. Comment in: Ann Intern Med 1999 May 18;130(10):857–8.

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Gould MK, et al. **Ann Intern Med** 1999 May 18; 130(10):800–9

Salvage of free flaps after secondary venous ischemia by local delivery of heparin. Kirschner RE, et al. **Ann Plast Surg** 1999 May;42(5):521–7; discussion 527–8

Evaluation of heparin-coated circuits with full heparin dose strategy. Sinci V, et al. **Ann Thorac Cardiovasc Surg** 1999 Jun;5(3):156–63

A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. McCarthy PM, et al. **Ann Thorac Surg** 1999 May;67(5):1268–73

Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Anand SS, et al. **Arch Intern Med** 1999 Sep 27;159(17):2029–32

When should heparin be given to patients with atrial fibrillation-related embolic brain infarcts? [editorial; comment] Caplan LR. **Arch Neurol** 1999 Sep;56(9):1059–60 . Comment on: Arch Neurol 1999 Sep;56(9):1098–102.

Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. deVeber G, et al. **Arch Neurol** 1998 Dec;55(12):1533–7

Is there still a role for intravenous heparin in acute stroke? Yes [see comments] Grau AJ, et al. **Arch Neurol** 1999 Sep; 56(9):1159–60. Comment in: Arch Neurol 1999 Sep;56(9):1160–1. Comment in: Arch Neurol 1999 Sep;56(9):1162.

Intravenous heparin in acute stroke [comment] Hachinski V. **Arch Neurol** 1999 Sep;56(9):1162. Comment on: Arch Neurol 1999 Sep;56(9):1159–60. Comment on: Arch Neurol 1999 Sep;56(9):1160–1.

Is there still a role for intravenous heparin in acute stroke? No [see comments] Sandercock P. **Arch Neurol** 1999 Sep; 56(9):1160–1. Comment in: Arch Neurol 1999 Sep;56(9):1159–60. Comment in: Arch Neurol 1999 Sep;56(9):1162.

Prediction of anticoagulation during hemodialysis by population kinetics and an artificial neural network. Smith BP, et al. **Artif Organs** 1998 Sep;22(9):731–9

Delivery system for targeted thrombolysis without the risk of hemorrhage. Byun Y, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M638–41

Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Park JW, et al. **Atherosclerosis** 1998 Aug;139(2):401–9

The GUSTO 2b and related studies. Global Use of Strategies to Open Occluded Coronary Arteries. Aylward P. **Aust N Z J Med** 1998 Aug;28(4):548–50

Heparin management in acute myocardial infarction (AMI). Granger CB. **Aust N Z J Med** 1998 Aug;28(4):541–7

Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Pineo GF, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):621–37 (112 ref.)

Managing atrial fibrillation in elderly people. Patients presenting acutely should be given anticoagulation with heparin [letter; comment] Mayet J, et al. **BMJ** 1999 Aug 14;319(7207):453. Comment on: BMJ 1999 Apr 24;318(7191):1088–9.

The treatment of heparin resistance with Antithrombin III in cardiac surgery. Kanbak M. **Can J Anaesth** 1999 Jun; 46(6):581–5

Anticoagulant therapy in unstable angina. Choy JB, et al. **Cardiol Clin** 1999 May;17(2):327–43, ix (98 ref.)

Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. Helft G, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):329–31

Heparin in acute ischemic stroke: the case for a new clinical trial. Chamorro A. **Cerebrovasc Dis** 1999;9 Suppl 3:16–23 (46 ref.)

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [published erratum appears in Chest 1999 Jun;115(6):1760] Hirsh J, et al. **Chest** 1998 Nov;114(5 Suppl):489S–510S (246 ref.)

Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Baughman RA, et al. **Circulation** 1998 Oct 20;98(16):1610–5

Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Kouretas PC, et al. **Circulation** 1999 Mar 2; 99(8):1062–8

Anticoagulation is unnecessary after biological aortic valve replacement. Moinuddeen K, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II95–8; discussion II98–9

Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study. Mattioli AV, et al. **Clin Cardiol** 1999 Mar;22(3):213–7

Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring. Manzato F, et al. **Clin Chem Lab Med** 1998 Dec;36(12):975–80

Effects of heparin on vascular dysfunction in diabetic rats. Oturai PS. **Clin Exp Pharmacol Physiol** 1999 May–Jun; 26(5–6):411–4

Outcome of fifty-five newborns of antiphospholipid antibody-positive mothers treated with calcium heparin during pregnancy. Ruffatti A, et al. **Clin Exp Rheumatol** 1998 Sep–Oct;16(5):605–10

Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Kovacs MJ, et al. **Clin Lab Haematol** 1999 Feb;21(1):55–60

Anticoagulation and platelet activation in hemodialysis: clinical results with PMMA. Coli L, et al. **Contrib Nephrol** 1999;125:111–9

Treatment options in unstable angina: a clinical update. Fox KA, et al. **Eur Heart J** 1998 Sep;19 Suppl K:K8–10 (4 ref.)

The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points [see comments] Näslund U, et al. **Eur Heart J** 1999 May;20(10):771–7. Comment in: Eur Heart J 1999 May;20(10):708–9.

Heparin and platelet reactivity in coronary artery disease [editorial; comment] Nurden AT. **Eur Heart J** 1998 Aug; 19(8):1130–1. Comment on: Eur Heart J 1998 Aug;19(8):1239–40.

Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial). Preisack MB, et al. **Eur Heart J** 1998 Aug;19(8):1232–8

Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter. A double-blind, randomized, placebo-controlled trial. Vilardell M, et al. **Eur J Clin Pharmacol** 1999 Feb; 54(12):917–21

Budd-Chiari syndrome following repair of a giant omphalocele. Kaabachi O, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):371–2

Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Dobosz M, et al. **Forum (Genova)** 1998 Jul–Sep;8(3):303–10

Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Altman R, et al. **Haemostasis** 1998 Sep–Oct;28(5):229–35

The special case of venous thromboembolism in pregnancy. Greer IA. **Haemostasis** 1998;28 Suppl 3:22–34 (45 ref.)

Unfractionated heparin and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism. Prandoni P. **Haemostasis** 1998;28 Suppl 3:85–90 (33 ref.)

Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment. Siegerstetter V, et al. **Hepatology** 1999 Jan;29(1):33–8

Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring [editorial] Hull RD, et al. **Int Angiol** 1998 Dec; 17(4):213–24 (95 ref.)

Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction. Chamuleau SA, et al. **Int J Cardiol** 1998 Dec 31;67(3):241–6

Efficacy of thrombolytic therapy in pulmonary embolism determined by MION-enhanced MRA: an experimental study in rabbits. Frank H, et al. **Invest Radiol** 1998 Dec; 33(12):853–7

Heparin for acute myocardial infarction: "news" from the "past" [letter; comment] [published erratum appears in J Am Coll Cardiol 1999 Feb;33(2):591] Di Tano G, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2102. Comment on: J Am Coll Cardiol 1998 Feb;31(2):289–93.

Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. Garcia E, et al. **J Am Coll Cardiol** 1999 Mar;33(3):605–11

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. Jang IK, et al. **J Am Coll Cardiol** 1999 Jun;33(7):1879–85

Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: are current methods of DVT prophylaxis insufficient? Velmahos GC, et al. **J Am Coll Surg** 1998 Nov;187(5):529–33

Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity. Fitch JC, et al. **J Cardiothorac Vasc Anesth** 1999 Feb;13(1):53–7

Normothermic cardiopulmonary bypass increases heparin requirements necessary to maintain anticoagulation. Ereth MH, et al. **J Clin Monit Comput** 1998 Jul;14(5):323–7

Low-molecular-weight heparin for deep venous thrombosis. Bielanski TE. **J Fam Pract** 1999 Sep;48(9):661–2

Thrombolysis is superior to heparin for non-obstructive mitral mechanical valve thrombosis. Lengyel M, et al. **J Heart Valve Dis** 1999 Mar;8(2):167–73

High-dose heparin plus warfarin administration in non-traumatic dural sinuses thrombosis. A clinical and neuroradiological study. Cipri S, et al. **J Neurosurg Sci** 1998 Mar;42(1):23–32

Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. Li Y, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):789–96

A randomized trial of heparin and saline for maintaining intravenous locks in neonates. Heilskov J, et al. **J Soc Pediatr Nurs** 1998 Jul–Sep;3(3):111–6

No-React anticalcification tissue treatment results with stentless heart valves in two adolescents. Milo S, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1222–3

Blunt vascular injuries of the head and neck: is heparinization necessary? Eachempati SR, et al. **J Trauma** 1998 Dec; 45(6):997–1004

The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients. Mohan P, et al. **J Urol** 1999 Sep;162(3 Pt 1):682–4

Potassium leak test predicts outcome in interstitial cystitis [see comments] Teichman JM, et al. **J Urol** 1999 Jun; 161(6):1791–4; discussion 1794–6. Comment in: J Urol 1999 Jun;161(6):1797.

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS–2) Investigators [see comments] **Lancet** 1999 Feb 6;353(9151):429–38. Comment in: Lancet

1999 Feb 6;353(9151):423–4.
Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Day R, et al. **Lancet** 1999 Jul 3; 354(9172):62–5 (37 ref.)
New antithrombotic treatment in unstable coronary syndrome--for whom? [comment] Wallentin L. **Lancet** 1999 Feb 6;353(9151):423–4. Comment on: Lancet 1999 Feb 6;353(9151):429–38.
Treatment of antiphospholipid syndrome in pregnancy. Cowchock S. **Lupus** 1998;7 Suppl 2:S95–7 (15 ref.)
Heparin in acute ischaemic stroke [letter; comment] Davis S, et al. **Med J Aust** 1999 Jun 7;170(11):566–8. Comment on: Med J Aust 1998 Nov 16;169(10):534–6.
Heparin in acute ischaemic stroke. The T wave is negative and it's time to stop [see comments] Hankey GJ. **Med J Aust** 1998 Nov 16;169(10):534–6 (19 ref.). Comment in: Med J Aust 1999 Jun 7;170(11):566–8.
Brief ex vivo perfusion with heparinized and/or citrated whole blood enhances tolerance of free muscle flaps to prolonged ischemia. Fowler JD, et al. **Microsurgery** 1999; 19(3):135–40
Survey of the use of thromboprophylaxis for medical patients at Christchurch Hospital. Egermayer P, et al. **N Z Med J** 1999 Jul 9;112(1091):246–8
Dialysis without heparin in a patient with combined hereditary deficit in coagulation factor V and protein C. Absy M. **Nephrol Dial Transplant** 1999 Mar;14(3):748–9
Renal vein thrombosis, diagnosis and treatment [letter] Hussein M, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):245–7
Therapeutic uses of heparinoids in renal disease patients [editorial] Striker GE. **Nephrol Dial Transplant** 1999 Mar; 14(3):540–3 (23 ref.)
Effects of conventional heparin and low-molecular-weight heparin treatment on lipid metabolism during a single hemodialysis session [letter] Camsari T, et al. **Nephron** 1999; 82(3):286–8
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma [letter; comment] Wijdicks EF, et al. **Neurology** 1999 Feb;52(3):676–7. Comment on: Neurology 1998 May;50(5):1489–91.
Evaluation of effect and distribution of heparin administered in vascular reconstructive surgery. Ohkado A, et al. **Panminerva Med** 1999 Mar;41(1):18–21
Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Devlin JW, et al. **Pharmacotherapy** 1998 Nov-Dec; 18(6):1335–42
Local subcutaneous heparin as treatment for venous insufficiency in replanted digits. Iglesias M, et al. **Plast Reconstr Surg** 1999 May;103(6):1719–24
Neuraxial anesthesia and analgesia in the presence of standard heparin. Liu SS, et al. **Reg Anesth Pain Med** 1998 Nov-Dec;23(6 Suppl 2):157–63 (37 ref.)
Fatal pulmonary embolism after atrial septal defect closure in a paediatric patient. Busch T, et al. **Scand Cardiovasc J** 1999;33(3):187–8
Anticoagulant and defibrinogenating agents in acute ischemic stroke and cerebral venous thrombosis. Meschia JF. **Semin Neurol** 1998;18(4):461–70 (90 ref.)
Current trends in the use of heparins in thromboprophylaxis. Green D. **Semin Thromb Hemost** 1999;25 Suppl 1:29–35
Treatment and prevention of venous thromboembolism. Hull RD, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:21–31 (128 ref.)
Prevention of venous thromboembolism in cancer patients. Kakkar AK, et al. **Semin Thromb Hemost** 1999;25(2):239–43 (39 ref.)
Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? [editorial; comment] Bousser MG. **Stroke** 1999 Mar;30(3):481–3. Comment on: Stroke 1999 Mar;30(3):484–8. Comment on: Stroke 1999 Mar;30(3):489–94.
Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin [see comments] Frey JL, et al. **Stroke** 1999 Mar;30(3):489–94. Comment in: Stroke 1999 Mar;30(3):481–3.
Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? [letter] Lewis MB. **Stroke** 1999 Aug; 30(8):1729
Increased cerebral CO(2) reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Pfefferkorn TK, et al. **Stroke** 1999 Sep;30(9):1802–6
Selective thrombolysis of central retinal artery occlusion without long-term systemic heparinization. Wirostko WJ, et al. **Surg Neurol** 1998 Nov;50(5):408–10
Differential inhibition of thrombin activity and thrombin generation by a synthetic direct thrombin inhibitor (napsagatran, Ro 46-6240) and unfractionated heparin in patients with deep vein thrombosis. ADVENT Investigators. Bounameaux H, et al. **Thromb Haemost** 1999 Apr;81(4):498–501
Use of a heparin nomogram for treatment of patients with venous thromboembolism in a community hospital. de Groot MR, et al. **Thromb Haemost** 1998 Jul;80(1):70–3
Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Toulon P, et al. **Thromb Haemost** 1998 Jul;80(1):104–8
Heparin and cancer. Zacharski LR, et al. **Thromb Haemost** 1998 Jul;80(1):10–23 (203 ref.)
Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulphate. Buchanan MR, et al. **Thromb Res** 1998 Aug 15;91(4):157–67
Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. Soejima H, et al. **Thromb Res** 1999 Jan 1;93(1):17–25
Early graft failure with thrombophilia and effects of anticoagulation. Fischereder M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):360–1
Venous thrombus stability during acute phase of therapy. Caps MT, et al. **Vasc Med** 1999;4(1):9–14
[Heparins, antivitamins K. Principles and rules for their use. Dosage of non-fractionated heparins] Sié P. **Rev Prat** 1998 Jun 15;48(12):1361–5 (3 ref.) **(Fre)**
[Preventive treatment of thrombosis: audit on heparin prescription] Aouizerate P, et al. **Therapie** 1998 Mar-Apr; 53(2):101–6 (Eng. Abstr.) **(Fre)**
[Prevention of venous thrombosis: role of heparins] Wahl D, et al. **Therapie** 1998 Nov-Dec;53(6):575–8 (27 ref.) (Eng. Abstr.) **(Fre)**
[Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects] Frank D, et al. **Schweiz Med Wochenschr** 1998 Sep 5;128(36):1328–33 (Eng. Abstr.) **(Ger)**
[Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis] Henzen C, et al. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1242–8 (Eng. Abstr.) **(Ger)**
[Heparin therapy: 1998 (current use of the 80-year-old heparin)] Rák K. **Orv Hetil** 1999 Jan 10;140(2):59–66 (59 ref.) (Eng. Abstr.) **(Hun)**
[Heparin therapy: from the viewpoint of 1998 (letter)] Takalo L, et al. **Orv Hetil** 1999 Apr 11;140(15):860–1 **(Hun)**
[Clinical aspects of heparin induced thrombocytopenia] Udvardy M, et al. **Orv Hetil** 1999 Jul 25;140(30):1667–71 (Eng. Abstr.) **(Hun)**
[Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism] Verso M, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2 Suppl 1):35–9 (28 ref.) **(Ita)**
[Rheologic modifications induced by heparin therapy. Capillary blood viscosity, erythrocyte deformability, aggregation index] Achilli E, et al. **Minerva Cardioangiol** 1999 Apr;47(4):95–119 (37 ref.) (Eng. Abstr.) **(Ita)**
[Anticoagulant therapy with i.v. non-fractionated sodium heparin with normogram based on body weight: evaluation of a series of 50 patients with venous thromboembolic disease] Landini G, et al. **Minerva Cardioangiol** 1998 Oct; 46(10):378–80 **(Ita)**
[Hyperhomocysteinemia: development of deep vein thrombosis in another location during heparin anticoagulation therapy] Tsuda H, et al. **Rinsho Ketsueki** 1999 May;40(5):396–401 (Eng. Abstr.) **(Jpn)**
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke] Warlow C. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(2):47–50 (0 ref.) **(Rus)**
[Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease? (editorial)] Ruiz Manzano J, et al. **Med Clin (Barc)** 1998 Nov 28; 111(18):697–9 **(Spa)**
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] López-Sendón J, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:76–89 (66 ref.) (Eng. Abstr.) **(Spa)**
[The effect of heparin on the functioning of the hemostasis system in patients with insulin-dependent diabetes mellitus in severe forms of diabetic foot] Garbaruchuk OI, et al. **Ukr Biokhim Zh** 1998 Sep-Oct;70(5):111–6 (Eng. Abstr.) **(Ukr)**

HEPARIN ANTAGONISTS

Miss-'n-mix and mimics. **Acta Anaesthesiol Belg** 1998; 49(3):221–2

ADMINISTRATION & DOSAGE

Relationship of protamine dosing with postoperative complications of carotid endarterectomy. Levison JA, et al. **Ann Vasc Surg** 1999 Jan;13(1):67–72
Do anticoagulation with heparin and protamine reversal alter thrombogenicity of coated and noncoated pulmonary artery catheters? Youngberg JA, et al. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4):405–9
Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. Shigeta O, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):354–60
[Heparin-protamine-protocol] Nomoto S. **Nippon Geka Hokan** 1997 May 1;66(2):49–50 **(Jpn)**

ADVERSE EFFECTS

The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administration. Ralley FE. **Anesth Analg** 1999 Mar;88(3):505–7
Noncardiogenic pulmonary edema immediately following rapid protamine administration. Brooks JC. **Ann Pharmacother** 1999 Sep;33(9):927–30
Heparin and protamine interaction [editorial] Blaise G. **Can J Anaesth** 1998 Dec;45(12):1144–7 **(Eng, Fre)**
Systemic hypotensive response to protamine following chronic inhibition of nitric oxide synthase in rats [see comments] Komatsu H, et al. **Can J Anaesth** 1998 Dec; 45(12):1186–9. Comment in: Can J Anaesth 1998 Dec;45(12):1144–7.
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. Kimmel SE, et al. **J Am Coll Cardiol** 1998 Dec; 32(7):1916–22
Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine. Tevaearai HT, et al. **Thorac Cardiovasc Surg** 1998 Oct;46(5):303–4
[Protamine allergy and cardiac surgery (letter)] Hynynen M, et al. **Duodecim** 1995;111(20):1969–70 **(Fin)**

ANALYSIS

Thromboplastins, heparin, and polybrene [letter; comment] Carroll WE. **Am J Clin Pathol** 1999 Apr;111(4):565. Comment on: Am J Clin Pathol 1996 Oct;106(4):556. Comment on: Am J Clin Pathol 1998 Jun;109(6):764–8.
The risks of heparin-neutralizing substances [letter; comment] Tripodi A. **Am J Clin Pathol** 1999 Apr; 111(4):566. Comment on: Am J Clin Pathol 1998 Jun;109(6):764–8.
Determination of protamine sulphate in drug formulations using high performance liquid chromatography. Snycerski A, et al. **J Pharm Biomed Anal** 1998 Dec;18(4–5):907–10

METABOLISM

Destruction of protamine in human sperm inhibits sperm binding and penetration in the zona-free hamster penetration test but increases sperm head decondensation and male pronuclear formation in the hamster-ICSI assay. Ahmadi A, et al. **J Assist Reprod Genet** 1999 Mar; 16(3):128–32

PHARMACOLOGY

Isoflurane and sodium nitroprusside reduce the depressant effects of protamine sulfate on isolated ischemic rat hearts. Hochhauser E, et al. **Anesth Analg** 1999 Apr;88(4):710–6
Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Mochizuki T, et al. **Anesth Analg** 1998 Oct;87(4):781–5
The direct effects of heparin and protamine on canine tracheal smooth muscle tone. Yamakage M, et al. **Anesth Analg** 1999 Jun;88(6):1232–8
Polybrene increases the efficiency of gene transfer by lipofection. Abe A, et al. **Gene Ther** 1998 May;5(5):708–11
Effects of protamine on nitric oxide level in the pulmonary circulation. Kalaycioğlu S, et al. **Jpn Heart J** 1999 May; 40(3):335–8
A synthetic polycation, a copolymer of 1-vinyl-3-methylimidazole iodide with maleic acid diethyl ester, increases passive ionic permeability in erythrocyte membranes modified by fatty acids. Glazunova OO, et al. **Membr Cell Biol** 1998;12(3):401–9
Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis. Silver PJ, et al. **Thromb Res** 1998 Aug 1;91(3):143–50
[Effect of the synthetic heparin antagonist--quaternary ammonium salt of 25-conidine oligomer on the regeneration of liver injured by CCl4] Golenchenko VA, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):56–60 **(Rus)**

THERAPEUTIC USE

Administration of protamine after coronary stent deployment. Briguori C, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):64–8
Recent experiences with hexadimethrine for neutralizing heparin after cardiopulmonary bypass. Cooney A, et al. **Anaesth Intensive Care** 1999 Jun;27(3):298–300
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. Arrieta O, et al. **Eur J Cancer** 1998 Dec;34(13):2101–6
Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. Kilgore KS, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1041–7

HEPARIN-BINDING FIBROBLAST GROWTH FACTOR CLASS I see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HEPARIN-BINDING GROWTH FACTOR, CLASS I see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HEPARIN-BINDING GROWTH FACTOR CLASS II see **FIBROBLAST GROWTH FACTOR, BASIC**

HEPARIN-CLEARING FACTOR see **LIPOPROTEIN LIPASE**

HEPARIN COFACTOR I see **ANTITHROMBIN III**

HEPARIN COFACTOR II

see related
ANTITHROMBIN III

CHEMISTRY

Amino acid residues of heparin cofactor II required for stimulation of thrombin inhibition by sulphated polyanions. Colwell NS, et al. **Biochim Biophys Acta** 1999 Apr 12; 1431(1):148–56

Covalent heparin cofactor II–heparin and heparin cofactor II–dermatan sulfate complexes. Characterization of novel anticoagulants. Monagle P, et al. **J Biol Chem** 1998 Dec 11;273(50):33566–71

DEFICIENCY

Heparin cofactor II deficiency in central retinal vein occlusion [letter] Hattenbach LO, et al.
Acta Ophthalmol Scand 1998 Dec;76(6):758–9

[Heparin cofactor II deficiency] Sakuragawa N.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):31–3 (20 ref.) **(Jpn)**

GENETICS

Rapid changes in the exon/intron structure of a mammalian thrombin inhibitor gene. Kamp PB, et al. **Gene** 1999 Mar 18;229(1–2):137–44

Isolation of frog and chicken cDNAs encoding heparin cofactor II. Colwell NS, et al. **Thromb Haemost** 1998 Nov; 80(5):784–90

METABOLISM

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. Becker DL, et al. **J Biol Chem** 1999 Mar 5;274(10):6226–33

Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes. Myles T, et al.
J Biol Chem 1998 Nov 20;273(47):31203–8

Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen. Hatton MW, et al. **J Lab Clin Med** 1999 Jan;133(1):81–7

Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thiozyloside compound. Masson P, et al. **Thromb Haemost** 1999 Jun; 81(6):945–50

PHYSIOLOGY

[Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role] Rossi EB, et al.
Medicina (B Aires) 1999;59(1):95–104 (77 ref.) (Eng. Abstr.) **(Spa)**

HEPARIN ELIMINASE see **HEPARIN LYASE**

HEPARIN, LOW-MOLECULAR-WEIGHT

Unexplained acronyms [letter; comment] Cheng TO.
Circulation 1999 Apr 13;99(14):1924–5. Comment on: Circulation 1998 Jul 28;98(4):287–9. Comment on: Circulation 1998 Jul 28;98(4):294–9.

In vitro evaluation of new surface coatings for extracorporeal circulation. Baksaas ST, et al. **Perfusion** 1999 Jan;14(1):11–9

ADMINISTRATION & DOSAGE

Thromboembolic complications after arthroscopic knee surgery [letter; comment] Sørensen JV.
Acta Orthop Scand 1998 Dec;69(6):663–4. Comment on: Acta Orthop Scand 1998 Apr;69(2):144–6.

The role of low molecular weight heparin in total knee arthroplasty. Iobst CA, et al. **Am J Knee Surg** 1999 Winter; 12(1):55–60 (14 ref.)

Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Ahmed T, et al.
Am J Respir Crit Care Med 1999 Aug;160(2):576–81

Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement [see comments] Hull RD, et al.
Arch Intern Med 1999 Jan 25;159(2):137–41. Comment in: Arch Intern Med 1999 Jul 26;159(14):1622–3.

Continuous infusion of recombinant activated factor VII: stability in infusion pump systems. Bonde C, et al.
Blood Coagul Fibrinolysis 1998 Mar;9 Suppl 1:S103–5

The end of the heparin pump? Epidural haematoma may occur after epidural and spinal regional anaesthesia [letter] Callander CC. **BMJ** 1999 Aug 28;319(7209):576

The end of the heparin pump? Dosage regimens for low molecular weight heparins differ [letter] Lloyd M. **BMJ** 1999 Aug 28;319(7209):575–6

Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: preliminary results of an ongoing study. Strecker EP, et al.
Cardiovasc Intervent Radiol 1998 Sep–Oct;21(5):375–9

The right stuff (to the right place, at the right dose...) [editorial; comment] Heldman AW, et al.
Catheter Cardiovasc Interv 1999 May;47(1):107–8. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):102–6.

Subcutaneous low molecular weight heparin in place of heparin infusion during warfarin dose optimisation in cerebral ischaemia. Venketasubramanian N, et al.
Clin Neurol Neurosurg 1998 Sep;100(3):193–5

Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Lausen I, et al.
Eur J Surg 1998 Sep;164(9):657–63

Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Marchetti M, et al. **Haematologica** 1999 Aug;84(8):726–9

Outpatient therapy with low-molecular-weight heparins: new perspectives for treatment of deep vein thrombosis. Büller HR. **Haemostasis** 1998;28 Suppl 3:91–4

Thromboprophylaxis in the cancer patient. Kakkar AK, et al. **Haemostasis** 1998;28 Suppl 3:61–5 (17 ref.)

Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. Leroyer C, et al. **Haemostasis** 1998 Mar–Apr;28(2):70–7

Are symptomatic endpoints acceptable in venous thromboprophylactic studies? Prentice CR. **Haemostasis** 1998;28 Suppl 3:109–12

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17–21 (15 ref.)

New perspectives for treatment of pulmonary embolism. Simonneau G. **Haemostasis** 1998;28 Suppl 3:95–9 (9 ref.)

Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. Kirchmaier CM, et al. **Int Angiol** 1998 Sep;17(3):135–45

Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. Salartash K, et al. **J Vasc Surg** 1999 Sep;30(3):526–31

Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Camici M, et al. **Minerva Med** 1998 Nov–Dec;89(11–12):405–9

Prevention of venous thrombosis after elective hip surgery [see comments] Turpie AG, et al. **Orthopedics** 1998 Dec; 21(12):1275–81 (45 ref.). Comment in: Orthopedics 1999 May;22(5):476–7.

The effects of intraperitoneal piroxicam and low molecular weight heparin in prevention of adhesion reformation in rat uterine horn. Tayyar M, et al. **Res Exp Med (Berl)** 1999 Mar;198(5):269–75

Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Dempfle CE, et al. **Thromb Haemost** 1999 May;81(5):701–4

Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Lopaciuk S, et al. **Thromb Haemost** 1999 Jan;81(1):26–31

Which DVT patients could be considered the best candidates for home therapy? [letter] Monreal M. **Thromb Haemost** 1999 Jun;81(6):996–7

Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Planès A, et al.
Thromb Haemost 1999 Jan;81(1):22–5

Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Hansen JB, et al. **Thromb Res** 1998 Aug 15;91(4):177–81

Outpatient treatment of deep vein thrombosis with LMWH. Koopman MM. **Wien Med Wochenschr** 1999;149(2–4):46–9; discussion 49 (18 ref.)

[Risk factors and prevention of thromboembolic risk in laparoscopy] Catheline JM, et al. **Ann Chir** 1998;52(9):890–5 (Eng. Abstr.) **(Fre)**

[Treatment of proximal deep venous thrombosis of the legs by low-molecular-weight heparin: a systematic review] Lamy O, et al. **Schweiz Med Wochenschr** 1999 May 8; 129(18):707–14 (Eng. Abstr.) **(Fre)**

[Antithrombotic therapy in pregnancy] Ostermann H.
Internist (Berl) 1998 Dec;39(12):1303–4 **(Ger)**

[Improved postoperative prevention of thrombosis in trauma surgery by dose adjusted low molecular weight heparin based on TAT and D-dimer values] Hansen M, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:1213–7 **(Ger)**

[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin] Göttman D, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jan;170(1):84–8 (Eng. Abstr.) **(Ger)**

[Ambulatory therapy of acute deep thrombophlebitis] Wuillemin WA, et al. **Ther Umsch** 1998 Sep;55(9):546–7 (Eng. Abstr.) **(Ger)**

[Therapy of thromboses with low-molecular-weight heparins] Haas S, et al. **Wien Med Wochenschr** 1999; 149(2–4):39–45; discussion 45 (24 ref.) (Eng. Abstr.) **(Ger)**

[Standard heparin versus low-molecular-weight heparin] Lockner D. **Wien Med Wochenschr** 1999;149(2–4):37–8 (Eng. Abstr.) **(Ger)**

[Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin] Hamann H.
Zentralbl Chir 1999;124(1):24–6 (Eng. Abstr.) **(Ger)**

[Prevention of thromboembolism with low-molecular-weight heparin in ambulatory surgery and unoperated surgical and orthopedic patients] Harenberg J, et al. **Zentralbl Chir** 1998;123(11):1284–7 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Low-molecular-weight heparin-induced skin necrosis. Füreder W, et al. **Ann Hematol** 1998 Sep;77(3):127–30 (28 ref.)

Dermatan sulphate in patients with heparin-induced thrombocytopenia. Taliani MR, et al. **Br J Haematol** 1999 Jan;104(1):87–9

Antibodies to platelet factor 4–heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Pouplard C, et al. **Circulation** 1999 May 18;99(19):2530–6

Concomitant sensitization to high and low molecular-weight heparins, heparinoid and pentosanpolysulfate. Hunzelmann N, et al. **Contact Dermatitis** 1998 Aug;39(2):88–9

Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Wütschert R, et al. **Drug Saf** 1999 Jun;20(6):515–25 (68 ref.)

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation? Schulman S. **Haemostasis** 1998;28 Suppl 3:17–21 (15 ref.)

Atheroembolic disease associated with the use of low-molecular-weight heparin during haemodialysis [letter] Carron PL, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):520–1

Low-molecular weight heparin, spinal hematomas, and the FDA: what's wrong with this picture? [editorial] Landow L, et al. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):8–10

[Acute adrenal insufficiency due to bilateral adrenal hematoma following severe thrombopenia induced by low-molecular-weight heparin] Caubet O, et al.
Presse Med 1999 May 22–29;28(19):1010–2 (Eng. Abstr.) **(Fre)**

ANALYSIS

Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes. Ramamurthy N, et al. **Anal Biochem** 1999 Jan 1;266(1):116–24

CHEMISTRY

Biocompatibility of heparin and low-molecular mass heparin in a new implantable medication pump. Schmid MG, et al. **Arzneimittelforschung** 1998 Sep;48(9):910–3

DIAGNOSTIC USE

[Evaluation of low molecular weight heparin prescription at the Centre Hospitalier Intercommunal de Créteil] Callaert S, et al. **Therapie** 1998 Nov–Dec;53(6):587–90 (Eng. Abstr.) **(Fre)**

ECONOMICS

The end of the heparin pump? Low molecular weight heparins have practical advantages, but clinical advantages are small [letter] Stein K, et al. **BMJ** 1999 Aug 28; 319(7209):576

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis [see comments] Rodger M, et al. **CMAJ** 1998 Oct 20; 159(8):931–8. Comment in: ACP J Club 1999 Mar–Apr;130(2):53.

The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Hull RD, et al. **Haemostasis** 1998; 28 Suppl 3:8–16

ISOLATION & PURIFICATION

Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Dietrich CP, et al.
Biochim Biophys Acta 1999 Aug 5;1428(2–3):273–83

METABOLISM

Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes. Ramamurthy N, et al. **Anal Biochem** 1999 Jan 1;266(1):116–24

PHARMACOLOGY

Effects of low molecular weight heparin, alone or combined with antithrombin III, on mortality, fibrin deposits and hemostatic parameters in endotoxin-induced disseminated intravascular coagulation in rabbits. Hermida J, et al.
Am J Hematol 1999 Jan;60(1):6–11

Heparin and low molecular weight heparin decrease nitric oxide production by human polymorphonuclear cells. Beltrán AE, et al. **Arch Med Res** 1999 Mar–Apr;30(2):116–9

Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma.

Gerotziafas GT, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):571-80

A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans. Kaiser B, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):517-23

Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion. Li PA, et al. **Brain Res** 1998 Aug 10;801(1-2):220-3

Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor [letter; comment] Cella G, et al. **Circulation** 1999 Jun 29;99(25):3323. Comment on: Circulation 1998 Jan 27;97(3):251-6.

Thrombin-induced platelet activation is inhibited by high- and low-molecular-weight heparin. De Candia E, et al. **Circulation** 1999 Jun 29;99(25):3308-14

Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters. Glusa E, et al. **Haemostasis** 1998 Jan-Feb;28(1):45-56

Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Di Simone N, et al. **Hum Reprod** 1999 Feb;14(2):489-95

Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses. Campo C, et al. **J Appl Physiol** 1999 Feb;86(2):549-57

Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin. Shapira OM, et al. **J Surg Res** 1999 Jul;85(1):83-7

Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. Downing LJ, et al. **J Vasc Surg** 1998 Nov;28(5):848-54

Low-molecular-weight heparin inhibits neutrophil transmigration through endothelial cell monolayers. Hofbauer R, et al. **Microvasc Res** 1999 Sep;58(2):190-2

The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Bhandari M, et al. **Thromb Haemost** 1998 Sep;80(3):413-7

Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Mauron T, et al. **Thromb Haemost** 1998 Jul;80(1):82-6

Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. Iomhair MM, et al. **Thromb Res** 1998 Dec 1; 92(5):229-32

Effect of low molecular weight heparin on graft vascular disease in the rat cardiac allograft model. Teranishi K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):103-5

[The pharmacological characteristics and clinical use of low-molecular-weight heparins] Golota VIa, et al. **Lik Sprava** 1998 Dec;(8):15-7 (26 ref.) **(Rus)**

THERAPEUTIC USE

Editorial on LMWH and regional anaesthesia--dangerous recommendations [letter; comment] Ljungström KG. **Acta Anaesthesiol Scand** 1999 Jan;43(1):116-8. Comment on: Acta Anaesthesiol Scand 1998 Jul;42(6):609-13.

Thromboprophylaxis in hip arthroplasty. New frontiers and future strategy [see comments] Dahl OE. **Acta Orthop Scand** 1998 Aug;69(4):339-42 (37 ref.). Comment in: Acta Orthop Scand 1998 Aug;69(4):343-4.

Low-molecular-weight heparin in preventing and treating DVT. Rydberg EJ, et al. **Am Fam Physician** 1999 Mar 15;59(6):1607-12 (21 ref.)

Low-molecular-weight heparin in outpatient treatment of DVT. Yeager BF, et al. **Am Fam Physician** 1999 Feb 15; 59(4):945-52 (22 ref.)

Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. Gimple LW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1524-9

Anticoagulants in acute coronary syndromes. Turpie AG. **Am J Cardiol** 1999 Sep 2;84(5A):2M-6M (14 ref.)

Low-molecular-weight heparin: an antithrombotic agent whose time has come. Futterman LG, et al. **Am J Crit Care** 1999 Jan;8(1):520-3

Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma [letter] Eikelboom JW, et al. **Am J Hematol** 1998 Nov;59(3):260-1

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Gould MK, et al. **Ann Intern Med** 1999 May 18; 130(10):800-9

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis [see comments] Gould MK, et al. **Ann Intern Med** 1999 May 18; 130(10):789-99. Comment in: Ann Intern Med 1999 May 18;130(10):857-8.

Low-molecular-weight heparin for treating venous thromboembolism [letter; comment] Mahoney MS, et al. **Ann Intern Med** 1999 Jan 5;130(1):77-8. Comment on: Ann Intern Med 1998 Jun 15;128(12 Pt 1):1037-9.

Weight watching in heparin [letter; comment] Cheng TO. **Arch Intern Med** 1999 May 24;159(10):1142. Comment on: Arch Intern Med 1998 Oct 12;158(18):2001-3.

Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery [letter; comment] Ghosh A. **Arch Intern Med** 1999 Jul 26;159(14):1622-3. Comment on: Arch Intern Med 1999 Jan 25;159(2):137-41.

Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Goldhaber SZ, et al. **Arch Intern Med** 1998 Nov 23;158(21):2325-8

Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin [see comments] Harrison L, et al. **Arch Intern Med** 1998 Oct 12; 158(18):2001-3. Comment in: Arch Intern Med 1998 Oct 12;158(18):1964. Comment in: Arch Intern Med 1999 May 24;159(10):1139-40. Comment in: Arch Intern Med 1999 May 24;159(10):1142.

Deep venous thrombosis: thinking inside out [editorial; comment] [see comments] Liebowitz RS. **Arch Intern Med** 1998 Oct 12;158(18):1964. Comment on: Arch Intern Med 1998 Oct 12;158(18):2001-3. Comment in: Arch Intern Med 1999 May 24;159(10):1139-40.

Outpatient protocols for treatment of venous thromboembolism using low-molecular-weight heparin: to treat or not to treat at home [letter; comment] Spyropoulos AC. **Arch Intern Med** 1999 May 24;159(10):1139-40. Comment on: Arch Intern Med 1998 Oct 12;158(18):1964. Comment on: Arch Intern Med 1998 Oct 12;158(18):2001-3.

Low-molecular-weight heparins in the management of acute coronary syndromes. Zed PJ, et al. **Arch Intern Med** 1999 Sep 13;159(16):1849-57 (89 ref.)

Deep vein thrombosis in elderly Hong Kong Chinese with hip fractures detected with compression ultrasound and Doppler imaging: incidence and effect of low molecular weight heparin. Kew J, et al. **Arch Orthop Trauma Surg** 1999;119(3-4):156-8

Low molecular weight heparins in acute ischaemic syndromes. White HD, et al. **Aust N Z J Med** 1998 Aug; 28(4):555-7

Prevention of venous thromboembolism in general surgery. Kakkar VV, et al. **Baillieres Clin Haematol** 1998 Sep; 11(3):605-19 (56 ref.)

Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. Pineo GF, et al. **Baillieres Clin Haematol** 1998 Sep;11(3):621-37 (112 ref.)

Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Planès A, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):499-505

Antithrombotic therapy in cancer [editorial] Kakkar AK, et al. **BMJ** 1999 Jun 12;318(7198):1571-2

The current use of low molecular weight heparins in clinical practice [letter] Phekoo K, et al. **Br J Haematol** 1998 Oct; 103(1):283

Clinical uses of low-molecular-weight heparins. Aguilar D, et al. **Chest** 1999 May;115(5):1418-23 (25 ref.)

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [published erratum appears in Chest 1999 Jun;115(6):1760] Hirsh J, et al. **Chest** 1998 Nov;114(5 Suppl):489S-510S (246 ref.)

Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Hirsh J. **Circulation** 1998 Oct 13; 98(15):1575-82 (44 ref.)

How to use low-molecular weight heparin for outpatient management of deep vein thrombosis. Deitcher SR, et al. **Cleve Clin J Med** 1999 Jun;66(6):329-31

Efficacy and tolerability of a very low molecular weight heparin compared with standard heparin in patients with unstable angina: a pilot study. Mattioli AV, et al. **Clin Cardiol** 1999 Mar;22(3):213-7

Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Kovacs MJ, et al. **Clin Lab Haematol** 1999 Feb;21(1):55-60

Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins. Hirsh J. **Curr Opin Hematol** 1998 Sep; 5(5):360-5 (12 ref.)

Heparin and low molecular weight heparin for treatment of acute pulmonary embolism [see comments] Raskob GE. **Curr Opin Pulm Med** 1999 Jul;5(4):216-21 (34 ref.). Comment in: Curr Opin Pulm Med 1999 Jul;5(4):209.

Transcapillary escape rate and albuminuria in Type II diabetes. Effects of short-term treatment with low-molecular weight heparin. Nielsen S, et al. **Diabetologia** 1999 Jan;42(1):60-7

Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Ho YH, et al. **Dis Colon Rectum** 1999 Feb;42(2):196-202; discussion 202-3

Aspirin and heparin in acute ischaemic stroke in older patients. Gubitz GJ, et al. **Drugs Aging** 1999 Jul;15(1):29-36 (33 ref.)

Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. van Gorp EC, et al. **Drugs Aging** 1998 Aug;13(2):145-57 (94 ref.)

Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial). Preisack MB, et al. **Eur Heart J** 1998 Aug;19(8):1232-8

Current roles and future possibilities for low-molecular-weight heparins in unstable angina. Purcell H, et al. **Eur Heart J** 1998 Sep;19 Suppl K:K18-23 (42 ref.)

Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease. FRISC study group. Fragmin during Instability in Coronary Artery Disease [see comments] Sätre H, et al. **Eur Heart J** 1999 May; 20(9):645-52. Comment in: Eur Heart J 1999 May;20(9):634-5.

Assessment of deep vein thrombosis prophylaxis in surgical patients: a study conducted at Nancy University Hospital, France. Lepaux DJ, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):671-6

Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Riyazi N, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):49-54

Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. Altman R, et al. **Haemostasis** 1998 Sep-Oct;28(5):229-35

Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Bossuyt PM, et al. **Haemostasis** 1998;28 Suppl 3:100-7 (14 ref.)

Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin. Monreal M, et al. **Haemostasis** 1998 Sep-Oct;28(5):236-43

Unfractionated heparin and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism. Prandoni P. **Haemostasis** 1998;28 Suppl 3:85-90 (33 ref.)

Antithrombotic therapy in coronary ischaemia: the expanding role of low-molecular-weight heparin. Turpie AG. **Haemostasis** 1998;28 Suppl 3:35-42 (24 ref.)

Advances in unstable angina: the role of low molecular weight heparins. Introduction and Chairmen's summary. Braunwald E, et al. **Heart** 1999 Sep;82 Suppl 1:I1, I21

Low-molecular-weight heparins. Huang JN, et al. **Hematol Oncol Clin North Am** 1998 Dec;12(6):1251-81, vi-vii (90 ref.)

Tinzaparin as an antithrombotic: an overview. Fegan CD. **Hosp Med** 1998 Feb;59(2):145-8

Low-molecular-weight heparin: more indications for use. Kujovich JL. **Hosp Pract (Off Ed)** 1999 Apr 15;34(4):67-8, 71-8, 83; discussion 83-4

Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme [editorial] Hull RD, et al. **Int Angiol** 1998 Sep;17(3):131-4 (31 ref.)

Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring [editorial] Hull RD, et al. **Int Angiol** 1998 Dec; 17(4):213-24 (95 ref.)

Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study. Makris PE, et al. **Int Angiol** 1998 Jun;17(2):69-79

ACOG committee opinion. Anticoagulation with low-molecular-weight heparin during pregnancy. Number 211, November 1998. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Apr;65(1):89-90

Unfractionated heparin, time for a change? Ridgway PF, et al. **Ir Med J** 1999 Apr;92(3):302-6

Outpatient management of deep vein thrombosis [see comments] O'Shaughnessy DF, et al. **J Accid Emerg Med** 1998 Sep;15(5):292-3. Comment in: J Accid Emerg Med 1999 Jul;16(4):313-4.

Treatment with low molecular weight heparin needs anticoagulation monitoring [letter; comment] Hassn A, et al. **J Am Coll Surg** 1999 Jul;189(1):141-2. Comment on: J Am Coll Surg 1998 Dec;187(6):641-58.

Low molecular weight heparins: current use and indications [see comments] Quader MA, et al. **J Am Coll Surg** 1998 Dec;187(6):641-58 (95 ref.). Comment in: J Am Coll Surg 1999 Jul;189(1):141-2.

Low-molecular-weight heparin for deep venous thrombosis. Bielanski TE. **J Fam Pract** 1999 Sep;48(9):661-2

Low molecular weight heparins in the cardiac catheterization laboratory. Montalescot G, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):319-23 (27 ref.)

Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. Gonzalez-Fajardo JA, et al. **J Vasc Surg** 1999 Aug; 30(2):283-92

Deep-vein thrombosis [letter; comment] Malhotra P. **Lancet** 1999 May 15;353(9165):1708. Comment on: Lancet 1999 Feb 6;353(9151):479-85.

Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy [letter] [see comments] Thomson AJ, et al. **Lancet** 1998 Dec 12; 352(9144):1904. Comment in: Lancet 1999 Mar 13;353(9156):932.

Pulmonary embolism [letter; comment] Schrijvers D, et al. **N Engl J Med** 1998 Nov 19;339(21):1555; discussion 1557 . Comment on: N Engl J Med 1998 Jul 9;339(2):93-104.

Thrombosis of the inferior vena cava in a pregnant woman with nephrotic syndrome--diagnostic and therapeutic dilemma. Tien YC, et al. **Nephrol Dial Transplant** 1999 Jan;

14(1):210–3

Effects of conventional heparin and low-molecular-weight heparin treatment on lipid metabolism during a single hemodialysis session [letter] Camsari T, et al. **Nephron** 1999; 82(3):286–8

Low molecular weight heparin use during pregnancy: issues of safety and practicality. Chan WS, et al. **Obstet Gynecol Surv** 1999 Oct;54(10):649–54 (38 ref.)

Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Groce JB 3rd. **Pharmacotherapy** 1998 Nov–Dec;18(6 Pt 3):175S–180S

Issues in developing an outpatient deep venous thrombosis treatment program: university hospital experience. Yurkowski P. **Pharmacotherapy** 1998 Nov–Dec;18(6 Pt 3):165S–169S

Low-molecular-weight heparin: biochemistry, pharmacology, and concurrent drug precautions. Heit JA. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6 Suppl 2):135–9 (22 ref.)

Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis [see comments] Horlocker TT, et al. **Reg Anesth Pain Med** 1998 Nov–Dec;23(6 Suppl 2):164–77 (27 ref.). Comment in: Reg Anesth Pain Med 1999 Jul–Aug;24(4):375–7.

Low-molecular weight heparin administration after subarachnoid block [letter; comment] Neal JM, et al. **Reg Anesth Pain Med** 1999 Jul–Aug;24(4):375–7. Comment on: Reg Anesth Pain Med 1998 Nov–Dec;23(6 Suppl 2):164–77.

Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes. Cohen M. **Semin Hematol** 1999 Jan;36(1 Suppl 1):33–6 (14 ref.)

Treatment and prevention of venous thromboembolism. Hull RD, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:21–31 (128 ref.)

Prevention of venous thromboembolism in cancer patients. Kakkar AK, et al. **Semin Thromb Hemost** 1999;25(2):239–43 (39 ref.)

Treatment of venous thromboembolism in cancer patients. Levine MN, et al. **Semin Thromb Hemost** 1999;25(2):245–9 (35 ref.)

Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis [see comments] de Bruijn SF, et al. **Stroke** 1999 Mar;30(3):484–8. Comment in: Stroke 1999 Mar;30(3):481–3.

Safety of low-molecular-weight heparin in pregnancy: a systematic review. Sanson BJ, et al. **Thromb Haemost** 1999 May;81(5):668–72 (33 ref.)

Effect of low-molecular-weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Hisatomi K. **Transplant Proc** 1998 Dec;30(8):4337–9

Low-molecular-weight heparin in the treatment of deep venous thrombosis. Hauer KE. **West J Med** 1998 Oct; 169(4):240–4

[Effects of low-molecular-weight heparin on proliferative glomerulonephritis] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Nov;36(11):731–5 (Eng. Abstr.) **(Chi)**

[Acute acalculous cholecystitis associated with primary antiphospholipid antibody syndrome. Cure with low-molecular-weight heparin and antivitamin K] Nolen N, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):144–6 (Eng. Abstr.) **(Fre)**

[How to provide practical treatment for ambulatory patients with deep venous thrombosis] Achkar A, et al. **J Mal Vasc** 1999 Feb;24(1):58–65 (42 ref.) (Eng. Abstr.) **(Fre)**

[Lengthened activated thromboplastin time in the course of tinzaparin therapy of accidental venous thromboembolism. Pilot study (letter)] Achkar A, et al. **Presse Med** 1998 Apr 11;27(14):667–8 **(Fre)**

[Low molecular weight heparin in unstable angina and myocardial infarction without Q wave] Choussat R, et al. **Presse Med** 1999 Jun 12;28(21):1128–34 (51 ref.) (Eng. Abstr.) **(Fre)**

[Prophylaxis of venous thromboembolism in medical patients: from medical decision tools to the use of low molecular weight heparin] Thilly N, et al. **Therapie** 1998 Nov–Dec; 53(6):579–86 (Eng. Abstr.) **(Fre)**

[Low molecular weight heparin in atherothrombotic cardiovascular diseases. Value in coronary disease, ischemic stroke and peripheral arterial occlusive disease] Stammler F, et al. **Dtsch Med Wochenschr** 1999 Jun 25; 124(25–26):802–9 (51 ref.) **(Ger)**

[Low-molecular heparin in doses adapted to body weight. Management of thromboembolic diseases] **Internist (Berl)** 1999 May;40(5 Suppl Management):1–16 **(Ger)**

[Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects] Frank D, et al. **Schweiz Med Wochenschr** 1998 Sep 5;128(36):1328–33 (Eng. Abstr.) **(Ger)**

[Low molecular weight heparin--1998 status] Marbet GA. **Schweiz Rundsch Med Prax** 1999 Apr 29;88(18):802–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Unstable coronary syndrome. Therapeutic possibilities of the use of low-molecular heparins] **Z Kardiol** 1999 Feb;88(2 Suppl Therapiepe):1–8 **(Ger)**

[Reliable anticoagulation in acute myocardial infarction. Acute coronary syndromes: advances with low-molecular heparin therapy] **Z Kardiol** 1998 Dec;87(12 Suppl Akute Koro):1–4 **(Ger)**

[Thrombophilia, anticoagulant therapy and pregnancy] Boda Z, et al. **Orv Hetil** 1998 Dec 27;139(52):3113–6 (Eng. Abstr.) **(Hun)**

[Preventive treatment in internal medicine by low-molecular-weight heparin (nadroparine calcium)] Martyin T, et al. **Orv Hetil** 1998 Dec 20;139(51):3065–9 (29 ref.) (Eng. Abstr.) **(Hun)**

[Prevention of deep vein thrombosis (DVT) with the low molecular weight heparin (LMWH) and epidural/spinal anesthesia. The efficacy viewpoint] Cyrkowicz A, et al. **Ginekol Pol** 1998 Nov;69(11):795–9 (Eng. Abstr.) **(Pol)**

[Spinal analgesia and perioperative low molecular weight heparin (LMWH) prophylaxis of thrombosis. Safety aspect] Cyrkowicz A, et al. **Ginekol Pol** 1997 Nov;68(11):523–7 (Eng. Abstr.) **(Pol)**

[Acute venous thrombosis: new directions in prophylaxis and treatment] Fedorov VD, et al. **Khirurgiia (Mosk)** 1998; (12):60–3 (26 ref.) **(Rus)**

[The pharmacological characteristics and clinical use of low-molecular-weight heparins] Golota VIa, et al. **Lik Sprava** 1998 Dec;(8):15–7 (26 ref.) **(Rus)**

[Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?] Panchenko EP. **Ter Arkh** 1998;70(12):71–4 (26 ref.) **(Rus)**

[Efficacy and safety of low molecular weight heparin in the treatment of pulmonary thromboembolism] Cereza G, et al. **Med Clin (Barc)** 1999 Jun 26;113(3):115–6 **(Spa)**

[Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease? (editorial)] Ruiz Manzano J, et al. **Med Clin (Barc)** 1998 Nov 28; 111(18):697–9 **(Spa)**

[The treatment with low-molecular-weight heparin of disseminated intravascular coagulation secondary to an aortic aneurysm (letter)] Callejas Rubio JL, et al. **Rev Clin Esp** 1998 Nov;198(11):781–2 (10 ref.) **(Spa)**

[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] López-Sendón J, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:76–89 (66 ref.) (Eng. Abstr.) **(Spa)**

HEPARIN LYASE

Ex vivo evaluation of a Taylor-Couette flow, immobilized heparinase I device for clinical application. Ameer GA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2350–5

ISOLATION & PURIFICATION

Immobilization of recombinant heparinase I fused to cellulose-binding domain. Shpigel E, et al. **Biotechnol Bioeng** 1999 Oct 5;65(1):17–23

METABOLISM

Regional heparinization via simultaneous separation and reaction in a novel Taylor-Couette flow device. Ameer GA, et al. **Biotechnol Bioeng** 1999 Jun 5;63(5):618–24

The calcium-binding sites of heparinase I from Flavobacterium heparinum are essential for enzymatic activity. Liu D, et al. **J Biol Chem** 1999 Feb 12; 274(7):4089–95

Biochemical investigations and mapping of the calcium-binding sites of heparinase I from Flavobacterium heparinum. Shriver Z, et al. **J Biol Chem** 1999 Feb 12; 274(7):4082–8

PHARMACOLOGY

Ex vivo reversal of heparin-mediated cardioprotection by heparinase after ischemia and reperfusion. Kilgore KS, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1041–7

Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis. Silver PJ, et al. **Thromb Res** 1998 Aug 1;91(3):143–50

HEPARINASE see **HEPARIN LYASE**

HEPARINASE I see **HEPARIN LYASE**

HEPARINIC ACID see **HEPARIN**

HEPARINOIDS

ADVERSE EFFECTS

Concomitant sensitization to high and low molecular-weight heparins, heparinoid and pentosanpolysulfate. Hunzelmann N, et al. **Contact Dermatitis** 1998 Aug;39(2):88–9

[Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives] Jappe U, et al. **Hautarzt** 1999 Jun;50(6):406–11 (49 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Direct observation of fibrinogen-heparinoid complexes formation using surface plasmon resonance. Sakamoto N, et al. **Bioconjug Chem** 1999 May–Jun;10(3):538–43

Heparinoids: structure, biological activities and therapeutic applications. Gunay NS, et al. **Planta Med** 1999 May; 65(4):301–6 (28 ref.)

IMMUNOLOGY

Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid. Sauer M, et al. **Med Pediatr Oncol** 1999 Jun;32(6):457–8

PHARMACOLOGY

Anticoagulant and antiprotease activities of a heparinoid sulfated glucoside-bearing polymer. Onishi M, et al. **J Biomater Sci Polym Ed** 1998;9(9):973–84

Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans [letter; comment] Mikhailidis DP, et al. **J Intern Med** 1998 Aug; 244(2):184. Comment on: J Intern Med 1997 Aug;242(2):125–9.

Heparinoids: structure, biological activities and therapeutic applications. Gunay NS, et al. **Planta Med** 1999 May; 65(4):301–6 (28 ref.)

THERAPEUTIC USE

Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. Wade WE. **Am J Orthop** 1999 Apr;28(4):229–31

Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Hale LP, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):318–22

Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin [see comments] Cantor WJ, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):352–5. Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):356.

Options to heparin anticoagulation for cardiac interventions [editorial; comment] Kahn JK. **Catheter Cardiovasc Interv** 1999 Mar;46(3):356. Comment on: Catheter Cardiovasc Interv 1999 Mar;46(3):352–5.

[The role of heparinoids in the treatment of vascular diseases] Undas A, et al. **Pol Arch Med Wewn** 1998 May;99(5):430–5 (29 ref.) **(Pol)**

HEPARITIN SULFATE

ADMINISTRATION & DOSAGE

Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. van der Pijl JW, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1331–6

Effects of oral administration of heparan sulphate in the rat remnant kidney model. Barsotti G, et al. **Nephron** 1999; 81(3):310–6

ADVERSE EFFECTS

Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses [letter] Tardy B, et al. **Thromb Haemost** 1998 Sep;80(3):530

ANALYSIS

Decreased staining of heparan sulfate in non-lesional skin of a subgroup of patients with systemic lupus erythematosus. Seyger MM, et al. **Acta Derm Venereol** 1998 Sep;78(5):326–30

Heparan sulfate composition of alternatively spliced CD44 fusion proteins. Piepkorn M, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):839–42

Variable expression of heparan sulfate epitopes in crescents of human glomerulonephritis. Morita H, et al. **Virchows Arch** 1999 Feb;434(2):145–51

ANTAGONISTS & INHIBITORS

Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA. Wichert A, et al. **Cancer Gene Ther** 1999 May–Jun;6(3):263–70

Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Fujiwara Y, et al. **Toxicology** 1999 Apr 15; 133(2–3):147–57

BIOSYNTHESIS

Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Graham LD, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):542–8

Molecular cloning and expression of a third member of the heparan sulfate/heparin GlcNAc N-deacetylase/ N-sulfotransferase family. Aikawa J, et al. **J Biol Chem** 1999 Jan 29;274(5):2690–5

The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. Lind T, et al. **J Biol Chem** 1998 Oct 9; 273(41):26265–8

Apolipoprotein E containing high density lipoprotein

stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein e. Paka L, et al. **J Biol Chem** 1999 Feb 19; 274(8):4816–23

The retinoic acid and cAMP-dependent up-regulation of 3-O-sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate biosynthesis in F9 embryonal carcinoma cells. Zhang L, et al. **J Biol Chem** 1998 Oct 23;273(43):27998–8003

Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. French MM, et al. **J Cell Biol** 1999 May 31;145(5):1103–15

Thymic epithelial cells synthesize a heparan sulfate with a highly sulfated region. Werneck CC, et al. **J Cell Physiol** 1999 Jan;178(1):51–62

Chondroitin sulphate and heparan sulfate proteoglycan are sequentially expressed in the uterine extracellular matrix during early pregnancy in the rat. Slater M, et al. **Matrix Biol** 1999 Apr;18(2):125–31

Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Fujiwara Y, et al. **Toxicology** 1999 Apr 15; 133(2–3):147–57

Lead inhibits the core protein synthesis of a large heparan sulfate proteoglycan perlecan by proliferating vascular endothelial cells in culture. Fujiwara Y, et al. **Toxicology** 1999 Apr 15;133(2–3):159–69

BLOOD

Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Yokoyama H, et al. **Kidney Int** 1999 Aug;56(2):650–8

CHEMISTRY

Sequence analysis of heparan sulphate and heparin oligosaccharides. Vivès RR, et al. **Biochem J** 1999 May 1;339 (Pt 3):767–73

Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Gupta P, et al. **Blood** 1998 Dec 15; 92(12):4641–51

Characterization of fibroblast growth factor 1 binding heparan sulfate domain. Kreuger J, et al. **Glycobiology** 1999 Jul;9(7):723–9

Differentiation-associated modulation of heparan sulfate structure and function in CaCo-2 colon carcinoma cells. Salmivirta M, et al. **Glycobiology** 1998 Oct;8(10):1029–36

Natural hepatocyte growth factor (HGF) from human serum and a bound form of recombinant HGF with heparan sulfate are indistinguishable in their physicochemical properties. Yano K, et al. **Int J Biol Macromol** 1998 Oct; 23(3):227–35

Highly sensitive sequencing of the sulfated domains of heparan sulfate. Merry CL, et al. **J Biol Chem** 1999 Jun 25;274(26):18455–62

Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion [see comments] Lyon M, et al. **Matrix Biol** 1998 Nov;17(7):485–93 (50 ref.) Comment in: Matrix Biol 1998 Nov;17(7):461–3.

DEFICIENCY

Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. Cano-Gauci DF, et al. **J Cell Biol** 1999 Jul 12;146(1):255–64

GENETICS

Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature. Belknap JK, et al. **Am J Respir Cell Mol Biol** 1999 Jan;20(1):24–34

Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Lin H, et al. **Cancer Res** 1999 Feb 15;59(4):807–10

Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Pellegrini M, et al. **Dev Dyn** 1998 Dec;213(4):431–9

Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Hopf M, et al. **Eur J Biochem** 1999 Feb; 259(3):917–25

Glypican 3 and glypican 4 are juxtaposed in Xq26.1. Huber R, et al. **Gene** 1998 Dec 28;225(1–2):9–16

GPC6, a novel member of the glypican gene family, encodes a product structurally related to GPC4 and is colocalized with GPC5 on human chromosome 13. Paine-Saunders S, et al. **Genomics** 1999 May 1;57(3):455–8

GPC4, the gene for human K-glypican, flanks GPC3 on xq26: deletion of the GPC3-GPC4 gene cluster in one family with Simpson-Golabi-Behmel syndrome. Veugelers M, et al. **Genomics** 1998 Oct 1;53(1):1–11

Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. Sharma B, et al. **J Clin Invest** 1998 Oct 15;102(8):1599–608

A clinical and molecular study of a patient with Simpson-Golabi-Behmel syndrome. Okamoto N, et al. **J Hum Genet** 1999;44(5):327–9

A small interstitial deletion in the GPC3 gene causes Simpson-Golabi-Behmel syndrome in a Dutch-Canadian family. Xuan JY, et al. **J Med Genet** 1999 Jan;36(1):57–8

DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. Huber R, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19; 96(2):616–21

A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Turnbull JE, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2698–703

IMMUNOLOGY

Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Tezel G, et al. **Arch Ophthalmol** 1999 Jul;117(7):917–24

Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid. Sauer M, et al. **Med Pediatr Oncol** 1999 Jun;32(6):457–8

[Autoantibodies to heparin polysaccharides bind to vascular endothelial cells] Shibata S. **Rinsho Byori** 1998 Dec; 46(12):1205–9 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Isolation and characterization of a highly sulfated heparan sulfate from ascidian test cells. Cavalcante MC, et al. **Biochim Biophys Acta** 1999 Jun 28;1428(1):77–87

METABOLISM

Immunohistochemical profile of basic fibroblast growth factor and heparan sulphate in adult rat mandibular condylar cartilage. Tajima Y, et al. **Arch Oral Biol** 1998 Nov;43(11):873–7

Mild oxidation of lipoproteins increases their affinity for surfaces covered by heparan sulfate and lipoprotein lipase. Makoveichuk E, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):703–10

Heparin and heparan sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Nissen NN, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):637–42

Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Gupta P, et al. **Blood** 1998 Dec 15; 92(12):4641–51

Selection of a high activity ribozyme against cytostatic drug resistance-associated glypican-3 using an in vitro assay containing total tumor RNA. Wichert A, et al. **Cancer Gene Ther** 1999 May-Jun;6(3):263–70

Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. de Nigris F, et al. **Cancer Res** 1998 Oct 15; 58(20):4745–51

The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction. Peng HB, et al. **Cell Adhes Commun** 1998 Sep;5(6):475–89

Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. Talts JF, et al. **EMBO J** 1999 Feb 15;18(4):863–70

Time course of the tilorone-induced lysosomal accumulation of sulphated glycosaminoglycans in cultured fibroblasts. Bispinck F, et al. **Exp Toxicol Pathol** 1998 Sep; 50(4–6):411–5

Identification and characterization of ligands for L-selectin in the kidney. II. Expression of chondroitin sulfate and heparan sulfate proteoglycans reactive with L-selectin. Li YF, et al. **FEBS Lett** 1999 Feb 12;444(2–3):201–5

Characterization of fibroblast growth factor 1 binding heparan sulfate domain. Kreuger J, et al. **Glycobiology** 1999 Jul;9(7):723–9

Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. Raats CJ, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1689–99

Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. Amara A, et al. **J Biol Chem** 1999 Aug 20;274(34):23916–25

The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. Ancsin JB, et al. **J Biol Chem** 1999 Mar 12;274(11):7172–81

Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. Dowd CJ, et al. **J Biol Chem** 1999 Feb 19;274(8):5236–44

Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44. Greenfield B, et al. **J Biol Chem** 1999 Jan 22;274(4):2511–7

Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. Kan M, et al. **J Biol Chem** 1999 May 28; 274(22):15947–52

The tumor suppressor EXT-like gene EXTL2 encodes an alpha1, 4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region. The key enzyme for the chain initiation of heparan sulfate. Kitagawa H, et al. **J Biol Chem** 1999 May 14; 274(20):13933–7

Multiple heparan sulfate chains are required for optimal syndecan-1 function. Langford JK, et al. **J Biol Chem** 1998 Nov 6;273(45):29965–71

Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex. McKeehan WL, et al. **J Biol Chem** 1999 Jul 30;274(31):21511–4

Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation. Pye DA, et al. **J Biol Chem** 1999 May 7;274(19):13456–61

Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex. Regulation by fibronectin attachment. Vallés S, et al. **J Biol Chem** 1999 Jul 16;274(29):20103–9

Anticoagulant heparan sulfate precursor structures in F9 embryonal carcinoma cells. Zhang L, et al. **J Biol Chem** 1999 Feb 26;274(9):5681–91

Acetylcholinesterase clustering at the neuromuscular junction involves perlecan and dystroglycan. Peng HB, et al. **J Cell Biol** 1999 May 17;145(4):911–21

Thymic epithelial cells synthesize a heparan sulfate with a highly sulfated region. Werneck CC, et al. **J Cell Physiol** 1999 Jan;178(1):51–62

Regulation of T cell homeostasis by heparan sulfate-bound IL-2. Wrenshall LE, et al. **J Immunol** 1999 Oct 1; 163(7):3793–800

Regulation of the heparan sulfate proteoglycan, perlecan, by injury and interleukin-1alpha. Garcia de Yébenes E, et al. **J Neurochem** 1999 Aug;73(2):812–20

The furin protease cleavage recognition sequence of Sindbis virus PE2 can mediate virion attachment to cell surface heparan sulfate. Klimstra WB, et al. **J Virol** 1999 Aug; 73(8):6299–306

Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion [see comments] Lyon M, et al. **Matrix Biol** 1998 Nov;17(7):485–93 (50 ref.) . Comment in: Matrix Biol 1998 Nov;17(7):461–3.

Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Whitelock JM, et al. **Matrix Biol** 1999 Apr; 18(2):163–78

Binding of interleukin-8 to heparan sulphate enhances cervical maturation in rabbits. Belayet HM, et al. **Mol Hum Reprod** 1999 Mar;5(3):261–9

Inflammatory mediators regulate cathepsin S in macrophages and microglia: A role in attenuating heparan sulfate interactions. Liuzzo JP, et al. **Mol Med** 1999 May; 5(5):320–33

Infectious laryngotracheitis virus, an alpha herpesvirus that does not interact with cell surface heparan sulfate. Kingsley DH, et al. **Virology** 1999 Apr 10;256(2):213–9

PHARMACOKINETICS

Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. Ishida M, et al. **Arzneimittelforschung** 1998 Aug;48(8):818–21

PHARMACOLOGY

The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate. Jagodzinski PP, et al. **Acta Biochim Pol** 1998;45(3):799–804

Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Chang Z, et al. **Am J Pathol** 1999 Jul; 155(1):71–6

Heparan sulphates upregulate regeneration of transected sciatic nerves of adult guinea-pigs. Chau CH, et al. **Eur J Neurosci** 1999 Jun;11(6):1914–26

Heparan sulphate and HB-GAM (heparin-binding growth-associated molecule) in the development of the thalamocortical pathway of rat brain. Kinnunen A, et al. **Eur J Neurosci** 1999 Feb;11(2):491–502

Heparan sulfate upregulates platelet-derived growth factor receptors on human lung fibroblasts. Malmström J, et al. **Glycobiology** 1998 Dec;8(12):1149–55

Regulation of basic fibroblast growth factor binding and activity by cell density and heparan sulfate. Richardson TP, et al. **J Biol Chem** 1999 May 7;274(19):13534–40

Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans [letter; comment] Mikhailidis DP, et al. **J Intern Med** 1998 Aug; 244(2):184. Comment on: J Intern Med 1997 Aug;242(2):125–9.

Identification of a signaling pathway activated specifically in the somatodendritic compartment by a heparan sulfate that regulates dendrite growth. Calvet S, et al. **J Neurosci** 1998 Dec 1;18(23):9751–65

Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Kovalszky I, et al. **Mol Cell Biochem** 1998 Jun; 183(1–2):11–23

PHYSIOLOGY

Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Sannes PL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L701–8

Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Jayson GC, et al. **Int J Cancer** 1999 Jul 19;82(2):298–304

Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF.

Med Hypotheses 1998 Jul;51(1):11–5 (63 ref.)
Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. Ibrahim J, et al. **Virus Res** 1999 Apr;60(2):159–69

SECRETION

Intracellular accumulation of secreted proteoglycans inhibits cationic lipid-mediated gene transfer. Co-transfer of glycosaminoglycans to the nucleus. Belting M, et al. **J Biol Chem** 1999 Jul 2;274(27):19375–82

THERAPEUTIC USE

Management of heparin-induced thrombocytopenia during continuous renal replacement therapy. Davenport A. **Am J Kidney Dis** 1998 Oct;32(4):E3
Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. Wade WE. **Am J Orthop** 1999 Apr;28(4):229–31
Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran). Saxon BR, et al. **Ann Thorac Surg** 1999 Sep;68(3):1076–8
Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Hale LP, et al. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):318–22
Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin [see comments] Cantor WJ, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):352–5. Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):356.
Options to heparin anticoagulation for cardiac interventions [editorial; comment] Kahn JK. **Catheter Cardiovasc Interv** 1999 Mar;46(3):356. Comment on: Catheter Cardiovasc Interv 1999 Mar;46(3):352–5.
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Tardy-Poncet B, et al. **Chest** 1999 Jun; 115(6):1616–20
Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Adams HP Jr, et al. **Neurology** 1999 Jul 13;53(1):122–5
Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Adams HP Jr, et al. **Neurology** 1999 Jul 13;53(1):126–31
A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Comp PC, et al. **Orthopedics** 1998 Oct;21(10):1123–8
Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses [letter] Tardy B, et al. **Thromb Haemost** 1998 Sep;80(3):530
The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. Fujishima Y, et al. **Thromb Res** 1998 Sep 1;91(5):221–7
[Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia] **Anaesthesist** 1998 Nov;47(11 Suppl Massnahmen):1–4 **(Ger)**
[Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia] **Chirurg** 1998 Nov;69(11 Suppl Massnahme):1–4 **(Ger)**
[Heparan sulphate in association with indobufen in the treatment of chronic peripheral obliterative arteriopathy of the lower extremities. Controlled clinical trial] Rossini A, et al. **Minerva Cardioangiol** 1998 Nov;46(11):457–69 (Eng. Abstr.) **(Ita)**

URINE

Corneal opacity and congenital glaucoma associated with massive heparan sulfaturia: report of one case. Lin SC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Jan-Feb;40(1):46–9
Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Yokoyama H, et al. **Kidney Int** 1999 Aug;56(2):650–8

HEPATECTOMY

see related
LIVER REGENERATION

A possible increase in plasma norepinephrine by removal of the liver. Irita K, et al. **Acta Anaesthesiol Scand** 1998 Nov; 42(10):1164–7
Hepatolobectomy-induced depression of hepatic circulation and metabolism in the dog is counteracted by isoflurane, but not by halothane. Matsumoto N, et al. **Acta Anaesthesiol Scand** 1999 Sep;43(8):850–4
Current surgical management of primary hepatocellular carcinoma. Hemming AW, et al. **Adv Surg** 1999;32:169–92 (97 ref.)
Combined preoperative embolization of the right portal vein and hepatic artery for hepatic resection in a high-risk patient. Takada T, et al. **AJR Am J Roentgenol** 1999 Jul; 173(1):165–7
Pharmacokinetics of the ethanol bioavailability in the regenerating rat liver induced by partial hepatectomy. Morales-González JA, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1557–63
Histopathological prognostic factors influencing long-term prognosis after surgical resection for hepatic metastases from colorectal cancer. Nagashima I, et al. **Am J Gastroenterol** 1999 Mar;94(3):739–43
Partial hepatectomy-induced polyploidy attenuates hepatocyte replication and activates cell aging events. Sigal SH, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1260–72
Benefits and safety of hepatic resection for colorectal metastases. Harmon KE, et al. **Am J Surg** 1999 May; 177(5):402–4
Aggressive surgical resection for hepatic metastases involving the inferior vena cava. Miyazaki M, et al. **Am J Surg** 1999 Apr;177(4):294–8
Surgical experience with hepatic colorectal metastasis. Bradley AL, et al. **Am Surg** 1999 Jun;65(6):560–6; discussion 566–7
Peripheral clear cell cholangiocarcinoma: a rare histologic variant. Falta EM, et al. **Am Surg** 1999 Jun;65(6):592–5
Effect of major hepatectomy on glucose and lactate metabolism. Chioléro R, et al. **Ann Surg** 1999 Apr; 229(4):505–13
Risk of major liver resection in patients with underlying chronic liver disease: a reappraisal. Farges O, et al. **Ann Surg** 1999 Feb;229(2):210–5
An analysis of 412 cases of hepatocellular carcinoma at a Western center. Fong Y, et al. **Ann Surg** 1999 Jun; 229(6):790–9; discussion 799–800
Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Nagasue N, et al. **Ann Surg** 1999 Jan;229(1):84–90
Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. McDonald ML, et al. **Ann Thorac Surg** 1999 Feb;67(2):537–9
Total blood exchange suppresses the early stage of liver regeneration following partial hepatectomy in rats. Eguchi S, et al. **Artif Organs** 1998 Oct;22(10):847–53
Assessment of an extracorporeal liver assist device in anhepatic dogs. Kelly JH, et al. **Artif Organs** 1992 Aug; 16(4):418–22
Nuclear membrane sphingomyelin-cholesterol changes in rat liver after hepatectomy. Albi E, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):692–5
Anesthetic management of living liver donors. Choudhry DK, et al. **Can J Anaesth** 1999 Aug;46(8):788–91
Should hepatomas be treated with hepatic resection or transplantation? Yamamoto J, et al. **Cancer** 1999 Oct 1; 86(7):1151–8
Nitric oxide synthase inhibition and the induction of cytochrome P-450 affect heme oxygenase-1 messenger RNA expression after partial hepatectomy and acute inflammation in rats [see comments] Lyoumi S, et al. **Crit Care Med** 1998 Oct;26(10):1683–9. Comment in: Crit Care Med 1998 Oct;26(10):1630–1.
Intra- and extrahepatic leukocytes and cytokine mRNA expression during liver regeneration after partial hepatectomy in rats. Sato Y, et al. **Dig Dis Sci** 1999 Apr; 44(4):806–16
Hepatectomy: preoperative analysis of hepatic function and postoperative liver failure [see comments] Zimmermann H, et al. **Dig Surg** 1998;15(1):1–11 (103 ref.). Comment in: Dig Surg 1998;15(3):191–2.
Primary hepatic neuroendocrine tumor: successful hepatectomy in two cases and review of the literature. Rückert RI, et al. **Digestion** 1999 Mar-Apr;60(2):110–6 (36 ref.)
Effect of cyclosporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat. Provencher SJ, et al. **Drug Metab Dispos** 1999 Apr; 27(4):449–55
Preoperative evaluation of hepatic functional reserve following hepatectomy by technetium-99m galactosyl human serum albumin liver scintigraphy and computed tomography. Mitsumori A, et al. **Eur J Nucl Med** 1998 Oct;25(10):1377–82
Hepatic resection and percutaneous ethanol injection for the treatment of selected patients with more than one hepatocellular carcinoma. Belli G, et al. **Eur J Surg** 1999 Jul;165(7):647–51
Changes of serum and urinary neopterin concentrations in rats after partial hepatectomy. Lai HS, et al. **Eur J Surg** 1999 Jun;165(6):604–8
Morbidity of major hepatic resections: a 100-case prospective study. Pol B, et al. **Eur J Surg** 1999 May;165(5):446–53
The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Koga H, et al. **Eur J Surg Oncol** 1999 Jun;25(3):292–6
FK506 with portal decompression exerts beneficial effects following extended hepatectomy in dogs. Mitsumoto Y, et al. **Eur Surg Res** 1999;31(1):48–56
Accelerated recovery of glycerol-induced acute renal failure in rats with previous partial hepatectomy. Homsi E, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):551–6
Endoscopic management of major bile leaks complicating hepatic resections for hepatocellular carcinoma. Lau JY, et al. **Gastrointest Endosc** 1999 Jul;50(1):99–101 (10 ref.)
Primary sclerosing cholangitis: resect, dilate, or transplant? Tarnasky PR. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):406–8
Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculatures. Asahara T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1862–9
Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma--results of long-term follow-up. Asahara T, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1042–8
Administration of prostaglandin E1 reduces post-operative hepatocellular damage and restores hepatic integrity in patients undergoing hepatectomy. Baek Y, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1836–41
Survival after repeat hepatic resection for recurrent colorectal metastases. Chiappa A, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1065–70
Diffuse bile duct carcinoma treated by major hepatectomy and pancreatoduodenectomy with the aid of pre-operative portal vein embolization. Report of two cases. Chijiiwa K, et al. **Hepatogastroenterology** 1999 May-Jun; 46(27):1634–8 (13 ref.)
Treatment of liver metastases with moderate peritoneal carcinomatosis by hepatectomy and cytoreductive surgery followed by immediate post-operative intraperitoneal chemotherapy: feasibility and preliminary results. Elias D, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):360–3
Natural history of hepatectomy regarding liver function: a study of both normal livers and livers with chronic hepatitis and cirrhosis. Ezaki T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1795–801
Risk factors associated with intra-operative blood loss in hepatectomized patients with giant cavernous hemangioma of the liver. Hanazaki K, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1089–93
Portal serum human hepatocyte growth factor levels after partial hepatectomy. Higaki I, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1078–82
Surgical management for lymph node recurrence of resected fibrolamellar hepatocellular carcinoma: a case report. Hiramatsu K, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1160–3
Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma. Hu RH, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1842–7
Correlation between human hepatocyte growth factor and interleukin-6 concentrations after surgery. Kimura F, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1030–5
GB virus C infection by blood transfusion during and following liver surgery. Kubo S, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2252–4
Major hepatectomy combined with pylorus-preserving pancreatoduodenectomy for middle bile duct cancer with multiple lymph node metastases: a case report of 5-year survival. Kurosaki I, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1623–6
Concomitant splenectomy for hypersplenic thrombocytopenia in hepatic resection for hepatocellular carcinoma. Lin MC, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):630–4
Surgical resection of hepatocellular carcinoma in elderly cirrhotic patients. Lui WY, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):640–5
Repeat hepatic resection for recurrent metastatic melanoma. Mondragon-Sanchez R, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):459–61
Serum alkaline phosphatase after extensive liver resection: a study in patients with biliary tract carcinoma. Nagino M, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):766–70
Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Nonami T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1669–72
Hepatic resection with and without surgical margins for hepatocellular carcinoma in patients with impaired liver function. Ochiai T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1885–9
Glutaraldehyde-fixed heterologous pericardium for vena cava grafting following hepatectomy. Ohwada S, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):855–8
Endoscopic sphincterotomy in the management of biliary leakage after partial hepatectomy. Okan A, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):790–1
Increased serum levels of soluble tumor necrosis factor a-receptors in patients undergoing partial liver resection. Schroder J, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1807–12
Evaluation of major hepatic resection for small hepatocellular carcinoma. Shimada M, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):401–6
Efficacy of major hepatic resection for large hepatocellular carcinoma. Shuto T, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):413–6
Surgery of icteric-type hepatoma after biliary drainage and transcatheter arterial embolization. Tada K, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):843–8
Predicting survival and post-operative complications with Tc-GSA liver scintigraphy in hepatocellular carcinoma. Takeuchi S, et al. **Hepatogastroenterology** 1999 May-Jun; 46(27):1855–61
Perioperative changes in hepatic function as assessed by asialoglycoprotein receptor indices by technetium 99m galactosyl human serum albumin. Tanaka A, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):369–75
Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular

carcinoma after hepatic resection. Tanaka K, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1083-8

Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Todoroki T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1585-91

Decreased hepatic nitric oxide synthesis during liver surgery. Ueda T, et al. **Hepatogastroenterology** 1999 May-Jun; 46(27):1917-22

Early post-operative hyperbaric oxygen therapy modifies neutrophile activation. Ueno S, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1798-9

Comparison of liver resection for hepatocellular carcinoma in hepatitis B and hepatitis C-related cirrhotic patients. Wu CC, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):651-5

The effect of octreotide on morphological hepatic regeneration and hepatic functional recovery after a two-thirds hepatectomy in rats. Yamamoto K, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1880-4

Intrasplenic transplantation of allogeneic hepatocytes prolongs survival in anhepatic rats. Arkadopoulos N, et al. **Hepatology** 1998 Nov;28(5):1365-70

Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat. Freeman TL, et al. **Hepatology** 1999 Aug;30(2):437-44

Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy. Sakamoto T, et al. **Hepatology** 1999 Feb;29(2):403-11

A patient with a large hepatocellular carcinoma alive 13 years after repeated transcatheter arterial chemoembolization and hepatectomy. Asahara T, et al. **Hiroshima J Med Sci** 1999 Mar;48(1):41-4

The time interval between primary colorectal carcinoma resection to occurrence of liver metastases is the most important factor for hepatic resection. Analysis of total course following primary resection of colorectal cancer. Sato T, et al. **Int Surg** 1998 Oct-Dec;83(4):340-2

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. Iwatsuki S, et al. **J Am Coll Surg** 1998 Oct;187(4):358-64

Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. Jarnagin WR, et al. **J Am Coll Surg** 1999 Jan;188(1):33-42

Comparison of treatments for hepatolithiasis: hepatic resection versus cholangioscopic lithotomy. Otani K, et al. **J Am Coll Surg** 1999 Aug;189(2):177-82

Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. Roayaie S, et al. **J Am Coll Surg** 1998 Oct;187(4):365-72

Resection versus transplantation for hepatocellular carcinoma. Esquivel CO, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S37-41 (29 ref.)

Treatment of cirrhotic rats with epidermal growth factor and insulin accelerates liver DNA synthesis after partial hepatectomy. Hashimoto M, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1259-65

Hepatic steatosis as a potential risk factor for major hepatic resection. Behrns KE, et al. **J Gastrointest Surg** 1998 May-Jun;2(3):292-8

Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. Chen H, et al. **J Gastrointest Surg** 1998 Mar-Apr;2(2):151-5

Surgical management of hepatocellular carcinoma: resection or transplantation? Philosophe B, et al. **J Gastrointest Surg** 1998 Jan-Feb;2(1):21-7

Intrahepatic cholangiocarcinoma in Taiwan. Chen MF, et al. **J Hepatobiliary Pancreat Surg** 1999;6(2):136-41

Intrahepatic cholangiocarcinoma in Hong Kong. Chu KM, et al. **J Hepatobiliary Pancreat Surg** 1999;6(2):149-53

Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. Isaji S, et al. **J Hepatobiliary Pancreat Surg** 1999;6(2):108-16

Clinical significance of intrahepatic biliary stricture in efficacy of hepatic resection for intrahepatic stones. Kim KH, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):303-8

Extended resection for intrahepatic cholangiocarcinoma in Japan. Yamamoto M, et al. **J Hepatobiliary Pancreat Surg** 1999;6(2):117-21

Active form of human hepatocyte growth factor is excreted into bile after hepatobiliary resection. Kurumiya Y, et al. **J Hepatol** 1999 Jan;30(1):22-8

Direct hyperplasia does not enhance the kinetics of liver repopulation in a new model of hepatocyte transplantation in the rat. Pani P, et al. **J Hepatol** 1999 Aug;31(2):354-9

Recovery of hepatic asialoglycoprotein receptors after major hepatic resection. Kokudo N, et al. **J Nucl Med** 1999 Jan; 40(1):137-41

Hepatocyte growth factor concentration in rat bile is affected by hepatic resection volume and external biliary drainage. Hayata A, et al. **J Surg Res** 1999 Jul;85(1):71-6

A predominant increase of arterial beta-hydroxybutyrate concentration during partial hepatectomies in patients with impaired indocyanine green clearance test. Higashi S, et al. **J Surg Res** 1999 Feb;81(2):243-8

Dynamics of portal and peripheral endothelin-1 in hepatic resection and its implication. Kuroda N, et al. **J Surg Res** 1999 Aug;85(2):279-85

Early gene expression associated with regeneration is intact after massive hepatectomy in rats. Panis Y, et al. **J Surg Res** 1998 Oct;79(2):103-8

The effect of neutrophil elastase inhibitor in hepatectomy with ischemia in dogs. Tomizawa N, et al. **J Surg Res** 1999 Feb;81(2):230-7

A new method to prevent wound infection: a controlled clinical trial in patients with combined liver and bile duct resection. Hiramatsu K, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):437-41

Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Rudroff C, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):243-9

Plasma-kallikrein clearance during liver regeneration after partial hepatectomy in the rat. Braulio VB, et al. **Liver** 1998 Dec;18(6):371-7

Differential regenerative response and expression of growth factors following hepatectomy of variable extent in rats. Masson S, et al. **Liver** 1999 Aug;19(4):312-7

Prolonged lactic acidosis after extended hepatectomy under in situ hypothermic perfusion. Davidson BR, et al. **Liver Transpl Surg** 1999 Mar;5(2):151-2

Impaired leukocyte phagocytosis in patients undergoing hemihepatectomy for liver metastases. Wiezer MJ, et al. **Liver Transpl Surg** 1999 May;5(3):238-45

Hepatic resection for metastases in colorectal carcinoma. Jourdan JL, et al. **N Z Med J** 1999 Mar 26;112(1084):91-3

Unnecessary surgical operation confirmed by individual identification by analyses of several short tandem repeat (STR) loci. Sasaki M, et al. **Nippon Hoigaku Zasshi** 1998 Aug;52(4):257-60

"Emergency hepatectomy" in a 16-month-old boy with a hepatoblastoma, severe cytomegalovirus-induced pancytopenia, and intractable diarrhea. Benesch M, et al. **Pediatr Surg Int** 1998 Dec;14(3):220-3

The role of the spleen, especially regarding changes in both thromboxane A2 and the remnant liver dysfunction after extensive hepatectomy. Kitagawa M, et al. **Surg Today** 1999;29(2):137-42

Right hepatic lobectomy for hepatocellular carcinoma which developed in primary biliary cirrhosis: report of a case. Morimoto T, et al. **Surg Today** 1999;29(7):646-50

Ratio of branched chain amino acid to tyrosine after hepatectomy. Niguma T, et al. **Surg Today** 1999;29(8):825-7

Changes and results of surgical strategies for hepatocellular carcinoma: results of a 15-year study on 452 consecutive patients. Shuto T, et al. **Surg Today** 1998;28(11):1124-9

Reduction of transfusion requirements during major hepatic resection for metastatic disease. Arnoletti JP, et al. **Surgery** 1999 Feb;125(2):166-71

Liver resection for hepatocellular carcinoma in octogenarians. Wu CC, et al. **Surgery** 1999 Mar; 125(3):332-8

Inflammatory cytokine production enhancement in the presence of lipopolysaccharide after hepatic resection in cirrhotic patients. Sato T, et al. **Ther Apher** 1997 Feb; 1(1):75-8

Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Colella G, et al. **Transpl Int** 1998;11 Suppl 1:S193-6

Preoperative evaluation of potential living donors for liver transplantation: the role of helical computed tomography-angiography. Chan JK, et al. **Transplant Proc** 1998 Nov;30(7):3197-8

Safety of the donor operation in living-related liver transplantation: analysis of 22 donors. Kawagishi N, et al. **Transplant Proc** 1998 Nov;30(7):3279-80

Liver transplantation for hepatocellular carcinoma. Neuhaus P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):469-71 (13 ref.)

Portosuprahepatic shunt as an alternative to portocaval shunt in an hepatic patients waiting for an orthotopic liver transplant. Robles R, et al. **Transplant Proc** 1999 Sep; 31(6):2400-1

Impact of 70% partial hepatectomy on administration of donor leukocytes in cardiac transplantation in rats. Sato Y, et al. **Transplant Proc** 1998 Nov;30(7):3873-5

Analysis of the risk and surgical stress for donors in living-related liver transplantation. Tojimbara T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):507-8

Is liver transplantation superior to resection in early stage hepatocellular carcinoma? Weimann A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):500-1

Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Kiuchi T, et al. **Transplantation** 1999 Jan 27;67(2):321-7

Rescue hepatectomy for initial graft non-function after liver transplantation. Oldhafer KJ, et al. **Transplantation** 1999 Apr 15;67(7):1024-8

Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. Asahara T, et al. **World J Surg** 1999 Jul;23(7):676-80

Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. Ishikawa M, et al. **World J Surg** 1999 Jan;23(1):75-9

Effect of partial hepatectomy on the expression of seven rat sulphotransferase mRNAs. Dunn RT 2nd, et al. **Xenobiotica** 1999 Jun;29(6):583-93

[Surgery of liver metastases of colorectal carcinoma] Adam R. **Ann Chir** 1998;52(1):85-7 (10 ref.) **(Fre)**

[Benign tumors of the liver: primum non nocere] Chiche L. **Ann Chir** 1998;52(1):64-7 (10 ref.) **(Fre)**

[Surgery of liver metastases of non-colorectal origin] Le Treut YP, et al. **Ann Chir** 1998;52(1):88-91 (12 ref.) **(Fre)**

[Surgical strategy in the treatment of synchronous hepatic metastases of colorectal cancers. Analysis of a series of 59 operated on patients] Jaeck D, et al. **Chirurgie** 1999 Jun; 124(3):258-63 (Eng. Abstr.) **(Fre)**

[Current treatment of closed injuries of the liver: benefits and pitfalls] Letoublon C, et al. **Chirurgie** 1999 Feb; 124(1):20-30 (Eng. Abstr.) **(Fre)**

[What are the real indications for hepatectomies in metastases of colorectal origin? (see comments)] Elias D, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1048-55 (Eng. Abstr.). Comment in: Gastroenterol Clin Biol 1998 Dec;22(12):1046-7. **(Fre)**

[Young woman, 27-years-old, presenting with abnormal hepatic ultrasound (clinical conference)] Porcheron J. **J Chir (Paris)** 1999 Mar;136(1):41-5 **(Fre)**

[Circulatory function and oxygenation during hemihepatectomy. Dopamine versus dopexamine] Höltje M, et al. **Anaesthesist** 1999 Apr;48(4):224-30 (Eng. Abstr.) **(Ger)**

[The continuous monitoring of hepatic venous oxygen saturation in patient monitoring following hemihepatectomy] Höltje M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Apr; 34(4):246-50 (Eng. Abstr.) **(Ger)**

[Is resection of colorectal liver metastases still justified in very elderly patients?] Brunken C, et al. **Chirurg** 1998 Dec; 69(12):1334-9 (Eng. Abstr.) **(Ger)**

[Principles of curative resection of liver metastases] Schlag PM, et al. **Chirurg** 1999 Feb;70(2):123-32 (69 ref.) (Eng. Abstr.) **(Ger)**

[Partial hepatectomy after post-traumatic liver abscess] Schmidt SC, et al. **Chirurg** 1998 Sep;69(9):985-8 (Eng. Abstr.) **(Ger)**

[Understanding microcirculation deficits as the key to surgical planning in visceral surgery] Klar E. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:72-7 (14 ref.) (Eng. Abstr.) **(Ger)**

[Resection of liver metastases--possibilities for a cure] Kremer B, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:143-7 (Eng. Abstr.) **(Ger)**

[Surgical therapy of liver metastases in breast carcinoma] Scheuerlein H, et al. **Zentralbl Chir** 1998;123 Suppl 5:130-4 (Eng. Abstr.) **(Ger)**

[Hepatic resections for primary and secondary malignant pathology of the liver: our experience] Soliani P, et al. **Acta Biomed Ateneo Parmense** 1998;69(1-2):47-59 (Eng. Abstr.) **(Ita)**

[Factors linked to 5-year survival after hepatectomy for hepatocellular carcinoma: univariate and multivariate analyses of 312 patients] Ohgaki K, et al. **Fukuoka Igaku Zasshi** 1999 Jul;90(7):324-8 (Eng. Abstr.) **(Jpn)**

[99mTc-GSA dynamic SPECT for regional hepatic functional reserve estimation: assessment of clinical value for hepatic resection] Hwang EH. **Kaku Igaku** 1999 May; 36(4):323-31 (Eng. Abstr.) **(Jpn)**

[Surface-induced mild hypothermia anesthesia for hepatectomy in a patient with a giant hemangioma of the liver (Kasabach-Merritt syndrome)] Wake M, et al. **Masui** 1998 Nov;47(11):1344-9 (Eng. Abstr.) **(Jpn)**

[Unexpected hyperkalemia during general anesthesia in three patients undergoing hepatic, cholangioler or pancreatic surgery] Yagi E, et al. **Masui** 1999 Feb;48(2):189-91 (Eng. Abstr.) **(Jpn)**

[Recurrence of hepatocellular carcinoma after liver resection] Ikai I, et al. **Nippon Geka Gakkai Zasshi** 1999 Feb; 100(2):191-4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The differences in liver regenerative rate after partial hepatectomy in rats treated wtih selected immunosuppressants] Polak W, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):70-2 (Eng. Abstr.) **(Pol)**

[Hepatic echinococcosis and its surgical treatment] Aliev MA, et al. **Khirurgiia (Mosk)** 1999;(3):15-7 (Eng. Abstr.) **(Rus)**

[The late results of extensive liver resection] Al'perovich BI, et al. **Khirurgiia (Mosk)** 1999;(6):68 **(Rus)**

[Repeated resection of liver in primary and metastatic cancer] Patiutko IuI, et al. **Khirurgiia (Mosk)** 1999;(3):4-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Augmented enhancement of in vitro production of inflammatory cytokines in peripheral blood mononuclear cells in patients undergoing simultaneous resection of the liver and gastrointestinal tract [see comments] Sasada K, et al. **Crit Care Med** 1999 May;27(5):929-36. Comment in: Crit Care Med 1999 May;27(5):859-60.

Arterialisation of the portal vein with an aortoportal jump graft for portal vein thrombosis following liver resection for malignancy. Jiao LR, et al. **HPB Surg** 1999;11(4):279-81

Postoperative liver failure [letter; comment] Bilimoria MM, et al. **J Am Coll Surg** 1999 Sep;189(3):336-8. Comment on: J Am Coll Surg 1999 Mar;188(3):304-9.

Omentoplasty in the prevention of deep abdominal complications after surgery for hydatid disease of the liver: a multicenter, prospective, randomized trial. French Associations for Surgical Research. Dziri C, et al. **J Am Coll Surg** 1999 Mar;188(3):281-9

Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special

reference to remnant liver volume [see comments] Shirabe K, et al. **J Am Coll Surg** 1999 Mar;188(3):304–9. Comment in: J Am Coll Surg 1999 Sep;189(3):336–8.

Experimental study on the bilirubin metabolism after major hepatectomy: alterations in the proportions of bile bilirubin subfractions. Igarashi Y, et al. **J Surg Res** 1999 Mar; 82(1):67–72

Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries. Kogure K, et al. **Life Sci** 1999;64(5):305–13

Is major liver surgery associated with an increased systemic inflammatory response? A prospective comparison of hemihepatectomy and other major abdominal surgery. Wiezer MJ, et al. **Liver** 1999 Jun;19(3):220–7

Treatment for accidental occlusion of the hepatic artery after hepatic resection: report of two cases. Tanabe G, et al. **Surg Today** 1999;29(3):268–72

Functional capacity of the cirrhotic liver after partial hepatectomy in the rat. Hashimoto M, et al. **Surgery** 1999 Sep;126(3):541–7

A comparative study of postoperative complications after hepatectomy in patients with and without chronic liver disease. Midorikawa Y, et al. **Surgery** 1999 Sep; 126(3):484–91

Apoptosis of hepatocytes is a main cause of inducing lethal hepatic failure after excessive hepatectomy in rats. Hasegawa S, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):558–9

Increased risk for living liver donors after extended right lobectomy. Lo CM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):533–4

Complications and treatments of donors and recipients in living-related liver transplantation. Ohkohchi N, et al. **Transplant Proc** 1998 Nov;30(7):3218–20

[Migration of a surgical clip to the biliary tract after a hepatectomy (letter)] Del Gallo G, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1112–3 **(Fre)**

CONTRAINDICATIONS

Is hepatic resection absolutely contraindicated for hepatocellular carcinoma in Child-Pugh class C cirrhotic patients? Wu CC, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):635–9

Total vascular exclusion for liver resections: pros and cons. Zografos GN, et al. **J Surg Oncol** 1999 Sep;72(1):50–5; discussion 55–6 (76 ref.)

HISTORY

The James Ewing Lecture. One life, many livers. Schwartz SI. **Ann Surg Oncol** 1998 Oct–Nov;5(7):573–9

INSTRUMENTATION

Effect of cautery with irrigation forceps on the remnant liver after hepatectomy in rats. Takao T, et al. **Eur Surg Res** 1999;31(2):173–9

[Cryosurgery--renaissance or real progress?] Feifel G, et al. **Chirurg** 1999 Feb;70(2):154–9 (30 ref.) (Eng. Abstr.) **(Ger)**

[Virtual surgical planning and surgical practice for liver surgery (editorial)] Herfarth C. **Chirurg** 1999 Mar; 70(3):231–2 **(Ger)**

[Virtual surgical planning in liver surgery] Lamadé W, et al. **Chirurg** 1999 Mar;70(3):239–45 (Eng. Abstr.) **(Ger)**

[3-dimensional (3-D) visualization of the liver for planning extensive liver resections] Oldhafer KJ, et al. **Chirurg** 1999 Mar;70(3):233–8 (Eng. Abstr.) **(Ger)**

[Open and laparoscopic liver resection with a new ultrasound scalpel] Trupka A, et al. **Chirurg** 1998 Dec;69(12):1352–6 (Eng. Abstr.) **(Ger)**

[Liver resection with the water dissector; preliminary experience of 8 cases] Fabbrucci P, et al. **Ann Ital Chir** 1999 Jan–Feb;70(1):99–103 (Eng. Abstr.) **(Ita)**

METHODS

Segment VIII resection of the cirrhotic liver under continuous pringle maneuver with in situ cooling followed by temporary portal decompression. Kim YI, et al. **Am J Surg** 1999 Mar;177(3):244–6

Extended subcostal hinge incision for right hepatic lobectomy. Ahrendt SA, et al. **Am Surg** 1999 Aug; 65(8):774–6

Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Belghiti J, et al. **Ann Surg** 1999 Mar;229(3):369–75

Hepatic vascular exclusion with preservation of the caval flow for liver resections. Cherqui D, et al. **Ann Surg** 1999 Jul;230(1):24–30

Prolonged continuous or intermittent vascular inflow occlusion during hemihepatectomy in pigs. van Wagensveld BA, et al. **Ann Surg** 1999 Mar;229(3):376–84

Technical aspects of orthotopic liver transplantation. Nyckowski P, et al. **Ann Transplant** 1996;1(4):10–21 (38 ref.)

Tolerance of the liver to intermittent pringle maneuver in hepatectomy for liver tumors. Man K, et al. **Arch Surg** 1999 May;134(5):533–9

The dorsal liver: an analysis [editorial] Hardy KJ. **Aust N Z J Surg** 1999 Mar;69(3):167–9

Results of surgical resection of liver metastases from non-colorectal primaries. Berney T, et al. **Br J Surg** 1998 Oct;85(10):1423–7

Interleukin 6 in bile as an indicator of liver function after hepatectomy in patients with biliary tract carcinoma. Maeda A, et al. **Br J Surg** 1999 Apr;86(4):458–64

Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Yamamoto J, et al. **Br J Surg** 1999 Mar;86(3):332–7

Non-heart-beating cadaver donor hepatectomy. The operative procedure. Olson L, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):98–103

Laparoscopic partial hepatectomy in the rat: a new resectional technique. Krähenbühl L, et al. **Dig Surg** 1998; 15(2):140–4

Central bisegmentectomy of the liver plus caudate lobectomy for carcinoma of the gallbladder. Ogura Y, et al. **Dig Surg** 1998;15(3):218–23

Serum hyaluronan as a predictor of hepatic regeneration after hepatectomy in humans. Ogata T, et al. **Eur J Clin Invest** 1999 Sep;29(9):780–5

Major compared with limited hepatic resection for hepatocellular carcinoma without underlying cirrhosis: a retrospective analysis. Nagasue N, et al. **Eur J Surg** 1999 Jul;165(7):638–46

Accelerated recovery of glycerol-induced acute renal failure in rats with previous partial hepatectomy. Homsi E, et al. **Exp Nephrol** 1998 Nov–Dec;6(6):551–6

Hepatic resection for hepatocellular carcinoma -- Japanese experience. Makuuchi M, et al. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1267–74

Liver regeneration after extended right hemihepatectomy in patients with hilar or diffuse bile duct carcinoma. Miyagawa S, et al. **Hepatogastroenterology** 1999 Jan–Feb; 46(25):364–8

Hepatic vein reconstruction at inferior vena cava confluence using left renal vein graft. Ohwada S, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1833–6

Extended hepatectomy with ePTFE graft vena caval replacement and hepatic vein reconstruction: a case report. Ohwada S, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1151–5

Laparoscopic liver resection compared with conventional partial hepatectomy--a prospective analysis. Rau HG, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2333–8

Pringle's maneuver lasting 322 min. Sakamoto Y, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):457–8

An approach for difficult hepatectomy--retrograde hepatectomy in 29 patients with liver malignant tumor. Wu ZQ, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1140–4

Topical cooling assisted hepatic resection of segment 7 and 8 oriented by en-bloc interruption of the targeted portal pedicles. Yamanaka N, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):417–24

Preoperative portal vein embolization: an audit of 84 patients. Imamura H, et al. **Hepatology** 1999 Apr;29(4):1099–105

Role of c-kit receptor tyrosine kinase in development of oval cells in the rat 2-acetylaminofluorene/partial hepatectomy model. Matsuoka S, et al. **Hepatology** 1999 Mar;29(3):670–6

Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Mochida S, et al. **Hepatology** 1999 May;29(5):1532–40

Laparoscopy-assisted hepatectomy for a large tumor of the liver. Asahara T, et al. **Hiroshima J Med Sci** 1998 Dec; 47(4):163–6

The need to handicap the recipient's native liver in the rat model of heterotopic auxiliary liver transplantation. Fan YD, et al. **HPB Surg** 1999;11(4):225–33; discussion 233–4

Liver resections for metastases from intraabdominal leiomyosarcoma. Kalil AN, et al. **HPB Surg** 1999; 11(4):261–4

Complete caudate lobectomy: its definition, indications, and surgical approaches. Sasada A, et al. **HPB Surg** 1998; 11(2):87–93; discussion 93–5

Left extended hemihepatectomy with preservation of large inferior right hepatic vein: a case report. Texler ML, et al. **HPB Surg** 1999;11(4):265–9; discussion 269–70

Effective vascular endostapler techniques in hepatic resection. Ramacciato G, et al. **Int Surg** 1998 Oct–Dec; 83(4):317–23

A 70% hepatectomy in the rat using a microsurgical technique. Rodriguez G, et al. **Int Surg** 1999 Apr–Jun; 84(2):135–8

A new technique of hepatic vein reconstruction in living related liver transplantation. Takano S, et al. **Int Surg** 1998 Oct–Dec;83(4):324–6

Segment-oriented hepatic resection in the management of malignant neoplasms of the liver [see comments] Billingsley KG, et al. **J Am Coll Surg** 1998 Nov;187(5):471–81. Comment in: J Am Coll Surg 1998 Nov;187(5):534–5.

Concomitant major hepatectomy and inferior vena cava reconstruction [letter; comment] Del Campo C. **J Am Coll Surg** 1999 Sep;189(3):338–9. Comment on: J Am Coll Surg 1999 Jan;188(1):63–71.

Omentoplasty in the prevention of deep abdominal complications after surgery for hydatid disease of the liver: a multicenter, prospective, randomized trial. French Associations for Surgical Research. Dziri C, et al. **J Am Coll Surg** 1999 Mar;188(3):281–9

Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. Elias D, et al. **J Am Coll Surg** 1998 Nov;187(5):487–93

Safety of selective vascular clamping for major hepatectomies. Malassagne B, et al. **J Am Coll Surg** 1998 Nov;187(5):482–6

Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. Melendez JA, et al. **J Am Coll Surg** 1998 Dec;187(6):620–5

We've come a long way, baby! [editorial; comment] Meyers WC, et al. **J Am Coll Surg** 1998 Nov;187(5):534–5. Comment on: J Am Coll Surg 1998 Nov;187(5):471–81.

Comparison of controlled and Glisson's pedicle transections of hepatic hilum occlusion for hepatic resection. Nakai T, et al. **J Am Coll Surg** 1999 Sep;189(3):300–4

Concomitant major hepatectomy and inferior vena cava reconstruction [see comments] Ohwada S, et al. **J Am Coll Surg** 1999 Jan;188(1):63–71. Comment in: J Am Coll Surg 1999 Sep;189(3):338–9.

Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume [see comments] Shirabe K, et al. **J Am Coll Surg** 1999 Mar;188(3):304–9. Comment in: J Am Coll Surg 1999 Sep;189(3):336–8.

Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure. Wu CC, et al. **J Am Coll Surg** 1999 May;188(5):508–15

Efficacy of hypothermic perfusion using University of Wisconsin solution in extended hepatectomy with hepatic inflow occlusion in a canine model. Ohya T, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):781–5

Major hepatic resection without blood transfusion: experience with total vascular exclusion. So SK, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S28–31

Isolated caudate lobectomy by anterior approach for hepatocellular carcinoma originating in the paracaval portion of the caudate lobe. Asahara T, et al. **J Hepatobiliary Pancreat Surg** 1998;5(4):416–21

Modified hepatoduodenal ligamentectomy for advanced carcinoma of the biliary tract: the importance of preservation of the replaced left hepatic artery. Maeba T, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):297–302

Hepatectomy with microwave tissue coagulation for hepatocellular carcinoma. Ryu M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(2):184–91

Repeat hepatectomy for colorectal metastases. Sugarbaker PH. **J Hepatobiliary Pancreat Surg** 1999;6(1):30–8

Simplified hepatic resection utilizing absorbable polyglycolic acid-based tape and other ligature apparatus. Suzuki M, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):292–6

Glissonean pedicle transection method for hepatic resection: a new concept of liver segmentation. Takasaki K. **J Hepatobiliary Pancreat Surg** 1998;5(3):286–91

Right hepatic lobectomy and subsegmental resection of the left caudate lobe for gallbladder carcinoma involving the hepatic hilus: preservation of the ventral portion of the left caudate lobe. Yamamoto H, et al. **J Hepatobiliary Pancreat Surg** 1998;5(2):207–11

Evaluation of methods of hepatotrophic stimulation in rat heterotopic hepatocyte transplantation using polymers. Kaufmann PM, et al. **J Pediatr Surg** 1999 Jul;34(7):1118–23

Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. Elias D, et al. **J Surg Oncol** 1998 Oct;69(2):88–93

Is cryosurgery appropriate treatment for hepatic malignancies? [editorial] Neifeld JP. **J Surg Oncol** 1999 Feb; 70(2):69–70

The Kidney's role in glucose balance following partial hepatectomy. Jones CE, et al. **J Surg Res** 1998 Oct; 79(2):136–40

A new splitting technique for liver grafts [letter] Colledan M, et al. **Lancet** 1999 May 22;353(9166):1763

One-stage total hepatectomy in the rat using microvascular anastomoses. Engelbrecht GH, et al. **Microsurgery** 1999; 19(2):95–7

Hepatectomy including more than half of liver volume with intermittent portal triad occlusion. Calleja Kempin J, et al. **Rev Esp Enferm Dig** 1998 Oct;90(10):695–700 **(Eng, Spa)**

Laparoscopic liver resections. Hüscher CGS, et al. **Semin Laparosc Surg** 1998 Sep;5(3):204–10

Role of shear stress and immune responses in liver regeneration after a partial hepatectomy. Sato Y, et al. **Surg Today** 1999;29(1):1–9 (70 ref.)

Liver resection using total vascular exclusion. Evans PM, et al. **Surgery** 1998 Oct;124(4):807–13; discussion 814–5

A new technique for total hepatectomy in the pig for testing liver support devices. Filipponi F, et al. **Surgery** 1999 Apr; 125(4):448–55

Cadaveric small bowel/split liver transplantation in a child. Xenos ES, et al. **Transpl Int** 1999;12(1):63–7

Need for inotropic and/or vasopressor drugs during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep; 31(6):2402–3

Initiation of split-liver transplantation in Taiwan. Chen CL, et al. **Transplant Proc** 1998 Nov;30(7):3249

Pediatric liver transplantation from living-related donors. Chen YS, et al. **Transplant Proc** 1998 Nov;30(7):3252–3

Radiologic anatomy in split liver transplantation. Cheng YF, et al. **Transplant Proc** 1998 Nov;30(7):3184–5

A simple method to avoid a biliary complication after living-related liver transplantation. Harihara Y, et al. **Transplant Proc** 1998 Nov;30(7):3199

Venoplasty of recipient hepatic veins in living-related liver

transplantation. Harihara Y, et al. **Transplant Proc** 1998 Nov;30(7):3205

Apoptosis of hepatocytes is a main cause of inducing lethal hepatic failure after excessive hepatectomy in rats. Hasegawa S, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):558–9

Combination splitting using both in situ and ex situ techniques in triple split–liver transplantation of pigs. Hayashi S, et al. **Transplant Proc** 1998 Nov;30(7):3223–4

Application of intraoperative intrahepatic portosystemic shunt in split–liver transplantation of the pig. Hayashi S, et al. **Transplant Proc** 1998 Nov;30(7):3225–8

Technique of triple split–liver transplantation in pigs using inferior vena cava reconstruction and intraoperative intrahepatic portosystemic shunt. Hayashi S, et al. **Transplant Proc** 1998 Nov;30(7):3229–31

Domino liver transplantation for familial amyloid polyneuropathy: optimal use of a scarce resource. Hemming AW, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):515

Auxiliary liver transplantation for urea–cycle enzyme deficiencies: lessons from three cases. Kiuchi T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):528–9

Increased risk for living liver donors after extended right lobectomy. Lo CM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):533–4

Development of auxiliary partial orthotopic liver transplantation model in the rat. Nishio K, et al. **Transplant Proc** 1998 Nov;30(7):3237–8

Selective hepatic denervation prior to organ harvest improves survival after liver transplantation. Schemmer P, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):537

A new, stable model of left lobectomy for living–related liver transplantation in the pig. Taira K, et al. **Transplant Proc** 1998 Nov;30(7):3207–8

Establishment of a swine model for auxiliary partial orthotopic liver transplantation. Taniguchi H, et al. **Transplant Proc** 1998 Nov;30(7):3232–6

Anterior transhepatic approach for isolated resection of the caudate lobe of the liver. Yamamoto J, et al. **World J Surg** 1999 Jan;23(1):97–101

[Extensive right–sided hepatectomy for a metastatic process in patients operated on for colonic carcinoma] Dudunkov Z, et al. **Khirurgiia (Sofiia)** 1998;51(1):5–7 (Eng. Abstr.) **(Bul)**

[Anatomy of the liver and hepatectomy techniques] Bismuth H. **Ann Chir** 1998;52(1):61–3 **(Fre)**

[Dorsal sector of the liver (editorial)] Couinaud C. **Chirurgie** 1998 Feb;123(1):8–15 (Eng. Abstr.) **(Fre)**

[Preoperative portal embolization: an effective means for inducing hypertrophy of the healthy liver and increasing indications for hepatic resection] Roche A, et al. **Chirurgie** 1998 Feb;123(1):67–72; discussion 73 (Eng. Abstr.) **(Fre)**

[Resection of hepatic segment I] Bail JP, et al. **J Chir (Paris)** 1998 Nov;135(5):230 **(Fre)**

[Technique for right hepatectomy] Belghiti J, et al. **J Chir (Paris)** 1998 Feb;135(1):19–22 **(Fre)**

[Segmental anatomy of the liver—a sonomorphological viewpoint] Hanisch E, et al. **Chirurg** 1999 Feb;70(2):169–73 (Eng. Abstr.) **(Ger)**

[Vascular clamping in cirrhotic liver surgery] Bartolotta M, et al. **Chir Ital** 1999 Mar–Apr;51(2):145–9 (Eng. Abstr.) **(Ita)**

[Hepatic vascular exclusion: indications and results] Nuzzo G, et al. **Chir Ital** 1998;50(5–6):23–33; discussion 33–4 (Eng. Abstr.) **(Ita)**

[A facilitated technique for donor hepatectomy: experimental study in the pig] Gruttadauria S, et al. **G Chir** 1998 Nov–Dec;19(11–12):485–8 (Eng. Abstr.) **(Ita)**

[Usefulness of arterio–portal shunt in 40% hepatectomized and hepatic artery–occluded model] Manase H. **Hokkaido Igaku Zasshi** 1999 Jan;74(1):19–30 (Eng. Abstr.) **(Jpn)**

[A case of total intravenous anesthesia with propofol, fentanyl and ketamine for lateral segmentectomy of the liver under pringle maneuver] Kakinohana M, et al. **Masui** 1999 May; 48(5):523–7 (Eng. Abstr.) **(Jpn)**

[Hepatic resection for advanced carcinoma of the gallbladder] Endo I, et al. **Nippon Geka Gakkai Zasshi** 1998 Oct;99(10):711–6 (Eng. Abstr.) **(Jpn)**

[Selective and unselective clamping in liver surgery] Sano K, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):331–4 (Eng. Abstr.) **(Jpn)**

[Usefulness and problems of total hepatic vascular exclusion in liver surgery] Shimahara Y, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):335–41 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Optimization of diagnosis and methods of liver resection in alveolar echinococcosis] Aliev MA, et al. **Khirurgiia (Mosk)** 1999;(5):11–4 (Eng. Abstr.) **(Rus)**

MORTALITY

Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Fan ST, et al. **Ann Surg** 1999 Mar; 229(3):322–30

APACHE III, unlike APACHE II, predicts posthepatectomy mortality in patients with biliary tract carcinoma. Acute Physiology and Chronic Health Evaluation. Hamahata N, et al. **Crit Care Med** 1998 Oct;26(10):1671–6

Preoperative assessment of mortality risk in hepatic resection by clinical variables: a multivariate analysis. Bolder U, et al. **Liver Transpl Surg** 1999 May;5(3):227–37

STATISTICS & NUMERICAL DATA

The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Glasgow RE, et al. **Arch Surg** 1999 Jan;134(1):30–5

Should hepatic resections be performed at high–volume referral centers? Choti MA, et al. **J Gastrointest Surg** 1998 Jan–Feb;2(1):11–20

VETERINARY

Two–stage surgical hepatectomy and its effects on formation and metabolism of Cx–reactive protein in the rabbit. Snow HD, et al. **Am J Vet Res** 1969 Oct;30(10):1857–64

HEPATIC AMEBIASIS see **LIVER ABSCESS, AMEBIC**

HEPATIC ARTERY

see related

LIVER CIRCULATION

Percutaneously implantable catheter–port system for chemotherapeutic infusion through the hepatic artery. Jung HY, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):641–4

Hepatic falciform artery: is prophylactic embolization needed before short–term hepatic arterial chemoinfusion? Kim DE, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1597–9

Combined preoperative embolization of the right portal vein and hepatic artery for hepatic resection in a high–risk patient. Takada T, et al. **AJR Am J Roentgenol** 1999 Jul; 173(1):165–7

Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Hsieh PS, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E930–7

Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation [see comments] Bloom AI, et al. **Ann Surg Oncol** 1999 Jun; 6(4):350–8. Comment in: Ann Surg Oncol 1999 Jun;6(4):328–9.

Hepatic artery administration of paclitaxel. Walton GD, et al. **Cancer Invest** 1999;17(2):118–20

Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. Hartnell GG, et al. **Cardiovasc Intervent Radiol** 1999 Jul–Aug;22(4):293–7

Coil embolization of arterioportal fistula that developed after partial gastrectomy. Ishigami K, et al. **Cardiovasc Intervent Radiol** 1999 Jul–Aug;22(4):328–30

Aneurysms and hypermobility in a 45–year–old woman. Santos–Ocampo AS, et al. **Cleve Clin J Med** 1999 Jul–Aug; 66(7):426–33 (38 ref.)

Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery. Seki H, et al. **Clin Radiol** 1999 Apr;54(4):221–7

Hepatic artery pseudoaneurysm with hemobilia following angioplasty after liver transplantation. Narumi S, et al. **Clin Transplant** 1998 Dec;12(6):508–10

Portal hypertension due to traumatic hepatic arterioportal fistula: report of successful embolization. Kirchgatterer A, et al. **Eur J Gastroenterol Hepatol** 1998 Dec;10(12):1057–9

Thrombectomy and in situ fibrinolysis in the treatment of acute hepatic arterial thrombosis after liver transplantation in two children. Olausson M, et al. **Eur J Surg** 1999 Jun; 165(6):618–20

Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Lindnér P, et al. **Eur J Surg Oncol** 1999 Apr; 25(2):179–85

Image of the month. Lazaridis KN, et al. **Gastroenterology** 1999 Feb;116(2):238, 505

Sudden abdominal pain and jaundice in a young man. Kohler H, et al. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):139–40, 143

Extraorganic hepatic artery aneurysm: failure of transcatheter embolization. Tarazov PG, et al. **HPB Surg** 1998; 11(1):55–9; discussion 59–60 (15 ref.)

Pseudoaneurysm in gall bladder fossa following laparoscopic cholecystectomy. Halbe S, et al. **Indian J Gastroenterol** 1999 Jul–Sep;18(3):122

Aneurysm of the gastroduodenal artery. Matsuzaki Y, et al. **Intern Med** 1998 Nov;37(11):930–3 (13 ref.)

Implantable hepatic arterial infusion device: placement without laparotomy via an intercostal artery. Castaing D, et al. **J Am Coll Surg** 1998 Nov;187(5):565–8

Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water–in–oil–in–water emulsion to hepatocellular carcinoma. Higashi S, et al. **J Pharmacol Exp Ther** 1999 May;289(2):816–9

Hepatic artery thrombosis: power Doppler sonographic demonstration of intraarterial thrombus. Shapiro RS, et al. **J Ultrasound Med** 1999 Aug;18(8):569–71

Unusual presentations of nonmycotic hepatic artery pseudoaneurysms after liver transplantation. Lowell JA, et al. **Liver Transpl Surg** 1999 May;5(3):200–3

Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. Mazariegos GV, et al. **Liver Transpl Surg** 1999 Sep;5(5):429–36

Hepatic aneurysm and portal vein thrombosis in a patient with lupus erythematosus on dialysis. Huang JW, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):753–6 (12 ref.)

Hepatic arterial pseudoaneurysm: a rare complication of blunt abdominal trauma in children. Basile KE, et al. **Pediatr Radiol** 1999 May;29(5):306–8

Vascular complications (splenic and hepatic artery aneurysms) in the occipital horn syndrome: report of a patient and review of the literature. Mentzel HJ, et al. **Pediatr Radiol** 1999 Jan;29(1):19–22 (12 ref.)

Post–traumatic hepatic pseudoaneurysms in children. Sidhu MK, et al. **Pediatr Radiol** 1999 Jan;29(1):46–52 (22 ref.)

Hepatic artery thrombosis in pediatric liver transplantation: graft salvage after thrombectomy. Garcia–Gallont R, et al. **Pediatr Transplant** 1999 Feb;3(1):74–8

Transcatheter arterial chemoembolization through collateral arteries for hepatocellular carcinoma after arterial occlusion. Shibata T, et al. **Radiat Med** 1998 Jul–Aug; 16(4):251–6

Hepatic arterial embolization [letter; comment] Jackson JE, et al. **Radiology** 1999 May;211(2):587–9. Comment on: Radiology 1998 Jul;208(1):217–22.

Changes in rat liver microcirculation after experimental hepatic arterial embolization: comparison of different embolic agents. Tancredi T, et al. **Radiology** 1999 Apr; 211(1):177–81

Hepatic artery aneurysm rupture: case report, imaging findings, and literature review. Thomas DE, et al. **S D J Med** 1998 Nov;51(11):413–6

Primary dissection of the hepatic artery: report of a case. Nakamura S, et al. **Surg Today** 1998;28(10):1065–8 (14 ref.)

Biliary complications secondary to late hepatic artery thrombosis in adult liver transplant patients. Margarit C, et al. **Transpl Int** 1998;11 Suppl 1:S251–4

Excision and immediate revascularization for hepatic artery pseudoaneurysm following liver transplantation. Bonham CA, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):443

Risk factors for late hepatic artery thrombosis in adult liver transplantation. Hidalgo E, et al. **Transplant Proc** 1999 Sep; 31(6):2416–7

A case report: split thickness skin grafting on a transplanted liver. Ogawa N, et al. **Transplant Proc** 1998 Nov; 30(7):3211–3

Vascular complications in a series of 300 orthotopic liver transplants. Sánchez–Bueno F, et al. **Transplant Proc** 1999 Sep;31(6):2409–10

Diagnostic and therapeutic management of hepatic artery thrombosis after liver transplantation. Torras J, et al. **Transplant Proc** 1999 Sep;31(6):2405

Biliary secretion of extracorporeal porcine livers with single and dual vessel perfusion. Foley DP, et al. **Transplantation** 1999 Aug 15;68(3):362–8

Acquired protein S deficiency with multiple thrombotic complications after orthotopic liver transplant. Schuetze SM, et al. **Transplantation** 1999 May 27;67(10):1366–9

[Visceral aneurysms. Two case reports] Skettrup M, et al. **Ugeskr Laeger** 1998 Dec 7;160(50):7270–1 (Eng. Abstr.) **(Dan)**

[A new application of balloon catheter in TAE] Hu D, et al. **J Tongji Med Univ** 1997;17(4):250–3 (Eng. Abstr.) **(Ger)**

[Splanchnic aneurysms: 10 treated cases and review of the literature] Bonardelli S, et al. **Ann Ital Chir** 1998 May–Jun; 69(3):325–30 (Eng. Abstr.) **(Ita)**

[Arterioportal fistula caused by liver biopsy demonstrated with magnetic resonance angiography. Report of a case] Blandino A, et al. **Radiol Med (Torino)** 1999 Jun;97(6):537–9 **(Ita)**

[Evaluation of hepatic artery occlusion after intra–arterial infusion of SMANCS in patients with hepatocellular carcinoma] Sakaguchi T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Oct; 58(12):700–4 (Eng. Abstr.) **(Jpn)**

[The unsuccessful embolization of an aneurysm of the common hepatic artery] Tarazov PG, et al. **Khirurgiia (Mosk)** 1998;(8):54–5 **(Rus)**

[Embolization of hepatic artery in liver cirrhosis complicated by ascites: long–term results] Tarazov PG. **Khirurgiia (Mosk)** 1999;(4):18–21 (Eng. Abstr.) **(Rus)**

[Cases of complications in surgical pathology of the branches of the celiac trunk] Tatarshaov Mkh, et al. **Klin Khir** 1999; (6):49–51 **(Rus)**

ABNORMALITIES

A case report of congenital intrahepatic arterioportal fistula. Alkim C, et al. **Am J Gastroenterol** 1999 Feb;94(2):523–5

Soft tissue case 24: arteriovenous fistula secondary to liver biopsy. Wong JK, et al. **Can J Surg** 1998 Dec;41(6):423, 438

Congenital hepatic arterioportal fistula complicated with gastrointestinal bleeding treated with transcatheter embolization: case report. Lin SL, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar;22(1):106–10

Arterial ring encircling the bile duct with coexisting anomalous liver irrigation. Dusanović AM, et al. **Dig Surg** 1999;16(1):72–5

Intrahepatic bilomas associated with hepatic arteriovenous malformation. Chen CH, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):443–7

A new alternative technique to preserve native flow, for continuous hepatic artery chemotherapy, in presence of a right hepatic artery arising from superior mesenteric artery. Di Carlo I, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1692–4

Demonstration of aberrant hepatic and gastric arteries with

helical CT. Ohgiya Y, et al. **Invest Radiol** 1999 Sep; 34(9):579–84

Osler–Rendu–Weber with liver involvement. Goris H, et al. **J Belge Radiol** 1998 Aug;81(4):184–5

Hepatic arterial anatomy: two new variants. Tarazov PG. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):285–7

Severe portal hypertension due to congenital hepatoportal arteriovenous fistula associated with intrahepatic portal vein aneurysm. Altuntaş B, et al. **J Clin Ultrasound** 1998 Sep;26(7):357–60

Successful embolization of congenital intrahepatic arterioportal fistula in two infants. Lamireau T, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):211–4

Congenital hepatic arterioportal fistula in a 3–year–old child. Marchand V, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr; 28(4):435–41

Microsurgical technique to improve the insertion of totally implantable arterial device (TIAD) in presence of hepatic artery anomalies. Puleo S, et al. **Microsurgery** 1998; 18(8):476–8

Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. Kondo F, et al. **Pathol Res Pract** 1998; 194(7):487–95

Hereditary hemorrhagic telangiectasia: effective protocol for embolization of hepatic vascular malformations--experience in five patients. Chavan A, et al. **Radiology** 1998 Dec;209(3):735–9

Accessory right hepatic artery arising from the left: implications for split liver transplantation. Rela M, et al. **Transplantation** 1998 Sep 27;66(6):792–4

[Description of an unusual case of congenital intraparenchymal aneurysm of the right hepatic artery communicating with the portal system] Maffei A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):116–8 **(Ita)**

ANATOMY & HISTOLOGY

Cystic artery origin of the segment V hepatic artery. Komatsu T, et al. **Cardiovasc Intervent Radiol** 1999 Mar–Apr;22(2):165–7

Analysis of the arterial supply of the extrahepatic bile ducts and its clinical significance. Chen WJ, et al. **Clin Anat** 1999; 12(4):245–9

Living–related liver transplantation: is Doppler sonography sufficient to define the hepatic artery anatomy before surgery? Puttemans T, et al. **Eur J Ultrasound** 1999 May; 9(2):155–9

The significance of the morphology of the dorsal pancreatic artery in determining the presence of the accessory right hepatic artery passing behind the portal vein. Matsumura H. **Kaibogaku Zasshi** 1998 Oct;73(5):517–27

Arterial supply of the duodenal bulb: an anatomoclinical study. Hentati N, et al. **Surg Radiol Anat** 1999;21(3):159–64

Accessory right hepatic artery arising from the left: implications for split liver transplantation. Rela M, et al. **Transplantation** 1998 Sep 27;66(6):792–4

DRUG EFFECTS

Contractile response of isolated human hepatic arteries to alpha–adrenoceptor agonists is not impaired in patients with cirrhosis. Hadoke PW, et al. **Clin Sci (Colch)** 1998 Oct; 95(4):505–11

Altered adrenergic responsiveness of endothelium–denuded hepatic arteries and portal veins in patients with cirrhosis. Heller J, et al. **Gastroenterology** 1999 Feb;116(2):387–93

Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride–induced acute hepatic injury. Tanaka N, et al. **Gastroenterology** 1999 Jul;117(1):173–80

EMBRYOLOGY

Is the liver of the fetus the 4th preferential organ for arterial blood supply besides brain, heart, and adrenal glands? Kilavuz O, et al. **J Perinat Med** 1999;27(2):103–6

GROWTH & DEVELOPMENT

Modeling of the parenchymous vascularization and perfusion. Rolland Y, et al. **Invest Radiol** 1999 Mar;34(3):171–5

INJURIES

Arterial bleeding after biliary drainage catheter placement: diagnosis and treatment. Maleux G, et al. **J Belge Radiol** 1998 Aug;81(4):176–7

Intrahepatic artery pseudoaneurysm: a possible complication of blind thoracentesis. Zironi G, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):151–5

Special exhibit for the SCVIR Annual Meeting Film Panel Session: diagnosis and discussion of cases 5–8. Society of Cardiovascular & Interventional Radiology. Case 5. Traumatic hepatic arterial injury with probable avulsion of the left hepatic artery origin. Hematoma within the porta hepatis. LaBerge JM, et al. **J Vasc Interv Radiol** 1999 May; 10(5):653–57

Intrahepatic arterioportal fistula: gadolinium–enhanced 3D magnetic resonance angiography findings and angiographic embolization with steel coils. Balci NC, et al. **Magn Reson Imaging** 1999 Apr;17(3):475–8

[A case of an isolated injury to the hepatic artery proper] Raichuk IO, et al. **Klin Khir** 1998;(11):50 **(Ukr)**

INNERVATION

Graft survival is improved by hepatic denervation before organ harvesting. Schemmer P, et al. **Transplantation** 1999 May 27;67(10):1301–7

METABOLISM

Tissue levels of chemotherapeutic agents for hepatic metastasis during hepatic arterial and portal injection. Kaneko A, et al. **In Vivo** 1999 Mar–Apr;13(2):195–8

Both positive and negative portal venous and hepatic arterial glucose gradients stimulate hepatic glucose uptake after the same amount of glucose is infused into the splanchnic bed in conscious dogs. Horikawa S, et al. **Metabolism** 1998 Nov;47(11):1295–302

Blockade of nitric oxide synthase potentiates the suppression of vasodilators by norepinephrine in the hepatic artery. Han C, et al. **Nitric Oxide** 1999;3(2):172–9

PATHOLOGY

Effect of temporary hepatic venous occlusion on hepatic arterial embolization. An experimental study. Horio K, et al. **Invest Radiol** 1999 May;34(5):341–7

MR imaging of hypervascular liver tumors: timing optimization during the arterial phase. Van Beers BE, et al. **J Magn Reson Imaging** 1999 Apr;9(4):562–7

Treatment for accidental occlusion of the hepatic artery after hepatic resection: report of two cases. Tanabe G, et al. **Surg Today** 1999;29(3):268–72

PHYSIOLOGY

Long–term measurement of liver microcirculation in dogs and humans. Kotzampassi K, et al. **Dig Surg** 1998; 15(4):357–63

Localisation of hepatic vascular resistance sites in the isolated dual–perfused rat liver. Yang W, et al. **Eur J Pharmacol** 1999 Jan 1;364(1):13–21

Presinusoidal portal hypertension does not affect hepatic artery resistance index. Erden A, et al. **Eur Radiol** 1999; 9(6):1131–4

Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver. Le Couteur DG, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1553–8

Extrahepatic arterial supply to the liver: observation with a unified CT and angiography system during temporary balloon occlusion of the proper hepatic artery. Takeuchi Y, et al. **Radiology** 1998 Oct;209(1):121–8

Effect of intraportal infusion of adenosine on hepatic blood flow and injury after ischemia and reperfusion of canine liver. Sakata C, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):509–10

PHYSIOPATHOLOGY

Altered adrenergic responsiveness of endothelium–denuded hepatic arteries and portal veins in patients with cirrhosis. Heller J, et al. **Gastroenterology** 1999 Feb;116(2):387–93

Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra–arterial Doppler and adenosine infusion. Kleber G, et al. **Gastroenterology** 1999 Apr; 116(4):906–14

Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride–induced acute hepatic injury. Tanaka N, et al. **Gastroenterology** 1999 Jul;117(1):173–80

Hepatic artery resistance in alcoholic liver disease. Colli A, et al. **Hepatology** 1998 Nov;28(5):1182–6

Hepatic microcirculatory changes induced by hepatic artery embolization in rats: original investigation. Koda Y, et al. **Invest Radiol** 1999 Feb;34(2):160–6

Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. Schneider AW, et al. **J Hepatol** 1999 May; 30(5):876–81

Preserved arterial flow secures hepatic oxygenation during haemorrhage in the pig. Rasmussen A, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):539–48

RADIOGRAPHY

Impact of double helical CT and three–dimensional CT arteriography on surgical planning for hepatic transplantation. Nghiem HV, et al. **Abdom Imaging** 1999 May–Jun;24(3):278–84

The cause of nontumorous defects of portal perfusion in the hepatic hilum revealed by CT during arterial portography. Yamagami T, et al. **AJR Am J Roentgenol** 1999 Feb; 172(2):397–402

Cystic artery origin of the segment V hepatic artery. Komatsu T, et al. **Cardiovasc Intervent Radiol** 1999 Mar–Apr;22(2):165–7

Hepatic artery angiography and embolization for hemobilia following laparoscopic cholecystectomy. Nicholson T, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):20–4

Case report: Dissecting aneurysm of the hepatic artery. Hashimoto M, et al. **Clin Radiol** 1998 Dec;53(12):913–4

Partially thrombosed hepatic artery aneurysm mimicking pancreatic head carcinoma. Elmas N, et al. **Comput Med Imaging Graph** 1998 Jan–Feb;22(1):67–70

Intrahepatic arterioportal shunt: helical CT findings. Quiroga S, et al. **Eur Radiol** 1999;9(6):1126–30

Demonstration of aberrant hepatic and gastric arteries with helical CT. Ohgiya Y, et al. **Invest Radiol** 1999 Sep; 34(9):579–84

Pseudolesion in segments II and III of the liver on CT during arterial portography caused by aberrant right gastric venous drainage. Yoon KH, et al. **J Comput Assist Tomogr** 1999 Mar–Apr;23(2):306–9 (12 ref.)

A rare case of haemobilia. Sarkar C, et al. **J Indian Med Assoc** 1998 Jun;96(6):186–7

Attenuation changes in periportal region during triple–phasic contrast–enhanced CT. Kanazawa S, et al. **Radiat Med** 1999 Mar–Apr;17(2):97–103

Transient hepatic attenuation difference (THAD) in patients without neoplasm: frequency, shape, distribution, and causes. Yamasaki M, et al. **Radiat Med** 1999 Mar–Apr; 17(2):91–6

Oxygen administration during hepatic DSA. Katsuda T, et al. **Radiol Technol** 1998 Nov–Dec;70(2):177–80

Diagnosis please. Case 13: polyarteritis nodosa--systemic necrotizing vasculitis with involvement of hepatic and superior mesenteric arteries. Hagspiel KD, et al. **Radiology** 1999 Aug;212(2):359–64

The arterial blood supply of the pancreas: a review. V. The dorsal pancreatic artery. An anatomic review and a radiologic study. Bertelli E, et al. **Surg Radiol Anat** 1998; 20(6):445–52

The watershed between right and left hepatic artery territories: findings on CT scans after transcatheter oily chemoembolization of hepatic tumors. A preliminary report. Oran I, et al. **Surg Radiol Anat** 1998;20(5):355–60

Preoperative evaluation of potential living donors for liver transplantation: the role of helical computed tomography–angiography. Chan JK, et al. **Transplant Proc** 1998 Nov;30(7):3197–8

[Hepatic artery sectorial enhancement as a sign of acute portal thrombosis. Report of 3 cases] Colagrande S, et al. **Radiol Med (Torino)** 1998 Dec;96(6):639–41 **(Ita)**

RADIONUCLIDE IMAGING

Hepatic perfusion changes in patients with cirrhosis indices of hepatic arterial blood flow. Koranda P, et al. **Clin Nucl Med** 1999 Jul;24(7):507–10

SURGERY

Comparison of arcuate–legged clipped versus sutured hepatic artery, portal vein, and bile duct anastomoses. Geevarghese SK, et al. **Am Surg** 1999 Apr;65(4):311–6

Porcine living liver transplantation using a vascular prosthesis to replace the intrahepatic vena cava. Nardo B, et al. **Eur Surg Res** 1999;31(4):364–70

Gonadal vein graft for hepatic artery reconstruction. Ohwada S, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1823–6

Modified hepatoduodenal ligamentectomy for advanced carcinoma of the biliary tract: the importance of preservation of the replaced left hepatic artery. Maeba T, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):297–302

Microsurgical reconstruction of the hepatic and superior mesenteric arteries using a back wall technique. Yamamoto Y, et al. **J Reconstr Microsurg** 1999 Jul;15(5):321–5

Iliac–to–isolated hepatic artery bypass in the treatment of intestinal angina: two cases. Cavallaro A, et al. **J Vasc Surg** 1998 Dec;28(6):1115–9

New technique for superselective arterial (chemo–) embolization of the rat liver. Kamphorst EJ, et al. **Lab Anim Sci** 1999 Apr;49(2):216–9

Additional techniques adopted for major vascular anastomoses during orthotopic liver transplantation. Kawamoto S, et al. **Surg Today** 1998;28(12):1237–41

Impact of early arterialization in the liver allograft. As AB, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):406–7

Versatility of the inferior epigastric artery as an interpositional vascular graft in living–related liver transplantation. Nakatsuka T, et al. **Transplantation** 1999 Jun 15;67(11):1490–2

Coeliac artery aneurysm: aorto–hepatic artery reconstruction. Ersoz S, et al. **Vasa** 1999 May;28(2):127–9

[Hepatic artery ligation for liver metastasis of a acinar cell carcinoma of the pancreas revealed by a nodular panniculitis] Viguier J, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep;22(8–9):715–9 (Eng. Abstr.) **(Fre)**

[What is the risk of resection of the right hepatic artery in resection of central bile duct carcinoma?] Hasse FM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:352–5 (Eng. Abstr.) **(Ger)**

[Aneurysm of the hepatic artery. Report of a case] Socrate AM, et al. **Minerva Cardioangiol** 1998 Apr;46(4):119–22 (Eng. Abstr.) **(Ita)**

[A case of ligation of the hepatic artery proper] Bondarev GA, et al. **Vestn Khir Im I I Grek** 1999;158(1):70–2 **(Rus)**

ULTRASONOGRAPHY

Living–related liver transplantation: is Doppler sonography sufficient to define the hepatic artery anatomy before surgery? Puttemans T, et al. **Eur J Ultrasound** 1999 May; 9(2):155–9

Hemobilia caused by a pseudoaneurysm of the hepatic artery diagnosed by EUS. Cattan P, et al. **Gastrointest Endosc** 1999 Feb;49(2):252–5

Hepatic arterial resistance after mixed–meal ingestion in healthy subjects and patients with chronic liver disease. Numata K, et al. **J Clin Ultrasound** 1999 Jun;27(5):239–48

HEPATIC ARTERY

Influence of systematic echodoppler arterial survey on hepatic artery thrombosis after liver transplantation in adults. Rode A, et al. **Transpl Int** 1998;11 Suppl 1:S292-5
Arterial waveforms on Doppler ultrasonography predicting or supporting hepatic arterial thrombosis in liver transplantation. Harihara Y, et al. **Transplant Proc** 1998 Nov;30(7):3188-9
[The diagnosis and imaging of the a. hepatica after orthoptic liver transplantation--a comparison of frequency-modulated and amplitude-modulated color Doppler sonography] Venz S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):284-9 (Eng. Abstr.) **(Ger)**
[Variants of the hepatic artery: detection with color--coded sonography pre and post levovist injection] Strunk H, et al. **Ultraschall Med** 1999 Feb;20(1):26-30 (Eng. Abstr.) **(Ger)**
[Changes in portal and hepatic blood flow in patients with chronic kidney failure as shown by Doppler ultrasonography] Dzhavad-zade MD, et al. **Urol Nefrol (Mosk)** 1998 Nov-Dec;(6):12-5 (Eng. Abstr.) **(Rus)**

HEPATIC CIRRHOSIS see **LIVER CIRRHOSIS**

HEPATIC COMA see **HEPATIC ENCEPHALOPATHY**

HEPATIC DUCT, COMMON

Multiple stents in treatment of obstructive jaundice associated with Klatskin's tumor. Mayo-Smith WW. **AJR Am J Roentgenol** 1999 Sep;173(3):846-7
Pseudo-Mirizzi syndrome in acute cholecystitis. Mergener K, et al. **Am J Gastroenterol** 1998 Dec;93(12):2605-6
Late bile duct cancer complicating biliary-enteric anastomosis for benign disease. Strong RW. **Am J Surg** 1999 Jun;177(6):472-4
Proximal bile duct cancer: high resectability rate and 5-year survival. Launois B, et al. **Ann Surg** 1999 Aug;230(2):266-75
Diagnostic and surgical features of Klatskin tumors. Santoro E, et al. **Chir Ital** 1999 Jan-Feb;51(1):1-7
Interventional radiology in percutaneous management of bile duct obstruction: biliary drainage through a spontaneous common hepatic duct-duodenal fistula. Mannella P, et al. **Clin Imaging** 1999 Mar-Apr;23(2):103-6
Spontaneous perforation of the hepatic duct in adults. Paladugu R, et al. **Dig Surg** 1998;15(5):417-20 (23 ref.)
Acute hepatobiliary tuberculosis: a report of two cases and a review of the literature. Hickey N, et al. **Eur Radiol** 1999; 9(5):886-9 (25 ref.)
Holmium laser for treatment of left hepatic duct stone. Burdick JS, et al. **Gastrointest Endosc** 1998 Nov;48(5):523-6
Leakage via aberrant bile duct due to cholangiocarcinoma. Stanton R, et al. **HPB Surg** 1998;11(2):125-8
Carcinoid tumor of common hepatic duct. Perakath B, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):127
Preservative treatment for biliobiliary fistula. Nakagawara M, et al. **J Clin Gastroenterol** 1999 Sep;29(2):190-2
Biliary cystadenocarcinoma: sonographic and cytologic findings. Filippi de la Palavesa MM, et al. **J Clin Ultrasound** 1999 May;27(4):210-2
Holmium:YAG laser lithotripsy of intrahepatic biliary calculi. Tarman GJ, et al. **J Endourol** 1999 Jun;13(5):381-3
Traumatic neuroma as a cause of obstructive jaundice. Chantranuwat C, et al. **J Med Assoc Thai** 1999 Jun; 82(6):619-22
Mirizzi syndrome--a report of 3 cases with a review of the present classifications. Khan TF, et al. **Singapore Med J** 1999 Mar;40(3):171-3
Combined endoscopic and surgical management of Mirizzi syndrome. Hazzan D, et al. **Surg Endosc** 1999 Jun; 13(6):618-20 (10 ref.)
Management of Mirizzi's syndrome in the laparoscopic era. Kok KY, et al. **Surg Endosc** 1998 Oct;12(10):1242-4
Liver transplantation in the management of Klatskin's tumor. Robles R, et al. **Transplant Proc** 1999 Sep;31(6):2494-5
[Diagnosis of hilar bile duct carcinoma (Klatskin tumor)] Lammert F, et al. **Dtsch Med Wochenschr** 1998 Sep 25; 123(39):1145-8 (16 ref.) **(Ger)**
[Therapeutic strategies in hilar bile duct carcinoma (Klatskin's tumor)] Lammert F, et al. **Dtsch Med Wochenschr** 1998 Oct 2;123(40):1179-82 (17 ref.) **(Ger)**
[An update in the diagnosis and treatment of tumors of the hepatic portal] Vadalà G, et al. **Minerva Chir** 1998 Sep; 53(9):701-7 (17 ref.) (Eng. Abstr.) **(Ita)**
[Cholangiography with ultrasonography and contrast media in the diagnosis of obstructive jaundice caused by ++Klatskin tumor. Report of a case] Spiezia S, et al. **Radiol Med (Torino)** 1999 Mar;97(3):203-5 **(Ita)**
[Treatment of cicatricial strictures fo hepatic ducts] Gal'perin EI, et al. **Khirurgiia (Mosk)** 1998;(9):26-30 (Eng. Abstr.) **(Rus)**
[Adenomatous hyperplasia of the common hepatic duct as the cause of high biliary duct stricture] Rukhliada NV, et al. **Vestn Khir Im I I Grek** 1998;157(3):93-5 (8 ref.) **(Rus)**
[Mirizzi syndrome. A rare cause of biliary tract obstruction] Thulin A. **Lakartidningen** 1999 Feb 24;96(8):901-2 **(Swe)**

ABNORMALITIES

Common hepatic duct stricture associated with ductal plate malformation in a 4.5-year-old child. Brown P, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):221-4
Double gallbladder originating from left hepatic duct: a case report and review of literature. Gorecki PJ, et al. **JSLS** 1998 Oct-Dec;2(4):337-9 (7 ref.)
Association of oesophageal atresia and cholecystohepatic duct. Redkar RG, et al. **Pediatr Surg Int** 1999;15(1):21-3 (20 ref.)
[Pathology of the ductal plaque] Escartín Marín P. **Gastroenterol Hepatol** 1998 Dec;21(10):492-7 (37 ref.) **(Spa)**

ANATOMY & HISTOLOGY

[Anatomic variants of the cystic duct and cysticohepatic junction: diagnosis with MR cholangiography] Tsunoda M, et al. **Nippon Rinsho** 1998 Nov;56(11):2918-22 (20 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Arterial ring encircling the bile duct with coexisting anomalous liver irrigation. Dusanović AM, et al. **Dig Surg** 1999;16(1):72-5

INJURIES

Operative repair of bile duct injuries involving the hepatic duct confluence. Jarnagin WR, et al. **Arch Surg** 1999 Jul; 134(7):769-75
[Precision terminolateral hepaticoduodenal anastomosis in damage to a small-diameter hepaticocholedochus] Radnaev VU. **Vestn Khir Im I I Grek** 1998;157(3):92 **(Rus)**

PATHOLOGY

Potential pitfall of MR cholangiopancreatography: right hepatic arterial impression of the common hepatic duct. Kondo H, et al. **J Comput Assist Tomogr** 1999 Jan-Feb; 23(1):60-2
Prognostic significance of tumor DNA content in carcinoma of the hepatic duct confluence. Iachino C, et al. **J Exp Clin Cancer Res** 1998 Dec;17(4):425-30
Extrahepatic biliary cystadenocarcinoma arising from the left hepatic duct. Kimura H, et al. **J Gastroenterol** 1998 Dec; 33(6):895-8 (12 ref.)
[Evaluation of the cystic duct and cysticohepatic junction with MR cholangiography: comparison of various techniques and clinical evaluation with respiratory-triggered three-dimensional multislab technique] Tsunoda M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Jul;58(8):420-5 (Eng. Abstr.) **(Jpn)**
[MR cholangiopancreatography of Mirizzi syndrome and Lemmel syndrome] Doai K, et al. **Nippon Rinsho** 1998 Nov; 56(11):2933-8 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Pathology of the ductal plaque] Escartín Marín P. **Gastroenterol Hepatol** 1998 Dec;21(10):492-7 (37 ref.) **(Spa)**

SURGERY

Operative repair of bile duct injuries involving the hepatic duct confluence. Jarnagin WR, et al. **Arch Surg** 1999 Jul; 134(7):769-75
A case of abscess formation in a remnant common bile duct after Roux-en-Y hepaticojejunostomy. Sugimoto K, et al. **Endoscopy** 1999 May;31(4):S30
Advanced adenosquamous carcinoma of the gallbladder with bilio-biliary fistula: an uncommon case treated by hepatopancreatoduodenectomy. Ercolani G, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1650-4 (18 ref.)
Major hepatectomy combined with pylorus-preserving pancreatoduodenectomy for middle bile duct cancer with multiple lymph node metastases: a case report of 5-year survival. Kurosaki I, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1623-6
US guided biliary drainage during hepatopancreatico-jejunostomy for diffuse bile duct carcinoma. Torzilli G, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):863-6
A new technique of Hepp-Couinaud hepaticojejunostomy using the posterior approach to the hepatic hilum. Launois B, et al. **J Am Coll Surg** 1999 Jan;188(1):59-62
Comparison of hepaticoantrostomy and hepaticojejunostomy [letter] Sheth NP. **Pediatr Surg Int** 1999;15(3-4):297
Long-term survival after resection of proximal bile duct carcinoma (Klatskin tumors). Gerhards MF, et al. **World J Surg** 1999 Jan;23(1):91-6
[The evaluation of endoscopic biliary drainage for 288 patients with malignant hilar obstruction] Hu B, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Feb;35(2):73-6 (Eng. Abstr.) **(Chi)**
[Klatskin tumor. A study of 15 resected cases] Santoro E, et al. **Chirurgie** 1999 Apr;124(2):132-9; discussion 139-40 (28 ref.) (Eng. Abstr.) **(Fre)**
[Anisoperistaltic Roux-en-Y reconstruction: rare cause for recurrent cholangitis after hepatic jejunostomy] Böhm SA, et al. **Chirurg** 1999 Jul;70(7):803-6 (Eng. Abstr.) **(Ger)**
[Lymphoepithelial carcinoma of the extrahepatic bile duct] Pratschke J, et al. **Chirurg** 1999 May;70(5):605-7 (Eng. Abstr.) **(Ger)**
[Palliative cholangiojejunostomy on the duct of hepatic segment III. Our experience] Confalonieri F, et al. **Minerva Chir** 1998 Sep;53(9):709-14 (Eng. Abstr.) **(Ita)**
[The performance of a radical operation for Klatskin's tumor] Kopchak VM, et al. **Klin Khir** 1998;(9-10):84-5 **(Rus)**
[Precision terminolateral hepaticoduodenal anastomosis in damage to a small-diameter hepaticocholedochus] Radnaev VU. **Vestn Khir Im I I Grek** 1998;157(3):92 **(Rus)**
[Clinical-statistical prognosis of gastroduodenal erosion and ulcer incidence after surgical treatment of inflammatory disease of hepato-biliary tract] Koval' AI, et al. **Klin Khir** 1998;(8):10-2 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Common duct diameter as an independent predictor of choledocholithiasis: is it useful? Majeed AW, et al. **Clin Radiol** 1999 Mar;54(3):170-2

HEPATIC ENCEPHALOPATHY

Cerebral changes in hepatic encephalopathy. Watanabe A. **J Gastroenterol Hepatol** 1998 Jul;13(7):752-60 (56 ref.)
Fulminant hepatic failure. Shakil AO, et al. **Surg Clin North Am** 1999 Feb;79(1):77-108 (177 ref.)
[Refractory liver diseases (editorial)] Omata M. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):569-71 **(Jpn)**

BLOOD

Plasma levels of pipecolic acid, both L- and D-enantiomers, in patients with chronic liver diseases, especially hepatic encephalopathy. Fujita T, et al. **Clin Chim Acta** 1999 Sep; 287(1-2):99-109
Assay to detect inhibitory substances in serum of patients with acute liver failure. Anderson C, et al. **Int J Artif Organs** 1999 Feb;22(2):113-7
Discrimination of two different clinical entities, acute-type and subacute-type, human fulminant hepatitis by peripheral blood lymphocyte subsets. Shimizu T, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):274-80
Opioid receptor ligands in human hepatic encephalopathy. Yurdaydin C, et al. **J Hepatol** 1998 Nov;29(5):796-801
Plasma concentrations of endogenous benzodiazepine-receptor ligands in patients with hepatic encephalopathy: a comparative study. Hernández-Avila CA, et al. **J Psychiatry Neurosci** 1998 Sep;23(4):217-22
Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. Suh KS, et al. **J Surg Res** 1999 Aug;85(2):243-50
Fibrinolysis in patients with fulminant hepatic failure [letter] Mandell MS, et al. **Liver Transpl Surg** 1999 Sep;5(5):464
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Perney P, et al. **Metab Brain Dis** 1998 Sep;13(3):201-10
Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Shiota G, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jul; 101(1):3-12

CEREBROSPINAL FLUID

Opioid receptor ligands in human hepatic encephalopathy. Yurdaydin C, et al. **J Hepatol** 1998 Nov;29(5):796-801
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Perney P, et al. **Metab Brain Dis** 1998 Sep;13(3):201-10

CHEMICALLY INDUCED

Herbal toxicity and fatal hepatic failure [letter] Hullar TE, et al. **Am J Med** 1999 Feb;106(2):267-8
Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model. Matkowskyj KA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G455-62
Fatal fulminant hepatitis associated with bromfenac use. Rabkin JM, et al. **Ann Pharmacother** 1999 Sep;33(9):945-7
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel [see comments] Nieto Y, et al. **Clin Cancer Res** 1999 Mar;5(3):501-6. Comment in: Clin Cancer Res 1999 Mar;5(3):481-6.
An autopsy case of troglitazone-induced fulminant hepatitis. Shibuya A, et al. **Diabetes Care** 1998 Dec;21(12):2140-3
Fatal fulminant hepatic failure due to cyproterone acetate. Friedman G, et al. **Dig Dis Sci** 1999 Jul;44(7):1362-3 (7 ref.)
Reversible fulminant hepatitis following intravenous amiodarone loading. Amiodarone hepatotoxicity [letter] Iliopoulou A, et al. **Int J Clin Pharmacol Ther** 1999 Jun; 37(6):312-3
The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure. Bruck R, et al. **J Hepatol** 1999 Jul;31(1):27-38
Fulminant liver failure associated with flutamide therapy for hirsutism [letter; comment] Andrade RJ, et al. **Lancet** 1999 Mar 20;353(9157):983. Comment on: Lancet 1997 Jan 18;349(9046):191-5.
Topiramate and fulminant liver failure [letter] Bjøro K, et

al. **Lancet** 1998 Oct 3;352(9134):1119

COX 2 inhibitor and fulminant hepatic failure [letter] [see comments] McCormick PA, et al. **Lancet** 1999 Jan 2; 353(9146):40–1. Comment in: Lancet 1999 Mar 6;353(9155):846. Comment in: Lancet 1999 Apr 24;353(9162):1447–8.

Stopping the pills. van der Cammen TJ, et al. **Lancet** 1999 Aug 14;354(9178):564

NSAIDs and hepatic reactions [letter; comment] Villa G. **Lancet** 1999 Mar 6;353(9155):846. Comment on: Lancet 1999 Jan 2;353(9146):40–1.

Case presentation: fulminant hepatic failure. Braunfeld MY. **Liver Transpl Surg** 1999 Jul;5(4):349–50

Terbinafine and fulminant hepatic failure [letter] Agarwal K, et al. **N Engl J Med** 1999 Apr 22;340(16):1292–3

Paracetamol-induced fulminant hepatic failure in a child after 5 days of therapeutic doses. Morton NS, et al. **Paediatr Anaesth** 1999;9(5):463–5

Prediction of hepatic encephalopathy in paracetamol overdose: a prospective and validated study. Schiødt FV, et al. **Scand J Gastroenterol** 1999 Jul;34(7):723–8

Fulminant hepatic failure after herbal medicine ingestion in children [letter] Bagheri H, et al. **Therapie** 1998 Jan–Feb; 53(1):82–3

[Fulminant hepatitis in two children treated with sulfasalazine for Crohn disease] Besnard M, et al. **Arch Pediatr** 1999 Jun;6(6):643–6 (Eng. Abstr.) **(Fre)**

[Regressive fulminant hepatitis, acute pancreatitis and renal insufficiency after taking ketoprofen (letter)] Flamenbaum M, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):975–6 **(Fre)**

[A case of drug-induced fulminant hepatic failure accompanied with marked increase of pancreatic enzymes] Tani S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May; 96(5):540–4 **(Jpn)**

CLASSIFICATION

Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. Tandon BN, et al. **J Gastroenterol Hepatol** 1999 May;14(5):403–4

COMPLICATIONS

Resolution of adult respiratory distress syndrome after recovery from fulminant hepatic failure. Khanlou H, et al. **Am J Med Sci** 1999 Feb;317(2):134–6

Acute pancreatitis and fulminant hepatic failure. Kuo PC, et al. **J Am Coll Surg** 1998 Nov;187(5):522–8

Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis. Chu CM, et al. **J Clin Microbiol** 1999 Jan;37(1):235–7

Acute hemolytic crisis with fulminant hepatic failure as the first manifestation of Wilson's disease: a case report. Lee JJ, et al. **J Korean Med Sci** 1998 Oct;13(5):548–50

Hepatic retinopathia: changes in retinal function [letter; comment] Kashani AA. **Vision Res** 1999 Jun;39(11):2027–9 . Comment on: Vision Res 1997 Jun;37(12):1699–706.

DIAGNOSIS

A new clinical application of MR spectroscopy in hepatic encephalopathy [editorial; comment] Bryan RN, et al. **AJNR Am J Neuroradiol** 1998 Oct;19(9):1593–4. Comment on: AJNR Am J Neuroradiol 1998 Oct;19(9):1681–6.

Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients. Zullo A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2214–8

Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Behar KL, et al. **Am J Psychiatry** 1999 Jun;156(6):952–4

Early detection and treatment of hepatic encephalopathy [editorial] Lockwood AH. **Curr Opin Neurol** 1998 Dec; 11(6):663–6 (28 ref.)

Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Ferlan-Marolt V, et al. **Dig Dis Sci** 1999 May;44(5):1054–8 (26 ref.)

Hepatic encephalopathy--a physostigmine-reactive central anticholinergic syndrome? Kabatnik M, et al. **Eur J Anaesthesiol** 1999 Feb;16(2):140–2

Diagnosis of hepatic encephalopathy: will in vivo proton MRS play a role? Jalan R, et al. **Hepatology** 1999 May; 29(5):1605–7

Stopping the pills. van der Cammen TJ, et al. **Lancet** 1999 Aug 14;354(9178):564

Proton magnetic resonance spectroscopy in portal-systemic encephalopathy. Köstler H. **Metab Brain Dis** 1998 Dec; 13(4):291–301 (58 ref.)

Fulminant hepatitis caused by hepatitis C virus. Taga T, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1174–6

Reversibility of hyperintense globus pallidus on T 1-weighted MRI follow- ing surgery for a portosystemic shunt in an 8-year-old girl. Ikeda S, et al. **Pediatr Radiol** 1999 Jun;29(6):449–50

Clinical correlation of neuropsychological tests with 1H magnetic resonance spectroscopy in hepatic encephalopathy. Huda A, et al. **Psychosom Med** 1998 Sep–Oct;60(5):550–6

[Pathognomonic significance of increased ammonia levels] Bosseckert H. **Dtsch Med Wochenschr** 1999 Mar 12; 124(10):300 **(Ger)**

[Prognostic factors in acute liver failure] Eisenhuber E, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):564–9 (Eng. Abstr.) **(Ger)**

[Hepatic encephalopathy: neuropsychological and neurophysiological diagnosis] Kuhlbusch R, et al. **Z Gastroenterol** 1998 Dec;36(12):1075–83 (30 ref.) (Eng. Abstr.) **(Ger)**

[Fulminant hepatitis: diagnostic standard and the extent of severity] Moriwaki H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):640–6 (5 ref.) **(Jpn)**

[On diagnostic criteria of fulminant hepatitis] Yoshiba M. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jul;96(7):803–8 **(Jpn)**

[Portosystemic encephalopathy and splanchnic hemodynamics in liver cirrhosis] Kotenko OG. **Klin Khir** 1999;(2):16–9 (Eng. Abstr.) **(Rus)**

DIET THERAPY

Dietary management of hepatic encephalopathy [editorial; comment] [see comments] Seymour CA, et al. **BMJ** 1999 May 22;318(7195):1364–5. Comment on: BMJ 1999 May 22;318(7195):1391. Comment in: BMJ 1999 Aug 14;319(7207):455.

Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom [see comments] Soulsby CT, et al. **BMJ** 1999 May 22; 318(7195):1391. Comment in: BMJ 1999 May 22;318(7195):1364–5. Comment in: BMJ 1999 Aug 14;319(7207):455.

Effects of a branched-chain amino acid-enriched diet on chronic hepatic encephalopathy in dogs. Meyer HP, et al. **Metab Brain Dis** 1999 Jun;14(2):103–15

Dietary management of patients with hepatic encephalopathy in hospitals in the United Kingdom [editorial] Soulsby CT. **Nutrition** 1998 Sep;14(9):714–5

DRUG THERAPY

A new clinical application of MR spectroscopy in hepatic encephalopathy [editorial; comment] Bryan RN, et al. **AJNR Am J Neuroradiol** 1998 Oct;19(9):1593–4. Comment on: AJNR Am J Neuroradiol 1998 Oct;19(9):1681–6.

Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy [see comments] Haseler LJ, et al. **AJNR Am J Neuroradiol** 1998 Oct;19(9):1681–6. Comment in: AJNR Am J Neuroradiol 1998 Oct;19(9):1593–4.

Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Chakrabarti S, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1209–11

Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Barbaro G, et al. **Eur J Emerg Med** 1998 Jun;5(2):213–8

Flumazenil and hepatic encephalopathy [letter; comment] Amaral OB, et al. **Hepatology** 1999 Apr;29(4):1338–9. Comment on: Hepatology 1998 Aug;28(2):374–8.

Nitric oxide ameliorates actinomycin D/endotoxin-induced apoptotic liver failure in mice. Akahori M, et al. **J Surg Res** 1999 Aug;85(2):286–93

Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil. Meyer HP, et al. **Metab Brain Dis** 1998 Sep;13(3):241–51

Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. Apelqvist G, et al. **Psychopharmacology (Berl)** 1999 Apr;143(4):408–16

Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. Uribe M, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1099–106

ENZYMOLOGY

Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. Yurdaydin C, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):503–7

Neuronal nitric oxide synthase and Hepatic Encephalopathy. Rao VL, et al. **Metab Brain Dis** 1998 Sep;13(3):175–89 (95 ref.)

EPIDEMIOLOGY

Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Bustamante J, et al. **J Hepatol** 1999 May; 30(5):890–5

[Fulminant hepatitis: epidemiology and diagnosis] Sato S, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):626–31 (5 ref.) **(Jpn)**

ETIOLOGY

Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature. Te HS, et al. **Am J Gastroenterol** 1999 Jan;94(1):262–6 (40 ref.)

Waldenstrom's macroglobulinemia in a patient with cirrhosis and chronic hepatitis C infection [letter] Trotter JF. **Am J Med** 1999 Sep;107(3):299–300

Fulminant hepatic failure caused by adenovirus infection following bone marrow transplantation for Hodgkin's disease. Somervaille TC, et al. **Bone Marrow Transplant** 1999 Jul;24(1):99–101

Congenital intrahepatic portosystemic shunt. Florio F, et al. **Cardiovasc Intervent Radiol** 1998 Sep–Oct;21(5):421–4 (11 ref.)

Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Ferlan-Marolt V, et al. **Dig Dis Sci** 1999 May;44(5):1054–8 (26 ref.)

Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study. Barbaro G, et al. **Eur J Emerg Med** 1998 Jun;5(2):213–8

Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Assy N, et al. **Gastrointest Endosc** 1999 Jun; 49(6):690–4

Encephalopathy without cirrhosis: hunt the shunt [comment] Howard ER. **Gut** 1999 Sep;45(3):329–30. Comment on: Gut 1999 Sep;45(3):442–5.

A case of non A, non B, non C hepatitis that relapsed into fulminant hepatic failure. Cuffari C, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2348–51

Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Nolte W, et al. **Hepatology** 1998 Nov;28(5):1215–25

Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Stuyver L, et al. **Hepatology** 1999 Jun;29(6):1876–83

Extrahepatic portal-systemic encephalopathy without portal hypertension [letter; comment] Watanabe M, et al. **Intern Med** 1998 Aug;37(8):716–7. Comment on: Intern Med 1997 Dec;36(12):886–9.

Case report: intrahepatic portal-hepatic venous shunts associated with a huge pelvic leiomyoma. Aiba N, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):158–62

Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. Farci P, et al. **J Infect Dis** 1999 Apr;179(4):1007–11

17-year-old female with IgA and abdominal pain: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Olay S, et al. **J Okla State Med Assoc** 1999 Feb;92(2):77–82

The long-term prognosis of congenital portosystemic venous shunt. Uchino T, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):254–6

Parvovirus B19 infection and fulminant hepatitis [letter; comment] Bernuau J, et al. **Lancet** 1999 Feb 27; 353(9154):754–5. Comment on: Lancet 1998 Nov 28;352(9142):1739–41.

Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Egawa H, et al. **Liver Transpl Surg** 1998 Nov;4(6):513–5

Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Feranchak AP, et al. **Liver Transpl Surg** 1998 Nov;4(6):469–76 (39 ref.)

A long-term intake of a protein hydrolysate seems to increase the risk of encephalopathy in mice infected with Schistosoma mansoni. Ferreira HS, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:199–203

Role of manganese in the pathogenesis of portal-systemic encephalopathy. Layrargues GP, et al. **Metab Brain Dis** 1998 Dec;13(4):311–7 (35 ref.)

Kikuchi's disease with multisystemic involvement and adverse reaction to drugs. Sierra ML, et al. **Pediatrics** 1999 Aug;104(2):e24

Successful surgical treatment for hepatic encephalopathy caused by a pancreatic siphon: report of a case. Nozaki H, et al. **Surg Today** 1998;28(10):1069–72

[Zinc deficiency in liver cirrhosis: a curiosity or a problem?] Marchetti P, et al. **Ann Ital Med Int** 1998 Jul–Sep; 13(3):157–62 (64 ref.) (Eng. Abstr.) **(Ita)**

[A case of leiomyosarcoma of the jejunum with postoperative hepatic encephalopathy] Otani S, et al. **Gan To Kagaku Ryoho** 1998 Nov;25(13):2127–30 (Eng. Abstr.) **(Jpn)**

[Hypothetical pathogenetic mechanisms of hepatic encephalopathy] Magiera M, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):359–64 (34 ref.) **(Pol)**

[The pathogenesis of hepatic encephalopathy] Córdoba J, et al. **Gastroenterol Hepatol** 1999 May;22(5):247–57 (133 ref.) **(Spa)**

[Portosystemic encephalopathy in hereditary hemorrhagic telangiectasia (letter)] Nuño Mateo FJ, et al. **Rev Esp Enferm Dig** 1999 Jan;91(1):79–80 **(Spa)**

GENETICS

Surgical correction of patent ductus venosus in three brothers. Ikeda S, et al. **Dig Dis Sci** 1999 Mar;44(3):582–9

Expression of the stem cell factor receptor c-kit in normal and diseased pediatric liver: identification of a human hepatic progenitor cell? Baumann U, et al. **Hepatology** 1999 Jul;30(1):112–7

Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy. Butterworth RF. **Metab Brain Dis** 1998 Dec;13(4):337–49

(70 ref.)

IMMUNOLOGY

Hepatitis B virus surface antigen (HBsAg) and antibody (anti-HBs) forming immune complexes in fulminant hepatitis. Soares MC, et al. **Rev Soc Bras Med Trop** 1999 May-Jun;32(3):295-7

METABOLISM

Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy [see comments] Haseler LJ, et al.
AJNR Am J Neuroradiol 1998 Oct;19(9):1681-6. Comment in: AJNR Am J Neuroradiol 1998 Oct;19(9):1593-4.

Preoperative metabolic profile of patients undergoing orthotopic liver transplantation [letter] Diaz J, et al.
Am J Gastroenterol 1999 Feb;94(2):544-5

Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Leifeld L, et al. **Am J Pathol** 1999 Jun; 154(6):1711-20

Chronic hyperammonemia in rats impairs activation of soluble guanylate cyclase in neurons and in lymphocytes: a putative peripheral marker for neurological alterations. Miñana MD, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):405-9

Hyperlactatemia and pulmonary lactate production in patients with fulminant hepatic failure. Walsh TS, et al. **Chest** 1999 Aug;116(2):471-6

Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy. Wikell C, et al. **Clin Neuropharmacol** 1998 Sep-Oct;21(5):296-306

Changes in the extracellular profiles of neuroactive amino acids in the rat striatum at the asymptomatic stage of hepatic failure. Hilgier W, et al. **J Neurosci Res** 1999 Apr 1;56(1):76-84

N-methyl-D-aspartate-evoked changes in the striatal extracellular levels of dopamine and its metabolites in vivo in rats with acute hepatic encephalopathy. Borkowska HD, et al. **Neurosci Lett** 1999 Jun 25;268(3):151-4

Ionotropic glutamate receptors and dopamine release in the frontal cortex in experimental hepatic encephalopathy. Borkowska HD, et al. **Proc West Pharmacol Soc** 1998; 41:107-9

18F-fluorodeoxyglucose positron emission tomography study of brain metabolism in cirrhosis: effect of liver transplantation. Burra P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):418-20

[Changes in gamma-amino-butyric acid and N-methyl-D-aspartic acid receptor-gated currents from freshly isolated hippocampal CA1 pyramidal neurons of hepatic encephalopathy rats] Zhang Z, et al.
Chung Hua I Hsueh Tsa Chih 1997 Jun;77(6):439-42 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Strauss E, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):900-4

Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. Vásconez C, et al. **J Hepatol** 1999 Feb;30(2):260-4

PATHOLOGY

Subclinical portal-systemic encephalopathy in a child with congenital absence of the portal vein. Wakamoto H, et al. **Brain Dev** 1999 Sep;21(6):425-8

[Hepatocyte dysfunction and apoptosis] Hayashi N, et al.
Nippon Naika Gakkai Zasshi 1999 Apr 10;88(4):659-63 (5 ref.) **(Jpn)**

[Serial hepatic and splenic volumetry in acute severe hepatitis] Obuchi M, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 Feb;96(2):147-53 (Eng. Abstr.) **(Jpn)**

[High intensity signal in basal ganglia on T1 weighted images: case report in Manson's Schistosomiasis with portal systemic encephalopathy] Machado Júnior MA, et al.
Arq Neuropsiquiatr 1999 Jun;57(2A):306-10 (39 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Proton magnetic resonance spectroscopy (1H-MRS) findings for the brain in patients with liver cirrhosis reflect the hepatic functional reserve. Lee JH, et al.
Am J Gastroenterol 1999 Aug;94(8):2206-13

Spectral versus visual EEG analysis in mild hepatic encephalopathy. Amodio P, et al. **Clin Neurophysiol** 1999 Aug;110(8):1334-44

Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. Yoneyama H, et al.
J Clin Invest 1998 Dec 1;102(11):1933-41

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G. Inoue K, et al. **J Hepatol** 1999 May;30(5):801-6

Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. Vásconez C, et al. **J Hepatol** 1999 Feb;30(2):260-4

Role of tryptophan in the elevated serotonin-turnover in hepatic encephalopathy. Herneth AM, et al.
J Neural Transm 1998;105(8-9):975-86

Astroglial dysfunction in hepatic encephalopathy. Norenberg MD. **Metab Brain Dis** 1998 Dec;13(4):319-35 (149 ref.)

The basal ganglia and portal-systemic encephalopathy. Weissenborn K, et al. **Metab Brain Dis** 1998 Dec; 13(4):261-72 (50 ref.)

[Fulminant hepatitis: description of its physiopathology] Fujiwara K, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):632-9 (46 ref.) **(Jpn)**

[Portal hemodynamics, collateral venous circulation and encephalopathy in patients with esophageal and gastric varices in liver cirrhosis] Kotenko OG. **Klin Khir** 1998; (11):7-9 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

The hydroxyl radical scavengers dimethylsulfoxide and dimethylthiourea protect rats against thioacetamide-induced fulminant hepatic failure. Bruck R, et al. **J Hepatol** 1999 Jul;31(1):27-38

PSYCHOLOGY

Neuropsychiatric condition must be thoroughly assessed before treatment of hepatic encephalopathy [letter] Lewis MB. **BMJ** 1999 Aug 14;319(7207):455

Neuropsychological aspects of portal-systemic encephalopathy. Schomerus H, et al. **Metab Brain Dis** 1998 Dec;13(4):361-77

Psychiatric aspects of portal-systemic encephalopathy. Wiltfang J, et al. **Metab Brain Dis** 1998 Dec;13(4):379-89 (65 ref.)

RADIONUCLIDE IMAGING

Tc-99m HMPAO brain perfusion SPECT images in a patient with portal-systemic encephalopathy. Ohta H, et al.
Clin Nucl Med 1998 Sep;23(9):634-6

Positron emission tomography in the study of hepatic encephalopathy. Lockwood AH. **Metab Brain Dis** 1998 Dec;13(4):303-9 (12 ref.)

SURGERY

Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Egawa H, et al. **Liver Transpl Surg** 1998 Nov;4(6):513-5

Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Feranchak AP, et al. **Liver Transpl Surg** 1998 Nov;4(6):469-76 (39 ref.)

Successful surgical treatment for hepatic encephalopathy caused by a pancreatic siphon: report of a case. Nozaki H, et al. **Surg Today** 1998;28(10):1069-72

ABO-incompatible living related liver transplantation for fulminant hepatitis: report of a successful pediatric case with long-term follow-up. Hashimoto T, et al.
Transplant Proc 1998 Nov;30(7):3510-2

Auxiliary orthotopic xenogeneic liver transplantation using pigs for fulminant hepatic failure: with special reference to the technique and immunosuppression. Hayashi S, et al. **Transplant Proc** 1998 Nov;30(7):3836

Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Kalicinski P, et al.
Transplant Proc 1999 Feb-Mar;31(1-2):378-9

Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. Vizuete SG, et al.
Transplant Proc 1999 Sep;31(6):2461-3

Artificial liver. Watanabe FD, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):371-3

[Fulminant hepatitis: liver transplantation] Tanaka K, et al.
Nippon Naika Gakkai Zasshi 1999 Apr 10;88(4):653-8 (5 ref.) **(Jpn)**

[Disappearance of globus pallidus hyperintensity in a patient with portal-systemic encephalopathy after occlusion of the shunt vessel] Taguchi Y, et al. **Rinsho Shinkeigaku** 1999 May;39(5):565-9 (Eng. Abstr.) **(Jpn)**

THERAPY

Management of fulminant hepatic failure. Detry O, et al.
Acta Chir Belg 1998 Dec;98(6):235-40 (52 ref.)

Oxygen delivery to and use by primary porcine hepatocytes in the HepatAssist 2000 system for extracorporeal treatment of patients in end-stage liver failure. Custer L, et al.
Adv Exp Med Biol 1998;454:261-71

Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Detry O, et al. **Am Surg** 1999 Oct;65(10):934-8

Hyperbaric oxygenation, plasma exchange, and hemodialysis for treatment of acute liver failure in a 3-year-old child. Ponikvar R, et al. **Artif Organs** 1998 Nov;22(11):952-7

Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Huang JL, et al.
Clin Rheumatol 1998;17(4):349-52

Management of acute liver failure. Herrera JL. **Dig Dis** 1998 Sep-Oct;16(5):274-83 (90 ref.)

Control of solitary gastric fundal varices and portosystemic encephalopathy accompanying liver cirrhosis by balloon-occluded retrograde transvenous obliteration (B-RTO): a case report. Ohmoto K, et al.
Hepatogastroenterology 1999 Mar-Apr;46(26):1249-52

Does the extend of the culture time of primary hepatocytes in a bioreactor affect the treatment efficacy of a bioartificial liver? Flendrig LM, et al. **Int J Artif Organs** 1998 Sep; 21(9):542-7

Bioartificial liver treatment in rats with fulminant hepatic failure: effect on DNA-binding activity of liver-enriched and growth-associated transcription factors. Suh KS, et al. **J Surg Res** 1999 Aug;85(2):243-50

Portal-systemic encephalopathy from a spontaneous gastrorenal shunt diagnosed by three-dimensional computed tomography and treated effectively by percutaneous vascular embolization. Kuramitsu T, et al.
Liver 1998 Jun;18(3):208-12

Nutritional support in hepatic encephalopathy. Mizock BA.
Nutrition 1999 Mar;15(3):220-8 (134 ref.)

Conventional care of fulminant hepatic failure: medical and surgical aspects [editorial] Hassanein TI, et al.
Ther Apher 1997 Feb;1(1):33-7 (22 ref.)

Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Seige M, et al.
Transplant Proc 1999 Feb-Mar;31(1-2):1371-5

Intracranial pressure during liver transplantation for fulminant hepatic failure. Detry O, et al.
Transplantation 1999 Mar 15;67(5):767-70

[Liver support effect of experimental extracorporeal bioartificial liver] Wang Y, et al.
Chung Hua Kan Tsang Ping Tsa Chih 1999 Mar;7(1):31-3 (Eng. Abstr.) **(Chi)**

[Therapy of acute and chronic hepatic encephalopathy in patients with liver cirrhosis] Ferenci P. **Z Gastroenterol** 1998 Oct;36(10):909-16 (37 ref.) **(Ger)**

[Liver protection and liver transplantation from a living donor for the treatment of acute hepatic failure] Inaba S.
Masui 1998 Dec;47 Suppl:S235-9 **(Jpn)**

[Refractory liver diseases: progress in treatment. Discussion] Omata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):670-87 **(Jpn)**

[Fulminant hepatitis: progress and the current status of treatment] Yoshiba M. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):647-52 (19 ref.) **(Jpn)**

ULTRASONOGRAPHY

The value of serial Doppler ultrasound as a predictor of clinical outcome and the need for transplantation in fulminant and severe acute liver failure. Deasy NP, et al.
Br J Radiol 1999 Feb;72(854):134-43

VETERINARY

Hepatic encephalopathy associated with paratuberculosis in a goat. Rubin JL, et al. **J Am Vet Med Assoc** 1999 Jul 15;215(2):236-8, 211

Fast resolution of hypercortisolism in dogs with portosystemic encephalopathy after surgical shunt closure. Sterczer A, et al. **Res Vet Sci** 1999 Feb;66(1):63-7

Evaluation of ammonia measurements in dogs with two analysers for use in veterinary practice. Sterczer A, et al.
Vet Rec 1999 May 8;144(19):523-6

Complete ligation of extrahepatic congenital portosystemic shunts in nonencephalopathic dogs. Harvey J, et al.
Vet Surg 1998 Sep-Oct;27(5):413-6

VIROLOGY

The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Muñoz SJ, et al. **Blood** 1999 Aug 15; 94(4):1460-4

Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products [published erratum appears in Gut 1999 Jun;44(6):898] Halasz R, et al. **Gut** 1999 Feb;44(2):274-8

Functional analysis of HBV genomes from patients with fulminant hepatitis. Sterneck M, et al. **Hepatology** 1998 Nov;28(5):1390-7

Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. Liu CJ, et al.
J Gastroenterol Hepatol 1999 Apr;14(4):352-7

Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. Madan K, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):125-30

The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. Sergi C, et al. **J Hepatol** 1998 Dec;29(6):861-71

No evidence of hepatitis G virus in fulminant hepatic failure in children. Perez RG, et al.
J Pediatr Gastroenterol Nutr 1999 Apr;28(4):400-3

Hepatitis G virus infection in acute fulminant hepatitis: prevalence of HGV infection and sequence analysis of a specific viral strain. Sheng L, et al. **J Viral Hepat** 1998 Sep;5(5):301-6

Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children [see comments] Sokal EM, et al. **Lancet** 1998 Nov 28; 352(9142):1739-41. Comment in: Lancet 1999 Feb 27;353(9154):753-4. Comment in: Lancet 1999 Feb 27;353(9154):754-5.

[Detection of HGV RNA in sera from patients with fulminant hepatitis in Shenyang] Shu B, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1998 Jun; 19(3):168-9 (Eng. Abstr.) **(Chi)**

[Fatal fulminating hepatitis due to Herpes simplex virus type

2 in a young immunocompetent female] Chauveau E, et al. **Med Trop (Mars)** 1999;59(1):58–60 (Eng. Abstr.) **(Fre)**

[Fulminant hepatitis and viral mutation] Yatsuhashi H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):664–9 (5 ref.) **(Jpn)**

HEPATIC ENTAMOEBIASIS see **LIVER ABSCESS, AMEBIC**

HEPATIC FAILURE, FULMINANT see **HEPATIC ENCEPHALOPATHY**

HEPATIC GLYCOGEN see **LIVER GLYCOGEN**

HEPATIC PORPHYRIA see **PORPHYRIA, HEPATIC**

HEPATIC PORTOENTEROSTOMY see **PORTOENTEROSTOMY, HEPATIC**

HEPATIC TRANSPLANTATION see **LIVER TRANSPLANTATION**

HEPATIC VEIN THROMBOSIS

Proposal of a new nomenclature for Budd–Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Okuda K, et al. **Hepatology** 1998 Nov;28(5):1191–8 (105 ref.)

Budd–Chiari syndrome in early pregnancy. Pérez J, et al. **P R Health Sci J** 1998 Sep;17(3):285–7

Hepatic venous outflow obstruction. Pande GK, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):82–95 (137 ref.)

[Pathophysiology and therapy of patients with Budd–Chiari syndrome] Hashizume M. **Fukuoka Igaku Zasshi** 1999 Jan; 90(1):1–5 (7 ref.) **(Jpn)**

COMPLICATIONS

Results of surgical treatment (modified Sugiura–Futagawa operation) of portal hypertension associated to complete splenomesoportal thrombosis and cirrhosis. Mercado MA, et al. **HPB Surg** 1999;11(3):157–62

Hepatocellular carcinoma [letter; comment] Kashyap AS, et al. **Lancet** 1999 Jul 17;354(9174):253. Comment on: Lancet 1999 Apr 10;353(9160):1253–7.

Spontaneous bacterial peritonitis by Campylobacter fetus in Budd–Chiari syndrome without liver cirrhosis [letter] Barrio J, et al. **Liver** 1999 Feb;19(1):69–70

Primary liver carcinoma complicating membranous obstruction of the inferior vena cava. Katoh M, et al. **Pathol Int** 1999 Mar;49(3):253–7

Superior sagittal sinus and inferior vena cava thrombosis with acute Budd–Chiari syndrome. Kakar A, et al. **Postgrad Med J** 1998 Sep;74(875):557–9

DIAGNOSIS

Budd–Chiari syndrome: blocked veins, open mind [comment] Patch D, et al. **Gut** 1999 Apr;44(4):452–3. Comment on: Gut 1999 Apr;44(4):568–74.

Clinical features, image analysis, and laparoscopic and histological liver findings in Budd–Chiari syndrome. Iwai M, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2359–68

SCVIR Annual Meeting Film Panel Session: case 4. Polycythemic rubra vera and Budd–Chiari syndrome. Society of Cardiovascular & Interventional Radiology. LaBerge JM, et al. **J Vasc Interv Radiol** 1999 Apr; 10(4):514–8

Hepatic nodules in Budd–Chiari syndrome: imaging features. Vilgrain V, et al. **Radiology** 1999 Feb;210(2):443–50

[The Budd–Chiari syndrome (hepatic vein obstruction). The diagnostic and therapeutic management of acute and subacute forms] Dumortier J, et al. **Presse Med** 1999 Apr 17;28(15):802–8 (74 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic veno–occlusive disease--a growing clinical problem] Swieboda A, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):365–72 (17 ref.) **(Pol)**

[The Budd–Chiari syndrome coinciding with a hemolytic crisis in a patient with paroxysmal nocturnal hemoglobinuria (letter)] Jiménez Marco M, et al. **Rev Clin Esp** 1999 Jan;199(1):50–1 (9 ref.) **(Spa)**

DRUG THERAPY

Budd–Chiari syndrome following repair of a giant omphalocele. Kaabachi O, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):371–2

EPIDEMIOLOGY

Three new diseases listed for Japanese research on their treatment [news] **Front Med Biol Eng** 1999;9(1):93

ETIOLOGY

Budd–Chiari syndrome: hepatic venous obstruction by an elevated diaphragm. Kim PN, et al. **Abdom Imaging** 1999 May–Jun;24(3):267–71

Budd–Chiari syndrome complicating restorative proctocolectomy for ulcerative colitis: report of a case. Whiteford MH, et al. **Dis Colon Rectum** 1999 Sep; 42(9):1220–4 (15 ref.)

Budd–Chiari syndrome following repair of a giant omphalocele. Kaabachi O, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):371–2

Surgical treatment of renal cell carcinoma associated with Budd–Chiari syndrome: report of four cases and review of the literature. Kume H, et al. **Eur J Surg Oncol** 1999 Feb;25(1):71–5 (15 ref.)

Budd–Chiari syndrome caused by Behçet's disease: treatment by side–to–side portacaval shunt. Orloff LA, et al. **J Am Coll Surg** 1999 Apr;188(4):396–407 (65 ref.)

Gastrointestinal case of the day. Primary leiomyosarcoma of the IVC with Budd–Chiari syndrome. Reuther WL 3rd, et al. **Radiographics** 1999 Jan–Feb;19(1):248–51

Endovascular treatment of hepatic venous outflow obstruction after piggyback technique liver transplantation. Sze DY, et al. **Transplantation** 1999 Aug 15;68(3):446–9

[Budd–Chiari syndrome due to membranous obstruction of the inferior vena cava of congenital origin. Ten–year follow–up after radiologic treatment] Croquet V, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):259–63 (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy using r–TPA in Budd–Chiari syndrome in the course of myeloproliferative diseases] Casciaro S, et al. **Minerva Cardioangiol** 1998 Jul–Aug; 46(7–8):241–53 (Eng. Abstr.) **(Ita)**

[Budd–Chiari syndrome and primary myelofibrosis (letter)] Marchante Cepillo I, et al. **Sangre (Barc)** 1998 Jun; 43(3):264–5 **(Spa)**

GENETICS

Budd–Chiari syndrome associated with homozygous factor V Leiden mutation [letter; comment] Garewal G, et al. **Br J Haematol** 1999 Jun;105(3):842. Comment on: Br J Haematol 1998 Sep;102(4):929–31.

Portal and mesenteric venous thrombosis in a patient heterozygous for the 20210 A allele of the prothrombin gene [letter] Zuazu–Jausoro I, et al. **Haematologica** 1998 Dec;83(12):1129–30

Homozygous factor V Leiden mutation in a child with Budd–Chiari syndrome. Gürakan F, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):516–7

Budd–Chiari syndrome associated with factor V leiden mutation: a report of 6 patients. Hoffman R, et al. **Liver Transpl Surg** 1999 Mar;5(2):96–100

Hepatic vein thrombosis in a patient with mutant prothrombin 20210A allele [letter] De Stefano V, et al. **Thromb Haemost** 1998 Sep;80(3):519

IMMUNOLOGY

Anticardiolipin antibody levels in patients with Budd–Chiari syndrome [letter; comment] Yarze JC. **Am J Gastroenterol** 1999 Jan;94(1):290. Comment on: Am J Gastroenterol 1998 Jun;93(6):954–7.

PATHOLOGY

Epithelioid hemangioendothelioma with marked liver deformity and secondary Budd–Chiari syndrome: pathological and radiological correlation. Hayashi Y, et al. **Pathol Int** 1999 Jun;49(6):547–52

[Syringomyelia and Chiari abnormality in the adult. Analysis of the results of a cooperative series of 285 cases] Aghakhani N, et al. **Neurochirurgie** 1999 Jun;45 Suppl 1:23–36 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Images of interest. Hepatobiliary and pancreatic patient: thread–like vessels in an arteriogram. Takaysau K, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):103; discussion 104

Images in Hepatology. Liver abscesses with bilioportal fistula. Skelly MM, et al. **J Hepatol** 1999 Aug;31(2):365

[Diagnosis and therapy of Budd–Chiari syndrome] Bachmann R, et al. **Aktuelle Radiol** 1998 Sep;8(5):213–9 (38 ref.) (Eng. Abstr.) **(Ger)**

[Budd–Chiari syndrome: retrospective study of 8 cases assessed with computerized tomography] Giovine S, et al. **Radiol Med (Torino)** 1998 Oct;96(4):339–43 (Eng. Abstr.) **(Ita)**

SURGERY

Transjugular intrahepatic portosystemic shunt (TIPS) for Budd–Chiari syndrome or portal vein thrombosis: review of indications and problems [see comments] Ganger DR, et al. **Am J Gastroenterol** 1999 Mar;94(3):603–8. Comment in: Am J Gastroenterol 1999 Mar;94(3):559–61.

Budd–Chiari syndrome: is TIPS tops? [editorial; comment] Sanyal AJ. **Am J Gastroenterol** 1999 Mar;94(3):559–61. Comment on: Am J Gastroenterol 1999 Mar;94(3):603–8.

Hepatoatrial anastomosis and tricuspid valve replacement in Budd–Chiari syndrome 8. Chiu CK, et al. **Ann Thorac Surg** 1998 Nov;66(5):1803–4

Radical surgery for Budd–Chiari syndrome. Direct excision and repair for obstruction of the vena cava (Budd–Chiari syndrome) under hepatic vascular exclusion using a centrifugal pump. Takano S, et al. **Eur J Surg** 1999 Jul; 165(7):632–7

Budd–Chiari syndrome. Treatment options and the value of liver transplantation. Kugelmas M. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1381–6

Recurrence of the Budd–Chiari syndrome after orthotopic liver transplantation. Rückert JC, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):867–71

Budd–Chiari syndrome: shunt or transplant? Orloff MJ. **HPB Surg** 1998;11(2):136–9

Surgical treatment of Budd–Chiari syndrome [editorial; comment] Chawla Y, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):57–9 (29 ref.). Comment on: Indian J Gastroenterol 1999 Apr–Jun;18(2):60–2.

Surgical management of the Budd–Chiari syndrome: early experience [see comments] Shah SR, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):60–2. Comment in: Indian J Gastroenterol 1999 Apr–Jun;18(2):57–9.

Budd–Chiari syndrome caused by Behçet's disease: treatment by side–to–side portacaval shunt. Orloff LA, et al. **J Am Coll Surg** 1999 Apr;188(4):396–407 (65 ref.)

Successful pregnancy following orthotopic liver transplantation for idiopathic Budd–Chiari syndrome. Ramsey PS, et al. **J Matern Fetal Med** 1998 Sep–Oct; 7(5):235–7

Role of TIPS as a bridge to hepatic transplantation in Budd–Chiari syndrome. Ryu RK, et al. **J Vasc Interv Radiol** 1999 Jun;10(6):799–805

Successful treatment of hepatic vein thrombosis following reduced–size liver transplantation. Chen YS, et al. **Transplant Proc** 1998 Nov;30(7):3203–4

[Porto–systemic shunts in Budd–Chiari syndrome with inferior vena cava obstruction] Trabelsi O, et al. **Tunis Med** 1998 Nov;76(11):412–6 **(Fre)**

[Treatment of advanced Budd–Chiari syndrome by liver transplantation] Knoop M, et al. **Chirurg** 1998 Dec; 69(12):1362–8 (Eng. Abstr.) **(Ger)**

[An iliac–mesenteric–atrial shunt in the Budd–Chiari syndrome with extensive thrombosis of the inferior vena cava] Bancu S, et al. **Chirurgia (Bucur)** 1998 May–Jun; 93(3):165–9 (7 ref.) (Eng. Abstr.) **(Rum)**

[Budd–Chiari syndrome: current medical–surgical management] Jiménez Romero C, et al. **Rev Esp Enferm Dig** 1998 Nov;90(11):813–7 (Eng. Abstr.) **(Spa)**

THERAPY

Managing Budd–Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting [see comments] Fisher NC, et al. **Gut** 1999 Apr; 44(4):568–74. Comment in: Gut 1999 Apr;44(4):452–3.

Outcome of Budd–Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Zeitoun G, et al. **Hepatology** 1999 Jul;30(1):84–9

Ultrasonically guided percutaneous transhepatic hepatic vein stent placement for Budd–Chiari syndrome. Chunqing Z, et al. **J Vasc Interv Radiol** 1999 Jul–Aug;10(7):933–40

A case of Budd–Chiari syndrome successfully treated by transcatheter recanalization of the right hepatic vein and transjugular intrahepatic portosystemic shunt. Yamada K, et al. **Radiat Med** 1999 Jan–Feb;17(1):85–9

Endovascular treatment of hepatic venous outflow obstruction after piggyback technique liver transplantation. Sze DY, et al. **Transplantation** 1999 Aug 15;68(3):446–9

Budd–Chiari syndrome in a patient with factor V Leiden--successful treatment by TIPSS placement followed by liver transplantation. Avenhaus W, et al. **Z Gastroenterol** 1999 Apr;37(4):277–81

[The Budd–Chiari syndrome (hepatic vein obstruction). The diagnostic and therapeutic management of acute and subacute forms] Dumortier J, et al. **Presse Med** 1999 Apr 17;28(15):802–8 (74 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic veno–occlusive disease--a growing clinical problem] Swieboda A, et al. **Pol Arch Med Wewn** 1998 Oct;100(4):365–72 (17 ref.) **(Pol)**

[A case of right hepatic vein stenosis in an adult] Olearchyk AS. **Klin Khir** 1999;(6):45–7 **(Ukr)**

ULTRASONOGRAPHY

[Duplex ultrasound of the liver and portal vein system] Mohr HH, et al. **Med Klin** 1998 Nov 15;93(11):669–77 (72 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Percutaneous treatment of caval obstruction and Budd–Chiari syndrome in a cat. Haskal ZJ, et al. **J Vasc Interv Radiol** 1999 Apr;10(4):487–9

HEPATIC VEINS

see related

LIVER CIRCULATION

Repetitive percutaneous transhepatic access for myocardial biopsy in pediatric cardiac transplant recipients. Book WM, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):167–9

Transhepatic access: coming of age [editorial; comment] Johnston TA, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):46. Comment on: Catheter Cardiovasc Interv 1999 May;47(1):41–5.

Transhepatic therapeutic cardiac catheterization: a new option for the pediatric interventionalist [see comments] Shim D, et al. **Catheter Cardiovasc Interv** 1999 May; 47(1):41–5. Comment in: Catheter Cardiovasc Interv 1999 May;47(1):46.

Development of a percutaneous fiberoptic hepatic venous localization catheter [see comments] Dahn MS, et al. **Crit Care Med** 1999 Aug;27(8):1598–602. Comment in: Crit Care Med 1999 Aug;27(8):1680–1.

HEPATIC VEINS

Why, when, and how to insert a hepatic vein catheter in critically ill patients [editorial; comment] De Backer D, et al. **Crit Care Med** 1999 Aug;27(8):1680-1 (16 ref.). Comment on: Crit Care Med 1999 Aug;27(8):1598-16-2.

Umbilical venous catheterization and development of Banti syndrome: the possible role of the factor V Leiden mutation [letter] Stankovics J, et al. **Eur J Pediatr** 1998 Aug; 157(8):696

Transcatheter occlusion of a post-Fontan residual hepatic vein to pulmonary venous atrium communication using the Amplatzer septal occluder. Tofeig M, et al. **Heart** 1998 Jun;79(6):624-6

Left extended hemihepatectomy with preservation of large inferior right hepatic vein: a case report. Texler ML, et al. **HPB Surg** 1999;11(4):265-9; discussion 269-70

Effect of temporary hepatic venous occlusion on hepatic arterial embolization. An experimental study. Horio K, et al. **Invest Radiol** 1999 May;34(5):341-7

Hepatic vein catheterization: a new technique in rats. Palmes D, et al. **J Invest Surg** 1998 Mar-Apr;11(2):147-51

Ultrasonically guided percutaneous transhepatic hepatic vein stent placement for Budd-Chiari syndrome. Chunqing Z, et al. **J Vasc Interv Radiol** 1999 Jul-Aug;10(7):933-40

Hepatic microcirculation during transient hepatic venous occlusion--intravital microscopic observation using hepatic vein clamp model in the mouse. Yamashita C, et al. **Kobe J Med Sci** 1998 Dec;44(5-6):199-203

Whole blood and plasma amino acid transfers across the portal drained viscera and liver of the pig. Le Floc'h N, et al. **Reprod Nutr Dev** 1999 Jul-Aug;39(4):433-42

Early evaluation of graft viability using hepatic venous oxygen saturation in pig liver transplantation. Katsuramaki T, et al. **Transplant Proc** 1998 Nov;30(7):3748-9

[A case of gas occurrence in the venous hepato-portal area after blunt trauma of the abdomen] Torriero F, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):118-20 (6 ref.) **(Ita)**

ABNORMALITIES

Intrahepatic venovenous shunting to an accessory hepatic vein after Fontan type operation. Yoshimura N, et al. **Ann Thorac Surg** 1999 May;67(5):1494-6

Congenital intrahepatic portosystemic shunt. Florio F, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):421-4 (11 ref.)

Re: Intrahepatic portosystemic shunt [letter] Schiller VL, et al. **Cardiovasc Intervent Radiol** 1999 Jul-Aug;22(4):351

Inferior vena cava hypoplasia with intrahepatic venous continuation: sonographic, angiographic and MR features including MR angiography. Chevallier P, et al. **Clin Imaging** 1999 Mar-Apr;23(2):99-102

Transcatheter embolization of symptomatic hepatic venous malformations. Görriz E, et al. **Eur Radiol** 1998;8(8):1416-9

Intrahepatic bilomas associated with hepatic arteriovenous malformation. Chen CH, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):443-7

Osler-Rendu-Weber with liver involvement. Goris H, et al. **J Belge Radiol** 1998 Aug;81(4):184-5

Images in clinical radiology. Spontaneous intrahepatic portohepatic shunt and focal nodular hyperplasia. Materne R, et al. **J Belge Radiol** 1998 Aug;81(4):180

Case report: intrahepatic portal-hepatic venous shunts associated with a huge pelvic leiomyoma. Aiba N, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):158-62

Successful coil embolization in an infant with congenital intrahepatic portosystemic shunts. Ikeda S, et al. **J Pediatr Surg** 1999 Jun;34(6):1031-2

Obstructed infracardiac total anomalous pulmonary venous connection in an adult. Juneja R, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):152-4

Hereditary hemorrhagic telangiectasia: effective protocol for embolization of hepatic vascular malformations--experience in five patients. Chavan A, et al. **Radiology** 1998 Dec;209(3):735-9

ANATOMY & HISTOLOGY

Identification of segments VI and VII of the liver based on the ramification patterns of the intrahepatic portal and hepatic veins. Hata F, et al. **Clin Anat** 1999;12(4):229-44

The cystic vein: the significance of a forgotten anatomic landmark. Fine A. **J Soc Laparoendosc Surg** 1997 Jul-Sep; 1(3):263-6

Configuration of hepatic veins in the right surgical lobe of the human liver with special reference to their complementary territorial relationships: morphometric analysis of controlled specimens with clearly defined portal segmentation. Hata F, et al. **Okajimas Folia Anat Jpn** 1999 May;76(1):1-16

Anatomy of the common trunk of the middle and left hepatic veins: application to liver transplantation. Wind P, et al. **Surg Radiol Anat** 1999;21(1):17-21

Magnetic resonance of the hepatic veins with angular reconstruction: application in living-related liver transplantation. Cheng YF, et al. **Transplantation** 1999 Jul 27;68(2):267-71

DRUG EFFECTS

Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. Jenkins SA, et al. **HPB Surg** 1998;11(1):13-21

EMBRYOLOGY

Intrahepatic vein fetal blood sampling: current role in prenatal diagnosis. Chinnaiya A, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):239-46

PATHOLOGY

Safety of selective vascular clamping for major hepatectomies. Malassagne B, et al. **J Am Coll Surg** 1998 Nov;187(5):482-6

Hepatic veno-occlusive disease in ataxia-telangiectasia. Srisiririojanakorn N, et al. **J Pediatr** 1999 Jun;134(6):786-8

[A case of right hepatic vein stenosis in an adult] Olearchyk AS. **Klin Khir** 1999;(6):45-7 **(Ukr)**

PHYSIOLOGY

Difference in hepatic tissue oxygenation between total vascular exclusion and inflow occlusion of the liver and the possible role of hepatic venous blood under liver ischemia. Sato T, et al. **Dig Surg** 1998;15(1):15-20

Ultrastructural study on the venous sphincter in the sublobular vein of the canine liver. Yamamoto K. **Microvasc Res** 1998 May;55(3):215-22

PHYSIOPATHOLOGY

Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection. Deplano A, et al. **Dig Dis Sci** 1999 Jan;44(1):155-62

RADIATION EFFECTS

Intraluminal irradiation for TIPS stenosis: preliminary results in a swine model. Lessie T, et al. **J Vasc Interv Radiol** 1999 Jul-Aug;10(7):899-906

RADIOGRAPHY

Hepatic and portal surface veins: a new anatomic variant revealed during abdominal CT. Sheporaitis L, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1559-64

Hepatic portal venous gas in a critically ill patient. Venkatesh B, et al. **Anaesth Intensive Care** 1998 Oct;26(5):575-8

Hepatobiliary and pancreatic: patient. Okuda K, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):970, 972-3

Wedged hepatic venography with biplane digital subtraction imaging to facilitate accessing the portal venous system for TIPS [letter] Borge MA, et al. **J Vasc Interv Radiol** 1998 Sep-Oct;9(5):853-4

Helical CT angiography of transjugular intrahepatic portosystemic shunts. Chopra S, et al. **Semin Ultrasound CT MR** 1999 Feb;20(1):25-35 (21 ref.)

[Angiographic study of the hepatic venous system with pressure gradient: basic evaluation or superfluous imposition (editorial)] D'Albuquerque LA, et al. **Arq Gastroenterol** 1998 Jul-Sep;35(3):153-6 **(Por)**

[Angiographic aspects of the hepatic veins in portal hypertension in schistosomiasis. The importance in assessing the hepatic vein pressure] Widman A, et al. **Arq Gastroenterol** 1998 Jul-Sep;35(3):157-63 (Eng. Abstr.) **(Por)**

SURGERY

Reconstruction of the hepatic and portal veins using a patch graft from the right ovarian vein. Kubota K, et al. **Am J Surg** 1998 Sep;176(3):295-7

Clinicopathologic effects of cryotherapy on hepatic vessels and bile ducts in a porcine model. Kahlenberg MS, et al. **Ann Surg Oncol** 1998 Dec;5(8):713-8

Hepatic vein to the azygous vein anastomosis for pulmonary arteriovenous fistulae. Baskett RJ, et al. **Ann Thorac Surg** 1999 Jul;68(1):232-3

Radical surgery for Budd-Chiari syndrome. Direct excision and repair for obstruction of the vena cava (Budd-Chiari syndrome) under hepatic vascular exclusion using a centrifugal pump. Takano S, et al. **Eur J Surg** 1999 Jul; 165(7):632-7

Mixed hepatocellular carcinoma and cholangiocarcinoma treated by extended left hepatic lobectomy with resection of the right hepatic vein and preservation of the inferior right hepatic vein after hepatic arterial infusion chemotherapy. Hanazaki K, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):812-5

Hepatic vein reconstruction at inferior vena cava confluence using left renal vein graft. Ohwada S, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1833-6

Extended hepatectomy with ePTFE graft vena caval replacement and hepatic vein reconstruction: a case report. Ohwada S, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1151-5

A new technique of hepatic vein reconstruction in living related liver transplantation. Takano S, et al. **Int Surg** 1998 Oct-Dec;83(4):324-6

Combined right hepatic and retrohepatic caval resection with reconstruction using a polytetrafluoroethylene graft for primary leiomyosarcoma of the liver: report of case. Enoki T, et al. **Surg Today** 1999;29(1):67-70

Cross-clamping of the three hepatic veins in the piggyback technique is a safe and well tolerated procedure. Margarit C, et al. **Transpl Int** 1998;11 Suppl 1:S248-50

Hemodynamic consequences of portal and lateral clamping of the inferior vena cava during liver transplantation. Acosta F, et al. **Transplant Proc** 1999 Sep;31(6):2413-4

Venoplasty of recipient hepatic veins in living-related liver transplantation. Harihara Y, et al. **Transplant Proc** 1998 Nov;30(7):3205

Complications related to hepatic venous outflow in piggy-back liver transplantation: two- versus three-suprahepatic-vein anastomosis. Robles R, et al. **Transplant Proc** 1999 Sep;31(6):2390-1

ULTRASONOGRAPHY

Evaluation of hepatic venous pulsatility and portal venous velocity with Doppler ultrasonography during the puerperium. Pekindil G, et al. **Eur J Radiol** 1999 Mar; 29(3):266-9

Improved investigation of portal-hepatic veins by echo-enhanced Doppler sonography. Fischer G, et al. **Ultrasound Med Biol** 1998 Nov;24(9):1345-9

ULTRASTRUCTURE

Ultrastructural study on the venous sphincter in the sublobular vein of the canine liver. Yamamoto K. **Microvasc Res** 1998 May;55(3):215-22

Spiral structures in the wall of the hepatic venous system in the dog. Okada S, et al. **Scanning Microsc** 1996; 10(3):851-8

HEPATIC VENO-OCCLUSIVE DISEASE

see related
HEPATIC VEIN THROMBOSIS

Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Richardson P, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):267-77 (86 ref.)

Hepatic venous outflow obstruction. Pande GK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):82-95 (137 ref.)

BLOOD

Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Lee JH, et al. **Bone Marrow Transplant** 1998 Nov; 22(9):883-8

Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver. Oh H, et al. **Bone Marrow Transplant** 1998 Oct;22(7):675-9

IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Ferrà C, et al. **Haematologica** 1998 Dec;83(12):1082-7

The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Salat C, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):25-32 (29 ref.)

CHEMICALLY INDUCED

Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation [see comments] Hägglund H, et al. **Blood** 1998 Dec 15;92(12):4568-72. Comment in: Blood 1999 May 1;93(9):3154.

Successful treatment of severe azathioprine-induced hepatic veno-occlusive disease in a kidney-transplanted patient with transjugular intrahepatic portosystemic shunt. Azoulay D, et al. **Clin Nephrol** 1998 Aug;50(2):118-22 (29 ref.)

Veno-occlusive disease of the liver in right-sided Wilms' tumours [see comments] Tornesello A, et al. **Eur J Cancer** 1998 Jul;34(8):1220-3 (21 ref.). Comment in: Eur J Cancer 1998 Jul;34(8):1145-7. Comment in: Eur J Cancer 1999 Mar;35(3):521-3.

[Veno-occlusive disease after prolonged treatment with senecionine (Hemoluol) (letter)] Bensaude RJ, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):363-4 **(Fre)**

[Veno-occlusive disease of the liver and POEMS syndrome] Andrès E, et al. **Presse Med** 1999 Feb 20;28(7):334-6 (Eng. Abstr.) **(Fre)**

[Veno-occlusive disease following chronic ingestion of drugs containing senecio (letter)] Radal M, et al. **Therapie** 1998 Sep-Oct;53(5):509-11 **(Fre)**

COMPLICATIONS

Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Ishida Y, et al. **Intern Med** 1998 Aug;37(8):694-9

The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Salat C, et al. **Leuk Lymphoma** 1999 Mar;33(1-2):25-32 (29 ref.)

DIAGNOSIS

Budd-Chiari syndrome: blocked veins, open mind [comment] Patch D, et al. **Gut** 1999 Apr;44(4):452-3. Comment on: Gut 1999 Apr;44(4):568-74.

DRUG THERAPY

Defibrotide as salvage therapy for refractory veno-occlusive

disease of the liver complicating allogeneic bone marrow transplantation. Abecasis MM, et al. **Bone Marrow Transplant** 1999 Apr;23(8):843–6

Recombinant human tissue plasminogen activator without heparin is effective in the treatment of hepatic veno–occlusive disease [letter] Gherlinzoni F, et al. **Haematologica** 1999 Feb;84(2):191–2

EPIDEMIOLOGY

Incidence and outcome of hepatic veno–occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Carreras E, et al. **Blood** 1998 Nov 15;92(10):3599–604

ETIOLOGY

Hepatic vein obstruction in a case of focal nodular hyperplasia. Arrivé L, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):857

Hepatic veno–occlusive lesions in severe alcoholic hepatitis and alcoholic liver cirrhosis: a comparative histopathological study in autopsy cases. Kishi M, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):47S–51S

The prothrombin gene variant G20210A but not factor V leiden may be associated with veno–occlusive disease following BMT (letter). Duggan C, et al. **Bone Marrow Transplant** 1999 Sep;24(6):693–4

Veno–occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Hasegawa S, et al. **Bone Marrow Transplant** 1998 Dec; 22(12):1191–7

Hepatic veno–occlusive disease after stem cell transplantation in Japan [letter] Oh H, et al. **Bone Marrow Transplant** 1999 Jul;24(2):223–4

Comments on: Veno–occlusive disease of the liver in right sided Wilms' tumours, Tornesello et al. Eur J Cancer 1998, 34, 1220–1223 [letter; comment] Bisogno G, et al. **Eur J Cancer** 1999 Mar;35(3):521–3. Comment on: Eur J Cancer 1998 Jul;34(8):1220–3.

PATHOLOGY

Hepatic veno–occlusive lesions in severe alcoholic hepatitis and alcoholic liver cirrhosis: a comparative histopathological study in autopsy cases. Kishi M, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):47S–51S

Recurring fibro–obliterative venopathy in liver allografts. Fiel MI, et al. **Am J Surg Pathol** 1999 Jun;23(6):734–7

Characterization of a reproducible rat model of hepatic veno–occlusive disease. DeLeve LD, et al. **Hepatology** 1999 Jun;29(6):1779–91

Hepatic stellate cells (Ito cells) in veno–occlusive disease of the liver after allogeneic bone marrow transplantation. Sato Y, et al. **Histopathology** 1999 Jan;34(1):66–70

Primary lymphoma of the liver with bile duct invasion and tumoral occlusion of the portal vein: report of a case. Yoneyama F, et al. **J Hepatol** 1998 Sep;29(3):485–8

PHYSIOPATHOLOGY

Characterization of a reproducible rat model of hepatic veno–occlusive disease. DeLeve LD, et al. **Hepatology** 1999 Jun;29(6):1779–91

PREVENTION & CONTROL

Intravenous immunoglobulin and the risk of hepatic veno–occlusive disease after bone marrow transplantation. Sullivan KM, et al. **Biol Blood Marrow Transplant** 1998; 4(1):20–6

SURGERY

Successful treatment of severe azathioprine–induced hepatic veno–occlusive disease in a kidney–transplanted patient with transjugular intrahepatic portosystemic shunt. Azoulay D, et al. **Clin Nephrol** 1998 Aug;50(2):118–22 (29 ref.)

THERAPY

Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno–occlusive disease (VOD). Kulkarni S, et al. **Bone Marrow Transplant** 1999 Apr; 23(8):803–7

Hemobilia in advanced pancreatic cancer with portal vein obstruction and a metal endobiliary stent: a case report. Cvetkovski B, et al. **Gastrointest Endosc** 1999 Sep; 50(3):420–2

Managing Budd–Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting [see comments] Fisher NC, et al. **Gut** 1999 Apr; 44(4):568–74. Comment in: Gut 1999 Apr;44(4):452–3.

Balloon dilatation for postoperative vascular and biliary stenoses in pediatric liver transplantation. Chan KL, et al. **Transplant Proc** 1998 Nov;30(7):3200–2

HEPATICOLA HEPATICA see **CAPILLARIA**

HEPATITIS

[Acute hepatitis after phytotherapy (letter)] Mennecier D, et al. **Presse Med** 1999 May 15;28(18):966 **(Fre)**

BLOOD

Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. Yamamoto Y, et al. **Biofactors** 1999;9(2–4):241–6

Clinical significance of serum soluble Fas ligand in patients with acute self–limited and fulminant hepatitis. Shiota G, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jul; 101(1):3–12

[An analysis of the fatty acid composition of the lipoprotein lipids in patients with chronic hepatitis and liver cirrhosis] Amosova EN, et al. **Lik Sprava** 1999 Mar;(2):47–50 (Eng. Abstr.) **(Rus)**

[Detection of TT DNA virus (TTV) in blood donors and patients with hepatitis of unclear etiology] Isaeva EI, et al. **Vopr Virusol** 1999 Jul–Aug;44(4):170–1 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED see HEPATITIS, TOXIC

COMPLICATIONS

Subclinical syphilitic hepatitis, which was markedly worsened by a Jarisch–Herxheimer reaction. Taniguchi Y, et al. **Am J Gastroenterol** 1999 Jun;94(6):1694–6

Acute eosinophilic interstitial nephritis and uveitis (TINU syndrome) associated with granulomatous hepatitis. Segev A, et al. **Clin Nephrol** 1999 May;51(5):310–3

Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Ferlan–Marolt V, et al. **Dig Dis Sci** 1999 May;44(5):1054–8 (26 ref.)

A case of non A, non B, non C hepatitis that relapsed into fulminant hepatic failure. Cuffari C, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2348–51

Hepatitis A and HIV: a clinical review of disease and strategies for prevention. Kwong JJ. **J Assoc Nurses AIDS Care** 1999 Mar–Apr;10(2):31–6 (20 ref.)

Hepatobiliary dysfunction as the initial manifestation of disseminated cryptococcosis. Lin JI, et al. **J Clin Gastroenterol** 1999 Apr;28(3):273–5

High prevalence of TT virus infection in healthy children and adults and in patients with liver disease in Taiwan. Hsieh SY, et al. **J Clin Microbiol** 1999 Jun;37(6):1829–31

Hepatic arterial resistance after mixed–meal ingestion in healthy subjects and patients with chronic liver disease. Numata K, et al. **J Clin Ultrasound** 1999 Jun;27(5):239–48

Fatal coxsackievirus B infection in early infancy characterized by fulminant hepatitis. Wang SM, et al. **J Infect** 1998 Nov;37(3):270–3

Effect of interferon on a nonenveloped DNA virus (TT virus) associated with acute and chronic hepatitis of unknown etiology. Akahane Y, et al. **J Med Virol** 1999 Jul; 58(3):196–200

Thrombocytopenia, hepatitis and pleural effusion in a three–month–old Mexican boy [see comments] Niederer AJ. **Pediatr Infect Dis J** 1998 Aug;17(8):761–2, 764–5. Comment in: Pediatr Infect Dis J 1999 Jan;18(1):80.

[A case of giant cell hepatitis complicated with insulin dependent diabetes mellitus] Otani Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1037–41 **(Jpn)**

[The evaluation of the psychosomatic development in children after infectious and idiopathic cholestatic jaundice in neonatal and infantile period] Woś H, et al. **Wiad Lek** 1998;51(7–8):347–51 (Eng. Abstr.) **(Pol)**

[Nonalcoholic steatohepatitis] Castellano Tortajada G. **Gastroenterol Hepatol** 1999 Feb;22 Suppl 1:13–9 **(Spa)**

DIAGNOSIS

Skin lesions, hepatitis, and nephropathy in a 30–year–old man. Tang S, et al. **Am J Kidney Dis** 1999 Aug;34(2):380–3

Presentation of T–cell–rich B–cell lymphoma mimicking acute hepatitis. Castroagudin JF, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1710–3

Acute exacerbation of overlapping autoimmune liver disease with development of giant cell hepatitis after 14 years' disease duration [letter] Stoffel MP, et al. **J Intern Med** 1998 Oct;244(4):355–60

Diagnosis and interpretation of steatosis and steatohepatitis. Burt AD, et al. **Semin Diagn Pathol** 1998 Nov;15(4):246–58 (115 ref.)

[Trachelodynia and unusual muscle ache. The first symptoms in an acute peripheral polyneuropathy patient: a 37 year old physician's assistant. Guillain–Barr'e syndrome with leg sensorimotor tetraparesis, infectious mononucleosis and low grade hepatitis] Zeller A, et al. **Schweiz Rundsch Med Prax** 1999 Mar 4;88(10):441–3 **(Ger)**

[On diagnostic criteria of fulminant hepatitis] Yoshiba M. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jul;96(7):803–8 **(Jpn)**

[Post–infantile giant–cell hepatitis of probable autoimmune origin (letter)] Elizalde IR, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):457–9 (6 ref.) **(Spa)**

DRUG THERAPY

Successful acyclovir treatment of herpes simplex type 2 hepatitis in a patient with systemic lupus erythematosus: a case report and meta analysis. Chung AB, et al. **Am J Med Sci** 1998 Dec;316(6):404–7

Steroids treatment of granulomatous hepatitis complicating Coxiella burnetii acute infection. Crespo M, et al. **Infection** 1999 Mar–Apr;27(2):132–3

ENZYMOLOGY

Lipoamide dehydrogenase deficiency: a newly discovered cause of acute hepatitis in adults. Barak N, et al. **J Hepatol** 1998 Sep;29(3):482–4

ETIOLOGY

Hypoxic hepatitis: a difficult diagnosis when the cardiomyopathy remains unrecognized and the course of liver enzymes follows an atypical pattern. A report of two cases. Henrion J, et al. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):385–9

Acute hepatitis in HIV–infected patients during ritonavir treatment [letter] Arribas JR, et al. **AIDS** 1998 Sep 10; 12(13):1722–4

Gallstones and isoflurane hepatitis. Meldrum DJ, et al. **Anaesthesia** 1998 Sep;53(9):905–9

Severe hepatitis and pure red cell aplasia in adult Still's disease: good response to immunosuppressive therapy. Janssen HL, et al. **Dig Dis Sci** 1999 Aug;44(8):1639–42

Caspase–1 is not involved in experimental hepatitis in mouse. van Molle W, et al. **FEBS Lett** 1999 Feb 19;445(1):115–8

Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case–controlled, hemodynamic study of 17 consecutive cases. Henrion J, et al. **Hepatology** 1999 Feb;29(2):427–33

Granulomatous hepatitis following intravesical bacillus Calmette–Guerin therapy. Ozbakkaloglu B, et al. **Int Urol Nephrol** 1999;31(1):49–53

Non–alcoholic steatohepatitis (NASH): a disease of emerging identity and importance [see comments] James OF, et al. **J Hepatol** 1998 Sep;29(3):495–501 (50 ref.). Comment in: J Hepatol 1999 Aug;31(2):384.

Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Chen PM, et al. **Transplantation** 1999 Jun 15;67(11):1425–33

Hepatitis in falciparum malaria. Murthy GL, et al. **Trop Gastroenterol** 1998 Oct–Dec;19(4):152–4

[Hepatic ischemia and hypophyseal macroadenoma] Thevenot T, et al. **Gastroenterol Clin Biol** 1999 Jan; 23(1):141–3 (Eng. Abstr.) **(Fre)**

[Idiopathic hypereosinophilia syndrome and specific hepatitis. A case report (letter)] Lamarque P, et al. **Rev Med Interne** 1998 Mar;19(3):209–10 **(Fre)**

[Kaleidoscopic autoimmunity] Shoenfeld Y. **Harefuah** 1998 Oct;135(7–8):262–4, 336 (Eng. Abstr.) **(Heb)**

HISTORY

Progress in diagnosis of hepatitis and the cirrhotic liver. Szakacs JG, et al. **Ann Clin Lab Sci** 1999 Apr–Jun; 29(2):87–103

IMMUNOLOGY

Auto–-antibodies to DNA in the sera of Nigerians attending a rheumatic diseases clinic. Adelowo OO, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):173–6

Detection of anti–LKM–1(anti–CYP2D6) by an enzyme–linked immunosorbent assay in adult patients with chronic liver diseases. Miyakawa H, et al. **Autoimmunity** 1999;30(2):107–14

Glutathione S–transferase as a major autoantigen in anti–SLA–positive autoimmune hepatitis [letter; comment] Klein R, et al. **Gastroenterology** 1999 Apr;116(4):1015–6. Comment on: Gastroenterology 1998 Feb;114(2):329–35.

METABOLISM

Expression of cytotoxic molecule TIA–1 in malignant lymphomas mimicking fulminant hepatitis. Sadahira Y, et al. **Pathol Int** 1998 Sep;48(9):695–704

MICROBIOLOGY

Salmonella hepatitis. Pramoolsinsap C, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):745–50 (67 ref.)

Disseminated Bartonella infection with granulomatous hepatitis in a liver transplant recipient. Humar A, et al. **Liver Transpl Surg** 1999 May;5(3):249–51

A case of enteric fever with unusual manifestations. Sood A, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):114

[Hepatic listeriosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):446–8 (20 ref.) **(Jpn)**

PATHOLOGY

Laparoscopic findings in patients with acute hepatitis by nonhepatitis virus viruses [letter] Akagi S, et al. **Am J Gastroenterol** 1998 Dec;93(12):2631–2

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Brunt EM, et al. **Am J Gastroenterol** 1999 Sep;94(9):2467–74

MIB–1 immunohistometry on Tru–cut biopsies in inflammatory and cirrhotic liver disease. Biesterfeld S, et al. **Anal Quant Cytol Histol** 1998 Aug;20(4):268–74

Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic

activity of hepatitis. Ueno S, et al. **Cancer** 1999 Jul 15; 86(2):248–54

Report of a fatal case of dengue infection with hepatitis: demonstration of dengue antigens in hepatocytes and liver apoptosis. Couvelard A, et al. **Hum Pathol** 1999 Sep; 30(9):1106–10

The role of C/EBP isoforms in the control of inflammatory and native immunity functions. Poli V. **J Biol Chem** 1998 Nov 6;273(45):29279–82 (69 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 27–1999. An 82–year–old woman with numerous chronic disorders and a recent febrile illness [clinical conference] **N Engl J Med** 1999 Sep 9;341(11):827–34

[Granulomatous hepatitis and myelitis: an unusual manifestation of extrapulmonary sarcoidosis] Trenn G, et al. **Z Gastroenterol** 1999 Feb;37(2):159–63 (Eng. Abstr.) **(Ger)**

[Serial hepatic and splenic volumetry in acute severe hepatitis] Obuchi M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):147–53 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Indocyanine green clearance test in non–cirrhotic hepatitis patients: a comparison and analysis between conventional blood sampling method and Finger Piece Monitoring method. Su MY, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar;22(1):17–23

Non–alcoholic steatohepatitis: another disease of affluence. James O, et al. **Lancet** 1999 May 15;353(9165):1634–6

[Adult multi–nuclear cell hepatitis. A study in 17 patients] Tordjmann T, et al. **Gastroenterol Clin Biol** 1998 Mar; 22(3):305–10 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Mental disorders in patients with chronic hepatitis] Podrezova LA, et al. **Klin Med (Mosk)** 1998;76(11):36–9 (7 ref.) (Eng. Abstr.) **(Rus)**

REHABILITATION

[The effect of combined therapy with a salt solution of Poltava bischofite on the clinical status, adaptive hormone level and blood rheology in patients with ischemic heart disease and chronic inflammatory diseases of the liver and gallbladder] Trybrat TA. **Lik Sprava** 1999 Mar;(2):120–3 (Eng. Abstr.) **(Ukr)**

SURGERY

[The prognosis of postoperative bronchopulmonary complications in the surgical treatment of inflammatory diseases of the hepatobiliary system] Koval' AI. **Lik Sprava** 1998 Dec;(8):110–3 (Eng. Abstr.) **(Ukr)**

THERAPY

[Clinical uses of plasma exchange therapy in some diseases] Han Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(6):553–4 **(Chi)**

[Refractory liver diseases: progress in treatment. Discussion] Omata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):670–87 **(Jpn)**

[The current methods for treating chronic calculous cholecystitis and reactive hepatitis] Zaĭka AV. **Lik Sprava** 1998 Dec;(8):101–2 (Eng. Abstr.) **(Ukr)**

URINE

A paucity of unusual trihydroxy bile acids in the urine of patients with severe liver diseases. Nakashima T, et al. **Hepatology** 1999 May;29(5):1518–22

VETERINARY see HEPATITIS, ANIMAL

VIROLOGY

Laparoscopic findings in patients with acute hepatitis by nonhepatitis virus viruses [letter] Akagi S, et al. **Am J Gastroenterol** 1998 Dec;93(12):2631–2

Subclinical syphilitic hepatitis, which was markedly worsened by a Jarisch–Herxheimer reaction. Taniguchi Y, et al. **Am J Gastroenterol** 1999 Jun;94(6):1694–6

Successful acyclovir treatment of herpes simplex type 2 hepatitis in a patient with systemic lupus erythematosus: a case report and meta analysis. Chung AB, et al. **Am J Med Sci** 1998 Dec;316(6):404–7

Sequence variability in the putative coding region of TT virus: evidence for two rather than several major types. Viazov S, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3085–9

Identification of antigenic sites on three hepatitis C virus proteins using phage–displayed peptide libraries. Pereboeva LA, et al. **J Med Virol** 1998 Oct;56(2):105–11

[TT virus(TTV) infection in patients with acute hepatitis] Hayashi K, et al. **Nippon Rinsho** 1999 Jun;57(6):1322–5 (Eng. Abstr.) **(Jpn)**

HEPATITIS A

Acute hepatitis A: what's new with it? Chalasani N, et al. **Am J Gastroenterol** 1998 Nov;93(11):2305–6

Hepatitis A. Tanuos H. **Pediatr Rev** 1999 Mar;20(3):102

[Hepatitis A] Baba M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):102–6 (14 ref.) **(Jpn)**

BLOOD

Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Robertson BH, et al. **Biologicals** 1998 Jun;26(2):95–9 (26 ref.)

Hepatitis A among health workers in Paris hospitals. Occupational Health Physicians of Paris Hospital (AP–HP). Domart M, et al. **J Med Virol** 1999 Aug; 58(4):321–4

Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. Whiteman D, et al. **J Viral Hepat** 1998 Jul;5(4):277–83

COMPLICATIONS

Hepatitis A–induced diabetes mellitus, acute renal failure, and liver failure. Vesely DL, et al. **Am J Med Sci** 1999 Jun; 317(6):419–24 (31 ref.)

Fetal meconium peritonitis after maternal hepatitis A. McDuffie RS Jr, et al. **Am J Obstet Gynecol** 1999 Apr; 180(4):1031–2

Prevalence of hepatitis C virus infection in patients hospitalized for hepatitis A [letter] Asselah T, et al. **Ann Intern Med** 1999 Mar 2;130(5):451

Acute hepatitis A in patients with chronic hepatitis C [letter] Heibling B, et al. **Ann Intern Med** 1999 Aug 17;131(4):314

Guillain–Barre syndrome following serological evidence of hepatitis A in a child [letter] Azuri J, et al. **Eur J Pediatr** 1999 Apr;158(4):341–2

Simultaneous amoebic liver abscess and hepatitis A infection. Schwartz E, et al. **J Travel Med** 1998 Jun;5(2):95–6

Nephrotic syndrome associated with hepatitis A virus infection. Aydin A, et al. **Pediatr Infect Dis J** 1999 Apr; 18(4):391

HIV seroconversion illness following acute hepatitis A [letter] Fox PA, et al. **Sex Transm Infect** 1999 Apr;75(2):133

[A case of hepatitis A–associated cryoglobulinemia] Murat G, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr;57(2):218–20 **(Fre)**

[Bone marrow aplasia complicating viral hepatitis A with significant cholestasis: a case report (letter)] Khouri K, et al. **Gastroenterol Clin Biol** 1998 May;22(5):559–60 **(Fre)**

[Shoulder arthritis in acute hepatitis A (letter)] Nizou C, et al. **Rev Med Interne** 1999 Apr;20(4):371–2 **(Fre)**

CONGENITAL

Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero. Fagan EA, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):389–91

DIAGNOSIS

Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. Mishra A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2292–5 (27 ref.)

Guidelines for serological testing in the diagnosis of acute hepatitis A and B. Chitkara YK, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):241–5

The significance of hepatitis G virus infection in patients with non–A to C hepatic diseases. Tanaka T, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1870–3

Relapsing hepatitis A: a case report and review of the literature. Bornstein JD, et al. **J Clin Gastroenterol** 1999 Jun;28(4):355–6 (6 ref.)

[Detection of hepatitis A antibodies falsified through vaccination?] Tiller FW. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):981 **(Ger)**

[Acute hepatitis A with accompanying cholestasis] Weber M. **Schweiz Rundsch Med Prax** 1998 Oct 28;87(44):1479–81 **(Ger)**

[Cholestatic–type hepatitis in childhood] Molina Merino A, et al. **An Esp Pediatr** 1998 Sep;49(3):253–6 (Eng. Abstr.) **(Spa)**

[The theoretical principles of the computer diagnosis of acute viral hepatitis] Vozianova ZhI, et al. **Lik Sprava** 1998 Aug; (6):59–62 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

The effect of folic acid on the drug metabolizing liver function in man with viral hepatitis. Zviarynski IU, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):455–7

ECONOMICS

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Das A. **Hepatology** 1999 Feb;29(2):548–52

Economic models of hepatitis A virus immunization [letter; comment] Meltzer M, et al. **Hepatology** 1999 Jul; 30(1):343–5. Comment on: Hepatology 1999 Feb;29(2):548–52.

Economic models of hepatitis A virus immunization [letter; comment] O'Connor JB, et al. **Hepatology** 1999 Jul; 30(1):343–5. Comment on: Hepatology 1999 Feb;29(2):548–52.

EPIDEMIOLOGY

Occupations at increased risk of hepatitis A: a 2–year nationwide historical prospective study. Lerman Y, et al. **Am J Epidemiol** 1999 Aug 1;150(3):312–20

Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Fujisawa T, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2094–9

The elimination of hepatitis B virus infection: changing seroepidemiology of hepatitis A and B virus infection in Okinawa, Japan over a 26–year period. Furusyo N, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):693–8

Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. Hau CH, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):277–80

Immunization against hepatitis A during an outbreak in a Jewish Orthodox community––Quebec, 1997–1998. Deshaies D, et al. **Can Commun Dis Rep** 1998 Sep 15; 24(18):145–51 **(Eng, Fre)**

Use of hepatitis A vaccine in a community–wide outbreak of hepatitis A. Craig AS, et al. **Clin Infect Dis** 1998 Sep; 27(3):531–5

Hepatitis A in Australia in the 1990s: future directions in surveillance and control [published erratum appears in Commun dis Intell 1999 Jun 10;23(6):172] Amin J, et al. **Commun Dis Intell** 1999 May 13;23(5):113–20

The epidemiology of acute hepatitis A in north Queensland, 1996–1997. Merritt A, et al. **Commun Dis Intell** 1999 May 13;23(5):120–4

Outbreak of hepatitis A in Rotterdam associated with visits to 'darkrooms' in gay bars. Reintjes R, et al. **Commun Dis Public Health** 1999 Jan;2(1):43–6

Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Bonanni P, et al. **Epidemiol Infect** 1998 Oct;121(2):377–80

Lack of evidence for increased risk of hepatitis A infection in homosexual men. Corona R, et al. **Epidemiol Infect** 1999 Aug;123(1):89–93

Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Ferson MJ, et al. **Epidemiol Infect** 1998 Dec; 121(3):631–6

Hepatitis A outbreak originating in a day care center: a community case report. Sadetzki S, et al. **Eur J Epidemiol** 1999 Jul;15(6):549–51

Is a vaccination program against hepatitis A needed in India? [letter] Das K, et al. **Indian J Gastroenterol** 1998 Oct–Dec; 17(4):158

Exposure of Indian children to hepatitis A virus & vaccination age. Chadha MS, et al. **Indian J Med Res** 1999 Jan;109:11–5

Prevalence of anti–hepatitis A antibodies, hepatitis B viral markers, and anti–hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990–1991. Almog R, et al. **Infection** 1999 May–Jun; 27(3):212–7

Seroprevalence of hepatitis A markers in subjects exposed to biological risk. Trevisan A, et al. **Int Arch Occup Environ Health** 1999 Mar;72(2):125–7

Hepatitis A incidence rate estimates from a pilot seroprevalence survey in Rio de Janeiro, Brazil. Struchiner CJ, et al. **Int J Epidemiol** 1999 Aug;28(4):776–81

Hepatitis A in urban Ireland. Rajan E, et al. **Ir J Med Sci** 1998 Oct–Dec;167(4):231–3

Prevalence of hepatitis A in an institution for the mentally retarded in an intermediate endemicity area: influence of age length of institutionalization. Gil A, et al. **J Infect** 1999 Mar;38(2):120–3

The diverse patterns of hepatitis A epidemiology in the United States–implications for vaccination strategies. Bell BP, et al. **J Infect Dis** 1998 Dec;178(6):1579–84

Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. De Serres G, et al. **J Infect Dis** 1999 Jan;179(1):37–43

The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas–Mexico border. Leach CT, et al. **J Infect Dis** 1999 Aug;180(2):509–13

The requirement for hepatitis A vaccine in Gurkha soldiers. Kitson MM, et al. **J R Army Med Corps** 1999 Jun; 145(2):84–5

Clinical and viral marker pattern of acute sporadic hepatitis in children in Madras, South India. Malathi S, et al. **J Trop Pediatr** 1998 Oct;44(5):275–8

Hepatitis A outbreaks among illicit drug users and their contacts in Queensland, 1997. Shaw DD, et al. **Med J Aust** 1999 Jun 21;170(12):584–7

Ascertainment of secondary cases of hepatitis A––Kansas, 1996–1997. **MMWR Morb Mortal Wkly Rep** 1999 Jul 23; 48(28):608–10, 619

A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team [see comments] Hutin YJ, et al. **N Engl J Med** 1999 Feb 25;340(8):595–602. Comment in: N Engl J Med 1999 Feb 25;340(8):644–5.

An outbreak of hepatitis A associated with an infected foodhandler. Massoudi MS, et al. **Public Health Rep** 1999 Mar–Apr;114(2):157–64

Epidemiology and prevention of enterically transmitted hepatitis in Italy. Coppola RC, et al. **Res Virol** 1998 Sep–Oct;149(5):271–6 (45 ref.)

Duality of patterns in hepatitis A epidemiology: a study involving two socioeconomically distinct populations in Campinas, São Paulo State, Brazil. Pinho JR, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar–Apr;40(2):105–6

Prolonged nosocomial outbreak of hepatitis A arising from

an alcoholic with pneumonia. Jensenius M, et al. **Scand J Infect Dis** 1998;30(2):119–23

Outbreak of hepatitis A in homosexual men in Riverside [letter] Newell A, et al. **Sex Transm Infect** 1998 Aug; 74(4):304–5

Low prevalence of anti-HAV among children in Southern Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):451–2

Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Kunasol P, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):255–62 (32 ref.)

Seroprevalence of hepatitis A in children--implications for hepatitis A vaccine. Mittal SK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):120–1

Control of hepatitis A infection in the U.S. Le C. **West J Med** 1999 Jun;170(6):324 (10 ref.)

Universal childhood immunization against hepatitis A: whoa! Takayama JI. **West J Med** 1999 Jun;170(6):325–6 (11 ref.)

[The epidemiology of hepatitis A in the Netherlands, 1957–1998 (letter)] Termorshuizen F, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2364–8 (Eng. Abstr.) **(Dut)**

[Annual epidemics of hepatitis A in four large cities related to holiday travel among immigrant children] van Gorkom J, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22; 142(34):1919–23 (Eng. Abstr.) **(Dut)**

[Fall in the seroprevalence of hepatitis A in French youth] Joussemet M, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):447–5 (Eng. Abstr.) **(Fre)**

[An outbreak caused by hepatitis A virus in an institution for the mentally handicapped--detection of hepatitis A virus RNA using CTAB method] Kitahashi T, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):794–800 (Eng. Abstr.) **(Jpn)**

[Hepatitis A in 1997] Sitarska-Gołębiowska J. **Przegl Epidemiol** 1999;53(1-2):67–74 (Eng. Abstr.) **(Pol)**

[The potential risk factors associated with acute viral hepatitis in children under 5 years old] Ion-Nedelcu N, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul-Sep; 43(3):133–8 **(Rum)**

[Hepatitis A, B, and C in an occupational center for the mentally handicapped] Arnedo A, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):370–3 (Eng. Abstr.) **(Spa)**

[Epidemic outbreak of hepatitis A related to a day care center] Pañella H, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):319–23 (Eng. Abstr.) **(Spa)**

[Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989–1996. Implications for new vaccination strategy] Bruguera M, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):406–8 (Eng. Abstr.) **(Spa)**

[Prevalence of antibodies against hepatitis A in school children] Riedemann S, et al. **Rev Med Chil** 1998 Oct; 126(10):1161–4 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak [published erratum appears in Am J Public Health 1999 Aug;89(8):1274] Hutin YJ, et al. **Am J Public Health** 1999 Jun;89(6):918–21

Hepatitis A outbreaks among illicit drug users and their contacts in Queensland, 1997. Shaw DD, et al. **Med J Aust** 1999 Jun 21;170(12):584–7

Risk of hepatitis A infection in sewage workers. Brugha R, et al. **Occup Environ Med** 1998 Aug;55(8):567–9

IMMUNOLOGY

Physico-chemical characterization of liposomes with covalently attached hepatitis A VP3(101–121) synthetic peptide. Muñoz M, et al. **Analyst** 1998 Nov;123(11):2223–8

Hepatitis A antibody prevalence among young adults in Israel--the decline continues. Gdalevich M, et al. **Epidemiol Infect** 1998 Oct;121(2):477–9

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Linder N, et al. **Infection** 1999 Mar-Apr;27(2):128–31

Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM). Vidor E, et al. **J Travel Med** 1998 Dec;5(4):167–72

Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Ashur Y, et al. **Vaccine** 1999 May 4;17(18):2290–6

[Familial autoimmune hepatitis and C4 deficiency] Constans J, et al. **Rev Med Interne** 1998 Oct;19(10):731–3 (Eng. Abstr.) **(Fre)**

[Detection of hepatitis A antibodies falsified through vaccination?] Tiller FW. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):981 **(Ger)**

[Combined hepatitis A/B immunization in children and adolescents. Economic evaluation of different immunization methods] Smala AM, et al. **MMW Fortschr Med** 1999 Jun 10;141(23):55–6 **(Ger)**

[Vaccination against hepatitis A] Zamir D, et al. **Harefuah** 1998 Aug;135(3-4):114–8 (40 ref.) **(Heb)**

[Secondary infection with hepatitis A in Rhesus monkeys after experimental inoculation] Korzaia LI, et al. **Vopr Virusol** 1998 Jul-Aug;43(4):158–63 (Eng. Abstr.) **(Rus)**

[Anti-actin antibodies in acute viral hepatitis A in children] López SI, et al. **Acta Gastroenterol Latinoam** 1998; 28(3):261–4 (Eng. Abstr.) **(Spa)**

[Serum antibodies against hepatitis A virus among subjects of middle and low socioeconomic levels in urban area of Santiago, Chile] Lagos R, et al. **Rev Med Chil** 1999 Apr; 127(4):429–36 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Hepatitis A in human immunodeficiency virus-infected patients. Wallace MR, et al. **Clin Infect Dis** 1998 Sep; 27(3):651–3

[Central and regional hepatic hemodynamics in patients with ischemic heart disease and concomitant chronic persistent hepatitis] Akimova LG. **Lik Sprava** 1998 Jun;(4):67–9 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Immunogenicity of hepatitis A vaccine in decompensated liver disease. Dumot JA, et al. **Am J Gastroenterol** 1999 Jun;94(6):1601–4

Prevention of hepatitis A [editorial] Gardner P. **Am J Med** 1998 Nov;105(5):452–3

Immune globulin and vaccine therapy to prevent hepatitis A infection. Levy MJ, et al. **Am J Med** 1998 Nov; 105(5):416–23 (97 ref.)

Hepatitis A vaccination of child care workers in Victoria: are recommendations being implemented? Thomson JA, et al. **Aust N Z J Public Health** 1998 Dec;22(7):832–4

Immunization against hepatitis A during an outbreak in a Jewish Orthodox community--Quebec, 1997–1998. Deshaies D, et al. **Can Commun Dis Rep** 1998 Sep 15; 24(18):145–51 **(Eng, Fre)**

Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Craig AS, et al. **Clin Infect Dis** 1998 Sep; 27(3):531–5

Acute hepatitis A in a traveler who had received preexposure inactivated hepatitis A virus vaccine. Kurup A, et al. **Clin Infect Dis** 1999 Jun;28(6):1324–5

Control of a community hepatitis A outbreak using hepatitis A vaccine. Irwin DJ, et al. **Commun Dis Public Health** 1999 Sep;2(3):184–7

Hepatitis A vaccine: evidence of efficacy after exposure. **Commun Dis Rep CDR Wkly** 1999 Apr 16;9(16):139, 142

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Das A. **Hepatology** 1999 Feb;29(2):548–52

Economic models of hepatitis A virus immunization [letter; comment] Meltzer M, et al. **Hepatology** 1999 Jul; 30(1):343–5. Comment on: Hepatology 1999 Feb;29(2):548–52.

Economic models of hepatitis A virus immunization [letter; comment] O'Connor JB, et al. **Hepatology** 1999 Jul; 30(1):343–5. Comment on: Hepatology 1999 Feb;29(2):548–52.

Cost-effectiveness analysis of hepatitis A vaccination strategies for adults. O'Connor JB, et al. **Hepatology** 1999 Oct;30(4):1077–81

Is a vaccination program against hepatitis A needed in India? [letter] Das K, et al. **Indian J Gastroenterol** 1998 Oct-Dec; 17(4):158

Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program [letter] Naef MR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):349–51

A two dose combined hepatitis A and B vaccine in Chinese youngsters. Lee SD, et al. **J Med Virol** 1999 Sep;59(1):1–4

Hepatitis A vaccination in chronic carriers of hepatitis B virus. Nebbia G, et al. **J Pediatr** 1999 Jun;134(6):784–5

Protection of travelers against Hepatitis A viral infection in developing countries [letter] Arya SC. **J Travel Med** 1998 Dec;5(4):228–9

What type of travelers would benefit from combined vaccination against hepatitis A and B? Iwarson S. **J Travel Med** 1998 Jun;5(2):80–3

Vaccination of travelers against hepatitis A and B. Löscher T, et al. **J Travel Med** 1999 Jun;6(2):107–14 (68 ref.)

Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM). Vidor E, et al. **J Travel Med** 1998 Dec;5(4):167–72

Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A [published erratum appears in J Travel Med 1998 Sep;5(3):inside front cover] Zuckerman JN, et al. **J Travel Med** 1998 Mar;5(1):18–22

Hepatitis A vaccine for secondary hepatitis A infection [letter; comment] Bell BP, et al. **Lancet** 1999 Jul 24; 354(9175):341; discussion 342–3. Comment on: Lancet 1999 Apr 3;353(9159):1136–9.

Hepatitis A vaccine for secondary hepatitis A infection [letter; comment] Beutels P, et al. **Lancet** 1999 Jul 24; 354(9175):340–1; discussion 342–3. Comment on: Lancet 1999 Apr 3;353(9159):1136–9.

Hepatitis A vaccine for secondary hepatitis A infection [letter; comment] Monto AS, et al. **Lancet** 1999 Jul 24; 354(9175):341–2; discussion 342–3. Comment on: Lancet 1999 Apr 3;353(9159):1136–9.

Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial [published erratum appears in Lancet 1999 Jun 12;353(9169):2078] [see comments] Sagliocca L, et al. **Lancet** 1999 Apr 3; 353(9159):1136–9. Comment in: Lancet 1999 Jul 24;354(9175):340–1; discussion 342–3. Comment in: Lancet 1999 Jul 24;354(9175):341; discussion 342–3. Comment in: Lancet 1999 Jul 24;354(9175):341–2; discussion 342–3. Comment in: Lancet 1999 Jul 24;354(9175):342–3. Comment in: ACP J Club 1999 Sep-Oct;131(2):45.

Hepatitis A vaccine for secondary hepatitis A infection [letter; comment] Shouval D, et al. **Lancet** 1999 Jul 24; 354(9175):342–3. Comment on: Lancet 1999 Apr 3;353(9159):1136–9.

Should hepatitis C antibody-positive inmates be vaccinated against hepatitis A virus? [letter] Awofeso N, et al. **Med J Aust** 1999 Apr 5;170(7):338

Vaccination against hepatitis A [letter; comment] Katz SL. **N Engl J Med** 1999 Jul 22;341(4):293. Comment on: N Engl J Med 1999 Feb 25;340(8):644–5.

The case for routine childhood vaccination against hepatitis A [editorial; comment] [see comments] Koff RS. **N Engl J Med** 1999 Feb 25;340(8):644–5. Comment on: N Engl J Med 1999 Feb 25;340(8):595–602. Comment in: N Engl J Med 1999 Jul 22;341(4):293.

A combined vaccine against hepatitis A and B in children and adolescents. Diaz-Mitoma F, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):109–14

Epidemiology and prevention of enterically transmitted hepatitis in Italy. Coppola RC, et al. **Res Virol** 1998 Sep-Oct;149(5):271–6 (45 ref.)

New target groups for vaccination against hepatitis A: homosexual men, injecting drug users and patients with chronic hepatitis. Iwarson S. **Scand J Infect Dis** 1998; 30(3):316–8

Seroprevalence of hepatitis A in children--implications for hepatitis A vaccine. Mittal SK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):120–1

[Epidemiology and cost-effectiveness analysis of hepatitis A vaccination in Liuzhou City] Li X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Apr; 19(2):93–6 (Eng. Abstr.) **(Chi)**

[Studies on re-immunization with live attenuated hepatitis A vaccine] Liu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May; 32(3):162–4 (Eng. Abstr.) **(Chi)**

[Studies on immunization strategy against hepatitis A in a highly prevalent area] Zhang Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):295–6 (Eng. Abstr.) **(Chi)**

[Thiomersal in gammaglobulin for pregnant travellers may not be safe for the fetus. National Coordination Center for Travel Advisory] Schilthuis HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1622 (Eng. Abstr.) **(Dut)**

[Viral hepatitis: vaccination for hepatitis A and B virus] Bégué P. **Arch Pediatr** 1999;6 Suppl 2:186s–189s **(Fre)**

-Vaccination against hepatitis A- Lagardère B. **Arch Pediatr** 1998 Mar;5(3):321–5 (Eng. Abstr.) **(Fre)**

[Vaccination against hepatitis A and B in HCV-infected patient?] Blum E. **Internist (Berl)** 1998 Sep;39(9):980 **(Ger)**

[Viral hepatitis: preventable illnesses] Baumgarten R. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):677–80 (6 ref.) (Eng. Abstr.) **(Ger)**

[The vaccinal prevention of viral hepatitis A in military groups] Sabanin IuV, et al. **Voen Med Zh** 1998 Aug; 319(8):58–60 **(Rus)**

[Characteristics of reactogenic and immunogenic properties of the children's variant of the domestic vaccine, "Gep-A-in-Vak", against hepatitis A] Ikoev VN, et al. **Vopr Virusol** 1999 May-Jun;44(3):133–6 (Eng. Abstr.) **(Rus)**

[A combined vaccine against hepatitis A and B (editorial)] Batalla J, et al. **Aten Primaria** 1999 May 31;23(9):513–4 **(Spa)**

[Recommendations for the use of the hepatitis A vaccine in day care centers. Committee on Vaccines of the Spanish Pediatric Society and Spanish Association for the Study of the Liver] **Gastroenterol Hepatol** 1998 Aug-Sep; 21(7):346–51 **(Spa)**

[Prevalence of anti-hepatitis A in patients with chronic liver disease] Diago M, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):324–6 (Eng. Abstr.) **(Spa)**

[Changes in seroepidemiology of hepatitis A virus infection in Catalonia in the period 1989–1996. Implications for new vaccination strategy] Bruguera M, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):406–8 (Eng. Abstr.) **(Spa)**

[Indications and prescription of hepatitis A vaccine in Spain. Report of the Spanish Association for the Study of the Liver] Bruguera M, et al. **Med Clin (Barc)** 1998 Sep 26; 111(9):341–6 **(Spa)**

THERAPY

[Serious hepatitis A in a child] Debray D. **Arch Pediatr** 1999; 6 Suppl 2:183s–185s **(Fre)**

TRANSMISSION

A case of vertical transmission of hepatitis A virus infection. Erkan T, et al. **Acta Paediatr** 1998 Sep;87(9):1008–9

Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Vesely DL, et al. **Am J Med Sci** 1999 Jun; 317(6):419–24 (31 ref.)

HEPATITIS A

Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Robertson BH, et al. **Biologicals** 1998 Jun;26(2):95–9 (26 ref.)

Sexual health of homosexual men and women. Universal vaccination against hepatitis A cannot be firmly recommended for homosexual men [letter] Brook G. **BMJ** 1999 Aug 28;319(7209):575

Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. De Serres G, et al. **J Infect Dis** 1999 Jan;179(1):37–43

Symptomatic neonatal hepatitis A disease from a virus variant acquired in utero. Fagan EA, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):389–91

An outbreak of hepatitis A associated with an infected foodhandler. Massoudi MS, et al. **Public Health Rep** 1999 Mar–Apr;114(2):157–64

Prolonged nosocomial outbreak of hepatitis A arising from an alcoholic with pneumonia. Jensenius M, et al. **Scand J Infect Dis** 1998;30(2):119–23

[Annual epidemics of hepatitis A in four large cities related to holiday travel among immigrant children] van Gorkom J, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22; 142(34):1919–23 (Eng. Abstr.) **(Dut)**

[Viral hepatitis of enteric origin] Debord T, et al. **Bull Soc Pathol Exot** 1998;91(5 Pt 1–2):428–31 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Gallbladder and pancreatic involvement in hepatitis A. Klar A, et al. **J Clin Gastroenterol** 1998 Sep;27(2):143–5

VIROLOGY

Increased infectivity of hepatitis A virus cDNA clones with engineered 5'-terminal extra-cistronic sequences. Silveira Carneiro J, et al. **New Microbiol** 1998 Oct;21(4):321–7

[An outbreak caused by hepatitis A virus in an institution for the mentally handicapped--detection of hepatitis A virus RNA using CTAB method] Kitahashi T, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):794–800 (Eng. Abstr.) **(Jpn)**

HEPATITIS A VIRUS see **HEPATOVIRUS**

HEPATITIS A VIRUS, HUMAN

pH-induced destabilization of lipid bilayers by a peptide from the VP3 protein of the capsid of hepatitis A virus. Chávez A, et al. **Analyst** 1998 Nov;123(11):2251–6

IMMUNOLOGY

Is a vaccination program against hepatitis A needed in India? [letter] Das K, et al. **Indian J Gastroenterol** 1998 Oct–Dec; 17(4):158

Hepatitis A incidence rate estimates from a pilot seroprevalence survey in Rio de Janeiro, Brazil. Struchiner CJ, et al. **Int J Epidemiol** 1999 Aug;28(4):776–81

Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A [published erratum appears in J Travel Med 1998 Sep;5(3):inside front cover] Zuckerman JN, et al. **J Travel Med** 1998 Mar;5(1):18–22

Low prevalence of anti-HAV among children in Southern Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):451–2

[Vaccination against hepatitis A] Zamir D, et al. **Harefuah** 1998 Aug;135(3–4):114–8 (40 ref.) **(Heb)**

[The vaccinal prevention of viral hepatitis A in military groups] Sabanin IuV, et al. **Voen Med Zh** 1998 Aug; 319(8):58–60 **(Rus)**

[A combined vaccine against hepatitis A and B (editorial)] Batalla J, et al. **Aten Primaria** 1999 May 31;23(9):513–4 **(Spa)**

[Indications and prescription of hepatitis A vaccine in Spain. Report of the Spanish Association for the Study of the Liver] Bruguera M, et al. **Med Clin (Barc)** 1998 Sep 26; 111(9):341–6 **(Spa)**

HEPATITIS AGENTS, GB

Prevalence of hepatitis G virus in a haemodialysis unit. Lamproye A, et al. **Acta Gastroenterol Belg** 1999 Jan–Mar; 62(1):13–5

Clinicopathological study of chronic hepatitis induced by alcohol with or without hepatitis G virus. Shimanaka K, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):29S–32S

Intraspousal transmission of GB virus C/hepatitis G virus in an hepatitis C virus hyperendemic area in Japan. Akiyoshi F, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1627–31

The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Brandhagen DJ, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1000–5

Hepatitis G virus and HCV related extrahepatic disease [letter] Grasso A, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1120–1

Hepatitis G virus infection in hemodialysis patients: fact or fancy? [letter; comment] Macedo G, et al. **Am J Gastroenterol** 1999 May;94(5):1423–4. Comment on: Am J Gastroenterol 1997 Nov;92(11):1986–91.

Membranoproliferative glomerulonephritis with subendothelial deposits (type 1) associated with hepatitis G virus infection in a renal transplant recipient. Berthoux P, et al. **Am J Nephrol** 1999;19(4):513–8

Outcome of mother to infant acquired GBV-C/HGV infection. Zuin G, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F72–3

Hepatitis G virus infection detected in a woman with intrahepatic cholestasis of pregnancy. Morton M, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):428–9

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377–84

Persistence and clinical outcome of hepatitis G virus infection in pediatric bone marrow transplant recipients and children treated for hematological malignancy. Yamada-Osaki M, et al. **Blood** 1999 Jan 15;93(2):721–7

Long-term liver function of recipients with hepatitis G virus infection after bone marrow transplantation. Maruta A, et al. **Bone Marrow Transplant** 1999 Aug;24(4):359–63

GBV-C/HGV and HCV infection in mixed cryoglobulinaemia. Crovatto M, et al. **Br J Haematol** 1999 Aug;106(2):510–4

Chronic infection with hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles County, California. Yuan JM, et al. **Cancer** 1999 Sep 15;86(6):936–43

Natural history and molecular biology of hepatitis G virus/GB virus C. Karayiannis P, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):103–11 (45 ref.)

Clinical course of chronic hepatitis C virus infection is not influenced by concurrent hepatitis G virus infection. Hayashi J, et al. **Dig Dis Sci** 1999 Mar;44(3):618–23

Hepatitis G virus infection among liver graft recipients: anatomoclinical correlations. Negro F, et al. **Dig Dis Sci** 1998 Dec;43(12):2577–83

Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Ohba K, et al. **Epidemiol Infect** 1999 Feb;122(1):139–43

Influence of hepatitis G virus coinfection on the clinical course of chronic hepatitis C. Cacopardo B, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):709–14

GB virus C infection by blood transfusion during and following liver surgery. Kubo S, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2252–4

The significance of hepatitis G virus infection in patients with non-A to C hepatic diseases. Tanaka T, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1870–3

Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Berg T, et al. **Hepatology** 1999 Jan;29(1):245–9

Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men [letter; comment] Sabin CA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):546–8. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1998 Mar 1;17(3):209–13.

Molecular detection and prevalence investigation of HGV infection among older patients undergoing chronic hemodialysis [letter] Bianchi D, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1040–1

Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. Menéndez C, et al. **J Clin Microbiol** 1999 Jul;37(7):2333–6

Biochemical and histological features of hepatitis G virus infection [see comments] Kobayashi M, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):767–72. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763–6.

Is GBV-C (hepatitis G virus) an innocent bystander? [editorial; comment] Okuda K. **J Gastroenterol Hepatol** 1998 Aug;13(8):763–6. Comment on: J Gastroenterol Hepatol 1998 Aug;13(8):773–80. Comment on: J Gastroenterol Hepatol 1998 Aug;13(8):767–72.

Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients. Kallinowski B, et al. **J Heart Lung Transplant** 1999 Mar;18(3):190–3

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G. Inoue K, et al. **J Hepatol** 1999 May;30(5):801–6

Detection of HGV in serum and peripheral blood mononuclear cells of maintenance haemodialysis patients. Basaras M, et al. **J Hosp Infect** 1999 Jun;42(2):155–9

Hepatitis G virus infection from needle-stick injuries in hospital employees. Shibuya A, et al. **J Hosp Infect** 1998 Dec;40(4):287–90

Hepatitis G virus infection in drug users in Liverpool [see comments] Kennedy N, et al. **J Infect** 1998 Sep;37(2):140–7 . Comment in: J Infect 1998 Sep;37(2):106–7.

HGV and the blood supply [comment] Mortimer PP. **J Infect** 1998 Sep;37(2):106–7. Comment on: J Infect 1998 Sep;37(2):140–7.

Prevalence, incidence, and clinical characteristics of hepatitis G virus/GB virus C infection in Scottish blood donors. Blair CS, et al. **J Infect Dis** 1998 Dec;178(6):1779–82

Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Devereux H, et al. **J Med Virol** 1998 Dec;56(4):316–20

High prevalence of GB-C/hepatitis G virus in a Brazilian population with helminth infection. Gallian P, et al. **J Med Virol** 1998 Dec;56(4):310–5

GB virus C/hepatitis G virus infection in KwaZulu Natal, South Africa. Sathar MA, et al. **J Med Virol** 1999 Sep; 59(1):38–44

Profiles of GBV-C/hepatitis G virus markers in patients coinfected with hepatitis C virus. Sauleda S, et al. **J Med Virol** 1999 Sep;59(1):45–51

Prevalence of GB virus-C/hepatitis G virus infection in an antenatal population. Skidmore SJ, et al. **J Med Virol** 1999 Mar;57(3):235–7

Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. Tanaka T, et al. **J Med Virol** 1999 Apr; 57(4):370–5

GBV-C/HGV infection in end-stage renal disease. Fabrizi F, et al. **J Nephrol** 1999 May–Jun;12(3):131–9 (90 ref.)

Prevalence of GBV-C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. El-Zayadi AR, et al. **J Virol Methods** 1999 Jun; 80(1):53–8

Influence of GB virus-C/hepatitis G virus infection on the long-term course of chronic hepatitis B. Fattovich G, et al. **Liver** 1998 Oct;18(5):360–5

Should we be screening blood donors for hepatitis G virus? The case for screening. Moaven LD. **Med J Aust** 1998 Oct 5;169(7):373–4

Should we be screening blood donors for hepatitis G virus? The case against screening. Wong PY, et al. **Med J Aust** 1998 Oct 5;169(7):375–7

High prevalence of hepatitis G virus (HGV) infection in renal transplantation. Berthoux P, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2909–13

Increased prevalence of markers of GBV-C/HGV infection in a selected cohort of haemodialysis patients negative for other blood-borne viruses [letter] Dalekos GN, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):255–6

High prevalence of hepatitis G virus (HGV) infections in dialysis staff. Gärtner BC, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):406–8

High prevalence of GB virus-C infection in haemodialysis patients [letter] Huang CC, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1802–3

GB virus C/hepatitis G virus infection in patients on continuous ambulatory peritoneal dialysis. Huang CH, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2914–9

Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. Campo N, et al. **Nephron** 1999;82(1):17–21

Hepatitis G virus infection among patients undergoing hemodialysis [letter] Mas MR, et al. **Nephron** 1998 Oct; 80(2):247–8

Hepatitis G virus infection in a high-risk subgroup of hospitalized dental patients. Takata Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):442–5

Hepatitis G Virus. Patrick CC. **Pediatr Infect Dis J** 1998 Nov;17(11):1045–6

Hepatitis G virus infection as a possible causative agent of community-acquired hepatitis and associated aplastic anaemia. Crespo J, et al. **Postgrad Med J** 1999 Mar; 75(881):159–60

Prevalence and patterns of HGV/GBV-C infection in patients with suspected HCV-related hepatitis. Garcia de Viedma D, et al. **Res Virol** 1998 Nov–Dec;149(6):433–8

Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Lefrère JJ, et al. **Transfusion** 1999 Jan;39(1):83–94

Hepatitis G virus infection in liver transplant recipients. Fischer L, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):496–9

Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. Meisel H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1382–3

Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Rostaing L, et al. **Transplantation** 1999 Feb 27;67(4):556–60

Does HCV screening of blood donors affect transmission of hepatitis G virus in dialysed patients? [letter] Gérard C, et al. **Vox Sang** 1998;75(1):77

Prevalence of hepatitis G-virus infection in alcohol abusing patients with and without liver cirrhosis. Schöniger-Hekele M, et al. **Wien Klin Wochenschr** 1998 Oct 16;110(19):686–90

[Detection of HGV RNA in sera from patients with fulminant hepatitis in Shenyang] Shu B, et al **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):168–9 (Eng. Abstr.) **(Chi)**

[A prospective study on post-transfusion hepatitis G virus infection] Lu Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):95–6 (Eng. Abstr.) **(Chi)**

[Follow-up studies on hepatitis G infection in plasma donors with positive antibody against hepatitis C] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):269–71 (Eng. Abstr.) **(Chi)**

[Hepatitis G virus or hepatitis GB virus C] Heinsen A, et al. **Ugeskr Laeger** 1999 May 3;161(18):2653–6 (37 ref.) (Eng. Abstr.) **(Dan)**

[Long-term consequences of co-infection by hepatitis G virus in hepatitis c virus infected kidney transplant patients]

Rostaing L, et al. **Nephrologie** 1999;20(3):165-70 (Eng. Abstr.) **(Fre)**

[Hepatitis G virus in blood donors] Moncharmont P, et al. **Presse Med** 1999 Feb 13;28(6):269-72 (Eng. Abstr.) **(Fre)**

[Hepatitis G] Kiyosawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):65-8 (13 ref.) **(Jpn)**

[Hepatitis F] Kiyosawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):111-4 (9 ref.) **(Jpn)**

[Viral hepatitis G--current knowledge] Vasiljević N, et al. **Vojnosanit Pregl** 1998 Nov-Dec;55(6):649-52 (24 ref.) **(Scc)**

[Hepatitis G--2 years after its discovery] Szántová M, et al. **Bratisl Lek Listy** 1999 Jan;100(1):54-8 (15 ref.) (Eng. Abstr.) **(Slo)**

[The response of the hepatitis C and hepatitis G viruses to treatment with recombinant interferon alfa-2b] Infante Pina D, et al. **An Esp Pediatr** 1998 Dec;49(6):609-14 (Eng. Abstr.) **(Spa)**

[Retrospective study of the incidence of hepatitis G virus infection in transfused patients] Salmerón J, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):409-11 (Eng. Abstr.) **(Spa)**

[Hepatitis G infection in Chilean patients with hepatitis C virus: a preliminary report (letter)] Venegas M, et al. **Rev Med Chil** 1998 Sep;126(9):1133-4 **(Spa)**

[Hepatitis G virus exists--but does hepatitis G?] Wejstål R, et al. **Lakartidningen** 1999 Jan 27;96(4):323-6 (45 ref.) (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. López-Alcorocho JM, et al. **Intervirology** 1998;41(6):233-7

Identification of a novel genotype of hepatitis G virus in Southeast Asia. Naito H, et al. **J Clin Microbiol** 1999 Apr; 37(4):1217-20

GB virus C/hepatitis G virus groups and subgroups: classification by a restriction fragment length polymorphism method based on phylogenetic analysis of the 5' untranslated region. Quarleri JF, et al. **J Clin Microbiol** 1999 May;37(5):1340-7

Phylogenetic analysis of GB viruses A and C: evidence for cospeciation between virus isolates and their primate hosts. Charrel RN, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2329-35

GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. Kao JH, et al. **J Infect Dis** 1999 Jul;180(1):191-4

DRUG EFFECTS

Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone. Kao JH, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1249-53

GENETICS

The complete coding sequence of a European isolate of GB-C/hepatitis G virus. Charrel RN, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):432-7

Detection of GB virus C/hepatitis G virus RNA by reverse-transcription polymerase chain reaction. Chang J, et al. **Clin Chem Lab Med** 1999 Jan;37(1):33-6

Mutation patterns for two flaviviruses: hepatitis C virus and GB virus C/hepatitis G virus. Mizokami M, et al. **FEBS Lett** 1999 May 7;450(3):294-8

Partial nucleotide sequencing of the NS3/helicase region of hepatitis G virus to prove vertical transmission. Takayama S, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):273-9

Higher detection rate of hepatitis G and C virus RNA in liver tissue than in serum of deceased injection drug users. Seidl S, et al. **Int J Legal Med** 1999;112(1):35-8

HGV infection in a cohort of patients with chronic active hepatitis HCV related [letter] Capra F, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):443

Epidemiology of hepatitis B, C, E, and G virus infections and molecular analysis of hepatitis G virus isolates in Bolivia. Konomi N, et al. **J Clin Microbiol** 1999 Oct; 37(10):3291-5

Identification of a novel genotype of hepatitis G virus in Southeast Asia. Naito H, et al. **J Clin Microbiol** 1999 Apr; 37(4):1217-20

Genetic evolution of hepatitis G virus in chronically infected individual patients. Giménez-Barcons M, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2623-9

The 5' untranslated region of GB virus B shows functional similarity to the internal ribosome entry site of hepatitis C virus. Grace K, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2337-41

Molecular analysis of GB virus C/hepatitis G virus in HIV-1-positive intravenous drug users in Belgium. Liu HF, et al. **J Hum Virol** 1999 Mar-Apr;2(2):115-20

Analysis of conserved ambisense sequences within GB virus C. Kondo Y, et al. **J Infect Dis** 1998 Oct;178(4):1185-8

Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. Anastassopoulou CG, et al. **J Med Virol** 1998 Nov; 56(3):246-52

Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. Bourlet T, et al. **J Med Virol** 1999 Aug; 58(4):373-7

Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy. Kato T, et al. **J Med Virol** 1999 Apr;57(4):376-82

Molecular characterization of the 5' non-coding region of South African GBV-C/HGV isolates: major deletion and evidence for a fourth genotype. Tucker TJ, et al. **J Med Virol** 1999 Sep;59(1):52-9

Diversity of GB virus C/hepatitis G virus isolates in Singapore: predominance of group 2a and the Asian group 3 variant. Wong SB, et al. **J Med Virol** 1999 Jun; 58(2):145-53

Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. Wu JC, et al. **J Med Virol** 1998 Oct;56(2):118-22

Slow evolutionary rate of GB virus C/hepatitis G virus. Suzuki Y, et al. **J Mol Evol** 1999 Apr;48(4):383-9

Structural constraints on RNA virus evolution. Simmonds P, et al. **J Virol** 1999 Jul;73(7):5787-94

Detection of GB virus C RNA by GBV-C LCx and two PCR assays with primers from the 5'non-coding and NS5B region. Berg ES, et al. **J Virol Methods** 1998 Dec; 76(1-2):43-9

Comparative study of 5' UTR and NS3R primers for the detection of GB virus C/hepatitis G virus RNA in Japanese. Tanaka H, et al. **Liver** 1998 Dec;18(6):378-82

Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population. Shibuya A, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2033-6

Hepatitis G virus infection in haemodialysis patients and its relationship with hepatitis C virus RNA positivity. Hizel N, et al. **Scand J Infect Dis** 1998;30(5):451-4

Lack of GB virus C/hepatitis G virus sequences in cerebrospinal fluid in patients with central nervous system infections [letter] Radkowski M, et al. **Scand J Infect Dis** 1998;30(5):539

Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease. Pramoolsinsap C, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):480-90

Prevalence of GB virus type C/hepatitis G virus RNA and anti-E2 among blood donors in Southeastern France. Cantaloube JF, et al. **Transfusion** 1999 Jan;39(1):95-102

Evaluation of RNA and E2 antibodies in prospectively followed recipients of hepatitis G virus-infected blood. Sauleda S, et al. **Transfusion** 1999 Jun;39(6):633-8

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. Bukh J, et al. **Virology** 1999 Sep 30;262(2):470-8

Sequence heterogeneity within three different regions of the hepatitis G virus genome. Cong M, et al. **Virology** 1999 Mar 15;255(2):250-9

Prevalence of TT virus and GBV-C infections among patients with liver diseases and the general population in Shanghai, China. Ding X, et al. **Virus Genes** 1999;19(1):51-8

Prevalence of GBV C/HGV RNA and GBV C/HGV antibodies in French volunteer blood donors: results of a collaborative study. Mercier B, et al. **Vox Sang** 1999; 76(3):166-9

[Comparison of partial sequencing of 5' non-coding region of seven HGV strains isolated from different areas in China] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):297-9 (Eng. Abstr.) **(Chi)**

[Sources of infections and genotypes of hepatitis C virus in children] Woźniakowska-Gęsicka T, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):65-7 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

GB virus C in systemic medium- and small-vessel necrotizing vasculitides. Servant A, et al. **Br J Rheumatol** 1998 Dec; 37(12):1292-4

Immunoreactivity to putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic subjects. Toniutto P, et al. **Clin Diagn Lab Immunol** 1999 Jul; 6(4):573-6

High prevalence of anti-HGV/E2 antibodies in HCV-positive patients with non Hodgkin's lymphoma [letter] Civardi G, et al. **Haematologica** 1998 Oct; 83(10):957-8

Gradual loss of IgG antibodies against GB virus C/hepatitis G virus in a patient with AIDS. Nerurkar VR, et al. **Hawaii Med J** 1998 Dec;57(12):733-4

HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. Silini E, et al. **J Hepatol** 1998 Oct; 29(4):533-40

Analysis of conserved ambisense sequences within GB virus C. Kondo Y, et al. **J Infect Dis** 1998 Oct;178(4):1185-8

Influence of CD4+ lymphocyte counts on GB virus C/hepatitis G virus carriership in HIV-positive individuals. Goubau P, et al. **J Med Virol** 1999 Apr;57(4):367-9

Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. Hassoba HM, et al. **J Med Virol** 1998 Nov;56(3):253-8

Detection of antibodies to E2-protein of GB virus-C/hepatitis G virus in patients with acute posttransfusion hepatitis. Hwang SJ, et al. **J Med Virol** 1999 Jan;57(1):85-9

Significance of antibodies to the recombinant E2 protein of hepatitis G virus in haemodialysis patients. Schulte-Frohlinde E, et al. **J Viral Hepat** 1998 Sep; 5(5):341-4

Antibodies to the E2 protein of hepatitis G virus in blood donors in New Zealand [letter] Woodfield G, et al. **N Z Med J** 1998 Nov 27;111(1078):459-60

GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Elkayam O, et al. **Pediatr Res** 1999 Jun;45(6):795-8

GB virus type C viremia and envelope antibodies among population subsets in The Netherlands. Jongerius J, et al. **Vox Sang** 1999;76(2):81-4

Antibodies to the E2 protein of GB virus C/hepatitis G virus: low prevalence in Asian countries. Ross RS, et al. **Zentralbl Bakteriol** 1998 Nov;288(3):415-9

[Prevalence of hepatitis G virus RNA and antibodies to HGV envelope protein (anti-E2) in patients with liver injury in Japan] Matsushita E, et al. **Nippon Rinsho** 1999 Jun; 57(6):1274-8 (9 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. Tagger A, et al. **Am J Gastroenterol** 1999 Feb;94(2):484-8

Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Abdulkarim AS, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):571-6

GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates. Woelfle J, et al. **Arch Dis Child** 1999 May;80(5):429-32

The complete coding sequence of a European isolate of GB-C/hepatitis G virus. Charrel RN, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):432-7

The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Muñoz SJ, et al. **Blood** 1999 Aug 15; 94(4):1460-4

Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. Ljungman P, et al. **Bone Marrow Transplant** 1998 Sep;22(5):499-501

Hepatitis G virus in patients with Hodgkin's lymphoma [letter] Persico M, et al. **Br J Haematol** 1998 Dec; 103(4):1206-7

A high prevalence of serum GB virus C/hepatitis G virus RNA in children with and without liver disease. Halasz R, et al. **Clin Infect Dis** 1999 Mar;28(3):537-40

Porphyria cutanea tarda and hepatitis G and C virus infection. Mancini C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):534-5

Lack of association between GBV-C infection and spontaneous abortion. Viazov S, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):458-9

Prevalence of hepatitis G virus infection among patients with chronic hepatitis. Yarkin F, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):154-6

GBV-C RNA presence in several high-risk groups of Spain. Quirós E, et al. **Eur J Epidemiol** 1998 Sep;14(6):617-9

Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products [published erratum appears in Gut 1999 Jun;44(6):898] Halasz R, et al. **Gut** 1999 Feb;44(2):274-8

HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C. Fabris P, et al. **Infection** 1998 Sep-Oct; 26(5):283-7

Clearance of hepatitis G virus infection in thalassaemic children [letter] Poovorawan Y, et al. **Infection** 1998 Nov-Dec;26(6):408

The effect of hepatitis G virus infection on hematological laboratory values in patients with chronic hepatitis C and B [letter] Radkowski M, et al. **Infection** 1999 Jan-Feb; 27(1):48

Hepatitis G, an old friend of elderly Italians [comment] Stroffolini T. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):528. Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):528.

Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. Woolley I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):408-12

Age-dependent acquisition of hepatitis G virus/GB virus C in a nonrisk population: detection of the virus by antibodies. Feucht HH, et al. **J Clin Microbiol** 1999 May;37(5):1294-7

High prevalence of GB virus C in Brazil and molecular evidence for intrafamilial transmission. Pinho JR, et al. **J Clin Microbiol** 1999 May;37(5):1634-7

Hepatitis G virus infection in lymphoma and in blood donors. Minton J, et al. **J Clin Pathol** 1998 Sep;51(9):676-8

GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China. Cao K, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1241-8

Effects of hepatitis G virus coinfection on severity of hepatitis C: relationship to risk factors and response to interferon treatment [see comments] Lin R, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):773-80. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763-6.

Minimal role of GB virus-C/hepatitis G virus in fulminant

and subfulminant hepatitis in Taiwan. Liu CJ, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):352–7

Hepatitis G virus in multitransfused thalassaemics from India. Panigrahi AK, et al. **J Gastroenterol Hepatol** 1998 Sep; 13(9):902–6

Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation. Bizollon T, et al. **J Hepatol** 1998 Dec; 29(6):893–900

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action [published erratum appears in J Hepatol 1998 Oct;29(4):686] Bréchot C, et al. **J Hepatol** 1998 Aug; 29(2):173–83

Quantitative analysis of GBV-C RNA in liver and serum by strand-specific reverse transcription-polymerase chain reaction. Kanda T, et al. **J Hepatol** 1998 Nov;29(5):707–14

Absence of the negative strand of GBV-C/HGV RNA from the liver. Laras A, et al. **J Hepatol** 1999 Mar;30(3):383–8

The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. Sergi C, et al. **J Hepatol** 1998 Dec;29(6):861–71

Prevalence of hepatitis G virus RNA in human immunodeficiency virus type 1-positive intravenous drug users. Zehender G, et al. **J Hum Virol** 1998 Jan–Feb; 1(2):96–100

Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. Lefrère JJ, et al. **J Infect Dis** 1999 Apr; 179(4):783–9

Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. Tan D, et al. **J Infect Dis** 1999 May;179(5):1055–61

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean island. Césaire R, et al. **J Med Virol** 1999 Oct;59(2):160–3

GBV-C/HGV coinfection in HIV-1-positive men: frequent detection of viral RNA in blood plasma but absence from seminal fluid plasma. Hollingsworth RC, et al. **J Med Virol** 1998 Dec;56(4):321–6

Identification of a novel GB type C virus/hepatitis G virus subtype in patients with hematologic malignancies. López-Alcorocho JM, et al. **J Med Virol** 1999 Jan; 57(1):80–4

High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. Nerurkar VR, et al. **J Med Virol** 1998 Oct; 56(2):123–7

Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential. Pavlova BG, et al. **J Med Virol** 1999 Apr; 57(4):361–6

High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus. Rey D, et al. **J Med Virol** 1999 Jan;57(1):75–9

Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. Wu JC, et al. **J Med Virol** 1998 Oct;56(2):118–22

No evidence of hepatitis G virus in fulminant hepatic failure in children. Perez RG, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):400–3

Hepatitis G virus infection in acute fulminant hepatitis: prevalence of HGV infection and sequence analysis of a specific viral strain. Sheng L, et al. **J Viral Hepat** 1998 Sep;5(5):301–6

Detection of GB virus C RNA by GBV-C LCx and two PCR assays with primers from the 5'non-coding and NS5B region. Berg ES, et al. **J Virol Methods** 1998 Dec; 76(1-2):43–9

A competitive reverse transcription-polymerase chain reaction assay for quantitation of GB virus C/hepatitis G virus RNA that circumvents heteroduplex artifact. Liu F, et al. **J Virol Methods** 1999 May;79(2):149–59

Multicyclic reverse transcription-polymerase chain reaction assay system for quantification of GB virus-C/hepatitis G virus RNA in serum. Saito T, et al. **J Virol Methods** 1998 Oct;74(2):185–91

GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in hemodialysis patients. Cabrerizo M, et al. **Kidney Int** 1999 Sep;56(3):1120–8

Hepatitis G virus infection in Spanish patients with hepatocellular carcinoma. Rodríguez Agulló JL, et al. **Liver** 1998 Aug;18(4):255–8

GBV-RNA detection by polymerase chain reaction with several primer pairs. Quirós E, et al. **Microbios** 1998; 95(381):125–30

Prevalence of GB virus C/hepatitis G virus ribonucleic acid and anti-hepatitis G virus-E2 antibodies among Japanese children with histories of transfusions or with liver diseases. Goto K, et al. **Pediatr Res** 1999 Jan;45(1):128–32

Mother-to-child transmission of hepatitis G virus [letter] Miura T, et al. **Pediatrics** 1998 Nov;102(5):1222–3

Lack of influence of hepatitis G virus infection on alcohol-related hepatic lesions. Tran A, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1209–12

Hepatitis GBV-C infection in intravenous drug users. Vimolket T, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):491–6

GB virus C/hepatitis G virus isolates in Japanese haemophiliacs and their origins. Toyoda H, et al. **Thromb Haemost** 1998 Aug;80(2):242–5

GB virus type C infection in patients treated for childhood acute lymphoblastic leukemia. Aricò M, et al. **Transfusion** 1999 Feb;39(2):212–7

Hepatitis G virus in intramuscular and intravenous immunoglobulin products manufactured in Europe [letter] Cristiano K, et al. **Transfusion** 1999 Apr;39(4):428

Transfusion-associated or nosocomial hepatitis G virus infection in patients undergoing surgery. Lunel F, et al. **Transfusion** 1998 Nov–Dec;38(11-12):1097–103

Hepatitis G virus or hepatitis GB virus type C infection in thalassemic patients [letter] Papaevangelou V, et al. **Transfusion** 1999 Mar;39(3):336–7

Absence of hepatitis G virus within liver tissue of patients undergoing liver transplantation for cryptogenic cirrhosis. Schiano TD, et al. **Transplantation** 1999 Apr 27; 67(8):1193–7

Prevalence of GB virus C/hepatitis G virus among blood donors in north-eastern Brazil. Goubau P, et al. **Trop Med Int Health** 1999 May;4(5):365–7

Establishment of a highly specific detection system for GB virus C (GBV-C) minus-strand RNA. Seipp S, et al. **Virus Res** 1998 Aug;56(2):183–9

GB virus C/hepatitis G virus and intravenous immunoglobulins. Nübling C, et al. **Vox Sang** 1998; 75(3):189–92

[Studies on multiple infection with hepatitis B, C and G viruses] Du S, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):13–5 (Eng. Abstr.) **(Chi)**

[Studies on GBV-C infection in blood donors in four provinces of China] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):349–51 (Eng. Abstr.) **(Chi)**

[GB virus-C/hepatitis G virus--discovery, epidemiology, diagnosis and clinical relevance] Sarrazin C, et al. **Z Gastroenterol** 1998 Nov;36(11):997–1008 (119 ref.) (Eng. Abstr.) **(Ger)**

[Hepatitis G virus infection in hemodialyzed children and adults following kidney transplantation] Szabó A, et al. **Orv Hetil** 1999 Jul 18;140(29):1619–23 (Eng. Abstr.) **(Hun)**

[Detection and genotype analysis of GB virus C/hepatitis G virus (GBV-C/HGV) in the sera of Japanese patients with hemophilia A] Okamoto Y, et al. **Rinsho Byori** 1999 Jun;47(6):571–5 (Eng. Abstr.) **(Jpn)**

[Coexistent hepatitis G virus infection and autoimmune hepatitis] Szaflarska-Szczepanik A. **Pol Merkuriusz Lek** 1999 Feb;6(32):82–3 (Eng. Abstr.) **(Pol)**

METABOLISM

RNA-Stimulated ATPase and RNA helicase activities and RNA binding domain of hepatitis G virus nonstructural protein 3. Gwack Y, et al. **J Virol** 1999 Apr;73(4):2909–15

Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3. Zhong W, et al. **Virology** 1999 Sep 1;261(2):216–26

PATHOGENICITY

High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis [see comments] De Filippi F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):529–33. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):467–9.

GB virus-C/hepatitis G virus infection in Taiwan: a virus that fails to cause a disease? Kao J, et al. **J Biomed Sci** 1999 Jul–Aug;6(4):220–5 (36 ref.)

GBV-C/HGV infection in children with chronic hepatitis C. Komatsu H, et al. **J Med Virol** 1999 Oct;59(2):154–9

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. Bukh J, et al. **Virology** 1999 Sep 30;262(2):470–8

["Hepatitis" A virus g: myth or reality? VHG/GBH-C: diagnosis, epidemiology, transfusion risk, and pathogenicity] Gérard C, et al. **Rev Med Liege** 1998 Sep; 53(9):524–8 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Analysis of hepatitis G virus/GB virus C quasispecies and replication sites in human subjects. Radkowski M, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):296–9

Hepatitis G virus and related flaviviruses: pathogens or passengers? He X, et al. **Curr Clin Top Infect Dis** 1998; 18:274–85 (43 ref.)

Absence of the negative strand of GBV-C/HGV RNA from the liver. Laras A, et al. **J Hepatol** 1999 Mar;30(3):383–8

Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell lines. Seipp S, et al. **J Hepatol** 1999 Apr;30(4):570–9

Is hepatitis G/GB virus-C virus hepatotropic? Detection of hepatitis G/GB virus-C viral RNA in liver and serum. Fan X, et al. **J Med Virol** 1999 Jun;58(2):160–4

GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. Lefrère JJ, et al. **J Med Virol** 1999 Sep; 59(1):32–7

In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus. Fogeda M, et al. **J Virol** 1999 May;73(5):4052–61

Replication of GB virus C (hepatitis G virus) in interferon-resistant Daudi cells. Shimizu YK, et al. **J Virol** 1999 Oct;73(10):8411–4

HGV: the identification, biology and prevalence of an orphan virus. Mphahlele MJ, et al. **Liver** 1998 Jun;18(3):143–55 (88 ref.)

HEPATITIS, ALCOHOLIC

CLASSIFICATION

[Does alcoholic chronic hepatitis exist?] Serov VV. **Arkh Patol** 1999 Jan–Feb;61(1):54–7 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Hepatic veno-occlusive lesions in severe alcoholic hepatitis and alcoholic liver cirrhosis: a comparative histopathological study in autopsy cases. Kishi M, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):47S–51S

[Hemophagocytic syndrome in a patient with anemia and liver pathology] D'Angelo G. **Recenti Prog Med** 1998 Nov; 89(11):573–4 (Eng. Abstr.) **(Ita)**

[A case of severe alcoholic hepatitis with iliopsoas abscess] Kamihira M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr;96(4):427–30 **(Jpn)**

DIAGNOSIS

Hyperhyaluronanemia in alcoholic hepatitis is associated with increased levels of circulating soluble intercellular adhesion molecule-1. Hill DB, et al. **Alcohol Clin Exp Res** 1998 Sep; 22(6):1324–7

DRUG THERAPY

[Corticosteroid therapy in acute severe alcoholic hepatitis: the end of a controversy?] Mathurin P, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):991–5 (29 ref.) **(Fre)**

[The use of Flamikar in patients with chronic hepatitis of alcoholic etiology] Kvacheniuk KL. **Lik Sprava** 1999 Apr–May;(3):142–4 (Eng. Abstr.) **(Ukr)**

ETIOLOGY

Alcoholic hepatitis as a T-cell mediated disorder: an hypothesis. Batey RG, et al. **Alcohol Clin Exp Res** 1999 Jul;23(7):1207–9 (32 ref.)

Ethanol co-exposure increases lethality of allyl alcohol in male Sprague-Dawley rats. Lee JY, et al. **J Toxicol Environ Health** 1999 Jan 22;56(2):121–30

GENETICS

Chemokine and cell adhesion molecule mRNA expression and neutrophil infiltration in lipopolysaccharide-induced hepatitis in ethanol-fed rats. Pennington HL, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1713–8

IMMUNOLOGY

Tumor necrosis factor and alcoholic liver disease. McClain CJ, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):248S–252S

A comparison of lipopolysaccharide-induced hepatitis in ethanol-fed Wistar and Lewis rats. Pennington HL, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1525–30

Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. Afford SC, et al. **J Pathol** 1998 Sep;186(1):82–9

Measurement of circulating T cell subsets positive for Fas antigen (CD95) in patients with alcoholic hepatitis. Ishimaru H. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1999 Jun;34(3):161–72

METABOLISM

Acetaldehyde prevents nuclear factor-kappa B activation and hepatic inflammation in ethanol-fed rats. Lindros KO, et al. **Lab Invest** 1999 Jul;79(7):799–806

Diet and risk of ethanol-induced hepatotoxicity: carbohydrate-fat relationships in rats. Korourian S, et al. **Toxicol Sci** 1999 Jan;47(1):110–7

PATHOLOGY

First International Symposium on the molecular pathology and clinical aspects of the inflamed liver: alcohol and cytokines. Neuman MG. **Clin Invest Med** 1998 Dec; 21(6):283–6

Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients. Conjeevaram HS, et al. **Transplantation** 1999 Jun 27; 67(12):1562–8

PHYSIOPATHOLOGY

Triggering of acute alcoholic hepatitis by alpha-interferon therapy. Zylberberg H, et al. **J Hepatol** 1999 Apr; 30(4):722–5

[Pro-inflammatory cytokines in the pathogenesis of alcoholic hepatitis] Mathurin P, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):311–9 (81 ref.) **(Fre)**

THERAPY

Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Ellis AJ, et al. **Int J Artif Organs** 1999 Jan;22(1):27–34

VIROLOGY

Clinicopathological study of chronic hepatitis induced by alcohol with or without hepatitis G virus. Shimanaka K, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):29S–32S

HEPATITIS, ALCOHOLIC, CHRONIC see **HEPATITIS, ALCOHOLIC**

HEPATITIS, ANIMAL

Clinical features of inflammatory liver disease in cats: 41 cases (1983–1993). Gagne JM, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):513–6

BLOOD

Copper increases in both plasma and red blood cells at the onset of acute hepatitis in LEC rats. Suzuki KT, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):189–94

DRUG THERAPY

Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Taguchi I, et al. **Inflamm Res** 1999 Jul; 48(7):380–5

ENZYMOLOGY

Chronic hepatitis in interferon-gamma transgenic mice is associated with elevated CPP32-like activity and interleukin-1beta-converting enzyme activity suppression. Okamoto T, et al. **Jpn J Pharmacol** 1999 Mar;79(3):289–94

ETIOLOGY

The mouse interferon-gamma transgene chronic hepatitis model (Review). Okamoto T, et al. **Int J Mol Med** 1999 May;3(5):517–20 (31 ref.)

GENETICS

Three for the price of one knockout--a mouse model of a congenital peroxisomal disorder, steatohepatitis, and hepatocarcinogenesis. Bass NM. **Hepatology** 1999 Feb; 29(2):606–8

IMMUNOLOGY

Induction and persistence of immune-mediated cholangiohepatitis in neonatally thymectomized mice. Masanaga T, et al. **Clin Immunol Immunopathol** 1998 Nov; 89(2):141–9

Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Tagawa Y, et al. **Eur J Immunol** 1998 Dec;28(12):4105–13

Propionibacterium acnes induces acute TNFalpha-mediated apoptosis of hepatocytes followed by inflammatory T-cell-mediated granulomatous hepatitis in mice. Chen YL, et al. **J Biomed Sci** 1999 Sep-Oct;6(5):349–56

METABOLISM

Cx32 mRNA in rat liver: effects of inflammation on poly(A) tail distribution and mRNA degradation. Theodorakis NG, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1249–57

Differential changes in alpha2-macroglobulin and hemopexin in brain and liver in response to acute inflammation. Saso L, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):839–44

Carcinoembryonic antigen-related cell-cell adhesion molecule C-CAM is greatly increased in serum and urine of rats with liver diseases. Lucka L, et al. **FEBS Lett** 1998 Oct 30;438(1-2):37–40

Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. Hartwell DW, et al. **J Cell Biol** 1998 Nov 16;143(4):1129–41

Effect of intravenous immunoglobulin G on the TNFalpha-mediated hepatic microvascular inflammatory response. Ito Y, et al. **Shock** 1999 Apr;11(4):291–5

PATHOLOGY

LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Mignon A, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1308–15

SCID/NCr mice naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis, and colitis. Li X, et al. **Infect Immun** 1998 Nov; 66(11):5477–84

Immunohistochemical characterization of the lesions of feline progressive lymphocytic cholangitis/cholangiohepatitis. Day MJ. **J Comp Pathol** 1998 Aug;119(2):135–47

Macrophage populations and apoptotic cells in the liver before spontaneous hepatitis in Long-Evans Cinnamon (LEC) rats. Yamate J, et al. **J Comp Pathol** 1999 May; 120(4):333–46

Does steatohepatitis impair liver regeneration? A study in a dietary model of non-alcoholic steatohepatitis in rats. Zhang BH, et al. **J Gastroenterol Hepatol** 1999 Feb; 14(2):133–7

Contrast-enhanced MR imaging of two superparamagnetic RES-contrast agents: functional assessment of experimental radiation-induced liver injury. Stiskal M, et al. **J Magn Reson Imaging** 1999 Jul;10(1):52–6

MR imaging of hepatic injury in the LEC rat under a high magnetic field (7.05 T). Asanuma T, et al. **J Vet Med Sci** 1999 Mar;61(3):239–44

PHYSIOPATHOLOGY

Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Knittel T, et al. **Am J Pathol** 1999 Jan; 154(1):153–67

Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis [see comments] Thompson K, et al. **Hepatology** 1998 Dec;28(6):1597–606 . Comment in: Hepatology 1998 Dec;28(6):1707–9.

Requirement of peptidergic sensory innervation for disease activity in murine models of immune hepatitis and protection by beta-adrenergic stimulation. Tiegs G, et al. **J Neuroimmunol** 1999 May 3;96(2):131–43

PREVENTION & CONTROL

Effects of various kinds of dietary amino acids on the hepatotoxic action of D-galactosamine in rats. Wang B, et al. **Biosci Biotechnol Biochem** 1999 Feb;63(2):319–22

Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. Okamoto T, et al. **Int J Mol Med** 1999 Aug;4(2):149–52

Preventive effect of zinc compounds, polaprezinc and zinc acetate against the onset of hepatitis in Long-Evans Cinnamon rat. Sugawara N, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):167–76

High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. Libert C, et al. **Transgenic Res** 1998 Nov;7(6):429–35

VIROLOGY

Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Ihrig M, et al. **Am J Pathol** 1999 Aug;155(2):571–82

Filamentous intranuclear inclusion bodies in psittacine birds. A structural and ultrastructural study. Scarlata E, et al. **Zentralbl Veterinarmed [B]** 1999 Aug;46(6):375–80

HEPATITIS ANTIBODIES

ANALYSIS

Prevalence of IgG-class antibodies against hepatitis E virus in a community of the southern Amazon: a randomized survey. Souto FJ, et al. **Ann Trop Med Parasitol** 1998 Jul; 92(5):623–5

Hepatitis A antibody prevalence among young adults in Israel--the decline continues. Gdalevich M, et al. **Epidemiol Infect** 1998 Oct;121(2):477–9

Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Bello PY, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):570–2

Hepatitis A incidence rate estimates from a pilot seroprevalence survey in Rio de Janeiro, Brazil. Struchiner CJ, et al. **Int J Epidemiol** 1999 Aug;28(4):776–81

Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. Huang YH, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):57–61

[Hepatitis E virus: detection of antibodies in blood donors in Lebanon] Irani Hakime N, et al. **J Med Liban** 1998 Mar-Apr;46(2):60–2 (Eng. Abstr.) **(Fre)**

[Prevalence of hepatitis G virus RNA and antibodies to HGV envelope protein (anti-E2) in patients with liver injury in Japan] Matsushita E, et al. **Nippon Rinsho** 1999 Jun; 57(6):1274–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[An autopsy case of primary squamous cell carcinoma of the liver associated with hepatitis C virus antibody positive liver cirrhosis] Yoshida T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1141–6 **(Jpn)**

[Filter paper sampling for the detection of anti-hepatitis A IgM antibodies] Rodriguez Lay LA, et al. **Rev Cubana Med Trop** 1998;50(1):42–7 (Eng. Abstr.) **(Spa)**

BLOOD

Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. Njoh J, et al. **East Afr Med J** 1998 Jun;75(6):327–8

Lack of evidence for increased risk of hepatitis A infection in homosexual men. Corona R, et al. **Epidemiol Infect** 1999 Aug;123(1):89–93

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Linder N, et al. **Infection** 1999 Mar-Apr;27(2):128–31

Age-dependent acquisition of hepatitis G virus/GB virus C in a nonrisk population: detection of the virus by antibodies. Feucht HH, et al. **J Clin Microbiol** 1999 May;37(5):1294–7

Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay. Touze A, et al. **J Clin Microbiol** 1999 Feb;37(2):438–41

HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. Silini E, et al. **J Hepatol** 1998 Oct; 29(4):533–40

A dose response study of hepatitis A vaccine in healthy adults who are > or = 30 years old and weigh > or = 77 kg. Bertino JS Jr, et al. **J Infect Dis** 1998 Oct;178(4):1181–4

The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. Leach CT, et al. **J Infect Dis** 1999 Aug;180(2):509–13

Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. Tan D, et al. **J Infect Dis** 1999 May;179(5):1055–61

Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. Bourlet T, et al. **J Med Virol** 1999 Aug; 58(4):373–7

Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. Tanaka T, et al. **J Med Virol** 1999 Apr; 57(4):370–5

Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. Whiteman D, et al. **J Viral Hepat** 1998 Jul;5(4):277–83

Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Dalekos GN, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1804–6

GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Elkayam O, et al. **Pediatr Res** 1999 Jun;45(6):795–8

Prevalence of GB virus C/hepatitis G virus ribonucleic acid and anti-hepatitis G virus-E2 antibodies among Japanese children with histories of transfusions or with liver diseases. Goto K, et al. **Pediatr Res** 1999 Jan;45(1):128–32

Duality of patterns in hepatitis A epidemiology: a study involving two socioeconomically distinct populations in Campinas, São Paulo State, Brazil. Pinho JR, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr;40(2):105–6

The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection [letter] Sylvan SP. **Scand J Infect Dis** 1998;30(4):429–30

Low prevalence of anti-HAV among children in Southern Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):451–2

Prevalence of anti-delta antibodies in central India. Jaiswal SP, et al. **Trop Gastroenterol** 1999 Jan-Mar;20(1):29–32

Prevalence of GB virus C/hepatitis G virus among blood donors in north-eastern Brazil. Goubau P, et al. **Trop Med Int Health** 1999 May;4(5):365–7

Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Dagan R, et al. **Vaccine** 1999 Apr 9;17(15-16):1919–25

Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Meng J, et al. **Virology** 1998 Sep 30;249(2):316–24

GB virus type C viremia and envelope antibodies among population subsets in The Netherlands. Jongerius J, et al. **Vox Sang** 1999;76(2):81–4

Prevalence of GBV C/HGV RNA and GBV C/HGV antibodies in French volunteer blood donors: results of a collaborative study. Mercier B, et al. **Vox Sang** 1999; 76(3):166–9

Antibodies to the E2 protein of GB virus C/hepatitis G virus: low prevalence in Asian countries. Ross RS, et al. **Zentralbl Bakteriol** 1998 Nov;288(3):415–9

[Serological character of hepatitis E virus mutants] Wang Y, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar; 7(1):24–5 (Eng. Abstr.) **(Chi)**

[Experimental in vivo passage of H2 strain of live attenuated vaccine of hepatitis A in common marmosets] Huang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):260–2 (Eng. Abstr.) **(Chi)**

[Detection of hepatitis A antibodies falsified through vaccination?] Tiller FW. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):981 **(Ger)**

[The first assessment of hepatitis E virus seroprevalence in northern Portugal] Macedo G, et al. **Acta Med Port** 1998 Dec;11(12):1065–8 (Eng. Abstr.) **(Por)**

[The prevalence of viral hepatitis markers in patients hospitalized in infectious disease wards with a diagnosis of acute viral hepatitis] Bălan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):247–53 (Eng. Abstr.) **(Rum)**

[Serologic markers to hepatitis E virus in residents in nonendemic regions] Fedorova OE. **Vopr Virusol** 1999 Jul-Aug;44(4):155–8 (48 ref.) (Eng. Abstr.) **(Rus)**

HEPATITIS ANTIBODIES

[Prevalence of anti-hepatitis A in patients with chronic liver disease] Diago M, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):324-6 (Eng. Abstr.) **(Spa)**

[Serum antibodies against hepatitis A virus among subjects of middle and low socioeconomic levels in urban area of Santiago, Chile] Lagos R, et al. **Rev Med Chil** 1999 Apr; 127(4):429-36 (Eng. Abstr.) **(Spa)**

[Prevalence of antibodies against hepatitis A in school children] Riedemann S, et al. **Rev Med Chil** 1998 Oct; 126(10):1161-4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. Hassoba HM, et al. **J Med Virol** 1998 Nov;56(3):253-8

Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India [letter] Agarwal SK, et al. **Nephron** 1999;81(4):448

HEPATITIS ANTIGENS

ANALYSIS

Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. Lin HP, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):91-6

Electrophoretic analysis of the ribonucleoproteins of hepatitis delta virus. Dingle K, et al. **J Virol Methods** 1998 Nov; 75(2):199-204

BIOSYNTHESIS

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Eliasson E, et al. **Chem Biol Interact** 1998 Nov 6;116(1-2):123-41

BLOOD

Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329-31

[The prevalence of viral hepatitis markers in patients hospitalized in infectious disease wards with a diagnosis of acute viral hepatitis] Bălan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):247-53 (Eng. Abstr.) **(Rum)**

CHEMISTRY

Identification and characterization of the RNA chaperone activity of hepatitis delta antigen peptides. Huang ZS, et al. **J Biol Chem** 1998 Oct 9;273(41):26455-61

Solution structure and RNA-binding activity of the N-terminal leucine-repeat region of hepatitis delta antigen. Lin IJ, et al. **Proteins** 1999 Oct 1;37(1):121-9

GENETICS

RNA binding domain of HDV antigen is homologous to the HMG box of SRY. Veretnik S, et al. **Arch Virol** 1999; 144(6):1139-58

Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA. Lo K, et al. **Virology** 1998 Oct 10;250(1):94-105

IMMUNOLOGY

Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. Njoh J, et al. **East Afr Med J** 1998 Jun;75(6):327-8

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. Khudyakov YE, et al. **J Clin Microbiol** 1999 Sep;37(9):2863-71

Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay. Touze A, et al. **J Clin Microbiol** 1999 Feb;37(2):438-41

GB virus C/hepatitis G virus infection in hemodialysis patients: determination of seroprevalence by a four-antigen recombinant immunoblot assay. Schröter M, et al. **J Med Virol** 1999 Mar;57(3):230-4

[Antigenic activity of delta-antigen peptides corresponding to three genotypes of the delta hepatitis virus] Dement'eva EV, et al. **Vopr Virusol** 1998 Sep-Oct;43(5):217-20 (Eng. Abstr.) **(Rus)**

METABOLISM

Cell cycle arrest mediated by hepatitis delta antigen. Hwang SB, et al. **FEBS Lett** 1999 Apr 16;449(1):41-4

Unique properties of the large antigen of hepatitis delta virus. Moraleda G, et al. **J Virol** 1999 Sep;73(9):7147-52

HEPATITIS, AUTOIMMUNE

Autoimmune sclerosing cholangitis in a child [letter; comment] Nagral A, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):91. Comment on: Indian J Gastroenterol 1999 Jan-Mar;18(1):31-2.

Remission of autoimmune hepatitis during pregnancy: a report of two cases. Colle I, et al. **Liver** 1999 Feb;19(1):55-7

[Physiopathology and treatment of autoimmune liver diseases] Nishioka M. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):456-60 (10 ref.) **(Jpn)**

[Refractory liver diseases (editorial)] Omata M. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):569-71 **(Jpn)**

BLOOD

Antineutrophil cytoplasmic antibodies in children. Sedivá A, et al. **Eur J Pediatr** 1998 Dec;157(12):987-91

Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Lapierre P, et al. **Gastroenterology** 1999 Mar;116(3):643-9

Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations. Yoshikawa M, et al. **J Gastroenterol** 1999 Apr;34(2):269-74

COMPLICATIONS

Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Volta U, et al. **Dig Dis Sci** 1998 Oct;43(10):2190-5

A case of Graves' disease associated with autoimmune hepatitis and mixed connective tissue disease. Inoue K, et al. **Endocr J** 1999 Feb;46(1):173-7

GH and zinc treatments for short stature caused by steroid treatments in a young patient with autoimmune hepatitis (type 1). Mori Y, et al. **Endocr J** 1998 Apr;45 Suppl:S163-5

Autoimmune sclerosing cholangitis: an overlap syndrome in a child [see comments] Gopal S, et al. **Indian J Gastroenterol** 1999 Jan-Mar;18(1):31-2. Comment in: Indian J Gastroenterol 1999 Apr-Jun;18(2):91.

Direct antiglobulin test negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Kondo H, et al. **Int J Hematol** 1998 Dec;68(4):439-43

An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Yamazaki K, et al. **Intern Med** 1999 May;38(5):422-5

Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. Viruet EJ, et al. **P R Health Sci J** 1998 Sep;17(3):297-300

Index of suspicion. Case 1. Autoimmune chronic hepatitis. Buetti-Sgouros M, et al. **Pediatr Rev** 1999 Jan;20(1):29-31

[Coexistent hepatitis G virus infection and autoimmune hepatitis] Szaflarska-Szczepanik A. **Pol Merkuriusz Lek** 1999 Feb;6(32):82-3 (Eng. Abstr.) **(Pol)**

[Autoimmune hepatitis and/or hepatitis C] Simonović J, et al. **Srp Arh Celok Lek** 1999 Mar-Apr;127(3-4):109-13 (Eng. Abstr.) **(Scc)**

DIAGNOSIS

Re: McNair et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis [letter; comment] Roberts EA. **Am J Gastroenterol** 1999 Jan;94(1):291-2. Comment on: Am J Gastroenterol 1998 May;93(5):777-84.

Chronic liver disease and hepatitis C virus in Egyptian patients. El-Medany OM, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1895-903

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Lohse AW, et al. **Hepatology** 1999 Apr; 29(4):1078-84

Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture, Japan. Omagari K, et al. **J Gastroenterol** 1999 Apr;34(2):221-6

Index of suspicion. Case 1. Autoimmune chronic hepatitis. Buetti-Sgouros M, et al. **Pediatr Rev** 1999 Jan;20(1):29-31

Index of suspicion. Case #1. Discussion: chronic autoimmune hepatitis. Devulapalli CS. **Pediatr Rev** 1999 Aug;20(8):273; discussion 274

[Diagnosis of autoimmune hepatitis] Rambusch EG, et al. **Med Klin** 1999 May 15;94(5):279-80 **(Ger)**

[Pruritus in liver disease: case report with discussion (published erratum appears in Schweiz Rundsch Med Prax 1999 Jan 28;88(5):197)] Hug B, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24;87(51-52):1805-10 (Eng. Abstr.) **(Ger)**

[Jaundice and progressive liver failure: delayed diagnosis of autoimmune hepatitis due to abrupt termination of steroid therapy?] Greving I, et al. **Z Gastroenterol** 1998 Sep; 36(9):847-51 (Eng. Abstr.) **(Ger)**

[Autoimmune hepatitis: Diagnostic standards and severity] Kakumu S. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):584-90 (4 ref.) **(Jpn)**

[The role of selected serologic markers in the diagnosis of autoimmune hepatitis] Marcinkiewicz M, et al. **Przegl Lek** 1998;55(11):614-8 (40 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Drug therapy in the management of type 1 autoimmune hepatitis. Czaja AJ. **Drugs** 1999 Jan;57(1):49-68 (152 ref.)

Clinical subgroup of autoimmune hepatitis type 1 sustaining remission without additional drugs. Ohana M, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1667-72

Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C. Nakamura K, et al. **J Gastroenterol Hepatol** 1999 May;14(5):413-8

Short-term cyclosporine induces a remission of autoimmune hepatitis in children. Alvarez F, et al. **J Hepatol** 1999 Feb; 30(2):222-7

Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. Burak KW, et al. **J Hepatol** 1998 Dec;29(6):990-3

Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. Debray D, et al. **J Pediatr** 1999 Jul; 135(1):111-4

Arthralgias, myalgias, and autoimmune hepatitis with minocycline therapy [letter] Matteson EL, et al. **J Rheumatol** 1998 Aug;25(8):1653-4

[Autoimmune hepatitis: importance of budesonide in intolerance to prednisolone (letter)] Audeguy P, et al. **Presse Med** 1999 Jan 30;28(4):176 **(Fre)**

[Autoimmune hepatitis: progress in its treatment] Nakamura K, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):591-6 (10 ref.) **(Jpn)**

ENZYMOLOGY

[Autoimmune hepatitis--a rare cause of elevated transaminases] Berdal JE, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4522-3 (Eng. Abstr.) **(Nor)**

EPIDEMIOLOGY

[Autoimmune hepatitis: an epidemiological study] Toda G, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):572-7 (10 ref.) **(Jpn)**

[Incidence and prevalence of autoimmune liver diseases] Berdal JE, et al. **Tidsskr Nor Laegeforen** 1998 Nov 30; 118(29):4517-9 (Eng. Abstr.) **(Nor)**

ETIOLOGY

Minocycline-related autoimmune hepatitis: case series and literature review. Teitelbaum JE, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1132-6 (13 ref.)

Clinical manifestations and immunological features of primary Sjögren's syndrome with liver involvement: analysis of thirty cases. Zhang Z, et al. **Chin Med J (Engl)** 1998 Mar;111(3):220-3

Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Jones DE, et al. **Hepatology** 1999 Jul;30(1):53-7

Minocycline induced lupus and autoimmune hepatitis [letter] Angulo JM, et al. **J Rheumatol** 1999 Jun;26(6):1420-1

Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Angulo JM, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):187-92 (41 ref.)

Outcome of autoimmune hepatitis after liver transplantation. Prados E, et al. **Transplantation** 1998 Dec 27;66(12):1645-50

GENETICS

Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Bittencourt PL, et al. **Am J Gastroenterol** 1999 Jul;94(7):1906-13

Two sister cases of autoimmune hepatitis. Ohira H, et al. **Fukushima J Med Sci** 1998 Dec;44(2):113-20

Searching for the needle in the haystack: another candidate needle in autoimmune hepatitis? [editorial; comment] Manns MP, et al. **Gastroenterology** 1999 Sep;117(3):728-32 . Comment on: Gastroenterology 1999 Sep;117(3):645-52.

Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Cookson S, et al. **Hepatology** 1999 Oct;30(4):851-6

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Lohse AW, et al. **Hepatology** 1999 Apr; 29(4):1078-84

IMMUNOLOGY

Immune reactivity to proteins biotransformed by alcohol metabolites. Klassen LW, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):204S-207S (15 ref.)

Pathogenesis of autoimmune hepatitis. McFarlane IG. **Biomed Pharmacother** 1999 Jun;53(5-6):255-63 (110 ref.)

Heterogeneity of anti-nuclear antibodies in autoimmune liver diseases. Nishioka M, et al. **Biomed Pharmacother** 1999 Aug;53(7):293-300 (42 ref.)

Argininosuccinate lyase: a new autoantigen in liver disease. Pelli N, et al. **Clin Exp Immunol** 1998 Dec;114(3):455-61

Increased bcl-2 expression in lymphocytes and its association with hepatocellular damage in patients with autoimmune hepatitis. Yachida M, et al. **Clin Exp Immunol** 1999 Apr; 116(1):140-5

Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Volta U, et al. **Dig Dis Sci** 1998 Oct;43(10):2190-5

Drug-induced immunotoxicity. Dansette PM, et al. **Eur J Drug Metab Pharmacokinet** 1998 Oct-Dec; 23(4):443-51 (70 ref.)

Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis [see comments] Czaja AJ, et al. **Gastroenterology** 1999 Sep; 117(3):645-52. Comment in: Gastroenterology 1999 Sep;117(3):728-31.

High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis [see comments] Sobajima J, et al. **Gut** 1999 Jun;44(6):867-73. Comment in: Gut 1999 Jun;44(6):776-7.

Autoimmune cholangitis: case report. Marinho R, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1949-52

Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Choudhuri K, et al. **Hepatology** 1998 Nov; 28(5):1177-81

Direct antiglobulin test negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Kondo H, et al. **Int J Hematol** 1998 Dec;68(4):439-43

Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. Czaja AJ. **J Hepatol** 1999 Mar; 30(3):394-401

Autoimmune cholangitis and primary biliary cirrhosis--an autoimmune enigma. Kinoshita H, et al. **Liver** 1999 Apr; 19(2):122-8

[Familial autoimmune hepatitis and C4 deficiency] Constans J, et al. **Rev Med Interne** 1998 Oct;19(10):731-3 (Eng. Abstr.) **(Fre)**

[Autoimmune cholangitis: a rare and ignored cause of cholestatic hepatitis (letter)] Marie I, et al. **Rev Med Interne** 1998 Aug;19(8):579-80 **(Fre)**

[Autoimmune hepatitis: description of its physiopathology] Tsuji T, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10; 88(4):578-83 (5 ref.) **(Jpn)**

METABOLISM

Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Tordjmann T, et al. **Liver** 1998 Dec;18(6):391-7

PATHOLOGY

Pathogenesis of autoimmune hepatitis. McFarlane IG. **Biomed Pharmacother** 1999 Jun;53(5-6):255-63 (110 ref.)

PHYSIOPATHOLOGY

Prednisone withdrawal advocates: beware of recurrent autoimmune hepatitis. Davila R, et al. **Hepatology** 1999 Jul; 30(1):338-9

Immunological liver diseases in children. Mieli-Vergani G, et al. **Semin Liver Dis** 1998;18(3):271-9 (49 ref.)

Recurrence of autoimmune hepatitis after liver transplantation. Götz G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):430-1

PREVENTION & CONTROL

Recurrence of autoimmune hepatitis after liver transplantation. Milkiewicz P, et al. **Transplantation** 1999 Jul 27;68(2):253-6

SURGERY

Prednisone withdrawal advocates: beware of recurrent autoimmune hepatitis. Davila R, et al. **Hepatology** 1999 Jul; 30(1):338-9

Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. Ratziu V, et al. **J Hepatol** 1999 Jan;30(1):131-41

Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Milkiewicz P, et al. **Liver** 1999 Feb;19(1):50-4

The immunoreactive propensity of autoimmune hepatitis: is It corticosteroid-dependent after liver transplantation? [editorial; comment] Czaja AJ. **Liver Transpl Surg** 1999 Sep;5(5):460-3 (29 ref.). Comment on: Liver Transpl Surg 1999 Sep;5(5):375-80.

Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis [see comments] Trouillot TE, et al. **Liver Transpl Surg** 1999 Sep;5(5):375-80 . Comment in: Liver Transpl Surg 1999 Sep;5(5):460-3.

Recurrence of autoimmune hepatitis after liver transplantation. Götz G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):430-1

Liver transplantation for autoimmune hepatitis: rejection and recurrence. Narumi S, et al. **Transplant Proc** 1999 Aug; 31(5):1955-6

Recurrence of autoimmune hepatitis after liver transplantation. Milkiewicz P, et al. **Transplantation** 1999 Jul 27;68(2):253-6

THERAPY

Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Fernandes NF, et al. **Am J Gastroenterol** 1999 Jan;94(1):241-8 (14 ref.)

[Therapy of autoimmune hepatitis] Rambusch EG, et al. **Med Klin** 1999 Mar 15;94(3):171-2 (5 ref.) **(Ger)**

[Autoimmune hepatitis. Clinical characteristics and response to treatment in a series of 49 spanish patients] Bruguera M, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):375-81 (Eng. Abstr.) **(Spa)**

HEPATITIS B

Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection. Gong ZJ, et al. **Hepatology** 1999 Feb;29(2):576-84

The Costa Rican experience on the serological response to the hepatitis B vaccine in health professionals [letter] Ruiz MA, et al. **Infect Control Hosp Epidemiol** 1999 May; 20(5):301

Follow-up to HBV and HCV carriers in a blood center [letter] Shimoyama R, et al. **Vox Sang** 1998;75(3):258

[Hepatitis viruses] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):62-5 (15 ref.) **(Jpn)**

[Hepatitis B] Kojima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):107-10 (15 ref.) **(Jpn)**

BLOOD

Viral markers in a blood donor population. Mwangi JW. **East Afr Med J** 1999 Jan;76(1):35-7

Discrimination of two different clinical entities, acute-type and subacute-type, human fulminant hepatitis by peripheral blood lymphocyte subsets. Shimizu T, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):274-80

Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. Ahmed SD, et al. **J Infect** 1998 Nov; 37(3):248-51

Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. Radovic M, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):369-73

A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg "a" determinant. Karthigesu VD, et al. **J Med Virol** 1999 Aug;58(4):346-52

Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results. Cardoso MS, et al. **Transfusion** 1998 Oct;38(10):905-7

Hepatitis B and blood safety. Kitchen A. **Vaccine** 1998 Nov; 16 Suppl:S34-7 (0 ref.)

[The serum insulin level in severe hepatitis patients] Liu S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):511-3 (Eng. Abstr.) **(Chi)**

[Prevalence of serologic markers of hepatitis B virus in hospital personnel] Fernandes JV, et al. **Rev Saude Publica** 1999 Apr;33(2):122-8 (Eng. Abstr.) **(Por)**

[The assessment of the course of an infectious process by the membrane status of the peripheral blood lymphocytes] Antonova TV, et al. **Klin Lab Diagn** 1999 Jul;(7):23-4 (Eng. Abstr.) **(Rus)**

[Functional status of the interferon system in inapparent and clinical infection with hepatitis B and C viruses] Priimiagi LS, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):85-8 (Eng. Abstr.) **(Rus)**

[Interferon system status in hemodialysis patients infected with hepatitis B and C viruses] Priimiagi LS, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):167-9 (Eng. Abstr.) **(Rus)**

[Intensity of the peroxidation of membrane lipids and metabolism of lymphocytes in viral hepatitis patients] Antonova TV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct;(5):64-7 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy [letter] Mastroianni CM, et al. **AIDS** 1998 Oct 1;12(14):1939-40

Reversible bilateral hydronephrosis without obstruction in hepatitis B-associated polyarteritis nodosa. Casserly LF, et al. **Am J Kidney Dis** 1999 Sep;34(3):e11 (29 ref.)

Appearance of nephrotic syndrome following interferon-alpha therapy in a patient with hepatitis B virus and hepatitis C virus coinfection. Endo M, et al. **Am J Nephrol** 1998;18(5):439-43

Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. Yates SC, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):714-20

Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcinogenesis in tree shrews. Li Y, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):67-71

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Chiaramonte M, et al. **Cancer** 1999 May 15;85(10):2132-7

Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma [see comments] Kubo S, et al. **Cancer** 1999 Sep 1;86(5):793-8. Comment in: Cancer 1999 Sep 1;86(5):741-3.

Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823-36 (67 ref.)

Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. Njoh J, et al. **East Afr Med J** 1998 Jun;75(6):327-8

The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania. Kondili LA, et al. **Epidemiol Infect** 1998 Oct;121(2):391-5

Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Fattovich G. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1206-13

Differences of resected hepatocellular carcinoma with hepatitis B or C virus. Shuto T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1722-5

Impact of hepatitis B and C virus on kidney transplantation outcome [see comments] Mathurin P, et al. **Hepatology** 1999 Jan;29(1):257-63. Comment in: Hepatology 1999 Jan;29(1):291-3.

Fibrosis/cirrhosis after orthotopic liver transplantation. Tabatabai L, et al. **Hum Pathol** 1999 Jan;30(1):39-47

Proceedings of the single theme consensus conference on Hepatitis B and C: Carrier to Cancer, Asian Perspectives. New Delhi, India, December 5-6, 1998. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S1-42 (0 ref.)

Prevalence of HBsAg in visceral leishmaniasis (kala-azar) [letter] Dhar KK, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):129

Hepatitis D infectivity profile among hepatitis B infected hospitalised patients in Calcutta. Bhattacharyya S, et al. **Indian J Public Health** 1998 Oct-Dec;42(4):108-12

Hepatitis B virus X protein inhibits nucleotide excision repair. Jia L, et al. **Int J Cancer** 1999 Mar 15;80(6):875-9

Erythema nodosum and associated diseases. A study of 129 cases. Cribier B, et al. **Int J Dermatol** 1998 Sep;37(9):667-72

Erythema multiforme following the exacerbation of hepatitis B virus infection. Tabata N, et al. **Int J Dermatol** 1999 Jan;38(1):52-3

A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Zhang JY, et al. **Int J Epidemiol** 1998 Aug; 27(4):574-8

Dapsone syndrome: hepatitis-B infection a risk factor for its development? [letter] Pavithran K, et al. **Int J Lepr Other Mycobact Dis** 1999 Jun;67(2):171-2

Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Guido M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):414-7

Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis? So SK, et al. **J Gastroenterol Hepatol** 1999 May; 14 Suppl:S48-52

Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Feitelson MA. **J Hepatobiliary Pancreat Surg** 1998;5(4):367-74 (111 ref.)

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action [published erratum appears in J Hepatol 1998 Oct;29(4):686] Bréchot C, et al. **J Hepatol** 1998 Aug; 29(2):173-83

Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis? Reus S, et al. **J Infect** 1998 Jul;37(1):84-6

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. Dore GJ, et al. **J Infect Dis** 1999 Sep;180(3):607-13

Prevalence of hepatitis B, C and HIV virus infection among beta thalassaemia major patients [letter] Shamsi T, et al. **JPMA J Pak Med Assoc** 1998 Mar;48(3):87

Long-term follow-up of a patient with hepatocellular carcinoma associated with triple hepatitis virus (HBV, HDV, HCV) infection. Koda T, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1188-92

HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy. Bhimma R, et al. **Kidney Int** 1999 Jun; 55(6):2440-9

Hepatocellular carcinoma [see comments] Schafer DF, et al. **Lancet** 1999 Apr 10;353(9160):1253-7 (57 ref.). Comment in: Lancet 1999 Jul 17;354(9174):253. Comment in: Lancet 1999 Jul 17;354(9174):253-4.

Prognosis of schistosomiasis mansoni patients infected with hepatitis B virus. Conceição MJ, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:255-8

Schistosomiasis and associated infections. Lambertucci JR, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:135-9 (49 ref.)

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. Cacciola I, et al. **N Engl J Med** 1999 Jul 1;341(1):22-6

Safety and efficacy of corticosteroids in childhood nephrotic syndrome with concomitant hepatitis B [letter] Butani L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1035-6

Remission of HBV-related mesangioproliferative glomerulonephritis after interferon therapy. Dhiman RK, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):176-8

Membranous nephropathy associated with hepatitis B virus infection: long-term clinical and histological outcome. Gonzalo A, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):416-8

Hepatitis B virus-associated nephropathy in black South African children. Bhimma R, et al. **Pediatr Nephrol** 1998 Aug;12(6):479-84

alpha-Interferon therapy for HBV-related glomerulonephritis. Lopes Neto EP, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1823-5

Virus-associated vasculitides [editorial] Guillevin L. **Rheumatology (Oxford)** 1999 Jul;38(7):588-90

Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha [letter] Wicki J, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):183-5

The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection [letter] Sylvan SP. **Scand J Infect Dis** 1998;30(4):429-30

Graft versus host disease in a liver transplant patient with

hepatitis B and hepatocellular carcinoma. Merhav HJ, et al. **Transplant Proc** 1999 Jun;31(4):1890–1

[A study on the multiple factorial causation of hepatoma among young patients] Luo TY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Feb; 18(1):37–9 (Eng. Abstr.) **(Chi)**

[Clinical analysis of spontaneous perforation of abdominal viscera in patients with severe viral hepatitis] Zuo D, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):262–4 (Eng. Abstr.) **(Chi)**

[Chronic hepatic porphyria and hepatitis B and C virus infections] Malina L, et al. **Cas Lek Cesk** 1998 Sep 21; 137(18):561–4 (Eng. Abstr.) **(Cze)**

[Cryoglobulinemia related to the hepatitis B and C viruses] Cohen P. **Pathol Biol (Paris)** 1999 Mar;47(3):232–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Periarteritis nodosa induced by hepatitis B virus] Mouthon L. **Pathol Biol (Paris)** 1999 Mar;47(3):237–44 (68 ref.) (Eng. Abstr.) **(Fre)**

[Between the infection and the vaccine, one must choose] Bouroz-Joly J, et al. **Rev Med Interne** 1998;19 Suppl 2:286s–289s **(Fre)**

[Exacerbation of hepatitis B and the expression of M proteinemia during the treatment of malignant lymphoma: a case study] Akiyama J, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):710–2 **(Jpn)**

[A comparative study of TTV co-infection in patients with chronic liver disease B, C and non-B non-C] Asaba N, et al. **Nippon Rinsho** 1999 Jun;57(6):1362–5 (Eng. Abstr.) **(Jpn)**

[Co-infection of HBV with HCV and a possible role of HBV DNA in hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1999 Jan;57(1):213–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[TTV superinfection on acute hepatitis B] Sakamoto M, et al. **Nippon Rinsho** 1999 Jun;57(6):1326–9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of acute hepatitis infected with hepatitis B virus during pregnancy and complicated by Gianotti-Crosti syndrome] Niitsuma H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr;96(4):423–6 **(Jpn)**

[Clinical picture, course and therapeutic efficiency of pulmonary tuberculosis in patients with organochlorine pesticides and hepatitis B markers] Mukhtarov DZ. **Probl Tuberk** 1998;(5):23–4 (Eng. Abstr.) **(Rus)**

[Characteristics of viral hepatitis in addicts with consideration of lymphocyte membrane condition] Antonova TV, et al. **Ter Arkh** 1998;70(11):21–4 (Eng. Abstr.) **(Rus)**

[Epidemiologic aspects of hepatocellular cancer in an environmentally unsafe area] Efimov GE, et al. **Vopr Onkol** 1998;44(6):662–6 **(Rus)**

CONGENITAL

Perinatal hepatitis B: update & recommendations. Corrarino JE. **MCN Am J Matern Child Nurs** 1998 Sep–Oct; 23(5):246–52; quiz 253 (23 ref.)

DIAGNOSIS

Deja vu: nosocomial hepatitis B virus transmission and fingerstick monitoring. Quale JM, et al. **Am J Med** 1998 Oct;105(4):296–301

Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions [see comments] Barr D, et al. **Am J Public Health** 1999 Jan;89(1):19–24. Comment in: Am J Public Health 1999 Jan;89(1):11–3.

Hepatitis B maternal screening, infant vaccination, and infant prophylaxis practices in North Carolina. Pierce RL, et al. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):619–23

Hepatitis B virus DNA in relation to duration of hepatitis B surface antigen carriage. Mendy ME, et al. **Br J Biomed Sci** 1999;56(1):34–8

Antenatal screening for hepatitis B infection and syphilis in the UK. Newell ML, et al. **Br J Obstet Gynaecol** 1999 Jan;106(1):66–71

Prevaccination screening for hepatitis B among sexually active adolescents and young adults [letter; comment] Buffington J, et al. **Clin Infect Dis** 1998 Dec;27(6):1562–3 . Comment on: Clin Infect Dis 1998 Jun;26(6):1459–60.

Chance finding of hepatitis B e antigen carriage in pregnant woman highlights need for antenatal screening, and vaccination of health care workers. **Commun Dis Rep CDR Wkly** 1999 May 21;9(21):183, 186

Guidelines for serological testing in the diagnosis of acute hepatitis A and B. Chitkara YK, et al. **Diagn Microbiol Infect Dis** 1999 Apr;33(4):241–5

The significance of hepatitis G virus infection in patients with non-A to C hepatic diseases. Tanaka T, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1870–3

HBsAg carrier with simultaneous amebic liver abscess and acute hepatitis E. Jain A, et al. **Indian J Gastroenterol** 1999 Jul–Sep;18(3):124

Human immunodeficiency virus and hepatitis B virus infection in pregnancy: diagnostic potential of viral genome detection. Berger A, et al. **Intervirology** 1998;41(4–5):201–7 (38 ref.)

Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. Ho SK, et al. **J Clin Microbiol** 1999 Aug;37(8):2461–5

Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. Weber B, et al. **J Clin Microbiol** 1999 Aug;37(8):2639–47

Predictors of positivity for hepatitis B and the derivation of a selective screening rule in a Canadian sexually transmitted disease clinic. Sellors J, et al. **J Clin Virol** 1998 Jul 24;11(1):85–91

Serological screening for hepatitis B and C and human herpesvirus 6 in Norwegian patients with primary Sjögren's syndrome [letter] Iakimtchouk K, et al. **J Rheumatol** 1999 Sep;26(9):2065–6

Voluntary blood tests for Canadian doctors? [news] Kondro W. **Lancet** 1998 Oct 10;352(9135):1205

Hepatitis B serology. Spearman CA, et al. **S Afr Med J** 1999 Jan;89(1):44

High prevalence of hepatitis B viral DNA in cirrhotic patients without surface antigen. Attallah AM, et al. **Trans R Soc Trop Med Hyg** 1998 Sep–Oct;92(5):516–7

Screening of pregnant women for hepatitis B. Boxall E. **Vaccine** 1998 Nov;16 Suppl:S30–3 (13 ref.)

[Missed infections in immigrant children] Obihara CC, et al. **Ned Tijdschr Geneeskd** 1999 Jul 24;143(30):1545–9 (Eng. Abstr.) **(Dut)**

[Hepatitis B virus infection in the school milieu of Kiffa and Selibaby, Mauritania] Rui WZ, et al. **Bull Soc Pathol Exot** 1998;91(3):247–8 (Eng. Abstr.) **(Fre)**

[Hepatitis B and HIV: the role of the family physician] Bucklitsch M, et al. **Fortschr Med** 1999 Apr 20;117(11):33 **(Ger)**

[Serologic diagnosis and follow-up of hepatitis B] Frei PC, et al. **Soz Praventivmed** 1998;43 Suppl 1:S10–3, S84–7 (Eng. Abstr.) **(Ger, Fre)**

[Hepatitis B: clinical manifestations, diagnosis and medical management] Pirovino M. **Soz Praventivmed** 1998;43 Suppl 1:S14–7, S88–91 (0 ref.) (Eng. Abstr.) **(Ger, Fre)**

[Maternal hepatitis B infection as the cause of nonimmunologic hydrops fetalis] Schröter B, et al. **Z Geburtshilfe Neonatol** 1999 Jan–Feb;203(1):36–8 (Eng. Abstr.) **(Ger)**

[What are the costs of the diagnosis and therapy of hepatitis B in a single patient in Hungary today? (letter)] Simon G Jr, et al. **Orv Hetil** 1998 Dec 27;139(52):3155–6 **(Hun)**

[Cholestatic-type hepatitis in childhood] Molina Merino A, et al. **An Esp Pediatr** 1998 Sep;49(3):253–6 (Eng. Abstr.) **(Spa)**

[Quantitative determination of HBV-DNA in chronic hepatitis B: comparison of three methods] Jardi R, et al. **Gastroenterol Hepatol** 1998 Aug–Sep;21(7):327–31 (Eng. Abstr.) **(Spa)**

[Cases of a combination of acute viral hepatitis B and obstructive jaundice] Shkurba AV. **Lik Sprava** 1998 Oct–Nov;(7):114–6 (Eng. Abstr.) **(Ukr)**

[A case of the combined course of viral hepatitis B and C with mechanical jaundice] Shkurba AV. **Lik Sprava** 1998 Jul–Aug;(5):146–8 **(Ukr)**

[The theoretical principles of the computer diagnosis of acute viral hepatitis] Vozianova ZhI, et al. **Lik Sprava** 1998 Aug; (6):59–62 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Ahmed A, et al. **Am J Gastroenterol** 1999 Jan;94(1):249–51

Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Ben-Ari Z, et al. **Am J Gastroenterol** 1999 Mar;94(3):663–7

Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir. Han SH, et al. **Am J Gastroenterol** 1998 Nov;93(11):2245–7

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection [published erratum appears in Antimicrob Agents Chemother 1999 Mar;43(3):726] Genovesi EV, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3209–17

Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Zhou T, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1947–54

Cell-based and animal models for hepatitis B and C viruses. Schinazi RF, et al. **Antivir Chem Chemother** 1999 May; 10(3):99–114 (180 ref.)

Current status of anti-HBV chemotherapy. Hong JH, et al. **Arch Pharm Res** 1998 Apr;21(2):89–105 (132 ref.)

Oral treatment for hepatitis B gets approval in the United States [news] [see comments] Josefson D. **BMJ** 1998 Oct 17;317(7165):1034. Comment in: BMJ 1999 May 1;318(7192):1213.

Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. ter Borg F, et al. **Dig Dis Sci** 1998 Oct;43(10):2267–70

Human immunodeficiency virus and hepatitis B virus co-infection in two siblings: viral loads markedly reduced by triple-therapy including lamivudine [letter] Horneff G, et al. **Eur J Pediatr** 1999 Aug;158(8):687–8

Food and Drug Administration approves lamivudine for hepatitis B. **Front Med Biol Eng** 1999;9(1):95

Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Niederau C, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):797–804

Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Toccaceli F, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1748–52

Global warming and therapeutic intervention for hepatitis B and C virus infection [letter] Arya SC. **Hepatology** 1999 Feb;29(2):610–11

The hepatitis B virus–trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Ilan E, et al. **Hepatology** 1999 Feb;29(2):553–62

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy [see comments] Liaw YF, et al. **Hepatology** 1999 Aug;30(2):567–72. Comment in: Hepatology 1999 Aug;30(2):579–81.

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.Lamivudine Transplant Group. Perrillo R, et al. **Hepatology** 1999 May;29(5):1581–6

Antiviral activity of ganciclovir, 9-(1,3-dihydroxy-2-propoxymethyl) guanine against woodchuck hepatitis virus: quantitative measurement of woodchuck hepatitis virus DNA using storage phosphor technology. Zahm FE, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):510–6

Effect of ursodeoxycholic acid in acute viral hepatitis. Galský J, et al. **J Clin Gastroenterol** 1999 Apr;28(3):249–53

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. Thibault V, et al. **J Clin Microbiol** 1999 Sep;37(9):3013–6

Lamivudine treatment for acute hepatitis B after liver transplantation. Andreone P, et al. **J Hepatol** 1998 Dec; 29(6):985–9

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. Günther S, et al. **J Hepatol** 1999 May;30(5):749–54

Lamivudine is safe and effective in fulminant hepatitis B [letter] Santantonio T, et al. **J Hepatol** 1999 Mar;30(3):551

Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis? Reus S, et al. **J Infect** 1998 Jul;37(1):84–6

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus–coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. Dore GJ, et al. **J Infect Dis** 1999 Sep;180(3):607–13

Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Eto T, et al. **Nat Med** 1999 May;5(5):577–81

alpha-Interferon therapy for HBV-related glomerulonephritis. Lopes Neto EP, et al. **Rev Paul Med** 1998 Sep–Oct;116(5):1823–5

Rx for B and C [news] Gibbs WW. **Sci Am** 1999 Mar; 280(3):17–20

Is nucleoside analogue monotherapy sufficient for treatment of HBV infection? Lessons from HIV [editorial] Pillay D, et al. **Sex Transm Infect** 1999 Apr;75(2):87–8

Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Durlik M, et al. **Transpl Int** 1998;11 Suppl 1:S135–9

Lamivudine therapy of hepatitis B virus-related liver disease: cirrhosis, posttransplantation recurrence, and de novo infection. Bárcena R, et al. **Transplant Proc** 1999 Sep; 31(6):2457–8

Treatment of hepatitis B–reinfection or de novo–infection after liver transplantation with famciclovir—how effective is it? Rayes N, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):481–2

Successful use of lamivudine for severe acute hepatitis B virus infection in a cardiac transplant recipient [letter] Dulai G, et al. **Transplantation** 1999 May 15;67(9):1288–9

[Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier] Hammond A, et al. **Dtsch Med Wochenschr** 1999 Jun 4;124(22):687–90 (Eng. Abstr.) **(Ger)**

[New management of hepatitis B virus] Sata M, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):713–7 (14 ref.) **(Jpn)**

[Successful treatment of an HB carrier developing severe hepatitis using lamivudine—case report] Handa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1136–40 **(Jpn)**

[Therapeutic efficacy of low-dose alpha interferon therapy in liver cirrhosis associated with HBV] Simon K, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):487–92 (Eng. Abstr.) **(Pol)**

[Treatment efficacy in acute intestinal infections, chronic diseases of the gastrointestinal tract and viral hepatitis B using large doses of Russian Bifidumbacterin-forte] Gracheva NM, et al. **Voen Med Zh** 1999 May;320(5):51–7, 96 (Eng. Abstr.) **(Rus)**

ECONOMICS

Economic evaluations applied to HB vaccination: general observations. Beutels P. **Vaccine** 1998 Nov;16 Suppl:S84–92 (31 ref.)

[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents] Szucs TD, et al. **Med Klin** 1998 Aug 15;93(8):468–77 (Eng. Abstr.) **(Ger)**

[Economic evaluation of various hepatitis B vaccination Strategies in Switzerland] Zurn P, et al. **Soz Praventivmed** 1998;43 Suppl 1:S61–4, S134–7 (Eng. Abstr.) **(Ger, Fre)**

ENZYMOLOGY

Further studies on aminopeptidase-M in blood in children with cholestatic liver diseases and viral hepatitis. Janas RM, et al. **Dig Dis Sci** 1999 Jan;44(1):170–6

Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Chemin I, et al. **Liver** 1999 Apr;19(2):81–7

Hepatitis B and C virus infection in patients with high serum transaminases [letter] Skliros EA, et al. **Postgrad Med J** 1998 Aug;74(874):511

[The enzymatic activity of IgG preparations in viral hepatitis] Zhil'tsov IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):73–7 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Bloodborne viral infection in Irish injecting drug users. Smyth BP, et al. **Addiction** 1998 Nov;93(11):1649–56

Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. Broers B, et al. **AIDS** 1998 Oct 22;12(15):2059–66

Surveillance and prevention of hepatitis B virus transmission [comment] Smith N, et al. **Am J Public Health** 1999 Jan; 89(1):11–3 (23 ref.). Comment on: Am J Public Health 1999 Jan;89(1):14–8. Comment on: Am J Public Health 1999 Jan;89(1):19–24.

Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Utsunomiya T, et al. **Am J Surg** 1999 Apr;177(4):279–81

Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-I infections in selected Solomon Islands populations. Furusyo N, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):85–91

The elimination of hepatitis B virus infection: changing seroepidemiology of hepatitis A and B virus infection in Okinawa, Japan over a 26-year period. Furusyo N, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):693–8

A survey on the vaccination practice for perinatal hepatitis B virus infection at a clinic in Okinawa, Japan. Hokama T, et al. **Asia Pac J Public Health** 1998;10(1):46–8

Hepatitis B sero-prevalence and risk factors among school-age children in a low socioeconomic community, Bangkok. Luksamijarulkul P, et al. **Asia Pac J Public Health** 1995;8(3):158–61

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377–84

More than third of world's population has been infected with hepatitis B virus [letter; comment] Zuckerman AJ. **BMJ** 1999 May 1;318(7192):1213. Comment on: BMJ 1998 Oct 17;317(7165):1034.

Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Lee CM, et al. **Cancer** 1999 Oct 1;86(7):1143–50

Hepatitis B virus infection among street youths in Montreal. Roy E, et al. **CMAJ** 1999 Sep 21;161(6):689–93

Outbreak of hepatitis B in an acupuncture clinic [see comments] Walsh B, et al. **Commun Dis Public Health** 1999 Jun;2(2):137–40. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.

Acute hepatitis B in injecting drug users is increasing as initiative to improve vaccine coverage begins. **Commun Dis Rep CDR Wkly** 1999 May 21;9(21):183, 186

Acute hepatitis B infection in England and Wales: 1985–96. Balogun MA, et al. **Epidemiol Infect** 1999 Feb; 122(1):125–31

The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Crampin AC, et al. **Epidemiol Infect** 1998 Oct;121(2):381–6

The prevalence of hepatitis B infection in adults in England and Wales. Gay NJ, et al. **Epidemiol Infect** 1999 Feb; 122(1):133–8

Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Ohba K, et al. **Epidemiol Infect** 1999 Feb;122(1):139–43

Risk factors for monoinfections and coinfections with HIV, hepatitis B and hepatitis C viruses in northern Spanish prisoners. Pallás J, et al. **Epidemiol Infect** 1999 Aug; 123(1):95–102

Hepatitis B virus infection among pregnant women in Split region. Ivić I, et al. **Eur J Epidemiol** 1999 Jul;15(6):589–90

Six years of sentinel surveillance of hepatitis B in general practice in France. Massari V, et al. **Eur J Epidemiol** 1998 Dec;14(8):765–7

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Santana Rodríguez OE, et al. **Eur J Epidemiol** 1998 Sep;14(6):555–61

Decline of hepatitis B infection in Greece. Stamouli M, et al. **Eur J Epidemiol** 1999 May;15(5):447–9

High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Kubo S, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):357–9

Prevalence of HBsAg in visceral leishmaniasis (kala-azar) [letter] Dhar KK, et al. **Indian J Gastroenterol** 1999 Jul–Sep;18(3):129

Incidence of hepatitis B virus (HBV) infection amongst clinically diagnosed acute viral hepatitis cases and relative risk of development of HBV infection in high risk groups in Calcutta. Hazra BR, et al. **Indian J Public Health** 1998 Apr–Jun;42(2):56–8

Prevalence of anti-hepatitis A antibodies, hepatitis B viral markers, and anti-hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990–1991. Almog R, et al. **Infection** 1999 May–Jun; 27(3):212–7

Seroprevalence of hepatitis B infection in Turkish children [letter] Kuyucu N, et al. **Infection** 1998 Sep–Oct; 26(5):317–8

Seroprevalence of syphilis, human immunodeficiency virus type-1, and hepatitis B virus infections among pregnant women in Turkey. Nas T, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):171–2

Seroprevalence of HIV, HBV, and syphilis and associated risk behaviours in male transvestites (Hijras) in Karachi, Pakistan. Baqi S, et al. **Int J STD AIDS** 1999 May; 10(5):300–4

An update on post-transfusion hepatitis in Italy [letter] Ciccozzi M, et al. **Ital J Gastroenterol Hepatol** 1998 Dec; 30(6):665

High prevalence of HBV infection markers in refugees from eastern countries [letter] Skliros EA, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):84–5

Epidemiology of hepatitis B, C, E, and G virus infections and molecular analysis of hepatitis G virus isolates in Bolivia. Konomi N, et al. **J Clin Microbiol** 1999 Oct; 37(10):3291–5

Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. Mbayed VA, et al. **J Clin Microbiol** 1998 Nov;36(11):3362–5

Seroepidemiology of HIV, HBV, HCV and treponemal infections. Kaur H, et al. **J Commun Dis** 1998 Mar; 30(1):29–31

Ten-year follow-up study of hepatitis B virus infection and vaccination status in hospital employees. Rosen E, et al. **J Hosp Infect** 1999 Mar;41(3):245–50

Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. Al-Faleh FZ, et al. **J Infect** 1999 May; 38(3):167–70

Pilot study to estimate survivors to 1995 of 1983–1984 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983–1984. Gore SM, et al. **J Infect** 1998 Sep; 37(2):159–65

Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. Lamden KH, et al. **J Infect** 1998 Nov;37(3):260–9

Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. Coleman PJ, et al. **J Infect Dis** 1998 Oct;178(4):954–9

Preimmunization epidemiology of hepatitis B virus infection in South African children. Vardas E, et al. **J Med Virol** 1999 Jun;58(2):111–5

Molecular epidemiology of hepatitis B virus mutants. Zuckerman AJ, et al. **J Med Virol** 1999 Jul;58(3):193–5

Prevalence of hepatitis B surface antigen (HBsAg) in children with sickle cell anaemia [letter] Angyo IA, et al. **J Trop Pediatr** 1998 Dec;44(6):376–7

Clinical and viral marker pattern of acute sporadic hepatitis in children in Madras, South India. Malathi S, et al. **J Trop Pediatr** 1998 Oct;44(5):275–8

Prevalence of hepatitis B Virus in dental clinics in Rawalpindi/Islamabad [letter] Fazli Z, et al. **JPMA J Pak Med Assoc** 1998 Aug;48(8):259

Inmates in Irish prisons face drug abuse and disease [news] Birchard K. **Lancet** 1999 Aug 28;354(9180):753

Occupational hepatitis B virus infection in sewage workers. Arvanitidou M, et al. **Med Lav** 1998 Sep–Oct;89(5):437–44

Hepatitis virus infection in haemodialysis patients from Moldavia. Covic A, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):40–5

Seroprevalence of blood borne transmissible diseases in trauma orthopaedic surgical patients. Sánchez LP, et al. **P R Health Sci J** 1998 Jun;17(2):113–6

Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Da Villa G, et al. **Res Virol** 1998 Sep–Oct;149(5):263–70

Hepatitis B virus infection profile in central Brazilian hemodialysis population. Teles SA, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):281–6

Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity. Martelli CM, et al. **Rev Panam Salud Publica** 1999 Jul;6(1):69–73 (33 ref.)

Epidemiology of acute hepatitis B in a university hospital in São Paulo, Brazil: retrospective study of two five-year periods. Ferraz ML, et al. **Rev Paul Med** 1998 May–Jun; 116(3):1695–9

The seroprevalence of hepatitis B and C in an Amerindian population in the southwestern Brazilian Amazon. Ferrari JO, et al. **Rev Soc Bras Med Trop** 1999 May–Jun; 32(3):299–302

Low prevalence of hepatitis B markers among Mexican female sex workers. Juárez-Figueroa L, et al. **Sex Transm Infect** 1998 Dec;74(6):448–50

Prevalence of hepatitis B and C virus infection among working women in Bangkok. Ikeda M, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):469–74

Prevalence of North India of hepatitis B carrier state amongst pregnant women. Prakash C, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):80–4

Prevalence of hepatitis B and C infection markers among adult women in urban and rural areas in Shaanxi Province, China. Shimbo S, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):263–8

Seroprevalence of hepatitis B and C, and human immunodeficiency type I viruses in a rural population from the Republic of Equatorial Guinea. Basaras M, et al. **Trans R Soc Trop Med Hyg** 1999 May–Jun;93(3):250–2

Hepatitis B virus infection in immigrants to the southern Brazilian Amazon. Souto FJ, et al. **Trans R Soc Trop Med Hyg** 1998 May–Jun;92(3):282–4

Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation. Maggi U, et al. **Transplant Proc** 1998 Dec;30(8):3946–7

Viral hepatitis in renal transplantation. Vathsala A. **Transplant Proc** 1999 Feb–Mar;31(1–2):337–9 (22 ref.)

Prevalence of hepatitis B infection among Tibetan refugees in northern India. Litch JA, et al. **Trop Doct** 1998 Oct; 28(4):229–30

Prevalence of hepatitis B infection in the general population: a rural community based study. Chowdhury A, et al. **Trop Gastroenterol** 1999 Apr–Jun;20(2):75–7

Prevalence of hepatitis B virus infection amongst healthy Nepalese males. Manandhar K, et al. **Trop Gastroenterol** 1998 Oct–Dec;19(4):145–7

Report on Working Group 1: Albania, Andorra, Canada, France, Italy, Moldova, Portugal, Poland, Romania and Spain. Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S58–60

Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board [editorial] Grob P, et al. **Vaccine** 1998 Nov;16 Suppl:S1–2 (12 ref.)

Report on Working Group 2: Austria, Belgium, Bulgaria, Germany, Greece, Hungary, Malta, Russia, Switzerland, Turkey and Uzbekistan [published erratum appears in Vaccine 1999 May 14;17(19):2472] Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S61–2

Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK). Iwarson S. **Vaccine** 1998 Nov;16 Suppl:S63–4

Control of hepatitis B in the United Kingdom. Ramsay M, et al. **Vaccine** 1998 Nov;16 Suppl:S52–5

The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients. Barton EN, et al. **West Indian Med J** 1998 Sep;47(3):105–7

[The relationship between viral hepatitis and primary liver cancer in four areas of China] Yu SZ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):214–6 (Eng. Abstr.) **(Chi)**

[Molecular epidemiologic analysis of hepatitis B] Wang P, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan; 32(1):10–2 (Eng. Abstr.) **(Chi)**

[Occurrence of hepatitis B and C among mentally retarded] Lunding S, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4393–6 (Eng. Abstr.) **(Dan)**

[Creation of a viral hepatitis B and C in the Côte-d'Or department. Methodology and initial results] Minello A, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):766–71 (Eng. Abstr.) **(Fre)**

[Seroprevalence of hepatitis B and C viruses in a psychiatric institution] Eveillard M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):543–8 (Eng. Abstr.) **(Fre)**

[Comorbidities in the addicted patient] Meiler A, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):747–50 **(Fre)**

[Early decline in an epidemic: evolution of the prevalences of HIV, hepatitis B, hepatitis C and aminotransferases in intravenous drug abusers in Strasbourg between 1980 and 1990] Will T. **Rev Med Suisse Romande** 1999 Apr; 119(4):329–34 (Eng. Abstr.) **(Fre)**

[Sclerotic plaques and vaccination against hepatitis B (editorial)] Gout O, et al. **Rev Neurol (Paris)** 1998 Apr; 154(3):205–7 **(Fre)**

[Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992–1996] Pillonel J, et al. **Transfus Clin Biol** 1998 Oct;5(5):305–12 (Eng. Abstr.) **(Fre)**

[Current hepatitis B epidemiology in Germany] Kralj N, et al. **Gesundheitswesen** 1998 Jul;60(7):450–5 (Eng. Abstr.) **(Ger)**

[Epidemiology of hepatitis B in Switzerland] Kammerlander R, et al. **Soz Praventivmed** 1998;43 Suppl 1:S27–30, S101–4 (Eng. Abstr.) **(Ger, Fre)**

[World-wide epidemiology of hepatitis B] Kane MA. **Soz Praventivmed** 1998;43 Suppl 1:S24–6, S98–100 (Eng. Abstr.) **(Ger, Fre)**

[The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants] Lutyński R, et al. **Folia Med Cracov** 1997;38(3–4):63–8 (Eng. Abstr.) **(Pol)**

[Analysis of liver function in patients with Turner syndrome (TS) and in patients with secondary hypogonadism with estrogen and estrogen- progestagens replacement therapy:

a preliminary report] Rujner J, et al. **Ginekol Pol** 1999 May; 70(5):338–42 (Eng. Abstr.) **(Pol)**

[Hepatitis B and C in 1997] Kuszewski K. **Przegl Epidemiol** 1999;53(1–2):75–81 (Eng. Abstr.) **(Pol)**

[Changes in the epidemiological situation of hepatitis B in Kielce region, after introduction of vaccination of infants against hepatitis B] Patrzalek M, et al. **Przegl Epidemiol** 1999;53(1–2):181–5 (Eng. Abstr.) **(Pol)**

[Prevalence of serologic markers of hepatitis B virus in hospital personnel] Fernandes JV, et al. **Rev Saude Publica** 1999 Apr;33(2):122–8 (Eng. Abstr.) **(Por)**

[The prevalence of viral hepatitis B in pregnant women in an area of southern Romania] Bălan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct–Dec; 43(4):254–60 (Eng. Abstr.) **(Rum)**

[The potential risk factors associated with acute viral hepatitis in children under 5 years old] Ion-Nedelcu N, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul–Sep; 43(3):133–8 **(Rum)**

[The clinico-epidemiological characteristics of the "carriage" of the causative agents of blood-contact viral hepatitides] Ogarkov PI, et al. **Voen Med Zh** 1998 Aug;319(8):38–44, 95 (Eng. Abstr.) **(Rus)**

[The theoretical bases of the epidemiology of viral hepatitis B] Shliakhtenko LI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):25–9 (Eng. Abstr.) **(Rus)**

[Viral hepatitis B morbidity in the Trebišov District after introduction of vaccination] Sallaiová M. **Epidemiol Mikrobiol Imunol** 1998 Aug;47(3):93–6 (Eng. Abstr.) **(Slo)**

[HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study] Cañero-Velasco MC, et al. **Acta Gastroenterol Latinoam** 1998;28(3):265–8 (Eng. Abstr.) **(Spa)**

[Hepatitis A, B, and C in an occupational center for the mentally handicapped] Arnedo A, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):370–3 (Eng. Abstr.) **(Spa)**

[Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain] Alfonso Gil R, et al. **Gac Sanit** 1999 Jan–Feb;13(1):16–21 (Eng. Abstr.) **(Spa)**

[Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia] León P, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):144–51 (32 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Hepatitis B and hepatocellular carcinoma in Eskimo/Inuit population. McMahon BJ, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:414–9 (40 ref.)

HIV and hepatitis B surveillance in First Nations alcohol and drug treatment centers in British Columbia, Canada. Martin JD, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:280–4

Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand. Blakely TA, et al. **Int J Epidemiol** 1999 Apr;28(2):204–10

ETIOLOGY

Role of the cell-mediated immune response in the pathogenesis of hepatitis B virus infection: possible immune-therapeutic strategies. Bertoletti A, et al. **Acta Biomed Ateneo Parmense** 1996;67(3–4):87–93 (17 ref.)

Increased risk of exposure to hepatitis B infection among butchers sharing knives. Mevorach D, et al. **Am J Med** 1999 Apr;106(4):479–80

Hepatitis B sero-prevalence and risk factors among school-age children in a low socioeconomic community, Bangkok. Luksamijarulkul P, et al. **Asia Pac J Public Health** 1995;8(3):158–61

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Kostaridou S, et al. **Bone Marrow Transplant** 1998 Nov;22(9):919–21

Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. Hutin YJ, et al. **Int J Epidemiol** 1999 Aug;28(4):782–6

Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.). Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.

Viral hepatitis and kidney transplantation. Lai MK. **J Formos Med Assoc** 1998 Dec;97(12):801–11 (147 ref.)

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. de Man RA, et al. **J Hepatol** 1998 Oct;29(4):669–75

Severe clinical course of de novo hepatitis B infection after liver transplantation. Crespo J, et al. **Liver Transpl Surg** 1999 May;5(3):175–83

Hepatitis after transplantation. Ye MQ, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S68–72 (15 ref.)

Hepatitis B: virus, pathogenesis and treatment. Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S11–6 (17 ref.)

[Fulminant hepatic failure related to immunosuppressive therapy in an asymptomatic HBsAg carrier with idiopathic interstitial pneumonia] Takagi S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):917–22 (Eng. Abstr.) **(Jpn)**

[Methotrexate and hepatitis B (letter; comment)] Callejas Rubio JL, et al. **Rev Clin Esp** 1999 Jun;199(6):409–10. Comment on: Rev Clin Esp 1998 Dec;198(12):822–4. **(Spa)**

GENETICS

Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Friedt M, et al. **Hepatology** 1999 Apr;29(4):1252–8

Genetic analysis of hepatitis B virus isolated from an infant with acute self-limited hepatitis. Sugiyama K, et al. **Pediatr Int** 1999 Apr;41(2):187–91

IMMUNOLOGY

Serologic hepatitis B immunity in vaccinated health care workers. Barash C, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1481–3

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners—NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377–84

Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Chen WN, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):757–61

Immunopathogenesis of viral hepatitis B and C. Tsai SL. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):159–70 (100 ref.)

False-positive tests for syphilis associated with human immunodeficiency virus and hepatitis B virus infection among intravenous drug abusers. Valencian Study Group on HIV Epidemiology. Hernández-Aguado I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):784–7

Study on proinflammatory cytokines (IL-1 beta, IL-6, TNF-alpha) and IL-2 in patients with acute hepatitis B. Geneva-Popova M, et al. **Folia Med (Plovdiv)** 1999; 41(1):78–81

Do T cells "see" the hepatitis B core and e antigens differently? [editorial; comment] Milich DR. **Gastroenterology** 1999 Mar;116(3):765–8 (25 ref.). Comment on: Gastroenterology 1999 Mar;116(3):650–7.

Immune status of individuals with differing clinical courses of HBV infection. Polat Eyigün C, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1890–4

Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299–305

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Böcher WO, et al. **Hepatology** 1999 Jan;29(1):238–44

Low response to hepatitis B vaccine in health care workers and medical students in Lisbon, Portugal [letter; comment] Marinho RT, et al. **Hepatology** 1998 Oct;28(4):1166. Comment on: Hepatology 1998 Feb;27(2):637.

Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, et al. **Hum Immunol** 1998 Dec;59(12):783–93

Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Akbar SK, et al. **Immunology** 1999 Jan;96(1):98–108

Immunological studies in hepatitis B carriers [letter; comment] Prasad AV. **Indian J Gastroenterol** 1999 Jan–Mar;18(1):43–4. Comment on: Indian J Gastroenterol 1998 Jul–Sep;17(3):83–6.

Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection. Akbar SK, et al. **Int J Exp Pathol** 1998 Oct;79(5):279–91 (49 ref.)

Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. Akbar SM, et al. **J Hepatol** 1999 May;30(5):755–64

The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. Schlaak JF, et al. **J Hepatol** 1999 Mar;30(3):353–8

Human class I supertypes and CTL repertoires extend to chimpanzees. Bertoni R, et al. **J Immunol** 1998 Oct 15; 161(8):4447–55

Isolated hepatitis B surface antibody as a sole marker for past HBV infection [letter] Bisharat N, et al. **J Infect** 1998 Sep;37(2):201–2

Class II HLA alleles and hepatitis B virus persistence in African Americans. Thio CL, et al. **J Infect Dis** 1999 Apr; 179(4):1004–6

Prevalence of hepatitis B surface antigen (HBsAg) in children with sickle cell anaemia [letter] Angyo IA, et al. **J Trop Pediatr** 1998 Dec;44(6):376–7

Immunogenicity of low-dose plasma-derived hepatitis B vaccine [letter; comment] Kane M, et al. **Lancet** 1997 Oct 11;350(9084):1102. Comment on: Lancet 1995 Jul 29;346(8970):318.

Reappearance of hepatitis B 10 years after kidney transplantation [letter] Kidd-Ljunggren K, et al. **N Engl J Med** 1999 Jul 8;341(2):127–8

Systemic lupus erythematosus and thrombocytopenic purpura in two members of the same family following hepatitis B vaccine [letter] Finielz P, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2420–1

Hepatitis B vaccine administered to children and adolescents at yearly intervals. Halsey NA, et al. **Pediatrics** 1999 Jun; 103(6 Pt 1):1243–7

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Losonsky GA, et al. **Pediatrics** 1999 Feb;103(2):E14

Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Ferrari C, et al. **Recent Results Cancer Res** 1998;154:330–6 (30 ref.)

The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Carlsson T, et al. **Scand J Infect Dis** 1999; 31(1):93–5

Viral clearance without destruction of infected cells during acute HBV infection. Guidotti LG, et al. **Science** 1999 Apr 30;284(5415):825–9

Cytokines in viral hepatitis. Koziel MJ. **Semin Liver Dis** 1999; 19(2):157–69 (147 ref.)

HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy. Vaughan RW, et al. **Tissue Antigens** 1998 Aug;52(2):130–4

The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Wilson JN, et al. **Vaccine** 1999 Feb 26;17(7–8):973–8

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Jung MC, et al. **Virology** 1999 Sep 1; 261(2):165–72

[Comments on hepatitis B vaccination in France] Poirriez J. **Presse Med** 1999 Jun 26;28(23):1242–4 (Eng. Abstr.) **(Fre)**

[Sclerotic plaques and vaccination against hepatitis B (editorial)] Gout O, et al. **Rev Neurol (Paris)** 1998 Apr; 154(3):205–7 **(Fre)**

[Combined hepatitis A/B immunization in children and adolescents. Economic evaluation of different immunization methods] Smala AM, et al. **MMW Fortschr Med** 1999 Jun 10;141(23):55–6 **(Ger)**

[Comparative studies on immunogenicity of Chinese hamster ovary cell drived HB vaccine and plasma drived HB vaccine] Yagura M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):21–8 (Eng. Abstr.) **(Jpn)**

[The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants] Lutyński R, et al. **Folia Med Cracov** 1997;38(3–4):63–8 (Eng. Abstr.) **(Pol)**

[The immunological and morphological aspects of chronic hepatitis caused by HBV] Gabriel A, et al. **Pol Merkuriusz Lek** 1998 May;4(23):292–4 (38 ref.) (Eng. Abstr.) **(Pol)**

[Does vaccination protect a child of an HBs Ag carrier mother against HBV infection?] Gołębiowska M, et al. **Przegl Epidemiol** 1998;52(3):255–62 (Eng. Abstr.) **(Pol)**

[Humoral response to HBV antigens in acute and chronic hepatitis B] Swiderska H, et al. **Przegl Epidemiol** 1998; 52(4):469–81 (Eng. Abstr.) **(Pol)**

[Factors associated with inadequate response to hepatitis B vaccination in health care personnel] Tolosa Martínez N, et al. **Rev Esp Salud Publica** 1998 Nov–Dec;72(6):509–15 (Eng. Abstr.) **(Spa)**

METABOLISM

Increase in serum carbamazepine concentrations after acute viral hepatitis [letter] Puente M, et al. **Ann Pharmacother** 1998 Dec;32(12):1369–70

Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.). Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.

[Expressions of Bcl-2, Bax and Bak proteins in liver tissues of hepatitis B patients and their significance] Zhang B, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):74–6 (Eng. Abstr.) **(Chi)**

MICROBIOLOGY

Weils' syndrome and concomitant hepatitis B infection. Kaushik SP, et al. **Singapore Med J** 1999 Feb;40(2):104–5

MORTALITY

Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. D'Arienzo A, et al. **Scand J Gastroenterol** 1998 Nov; 33(11):1213–8

Post-hepatitis primary disease does not influence 6-year survival after liver transplantation beyond 1 year. Caccamo L, et al. **Transpl Int** 1998;11 Suppl 1:S212–20

NURSING

A program to educate woman who test positive for the hepatitis B virus during the perinatal period. Corrarino JE, et al. **MCN Am J Matern Child Nurs** 1999 May–Jun; 24(3):151–5

PATHOLOGY

Viral-induced cirrhosis: grading of severity using MR imaging. Ito K, et al. **AJR Am J Roentgenol** 1999 Sep;

173(3):591–6
Fibrosing cholestatic hepatitis after living related–donor renal transplantation. Waguri N, et al.
J Gastroenterol Hepatol 1998 Nov;13(11):1133–7
Prediction of hepatic inflammatory activity in hepatitis B [letter; comment] ter Borg F, et al. **Lancet** 1998 Nov 7; 352(9139):1555. Comment on: Lancet 1998 Sep 12;352(9131):907–8.
Hepatitis after transplantation. Ye MQ, et al.
Liver Transpl Surg 1998 Sep;4(5 Suppl 1):S68–72 (15 ref.)
Hepatitis B virus–induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Chomarat P, et al. **Toxicol Lett** 1998 Dec 28; 102–103:595–601
Immunohistochemical study of HBV antigens in 338 liver cell carcinomas. Herrmann G. **Z Gastroenterol** 1999 May; 37(5):329–42
[Liver changes in people of conscription age—"carriers" of hepatitis B and C viruses] Povzun SA, et al.
Arkh Patol 1999 Jan–Feb;61(1):36–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Reactivation of hepatitis B in a long–term anti–HBs–positive patient with AIDS following lamivudine withdrawal. Altfeld M, et al. **J Hepatol** 1998 Aug;29(2):306–9
Characteristics of the early phase of chronicity in acute hepatitis B infection. Heijtink RA, et al. **J Med Virol** 1999 Apr;57(4):331–6
Effects of testosterone suppression on serum levels of hepatitis B surface antigen and HBV–DNA in men. Jilma B, et al. **Liver** 1998 Jun;18(3):162–5
Hepatitis B virus variants associated with clinically severe recurrence after liver transplantation. Fischer L, et al.
Transplant Proc 1999 Feb–Mar;31(1–2):492–3
Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. Vizuete SG, et al.
Transplant Proc 1999 Sep;31(6):2461–3

PREVENTION & CONTROL

Retesting of bone donors 2 months after donation guarantees sufficient safety of bone allografts. Hirn MY, et al.
Acta Orthop Scand 1998 Dec;69(6):566–9
Hepatitis B vaccination in preterm infants [letter; comment] Lau YL. **Acta Paediatr** 1998 Oct;87(10):1100–1. Comment on: Acta Paediatr 1998 Mar;87(3):336–8.
Syringe exchange and risk of infection with hepatitis B and C viruses [see comments] Hagan H, et al.
Am J Epidemiol 1999 Feb 1;149(3):203–13. Comment in: Am J Epidemiol 1999 Feb 1;149(3):214–6; discussion 217–8.
Invited commentary: needle exchange—no help for hepatitis? [comment] Moss AR, et al. **Am J Epidemiol** 1999 Feb 1; 149(3):214–6; discussion 217–8. Comment on: Am J Epidemiol 1999 Feb 1;149(3):203–13.
Hepatitis B vaccination program at a New York City hospital: seroprevalence, seroconversion, and declination. Louther J, et al. **Am J Infect Control** 1998 Aug;26(4):423–7
Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Miller ER, et al.
Am J Kidney Dis 1999 Feb;33(2):356–60
Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy. Ingardia CJ, et al. **Am J Perinatol** 1999;16(3):129–32
Costs and cost–effectiveness of a universal, school–based hepatitis B vaccination program. Krahn M, et al.
Am J Public Health 1998 Nov;88(11):1638–44
Vaccinating high school students against hepatitis B: a school/STD clinic collaboration. Peavey L, et al.
Am J Public Health 1999 Mar;89(3):412–3
Surveillance and prevention of hepatitis B virus transmission [comment] Smith N, et al. **Am J Public Health** 1999 Jan; 89(1):11–3 (23 ref.). Comment on: Am J Public Health 1999 Jan;89(1):14–8. Comment on: Am J Public Health 1999 Jan;89(1):19–24.
Prevention of hepatitis B flare–up during chemotherapy using lamivudine: case report and review of the literature. Al–Taie OH, et al. **Ann Hematol** 1999 May;78(5):247–9 (18 ref.)
Immunogenicity of hepatitis B vaccine in preterm infants. Blondheim O, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F206–8
Serologic hepatitis B immunity in vaccinated health care workers. Barash C, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1481–3
Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost–effectiveness using decision analysis. Fendrick AM, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):126–36
Hepatitis B maternal screening, infant vaccination, and infant prophylaxis practices in North Carolina. Pierce RL, et al.
Arch Pediatr Adolesc Med 1999 Jun;153(6):619–23
A survey on the vaccination practice for perinatal hepatitis B virus infection at a clinic in Okinawa, Japan. Hokama T, et al. **Asia Pac J Public Health** 1998;10(1):46–8
Preventive health behaviour among general practitioners in Victoria. McCall L, et al. **Aust Fam Physician** 1999 Aug; 28(8):854–7
Should immunisation against hepatitis B take priority over provision of clean drinking water? [letter] Puliyel JM.
BMJ 1999 Jul 17;319(7203):188
Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake. Wallis DE, et al. **BMJ** 1999 Apr 24;318(7191):1112–3
Hepatitis B virus infection. Margolis HS.
Bull World Health Organ 1998;76 Suppl 2:152–3
Impact of the media on vaccine uptake in British Columbia's grade 6 hepatitis B immunization program. Bigham M, et al. **Can Commun Dis Rep** 1999 May 15;25(10):89–93; discussion 93–4 **(Eng, Fre)**
Control of hepatitis B virus infection by vaccination: the Taiwan experience. Lee SD, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1998 Sep;61(9):501–6 (32 ref.)
A mathematical model predicting anti–hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Honorati MC, et al. **Clin Exp Immunol** 1999 Apr;116(1):121–6
Chaos reigns at medical schools over hepatitis B testing. Sibbald B. **CMAJ** 1999 May 18;160(10):1492–3
Assessing the infectivity of hepatitis B carriers. Ballard AL, et al. **Commun Dis Public Health** 1999 Sep;2(3):178–83
Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost–effectiveness studies. Edmunds WJ.
Commun Dis Public Health 1998 Dec;1(4):221–8 (34 ref.)
Lessons from patient notification exercises following the identification of hepatitis B e antigen positive surgeons in an English health region [see comments] [published erratum appears in Commun Dis Public Health 1999 Sep;2(3):222] Oliver SE, et al. **Commun Dis Public Health** 1999 Jun; 2(2):130–6. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.
Hepatitis B vaccination for occupational risk: an audit in general practice. Tatham D, et al.
Commun Dis Public Health 1999 Sep;2(3):219–21
Lookback in angst [editorial; comment] Weller I.
Commun Dis Public Health 1999 Jun;2(2):79–81. Comment on: Commun Dis Public Health 1999 Jun;2(2):126–9. Comment on: Commun Dis Public Health 1999 Jun;2(2):130–6. Comment on: Commun Dis Public Health 1999 Jun;2(2):137–40.
Generalized granuloma annulare and hepatitis B vaccination. Wolf F, et al. **Eur J Dermatol** 1998 Sep;8(6):435–6
Hepatitis B vaccination in preterm infants. Gołębiowska M, et al. **Eur J Pediatr** 1999 Apr;158(4):293–7
Is there room for general practice in penitentiary institutions: screening and vaccinating high–risk groups against hepatitis. Chatziarsenis M, et al. **Fam Pract** 1999 Aug; 16(4):366–8
Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Kondo R, et al.
Gene Ther 1998 May;5(5):575–82
Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299–305
Long–term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Huang LM, et al. **Hepatology** 1999 Mar; 29(3):954–9
Preventing hepatitis B and hepatitis C virus infections in end–stage renal disease patients: back to basics [editorial; comment] Kellerman S, et al. **Hepatology** 1999 Jan; 29(1):291–3. Comment on: Hepatology 1999 Jan;29(1):257–63.
Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Ogata N, et al.
Hepatology 1999 Sep;30(3):779–86
Twelve–year follow–up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma–derived vaccine without booster doses in children. Yuen MF, et al. **Hepatology** 1999 Mar;29(3):924–7
Lack of in vitro lymphoproliferative response to hepatitis B surface antigen in healthy vaccine recipients. Nagaraju K, et al. **Indian J Med Res** 1998 Sep;108:80–4
Immunogenic response to hepatitis B vaccine in Indian infants. Karthikeyan G. **Indian Pediatr** 1998 Apr; 35(4):375–6; discussion 376–7
Hepatitis B immunization coverage and awareness in middle and upper–class population in Chennai City [letter] Pai M, et al. **Indian Pediatr** 1998 Sep;35(9):922–3
Newer vaccines: like Marie Antoinette said, "let the poor eat cake" [letter; comment] Puliyel JM. **Indian Pediatr** 1998 Dec;35(12):1245–9. Comment on: Indian Pediatr 1998 Aug;35(8):791–5.
Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses [letter; comment] Lyerla R, et al.
Infect Control Hosp Epidemiol 1999 Mar;20(3):156–7. Comment on: Infect Control Hosp Epidemiol 1998 Jul;19(7):508–10.
Personalized education improves hepatitis B vaccination rate among physicians in Saudi Arabia [letter] Memish ZA, et al. **Infect Control Hosp Epidemiol** 1998 Dec;19(12):887–8
Hepatitis B vaccination coverage among healthcare workers in Italy. Stroffolini T, et al.
Infect Control Hosp Epidemiol 1998 Oct;19(10):789–91
Hepatitis B vaccination of personnel employed in Victorian hospitals: are those at risk adequately protected? Thompson SC, et al. **Infect Control Hosp Epidemiol** 1999 Jan; 20(1):51–4
ACOG committee opinion. Hepatitis virus infections in obstetrician–gynecologists. Number 199, February 1998. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet 1998 Jul;62(1):91–2
Molecular analysis of the a determinant of HBsAg in children of HBeAg–positive mothers upon failure of postexposure prophylaxis. Poovorawan Y, et al. **Int J Infect Dis** 1998 Apr–Jun;2(4):216–20
Efficacy of informational letters on hepatitis B immunization rates in university students. Marron RL, et al.
J Am Coll Health 1998 Nov;47(3):123–7
Awareness and utilization of the hepatitis B vaccine among young men in the Ann Arbor area who have sex with men. Neighbors K, et al. **J Am Coll Health** 1999 Jan;47(4):173–8
Many ways to contract hepatitis B, one key way to prevent it. Grabenstein JD. **J Am Pharm Assoc (Wash)** 1998 Sep–Oct;38(5):636
Viral screening and assisted conception treatment—the Bourn Hall experience. Abusheikha N, et al.
J Assist Reprod Genet 1999 Jul;16(6):337–9
Hepatitis B vaccination [letter] Ames H.
J Can Dent Assoc 1998 Oct;64(9):612
Relation between experimental and non–experimental study designs. HB vaccines: a case study. Jefferson T, et al.
J Epidemiol Community Health 1999 Jan;53(1):51–4
How important is early childhood hepatitis B vaccination? A survey of primary care physicians. Zimmerman RK, et al. **J Fam Pract** 1998 Nov;47(5):370–4
Hematopoietic stem cell transplantation from non–replicative hepatitis B virus carriers is safe. Ustün C, et al.
J Hepatol 1999 Aug;31(2):202–9
Ten–year follow–up study of hepatitis B virus infection and vaccination status in hospital employees. Rosen E, et al.
J Hosp Infect 1999 Mar;41(3):245–50
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. McCluskie MJ, et al.
J Immunol 1998 Nov 1;161(9):4463–6
Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. Al–Faleh FZ, et al. **J Infect** 1999 May; 38(3):167–70
Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong–Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259–63
Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. Hsu HM, et al. **J Infect Dis** 1999 Feb;179(2):367–70
What level of hepatitis B antibody is protective? Jack AD, et al. **J Infect Dis** 1999 Feb;179(2):489–92
Hepatitis B vaccination in high–risk infants: 10–year follow–up. Wu JS, et al. **J Infect Dis** 1999 Jun; 179(6):1319–25
DNA–mediated immunization of mice with plasmid encoding HBs antigen. Yoon SJ, et al. **J Korean Med Sci** 1999 Apr; 14(2):187–92
Detection of HBV genome by gene amplification method in HBsAg negative blood donors. Bodhiphala P, et al.
J Med Assoc Thai 1999 May;82(5):491–5
A two dose combined hepatitis A and B vaccine in Chinese youngsters. Lee SD, et al. **J Med Virol** 1999 Sep;59(1):1–4
What type of travelers would benefit from combined vaccination against hepatitis A and B? Iwarson S.
J Travel Med 1998 Jun;5(2):80–3
Vaccination of travelers against hepatitis A and B. Löscher T, et al. **J Travel Med** 1999 Jun;6(2):107–14 (68 ref.)
Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. Thomas HC. **J Viral Hepat** 1998 Nov;5 Suppl 2:31–6
Evidence for the genetic basis of non–response in mice. Waters JA. **J Viral Hepat** 1998 Nov;5 Suppl 2:1–4
From the Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission—United States. **JAMA** 1999 Mar 3;281(9):790
Debate revived on hepatitis B vaccine value [news] Marwick C, et al. **JAMA** 1999 Jul 7;282(1):15–7
Vaccination against HBV in France [letter] Barquet N, et al. **Lancet** 1999 Jan 30;353(9150):414
Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Roche B, et al.
Liver Transpl Surg 1999 May;5(3):166–74
Perinatal hepatitis B: update & recommendations. Corrarino JE. **MCN Am J Matern Child Nurs** 1998 Sep–Oct; 23(5):246–52; quiz 253 (23 ref.)
Juvenile offenders and hepatitis B: risk, vaccine uptake and vaccination status. Thompson SC, et al. **Med J Aust** 1998 Sep 21;169(6):306–9
Update: recommendations to prevent hepatitis B virus transmission—United States.
MMWR Morb Mortal Wkly Rep 1999 Jan 22;48(2):33–4
DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Davis HL. **Mt Sinai J Med** 1999 Mar;66(2):84–90 (48 ref.)
A combined vaccine against hepatitis A and B in children and adolescents. Diaz–Mitoma F, et al.
Pediatr Infect Dis J 1999 Feb;18(2):109–14
Long term immune response of universal hepatitis B vaccination in infancy: a community–based study in Taiwan. Shih HH, et al. **Pediatr Infect Dis J** 1999 May; 18(5):427–32

Hepatitis B vaccine administered to children and adolescents at yearly intervals. Halsey NA, et al. **Pediatrics** 1999 Jun; 103(6 Pt 1):1243-7

Regional differences in infant immunization against hepatitis B: did intervention work? Takayama JI, et al. **Prev Med** 1999 Feb;28(2):160-6

No scientific justification to suspend hepatitis B immunization [news] **Public Health** 1998 Nov-Dec;113(6):487

No scientific justification to suspend hepatitis B immunization [news] **Public Health Rep** 1998 Nov-Dec;113(6):487

Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Da Villa G, et al. **Res Virol** 1998 Sep-Oct;149(5):263-70

Is the strategy of universal hepatitis B vaccination necessary in low-endemic countries? Poirriez J. **Scand J Gastroenterol** 1998 Sep;33(9):897-9

Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Cardell K, et al. **Scand J Infect Dis** 1999; 31(2):197-200

Factors associated with hepatitis B vaccination among men having sexual relations with men in Montreal, Quebec, Canada. Omega Study Group. Dufour A, et al. **Sex Transm Dis** 1999 Jul;26(6):317-24

Impact of the hepatitis B mass vaccination program in the southern part of Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):464-8

Motivating factors influencing participation in hepatitis B immunization programs in rural populations. Meert M, et al. **Stat Bull Metrop Insur Co** 1998 Oct-Dec;79(4):2-7

Mcnee bequest. Awareness of and protection against hepatitis B virus infection among healthcare workers in Nepal, 1997. Report on a period of elective study. Gyawali P. **Trans Med Soc Lond** 1996-97;113:91-3

Response to hepatitis B virus vaccine in patients transplanted for HBV-related liver disease under specific gammaglobulin prophylaxis. Bárcena R, et al. **Transplant Proc** 1999 Sep;31(6):2459-60

HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Golling M, et al. **Transplant Proc** 1998 Nov;30(7):3316-7

Good results of lamivudine in hepatitis B surface antigen-positive patienis with active viral replication before liver transplantation. Gugenheim J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):554-5

Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Lo CM, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):535-6

Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Ben-Ari Z, et al. **Transplantation** 1999 Jul 27;68(2):232-6

DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr-Jun;20(2):64-7 (30 ref.)

Control of Hepatitis B in Europe: Where are we in 1997? Proceedings of VHPB International Congress. Madrid, Spain, 17-19 November 1997. **Vaccine** 1998 Nov;16 Suppl:S1-110

Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Abraham P, et al. **Vaccine** 1999 Mar 5; 17(9-10):1125-9

Economic evaluations applied to HB vaccination: general observations. Beutels P. **Vaccine** 1998 Nov;16 Suppl:S84-92 (31 ref.)

Report on Working Group 1: Albania, Andorra, Canada, France, Italy, Moldova, Portugal, Poland, Romania and Spain. Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S58-60

Universal hepatitis B immunization: infant, and infant plus adolescent immunization [published erratum appears in Vaccine 1999 Apr 9;17(15-16):I] Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S17-22 (13 ref.)

Success stories in the implementation of universal hepatitis B vaccination: an update on Italy [published erratum appears in Vaccine 1999 Apr 9;17(15-16):I-II] Bonanni P, et al. **Vaccine** 1998 Nov;16 Suppl:S38-42 (13 ref.)

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Da Villa G, et al. **Vaccine** 1999 Mar 26;17(13-14):1734-8 (17 ref.)

Hepatitis B immunization programme: Spain. de la Torre J. **Vaccine** 1998 Nov;16 Suppl:S43-4

Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board [editorial] Grob P, et al. **Vaccine** 1998 Nov;16 Suppl:S1-2 (12 ref.)

Report on Working Group 2: Austria, Belgium, Bulgaria, Germany, Greece, Hungary, Malta, Russia, Switzerland, Turkey and Uzbekistan [published erratum appears in Vaccine 1999 May 14;17(19):2472] Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S61-2

Assessing immunization coverage: how and why? Guérin N. **Vaccine** 1998 Nov;16 Suppl:S81-3 (6 ref.)

Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK). Iwarson S. **Vaccine** 1998 Nov;16 Suppl:S63-4

Why the Scandinavian countries have not implemented universal vaccination against hepatitis B. Iwarson S. **Vaccine** 1998 Nov;16 Suppl:S56-7

Status of hepatitis B immunization programmes in 1998. Kane MA. **Vaccine** 1998 Nov;16 Suppl:S104-8 (25 ref.)

Evolution of the Viral Hepatitis Prevention Board--VHPB. McCloy E, et al. **Vaccine** 1998 Nov;16 Suppl:S7-10 (18 ref.)

Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Mast EE, et al. **Vaccine** 1998 Nov;16 Suppl:S27-9 (7 ref.)

Progress toward elimination of hepatitis B virus transmission in the United States. Mast EE, et al. **Vaccine** 1998 Nov; 16 Suppl:S48-51 (11 ref.)

Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Mast EE, et al. **Vaccine** 1999 Mar 26;17(13-14):1730-3 (16 ref.)

Control of hepatitis B in central and eastern Europe (CEE) and the Newly Independent States (NIS): recommendations of the October 1996 meeting in Siófok, Hungary. Meheus A. **Vaccine** 1998 Nov;16 Suppl:S99-103

Hepatitis B immunization programme: lessons learnt in Greece. Papaevangelou G. **Vaccine** 1998 Nov;16 Suppl:S45-7

Control of hepatitis B in the United Kingdom. Ramsay M, et al. **Vaccine** 1998 Nov;16 Suppl:S52-5

Surveillance of hepatitis B: an example of a vaccine preventable disease. Ramsay ME, et al. **Vaccine** 1998 Nov; 16 Suppl:S76-80 (12 ref.)

Universal hepatitis B immunization: young adolescent immunization. Tepper ML. **Vaccine** 1998 Nov;16 Suppl:S23-6 (34 ref.)

Effect of plasmid DNA on immunogenicity of HBsAg-anti-HBs complex. Qu D, et al. **Viral Immunol** 1998;11(2):65-72

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147-54 (79 ref.)

Hepatitis B immunization. **Wkly Epidemiol Rec** 1998 Oct 23; 73(43):329 **(Eng, Fre)**

[A study on the effectiveness of hepatitis B vaccine among the vaccinated population] Wang C, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):43-6 (Eng. Abstr.) **(Chi)**

[A study on the coverage, strategy and cost of hepatitis B vaccination in China, 1996] Zeng X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):277-81 (Eng. Abstr.) **(Chi)**

[Antibody reaction to immunization with different recombinant hepatitis B vaccine in primary school children] Liang Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May;32(3):165-7 (Eng. Abstr.) **(Chi)**

[Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg] Ren F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):7-9 (Eng. Abstr.) **(Chi)**

[Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine] Xu H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul;32(4):205-7 (Eng. Abstr.) **(Chi)**

[Follow-up on hepatitis B immunized neonates born to HBsAg positive mothers] Zhang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):97-9 (Eng. Abstr.) **(Chi)**

[Viral hepatitis: vaccination for hepatitis A and B virus] Bégué P. **Arch Pediatr** 1999;6 Suppl 2:186s-189s **(Fre)**

-Vaccination against hepatitis B- Merle P, et al. **Arch Pediatr** 1998 Mar;5(3):326-32 (Eng. Abstr.) **(Fre)**

[Prophylactic vaccination against hepatitis B: present and future] Momméja-Marin H, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):452-63 (80 ref.) **(Fre)**

[Suspension of vaccination for hepatitis B. No scientific justification for the plan (editorial)] **J Pharm Belg** 1998 Nov-Dec;53(6):362 **(Fre)**

[Vaccination against hepatitis B or chasing shadows (editorial)] Sicard D. **Rev Med Interne** 1999 Feb; 20(2):119-20 **(Fre)**

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587-92 (9 ref.) **(Fre)**

[Hepatitis B vaccination in 7th year students in Lausanne] Woringer V. **Rev Med Suisse Romande** 1999 Aug; 119(8):647-52 **(Fre)**

[Vaccination against hepatitis A and B in HCV-infected patient?] Blum E. **Internist (Berl)** 1998 Sep;39(9):980 **(Ger)**

[Active hepatitis B vaccination in ulcerative colitis treated with azathioprine] Hinrichsen H, et al. **Internist (Berl)** 1999 Mar;40(3):327-8 **(Ger)**

[Prevention of Hepatitis B in Switzerland by general vaccination] **Soz Praventivmed** 1998;43 Suppl 1:S1-151 **(Ger, Fre)**

[Information strategy for physicians and public health regarding introduction of general hepatitis B vaccination in Switzerland] Bourquin C, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S72-4, S146-8 (Eng. Abstr.) **(Ger, Fre)**

[Vaccination against hepatitis B] Desgrandchamps D, et al. **Soz Praventivmed** 1998;43 Suppl 1:S37-40, S111-4 (27 ref.) (Eng. Abstr.) **(Ger, Fre)**

[Hepatitis B vaccination: knowledge and acceptance by Swiss physicians] Gugelmann RJ, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S57-60, S130-3 (Eng. Abstr.) **(Ger, Fre)**

[Hepatitis B vaccination strategies] Kammerlander R, et al. **Soz Praventivmed** 1998;43 Suppl 1:S41-3, S115-7 (Eng. Abstr.) **(Ger, Fre)**

[World-wide status of hepatitis B vaccination 1998] Kane MA. **Soz Praventivmed** 1998;43 Suppl 1:S44-6, S118-20 (Eng. Abstr.) **(Ger, Fre)**

[General hepatitis B vaccination--a challenge for public health in the year 2000 (editorial)] Raeber PA, et al. **Soz Praventivmed** 1998;43 Suppl 1:S3-4, S78 **(Ger, Fre)**

[When competence and creativeness coincide] Thorens JJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S75-7, S149-51 (Eng. Abstr.) **(Ger, Fre)**

[General hepatitis B vaccination in Switzerland: what is the attitude of vaccinating physicians?] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S47-56, S121-9 (Eng. Abstr.) **(Ger, Fre)**

[Practical recommendations for general introduction of hepatitis B vaccination] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S69-71, S143-5 (Eng. Abstr.) **(Ger, Fre)**

[Introduction of general hepatitis B vaccination in Switzerland] Zimmermann H, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S65-8, S138-42 (Eng. Abstr.) **(Ger, Fre)**

[Prevention of hepatitis B (excluding vaccination)] Zimmermann H, et al. **Soz Praventivmed** 1998;43 Suppl 1:S34-6, S108-10 (Eng. Abstr.) **(Ger, Fre)**

[Viral hepatitis: preventable illnesses] Baumgarten R. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):677-80 (6 ref.) (Eng. Abstr.) **(Ger)**

[De novo hepatitis B infection after liver transplantation--evidence for the need of active hepatitis B vaccination of liver transplantation candidates] Rambusch EG, et al. **Z Gastroenterol** 1998 Dec; 36(12):1027-35 (Eng. Abstr.) **(Ger)**

[Immunoprophylaxis of hepatitis in the Hungarian literature (letter; comment)] Kékesi Z, et al. **Orv Hetil** 1998 Dec 13;139(50):3053. Comment on: Orv Hetil 1998 Aug 2;139(31):1835-42. **(Hun)**

[Blood-borne viral infection in hemodialysis units: special reference to hepatitis B virus, hepatitis C virus and human T-lymphotropic virus type 1] Washio M. **Nippon Koshu Eisei Zasshi** 1998 Oct;45(10):960-7 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Changes in the epidemiological situation of hepatitis B in Kielce region, after introduction of vaccination of infants against hepatitis B] Patrzałek M, et al. **Przegl Epidemiol** 1999;53(1-2):181-5 (Eng. Abstr.) **(Pol)**

[Vaccine against hepatitis B. Eight years of experience] Marinho RT, et al. **Acta Med Port** 1998 Nov;11(11):971-7 (Eng. Abstr.) **(Por)**

[Hepatitis B immunization in hemodialysis patients] Skladaný L, et al. **Vnitr Lek** 1998 Sep;44(9):535-7 (Eng. Abstr.) **(Slo)**

[A combined vaccine against hepatitis A and B (editorial)] Batalla J, et al. **Aten Primaria** 1999 May 31;23(9):513-4 **(Spa)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240-1 **(Spa)**

PSYCHOLOGY

Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Best D, et al. **BMJ** 1999 Jul 31;319(7205):290-1

SURGERY

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. Lerut JP, et al. **J Hepatol** 1999 Apr;30(4):706-14

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. Mutimer D, et al. **J Hepatol** 1999 Apr;30(4):715-21

Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Roche B, et al. **Liver Transpl Surg** 1999 May;5(3):166-74

Response to hepatitis B virus vaccine in patients transplanted for HBV-related liver disease under specific gammaglobulin prophylaxis. Bárcena R, et al. **Transplant Proc** 1999 Sep;31(6):2459-60

Lamivudine therapy of hepatitis B virus-related liver disease: cirrhosis, posttransplantation recurrence, and de novo infection. Bárcena R, et al. **Transplant Proc** 1999 Sep; 31(6):2457-8

Hepatitis B virus variants associated with clinically severe recurrence after liver transplantation. Fischer L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):492-3

HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Golling M, et al. **Transplant Proc** 1998 Nov;30(7):3316-7

Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation. Gugenheim J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):554-5

Orthotopic liver transplantation in HBs-antigen positive patients: short-term results. Lee SK, et al. **Transplant Proc** 1998 Nov;30(7):3314-5

Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Lo CM, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):535-6

Liver transplantation in HBsAg+ patients: results according to patient selection and treatment strategies. Loinaz C, et

al. **Transplant Proc** 1998 Nov;30(7):3305–6

Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Nery JR, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):485–6

Treatment of hepatitis B–reinfection or de novo–infection after liver transplantation with famciclovir—how effective is it? Rayes N, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):481–2

Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. Vizuete SG, et al. **Transplant Proc** 1999 Sep;31(6):2461–3

THERAPY

Update on diagnosis, management, and prevention of hepatitis B virus infection. Mahoney FJ. **Clin Microbiol Rev** 1999 Apr;12(2):351–66 (166 ref.)

Potent synergistic effect of sho–saiko–to, a herbal medicine, during vaccine therapy in a murine model of hepatitis B virus carrier. Akbar SM, et al. **Eur J Clin Invest** 1999 Sep; 29(9):786–92

Anti–HBV vaccination before therapy with interferon (IFN) in chronic B hepatitis. Fruttaldo L, et al. **Eur Rev Med Pharmacol Sci** 1997 Nov–Dec;1(6):197–201

Viral hepatitis and liver transplantation. Bzowej NH, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S53–60 (19 ref.)

Hepatitis B and C: an overview. Bodenheimer HC Jr. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S65–7 (26 ref.)

Management of posttransplantation viral hepatitis—hepatitis B. Dickson RC. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S73–8 (40 ref.)

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Davis HL. **Mt Sinai J Med** 1999 Mar;66(2):84–90 (48 ref.)

Remission of HBV–related mesangioproliferative glomerulonephritis after interferon therapy. Dhiman RK, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):176–8

Interferon therapy for hepatitis B and C. Murray JA. **Postgrad Med** 1998 Dec;104(6):25, 28

Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Nery JR, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):485–6

[Hepatitis B and C: current therapy] Bruch HR, et al. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1408–12 (42 ref.) (Eng. Abstr.) **(Ger)**

[Advances in the treatment of severe refractory diseases. 2) Viral hepatitis] Zeniya M, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2245–9 (8 ref.) **(Jpn)**

[A close association of prognosis with effect of interferon in HBV carriers developing acute severe exacervation] Higuchi D, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Sep;95(9):1001–7 (Eng. Abstr.) **(Jpn)**

[The use of recombinant alfa–2 interferon in treating patients with acute and chronic viral hepatitis B] Vovk AD, et al. **Lik Sprava** 1998 Oct–Nov;(7):117–21 (Eng. Abstr.) **(Rus)**

TRANSMISSION

Deja vu: nosocomial hepatitis B virus transmission and fingerstick monitoring. Quale JM, et al. **Am J Med** 1998 Oct;105(4):296–301

Balancing rights and duties. Hassed C. **Aust Fam Physician** 1999 Aug;28(8):839, 841

Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991–7: review of database. Soldan K, et al. **BMJ** 1999 Jan 9;318(7176):95

Hepatitis outbreak in UK blamed on alternative doctor [news] Richmond C. **CMAJ** 1999 Sep 21;161(6):678

Outbreak of hepatitis B in an acupuncture clinic [see comments] Walsh B, et al. **Commun Dis Public Health** 1999 Jun;2(2):137–40. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.

Chance finding of hepatitis B e antigen carriage in pregnant woman highlights need for antenatal screening, and vaccination of health care workers. **Commun Dis Rep CDR Wkly** 1999 May 21;9(21):183, 186

Leukocytoclastic vasculitis, hepatitis B, and the risk of endoscopy. Federman DG, et al. **Cutis** 1999 Feb;63(2):86–7

Maternal antibody to hepatitis B core antigen detected in dried neonatal blood spot samples. Tappin DM, et al. **Epidemiol Infect** 1998 Oct;121(2):387–90

Three cases of severe subfulminant hepatitis in heart–transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Stuyver L, et al. **Hepatology** 1999 Jun;29(6):1876–83

Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses [letter; comment] Lyerla R, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):156–7. Comment on: Infect Control Hosp Epidemiol 1998 Jul;19(7):508–10.

ACOG committee opinion. Hepatitis virus infections in obstetrician–gynecologists. Number 203, July 1998 (replaces No. 199, February 1998). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov; 63(2):203–4

Hepatitis B maternal–fetal transmission in Southern Europe. Papaevangelou G, et al. **Intervirology** 1998;41(4–5):197–200 (16 ref.)

Many ways to contract hepatitis B, one key way to prevent it. Grabenstein JD. **J Am Pharm Assoc (Wash)** 1998 Sep–Oct;38(5):636

Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. Coffin CS, et al. **J Clin Invest** 1999 Jul;104(2):203–12

Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. Huo TI, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1138–42

Early mortality of undiagnosed but prevalent (in 1983–1984) HIV infection in Lothian injectors who tested hepatitis B surface antigen positive (group A) or negative but were high risk for blood–borne virus transmission (group B) in 1983–1984. Gore SM, et al. **J Infect** 1998 Sep;37(2):166–72

Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong–Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259–63

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti–hepatitis B core– and anti–hepatitis B surface antibody–positive. Lau GK, et al. **J Infect Dis** 1998 Dec; 178(6):1585–91

Ethics of transmission of hepatitis B virus by health–care workers [see comments] Ristinen E, et al. **Lancet** 1998 Oct 24;352(9137):1381–3. Comment in: Lancet 1999 Jan 23;353(9149):324–5.

Provider–to–patient transmission of hepatitis B virus [letter; comment] Ross RS, et al. **Lancet** 1999 Jan 23; 353(9149):324–5. Comment on: Lancet 1998 Oct 24;352(9137):1381–3.

Hepatitis B carrier: the correct nomenclature [letter] Tandon BN. **Natl Med J India** 1999 May–Jun;12(3):141

Hepatitis B—are surgeons putting patients at risk? Birrell LN, et al. **Occup Med (Lond)** 1998 Nov;48(8):529–31 (13 ref.)

Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen–positive/hepatitis B e antigen–negative carriers. Zamir C, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):262–6

Research of antigen and antibodies from retroviruses, CMV and HBV among prisoners of the penitentiary complex of the region of Campinas, SP, Brazil. Osti NM, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul–Aug;40(4):209–13

Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Castells L, et al. **Transplant Proc** 1999 Sep; 31(6):2464–5

Hepatitis virus infection after living related liver transplantation: a report of 2 cases. Suzuki T, et al. **Transplant Proc** 1998 Nov;30(7):3312–3

Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Chen PM, et al. **Transplantation** 1999 Jun 15;67(11):1425–33

Occupational risk of hepatitis B and C infections in urologists. Oge O, et al. **Urol Int** 1998;61(4):206–9

Kidney transplantation in a child with posterior urethral valve from a hepatitis B virus–carrier mother. Report of a case with special reference to urinary tract reconstruction for dysfunctionalized uropathies and seroimmunological preparation against viral transmission. Seki T, et al. **Urol Int** 1998;61(4):237–9

Hepatitis B and blood safety. Kitchen A. **Vaccine** 1998 Nov; 16 Suppl:S34–7 (0 ref.)

Progress toward elimination of hepatitis B virus transmission in the United States. Mast EE, et al. **Vaccine** 1998 Nov; 16 Suppl:S48–51 (11 ref.)

A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient. Jongerius JM, et al. **Vox Sang** 1998;75(1):66–9

[A molecular epidemiologic study on the mechanism of intrauterine transmission of hepatitis B virus] Xu D, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):131–3 (Eng. Abstr.) **(Chi)**

[A study on familial aggregation of hepatitis virus infection in Fujian province] Li L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):362–4 (Eng. Abstr.) **(Chi)**

[A follow–up study on correlated factors for intrauterine infection of hepatitis B virus] Liu ZH, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):263–5 (Eng. Abstr.) **(Chi)**

[Hospital medical students: a population at risk for accidental exposure to blood] Keita–Perse O, et al. **Presse Med** 1998 Nov 7;27(34):1723–6 (Eng. Abstr.) **(Fre)**

[Materno–fetal transmission of hepatitis B virus in Ivory Coast. Plea for mass vaccination] Lohoués–Kouacou MJ, et al. **Sante** 1998 Nov–Dec;8(6):401–4 (Eng. Abstr.) **(Fre)**

[Post–exposure prophylaxis. What to do when nosocomial infection by HBV, HCV or HIV is suspected?] Gürtler L. **Fortschr Med** 1999 Jan 30;117(3):18–20 **(Ger)**

[Nosocomial hepatitis B virus, hepatitis C virus and HIV infections by infectious medial personnel] Hasselhorn HM, et al. **Gesundheitswesen** 1998 Oct;60(10):545–51 (38 ref.) (Eng. Abstr.) **(Ger)**

[Transmission of infectious diseases during imprisonment—results of a study and introduction of a model project for infection prevention in Lower Saxony] Keppler K, et al. **Gesundheitswesen** 1999 Apr;61(4):207–13 (Eng. Abstr.) **(Ger)**

[Risk of infection by needle–stick injury] Goebel FD, et al. **Internist (Berl)** 1999 Jan;40(1):117–8 **(Ger)**

[Transmission of hepatitis B] Kammerlander R, et al. **Soz Praventivmed** 1998;43 Suppl 1:S31–3, S105–7 (22 ref.) (Eng. Abstr.) **(Ger, Fre)**

[Does vaccination protect a child of an HBs Ag carrier mother against HBV infection?] Gołębiowska M, et al. **Przegl Epidemiol** 1998;52(3):255–62 (Eng. Abstr.) **(Pol)**

[Accidental contact with syringes used by intravenous drug users (IDU): a decade of study] Gómez Campderá J, et al. **An Esp Pediatr** 1998 Oct;49(4):375–80 (Eng. Abstr.) **(Spa)**

VETERINARY

Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half–life and association with the nuclear framework. Dandri M, et al. **J Virol** 1998 Nov;72(11):9359–64

VIROLOGY

Antiviral activity of 1,7–disulphoanthraquinone. Ciebiada I, et al. **Acta Microbiol Pol** 1998;47(3):261–6

Emergence of drug–resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Zhou T, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1947–54

Hepatitis B virus variants with lamivudine–related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Oon CJ, et al. **Antiviral Res** 1999 Apr;41(3):113–8

Clinical implications of mutations in the hepatitis B virus genome. Torre F, et al. **Eur J Clin Invest** 1998 Aug; 28(8):604–14 (153 ref.)

Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Shields PL, et al. **Gut** 1999 Aug;45(2):306–9

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy [see comments] Liaw YF, et al. **Hepatology** 1999 Aug;30(2):567–72. Comment in: Hepatology 1999 Aug;30(2):579–81.

Functional analysis of HBV genomes from patients with fulminant hepatitis. Sterneck M, et al. **Hepatology** 1998 Nov;28(5):1390–7

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Tillmann HL, et al. **Hepatology** 1999 Jul;30(1):244–56

Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Guido M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):414–7

Severe hepatitis in a HIV–positive subject under treatment with protease inhibitor [letter] Nigro L, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):85–6

Patterns of circulating hepatitis B surface antigen variants among vaccinated children born to hepatitis B surface antigen carrier and non–carrier mothers. A population–based comparative study. Ho M, et al. **J Biomed Sci** 1998 Sep–Oct;5(5):355–62

Quantitative detection of hepatitis B virus by transcription–mediated amplification and hybridization protection assay. Kamisango K, et al. **J Clin Microbiol** 1999 Feb;37(2):310–4

Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. Mbayed VA, et al. **J Clin Microbiol** 1998 Nov;36(11):3362–5

Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. Yeh CT, et al. **J Gastroenterol Hepatol** 1998 Feb; 13(2):131–6

Hepadnavirus evolution and molecular strategy of adaptation in a new host. Argentini C, et al. **J Gen Virol** 1999 Mar; 80 (Pt 3):617–26

Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells. Preikschat P, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1777–88

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. Günther S, et al. **J Hepatol** 1999 May;30(5):749–54

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. Lindh M, et al. **J Infect Dis** 1999 Apr; 179(4):775–82

Immunoassay detection of hepatitis B surface antigen mutants. Coleman PF, et al. **J Med Virol** 1999 Sep; 59(1):19–24

Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially. Petzold DR, et al. **J Med Virol** 1999 May;58(1):1–10

Evolution of wild–type and precore mutant HBV infection after liver transplantation. Torre F, et al. **J Med Virol** 1999 Sep;59(1):5–13

Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy [letter] Narváez J, et al. **J Rheumatol** 1998 Oct;25(10):2037–8

Current aspects of hepatitis B surface antigen mutants in Singapore. Oon CJ, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:17–23

HBV viral load within subpopulations of peripheral blood

mononuclear cells in HBV infection using limiting dilution PCR. Trippler M, et al. **J Virol Methods** 1999 Mar; 78(1-2):129-47

Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Rodriguez-Frias F, et al. **Liver** 1999 Jun; 19(3):177-82

Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Wietzke P, et al. **Liver** 1999 Aug; 19(4):348-53

Hepatitis B: virus, pathogenesis and treatment. Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S11-6 (17 ref.)

The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Wilson JN, et al. **Vaccine** 1999 Feb 26;17(7-8):973-8

[Research on the variation of hepatitis B virus and problems in the evaluation of its clinical significance (editorial)] Luo K. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):565-6 **(Chi)**

[Progress in the study of communicable diseases in China, 1997] Luo K, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):893-5 (0 ref.) **(Chi)**

[Mutations and their significance in the corepromoter region of hepatitis B virus] Tu H, et al. **Chuag Hua I Hsueh Tsa Chih** 1997 Aug;77(8):571-4 (Eng. Abstr.) **(Chi)**

[Studies on multiple infection with hepatitis B, C and G viruses] Du S, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):13-5 (Eng. Abstr.) **(Chi)**

[Comparison of sequences of hepatitis B virus S gene fragment in eight cities of China] Fan J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):140-3 (Eng. Abstr.) **(Chi)**

[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B] Romand F, et al. **Gastroenterol Clin Biol** 1999 Jun-Jul; 23(6-7):770-4 (Eng. Abstr.) **(Fre)**

[Monitoring and secondary effects of transfusion of labile blood products] Lapierre V, et al. **Presse Med** 1999 Jul 3-10;28(24):1327-35 (Eng. Abstr.) **(Fre)**

[Hepatitis B virus and pathogenesis] Grob PJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S5-9, S79-83 (9 ref.) (Eng. Abstr.) **(Ger, Fre)**

[The immunological and morphological aspects of chronic hepatitis caused by HBV] Gabriel A, et al. **Pol Merkuriusz Lek** 1998 May;4(23):292-4 (38 ref.) (Eng. Abstr.) **(Pol)**

HEPATITIS B ANTIBODIES

ANALYSIS

Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Oliveri F, et al. **Am J Gastroenterol** 1999 May; 94(5):1366-72

Maternal antibody to hepatitis B core antigen detected in dried neonatal blood spot samples. Tappin DM, et al. **Epidemiol Infect** 1998 Oct;121(2):387-90

Protective level of antibody induced by hepatitis B vaccine [letter; comment] Subramanyam V, et al. **Indian Pediatr** 1998 Aug;35(8):800-1. Comment on: Indian Pediatr 1997 Jun;34(6):555-6.

Prevalence of specific IgA and IgM anti-HBc antibodies compared with HBV DNA in the sera of HBsAg chronic carriers. Elsana S, et al. **J Hum Virol** 1997 Nov-Dec; 1(1):52-7

Hepatitis B virus surface antigen (HBsAg) and antibody (anti-HBs) forming immune complexes in fulminant hepatitis. Soares MC, et al. **Rev Soc Bras Med Trop** 1999 May-Jun;32(3):295-7

Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Blanpain C, et al. **Transplantation** 1998 Oct 15; 66(7):883-6

[The level of anti-HBs in blood serum of persons selected from a group of Krakow inhabitants] Lutyński R, et al. **Folia Med Cracov** 1997;38(3-4):63-8 (Eng. Abstr.) **(Pol)**

[Clinical picture, course and therapeutic efficiency of pulmonary tuberculosis in patients with organochlorine pesticides and hepatitis B markers] Mukhtarov DZ. **Probl Tuberk** 1998;(5):23-4 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG, et al. **Biochemistry (Mosc)** 1998 May;63(5):551-8

Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Kim SJ, et al. **Biotechnol Bioeng** 1998 Apr 5; 58(1):73-84

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Böcher WO, et al. **Hepatology** 1999 Jan;29(1):238-44

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. McCluskie MJ, et al. **J Immunol** 1998 Nov 1;161(9):4463-6

Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene): evidence for superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:5-8

Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. McDermott AB, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:9-11

Current aspects of hepatitis B surface antigen mutants in Singapore. Oon CJ, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:17-23

Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response. Zuckerman JN. **J Viral Hepat** 1998 Nov;5 Suppl 2:13-5

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Brazolot Millan CL, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15553-8

Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Langö-Warensjö A, et al. **Tissue Antigens** 1998 Oct;52(4):374-80

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **Vaccine** 1999 Jun 4;17(20-21):2528-37

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Koike Y, et al. **Vaccine** 1998 Dec;16(20):1982-9

DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response. Prange R, et al. **Vaccine** 1999 Feb 26; 17(7-8):617-23

[Expression of chimeric single-chain antibody with specificity for HBsAg in E. coli] Pan H, et al. **I Chuan Hsueh Pao** 1999;26(1):87-91 (Eng. Abstr.) **(Chi)**

BLOOD

Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Propst T, et al. **Am J Kidney Dis** 1998 Dec;32(6):1041-5

Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy. Ingardia CJ, et al. **Am J Perinatol** 1999;16(3):129-32

Antibody titers to hepatitis B surface antigen among vaccinated emergency physicians: three years' experience with a wellness booth. Goldberg R, et al. **Ann Emerg Med** 1999 Feb;33(2):156-9

Watchful monitoring for hepatitis B reactivation after intensive chemotherapy [letter; comment] Chalandon Y, et al. **Ann Oncol** 1999 Apr;10(4):483-4. Comment on: Ann Oncol 1998 Apr;9(4):385-7.

Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Barbieri B, et al. **Biofactors** 1999;9(2-4):351-7

High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan [see comments] Marusawa H, et al. **Gut** 1999 Aug;45(2):284-8. Comment in: Gut 1999 Aug;45(2):168-9.

Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Ruiz-Moreno M, et al. **Hepatology** 1999 Feb; 29(2):572-5

The Costa Rican experience on the serological response to the hepatitis B vaccine in health professionals [letter] Ruiz MA, et al. **Infect Control Hosp Epidemiol** 1999 May; 20(5):301

Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. Akbar SM, et al. **J Hepatol** 1999 May;30(5):755-64

Isolated hepatitis B surface antibody as a sole marker for past HBV infection [letter] Bisharat N, et al. **J Infect** 1998 Sep;37(2):201-2

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. Lau GK, et al. **J Infect Dis** 1998 Dec; 178(6):1585-91

Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels. Cabrerizo M, et al. **J Med Virol** 1998 Dec;56(4):294-9

Prognosis of schistosomiasis mansoni patients infected with hepatitis B virus. Conceição MJ, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:255-8

Fetal immunization of baboons induces a fetal-specific antibody response. Watts AM, et al. **Nat Med** 1999 Apr; 5(4):427-30

Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Shih HH, et al. **Pediatr Infect Dis J** 1999 May; 18(5):427-32

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Losonsky GA, et al. **Pediatrics** 1999 Feb;103(2):E14

Hepatitis B virus infection profile in central Brazilian hemodialysis population. Teles SA, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep-Oct;40(5):281-6

Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Castells L, et al. **Transplant Proc** 1999 Sep; 31(6):2464-5

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Van Herck K, et al. **Vaccine** 1998 Dec; 16(20):1933-5

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147-54 (79 ref.)

[A study on the effectiveness of hepatitis B vaccine among the vaccinated population] Wang C, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):43-6 (Eng. Abstr.) **(Chi)**

[Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg] Ren F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):7-9 (Eng. Abstr.) **(Chi)**

[Serologic diagnosis and follow-up of hepatitis B] Frei PC, et al. **Soz Praventivmed** 1998;43 Suppl 1:S10-3, S84-7 (Eng. Abstr.) **(Ger, Fre)**

[The development and certification of the Hepabest anti-HBc IgG test system for detecting antibodies to the core antigen of the hepatitis B virus] Iaroslavtseva OA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):49-52 (Eng. Abstr.) **(Rus)**

[The prevalence of serological markers of the hepatitis B virus in the hospital and primary health care workers of the Jerez area (Cádiz)] Alamillos Ortega P, et al. **Aten Primaria** 1999 Mar 15;23(4):212-7 (Eng. Abstr.) **(Spa)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240-1 **(Spa)**

GENETICS

[Improvement in affinity of phage antibodies against HBsAg by light chain shuffling] Mao C, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):36-8 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. Heijtink R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1529-35

What level of hepatitis B antibody is protective? Jack AD, et al. **J Infect Dis** 1999 Feb;179(2):489-92

Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. zu Putlitz J, et al. **J Virol** 1999 May;73(5):4188-96

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. Usuda S, et al. **J Virol Methods** 1999 Jun;80(1):97-112

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Kratz PA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1915-20

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. McCluskie MJ, et al. **Viral Immunol** 1998;11(4):245-52

Effect of plasmid DNA on immunogenicity of HBsAg-anti-HBs complex. Qu D, et al. **Viral Immunol** 1998;11(2):65-72

[Acute transverse cervical myelitis following hepatitis B vaccination. Evolution of anti-HBs antibodies] Renard JL, et al. **Presse Med** 1999 Jul 3-10;28(24):1290-2 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

[HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study] Cañero-Velasco MC, et al. **Acta Gastroenterol Latinoam** 1998;28(3):265-8 (Eng. Abstr.) **(Spa)**

METABOLISM

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Honorati MC, et al. **Clin Exp Immunol** 1999 Apr;116(1):121-6

Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299-305

Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Van Thiel DH, et al. **Transplantation** 1999 Aug 27; 68(4):519-22

THERAPEUTIC USE

Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299–305

HEPATITIS B ANTIGENS

ANALYSIS

The expression of insulin-like growth factor II, hepatitis B virus X antigen and p21 in experimental hepatocarcinogenesis in tree shrews. Su JJ, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):62–6

Human hepatitis B virus X protein is detectable in nuclei of transfected cells, and is active for transactivation. Nomura T, et al. **Biochim Biophys Acta** 1999 Mar 30; 1453(3):330–40

Immunohistochemical study of HBV antigens in 338 liver cell carcinomas. Herrmann G. **Z Gastroenterol** 1999 May; 37(5):329–42

BLOOD

Effects of testosterone suppression on serum levels of hepatitis B surface antigen and HBV-DNA in men. Jilma B, et al. **Liver** 1998 Jun;18(3):162–5

Hepatitis B virus infection profile in central Brazilian hemodialysis population. Teles SA, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):281–6

[Serologic diagnosis and follow-up of hepatitis B] Frei PC, et al. **Soz Praventivmed** 1998;43 Suppl 1:S10–3, S84–7 (Eng. Abstr.) **(Ger, Fre)**

[The prevalence of serological markers of the hepatitis B virus in the hospital and primary health care workers of the Jerez area (Cádiz)] Alamillos Ortega P, et al. **Aten Primaria** 1999 Mar 15;23(4):212–7 (Eng. Abstr.) **(Spa)**

[Transient blood surface antigens of hepatitis B in patients on hemodialysis] Santana Rodriguez OE, et al. **Rev Clin Esp** 1999 Apr;199(4):198–201 (Eng. Abstr.) **(Spa)**

GENETICS

The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Bergametti F, et al. **Oncogene** 1999 May 6;18(18):2860–71

IMMUNOLOGY

Lack of in vitro lymphoproliferative response to hepatitis B surface antigen in healthy vaccine recipients. Nagaraju K, et al. **Indian J Med Res** 1998 Sep;108:80–4

Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen. Chung MK, et al. **J Immunother** 1999 Jul; 22(4):279–87

METABOLISM

Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis. Koike K, et al. **Cancer Lett** 1998 Dec 25;134(2):181–6

Interaction of hepatitis B viral X protein and CCAAT/enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. Choi BH, et al. **J Biol Chem** 1999 Jan 29;274(5):2858–65

The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region/leucine zipper proteins by targeting the conserved basic region. Perini G, et al. **J Biol Chem** 1999 May 14;274(20):13970–7

Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Feitelson MA. **J Hepatobiliary Pancreat Surg** 1998;5(4):367–74 (111 ref.)

Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. Ohno H, et al. **J Med Virol** 1999 May; 58(1):11–8

The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Bergametti F, et al. **Oncogene** 1999 May 6;18(18):2860–71

PHYSIOLOGY

Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines. Tarn C, et al. **J Biol Chem** 1999 Jan 22;274(4):2327–36

HEPATITIS B, CHRONIC

Changing terminology of hepatitis B and C carrier: consensus statement. Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S15–20 (0 ref.)

Report on "The Asian collaborative survey on hepatitis B and C virus carriers". Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S3–5

Results of "The Asian collaborative survey on hepatitis B and C virus carriers: how do you assess?". The Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S6–8

"Hepatitis B and C: carrier to cancer--Asian perspectives": pre-conference expert group deliberations. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S9–14

Hepatitis B and C: carrier to cancer--current trends [editorial] Williams R. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S2

Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient [letter] Velasco M, et al. **N Engl J Med** 1999 Jun 3;340(22):1765–6

A virus questions human definitions of health. Anand AC. **Natl Med J India** 1998 Nov–Dec;11(6):290–1

BLOOD

The effect of interferon therapy on erythrocyte membrane Na+,K+ ATP activity in patients with chronic hepatitis B and C virus infections. Kuralay F, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1189–98

Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. Sawayama Y, et al. **Dig Dis Sci** 1999 Jan; 44(1):163–9

The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Bayraktar Y, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2322–7

Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Yuen MF, et al. **Hepatology** 1999 Apr;29(4):1248–51

Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. Murawaki Y, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):680–4

Outcome of chronic hepatitis B in children with normal transaminase levels [letter; comment] Ozen H, et al. **J Hepatol** 1999 May;30(5):962. Comment on: J Hepatol 1998 Aug;29(2):184–90.

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. Fukuda R, et al. **J Med Virol** 1999 Jul;58(3):201–7

Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. Oketani M, et al. **J Med Virol** 1999 Aug;58(4):332–7

Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. Saito T, et al. **J Med Virol** 1999 Aug;58(4):325–31

Long-term outcome of chronic hepatitis B in heart transplant recipients. Wedemeyer H, et al. **Transplantation** 1998 Nov 27;66(10):1347–53

[Clinical study on relationship between liver-blood stasis and liver fibrosis] Tang ZM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb; 17(2):81–3 (Eng. Abstr.) **(Chi)**

[The serum insulin level in severe hepatitis patients] Liu S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):511–3 (Eng. Abstr.) **(Chi)**

COMPLICATIONS

Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Yu MW, et al. **Am J Epidemiol** 1999 Aug 15;150(4):367–74

Primary hepatic lymphoma in a patient with chronic hepatitis B. Matano S, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2301–2

Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection. Faurschou M, et al. **Am J Hematol** 1999 Jun;61(2):135–8

Recombinant alpha-2a interferon treatment in a child with T-cell leukemia and chronic hepatitis B. Oren H, et al. **Ann Hematol** 1998 Oct;77(4):187–90

Clinical course of concomitant Hbv and Hcv infection in renal allograft recipients. Durlik M, et al. **Ann Transplant** 1996;1(2):11–2

Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal? Wolters LM, et al. **Antiviral Res** 1999 May;42(1):71–6

Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. Fan XG, et al. **Br J Biomed Sci** 1998 Sep;55(3):176–8

Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Yu MW, et al. **Br J Cancer** 1999 May; 80(3-4):598–603

Hepatocellular carcinoma and coinfection with hepatitis B and C. Making a difficult situation worse [editorial; comment] Kurtz RC. **Cancer** 1999 Sep 1;86(5):741–3. Comment on: Cancer 1999 Sep 1;86(5):793–8.

Chronic hepatitis B exacerbated by Guillain-Barré syndrome: a report of two cases. Han HF, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep;62(9):652–6

Chronic hepatitis B and neurogenic muscle disease: case report. Kamper AM, et al. **East Afr Med J** 1998 Nov; 75(11):667–8

Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329–31

Dyskeratosis congenita associated with Hodgkin's disease. Baykal C, et al. **Eur J Dermatol** 1998 Sep;8(6):385–7

Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Corrao G, et al. **Eur J Epidemiol** 1998 Jul;14(5):447–56

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Soriano V, et al. **Eur J Epidemiol** 1999 Jan;15(1):1–4

HBV + HCV = HCC? [comment] Cramp ME. **Gut** 1999 Aug;45(2):168–9. Comment on: Gut 1999 Aug;45(2):284–8.

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Colin JF, et al. **Hepatology** 1999 Apr;29(4):1306–10

Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1 [see comments] Sun Z, et al. **Hepatology** 1999 Aug;30(2):379–83. Comment in: Hepatology 1999 Aug;30(2):573–5.

Aflatoxin as a human carcinogen [editorial; comment] Wogan GN. **Hepatology** 1999 Aug;30(2):573–5. Comment on: Hepatology 1999 Aug;30(2):379–83.

Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis. Chu CM, et al. **J Clin Microbiol** 1999 Jan;37(1):235–7

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. Liang R, et al. **J Clin Oncol** 1999 Jan; 17(1):394–8 (50 ref.)

Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. Nagai K, et al. **J Gastroenterol** 1999 Apr;34(2):275–81

Natural history of chronic hepatitis B and C. Imperial JC. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S1–5 (30 ref.)

Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients. Lau GK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):52–6

Posterior mediastinal mass in a young male with chronic hepatitis B infection. Fortman BJ, et al. **Md Med J** 1999 Mar–Apr;48(2):59–61

Chronic carriers of hepatitis B surface antigen in an endemic area for schistosomiasis mansoni in Brazil. Serufo JC, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:249–53

The rising incidence of hepatocellular carcinoma [letter; comment] Watson RW. **N Engl J Med** 1999 Aug 5; 341(6):451–2. Comment on: N Engl J Med 1999 Mar 11;340(10):798–9.

Hepatitis viruses and hepatocellular carcinoma. Kew MC. **Res Virol** 1998 Sep–Oct;149(5):257–62 (55 ref.)

Prominent effect of immunoadsorption plasmapheresis therapy in a patient with chronic inflammatory demyelinating polyneuropathy associated with hepatitis B infection. Inoue A, et al. **Ther Apher** 1998 Nov;2(4):305–7

Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Younossi ZM, et al. **Transplantation** 1999 Jan 27;67(2):272–5

[Complications in chronic HBV infection] Hadengue A, et al. **Soz Praventivmed** 1998;43 Suppl 1:S18–20, S92–4 (Eng. Abstr.) **(Fre, Ger)**

[Treatment of sever polyneuropathy caused by hepatitis B virus with interferon alpha] Il'iankova AA, et al. **Ter Arkh** 1998;70(11):24–5 **(Rus)**

CONGENITAL

Survey of neonatal hepatitis B vaccination in Leicestershire. Dunn J, et al. **Commun Dis Public Health** 1999 Sep; 2(3):218–9

DIAGNOSIS

Watchful monitoring for hepatitis B reactivation after intensive chemotherapy [letter; comment] Chalandon Y, et al. **Ann Oncol** 1999 Apr;10(4):483–4. Comment on: Ann Oncol 1998 Apr;9(4):385–7.

An unusual cause of back pain. Rentsch JL, et al. **Aust Fam Physician** 1999 Apr;28(4):354–5

HBV DNA amplification by polymerase chain reaction in patients with serological evidence of chronic hepatitis B infection [letter] Rodrigues C, et al. **Indian J Gastroenterol** 1999 Jul–Sep;18(3):130–1

[How well do laboratory values correlate with histological activity of chronic hepatitis B infection?] Ritzmann P. **Schweiz Rundsch Med Prax** 1999 Jun 3;88(23):1055 **(Ger)**

[The natural course of hepatitis B and hepatitis C virus infection] Schwabe RF, et al. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1403–7 (56 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Lamivudine for chronic hepatitis B and HIV co-infection [letter] Carton JA, et al. **AIDS** 1999 May 28;13(8):1002–3

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Bessesen M, et al. **Clin Infect Dis** 1999 May;28(5):1032–5

Long-term treatment of chronic hepatitis B with oral ganciclovir in two kidney transplant recipients [letter; comment] Auinger M, et al. **Clin Nephrol** 1998 Dec; 50(6):392. Comment on: Clin Nephrol 1998 Jun;49(6):385–8.

Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Bécheur H, et al.

Dig Dis Sci 1998 Nov;43(11):2479–82 (30 ref.)

Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Jarvis B, et al. **Drugs** 1999 Jul;58(1):101–41 (279 ref.)

A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Dalekos GN, et al. **Eur J Gastroenterol Hepatol** 1998 Nov; 10(11):933–9

Lamivudine for chronic hepatitis B: the magic bullet or just another bright prospect? Kowdley KV. **Gastroenterology** 1999 Jun;116(6):1498–9

Therapy for chronic hepatitis B and C infection in haemophilia. Dusheiko GM. **Haemophilia** 1998 Jul; 4(4):577–86 (65 ref.)

The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Bayraktar Y, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2322–7

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Chien RN, et al. **Hepatology** 1999 Sep;30(3):770–4

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Dienstag JL, et al. **Hepatology** 1999 Oct; 30(4):1082–7

Hepatitis B therapy: the plot thickens [comment] Malik AH, et al. **Hepatology** 1999 Aug;30(2):579–81. Comment on: Hepatology 1999 Aug;30(2):546–9. Comment on: Hepatology 1999 Aug;30(2):567–72.

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Tassopoulos NC, et al. **Hepatology** 1999 Mar; 29(3):889–96

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Tsiang M, et al. **Hepatology** 1999 Jun;29(6):1863–9

Perspectives for the treatment of hepatitis B virus infections. De Clercq E. **Int J Antimicrob Agents** 1999 Jul;12(2):81–95 (72 ref.)

Treatment with low-dose interferon-alpha in Bulgarian HBeAg-negative patients with chronic hepatitis B [letter; comment] Krastev Z, et al. **J Clin Gastroenterol** 1998 Dec; 27(4):367–8. Comment on: J Clin Gastroenterol 1997 Sep;25(2):440–5.

Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. Nagai K, et al. **J Gastroenterol** 1999 Apr;34(2):275–81

Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? [editorial; comment] Farrell GC. **J Gastroenterol Hepatol** 1999 Aug;14(8):741–4. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):801–3. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):804–6.

Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B [see comments] Liaw YF, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):804–6. Comment in: J Gastroenterol Hepatol 1999 Aug;14(8):741–4.

Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy [see comments] Maguire CM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):801–3. Comment in: J Gastroenterol Hepatol 1999 Aug;14(8):741–4.

Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. Hadziyannis SJ, et al. **J Hepatol** 1999 Aug;31(2):210–4

Clinical impact of lamivudine resistance in chronic hepatitis B [letter] Honkoop P, et al. **J Hepatol** 1998 Sep;29(3):510–1

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Locarnini S, et al. **J Hepatol** 1999 Mar;30(3):536–50 (127 ref.)

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. Suzuki Y, et al. **J Hepatol** 1999 May;30(5):743–8

Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. Marques AR, et al. **J Infect Dis** 1998 Nov;178(5):1483–7

Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatitis B before and after interferon treatment. Cabrerizo M, et al. **J Med Virol** 1999 Jul; 58(3):208–14

Pediatric drug trials: women and children last? [editorial; comment] Shneider BL. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):125–6. Comment on: J Pediatr Gastroenterol Nutr 1999 Aug;29(2):163–70.

Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. Habersetzer F, et al. **J Viral Hepat** 1998 Nov;5(6):407–14

Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. Honkoop P, et al. **J Viral Hepat** 1998 Sep;5(5):307–12

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. Krogsgaard K. **J Viral Hepat** 1998 Nov; 5(6):389–97

A pill a day, or two, for hepatitis B? [published erratum appears in Lancet 1999 May 15;353(9165):1714] Dusheiko G. **Lancet** 1999 Mar 27;353(9158):1032–3

Lamivudine for chronic hepatitis B [letter; comment] Bernasconi E, et al. **N Engl J Med** 1998 Dec 10; 339(24):1786–7. Comment on: N Engl J Med 1998 Jul 9;339(2):61–8.

Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment. Malaguarnera M, et al. **Panminerva Med** 1999 Mar;41(1):59–61

Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Meisel H, et al. **Transpl Int** 1999;12(4):283–7

Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Jung YO, et al. **Transplantation** 1998 Sep 27;66(6):733–7

Recombinant interferon-alpha-2A with or without steroid pretreatment in children with chronic hepatitis B. Ozen H, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):503–14

[Long-term effect of lamivudine treatment in chronic hepatitis B virus infection] Yao G, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):80–3 (Eng. Abstr.) **(Chi)**

[Treatment of severe cholestatic hepatitis by integrated traditional Chinese and Western medicine] He JP, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Sep; 17(9):540–1 (Eng. Abstr.) **(Chi)**

[Clinical and experimental study on treatment of chronic hepatitis B with yanggan aoping mixture] Yu RQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Mar; 17(3):155–8 (Eng. Abstr.) **(Chi)**

[Observation on short-term efficacy of shuganmei in treating chronic hepatitis B and post-hepatitis cirrhosis] Zheng DZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb;17(2):84–5 **(Chi)**

[Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome] Podymova SD, et al. **Klin Med (Mosk)** 1998;76(10):45–8 (Eng. Abstr.) **(Rus)**

[Experience in heptral treatment of diffuse liver diseases] Gorbakov VV, et al. **Ter Arkh** 1998;70(10):82–6 (Eng. Abstr.) **(Rus)**

[One year treatment with lamivudine in different hepatitis B virus related hepatic diseases] Buti M, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):117–21 (Eng. Abstr.) **(Spa)**

[Interferon treatment of chronic viral hepatitis in Catalonia, Spain. Retrospective analysis] Buti M, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):127–31 (Eng. Abstr.) **(Spa)**

ECONOMICS

Health care costs associated with chronic hepatitis B. Metcalf M, et al. **Am J Health Syst Pharm** 1999 Feb 1;56(3):232–6

ENZYMOLOGY

Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Yu MW, et al. **Br J Cancer** 1999 May; 80(3–4):598–603

Serum pancreatic enzyme concentrations in chronic viral liver diseases. Pezzilli R, et al. **Dig Dis Sci** 1999 Feb; 44(2):350–5

Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. Murawaki Y, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):138–45

[The enzymatic activity of IgG preparations in viral hepatitis] Zhil'tsov IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):73–7 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994 [see comments] McQuillan GM, et al. **Am J Public Health** 1999 Jan;89(1):14–8. Comment in: Am J Public Health 1999 Jan;89(1):11–3.

Chronic hepatitis B in children in Gothenburg, Sweden. Söderström A, et al. **Scand J Infect Dis** 1999;31(2):109–14

A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Wang JH, et al. **Trans R Soc Trop Med Hyg** 1999 May–Jun;93(3):253–4

Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. Meisel H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1382–3

[Adoption and chronic hepatitis B carrier state] Choulot JJ, et al. **Arch Pediatr** 1998 Aug;5(8):869–72 (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection. Nagasaka A, et al. **Dig Dis Sci** 1998 Nov;43(11):2473–8

ETIOLOGY

Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks) [news] Menne S, et al. **Nat Med** 1999 Oct;5(10):1125–6

GENETICS

Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection. Nagasaka A, et al. **Dig Dis Sci** 1998 Nov;43(11):2473–8

No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Höhler T, et al. **Exp Clin Immunogenet** 1998;15(3):130–3

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105–9

Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. Bellamy R, et al. **J Infect Dis** 1999 Mar;179(3):721–4

Hepatitis B virus transgenic mouse model of chronic liver disease. Larkin J, et al. **Nat Med** 1999 Aug;5(8):907–12

IMMUNOLOGY

Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Chen WN, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):757–61

Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Kinugasa N, et al. **Br J Cancer** 1999 Aug;80(11):1820–5

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Schlaak JF, et al. **Clin Exp Immunol** 1999 Mar;115(3):508–14

Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329–31

High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan [see comments] Marusawa H, et al. **Gut** 1999 Aug;45(2):284–8. Comment in: Gut 1999 Aug;45(2):168–9.

Immune status of individuals with differing clinical courses of HBV infection. Polat Eyigün C, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1890–4

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Böcher WO, et al. **Hepatology** 1999 Jan;29(1):238–44

What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B. Koziel MJ. **Hepatology** 1999 Apr;29(4):1331–3

Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response [letter; comment] Liaw YF, et al. **Hepatology** 1999 Jan;29(1):296–7. Comment on: Hepatology 1998 Jul;28(1):231–6.

Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Ruiz-Moreno M, et al. **Hepatology** 1999 Feb; 29(2):572–5

Analysis of T cell receptor Vbeta gene usage during the course of disease in patients with chronic hepatitis B. Dou HY, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):428–34

Treatment with low-dose interferon-alpha in Bulgarian HBeAg-negative patients with chronic hepatitis B [letter; comment] Krastev Z, et al. **J Clin Gastroenterol** 1998 Dec; 27(4):367–8. Comment on: J Clin Gastroenterol 1997 Sep;25(2):440–5.

An analysis of T cell antigen receptor variable beta genes during the clinical course of patients with chronic hepatitis B. Sugyo S, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):333–8

In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. Heijtink R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1529–35

Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. Alexopoulou A, et al. **J Hepatol** 1998 Sep;29(3):345–51

Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. Carman WF, et al. **J Hepatol** 1999 Aug;31(2):195–201

Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. Gregorio GV, et al. **J Immunol** 1999 Feb 1;162(3):1802–10

Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. Livingston BD, et al. **J Immunol** 1999 Mar 1;162(5):3088–95

Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients. Lee M, et al. **J Korean Med Sci** 1999 Apr;14(2):175–81

Hepatitis A vaccination in chronic carriers of hepatitis B virus. Nebbia G, et al. **J Pediatr** 1999 Jun;134(6):784–5

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral

Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. Krogsgaard K. **J Viral Hepat** 1998 Nov; 5(6):389–97

T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b. Im EH, et al. **Korean J Intern Med** 1999 Jan;14(1):1–8

Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Löhr HF, et al. **Liver** 1998 Dec;18(6):405–13

Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Guido M, et al. **Mod Pathol** 1999 Jun;12(6):599–603

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Jung MC, et al. **Virology** 1999 Sep 1; 261(2):165–72

[Apoptosis of peripheral blood lymphocytes of patients with chronic hepatitis B and clinical significance] Ji W, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):77–9 (Eng. Abstr.) **(Chi)**

[The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B] Xuan SY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):80–2 (Eng. Abstr.) **(Chi)**

[Humoral response to HBV antigens in acute and chronic hepatitis B] Swiderska H, et al. **Przegl Epidemiol** 1998; 52(4):469–81 (Eng. Abstr.) **(Pol)**

METABOLISM

Serum IL-8 levels and localization of IL-8 in liver from patients with chronic viral hepatitis. Masumoto T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1630–4

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105–9

Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations. Vergani A, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul; 31(5):395–400

HBeAg immunostaining of liver tissue in various stages of chronic hepatitis B. Lindh M, et al. **Liver** 1999 Aug; 19(4):294–8

Cytoplasmic expression of hepatitis B core antigen in chronic hepatitis B virus infection: role of precore stop mutants. Park YN, et al. **Liver** 1999 Jun;19(3):199–205

Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Tordjmann T, et al. **Liver** 1998 Dec;18(6):391–7

Bcl-2 protein expression in acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma. Nakopoulou L, et al. **Pathol Res Pract** 1999;195(1):19–24

Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection. Helvaci M, et al. **Pediatr Int** 1999 Jun;41(3):270–3

PATHOLOGY

Morphometric analysis of lymphatic and blood vessels in human chronic viral liver diseases. Yamauchi Y, et al. **Am J Pathol** 1998 Oct;153(4):1131–7

Role of angiogenesis in hepatitis and hepatocellular carcinoma. Ker CG, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):646–50

Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Ruiz-Moreno M, et al. **Hepatology** 1999 Feb; 29(2):572–5

Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer. Lau GK, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):262–8

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. Suzuki Y, et al. **J Hepatol** 1999 May;30(5):743–8

Areas of sinusoidal surface hepatocyte nuclear predominance in type C chronic hepatitis. Tanaka Y, et al. **Liver** 1998 Dec;18(6):383–90

A transient emergence of hepatic granulomas in a patient with chronic hepatitis B. Kanno A, et al. **Tohoku J Exp Med** 1998 Aug;185(4):281–5

[The clinical and pathology study of HBV precore mutant infection in chronic HBV patients] Zheng X, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):17–9 (Eng. Abstr.) **(Chi)**

[Comment on the consensus report, "Treatment of chronic B/D viral hepatitis and acute and chronic C virus hepatitis" (letter; comment)] Dienes HP, et al. **Z Gastroenterol** 1998 Nov;36(11):XX–XXI. Comment on: Z Gastroenterol 1997 Nov; 35(11):971–86. **(Ger)**

[An evaluation of the degree of the morphological activity and the stage of the process in patients with chronic liver diseases caused by coinfection with the hepatitis B, C and/or D viruses] Siutkin VE, et al. **Arkh Patol** 1998 Nov-Dec;60(6):37–41 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The long-term course of chronic hepatitis B. Di Marco V, et al. **Hepatology** 1999 Jul;30(1):257–64

Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period [see comments] Bortolotti F, et al. **J Hepatol** 1998 Aug;29(2):184–90. Comment in: J Hepatol 1999 May;30(5):962.

Characteristics of the early phase of chronicity in acute hepatitis B infection. Heijtink RA, et al. **J Med Virol** 1999 Apr;57(4):331–6

Hepatitis B virus infection in microcarrier-attached immortalized human hepatocytes cultured in molecularporous membrane bags: a model for long-term episomal replication of HBV. Gong ZJ, et al. **J Viral Hepat** 1998 Nov;5(6):377–87

Influence of GB virus-C/hepatitis G virus infection on the long-term course of chronic hepatitis B. Fattovich G, et al. **Liver** 1998 Oct;18(5):360–5

Is azathioprine harmful to chronic viral hepatitis in renal transplantation? A long-term study on azathioprine withdrawal. David-Neto E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1149–50

PREVENTION & CONTROL

Survey of neonatal hepatitis B vaccination in Leicestershire. Dunn J, et al. **Commun Dis Public Health** 1999 Sep; 2(3):218–9

Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. Carman WF, et al. **J Hepatol** 1999 Aug;31(2):195–201

Current status of HBV vaccine escape variants--a mathematical model of their epidemiology. Wilson JN, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:25–30

SURGERY

Viral hepatitis in the transplant recipient [news] Steinbrecher U. **Can J Gastroenterol** 1998 Sep;12(6):393–6

Is hepatic resection absolutely contraindicated for hepatocellular carcinoma in Child-Pugh class C cirrhotic patients? Wu CC, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):635–9

Comparison of liver resection for hepatocellular carcinoma in hepatitis B and hepatitis C-related cirrhotic patients. Wu CC, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):651–5

Liver transplantation for chronic viral hepatitis. Dodson SF, et al. **Surg Clin North Am** 1999 Feb;79(1):131–45 (93 ref.)

THERAPY

Combination therapy with hepatitis B vaccine and interferon alfa in chronic hepatitis B [letter] Kaymakoğlu S, et al. **Am J Gastroenterol** 1999 Mar;94(3):856–7

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Mazzella G, et al. **Am J Gastroenterol** 1999 Aug;94(8):2246–50

Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Oliveri F, et al. **Am J Gastroenterol** 1999 May; 94(5):1366–72

Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis. Fukuhara M, et al. **Am J Hypertens** 1999 May;12(5):519–23

Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Csatary LK, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):629–33

Treatment of chronic viral hepatitis. Main J, et al. **Antivir Chem Chemother** 1998 Nov;9(6):449–60 (110 ref.)

Summary of the first international symposium on viral hepatitis. González-Peralta RP, et al. **Antiviral Res** 1999 Jun;42(2):77–96

Principles in the management of chronic hepatitis B viral infection. Minuk GY. **Can J Gastroenterol** 1999 Jan-Feb; 13(1):75–7 (9 ref.)

Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. Sawayama Y, et al. **Dig Dis Sci** 1999 Jan; 44(1):163–9

Interferon therapy of Turkish patients with chronic hepatitis B virus infection. Besirbellioglu B, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):387–90

In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients. Kountouras J, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2295–302

Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Musch E, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2282–94

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Carreño V, et al. **Hepatology** 1999 Jul;30(1):277–82

The long-term course of chronic hepatitis B. Di Marco V, et al. **Hepatology** 1999 Jul;30(1):257–64

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Heathcote J, et al. **Hepatology** 1999 Aug;30(2):531–6

Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Janssen HL, et al. **Hepatology** 1999 Jul;30(1):238–43

Life tables and denominators [letter; comment] Koretz RL. **Hepatology** 1999 Jul;30(1):340–1. Comment on: Hepatology 1999 Mar;29(3):971–5.

What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B. Koziel MJ. **Hepatology** 1999 Apr;29(4):1331–3

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Lin SM, et al. **Hepatology** 1999 Mar;29(3):971–5

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Sällberg M, et al. **Hum Gene Ther** 1999 Aug 10;9(12):1719–29

Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians. Guptan RK, et al. **J Gastroenterol Hepatol** 1998 Jul; 13(7):675–9

Antiviral therapy for hepatitis B and C in Asians. Lai CL. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S19–21

Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective [see comments] Lau GK, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):3–12. Comment in: J Gastroenterol Hepatol 1999 Jan;14(1):1–2.

Treatment of chronic hepatitis B: a need for consensus [editorial; comment] Liaw YF. **J Gastroenterol Hepatol** 1999 Jan;14(1):1–2. Comment on: J Gastroenterol Hepatol 1999 Jan;14(1):3–12.

Update on clinical trials in the treatment of hepatitis B. Pessoa MG, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S6–11 (30 ref.)

Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period [see comments] Bortolotti F, et al. **J Hepatol** 1998 Aug;29(2):184–90. Comment in: J Hepatol 1999 May;30(5):962.

Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. Chen DK, et al. **J Hepatol** 1999 Apr;30(4):557–63

Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection [letter; comment] Luers C, et al. **J Hepatol** 1999 Feb; 30(2):347. Comment on: J Hepatol 1998 Jun;28(6):1058–63.

The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. Nagata I, et al. **J Hepatol** 1999 Jun;30(6):965–9

Outcome of chronic hepatitis B in children with normal transaminase levels [letter; comment] Ozen H, et al. **J Hepatol** 1999 May;30(5):962. Comment on: J Hepatol 1998 Aug;29(2):184–90.

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. Couillin I, et al. **J Infect Dis** 1999 Jul;180(1):15–26

Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children [see comments] Jara P, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):163–70 (19 ref.). Comment in: J Pediatr Gastroenterol Nutr 1999 Aug;29(2):125–6.

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. Gerken G, et al. **J Virol Methods** 1998 Oct;74(2):155–65

Alpha-interferon treatment in HBeAg positive children with chronic hepatitis B and associated hepatitis D. Schneider A, et al. **Klin Padiatr** 1998 Sep-Oct;210(5):363–5

T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b. Im EH, et al. **Korean J Intern Med** 1999 Jan;14(1):1–8

Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders [letter] Pariante CM, et al. **Lancet** 1999 Jul 10;354(9173):131–2

Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection. Helvaci M, et al. **Pediatr Int** 1999 Jun;41(3):270–3

[Cost-effectiveness analysis of treatment of chronic hepatitis B with interferon in Chinese city] Lin X, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):84–7 (Eng. Abstr.) **(Chi)**

[The clinical study on treatment of hepatic fibrosis of hepatitis B by IFN-alpha 1 and Chinese medical preparation] Cheng ML, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Aug;17(8):453–5 (Eng. Abstr.) **(Chi)**

[New therapeutic possibilities in the treatment of hepatitis B] Horsmans Y. **Arch Pediatr** 1999;6 Suppl 2:180s–182s **(Fre)**

[Interferon in hepatitis B] Blum HE. **Dtsch Med Wochenschr** 1998 Nov 27;123(48):1462–3 **(Ger)**

[Therapy of chronic hepatitis B and C] Müllhaupt B, et al. **Schweiz Rundsch Med Prax** 1999 Apr 1;88(14):619–32 (119 ref.) (Eng. Abstr.) **(Ger)**

[Drug therapy of chronic hepatitis B] Renner EL, et al. **Soz Praventivmed** 1998;43 Suppl 1:S21–3, S95–7 (Eng. Abstr.) **(Ger, Fre)**

[The use of recombinant alfa-2 interferon in treating patients with acute and chronic viral hepatitis B] Vovk AD, et al. **Lik Sprava** 1998 Oct-Nov;(7):117–21 (Eng. Abstr.) **(Rus)**

VIROLOGY

The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Shindo M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2237–45

Hepatitis B surface antigen disappearance and hepatitis B

surface antigen subtype: a prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. Furusyo N, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):616–22

Heterogeneous HBV mutants coexist in Korean hepatitis B patients. Keum WK, et al. **Exp Mol Med** 1998 Jun 30; 30(2):115–22

Clinical significance of serum HBeAg and HBV-DNA-specific values of virus replication in chronic hepatitis-B virus infection. Alagiozian-Angelova V, et al. **Folia Med (Plovdiv)** 1998;40(4):34–41

Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis. Santantonio T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1848–54

Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. López-Alcorocho JM, et al. **Intervirology** 1998;41(6):233–7

In situ detection of mutated hepatitis B virus in microdissected, formalin-fixed liver tissues from patients with chronic hepatitis B. Kojima N, et al. **J Hepatol** 1999 Mar;30(3):359–65

Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels. Cabrerizo M, et al. **J Med Virol** 1998 Dec;56(4):294–9

Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status. Honda A, et al. **J Med Virol** 1999 Apr;57(4):337–44

Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. Knöll A, et al. **J Med Virol** 1999 Sep;59(1):14–8

Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen-positive asymptomatic healthy carriers. Tsubota A, et al. **J Med Virol** 1998 Dec;56(4):287–93

A novel deletion mutant of hepatitis B virus surface antigen. Weinberger KM, et al. **J Med Virol** 1999 Jun;58(2):105–10

Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. Krajden M, et al. **J Viral Hepat** 1998 Nov;5(6):415–22

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. Laras A, et al. **J Viral Hepat** 1998 Jul;5(4):241–8

Detection and sequence analysis of hepatitis B virus integration in peripheral blood mononuclear cells. Laskus T, et al. **J Virol** 1999 Feb;73(2):1235–8

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. Gerken G, et al. **J Virol Methods** 1998 Oct;74(2):155–65

Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Rodriguez-Frias F, et al. **Liver** 1999 Jun; 19(3):177–82

Hepatitis B virus transgenic mouse model of chronic liver disease. Larkin J, et al. **Nat Med** 1999 Aug;5(8):907–12

Natural emergence of an anti-hepatitis B s escape mutant in a young female hepatitis B virus carrier. Sugiyama K, et al. **Pediatr Int** 1999 Jun;41(3):311–4

Chronic hepatitis B in children in Gothenburg, Sweden. Söderström A, et al. **Scand J Infect Dis** 1999;31(2):109–14

Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B. Ichikawa T, et al. **Tohoku J Exp Med** 1998 Dec;186(4):323–33

[Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study] Pár A, et al. **Orv Hetil** 1999 May 30;140(22):1227–33 (36 ref.) (Eng. Abstr.) **(Hun)**

[Prevalence of anti-hepatitis A in patients with chronic liver disease] Diago M, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):324–6 (Eng. Abstr.) **(Spa)**

HEPATITIS B CORE ANTIGENS

ADMINISTRATION & DOSAGE

Use of a liposome antigen delivery system to alter immune responses in vivo. Lutsiak CM, et al. **J Pharm Sci** 1998 Nov;87(11):1428–32

Microencapsulation of hepatitis B core antigen for vaccine preparation. Uchida T, et al. **Pharm Res** 1998 Nov; 15(11):1708–13

ANALYSIS

Maternal antibody to hepatitis B core antigen detected in dried neonatal blood spot samples. Tappin DM, et al. **Epidemiol Infect** 1998 Oct;121(2):387–90

Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Guido M, et al. **Mod Pathol** 1999 Jun;12(6):599–603

BIOSYNTHESIS

Cytoplasmic expression of hepatitis B core antigen in chronic hepatitis B virus infection: role of precore stop mutants. Park YN, et al. **Liver** 1999 Jun;19(3):199–205

BLOOD

[Serum hepatitis B markers in blood donors in Venezuela. What do they mean?] León G, et al. **Sangre (Barc)** 1998 Oct;43(5):385–91 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Crystallization of hepatitis B virus core protein shells: determination of cryoprotectant conditions and preliminary X-ray characterization. Wynne SA, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Feb;55 (Pt 2):557–60

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Kratz PA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1915–20

Difference mapping cryo-EM. Peters R, et al. **Science** 1999 Feb 19;283(5405):1133

DRUG EFFECTS

Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatitis B before and after interferon treatment. Cabrerizo M, et al. **J Med Virol** 1999 Jul; 58(3):208–14

GENETICS

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Chan HL, et al. **Hepatology** 1999 Mar;29(3):976–84

Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Friedt M, et al. **Hepatology** 1999 Apr;29(4):1252–8

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Sällberg M, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1719–29

Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope. Lachmann S, et al. **Intervirology** 1999; 42(1):51–6

Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. Alexopoulou A, et al. **J Hepatol** 1998 Sep;29(3):345–51

Evolution of wild-type and precore mutant HBV infection after liver transplantation. Torre F, et al. **J Med Virol** 1999 Sep;59(1):5–13

Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen-positive asymptomatic healthy carriers. Tsubota A, et al. **J Med Virol** 1998 Dec;56(4):287–93

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. Laras A, et al. **J Viral Hepat** 1998 Jul;5(4):241–8

Evidence for the genetic basis of non-response in mice. Waters JA. **J Viral Hepat** 1998 Nov;5 Suppl 2:1–4

Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. Li J, et al. **J Virol** 1999 Feb;73(2):1239–44

The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. Yuan TT, et al. **J Virol** 1999 Jul;73(7):5731–40

Cytoplasmic expression of hepatitis B core antigen in chronic hepatitis B virus infection: role of precore stop mutants. Park YN, et al. **Liver** 1999 Jun;19(3):199–205

Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Meisel H, et al. **Transpl Int** 1999;12(4):283–7

[Specific immune responses in H-2d mice after DNA immunization of HBV core gene] Huang Z, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):107–9 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region. Street M, et al. **Arch Virol** 1999;144(7):1323–43

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG, et al. **Biochemistry (Mosc)** 1998 May;63(5):551–8

Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Borisova G, et al. **Biol Chem** 1999 Mar; 380(3):315–24

HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Koletzki D, et al. **Biol Chem** 1999 Mar;380(3):325–33

The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Murray K, et al. **Biol Chem** 1999 Mar;380(3):277–83 (37 ref.)

Construction and immunologic evaluation of a Porphyromonas gingivalis subsequence peptide fused to hepatitis B virus core antigen. Dawson JA, et al. **FEMS Microbiol Lett** 1999 Jun 1;175(1):119–25

Differential antigen-processing pathways of the hepatitis B virus e and core proteins [see comments] Diepolder HM, et al. **Gastroenterology** 1999 Mar;116(3):650–7. Comment in: Gastroenterology 1999 Mar;116(3):765–8.

Do T cells "see" the hepatitis B core and e antigens differently? [editorial; comment] Milich DR. **Gastroenterology** 1999 Mar;116(3):765–8 (25 ref.). Comment on: Gastroenterology 1999 Mar;116(3):650–7.

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Heathcote J, et al. **Hepatology** 1999 Aug;30(2):531–6

Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Yamamoto M, et al. **Hepatology** 1999 Jul; 30(1):300–7

New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. Ulrich R, et al. **J Biotechnol** 1999 Aug 20;73(2–3):141–53 (41 ref.)

Baculovirus expression of chimeric hepatitis B virus core particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay. Touze A, et al. **J Clin Microbiol** 1999 Feb;37(2):438–41

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. Lau GK, et al. **J Infect Dis** 1998 Dec; 178(6):1585–91

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Kratz PA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1915–20

Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Castells L, et al. **Transplant Proc** 1999 Sep; 31(6):2464–5

Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Van Thiel DH, et al. **Transplantation** 1999 Aug 27; 68(4):519–22

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147–54 (79 ref.)

[Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg] Ren F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):7–9 (Eng. Abstr.) **(Chi)**

[The development and certification of the Hepabest anti-HBc IgG test system for detecting antibodies to the core antigen of the hepatitis B virus] Iaroslavtseva OA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):49–52 (Eng. Abstr.) **(Rus)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240–1 **(Spa)**

ISOLATION & PURIFICATION

Separation and crystallization of T = 3 and T = 4 icosahedral complexes of the hepatitis B virus core protein. Zlotnick A, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):717–20

Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+ -chelate affinity chromatography. Wizemann H, et al. **J Virol Methods** 1999 Feb;77(2):189–97

METABOLISM

Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. Kann M, et al. **J Cell Biol** 1999 Apr 5;145(1):45–55

PHYSIOLOGY

Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation. Koschel M, et al. **J Virol** 1999 Mar;73(3):2153–60

HEPATITIS B E ANTIGENS

Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Bécheur H, et al. **Dig Dis Sci** 1998 Nov;43(11):2479–82 (30 ref.)

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. Laras A, et al. **J Viral Hepat** 1998 Jul;5(4):241–8

ANALYSIS

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Chan HL, et al. **Hepatology** 1999 Mar;29(3):976–84

Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Huang LM, et al. **Hepatology** 1999 Mar; 29(3):954–9

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Tassopoulos NC, et al. **Hepatology** 1999 Mar;

29(3):889–96
Immunological characterization of two major secreted forms of recombinant hepatitis B virus e antigens. Hwang GY, et al. **Virus Res** 1999 Feb;59(2):203–10

BIOSYNTHESIS

[Inhibitory effect of triplex forming oligodeoxynucleotides on HBV replication and synthesis of antigen] Yang L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):8–10 (Eng. Abstr.) **(Chi)**

BLOOD

Lessons from patient notification exercises following the identification of hepatitis B e antigen positive surgeons in an English health region [see comments] [published erratum appears in Commun Dis Public Health 1999 Sep;2(3):222] Oliver SE, et al. **Commun Dis Public Health** 1999 Jun; 2(2):130–6. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.
Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Carreño V, et al. **Hepatology** 1999 Jul;30(1):277–82
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Chien RN, et al. **Hepatology** 1999 Sep;30(3):770–4
HBV DNA amplification by polymerase chain reaction in patients with serological evidence of chronic hepatitis B infection [letter] Rodrigues C, et al.
Indian J Gastroenterol 1999 Jul–Sep;18(3):130–1
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. Alexopoulou A, et al. **J Hepatol** 1998 Sep;29(3):345–51
Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. Oketani M, et al. **J Med Virol** 1999 Aug;58(4):332–7
Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen–positive asymptomatic healthy carriers. Tsubota A, et al.
J Med Virol 1998 Dec;56(4):287–93
Alpha-interferon treatment in HBeAg positive children with chronic hepatitis B and associated hepatitis D. Schneider A, et al. **Klin Padiatr** 1998 Sep–Oct;210(5):363–5
Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen–positive/hepatitis B e antigen–negative carriers. Zamir C, et al.
Pediatr Infect Dis J 1999 Mar;18(3):262–6

GENETICS

Molecular analysis of the a determinant of HBsAg in children of HBeAg-positive mothers upon failure of postexposure prophylaxis. Poovorawan Y, et al. **Int J Infect Dis** 1998 Apr–Jun;2(4):216–20
Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. Aritomi T, et al.
J Gastroenterol Hepatol 1998 Nov;13(11):1125–32
Analysis of the precore and core promoter DNA sequence in liver tissues from patients with hepatocellular carcinoma. Cho SW, et al. **J Korean Med Sci** 1999 Aug;14(4):424–30
Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. Knöll A, et al.
J Med Virol 1999 Sep;59(1):14–8
A short region in the genome of hepatitis B virus is critical for maintenance of high transcript levels. zu Putlitz J, et al. **Virology** 1999 Feb 15;254(2):245–56

IMMUNOLOGY

Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Oliveri F, et al. **Am J Gastroenterol** 1999 May; 94(5):1366–72
Differential antigen-processing pathways of the hepatitis B virus e and core proteins [see comments] Diepolder HM, et al. **Gastroenterology** 1999 Mar;116(3):650–7. Comment in: Gastroenterology 1999 Mar;116(3):765–8.
Do T cells "see" the hepatitis B core and e antigens differently? [editorial; comment] Milich DR.
Gastroenterology 1999 Mar;116(3):765–8 (25 ref.). Comment on: Gastroenterology 1999 Mar;116(3):650–7.
Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Ruiz-Moreno M, et al. **Hepatology** 1999 Feb; 29(2):572–5
A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood. Yamane K, et al.
Immunopharmacol Immunotoxicol 1998 Nov;20(4):531–9
Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels. Cabrerizo M, et al.
J Med Virol 1998 Dec;56(4):294–9
Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. Lu M, et al. **J Virol** 1999 Jan;73(1):281–9

METABOLISM

HBeAg immunostaining of liver tissue in various stages of chronic hepatitis B. Lindh M, et al. **Liver** 1999 Aug; 19(4):294–8

HEPATITIS B SURFACE ANTIGENS

ADMINISTRATION & DOSAGE

Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen. Schirmbeck R, et al. **Int Immunol** 1999 Jul;11(7):1093–102
Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Wild J, et al. **J Immunol** 1999 Aug 15; 163(4):1880–7

ANALYSIS

Highly sensitive hepatitis B surface antigen detection by measuring stable nitroxide radical formation with ESR spectroscopy. Matsuo T, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):929–35
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1 [see comments] Sun Z, et al. **Hepatology** 1999 Aug;30(2):379–83. Comment in: Hepatology 1999 Aug;30(2):573–5.
Prevalence of HBsAg in visceral leishmaniasis (kala–azar) [letter] Dhar KK, et al. **Indian J Gastroenterol** 1999 Jul–Sep;18(3):129
Immunogenic response to hepatitis B vaccine in Indian infants. Karthikeyan G. **Indian Pediatr** 1998 Apr; 35(4):375–6; discussion 376–7
Hepatitis A vaccination in chronic carriers of hepatitis B virus. Nebbia G, et al. **J Pediatr** 1999 Jun;134(6):784–5
Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Guido M, et al.
Mod Pathol 1999 Jun;12(6):599–603
Spurious hepatitis B surface antigen detection in adult haemodialysis patients following vaccination [letter; comment] Esparza N, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):794. Comment on: Nephrol Dial Transplant 1998 Jul;13(7):1897–8.
Hepatitis B virus surface antigen (HBsAg) and antibody (anti-HBs) forming immune complexes in fulminant hepatitis. Soares MC, et al. **Rev Soc Bras Med Trop** 1999 May–Jun;32(3):295–7
Orthotopic liver transplantation in HBs-antigen positive patients: short-term results. Lee SK, et al.
Transplant Proc 1998 Nov;30(7):3314–5
Liver transplantation in HBsAg+ patients: results according to patient selection and treatment strategies. Loinaz C, et al. **Transplant Proc** 1998 Nov;30(7):3305–6
[A molecular epidemiologic study on the mechanism of intrauterine transmission of hepatitis B virus] Xu D, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):131–3 (Eng. Abstr.) **(Chi)**
[Fulminant hepatic failure related to immunosuppressive therapy in an asymptomatic HBsAg carrier with idiopathic interstitial pneumonia] Takagi S, et al.
Nihon Kokyuki Gakkai Zasshi 1998 Oct;36(10):917–22 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Chemin I, et al. **Liver** 1999 Apr;19(2):81–7
Muscle-specific expression of hepatitis B surface antigen: no effect on DNA-raised immune responses. Loirat D, et al. **Virology** 1999 Jul 20;260(1):74–83
[Expression of HBsAg by using various eukaryotic expression vectors] Gu B, et al.
Chung Hua Kan Tsang Ping Tsa Chih 1999 Jun;7(2):98–100 (Eng. Abstr.) **(Chi)**
[Inhibitory effect of triplex forming oligodeoxynucleotides on HBV replication and synthesis of antigen] Yang L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):8–10 (Eng. Abstr.) **(Chi)**

BLOOD

Antiviral activity of 1,7-disulphoanthraquinone. Ciebiada I, et al. **Acta Microbiol Pol** 1998;47(3):261–6
Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: a prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. Furusyo N, et al.
Am J Trop Med Hyg 1999 Apr;60(4):616–22
Hepatitis B virus DNA in relation to duration of hepatitis B surface antigen carriage. Mendy ME, et al.
Br J Biomed Sci 1999;56(1):34–8
Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329–31
Fine structure of hepatitis B virus surface antigen produced by recombinant yeast: comparison with HBsAg of human origin. Yamaguchi M, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):363–7
HBV DNA amplification by polymerase chain reaction in patients with serological evidence of chronic hepatitis B infection [letter] Rodrigues C, et al.
Indian J Gastroenterol 1999 Jul–Sep;18(3):130–1
Hepatitis D infectivity profile among hepatitis B infected hospitalised patients in Calcutta. Bhattacharyya S, et al.
Indian J Public Health 1998 Oct–Dec;42(4):108–12
Incidence of hepatitis B virus (HBV) infection amongst clinically diagnosed acute viral hepatitis cases and relative risk of development of HBV infection in high risk groups in Calcutta. Hazra BR, et al. **Indian J Public Health** 1998 Apr–Jun;42(2):56–8
High prevalence of HBV infection markers in refugees from eastern countries [letter] Skliros EA, et al.
Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):84–5
Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer. Lau GK, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):262–8
In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee. Heijtink R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1529–35
Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. Altfeld M, et al. **J Hepatol** 1998 Aug;29(2):306–9
Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. Lerut JP, et al. **J Hepatol** 1999 Apr;30(4):706–14
Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. Ustün C, et al.
J Hepatol 1999 Aug;31(2):202–9
Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core– and anti-hepatitis B surface antibody–positive. Lau GK, et al. **J Infect Dis** 1998 Dec; 178(6):1585–91
Preimmunization epidemiology of hepatitis B virus infection in South African children. Vardas E, et al.
J Med Virol 1999 Jun;58(2):111–5
Prevalence of hepatitis B surface antigen (HBsAg) in children with sickle cell anaemia [letter] Angyo IA, et al.
J Trop Pediatr 1998 Dec;44(6):376–7
Prognosis of schistosomiasis mansoni patients infected with hepatitis B virus. Conceição MJ, et al.
Mem Inst Oswaldo Cruz 1998;93 Suppl 1:255–8
Chronic carriers of hepatitis B surface antigen in an endemic area for schistosomiasis mansoni in Brazil. Serufo JC, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:249–53
Spurious hepatitis B surface antigen detection in a haemodialysis patient [letter] [see comments] Riley S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1897–8. Comment in: Nephrol Dial Transplant 1999 Mar;14(3):794.
Evaluation of screening for hepatitis B surface antigen during pregnancy in a population with a high prevalence of hepatitis B surface antigen–positive/hepatitis B e antigen–negative carriers. Zamir C, et al.
Pediatr Infect Dis J 1999 Mar;18(3):262–6
Effectiveness of a highly sensitive chemiluminescent immunoassay in screening for hepatitis B surface antigen in Japanese blood donors [letter] Sekiguchi S, et al.
Transfusion 1999 Jun;39(6):660–1
Characteristics of hepatocellular carcinoma in patients with negative virus markers: clinicopathologic study of resected tumors. Shiraishi M, et al. **World J Surg** 1999 Mar; 23(3):301–5
[Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg] Ren F, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1998 Jan;32(1):7–9 (Eng. Abstr.) **(Chi)**
[Follow-up on hepatitis B immunized neonates born to HBsAg positive mothers] Zhang X, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1998 Mar;32(2):97–9 (Eng. Abstr.) **(Chi)**
[Prevalence of serum markers of hepatitis B and C virus in blood donors of Nouakchott, Mauritania] Lo BB, et al.
Bull Soc Pathol Exot 1999 May;92(2):83–4 (Eng. Abstr.) **(Fre)**
[Serum hepatitis B markers in blood donors in Venezuela. What do they mean?] León G, et al. **Sangre (Barc)** 1998 Oct;43(5):385–91 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Physicochemical properties of recombinant hepatitis B surface antigen expressed in mammalian cell (C127). Lee YS, et al. **Arch Pharm Res** 1998 Oct;21(5):521–6
Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. Schmitt S, et al. **J Biol Chem** 1999 Apr 23;274(17):11945–57
Physico-chemical characterization of recombinant hepatitis B surface antigen by a multidimensional approach. Tleugabulova D, et al. **J Chromatogr A** 1999 Jun 11; 845(1–2):171–9
Aggregation of recombinant hepatitis B surface antigen in Pichia pastoris. Tleugabulova D, et al.
J Chromatogr B Biomed Sci Appl 1998 Sep 25; 716(1–2):209–19
Size-exclusion chromatographic study of the reduction of recombinant hepatitis B surface antigen. Tleugabulova D.
J Chromatogr B Biomed Sci Appl 1998 Aug 25;713(2):401–7
Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel. Tleugabulova D, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11;

720(1-2):153-63
Removal of iodine by solid phase adsorption to charcoal following iodine oxidation of acetamidomethyl-protected peptide precursors to their disulfide bonded products: oxytocin and a Pre-S1 peptide of hepatitis B virus illustrate the method. Sahal D. **J Pept Res** 1999 Jan;53(1):91-7

DRUG EFFECTS

[The in-vitro inactivation of HBsAg by extracts of plants in the genus Phyllanthus] del Barrio Alonso G, et al. **Rev Cubana Med Trop** 1995;47(2):127-30 (Eng. Abstr.) **(Spa)**

GENETICS

Detection of hepatitis B surface antigen mutants and their integration in human hepatocellular carcinoma. Oon CJ, et al. **Cancer Lett** 1999 Feb 8;136(1):95-9
Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. Bryder K, et al. **DNA Cell Biol** 1999 Mar; 18(3):219-25
Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Kondo R, et al. **Gene Ther** 1998 May;5(5):575-82
Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Shields PL, et al. **Gut** 1999 Aug;45(2):306-9
Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis. Santantonio T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1848-54
Expression of foreign antigens on the surface of Escherichia coli by fusion to the outer membrane protein traT. Chang HJ, et al. **J Biomed Sci** 1999 Jan;6(1):64-70
Patterns of circulating hepatitis B surface antigen variants among vaccinated children born to hepatitis B surface antigen carrier and non-carrier mothers. A population-based comparative study. Ho M, et al. **J Biomed Sci** 1998 Sep-Oct;5(5):355-62
Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Hui J, et al. **J Biotechnol** 1999 Jun 11;72(1-2):49-59
Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. Carman WF, et al. **J Hepatol** 1999 Aug;31(2):195-201
Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. Mancini M, et al. **J Immunol** 1998 Nov 15; 161(10):5564-70
Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong-Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259-63
DNA-mediated immunization of mice with plasmid encoding HBs antigen. Yoon SJ, et al. **J Korean Med Sci** 1999 Apr; 14(2):187-92
Immunoassay detection of hepatitis B surface antigen mutants. Coleman PF, et al. **J Med Virol** 1999 Sep; 59(1):19-24
A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg "a" determinant. Karthigesu VD, et al. **J Med Virol** 1999 Aug;58(4):346-52
A novel deletion mutant of hepatitis B virus surface antigen. Weinberger KM, et al. **J Med Virol** 1999 Jun;58(2):105-10
Current aspects of hepatitis B surface antigen mutants in Singapore. Oon CJ, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:17-23
Evidence for the genetic basis of non-response in mice. Waters JA. **J Viral Hepat** 1998 Nov;5 Suppl 2:1-4
High level expression of hepatitis B virus surface antigen in stably transfected Drosophila Schneider-2 cells. Deml L, et al. **J Virol Methods** 1999 May;79(2):191-203
Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Rodriguez-Frias F, et al. **Liver** 1999 Jun; 19(3):177-82
Natural emergence of an anti-hepatitis B s escape mutant in a young female hepatitis B virus carrier. Sugiyama K, et al. **Pediatr Int** 1999 Jun;41(3):311-4
Transgenic cattle produced by reverse-transcribed gene transfer in oocytes. Chan AW, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14028-33
Miracle heifer? [letter; comment] Ebeler J. **Science** 1999 Jan 1;283(5398):33. Comment on: Science 1998 Nov 27;282(5394):1619-20.
Immunoadjuvant action of plasmid DNA in liposomes. Gürsel M, et al. **Vaccine** 1999 Mar 17;17(11-12):1376-83
Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes. Hui J, et al. **Vaccine** 1999 Mar 26; 17(13-14):1711-8
[Humoral and cell mediated immunity induced by HBV-S gene recombinant retroviral vector] Zhou Z, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):3-5 (Eng. Abstr.) **(Chi)**
[Comparison of sequences of hepatitis B virus S gene fragment in eight cities of China] Fan J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):140-3 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Antibody titers to hepatitis B surface antigen among vaccinated emergency physicians: three years' experience with a wellness booth. Goldberg R, et al. **Ann Emerg Med** 1999 Feb;33(2):156-9
Immunological properties of recombinant hepatitis B surface antigen expressed in mammalian cell (C127). Lee YS, et al. **Arch Pharm Res** 1998 Oct;21(5):543-8
Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Chen WN, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):757-61
Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. zu Putlitz J, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):785-91
Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Borisova G, et al. **Biol Chem** 1999 Mar; 380(3):315-24
Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R, et al. **Biol Chem** 1999 Mar; 380(3):285-91 (90 ref.)
Characterization of chimeric antibody producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Kim SJ, et al. **Biotechnol Bioeng** 1998 Apr 5; 58(1):73-84
Truncated or chimeric endogenous protein antigens gain immunogenicity for B cells by stress protein-facilitated expression. Schirmbeck R, et al. **Eur J Immunol** 1999 May; 29(5):1740-9
Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Schirmbeck R, et al. **Eur J Immunol** 1998 Dec;28(12):4149-61
Sequence analysis of a monoclonal antibody specific for the preS2 region of hepatitis B surface antigen, and the cloning, expression and characterisation of its single-chain Fv construction. Passafiume M, et al. **FEBS Lett** 1998 Dec 28;441(3):407-12
Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Kondo R, et al. **Gene Ther** 1998 May;5(5):575-82
Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Böcher WO, et al. **Hepatology** 1999 Jan;29(1):238-44
Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response [letter; comment] Liaw YF, et al. **Hepatology** 1999 Jan;29(1):296-7. Comment on: Hepatology 1998 Jul;28(1):231-6.
Generation of human Fab monoclonal antibodies against preS1 of hepatitis B virus using repertoire cloning. Choi IH, et al. **Hybridoma** 1998 Dec;17(6):535-40
Expression and characterization of chimeric hepatitis B surface antigen particles carrying preS epitopes. Hui J, et al. **J Biotechnol** 1999 Jun 11;72(1-2):49-59
High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen. Sánchez L, et al. **J Biotechnol** 1999 Jun 11;72(1-2):13-20
Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. Weber B, et al. **J Clin Microbiol** 1999 Aug;37(8):2639-47
Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. Paulij WP, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2121-6
Prevalence of specific IgA and IgM anti-HBc antibodies compared with HBV DNA in the sera of HBsAg chronic carriers. Elsana S, et al. **J Hum Virol** 1997 Nov-Dec; 1(1):52-7
Polyclonality and multispecificity of the CTL response to a single viral epitope. Ishikawa T, et al. **J Immunol** 1998 Dec 1;161(11):5842-50
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. McCluskie MJ, et al. **J Immunol** 1998 Nov 1;161(9):4463-6
Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, et al. **J Immunol** 1998 Nov 1;161(9):4520-9
Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Wild J, et al. **J Immunol** 1999 Aug 15; 163(4):1880-7
Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong-Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259-63
Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. Couillin I, et al. **J Infect Dis** 1999 Jul;180(1):15-26
Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. Lau GK, et al. **J Infect Dis** 1998 Dec; 178(6):1585-91
Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients. Lee M, et al. **J Korean Med Sci** 1999 Apr;14(2):175-81
Bacterial expression of a human recombinant monoclonal antibody fab fragment against hepatitis B surface antigen. Maeda F, et al. **J Med Virol** 1999 Aug;58(4):338-45
A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. Eyigün CP, et al. **J Viral Hepat** 1998 Jul;5(4):265-9
Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:5-8
Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. McDermott AB, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:9-11
Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response. Zuckerman JN. **J Viral Hepat** 1998 Nov;5 Suppl 2:13-5
Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations. Geissler M, et al. **J Virol** 1999 May; 73(5):4284-92
Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. Lu M, et al. **J Virol** 1999 Jan;73(1):281-9
A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. Singh M, et al. **J Virol** 1999 Jun;73(6):4823-8
Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells. Deml L, et al. **J Virol Methods** 1999 May;79(2):205-17
Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. Usuda S, et al. **J Virol Methods** 1999 Jun;80(1):97-112
Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Sawabe M, et al. **Liver** 1999 Aug;19(4):335-42
Structural characterization of viral neutralizing monoclonal antibodies to hepatitis B surface antigen. Shearer MH, et al. **Mol Immunol** 1998 Dec;35(18):1149-60
Fetal immunization of baboons induces a fetal-specific antibody response. Watts AM, et al. **Nat Med** 1999 Apr; 5(4):427-30
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Brazolot Millan CL, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15553-8
The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Carlsson T, et al. **Scand J Infect Dis** 1999; 31(1):93-5
Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Langö-Warensjö A, et al. **Tissue Antigens** 1998 Oct;52(4):374-80
Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Blanpain C, et al. **Transplantation** 1998 Oct 15; 66(7):883-6
Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Chengalvala MV, et al. **Vaccine** 1999 Mar 5; 17(9-10):1035-41
T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **Vaccine** 1999 Jun 4;17(20-21):2528-37
Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. McCluskie MJ, et al. **Viral Immunol** 1998;11(4):245-52
Effect of plasmid DNA on immunogenicity of HBsAg-anti-HBs complex. Qu D, et al. **Viral Immunol** 1998;11(2):65-72
[Improvement in affinity of phage antibodies against HBsAg by light chain shuffling] Mao C, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):36-8 (Eng. Abstr.) **(Chi)**
[Expression of chimeric single-chain antibody with specificity for HBsAg in E. coli] Pan H, et al. **I Chuan Hsueh Pao** 1999;26(1):87-91 (Eng. Abstr.) **(Chi)**
[Does vaccination protect a child of an HBs Ag carrier mother against HBV infection?] Gołębiowska M, et al. **Przegl Epidemiol** 1998;52(3):255-62 (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

HBsAg carrier with simultaneous amebic liver abscess and acute hepatitis E. Jain A, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):124

METABOLISM

The acute phase protein alpha-1-antitrypsin inhibits transferrin uptake in PLC/PRF/5 cells and increases release of hepatitis B virus surface antigen and alpha-fetoprotein. Propst A, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):497–502

Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, et al. **Hum Immunol** 1998 Dec;59(12):783–93

A cellular protein which binds hepatitis B virus but not hepatitis B surface antigen. Harvey TJ, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):607–15

Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Jenna S, et al. **Virology** 1998 Nov 10;251(1):176–86

PHYSIOLOGY

Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen. Schirmbeck R, et al. **Int Immunol** 1999 Jul;11(7):1093–102

Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. Le Seyec J, et al. **J Virol** 1999 Mar;73(3):2052–7

The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Hildt E, et al. **Recent Results Cancer Res** 1998;154:315–29 (50 ref.)

DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response. Prange R, et al. **Vaccine** 1999 Feb 26; 17(7–8):617–23

THERAPEUTIC USE

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Honorati MC, et al. **Clin Exp Immunol** 1999 Apr;116(1):121–6

TOXICITY

Metallothionein overexpression suppresses hepatic hyperplasia induced by hepatitis B surface antigen. Quaife CJ, et al. **Toxicol Appl Pharmacol** 1999 Mar 1;155(2):107–16

ULTRASTRUCTURE

Fine structure of hepatitis B virus surface antigen produced by recombinant yeast: comparison with HBsAg of human origin. Yamaguchi M, et al. **FEMS Microbiol Lett** 1998 Aug 15;165(2):363–7

HEPATITIS B VACCINES

Hepatitis B maternal screening, infant vaccination, and infant prophylaxis practices in North Carolina. Pierce RL, et al. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):619–23

Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers—a single blind placebo-controlled and randomized clinical study. Barbieri B, et al. **Biofactors** 1999;9(2–4):351–7

Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake. Wallis DE, et al. **BMJ** 1999 Apr 24;318(7191):1112–3

Survey of neonatal hepatitis B vaccination in Leicestershire. Dunn J, et al. **Commun Dis Public Health** 1999 Sep; 2(3):218–9

Strategies to ensure delivery of hepatitis B vaccine to injecting drug users [editorial; comment] Heptonstall J. **Commun Dis Public Health** 1999 Sep;2(3):154–6. Comment on: Commun Dis Public Health 1999 Sep;2(3):174–7.

Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996 [see comments] Lamagni TL, et al. **Commun Dis Public Health** 1999 Sep;2(3):174–7. Comment in: Commun Dis Public Health 1999 Sep;2(3):154–9.

Hepatitis B vaccination for occupational risk: an audit in general practice. Tatham D, et al. **Commun Dis Public Health** 1999 Sep;2(3):219–21

Newer vaccines: like Marie Antoinette said, "let the poor eat cake" [letter; comment] Puliyel JM. **Indian Pediatr** 1998 Dec;35(12):1245–9. Comment on: Indian Pediatr 1998 Aug;35(8):791–5.

Hepatitis B vaccination of personnel employed in Victorian hospitals: are those at risk adequately protected? Thompson SC, et al. **Infect Control Hosp Epidemiol** 1999 Jan; 20(1):51–4

Awareness and utilization of the hepatitis B vaccine among young men in the Ann Arbor area who have sex with men. Neighbors K, et al. **J Am Coll Health** 1999 Jan;47(4):173–8

Many ways to contract hepatitis B, one key way to prevent it. Grabenstein JD. **J Am Pharm Assoc (Wash)** 1998 Sep–Oct;38(5):636

Relation between experimental and non-experimental study designs. HB vaccines: a case study. Jefferson T, et al. **J Epidemiol Community Health** 1999 Jan;53(1):51–4

How important is early childhood hepatitis B vaccination? A survey of primary care physicians. Zimmerman RK, et al. **J Fam Pract** 1998 Nov;47(5):370–4

Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. Al-Faleh FZ, et al. **J Infect** 1999 May; 38(3):167–70

What type of travelers would benefit from combined vaccination against hepatitis A and B? Iwarson S. **J Travel Med** 1998 Jun;5(2):80–3

Vaccination of travelers against hepatitis A and B. Löscher T, et al. **J Travel Med** 1999 Jun;6(2):107–14 (68 ref.)

From the Centers for Disease Control and Prevention. Availability of hepatitis B vaccine that does not contain thimerosal as a preservative. **JAMA** 1999 Oct 6; 282(13):1219–20

Debate revived on hepatitis B vaccine value [news] Marwick C, et al. **JAMA** 1999 Jul 7;282(1):15–7

Public pressure alters French vaccination policy [news] Birmingham K. **Nat Med** 1998 Nov;4(11):1217

How to increase by 40% the number of pediatric doses recovered from multidose vials of hepatitis B vaccines. Duval B, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):560–1

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Brazolot Millan CL, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15553–8

No scientific justification to suspend hepatitis B immunization [news] **Public Health Rep** 1998 Nov–Dec;113(6):487

Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Da Villa G, et al. **Res Virol** 1998 Sep–Oct;149(5):263–70

Is the strategy of universal hepatitis B vaccination necessary in low-endemic countries? Poirriez J. **Scand J Gastroenterol** 1998 Sep;33(9):897–9

Impact of the hepatitis B mass vaccination program in the southern part of Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):464–8

DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr–Jun;20(2):64–7 (30 ref.)

Control of Hepatitis B in Europe: Where are we in 1997? Proceedings of VHPB International Congress. Madrid, Spain, 17–19 November 1997. **Vaccine** 1998 Nov;16 Suppl:S1–110

Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Abraham P, et al. **Vaccine** 1999 Mar 5; 17(9–10):1125–9

Novel hepatitis B vaccines. Jilg W. **Vaccine** 1998 Nov;16 Suppl:S65–8 (21 ref.)

[A study on the coverage, strategy and cost of hepatitis B vaccination in China, 1996] Zeng X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):277–81 (Eng. Abstr.) **(Chi)**

[Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine] Xu H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul;32(4):205–7 (Eng. Abstr.) **(Chi)**

[Viral hepatitis: vaccination for hepatitis A and B virus] Béguè P. **Arch Pediatr** 1999;6 Suppl 2:186s–189s **(Fre)**

-Vaccination against hepatitis B- Merle P, et al. **Arch Pediatr** 1998 Mar;5(3):326–32 (Eng. Abstr.) **(Fre)**

[Hepatitis B vaccination in 7th year students in Lausanne] Woringer V. **Rev Med Suisse Romande** 1999 Aug; 119(8):647–52 **(Fre)**

[Prevention of Hepatitis B in Switzerland by general vaccination] **Soz Praventivmed** 1998;43 Suppl 1:S1–151 **(Ger, Fre)**

[Immunoprophylaxis of hepatitis in the Hungarian literature (letter; comment)] Kékesi Z, et al. **Orv Hetil** 1998 Dec 13;139(50):3053. Comment on: Orv Hetil 1998 Aug 2;139(31):1835–42. **(Hun)**

[Vaccine against hepatitis B. Eight years of experience] Marinho RT, et al. **Acta Med Port** 1998 Nov;11(11):971–7 (Eng. Abstr.) **(Por)**

ADMINISTRATION & DOSAGE

Combination therapy with hepatitis B vaccine and interferon alfa in chronic hepatitis B [letter] Kaymakoğlu S, et al. **Am J Gastroenterol** 1999 Mar;94(3):856–7

Hepatitis B vaccination program at a New York City hospital: seroprevalence, seroconversion, and declination. Louther J, et al. **Am J Infect Control** 1998 Aug;26(4):423–7

Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Propst T, et al. **Am J Kidney Dis** 1998 Dec;32(6):1041–5

Serologic hepatitis B immunity in vaccinated health care workers. Barash C, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1481–3

Parent and general practitioner preferences for infant immunisation. Reactogenicity or multiple injections? Bartlett MJ, et al. **Aust Fam Physician** 1999 Jan;28 Suppl 1:S22–7

Should immunisation against hepatitis B take priority over provision of clean drinking water? [letter] Puliyel JM. **BMJ** 1999 Jul 17;319(7203):188

Impact of the media on vaccine uptake in British Columbia's grade 6 hepatitis B immunization program. Bigham M, et al. **Can Commun Dis Rep** 1999 May 15;25(10):89–93; discussion 93–4 **(Eng, Fre)**

Hepatitis B vaccination in preterm infants. Gołębiowska M, et al. **Eur J Pediatr** 1999 Apr;158(4):293–7

Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Kondo R, et al. **Gene Ther** 1998 May;5(5):575–82

Lack of in vitro lymphoproliferative response to hepatitis B surface antigen in healthy vaccine recipients. Nagaraju K, et al. **Indian J Med Res** 1998 Sep;108:80–4

Hepatitis B vaccination coverage among healthcare workers in Italy. Stroffolini T, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):789–91

Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Petersen K, et al. **Int J Circumpolar Health** 1998; 57 Suppl 1:285–92

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. Hsu HM, et al. **J Infect Dis** 1999 Feb;179(2):367–70

What level of hepatitis B antibody is protective? Jack AD, et al. **J Infect Dis** 1999 Feb;179(2):489–92

A two dose combined hepatitis A and B vaccine in Chinese youngsters. Lee SD, et al. **J Med Virol** 1999 Sep;59(1):1–4

Use of a liposome antigen delivery system to alter immune responses in vivo. Lutsiak CM, et al. **J Pharm Sci** 1998 Nov;87(11):1428–32

From the Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission--United States. **JAMA** 1999 Mar 3;281(9):790

From the Centers for Disease Control and Prevention. Recommended childhood immunization schedule--United States, 1999. **JAMA** 1999 Feb 17;281(7):601–3

Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Somjee S, et al. **Leuk Res** 1999 Apr;23(4):365–7

Update: recommendations to prevent hepatitis B virus transmission--United States. **MMWR Morb Mortal Wkly Rep** 1999 Jan 22;48(2):33–4

Recommended childhood immunization schedule--United States, 1999. **MMWR Morb Mortal Wkly Rep** 1999 Jan 15;48(1):12–6

Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. McCluskie MJ, et al. **Mol Med** 1999 May;5(5):287–300

The effect of alpha interferon therapy and short-interval intradermal administration on response to hepatitis B vaccine in haemodialysis patients [letter] Ozener C, et al. **Nephrol Dial Transplant** 1999 May;14(5):1339–40

Exposure to blood borne viruses and the hepatitis B vaccination status among healthcare workers in inner London. Gyawali P, et al. **Occup Environ Med** 1998 Aug; 55(8):570–2

Hepatitis B vaccine administered to children and adolescents at yearly intervals. Halsey NA, et al. **Pediatrics** 1999 Jun; 103(6 Pt 1):1243–7

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Losonsky GA, et al. **Pediatrics** 1999 Feb;103(2):E14

Microencapsulation of hepatitis B core antigen for vaccine preparation. Uchida T, et al. **Pharm Res** 1998 Nov; 15(11):1708–13

Regional differences in infant immunization against hepatitis B: did intervention work? Takayama JI, et al. **Prev Med** 1999 Feb;28(2):160–6

No scientific justification to suspend hepatitis B immunization [news] **Public Health** 1998 Nov–Dec;113(6):487

Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Cardell K, et al. **Scand J Infect Dis** 1999; 31(2):197–200

The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Carlsson T, et al. **Scand J Infect Dis** 1999; 31(1):93–5

Factors associated with hepatitis B vaccination among men having sexual relations with men in Montreal, Quebec, Canada. Omega Study Group. Dufour A, et al. **Sex Transm Dis** 1999 Jul;26(6):317–24

Kidney transplantation in a child with posterior urethral valve from a hepatitis B virus-carrier mother. Report of a case with special reference to urinary tract reconstruction for dysfunctionalized uropathies and seroimmunological preparation against viral transmission. Seki T, et al. **Urol Int** 1998;61(4):237–9

Universal hepatitis B immunization: infant, and infant plus adolescent immunization [published erratum appears in Vaccine 1999 Apr 9;17(15–16):1] Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S17–22 (13 ref.)

Do we need 3 doses of hepatitis B vaccine? Wilson JN, et al. **Vaccine** 1999 Jun 4;17(20–21):2667–73

Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Wiström J, et al. **Vaccine** 1999 Apr 23;17(17):2162–5

[Materno-fetal transmission of hepatitis B virus in Ivory Coast. Plea for mass vaccination] Lohoués-Kouacou MJ, et al. **Sante** 1998 Nov–Dec;8(6):401–4 (Eng. Abstr.) **(Fre)**

[Vaccination against hepatitis A and B in HCV-infected patient?] Blum E. **Internist (Berl)** 1998 Sep;39(9):980 **(Ger)**

[Active hepatitis B vaccination in ulcerative colitis treated with azathioprine] Hinrichsen H, et al. **Internist (Berl)** 1999 Mar;40(3):327–8 **(Ger)**

[Information strategy for physicians and public health regarding introduction of general hepatitis B vaccination in Switzerland] Bourquin C, et al. **Soz Praventivmed** 1998;

43 Suppl 1:S72–4, S146–8 (Eng. Abstr.) **(Ger, Fre)**
[Vaccination against hepatitis B] Desgrandchamps D, et al. **Soz Praventivmed** 1998;43 Suppl 1:S37–40, S111–4 (27 ref.) (Eng. Abstr.) **(Ger, Fre)**
[Hepatitis B vaccination: knowledge and acceptance by Swiss physicians] Gugelmann RJ, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S57–60, S130–3 (Eng. Abstr.) **(Ger, Fre)**
[Hepatitis B vaccination strategies] Kammerlander R, et al. **Soz Praventivmed** 1998;43 Suppl 1:S41–3, S115–7 (Eng. Abstr.) **(Ger, Fre)**
[General hepatitis B vaccination--a challenge for public health in the year 2000 (editorial)] Raeber PA, et al. **Soz Praventivmed** 1998;43 Suppl 1:S3–4, S78 **(Ger, Fre)**
[When competence and creativeness coincide] Thorens JJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S75–7, S149–51 (Eng. Abstr.) **(Ger, Fre)**
[Practical recommendations for general introduction of hepatitis B vaccination] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S69–71, S143–5 (Eng. Abstr.) **(Ger, Fre)**
[General hepatitis B vaccination in Switzerland: what is the attitude of vaccinating physicians?] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S47–56, S121–9 (Eng. Abstr.) **(Ger, Fre)**
[Introduction of general hepatitis B vaccination in Switzerland] Zimmermann H, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S65–8, S138–42 (Eng. Abstr.) **(Ger, Fre)**
[Viral hepatitis: preventable illnesses] Baumgarten R. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):677–80 (6 ref.) (Eng. Abstr.) **(Ger)**
[De novo hepatitis B infection after liver transplantation--evidence for the need of active hepatitis B vaccination of liver transplantation candidates] Rambusch EG, et al. **Z Gastroenterol** 1998 Dec; 36(12):1027–35 (Eng. Abstr.) **(Ger)**
[A case of intense cytolysis following the administration of a hepatitis B vaccine (letter)] Lasheras Carbajo MD, et al. **Rev Clin Esp** 1999 Jan;199(1):49–50 (11 ref.) **(Spa)**
[A comparative study between different regimens for administering 2 doses of the Cuban anti-hepatitis B vaccine] González-Griego M de J, et al. **Rev Cubana Med Trop** 1998;50(3):218–20 (Eng. Abstr.) **(Spa)**
[Factors associated with inadequate response to hepatitis B vaccination in health care personnel] Tolosa Martinez N, et al. **Rev Esp Salud Publica** 1998 Nov-Dec;72(6):509–15 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Graham Little-Piccardi-Lasseur syndrome following HBV vaccination [letter] Bardazzi F, et al. **Acta Derm Venereol** 1999 Jan;79(1):93
The bald truth. Flemmer M, et al. **Am J Gastroenterol** 1999 Apr;94(4):1104
Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al [letter; comment] Senécal JL, et al. **Arthritis Rheum** 1999 Jun;42(6):1307–8. Comment on: Arthritis Rheum 1998 Oct;41(10):1828–34.
Should hepatitis B vaccine be contra-indicated in myasthenia gravis? Domigo V, et al. **Autoimmunity** 1999;29(2):139–40
Allergic mechanisms and urticaria/angioedema after hepatitis B immunization [letter] Barbaud A, et al. **Br J Dermatol** 1998 Nov;139(5):925–6
Lichen planus following hepatitis B vaccination [letter] Ferrando MF, et al. **Br J Dermatol** 1998 Aug;139(2):350
Vaccine-induced necrobiotic granuloma. Ajithkumar K, et al. **Clin Exp Dermatol** 1998 Sep;23(5):222–4
Eczematous reaction to hepatitis B vaccine. McKenna KE. **Contact Dermatitis** 1999 Mar;40(3):158–9
Persistent nodules at sites of hepatitis B vaccination due to aluminium sensitization. Skowron F, et al. **Contact Dermatitis** 1998 Sep;39(3):135–6
Solitary mastocytoma arising at a hepatitis B vaccination site. Poulton JK, et al. **Cutis** 1999 Jan;63(1):37–40
Lichen planus as a side effect of HBV vaccination [editorial] [published erratum appears in Dermatology 1999;198(2):222] Rebora A, et al. **Dermatology** 1999; 198(1):1–2 (16 ref.)
Hepatitis B vaccine and liver problems in U.S. children less than 6 years old, 1993 and 1994. Fisher MA, et al. **Epidemiology** 1999 May;10(3):337–9
Generalized granuloma annulare and hepatitis B vaccination. Wolf F, et al. **Eur J Dermatol** 1998 Sep;8(6):435–6
The benefit-risk politics of vaccination against hepatitis B virus [comment] Degos F. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):392–4 (17 ref.). Comment on: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):388–91.
Multiple sclerosis and vaccination against hepatitis B: analysis of risk benefit profile [see comments] Tosti ME, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):388–91. Comment in: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):392–4.
Suspected hepatitis B vaccination related vasculitis. Le Hello C, et al. **J Rheumatol** 1999 Jan;26(1):191–4 (28 ref.)
The development of rheumatoid arthritis after recombinant hepatitis B vaccination. Pope JE, et al. **J Rheumatol** 1998 Sep;25(9):1687–93
First case of erythermalgia related to hepatitis B vaccination [letter] Rabaud C, et al. **J Rheumatol** 1999 Jan;26(1):233–4
Hepatitis B vaccination and diabetes [letter] Petousis-Harris H, et al. **N Z Med J** 1999 Aug 13;112(1093):303–4
No increase in demyelinating diseases after hepatitis B vaccination [letter] Zipp F, et al. **Nat Med** 1999 Sep; 5(9):964–5
Nephrotic syndrome associated with recombinant hepatitis B vaccination: a causal relationship or just a mere association? [letter] Ozdemir S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1888–9
Spurious hepatitis B surface antigen detection in a haemodialysis patient [letter] [see comments] Riley S, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1897–8. Comment in: Nephrol Dial Transplant 1999 Mar;14(3):794.
Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Tourbah A, et al. **Neurology** 1999 Jul 22;53(2):396–401
Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Halsey NA, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):23–4 (0 ref.)
Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Neau D, et al. **Scand J Infect Dis** 1998;30(2):115–8
Multiple sclerosis and hepatitis B vaccine? Hall A, et al. **Vaccine** 1999 Jun 4;17(20–21):2473–5
[Exacerbation of chronic juvenile arthritis induced by hepatitis B vaccination (letter)] Sebag O, et al. **Arch Pediatr** 1998 Sep;5(9):1046 **(Fre)**
[Multifocal placoid epitheliopathy and anti-hepatitis B vaccination] Bourges JL, et al. **J Fr Ophtalmol** 1998 Nov; 21(9):696–700 (Eng. Abstr.) **(Fre)**
[Cutaneous vasculitis after hepatitis B vaccination with recombinant vaccine in a renal transplant patient] Bui-Quang D, et al. **Presse Med** 1998 Sep 12;27(26):1321–3 (Eng. Abstr.) **(Fre)**
[Hypersensitivity vasculitis after hepatitis B vaccination (letter)] Masse I, et al. **Presse Med** 1998 Jun 6;27(20):965–6 **(Fre)**
[Acute transverse cervical myelitis following hepatitis B vaccination. Evolution of anti-HBs antibodies] Renard JL, et al. **Presse Med** 1999 Jul 3–10;28(24):1290–2 (Eng. Abstr.) **(Fre)**
[Between the infection and the vaccine, one must choose] Bouroz-Joly J, et al. **Rev Med Interne** 1998;19 Suppl 2:286s–289s **(Fre)**
[Adult-onset Still's disease after hepatitis A and B vaccination?] Grasland A, et al. **Rev Med Interne** 1998 Feb; 19(2):134–6 (Eng. Abstr.) **(Fre)**
[Vaccination against hepatitis B or chasing shadows (editorial)] Sicard D. **Rev Med Interne** 1999 Feb; 20(2):119–20 **(Fre)**
[Sclerotic plaques and vaccination against hepatitis B (editorial)] Gout O, et al. **Rev Neurol (Paris)** 1998 Apr; 154(3):205–7 **(Fre)**
[Hepatitis B vaccine and multiple sclerosis (editorial)] Campins Marti M, et al. **An Esp Pediatr** 1998 Dec; 49(6):555–7 (15 ref.) **(Spa)**
[Vaccination against hepatitis B and multiple sclerosis (letter)] Diego Núñez MA, et al. **An Esp Pediatr** 1999 Jan;50(1):97 **(Spa)**
[Juvenile dermatomyositis concomitant with hepatitis B vaccination (letter)] Fernández-Fúnez A, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):675 **(Spa)**
[A case of intense cytolysis following the administration of a hepatitis B vaccine (letter)] Lasheras Carbajo MD, et al. **Rev Clin Esp** 1999 Jan;199(1):49–50 (11 ref.) **(Spa)**
[The reactogenicity of Heberbiovac-HB vaccine at different doses] Diaz González M, et al. **Rev Cubana Med Trop** 1995; 47(1):65–70 (Eng. Abstr.) **(Spa)**

ECONOMICS

Clinical and economic impact of a combination Haemophilus influenzae and Hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Fendrick AM, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):126–36
Prevaccination screening for hepatitis B among sexually active adolescents and young adults [letter; comment] Buffington J, et al. **Clin Infect Dis** 1998 Dec;27(6):1562–3 . Comment on: Clin Infect Dis 1998 Jun;26(6):1459–60.
Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Edmunds WJ. **Commun Dis Public Health** 1998 Dec;1(4):221–8 (34 ref.)
Economic evaluations applied to HB vaccination: general observations. Beutels P. **Vaccine** 1998 Nov;16 Suppl:S84–92 (31 ref.)
[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents] Szucs TD, et al. **Med Klin** 1998 Aug 15;93(8):468–77 (Eng. Abstr.) **(Ger)**
[Economic evaluation of various hepatitis B vaccination Strategies in Switzerland] Zurn P, et al. **Soz Praventivmed** 1998;43 Suppl 1:S61–4, S134–7 (Eng. Abstr.) **(Ger, Fre)**

IMMUNOLOGY

Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Vesikari T, et al. **Acta Paediatr** 1999 May;88(5):513–20
Correlation of maternal and fetal hepatitis B antibody titers following maternal vaccination in pregnancy. Ingardia CJ, et al. **Am J Perinatol** 1999;16(3):129–32
Immunogenicity of hepatitis B vaccine in preterm infants. Blondheim O, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F206–8
Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region. Street M, et al. **Arch Virol** 1999;144(7):1323–43
Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Poovorawan Y, et al. **Asian Pac J Allergy Immunol** 1999 Jun;17(2):113–20
The core antigen of hepatitis B virus as a carrier for immunogenic peptides. Murray K, et al. **Biol Chem** 1999 Mar;380(3):277–83 (37 ref.)
Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R, et al. **Biol Chem** 1999 Mar; 380(3):285–91 (90 ref.)
Control of hepatitis B virus infection by vaccination: the Taiwan experience. Lee SD, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Sep;61(9):501–6 (32 ref.)
Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Chen CC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 May-Jun;40(3):157–60
Human plasma derived hepatitis B vaccine: Kenyan experience. Okoth FA, et al. **East Afr Med J** 1998 Nov; 75(11):647–8
Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines? Usonis V, et al. **Eur J Pediatr** 1999 May;158(5):398–402
Anti-HBV vaccination before therapy with interferon (IFN) in chronic B hepatitis. Fruttaldo L, et al. **Eur Rev Med Pharmacol Sci** 1997 Nov-Dec;1(6):197–201
Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Böcher WO, et al. **Hepatology** 1999 Jan;29(1):238–44
Low response to hepatitis B vaccine in health care workers and medical students in Lisbon, Portugal [letter; comment] Marinho RT, et al. **Hepatology** 1998 Oct;28(4):1166. Comment on: Hepatology 1998 Feb;27(2):637.
Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Ogata N, et al. **Hepatology** 1999 Sep;30(3):779–86
Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, et al. **Hum Immunol** 1998 Dec;59(12):783–93
Immunogenic response to hepatitis B vaccine in Indian infants. Karthikeyan G. **Indian Pediatr** 1998 Apr; 35(4):375–6; discussion 376–7
Hepatitis B immunization coverage and awareness in middle and upper-class population in Chennai City [letter] Pai M, et al. **Indian Pediatr** 1998 Sep;35(9):922–3
Protective level of antibody induced by hepatitis B vaccine [letter; comment] Subramanyam V, et al. **Indian Pediatr** 1998 Aug;35(8):800–1. Comment on: Indian Pediatr 1997 Jun;34(6):555–6.
Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Petersen K, et al. **Int J Circumpolar Health** 1998; 57 Suppl 1:285–92
Immunogenicity and reactogenicity of a combined hepatitis A-hepatitis B vaccine in adolescents. Thompson SC, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):193–6
The benefit-risk politics of vaccination against hepatitis B virus [comment] Degos F. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):392–4 (17 ref.). Comment on: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):388–91.
Multiple sclerosis and vaccination against hepatitis B: analysis of risk benefit profile [see comments] Tosti ME, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):388–91. Comment in: Ital J Gastroenterol Hepatol 1999 Jun-Jul;31(5):392–4.
Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. Akbar SM, et al. **J Hepatol** 1999 May;30(5):755–64
Ten-year follow-up study of hepatitis B virus infection and vaccination status in hospital employees. Rosen E, et al. **J Hosp Infect** 1999 Mar;41(3):245–50
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. McCluskie MJ, et al. **J Immunol** 1998 Nov 1;161(9):4463–6
Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. Mancini M, et al. **J Immunol** 1998 Nov 15; 161(10):5564–70
Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, et al. **J Immunol** 1998 Nov 1;161(9):4520–9
Identification of hepatitis B surface antigen variants with

alterations outside the "a" determinant in immunized Singapore infants. Chong-Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259–63

DNA-mediated immunization of mice with plasmid encoding HBs antigen. Yoon SJ, et al. **J Korean Med Sci** 1999 Apr; 14(2):187–92

A genetic marker associated with non-response to recombinant hepatitis B vaccine by indigenous Australian children [letter] Sullivan JS, et al. **J Paediatr Child Health** 1999 Aug;35(4):412–3

A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. Eyigün CP, et al. **J Viral Hepat** 1998 Jul;5(4):265–9

Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:5–8

Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. McDermott AB, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:9–11

Current aspects of hepatitis B surface antigen mutants in Singapore. Oon CJ, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:17–23

Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. Thomas HC. **J Viral Hepat** 1998 Nov;5 Suppl 2:31–6

Evidence for the genetic basis of non-response in mice. Waters JA. **J Viral Hepat** 1998 Nov;5 Suppl 2:1–4

Current status of HBV vaccine escape variants--a mathematical model of their epidemiology. Wilson JN, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:25–30

Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--third generation pre-S/S vaccines overcome non-response. Zuckerman JN. **J Viral Hepat** 1998 Nov;5 Suppl 2:13–5

Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations. Geissler M, et al. **J Virol** 1999 May; 73(5):4284–92

Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. Lu M, et al. **J Virol** 1999 Jan;73(1):281–9

A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. Singh M, et al. **J Virol** 1999 Jun;73(6):4823–8

Vaccination against HBV in France [letter] Barquet N, et al. **Lancet** 1999 Jan 30;353(9150):414

Immunogenicity of low-dose plasma-derived hepatitis B vaccine [letter; comment] Kane M, et al. **Lancet** 1997 Oct 11;350(9084):1102. Comment on: Lancet 1995 Jul 29;346(8970):318.

Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. McCluskie MJ, et al. **Mol Med** 1999 May;5(5):287–300

DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Davis HL. **Mt Sinai J Med** 1999 Mar;66(2):84–90 (48 ref.)

Fetal immunization of baboons induces a fetal-specific antibody response. Watts AM, et al. **Nat Med** 1999 Apr; 5(4):427–30

Spurious hepatitis B surface antigen detection in adult haemodialysis patients following vaccination [letter; comment] Esparza N, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):794. Comment on: Nephrol Dial Transplant 1998 Jul;13(7):1897–8.

Hepatitis B vaccination in pregnancy: factors influencing efficacy. Ingardia CJ, et al. **Obstet Gynecol** 1999 Jun; 93(6):983–6

Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Shih HH, et al. **Pediatr Infect Dis J** 1999 May; 18(5):427–32

Response to hepatitis B vaccine: multiple HLA genes are involved. Desombere I, et al. **Tissue Antigens** 1998 Jun; 51(6):593–604

Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age. Aristegui J, et al. **Vaccine** 1998 Dec;16(20):1976–81

Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Brunel F, et al. **Vaccine** 1999 Apr 23; 17(17):2192–203

Immunoadjuvant action of plasmid DNA in liposomes. Gürsel M, et al. **Vaccine** 1999 Mar 17;17(11–12):1376–83

Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes. Hui J, et al. **Vaccine** 1999 Mar 26; 17(13–14):1711–8

Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Johnson D, et al. **Vaccine** 1999 Jun 4; 17(20–21):2583–7

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Jones CD, et al. **Vaccine** 1999 Jun 4;17(20–21):2528–37

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Koike Y, et al. **Vaccine** 1998 Dec;16(20):1982–9

Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Liao SS, et al. **Vaccine** 1999 Jun 4;17(20–21):2661–6

The influence of host factors and immunogenetics on lymphocyte responses to Hepagene vaccination. McDermott AB, et al. **Vaccine** 1999 Mar 17; 17(11–12):1329–37

Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. McDermott AB, et al. **Vaccine** 1999 Jan 28;17(4):330–9

A combined liquid Hib (PRP-OMP), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: uncontrolled preliminary clinical trial of immunogenicity and reactogenicity. Nolan T, et al. **Vaccine** 1998 Dec; 16(20):2085–9

DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response. Prange R, et al. **Vaccine** 1999 Feb 26; 17(7–8):617–23

The first combined vaccine against hepatitis A and B: an overview. Thoelen S, et al. **Vaccine** 1999 Mar 26; 17(13–14):1657–62

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Van Herck K, et al. **Vaccine** 1998 Dec; 16(20):1933–5

Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vellinga A, et al. **Vaccine** 1999 Feb 12; 17(6):602–6

The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Wilson JN, et al. **Vaccine** 1999 Feb 26;17(7–8):973–8

The capacity of a combined liposomal hepatitis B and C vaccine to stimulate humoral and cellular responses in mice. Khemka V, et al. **Viral Immunol** 1998;11(2):73–8

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. McCluskie MJ, et al. **Viral Immunol** 1998;11(4):245–52

[Specific immune responses in H-2d mice after DNA immunization of HBV core gene] Huang Z, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):107–9 (Eng. Abstr.) **(Chi)**

[Detection of NV-HB/s DNA and c-myc mRNA in mice inoculated with hepatitis B nucleic acid vaccine--NV-HB/s] Qin S, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):6–7 (Eng. Abstr.) **(Chi)**

[A study on the effectiveness of hepatitis B vaccine among the vaccinated population] Wang C, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):43–6 (Eng. Abstr.) **(Chi)**

[Antibody reaction to immunization with different recombinant hepatitis B vaccine in primary school children] Liang Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May;32(3):165–7 (Eng. Abstr.) **(Chi)**

[A follow-up study on correlated factors for intrauterine infection of hepatitis B virus] Liu ZH, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):263–5 (Eng. Abstr.) **(Chi)**

[Follow-up on hepatitis B immunized neonates born to HBsAg positive mothers] Zhang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):97–9 (Eng. Abstr.) **(Chi)**

[Comparative studies on immunogenicity of Chinese hamster ovary cell drived HB vaccine and plasma drived HB vaccine] Yagura M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jan;96(1):21–8 (Eng. Abstr.) **(Jpn)**

[A combined vaccine against hepatitis A and B (editorial)] Batalla J, et al. **Aten Primaria** 1999 May 31;23(9):513–4 **(Spa)**

[The immunogenicity of the Heberbiovac-HB vaccine in children] Díaz González M, et al. **Rev Cubana Med Trop** 1996;48(3):195–8 (Eng. Abstr.) **(Spa)**

[The immunogenicity of the Heberbiovac-HB vaccine in the elderly] Pedroso Flaquet P, et al. **Rev Cubana Med Trop** 1996;48(3):200–3 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Hepatitis B vaccine. Capiau C. **Dev Biol Stand** 1998;96:127–9

PHARMACOLOGY

Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Brunel F, et al. **Vaccine** 1999 Apr 23; 17(17):2192–203

STANDARDS

The Costa Rican experience on the serological response to the hepatitis B vaccine in health professionals [letter] Ruiz MA, et al. **Infect Control Hosp Epidemiol** 1999 May; 20(5):301

THERAPEUTIC USE

Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Miller ER, et al. **Am J Kidney Dis** 1999 Feb;33(2):356–60

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Honorati MC, et al. **Clin Exp Immunol** 1999 Apr;116(1):121–6

Potent synergistic effect of sho-saiko-to, a herbal medicine, during vaccine therapy in a murine model of hepatitis B virus carrier. Akbar SM, et al. **Eur J Clin Invest** 1999 Sep; 29(9):786–92

Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Huang LM, et al. **Hepatology** 1999 Mar; 29(3):954–9

Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Yuen MF, et al. **Hepatology** 1999 Mar;29(3):924–7

Hepatitis B vaccination in hospital personnel and medical students. Marinho RT, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):317–22

Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. Livingston BD, et al. **J Immunol** 1999 Mar 1;162(5):3088–95

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. Couillin I, et al. **J Infect Dis** 1999 Jul;180(1):15–26

Hepatitis B vaccination in high-risk infants: 10-year follow-up. Wu JS, et al. **J Infect Dis** 1999 Jun; 179(6):1319–25

Response to hepatitis B virus vaccine in patients transplanted for HBV-related liver disease under specific gammaglobulin prophylaxis. Bárcena R, et al. **Transplant Proc** 1999 Sep;31(6):2459–60

Success stories in the implementation of universal hepatitis B vaccination: an update on Italy [published erratum appears in Vaccine 1999 Apr 9;17(15–16):I–II] Bonanni P, et al. **Vaccine** 1998 Nov;16 Suppl:S38–42 (13 ref.)

Hepatitis B immunization programme: Spain. de la Torre J. **Vaccine** 1998 Nov;16 Suppl:S43–4

Status of hepatitis B immunization programmes in 1998. Kane MA. **Vaccine** 1998 Nov;16 Suppl:S104–8 (25 ref.)

Evolution of the Viral Hepatitis Prevention Board--VHPB. McCloy E, et al. **Vaccine** 1998 Nov;16 Suppl:S7–10 (18 ref.)

Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Mast EE, et al. **Vaccine** 1998 Nov;16 Suppl:S27–9 (7 ref.)

Current combined vaccines with hepatitis B. Papaevangelou G. **Vaccine** 1998 Nov;16 Suppl:S69–72 (16 ref.)

Universal hepatitis B immunization: young adolescent immunization. Tepper ML. **Vaccine** 1998 Nov;16 Suppl:S23–6 (34 ref.)

From Cannes 1993 to the present. Van Damme P, et al. **Vaccine** 1998 Nov;16 Suppl:S3–6 (11 ref.)

[Changes in the epidemiological situation of hepatitis B in Kielce region, after introduction of vaccination of infants against hepatitis B] Patrzałek M, et al. **Przegl Epidemiol** 1999;53(1–2):181–5 (Eng. Abstr.) **(Pol)**

[Hepatitis B immunization in hemodialysis patients] Skladany L, et al. **Vnitr Lek** 1998 Sep;44(9):535–7 (Eng. Abstr.) **(Slo)**

HEPATITIS B VIRUS

see related

HEPATITIS B SURFACE ANTIGENS

Hepatitis B virus infection among street youths in Montreal. Roy E, et al. **CMAJ** 1999 Sep 21;161(6):689–93

Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses [letter; comment] Lyerla R, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):156–7. Comment on: Infect Control Hosp Epidemiol 1998 Jul;19(7):508–10.

Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy [letter] Narváez J, et al. **J Rheumatol** 1998 Oct;25(10):2037–8

Influence of GB virus-C/hepatitis G virus infection on the long-term course of chronic hepatitis B. Fattovich G, et al. **Liver** 1998 Oct;18(5):360–5

Screening of pregnant women for hepatitis B. Boxall E. **Vaccine** 1998 Nov;16 Suppl:S30–3 (13 ref.)

Hepatitis B: virus, pathogenesis and treatment. Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S11–6 (17 ref.)

Hepatitis B and blood safety. Kitchen A. **Vaccine** 1998 Nov; 16 Suppl:S34–7 (0 ref.)

Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Oshima KH, et al. **Vox Sang** 1998; 75(3):181–8

[Hepatitis virus and hepatocellular carcinoma] Rosmorduc O, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):363–75 (126 ref.) **(Fre)**

[Cryoglobulinemia related to the hepatitis B and C viruses] Cohen P. **Pathol Biol (Paris)** 1999 Mar;47(3):232–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Viral vasculitis not related to HBV, HCV and HIV] Lortholary O, et al. **Pathol Biol (Paris)** 1999 Mar;

47(3):248–51 (38 ref.) (Eng. Abstr.) **(Fre)**

[Periarteritis nodosa induced by hepatitis B virus] Mouthon L. **Pathol Biol (Paris)** 1999 Mar;47(3):237–44 (68 ref.) (Eng. Abstr.) **(Fre)**

[The immunological and morphological aspects of chronic hepatitis caused by HBV] Gabriel A, et al. **Pol Merkuriusz Lek** 1998 May;4(23):292–4 (38 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Hepatitis B core particles as a universal display model: a structure–function basis for development. Pumpens P, et al. **FEBS Lett** 1999 Jan 8;442(1):1–6 (70 ref.)

Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus. Schmitt S, et al. **J Biol Chem** 1999 Apr 23;274(17):11945–57

The crystal structure of the human hepatitis B virus capsid. Wynne SA, et al. **Mol Cell** 1999 Jun;3(6):771–80

Localization of the N terminus of hepatitis B virus capsid protein by peptide-based difference mapping from cryoelectron microscopy. Conway JF, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14622–7

Difference mapping cryo-EM. Peters R, et al. **Science** 1999 Feb 19;283(5405):1133

CLASSIFICATION

A polymerase chain reaction-based assay to identify genotype F of hepatitis B virus. Moraes MT, et al. **Braz J Med Biol Res** 1999 Jan;32(1):45–9

Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. Allen MI, et al. **J Clin Microbiol** 1999 Oct; 37(10):3338–47

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. Usuda S, et al. **J Virol Methods** 1999 Jun;80(1):97–112

DRUG EFFECTS

Antiviral activity of 1,7-disulphoanthraquinone. Ciebiada I, et al. **Acta Microbiol Pol** 1998;47(3):261–6

Use of surrogate models for testing efficacy of disinfectants against hepatitis B virus [letter] Pugh JC, et al. **Am J Infect Control** 1999 Aug;27(4):375–6

Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Cane PA, et al. **Antimicrob Agents Chemother** 1999 Jul; 43(7):1600–8

Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (–)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Delaney WE 4th, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2017–26

Pharmacodynamics of (–)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans [published erratum appears in Antimicrob Agents Chemother 1998 Dec;42(12):3337] Hurwitz SJ, et al. **Antimicrob Agents Chemother** 1998 Nov; 42(11):2804–9

Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (–)beta-L-2',3'-dideoxy-3'-thiacytidine [published erratum appears in Antimicrob Agents Chemother 1999 Mar;43(3):726] King RW, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3179–86

In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Peghini PA, et al. **Antivir Chem Chemother** 1998 Mar;9(2):117–26

Cell-based and animal models for hepatitis B and C viruses. Schinazi RF, et al. **Antivir Chem Chemother** 1999 May; 10(3):99–114 (180 ref.)

Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Morrey JD, et al. **Antiviral Res** 1999 Jun;42(2):97–108

Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Oon CJ, et al. **Antiviral Res** 1999 Apr;41(3):113–8

The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis(S-acyl-2-thioethyl)phosphotriester derivatives of acyclovir. Périgaud C, et al. **Antiviral Res** 1999 Jan;40(3):167–78

Robustaflavone, a potential non-nucleoside anti-hepatitis B agent. Zembower DE, et al. **Antiviral Res** 1998 Aug; 39(2):81–8

Current status of anti-HBV chemotherapy. Hong JH, et al. **Arch Pharm Res** 1998 Apr;21(2):89–105 (132 ref.)

Sensitivity of L-(–)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Fu L, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1351–9

Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent. Li X, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):57–62

Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein. Chi WJ, et al. **Carcinogenesis** 1998 Dec;19(12):2133–8

Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection. Böttcher B, et al. **EMBO J** 1998 Dec 1;17(23):6839–45

Resistance of hepatitis B to antiviral agents [letter; comment] Fischer KP. **Hepatology** 1999 Mar;29(3):996. Comment on: Hepatology 1998 Dec;28(6):1669–73.

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. Ono-Nita SK, et al. **J Clin Invest** 1999 Jun;103(12):1635–40

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Locarnini S, et al. **J Hepatol** 1999 Mar;30(3):536–50 (127 ref.)

Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2', 3'-unsaturated L-nucleosides. Lee K, et al. **J Med Chem** 1999 Apr 8;42(7):1320–8

Sequence variation of hepatitis B virus precore-core open reading frame isolated from serum and liver of children with chronic hepatitis B before and after interferon treatment. Cabrerizo M, et al. **J Med Virol** 1999 Jul; 58(3):208–14

Disinfection of dental diamond burs contaminated with hepatitis B virus. Leontiou AP, et al. **J Prosthet Dent** 1999 Sep;82(3):332–5

Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. Honkoop P, et al. **J Viral Hepat** 1998 Sep;5(5):307–12

Potent anti-hepatitis B viral activity and inhibition of bacteriophage T7 RNA polymerase by a "fat" nucleoside and its 5'-triphosphate derivative: synthetic, biochemical, and biological studies of 4,8-diamino-6-imino-6H-1-beta-D-ribofuranosyl-imidazo[4,5-E] [1,3]diazepine-5'-triphosphate. Bretner M, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):837–8

An efficient, short synthesis and potent anti-hepatitis B viral activity of a novel ring-expanded purine nucleoside analogue containing a 5:7-fused, planar, aromatic, imidazo[4,5-e][1,3]diazepine ring system. Chen HM, et al. **Nucleosides Nucleotides** 1999 Mar;18(3):331–5

Intracellular metabolism of beta-L-ddAMP-bis(tbutylSATE), a potent inhibitor of hepatitis B virus replication. Faraj A, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):987–8

Comparison of anti-HBV activity of beta-D- and beta-L-DDA-5'monophosphate prodrugs and effectiveness in combination with lamivudine. Loi AG, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):1005–6

Synthesis of new thiolated acyclonucleosides with potential anti-HBV activity. Zeid IF, et al. **Nucleosides Nucleotides** 1999 Jan;18(1):95–111

Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation. Gugenheim J, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):554–5

[Inhibitory effect of triplex forming oligodeoxynucleotides on HBV replication and synthesis of antigen] Yang L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):8–10 (Eng. Abstr.) **(Chi)**

[Antiviral effect of antisense oligodeoxynucleotides complementary to hepatitis B virus X gene in vitro] Feng Z, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):246–9 (Eng. Abstr.) **(Chi)**

[Progress in experimental and clinical study on extracorporal screening drugs of anti-hepatitis B virus with 2.2.15 cell line] Chen BM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 May; 17(5):316–20 (23 ref.) (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Ladner SK, et al. **Antivir Chem Chemother** 1998 Jan;9(1):65–72

Expression of an enzymatically active polymerase of human hepatitis B virus in an coupled transcription–translation system. Li Z, et al. **Biochem Cell Biol** 1999;77(2):119–26

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Pichoud C, et al. **Hepatology** 1999 Jan;29(1):230–7

Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. Gregorio GV, et al. **J Immunol** 1999 Feb 1;162(3):1802–10

Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein–protein interaction. Lanford RE, et al. **J Virol** 1999 Mar;73(3):1885–93

Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. zu Putlitz J, et al. **J Virol** 1999 May;73(5):4188–96

GENETICS

Naturally occurring variants of hepatitis B virus. Günther S, et al. **Adv Virus Res** 1999;52:25–137 (508 ref.)

Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Ben-Ari Z, et al. **Am J Gastroenterol** 1999 Mar;94(3):663–7

The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Shindo M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2237–45

Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Oon CJ, et al. **Antiviral Res** 1999 Apr;41(3):113–8

Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Takahashi K, et al. **Arch Virol** 1998; 143(12):2313–26

Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Takahashi K, et al. **Arch Virol** 1999;144(7):1299–308

Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Chen WN, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):757–61

Replication of hepatitis B virus which carries foreign DNA in vitro. Hanafusa T, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):530–3

Hepatitis B virus: DNA polymerase activity of deletion mutants. Kim Y, et al. **Biochem Mol Biol Int** 1999 Feb; 47(2):301–8

c-Myb protein binds to the EP element of the HBV enhancer and regulates transcription in synergy with NF-M. David-Cordonnier MH, et al. **Biochim Biophys Acta** 1999 Jul 7;1446(1-2):82–92

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101–4

A polymerase chain reaction-based assay to identify genotype F of hepatitis B virus. Moraes MT, et al. **Braz J Med Biol Res** 1999 Jan;32(1):45–9

The presence of HBV genomic DNA in tumor tissue correlates with P53 aberrations in human hepatocellular carcinoma in Qidong, China [letter] Wang SK, et al. **Cancer Genet Cytogenet** 1999 Sep;113(2):191–2

Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection. Nagasaka A, et al. **Dig Dis Sci** 1998 Nov;43(11):2473–8

Insulin activates the hepatitis B virus X gene through the activating protein-1 binding site in HepG2 cells. Choi BH, et al. **DNA Cell Biol** 1998 Nov;17(11):951–6

Isolation of NotI clusters hypomethylated in HBV-integrated hepatocellular carcinomas by two-dimensional electrophoresis. Nagai H, et al. **DNA Res** 1999 Aug 31; 6(4):219–25

Clinical implications of mutations in the hepatitis B virus genome. Torre F, et al. **Eur J Clin Invest** 1998 Aug; 28(8):604–14 (153 ref.)

Heterogeneous HBV mutants coexist in Korean hepatitis B patients. Keum WK, et al. **Exp Mol Med** 1998 Jun 30; 30(2):115–22

Human hepatitis B virus mutants: significance of molecular changes. Chen WN, et al. **FEBS Lett** 1999 Jun 25; 453(3):237–42 (74 ref.)

The X gene of hepatitis B virus shows a high level stimulation of the Rous sarcoma virus long terminal repeat in the methylotropic yeast, Pichia pastoris. Lal SK, et al. **FEBS Lett** 1999 Jul 30;456(1):108–12

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. Mizokami M, et al. **FEBS Lett** 1999 Apr 30;450(1-2):66–71

Post-transcriptional control of the level of mRNA by hepatitis B virus X gene in the transient expression system using human hepatic cells. Shimazu T, et al. **Genes Cells** 1998 Jul;3(7):477–84

Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Shields PL, et al. **Gut** 1999 Aug;45(2):306–9

Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis. Santantonio T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1848–54

High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Baptista M, et al. **Hepatology** 1999 Mar;29(3):946–53

The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Bock CT, et al. **Hepatology** 1999 Aug;30(2):517–25

Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factor. Bock CT, et al. **Hepatology** 1999 Apr;29(4):1236–47

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Chan HL, et al. **Hepatology** 1999 Mar;29(3):976–84

Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Friedt M, et al. **Hepatology** 1999 Apr;29(4):1252–8

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy [see comments] Liaw YF, et al. **Hepatology** 1999

Aug;30(2):567–72. Comment in: Hepatology 1999 Aug;30(2):579–81.

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Ono-Nita SK, et al. **Hepatology** 1999 Mar;29(3):939–45

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Pichoud C, et al. **Hepatology** 1999 Jan;29(1):230–7

Functional analysis of HBV genomes from patients with fulminant hepatitis. Sterneck M, et al. **Hepatology** 1998 Nov;28(5):1390–7

Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Stuyver L, et al. **Hepatology** 1999 Jun;29(6):1876–83

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Tassopoulos NC, et al. **Hepatology** 1999 Mar; 29(3):889–96

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Tillmann HL, et al. **Hepatology** 1999 Jul;30(1):244–56

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro [see comments] Xiong X, et al. **Hepatology** 1998 Dec;28(6):1669–73. Comment in: Hepatology 1999 Mar;29(3):996.

Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Yamamoto T, et al. **Hepatology** 1999 May;29(5):1446–52

Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection. Akbar SK, et al. **Int J Exp Pathol** 1998 Oct;79(5):279–91 (49 ref.)

Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Shibata Y, et al. **Int J Oncol** 1999 Jun;14(6):1153–6

Human immunodeficiency virus and hepatitis B virus infection in pregnancy: diagnostic potential of viral genome detection. Berger A, et al. **Intervirology** 1998;41(4–5):201–7 (38 ref.)

Cloning and characterization of a novel human hepatocyte transcription factor, hB1F, which binds and activates enhancer II of hepatitis B virus. Li M, et al. **J Biol Chem** 1998 Oct 30;273(44):29022–31

The hepatitis B virus X protein is a co-activator of activated transcription that modulates the transcription machinery and distal binding activators. Lin Y, et al. **J Biol Chem** 1998 Oct 16;273(42):27097–103

Patterns of circulating hepatitis B surface antigen variants among vaccinated children born to hepatitis B surface antigen carrier and non-carrier mothers. A population-based comparative study. Ho M, et al. **J Biomed Sci** 1998 Sep–Oct;5(5):355–62

A novel regulator inhibits HBV gene expression. Liou J, et al. **J Biomed Sci** 1998 Sep–Oct;5(5):343–54

Quantitation of hepatitis B virus genomic DNA by real-time detection PCR. Abe A, et al. **J Clin Microbiol** 1999 Sep; 37(9):2899–903

Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. Mbayed VA, et al. **J Clin Microbiol** 1998 Nov;36(11):3362–5

Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test. Noborg U, et al. **J Clin Microbiol** 1999 Sep;37(9):2793–7

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. Thibault V, et al. **J Clin Microbiol** 1999 Sep;37(9):3013–6

Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. Aritomi T, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1125–32

Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians. Guptan RK, et al. **J Gastroenterol Hepatol** 1998 Jul; 13(7):675–9

Evidence of transmission of hepatitis B virus to spouses from sequence analysis of the viral genome. Huo TI, et al. **J Gastroenterol Hepatol** 1998 Nov;13(11):1138–42

Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. Yeh CT, et al. **J Gastroenterol Hepatol** 1998 Feb; 13(2):131–6

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. Ling R, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):601–6

Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. Rosmorduc O, et al. **J Gen Virol** 1999 May;80 (Pt 5):1253–62

Hepatitis B x antigen and p53 in the development of hepatocellular carcinoma. Feitelson MA. **J Hepatobiliary Pancreat Surg** 1998;5(4):367–74 (111 ref.)

Transactivation of the human MDR1 gene by hepatitis B virus X gene product. Doong SL, et al. **J Hepatol** 1998 Dec;29(6):872–8

Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. Günther S, et al. **J Hepatol** 1999 May;30(5):749–54

Mother-to-infant transmission of hepatitis C virus: molecular evidence of superinfection by homologous virus in children. Halfon P, et al. **J Hepatol** 1999 Jun;30(6):970–8

The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. Nagata I, et al. **J Hepatol** 1999 Jun;30(6):965–9

Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. Yu DY, et al. **J Hepatol** 1999 Jul;31(1):123–32

Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. Mancini M, et al. **J Immunol** 1998 Nov 15; 161(10):5564–70

Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong-Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259–63

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. Lindh M, et al. **J Infect Dis** 1999 Apr; 179(4):775–82

Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels. Cabrerizo M, et al. **J Med Virol** 1998 Dec;56(4):294–9

Immunoassay detection of hepatitis B surface antigen mutants. Coleman PF, et al. **J Med Virol** 1999 Sep; 59(1):19–24

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. Fukuda R, et al. **J Med Virol** 1999 Jul;58(3):201–7

Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status. Honda A, et al. **J Med Virol** 1999 Apr;57(4):337–44

A hepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg "a" determinant. Karthigesu VD, et al. **J Med Virol** 1999 Aug;58(4):346–52

Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. Knöll A, et al. **J Med Virol** 1999 Sep;59(1):14–8

Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. Oketani M, et al. **J Med Virol** 1999 Aug;58(4):332–7

Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially. Petzold DR, et al. **J Med Virol** 1999 May;58(1):1–10

Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. Saito T, et al. **J Med Virol** 1999 Aug;58(4):325–31

Evolution of wild-type and precore mutant HBV infection after liver transplantation. Torre F, et al. **J Med Virol** 1999 Sep;59(1):5–13

Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen-positive asymptomatic healthy carriers. Tsubota A, et al. **J Med Virol** 1998 Dec;56(4):287–93

A novel deletion mutant of hepatitis B virus surface antigen. Weinberger KM, et al. **J Med Virol** 1999 Jun;58(2):105–10

Molecular epidemiology of hepatitis B virus mutants. Zuckerman AJ, et al. **J Med Virol** 1999 Jul;58(3):193–5

Reconstructing the complex evolutionary history of hepatitis B virus. Bollyky PL, et al. **J Mol Evol** 1999 Jul;49(1):130–41

Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. Habersetzer F, et al. **J Viral Hepat** 1998 Nov;5(6):407–14

Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. Laras A, et al. **J Viral Hepat** 1998 Jul;5(4):241–8

Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. Thomas HC. **J Viral Hepat** 1998 Nov;5 Suppl 2:31–6

Current status of HBV vaccine escape variants--a mathematical model of their epidemiology. Wilson JN, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:25–30

La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. Heise T, et al. **J Virol** 1999 Jul; 73(7):5767–76

Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. Heise T, et al. **J Virol** 1999 Jan; 73(1):474–81

Transcriptional repression of human hepatitis B virus genes by a bZIP family member, E4BP4. Lai CK, et al. **J Virol** 1999 Apr;73(4):3197–209

Detection and sequence analysis of hepatitis B virus integration in peripheral blood mononuclear cells. Laskus T, et al. **J Virol** 1999 Feb;73(2):1235–8

Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. Li J, et al. **J Virol** 1999 Feb;73(2):1239–44

The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. Yuan TT, et al. **J Virol** 1999 Jul;73(7):5731–40

Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. zu Putlitz J, et al. **J Virol** 1999 Jul;73(7):5381–7

High level expression of hepatitis B virus surface antigen in stably transfected Drosophila Schneider-2 cells. Deml L, et al. **J Virol Methods** 1999 May;79(2):191–203

Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Rodriguez-Frias F, et al. **Liver** 1999 Jun; 19(3):177–82

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. Cacciola I, et al. **N Engl J Med** 1999 Jul 1;341(1):22–6

The hepatitis B virus post-transcriptional regulatory element contains two conserved RNA stem-loops which are required for function. Smith GJ 3rd, et al. **Nucleic Acids Res** 1998 Nov 1;26(21):4818–27

Natural emergence of an anti-hepatitis B s escape mutant in a young female hepatitis B virus carrier. Sugiyama K, et al. **Pediatr Int** 1999 Jun;41(3):311–4

Genetic analysis of hepatitis B virus isolated from an infant with acute self-limited hepatitis. Sugiyama K, et al. **Pediatr Int** 1999 Apr;41(2):187–91

Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Protzer U, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14; 96(19):10818–23

Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B. Ichikawa T, et al. **Tohoku J Exp Med** 1998 Dec;186(4):323–33

High prevalence of hepatitis B viral DNA in cirrhotic patients without surface antigen. Attallah AM, et al. **Trans R Soc Trop Med Hyg** 1998 Sep–Oct;92(5):516–7

Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Meisel H, et al. **Transpl Int** 1999;12(4):283–7

Hepatitis B virus variants associated with clinically severe recurrence after liver transplantation. Fischer L, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):492–3

Biochemical and functional properties of a palindromic sequence motif within the hepatitis B virus enhancer 1. Kosovsky MJ, et al. **Virology** 1999 Jun 20;259(1):60–6

Distinct export pathway utilized by the hepatitis B virus posttranscriptional regulatory element. Zang WQ, et al. **Virology** 1999 Jul 5;259(2):299–304

A short region in the genome of hepatitis B virus is critical for maintenance of high transcript levels. zu Putlitz J, et al. **Virology** 1999 Feb 15;254(2):245–56

Immunological characterization of two major secreted forms of recombinant hepatitis B virus e antigens. Hwang GY, et al. **Virus Res** 1999 Feb;59(2):203–10

[Transfer and expression of antisense genes of hepatitis B virus (HBV) and their anti-HBV effects] Ji W, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):425–9 (Eng. Abstr.) **(Chi)**

[Research on the variation of hepatitis B virus and problems in the evaluation of its clinical significance (editorial)] Luo K. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):565–6 **(Chi)**

[Mutations and their significance in the corepromoter region of hepatitis B virus] Tu H, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):571–4 (Eng. Abstr.) **(Chi)**

[Effect of mutation (T1762A1764) on hepatitis B virus core promoter activity] Guo Y, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):15–6 (Eng. Abstr.) **(Chi)**

[Study of transcription and cleavage in vitro of HDV with HBV-specific hammerhead ribozyme] Wen S, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):11–2 (Eng. Abstr.) **(Chi)**

[The clinical and pathology study of HBV precore mutant infection in chronic HBV patients] Zheng X, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):17–9 (Eng. Abstr.) **(Chi)**

[Humoral and cell mediated immunity induced by HBV-S gene recombinant retroviral vector] Zhou Z, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):3–5 (Eng. Abstr.) **(Chi)**

[Comparison of sequences of hepatitis B virus S gene fragment in eight cities of China] Fan J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):140–3 (Eng. Abstr.) **(Chi)**

[Molecular epidemiologic analysis of hepatitis B] Wang P, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan; 32(1):10–2 (Eng. Abstr.) **(Chi)**

[Hepatitis B virus and pathogenesis] Grob PJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S5–9, S79–83 (9 ref.) (Eng. Abstr.) **(Ger, Fre)**

[Fulminant hepatitis and viral mutation] Yatsuhashi H, et al. **Nippon Naika Gakkai Zasshi** 1999 Apr 10;88(4):664–9 (5 ref.) **(Jpn)**

[Quantitative determination of HBV-DNA in chronic hepatitis B: comparison of three methods] Jardi R, et al. **Gastroenterol Hepatol** 1998 Aug–Sep;21(7):327–31 (Eng. Abstr.) **(Spa)**

HEPATITIS B VIRUS

GROWTH & DEVELOPMENT

Erythema multiforme following the exacerbation of hepatitis B virus infection. Tabata N, et al. **Int J Dermatol** 1999 Jan;38(1):52–3

Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? [editorial; comment] Farrell GC. **J Gastroenterol Hepatol** 1999 Aug;14(8):741–4. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):801–3. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):804–6.

Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy [see comments] Maguire CM, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):801–3. Comment in: J Gastroenterol Hepatol 1999 Aug;14(8):741–4.

Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. Altfeld M, et al. **J Hepatol** 1998 Aug;29(2):306–9

[Reactivation of HBV following allogeneic bone marrow transplantation: new outlook (the hepatitis B virus and the bone marrow transplant) (letter)] Otero López-Cubero S, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):229–30 (5 ref.) **(Spa)**

IMMUNOLOGY

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG, et al. **Biochemistry (Mosc)** 1998 May;63(5):551–8

Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Borisova G, et al. **Biol Chem** 1999 Mar; 380(3):315–24

HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Koletzki D, et al. **Biol Chem** 1999 Mar;380(3):325–33

Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma [see comments] Kubo S, et al. **Cancer** 1999 Sep 1;86(5):793–8. Comment in: Cancer 1999 Sep 1;86(5):741–3.

Compensatory apoptosis in preneoplastic liver of a transgenic mouse model for viral hepatocarcinogenesis. Koike K, et al. **Cancer Lett** 1998 Dec 25;134(2):181–6

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Schlaak JF, et al. **Clin Exp Immunol** 1999 Mar;115(3):508–14

Lessons from patient notification exercises following the identification of hepatitis B e antigen positive surgeons in an English health region [see comments] [published erratum appears in Commun Dis Public Health 1999 Sep;2(3):222] Oliver SE, et al. **Commun Dis Public Health** 1999 Jun; 2(2):130–6. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.

Concurrent emergence of hepatitis B e antigen-negative hepatitis B virus variant and autoimmune hepatitis cured by adenine arabinoside monophosphate. Bécheur H, et al. **Dig Dis Sci** 1998 Nov;43(11):2479–82 (30 ref.)

Human hepatitis B virus mutants: significance of molecular changes. Chen WN, et al. **FEBS Lett** 1999 Jun 25; 453(3):237–42 (74 ref.)

High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan [see comments] Marusawa H, et al. **Gut** 1999 Aug;45(2):284–8. Comment in: Gut 1999 Aug;45(2):168–9.

Generation of human Fab monoclonal antibodies against preS1 of hepatitis B virus using repertoire cloning. Choi IH, et al. **Hybridoma** 1998 Dec;17(6):535–40

Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope. Lachmann S, et al. **Intervirology** 1999; 42(1):51–6

High prevalence of HBV infection markers in refugees from eastern countries [letter] Skliros EA, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):84–5

Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. Weber B, et al. **J Clin Microbiol** 1999 Aug;37(8):2639–47

Significance of the minor i and t determinants of hepatitis B virus in hepatocellular carcinoma. Zhao Y, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1237–40

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. Hultgren C, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2381–91

Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. Paulij WP, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2121–6

Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. Carman WF, et al. **J Hepatol** 1999 Aug;31(2):195–201

The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. Schlaak JF, et al. **J Hepatol** 1999 Mar;30(3):353–8

Prevalence of specific IgA and IgM anti-HBc antibodies compared with HBV DNA in the sera of HBsAg chronic carriers. Elsana S, et al. **J Hum Virol** 1997 Nov-Dec; 1(1):52–7

Human class I supertypes and CTL repertoires extend to chimpanzees. Bertoni R, et al. **J Immunol** 1998 Oct 15; 161(8):4447–55

Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. Gregorio GV, et al. **J Immunol** 1999 Feb 1;162(3):1802–10

Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, et al. **J Immunol** 1998 Nov 1;161(9):4520–9

Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen. Chung MK, et al. **J Immunother** 1999 Jul; 22(4):279–87

Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. Chong-Jin O, et al. **J Infect Dis** 1999 Jan;179(1):259–63

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. Hsu HM, et al. **J Infect Dis** 1999 Feb;179(2):367–70

Hepatitis A vaccination in chronic carriers of hepatitis B virus. Nebbia G, et al. **J Pediatr** 1999 Jun;134(6):784–5

Current aspects of hepatitis B surface antigen mutants in Singapore. Oon CJ, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:17–23

Mechanism of emergence of hepatitis B virus escape variants: approaches to prevention. Thomas HC. **J Viral Hepat** 1998 Nov;5 Suppl 2:31–6

Evidence for the genetic basis of non-response in mice. Waters JA. **J Viral Hepat** 1998 Nov;5 Suppl 2:1–4

Current status of HBV vaccine escape variants--a mathematical model of their epidemiology. Wilson JN, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:25–30

Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations. Geissler M, et al. **J Virol** 1999 May; 73(5):4284–92

Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells. Deml L, et al. **J Virol Methods** 1999 May;79(2):205–17

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. Usuda S, et al. **J Virol Methods** 1999 Jun;80(1):97–112

HBeAg immunostaining of liver tissue in various stages of chronic hepatitis B. Lindh M, et al. **Liver** 1999 Aug; 19(4):294–8

Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Ilan Y, et al. **Med Hypotheses** 1999 Jun;52(6):505–9 (41 ref.)

Research of antigen and antibodies from retroviruses, CMV and HBV among prisoners of the penitentiary complex of the region of Campinas, SP, Brazil. Osti NM, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):209–13

Viral clearance without destruction of infected cells during acute HBV infection. Guidotti LG, et al. **Science** 1999 Apr 30;284(5415):825–9

Prevalence of hepatitis B infection in the general population: a rural community based study. Chowdhury A, et al. **Trop Gastroenterol** 1999 Apr-Jun;20(2):75–7

Kidney transplantation in a child with posterior urethral valve from a hepatitis B virus-carrier mother. Report of a case with special reference to urinary tract reconstruction for dysfunctionalized uropathies and seroimmunological preparation against viral transmission. Seki T, et al. **Urol Int** 1998;61(4):237–9

The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Wilson JN, et al. **Vaccine** 1999 Feb 26;17(7-8):973–8

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. McCluskie MJ, et al. **Viral Immunol** 1998;11(4):245–52

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Jung MC, et al. **Virology** 1999 Sep 1; 261(2):165–72

[The determination of the viral markers of the hepatitis B virus and protein p53 in liver biopsy samples] Lőrinczi L, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul-Sep; 43(3):161–6 (Eng. Abstr.) **(Rum)**

[Clinical picture, course and therapeutic efficiency of pulmonary tuberculosis in patients with organochlorine pesticides and hepatitis B markers] Mukhtarov DZ. **Probl Tuberk** 1998;(5):23–4 (Eng. Abstr.) **(Rus)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240–1 **(Spa)**

ISOLATION & PURIFICATION

Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Takahashi K, et al. **Arch Virol** 1998; 143(12):2313–26

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101–4

Hepatitis B virus DNA in relation to duration of hepatitis B surface antigen carriage. Mendy ME, et al. **Br J Biomed Sci** 1999;56(1):34–8

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Alexopoulos CG, et al. **Br J Cancer** 1999 Sep;81(1):69–74

Quantitative detection of hepatitis B virus DNA with a new PCR assay. Kessler HH, et al. **Clin Chem Lab Med** 1998 Aug;36(8):601–4

Assessing the infectivity of hepatitis B carriers. Ballard AL, et al. **Commun Dis Public Health** 1999 Sep;2(3):178–83

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Tsiang M, et al. **Hepatology** 1999 Jun;29(6):1863–9

HBV DNA amplification by polymerase chain reaction in patients with serological evidence of chronic hepatitis B infection [letter] Rodrigues C, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):130–1

Association of hepatitis C virus & hepatitis B virus in chronic liver disease. Berry N, et al. **Indian J Med Res** 1998 Dec; 108:255–9

Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Tagger A, et al. **Int J Cancer** 1999 May 31;81(5):695–9

Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group. Heermann KH, et al. **J Clin Microbiol** 1999 Jan;37(1):68–73

Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. Ho SK, et al. **J Clin Microbiol** 1999 Aug;37(8):2461–5

Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. Kamisango K, et al. **J Clin Microbiol** 1999 Feb;37(2):310–4

Effect of multiple freeze-thaw cycles on hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched-DNA technology. Krajden M, et al. **J Clin Microbiol** 1999 Jun;37(6):1683–6

Nucleic acid-based cross-linking assay for detection and quantification of hepatitis B virus DNA. Lai VCH, et al. **J Clin Microbiol** 1999 Jan;37(1):161–4

Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. Mbayed VA, et al. **J Clin Microbiol** 1998 Nov;36(11):3362–5

Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. Weber B, et al. **J Clin Microbiol** 1999 Aug;37(8):2639–47

Comparison of two methods for quantification of hepatitis B viral DNA. Kao JH, et al. **J Gastroenterol Hepatol** 1999 May;14(5):423–6

Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients. Lau GK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):52–6

In situ detection of mutated hepatitis B virus in microdissected, formalin-fixed liver tissues from patients with chronic hepatitis B. Kojima N, et al. **J Hepatol** 1999 Mar;30(3):359–65

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. Mutimer D, et al. **J Hepatol** 1999 Apr;30(4):715–21

The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. Sergi C, et al. **J Hepatol** 1998 Dec;29(6):861–71

Localization of hepatitis B virus DNA in hepatocellular carcinoma by polymerase chain reaction in situ hybridization. Shin YJ, et al. **J Korean Med Sci** 1998 Aug; 13(4):377–82

Detection of HBV genome by gene amplification method in HBsAg negative blood donors. Bodhiphala P, et al. **J Med Assoc Thai** 1999 May;82(5):491–5

Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. Krajden M, et al. **J Viral Hepat** 1998 Nov;5(6):415–22

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. Gerken G, et al. **J Virol Methods** 1998 Oct;74(2):155–65

Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing. Lefrère JJ, et al. **J Virol Methods** 1999 Jun;80(1):33–44

Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay. Mercier B, et al. **J Virol Methods** 1999 Jan;77(1):1–9

HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. Trippler M, et al. **J Virol Methods** 1999 Mar; 78(1-2):129–47

Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting [see comments] Roth WK, et al. **Lancet** 1999 Jan 30;353(9150):359–63. Comment in: Lancet 1999 Apr 24;353(9162):1441.

Prediction of hepatic inflammatory activity in hepatitis B [letter; comment] ter Borg F, et al. **Lancet** 1998 Nov 7; 352(9139):1555. Comment on: Lancet 1998 Sep 12;352(9131):907–8.

Safety and efficacy of corticosteroids in childhood nephrotic syndrome with concomitant hepatitis B [letter] Butani L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1035–6

Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha [letter] Wicki J, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):183–5

Hepatitis B serology. Spearman CA, et al. **S Afr Med J** 1999 Jan;89(1):44

Chronic hepatitis B in children in Gothenburg, Sweden. Söderström A, et al. **Scand J Infect Dis** 1999;31(2):109–14

Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Van Thiel DH, et al. **Transplantation** 1999 Aug 27; 68(4):519–22

Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin. Murozuka T, et al. **Vox Sang** 1999;76(3):181–6

[The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B] Xuan SY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):80–2 (Eng. Abstr.) **(Chi)**

[Prevalence of serologic markers of hepatitis B virus in hospital personnel] Fernandes JV, et al. **Rev Saude Publica** 1999 Apr;33(2):122–8 (Eng. Abstr.) **(Por)**

METABOLISM

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Yamanaka G, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):190–3

Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. Kann M, et al. **J Cell Biol** 1999 Apr 5;145(1):45–55

A cellular protein which binds hepatitis B virus but not hepatitis B surface antigen. Harvey TJ, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):607–15

Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. Ohno H, et al. **J Med Virol** 1999 May; 58(1):11–8

Two distinct segments of the hepatitis B virus surface antigen contribute synergistically to its association with the viral core particles. Tan WS, et al. **J Mol Biol** 1999 Feb 26; 286(3):797–808

Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. Hu Z, et al. **J Virol** 1999 Sep;73(9):7231–40

Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Chemin I, et al. **Liver** 1999 Apr;19(2):81–7

Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Weil R, et al. **Mol Cell Biol** 1999 Sep;19(9):6345–54

Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Jenna S, et al. **Virology** 1998 Nov 10;251(1):176–86

PATHOGENICITY

Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. Furusyo N, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):85–91

Pro-apoptotic effect of the hepatitis B virus X gene. Pollicino T, et al. **Biomed Pharmacother** 1998;52(9):363–8

Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe. Ustün C, et al. **J Hepatol** 1999 Aug;31(2):202–9

Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. Idilman R, et al. **J Viral Hepat** 1998 Sep; 5(5):285–99 (86 ref.)

Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Abbas NA, et al. **Nephrol Dial Transplant** 1999 May;14(5):1272–5

PHYSIOLOGY

Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Delaney WE 4th, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2017–26

Specific inhibition of hepatitis B virus replication by sense RNA. zu Putlitz J, et al. **Antisense Nucleic Acid Drug Dev** 1999 Jun;9(3):241–52

Chaperones involved in hepatitis B virus morphogenesis. Prange R, et al. **Biol Chem** 1999 Mar;380(3):305–14

Cytokine-mediated apoptosis and inhibition of virus production and anchorage independent growth of viral transfected hepatoblastoma cells. Yared G, et al. **Cytokine** 1998 Aug;10(8):586–95

Molecular mechanisms of hepatitis B and C viruses related to liver carcinogenesis. Brechot C. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1189–96 (46 ref.)

Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Delaney WE 4th, et al. **Hepatology** 1998 Oct;28(4):1134–46

The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Lara-Pezzi E, et al. **Hepatology** 1998 Oct;28(4):1013–21

Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis. Roingeard P, et al. **Hepatology** 1998 Oct;28(4):1128–33

Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Yamamoto M, et al. **Hepatology** 1999 Jul; 30(1):300–7

Hepatitis B virus X protein inhibits nucleotide excision repair. Jia L, et al. **Int J Cancer** 1999 Mar 15;80(6):875–9

Differential immediate early gene expression in conditional hepatitis B virus pX-transforming versus nontransforming hepatocyte cell lines. Tarn C, et al. **J Biol Chem** 1999 Jan 22;274(4):2327–36

Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein. Henkler F, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2737–42

The encapsidation signal of hepatitis B virus facilitates preC AUG recognition resulting in inefficient translation of the downstream genes. Hwang WL, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1769–76

Expression, assembly competence and antigenic properties of hepatitis B virus core gene deletion variants from infected liver cells. Preikschat P, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1777–88

Hepatitis B virus infection in microcarrier-attached immortalized human hepatocytes cultured in molecularporous membrane bags: a model for long-term episomal replication of HBV. Gong ZJ, et al. **J Viral Hepat** 1998 Nov;5(6):377–87

Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles. Jenna S, et al. **J Virol** 1999 Apr;73(4):3351–8

Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. Le Seyec J, et al. **J Virol** 1999 Mar;73(3):2052–7

Carboxypeptidase D is an avian hepatitis B virus receptor. Tong S, et al. **J Virol** 1999 Oct;73(10):8696–702

The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. Yuan TT, et al. **J Virol** 1999 Jul;73(7):5731–40

HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. Trippler M, et al. **J Virol Methods** 1999 Mar; 78(1-2):129–47

Effects of testosterone suppression on serum levels of hepatitis B surface antigen and HBV-DNA in men. Jilma B, et al. **Liver** 1998 Jun;18(3):162–5

Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Wietzke P, et al. **Liver** 1999 Aug; 19(4):348–53

The hepatitis B virus post-transcriptional regulatory element contains two conserved RNA stem-loops which are required for function. Smith GJ 3rd, et al. **Nucleic Acids Res** 1998 Nov 1;26(21):4818–27

p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Terradillos O, et al. **Oncogene** 1998 Oct 22;17(16):2115–23

Influence of antiviral therapy on the natural history of hepatitis B virus recurrence after liver transplantation: retrospective study of 14 cases. Vizuete SG, et al. **Transplant Proc** 1999 Sep;31(6):2461–3

Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Blanpain C, et al. **Transplantation** 1998 Oct 15; 66(7):883–6

Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication. Lan YT, et al. **Virology** 1999 Jul 5;259(2):342–8

[Apoptosis in MT2 cells induced by HepG2.2.15 cells] Zhou W, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar; 7(1):34–5 (Eng. Abstr.) **(Chi)**

[Inhibitory effects of co-cinobufotalin oral liquor on hepatitis B in vitro] Liu Z, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Dec; 16(12):738–40 (Eng. Abstr.) **(Chi)**

ULTRASTRUCTURE

Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis. Roingeard P, et al. **Hepatology** 1998 Oct;28(4):1128–33

HEPATITIS B VIRUS, DUCK

Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Soni PN, et al. **Hepatology** 1998 Nov;28(5):1402–10

Evaluation of disinfection and sterilization of reusable angioscopes with the duck hepatitis B model. Chaufour X, et al. **J Vasc Surg** 1999 Aug;30(2):277–82

DRUG EFFECTS

Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Nicoll AJ, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3130–5

The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Hantz O, et al. **Antiviral Res** 1999 Jan;40(3):179–87

Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes. Schultz U, et al. **J Virol** 1999 Jul;73(7):5459–65

GENETICS

Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Barraud L, et al. **Hepatology** 1999 Apr;29(4):1317–23

Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. von Weizsäcker F, et al. **Hepatology** 1999 Jul;30(1):308–15

Double-stranded linear duck hepatitis B virus (DHBV) stably integrates at a higher frequency than wild-type DHBV in LMH chicken hepatoma cells. Gong SS, et al. **J Virol** 1999 Feb;73(2):1492–502

Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. Zhang YY, et al. **J Virol** 1999 May;73(5):3616–22

Formation of a functional hepatitis B virus replication initiation complex involves a major structural alteration in the RNA template. Beck J, et al. **Mol Cell Biol** 1998 Nov;18(11):6265–72

Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Pourquier P, et al. **Nucleic Acids Res** 1999 Apr 15; 27(8):1919–25

Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Lenhoff RJ, et al. **Virology** 1998 Nov 10;251(1):85–95

IMMUNOLOGY

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Rollier C, et al. **Gastroenterology** 1999 Mar;116(3):658–65

Cellular immune response of ducks to duck hepatitis B virus infection. Vickery K, et al. **J Med Virol** 1999 May; 58(1):19–25

METABOLISM

A soluble form of the avian hepatitis B virus receptor. Biochemical characterization and functional analysis of the receptor ligand complex. Urban S, et al. **J Biol Chem** 1999 Feb 26;274(9):5707–15

Fusogenic activity of hepadnavirus peptides corresponding to sequences downstream of the putative cleavage site. Rodriguez-Crespo I, et al. **Virology** 1999 Aug 15; 261(1):133–42

PATHOGENICITY

Host cell-virus cross talk: phosphorylation of a hepatitis B virus envelope protein mediates intracellular signaling. Rothmann K, et al. **J Virol** 1998 Dec;72(12):10138–47

Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. Yang W, et al. **J Virol** 1998 Nov; 72(11):8710–7

PHYSIOLOGY

Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus. Lenhoff RJ, et al. **Hepatology** 1999 Feb;29(2):563–71

Normal phosphorylation of duck hepatitis B virus L protein is dispensable for infectivity. Grgacic EV, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2743–51

Kinetics of early molecular events in duck hepatitis B virus replication in primary duck hepatocytes. Qiao M, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2127–35

Inactivation of duck hepatitis B virus by a hydrogen peroxide gas plasma sterilization system: laboratory and 'in use' testing. Vickery K, et al. **J Hosp Infect** 1999 Apr; 41(4):317–22

Duck hepatitis B virus nucleocapsids formed by N-terminally extended or C-terminally truncated core proteins disintegrate during viral DNA maturation. Köck J, et al. **J Virol** 1998 Nov;72(11):9116–20

Host cell-virus cross talk: phosphorylation of a hepatitis B virus envelope protein mediates intracellular signaling. Rothmann K, et al. **J Virol** 1998 Dec;72(12):10138–47

Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. Schultz U, et al. **J Virol** 1999 Apr;73(4):3162–8

Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. Sunyach C, et al. **J Virol** 1999 Apr;73(4):2569–75

Infection of ducklings with virus particles containing linear double-stranded duck hepatitis B virus DNA: illegitimate replication and reversion. Yang W, et al. **J Virol** 1998 Nov; 72(11):8710–7

Enrichment of a precore-minus mutant of duck hepatitis B

virus in experimental mixed infections. Zhang YY, et al. **J Virol** 1999 May;73(5):3616–22

HEPATITIS B VIRUS, WOODCHUCK

Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection [published erratum appears in Antimicrob Agents Chemother 1999 Mar;43(3):726] Genovesi EV, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3209–17

Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. Coffin CS, et al. **J Clin Invest** 1999 Jul;104(2):203–12

DRUG EFFECTS

Pharmacodynamics of (–)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans [published erratum appears in Antimicrob Agents Chemother 1998 Dec;42(12):3337] Hurwitz SJ, et al. **Antimicrob Agents Chemother** 1998 Nov; 42(11):2804–9

Antiviral activity of ganciclovir, 9-(1,3-dihydroxy-2-propoxymethyl) guanine against woodchuck hepatitis virus: quantitative measurement of woodchuck hepatitis virus DNA using storage phosphor technology. Zahm FE, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):510–6

GENETICS

Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Zhou T, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1947–54

Hepadnavirus evolution and molecular strategy of adaptation in a new host. Argentini C, et al. **J Gen Virol** 1999 Mar; 80 (Pt 3):617–26

Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. Zufferey R, et al. **J Virol** 1999 Apr; 73(4):2886–92

Activation of the N-myc2 oncogene by woodchuck hepatitis virus integration in the linked downstream b3n locus in woodchuck hepatocellular carcinoma. Bruni R, et al. **Virology** 1999 May 10;257(2):483–90

Evidence for a bidirectional promoter complex within the X gene of woodchuck hepatitis virus. Shimoda A, et al. **Virus Res** 1998 Jul;56(1):25–39

IMMUNOLOGY

Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. Lu M, et al. **J Virol** 1999 Jan;73(1):281–9

METABOLISM

Metabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework. Dandri M, et al. **J Virol** 1998 Nov;72(11):9359–64

Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. Tolle TK, et al. **J Virol** 1998 Dec;72(12):9978–85

Fusogenic activity of hepadnavirus peptides corresponding to sequences downstream of the putative cleavage site. Rodriguez-Crespo I, et al. **Virology** 1999 Aug 15; 261(1):133–42

PHYSIOLOGY

Hepadnavirus evolution and molecular strategy of adaptation in a new host. Argentini C, et al. **J Gen Virol** 1999 Mar; 80 (Pt 3):617–26

HEPATITIS C

Hepatitis C virus infection. Moyer MS. **Adv Pediatr Infect Dis** 1999;14:109–27 (76 ref.)

APIC position paper: hepatitis C exposure in the health care setting. Association for Professionals in Infection Control and Epidemiology, Inc. DeCastro MG, et al. **Am J Infect Control** 1999 Feb;27(1):54–5

The challenge of hepatitis management in Australian general practice [editorial] Kidd M. **Aust Fam Physician** 1998 Sep; 27(9):769

Patient education. Hepatitis C. What is it and how did I get it? McCoy R. **Aust Fam Physician** 1998 Sep;27(9):838

Practice tip. Hepatitis C counselling. An overview [see comments] Rowe J. **Aust Fam Physician** 1998 Sep;27(9):839 . Comment in: Aust Fam Physician 1998 Dec;27(12):1086.

Perinatal consequences of hepatitis C. Eriksen NL. **Clin Obstet Gynecol** 1999 Mar;42(1):121–33; quiz 174–5 (85 ref.)

Hepatitis C: controversies, strategies and challenges. Gitnick G. **Eur J Surg Suppl** 1998;(582):65–70 (25 ref.)

HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Dragoni F, et al. **Haematologica** 1999 Jun;84(6):525–9

Biochemical and histological features of hepatitis G virus infection [see comments] Kobayashi M, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):767–72. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763–6.

EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. **J Hepatol** 1999 May;30(5):956–61 (0 ref.)

Third millennium challenge: hepatitis C [news] Friedrich MJ. **JAMA** 1999 Jul 21;282(3):221–2

HCV Infection: Six years after' in a dialysis unit [letter; comment] Brugnano R, et al. **Nephron** 1999 Feb;81(2):244–5 . Comment on: Nephron 1992;61(3):263–5.

Transfusion issues in a gravida with sickle cell disease. Plante LA. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):712

Update on hepatitis C for the general pediatrician. Wiedermann BL. **Pediatr Infect Dis J** 1999 Jan;18(1):67–8 (10 ref.)

Hepatitis C. Rajan-Mohandas N. **Pediatr Rev** 1999 Sep; 20(9):323

Chiron's licensing policy [letter] Blackburn RP. **Science** 1999 Aug 13;285(5430):1015

The scientific challenge of hepatitis C [news; comment] Cohen J. **Science** 1999 Jul 2;285(5424):26–30. Comment on: Science 1999 Jul 2;285(5424):107–10. Comment on: Science 1999 Jul 2;285(5424):110–3.

Follow-up to HBV and HCV carriers in a blood center [letter] Shimoyama R, et al. **Vox Sang** 1998;75(3):258

[International consensus conference on hepatitis C. Conclusions. The European Association for the Study of the Liver (EASL) Paris, February 26–28, 1999] **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6–7):730–5 (0 ref.) **(Fre)**

[Infectious diseases in 1998] Bricaire F. **Rev Med Interne** 1999 Apr;20(4):365–8 **(Fre)**

[AIDS research benefits patients with hepatitis C (news)] Kowalski A. **Dtsch Med Wochenschr** 1999 Mar 19; 124(11):A9 **(Ger)**

[Hepatitis C virus infection and cardiomyopathy] Matsumori A. **Nippon Rinsho** 1999 Feb;57(2):455–63 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatitis C virus infection] Chayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):55–8 (15 ref.) **(Jpn)**

[Hepatitis viruses] Kashiwagi S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):62–5 (15 ref.) **(Jpn)**

[Hepatitis C virus in liver transplantation] Sanchez Fueyo A, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):139–46 (66 ref.) **(Spa)**

[Vasculitis and hepatitis C virus (letter)] Bernardino de la Serna JI, et al. **Med Clin (Barc)** 1999 Feb 20;112(6):239 **(Spa)**

BLOOD

Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Trestard A, et al. **Arch Virol** 1998;143(11):2241–5

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease. da Silva CM, et al. **Br J Clin Pharmacol** 1998 Aug; 46(2):176–80

Early HCV RNA values after interferon predict response. Wiley TE, et al. **Dig Dis Sci** 1998 Oct;43(10):2169–72

Viral markers in a blood donor population. Mwangi JW. **East Afr Med J** 1999 Jan;76(1):35–7

Hepatitis C virus RNA viremia in Central Africa [letter] Cancré N, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):484–5

Recurrent and new hepatitis C virus infection after liver transplantation. Everhart JE, et al. **Hepatology** 1999 Apr; 29(4):1220–6

Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis [letter; comment] Shaker JL, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):384–5. Comment on: J Clin Endocrinol Metab 1998 Jan;83(1):93–8.

Discrimination of two different clinical entities, acute-type and subacute-type, human fulminant hepatitis by peripheral blood lymphocyte subsets. Shimizu T, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):274–80

Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. Ahmed SD, et al. **J Infect** 1998 Nov; 37(3):248–51

Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus. Fukuda Y, et al. **J Int Med Res** 1998 Dec;26(6):313–8

Serum erythropoietin and interleukin-6 levels in hemodialysis patients with hepatitis virus infection. Radovic M, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):369–73

Relationship of TT virus infection with prevalence of hepatitis C virus infection and elevated alanine aminotransferase levels. Watanabe H, et al. **J Med Virol** 1999 Jul;58(3):235–8

Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Loguercio C, et al. **Liver** 1998 Jun;18(3):166–72

The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Boran M, et al. **Nephron** 1999;82(1):22–6

Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Fabrizi F, et al. **Nephron** 1998 Dec;80(4):428–33

Hepatitis G virus infection in haemodialysis patients and its relationship with hepatitis C virus RNA positivity. Hizel N, et al. **Scand J Infect Dis** 1998;30(5):451–4

Serological and histological features of anti-HCV-positive individuals without serum HCV RNA. Kanno A, et al. **Tohoku J Exp Med** 1998 Dec;186(4):303–11

Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results. Cardoso MS, et al. **Transfusion** 1998 Oct;38(10):905–7

Hepatitis C virus infection in blood donors in the People's Republic of China [letter] Shi XL, et al. **Transfusion** 1999 Aug;39(8):913

[The assessment of the course of an infectious process by the membrane status of the peripheral blood lymphocytes] Antonova TV, et al. **Klin Lab Diagn** 1999 Jul;(7):23–4 (Eng. Abstr.) **(Rus)**

[Functional status of the interferon system in inapparent and clinical infection with hepatitis B and C viruses] Priimiagi LS, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):85–8 (Eng. Abstr.) **(Rus)**

[Interferon system status in hemodialysis patients infected with hepatitis B and C viruses] Priimiagi LS, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):167–9 (Eng. Abstr.) **(Rus)**

[Intensity of the peroxidation of membrane lipids and metabolism of lymphocytes in viral hepatitis patients] Antonova TV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct;(5):64–7 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. Maggi F, et al. **J Neurovirol** 1999 Jun;5(3):319–23

CLASSIFICATION

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin [letter] Bonis PA. **N Engl J Med** 1999 Sep 2;341(10):763

COMPLICATIONS

Systematic cutaneous examination in hepatitis C virus infected patients. Cribier B, et al. **Acta Derm Venereol** 1998 Sep;78(5):355–7

Hepatitis C virus and immunoglobulin gene rearrangements: an early step in lymphomagenesis? Santini GF, et al. **Acta Haematol** 1998 Dec;100(3):117–22

Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. Woitas RP, et al. **AIDS** 1999 Jul 30;13(11):1313–22

Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. Ishikawa T, et al. **Am J Gastroenterol** 1999 Jun;94(6):1682–5

An unusual hyperplastic hepatocellular nodule in a patient with hepatitis C virus-related liver cirrhosis. Kageyama F, et al. **Am J Gastroenterol** 1998 Dec;93(12):2588–93

HCV and diabetes mellitus: evidence for a negative association [see comments] Mangia A, et al. **Am J Gastroenterol** 1998 Dec;93(12):2363–7. Comment in: Am J Gastroenterol 1998 Dec;93(12):2320–2. Comment in: Am J Gastroenterol 1999 Jun;94(6):1709–10.

HCV and diabetes mellitus: influence of nosocomial transmission with the use of a finger stick device [letter; comment] Petit JM, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1709–10. Comment on: Am J Gastroenterol 1998 Dec;93(12):2363–7.

Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Reid AE, et al. **Am J Gastroenterol** 1999 Jun;94(6):1619–26

Hepatitis C and diabetes mellitus: an ongoing controversy [editorial; comment] Zein NN. **Am J Gastroenterol** 1998 Dec;93(12):2320–2 (30 ref.). Comment on: Am J Gastroenterol 1998 Dec;93(12):2363–7.

Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection. Faurschou M, et al. **Am J Hematol** 1999 Jun;61(2):135–8

Renal manifestations of hepatitis C infection. Daghestani L, et al. **Am J Med** 1999 Mar;106(3):347–54 (103 ref.)

Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Vallisa D, et al. **Am J Med** 1999 May;106(5):556–60

Appearance of nephrotic syndrome following interferon-alpha therapy in a patient with hepatitis B virus and hepatitis C virus coinfection. Endo M, et al. **Am J Nephrol** 1998;18(5):439–43

Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)

Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: association with hepatitis C virus (HCV) infection but not with (HCV) RNA level. Yates SC, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):714–20

Primary hepatic lymphoma in hepatitis C: case report and review of the literature. Chowla A, et al. **Am Surg** 1999

Sep;65(9):881–3 (6 ref.)
Prevalence of hepatitis C virus infection in patients hospitalized for hepatitis A [letter] Asselah T, et al. **Ann Intern Med** 1999 Mar 2;130(5):451
Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases [letter] Soufir N, et al. **Arch Dermatol** 1999 Aug;135(8):1001–2
Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome [letter] Ragni MV, et al. **Blood** 1999 Feb 1;93(3):1113–4
Trends in deaths from malignant neoplasia of liver are poor indicator of hepatitis C infection [letter] Harris HE, et al. **BMJ** 1999 Mar 20;318(7186):808–9
Lack of association between HCV infection and HIV–related lymphoma [letter] Besson C, et al. **Br J Haematol** 1999 May;105(2):568–9
Acute liver failure induced by alcohol and paracetamol in an HCV–infected haemophiliac. Leach M, et al. **Br J Haematol** 1998 Dec;103(3):891–3
Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy. Locatelli A, et al. **Br J Obstet Gynaecol** 1999 May;106(5):498–500
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Chiaramonte M, et al. **Cancer** 1999 May 15;85(10):2132–7
Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus–related hepatocellular carcinoma [see comments] Kubo S, et al. **Cancer** 1999 Sep 1;86(5):793–8. Comment in: Cancer 1999 Sep 1;86(5):741–3.
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients. Pontisso P, et al. **Cancer** 1998 Oct 15;83(8):1489–94
Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus–associated cirrhosis. Tarao K, et al. **Cancer** 1999 Aug 15;86(4):589–95
Essential mixed type II cryoglobulinemia in a HCV positive pregnant woman: case report. Alberico S, et al. **Clin Exp Obstet Gynecol** 1998;25(4):129–31
Jaw and leg claudication in a patient with temporal arteritis, chronic sialoadenitis and previous hepatitis C virus infection. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):463–8
Rapidly evolving hepatitis C virus–related cirrhosis in a human immunodeficiency virus–infected patient receiving triple antiretroviral therapy. Zylberberg H, et al. **Clin Infect Dis** 1998 Nov;27(5):1255–8
Management of liver failure in a haemophilic patient co–infected with human immunodeficiency and hepatitis C viruses. Nitu IC, et al. **Clin Lab Haematol** 1999 Apr; 21(2):139–41
Hepatocellular carcinoma among hemodialysis patients infected with hepatitis C virus--early evolution and rapid progression [letter] Hayashi H, et al. **Clin Nephrol** 1999 May;51(5):321–3
Diabetic nephropathy with concurrent hepatitis C virus infection related membranoproliferative glomerulonephritis. Ramesh Prasad GV, et al. **Clin Nephrol** 1999 Jan;51(1):50–3
Sjögren's syndrome and hepatitis C virus. Ramos–Casals M, et al. **Clin Rheumatol** 1999;18(2):93–100 (98 ref.)
Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis. Güngör E, et al. **Dermatology** 1999;198(1):26–8
Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection. Deplano A, et al. **Dig Dis Sci** 1999 Jan;44(1):155–62
Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Rich JD, et al. **Dig Dis Sci** 1999 May; 44(5):1034–7
The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case–control study in Albania. Kondili LA, et al. **Epidemiol Infect** 1998 Oct;121(2):391–5
Porphyria cutanea tarda and hepatitis G and C virus infection. Mancini C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):534–5
Guess what! Cutaneous sarcoidosis, Sjögren's syndrome and autoimmune thyroiditis associated with hepatitis C virus infection. Belgodere X, et al. **Eur J Dermatol** 1999 Apr–May;9(3):235–6
Porphyria cutanea tarda associated with human immunodeficiency virus infection. Drobacheff C, et al. **Eur J Dermatol** 1998 Oct–Nov;8(7):492–6
Transplantation for hepatitis C: good news and bad news. Blendis L, et al. **Gastroenterology** 1999 Aug;117(2):502–3
Cryoglobulinaemia in HCV infection: coming in from the cold [comment] Crosbie OM, et al. **Gut** 1999 Jul;45(1):8–9 . Comment on: Gut 1999 Jul;45(1):122–8.
High prevalence of anti–HGV/E2 antibodies in HCV–positive patients with non Hodgkin's lymphoma [letter] Civardi G, et al. **Haematologica** 1998 Oct; 83(10):957–8
B–lymphoproliferative disorders in patients with hepatitis C virus infection [letter] Pérez Sánchez I, et al. **Haematologica** 1998 Oct;83(10):946–8
HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload [letter] Remacha AF, et al. **Haematologica** 1999 Mar;84(3):284–5
Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Fattovich G. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1206–13
Impact of hepatitis C virus infection on schistosomal liver disease. Mohamed A, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1492–6
Differences of resected hepatocellular carcinoma with hepatitis B or C virus. Shuto T, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1722–5
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Benhamou Y, et al. **Hepatology** 1999 Oct; 30(4):1054–8
Hepatitis C virus infection, mixed cryoglobulinemia, and B–cell non–Hodgkin's lymphoma [letter] Germanidis G, et al. **Hepatology** 1999 Sep;30(3):822–3
Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hézode C, et al. **Hepatology** 1999 Sep;30(3):775–8
The long–term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the United States. Hu KQ, et al. **Hepatology** 1999 Apr;29(4):1311–6
Impact of hepatitis B and C virus on kidney transplantation outcome [see comments] Mathurin P, et al. **Hepatology** 1999 Jan;29(1):257–63. Comment in: Hepatology 1999 Jan;29(1):291–3.
Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Sherman KE, et al. **Hepatology** 1999 Jul;30(1):265–70
Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Tamori A, et al. **Hepatology** 1999 May;29(5):1429–34
Fibrosis/cirrhosis after orthotopic liver transplantation. Tabatabai L, et al. **Hum Pathol** 1999 Jan;30(1):39–47
Proceedings of the single theme consensus conference on Hepatitis B and C: Carrier to Cancer, Asian Perspectives. New Delhi, India, December 5–6, 1998. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S1–42 (0 ref.)
Case–control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Tagger A, et al. **Int J Cancer** 1999 May 31;81(5):695–9
Oral lichen planus and HCV infection: a clinical evaluation of 263 cases. Mignogna MD, et al. **Int J Dermatol** 1998 Aug;37(8):575–8
Long–term administration of cyclosporin A to HCV–antibody–positive patients with dermatologic diseases. Miura H, et al. **Int J Dermatol** 1999 Apr; 38(4):310–4
A case–control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Zhang JY, et al. **Int J Epidemiol** 1998 Aug; 27(4):574–8
Low MIB–1 labeling index in anti–HCV positive hepatocellular carcinoma. Watanuki A, et al. **Int J Oncol** 1998 Nov;13(5):1017–22
Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus–related mixed cryoglobulinemia. Gómez–Tello V, et al. **Intensive Care Med** 1999 Mar; 25(3):319–22
Glomerulonephritis in autopsy cases with hepatitis C virus infection [see comments] Arase Y, et al. **Intern Med** 1998 Oct;37(10):836–40. Comment in: Intern Med 1998 Oct;37(10):800–1.
HCV infection, cryoglobulinaemia, membranoproliferative glomerulonephritis and low grade non–Hodgkin lymphoma [comment] Lunel F, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):54–5 (18 ref.). Comment on: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):45–53.
Hepatitis C virus, mixed cryoglobulinaemia and non–Hodgkin's lymphoma. Mazzaro C, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):428–34 (49 ref.)
High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Zaltron S, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):391–5
Lack of association between hepatitis C infection and development of AIDS–related lymphoma. Levine AM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):255–8
Porphyria cutanea tarda and hepatitis C virus: a case–control study and meta–analysis of the literature. Chuang TY, et al. **J Am Acad Dermatol** 1999 Jul;41(1):31–6
Scarring alopecia and sclerodermatous changes of the scalp in a patient with hepatitis C infection. Jackson JM, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):824–6
Early–stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. Lim HW, et al. **J Am Acad Dermatol** 1998 Dec;39(6):956–9
Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C–positive renal allograft recipients. Baid S, et al. **J Am Soc Nephrol** 1999 Jan;10(1):146–53
Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. Markowitz GS, et al. **J Am Soc Nephrol** 1998 Dec; 9(12):2244–52
Endoscopic variceal ligation is a sufficient procedure for the treatment of oesophageal varices in patients with hepatitis C liver cirrhosis: comparison with injection sclerotherapy. Hata Y, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):236–40
Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients. Lau GK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):52–6
Impact of HBV, HCV and GBV–C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action [published erratum appears in J Hepatol 1998 Oct;29(4):686] Bréchot C, et al. **J Hepatol** 1998 Aug; 29(2):173–83
Hepatitis C virus (HCV)–infection and oral lichen planus [letter] Grote M, et al. **J Hepatol** 1998 Dec;29(6):1034–5
Hepatitis C virus infection and cryoglobulinemia. Lunel F, et al. **J Hepatol** 1998 Nov;29(5):848–55 (87 ref.)
Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. Muñoz–Rodríguez FJ, et al. **J Hepatol** 1999 May;30(5):770–3
A clinical and virological study of hepatitis C virus–related cryoglobulinemia in Germany. Weiner SM, et al. **J Hepatol** 1998 Sep;29(3):375–84
The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. Laskus T, et al. **J Infect Dis** 1998 Oct;178(4):1189–92
Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus–positive hemophiliacs and should be treated as an opportunistic infection. Lesens O, et al. **J Infect Dis** 1999 May;179(5):1254–8
Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. Tan D, et al. **J Infect Dis** 1999 May;179(5):1055–61
Profiles of GBV–C/hepatitis G virus markers in patients coinfected with hepatitis C virus. Sauleda S, et al. **J Med Virol** 1999 Sep;59(1):45–51
Diagnostic confusion caused by hepatitis C: hemochromatosis presenting as rheumatoid arthritis. Espinosa–Morales R, et al. **J Rheumatol** 1998 Dec;25(12):2459–63
Antiphospholipid antibody syndrome associated with hepatitis C infection [letter] Puri V, et al. **J Rheumatol** 1999 Feb;26(2):509–10
Prevalence of hepatitis B, C and HIV virus infection among beta thalassaemia major patients [letter] Shamsi T, et al. **JPMA J Pak Med Assoc** 1998 Mar;48(3):87
Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Matsumori A, et al. **Jpn Circ J** 1999 Jun; 63(6):433–8
Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Kubo S, et al. **Jpn J Cancer Res** 1999 Feb; 90(2):162–70
Long–term follow–up of a patient with hepatocellular carcinoma associated with triple hepatitis virus (HBV, HDV, HCV) infection. Koda T, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1188–92
Effects of ribavirin on hepatitis C–associated nephrotic syndrome in four liver transplant recipients. Pham HP, et al. **Kidney Int** 1998 Oct;54(4):1311–9
Hepatocellular carcinoma [see comments] Schafer DF, et al. **Lancet** 1999 Apr 10;353(9160):1253–7 (57 ref.). Comment in: Lancet 1999 Jul 17;354(9174):253. Comment in: Lancet 1999 Jul 17;354(9174):253–4.
Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Delladetsima JK, et al. **Liver Transpl Surg** 1999 Jul;5(4):294–300
De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Saxena R, et al. **Liver Transpl Surg** 1999 Jan;5(1):81–2
Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Scelsa SN, et al. **Muscle Nerve** 1998 Nov;21(11):1526–9
Images in clinical medicine. Caput medusae. Cohen SM. **N Engl J Med** 1999 Aug 5;341(6):419
The care of patients undergoing hemodialysis [letter; comment] Knoll G, et al. **N Engl J Med** 1999 Mar 4; 340(9):736–7. Comment on: N Engl J Med 1998 Oct 8;339(15):1054–62.
Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Fabrizi F, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1991–7
High incidence of diabetes mellitus after kidney transplant in patients with hepatitis C [letter] Gentil MA, et al. **Nephron** 1999;82(1):85
Hepatitis C virus in patients with porphyria cutanea tarda: relationship to HCV–genotypes. Rivanera D, et al. **New Microbiol** 1998 Oct;21(4):329–34
HIV and HCV [letter; comment] Geiger D. **Nurse Pract** 1999 Apr;24(4):16. Comment on: Nurse Pract 1998 Dec;23(12):78, 81.
The role of hepatitis C virus in hepatocellular carcinoma. Colombo M. **Recent Results Cancer Res** 1998;154:337–44 (50 ref.)
Prevalence and patterns of HGV/GBV–C infection in patients with suspected HCV–related hepatitis. García de Viedma D, et al. **Res Virol** 1998 Nov–Dec;149(6):433–8
The hepatitis C virus and systemic diseases [editorial] Mariette X. **Rev Rhum Engl Ed** 1998 Dec;65(12):737–40 (21 ref.)
Hepatitis C virus–infected, HCV–RNA–negative patients with bleeding disorders--relationship to age, HIV and treatment. Schulman S, et al. **Scand J Infect Dis** 1998;

30(5):455–8
Quality of life and functional status of liver transplant recipients with recurrent viral hepatitis C. Gayowski T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1386–7
Renal transplantation in anti–HCV–positive patients with end–stage renal disease. Shaheen FA, et al. **Transplant Proc** 1998 Nov;30(7):3142–3
Donor hepatitis C virus status does not adversely affect short–term outcomes in HCV+ recipients in renal transplantation. Ali MK, et al. **Transplantation** 1998 Dec 27;66(12):1694–7
Long–term impact of superinfection by hepatitis G virus in hepatitis C virus–positive renal transplant patients. Rostaing L, et al. **Transplantation** 1999 Feb 27;67(4):556–60
Hepatitis C virus–associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon–alpha therapy. Toth CM, et al. **Transplantation** 1998 Nov 15; 66(9):1254–8
Wilson's disease coexisting with viral hepatitis type C: a case report with histological and ultrastructural studies of the liver. Lembowicz K, et al. **Ultrastruct Pathol** 1999 Jan–Feb; 23(1):39–44
Hepatitis C virus infection of peripheral nerves in type II cryoglobulinacmia. Bonetti B, et al. **Virchows Arch** 1999 Jun;434(6):533–5
Asymptomatic type II mixed cryoglobulinemia with a very high cryocrit level secondary to HCV infection [letter] Perseghin P, et al. **Vox Sang** 1998;75(1):78–9
[Follow–up studies on hepatitis G infection in plasma donors with positive antibody against hepatitis C] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):269–71 (Eng. Abstr.) **(Chi)**
[Chronic hepatic porphyria and hepatitis B and C virus infections] Malina L, et al. **Cas Lek Cesk** 1998 Sep 21; 137(18):561–4 (Eng. Abstr.) **(Cze)**
[Hepatitis C–associated osteosclerosis. A rare disease with possible relevance for osteoporosis therapy] Kassem M, et al. **Ugeskr Laeger** 1998 Nov 30;160(49):7142–3 **(Dan)**
[Prevalence of hepatitis C virus in oral erosive lichen] Dupond AS, et al. **Ann Dermatol Venereol** 1998 Oct; 125(10):676–8 (Eng. Abstr.) **(Fre)**
[Epidermolysis bullosa acquisita and hepatitis C] Thiery S, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):264–7 (Eng. Abstr.) **(Fre)**
[Central nervous system involvement in hepatitis C virus infection] Cacoub P, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul;22(6–7):631–3 (Eng. Abstr.) **(Fre)**
[Cryoglobulinemia and hepatitis c: worsening of peripheral neuropathy after interferon alpha treatment] Lidove O, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):403–6 (Eng. Abstr.) **(Fre)**
Does hepatitis C have a direct oncogenic effect? Scoazec JY. **Gastroenterol Clin Biol** 1998 Dec;22(12):1120–1 **(Fre)**
[Extrahepatic manifestations of hepatitis C virus] Tohme A, et al. **J Med Liban** 1998 Mar–Apr;46(2):84–8 (58 ref.) **(Fre)**
[Long–term consequences of co–infection by hepatitis G virus in hepatitis c virus infected kidney transplant patients] Rostaing L, et al. **Nephrologie** 1999;20(3):165–70 (Eng. Abstr.) **(Fre)**
[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412–5 (Eng. Abstr.) **(Fre)**
[Rapid progress of cirrhosis in hepatitis C: the role of age at the time of viral contamination] Lucidarme D, et al. **Presse Med** 1998 Apr 4;27(13):608–11 (Eng. Abstr.) **(Fre)**
[Should we treat cirrhosis in hepatitis C carriers with antiviral agents?] Brenard R, et al. **Rev Med Brux** 1999 Feb; 20(1):A50 **(Fre)**
[Does hepatitis c virus–related autoimmune thyroiditis exist? Reflections on a controlled study of 58 consecutive subjects] Blot E, et al. **Rev Med Interne** 1999 Mar; 20(3):220–5 (Eng. Abstr.) **(Fre)**
[Diagnosis of hereditary hemochromatosis with molecular analysis of DNA in patients with anti–HCV positive liver cirrhosis. Clinical case] Carella AM, et al. **Minerva Med** 1998 Sep;89(9):323–7 (Eng. Abstr.) **(Ita)**
[Frequent occurrence of diabetes mellitus after corticosteroid treatment in mixed cryoglobulinemia. An HCV–related complication?] Marson P, et al. **Minerva Med** 1998 Jul–Aug;89(7–8):277–81 (42 ref.) (Eng. Abstr.) **(Ita)**
[A comparative study of TTV co–infection in patients with chronic liver disease B, C and non–B non–C] Asaba N, et al. **Nippon Rinsho** 1999 Jun;57(6):1362–5 (Eng. Abstr.) **(Jpn)**
[Co–infection of HBV with HCV and a possible role of HBV DNA in hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1999 Jan;57(1):213–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Glomerulonephritis associated with hepatitis c virus infection] Lopes LM, et al. **Rev Soc Bras Med Trop** 1999 Jan–Feb;32(1):1–6 (Eng. Abstr.) **(Por)**
[Autoimmune hepatitis and/or hepatitis C] Simonović J, et al. **Srp Arh Celok Lek** 1999 Mar–Apr;127(3–4):109–13 (Eng. Abstr.) **(Scc)**
[Hepatitis C virus pathogenic potential (letter; comment)] Mora Fernández C, et al. **An Med Interna** 1998 Aug; 15(8):454. Comment on: An Med Interna 1995 Oct;12(10):517–8. **(Spa)**
[Alveolar hemorrhage in mixed cryoglobulinemia associated with hepatitis C virus infection] Rodríguez–Vidigal FF, et al. **An Med Interna** 1998 Dec;15(12):661–3 (Eng. Abstr.) **(Spa)**
[Extrahepatic involvement as first manifestation + + of hepatitis C virus infection] Rivera Redondo J, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):667–9 (58 ref.) **(Spa)**
[Polyarthritis in hepatitis C virus infection (letter; comment)] Brahm J, et al. **Rev Med Chil** 1998 Jun;126(6):725–6. Comment on: Rev Med Chil 1997 Nov;125(11):1357–60. **(Spa)**

DIAGNOSIS

Analysis of human immune response to potential hepatitis C viral epitopes. Khanna A, et al. **Acta Virol** 1998 Jun; 42(3):141–5
Hepatitis C: Part I. Routine serologic testing and diagnosis. Moyer LA, et al. **Am Fam Physician** 1999 Jan 1;59(1):79–88, 91–2 (45 ref.)
AAP releases hepatitis C screening recommendations. Rose VL. **Am Fam Physician** 1998 Oct 1;58(5):1218
CDC issues new recommendations for the prevention and control of hepatitis C virus infection. Rose VL. **Am Fam Physician** 1999 Mar 1;59(5):1321–3
Serodiagnosis of hepatitis C virus. Effect of new evaluation of cutoff values for enzyme–linked immunosorbent assay in Brazilian patients. dos Santos VA, et al. **Am J Clin Pathol** 1999 Sep;112(3):418–24
Hepatitis C: natural history, diagnosis, and management. Lam NP. **Am J Health Syst Pharm** 1999 May 15;56(10):961–73; quiz 974–5 (87 ref.)
Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Fabrizi F, et al. **Am J Nephrol** 1999;19(3):383–8
Hepatitis C virus infection and hypertrophic cardiomyopathy [letter] Matsumori A, et al. **Ann Intern Med** 1998 Nov 1; 129(9):749–50
Acute hepatitis C during pregnancy. Case report and review of the literature. Rimon E, et al. **Arch Gynecol Obstet** 1998; 262(1–2):95–7
Hepatitis C update: implications of the blood transfusion "lookback". Younossi ZM, et al. **Cleve Clin J Med** 1998 Sep;65(8):412–5, 418–22 (22 ref.)
Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV–associated hepatitis. El–Awady MK, et al. **Clin Chim Acta** 1999 May;283(1–2):1–14
Hepatitis C virus infection risk factors in patients admitted in hospital emergency departments in Picardy. Value of oriented screening based on recommendations of the 'Direction Générale de la Santé'. Capron D, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):643–8
Inquiries on intraspousal transmission of hepatitis C virus: benefits and limitations of genome sequencing and phylogenetic analysis. Ross RS, et al. **Forensic Sci Int** 1999 Mar 15;100(1–2):69–76
"Real–time" polymerase chain reaction [editorial; comment] Oldach D. **Gastroenterology** 1999 Mar;116(3):763–4 (13 ref.) . Comment on: Gastroenterology 1999 Mar;116(3):636–42.
Real–time detection system for quantification of hepatitis C virus genome [see comments] Takeuchi T, et al. **Gastroenterology** 1999 Mar;116(3):636–42. Comment in: Gastroenterology 1999 Mar;116(3):763–5.
The significance of hepatitis G virus infection in patients with non–A to C hepatic diseases. Tanaka T, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1870–3
Diagnosis of hepatitis C virus infection by ELISA, RIBA and RT–PCR: a comparative evaluation. Mohan KV, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):73–5
A prospective study on mother–to–infant transmission of hepatitis C virus. Zanetti AR, et al. **Intervirology** 1998; 41(4–5):208–12
Hepatitis C test needed [news] **J Am Dent Assoc** 1999 Jul; 130(7):931
Comparison of the enzyme–linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. Garinis G, et al. **J Clin Lab Anal** 1999;13(3):122–5
Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. Abe K, et al. **J Clin Microbiol** 1998 Oct;36(10):3070–2
Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. Aoyagi K, et al. **J Clin Microbiol** 1999 Jun;37(6):1802–8
Diagnostic value of anti–hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. Casino C, et al. **J Clin Microbiol** 1999 Aug;37(8):2726–8
Use of a novel hepatitis C virus (HCV) major–epitope chimeric polypeptide for diagnosis of HCV infection. Chien DY, et al. **J Clin Microbiol** 1999 May;37(5):1393–7
Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan. Parker SP, et al. **J Clin Microbiol** 1999 Jun; 37(6):2061–3
Definition of false–positive reactions in screening for hepatitis C virus antibodies. Schröter M, et al. **J Clin Microbiol** 1999 Jan;37(1):233–4
Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. Madan K, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):125–30
Hepatitis C virus infection and lung transplantation: a survey of practices. Cotler SJ, et al. **J Heart Lung Transplant** 1999 May;18(5):456–9
Hepatitis C in the patient with human immunodeficiency virus infection. Spengler U, et al. **J Hepatol** 1998 Dec; 29(6):1023–30 (84 ref.)
IgM anti–hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Negro F, et al. **J Med Virol** 1998 Nov;56(3):224–9
Development of low cost peptide–based anti–hepatitis C virus screening and confirmatory assays: comparison with commercially available tests. Palacios A, et al. **J Med Virol** 1999 Jul;58(3):221–6
From the Oklahoma State Department of Health. CDC recommendations for diagnosis and initial management of hepatitis C virus infection. Crutcher M, et al. **J Okla State Med Assoc** 1999 Feb;92(2):93–5
Serological screening for hepatitis B and C and human herpesvirus 6 in Norwegian patients with primary Sjögren's syndrome [letter] Iakimtchouk K, et al. **J Rheumatol** 1999 Sep;26(9):2065–6
Hepatitis C virus infection presenting as rheumatoid arthritis. Why not? [letter] Rivera J, et al. **J Rheumatol** 1999 Sep; 26(9):2062–3
Voluntary blood tests for Canadian doctors? [news] Kondro W. **Lancet** 1998 Oct 10;352(9135):1205
Screening blood donations for hepatitis C in Central Africa: analysis of a risk– and cost–based decision tree. Cancré N, et al. **Med Decis Making** 1999 Jul–Sep;19(3):296–306
Clinical outcomes after hepatitis C infection from contaminated anti–D immune globulin [letter] Lawlor E, et al. **N Engl J Med** 1999 Sep 2;341(10):762; discussion 763
Absence of HCV viraemia in anti–HCV–negative haemodialysis patients. Dalekos GN, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1804–6
Broadsheet. Number 49: Laboratory investigation of hepatitis C: a review. Cossart YE. **Pathology** 1999 May;31(2):102–8 (56 ref.)
Fulminant hepatitis caused by hepatitis C virus. Taga T, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1174–6
Acute hepatitis C. Slifer A, et al. **Tenn Med** 1998 Dec; 91(12):468–9
Evaluation of a new anti–HCV–assay kit for anti–HCV screening in early childhood. Sugiyama K, et al. **Tohoku J Exp Med** 1999 Mar;187(3):257–62
Failure of third–generation recombinant immunoblot assay to detect hepatitis C virus core antibodies [letter] Hennig H, et al. **Transfusion** 1999 Mar;39(3):335–6
Quantitation of hepatitis C virus RNA in liver tissue of allografts: correlation with histologic features and liver function tests. Aardema KL, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):477–8
Immunogenetic factors, HCV genotypes, and HCV recurrence after liver transplantation. Belli LS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):483–4
Pretransplant anti–hepatitis C virus antibody and HCV–RNA–polymerase chain reaction as predictor of posttransplant liver dysfunction. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):3216–7
Hepatitis C reinfection after liver transplantation in relation to virus genotype. Tisone G, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):490–1
Evaluation of third generation anti–HCV enzyme immunoassays. Panigrahi AK, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):105–7
Does HCV screening of blood donors affect transmission of hepatitis G virus in dialysed patients? [letter] Gérard C, et al. **Vox Sang** 1998;75(1):77
Use of overlapping synthetic peptides to characterize samples from blood donors with indeterminate results to hepatitis C virus core antigen. León P, et al. **Vox Sang** 1998; 75(1):32–6
[How to detect, diagnose and survey hepatitis C? Biological tests used by the physician in current practice (editorial)] Doffoël M. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):387–9 (7 ref.) **(Fre)**
[Anti–HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot] Dubois F, et al. **Ann Biol Clin (Paris)** 1998 Jul–Aug;56(4):417–26 (11 ref.) (Eng. Abstr.) **(Fre)**
[Screening of patients at risk for hepatitis C virus infection in general medicine] Altman C, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):359–62 (Eng. Abstr.) **(Fre)**
[Hepatitic C in a prison environment: is screening necessary? (editorial)] Roudot–Thoraval F. **Gastroenterol Clin Biol** 1998 Jan;22(1):41–2 **(Fre)**
[Retrospective study of the value of the RIBA–3 test in 68 patients with discordant serologies with regard to hepatitis C obtained with third generation ELISA tests. Is there still a value in RIBA–3?] Cecille A, et al. **Pathol Biol (Paris)** 1999 May;47(5):508–11 (Eng. Abstr.) **(Fre)**
[Digestive disorders: improving the accuracy and safety of tests] Bonnaud G. **Presse Med** 1998 May 16;27(18):869–70 **(Fre)**
[Prospective comparative study of HCV serologic status in and AIDS population] Chaillou S, et al. **Presse Med** 1999 Jun 12;28(21):1101–4 (Eng. Abstr.) **(Fre)**
[Superinfection in hepatitis C] Köppe B, et al.

Internist (Berl) 1998 Oct;39(10):1072–3 **(Ger)**
[Extrahepatic manifestations of hepatitis C infection] Rambusch EG, et al. **Z Gastroenterol** 1998 Jul;36(7):579–86 (69 ref.) (Eng. Abstr.) **(Ger)**
[A case of the combined course of viral hepatitis B and C with mechanical jaundice] Shkurba AV. **Lik Sprava** 1998 Jul–Aug;(5):146–8 **(Ukr)**
[The characteristics of the course of viral hepatitis C] Shkurba AV. **Lik Sprava** 1998 Dec;(8):140–1 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

Hepatitis C: who should we be treating? [editorial; comment] Kirchner JT. **Am Fam Physician** 1999 Jan 15;59(2):273–4, 277. Comment on: Am Fam Physician 1999 Jan 15;59(2):349–54, 357.
Hepatitis C: Part II. Prevention counseling and medical evaluation [see comments] Moyer LA, et al.
Am Fam Physician 1999 Jan 15;59(2):349–54, 357 (16 ref.) . Comment in: Am Fam Physician 1999 Jan 15;59(2):273–4, 277.
Hepatitis C: natural history, diagnosis, and management. Lam NP. **Am J Health Syst Pharm** 1999 May 15;56(10):961–73; quiz 974–5 (87 ref.)
Treatment of hepatitis C: a decision that needs careful consideration [editorial; comment] Wright TL.
Am J Med 1999 Aug;107(2):180–1. Comment on: Am J Med 1999 Aug;107(2):112–8.
Depression from interferon therapy in patients with hepatitis C [letter] Miyaoka H, et al. **Am J Psychiatry** 1999 Jul; 156(7):1120
Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV–vaccinia virus recombinant. Zhang H, et al.
Antimicrob Agents Chemother 1999 Feb;43(2):347–53
Cell-based and animal models for hepatitis B and C viruses. Schinazi RF, et al. **Antivir Chem Chemother** 1999 May; 10(3):99–114 (180 ref.)
Hepatitis C virus NS3/4A protease. Kwong AD, et al.
Antiviral Res 1999 Feb;41(1):67–84 (100 ref.)
Hepatitis C and the 'cure' [letter; comment] Cooksley WG.
Aust Fam Physician 1998 Dec;27(12):1086. Comment on: Aust Fam Physician 1998 Sep;27(9):839.
How Greek GPs manage hepatitis C infected patients: experiences gained from a primary health care district in rural Crete [letter; comment] Lionis C, et al.
Aust Fam Physician 1999 Mar;28(3):207. Comment on: Aust Fam Physician 1998 Sep;27(9):780–6. Comment on: Aust Fam Physician 1998 Sep;27(9):787–90.
Interferon toxicity in hepatitis C virus–associated type II cryoglobulinemia [letter] Di Lullo L, et al.
Clin Exp Rheumatol 1998 Jul–Aug;16(4):506
Failure of cyclosporin therapy in type II mixed cryoglobulinemia associated with hepatitis C virus infection [letter] Horsmans Y, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):514–5
Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi–center, randomized, double–blind, placebo–controlled trial. Leich Study Group. Niederau C, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):797–804
Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Toccaceli F, et al.
Hepatogastroenterology 1998 Sep–Oct;45(23):1748–52
Global warming and therapeutic intervention for hepatitis B and C virus infection [letter] Arya SC. **Hepatology** 1999 Feb;29(2):610–11
Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Murakami T, et al. **Hepatology** 1999 Oct;30(4):1045–53
Current practice patterns of primary care physicians in the management of patients with hepatitis C. Shehab TM, et al. **Hepatology** 1999 Sep;30(3):794–800
Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. Tao Q, et al. **J Gastroenterol** 1998 Oct;33(5):684–93
Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection [letter] Fialaire P, et al. **J Infect Dis** 1999 Aug;180(2):574–5
Monitoring antibody titers to recombinant Core–NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon–alpha therapy. Park YM, et al. **J Korean Med Sci** 1999 Apr;14(2):165–70
Chronic inflammatory demyelinating polyneuropathy during treatment with interferon–alpha [letter] Marzo ME, et al.
J Neurol Neurosurg Psychiatry 1998 Oct;65(4):604
Hepatitis C: current status, future progress. Marcellin P.
J Viral Hepat 1998 Sep;5 Suppl 1:1
Effects of ribavirin on hepatitis C–associated nephrotic syndrome in four liver transplant recipients. Pham HP, et al. **Kidney Int** 1998 Oct;54(4):1311–9
Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis [letter] Minakuchi K, et al. **Lancet** 1999 Jun 19; 353(9170):2127–8
The treatment of hepatitis C [editorial] Sievert W, et al.
Med J Aust 1999 Mar 1;170(5):200–2
East meets west at Hennepin County Medical Center. Feldman MK. **Minn Med** 1999 May;82(5):6–9
Combination therapy for hepatitis C infection [letter; comment] Clay CM. **N Engl J Med** 1999 Apr 15; 340(15):1207; discussion 1208–9. Comment on: N Engl J Med 1998 Nov 19;339(21):1485–92. Comment on: N Engl J Med 1998 Nov 19;339(21):1493–9.
Combination therapy for hepatitis C infection [letter; comment] Newman TB. **N Engl J Med** 1999 Apr 15; 340(15):1207; discussion 1208–9. Comment on: N Engl J Med 1998 Nov 19;339(21):1485–92. Comment on: N Engl J Med 1998 Nov 19;339(21):1493–9.
Successful treatment of HCV–associated cryoglobulinaemic glomerulonephritis with a combination of interferon–alpha and ribavirin. Misiani R, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1558–60
Two options for hepatitis C treatment. **Pa Med** 1999 Apr; 102(4):22–3 (9 ref.)
Interferon treatment of hepatitis C associated with symptoms of PTSD. Maunder RG, et al. **Psychosomatics** 1998 Sep–Oct;39(5):461–4
Rx for B and C [news] Gibbs WW. **Sci Am** 1999 Mar; 280(3):17–20
Long–term results of treatment of chronic hepatitis B, C and D with interferon–alpha in renal allograft recipients. Durlik M, et al. **Transpl Int** 1998;11 Suppl 1:S135–9
Searching for the optimal management of hepatitis C patients after liver transplantation. Platz KP, et al. **Transpl Int** 1998; 11 Suppl 1:S209–11
[The management of acute hepatitis C and needlestick accidents with hepatitis–C virus positive blood] Cooreman MP, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2298–300 (12 ref.) (Eng. Abstr.) **(Dut)**
[Epidermolysis bullosa acquisita and hepatitis C] Thiery S, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):264–7 (Eng. Abstr.) **(Fre)**
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)] Delwaide J. **Rev Med Liege** 1998 Aug;53(8):467–9 (17 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Blood money [letter; comment] Massel D. **CMAJ** 1999 Jul 27;161(2):129. Comment on: CMAJ 1999 Mar 9;160(5):699–700.
A double standard? Disease v injury [editorial] Pless IB.
Inj Prev 1998 Sep;4(3):165
Compensation for Canada's hepatitis C victims to be re–evaluated [news] Kondro W. **Lancet** 1998 May 23; 351(9115):1567

ENZYMOLOGY

A prospective, community–based evaluation of liver enzymes in individuals with hepatitis C after drug use. Inglesby TV, et al. **Hepatology** 1999 Feb;29(2):590–6
Significance of repeatedly normal aminotransferase activities in HCV–infected patients. Zylberberg H, et al.
J Clin Gastroenterol 1999 Jul;29(1):71–5
Comparison between serum alpha–glutathione S–transferase and aminotransaminases in detecting cytolysis in hepatitis C–infected children. Namour F, et al.
J Pediatr Gastroenterol Nutr 1999 May;28(5):534–7
Hepatitis B and C virus infection in patients with high serum transaminases [letter] Skliros EA, et al. **Postgrad Med J** 1998 Aug;74(874):511

EPIDEMIOLOGY

Seroepidemiologic studies of hepatitis C virus infection in a population of Okayama Prefecture screened for liver disease. Uesugi S, et al. **Acta Med Okayama** 1999 Feb; 53(1):31–8
Bloodborne viral infection in Irish injecting drug users. Smyth BP, et al. **Addiction** 1998 Nov;93(11):1649–56
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. Broers B, et al.
AIDS 1998 Oct 22;12(15):2059–66
Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Sandhu J, et al.
Am J Epidemiol 1999 Jul 1;150(1):58–66
Hepatitis G virus and HCV related extrahepatic disease [letter] Grasso A, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1120–1
Risk of hepatitis C virus infection in a population exposed to biological materials. Trevisan A, et al.
Am J Ind Med 1999 May;35(5):532–5
Can risk factor screening predict hepatitis C antibody reactivity? Magriples U, et al. **Am J Perinatol** 1998 Jun; 15(6):395–8
Rare occurrence of colorectal cancer metastasis in livers infected with hepatitis B or C virus. Utsunomiya T, et al.
Am J Surg 1999 Apr;177(4):279–81
Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type–I infections in selected Solomon Islands populations. Furusyo N, et al.
Am J Trop Med Hyg 1999 Jul;61(1):85–91
Nosocomial transmission of HCV in hemodialysis centres. Patti AM, et al. **Ann Ig** 1998 May–Jun;10(3):147–54
Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Widell A, et al. **Ann Intern Med** 1999 Jan 19;130(2):130–4
Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al.
Aust N Z J Public Health 1999 Aug;23(4):377–84
HIV and HCV prevalence among trawler crew. MacDonald M, et al. **Aust N Z J Public Health** 1998 Dec;22(7):829–31
Prevalence of HCV infection in health care workers of a UK dental hospital. Lodi G, et al. **Br Dent J** 1997 Nov 8;183(9):329–32
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. Paydas S, et al. **Br J Cancer** 1999 Jul;80(9):1303–5
Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Staples CT Jr, et al. **Clin Infect Dis** 1999 Jul;29(1):150–4
Low prevalence of hepatitis C virus infection in Greek diabetic patients. Sotiropoulos A, et al. **Diabet Med** 1999 Mar;16(3):250–2
Hepatitis C virus RNA viremia in Central Africa [letter] Cancré N, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):484–5
Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus–C infections in Siberia. Ohba K, et al.
Epidemiol Infect 1999 Feb;122(1):139–43
Risk factors for monoinfections and coinfections with HIV, hepatitis B and hepatitis C viruses in northern Spanish prisoners. Pallás J, et al. **Epidemiol Infect** 1999 Aug; 123(1):95–102
Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan. Abdourakhmanov DT, et al. **Eur J Epidemiol** 1998 Sep; 14(6):549–53
Risk factors of hepatitis C virus infection in patients on hemodialysis: a multivariate analysis based on a dialysis register in Central Italy. Di Lallo D, et al.
Eur J Epidemiol 1999 Jan;15(1):11–4
Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners: preponderance of parenteral transmission. Massad E, et al. **Eur J Epidemiol** 1999 May;15(5):439–45
How do general practitioners approach hepatitis C virus screening in France? Massari V, et al. **Eur J Epidemiol** 1999 Feb;15(2):119–24
Hepatitis C in France: a national survey in the Departments of Internal Medicine and Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases). Raguin G, et al.
Eur J Epidemiol 1998 Sep;14(6):545–8
Prevalence of serologic markers of HBV, HDV, HCV and HIV in non–injection drug users compared to injection drug users in Gran Canaria, Spain. Santana Rodriguez OE, et al. **Eur J Epidemiol** 1998 Sep;14(6):555–61
High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Wong DA, et al.
Eur J Epidemiol 1998 Jul;14(5):421–6
Hepatitis C virus infection risk factors in patients admitted in hospital emergency departments in Picardy. Value of oriented screening based on recommendations of the 'Direction Générale de la Santé'. Capron D, et al.
Eur J Gastroenterol Hepatol 1999 Jun;11(6):643–8
Liver transplantation in hepatitis C. A Spanish multi–centre experience. Prieto M, et al.
Eur J Gastroenterol Hepatol 1998 Sep;10(9):771–6
Prevalence of hepatitis C virus antibody in patients on chronic hemodialysis. Nomiyama K, et al.
Fukuoka Igaku Zasshi 1998 Aug;89(8):232–7
The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non–A, non–B hepatitis in a plasmapheresis centre. Datz C, et al. **Gut** 1999 Apr; 44(4):563–7
High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Kubo S, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):357–9
No association between hepatitis C and B–cell lymphoma. Collier JD, et al. **Hepatology** 1999 Apr;29(4):1259–61
Modeling the hepatitis C virus epidemic in France. Deuffic S, et al. **Hepatology** 1999 May;29(5):1596–601
Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10–year follow–up. Strasser SI, et al.
Hepatology 1999 Jun;29(6):1893–9
Insignificant prevalence of antibodies to hepatitis C in a rural area of western Maharashtra. Chadha MS, et al.
Indian J Gastroenterol 1999 Jan–Mar;18(1):22–3
Prevalence of anti–hepatitis A antibodies, hepatitis B viral markers, and anti–hepatitis C antibodies among immigrants from the former USSR who arrived in Israel during 1990–1991. Almog R, et al. **Infection** 1999 May–Jun; 27(3):212–7
Risk of HCV infections among children with cancer and health–care workers in children's hospitals. Styczynski J, et al. **Infection** 1999 Jan–Feb;27(1):36–8
A likelihood–based method of identifying contaminated lots of blood product. Reilly M, et al. **Int J Epidemiol** 1999 Aug;28(4):787–92
Hepatitis C virus infection in a cohort of 1161 HIV–infected patients [letter] Muñoz–Pérez MA, et al.
Int J STD AIDS 1999 Jan;10(1):69–70
An update on post–transfusion hepatitis in Italy [letter] Ciccozzi M, et al. **Ital J Gastroenterol Hepatol** 1998 Dec; 30(6):665
Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV–I carriers in Japan. Hisada M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 1;19(4):421–5
Epidemiology of hepatitis B, C, E, and G virus infections

and molecular analysis of hepatitis G virus isolates in Bolivia. Konomi N, et al. **J Clin Microbiol** 1999 Oct; 37(10):3291–5

Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. Osella AR, et al. **J Clin Microbiol** 1999 Jul;37(7):2371–2

Prevalence of HIV and hepatitis C markers among a cadaver population in Milan. Cattaneo C, et al. **J Clin Pathol** 1999 Apr;52(4):267–70

Seroepidemiology of HIV, HBV, HCV and treponemal infections. Kaur H, et al. **J Commun Dis** 1998 Mar; 30(1):29–31

The risk of hepatitis C virus infection among blood donors in Osaka, Japan. Tanaka H, et al. **J Epidemiol** 1998 Dec; 8(5):292–6

Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. Smyth BP, et al. **J Epidemiol Community Health** 1999 Jul;53(7):434–5

Seroepidemiology of hepatitis C virus infection among drug abusers in southern Taiwan. Chang CJ, et al. **J Formos Med Assoc** 1998 Dec;97(12):826–9

Molecular epidemiology of hepatitis C in Australia. Kaba S, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):914–20

Dilemma of the natural history of hepatitis C [editorial; comment] Seeff LB. **J Gastroenterol Hepatol** 1999 Mar; 14(3):199–201. Comment on: J Gastroenterol Hepatol 1999 Mar;14(3):269–73.

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. Muñoz-Rodriguez FJ, et al. **J Hepatol** 1999 May;30(5):770–3

Pilot study to estimate survivors to 1995 of 1983–1984 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983–1984. Gore SM, et al. **J Infect** 1998 Sep; 37(2):159–65

Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. Lamden KH, et al. **J Infect** 1998 Nov;37(3):260–9

Prevalence, incidence, and clinical characteristics of hepatitis G virus/GB virus C infection in Scottish blood donors. Blair CS, et al. **J Infect Dis** 1998 Dec;178(6):1779–82

Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). Prati D, et al. **J Med Virol** 1999 Jun; 58(2):116–20

Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. Shemer-Avni Y, et al. **J Med Virol** 1998 Nov;56(3):230–3

"Look back" program initiated for hepatitis C infection [news] Randal J. **J Natl Cancer Inst** 1999 Jun 2;91(11):907

Update on hepatitis C virus (HCV) infection [news] **J Okla State Med Assoc** 1997 Nov-Dec;90(8):458–60

Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. Taglione E, et al. **J Rheumatol** 1999 Feb; 26(2):370–2

Making sense of hepatitis C [editorial] [see comments] **Lancet** 1998 Nov 7;352(9139):1485. Comment in: Lancet 1999 Feb 6;353(9151):500.

Inmates in Irish prisons face drug abuse and disease [news] Birchard K. **Lancet** 1999 Aug 28;354(9180):753

A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Kuboki M, et al. **Liver** 1999 Apr;19(2):88–96

Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Charlton M, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S107–14

Hepatitis C virus (HCV): a silent epidemic. Bandy U. **Med Health R I** 1999 Jun;82(6):223–4 (1 ref.)

The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital, 1971–1975. Thomson JA, et al. **Med J Aust** 1998 Oct 5; 169(7):360–3

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening [see comments] Vogt M, et al. **N Engl J Med** 1999 Sep 16;341(12):866–70 . Comment in: N Engl J Med 1999 Sep 16;341(12):912–3.

Hepatitis virus infection in haemodialysis patients from Moldavia. Covic A, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):40–5

Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Katsoulidou A, et al. **Nephrol Dial Transplant** 1999 May;14(5):1188–94

HCV infection in haemodialysis and CAPD patients [letter] Sayiner AA, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):256–7

Implications of HIV and hepatitis C coinfection [news] [see comments] Klaus BD, et al. **Nurse Pract** 1998 Dec; 23(12):78, 81. Comment in: Nurse Pract 1999 Apr;24(4):16.

Seroprevalence of blood borne transmissible diseases in trauma orthopaedic surgical patients. Sánchez LP, et al. **P R Health Sci J** 1998 Jun;17(2):113–6

Hepatitis C in state correctional facilities. Spaulding A, et al. **Prev Med** 1999 Jan;28(1):92–100

Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours. Gore SM, et al. **QJM** 1999 Jan;92(1):25–32

Epidemiology and prevalence of seropositivity for hepatitis C virus in pregnant women in Granada. Salmerón J, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):841–50 **(Eng, Spa)**

The seroprevalence of hepatitis B and C in an Amerindian population in the southwestern Brazilian Amazon. Ferrari JO, et al. **Rev Soc Bras Med Trop** 1999 May-Jun; 32(3):299–302

Prevalence of hepatitis C and G virus infections among intravenous drug users in Slovenia and Croatia. Trišler Z, et al. **Scand J Infect Dis** 1999;31(1):33–5

Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Buskila D, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):107–13

Cryoglobulinemia in primary Sjögren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Ramos-Casals M, et al. **Semin Arthritis Rheum** 1998 Dec; 28(3):200–5

Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Hershow RC, et al. **Sex Transm Dis** 1998 Nov; 25(10):527–32

Prevalence of hepatitis B and C virus infection among working women in Bangkok. Ikeda M, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):469–74

Hepatitis C and hepatitis E in acute sporadic non-A non-B hepatitis in hospital patients of Delhi (India). Prakash C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):475–9

Prevalence of hepatitis B and C infection markers among adult women in urban and rural areas in Shaanxi Province, China. Shimbo S, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):263–8

Seroprevalence of hepatitis B and C, and human immunodeficiency type 1 viruses in a rural population from the Republic of Equatorial Guinea. Basaras M, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):250–2

Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Wansbrough-Jones MH, et al. **Trans R Soc Trop Med Hyg** 1998 Sep-Oct;92(5):496–9

Risk of hepatitis C infection in neonates transfused with blood from donors infected with hepatitis C. O'Riordan JM, et al. **Transfus Med** 1998 Dec;8(4):303–8

GB virus type C infection in patients treated for childhood acute lymphoblastic leukemia. Aricò M, et al. **Transfusion** 1999 Feb;39(2):212–7

Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation. Maggi U, et al. **Transplant Proc** 1998 Dec;30(8):3946–7

Hepatitis C virus infection and renal transplantation. Morales JM. **Transplant Proc** 1999 Sep;31(6):2221–4 (32 ref.)

Viral hepatitis in renal transplantation. Vathsala A. **Transplant Proc** 1999 Feb-Mar;31(1–2):337–9 (22 ref.)

Hepatitis C infection in patients undergoing liver retransplantation. Rosen HR, et al. **Transplantation** 1998 Dec 27;66(12):1612–6

Epidemiology of hepatitis C virus infection in Nepal. Shrestha SM, et al. **Trop Gastroenterol** 1998 Jul-Sep; 19(3):102–4

Epidemiology of the hepatitis C virus. Ebeling F. **Vox Sang** 1998;74 Suppl 2:143–6 (14 ref.)

Estimated risk of transmission of hepatitis C virus by blood transfusion. Koerner K, et al. **Vox Sang** 1998;74(4):213–6

Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. Ruiz JD, et al. **West J Med** 1999 Mar;170(3):156–60

[The relationship between viral hepatitis and primary liver cancer in four areas of China] Yu SZ, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):214–6 (Eng. Abstr.) **(Chi)**

[Occurrence of hepatitis B and C among mentally retarded] Lunding S, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4393–6 (Eng. Abstr.) **(Dan)**

[Risk factors of hepatitis C virus contamination among patients admitted at the Emergency Service of the Picardie Hospitals. Role of screening carried out according to the recommendations of the General Direction of Health (letter)] Capron D, et al. **Gastroenterol Clin Biol** 1998 Jun-Jul;22(6–7):646–7 **(Fre)**

[Prevalence of hepatitis C virus infection in pregnant woman on the island of Réunion] Faulques B, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):355–8 (Eng. Abstr.) **(Fre)**

[Epidemiology of hepatitis C virus infection in 1,304 HCV positive patients: variations according to the origin of transmission and year of diagnosis] Guyader D, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):375–80 (Eng. Abstr.) **(Fre)**

[Infection with hepatitis C virus in a prison environment. A prospective study in Loos-lez-Lille, France] Hedouin V, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):55–8 (Eng. Abstr.) **(Fre)**

[What is the status of hepatitis C virus infection in France?] Leroy V, et al. **Gastroenterol Clin Biol** 1999 Mar; 23(3):349–51 **(Fre)**

[Creation of a viral hepatitis B and C in the Côte-d'Or department. Methodology and initial results] Minello A, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):766–71 (Eng. Abstr.) **(Fre)**

[Seroprevalence of hepatitis B and C viruses in a psychiatric institution] Eveillard M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):543–8 (Eng. Abstr.) **(Fre)**

[Comorbidities in the addicted patient] Meiler A, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):747–50 **(Fre)**

[Early decline in an epidemic: evolution of the prevalences of HIV, hepatitis B, hepatitis C and aminotransferases in intravenous drug abusers in Strasbourg between 1980 and 1990] Will T. **Rev Med Suisse Romande** 1999 Apr; 119(4):329–34 (Eng. Abstr.) **(Fre)**

[The prevalence of hepatitis C infection among Swiss dentists. The silent epidemic (news)] Meyer J. **Schweiz Monatsschr Zahnmed** 1999;109(4):414, 416, 439–40 **(Fre, Ger)**

[Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992–1996] Pillonel J, et al. **Transfus Clin Biol** 1998 Oct;5(5):305–12 (Eng. Abstr.) **(Fre)**

[Epidemiology of hepatitis C virus infection and circulating genotypes in the Sfax region--Tunisia] Karray-Hakim H, et al. **Tunis Med** 1999 Mar;77(3):139–44 **(Fre)**

[Clinical aspects and epidemiology of hepatitis C in immunosuppressed children with mostly oncologic diseases] Rieske K, et al. **Klin Padiatr** 1998 Jul-Aug; 210(4):274–8 (Eng. Abstr.) **(Ger)**

[The very low prevalence of hepatitis C infection in Swiss dentists (news)] Meyer J. **Schweiz Monatsschr Zahnmed** 1999;109(7):766–7, 790–1 **(Ger, Fre)**

[Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients] Biamino E, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):53–5 (Eng. Abstr.) **(Ita)**

[Seroepidemiological survey of TT virus (TTV) infection in an endemic area for hepatitis C virus] Sugiyama T, et al. **Nippon Rinsho** 1999 Jun;57(6):1402–5 (Eng. Abstr.) **(Jpn)**

[TT virus infection in an area of high-endemicity for hepatitis C] Umemura T, et al. **Nippon Rinsho** 1999 Jun; 57(6):1397–401 (Eng. Abstr.) **(Jpn)**

[The prevalence of TTV infection and the route of TTV transmission in hemodialysis patients--compared with HCV infection] Utsunomiya S, et al. **Nippon Rinsho** 1999 Jun;57(6):1417–20 (Eng. Abstr.) **(Jpn)**

[Analysis of liver function in patients with Turner syndrome (TS) and in patients with secondary hypogonadism with estrogen and estrogen- progestagens replacement therapy: a preliminary report] Rujner J, et al. **Ginekol Pol** 1999 May; 70(5):338–42 (Eng. Abstr.) **(Pol)**

[Hepatitis B and C in 1997] Kuszewski K. **Przegl Epidemiol** 1999;53(1–2):75–81 (Eng. Abstr.) **(Pol)**

[The potential risk factors associated with acute viral hepatitis in children under 5 years old] Ion-Nedelcu N, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul-Sep; 43(3):133–8 **(Rum)**

[The epidemiological aspects and prevalence of markers in those with viral hepatitis C in some population categories in 1994–1997 in Iaşi County] Ivan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):275–9 (Eng. Abstr.) **(Rum)**

[The risk of becoming infected with the hepatitis C virus in patients and medical workers in therapeutic institutions] Marievskii VF. **Lik Sprava** 1998 Jun;(4):64–7 (Eng. Abstr.) **(Rus)**

[The clinico-epidemiological characteristics of the "carriage" of the causative agents of blood-contact viral hepatitides] Ogarkov PI, et al. **Voen Med Zh** 1998 Aug;319(8):38–44, 95 (Eng. Abstr.) **(Rus)**

[Spread of hepatitis C and separate genotypes of hepatitis C virus in a region with a moderately active epidemic process] Kuzin SN, et al. **Vopr Virusol** 1999 Mar-Apr; 44(2):79–82 (Eng. Abstr.) **(Rus)**

[HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study] Cañero-Velasco MC, et al. **Acta Gastroenterol Latinoam** 1998;28(3):265–8 (Eng. Abstr.) **(Spa)**

[Hepatitis A, B, and C in an occupational center for the mentally handicapped] Arnedo A, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):370–3 (Eng. Abstr.) **(Spa)**

[Prevalence of hepatitis C virus genotypes: epidemiology and histologic characteristics] Pena MJ, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):456–60 (Eng. Abstr.) **(Spa)**

[Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain] Alfonso Gil R, et al. **Gac Sanit** 1999 Jan-Feb;13(1):16–21 (Eng. Abstr.) **(Spa)**

[Occupational risk of hepatitis C virus infection after accidental exposure. Catalonia Group for the Study of the Occupational Risk of HCV Infection at Hospitals [see comments]] Serra C, et al. **Med Clin (Barc)** 1998 Nov 21; 111(17):645–9. Comment in: Med Clin (Barc) 1998 Nov 21;111(17):653–9. **(Spa)**

[Incidence of hepatitis C infection among donors of femur heads to the tissue bank] Bonanad Boix S, et al. **Rev Esp Salud Publica** 1998 May-Jun;72(3):267–71 (Eng. Abstr.) **(Spa)**

[Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia] León P, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):144–51 (32 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Hepatitis C prevalence and risk factors in the northern Alberta dialysis population. Sandhu J, et al. **Am J Epidemiol** 1999 Jul 1;150(1):58–66

Porphyria cutanea tarda, hepatitis C infection, and iron overload in a patient on hemodialysis [letter; comment] Albitar S, et al. **Am J Med** 1999 Feb;106(2):266–7. Comment on: Am J Med 1997 Aug;103(2):163–4.

Sewer workers: occupational risk for hepatitis C--report of two cases and review of literature. Brautbar N, et al. **Arch Environ Health** 1999 Sep–Oct;54(5):328–30

Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center [letter] Germanidis G, et al. **Blood** 1999 Mar 1;93(5):1778–9

Transplantation of allogeneic CD34-selected peripheral stem cells does not prevent transmission of hepatitis C virus from an infected donor. Tomás JF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):109–12

Prevalence of hepatitis C virus RNA in patients with chronic renal diseases. Shaker O, et al. **East Mediterr Health J** 1998 Dec;4(3):548–53

Natural history of hepatitis C [editorial; comment] Cooksley WG. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):1–3 (21 ref.). Comment on: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):28–44.

Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.). Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.

Viral hepatitis and kidney transplantation. Lai MK. **J Formos Med Assoc** 1998 Dec;97(12):801–11 (147 ref.)

Prospective follow-up study of hepatitis C virus infection in patients undergoing maintenance haemodialysis: comparison among haemodialysis units. Kobayashi M, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):604–9

"Look back" program initiated for hepatitis C infection [news] Randal J. **J Natl Cancer Inst** 1999 Jun 2;91(11):907

Hepatitis after transplantation. Ye MQ, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S68–72 (15 ref.)

Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Tannapfel A, et al. **Transplantation** 1999 Apr 15;67(7):1079–83

[Hepatitis C virus reinfection after an intravenous drug injection (letter)] Payen JL, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):469–70 **(Fre)**

[Hepatitis C following kidney transplantation] Rostaing L, et al. **Presse Med** 1998 Apr 11;27(14):684–8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C and drug dependence] Monnat M, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):755–6 (12 ref.) **(Fre)**

GENETICS

Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Frommel TO, et al. **Am J Gastroenterol** 1999 Jan;94(1):178–82

Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Sakakura C, et al. **Br J Cancer** 1999 Aug;80(12):2034–9

Hemochromatosis mutation in hepatitis C: histopathology [letter; comment] Knöll A, et al. **Gastroenterology** 1998 Nov;115(5):1307–9. Comment on: Gastroenterology 1998 Feb;114(2):311–8.

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Murakami T, et al. **Hepatology** 1999 Oct;30(4):1045–53

Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. Cramp ME, et al. **J Hepatol** 1998 Aug;29(2):207–13

The GOR47-1 sequence in human DNA encoding for a potential autoantigen in connection with hepatitis C--a sequence not only reserved for humans. Dennin RH, et al. **Z Gastroenterol** 1998 Oct;36(10):877–82

[Hepatitis C: contemporary views on molecular biology of HCV] Adamek A. **Pol Merkuriusz Lek** 1999 Jan;6(31):53–6 (36 ref.) (Eng. Abstr.) **(Pol)**

[Clinical and morphological picture of hepatitis C in children with genotype 4c4d] Czerwionka-Szaflarska M, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):68–9 (Eng. Abstr.) **(Pol)**

[Genetic diagnosis of hepatitis C virus infection] Stanczak JJ. **Pol Merkuriusz Lek** 1999 Feb;6(32):92–5 (35 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Hepatitis C virus and immunoglobulin gene rearrangements: an early step in lymphomagenesis? Santini GF, et al. **Acta Haematol** 1998 Dec;100(3):117–22

Seroepidemiologic studies of hepatitis C virus infection in a population of Okayama Prefecture screened for liver disease. Uesugi S, et al. **Acta Med Okayama** 1999 Feb;53(1):31–8

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? John M, et al. **AIDS** 1998 Dec 3;12(17):2289–93

Hepatitis C virus and autoimmune manifestations [editorial] Indiveri F. **Ann Ital Med Int** 1998 Oct–Dec;13(4):191–3

Mixed cryoglobulinaemia after hepatitis C virus: more and less ambiguity. Agnello V. **Ann Rheum Dis** 1998 Dec;57(12):701–2

Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia. Cacoub P, et al. **Ann Rheum Dis** 1998 Jul;57(7):422–4

Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Lee YH, et al. **Ann Rheum Dis** 1998 Dec;57(12):728–31

Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Esumi M, et al. **Arch Virol** 1999;144(5):973–80

Autoantibodies in human immunodeficiency virus-infected patients with and without concurrent hepatitis C infection. Montero A, et al. **Arthritis Rheum** 1998 Nov;41(11):2077–9

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377–84

Auto-antibodies in hepatitis C. Zauli D, et al. **Biomed Pharmacother** 1999 Jun;53(5–6):234–41 (87 ref.)

Immunopathogenesis of viral hepatitis B and C. Tsai SL. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):159–70 (100 ref.)

Restricted isotypic antibody reactivity to hepatitis C virus synthetic peptides in immunocompromised patients. Devesa M, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):279–81

IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Toniutto P, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):69–73

The interrelationship between hepatitis C virus and HLA [comment] Donaldson PT. **Eur J Clin Invest** 1999 Apr;29(4):280–3. Comment on: Eur J Clin Invest 1999 Apr;29(4):337–43.

Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection [see comments] Lechmann M, et al. **Eur J Clin Invest** 1999 Apr;29(4):337–43. Comment in: Eur J Clin Invest 1999 Apr;29(4):280–3.

Limited humoral immunity in hepatitis C virus infection. Chen M, et al. **Gastroenterology** 1999 Jan;116(1):135–43

Humoral immunity in acute and chronic hepatitis C infection [letter; comment] Zein NN, et al. **Gastroenterology** 1999 Aug;117(2):510. Comment on: Gastroenterology 1999 Jan;116(1):135–43.

NOSA in HCV infection: markers or makers of disease? [comment] Vergani D. **Gut** 1999 Sep;45(3):328–9. Comment on: Gut 1999 Sep;45(3):435–41.

Extreme CA125 elevation from hepatitis C and ascites [letter] Nguyen HN. **Gynecol Oncol** 1998 Sep;70(3):441–2

In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. Eckels DD, et al. **Hum Immunol** 1999 Mar;60(3):187–99

Analysis of a successful immune response against hepatitis C virus. Cooper S, et al. **Immunity** 1999 Apr;10(4):439–49

Cross-linking of Fc(gamma)-receptor on monocytes inhibits hepatitis C virus-specific cytotoxic T-lymphocyte induction in vitro. Kanto T, et al. **Immunology** 1998 Aug;94(4):461–8

Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Eckels DD, et al. **Int Immunol** 1999 Apr;11(4):577–83

Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. Rodriguez-López M, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):727–38

Hepatitis C virus infection and cryoglobulinemia. Lunel F, et al. **J Hepatol** 1998 Nov;29(5):848–55 (87 ref.)

Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. Zibert A, et al. **J Hepatol** 1999 Feb;30(2):177–84

Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. Kanto T, et al. **J Immunol** 1999 May 1;162(9):5584–91

Association between genes of the major histocompatibility complex class II and the outcome of hepatitis C virus infection [letter; comment] Alric L, et al. **J Infect Dis** 1999 May;179(5):1309–10. Comment on: J Infect Dis 1998 Jul;178(1):39–44.

Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. Park YM, et al. **J Korean Med Sci** 1999 Apr;14(2):165–70

Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. Jackson M, et al. **J Med Virol** 1999 Jul;58(3):239–46

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. Schlaak JF, et al. **J Med Virol** 1998 Oct;56(2):112–7

Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity. Carrozzo M, et al. **J Oral Pathol Med** 1999 Jan;28(1):16–9

Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. Taglione E, et al. **J Rheumatol** 1999 Feb;26(2):370–2

Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Bassett SE, et al. **J Virol** 1999 Feb;73(2):1118–26

Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Fan XG, et al. **Mediators Inflamm** 1998;7(4):295–7

Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. Ferrari C, et al. **Recent Results Cancer Res** 1998;154:330–6 (30 ref.)

TOFE human-B-cell-line-based adsorption-inhibition assay to detect HCV neutralizing antibodies. Valli MB, et al. **Res Virol** 1998 Sep–Oct;149(5):331–3

Different IL-12p40 responses in hepatitis C virus-induced and alcohol-induced cirrhosis [letter] Hanck C, et al. **Scand J Gastroenterol** 1999 Feb;34(2):221–2

Cytokines in viral hepatitis. Koziel MJ. **Semin Liver Dis** 1999;19(2):157–69 (147 ref.)

Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Gane EJ, et al. **Transplantation** 1999 Jan 15;67(1):78–84

[Hepatitis C virus and peripheral neurologic involvement: role of anti-ganglioside antibodies] Andrès E, et al. **Gastroenterol Clin Biol** 1999 May;23(5):588 **(Fre)**

METABOLISM

CXCR4 mRNA expression in colon, esophageal and gastric cancers and hepatitis C infected liver. Mitra P, et al. **Int J Oncol** 1999 May;14(5):917–25

Iron and hepatitis viruses [editorial; comment] Deugnier Y, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):467–9 (30 ref.). Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):529–33.

MORTALITY

Increased mortality from liver cancer in England and Wales is not related to hepatitis C [letter] Taylor-Robinson SD, et al. **BMJ** 1999 Sep 4;319(7210):640

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hu KQ, et al. **Hepatology** 1999 Apr;29(4):1311–6

Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. D'Arienzo A, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1213–8

Post-hepatitis primary disease does not influence 6-year survival after liver transplantation beyond 1 year. Caccamo L, et al. **Transpl Int** 1998;11 Suppl 1:S212–20

NURSING

HIV and HCV [letter; comment] Geiger D. **Nurse Pract** 1999 Apr;24(4):16. Comment on: Nurse Pract 1998 Dec;23(12):78, 81.

PATHOLOGY

Viral-induced cirrhosis: grading of severity using MR imaging. Ito K, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):591–6

Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients. Relationship with histologic outcome of recurrent hepatitis C. Costes V, et al. **Am J Clin Pathol** 1999 Feb;111(2):252–8

Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Glicklich D, et al. **Am J Gastroenterol** 1999 Jan;94(1):159–63

Agreement in pathologic interpretation of liver biopsy specimens in posttransplant hepatitis C infection. Younossi ZM, et al. **Arch Pathol Lab Med** 1999 Feb;123(2):143–5

Relationship between erythema of the proximal nailfold in HIV-infected patients and hepatitis C virus infection. Courvoisier S, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):596–7

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Prieto M, et al. **Hepatology** 1999 Jan;29(1):250–6

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? Delgado J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):607–10

Membranoproliferative glomerulonephritis associated with HCV infection in native kidneys and renal allograft. Jeong HJ, et al. **J Korean Med Sci** 1998 Dec;13(6):670–5

Molecular diagnosis and liver histology of children with mother-to-child-transmitted hepatitis C virus infection [letter] Etani Y, et al. **J Pediatr** 1998 Oct;133(4):588

Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Puoti C, et al. **Liver** 1999 Apr;19(2):104–9

Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation. Baiocchi L, et al. **Liver Transpl Surg** 1998 Nov;4(6):441–7

Hepatitis after transplantation. Ye MQ, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S68–72 (15 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1999. A 41-year-old woman with muscle weakness, painful paresthesias, and visual problems [clinical conference] [published erratum

appears in N Engl J Med 1999 Mar 11;340(10):824] **N Engl J Med** 1999 Jan 28;340(4):300–7

Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Ok E, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3103–7

Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Stehman-Breen C, et al. **Nephron** 1999 Jan;81(1):37–40

Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Yoshihara H, et al. **Recent Dev Alcohol** 1998;14:457–69 (58 ref.)

Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Hong Z, et al. **Virology** 1999 Mar 30;256(1):36–44

[Comment on the consensus report, "Treatment of chronic B/D viral hepatitis and acute and chronic C virus hepatitis" (letter; comment)] Dienes HP, et al. **Z Gastroenterol** 1998 Nov;36(11):XX–XXI. Comment on: Z Gastroenterol 1997 Nov; 35(11):971–86. **(Ger)**

[Liver changes in people of conscription age--"carriers" of hepatitis B and C viruses] Povzun SA, et al. **Arkh Patol** 1999 Jan-Feb;61(1):36–9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV-HCV-coinfected patients [letter; comment] Piroth L, et al. **AIDS** 1999 Mar 11;13(4):523–4. Comment on: AIDS 1998 Mar 5;12(4):381–8.

Mechanisms of hepatic toxicity. IV. Pathogenetic mechanisms involved in hepatitis C virus-inducedliver diseases. Lau JYN. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1217–20 (30 ref.)

Spontaneous recovery from perinatal infection due to hepatitis C virus. Padula D, et al. **Clin Infect Dis** 1999 Jan; 28(1):141–2

Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? [editorial; comment] Féray C, et al. **Gastroenterology** 1999 Jul;117(1):263–5 (14 ref.). Comment on: Gastroenterology 1999 Jul;117(1):149–53.

Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Bassett SE, et al. **Hepatology** 1999 Jun;29(6):1884–92

Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289–93

The natural history of hepatitis C-A quandary [editorial; comment] Seeff LB. **Hepatology** 1998 Dec;28(6):1710–2 (23 ref.). Comment on: Hepatology 1998 Dec;28(6):1687–95. Comment on: Hepatology 1998 Dec;28(6):1696–1701.

Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. Mondelli MU, et al. **J Hepatol** 1998 Dec;29(6):879–86

The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? Papatheodoridis GV, et al. **J Hepatol** 1999 Apr;30(4):731–8 (87 ref.)

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. Major ME, et al. **J Virol** 1999 Apr;73(4):3317–25

Mathematicians turn their attention to hepatitis C [news] Blower S, et al. **Nat Med** 1998 Nov;4(11):1233–4

Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Ok E, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3103–7

In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Yanagi M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2291–5

Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Singh N, et al. **Transplantation** 1999 Jan 15;67(1):69–72

Hepatic dysfunction in a population of antibody-deficient patients: prevalence, aetiology and outcome of PCR screening for hepatitis C and G viruses. O'Leary PF, et al. **Vox Sang** 1999;76(3):144–8

[Natural history of hepatitis C in children] Broué P. **Arch Pediatr** 1999;6 Suppl 2:176s–177s **(Fre)**

PREVENTION & CONTROL

Retesting of bone donors 2 months after donation guarantees sufficient safety of bone allografts. Hirn MY, et al. **Acta Orthop Scand** 1998 Dec;69(6):566–9

Hepatitis C: Part II. Prevention counseling and medical evaluation [see comments] Moyer LA, et al. **Am Fam Physician** 1999 Jan 15;59(2):349–54, 357 (16 ref.) . Comment in: Am Fam Physician 1999 Jan 15;59(2):273–4, 277.

CDC issues new recommendations for the prevention and control of hepatitis C virus infection. Rose VL. **Am Fam Physician** 1999 Mar 1;59(5):1321–3

Syringe exchange and risk of infection with hepatitis B and C viruses [see comments] Hagan H, et al. **Am J Epidemiol** 1999 Feb 1;149(3):203–13. Comment in: Am J Epidemiol 1999 Feb 1;149(3):214–6; discussion 217–8.

Invited commentary: needle exchange--no help for hepatitis? [comment] Moss AR, et al. **Am J Epidemiol** 1999 Feb 1; 149(3):214–6; discussion 217–8. Comment on: Am J Epidemiol 1999 Feb 1;149(3):203–13.

Hepatitis C position paper [letter] Algie B. **Am J Infect Control** 1999 Aug;27(4):373

Uncertain knowledge: a national survey of high school students' knowledge and beliefs about hepatitis C. Lindsay J, et al. **Aust N Z J Public Health** 1999 Apr;23(2):135–9

Medical student electives and infectious diseases. Risk of hepatitis C is greater than HIV [letter] Green ST. **BMJ** 1999 Apr 24;318(7191):1146

Hepatitis C--prevention and control: a public health consensus. Ottawa, Canada, October 14–16, 1998. **Can Commun Dis Rep** 1999;25 Suppl 2:i–iii, 1–25 (6 ref.) **(Eng, Fre)**

Perspectives for a hepatitis C virus vaccine. Abrignani S, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):181–5 (16 ref.)

Is there room for general practice in penitentiary institutions: screening and vaccinating high-risk groups against hepatitis. Chatziarsenis M, et al. **Fam Pract** 1999 Aug; 16(4):366–8

Effectiveness of a manual disinfection procedure in eliminating hepatitis C virus from experimentally contaminated endoscopes [see comments] Chanzy B, et al. **Gastrointest Endosc** 1999 Aug;50(2):147–51. Comment in: Gastrointest Endosc 1999 Aug;50(2):287–91.

Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics [editorial; comment] Kellerman S, et al. **Hepatology** 1999 Jan; 29(1):291–3. Comment on: Hepatology 1999 Jan;29(1):257–63.

Analysis of a successful immune response against hepatitis C virus. Cooper S, et al. **Immunity** 1999 Apr;10(4):439–49

Risk and prevention of hepatitis C virus infection. Implications for dentistry. Cleveland JL, et al. **J Am Dent Assoc** 1999 May;130(5):641–7 (44 ref.)

Viral screening and assisted conception treatment--the Bourn Hall experience. Abusheikha N, et al. **J Assist Reprod Genet** 1999 Jul;16(6):337–9

DNA vaccine strategies for hepatitis C. Inchauspé G. **J Hepatol** 1999 Feb;30(2):339–46 (44 ref.)

Hepatitis C vaccine hampered by viral complexity, many technical restraints [news] Randal J. **J Natl Cancer Inst** 1999 Jun 2;91(11):906–8

JAMA patient page. Hepatitis C. **JAMA** 1998 Dec 23–30; 280(24):2188

Making sense of hepatitis C [letter; comment] Hurtado K. **Lancet** 1999 Feb 6;353(9151):500. Comment on: Lancet 1998 Nov 7;352(9139):1485.

Should hepatitis C antibody-positive inmates be vaccinated against hepatitis A virus? [letter] Awofeso N, et al. **Med J Aust** 1999 Apr 5;170(7):338

Audit on the degree of application of universal precautions in a haemodialysis unit. Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1001–3

Isolation of HCV patient is efficient in reducing the annual incidence of HCV infection, but is it really necessary? [letter] Arenas Jiménez D, et al. **Nephrol Dial Transplant** 1999 May;14(5):1337–9

Infection control of hepatitis C in Dutch dialysis centres [news] Schneeberger PM, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3037–40

Hepatitis B vaccination in pregnancy: factors influencing efficacy. Ingardia CJ, et al. **Obstet Gynecol** 1999 Jun; 93(6):983–6

Hepatitis C in state correctional facilities. Spaulding A, et al. **Prev Med** 1999 Jan;28(1):92–100

Hepatitis C: universal or selective screening? Brettle RP. **Sex Transm Infect** 1998 Oct;74(5):374–5 (6 ref.)

PCR testing of plasma pools: from concept to reality. Flanagan P, et al. **Transfus Med Rev** 1999 Jul;13(3):164–76 (40 ref.)

DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr-Jun;20(2):64–7 (30 ref.)

Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Mast EE, et al. **Vaccine** 1999 Mar 26;17(13–14):1730–3 (16 ref.)

From Cannes 1993 to the present. Van Damme P, et al. **Vaccine** 1998 Nov;16 Suppl:S3–6 (11 ref.)

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147–54 (79 ref.)

Hepatitis C: the physician's responsibility? **W V Med J** 1999 May-Jun;95(3):114

[Current status and strategy of the research on hepatitis C vaccine] Nie Q, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb; 19(1):47–9 (15 ref.) **(Chi)**

[Which precautions should be taken in case of hepatitis C? From the statement of the question to the dissemination of the response in a consensus conference] Carpentier F, et al. **Gastroenterol Clin Biol** 1998 Jun;22(5 Suppl):B48–54 **(Fre)**

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587–92 (9 ref.) **(Fre)**

[Blood-borne viral infection in hemodialysis units: special reference to hepatitis B virus, hepatitis C virus and human T-lymphotropic virus type 1] Washio M. **Nippon Koshu Eisei Zasshi** 1998 Oct;45(10):960–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatitis C virus infection among the health personnel and prophylaxis with human immunoglobulin (letter)] Echevarria JM, et al. **Med Clin (Barc)** 1998 Oct 10; 111(11):438–9 **(Spa)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240–1 **(Spa)**

PSYCHOLOGY

Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Best D, et al. **BMJ** 1999 Jul 31;319(7205):290–1

Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Singh N, et al. **Transplantation** 1999 Jan 15;67(1):69–72

SURGERY

Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients. Relationship with histologic outcome of recurrent hepatitis C. Costes V, et al. **Am J Clin Pathol** 1999 Feb;111(2):252–8

Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. Min AD, et al. **Am J Gastroenterol** 1998 Nov;93(11):2148–53

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ghobrial RM, et al. **Ann Surg** 1999 Jun; 229(6):824–31; discussion 831–3

Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? [editorial; comment] Féray C, et al. **Gastroenterology** 1999 Jul;117(1):263–5 (14 ref.). Comment on: Gastroenterology 1999 Jul;117(1):149–53.

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Féray C, et al. **Gastroenterology** 1999 Sep;117(3):619–25

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts [see comments] Vargas HE, et al. **Gastroenterology** 1999 Jul; 117(1):149–53. Comment in: Gastroenterology 1999 Jul;117(1):263–5.

Hepatitis C and liver transplantation. Berenguer M, et al. **Gut** 1999 Aug;45(2):159–63 (52 ref.)

Hepatitis C virus recurrence after liver transplantation. Bizollon T, et al. **Gut** 1999 Apr;44(4):575–8 (57 ref.)

Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation. Bizollon T, et al. **J Hepatol** 1998 Dec; 29(6):893–900

The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? Papatheodoridis GV, et al. **J Hepatol** 1999 Apr;30(4):731–8 (87 ref.)

Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Casavilla FA, et al. **Liver Transpl Surg** 1998 Nov;4(6):448–54

The effect of recurrence of HCV infection of life after liver transplantation. Bona MD, et al. **Transpl Int** 1998;11 Suppl 1:S475–9

Quantitation of hepatitis C virus RNA in liver tissue of allografts: correlation with histologic features and liver function tests. Aardema KL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):477–8

Immunogenetic factors, HCV genotypes, and HCV recurrence after liver transplantation. Belli LS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):483–4

Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Fischer L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):494–5

Quality of life and functional status of liver transplant recipients with recurrent viral hepatitis C. Gayowski T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1386–7

Hepatitis C reinfection after liver transplantation in relation to virus genotype. Tisone G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):490–1

In situ enzymatic oligonucleotide amplification of hepatitis C virus-RNA in liver biopsy specimens (reverse transcriptase in situ polymerase chain reaction) after orthotopic liver transplantation for hepatitis C-related liver disease. Fragulidis GP, et al. **Transplantation** 1998 Dec 15; 66(11):1472–6

[Severe relapse of hepatitis C following liver transplantation. Successful treatment with a combination of interferon-alpha and ribavirin] Telegdy L, et al. **Orv Hetil** 1999 Aug 22;140(34):1891–3 (Eng. Abstr.) **(Hun)**

THERAPY

Anaesthesia for a patient on interferon therapy [letter] Coleman M, et al. **Acta Anaesthesiol Scand** 1999 Jan; 43(1):115–6

Perspective of a patient with HCV for over twenty years [letter] Donnelly K. **Am J Crit Care** 1999 May;8(3):203–4

Follow-up of hepatitis C virus RNA in peripheral blood mononuclear cells during interferon therapy. Cribier B, et al. **Arch Virol** 1999;144(2):355–64

Internal initiation of translation efficiency in different hepatitis C genotypes isolated from interferon treated

patients. Sáiz JC, et al. **Arch Virol** 1999;144(2):215–29
Support for patients with hepatitis C: an exploratory qualitative study of medical specialists' perceptions. Teague W, et al. **Aust N Z J Public Health** 1999 Apr;23(2):201–3
Treatment of hepatitis C infection. Review underplayed important public health issues [letter] Agarwal K, et al. **BMJ** 1999 Aug 14;319(7207):450–1
New treatment for hepatitis C. Williams CN. **Can J Gastroenterol** 1999 Jan–Feb;13(1):19–20
Hepatitis C update: implications of the blood transfusion "lookback". Younossi ZM, et al. **Cleve Clin J Med** 1998 Sep;65(8):412–5, 418–22 (22 ref.)
Ribozyme gene therapy for hepatitis C virus infection. Welch PJ, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):163–71
Treatment of hepatitis C infection in patients with renal disease. Diego JM, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):557–62 (61 ref.)
Interferon-alpha and development of type 1 diabetes: a case without insulin resistance [letter] Tohda G, et al. **Diabetes Care** 1998 Oct;21(10):1774
Early HCV RNA values after interferon predict response. Wiley TE, et al. **Dig Dis Sci** 1998 Oct;43(10):2169–72
Development of myasthenia gravis after interferon alpha therapy. Gurtubay IG, et al. **Electromyogr Clin Neurophysiol** 1999 Mar;39(2):75–8
Mode of transmission of hepatitis C and clinical outcome correction [letter; comment] Dowling D. **Hepatology** 1999 Jan;29(1):298. Comment on: Hepatology 1998 Aug;28(2):562–7.
Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Frangeul L, et al. **Hepatology** 1998 Dec; 28(6):1674–9
Interferon-induced thrombocytopenia: is it time for thrombopoietin [editorial; comment] Martin TG, et al. **Hepatology** 1998 Nov;28(5):1430–2. Comment on: Hepatology 1998 Nov;28(5):1424–9.
Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C [see comments] Peck-Radosavljevic M, et al. **Hepatology** 1998 Nov;28(5):1424–9. Comment in: Hepatology 1998 Nov;28(5):1430–2.
Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. Oketani M, et al. **J Clin Gastroenterol** 1999 Jan;28(1):49–51
Viral hepatitis and liver transplantation. Bzowej NH, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S53–60 (19 ref.)
Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. Chung RT, et al. **J Med Virol** 1999 Aug;58(4):353–8
From the Oklahoma State Department of Health. CDC recommendations for diagnosis and initial management of hepatitis C virus infection. Crutcher M, et al. **J Okla State Med Assoc** 1999 Feb;92(2):93–5
Consensus interferon: a novel interferon for the treatment of hepatitis C. Heathcote J. **J Viral Hepat** 1998 Sep;5 Suppl 1:13–8
Hepatitis treatment in developing countries [letter] Smeeth L. **Lancet** 1998 Nov 21;352(9141):1711–2
Hepatitis B and C: an overview. Bodenheimer HC Jr. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S65–7 (26 ref.)
Management of posttransplantation viral hepatitis C. Shiffman ML. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S79–86 (43 ref.)
Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist [editorial] Fabrizi F, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2079–81 (10 ref.)
The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Boran M, et al. **Nephron** 1999;82(1):22–6
Chronic hepatitis C: treatment comparison between 3 and 5 million units of interferon alpha-2b. Castro F, et al. **P R Health Sci J** 1998 Sep;17(3):221–5
Interferon therapy for hepatitis B and C. Murray JA. **Postgrad Med** 1998 Dec;104(6):25, 28
Future options for the management of hepatitis C. Davis GL, et al. **Semin Liver Dis** 1999;19 Suppl 1:103–12 (75 ref.)
Hepatitis C not incurable [letter] Hill N. **Tex Med** 1998 Oct; 94(10):11–2
Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferon alpha. Fischer L, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):494–5
[The role of virologic tests in the treatment of chronic hepatitis C] Castera L, et al. **Gastroenterol Clin Biol** 1999 Jun–Jul;23(6–7):707–9 (10 ref.) **(Fre)**
[Does hepatitis c virus-related autoimmune thyroiditis exist? Reflections on a controlled study of 58 consecutive subjects] Blot E, et al. **Rev Med Interne** 1999 Mar; 20(3):220–5 (Eng. Abstr.) **(Fre)**
[Hepatitis C and drug dependence] Monnat M, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):755–6 (12 ref.) **(Fre)**
[Hepatitis B and C: current therapy] Bruch HR, et al. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1408–12 (42 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of recurrent hepatitis C after liver transplantation] Hug B. **Schweiz Rundsch Med Prax** 1998 Sep 2;87(36):1160 **(Ger)**
[Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy] Ezaki Y, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):83–8 (Eng. Abstr.) **(Jpn)**
[Advances in the treatment of severe refractory diseases. 2) Viral hepatitis] Zeniya M, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2245–9 (8 ref.) **(Jpn)**
[Virological response to interferon therapy in patients dually infected with TT virus and hepatitis C virus] Matsumoto H, et al. **Nippon Rinsho** 1999 Jun;57(6):1387–9 (Eng. Abstr.) **(Jpn)**
[Therapeutic response to alpha-interferon in chronic alcoholics with viral hepatitis C] Nikitin IG, et al. **Klin Med (Mosk)** 1998;76(8):33–5 (Eng. Abstr.) **(Rus)**

TRANSMISSION

A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States [see comments] Balasekaran R, et al. **Am J Gastroenterol** 1999 May;94(5):1341–6. Comment in: Am J Gastroenterol 1999 May;94(5):1135–6.
Etiology of hepatitis C: a reassessment [editorial; comment] Conjeevaram HS. **Am J Gastroenterol** 1999 May; 94(5):1135–6. Comment on: Am J Gastroenterol 1999 May;94(5):1341–6.
Triple therapy prevents HIV but not HCV transmission after needlestick injury [letter] Fabris P, et al. **Am J Gastroenterol** 1999 Jul;94(7):1990–1
Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil [letter] Paraná R, et al. **Am J Gastroenterol** 1999 Mar;94(3):857–8
HCV and diabetes mellitus: influence of nosocomial transmission with the use of a finger stick device [letter; comment] Petit JM, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1709–10. Comment on: Am J Gastroenterol 1998 Dec;93(12):2363–7.
Barbering, a probable risk factor for HCV transmission [letter; comment] Schmidt M. **Am J Gastroenterol** 1998 Oct;93(10):1999. Comment on: Am J Gastroenterol 1998 Apr;93(4):597–600.
Hepatitis C virus infection in dialysis: a continuing problem. Pereira BJ. **Artif Organs** 1999 Jan;23(1):51–60 (87 ref.)
Balancing rights and duties. Hassed C. **Aust Fam Physician** 1999 Aug;28(8):839, 841
Hepatitis C--role of perinatal transmission. Garland SM, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):424–7
Transplantation of allogeneic CD34-selected peripheral stem cells does not prevent transmission of hepatitis C virus from an infected donor. Tomás JF, et al. **Bone Marrow Transplant** 1999 Jul;24(1):109–12
Spontaneous recovery from perinatal infection due to hepatitis C virus. Padula D, et al. **Clin Infect Dis** 1999 Jan; 28(1):141–2
Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies [letter] Caramelo C, et al. **Clin Nephrol** 1999 Jan;51(1):59–60
Transmission of hepatitis C virus from a surgeon to a patient. The Incident Control Team. Duckworth GJ, et al. **Commun Dis Public Health** 1999 Sep;2(3):188–92
A study on the role of the family and other risk factors in HCV transmission. Brusaferro S, et al. **Eur J Epidemiol** 1999 Feb;15(2):125–32
A computer model of the spread of hepatitis C virus among injecting drug users. Mather D, et al. **Eur J Epidemiol** 1999 Jan;15(1):5–10
Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Delage G, et al. **Gastroenterology** 1999 Apr;116(4):893–9
Sex and drugs and HCV? [comment] Rosenberg W. **Gut** 1999 Jul;45(1):7–8. Comment on: Gut 1999 Jul;45(1):112–6.
Epidemiological and virological analysis of couples infected with hepatitis C virus [see comments] Zylberberg H, et al. **Gut** 1999 Jul;45(1):112–6. Comment in: Gut 1999 Jul;45(1):7–8.
Lack of transmission of hepatitis C virus following needlestick accidents. Hasan F, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1678–81
Mode of transmission of hepatitis C and clinical outcome correction [letter; comment] Dowling D. **Hepatology** 1999 Jan;29(1):298. Comment on: Hepatology 1998 Aug;28(2):562–7.
Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289–93
Immunoglobulin transmits hepatitis C. True or false? [letter; comment] Piazza M. **Hepatology** 1999 Jan;29(1):299–300. Comment on: Hepatology 1997 Sep;26(3):521–6.
Mother-infant hepatitis C transmission: second generation research. Thomas DL. **Hepatology** 1999 Mar;29(3):992–3
Hepatitis C virus and professional risk in anesthesia and intensive care: a case report [letter] Bakir L, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):823
Risk of transmission and features of hepatitis C after needlestick injuries. Hamid SS, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):63–4
High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners. Fabris P, et al. **Infection** 1999 Mar–Apr;27(2):86–91
Lack of familial clustering of hepatitis C virus infection. Kim YS, et al. **Int J Epidemiol** 1998 Jun;27(3):525–9
ACOG committee opinion. Hepatitis virus infections in obstetrician-gynecologists. Number 203, July 1998 (replaces No. 199, February 1998). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov; 63(2):203–4
A prospective study on mother-to-infant transmission of hepatitis C virus. Zanetti AR, et al. **Intervirology** 1998; 41(4–5):208–12
Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. Oketani M, et al. **J Clin Gastroenterol** 1999 Jan;28(1):49–51
Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies. Beld M, et al. **J Clin Microbiol** 1998 Oct; 36(10):3002–6
Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. Le Pogam S, et al. **J Clin Microbiol** 1998 Oct;36(10):3040–3
Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units. Mizuno M, et al. **J Clin Microbiol** 1998 Oct;36(10):2926–31
Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. Norder H, et al. **J Clin Microbiol** 1998 Oct;36(10):3066–9
Acute hepatitis C among renal failure patients on chronic haemodialysis. Okuda K, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):62–7
Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. Casino C, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):717–25
Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. Kumar RM, et al. **J Hepatol** 1998 Aug;29(2):191–7
Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: model-based estimates in France. Yazdanpanah Y, et al. **J Hepatol** 1999 May;30(5):765–9
Pilot study to estimate survivors to 1995 of 1983–1984 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983–1984. Gore SM, et al. **J Infect** 1998 Sep; 37(2):159–65
Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. Bukh J, et al. **J Infect Dis** 1998 Oct;178(4):1193–7
Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. Farci P, et al. **J Infect Dis** 1999 Apr;179(4):1007–11
Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. Papaevangelou V, et al. **J Infect Dis** 1998 Oct; 178(4):1047–52
Hepatitis C virus transmission following invasive medical procedures [letter] Delwaide J, et al. **J Intern Med** 1999 Jan;245(1):107–8
Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. Irish DN, et al. **J Med Virol** 1999 Oct;59(2):135–40
Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. Izopet J, et al. **J Med Virol** 1999 Jun;58(2):139–44
Molecular diagnosis and liver histology of children with mother-to-child-transmitted hepatitis C virus infection [letter] Etani Y, et al. **J Pediatr** 1998 Oct;133(4):588
Lack of transmission of hepatitis C virus in very close family contacts of patients undergoing multitransfusions for thalassemia. Rosenthal E, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):101–3
Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. Sullivan DG, et al. **J Virol** 1998 Dec; 72(12):10036–43
Hidden risk of hepatitis C [news] Greenberger P. **J Womens Health** 1998 Sep;7(7):797–8
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not [see comments] Crofts N, et al. **Med J Aust** 1999 Mar 1; 170(5):220–1. Comment in: Med J Aust 1999 Aug 2;171(3):165–6.
Transmission of hepatitis C within Australian prisons [see comments] Haber PS, et al. **Med J Aust** 1999 Jul 5; 171(1):31–3. Comment in: Med J Aust 1999 Jul 5;171(1):7–8.
The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not [letter; comment] Sullivan LG. **Med J Aust** 1999 Aug 2; 171(3):165–6. Comment on: Med J Aust 1999 Mar 1;170(5):220–1.
Hepatitis C infection in children [editorial; comment] Jonas MM. **N Engl J Med** 1999 Sep 16;341(12):912–3. Comment on: N Engl J Med 1999 Sep 16;341(12):866–70.
Isolation of HCV patient is efficient in reducing the annual incidence of HCV infection, but is it really necessary?

[letter] Arenas Jiménez D, et al.
Nephrol Dial Transplant 1999 May;14(5):1337–9
Transmission of hepatitis C virus infection to spouses of patients undergoing chronic hemodialysis [letter] Akarsu E, et al. **Nephron** 1999;82(4):359–60
Evidence of hepatitis C virus passage across dialysis membrane. Valtuille R, et al. **Nephron** 1998 Oct;80(2):194–6
Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. Vitale F, et al. **New Microbiol** 1998 Oct;21(4):335–42
Iatrogenic hepatitis C virus transmission via commercial plasma donation in Spain [letter] Davis AR. **Pathology** 1998 Nov;30(4):427
Shift in the buoyant density of hepatitis C virus particles in infants infected by mother-to-infant transmission. Okamoto M, et al. **Pediatr Int** 1999 Aug;41(4):369–73
Transplacental transmission of hepatitis C virus in HIV-negative mothers. Agha S, et al. **Res Virol** 1998 Jul–Aug;149(4):229–34
Spouses of HCV carriers are not at serious risk [letter] Mert A, et al. **Scand J Infect Dis** 1998;30(6):644
Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Hershow RC, et al. **Sex Transm Dis** 1998 Nov; 25(10):527–32
Sexual transmission of hepatitis C virus infection. Rooney G, et al. **Sex Transm Infect** 1998 Dec;74(6):399–404 (77 ref.)
Risk of hepatitis C infection in neonates transfused with blood from donors infected with hepatitis C. O'Riordan JM, et al. **Transfus Med** 1998 Dec;8(4):303–8
Transfusion-acquired hepatitis C: the Danish lookback experience. The Danish HCV [hepatitis C virus] Lookback Group [see comments] Christensen PB, et al.
Transfusion 1999 Feb;39(2):188–93. Comment in: Transfusion 1999 Feb;39(2):123–7.
Targeted hepatitis C lookback: Quebec, Canada [see comments] Long A, et al. **Transfusion** 1999 Feb; 39(2):194–200. Comment in: Transfusion 1999 Feb;39(2):123–7.
Hepatitis virus infection after living related liver transplantation: a report of 2 cases. Suzuki T, et al. **Transplant Proc** 1998 Nov;30(7):3312–3
Hepatitis C virus in peripheral blood mononuclear cells from a chronically infected patient receiving liver graft from infected donor. Radkowski M, et al. **Transplantation** 1999 Feb 27;67(4):627–9
Occupational risk of hepatitis B and C infections in urologists. Oge O, et al. **Urol Int** 1998;61(4):206–9
Hepatitis C virus stability: the issue! Cardoso MS, et al. **Vox Sang** 1999;76(2):124–7
Estimated risk of transmission of hepatitis C virus by blood transfusion. Koerner K, et al. **Vox Sang** 1998;74(4):213–6
Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation [see comments] Lawlor E, et al. **Vox Sang** 1999;76(3):138–43. Comment in: Vox Sang 1999 ;76(3):135–7.
A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. Smith DB, et al. **Vox Sang** 1999; 76(3):175–80
[Current status of the study on mother to infant transmission of hepatitis C virus] Li K, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Jun; 18(3):171–3 (17 ref.) **(Chi)**
[Hepatitis C virus infection among long-term hemodialysis patients] Lu A, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun;36(6):402–5 (Eng. Abstr.) **(Chi)**
[Nosocomial transmission of hepatitis C virus in a Dutch dialysis center] Schneeberger PM, et al.
Ned Tijdschr Geneeskd 1999 Apr 10;143(15):801–6 (Eng. Abstr.) **(Dut)**
[Epidemiology of hepatitis C virus infection in 1,304 HCV positive patients: variations according to the origin of transmission and year of diagnosis] Guyader D, et al.
Gastroenterol Clin Biol 1998 Apr;22(4):375–80 (Eng. Abstr.) **(Fre)**
[Risk factors of contamination by hepatitis C virus. Case-control study in the general population] Merle V, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):439–46 (Eng. Abstr.) **(Fre)**
[Transmission modes of hepatitis C virus] Karmochkine M, et al. **Presse Med** 1998 May 16;27(18):871–6 (68 ref.) (Eng. Abstr.) **(Fre)**
[Hospital medical students: a population at risk for accidental exposure to blood] Keita-Perse O, et al. **Presse Med** 1998 Nov 7;27(34):1723–6 (Eng. Abstr.) **(Fre)**
[Risk of transmission of hepatitis C through endoscopy of the digestive tract] Ouzan D. **Presse Med** 1999 Jun 5; 28(20):1091–4 (Eng. Abstr.) **(Fre)**
[Non-transfusional and non-intravenous drug addiction related transmission of hepatitis C virus] Serfaty L.
Presse Med 1999 Jun 12;28(21):1135–40 (56 ref.) (Eng. Abstr.) **(Fre)**
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)] Delwaide J. **Rev Med Liege** 1998 Aug;53(8):467–9 (17 ref.) (Eng. Abstr.) **(Fre)**
[Nosocomial hepatitis B virus, hepatitis C virus and HIV infections by infectious medial personnel] Hasselhorn HM, et al. **Gesundheitswesen** 1998 Oct;60(10):545–51 (38 ref.) (Eng. Abstr.) **(Ger)**
[Transmission of infectious diseases during imprisonment--results of a study and introduction of a model project for infection prevention in Lower Saxony] Keppler K, et al. **Gesundheitswesen** 1999 Apr;61(4):207–13 (Eng. Abstr.) **(Ger)**
[Risk of infection by needle-stick injury] Goebel FD, et al. **Internist (Berl)** 1999 Jan;40(1):117–8 **(Ger)**
[Maternal-fetal transmission of HCV. Role of HIV as a risk factor] Catalano D, et al. **Minerva Ginecol** 1999 Apr; 51(4):117–9 (Eng. Abstr.) **(Ita)**
[Clinical characteristics of HCV infection in pregnancy: the role of sexual transmission] Minola E, et al.
Minerva Ginecol 1999 Apr;51(4):121–3 (Eng. Abstr.) **(Ita)**
[Familial and sexual transmission of hepatitis C virus (letter; comment)] Bachiller Luque P, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):677. Comment on: Med Clin (Barc) 1998 Jan 24;110(2):76. **(Spa)**
[Sporadic hepatitis C: relative significance of non-apparent vertical, sexual, and parenteral transmission of the hepatitis C virus (editorial; comment)] Bruguera M.
Med Clin (Barc) 1998 Nov 21;111(17):658–9. Comment on: Med Clin (Barc) 1998 Nov 21;111(17):645–9. **(Spa)**

ULTRASONOGRAPHY

Ultrasound evaluation of hepatic lymph nodes in patients with anti-hepatitis C virus antibody reactivity. Spinetti A, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):295–300

VIROLOGY

Vertical transmission of HCV. La Torre A, et al.
Acta Obstet Gynecol Scand 1998 Oct;77(9):889–92
Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients [letter] Uberti-Foppa C, et al. **AIDS** 1999 Jan 14;13(1):140–1
Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Fan X, et al.
Am J Gastroenterol 1999 May;94(5):1347–54
Hepatitis C: does a healing state exist? [letter] Paraná R, et al. **Am J Gastroenterol** 1999 Mar;94(3):862–3
Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Beld M, et al. **Blood** 1999 Aug 15; 94(4):1183–91
Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy. Grumbach IM, et al. **Cardiology** 1998 Oct;90(2):75–8
Study of hepatitis C virus genotype in Guizhou area of southwestern China. Ding J, et al. **Chin Med J (Engl)** 1998 Feb;111(2):128–31
Long-term persistence of hepatitis C viremia in hemodialysis patients [letter; comment] Piazza V, et al. **Clin Nephrol** 1999 Feb;51(2):129–30. Comment on: Clin Nephrol 1996 Apr;45(4):257–60.
Improved sensitivity of reverse transcriptase polymerase chain reaction for hepatitis C virus using random hexamer primers. Radhakrishnan S, et al.
Diagn Microbiol Infect Dis 1999 Mar;33(3):153–6
Inquiries on intraspousal transmission of hepatitis C virus: benefits and limitations of genome sequencing and phylogenetic analysis. Ross RS, et al. **Forensic Sci Int** 1999 Mar 15;100(1–2):69–76
Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese. Tanaka K, et al. **Fukuoka Igaku Zasshi** 1998 Aug; 89(8):238–48
Importance of RT-PCR for detection of hepatitis C virus among different patient groups. Ramalingam S, et al.
Indian J Med Res 1998 Sep;108:85–7
Risk of non-Hodgkin's lymphoma in patients with hepatitis C virus infection. Ohsawa M, et al. **Int J Cancer** 1999 Jan 18;80(2):237–9
Effects of corticosteroids on HCV infection. Magy N, et al.
Int J Immunopharmacol 1999 Apr;21(4):253–61
Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Shibata Y, et al. **Int J Oncol** 1999 Jun;14(6):1153–6
Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. Germer JJ, et al. **J Clin Microbiol** 1999 Aug; 37(8):2625–30
High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. Martell M, et al.
J Clin Microbiol 1999 Feb;37(2):327–32
Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. Mellor J, et al. **J Clin Microbiol** 1999 Aug;37(8):2525–32
Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay. Schröter M, et al. **J Clin Microbiol** 1999 Aug;37(8):2576–80
Direct in situ reverse transcriptase-linked polymerase chain reaction with biotinylated primers for the detection of hepatitis C virus RNA in liver biopsies. Bettinger D, et al. **J Clin Virol** 1999 May;12(3):233–41
HCV genotyping by three methods: analysis of discordant results based on sequencing. Furione M, et al.
J Clin Virol 1999 Aug;13(3):121–30
Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. Yeh CT, et al. **J Gastroenterol Hepatol** 1998 Feb; 13(2):131–6
Evidence of increasing diversification of hepatitis C viruses. Colina R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1377–82
Characteristics of patients sero-positive for hepatitis C virus (HCV) antibodies but negative for HCV-RNA by polymerase chain reaction [letter] Hashimoto E, et al.
J Hepatol 1998 Nov;29(5):856–7
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. Leone F, et al.
J Hepatol 1998 Nov;29(5):689–94
Dynamics of hepatitis C viremia [letter; comment] Carroll AR. **J Infect Dis** 1999 Jan;179(1):291. Comment on: J Infect Dis 1998 Jun;177(6):1475–9.
Distribution of genotypes in the 5' untranslated region of hepatitis C virus in Korea. Park YS, et al.
J Med Microbiol 1998 Jul;47(7):643–7
The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. Harris KA, et al.
J Med Virol 1999 Jun;58(2):127–31
Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. Ni YH, et al.
J Med Virol 1999 Jun;58(2):132–8
Profiles of GBV-C/hepatitis G virus markers in patients coinfected with hepatitis C virus. Sauleda S, et al.
J Med Virol 1999 Sep;59(1):45–51
Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Heim MH, et al. **J Virol** 1999 Oct;73(10):8469–75
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. Ray SC, et al. **J Virol** 1999 Apr;73(4):2938–46
Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes. Pérez-Gracia T, et al. **Liver** 1999 Aug;19(4):288–93
Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Katsoulidou A, et al.
Nephrol Dial Transplant 1999 May;14(5):1188–94
Is hepatitis C virus genotype 4 predominant in Saudi Arabia? Boriskin YS, et al. **New Microbiol** 1999 Jul;22(3):173–80
Recurrence of hepatitis C virus infection after orthotopic liver transplantation: role of genotypes. Casino C, et al.
New Microbiol 1999 Jan;22(1):11–8
Rapid genotyping of hepatitis C virus by direct cycle sequencing of PCR-amplified cDNAs and capillary electrophoresis analysis. Doglio A, et al. **Res Virol** 1998 Jul–Aug;149(4):219–27
Molecular heterogeneity and new subtypes of HCV genotype 4. Rapicetta M, et al. **Res Virol** 1998 Sep–Oct;149(5):293–7
Genotyping HCV isolates from Italy by type-specific PCR assay in the core region. Spada E, et al. **Res Virol** 1998 Jul–Aug;149(4):209–18
A quantitative HCV-PCR test for routine diagnostics. Krarup HB, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):415–22
Viral gene screen. Netting J. **Sci Am** 1999 Aug;281(2):31–2
A single nucleotide insertion in the 5'-untranslated region of hepatitis C virus leads to enhanced cap-independent translation. Zhang J, et al. **Virology** 1999 Sep 1; 261(2):263–70
Molecular characterization of HCV 1b intra-familiar infection through three generations. Argentini C, et al.
Virus Genes 1999;18(2):169–74
Supplementary anti-hepatitis C virus (HCV) testing with 2nd and 3rd generation recombinant immunoblot assay and matrix applied to enzyme immunoassay positive sera and comparison with HCV-RNA detection. Engel PM, et al.
Zentralbl Bakteriol 1998 Oct;288(2):267–75
[Progress in the study of communicable diseases in China, 1997] Luo K, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):893–5 (0 ref.) **(Chi)**
[Comparison of hypervariable region gene of hepatitis C virus between an individual infected persistently and an individual recovered from infection] Pan W, et al.
Chung Hua Kan Tsang Ping Tsa Chih 1999 Mar;7(1):26–8 (Eng. Abstr.) **(Chi)**
[Sequence diversity of genotype II/1b hepatitis C virus (HCV) HVR1 of 46 patients in Beijing areas] Zhao J, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun; 7(2):88–90 (Eng. Abstr.) **(Chi)**
[Study on HCV infection and the distribution of HCV genotypes in different populations in Shenyang area] Huang F, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun;19(3):134–7 (Eng. Abstr.) **(Chi)**
[An investigation on genotypes of hepatitis C virus in Anhui province] Su H, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Aug; 18(4):205–7 (Eng. Abstr.) **(Chi)**
[Studies on multiple infection with hepatitis B, C and G viruses] Du S, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1998 Jan;32(1):13–5 (Eng. Abstr.) **(Chi)**
[The role of virologic tests in the treatment of chronic hepatitis C] Castera L, et al. **Gastroenterol Clin Biol** 1999 Jun–Jul;23(6–7):707–9 (10 ref.) **(Fre)**
[Antibodies against cytomegalovirus and risk of hepatitis C (letter)] Moncharmont P, et al. **Presse Med** 1998 Apr 4; 27(13):617 **(Fre)**
[Epidemiology of hepatitis C virus infection and circulating genotypes in the Sfax region--Tunisia] Karray-Hakim H, et al. **Tunis Med** 1999 Mar;77(3):139–44 **(Fre)**

[Hepatitis C--the silent epidemic (news)]
Schweiz Monatsschr Zahnmed 1999;109(3):295-9, 329-32 **(Ger, Fre)**

[Hepatitis C: contemporary views on molecular biology of HCV] Adamek A. **Pol Merkuriusz Lek** 1999 Jan;6(31):53-6 (36 ref.) (Eng. Abstr.) **(Pol)**

HEPATITIS C ANTIBODIES

ANALYSIS

Prevalence of hepatitis C virus antibodies in primary glomerulonephritis in Brazil. Lopes LM, et al. **Am J Nephrol** 1998;18(6):495-7

Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy. Grumbach IM, et al. **Cardiology** 1998 Oct;90(2):75-8

Prevalence of hepatitis C virus antibody in patients on chronic hemodialysis. Nomiyama K, et al. **Fukuoka Igaku Zasshi** 1998 Aug;89(8):232-7

Ultrasound evaluation of hepatic lymph nodes in patients with anti-hepatitis C virus antibody reactivity. Spinetti A, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):295-300

Definition of false-positive reactions in screening for hepatitis C virus antibodies. Schröter M, et al. **J Clin Microbiol** 1999 Jan;37(1):233-4

A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Kuboki M, et al. **Liver** 1999 Apr;19(2):88-96

Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Sawabe M, et al. **Liver** 1999 Aug;19(4):335-42

Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Ok E, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3103-7

Anti-HCV seropositivity among haemodialysis patients of Iranian origin [letter] Rais-Jalali G, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2055-6

Serological and histological features of anti-HCV-positive individuals without serum HCV RNA. Kanno A, et al. **Tohoku J Exp Med** 1998 Dec;186(4):303-11

[Anti-HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot] Dubois F, et al. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):417-26 (11 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology of hepatitis C virus infection in 1,304 HCV positive patients: variations according to the origin of transmission and year of diagnosis] Guyader D, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):375-80 (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. Majid A, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):317-25

Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. Encke J, et al. **J Immunol** 1998 Nov 1;161(9):4917-23

Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. Fournillier A, et al. **J Virol** 1999 Sep;73(9):7497-504

BLOOD

Analysis of human immune response to potential hepatitis C viral epitopes. Khanna A, et al. **Acta Virol** 1998 Jun; 42(3):141-5

Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes. Toyoda H, et al. **Am J Gastroenterol** 1999 Aug;94(8):2230-6

Can risk factor screening predict hepatitis C antibody reactivity? Magriples U, et al. **Am J Perinatol** 1998 Jun; 15(6):395-8

Distribution of HCV genotypes among different exposure categories in Brazil. Oliveira ML, et al. **Braz J Med Biol Res** 1999 Mar;32(3):279-82

Hepatitis C virus-specific DNA sequences in human DNA: differentiation by means of restriction enzyme analysis at the DNA level in healthy, anti-HCV-negative individuals. Dennin RH, et al. **Clin Chem Lab Med** 1999 Jun; 37(6):623-30

Hepatitis C virus RNA viremia in Central Africa [letter] Cancré N, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):484-5

Humoral immunity in acute and chronic hepatitis C infection [letter; comment] Zein NN, et al. **Gastroenterology** 1999 Aug;117(2):510. Comment on: Gastroenterology 1999 Jan;116(1):135-43.

Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Beld M, et al. **Hepatology** 1999 Apr; 29(4):1288-98

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Ishii K, et al. **Hepatology** 1998 Oct; 28(4):1117-20

Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. Mondelli MU, et al. **Hepatology** 1999 Aug;30(2):537-45

Importance of RT-PCR for detection of hepatitis C virus among different patient groups. Ramalingam S, et al. **Indian J Med Res** 1998 Sep;108:85-7

Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Miura H, et al. **Int J Dermatol** 1999 Apr; 38(4):310-4

Significance of repeatedly normal aminotransferase activities in HCV-infected patients. Zylberberg H, et al. **J Clin Gastroenterol** 1999 Jul;29(1):71-5

Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies. Beld M, et al. **J Clin Microbiol** 1998 Oct; 36(10):3002-6

Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection. Chien DY, et al. **J Clin Microbiol** 1999 May;37(5):1393-7

Detection of antibodies to hepatitis C virus in dried blood spot samples from mothers and their offspring in Lahore, Pakistan. Parker SP, et al. **J Clin Microbiol** 1999 Jun; 37(6):2061-3

Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. Stapleton JT, et al. **J Clin Microbiol** 1999 Mar;37(3):484-9

Seroepidemiology of hepatitis C virus infection among drug abusers in southern Taiwan. Chang CJ, et al. **J Formos Med Assoc** 1998 Dec;97(12):826-9

Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. Kumar RM, et al. **J Hepatol** 1998 Aug;29(2):191-7

Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. Scognamiglio P, et al. **J Immunol** 1999 Jun 1;162(11):6681-9

Serum levels of thyroid-stimulating hormone receptor antibodies during IFN-alpha2a treatment of chronic hepatitis C [published erratum appears in J Interferon Cytokine Res 1999 Apr;19(4):428] Wada M, et al. **J Interferon Cytokine Res** 1999 Jan;19(1):85-8

Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis. Allain JP, et al. **J Med Virol** 1999 Sep; 59(1):25-31

IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Negro F, et al. **J Med Virol** 1998 Nov;56(3):224-9

Development of low cost peptide-based anti-hepatitis C virus screening and confirmatory assays: comparison with commercially available tests. Palacios A, et al. **J Med Virol** 1999 Jul;58(3):221-6

Multicenter study on hepatitis C virus infection in patients with dilated cardiomyopathy. North Italy Transplant Program (NITP). Prati D, et al. **J Med Virol** 1999 Jun; 58(2):116-20

Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Zein NN, et al. **Mayo Clin Proc** 1999 May;74(5):454-60

High prevalence of hepatitis C virus antibodies in older patients with membranoproliferative glomerulonephritis [letter] Ohsawa I, et al. **Nephron** 1999;82(4):366-7

Different reactivity against HCV proteins (RIBA 3) according to progression of liver damage. Barbacini IG, et al. **Panminerva Med** 1998 Dec;40(4):269-72

Transplacental transmission of hepatitis C virus in HIV-negative mothers. Agha S, et al. **Res Virol** 1998 Jul-Aug;149(4):229-34

Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. Morisco F, et al. **Res Virol** 1998 Sep-Oct;149(5):277-82

TOFE human-B-cell-line-based adsorption-inhibition assay to detect HCV neutralizing antibodies. Valli MB, et al. **Res Virol** 1998 Sep-Oct;149(5):331-3

Elevated alanine aminotransferase (ALT) in blood donors: an assessment of the main associated conditions and its relationship to the development of hepatitis C. Gonçales Júnior FL, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):219-24

Lack of correlation between sensitivity characteristics of the tests for hepatitis C virus antibodies estimated with serially diluted and natural low-reactive control specimens. Bondarenko IG, et al. **Scand J Clin Lab Invest** 1999 Apr; 59(2):153-8

Failure of third-generation recombinant immunoblot assay to detect hepatitis C virus core antibodies [letter] Hennig H, et al. **Transfusion** 1999 Mar;39(3):335-6

Pretransplant anti-hepatitis C virus antibody and HCV-RNA-polymerase chain reaction as predictor of posttransplant liver dysfunction. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):3216-7

Evaluation of third generation anti-HCV enzyme immunoassays. Panigrahi AK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):105-7

Use of overlapping synthetic peptides to characterize samples from blood donors with indeterminate results to hepatitis C virus core antigen. León P, et al. **Vox Sang** 1998; 75(1):32-6

Persistence of HCV-RNA in a blood donor with negative antibody assays [letter] Rapicetta M, et al. **Vox Sang** 1999; 76(3):192-3

Characteristics of hepatocellular carcinoma in patients with negative virus markers: clinicopathologic study of resected tumors. Shiraishi M, et al. **World J Surg** 1999 Mar; 23(3):301-5

[Study on HCV infection and the distribution of HCV genotypes in different populations in Shenyang area] Huang F, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun;19(3):134-7 (Eng. Abstr.) **(Chi)**

[An epidemiological study on the rate of becoming chronic in HCV infection] Ni J, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):144-6 (Eng. Abstr.) **(Chi)**

[Follow-up studies on hepatitis G infection in plasma donors with positive antibody against hepatitis C] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):269-71 (Eng. Abstr.) **(Chi)**

[Prevalence of serum markers of hepatitis B and C virus in blood donors of Nouakchott, Mauritania] Lo BB, et al. **Bull Soc Pathol Exot** 1999 May;92(2):83-4 (Eng. Abstr.) **(Fre)**

[Infection with hepatitis C virus in a prison environment. A prospective study in Loos-lez-Lille, France] Hedouin V, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):55-8 (Eng. Abstr.) **(Fre)**

[Prevalence of anti-HCV antibody positivity and seroconversion incidence in hemodialysis patients] Biamino E, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):53-5 (Eng. Abstr.) **(Ita)**

DIAGNOSTIC USE

Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. Doughty AL, et al. **Liver Transpl Surg** 1999 Jan;5(1):40-5

IMMUNOLOGY

Vertical transmission of HCV. La Torre A, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):889-92

Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein. Heintges T, et al. **Biochem Biophys Res Commun** 1999 Sep 24; 263(2):410-8

IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Toniutto P, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):69-73

Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. Casino C, et al. **J Clin Microbiol** 1999 Aug;37(8):2726-8

High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow-up. Feucht HH, et al. **J Clin Virol** 1999 Jun;13(1-2):43-51

Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. Park YM, et al. **J Korean Med Sci** 1999 Apr;14(2):165-70

New monoclonal antibodies against a recombinant second envelope protein of Hepatitis C virus. Inudoh M, et al. **Microbiol Immunol** 1998;42(12):875-7

Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Gane EJ, et al. **Transplantation** 1999 Jan 15;67(1):78-84

Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Esumi M, et al. **Virology** 1998 Nov 10;251(1):158-64

Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Shang D, et al. **Virology** 1999 Jun 5;258(2):396-405

Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus. Zhou YH, et al. **Virology** 1999 Apr 10; 256(2):360-70

[Hepatitis G virus in blood donors] Moncharmont P, et al. **Presse Med** 1999 Feb 13;28(6):269-72 (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

[HCV and HBV prevalence in hemodialyzed pediatric patients. Multicenter study] Cañero-Velasco MC, et al. **Acta Gastroenterol Latinoam** 1998;28(3):265-8 (Eng. Abstr.) **(Spa)**

HEPATITIS C ANTIGENS

Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Martin J, et al. **Cytokine** 1999 Apr; 11(4):267-73

ANALYSIS

Identification of antigenic sites on three hepatitis C virus proteins using phage-displayed peptide libraries. Pereboeva LA, et al. **J Med Virol** 1998 Oct;56(2):105-11

Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients

with cholestatic hepatitis. Doughty AL, et al. **Liver Transpl Surg** 1999 Jan;5(1):40–5

[Pathological features of hepatocellular carcinoma carrying hepatitis C virus antigen] Liu B, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct;26(5):297–300 (Eng. Abstr.) **(Chi)**

BLOOD

Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Beld M, et al. **Blood** 1999 Aug 15; 94(4):1183–91

IMMUNOLOGY

Analysis of human immune response to potential hepatitis C viral epitopes. Khanna A, et al. **Acta Virol** 1998 Jun; 42(3):141–5

Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. Woitas RP, et al. **AIDS** 1999 Jul 30;13(11):1313–22

IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Toniutto P, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):69–73

In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. Eckels DD, et al. **Hum Immunol** 1999 Mar; 60(3):187–99

Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies. Beld M, et al. **J Clin Microbiol** 1998 Oct; 36(10):3002–6

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. Hiranuma K, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):187–93

Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. Rodriguez-López M, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):727–38

The impact of HCV genotypes on seroreactivity against HCV antigens immobilized on the RIBA 3.0 SIA [letter] Jain N, et al. **J Hepatol** 1999 Jan;30(1):173

Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. Encke J, et al. **J Immunol** 1998 Nov 1;161(9):4917–23

Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. Park YM, et al. **J Korean Med Sci** 1999 Apr;14(2):165–70

HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. Jolivet-Reynaud C, et al. **J Med Virol** 1998 Dec; 56(4):300–9

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. Schlaak JF, et al. **J Med Virol** 1998 Oct;56(2):112–7

Different reactivity against HCV proteins (RIBA 3) according to progression of liver damage. Barbacini IG, et al. **Panminerva Med** 1998 Dec;40(4):269–72

Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus. Zhou YH, et al. **Virology** 1999 Apr 10; 256(2):360–70

HEPATITIS C, CHRONIC

Hepatitis C. Issues for women and their partners. Mazza D. **Aust Fam Physician** 1998 Sep;27(9):795–8

Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Loriot MA, et al. **Hepatology** 1999 May;29(5):1587–95

Changing terminology of hepatitis B and C carrier: consensus statement. Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S15–20 (0 ref.)

Report on "The Asian collaborative survey on hepatitis B and C virus carriers". Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S3–5

"Hepatitis B and C: carrier to cancer--Asian perspectives": pre-conference expert group deliberations. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S9–14

Results of "The Asian collaborative survey on hepatitis B and C virus carriers: how do you assess?". The Indian Association for Study of the Liver (INASL). **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S6–8

Hepatitis B and C: carrier to cancer--current trends [editorial] Williams R. **Indian J Gastroenterol** 1999 Mar;18 Suppl 1:S2

Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. Ninomiya T, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):68–74

Chronic hepatitis C: the virus, its discovery and the natural history of the disease. Booth JC. **J Viral Hepat** 1998 Jul; 5(4):213–22 (111 ref.)

Hepatitis C virus infection: pathogenesis, diagnosis and treatment. Pär A, et al. **Scand J Gastroenterol Suppl** 1998; 228:107–14 (46 ref.)

Hepatitis C. Lindsay KL, et al. **West J Med** 1998 Dec; 169(6):372–3

BLOOD

Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Lo Iacono O, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1091–9

Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Goldstein NS, et al. **Am J Clin Pathol** 1999 Jun;111(6):811–6

Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Bayati N, et al. **Am J Gastroenterol** 1998 Dec;93(12):2452–6

Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Sugano S, et al. **Am J Gastroenterol** 1998 Dec;93(12):2441–4

The effect of interferon therapy on erythrocyte membrane Na+,K+ ATP activity in patients with chronic hepatitis B and C virus infections. Kuralay F, et al. **Biochem Mol Biol Int** 1998 Sep;45(6):1189–98

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Martin J, et al. **Cytokine** 1998 Aug; 10(8):635–44

Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Ninomiya T, et al. **Dig Dis Sci** 1999 May;44(5):1027–33

Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Walsh KM, et al. **Dig Dis Sci** 1999 Mar;44(3):624–30

Making end points meet. Koretz RL. **Gastroenterology** 1999 May;116(5):1266–7

Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Kuratsune H, et al. **Int J Mol Med** 1998 Jul;2(1):51–6

Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-beta in patients with chronic hepatitis C. Ohno Y, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3681–7

Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN [see comments] Fabris P, et al. **J Gastroenterol** 1999 Jun;34(3):345–50. Comment in: J Gastroenterol 1999 Jun;34(3):426–7.

Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. Murawaki Y, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):680–4

Serum level of interleukin-4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C [letter; comment] Higashi N, et al. **J Hepatol** 1999 Aug;31(2):383. Comment on: J Hepatol 1997 Mar;26(3):471–8.

Serum levels of soluble Fas antigen in chronic hepatitis C patients. Iio S, et al. **J Hepatol** 1998 Oct;29(4):517–23

Effects of long-term interferon-alpha treatment on glucose tolerance in patients with chronic hepatitis C. Ito Y, et al. **J Hepatol** 1999 Aug;31(2):215–20

Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. Tsushima H, et al. **J Hepatol** 1999 Jan;30(1):1–7

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. Zylberberg H, et al. **J Hepatol** 1999 Feb;30(2):185–91

Genomic and phylogenetic analysis of hepatitis C virus strains from Argentina. Quarleri JF, et al. **Medicina (B Aires)** 1998; 58(2):153–9

[Influence of pregnancy in chronic hepatitis C virus infection] Romero-Gómez M, et al. **Med Clin (Barc)** 1998 Nov 21; 111(17):641–4 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):431–7 (53 ref.)

Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection. Davidovitz Y, et al. **Acta Haematol** 1998;100(4):213–5

Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Yu MW, et al. **Am J Epidemiol** 1999 Aug 15;150(4):367–74

Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Barkhuizen A, et al. **Am J Gastroenterol** 1999 May; 94(5):1355–60

A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Bonis PA, et al. **Am J Gastroenterol** 1999 Jun;94(6):1605–12

Prevalence and clinical significance of TT virus coinfection in patients with chronic hepatitis C treated with interferon [letter] Brandhagen DJ, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1715–6

The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Brandhagen DJ, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1000–5

Evaluation by ultrasound of abdominal lymphadenopathy in chronic hepatitis C. Soresi M, et al. **Am J Gastroenterol** 1999 Feb;94(2):497–501

Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia. Waldron P. **Am J Hematol** 1999 Jun;61(2):130–4

Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy [see comments] Ohta S, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1040–8. Comment in: Am J Kidney Dis 1999 Jun;33(6):1174–6.

Primary central nervous system lymphoma, presenting as diabetes insipidus, as a sequela of hepatitis C [letter] Agarwal S, et al. **Am J Med** 1999 Sep;107(3):303–4

Waldenstrom's macroglobulinemia in a patient with cirrhosis and chronic hepatitis C infection [letter] Trotter JF. **Am J Med** 1999 Sep;107(3):299–300

Primary hepatic diffuse large B-cell lymphoma in a patient with chronic hepatitis C. Rubbia-Brandt L, et al. **Am J Surg Pathol** 1999 Sep;23(9):1124–30

Effect of schistosomiasis and hepatitis on liver disease. Halim AB, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):915–20

Acute hepatitis A in patients with chronic hepatitis C [letter] Heibling B, et al. **Ann Intern Med** 1999 Aug 17;131(4):314

Autoimmune thrombocytopenic purpura and dermatomyositis associated with chronic hepatitis C. A therapeutic dilemma. Moccia F. **Ann Ital Med Int** 1998 Oct-Dec;13(4):240–3

Clinical course of concomitant Hbv and Hcv infection in renal allograft recipients. Durlik M, et al. **Ann Transplant** 1996;1(2):11–2

Hepatitis C virus (HCV) infection: serum rheumatoid factor activity and HCV genotype correlate with cryoglobulin clonality [letter] Antonescu C, et al. **Blood** 1998 Nov 1; 92(9):3486–7

Pyoderma gangrenosum and hepatitis C virus infection [letter] Keane FM, et al. **Br J Dermatol** 1998 Nov; 139(5):924–5

Chronic hepatitis c virus infection and primary cutaneous B-cell lymphoma [letter] Prati D, et al. **Br J Haematol** 1999 Jun;105(3):841

Hepatocellular carcinoma and coinfection with hepatitis B and C. Making a difficult situation worse [editorial; comment] Kurtz RC. **Cancer** 1999 Sep 1;86(5):741–3. Comment on: Cancer 1999 Sep 1;86(5):793–8.

Hepatocellular carcinoma among hemodialysis patients infected with hepatitis C virus--early evolution and rapid progression [letter] Hayashi H, et al. **Clin Nephrol** 1999 May;51(5):321–3

Beneficial effect of phlebotomy on hepatitis C virus-associated musculoskeletal manifestations. Hilzenrat N, et al. **Clin Rheumatol** 1998;17(5):390–2

Pruritus as a presenting symptom of chronic hepatitis C. Chia SC, et al. **Dig Dis Sci** 1998 Oct;43(10):2177–83

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dufour JF, et al. **Dig Dis Sci** 1998 Dec;43(12):2573–6

Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection. Eddy S, et al. **Dig Dis Sci** 1999 Jan;44(1):186–9

Influence of hepatitis G virus coinfection on the clinical course of chronic hepatitis C. Cacopardo B, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):709–14

Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus infections on the risk of symptomatic liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Corrao G, et al. **Eur J Epidemiol** 1998 Jul;14(5):447–56

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Soriano V, et al. **Eur J Epidemiol** 1999 Jan;15(1):1–4

The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Haydon GH, et al. **Eur J Gastroenterol Hepatol** 1998 Jun; 10(6):485–9

Primary cutaneous B-cell lymphoma: an association of chronic hepatitis C infection. McKiernan S, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):669–72

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Kowdley KV. **Gastroenterology** 1999 Sep;117(3):738–9

Histological improvement of oral Lichen planus in patients with chronic hepatitis C treated with interferon [letter] Nagao Y, et al. **Gastroenterology** 1999 Jul;117(1):283–4

HCV and C282Y: a sinister synergism? Russo M, et al. **Gastroenterology** 1999 Feb;116(2):494–5

HBV + HCV = HCC? [comment] Cramp ME. **Gut** 1999 Aug;45(2):168–9. Comment on: Gut 1999 Aug;45(2):284–8.

Hepatitis C virus infection and mixed cryoglobulinemia in patients with lymphoproliferative diseases [letter] Domingo JM, et al. **Haematologica** 1999 Jan;84(1):94–6

Detection of non-Hodgkin's lymphoma liver disease in cirrhotic patients [letter] Picardi M, et al. **Haematologica** 1999 Mar;84(3):278–9

Idiopathic dilated cardiomyopathy: lack of association with

hepatitis C virus infection. Dalekos GN, et al. **Heart** 1998 Sep;80(3):270–5

Association of diabetes mellitus and chronic hepatitis C virus infection [letter; comment] Balik I, et al. **Hepatology** 1999 Aug;30(2):584. Comment on: Hepatology 1999 Feb;29(2):328–33.

Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Caronia S, et al. **Hepatology** 1999 Oct;30(4):1059–63

Diabetes mellitus and chronic hepatitis C virus infection [see comments] Hadziyannis S, et al. **Hepatology** 1999 Feb; 29(2):604–5. Comment in: Hepatology 1999 Feb;29(2):328–33.

No evidence for anti-islet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection [letter; comment] Harman-Boehm I, et al. **Hepatology** 1999 Jul; 30(1):342. Comment on: Hepatology 1999 Feb;29(2):328–33.

Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis [letter; comment] Hézode C, et al. **Hepatology** 1999 Apr;29(4):1338. Comment on: Hepatology 1998 Jun;27(6):1695–9.

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Ikeda K, et al. **Hepatology** 1999 Apr;29(4):1124–30

Association of diabetes mellitus and chronic hepatitis C virus infection [see comments] Mason AL, et al. **Hepatology** 1999 Feb;29(2):328–33. Comment in: Hepatology 1999 Feb;29(2):604–5.

Prognosis of chronic hepatitis C: results of a large, prospective cohort study [see comments] Niederau C, et al. **Hepatology** 1998 Dec;28(6):1687–95. Comment in: Hepatology 1998 Dec;28(6):1710–2.

Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Rasul I, et al. **Hepatology** 1999 Feb;29(2):543–7

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Shiratori Y, et al. **Hepatology** 1999 May;29(5):1573–80

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Valla DC, et al. **Hepatology** 1999 Jun; 29(6):1870–5

Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Dutta U, et al. **Hum Pathol** 1998 Nov; 29(11):1279–84

Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Antonaci S, et al.
Immunopharmacol Immunotoxicol 1998 Nov;20(4):455–72 (62 ref.)

HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C. Fabris P, et al. **Infection** 1998 Sep–Oct; 26(5):283–7

Acquired factor VIII inhibitor in a non-hemophilic patient with chronic hepatitis C viral infection. Sugishita K, et al. **Intern Med** 1999 Mar;38(3):283–6

HGV infection in a cohort of patients with chronic active hepatitis HCV related [letter] Capra F, et al.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):443

Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Guido M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):414–7

Cryoglobulinaemic membranoproliferative glomerulonephritis and hepatits C virus infection [see comments] Mazzaro C, et al.
Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):45–53. Comment in: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):54–5.

Natural history of chronic hepatitis C [see comments] Pagliaro L, et al. **Ital J Gastroenterol Hepatol** 1999 Jan–Feb;31(1):28–44 (152 ref.). Comment in: Ital J Gastroenterol Hepatol 1999 Jan–Feb;31(1):1–3.

Acquired angioedema associated with chronic hepatitis C. Farkas H, et al. **J Allergy Clin Immunol** 1999 Apr; 103(4):711–2

Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. Cheng JT, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1566–74

Hemolytic anemia secondary to alpha-interferon treatment in a patient with chronic C hepatitis [see comments] de-la-Serna-Higuera C, et al. **J Clin Gastroenterol** 1999 Jun;28(4):358–9. Comment in: J Clin Gastroenterol 1999 Jun;28(4):289–90.

Hemolytic anemia and the treatment of chronic hepatitis C [editorial; comment] Saab S, et al. **J Clin Gastroenterol** 1999 Jun;28(4):289–90. Comment on: J Clin Gastroenterol 1999 Jun;28(4):358–9.

Acute hepatic failure due to hepatosplenic B-cell non-Hodgkin's lymphoma in a patient infected with hepatitis C virus. Yoshikawa M, et al. **J Gastroenterol** 1998 Dec;33(6):880–5 (33 ref.)

Natural history of chronic hepatitis B and C. Imperial JC. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S1–5 (30 ref.)

Host- and disease-specific factors affecting steatosis in chronic hepatitis C. Czaja AJ, et al. **J Hepatol** 1998 Aug; 29(2):198–206

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. Okanoue T, et al. **J Hepatol** 1999 Apr;30(4):653–9

Chronic liver disease and lymphoproliferative disorders in HCV-positive patients: a working hypothesis [letter] Persico M, et al. **J Hepatol** 1998 Nov;29(5):857–8

Hepatitis C virus infection-associated non-cryoglobulinaemic monoclonal IgMkappa gammopathy responsive to interferon-alpha treatment. Schott P, et al. **J Hepatol** 1998 Aug;29(2):310–5

Extrahepatic manifestations of HCV infection: facts and controversies. Zignego AL, et al. **J Hepatol** 1999 Aug; 31(2):369–76 (99 ref.)

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. Eyster ME, et al.
J Infect Dis 1999 May;179(5):1062–9

TT virus infection in patients with hepatitis C: frequency, persistence, and sequence heterogeneity. Irving WL, et al. **J Infect Dis** 1999 Jul;180(1):27–34

Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. Verbaan H, et al. **J Intern Med** 1999 Feb;245(2):127–32

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. Fukuda R, et al.
J Med Virol 1999 Jul;58(3):201–7

Neurological manifestations of chronic hepatitis C. Heckmann JG, et al. **J Neurol** 1999 Jun;246(6):486–91

Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. Harada H, et al. **J Neurol Sci** 1999 Jun 1;165(2):182–3

Arthritis in patients with chronic hepatitis C virus infection. Rivera J, et al. **J Rheumatol** 1999 Feb;26(2):420–4

Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. Haydon GH, et al. **J Viral Hepat** 1998 Jul; 5(4):255–64

Prevalence of GBV-C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. El-Zayadi AR, et al. **J Virol Methods** 1999 Jun; 80(1):53–8

Thyroid cancer in patients with hepatitis C infection [letter] Antonelli A, et al. **JAMA** 1999 May 5;281(17):1588

Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. Dammacco F, et al. **Leuk Lymphoma** 1998 Nov; 31(5-6):463–76 (89 ref.)

Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Bini EJ, et al. **Mayo Clin Proc** 1999 Apr; 74(4):367–70

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. Cacciola I, et al.
N Engl J Med 1999 Jul 1;341(1):22–6

Hepatitis viruses and hepatocellular carcinoma. Kew MC. **Res Virol** 1998 Sep–Oct;149(5):257–62 (55 ref.)

Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Younossi ZM, et al. **Transplantation** 1999 Jan 27;67(2):272–5

Association of chronic hepatitis C infection and diabetes mellitus. el-Zayadi AR, et al. **Trop Gastroenterol** 1998 Oct-Dec;19(4):141–4

Orthotopic liver transplantation for hepatitis C infection: the best Christmas present? Johnston SD, et al.
Ulster Med J 1998 Nov;67(2):134–6

[Hepatitis C and neurological disorders (editorial; comment)] Cacoub P. **Gastroenterol Clin Biol** 1998 Nov;22(11):889–90 (14 ref.). Comment on: Gastroenterol Clin Biol 1998 Nov;22(11):891–6. **(Fre)**

[Peripheral neuropathies and chronic hepatitis C: a frequent association? (see comments)] Ripault MP, et al.
Gastroenterol Clin Biol 1998 Nov;22(11):891–6 (Eng. Abstr.). Comment in: Gastroenterol Clin Biol 1998 Nov;22(11):889–90. **(Fre)**

[Cryoglobulinemia related to the hepatitis B and C viruses] Cohen P. **Pathol Biol (Paris)** 1999 Mar;47(3):232–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Interactions between the human immunodeficiency virus and hepatitis C virus] Pol S, et al. **Rev Med Interne** 1998 Dec; 19(12):885–91 (48 ref.) (Eng. Abstr.) **(Fre)**

[Occurrence of non-Hodgkin's lymphoma in chronic viral hepatitis C] Vuillemin E, et al. **Rev Med Interne** 1998 May; 19(5):341–3 (Eng. Abstr.) **(Fre)**

[Skin diseases associated with chronic hepatitis C] Podányi B, et al. **Orv Hetil** 1998 Nov 1;139(44):2633–7 (33 ref.) (Eng. Abstr.) **(Hun)**

[Chronic HCV hepatopathy and cryoglobulinemia. The associated clinical spectrum] Pellicano R, et al.
Minerva Med 1999 Jan-Feb;90(1-2):1–5 (Eng. Abstr.) **(Ita)**

[Occurrence of hepatocellular carcinoma in patients with chronic hepatitis C who continued to be HCV-RNA negative for up to 3 years by interferon] Miyao N, et al.
Nippon Shokakibyo Gakkai Zasshi 1999 May;96(5):535–9 **(Jpn)**

[Extrahepatic manifestations of chronic hepatitis C] Ignatova TM, et al. **Ter Arkh** 1998;70(11):9–16 (Eng. Abstr.) **(Rus)**

[Characteristics of the carriers of antibodies to hepatitis C virus with normal transaminases levels in HIV infected patients] Ramos Paesa C, et al. **An Med Interna** 1998 Sep; 15(9):459–63 (Eng. Abstr.) **(Spa)**

[Viremia levels of the chronic hepatitis c virus in HIV infected patients, clinical implications] Ramos Paesa C, et al. **An Med Interna** 1998 Sep;15(9):464–9 (Eng. Abstr.) **(Spa)**

[Chronic hepatitis C virus positive hepatitis and antiphospholipid syndrome] Calvo Romero JM, et al.
Gastroenterol Hepatol 1998 Nov;21(9):437–8 (10 ref.) (Eng. Abstr.) **(Spa)**

[High prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection (letter)] Guerreo Igea FJ, et al.
Med Clin (Barc) 1998 Nov 21;111(17):676–7 **(Spa)**

[Mixed cryoglobulinemia due to hepatitis C viral infection in a post-liver transplant patient (letter)] López Hidalgo JL, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):117–8 (10 ref.) **(Spa)**

[Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population] Muñoz G, et al. **Rev Med Chil** 1998 Sep;126(9):1035–42 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Multifocal fatty infiltration of the liver; an aspecific presentation form of hepatitis C infection. Van Vlierberghe H, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep;61(3):379–81

Hepatitis C: implications for the general physician. Fallon HJ. **Compr Ther** 1999 May;25(5):253–7 (8 ref.)

Interaction of alcohol and hepatitis C virus infection on severity of liver disease. Nevins CL, et al. **Dig Dis Sci** 1999 Jun;44(6):1236–42

Epidemiological risk factors and clinico-pathological presentation in chronic hepatitis C. Lo Iacono O, et al.
Hepatogastroenterology 1998 Sep–Oct;45(23):1715–21

Chronic liver disease and hepatitis C virus in Egyptian patients. El-Medany OM, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1895–903

Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. Stapleton JT, et al. **J Clin Microbiol** 1999 Mar;37(3):484–9

Superinfection of TT virus and hepatitis C virus among chronic haemodialysis patients. Ikeuchi T, et al.
J Gastroenterol Hepatol 1999 Aug;14(8):796–800

Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. Luo JC, et al.
J Gastroenterol Hepatol 1998 Jul;13(7):685–90

Glomerulonephritis [letter] Durand JM, et al. **Lancet** 1999 Jul 31;354(9176):428–9

New perspectives in the diagnosis of hepatitis C. Schiff ER, et al. **Semin Liver Dis** 1999;19 Suppl 1:3–15 (48 ref.)

[Aquagenic pruritus and hepatitis C] Gregor M.
Internist (Berl) 1999 Feb;40(2):220–1 **(Ger)**

[The natural course of hepatitis B and hepatitis C virus infection] Schwabe RF, et al.
Schweiz Rundsch Med Prax 1998 Oct 14;87(42):1403–7 (56 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. Poynard T, et al.
Acta Gastroenterol Belg 1998 Oct-Dec;61(4):431–7 (53 ref.)

Up to date treatment of hepatitis C in adults. Schalm SW, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):397–9 (12 ref.)

Pure red cell aplasia responsive to interferon-alpha in a patient with hepatitis C virus infection. Davidovitz Y, et al. **Acta Haematol** 1998;100(4):213–5

Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Kamei S, et al. **Acta Neurol Scand** 1999 Jul;100(1):25–33

Management of chronic hepatitis C in HIV-infected patients [editorial] Soriano V, et al. **AIDS** 1999 Apr 1;13(5):539–46 (74 ref.)

Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Lo Iacono O, et al.
Aliment Pharmacol Ther 1998 Nov;12(11):1091–9

Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy. Moreno-Monteagudo JA, et al.
Aliment Pharmacol Ther 1998 Aug;12(8):717–23

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Barbaro G, et al. **Am J Gastroenterol** 1998 Dec;93(12):2445–51

A pilot study of rimantadine for patients with chronic hepatitis C unresponsive to interferon therapy. Fong TL, et al. **Am J Gastroenterol** 1999 Apr;94(4):990–3

Treatment of chronic hepatitis C with amantadine [letter] Hubert IF, et al. **Am J Gastroenterol** 1999 Aug;94(8):2316–7

A randomized, double-blind, controlled trial of consensus

interferon in the treatment of Chinese patients with chronic hepatitis C. Hwang SJ, et al. **Am J Gastroenterol** 1999 Sep; 94(9):2496–500

Response to retreatment with interferon–alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence. Ibarrola N, et al. **Am J Gastroenterol** 1999 Sep;94(9):2487–95

Interferon–induced hepatic failure in a patient with hepatitis C [letter] Lock G, et al. **Am J Gastroenterol** 1999 Sep; 94(9):2570–1

Interferon alpha–2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial [see comments] Barbaro G, et al. **Am J Med** 1999 Aug; 107(2):112–8. Comment in: Am J Med 1999 Aug;107(2):180–1.

Oral thymic extract to treat hepatitis C [letter] Blank RD. **Ann Intern Med** 1999 Aug 17;131(4):312

Oral thymic extract to treat hepatitis C [letter] Frossard JL. **Ann Intern Med** 1999 Aug 17;131(4):312

Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double–blind, placebo–controlled trial. Raymond RS, et al. **Ann Intern Med** 1998 Nov 15;129(10):797–800

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Yoshida H, et al. **Ann Intern Med** 1999 Aug 3;131(3):174–81

Autoimmune thrombocytopenic purpura and dermatomyositis associated with chronic hepatitis C. A therapeutic dilemma. Moccia F. **Ann Ital Med Int** 1998 Oct–Dec;13(4):240–3

High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus [letter] Sookoian S, et al. **Arch Dermatol** 1999 Aug;135(8):1000–1

Failure to respond to interferon–alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Kageyama F, et al. **Biol Trace Elem Res** 1998 Summer;64(1–3):185–96

Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia [letter] Donada C, et al. **Blood** 1998 Oct 15;92(8):2983–4

Ribavirin and interferon alfa–2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Khakoo S, et al. **Br J Clin Pharmacol** 1998 Dec;46(6):563–70

Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Shindo M, et al. **Cancer** 1999 May 1;85(9):1943–50

Kinetics of serum soluble tumour necrosis factor receptor (TNF–R) type–I and type–II after a single interferon–alpha (IFN–alpha) injection in chronic hepatitis C. Fabris C, et al. **Clin Exp Immunol** 1999 Sep;117(3):556–60

mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)–infected patients: effects of interferon–alpha (IFN–alpha) treatment. Shapiro S, et al. **Clin Exp Immunol** 1998 Oct;114(1):55–60

Pericarditis after therapy with interferon–alpha for chronic hepatitis C. Boonen A, et al. **Clin Rheumatol** 1999; 18(2):177–9

Regression of hepatic fibrosis in hepatitis C with long–term interferon treatment. Dufour JF, et al. **Dig Dis Sci** 1998 Dec;43(12):2573–6

A prospective evaluation of dermatological side–effects during alpha–interferon therapy for chronic viral hepatitis. Dalekos GN, et al. **Eur J Gastroenterol Hepatol** 1998 Nov; 10(11):933–9

Severe hypertriglyceridaemia in a non–diabetic patient after alpha–interferon [letter] Elisaf M, et al. **Eur J Gastroenterol Hepatol** 1999 Apr;11(4):463

The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Kikuchi I, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):859–63

Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Kowdley KV. **Gastroenterology** 1999 Sep;117(3):738–9

Interferon–ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Schalm SW, et al. **Gastroenterology** 1999 Aug;117(2):408–13

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Sobesky R, et al. **Gastroenterology** 1999 Feb;116(2):378–86

A case of akathisia during interferon–alpha therapy for chronic hepatitis type C [letter] Horikawa N, et al. **Gen Hosp Psychiatry** 1999 Mar–Apr;21(2):134–5

Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus [see comments] Cresta P, et al. **Gut** 1999 Jul; 45(1):122–8. Comment in: Gut 1999 Jul;45(1):8–9.

Adding ribavirin to interferon alpha–2b for chronic hepatitis C infection increased virological response and nausea. Schalm SW. **Gut** 1998 Nov;43(5):602

Therapy for chronic hepatitis B and C infection in haemophilia. Dusheiko GM. **Haemophilia** 1998 Jul; 4(4):577–86 (65 ref.)

Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon–alpha–2b treatment. Laursen AL, et al. **Haemophilia** 1998 Jan; 4(1):25–32

Tauroursodeoxycholic acid for the treatment of HCV–related chronic hepatitis: a multicenter placebo–controlled study. Crosignani A, et al. **Hepatogastroenterology** 1998 Sep–Oct; 45(23):1624–9

Interferon alpha treatment of chronic hepatitis C in HIV–infected patients receiving zidovudine: efficacy, tolerance and response related factors. Del Pozo MA, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1695–701

Initial daily interferon administration can gain more eradication of HCV–RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Nakamura H, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1131–9

The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial. Nakamura H, et al. **Hepatogastroenterology** 1998 Jul–Aug; 45(22):1045–55

Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. Wedemeyer H, et al. **Hepatogastroenterology** 1998 Jul–Aug;45(22):1062–8

Reduction of health–related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group [see comments] Bonkovsky HL, et al. **Hepatology** 1999 Jan;29(1):264–70. Comment in: Hepatology 1999 Jan;29(1):277–9.

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long–term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Ikeda K, et al. **Hepatology** 1999 Apr;29(4):1124–30

r–Interferon alfa–2b/ribavirin combined therapy followed by low–dose r–interferon alfa–2b in chronic hepatitis C interferon nonresponders [letter; comment] Perasso A, et al. **Hepatology** 1999 Jan;29(1):297–8. Comment on: Hepatology 1998 Aug;28(2):341–6.

A phase I/II study of recombinant human interleukin–12 in patients with chronic hepatitis C. Zeuzem S, et al. **Hepatology** 1999 Apr;29(4):1280–7

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Alric L, et al. **Hum Immunol** 1999 Jun;60(6):516–23

Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ascione A, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):517–23

Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus–related chronic hepatitis with reference to the genotype [letter] Belloni G, et al. **Ital J Gastroenterol Hepatol** 1999 Jun–Jul;31(5):427

Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non–responders [see comments] Brillanti S, et al. **Ital J Gastroenterol Hepatol** 1999 Mar; 31(2):130–4. Comment in: Ital J Gastroenterol Hepatol 1999 Mar;31(2):135–6.

"Breakthrough" during interferon therapy for chronic hepatitis C. Overview on the diagnosis, possible aetiology and recommendations for management. Colloredo G, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):333–7 (37 ref.)

Amantadine in the treatment of patients with chronic hepatitis C. Foster GR. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):614–5

Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus [comment] Iino S. **Ital J Gastroenterol Hepatol** 1999 Apr; 31(3):216–7. Comment on: Ital J Gastroenterol Hepatol 1999 Apr;31(3):211–5.

Combination therapy for chronic hepatitis C [comment] Marcellin P. **Ital J Gastroenterol Hepatol** 1999 Mar; 31(2):135–6. Comment on: Ital J Gastroenterol Hepatol 1999 Mar;31(2):130–4.

Retreatment of non–responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone [see comments] Milella M, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):211–5. Comment in: Ital J Gastroenterol Hepatol 1999 Apr;31(3):216–7.

Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV–RNA in chronic hepatitis C patients. Tabone M, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):611–3

Pharmacokinetics of alphaIFN–2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. Rostaing L, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2344–8

Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report. Nyberg L, et al. **J Clin Gastroenterol** 1999 Jun;28(4):313–6

Enhancing the response to interferon–alpha. Begemann F, et al. **J Clin Virol** 1999 Jun;13(1–2):1–7

Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha–IFN [see comments] Fabris P, et al. **J Gastroenterol** 1999 Jun;34(3):345–50. Comment in: J Gastroenterol 1999 Jun;34(3):426–7.

Antifibrogenic activity of interferon alpha in chronic hepatitis C [editorial; comment] Suou T. **J Gastroenterol** 1999 Jun; 34(3):426–7. Comment on: J Gastroenterol 1999 Jun;34(3):345–50.

Disappearance of serum HCV–RNA after short–term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis–like serological manifestations. Yoshikawa M, et al. **J Gastroenterol** 1999 Apr;34(2):269–74

Effect of ursodeoxycholic acid on autoimmune–associated chronic hepatitis C. Nakamura K, et al. **J Gastroenterol Hepatol** 1999 May;14(5):413–8

Long–term efficacy of interferon alpha treatment in chronic hepatitis C [letter] Berg T, et al. **J Hepatol** 1998 Sep; 29(3):511–2

Serum level of interleukin–4 is a possible marker of therapeutic response to interferon treatment in patients with chronic hepatitis C [letter; comment] Higashi N, et al. **J Hepatol** 1999 Aug;31(2):383. Comment on: J Hepatol 1997 Mar;26(3):471–8.

Effects of long–term interferon–alpha treatment on glucose tolerance in patients with chronic hepatitis C. Ito Y, et al. **J Hepatol** 1999 Aug;31(2):215–20

Is there an optimal time to measure quantitative HCV RNA to predict non–response following interferon treatment for chronic HCV infection? McHutchison J, et al. **J Hepatol** 1998 Sep;29(3):362–8

Treatment of chronic hepatitis C with alpha–interferon plus ofloxacin in patients not responding to alpha–interferon alone. Negro F, et al. **J Hepatol** 1998 Sep;29(3):369–74

Severe anemia following combined alpha–interferon/ribavirin therapy of chronic hepatitis C [letter] Tappero G, et al. **J Hepatol** 1998 Dec;29(6):1033–4

Correlation of interferon–induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN–alpha therapy. Antonelli G, et al. **J Interferon Cytokine Res** 1999 Mar;19(3):243–51

Serum intercellular adhesion molecule–1 and long–term response to IFN–alpha2b therapy in chronic hepatitis C. Bagnasco M, et al. **J Interferon Cytokine Res** 1998 Nov; 18(11):963–6

Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN–alpha in chronic hepatitis C. Fabris C, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):705–9

Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha–interferon: a possible autoimmune–microvascular pathogenesis. Cadoni G, et al. **J Laryngol Otol** 1998 Oct;112(10):962–3

Ratio of serum gamma–GT/ALT rather than ISDR variability is predictive for initial virological response to IFN–alpha in chronic HCV infection. Mihm S, et al. **J Med Virol** 1999 Jul;58(3):227–34

Prediction of successful outcome in a randomised controlled trial of the long–term efficacy of interferon alpha treatment for chronic hepatitis C. Vandelli C, et al. **J Med Virol** 1999 May;58(1):26–34

Neurological manifestations of chronic hepatitis C. Heckmann JG, et al. **J Neurol** 1999 Jun;246(6):486–91

A clinical study on bing gan ling oral liquid for treatment of hepatitis C. You S, et al. **J Tradit Chin Med** 1998 Sep; 18(3):209–14

Leucocyte interferon–alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. Cacopardo B, et al. **J Viral Hepat** 1998 Sep;5(5):333–9

Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. Davis GL, et al. **J Viral Hepat** 1998 Sep;5(5):313–21

Viral and host factors in the prediction of response to interferon–alpha therapy in chronic hepatitis C after long–term follow–up. Knolle PA, et al. **J Viral Hepat** 1998 Nov;5(6):399–406

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. Pockros PJ, et al. **J Viral Hepat** 1998 Jul;5(4):271–6

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. Sim H, et al. **J Viral Hepat** 1998 Jul;5(4):249–53

Long–term retreatment in chronic hepatitis C patients who were non–responders to an initial course of interferon–alpha 2b. Tong MJ, et al. **J Viral Hepat** 1998 Sep;5(5):323–31

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Gerotto M, et al. **J Virol** 1999 Sep;73(9):7241–7

Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. Pawlotsky JM, et al. **J Virol** 1999 Aug;73(8):6490–9

Cost–effectiveness of interferon treatment for hepatitis C [letter; comment] Henley E. **JAMA** 1999 Jun 9; 281(22):2083; discussion 2084. Comment on: JAMA 1998 Dec 23–30;280(24):2088–93.

Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Tanaka K, et al. **Jpn J Cancer Res** 1999 Apr;90(4):367–71

Relief from profound fatigue associated with chronic liver disease by long–term ondansetron therapy [letter] Jones EA. **Lancet** 1999 Jul 31;354(9176):397

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) [see comments] Poynard T, et al. **Lancet** 1998 Oct 31;352(9138):1426–32. Comment in: Lancet 1999 Feb 6;353(9151):499; discussion 500. Comment in: Lancet 1999 Feb 6;353(9151):499–500. Comment in: ACP J Club 1999 May–Jun;130(3):70.

Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Moscarella S, et al. **Liver** 1998 Oct;18(5):366–9

Secondary structure of the hepatitis C virus 5' untranslated region and efficacy of interferon therapy for chronic hepatitis C. Suzuki K, et al. **Liver** 1998 Oct;18(5):331–6

Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C. Walsh KM, et al. **Liver** 1998 Jun; 18(3):191–5

Rimantadine for treatment of hepatitis C infection in liver transplant recipients. Sherman KE, et al. **Liver Transpl Surg** 1999 Jan;5(1):25–8

Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C. Bini EJ, et al. **Mayo Clin Proc** 1999 Apr; 74(4):367–70

Hepatitis C: an economic evaluation of extended treatment with interferon. Shiell A, et al. **Med J Aust** 1999 Aug 16; 171(4):189–93

Interferon plus ribavirin for chronic hepatitis C. **Med Lett Drugs Ther** 1999 Jun 4;41(1054):53–4

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group [see comments] Davis GL, et al. **N Engl J Med** 1998 Nov 19;339(21):1493–9 . Comment in: N Engl J Med 1998 Nov 19;339(21):1549–50. Comment in: N Engl J Med 1999 Apr 15;340(15):1207; discussion 1208–9.

Combination therapy for hepatitis C infection [editorial; comment] Liang TJ. **N Engl J Med** 1998 Nov 19; 339(21):1549–50. Comment on: N Engl J Med 1998 Nov 19;339(21):1485–92. Comment on: N Engl J Med 1998 Nov 19;339(21):1493–9.

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments] McHutchison JG, et al. **N Engl J Med** 1998 Nov 19; 339(21):1485–92. Comment in: N Engl J Med 1998 Nov 19;339(21):1549–50. Comment in: N Engl J Med 1999 Apr 15;340(15):1207; discussion 1208–9.

Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment. Malaguarnera M, et al. **Panminerva Med** 1999 Mar;41(1):59–61

Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. Piccinino F, et al. **Res Virol** 1998 Sep–Oct;149(5):283–91

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Bell H, et al. **Scand J Gastroenterol** 1999 Feb;34(2):194–8

Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Murashima S, et al. **Scand J Infect Dis** 1999; 31(1):27–32

Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C. Weiland O, et al. **Scand J Infect Dis** 1999; 31(2):115–8

A case of interferon alpha-induced manic psychosis in chronic hepatitis C. Kanno A, et al. **Tohoku J Exp Med** 1999 Jan;187(1):79–82

Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Cattral MS, et al. **Transplantation** 1999 May 15;67(9):1277–80

[Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin] Fontaine H, et al. **Gastroenterol Clin Biol** 1999 Apr;23(4):541–4 **(Fre)**

[Interferon treatment of chronic hepatitis C viral hepatitis patients with normal transaminases (letter)] Remy AJ, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep;22(8–9):748–9 **(Fre)**

[Murderous impulses in two patients with chronic hepatitis C treated with interferon alpha (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):105–6 **(Fre)**

[Opinion on interferon-ribavirin association in the primary treatment of chronic hepatitis C] Bergmann JF. **Presse Med** 1999 Jan 16;28(2):77–8 **(Fre)**

[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C] Zeuzem S. **Dtsch Med Wochenschr** 1999 May 21;124(20):636–42 (42 ref.) **(Ger)**

[Experience with combined interferon alpha-2b and ribavirin in the therapy of chronic hepatitis C. Experience with one-year therapy of 100 patients. Multicenter study] Fehér J, et al. **Orv Hetil** 1999 May 30;140(22):1235–8 (Eng. Abstr.) **(Hun)**

[Combined polychemotherapy of patients with chronic hepatitis C] Nikitin IG, et al. **Klin Med (Mosk)** 1999; 77(5):24–6 **(Rus)**

[Interferon therapy in chronic hepatitis C and cellular immunity] Nikitin IG, et al. **Klin Med (Mosk)** 1999; 77(6):33–7 **(Rus)**

[Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome] Podymova SD, et al. **Klin Med (Mosk)** 1998;76(10):45–8 (Eng. Abstr.) **(Rus)**

[Experience in heptral treatment of diffuse liver diseases] Gorbakov VV, et al. **Ter Arkh** 1998;70(10):82–6 (Eng. Abstr.) **(Rus)**

[Interferon treatment of chronic viral hepatitis in Catalonia, Spain. Retrospective analysis] Buti M, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):127–31 (Eng. Abstr.) **(Spa)**

[The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study] Ortiz V, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):122–6 (Eng. Abstr.) **(Spa)**

ECONOMICS

Hepatitis C therapy: is it really worth it? Johanson JF. **Am J Gastroenterol** 1999 May;94(5):1412–3

Cost-effectiveness of interferon treatment for hepatitis C [letter; comment] van Leeuwen DJ. **JAMA** 1999 Jun 9; 281(22):2083–4. Comment on: JAMA 1998 Dec 23–30;280(24):2088–93.

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs [see comments] Wong JB, et al. **JAMA** 1998 Dec 23–30;280(24):2088–93. Comment in: JAMA 1999 Jun 9;281(22):2083; discussion 2084. Comment in: JAMA 1999 Jun 9;281(22):2083–4.

Hepatitis C: an economic evaluation of extended treatment with interferon. Shiell A, et al. **Med J Aust** 1999 Aug 16; 171(4):189–93

ENZYMOLOGY

Transient marked decrease in serum transaminases in chronic hepatitis C after surgery [letter] Trotter JF. **Am J Gastroenterol** 1999 Jul;94(7):1988–90

Aberrant expression of double-stranded RNA-dependent protein kinase in hepatocytes of chronic hepatitis and differentiated hepatocellular carcinoma. Shimada A, et al. **Cancer Res** 1998 Oct 1;58(19):4434–8

Serum pancreatic enzyme concentrations in chronic viral liver diseases. Pezzilli R, et al. **Dig Dis Sci** 1999 Feb; 44(2):350–5

Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. Murawaki Y, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):138–45

HCV NS5A 2209–2248 amino acid substitutions affect serum 2,5AS activities [letter] Murashima S, et al. **J Hepatol** 1999 Aug;31(2):382

[The enzymatic activity of IgG preparations in viral hepatitis] Zhil'tsov IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):73–7 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Effects of alcohol intake and low Km aldehyde dehydrogenase on hepatic function in a high hepatitis C virus-prevalent Japanese island population. Yang X, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4):751–6

Hepatitis C and depression. Yates WR, et al. **Depress Anxiety** 1998;7(4):188–93 (23 ref.)

Clinical course of chronic hepatitis C virus infection is not influenced by concurrent hepatitis G virus infection. Hayashi J, et al. **Dig Dis Sci** 1999 Mar;44(3):618–23

Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy. Dentico P, et al. **Infection** 1999 Mar–Apr;27(2):118–21

Prevalence and characterization of hepatitis C virus in hemodialysis patients [see comments] Morikawa T, et al. **Intern Med** 1999 Aug;38(8):626–31. Comment in: Intern Med 1999 Aug;38(8):615–6.

Hepatitis C virus seroconversion and genotype prevalence in patients and staff on chronic hemodialysis. Zamir D, et al. **J Clin Gastroenterol** 1999 Jan;28(1):23–8

Prevalence of anti-hepatitis C antibodies in a rural community without high mortality from liver disease in Niigata prefecture. Kayaba K, et al. **J Epidemiol** 1998 Oct; 8(4):250–5

Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971–1975: results of a pilot study [see comments] Rodger AJ, et al. **J Gastroenterol Hepatol** 1999 Mar;14(3):269–73 . Comment in: J Gastroenterol Hepatol 1999 Mar;14(3):199–201.

Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea Study. Monica F, et al. **J Viral Hepat** 1998 Sep;5(5):345–51

Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection [see comments] Westin J, et al. **Liver** 1999 Jun;19(3):183–7 . Comment in: Liver 1999 Jun;19(3):169–70.

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. Alter MJ, et al. **N Engl J Med** 1999 Aug 19;341(8):556–62

A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Wang JH, et al. **Trans R Soc Trop Med Hyg** 1999 May–Jun;93(3):253–4

Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. Meisel H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1382–3

[An epidemiological study on the rate of becoming chronic in HCV infection] Ni J, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):144–6 (Eng. Abstr.) **(Chi)**

[Increased occurrence of oral lichen planus in hepatitis C infection] Grote M, et al. **Mund Kiefer Gesichtschir** 1999 Jan;3(1):30–3 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Paul IM, et al. **Blood** 1999 Jun 1;93(11):3672–7

Epidemiological risk factors and clinico-pathological presentation in chronic hepatitis C. Lo Iacono O, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1715–21

Current problems of hepatitis C virus infection in hemodialysis patients [editorial; comment] Kiyosawa K. **Intern Med** 1999 Aug;38(8):615–6. Comment on: Intern Med 1999 Aug;38(8):626–31.

Mother-to-infant transmission of hepatitis C virus: molecular evidence of superinfection by homologous virus in children. Halfon P, et al. **J Hepatol** 1999 Jun;30(6):970–8

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. Kenny-Walsh E. **N Engl J Med** 1999 Apr 22;340(16):1228–33

[Isolated chronic cough during interferon therapy (letter)] Pileire G, et al. **Presse Med** 1999 May 1–8;28(17):913 **(Fre)**

GENETICS

HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Adinolfi LE, et al. **Am J Gastroenterol** 1998 Nov;93(11):2162–6

Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Gramantieri L, et al. **Clin Exp Immunol** 1999 Mar; 115(3):515–20

The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Kikuchi I, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):859–63

Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Kuzushita N, et al. **Gastroenterology** 1999 May;116(5):1149–54

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105–9

Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. Cramp ME, et al. **J Hepatol** 1998 Aug;29(2):207–13

Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. Matsushita M, et al. **J Hepatol** 1998 Nov;29(5):695–700

HCV NS5A 2209–2248 amino acid substitutions affect serum 2,5AS activities [letter] Murashima S, et al. **J Hepatol** 1999 Aug;31(2):382

Ethnic difference in the prevalence of monoclonal B-cell proliferation in patients affected by hepatitis C virus chronic liver disease. Pozzato G, et al. **J Hepatol** 1999 Jun; 30(6):990–4

Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection [see comments] Squadrito G, et al. **J Hepatol** 1999 Jun; 30(6):1023–7. Comment in: J Hepatol 1999 Jun;30(6):1152–4.

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. Sim H, et al. **J Viral Hepat** 1998 Jul;5(4):249–53

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Gerotto M, et al. **J Virol** 1999 Sep;73(9):7241–7

IMMUNOLOGY

Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes. Toyoda H, et al. **Am J Gastroenterol** 1999 Aug;94(8):2230–6

Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Kinugasa N, et al. **Br J Cancer** 1999 Aug;80(11):1820–5

Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Huang YS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jun; 62(6):327–33

Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Huang MJ, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):503–9

Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C. Fabris C, et al. **Clin Exp Immunol** 1999 Sep;117(3):556–60

Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Gramantieri L, et al. **Clin Exp Immunol** 1999 Mar;

115(3):515-20

mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment. Shapiro S, et al. **Clin Exp Immunol** 1998 Oct;114(1):55-60

Serological and clinical markers of autoimmune disease in HCV-infected subjects with different disease conditions. Valentini G, et al. **Clin Exp Rheumatol** 1999 Jan-Feb; 17(1):75-9

Antibodies to GAD in diabetic patients with chronic hepatitis C [letter] Ando H, et al. **Diabet Med** 1998 Sep;15(9):797

Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Nuti S, et al. **Eur J Immunol** 1998 Nov;28(11):3448-55

Antineutrophil cytoplasmic antibody in patients with antinuclear antibody-positive chronic hepatitis C. Ohira H, et al. **Fukushima J Med Sci** 1998 Dec;44(2):83-92

Humoral immunity in acute and chronic hepatitis C infection [letter; comment] Zein NN, et al. **Gastroenterology** 1999 Aug;117(2):510. Comment on: Gastroenterology 1999 Jan;116(1):135-43.

Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort [see comments] Lenzi M, et al. **Gut** 1999 Sep;45(3):435-41. Comment in: Gut 1999 Sep;45(3):328-9.

High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan [see comments] Marusawa H, et al. **Gut** 1999 Aug;45(2):284-8. Comment in: Gut 1999 Aug;45(2):168-9.

Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Asti M, et al. **Hepatology** 1999 Apr;29(4):1272-9

Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Castelruiz Y, et al. **Hepatology** 1999 Jun;29(6):1900-4

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Cerny A, et al. **Hepatology** 1999 Sep;30(3):595-601 (99 ref.)

No evidence for anti-islet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection [letter; comment] Harman-Boehm I, et al. **Hepatology** 1999 Jul; 30(1):342. Comment on: Hepatology 1999 Feb;29(2):328-33.

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Ishii K, et al. **Hepatology** 1998 Oct; 28(4):1117-20

Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C. Murakami J, et al. **Hepatology** 1999 Jul;30(1):143-50

Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats [see comments] Roulot D, et al. **Hepatology** 1999 Jun;29(6):1730-8. Comment in: Hepatology 1999 Jun;29(6):1909-10.

Epithelioid cell granulomas in chronic hepatitis C: immunohistochemical character and histological marker of favourable response to interferon-alpha therapy. Harada K, et al. **Histopathology** 1998 Sep;33(3):216-21

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Alric L, et al. **Hum Immunol** 1999 Jun;60(6):516-23

Costimulatory molecules and cytotoxic T cells in chronic hepatitis C: defence mechanisms devoted to host integrity or harmful events favouring liver injury progression? A review. Antonaci S, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):455-72 (62 ref.)

Immunoresponsiveness in chronic hepatitis C patients: correlation between tissue and serum findings. Piazzolla G, et al. **Immunopharmacol Immunotoxicol** 1998 Aug; 20(3):337-54

Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. Bell TM, et al. **J Gastroenterol Hepatol** 1999 May;14(5):419-22

Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. Majid A, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):317-25

Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. Dalekos GN, et al. **J Hepatol** 1999 Mar; 30(3):366-75

HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Kakizaki S, et al. **J Hepatol** 1999 May;30(5):794-800

Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. Chang KM, et al. **J Immunol** 1999 Jan 15; 162(2):1156-64

In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. Fernández M, et al. **J Infect Dis** 1999 Aug;180(2):262-7

Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis. Allain JP, et al. **J Med Virol** 1999 Sep; 59(1):25-31

Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. Mizukoshi E, et al. **J Med Virol** 1998 Nov;56(3):217-23

Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Zein NN, et al. **Mayo Clin Proc** 1999 May;74(5):454-60

Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities. Fiore G, et al. **Microbios** 1999;97(386):29-38

Intrahepatic expression of hepatitis B virus antigens: effect of hepatitis C virus infection. Guido M, et al. **Mod Pathol** 1999 Jun;12(6):599-603

Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection. Chan TM, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):717-22

Different reactivity against HCV proteins (RIBA 3) according to progression of liver damage. Barbacini IG, et al. **Panminerva Med** 1998 Dec;40(4):269-72

Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies. Garrido Palma G, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):168-81 **(Eng, Spa)**

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Cotler SJ, et al. **Tissue Antigens** 1998 Nov;52(5):435-43

Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects. Giuggio VM, et al. **Virology** 1998 Nov 10;251(1):132-40

[Influence of HIV-related immunodeficiency on the histopathology of chronic hepatitis C] Roger PM, et al. **Presse Med** 1998 Oct 24;27(32):1617-20 (Eng. Abstr.) **(Fre)**

[Vaccination against hepatitis A and B in HCV-infected patient?] Blum E. **Internist (Berl)** 1998 Sep;39(9):980 **(Ger)**

[Interferon therapy in chronic hepatitis C and cellular immunity] Nikitin IG, et al. **Klin Med (Mosk)** 1999; 77(6):33-7 **(Rus)**

METABOLISM

Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Pageaux GP, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):491-5

The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Kazemi-Shirazi L, et al. **Gastroenterology** 1999 Jan; 116(1):127-34

Serum IL-8 levels and localization of IL-8 in liver from patients with chronic viral hepatitis. Masumoto T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1630-4

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105-9

Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Shimoda K, et al. **Int J Oncol** 1999 Feb;14(2):353-9

Evaluation of iron status in patients with chronic hepatitis C [see comments] Sartori M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):396-401. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):402-4.

Hepatic iron, serum indices of iron status and chronic hepatitis C: activity, stage and response to therapy [comment] Van Thiel DH, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):402-4. Comment on: Ital J Gastroenterol Hepatol 1998 Aug;30(4):396-401.

Semiquantitative and qualitative assessment of hepatic iron in patients with chronic viral hepatitis: relation with grading, staging and haemochromatosis mutations. Vergani A, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul; 31(5):395-400

Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. Barbaro G, et al. **J Hepatol** 1999 May; 30(5):774-82

Perforin and granzyme B lytic protein expression during chronic viral and autoimmune hepatitis. Tordjmann T, et al. **Liver** 1998 Dec;18(6):391-7

Bcl-2 protein expression in acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma. Nakopoulou L, et al. **Pathol Res Pract** 1999;195(1):19-24

The clinical pharmacology of ribavirin. Glue P. **Semin Liver Dis** 1999;19 Suppl 1:17-24 (28 ref.)

[Effect of interferon therapy on carbohydrate metabolism in chronic hepatitis C patients] Pusztay M, et al. **Orv Hetil** 1999 Jul 11;140(28):1579-81 (Eng. Abstr.) **(Hun)**

MORTALITY

Prognosis of chronic hepatitis C: results of a large, prospective cohort study [see comments] Niederau C, et al. **Hepatology** 1998 Dec;28(6):1687-95. Comment in: Hepatology 1998 Dec;28(6):1710-2.

Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Natov SN, et al. **Kidney Int** 1999 Aug;56(2):700-6

PATHOLOGY

Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Goldstein NS, et al. **Am J Clin Pathol** 1999 Jun;111(6):811-6

HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Adinolfi LE, et al. **Am J Gastroenterol** 1998 Nov;93(11):2162-6

Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings [see comments] Barbaro G, et al. **Am J Gastroenterol** 1999 Aug;94(8):2198-205. Comment in: Am J Gastroenterol 1999 Aug;94(8):2003-5.

Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Bayati N, et al. **Am J Gastroenterol** 1998 Dec;93(12):2452-6

High alpha-fetoprotein level in HCV-related nodular liver cell dysplasia. Fook-Hong N, et al. **Am J Gastroenterol** 1999 Aug;94(8):2296-7

Clinical significance of portal lymphoid aggregates/follicles in Chinese patients with chronic hepatitis C. Luo JC, et al. **Am J Gastroenterol** 1999 Apr;94(4):1006-11

Intraperitoneal rupture of cholangiocarcinoma in a patient with liver cirrhosis, type C, with hepatocellular carcinoma [letter] Watanabe M, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2320-1

Oval cell numbers in human chronic liver diseases are directly related to disease severity. Lowes KN, et al. **Am J Pathol** 1999 Feb;154(2):537-41

Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Rodriguez-Iñigo E, et al. **Am J Pathol** 1999 Jun;154(6):1877-81

Morphometric analysis of lymphatic and blood vessels in human chronic viral liver diseases. Yamauchi Y, et al. **Am J Pathol** 1998 Oct;153(4):1131-7

Chronic hepatitis C in children: the pathological and clinical spectrum. Guido M, et al. **Gastroenterology** 1998 Dec; 115(6):1525-9

Role of angiogenesis in hepatitis and hepatocellular carcinoma. Ker CG, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):646-50

Asymptomatic intrahepatic choledochal cyst associated with chronic active hepatitis C. Shito M, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2356-8

Factors associated with severity and disease progression in chronic hepatitis C. Tassopoulos NC, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1678-83

Histopathology of the liver in children with chronic hepatitis C viral infection. Badizadegan K, et al. **Hepatology** 1998 Nov;28(5):1416-23

Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Fanning L, et al. **Hepatology** 1999 Mar;29(3):904-7

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis [see comments] Hourigan LF, et al. **Hepatology** 1999 Apr;29(4):1215-9. Comment in: Hepatology 1999 Apr;29(4):1328-30.

Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Dutta U, et al. **Hum Pathol** 1998 Nov; 29(11):1279-84

Higher detection rate of hepatitis G and C virus RNA in liver tissue than in serum of deceased injection drug users. Seidl S, et al. **Int J Legal Med** 1999;112(1):35-8

Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. Murakami C, et al. **J Clin Gastroenterol** 1999 Mar;28(2):148-52

Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. Farrell RJ, et al. **J Hepatol** 1999 Apr;30(4):580-7

The natural course of chronic hepatitis C: implications for clinical practice. Dusheiko GM. **J Viral Hepat** 1998 Sep; 5 Suppl 1:9-12 (15 ref.)

Morphological study of liver in patients of chronic hepatitis C treated with interferon. Muzaffar M, et al. **JPMA J Pak Med Assoc** 1998 Nov;48(11):325-8

Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Baroni GS, et al. **Liver** 1999 Jun; 19(3):212-9

Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Sawabe M, et al. **Liver** 1999 Aug;19(4):335-42

Areas of sinusoidal surface hepatocyte nuclear predominance in type C chronic hepatitis. Tanaka Y, et al. **Liver** 1998 Dec;18(6):383-90

Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection [see comments] Westin J, et al. **Liver** 1999 Jun;19(3):183-7 . Comment in: Liver 1999 Jun;19(3):169-70.

Different reactivity against HCV proteins (RIBA 3) according to progression of liver damage. Barbacini IG, et al. **Panminerva Med** 1998 Dec;40(4):269-72

[Comment on the consensus report, "Treatment of chronic B/D viral hepatitis and acute and chronic C virus hepatitis"

(letter; comment)] Dienes HP, et al. **Z Gastroenterol** 1998 Nov;36(11):XX–XXI. Comment on: Z Gastroenterol 1997 Nov; 35(11):971–86. **(Ger)**

[Electron microscopic study of the liver in chronic viral hepatitis C complicated by alcoholic liver disease] Sekamova SM, et al. **Arkh Patol** 1998 Sep–Oct;60(5):52–8 (Eng. Abstr.) **(Rus)**

[An evaluation of the degree of the morphological activity and the stage of the process in patients with chronic liver diseases caused by coinfection with the hepatitis B, C and/or D viruses] Siutkin VE, et al. **Arkh Patol** 1998 Nov–Dec;60(6):37–41 (Eng. Abstr.) **(Rus)**

[Alteration and intracellular regeneration of hepatocytes during RNA-genomic hepatitis C virus exposure] Nepomniashchikh GI, et al. **Biull Eksp Biol Med** 1999 May; 127(5):583–7 **(Rus)**

PHYSIOPATHOLOGY

TNF-alpha in chronic hepatitis C: the smoking gun? [editorial; comment] Kowdley KV. **Am J Gastroenterol** 1999 May;94(5):1132–5. Comment on: Am J Gastroenterol 1999 May;94(5):1332–40.

Does hepatitis C cause liver injury by pathways associated with mitochondrial dysfunction? [editorial; comment] Rust C, et al. **Am J Gastroenterol** 1999 Aug;94(8):2003–5. Comment on: Am J Gastroenterol 1999 Aug;94(8):2198–205.

Hepatic blood flow changes in chronic hepatitis C measured by duplex Doppler color sonography: relationship to histological features. Walsh KM, et al. **Dig Dis Sci** 1998 Dec;43(12):2584–90

[13C]-Galactose breath test: correlation with liver fibrosis in chronic hepatitis C. Mion F, et al. **Eur J Clin Invest** 1999 Jul;29(7):624–9

Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients [see comments] García-Monzón C, et al. **Hepatology** 1998 Dec;28(6):1696–701. Comment in: Hepatology 1998 Dec;28(6):1710–2.

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Ishii K, et al. **Hepatology** 1998 Oct; 28(4):1117–20

Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon] [published erratum appears in Hepatology 1999 Jun;29(6):1915] López-Labrador FX, et al. **Hepatology** 1999 Mar;29(3):897–903

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Pontisso P, et al. **Hepatology** 1999 Feb;29(2):585–9

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users [letter; comment] Bonacini M. **J Hepatol** 1999 Feb;30(2):347–8. Comment on: J Hepatol 1998 Jun;28(6):945–50.

Is azathioprine harmful to chronic viral hepatitis in renal transplantation? A long-term study on azathioprine withdrawal. David-Neto E, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1149–50

[Changes of 24-h Holter monitor recordings in association with interferon alpha therapy for chronic hepatitis C] Masutani M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov;95(11):1222–8 (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs [see comments] Wong JB, et al. **JAMA** 1998 Dec 23–30;280(24):2088–93. Comment in: JAMA 1999 Jun 9;281(22):2083; discussion 2084. Comment in: JAMA 1999 Jun 9;281(22):2083–4.

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1998 Oct 16; 47(RR-19):1–39

[The management of acute hepatitis C and needlestick accidents with hepatitis-C virus positive blood] Cooreman MP, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2298–300 (12 ref.) (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group [see comments] Bonkovsky HL, et al. **Hepatology** 1999 Jan;29(1):264–70. Comment in: Hepatology 1999 Jan;29(1):277–9.

Impaired health-related quality of life in chronic hepatitis C: the how, but not the why [editorial; comment] Koff RS. **Hepatology** 1999 Jan;29(1):277–9. Comment on: Hepatology 1999 Jan;29(1):264–70.

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Ware JEJr, et al. **Hepatology** 1999 Aug; 30(2):550–5

[Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha] Rifflet H, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):353–7 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Schröder O, et al. **Nuklearmedizin** 1998;37(8):279–85

Correlation of 99mTc-GSA hepatic scintigraphy with liver biopsies in patients with chronic active hepatitis type C. Kira T, et al. **Radiat Med** 1999 Mar–Apr;17(2):125–30

SURGERY

Viral hepatitis in the transplant recipient [news] Steinbrecher U. **Can J Gastroenterol** 1998 Sep;12(6):393–6

Transplantation in HCV: whither immunosuppression [comment] Bizollon T, et al. **Gut** 1999 Sep;45(3):327–8. Comment on: Gut 1999 Sep;45(3):427–34.

Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [see comments] Papatheodoridis GV, et al. **Gut** 1999 Sep;45(3):427–34. Comment in: Gut 1999 Sep;45(3):327–8.

Successful liver transplantation using an 87 year-old donor. Mazziotti A, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1819–22

Comparison of liver resection for hepatocellular carcinoma in hepatitis B and hepatitis C-related cirrhotic patients. Wu CC, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):651–5

Rimantadine for treatment of hepatitis C infection in liver transplant recipients. Sherman KE, et al. **Liver Transpl Surg** 1999 Jan;5(1):25–8

Liver transplantation for endstage hepatitis C cirrhosis in a patient with primary hypogammaglobulinaemia. Bjøro K, et al. **Scand J Infect Dis** 1998;30(5):520–2

THERAPY

Treatment of chronic hepatitis C. Pol S, et al. **Acta Gastroenterol Belg** 1999 Jan–Mar;62(1):32–9; discussion 39–40 (72 ref.)

Prevalence and clinical significance of TT virus coinfection in patients with chronic hepatitis C treated with interferon [letter] Brandhagen DJ, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1715–6

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials [see comments] Cammà C, et al. **Am J Gastroenterol** 1999 Mar;94(3):581–95. Comment in: Am J Gastroenterol 1999 Mar;94(3):555–6.

Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Fernández-Miranda C, et al. **Am J Gastroenterol** 1998 Oct;93(10):1901–4

A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Guyader D, et al. **Am J Gastroenterol** 1999 Jun;94(6):1696–8

Treatment of chronic hepatitis C virus infection: the end of an era [editorial; comment] Imperial J. **Am J Gastroenterol** 1999 Mar;94(3):555–6. Comment on: Am J Gastroenterol 1999 Mar;94(3):581–95.

Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection [see comments] Itoh Y, et al. **Am J Gastroenterol** 1999 May;94(5):1332–40. Comment in: Am J Gastroenterol 1999 May;94(5):1132–5.

Hepatitis C therapy: is it really worth it? Johanson JF. **Am J Gastroenterol** 1999 May;94(5):1412–3

Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Sakaida I, et al. **Am J Gastroenterol** 1999 Feb;94(2):489–96

Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Sugano S, et al. **Am J Gastroenterol** 1998 Dec;93(12):2441–4

Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine. Yoshioka K, et al. **Am J Gastroenterol** 1999 Jan;94(1):164–8

Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia. Waldron P. **Am J Hematol** 1999 Jun;61(2):130–4

Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis. Fukuhara M, et al. **Am J Hypertens** 1999 May;12(5):519–23

Interferon therapy: a double-edged sword? [editorial; comment] Cattran DC. **Am J Kidney Dis** 1999 Jun; 33(6):1174–6. Comment on: Am J Kidney Dis 1999 Jun;33(6):1040–8. Comment on: Am J Kidney Dis 1999 Jun;33(6):1142–6.

Interferon-alpha in chronic hepatitis C infection in dialysis patients. Huraib S, et al. **Am J Kidney Dis** 1999 Jul; 34(1):55–60

Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy [see comments] Ohta S, et al. **Am J Kidney Dis** 1999 Jun; 33(6):1040–8. Comment in: Am J Kidney Dis 1999 Jun;33(6):1174–6.

Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Csatary LK, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):629–33

Treatment of chronic viral hepatitis. Main J, et al. **Antivir Chem Chemother** 1998 Nov;9(6):449–60 (110 ref.)

Summary of the first international symposium on viral hepatitis. González-Peralta RP, et al. **Antiviral Res** 1999 Jun;42(2):77–96

Chronic hepatitis C infection. A disease ideally suited to management in the primary care setting. Dore GJ. **Aust Fam Physician** 1998 Sep;27(9):791–3

Caring for the hepatitis C patient. A step by step guide. National Hepatitis C Education Program for GPs, Gastroenterology Society of Australia (GESA)-Hepatology Section. Hall S. **Aust Fam Physician** 1998 Sep;27(9):799–803

Update on the management of hepatitis C [see comments] Vakil D, et al. **Aust Fam Physician** 1998 Sep;27(9):780–6 . Comment in: Aust Fam Physician 1999 Mar;28(3):207.

Aspects of care for the hepatitis C positive patient [see comments] Wodak A. **Aust Fam Physician** 1998 Sep; 27(9):787–90. Comment in: Aust Fam Physician 1999 Mar;28(3):207.

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Ghilardi G, et al. **Br J Rheumatol** 1998 Dec;37(12):1349–51

Future directions in the treatment of patients with chronic hepatitis C virus infection. Gish RG. **Can J Gastroenterol** 1999 Jan–Feb;13(1):57–62 (78 ref.)

Recombinant interferon alpha (rIFN-alpha) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Minelli R, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):95–100

Hepatitis C: implications for the general physician. Fallon HJ. **Compr Ther** 1999 May;25(5):253–7 (8 ref.)

Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Benci A, et al. **Curr Med Res Opin** 1998;14(3):141–4

Comparative responses to three different types of interferon-alpha in patients with chronic hepatitis C. Montalto G, et al. **Curr Med Res Opin** 1998;14(4):235–41

Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Almasio PL, et al. **Dig Dis Sci** 1999 May;44(5):1013–9

Fatal exacerbation of hepatitis C-related cryoglobulinemia with interferon-alpha therapy. Friedman G, et al. **Dig Dis Sci** 1999 Jul;44(7):1364–5

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Furusyo N, et al. **Dig Dis Sci** 1999 Mar;44(3):608–17

Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C [letter] Landau A, et al. **Dig Dis Sci** 1999 Jul;44(7):1366–7

Extracorporeal photopheresis alone and with interferon-alpha2a in chronic hepatitis C patients who failed previous interferon therapy. O'Brien CB, et al. **Dig Dis Sci** 1999 May;44(5):1020–6

Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon. Scotto G, et al. **Dig Dis Sci** 1998 Oct;43(10):2173–6

Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use. Picciotto A, et al. **Eur J Gastroenterol Hepatol** 1999 Jun;11(6):649–53

Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Romero MJ, et al. **Free Radic Biol Med** 1998 Dec;25(9):993–7

Making end points meet. Koretz RL. **Gastroenterology** 1999 May;116(5):1266–7

Histological improvement of oral Lichen planus in patients with chronic hepatitis C treated with interferon [letter] Nagao Y, et al. **Gastroenterology** 1999 Jul;117(1):283–4

Interferon alpha-2b in the treatment of chronic hepatitis C: early experience. Ching NP, et al. **Hawaii Med J** 1998 Dec; 57(12):735–9

A novel treatment of patients with chronic hepatitis C. Tsai NC, et al. **Hawaii Med J** 1999 Apr;58(4):85–8

Escalating interferon-alpha-2b dose for patients with chronic hepatitis C. De La Riva E, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2308–14

Increased serum soluble IL-2 receptor levels following interferon therapy in patients with chronic hepatitis C. Sugimura T, et al. **Hepatogastroenterology** 1999 May–Jun; 46(27):1827–30

Probability of non-response during interferon therapy in patients with chronic hepatitis C. Testa R, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1928–36

Interferon treatment in patients with chronic hepatitis C with normal alanine-aminotransferase activity. Yagura M, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1094–9

Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients. Yao GB, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1059–64

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). Cammà C, et al. **Hepatology** 1999 Sep;30(3):801–7

Immune response in chronic hepatitis C-infected patients undergoing interferon treatment [letter; comment] Cargnel A, et al. **Hepatology** 1999 Aug;30(2):584–5. Comment on: Hepatology 1998 Sep;28(3):815–22.

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Edwards-Smith CJ, et al. **Hepatology** 1999 Aug;

30(2):526–30
Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Everson GT, et al. **Hepatology** 1999 Jul; 30(1):271–6
Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Heathcote EJ, et al. **Hepatology** 1999 Aug; 30(2):562–6
Life tables and denominators [letter; comment] Koretz RL. **Hepatology** 1999 Jul;30(1):340–1. Comment on: Hepatology 1999 Mar;29(3):971–5.
10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Lau DTY, et al. **Hepatology** 1998 Oct; 28(4):1121–7
Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon] [published erratum appears in Hepatology 1999 Jun;29(6):1915] López-Labrador FX, et al. **Hepatology** 1999 Mar;29(3):897–903
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc). Payen JL, et al. **Hepatology** 1998 Dec;28(6):1680–6
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Reddy KR, et al. **Hepatology** 1999 Sep;30(3):787–93
Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Schmidt WN, et al. **Hepatology** 1998 Oct;28(4):1110–6
Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Shiratori Y, et al. **Hepatology** 1999 May;29(5):1573–80
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Valla DC, et al. **Hepatology** 1999 Jun; 29(6):1870–5
Combination therapy for chronic hepatitis C: interferon and ribavirin. Christie JM, et al. **Hosp Med** 1999 May; 60(5):357–61 (24 ref.)
Autoimmune thyroiditis and myelosuppression following treatment with interferon-alpha for hepatitis C. Schmitt K, et al. **Int J Clin Pharmacol Ther** 1999 Apr;37(4):165–7
Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA. Arase Y, et al. **Intern Med** 1999 Jun;38(6):461–6
Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-beta in patients with chronic hepatitis C. Ohno Y, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3681–7
Hemolytic anemia and the treatment of chronic hepatitis C [editorial; comment] Saab S, et al. **J Clin Gastroenterol** 1999 Jun;28(4):289–90. Comment on: J Clin Gastroenterol 1999 Jun;28(4):358–9.
Long-term interferon alpha maintenance therapy for chronic hepatitis C infection in a patient with common variable immune deficiency. Willson RA, et al. **J Clin Gastroenterol** 1999 Sep;29(2):203–6
Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. Yamaguchi K, et al. **J Clin Gastroenterol** 1999 Sep;29(2):207–9
Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference. Ahmed A, et al. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S12–8 (49 ref.)
Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene. Horiike N, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):345–51
High-dose natural interferon-alpha therapy for chronic hepatitis C with a high viral load: predictors of efficacy. The Aomori, Akita and Iwate Areas Viral Hepatitis Research Group. Komatsu M, et al. **J Gastroenterol Hepatol** 1999 Jul;14(7):675–81
Antiviral therapy for hepatitis B and C in Asians. Lai CL. **J Gastroenterol Hepatol** 1999 May;14 Suppl:S19–21
Case report: a patient who developed an amoebic liver abscess during treatment with interferon. Matsuo T, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1068–71
The effects of a high dose, short course of interferon on hepatitis C. Nomura H, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):85–9
How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C? Tokyo-Chiba Hepatitis Research Group. Shiratori Y, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):79–84
Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial. Andreone P, et al. **J Hepatol** 1999 May; 30(5):788–93
Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? Bellobuono A, et al. **J Hepatol** 1999 Jan;30(1):8–13
Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. Brouwer JT, et al. **J Hepatol** 1999 Feb;30(2):192–8
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group [see comments] Degos F, et al. **J Hepatol** 1998 Aug; 29(2):224–32. Comment in: ACP J Club 1999 Mar-Apr;130(2):37.
HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Kakizaki S, et al. **J Hepatol** 1999 May;30(5):794–800
The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome. Löhr HF, et al. **J Hepatol** 1998 Oct;29(4):524–32
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Martinot-Peignoux M, et al. **J Hepatol** 1998 Aug;29(2):214–23
Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? [see comments] Nakano I, et al. **J Hepatol** 1999 Jun;30(6):1014–22. Comment in: J Hepatol 1999 Jun;30(6):1152–4.
Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. Okanoue T, et al. **J Hepatol** 1999 Apr;30(4):653–9
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. Pol S, et al. **J Hepatol** 1999 Jul;31(1):1–7
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. Reichard O, et al. **J Hepatol** 1999 May;30(5):783–7
A suggested extension of the HCV ISDR does not alter our former conclusions on its predictive value for IFN response [letter; comment] Rispeter K, et al. **J Hepatol** 1999 Jun; 30(6):1163–4. Comment on: J Hepatol 1999 Jun;30(6):1152–4.
Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy [see comments] Sarrazin C, et al. **J Hepatol** 1999 Jun;30(6):1004–13. Comment in: J Hepatol 1999 Jun;30(6):1152–4.
Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection [see comments] Squadrito G, et al. **J Hepatol** 1999 Jun; 30(6):1023–7. Comment in: J Hepatol 1999 Jun;30(6):1152–4.
Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. Tsushima H, et al. **J Hepatol** 1999 Jan;30(1):1–7
Combination therapy of chronic hepatitis C: an important step but not the final goal! [editorial] Wedemeyer H, et al. **J Hepatol** 1998 Dec;29(6):1010–4
Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C. Yatsuhashi H, et al. **J Hepatol** 1999 Jun;30(6):995–1003
Triggering of acute alcoholic hepatitis by alpha-interferon therapy. Zylberberg H, et al. **J Hepatol** 1999 Apr; 30(4):722–5
Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection. McHutchison JG, et al. **J Med Virol** 1999 Apr;57(4):351–5
Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. Morita K, et al. **J Med Virol** 1999 Aug; 58(4):359–65
Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. Tanaka T, et al. **J Med Virol** 1999 Apr; 57(4):370–5
Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C. Harada H, et al. **J Neurol Sci** 1999 Jun 1;165(2):182–3
Interferon alfa for chronic hepatitis C infection [letter; comment] Delgado Fernández M, et al. **Lancet** 1999 Feb 6;353(9151):499–500. Comment on: Lancet 1998 Oct 31;352(9138):1426–32.
Interferon alfa for chronic hepatitis C infection [letter; comment] Kingsley D. **Lancet** 1999 Feb 6;353(9151):499; discussion 500. Comment on: Lancet 1998 Oct 31;352(9138):1426–32.
Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders [letter] Pariante CM, et al. **Lancet** 1999 Jul 10;354(9173):131–2
Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Salmerón J, et al. **Liver** 1999 Aug;19(4):275–80
Serum ferritin level required for adequate response to recombinant human erythropoietin in haemodialysis patients with hepatitis C virus infection [letter] Hung KY, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2709–10
Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C [letter] Ubara Y, et al. **Nephron** 1998 Sep;80(1):107–8
Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Uchihara M, et al. **Nephron** 1998 Sep;80(1):51–6
A case of seizures 1 week after the cessation of interferon-alpha therapy. Seno H, et al. **Psychiatry Clin Neurosci** 1999 Jun;53(3):417–20
Efficacy of alpha 2b versus lymphoblastoid interferon in treatment of chronic hepatitis C. A randomized trial. González Sánchez M, et al. **Rev Esp Enferm Dig** 1998 Aug; 90(8):553–62 **(Eng, Spa)**
Histological evaluation of the response to interferon-alpha therapy in chronic hepatitis C. Jármay K, et al. **Scand J Gastroenterol Suppl** 1998;228:56–61
Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Davis GL. **Semin Liver Dis** 1999;19 Suppl 1:49–55 (46 ref.)
Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Dieterich DT, et al. **Semin Liver Dis** 1999;19 Suppl 1:87–94 (63 ref.)
Standards of treatment in chronic hepatitis C. Gish RG. **Semin Liver Dis** 1999;19 Suppl 1:35–47 (187 ref.)
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. McHutchison JG, et al. **Semin Liver Dis** 1999;19 Suppl 1:57–65
Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Maddrey WC. **Semin Liver Dis** 1999;19 Suppl 1:67–75
Use of high-dose interferon in the treatment of chronic hepatitis C. Shiffman ML. **Semin Liver Dis** 1999;19 Suppl 1:25–33 (54 ref.)
The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Younossi ZM, et al. **Semin Liver Dis** 1999;19 Suppl 1:95–102 (32 ref.)
Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Tokumoto T, et al. **Transplant Proc** 1998 Nov;30(7):3270–2
[Should one treat children with chronic hepatitis C with interferon?] Hadchouel M. **Arch Pediatr** 1999;6 Suppl 2:178s–179s **(Fre)**
[When should one treat a child with chronic hepatitis C with interferon?] Maggiore G, et al. **Arch Pediatr** 1999;6 Suppl 2:174s–175s **(Fre)**
[Indications for combination interferon-ribavirin therapy in chronic hepatitis C] Blum HE. **Internist (Berl)** 1998 Sep; 39(9):981 **(Ger)**
[Therapy concepts in chronic hepatitis C] Meyer-Wyss B. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1940–5 (31 ref.) (Eng. Abstr.) **(Ger)**
[Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?] Renner EL. **Schweiz Med Wochenschr** 1999 Jan 12;129(1-2):8–10 (6 ref.) **(Ger)**
[Chronic hepatitis C--therapeutic modalities for interferon failure] Hermann R. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1413–20 (82 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of chronic hepatitis B and C] Müllhaupt B, et al. **Schweiz Rundsch Med Prax** 1999 Apr 1;88(14):619–32 (119 ref.) (Eng. Abstr.) **(Ger)**
[Interferon-alpha plus ribavirin combination therapy in chronic hepatitis C] Sarrazin C, et al. **Z Gastroenterol** 1999 Jul;37(7):669–74 **(Ger)**
[Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C] Seifarth C, et al. **Z Gastroenterol** 1999 Mar;37(3):235–9 (Eng. Abstr.) **(Ger)**
[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature] Wedemeyer H, et al. **Z Gastroenterol** 1998 Sep;36(9):819–27 (35 ref.) (Eng. Abstr.) **(Ger)**
[A study of hypertriglyceridemia occurring in patients with chronic hepatitis C during administration of interferon beta] Kioka K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr;96(4):392–7 (Eng. Abstr.) **(Jpn)**
[Changes of 24-h Holter monitor recordings in association with interferon alpha therapy for chronic hepatitis C] Masutani M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov;95(11):1222–8 (Eng. Abstr.) **(Jpn)**
[Occurrence of hepatocellular carcinoma in patients with chronic hepatitis C who continued to be HCV-RNA negative for up to 3 years by interferon] Miyao N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May;96(5):535–9 **(Jpn)**
[The response of the hepatitis C and hepatitis G viruses to treatment with recombinant interferon alfa-2b] Infante Pina D, et al. **An Esp Pediatr** 1998 Dec;49(6):609–14 (Eng. Abstr.) **(Spa)**
[How should a patient with chronic hepatitis C be advised?] Bruguera M. **Gastroenterol Hepatol** 1998 Nov;21(9):459–63 **(Spa)**
[Predictive value of diverse viral factors in the response to treatment with interferon in patients with chronic hepatitis C] Giménez-Barcons M, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):404–12 (69 ref.) **(Spa)**

[Chronic hepatitis C, autoimmunity and interferon alfa treatment (editorial; comment)] Garcia Buey L, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):165-7 (18 ref.). Comment on: Rev Esp Enferm Dig 1999 Mar;91(3):168-81. **(Spa)**

ULTRASONOGRAPHY

Hepatic blood flow changes in chronic hepatitis C measured by duplex Doppler color sonography: relationship to histological features. Walsh KM, et al. **Dig Dis Sci** 1998 Dec;43(12):2584-90

Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. Wedemeyer H, et al. **Hepatogastroenterology** 1998 Jul-Aug;45(22):1062-8

[Analysis of hepatic echo patterns in chronic hepatitis C] Dietrich CF, et al. **Ultraschall Med** 1999 Feb;20(1):9-14 (Eng. Abstr.) **(Ger)**

VIROLOGY

Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. Garcia-Bengoechea M, et al. **Am J Gastroenterol** 1999 Jul; 94(7):1902-5

A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Quinn PG, et al. **Am J Gastroenterol** 1999 Mar;94(3):668-73

Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Rodriguez-Iñigo E, et al. **Am J Pathol** 1999 Jun;154(6):1877-81

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. Martin J, et al. **Antiviral Res** 1999 May;42(1):59-70

Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Sansonno D, et al. **Blood** 1998 Nov 1;92(9):3328-37

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. Steele RW. **Clin Pediatr (Phila)** 1998 Dec;37(12):759-60

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Bellentani S, et al. **Gut** 1999 Jun; 44(6):874-80

Quantitative hepatitis C RNA-polymerase chain reaction and detection with DNA-ELISA. Heintges T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1684-9

Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population. Fanning L, et al. **Hepatology** 1999 Mar;29(3):904-7

Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Negro F, et al. **Hepatology** 1999 Feb;29(2):536-42

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Pontisso P, et al. **Hepatology** 1999 Feb;29(2):585-9

Quasispecies of hepatitis C virus in serum and in three different parts of the liver of patients with chronic hepatitis. Sakai A, et al. **Hepatology** 1999 Aug;30(2):556-61

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Villano SA, et al. **Hepatology** 1999 Mar;29(3):908-14

High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners. Fabris P, et al. **Infection** 1999 Mar-Apr;27(2):86-91

Phylogenetic analysis of hepatitis GB virus type C/hepatitis G virus in Spanish patients with chronic hepatitis B or C virus infection. López-Alcorocho JM, et al. **Intervirology** 1998;41(6):233-7

Prompt hepatitis C virus suppression following hepatitis B virus superinfection in chronic untreated hepatitis C. Guido M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):414-7

High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow-up. Feucht HH, et al. **J Clin Virol** 1999 Jun;13(1-2):43-51

Hepatitis C virus 1b(II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. Tanaka H, et al. **J Epidemiol** 1998 Oct;8(4):244-9

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha. Kobayashi M, et al. **J Gastroenterol** 1999 Feb; 34(1):94-9

Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. Gish RG, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):339-44

Effects of hepatitis G virus coinfection on severity of hepatitis C: relationship to risk factors and response to interferon treatment [see comments] Lin R, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):773-80. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763-6.

Differences between hepatitis C virus 5' untranslated region quasispecies in serum and liver. Jang SJ, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):711-6

Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. Majid A, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):317-25

Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. Barbaro G, et al. **J Hepatol** 1999 May; 30(5):774-82

Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Barrett S, et al. **J Hepatol** 1999 Jun;30(6):979-83

Prevalence of transmitted transfusion virus (TTV) in populations at different risk for hepatitis virus: hemodialysis, chronic hepatitis C and cryptogenetic hepatitis patients [letter] Halfon P, et al. **J Hepatol** 1999 Mar;30(3):552

High prevalance of TT virus infection in Japanese patients with liver diseases and in blood donors. Kato T, et al. **J Hepatol** 1999 Aug;31(2):221-7

HLA class II favors clearance of HCV infection and progression of the chronic liver damage. Mangia A, et al. **J Hepatol** 1999 Jun;30(6):984-9

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. Roffi L, et al. **J Hepatol** 1998 Nov;29(5):701-6

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy [see comments] Sarrazin C, et al. **J Hepatol** 1999 Jun;30(6):1004-13. Comment in: J Hepatol 1999 Jun;30(6):1152-4.

Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy. Kessler HH, et al. **J Hum Virol** 1998 Jul-Aug;1(5):314-9

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. Eyster ME, et al. **J Infect Dis** 1999 May;179(5):1062-9

Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. Giannini C, et al. **J Lab Clin Med** 1999 Jul; 134(1):68-73

Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. Fujie H, et al. **J Med Virol** 1999 Oct;59(2):141-5

GBV-C/HGV infection in children with chronic hepatitis C. Komatsu H, et al. **J Med Virol** 1999 Oct;59(2):154-9

Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy. Lu M, et al. **J Med Virol** 1999 Oct;59(2):146-53

Divergent evolution of hepatitis C virus in liver and peripheral blood mononuclear cells of infected patients. Maggi F, et al. **J Med Virol** 1999 Jan;57(1):57-63

Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. Olmedo E, et al. **J Med Virol** 1999 May;58(1):35-43

Hepatitis C genotypes and subtypes in Saudi Arabia. Shobokshi OA, et al. **J Med Virol** 1999 May;58(1):44-8

Serum levels of hepatitis C virus RNA in infants and children with chronic hepatitis C. Azzari C, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):314-7

Hepatitis C virus infection: virus/host interactions. Pawlotsky JM. **J Viral Hepat** 1998 Sep;5 Suppl 1:3-8 (19 ref.)

Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. Pawlotsky JM, et al. **J Virol** 1999 Aug;73(8):6490-9

Detection of GB virus C RNA by GBV-C LCx and two PCR assays with primers from the 5'non-coding and NS5B region. Berg ES, et al. **J Virol Methods** 1998 Dec; 76(1-2):43-9

Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. Pawlotsky JM, et al. **J Virol Methods** 1999 May; 79(2):227-35

Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C. Walsh KM, et al. **Liver** 1998 Jun; 18(3):191-5

Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Wietzke P, et al. **Liver** 1999 Aug; 19(4):348-53

Single-step reverse transcription-polymerase chain reaction for the detection of hepatitis C virus RNA. Mizutani T, et al. **Microbiol Immunol** 1998;42(8):549-53

Subtype distribution among intravenous drug users with chronic type C hepatitis in southern Spain. Garcia F, et al. **Microbios** 1998;95(380):15-24

Detection of virus-like particles in liver biopsies from HCV-infected patients. Bosman C, et al. **Res Virol** 1998 Sep-Oct;149(5):311-4

Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. Morisco F, et al. **Res Virol** 1998 Sep-Oct;149(5):277-82

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Reichard O, et al. **Scand J Infect Dis** 1998;30(5):441-6

HCV-RNA levels increase during pregnancy in women with chronic hepatitis C. Wejstål R, et al. **Scand J Infect Dis** 1998;30(2):111-3

Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Neary MP, et al. **Semin Liver Dis** 1999;19 Suppl 1:77-85

Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients. Rodrigues A, et al. **Transpl Int** 1998;11 Suppl 1:S115-8

[Interactions between the human immunodeficiency virus and hepatitis C virus] Pol S, et al. **Rev Med Interne** 1998 Dec; 19(12):885-91 (48 ref.) (Eng. Abstr.) **(Fre)**

[Interferon therapy of chronic viral hepatitis in Hungary: 5-year experience. A multicenter study] Pár A, et al. **Orv Hetil** 1999 May 30;140(22):1227-33 (36 ref.) (Eng. Abstr.) **(Hun)**

[Prevalence of anti-hepatitis A in patients with chronic liver disease] Diago M, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):324-6 (Eng. Abstr.) **(Spa)**

[Predictive value of diverse viral factors in the response to treatment with interferon in patients with chronic hepatitis C] Giménez-Barcons M, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):404-12 (69 ref.) **(Spa)**

[Distribution of the genotypes of hepatitis C virus in intravenous drug addicts in Argentina] Findor JA, et al. **Medicina (B Aires)** 1999;59(1):49-54 (Eng. Abstr.) **(Spa)**

HEPATITIS C-LIKE VIRUSES

Systematic cutaneous examination in hepatitis C virus infected patients. Cribier B, et al. **Acta Derm Venereol** 1998 Sep;78(5):355-7

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease. da Silva CM, et al. **Br J Clin Pharmacol** 1998 Aug; 46(2):176-80

Low prevalence of hepatitis C virus antibodies and RNA in patients with myocarditis and dilated cardiomyopathy. Grumbach IM, et al. **Cardiology** 1998 Oct;90(2):75-8

Beneficial effect of phlebotomy on hepatitis C virus-associated musculoskeletal manifestations. Hilzenrat N, et al. **Clin Rheumatol** 1998;17(5):390-2

Hepatitis C virus infection and cryoglobulinemia. Lunel F, et al. **J Hepatol** 1998 Nov;29(5):848-55 (87 ref.)

Chronic liver disease and lymphoproliferative disorders in HCV-positive patients: a working hypothesis [letter] Persico M, et al. **J Hepatol** 1998 Nov;29(5):857-8

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. Lesens O, et al. **J Infect Dis** 1999 May;179(5):1254-8

Lack of transmission of hepatitis C virus in very close family contacts of patients undergoing multitransfusions for thalassemia. Rosenthal E, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):101-3

Diagnostic confusion caused by hepatitis C: hemochromatosis presenting as rheumatoid arthritis. Espinosa-Morales R, et al. **J Rheumatol** 1998 Dec;25(12):2459-63

Chronic hepatitis C: the virus, its discovery and the natural history of the disease. Booth JC. **J Viral Hepat** 1998 Jul; 5(4):213-22 (111 ref.)

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. Major ME, et al. **J Virol** 1999 Apr;73(4):3317-25

Hepatic hydrothorax in the absence of ascites. Kakizaki S, et al. **Liver** 1998 Jun;18(3):216-20

Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Loguercio C, et al. **Liver** 1998 Jun;18(3):166-72

Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Puoti C, et al. **Liver** 1999 Apr;19(2):104-9

Persistent infection of hepatitis C virus in the elderly: a clinical and quantitative pathological study of autopsy cases. Sawabe M, et al. **Liver** 1999 Aug;19(4):335-42

Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Fabrizi F, et al. **Nephron** 1998 Dec;80(4):428-33

Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Stehman-Breen C, et al. **Nephron** 1999 Jan;81(1):37-40

hnRNP C and polypyrimidine tract-binding protein specifically interact with the pyrimidine-rich region within the 3'NTR of the HCV RNA genome. Gontarek RR, et al. **Nucleic Acids Res** 1999 Mar 15;27(6):1457-63

Shift in the buoyant density of hepatitis C virus particles in infants infected by mother-to-infant transmission. Okamoto M, et al. **Pediatr Int** 1999 Aug;41(4):369-73

Chiron's licensing policy [letter] Blackburn RP. **Science** 1999 Aug 13;285(5430):1015

The scientific challenge of hepatitis C [news; comment] Cohen J. **Science** 1999 Jul 2;285(5424):26-30. Comment on: Science 1999 Jul 2;285(5424):107-10. Comment on: Science 1999 Jul 2;285(5424):110-3.

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein [see comments] Taylor DR, et al. **Science** 1999 Jul 2;285(5424):107-10. Comment in: Science 1999 Jul 2;285(5424):26-30.

Wilson's disease coexisting with viral hepatitis type C: a case report with histological and ultrastructural studies of the liver. Lembowicz K, et al. **Ultrastruct Pathol** 1999 Jan-Feb; 23(1):39-44

Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Oshima KH, et al. **Vox Sang** 1998; 75(3):181–8

[Hepatitis virus and hepatocellular carcinoma] Rosmorduc O, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):363–75 (126 ref.) **(Fre)**

[Cryoglobulinemia related to the hepatitis B and C viruses] Cohen P. **Pathol Biol (Paris)** 1999 Mar;47(3):232–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Viral vasculitis not related to HBV, HCV and HIV] Lortholary O, et al. **Pathol Biol (Paris)** 1999 Mar; 47(3):248–51 (38 ref.) (Eng. Abstr.) **(Fre)**

[Rapid resolution of acute myocarditis: side effect of a drug or effect of hepatitis C virus? (letter)] Niquet L, et al. **Presse Med** 1999 Apr 24;28(16):845–6 **(Fre)**

[Hepatitis G infection in Chilean patients with hepatitis C virus: a preliminary report (letter)] Venegas M, et al. **Rev Med Chil** 1998 Sep;126(9):1133–4 **(Spa)**

CHEMISTRY

Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Trestard A, et al. **Arch Virol** 1998;143(11):2241–5

The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. Love RA, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):151–6

Rational design and functional expression of a constitutively active single-chain NS4A–NS3 proteinase. Pasquo A, et al. **Fold Des** 1998;3(6):433–41

Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Dries V, et al. **Hepatology** 1999 Jan;29(1):223–9

Lack of evidence for distinct hepatitis C virus variants associated with cryoglobulin [letter; comment] Smith DB. **Hepatology** 1999 Feb;29(2):614–5. Comment on: Hepatology 1996 Dec;24(6):1346–50.

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. Meunier JC, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):887–96

Structure-based mutagenesis study of hepatitis C virus NS3 helicase. Lin C, et al. **J Virol** 1999 Oct;73(10):8798–807

A novel recombinant single-chain hepatitis C virus NS3–NS4A protein with improved helicase activity. Howe AY, et al. **Protein Sci** 1999 Jun;8(6):1332–41

CLASSIFICATION

Hepatitis C virus genotypes and hepatitis G virus in hemodialysis patients from Syria: identification of two novel hepatitis C virus subtypes. Abdulkarim AS, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):571–6

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy [news] Robertson B, et al. **Arch Virol** 1998; 143(12):2493–503

Sequencing analysis of hepatitis C virus mixed genotype in a hemodialysis patients. Lee HF, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Nov;28(4):280–90

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Beard MR, et al. **Hepatology** 1999 Jul; 30(1):316–24

Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy. Dentico P, et al. **Infection** 1999 Mar–Apr;27(2):118–21

Hepatitis C virus serotype-specific core and NS4 antibodies in injecting drug users participating in the Amsterdam cohort studies. Beld M, et al. **J Clin Microbiol** 1998 Oct; 36(10):3002–6

Classification of hepatitis C virus type 2 isolates by phylogenetic analysis of core and NS5 regions [letter; comment] Pistello M, et al. **J Clin Microbiol** 1999 Jun; 37(6):2116–7. Comment on: J Clin Microbiol 1995 Oct;33(10):2781–4. Comment on: J Clin Microbiol 1997 Jan;35(1):161–4. Comment on: J Clin Microbiol 1998 May;36(5):1461–3.

HCV genotyping by three methods: analysis of discordant results based on sequencing. Furione M, et al. **J Clin Virol** 1999 Aug;13(3):121–30

Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. Gish RG, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):339–44

Molecular epidemiology of hepatitis C in Australia. Kaba S, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):914–20

Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. Ni YH, et al. **J Med Virol** 1999 Jun;58(2):132–8

Hepatitis C genotypes and subtypes in Saudi Arabia. Shobokshi OA, et al. **J Med Virol** 1999 May;58(1):44–8

Subtype distribution among intravenous drug users with chronic type C hepatitis in southern Spain. García F, et al. **Microbios** 1998;95(380):15–24

Rapid genotyping of hepatitis C virus by direct cycle sequencing of PCR-amplified cDNAs and capillary electrophoresis analysis. Doglio A, et al. **Res Virol** 1998 Jul–Aug;149(4):219–27

Molecular heterogeneity and new subtypes of HCV genotype 4. Rapicetta M, et al. **Res Virol** 1998 Sep–Oct;149(5):293–7

Genotyping HCV isolates from Italy by type-specific PCR assay in the core region. Spada E, et al. **Res Virol** 1998 Jul–Aug;149(4):209–18

[Genotyping of HCV isolates from different populations in Shanghai by using second generation line probe assay] Jiang W, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):29–30 (Eng. Abstr.) **(Chi)**

[Sequence diversity of genotype II/1b hepatitis C virus (HCV) HVR1 of 46 patients in Beijing areas] Zhao J, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun; 7(2):88–90 (Eng. Abstr.) **(Chi)**

[Serotyping of hepatis C virus in Tunisia] Ben Halima M, et al. **Tunis Med** 1998 Jun–Jul;76(6–7):200–3 (Eng. Abstr.) **(Fre)**

[Epidemiology of hepatitis C virus infection and circulating genotypes in the Sfax region--Tunisia] Karray-Hakim H, et al. **Tunis Med** 1999 Mar;77(3):139–44 **(Fre)**

DRUG EFFECTS

Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. Agolini G, et al. **Am J Infect Control** 1999 Jun;27(3):236–9

Treatment of hepatitis C: a decision that needs careful consideration [editorial; comment] Wright TL. **Am J Med** 1999 Aug;107(2):180–1. Comment on: Am J Med 1999 Aug;107(2):112–8.

Cell-based and animal models for hepatitis B and C viruses. Schinazi RF, et al. **Antivir Chem Chemother** 1999 May; 10(3):99–114 (180 ref.)

Hepatitis C virus NS3/4A protease. Kwong AD, et al. **Antiviral Res** 1999 Feb;41(1):67–84 (100 ref.)

In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. Martin J, et al. **Antiviral Res** 1999 May;42(1):59–70

Follow-up of hepatitis C virus RNA in peripheral blood mononuclear cells during interferon therapy. Cribier B, et al. **Arch Virol** 1999;144(2):355–64

Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Gale MJ Jr, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):157–62 (30 ref.)

Effectiveness of a manual disinfection procedure in eliminating hepatitis C virus from experimentally contaminated endoscopes [see comments] Chanzy B, et al. **Gastrointest Endosc** 1999 Aug;50(2):147–51. Comment in: Gastrointest Endosc 1999 Aug;50(2):287–91.

Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Nakamura H, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1131–9

Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Thomas HC, et al. **Hepatology** 1999 Apr;29(4):1333–4

Effects of corticosteroids on HCV infection. Magy N, et al. **Int J Immunopharmacol** 1999 Apr;21(4):253–61

Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype [letter] Belloni G, et al. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):427

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha. Kobayashi M, et al. **J Gastroenterol** 1999 Feb; 34(1):94–9

Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. Tao Q, et al. **J Gastroenterol** 1998 Oct;33(5):684–93

Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. Chung RT, et al. **J Med Virol** 1999 Aug;58(4):353–8

Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. Morita K, et al. **J Med Virol** 1999 Aug; 58(4):359–65

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Gerotto M, et al. **J Virol** 1999 Sep;73(9):7241–7

Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C. Walsh KM, et al. **Liver** 1998 Jun; 18(3):191–5

Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. Piccinino F, et al. **Res Virol** 1998 Sep–Oct;149(5):283–91

[Inhibition of hepatitis C virus by antisense oligodeoxynucleotide in vitro] Liu Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):567–70 (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction. Liu Y, et al. **Anal Biochem** 1999 Feb 15;267(2):331–5

A continuous spectrophotometric assay for the hepatitis C virus serine protease. Zhang R, et al. **Anal Biochem** 1999 Jun 1;270(2):268–75

Hepatitis C virus NS3/4A protease. Kwong AD, et al. **Antiviral Res** 1998 Dec;40(1–2):1–18 (98 ref.)

An ELISA for RNA helicase activity: application as an assay of the NS3 helicase of hepatitis C virus. Hsu CC, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):594–9

Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Gallinari P, et al. **Biochemistry** 1999 Apr 27;38(17):5620–32

Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide. Urbani A, et al. **Biochemistry** 1999 Apr 20;38(16):5206–15

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Llinàs-Brunet M, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2719–24

Peptide-based inhibitors of the hepatitis C virus serine protease. Llinàs-Brunet M, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1713–8

The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. Love RA, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):151–6

Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. Lohmann V, et al. **J Biol Chem** 1999 Apr 16;274(16):10807–15

Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. Wardell AD, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):701–9

The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. Barbato G, et al. **J Mol Biol** 1999 Jun 4;289(2):371–84

Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. Cicero DO, et al. **J Mol Biol** 1999 Jun 4;289(2):385–96

Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. Cheng JC, et al. **J Virol** 1999 Aug;73(8):7044–9

Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. Ferrari E, et al. **J Virol** 1999 Feb;73(2):1649–54

Selection of functional variants of the NS3–NS4A protease of hepatitis C virus by using chimeric sindbis viruses. Filocamo G, et al. **J Virol** 1999 Jan;73(1):561–75

A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. Oh JW, et al. **J Virol** 1999 Sep;73(9):7694–702

A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. Kakiuchi N, et al. **J Virol Methods** 1999 Jun;80(1):77–84

Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein. Dimasi N, et al. **Protein Eng** 1998 Dec;11(12):1257–65

An uniquely purified HCV NS3 protease and NS4A(21–34) peptide form a highly active serine protease complex in peptide hydrolysis. Sardana VV, et al. **Protein Expr Purif** 1999 Aug;16(3):440–7

Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry. Orrù S, et al. **Protein Sci** 1999 Jul; 8(7):1445–54

Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Taremi SS, et al. **Protein Sci** 1998 Oct; 7(10):2143–9

Functional interactions between conserved motifs of the hepatitis C virus RNA helicase protein NS3. Min KH, et al. **Virus Genes** 1999;19(1):33–43

GENETICS

Hepatitis C virus (HCV) genotype does not appear to be a significant prognostic factor in HIV–HCV-coinfected patients [letter; comment] Piroth L, et al. **AIDS** 1999 Mar 11;13(4):523–4. Comment on: AIDS 1998 Mar 5;12(4):381–8.

Hepatitis C virus genotypes and quantification of serum hepatitis C RNA in liver transplant recipients. Relationship with histologic outcome of recurrent hepatitis C. Costes V, et al. **Am J Clin Pathol** 1999 Feb;111(2):252–8

HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Adinolfi LE, et al. **Am J Gastroenterol** 1998 Nov;93(11):2162–6

Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Fan X, et al. **Am J Gastroenterol** 1999 May;94(5):1347–54

Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Reid AE, et al. **Am J Gastroenterol** 1999 Jun;94(6):1619–26

Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes. Toyoda H, et al. **Am J Gastroenterol** 1999 Aug;94(8):2230–6

Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Widell A, et al. **Ann Intern Med** 1999 Jan 19;130(2):130–4

Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Zhang H, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):347-53

Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Brown-Driver V, et al. **Antisense Nucleic Acid Drug Dev** 1999 Apr; 9(2):145-54

Internal initiation of translation efficiency in different hepatitis C genotypes isolated from interferon treated patients. Sáiz JC, et al. **Arch Virol** 1999;144(2):215-29

Heterogeneous nuclear ribonucleoprotein I (hnRNP-I/PTB) selectively binds the conserved 3' terminus of hepatitis C viral RNA. Chung RT, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):351-62

Involvement of the 5' proximal coding sequences of hepatitis C virus with internal initiation of viral translation. Hwang LH, et al. **Biochem Biophys Res Commun** 1998 Nov 18; 252(2):455-60

Mutational analysis of two unstructured domains of the 5' untranslated region of HCV RNA. Varaklioti A, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):678-85

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101-4

Rapid isolation of HCV RNA from Catrimox-lysed whole blood using QIAamp spin columns [published erratum appears in Biotechniques 1999 Apr;26(4):716] Ali SA, et al. **Biotechniques** 1998 Dec;25(6):975-8

Hepatitis C virus (HCV) infection: serum rheumatoid factor activity and HCV genotype correlate with cryoglobulin clonality [letter] Antonescu C, et al. **Blood** 1998 Nov 1; 92(9):3486-7

Distribution of HCV genotypes among different exposure categories in Brazil. Oliveira ML, et al. **Braz J Med Biol Res** 1999 Mar;32(3):279-82

Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma [see comments] Kubo S, et al. **Cancer** 1999 Sep 1;86(5):793-8. Comment in: Cancer 1999 Sep 1;86(5):741-3.

Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients. Pontisso P, et al. **Cancer** 1998 Oct 15;83(8):1489-94

Study of hepatitis C virus genotype in Guizhou area of southwestern China. Ding J, et al. **Chin Med J (Engl)** 1998 Feb;111(2):128-31

A simple PCR with different 3' ends of the third primer for detection of defined point mutations: HCV genotyping as an example. Alavantic D, et al. **Clin Chem Lab Med** 1998 Aug;36(8):587-8

Hepatitis C virus-specific DNA sequences in human DNA: differentiation by means of restriction enzyme analysis at the DNA level in healthy, anti-HCV-negative individuals. Dennin RH, et al. **Clin Chem Lab Med** 1999 Jun; 37(6):623-30

Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV-associated hepatitis. El-Awady MK, et al. **Clin Chim Acta** 1999 May;283(1-2):1-14

Ribozyme gene therapy for hepatitis C virus infection. Welch PJ, et al. **Clin Diagn Virol** 1998 Jul 15;10(2-3):163-71

RNA from decades-old archival tissue blocks for retrospective studies. Mizuno T, et al. **Diagn Mol Pathol** 1998 Aug;7(4):202-8

Early HCV RNA values after interferon predict response. Wiley TE, et al. **Dig Dis Sci** 1998 Oct;43(10):2169-72

Prevalence of hepatitis C virus RNA in patients with chronic renal diseases. Shaker O, et al. **East Mediterr Health J** 1998 Dec;4(3):548-53

High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Wong DA, et al. **Eur J Epidemiol** 1998 Jul;14(5):421-6

Mutation patterns for two flaviviruses: hepatitis C virus and GB virus C/hepatitis G virus. Mizokami M, et al. **FEBS Lett** 1999 May 7;450(3):294-8

Mutational analysis of a conserved tetraloop in the 5' untranslated region of hepatitis C virus identifies a novel RNA element essential for the internal ribosome entry site function. Psaridi L, et al. **FEBS Lett** 1999 Jun 18; 453(1-2):49-53

Inquiries on intraspousal transmission of hepatitis C virus: benefits and limitations of genome sequencing and phylogenetic analysis. Ross RS, et al. **Forensic Sci Int** 1999 Mar 15;100(1-2):69-76

Inhibition of internal entry site (IRES)-mediated translation by a small yeast RNA: a novel strategy to block hepatitis C virus protein synthesis. Das S, et al. **Front Biosci** 1998 Dec 1;3:D1241-52 (61 ref.)

Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese. Tanaka K, et al. **Fukuoka Igaku Zasshi** 1998 Aug; 89(8):238-48

"Real-time" polymerase chain reaction [editorial; comment] Oldach D. **Gastroenterology** 1999 Mar;116(3):763-4 (13 ref.) . Comment on: Gastroenterology 1999 Mar;116(3):636-42.

Real-time detection system for quantification of hepatitis C virus genome [see comments] Takeuchi T, et al. **Gastroenterology** 1999 Mar;116(3):636-42. Comment in: Gastroenterology 1999 Mar;116(3):763-5.

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Bellentani S, et al. **Gut** 1999 Jun; 44(6):874-80

HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Dragoni F, et al. **Haematologica** 1999 Jun;84(6):525-9

Quantitative hepatitis C RNA-polymerase chain reaction and detection with DNA-ELISA. Heintges T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1684-9

Genotype distributions of hepatitis C virus in São Paulo, Brazil: rare subtype found [letter] Bassit L, et al. **Hepatology** 1999 Mar;29(3):994-5

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Beard MR, et al. **Hepatology** 1999 Jul; 30(1):316-24

Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Christie JM, et al. **Hepatology** 1999 Oct;30(4):1037-44

Quantification of serum hepatitis C virus RNA [letter] Fang JW, et al. **Hepatology** 1999 Mar;29(3):997-8

Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Frangeul L, et al. **Hepatology** 1998 Dec; 28(6):1674-9

Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein. Fukuma T, et al. **Hepatology** 1998 Oct;28(4):1147-53

Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification [published erratum appears in Hepatology 1999 Feb;29(2):616] Gordon SC, et al. **Hepatology** 1998 Dec;28(6):1702-6

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Lamonaca V, et al. **Hepatology** 1999 Oct; 30(4):1088-98

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Lee WM, et al. **Hepatology** 1998 Nov;28(5):1411-5

Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon] [published erratum appears in Hepatology 1999 Jun;29(6):1915] López-Labrador FX, et al. **Hepatology** 1999 Mar;29(3):897-903

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays. Lunel F, et al. **Hepatology** 1999 Feb;29(2):528-35

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Murakami T, et al. **Hepatology** 1999 Oct;30(4):1045-53

Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Negro F, et al. **Hepatology** 1999 Feb;29(2):536-42

Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Okuda M, et al. **Hepatology** 1999 Jan; 29(1):217-22

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Pontisso P, et al. **Hepatology** 1999 Feb;29(2):585-9

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Prieto M, et al. **Hepatology** 1999 Jan;29(1):250-6

Quasispecies of hepatitis C virus in serum and in three different parts of the liver of patients with chronic hepatitis. Sakai A, et al. **Hepatology** 1999 Aug;30(2):556-61

Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Sherman KE, et al. **Hepatology** 1999 Jul;30(1):265-70

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Shiratori Y, et al. **Hepatology** 1999 May;29(5):1573-80

Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Eckels DD, et al. **Int Immunol** 1999 Apr;11(4):577-83

Higher detection rate of hepatitis G and C virus RNA in liver tissue than in serum of deceased injection drug users. Seidl S, et al. **Int J Legal Med** 1999;112(1):35-8

Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Shibata Y, et al. **Int J Oncol** 1999 Jun;14(6):1153-6

Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA. Arase Y, et al. **Intern Med** 1999 Jun;38(6):461-6

Current problems of hepatitis C virus infection in hemodialysis patients [editorial; comment] Kiyosawa K. **Intern Med** 1999 Aug;38(8):615-6. Comment on: Intern Med 1999 Aug;38(8):626-31.

Prevalence and characterization of hepatitis C virus in hemodialysis patients [see comments] Morikawa T, et al. **Intern Med** 1999 Aug;38(8):626-31. Comment in: Intern Med 1999 Aug;38(8):615-6.

Typing of hepatitis C virus by a new method based on restriction fragment length polymorphism. Buoro S, et al. **Intervirology** 1999;42(1):1-8

Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. Doglio A, et al. **J Clin Microbiol** 1999 May; 37(5):1567-9

Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. Germer JJ, et al. **J Clin Microbiol** 1999 Aug; 37(8):2625-30

Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. Le Pogam S, et al. **J Clin Microbiol** 1998 Oct;36(10):3040-3

Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. Mellor J, et al. **J Clin Microbiol** 1999 Aug;37(8):2525-32

Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units. Mizuno M, et al. **J Clin Microbiol** 1998 Oct;36(10):2926-31

Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. Norder H, et al. **J Clin Microbiol** 1998 Oct;36(10):3066-9

Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. Osella AR, et al. **J Clin Microbiol** 1999 Jul;37(7):2371-2

Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs. Wang YM, et al. **J Clin Microbiol** 1998 Oct;36(10):2982-9

Direct in situ reverse transcriptase-linked polymerase chain reaction with biotinylated primers for the detection of hepatitis C virus RNA in liver biopsies. Bettinger D, et al. **J Clin Virol** 1999 May;12(3):233-41

Hepatitis C virus 1b(II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. Tanaka H, et al. **J Epidemiol** 1998 Oct;8(4):244-9

Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. Tao Q, et al. **J Gastroenterol** 1998 Oct;33(5):684-93

Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene. Horiike N, et al. **J Gastroenterol Hepatol** 1999 Apr; 14(4):345-51

Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. Madan K, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):125-30

Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution. Casino C, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):717-25

Evidence of increasing diversification of hepatitis C viruses. Colina R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1377-82

Translation efficiencies of the 5' untranslated region from representatives of the six major genotypes of hepatitis C virus using a novel bicistronic reporter assay system. Collier AJ, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2359-66

The 5' untranslated region of GB virus B shows functional similarity to the internal ribosome entry site of hepatitis C virus. Grace K, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2337-41

Lower concentration of La protein required for internal ribosome entry on hepatitis C virus RNA than on poliovirus RNA. Isoyama T, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2319-27

Differences between hepatitis C virus 5' untranslated region quasispecies in serum and liver. Jang SJ, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):711-6

Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. Majid A, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):317-25

Poly(C)-binding protein interacts with the hepatitis C virus 5' untranslated region. Spångberg K, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1371-6

Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. Barbaro G, et al. **J Hepatol** 1999 May; 30(5):774-82

Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? Bellobuono A, et al. **J Hepatol** 1999 Jan;30(1):8-13

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. Brouwer JT, et al. **J Hepatol** 1999 Feb;30(2):192-8

Infection with an unenveloped DNA virus (TTV) in patients with acute or chronic liver disease of unknown etiology and in those positive for hepatitis C virus RNA. Ikeda H, et al. **J Hepatol** 1999 Feb;30(2):205-12

The impact of HCV genotypes on seroreactivity against HCV antigens immobilized on the RIBA 3.0 SIA [letter] Jain N, et al. **J Hepatol** 1999 Jan;30(1):173

Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. Leone F, et al. **J Hepatol** 1998 Nov;29(5):689-94

HCV NS5A 2209-2248 amino acid substitutions affect serum 2,5AS activities [letter] Murashima S, et al. **J Hepatol** 1999 Aug;31(2):382

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? [see comments] Nakano I, et al. **J Hepatol** 1999 Jun;30(6):1014-22. Comment in: J Hepatol 1999 Jun;30(6):1152-4.

The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. Rispeter K, et al. **J Hepatol** 1998 Sep;29(3):352-61

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. Roffi L, et al. **J Hepatol** 1998 Nov;29(5):701-6

Extrahepatic manifestations of HCV infection: facts and controversies. Zignego AL, et al. **J Hepatol** 1999 Aug; 31(2):369-76 (99 ref.)

Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy. Kessler HH, et al. **J Hum Virol** 1998 Jul-Aug;1(5):314-9

Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. Bukh J, et al. **J Infect Dis** 1998 Oct;178(4):1193-7

Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. Eyster ME, et al. **J Infect Dis** 1999 May;179(5):1062-9

Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. Giannini C, et al. **J Lab Clin Med** 1999 Jul; 134(1):68-73

Distribution of genotypes in the 5' untranslated region of hepatitis C virus in Korea. Park YS, et al. **J Med Microbiol** 1998 Jul;47(7):643-7

Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis. Allain JP, et al. **J Med Virol** 1999 Sep; 59(1):25-31

Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. Fukuda R, et al. **J Med Virol** 1999 Jul;58(3):201-7

The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. Harris KA, et al. **J Med Virol** 1999 Jun;58(2):127-31

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region. Hashimoto M, et al. **J Med Virol** 1999 Jul;58(3):247-55

Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. Irish DN, et al. **J Med Virol** 1999 Oct;59(2):135-40

Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy. Lu M, et al. **J Med Virol** 1999 Oct;59(2):146-53

Divergent evolution of hepatitis C virus in liver and peripheral blood mononuclear cells of infected patients. Maggi F, et al. **J Med Virol** 1999 Jan;57(1):57-63

Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. Müller-Breitkreutz K, et al. **J Med Virol** 1998 Nov; 56(3):239-45

Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. Olmedo E, et al. **J Med Virol** 1999 May;58(1):35-43

Hepatitis C virus infection and genotypes in Southern Israel and the Gaza Strip. Shemer-Avni Y, et al. **J Med Virol** 1998 Nov;56(3):230-3

Hepatitis C genotypes and subtypes in Saudi Arabia. Shobokshi OA, et al. **J Med Virol** 1999 May;58(1):44-8

Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. Wakita T, et al. **J Med Virol** 1999 Mar;57(3):217-22

Serum levels of hepatitis C virus RNA in infants and children with chronic hepatitis C. Azzari C, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):314-7

Hepatitis C virus infection: virus/host interactions. Pawlotsky JM. **J Viral Hepat** 1998 Sep;5 Suppl 1:3-8 (19 ref.)

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group. Pockros PJ, et al. **J Viral Hepat** 1998 Jul;5(4):271-6

Degree and distribution of variability in the 5' untranslated, E1, E2/NS1 and NS5 regions of the hepatitis C virus (HCV). Vizmanos JL, et al. **J Viral Hepat** 1998 Jul; 5(4):227-40

Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. Hahm B, et al. **J Virol** 1998 Nov;72(11):8782-8

A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. Honda M, et al. **J Virol** 1999 Feb;73(2):1165-74

Natural variation in translational activities of the 5' nontranslated RNAs of hepatitis C virus genotypes 1a and 1b: evidence for a long-range RNA-RNA interaction outside of the internal ribosomal entry site. Honda M, et al. **J Virol** 1999 Jun;73(6):4941-51

The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. Ito T, et al. **J Virol** 1998 Nov;72(11):8789-96

Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. Pawlotsky JM, et al. **J Virol** 1999 Aug;73(8):6490-9

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. Ray SC, et al. **J Virol** 1999 Apr;73(4):2938-46

Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. Shrivastava A, et al. **J Virol** 1998 Dec;72(12):9722-8

Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. Sullivan DG, et al. **J Virol** 1998 Dec; 72(12):10036-43

Alterations to both the primary and predicted secondary structure of stem-loop IIIc of the hepatitis C virus 1b 5' untranslated region (5'UTR) lead to mutants severely defective in translation which cannot be complemented in trans by the wild-type 5'UTR sequence. Tang S, et al. **J Virol** 1999 Mar;73(3):2359-64

Total chemical synthesis of the 3' untranslated region of the hepatitis C virus with long oligodeoxynucleotides. Encke J, et al. **J Virol Methods** 1998 Sep;74(1):117-21

Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. Pawlotsky JM, et al. **J Virol Methods** 1999 May; 79(2):227-35

Third millennium challenge: hepatitis C [news] Friedrich MJ. **JAMA** 1999 Jul 21;282(3):221-2

Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Natov SN, et al. **Kidney Int** 1999 Aug;56(2):700-6

Detection of hepatitis C virus RNA in more than 20-year-old paraffin-embedded liver tissue. Soguero C, et al. **Lab Invest** 1999 Mar;79(3):365-6

Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes. Pérez-Gracia T, et al. **Liver** 1999 Aug;19(4):288-93

Secondary structure of the hepatitis C virus 5' untranslated region and efficacy of interferon therapy for chronic hepatitis C. Suzuki K, et al. **Liver** 1998 Oct;18(5):331-6

Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Zein NN, et al. **Mayo Clin Proc** 1999 May;74(5):454-60

Genomic and phylogenetic analysis of hepatitis C virus strains from Argentina. Quarleri JF, et al. **Medicina (B Aires)** 1998; 58(2):153-9

Single-step reverse transcription-polymerase chain reaction for the detection of hepatitis C virus RNA. Mizutani T, et al. **Microbiol Immunol** 1998;42(8):549-53

Is hepatitis C virus genotype 4 predominant in Saudi Arabia? Boriskin YS, et al. **New Microbiol** 1999 Jul;22(3):173-80

Recurrence of hepatitis C virus infection after orthotopic liver transplantation: role of genotypes. Casino C, et al. **New Microbiol** 1999 Jan;22(1):11-8

Hepatitis C virus in patients with porphyria cutanea tarda: relationship to HCV-genotypes. Rivanera D, et al. **New Microbiol** 1998 Oct;21(4):329-34

Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. Vitale F, et al. **New Microbiol** 1998 Oct;21(4):335-42

Thermodynamic studies on hairpin forming antisense-oligodeoxynucleotides directed against hepatitis C virus RNA. Lehmann TJ, et al. **Nucleosides Nucleotides** 1999 Jun-Jul;18(6-7):1689-91

In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Yanagi M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2291-5

Comparison of secretion of a hepatitis C virus glycoprotein in Saccharomyces cerevisiae and Kluyveromyces lactis. Mustilli AC, et al. **Res Microbiol** 1999 Apr;150(3):179-87

Rapid genotyping of hepatitis C virus by direct cycle sequencing of PCR-amplified cDNAs and capillary electrophoresis analysis. Doglio A, et al. **Res Virol** 1998 Jul-Aug;149(4):219-27

Development of a multigenic plasmid vector for HCV DNA immunization. Papa S, et al. **Res Virol** 1998 Sep-Oct; 149(5):315-9

Molecular heterogeneity and new subtypes of HCV genotype 4. Rapicetta M, et al. **Res Virol** 1998 Sep-Oct;149(5):293-7

Genetic evolution of the hypervariable region 1 in hepatitis C virus carriers with normal aminotransferase activities. Ravaggi A, et al. **Res Virol** 1998 Nov-Dec;149(6):439-44

Genotyping HCV isolates from Italy by type-specific PCR assay in the core region. Spada E, et al. **Res Virol** 1998 Jul-Aug;149(4):209-18

Characterization of hepatitis C virus genotypes in an hemodialysis unit in Paysandú, Uruguay. Burjel L, et al. **Rev Argent Microbiol** 1998 Oct-Dec;30(4):190-4

cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5' nontranslated region chimeras. Frolov I, et al. **RNA** 1998 Nov; 4(11):1418-35

Hepatitis G virus infection in haemodialysis patients and its relationship with hepatitis C virus RNA positivity. Hizel N, et al. **Scand J Infect Dis** 1998;30(5):451-4

Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Murashima S, et al. **Scand J Infect Dis** 1999; 31(1):27-32

Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Reichard O, et al. **Scand J Infect Dis** 1998;30(5):441-6

Hepatitis C virus-infected, HCV-RNA-negative patients with bleeding disorders--relationship to age, HIV and treatment. Schulman S, et al. **Scand J Infect Dis** 1998; 30(5):455-8

Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Neary MP, et al. **Semin Liver Dis** 1999;19 Suppl 1:77-85

Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Wansbrough-Jones MH, et al. **Trans R Soc Trop Med Hyg** 1998 Sep-Oct;92(5):496-9

Summary of a Food and Drug Administration workshop on nucleic acid testing to screen donations of blood and plasma for the hepatitis C virus [letter] Tabor E, et al. **Transfusion** 1999 Aug;39(8):912-3

The use of polymerase chain reaction in plasma pools for the concomitant detection of hepatitis C virus and HIV type 1 RNA. Yerly S, et al. **Transfusion** 1998 Oct; 38(10):908-14

Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients. Rodrigues A, et al. **Transpl Int** 1998;11 Suppl 1:S115-8

Immunogenetic factors, HCV genotypes, and HCV recurrence after liver transplantation. Belli LS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):483-4

Hepatitis C reinfection after liver transplantation in relation to virus genotype. Tisone G, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):490-1

In situ enzymatic oligonucleotide amplification of hepatitis C virus-RNA in liver biopsy specimens (reverse transcriptase in situ polymerase chain reaction) after orthotopic liver transplantation for hepatitis C-related liver disease. Fragulidis GP, et al. **Transplantation** 1998 Dec 15; 66(11):1472-6

A human liver cell line exhibits efficient translation of HCV RNAs produced by a recombinant adenovirus expressing T7 RNA polymerase. Aoki Y, et al. **Virology** 1998 Oct 10;250(1):140-50

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. Bukh J, et al. **Virology** 1999 Sep 30;262(2):470-8

Expression of hepatitis C virus cDNA in human hepatoma cell line mediated by a hybrid baculovirus-HCV vector. Fipaldini C, et al. **Virology** 1999 Mar 15;255(2):302-11

Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Hong Z, et al. **Virology** 1999 Mar 30;256(1):36-44

An internal polypyrimidine-tract-binding protein-binding site in the hepatitis C virus RNA attenuates translation, which is relieved by the 3'-untranslated sequence. Ito T, et al. **Virology** 1999 Feb 15;254(2):288-96

Cellular proteins bind to the poly(U) tract of the 3' untranslated region of hepatitis C virus RNA genome. Luo G. **Virology** 1999 Mar 30;256(1):105-18

Molecular characterization of HCV 1b intra-familiar infection through three generations. Argentini C, et al. **Virus Genes** 1999;18(2):169-74

Phylogenetic evidence for the improved RNA higher-order structure in internal ribosome entry sequences of HCV and pestiviruses. Le SY, et al. **Virus Genes** 1998;17(3):279-95

Functional interactions between conserved motifs of the hepatitis C virus RNA helicase protein NS3. Min KH, et al. **Virus Genes** 1999;19(1):33-43

Functional analysis of a transrepressor domain in the hepatitis C virus core protein. Ray RB, et al. **Virus Res** 1999 Feb; 59(2):211-7

Comparison of amino acid sequences in hypervariable region-1 of hepatitis C virus clones between human inocula and the infected chimpanzee sera. Sugitani M, et al. **Virus Res** 1998 Aug;56(2):177-82

Use of bovine viral diarrhoea virus as an internal control for amplification of hepatitis C virus. Cleland A, et al. **Vox Sang** 1999;76(3):170-4

Large-scale HCV RNA screening in first-time blood donors: the first step towards genomic screening of blood donations. HCV RNA Screening Study Group. Petrik J, et al. **Vox Sang** 1999;76(3):159-62

Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Saldanha J, et al. **Vox Sang** 1999;76(3):149-58

[Comparison of hypervariable region gene of hepatitis C virus between an individual infected persistently and an individual recovered from infection] Pan W, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):26-8 (Eng. Abstr.) **(Chi)**

[Study on HCV infection and the distribution of HCV genotypes in different populations in Shenyang area] Huang F, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun;19(3):134-7 (Eng. Abstr.) **(Chi)**

[An investigation on genotypes of hepatitis C virus in Anhui province] Su H, et al.

Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1997 Aug; 18(4):205–7 (Eng. Abstr.) **(Chi)**

[Construction of HCV transgenic mice with Cre/loxP switching expression system] Wakita T. **Uirusu** 1998 Jun; 48(1):9–18 (32 ref.) **(Jpn)**

[Hepatitis C: contemporary views on molecular biology of HCV] Adamek A. **Pol Merkuriusz Lek** 1999 Jan;6(31):53–6 (36 ref.) (Eng. Abstr.) **(Pol)**

[Genetic diagnosis of hepatitis C virus infection] Stańczak JJ. **Pol Merkuriusz Lek** 1999 Feb;6(32):92–5 (35 ref.) (Eng. Abstr.) **(Pol)**

[Spread of hepatitis C and separate genotypes of hepatitis C virus in a region with a moderately active epidemic process] Kuzin SN, et al. **Vopr Virusol** 1999 Mar–Apr; 44(2):79–82 (Eng. Abstr.) **(Rus)**

[Prevalence of hepatitis C virus genotypes: epidemiology and histologic characteristics] Pena MJ, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):456–60 (Eng. Abstr.) **(Spa)**

[The genotype of the hepatitis C virus in patients with essential mixed cryoglobulinemia (letter; comment)] Yebra-Bango M, et al. **Med Clin (Barc)** 1999 Jan 30; 112(3):119. Comment on: Med Clin (Barc) 1998 May 23;110(18):681–6. **(Spa)**

[Distribution of the genotypes of hepatitis C virus in intravenous drug addicts in Argentina] Findor JA, et al. **Medicina (B Aires)** 1999;59(1):49–54 (Eng. Abstr.) **(Spa)**

[Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population] Muñoz G, et al. **Rev Med Chil** 1998 Sep;126(9):1035–42 (Eng. Abstr.) **(Spa)**

GROWTH & DEVELOPMENT

Yellow fever 5' noncoding region as a potential element to improve hepatitis C virus production through modification of translational control [published erratum appears in Biochem Biophys Res Commun 1999 Apr 2;257(1):250] Malet I, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):257–64

The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. Laskus T, et al. **J Infect Dis** 1998 Oct;178(4):1189–92

Future options for the management of hepatitis C. Davis GL, et al. **Semin Liver Dis** 1999;19 Suppl 1:103–12 (75 ref.)

IMMUNOLOGY

Analysis of human immune response to potential hepatitis C viral epitopes. Khanna A, et al. **Acta Virol** 1998 Jun; 42(3):141–5

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? John M, et al. **AIDS** 1998 Dec 3;12(17):2289–93

Can risk factor screening predict hepatitis C antibody reactivity? Magriples U, et al. **Am J Perinatol** 1998 Jun; 15(6):395–8

Hepatitis C virus and autoimmune manifestations [editorial] Indiveri F. **Ann Ital Med Int** 1998 Oct–Dec;13(4):191–3

Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Esumi M, et al. **Arch Virol** 1999;144(5):973–80

Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Beld M, et al. **Blood** 1999 Aug 15; 94(4):1183–91

Restricted isotypic antibody reactivity to hepatitis C virus synthetic peptides in immunocompromised patients. Devesa M, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):279–81

Perspectives for a hepatitis C virus vaccine. Abrignani S, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):181–5 (16 ref.)

mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment. Shapiro S, et al. **Clin Exp Immunol** 1998 Oct;114(1):55–60

Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis. Güngör E, et al. **Dermatology** 1999;198(1):26–8

IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Toniutto P, et al. **Diagn Microbiol Infect Dis** 1999 Feb;33(2):69–73

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. Vidalin O, et al. **DNA Cell Biol** 1999 Aug;18(8):611–21

The interrelationship between hepatitis C virus and HLA [comment] Donaldson PT. **Eur J Clin Invest** 1999 Apr; 29(4):280–3. Comment on: Eur J Clin Invest 1999 Apr;29(4):337–43.

Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection [see comments] Lechmann M, et al. **Eur J Clin Invest** 1999 Apr;29(4):337–43. Comment in: Eur J Clin Invest 1999 Apr;29(4):280–3.

Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. Bello PY, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):570–2

Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Beld M, et al. **Hepatology** 1999 Apr; 29(4):1288–98

Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Christie JM, et al. **Hepatology** 1999 Oct;30(4):1037–44

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Lamonaca V, et al. **Hepatology** 1999 Oct; 30(4):1088–98

Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. Mondelli MU, et al. **Hepatology** 1999 Aug;30(2):537–45

Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Alexander J, et al. **Hum Immunol** 1998 Dec;59(12):776–82

Functionally distinct T-cell epitopes within the hepatitis C virus non-structural 3 protein. Tabatabai NM, et al. **Hum Immunol** 1999 Feb;60(2):105–15

Analysis of a successful immune response against hepatitis C virus. Cooper S, et al. **Immunity** 1999 Apr;10(4):439–49

Insignificant prevalence of antibodies to hepatitis C in a rural area of western Maharashtra. Chadha MS, et al. **Indian J Gastroenterol** 1999 Jan–Mar;18(1):22–3

Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV-I carriers in Japan. Hisada M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):421–5

Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. Casino C, et al. **J Clin Microbiol** 1999 Aug;37(8):2726–8

Definition of false-positive reactions in screening for hepatitis C virus antibodies. Schröter M, et al. **J Clin Microbiol** 1999 Jan;37(1):233–4

High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow-up. Feucht HH, et al. **J Clin Virol** 1999 Jun;13(1–2):43–51

Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. Kammer AR, et al. **J Exp Med** 1999 Jul 19;190(2):169–76

Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. Hiranuma K, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):187–93

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. Hultgren C, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2381–91

Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. Majid A, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):317–25

Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. Rodriguez-López M, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):727–38

Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. Chang KM, et al. **J Immunol** 1999 Jan 15; 162(2):1156–64

Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. Encke J, et al. **J Immunol** 1998 Nov 1;161(9):4917–23

Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. Frasca L, et al. **J Immunol** 1999 Jul 15;163(2):650–8

Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. Kanto T, et al. **J Immunol** 1999 May 1; 162(9):5584–91

Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. Large MK, et al. **J Immunol** 1999 Jan 15;162(2):931–8

Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. Scognamiglio P, et al. **J Immunol** 1999 Jun 1;162(11):6681–9

Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. Selby M, et al. **J Immunol** 1999 Jan 15;162(2):669–76

T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] Shirai M, et al. **J Immunol** 1999 Jan 1; 162(1):568–76

Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. Wang H, et al. **J Immunol** 1999 Apr 1;162(7):4177–83

Association between genes of the major histocompatibility complex class II and the outcome of hepatitis C virus infection [letter; comment] Alric L, et al. **J Infect Dis** 1999 May;179(5):1309–10. Comment on: J Infect Dis 1998 Jul;178(1):39–44.

Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy. Park YM, et al. **J Korean Med Sci** 1999 Apr;14(2):165–70

Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis. Allain JP, et al. **J Med Virol** 1999 Sep; 59(1):25–31

Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. Jackson M, et al. **J Med Virol** 1999 Jul; 58(3):239–46

HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. Jolivet-Reynaud C, et al. **J Med Virol** 1998 Dec; 56(4):300–9

Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: different antigenic determinants from human B cells. Ou-Yang P, et al. **J Med Virol** 1999 Apr;57(4):345–50

Identification of antigenic sites on three hepatitis C virus proteins using phage-displayed peptide libraries. Pereboeva LA, et al. **J Med Virol** 1998 Oct;56(2):105–11

Interleukin 12 enhances deficient HCV-antigen-induced Th1-type immune response of peripheral blood mononuclear cells. Schlaak JF, et al. **J Med Virol** 1998 Oct;56(2):112–7

The natural course of chronic hepatitis C: implications for clinical practice. Dusheiko GM. **J Viral Hepat** 1998 Sep; 5 Suppl 1:9–12 (15 ref.)

Consensus interferon: a novel interferon for the treatment of hepatitis C. Heathcote J. **J Viral Hepat** 1998 Sep;5 Suppl 1:13–8

Hepatitis C: current status, future progress. Marcellin P. **J Viral Hepat** 1998 Sep;5 Suppl 1:1

Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Bassett SE, et al. **J Virol** 1999 Feb; 73(2):1118–26

Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. Fournillier A, et al. **J Virol** 1999 Sep;73(9):7497–504

Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies. Lee JW, et al. **J Virol** 1999 Jan; 73(1):11–8

A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Kuboki M, et al. **Liver** 1999 Apr;19(2):88–96

Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Lee SW, et al. **Mol Cells** 1998 Aug 31;8(4):444–51

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. He XS, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5692–7

Development of a multigenic plasmid vector for HCV DNA immunization. Papa S, et al. **Res Virol** 1998 Sep-Oct; 149(5):315–9

Lack of correlation between sensitivity characteristics of the tests for hepatitis C virus antibodies estimated with serially diluted and natural low-reactive control specimens. Bondarenko IG, et al. **Scand J Clin Lab Invest** 1999 Apr; 59(2):153–8

DNA-vaccines against hepatitis B and C viral infections: a brief overview. Irshad M. **Trop Gastroenterol** 1999 Apr-Jun;20(2):64–7 (30 ref.)

Evaluation of third generation anti-HCV enzyme immunoassays. Panigrahi AK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):105–7

Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Cho JH, et al. **Vaccine** 1999 Mar 5;17(9–10):1136–44

DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Forns X, et al. **Vaccine** 1999 Apr 9;17(15–16):1992–2002

Antigenic heterogeneity of the hepatitis C virus NS4 protein as modeled with synthetic peptides. Chang JC, et al. **Virology** 1999 Apr 25;257(1):177–90

Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus. Esumi M, et al. **Virology** 1998 Nov 10;251(1):158–64

Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects. Giuggio VM, et al. **Virology** 1998 Nov 10;251(1):132–40

Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Shang D, et al. **Virology** 1999 Jun 5;258(2):396–405

Multiple sequence-reactive antibodies induced by a single

peptide immunization with hypervariable region 1 of hepatitis C virus. Zhou YH, et al. **Virology** 1999 Apr 10; 256(2):360–70

A comparative evaluation of the sensitivity of five anti-hepatitis C virus immunoblot assays. Couroucé AM, et al. **Vox Sang** 1998;74(4):217–24

[Studies on synthetic peptide. XX: the antigenicity and linear epitope map of synthetic peptide hepatitis C virus] Liu G, et al. **Yao Hsueh Hsueh Pao** 1996;31(10):751–6 (Eng. Abstr.) **(Chi)**

[An autopsy case of primary squamous cell carcinoma of the liver associated with hepatitis C virus antibody positive liver cirrhosis] Yoshida T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1141–6 **(Jpn)**

ISOLATION & PURIFICATION

Hepatitis C: Part I. Routine serologic testing and diagnosis. Moyer LA, et al. **Am Fam Physician** 1999 Jan 1;59(1):79–88, 91–2 (45 ref.)

CDC issues new recommendations for the prevention and control of hepatitis C virus infection. Rose VL. **Am Fam Physician** 1999 Mar 1;59(5):1321–3

Serodiagnosis of hepatitis C virus. Effect of new evaluation of cutoff values for enzyme-linked immunosorbent assay in Brazilian patients. dos Santos VA, et al. **Am J Clin Pathol** 1999 Sep;112(3):418–24

Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. Garcia-Bengoechea M, et al. **Am J Gastroenterol** 1999 Jul; 94(7):1902–5

Hepatitis C: does a healing state exist? [letter] Paraná R, et al. **Am J Gastroenterol** 1999 Mar;94(3):862–3

A case-control study of the factors associated with spontaneous resolution of hepatitis C viremia. Quinn PG, et al. **Am J Gastroenterol** 1999 Mar;94(3):668–73

Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)

Oral thymic extract to treat hepatitis C [letter] Blank RD. **Ann Intern Med** 1999 Aug 17;131(4):312

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101–4

Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Beld M, et al. **Blood** 1999 Aug 15; 94(4):1183–91

Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center [letter] Germanidis G, et al. **Blood** 1999 Mar 1;93(5):1778–9

Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Paul IM, et al. **Blood** 1999 Jun 1;93(11):3672–7

Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Sansonno D, et al. **Blood** 1998 Nov 1;92(9):3328–37

Automation of polymerase chain reaction-based systems for detection of hepatitis C virus RNA. Kessler HH, et al. **Clin Chem Lab Med** 1998 Aug;36(8):583–6

Monitoring of inhibitors of enzymatic amplification in polymerase chain reaction and evaluation of efficacy of RNA extraction for the detection of hepatitis C virus using the internal control. Miyachi H, et al. **Clin Chem Lab Med** 1998 Aug;36(8):571–5

Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. Nitu IC, et al. **Clin Lab Haematol** 1999 Apr; 21(2):139–41

Improved sensitivity of reverse transcriptase polymerase chain reaction for hepatitis C virus using random hexamer primers. Radhakrishnan S, et al. **Diagn Microbiol Infect Dis** 1999 Mar;33(3):153–6

Hepatitis C virus RNA viremia in Central Africa [letter] Cancré N, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):484–5

Porphyria cutanea tarda and hepatitis G and C virus infection. Mancini C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):534–5

In situ reverse transcriptase-polymerase chain reaction: an innovative tool for hepatitis C virus RNA detection and localisation, and for quantification of infected cells. Muratori L. **Eur J Histochem** 1998;42(2):133–6 (20 ref.)

"Real-time" polymerase chain reaction [editorial; comment] Oldach D. **Gastroenterology** 1999 Mar;116(3):763–4 (13 ref.) . Comment on: Gastroenterology 1999 Mar;116(3):636–42.

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts [see comments] Vargas HE, et al. **Gastroenterology** 1999 Jul; 117(1):149–53. Comment in: Gastroenterology 1999 Jul;117(1):263–5.

High prevalence of anti-HGV/E2 antibodies in HCV-positive patients with non Hodgkin's lymphoma [letter] Civardi G, et al. **Haematologica** 1998 Oct; 83(10):957–8

B-lymphoproliferative disorders in patients with hepatitis C virus infection [letter] Pérez Sánchez I, et al. **Haematologica** 1998 Oct;83(10):946–8

Hepatitis C viral load, genotype and histological severity in patients with bleeding disorders. Ahmed MM, et al. **Haemophilia** 1999 Jan;5(1):49–55

Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Schmidt WN, et al. **Hepatology** 1998 Oct;28(4):1110–6

Diagnosis of hepatitis C virus infection by ELISA, RIBA and RT-PCR: a comparative evaluation. Mohan KV, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):73–5

Association of hepatitis C virus & hepatitis B virus in chronic liver disease. Berry N, et al. **Indian J Med Res** 1998 Dec; 108:255–9

Importance of RT-PCR for detection of hepatitis C virus among different patient groups. Ramalingam S, et al. **Indian J Med Res** 1998 Sep;108:85–7

HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C. Fabris P, et al. **Infection** 1998 Sep-Oct; 26(5):283–7

High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners. Fabris P, et al. **Infection** 1999 Mar-Apr;27(2):86–91

Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Tagger A, et al. **Int J Cancer** 1999 May 31;81(5):695–9

Hepatitis C virus seroconversion and genotype prevalence in patients and staff on chronic hemodialysis. Zamir D, et al. **J Clin Gastroenterol** 1999 Jan;28(1):23–8

Significance of repeatedly normal aminotransferase activities in HCV-infected patients. Zylberberg H, et al. **J Clin Gastroenterol** 1999 Jul;29(1):71–5

Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. Abe K, et al. **J Clin Microbiol** 1998 Oct;36(10):3070–2

Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. Casino C, et al. **J Clin Microbiol** 1999 Aug;37(8):2726–8

Effect of multiple freeze-thaw cycles on hepatitis B virus DNA and hepatitis C virus RNA quantification as measured with branched-DNA technology. Krajden M, et al. **J Clin Microbiol** 1999 Jun;37(6):1683–6

High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. Martell M, et al. **J Clin Microbiol** 1999 Feb;37(2):327–32

Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. Mellor J, et al. **J Clin Microbiol** 1999 Aug;37(8):2525–32

Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay. Schröter M, et al. **J Clin Microbiol** 1999 Aug;37(8):2576–80

Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. Stapleton JT, et al. **J Clin Microbiol** 1999 Mar;37(3):484–9

High-throughput extraction, amplification, and detection (HEAD) of HCV-RNA in individual blood donations. Legler TJ, et al. **J Clin Virol** 1999 Jun;13(1-2):95–103

Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations. Yoshikawa M, et al. **J Gastroenterol** 1999 Apr;34(2):269–74

Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients. Lau GK, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):52–6

Effects of hepatitis G virus coinfection on severity of hepatitis C: relationship to risk factors and response to interferon treatment [see comments] Lin R, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):773–80. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763–6.

Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan. Luo JC, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):685–90

Evidence of increasing diversification of hepatitis C viruses. Colina R, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1377–82

Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma. De Mitri MS, et al. **J Hepatol** 1998 Dec;29(6):887–92

Characteristics of patients sero-positive for hepatitis C virus (HCV) antibodies but negative for HCV-RNA by polymerase chain reaction [letter] Hashimoto E, et al. **J Hepatol** 1998 Nov;29(5):856–7

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? McHutchison J, et al. **J Hepatol** 1998 Sep;29(3):362–8

The distribution of HBV, HCV and HGV among livers with fulminant hepatic failure of different aetiology. Sergi C, et al. **J Hepatol** 1998 Dec;29(6):861–71

Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. Abdel-Hamid M, et al. **J Hum Virol** 1997 Nov-Dec;1(1):58–65

Evidence of hepatitis C virus in cervical smears [letter] Manavi M, et al. **J Infect** 1999 Jan;38(1):60–1

Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus. Fukuda Y, et al. **J Int Med Res** 1998 Dec;26(6):313–8

Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. Fujie H, et al. **J Med Virol** 1999 Oct;59(2):141–5

Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay. Kawai S, et al. **J Med Virol** 1999 Jun;58(2):121–6

Ultracentrifugation and concentration of a large volume of serum for HCV RNA during treatment may predict sustained and relapse response in chronic HCV infection. McHutchison JG, et al. **J Med Virol** 1999 Apr;57(4):351–5

Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. Maggi F, et al. **J Neurovirol** 1999 Jun;5(3):319–23

Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing. Lefrère JJ, et al. **J Virol Methods** 1999 Jun;80(1):33–44

Critical level and detection limit: performance measures for PCR-based assays. Markert-Hahn C, et al. **J Virol Methods** 1998 Oct;74(2):139–48

Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay. Mercier B, et al. **J Virol Methods** 1999 Jan;77(1):1–9

Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting [see comments] Roth WK, et al. **Lancet** 1999 Jan 30;353(9150):359–63. Comment in: Lancet 1999 Apr 24;353(9162):1441.

Nonspecificity of monoclonal antibody Tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. Doughty AL, et al. **Liver Transpl Surg** 1999 Jan;5(1):40–5

Reverse transcriptase-polymerase chain reaction fails to detect peripheral-blood hepatitis C RNA in formalin-fixed liver tissue. Guerrero RB, et al. **Liver Transpl Surg** 1998 Nov;4(6):455–60

Hepatitis C virus (HCV): a silent epidemic. Bandy U. **Med Health R I** 1999 Jun;82(6):223–4 (1 ref.)

Single-step reverse transcription-polymerase chain reaction for the detection of hepatitis C virus RNA. Mizutani T, et al. **Microbiol Immunol** 1998;42(8):549–53

Hepatitis C infection in children [editorial; comment] Jonas MM. **N Engl J Med** 1999 Sep 16;341(12):912–3. Comment on: N Engl J Med 1999 Sep 16;341(12):866–70.

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening [see comments] Vogt M, et al. **N Engl J Med** 1999 Sep 16;341(12):866–70 . Comment in: N Engl J Med 1999 Sep 16;341(12):912–3.

Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Dalekos GN, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1804–6

Hepatitis C virus in the haemodialysis units: novel insights by new techniques? [editorial] Fabrizi F, et al. **Nephrol Dial Transplant** 1999 May;14(5):1072–5 (26 ref.)

Evidence of hepatitis C virus passage across dialysis membrane. Valtuille R, et al. **Nephron** 1998 Oct;80(2):194–6

Iatrogenic hepatitis C virus transmission via commercial plasma donation in Spain [letter] Davis AR. **Pathology** 1998 Nov;30(4):427

Fulminant hepatitis caused by hepatitis C virus. Taga T, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1174–6

Transplacental transmission of hepatitis C virus in HIV-negative mothers. Agha S, et al. **Res Virol** 1998 Jul-Aug;149(4):229–34

Detection of virus-like particles in liver biopsies from HCV-infected patients. Bosman C, et al. **Res Virol** 1998 Sep-Oct;149(5):311–4

A quantitative HCV-PCR test for routine diagnostics. Krarup HB, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):415–22

Detection of hepatitis-C virus and hepatitis-C virus replication in hepatocellular carcinoma by in situ hybridization. Ohishi M, et al. **Scand J Gastroenterol** 1999 Apr;34(4):432–8

HCV-RNA levels increase during pregnancy in women with chronic hepatitis C. Wejstål R, et al. **Scand J Infect Dis** 1998;30(2):111–3

Evaluation of a new anti-HCV-assay kit for anti-HCV screening in early childhood. Sugiyama K, et al. **Tohoku J Exp Med** 1999 Mar;187(3):257–62

Characteristics of hepatitis C-positive blood donors in Victoria, Australia. Wong PY, et al. **Transfus Med** 1999 Mar;9(1):15–9

PCR testing of plasma pools: from concept to reality. Flanagan P, et al. **Transfus Med Rev** 1999 Jul;13(3):164–76 (40 ref.)

Public health, public trust, and public decision making: making hepatitis C virus lookback work [editorial; comment] AuBuchon JP. **Transfusion** 1999 Feb;39(2):123–7 . Comment on: Transfusion 1999 Feb;39(2):188–93. Comment on: Transfusion 1999 Feb;39(2):194–200.

Transfusion-acquired hepatitis C: the Danish lookback experience. The Danish HCV [hepatitis C virus] Lookback Group [see comments] Christensen PB, et al. **Transfusion** 1999 Feb;39(2):188–93. Comment in: Transfusion 1999 Feb;39(2):123–7.

Quantitation of hepatitis C virus RNA in liver tissue of allografts: correlation with histologic features and liver function tests. Aardema KL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):477–8

Hepatitis C virus in peripheral blood mononuclear cells from

a chronically infected patient receiving liver graft from infected donor. Radkowski M, et al. **Transplantation** 1999 Feb 27;67(4):627–9

Evaluation of third generation anti-HCV enzyme immunoassays. Panigrahi AK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):105–7

Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Hong Z, et al. **Virology** 1999 Mar 30;256(1):36–44

Estimated risk of transmission of hepatitis C virus by blood transfusion. Koerner K, et al. **Vox Sang** 1998;74(4):213–6

Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation [see comments] Lawlor E, et al. **Vox Sang** 1999;76(3):138–43. Comment in: Vox Sang 1999 ;76(3):135–7.

Persistence of HCV-RNA in a blood donor with negative antibody assays [letter] Rapicetta M, et al. **Vox Sang** 1999; 76(3):192–3

Supplementary anti-hepatitis C virus (HCV) testing with 2nd and 3rd generation recombinant immunoblot assay and matrix applied to enzyme immunoassay positive sera and comparison with HCV-RNA detection. Engel PM, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):267–75

[Hepatitis C virus infection among long-term hemodialysis patients] Lu A, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun;36(6):402–5 (Eng. Abstr.) **(Chi)**

[Prospect of the study on the relation between hepatitis C virus and hepatocellular carcinoma] Wang W. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Oct;26(5):315–6 (10 ref.) **(Chi)**

[Retrospective study of the value of the RIBA-3 test in 68 patients with discordant serologies with regard to hepatitis C obtained with third generation ELISA tests. Is there still a value in RIBA-3?] Cecille A, et al. **Pathol Biol (Paris)** 1999 May;47(5):508–11 (Eng. Abstr.) **(Fre)**

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412–5 (Eng. Abstr.) **(Fre)**

[Pseudo-sarcoidotic lymphoma and nephrotic syndrome in a hepatitis C-carrying female patient (letter)] Morand JJ, et al. **Presse Med** 1998 Apr 11;27(14):668 **(Fre)**

[Hepatoblastoma in an HCV-positive adult. Report of a case] Diotallevi P, et al. **Radiol Med (Torino)** 1999 Apr; 97(4):319–21 **(Ita)**

[Hepatitis C virus infection and cardiomyopathy] Matsumori A. **Nippon Rinsho** 1999 Feb;57(2):455–63 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Viremia levels of the chronic hepatitis c virus in HIV infected patients, clinical implications] Ramos Paesa C, et al. **An Med Interna** 1998 Sep;15(9):464–9 (Eng. Abstr.) **(Spa)**

[Prevalence and genotypes of hepatitis C virus in blood donors and in patients with chronic liver disease and hepatocarcinoma in a Chilean population] Muñoz G, et al. **Rev Med Chil** 1998 Sep;126(9):1035–42 (Eng. Abstr.) **(Spa)**

METABOLISM

Subcellular localization of hepatitis C viral proteins in mammalian cells. Kim JE, et al. **Arch Virol** 1999; 144(2):329–43

Hepatitis C virus NS5A protein is phosphorylated by casein kinase II. Kim J, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):777–81

Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. Ishido S, et al. **FEBS Lett** 1998 Nov 6;438(3):258–62

Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Thomas HC, et al. **Hepatology** 1999 Apr;29(4):1333–4

Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. LaPlante SR, et al. **J Biol Chem** 1999 Jun 25;274(26):18618–24

Hepatitis C virus core protein binds to a DEAD box RNA helicase. Mamiya N, et al. **J Biol Chem** 1999 May 28; 274(22):15751–6

Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. Borowski P, et al. **J Clin Virol** 1999 Jun;13(1-2):61–9

The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. Flint M, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1943–7

Covalent interactions are not required to permit or stabilize the non-covalent association of hepatitis C virus glycoproteins E1 and E2. Patel J, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1681–90

Poly(C)-binding protein interacts with the hepatitis C virus 5' untranslated region. Spångberg K, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1371–6

Suramin blocks hepatitis C binding to human hepatoma cells in vitro. Garson JA, et al. **J Med Virol** 1999 Mar; 57(3):238–42

Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. Monazahian M, et al. **J Med Virol** 1999 Mar;57(3):223–9

The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. Cocquerel L, et al. **J Virol** 1999 Apr; 73(4):2641–9

Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Flint M, et al. **J Virol** 1999 Aug;73(8):6235–44

Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. Flint M, et al. **J Virol** 1999 Aug; 73(8):6782–90

Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. Hahm B, et al. **J Virol** 1998 Nov;72(11):8782–8

Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. Koch JO, et al. **J Virol** 1999 Sep;73(9):7138–46

Membrane compatibility and clearance of hepatitis C virus in chronic dialysis patients [letter] Adorati M, et al. **Nephron** 1999;82(4):358

Binding of hepatitis C virus to CD81. Pileri P, et al. **Science** 1998 Oct 30;282(5390):938–41

Phosphorylation of nonstructural 5A protein of hepatitis C virus: HCV group-specific hyperphosphorylation. Hirota M, et al. **Virology** 1999 Apr 25;257(1):130–7

Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Owsianka AM, et al. **Virology** 1999 May 10;257(2):330–40

Internal processing of hepatitis C virus NS3 protein. Shoji I, et al. **Virology** 1999 Feb 15;254(2):315–23

Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Tsuchihara K, et al. **Virology** 1999 May 25;258(1):100–7

Secretion and purification of HCV E1 protein forms as glutathione-S-transferase fusion in the baculovirus insect cell system. Ciccaglione AR, et al. **Virus Res** 1998 Jun; 55(2):157–65

Characterization of the structural proteins of hepatitis C virus expressed by an adenovirus recombinant. Seong YR, et al. **Virus Res** 1998 Jun;55(2):177–85

PATHOGENICITY

Hepatitis C virus and immunoglobulin gene rearrangements: an early step in lymphomagenesis? Santini GF, et al. **Acta Haematol** 1998 Dec;100(3):117–22

Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Rodriguez-Iñigo E, et al. **Am J Pathol** 1999 Jun;154(6):1877–81

Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. Furusyo N, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):85–91

Sjögren's syndrome and hepatitis C virus. Ramos-Casals M, et al. **Clin Rheumatol** 1999;18(2):93–100 (98 ref.)

Hepatitis C virus association with non-Hodgkin's lymphoma. Timurağlu A, et al. **Haematologia (Budap)** 1999;29(4):301–4

Hepatitis C virus infection and mixed cryoglobulinemia in patients with lymphoproliferative diseases [letter] Domingo JM, et al. **Haematologica** 1999 Jan;84(1):94–6

Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Bassett SE, et al. **Hepatology** 1999 Jun;29(6):1884–92

Cryoglobulinaemic membranoproliferative glomerulonephritis and hepatits C virus infection [see comments] Mazzaro C, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):45–53. Comment in: Ital J Gastroenterol Hepatol 1999 Jan-Feb;31(1):54–5.

Extrahepatic manifestations of HCV infection: facts and controversies. Zignego AL, et al. **J Hepatol** 1999 Aug; 31(2):369–76 (99 ref.)

Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. Large MK, et al. **J Immunol** 1999 Jan 15;162(2):931–8

Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. Idilman R, et al. **J Viral Hepat** 1998 Sep; 5(5):285–99 (86 ref.)

Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. Sullivan DG, et al. **J Virol** 1998 Dec; 72(12):10036–43

Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. Dammacco F, et al. **Leuk Lymphoma** 1998 Nov; 31(5-6):463–76 (89 ref.)

NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Tan SL, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5533–8

The hepatitis C virus and systemic diseases [editorial] Mariette X. **Rev Rhum Engl Ed** 1998 Dec;65(12):737–40 (21 ref.)

Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Neary MP, et al. **Semin Liver Dis** 1999;19 Suppl 1:77–85

[Hepatitis C virus pathogenic potential (letter; comment)] Mora Fernández C, et al. **An Med Interna** 1998 Aug; 15(8):454. Comment on: An Med Interna 1995 Oct;12(10):517–8. **(Spa)**

[The hepatitis C virus: after the track of the human immunodeficiency virus (editorial)] Pérez-Olmeda M, et al. **Rev Clin Esp** 1999 Jan;199(1):5–7 (42 ref.) **(Spa)**

PHYSIOLOGY

Characterisation of non-structural protein 3 of hepatitis C virus as modulator of protein phosphorylation mediated by PKA and PKC: evidences for action on the level of substrate and enzyme. Borowski P, et al. **Arch Virol** 1999; 144(4):687–701

Replication of hepatitis C virus in B lymphocytes (CD19+) [letter] Morsica G, et al. **Blood** 1999 Aug 1;94(3):1138–9

Molecular mechanisms of hepatitis B and C viruses related to liver carcinogenesis. Brechot C. **Hepatogastroenterology** 1998 Aug;45 Suppl 3:1189–96 (46 ref.)

Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Laskus T, et al. **Hepatology** 1998 Nov; 28(5):1398–401

Is CD81 the key to hepatitis C virus entry? Rice CM. **Hepatology** 1999 Mar;29(3):990–2 (21 ref.)

A tale of two strands: reverse-transcriptase polymerase chain reaction detection of hepatitis C virus replication. Sangar DV, et al. **Hepatology** 1998 Nov;28(5):1173–6 (31 ref.)

Evaluation of a disinfection procedure for hysteroscopes contaminated by hepatitis C virus. Sartor C, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):434–6

Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. Duvet S, et al. **J Biol Chem** 1998 Nov 27;273(48):32088–95

In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. Fournier C, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2367–74

Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. Ghosh AK, et al. **J Gen Virol** 1999 May;80 (Pt 5):1179–83

The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. Song J, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):879–86

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection [letter] Fialaire P, et al. **J Infect Dis** 1999 Aug;180(2):574–5

Specific in vitro association between the hepatitis C viral genome and core protein. Fan Z, et al. **J Med Virol** 1999 Oct;59(2):131–4

Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. Knolle PA, et al. **J Viral Hepat** 1998 Nov;5(6):399–406

Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. Bassett SE, et al. **J Virol** 1999 Feb; 73(2):1118–26

Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. Gale M Jr, et al. **J Virol** 1999 Aug;73(8):6506–16

Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. Heim MH, et al. **J Virol** 1999 Oct;73(10):8469–75

Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. Shrivastava A, et al. **J Virol** 1998 Dec;72(12):9722–8

Hepatitis C virus core protein interacts with cellular putative RNA helicase. You LR, et al. **J Virol** 1999 Apr; 73(4):2841–53

Poliovirus/Hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. Zhao WD, et al. **J Virol** 1999 Feb;73(2):1546–54

Susceptibility of human and non-human cell lines to HCV infection as determined by the centrifugation-facilitated method. Morrica A, et al. **J Virol Methods** 1999 Feb; 77(2):207–15

Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Wietzke P, et al. **Liver** 1999 Aug; 19(4):348–53

Mathematicians turn their attention to hepatitis C [news] Blower S, et al. **Nat Med** 1998 Nov;4(11):1233–4

Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. Morisco F, et al. **Res Virol** 1998 Sep-Oct;149(5):277–82

Morphological modifications induced by HCV infection in the TOFE human lymphoblastoid cell line. Serafino A, et al. **Res Virol** 1998 Sep-Oct;149(5):299–305

TOFE human-B-cell-line-based adsorption-inhibition assay to detect HCV neutralizing antibodies. Valli MB, et al. **Res Virol** 1998 Sep-Oct;149(5):331–3

Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C. Weiland O, et al. **Scand J Infect Dis** 1999; 31(2):115–8

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line [see comments] Lohmann V, et al. **Science** 1999 Jul 2;285(5424):110–3. Comment in: Science 1999 Jul 2;285(5424):26–30.

Ultrastructural and immunocytochemical evidences of core-particle formation in the methylotrophic Pichia pastoris yeast when expressing HCV structural proteins

(core-E1). Falcón V, et al. **Tissue Cell** 1999 Apr; 31(2):117-25

A single nucleotide insertion in the 5'-untranslated region of hepatitis C virus leads to enhanced cap-independent translation. Zhang J, et al. **Virology** 1999 Sep 1; 261(2):263-70

Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Ikeda M, et al. **Virus Res** 1998 Aug;56(2):157-67

Hepatitis C virus stability: the issue! Cardoso MS, et al. **Vox Sang** 1999;76(2):124-7

[The role of chaperone proteins in the assembly of envelope proteins of hepatitis C virus] Dubuisson J. **Bull Mem Acad R Med Belg** 1998;153(7-9):343-9; discussion 350-1 (Eng. Abstr.) **(Fre)**

[Transmission modes of hepatitis C virus] Karmochkine M, et al. **Presse Med** 1998 May 16;27(18):871-6 (68 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Trestard A, et al. **Arch Virol** 1998;143(11):2241-5

HEPATITIS C VIRUS see **HEPATITIS C-LIKE VIRUSES**

HEPATITIS, CHRONIC

Nonalcoholic steatohepatitis. Diehl AM. **Semin Liver Dis** 1999;19(2):221-9 (73 ref.)

BLOOD

Acquired inhibitors to the coagulation factor XII associated with liver disease. Chalkiadakis G, et al. **Am J Gastroenterol** 1999 Sep;94(9):2551-3

Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma. Huang YS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Aug; 62(8):487-95

Plasma levels of mevalonate and 7alpha-hydroxy-4-cholesten-3-one in chronic liver disease. Yoshida T, et al. **J Gastroenterol Hepatol** 1999 Feb; 14(2):150-5

Increased serum nitrite and nitrate concentrations in chronic hepatitis [letter; comment] Tankurt E, et al. **J Hepatol** 1998 Sep;29(3):512-3. Comment on: J Hepatol 1997 Dec;27(6):1120-32.

[The significance of sIL-2R detection in various hepatic diseases] Xuan SY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):92-4 (Eng. Abstr.) **(Chi)**

[The antioxidant system of patients with chronic inflammatory liver diseases after exposure to ionizing radiation] Tribrat TA, et al. **Lik Sprava** 1999 Jan-Feb; (1):23-5 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED see HEPATITIS, CHRONIC, DRUG-INDUCED

CLASSIFICATION

[New histological classification of chronic hepatitis] Yamada G. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr; 96(4):377-84 (18 ref.) **(Jpn)**

COMPLICATIONS

Acquired inhibitors to the coagulation factor XII associated with liver disease. Chalkiadakis G, et al. **Am J Gastroenterol** 1999 Sep;94(9):2551-3

Mycobacterium chelonei infection in a patient with chronic active hepatitis [letter] Whittam LR, et al. **Clin Exp Dermatol** 1998 Sep;23(5):238-9

Natural history of hepatectomy regarding liver function: a study of both normal livers and livers with chronic hepatitis and cirrhosis. Ezaki T, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1795-801

Effect of interferon on a nonenveloped DNA virus (TT virus) associated with acute and chronic hepatitis of unknown etiology. Akahane Y, et al. **J Med Virol** 1999 Jul; 58(3):196-200

Brief report: Pediatric Burkitt lymphoma with concurrent chronic Epstein-Barr virus hepatitis. Preciado MV, et al. **Med Pediatr Oncol** 1999 Aug;33(2):134-6

A comparative study of postoperative complications after hepatectomy in patients with and without chronic liver disease. Midorikawa Y, et al. **Surgery** 1999 Sep; 126(3):484-91

Asymptomatic type II mixed cryoglobulinemia with a very high cryocrit level secondary to HCV infection [letter] Perseghin P, et al. **Vox Sang** 1998;75(1):78-9

[Bacteremia by Streptococcus bovis in a patient with chronic liver disease without colon disease (letter)] Indart A, et al. **Gastroenterol Hepatol** 1999 Feb;22(2):114-5 **(Spa)**

DIAGNOSIS

Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein. Hada T, et al. **Clin Chim Acta** 1999 Mar;281(1-2):37-46

[Chronic viral hepatitis--diagnosis, therapy and prognosis (published erratum appears in Versicherungsmedizin 1999 Jun 1;51(2):86)] Trautwein C, et al. **Versicherungsmedizin** 1999 Mar 1;51(1):3-11 (16 ref.) (Eng. Abstr.) **(Ger)**

[The importance of different sociomedical factors in the expertise of the work capacity of patients with chronic hepatitis and liver cirrhosis] Tynianov IuA, et al. **Lik Sprava** 1998 Jul-Aug;(5):160-3 **(Rus)**

[Febrile syndrome and adrenal lesion in a patient receiving a hepatic transplant (clinical conference)] Quereda Navarro DC, et al. **Rev Clin Esp** 1998 Oct;198(10):690-700 **(Spa)**

DRUG THERAPY

Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients. Akbar N, et al. **Chin Med J (Engl)** 1998 Mar;111(3):248-51

New antiviral agents for viral hepatitis: our cup runneth over but is only half full. Dienstag JL. **Gastroenterology** 1999 Sep;117(3):525

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter; comment] Basaranoglu M, et al. **J Hepatol** 1999 Aug;31(2):384. Comment on: J Hepatol 1998 Sep;29(3):495-501.

Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. Tabata Y, et al. **J Interferon Cytokine Res** 1999 Mar;19(3):287-92

[Thyroid disorders associated with interferon treatment in patients with chronic viral hepatitis or multiple sclerosis] Diago JI, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):50-1 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Isoenzymes of class I and II alcohol dehydrogenase in chronic hepatitis. Chrostek L, et al. **Clin Chem Lab Med** 1999 Feb;37(2):145-7

Quantitative analysis and in situ localization of human telomerase RNA in chronic liver disease and hepatocellular carcinoma. Ogami M, et al. **Lab Invest** 1999 Jan;79(1):15-26

EPIDEMIOLOGY

The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania. Kondili LA, et al. **Epidemiol Infect** 1998 Oct;121(2):391-5

ETIOLOGY

The mouse interferon-gamma transgene chronic hepatitis model (Review). Okamoto T, et al. **Int J Mol Med** 1999 May;3(5):517-20 (31 ref.)

Chronic cryptogenic hepatitis in childhood is unrelated to hepatitis G virus. Iorio R, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):347-51

GENETICS

Long lasting chronic hepatitis is accompanied by cyclin D1 gene expression in the mouse. Okamoto T, et al. **Int J Mol Med** 1999 Sep;4(3):261-6

IMMUNOLOGY

Antiphospholipid syndrome, adrenal failure, dilated cardiomyopathy and chronic hepatitis: an unusual manifestation of multiorgan autoimmune injury? Tauchmanova L, et al. **Eur J Endocrinol** 1998 Dec; 139(6):641-5

METABOLISM

Immunohistochemical detection of collagen type III and IV in relation with transformation of Ito cells in liver sinusoids of patients with reactive biliary hepatitis. Gulubova MV, et al. **Acta Histochem** 1999 Apr;101(2):213-28

Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Chan JY, et al. **Eur J Cancer** 1998 Jun;34(7):1015-22

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter; comment] Basaranoglu M, et al. **J Hepatol** 1999 Aug;31(2):384. Comment on: J Hepatol 1998 Sep;29(3):495-501.

Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Harada K, et al. **Liver** 1999 Aug;19(4):318-25

PATHOLOGY

Influence of histological inflammatory activity on regenerative capacity of liver after percutaneous transhepatic portal vein embolization [see comments] Tanaka H, et al. **J Gastroenterol** 1999 Feb;34(1):100-4. Comment in: J Gastroenterol 1999 Feb;34(1):152-3.

Histological grading and staging in chronic hepatitis: clinical applications and problems. Hübscher SG. **J Hepatol** 1998 Dec;29(6):1015-22

Reproducibility of liver biopsy grading and staging [editorial; comment] Hunt N, et al. **Liver** 1999 Jun;19(3):169-70. Comment on: Liver 1999 Jun;19(3):183-7.

Broadsheet number 47: Chronic hepatitis: an update with guidelines for histopathological assessment of liver biopsies. Board of Education of The Royal College of Pathologists of Australasia. Hall PD. **Pathology** 1998 Nov;30(4):369-80 (68 ref.)

PHYSIOPATHOLOGY

[Quantitative assessment of portal vein flow in subjects with active chronic hepatitis: comparison of magnetic resonance angiography with bolus tracking with color Doppler ultrasonography] Manfredi R, et al. **Radiol Med (Torino)** 1999 Mar;97(3):132-7 (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Advances in the treatment of chronic viral hepatitis. Koff RS. **JAMA** 1999 Aug 11;282(6):511-2

SURGERY

Liver transplantation for chronic viral liver disease. Colantoni A, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1357-63

THERAPY

[Chronic viral hepatitis--diagnosis, therapy and prognosis (published erratum appears in Versicherungsmedizin 1999 Jun 1;51(2):86)] Trautwein C, et al. **Versicherungsmedizin** 1999 Mar 1;51(1):3-11 (16 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Disease-related variations of the glycosylation of haptoglobin in the dog. Andersson M, et al. **J Comp Pathol** 1998 Oct; 119(3):227-38

Use of polymerase chain reaction and immunohistochemistry for detection of canine adenovirus type 1 in formalin-fixed, paraffin-embedded liver of dogs with chronic hepatitis or cirrhosis. Chouinard L, et al. **J Vet Diagn Invest** 1998 Oct; 10(4):320-5

Enterohepatic lesions in SCID mice infected with Helicobacter bilis. Franklin CL, et al. **Lab Anim Sci** 1998 Aug;48(4):334-9

Lesions of subclinical doberman hepatitis. Speeti M, et al. **Vet Pathol** 1998 Sep;35(5):361-9

Histomorphological and immunohistochemical studies of chronic active hepatitis in Doberman Pinschers. Thornburg LP. **Vet Pathol** 1998 Sep;35(5):380-5

Pathological changes in cobalt-supplemented and non-supplemented twin lambs in relation to blood concentrations of methylmalonic acid and homocysteine. Vellema P, et al. **Vet Q** 1999 Jun;21(3):93-8

VIROLOGY

Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. Takahashi K, et al. **Arch Virol** 1999;144(7):1299-308

Prevalence of hepatitis G virus infection among patients with chronic hepatitis. Yarkin F, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):154-6

TT virus infection in chronic liver disease. Tangkijvanich P, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1053-8

HEPATITIS, CHRONIC, CRYPTOGENIC see **HEPATITIS, CHRONIC**

HEPATITIS, CHRONIC, DRUG-INDUCED

ENZYMOLOGY

Mature hepatocytes actively divide and express gamma-glutamyl transpeptidase after D-galactosamine liver injury. Kitten O, et al. **Liver** 1998 Dec;18(6):398-404

ETIOLOGY

[Cholestatic hepatitis ascribed to the use of thiabendazole] Eland IA, et al. **Ned Tijdschr Geneeskd** 1998 Jun 6; 142(23):1331-4 (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Drug-induced immunotoxicity. Dansette PM, et al. **Eur J Drug Metab Pharmacokinet** 1998 Oct-Dec; 23(4):443-51 (70 ref.)

PATHOLOGY

Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Deltenre P, et al. **Gut** 1999 Jun;44(6):886-8

HEPATITIS D

[Hepatitis D] Arase Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):59-61 (14 ref.) **(Jpn)**

COMPLICATIONS

Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. Njoh J, et al. **East Afr Med J** 1998 Jun;75(6):327-8

The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a

case-control study in Albania. Kondili LA, et al. **Epidemiol Infect** 1998 Oct;121(2):391-5
Long-term follow-up of a patient with hepatocellular carcinoma associated with triple hepatitis virus (HBV, HDV, HCV) infection. Koda T, et al. **Kansenshogaku Zasshi** 1998 Nov;72(11):1188-92

DIAGNOSIS

Prevalence and clinical features of hepatitis delta virus infection in the Miyako Islands, Okinawa, Japan. Nakasone H, et al. **J Gastroenterol** 1998 Dec;33(6):850-4
Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. Huang YH, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):57-61

DRUG THERAPY

Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Durlik M, et al. **Transpl Int** 1998;11 Suppl 1:S135-9

EPIDEMIOLOGY

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Santana Rodriguez OE, et al. **Eur J Epidemiol** 1998 Sep;14(6):555-61
Hepatitis D infectivity profile among hepatitis B infected hospitalised patients in Calcutta. Bhattacharyya S, et al. **Indian J Public Health** 1998 Oct-Dec;42(4):108-12
Prevalence and clinical features of hepatitis delta virus infection in the Miyako Islands, Okinawa, Japan. Nakasone H, et al. **J Gastroenterol** 1998 Dec;33(6):850-4
Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan. Sakugawa H, et al. **J Med Virol** 1999 Aug;58(4):366-72
[Study of HDV infection in Shandong province] Chen X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun;19(3):138-40 (Eng. Abstr.) **(Chi)**
[The clinico-epidemiological characteristics of the "carriage" of the causative agents of blood-contact viral hepatitides] Ogarkov PI, et al. **Voen Med Zh** 1998 Aug;319(8):38-44, 95 (Eng. Abstr.) **(Rus)**
[Viral hepatitis delta in the republic of Belarus] Kalinin AL, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec; (6):74-7 (Eng. Abstr.) **(Rus)**
[Hepatotropic delta-virus infection in children] Kupershtein AP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug;(4):29-33 (Eng. Abstr.) **(Rus)**
[Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia] León P, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):144-51 (32 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Prevalence of antibody to hepatitis D virus among HBsAg-positive drug-dependent patients in Jeddah, Saudi Arabia. Njoh J, et al. **East Afr Med J** 1998 Jun;75(6):327-8

SURGERY

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. Lerut JP, et al. **J Hepatol** 1999 Apr;30(4):706-14

THERAPY

Alpha-interferon treatment in HBeAg positive children with chronic hepatitis B and associated hepatitis D. Schneider A, et al. **Klin Padiatr** 1998 Sep-Oct;210(5):363-5

TRANSMISSION

Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. Huang YH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jan; 62(1):28-32
Intrafamilial transmission of hepatitis delta virus: molecular evidence. Niro GA, et al. **J Hepatol** 1999 Apr;30(4):564-9

VIROLOGY

Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. Huang YH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jan; 62(1):28-32
Mixed genotypes infection with hepatitis D virus. Wu JC, et al. **J Med Virol** 1999 Jan;57(1):64-7

HEPATITIS D, CHRONIC

COMPLICATIONS

Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329-31
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Soriano V, et al. **Eur J Epidemiol** 1999 Jan;15(1):1-4

DRUG THERAPY

Lamivudine for chronic delta hepatitis [see comments] Lau DT, et al. **Hepatology** 1999 Aug;30(2):546-9. Comment in: Hepatology 1999 Aug;30(2):579-81.
Hepatitis B therapy: the plot thickens [comment] Malik AH, et al. **Hepatology** 1999 Aug;30(2):579-81. Comment on: Hepatology 1999 Aug;30(2):546-9. Comment on: Hepatology 1999 Aug;30(2):567-72.

EPIDEMIOLOGY

Prevalence of anti-delta antibodies in central India. Jaiswal SP, et al. **Trop Gastroenterol** 1999 Jan-Mar;20(1):29-32

IMMUNOLOGY

Hepatitis D virus antigen in HBsAg positive chronic liver disease in Nigeria. Ojo OS, et al. **East Afr Med J** 1998 Jun;75(6):329-31

PATHOLOGY

Changing pattern of chronic hepatitis D in Southern Europe. Rosina F, et al. **Gastroenterology** 1999 Jul;117(1):161-6
[Comment on the consensus report, "Treatment of chronic B/D viral hepatitis and acute and chronic C virus hepatitis" (letter; comment)] Dienes HP, et al. **Z Gastroenterol** 1998 Nov;36(11):XX-XXI. Comment on: Z Gastroenterol 1997 Nov; 35(11):971-86. **(Ger)**
[An evaluation of the degree of the morphological activity and the stage of the process in patients with chronic liver diseases caused by coinfection with the hepatitis B, C and/or D viruses] Siutkin VE, et al. **Arkh Patol** 1998 Nov-Dec;60(6):37-41 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Changing pattern of chronic hepatitis D in Southern Europe. Rosina F, et al. **Gastroenterology** 1999 Jul;117(1):161-6

SURGERY

Liver transplantation for chronic viral hepatitis. Dodson SF, et al. **Surg Clin North Am** 1999 Feb;79(1):131-45 (93 ref.)

THERAPY

Exacerbation of chronic hepatitis D during interferon alpha administration. Crosignani A, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):66-9

HEPATITIS D VIRUS see **HEPATITIS DELTA VIRUS**

HEPATITIS, DELTA see **HEPATITIS D**

HEPATITIS DELTA VIRUS

Kinetic analysis of delta ribozyme cleavage. Mercure S, et al. **Biochemistry** 1998 Dec 1;37(48):16975-82
Mutational analysis of the antigenomic trans-acting delta ribozyme: the alterations of the middle nucleotides located on the P1 stem. Anantvoranich S, et al. **Nucleic Acids Res** 1999 Mar 15;27(6):1473-9

CHEMISTRY

Detailed analysis of stem I and its 5' and 3' neighbor regions in the trans-acting HDV ribozyme. Nishikawa F, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):403-10

CLASSIFICATION

Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. Huang YH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jan; 62(1):28-32

DRUG EFFECTS

Mimicry of the hepatitis delta virus replication cycle mediated by synthetic circular oligodeoxynucleotides. Diegelman AM, et al. **Chem Biol** 1999 Aug;6(8):569-76
In vitro inhibition of the hepatitis delta virus replication mediated by interferon and trans-ribozyme or antisense probes. Madejón A, et al. **J Hepatol** 1998 Sep;29(3):385-93
Use of a prenylation inhibitor as a novel antiviral agent. Glenn JS, et al. **J Virol** 1998 Nov;72(11):9303-6
[Inhibitory effect of replication and expression of HDV by antisense oligodeoxynucleotides in H1 delta 9 cell] Li H, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar; 7(1):13-4 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Delta ribozyme has the ability to cleave in transan mRNA. Roy G, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):942-8
Imidazole rescue of a cytosine mutation in a self-cleaving ribozyme [see comments] Perrotta AT, et al. **Science** 1999 Oct 1;286(5437):123-6. Comment in: Science 1999 Oct 1;286(5437):61-2.
Chemical diversity in RNA cleavage [comment] Westhof E. **Science** 1999 Oct 1;286(5437):61-2. Comment on: Science 1999 Oct 1;286(5437):123-6.

GENETICS

RNA binding domain of HDV antigen is homologous to the HMG box of SRY. Veretnik S, et al. **Arch Virol** 1999; 144(6):1139-58
Human hepatitis delta virus: an agent with similarities to certain satellite RNAs of plants. Taylor JM. **Curr Top Microbiol Immunol** 1999;239:107-22 (64 ref.)
Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan. Sakugawa H, et al. **J Med Virol** 1999 Aug;58(4):366-72
Mixed genotypes infection with hepatitis D virus. Wu JC, et al. **J Med Virol** 1999 Jan;57(1):64-7
Sequential folding of the genomic ribozyme of the hepatitis delta virus: structural analysis of RNA transcription intermediates. Matysiak M, et al. **J Mol Biol** 1999 Aug 13;291(2):283-94
Crystal structure of a hepatitis delta virus ribozyme [see comments] Ferré-D'Amaré AR, et al. **Nature** 1998 Oct 8;395(6702):567-74. Comment in: Nature 1998 Oct 8;395(6702):548-9.
Ribozyme crevices and catalysis [news; comment] Herschlag D. **Nature** 1998 Oct 8;395(6702):548-9. Comment on: Nature 1998 Oct 8;395(6702):567-74.
The viroid and viroid-like RNA database. Lafontaine DA, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):186-7
Presence of a coordinated metal ion in a trans-acting antigenomic delta ribozyme. Lafontaine DA, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):3236-43
A conserved bulged adenosine in a peripheral duplex of the antigenomic HDV self-cleaving RNA reduceskinetic trapping of inactive conformations. Perrotta AT, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):795-802
Delta ribozyme has the ability to cleave in transan mRNA. Roy G, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):942-8
Solution structure and RNA-binding activity of the N-terminal leucine-repeat region of hepatitis delta antigen. Lin IJ, et al. **Proteins** 1999 Oct 1;37(1):121-9
Ribozyme cleavage of a 2,5-phosphodiester linkage: mechanism and a restricted divalent metal-ion requirement. Shih IH, et al. **RNA** 1999 Sep;5(9):1140-8
Ribozyme architectural diversity made visible [comment] Westhof E, et al. **Science** 1998 Oct 9;282(5387):251-2. Comment on: Science 1998 Oct 9;282(5387):259-64.
Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA. Lo K, et al. **Virology** 1998 Oct 10;250(1):94-105
[Study of transcription and cleavage in vitro of HDV with HBV-specific hammerhead ribozyme] Wen S, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):11-2 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Identification and characterization of the RNA chaperone activity of hepatitis delta antigen peptides. Huang ZS, et al. **J Biol Chem** 1998 Oct 9;273(41):26455-61
Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. Lin HP, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):91-6
Electrophoretic analysis of the ribonucleoproteins of hepatitis delta virus. Dingle K, et al. **J Virol Methods** 1998 Nov; 75(2):199-204
Prevalence of anti-delta antibodies in central India. Jaiswal SP, et al. **Trop Gastroenterol** 1999 Jan-Mar;20(1):29-32
[Antigenic activity of delta-antigen peptides corresponding to three genotypes of the delta hepatitis virus] Dement'eva EV, et al. **Vopr Virusol** 1998 Sep-Oct;43(5):217-20 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Prevalence and clinical features of hepatitis delta virus infection in the Miyako Islands, Okinawa, Japan. Nakasone H, et al. **J Gastroenterol** 1998 Dec;33(6):850-4
Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. Huang YH, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):57-61
Intrafamilial transmission of hepatitis delta virus: molecular evidence. Niro GA, et al. **J Hepatol** 1999 Apr;30(4):564-9

METABOLISM

Cell cycle arrest mediated by hepatitis delta antigen. Hwang SB, et al. **FEBS Lett** 1999 Apr 16;449(1):41-4
The effect of Lp3 enlargement on the folding and catalysis of hepatitis delta virus cis-cleaving ribozyme. Wu HN, et al. **FEBS Lett** 1998 Nov 20;439(3):312-6
Unique properties of the large antigen of hepatitis delta virus. Moraleda G, et al. **J Virol** 1999 Sep;73(9):7147-52
A nested double pseudoknot is required for self-cleavage activity of both the genomic and antigenomic hepatitis delta virus ribozymes. Wadkins TS, et al. **RNA** 1999 Jun; 5(6):720-7

PHYSIOLOGY

Characterization of the 5' ends for polyadenylated RNAs synthesized during the replication of hepatitis delta virus. Gudima S, et al. **J Virol** 1999 Aug;73(8):6533-9
Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles. Jenna S, et al. **J Virol** 1999 Apr;73(4):3351-8
Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Jenna S, et al. **Virology** 1998 Nov 10;251(1):176-86

HEPATITIS, DRUG-INDUCED see **HEPATITIS, TOXIC**

HEPATITIS E

Self-learning review. Hepatitis E. **Can Fam Physician** 1998 Dec;44:2648, 2652 **(Eng, Fre)**

Sporadic hepatitis E in Austria [letter] Worm HC, et al. **N Engl J Med** 1998 Nov 19;339(21):1554-5

[Hepatitis E] Tanaka E. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):62-4 (12 ref.) **(Jpn)**

COMPLICATIONS

The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection [letter] Sylvan SP. **Scand J Infect Dis** 1998;30(4):429-30

DIAGNOSIS

Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. Mishra A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2292-5 (27 ref.)

HBsAg carrier with simultaneous amebic liver abscess and acute hepatitis E. Jain A, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):124

Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. Madan K, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):125-30

Prevalence of hepatitis E virus antibody in hemodialysis patients [letter] Arinsoy T, et al. **Nephron** 1998 Sep;80(1):85

Serological diagnosis of jaundice epidemics in India. Prakash C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):497-502 (21 ref.)

[Severe viral hepatitis (letter)] Mennecier D, et al. **Presse Med** 1999 Sep 4;28(25):1361 **(Fre)**

[A new case of acute hepatitis type E in France (letter)] Dupuy O, et al. **Rev Med Interne** 1998 Jun;19(6):448-9 **(Fre)**

[Suspicion of viral hepatitis E] Quadri L, et al. **Schweiz Rundsch Med Prax** 1999 Jun 24;88(25-26):1141-3 **(Ger)**

[General practice case. Hepatitis E with acute jaundice] Stäuble S, et al. **Schweiz Rundsch Med Prax** 1998 Nov 19; 87(47):1619-20 **(Ger)**

[Acute hepatitis E in Spain] Sanz E, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):180-2 (35 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

The socioeconomic impact of hepatitis E in Nepal. Clark KL, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):505-10

EPIDEMIOLOGY

The socioeconomic impact of hepatitis E in Nepal. Clark KL, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):505-10

Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. Hau CH, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):277-80

Seroepidemiology of hepatitis E virus infection in Mexican subjects 1 to 29 years of age. Alvarez-Muñoz MT, et al. **Arch Med Res** 1999 May-Jun;30(3):251-4

Anti-HEV in dialysis and renal transplant patients in an endemic region in Chile [letter] Ibarra H, et al. **Clin Nephrol** 1998 Oct;50(4):267-8

Absence of antibody to hepatitis E virus in Turkish children [letter] Yüce A, et al. **Eur J Pediatr** 1999 Aug;158(8):685-6

Hepatitis E in Damascus, Syria. al-Azmeh J, et al. **Infection** 1999 May-Jun;27(3):221-3

Epidemiology of hepatitis B, C, E, and G virus infections and molecular analysis of hepatitis G virus isolates in Bolivia. Konomi N, et al. **J Clin Microbiol** 1999 Oct; 37(10):3291-5

Hepatitis E infection in children: study of an outbreak. Arora NK, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):572-7

Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino. Rapicetta M, et al. **J Med Virol** 1999 May;58(1):49-53

Clinical and viral marker pattern of acute sporadic hepatitis in children in Madras, South India. Malathi S, et al. **J Trop Pediatr** 1998 Oct;44(5):275-8

Hepatitis E virus -- an update. Harrison TJ. **Liver** 1999 Jun; 19(3):171-6 (37 ref.)

Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India [letter] Agarwal SK, et al. **Nephron** 1999;81(4):448

Epidemiology and prevention of enterically transmitted hepatitis in Italy. Coppola RC, et al. **Res Virol** 1998 Sep-Oct;149(5):271-6 (45 ref.)

The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection [letter] Sylvan SP. **Scand J Infect Dis** 1998;30(4):429-30

Hepatitis C and hepatitis E in acute sporadic non-A non-B hepatitis in hospital patients of Delhi (India). Prakash C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):475-9

Routes of transmission in the hepatitis E epidemic of Saharanpur. Singh V, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):107-9

Hepatitis E virus seroprevalence in children living in rural Ghana. Martinson FE, et al. **West Afr J Med** 1999 Apr-Jun; 18(2):76-9

[A study on the epidemiology and clinical characteristics of hepatitis E in Tianjin area] Shao FZ. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Oct; 18(5):267-9 (Eng. Abstr.) **(Chi)**

[Epidemiological characteristics and risk factors of hepatitis E in Taiyuan] Zhang Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):144-6 (Eng. Abstr.) **(Chi)**

[Hepatitis E virus: detection of antibodies in blood donors in Lebanon] Irani Hakime N, et al. **J Med Liban** 1998 Mar-Apr;46(2):60-2 (Eng. Abstr.) **(Fre)**

[The first assessment of hepatitis E virus seroprevalence in northern Portugal] Macedo G, et al. **Acta Med Port** 1998 Dec;11(12):1065-8 (Eng. Abstr.) **(Por)**

[Serologic markers to hepatitis E virus in residents in nonendemic regions] Fedorova OE. **Vopr Virusol** 1999 Jul-Aug;44(4):155-8 (48 ref.) (Eng. Abstr.) **(Rus)**

[Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia] León P, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):144-51 (32 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus. Arankalle VA, et al. **J Hepatol** 1999 Feb; 30(2):199-204

Seroprevalence of antibodies to hepatitis E virus in the normal blood donor population and two aboriginal communities in Malaysia. Seow HF, et al. **J Med Virol** 1999 Oct;59(2):164-8

Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India [letter] Agarwal SK, et al. **Nephron** 1999;81(4):448

Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Meng J, et al. **Virology** 1998 Sep 30;249(2):316-24

[Detection of the level of serum IgG antibody to hepatitis E virus] Xie Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):223-5 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Characterization of a strain of infectious hepatitis E virus isolated from sewage in an area where hepatitis E is not endemic. Pina S, et al. **Appl Environ Microbiol** 1998 Nov; 64(11):4485-8

Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289-93

PREVENTION & CONTROL

Epidemiology and prevention of enterically transmitted hepatitis in Italy. Coppola RC, et al. **Res Virol** 1998 Sep-Oct;149(5):271-6 (45 ref.)

TRANSMISSION

Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289-93

Transmission of hepatitis E in Germany [letter] Hartmann WJ, et al. **Infection** 1998 Nov-Dec;26(6):409

Hepatitis E virus -- an update. Harrison TJ. **Liver** 1999 Jun; 19(3):171-6 (37 ref.)

The unique riverine ecology of hepatitis E virus transmission in South-East Asia. Corwin AL, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):255-60 (30 ref.)

Routes of transmission in the hepatitis E epidemic of Saharanpur. Singh V, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):107-9

Hepatitis E virus: relevance in blood donors and risk groups. Mateos ML, et al. **Vox Sang** 1999;76(2):78-80

Hepatitis E virus: relevance in blood donors and other risk groups. Mateos ML, et al. **Vox Sang** 1998;75(4):267-9

[Viral hepatitis of enteric origin] Debord T, et al. **Bull Soc Pathol Exot** 1998;91(5 Pt 1-2):428-31 (Eng. Abstr.) **(Fre)**

VETERINARY

Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Kabrane-Lazizi Y, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):331-5

VIROLOGY

Phylogenetic analysis of hepatitis E virus isolates from India (1976-1993). Arankalle VA, et al. **J Gen Virol** 1999 Jul; 80 (Pt 7):1691-700

A hepatitis E virus variant from the United States: molecular characterization and transmission in cynomolgus macaques. Erker JC, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):681-90

A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. Wang Y, et al. **J Gen Virol** 1999 Jan; 80 (Pt 1):169-77

Novel hepatitis E virus (HEV) isolates from Europe: evidence for additional genotypes of HEV. Schlauder GG, et al. **J Med Virol** 1999 Mar;57(3):243-51

Identification of a novel variant of hepatitis E virus in Italy. Zanetti AR, et al. **J Med Virol** 1999 Apr;57(4):356-60

Hepatitis E virus RNA detection in serum and feces specimens with the use of microspin columns. Aggarwal R, et al. **J Virol Methods** 1998 Oct;74(2):209-13

Evidence of hepatitis E virus replication on cell cultures. Divizia M, et al. **New Microbiol** 1999 Apr;22(2):77-83

Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Meng J, et al. **Virology** 1998 Sep 30;249(2):316-24

[Partial nucleotide sequencing of 7 hepatitis E virus strains isolated from sera of patients with acute sporadic hepatitis E in China] Zhu X, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):447-9 (Eng. Abstr.) **(Chi)**

[A study on viremia in patients with hepatitis E] Ruan B, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):352-4 (Eng. Abstr.) **(Chi)**

HEPATITIS E VIRUS

Hepatitis E virus seroprevalence in children living in rural Ghana. Martinson FE, et al. **West Afr J Med** 1999 Apr-Jun; 18(2):76-9

CHEMISTRY

[Antigenic specificity of recombinant polypeptides, containing fragments of hepatitis E virus proteins] Alatortseva GI, et al. **Vopr Virusol** 1999 Mar-Apr; 44(2):60-4 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Novel hepatitis E virus (HEV) isolates from Europe: evidence for additional genotypes of HEV. Schlauder GG, et al. **J Med Virol** 1999 Mar;57(3):243-51

Identification of a novel variant of hepatitis E virus in Italy. Zanetti AR, et al. **J Med Virol** 1999 Apr;57(4):356-60

GENETICS

Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. Madan K, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):125-30

Phylogenetic analysis of hepatitis E virus isolates from India (1976-1993). Arankalle VA, et al. **J Gen Virol** 1999 Jul; 80 (Pt 7):1691-700

A hepatitis E virus variant from the United States: molecular characterization and transmission in cynomolgus macaques. Erker JC, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):681-90

A divergent genotype of hepatitis E virus in Chinese patients with acute hepatitis. Wang Y, et al. **J Gen Virol** 1999 Jan; 80 (Pt 1):169-77

Novel hepatitis E virus (HEV) isolates from Europe: evidence for additional genotypes of HEV. Schlauder GG, et al. **J Med Virol** 1999 Mar;57(3):243-51

Phylogenetic analysis of hepatitis E virus isolates from Egypt. Tsarev SA, et al. **J Med Virol** 1999 Jan;57(1):68-74

Identification of a novel variant of hepatitis E virus in Italy. Zanetti AR, et al. **J Med Virol** 1999 Apr;57(4):356-60

Evidence that the genomic RNA of hepatitis E virus is capped. Kabrane-Lazizi Y, et al. **J Virol** 1999 Oct; 73(10):8848-50

Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. Meng XJ, et al. **J Virol** 1998 Dec;72(12):9714-21

Hepatitis E virus: complete genome sequence and phylogenetic analysis of a Nepali isolate. Gouvea V, et al. **Virus Res** 1998 Sep;57(1):21-6

[Partial nucleotide sequencing of 7 hepatitis E virus strains isolated from sera of patients with acute sporadic hepatitis E in China] Zhu X, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):447-9 (Eng. Abstr.) **(Chi)**

[Serological character of hepatitis E virus mutants] Wang Y, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar; 7(1):24-5 (Eng. Abstr.) **(Chi)**

GROWTH & DEVELOPMENT

Evidence of hepatitis E virus replication on cell cultures. Divizia M, et al. **New Microbiol** 1999 Apr;22(2):77-83

IMMUNOLOGY

Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. Hau CH, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):277-80

Prevalence of IgG-class antibodies against hepatitis E virus in a community of the southern Amazon: a randomized survey. Souto FJ, et al. **Ann Trop Med Parasitol** 1998 Jul; 92(5):623-5

Absence of antibody to hepatitis E virus in Turkish children [letter] Yüce A, et al. **Eur J Pediatr** 1999 Aug;158(8):685-6

Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. Khudyakov YE, et al. **J Clin Microbiol** 1999 Sep;37(9):2863-71

Baculovirus expression of chimeric hepatitis B virus core

particles with hepatitis E virus epitopes and their use in a hepatitis E immunoassay. Touze A, et al. **J Clin Microbiol** 1999 Feb;37(2):438–41

Seroprevalence of antibodies to hepatitis E virus in the normal blood donor population and two aboriginal communities in Malaysia. Seow HF, et al. **J Med Virol** 1999 Oct;59(2):164–8

Prevalence of antibodies against hepatitis E virus in haemodialysis patients in India [letter] Agarwal SK, et al. **Nephron** 1999;81(4):448

Prevalence of hepatitis E virus antibody in hemodialysis patients [letter] Arinsoy T, et al. **Nephron** 1998 Sep;80(1):85

The high rate of antibodies to hepatitis E virus in young, intravenous drug-abusers with acute hepatitis B-virus infection in a Swedish community: a study of hepatitis markers in individuals with intravenously or sexually acquired hepatitis B-virus infection [letter] Sylvan SP. **Scand J Infect Dis** 1998;30(4):429–30

Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Meng J, et al. **Virology** 1998 Sep 30;249(2):316–24

[Serological character of hepatitis E virus mutants] Wang Y, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar; 7(1):24–5 (Eng. Abstr.) **(Chi)**

[Preparation of monoclonal antibodies against hepatitis E and its application] Jiang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May; 32(3):174–6 (Eng. Abstr.) **(Chi)**

[Detection of the level of serum IgG antibody to hepatitis E virus] Xie Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):223–5 (Eng. Abstr.) **(Chi)**

[Hepatitis E virus: detection of antibodies in blood donors in Lebanon] Irani Hakime N, et al. **J Med Liban** 1998 Mar–Apr;46(2):60–2 (Eng. Abstr.) **(Fre)**

[The first assessment of hepatitis E virus seroprevalence in northern Portugal] Macedo G, et al. **Acta Med Port** 1998 Dec;11(12):1065–8 (Eng. Abstr.) **(Por)**

[Preparation of recombinant polypeptides containing antigenic determinants of hepatitis E virus] Alatortseva GI, et al. **Vopr Virusol** 1998 Nov–Dec;43(6):266–9 (Eng. Abstr.) **(Rus)**

[Serologic markers to hepatitis E virus in residents in nonendemic regions] Fedorova OE. **Vopr Virusol** 1999 Jul–Aug;44(4):155–8 (48 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Kabrane-Lazizi Y, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):331–5

Characterization of a strain of infectious hepatitis E virus isolated from sewage in an area where hepatitis E is not endemic. Pina S, et al. **Appl Environ Microbiol** 1998 Nov; 64(11):4485–8

Transmission of hepatitis E in Germany [letter] Hartmann WJ, et al. **Infection** 1998 Nov–Dec;26(6):409

Phylogenetic analysis of hepatitis E virus isolates from India (1976–1993). Arankalle VA, et al. **J Gen Virol** 1999 Jul; 80 (Pt 7):1691–700

Hepatitis E virus RNA detection in serum and feces specimens with the use of microspin columns. Aggarwal R, et al. **J Virol Methods** 1998 Oct;74(2):209–13

Routes of transmission in the hepatitis E epidemic of Saharanpur. Singh V, et al. **Trop Gastroenterol** 1998 Jul–Sep;19(3):107–9

Hepatitis E virus: relevance in blood donors and risk groups. Mateos ML, et al. **Vox Sang** 1999;76(2):78–80

[A study on viremia in patients with hepatitis E] Ruan B, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):352–4 (Eng. Abstr.) **(Chi)**

[Suspicion of viral hepatitis E] Quadri L, et al. **Schweiz Rundsch Med Prax** 1999 Jun 24;88(25–26):1141–3 **(Ger)**

METABOLISM

Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. Torresi J, et al. **J Gen Virol** 1999 May;80 (Pt 5):1185–8

Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. Zafrullah M, et al. **J Virol** 1999 May;73(5):4074–82

PATHOGENICITY

Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. Meng XJ, et al. **J Virol** 1998 Dec;72(12):9714–21

Hepatitis E virus -- an update. Harrison TJ. **Liver** 1999 Jun; 19(3):171–6 (37 ref.)

HEPATITIS G VIRUS see **HEPATITIS AGENTS, GB**

HEPATITIS, INFECTIOUS see **HEPATITIS A**

HEPATITIS, TOXIC

Symptomatic liver injury probably related to sertraline [letter]. Hautekeete ML, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):364–5

The case for case reports [comment] Lee WM. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):318–9. Comment on: Ital J Gastroenterol Hepatol 1998 Jun;30(3):310–4. Comment on: Ital J Gastroenterol Hepatol 1998 Jun;30(3):315–7.

Acute hepatitis after riluzole administration. Remy AJ, et al. **J Hepatol** 1999 Mar;30(3):527–30

Liver damage induced by coumarin anticoagulants. Ehrenforth S, et al. **Semin Thromb Hemost** 1999;25(1):79–83

BLOOD

Plasma amino acid levels after carbon tetrachloride induced acute liver damage. A dose-response and time-response study in rats. Holeček M, et al. **Amino Acids** 1999;16(1):1–11

COMPLICATIONS

Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion. Mertens PR, et al. **Blood Purif** 1998;16(6):341–8

DIAGNOSIS

In vivo assessment of microcystin-LR-induced hepatotoxicity in the rat using proton nuclear magnetic resonance (1H-NMR) imaging. Sturgeon SA, et al. **Biochim Biophys Acta** 1999 Aug 30;1454(3):227–35

Fatal fulminant hepatic failure due to cyproterone acetate. Friedman G, et al. **Dig Dis Sci** 1999 Jul;44(7):1362–3 (7 ref.)

Routine screening for acetaminophen (APAP) toxicity of patients requesting alcohol detoxification [letter] Kenny JF, et al. **J Stud Alcohol** 1999 Jan;60(1):139–40

Cholestatic liver dysfunction [letter] Wierzbicki AS, et al. **Lancet** 1999 Sep 11;354(9182):954

Acute hepatitis due to fluoxetine therapy. Cai Q, et al. **Mayo Clin Proc** 1999 Jul;74(7):692–4

Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate--recurrence following therapy with erythromycin succinate. Horn S, et al. **Wien Klin Wochenschr** 1999 Jan 29;111(2):76–7

[Acute liver failure (letter)] Friebe M, et al. **Internist (Berl)** 1998 Sep;39(9):999–1000 **(Ger)**

[ACC in liver failure] Wronski R, et al. **Internist (Berl)** 1999 Jan;40(1):109–10 **(Ger)**

[Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin] König SA, et al. **Nervenarzt** 1998 Oct; 69(10):835–40 (32 ref.) (Eng. Abstr.) **(Ger)**

[Hypertransaminemia and methotrexate: not always a toxic effect? (see comments)] Montilla Morales C, et al. **Rev Clin Esp** 1998 Dec;198(12):822–4 (Eng. Abstr.). Comment in: Rev Clin Esp 1999 Jun;199(6):409–10. **(Spa)**

DRUG THERAPY

Antihepatotoxic activity of p-methoxy benzoic acid from Capparis spinosa. Gadgoli C, et al. **J Ethnopharmacol** 1999 Aug;66(2):187–92

Anti-hepatotoxic effects of root and root callus extracts of Cichorium intybus L. Zafar R, et al. **J Ethnopharmacol** 1998 Dec;63(3):227–31

Hepatoprotective activity of Ficus racemosa leaf extract on liver damage caused by carbon tetrachloride in rats. Mandal SC, et al. **Phytother Res** 1999 Aug;13(5):430–2

[Clinical observation on treatment of complications with Chinese medicine according to syndrome differentiation of post-bone marrow transplantation in 22 patients with leukemia] Li HY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Oct; 17(10):581–3 (Eng. Abstr.) **(Chi)**

[Effects of 16 drugs on immunological liver injury induced by BCG + lipopolysaccharides in mice] Yang TJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):185–8 (Eng. Abstr.) **(Chi)**

[Hepato-protective effect of a plant from the Senegalese pharmacopoeia: Tinospora bakis (Menispermaceae)using and in vitro model] Diallo-Sall A, et al. **Dakar Med** 1997; 42(1):15–8 (Eng. Abstr.) **(Fre)**

[Lomefloxacin in phthisiatric practice] Grishin VK, et al. **Antibiot Khimioter** 1998;43(10):17–8 (Eng. Abstr.) **(Rus)**

[The pharmacological correction of the hepatotoxic action of platidiam] Fomina TI, et al. **Eksp Klin Farmakol** 1999 Jan–Feb;62(1):62–4 (Eng. Abstr.) **(Rus)**

[The efficacy of the polyphenol plant preparation piflamin in drug damage to the liver] Iakovleva LV, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):48–50 (Eng. Abstr.) **(Rus)**

[A comparative study of the efficacy of pharmacological agents in regulating the level of NADPH in the hepatocytes in an acute lesion] Inoiatova FKh, et al. **Eksp Klin Farmakol** 1999 May–Jun;62(3):50–2 (Eng. Abstr.) **(Rus)**

[The joint use of prednisolone and phospholipid-containing hepatoprotectors in experimental chronic hepatitis] Vengerovskii AI, et al. **Eksp Klin Farmakol** 1999 Mar–Apr; 62(2):28–30 (Eng. Abstr.) **(Rus)**

[The efficacy of treating patients with destructive pulmonary tuberculosis with liver involvement] Novozhylova IO. **Lik Sprava** 1998 Oct–Nov;(7):121–3 (Eng. Abstr.) **(Ukr)**

[Protective effect of cresacin in D-galactosamine-induced acute experimental hepatitis] Korda MM. **Ukr Biokhim Zh** 1998 Jan–Feb;70(1):63–8 (Eng. Abstr.) **(Ukr)**

ENZYMOLOGY

Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Basu S. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):764–7

Induction of CPP32-like activity and inhibition of interleukin 1beta converting enzyme activity in the liver of a mouse concanavalin A-induced hepatitis model. Okamoto T, et al. **Jpn J Pharmacol** 1998 Jul;77(3):257–9

Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Amacher DE. **Regul Toxicol Pharmacol** 1998 Apr;27(2):119–30 (107 ref.)

2-(allylthio)pyrazine inhibition of aflatoxin B1-induced hepatotoxicity in rats: inhibition of cytochrome P450 2B- and 3A2-mediated bioactivation. Ha TG, et al. **Res Commun Mol Pathol Pharmacol** 1998 Oct;102(1):69–78

Effects of induction and inhibition of cytochromes P450 on the hepatotoxicity of methapyrilene. Ratra GS, et al. **Toxicol Sci** 1998 Nov;46(1):185–96

[Effect of Arnica montana tincture on some hydrolytic enzyme activities of rat liver in experimental toxic hepatitis] Iaremii IM, et al. **Ukr Biokhim Zh** 1998 Nov–Dec; 70(6):88–91 (Eng. Abstr.) **(Ukr)**

ETIOLOGY

Valaciclovir-induced hepatitis. Renkes P, et al. **Acta Clin Belg** 1999 Jan–Feb;54(1):17–8

Acute hepatitis due to poisoning. Geubel AP, et al. **Acta Gastroenterol Belg** 1998 Oct–Dec;61(4):468–9 (7 ref.)

Meloxicam-induced liver toxicity. Staerkel P, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):255–6

Mesalamine-induced granulomatous hepatitis. Braun M, et al. **Am J Gastroenterol** 1999 Jul;94(7):1973–4

Simultaneous pancreatitis and hepatitis associated with trimethoprim-sulfamethoxazole. Brett AS, et al. **Am J Gastroenterol** 1999 Jan;94(1):267–8

Acute cholestatic hepatitis associated with pravastatin. Hartleb M, et al. **Am J Gastroenterol** 1999 May; 94(5):1388–90

Severe hepatotoxicity associated with bromfenac sodium. Moses PL, et al. **Am J Gastroenterol** 1999 May;94(5):1393–6

Acute hepatitis related to omeprazole [letter] Romero-Gómez M, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1119–20

Norfloxacin-induced acute cholestatic hepatitis in a patient with alcoholic liver cirrhosis [letter] Romero-Gómez M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2324–5

Venlafaxine-associated hepatitis [letter] Horsmans Y, et al. **Ann Intern Med** 1999 Jun 1;130(11):944

Troglitazone-associated hepatic failure [letter; comment] Misbin RI. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):330 Comment on: Ann Intern Med 1998 Jul 1;129(1):36–8. Comment on: Ann Intern Med 1998 Jul 1;129(1):38–41. Comment on: Ann Intern Med 1998 Dec 15;129(12):1080.

Fatal hepatotoxicity associated with troglitazone [letter; comment] [see comments] Vella A, et al. **Ann Intern Med** 1998 Dec 15;129(12):1080. Comment on: Ann Intern Med 1998 May 15;128(10):871. Comment in: Ann Intern Med 1999 Feb 16;130(4 Pt 1):330.

Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Floren LC, et al. **Ann Oncol** 1998 Oct; 9(10):1123–6

Acute liver damage possibly related to sertraline and venlafaxine ingestion [letter] Kim KY, et al. **Ann Pharmacother** 1999 Mar;33(3):381–2

Hepatitis during chloroguanide prophylaxis [comment] Oostweegel LM, et al. **Ann Pharmacother** 1998 Oct; 32(10):1023–5. Comment on: Ann Pharmacother 1998 Oct;32(10):1104–6.

Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves [letter] Jiménez-Alonso J, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1811–2

Hydroxyurea-induced fever and hepatitis. Westerman DA, et al. **Aust N Z J Med** 1998 Oct;28(5):657–9

Clinical manifestations and immunological features of primary Sjögren's syndrome with liver involvement: analysis of thirty cases. Zhang Z, et al. **Chin Med J (Engl)** 1998 Mar;111(3):220–3

Characteristics and risk factors of acetaminophen-induced hepatitis in Taiwan. Wang K, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jun; 62(6):369–75

Hepatotoxicity of parenteral gold therapy in rheumatoid arthritis: a case report and review of the literature. te Boekhorst PA, et al. **Clin Exp Rheumatol** 1999 May–Jun; 17(3):359–62 (22 ref.)

Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Benveniste O, et al. **Clin Infect Dis** 1999 May;28(5):1180–1

Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Weissman SB, et al. **Clin Infect Dis** 1999 Jul;29(1):223–4

Ticlopidine-induced cholestatic hepatitis: report of three cases and review of the literature. Iqbal M, et al. **Dig Dis Sci** 1998 Oct;43(10):2223–6 (33 ref.)

Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate

hepatotoxicity in adults. König SA, et al. **Epilepsia** 1999 Jul;40(7):1036–40

Omeprazole and the development of acute hepatitis. Koury SI, et al. **Eur J Emerg Med** 1998 Dec;5(4):467–9

Cyamamezine-induced acute hepatitis after unique massive intake: a case report. Cadranel JF, et al. **Eur J Gastroenterol Hepatol** 1999 Apr;11(4):451–3

Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Grieco A, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):713–5 (24 ref.)

Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation [see comments] Lo SK, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):635–9. Comment in: Eur J Gastroenterol Hepatol 1998 Aug;10(8):631–3.

Halothane hepatitis [comment] Neuberger J. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):631–3. Comment on: Eur J Gastroenterol Hepatol 1998 Aug;10(8):635–9.

Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. Schreiber J, et al. **Eur J Med Res** 1999 Feb 25;4(2):67–71

Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Garty BZ, et al. **Eur J Pediatr** 1999 May;158(5):367–70

Subchronic oral hepatotoxicity of turmeric in mice--histopathological and ultrastructural studies. Kandarkar SV, et al. **Indian J Exp Biol** 1998 Jul;36(7):675–9

Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir [letter] Vandercam B, et al. **Infection** 1998 Sep-Oct;26(5):313

Ritodrine-related liver injury. Case reports and review of the literature [see comments] Ceriani R, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):315–7 (8 ref.) . Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.

Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms [see comments] Pontiroli L, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):310–4 . Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.

Is liver function monitoring warranted during risperidone treatment? [letter; comment] Landau J, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Oct; 37(10):1007–8. Comment on: J Am Acad Child Adolesc Psychiatry 1997 May;36(5):701–5. Comment on: J Am Acad Child Adolesc Psychiatry 1998 Mar;37(3):246–7.

Atrium and paroxetine-related severe hepatitis. Cadranel JF, et al. **J Clin Gastroenterol** 1999 Jan;28(1):52–5

Granulomatous hepatitis due to mebendazole. Colle I, et al. **J Clin Gastroenterol** 1999 Jan;28(1):44–5

Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. Kristensen T, et al. **J Comput Assist Tomogr** 1999 Mar-Apr;23(2):314–7 (26 ref.)

Inhibitory effect of Oren-gedoku-to (Huanglian-Jie-Du-Tang) extract on hepatic triglyceride accumulation with the progression of carbon tetrachloride-induced acute liver injury in rats. Ohta Y, et al. **J Ethnopharmacol** 1998 May;61(1):75–80

Propylthiouracil-induced severe hepatitis: a case report and review of the literature. Ichiki Y, et al. **J Gastroenterol** 1998 Oct;33(5):747–50 (24 ref.)

Reversible pancreatitis, hepatitis, and peripheral polyneuropathy associated with parenteral gold therapy. Ben-Ami H, et al. **J Rheumatol** 1999 Sep;26(9):2049–50

NO contribution to lipopolysaccharide-induced hepatic damage in galactosamine-sensitized mice. Takayama F, et al. **J Toxicol Sci** 1999 Feb;24(1):69–75

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. Nolan CM, et al. **JAMA** 1999 Mar 17;281(11):1014–8

Nimesulide and COX-2 inhibitors [letter] Bakhle YS. **Lancet** 1999 Aug 28;354(9180):772

Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin [letter] Nakad A, et al. **Lancet** 1999 May 22;353(9166):1763–4

Raloxifene-associated hepatitis [letter] Vilches AR, et al. **Lancet** 1998 Nov 7;352(9139):1524–5

Nonalcoholic steatohepatitis (NASH): further expansion of this clinical entity? [editorial; comment] Brunt EM. **Liver** 1999 Aug;19(4):263–4 (12 ref.). Comment on: Liver 1999 Aug;19(4):299–304.

Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers [see comments] Cotrim HP, et al. **Liver** 1999 Aug; 19(4):299–304. Comment in: Liver 1999 Aug;19(4):263–4.

Acute cholestatic hepatitis induced by nimesulide [letter] Romero-Gómez M, et al. **Liver** 1999 Apr;19(2):164–5

Acute hepatitis due to fluoxetine therapy. Cai Q, et al. **Mayo Clin Proc** 1999 Jul;74(7):692–4

Adverse effect of nefazodone: hepatitis [letter] Schrader GD, et al. **Med J Aust** 1999 May 3;170(9):452

The role of oxygen free radicals in isoniazid-induced hepatotoxicity. Walubo A, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):649–55

Halothane and post-halothane exposure hepatitis [letter] Buchanan CC, et al. **N Z Med J** 1999 Jan 22; 112(1080):19–20

Hepatitis after alendronate [letter] Lieverse RJ. **Neth J Med** 1998 Dec;53(6):271–2

Acetaminophen hepatotoxicity without intentional overdose. Mege J. **Pa Med** 1999 Jun;102(6):14–5

Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Braun JS, et al. **Pharmacopsychiatry** 1998 Jul;31(4):152–5

Suspected carbamazepine-induced hepatotoxicity. Morales-Diaz M, et al. **Pharmacotherapy** 1999 Feb; 19(2):252–5

Carbamazepine, hepatotoxicity, organic solvents, and paints. Kaufman KR. **Seizure** 1999 Jun;8(4):250–2

Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Roughead EE, et al. **Soc Sci Med** 1999 Mar;48(6):845–53

Diclofenac-associated hepatitis. Bhogaraju A, et al. **South Med J** 1999 Jul;92(7):711–3

Characterization of hepatocellular resistance and susceptibility to styrene toxicity in B6C3F1 mice. Mahler JF, et al. **Toxicol Sci** 1999 Mar;48(1):123–33

Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Brown SL, et al. **Urology** 1998 Nov; 52(5):844–7

[Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid] Xing T, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Feb; 20(1):33–5 (Eng. Abstr.) **(Chi)**

[Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects] Van Puijenbroek EP, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2416–8 (Eng. Abstr.) **(Dut)**

[Hepatonephritis and massive ingestion of buprenorphine] Houdret N, et al. **Acta Clin Belg Suppl** 1999;1:29–31 (Eng. Abstr.) **(Fre)**

[Fatal hepatitis in a young child: probable role of halothane] Mjahed K, et al. **Ann Fr Anesth Reanim** 1997;16(5):531–3 (Eng. Abstr.) **(Fre)**

[Immunoallergic reaction with hepatitis induced by minocycline] Pavese P, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):521–3 (Eng. Abstr.) **(Fre)**

[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)] Mbaye PS, et al. **Dakar Med** 1995; 40(2):129–31 (Eng. Abstr.) **(Fre)**

[Drug-induced hepatotoxicity. Eleventh update of the bibliographic database on liver injuries and responsible drugs] Biour M, et al. **Gastroenterol Clin Biol** 1998 Dec; 22(12):1004–44 (Eng. Abstr.) **(Fre)**

[Cibenzoline-induced acute hepatitis (letter)] Caroli-Bosc FX, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):106–7 **(Fre)**

[Flupentixol-induced acute hepatitis (letter)] Demuth N, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):152–3 **(Fre)**

[Hepatitis imputable to dimethylformamide with reintroduction (letter)] Drouet D'Aubigny F, et al. **Gastroenterol Clin Biol** 1998 Aug-Sep;22(8–9):745–6 **(Fre)**

[Regressive fulminant hepatitis, acute pancreatitis and renal insufficiency after taking ketoprofen (letter)] Flamenbaum M, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):975–6 **(Fre)**

[A new drug responsible for microvesicular steatosis: ticlopidine (letter)] Remy AJ, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):151–2 **(Fre)**

[Dexchlorpheniramine-induced acute hepatitis: a case with positive rechallenge] Remy AJ, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):831–2 **(Fre)**

[Acute hepatitis after phytotherapy (letter)] Mennecier D, et al. **Presse Med** 1999 May 15;28(18):966 **(Fre)**

[Clinical case of the month. Hepatoportal sclerosis in a patient treated with azathioprine] Roland S, et al. **Rev Med Liege** 1998 Aug;53(8):450–3 (Eng. Abstr.) **(Fre)**

[Severe cholestasis with kidney failure from anabolic steroids in a body builder] Habscheid W, et al. **Dtsch Med Wochenschr** 1999 Sep 10;124(36):1029–32 (17 ref.) (Eng. Abstr.) **(Ger)**

[Necrotizing hepatitis after taking herbal remedies] Strahl S, et al. **Dtsch Med Wochenschr** 1998 Nov 20; 123(47):1410–4 (Eng. Abstr.) **(Ger)**

[Severe hepatocellular damage after administration of paracetamol and chlorzoxazone in therapeutic dosage] Kronenberg A, et al. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1356–60 (Eng. Abstr.) **(Ger)**

[Liver damage caused by drugs] Strohmeyer G, et al. **Z Gastroenterol** 1999 May;37(5):367–78 (71 ref.) (Eng. Abstr.) **(Ger)**

[Acute renal failure, intravascular hemodialysis and toxic hepatitis caused by repeated use of rifampicin (case report)] Sefer S, et al. **Lijec Vjesn** 1999 Apr-May;121(4–5):126–8 (Eng. Abstr.) **(Scr)**

[Cholestatic hepatitis from ticlopidine (letter)] Torrano Larrión F. **Aten Primaria** 1999 Jun 30;24(2):115 **(Spa)**

[Severe hepatitis from therapeutic doses of paracetamol in an alcoholic patient] Andreu V, et al. **Gastroenterol Hepatol** 1999 May;22(5):235–7 (25 ref.) (Eng. Abstr.) **(Spa)**

[Non-immunoallergic hepatotoxicity due to mesalazine] Barroso N, et al. **Gastroenterol Hepatol** 1999 Apr; 22(4):176–9 (30 ref.) (Eng. Abstr.) **(Spa)**

[Cholestatic hepatitis by josamycin (letter)] Lavín I, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):160 **(Spa)**

[Acute flutamide-induced hepatitis (letter; comment)] Nicolás D, et al. **Gastroenterol Hepatol** 1999 May; 22(5):262–3 (10 ref.). Comment on: Gastroenterol Hepatol 1998 Feb;21(2):97–9. **(Spa)**

[Hepatoxicity by enalapril (letter)] Quílez C, et al. **Gastroenterol Hepatol** 1999 Feb;22(2):113–4 **(Spa)**

[Ebrotidine-induced acute hepatitis (letter) Rausell V, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):28 (10 ref.) **(Spa)**

[Tizanidine-induced toxic hepatitis (letter)] Afonso Pérez E, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):478–9 (9 ref.) **(Spa)**

[Toxic hepatitis caused by ebrotidine (letter)] Castellote J, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):676 **(Spa)**

[Acute hepatitis due to ritodrine (letter)] Castro Fernández M, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):239 (9 ref.) **(Spa)**

[Acute hepatitis associated with lamotrigine administration (letter)] Gómez Caturla A, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):675–6 **(Spa)**

[Amphotericin B associated with severe liver toxicity (letter)] Campo C, et al. **Rev Clin Esp** 1999 Jan;199(1):49 **(Spa)**

[Hepatotoxic reaction associated with metformin and chlorpropamide treatment (letter)] Crespo Valadés E, et al. **Rev Clin Esp** 1999 Feb;199(2):118–9 **(Spa)**

[The use of oral amiodarone as a chronic treatment in a patient with prior fulminant hepatitis due to intravenous amiodarone] López-Gómez D, et al. **Rev Esp Cardiol** 1999 Mar;52(3):201–3 (5 ref.) (Eng. Abstr.) **(Spa)**

[Acetaminophen hepatotoxicity in an alcohol addicted student. Case report] Fercovic A, et al. **Rev Med Chil** 1999 Feb;127(2):202–5 (Eng. Abstr.) **(Spa)**

[Cholestatic hepatitis associated with piroxicam use. Case report] Poniachik J, et al. **Rev Med Chil** 1998 May; 126(5):548–52 (Eng. Abstr.) **(Spa)**

GENETICS

Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. Ku NO, et al. **J Cell Biol** 1998 Dec 28;143(7):2023–32

Metallothionein-I/II knockout mice are sensitive to acetaminophen-induced hepatotoxicity. Liu J, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):580–6

IMMUNOLOGY

Effect of matrine on lipopolysaccharides/D-galactosamine-induced hepatitis and tumor necrosis factor release from macrophages in vitro. Hu ZL, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):351–3

Allergic hepatitis: a drug-mediated organ-specific immune reaction. Castell JV. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:13–9 (47 ref.)

Immunological investigation in hepatic drug reactions. Maria VA, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:71–7 (40 ref.)

The role of complement activation in tumour necrosis factor-induced lethal hepatitis. Libert C, et al. **Cytokine** 1999 Aug;11(8):617–25

Diagnostic value of T cell reactivity in drug induced hepatitis [letter; comment] Bartle WR. **Gut** 1998 Nov;43(5):730–1. Comment on: Gut 1997 Oct;41(4):534–40.

Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms [see comments] Pontiroli L, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):310–4 . Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):318–9.

Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. Eliasson E, et al. **J Hepatol** 1998 Nov;29(5):819–25

Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4: the cytokine milieu of concanavalin A hepatitis. Nishikage T, et al. **J Hepatol** 1999 Jul;31(1):18–26

[Autoimmune hepatitis induced by fibrates] Ganne-Carrié N, et al. **Gastroenterol Clin Biol** 1998 May;22(5):525–9 (Eng. Abstr.) **(Fre)**

METABOLISM

Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Eliasson E, et al. **Chem Biol Interact** 1998 Nov 6;116(1–2):123–41

Structure-activity relationship of schisandrins in enhancing liver mitochondrial glutathione status in CCl4-poisoned mice. Ip SP, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):313–6

Pharmacokinetics of flutamide and its metabolite 2-hydroxyflutamide in normal and hepatic injury rats. Xu CJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan; 19(1):39–43

Interactive toxicity and stress protein expression by vinylidene chloride and monochloroacetate in precision-cut rat liver slices. Wijeweera J, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1319–23

Expression of cytokine mRNA in extrahepatic organs in a mouse concanavalin A-hepatitis model. Okamoto T, et al. **Jpn J Pharmacol** 1998 Jul;77(3):219–25

[Actions of salvianolic acid A on CCl4-poisoned liver injury and fibrosis in rats] Hu YY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):478–80 (Eng. Abstr.) **(Chi)**

[Effect of matrine on mouse hepatitis and tumor necrosis factor production induced by Propionibacterium acnes/lipopolysaccharides] Hu ZL, et al.

Yao Hsueh Hsueh Pao 1996;31(9):662-5 (Eng. Abstr.) **(Chi)**

[Effect of silymarin on mouse liver damage, production and activity of tumor necrosis factor] Zhang JP, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):577-80 (Eng. Abstr.) **(Chi)**

[Effect of carbon tetrachloride-induced hepatic injury on stereoselective N-demethylation of chlorpheniramine by rat hepatic cytochrome P450 2C11 isozyme] Nomura A, et al. **Yakugaku Zasshi** 1998 Aug;118(8):317-23 (Eng. Abstr.) **(Jpn)**

[Effects of hepatoprotective agents containing phospholipids on cytochrome P-450-dependent antitoxic liver function during experimental toxic hepatitis] Saratikov AS, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):392-4 **(Rus)**

[Effect of Arnica montana on the state of lipid peroxidation and protective glutathione system of rat liver in experimental toxic hepatitis] Iamemil IM, et al. **Ukr Biokhim Zh** 1998 Mar-Apr;70(2):78-82 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Horn KD, et al. **Am J Clin Pathol** 1999 Sep;112(3):351-7

Hepatotoxicity possibly caused by amphotericin B. Gill J, et al. **Ann Pharmacother** 1999 Jun;33(6):683-5

Toxicity of 4-chloroaniline in early life stages of zebrafish (Danio rerio): II. Cytopathology and regeneration of liver and gills after prolonged exposure to waterborne 4-chloroaniline. Burkhardt-Holm P, et al. **Arch Environ Contam Toxicol** 1999 Jul;37(1):85-102

Hepatoprotective and hepatotoxic actions of oleanolic acid-type triterpenoidal glucuronides on rat primary hepatocyte cultures. Kinjo J, et al. **Chem Pharm Bull (Tokyo)** 1999 Feb;47(2):290-2

Influences of Kupffer cell stimulation and suppression on immunological liver injury in mice. Wang GS, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):173-6

First International Symposium on the molecular pathology and clinical aspects of the inflamed liver: alcohol and cytokines. Neuman MG. **Clin Invest Med** 1998 Dec; 21(6):283-6

Cyclosiloxanes produce fatal liver and lung damage in mice. Lieberman MW, et al. **Environ Health Perspect** 1999 Feb; 107(2):161-5

Role of tissue repair in toxicologic interactions among hepatotoxic organics. Soni MG, et al. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1307-17 (79 ref.)

Acarbose alone or in combination with ethanol potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen in rats [see comments] Wang PY, et al. **Hepatology** 1999 Jan;29(1):161-5. Comment in: Hepatology 1999 Jan;29(1):285-7.

Effect of PGE1 on TNF-alpha status and hepatic D-galactosamine-induced apoptosis in rats. Muntané J, et al. **J Gastroenterol Hepatol** 1998 Feb;13(2):197-207

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? Delgado J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):607-10

Pretreatment of male BALB/c mice with beta-ionone potentiates thioacetamide-induced hepatotoxicity. Jeong TC, et al. **Toxicol Lett** 1999 Mar 8;105(1):39-46

Disposition of lantadene A, the pentacyclic triterpenoid hepatotoxin, orally administered to guinea pigs. Sharma S, et al. **Toxicol Lett** 1999 Mar 8;105(1):59-66

Bile duct epithelial cells exposed to alpha-naphthylisothiocyanate produce a factor that causes neutrophil-dependent hepatocellular injury in vitro. Hill DA, et al. **Toxicol Sci** 1999 Jan;47(1):118-25

Prolonged sublethal exposure to the protein phosphatase inhibitor microcystin-LR results in multiple dose-dependent hepatotoxic effects. Solter PF, et al. **Toxicol Sci** 1998 Jul;44(1):87-96

[Protective effects of 15-methyl-prostaglandin F2 alpha on primary cultured rat hepatocyte against CCl4-induced injury] Wu B, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):177-80 (Eng. Abstr.) **(Chi)**

[Effect of the synthetic heparin antagonist--quaternary ammonium salt of 25-conidine oligomer on the regeneration of liver injured by CCl4] Golenchenko VA, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):56-60 **(Rus)**

[Acute hepatitis caused by gemfibrozil (letter)] Bustamante Balén M, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):419-20 **(Spa)**

[Toxic hepatitis caused by flutamide (letter)] Cuevas Campos MA, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):499-500 **(Spa)**

[Acute hepatitis induced by Ecstasy (letter)] Indart Pérez A, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):499 **(Spa)**

PHYSIOPATHOLOGY

Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Knittel T, et al. **Am J Pathol** 1999 Jan; 154(1):153-67

Gastric emptying in rats with acetaminophen-induced hepatitis. Hessel G, et al. **Braz J Med Biol Res** 1998 Sep; 31(9):1133-9

Risperidone-induced hepatotoxicity. Benazzi F. **Pharmacopsychiatry** 1998 Nov;31(6):241

[Role of mitochondria in drug-induced hepatotoxicity] Berson A, et al. **Gastroenterol Clin Biol** 1998 Jan; 22(1):59-72 (96 ref.) **(Fre)**

PREVENTION & CONTROL

Mechanism of the protective effects of sumac gall extract and gallic acid on the progression of CCl4-induced acute liver injury in rats. Kanai S, et al. **Am J Chin Med** 1998; 26(3-4):333-41

Hepatoprotective effect of Vitex negundo against carbon tetrachloride-induced liver damage. Avadhoot Y, et al. **Arch Pharm Res** 1991 Mar;14(1):96-8

Hepatoprotective activity of scopoletin, a constituent of Solanum lyratum. Kang SY, et al. **Arch Pharm Res** 1998 Dec;21(6):718-22

Antihepatotoxic potential of Trianthema portulacastrum in carbon tetrachloride-induced chronic hepatocellular injury in mice: reflection in haematological, histological and biochemical characteristics. Mandal A, et al. **Arch Pharm Res** 1998 Jun;21(3):223-30

Hepatoprotective effects of Andrographis paniculata against carbon tetrachloride-induced liver damage. Rana AC, et al. **Arch Pharm Res** 1991 Mar;14(1):93-5

Studies on protective effect of DA-9601, Artemisia asiatica extract, on acetaminophen- and CCl4-induced liver damage in rats. Ryu BK, et al. **Arch Pharm Res** 1998 Oct; 21(5):508-13

Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Kim DH, et al. **Biol Pharm Bull** 1999 Feb;22(2):162-4

Effect of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'- dicarboxylate (DDB) on chemical-induced liver injury. Kim SN, et al. **Biol Pharm Bull** 1999 Jan;22(1):93-5

Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on D-galactosamine/lipopolysaccharide-induced liver injury. Matsuda H, et al. **Bioorg Med Chem Lett** 1998 Feb 17; 8(4):339-44

Suppression of D-galactosamine-induced rat liver injury by glycosidic flavonoids-rich fraction from green tea. Wada S, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):570-2

HPLC profile analysis of hepatoprotective oleanene-glucuronides in Puerariae Flos. Kinjo J, et al. **Chem Pharm Bull (Tokyo)** 1999 May;47(5):708-10

Differential chemoprotection against acetaminophen-induced hepatotoxicity by latentiated L-cysteines. Roberts JC, et al. **Chem Res Toxicol** 1998 Nov;11(11):1274-82

Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. Bruck R, et al. **Dig Dis Sci** 1999 Jun; 44(6):1228-35

Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. Xiang M, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):399-404

Protective effects of green tea on hepatotoxicity, oxidative DNA damage and cell proliferation in the rat liver induced by repeated oral administration of 2-nitropropane. Sai K, et al. **Food Chem Toxicol** 1998 Dec;36(12):1043-51

The role of colchicine in prevention of hepatic cirrhosis induced by carbon tetrachloride. Rhoden EL, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1111-5

Medicinal herb, Thonningia sanguinea protects against aflatoxin B1 acute hepatotoxicity in Fischer 344 rats. Gyamfi MA, et al. **Hum Exp Toxicol** 1998 Aug; 17(8):418-23

Protective effect of HD-03, a herbal formulation, against various hepatotoxic agents in rats. Mitra SK, et al. **J Ethnopharmacol** 1998 Dec;63(3):181-6

Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice. Akamatsu K, et al. **J Pharmacol Exp Ther** 1999 Sep; 290(3):1242-9

Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. Sarich TC, et al. **J Pharmacol Exp Ther** 1999 May;289(2):695-702

The PPAR activator docosahexaenoic acid prevents acetaminophen hepatotoxicity in male CD-1 mice. Nguyen KA, et al. **J Toxicol Environ Health** 1999 Oct 15; 58(3):171-86

The protective effect of cyclosporine A on anti-Fas antibody-induced hepatitis in mice. Okamoto T, et al. **Jpn J Pharmacol** 1999 Apr;79(4):485-8

Acteoside inhibits apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury. Xiong Q, et al. **Life Sci** 1999;65(4):421-30

Antihepatotoxic activity of Swertia chirata on carbon tetrachloride induced hepatotoxicity in rats. Karan M, et al. **Phytother Res** 1999 Feb;13(1):24-30

2-(allylthio)pyrazine inhibition of aflatoxin B1-induced hepatotoxicity in rats: inhibition of cytochrome P450 2B- and 3A2-mediated bioactivation. Ha TG, et al. **Res Commun Mol Pathol Pharmacol** 1998 Oct;102(1):69-78

Preventive effect of zinc compounds, polaprezinc and zinc acetate against the onset of hepatitis in Long-Evans Cinnamon rat. Sugawara N, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):167-76

Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium. Ishiwata Y, et al. **Scand J Immunol** 1998 Dec;48(6):605-14

Modulation of halobenzene-induced hepatotoxicity by DT-diaphorase modulators, butylated hydroxyanisole and dicoumarol: evidence for possible involvement of quinone metabolites in the toxicity of halobenzenes. Mizutani T, et al. **Toxicol Lett** 1999 Mar 8;105(1):25-30

Hepatoprotection by dimethyl sulfoxide. I. Protection when given twenty-four hours after chloroform or bromobenzene. Lind RC, et al. **Toxicol Pathol** 1999 May-Jun;27(3):342-7

Dietary beta-carotene protects lung and liver parenchyma of rats treated with monocrotaline. Baybutt RC, et al. **Toxicology** 1999 Sep 20;137(2):69-80

[Protective effect of interleukin-1 beta on acetaminophen induced liver damage in mice] Sun H, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):153-9 (Eng. Abstr.) **(Chi)**

[Inhibitory effect of green tea infusion of hepatotoxicity] Hasegawa R, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):82-91 (63 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Chemically-induced liver failure. Van Hoenacker FM, et al. **J Belge Radiol** 1998 Oct;81(5):252

ULTRASONOGRAPHY

Ultrasonographic findings in niacin-induced hepatitis. Scheer MS, et al. **J Ultrasound Med** 1999 Apr;18(4):321-3

HEPATITIS, VIRAL, ANIMAL

Animal models of human hepatitides. Tabor E. **Lab Anim Sci** 1998 Dec;48(6):593-5 (0 ref.)

BLOOD

Haematological and biochemical studies in broiler chicks fed ochratoxin and inoculated with inclusion body hepatitis virus, singly and in concurrence. Sandhu BS, et al. **Vet Res Commun** 1998 Jul;22(5):335-46

DIAGNOSIS

Application of nested polymerase chain reaction to detection of mouse hepatitis virus in fecal specimens during a natural outbreak in an immunodeficient mouse colony. Yamada YK, et al. **Exp Anim** 1998 Oct;47(4):261-4

Use of polymerase chain reaction to diagnose a natural outbreak of mouse hepatitis virus infection in nude mice. Matthaei KI, et al. **Lab Anim Sci** 1998 Apr;48(2):137-44

Diagnosis of mouse hepatitis virus contamination in mouse population by using nude mice and RT-PCR. Wang RF, et al. **Mol Cell Probes** 1999 Feb;13(1):29-33

DRUG THERAPY

Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Morrey JD, et al. **Antiviral Res** 1999 Jun;42(2):97-108

EPIDEMIOLOGY

Characterization of fowl adenoviruses from outbreaks of inclusion body hepatitis/hydropericardium syndrome in Chile. Toro H, et al. **Avian Dis** 1999 Apr-Jun;43(2):262-70

IMMUNOLOGY

Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Koo M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7774-9

PATHOLOGY

The association between murine cytomegalovirus induced hepatitis and the accumulation of oval cells. Cassell HS, et al. **Int J Exp Pathol** 1998 Dec;79(6):433-41

Spontaneous low-virulence mouse hepatitis virus infection in severe combined immunodeficiency mice. Choi YK, et al. **Lab Anim Sci** 1999 Jun;49(3):324-7

[Modeling and characteristics of liver damage in herpes infection] Tereshko AB, et al. **Vopr Virusol** 1999 May-Jun; 44(3):120-4 (Eng. Abstr.) **(Rus)**

TRANSMISSION

The use of non-human primates as animal models for the study of hepatitis viruses. Vitral CL, et al. **Braz J Med Biol Res** 1998 Aug;31(8):1035-48 (130 ref.)

VIROLOGY

Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Michalak TI, et al. **Hepatology** 1999 Mar;29(3):928-38

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. Bukh J, et al. **Virology** 1999 Sep 30;262(2):470-8

HEPATITIS, VIRAL, HUMAN

Viral hepatitis and pregnancy. Michielsen PP, et al. **Acta Gastroenterol Belg** 1999 Jan-Mar;62(1):21-9 (101 ref.)

When physicians are not physicians [letter; comment] Merrill JM. **Am J Med Sci** 1999 May;317(5):353. Comment on: Am J Med Sci 1999 Jan;317(1):1-4. Comment on: Am J Med Sci 1999 Jan;317(1):5-8.

Hepatitis G virus infection among liver graft recipients: anatomoclinical correlations. Negro F, et al. **Dig Dis Sci** 1998 Dec;43(12):2577-83

Hepatitis viruses A, B, C, D, E and G: implications for dental personnel. Gillcrist JA. **J Am Dent Assoc** 1999 Apr; 130(4):509-20 (97 ref.)

Biochemical and histological features of hepatitis G virus infection [see comments] Kobayashi M, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):767-72. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763-6.

Report from the International Symposium on viral hepatitis, 24-25 October 1997, Warsaw, Poland. Madaliński K, et al. **J Viral Hepat** 1998 Jul;5(4):223-5

Hepatitis: implications for dental care. Demas PN, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):2-4

Hepatitis G Virus. Patrick CC. **Pediatr Infect Dis J** 1998 Nov;17(11):1045-6

Hepatitis in pregnancy. Duff P. **Semin Perinatol** 1998 Aug; 22(4):277-83 (35 ref.)

The hepatitis alphabet--hepatitis A-G and TTV. Müller C. **Wien Klin Wochenschr** 1999 Jun 18;111(12):461-8 (61 ref.)

[Hepatitis G virus or hepatitis GB virus C] Heinsen A, et al. **Ugeskr Laeger** 1999 May 3;161(18):2653-6 (37 ref.) (Eng. Abstr.) **(Dan)**

["Hepatitis" A virus g: myth or reality? VHG/GBH-C: diagnosis, epidemiology, transfusion risk, and pathogenicity] Gérard C, et al. **Rev Med Liege** 1998 Sep; 53(9):524-8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Acute viral hepatitis A, B, C, D and E: epidemiology, etiology, diagnosis, course, prevention] Zarski JP, et al. **Rev Prat** 1998 Sep 15;48(14):1609-14 (0 ref.) **(Fre)**

[TTV hepatitis] Iino S. **Ryoikibetsu Shokogun Shirizu** 1999; (23 Pt 1):69-72 (12 ref.) **(Jpn)**

[Hepatitis G] Kiyosawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):65-8 (13 ref.) **(Jpn)**

[Hepatitis F] Kiyosawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):111-4 (9 ref.) **(Jpn)**

[Adenoviral hepatitis] Nishiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):115-6 (3 ref.) **(Jpn)**

[Hepatitis associated with HIV] Nishiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):117-9 (15 ref.) **(Jpn)**

[Herpes simplex virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):120-2 (9 ref.) **(Jpn)**

[Cytomegalovirus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):123-5 (10 ref.) **(Jpn)**

[EB virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):126-8 (10 ref.) **(Jpn)**

[Hepatitis G--2 years after its discovery] Szántová M, et al. **Bratisl Lek Listy** 1999 Jan;100(1):54-8 (15 ref.) (Eng. Abstr.) **(Slo)**

[The TT virus: another accidental tourist? (editorial)] Giménez-Barcons M, et al. **Gastroenterol Hepatol** 1999 Mar;22(3):154-6 **(Spa)**

[Hepatitis G virus exists--but does hepatitis G?] Wejstål R, et al. **Lakartidningen** 1999 Jan 27;96(4):323-6 (45 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Kawasaki T, et al. **Am J Gastroenterol** 1999 Jul;94(7):1918-22

Differential tumor markers and hepatitis markers profile in liver tumors. Khalifa A, et al. **Anticancer Res** 1999 Jul-Aug; 19(4A):2495-500

Immunoreactivity to putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic subjects. Toniutto P, et al. **Clin Diagn Lab Immunol** 1999 Jul; 6(4):573-6

Plasma levels of fibronectin in patients with chronic viral and alcoholic liver disease. Grieco A, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1731-6

The effect of hepatitis G virus infection on hematological laboratory values in patients with chronic hepatitis C and B [letter] Radkowski M, et al. **Infection** 1999 Jan-Feb; 27(1):48

Analysis of conserved ambisense sequences within GB virus C. Kondo Y, et al. **J Infect Dis** 1998 Oct;178(4):1185-8

Adenosine deaminase and guanosine deaminase activities in sera of patients with viral hepatitis. Kalkan A, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun;94(3):383-6

Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Shiota G, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jul; 101(1):3-12

Hepatitis G virus infection in haemodialysis patients and its relationship with hepatitis C virus RNA positivity. Hizel N, et al. **Scand J Infect Dis** 1998;30(5):451-4

GB virus type C/hepatitis G virus infection in French blood donors with anti-NS5 isolated reactivities by recombinant immunoblot assay for hepatitis C virus [letter] LaPerche S, et al. **Transfusion** 1999 Jul;39(7):790-1

Evaluation of RNA and E2 antibodies in prospectively followed recipients of hepatitis G virus-infected blood. Sauleda S, et al. **Transfusion** 1999 Jun;39(6):633-8

GB virus type C viremia and envelope antibodies among population subsets in The Netherlands. Jongerius J, et al. **Vox Sang** 1999;76(2):81-4

[The significance of sIL-2R detection in various hepatic diseases] Xuan SY, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Apr; 18(2):92-4 (Eng. Abstr.) **(Chi)**

[Plasma middle mass molecules in viral hepatitis] Nagoev BS, et al. **Ter Arkh** 1998;70(11):26-7 (Eng. Abstr.) **(Rus)**

[The detection of viral hepatitis markers in HIV-infected patients] Kishtanova NA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):36-7 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Lack of GB virus C/hepatitis G virus sequences in cerebrospinal fluid in patients with central nervous system infections [letter] Radkowski M, et al. **Scand J Infect Dis** 1998;30(5):539

CLASSIFICATION

Follow up of clinical, laboratory, and serological findings of adult Hungarian hospitalized acute hepatitis patients and characteristics of recovery. Kassas AL. **Acta Microbiol Immunol Hung** 1998;45(2):209-19

COMPLICATIONS

The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Brandhagen DJ, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1000-5

Ascites and severe hepatitis complicating Epstein-Barr infection. Devereaux CE, et al. **Am J Gastroenterol** 1999 Jan;94(1):236-40

Myoglobinuria in acute viral hepatitis [letter] Sood A, et al. **Am J Gastroenterol** 1999 Mar;94(3):859-60

Membranoproliferative glomerulonephritis with subendothelial deposits (type 1) associated with hepatitis G virus infection in a renal transplant recipient. Berthoux P, et al. **Am J Nephrol** 1999;19(4):513-8

Hepatitis G virus infection detected in a woman with intrahepatic cholestasis of pregnancy. Morton M, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):428-9

Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Dumoulin FL, et al. **Biomed Pharmacother** 1999 Jun;53(5-6):242-54 (157 ref.)

GBV-C/HGV and HCV infection in mixed cryoglobulinaemia. Crovatto M, et al. **Br J Haematol** 1999 Aug;106(2):510-4

Hepatitis G virus in patients with Hodgkin's lymphoma [letter] Persico M, et al. **Br J Haematol** 1998 Dec; 103(4):1206-7

Chronic infection with hepatitis G virus in relation to hepatocellular carcinoma among non-Asians in Los Angeles County, California. Yuan JM, et al. **Cancer** 1999 Sep 15;86(6):936-43

Influence of hepatitis G virus coinfection on the clinical course of chronic hepatitis C. Cacopardo B, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):709-14

Porphyria cutanea tarda and hepatitis G and C virus infection. Mancini C, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):534-5

Lack of association between GBV-C infection and spontaneous abortion. Viazov S, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):458-9

Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Frieden TR, et al. **Hepatology** 1999 Mar; 29(3):883-8

The role of TT virus infection in acute viral hepatitis. Kanda T, et al. **Hepatology** 1999 Jun;29(6):1905-8

HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C. Fabris P, et al. **Infection** 1998 Sep-Oct; 26(5):283-7

Hepatitis virus and glomerulonephritis [editorial; comment] Yamabe H. **Intern Med** 1998 Oct;37(10):800-1. Comment on: Intern Med 1998 Oct;37(10):836-40.

HGV infection in a cohort of patients with chronic active hepatitis HCV related [letter] Capra F, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):443

Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men [letter; comment] Sabin CA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):546-8. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1998 Mar 1;17(3):209-13.

Hepatitis G virus infection in lymphoma and in blood donors. Minton J, et al. **J Clin Pathol** 1998 Sep;51(9):676-8

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action [published erratum appears in J Hepatol 1998 Oct;29(4):686] Bréchot C, et al. **J Hepatol** 1998 Aug; 29(2):173-83

Prevalence of hepatitis G virus RNA in human immunodeficiency virus type 1-positive intravenous drug users. Zehender G, et al. **J Hum Virol** 1998 Jan-Feb; 1(2):96-100

Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. Tan D, et al. **J Infect Dis** 1999 May;179(5):1055-61

Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Devereux H, et al. **J Med Virol** 1998 Dec;56(4):316-20

High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. Nerurkar VR, et al. **J Med Virol** 1998 Oct; 56(2):123-7

Association of GB virus C (GBV-C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential. Pavlova BG, et al. **J Med Virol** 1999 Apr; 57(4):361-6

Profiles of GBV-C/hepatitis G virus markers in patients coinfected with hepatitis C virus. Sauleda S, et al. **J Med Virol** 1999 Sep;59(1):45-51

Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. Tanaka T, et al. **J Med Virol** 1999 Apr; 57(4):370-5

GBV-C/HGV infection in end-stage renal disease. Fabrizi F, et al. **J Nephrol** 1999 May-Jun;12(3):131-9 (90 ref.)

Brief report: Pediatric Burkitt lymphoma with concurrent chronic Epstein-Barr virus hepatitis. Preciado MV, et al. **Med Pediatr Oncol** 1999 Aug;33(2):134-6

A case of Whipple's disease associated with acute Ebstein Barr virus hepatitis and Berger's disease [letter] Evrenkaya R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):241-2

Prevalence and patterns of HGV/GBV-C infection in patients with suspected HCV-related hepatitis. Garcia de Viedma D, et al. **Res Virol** 1998 Nov-Dec;149(6):433-8

Viral hepatitis as a cause of renal disease. Krane NK, et al. **South Med J** 1999 Apr;92(4):354-60 (53 ref.)

Hepatitis GBV-C infection in intravenous drug users. Vimolket T, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):491-6

Hepatitis G virus or hepatitis GB virus type C infection in thalassemic patients [letter] Papaevangelou V, et al. **Transfusion** 1999 Mar;39(3):336-7

Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Rostaing L, et al. **Transplantation** 1999 Feb 27;67(4):556-60

[Long-term consequences of co-infection by hepatitis G virus in hepatitis c virus infected kidney transplant patients] Rostaing L, et al. **Nephrologie** 1999;20(3):165-70 (Eng. Abstr.) **(Fre)**

[A comparative study of TTV co-infection in patients with chronic liver disease B, C and non-B non-C] Asaba N, et al. **Nippon Rinsho** 1999 Jun;57(6):1362-5 (Eng. Abstr.) **(Jpn)**

[Clinical feature of TTV-related hepatitis] Kanda T, et al. **Nippon Rinsho** 1999 Jun;57(6):1330-4 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of TT virus (TTV) in non-B, non-C hepatitis patients with hepatocellular carcinoma, and clinical features of these patients] Kusama K, et al. **Nippon Rinsho** 1999 Jun;57(6):1366-9 (Eng. Abstr.) **(Jpn)**

[TTV superinfection on acute hepatitis B] Sakamoto M, et al. **Nippon Rinsho** 1999 Jun;57(6):1326-9 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Coexistent hepatitis G virus infection and autoimmune hepatitis] Szaflarska-Szczepanik A. **Pol Merkuriusz Lek** 1999 Feb;6(32):82-3 (Eng. Abstr.) **(Pol)**

[Aplastic anemia and viral hepatitis (posthepatitic aplastic anemia)] Mikhailova EA, et al. **Ter Arkh** 1999;71(7):64-9 (Eng. Abstr.) **(Rus)**

CONGENITAL

[The perinatal infection problem in viral hepatitides] Shaginian VR. **Mikrobiol Z** 1999 May-Jun;61(3):71-9 (59 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Differential tumor markers and hepatitis markers profile in liver tumors. Khalifa A, et al. **Anticancer Res** 1999 Jul-Aug; 19(4A):2495-500

GB virus C in systemic medium- and small-vessel necrotizing vasculitides. Servant A, et al. **Br J Rheumatol** 1998 Dec; 37(12):1292-4

Discrimination of liver cirrhosis from chronic hepatitis by measuring the ratio of Aleuria aurantia lectin-reactive serum cholinesterase to immunoreactive protein. Hada T, et al. **Clin Chim Acta** 1999 Mar;281(1-2):37-46

The significance of hepatitis G virus infection in patients with non-A to C hepatic diseases. Tanaka T, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1870-3

ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov;63(2):195-202 (24 ref.)

Jaundice in pregnant Nigerians. Anya SE, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):59-60

Fatal herpetic hepatitis in adult following short corticotherapy: a case report. Seksik P, et al. **Intensive Care Med** 1999 Apr;25(4):415-7

Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. Woolley I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):408–12

Molecular detection and prevalence investigation of HGV infection among older patients undergoing chronic hemodialysis [letter] Bianchi D, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1040–1

The polymerase chain reaction--a time of transition from research to routine [editorial] Harrison TJ. **J Clin Pathol** 1998 Jul;51(7):491–2

Severe cholestatic jaundice induced by Epstein–Barr virus infection in the elderly. Edoute Y, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):821–4

Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients. Kallinowski B, et al. **J Heart Lung Transplant** 1999 Mar;18(3):190–3

Comparative study of 5' UTR and NS3R primers for the detection of GB virus C/hepatitis G virus RNA in Japanese. Tanaka H, et al. **Liver** 1998 Dec;18(6):378–82

Listeria monocytogenes–associated acute hepatitis in a liver transplant recipient. Vargas V, et al. **Liver** 1998 Jun; 18(3):213–5

Should we be screening blood donors for hepatitis G virus? The case for screening. Moaven LD. **Med J Aust** 1998 Oct 5;169(7):373–4

Should we be screening blood donors for hepatitis G virus? The case against screening. Wong PY, et al. **Med J Aust** 1998 Oct 5;169(7):375–7

Viral hepatitis: primary care diagnosis and management. Alexander IM. **Nurse Pract** 1998 Oct;23(10):13–4, 17–20, 25–6 passim; quiz 44–5 (66 ref.)

Parvovirus B19–associated interstitial lung disease, hepatitis, and myositis. Bousvaros A, et al. **Pediatr Pulmonol** 1998 Nov;26(5):365–9 (24 ref.)

Polymerase chain reaction and in situ hybridization of Epstein–Barr virus in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Barkholt L, et al. **Transpl Int** 1998;11(5):336–44

[Detection of TTV DNA in liver tissue of patients with non A–G hepatitis] Xu D, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):96–7 **(Chi)**
(Eng. Abstr.)

[Studies on serotyping of sporadic acute viral hepatitis] Wang Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 May; 31(3):147–8 (Eng. Abstr.) **(Chi)**

[Parvovirus B19 as a cause of acute liver symptoms in adults] Hillingsø JG, et al. **Ugeskr Laeger** 1998 Oct 26; 160(44):6355–6 (Eng. Abstr.) **(Dan)**

[Fatal fulminating hepatitis due to Herpes simplex virus type 2 in a young immunocompetent female] Chauveau E, et al. **Med Trop (Mars)** 1999;59(1):58–60 (Eng. Abstr.) **(Fre)**

[Manganese superoxide dismutase–inhibiting autoantibodies in cholestatic Epstein–Barr viral hepatitis] Schaade L, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1478–82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Viral hepatitis: molecular diagnosis] Blum HE. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

[GB virus–C/hepatitis G virus--discovery, epidemiology, diagnosis and clinical relevance] Sarrazin C, et al. **Z Gastroenterol** 1998 Nov;36(11):997–1008 (119 ref.) (Eng. Abstr.) **(Ger)**

[Laboratory diagnosis of viral infections. 5. Viral hepatitis] Sandai T. **Rinsho Byori** 1998 Nov;Suppl 108:84–92 (3 ref.) **(Jpn)**

[Genetic diagnosis of viral hepatitis] Shiratori Y. **Rinsho Byori** 1999 Feb;Suppl 109:159–67 (12 ref.) **(Jpn)**

[The prevalence of viral hepatitis markers in patients hospitalized in infectious disease wards with a diagnosis of acute viral hepatitis] Bălan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct–Dec; 43(4):247–53 (Eng. Abstr.) **(Rum)**

[Cytomegalovirus granulomatous hepatitis in an immunocompetent patient] de la Serna–Higuera C, et al. **Gastroenterol Hepatol** 1999 May;22(5):230–1 (12 ref.) (Eng. Abstr.) **(Spa)**

[Legionnaires' disease and hepatitis (letter)] Gavilán JC, et al. **Rev Clin Esp** 1998 Nov;198(11):781 (5 ref.) **(Spa)**

[Errors in the diagnosis of acute viral hepatitides] Shkurba AV, et al. **Lik Sprava** 1999 Jan–Feb;(1):73–5 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients. Akbar N, et al. **Chin Med J (Engl)** 1998 Mar;111(3):248–51

Interferons in the management of viral hepatitis. Zein NN. **Cytokines Cell Mol Ther** 1998 Dec;4(4):229–41 (151 ref.)

New antiviral agents for viral hepatitis: our cup runneth over but is only half full. Dienstag JL. **Gastroenterology** 1999 Sep;117(3):525

Efficacy of ribavirin plus interferon alpha on viraemia of GB virus–C/hepatitis G virus: comparison with interferon alpha alone. Kao JH, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1249–53

Hepatitis. Advances in antiviral therapy for hepatitis. Berenguer M, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV15 (5 ref.)

Antiviral therapy in the chronic viral hepatitides [editorial] Mutimer D. **QJM** 1998 Sep;91(9):593–6

Severe cytomegalovirus hepatitis in a pregnant woman treated with ganciclovir. Miguelez M, et al. **Scand J Infect Dis** 1998;30(3):304–5

[Clinical observation on treatment of infantile cholestatic hepatitis syndrome by rhubarb] Huang ZH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Aug; 17(8):459–61 (Eng. Abstr.) **(Chi)**

ENZYMOLOGY

Adenosine deaminase and guanosine deaminase activities in sera of patients with viral hepatitis. Kalkan A, et al. **Mem Inst Oswaldo Cruz** 1999 May–Jun;94(3):383–6

EPIDEMIOLOGY

Intraspousal transmission of GB virus C/hepatitis G virus in an hepatitis C virus hyperendemic area in Japan. Akiyoshi F, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1627–31

Hepatitis G virus and HCV related extrahepatic disease [letter] Grasso A, et al. **Am J Gastroenterol** 1999 Apr; 94(4):1120–1

Prevalence of GB virus–C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. Tagger A, et al. **Am J Gastroenterol** 1999 Feb;94(2):484–8

RNA virus of hepatitis G (GB virus) prevalence in health care personnel [letter] Quirós E, et al. **Am J Infect Control** 1999 Apr;27(2):176–7

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377–84

TT virus viremia and liver transplantation: no significant increase of the prevalence [letter] Schröter M, et al. **Blood** 1998 Dec 15;92(12):4877–8

Prevalence and persistence of a novel DNA TT virus (TTV) infection in Japanese haemophiliacs. Takayama S, et al. **Br J Haematol** 1999 Mar;104(3):626–9

Clinical course of chronic hepatitis C virus infection is not influenced by concurrent hepatitis G virus infection. Hayashi J, et al. **Dig Dis Sci** 1999 Mar;44(3):618–23

Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus–C infections in Siberia. Ohba K, et al. **Epidemiol Infect** 1999 Feb;122(1):139–43

Prevalence of hepatitis G virus infection among patients with chronic hepatitis. Yarkin F, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):154–6

GBV–C RNA presence in several high–risk groups of Spain. Quirós E, et al. **Eur J Epidemiol** 1998 Sep;14(6):617–9

Transfusion–associated TT virus infection and its relationship to liver disease. Matsumoto A, et al. **Hepatology** 1999 Jul; 30(1):283–8

Hepatitis TT virus infection in high–risk groups. Poovorawan Y, et al. **Infection** 1998 Nov–Dec;26(6):355–8

High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis [see comments] De Filippi F, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):529–33. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):467–9.

Hepatitis G virus infection in the elderly [see comments] Sampietro M, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):524–7. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):528.

Hepatitis G, an old friend of elderly Italians [comment] Stroffolini T. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):528. Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):528.

Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: risk factors and challenges. Ogilvie EL, et al. **J Adolesc Health** 1999 Jul;25(1):46–51

Seroprevalence of viral hepatitis in an older nursing home population. Chien NT, et al. **J Am Geriatr Soc** 1999 Sep; 47(9):1110–3

GB virus–C/hepatitis G virus infection in Taiwan: a virus that fails to cause a disease? Kao J, et al. **J Biomed Sci** 1999 Jul–Aug;6(4):220–5 (36 ref.)

Epidemiology of hepatitis B, C, E, and G virus infections and molecular analysis of hepatitis G virus isolates in Bolivia. Konomi N, et al. **J Clin Microbiol** 1999 Oct; 37(10):3291–5

TT virus (TTV) is unlikely to cause chronic liver damage [editorial; comment] Imawari M. **J Gastroenterol** 1999 Apr; 34(2):292–3. Comment on: J Gastroenterol 1999 Apr;34(2):234–40.

Transmission of and liver injury by TT virus in patients on maintenance hemodialysis [see comments] Oguchi T, et al. **J Gastroenterol** 1999 Apr;34(2):234–40. Comment in: J Gastroenterol 1999 Apr;34(2):292–3.

Association of hepatitis viruses with hepatocellular carcinoma in Thailand. Tangkijvanich P, et al. **J Gastroenterol** 1999 Apr;34(2):227–33

GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China. Cao K, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1241–8

High prevalance of TT virus infection in Japanese patients with liver diseases and in blood donors. Kato T, et al. **J Hepatol** 1999 Aug;31(2):221–7

Detection of HGV in serum and peripheral blood mononuclear cells of maintenance haemodialysis patients. Basaras M, et al. **J Hosp Infect** 1999 Jun;42(2):155–9

Hepatitis G virus infection in drug users in Liverpool [see comments] Kennedy N, et al. **J Infect** 1998 Sep;37(2):140–7 . Comment in: J Infect 1998 Sep;37(2):106–7.

Prevalence, incidence, and clinical characteristics of hepatitis G virus/GB virus C infection in Scottish blood donors. Blair CS, et al. **J Infect Dis** 1998 Dec;178(6):1779–82

Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. Desai SM, et al. **J Infect Dis** 1999 May; 179(5):1242–4

Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. Anastassopoulou CG, et al. **J Med Virol** 1998 Nov; 56(3):246–52

High prevalence of GB–C/hepatitis G virus in a Brazilian population with helminth infection. Gallian P, et al. **J Med Virol** 1998 Dec;56(4):310–5

Detection rates of TT virus among children who visited a general hospital in Japan. Goto K, et al. **J Med Virol** 1999 Apr;57(4):405–7

GBV–C/HGV coinfection in HIV–1–positive men: frequent detection of viral RNA in blood plasma but absence from seminal fluid plasma. Hollingsworth RC, et al. **J Med Virol** 1998 Dec;56(4):321–6

High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. Nerurkar VR, et al. **J Med Virol** 1998 Oct; 56(2):123–7

High prevalence of TT virus infection in Brazilian blood donors. Niel C, et al. **J Med Virol** 1999 Mar;57(3):259–63

GB virus C/hepatitis G virus infection in KwaZulu Natal, South Africa. Sathar MA, et al. **J Med Virol** 1999 Sep; 59(1):38–44

Prevalence of GB virus–C/hepatitis G virus infection in an antenatal population. Skidmore SJ, et al. **J Med Virol** 1999 Mar;57(3):235–7

Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non–A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. Tanaka H, et al. **J Med Virol** 1998 Nov;56(3):234–8

Prevalence, implication, and viral nucleotide sequence analysis of GB virus–C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. Wu JC, et al. **J Med Virol** 1998 Oct;56(2):118–22

Prevalence of GBV–C/hepatitis G virus viraemia among blood donors, health care personnel, chronic non–B non–C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. El–Zayadi AR, et al. **J Virol Methods** 1999 Jun; 80(1):53–8

High prevalence of hepatitis G virus (HGV) infection in renal transplantation. Berthoux P, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2909–13

Increased prevalence of markers of GBV–C/HGV infection in a selected cohort of haemodialysis patients negative for other blood–borne viruses [letter] Dalekos GN, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):255–6

High prevalence of hepatitis G virus (HGV) infections in dialysis staff. Gärtner BC, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):406–8

High prevalence of GB virus–C infection in haemodialysis patients [letter] Huang CC, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1802–3

Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. Campo N, et al. **Nephron** 1999;82(1):17–21

Hepatitis G virus infection in a high–risk subgroup of hospitalized dental patients. Takata Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):442–5

Prevalence of GB virus C/hepatitis G virus ribonucleic acid and anti–hepatitis G virus–E2 antibodies among Japanese children with histories of transfusions or with liver diseases. Goto K, et al. **Pediatr Res** 1999 Jan;45(1):128–32

Viral hepatitis in the third millennium. Rizzetto M. **Res Virol** 1998 Sep–Oct;149(5):251–6 (31 ref.)

Prevalence of hepatitis C and G virus infections among intravenous drug users in Slovenia and Croatia. Trišler Z, et al. **Scand J Infect Dis** 1999;31(1):33–5

GB virus C/hepatitis G virus isolates in Japanese haemophiliacs and their origins. Toyoda H, et al. **Thromb Haemost** 1998 Aug;80(2):242–5

Prevalence of GB virus type C/hepatitis G virus RNA and anti–E2 among blood donors in Southeastern France. Cantaloube JF, et al. **Transfusion** 1999 Jan;39(1):95–102

Prevalence of GB virus type C/hepatitis G virus RNA and of anti–E2 in individuals at high or low risk for blood–borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Lefrère JJ, et al. **Transfusion** 1999 Jan;39(1):83–94

Hepatitis G virus infection in liver transplant recipients. Fischer L, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):496–9

Long–term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co–infection. Meisel H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1382–3

Prevalence of GB virus C/hepatitis G virus among blood donors in north–eastern Brazil. Goubau P, et al. **Trop Med Int Health** 1999 May;4(5):365–7

Prevalence of hepatitis G–virus infection in alcohol abusing

patients with and without liver cirrhosis. Schöniger-Hekele M, et al. **Wien Klin Wochenschr** 1998 Oct 16;110(19):686-90

Antibodies to the E2 protein of GB virus C/hepatitis G virus: low prevalence in Asian countries. Ross RS, et al. **Zentralbl Bakteriol** 1998 Nov;288(3):415-9

[Epidemiologic features of viral hepatitis in Fujian] Li L, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Apr;19(2):89-92 (Eng. Abstr.) **(Chi)**

[Research on risk factors of 5 types of viral hepatities among population with high risk behaviors] Pang Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):141-3 (Eng. Abstr.) **(Chi)**

[Detection of HGV RNA in sera from patients with fulminant hepatitis in Shenyang] Shu B, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Jun; 19(3):168-9 (Eng. Abstr.) **(Chi)**

[Demonstration on Z-D phenomenon in the occurrence of infectious diseases] Zeng G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Oct; 18(5):270-4 (Eng. Abstr.) **(Chi)**

[Studies on GBV-C infection in blood donors in four provinces of China] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):349-51 (Eng. Abstr.) **(Chi)**

[Molecular epidemiology of TT virus infection in some parts of China] Zhou Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):352-5 (Eng. Abstr.) **(Chi)**

[Social determinants and risk of acute viral hepatitis] Malvasio P, et al. **Ann Ist Super Sanita** 1998;34(4):489-94 (Eng. Abstr.) **(Ita)**

[Incidence of TT virus infection in patients with non-A to G liver disease] Arakawa Y, et al. **Nippon Rinsho** 1999 Jun;57(6):1290-4 (Eng. Abstr.) **(Jpn)**

[Detection of TT virus in healthy volunteer] Hadama T, et al. **Nippon Rinsho** 1999 Jun;57(6):1300-4 (Eng. Abstr.) **(Jpn)**

[Detection of TT virus in hemodialysis patients] Hino K, et al. **Nippon Rinsho** 1999 Jun;57(6):1413-6 (Eng. Abstr.) **(Jpn)**

[Prevalence of hepatitis G virus RNA and antibodies to HGV envelope protein (anti-E2) in patients with liver injury in Japan] Matsushita E, et al. **Nippon Rinsho** 1999 Jun; 57(6):1274-8 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Genoepidemiology and pathogenicity of TT virus in Japanese men with history of intravenous drug abuse and tattoo] Niitsuma H, et al. **Nippon Rinsho** 1999 Jun; 57(6):1424-6 (Eng. Abstr.) **(Jpn)**

[Non A-G chronic hepatitis in Japan] Orii K, et al. **Nippon Rinsho** 1999 Jun;57(6):1269-73 (14 ref.) (Eng. Abstr.) **(Jpn)**

[TTV infection in healthy subjects] Seta T, et al. **Nippon Rinsho** 1999 Jun;57(6):1305-9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The prevalence of TTV infection in non-A to G chronic liver disease, especially non-A to G hepatocellular carcinoma, and the clinical significance of TTV infection] Shibayama T, et al. **Nippon Rinsho** 1999 Jun;57(6):1356-61 (Eng. Abstr.) **(Jpn)**

[Seroepidemiological survey of TT virus (TTV) infection in an endemic area for hepatitis C virus] Sugiyama T, et al. **Nippon Rinsho** 1999 Jun;57(6):1402-5 (Eng. Abstr.) **(Jpn)**

[Detection of TT virus (TTV) in Japanese hemodialysis (HD) patients] Tanaka H, et al. **Nippon Rinsho** 1999 Jun; 57(6):1410-2 (Eng. Abstr.) **(Jpn)**

[Prevalence of TT virus in patients with fulminant hepatic failure in Japan] Tanaka M, et al. **Nippon Rinsho** 1999 Jun; 57(6):1335-8 (Eng. Abstr.) **(Jpn)**

[TT virus infection in an area of high-endemicity for hepatitis C] Umemura T, et al. **Nippon Rinsho** 1999 Jun; 57(6):1397-401 (Eng. Abstr.) **(Jpn)**

[The prevalence of TTV infection and the route of TTV transmission in hemodialysis patients--compared with HCV infection] Utsunomiya S, et al. **Nippon Rinsho** 1999 Jun;57(6):1417-20 (Eng. Abstr.) **(Jpn)**

[Prevalence of TT virus infection and viral integration in human hepatocellular carcinoma] Yamamoto T, et al. **Nippon Rinsho** 1999 Jun;57(6):1370-4 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical characteristics and incidence in acute non A-G hepatitis] Yatsuhashi H, et al. **Nippon Rinsho** 1999 Jun; 57(6):1265-8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[TT virus (TTV) in Japanese haemophiliacs] Yokozaki S, et al. **Nippon Rinsho** 1999 Jun;57(6):1427-32 (Eng. Abstr.) **(Jpn)**

[Epidemiological and clinical features of viral hepatitis in convicts of penitentiaries] Savin EA. **Ter Arkh** 1998; 70(11):16-21 (Eng. Abstr.) **(Rus)**

[The epidemiological aspects of viral hepatitides in Estonia] Tefanova VT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):39-42 (Eng. Abstr.) **(Rus)**

[Prevalence of serologic markers of hepatitis virus infection in local police (letter)] Abril López de Medrano V, et al. **An Med Interna** 1998 Aug;15(8):453 **(Spa)**

[Hospital detoxification unit: 4-year experience. Treatment and infections] Gutiérrez del Río C, et al. **An Med Interna** 1998 Oct;15(10):528-30 (Eng. Abstr.) **(Spa)**

[Retrospective study of the incidence of hepatitis G virus infection in transfused patients] Salmerón J, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):409-11 (Eng. Abstr.) **(Spa)**

[Prevalence of infections by hepatitis B, C, D and E viruses in Bolivia] León P, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):144-51 (32 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

TT virus in frequently transfused patients. Kanda Y, et al. **Am J Med** 1999 Jan;106(1):116-7

Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. Ljungman P, et al. **Bone Marrow Transplant** 1998 Sep;22(5):499-501

Hepatitis in haemophilia. Giangrande PL. **Br J Haematol** 1998 Oct;103(1):1-9 (105 ref.)

TT viruses (TTV) of non-human primates and their relationship to the human TTV genotypes. Verschoor EJ, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2491-9

HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. Silini E, et al. **J Hepatol** 1998 Oct; 29(4):533-40

Hepatitis G virus infection from needle-stick injuries in hospital employees. Shibuya A, et al. **J Hosp Infect** 1998 Dec;40(4):287-90

Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis. Okamoto H, et al. **J Med Virol** 1998 Oct;56(2):128-32

17-year-old female with IgA and abdominal pain: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Olay S, et al. **J Okla State Med Assoc** 1999 Feb;92(2):77-82

Determination of antibodies to TT virus (TTV) and application to blood donors and patients with post-transfusion non-A to G hepatitis in Japan. Tsuda F, et al. **J Virol Methods** 1999 Feb;77(2):199-206

GB virus C/hepatitis G virus infection in patients on continuous ambulatory peritoneal dialysis. Huang CH, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2914-9

GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Elkayam O, et al. **Pediatr Res** 1999 Jun;45(6):795-8

Infection by an unenveloped DNA virus associated with non-A to -G hepatitis in Japanese blood donors with or without elevated ALT levels. Itoh K, et al. **Transfusion** 1999 May;39(5):522-6

Transfusion-associated or nosocomial hepatitis G virus infection in patients undergoing surgery. Lunel F, et al. **Transfusion** 1998 Nov-Dec;38(11-12):1097-103

[Liver changes in HIV/AIDS] Telegdy L, et al. **Orv Hetil** 1999 Apr 11;140(15):811-4 (36 ref.) (Eng. Abstr.) **(Hun)**

[Sources of infections and genotypes of hepatitis C virus in children] Woźniakowska-Gęsicka T, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):65-7 (Eng. Abstr.) **(Pol)**

GENETICS

RNA virus of hepatitis G (GB virus) prevalence in health care personnel [letter] Quirós E, et al. **Am J Infect Control** 1999 Apr;27(2):176-7

Prevalence of TT virus and GBV-C infections among patients with liver diseases and the general population in Shanghai, China. Ding X, et al. **Virus Genes** 1999;19(1):51-8

High prevalence and phylogenetic analysis of TT-virus infection in Mongolia. Kato H, et al. **Virus Res** 1999 Apr; 60(2):171-9

[Sources of infections and genotypes of hepatitis C virus in children] Woźniakowska-Gęsicka T, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):65-7 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Seroprevalence of markers for hepatitis B, C and G in male and female prisoners--NSW, 1996. Butler T, et al. **Aust N Z J Public Health** 1999 Aug;23(4):377-84

Mechanisms of immune escape in viral hepatitis. Rosenberg W. **Gut** 1999 May;44(5):759-64 (78 ref.)

Gradual loss of IgG antibodies against GB virus C/hepatitis G virus in a patient with AIDS. Nerurkar VR, et al. **Hawaii Med J** 1998 Dec;57(12):733-4

Clearance of hepatitis G virus infection in thalassaemic children [letter] Poovorawan Y, et al. **Infection** 1998 Nov-Dec;26(6):408

Cell mediated immune response in chronic liver diseases: schistosomal, viral and neoplastic. Wahib AA, et al. **J Egypt Soc Parasitol** 1998 Dec;28(3):929-39

Hepatitis viruses under immunosuppressive agents. Liaw YF. **J Gastroenterol Hepatol** 1998 Jan;13(1):14-20 (75 ref.)

Influence of CD4+ lymphocyte counts on GB virus C/hepatitis G virus carriership in HIV-positive individuals. Goubau P, et al. **J Med Virol** 1999 Apr;57(4):367-9

Detection of antibodies to E2-protein of GB virus-C/hepatitis G virus in patients with acute posttransfusion hepatitis. Hwang SJ, et al. **J Med Virol** 1999 Jan;57(1):85-9

GB virus C/hepatitis G virus infection in hemodialysis patients: determination of seroprevalence by a four-antigen recombinant immunoblot assay. Schröter M, et al. **J Med Virol** 1999 Mar;57(3):230-4

Determination of antibodies to TT virus (TTV) and application to blood donors and patients with post-transfusion non-A to G hepatitis in Japan. Tsuda F, et al. **J Virol Methods** 1999 Feb;77(2):199-206

GB virus C (GBV-C/HGV) and E2 antibodies in children preliver and postliver transplant. Elkayam O, et al. **Pediatr Res** 1999 Jun;45(6):795-8

[The state of cellular immunity in women with a history of viral hepatitis] Dyndar OA. **Lik Sprava** 1998 Aug;(6):102-4 (Eng. Abstr.) **(Ukr)**

METABOLISM

Histologic distribution of hepatitis A, B, C, D, E, and G with concomitant cytokine response in liver tissue. Nuovo GJ. **Diagn Mol Pathol** 1998 Oct;7(5):267-75

PATHOLOGY

First International Symposium on the molecular pathology and clinical aspects of the inflamed liver: alcohol and cytokines. Neuman MG. **Clin Invest Med** 1998 Dec; 21(6):283-6

Higher detection rate of hepatitis G and C virus RNA in liver tissue than in serum of deceased injection drug users. Seidl S, et al. **Int J Legal Med** 1999;112(1):35-8

Hepatitis G virus infection in Spanish patients with hepatocellular carcinoma. Rodriguez Agulló JL, et al. **Liver** 1998 Aug;18(4):255-8

[Histological findings of TTV-positive non-B non-C chronic hepatitis patients] Hasebe C, et al. **Nippon Rinsho** 1999 Jun; 57(6):1350-5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical manifestations and histopathologic features of chronic liver disease with serum TT virus (TTV) DNA positive alone as measured by first generation primer sets] Tsubota A. **Nippon Rinsho** 1999 Jun;57(6):1345-9 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Follow up of clinical, laboratory, and serological findings of adult Hungarian hospitalized acute hepatitis patients and characteristics of recovery. Kassas AL. **Acta Microbiol Immunol Hung** 1998;45(2):209-19

Long-term liver function of recipients with hepatitis G virus infection after bone marrow transplantation. Maruta A, et al. **Bone Marrow Transplant** 1999 Aug;24(4):359-63

Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289-93

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G. Inoue K, et al. **J Hepatol** 1999 May;30(5):801-6

Influence of GB virus-C/hepatitis G virus infection on the long-term course of chronic hepatitis B. Fattovich G, et al. **Liver** 1998 Oct;18(5):360-5

PREVENTION & CONTROL

Vaccines for prevention of viral hepatitis. Shouval D. **Haemophilia** 1998 Jul;4(4):587-94 (96 ref.)

Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. Hassoba HM, et al. **J Med Virol** 1998 Nov;56(3):253-8

Advances in the treatment of chronic viral hepatitis. Koff RS. **JAMA** 1999 Aug 11;282(6):511-2

Does HCV screening of blood donors affect transmission of hepatitis G virus in dialysed patients? [letter] Gérard C, et al. **Vox Sang** 1998;75(1):77

Interactions between science, government and media on selection and testing of donors. Sazama K. **Vox Sang** 1998; 74 Suppl 2:503-6 (24 ref.)

Donor selection: the exclusion of high risk donors? van den Burg PJ, et al. **Vox Sang** 1998;74 Suppl 2:499-502 (22 ref.)

[Anti-hepatitis vaccination in children] Azzari C, et al. **Minerva Pediatr** 1998 Jun;50(6):249-53 (18 ref.) **(Ita)**

SURGERY

Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Sato S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):68-71

Liver transplantation for chronic viral liver disease. Colantoni A, et al. **Hepatogastroenterology** 1998 Sep-Oct; 45(23):1357-63

Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation. Bizollon T, et al. **J Hepatol** 1998 Dec; 29(6):893-900

Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. Sato S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):521-2

THERAPY

Summary of the first international symposium on viral hepatitis. González-Peralta RP, et al. **Antiviral Res** 1999 Jun;42(2):77-96

Ocular complications with high-dose interferon alpha in chronic active hepatitis. Kadayifcilar S, et al. **Eye** 1999 Apr;13 (Pt 2):241-6

ACOG educational bulletin. Viral hepatitis in pregnancy. Number 248, July 1998 (replaces No. 174, November 1992). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1998 Nov;63(2):195-202 (24 ref.)

Amino acid substitutions in NS5A region of GB virus C and response to interferon therapy. Kato T, et al. **J Med Virol** 1999 Apr;57(4):376–82

Viral hepatitis: primary care diagnosis and management. Alexander IM. **Nurse Pract** 1998 Oct;23(10):13–4, 17–20, 25–6 passim; quiz 44–5 (66 ref.)

Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease. Pramoolsinsap C, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):480–90

[Role of biology in the follow up of viral hepatitis] Myara A, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):527–37 (61 ref.) (Eng. Abstr.) **(Fre)**

[Susceptibility of TT virus to interferon therapy] Chayama K. **Nippon Rinsho** 1999 Jun;57(6):1390–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Virological response to interferon therapy in patients dually infected with TT virus and hepatitis C virus] Matsumoto H, et al. **Nippon Rinsho** 1999 Jun;57(6):1387–9 (Eng. Abstr.) **(Jpn)**

[The response of the hepatitis C and hepatitis G viruses to treatment with recombinant interferon alfa-2b] Infante Pina D, et al. **An Esp Pediatr** 1998 Dec;49(6):609–14 (Eng. Abstr.) **(Spa)**

TRANSMISSION

Prevalence of hepatitis G virus in a haemodialysis unit. Lamproye A, et al. **Acta Gastroenterol Belg** 1999 Jan–Mar; 62(1):13–5

Intraspousal transmission of GB virus C/hepatitis G virus in an hepatitis C virus hyperendemic area in Japan. Akiyoshi F, et al. **Am J Gastroenterol** 1999 Jun; 94(6):1627–31

Hepatitis G virus infection in hemodialysis patients: fact or fancy? [letter; comment] Macedo G, et al. **Am J Gastroenterol** 1999 May;94(5):1423–4. Comment on: Am J Gastroenterol 1997 Nov;92(11):1986–91.

GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates. Woelfle J, et al. **Arch Dis Child** 1999 May;80(5):429–32

Outcome of mother to infant acquired GBV-C/HGV infection. Zuin G, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F72–3

A prospective study on TT virus infection in transfusion-dependent patients with beta-thalassemia. Prati D, et al. **Blood** 1999 Mar 1;93(5):1502–5

TT virus viremia and liver transplantation: no significant increase of the prevalence [letter] Schröter M, et al. **Blood** 1998 Dec 15;92(12):4877–8

Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Strasser SI, et al. **Blood** 1999 Feb 15;93(4):1127–36 (129 ref.)

Long-term liver function of recipients with hepatitis G virus infection after bone marrow transplantation. Maruta A, et al. **Bone Marrow Transplant** 1999 Aug;24(4):359–63

Infections associated with medical intervention: hepatitis viruses and HGV. Carman WF. **Br Med Bull** 1998; 54(3):731–48 (70 ref.)

Partial nucleotide sequencing of the NS3/helicase region of hepatitis G virus to prove vertical transmission. Takayama S, et al. **FEMS Microbiol Lett** 1999 Jun 15;175(2):273–9

Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products [published erratum appears in Gut 1999 Jun;44(6):898] Halasz R, et al. **Gut** 1999 Feb;44(2):274–8

Intraoperative transmission of blood-borne disease in haemophilia. Rodriguez-Merchan EC. **Haemophilia** 1998 Mar;4(2):75–8 (15 ref.)

GB virus C infection by blood transfusion during and following liver surgery. Kubo S, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2252–4

Transfusion-associated TT virus infection and its relationship to liver disease. Matsumoto A, et al. **Hepatology** 1999 Jul; 30(1):283–8

Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: etiology and natural history. Paraná R, et al. **Hepatology** 1999 Jul;30(1):289–93

GB virus-C/hepatitis G virus infection in Taiwan: a virus that fails to cause a disease? Kao J, et al. **J Biomed Sci** 1999 Jul–Aug;6(4):220–5 (36 ref.)

Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. Menéndez C, et al. **J Clin Microbiol** 1999 Jul;37(7):2333–6

High prevalence of GB virus C in Brazil and molecular evidence for intrafamilial transmission. Pinho JR, et al. **J Clin Microbiol** 1999 May;37(5):1634–7

HGV and the blood supply [comment] Mortimer PP. **J Infect** 1998 Sep;37(2):106–7. Comment on: J Infect 1998 Sep;37(2):140–7.

GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. Kao JH, et al. **J Infect Dis** 1999 Jul;180(1):191–4

Analysis of hepatitis G virus (HGV) RNA, antibody to HGV envelope protein, and risk factors for blood donors coinfected with HGV and hepatitis C virus. Tan D, et al. **J Infect Dis** 1999 May;179(5):1055–61

Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. Menendez C, et al. **J Med Virol** 1999 Jul;58(3):215–20

Transfusion transmitted virus [letter; comment] Gerolami V, et al. **Lancet** 1998 Oct 17;352(9136):1309; discussion 1310–1 . Comment on: Lancet 1998 Jul 18;352(9123):191–5.

HGV: the identification, biology and prevalence of an orphan virus. Mphahlele MJ, et al. **Liver** 1998 Jun;18(3):143–55 (88 ref.)

Antibodies to the E2 protein of hepatitis G virus in blood donors in New Zealand [letter] Woodfield G, et al. **N Z Med J** 1998 Nov 27;111(1078):459–60

Hepatitis G virus infection among patients undergoing hemodialysis [letter] Mas MR, et al. **Nephron** 1998 Oct; 80(2):247–8

Mother-to-child transmission of hepatitis G virus [letter] Miura T, et al. **Pediatrics** 1998 Nov;102(5):1222–3

Transfusion-transmitted virus (TTV) in Brazil. Preliminary report. Pinho JR, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):335–6 **(Eng, Por)**

Sexual transmission and prevention of the hepatitis viruses A–E and G. Brook MG. **Sex Transm Infect** 1998 Dec; 74(6):395–8 (61 ref.)

Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually transmitted viruses: evidence of sexual and parenteral transmission. Lefrère JJ, et al. **Transfusion** 1999 Jan;39(1):83–94

Post-transfusion chronic liver disease in thalassemics. Rajeshwari K, et al. **Trop Gastroenterol** 1998 Oct–Dec; 19(4):159–62 (22 ref.)

Post-transfusion hepatitis: current risks and causes. Holland PV. **Vox Sang** 1998;74 Suppl 2:135–41 (54 ref.)

GB virus C/hepatitis G virus and intravenous immunoglobulins. Nübling C, et al. **Vox Sang** 1998; 75(3):189–92

[A prospective study on post-transfusion hepatitis G virus infection] Lu Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):95–6 (Eng. Abstr.) **(Chi)**

[Follow-up studies on hepatitis G infection in plasma donors with positive antibody against hepatitis C] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):269–71 (Eng. Abstr.) **(Chi)**

[TTV materno-infantile infection--a study on the TTV frequency in Japanese pregnant women and the natural history of TTV mother-to-infant infection] Inaba N, et al. **Nippon Rinsho** 1999 Jun;57(6):1406–9 (Eng. Abstr.) **(Jpn)**

[Laboratory diagnosis of viral infections. 9. Viral infections related to blood transfusion and organ transplantation] Miyamoto A, et al. **Rinsho Byori** 1998 Nov;Suppl 108:111–5 (6 ref.) **(Jpn)**

VIROLOGY

Emerging viral infections. Khabbaz RF. **Adv Pediatr Infect Dis** 1999;14:1–27 (111 ref.)

A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. Fimmel CJ, et al. **Am J Gastroenterol** 1998 Oct;93(10):1931–7

The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Muñoz SJ, et al. **Blood** 1999 Aug 15; 94(4):1460–4

Evidence against a direct role played by transfusion-transmitted virus infection in causing hepatic or hematologic manifestations [letter] Toniutto P, et al. **Blood** 1999 Apr 1;93(7):2426–7

Persistence and clinical outcome of hepatitis G virus infection in pediatric bone marrow transplant recipients and children treated for hematological malignancy. Yamada-Osaki M, et al. **Blood** 1999 Jan 15;93(2):721–7

Infection with an unenveloped DNA virus (TTV) associated with non-A to G hepatitis in patients with rheumatoid arthritis [letter] Hirata D, et al. **Br J Rheumatol** 1998 Dec; 37(12):1361–2

Natural history and molecular biology of hepatitis G virus/GB virus C. Karayiannis P, et al. **Clin Diagn Virol** 1998 Jul 15;10(2–3):103–11 (45 ref.)

Acute jaundice in Vientiane, Lao People's Democratic Republic. Bounlu K, et al. **Clin Infect Dis** 1998 Oct; 27(4):717–21

A high prevalence of serum GB virus C/hepatitis G virus RNA in children with and without liver disease. Halasz R, et al. **Clin Infect Dis** 1999 Mar;28(3):537–40

Hepatitis G virus and related flaviviruses: pathogens or passengers? He X, et al. **Curr Clin Top Infect Dis** 1998; 18:274–85 (43 ref.)

Prevalence of hepatitis G virus infection among patients with chronic hepatitis. Yarkin F, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):154–6

GBV-C RNA presence in several high-risk groups of Spain. Quirós E, et al. **Eur J Epidemiol** 1998 Sep;14(6):617–9

New genotypes of TT virus (TTV) and a genotyping assay based on restriction fragment length polymorphism. Tanaka Y, et al. **FEBS Lett** 1998 Oct 23;437(3):201–6

TT virus infection in chronic liver disease. Tangkijvanich P, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1053–8

TT virus (TTV) is not associated with acute sporadic hepatitis. Fukuda Y, et al. **Infection** 1999 Mar-Apr; 27(2):125–7

Overview of viral hepatitis. Hollinger FB. **Int J Circumpolar Health** 1998;57 Suppl 1:276–9

HGV infection in a cohort of patients with chronic active hepatitis HCV related [letter] Capra F, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):443

TT virus. Bonis PA. **J Am Soc Nephrol** 1999 Aug; 10(8):1828–32 (61 ref.)

Fulminant herpes hepatitis in a healthy adult: a treatable disorder? Velasco M, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):386–9

TT virus infection is widespread in the general populations from different geographic regions. Abe K, et al. **J Clin Microbiol** 1999 Aug;37(8):2703–5

TT virus (TTV) is unlikely to cause chronic liver damage [editorial; comment] Imawari M. **J Gastroenterol** 1999 Apr; 34(2):292–3. Comment on: J Gastroenterol 1999 Apr;34(2):234–40.

Transmission of and liver injury by TT virus in patients on maintenance hemodialysis [see comments] Oguchi T, et al. **J Gastroenterol** 1999 Apr;34(2):234–40. Comment in: J Gastroenterol 1999 Apr;34(2):292–3.

TT virus: an agent of transfusion-associated hepatitis or yellow herring? [editorial; comment] Bowden S, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):299–300. Comment on: J Gastroenterol Hepatol 1999 Apr;14(4):358–63.

GB virus C/hepatitis G virus infection among patients with hepatocellular carcinoma in the inshore area of the Yangtze River, China. Cao K, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1241–8

Effects of hepatitis G virus coinfection on severity of hepatitis C: relationship to risk factors and response to interferon treatment [see comments] Lin R, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):773–80. Comment in: J Gastroenterol Hepatol 1998 Aug;13(8):763–6.

Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. Liu CJ, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):352–7

Is GBV-C (hepatitis G virus) an innocent bystander? [editorial; comment] Okuda K. **J Gastroenterol Hepatol** 1998 Aug;13(8):763–6. Comment on: J Gastroenterol Hepatol 1998 Aug;13(8):773–80. Comment on: J Gastroenterol Hepatol 1998 Aug;13(8):767–72.

TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types. Ball JK, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1759–68

Genetic evolution of hepatitis G virus in chronically infected individual patients. Giménez-Barcons M, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2623–9

Sequence diversity of TT virus in geographically dispersed human populations. Prescott LE, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1751–8

Prevalence of transmitted transfusion virus (TTV) in populations at different risk for hepatitis virus: hemodialysis, chronic hepatitis C and cryptogenetic hepatitis patients [letter] Halfon P, et al. **J Hepatol** 1999 Mar;30(3):552

Quantitative analysis of GBV-C RNA in liver and serum by strand-specific reverse transcription-polymerase chain reaction. Kanda T, et al. **J Hepatol** 1998 Nov;29(5):707–14

Absence of the negative strand of GBV-C/HGV RNA from the liver. Laras A, et al. **J Hepatol** 1999 Mar;30(3):383–8

TT virus infection among blood donors and patients with non-B, non-C liver diseases in Korea. Nakano T, et al. **J Hepatol** 1999 Mar;30(3):389–93

Hepatotropism of GB virus C (GBV-C): GBV-C replication in human hepatocytes and cells of human hepatoma cell lines. Seipp S, et al. **J Hepatol** 1999 Apr;30(4):570–9

Molecular analysis of GB virus C/hepatitis G virus in HIV-1-positive intravenous drug users in Belgium. Liu HF, et al. **J Hum Virol** 1999 Mar-Apr;2(2):115–20

Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. Lefrère JJ, et al. **J Infect Dis** 1999 Apr; 179(4):783–9

Excretion into bile of a novel unenveloped DNA virus (TT virus) associated with acute and chronic non-A-G hepatitis. Ukita M, et al. **J Infect Dis** 1999 May; 179(5):1245–8

Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. Bourlet T, et al. **J Med Virol** 1999 Aug; 58(4):373–7

Infection with GB virus C/hepatitis G virus among blood donors and hemophiliacs in Martinique, a Caribbean island. Césaire R, et al. **J Med Virol** 1999 Oct;59(2):160–3

Etiology of sporadic acute viral hepatitis in Taiwan: the role of hepatitis C virus, hepatitis E virus and GB virus-C/hepatitis G virus in an endemic area of hepatitis A and B. Chu CM, et al. **J Med Virol** 1999 Jun;58(2):154–9

GBV-C/HGV infection in children with chronic hepatitis C. Komatsu H, et al. **J Med Virol** 1999 Oct;59(2):154–9

GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. Lefrère JJ, et al. **J Med Virol** 1999 Sep; 59(1):32–7

Prevalence of TT virus DNA in eastern Taiwan aborigines. Lo SY, et al. **J Med Virol** 1999 Oct;59(2):198–203

Fecal excretion of a nonenveloped DNA virus (TTV) associated with posttransfusion non-A-G hepatitis. Okamoto H, et al. **J Med Virol** 1998 Oct;56(2):128–32

Distinct genotypes of a nonenveloped DNA virus associated with posttransfusion non-A to G hepatitis (TT virus) in plasma and peripheral blood mononuclear cells. Okamoto

H, et al. **J Med Virol** 1999 Mar;57(3):252–8

Association of GB virus C (GBV–C)/hepatitis G virus (HGV) with haematological diseases of different malignant potential. Pavlova BG, et al. **J Med Virol** 1999 Apr; 57(4):361–6

Profiles of GBV–C/hepatitis G virus markers in patients coinfected with hepatitis C virus. Sauleda S, et al. **J Med Virol** 1999 Sep;59(1):45–51

Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non–A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. Tanaka H, et al. **J Med Virol** 1998 Nov;56(3):234–8

A new genotype of TT virus (TTV) infection among Colombian native Indians. Tanaka Y, et al. **J Med Virol** 1999 Mar;57(3):264–8

Molecular characterization of the 5' non–coding region of South African GBV–C/HGV isolates: major deletion and evidence for a fourth genotype. Tucker TJ, et al. **J Med Virol** 1999 Sep;59(1):52–9

Diversity of GB virus C/hepatitis G virus isolates in Singapore: predominance of group 2a and the Asian group 3 variant. Wong SB, et al. **J Med Virol** 1999 Jun; 58(2):145–53

Prevalence, implication, and viral nucleotide sequence analysis of GB virus–C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. Wu JC, et al. **J Med Virol** 1998 Oct;56(2):118–22

Hepatitis G virus infection in acute fulminant hepatitis: prevalence of HGV infection and sequence analysis of a specific viral strain. Sheng L, et al. **J Viral Hepat** 1998 Sep;5(5):301–6

Replication of GB virus C (hepatitis G virus) in interferon–resistant Daudi cells. Shimizu YK, et al. **J Virol** 1999 Oct;73(10):8411–4

Detection of GB virus C RNA by GBV–C LCx and two PCR assays with primers from the 5'non–coding and NS5B region. Berg ES, et al. **J Virol Methods** 1998 Dec; 76(1–2):43–9

A competitive reverse transcription–polymerase chain reaction assay for quantitation of GB virus C/hepatitis G virus RNA that circumvents heteroduplex artifact. Liu F, et al. **J Virol Methods** 1999 May;79(2):149–59

Multicyclic reverse transcription–polymerase chain reaction assay system for quantification of GB virus–C/hepatitis G virus RNA in serum. Saito T, et al. **J Virol Methods** 1998 Oct;74(2):185–91

Transfusion transmitted virus [letter; comment] Gerolami V, et al. **Lancet** 1998 Oct 17;352(9136):1309; discussion 1310–1 . Comment on: Lancet 1998 Jul 18;352(9123):191–5.

Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children [see comments] Sokal EM, et al. **Lancet** 1998 Nov 28; 352(9142):1739–41. Comment in: Lancet 1999 Feb 27;353(9154):753–4. Comment in: Lancet 1999 Feb 27;353(9154):754–5.

HGV: the identification, biology and prevalence of an orphan virus. Mphahlele MJ, et al. **Liver** 1998 Jun;18(3):143–55 (88 ref.)

Fulminant Epstein–Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Feranchak AP, et al. **Liver Transpl Surg** 1998 Nov;4(6):469–76 (39 ref.)

Hepatitis after liver transplantation: the role of the known and unknown viruses. Pessoa MG, et al. **Liver Transpl Surg** 1998 Nov;4(6):461–8

Herpes simplex hepatitis in pregnancy: a case report and review of the literature. Kang AH, et al. **Obstet Gynecol Surv** 1999 Jul;54(7):463–8 (36 ref.)

Hepatitis G virus infection as a possible causative agent of community–acquired hepatitis and associated aplastic anaemia. Crespo J, et al. **Postgrad Med J** 1999 Mar; 75(881):159–60

Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans. Mushahwar IK, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3177–82

Transfusion–transmitted virus (TTV) in Brazil. Preliminary report. Pinho JR, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):335–6 **(Eng, Por)**

Lack of influence of hepatitis G virus infection on alcohol–related hepatic lesions. Tran A, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1209–12

Report of new hepatitis virus has researchers intrigued and upset [news] Cohen J. **Science** 1999 Jul 30;285(5428):644–5

Sequence heterogeneity within three different regions of the hepatitis G virus genome. Cong M, et al. **Virology** 1999 Mar 15;255(2):250–9

The entire nucleotide sequence of a TT virus isolate from the United States (TUS01): comparison with reported isolates and phylogenetic analysis. Okamoto H, et al. **Virology** 1999 Jul 5;259(2):437–48

Marked genomic heterogeneity and frequent mixed infection of TT virus demonstrated by PCR with primers from coding and noncoding regions. Okamoto H, et al. **Virology** 1999 Jul 5;259(2):428–36

[Selection of diagnostic indexes in the diagnosis of virus hepatitis (editorial)] Tao Q. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):563–4 **(Chi)**

[Studies on multiple infection with hepatitis B, C and G viruses] Du S, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):13–5 (Eng. Abstr.) **(Chi)**

[Comparison of partial sequencing of 5' non–coding region of seven HGV strains isolated from different areas in China] Wang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):297–9 (Eng. Abstr.) **(Chi)**

[Clinical characteristics of acute non A to G hepatitis caring TTV–DNA] Abe K, et al. **Nippon Rinsho** 1999 Jun; 57(6):1285–9 (Eng. Abstr.) **(Jpn)**

[Detection of TT virus DNA in patients with non–A to G liver diseases] Chayama K. **Nippon Rinsho** 1999 Jun; 57(6):1295–9 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Susceptibility of TT virus to interferon therapy] Chayama K. **Nippon Rinsho** 1999 Jun;57(6):1390–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Histological findings of TTV–positive non–B non–C chronic hepatitis patients] Hasebe C, et al. **Nippon Rinsho** 1999 Jun; 57(6):1350–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[TT virus(TTV) infection in patients with acute hepatitis] Hayashi K, et al. **Nippon Rinsho** 1999 Jun;57(6):1322–5 (Eng. Abstr.) **(Jpn)**

[Distinct genotypes of TTV infection in non A–non C hepatitis] Hoshino H, et al. **Nippon Rinsho** 1999 Jun; 57(6):1310–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Detection rate of TTV–DNA in healthy medical workers] Kakinuma K, et al. **Nippon Rinsho** 1999 Jun;57(6):1421–3 (Eng. Abstr.) **(Jpn)**

[Involvement of TTV, a new infectious factor in post–transfusion hepatitis, non A–non G] Konishi K, et al. **Nippon Rinsho** 1999 Jun;57(6):1279–84 (11 ref.) (Eng. Abstr.) **(Jpn)**

[High prevalence of TT virus(TTV) in patients with non A to non G fulminant hepatitis: differences of clinical features and prognosis between TTV positive and negative patients] Miyasaka A, et al. **Nippon Rinsho** 1999 Jun; 57(6):1339–44 (Eng. Abstr.) **(Jpn)**

[Positivity rate of TTV–DNA in patients with acute liver injury of undetermined etiology] Murohisa T, et al. **Nippon Rinsho** 1999 Jun;57(6):1318–21 (Eng. Abstr.) **(Jpn)**

[Clinical manifestations and histopathologic features of chronic liver disease with serum TT virus (TTV) DNA positive alone as measured by first generation primer sets] Tsubota A. **Nippon Rinsho** 1999 Jun;57(6):1345–9 (Eng. Abstr.) **(Jpn)**

[Prevalence of TT virus infection and viral integration in human hepatocellular carcinoma] Yamamoto T, et al. **Nippon Rinsho** 1999 Jun;57(6):1370–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Coexistent hepatitis G virus infection and autoimmune hepatitis] Szaflarska–Szczepanik A. **Pol Merkuriusz Lek** 1999 Feb;6(32):82–3 (Eng. Abstr.) **(Pol)**

[Viral hepatitis G––current knowledge] Vasiljević N, et al. **Vojnosanit Pregl** 1998 Nov–Dec;55(6):649–52 (24 ref.) **(Scc)**

[Hepatitis G infection in Chilean patients with hepatitis C virus: a preliminary report (letter)] Venegas M, et al. **Rev Med Chil** 1998 Sep;126(9):1133–4 **(Spa)**

HEPATITIS, VIRAL, NON–A, NON–B, ENTERICALLY–TRANSMITTED see **HEPATITIS E**

HEPATITIS, VIRAL, NON–A, NON–B, PARENTERALLY–TRANSMITTED see **HEPATITIS C**

HEPATITIS, VIRAL, VACCINES see **VIRAL HEPATITIS VACCINES**

HEPATITIS VIRUS, DUCK

METABOLISM

Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin. Adcock WL, et al. **Biotechnol Appl Biochem** 1998 Oct;28 (Pt 2):169–78

HEPATITIS VIRUS, HOMOLOGOUS SERUM see **HEPATITIS B VIRUS**

HEPATITIS VIRUS, INFECTIOUS see **HEPATOVIRUS**

HEPATITIS VIRUS, INFECTIOUS CANINE see **ADENOVIRUSES, CANINE**

HEPATITIS VIRUS, MARMOSET see **HEPATITIS VIRUSES**

HEPATITIS VIRUS, MOUSE see **GASTROENTERITIS VIRUS, MURINE**

HEPATITIS VIRUS, WOODCHUCK see **HEPATITIS B VIRUS, WOODCHUCK**

HEPATITIS VIRUSES

The hepatitis alphabet––hepatitis A–G and TTV. Müller C. **Wien Klin Wochenschr** 1999 Jun 18;111(12):461–8 (61 ref.)

CLASSIFICATION

Overview of viral hepatitis. Hollinger FB. **Int J Circumpolar Health** 1998;57 Suppl 1:276–9

[Molecular epidemiology of TT virus infection in some parts of China] Zhou Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):352–5 (Eng. Abstr.) **(Chi)**

DRUG EFFECTS

Hepatitis viruses under immunosuppressive agents. Liaw YF. **J Gastroenterol Hepatol** 1998 Jan;13(1):14–20 (75 ref.)

GENETICS

Determination and phylogenetic analysis of partial sequences from TT virus isolates. Biagini P, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):419–24

Early acquisition of TT virus (TTV) in an area endemic for TTV infection. Davidson F, et al. **J Infect Dis** 1999 May; 179(5):1070–6

The entire nucleotide sequence of a TT virus isolate from the United States (TUS01): comparison with reported isolates and phylogenetic analysis. Okamoto H, et al. **Virology** 1999 Jul 5;259(2):437–48

Marked genomic heterogeneity and frequent mixed infection of TT virus demonstrated by PCR with primers from coding and noncoding regions. Okamoto H, et al. **Virology** 1999 Jul 5;259(2):428–36

[Molecular epidemiology of TT virus infection in some parts of China] Zhou Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):352–5 (Eng. Abstr.) **(Chi)**

[Viral hepatitis: molecular diagnosis] Blum HE. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. zu Putlitz J, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):785–91

ISOLATION & PURIFICATION

Effect of schistosomiasis and hepatitis on liver disease. Halim AB, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):915–20

Hepatocellular carcinomas infected with the novel TT DNA virus lack viral integration. Yamamoto T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):339–43

A prospective study on TT virus infection in transfusion–dependent patients with beta–thalassemia. Prati D, et al. **Blood** 1999 Mar 1;93(5):1502–5

Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Strasser SI, et al. **Blood** 1999 Feb 15;93(4):1127–36 (129 ref.)

Infection with an unenveloped DNA virus (TTV) associated with non–A to G hepatitis in patients with rheumatoid arthritis [letter] Hirata D, et al. **Br J Rheumatol** 1998 Dec; 37(12):1361–2

Histologic distribution of hepatitis A, B, C, D, E, and G with concomitant cytokine response in liver tissue. Nuovo GJ. **Diagn Mol Pathol** 1998 Oct;7(5):267–75

Hepatitis TT virus infection in high–risk groups. Poovorawan Y, et al. **Infection** 1998 Nov–Dec;26(6):355–8

Association of hepatitis viruses with hepatocellular carcinoma in Thailand. Tangkijvanich P, et al. **J Gastroenterol** 1999 Apr;34(2):227–33

Determination and phylogenetic analysis of partial sequences from TT virus isolates. Biagini P, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):419–24

Prevalence of TT virus infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. Desai SM, et al. **J Infect Dis** 1999 May; 179(5):1242–4

Excretion into bile of a novel unenveloped DNA virus (TT virus) associated with acute and chronic non–A–G hepatitis. Ukita M, et al. **J Infect Dis** 1999 May; 179(5):1245–8

Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non–A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. Tanaka H, et al. **J Med Virol** 1998 Nov;56(3):234–8

Report of new hepatitis virus has researchers intrigued and upset [news] Cohen J. **Science** 1999 Jul 30;285(5428):644–5

[Selection of diagnostic indexes in the diagnosis of virus hepatitis (editorial)] Tao Q. **Chung Hua I Hsueh Tsa Chih** 1997 Aug;77(8):563–4 **(Chi)**

PATHOGENICITY

The use of non–human primates as animal models for the study of hepatitis viruses. Vitral CL, et al. **Braz J Med Biol Res** 1998 Aug;31(8):1035–48 (130 ref.)

TT virus infection in chronic liver disease. Tangkijvanich P, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1053–8

Animal models of human hepatitides. Tabor E. **Lab Anim Sci** 1998 Dec;48(6):593–5 (0 ref.)

HEPATITIS, WATER–BORNE see **HEPATITIS E**

HEPATOBLASTOMA

Congenital hepatoblastoma: a distinct entity? Ammann RA, et al. **Med Pediatr Oncol** 1999 Jun;32(6):466–8

BLOOD

Thrombopoietin in patients with hepatoblastoma. Komura E, et al. **Stem Cells** 1998;16(5):329–33

COMPLICATIONS

Glomerulocystic disease with hepatoblastoma in a neonate: a case report. Greer MLC, et al. **Pediatr Radiol** 1998 Sep; 28(9):703–5

CONGENITAL

Placental involvement in congenital hepatoblastoma. Doss BJ, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):538–42

DIAGNOSIS

Mixed hepatoblastoma diagnosed by fine-needle aspiration biopsy cytology: a case report. Jain R, et al. **Diagn Cytopathol** 1998 Oct;19(4):306–8

Prematurity and hepatoblastoma: more than just an association? [letter; comment] Feusner J, et al. **J Pediatr** 1998 Oct;133(4):585–6. Comment on: J Pediatr 1997 Apr;130(4):557–60.

12000 miles for parental reassurance [letter] van Delft F, et al. **Lancet** 1998 Oct 3;352(9134):1122

DRUG THERAPY

Antitumor effect of hepatocyte growth factor on hepatoblastoma. Tsunoda Y, et al. **Anticancer Res** 1998 Nov–Dec;18(6A):4339–42

Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Fuchs J, et al. **Cancer** 1998 Dec 1; 83(11):2400–7

Paclitaxel: an effective antineoplastic agent in the treatment of xenotransplanted hepatoblastoma. Fuchs J, et al. **Med Pediatr Oncol** 1999 Mar;32(3):209–15

ETIOLOGY

Prenatal and postnatal histories of very low birthweight infants who developed hepatoblastoma. Maruyama K, et al. **Pediatr Int** 1999 Feb;41(1):82–9

GENETICS

Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Koch A, et al. **Cancer Res** 1999 Jan 15;59(2):269–73

Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Bläker H, et al. **Genes Chromosomes Cancer** 1999 Aug;25(4):399–402

Copper resistant human hepatoblastoma mutant cell lines without metallothionein induction overexpress ATP7B. Schilsky ML, et al. **Hepatology** 1998 Nov;28(5):1347–56

High frequency of inactivation of the imprinted H19 gene in "sporadic" hepatoblastoma. Fukuzawa R, et al. **Int J Cancer** 1999 Aug 12;82(4):490–7

Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Minemura M, et al. **Int J Oncol** 1999 Sep;15(3):559–63

Primary malignant epithelial tumors of the liver in children: a study of DNA content and oncogene expression. Zerbini MC, et al. **Pediatr Dev Pathol** 1998 Jul–Aug;1(4):270–80

METABOLISM

Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Jin FY, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):1051–9

Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Guendouzi K, et al. **Biochemistry** 1998 Oct 20; 37(42):14974–80

Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas. Kim H, et al. **Cancer Lett** 1998 Sep 25;131(2):177–83

Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Bläker H, et al. **Genes Chromosomes Cancer** 1999 Aug;25(4):399–402

Effects of fibrillar C-terminal fragment of cleaved alpha1-antitrypsin on cholesterol homeostasis in HepG2 cells. Janciauskiene S, et al. **Hepatology** 1999 Feb; 29(2):434–42

MORTALITY

Survival and distribution pattern of childhood liver cancer in Taiwan. Lee CL, et al. **Eur J Cancer** 1998 Dec; 34(13):2064–7 (2 ref.)

PATHOLOGY

IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Vucenik I, et al. **Anticancer Res** 1998 Nov–Dec;18(6A):4083–90

Role of Ca2+ influx in the tert-butyl hydroperoxide-induced apoptosis of HepG2 human hepatoblastoma cells. Kim JA, et al. **Exp Mol Med** 1998 Sep 30;30(3):137–44

Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Fasano M, et al. **Mod Pathol** 1998 Oct;11(10):934–8

Hepatic neoplasms in childhood – a clinicopathologic study. Bhattacharya S, et al. **Pediatr Surg Int** 1998 Nov; 14(1–2):51–4 (22 ref.)

SECONDARY

A study of therapy for pediatric hepatoblastoma: prevention and treatment of pulmonary metastasis. Uchiyama M, et al. **Eur J Pediatr Surg** 1999 Jun;9(3):142–5

SURGERY

Orthotopic liver transplantation for unresectable hepatoblastoma: a single center's experience. Al-Qabandi W, et al. **J Pediatr Surg** 1999 Aug;34(8):1261–4

"Emergency hepatectomy" in a 16-month-old boy with a hepatoblastoma, severe cytomegalovirus-induced pancytopenia, and intractable diarrhea. Benesch M, et al. **Pediatr Surg Int** 1998 Dec;14(3):220–3

THERAPY

Transcatheter arterial chemoembolization in the treatment of hepatoblastoma. Oue T, et al. **J Pediatr Surg** 1998 Dec; 33(12):1771–5

VIROLOGY

[Hepatoblastoma in an HCV-positive adult. Report of a case] Diotallevi P, et al. **Radiol Med (Torino)** 1999 Apr; 97(4):319–21 **(Ita)**

HEPATOCELLULAR CARCINOMA see **CARCINOMA, HEPATOCELLULAR**

HEPATOCYTE GROWTH FACTOR

Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Jiang W, et al. **Crit Rev Oncol Hematol** 1999 Feb;29(3):209–48 (376 ref.)

ADMINISTRATION & DOSAGE

Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. Tahara M, et al. **J Clin Invest** 1999 Feb;103(3):313–20

Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome. Alavi K, et al. **J Pediatr Surg** 1998 Nov;33(11):1666–9

Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. Uematsu Y, et al. **J Pharm Sci** 1999 Jan;88(1):131–5

ANALYSIS

Hepatocyte growth factor in human breast milk. Yamada Y, et al. **Am J Reprod Immunol** 1998 Aug;40(2):112–20

Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells. Welch WC, et al. **Anticancer Res** 1999 May–Jun;19(3A):1635–40

Expression of hepatocyte growth factor/scatter factor and c-Met in human dental papilla and fibroblasts from dental papilla. Kajihara T, et al. **Arch Oral Biol** 1999 Feb; 44(2):135–47

High levels of hepatocyte growth factor/scatter factor in diffuse-type bronchioloalveolar cell carcinoma. Yamashita J, et al. **Cancer** 1998 Nov 15;83(10):2091–8

Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders. Katsura Y, et al. **Diabetes Care** 1998 Oct; 21(10):1759–63

Localization and effects of hepatocyte growth factor on smooth muscle cells during neointimal formation after balloon denudation. Aoyagi M, et al. **Histochem Cell Biol** 1999 Jun;111(6):419–28

Hepatocyte growth factor concentrations are elevated in peritoneal fluid of women with endometriosis. Osuga Y, et al. **Hum Reprod** 1999 Jun;14(6):1611–3

Tissue hepatocyte growth factor and proliferating cell nuclear antigen in hepatocellular carcinoma. Huang GT, et al. **J Formos Med Assoc** 1999 Feb;98(2):92–6

Hepatocyte growth factor concentration in rat bile is affected by hepatic resection volume and external biliary drainage. Hayata A, et al. **J Surg Res** 1999 Jul;85(1):71–6

ANTAGONISTS & INHIBITORS

Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. Abounader R, et al. **J Natl Cancer Inst** 1999 Sep 15; 91(18):1548–56

Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Date K, et al. **Oncogene** 1998 Dec 10;17(23):3045–54

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Michieli P, et al. **Oncogene** 1999 Sep 16;18(37):5221–31

BIOSYNTHESIS

Expression of the hepatocyte growth factor-like protein gene in human hepatocellular carcinoma and interleukin-6-induced increased expression in hepatoma cells. Zhu M, et al. **Biochim Biophys Acta** 1999 Feb 4; 1449(1):63–72

Expression of hepatocyte growth factor in cultured human endometrial stromal cells is induced through a protein kinase C-dependent pathway. Nasu K, et al. **Biol Reprod** 1999 May;60(5):1183–7

Hepatocyte growth factor expression in the developing myocardium: evidence for a role in the regulation of the mesenchymal cell phenotype and urokinase expression. Song W, et al. **Dev Dyn** 1999 Jan;214(1):92–100

Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts. Blanquaert F, et al. **Endocrinology** 1999 Mar;140(3):1069–74

Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Ota S, et al. **Eur J Pharmacol** 1999 Feb 12; 367(1):131–8

Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Matsumoto K, et al. **Hypertension** 1999 Aug;34(2):279–84

Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Yasuda S, et al. **Hypertension** 1999 Jun;33(6):1374–8

Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Li B, et al. **Int J Urol** 1998 Sep;5(5):436–40

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Okano JI, et al. **Liver** 1999 Apr;19(2):151–9

Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Hida Y, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1051–6

[Hepatocyte growth factor is an important signal exchanger between mesenchyme and epithelia during development] Guo SH, et al. **Sheng Li Ko Hsueh Chin Chan** 1996 Jul; 27(3):249–51 (8 ref.) **(Chi)**

[Expression of hepatocyte growth factor by activated eosinophiles in inflammatory lung tissue] Shindoh S, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):25–30 (Eng. Abstr.) **(Jpn)**

[Thermostable hepatocyte growth factor and energy metabolism following partial hepatectomy in rats] Gal'perin EI, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):53–6 **(Rus)**

BLOOD

Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Kulseng B, et al. **Acta Diabetol** 1998 Jul;35(2):77–80

Serum hepatocyte growth factor levels in patients with renal diseases. Nishida M, et al. **Am J Nephrol** 1999;19(4):509–12

Serum hepatocyte growth factor level associate with gastric cancer progression. Wu CW, et al. **Anticancer Res** 1998 Sep–Oct;18(5B):3657–9

Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Dosquet C, et al. **Clin Cancer Res** 1997 Dec; 3(12 Pt 1):2451–8

Serum concentrations of hepatocyte growth factor in breast cancer patients. Taniguchi T, et al. **Clin Cancer Res** 1995 Sep;1(9):1031–4

Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Hjorth-Hansen H, et al. **Eur J Haematol** 1999 Feb;62(2):129–34

Serum hepatocyte growth factor as an index of extensive catabolism of patients awaiting liver transplantation. Miki C, et al. **Gut** 1999 Jun;44(6):862–6

Hepatocyte growth factor(HGF): a new biochemical marker for acute myocardial infarction. Sato T, et al. **Heart Vessels** 1997;12(5):241–6

Portal serum human hepatocyte growth factor levels after partial hepatectomy. Higaki I, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1078–82

Serum endothelin-1 and hepatocyte growth factor levels in patients with obstructive jaundice. Higaki I, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1599–602

Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma. Hu RH, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1842–7

Correlation between human hepatocyte growth factor and interleukin-6 concentrations after surgery. Kimura F, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1030–5

Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Niki M, et al. **Hepatogastroenterology** 1999 Jan–Feb;46(25):568–73

Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Niki M, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2458–63

Decreased maternal circulating hepatocyte growth factor (HGF) concentrations in pregnancies with small for gestational age infants. Aoki S, et al. **Hum Reprod** 1998 Oct;13(10):2950–3

Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. Junbo H, et al. **In Vivo** 1999 Mar–Apr;13(2):177–80

Serum hepatocyte growth factor as a possible indicator of vascular lesions. Nishimura M, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2475–80

Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. Yoshitomi Y, et al.

J Clin Endocrinol Metab 1999 Jul;84(7):2425–8
Immediate increase in circulating hepatocyte growth factor/scatter factor by heparin. Matsumori A, et al. **J Mol Cell Cardiol** 1998 Oct;30(10):2145–9
Increased levels of hepatocyte growth factor in sera of patients with systemic sclerosis [letter] Kawaguchi Y, et al. **J Rheumatol** 1999 Apr;26(4):1012–3
Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes. Sato T, et al. **Jpn Circ J** 1999 Aug;63(8):583–8
Serum hepatocyte growth factor levels in patients with inflammatory lung diseases. Huang MS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Apr; 15(4):195–201
Failure of urinary and serum hepatocyte growth factor assay as an early marker of diabetic nephropathy [letter] Ebihara I, et al. **Nephron** 1999;82(4):365
Stimulation of hepatocyte growth factor in human acute renal failure. Libetta C, et al. **Nephron** 1998 Sep;80(1):41–5
Hepatocyte growth factor levels during normal and intra-uterine growth-restricted pregnancies. Clark DE, et al. **Placenta** 1998 Nov;19(8):671–3
The changes in circulating hepatocyte growth factor after partial hepatectomy in the baboon. Winters Z, et al. **S Afr J Surg** 1999 May;37(2):31–7
Hepatocyte growth factor (HGF) in patients with pneumonia: a comparison between survivors and non-survivors. Nayeri F, et al. **Scand J Infect Dis** 1998; 30(4):405–9
[Significance of hepatocyte growth factor measurement in patients with acute myocardial infarction] Sato T, et al. **J Cardiol** 1998 Aug;32(2):77–82 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Natural hepatocyte growth factor (HGF) from human serum and a bound form of recombinant HGF with heparan sulfate are indistinguishable in their physicochemical properties. Yano K, et al. **Int J Biol Macromol** 1998 Oct; 23(3):227–35
Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Chirgadze DY, et al. **Nat Struct Biol** 1999 Jan; 6(1):72–9
Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Ultsch M, et al. **Structure** 1998 Nov 15;6(11):1383–93

DIAGNOSTIC USE

Prognostic value of serum hepatocyte growth factor in patients with acute coronary syndromes. Sato T, et al. **Jpn Circ J** 1999 Aug;63(8):583–8

GENETICS

Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ueda H, et al. **Ann Thorac Surg** 1999 Jun;67(6):1726–31
Adrenergic stimulation of hepatocyte growth factor expression. Broten J, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):76–9
Expression of the human hepatocyte growth factor cDNA in primary cultures of rat hepatocytes. Runge DM, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):199–205
Scatter factor/hepatocyte growth factor gene transfer increases rat blood–glioma barrier permeability. Book AA, et al. **Brain Res** 1999 Jul 3;833(2):173–80
The expression of mRNAs for hepatocyte growth factor/scatter factor, its receptor c-met, and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus. Thewke DP, et al. **Brain Res** 1999 Mar 13;821(2):356–67
Reversing liver cirrhosis: impact of gene therapy for liver cirrhosis [editorial] Fujimoto J, et al. **Gene Ther** 1999 Mar; 6(3):305–6
TOM1 genes map to human chromosome 22q13.1 and mouse chromosome 8C1 and encode proteins similar to the endosomal proteins HGS and STAM. Seroussi E, et al. **Genomics** 1999 May 1;57(3):380–8
The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in damaged human liver and kidney tissues. Ho RT, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1904–9
Gene therapy for hepatic fibrosis–bringing treatment into the new millennium. Rockey DC. **Hepatology** 1999 Sep; 30(3):816–8
Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice. Gao C, et al. **Hum Gene Ther** 1999 Apr 10;10(6):911–22
Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Morishita R, et al. **Hypertension** 1999 Jun;33(6):1379–84
Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Wilson SE, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2185–90
Effects of deletion-type human hepatocyte growth factor on murine septic model. Kondo H, et al. **J Surg Res** 1999 Jul;85(1):88–95
Evidence for the presence of hepatocyte growth factor expression in human ovarian follicles. Osuga Y, et al. **Mol Hum Reprod** 1999 Aug;5(8):703–7
Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Ueki T, et al. **Nat Med** 1999 Feb;5(2):226–30
Hepatocyte growth factor and fibroblast growth factor 2 are overexpressed after cerulein-induced acute pancreatitis. Menke A, et al. **Pancreas** 1999 Jan;18(1):28–33
Deletion variant of hepatocyte growth factor prolongs allograft survival after liver transplantation in rats. Ikegami T, et al. **Surgery** 1999 Jun;125(6):602–7
Effects of deletion variant of hepatocyte growth factor on reduced-size liver transplantation in rats. Uchiyama H, et al. **Transplantation** 1999 Jul 15;68(1):39–44

METABOLISM

Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin. Adamson IY, et al. **Am J Pathol** 1999 Sep;155(3):949–54
Ontogeny of hepatocyte growth factor (HGF) and its receptor (c-met) in human placenta: reduced HGF expression in intrauterine growth restriction. Somerset DA, et al. **Am J Pathol** 1998 Oct;153(4):1139–47
Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. Liu KX, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E835–42
The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Siegfried JM, et al. **Ann Thorac Surg** 1998 Dec;66(6):1915–8
Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in madin-darby canine kidney epithelial cells. Kadono Y, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):681–7
Hepatocyte growth factor activator: a possible regulator of morphogenesis during fetal development of the rat gastrointestinal tract. Matsubara Y, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):477–84
Expression of the human hepatocyte growth factor cDNA in primary cultures of rat hepatocytes. Runge DM, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):199–205
Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Seidel C, et al. **Br J Haematol** 1999 Jun;105(3):641–7
Wy-14,643, a peroxisome proliferator, inhibits compensative cell proliferation and hepatocyte growth factor mRNA expression in the rat liver. Motoki Y, et al. **Cancer Lett** 1999 Jan 29;135(2):145–50
c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Otsuka T, et al. **Cancer Res** 1998 Nov 15;58(22):5157–67
Suppressed apoptotic susceptibility in human endometrial epithelial cells pretreated with hepatocyte growth factor. Tanaka T, et al. **Clin Exp Obstet Gynecol** 1998;25(4):125–8
Hepatocyte growth factor and c-MET are expressed in rat prepuberal testis. Catizone A, et al. **Endocrinology** 1999 Jul;140(7):3106–13
Hepatocyte growth factor enables enhanced integrin-cytoskeleton linkage by affecting integrin expression in subconfluent epithelial cells. Nebe B, et al. **Exp Cell Res** 1998 Sep 15;243(2):263–73
Regulation of the HGF-receptor c-met in the thyroid gland. Schulte KM, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(4):310–8
Interactions between scatter factors and their receptors: hints for therapeutic applications. Trusolino L, et al. **FASEB J** 1998 Oct;12(13):1267–80 (152 ref.)
Intercellular adhesion molecule-1 and hepatocyte growth factor in human endometriosis: original investigation and a review of literature. Fukaya T, et al. **Gynecol Obstet Invest** 1999;47 Suppl 1:11–6; discussion 16–7 (23 ref.)
Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Liu Z, et al. **Hepatology** 1998 Nov;28(5):1260–8
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Schmidt NO, et al. **Int J Cancer** 1999 Feb 19;84(1):10–8
Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Moriyama T, et al. **Int J Mol Med** 1999 May;3(5):531–6 (66 ref.)
Three isoforms of a hepatocyte nuclear factor-4 transcription factor with tissue- and stage-specific expression in the adult mosquito. Kapitskaya MZ, et al. **J Biol Chem** 1998 Nov 6;273(45):29801–10
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. Ried S, et al. **J Biol Chem** 1999 Jun 4; 274(23):16377–86
Identification and characterization of receptor for mammalian hepatopoietin that is homologous to yeast ERV1. Wang G, et al. **J Biol Chem** 1999 Apr 23;274(17):11469–72
Increased vitreous concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. Nishimura M, et al. **J Clin Endocrinol Metab** 1999 Feb; 84(2):659–62
Role of cyclooxygenase 2 in hepatocyte growth factor-mediated gastric epithelial restitution. Horie-Sakata K, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S40–6
Sustained induction of hepatocyte growth factor by sensitization with freeze-thawed hepatic tissue. Adachi T, et al. **J Hepatobiliary Pancreat Surg** 1998;5(3):320–6
Active form of human hepatocyte growth factor is excreted into bile after hepatobiliary resection. Kurumiya Y, et al. **J Hepatol** 1999 Jan;30(1):22–8
Hepatocyte-stimulated expression of hepatocyte growth factor (HGF) in cultured rat hepatic stellate cells. Skrtic S, et al. **J Hepatol** 1999 Jan;30(1):115–24
Hepatocyte growth factor as a potential index of complication in diabetes mellitus. Nakamura S, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2019–26
Differential regenerative response and expression of growth factors following hepatectomy of variable extent in rats. Masson S, et al. **Liver** 1999 Aug;19(4):312–7
Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Seidel C, et al. **Med Oncol** 1998 Sep; 15(3):145–53 (72 ref.)
Evidence for the presence of hepatocyte growth factor expression in human ovarian follicles. Osuga Y, et al. **Mol Hum Reprod** 1999 Aug;5(8):703–7
Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Day RM, et al. **Oncogene** 1999 Jun 3;18(22):3399–406
Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Fukuda T, et al. **Pathol Int** 1998 Oct;48(10):757–62
Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Motoi T, et al. **Pathol Int** 1998 Oct;48(10):769–75
Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development. Kos L, et al. **Pigment Cell Res** 1999 Feb;12(1):13–21
Evidence for a functional hepatocyte growth factor receptor in human mesangial cells. Kallincos NC, et al. **Regul Pept** 1998 Jun 30;74(2-3):137–42
Enhanced hepatocyte growth factor expression associated with prolonged rat hepatic allograft survival in recipients pretreated with donor-specific blood. Ichiguchi O, et al. **Transplantation** 1999 Jan 15;67(1):115–23

PHARMACOKINETICS

Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. Kato M, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):373–9

PHARMACOLOGY

Transplanted hepatocytes proliferate differently after CCl4 treatment and hepatocyte growth factor infusion. Gupta S, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G629–38
Zonal differences in effects of HGF/SF and EGF on DNA synthesis in hepatocytes under fed or starved conditions. Imai K, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1394–401
Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell–cell adhesion: involvement of beta-catenin. Hiscox S, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):509–17
Activated rat stellate cells express c-met and respond to hepatocyte growth factor to enhance transforming growth factor beta1 expression and DNA synthesis. Ikeda H, et al. **Biochem Biophys Res Commun** 1998 Sep 29; 250(3):769–75
A mutant of deleted variant of hepatocyte growth factor (dHGF) with alanine substitution in the N-terminal basic region has higher activity in vivo. Kinosaki M, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):363–7
Involvement of polyamines in retinoblastoma protein phosphorylation. Omura T, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):731–4
Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Rosenthal EL, et al. **Cancer Res** 1998 Nov 15; 58(22):5221–30
HGF-mediated apoptosis via p53/bax-independent pathway activating JNK1. Conner EA, et al. **Carcinogenesis** 1999 Apr;20(4):583–90
Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells. Ronen D, et al. **Cell Growth Differ** 1999 Feb;10(2):131–40
Regional regulation of microtubule dynamics in polarized, motile cells. Wadsworth P. **Cell Motil Cytoskeleton** 1999; 42(1):48–59
Hepatocyte growth factor stimulates migration of type II alveolar epithelial cells on the provisional matrix proteins fibronectin and fibrinogen. Kim HJ, et al. **Chest** 1999 Jul; 116(1 Suppl):94S–95S
Hepatocyte growth factor secreted by human liver myofibroblasts increases invasiveness of hepatocellular carcinoma cells. Neaud V, et al. **Curr Top Pathol** 1999; 93:195–203
Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell–cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Pollack AL, et al. **Dev Biol** 1998 Dec 1;204(1):64–79
Role of mitogen-activated protein kinase and phosphoinositide 3-kinase in the differentiation of rat pancreatic AR42J cells induced by hepatocyte growth

factor. Furukawa M, et al. **Diabetologia** 1999 Apr; 42(4):450–6

Regulation of hepatic cytochrome P450 2C11 by transforming growth factor-beta, hepatocyte growth factor, and interleukin-11. Iber H, et al. **Drug Metab Dispos** 1998 Oct;26(10):1042–4

Hepatocyte growth factor induces rat ovarian surface epithelial cell mitosis or apoptosis depending on the presence or absence of an extracellular matrix. Hess S, et al. **Endocrinology** 1999 Jun;140(6):2908–16

Hepatocyte growth factor/scatter factor promotes a switch from E- to N-cadherin in chick embryo epiblast cells. DeLuca SM, et al. **Exp Cell Res** 1999 Aug 25;251(1):3–15

Morphogenetic events in mixed cultures of rat hepatocytes and nonparenchymal cells maintained in biological matrices in the presence of hepatocyte growth factor and epidermal growth factor [see comments] Michalopoulos GK, et al. **Hepatology** 1999 Jan;29(1):90–100. Comment in: Hepatology 1999 Jan;29(1):288–90.

Effects of keratinocyte and hepatocyte growth factor in vivo: implications for retrovirus-mediated gene transfer to liver. Bosch A, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1747–54

Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Morishita R, et al. **Hypertension** 1999 Jun;33(6):1379–84

Hepatocyte growth factor regulates activin betaA mRNA in submandibular gland [letter] Furue M, et al. **In Vitro Cell Dev Biol Anim** 1998 Jul-Aug;34(7):520–3

Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Hamasuna R, et al. **Int J Cancer** 1999 Jul 19;82(2):274–81

Hepatocyte growth factor/scatter factor induces not only scattering but also cohort migration of human colorectal-adenocarcinoma cells. Nabeshima K, et al. **Int J Cancer** 1998 Dec 9;78(6):750–9

Role of fibroblasts in HGF/SF-induced cohort migration of human colorectal carcinoma cells: fibroblasts stimulate migration associated with increased fibronectin production via upregulated TGF-beta1. Shimao Y, et al. **Int J Cancer** 1999 Jul 30;82(3):449–58

Ameloblast-lineage cells of rat tooth germs proliferate and scatter in response to hepatocyte growth factor in culture. Matsumura T, et al. **Int J Dev Biol** 1998 Nov;42(8):1137–42

Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. Morishita R, et al. **J Atheroscler Thromb** 1998; 4(3):128–34 (48 ref.)

Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. van der Voort R, et al. **J Biol Chem** 1999 Mar 5;274(10):6499–506

Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. Lee HS, et al. **J Biomed Sci** 1998;5(3):180–4

Hepatocyte growth factor induces tubulogenesis of primary renal proximal tubular epithelial cells. Bowes RC 3rd, et al. **J Cell Physiol** 1999 Jul;180(1):81–90

Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. Zeigler ME, et al. **J Cell Physiol** 1999 Aug;180(2):271–84

Hepatocyte growth factor stimulates chemotactic response in mouse embryonic limb myogenic cells in vitro. Lee KK, et al. **J Exp Zool** 1999 Feb 1;283(2):170–80

Hepatocyte apoptosis and hepatic expression of transforming growth factor-beta1 mRNA during involution of hyperplastic rat liver induced by hepatocyte growth factor. Nagoshi S, et al. **J Gastroenterol Hepatol** 1998 Aug; 13(8):786–93

Hepatocyte growth factor activates the AP-1 complex: a comparison between normal and transformed rat hepatocytes. Rahmani M, et al. **J Hepatol** 1999 May; 30(5):916–25

Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. Gille J, et al. **J Invest Dermatol** 1998 Dec;111(6):1160–5

Autocrine hepatocyte growth factor provides a local mechanism for promoting axonal growth. Yang XM, et al. **J Neurosci** 1998 Oct 15;18(20):8369–81

Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects. Uematsu Y, et al. **J Pharm Sci** 1999 Jan;88(1):131–5

Hepatocyte growth factor prevents lipopolysaccharide-induced hepatic sinusoidal endothelial cell injury and intrasinusoidal fibrin deposition in rats. Seto Si, et al. **J Surg Res** 1998 Dec;80(2):194–9

Mammary fibroblast-derived hepatocyte growth factor stimulates growth and morphogenesis of mouse mammary tumor cells in primary culture. Sasaki M, et al. **Jpn J Cancer Res** 1998 Nov;89(11):1134–43

Endothelin release by rabbit proximal tubule cells: modulatory effects of cyclosporine A, tacrolimus, HGF and EGF. Haug C, et al. **Kidney Int** 1998 Nov; 54(5):1626–36

Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells [see comments] Yo Y, et al. **Kidney Int** 1998 Oct;54(4):1128–38. Comment in: Kidney Int 1998 Oct;54(4):1392–3.

Pleiotropic effects of hepatocyte growth factor in proximal tubule involve different signaling pathways. Jehle PM, et al. **Kidney Int Suppl** 1998 Sep;67:S152–4

Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Wojta J, et al. **Lab Invest** 1999 Apr; 79(4):427–38

Evidence that hepatocyte growth factor abrogates contact inhibition of mitosis in Madin-Darby canine kidney cell monolayers. Balkovetz DF. **Life Sci** 1999;64(16):1393–401

Hepatocyte growth factor and Madin-Darby canine kidney cells: in vitro models of epithelial cell movement and morphogenesis. Balkovetz DF. **Microsc Res Tech** 1998 Dec 1;43(5):456–63

The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Koochekpour S, et al. **Mol Cell Biol** 1999 Sep;19(9):5902–12

Hepatocyte growth factor releases mink epithelial cells from transforming growth factor beta1-induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2 activity. Tsubari M, et al. **Mol Cell Biol** 1999 May; 19(5):3654–63

Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. Taylor GA, et al. **Oncogene** 1998 Sep 3; 17(9):1179–83

Hepatocyte growth factor inhibits amiloride-sensitive Na(+) channel function in cystic fibrosis airway epithelium in vitro. Shen BQ, et al. **Pulm Pharmacol Ther** 1999; 12(3):157–64

Effect of hepatocyte growth factor on tacrolimus-induced nephrotoxicity in spontaneously hypertensive rats. Takada S, et al. **Transpl Int** 1999;12(1):27–32

Morphologic alteration of hepatocytes and sinusoidal endothelial cells in rat fatty liver during cold preservation and the protective effect of hepatocyte growth factor. Takeda Y, et al. **Transplantation** 1999 Mar 27;67(6):820–8

[Effects of hepatocyte growth factor on dose- and time-response of DNA synthesis in rat hepatocytes in vitro] Zou Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):53–6 (Eng. Abstr.) **(Chi)**

[Protection of hepatocyte growth factor against carbon tetrachloride injury in primary rat hepatocyte culture] Zou Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):228–30 (Eng. Abstr.) **(Chi)**

[Effects of HGF on the production of matrix metalloproteinases by colonic cancer cells DHD/K12] Aparicio T, et al. **C R Seances Soc Biol Fil** 1998; 192(2):311–5 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Hepatocyte growth Factor/Scatter factor (HGF/SF) is a regulator of fibronectin splicing in MDCK cells: comparison between the effects of HGF/SF and TGF-beta1 on fibronectin splicing at the EDA region. Inoue T, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):225–31

Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Hasina R, et al. **Br J Cancer** 1999 Aug; 80(11):1708–17

Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts. Matsumoto-Taniura N, et al. **Br J Cancer** 1999 Sep;81(2):194–202

HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice. Weimar IS, et al. **Br J Cancer** 1999 Sep;81(1):43–53

Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Tamatani T, et al. **Carcinogenesis** 1999 Jun;20(6):957–62

The role of SF/HGF and c-Met in the development of skeletal muscle. Dietrich S, et al. **Development** 1999 Apr; 126(8):1621–9

Characterization of a functional relationship between hepatocyte growth factor and mouse bone marrow-derived mast cells. Fehlner-Gardiner CC, et al. **Differentiation** 1999 Jul;65(1):27–42

HGF controls branched morphogenesis in tubular glands. Maffè A, et al. **Eur J Morphol** 1998 Aug;36 Suppl:74–81 (55 ref.)

Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Bae-Jump V, et al. **Gynecol Oncol** 1999 May;73(2):265–72

The role of polyamines in growth factor induced DNA synthesis in cultured rat hepatocytes. Higaki I, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1874–9

Establishment of a functional HGF/C-MET autocrine loop in spontaneous transformants of WB-F344 rat liver stem-like cells. Presnell SC, et al. **Hepatology** 1998 Nov; 28(5):1253–9

Effects of hepatocyte growth factor (HGF) and activin A on the morphogenesis of rat submandibular gland-derived epithelial cells in serum-free collagen gel culture. Furue M, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar;35(3):131–5

Hepatocyte growth factor in transgenic mice. Shiota G, et al. **Int J Exp Pathol** 1998 Oct;79(5):267–77 (31 ref.)

Hepatocyte growth factor and the kidney: it is not just for the liver. Balkovetz DF, et al. **Int Rev Cytol** 1999; 186:225–60 (202 ref.)

Involvement of oxidative stress in tumor cytotoxic activity of hepatocyte growth factor/scatter factor. Arakaki N, et al. **J Biol Chem** 1999 May 7;274(19):13541–6

c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. Rahimi N, et al. **J Biol Chem** 1998 Dec 11;273(50):33714–21

Hepatocyte growth factor/scatter factor and hepatocytes are potent downregulators of tyrosinase expression in B16 melanoma cells. Rusciano D, et al. **J Cell Biochem** 1998 Nov 1;71(2):264–76

Met overexpression confers HGF-dependent invasive phenotype to human thyroid carcinoma cells in vitro. de Luca A, et al. **J Cell Physiol** 1999 Sep;180(3):365–71

Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. Deakin JA, et al. **J Cell Sci** 1999 Jun;112 (Pt 12):1999–2009

HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models. Kamalati T, et al. **J Mammary Gland Biol Neoplasia** 1999 Jan;4(1):69–77 (55 ref.)

Hepatocyte growth factor supply accelerates compensatory hypertrophy caused by portal branch ligation in normal and jaundiced rats. Kaido T, et al. **J Surg Res** 1999 Jul; 85(1):115–9

Biological role of HGF/MET pathway in renal cell carcinoma. Horie S, et al. **J Urol** 1999 Mar;161(3):990–7

Hepatocyte growth factor: mesenchymal signal for epithelial homeostasis [editorial; comment] Kopp JB. **Kidney Int** 1998 Oct;54(4):1392–3 (17 ref.). Comment on: Kidney Int 1998 Oct;54(4):1128–38.

Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Liu Y, et al. **Kidney Int** 1999 Feb;55(2):442–53

Potential role of hepatocyte growth factor in the maintenance of renal structure: anti-apoptotic action of HGF on epithelial cells [see comments] Yo Y, et al. **Kidney Int** 1998 Oct;54(4):1128–38. Comment in: Kidney Int 1998 Oct;54(4):1392–3.

Hepatocyte growth factor is a potent trigger of neutrophil adhesion through rapid activation of lymphocyte function-associated antigen-1. Mine S, et al. **Lab Invest** 1998 Nov;78(11):1395–404

The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Børset M, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):249–56 (60 ref.)

Hepatocyte growth factor, a versatile signal for developing neurons. Maina F, et al. **Nat Neurosci** 1999 Mar;2(3):213–7 (50 ref.)

In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Badie B, et al. **Neurosurgery** 1999 May;44(5):1077–82; discussion 1082–3

The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Bell A, et al. **Oncogene** 1999 Jan 28;18(4):887–95

HGF activates signal transduction from EPO receptor on human cord blood CD34+/CD45+ cells. Iguchi T, et al. **Stem Cells** 1999;17(2):82–91

Deletion variant of hepatocyte growth factor prolongs allograft survival after liver transplantation in rats. Ikegami T, et al. **Surgery** 1999 Jun;125(6):602–7

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Birchmeier C, et al. **Trends Cell Biol** 1998 Oct;8(10):404–10 (60 ref.)

[Neovascularization and HGF: neovascularization in proliferative diabetic retinopathy and intraocular HGF] Nishimura M, et al. **Rinsho Byori** 1998 Nov;46(11):1156–61 (Eng. Abstr.) **(Jpn)**

[Physiologic and physiopathologic role of hepatocyte growth factor] Rodriguez-Fragoso L. **Rev Invest Clin** 1998 Jul-Aug;50(4):355–67 (121 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Effects of PMMA membrane on hepatocyte growth factor release. Dal Canton A. **Contrib Nephrol** 1999;125:197–204 (21 ref.)

Secretion of acute-phase proteins before and after hepatocellular carcinoma resection. Hu RH, et al. **J Formos Med Assoc** 1999 Feb;98(2):85–91

THERAPEUTIC USE

Antitumor effect of hepatocyte growth factor on hepatoblastoma. Tsunoda Y, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4339–42

Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice [see comments] Kosai K, et al. **Hepatology** 1999 Jul;30(1):151–9. Comment in: Hepatology 1999 Jul;30(1):333–4.

Hepatocyte growth factor for liver disease [editorial; comment] Tsubouchi H. **Hepatology** 1999 Jul;30(1):333–4 (22 ref.). Comment on: Hepatology 1999 Jul;30(1):151–9.

Effects of deletion-type human hepatocyte growth factor on murine septic model. Kondo H, et al. **J Surg Res** 1999 Jul;85(1):88–95

HEPATOCYTE GROWTH FACTOR

Effect of hepatocyte growth factor on chronic rejection in rat renal allografts. Azuma H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):854-5

URINE

Failure of urinary and serum hepatocyte growth factor assay as an early marker of diabetic nephropathy [letter] Ebihara I, et al. **Nephron** 1999;82(4):365

HEPATOCYTE GROWTH FACTOR RECEPTORS see **PROTO-ONCOGENE PROTEINS C-MET**

HEPATOCYTE-STIMULATING FACTOR see **INTERLEUKIN-6**

HEPATOLENTICULAR DEGENERATION

Animal models of Wilson's disease. Howell JM. **Adv Exp Med Biol** 1999;448:139-52 (56 ref.)

Five successful deliveries following 9 consecutive spontaneous abortions in a patient with Wilson disease. Mustafa MS, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug; 38(3):312-4

Wilson disease. Roberts EA, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):237-56 (91 ref.)

Wilson's disease. Update of a systemic disorder with protean manifestations. Cuthbert JA. **Gastroenterol Clin North Am** 1998 Sep;27(3):655-81, vi-vii (121 ref.)

Wilson's disease. Ferenci P. **Ital J Gastroenterol Hepatol** 1999 Jun-Jul;31(5):416-25 (55 ref.)

The Long-Evans Cinnamon rat: an animal model for Wilson's disease. Terada K, et al. **Pediatr Int** 1999 Aug; 41(4):414-8

[Wilson's diseases] Guardia J. **Gastroenterol Hepatol** 1999 Feb;22 Suppl 1:6-7 **(Spa)**

BLOOD

Heinz body haemolytic anaemia in Wilson's disease. Bain BJ. **Br J Haematol** 1999 Mar;104(4):647

A marked increase in free copper levels in the plasma and liver of LEC rats: an animal model for Wilson disease and liver cancer. Koizumi M, et al. **Free Radic Res** 1998 May; 28(5):441-50

Inverse correlation of serum bilirubin and alkaline phosphatase in fulminant Wilson's disease. Kenngott S, et al. **J Hepatol** 1998 Oct;29(4):683

Pilot study of screening for Wilson disease using dried blood spots obtained from children seen at outpatient clinics. Ohura T, et al. **J Inherit Metab Dis** 1999 Feb;22(1):74-80

COMPLICATIONS

Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature. Ferlan-Marolt V, et al. **Dig Dis Sci** 1999 May;44(5):1054-8 (26 ref.)

Generators of brain electrical activity in patients with Wilson's disease. Dierks T, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(1):15-20

Idiopathic thrombocytopenia associated with Wilson's disease. Donfrid M, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1774-6

Wilson's disease with concomitant beta thalassaemia and factor V deficiency. Giannini E, et al. **Ital J Gastroenterol Hepatol** 1998 Dec;30(6):633-5

Acute hemolytic crisis with fulminant hepatic failure as the first manifestation of Wilson's disease: a case report. Lee JJ, et al. **J Korean Med Sci** 1998 Oct;13(5):548-50

A homesick student. McDonnell GV, et al. **Postgrad Med J** 1999 Jun;75(884):375-8

[Severe hemolytic anemia with tear drop red cells as initial manifestation of Wilson's disease] Kawahara S, et al. **Rinsho Ketsueki** 1998 Sep;39(9):665-9 (Eng. Abstr.) **(Jpn)**

[Type-III hyperlipoproteinemia in a girl with Wilson's disease] Bonet Serra B, et al. **An Esp Pediatr** 1999 Jan; 50(1):71-3 (12 ref.) **(Spa)**

DIAGNOSIS

Sherlock Holmes' magnifying glass to identify Wilson's disease? [letter] Delpre G, et al. **Am J Gastroenterol** 1998 Dec;93(12):2635-6

Caeruloplasmin isoforms in Wilson's disease in neonates. Chowrimootoo GF, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F198-201

Growing pains [letter; comment] Phillips L. **Aust Fam Physician** 1999 May;28(5):427-8. Comment on: Aust Fam Physician 1999 Feb;28(2):124-7.

Value of histochemical stains for copper in the diagnosis of Wilson's disease [see comments] Pilloni L, et al. **Histopathology** 1998 Jul;33(1):28-33. Comment in: Histopathology 1999 May;34(5):471.

Value of histochemical stains for copper in the diagnosis of paediatric copper storage disorders [letter; comment] Sethi S. **Histopathology** 1999 May;34(5):471. Comment on: Histopathology 1998 Jul;33(1):28-33.

Use of the stable isotope 65Cu test for the screening of Wilson's disease in a family with two affected members. Merli M, et al. **Ital J Gastroenterol Hepatol** 1998 Jun; 30(3):270-5

Wilson's disease: copper unfettered. Pfeil SA, et al. **J Clin Gastroenterol** 1999 Jul;29(1):22-31 (78 ref.)

Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. Lauterbach EC, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer; 10(3):249-66 (256 ref.)

A high index of suspicion: the key to an early diagnosis of Wilson's disease in childhood. Sánchez-Albisua I, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):186-90

Mass screening for Wilson's disease: results and recommendations. Yamaguchi Y, et al. **Pediatr Int** 1999 Aug;41(4):405-8

[Clinical application of chromosome haplotype analysis and mutation analysis to the diagnosis of Wilson's disease] Shi X, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Feb 10;16(1):32-5 (Eng. Abstr.) **(Chi)**

[Picture of the month] Ott P, et al. **Ugeskr Laeger** 1999 May 31;161(22):3303 **(Dan)**

[Wilson's disease. The making of a diagnosis by conventional and molecular biology methods] Maier-Dobersberger T. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):493-6 (22 ref.) **(Ger)**

[Modern views on the pathogenesis of Wilson's disease] Bertrand E, et al. **Neurol Neurochir Pol** 1998 Mar-Apr; 32(2):367-77 (32 ref.) (Eng. Abstr.) **(Pol)**

[Wilson's disease ("hepatic form") in a region endemic for schistosomiasis mansoni: clinical presentation of 25 patients] Galizzi-Filho J, et al. **Arq Gastroenterol** 1998 Jan-Mar; 35(1):11-7 (Eng. Abstr.) **(Por)**

DRUG THERAPY

The treatment of Wilson's disease. Brewer GJ. **Adv Exp Med Biol** 1999;448:115-26 (30 ref.)

Zinc therapy induction of intestinal metallothionein in Wilson's disease [editorial; comment] Brewer GJ. **Am J Gastroenterol** 1999 Feb;94(2):301-2. Comment on: Am J Gastroenterol 1999 Feb;94(2):334-8.

Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease. Siafakas CG, et al. **Am J Gastroenterol** 1998 Dec;93(12):2544-6

Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients [see comments] Sturniolo GC, et al. **Am J Gastroenterol** 1999 Feb;94(2):334-8. Comment in: Am J Gastroenterol 1999 Feb;94(2):301-2.

D-penicillamine-induced pancreatic islet autoantibody production is independent of the immunogenetic background: a lesson from patients with Wilson's disease. Kauschansky A, et al. **Clin Immunol Immunopathol** 1998 Dec;89(3):279-83

Treatment of Wilson's disease with zinc: XV long-term follow-up studies. Brewer GJ, et al. **J Lab Clin Med** 1998 Oct;132(4):264-78

Treatment of Wilson's disease with zinc [letter] Brewer GJ. **J Lab Clin Med** 1999 Sep;134(3):322-4 (30 ref.)

Zinc treatment of Wilson's disease [editorial] Hoogenraad TU. **J Lab Clin Med** 1998 Oct;132(4):240-1 (13 ref.)

Therapeutic effects of tetrathiomolybdate on hepatic dysfunction occurring naturally in Long-Evans Cinnamon (LEC) rats: a bona fide animal model for Wilson's disease. Sugawara N, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb;103(2):177-87

[Long-term follow-up of combined therapy with large-dose zinc sulfate and low-dose penicillamine in children with hepatolenticular degeneration] Li T, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Feb 10;16(1):19-21 (Eng. Abstr.) **(Chi)**

[Clinical study of integrated traditional and Western medicine therapy on hepatolenticular degeneration] Ren MS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Mar; 17(3):136-8 (Eng. Abstr.) **(Chi)**

[Pregnancy in a patient treated with trientine dihydrochloride for Wilson's disease (letter)] Desbriere R, et al. **Presse Med** 1998 May 2-9;27(17):806 **(Fre)**

[Therapy of Wilson disease] Smolarek C, et al. **Z Gastroenterol** 1999 Apr;37(4):293-300 (64 ref.) (Eng. Abstr.) **(Ger)**

[Acute hemolytic anemia associated with D-penicillamine absorption deficiency in Wilson's disease (letter)] Ramirez Sánchez MJ, et al. **Rev Clin Esp** 1999 Feb;199(2):117-8 **(Spa)**

ENZYMOLOGY

Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Schaefer M, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G639-46

Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease. Forbes JR, et al. **J Biol Chem** 1999 Apr 30; 274(18):12408-13

ETIOLOGY

Mechanism of hepatorenal syndrome in rats of Long-Evans Cinnamon strain, an animal model of fulminant Wilson's disease. Nomiyama K, et al. **Toxicology** 1999 Feb 15; 132(2-3):201-14

GENETICS

New knowledge of genetic pathogenesis of hemochromatosis and Wilson's disease. Bacon BR, et al. **Adv Intern Med** 1999;44:91-116 (77 ref.)

Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Forbes JR, et al. **Am J Hum Genet** 1998 Dec;63(6):1663-74

Detection of a rare Wilson disease mutation associated with arylsulfatase A pseudodeficiency. Battisti C, et al. **Am J Med Genet** 1999 Jul 16;85(2):175-8

Cloning and characterization of the promoter region of the Wilson disease gene. Oh WJ, et al. **Biochem Biophys Res Commun** 1999 May 27;259(1):206-11

Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Nair J, et al. **Cancer Epidemiol Biomarkers Prev** 1998 May; 7(5):435-40

RESPONSIVE-TO-ANTAGONIST1, a Menkes/Wilson disease-related copper transporter, is required for ethylene signaling in Arabidopsis. Hirayama T, et al. **Cell** 1999 Apr 30;97(3):383-93

Identification of a novel missense mutation in Wilson's disease gene. Fan Y, et al. **Chin Med J (Engl)** 1997 Nov; 110(11):887-90

His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. Duc HH, et al. **Eur J Hum Genet** 1998 Nov-Dec;6(6):616-23

Haplotype and mutation analysis in Greek patients with Wilson disease. Loudianos G, et al. **Eur J Hum Genet** 1998 Sep-Oct;6(5):487-91

Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease. Wijmenga C, et al. **Eur J Hum Genet** 1998 Nov-Dec;6(6):624-8

Mutation analysis in patients with Wilson disease: identification of 4 novel mutations. Mutation in brief no. 250. Online. Haas R, et al. **Hum Mutat** 1999;14(1):88

Mutation analysis of Wilson disease in Taiwan and description of six new mutations. Tsai CH, et al. **Hum Mutat** 1998;12(6):370-6

Mutations of ATP7B gene in Wilson disease in Japan: identification of nine mutations and lack of clear founder effect in a Japanese population. Yamaguchi A, et al. **Hum Mutat** 1998;Suppl 1:S320-2

ATP7B (WND) protein. Terada K, et al. **Int J Biochem Cell Biol** 1998 Oct;30(10):1063-7 (17 ref.)

The His1069Gln mutation in the ATP7B gene in Russian patients with Wilson disease [letter] Ivanova-Smolenskaya IA, et al. **J Med Genet** 1999 Feb;36(2):174

Molecular analysis and diagnosis in Japanese patients with Wilson's disease. Shimizu N, et al. **Pediatr Int** 1999 Aug; 41(4):409-13

Aceruloplasminemia. Gitlin JD. **Pediatr Res** 1998 Sep; 44(3):271-6 (60 ref.)

[Identification of a mutation hotspot in exon 8 of Wilson's disease gene by cycle sequencing] Xu Y, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1998 Oct 10;15(5):284-7 (Eng. Abstr.) **(Chi)**

[Identification of a novel missense mutation in Wilson disease gene] Yang R, et al. **Chung Hua I Hsueh Tsa Chih** 1997 May;77(5):344-7 (Eng. Abstr.) **(Chi)**

[Hemochromatosis and Wilson disease] Herrmann T, et al. **Internist (Berl)** 1999 May;40(5):513-21 (44 ref.) **(Ger)**

[Molecular biology analysis: hereditary hemochromatosis, Wilson disease, alpha 1-antitrypsin deficiency and Dubin-Johnson syndrome] Arnold C. **Schweiz Rundsch Med Prax** 1998 Oct 14;87(42):1390-6 (28 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

D-penicillamine-induced pancreatic islet autoantibody production is independent of the immunogenetic background: a lesson from patients with Wilson's disease. Kauschansky A, et al. **Clin Immunol Immunopathol** 1998 Dec;89(3):279-83

METABOLISM

Expression, purification, and metal binding characteristics of the putative copper binding domain from the Wilson disease copper transporting ATPase (ATP7B). DiDonato M, et al. **Adv Exp Med Biol** 1999;448:165-73 (19 ref.)

Genetic disorders of membrane transport. IV. Wilson's disease and Menkes disease. Schaefer M, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G311-4 (24 ref.)

A critical evaluation of copper metabolism in Indian Wilson's disease children with special reference to their phenotypes and relatives. Prasad R, et al. **Biol Trace Elem Res** 1998 Nov;65(2):153-65

Increased abundance of GABAA receptor subunit mRNAs in the brain of Long-Evans Cinnamon rats, an animal model of Wilson's disease. Follesa P, et al. **Brain Res Mol Brain Res** 1999 Jan 8;63(2):268-75

Value of histochemical stains for copper in the diagnosis of paediatric copper storage disorders [letter; comment] Sethi S. **Histopathology** 1999 May;34(5):471. Comment on: Histopathology 1998 Jul;33(1):28-33.

Copper and ceruloplasmin metabolism in the LEC rat, an animal model for Wilson disease. Kodama H, et al. **J Inherit Metab Dis** 1998 Jun;21(3):203-6

Magnetic resonance proton spectroscopy of the brain in Wilson's disease. Kraft E, et al. **J Neurol** 1999 Aug;

246(8):693–9
Iron depletion prevents adenine nucleotide decomposition and an increase of xanthine oxidase activity in the liver of the Long Evans Cinnamon (LEC) rat, an animal model of Wilson's disease. Sugawara N, et al. **Life Sci** 1999; 65(13):1423–31
Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Suzuki M, et al. **Pediatr Int** 1999 Aug;41(4):436–42 (26 ref.)
The effect of subcutaneous tetrathiomolybdate administration on copper and iron metabolism, including their regional redistribution in the brain, in the Long-Evans Cinnamon rat, a bona fide animal model for Wilson's disease. Sugawara N, et al. **Pharmacol Toxicol** 1999 May; 84(5):211–7
Differential expression of proteins associated with liver transplantation in Wilson's disease patients. Chiang KC, et al. **Transplant Proc** 1998 Nov;30(7):3263–4
[A case of neurologic type of Wilson's disease with increased aluminum in liver: comparative study with histological findings to metal contents in the liver] Yasui M, et al. **No To Shinkei** 1998 Aug;50(8):767–72 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Quantitative study of pathological forms of astroglia in Wilson's disease. Bertrand E, et al. **Folia Neuropathol** 1997; 35(4):227–32
Spontaneous cholangiofibrosis in Long-Evans Cinnamon rats: a rodent model for Wilson's disease. Schilsky ML, et al. **Lab Anim Sci** 1998 Apr;48(2):156–61
Wilson's disease: presymptomatic patients and Kayser-Fleischer rings [letter; comment] Kashani AA. **Ophthalmic Genet** 1998 Dec;19(4):215–8. Comment on: Ophthalmic Genet 1997 Jun;18(2):79–85.
Wilson's disease coexisting with viral hepatitis type C: a case report with histological and ultrastructural studies of the liver. Lembowicz K, et al. **Ultrastruct Pathol** 1999 Jan–Feb; 23(1):39–44
[Multiple histochemical methods in the diagnosis of Wilson's disease. (Presentation of 74 cases and review of the literature)] Lecca S, et al. **Pathologica** 1998 Dec;90(6):771–5 (31 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Oculogyric crisis as an initial manifestation of Wilson's disease. Lee MS, et al. **Neurology** 1999 May 12;52(8):1714–5
Wilson's disease: presymptomatic patients and Kayser-Fleischer rings [letter; comment] Kashani AA. **Ophthalmic Genet** 1998 Dec;19(4):215–8. Comment on: Ophthalmic Genet 1997 Jun;18(2):79–85.
Wilson's disease and Menkes disease. Aoki T. **Pediatr Int** 1999 Aug;41(4):403–4
Recovery of neurological deficits in a case of Wilson's disease after liver transplantation. Lui CC, et al. **Transplant Proc** 1998 Nov;30(7):3324–5
[Contrast analysis of brainstem auditory evoked potential in untreated and treated hepatolenticular degeneration patients with treatment of combining traditional Chinese and Western medicine] Xu SH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):17–9 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Wilson's disease before and after 5 years of treatment with D-penicillamine. Zachoval R, et al. **J Hepatol** 1998 Sep; 29(3):489

SURGERY

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease — possible association with a steroid-resistant transplant rejection episode. Lohse AW, et al. **J Hepatol** 1999 Jul;31(1):149–55
Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease [see comments] Asonuma K, et al. **Pediatr Transplant** 1999 Aug; 3(3):201–5. Comment in: Pediatr Transplant 1999 Aug;3(3):169–70.
This liver is a giver: Wilson disease and living related liver transplantation [editorial; comment] Rand EB. **Pediatr Transplant** 1999 Aug;3(3):169–70. Comment on: Pediatr Transplant 1999 Aug;3(3):201–5.
Liver transplantation for metabolic liver diseases. Khanna A, et al. **Surg Clin North Am** 1999 Feb;79(1):153–62, ix (61 ref.)
Differential expression of proteins associated with liver transplantation in Wilson's disease patients. Chiang KC, et al. **Transplant Proc** 1998 Nov;30(7):3263–4
Recovery of neurological deficits in a case of Wilson's disease after liver transplantation. Lui CC, et al. **Transplant Proc** 1998 Nov;30(7):3324–5
Indications and results of liver transplants in Wilson's disease. Robles R, et al. **Transplant Proc** 1999 Sep;31(6):2453–4

THERAPY

Wilson's disease: gall stone copper following liver transplantation. Walshe JM. **Ann Clin Biochem** 1998 Sep; 35 (Pt 5):681–2
Wilson's disease: copper unfettered. Pfeil SA, et al. **J Clin Gastroenterol** 1999 Jul;29(1):22–31 (78 ref.)
Treatment and management of Wilson's disease. Shimizu N, et al. **Pediatr Int** 1999 Aug;41(4):419–22 (21 ref.)
[Chronic acquired hepatocerebral degeneration: the role of manganese and treatment by endovascular occlusion of a porto-systemic shunt] Condat B, et al. **Gastroenterol Clin Biol** 1999 Feb;23(2):268–70 (Eng. Abstr.) **(Fre)**
[Treatment of chronic Wilson's disease in 2 patients using plasmapheresis--clinico-biochemical observations] Milovanović DD, et al. **Srp Arh Celok Lek** 1998 Sep–Oct; 126(9–10):327–34 (Eng. Abstr.) **(Scc)**

VETERINARY

MR imaging of hepatic injury in the LEC rat under a high magnetic field (7.05 T). Asanuma T, et al. **J Vet Med Sci** 1999 Mar;61(3):239–44

VIROLOGY

Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. Tagger A, et al. **Am J Gastroenterol** 1999 Feb;94(2):484–8

HEPATOLOGY see **GASTROENTEROLOGY**

HEPATOMA see **CARCINOMA, HEPATOCELLULAR**

HEPATOMA, BENIGN see **ADENOMA, LIVER CELL**

HEPATOMA, EXPERIMENTAL see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOMA, MORRIS see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOMA, NOVIKOFF see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOMEGALY

Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura. Patriarca F, et al. **Bone Marrow Transplant** 1999 Aug;24(4):433–5

CHEMICALLY INDUCED

The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Lenhard JM, et al. **Diabetologia** 1999 May;42(5):545–54
Dexamethasone-induced hepatomegaly in three children. Verrips A, et al. **Pediatr Neurol** 1998 Nov;19(5):388–91
Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. Acosta BS, et al. **South Med J** 1999 Apr;92(4):421–3
The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51

ETIOLOGY

Transient myeloproliferative disorder associated with trisomy 21: is a short course of chemotherapy indicated in patients with liver impairment and severe clinical problems? Rizzari C, et al. **Med Pediatr Oncol** 1999 Jun;32(6):453–4
Experience in the evaluation of children with hepatosplenomegaly at a teaching ambulatory, São Paulo, Brazil. Bricks LF, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):269–75
[Hepatosplenomegaly and large kidneys with renal failure] Viget N, et al. **Rev Med Interne** 1999;20 Suppl 2:299s–300s **(Fre)**
[Breastfeeding minor with persistent fever and visceromegaly (clinical conference)] Ridaura-Sanz C, et al. **Gac Med Mex** 1999 May–Jun;135(3):305–10 **(Spa)**

PATHOLOGY

New approaches to the quantitation of hypertrophy and hyperplasia in hepatomegaly. Carthew P, et al. **Toxicol Lett** 1998 Dec 28;102–103:411–5
The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51
Decreased apoptosis as a mechanism for hepatomegaly in streptozotocin-induced diabetic rats. Herrman CE, et al. **Toxicol Sci** 1999 Jul;50(1):146–51
[Fever, general malaise, adenopathies and hepatosplenomegaly in a 17-year-old woman after an allogeneic transplant of peripheral blood hematopoietic progenitors for chronic myeloid leukemia (clinical conference)] Conde E, et al. **Med Clin (Barc)** 1999 Jan 30; 112(3):106–14 **(Spa)**

RADIONUCLIDE IMAGING

Diffuse radiocolloid uptake in the bone marrow on thoracolumbar vertebrae extending to the skull, upper sternum, clavicles, long bones, and the lung secondary to lymphoma infiltration of the bone marrow. Shih WJ, et al. **Clin Nucl Med** 1999 Sep;24(9):712–3

ULTRASONOGRAPHY

Ultrasound findings in children with toxocariasis: report on 18 cases. Baldisserotto M, et al. **Pediatr Radiol** 1999 May; 29(5):316–9

HEPATOPANCREAS see **DIGESTIVE SYSTEM**

HEPATOPOIETIN see **HEPATOCYTE GROWTH FACTOR**

HEPATOPOIETIN A see **HEPATOCYTE GROWTH FACTOR**

HEPATOPULMONARY SYNDROME

The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Jones FD, et al. **Anesthesiology** 1999 Feb;90(2):626–9
The hepatopulmonary syndrome. Scott VL, et al. **Surg Clin North Am** 1999 Feb;79(1):23–41, vii (94 ref.)
[Hepatopulmonary syndrome] Aller de la Fuente R, et al. **Rev Clin Esp** 1999 Jun;199(6):391–8 (80 ref.) **(Spa)**
[Hepatopulmonary syndrome] López Aznar DJ, et al. **Rev Clin Esp** 1998 Dec;198(12):825–8 (43 ref.) **(Spa)**

COMPLICATIONS

Cardiopulmonary dysfunction in cirrhosis. Liu H, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):600–8 (87 ref.)
Hepatopulmonary syndrome associated with cardiorespiratory disease. Martinez G, et al. **J Hepatol** 1999 May;30(5):882–9
Brain abscess in hepatopulmonary syndrome. Molleston JP, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):225–6
Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Meyers C, et al. **Liver Transpl Surg** 1998 Nov;4(6):510–2
Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications. Egawa H, et al. **Transplantation** 1999 Mar 15;67(5):712–7

DIAGNOSIS

Evaluation of contrast echocardiography and lung perfusion scan in detecting intrapulmonary vascular dilatation in normoxemic patients with early liver cirrhosis. Mimidis KP, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2303–7
Diagnosis of hepatopulmonary syndrome with contrast transthoracic echocardiography and histological confirmation. Aller R, et al. **Liver** 1998 Aug;18(4):285–7
Hepatopulmonary syndrome. Müller C, et al. **Wien Klin Wochenschr** 1999 May 7;111(9):339–47 (96 ref.)

ETIOLOGY

Hepatopulmonary syndrome associated with sarcoidosis of the liver: case report. Ganguli SN, et al. **Can Assoc Radiol J** 1998 Dec;49(6):411–4
Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. Luo B, et al. **J Hepatol** 1998 Oct;29(4):571–8
Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. Mal H, et al. **J Hepatol** 1999 Aug;31(2):360–4
Late recurrence and rapid evolution of severe hepatopulmonary syndrome after liver transplantation. Krowka MJ, et al. **Liver Transpl Surg** 1999 Sep;5(5):451–3
Pulmonary arteriovenous shunting and pulmonary artery hypertension in children with liver disease. Bernard O. **Pediatr Pulmonol Suppl** 1999;18:88–90

METABOLISM

Exhaled nitric oxide and hepatopulmonary syndrome in a 6-year-old child. Azzolin N, et al. **Pediatrics** 1999 Aug; 104(2 Pt 1):299–300

PHYSIOPATHOLOGY

Hepatopulmonary syndrome associated with cardiorespiratory disease. Martinez G, et al. **J Hepatol** 1999 May;30(5):882–9
Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction [letter] Vettukattil JJ, et al. **J Hepatol** 1999 Jul;31(1):192–3

RADIOGRAPHY

Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. Lee KN, et al. **Radiology** 1999 May;211(2):549–53

RADIONUCLIDE IMAGING

Hepatopulmonary syndrome in Gaucher disease with right-to-left shunt: evaluation and measurement using Tc-99m MAA. Kim JH, et al. **Clin Nucl Med** 1999 Mar; 24(3):164–6

HEPATOPULMONARY SYNDROME

SURGERY

Effect of liver transplantation on hepatopulmonary syndrome. Orii T, et al. **Transplant Proc** 1998 Nov; 30(7):3254–5

THERAPY

Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. Abrams GA, et al. **J Clin Gastroenterol** 1998 Oct;27(3):232–5

ULTRASONOGRAPHY

Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. Aller R, et al. **Dig Dis Sci** 1999 Jun;44(6):1243–8

Localizing intrapulmonary shunt in hepatopulmonary syndrome by transesophageal echocardiography. Ho WJ, et al. **Jpn Heart J** 1999 May;40(3):369–74

HEPATORENAL GLYCOGEN STORAGE DISEASE see **GLYCOGEN STORAGE DISEASE TYPE I**

HEPATORENAL SYNDROME

BLOOD

Serum endothelin and atrial natriuretic peptide in cirrhotic patients with ascites and hepatorenal syndrome. Lo GH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):596–602

Plasma levels of arginine vasopressin in hepatorenal syndrome. Pasqualetti P, et al. **Panminerva Med** 1998 Dec; 40(4):294–8

COMPLICATIONS

Fetal enterolithiasis and anhydramnios; due to in utero hepatorenal syndrome? Achiron R, et al. **Prenat Diagn** 1998 Nov;18(11):1195–7

DIAGNOSIS

Hepatorenal syndrome. Ginès P, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1833–9 (33 ref.)

[Abdominal pain with ascites. Hepatorenal syndrome] Schwietert M. **Schweiz Rundsch Med Prax** 1999 May 12; 88(20):920–2 **(Ger)**

DRUG THERAPY

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Angeli P, et al. **Hepatology** 1999 Jun;29(6):1690–7

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Gülberg V, et al. **Hepatology** 1999 Oct;30(4):870–5

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Hadengue A, et al. **J Hepatol** 1998 Oct;29(4):565–70

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [letter] Kaffy F, et al. **J Hepatol** 1999 Jan;30(1):174

Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. Eisenman A, et al. **J Intern Med** 1999 Aug; 246(2):183–90

Improvement in renal function in hepatorenal syndrome with N-acetylcysteine [letter] Holt S, et al. **Lancet** 1999 Jan 23; 353(9149):294–5

[Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin] Gülberg V, et al. **Z Gastroenterol** 1998 Dec;36(12):1053–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [letter] Kaffy F, et al. **J Hepatol** 1999 Jan;30(1):174

Mechanism of hepatorenal syndrome in rats of Long-Evans Cinnamon strain, an animal model of fulminant Wilson's disease. Nomiyama K, et al. **Toxicology** 1999 Feb 15; 132(2–3):201–14

[An unusual cause of hepatorenal symptoms] Frank H, et al. **Med Klin** 1999 May 15;94(5):274–8 (Eng. Abstr.) **(Ger)**

METABOLISM

The hepato-renal syndrome: renal amino acid transport in bile duct ligated rats (DL)--influence of treatment with triiodothyronine or dexamethasone on renal amino acid handling in amino acid loaded rats. Fleck C, et al. **Exp Toxicol Pathol** 1998 Sep;50(4–6):356–64

MICROBIOLOGY

Comparison of darkground microscopy with serological tests in the diagnosis of leptospirosis with hepatorenal involvement--A preliminary study. Rao PS, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):427–9

PHYSIOPATHOLOGY

Hepatorenal syndrome and ascites--questions and answers. Bernardi M, et al. **Liver** 1999;19(1 Suppl):15–74

Hepatorenal syndrome and ascites--an introduction. Gentilini P. **Liver** 1999;19(1 Suppl):5–14 (102 ref.)

SURGERY

More therapy for hepatorenal syndrome. Blendis L, et al. **Gastroenterology** 1999 May;116(5):1264–6

THERAPY

More therapy for hepatorenal syndrome. Blendis L, et al. **Gastroenterology** 1999 May;116(5):1264–6

Hepatorenal syndrome. Ginès P, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1833–9 (33 ref.)

[The therapy of the hepatorenal syndrome in liver cirrhosis] Biecker E, et al. **Dtsch Med Wochenschr** 1999 Sep 10; 124(36):1039–42 (26 ref.) **(Ger)**

HEPATOVIRUS

Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. Steele RW. **Clin Pediatr (Phila)** 1998 Dec;37(12):759–60

CHEMISTRY

Conformational changes in the hepatitis A virus capsid in response to acidic conditions. Bishop NE. **J Med Microbiol** 1999 May;48(5):443–50

Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. Graff J, et al. **J Virol** 1999 Jul;73(7):6015–23

DRUG EFFECTS

Examination of potential inhibitors of hepatitis A virus uncoating. Bishop NE. **Intervirology** 1998;41(6):261–71

GENETICS

Quantification of hepatitis A virus in shellfish by competitive reverse transcription–PCR with coextraction of standard RNA. Arnal C, et al. **Appl Environ Microbiol** 1999 Jan; 65(1):322–6

Avian encephalomyelitis virus is a picornavirus and is most closely related to hepatitis A virus. Marvil P, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):653–62

Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. De Serres G, et al. **J Infect Dis** 1999 Jan;179(1):37–43

Interaction of poly(rC) binding protein 2 with the 5' noncoding region of hepatitis A virus RNA and its effects on translation. Graff J, et al. **J Virol** 1998 Dec; 72(12):9668–75

Genomic classification and genetic relationships of a new variant of hepatitis A virus isolated in Cuba. Diaz BI, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun;94(3):361–3

A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team [see comments] Hutin YJ, et al. **N Engl J Med** 1999 Feb 25;340(8):595–602. Comment in: N Engl J Med 1999 Feb 25;340(8):644–5.

Folding of pyrimidine-enriched RNA fragments from the vicinity of the internal ribosomal entry site of hepatitis A virus. Hardin CC, et al. **Nucleic Acids Res** 1999 Jan 15; 27(2):665–73

Proof of hepatitis A virus negative-sense RNA by RNA/DNA-hybrid detection: a method for specific detection of both viral negative- and positive-strand RNA species. Schmitz G, et al. **Nucleic Acids Res** 1998 Nov 15; 26(22):5230–2

Hepatitis A virus translation is rate-limiting for virus replication in MRC-5 cells. Funkhouser AW, et al. **Virology** 1999 Feb 15;254(2):268–78

Sensitivity of PCR assays for the determination of hepatitis A virus RNA in plasma pools. A collaborative study [see comments] Saldanha J. **Vox Sang** 1999;76(3):163–5. Comment in: Vox Sang 1999 ;76(3):135–7.

[Detection of HAV, SRSV and astrovirus genomes from native oysters in Chiba City, Japan] Kitahashi T, et al. **Kansenshogaku Zasshi** 1999 Jun;73(6):559–64 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Fujisawa T, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2094–9

Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. Hau CH, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):277–80

Comparison of the reactogenicity and immunogenicity of two different dose levels of hepatitis A vaccine in healthy children and adolescents. Poovorawan Y, et al. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2-3):111–7

Hepatitis A vaccine: evidence of efficacy after exposure. **Commun Dis Rep CDR Wkly** 1999 Apr 16;9(16):139, 142

Lack of evidence for increased risk of hepatitis A infection in homosexual men. Corona R, et al. **Epidemiol Infect** 1999 Aug;123(1):89–93

Enhancement of the immunogenicity of a synthetic peptide bearing a VP3 epitope of hepatitis A virus. Pintó RM, et al. **FEBS Lett** 1998 Oct 30;438(1–2):106–10

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Das A. **Hepatology** 1999 Feb;29(2):548–52

Prevalence of hepatitis A in an institution for the mentally retarded in an intermediate endemicity area: influence of age length of institutionalization. Gil A, et al. **J Infect** 1999 Mar;38(2):120–3

A dose response study of hepatitis A vaccine in healthy adults who are > or = 30 years old and weigh > or = 77 kg. Bertino JS Jr, et al. **J Infect Dis** 1998 Oct;178(4):1181–4

Prevalence and determinants of hepatitis A virus exposure among prison entrants in Queensland, Australia: implications for public health control. Whiteman D, et al. **J Viral Hepat** 1998 Jul;5(4):277–83

Vaccination against hepatitis A [letter; comment] Katz SL. **N Engl J Med** 1999 Jul 22;341(4):293. Comment on: N Engl J Med 1999 Feb 25;340(8):644–5.

Inflammatory arthritis after hepatitis A immunization [letter; comment] Maillefert JF, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):598. Comment on: Rev Rhum Engl Ed 1997 Apr;64(4):227–32.

Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Ashur Y, et al. **Vaccine** 1999 May 4;17(18):2290–6

Long-term follow-up of hepatitis A vaccination in children. Chan CY, et al. **Vaccine** 1999 Jan 28;17(4):369–72

Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Dagan R, et al. **Vaccine** 1999 Apr 9;17(15–16):1919–25

Antigenic epitopes of the hepatitis A virus polyprotein. Khudyakov YE, et al. **Virology** 1999 Aug 1;260(2):260–72

[Experimental in vivo passage of H2 strain of live attenuated vaccine of hepatitis A in common marmosets] Huang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep; 31(5):260–2 (Eng. Abstr.) **(Chi)**

[Adult-onset Still's disease after hepatitis A and B vaccination?] Grasland A, et al. **Rev Med Interne** 1998 Feb; 19(2):134–6 (Eng. Abstr.) **(Fre)**

[Recommendations for the use of the hepatitis A vaccine in day care centers. Committee on Vaccines of the Spanish Pediatric Society and Spanish Association for the Study of the Liver] **Gastroenterol Hepatol** 1998 Aug-Sep; 21(7):346–51 **(Spa)**

[Prevalence of anti-hepatitis A in patients with chronic liver disease] Diago M, et al. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):324–6 (Eng. Abstr.) **(Spa)**

[Indications and prescription of hepatitis A vaccine in Spain. Report of the Spanish Association for the Study of the Liver] Bruguera M, et al. **Med Clin (Barc)** 1998 Sep 26; 111(9):341–6 **(Spa)**

[Serum antibodies against hepatitis A virus among subjects of middle and low socioeconomic levels in urban area of Santiago, Chile] Lagos R, et al. **Rev Med Chil** 1999 Apr; 127(4):429–36 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Quantification of hepatitis A virus in shellfish by competitive reverse transcription–PCR with coextraction of standard RNA. Arnal C, et al. **Appl Environ Microbiol** 1999 Jan; 65(1):322–6

Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Robertson BH, et al. **Biologicals** 1998 Jun;26(2):95–9 (26 ref.)

Detection of hepatitis A virus in shellfish by nested reverse transcription–PCR. Croci L, et al. **Int J Food Microbiol** 1999 Apr 1;48(1):67–71

Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. De Serres G, et al. **J Infect Dis** 1999 Jan;179(1):37–43

Comparison of seven RNA extraction methods on stool and shellfish samples prior to hepatitis A virus amplification. Arnal C, et al. **J Virol Methods** 1999 Jan;77(1):17–26

Recovery and detection of enterovirus, hepatitis A virus and Norwalk virus in hardshell clams (Mercenaria mercenaria) by RT–PCR methods. Suñén E, et al. **J Virol Methods** 1999 Feb;77(2):179–87

Seroprevalence of hepatitis A in children--implications for hepatitis A vaccine. Mittal SK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):120–1

[An outbreak caused by hepatitis A virus in an institution for the mentally handicapped--detection of hepatitis A virus RNA using CTAB method] Kitahashi T, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):794–800 (Eng. Abstr.) **(Jpn)**

[Purification and proteic characterization of a Cuban strain of the hepatitis A virus] Díaz Mendiondo BI, et al. **Rev Cubana Med Trop** 1996;48(2):123–9 (Eng. Abstr.) **(Spa)**

[Isolation of hepatitis A virus in tissue culture. Preliminary report (letter)] Más Lago P, et al. **Rev Cubana Med Trop** 1991;43(3):206–7 **(Spa)**

METABOLISM

Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A. Probst C, et al. **J Biol Chem** 1999 Feb 19;274(8):4527–31

Interaction of poly(rC) binding protein 2 with the 5' noncoding region of hepatitis A virus RNA and its effects on translation. Graff J, et al. **J Virol** 1998 Dec; 72(12):9668–75

Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. Martin A, et al. **J Virol** 1999 Aug;73(8):6220–7

PATHOGENICITY

Membrane permeability induced by hepatitis A virus proteins 2B and 2BC and proteolytic processing of HAV 2BC. Jecht M, et al. **Virology** 1998 Dec 5;252(1):218-27

PHYSIOLOGY

Increased infectivity of hepatitis A virus cDNA clones with engineered 5'-terminal extra-cistronic sequences. Silveira Carneiro J, et al. **New Microbiol** 1998 Oct;21(4):321-7

Persistence of infectious hepatitis A virus and its genome in artificial seawater. Arnal C, et al. **Zentralbl Hyg Umweltmed** 1998 Sep;201(3):279-84

HEPES

Physiological HEPES buffer proposed as a calibrator for pH measurement in human blood. Lang W, et al. **Clin Chem Lab Med** 1999 May;37(5):563-71

ANALYSIS

Validation of analytical capillary electrophoresis methods for use in a regulated environment. Wielgos T, et al. **J Capillary Electrophor** 1997 Nov-Dec;4(6):273-8

PHARMACOLOGY

[Optimum choice for the cultivation of CFU-GM in media buffered with HEPES] Jiang D, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):99-101 **(Chi)** (Eng. Abstr.)

HEPTACHLOR

PHARMACOLOGY

Effect of lindane and heptachlor on delta-aminolaevulinate synthase and its regulation. Taira MC, et al. **Arch Toxicol** 1998 Nov;72(11):722-30

HEPTANES

CHEMISTRY

1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives. Jeppesen L, et al. **J Med Chem** 1999 Jun 3;42(11):1999-2006

Hydrogen bonding. 47. Characterization of the ethylene glycol-heptane partition system: hydrogen bond acidity and basicity of peptides. Abraham MH, et al. **J Pharm Sci** 1999 Feb;88(2):241-7

METABOLISM

Influence of hydration degree of aerosol OT reversed micelles in heptane on inhibitory effect of gallic acid polydisulfide in peroxidase-dependent oxidation of 3,3;,5,5;-tetramethylbenzidine. Karasyova EI, et al. **Biochemistry (Mosc)** 1999 Jan;64(1):54-60

HEPTANOATES

ANALYSIS

Genotyping of a case of tyrosinaemia type I with normal level of succinylacetone in amniotic fluid. Poudrier J, et al. **Prenat Diagn** 1999 Jan;19(1):61-3

HEPTANOIC ACIDS

[Thromboxane A2 antagonist--discovery of seratrodast] Terao S, et al. **Yakugaku Zasshi** 1999 May;119(5):377-90 **(Jpn)** (26 ref.) (Eng. Abstr.)

[Atorvastatin . A new generation of hypolipemic agents?] Azanza JR, et al. **Rev Med Univ Navarra** 1998 Jan-Mar; 42(1):51-5 (35 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Crouse JR 3rd, et al. **Am J Cardiol** 1999 May 15; 83(10):1476-7, A7

More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia [letter] Bertolotto A, et al. **Atherosclerosis** 1999 Apr;143(2):455-7

Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Alfon J, et al. **Thromb Haemost** 1999 May;81(5):822-7

ADVERSE EFFECTS

Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves [letter] Jiménez-Alonso J, et al. **Arch Intern Med** 1999 Aug 9-23;159(15):1811-2

Atorvastatin-induced severe thrombocytopenia [letter] González-Ponte ML, et al. **Lancet** 1998 Oct 17; 352(9136):1284

Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin [letter] Nakad A, et al. **Lancet** 1999 May 22;353(9166):1763-4

Cholestatic liver dysfunction [letter] Wierzbicki AS, et al. **Lancet** 1999 Sep 11;354(9182):954

BLOOD

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Lilja JJ, et al. **Clin Pharmacol Ther** 1999 Aug;66(2):118-27

Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. Bullen WW, et al. **J Am Soc Mass Spectrom** 1999 Jan; 10(1):55-66

Erythromycin coadministration increases plasma atorvastatin concentrations. Siedlik PH, et al. **J Clin Pharmacol** 1999 May;39(5):501-4

Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Jemal M, et al. **Rapid Commun Mass Spectrom** 1999;13(11):1003-15

CHEMICAL SYNTHESIS

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds. Takeuchi K, et al. **J Med Chem** 1998 Dec 31;41(27):5362-74

PHARMACOKINETICS

Metabolism and excretion of atorvastatin in rats and dogs. Black AE, et al. **Drug Metab Dispos** 1999 Aug;27(8):916-23

PHARMACOLOGY

Effect of atorvastatin on low-density lipoprotein subfraction profile. Landray MJ, et al. **Ann Clin Biochem** 1999 Mar; 36 (Pt 2):240-1

Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Alfon J, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1812-7

The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Burnett JR, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec; 18(12):1906-14

Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Conde K, et al. **Biochem Pharmacol** 1999 Oct 1;58(7):1209-19

Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery. He GW, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):207-15

Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates. Matsuno H, et al. **Br J Pharmacol** 1999 Jul;127(5):1129-34

Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Verd JC, et al. **Br J Pharmacol** 1999 Jul;127(6):1479-85

Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma. Hoshino M, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1054-61

Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. Stern RH, et al. **J Clin Pharmacol** 1998 Aug;38(8):753-7

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Wilcox LJ, et al. **J Lipid Res** 1999 Jun;40(6):1078-89

AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. Walsh SW, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):220-6

Effects of thromboxane A2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics. Aizawa H, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Sep; 59(3):185-90

THERAPEUTIC USE

Atorvastatin for protease inhibitor-related hyperlipidaemia [letter] Murillas J, et al. **AIDS** 1999 Jul 30;13(11):1424-5

Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). März W, et al. **Am J Cardiol** 1999 Jul 1;84(1):7-13

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski JM. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2253-67; quiz 2302-3 (90 ref.)

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS, et al. **Ann Pharmacother** 1998 Oct;32(10):1030-43 (99 ref.)

Atorvastatin in the management of an index patient with complete hepatic lipase deficiency [letter] Hegele RA, et al. **Atherosclerosis** 1999 Mar;143(1):219-22

Atorvastatin and fibrinogen--a small subgroup shows extreme response [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Aug;145(2):415-7

Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. Obase Y, et al. **Chest** 1998 Oct;114(4):1028-32

Therapy and clinical trials [editorial] Bachorik PS. **Curr Opin Lipidol** 1998 Oct;9(5):515-7

Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Naoumova RP, et al. **Eur J Clin Invest** 1999 May;29(5):404-12

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Bustos C, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2057-64

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Bairaktari ET, et al. **J Cardiovasc Risk** 1999 Apr;6(2):113-6

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. Hunninghake D, et al. **J Fam Pract** 1998 Nov; 47(5):349-56

Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Geiss HC, et al. **J Intern Med** 1999 Jan; 245(1):47-55

Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Hoogerbrugge N. **J Intern Med** 1998 Aug;244(2):143-7

Effect of statins on C-reactive protein in patients with coronary artery disease [letter] [see comments] Strandberg TE, et al. **Lancet** 1999 Jan 9;353(9147):118-9. Comment in: Lancet 1999 Apr 10;353(9160):1274. Comment in: Lancet 1999 Apr 10;353(9160):1274-5.

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. Pitt B, et al. **N Engl J Med** 1999 Jul 8;341(2):70-6

No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin [letter] Singhal MK, et al. **Perit Dial Int** 1999 Jan-Feb;19(1):89-91

Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation. Alvarez ML, et al. **Transplant Proc** 1999 Sep;31(6):2328-9

[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?] **Internist (Berl)** 1999 Mar;40(3 Suppl Gibt Es):1-4 **(Ger)**

[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering] **Z Kardiol** 1999 Mar;88(3 Suppl):1-4 **(Ger)**

[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia] Liguori E, et al. **Minerva Cardioangiol** 1998 Sep;46(9):317-8 **(Ita)**

TOXICITY

Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Walsh KM, et al. **Toxicol Pathol** 1999 Jul-Aug;27(4):395-401

HEPTANOL

ANALOGS & DERIVATIVES

Isolation and structure elucidation of new PKCalpha inhibitors from Pinus flexilis. Lee KK, et al. **J Nat Prod** 1998 Nov;61(11):1407-9

PHARMACOLOGY

Further evidence for the selective disruption of intercellular communication by heptanol. Christ GJ, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1911-7

Effects of heptanol on the neurogenic and myogenic contractions of the guinea-pig vas deferens. Venkateswarlu K, et al. **Br J Pharmacol** 1999 Jan;126(1):227-34

Heptanol exerts epileptiform effects in identified neurons of the buccal ganglia of Helix pomatia. Tarner IH, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):73-6

N-HEPTANOL see **HEPTANOL**

1-HEPTANOL see **HEPTANOL**

HEPTOSES

ANALYSIS

Synthesis and serological characterization of L-glycero-alpha-D-manno-heptopyranose-containing di- and tri-saccharides of the non-reducing terminus of the Escherichia coli K-12 LPS core oligosaccharide. Antonov KV, et al. **Carbohydr Res** 1998 Dec 21;314(1-2):85-93

HER-2 PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

HERALDRY

HERALDRY see **GENEALOGY AND HERALDRY**

HERBAL TEAS see **BEVERAGES**

HERBALISM see **MEDICINE, HERBAL**

HERBALS see **MEDICINE, HERBAL**

HERBICIDES

Herbicide and insecticide exposures among dairy farm pesticide applicators [letter] Perry MJ, et al. **Am J Public Health** 1999 Jul;89(7):1118–9

Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brooks AI, et al. **Brain Res** 1999 Mar 27;823(1–2):1–10

Pesticide use in the U.S. and policy implications: a focus on herbicides. Short P, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):240–75

ADVERSE EFFECTS

Airspace configuration at different transpulmonary pressures in normal and paraquat-induced lung injury in rats. Silva MF, et al. **Am J Respir Crit Care Med** 1998 Oct; 158(4):1230–4

Incidence rates of lymphomas and environmental measurements of phenoxy herbicides: ecological analysis and case–control study. Fontana A, et al. **Arch Environ Health** 1998 Nov–Dec;53(6):384–7

A case–control study of non-Hodgkin lymphoma and exposure to pesticides [letter] Acquavella J, et al. **Cancer** 1999 Aug 15;86(4):729–31

Promotion of NCI-Black-Reiter male rat bladder carcinogenesis by dimethylarsinic acid an organic arsenic compound. Li W, et al. **Cancer Lett** 1998 Dec 11; 134(1):29–36

Cytogenetic characteristics of herbicide production workers in Ufa. Kaioumova DF, et al. **Chemosphere** 1998 Oct–Nov; 37(9–12):1755–9

Herbicide (Roundup) pneumonitis. Pushnoy LA, et al. **Chest** 1998 Dec;114(6):1769–71

The estrogen-like effect of herbicides: a patient report. Barnard RJ, et al. **Clin Pediatr (Phila)** 1998 Oct; 37(10):633–4

Cytotoxic effect of paraquat on rat C6 glioma cells: evidence for the possibility of non-oxidative damage to the cells. Morita K, et al. **Jpn J Pharmacol** 1999 Jan;79(1):121–4

Long-term respiratory health effects of the herbicide, paraquat, among workers in the Western Cape. Dalvie MA, et al. **Occup Environ Med** 1999 Jun;56(6):391–6

Herbicides and adjuvants: an evolving view. Garry VF, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):159–67

Immune parameters in biological monitoring of pesticide exposure: current knowledge and perspectives. Colosio C, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):285–95 (28 ref.)

Re-analysis of 2,4-D use and the occurrence of canine malignant lymphoma. Kaneene JB, et al. **Vet Hum Toxicol** 1999 Jun;41(3):164–70

[Intoxications caused by plant protection chemicals in 1997] Przybylska A. **Przegl Epidemiol** 1999;53(1–2):121–8 (Eng. Abstr.) **(Pol)**

[Pneumocystis carinii pneumonia in an immunocompetent patient after paraquat spraying (letter)] Lillo A, et al. **An Med Interna** 1999 Jul;16(7):381 (9 ref.) **(Spa)**

ANALYSIS

Quantitative analysis of alachlor protein adducts by gas chromatography–mass spectrometry. Lambert GR, et al. **Anal Biochem** 1999 Mar 15;268(2):289–96

An immunomagnetic electrochemical sensor based on a perfluorosulfonate-coated screen-printed electrode for the determination of 2,4-dichlorophenoxyacetic acid. Dequaire M, et al. **Anal Chem** 1999 Jul 1;71(13):2571–7

Double-disk solid-phase extraction: simultaneous cleanup and trace enrichment of herbicides and metabolites from environmental samples. Ferrer I, et al. **Anal Chem** 1999 Mar 1;71(5):1009–15

Imprinted polymer-based sensor system for herbicides using differential-pulse voltammetry on screen-printed electrodes. Kröger S, et al. **Anal Chem** 1999 Sep 1; 71(17):3698–702

Immunoassay techniques for detection of the herbicide simazine based on use of oppositely charged water-soluble polyelectrolytes. Yazynina EV, et al. **Anal Chem** 1999 Aug 15;71(16):3538–43

Sensitive determination of paraquat and diquat at the sub-ng ml-1 level by continuous amperometric flow methods. Luque M, et al. **Analyst** 1998 Nov;123(11):2383–7

Spectrofluorimetric determination of paraquat by manual and flow injection methods. Pérez-Ruiz T, et al. **Analyst** 1998 Jul;123(7):1577–81

Laccase from Coriolus hirsutus as alternate label for enzyme immunoassay. Determination of pesticide 2,4-dichlorophenoxyacetic acid. Zherdev AV, et al. **Appl Biochem Biotechnol** 1999 Mar;76(3):203–15

Health hazard evaluation of methyl bromide soil fumigations. Lenhart SW, et al. **Appl Occup Environ Hyg** 1999 Jul; 14(7):407–12

The environmental occurrence of herbicides: the importance of degradates in ground water. Kolpin DW, et al. **Arch Environ Contam Toxicol** 1998 Oct;35(3):385–90

Glove permeation tests using novel microchemical techniques for 2, 4-dichlorophenoxyacetic acid (2,4-D) derivatives. Lin YW, et al. **Arch Environ Contam Toxicol** 1999 May; 36(4):485–9

A sensitive photosystem II-based biosensor for detection of a class of herbicides. Koblizek M, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):664–9

Efficiency of grass buffer strips and cropping system on off-site Dacthal movement. Antonious GF. **Bull Environ Contam Toxicol** 1999 Jul;63(1):25–32

Use of ozone to remove alachlor from surface water. Beltrán F, et al. **Bull Environ Contam Toxicol** 1999 Mar;62(3):324–9

Residue analysis of imazapyr and chlozolinate in water using sunlight. Santoro A, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):33–8

Atrazine and metolachlor residues in Brookston CL following conventional and conservation tillage culture. Gaynor JD, et al. **Chemosphere** 1998 Jun;36(15):3199–210

The carry-through of residues of maleic hydrazide from treated potatoes, following manufacture into potato crisps and 'jacket' potato crisps. Lewis DJ, et al. **Food Addit Contam** 1998 Jul;15(5):506–9

Capillary electrophoresis determinative and LC–MS confirmatory method for screening selected imidazolinone herbicides from soil. Nejad H, et al. **J Capillary Electrophor** 1998 Jan–Apr;5(1–2):81–7

Ion-pair liquid chromatography--atmospheric pressure ionization mass spectrometry for the determination of quaternary ammonium herbicides. Castro R, et al. **J Chromatogr A** 1999 Jan 8;830(1):145–54

Rapid determination of glyphosate in cereal samples by means of pre-column derivatisation with 9-fluorenylmethyl chloroformate and coupled-column liquid chromatography with fluorescence detection. Hogendoorn EA, et al. **J Chromatogr A** 1999 Feb 12;833(1):67–73

Analysis and degradation study of glyphosate and of aminomethylphosphonic acid in natural waters by means of polymeric and ion-exchange solid-phase extraction columns followed by ion chromatography-post-column derivatization with fluorescence detection. Mallat E, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):129–36

Determination of chlorinated acid herbicides and related compounds in water by capillary electrophoresis–electrospray negative ion mass spectrometry. Song X, et al. **J Chromatogr A** 1998 Dec 31;829(1–2):327–40

Headspace solid-phase microextraction and gas chromatographic determination of dinitroaniline herbicides in human blood, urine and environmental water. Guan F, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 4; 714(2):205–13

High-performance liquid chromatography column switching applied to the trace determination of herbicides in environmental and drinking water samples. Nemth Konda L, et al. **J Chromatogr Sci** 1999 Mar;37(3):71–6

Runoff and leaching of atrazine and alachlor on a sandy soil as affected by application in sprinkler irrigation. Abdel-Rahman AR, et al. **J Environ Sci Health B** 1999 May;34(3):381–96

Pesticide contamination of ground and surface water in Bulgarian Danube plain. Balinova AM, et al. **J Environ Sci Health B** 1999 Jan;34(1):33–46

Atrazine, alachlor, and total inorganic nitrogen concentrations of winter wind-eroded sediment samples. DeSutter TM, et al. **J Environ Sci Health B** 1998 Nov; 33(6):683–91

Simultaneous analysis of triasulfuron, metsulfuron-methyl and chlorsulfuron in water and alkaline soils by high-performance liquid chromatography. Sarmah AK, et al. **J Environ Sci Health B** 1999 May;34(3):363–80

Herbicide residues in grapes and wine. Ying GG, et al. **J Environ Sci Health B** 1999 May;34(3):397–411

Spatial and temporal variations of herbicide (triazines and phenylureas) concentrations in the catchment basin of the Marne river (France). Garmouma M, et al. **Sci Total Environ** 1998 Dec 11;224(1–3):93–107

CHEMICAL SYNTHESIS

Rational herbicide design by inhibition of tryptophan biosynthesis. Finn J, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2297–302

CHEMISTRY

The design and synthesis of inhibitors of adenosine 5'-monophosphate deaminase. Lindell SD, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):1985–90

Reduction of norflurazon leaching in a sandy soil by adjuvants. Chandran RS, et al. **Bull Environ Contam Toxicol** 1999 Mar;62(3):315–23

Effect of simulated sunlight on atrazine and metolachlor toxicity of surface waters. Lin YJ, et al. **Ecotoxicol Environ Saf** 1999 May;43(1):35–7

Abiotic degradation of halobenzonitriles: investigation of the photolysis in solution. Millet M, et al. **Ecotoxicol Environ Saf** 1998 Sep;41(1):44–50

OH radical reactivity of pesticides adsorbed on aerosol materials: first results of experiments with filter samples. Palm WU, et al. **Ecotoxicol Environ Saf** 1998 Sep; 41(1):36–43

Light regime, riboflavin, and pH effects on 2,4-D photodegradation in water. Harrison SK, et al. **J Environ Sci Health B** 1999 May;34(3):469–89

Control of photoinduced electron transfer from zinc-porphyrin to methyl viologen by supramolecular formation between monoclonal antibody and zinc-porphyrin. Harada A, et al. **Photochem Photobiol** 1999 Sep;70(3):298–302

Structures of herbicides in complex with their detoxifying enzyme glutathione S-transferase - explanations for the selectivity of the enzyme in plants. Prade L, et al. **Structure** 1998 Nov 15;6(11):1445–52

ISOLATION & PURIFICATION

Use of ozone and hydrogen peroxide to remove alachlor from surface water. Beltrán F, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):9–14

Acremolactone A, a novel herbicidal epoxydihydropyranyl gamma-lactone from Acremonium roseum I4267 [letter] Sassa T, et al. **J Antibiot (Tokyo)** 1998 Oct;51(10):967–9

Improving the solid-phase extraction of "quat" pesticides from water samples. Removal of interferences. Ibáñez M, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):137–46

METABOLISM

Characterization of two novel propachlor degradation pathways in two species of soil bacteria. Martin M, et al. **Appl Environ Microbiol** 1999 Feb;65(2):802–6

Uptake of the herbicidal glyphosate by Escherichia coli K-12. Cherepenko E, et al. **Biosci Rep** 1999 Feb;19(1):43–9

Sulcotrione soil metabolism in summer corn crops. Rouchaud J, et al. **Bull Environ Contam Toxicol** 1998 Nov; 61(5):669–76

In vitro metabolism of alachlor by human liver microsomes and human cytochrome P450 isoforms. Coleman S, et al. **Chem Biol Interact** 1999 Aug 30;122(1):27–39

Bioavailability of 2,4-D sorbed to a chlorite-like complex. McGhee I, et al. **Chemosphere** 1999 Jul;39(2):285–91

Simulation of herbicide degradation in different soils by use of Pedo-transfer functions (PTF) and non-linear kinetics. von Götz N, et al. **Chemosphere** 1999 Mar;38(6):1401–7

Etherolytic cleavage of 4-(2,4-dichlorophenoxy)butyric acid and 4-(4-chloro-2-methylphenoxy)butyric acid by species of Rhodococcus and Aureobacterium isolated from an alkaline environment. Mertingk H, et al. **J Basic Microbiol** 1998;38(4):257–267

Leaching of mecoprop and dichlorprop in calcareous soil. Effect of the exogen organic matter addition in this process. Matallo M, et al. **J Environ Sci Health B** 1999 Jul; 34(4):617–32

Evidence of a strong interaction of 2,4-dichlorophenoxyacetic acid herbicide with human serum albumin. Rosso SB, et al. **Life Sci** 1998; 63(26):2343–51

Evidence for site-specific bioactivation of alachlor in the olfactory mucosa of the Long-Evans rat. Wetmore BA, et al. **Toxicol Sci** 1999 Jun;49(2):202–12

PHARMACOKINETICS

Herbicide mobility using soil leaching columns. Futch SH, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):520–9

Effects of elevated ozone concentration on the degradation of dichlorprop in soil. Haberhauer G, et al. **Chemosphere** 1999 Oct;39(9):1459–66

Effects of culture parameters on the degradation of 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4-dichlorophenol (2,4-DCP) by selected fungi. Groupe pour l'Etude du Devenir des Xénobiotiques dans l'Environnement (GEDEXE). Vroumsia T, et al. **Chemosphere** 1999 Oct;39(9):1397–405

Plant and soil enantioselective biodegradation of racemic phenoxyalkanoic herbicides. Schneiderheinze JM, et al. **Chirality** 1999;11(4):330–7

The renal excretory mechanisms and the role of organic cations in modulating the renal handling of paraquat. Chan BS, et al. **Pharmacol Ther** 1998 Sep;79(3):193–203 (69 ref.)

Transport of paraquat by isolated renal proximal tubular segments from rabbits. Mølck AM, et al. **Pharmacol Toxicol** 1998 Nov;83(5):208–13

Expression of a soybean cytochrome P450 monooxygenase cDNA in yeast and tobacco enhances the metabolism of phenylurea herbicides. Siminszky B, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1750–5

PHARMACOLOGY

Mutagenesis of Escherichia coli acetohydroxyacid synthase isoenzyme II and characterization of three herbicide-insensitive forms. Hill CM, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):653–61

Purification and characterization of maleylacetate reductase from Nocardioides simplex 3E utilizing phenoxyalcanoic herbicides 2,4-D and 2,4,5-T. Travkin VM, et al. **Biochemistry (Mosc)** 1999 Jun;64(6):625–30

Oxidation of NADH by intact segments of soybean hypocotyls and stimulation by 2,4-D. Hicks C, et al. **Biochim Biophys Acta** 1998 Oct 15;1375(1–2):1–5

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by sethoxydim, a potent inhibitor of acetyl-coenzyme A carboxylase. Lin S, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):551–4

Herbicide resistance and supersensitivity in photosystem II. Oettmeier W. **Cell Mol Life Sci** 1999 Aug 15;55(10):1255–77

(141 ref.)
Effect of mutagenesis at serine 653 of Arabidopsis thaliana acetohydroxyacid synthase on the sensitivity to imidazolinone and sulfonylurea herbicides. Lee YT, et al. **FEBS Lett** 1999 Jun 11;452(3):341-5
Inhibitors of branched-chain amino acid biosynthesis as potential antituberculosis agents. Grandoni JA, et al. **J Antimicrob Chemother** 1998 Oct;42(4):475-82
Activation of hepatic NF-kappaB by the herbicide Dicamba (2-methoxy-3,6-dichlorobenzoic acid) in female and male rats. Espandiari P, et al. **J Biochem Mol Toxicol** 1998; 12(6):339-44
Locoweed grazing. Ralphs MH, et al. **J Nat Toxins** 1999 Feb;8(1):47-51 (42 ref.)
Paraquat induced activation of transcription factor AP-1 and apoptosis in PC12 cells. Li X, et al. **J Neural Transm** 1999; 106(1):1-21
Dynamics of multigene expression during catabolic adaptation of Ralstonia eutropha JMP134 (pJP4) to the herbicide 2, 4-dichlorophenoxyacetate. Leveau JH, et al. **Mol Microbiol** 1999 Jul;33(2):396-406
Dinitroaniline herbicide-resistant transgenic tobacco plants generated by co-overexpression of a mutant alpha-tubulin and a beta-tubulin. Anthony RG, et al. **Nat Biotechnol** 1999 Jul;17(7):712-6
Effects of trifluralin on Trypanosoma cruzi in vitro and in vivo. Zaidenberg A, et al. **Pharmacol Toxicol** 1999 Feb; 84(2):98-100
Isolation and characterization of a mutant protoporphyrinogen oxidase gene from Chlamydomonas reinhardtii conferring resistance to porphyric herbicides. Randolph-Anderson BL, et al. **Plant Mol Biol** 1998 Nov; 38(5):839-59
Molecular characterization of four beta-tubulin genes from dinitroaniline susceptible and resistant biotypes of Eleusine indica. Yamamoto E, et al. **Plant Mol Biol** 1999 Jan; 39(1):45-61
An introduction to ALS-inhibiting herbicides. Whitcomb CE. **Toxicol Ind Health** 1999 Jan-Mar;15(1-2):231-9 (114 ref.)
Apicomplexan plastids as drug targets. McFadden GI, et al. **Trends Microbiol** 1999 Aug;7(8):328-33 (44 ref.)
Effect of chlorophenoxyacetic acid herbicides on glycine conjugation of benzoic acid. Gregus Z, et al. **Xenobiotica** 1999 Jun;29(6):547-59
Influence of chemical treatments on glutathione S-transferases of maize with activity towards metolachlor and cinnamic acid. Cottingham CK, et al. **Z Naturforsch [C]** 1998 Nov-Dec;53(11-12):973-9

POISONING

Homicidal poisoning by paraquat [letter; comment] Book RG. **Am J Forensic Med Pathol** 1998 Sep;19(3):294-5. Comment on: Am J Forensic Med Pathol 1997 Mar;18(1):33-9.
A prospective clinical trial of pulse therapy with glucocorticoid and cyclophosphamide in moderate to severe paraquat-poisoned patients. Lin JL, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):357-60
Renal failure and corrosive airway and gastrointestinal injury after ingestion of diluted diquat solution. Tanen DA, et al. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):542-5
Primary hepatic angiosarcoma: report of a case involving environmental arsenic exposure. Tsai MH, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):469-74
Acute paraquat intoxication: using nuclear pulmonary studies to predict patient outcome. Kao CH, et al. **Chest** 1999 Sep; 116(3):709-14
Surfactant therapy restores gas exchange in lung injury due to paraquat intoxication in rats. So KL, et al. **Eur Respir J** 1998 Aug;12(2):284-7
Paraquat myopathy: report on two suicide cases. Tabata N, et al. **Forensic Sci Int** 1999 Mar 15;100(1-2):117-26
Human ocular effects from self-reported exposures to Roundup herbicides. Acquavella JF, et al. **Hum Exp Toxicol** 1999 Aug;18(8):479-86
Clinical impact of upper gastrointestinal tract injuries in glyphosate-surfactant oral intoxication. Chang CY, et al. **Hum Exp Toxicol** 1999 Aug;18(8):475-8
A toxicokinetic analysis in a patient with acute glufosinate poisoning. Hirose Y, et al. **Hum Exp Toxicol** 1999 May; 18(5):305-8
Acute basagran poisoning mimicking neuroleptic malignant syndrome. Lin TJ, et al. **Hum Exp Toxicol** 1999 Aug; 18(8):493-4
Nitric oxide inhalation for paraquat-induced lung injury [see comments] Eisenman A, et al. **J Toxicol Clin Toxicol** 1998; 36(6):575-84. Comment in: J Toxicol Clin Toxicol 1998 ;36(6):585-6.
Nitric oxide inhalation for paraquat--surviving both poisoning and therapy? [editorial; comment] Hall AH. **J Toxicol Clin Toxicol** 1998;36(6):585-6. Comment on: J Toxicol Clin Toxicol 1998 ;36(6):575-84.
Acute poisoning with a herbicide containing imazapyr (Arsenal): a report of six cases. Lee HL, et al. **J Toxicol Clin Toxicol** 1999;37(1):83-9
Paraquat poisoning [letter] [see comments] Daisley H, et al. **Lancet** 1998 Oct 24;352(9137):1393-4. Comment in: Lancet 1999 Jan 23;353(9149):321-2. Comment in: Lancet 1999 Jan 23;353(9149):322-3. Comment in: Lancet 1999 Jan 23;353(9149):323.
Paraquat poisoning [letter; comment] Eddleston M, et al. **Lancet** 1999 Jan 23;353(9149):323. Comment on: Lancet 1998 Oct 24;352(9137):1393-4.
Paraquat poisoning [letter; comment] Van der Stuyft P. **Lancet** 1999 Jan 23;353(9149):322-3. Comment on: Lancet 1998 Oct 24;352(9137):1393-4.
Paraquat poisoning [letter; comment] Wilks MF. **Lancet** 1999 Jan 23;353(9149):321-2. Comment on: Lancet 1998 Oct 24;352(9137):1393-4.
Morphological changes in mitochondria and lysosomes of hepatocytes in acute intoxication with 2,4-dichlorophenoxyacetic acid (2,4-D). Sulik M, et al. **Mater Med Pol** 1998 Jan-Jun;30(1-2):16-9
High rates of paraquat-induced suicide in southern Trinidad. Hutchinson G, et al. **Suicide Life Threat Behav** 1999 Summer;29(2):186-91
Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning [see comments] Licker M, et al. **Thorax** 1998 Jul;53(7):620-1. Comment in: Thorax 1998 Jul;53(7):619.
Glyphosate toxicosis in domestic animals: a survey from the data of the Centre National d'Informations Toxicologiques Veterinaires (CNITV). Burgat V, et al. **Vet Hum Toxicol** 1998 Dec;40(6):363-7
[Massive paraquat poisoning. Favorable course after treatment with n-acetylcysteine and early hemodialysis] Drault JN, et al. **Ann Fr Anesth Reanim** 1999 May; 18(5):534-7 (Eng. Abstr.) **(Fre)**
[Paraquat poisoning in children] Gerbaka B, et al. **J Med Liban** 1998 Mar-Apr;46(2):93-6 (25 ref.) **(Fre)**
[Computer analysis of microimages of adrenal glands during poisoning with organochlorine compounds] Popuchiev VV, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):666-8 **(Rus)**

STANDARDS

Efficiency of safety measures applied to a manual knapsack sprayer for paraquat application to maize (Zea mays L.). Machado-Neto JG, et al. **Arch Environ Contam Toxicol** 1998 Nov;35(4):698-701

THERAPEUTIC USE

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):498-506 (30 ref.)

TOXICITY

Embryonic toxicity of insecticide Sumithion 50 EC and herbicide Fusilade S in pheasants after individual or combined administration. Varga T, et al. **Acta Vet Hung** 1999;47(1):123-8
Model field study of Sumithion 50 EC and Fusilade S on pheasants. Várnagy L, et al. **Acta Vet Hung** 1999; 47(2):271-7
A comparison of the relative sensitivity of structural and functional cellular responses in the alga chlamydomonas eugametos exposed to the herbicide paraquat. Franqueira D, et al. **Arch Environ Contam Toxicol** 1999 Apr; 36(3):264-9
Acute 2,4-D poisoning in tench (Tinca tinca L.): lesions in the hematopoietic portion of the kidney. Gómez L, et al. **Arch Environ Contam Toxicol** 1998 Oct;35(3):479-83
The toxicity of glyphosate and several glyphosate formulations to four species of southwestern Australian frogs. Mann RM, et al. **Arch Environ Contam Toxicol** 1999 Feb;36(2):193-9
MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters. Kitayama S, et al. **Biochim Biophys Acta** 1998 Sep 16;1404(3):305-13
Protective effects of dietary nasunin on paraquat-induced oxidative stress in rats. Kimura Y, et al. **Biosci Biotechnol Biochem** 1999 May;63(5):799-804
Cytotoxicity of lindane and paraquat to human hepatoma cell lines. Descampiaux B, et al. **Bull Environ Contam Toxicol** 1999 Jan;62(1):16-24
2,4-D treatment in tench (Tinca tinca L.): pathological processes on the excretory kidney. Gómez L, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):600-7
Toxicity of metals and pesticides using the sperm cell bioassay with the sea urchin Arbacia spatuligera. Larrain A, et al. **Bull Environ Contam Toxicol** 1999 Jun;62(6):749-57
Toxic action of the herbicide 2,4-D on the neuroepithelial synapse and on the nonstimulated skin of the frog Caudiverbera caudiverbera. Suwalsky M, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):570-7
Dimethylarsinic acid effects on DNA damage and oxidative stress related biochemical parameters in B6C3F1 mice. Ahmad S, et al. **Cancer Lett** 1999 May 24;139(2):129-35
Involvement of capsaicin-sensitive nerves in paraquat-induced mortality. Atzori L, et al. **Chem Biol Interact** 1998 Nov 6;116(1-2):93-103
Urinary excretion of biomarkers for radical-induced damage in rats treated with NDMA or diquat and the effects of calcium carbimide co-administration. de Zwart LL, et al. **Chem Biol Interact** 1999 Jan 29;117(2):151-72
Molecular approaches to evaluate pollutants. Camatini M, et al. **Chemosphere** 1998 Dec;37(14-15):2717-38
The organochlorine herbicide chloridazon interacts with cell membranes. Suwalsky M, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):29-35
Effect of simulated sunlight on atrazine and metolachlor toxicity of surface waters. Lin YJ, et al. **Ecotoxicol Environ Saf** 1999 May;43(1):35-7
Effects of trifluralin on carp: biochemical and histological evaluation. Poleksić V, et al. **Ecotoxicol Environ Saf** 1999 Jun;43(2):213-21
Environmental casualties of the war on drugs. Joyce S. **Environ Health Perspect** 1999 Feb;107(2):A74-7
In vivo studies on genotoxicity of a soil fumigant, dazomet. Peluso M, et al. **Environ Mol Mutagen** 1998;32(2):179-84
Cytotoxic and porphyrinogenic effects of diphenyl ethers in cultured rat hepatocytes: chlornitrofen (CNP), CNP-amino, chlomethoxyfen and bifenox. Jinno H, et al. **Food Chem Toxicol** 1999 Jan;37(1):69-74
An evaluation of the carcinogenic potential of the herbicide alachlor to man. Heydens WF, et al. **Hum Exp Toxicol** 1999 Jun;18(6):363-91 (76 ref.)
Liver preneoplastic changes in mice treated with the herbicide fomesafen. Krijt J, et al. **Hum Exp Toxicol** 1999 May;18(5):338-44
Promoting activity of the herbicide dicamba (2-methoxy-3, 6-dichlorobenzoic acid) in two stage hepatocarcinogenesis. Espandiari P, et al. **Int J Oncol** 1999 Jan;14(1):79-84
Thiobencarb toxicity and plasma AChE inhibition in the European eel. Fernández-Vega C, et al. **J Environ Sci Health B** 1999 Jan;34(1):61-73
From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):498-506 (30 ref.)
Cytokine production by C57BL/6 mouse spleen cells is selectively reduced by exposure to propanil. Zhao W, et al. **J Toxicol Environ Health** 1998 Sep 25;55(2):107-20
Ames assays and unscheduled DNA synthesis assays on 2, 4-dichlorophenoxyacetic acid and its derivatives. Charles JM, et al. **Mutat Res** 1999 Jul 21;444(1):207-16
Buthionine sulfoximine prevents the reduction of the genotoxic activity of maleic hydrazide by soil humic substances in Vicia faba seedlings. De Marco A, et al. **Mutat Res** 1999 Jan 13;438(2):89-95
Evaluation of the genotoxicity of 2,4-dichlorophenoxyacetic acid and its derivatives in mammalian cell cultures. Gollapudi BB, et al. **Mutat Res** 1999 Jul 21;444(1):217-25
An evaluation of the feasibility of using cytogenetic damage as a biomarker for alachlor exposure. Kligerman AD, et al. **Mutat Res** 1999 Apr 26;441(1):95-101
Tradescantia-micronucleus and -stamen hair mutation assays on genotoxicity of the gaseous and liquid forms of pesticides. Mohammed KB, et al. **Mutat Res** 1999 May 19;426(2):193-9
Genotoxic activity of the commercial herbicide containing bifenox in bovine peripheral lymphocytes. Siviková K, et al. **Mutat Res** 1999 Feb 19;439(2):129-35
Paraquat-induced cell death in PC12 cells. Yang WL, et al. **Neurochem Res** 1998 Nov;23(11):1387-94
Behavioral alterations induced in rats by a pre- and postnatal exposure to 2,4-dichlorophenoxyacetic acid. Bortolozzi AA, et al. **Neurotoxicol Teratol** 1999 Jul-Aug;21(4):451-65
Nitric oxide protects against cellular damage produced by methylviologen herbicides in potato plants. Beligni MV, et al. **Nitric Oxide** 1999 Jun;3(3):199-208
Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Corasaniti MT, et al. **Pharmacol Toxicol** 1998 Jul;83(1):1-7 (53 ref.)
Fetotoxic effect of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats. Sulik M, et al. **Rocz Akad Med Bialymst** 1998; 43:298-308
Ultrastructural changes in rat hepatocytes in acute intoxication with 2,4-dichlorophenoxyacetic acid (2,4-D). Sulik M, et al. **Rocz Akad Med Bialymst** 1998;43:314-26
Maternal and developmental toxicity of halogenated 4'-nitrodiphenyl ethers in mice. Francis BM, et al. **Teratology** 1999 Feb;59(2):69-80
Low-level exposure to diquat induces a neurally mediated intestinal hypersecretion in rats: involvement of nitric oxide and mast cells. Anton P, et al. **Toxicol Appl Pharmacol** 1998 Sep;152(1):77-82
Propanil affects transcriptional and posttranscriptional regulation of IL-2 expression in activated EL-4 cells. Zhao W, et al. **Toxicol Appl Pharmacol** 1999 Jan 15;154(2):153-9
Herbicide use on railway tracks for safety reasons in Germany? Schweinsberg F, et al. **Toxicol Lett** 1999 Jun 30;107(1-3):201-5
Chronic dietary toxicity/oncogenicity studies on 2,4-dichlorophenoxybutyric acid in rodents. Charles JM, et al. **Toxicol Sci** 1998 Nov;46(1):21-30
Chronic dietary toxicity study on 2,4-dichlorophenoxybutyric acid in the dog. Charles JM, et al. **Toxicol Sci** 1998 Nov;46(1):134-42
Effects of a herbicide formulation, Tordon 75D, and its individual components on the oxidative functions of mitochondria. Oakes DJ, et al. **Toxicology** 1999 Aug 13; 136(1):41-52
[Effect of 2,4-D ecotoxicants on spermatogenesis and fertility of albino rats] Galimov ShN, et al. **Aviakosm Ekolog Med** 1999;33(1):32-4 (Eng. Abstr.) **(Rus)**

HERBICIDES

[Effect of beta-carotene oil and bee pollen on ion transport in rat brain slices following radiation-chemical exposure] Anan'eva TV, et al. **Radiats Biol Radioecol** 1999 Mar-Jun; 39(2-3):341-4 (Eng. Abstr.) **(Rus)**

URINE

Isotope dilution high-performance liquid chromatography/tandem mass spectrometry method for quantifying urinary metabolites of atrazine, malathion, and 2,4-dichlorophenoxyacetic acid. Beeson MD, et al. **Anal Chem** 1999 Aug 15;71(16):3526-30

Determination of monomethylarsonic acid and dimethylarsinic acid in urine by liquid chromatography-tandem mass spectrometry. Le Bouil A, et al. **J Anal Toxicol** 1999 Jul-Aug;23(4):257-61

Semiautomated preparation of 3,5,6-trichloro-2-pyridinol in human urine using a Zymate XP laboratory robot with quantitative determination by gas chromatography-negative-ion chemical ionization mass spectrometry. Ormand JR, et al. **J Anal Toxicol** 1999 Jan-Feb;23(1):35-40

HERBICIDES, CARBAMATE

ANALYSIS

Automated determination of phenylcarbamate herbicides in environmental waters by on-line trace enrichment and reversed-phase liquid chromatography-diode array detection. Hidalgo C, et al. **J Chromatogr A** 1998 Oct 9; 823(1-2):121-8

METABOLISM

In vivo and in vitro promutagen activation by Vicia faba of thiocarbamate herbicides molinate and butylate to products inducing sister chromatid exchanges in human lymphocyte cultures. Calderón-Segura ME, et al. **Mutat Res** 1999 Jan 13;438(2):81-8

PHARMACOKINETICS

Comparison of human and rat metabolism of molinate in liver microsomes and slices. Jewell WT, et al. **Drug Metab Dispos** 1999 Jul;27(7):842-7

TOXICITY

Effects of molinate on growth of five freshwater species of phytoplankton. Sabater C, et al. **Bull Environ Contam Toxicol** 1998 Oct;61(4):534-40

Molinate: rodent reproductive toxicity and its relevance to humans--a review. Wickramaratne GA, et al. **Regul Toxicol Pharmacol** 1998 Apr;27(2):112-8 (17 ref.)

HERBICIDES, TRIAZINE

ADVERSE EFFECTS

Effects of the herbicide atrazine on Ambystoma tigrinum metamorphosis: duration, larval growth, and hormonal response. Larson DL, et al. **Physiol Zool** 1998 Nov-Dec; 71(6):671-9

ANALYSIS

Influence of the hapten design on the development of a competitive ELISA for the determination of the antifouling agent Irgarol 1051 at trace levels. Ballesteros B, et al. **Anal Chem** 1998 Oct 1;70(19):4004-14

Integrated optical surface plasmon resonance immunoprobe for simazine detection. Harris RD, et al. **Biosens Bioelectron** 1999 Apr 30;14(4):377-86

Separation-free electrochemical immunosensor for rapid determination of atrazine. Keay RW, et al. **Biosens Bioelectron** 1998 Oct 15;13(9):963-70

Determination of ametryn herbicide by bioassay and gas chromatography-mass spectrometry in analysis of residues in drinking water. Queiroz RH, et al. **Boll Chim Farm** 1999 Jun;138(6):249-52

Soil leaching column chromatographic technique for estimation of leaching behavior of atrazine, deethylatrazine, deisopropylatrazine, and hydroxyatrazine on soil. Xu F, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):87-93

On-line coupling of immunoaffinity-based solid-phase extraction and gas chromatography for the determination of s-triazines in aqueous samples. Dallüge J, et al. **J Chromatogr A** 1999 Jan 15;830(2):377-86

Analysis of trace atrazine and simazine in environmental samples by liquid chromatography-fluorescence detection with pre-column derivatization reaction. Gong A, et al. **J Chromatogr A** 1998 Dec 4;827(1):57-63

Analysis of atrazine, terbutylazine and their N-dealkylated chloro and hydroxy metabolites by solid-phase extraction and gas chromatography-mass spectrometry and capillary electrophoresis-ultraviolet detection. Loos R, et al. **J Chromatogr A** 1999 Mar 12;835(1-2):217-29

Solid-phase microextraction of the antifouling Irgarol 1051 and the fungicides dichlofluanid and 4-chloro-3-methylphenol in water samples. Peñalver A, et al. **J Chromatogr A** 1999 Apr 16;839(1-2):253-60

Electrochemical immunosensor for the detection of atrazine. López MA, et al. **J Mol Recognit** 1998 Winter; 11(1-6):178-81

CHEMISTRY

Rapid treatment of water contamined with atrazine and parathion with zero-valent iron. Ghauch A, et al. **Chemosphere** 1999 Oct;39(8):1309-15

Effect of simulated sunlight on atrazine and metolachlor toxicity of surface waters. Lin YJ, et al. **Ecotoxicol Environ Saf** 1999 May;43(1):35-7

IMMUNOLOGY

Effect of methanol on the interaction of monoclonal antibody with free and immobilized atrazine studied using the resonant mirror-based biosensor. Skládal P. **Biosens Bioelectron** 1999 Mar 15;14(3):257-63

Production and characterization of monoclonal antibodies specific to atrazine group compounds: effects of coating ligand structure on the variation of sensitivity and specificity. Choi MJ, et al. **J Immunoassay** 1999 Feb-May; 20(1-2):57-77

Electrochemical immunosensor for the detection of atrazine. López MA, et al. **J Mol Recognit** 1998 Winter; 11(1-6):178-81

ISOLATION & PURIFICATION

Atrazine removal by ozonation processes in surface waters. Beltrán FJ, et al. **J Environ Sci Health B** 1999 May; 34(3):449-68

METABOLISM

Biodegradation of atrazine by Agrobacterium radiobacter J14a and use of this strain in bioremediation of contaminated soil. Struthers JK, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3368-75

Inhibition of atrazine degradation by cyanazine and exogenous nitrogen in bacterial isolate M91-3. Gebendinger N, et al. **Appl Microbiol Biotechnol** 1999 Mar; 51(3):375-81

In vitro metabolism of chlorotriazines: characterization of simazine, atrazine, and propazine metabolism using liver microsomes from rats treated with various cytochrome P450 inducers. Hanioka N, et al. **Toxicol Appl Pharmacol** 1999 May 1;156(3):195-205

PHARMACOKINETICS

In vitro biotransformation of atrazine by rat liver microsomal cytochrome P450 enzymes. Hanioka N, et al. **Chem Biol Interact** 1998 Nov 27;116(3):181-98

TOXICITY

Reproductive disturbance caused by an S-triazine herbicide in pigs. Gojmerac T, et al. **Acta Vet Hung** 1999;47(1):129-35

Behavioral responses to atrazine and diuron in goldfish. Saglio P, et al. **Arch Environ Contam Toxicol** 1998 Oct; 35(3):484-91

Application of anterior pituitary cell culture in toxicological research. Zechner-Krpan V, et al. **Arh Hig Rada Toksikol** 1998 Sep;49(3):219-29

An ecological risk assessment for the use of Irgarol 1051 as an algaecide for antifoulant paints. Hall LW Jr, et al. **Crit Rev Toxicol** 1999 Jul;29(4):367-437 (103 ref.)

Effect of simulated sunlight on atrazine and metolachlor toxicity of surface waters. Lin YJ, et al. **Ecotoxicol Environ Saf** 1999 May;43(1):35-7

A risk characterization for atrazine: oncogenicity profile. Stevens JT, et al. **J Toxicol Environ Health** 1999 Jan 22; 56(2):69-109

Characterization of maternal influence on teratogenicity: an assessment of developmental toxicity studies for the herbicide cyanazine. Iyer P, et al. **Regul Toxicol Pharmacol** 1999 Feb;29(1):88-95

The functional and structural observations of the neonatal reproductive system of alligators exposed in ovo to atrazine, 2,4-D, or estradiol. Crain DA, et al. **Toxicol Ind Health** 1999 Jan-Mar;15(1-2):180-5

Endocrine, immune, and behavioral effects of aldicarb (carbamate), atrazine (triazine) and nitrate (fertilizer) mixtures at groundwater concentrations. Porter WP, et al. **Toxicol Ind Health** 1999 Jan-Mar;15(1-2):133-50

URINE

HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Buchholz BA, et al. **Anal Chem** 1999 Aug 15;71(16):3519-25

HERBICIDES, UREA

ANALYSIS

Determination of phenylurea herbicide residues in vegetables by liquid chromatography after gel permeation chromatography and Florisil cartridge cleanup. Sannino A. **J AOAC Int** 1998 Sep-Oct;81(5):1048-53

Quantification of phenylurea herbicides and their free and humic acid-associated metabolites in natural waters. Di Corcia A, et al. **J Chromatogr A** 1999 Aug 13;852(2):465-74

Simultaneous quantitative determination of thirteen urea pesticides at sub-ppb levels on a Zorbax SB-C18 column. Dommarco R, et al. **J Chromatogr A** 1998 Nov 6; 825(2):200-4

METABOLISM

Influence of herbicide binding on the redox potential of the quinone acceptor in photosystem II: relevance to photodamage and phytotoxicity. Krieger-Liszkay A, et al. **Biochemistry** 1998 Dec 15;37(50):17339-44

Degradation of three phenylurea herbicides (chlortoluron, isoproturon and diuron) by micromycetes isolated from soil. Khadrani A, et al. **Chemosphere** 1999 Jun; 38(13):3041-50

A model for the formation and degradation of bound residues of the herbicide 14C-isoproturon in soil. Reuter S, et al. **Chemosphere** 1999 Aug;39(4):627-39

PHARMACOLOGY

Application of an androgen receptor assay for the characterisation of the androgenic or antiandrogenic activity of various phenylurea herbicides and their derivatives. Bauer ER, et al. **Analyst** 1998 Dec; 123(12):2485-7

Effect of phenylurea herbicides on soil microbial communities estimated by analysis of 16S rRNA gene fingerprints and community-level physiological profiles. el Fantroussi S, et al. **Appl Environ Microbiol** 1999 Mar; 65(3):982-8

TOXICITY

Chronic effects of the herbicide diuron on freshwater cladocerans, amphipods, midges, minnows, worms, and snails. Nebeker AV, et al. **Arch Environ Contam Toxicol** 1998 Oct;35(3):441-6

Behavioral responses to atrazine and diuron in goldfish. Saglio P, et al. **Arch Environ Contam Toxicol** 1998 Oct; 35(3):484-91

Influence of herbicide binding on the redox potential of the quinone acceptor in photosystem II: relevance to photodamage and phytotoxicity. Krieger-Liszkay A, et al. **Biochemistry** 1998 Dec 15;37(50):17339-44

Hepato-toxic effect of diuron in albino rats. Agrawal RC, et al. **Indian J Exp Biol** 1999 May;37(5):503-4

HERBS

see related
LAMIACEAE
MEDICINE, HERBAL

Aerobiological study of Chenopodiaceae and Amaranthaceae in the Mediterranean area of southwestern Spain. González Minero FJ, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec;8(6):370-5

Antioxidant effects of herbs in Crete [letter] Lionis C, et al. **Lancet** 1998 Dec 19-26;352(9145):1987-8

CHEMISTRY

Health-promoting properties of common herbs. Craig WJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):491S-499S (115 ref.)

Computational analysis of the amino acid residue sequences of amaranth and some other proteins. Gorinstein S, et al. **Biosci Biotechnol Biochem** 1998 Oct;62(10):1845-51

Pectins in extracellular polysaccharides from a cell-suspension culture of Mentha. Maruyama K, et al. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2223-5

Solution structure of the major alpha-amylase inhibitor of the crop plant amaranth. Lu S, et al. **J Biol Chem** 1999 Jul 16;274(29):20473-8

[Protein concentrate from Amaranthus mantegazzianus. Physical, chemical and biological characterization] de Luquez N, et al. **Arch Latinoam Nutr** 1997 Dec; 47(4):359-61 (Eng. Abstr.) **(Spa)**

GENETICS

Polymorphic microsatellite markers in the perennial herb Heloniopsis orientalis (Thunb.) C. Tanaka. Miyazaki Y, et al. **Mol Ecol** 1999 Aug;8(8):1360-2

Cleistogamy in Scutellaria indica (Labiatae): effective mating system and population genetic structure. Sun M. **Mol Ecol** 1999 Aug;8(8):1285-95

HISTORY

Antioxidant effects of herbs [letter] Warren CP. **Lancet** 1999 Feb 20;353(9153):676

MICROBIOLOGY

[Cholera in a Paris resident with no history of travel. A case report] Infuso A, et al. **Presse Med** 1998 Feb 7;27(5):202-4 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Health-promoting properties of common herbs. Craig WJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):491S-499S (115 ref.)

Herbal remedies in psychiatric practice. Wong AH, et al. **Arch Gen Psychiatry** 1998 Nov;55(11):1033-44 (303 ref.)

Herbs as medicines. Winslow LC, et al. **Arch Intern Med** 1998 Nov 9;158(20):2192-9 (70 ref.)

Effect of Kumhwang-San on anaphylactic reaction in a murine model. Kim HM, et al. **Immunopharmacol Immunotoxicol** 1999 Feb;21(1):163-74

Complementary and alternative medicines for Alzheimer's disease. Ott BR, et al. **J Geriatr Psychiatry Neurol** 1998 Winter;11(4):163-73 (117 ref.)

HERBS, MEDICINAL see **PLANTS, MEDICINAL**

HEREDITARY DISEASES

Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives? Wilcke JT. **BMJ** 1998 Sep 12; 317(7160):744–7 (17 ref.)

The relative power of family–based and case–control designs for linkage disequilibrium studies of complex human diseases. II. Individual genotyping. Teng J, et al. **Genome Res** 1999 Mar;9(3):234–41

Geneticizing disability: the Human Genome Project and the commodification of self. Fitzgerald J. **Issues Law Med** 1998 Fall;14(2):147–63

The human genome project and the future of diagnostics, treatment, and prevention. van Ommen GJ, et al. **Lancet** 1999 Jul;354 Suppl 1:SI5–10 (49 ref.)

Congenital disorders sharing oxidative stress and cancer proneness as phenotypic hallmarks: prospects for joint research in pharmacology. Pagano G, et al. **Med Hypotheses** 1998 Sep;51(3):253–66 (163 ref.)

A multifunctional system of the national genetic register. Kobrinsky B, et al. **Medinfo** 1998;9 Pt 1:121–5

Bragdon v. Abbott: the Americans with Disabilities Act and HIV infection [letter; comment] Greely HT. **N Engl J Med** 1999 Apr 15;340(15):1213–4. Comment on: N Engl J Med 1998 Oct 22;339(17):1255–9.

MITOP: database for mitochondria–related proteins, genes and diseases. Scharfe C, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):153–5

Proceedings of the 6th Symposium of Human Genetics. Paris, France, 15–16 May 1998. **Pathol Biol (Paris)** 1998 Nov; 46(9):669–720 **(Eng, Fre)**

Physician's duty to warn third parties about the risk of genetic diseases [letter; comment] Olick RS. **Pediatrics** 1999 Apr;103(4 Pt 1):855. Comment on: Pediatrics 1998 Jul;102(1 Pt 1):140–2.

Use of isolated inbred human populations for identification of disease genes. Sheffield VC, et al. **Trends Genet** 1998 Oct;14(10):391–6

When some fine old genes meet a 'new' environment. Neel JV. **World Rev Nutr Diet** 1999;84:1–18 (67 ref.)

[Genetic diseases on the Internet: OMIM] Machet L. **Ann Dermatol Venereol** 1998 Sep;125(9):645 **(Fre)**

[Information on rare diseases: the Orphanet project] Aymé S, et al. **Rev Med Interne** 1998;19 Suppl 3:376S–377S **(Fre)**

[Hereditary alcoholism: some neurochemical and genetic mechanisms] Anokhina IP, et al. **Vestn Ross Akad Med Nauk** 1999;(6):43–7 **(Rus)**

BLOOD

[Genetic diseases of erythrocyte membrane permeability] Delaunay J. **Ann Biol Clin (Paris)** 1999 Jul–Aug; 57(4):383–91 (54 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Cardiac involvement in Coffin–Lowry syndrome. Massin MM, et al. **Acta Paediatr** 1999 Apr;88(4):468–70

Signal transduction defects in growth hormone insensitivity. Clayton PE, et al. **Acta Paediatr Suppl** 1999 Feb; 88(428):174–8; discussion 179 (18 ref.)

Molecular testing for inherited diseases. Vnencak–Jones CL. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S19–32 (121 ref.)

Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Karlan BY, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):917–28

Can children and young people consent to be tested for adult onset genetic disorders? Dickenson DL. **BMJ** 1999 Apr 17;318(7190):1063–5 (27 ref.)

Commentary: weighing burdens and benefits rather than competence. Geller G. **BMJ** 1999 Apr 17;318(7190):1065–6

Genetic knowledge and third–party interests. Boetzkes E. **Camb Q Healthc Ethics** 1999 Summer;8(3):386–92

Fibre–fluorescence in situ hybridization directly performed from fresh biological samples: novel perspectives for genetic diagnosis. Pulcini F, et al. **Chromosome Res** 1998 Sep;6(6):501–3

Mutation detection and mutation databases. Cotton RG. **Clin Chem Lab Med** 1998 Aug;36(8):519–22

Physician knowledge and attitudes towards molecular genetic (DNA) testing of their patients. Hunter A, et al. **Clin Genet** 1998 Jun;53(6):447–55

Rapid detection of genetic mutations using the chemiluminescent hybridization protection assay (HPA): overview and comparison with other methods. Nelson NC. **Crit Rev Clin Lab Sci** 1998 Sep;35(5):369–414 (166 ref.)

Genetic diseases and testing in Ashkenazi Jews: Part 1. Gilbert F. **Genet Test** 1997;1(1):3–4

The role of physician preferences in the choice of amniocentesis or chorionic villus sampling for prenatal genetic testing. Heckerling PS, et al. **Genet Test** 1998; 2(1):61–6

A practical guide for the validation of genetic tests. Prence EM. **Genet Test** 1999;3(2):201–5

Preimplantation genetic diagnosis principles and ethics. Fasouliotis SJ, et al. **Hum Reprod** 1998 Aug;13(8):2238–45

Successful preimplantation genetic diagnosis is related to the number of available cumulus–oocyte complexes. Vandervorst M, et al. **Hum Reprod** 1998 Nov; 13(11):3169–76

Genetic counselling and testing in Europe. Harris R. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):335–8

Time for reassessment of use of all medical information by UK insurers [see comments] Thomson B. **Lancet** 1998 Oct 10;352(9135):1216–8. Comment in: Lancet 1998 Dec 12;352(9144):1941.

Newborn screening program in Rhode Island: an update. Simon P, et al. **Med Health R I** 1999 May;82(5):155–7

Molecular genetics for the practitioner. Tantravahi U. **Med Health R I** 1999 May;82(5):157–60

Rapid and effective processing of blood specimens for diagnostic PCR using filter paper and Chelex–100. Polski JM, et al. **Mol Pathol** 1998 Aug;51(4):215–7

Shattuck lecture––medical and societal consequences of the Human Genome Project. Collins FS. **N Engl J Med** 1999 Jul 1;341(1):28–37

Incidental diagnosis of genetic disease at autopsy––a point of view [editorial] Berry PJ. **Pediatr Dev Pathol** 1999 Sep–Oct;2(5):399–401

Incidental diagnosis of genetic disease at autopsy––another point of view [editorial] Durfy SJ. **Pediatr Dev Pathol** 1999 Sep–Oct;2(5):402–3

Clinical evaluation of preimplantation genetic diagnosis. Handyside AH. **Prenat Diagn** 1998 Dec;18(13):1345–8 (16 ref.)

Recent advances in molecular and molecular cytogenetic techniques have enabled the diagnosis of some inherited diseases from a single cell [editorial; comment] Harper J, et al. **Prenat Diagn** 1998 Dec;18(13):1343–4 (14 ref.). Comment on: Prenat Diagn 1998 Dec;18(13):1437–49.

Application of single–needle blastomere biopsy in human preimplantation genetic diagnosis. Inzunza J, et al. **Prenat Diagn** 1998 Dec;18(13):1381–8

Prenatal diagnosis of genetic syndromes may be facilitated by serendipitous findings at fetal blood sampling. Lalatta F, et al. **Prenat Diagn** 1998 Aug;18(8):834–7

Results of a survey of the legal status and attitudes towards preimplantation genetic diagnosis conducted in 13 different countries. Viville S, et al. **Prenat Diagn** 1998 Dec; 18(13):1374–80

Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Wells D, et al. **Prenat Diagn** 1998 Dec;18(13):1389–401 (78 ref.)

Genetic markers to predict polygenic disease: a new problem for social genetics. Galton DJ, et al. **QJM** 1999 Apr; 92(4):223–32

[Contribution of genetics] Lyonnet S, et al. **Arch Pediatr** 1999;6 Suppl 2:246s–248s **(Fre)**

[Pre–implantation genetic diagnosis: indications, techniques, and results] Veiga A, et al. **Contracept Fertil Sex** 1998 Jul–Aug;26(7–8):568–72 (Eng. Abstr.) **(Fre)**

[The pediatrician's role in the evaluation of a "dysmorphic" child] Bottani A. **Rev Med Suisse Romande** 1999 Feb; 119(2):107–9 **(Fre)**

[Ethical problems within the context of genetic counseling and diagnosis] Murken J. **Internist (Berl)** 1999 Mar; 40(3):286–93 (14 ref.) **(Ger)**

[Prenatal diagnosis with fetal cells in maternal blood: report of experiences in Basal] Holzgreve W, et al. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1641–5 (Eng. Abstr.) **(Ger)**

[Preimplantation genetic diagnosis] Reubinoff BE, et al. **Harefuah** 1998 Sep;135(5–6):202–8 (43 ref.) **(Heb)**

[Predictive medicine: an ethical challenge to medical practice] Frontali M, et al. **Ann Ist Super Sanita** 1998; 34(2):237–43 (Eng. Abstr.) **(Ita)**

[Genetic diagnosis of hereditary diseases] Narisawa K. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2322–8 (10 ref.) **(Jpn)**

[Genetic tests and items to be noted at the diagnostic laboratory] Ueno I, et al. **Rinsho Byori** 1999 Feb;Suppl 109:190–200 (10 ref.) **(Jpn)**

DRUG THERAPY

Serotonin receptor variants in disease: new therapeutic opportunities? Peroutka SJ. **Ann N Y Acad Sci** 1998 Dec 15;861:16–25 (21 ref.)

Recombinant proteins for genetic disease. Russell CS, et al. **Clin Genet** 1999 Jun;55(6):389–94 (34 ref.)

Growth hormone treatment of Russell–Silver syndrome. Stanhope R, et al. **Horm Res** 1998;49 Suppl 2:37–40 (24 ref.)

[Genetics and therapeutic intervention] Brousseau T. **Ann Pharm Fr** 1999 Jan;57(1):56–60 (18 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. Low L, et al. **BMJ** 1998 Dec 12; 317(7173):1632–5

'Wrongful life' claims [editorial; comment] Gillon R. **J Med Ethics** 1998 Dec;24(6):363–4. Comment on: J Med Ethics 1998 Dec;24(6):369–75.

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.). Comment in: J Med Ethics 1998 Dec;24(6):363–4.

ENZYMOLOGY

Human genetic diseases of proteolysis. Kato GJ. **Hum Mutat** 1999;13(2):87–98 (99 ref.)

KinMutBase, a database of human disease–causing protein kinase mutations. Stenberg KA, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):362–4

EPIDEMIOLOGY

Familial hypocalciuric hypercalcaemia in Australia [comment] Gutteridge DH, et al. **Calcif Tissue Int** 1999 May;64(5):456 (3 ref.). Comment on: Calcif Tissue Int 1997 Jul;61(1):36–8.

Genetic risk assessment and insurance. Reilly PR. **Genet Test** 1998;2(1):1–2

Prevalence of congenital malformations and genetic diseases in Korea. Jung SC, et al. **J Hum Genet** 1999;44(1):30–4

Microvillous inclusion disease in Japan [letter] Kaneko K, et al. **J Pediatr** 1999 Sep;135(3):400

Ionizing radiation and genetic risks IX. Estimates of the frequencies of mendelian diseases and spontaneous mutation rates in human populations: a 1998 perspective. Sankaranarayanan K. **Mutat Res** 1998 Sep;411(2):129–78 (285 ref.)

Social transmission of reproductive behavior increases frequency of inherited disorders in a young–expanding population. Austerlitz F, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):15140–4

[Burden of hereditary diseases in residents of the Mari El Republic] Ginter EK, et al. **Genetika** 1999 Mar;35(2):385–91 (Eng. Abstr.) **(Rus)**

[East European gene pool and diseases in the rural population of European Russia] Rychkov IuG, et al. **Genetika** 1998 Aug;34(8):1138–50 (Eng. Abstr.) **(Rus)**

[Genetic counseling in hereditary diseases in Finland] Lönnberg M. **Lakartidningen** 1999 Jan 27;96(4):304 **(Swe)**

ETIOLOGY

[Ribosomal abnormalities and human diseases] Kenmochi N. **Seikagaku** 1999 Mar;71(3):205–10 (19 ref.) **(Jpn)**

GENETICS

A new method for estimating the risk ratio in studies using case–parental control design [see comments] Sun F, et al. **Am J Epidemiol** 1998 Nov 1;148(9):902–9. Comment in: Am J Epidemiol 1999 Aug 15;150(4):428–9.

Re: "Distinguishing the effects of maternal and offspring genes through studies of 'case–parent triads'" and "a new method for estimating the risk ratio in studies using case–parental control design" [letter; comment] Weinberg CR, et al. **Am J Epidemiol** 1999 Aug 15;150(4):428–9. Comment on: Am J Epidemiol 1998 Nov 1;148(9):893–901. Comment on: Am J Epidemiol 1998 Nov 1;148(9):902–9.

Exclusion of the stomatin, alpha–adducin and beta–adducin loci in a large kindred with dehydrated hereditary stomatocytosis. Innes DS, et al. **Am J Hematol** 1999 Jan; 60(1):72–4

Maximum–likelihood expression of the transmission/disequilibrium test and power considerations [letter] Abel L, et al. **Am J Hum Genet** 1998 Aug; 63(2):664–7

Direct power comparisons between simple LOD scores and NPL scores for linkage analysis in complex diseases. Abreu PC, et al. **Am J Hum Genet** 1999 Sep;65(3):847–57

Disequilibrium likelihoods for fine–scale mapping of a rare allele. Graham J, et al. **Am J Hum Genet** 1998 Nov; 63(5):1517–30

Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Hodges M, et al. **Am J Hum Genet** 1998 Aug;63(2):297–304 (68 ref.)

Neighboring–nucleotide effects on the rates of germ–line single–base–pair substitution in human genes. Krawczak M, et al. **Am J Hum Genet** 1998 Aug;63(2):474–88

A comparative study of sibship tests of linkage and/or association. Monks SA, et al. **Am J Hum Genet** 1998 Nov; 63(5):1507–16

Detecting marker–disease association by testing for Hardy–Weinberg disequilibrium at a marker locus. Nielsen DM, et al. **Am J Hum Genet** 1998 Nov;63(5):1531–40

Replication of linkage studies of complex traits: an examination of variation in location estimates. Roberts SB, et al. **Am J Hum Genet** 1999 Sep;65(3):876–84

Use of parents, sibs, and unrelated controls for detection of associations between genetic markers and disease. Schaid DJ, et al. **Am J Hum Genet** 1998 Nov;63(5):1492–506

On the assessment of statistical significance in disease–gene discovery. Zhao LP, et al. **Am J Hum Genet** 1999 Jun; 64(6):1739–53

Revertant mosaicism in human genetic disorders. Jonkman MF. **Am J Med Genet** 1999 Aug 6;85(4):361–4 (30 ref.)

Further evidence of autosomal dominant inheritance of the nonsyndromal anorectal malformations [letter; comment] Robb L, et al. **Am J Med Genet** 1998 Oct 12;79(5):400. Comment on: Am J Med Genet 1997 Aug 22;71(3):280–2.

Low frequency of inherited deletions of 22q11 [letter] Smith A, et al. **Am J Med Genet** 1999 Aug 27;85(5):513–4

Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Hummler E, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G567–71 (34 ref.)

Prediction of inherited portosystemic shunts in Irish Wolfhounds on the basis of pedigree analysis. Ubbink GJ, et al. **Am J Vet Res** 1998 Dec;59(12):1553–6

Semiparametric linkage analysis using pseudolikelihoods on neighbouring sets. Li H, et al. **Ann Hum Genet** 1998 Jul; 62 (Pt 4):323–36

Hidden linkage: a comparison of the affected sib pair (ASP) test and transmission/disequilibrium test (TDT). McGinnis RE. **Ann Hum Genet** 1998 Mar;62 (Pt 2):159–79

Serotonin receptor variants in disease: new therapeutic opportunities? Peroutka SJ. **Ann N Y Acad Sci** 1998 Dec 15;861:16–25 (21 ref.)

Genetic linkage analysis. Pulst SM. **Arch Neurol** 1999 Jun; 56(6):667–72 (16 ref.)

Transcriptional deregulation in hereditary disorders and cancer: the 12th annual CABM symposium, October 21–22, 1998, Piscataway, NJ. Rabson AB. **Biochim Biophys Acta** 1999 Jul 29;1424(1):R21–36

Genealogy certainly matters for multifactorial genetic disease [letter] Kong A, et al. **BMJ** 1999 Aug 28;319(7209):578–9

Multiple mutations in a specific gene in a small population. Feingold J. **C R Acad Sci III** 1998 Jul;321(7):553–5 (27 ref.)

Genatlas database, genes and development defects. Frézal J. **C R Acad Sci III** 1998 Oct;321(10):805–17 (15 ref.)

Will the genetic individualization of disease force a new paradigm? [editorial] Nagel RL. **C R Acad Sci III** 1999 Jan;322(1):1–4

Gene patents can be ethical [see comments] McGee G. **Camb Q Healthc Ethics** 1998 Fall;7(4):417–21. Comment in: Camb Q Healthc Ethics 1998 Fall;7(4):422–4. Comment in: Camb Q Healthc Ethics 1998 Fall;7(4):425–8. Comment in: Camb Q Healthc Ethics 1998 Fall;7(4):433–5.

Disease gene patenting: the clinician's dilemma [comment] Magnus D. **Camb Q Healthc Ethics** 1998 Fall;7(4):433–5. Comment on: Camb Q Healthc Ethics 1998 Fall;7(4):417–22.

Modification of cancer risk in offspring by parental cancer (Sweden). Hemminki K, et al. **Cancer Causes Control** 1999 Apr;10(2):125–9

Disease gene patents: overcoming unethical constraints on clinical laboratory medicine. Merz JF. **Clin Chem** 1999 Mar; 45(3):324–30

Population genomics: laying the groundwork for genetic disease modeling and targeting. Gulcher J, et al. **Clin Chem Lab Med** 1998 Aug;36(8):523–7

The assent of a nation: genethics and Iceland. McInnis MG. **Clin Genet** 1999 Apr;55(4):234–9

Recessive or dominant? Reclassification in the molecular age. Zlotogora J. **Clin Genet** 1998 Jun;53(6):423–5 (11 ref.)

Joe Doupe Young Investigators Award. The Human Genome Project: tools for the identification of disease genes. Hudson TJ. **Clin Invest Med** 1998 Dec;21(6):267–76 (16 ref.)

Medical implications of understanding complex disease traits. Bell J. **Curr Opin Biotechnol** 1998 Dec;9(6):573–7 (52 ref.)

Linkage disequilibrium mapping of complex disease: fantasy or reality? Terwilliger JD, et al. **Curr Opin Biotechnol** 1998 Dec;9(6):578–94 (156 ref.)

Genetics of diseases. Web alert. Makalowski W, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):269–70

Pathogenesis of the developmental epilepsies. Giza CC, et al. **Curr Opin Pediatr** 1998 Dec;10(6):567–74 (48 ref.)

Modifier genes in humans: strategies for identification. Houlston RS, et al. **Eur J Hum Genet** 1998 Jan;6(1):80–8 (42 ref.)

Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease. Liechti-Gallati S, et al. **Eur J Hum Genet** 1999 Jul; 7(5):590–8

First International SNP Meeting at Skokloster, Sweden, August 1998. Enthusiasm mixed with scepticism about single-nucleotide polymorphism markers for dissecting complex disorders. Syvänen AC, et al. **Eur J Hum Genet** 1999 Jan;7(1):98–101

Reverse mutations--spontaneous amelioration or cure of inherited disorders? Wahn V, et al. **Eur J Pediatr** 1998 Aug;157(8):613–7 (13 ref.)

Single nucleotide polymorphism spectra in newborns and centenarians: identification of genes coding for rise of mortal disease. Tomita-Mitchell A, et al. **Gene** 1998 Nov 26;223(1–2):381–91

Testing for contributions of mitochondrial DNA mutations to complex diseases. Sun F, et al. **Genet Epidemiol** 1998; 15(5):451–69

Disease genes and chromosomes: disease maps of the human genome. Chromosome 16. Gilbert F. **Genet Test** 1999; 3(2):243–54

Genetic diseases and testing in Ashkenazi Jews: Part 1. Gilbert F. **Genet Test** 1997;1(1):3–4

Disease genes and chromosomes: disease maps of the human genome. Chromosome 18. Gilbert F. **Genet Test** 1997; 1(1):69–71

Disease genes and chromosomes: disease maps of the human genome. Chromosome 19. Gilbert F. **Genet Test** 1997; 1(2):145–9

Disease genes and chromosomes: disease maps of the human genome. Gilbert F. **Genet Test** 1997–98;1(3):225–9

A practical guide for the validation of genetic tests. Prence EM. **Genet Test** 1999;3(2):201–5

Prepregnancy testing for single-gene disorders by polar body analysis. Verlinsky Y, et al. **Genet Test** 1999;3(2):185–90

The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Risch N, et al. **Genome Res** 1998 Dec;8(12):1273–88 (23 ref.)

Zebrafish: a new model for human disease [comment] Zon LI. **Genome Res** 1999 Feb;9(2):99–100 (17 ref.). Comment on: Genome Res 1999 Feb;9(2):121–9.

Genomic organization of a 225-kb region in Xq28 containing the gene for X-linked myotubular myopathy (MTM1) and a related gene (MTMR1). Kioschis P, et al. **Genomics** 1998 Dec 1;54(2):256–66

Identification and mapping of human histone acetylation modifier gene homologues. Randhawa GS, et al. **Genomics** 1998 Jul 15;51(2):262–9

Genetics of Silver–Russell syndrome. Wakeling EL, et al. **Horm Res** 1998;49 Suppl 2:32–6 (28 ref.)

One founder/one gene hypothesis in a new expanding population: Saguenay (Quebec, Canada). Heyer E. **Hum Biol** 1999 Feb;71(1):99–109

Position effect in human genetic disease. Kleinjan DJ, et al. **Hum Mol Genet** 1998;7(10):1611–8 (85 ref.)

Ribozymes as therapeutic tools for genetic disease. Phylactou LA, et al. **Hum Mol Genet** 1998;7(10):1649–53 (54 ref.)

Accuracy of preimplantation diagnosis of single-gene disorders by polar body analysis of oocytes. Rechitsky S, et al. **J Assist Reprod Genet** 1999 Apr;16(4):192–8

DNA polymorphisms of genetic diseases in Italy. Piazza A. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):1–7 (36 ref.)

Clinical genetics: an overview. Nehring WM, et al. **J Cardiovasc Nurs** 1999 Jul;13(4):19–33 (29 ref.)

Familial hypertrophic cardiomyopathy. Piano MR. **J Cardiovasc Nurs** 1999 Jul;13(4):46–58

Correction of genetic disease by making sense from nonsense [comment] Kaufman RJ. **J Clin Invest** 1999 Aug; 104(4):367–8 (24 ref.). Comment on: J Clin Invest 1999 Aug;104(4):375–81.

Mouse models of genetic disease: new approaches, new paradigms. Brown SD. **J Inherit Metab Dis** 1998 Aug; 21(5):532–9 (35 ref.)

Microvillous inclusion disease in Japan [letter] Kaneko K, et al. **J Pediatr** 1999 Sep;135(3):400

Are only repeated triplets guilty? De Fonzo V, et al. **J Theor Biol** 1998 Sep 7;194(1):125–42

Strategies for cloning mammalian DNA repair genes. Thompson LH. **Methods Mol Biol** 1999;113:57–85 (123 ref.)

Novel complementation assays for DNA repair-deficient cells. Transient and stable expression of DNA repair genes. Zeng L, et al. **Methods Mol Biol** 1999;113:87–100

May-Hegglin anomaly in a pregnancy complicated by intrauterine growth restriction and ambiguous genitalia. Kinsella MJ, et al. **Mil Med** 1999 Aug;164(8):607–8

B30.2-like domain proteins: update and new insights into a rapidly expanding family of proteins. Henry J, et al. **Mol Biol Evol** 1998 Dec;15(12):1696–705

Exclusivity in testing for patented disease genes [news] Press RD. **Mol Diagn** 1999 Mar;4(1):72–3

Alu repeats and human disease. Deininger PL, et al. **Mol Genet Metab** 1999 Jul;67(3):183–93 (96 ref.)

A new gene Web site for all [news] Sansom C. **Mol Med Today** 1998 Dec;4(12):509

Applications of DNA chips for genomic analysis. Hacia JG, et al. **Mol Psychiatry** 1998 Nov;3(6):483–92 (49 ref.)

SNPs and polygenic disorders: a less gloomy view [letter] MD DC. **Mol Psychiatry** 1999 Jul;4(4):314–6

Phenotype definition and association studies in behavioral genetics [letter] MD LS. **Mol Psychiatry** 1999 Jul;4(4):316

Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Kruglyak L. **Nat Genet** 1999 Jun;22(2):139–44

The application of microsatellites in molecular pathology. Naidoo R, et al. **Pathol Oncol Res** 1998;4(4):310–5 (48 ref.)

Results of a survey of the legal status and attitudes towards preimplantation genetic diagnosis conducted in 13 different countries. Viville S, et al. **Prenat Diagn** 1998 Dec; 18(13):1374–80

Strategies for preimplantation genetic diagnosis of single gene disorders by DNA amplification. Wells D, et al. **Prenat Diagn** 1998 Dec;18(13):1389–401 (78 ref.)

Linkage disequilibrium mapping in isolated populations: the example of Finland revisited. de la Chapelle A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12416–23

Informatic selection of a neural crest-melanocyte cDNA set for microarray analysis. Loftus SK, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9277–80

DNA secondary structure: a common and causative factor for expansion in human disease. McMurray CT. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1823–5 (44 ref.)

Tests and estimates of allelic association in complex inheritance. Morton NE, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11389–93

DNA repair and chromatin structure in genetic diseases. Lambert MW, et al. **Prog Nucleic Acid Res Mol Biol** 1999; 63:257–310 (269 ref.)

Genetic disorders associated with cancer predisposition and genomic instability. Vessey CJ, et al. **Prog Nucleic Acid Res Mol Biol** 1999;63:189–221 (229 ref.)

Human diseases and genomic imprinting. Hall JG. **Results Probl Cell Differ** 1999;25:119–32 (60 ref.)

Incorporation of family history in logistic regression models. Houwing-Duistermaat JJ, et al. **Stat Med** 1998 Dec 30; 17(24):2865–82

RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Culbertson MR. **Trends Genet** 1999 Feb;15(2):74–80 (59 ref.)

Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. Lupski JR. **Trends Genet** 1998 Oct;14(10):417–22 (79 ref.)

Heritable collagen disorders: from phenotype to genotype. De Paepe A. **Verh K Acad Geneeskd Belg** 1998; 60(5):463–82; discussion 482–4 (52 ref.)

[Human genetics and noncommunicable diseases] **J Pharm Belg** 1999 Jan–Feb;54(1):29–31 (0 ref.) **(Fre)**

[Determining the genetic component of common diseases] Feingold J. **Pathol Biol (Paris)** 1998 Nov;46(9):701–4 (0 ref.) (Eng. Abstr.) **(Fre)**

[Genomic imprinting] Tachdjian G, et al. **Presse Med** 1998 Feb 28;27(8):365–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Hereditary neurological diseases caused by amplification of triplet repetitions] Warter JM, et al. **Presse Med** 1998 Feb 28;27(8):376–81 (70 ref.) (Eng. Abstr.) **(Fre)**

[Monofactorial heredity] de Lonlay P. **Rev Prat** 1998 Jan 15;48(2):223–7 **(Fre)**

[Highlights and trends German Genome Product 1999 anniversity in Ulm: from the sick-bed to workbench or "from bench to bedside"] Schober O. **Nuklearmedizin** 1999; 38(5):51–60 **(Ger)**

[Molecular pediatrics: "childhood illnesses" as pioneers in medicine] Steinmann B. **Schweiz Med Wochenschr** 1999 Jan 12;129(1–2):25–9 **(Ger)**

[Cloning of disease genes by chromosome mapping] Suzuki M, et al. **Seikagaku** 1999 Jan;71(1):65–9 (16 ref.) **(Jpn)**

[Molecular genetic mechanisms and hereditary disease] Nesland JM. **Tidsskr Nor Laegeforen** 1999 Feb 28; 119(6):779 **(Nor)**

[Diversity of hereditary pathology in the population of Marii El Republic and its differentiation with respect to gene frequencies for hereditary diseases] Ginter EK, et al. **Genetika** 1998 Jul;34(7):963–72 (Eng. Abstr.) **(Rus)**

[A medico-genetic description of inhabitants of two regions of the Kransnodar Krai] Mamedova RA, et al. **Genetika** 1999 Jan;35(1):68–73 (Eng. Abstr.) **(Rus)**

[Essays on modern molecular genetic. Essay 8. Genomic diseases and new molecular genetics. Part 2. Cancer--a genomic disease. "Cancer genes" and signal transduction in the cell] Sverdlov ED. **Mol Gen Mikrobiol Virusol** 1999; (2):3–22 **(Rus)**

[Hereditary diseases with primary and secondary DNA repair defects] Spivak IM. **Tsitologiia** 1999;41(5):338–79 (614 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

[Genetic diseases in the Mediterranean region: a historical perspective] Battin J. **Arch Pediatr** 1998;5 Suppl 4:397S–406S **(Fre)**

[Different interpretations of the "regulation for preventing genetically defective progeny" by the Marburg Medical Faculty] Krähwinkel E. **Medizinhist J** 1999;34(2):159–209 **(Ger)**

METABOLISM

Protein misfolding and degradation in genetic diseases. Bross P, et al. **Hum Mutat** 1999;14(3):186–98 (66 ref.)

[Structure and metabolism of collagens in various pathologies] Bondarenko LB. **Ukr Biokhim Zh** 1998 May–Jun;70(3):12–23 (111 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Extracutaneous analogies of Blaschko lines. Rott HD. **Am J Med Genet** 1999 Aug 6;85(4):338–41 (18 ref.)

Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Werness BA, et al. **Hum Pathol** 1999 Feb; 30(2):151–7

PHYSIOPATHOLOGY

Genetic diseases and gene knockouts reveal diverse connexin functions. White TW, et al. **Annu Rev Physiol** 1999; 61:283–310 (143 ref.)

The burden of genetic disease and attitudes towards gene testing in Alport syndrome. Pajari H, et al. **Pediatr Nephrol** 1999 Aug;13(6):471–6

[Genetic diseases at an adult age: from pediatric occurrence to slow disclosure in internal medicine] Rousset H, et al. **Rev Med Interne** 1998;19 Suppl 3:355S–357S **(Fre)**

PREVENTION & CONTROL

National Confidential Enquiry into counselling for genetic disorders by non-geneticists: general recommendations and specific standards for improving care. Harris R, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):658–63

Prepregnancy testing for single-gene disorders by polar body analysis. Verlinsky Y, et al. **Genet Test** 1999;3(2):185–90

Prevention of genetic disorders. Panthaki MH. **Indian J Med Sci** 1998 Feb;52(2):66–9 (3 ref.)

Genetics, age, and infertility. Nasseri A, et al. **Maturitas** 1998 Oct 12;30(2):189–92 (21 ref.)

[Neonatal screening in Denmark. Status and future perspectives] Simonsen H, et al. **Ugeskr Laeger** 1998 Sep

28;160(40):5777–82 (32 ref.) (Eng. Abstr.) **(Dan)**
[Neonatal screening for hereditary diseases (editorial)] Skovby F. **Ugeskr Laeger** 1998 Sep 28;160(40):5765 **(Dan)**
[Monofactorial heredity] de Lonlay P. **Rev Prat** 1998 Jan 15;48(2):223–7 **(Fre)**
[Medicine of the future] González Liboy G. **Bol Asoc Med P R** 1998 Jul–Dec;90(7–12):105 **(Spa)**

PSYCHOLOGY

Phenotype definition and association studies in behavioral genetics [letter] MD LS. **Mol Psychiatry** 1999 Jul;4(4):316

THERAPY

The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Rosales F, et al. **Bone Marrow Transplant** 1999 May;23(9):861–5
Genetic research stimulates development of individual treatment. Kluft C. **Cardiologia** 1999 Feb;44(2):119–24 (25 ref.)
Genetics of diseases. Web alert. Makalowski W, et al. **Curr Opin Genet Dev** 1998 Jun;8(3):269–70
Gene Therapy Advisory Committee. Report on the potential use of gene therapy in utero. Health Departments of the United Kingdom, November 1998 [news] **Hum Gene Ther** 1999 Mar 1;10(4):689–92
Ribozymes as therapeutic tools for genetic disease. Phylactou LA, et al. **Hum Mol Genet** 1998;7(10):1649–53 (54 ref.)
In pursuit of new developments for gene therapy of human diseases. Palù G, et al. **J Biotechnol** 1999 Feb 5;68(1):1–13 (45 ref.)
Correction of genetic disease by making sense from nonsense [comment] Kaufman RJ. **J Clin Invest** 1999 Aug; 104(4):367–8 (24 ref.). Comment on: J Clin Invest 1999 Aug;104(4):375–81.
The J.I.M. interview. James M. Wilson, MD, PhD [interview] Wilson JM. **J Investig Med** 1998 Dec; 46(9):425–9
In utero gene therapy is still a distant promise [news] Jenks S. **J Natl Cancer Inst** 1999 May 19;91(10):829–30
Prospects for in utero human gene therapy [see comments] Zanjani ED, et al. **Science** 1999 Sep 24;285(5436):2084–8 (39 ref.). Comment in: Science 1999 Sep 24;285(5436):2071–2.
[Treatment of hereditary and malignant diseases by regulating genetic transcription?] Skovby F. **Ugeskr Laeger** 1998 Dec 14;160(51):7447 **(Dan)**
[Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII] Favrot MC. **Therapie** 1998 Jul–Aug;53(4):381–4 (6 ref.) (Eng. Abstr.) **(Fre)**
[Antisense oligonucleotides arrest the synthesis of disease promoting proteins] Schnädelbach S. **Med Monatsschr Pharm** 1998 Dec;21(12):394–5 **(Ger)**
[The advances of gene therapy in this quarter century] Ito Y, et al. **Gan To Kagaku Ryoho** 1999 Jun;26 Suppl 1:51–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Attitudes of Finnish veterinarians about programs to control canine genetic diseases. Leppänen M, et al. **Prev Vet Med** 1999 Feb 15;38(4):239–57

HEREDITARY MOTOR AND SENSORY NEUROPATHIES see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HEREDITARY MULTIPLE EXOSTOSES see **EXOSTOSES, MULTIPLE HEREDITARY**

HEREDITARY NONPOLYPOSIS COLORECTAL NEOPLASMS see **COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS**

HEREDITARY OPALESCENT DENTIN see **DENTINOGENESIS IMPERFECTA**

HEREDITARY OPTIC ATROPHY see **OPTIC ATROPHY, HEREDITARY**

HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HEREDITARY SPASTIC PARAPLEGIA see **SPASTIC PARAPLEGIA, HEREDITARY**

HEREDITARY SPINAL SCLEROSIS see **FRIEDREICH'S ATAXIA**

HEREDITARY TYPE I MOTOR AND SENSORY NEUROPATHY see **CHARCOT-MARIE DISEASE**

HEREDITARY TYPE IV MOTOR AND SENSORY NEUROPATHY see **REFSUM DISEASE**

HEREDITY see **GENETICS**

HEREDOPATHIA ATACTICA POLYNEURITIFORMIS see **REFSUM DISEASE**

HERELLEA see **ACINETOBACTER**

HERLITZ DISEASE see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

HERMANSKI-PUDLAK SYNDROME see **ALBINISM, OCULOCUTANEOUS**

HERMAPHRODITISM

Sperm competition in the absence of fertilization in Caenorhabditis elegans. Singson A, et al. **Genetics** 1999 May;152(1):201–8
A history of intersexuality: from the age of gonads to the age of consent. Dreger AD. **J Clin Ethics** 1998 Winter; 9(4):345–55 (22 ref.)
Macroevolutionary patterns of male reproductive investment in a clade of parasitic hermaphrodites. Zamparo D, et al. **J Parasitol** 1999 Jun;85(3):540–4
Solving the complementarity dilemma: evolving strategies for simultaneous hermaphroditism. Crowley PH, et al. **J Theor Biol** 1998 Nov 7;195(1):13–26
Evidence for strategic egg production in a hermaphroditic cestode. Wedekind C, et al. **Parasitology** 1998 Oct;117 (Pt 4):373–82

BLOOD

A reliable endocrine test with human menopausal gonadotropins for diagnosis of true hermaphroditism in early infancy. Mendez JP, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3523–6

COMPLICATIONS

May–Hegglin anomaly in a pregnancy complicated by intrauterine growth restriction and ambiguous genitalia. Kinsella MJ, et al. **Mil Med** 1999 Aug;164(8):607–8

DIAGNOSIS

A reliable endocrine test with human menopausal gonadotropins for diagnosis of true hermaphroditism in early infancy. Mendez JP, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3523–6
Betwixt and between: the past and future of intersexuality. Crouch RA. **J Clin Ethics** 1998 Winter;9(4):372–84 (85 ref.)
Intersexuality: what should careproviders do now. Howe EG. **J Clin Ethics** 1998 Winter;9(4):337–44 (36 ref.)
[Change in gender identity in male pseudohermaphroditism. Differential diagnosis of transsexualism and intersexuality] Windgassen K, et al. **Nervenarzt** 1997 Nov;68(11):917–9 (Eng. Abstr.) **(Ger)**
[A case of true hermaphroditism] Warenik-Szymankiewicz A, et al. **Ginekol Pol** 1997 Sep;68(9):440–3 (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

P450scc-like immunoreactivity throughout gonadal restructuring in the protogynous hermaphrodite Thalassoma duperrey. Morrey CE, et al. **Int J Dev Biol** 1998 Sep;42(6):811–6

EPIDEMIOLOGY

The incidence of intersexuality in children with cryptorchidism and hypospadias: stratification based on gonadal palpability and meatal position. Kaefer M, et al. **J Urol** 1999 Sep;162(3 Pt 2):1003–6; discussion 1006–7

GENETICS

True hermaphroditism with partial duplication of chromosome 22 and without SRY. Aleck KA, et al. **Am J Med Genet** 1999 Jul 2;85(1):2–4
Abnormalities of gonadal differentiation. Berkovitz GD, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):133–42 (42 ref.)
Endocrine and metabolism [editorial] Root AW. **Curr Opin Pediatr** 1999 Aug;11(4):329–32 (12 ref.)
True hermaphroditism associated with microphthalmia. Hayashi T, et al. **Eur J Endocrinol** 1999 Jan;140(1):62–5
Homologs of the Caenorhabditis elegans masculinizing gene her-1 in C. briggsae and the filarial parasite Brugia malayi. Streit A, et al. **Genetics** 1999 Aug;152(4):1573–84
Analysis of the doublesex female protein in Drosophila melanogaster: role on sexual differentiation and behavior and dependence on intersex. Waterbury JA, et al. **Genetics** 1999 Aug;152(4):1653–67
High-resolution human/goat comparative map of the goat polled/intersex syndrome (PIS): the human homologue is contained in a human YAC from HSA3q23. Vaiman D, et al. **Genomics** 1999 Feb 15;56(1):31–9
Sex-determining mechanism in Buergeria buergeri (Anura, Rhacophoridae). III. Does the ZZW triploid frog become female or male? Ohta S, et al. **J Exp Zool** 1999 Feb 15; 283(3):295–306
True hermaphrodites in the southeastern region of Brazil: a different cytogenetic and gonadal profile. Guerra Júnior G, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug; 11(4):519–24
Long-term, quantitative analysis of gametogenesis in autotriploid rainbow trout, Oncorhynchus mykiss. Carrasco LA, et al. **J Reprod Fertil** 1998 Jul;113(2):197–210
A 39,X/40,XY true hermaphrodite mouse with normal ovarian function. Ishikawa H, et al. **Reprod Fertil Dev** 1997; 9(8):775–9

PHYSIOPATHOLOGY

Relationships between sex and the size and number of forebrain gonadotropin-releasing hormone-immunoreactive neurones in the ballan wrasse (Labrus berggylta), a protogynous hermaphrodite. Elofsson UO, et al. **J Comp Neurol** 1999 Jul 19;410(1):158–70

PSYCHOLOGY

Health-related quality of life in intersexuality. Meyer-Bahlburg HF. **Acta Paediatr Suppl** 1999 Feb; 88(428):114–5 (14 ref.)
Intersexuality: recommendations for management [letter] Diamond M. **Arch Sex Behav** 1998 Dec;27(6):634–41
Abnormal sexual development and psychosexual issues. Hines M. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):173–89 (69 ref.)
Long-term outcomes and changing attitudes to intersexuality. Schober JM. **BJU Int** 1999 Apr;83 Suppl 3:39–50 (106 ref.)
Assignment of sex in neonates with ambiguous genitalia. Reiner WG. **Curr Opin Pediatr** 1999 Aug;11(4):363–5 (14 ref.)
Intersexuality: waiting for change? [letter; comment] Chase C. **Hastings Cent Rep** 1999 Mar–Apr;29(2):4. Comment on: Hastings Cent Rep 1998 May–Jun;28(3):36–9.
The Hanukkah bush: ethical implications in the clinical management of intersex. Groveman SA. **J Clin Ethics** 1998 Winter;9(4):356–9
For the sake of the children: destigmatizing intersexuality. Preves SE. **J Clin Ethics** 1998 Winter;9(4):411–20 (24 ref.)
An unusual case of delusional misidentification: 'delusional hermaphroditism'. Mulholland C, et al. **Psychopathology** 1999 Jul–Aug;32(4):220–4
Quality-of-life studies in patients with ambiguous genitalia. Schober JM. **World J Urol** 1999 Aug;17(4):249–52

SURGERY

Psychological evaluation of intersex children [letter; comment] Chase C. **Arch Sex Behav** 1999 Feb;28(1):103–5 . Comment on: Arch Sex Behav 1998 Apr;27(2):125–44.
Abnormal prostatic utricle configuration in hypospadias and intersex patients. Ciftçi AO, et al. **Eur J Pediatr Surg** 1999 Jun;9(3):167–72
Surgical progress is not the answer to intersexuality. Chase C. **J Clin Ethics** 1998 Winter;9(4):385–92 (40 ref.)
Intersexuality: what should careproviders do now. Howe EG. **J Clin Ethics** 1998 Winter;9(4):337–44 (36 ref.)
Pediatric ethics and the surgical assignment of sex. Kipnis K, et al. **J Clin Ethics** 1998 Winter;9(4):398–410 (56 ref.)
A surgeon's response to the intersex controversy. Schober JM. **J Clin Ethics** 1998 Winter;9(4):393–7 (12 ref.)
Ambiguous genitalia, gender-identity problems, and sex reassignment. Dittmann RW. **J Sex Marital Ther** 1998 Oct–Dec;24(4):255–71
Pediatric management of ambiguous and traumatized genitalia. Diamond M. **J Urol** 1999 Sep;162(3 Pt 2):1021–8 (81 ref.)
[Two cases of true hermaphrodite: the usefulness of laparoscopic gonadectomy in childhood. A case report] Sugimoto S, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Dec;89(12):971–4 (Eng. Abstr.) **(Jpn)**

THERAPY

Betwixt and between: the past and future of intersexuality. Crouch RA. **J Clin Ethics** 1998 Winter;9(4):372–84 (85 ref.)
The Hanukkah bush: ethical implications in the clinical management of intersex. Groveman SA. **J Clin Ethics** 1998 Winter;9(4):356–9
For the sake of the children: destigmatizing intersexuality. Preves SE. **J Clin Ethics** 1998 Winter;9(4):411–20 (24 ref.)
Management of intersex: a shifting paradigm. Wilson BE, et al. **J Clin Ethics** 1998 Winter;9(4):360–9 (32 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of fetal ambiguous gender using three-dimensional sonography [letter] Merz E, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):217–9

VETERINARY

Xenoendorine disrupters--environmental impacts. Sumpter JP. **Toxicol Lett** 1998 Dec 28;102–103:337–42 (20 ref.)

HERMES ANTIGEN FAMILY see **RECEPTORS, LYMPHOCYTE HOMING**

HERNIA

COMPLICATIONS

Chronic pelvic pain, hernias and the general surgeon [editorial] Kavic MS. **JSLS** 1999 Apr–Jun;3(2):89–90
Transient locked-in syndrome after uncal herniation. Wijdicks EF, et al. **Neurology** 1999 Apr 12;52(6):1296–7
[A strangulated perineal hernia. A rare case of intestinal obstruction] Sciacca P, et al. **Minerva Chir** 1998 Sep; 53(9):739–41 (5 ref.) (Eng. Abstr.) **(Ita)**

HERNIA

DIAGNOSIS

Images in cardiothoracic surgery. Herniation of emphysematous bulla through a chest tube site. Konecny JA, et al. **Ann Thorac Surg** 1999 Aug;68(2):584

Descending mesocolon defect herniation: case report. Liew KL, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar; 22(1):133–7

Acute testicular pain. Kumar N, et al. **Postgrad Med J** 1998 Oct;74(876):635–6

Rectal duplication cyst with a large perineal hernia presenting as recurrent perineal abscesses. Connaughton JC, et al. **Surgery** 1998 Nov;124(5):926–8

[Importance of defecography in the evaluation of genital prolapses] Jamet F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1999 Feb;28(1):17–23 (Eng. Abstr.) **(Fre)**

[Laparoscopic treatment for parapubic hernia, complications after radical prostatectomy] Matuszewski M, et al.
Wiad Lek 1998;51 Suppl 3:20–4 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Efficacy of lumbar chemonucleolysis in the treatment of foraminal and extra-foraminal hernias] Riquelme C, et al. **J Neuroradiol** 1999 Mar;26(1 Suppl):35–48 (Eng. Abstr.) **(Fre)**

[Effective treatment of a large muscle hernia by local botulinum toxin administration] Burg D, et al.
Handchir Mikrochir Plast Chir 1999 Mar;31(2):75–8 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiologic, economic, and sociologic aspects of hernia surgery in the United States in the 1990s. Rutkow IM. **Surg Clin North Am** 1998 Dec;78(6):941–51, v–vi (20 ref.)

ETIOLOGY

[Intercostal incisional hernia: case report] Centorrino T, et al. **G Chir** 1998 Nov-Dec;19(11–12):445–7 (Eng. Abstr.) **(Ita)**

GENETICS

Familial synspondylism: progressive scoliosis and multiple hernias in a kinship. Mullins DA, et al.
J Pediatr Orthop 1998 Sep–Oct;18(5):606–10

HISTORY

The historical development of prosthetics in hernia surgery. DeBord JR. **Surg Clin North Am** 1998 Dec;78(6):973–1006, vi

RADIOGRAPHY

An unusual complication of a biliary stent-small bowel perforation of an incarcerated hernia sac. Mastorakos DP, et al. **Am J Gastroenterol** 1998 Dec;93(12):2533–5

Herniography in the investigation of groin pain in adults. Jones RL, et al. **Clin Radiol** 1998 Nov;53(11):805–8 (11 ref.)

[Picture of the month. Iatrogenic hernia] Larsen CG, et al. **Ugeskr Laeger** 1999 Mar 29;161(13):1934 **(Dan)**

[Computerized tomography in the diagnosis of lumbar incisional hernia. Report of 3 cases] Catalano O, et al.
Radiol Med (Torino) 1998 Nov;96(5):523–4 **(Ita)**

SURGERY

Large incisional hernia repair using intraperitoneal placement of expanded polytetrafluoroethylene. Utrera González A, et al. **Am J Surg** 1999 Apr;177(4):291–3

Communication between hospital and general practitioners after day case surgery: a patient safety issue. Gui GP, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1 Suppl):8–9, 12

The continuing challenge of parastomal hernia: failure of a novel polypropylene mesh repair [letter; comment] Tekkis PP, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):140–1. Comment on: Ann R Coll Surg Engl 1998 May;80(3):184–7.

Controlled trial of preperitoneal local anaesthesia for reducing pain following laparoscopic hernia repair [letter; comment] de Souza RM, et al. **Br J Surg** 1999 Jan;86(1):137 . Comment on: Br J Surg 1998 Jul;85(7):1013–4.

Methods of repair and risk for reoperation in Swedish hernia surgery from 1992 to 1996. Nilsson E, et al. **Br J Surg** 1998 Dec;85(12):1686–91

Extraperitoneoscopic ureterocutaneostomy with hernia repair. Aydin S, et al. **Int Urol Nephrol** 1998;30(5):559–60

Laparoscopic repair of paracolostomy hernia. Bickel A, et al. **J Laparoendosc Adv Surg Tech A** 1999 Aug;9(4):353–5

Hernia audit in private practice [letter; comment] Kark AE, et al. **J R Soc Med** 1999 Feb;92(2):102–3. Comment on: J R Soc Med 1998 Nov;91(11):567. Comment on: J R Soc Med 1998 Nov;91(11):583–4.

A new laparoscopic retroperitoneal posterior culdoplasty technique. Ostrzenski A. **J Reprod Med** 1999 Jun; 44(6):504–10

Virgin and recurrent groin hernia: a comparison of patient recovery following endoscopic preperitoneal herniorrhaphy. Ahmad SA, et al.
J Soc Laparoendosc Surg 1997 Oct–Dec;1(4):337–40

Repair of fascial defects in dogs using carbon fibers. Morris DM, et al. **J Surg Res** 1998 Dec;80(2):300–3

Update of hernia repair–1998 [news] Patton ML. **JSLS** 1999 Jan–Mar;3(1):88b

Overview of nonrandomized studies of laparoscopic hernia repair. Horgan PG. **Semin Laparosc Surg** 1998 Dec; 5(4):233–7

The learning curve for laparoscopic hernia repair. Wright D, et al. **Semin Laparosc Surg** 1998 Dec;5(4):227–32 (26 ref.)

Totally extraperitoneal laparoscopic hernia repair. Wright D, et al. **Semin Laparosc Surg** 1998 Dec;5(4):217–23

Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Deysine M.
Surg Clin North Am 1998 Dec;78(6):1105–15, viii (26 ref.)

Hernia registers and specialization. Nilsson E, et al.
Surg Clin North Am 1998 Dec;78(6):1141–55, ix

Epidemiologic, economic, and sociologic aspects of hernia surgery in the United States in the 1990s. Rutkow IM.
Surg Clin North Am 1998 Dec;78(6):941–51, v–vi (20 ref.)

Laparoscopic herniorrhaphy: where are we now? [editorial; comment] Brooks DC. **Surg Endosc** 1999 Apr;13(4):321–2 . Comment on: Surg Endosc 1999 Apr;13(4):328–31.

Endoscopic vs conventional hernia repair from an immunologic point of view. Decker D, et al.
Surg Endosc 1999 Apr;13(4):335–9

Laparoscopic hernioplasty: significant complications [see comments] Felix EL, et al. **Surg Endosc** 1999 Apr; 13(4):328–31. Comment in: Surg Endosc 1999 Apr;13(4):321–2.

Video-assisted thoracoscopic repair of an intercostal pulmonary hernia. Van Den Bossche MRP, et al.
Surg Endosc 1999 Feb;13(2):166–7

Cigarette smoking, herniation, and recurrence [letter; comment] Read RC. **Surgery** 1998 Nov;124(5):942. Comment on: Surgery 1998 Apr;123(4):450–5.

[Postoperative analgesia in children after hernioplasty. Wound infiltration with different concentrations of bupivacaine: a pilot study] Bültmann M, et al.
Anaesthesist 1999 Jul;48(7):439–43 (Eng. Abstr.) **(Ger)**

[Intercostal incisional hernia: case report] Centorrino T, et al. **G Chir** 1998 Nov-Dec;19(11–12):445–7 (Eng. Abstr.) **(Ita)**

[A case of internal hernia through a defect in the falciform ligament treated with laparoscopic surgery] Kobayashi S, et al. **Nippon Geka Gakkai Zasshi** 1999 Aug;100(8):513–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic treatment for parapubic hernia, complications after radical prostatectomy] Matuszewski M, et al.
Wiad Lek 1998;51 Suppl 3:20–4 (Eng. Abstr.) **(Pol)**

[Surgical treatment of true muscle hernias of the extremities] Nochëvkin VA, et al. **Vestn Khir Im I I Grek** 1999; 158(3):70–1 (Eng. Abstr.) **(Rus)**

VETERINARY

Perineal hernia with bladder retroflexion in a female cocker spaniel. Niles JD, et al. **J Small Anim Pract** 1999 Feb; 40(2):92–4

HERNIA, ABDOMINAL see **HERNIA, VENTRAL**

HERNIA, CEREBRAL see **ENCEPHALOCELE**

HERNIA, DIAPHRAGMATIC

[Bochdalek's diaphragmatic hernia in adults. Description of a clinical case] La Ganga V, et al. **Minerva Chir** 1999 Jun; 54(6):443–5 (Eng. Abstr.) **(Ita)**

BLOOD

Retinol status of newborn infants with congenital diaphragmatic hernia. Major D, et al. **Pediatr Surg Int** 1998 Oct;13(8):547–9

COMPLICATIONS

High prevalence of sensorineural hearing loss among survivors of neonatal congenital diaphragmatic hernia. Western Canadian ECMO Follow-up Group. Robertson CM, et al. **Am J Otol** 1998 Nov;19(6):730–6

Congenital diaphragmatic hernia. A cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Thébaud B, et al. **Biol Neonate** 1998 Nov; 74(5):323–36 (106 ref.)

Diagnosis and hazards of unexpected diaphragmatic hernias during colonoscopy: report of two cases. Baumann UA, et al. **Endoscopy** 1999 Mar;31(3):274–6

Morgagni hernia: unique presentations in elderly patients. Lev-Chelouche D, et al. **J Clin Gastroenterol** 1999 Jan; 28(1):81–2

Left heart hypoplasia in neonates having congenital diaphragmatic hernia and treated with ECMO [letter; comment] Baumgart S, et al. **J Pediatr Surg** 1998 Dec; 33(12):1848. Comment on: J Pediatr Surg 1998 Jun;33(6):943–5.

Postnatal pulmonary hypertension after repair of congenital diaphragmatic hernia: predicting risk and outcome. Iocono JA, et al. **J Pediatr Surg** 1999 Feb;34(2):349–53

Bochdalek diaphragmatic hernia presenting with acute gastric dilatation. Quah BS, et al. **J Pediatr Surg** 1999 Mar; 34(3):512–4

Acquired intrathoracic kidney. Suárez S, et al.
P R Health Sci J 1998 Sep;17(3):289–91

Internal cardioversion of atrial fibrillation with a single lead configuration in a patient with massive diaphragmatic herniation. Schneider MA, et al.
Pacing Clin Electrophysiol 1998 Nov;21(11 Pt 1):2149–51

Liver herniation into the pericardial sac [letter; comment] Milovic I. **Pediatr Radiol** 1999 Jan;29(1):77. Comment on: Pediatr Radiol 1996 Nov;26(11):791–3.

Congenital diaphragmatic hernia and chromosomal abnormalities: report of a lethal association. Hilfiker ML, et al. **Pediatr Surg Int** 1998 Oct;13(8):550–2

CONGENITAL

Intubation of newborn during delivery with intact umbilical cord--a case report. Huang CJ, et al.
Acta Anaesthesiol Sin 1999 Jun;37(2):97–100

Helical CT amniography of congenital diaphragmatic hernia. Urban BA, et al. **AJR Am J Roentgenol** 1999 Mar; 172(3):809–12

Congenital diaphragmatic hernia with gastric volvulus presenting as an acute tension gastrothorax. Beckmann KR, et al. **Am J Emerg Med** 1999 Jan;17(1):35–7

High prevalence of sensorineural hearing loss among survivors of neonatal congenital diaphragmatic hernia. Western Canadian ECMO Follow-up Group. Robertson CM, et al. **Am J Otol** 1998 Nov;19(6):730–6

Congenital diaphragmatic hernia: experience with preoperative stabilization and delayed surgery without ECMO and inhaled nitric oxide. Al-Hathal M, et al.
Am J Perinatol 1998 Aug;15(8):487–90

Diagnosis and differentiation of congenital diaphragmatic hernia from other noncardiac thoracic fetal masses. Kasales CJ, et al. **Am J Perinatol** 1998;15(11):623–8

Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Elliott ES, et al. **Ann Pharmacother** 1999 Apr;33(4):419–22

Detrimental effects of standard medical therapy in congenital diaphragmatic hernia. Kays DW, et al. **Ann Surg** 1999 Sep; 230(3):340–8; discussion 348–51

Management of congenital diaphragmatic hernia. Davis CF, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F1–3

Congenital diaphragmatic hernia. A cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Thébaud B, et al. **Biol Neonate** 1998 Nov; 74(5):323–36 (106 ref.)

Primary surfactant deficiency [letter; comment] McCabe AJ, et al. **Crit Care Med** 1999 Jun;27(6):1219–21 (19 ref.). Comment on: Crit Care Med 1998 Mar;26(3):573–80.

A new ventilator improves CO2 removal in newborn lambs with congenital diaphragmatic hernia [see comments] Schnitzer JJ, et al. **Crit Care Med** 1999 Jan;27(1):109–12 . Comment in: Crit Care Med 1999 Jan;27(1):18–9.

Congenital diaphragmatic hernia: report of three cases. Kiguli-Malwadde E, et al. **East Afr Med J** 1998 Oct; 75(10):614–5

Tracheoscopic endoluminal plugging using an inflatable device in the fetal lamb model. Deprest JA, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Dec;81(2):165–9

Extreme Poland anomaly associated with congenital diaphragmatic hernia [letter] Hou JW, et al.
Eur J Pediatr 1999 May;158(5):433–4

Recurrent congenital diaphragmatic hernia; which factors are involved? Hajer GF, et al. **Eur J Pediatr Surg** 1998 Dec; 8(6):329–33

Bochdalek hernia in adulthood: a case report and review of recent literature. Jastaniah S, et al.
Indian J Chest Dis Allied Sci 1998 Oct–Dec;40(4):281–5 (14 ref.)

Dypiridamole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia. Thébaud B, et al. **Intensive Care Med** 1999 Mar;25(3):300–3

Fetal tracheal occlusion in the rat model of nitrofen-induced congenital diaphragmatic hernia. Kitano Y, et al.
J Appl Physiol 1999 Aug;87(2):769–75

Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. Cheung PY, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):233–9

Pulmonary arterioles from rats with congenital diaphragmatic hernias are hypoplastic but not hyperresponsive. Au-Fliegner M, et al. **J Pediatr Surg** 1998 Sep;33(9):1366–70

Congenital diaphragmatic hernia: developing a protocolized approach. Finer NN, et al. **J Pediatr Surg** 1998 Sep; 33(9):1331–7

Postnatal pulmonary hypertension after repair of congenital diaphragmatic hernia: predicting risk and outcome. Iocono JA, et al. **J Pediatr Surg** 1999 Feb;34(2):349–53

A population-based study of congenital diaphragmatic hernia: impact of associated anomalies and preoperative blood gases on survival. Kaiser JR, et al.
J Pediatr Surg 1999 Aug;34(8):1196–202

Tracheal ligation and mechanical ventilation do not improve the antioxidant enzyme status in the lamb model of congenital diaphragmatic hernia. Kapur P, et al.
J Pediatr Surg 1999 Feb;34(2):270–2

Less invasive ways to treat CDH prenatally [letter; comment] Laberge JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1183–4. Comment on: J Pediatr Surg 1998 Aug;33(8):1198–205.

Cardiovascular malformations in experimental congenital diaphragmatic hernia. Losty PD, et al. **J Pediatr Surg** 1999 Aug;34(8):1203–7

Improved pulmonary function after surgical reduction of congenital diaphragmatic hernia in lambs. Major D, et al.

J Pediatr Surg 1999 Mar;34(3):426–9

Hypoxic pulmonary vasoconstriction is impaired in rats with nitrofen-induced congenital diaphragmatic hernia. Newell MA, et al. **J Pediatr Surg** 1998 Sep;33(9):1358–62

Bochdalek diaphragmatic hernia presenting with acute gastric dilatation. Quah BS, et al. **J Pediatr Surg** 1999 Mar; 34(3):512–4

The effects of prenatal intraamniotic surfactant or dexamethasone administration on lung development are comparable to changes induced by tracheal ligation in an animal model of congenital diaphragmatic hernia [see comments] Tannuri U, et al. **J Pediatr Surg** 1998 Aug; 33(8):1198–205. Comment in: J Pediatr Surg 1999 Jul;34(7):1183–4.

Ventilatory casebook. Late presentation of congenital diaphragmatic hernia in association with group B streptococcal sepsis and meningitis. McGettigan MC. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):485–8

The laparoscopic approach for repair of Morgagni hernias. Nguyen T, et al. **J Soc Laparoendosc Surg** 1998 Jan–Mar; 2(1):85–8 (20 ref.)

Congenital diaphragmatic hernia: mortality determinants in a Hispanic population. Serrano P, et al. **P R Health Sci J** 1998 Dec;17(4):317–21

Severe bronchial hyperreactivity as a sequel to congenital diaphragmatic hernia. Skousgaard SG. **Paediatr Anaesth** 1998;8(6):503–5

Differential gene expression at gestational days 14 and 16 in normal and nitrogen-induced hypoplastic murine fetal lungs with coexistent diaphragmatic hernia. Causak RA, et al. **Pediatr Pulmonol** 1998 Nov;26(5):301–11

The lungs in congenital diaphragmatic hernia: do we understand? IJsselstijn H, et al. **Pediatr Pulmonol** 1998 Sep; 26(3):204–18 (187 ref.)

Expression of clara cell 10-kDa protein (CC10) in congenital diaphragmatic hernia. Asabe K, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):36–9

Unilateral agenesis of the diaphragm: a separate entity or an extremely large defect? Baglaj M, et al. **Pediatr Surg Int** 1999;15(3–4):206–9

Tracheal ligation in CDH: bigger may not be better [letter] Bambini DA, et al. **Pediatr Surg Int** 1998 Sep;13(7):537–8

Pulmonary neuroendocrine cells in nitrofen-induced diaphragmatic hernia and the effect of prenatal glucocorticoids. Gosney JR, et al. **Pediatr Surg Int** 1999; 15(3–4):180–3

Congenital diaphragmatic hernia and chromosomal abnormalities: report of a lethal association. Hilfiker ML, et al. **Pediatr Surg Int** 1998 Oct;13(8):550–2

Prolonged preoperative stabilization using high-frequency oscillatory ventilation does not improve the outcome in neonates with congenital diaphragmatic hernia. Kamata S, et al. **Pediatr Surg Int** 1998 Oct;13(8):542–6

Familial bilateral congenital diaphragmatic hernia. Kufeji DI, et al. **Pediatr Surg Int** 1999;15(1):58–60 (15 ref.)

Lung hypoplasia caused by nitrofen is mediated by down-regulation of thyroid transcription factor TTF-1. Losada A, et al. **Pediatr Surg Int** 1999;15(3–4):188–91

Retinol status of newborn infants with congenital diaphragmatic hernia. Major D, et al. **Pediatr Surg Int** 1998 Oct;13(8):547–9

Analysis of patients with congenital diaphragmatic hernia requiring pre-operative extracorporeal membrane oxygenation (ECMO). Nagaya M, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):25–9

Prediction of outcome in congenital diaphragmatic hernia. Numanoglu A, et al. **Pediatr Surg Int** 1998 Oct;13(8):564–8

Upregulated tumor necrosis factor-alpha gene expression in the hypoplastic lung in patients with congenital diaphragmatic hernia. Ohshiro K, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):21–4

Effect of antenatal glucocorticoid administration on insulin-like growth factor I and II levels in hypoplastic lung in nitrofen-induced congenital diaphragmatic hernia in rats. Oue T, et al. **Pediatr Surg Int** 1999;15(3–4):175–9

Congenital diaphragmatic hernia: studies on outcome and etiology [editorial] Schärli AF. **Pediatr Surg Int** 1998 Oct; 13(8):541

Comparison of the pulmonary vasculature in newborns and stillborns with congenital diaphragmatic hernia. Taira Y, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):30–5

Concurrent right diaphragmatic hernia and esophageal atresia. Thakral CL, et al. **Pediatr Surg Int** 1998 Nov; 14(1–2):96–7 (14 ref.)

The tracheobronchial tree is abnormal in experimental congenital diaphragmatic hernia. Xia H, et al. **Pediatr Surg Int** 1999;15(3–4):184–7

Fetal liver position and perinatal outcome for congenital diaphragmatic hernia. Albanese CT, et al. **Prenat Diagn** 1998 Nov;18(11):1138–42

Management of congenital diaphragmatic hernia diagnosed prenatally: an update. Geary M. **Prenat Diagn** 1998 Nov; 18(11):1155–8 (28 ref.)

Diaphragmatic hernia of Morgagni. LaRosa DV Jr, et al. **South Med J** 1999 Apr;92(4):409–11

Immunohistochemical distribution of bombesin-positive pulmonary neuroendocrine cells in a congenital diaphragmatic hernia. Asabe K, et al. **Surg Today** 1999; 29(5):407–12

Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Shehata SM, et al. **Thorax** 1999 May;54(5):427–31

Doppler assessment of tracheal fluid flow during fetal breathing movements in cases of congenital diaphragmatic hernia. Kalache KD, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):27–32

[Epidemiological studies on 321 children with congenital diaphragmatic hernia in China] Zhu J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):266–8 (Eng. Abstr.) **(Chi)**

[Diagnostic error of congenital diaphragmatic hernia in 11 children] He Q. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(2):188 **(Chi)**

[Prenatal diagnosis and therapy of congenital diaphragmatic hernia] Straňák Z, et al. **Ceska Gynekol** 1998 Oct; 63(5):377–82 (Eng. Abstr.) **(Cze)**

[Congenital diaphragmatic hernia. I. Simple defect of the diaphragm or anomaly of the pulmonary mesenchyme?] Thébaud B, et al. **Arch Pediatr** 1998 Sep;5(9):1009–19 (86 ref.) (Eng. Abstr.) **(Fre)**

[Congenital diaphragmatic hernia. II. Is pulmonary hypoplasia an indefinable obstacle?] Thébaud B, et al. **Arch Pediatr** 1999 Feb;6(2):186–98 (120 ref.) (Eng. Abstr.) **(Fre)**

[Thoracic pain and bloody diarrhea] Lüthi A, et al. **Schweiz Med Wochenschr** 1999 Jun 19;129(24):934 **(Ger)**

[Reconstruction of the diaphragm in extensive congenital diaphragmatic hernia] Bagłaj M. **Polim Med** 1998; 28(3–4):55–62 (21 ref.) (Eng. Abstr.) **(Pol)**

[Congenital diaphragmatic hernia manifesting after the neonatal period] Drahovský P, et al. **Rozhl Chir** 1999 Mar; 78(3):123–6 (Eng. Abstr.) **(Slo)**

DIAGNOSIS

Pulmonary agenesis, microphthalmia, and diaphragmatic defect (PMD): new syndrome or association? Berkenstadt M, et al. **Am J Med Genet** 1999 Sep 3;86(1):6–8

Management of congenital diaphragmatic hernia. Davis CF, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F1–3

Adult incarcerated right-sided Bochdalek hernia. Mar Fan MJ, et al. **Aust N Z J Surg** 1999 Mar;69(3):239–41

Delayed diaphragmatic herniation masquerading as a complicated parapneumonic effusion. Tsang J, et al. **Can Respir J** 1999 Jul–Aug;6(4):361–6

Diagnosis and hazards of unexpected diaphragmatic hernias during colonoscopy: report of two cases. Baumann UA, et al. **Endoscopy** 1999 Mar;31(3):274–6

Bochdalek hernia in adulthood: a case report and review of recent literature. Jastaniah S, et al. **Indian J Chest Dis Allied Sci** 1998 Oct–Dec;40(4):281–5 (14 ref.)

Bochdalek's hernia in the adult. Mylarappa P, et al. **J Indian Med Assoc** 1998 Mar;96(3):100

Delayed appearance of bilateral morgagni herniae in a child with Down's syndrome. Kubiak R, et al. **Pediatr Surg Int** 1998 Oct;13(8):600–1

Diaphragmatic hernia of Morgagni. LaRosa DV Jr, et al. **South Med J** 1999 Apr;92(4):409–11

[Diagnostic error of congenital diaphragmatic hernia in 11 children] He Q. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(2):188 **(Chi)**

[Diaphragmatic hernias] Jarreau PH, et al. **Arch Pediatr** 1999; 6 Suppl 2:235s–237s **(Fre)**

[A case of Morgagni's foramen hernia difficult to differentiate from lipoma] Nakamura H, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Apr;37(4):317–20 (Eng. Abstr.) **(Jpn)**

[Pulmonary mass and hemoptysis] Cuesta Rodriguez-Torices MM, et al. **Rev Clin Esp** 1999 Mar;199(3):177–8 **(Spa)**

DRUG THERAPY

Prolonged use of pancuronium bromide and sensorineural hearing loss in childhood survivors of congenital diaphragmatic hernia. Cheung PY, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):233–9

Lung physiological and metabolic changes in lambs with congenital diaphragmatic hernia after administration of prenatal maternal corticosteroids. Kapur P, et al. **J Pediatr Surg** 1999 Feb;34(2):354–6

Less invasive ways to treat CDH prenatally [letter; comment] Laberge JM, et al. **J Pediatr Surg** 1999 Jul;34(7):1183–4. Comment on: J Pediatr Surg 1998 Aug;33(8):1198–205.

EMBRYOLOGY

Ultrastructural evaluation of lung maturation in a sheep model of diaphragmatic hernia and tracheal occlusion. Benachi A, et al. **Am J Respir Cell Mol Biol** 1999 Apr; 20(4):805–12

EPIDEMIOLOGY

[Epidemiological studies on 321 children with congenital diaphragmatic hernia in China] Zhu J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):266–8 (Eng. Abstr.) **(Chi)**

ETIOLOGY

Diaphragmatic herniation following oesophagectomy. van Sandick JW, et al. **Br J Surg** 1999 Jan;86(1):109–12

Ruptured hemidiaphragm after bilateral lung transplantation. Gómez-Arnau J, et al. **Eur J Anaesthesiol** 1999 Apr; 16(4):259–62

Diaphragmatic hernia in an 8-year-old with Ehlers-Danlos syndrome. Iglesias JL, et al. **Pediatr Surg Int** 1998 Oct; 13(8):553–5

Delayed appearance of bilateral morgagni herniae in a child with Down's syndrome. Kubiak R, et al. **Pediatr Surg Int** 1998 Oct;13(8):600–1

Diaphragmatic hernia seen as a late complication of laparoscopic cholecystectomy. Armstrong PA, et al. **Surg Endosc** 1999 Aug;13(8):817–8

GENETICS

Familial congenital diaphragmatic hernia: is an imprinting mechanism involved? [letter] Austin-Ward ED, et al. **J Med Genet** 1999 Jul;36(7):578–9

Differential gene expression at gestational days 14 and 16 in normal and nitrogen-induced hypoplastic murine fetal lungs with coexistent diaphragmatic hernia. Causak RA, et al. **Pediatr Pulmonol** 1998 Nov;26(5):301–11

Familial bilateral congenital diaphragmatic hernia. Kufeji DI, et al. **Pediatr Surg Int** 1999;15(1):58–60 (15 ref.)

Prenatal diagnosis of an 8p23.1 deletion in a fetus with a diaphragmatic hernia and review of the literature. Faivre L, et al. **Prenat Diagn** 1998 Oct;18(10):1055–60 (24 ref.)

METABOLISM

Altered insulin-like growth factor I mRNA expression in human hypoplastic lung in congenital diaphragmatic hernia. Miyazaki E, et al. **J Pediatr Surg** 1998 Oct; 33(10):1476–9

Increased tropoelastin and procollagen expression in the lung of nitrofen-induced diaphragmatic hernia in rats. Taira Y, et al. **J Pediatr Surg** 1999 May;34(5):715–9

Expression of clara cell 10-kDa protein (CC10) in congenital diaphragmatic hernia. Asabe K, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):36–9

MORTALITY

A population-based study of congenital diaphragmatic hernia: impact of associated anomalies and preoperative blood gases on survival. Kaiser JR, et al. **J Pediatr Surg** 1999 Aug;34(8):1196–202

Late death after extracorporeal membrane oxygenation for congenital diaphragmatic hernia. Schoeman L, et al. **J Pediatr Surg** 1999 Feb;34(2):357–9

Congenital diaphragmatic hernia: mortality determinants in a Hispanic population. Serrano P, et al. **P R Health Sci J** 1998 Dec;17(4):317–21

PATHOLOGY

Ultrastructural evaluation of lung maturation in a sheep model of diaphragmatic hernia and tracheal occlusion. Benachi A, et al. **Am J Respir Cell Mol Biol** 1999 Apr; 20(4):805–12

Cameron erosions. Bornstein JD, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):514

Airway muscle in infants with congenital diaphragmatic hernia: response to treatment. Broughton AR, et al. **J Pediatr Surg** 1998 Oct;33(10):1471–5

Heart hypoplasia in experimental congenital diaphragmatic hernia. Migliazza L, et al. **J Pediatr Surg** 1999 May; 34(5):706–10; discussion 710–1

Fetal liver position and perinatal outcome for congenital diaphragmatic hernia. Albanese CT, et al. **Prenat Diagn** 1998 Nov;18(11):1138–42

PHYSIOPATHOLOGY

Vitamin A decreases the incidence and severity of nitrofen-induced congenital diaphragmatic hernia in rats. Thébaud B, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L423–9

Prenatal vitamin E treatment improves lung growth in fetal rats with congenital diaphragmatic hernia. Islam S, et al. **J Pediatr Surg** 1999 Jan;34(1):172–6 discussion 176–7

Tracheal ligation and mechanical ventilation do not improve the antioxidant enzyme status in the lamb model of congenital diaphragmatic hernia. Kapur P, et al. **J Pediatr Surg** 1999 Feb;34(2):270–2

The effects of prenatal intraamniotic surfactant or dexamethasone administration on lung development are comparable to changes induced by tracheal ligation in an animal model of congenital diaphragmatic hernia: studies of lung glycogen content, elastic fiber density, and collagen content. Tannuri U, et al. **J Pediatr Surg** 1998 Dec; 33(12):1776–83

Excision of spinal tumor in a patient with severe pulmonary dysfunction using combined spinal and epidural anesthesia with two epidural catheters. Takiguchi T, et al. **Reg Anesth Pain Med** 1999 May–Jun;24(3):267–71

PREVENTION & CONTROL

Vitamin A decreases the incidence and severity of nitrofen-induced congenital diaphragmatic hernia in rats. Thébaud B, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L423–9

Tracheoscopic endoluminal plugging using an inflatable device in the fetal lamb model. Deprest JA, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):165–9

HERNIA, DIAPHRAGMATIC

RADIOGRAPHY

Congenital diaphragmatic hernia: report of three cases. Kiguli-Malwadde E, et al. **East Afr Med J** 1998 Oct; 75(10):614–5

Esophageal duplication cyst coexisting with Bochdalek's hernia and polysplenia. Seçil M, et al. **Eur Radiol** 1999; 9(3):478–80

Diaphragmatic rupture [letter; comment] Simpson J, et al. **J R Soc Med** 1999 Jun;92(6):326. Comment on: J R Soc Med 1999 Mar;92(3):134–5.

[Diaphragmatic rupture after closed injury] Peloponissios N, et al. **Schweiz Med Wochenschr** 1999 Aug 28;129(34):1230 **(Fre)**

[Diaphragmatic hernia with omental vessels delineated by computed tomography] Masuo T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):495–8 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Pseudotumor of the lung: foramen of Morgani hernia confirmed by liver scan. Nachar O, et al. **Clin Nucl Med** 1998 Oct;23(10):712–4

Isolated rupture of the right hemidiaphragm with eventration of the liver demonstrated by liver scan. Young TH, et al. **Clin Nucl Med** 1998 Oct;23(10):703–4

SURGERY

Hernia of the diaphragm with gastric volvulus: laparoscopic repair. Veys E, et al. **Acta Chir Belg** 1998 Aug;98(4):158–60

Congenital diaphragmatic hernia: experience with preoperative stabilization and delayed surgery without ECMO and inhaled nitric oxide. Al-Hathal M, et al. **Am J Perinatol** 1998 Aug;15(8):487–90

Intercostal transdiaphragmatic hernia with abdominal contents [letter] Madrigal M, et al. **Ann Chir** 1998;52(2):204

Intrathoracic application of the reverse latissimus dorsi muscle flap. Paletta CE, et al. **Ann Plast Surg** 1999 Sep; 43(3):227–31

Bochdalek's hernia in the adult. Mylarappa P, et al. **J Indian Med Assoc** 1998 Mar;96(3):100

Laparoscopic repair of a Morgagni-Larrey hernia. Bortul M, et al. **J Laparoendosc Adv Surg Tech A** 1998 Oct; 8(5):309–13 (15 ref.)

Laparoscopic repair of a Morgagni hernia: report of a case and review of the literature. Contini S, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):93–9 (15 ref.)

Evaluation of small intestine submucosa and acellular dermis as diaphragmatic prostheses. Dalla Vecchia L, et al. **J Pediatr Surg** 1999 Jan;34(1):167–71

Neurodevelopmental outcome after open fetal surgery. Gibbs DL, et al. **J Pediatr Surg** 1998 Aug;33(8):1254–6

Improved pulmonary function after surgical reduction of congenital diaphragmatic hernia in lambs. Major D, et al. **J Pediatr Surg** 1999 Mar;34(3):426–9

The laparoscopic approach for repair of Morgagni hernias. Nguyen T, et al. **J Soc Laparoendosc Surg** 1998 Jan–Mar; 2(1):85–8 (20 ref.)

Tracheal ligation in CDH: bigger may not be better [letter] Bambini DA, et al. **Pediatr Surg Int** 1998 Sep;13(7):537–8

Diaphragmatic hernia in an 8-year-old with Ehlers-Danlos syndrome. Iglesias JL, et al. **Pediatr Surg Int** 1998 Oct; 13(8):553–5

Laparoscopic orchiopexy of intraabdominal undescended testis associated with congenital diaphragmatic hernia. Hisano K, et al. **Surg Today** 1998;28(11):1224–6

[Laparoscopic therapy of a retro-costo-xiphoid hernia complicated by an obstruction caused by an intrathoracic gastric volvulus] Arimont JM, et al. **Ann Chir** 1998; 52(7):660–4 **(Fre)**

[Laparoscopic treatment of a diaphragmatic hernia through the foramen of Morgagni in children. A case report and review of eleven cases reported in the adult literature] Becmeur F, et al. **Ann Chir** 1998;52(10):1060–3 (16 ref.) (Eng. Abstr.) **(Fre)**

[Bochdalek hernia in Adulthood: case report and overview] Sterk P, et al. **Zentralbl Chir** 1998;123(10):1184–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[Reconstruction of the diaphragm in extensive congenital diaphragmatic hernia] Bagłaj M. **Polim Med** 1998; 28(3–4):55–62 (21 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Elliott ES, et al. **Ann Pharmacother** 1999 Apr;33(4):419–22

Detrimental effects of standard medical therapy in congenital diaphragmatic hernia. Kays DW, et al. **Ann Surg** 1999 Sep; 230(3):340–8; discussion 348–51

A new ventilator improves CO2 removal in newborn lambs with congenital diaphragmatic hernia [see comments] Schnitzer JJ, et al. **Crit Care Med** 1999 Jan;27(1):109–12 . Comment in: Crit Care Med 1999 Jan;27(1):18–9.

Extracorporeal membrane oxygenation--a last-resort therapy for newborns with congenital diaphragmatic hernia or other causes of severe respiratory failure. van der Staak F. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):195–7 (5 ref.)

Dypiridamole, a cGMP phosphodiesterase inhibitor, transiently improves the response to inhaled nitric oxide in two newborns with congenital diaphragmatic hernia. Thébaud B, et al. **Intensive Care Med** 1999 Mar;25(3):300–3

Does extracorporeal membrane oxygenation improve survival in neonates with congenital diaphragmatic hernia? The Congenital Diaphragmatic Hernia Study Group. **J Pediatr Surg** 1999 May;34(5):720–4; discussion 724–5

Congenital diaphragmatic hernia: developing a protocolized approach. Finer NN, et al. **J Pediatr Surg** 1998 Sep; 33(9):1331–7

Late death after extracorporeal membrane oxygenation for congenital diaphragmatic hernia. Schoeman L, et al. **J Pediatr Surg** 1999 Feb;34(2):357–9

[Results of extracorporeal membrane oxygenation in 100 newborns with cardiorespiratory insufficiency (published erratum appears in Ned Tijdschr Geneeskd 1999 Mar 20;143(12):648)] van Heijst AF, et al. **Ned Tijdschr Geneeskd** 1999 Feb 13;143(7):356–60 (Eng. Abstr.) **(Dut)**

ULTRASONOGRAPHY

Diagnosis and differentiation of congenital diaphragmatic hernia from other noncardiac thoracic fetal masses. Kasales CJ, et al. **Am J Perinatol** 1998;15(11):623–8

Management of congenital diaphragmatic hernia diagnosed prenatally: an update. Geary M. **Prenat Diagn** 1998 Nov; 18(11):1155–8 (28 ref.)

Ultrasound diagnosis of fetal diaphragmatic hernia and complex congenital heart disease at 12 weeks' gestation--a case report. Lam YH, et al. **Prenat Diagn** 1998 Nov; 18(11):1159–62

Perinatal outcome and prognostic factors in prenatally diagnosed congenital diaphragmatic hernia. Geary MP, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):107–11

VETERINARY

Benign masses in the pericardium of two dogs. Simpson DJ, et al. **Aust Vet J** 1999 Apr;77(4):225–9

Surgical repair of a diaphragmatic hernia in a racehorse. Dabareiner RM, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1517–8, 1496

What is your diagnosis? Metallic foreign body (fish hook) and diaphragmatic hernia. Grevemeyer B, et al. **J Am Vet Med Assoc** 1999 Jan 1;214(1):31–2

What is your diagnosis? Peritoneopericardial diaphragmatic hernia with herniation of mineralized fetuses. Iwasaki M, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1775–6

What is your diagnosis? A 2-cm rounded structure similar in opacity to adjacent falciform fat located between the apex of the heart and the cupula of the diaphragm along the ventral midline of the thorax. Smith SA, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):479–80

HERNIA, DIAPHRAGMATIC, TRAUMATIC

A case of traumatic pericardiophrenic rupture. Stefani A, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):859–61 (10 ref.)

COMPLICATIONS

[Post-traumatic diaphragmatic hernia: a rare cause of acute circulatory insufficiency (letter)] Bouaggad A, et al. **Ann Fr Anesth Reanim** 1999 May;18(5):604–5 **(Fre)**

DIAGNOSIS

Traumatic diaphragmatic hernia with delayed presentation. Lin YK, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Apr;62(4):223–9

Bochdalek hernia in adulthood: a case report and review of recent literature. Jastaniah S, et al. **Indian J Chest Dis Allied Sci** 1998 Oct–Dec;40(4):281–5 (14 ref.)

[An unusual trauma in labor: diaphragmatic rupture] Zimmermann T. **Zentralbl Gynakol** 1999;121(2):92–4 (Eng. Abstr.) **(Ger)**

[Late diagnosis of post-traumatic diaphragmatic hernia (letter)] Mateos Diaz E, et al. **Rev Esp Enferm Dig** 1998 Nov;90(11):819–20 **(Spa)**

ETIOLOGY

Posttraumatic diaphragmatic hernia and death--etiologic factor or putrefactive artifact? James R, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):66–9

Diaphragmatic rupture presenting forty years after injury. Faul JL. **Injury** 1998 Jul;29(6):479–80

Transdiaphragmatic intercostal hernia resulting from blunt trauma: case report. Hruska LA, et al. **J Trauma** 1998 Oct; 45(4):822–4

A patient with a traumatic right diaphragmatic hernia occurring 4 years after sustaining injury--statistical observations of a delayed diaphragmatic hernia caused by uncomplicated injury in Japan. Maekawa T, et al. **Nippon Geka Hokan** 1997 Dec 1;66(4):116–25 (12 ref.)

A late complication from a self-inflicted stab wound. Kennedy RJ, et al. **Ulster Med J** 1999 May;68(1):40–2

RADIOGRAPHY

Tension fecopneumothorax due to colonic perforation in a diaphragmatic hernia. Seelig MH, et al. **Chest** 1999 Jan; 115(1):288–91

Right diaphragmatic rupture and hepatic hernia: an indirect sign on computed tomography. Sadeghi N, et al. **Eur Radiol** 1999;9(5):972–4

Traumatic hernia of the pericardium. Valestaqui R, et al. **J Trauma** 1999 Mar;46(3):513–4

Tube thoracostomy complicates unrecognized diaphragmatic rupture. Zieren J, et al. **Thorac Cardiovasc Surg** 1999 Jun; 47(3):199–202

[A rare sequela of cardiopulmonary resuscitation. Left-sided diaphragmatic rupture] Funke C, et al. **Radiologe** 1999 Jul; 39(7):621–3 **(Ger)**

SURGERY

Intraoperative management of a patient with a chronic, previously undiagnosed traumatic diaphragmatic hernia. Katz RI, et al. **J Clin Anesth** 1998 Sep;10(6):506–9

Laparoscopic treatment of traumatic diaphragmatic hernia. Domene CE, et al. **J Laparoendosc Adv Surg Tech A** 1998 Aug;8(4):225–9

Thoracoscopic repair of a recurrent diaphragmatic hernia four years after initial trauma, laparotomy, and repair. Kamelgard JI, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):171–5

Traumatic hernia of the pericardium. Valestaqui R, et al. **J Trauma** 1999 Mar;46(3):513–4

Laparoscopic repair of missed blunt diaphragmatic rupture using a prosthesis. Slim K, et al. **Surg Endosc** 1998 Nov; 12(11):1358–60

[Indirect traumatic diaphragmatic ruptures after blunt abdominal or thoracic trauma] Limmer JC, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1221–3 (Eng. Abstr.) **(Ger)**

VETERINARY

What is your diagnosis? Small intestinal obstruction as a result of incarceration in a diaphragmatic hernia. Ethell MT, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):321–2

HERNIA, ESOPHAGEAL see **HERNIA, HIATAL**

HERNIA, FEMORAL

[Inguinal, femoral and umbilical hernia. Physiopathology, diagnosis, complication, treatment] Palot JP, et al. **Rev Prat** 1999 Jun 1;49(11):1242–8 **(Fre)**

EPIDEMIOLOGY

Femoral hernia in children. Al-Shanafey S, et al. **J Pediatr Surg** 1999 Jul;34(7):1104–6

ETIOLOGY

Bladder diverticulum as an unusual content of a femoral hernia. Buchholz NP, et al. **Br J Urol** 1998 Sep;82(3):457–8

SURGERY

Is elective hernia repair worthwhile in old patients? Gunnarsson U, et al. **Eur J Surg** 1999 Apr;165(4):326–32

A randomized prospective controlled trial of laparoscopic extraperitoneal hernia repair and mesh-plug hernioplasty: a study of 315 cases. Khoury N. **J Laparoendosc Adv Surg Tech A** 1998 Dec;8(6):367–72

Femoral hernia in children. Al-Shanafey S, et al. **J Pediatr Surg** 1999 Jul;34(7):1104–6

Laparoscopic versus open repair of groin hernia: a randomised comparison. The MRC Laparoscopic Groin Hernia Trial Group [see comments] **Lancet** 1999 Jul 17; 354(9174):185–90. Comment in: Lancet 1999 Jul 17;354(9174):175–6.

Mesh plug repair and groin hernia surgery. Robbins AW, et al. **Surg Clin North Am** 1998 Dec;78(6):1007–23, vi–vii (54 ref.)

The mesh plug technique for recurrent groin herniorrhaphy: a nine-year experience of 407 repairs. Rutkow IM, et al. **Surgery** 1998 Nov;124(5):844–7

[Prosthetic hernia surgery. Our experience] Pugliano G. **Acta Biomed Ateneo Parmense** 1997;68(3–4):47–52 (Eng. Abstr.) **(Ita)**

[Surgery of inguinal and femoral hernia in the elderly] Spirch S, et al. **Chir Ital** 1997;49(4–5):53–5 (Eng. Abstr.) **(Ita)**

[Femoral hernia in a child] Losiev OO, et al. **Klin Khir** 1998; (6):50 **(Ukr)**

[The successful surgical treatment of a femoral hernia with a large fecal phlegmon in an elderly female patient] Puzych IaI. **Klin Khir** 1998;(9–10):96 **(Ukr)**

HERNIA, HIATAL

COMPLICATIONS

Life-threatening complications of hiatus hernia [letter] Neumann L, et al. **Anaesthesia** 1999 Jan;54(1):93–4

Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate [letter] Kaye PS. **Dig Dis Sci** 1999 May;44(5):903–4

Transient left vocal cord paralysis during laparoscopic surgery for an oesophageal hiatus hernia. Kanski A, et al. **Eur J Anaesthesiol** 1999 Jul;16(7):495–9

Oesophageal hiatal hernia-induced hydropneumothorax. Fukuda T, et al. **J Gastroenterol Hepatol** 1998 Sep;

13(9):931-5
Reflux esophagitis and its relationship to hiatal hernia. Yeom JS, et al. **J Korean Med Sci** 1999 Jun;14(3):253-6
Hiatal hernia in achalasia. Khan AA, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):196-7
An unusual acute gastric emergency. Harinath G, et al. **Postgrad Med J** 1998 Jun;74(872):373-4
[Para-esophageal hiatal hernia with acute gastric volvulus] Alamowitch B, et al. **Gastroenterol Clin Biol** 1999 Feb; 23(2):271-4 (Eng. Abstr.) **(Fre)**
[Peptic esophagitis and Barrett's esophagus: two often associated complication of hiatal hernia] Vitaux J, et al. **Presse Med** 1998 Jun 6;27(20):987 **(Fre)**
[A complicated paraesophageal diaphragmatic hernia. A clinical case report] Foscolo PP, et al. **Minerva Chir** 1998 Jun;53(6):523-6 (7 ref.) (Eng. Abstr.) **(Ita)**
[Automated profiloesophagotonometry in diagnosis of cardial insufficiency in patients with hiatal hernia] Chernov VN, et al. **Klin Med (Mosk)** 1998;76(10):56-9 **(Rus)**

CONGENITAL

Right-sided hiatal hernia of the oesophagus. Kaptanoglu M, et al. **Scand Cardiovasc J** 1999;33(1):54-6 (8 ref.)

DIAGNOSIS

Intrathoracic stomach presenting as acute tension gastrothorax. Tadler SC, et al. **Am J Emerg Med** 1999 Jul; 17(4):370-1
The spectrum of diaphragmatic hernia. Mittal RK. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):65-6, 69-70, 73-5 passim
Massive hiatal hernia. Villa A, et al. **J Accid Emerg Med** 1999 Jul;16(4):301-2
Paraoesophageal hernia in children: familial occurrence and review of the literature. Baglaj SM, et al. **Pediatr Surg Int** 1999;15(2):85-7 (15 ref.)
Intrathoracic omental herniation through the esophageal hiatus: report of a case. Kato N, et al. **Surg Today** 1999; 29(4):347-50
[The diagnosis and treatment of the epiphrenal-cardial syndrome in patients with axial hiatal hernias] Chernov VN, et al. **Vestn Khir Im I I Grek** 1998;157(4):89-92 (Eng. Abstr.) **(Rus)**
[Diagnostic errors in hiatal hernia (letter)] De Arzua Zulaica E. **Rev Esp Enferm Dig** 1998 Nov;90(11):821 **(Spa)**

EPIDEMIOLOGY

Barrett's esophagus: prevalence and size of hiatal hernia. Cameron AJ. **Am J Gastroenterol** 1999 Aug;94(8):2054-9
Pressure-overload-induced sliding hiatal hernia in power athletes. Smith AB, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):352-4

ETIOLOGY

Thoracic complications of peritoneal dialysis. Hughes GC, et al. **Ann Thorac Surg** 1999 May;67(5):1518-22
Classification of adenocarcinoma of the oesophagogastric junction [letter; comment] Maric R, et al. **Br J Surg** 1999 Aug;86(8):1098-9. Comment on: Br J Surg 1998 Nov;85(11):1457-9.
Simultaneous pyloric and colonic obstruction associated with hiatus hernia in a weightlifter: a case report. Casey P, et al. **Can J Surg** 1999 Jun;42(3):220-2
Pressure-overload-induced sliding hiatal hernia in power athletes. Smith AB, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):352-4
Laparoscopic Nissen fundoplication complicated by late gastroesophageal herniation and intrathoracic perforation: a case report with review of the literature. Boggi U, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):57-9 (14 ref.)

GENETICS

Familial hiatal hernia and gastro-oesophageal reflux disease. Coelho J, et al. **Eur J Surg** 1999 Apr;165(4):392-4
Paraoesophageal hernia in children: familial occurrence and review of the literature. Baglaj SM, et al. **Pediatr Surg Int** 1999;15(2):85-7 (15 ref.)

PARASITOLOGY

[Anisakiasis in incarcerated epigastric hernia (letter)] Cusí Sánchez V, et al. **An Esp Pediatr** 1999 Apr;50(4):413-4 **(Spa)**

PATHOLOGY

[Paraesophageal hiatal hernia] Trombini R, et al. **Minerva Chir** 1998 May;53(5):411-7 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Manometric study of hiatal hernia and its correlation with esophageal peristalsis. Cuomo R, et al. **Dig Dis Sci** 1999 Sep;44(9):1747-53
The hiatus hernia slides back into prominence [comment] Dent J. **Gut** 1999 Apr;44(4):449-50. Comment on: Gut 1999 Apr;44(4):476-82.
The effect of hiatus hernia on gastro-oesophageal junction pressure [see comments] Kahrilas PJ, et al. **Gut** 1999 Apr; 44(4):476-82. Comment in: Gut 1999 Apr;44(4):449-50.

RADIOGRAPHY

Iatrogenic oesophageal perforations: a clinical review [letter; comment] De K, et al. **Ann R Coll Surg Engl** 1999 Jan; 81(1):71. Comment on: Ann R Coll Surg Engl 1998 Mar;80(2):115-8.
Tube thoracostomy complicates unrecognized diaphragmatic rupture. Zieren J, et al. **Thorac Cardiovasc Surg** 1999 Jun; 47(3):199-202

RADIONUCLIDE IMAGING

Incidental finding of hiatal hernia uptake on Tc-99m sestamibi breast imaging. Beaulieu S, et al. **Clin Nucl Med** 1999 Jun;24(6):455-6
Hiatus hernia: a potential cause of false-positive iodine-131 scan in thyroid carcinoma. Ho Y, et al. **Clin Nucl Med** 1998 Sep;23(9):621-2
Scintigraphic intervention in a lung scan confirming a large hiatal hernia. Sherigar RM, et al. **Clin Nucl Med** 1999 Feb; 24(2):127-8

SURGERY

Repair of paraesophageal hernias. Horgan S, et al. **Am J Surg** 1999 May;177(5):354-8
Comparison of laparoscopic versus open repair of paraesophageal hernia. Schauer PR, et al. **Am J Surg** 1998 Dec;176(6):659-65
Esophageal motility and outcomes following laparoscopic paraesophageal hernia repair and fundoplication. Swanstrom LL, et al. **Am J Surg** 1999 May;177(5):359-63
Durability of laparoscopic repair of paraesophageal hernia. Edye MB, et al. **Ann Surg** 1998 Oct;228(4):528-35 (30 ref.)
Elective laparoscopic repair of type II paraesophageal hernias [letter; comment] van den Berg M, et al. **Ann Surg** 1998 Oct;228(4):623-4. Comment on: Ann Surg 1997 Jan;225(1):31-8.
Respiratory compliance during laparoscopic hiatal and inguinal hernia repair. Mäkinen MT, et al. **Can J Anaesth** 1998 Sep;45(9):865-70
Laparoscopic cut Collis gastroplasty: a novel technique. Falk GL, et al. **Dis Esophagus** 1998 Oct;11(4):260-2
Management of patients with giant paraesophageal hernia. Leese T, et al. **Dis Esophagus** 1998 Jul;11(3):177-80
Prolonged dysphagia after a paraesophageal hernia repair with Nissen fundoplication [clinical conference] Floch NR, et al. **J Clin Gastroenterol** 1999 Apr;28(3):224-7
Parahiatal hernia with volvulus and incarceration: laparoscopic repair of a rare defect. Rodefeld MD, et al. **J Gastrointest Surg** 1998 Mar-Apr;2(2):193-7
Safe esophageal bougie placement for laparoscopic hiatal hernia repair. Edelman DS, et al. **J Soc Laparoendosc Surg** 1998 Jan-Mar;2(1):31-3
Laparoscopic paraesophageal hernia repair. Medina L, et al. **J Soc Laparoendosc Surg** 1998 Jul-Sep;2(3):269-72
A new surgical technique for the silicone gastric band in the presence of a large hiatus hernia. Anderson PG, et al. **Obes Surg** 1999 Apr;9(2):202-4; discussion 204-5
Treatment of morbid obesity and gastroesophageal reflux with hiatal hernia by Lap-Band. Angrisani L, et al. **Obes Surg** 1999 Aug;9(4):396-8
Sac excision is essential to adequate laparoscopic repair of paraesophageal hernia. Edye M, et al. **Surg Endosc** 1998 Oct;12(10):1259-63
Laparoscopic repair of large hiatal hernia with polytetrafluoroethylene. Frantzides CT, et al. **Surg Endosc** 1999 Sep;13(9):906-8
Emergency laparoscopic repair of a paraesophageal hernia. Nattakom T, et al. **Surg Endosc** 1999 Jan;13(1):75-6
Clinical and radiologic assessment of laparoscopic paraesophageal hernia repair. Wu JS, et al. **Surg Endosc** 1999 May;13(5):497-502
[Videolaparoscopic treatment of paraesophageal hiatal hernia] Mosnier H, et al. **Chirurgie** 1998 Dec;123(6):594-9; discussion 598-9 (Eng. Abstr.) **(Fre)**
[Laparoscopic repair of large hiatal hernias with polypropylene mesh] Bärlehner E, et al. **Zentralbl Chir** 1998;123(11):1303-5 (Eng. Abstr.) **(Ger)**
[Total duodenal diversion in hiatal hernia with pathological duodenoesophageal reflux (preliminary results)] Constantinoiu S, et al. **Chirurgia (Bucur)** 1998 Sep-Oct; 93(5):299-315 (74 ref.) (Eng. Abstr.) **(Rum)**

THERAPY

Percutaneous endoscopic gastrostomy to treat upside-down stomach before stent insertion in a patient with distal esophageal carcinoma. Criblez DH. **Am J Gastroenterol** 1998 Oct;93(10):1938-41
Paraesophageal hernias: current concepts [editorial; comment] Floch NR. **J Clin Gastroenterol** 1999 Jul; 29(1):6-7. Comment on: J Clin Gastroenterol 1999 Jul;29(1):8-13.
Current concepts in the management of paraesophageal hiatal hernia [see comments] Hashemi M, et al. **J Clin Gastroenterol** 1999 Jul;29(1):8-13 (22 ref.). Comment in: J Clin Gastroenterol 1999 Jul;29(1):6-7.

ULTRASONOGRAPHY

[A 70-year-old woman with left atrial mass] Kataoka H. **J Cardiol** 1999 May;33(5):283-5 **(Jpn)**

VETERINARY

Abnormalities of the thoracic bellows: stress fractures of the ribs and hiatal hernia [see comments] Hardie EM, et al. **J Vet Intern Med** 1998 Jul-Aug;12(4):279-87. Comment in: J Vet Intern Med 1998 Nov-Dec;12(6):478-80.
Abnormalities of the thoracic bellows: stress fractures of the ribs and hiatal hernia [letter; comment] Mackin A. **J Vet Intern Med** 1998 Nov-Dec;12(6):478-80. Comment on: J Vet Intern Med 1998 Jul-Aug;12(4):279-87.

HERNIA, INGUINAL

The hernia. Bobrow RS. **J Am Board Fam Pract** 1999 Jan-Feb;12(1):95-6
Etiology and pathophysiology of primary and recurrent groin hernia formation. Abrahamson J. **Surg Clin North Am** 1998 Dec;78(6):953-72, vi (50 ref.)
[Inguinal, femoral and umbilical hernia. Physiopathology, diagnosis, complication, treatment] Palot JP, et al. **Rev Prat** 1999 Jun 1;49(11):1242-8 **(Fre)**

CLASSIFICATION

Classification systems and groin hernias. Rutkow IM, et al. **Surg Clin North Am** 1998 Dec;78(6):1117-27, viii (19 ref.)
Preoperative Nyhus classification of inguinal hernias and type-related individual hernia repair [letter; comment] Crawford DL, et al. **Surg Laparosc Endosc** 1998 Aug; 8(4):328. Comment on: Surg Laparosc Endosc 1997 Oct;7(5):373-7.

COMPLICATIONS

Strangulated Meckel's diverticulum. Baird J. **Can J Surg** 1998 Dec;41(6):422
Peritoneal rosetting microgranulomas in an incarcerated small bowel loop [letter] Lespi PJ, et al. **Histopathology** 1999 Feb;34(2):181-3
Acute scrotum caused by appendicitis [letter; comment] Dilley A, et al. **J Pediatr Surg** 1999 Jul;34(7):1183. Comment on: J Pediatr Surg 1998 Sep;33(9):1435-6.
Small-bowel obstruction caused by passage of a self-expanding hexagonal cell nitinol stent in the clinical setting of an inguinal hernia. Venbrux AC, et al. **J Vasc Interv Radiol** 1999 Mar;10(3):359-62
Bilateral lumbar hernia associated with abdominal hernias. A case report. Cocozza E, et al. **Minerva Chir** 1999 Jun; 54(6):421-3
Breathlessness with bilateral inguinal herniae. Raza N, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2128-9
Testicular volume of boys after inguinal herniotomy: combined clinical and radiological follow-up. Leung WY, et al. **Pediatr Surg Int** 1999;15(1):40-1
Inguinal abscess in a CAPD patient secondary to inguinal hernia and repeated episodes of peritonitis: a case report. Chang YP, et al. **Perit Dial Int** 1999 Mar-Apr;19(2):177-8
Inguinal hernia repair in patients with coagulation problems: prevention of postoperative bleeding with human fibrin glue. Canonico S, et al. **Surgery** 1999 Mar;125(3):315-7
Non-cardiac surgery and anaesthesia in children with congenital heart disease. Soyannwo OA, et al. **West Afr J Med** 1999 Apr-Jun;18(2):87-90
[Bladder herniation in a inguinal-scrotal hernia complicated by acute renal insufficiency] Barea D, et al. **J Radiol** 1998 Mar;79(3):263-5 (Eng. Abstr.) **(Fre)**
[Bladder hernias] Bahloul A, et al. **J Urol (Paris)** 1996; 102(5-6):233-9 (Eng. Abstr.) **(Fre)**
[The involvement of the urinary tract in inguinal hernias] Carrieri P, et al. **Ann Ital Chir** 1998 Nov-Dec;69(6):795-7 (7 ref.) (Eng. Abstr.) **(Ita)**
[The strangulation of the appendicular process in the direct inguinal hernia] Portnov AN. **Klin Khir** 1999;(5):55 **(Rus)**
[Acute kidney failure secondary to inguinoscrotal bladder hernia] Casamayor Franco MC, et al. **Actas Urol Esp** 1999 Feb;23(2):171-5 (Eng. Abstr.) **(Spa)**
[Incarceration of a colonoscope in an inguinal hernia and the technique for its removal (letter)] González-Conde B, et al. **Rev Esp Enferm Dig** 1999 Mar;91(3):224-5 **(Spa)**

CONGENITAL

Laparoscopic treatment of congenital inguinal hernia in children. Montupet P, et al. **J Pediatr Surg** 1999 Mar; 34(3):420-3

DIAGNOSIS

Gastrointestinal/genitourinary case of the day. Incarcerated inguinal hernia of the left fallopian tube and ovary. Roth CG, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):787, 791-2
Inguinal swelling: a rare presentation of retroperitoneal hydatidosis. Spiliotis JD, et al. **Eur J Surg** 1999 Jan; 165(1):75-6
Enterogenous duplication cyst presenting as obstructed inguinal hernia. Iyer S, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):123
Chronic inguinal hernia. Levine BJ, et al. **J Emerg Med** 1999 May-Jun;17(3):515-6
Diagnostic flexible peritoneoscopy: assessment of the contralateral internal inguinal ring during unilateral herniorrhaphy. Gardner TA, et al. **J Pediatr Surg** 1998 Oct;33(10):1486-9
Laparoscopic herniorrhaphy in girls. Schier F.

J Pediatr Surg 1998 Oct;33(10):1495-7

Laparoscopic diagnosis of contralateral patent processus vaginalis in children under 1 year of age with unilateral inguinal hernia: comparison with herniography. Van Glabeke E, et al. **J Pediatr Surg** 1999 Aug;34(8):1213-5

Intraoperative laparoscopy by a flexible scope: is it reliable in contralateral childhood hernias? Gursoy MH, et al. **J Soc Laparoendosc Surg** 1997 Jul-Sep;1(3):225-6

Obturator hernia: laparoscopic diagnosis and repair. Haith LR Jr, et al. **J Soc Laparoendosc Surg** 1998 Apr-Jun; 2(2):191-3

Diagnostic laparoscopy for contralateral patent processus vaginalis and nonpalpable testes. Holcomb GW 3rd. **Semin Pediatr Surg** 1998 Nov;7(4):232-8 (32 ref.)

Case no. 4. Meconium peritonitis and a right hernia. Baskin LS. **Tech Urol** 1998 Sep;4(3):154-5

Flexible transinguinal laparoscopy to assess the contralateral ring in pediatric inguinal hernias. Pavlovich CP, et al. **Tech Urol** 1998 Sep;4(3):141-4

[Contralateral transinguinal laparoscopy in unilateral inguinal hernia] Delarue A, et al. **Arch Pediatr** 1999 Jan;6(1):22-6 (Eng. Abstr.) **(Fre)**

[A survey of the contralateral inguinal hernial sac in infants less than 1 year of age using laparoscopy with anatomic verification using peritoneal radiography or surgery] Van Glabeke E, et al. **Chirurgie** 1998 Nov;123(5):478-81 (Eng. Abstr.) **(Fre)**

ECONOMICS

Decreasing lengths of stay: the cost to the community. Caplan G, et al. **Aust N Z J Surg** 1999 Jun;69(6):433-7

Cost-effectiveness of open versus laparoscopic repair for primary inguinal hernia. Dirksen CD, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):472-83

A cost and outcome comparison between laparoscopic and Lichtenstein hernia operations in a day-case unit. A randomized prospective study [see comments] Heikkinen TJ, et al. **Surg Endosc** 1998 Oct;12(10):1199-203. Comment in: Surg Endosc 1998 Oct;12(10):1197.

[Medico-economic evaluation of treatment of inguinal hernia: Shouldice vs. laparoscopy] Damamme A, et al. **Ann Chir** 1998;52(1):11-6 (Eng. Abstr.) **(Fre)**

[The use of prosthetic meshes in the surgical treatment of inguinal hernia: the costs and profits for the local health screening unit] Leardi S, et al. **Minerva Chir** 1998 Jun; 53(6):581-5 (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Prognostic factors in childhood inguinal hernia at Wesley Guild Hospital, Ilesa, Nigeria. Adesunkanmi AR, et al. **East Afr Med J** 1999 Mar;76(3):144-7

Herniography in women under 40 years old with chronic groin pain. Kesek P, et al. **Eur J Surg** 1999 Jun;165(6):573-8

Incidence of contralateral inguinal hernia: a prospective analysis. Tackett LD, et al. **J Pediatr Surg** 1999 May; 34(5):684-7; discussion 687-8

Risk of contralateral hydrocele or hernia after unilateral hydrocele repair in children. Lym L, et al. **J Urol** 1999 Sep;162(3 Pt 2):1169-70; discussion 1171

Increased incidence of inguinal hernias following abdominoplasty [letter] Benvenuti D. **Plast Reconstr Surg** 1999 May;103(6):1798

ETIOLOGY

Painful incarcerated hernia following a rugby union lineout. Thomas RH, et al. **Br J Sports Med** 1999 Feb;33(1):52-3

Is inguinal hernia a defect in human evolution and would this insight improve methods of surgical repair [letter; comment] McArdle GC. **Clin Anat** 1998;11(5):361-2. Comment on: Clin Anat 1998;11(1):65.

Richter's hernia: a rare presentation of abdominal tuberculosis. Rao BJ, et al. **Indian J Gastroenterol** 1999 Jan-Mar;18(1):33

[New prospects in the etiology of groin hernias] Pans A. **Chirurgie** 1999 Jun;124(3):288-97 (Eng. Abstr.) **(Fre)**

[Inguinal bladder hernia in the adult] Sousa Escandón A, et al. **Arch Esp Urol** 1999 Mar;52(2):114-8 (Eng. Abstr.) **(Spa)**

HISTORY

Transversalis fascia: historical aspects and its place in contemporary inguinal herniorrhaphy. Memon MA, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):267-72

Historical aspects of laparoscopic hernia repair. Ger R. **Semin Laparosc Surg** 1998 Dec;5(4):212-6

A selective history of groin hernia surgery in the early 19th century. The anatomic atlases of Astley Cooper, Franz Hesselbach, Antonio Scarpa, and Jules-Germain Cloquet. Rutkow IM. **Surg Clin North Am** 1998 Dec;78(6):921-40, v

IMMUNOLOGY

[Surgical and experimental-biological aspects of inguinal hernia] Mamchych VI, et al. **Klin Khir** 1999;(1):25-7 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Inguinal hernia in the male child: where the latest skirmish line has formed [editorial; comment] Dehner LP. **Am J Surg Pathol** 1999 Aug;23(8):869-71. Comment on: Am J Surg Pathol 1999 Aug;23(8):880-5.

The incidence of spermatic cord structures in inguinal hernia sacs from male children [see comments] Steigman CK, et al. **Am J Surg Pathol** 1999 Aug;23(8):880-5. Comment in: Am J Surg Pathol 1999 Aug;23(8):869-71.

Omental fibromatosis presenting as an incarcerated inguinal hernia. Lam KY, et al. **Aust N Z J Surg** 1998 Apr; 69(4):322-4

Some structural characteristics of the inguinal region in the northern Croatia. Ledinsky M, et al. **Coll Antropol** 1998 Dec;22(2):515-24

Ovary in hernia sac: prolapsed or a descended gonad? Ozbey H, et al. **J Pediatr Surg** 1999 Jun;34(6):977-80

Surgical pathology reports from 7,314 male patients who underwent inguinal herniorrhaphy [letter; comment] Steigman C, et al. **J Pediatr Surg** 1999 Jun;34(6):1052. Comment on: J Pediatr Surg 1998 May;33(5):717-8.

The pathological evaluation of the pediatric inguinal hernia sac [letter; comment] Steigman C, et al. **J Pediatr Surg** 1999 Feb;34(2):376. Comment on: J Pediatr Surg 1998 May;33(5):717-8.

Inguinal hernia revisited through comparative evaluation of peritoneum, processus vaginalis, and sacs obtained from children with hernia, hydrocele, and undescended testis. Tanyel FC, et al. **J Pediatr Surg** 1999 Apr;34(4):552-5

Simultaneous repair of bilateral groin hernias: open or laparoscopic approach? Krähenbühl L, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):313-8

Anatomic basis of chronic groin pain with special reference to sports hernia. Akita K, et al. **Surg Radiol Anat** 1999; 21(1):1-5

PHYSIOPATHOLOGY

Contractility and electrophysiological parameters of cremaster muscles of boys with a hernia or undescended testis. Bingöl-Koloğlu M, et al. **J Pediatr Surg** 1998 Oct; 33(10):1490-4

RADIOGRAPHY

The use, value and safety of herniography. Sutcliffe JR, et al. **Clin Radiol** 1999 Jul;54(7):468-72

[Bladder herniation in a inguinal-scrotal hernia complicated by acute renal insufficiency] Barea D, et al. **J Radiol** 1998 Mar;79(3):263-5 (Eng. Abstr.) **(Fre)**

[Inguinal bladder hernias. A report of 2 cases] Andreu Garcia A, et al. **Actas Urol Esp** 1999 Jul-Aug;23(7):625-8 (5 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Comparison of local infiltration of tenoxicam and intravenous tenoxicam for postoperative analgesia in herniorrhaphy. Lin CF, et al. **Acta Anaesthesiol Sin** 1998 Mar;36(1):23-9

Posterior approaches in groin hernia repair with prosthesis: open or closed. Bostanci BE, et al. **Acta Chir Belg** 1998 Dec;98(6):241-4

Surgical options in the management of groin hernias [corrected and republished article originally printed in Am Fam Physician 1999 Jan 1;59(1):143-56] Bax T, et al. **Am Fam Physician** 1999 Feb 15;59(4):893-906 (27 ref.)

Surgical options in the management of groin hernias [corrected and republished in Am Fam Physician 1999 Feb 15;59(4):893-906] Bax T, et al. **Am Fam Physician** 1999 Jan 1;59(1):143-56 (27 ref.)

Modeling surgical expertise for motor skill acquisition. Cauraugh JH, et al. **Am J Surg** 1999 Apr;177(4):331-6

Laparoscopic intraperitoneal onlay inguinal herniorrhaphy. Kingsley D, et al. **Am J Surg** 1998 Dec;176(6):548-53

Groin hernia and surgical truth [editorial] McGreevy JM. **Am J Surg** 1998 Oct;176(4):301-4 (22 ref.)

A randomized controlled trial of extraperitoneal bupivacaine analgesia in laparoscopic hernia repair. O'Riordain DS, et al. **Am J Surg** 1998 Sep;176(3):254-7

Prospective evaluation of the giant prosthetic reinforcement of the visceral sac for recurrent and complex bilateral inguinal hernias. Solorzano CC, et al. **Am J Surg** 1999 Jan; 177(1):19-22

Inguinal hernia in the male child: where the latest skirmish line has formed [editorial; comment] Dehner LP. **Am J Surg Pathol** 1999 Aug;23(8):869-71. Comment on: Am J Surg Pathol 1999 Aug;23(8):880-5.

The incidence of spermatic cord structures in inguinal hernia sacs from male children [see comments] Steigman CK, et al. **Am J Surg Pathol** 1999 Aug;23(8):880-5. Comment in: Am J Surg Pathol 1999 Aug;23(8):869-71.

Laparoscopic repair of bilateral and recurrent hernias. Frankum CE, et al. **Am Surg** 1999 Sep;65(9):839-42; discussion 842-3

Prevention of postherniorrhaphy urinary retention with prazosin. Gönüllü NN, et al. **Am Surg** 1999 Jan;65(1):55-8

Delayed onset femoral nerve block following an inguinal field block for hernia repair [letter] Kluger MT. **Anaesth Intensive Care** 1998 Oct;26(5):592-3

Postoperative outcome in high-risk infants undergoing herniorrhaphy: comparison between spinal and general anaesthesia. Somri M, et al. **Anaesthesia** 1998 Aug; 53(8):762-6

Cryoanalgesia: effect on postherniorrhaphy pain. Callesen T, et al. **Anesth Analg** 1998 Oct;87(4):896-9

Sameridine is safe and effective for spinal anesthesia: a comparative dose-ranging study with lidocaine for inguinal hernia repair. Mulroy MF, et al. **Anesth Analg** 1999 Apr; 88(4):815-21

Pneumothorax during endoscopic extraperitoneal herniorrhaphy [letter] Toyoshima Y, et al. **Anesthesiology** 1998 Oct;89(4):1040

Adult hernia surgery in Wales revisited: impact of the guidelines of The Royal College of Surgeons of England. Ciampolini J, et al. **Ann R Coll Surg Engl** 1998 Sep; 80(5):335-8

Groin hernia surgery: a systematic review [letter] Mann A. **Ann R Coll Surg Engl** 1999 Jan;81(1):69-71

Conventional or laparoscopic inguinal hernia repair? The surgeon's choice. Williams N, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):56-7

Laparoscopic mesh versus open preperitoneal mesh versus conventional technique for inguinal hernia repair: a randomized multicenter trial (SCUR Hernia Repair Study). Johansson B, et al. **Ann Surg** 1999 Aug;230(2):225-31

A prospective audit of Lichtenstein's tension-free herniorrhaphy in Taranaki, New Zealand. Hulme-Moir M, et al. **Aust N Z J Surg** 1998 Nov;68(11):801-3

Inguinal hernia repair: a comparison between local and general anaesthesia. Subramaniam P, et al. **Aust N Z J Surg** 1998 Nov;68(11):799-800

'Stab and Split': a 'bloodless' and 'scarless' skin incision technique for minor surgery. Yamataka A, et al. **Aust N Z J Surg** 1999 Mar;69(3):229-30

Laparoscopic versus open mesh repair of inguinal hernia. Unblinded trails may not be more reliable than observational studies [letter] [see comments] Anyanwu A, et al. **BMJ** 1999 Jan 16;318(7177):190. Comment in: BMJ 1999 May 1;318(7192):1214.

Laparoscopic verses open mesh repair of inguinal hernia. Laparoscopic repair is much more expensive [letter] Johnson AG. **BMJ** 1999 Jan 16;318(7177):191

Laparoscopic versus open mesh repair of inguinal hernia. Laparoscopic repair is good when undertaken by experienced surgeons [letter] [see comments] Kark AE, et al. **BMJ** 1999 Jan 16;318(7177):189-90. Comment in: BMJ 1999 May 1;318(7192):1214.

Laparoscopic verses open mesh repair of inguinal hernia. Costs and outcomes should always be presented in disaggregated form [letter] [see comments] Kernick DP, et al. **BMJ** 1999 Jan 16;318(7177):190. Comment in: BMJ 1999 May 1;318(7192):1214.

Laparoscopic versus open mesh repair of inguinal hernia. For most patients hernias provoke minimal symptoms [letter] Notaras MJ. **BMJ** 1999 Jan 16;318(7177):189

Laparoscopic versus open mesh repair of inguinal hernia. Recurrence rate is true test of hernia repair [letter] [see comments] Rose K, et al. **BMJ** 1999 Jan 16;318(7177):189 . Comment in: BMJ 1999 May 1;318(7192):1214.

Laparoscopic versus open mesh repair of inguinal hernia. Laparoscopic repair can be made less expensive [letter] Taylor RS, et al. **BMJ** 1999 Jan 16;318(7177):190

Laparoscopic versus open mesh repair of inguinal hernia [letter] Wellwood J, et al. **BMJ** 1999 May 1;318(7192):1214

Levobupivacaine vs bupivacaine as infiltration anaesthesia in inguinal herniorrhaphy. Bay-Nielsen M, et al. **Br J Anaesth** 1999 Feb;82(2):280-2

Prospective randomized controlled trial to compare skin staples and polypropylene for securing the mesh in inguinal hernia repair [letter; comment] Amid PK. **Br J Surg** 1999 Jan;86(1):139. Comment on: Br J Surg 1998 Jun;85(6):790-2.

Randomized placebo-controlled trial of local anaesthetic infusion in day-case inguinal hernia repair [letter; comment] Bailey ME, et al. **Br J Surg** 1998 Oct;85(10):1451. Comment on: Br J Surg 1998 Jun;85(6):797-9.

Pain after groin hernia repair. Callesen T, et al. **Br J Surg** 1998 Oct;85(10):1412-4

Randomized clinical trial of laparoscopic versus open inguinal hernia repair. Juul P, et al. **Br J Surg** 1999 Mar; 86(3):316-9

Inguinal hernia repair. Nicholson S. **Br J Surg** 1999 May; 86(5):577-8

Prospective randomized controlled trial to compare skin staples and polypropylene for securing the mesh in inguinal hernia repair [letter; comment] RoshanLall C, et al. **Br J Surg** 1998 Oct;85(10):1451. Comment on: Br J Surg 1998 Jun;85(6):790-2.

Chronic groin sepsis following tension-free inguinal hernioplasty. Taylor SG, et al. **Br J Surg** 1999 Apr; 86(4):562-5

Respiratory compliance during laparoscopic hiatal and inguinal hernia repair. Mäkinen MT, et al. **Can J Anaesth** 1998 Sep;45(9):865-70

Inguinal hernia repair: a survey of Canadian practice patterns. DesCôteaux JG, et al. **Can J Surg** 1999 Apr;42(2):127-32

The learning curve in laparoscopic inguinal hernia repair for the community general surgeon. Voitk AJ. **Can J Surg** 1998 Dec;41(6):446-50

Is inguinal hernia a defect in human evolution and would this insight improve methods of surgical repair [letter; comment] McArdle GC. **Clin Anat** 1998;11(5):361-2. Comment on: Clin Anat 1998;11(1):65.

Pseudomonas osteomyelitis of the symphysis pubis after inguinal hernia repair. Mader R, et al. **Clin Rheumatol** 1999; 18(2):167-9

Update: what is left for laparoscopic hernia repair? Bittner R, et al. **Dig Surg** 1998;15(2):167-71

Laparoscopic hernia surgery: an overview. Krähenbühl L, et al. **Dig Surg** 1998;15(2):158–66 (72 ref.)
Effect of caudal block on the plasma adrenaline and noradrenaline concentrations in paediatric patients undergoing ilioinguinal herniorrhaphy [see comments] Gaitini LA, et al. **Eur J Anaesthesiol** 1999 Feb;16(2):92–7 . Comment in: Eur J Anaesthesiol 1999 Feb;16(2):73–6.
Modified posterior preperitoneal mesh hernioplasty for repair of inguinal hernia. Akinci OF, et al. **Eur J Surg** 1999 May; 165(5):500–1
Short convalescence after inguinal herniorrhaphy with standardised recommendations: duration and reasons for delayed return to work. Callesen T, et al. **Eur J Surg** 1999 Mar;165(3):236–41
Randomised study of Lichtenstein compared with Shouldice inguinal hernia repair by surgeons in training. Danielsson P, et al. **Eur J Surg** 1999 Jan;165(1):49–53
Is elective hernia repair worthwhile in old patients? Gunnarsson U, et al. **Eur J Surg** 1999 Apr;165(4):326–32
Comparison of polydioxanone (PDS) and polypropylene (Prolene) for Shouldice repair of primary inguinal hernias: a prospective randomised trial. Hilgert RE, et al. **Eur J Surg** 1999 Apr;165(4):333–8
Subtotal cystectomy as a complication of infant hernia repair. Koot VC, et al. **Eur J Surg** 1998 Nov;164(11):873–4
Repeated boluses of local anaesthetic for pain relief after inguinal hernia repair. Zieren J, et al. **Eur J Surg** 1999 May;165(5):460–4
Laparoscopic inguinal herniorrhaphy: the new gold standard of hernia repair? Oishi AJ, et al. **Hawaii Med J** 1998 Nov; 57(11):700–3 (7 ref.)
Are day case inguinal hernia repair and varicose vein surgery substitutes for inpatient treatment? [letter] Jarrett M. **Int J Clin Pract** 1999 Jan–Feb;53(1):83
Laparoscopic inguinal hernia repair. Hussein MK, et al. **Int Surg** 1998 Jul–Sep;83(3):253–6
Laparoscopic versus open preperitoneal prosthetic herniorrhaphy for recurrent inguinal hernia. Mok KT, et al. **Int Surg** 1998 Apr–Jun;83(2):174–6
Internal hernia in adults. Ozenç A, et al. **Int Surg** 1998 Apr–Jun;83(2):167–70
Pain after primary inguinal herniorrhaphy: influence of surgical technique. Callesen T, et al. **J Am Coll Surg** 1999 Apr;188(4):355–9
Prospective randomized study of stapled versus unstapled mesh in a laparoscopic preperitoneal inguinal hernia repair [see comments] Ferzli GS, et al. **J Am Coll Surg** 1999 May; 188(5):461–5. Comment in: J Am Coll Surg 1999 May;188(5):531.
Mesh inguinodynia: a new clinical syndrome after inguinal herniorrhaphy? Heise CP, et al. **J Am Coll Surg** 1998 Nov; 187(5):514–8
Laparoscopic hernioplasty without staples [editorial; comment] Wantz GE. **J Am Coll Surg** 1999 May;188(5):531 . Comment on: J Am Coll Surg 1999 May;188(5):461–5.
Small bowel obstruction as a complication of laparoscopic extraperitoneal inguinal hernia repair. Eugene JR, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):510–1
Scrotal sonography: a valuable tool in the evaluation of complications following inguinal hernia repair. Holloway BJ, et al. **J Clin Ultrasound** 1998 Sep;26(7):341–4
Surgical treatment of recurrent groin hernia. Huang CS. **J Formos Med Assoc** 1999 Feb;98(2):122–7
The value of intraoperative laparoscopic examination of the contralateral inguinal ring during hernia repair in children. Birk D, et al. **J Laparoendosc Adv Surg Tech A** 1998 Dec; 8(6):373–9
Synchronous laparoscopic vasectomy and hernia repair. Kasirajan K, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):177–80
A randomized prospective controlled trial of laparoscopic extraperitoneal hernia repair and mesh–plug hernioplasty: a study of 315 cases. Khoury N. **J Laparoendosc Adv Surg Tech A** 1998 Dec;8(6):367–72
Tack entrapment of the ilioinguinal nerve during laparoscopic hernia repair. Lantis JC 2nd, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):285–9
Transversalis fascia: historical aspects and its place in contemporary inguinal herniorrhaphy. Memon MA, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):267–72
Laparoscopic preperitoneal repair of recurrent inguinal hernias. Sayad P, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):127–30
Regarding: Self–expanding knitted polypropylene mesh facilitates laparoscopic inguinal herniorrhaphy [letter] Steinberg SD, et al. **J Laparoendosc Adv Surg Tech A** 1999 Aug;9(4):371–2
Diagnostic flexible peritoneoscopy: assessment of the contralateral internal inguinal ring during unilateral herniorrhaphy. Gardner TA, et al. **J Pediatr Surg** 1998 Oct;33(10):1486–9
Laparoscopic treatment of congenital inguinal hernia in children. Montupet P, et al. **J Pediatr Surg** 1999 Mar; 34(3):420–3
Laparoscopic herniorrhaphy in girls. Schier F. **J Pediatr Surg** 1998 Oct;33(10):1495–7
Painful ejaculation after inguinal hernia repair. Butler JD, et al. **J R Soc Med** 1998 Aug;91(8):432–3
Primary inguinal hernia repair: how audit changed a surgeon's practice [see comments] Drew PJ, et al. **J R Soc Med** 1998 Nov;91(11):583–4. Comment in: J R Soc Med 1998 Nov;91(11):567. Comment in: J R Soc Med 1999 Feb;92(2):102–3.
Male menopause after unilateral inguinal herniorrhaphy. Vanderpump MP. **J R Soc Med** 1998 Oct;91(10):536–7
The role of laparoscopy in the management of groin hernia. Ahmad S, et al. **J Soc Laparoendosc Surg** 1998 Apr–Jun; 2(2):169–73
A comparison of patient recovery following unilateral and bilateral endoscopic preperitoneal herniorrhaphy. Ahmad SA, et al. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):231–5
Laparoscopic access to the preperitoneal space. Christensen BJ, et al. **J Soc Laparoendosc Surg** 1998 Jan–Mar;2(1):97–8
Bowel obstruction in the postoperative period of laparoscopic inguinal hernia repair (TAPP): review of the literature. Cueto J, et al. **J Soc Laparoendosc Surg** 1998 Jul–Sep; 2(3):277–80 (27 ref.)
Intraoperative laparoscopy by a flexible scope: is it reliable in contralateral childhood hernias? Gursoy MH, et al. **J Soc Laparoendosc Surg** 1997 Jul–Sep;1(3):225–6
Obturator hernia: laparoscopic diagnosis and repair. Haith LR Jr, et al. **J Soc Laparoendosc Surg** 1998 Apr–Jun; 2(2):191–3
Laparoscopic re–do repairs of recurrent inguinal hernias using double–mesh technique. Jones MW. **J Soc Laparoendosc Surg** 1998 Apr–Jun;2(2):175–6
Laparoscopic hernia repair––complications. Miguel PR, et al. **J Soc Laparoendosc Surg** 1998 Jan–Mar;2(1):35–40
A comparison of epidural versus general anesthesia for outpatient endoscopic preperitoneal herniorrhaphy. Schuricht AL, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):141–4
Incidental liposarcomas identified during hernia repair operations. Montgomery E, et al. **J Surg Oncol** 1999 May; 71(1):50–3
Preperitoneal prosthetic mesh hernioplasty during radical retropubic prostatectomy. Choi BB, et al. **J Urol** 1999 Mar; 161(3):840–3
The effects of mesh bioprosthesis on the spermatic cord structures: a preliminary report in a canine model. Uzzo RG, et al. **J Urol** 1999 Apr;161(4):1344–9
Comparison of laparoscopic vs open modified Shouldice technique in inguinal hernia repair. Nicholson T, et al. **JSLS** 1999 Jan–Mar;3(1):39–43
Laparoscopic versus open repair of groin hernia: a randomised comparison. The MRC Laparoscopic Groin Hernia Trial Group [see comments] **Lancet** 1999 Jul 17; 354(9174):185–90. Comment in: Lancet 1999 Jul 17;354(9174):175–6.
Inguinal herniorrhaphy: for surgical specialists only? [comment] Rattner DW. **Lancet** 1999 Jul 17; 354(9174):175–6. Comment on: Lancet 1999 Jul 17;354(9174):185–90.
Laparoscopic hernia repair –– the facts, but no fashion. Leibl BJ, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):302–11 (80 ref.)
When to operate nonreducible ovary? Marinković S, et al. **Med Pregl** 1998 Nov–Dec;51(11–12):537–40 **(Eng, Scr)**
A comparison of two concentrations of bupivacaine and adrenaline with and without fentanyl in paediatric inguinal herniorrhaphy. Joshi W, et al. **Paediatr Anaesth** 1999; 9(4):317–20
Laparoscopic treatment of recurrent inguinal hernia in children. Esposito C, et al. **Pediatr Surg Int** 1998 Dec; 14(3):182–4
The infantile inguinal hernia – a bilateral disease? Schwöbel MG, et al. **Pediatr Surg Int** 1999;15(2):115–8
Early repair of inguinal hernia in premature babies. Uemura S, et al. **Pediatr Surg Int** 1999;15(1):36–9
Management of inguinal herniae in patients on continuous ambulatory peritoneal dialysis: an audit of current UK practice. Morris–Stiff GJ, et al. **Postgrad Med J** 1998 Nov; 74(877):669–70
Paravertebral somatic nerve block for outpatient inguinal herniorrhaphy [letter; comment] Karmakar MK. **Reg Anesth Pain Med** 1999 Jan–Feb;24(1):96–7. Comment on: Reg Anesth Pain Med 1998 May–Jun;23(3):306–10.
Ropivacaine 0.25% and 0.5%, but not 0.125%, provide effective wound infiltration analgesia after outpatient hernia repair, but with sustained plasma drug levels. Mulroy MF, et al. **Reg Anesth Pain Med** 1999 Mar–Apr;24(2):136–41
The paravertebral nerve root block for inguinal herniorrhaphy––a comparison with the field block approach. Wassef MR, et al. **Reg Anesth Pain Med** 1998 Sep–Oct;23(5):451–6
Overview of randomized trials in laparoscopic inguinal hernia repair. Go PM. **Semin Laparosc Surg** 1998 Dec;5(4):238–41
Economic evaluation of open versus laparoscopic hernia repair: some pragmatic considerations for the measurement of costs. McIntosh E, et al. **Semin Laparosc Surg** 1998 Dec; 5(4):242–7
Does the mesh require fixation? Macintyre IMC. **Semin Laparosc Surg** 1998 Dec;5(4):224–6 (20 ref.)
Other methods of laparoendoscopic hernia repair: mini–hernia––inguinal hernia repair through a 2–cm incision. Nduka C, et al. **Semin Laparosc Surg** 1998 Dec; 5(4):248–52
Percutaneous endoscopic external ring hernioplasty using Dundee inguinal canal retractor. Waldron B, et al. **Semin Laparosc Surg** 1998 Dec;5(4):253–8
Complications of groin hernia surgery. Bendavid R. **Surg Clin North Am** 1998 Dec;78(6):1089–103 (79 ref.)
Laparoscopic repair and groin hernia surgery. Crawford DL, et al. **Surg Clin North Am** 1998 Dec;78(6):1047–62 (37 ref.)
The Lichtenstein repair. Kurzer M, et al. **Surg Clin North Am** 1998 Dec;78(6):1025–46 (61 ref.)
Audit of patient outcomes after herniorrhaphy. O'Riordan DC, et al. **Surg Clin North Am** 1998 Dec;78(6):1129–39, viii–ix (22 ref.)
Inguinal hernia repair. The Nyhus posterior preperitoneal operation. Patiño JF, et al. **Surg Clin North Am** 1998 Dec; 78(6):1063–74 (39 ref.)
Mesh plug repair and groin hernia surgery. Robbins AW, et al. **Surg Clin North Am** 1998 Dec;78(6):1007–23, vi–vii (54 ref.)
Giant prosthetic reinforcement of the visceral sac. The Stoppa groin hernia repair. Wantz GE. **Surg Clin North Am** 1998 Dec;78(6):1075–87 (16 ref.)
Open or laparoscopic preperitoneal mesh repair for recurrent inguinal hernia? A randomized controlled trial. Beets GL, et al. **Surg Endosc** 1999 Apr;13(4):323–7
Meta–analyses of randomized controlled trials of laparoscopic vs conventional inguinal hernia repairs. Chung RS, et al. **Surg Endosc** 1999 Jul;13(7):689–94
Long distance telementoring. A novel tool for laparoscopy aboard the USS Abraham Lincoln. Cubano M, et al. **Surg Endosc** 1999 Jul;13(7):673–8
Needlescopic extraperitoneal repair of inguinal hernias. Ferzli G, et al. **Surg Endosc** 1999 Aug;13(8):822–3
Endoscopic extraperitoneal herniorrhaphy. A 5–year experience. Ferzli G, et al. **Surg Endosc** 1998 Nov; 12(11):1311–3
The feasibility of laparoscopic extraperitoneal hernia repair under local anesthesia. Ferzli G, et al. **Surg Endosc** 1999 Jun;13(6):588–90
Laparoscopic repair of bilateral spigelian and inguinal hernias. Gedebou TM, et al. **Surg Endosc** 1998 Dec; 12(12):1424–5
Missed lipoma of the spermatic cord. A pitfall of transabdominal preperitoneal laparoscopic hernia repair. Gersin KS, et al. **Surg Endosc** 1999 Jun;13(6):585–7
Intraabdominal adhesion formation after preperitoneal dissection in the murine model. Halverson AL, et al. **Surg Endosc** 1999 Jan;13(1):14–6
A cost and outcome comparison between laparoscopic and Lichtenstein hernia operations in a day–case unit. A randomized prospective study [see comments] Heikkinen TJ, et al. **Surg Endosc** 1998 Oct;12(10):1199–203. Comment in: Surg Endosc 1998 Oct;12(10):1197.
Endoscopic total extraperitoneal repair of primary and recurrent inguinal hernias. Knook MT, et al. **Surg Endosc** 1999 May;13(5):507–11
Laparoscopic repair of recurrent hernias. Memon MA, et al. **Surg Endosc** 1999 Aug;13(8):807–10
Femoral venous flow dynamics during intraperitoneal and preperitoneal laparoscopic insufflation. Morrison CA, et al. **Surg Endosc** 1998 Oct;12(10):1213–6
Minihernia repair [letter; comment] Ng WT, et al. **Surg Endosc** 1999 May;13(5):539–40. Comment on: Surg Endosc 1997 Jul;11(7):782–4.
Laparoscopic extraperitoneal inguinal hernia repair in the day–care setting. O'Riordain DS, et al. **Surg Endosc** 1999 Sep;13(9):914–7
Stapled and nonstapled laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair. A prospective randomized trial. Smith AI, et al. **Surg Endosc** 1999 Aug; 13(8):804–6
A randomized comparison of driver reaction time after open and endoscopic tension–free inguinal hernia repair. Wright DM, et al. **Surg Endosc** 1999 Apr;13(4):332–4
Transabdominal or totally extraperitoneal laparoscopic hernia repair? Cohen RV, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):264–8
Laparoscopic approach to the management of incarcerated hernia of appendices epiploicae: report of two cases and review of the literature. Habib FA, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):425–8
A prospective randomized outcome and cost comparison of totally extraperitoneal endoscopic hernioplasty versus Lichtenstein hernia operation among employed patients. Heikkinen TJ, et al. **Surg Laparosc Endosc** 1998 Oct; 8(5):338–44
Initial experience with the use of N–butyl 2–cyanoacrylate glue for the fixation of polypropylene mesh in laparoscopic hernia repair. Jourdan IC, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):291–3
Laparoscopic inguinal hernia repair using fine–caliber instruments and polyester mesh. Kimura T, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):300–3
Simultaneous repair of bilateral groin hernias: open or laparoscopic approach? Krähenbühl L, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):313–8
Stoppa–type laparoscopic repair of complex groin defects. Weber A, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):14–6
A measurement of the ability to drive after different types of inguinal hernia repair. Wilson MS, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):384–7
Transabdominal inguinal hernioplasty combined with abdominal aortic aneurysm repair. Tsuji Y, et al. **Surg Today** 1999;29(5):486–8
Inguinal hernia repair in patients with coagulation problems: prevention of postoperative bleeding with human fibrin glue. Canonico S, et al. **Surgery** 1999 Mar;125(3):315–7
The mesh plug technique for recurrent groin herniorrhaphy: a nine–year experience of 407 repairs. Rutkow IM, et al. **Surgery** 1998 Nov;124(5):844–7

Scrotal (Bianchi) approach to patent processus vaginalis in children. Koyle MA, et al. **Tech Urol** 1999 Jun;5(2):95–9
Non-cardiac surgery and anaesthesia in children with congenital heart disease. Soyannwo OA, et al. **West Afr J Med** 1999 Apr–Jun;18(2):87–90
Minimally invasive surgery for inguinal hernia. Lucas SW, et al. **World J Surg** 1999 Apr;23(4):350–5 (23 ref.)
[The Shouldice Clinic--the Shouldice operation] Pafko P. **Rozhl Chir** 1998 Aug;77(8):370–1 **(Cze)**
[Laparoscopic herniotomy in recurrent inguinal hernia] Gad D, et al. **Ugeskr Laeger** 1999 Jan 25;161(4):429–31 (Eng. Abstr.) **(Dan)**
[Inguinal hernia. 4-year follow-up of 2 comparative prospective randomized studies of Shouldice and Stoppa operations with pre-peritoneal totally laparoscopic approach (461 patients)] Champault G, et al. **Ann Chir** 1998; 52(2):132–6 (Eng. Abstr.) **(Fre)**
[Outpatient management, patient comfort and satisfaction of 100 consecutive inguinal hernias treated by Shouldice procedures with steel wire under local anesthesia] Félix P, et al. **Ann Chir** 1999;53(5):387–96 (Eng. Abstr.) **(Fre)**
[Time off of work after inguinal hernia repair. Results of a multicenter prospective study] Johanet H, et al. **Ann Chir** 1999;53(4):297–301 (Eng. Abstr.) **(Fre)**
[Laparoscopic treatment of recurrent inguinal hernia after only mesh] Johanet H, et al. **Ann Chir** 1999;53(1):29–31; discussion 32 (Eng. Abstr.) **(Fre)**
[Inguinal hernia in the infant] Lemelle JL, et al. **Ann Chir** 1998;52(10):1008–16 (Eng. Abstr.) **(Fre)**
[Inguinal hernia of the bladder. Report of 6 cases] Benchekroun A, et al. **Ann Urol (Paris)** 1999;33(2):67–70 (Eng. Abstr.) **(Fre)**
[Contralateral transinguinal laparoscopy in unilateral inguinal hernia] Delarue A, et al. **Arch Pediatr** 1999 Jan;6(1):22–6 (Eng. Abstr.) **(Fre)**
[Effects of surgical education and training on the results of laparoscopic treatment of inguinal hernias] Barrat C, et al. **Chirurgie** 1999 Jun;124(3):298–303 (Eng. Abstr.) **(Fre)**
[Laparoscopy versus the Shouldice intervention in the treatment of unilateral inguinal hernia: can the operative surcosts be minimized?] Perniceni T, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1061–4 (Eng. Abstr.) **(Fre)**
[Inguinal hernia treatment] Boudet MJ, et al. **J Chir (Paris)** 1998 May;135(2):57–64 (89 ref.) (Eng. Abstr.) **(Fre)**
[The use of a plug in inguinal hernia] Pélissier EP, et al. **J Chir (Paris)** 1998 Nov;135(5):223–7 **(Fre)**
[Tension and suture free repair of groin hernias using a large, bilateral prosthesis and by the pre-peritoneal way] Stoppa R, et al. **J Chir (Paris)** 1998 May;135(2):71–3 **(Fre)**
[Pubic osteoarthritis after laparoscopic treatment for an inguinal hernia (letter)] Coutant G, et al. **Rev Med Interne** 1998 Dec;19(12):937–8 **(Fre)**
["No-puncture-laparoscopy" in hernia management in childhood--reliable complement to established therapy concepts] Birk D, et al. **Chirurg** 1999 Mar;70(3):290–3 (Eng. Abstr.) **(Ger)**
[Risks and benefits of laparoscopic hernia-plasty (TAPP). 5 years experiences with 3,400 hernia repairs] Bittner R, et al. **Chirurg** 1998 Aug;69(8):854–8 (Eng. Abstr.) **(Ger)**
[Management of inguinal hernia--a comparison of current methods] Köninger JS, et al. **Chirurg** 1998 Dec; 69(12):1340–4 (Eng. Abstr.) **(Ger)**
[Intraoperative measurement of suture forces in Shouldice repair of primary inguinal hernias] Peiper C, et al. **Chirurg** 1998 Oct;69(10):1077–81; discussion 1081 (Eng. Abstr.) **(Ger)**
[Perforated appendiceal apex in an inguinal hernia as the cause of chronic abdominal wall abscess] Schwonbeck M, et al. **Chirurg** 1998 Dec;69(12):1386–7 (Eng. Abstr.) **(Ger)**
[Laparoscopic hernia repair of recurrent hernias] Götzen V, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1031–3 (Eng. Abstr.) **(Ger)**
[Surgery of inguinal hernia with local anesthesia--technique and results of a minimal invasive procedure] Rau HM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1024–6 (Eng. Abstr.) **(Ger)**
[Quality of life after inguinal hernia operation--results of a prospective study (Shouldice, Lichtenstein, TAPP)] Stengel D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1020–3 (Eng. Abstr.) **(Ger)**
[Inguinal hernia 1998--an assessment of current status] Gianom D, et al. **Schweiz Med Wochenschr** 1998 Nov 21; 128(47):1857–65 (46 ref.) (Eng. Abstr.) **(Ger)**
[Mesh-plug operation: a simple, rapid and complication-free technique for managing inguinal hernia] Metzger J, et al. **Schweiz Med Wochenschr** 1998 Sep 19;128(38):1401–7 (Eng. Abstr.) **(Ger)**
[Transabdominal preperitoneal hernia repair (TAPP). Results of 1,000 completed operations] Hernandez-Richter T, et al. **Zentralbl Chir** 1999;124(7):657–63 (Eng. Abstr.) **(Ger)**
[Technique of total extraperitoneal endoscopic hernioplasty of the inguinal canal] Kuthe A, et al. **Zentralbl Chir** 1998; 123(12):1428–35 (29 ref.) (Eng. Abstr.) **(Ger)**
[Prosthetic hernia surgery. Our experience] Pugliano G. **Acta Biomed Ateneo Parmense** 1997;68(3–4):47–52 (Eng. Abstr.) **(Ita)**
[Surgery of inguinal and femoral hernia in the elderly] Spirch S, et al. **Chir Ital** 1997;49(4–5):53–5 (Eng. Abstr.) **(Ita)**
[Tension-free hernioplasty. Our experience] Bellone D, et al. **Minerva Chir** 1999 Mar;54(3):123–5 (Eng. Abstr.) **(Ita)**
[Traditional cutaneous suture and synthesis with Fasterzip. Comparative esthetic results] Boltri M. **Minerva Chir** 1998 May;53(5):453–6 (Eng. Abstr.) **(Ita)**
[Preliminary results of a new technique for inguinal hernia repair] Gramegna A, et al. **Minerva Chir** 1998 Oct; 53(10):865–9 (Eng. Abstr.) **(Ita)**
[Bilateral inguinal hernia. Which treatment?] Paino O, et al. **Minerva Chir** 1998 May;53(5):381–3 (Eng. Abstr.) **(Ita)**
[Acute appendicitis following laparoscopic inguinal hernioplasty. Coincidence or complication?] Domene CE, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul–Aug; 53(4):199–201 (Eng. Abstr.) **(Por)**
[Method of surgical treatment of inguinal hernia] Archvadze VSh. **Khirurgiia (Mosk)** 1999;(7):55 **(Rus)**
[The strangulation of the appendicular process in the direct inguinal hernia] Portnov AN. **Klin Khir** 1999;(5):55 **(Rus)**
[The peritoneal autoplasty of the hernial hili in patients with large strangulated recurrent inguinal-scrotal hernias] Antonov AM, et al. **Vestn Khir Im I I Grek** 1999; 158(1):57–8 (Eng. Abstr.) **(Rus)**
[Should hernioplasty be combined with surgery of the prostate?] Granados EA, et al. **Arch Esp Urol** 1998 Oct; 51(8):767–70 (Eng. Abstr.) **(Spa)**
[Use pf patient management categories (PMC) in the study of the variability of mean hospital stay for 3 surgical procedures] Aróstegui I, et al. **Gac Sanit** 1998 Jul–Aug; 12(4):169–75 (Eng. Abstr.) **(Spa)**
[Epidural anesthesia and analgesia in the perioperative treatment of a patient with Kartagener syndrome] Errando CL, et al. **Rev Esp Anestesiol Reanim** 1998 Dec; 45(10):431–2 (8 ref.) (Eng. Abstr.) **(Spa)**
[Convulsions after balanced general anesthesia in a newborn infant (letter)] Rubio González MV, et al. **Rev Esp Anestesiol Reanim** 1999 Mar;46(3):134–5 **(Spa)**
[Substantiation of complex surgical treatment of inguinal hernia in children based on pathogenetic criteria] Horbatiuk OM. **Klin Khir** 1998;(12):30–1 (Eng. Abstr.) **(Ukr)**
[Surgical and experimental-biological aspects of inguinal hernia] Mamchych VI, et al. **Klin Khir** 1999;(1):25–7 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Preoperative sonographic diagnosis of sliding appendiceal inguinal hernia. Akfirat M, et al. **J Clin Ultrasound** 1999 Mar–Apr;27(3):156–8
Ultrasonography for inguinal hernias in boys. Chen KC, et al. **J Pediatr Surg** 1998 Dec;33(12):1784–7
Color duplex sonography: diagnostic tool in the differentiation of inguinal hernias. Korenkov M, et al. **J Ultrasound Med** 1999 Aug;18(8):565–8
[Ultrasound assessment in diagnosis of uncomplicated inguinal hernia] Babkova IV, et al. **Khirurgiia (Mosk)** 1999; (2):46–50 (Eng. Abstr.) **(Rus)**

HERNIA, OBTURATOR

DIAGNOSIS

Photo quiz. A pelvic mass. Mian J. **Am Fam Physician** 1999 Apr 1;59(7):1919–20
Obturator hernia revisited: a review of 12 cases in 7 years [letter; comment] Lo CY. **J R Coll Surg Edinb** 1998 Oct; 43(5):364. Comment on: J R Coll Surg Edinb 1997 Apr;42(2):82–4.
Strangulated obturator hernia: 'old' and 'new' standards: in making the diagnosis [letter; comment] Losanoff JE, et al. **J R Coll Surg Edinb** 1998 Oct;43(5):362–4. Comment on: J R Coll Surg Edinb 1997 Apr;42(2):82–4.
Obturator hernia: laparoscopic diagnosis and repair. Haith LR Jr, et al. **J Soc Laparoendosc Surg** 1998 Apr–Jun; 2(2):191–3

RADIOGRAPHY

Thirty-six cases of obturator hernia: does computed tomography contribute to postoperative outcome? Yokoyama Y, et al. **World J Surg** 1999 Feb;23(2):214–6; discussion 217

SURGERY

Obturator hernia: laparoscopic diagnosis and repair. Haith LR Jr, et al. **J Soc Laparoendosc Surg** 1998 Apr–Jun; 2(2):191–3

ULTRASONOGRAPHY

Preoperative diagnosis of strangulated obturator hernia using ultrasonography [letter; comment] Losanoff J, et al. **Am J Surg** 1999 Jun;177(6):525–6. Comment on: Am J Surg 1997 Jul;174(1):76–8.

HERNIA, PARAESOPHAGEAL see **HERNIA, HIATAL**

HERNIA, UMBILICAL

see related
BECKWITH-WIEDEMANN SYNDROME
Exomphalos. Shrivastava J, et al. **Indian Pediatr** 1998 Apr; 35(4):372
Umbilical hernial defects encountered before and after abdominal laparoscopic procedures. Ramachandran CS. **Int Surg** 1998 Apr–Jun;83(2):171–3
A case with Weaver syndrome operated for congenital cardiac defect. Sarigül A, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):375–6
Exomphalos (omphalocele). Kilby MD, et al. **Prenat Diagn** 1998 Dec;18(12):1283–8 (41 ref.)
[Inguinal, femoral and umbilical hernia. Physiopathology, diagnosis, complication, treatment] Palot JP, et al. **Rev Prat** 1999 Jun 1;49(11):1242–8 **(Fre)**

CHEMICALLY INDUCED

Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. Genest DR, et al. **Clin Dysmorphol** 1999 Jan;8(1):53–8 (24 ref.)

COMPLICATIONS

Heterogeneity in omphalocoele with absent radial ray complex [letter; comment] Devriendt K, et al. **Am J Med Genet** 1999 Jan 1;82(1):95–6. Comment on: Am J Med Genet 1998 Jan 23;75(3):235–9.
Spontaneous rupture of infantile umbilical hernia: report of three cases. Ahmed A, et al. **Ann Trop Paediatr** 1998 Sep; 18(3):239–41
Giant omphalocele filled by a duplication cyst. Kiristioğlu I, et al. **Eur J Pediatr Surg** 1998 Oct;8(5):315–6
A case of painful umbilical hernia [letter] Balaji V, et al. **Int J Clin Pract** 1998 Jul–Aug;52(5):356
Gastroesophageal reflux in children with a congenital abdominal wall defect. Koivusalo A, et al. **J Pediatr Surg** 1999 Jul;34(7):1127–9
Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. Trotter JF, et al. **Liver Transpl Surg** 1999 May; 5(3):209–10
Incarceration of umbilical hernias in children: a rare but important complication. Papagrigoriadis S, et al. **Pediatr Surg Int** 1998 Dec;14(3):231–2

DRUG THERAPY

Iatrogenic neonatal mercury poisoning from Mercurochrome treatment of a large omphalocele. Mullins ME, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):111–2

EMBRYOLOGY

An accessory lobe of the liver disturbing closure of the umbilical ring. Ito F, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):394–6

EPIDEMIOLOGY

Artefactual increasing frequency of omphaloceles in the Northern Netherlands: lessons for systematic analysis of apparent epidemics. Reefhuis J, et al. **Int J Epidemiol** 1999 Apr;28(2):258–62
[Omphalocele and gastroschisis in Tirol-incidence and epidemiology 1985-1996] Penz H, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(4):216–21 (Eng. Abstr.) **(Ger)**

GENETICS

Is there an association of Down Syndrome and omphalocele? [letter; comment] Mastroiacovo P, et al. **Am J Med Genet** 1999 Feb 19;82(5):443. Comment on: Am J Med Genet 1997 Dec 31;73(4):400–3.
A new lethal syndrome of exomphalos, short limbs, and macrogonadism. Faivre L, et al. **J Med Genet** 1999 Feb; 36(2):131–6

SURGERY

Repair of mild umbilical hernia. Park S, et al. **Ann Plast Surg** 1999 Jun;42(6):634–7
Budd-Chiari syndrome following repair of a giant omphalocele. Kaabachi O, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):371–2
Myomectomy in pregnancy: incarcerated pedunculated fibroid in an umbilical hernia sac. Ehigiegba AE, et al. **Int J Clin Pract** 1999 Jan–Feb;53(1):80
Reduction of prosthetic silo: a novel technique using a desktop stapler [letter] Kimura K, et al. **J Pediatr Surg** 1998 Nov;33(11):1733–4
One-stop surgery: evolving approach to pediatric outpatient surgery. Tagge EP, et al. **J Pediatr Surg** 1999 Jan; 34(1):129–32
An accessory lobe of the liver disturbing closure of the umbilical ring. Ito F, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):394–6
"One-stop" surgery: implications for anesthesiologists of an expedited pediatric surgical process. Overdyk FJ, et al. **South Med J** 1999 Mar;92(3):308–12
[The use of prosthesis material in emergency surgery. Comments on a clinical case] Pacifico G, et al. **Minerva Chir** 1998 Oct;53(10):837–40 (Eng. Abstr.) **(Ita)**
[Anesthesia of a patient with morbid obesity: anesthetic and logistic management (letter)] Quintana Górdon FB, et al. **Rev Esp Anestesiol Reanim** 1998 Aug–Sep;45(7):303–5 **(Spa)**

THERAPY

Omphalocele delivery enigma: the best mode of delivery still remains dubious. Lurie S, et al.
Eur J Obstet Gynecol Reprod Biol 1999 Jan;82(1):19–22 (24 ref.)

Influence of antenatal ultrasound on the management of fetal exomphalos. Holland AJ, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):223–8

ULTRASONOGRAPHY

Prenatal diagnosis of complicated abdominal wall defects. Fogata ML, et al. **Curr Probl Diagn Radiol** 1999 Jul–Aug; 28(4):101–28 (98 ref.)

Influence of antenatal ultrasound on the management of fetal exomphalos. Holland AJ, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):223–8

[Color Doppler in the prenatal diagnosis of umbilical cord hernia] Dreyfus M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Nov; 27(7):718–20 (Eng. Abstr.) **(Fre)**

VETERINARY

Case report: umbilical foreign-body granuloma in a lamb. Yeruham I, et al. **Berl Munch Tierarztl Wochenschr** 1999 Feb;112(2):44–5

HERNIA, VENTRAL

[Spigelian hernia: clinical, diagnostic and therapeutical aspects] Versaci A, et al. **G Chir** 1998 Nov–Dec; 19(11–12):453–7 (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Foreign body reaction to meshes used for the repair of abdominal wall hernias. Klinge U, et al. **Eur J Surg** 1999 Jul;165(7):665–73

Bilateral lumbar hernia associated with abdominal hernias. A case report. Cocozza E, et al. **Minerva Chir** 1999 Jun; 54(6):421–3

Retroposas hernia as a cause of chronic abdominal pain: CT diagnosis. Benson JE, et al. **Pediatr Radiol** 1998 May; 28(5):312–4

Spigelian hernia with Crohn's appendicitis. Carr JA, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):398–9

Non-cardiac surgery and anaesthesia in children with congenital heart disease. Soyannwo OA, et al.
West Afr J Med 1999 Apr–Jun;18(2):87–90

[Incarcerated Waldeyer's hernia as the cause of necrosis of the small intestine (case report)] Sváb J, et al.
Rozhl Chir 1999 Apr;78(4):154–7 (Eng. Abstr.) **(Cze)**

[The negative sequelae of surgical treatment in postoperative ventral hernias. The prognostic possibilities and prophylactic means] Maistrenko NA, et al.
Vestn Khir Im I I Grek 1998;157(4):130–6 (72 ref.) **(Rus)**

[Surgical treatment of postop large size abdominal hernia in patients with obesity] Lysenko RB. **Klin Khir** 1999; (4):26–9 (Eng. Abstr.) **(Ukr)**

CONGENITAL

Undescended testicle associated with spigelian hernia. Ostlie DJ, et al. **J Pediatr Surg** 1998 Sep;33(9):1426–8

Congenital hernia of the abdominal wall: a differential diagnosis of fetal abdominal wall defects. Stepan H, et al.
Ultrasound Obstet Gynecol 1999 Mar;13(3):207–9

Giant congenital epigastric hernia. Ameh EA.
West Afr J Med 1999 Apr–Jun;18(2):151–2

DIAGNOSIS

Intestinal occlusion and spigelian hernia [letter] Benito MP, et al. **J Clin Gastroenterol** 1999 Sep;29(2):213–4

Appendix into the bladder. Antonelli M, et al. **J Pediatr** 1998 Nov;133(5):693

Spigelian hernia with Crohn's appendicitis. Carr JA, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):398–9

[A rare case of bilateral spigelian hernia] Pastore S, et al.
Minerva Chir 1998 Sep;53(9):735–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Surgical treatment of postop large size abdominal hernia in patients with obesity] Lysenko RB. **Klin Khir** 1999; (4):26–9 (Eng. Abstr.) **(Ukr)**

ETIOLOGY

Incisional hernias in patients with aortic aneurysmal disease: the importance of suture technique. Israelsson LA.
Eur J Vasc Endovasc Surg 1999 Feb;17(2):133–5

Incarcerated lumbar hernia--delayed consequence of a seat belt injury. Zamir G, et al. **Injury** 1998 Sep;29(7):561–3

Abdominal pseudohernia caused by diabetic truncal radiculoneuropathy. Weeks RA, et al.
J Neurol Neurosurg Psychiatry 1999 Mar;66(3):405

Traumatic lumbar hernia due to seat belt injury: case report. Balkan M, et al. **J Trauma** 1999 Jul;47(1):154–5

Rarity of traumatic abdominal wall hernias [letter; comment] Iuchtman M. **J Trauma** 1998 Oct;45(4):853. Comment on: J Trauma 1998 Mar;44(3):568.

Seat belt injury presenting as bilateral abdominal wall herniations in a child. Levine JL, et al.
Pediatr Emerg Care 1998 Oct;14(5):352–3 (11 ref.)

Handlebar hernia: case report and review of pediatric cases. Kubota A, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):411–2 (15 ref.)

Scroto-peritoneal port for laparoscopic orchidopexy [letter] Ng JW, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):452

Traumatic abdominal wall hernia caused by persistent cough. Vasquez JC, et al. **South Med J** 1999 Sep;92(9):907–8 (11 ref.)

Combined abdominal wall paresis and incisional hernia after laparoscopic cholecystectomy. Korenkov M, et al.
Surg Endosc 1999 Mar;13(3):268–9 (5 ref.)

Incisional hernias after laparoscopic vs open cholecystectomy. Sanz-López R, et al. **Surg Endosc** 1999 Sep;13(9):922–4

Abdominal incisional hernia occurring after an esophagectomy reconstructed with a gastric tube through an antesternal route: report of a case. Saeki H, et al.
Surg Today 1998;28(12):1254–6

[Post-traumatic flank hernias. Report of two cases] Kassasseya A, et al. **Ann Chir** 1998;52(10):1065–8 (Eng. Abstr.) **(Fre)**

MORTALITY

Who dies from hernia? Reaveley AM, et al.
J Epidemiol Community Health 1998 Aug;52(8):532–3

PATHOLOGY

Massive abdominal wall hernia--coincidence of bilateral semilunar hernias and a linea alba hernia [letter] Yamamoto N, et al. **Ann Plast Surg** 1999 Aug;43(2):220–1

[Morpho-functional aspects of pathogenesis and surgical treatment of the abdominal wall hernia in elderly and senile patients] Feleshtinskiĭ IaP, et al. **Klin Khir** 1998;(7):35–6 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Intraperitoneal polyglactin 910 absorbable prosthesis: a risk-free preventive method?] Cougard P, et al.
Ann Chir 1999;53(6):529–30 **(Fre)**

RADIOGRAPHY

CT findings after laparoscopic repair of ventral hernia. Lin BH, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):389–92

Retroposas hernia as a cause of chronic abdominal pain: CT diagnosis. Benson JE, et al. **Pediatr Radiol** 1998 May; 28(5):312–4

[Giant Spigelian hernia: assessment with computerized tomography and surgical correlations. Report of a case] Rossi E, et al. **Radiol Med (Torino)** 1999 Mar;97(3):196–7 **(Ita)**

SURGERY

Intraparietal retrorectus tension-free prosthetic mesh: a simple and effective method of repair of complex ventral hernias via a modified Stoppa technique. Surgical technique. Sakorafas GH, et al. **Acta Chir Belg** 1999 May–Jun;99(3):109–12 (12 ref.)

CT findings after laparoscopic repair of ventral hernia. Lin BH, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):389–92

Initial experience with laparoscopic repair of incisional hernias. Sanders LM, et al. **Am J Surg** 1999 Mar; 177(3):227–31

Re: Prevention of adhesions by Seprafilm, an absorbable adhesions barrier: an incisional hernia model in rats [letter; comment] Amid PK. **Am Surg** 1999 Feb;65(2):188–90. Comment on: Am Surg 1997 Sep;63(9):818–9.

Laparoscopic repair of recurrent ventral hernias. Costanza MJ, et al. **Am Surg** 1998 Dec;64(12):1121–5; discussion 1126–7

Paraduodenal hernia. Khan MA, et al. **Am Surg** 1998 Dec; 64(12):1218–22

Comparison of laparoscopic and open ventral herniorrhaphy. Ramshaw BJ, et al. **Am Surg** 1999 Sep;65(9):827–31; discussion 831–2

Dynamic reconstruction of the abdominal wall using a reinnervated free rectus femoris muscle transfer. Koshima I, et al. **Ann Plast Surg** 1999 Aug;43(2):199–203

Problems associated with prosthetic repair of incisional hernias [letter; comment] Gilbert AI, et al. **Arch Surg** 1998 Oct;133(10):1137. Comment on: Arch Surg 1998 Apr;133(4):378–82.

Long-term complications of prosthetic incisional hernioplasty [letter; comment] Stoppa R. **Arch Surg** 1998 Nov;133(11):1254–5. Comment on: Arch Surg 1998 Apr;133(4):378–82.

Incisional hernioplasty with polyester mesh [letter; comment] Wantz GE. **Arch Surg** 1998 Oct;133(10):1137. Comment on: Arch Surg 1998 Apr;133(4):378–82.

Functional and morphological evaluation of different polypropylene-mesh modifications for abdominal wall repair. Klosterhalfen B, et al. **Biomaterials** 1998 Dec; 19(24):2235–46

Repair of ventral hernias with expanded polytetrafluoroethylene patch [see comments] Balén EM, et al. **Br J Surg** 1998 Oct;85(10):1415–8. Comment in: Br J Surg 1999 May;86(5):712–3.

Repair of ventral hernias with expanded polytetrafluoroethylene patch [letter; comment] Gillion JF. **Br J Surg** 1999 May;86(5):712–3. Comment on: Br J Surg 1998 Oct;85(10):1415–8.

The use of prosthesis in abdominal and thoracic wall defect, 15 year experience: evaluation of tissue reactions and complications. Francioni G, et al. **Chir Ital** 1999 Jan–Feb; 51(1):21–30

New method for paracolostomy hernia repair? [letter; comment] [published erratum appears in Dis Colon Rectum 1999 Jul;42(7):880] Stelzner S, et al. **Dis Colon Rectum** 1999 Jun;42(6):823. Comment on: Dis Colon Rectum 1998 Aug;41(8):1054–5.

Modified mesh for hernia repair that is adapted to the physiology of the abdominal wall. Klinge U, et al.
Eur J Surg 1998 Dec;164(12):951–60

Ileus with incarceration of Spigelian hernia. Nozoe T, et al.
Hepatogastroenterology 1999 Mar–Apr;46(26):1010–2

Elective repair of abdominal wall hernias in decompensated cirrhosis. Ozden I, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1516–8

Incisional hernia: the problem and the cure.
J Am Coll Surg 1999 Apr;188(4):429–47

A simple and inexpensive technique for closing trocar sites and grasping sutures. Earle DB.
J Laparoendosc Adv Surg Tech A 1999 Feb;9(1):81–5

Simplified technique of mesh fixation during laparoscopic repair of abdominal ventral hernia. Piskun G, et al.
J Laparoendosc Adv Surg Tech A 1999 Apr;9(2):193–6

Laparoscopic retroperitoneal repair of recurrent postoperative lumbar hernia. Woodward AM, et al.
J Laparoendosc Adv Surg Tech A 1999 Apr;9(2):181–6

Undescended testicle associated with spigelian hernia. Ostlie DJ, et al. **J Pediatr Surg** 1998 Sep;33(9):1426–8

A combined fascia and mesh closure of large incisional hernias [letter; comment] Naraynsingh V, et al.
J R Coll Surg Edinb 1998 Dec;43(6):430–1. Comment on: J R Coll Surg Edinb 1998 Feb;43(1):29–30.

Laparoscopic repair of abdominal hernias using an ePTFE patch--a modification of a previously described technique. Phillips E, et al. **J Soc Laparoendosc Surg** 1997 Jul–Sep; 1(3):277–9

Is mesh fixation necessary in abdominal hernia repair? Results of an experimental study in the rat. Zieren J, et al.
Langenbecks Arch Surg 1999 Feb;384(1):71–5

Twelve-year experience with expanded polytetrafluoroethylene in the repair of abdominal wall defects. Bauer JJ, et al. **Mt Sinai J Med** 1999 Jan;66(1):20–5

Polypropylene mesh hernia repair--an alternative permitting rapid return to peritoneal dialysis. Lewis DM, et al.
Nephrol Dial Transplant 1998 Oct;13(10):2488–9

Repair of midline incisional hernias [letter] Elejabeitia J.
Plast Reconstr Surg 1999 Sep;104(3):886–7

Laparoscopic incisional hernia repair after transverse rectus abdominis myocutaneous flap reconstruction. Jansen DA, et al. **Plast Reconstr Surg** 1998 Oct;102(5):1623–5

A simplified laparoscopic technique for mesh placement in ventral hernia repair. Bickel A, et al. **Surg Endosc** 1999 May;13(5):532–4

Laparoscopic treatment vs open surgery in the solution of major incisional and abdominal wall hernias with mesh. Carbajo MA, et al. **Surg Endosc** 1999 Mar;13(3):250–2

Laparoscopic repair of bilateral spigelian and inguinal hernias. Gedebou TM, et al. **Surg Endosc** 1998 Dec; 12(12):1424–5

Laparoscopic repair of postoperation ventral hernia. Early postoperation results. Kyzer S, et al. **Surg Endosc** 1999 Sep; 13(9):928–31

Laparoscopic ventral and incisional hernia repair. Franklin ME, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):294–9

Laparoscopic intraperitoneal onlay mesh repair of incisional hernia. Tsimoyiannis EC, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):360–2

Abdominal incisional hernia occurring after an esophagectomy reconstructed with a gastric tube through an antesternal route: report of a case. Saeki H, et al.
Surg Today 1998;28(12):1254–6

Prevention of adhesion formation with use of sodium hyaluronate-based bioresorbable membrane in a rat model of ventral hernia repair with polypropylene mesh--a randomized, controlled study. Hooker GD, et al.
Surgery 1999 Feb;125(2):211–6

Laparoscopic and open incisional hernia repair: a comparison study. Park A, et al. **Surgery** 1998 Oct;124(4):816–21; discussion 821–2

Non-cardiac surgery and anaesthesia in children with congenital heart disease. Soyannwo OA, et al.
West Afr J Med 1999 Apr–Jun;18(2):87–90

Regeneration of abdominal wall aponeurosis: new dimension in Marlex peritoneal sandwich repair of incisional hernia. Matapurkar BG, et al. **World J Surg** 1999 May; 23(5):446–50; discussion 451

[Surgery of a large ventral hernia using Gore-tex] Sequens R. **Rozhl Chir** 1999 Feb;78(2):83–7 (Eng. Abstr.) **(Cze)**

[Spigelian hernia. A case of typical Spigelian hernia in an elderly man] Kalaba Z. **Ugeskr Laeger** 1999 Apr 5; 161(14):2095–6 (Eng. Abstr.) **(Dan)**

[Long-term results of 186 patients with large incisional abdominal wall hernia treated by intraperitoneal mesh] Oussoultzoglou E, et al. **Ann Chir** 1999;53(1):33–40 (Eng. Abstr.) **(Fre)**

[Postoperative incisional hernias: intra- or extraperitoneal prosthesis implantation?] Mathonnet M, et al. **Chirurgie** 1998 Apr;123(2):154–9; discussion 159–61 (Eng. Abstr.) **(Fre)**

[Management of complicated scar hernias (letter; comment)]

Höferlin A. **Chirurg** 1999 Feb;70(2):217. Comment on: Chirurg 1998 Jul;69(7):766–72. **(Ger)**

[Minimized polypropylene mesh for preperitoneal net plasty (PNP) of incisional hernias] Schumpelick V, et al. **Chirurg** 1999 Apr;70(4):422–30 (Eng. Abstr.) **(Ger)**

[Management of complicated incisional hernias with underlay-technique implanted polypropylene mesh. An effective technique in French hernia surgery] Trupka AW, et al. **Chirurg** 1998 Jul;69(7):766–72 (Eng. Abstr.) **(Ger)**

[Reconstruction of incisional hernias with defined tensiometrically controlled tension--a possibility for anatomically correct reconstruction of the abdominal wall] Klein P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1027–30 (Eng. Abstr.) **(Ger)**

[Organizational and surgical-technical aspects of the service of abdominal hernioplasty] Zanghi G, et al. **Ann Ital Chir** 1998 Sep–Oct;69(5):563–74 (41 ref.) (Eng. Abstr.) **(Ita)**

[The use of Dacron prostheses in laparoceles] Basile G, et al. **Minerva Chir** 1999 Jan–Feb;54(1–2):91–5 (Eng. Abstr.) **(Ita)**

[Laparoalloplasty by the Rives' technique for the treatment of large ventral hernias. Ten-year experience] D'Amico G, et al. **Minerva Chir** 1998 Jul–Aug;53(7–8):635–9 (Eng. Abstr.) **(Ita)**

[Spigelian hernia: anatomo-clinical considerations] Pichi Graziani M, et al. **Minerva Chir** 1999 Jun;54(6):425–31 (Eng. Abstr.) **(Ita)**

[Giant Spigelian hernia: assessment with computerized tomography and surgical correlations. Report of a case] Rossi E, et al. **Radiol Med (Torino)** 1999 Mar;97(3):196–7 **(Ita)**

[Application of argon coagulator in surgical treatment of ventral hernia] Tkachenko AE, et al. **Khirurgiia (Mosk)** 1999;(7):33–4 (Eng. Abstr.) **(Rus)**

[Morpho-functional aspects of pathogenesis and surgical treatment of the abdominal wall hernia in elderly and senile patients] Feleshtinskii IaP, et al. **Klin Khir** 1998;(7):35–6 (Eng. Abstr.) **(Rus)**

[Alloplasty of giant postoperative abdominal hernia in middle aged and aged patients] Feleshtinskii IaP. **Klin Khir** 1999; (7):24–6 (Eng. Abstr.) **(Rus)**

[The surgical treatment of a large postoperative ventral hernia in patients over 60 (see comments)] Antonov AM, et al. **Vestn Khir Im I I Grek** 1998;157(5):144–5. Comment in: Vestn Khir Im I I Grek 1998 ;157(5):146–7. **(Rus)**

[A rare complication in hernia of the anterior abdominal wall] Boitsov VD, et al. **Vestn Khir Im I I Grek** 1999;158(3):83 **(Rus)**

[The autoplasty of the abdominal wall in postoperative ventral hernias in middle-aged and elderly subjects using N. I. Napalkov's modified method (comment)] Uglov FG, et al. **Vestn Khir Im I I Grek** 1998;157(5):146–7. Comment on: Vestn Khir Im I I Grek 1998 ;157(5):144–5. **(Rus)**

[Nutritional status of surgical patients without apparent nutritional compromise] Zago L, et al. **Arch Latinoam Nutr** 1999 Mar;49(1):1–7 (Eng. Abstr.) **(Spa)**

[Surgical treatment of postop large size abdominal hernia in patients with obesity] Lysenko RB. **Klin Khir** 1999; (4):26–9 (Eng. Abstr.) **(Ukr)**

THERAPY

Effects of fibrin glue and growth factors released from platelets on abdominal hernia repair with a resorbable PGA mesh: experimental study. Zieren J, et al. **J Surg Res** 1999 Aug;85(2):267–72

ULTRASONOGRAPHY

Anterior abdominal wall pathologies detected by high-frequency annular array. Ishida H, et al. **Eur J Ultrasound** 1998 Aug;7(3):167–74

Ultrasonographic detection of herniation of stomach in paraumbilical hernia. Saggar K, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):87–8

Sonographic diagnosis of abdominal wall relaxation. Müller M, et al. **J Clin Ultrasound** 1999 May;27(4):183–6

The diagnosis of Spigelian hernia (SH) by high-resolution real-time sonography [letter; comment] Losanoff J, et al. **J Ultrasound Med** 1998 Sep;17(9):599–600. Comment on: J Ultrasound Med 1997 Mar;16(3):183–7.

VIROLOGY

Self-limiting abdominal wall herniation and constipation following herpes zoster infection [letter] Healy C, et al. **QJM** 1998 Nov;91(11):788–9

HEROIN

Polydrug abuse in heroin addicts: a behavioral economic analysis. Petry NM, et al. **Addiction** 1998 Mar;93(3):321–35

Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. De Vries TJ, et al. **Eur J Neurosci** 1998 Nov;10(11):3565–71

HIV serostatus and risk behaviors in a multisite sample of drug users. Deren S, et al. **J Psychoactive Drugs** 1998 Jul–Sep;30(3):239–45

Wound botulism associated with black tar heroin [letter; comment] Bamberger J, et al. **JAMA** 1998 Nov 4; 280(17):1479; discussion 1480. Comment on: JAMA 1998 Mar 18;279(11):859–63.

Wound botulism associated with black tar heroin [letter; comment] Horowitz BZ, et al. **JAMA** 1998 Nov 4; 280(17):1479–80. Comment on: JAMA 1998 Mar 18;279(11):859–63.

ADMINISTRATION & DOSAGE

Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis. Pillitteri LC, et al. **Bone Marrow Transplant** 1998 Sep;22(5):495–8

Comparison of intrathecal and epidural diamorphine for elective caesarean section using a combined spinal-epidural technique. Hallworth SP, et al. **Br J Anaesth** 1999 Feb; 82(2):228–32

Characteristics of hospitalized heroin smokers and heroin injectors in Taiwan. Chen CK, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):197–203

Effects of beta-funaltrexamine on dose-effect curves for heroin self-administration in rats: comparison with alteration of [3H]DAMGO binding to rat brain sections. Martin TJ, et al. **Drug Alcohol Depend** 1998 Oct 1; 52(2):135–47

The Zelen design may be the best choice for a heroin-provision experiment. Schellings R, et al. **J Clin Epidemiol** 1999 Jun;52(6):503–7

Opioid receptor selectivity of heroin given intracerebroventricularly differs in six strains of inbred mice. Rady JJ, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):438–45

Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. Xi ZX, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1369–74

Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Comer SD, et al. **Psychopharmacology (Berl)** 1999 Apr; 143(4):327–38

Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. De Vries TJ, et al. **Psychopharmacology (Berl)** 1999 Apr;143(3):254–60

Cellular responses of nucleus accumbens neurons to opiate-seeking behavior: I. Sustained responding during heroin self-administration. Lee RS, et al. **Synapse** 1999 Jul; 33(1):49–58

[Heroin-assisted treatment of opiate dependent patients. Experiences from Swiss trials for medical prescription of narcotics (PROVE)] Steffen T, et al. **Internist (Berl)** 1999 Jun;40(6):651–6 (30 ref.) **(Ger)**

ADVERSE EFFECTS

Heroin-induced deoxygenation of cerebral hemoglobin: monitoring by means of near-infrared spectroscopy [letter] Hock C, et al. **Ann Neurol** 1999 Jan;45(1):134–5

Hypoxic/ischaemic brain damage, especially pallidal lesions, in heroin addicts. Andersen SN, et al. **Forensic Sci Int** 1999 May 31;102(1):51–9

[Severe hypercorticism due to opiate withdrawal (letter)] Dejager S, et al. **Presse Med** 1998 May 23–30;27(19):912–3 **(Fre)**

[Accelerated detoxication in the preoperative period in surgical clinic patients suffering from heroin addiction] Sivolap IuP, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(7):60–2 **(Rus)**

ANALYSIS

Capillary electrophoresis--time-of-flight mass spectrometry of drugs of abuse. Lazar IM, et al. **Analyst** 1998 Jul; 123(7):1449–54

Evaluation of acetylcodeine as a specific marker of illicit heroin in human hair. Kintz P, et al. **J Anal Toxicol** 1998 Oct;22(6):425–9

ANTAGONISTS & INHIBITORS

Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. Xi ZX, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1369–74

Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Carrera MR, et al. **Psychopharmacology (Berl)** 1999 May;144(2):111–20

Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Gerasimov MR, et al. **Synapse** 1999 Oct;34(1):11–9

CHEMISTRY

Fluctuations in heroin purity and the incidence of fatal heroin overdose. Darke S, et al. **Drug Alcohol Depend** 1999 Apr 1;54(2):155–61

Development of a predictive model for batch membership of street samples of heroin. Janhunen K, et al. **Forensic Sci Int** 1999 May 31;102(1):1–11

Metal contamination in illicit samples of heroin. Infante F, et al. **J Forensic Sci** 1999 Jan;44(1):110–3

ECONOMICS

Methadone dosing, heroin affordability, and the severity of addiction. Bach PB, et al. **Am J Public Health** 1999 May; 89(5):662–5

HISTORY

The discovery of heroin. Sneader W. **Lancet** 1998 Nov 21; 352(9141):1697–9

METABOLISM

Opioid receptor selectivity of heroin given intracerebroventricularly differs in six strains of inbred mice. Rady JJ, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):438–45

PHARMACOKINETICS

Detection of 6-acetylmorphine in vitreous humor and cerebrospinal fluid--comparison with urinary analysis for proving heroin administration in opiate fatalities. Pragst F, et al. **J Anal Toxicol** 1999 May–Jun;23(3):168–72

Lemon juice as a solvent for heroin in Spain. Page JB, et al. **Subst Use Misuse** 1999 Jun;34(8):1193–7

Formation and clearance of active and inactive metabolites of opiates in humans. Aderjan RE, et al. **Ther Drug Monit** 1998 Oct;20(5):561–9 (60 ref.)

Recent discoveries in pharmacokinetics of drugs of abuse. Cone EJ. **Toxicol Lett** 1998 Dec 28;102–103:97–101

PHARMACOLOGY

Opioids accelerate fetal rat lung maturation in vitro. Gewolb IH, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):511–6

Choice between money and intranasal heroin in morphine-maintained humans. Comer SD, et al. **Behav Pharmacol** 1997 Dec;8(8):677–90

A heroin-, but not a cocaine-expecting, self-administration state preferentially alters endogenous brain peptides. Cappendijk SL, et al. **Eur J Pharmacol** 1999 Jan 22; 365(2–3):175–82

No heroin or morphine 6beta-glucuronide analgesia in mu-opioid receptor knockout mice. Kitanaka N, et al. **Eur J Pharmacol** 1998 Aug 14;355(1):R1–3

Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. Hemby SE, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):274–80

Heroin antinociception changed from mu to delta receptor in streptozotocin-treated mice. Rady JJ, et al. **Jpn J Pharmacol** 1998 Dec;78(4):443–54

Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Schuller AG, et al. **Nat Neurosci** 1999 Feb;2(2):151–6

Polydrug self-administration in rats: cocaine-heroin is more rewarding than cocaine-alone. Ranaldi R, et al. **Neuroreport** 1998 Aug 3;9(11):2463–6

The synergistic effects of combining cocaine and heroin ("speedball") using a progressive-ratio schedule of drug reinforcement. Duvauchelle CL, et al. **Pharmacol Biochem Behav** 1998 Nov;61(3):297–302

Haloperidol does not attenuate conditioned place preferences or locomotor activation produced by food- or heroin-predictive discriminative cues. McFarland K, et al. **Pharmacol Biochem Behav** 1999 Apr;62(4):631–41

Sensitization to the motor effects of contingent infusions of heroin but not of kappa agonist RU 51599. Marinelli M, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):281–5

Repeated heroin administration increases extracellular opioid peptide-like immunoreactivity in the globus pallidus/ventral pallidum of freely moving rats. Olive MF, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):251–4

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Spanagel R, et al. **Psychopharmacology (Berl)** 1998 Oct; 139(4):391–401

POISONING

Heroin fatality due to penile injection. Winek CL, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):90–2

Acute heroin overdose. Sporer KA. **Ann Intern Med** 1999 Apr 6;130(7):584–90 (114 ref.)

Fatal injections of heroin. Interpretation of toxicological findings in multiple specimens. Druid H, et al. **Int J Legal Med** 1999;112(1):62–6

Immunoaffinity extraction of morphine, morphine-3-glucuronide and morphine-6-glucuronide from blood of heroin victims for simultaneous high-performance liquid chromatographic determination. Beike J, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 16;726(1–2):111–9

Laboratory confirmation of scopolamine co-intoxication in patients using tainted heroin. Perrone J, et al. **J Toxicol Clin Toxicol** 1999;37(4):491–6

Are heroin overdose deaths related to patient release after prehospital treatment with naloxone? Vilke GM, et al. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):183–6

Profound circulatory shock following heroin overdose. Remskar M, et al. **Resuscitation** 1998 Jul;38(1):51–3 (6 ref.)

[Prehospital treatment of heroin intoxication in Oslo in 1996] Stokland O, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30; 118(20):3144–6 (Eng. Abstr.) **(Nor)**

[A case of acute heroin poisoning] Barinov EKh. **Sud Med Ekspert** 1999 Jul–Aug;42(4):38 **(Rus)**

THERAPEUTIC USE

Divergent illicit drug policies in Europe [news] **Ann Oncol** 1998 Dec;9(12):1257

The Swiss heroin trials. Trial is needed comparing decriminalisation of heroin with existing policy of prohibition [letter; comment] Venning GR. **BMJ** 1998 Oct 10;317(7164):1011; discussion 1011-2. Comment on: **BMJ** 1998 Feb 28;316(7132):639.

The Swiss heroin trials. Further studies of heroin treatment are needed [letter; comment] Wodak A. **BMJ** 1998 Oct 10;317(7164):1011; discussion 1011-2. Comment on: **BMJ** 1998 Feb 28;316(7132):639.

Intrathecal diamorphine for postoperative analgesia after Caesarean section [letter; comment] Cutts MW, et al. **Br J Anaesth** 1998 Dec;81(6):993; discussion 993-4. Comment on: Br J Anaesth 1998 Aug;81(2):135-9.

Intrathecal diamorphine compared with morphine for postoperative analgesia after caesarean section under spinal anaesthesia [see comments] Husaini SW, et al. **Br J Anaesth** 1998 Aug;81(2):135-9. Comment in: Br J Anaesth 1998 Dec;81(6):992; discussion 992-3. Comment in: Br J Anaesth 1998 Dec;81(6):993; discussion 993-4.

Intrathecal diamorphine for postoperative analgesia after caesarean section [letter; comment] Levy DM. **Br J Anaesth** 1998 Dec;81(6):992; discussion 992-3. Comment on: Br J Anaesth 1998 Aug;81(2):135-9.

Anti-allodynic actions of intravenous opioids in the nerve injured rat: potential utility of heroin and dihydroetorphine against neuropathic pain. Martin TJ, et al. **Eur J Pharmacol** 1998 Sep 11;357(1):25-32

Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence. Drucker E, et al. **Lancet** 1999 May 8;353(9164):1543-4 (1 ref.)

Postoperative extradural infusions in children: preliminary data from a comparison of bupivacaine/diamorphine with plain ropivacaine. Moriarty A. **Paediatr Anaesth** 1999; 9(5):423-7

The heroin prescribing debate: integrating science and politics [see comments] Bammer G, et al. **Science** 1999 May 21;284(5418):1277-8. Comment in: Science 1999 Jul 23;285(5427):532; discussion 533. Comment in: Science 1999 Jul 23;285(5427):532-3; discussion 533.

Prescribing heroin [letter; comment] Caltrider W. **Science** 1999 Jul 23;285(5427):532-3; discussion 533. Comment on: Science 1999 May 21;284(5418):1277-8.

Prescribing heroin [letter; comment] Rusche S. **Science** 1999 Jul 23;285(5427):532; discussion 533. Comment on: Science 1999 May 21;284(5418):1277-8.

[Is the medical prescription of heroin a treatment option for heroin addiction? The PEPSA Team (The Experimental Program of Narcotic Prescription in Andalucía (editorial)] Zunzunegui MV. **Med Clin (Barc)** 1999 Sep 4;113(6):219-21 (30 ref.) **(Spa)**

TOXICITY

Detection of 6-acetylmorphine in vitreous humor and cerebrospinal fluid--comparison with urinary analysis for proving heroin administration in opiate fatalities. Pragst F, et al. **J Anal Toxicol** 1999 May-Jun;23(3):168-72

Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Laulin JP, et al. **Neuroscience** 1999 Mar;89(3):631-6

HEROIN ABUSE see **HEROIN DEPENDENCE**

HEROIN ADDICTION see **HEROIN DEPENDENCE**

HEROIN DEPENDENCE

Acute heroin overdose. Sporer KA. **Ann Intern Med** 1999 Apr 6;130(7):584-90 (114 ref.)

Thoracotomy without opioids in a heroin addict maintained with oral methadone [letter] Voyagis GS, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):806-7

Obstacles to needle exchange participation in Rhode Island. Rich JD, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):396-400

Evaluation of acetylcodeine as a specific marker of illicit heroin in human hair. Kintz P, et al. **J Anal Toxicol** 1998 Oct;22(6):425-9

Carious lesions in the heroin addicted patient. A case report. Shen EC, et al. **J Periodontol** 1998 Aug;69(8):938-40

Heroin, HIV and harm in New York and Sydney [letter] Maher LS, et al. **Med J Aust** 1999 Aug 2;171(3):163, 165

Adolescent heroin use: a review. Schwartz RH. **Pediatrics** 1998 Dec;102(6):1461-6 (82 ref.)

Regional cerebral blood flow and comorbid diagnosis in abstinent opioid addicts. Gerra G, et al. **Psychiatry Res** 1998 Aug 26;83(2):117-26

BLOOD

Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. Ferrari A, et al. **Drug Alcohol Depend** 1998 Nov 1;52(3):211-20

Determination of buprenorphine in plasma by liquid chromatography: application to heroin-dependent subjects. Lagrange F, et al. **J Pharm Biomed Anal** 1998 Apr; 16(8):1295-300

COMPLICATIONS

Abdominal pain and drug addiction [letter] Stuebe D. **Aust Fam Physician** 1999 Jan;28(1):15

Characteristics of hospitalized heroin smokers and heroin injectors in Taiwan. Chen CK, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):197-203

Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy [see comments] Martínez-Vázquez C, et al. **Clin Infect Dis** 1998 Nov;27(5):1130-3. Comment in: Clin Infect Dis 1998 Nov;27(5):1134-6.

Motor neuron disease and HIV-1 infection in a 30-year-old HIV-positive heroin abuser: a causal relationship? Galassi G, et al. **Clin Neuropathol** 1998 May-Jun;17(3):131-5 (23 ref.)

Antisocial personality disorder, psychopathy and injecting heroin use. Darke S, et al. **Drug Alcohol Depend** 1998 Sep 1;52(1):63-9

Leg pain and swelling in an HIV-infected drug abuser. Formica R, et al. **Hosp Pract (Off Ed)** 1998 Oct 15; 33(10):195-7

Pemphigus vegetans-Neumann variant associated with intranasal heroin abuse. Downie JB, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):872-5

Compartment syndrome of the hand following intra-arterial injection of heroin. Funk L, et al. **J Hand Surg [Br]** 1999 Jun;24(3):366-7

Bilateral borderzone brain infarctions in association with heroin abuse. Niehaus L, et al. **J Neurol Sci** 1998 Oct 8; 160(2):180-2

Epidemiology of Candida albicans isolates from heroin addicts analysed by DNA typing [published erratum appears in Med Mycol 1998 Dec;36(6):441] McCullough MJ, et al. **Med Mycol** 1998 Aug;36(4):213-7

Focal rhabdomyolysis and brachial plexopathy: an association with heroin and chronic ethanol use. Riggs JE, et al. **Mil Med** 1999 Mar;164(3):228-9

Haemolytic-uraemic syndrome in a heroin addict. Peces R, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3197-9

Spinal cord abscess in a heroin addict: case report. Sverzut JM, et al. **Neuroradiology** 1998 Jul;40(7):455-8

Anticholinergic syndrome precipitated by opioid reversal [clinical conference] Hicks SD, et al. **Prehosp Emerg Care** 1998 Oct-Dec;2(4):328-9

Profound circulatory shock following heroin overdose. Remskar M, et al. **Resuscitation** 1998 Jul;38(1):51-3 (6 ref.)

[Drug addict with ptosis. Myasthenia gravis] Wild P, et al. **Schweiz Rundsch Med Prax** 1999 May 6;88(19):871-5 (Eng. Abstr.) **(Ger)**

[Wound botulism in heroin addiction] Holmaas G, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4357-9 (Eng. Abstr.) **(Nor)**

[Prehospital treatment of heroin intoxication in Oslo in 1996] Stokland O, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30; 118(20):3144-6 (Eng. Abstr.) **(Nor)**

[Rhabdomyolysis and compartment syndrome associated with drug abuse (letter)] Blanco García S, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):46-7 **(Spa)**

DIAGNOSIS

Validity of drug use reporting in a high-risk community sample: a comparison of cocaine and heroin survey reports with hair tests. Fendrich M, et al. **Am J Epidemiol** 1999 May 15;149(10):955-62

Vitreous humor as an alternative sample to blood for the supercritical fluid extraction of morphine and 6-monoacetylmorphine. Scott KS, et al. **Med Sci Law** 1999 Jan;39(1):77-81

DRUG THERAPY

Methadone dosing, heroin affordability, and the severity of addiction. Bach PB, et al. **Am J Public Health** 1999 May; 89(5):662-5

Rapid detoxification of heroin dependence by buprenorphine. Liu ZM, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar; 18(2):112-4

Methadone and quality of life [letter; comment] Torrens M, et al. **Lancet** 1999 Mar 27;353(9158):1101. Comment on: Lancet 1999 Jan 16;353(9148):221-6.

A pilot study of naltrexone-accelerated detoxification in opioid dependence [see comments] Bell JR, et al. **Med J Aust** 1999 Jul 5;171(1):26-30. Comment in: Med J Aust 1999 Jul 5;171(1):9-10.

Quinine-induced blindness during attempted heroin withdrawal. Feeney GF, et al. **Med J Aust** 1999 May 3; 170(9):449

Is naltrexone a cure for heroin dependence? [editorial; comment] Hall WD, et al. **Med J Aust** 1999 Jul 5; 171(1):9-10. Comment on: Med J Aust 1999 Jul 5;171(1):26-30.

Methadone-related deaths in New Zealand [letter] Sibley J, et al. **N Z Med J** 1999 Aug 13;112(1093):303

Effects of flupenthixol and quadazocine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Mello NK, et al. **Neuropsychopharmacology** 1999 Oct;21(4):575-88

Patient outcomes after initiation of Sabbath closure of a methadone maintenance clinic in Israel. Gelkopf M, et al. **Psychiatr Serv** 1998 Nov;49(11):1483-5

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress. Spanagel R, et al. **Psychopharmacology (Berl)** 1998 Oct; 139(4):391-401

Temporal patterns of heroin and cocaine use among methadone patients. Magura S, et al. **Subst Use Misuse** 1998 Oct;33(12):2441-67

[Colonic dialysis therapy of Chinese herbal medicine in abstinance of heroin addicts--report of 75 cases] Sha LJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb;17(2):76-8 (Eng. Abstr.) **(Chi)**

['Methadone substitution therapy and driving'. Results of an experimental study] Dittert S, et al. **Nervenarzt** 1999 May; 70(5):457-62 (Eng. Abstr.) **(Ger)**

[Pharmacological principles for the treatment of heroin abuse] Oye I. **Tidsskr Nor Laegeforen** 1999 May 30; 119(14):2066-9 (15 ref.) **(Nor)**

ECONOMICS

Methadone dosing, heroin affordability, and the severity of addiction. Bach PB, et al. **Am J Public Health** 1999 May; 89(5):662-5

Gender, heroin consumption and economic behaviour. Bretteville-Jensen AL. **Health Econ** 1999 Aug;8(5):379-89

ENZYMOLOGY

Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin. Kish SJ, et al. **Mol Psychiatry** 1999 Jan;4(1):26-32

EPIDEMIOLOGY

Heroin smoking by "chasing the dragon": its evolution in Spain [letter] de la Fuente L, et al. **Addiction** 1998 Mar; 93(3):444-6

Heroin chasers and heroin injectors: differences observed in a community sample in London, UK. Strang J, et al. **Am J Addict** 1999 Spring;8(2):148-60

Validity of drug use reporting in a high-risk community sample: a comparison of cocaine and heroin survey reports with hair tests. Fendrich M, et al. **Am J Epidemiol** 1999 May 15;149(10):955-62

Estimating the extent of the heroin problem in Slovenia: application of the key informant approach and the nomination technique where there are no other reliable sources of information. Nolimal D. **Bull Narc** 1996; 48(1-2):121-34

Gender, heroin consumption and economic behaviour. Bretteville-Jensen AL. **Health Econ** 1999 Aug;8(5):379-89

Psychiatric comorbidity in methadone maintained patients. Mason BJ, et al. **J Addict Dis** 1998;17(3):75-89

Britain on the brink of new heroin epidemic [news] Dean M. **Lancet** 1999 Jun 5;353(9168):1947

The heroin/cocaine epidemic in Switzerland 1979-1997: a mathematical analysis of law enforcement data. Knolle H. **Subst Use Misuse** 1999 Jun;34(8):1117-36

Lemon juice as a solvent for heroin in Spain. Page JB, et al. **Subst Use Misuse** 1999 Jun;34(8):1193-7

[Consumer trends in heroin and cocaine use: learning from an unfortunate controversy (editorial; comment)] Abelin T, et al. **Soz Praventivmed** 1999;44(2):39-43. Comment on: Soz Praventivmed 1997;42(2):105-13. **(Ger)**

ETHNOLOGY

Cross-cultural similarities in the personality dimensions of heroin users [comment] Patalano F. **J Psychol** 1998 Nov; 132(6):671-3. Comment on: J Psychol 1997 Jan;131(1):125-7.

GENETICS

No association between the serotonin transporter promoter region (5-HTTLPR) and the dopamine D3 receptor (Ball D3DR) polymorphisms and heroin addiction [letter] Kotler M, et al. **Mol Psychiatry** 1999 Jul;4(4):313-4

Evidence for an association between heroin dependence and a VNTR polymorphism at the serotonin transporter locus [letter] Tan EC, et al. **Mol Psychiatry** 1999 May;4(3):215-7

The proenkephalin gene (PENK) and opioid dependence. Comings DE, et al. **Neuroreport** 1999 Apr 6;10(5):1133-5

IMMUNOLOGY

Induction of antibodies to methadone during methadone maintenance treatment of heroin addicts and its possible clinical implications. Gamaleya N, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):357-64

MICROBIOLOGY

[Picture of the month (Staph infection)] Kristensen LH, et al. **Ugeskr Laeger** 1999 Jan 25;161(4):443 **(Dan)**

[Clinical wound botulism in injecting drug addicts] Jensen T, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20; 118(28):4363-5 (Eng. Abstr.) **(Nor)**

[Serious bacterial and fungal infections in intravenous drug addicts] Jensenius M, et al. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1759-62 (Eng. Abstr.) **(Nor)**

MORTALITY

Fluctuations in heroin purity and the incidence of fatal heroin overdose. Darke S, et al. **Drug Alcohol Depend** 1999 Apr 1;54(2):155-61

One-year mortality rates following methadone treatment

discharge. Zanis DA, et al. **Drug Alcohol Depend** 1998 Nov 1;52(3):257–60

Remembering those who died from heroin addiction. Birchard K. **Lancet** 1999 Jul 31;354(9176):436

Accidental illicit drug deaths in Sydney: how common are they? [letter] Garrick TM, et al. **Med J Aust** 1999 Feb 1;170(3):139

[On the heroin epidemic, its impact, its context, and health policy (editorial; comment)] Villalbi JR, et al.
Med Clin (Barc) 1999 May 29;112(19):736–7. Comment on: Med Clin (Barc) 1999 May 29;112(19):721–5. **(Spa)**

PATHOLOGY

Fatal injections of heroin. Interpretation of toxicological findings in multiple specimens. Druid H, et al.
Int J Legal Med 1999;112(1):62–6

PHYSIOPATHOLOGY

Physical health problems in depressed and nondepressed children and adolescents of parents with opiate dependence. McAvay G, et al. **Depress Anxiety** 1999; 9(2):61–9

Effects of beta-funaltrexamine on dose-effect curves for heroin self-administration in rats: comparison with alteration of [3H]DAMGO binding to rat brain sections. Martin TJ, et al. **Drug Alcohol Depend** 1998 Oct 1; 52(2):135–47

Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. De Vries TJ, et al. **Eur J Neurosci** 1998 Nov;10(11):3565–71

Activation of reward circuitry in human opiate addicts. Sell LA, et al. **Eur J Neurosci** 1999 Mar;11(3):1042–8

Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. Shaham Y, et al. **J Neurosci** 1997 Apr 1;17(7):2605–14

PREVENTION & CONTROL

Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. Rothbard A, et al.
J Subst Abuse Treat 1999 Jun;16(4):329–35

PSYCHOLOGY

Drug use and injection risk-taking among prison methadone maintenance patients. Darke S, et al. **Addiction** 1998 Aug; 93(8):1169–75

An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors. Zule WA, et al. **Am J Drug Alcohol Abuse** 1999 Feb;25(1):1–23

Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use. Best D, et al.
Drug Alcohol Depend 1999 Feb 1;53(3):191–5

Naloxone blocks reinforcement but not motivation in an operant runway model of heroin-seeking behavior. McFarland K, et al. **Exp Clin Psychopharmacol** 1998 Nov; 6(4):353–9

Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Kirby KN, et al. **J Exp Psychol Gen** 1999 Mar;128(1):78–87

Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. Shaham Y, et al. **J Neurosci** 1997 Apr 1;17(7):2605–14

Cue reactivity and effects of cue exposure in abstinent posttreatment drug users. Franken IH, et al.
J Subst Abuse Treat 1999 Jan;16(1):81–5

Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Comer SD, et al. **Psychopharmacology (Berl)** 1999 Apr; 143(4):327–38

Rated well-being in relation to plasma concentrations of l- and d-methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Hiltunen AJ, et al.
Psychopharmacology (Berl) 1999 Apr;143(4):385–93

The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments [see comments] Bourgois P. **Subst Use Misuse** 1998 Sep;33(11):2323–51. Comment in: Subst Use Misuse 1998 Sep;33(11):2353–5. Comment in: Subst Use Misuse 1998 Sep;33(11):2357–9. Comment in: Subst Use Misuse 1998 Sep;33(11):2361–3. Comment in: Subst Use Misuse 1998 Sep;33(11):2365–8.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Courtwright DT.
Subst Use Misuse 1998 Sep;33(11):2353–5. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–4.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Fielding NG.
Subst Use Misuse 1998 Sep;33(11):2361–3. Comment on: Subst Use Misuse 1998 Sep;33(11):2361–3.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Latkin CA. **Subst Use Misuse** 1998 Sep; 33(11):2375–82

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Leshner AI. **Subst Use Misuse** 1998 Sep;33(11):2369–74

Temporal patterns of heroin and cocaine use among methadone patients. Magura S, et al. **Subst Use Misuse** 1998 Oct;33(12):2441–67

REHABILITATION

Maternal use of heroin and methadone and infant birth weight [letter] MacQueen AR. **Addiction** 1998 Sep;93(9):1433–4

Relationship of HIV testing and high-risk behaviors among clients in methadone maintenance treatment. Grella CE, et al. **AIDS Educ Prev** 1998 Oct;10(5):403–16

Divergent illicit drug policies in Europe [news]
Ann Oncol 1998 Dec;9(12):1257

The Swiss heroin trials. Trial is needed comparing decriminalisation of heroin with existing policy of prohibition [letter; comment] Venning GR. **BMJ** 1998 Oct 10;317(7164):1011; discussion 1011–2. Comment on: BMJ 1998 Feb 28;316(7132):639.

The Swiss heroin trials. Further studies of heroin treatment are needed [letter; comment] Wodak A. **BMJ** 1998 Oct 10;317(7164):1011; discussion 1011–2. Comment on: BMJ 1998 Feb 28;316(7132):639.

Nuns to run first heroin injecting room [news] Zinn C.
BMJ 1999 Aug 14;319(7207):400

Recent developments in maintenance prescribing and monitoring in the United Kingdom. Brewer C.
Bull N Y Acad Med 1995 Winter;72(2):359–70

Methadone treatment by general practitioners in Amsterdam. van Brussel G. **Bull N Y Acad Med** 1995 Winter; 72(2):348–58

The methadone-maintained pregnancy. Kandall SR, et al.
Clin Perinatol 1999 Mar;26(1):173–83 (63 ref.)

Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use. Best D, et al.
Drug Alcohol Depend 1999 Feb 1;53(3):191–5

Staff attitudes and retention of patients in methadone maintenance programs. Caplehorn JR, et al.
Drug Alcohol Depend 1998 Sep 1;52(1):57–61

Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Cucchia AT, et al. **Drug Alcohol Depend** 1998 Nov 1;52(3):243–50

Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. D'Ippoliti D, et al. **Drug Alcohol Depend** 1998 Oct 1; 52(2):167–71

Improvement in naltrexone treatment compliance with contingency management. Preston KL, et al.
Drug Alcohol Depend 1999 Apr 1;54(2):127–35

The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Rosen MI, et al. **Drug Alcohol Depend** 1998 Oct 1;52(2):173–6

Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Torrens M, et al.
Drug Alcohol Depend 1998 Nov 1;52(3):193–200

Factors associated with lapses to heroin use during methadone maintenance. Wasserman DA, et al.
Drug Alcohol Depend 1998 Nov 1;52(3):183–92

NIH consensus panel recommends expanding access to and improving methadone treatment programs for heroin addiction. **Eur Addict Res** 1999 Mar;5(1):50–1 (0 ref.)

Therapeutic drug monitoring for methadone: scanning the horizon. Wolff K, et al. **Eur Addict Res** 1999 Mar;5(1):36–42 (85 ref.)

Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment [see comments] Lewis DC. **J Addict Dis** 1999; 18(2):5–21 (82 ref.). Comment in: J Addict Dis 1999 ;18(2):1–4.

Heroin addiction and methadone maintenance: when will we ever learn [editorial; comment] Stimmel B.
J Addict Dis 1999;18(2):1–4. Comment on: J Addict Dis 1999 ;18(2):5–21.

Methadone maintenance: results of treatment in heroin addict at Thanyarak Hospital (1990–1996). Verachai V, et al.
J Med Assoc Thai 1998 Dec;81(12):947–52

Use of methadone take-home contingencies with persistent opiate and cocaine abusers. Chutuape MA, et al.
J Subst Abuse Treat 1999 Jan;16(1):23–30

Mortality associated with New South Wales methadone programs in 1994: lives lost and saved [see comments] Caplehorn JR, et al. **Med J Aust** 1999 Feb 1;170(3):104–9 . Comment in: Med J Aust 1999 Feb 1;170(3):100–1.

An addict who wants to detoxify. Smith P, et al.
Practitioner 1998 Nov;242(1592):735–6, 739–40 (0 ref.)

Effectiveness of methadone maintenance for heroin addiction. Murray JB. **Psychol Rep** 1998 Aug;83(1):295–302 (50 ref.)

Rated well-being in relation to plasma concentrations of l- and d-methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Hiltunen AJ, et al.
Psychopharmacology (Berl) 1999 Apr;143(4):385–93

The heroin prescribing debate: integrating science and politics [see comments] Bammer G, et al. **Science** 1999 May 21;284(5418):1277–8. Comment in: Science 1999 Jul 23;285(5427):532; discussion 533. Comment in: Science 1999 Jul 23;285(5427):532–3; discussion 533.

Prescribing heroin [letter; comment] Caltrider W. **Science** 1999 Jul 23;285(5427):532–3; discussion 533. Comment on: Science 1999 May 21;284(5418):1277–8.

Prescribing heroin [letter; comment] Rusche S. **Science** 1999 Jul 23;285(5427):532; discussion 533. Comment on: Science 1999 May 21;284(5418):1277–8.

Gender differences at admission and follow-up in a sample of methadone maintenance clients. Chatham LR, et al.
Subst Use Misuse 1999 Jun;34(8):1137–65

[Pregnancy, abortion and delivery in a cohort of heroin dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine (letter)] Auriacombe M, et al. **Presse Med** 1999 Jan 30;28(4):177 **(Fre)**

[Frequency of injection of oral methadone solutions at treatment center for opiate dependence] Waldvogel D, et al. **Fortschr Neurol Psychiatr** 1999 Jun;67(6):281–3 (Eng. Abstr.) **(Ger)**

[Drug substitution in heroin dependence with methadone] Krausz M, et al. **Internist (Berl)** 1999 Jun;40(6):645–50 (27 ref.) **(Ger)**

[Driving fitness/driving capacity of patients treated with methadone] Hauri-Bionda R, et al.
Schweiz Med Wochenschr 1998 Oct 10;128(41):1538–47 (Eng. Abstr.) **(Ger)**

[Is methadone efficient? Methadone therapy versus evidence-based medicine (see comments)] Aavitsland P. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3105. Comment in: Tidsskr Nor Laegeforen 1998 Sep 30;118(23):3673. **(Nor)**

[The Oslo methadone project] Blix O, et al.
Tidsskr Nor Laegeforen 1999 Jan 20;119(2):242–6 (Eng. Abstr.) **(Nor)**

[What effects does methadone maintenance treatment have on the rehabilitation of heroin addicts? (see comments)] Hermstad R, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30; 118(20):3139–41 (30 ref.) (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1998 Sep 30;118(23):3673. **(Nor)**

[Is methadone a solution?] Waal H.
Tidsskr Nor Laegeforen 1998 Aug 30;118(20):3104 **(Nor)**

[Methadone used in the treatment of opioid dependence] Waal H, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20; 119(2):237–41 (Eng. Abstr.) **(Nor)**

[Accelerated detoxication in the preoperative period in surgical clinic patients suffering from heroin addiction] Sivolap IuP, et al.
Zh Nevrol Psikhiatr Im S S Korsakova 1999;99(7):60–2 **(Rus)**

[Use of methadone in the treatment of narcotic addiction] Tiljak H. **Lijec Vjesn** 1998 May;120(5):125–31 (79 ref.) (Eng. Abstr.) **(Scr)**

[Is the medical prescription of heroin a treatment option for heroin addiction? The PEPSA Team (The Experimental Program of Narcotic Prescription in Andalucia (editorial)] Zunzunegui MV. **Med Clin (Barc)** 1999 Sep 4;113(6):219–21 (30 ref.) **(Spa)**

THERAPY

The Zelen design may be the best choice for a heroin-provision experiment. Schellings R, et al.
J Clin Epidemiol 1999 Jun;52(6):503–7

Engaging hospitalized heroin-dependent patients into substance abuse treatment. Aszalos R, et al.
J Subst Abuse Treat 1999 Jul-Sep;17(1-2):149–58

Cue reactivity and effects of cue exposure in abstinent posttreatment drug users. Franken IH, et al.
J Subst Abuse Treat 1999 Jan;16(1):81–5

Heroin addiction: the science and ethics of the new treatment pluralism. Gaughwin MD, et al. **Med J Aust** 1999 Feb 1; 170(3):129–30

Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment. Fugelstad A, et al.
Subst Use Misuse 1998 Dec;33(14):2803–17

URINE

An evaluation of the role of ROC plots in the prediction of heroin use from total codeine and total morphine concentrations in urine. O'Neal CL, et al.
J Anal Toxicol 1998 Oct;22(6):487–92

HEROIN USERS see **HEROIN DEPENDENCE**

HERPANGINA

[Herpangina] Fujita T, et al.
Ryoikibetsu Shokogun Shirizu 1999;(25 Pt 3):151–3 (8 ref.) **(Jpn)**

EPIDEMIOLOGY

An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group [see comments] Ho M, et al. **N Engl J Med** 1999 Sep 23;341(13):929–35. Comment in: N Engl J Med 1999 Sep 23;341(13):984–5.

HERPANGINA VIRUS see **COXSACKIEVIRUSES A**

HERPES GENITALIS

New developments in the epidemiology, natural history and management of genital herpes. Stanberry L, et al.
Antiviral Res 1999 May;42(1):1–14 (90 ref.)

An interactive, computer-based program to educate patients about genital herpes. Bensen C, et al. **Sex Transm Dis** 1999 Jul;26(6):364–8

[Virology, epidemiology and diagnosis of herpes genitalis] Chenot JF, et al. **Dtsch Med Wochenschr** 1999 Feb 12; 124(6):158–62 (31 ref.) **(Ger)**

[Radiculomyelopathy due to genital herpes simplex virus infection (Elsberg syndrome)] Kido M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):52–4 (15 ref.) **(Jpn)**

[Genital herpes] Matsukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):70–3 (11 ref.) **(Jpn)**

COMPLICATIONS

A case of vulvitis circumscripta plasmacellularis positive for herpes simplex type II antigen [letter] Kuniyuki S, et al. **Clin Exp Dermatol** 1998 Sep;23(5):230–1

Genital herpes complicating pregnancy. Brown ZA. **Dermatol Clin** 1998 Oct;16(4):805–10, xiv (24 ref.)

Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study [see comments] Perez G, et al. **Int J Infect Dis** 1998 Jul–Sep;3(1):5–11. Comment in: Int J Infect Dis 1998 Jul–Sep;3(1):1–4.

Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus–infected men. Schacker T, et al. **J Infect Dis** 1998 Dec;178(6):1616–22

Disseminated herpes simplex virus infection in a renal transplant patient as possible cause of repeated urinary extravasations. Gómez E, et al. **Nephron** 1999;82(1):59–64

Aseptic herpetic meningitis: an uncommon genital herpes sequelae. Bumbalough MR, et al. **Nurse Pract** 1999 Jul; 24(7):84–6, 88

Genital ulcers associated with acute Epstein-Barr virus infection. Taylor S, et al. **Sex Transm Infect** 1998 Aug; 74(4):296–7 (6 ref.)

[Recurrent Mollaret's meningitis of herpetic origin] Gignoux L, et al. **Presse Med** 1998 Oct 3;27(29):1470–2 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Another cause for transient radicular pain [letter; comment] Elias M. **Acta Anaesthesiol Scand** 1999 Jan;43(1):115. Comment on: Acta Anaesthesiol Scand 1998 Apr;42(4):425–9.

Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis. Jensenius M, et al. **Acta Neurol Scand** 1998 Sep;98(3):209–12

Comparison between virus isolation method, Papanicolaou stain, immunoperoxidase stain and polymerase chain reaction in the diagnosis of genital herpes. Puthavathana P, et al. **Asian Pac J Allergy Immunol** 1998 Dec; 16(4):177–83

You're the flight surgeon. Herpes simplex virus type 2(HSV-2). Fisher CR Jr. **Aviat Space Environ Med** 1999 Apr;70(4):351–2

Atypical presentation of herpes simplex virus in a patient with chronic lymphocytic leukemia. Brown TS, et al. **Cutis** 1999 Aug;64(2):123–5

Genital herpes. Type-specific antibodies for diagnosis and management. Ashley RL. **Dermatol Clin** 1998 Oct; 16(4):789–93, xiii–xiv

Herpes. Atypical clinical manifestations. Tyring SK, et al. **Dermatol Clin** 1998 Oct;16(4):783–8, xiii (34 ref.)

Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay. Enders G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):870–2

Performance of a rapid screening test POCkit HSV2 Rapid Test [letter] Ly TD, et al. **Int J STD AIDS** 1999 Jan; 10(1):68

Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies. Liljeqvist JA, et al. **J Clin Microbiol** 1999 Aug;37(8):2717–8

Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. Ryncarz AJ, et al. **J Clin Microbiol** 1999 Jun;37(6):1941–7

Genital herpes, "the new paradigm". Taylor S, et al. **J Clin Pathol** 1999 Jan;52(1):1–4

A sore anus for 6 months. Winceslaus SJ, et al. **Lancet** 1999 May 15;353(9165):1672

Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease [see comments] Diamond C, et al. **Sex Transm Dis** 1999 Apr;26(4):221–5. Comment in: Sex Transm Dis 1999 Apr;26(4):226–7.

Clinical misidentification of patients with first episode genital herpes: a note of caution [editorial; comment] Fife KH, et al. **Sex Transm Dis** 1999 Apr;26(4):226–7. Comment on: Sex Transm Dis 1999 Apr;26(4):221–5.

Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Arvaja M, et al. **Sex Transm Infect** 1999 Jun;75(3):168–71

Evaluation of a novel point of care test for antibodies to herpes simplex virus type 2 [letter] Ashley RL, et al. **Sex Transm Infect** 1998 Jun;74(3):228–9

Should we be screening for asymptomatic HSV infections? [editorial] Brugha R, et al. **Sex Transm Infect** 1999 Jun; 75(3):142–4

When recurrent genital sores are not genital herpes. Maiti H, et al. **Sex Transm Infect** 1999 Feb;75(1):58–9

Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Munday PE, et al. **Sex Transm Infect** 1998 Jun;74(3):175–8

[Case for diagnosis. Herpes rugbiorum] Estève E, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):527–8 **(Fre)**

[Iatrogenic aseptic meningitis (letter)] Bonnotte B, et al. **Presse Med** 1998 Jun 20;27(22):1102 **(Fre)**

[Laboratory diagnosis of viral infections. 12. Urogenital diseases and sexually transmitted diseases] Kubota T. **Rinsho Byori** 1998 Nov;Suppl 108:128–31 (2 ref.) **(Jpn)**

DRUG THERAPY

Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Kimberlin DF, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):846–51

Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes. Jennings R, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):53–61

A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Sacks SL, et al. **Antimicrob Agents Chemother** 1998 Nov; 42(11):2996–9

3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection. Kokuba H, et al. **Antivir Chem Chemother** 1998 Jul; 9(4):353–7

Effect of undecylenic acid as a topical microbicide against genital herpes infection in mice and guinea pigs. Bourne N, et al. **Antiviral Res** 1999 Jan;40(3):139–44

Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs [published erratum appears in Antiviral Res 1999 Apr;41(3):153–4] Nakano M, et al. **Antiviral Res** 1998 Jul;39(1):25–33

You're the flight surgeon. Herpes simplex virus type 2(HSV-2). Fisher CR Jr. **Aviat Space Environ Med** 1999 Apr;70(4):351–2

Valacyclovir. New indication: for genital herpes, simpler administration. **Can Fam Physician** 1999 Jul;45:1698–700, 1703–5 **(Eng, Fre)**

Syndromic management of sexually transmitted diseases. Part 3—The management of genital ulcers and inguinal buboes. Latif AS. **Cent Afr J Med** 1998 Oct;44(10):266–71

Advances in the treatment of herpesvirus infection: the role of famciclovir. Tyring SK. **Clin Ther** 1998 Jul–Aug; 20(4):661–70 (45 ref.)

Herpes management and prophylaxis. Barton SE. **Dermatol Clin** 1998 Oct;16(4):799–803 (29 ref.)

Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis. Pechère M, et al. **Dermatology** 1998;197(3):278–80

Update on drugs for herpes zoster and genital herpes. **Drug Ther Bull** 1998 Oct;36(10):77–9 (25 ref.)

Improving the management of genital herpes. Sacks SL. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):41–9; quiz 139 (7 ref.)

Do we need antivirals for genital herpes simplex virus and human papillomavirus infection? Gross G. **Int J Antimicrob Agents** 1999 Jun;12(1):1–3

Antiviral therapy for genital herpes in nonpregnant and pregnant women. Baker DA. **Int J Fertil Womens Med** 1998 Sep–Oct;43(5):243–8 (22 ref.)

Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Baker DA, et al. **Obstet Gynecol** 1999 Jul;94(1):103–6

Recurrent urogenital herpes simplex—successful treatment with imiquimod? [letter] Christensen B, et al. **Sex Transm Infect** 1999 Apr;75(2):132–3

Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. White PJ, et al. **Sex Transm Infect** 1999 Feb; 75(1):49–54

[Expensive long-term care with virustatic drugs frequently reduces herpes genitalis episodes] Ritzmann P. **Schweiz Rundsch Med Prax** 1999 Jun 10;88(24):1100 **(Ger)**

EPIDEMIOLOGY

Genital herpes: review of the epidemic and potential use of type-specific serology. Ashley RL, et al. **Clin Microbiol Rev** 1999 Jan;12(1):1–8 (139 ref.)

Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay. Enders G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):870–2

Epidemiology of genital herpes - recent advances. Halioua B, et al. **Eur J Dermatol** 1999 Apr–May;9(3):177–84 (91 ref.)

Analysis of herpes simplex virus 1 and 2 infection in women with high risk sexual behaviour in Mexico. Conde-Glez CJ, et al. **Int J Epidemiol** 1999 Jun;28(3):571–6

Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986–1992). Bogaerts J, et al. **Int J STD AIDS** 1998 Nov; 9(11):706–10

Seroprevalence of herpes simplex virus type 2 antibodies in an STD clinic in Paris. Janier M, et al. **Int J STD AIDS** 1999 Aug;10(8):522–6

Risk factors for herpes simplex virus type 2 infection among female commercial sex workers in Mexico City. Uribe-Salas F, et al. **Int J STD AIDS** 1999 Feb; 10(2):105–11

Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. Ghebrekidan H, et al. **J Clin Virol** 1999 Jan; 12(1):53–64

Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. Obasi A, et al. **J Infect Dis** 1999 Jan;179(1):16–24

Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus–infected men. Schacker T, et al. **J Infect Dis** 1998 Dec;178(6):1616–22

Prevalence of type specific Epstein-Barr virus in the genital tract of genital herpes suspected patients. Kantakamalakul W, et al. **J Med Assoc Thai** 1999 Mar;82(3):263–7

Seroprevalence of herpes simplex virus-type 2 in African-American college women. Lewis LM, et al. **J Natl Med Assoc** 1999 Apr;91(4):210–2

Strategies to control the genital herpes epidemic. Schinazi RB. **Math Biosci** 1999 Jul;159(2):113–21

Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Austin H, et al. **Sex Transm Dis** 1999 Jul;26(6):329–34

Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Dobbins JG, et al. **Sex Transm Dis** 1999 Feb;26(2):67–74

Herpes simplex type 2 infection in a cohort aged 21 years. Eberhart-Phillips J, et al. **Sex Transm Infect** 1998 Jun; 74(3):216–8

Difference in seroprevalence of herpes simplex virus type 2 infection among antenatal women in Hong Kong and southern China. Lo JY, et al. **Sex Transm Infect** 1999 Apr; 75(2):123

[Prevalence of Herpes simplex virus infection in pregnant women in Yopougon (Côte d'Ivoire)] Akoua-Koffi GC, et al. **Bull Soc Pathol Exot** 1999 Feb;92(1):3–5 (Eng. Abstr.) **(Fre)**

[Antibodies against Herpes simplex virus type 2 among pregnant women in Norway] Eskild A, et al. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2323–6 (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Parr MB, et al. **Immunology** 1998 Oct; 95(2):208–13

Prevalence of herpes simplex type 2 antibodies and a clinical history of herpes in three different populations in Campinas City, Brazil. Carvalho M, et al. **Int J Infect Dis** 1998–99 Winter;3(2):94–8

The use of peptides from glycoproteins G-2 and D-1 for detecting herpes simplex virus type 2 and type-common antibodies. Levi M, et al. **J Clin Virol** 1999 May; 12(3):243–52

Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. Grabowska A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1789–98

Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. Lekstrom-Himes JA, et al. **J Infect Dis** 1999 May; 179(5):1077–85

Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. Obasi A, et al. **J Infect Dis** 1999 Jan;179(1):16–24

Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. Milligan GN. **J Virol** 1999 Aug;73(8):6380–6

Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Da Costa XJ, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8; 96(12):6994–8

The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Parr MB, et al. **Virology** 1999 Jun 5;258(2):282–94

METABOLISM

NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production in macrophages. Paludan SR, et al. **J Gen Virol** 1998 Nov; 79 (Pt 11):2785–93

MORTALITY

Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. O'Hagan D, et al. **Vaccine** 1999 May 4;17(18):2229–36

NURSING

Aseptic herpetic meningitis: an uncommon genital herpes sequelae. Bumbalough MR, et al. **Nurse Pract** 1999 Jul; 24(7):84–6, 88

HERPES GENITALIS

PATHOLOGY

A five-year-old girl with genital trauma [clinical case conference] Knapp J, et al. **Pediatr Emerg Care** 1998 Oct; 14(5):367-71

PREVENTION & CONTROL

Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Neyts J, et al. **Antiviral Res** 1998 Dec;40(1-2):53-6

Prevention of perinatal herpes: prophylactic antiviral therapy? Scott LL. **Clin Obstet Gynecol** 1999 Mar; 42(1):134-48; quiz 174-5 (53 ref.)

The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. Bourne N, et al. **J Infect Dis** 1999 Jul;180(1):203-5

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. Zeitlin L, et al. **J Reprod Immunol** 1998 Oct; 40(1):93-101

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group [see comments] Corey L, et al. **JAMA** 1999 Jul 28;282(4):331-40. Comment in: JAMA 1999 Jul 28;282(4):379-80.

Antiviral therapies for long-term suppression of genital herpes [letter; comment] Jefferson JW. **JAMA** 1999 Apr 7;281(13):1170-1. Comment on: JAMA 1998 Sep 9;280(10):928-9.

Herpes simplex virus vaccines--why don't antibodies protect? [editorial; comment] Mascola JR. **JAMA** 1999 Jul 28;282(4):379-80. Comment on: JAMA 1999 Jul 28;282(4):331-40.

Antiviral therapies for long-term suppression of genital herpes [letter; comment] Wald A, et al. **JAMA** 1999 Apr 7;281(13):1169-70; discussion 1170-1. Comment on: JAMA 1998 Sep 9;280(10):928-9.

Strategies to control the genital herpes epidemic. Schinazi RB. **Math Biosci** 1999 Jul;159(2):113-21

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Zeitlin L, et al. **Nat Biotechnol** 1998 Dec; 16(13):1361-4

Prevention agenda for genital herpes. Handsfield HH, et al. **Sex Transm Dis** 1999 Apr;26(4):228-31

Carrageenan-based nonoxynol-9 spermicides for prevention of sexually transmitted infections. Maguire RA, et al. **Sex Transm Dis** 1998 Oct;25(9):494-500

Control of STDs--the role of prophylactic vaccines against herpes simplex virus. Stanberry LR. **Sex Transm Infect** 1998 Dec;74(6):391-4 (40 ref.)

Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Bernstein DI, et al. **Vaccine** 1999 Apr 9; 17(15-16):1964-9

Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. O'Hagan D, et al. **Vaccine** 1999 May 4;17(18):2229-36

PSYCHOLOGY

Effects of psycho-educational interventions on sexual health risks and psycho-social adaptation in young adults with genital herpes. Swanson JM, et al. **J Adv Nurs** 1999 Apr; 29(4):840-51

Recurrent genital herpes and quality of life in France. Spencer B, et al. **Qual Life Res** 1999 Jun;8(4):365-71

Genital herpes: Heisenberg revisited. Goldmeier D. **Sex Transm Infect** 1998 Jun;74(3):219-20

THERAPY

Effect of herbal therapy on herpes labialis and herpes genitalis. Hijikata Y, et al. **Biotherapy** 1998;11(4):235-40

Randomised double blind trial of EMLA for the control of pain related to cryotherapy in the treatment of genital HPV lesions. Mansell-Gregory M, et al. **Sex Transm Infect** 1998 Aug;74(4):274-5

Management of women with recurrent genital herpes in pregnancy in Australia. Marks C, et al. **Sex Transm Infect** 1999 Feb;75(1):55-7

TRANSMISSION

Herpetic pharyngitis with mammary and genital herpes due to sexual contact [letter] Yoshida M. **Acta Derm Venereol** 1999 May;79(3):250

Herpes. Transmission and viral shedding. Wald A. **Dermatol Clin** 1998 Oct;16(4):795-7, xiv

Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? Garcia-Corbeira P, et al. **J Med Virol** 1999 Oct;59(2):194-7

Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. Wald A, et al. **Sex Transm Dis** 1999 Jan;26(1):1-3

Public and personal health implications of asymptomatic viral shedding in genital herpes [editorial] Mindel A, et al. **Sex Transm Infect** 1998 Dec;74(6):387-9

VIROLOGY

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Benedetti JK, et al. **Ann Intern Med** 1999 Jul 6;131(1):14-20

Genital herpes: review of the epidemic and potential use of type-specific serology. Ashley RL, et al. **Clin Microbiol Rev** 1999 Jan;12(1):1-8 (139 ref.)

Evaluation of a fully automated glycoprotein G-2 based assay for the detection of HSV-2 specific IgG antibodies in serum and plasma. Groen J, et al. **J Clin Virol** 1999 May; 12(3):193-200

NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production in macrophages. Paludan SR, et al. **J Gen Virol** 1998 Nov; 79 (Pt 11):2785-93

Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. Krone MR, et al. **J Infect Dis** 1998 Oct;178(4):978-82

Prevalence of type specific Epstein-Barr virus in the genital tract of genital herpes suspected patients. Kantakamalakul W, et al. **J Med Assoc Thai** 1999 Mar;82(3):263-7

Progression of intravaginal infection by herpes simplex-2 in genetically athymic mice. Sanjuan NA. **Medicina (B Aires)** 1998;58(5 Pt 1):492-6

HERPES GESTATIONIS

DIAGNOSIS

Herpes gestationis in a mother and child. Chen SH, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):847-9

Severe subepidermal blistering disorder with features of bullous pemphigoid and herpes gestationis. Triffet MK, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):797-801

DRUG THERAPY

[Herpes gestationis--oral corticosteroids cannot be avoided] Pönnighaus JM, et al. **Zentralbl Gynakol** 1998; 120(11):548-50 (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Class II major histocompatibility complex typing across the ethnic barrier in pemphigoid gestationis. A study in Mexicans. Garcia-González E, et al. **Int J Dermatol** 1999 Jan;38(1):46-51

GENETICS

Class II major histocompatibility complex typing across the ethnic barrier in pemphigoid gestationis. A study in Mexicans. Garcia-González E, et al. **Int J Dermatol** 1999 Jan;38(1):46-51

IMMUNOLOGY

Molecular mapping of the major epitopes of BP180 recognized by herpes gestationis autoantibodies. Lin MS, et al. **Clin Immunol** 1999 Sep;92(3):285-92

Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. Lin MS, et al. **J Immunol** 1999 Apr 15; 162(8):4991-7

IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis [letter] Chimanovitch I, et al. **J Invest Dermatol** 1999 Jul;113(1):140-2

PATHOLOGY

Basal cell destruction of herpes gestationis and bullous pemphigoid [letter] Ban M, et al. **Eur J Dermatol** 1998 Sep; 8(6):449-50

HERPES LABIALIS

see related
STOMATITIS, HERPETIC

COMPLICATIONS

Acyclovir can abort rejection of punch grafts in herpes-simplex-induced lip leucoderma [letter] Malakar S, et al. **Dermatology** 1999;199(1):75

[Case of multiple cranial nerve palsy following herpes simplex labialis] Sikama Y, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1374-5 **(Jpn)**

DRUG THERAPY

Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. Spruance SL, et al. **J Infect Dis** 1999 Feb; 179(2):303-10

A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis. Horwitz E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):700-5

[Recurrent postherpetic erythema multiforme presenting as a polymorphous light eruption and 'juvenile spring eruption] Ostertag JU. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2711-2 **(Dut)**

THERAPY

Effect of herbal therapy on herpes labialis and herpes genitalis. Hijikata Y, et al. **Biotherapy** 1998;11(4):235-40

HERPES LABIALIS VIRUS see **SIMPLEXVIRUS**

HERPES SIMPLEX

Herpes simplex esophagitis [letter; comment] Zagnoon A, et al. **Am J Gastroenterol** 1999 Jun;94(6):1708-9. Comment on: Am J Gastroenterol 1998 Nov;93(11):2239-40.

Imaging and laboratory investigation in herpes simplex encephalitis. Coren ME, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):243-5

Herpes simplex encephalitis after brain surgery: case report and review of the literature. Spuler A, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):239-42 (29 ref.)

Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. Hobbs WE 2nd, et al. **J Virol** 1999 Oct;73(10):8245-55

Disseminated neonatal herpes infection. Witlin AG, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):721

Herpes simplex virus. Riley LE. **Semin Perinatol** 1998 Aug; 22(4):284-92 (75 ref.)

[Neonatal herpetic infection] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):175-6 (6 ref.) **(Jpn)**

[Herpes simplex virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):120-2 (9 ref.) **(Jpn)**

[Herpes simplex encephalitis, Japanese encephalitis, cytomegalovirus encephalitis] Watanabe T. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):17-21 (10 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Two-centre study comparing DNA preparation and PCR amplification protocols for herpes simplex virus detection in cerebrospinal fluids of patients with suspected herpes simplex encephalitis. Hirsch HH, et al. **J Med Virol** 1999 Jan;57(1):31-5

Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid. Domingues RB, et al. **J Neurol Sci** 1998 May 7;157(2):148-53

Epstein-Barr virus DNA in cerebrospinal fluid from an immunocompetent man with herpes simplex virus encephalitis. Portolani M, et al. **J Neurovirol** 1998 Aug; 4(4):461-4

COMPLICATIONS

Aetiology of delayed facial palsy after vestibular schwannoma surgery: clinical data and hypothesis. Ohata K, et al. **Acta Neurochir (Wien)** 1998;140(9):913-7

Delayed facial palsy following uneventful middle ear surgery: a herpes simplex virus type 1 reactivation? Bonkowsky V, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):901-5

Acquired lymphedema of the hand due to herpes simplex virus type 2 [letter] Butler DF, et al. **Arch Dermatol** 1999 Sep;135(9):1125-6

Lethal systemic herpes simplex virus type 1 infection during chemotherapy for acute lymphoblastic leukaemia [letter] Wirth K, et al. **Br J Haematol** 1999 Jan;104(1):197-8

Acute retinal necrosis after neonatal herpes encephalitis [letter; comment] Levinson RD, et al. **Br J Ophthalmol** 1999 Jan;83(1):123-4 (6 ref.). Comment on: Br J Ophthalmol 1997 May;81(5):415-6.

Herpes lymphadenitis in association with chronic lymphocytic leukemia. Higgins JP, et al. **Cancer** 1999 Oct 1;86(7):1210-5

Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Cinque P, et al. **Clin Infect Dis** 1998 Aug;27(2):303-9

Kluver Bucy syndrome in young children. Pradhan S, et al. **Clin Neurol Neurosurg** 1998 Dec;100(4):254-8

TORCH testing in HIV-infected women. Helfgott A. **Clin Obstet Gynecol** 1999 Mar;42(1):149-62; quiz 174-5 (69 ref.)

Understanding the pathogenesis of HSV-associated erythema multiforme. Aurelian L, et al. **Dermatology** 1998; 197(3):219-22

Longitudinal study of a patient with herpes-simplex-virus-associated erythema multiforme: viral gene expression and T cell repertoire usage. Kokuba H, et al. **Dermatology** 1999;198(3):233-42

Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Leissring MA, et al. **Drugs Aging** 1998 Sep;13(3):193-8 (31 ref.)

Rothmund-Thomson syndrome with herpes encephalitis. Ito T, et al. **Eur J Dermatol** 1999 Jul-Aug;9(5):354-6

Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Sohn S, et al. **Eur J Dermatol** 1998 Jan-Feb;8(1):21-3

Black esophagus associated with herpes esophagitis. Cattan P, et al. **Gastrointest Endosc** 1999 Jan;49(1):105-7

Course of herpes simplex esophagitis in a debilitated patient.

Kurahara K, et al. **Gastrointest Endosc** 1998 Oct; 48(4):420–2

Herpetic salpingitis and fallopian tube prolapse. Lefrancq T, et al. **Histopathology** 1999 Jun;34(6):548–50

Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. Javaly K, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):301–6

Fulminant herpes hepatitis in a healthy adult: a treatable disorder? Velasco M, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):386–9

Pneumococcal pneumonia associated with perianal herpes simplex virus type 2 in a HIV seropositive patient [letter] Clarke S, et al. **J Eur Acad Dermatol Venereol** 1998 Nov; 11(3):257–8

Gastrointestinal: herpes simplex oesophagitis. Wigg AJ, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1285

17-year-old female with IgA and abdominal pain: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Olay S, et al. **J Okla State Med Assoc** 1999 Feb;92(2):77–82

Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Egawa H, et al. **Liver Transpl Surg** 1998 Nov;4(6):513–5

Urinary retention due to herpes virus infections. Yamanishi T, et al. **Neurourol Urodyn** 1998;17(6):613–9

A case of herpetic whitlow associated with erythema multiforme. de Ocariz MM, et al. **Pediatr Dermatol** 1998 Sep–Oct;15(5):384–5

Atypical herpes simplex encephalitis presenting as operculum syndrome. Wolf RW, et al. **Pediatr Radiol** 1999 Mar; 29(3):191–3

[A septicemia associated with neurological disorders] Serpentini A, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr; 57(2):211–3 **(Fre)**

[Cervical myelitis in herpes simplex virus (HSV) infections] Weiss A, et al. **Dtsch Med Wochenschr** 1999 Jun 18; 124(24):781 **(Ger)**

[Experience in managing refractory status epilepticus caused by viral encephalitis under long-term anesthesia with barbiturate: a case report] Ohori N, et al. **Rinsho Shinkeigaku** 1998 May;38(5):474–7 (Eng. Abstr.) **(Jpn)**

[Lumbosacral polyradiculomyelitis caused by herpes simplex virus (HSV) in a patient with AIDS] Miguélez M, et al. **An Med Interna** 1999 Aug;16(8):417–9 (Eng. Abstr.) **(Spa)**

CONGENITAL

[TORCH syndrome] Hidaka Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):85–8 (7 ref.) **(Jpn)**

DIAGNOSIS

Clinical and virological comparison of 3 patients with erythema multiforme [letter] Kokuba H, et al. **Acta Derm Venereol** 1999 May;79(3):247–8

Use of the polymerase chain reaction in the diagnosis of herpes simplex encephalitis: a decision analysis model. Tebas P, et al. **Am J Med** 1998 Oct;105(4):287–95

Triple viral retinitis diagnosed by polymerase chain reaction of the vitreous biopsy in a patient with Richter syndrome. Levinson RD, et al. **Am J Ophthalmol** 1998 Nov; 126(5):732–3

Adult-onset MELAS presenting as herpes encephalitis. Sharfstein SR, et al. **Arch Neurol** 1999 Feb;56(2):241–3

Operative treatment of tentorial herniation in herpes encephalitis. Ebel H, et al. **Childs Nerv Syst** 1999 Mar; 15(2–3):84–6

Coexistence of Pemphigus vulgaris and herpes simplex virus infection in oral mucosa diagnosed by cytology, immunohistochemistry, and polymerase chain reaction. Takahashi I, et al. **Diagn Cytopathol** 1998 Dec;19(6):446–50

Cytospin-enhanced direct immunofluorescence assay versus cell culture for detection of herpes simplex virus in clinical specimens. Sanders C, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):111–3

Type-specific serological testing for herpes simplex infection. Kinghorn GR. **Int J STD AIDS** 1998 Sep;9(9):497–500 (39 ref.)

Fatal herpetic hepatitis in adult following short corticotherapy: a case report. Seksik P, et al. **Intensive Care Med** 1999 Apr;25(4):415–7

Herpes simplex virus infection in pregnancy: diagnosis and significance. Desselberger U. **Intervirology** 1998; 41(4–5):185–90 (30 ref.)

Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies. Liljeqvist JA, et al. **J Clin Microbiol** 1999 Aug;37(8):2717–8

Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. Ryncarz AJ, et al. **J Clin Microbiol** 1999 Jun;37(6):1941–7

Molecular diagnosis of herpes simplex virus infections in the central nervous system. Tang YW, et al. **J Clin Microbiol** 1999 Jul;37(7):2127–36 (108 ref.)

Diaschisis in chronic viral encephalitis with Koshevnikov syndrome. Thajeb P, et al. **J Neuroimaging** 1999 Apr; 9(2):122–5

Early cerebellar involvement on diffusion-weighted magnetic resonance images in herpes simplex encephalitis [letter] Ohta K, et al. **J Neurol** 1999 Aug;246(8):736–8

Perfusion and thallium single photon emission computed tomography in herpes simplex encephalitis. De Deyn PP, et al. **J Neurol Sci** 1998 Apr 15;157(1):96–9

Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid. Domingues RB, et al. **J Neurol Sci** 1998 May 7;157(2):148–53

A 6-year-old child with vacant episodes and unilateral convulsions. Burgner D, et al. **Lancet** 1998 Nov 28; 352(9142):1750

Highly variable distribution of HSV-1-specific DNA in human geniculate, vestibular and spiral ganglia. Schulz P, et al. **Neurosci Lett** 1998 Aug 14;252(2):139–42

Herpes simplex hepatitis in pregnancy: a case report and review of the literature. Kang AH, et al. **Obstet Gynecol Surv** 1999 Jul;54(7):463–8 (36 ref.)

Viremia in neonatal herpes simplex virus infections. Diamond C, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):487–9

PCR-based diagnosis of a case of herpetic whitlow in an AIDS patient. Nogueira ML, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep–Oct;40(5):317–9

Herpes encephalitis in children. MRI assessment. Cakmakçi H, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):559–66

[Imaging in pediatric Herpes simplex virus type I encephalitis] Panisset S, et al. **J Radiol** 1999 Jan;80(1):31–5 (Eng. Abstr.) **(Fre)**

[Fatal fulminating hepatitis due to Herpes simplex virus type 2 in a young immunocompetent female] Chauveau E, et al. **Med Trop (Mars)** 1999;59(1):58–60 (Eng. Abstr.) **(Fre)**

[Cervical myelitis in herpes simplex virus (HSV) infections] Weiss A, et al. **Dtsch Med Wochenschr** 1999 Jun 18; 124(24):781 **(Ger)**

[Serology in herpes infection] Einsele H, et al. **Internist (Berl)** 1999 May;40(5):565–6 **(Ger)**

[FLAIR images MRI in a patient with herpes simplex encephalitis] Odaka M, et al. **No To Shinkei** 1999 Jan; 51(1):76–7 **(Jpn)**

[Serial MRI, SPECT and 1H-MRS findings in a case of herpes simplex encephalitis] Tajima Y, et al. **No To Shinkei** 1998 Nov;50(11):1023–7 (Eng. Abstr.) **(Jpn)**

[Laboratory diagnosis of viral infections. 3. Exanthema and muco- cutaneous infections] Morishima T. **Rinsho Byori** 1998 Nov;Suppl 108:65–73 (2 ref.) **(Jpn)**

[Herpes simplex and lymphocytic choriomeningitis viruses in infections of the central nervous system--clinical and cerebrospinal fluid characteristics] Turkulov V, et al. **Med Pregl** 1998 Sep–Oct;51(9–10):436–40 (Eng. Abstr.) **(Scr)**

[Herpetic pseudotumor laryngitis] del Toro JJ, et al. **An Otorrinolaringol Ibero Am** 1999;26(1):39–45 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Treatment of herpes simplex esophagitis in an immunocompetent patient with intravenous acyclovir: a case report and review of the literature [see comments] Kurahara K, et al. **Am J Gastroenterol** 1998 Nov; 93(11):2239–40 (15 ref.). Comment in: Am J Gastroenterol 1999 Jun;94(6):1708–9.

Therapy of idiopathic sudden sensorineural hearing loss: antiviral treatment of experimental herpes simplex virus infection of the inner ear. Stokroos RJ, et al. **Ann Otol Rhinol Laryngol** 1999 May;108(5):423–8

Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Lazarus HM, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1192–7

Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model. Awan AR, et al. **Antivir Chem Chemother** 1998 Jan;9(1):19–24

Herpes simplex virus latency and nucleoside analogues. Efstathiou S, et al. **Antiviral Res** 1999 Apr;41(3):85–100 (60 ref.)

Evaluation of anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]- guanine (A-5021) in mice. Iwayama S, et al. **Antiviral Res** 1999 Jun;42(2):139–48

Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS [letter; comment] Lateef F, et al. **Arch Dermatol** 1998 Sep; 134(9):1169–70. Comment on: Arch Dermatol 1997 Aug;133(8):987–90.

Long term neurological outcome of herpes encephalitis. Lahat E, et al. **Arch Dis Child** 1999 Jan;80(1):69–71

Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir. Kim DK, et al. **Bioorg Med Chem** 1998 Dec;6(12):2525–30

Recurrent aciclovir-resistant herpes simplex in a child with Wiskott-Aldrich syndrome. Saijo M, et al. **Br J Dermatol** 1998 Aug;139(2):311–4

The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Anderson BJ. **Clin J Sport Med** 1999 Apr;9(2):86–90

Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis. Pechère M, et al. **Dermatology** 1998;197(3):278–80

Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. Javaly K, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):301–6

The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. LeBlanc RA, et al. **J Infect Dis** 1999 Sep;180(3):594–9

Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice. Afouna MI, et al. **J Pharm Sci** 1999 May;88(5):530–4

Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Egawa H, et al. **Liver Transpl Surg** 1998 Nov;4(6):513–5

Acyclovir treatment of experimentally induced herpes simplex virus encephalitis: monitoring the changes in immunologic NO synthase expression and viral load within brain tissue of SJL mice. Haas J, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):129–32

Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Nawawi A, et al. **Phytother Res** 1999 Feb;13(1):37–41

Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate. Cheng L, et al. **Retina** 1999;19(4):325–31

Successful treatment of generalized primary herpes simplex type 2 infection during pregnancy. Anderson R, et al. **Scand J Infect Dis** 1999;31(2):201–2

The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine against different herpes viruses. Neyts J, et al. **Transplantation** 1999 Mar 15;67(5):760–4

[Acyclovir and ganciclovir in the treatment of malignant hematological diseases] Zhou X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):349–51 (19 ref.) **(Chi)**

EPIDEMIOLOGY

Ten years' surveillance of viral conjunctivitis in Sapporo, Japan. Saitoh-Inagawa W, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):35–8

Analysis of herpes simplex virus 1 and 2 infection in women with high risk sexual behaviour in Mexico. Conde-Glez CJ, et al. **Int J Epidemiol** 1999 Jun;28(3):571–6

Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. Schmid DS, et al. **J Clin Microbiol** 1999 Feb;37(2):376–9

Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella-zoster virus infections in Eritrea. Ghebrekidan H, et al. **J Clin Virol** 1999 Jan; 12(1):53–64

The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. Gutierrez KM, et al. **J Infect Dis** 1999 Jul;180(1):199–202

An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. Mertz KJ, et al. **J Infect Dis** 1998 Oct; 178(4):1060–6

Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Austin H, et al. **Sex Transm Dis** 1999 Jul;26(6):329–34

Historical findings in subjects from a high socioeconomic group who have genital infections with herpes simplex virus. Knox SR, et al. **Sex Transm Dis** 1982 Jan–Mar; 9(1):15–20

[Prevalence of Herpes simplex virus infection in pregnant women in Yopougon (Côte d'Ivoire)] Akoua-Koffi GC, et al. **Bull Soc Pathol Exot** 1999 Feb;92(1):3–5 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Herpes simplex virus encephalitis following corticosteroids and cranial irradiation [letter; comment] Jacobs DH. **Neurology** 1999 Mar 23;52(5):1108–9. Comment on: Neurology 1998 Aug;51(2):554–9.

Simultaneous Aspergillus fischeri and Herpes simplex pneumonia in a patient with multiple myeloma. Chim CS, et al. **Scand J Infect Dis** 1998;30(2):190–1

[Primary herpetic infection after transfixing keratoplasty] Rasquin F, et al. **Bull Soc Belge Ophtalmol** 1998;268:79–85 (Eng. Abstr.) **(Fre)**

GENETICS

Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Lanuti M, et al. **Hum Gene Ther** 1999 Feb 10;10(3):463–75

Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. LeBlanc RA, et al. **J Virol** 1999 Oct;73(10):8145–51

IMMUNOLOGY

The effect of UV-B irradiation on primary and secondary

HSV-1 infections in interleukin-4 knockout mice. El-Ghorr AA, et al. **Arch Dermatol Res** 1999 Jul-Aug; 291(7-8):459-65

The role of polymorphonuclear leukocyte infiltration in herpes simplex virus infection of murine skin. Watanabe D, et al. **Arch Dermatol Res** 1999 Jan;291(1):28-36

Characteristics of a macrophage culture persistently infected with herpes simplex virus type 1. Bustos J, et al. **Arch Med Res** 1999 May-Jun;30(3):255-62

Natural killer (NK) cells prevent virus production in cell culture. Baraz L, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):179-89

The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Baker M, et al. **Brain Behav Immun** 1999 Sep;13(3):201-11 (64 ref.)

The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point. Glaser R, et al. **Brain Behav Immun** 1999 Sep;13(3):240-51

Herpes simplex virus latency and the immune response. Daheshia M, et al. **Curr Opin Microbiol** 1998 Aug; 1(4):430-5 (50 ref.)

Systemic T cell expansion during localized viral infection. Haanen JB, et al. **Eur J Immunol** 1999 Apr;29(4):1168-74

IgG and IgM antibodies of Herpes Simplex Virus type-1 and type-2 in 233 maternal and neonatal sera. Dong Z, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):69-70

Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. Grabowska A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1789-98

Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. Kobayashi H, et al. **J Immunol** 1999 Jun 15;162(12):7148-54

Phenotypic identification of antigen-dependent and antigen-independent CD8 CTL precursors in the draining lymph node during acute cutaneous herpes simplex virus type 1 infection. McNally JM, et al. **J Immunol** 1999 Jul 15;163(2):675-81

Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. Yasukawa M, et al. **J Immunol** 1999 May 15;162(10):6100-6

Changes in intracellular cytokine levels in newborn and adult lymphocytes induced by HSV-1. Ito M, et al. **J Med Virol** 1998 Oct;56(2):145-50

In the absence of T cells, natural killer cells protect from mortality due to HSV-1 encephalitis. Adler H, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):208-13

B cell-deficient mice have increased susceptibility to HSV-1 encephalomyelitis and mortality. Beland JL, et al. **J Neuroimmunol** 1999 Feb 1;94(1-2):122-6

Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. Noisakran S, et al. **J Neuroimmunol** 1999 Mar 1; 95(1-2):126-35

Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type-1. Song GY, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):1-7

Differential effect of phototherapy on the activities of human natural killer cells and cytotoxic T cells. Neill WA, et al. **J Photochem Photobiol B** 1998 Dec;47(2-3):129-35

Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand null-mutant mice. Cantin E, et al. **J Virol** 1999 Jun;73(6):5196-200

An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection. Holterman AX, et al. **J Virol** 1999 Mar; 73(3):2058-63

The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. Wallace ME, et al. **J Virol** 1999 Sep;73(9):7619-26

UV-induced immunosuppression in virus infections. Norval M, et al. **Mutat Res** 1998 Nov 9;422(1):131-8 (29 ref.)

Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. McKie EA, et al. **Neuropathol Appl Neurobiol** 1998 Oct;24(5):367-72

Interleukin-4-mediated inhibition of nitric oxide production in interferon-gamma-treated and virus-infected macrophages. Paludan SR, et al. **Scand J Immunol** 1999 Feb;49(2):169-76

Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice. Ghiasi H, et al. **Vaccine** 1999 Jun 4;17(20-21):2576-82

Specific and nonspecific immune stimulation of MHC-II-deficient mice results in chronic HSV-1 infection of the trigeminal ganglia following ocular challenge. Ghiasi H, et al. **Virology** 1999 Jun 5;258(2):208-16

METABOLISM

Exercise effects on IFN-beta expression and viral replication in lung macrophages after HSV-1 infection. Kohut ML, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):L1089-94

Kinetics of cytokine production in the cornea and trigeminal ganglion of C57BL/6 mice after corneal HSV-1 infection. He J, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):609-15

GABA synthesis in astrocytes after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase 65 or 67. New KC, et al. **J Neurochem** 1998 Dec;71(6):2304-12

Herpes simplex virus 1 regulatory protein ICP22 interacts with a new cell cycle-regulated factor and accumulates in a cell cycle-dependent fashion in infected cells. Bruni R, et al. **J Virol** 1998 Nov;72(11):8525-31

Anterograde transport of herpes simplex virus proteins in axons of peripheral human fetal neurons: an immunoelectron microscopy study. Holland DJ, et al. **J Virol** 1999 Oct;73(10):8503-11

Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Chelbi-Alix MK, et al. **Oncogene** 1999 Jan 28;18(4):935-41

MORTALITY

Occult herpes family viruses may increase mortality in critically ill surgical patients. Cook CH, et al. **Am J Surg** 1998 Oct;176(4):357-60

PATHOLOGY

An erythematous nodule on the vulva. Schaller M, et al. **Arch Dermatol** 1999 Feb;135(2):203-4, 207

Herpes simplex virus encephalitis: chronic progressive cerebral magnetic resonance imaging abnormalities in patients despite good clinical recovery. Meyding-Lamadé UK, et al. **Clin Infect Dis** 1999 Jan;28(1):148-9

Herpes simplex peritonitis: case report. Yakulis R, et al. **Clin Infect Dis** 1999 Jun;28(6):1212-5

Herpetic whitlow in an AIDS patient. García-Plata MD, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):241-2

Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. Rösler A, et al. **J Neurol Sci** 1998 Apr 15;157(1):82-9

The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. Aubert M, et al. **J Virol** 1999 Apr; 73(4):2803-13

Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. Galvan V, et al. **J Virol** 1999 Apr;73(4):3219-26

Images in clinical medicine. Severe herpes simplex infection. Justman J, et al. **N Engl J Med** 1999 Apr 22;340(16):1253

Images in clinical medicine. Herpes simplex esophagitis. Urbano FL, et al. **N Engl J Med** 1999 Apr 22;340(16):1254

MRI follow-up of herpes simplex virus (type 1) radiculomyelitis. Küker W, et al. **Neurology** 1999 Mar 23; 52(5):1102-3

Herpes simplex virus encephalitis: cranial magnetic resonance imaging and neuropathology in a mouse model. Meyding-Lamadé U, et al. **Neurosci Lett** 1998 May 22; 248(1):13-6

PHYSIOPATHOLOGY

Nuclear redistribution of BRCA1 during viral infection. Maul GG, et al. **Cell Growth Differ** 1998 Sep;9(9):743-55

A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 In vivo reactivation in the mouse trigeminal ganglia. Sawtell NM, et al. **J Infect Dis** 1999 Sep;180(3):821-3

Role for gamma interferon in control of herpes simplex virus type 1 reactivation. Cantin E, et al. **J Virol** 1999 Apr; 73(4):3418-23

Caffeine inhibits paresthesia induced by herpes simplex virus through action on primary sensory neurons in rats. Shiraki K, et al. **Neurosci Res** 1998 Jul;31(3):235-40

A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Pelosi E, et al. **Virology** 1998 Dec 20;252(2):364-72

PREVENTION & CONTROL

Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Neyts J, et al. **Antiviral Res** 1998 Dec;40(1-2):53-6

Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Beland JL, et al. **Blood** 1998 Dec 1;92(11):4472-8

Herpes. Vaccines for HSV. Stanberry LR. **Dermatol Clin** 1998 Oct;16(4):811-6, xiv (27 ref.)

Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Alster TS, et al. **Dermatol Surg** 1999 Mar;25(3):242-6

The regulation of burn-associated infections with herpes simplex virus type 1 or Candida albicans by a non-toxic aconitine-hydrolysate, benzoylmesaconine. Part 1: Antiviral and anti-fungal activities in thermally injured mice. Kobayashi M, et al. **Immunol Cell Biol** 1998 Jun; 76(3):202-8

The regulation of burn-associated infections with herpes simplex virus type 1 or Candida albicans by a non-toxic aconitine-hydrolysate, benzoylmesaconine. Part 2: Mechanism of the antiviral action. Kobayashi M, et al. **Immunol Cell Biol** 1998 Jun;76(3):209-16

Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. Kobayashi H, et al. **J Immunol** 1999 Jun 15;162(12):7148-54

Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. Noisakran S, et al. **J Immunol** 1999 Apr 1;162(7):4184-90

Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. Fujioka N, et al. **J Virol** 1999 Mar; 73(3):2401-9

RADIONUCLIDE IMAGING

Mapping the in vivo distribution of herpes simplex virions [published erratum appears in Hum Gene Ther 1998 Nov 20;9(17):2652] Schellingerhout D, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1543-9

RADIOTHERAPY

Low-intensity laser therapy is an effective treatment for recurrent herpes simplex infection. Results from a randomized double-blind placebo-controlled study. Schindl A, et al. **J Invest Dermatol** 1999 Aug;113(2):221-3

Differential effect of phototherapy on the activities of human natural killer cells and cytotoxic T cells. Neill WA, et al. **J Photochem Photobiol B** 1998 Dec;47(2-3):129-35

THERAPY

Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Leissring MA, et al. **Drugs Aging** 1998 Sep;13(3):193-8 (31 ref.)

TRANSMISSION

Sequential peripartum herpes simplex virus type 2 disease in parents and their newborn mimicking intrafamily spread of common viruses. Klauber EV, et al. **Am J Perinatol** 1999;16(1):43-5

The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. Gutierrez KM, et al. **J Infect Dis** 1999 Jul;180(1):199-202

VETERINARY

Long-term immunity in cats vaccinated with an inactivated trivalent vaccine [published erratum appears in Am J Vet Res 1999 Jun;60(6):763] Scott FW, et al. **Am J Vet Res** 1999 May;60(5):652-8

A new technique: serial puncture of the cisterna magna for obtaining cerebrospinal fluid in the mouse--application in a model of herpes simplex virus encephalitis. Meyding-Lamadé U, et al. **J Exp Anim Sci** 1996-97; 38(2):77-81

VIROLOGY

Exercise effects on IFN-beta expression and viral replication in lung macrophages after HSV-1 infection. Kohut ML, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):L1089-94

Detection of herpes simplex virus-1 by nested PCR. An experimental model. Llorente JL, et al. **Auris Nasus Larynx** 1998 Dec;25(4):387-92

Performance of six cell lines in the suspension-infection test used for the detection of herpes simplex virus. Rich T, et al. **Diagn Microbiol Infect Dis** 1998 Oct;32(2):81-4

Herpes simplex anterior uveitis. Tabbara KF, et al. **Int Ophthalmol Clin** 1998 Fall;38(4):137-47 (31 ref.)

An analysis of herpes simplex virus gene expression during latency establishment and reactivation. Lachmann RH, et al. **J Gen Virol** 1999 May;80 (Pt 5):1271-82

Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. Schmit I, et al. **J Infect Dis** 1999 Aug; 180(2):487-90

Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus. Saijo M, et al. **J Med Virol** 1999 Aug; 58(4):387-93

Tissue specific distribution of the herpes simplex virus type 1 latency-associated transcripts on polyribosomes during latent infection. Goldenberg D, et al. **J Neurovirol** 1998 Aug;4(4):426-32

Herpes simplex virus latency after direct ganglion virus inoculation. Hay KA, et al. **J Neurovirol** 1998 Oct; 4(5):531-8

Presence of HSV-1 DNA in semen and menstrual blood. El Borai N, et al. **J Reprod Immunol** 1998 Dec; 41(1-2):137-47

The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. Aubert M, et al. **J Virol** 1999 Apr; 73(4):2803-13

Herpes simplex virus 1 regulatory protein ICP22 interacts with a new cell cycle-regulated factor and accumulates in a cell cycle-dependent fashion in infected cells. Bruni R, et al. **J Virol** 1998 Nov;72(11):8525-31

Genetic analysis of the role of herpes simplex virus type 1 glycoprotein K in infectious virus production and egress. Foster TP, et al. **J Virol** 1999 Oct;73(10):8457-68

Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes

simplex virus type 1 in IL-6 knockout mice. LeBlanc RA, et al. **J Virol** 1999 Oct;73(10):8145–51
Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. McLean TI, et al. **J Virol** 1999 Oct;73(10):8415–26
A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation. Perng GC, et al. **J Virol** 1999 Feb;73(2):920–9
Chronic active destructive herpes simplex encephalitis with recovery of viral DNA 12 years after disease onset. Asenbauer B, et al. **Neuropediatrics** 1998 Jun;29(3):120–3
LAT expression during an acute HSV infection in the mouse. Jarman RG, et al. **Virology** 1999 Sep 30;262(2):384–97
The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems. Tal-Singer R, et al. **Virology** 1999 Jun 20; 259(1):20–33
Glycoprotein K of herpes simplex virus: a transmembrane protein encoded by the UL53 gene which regulates membrane fusion. Rajčáni J, et al. **Virus Genes** 1999; 18(1):81–90 (63 ref.)

HERPES SIMPLEX, GENITAL see **HERPES GENITALIS**

HERPES SIMPLEX KERATITIS see **KERATITIS, HERPETIC**

HERPES SIMPLEX, LABIAL see **HERPES LABIALIS**

HERPES SIMPLEX, OCULAR see **KERATITIS, HERPETIC**

HERPES SIMPLEX, ORAL see **STOMATITIS, HERPETIC**

HERPES SIMPLEX VIRUS see **SIMPLEXVIRUS**

HERPES SIMPLEX VIRUS PROTEIN VMW65

BIOSYNTHESIS

High level expression and structural characterisation of herpes simplex virus type I transcriptional activator VP16 (alpha-trans inducing factor). Spatz AM, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):235–8

CHEMISTRY

High level expression and structural characterisation of herpes simplex virus type I transcriptional activator VP16 (alpha-trans inducing factor). Spatz AM, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):235–8
The use of variable density self-assembled monolayers to probe the structure of a target molecule. Bamdad C. **Biophys J** 1998 Oct;75(4):1989–96
Crystal structure of the conserved core of the herpes simplex virus transcriptional regulatory protein VP16. Liu Y, et al. **Genes Dev** 1999 Jul 1;13(13):1692–703

GENETICS

Plasmid harboring lac repressor and tTA activator genes can regulate two inducible genes in mammalian cells. Chang TY, et al. **Biotechniques** 1999 Sep;27(3):466–9
Mutational analysis of a transcriptional activation region of the VP16 protein of herpes simplex virus [published erratum appears in Nucleic Acids Res 1998 Dec 1;26(23):537–8] Sullivan SM, et al. **Nucleic Acids Res** 1998 Oct 1;26(19):4487–96
The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems. Tal-Singer R, et al. **Virology** 1999 Jun 20; 259(1):20–33

IMMUNOLOGY

Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Kwok WW, et al. **Hum Immunol** 1999 Jul; 60(7):619–26
MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Reichstetter S, et al. **Hum Immunol** 1999 Jul;60(7):608–18

METABOLISM

The herpes simplex virus VP16-induced complex: mechanisms of combinatorial transcriptional regulation. Herr W. **Cold Spring Harb Symp Quant Biol** 1998; 63:599–607 (61 ref.)
HCF-dependent nuclear import of VP16. La Boissière S, et al. **EMBO J** 1999 Jan 15;18(2):480–9
Analysis of functional domains of the host cell factor involved in VP16 complex formation. Hughes TA, et al. **J Biol Chem** 1999 Jun 4;274(23):16437–43
Large-scale chromatin unfolding and remodeling induced by VP16 acidic activation domain. Tumbar T, et al. **J Cell Biol** 1999 Jun 28;145(7):1341–54
Herpes simplex virus transactivator VP16 discriminates between HCF-1 and a novel family member, HCF-2. Johnson KM, et al. **J Virol** 1999 May;73(5):3930–40
Selected elements of herpes simplex virus accessory factor HCF are highly conserved in Caenorhabditis elegans. Liu Y, et al. **Mol Cell Biol** 1999 Jan;19(1):909–15
Nuclear localization of the C1 factor (host cell factor) in sensory neurons correlates with reactivation of herpes simplex virus from latency. Kristie TM, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1229–33
Impaired binding of a DQ2 and DQ8-binding HSV VP16 peptide to a DQA1*0501/DQB1*0302 trans class II heterodimer. Reichstetter S, et al. **Tissue Antigens** 1999 Jan; 53(1):101–5

PHYSIOLOGY

Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects. Thomas SK, et al. **J Virol** 1999 Sep;73(9):7399–409

HERPES SIMPLEX VIRUS PROTEIN VP16 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

HERPES SIMPLEX VIRUS TRANSCRIPTIONAL ACTIVATOR VMW65 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

HERPES SIMPLEX VIRUS 1 see **HERPESVIRUS 1, HUMAN**

HERPES SIMPLEX VIRUS 2 see **HERPESVIRUS 2, HUMAN**

HERPES ZOSTER

Recent advances in varicella-zoster virus infection. Cohen JI, et al. **Ann Intern Med** 1999 Jun 1;130(11):922–32 (104 ref.)
Varicella zoster virus. McCrary ML, et al. **J Am Acad Dermatol** 1999 Jul;41(1):1–14; quiz 15–6 (168 ref.)
[Varicella and herpes zoster encephalitis] Fujita T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):22–4 (15 ref.) **(Jpn)**
[Varicella pneumonia] Higashiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):96–8 (11 ref.) **(Jpn)**
[Herpes zoster] Honda M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):133–6 (4 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system. Iten A, et al. **J Neurovirol** 1999 Apr;5(2):172–80
CSF and MRI findings in patients with acute herpes zoster. Haanpää M, et al. **Neurology** 1998 Nov;51(5):1405–11

CHEMICALLY INDUCED

Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Korelitz BI, et al. **Am J Gastroenterol** 1999 Feb;94(2):424–6
High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors [see comments] Martinez E, et al. **Clin Infect Dis** 1998 Dec;27(6):1510–3 . Comment in: Clin Infect Dis 1998 Dec;27(6):1514–6.
Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Wortmann GW, et al. **Clin Infect Dis** 1998 Sep;27(3):509–12

COMPLICATIONS

Localized chronic urticaria at the site of healed herpes zoster [letter] Lee HJ, et al. **Acta Derm Venereol** 1999 Mar; 79(2):168
Effect of Ganoderma lucidum on postherpetic neuralgia. Hijikata Y, et al. **Am J Chin Med** 1998;26(3–4):375–81
Oral corticosteroids for pain associated with herpes zoster. Ernst ME, et al. **Ann Pharmacother** 1998 Oct; 32(10):1099–103 (15 ref.)
Unilateral abdominal distention following herpes zoster outbreak [letter] Vincent KD, et al. **Arch Dermatol** 1998 Sep;134(9):1168–9
Cerebral infarction associated with vasculitis due to varicella zoster virus in patients infected with the human immunodeficiency virus. Picard O, et al. **Biomed Pharmacother** 1997;51(10):449–54
Herpes zoster in Japanese patients with systemic lupus erythematosus. Ishikawa O, et al. **Clin Exp Dermatol** 1999 Jul;24(4):327–8
Are granulomatous reactions in old zoster lesions due to an immune response to varicella zoster virus envelope glucoproteins? [letter] Nikkels AF, et al. **Clin Exp Dermatol** 1998 Sep;23(5):237–8
Varicella-Zoster virus infection associated with acute liver failure [letter; comment] Vartian CV. **Clin Infect Dis** 1999 Feb;28(2):412–3. Comment on: Clin Infect Dis 1998 Jul;27(1):209–10.
A prognostic score for postherpetic neuralgia in ambulatory patients. Meister W, et al. **Infection** 1998 Nov-Dec; 26(6):359–63
Cutaneous infections by papillomavirus, herpes zoster and Candida albicans as the only manifestation of idiopathic CD4+ T lymphocytopenia. Manchado Lopez P, et al. **Int J Dermatol** 1999 Feb;38(2):119–21
Acute varicella zoster with postherpetic hyperhidrosis as the initial presentation of HIV infection. Chopra KF, et al. **J Am Acad Dermatol** 1999 Jul;41(1):119–21
Rare presentation of acute urinary retention secondary to herpes zoster. Ginsberg PC, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):508–9
Treatment of postherpetic neuralgia. Menke JJ, et al. **J Am Pharm Assoc (Wash)** 1999 Mar-Apr;39(2):217–21 (21 ref.)
Multidisciplinary approach for the management of post-herpetic neuralgia in elderly patients. Ackerman WE 3rd, et al. **J Ark Med Soc** 1999 May;95(12):528–31 (13 ref.)
Follow-up of clinical efficacy of iontophoresis therapy for postherpetic neuralgia (PHN). Ozawa A, et al. **J Dermatol** 1999 Jan;26(1):1–10
Scar sarcoidosis following herpes zoster [letter] Cecchi R, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):280–2
Unusual isotopic responses on healed herpes zoster lesions--report on two cases [letter] Khanna N, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):194–5
Bullous erythema multiforme following herpes zoster and varicella-zoster virus infection. Weisman K, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):147–50
Disseminated superficial actinic porokeratosis like drug eruption: a case report. Hwang SM, et al. **J Korean Med Sci** 1999 Apr;14(2):227–9
VZV fulminant necrotizing encephalitis with concomitant EBV-related lymphoma and CMV ventriculitis: report of an AIDS case. Nebuloni M, et al. **J Neurovirol** 1998 Aug; 4(4):457–60
Gabapentin for postherpetic neuralgia [letter; comment] Colman E, et al. **JAMA** 1999 Jul 14;282(2):134–5. Comment on: JAMA 1998 Dec 2;280(21):1837–42.
Symptomatic treatment of painful neuropathy [editorial; comment] Low PA, et al. **JAMA** 1998 Dec 2; 280(21):1863–4. Comment on: JAMA 1998 Dec 2;280(21):1831–6. Comment on: JAMA 1998 Dec 2;280(21):1837–42.
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial [see comments] Rowbotham M, et al. **JAMA** 1998 Dec 2;280(21):1837–42. Comment in: JAMA 1998 Dec 2;280(21):1863–4. Comment in: JAMA 1999 Jul 14;282(2):134–5.
Prevention of postherpetic neuralgia. Dworkin RH. **Lancet** 1999 May 15;353(9165):1636–7
37-year-old man with back pain. Montori VM, et al. **Mayo Clin Proc** 1999 Sep;74(9):923–6
Postherpetic neuralgia: irritable nociceptors and deafferentation. Fields HL, et al. **Neurobiol Dis** 1998 Oct; 5(4):209–27 (178 ref.)
Varicella zoster virus-associated focal vasculitis without herpes zoster [letter; comment] Rosenblum WI. **Neurology** 1999 Jul 13;53(1):242. Comment on: Neurology 1998 Sep;51(3):914–5.
Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Watson CP, et al. **Neurology** 1998 Oct; 51(4):1166–71
Urinary retention due to herpes virus infections. Yamanishi T, et al. **Neurourol Urodyn** 1998;17(6):613–9
Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Galer BS, et al. **Pain** 1999 Apr; 80(3):533–8
Acute generalized varicella zoster in the setting of preexisting generalized erythema. Egan CA, et al. **Pediatr Dermatol** 1999 Mar-Apr;16(2):111–2
Varicella and zoster in children with human immunodeficiency virus infection. Derryck A, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):931–3
Neurological manifestations in a patient with visceral leishmaniasis. Karak B, et al. **Postgrad Med J** 1998 Jul; 74(873):423–5
Self-limiting abdominal wall herniation and constipation following herpes zoster infection [letter] Healy C, et al. **QJM** 1998 Nov;91(11):788–9
Intrathecal steroid injection for postherpetic neuralgia: what are the risks? [editorial; comment] Abram SE. **Reg Anesth Pain Med** 1999 Jul-Aug;24(4):283–5. Comment on: Reg Anesth Pain Med 1999 Jul-Aug;24(4):287–93.
Acute herpetic neuralgia and postherpetic neuralgia in the head and neck: response to gabapentin in five cases. Filadora VA 2nd, et al. **Reg Anesth Pain Med** 1999 Mar-Apr;24(2):170–4
Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia [see comments] Kikuchi A, et al. **Reg Anesth Pain Med** 1999 Jul-Aug;24(4):287–93. Comment in: Reg Anesth Pain Med 1999 Jul-Aug;24(4):283–5.
Postherpetic neuralgia in immunocompetent elderly people. Schmader K. **Vaccine** 1998 Nov;16(18):1768–70 (34 ref.)
[Chickenpox: varicella pneumonia in adults] Aerts JG, et al. **Ned Tijdschr Geneeskd** 1998 Sep 5;142(36):1977–9 (Eng. Abstr.) **(Dut)**
[Herpes Zoster and post-herpetic neuralgia: everything to revise?] Pasqualucci A. **Minerva Anestesiol** 1999 Jul-Aug; 65(7-8):541–8 (48 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of postherpetic neuralgia by topical application of prostaglandin E1-vaseline mixture--a single blind

controlled clinical trial] Tamakawa S, et al. **Masui** 1999 Mar;48(3):292–4 (Eng. Abstr.) **(Jpn)**

[Acute retinal necrosis with varicella zoster dermatitis in the fellow eyelid (see comments)] Nakanishi F, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jun;103(6):477–81 (Eng. Abstr.). Comment in: Nippon Ganka Gakkai Zasshi 1999 Jun;103(6):413–4. **(Jpn)**

[An adult case of peripheral facial nerve palsy following acute cerebellitis associated with high antibody titers against varicella-zoster virus] Ogata K, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1070–2 (Eng. Abstr.) **(Jpn)**

[Postherpetic neuralgia in herpes zoster: its treatment with Zovirax] Dekonenko EP, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(6):56–8 **(Rus)**

[Clinical course and treatment of herpetic trigeminal ganglionic neuropathy] Grachev IuV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):4–8 (Eng. Abstr.) **(Rus)**

[Meningitis caused by varicella–zoster virus and ophthalmic trigeminal neuralgia without skin lesions in an immunocompetent woman (letter)] Maigues Llácer JM, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):238–9 **(Spa)**

DIAGNOSIS

Multifocal varicella–zoster virus leukoencephalitis in a patient with AIDS: MR findings. Aygun N, et al. **AJNR Am J Neuroradiol** 1998 Nov–Dec;19(10):1897–9

An atypical presentation of a common disease. Herpes zoster without vesicles. Unger S, et al. **Arch Dermatol** 1998 Oct; 134(10):1280–1, 1283–4

Zosteriform cutaneous metastases from squamous cell carcinoma of the stump of an amputated arm. Cuq–Viguier L, et al. **Clin Exp Dermatol** 1998 May;23(3):116–8

Significance of herpes zoster in HIV/AIDS in Kweneng district, Botswana [see comments] Edhonu–Elyetu Y. **East Afr Med J** 1998 Jul;75(7):379–81. Comment in: East Afr Med J 1998 Jul;75(7):377–8.

Herpes zoster in HIV/AIDS--a little recognised opportunistic infection with important clinical and cost implications [editorial; comment] McLigeyo SO. **East Afr Med J** 1998 Jul;75(7):377–8 (32 ref.). Comment on: East Afr Med J 1998 Jul;75(7):379–81.

Shingles: a review of diagnosis and management. Morgan R, et al. **Hosp Med** 1998 Oct;59(10):770–6 (36 ref.)

Zosteriform distribution of acantholytic dyskeratotic epidermal nevus? [letter] Elston DM. **J Am Acad Dermatol** 1999 Apr;40(4):647

Shingles developing within recent surgical scars. Nikkels AF, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):309–11

Chemotherapy–induced inflammation in seborrheic keratoses mimicking disseminated herpes zoster. Williams JV, et al. **J Am Acad Dermatol** 1999 Apr;40(4):643–4

Herpes zoster infection of the maxilla: case report. Owotade FJ, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1249–51 (21 ref.)

37–year–old man with back pain. Montori VM, et al. **Mayo Clin Proc** 1999 Sep;74(9):923–6

Rapid diagnosis of varicella zoster virus infection in acute facial palsy. Murakami S, et al. **Neurology** 1998 Oct; 51(4):1202–5

[Value of PCR for the early diagnosis of atypical zoster] Bellagra N, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec; 56(6):717–8 **(Fre)**

[Images. Severe infections] **J Fr Ophtalmol** 1999 Mar; 22(2):268 **(Fre)**

[Zona of the cranial nerves. Current aspects] Carreau JP, et al. **Rev Stomatol Chir Maxillofac** 1998 Oct;99(3):155–64 (43 ref.) (Eng. Abstr.) **(Fre)**

[Laboratory diagnosis of viral infections. 3. Exanthema and muco– cutaneous infections] Morishima T. **Rinsho Byori** 1998 Nov;Suppl 108:65–73 (2 ref.) **(Jpn)**

[A case of atypical pneumonia caused by viral–bacterial–fungal association] Ovcharenko SI, et al. **Ter Arkh** 1999;71(3):41–5 **(Rus)**

DRUG THERAPY

Should we offer famciclovir to patients with new–onset herpes zoster? Martin F, et al. **Can Fam Physician** 1999 May;45:1195–6

Acyclovir–resistant herpes zoster in human immunodeficiency virus–infected patients: results of foscarnet therapy. Breton G, et al. **Clin Infect Dis** 1998 Dec;27(6):1525–7

Advances in the treatment of herpesvirus infection: the role of famciclovir. Tyring SK. **Clin Ther** 1998 Jul–Aug; 20(4):661–70 (45 ref.)

Update on drugs for herpes zoster and genital herpes. **Drug Ther Bull** 1998 Oct;36(10):77–9 (25 ref.)

Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Snoeck R, et al. **Drugs** 1999 Feb;57(2):187–206 (230 ref.)

Herpes zoster in HIV/AIDS--a little recognised opportunistic infection with important clinical and cost implications [editorial; comment] McLigeyo SO. **East Afr Med J** 1998 Jul;75(7):377–8 (32 ref.). Comment on: East Afr Med J 1998 Jul;75(7):379–81.

Shingles: a review of diagnosis and management. Morgan R, et al. **Hosp Med** 1998 Oct;59(10):770–6 (36 ref.)

A retrospective study on the clinical outcome of herpes zoster in patients treated with acyclovir or valaciclovir vs. patients not treated with antiviral. Goh CL, et al. **Int J Dermatol** 1998 Jul;37(7):544–6

Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. Dworkin RH, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S76–80

Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty? Smith KJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S85–90

Herpes zoster: risk categories for persistent pain. Whitley RJ, et al. **J Infect Dis** 1999 Jan;179(1):9–15

Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48–72 h) therapy with acyclovir and valaciclovir on prolonged pain. Wood MJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S81–4

In vitro activity of acetylsalicylic acid on replication of varicella–zoster virus. Primache V, et al. **New Microbiol** 1998 Oct;21(4):397–401

[Treatment of chickenpox and shingles (editorial)] Gerstoft J. **Ugeskr Laeger** 1998 Nov 23;160(48):6943 **(Dan)**

[Antiviral treatment of Varicella zoster virus infection] Petersen CS. **Ugeskr Laeger** 1998 Nov 23;160(48):6993–6 **(Dan)**

[Management of VZV infections. Short text of the 11th consensus conference on anti–infectious therapies] **Presse Med** 1998 Jul 4–11;27(24):1231–6 (0 ref.) **(Fre)**

[Drug clinics. How I treat zona] Nikkels AF, et al. **Rev Med Liege** 1999 Feb;54(2):71–5 (Eng. Abstr.) **(Fre)**

[Delirium during oral therapy of herpes zoster with acyclovir. Case report and brief review of central nervous system side–effects of acyclovir] Braun JS, et al. **Nervenarzt** 1998 Nov;69(11):1015–8 (Eng. Abstr.) **(Ger)**

[Hypotension in acyclovir therapy] Wolters H, et al. **Schweiz Rundsch Med Prax** 1998 Nov 19;87(47):1614–8 (Eng. Abstr.) **(Ger)**

[Non–Hodgkin's lymphoma complicated by recurrent intractable generalized herpes zoster responsive to long–term acyclovir therapy] Endo K, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):341–5 (Eng. Abstr.) **(Jpn)**

[Neuralgia and zovirax treatment of patients with herpes zoster] Dekonenko EP, et al. **Ter Arkh** 1998;70(12):63–5 (Eng. Abstr.) **(Rus)**

[Varicella zoster virus and prednisone (letter)] Arjona A. **Neurologia** 1999 Mar;14(3):139–40 **(Spa)**

ECONOMICS

Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty? Smith KJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S85–90

EPIDEMIOLOGY

Varicella–zoster virus disease. **Can Commun Dis Rep** 1999 Aug;25 Suppl 6:7–19 (36 ref.) **(Eng, Fre)**

Herpes zoster and multiple sclerosis. Ross RT, et al. **Can J Neurol Sci** 1999 Feb;26(1):29–32

Prevalence of herpes simplex virus types 1 and 2, cytomegalovirus, and varicella–zoster virus infections in Eritrea. Ghebrekidan H, et al. **J Clin Virol** 1999 Jan; 12(1):53–64

Herpes zoster and its complications in Italy: an observational survey. di Luzio Paparatti U, et al. **J Infect** 1999 Mar; 38(2):116–20

Racial and psychosocial risk factors for herpes zoster in the elderly. Schmader K, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S67–70

Herpes zoster in children and adolescents. Petursson G, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):905–8

ETIOLOGY

Herpes zoster infection in HIV–seropositive patients associated with highly active antiretroviral therapy [letter] Aldeen T, et al. **AIDS** 1998 Sep 10;12(13):1719–20

Varicella zoster virus infection associated with high–dose chemotherapy and autologous stem–cell rescue. Bilgrami S, et al. **Bone Marrow Transplant** 1999 Mar;23(5):469–74

[Complications in two children with acute lymphatic leukemia caused by vaccination against varicella zoster virus] Christensen CL, et al. **Ugeskr Laeger** 1999 Feb 8; 161(6):794–6 (Eng. Abstr.) **(Dan)**

[Herpes zoster unleashed by rehabilitative therapy (letter)] Justo Firvida E, et al. **An Med Interna** 1999 Jan;16(1):49–50 **(Spa)**

GENETICS

Viral gene expression in rat trigeminal ganglia following neonatal infection with varicella–zoster virus. Brunell PA, et al. **J Med Virol** 1999 Jul;58(3):286–90

IMMUNOLOGY

Elevated soluble Fas levels in herpes zoster patients [letter] Kato M, et al. **Br J Dermatol** 1998 Aug;139(2):357–8

Varicella–zoster virus immune evasion. Abendroth A, et al. **Immunol Rev** 1999 Apr;168:143–56 (123 ref.)

Use of a live attenuated varicella vaccine to boost varicella–specific immune responses in seropositive people 55 years of age and older: duration of booster effect. Levin MJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S109–12

Herpes varicella zoster encephalitis in immunocompromised patients. Weaver S, et al. **Neurology** 1999 Jan 1;52(1):193–5

PATHOLOGY

Post–herpes zoster scar sarcoidosis [letter] Corazza M, et al. **Acta Derm Venereol** 1999 Jan;79(1):95

Zosteriform cutaneous metastases arising from adenocarcinoma of the colon: diagnostic smear cytology from cutaneous lesions [letter] Maeda S, et al. **Acta Derm Venereol** 1999 Jan;79(1):90–1

Acute infiltration by non–Hodgkin's B–cell lymphoma of lesions of disseminated herpes zoster. Turner RJ, et al. **Br J Dermatol** 1998 Aug;139(2):295–8

Herpes zoster in a 7–month–old infant: a case report and review. Elmer KB, et al. **Cutis** 1999 Apr;63(4):217–8 (8 ref.)

Herpes zoster in seven disparate dermatomes (zoster multiplex): report of a case and review of the literature. Vu AQ, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):868–9 (13 ref.)

CSF and MRI findings in patients with acute herpes zoster. Haanpää M, et al. **Neurology** 1998 Nov;51(5):1405–11

Is herpes zoster unilateral? Usatine RP, et al. **West J Med** 1999 May;170(5):263

[Magnetic resonance findings in a case of herpes zoster myelitis] Pierallini A, et al. **Radiol Med (Torino)** 1998 Jul–Aug;96(1–2):107–8 (15 ref.) **(Ita)**

PHYSIOPATHOLOGY

Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Oaklander AL, et al. **Ann Neurol** 1998 Nov;44(5):789–95

Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician–based survey in Germany. Meister W, et al. **Intervirology** 1998;41(6):272–7

Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. Dworkin RH, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S76–80

Postherpetic neuralgia: the importance of preventing this intractable end–stage disorder. Watson CP. **J Infect Dis** 1998 Nov;178 Suppl 1:S91–4 (19 ref.)

The identification of risk factors associated with persistent pain following herpes zoster. Whitley RJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S71–5

Herpes zoster: risk categories for persistent pain. Whitley RJ, et al. **J Infect Dis** 1999 Jan;179(1):9–15

Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48–72 h) therapy with acyclovir and valaciclovir on prolonged pain. Wood MJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S81–4

A mixed model for factors predictive of pain in AIDS patients with herpes zoster. Harrison RA, et al. **J Pain Symptom Manage** 1999 Jun;17(6):410–7

[Zona in children] Banerjee A. **Arch Pediatr** 1998 Feb; 5(2):199–203 (30 ref.) (Eng. Abstr.) **(Fre)**

[Chronic pain in herpes zoster] Mergenthaler HG, et al. **Internist (Berl)** 1999 Feb;40(2):162–7 (23 ref.) **(Ger)**

PREVENTION & CONTROL

A cost–effectiveness model for analyzing two varicella vaccination strategies. Gayman J. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S4–8

Varicella: to vaccinate or not to vaccinate? Gershon A. **Arch Dis Child** 1998 Dec;79(6):470–1

Varicella–zoster virus disease. **Can Commun Dis Rep** 1999 Aug;25 Suppl 6:7–19 (36 ref.) **(Eng, Fre)**

Proceedings of the 3rd International Conference on the Varicella–Zoster Virus. Palm Beach Gardens, Florida, USA. 9–11 March 1997. **J Infect Dis** 1998 Nov;178 Suppl 1:S1–112

Use of a live attenuated varicella vaccine to boost varicella–specific immune responses in seropositive people 55 years of age and older: duration of booster effect. Levin MJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S109–12

[Secondary prophylaxis for herpes zoster wi oral acyclovir in HIV patients] Léautez S, et al. **Pathol Biol (Paris)** 1999 May;47(5):570–2 (Eng. Abstr.) **(Fre)**

[Management of varicella–zoster virus infections. No systematic vaccination against varicella in France] Lorette G. **Presse Med** 1998 Jul 4–11;27(24):1237 **(Fre)**

PSYCHOLOGY

Behavioural changes in the rat following infection with varicella–zoster virus. Fleetwood–Walker SM, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2433–6

RADIOGRAPHY

CT appearances of hepatic involvement in systemic varicella–zoster. Ruehm SG, et al. **Br J Radiol** 1998 Dec; 71(852):1317–9

THERAPY

Patient–controlled epidural analgesia for postherpetic neuralgia in an HIV–infected patient as a therapeutic ambulatory modality. Kang FC, et al. **Acta Anaesthesiol Sin** 1998 Dec;36(4):235–9

Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Ahmed HE, et al. **Anesth Analg** 1998 Oct;87(4):911–4

Management of infections due to the varicella–zoster virus. 11th consensus conference on anti–infectious therapy of the French–speaking Society of Infectious Diseases

(SPILF). Peyramond D, et al. **Eur J Dermatol** 1998 Sep; 8(6):397–402 (0 ref.)
Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Estrada-Parra S, et al. **Int J Immunopharmacol** 1998 Oct;20(10):521–35
Postherpetic neuralgia: the importance of preventing this intractable end-stage disorder. Watson CP. **J Infect Dis** 1998 Nov;178 Suppl 1:S91–4 (19 ref.)
Clinical application of contralateral acupuncture technique. Lu F. **J Tradit Chin Med** 1997 Jun;17(2):124–6
21 cases of herpes zoster treated by scratching method with three-edged needle. Yuan F. **J Tradit Chin Med** 1997 Dec; 17(4):282–3
[Management of varicella-zoster virus infections] **Ann Dermatol Venereol** 1998 Sep;125(9):630–6 (0 ref.) **(Fre)**
[Management of varicella-zona virus infections. A consensus conference of the French-speaking Society of Infectious Pathology, Lyon, 25 March 1998] **Arch Pediatr** 1999 Apr; 6(4):469–76 (0 ref.) (Eng. Abstr.) **(Fre)**
[Clinical course and treatment of herpetic trigeminal ganglionic neuropathy] Grachev IuV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):4–8 (Eng. Abstr.) **(Rus)**

TRANSMISSION

In utero varicella-zoster infections. Derrick CW Jr, et al. **South Med J** 1998 Nov;91(11):1064–6 (15 ref.)

VIROLOGY

Detection of varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. Terada K, et al. **J Med Virol** 1998 Dec;56(4):359–63
Prevalence of varicella-zoster virus DNA in dissociated human trigeminal ganglion neurons and nonneuronal cells. LaGuardia JJ, et al. **J Virol** 1999 Oct;73(10):8571–7
Development of a fluorogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. Hawrami K, et al. **J Virol Methods** 1999 Apr;79(1):33–40
Latent Varicella-zoster virus in human dorsal root ganglia. Kennedy PG, et al. **Virology** 1999 Jun 5;258(2):451–4
Is herpes zoster unilateral? Usatine RP, et al. **West J Med** 1999 May;170(5):263
[Varicella-zoster virus meningo-encephalomyelitis without skin eruption] Sissoko D, et al. **Ann Biol Clin (Paris)** 1998 Mar-Apr;56(2):211–2 **(Fre)**
[Clinical course and treatment of herpetic trigeminal ganglionic neuropathy] Grachev IuV, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(11):4–8 (Eng. Abstr.) **(Rus)**

HERPES ZOSTER AURICULARIS see **HERPES ZOSTER OTICUS**

HERPES ZOSTER, OCULAR see **HERPES ZOSTER OPHTHALMICUS**

HERPES ZOSTER OPHTHALMICUS

Varicella-zoster virus eye disease. Liesegang TJ. **Cornea** 1999 Sep;18(5):511–31 (203 ref.)
Varicella zoster virus ocular disease. Chern KC, et al. **Int Ophthalmol Clin** 1998 Fall;38(4):149–60 (66 ref.)

COMPLICATIONS

[Optic neuromyelitis and bilateral acute retinal necrosis due to varicella zoster in a patient with AIDS] Merle H, et al. **J Fr Ophtalmol** 1998 May;21(5):381–6 (Eng. Abstr.) **(Fre)**
[A case of delayed cerebral infarction occurring in puerperium preceded by herpes zoster ophthalmicus in late pregnancy] Hoshino S, et al. **No To Shinkei** 1999 Jun; 51(6):529–33 (Eng. Abstr.) **(Jpn)**
[Meningitis caused by varicella-zoster virus and ophthalmic trigeminal neuralgia without skin lesions in an immunocompetent woman (letter)] Maigues Llácer JM, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):238–9 **(Spa)**

DIAGNOSIS

Triple viral retinitis diagnosed by polymerase chain reaction of the vitreous biopsy in a patient with Richter syndrome. Levinson RD, et al. **Am J Ophthalmol** 1998 Nov; 126(5):732–3
Adult-onset MELAS presenting as herpes encephalitis. Sharfstein SR, et al. **Arch Neurol** 1999 Feb;56(2):241–3
[Bilateral neuroretinitis with zoster infection] Nicaeus T, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):175–7 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Failure of sorivudine therapy in progressive outer retinal necrosis caused by varicella zoster virus. Rosenthal G, et al. **Aust N Z J Ophthalmol** 1998 Nov;26(4):327–8

ETIOLOGY

Herpes zoster ophthalmicus following bone marrow transplantation in children. Walton RC, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1317–20

VIROLOGY

Recurrent nodular scleritis associated with varicella zoster virus. Livir-Rallatos C, et al. **Am J Ophthalmol** 1998 Oct; 126(4):594–7
Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Satoh N, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):185–8

HERPES ZOSTER OTICUS

[Ramsay Hunt syndrome] Araga S. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):55–6 (6 ref.) **(Jpn)**

COMPLICATIONS

Sympathetic contralateral vestibulopathy after unilateral zoster oticus. Schulz P, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):672–6
[Ramsay Hunt syndrome associated with eosinophilic pneumonia] Kodama K. **Nihon Kokyuki Gakkai Zasshi** 1998 Jun;36(6):531–4 (Eng. Abstr.) **(Jpn)**
[A case of Ramsay Hunt syndrome associated with local meningitis, multiple cranial neuropathy, and the second cervical nerve involvement] Nagano K, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):475–7 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Ramsay-Hunt syndrome in a 4-year-old child. Kimitsuki T, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S6–7

PATHOLOGY

Ramsay Hunt syndrome associated with brain stem enhancement. Sartoretti-Schefer S, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):278–80

SURGERY

Endoscopy during neurotomy of the nervus intermedius for geniculate neuralgia. Alcaraz N, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):334–5

VIROLOGY

Detection of varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. Terada K, et al. **J Med Virol** 1998 Dec;56(4):359–63

HERPES ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

HERPESTES see **MONGOOSES**

HERPESVIRIDAE

Herpesviruses--a rationale for antiviral treatment in multiple sclerosis. Bergström T. **Antiviral Res** 1999 Feb;41(1):1–19 (160 ref.)
Expression of NMDA receptor channel subunit proteins using baculovirus and herpesvirus vectors. Kawamoto S, et al. **Methods Mol Biol** 1999;128:19–32 (40 ref.)
[The molecular epidemiology of herpesvirus] Umene K, et al. **Uirusu** 1998 Dec;48(2):163–71 (51 ref.) **(Jpn)**

CLASSIFICATION

Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. Pozo F, et al. **J Virol Methods** 1999 Apr;79(1):9–19

DRUG EFFECTS

The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Neyts J, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3285–9
3-Hydroxyphthaloyl beta-lactoglobulin. III. Antiviral activity against herpesviruses. Neurath AR, et al. **Antivir Chem Chemother** 1998 Mar;9(2):177–84
Anti-herpesvirus activities and cytotoxicities of 2-thiopyrimidine nucleoside analogues in vitro. Shigeta S, et al. **Antivir Chem Chemother** 1999 Jul;10(4):195–209
Drug-resistant herpesviruses: should we look for them? [editorial] Boivin G. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):539–41

ENZYMOLOGY

Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones. Jarvest RL, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):443–8
Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. Degrève B, et al. **J Virol** 1998 Dec;72(12):9535–43

GENETICS

Analysis of the thymidine kinase genes of macropodid herpesviruses 1 and 2. Lee SM, et al. **Arch Virol** 1999; 144(2):397–405
Detection of duck enteritis virus by polymerase chain reaction. Plummer PJ, et al. **Avian Dis** 1998 Jul-Sep; 42(3):554–64
Amplification of the six major human herpesviruses from cerebrospinal fluid by a single PCR. Minjolle S, et al. **J Clin Microbiol** 1999 Apr;37(4):950–3
Purification and partial genome characterization of a herpes-like virus infecting the Japanese oyster, Crassostrea gigas. Le Deuff RM, et al. **J Gen Virol** 1999 May;80 (Pt 5):1317–22
Comparison of PCR, virus isolation, and indirect fluorescent antibody staining in the detection of naturally occurring feline herpesvirus infections. Burgesser KM, et al. **J Vet Diagn Invest** 1999 Mar;11(2):122–6
Diagnosis of malignant catarrhal fever by PCR using formalin-fixed, paraffin-embedded tissues. Crawford TB, et al. **J Vet Diagn Invest** 1999 Mar;11(2):111–6
Properties and functions of feline herpesvirus type 1 glycoproteins. Maeda K, et al. **J Vet Med Sci** 1998 Aug; 60(8):881–8 (97 ref.)
Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. Degrève B, et al. **J Virol** 1998 Dec;72(12):9535–43
A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Martino G, et al. **Mult Scler** 1998 Jun; 4(3):222–7 (37 ref.)
The prevalence of herpes family virus DNA in the conjunctiva of patients positive and negative for human immunodeficiency virus using the polymerase chain reaction. Lee-Wing MW, et al. **Ophthalmology** 1999 Feb; 106(2):350–4
Restriction endonuclease analysis of feline herpesvirus 1 DNA isolated from wild felids. Pratelli A, et al. **Vet Rec** 1999 May 8;144(19):537–8
Sequence comparison of JSRV with endogenous proviruses: envelope genotypes and a novel ORF with similarity to a G-protein-coupled receptor. Bai J, et al. **Virology** 1999 Jun 5;258(2):333–43
Channel catfish virus gene 50 encodes a secreted, mucin-like glycoprotein. Vanderheijden N, et al. **Virology** 1999 Apr 25;257(1):220–7
Detection of new DNA polymerase genes of known and potentially novel herpesviruses by PCR with degenerate and deoxyinosine-substituted primers. Ehlers B, et al. **Virus Genes** 1999;18(3):211–20
Structural organization of a conserved gene cluster of Tupaia herpesvirus encoding the DNA polymerase, glycoprotein B, a probable processing and transport protein, and the major DNA binding protein. Bahr U, et al. **Virus Res** 1999 Apr;60(2):123–35

GROWTH & DEVELOPMENT

Natural reactivation of caprine herpesvirus 1 in latently infected goats. Tempesta M, et al. **Vet Rec** 1998 Aug 15; 143(7):200

IMMUNOLOGY

Production of a falcon herpesvirus vaccine. Wernery U, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep; 112(9):339–44
Herpesvirus vaccines. Development, controversies, and applications. Krause PR, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):61–81, vi (88 ref.)
Questions long-term immunity in cats [letter] Norsworthy GD. **J Am Vet Med Assoc** 1999 Aug 1;215(3):316–7
Serum antibodies to human herpesvirus 7, human herpesvirus 6 and cytomegalovirus in patients with idiopathic facial nerve palsy or sudden deafness. Takasaki T, et al. **J Laryngol Otol** 1998 Jul;112(7):617–21
Encephalitis induced by bovine herpesvirus 5 and protection by prior vaccination or infection with bovine herpesvirus 1. Cascio KE, et al. **J Vet Diagn Invest** 1999 Mar; 11(2):134–9
An enzyme-linked immunosorbent assay using nuclear antigen for detection of feline herpesvirus 1 antibody. Satoh Y, et al. **J Vet Diagn Invest** 1999 Jul;11(4):334–40
Serosurvey for antibodies to malignant catarrhal fever-associated viruses in free-living and captive cervids in Germany. Frölich K, et al. **J Wildl Dis** 1998 Oct; 34(4):777–82
[The significance of determining antibodies to viruses of the Herpesviridae family in rheumatic diseases] Egorova ON, et al. **Ter Arkh** 1999;71(5):57–61 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Quantitation of 8 human herpesviruses in peripheral blood of human immunodeficiency virus-infected patients and healthy blood donors by polymerase chain reaction. Hoang MP, et al. **Am J Clin Pathol** 1999 May;111(5):655–9
Isolation of Inoue-Melnick virus [letter; comment] Dorta-Contreras AJ. **Arch Pathol Lab Med** 1999 Apr; 123(4):282. Comment on: Arch Pathol Lab Med 1998 Jun;122(6):520–2.
Antigenic and nucleotide characterization of a herpesvirus isolated from Pacific harbor seals (Phoca vitulina richardsii). King DP, et al. **Arch Virol** 1998;143(10):2021–7
Identification of duck plague virus by polymerase chain reaction. Hansen WR, et al. **Avian Dis** 1999 Jan-Mar; 43(1):106–15

HERPESVIRIDAE

Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Akhtar N, et al. **Circulation** 1999 Apr 20; 99(15):2011–8

Human herpesviruses in chronic fatigue syndrome. Wallace HL 2nd, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):216–23

Hematogenously spread herpesviruses are detected as frequently as neuronally spread herpesviruses in cerebrospinal fluid by polymerase chain reaction assay. Studahl M, et al. **Clin Infect Dis** 1999 Jul;29(1):216–8

Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus–1 infection in cats with acute respiratory tract or chronic ocular disease. Maggs DJ, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):502–7

Amplification of the six major human herpesviruses from cerebrospinal fluid by a single PCR. Minjolle S, et al. **J Clin Microbiol** 1999 Apr;37(4):950–3

Detection of caprine herpesvirus 1 in sacral ganglia of latently infected goats by PCR. Tempesta M, et al. **J Clin Microbiol** 1999 May;37(5):1598–9

Detection of two novel porcine herpesviruses with high similarity to gammaherpesviruses. Ehlers B, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):971–8

Purification and partial genome characterization of a herpes–like virus infecting the Japanese oyster, Crassostrea gigas. Le Deuff RM, et al. **J Gen Virol** 1999 May;80 (Pt 5):1317–22

Enzyme–linked immunosorbent assay for detection of feline herpesvirus 1 IgG in serum, aqueous humor, and cerebrospinal fluid. Dawson DA, et al. **J Vet Diagn Invest** 1998 Oct;10(4):315–9

Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. Pozo F, et al. **J Virol Methods** 1999 Apr;79(1):9–19

Detection of microorganisms in vessel wall specimens of the abdominal aorta: development of a PCR assay in the absence of a gold standard. Meijer A, et al. **Res Microbiol** 1998 Sep;149(8):577–83

Virus suspect identified in elephant deaths [news; comment] Ferber D. **Science** 1999 Feb 19;283(5405):1093–4. Comment on: Science 1999 Feb 19;283(5405):1171–6.

Novel endotheliotropic herpesviruses fatal for Asian and African elephants [see comments] Richman LK, et al. **Science** 1999 Feb 19;283(5405):1171–6. Comment in: Science 1999 Feb 19;283(5405):1093–4.

Detection of herpesvirus–like and papillomavirus–like particles associated with diseases of tortoises. Drury SE, et al. **Vet Rec** 1998 Dec 5;143(23):639

Malignant catarrhal fever caused by ovine herpesvirus–2 in pigs in Norway. Løken T, et al. **Vet Rec** 1998 Oct 24; 143(17):464–7

[Biotin–rich pseudoherpetic intranuclear inclusions. A diagnostic pitfall] Leteurtre E, et al. **Arch Anat Cytol Pathol** 1999;47(1):44–7 (Eng. Abstr.) **(Fre)**

[Elephant herpes virus––a problem for breeding and housing of elephants] Burkhardt S, et al. **Berl Munch Tierarztl Wochenschr** 1999 Jun;112(5):174–9 (Eng. Abstr.) **(Ger)**

[Human type 6, 7, and 8 herpesviruses––new pathogens in the Herpesviridae family] L'vov ND, et al. **Vopr Virusol** 1999 May–Jun;44(3):105–11 (64 ref.) (Eng. Abstr.) **(Rus)**

[Herpesvirus detection in immunocompromised patients with meningoencephalitis by the polymerase chain reaction technic] Kouri V, et al. **Rev Cubana Med Trop** 1998; 50(3):186–90 (Eng. Abstr.) **(Spa)**

PATHOGENICITY

Response of embryonic chicken lymphocytes to in ovo exposure to lymphotropic viruses. St. Hill CA, et al. **Am J Vet Res** 1999 Aug;60(8):937–41

Herpesviruses and thrombosis: activation of coagulation on the endothelium. Nicholson AC, et al. **Clin Chim Acta** 1999 Aug;286(1–2):23–9 (27 ref.)

A preliminary study on the pathogenicity of a strain of caprine herpesvirus–1. Tempesta M, et al. **Comp Immunol Microbiol Infect Dis** 1999 Apr;22(2):137–43

Experimental simian varicella virus infection of St. Kitts vervet monkeys. Gray WL, et al. **J Med Primatol** 1998 Aug;27(4):177–83

Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein–Barr virus (EBV) infections. Syrjänen S, et al. **J Oral Pathol Med** 1999 May; 28(5):204–9

A viral epizootic in cultured populations of juvenile goldfish due to a putative herpesvirus etiology. Groff JM, et al. **J Vet Diagn Invest** 1998 Oct;10(4):375–8

PHYSIOLOGY

Kaposi's sarcoma: breeding ground of herpesviridae – A tour de force over viral evolution (review). Sinkovics JG, et al. **Int J Oncol** 1999 Apr;14(4):615–46 (300 ref.)

Overcoming inhibitions: subversion of CKI function by viral cyclins. Swanton C, et al. **Trends Biochem Sci** 1999 Mar; 24(3):116–20 (58 ref.)

HERPESVIRIDAE INFECTIONS

Human herpesvirus 6: An emerging pathogen. Campadelli–Fiume G, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):353–66 (105 ref.)

Kaposi's sarcoma–associated herpesvirus infection in the lung in multicentric Castleman's disease [see comments] Hayashi M, et al. **Intern Med** 1999 Mar;38(3):279–82. Comment in: Intern Med 1999 Mar;38(3):221–2.

Human herpesvirus–6: neurologic implications of a newly–described viral pathogen [see comments] Kimberlin DW, et al. **J Neurovirol** 1998 Oct;4(5):474–85 (130 ref.). Comment in: J Neurovirol 1998 Oct;4(5):471–3.

Lymphoproliferative disease induced by murine herpesvirus–68. Usherwood EJ, et al. **Lab Anim Sci** 1998 Aug;48(4):344–5

Human herpesvirus 8 and sarcoidosis [letter; comment] Di Alberti L, et al. **Lancet** 1998 May 23;351(9115):1589–90. Comment on: Lancet 1998 Feb 28;351(9103):679–80.

Epstein–Barr virus involvement in T–cell malignancy: significance in adult T–cell leukemia. Ohtsubo H, et al. **Leuk Lymphoma** 1999 May;33(5–6):451–8 (71 ref.)

Epstein–Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Jarrett RF, et al. **Semin Hematol** 1999 Jul;36(3):260–9 (102 ref.)

[Epstein–Barr virus infection and the expression of bcl–2 proto–oncogene in Hodgkin's disease] Liu C, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Jun;26(3):155–7 (Eng. Abstr.) **(Chi)**

[Human Herpesvirus 6: general information and infections in organ transplantations and hematopoietic stem cell grafts] Fontan J, et al. **Presse Med** 1999 Jan 23;28(3):149–56 (60 ref.) (Eng. Abstr.) **(Fre)**

[Primary effusion lymphoma: a rare form of lymphoma associated with herpesvirus 8 in AIDS (letter)] Boutoille D, et al. **Rev Med Interne** 1999 Jun;20(6):544 **(Fre)**

[Epstein–Barr virus encephalitis] Fukaya S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):25–8 (20 ref.) **(Jpn)**

[HHV–6 infection, HHV–7 infection] Suga S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):48–50 (15 ref.) **(Jpn)**

[EB virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):126–8 (10 ref.) **(Jpn)**

[HHV 6,7 and 8. Recently discovered herpesviruses explain the etiology of well–known diseases] Bergström T. **Lakartidningen** 1999 Jun 30;96(26–27):3161–5 (40 ref.) (Eng. Abstr.) **(Swe)**

BLOOD

Human herpesvirus 7 and pityriasis rosea [letter] Watanabe T, et al. **J Invest Dermatol** 1999 Aug;113(2):288–9

CEREBROSPINAL FLUID

Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations. van den Berg JS, et al. **Neurology** 1999 Mar 23;52(5):1077–9

CHEMICALLY INDUCED

Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Byrd JC, et al. **Br J Haematol** 1999 May;105(2):445–7

COMPLICATIONS

Erythema elevatum diutinum in a patient with human herpesvirus 6 infection [letter] Drago F, et al. **Acta Derm Venereol** 1999 Jan;79(1):91–2

Herpesvirus–6 (HHV–6) encephalitis in a child presenting as a focal necrotic lesion. Matsumoto K, et al. **Acta Neurochir (Wien)** 1999;141(4):439–40

Pediatric AIDS–associated lymphocytic interstitial pneumonia and pulmonary arterio–occlusive disease: role of VCAM–1/VLA–4 adhesion pathway and human herpesviruses. Brodie SJ, et al. **Am J Pathol** 1999 May; 154(5):1453–64

Epstein–Barr virus related hemophagocytic syndrome in a T–cell rich B–cell lymphoma. Mitterer M, et al. **Ann Oncol** 1999 Feb;10(2):231–4

No evidence of HHV–8 infection in patients with pemphigus vulgaris/foliaceus [letter; comment] Cathomas G, et al. **Arch Dermatol** 1998 Sep;134(9):1162. Comment on: Arch Dermatol 1997 Oct;133(10):1247–51.

Human herpesviruses 6 and 7. New roles yet to be discovered? [editorial] Le Cleach L, et al. **Arch Dermatol** 1998 Sep;134(9):1155–7

Human herpesvirus 6 infection as a risk factor for the development of severe drug–induced hypersensitivity syndrome. Suzuki Y, et al. **Arch Dermatol** 1998 Sep; 134(9):1108–12

Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Tohyama M, et al. **Arch Dermatol** 1998 Sep;134(9):1113–7

Human herpesvirus 8 infection in patients with POEMS syndrome–associated multicentric Castleman's disease. Bélec L, et al. **Blood** 1999 Jun 1;93(11):3643–53

HHV–8 is present in multiple myeloma patients. Berenson JR, et al. **Blood** 1999 May 15;93(10):3157–9; discussion 3164–6 (29 ref.)

Kaposi's sarcoma–associated herpesvirus and multiple myeloma: lack of criteria for causality. Tarte K, et al. **Blood** 1999 May 15;93(10):3159–63; discussion 3163–4 (41 ref.)

Direct Epstein–Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome–related non–Hodgkin's lymphoma. van Baarle D, et al. **Blood** 1999 Jun 1; 93(11):3949–55

Microsatellite instability, Epstein–Barr virus, mutation of type II transforming growth factor beta receptor and BAX in gastric carcinomas in Hong Kong Chinese. Leung SY, et al. **Br J Cancer** 1999 Feb;79(3–4):582–8

Pulmonary embolism associated with varicella infection [letter] McColl MD, et al. **Br J Haematol** 1998 Sep; 102(5):1384–5

Paediatric Hodgkin's disease in Spain: association with Epstein–Barr virus strains carrying latent membrane protein–1 oncogene deletions and high frequency of dual infections. Santón A, et al. **Br J Haematol** 1998 Oct; 103(1):129–36

Infectious agents that play a role in atherosclerosis and vasculopathies. What are they? What do we do about them? Vercellotti G. **Can J Cardiol** 1999 Apr;15 Suppl B:13B–15B

Clonal change of infiltrating T–cells in children with familial hemophagocytic lymphohistiocytosis: possible association with Epstein–Barr virus infection. Ishii E, et al. **Cancer** 1999 Apr 1;85(7):1636–43

Human herpesvirus–7 infection in a patient with systemic lupus erythematosus [letter] Taccetti G, et al. **Clin Exp Rheumatol** 1999 Jan–Feb;17(1):126

Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease. Bélec L, et al. **Clin Infect Dis** 1999 Mar;28(3):678–9

Suspected Brazilian purpuric fever in a toddler with overwhelming Epstein–Barr virus infection. Virata M, et al. **Clin Infect Dis** 1998 Nov;27(5):1238–40

Kaposi's sarcoma herpesvirus as a new paradigm for virus–induced oncogenesis. Whitby D, et al. **Curr Opin Oncol** 1998 Sep;10(5):405–12 (82 ref.)

Pityriasis rosea and herpesvirus 7: action or interaction? [letter; comment] Drago F, et al. **Dermatology** 1998; 197(3):275. Comment on: Dermatology 1998;196(2):275.

Image of the month. What is the etiology of these ulcers? Rudolph JA, et al. **Gastroenterology** 1999 Apr;116(4):788, 1018

Kaposi's sarcoma–associated herpesvirus in Kikuchi's disease. Huh J, et al. **Hum Pathol** 1998 Oct;29(10):1091–6

Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA, et al. **J Infect Dis** 1998 Dec; 178(6):1783–6

Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother–child pairs with KS. He J, et al. **J Infect Dis** 1998 Dec;178(6):1787–90

Natural history of primary Epstein–Barr virus infection in children of mothers infected with human immunodeficiency virus type 1. Jenson H, et al. **J Infect Dis** 1999 Jun;179(6):1395–404

Neonatal stridor in association with herpes simplex infection of the larynx. Sharp HR, et al. **J Laryngol Otol** 1998 Dec; 112(12):1192–3 (7 ref.)

Breast cancer: a new Epstein–Barr virus–associated disease? [editorial; comment] Magrath I, et al. **J Natl Cancer Inst** 1999 Aug 18;91(16):1349–50. Comment on: J Natl Cancer Inst 1999 Aug 18;91(16):1376–81.

Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome–related diseases [see comments] Rezza G, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1468–74. Comment in: J Natl Cancer Inst 1999 Sep 1;91(17):1440–1.

Primary EBV–associated cauda equina lymphoma [letter] Giobbia M, et al. **J Neurol** 1999 Aug;246(8):739–40

A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. Baranowski AP, et al. **J Pain Symptom Manage** 1999 Jun;17(6):429–33

Iontophoretic vincristine in the treatment of postherpetic neuralgia: a double–blind, randomized, controlled trial. Dowd NP, et al. **J Pain Symptom Manage** 1999 Mar; 17(3):175–80

Central nervous system T–cell lymphoproliferative disorder in a patient with chronic active Epstein–Barr virus infection. Ohga S, et al. **J Pediatr Hematol Oncol** 1999 Jan–Feb;21(1):42–6

Thrombocytopenia after human herpesvirus–7 infection in a patient with DiGeorge syndrome [letter] Sato A, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):171–2

Relationship between herpesviruses and adult periodontitis and periodontopathic bacteria. Contreras A, et al. **J Periodontol** 1999 May;70(5):478–84

Polysynovitis associated with acute Epstein–Barr virus infection [letter] McCarty DJ, et al. **J Rheumatol** 1998 Oct; 25(10):2039–40 (6 ref.)

Epstein–Barr virus induced renal leiomyoma. Krishnan R, et al. **J Urol** 1999 Jan;161(1):212

Post transplant CD8+ gammadelta T–cell lymphoma associated with human herpes virus–6 infection. Lin WC, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):377–84 (40 ref.)

HHV–8 infection is specific for cell lines derived from primary effusion (body cavity–based) lymphomas. Uphoff CC, et al. **Leukemia** 1998 Nov;12(11):1806–9

Brief report: Pediatric Burkitt lymphoma with concurrent chronic Epstein-Barr virus hepatitis. Preciado MV, et al. **Med Pediatr Oncol** 1999 Aug;33(2):134–6

Human Herpesvirus–6 (HHV–6) infection in multiple sclerosis: a preliminary report. Ablashi DV, et al. **Mult Scler** 1998 Dec;4(6):490–6

Host response to EBV infection in X–linked lymphoproliferative disease results from mutations in an SH2–domain encoding gene [see comments] Coffey AJ, et al. **Nat Genet** 1998 Oct;20(2):129–35. Comment in: Nat Genet 1998 Oct;20(2):103–4.

Why commonplace encounters turn to fatal attraction [news; comment] Sadelain M, et al. **Nat Genet** 1998 Oct; 20(2):103–4. Comment on: Nat Genet 1998 Oct;20(2):129–35.

Epstein–Barr–virus–induced interstitial nephritis in an HIV–positive patient with progressive renal failure. Frazão JM, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1849–52

Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post–herpetic neuralgia. Attal N, et al. **Pain** 1999 May;81(1–2):203–9

Sudden unexpected death associated with HHV–6 in an adolescent with tuberous sclerosis. Wang J, et al. **Pediatr Neurol** 1999 Jul;21(1):488–91

Perinatal Epstein Barr virus infection in a premature infant. Andronikou S, et al. **Scand J Infect Dis** 1999;31(1):96–8

Adult onset Still's disease associated with Epstein–Barr virus infection in a 66–year–old woman. Schifter T, et al. **Scand J Rheumatol** 1998;27(6):458–60

HLA–A33 and –B44 and susceptibility to postherpetic neuralgia (PHN). Ozawa A, et al. **Tissue Antigens** 1999 Mar;53(3):263–8

Kaposi sarcoma–associated herpesvirus/human herpesvirus type 8 and Epstein–Barr virus in immunosuppressed renal transplant recipients. Demirağ A, et al. **Transplant Proc** 1998 Nov;30(7):3166–7

Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Dockrell DH, et al. **Transplantation** 1999 Feb 15;67(3):399–403

Human herpes virus–8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Farge D, et al. **Transplantation** 1999 May 15;67(9):1236–42

Evidence against KSHV infection in the pathogenesis of multiple myeloma. Olsen SJ, et al. **Virus Res** 1998 Oct; 57(2):197–202

[Human herpesvirus 8 (HHV8). II. Pathogenic role and sensitivity to antiviral drugs] Boulanger E. **Ann Biol Clin (Paris)** 1999 Jan–Feb;57(1):19–28 (48 ref.) (Eng. Abstr.) **(Fre)**

[A cause of acute encephalitis: primary infection due to Epstein–Barr virus] Follet–Bouhamed C, et al. **Arch Pediatr** 1999 Mar;6(3):286–9 (Eng. Abstr.) **(Fre)**

[Post–transplantation lymphomas and Epstein–Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481–8 (100 ref.) (Eng. Abstr.) **(Fre)**

[A case with chronic active EB virus infection accompanied with pulmonary candidiasis] Karino T, et al. **Kansenshogaku Zasshi** 1998 Dec;72(12):1306–10 (Eng. Abstr.) **(Jpn)**

[Leiomyosarcoma associated with Epstein–Barr virus in an adult with renal transplant] Uribe–Uribe NO, et al. **Rev Invest Clin** 1998 May–Jun;50(3):255–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Hypothyroidism presenting as acute cardiac tamponade with viral pericarditis. Gupta R, et al. **Am J Emerg Med** 1999 Mar;17(2):176–8

Fever and rash in a young boy. Golledge C. **Aust Fam Physician** 1999 Mar;28(3):271

Human herpesviruses in chronic fatigue syndrome. Wallace HL 2nd, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):216–23

Evaluation of antibodies to the Epstein–Barr virus immediate early gene product ZEBRA by a new enzyme–linked immunosorbent assay. Yamauchi Y, et al. **Intervirology** 1998;41(6):278–84

Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein–Barr virus–associated lymphoid malignancy [letter; comment] Iwatsuki K, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):283–4. Comment on: J Am Acad Dermatol 1998 Apr;38(4):574–9.

Human herpes–virus 8 seropositive patient with skin and graft Kaposi's sarcoma after lung transplantation. Sachsenberg–Studer EM, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):308–11

Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein–Barr virus primary infection and reactivation. Buisson M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2709–14

Serodiagnosis of Epstein–Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion. Hinderer W, et al. **J Clin Microbiol** 1999 Oct; 37(10):3239–44

Evaluation of an Epstein–Barr virus (EBV) immunoglobulin M enzyme–linked immunosorbent assay using a synthetic convergent peptide library, or mixotope, for diagnosis of primary EBV infection. Tranchand–Bunel D, et al. **J Clin Microbiol** 1999 Jul;37(7):2366–8

Human herpesvirus 6 latently infects mononuclear cells but not liver tissue. Yoshikawa T, et al. **J Clin Pathol** 1999 Jan;52(1):65–7

Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections. Schubert J, et al. **J Clin Virol** 1998 Dec;11(3):161–72

Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1–seropositive and –seronegative women. Calabrò ML, et al. **J Infect Dis** 1999 Jun;179(6):1534–7

Searching for human herpesvirus 8 antibodies in serum samples from patients infected with human immunodeficiency virus type 1 and blood donors from São Paulo, Brazil [letter] Caterino–de–Araujo A, et al. **J Infect Dis** 1999 Jun;179(6):1591–2

No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris, or pemphigus foliaceus. Cohen SS, et al. **J Invest Dermatol** 1998 Nov;111(5):781–3

Characterization of natural Epstein–Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma. Jenson HB, et al. **J Med Virol** 1999 Jan;57(1):36–46

Transient synovitis: lack of serologic evidence for acute parvovirus B–19 or human herpesvirus–6 infection. Lockhart GR, et al. **J Pediatr Orthop** 1999 Mar–Apr; 19(2):185–7

Serological screening for hepatitis B and C and human herpesvirus 6 in Norwegian patients with primary Sjögren's syndrome [letter] Iakimtchouk K, et al. **J Rheumatol** 1999 Sep;26(9):2065–6

Epstein–Barr virus and oral squamous cell carcinoma in patients without HIV infection: viral detection by polymerase chain reaction. González–Moles M, et al. **Microbios** 1998;96(383):23–31

BHV–1: new molecular approaches to control a common and widespread infection. Turin L, et al. **Mol Med** 1999 May;5(5):261–84 (195 ref.)

Epstein–Barr virus polymerase chain reaction and serology in pediatric post–transplant lymphoproliferative disorder: three–year experience. Rogers BB, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):480–6

Characteristic MR features of encephalitis caused by Epstein–Barr virus: a case report. Ono J, et al. **Pediatr Radiol** 1998 Aug;28(8):569–70

HPV testing in cervical screening. Cuzick J. **Sex Transm Infect** 1998 Aug;74(4):300–1

Polymerase chain reaction and in situ hybridization of Epstein–Barr virus in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Barkholt L, et al. **Transpl Int** 1998;11(5):336–44

Natural history of Epstein–Barr viral load in peripheral blood of pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disorder. Cacciarelli TV, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):488–9

Acute disseminated encephalomyelitis after renal transplantation in patients with positive Epstein–Barr virus antibody. Kim SC, et al. **Transplant Proc** 1998 Nov; 30(7):3139

[Recurrent postherpetic erythema multiforme presenting as a polymorphous light eruption and 'juvenile spring eruption] Ostertag JU. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2711–2 **(Dut)**

[Orbital lymphoma and AIDS. Apropos of a case] Than–Trong T, et al. **J Fr Ophtalmol** 1999 May;22(5):594–8 (Eng. Abstr.) **(Fre)**

[Presence of antibodies to human herpesvirus type 6 and 7 in Hungarian children] Ongrádi J, et al. **Orv Hetil** 1999 Apr 25;140(17):935–40 (58 ref.) (Eng. Abstr.) **(Hun)**

[Laboratory diagnosis of viral infections. 7. Opportunistic infection by herpesviruses (human cytomegalovirus, Epstein–Barr virus, and human herpesvirus 8)] Okuno T. **Rinsho Byori** 1998 Nov;Suppl 108:98–104 (5 ref.) **(Jpn)**

[A case of diagnosis of Landry ascending paralysis of herpetic etiology] Ponomarev VV, et al. **Arkh Patol** 1999 Mar–Apr; 61(2):34–7 (Eng. Abstr.) **(Rus)**

[Differential diagnosis of the transplant rejection and herpesvirus–related infections in kidney transplant recipients] Baran EI, et al. **Klin Khir** 1998;(5):11–2 (Eng. Abstr.) **(Rus)**

[Detection and characterization of gastric carcinoma associated with epstein–barr herpes virus] Gurtsevich VE, et al. **Vestn Ross Akad Med Nauk** 1999;(3):56–9 (Eng. Abstr.) **(Rus)**

[Immunoglobulin avidity in the diagnosis acute infectious processes] Maroto Vela MC. **An R Acad Nac Med (Madr)** 1998;115(2):519–30; discussion 530–7 **(Spa)**

[Magnetic resonance in herpetic encephalitis in an adult] González de las Heras E, et al. **Rev Neurol** 1998 Apr; 26(152):659–60 **(Spa)**

DRUG THERAPY

Herpesviruses—a rationale for antiviral treatment in multiple sclerosis. Bergström T. **Antiviral Res** 1999 Feb;41(1):1–19 (160 ref.)

Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Cole PD, et al. **Clin Infect Dis** 1998 Sep;27(3):653–4

Protective effects of hochu–ekki–to, a Chinese traditional herbal medicine against murine cytomegalovirus infection. Hossain MS, et al. **Immunopharmacology** 1999 Apr; 41(3):169–81

[Recurrent postherpetic erythema multiforme presenting as a polymorphous light eruption and 'juvenile spring eruption] Ostertag JU. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2711–2 **(Dut)**

[Valacyclovir] Biernat–Sudolska M. **Przegl Lek** 1998; 55(11):596–8 (22 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Murine cytomegalovirus induces expression and enzyme activity of cellular dihydrofolate reductase in quiescent cells. Lembo D, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2803–7

EPIDEMIOLOGY

Epidemiology of Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8. Schulz TF. **Adv Cancer Res** 1999;76:121–60 (172 ref.)

Increasing Kaposi's sarcoma–associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. Olsen SJ, et al. **AIDS** 1998 Oct 1;12(14):1921–5

Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan. Takeshita H, et al. **Auris Nasus Larynx** 1999 Jul;26(3):277–86

Human herpesvirus–8 and relatives of patients with plasmocytic diseases [letter; comment] Jaccard A, et al. **Blood** 1998 Nov 1;92(9):3488. Comment on: Blood 1997 Dec 1;90(11):4278–82. Comment on: Blood 1998 Jun 1;91(11):4391–3.

Absence of a correlation between Kaposi's sarcoma–associated herpesvirus (KSHV/HHV–8) and multiple myeloma [letter] Schönrich G, et al. **Blood** 1998 Nov 1;92(9):3474–5

Effect of material deprivation on Epstein–Barr virus infection in Hodgkin's disease in the West Midlands. Flavell K, et al. **Br J Cancer** 1999 May;80(3–4):604–8

Encephalitis in the first three years of life. **Commun Dis Rep CDR Wkly** 1998 Sep 25;8(39):343

Seroprevalence of Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8 in several regions of Italy. Calabrò ML, et al. **J Hum Virol** 1998 Mar–Apr;1(3):207–13

Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. Blackbourn DJ, et al. **J Infect Dis** 1999 Jan;179(1):237–9

Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother–child pairs with KS. He J, et al. **J Infect Dis** 1998 Dec;178(6):1787–90

Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. Kositanont U, et al. **J Infect Dis** 1999 Jul;180(1):50–5

Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. Whitby D, et al. **J Infect Dis** 1999 Jan;179(1):234–6

Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus) in Brazil and Colorado. Zhang Xq, et al. **J Infect Dis** 1998 Nov;178(5):1488–91

Human herpesvirus 8 and renal transplantation [letter; comment] Rabkin CS, et al. **N Engl J Med** 1999 Apr 1; 340(13):1045–6. Comment on: N Engl J Med 1998 Nov 5;339(19):1358–63.

Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. Lanphear BP, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):792–5

Prevalence of infection with human herpesvirus 8/Kaposi's sarcoma herpesvirus in rural South Africa. Wilkinson D, et al. **S Afr Med J** 1999 May;89(5):554–7

Epstein–Barr virus infection after kidney transplantation. Kaden J, et al. **Transpl Int** 1998;11 Suppl 1:S119–24

Prospective study of Epstein–Barr virus chronic infection in renal transplant recipients. Lauzurica R, et al. **Transplant Proc** 1999 Sep;31(6):2339–40

Comparison of seroprevalences of human herpesvirus–6 and –7 in healthy blood donors from nine countries. Krueger GR, et al. **Vox Sang** 1998;75(3):193–7

ETHNOLOGY

Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein–Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation–dependent polymerase chain reaction. Punwaney R, et al. **Head Neck** 1999 Jan; 21(1):21–9

ETIOLOGY

Infection and spread of alphaherpesviruses in the nervous system. Enquist LW, et al. **Adv Virus Res** 1998;51:237–347 (482 ref.)

Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bosi A, et al. **Bone Marrow Transplant** 1998 Aug;22(3):285–8

Post–transplant Epstein–Barr virus–associated meningoencephalitis and lymphoid interstitial pneumonitis [letter] Davis K, et al. **Bone Marrow Transplant** 1999 Aug; 24(4):443–4

Studies on the pathogenicity of bovine herpesvirus type 5

in sheep. Belák K, et al.
Comp Immunol Microbiol Infect Dis 1999 Jul;22(3):207–20
Human herpesvirus–6 encephalitis after bone marrow transplantation: magnetic resonance imaging could identify the involved sites of encephalitis [letter] Tsujimura H, et al. **Eur J Haematol** 1998 Oct;61(4):284–5
Genetic characterization of HHV–8/KSHV–positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Gaidano G, et al. **Genes Chromosomes Cancer** 1999 Jan; 24(1):16–23
Human herpesvirus–8 infection in hemodialysis patients from northern Italy [letter] Luppi M, et al. **Kidney Int** 1999 Jan; 55(1):340
Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Kadakia MP.
Leuk Lymphoma 1998 Oct;31(3–4):251–66 (130 ref.)
Fatal Cercopithecine herpesvirus 1 (B virus) infection following a mucocutaneous exposure and interim recommendations for worker protection.
MMWR Morb Mortal Wkly Rep 1998 Dec 18; 47(49):1073–6, 1083
Post–transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? [editorial; comment] Webber SA. **Pediatr Transplant** 1999 May; 3(2):95–9. Comment on: Pediatr Transplant 1999 May;3(2):100–3.
Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Ratnamohan VM, et al. **Transplantation** 1998 Oct 15;66(7):877–82
Pathogenesis of murine gammaherpesvirus–68 infection in interleukin–6–deficient mice. Sarawar SR, et al.
Virology 1998 Sep 30;249(2):359–66
Primary and challenge infection of mice with equine herpesvirus 1, strain HSV25A. Walker C, et al.
Virus Res 1998 Oct;57(2):151–62
[Varicella zoster virus infection area in 39 HIV–infected patients. Therapeutic management] Léautez S, et al.
Presse Med 1999 Mar 6;28(9):473–5 (Eng. Abstr.) **(Fre)**
[Infantile T cell acute lymphoblastic leukemia complicated by thrombotic microangiopathy and human herpes virus 6 infection after allogeneic peripheral blood stem cell transplantation using CD34–positive cells] Hasegawa D, et al. **Rinsho Ketsueki** 1999 Jul;40(7):574–80 (Eng. Abstr.) **(Jpn)**
[Characteristics of infection in children during prolonged oxidative stress after radiation exposure] Buchneva NN, et al. **Radiats Biol Radioecol** 1999 Mar–Jun;39(2–3):299–303 (Eng. Abstr.) **(Rus)**

GENETICS

Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T–cell phenotype. Said JW, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):257–60
An equine herpesvirus 1 mutant with a lacZ insertion between open reading frames 62 and 63 is replication competent and causes disease in the murine respiratory model. Csellner H, et al. **Arch Virol** 1998;143(11):2215–31
Infectious simian varicella virus expressing the green fluorescent protein. Mahalingam R, et al. **J Neurovirol** 1998 Aug;4(4):438–44
Additive effect of Sp1 and Sp3 in regulation of the ED–L1E promoter of the EBV LMP 1 gene in human epithelial cells. Tsai CN, et al. **Virology** 1999 Sep 1;261(2):288–94
[The viral genome status studied under the conditions of a mixed infection in lymphoblastoid cells by adenovirus and the Epstein–Barr virus] Nosach LN, et al. **Tsitol Genet** 1998 Jul–Aug;32(4):82–8 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. Secchiero P, et al. **Blood** 1998 Dec 15;92(12):4521–8
Unraveling immunity to gamma–herpesviruses: a new model for understanding the role of immunity in chronic virus infection. Virgin HW, et al. **Curr Opin Immunol** 1999 Aug; 11(4):371–9 (73 ref.)
Host and viral genetics of chronic infection: a mouse model of gamma–herpesvirus pathogenesis. Speck SH, et al.
Curr Opin Microbiol 1999 Aug;2(4):403–9 (44 ref.)
Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine gamma–herpesvirus infection. Stevenson PG, et al.
Eur J Immunol 1999 Apr;29(4):1059–67
The role of IL–12 in the control of MCMV is fundamentally different in mice with a retroviral immunodeficiency syndrome (MAIDS). Peacock CD, et al.
Immunol Cell Biol 1999 Apr;77(2):131–8
Cytomegaloviral control of MHC class I function in the mouse. Hengel H, et al. **Immunol Rev** 1999 Apr;168:167–76 (65 ref.)
Epstein–Barr virus and cytomegalovirus infections cause false–positive results in IgM two–test protocol for early Lyme borreliosis [letter] Goossens HA, et al. **Infection** 1999 May–Jun;27(3):231
A functional link for major TCR expansions in healthy adults caused by persistent Epstein–Barr virus infection. Silins SL, et al. **J Clin Invest** 1998 Oct 15;102(8):1551–8
Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus–seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. Cattani P, et al.
J Clin Microbiol 1999 Apr;37(4):1150–3
Induction of B cell hyperplasia in simian immunodeficiency virus–infected rhesus macaques with the simian homologue of Kaposi's sarcoma–associated herpesvirus. Wong SW, et al. **J Exp Med** 1999 Sep 20;190(6):827–40
Apparent MHC–independent stimulation of CD8+ T cells in vivo during latent murine gammaherpesvirus infection. Coppola MA, et al. **J Immunol** 1999 Aug 1;163(3):1481–9
Requirement for CD4+ T cells in V beta 4+CD8+ T cell activation associated with latent murine gammaherpesvirus infection. Flaño E, et al. **J Immunol** 1999 Sep 15; 163(6):3403–8
Lytic cycle T cell epitopes are expressed in two distinct phases during MHV–68 infection. Liu L, et al.
J Immunol 1999 Jul 15;163(2):868–74
Virus and autoimmunity: induction of autoimmune disease in mice by mouse T lymphotropic virus (MTLV) destroying CD4+ T cells. Morse SS, et al. **J Immunol** 1999 May 1;162(9):5309–16
Endogenous glucocorticoids protect against cytokine–mediated lethality during viral infection. Ruzek MC, et al. **J Immunol** 1999 Mar 15;162(6):3527–33
Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. Blackbourn DJ, et al. **J Infect Dis** 1999 Jan;179(1):237–9
HHV–8 infection and multiple myeloma. Sjak–Shie NN, et al. **J Leukoc Biol** 1999 Aug;66(2):357–60
High seroprevalence of antibodies to human herpesvirus–8 in Egyptian children: evidence of nonsexual transmission. Andreoni M, et al. **J Natl Cancer Inst** 1999 Mar 3; 91(5):465–9
Broad, intense anti–human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1–infected patients: comparison with anti–Epstein–Barr virus responses and changes during antiretroviral therapy. Dalod M, et al.
J Virol 1999 Sep;73(9):7108–16
Turnover of T cells in murine gammaherpesvirus 68–infected mice. Hamilton–Easton AM, et al. **J Virol** 1999 Sep; 73(9):7866–9
Non–antigen–specific B–cell activation following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo. Stevenson PG, et al.
J Virol 1999 Feb;73(2):1075–9
Reactivation of herpesvirus infections after vaccinations? [letter] Walter R, et al. **Lancet** 1999 Mar 6;353(9155):810
Role of macrophages in acute murine cytomegalovirus infection. Hamano S, et al. **Microbiol Immunol** 1998; 42(9):607–16
Significance of Epstein–Barr virus status and post–transplant lymphoproliferative disease in pediatric thoracic transplantation [see comments] Harwood JS, et al.
Pediatr Transplant 1999 May;3(2):100–3. Comment in: Pediatr Transplant 1999 May;3(2):95–9.
CD4(+) T cell–mediated control of a gamma–herpesvirus in B cell–deficient mice is mediated by IFN–gamma. Christensen JP, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5135–40
Virus–specific CD8(+) T cell numbers are maintained during gamma–herpesvirus reactivation in CD4–deficient mice. Stevenson PG, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15565–70
A gamma–herpesvirus sneaks through a CD8(+) T cell response primed to a lytic–phase epitope. Stevenson PG, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9281–6
Human herpesvirus 6 infection increases adhesion molecule expression in liver allografts. Lautenschlager I, et al.
Transplant Proc 1999 Feb–Mar;31(1–2):479–80
Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and L–selectin during primary viral infection in renal allograft recipients. ten Berge IJ, et al. **Transplant Proc** 1998 Dec;30(8):3975–7
Type I interferons and IRF–1 play a critical role in the control of a gammaherpesvirus infection. Dutia BM, et al.
Virology 1999 Sep 1;261(2):173–9
Primary and challenge infection of mice with equine herpesvirus 1, strain HSV25A. Walker C, et al.
Virus Res 1998 Oct;57(2):151–62
Protective immunity against equine herpesvirus type–1 (EHV–1) infection in mice induced by recombinant EHV–1 gD. Zhang Y, et al. **Virus Res** 1998 Jul;56(1):11–24
[Presence of antibodies to human herpesvirus type 6 and 7 in Hungarian children] Ongrádi J, et al. **Orv Hetil** 1999 Apr 25;140(17):935–40 (58 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Low rate of apoptosis and overexpression of bcl–2 in Epstein–Barr virus–associated gastric carcinoma. Kume T, et al. **Histopathology** 1999 Jun;34(6):502–9
Human herpesvirus 8 interleukin–6 (vIL–6) signals through gp130 but has structural and receptor–binding properties distinct from those of human IL–6. Wan X, et al.
J Virol 1999 Oct;73(10):8268–78
Constitutive cytokine production by primary effusion (body cavity–based) lymphoma–derived cell lines. Drexler HG, et al. **Leukemia** 1999 Apr;13(4):634–40
Levels of p53 in Epstein–Barr virus–infected cells determine cell fate: apoptosis, cell cycle arrest at the G1/S boundary without apoptosis, cell cycle arrest at the G2/M boundary without apoptosis, or unrestricted proliferation. Chen W, et al. **Virology** 1998 Nov 25;251(2):217–26

MORTALITY

Endogenous glucocorticoids protect against cytokine–mediated lethality during viral infection. Ruzek MC, et al. **J Immunol** 1999 Mar 15;162(6):3527–33

PATHOLOGY

Association of body cavity–based lymphoma and human herpesvirus 8 in an HIV–seronegative male. Report of a case with immunocytochemical and molecular studies. San Miguel P, et al. **Acta Cytol** 1999 Mar–Apr;43(2):299–302
Malignant lymphoma of the thyroid. A 30–year clinicopathologic experience and an evaluation of the presence of Epstein–Barr virus. Lam KY, et al.
Am J Clin Pathol 1999 Aug;112(2):263–70
Primary intracerebral Hodgkin's disease: report of a case with Epstein–Barr virus association and review of the literature. Klein R, et al. **Am J Surg Pathol** 1999 Apr;23(4):477–81 (31 ref.)
Preferential involvement of U–fibers in human herpesvirus 6–associated acute encephalopathy [letter] Kurachi Y, et al. **Ann Neurol** 1999 May;45(5):684
The new herpesviruses: emerging pathogens of dermatological interest. Drago F, et al. **Arch Dermatol** 1999 Jan;135(1):71–5 (110 ref.)
Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T–cell phenotype. Said JW, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):257–60
Lymphoepithelioma–like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein–Barr virus infection. Wang HH, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1214–9
Low rate of apoptosis and overexpression of bcl–2 in Epstein–Barr virus–associated gastric carcinoma. Kume T, et al. **Histopathology** 1999 Jun;34(6):502–9
The association between murine cytomegalovirus induced hepatitis and the accumulation of oval cells. Cassell HS, et al. **Int J Exp Pathol** 1998 Dec;79(6):433–41
Human herpesvirus–6 and sudden death in infancy: report of a case and review of the literature. Hoang MP, et al.
J Forensic Sci 1999 Mar;44(2):432–7 (26 ref.)
Requirement for cell–to–cell contact in Epstein–Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. Chang Y, et al. **J Virol** 1999 Oct; 73(10):8857–66
Bovine herpesvirus 1 can infect CD4(+) T lymphocytes and induce programmed cell death during acute infection of cattle. Winkler MT, et al. **J Virol** 1999 Oct;73(10):8657–68
Lymphoepithelioma–like carcinoma of the renal pelvis: a case report with immunohistochemical analysis and in situ hybridization for the Epstein–Barr viral genome. Fukunaga M, et al. **Mod Pathol** 1998 Dec;11(12):1252–6
Clinicopathological findings of virus–associated hemophagocytic syndrome in bone marrow: association with Epstein–Barr virus and apoptosis. Ohshima K, et al.
Pathol Int 1999 Jun;49(6):533–40
Clinicopathological study of severe chronic active Epstein–Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Ohshima K, et al. **Pathol Int** 1998 Dec; 48(12):934–43
X–linked lymphoproliferative disease: pathology and diagnosis. Maia DM, et al. **Pediatr Dev Pathol** 1999 Jan–Feb;2(1):72–7 (18 ref.)
Primary ocular Epstein–Barr virus–associated non–Hodgkin's lymphoma in a patient with AIDS: a clinicopathologic report. Mittra RA, et al. **Retina** 1999;19(1):45–50
[Modeling and characteristics of liver damage in herpes infection] Tereshko AB, et al. **Vopr Virusol** 1999 May–Jun; 44(3):120–4 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA, et al. **J Infect Dis** 1998 Dec; 178(6):1783–6
Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. Hudnall SD, et al. **J Infect Dis** 1998 Dec;178(6):1791–4
Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Kadakia MP.
Leuk Lymphoma 1998 Oct;31(3–4):251–66 (130 ref.)
Lymphoid disorders associated with HHV–8/KSHV infection: facts and contentions. Gaidano G, et al.
Med Oncol 1999 Apr;16(1):8–12
In vivo disturbance of hematopoiesis in mice persistently infected with murine cytomegalovirus: impairment of stromal cell function. Mori T, et al. **Virology** 1999 Jan 20; 253(2):145–54

PREVENTION & CONTROL

Allogeneic bone marrow transplantation: implications of herpesvirus screening and diagnosis. Barber S.
Br J Biomed Sci 1998 Dec;55(4):281–6 (27 ref.)
Herpesvirus vaccines. Development, controversies, and applications. Krause PR, et al.
Infect Dis Clin North Am 1999 Mar;13(1):61–81, vi (88 ref.)

Protection against murine cytomegalovirus retinitis by adoptive transfer of virus-specific CD8+ T cells. Bigger JE, et al. **Invest Ophthalmol Vis Sci** 1999 Oct; 40(11):2608-13

Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity. Steinbach F, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3005-14

Protection against herpes B virus infection in rabbits with a recombinant vaccinia virus expressing glycoprotein D. Bennett AM, et al. **J Med Virol** 1999 Jan;57(1):47-56

BHV-1: new molecular approaches to control a common and widespread infection. Turin L, et al. **Mol Med** 1999 May;5(5):261-84 (195 ref.)

Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV. Birkeland SA, et al. **Scand J Infect Dis** 1998;30(3):221-6

Prevention of symptomatic infection by herpesvirus in patients after heart transplantation. Arazi HC, et al. **Transplant Proc** 1999 Sep;31(6):2530

Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Birkeland SA, et al. **Transplantation** 1999 May 15;67(9):1209-14

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. McDiarmid SV, et al. **Transplantation** 1998 Dec 27; 66(12):1604-11

Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Aurelian L, et al. **Vaccine** 1999 Apr 9;17(15-16):1951-63

DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Ruitenberg KM, et al. **Vaccine** 1999 Jan 21;17(3):237-44

Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Stewart JP, et al. **Vaccine** 1999 Jan;17(2):152-7

Induction of immunity in the respiratory tract and protection from bovine herpesvirus type 1 infection by different routes of immunization with recombinant adenovirus. Papp Z, et al. **Viral Immunol** 1998;11(2):79-91

Immunization of neonates with DNA encoding a bovine herpesvirus glycoprotein is effective in the presence of maternal antibodies. Van Drunen Littel-van den Hurk S, et al. **Viral Immunol** 1999;12(1):67-77

Phenotypic and functional characterization of CD8(+) T cell clones specific for a mouse cytomegalovirus epitope. Fernandez JA, et al. **Virology** 1999 Mar 1;255(1):40-9

PSYCHOLOGY

[Naming impairment for man-made objects in a case of herpes encephalitis] Gaillard MJ, et al. **Rev Neurol (Paris)** 1998 Oct;154(10):683-9 (Eng. Abstr.) **(Fre)**

SURGERY

[Preoperative classification of malignant stomach tumors] Totkas S, et al. **Chirurg** 1999 Jun;70(6):713-7 (Eng. Abstr.) **(Ger)**

THERAPY

Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Ruther U, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):691-9

Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies. Moss DJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S80-3 (27 ref.)

TRANSMISSION

Cadaveric skin allograft-associated cytomegalovirus transmission in a mouse model of thermal injury. Kobayashi H, et al. **Clin Immunol** 1999 Aug;92(2):181-7

Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. Cattani P, et al. **J Clin Microbiol** 1999 Apr;37(4):1150-3

Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Smith NA, et al. **J Infect Dis** 1999 Sep;180(3):600-6

Detection of human herpesvirus 7 (HHV-7) DNA in breast milk by polymerase chain reaction and prevalence of HHV-7 antibody in breast-fed and bottle-fed children. Fujisaki H, et al. **J Med Virol** 1998 Nov;56(3):275-9

High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. Andreoni M, et al. **J Natl Cancer Inst** 1999 Mar 3; 91(5):465-9

Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8 [letter] Sitas F, et al. **N Engl J Med** 1999 Jun 17; 340(24):1923

[HPV infection as a disease of couples. Prevalence of the infection in the male partner] Atlante M, et al. **Minerva Ginecol** 1999 May;51(5):161-4 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Case report: hypoechoic submucosal nodules: a sign of Epstein-Barr virus-associated early gastric cancer [published erratum appears in J Gastroenterol Hepatol 1998 Oct;13(10):1080] Nishikawa J, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):585-90

VETERINARY

Prevalence of bovine herpesvirus 1 (BHV-1) infection in Hungarian cattle herds. Tekes L, et al. **Acta Vet Hung** 1999; 47(3):303-9

In situ hybridization for the detection of infectious laryngotracheitis virus in sections of trachea from experimentally infected chickens. Nielsen OL, et al. **Acta Vet Scand** 1998;39(4):415-21

Reintroduction of bovine herpes virus type 1 into Danish cattle herds during the period 1991-1995: a review of the investigations in the infected herds. Nylin B, et al. **Acta Vet Scand** 1998;39(4):401-13

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447-61 (60 ref.)

Detection of feline herpesvirus-specific antibodies and DNA in aqueous humor from cats with or without uveitis. Maggs DJ, et al. **Am J Vet Res** 1999 Aug;60(8):932-6

Questions efficacy of vaccinating cats at 3-year intervals [letter] Norsworthy GD. **Am J Vet Res** 1999 Aug; 60(8):918-9

Epidemiology of equine herpesvirus abortion: searching for clues to the future [comment] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):675-6 (12 ref.). Comment on: Aust Vet J 1998 Oct;76(10):677-82.

Seroprevalence of equine herpesvirus 1 in thoroughbred foals before and after weaning [see comments] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):677-82. Comment in: Aust Vet J 1998 Oct;76(10):675-6.

Detection of duck enteritis virus by polymerase chain reaction. Plummer PJ, et al. **Avian Dis** 1998 Jul-Sep; 42(3):554-64

Production of a falcon herpesvirus vaccine. Wernery U, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep; 112(9):339-44

Studies on the pathogenicity of bovine herpesvirus type 5 in sheep. Belák K, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jul;22(3):207-20

Periodic reappearance of bovine herpesvirus type 4 DNA in the sera of naturally and experimentally infected rabbits and calves. Egyed L, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jul;22(3):199-206

A preliminary study on the pathogenicity of a strain of caprine herpesvirus-1. Tempesta M, et al. **Comp Immunol Microbiol Infect Dis** 1999 Apr;22(2):137-43

BHV-1 infections in Styria (Austria) caused by intra-community trade. Köfer J, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Jun;106(6):231-3

Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1 infection in cats with acute respiratory tract or chronic ocular disease. Maggs DJ, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):502-7

Diva vaccines that reduce virus transmission. van Oirschot JT. **J Biotechnol** 1999 Aug 20;73(2-3):195-205 (69 ref.)

Systemic infection by equid herpesvirus-1 in a Grevy's zebra stallion (Equus grevyi) with particular reference to genital pathology. Blunden AS, et al. **J Comp Pathol** 1998 Nov; 119(4):485-93

Infection with equine herpesvirus 1 (EHV-1) strain HVS25A in pregnant mice. Walker C, et al. **J Comp Pathol** 1999 Jan;120(1):15-27

Neuropathological study of gazelle herpesvirus 1 (equine herpesvirus 9) infection in Thomson's gazelles (Gazella thomsoni). Yanai T, et al. **J Comp Pathol** 1998 Aug; 119(2):159-68

Modeling the effect of an outbreak of bovine herpesvirus type 1 on herd-level milk production of Dutch dairy farms. van Schaik G, et al. **J Dairy Sci** 1999 May;82(5):944-52

Latency-associated transcripts of equine herpesvirus type 4 in trigeminal ganglia of naturally infected horses. Borchers K, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2165-71

Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. Zakhartchouk AN, et al. **J Gen Virol** 1999 May;80 (Pt 5):1263-9

Comparison of PCR, virus isolation, and indirect fluorescent antibody staining in the detection of naturally occurring feline herpesvirus infections. Burgesser KM, et al. **J Vet Diagn Invest** 1999 Mar;11(2):122-6

Enzyme-linked immunosorbent assay for detection of feline herpesvirus 1 IgG in serum, aqueous humor, and cerebrospinal fluid. Dawson DA, et al. **J Vet Diagn Invest** 1998 Oct;10(4):315-9

Evaluation of an immunofluorescent antibody test to detect bovine herpesvirus 1-specific IgM. Graham DA, et al. **J Vet Diagn Invest** 1999 Jul;11(4):324-9

A viral epizootic in cultured populations of juvenile goldfish due to a putative herpesvirus etiology. Groff JM, et al. **J Vet Diagn Invest** 1998 Oct;10(4):375-8

An enzyme-linked immunosorbent assay using nuclear antigen for detection of feline herpesvirus 1 antibody. Satoh Y, et al. **J Vet Diagn Invest** 1999 Jul;11(4):334-40

Properties and functions of feline herpesvirus type 1 glycoproteins. Maeda K, et al. **J Vet Med Sci** 1998 Aug; 60(8):881-8 (97 ref.)

Detection of canine herpesvirus DNA in the ganglionic neurons and the lymph node lymphocytes of latently infected dogs. Miyoshi M, et al. **J Vet Med Sci** 1999 Apr; 61(4):375-9

Diagnosis and sero-epizootiology of equine herpesvirus type 1 and type 4 infections in Japan using a type-specific ELISA. Yasunaga S, et al. **J Vet Med Sci** 1998 Oct; 60(10):1133-7

Rhesus rhadinovirus establishes a latent infection in B lymphocytes in vivo. Bergquam EP, et al. **J Virol** 1999 Sep;73(9):7874-6

Development of a competitive ELISA for detection of primates infected with monkey B virus (Herpesvirus simiae). Blewett EL, et al. **J Virol Methods** 1999 Jan; 77(1):59-67

Diagnostic exercise: lethal pneumonia in neonatal kittens. Feinstein L, et al. **Lab Anim Sci** 1998 Apr;48(2):190-2

Diagnostic exercise: vesicular epidermal rash, mucosal ulcerations, and hepatic necrosis in a cynomolgus monkey (Macaca fascicularis). Treuting PM, et al. **Lab Anim Sci** 1998 Aug;48(4):384-6

Adaptive conjoint analysis to determine perceived risk factors of farmers, veterinarians and AI technicians for introduction of BHV1 to dairy farms. van Schaik G, et al. **Prev Vet Med** 1998 Dec 1;37(1-4):101-12

Virus suspect identified in elephant deaths [news; comment] Ferber D. **Science** 1999 Feb 19;283(5405):1093-4. Comment on: Science 1999 Feb 19;283(5405):1171-6.

Novel endotheliotropic herpesviruses fatal for Asian and African elephants [see comments] Richman LK, et al. **Science** 1999 Feb 19;283(5405):1171-6. Comment in: Science 1999 Feb 19;283(5405):1093-4.

Equine herpesvirus type 1 infects dendritic cells in vitro: stimulation of T lymphocyte proliferation and cytotoxicity by infected dendritic cells. Siedek EM, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):17-32

Protective effects of equine herpesvirus-1 (EHV-1) glycoprotein B in a murine model of EHV-1-induced abortion. Kukreja A, et al. **Vet Microbiol** 1998 Aug 15; 62(4):303-11

Prevalence of antibodies against canine herpesvirus 1 in dogs in The Netherlands in 1997-1998. Rijsewijk FA, et al. **Vet Microbiol** 1999 Feb 23;65(1):1-7

A high sensitivity-nested PCR assay for BHV-1 detection in semen of naturally infected bulls. Rocha MA, et al. **Vet Microbiol** 1998 Aug 28;63(1):1-11

Experimental infection of sheep with bovine herpesvirus type-5 (BHV-5): acute and latent infection. Silva AM, et al. **Vet Microbiol** 1999 Apr 1;66(2):89-99

Strains of bovine herpesvirus 1 that do not express an epitope on glycoprotein E in cell culture still induce antibodies that can be detected in a gE-blocking ELISA. van Oirschot JT, et al. **Vet Microbiol** 1999 Mar 1;65(2):103-13

Combined outbreak of the genital and conjunctival forms of bovine herpesvirus 1 infection in a UK dairy herd. Cook N. **Vet Rec** 1998 Nov 14;143(20):561-2

Detection of herpesvirus-like and papillomavirus-like particles associated with diseases of tortoises. Drury SE, et al. **Vet Rec** 1998 Dec 5;143(23):639

Antibody response to glycoprotein E after bovine herpesvirus type 1 infection in passively immunised, glycoprotein E-negative calves. Lemaire M, et al. **Vet Rec** 1999 Feb 13;144(7):172-6

Restriction endonuclease analysis of feline herpesvirus 1 DNA isolated from wild felids. Pratelli A, et al. **Vet Rec** 1999 May 8;144(19):537-8

Natural reactivation of caprine herpesvirus 1 in latently infected goats. Tempesta M, et al. **Vet Rec** 1998 Aug 15; 143(7):200

Possible case of EHV-4 ataxia in warmblood mare [letter] Verheyen K, et al. **Vet Rec** 1998 Oct 17;143(16):456

Detection of BHV-1 in a naturally infected bovine fetus by a nested PCR assay. Rocha MA, et al. **Vet Res Commun** 1999 Mar;23(2):133-41

Salmonellosis in relation to chlamydiosis and pox and Salmonella infections in captive falcons in the United Arab Emirates. Wernery U, et al. **Zentralbl Veterinarmed [B]** 1998 Dec;45(10):577-83

[Elephant herpes virus--a problem for breeding and housing of elephants] Burkhardt S, et al. **Berl Munch Tierarztl Wochenschr** 1999 Jun;112(5):174-9 (Eng. Abstr.) **(Ger)**

[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation] Neubauer A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep;112(9):351-4 (Eng. Abstr.) **(Ger)**

VIROLOGY

Clinical utility of PCR on cerebrospinal fluid for the diagnosis and management of HIV neurological complications [letter] Sadler M, et al. **AIDS** 1998 Dec 3;12(17):2352-3

Epstein-Barr virus-associated intravascular lymphomatosis within Kaposi's sarcoma in an AIDS patient. Hsiao CH, et al. **Am J Surg Pathol** 1999 Apr;23(4):482-7

Epstein-Barr virus-associated leiomyosarcoma of the thyroid in a child with congenital immunodeficiency: a case report.

Tulbah A, et al. **Am J Surg Pathol** 1999 Apr;23(4):473–6

Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Tisdale JF, et al. **Blood** 1998 Oct 15;92(8):2681–7

Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Tokunaga M, et al. **Cancer Epidemiol Biomarkers Prev** 1998 May;7(5):449–50

Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Akhtar N, et al. **Circulation** 1999 Apr 20; 99(15):2011–8

Hematogenously spread herpesviruses are detected as frequently as neuronally spread herpesviruses in cerebrospinal fluid by polymerase chain reaction assay. Studahl M, et al. **Clin Infect Dis** 1999 Jul;29(1):216–8

Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Wang FZ, et al. **Clin Infect Dis** 1999 Mar;28(3):562–8

Periodic reappearance of bovine herpesvirus type 4 DNA in the sera of naturally and experimentally infected rabbits and calves. Egyed L, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jul;22(3):199–206

Herpesvirus vaccines. Development, controversies, and applications. Krause PR, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):61–81, vi (88 ref.)

Meningoencephalitis caused by human herpesvirus-6 in an immunocompetent adult patient: case report and review of the literature. Torre D, et al. **Infection** 1998 Nov-Dec; 26(6):402–4 (28 ref.)

Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV-associated reactive and malignant lympho-proliferations. Berger C, et al. **Int J Cancer** 1999 May 5;81(3):371–5

An attractive relation of human herpesvirus-8 with multicentric Castleman's disease [editorial; comment] Katano H, et al. **Intern Med** 1999 Mar;38(3):221–2 (10 ref.) . Comment on: Intern Med 1999 Mar;38(3):279–82.

Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. Buisson M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2709–14

Detection of bovine herpesvirus type 1 in blood from naturally infected cattle by using a sensitive PCR that discriminates between wild-type virus and virus lacking glycoprotein E. Fuchs M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2498–507

Analysis of murine gammaherpesvirus-68 transcription during lytic and latent infection. Simas JP, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):75–82

Cellular localization of human herpesvirus 8 in nonneoplastic lymphadenopathies and chronic interstitial pneumonitis by in situ polymerase chain reaction studies. Trovato R, et al. **J Hum Virol** 1999 Jan-Feb;2(1):38–44

Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. Cone RW, et al. **J Infect Dis** 1999 Feb;179(2):311–8

Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. Maeda A, et al. **J Infect Dis** 1999 Apr;179(4):1012–5

Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections. Syrjänen S, et al. **J Oral Pathol Med** 1999 May; 28(5):204–9

Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. Lee MA, et al. **J Virol** 1999 Apr;73(4):2974–82

Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. Luppi M, et al. **J Virol** 1999 Jan; 73(1):754–9

The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component. Meindl A, et al. **J Virol** 1999 Apr;73(4):3430–7

Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. Pozo F, et al. **J Virol Methods** 1999 Apr;79(1):9–19

Reactivation of herpesvirus infections after vaccinations? [letter] Walter R, et al. **Lancet** 1999 Mar 6;353(9155):810

Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA. Ohyashiki JH, et al. **Leuk Res** 1999 Jul; 23(7):625–30

Encephalopathy associated with human herpesvirus 6 in a liver transplant recipient. Paterson DL, et al. **Liver Transpl Surg** 1999 Sep;5(5):454–5

Human herpesvirus 6. Dockrell DH, et al. **Mayo Clin Proc** 1999 Feb;74(2):163–70 (56 ref.)

Inhibition of human immunodeficiency virus 1 (HIV-1) by variant B of human herpesvirus 6 (HHV-6). Bonura F, et al. **New Microbiol** 1999 Jul;22(3):161–71

Human herpesvirus 8 in hematologic diseases. Mikala G, et al. **Pathol Oncol Res** 1999;5(1):73–9 (42 ref.)

Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes. Husain SM, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22; 96(13):7508–13

HHV-8 and multistep tumorigenesis [letter] Ensoli B, et al. **Trends Microbiol** 1999 Aug;7(8):310–2

Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Edwards RH, et al. **Virology** 1999 Aug 15;261(1):79–95

Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Meng YX, et al. **Virology** 1999 Aug 15; 261(1):106–19

Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Sugawara Y, et al. **Virology** 1999 Apr 10;256(2):196–202

Functional analysis of different LMP1 proteins isolated from Epstein-Barr virus-positive carriers. Fischer N, et al. **Virus Res** 1999 Mar;60(1):41–54

[Epstein-Barr virus and associated tumors] Raphaël M. **Ann Pathol** 1998;18(5 Suppl):74 **(Fre)**

[Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma] Niedobitek G. **Pathologe** 1998 Sep;19(5):337–44 (16 ref.) (Eng. Abstr.) **(Ger)**

[In vitro cytokine induction in leukocytes by human herpesvirus 7] Ongrádi J, et al. **Orv Hetil** 1999 Aug 29; 140(35):1935–9 (Eng. Abstr.) **(Hun)**

HERPESVIRUS 1 (ALPHA), BOVINE see **HERPESVIRUS 1, BOVINE**

HERPESVIRUS 1 (ALPHA), CANINE see **HERPESVIRUS 1, CANID**

HERPESVIRUS 1 (ALPHA), CERCOPITHECINE see **HERPESVIRUS 1, CERCOPITHECINE**

HERPESVIRUS 1 (ALPHA), EQUINE see **HERPESVIRUS 1, EQUID**

HERPESVIRUS 1 (ALPHA), GALLID see **HERPESVIRUS 1, GALLID**

HERPESVIRUS 1 (ALPHA), HUMAN see **HERPESVIRUS 1, HUMAN**

HERPESVIRUS 2 (ALPHA), HUMAN see **HERPESVIRUS 2, HUMAN**

HERPESVIRUS 3 (ALPHA), HUMAN see **HERPESVIRUS 3, HUMAN**

HERPESVIRUS 1 (ALPHA), SAIMIRINE see **SIMPLEXVIRUS**

HERPESVIRUS 1 (ALPHA), SUID see **HERPESVIRUS 1, SUID**

HERPESVIRUS 2, ATELINE see **RHADINOVIRUS**

HERPESVIRUS B see **HERPESVIRUS 1, CERCOPITHECINE**

HERPESVIRUS 5 (BETA), HUMAN see **CYTOMEGALOVIRUS**

HERPESVIRUS 1 (BETA), MURID see **MUROMEGALOVIRUS**

HERPESVIRUS 1, BOVINE

Bovine herpesvirus type 1 glycoprotein C expression in MDBK cells and its reactivity in enzyme-linked immunosorbent assay. Gupta PK, et al. **Acta Virol** 1998 Dec;42(6):397–400

BHV-1 infections in Styria (Austria) caused by intra-community trade. Köfer J, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Jun;106(6):231–3

Modeling the effect of an outbreak of bovine herpesvirus type 1 on herd-level milk production of Dutch dairy farms. van Schaik G, et al. **J Dairy Sci** 1999 May;82(5):944–52

Evaluation of an immunofluorescent antibody test to detect bovine herpesvirus 1-specific IgM. Graham DA, et al. **J Vet Diagn Invest** 1999 Jul;11(4):324–9

Bovine herpes virus expressing envelope protein (E2) of bovine viral diarrhea virus as a vaccine candidate. Kweon CH, et al. **J Vet Med Sci** 1999 Apr;61(4):395–401

Bovine herpesvirus 1 can infect CD4(+) T lymphocytes and induce programmed cell death during acute infection of cattle. Winkler MT, et al. **J Virol** 1999 Oct;73(10):8657–68

Adaptive conjoint analysis to determine perceived risk factors of farmers, veterinarians and AI technicians for introduction of BHV1 to dairy farms. van Schaik G, et al. **Prev Vet Med** 1998 Dec 1;37(1–4):101–12

An epidemiological and economic simulation model to evaluate the spread and control of infectious bovine rhinotracheitis in The Netherlands. Vonk Noordegraaf A, et al. **Prev Vet Med** 1998 Sep 1;36(3):219–38

CHEMISTRY

Construction and characterization of a glycoprotein E gene-deleted bovine herpesvirus type 1 recombinant. Chowdhury SI, et al. **Am J Vet Res** 1999 Feb;60(2):227–32

CLASSIFICATION

Comparative molecular epidemiological investigation on different bovine herpes viruses. Peshev R, et al. **Comp Immunol Microbiol Infect Dis** 1998 Oct;21(4):247–55

Epitopes on glycoprotein C of bovine herpesvirus-1 (BHV-1) that allow differentiation between BHV-1.1 and BHV-1.2 strains. Rijsewijk FA, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1477–83

GENETICS

Spontaneous BHV1 recombinants in which the gI/gE/US9 region is replaced by a duplication/inversion of the US1.5/US2 region. Rijsewijk FA, et al. **Arch Virol** 1999; 144(8):1527–37

Cloning and expression of bovine herpesvirus-1 glycoprotein C. Gupta PK, et al. **Biochem Mol Biol Int** 1999 Feb; 47(2):275–82

Detection of bovine herpesvirus type 1 in blood from naturally infected cattle by using a sensitive PCR that discriminates between wild-type virus and virus lacking glycoprotein E. Fuchs M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2498–507

Characterization of promoters integrated in the genome of bovine herpesvirus-1 (BHV-1). Murata T, et al. **J Vet Med Sci** 1999 May;61(5):453–7

GROWTH & DEVELOPMENT

Growth behavior of bovine herpesvirus-1 in permissive and semi-permissive cells. Murata T, et al. **Virus Res** 1999 May; 61(1):29–41

IMMUNOLOGY

Reintroduction of bovine herpes virus type 1 into Danish cattle herds during the period 1991–1995: a review of the investigations in the infected herds. Nylin B, et al. **Acta Vet Scand** 1998;39(4):401–13

Epitopes on glycoprotein C of bovine herpesvirus-1 (BHV-1) that allow differentiation between BHV-1.1 and BHV-1.2 strains. Rijsewijk FA, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1477–83

Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. Zakhartchouk AN, et al. **J Gen Virol** 1999 May;80 (Pt 5):1263–9

Encephalitis induced by bovine herpesvirus 5 and protection by prior vaccination or infection with bovine herpesvirus 1. Cascio KE, et al. **J Vet Diagn Invest** 1999 Mar; 11(2):134–9

Susceptibility of bovine antigen-presenting cells to infection by bovine herpesvirus 1 and in vitro presentation to T cells: two independent events. Renjifo X, et al. **J Virol** 1999 Jun; 73(6):4840–6

Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BHV-1) vaccine. Belknap EB, et al. **Vaccine** 1999 May 4;17(18):2297–305

The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Papp Z, et al. **Vaccine** 1999 Feb 26;17(7–8):933–43

Identification of murine cytotoxic T-lymphocyte epitopes of bovine herpesvirus 1. Zatechka DS Jr, et al. **Vaccine** 1999 Feb 26;17(7–8):686–94

A chimeric protein comprised of bovine herpesvirus type 1 glycoprotein D and bovine interleukin-6 is secreted by yeast and possesses biological activities of both molecules. Zhu X, et al. **Vaccine** 1999 Jan 21;17(3):269–82

Airborne transmission of BHV1, BRSV, and BVDV among cattle is possible under experimental conditions. Mars MH, et al. **Vet Microbiol** 1999 Apr 19;66(3):197–207

Strains of bovine herpesvirus 1 that do not express an epitope on glycoprotein E in cell culture still induce antibodies that can be detected in a gE-blocking ELISA. van Oirschot JT, et al. **Vet Microbiol** 1999 Mar 1;65(2):103–13

Antibody response to glycoprotein E after bovine herpesvirus type 1 infection in passively immunised, glycoprotein E-negative calves. Lemaire M, et al. **Vet Rec** 1999 Feb 13;144(7):172–6

Bovine lymphocyte antigen-A11--specific peptide motif as a means to identify cytotoxic T-lymphocyte epitopes of bovine herpesvirus 1. Hegde NR, et al. **Viral Immunol** 1999; 12(2):149–61

Induction of immunity in the respiratory tract and protection from bovine herpesvirus type 1 infection by different routes of immunization with recombinant adenovirus. Papp Z, et al. **Viral Immunol** 1998;11(2):79–91

Antigen-specific in vitro activation of T-lymphocyte subsets of cattle immunized with a modified live bovine herpesvirus 1 vaccine. Quade MJ, et al. **Viral Immunol** 1999;12(1):9–21

Immunization of neonates with DNA encoding a bovine herpesvirus glycoprotein is effective in the presence of maternal antibodies. Van Drunen Littel-van den Hurk S, et al. **Viral Immunol** 1999;12(1):67–77

Bovine herpesvirus 1-induced apoptotic cell death: role of glycoprotein D. Hanon E, et al. **Virology** 1999 Apr 25; 257(1):191–7

Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Zakhartchouk AN, et al. **Virology** 1998 Oct 10;250(1):220–9

ISOLATION & PURIFICATION

Detection of bovine herpesvirus type 1 in blood from naturally infected cattle by using a sensitive PCR that

discriminates between wild-type virus and virus lacking glycoprotein E. Fuchs M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2498–507

Improved detection of bovine herpesvirus 1 in artificially infected bovine semen by protein amplification. Zhou J, et al. **J Virol Methods** 1999 May;79(2):181–9

A high sensitivity-nested PCR assay for BHV-1 detection in semen of naturally infected bulls. Rocha MA, et al. **Vet Microbiol** 1998 Aug 28;63(1):1–11

A specific PCR to differentiate between gE negative vaccine and wildtype bovine herpesvirus type 1 strains. Schynts F, et al. **Vet Microbiol** 1999 Apr 19;66(3):187–95

Detection of BHV-1 in a naturally infected bovine fetus by a nested PCR assay. Rocha MA, et al. **Vet Res Commun** 1999 Mar;23(2):133–41

METABOLISM

Effect of bovine herpesvirus-1 or bovine viral diarrhea virus on development of in vitro-produced bovine embryos. Vanroose G, et al. **Mol Reprod Dev** 1999 Nov;54(3):255–63

PATHOGENICITY

Novel entry pathway of bovine herpesvirus 1 and 5. Wild P, et al. **J Virol** 1998 Dec;72(12):9561–6

BHV-1: new molecular approaches to control a common and widespread infection. Turin L, et al. **Mol Med** 1999 May;5(5):261–84 (195 ref.)

Combined outbreak of the genital and conjunctival forms of bovine herpesvirus 1 infection in a UK dairy herd. Cook N. **Vet Rec** 1998 Nov 14;143(20):561–2

PHYSIOLOGY

Evaluation of the effects of different trypsin treatments on semen quality after BHV-1 inactivation, and a comparison of the results before and after freezing, assessed by a computer image analyzer. Silva N, et al. **Anim Reprod Sci** 1999 Jan 29;54(4):227–35

Bovine herpesvirus 1 requires glycoprotein H for infectivity and direct spreading and glycoproteins gH(W450) and gB for glycoprotein D-independent cell-to-cell spread. Schröder C, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):57–61

Activation of caspases and p53 by bovine herpesvirus 1 infection results in programmed cell death and efficient virus release. Devireddy LR, et al. **J Virol** 1999 May; 73(5):3778–88

Cellular expression of bovine herpesvirus 1 gD inhibits cell-to-cell spread of two closely related viruses without blocking their primary infection. Dasika GK, et al. **Virology** 1999 Feb 1;254(1):24–36

[Apoptosis induced by bovine herpesvirus 1] Hanon E, et al. **Bull Mem Acad R Med Belg** 1998;153(10–11):405–13; discussion 412–3 (9 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Novel entry pathway of bovine herpesvirus 1 and 5. Wild P, et al. **J Virol** 1998 Dec;72(12):9561–6

HERPESVIRUS 1, CANID

GENETICS

Structure of the immediate early gene of canine herpesvirus. Miyoshi M, et al. **Arch Virol** 1999;144(2):407–20

Detection of canine herpesvirus DNA in the ganglionic neurons and the lymph node lymphocytes of latently infected dogs. Miyoshi M, et al. **J Vet Med Sci** 1999 Apr; 61(4):375–9

Construction of canine herpesvirus vector expressing foreign genes using a lacZ-TK gene cassette as a double selectional marker. Xuan X, et al. **Virus Genes** 1998;17(1):25–32

Identification and characterization of the glycoprotein E and I genes of canine herpesvirus. Nishikawa Y, et al. **Virus Res** 1998 Jul;56(1):77–92

IMMUNOLOGY

Prevalence of antibodies against canine herpesvirus 1 in dogs in The Netherlands in 1997–1998. Rijsewijk FA, et al. **Vet Microbiol** 1999 Feb 23;65(1):1–7

ISOLATION & PURIFICATION

Detection of high levels of canine herpes virus-1 neutralising antibody in kennel dogs using a novel serum neutralisation test. Reading MJ, et al. **Res Vet Sci** 1999 Jun;66(3):273–5

HERPESVIRUS 1, CERCOPITHECINE

Diagnostic exercise: vesicular epidermal rash, mucosal ulcerations, and hepatic necrosis in a cynomolgus monkey (Macaca fascicularis). Treuting PM, et al. **Lab Anim Sci** 1998 Aug;48(4):384–6

GENETICS

Infectious simian varicella virus expressing the green fluorescent protein. Mahalingam R, et al. **J Neurovirol** 1998 Aug;4(4):438–44

Molecular evidence for distinct genotypes of monkey B virus (herpesvirus simiae) which are related to the macaque host species. Smith AL, et al. **J Virol** 1998 Nov;72(11):9224–32

The existence of differing monkey B virus genotypes with possible implications for degree of virulence in humans. Hilliard JK, et al. **Lab Anim Sci** 1999 Feb;49(1):10–1

IMMUNOLOGY

Prevalence of herpes B virus antibody in nonhuman primates reared at the National University of Japan. Sato H, et al. **Exp Anim** 1998 Jul;47(3):199–202

Protection against herpes B virus infection in rabbits with a recombinant vaccinia virus expressing glycoprotein D. Bennett AM, et al. **J Med Virol** 1999 Jan;57(1):47–56

Development of a competitive ELISA for detection of primates infected with monkey B virus (Herpesvirus simiae). Blewett EL, et al. **J Virol Methods** 1999 Jan; 77(1):59–67

ISOLATION & PURIFICATION

B-virus specific-pathogen-free breeding colonies of macaques (Macaca mulatta): retrospective study of seven years of testing. Hilliard JK, et al. **Lab Anim Sci** 1999 Apr; 49(2):144–8

Fatal Cercopithecine herpesvirus 1 (B virus) infection following a mucocutaneous exposure and interim recommendations for worker protection. **MMWR Morb Mortal Wkly Rep** 1998 Dec 18; 47(49):1073–6, 1083

[Cytogenic characteristics and virogenic status of lymphoid cells from malignant baboon lymphomas] Agrba VZ, et al. **Vestn Ross Akad Med Nauk** 1999;(7):49–53 (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Molecular evidence for distinct genotypes of monkey B virus (herpesvirus simiae) which are related to the macaque host species. Smith AL, et al. **J Virol** 1998 Nov;72(11):9224–32

The existence of differing monkey B virus genotypes with possible implications for degree of virulence in humans. Hilliard JK, et al. **Lab Anim Sci** 1999 Feb;49(1):10–1

HERPESVIRUS 1, EQUID

Epidemiology of equine herpesvirus abortion: searching for clues to the future [comment] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):675–6 (12 ref.). Comment on: Aust Vet J 1998 Oct;76(10):677–82.

Diagnosis and sero-epizootiology of equine herpesvirus type 1 and type 4 infections in Japan using a type-specific ELISA. Yasunaga S, et al. **J Vet Med Sci** 1998 Oct; 60(10):1133–7

GENETICS

An equine herpesvirus 1 mutant with a lacZ insertion between open reading frames 62 and 63 is replication competent and causes disease in the murine respiratory model. Csellner H, et al. **Arch Virol** 1998;143(11):2215–31

The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component. Meindl A, et al. **J Virol** 1999 Apr;73(4):3430–7

Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects. Thomas SK, et al. **J Virol** 1999 Sep;73(9):7399–409

The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins. Kim SK, et al. **Virology** 1999 Apr 10; 256(2):173–9

The defective interfering particles of equine herpesvirus 1 encode an ICP22/ICP27 hybrid protein that alters viral gene regulation. Chen M, et al. **Virus Res** 1999 Feb; 59(2):149–64

Construction and characterization of an equine herpesvirus 1 glycoprotein C negative mutant. Osterrieder N. **Virus Res** 1999 Feb;59(2):165–77

The equid herpesvirus-1 gene 63 is expressed as a leaky late (gamma 1) transcript and is nonessential for replication in vitro. Purewal AS, et al. **Virus Res** 1998 Apr;54(2):189–95

[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation] Neubauer A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep;112(9):351–4 (Eng. Abstr.) **(Ger)**

GROWTH & DEVELOPMENT

In vitro reactivation of latent equid herpesvirus-1 from CD5+/CD8+ leukocytes indirectly by IL-2 or chorionic gonadotrophin. Smith DJ, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2997–3004

IMMUNOLOGY

Seroprevalence of equine herpesvirus 1 in thoroughbred foals before and after weaning [see comments] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):677–82. Comment in: Aust Vet J 1998 Oct;76(10):675–6.

Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity. Steinbach F, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3005–14

DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Ruitenberg KM, et al. **Vaccine** 1999 Jan 21;17(3):237–44

Protective effects of equine herpesvirus-1 (EHV-1) glycoprotein B in a murine model of EHV-1-induced abortion. Kukreja A, et al. **Vet Microbiol** 1998 Aug 15; 62(4):303–11

Primary and challenge infection of mice with equine herpesvirus 1, strain HSV25A. Walker C, et al. **Virus Res** 1998 Oct;57(2):151–62

Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD. Zhang Y, et al. **Virus Res** 1998 Jul;56(1):11–24

[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation] Neubauer A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep;112(9):351–4 (Eng. Abstr.) **(Ger)**

METABOLISM

The equine herpesvirus 1 IR6 protein that colocalizes with nuclear lamins is involved in nucleocapsid egress and migrates from cell to cell independently of virus infection. Osterrieder N, et al. **J Virol** 1998 Dec;72(12):9806–17

PATHOGENICITY

Systemic infection by equid herpesvirus-1 in a Grevy's zebra stallion (Equus grevyi) with particular reference to genital pathology. Blunden AS, et al. **J Comp Pathol** 1998 Nov; 119(4):485–93

Infection with equine herpesvirus 1 (EHV-1) strain HVS25A in pregnant mice. Walker C, et al. **J Comp Pathol** 1999 Jan;120(1):15–27

Neuropathological study of gazelle herpesvirus 1 (equine herpesvirus 9) infection in Thomson's gazelles (Gazella thomsoni). Yanai T, et al. **J Comp Pathol** 1998 Aug; 119(2):159–68

Equine herpesvirus type 1 infects dendritic cells in vitro: stimulation of T lymphocyte proliferation and cytotoxicity by infected dendritic cells. Siedek EM, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):17–32

Primary and challenge infection of mice with equine herpesvirus 1, strain HSV25A. Walker C, et al. **Virus Res** 1998 Oct;57(2):151–62

HERPESVIRUS 4, EQUID see **VARICELLOVIRUS**

HERPESVIRUS 1, GALLID

GENETICS

DNA sequence of the UL6 to UL20 genes of infectious laryngotracheitis virus and characterization of the UL10 gene product as a nonglycosylated and nonessential virion protein. Fuchs W, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2173–82

ISOLATION & PURIFICATION

In situ hybridization for the detection of infectious laryngotracheitis virus in sections of trachea from experimentally infected chickens. Nielsen OL, et al. **Acta Vet Scand** 1998;39(4):415–21

Use of polymerase chain reaction (PCR) for the detection of vaccine contamination by infectious laryngotracheitis virus. Vögtlin A, et al. **Vaccine** 1999 Jun 4;17(20–21):2501–6

METABOLISM

Infectious laryngotracheitis virus, an alpha herpesvirus that does not interact with cell surface heparan sulfate. Kingsley DH, et al. **Virology** 1999 Apr 10;256(2):213–9

HERPESVIRUS 2, GALLID

Occurrence of acute paralysis virus of the honey bee (Apis mellifera) in a Hungarian apiary infested with the parasitic mite Varroa jacobsoni. Békési L, et al. **Acta Vet Hung** 1999; 47(3):319–24

Ultrastructural recognition of dendritic cells in the intimal lesions of aortas of chickens affected with Marek's disease. Bobryshev YV, et al. **J Submicrosc Cytol Pathol** 1999 Apr; 31(2):179–85

GENETICS

Genome analysis of Marek's disease virus strain CVI-988: effect of cell culture passage on the inverted repeat regions. van Iddekinge BJ, et al. **Avian Dis** 1999 Apr-Jun; 43(2):182–8

Identification and transcriptional analysis of the homologues of the herpes simplex virus type 1 UL30 to UL40 genes in the genome of nononcogenic Marek's disease virus serotype 2. Izumiya Y, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2417–22

Cis-acting elements in the lytic origin of DNA replication of Marek's disease virus type 1. Katsumata A, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3015–8

Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family. Cai JS, et al. **J Vet Med Sci** 1999 May;61(5):503–11

Identification and DNA sequence analysis of the Marek's disease virus serotype 2 genes homologous to the herpes simplex virus type 1 UL20 and UL21. Hatama S, et al. **J Vet Med Sci** 1999 Jun;61(6):587–93

HERPESVIRUS 2, GALLID

Antisense oligonucleotide complementary to the BamHI-H gene family of Marek's disease virus induced growth arrest of MDCC-MSB1 cells in the S-phase. Hayashi M, et al. **J Vet Med Sci** 1999 Apr;61(4):389–94

Identification and sequence analysis of the Marek's disease virus serotype 2 gene homologous to the herpes simplex virus type 1 UL52 protein. Izumiya Y, et al. **J Vet Med Sci** 1999 Jun;61(6):683–7

Identification and sequence analysis of the Marek's disease virus serotype 2 homologous genes of the herpes simplex virus type 1 UL25, UL26 and UL26.5 genes. Kato K, et al. **J Vet Med Sci** 1999 Jul;61(7):787–93

Transcriptional analysis of Marek's disease virus (MDV) genes in MDV-transformed lymphoblastoid cell lines without MDV-activated cells. Ui M, et al. **J Vet Med Sci** 1998 Jul;60(7):823–9

Recombinant Marek's disease virus (MDV)-derived lymphoblastoid cell lines: regulation of a marker gene within the context of the MDV genome. Parcells MS, et al. **J Virol** 1999 Feb;73(2):1362–73

Lack of evidence for Marek's disease virus genomic sequences in leukocyte DNA from multiple sclerosis patients in Germany. Hennig H, et al. **Neurosci Lett** 1998 Jul 3;250(2):138–40

The genetic organization and transcriptional analysis of the short unique region in the genome of nononcogenic Marek's disease virus serotype 2. Jang HK, et al. **Virus Res** 1998 Nov;58(1–2):137–47

Gene arrangement and RNA transcription of the BamHI fragments K and M2 within the non-oncogenic Marek's disease virus serotype 2 unique long genome region. Tsushima Y, et al. **Virus Res** 1999 Mar;60(1):101–10

[Detection and typing of the genome of Marek's disease virus using polymerase chain reaction] Aminev AG, et al. **Mol Biol (Mosk)** 1998 Sep–Oct;32(5):916–22 **(Rus)**

IMMUNOLOGY

In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. Gagic M, et al. **Avian Dis** 1999 Apr–Jun;43(2):293–301

Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Tsukamoto K, et al. **Virology** 1999 May 10;257(2):352–62

ISOLATION & PURIFICATION

Re-isolation of Marek's disease virus from T cell subsets of vaccinated and non-vaccinated chickens. Lee SI, et al. **Arch Virol** 1999;144(1):45–54

Electron microscopic and immunohistochemical localization of Marek's disease (MD) herpesvirus particles in MD skin lymphomas. Cho KO, et al. **Vet Pathol** 1999 Jul; 36(4):314–20

METABOLISM

Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2. Liu JL, et al. **J Virol** 1999 May;73(5):4208–19

PATHOGENICITY

Response of embryonic chicken lymphocytes to in ovo exposure to lymphotropic viruses. St. Hill CA, et al. **Am J Vet Res** 1999 Aug;60(8):937–41

PHYSIOLOGY

T-cell transformation by Marek's disease virus. Ross NL. **Trends Microbiol** 1999 Jan;7(1):22–9 (62 ref.)

HERPESVIRUS 2 (GAMMA), ATELINE see **RHADINOVIRUS**

HERPESVIRUS 2 (GAMMA), GALLID see **HERPESVIRUS 2, GALLID**

HERPESVIRUS 4 (GAMMA), HUMAN see **HERPESVIRUS 4, HUMAN**

HERPESVIRUS 2 (GAMMA), SAIMIRINE see **HERPESVIRUS 2, SAIMIRINE**

HERPESVIRUS HOMINIS see **SIMPLEXVIRUS**

HERPESVIRUS 1, HUMAN

New developments in the epidemiology, natural history and management of genital herpes. Stanberry L, et al. **Antiviral Res** 1999 May;42(1):1–14 (90 ref.)

The effect of UV-B irradiation on primary and secondary HSV-1 infections in interleukin-4 knockout mice. El-Ghorr AA, et al. **Arch Dermatol Res** 1999 Jul–Aug; 291(7–8):459–65

Characteristics of a macrophage culture persistently infected with herpes simplex virus type 1. Bustos J, et al. **Arch Med Res** 1999 May–Jun;30(3):255–62

Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Tambasco FP, et al. **Arch Ophthalmol** 1999 Apr;117(4):445–9

Pathological case of the month. Eczema herpeticum. Bajoghli A, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):891–2

Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Beland JL, et al. **Blood** 1998 Dec 1;92(11):4472–8

Nuclear redistribution of BRCA1 during viral infection. Maul GG, et al. **Cell Growth Differ** 1998 Sep;9(9):743–55

Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: implication for gene therapy. Chun S, et al. **Cell Immunol** 1999 Jun 15;194(2):194–204

Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Bradley JD, et al. **Clin Cancer Res** 1999 Jun;5(6):1517–22

Coexistence of Pemphigus vulgaris and herpes simplex virus infection in oral mucosa diagnosed by cytology, immunohistochemistry, and polymerase chain reaction. Takahashi I, et al. **Diagn Cytopathol** 1998 Dec;19(6):446–50

Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Leissring MA, et al. **Drugs Aging** 1998 Sep;13(3):193–8 (31 ref.)

Apolipoprotein E and herpes virus diseases: herpes simplex keratitis. Lin WR, et al. **Eur J Hum Genet** 1999 Apr; 7(3):401–3

CD4+ T-cell type 1 and type 2 cytokines in the HSV-1 infected cornea. Heiligenhaus A, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 May; 237(5):399–406

Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Heiligenhaus A, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 May;237(5):435–8

Herpes simplex virus infection in pregnancy: diagnosis and significance. Desselberger U. **Intervirology** 1998; 41(4–5):185–90 (30 ref.)

Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Romanowski EG, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):378–84

Microcalorimetric study of antiviral effect of drug. Tan AM, et al. **J Biochem Biophys Methods** 1999 Feb 8;38(3):225–8

Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. Kobayashi H, et al. **J Immunol** 1999 Jun 15;162(12):7148–54

The organization of cerebellar and basal ganglia outputs to primary motor cortex as revealed by retrograde transneuronal transport of herpes simplex virus type 1. Hoover JE, et al. **J Neurosci** 1999 Feb 15;19(4):1446–63

Chemokines and ocular pathology caused by corneal infection with herpes simplex virus. Kumaraguru U, et al. **J Neurovirol** 1999 Feb;5(1):42–7 (39 ref.)

Epstein-Barr virus DNA in cerebrospinal fluid from an immunocompetent man with herpes simplex virus encephalitis. Portolani M, et al. **J Neurovirol** 1998 Aug; 4(4):461–4

Three-dimensional structure of herpes simplex virus type 1 glycoprotein D at 2.4-nanometer resolution. Pilling A, et al. **J Virol** 1999 Sep;73(9):7830–4

MRI follow-up of herpes simplex virus (type 1) radiculomyelitis. Küker W, et al. **Neurology** 1999 Mar 23; 52(5):1102–3

Caffeine inhibits paresthesia induced by herpes simplex virus through action on primary sensory neurons in rats. Shiraki K, et al. **Neurosci Res** 1998 Jul;31(3):235–40

Reactivation of herpes virus after surgery for epilepsy in a pediatric patient with mesial temporal sclerosis: case report. Bourgeois M, et al. **Neurosurgery** 1999 Mar;44(3):633–5; discussion 635–6

Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Chelbi-Alix MK, et al. **Oncogene** 1999 Jan 28;18(4):935–41

Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Nawawi A, et al. **Phytother Res** 1999 Feb;13(1):37–41

Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Nesburn AB, et al. **Virology** 1998 Dec 5;252(1):200–9

[Primary herpetic infection after transfixing keratoplasty] Rasquin F, et al. **Bull Soc Belge Ophtalmol** 1998;268:79–85 (Eng. Abstr.) **(Fre)**

CHEMISTRY

High level expression and structural characterisation of herpes simplex virus type I transcriptional activator VP16 (alpha-trans inducing factor). Spatz AM, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):235–8

Manipulation of herpes simplex virus type 1 by dielectrophoresis. Hughes MP, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):119–26

A novel protein tag from herpes simplex virus type 1 DNA polymerase. Schreiner U, et al. **Intervirology** 1999; 42(1):17–21

Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells. Morrison EE, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2517–28

Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. de Julián-Ortiz JV, et al. **J Med Chem** 1999 Aug 26;42(17):3308–14

Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase. Sun H, et al. **J Med Chem** 1999 Jul 1;42(13):2344–50

Colocalization of the herpes simplex virus 1 UL4 protein with infected cell protein 22 in small, dense nuclear structures formed prior to onset of DNA synthesis. Jahedi S, et al. **J Virol** 1999 Jun;73(6):5132–8

The herpes simplex virus triplex protein, VP23, exists as a molten globule. Kirkitadze MD, et al. **J Virol** 1998 Dec; 72(12):10066–72

CLASSIFICATION

Evaluation of ELVIS HSV ID/Typing System for the detection and typing of herpes simplex virus from clinical specimens. Turchek BM, et al. **J Clin Virol** 1999 Jan; 12(1):65–9

DRUG EFFECTS

Limited use of cationic liposomes as tools to enhance the antiherpetic activities of oligonucleotides in vero cells infected with herpes simplex virus type 1. Shoji Y, et al. **Antisense Nucleic Acid Drug Dev** 1998 Aug;8(4):255–63

Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Beadle JR, et al. **Antivir Chem Chemother** 1998 Jan;9(1):33–40

Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues. Meier C, et al. **Antivir Chem Chemother** 1998 Sep; 9(5):389–402

Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication. Sudo K, et al. **Antivir Chem Chemother** 1998 May;9(3):263–7

Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Watkins AM, et al. **Antivir Chem Chemother** 1998 Jan; 9(1):9–18

The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture. Lawetz C, et al. **Antiviral Res** 1998 Jul;39(1):35–46

The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Pope LE, et al. **Antiviral Res** 1998 Dec;40(1–2):85–94

Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus. Thompson KD. **Antiviral Res** 1998 Jul;39(1):55–61

Cidofovir and experimental herpetic stromal disease. Kaufman HE, et al. **Arch Ophthalmol** 1999 Jul;117(7):925–8

The mechanism of poly I:C-induced antiviral activity in peritoneal macrophage. Pyo S. **Arch Pharm Res** 1994 Apr; 17(2):93–9

Synthesis of [(2'S, 3'S)-bis(hydroxylmethyl)pyrrolidin-1-yl] purine and pyrimidine nucleosides as potential antiviral agents. Oohashi T, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1187–8

The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Anderson BJ. **Clin J Sport Med** 1999 Apr;9(2):86–90

The regulation of burn-associated infections with herpes simplex virus type 1 or Candida albicans by a non-toxic aconitine-hydrolysate, benzoylmesaconine. Part 2: Mechanism of the antiviral action. Kobayashi M, et al. **Immunol Cell Biol** 1998 Jun;76(3):209–16

The regulation of burn-associated infections with herpes simplex virus type 1 or Candida albicans by a non-toxic aconitine-hydrolysate, benzoylmesaconine. Part 1: Antiviral and anti-fungal activities in thermally injured mice. Kobayashi M, et al. **Immunol Cell Biol** 1998 Jun; 76(3):202–8

Antiviral activity of enterocin CRL35 against herpesviruses. Wachsman MB, et al. **Int J Antimicrob Agents** 1999 Aug; 12(4):293–9

Antiviral activity in Argentine medicinal plants. Kott V, et al. **J Ethnopharmacol** 1999 Jan;64(1):79–84

Effect of the extract of Annona muricata and Petunia nyctaginiflora on Herpes simplex virus. Padma P, et al. **J Ethnopharmacol** 1998 May;61(1):81–3

Antiherpes virus activity of extracts from the medicinal plant Geranium sanguineum L. Serkedjieva J, et al. **J Ethnopharmacol** 1999 Jan;64(1):59–68

The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. LeBlanc RA, et al. **J Infect Dis** 1999 Sep;180(3):594–9

A temporal analysis of acyclovir inhibition of induced herpes simplex virus type 1 In vivo reactivation in the mouse trigeminal ganglia. Sawtell NM, et al. **J Infect Dis** 1999 Sep;180(3):821–3

Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. Kudo E, et al. **J Med Virol** 1998 Oct;56(2):151–8

A new prenylated flavonol from the roots of Sophora flavescens. Woo ER, et al. **J Nat Prod** 1998 Dec; 61(12):1552–4

Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. Kurokawa M, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):72–8

Synthesis and biological application of a new heterodinucleotide with both anti-HSV and anti-HIV activity. Franchetti P, et al. **Nucleosides Nucleotides** 1999

Apr-May;18(4-5):989-90
Antiviral activity of sandalwood oil against herpes simplex viruses-1 and -2. Benencia F, et al. **Phytomedicine** 1999 May;6(2):119-23
Antiviral activity of some South American medicinal plants. Abad MJ, et al. **Phytother Res** 1999 Mar;13(2):142-6
Mechanism of antiviral activity of triterpenoid saponins. Simões CM, et al. **Phytother Res** 1999 Jun;13(4):323-8
Biological and chemical characterization of the fraction with antiherpetic activity from Achyrocline flaccida. García G, et al. **Planta Med** 1999 May;65(4):343-6
Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum [letter] Lee JB, et al. **Planta Med** 1999 Jun;65(5):439-41
Spectral and biological characteristics of some Acyclovir salts. Zaharia CN, et al. **Rom J Virol** 1997 Jan-Dec; 48(1-4):61-9
The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine against different herpes viruses. Neyts J, et al. **Transplantation** 1999 Mar 15;67(5):760-4
The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells. Aguilar JS, et al. **Virology** 1999 May 25;258(1):141-51
Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16. Preston CM, et al. **Virology** 1998 Sep 30;249(2):418-26
[Development of antiviral therapeutic agents from traditional medicines] Namba T, et al. **Yakugaku Zasshi** 1998 Sep; 118(9):383-400 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Effect of L-lysine-a-oxidase on reproduction of herpes simplex type 1 virus in vitro] Smirnova IP, et al. **Vopr Med Khim** 1998 Jul-Aug;44(4):384-7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

High-throughput screening assay for helicase enzymes. Sivaraja M, et al. **Anal Biochem** 1998 Dec 1;265(1):22-7
The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Gustafson EA, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2923-31
The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. Martin JA, et al. **Antivir Chem Chemother** 1998 Jan;9(1):1-8
Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Soler MN, et al. **Cancer Immunol Immunother** 1999 May-Jun; 48(2-3):91-9
Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Rubsam LZ, et al. **Cancer Res** 1999 Feb 1;59(3):669-75
Structure to 1.9 A resolution of a complex with herpes simplex virus type-1 thymidine kinase of a novel, non-substrate inhibitor: X-ray crystallographic comparison with binding of aciclovir. Bennett MS, et al. **FEBS Lett** 1999 Jan 25;443(2):121-5
Kinetic properties and stereospecificity of the monomeric dUTPase from herpes simplex virus type 1. Bergman AC, et al. **FEBS Lett** 1998 Dec 18;441(2):327-30
Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats. Engelmann C, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1545-51
Herpes simplex virus type 1 DNase: functional analysis of the enzyme expressed by recombinant baculovirus. Kehm E, et al. **Intervirology** 1998;41(2-3):110-9
The herpes simplex virus type 1 helicase-primase. Analysis of helicase activity. Falkenberg M, et al. **J Biol Chem** 1998 Nov 27;273(48):32154-7
The unique N terminus of herpes simplex virus type 1 ribonucleotide reductase large subunit is phosphorylated by casein kinase 2, which may have a homologue in Escherichia coli. Conner J. **J Gen Virol** 1999 Jun;80 (Pt 6):1471-6
Two-hybrid analysis of the interaction between the UL52 and UL8 subunits of the herpes simplex virus type 1 helicase-primase. Constantin N, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2411-5
Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. Gambhir SS, et al. **J Nucl Med** 1998 Nov;39(11):2003-11
Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. Degrève B, et al. **J Virol** 1998 Dec;72(12):9535-43
Effects of exonuclease activity and nucleotide selectivity of the herpes simplex virus DNA polymerase on the fidelity of DNA replication in vivo. Hwang YT, et al. **J Virol** 1999 Jul;73(7):5326-32
Splicing-independent expression of the herpes simplex virus type 1 thymidine kinase gene is mediated by three cis-acting RNA subelements. Otero GC, et al. **J Virol** 1998 Dec;72(12):9889-96
Activation of the thymidine kinase promoter by herpes simplex virus type 1 immediate early proteins. Kwun HJ, et al. **Mol Cells** 1999 Jun 30;9(3):277-80
Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Christians FC, et al. **Nat Biotechnol** 1999 Mar;17(3):259-64
Inhibition of a DNA-helicase by peptide nucleic acids. Bastide L, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):551-4
Interaction of the recombinant herpes simplex virus type 1 thymidine kinase with thymidine and aciclovir: a kinetic study. Kussmann-Gerber S, et al. **Nucleosides Nucleotides** 1999 Mar;18(3):311-30
Synthesis and molecular modeling of novel HSV1 uracil-DNA glycosylase inhibitors. Pregnolato M, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):709-11
Radiolabelled pyrimidine nucleosides to monitor the expression of HSV-1 thymidine kinase in gene therapy. Wiebe LI, et al. **Nucleosides Nucleotides** 1999 Apr-May; 18(4-5):1065-6
Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector. Marcello A, et al. **Res Virol** 1998 Nov-Dec;149(6):419-31
Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene. Cohen JL, et al. **Transgenic Res** 1998 Sep;7(5):321-30
DNA and protein interactions of the small subunit of herpes simplex virus type 1 DNA polymerase. Franz C, et al. **Virology** 1999 Jan 5;253(1):55-64
Functional conservations of the alkaline nuclease of herpes simplex type 1 and human cytomegalovirus. Gao M, et al. **Virology** 1998 Sep 30;249(2):460-70
Expression analysis of recombinant herpes simplex virus type 1 DNase. Kehm E, et al. **Virus Genes** 1998;17(2):129-38

GENETICS

Analysis of nucleotide sequence variations in herpes simplex virus types 1 and 2, and varicella-zoster virus. Chiba A, et al. **Acta Virol** 1998 Dec;42(6):401-7
HSV-1 thymidine kinase gene therapy for peritoneal carcinomatosis. Lechanteur C, et al. **Adv Exp Med Biol** 1998;451:115-9
Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. Carew JF, et al. **Am J Surg** 1998 Nov;176(5):404-8
Evolution of herpes simplex virus type 1 under herpesviral evolutionary processes. Umene K, et al. **Arch Virol** 1999; 144(4):637-56 (115 ref.)
Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy. Suzuki T, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):686-90
Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors. Simonato M, et al. **Brain Res** 1999 Jul 17;835(1):37-45 (41 ref.)
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Barnett FH, et al. **Cancer Gene Ther** 1999 Jan-Feb;6(1):14-20
Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Moriuchi S, et al. **Cancer Res** 1998 Dec 15;58(24):5731-7
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Tjuvajev JG, et al. **Cancer Res** 1998 Oct 1;58(19):4333-41
Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Meeker TC, et al. **Clin Cancer Res** 1997 Mar;3(3):357-64
Polymeric display of immunogenic epitopes from herpes simplex virus and transmissible gastroenteritis virus surface proteins on an enteroadherent fimbria. Rani DB, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):30-40
Detection of herpes simplex virus in aqueous humor in iridocorneal endothelial (ICE) syndrome. Groh MJ, et al. **Cornea** 1999 May;18(3):359-60
Identification of a herpes simplex virus-induced dendrite in an eye-bank donor cornea. Neufeld MV, et al. **Cornea** 1999 Jul;18(4):489-92
Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Miller CS, et al. **Crit Rev Oral Biol Med** 1998;9(4):541-62 (273 ref.)
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Krisky DM, et al. **Gene Ther** 1998 Dec;5(12):1593-603
Gene transfer using a disabled herpes virus vector containing the EMCV IRES allows multiple gene expression in vitro and in vivo. Wagstaff MJ, et al. **Gene Ther** 1998 Nov; 5(11):1566-70
High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Wang M, et al. **Gynecol Oncol** 1998 Nov; 71(2):278-87
Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Derby ML, et al. **Hear Res** 1999 Aug;134(1-2):1-8
Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Furlan R, et al. **Hum Gene Ther** 1998 Nov 20;9(17):2605-17
A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Klatzmann D, et al. **Hum Gene Ther** 1998 Nov 20;9(17):2585-94
A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Klatzmann D, et al. **Hum Gene Ther** 1998 Nov 20; 9(17):2595-604
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Saeki Y, et al. **Hum Gene Ther** 1998 Dec 10;9(18):2787-94
Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Toda M, et al. **Hum Gene Ther** 1998 Oct 10;9(15):2177-85
The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ). Ghiasi H, et al. **Intervirology** 1998;41(2-3):91-7
The herpes simplex virus 2 kb latency associated transcript (LAT) leader sequence allows efficient expression of downstream proteins which is enhanced in neuronal cells: possible function of LAT ORFs. Coffin RS, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3019-26
Identification and transcriptional analysis of the homologues of the herpes simplex virus type 1 UL30 to UL40 genes in the genome of nononcogenic Marek's disease virus serotype 2. Izumiya Y, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2417-22
Identification of a novel multifunctional structural domain in the herpes simplex virus type 1 genome: implications for virus latency. Quinn JP, et al. **J Gen Virol** 1998 Oct; 79 (Pt 10):2529-32
Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. Kudo E, et al. **J Med Virol** 1998 Oct;56(2):151-8
Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus. Saijo M, et al. **J Med Virol** 1999 Aug; 58(4):387-93
Tissue specific distribution of the herpes simplex virus type 1 latency-associated transcripts on polyribosomes during latent infection. Goldenberg D, et al. **J Neurovirol** 1998 Aug;4(4):426-32
Cyclosporin A reduces the inflammatory response to a multi-mutant herpes simplex virus type-1 leading to improved transgene expression in sympathetic preganglionic neurons in hamsters. Mabon PJ, et al. **J Neurovirol** 1999 Jun;5(3):268-79
Identification and structure of the Marek's disease virus serotype 2 glycoprotein M gene: comparison with glycoprotein M genes of Herpesviridae family. Cai JS, et al. **J Vet Med Sci** 1999 May;61(5):503-11
Genetic studies exposing the splicing events involved in herpes simplex virus type 1 latency-associated transcript production during lytic and latent infection. Alvira MR, et al. **J Virol** 1999 May;73(5):3866-76
Intrastrain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness. Bower JR, et al. **J Virol** 1999 May; 73(5):3843-53
The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. Cassady KA, et al. **J Virol** 1998 Nov;72(11):8620-6
Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK. Degrève B, et al. **J Virol** 1998 Dec;72(12):9535-43
Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. Galvan V, et al. **J Virol** 1999 Apr;73(4):3219-26
Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. Goins WF, et al. **J Virol** 1999 Jan; 73(1):519-32
Activation of herpesvirus gene expression by the human cytomegalovirus protein pp71. Homer EG, et al. **J Virol** 1999 Oct;73(10):8512-8
Regulated expression of a Sindbis virus replicon by herpesvirus promoters. Ivanova L, et al. **J Virol** 1999 Mar; 73(3):1998-2005
Transactivation of herpes simplex virus type 1 immediate-early gene expression by virion-associated factors is blocked by an inhibitor of cyclin-dependent protein kinases. Jordan R, et al. **J Virol** 1999 Oct; 73(10):8843-7
Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. Laquerre S, et al. **J Virol** 1998 Dec;72(12):9683-97
Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. Loutsch JM,

et al. **J Virol** 1999 Jan;73(1):767–71

Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US1.5 protein. Ogle WO, et al. **J Virol** 1999 May;73(5):4305–15

Splicing-independent expression of the herpes simplex virus type 1 thymidine kinase gene is mediated by three cis-acting RNA subelements. Otero GC, et al. **J Virol** 1998 Dec;72(12):9889–96

Activation of the thymidine kinase promoter by herpes simplex virus type 1 immediate early proteins. Kwun HJ, et al. **Mol Cells** 1999 Jun 30;9(3):277–80

Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. McKie EA, et al. **Neuropathol Appl Neurobiol** 1998 Oct;24(5):367–72

Highly variable distribution of HSV-1-specific DNA in human geniculate, vestibular and spiral ganglia. Schulz P, et al. **Neurosci Lett** 1998 Aug 14;252(2):139–42

A live non-neurovirulent herpes simplex virus vector expresses beta-galactosidase in the nervous system of the Wistar and Sprague-Dawley strain rat for a prolonged period. Shiraki K, et al. **Neurosci Lett** 1998 Apr 3; 245(2):69–72

Analysis of a multi-mutant herpes simplex virus type 1 for gene transfer into sympathetic preganglionic neurons and a comparison to adenovirus vectors. Levatte MA, et al. **Neuroscience** 1998 Oct;86(4):1321–36

Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Gambhir SS, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2333–8

Inhibition of viral gene expression by human ribonuclease P. Kawa D, et al. **RNA** 1998 Nov;4(11):1397–406

A perspective of gene therapy in the glaucomas. Kaufman PL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S91–7

Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene. Cohen JL, et al. **Transgenic Res** 1998 Sep;7(5):321–30

Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant. Drolet BS, et al. **Virology** 1999 Jan 5;253(1):96–106

LAT expression during an acute HSV infection in the mouse. Jarman RG, et al. **Virology** 1999 Sep 30;262(2):384–97

Posttranscriptional regulation of US11 in cells infected with a herpes simplex virus 1 recombinant lacking both 222-bp domains containing S-component origins of DNA synthesis. McCormick L, et al. **Virology** 1999 Jul 5; 259(2):286–98

A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Pelosi E, et al. **Virology** 1998 Dec 20;252(2):364–72

Herpes simplex virus 1 DNA cleavage/packaging: the UL28 gene encodes a minor component of B capsids. Taus NS, et al. **Virology** 1998 Dec 20;252(2):443–9

The herpes simplex virus 1 UL 17 gene is required for localization of capsids and major and minor capsid proteins to intranuclear sites where viral DNA is cleaved and packaged. Taus NS, et al. **Virology** 1998 Dec 5; 252(1):115–25

Characterization of the initiator and downstream promoter elements of herpes simplex virus 1 late genes. Woerner AM, et al. **Virology** 1998 Sep 30;249(2):219–30

[Advance of gene therapy for neurological diseases by direct in vivo gene transfer] Li BY, et al.
Sheng Li Ko Hsueh Chin Chan 1996 Jul;27(3):215–20 (20 ref.) (Eng. Abstr.) **(Chi)**

[French clinical trials of gene therapy with "suicide gene" (news)] Jeanteur P. **Bull Cancer** 1999 Feb;86(2):137–8 **(Fre)**

GROWTH & DEVELOPMENT

Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit [comment] Kaufman HE, et al. **Am J Ophthalmol** 1999 May;127(5):531–6. Comment on: Am J Ophthalmol 1999 May;127(5):602–4.

Latanoprost and herpes simplex keratitis [see comments] Wand M, et al. **Am J Ophthalmol** 1999 May;127(5):602–4 . Comment in: Am J Ophthalmol 1999 May;127(5):531–6.

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Benedetti JK, et al. **Ann Intern Med** 1999 Jul 6;131(1):14–20

A viral activator of gene expression functions via the ubiquitin-proteasome pathway. Everett RD, et al. **EMBO J** 1998 Dec 15;17(24):7161–9

Lack of detectable interaction between HSV-1 and integrins or tachykinins. Israel BA, et al. **Intervirology** 1998; 41(2-3):132–4

Herpes simplex keratitis after LASIK [letter] Davidorf JM. **J Refract Surg** 1998 Nov-Dec;14(6):667

Human corneal cells and other fibroblasts can stimulate the appearance of herpes simplex virus from quiescently infected PC12 cells. Su YH, et al. **J Virol** 1999 May; 73(5):4171–80

Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects. Thomas SK, et al. **J Virol** 1999 Sep;73(9):7399–409

Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency. Thomas SK, et al. **J Virol** 1999 Aug; 73(8):6618–25

IMMUNOLOGY

Herpes simplex virus in the trabeculum of an eye with corneal endotheliitis. Amano S, et al. **Am J Ophthalmol** 1999 Jun; 127(6):721–2

Natural killer (NK) cells prevent virus production in cell culture. Baraz L, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):179–89

The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Baker M, et al. **Brain Behav Immun** 1999 Sep;13(3):201–11 (64 ref.)

The differential impact of training stress and final examination stress on herpesvirus latency at the United States Military Academy at West Point. Glaser R, et al.
Brain Behav Immun 1999 Sep;13(3):240–51

Phenotypic characteristics associated with the acquisition of HSV-specific CD8 T-lymphocyte-mediated cytolytic function in vitro. McNally JM, et al. **Cell Immunol** 1999 May 25;194(1):103–11

Polymeric display of immunogenic epitopes from herpes simplex virus and transmissible gastroenteritis virus surface proteins on an enteroadherent fimbria. Rani DB, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):30–40

Herpes simplex virus vaccine in recurrent herpetic ocular infection. Pivetti-Pezzi P, et al. **Cornea** 1999 Jan; 18(1):47–51

The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Ghiasi H, et al. **Immunology** 1998 Nov;95(3):352–9

IgG and IgM antibodies of Herpes Simplex Virus type-1 and type-2 in 233 maternal and neonatal sera. Dong Z, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):69–70

Environmental influence on immune inhibition of release of herpes simplex virus from cells. Benitez J, et al.
Intervirology 1998;41(2-3):120–6

Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. Schmid DS, et al. **J Clin Microbiol** 1999 Feb;37(2):376–9

Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. Grabowska A, et al.
J Gen Virol 1999 Jul;80 (Pt 7):1789–98

Phenotypic identification of antigen-dependent and antigen-independent CD8 CTL precursors in the draining lymph node during acute cutaneous herpes simplex virus type 1 infection. McNally JM, et al. **J Immunol** 1999 Jul 15;163(2):675–81

Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. Noisakran S, et al. **J Immunol** 1999 Apr 1;162(7):4184–90

HSV-1 glycoprotein I-reactive TCR gamma delta cells directly recognize the peptide backbone in a conformationally dependent manner. Sciammas R, et al. **J Immunol** 1998 Nov 15;161(10):5187–92

Changes in intracellular cytokine levels in newborn and adult lymphocytes induced by HSV-1. Ito M, et al.
J Med Virol 1998 Oct;56(2):145–50

In the absence of T cells, natural killer cells protect from mortality due to HSV-1 encephalitis. Adler H, et al.
J Neuroimmunol 1999 Jan 1;93(1-2):208–13

B cell-deficient mice have increased susceptibility to HSV-1 encephalomyelitis and mortality. Beland JL, et al.
J Neuroimmunol 1999 Feb 1;94(1-2):122–6

Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. Noisakran S, et al. **J Neuroimmunol** 1999 Mar 1; 95(1-2):126–35

Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type-1. Song GY, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):1–7

Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis. Rösler A, et al. **J Neurol Sci** 1998 Apr 15;157(1):82–9

Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. Mikloska Z, et al. **J Virol** 1999 Jul;73(7):5934–44

Cell surface expression of H2 antigens on primary sensory neurons in response to acute but not latent herpes simplex virus infection in vivo. Pereira RA, et al. **J Virol** 1999 Aug;73(8):6484–9

The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. Wallace ME, et al. **J Virol** 1999 Sep;73(9):7619–26

Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. Hashido M, et al. **Microbiol Immunol** 1999; 43(2):177–80

Overproduction of gamma interferon in B/Jas inbred rabbits with herpes simplex virus encephalitis. Yuasa T, et al.
Microbiol Immunol 1999;43(4):365–71

A new subtraction technique for molecular cloning of rare antiviral antibody specificities from phage display libraries. Burioni R, et al. **Res Virol** 1998 Sep-Oct;149(5):327–30

Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Austin H, et al. **Sex Transm Dis** 1999 Jul;26(6):329–34

Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Arvaja M, et al.
Sex Transm Infect 1999 Jun;75(3):168–71

Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Munday PE, et al. **Sex Transm Infect** 1998 Jun;74(3):175–8

Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice. Ghiasi H, et al.
Vaccine 1999 Jun 4;17(20-21):2576–82

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Rosenthal KS, et al. **Vaccine** 1999 Feb 12; 17(6):535–42

Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. Brehm M, et al. **Virology** 1999 Apr 10;256(2):258–69

Resistance to herpetic stromal keratitis in immunized B-cell-deficient mice. Daheshia M, et al. **Virology** 1999 Apr 25;257(1):168–76

Specific and nonspecific immune stimulation of MHC-II-deficient mice results in chronic HSV-1 infection of the trigeminal ganglia following ocular challenge. Ghiasi H, et al. **Virology** 1999 Jun 5;258(2):208–16

ISOLATION & PURIFICATION

Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Arbusow V, et al. **Ann Neurol** 1999 Sep; 46(3):416–9

Manipulation of herpes simplex virus type 1 by dielectrophoresis. Hughes MP, et al.
Biochim Biophys Acta 1998 Sep 16;1425(1):119–26

Black esophagus associated with herpes esophagitis. Cattan P, et al. **Gastrointest Endosc** 1999 Jan;49(1):105–7

Detection of herpes simplex virus DNA in human spermatozoa by in situ hybridization technique. Kotronias D, et al. **In Vivo** 1998 Jul-Aug;12(4):391–4

Detection of herpes simplex virus in genital specimens by type-specific polymerase chain reaction. Waldhuber MG, et al. **Int J STD AIDS** 1999 Feb;10(2):89–92

Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies. Liljeqvist JA, et al. **J Clin Microbiol** 1999 Aug;37(8):2717–8

Presence of HSV-1 DNA in semen and menstrual blood. El Borai N, et al. **J Reprod Immunol** 1998 Dec; 41(1-2):137–47

Persistence of herpes simplex virus type 1 DNA in chronic conjunctival and eyelid lesions of mice. Maggs DJ, et al. **J Virol** 1998 Nov;72(11):9166–72

Localization of a passively transferred human recombinant monoclonal antibody to herpes simplex virus glycoprotein D to infected nerve fibers and sensory neurons in vivo. Sanna PP, et al. **J Virol** 1999 Oct;73(10):8817–23

Apolipoprotein E and herpes simplex virus 1 in Alzheimer's disease [letter; comment] Corder E, et al. **Lancet** 1998 Oct 17;352(9136):1312–3. Comment on: Lancet 1998 Jul 18;352(9123):238.

Chronic active destructive herpes simplex encephalitis with recovery of viral DNA 12 years after disease onset. Asenbauer B, et al. **Neuropediatrics** 1998 Jun;29(3):120–3

The natural history of primary herpes simplex type 1 gingivostomatitis in children. Amir J, et al.
Pediatr Dermatol 1999 Jul-Aug;16(4):259–63

PCR-based diagnosis of a case of herpetic whitlow in an AIDS patient. Nogueira ML, et al.
Rev Inst Med Trop Sao Paulo 1998 Sep-Oct;40(5):317–9

[Virology, epidemiology and diagnosis of herpes genitalis] Chenot JF, et al. **Dtsch Med Wochenschr** 1999 Feb 12; 124(6):158–62 (31 ref.) **(Ger)**

METABOLISM

Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. Chapman TL, et al. **J Biol Chem** 1999 Mar 12; 274(11):6911–9

Identification and characterization of the herpes simplex virus type 1 UL51 gene product. Daikoku T, et al.
J Gen Virol 1998 Dec;79 (Pt 12):3027–31

Identification of the UL4 protein of herpes simplex virus type 1. Eide T, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3033–8

A novel cellular protein, p60, interacting with both herpes simplex virus 1 regulatory proteins ICP22 and ICP0 is modified in a cell-type-specific manner and Is recruited to the nucleus after infection. Bruni R, et al. **J Virol** 1999 May;73(5):3810–7

Herpes simplex virus 1 regulatory protein ICP22 interacts with a new cell cycle-regulated factor and accumulates in a cell cycle-dependent fashion in infected cells. Bruni R, et al. **J Virol** 1998 Nov;72(11):8525–31

The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. Cassady KA, et al.
J Virol 1998 Nov;72(11):8620–6

In vitro processing of herpes simplex virus type 1 DNA replication intermediates by the viral alkaline nuclease, UL12. Goldstein JN, et al. **J Virol** 1998 Nov;72(11):8772–81

Physical and functional interactions between the herpes simplex virus UL15 and UL28 DNA cleavage and packaging proteins. Koslowski KM, et al. **J Virol** 1999 Feb; 73(2):1704–7

Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor–bearing cells. Laquerre S, et al. **J Virol** 1998 Dec;72(12):9683–97

ICP22 and the UL13 protein kinase are both required for herpes simplex virus–induced modification of the large subunit of RNA polymerase II. Long MC, et al. **J Virol** 1999 Jul;73(7):5593–604

Modified VP22 localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection. Pomeranz LE, et al. **J Virol** 1999 Aug;73(8):6769–81

The murine homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies virus but not herpes simplex virus types 1 and 2. Shukla D, et al. **J Virol** 1999 May;73(5):4493–7

Analysis of the phosphorylation sites of herpes simplex virus type 1 regulatory protein ICP27. Zhi Y, et al. **J Virol** 1999 Apr;73(4):3246–57

Expression of the enhanced green fluorescent protein by herpes simplex virus type 1 (HSV-1) as an in vitro or in vivo marker for virus entry and replication. Foster TP, et al. **J Virol Methods** 1998 Nov;75(2):151–60

Induction of interferon-alpha by glycoprotein D of herpes simplex virus: a possible role of chemokine receptors. Ankel H, et al. **Virology** 1998 Nov 25;251(2):317–26

Functional characterization of the HveA homolog specified by African green monkey kidney cells with a herpes simplex virus expressing the green fluorescence protein. Foster TP, et al. **Virology** 1999 Jun 5;258(2):365–74

Herpes simplex virus induces intracellular redistribution of E2F4 and accumulation of E2F pocket protein complexes. Olgiate J, et al. **Virology** 1999 Jun 5;258(2):257–70

Stable ubiquitination of the ICP0R protein of herpes simplex virus type 1 during productive infection. Weber PC, et al. **Virology** 1999 Jan 20;253(2):288–98

Domains of glycoprotein H of herpes simplex virus type 1 involved in complex formation with glycoprotein L. Westra DF, et al. **Virology** 1999 Aug 15;261(1):96–105

Self-interaction of the herpes simplex virus type 1 regulatory protein ICP27. Zhi Y, et al. **Virology** 1999 May 10; 257(2):341–51

PATHOGENICITY

Electrorotation studies of baby hamster kidney fibroblasts infected with herpes simplex virus type 1. Archer S, et al. **Biophys J** 1999 May;76(5):2833–42

Lack of detectable interaction between HSV-1 and integrins or tachykinins. Israel BA, et al. **Intervirology** 1998; 41(2–3):132–4

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. Chung RY, et al. **J Virol** 1999 Sep; 73(9):7556–64

Persistence of herpes simplex virus type 1 DNA in chronic conjunctival and eyelid lesions of mice. Maggs DJ, et al. **J Virol** 1998 Nov;72(11):9166–72

Generation and use of recombinant reporter viruses for study of herpes simplex virus infections in vivo. Bloom DC, et al. **Methods** 1998 Sep;16(1):117–25

A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Van Sant C, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8184–9

A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Pelosi E, et al. **Virology** 1998 Dec 20;252(2):364–72

PHYSIOLOGY

The survival of herpes simplex virus in multidose office ophthalmic solutions. Romanowski EG, et al. **Am J Ophthalmol** 1999 Aug;128(2):239–40

Herpes simplex virus type 1 inhibits in vitro differentiation and selected functions of human blood-derived monocytes. Bruun T, et al. **APMIS** 1998 Dec;106(12):1194–203

Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Miller CS, et al. **Crit Rev Oral Biol Med** 1998;9(4):541–62 (273 ref.)

Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. Everett RD, et al. **EMBO J** 1999 Mar 15;18(6):1526–38

Infection of rat brain cell aggregates with neurovirulent and nonneurovirulent strains of herpes simplex virus type 1. Rødahl E, et al. **Exp Cell Res** 1999 Apr 10;248(1):306–13

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Kooby DA, et al. **FASEB J** 1999 Aug; 13(11):1325–34

Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Carew JF, et al. **Hum Gene Ther** 1999 Jul 1;10(10):1599–606

HSV-1 migration in latently infected and naive rabbits after penetrating keratoplasty. Zheng X, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2490–7

Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. Calistri A, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):90–8

The interaction of herpes simplex type 1 virus origin-binding protein (UL9 protein) with Box I, the high affinity element of the viral origin of DNA replication. Lee SS, et al. **J Biol Chem** 1999 Jun 25;274(26):18613–7

Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1. Zachos G, et al. **J Biol Chem** 1999 Feb 19;274(8):5097–103

ATF/CREB elements in the herpes simplex virus type 1 latency-associated transcript promoter interact with members of the ATF/CREB and AP-1 transcription factor families. Millhouse S, et al. **J Biomed Sci** 1998 Nov-Dec; 5(6):451–64

A study of primary neuronal infection by mutants of herpes simplex virus type 1 lacking dispensable and non-dispensable glycoproteins. Babic N, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2403–9

Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. Hukkanen V, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2149–55

Translational control of viral and host protein synthesis during the course of herpes simplex virus type 1 infection: evidence that initiation of translation is the limiting step. Laurent AM, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2765–75

Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. Kodukula P, et al. **J Immunol** 1999 Mar 1;162(5):2895–905

The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. Ghiasi H, et al. **J Infect Dis** 1999 May;179(5):1086–93

Establishment of a quiescent herpes simplex virus type 1 infection in neurally-differentiated PC12 cells. Danaher RJ, et al. **J Neurovirol** 1999 Jun;5(3):258–67

Heat stress activates production of herpes simplex virus type 1 from quiescently infected neurally differentiated PC12 cells. Danaher RJ, et al. **J Neurovirol** 1999 Aug;5(4):374–83

Differential anterograde transport of HSV type 1 viral strains in the murine optic pathway. Garner JA, et al. **J Neurovirol** 1999 Apr;5(2):140–50

Differential effects on the survival of neuronal and non-neuronal cells after infection by herpes simplex virus type 1 mutants. Garrido JJ, et al. **J Neurovirol** 1999 Jun; 5(3):280–8

The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. Aubert M, et al. **J Virol** 1999 Apr; 73(4):2803–13

ND10 protein PML is recruited to herpes simplex virus type 1 prereplicative sites and replication compartments in the presence of viral DNA polymerase. Burkham J, et al. **J Virol** 1998 Dec;72(12):10100–7

Role for gamma interferon in control of herpes simplex virus type 1 reactivation. Cantin E, et al. **J Virol** 1999 Apr; 73(4):3418–23

The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. Cocchi F, et al. **J Virol** 1998 Dec;72(12):9992–10002

Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. Elliott G, et al. **J Virol** 1999 May;73(5):4110–9

The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication. Everett RD, et al. **J Virol** 1999 Jan;73(1):417–26

Genetic analysis of the role of herpes simplex virus type 1 glycoprotein K in infectious virus production and egress. Foster TP, et al. **J Virol** 1999 Oct;73(10):8457–68

Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. Hobbs WE 2nd, et al. **J Virol** 1999 Oct;73(10):8245–55

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. Hunter WD, et al. **J Virol** 1999 Aug;73(8):6319–26

Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. LeBlanc RA, et al. **J Virol** 1999 Oct;73(10):8145–51

Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. Loutsch JM, et al. **J Virol** 1999 Jan;73(1):767–71

Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. McLean TI, et al. **J Virol** 1999 Oct;73(10):8415–26

The U(L)3 protein of herpes simplex virus 1 is translated predominantly from the second in-frame methionine codon and is subject to at least two posttranslational modifications. Markovitz NS, et al. **J Virol** 1999 Oct;73(10):8010–8

Assembly of the herpes simplex virus procapsid from purified components and identification of small complexes containing the major capsid and scaffolding proteins. Newcomb WW, et al. **J Virol** 1999 May;73(5):4239–50

Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. Parkinson J, et al. **J Virol** 1999 Jan;73(1):650–7

A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation. Perng GC, et al. **J Virol** 1999 Feb;73(2):920–9

Packaging-competent capsids of a herpes simplex virus temperature-sensitive mutant have properties similar to those of in vitro-assembled procapsids. Rixon FJ, et al. **J Virol** 1999 Jul;73(7):5714–21

Proteolytic cleavage of the amino terminus of the U(L)15 gene product of herpes simplex virus type 1 is coupled with maturation of viral DNA into unit-length genomes. Salmon B, et al. **J Virol** 1999 Oct;73(10):8338–48

Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: an in vivo study of virus antigen and cytokines. Shimeld C, et al. **J Virol** 1999 Mar;73(3):1767–73

Reactivation of herpes virus after lamellar keratoplasty. Zheng X, et al. **Jpn J Ophthalmol** 1999 Jul–Aug; 43(4):257–61

The V domain of herpesvirus Ig-like receptor (HIgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D. Cocchi F, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15700–5

Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin. Loregian A, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5221–6

A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Van Sant C, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8184–9

The normal association between newly replicated DNA and the nuclear matrix is abolished in cells infected by herpes simplex virus type 1. Aranda-Anzaldo A. **Res Virol** 1998 Jul–Aug;149(4):195–208

A surprising role for the proteasome in the regulation of herpesvirus infection. Everett RD. **Trends Biochem Sci** 1999 Aug;24(8):293–5 (29 ref.)

Cellular expression of bovine herpesvirus 1 gD inhibits cell-to-cell spread of two closely related viruses without blocking their primary infection. Dasika GK, et al. **Virology** 1999 Feb 1;254(1):24–36

Comparison of the intranuclear distributions of herpes simplex virus proteins involved in various viral functions. de Bruyn Kops A, et al. **Virology** 1998 Dec 5;252(1):162–78

Second site mutations in the N-terminus of the major capsid protein (VP5) overcome a block at the maturation cleavage site of the capsid scaffold proteins of herpes simplex virus type 1. Desai P, et al. **Virology** 1999 Sep 1;261(2):357–66

Role of nitric oxide in pathogenesis of herpes simplex virus encephalitis in rats. Fujii S, et al. **Virology** 1999 Apr 10; 256(2):203–12

The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Panagiotidis CA, et al. **Virology** 1999 Mar 30; 256(1):64–74

Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16. Preston CM, et al. **Virology** 1998 Sep 30;249(2):418–26

Herpes simplex virus entry is associated with tyrosine phosphorylation of cellular proteins. Qie L, et al. **Virology** 1999 Apr 10;256(2):220–7

The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems. Tal-Singer R, et al. **Virology** 1999 Jun 20; 259(1):20–33

Interference of the low-pH inactivated herpes simplex virus type 1 (HSV-1) strain HSZP with the early shutoff function of superinfecting HSV-1 strain KOS. Matis J, et al. **Virus Res** 1999 Mar;60(1):81–6

ULTRASTRUCTURE

Infection of the corneal endothelium in herpes simplex keratitis. Holbach LM, et al. **Am J Ophthalmol** 1998 Oct; 126(4):592–4

Roles of triplex and scaffolding proteins in herpes simplex virus type 1 capsid formation suggested by structures of recombinant particles. Saad A, et al. **J Virol** 1999 Aug; 73(8):6821–30

Visualization of tegument–capsid interactions and DNA in intact herpes simplex virus type 1 virions. Zhou ZH, et al. **J Virol** 1999 Apr;73(4):3210–8

Identification of the UL56 protein of herpes simplex virus type 1 within the virion by immuno electron microscopy. Kehm R, et al. **Virus Genes** 1998;17(1):49–53

HERPESVIRUS 2, HUMAN

Successful acyclovir treatment of herpes simplex type 2 hepatitis in a patient with systemic lupus erythematosus: a case report and meta analysis. Chung AB, et al. **Am J Med Sci** 1998 Dec;316(6):404–7

New developments in the epidemiology, natural history and management of genital herpes. Stanberry L, et al. **Antiviral Res** 1999 May;42(1):1–14 (90 ref.)

Acquired lymphedema of the hand due to herpes simplex virus type 2 [letter] Butler DF, et al. **Arch Dermatol** 1999

Sep;135(9):1125–6
You're the flight surgeon. Herpes simplex virus type 2(HSV-2). Fisher CR Jr. **Aviat Space Environ Med** 1999 Apr;70(4):351–2
Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study [see comments] Perez G, et al. **Int J Infect Dis** 1998 Jul-Sep;3(1):5–11. Comment in: Int J Infect Dis 1998 Jul-Sep;3(1):1–4.
Seroprevalence of herpes simplex virus type 2 antibodies in an STD clinic in Paris. Janier M, et al. **Int J STD AIDS** 1999 Aug;10(8):522–6
Performance of a rapid screening test POCkit HSV2 Rapid Test [letter] Ly TD, et al. **Int J STD AIDS** 1999 Jan; 10(1):68
Risk factors for herpes simplex virus type 2 infection among female commercial sex workers in Mexico City. Uribe-Salas F, et al. **Int J STD AIDS** 1999 Feb; 10(2):105–11
Pneumococcal pneumonia associated with perianal herpes simplex virus type 2 in a HIV seropositive patient [letter] Clarke S, et al. **J Eur Acad Dermatol Venereol** 1998 Nov; 11(3):257–8
Nucleolar localization of the UL3 protein of herpes simplex virus type 2. Yamada H, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2157–64
Neonatal stridor in association with herpes simplex infection of the larynx. Sharp HR, et al. **J Laryngol Otol** 1998 Dec; 112(12):1192–3 (7 ref.)
Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. White PJ, et al. **Sex Transm Infect** 1999 Feb; 75(1):49–54
[Iatrogenic aseptic meningitis (letter)] Bonnotte B, et al. **Presse Med** 1998 Jun 20;27(22):1102 **(Fre)**
[Recurrent Mollaret's meningitis of herpetic origin] Gignoux L, et al. **Presse Med** 1998 Oct 3;27(29):1470–2 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Identification and characterization of the UL14 gene product of herpes simplex virus type 2. Wada K, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2423–31

CLASSIFICATION

Genital herpes: review of the epidemic and potential use of type-specific serology. Ashley RL, et al. **Clin Microbiol Rev** 1999 Jan;12(1):1–8 (139 ref.)
Evaluation of ELVIS HSV ID/Typing System for the detection and typing of herpes simplex virus from clinical specimens. Turchek BM, et al. **J Clin Virol** 1999 Jan; 12(1):65–9

DRUG EFFECTS

A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Howett MK, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):314–21
3-Hydroxyphthaloyl beta-lactoglobulin. IV Antiviral activity in the mouse model of genital herpesvirus infection. Kokuba H, et al. **Antivir Chem Chemother** 1998 Jul; 9(4):353–7
Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo. Watkins AM, et al. **Antivir Chem Chemother** 1998 Jan; 9(1):9–18
Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Bourne KZ, et al. **Antiviral Res** 1999 Jul; 42(3):219–26
The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Pope LE, et al. **Antiviral Res** 1998 Dec;40(1–2):85–94
Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus. Thompson KD. **Antiviral Res** 1998 Jul;39(1):55–61
Antiviral activity of enterocin CRL35 against herpesviruses. Wachsman MB, et al. **Int J Antimicrob Agents** 1999 Aug; 12(4):293–9
A new prenylated flavonol from the roots of Sophora flavescens. Woo ER, et al. **J Nat Prod** 1998 Dec; 61(12):1552–4
Quantitation of herpes simplex viral DNA in Vero cells for evaluation of an antiviral agent using the polymerase chain reaction. Dan K, et al. **J Virol Methods** 1998 Dec; 76(1–2):73–9
Antiviral activity of sandalwood oil against herpes simplex viruses-1 and -2. Benencia F, et al. **Phytomedicine** 1999 May;6(2):119–23

ENZYMOLOGY

The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase. Martin JA, et al. **Antivir Chem Chemother** 1998 Jan;9(1):1–8
US3 protein kinase of herpes simplex virus type 2 plays a role in protecting corneal epithelial cells from apoptosis in infected mice. Asano S, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):51–6
The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. Smith CC, et al. **J Virol** 1998 Nov;72(11):9131–41
Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Christians FC, et al. **Nat Biotechnol** 1999 Mar;17(3):259–64
[Structural organization of 2C-terminal region and its analogs in a subunit of ribonucleotide reductase from herpes virus] Akhmedov NA, et al. **Bioorg Khim** 1998 Aug;24(8):586–92 (Eng. Abstr.) **(Rus)**

GENETICS

Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis. Jensenius M, et al. **Acta Neurol Scand** 1998 Sep;98(3):209–12
Analysis of nucleotide sequence variations in herpes simplex virus types 1 and 2, and varicella-zoster virus. Chiba A, et al. **Acta Virol** 1998 Dec;42(6):401–7
Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Boursnell ME, et al. **Adv Exp Med Biol** 1998;451:379–84
The herpes simplex virus 2 kb latency associated transcript (LAT) leader sequence allows efficient expression of downstream proteins which is enhanced in neuronal cells: possible function of LAT ORFs. Coffin RS, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3019–26
Characterization of the herpes simplex virus type 2 (HSV-2) US2 gene product and a US2-deficient HSV-2 mutant. Jiang YM, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2777–84
The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. Smith CC, et al. **J Virol** 1998 Nov;72(11):9131–41
Genomic heterogeneity maps to tandem repeat sequences in the herpes simplex virus type 2 UL region. Yamaguchi T, et al. **Virus Res** 1998 Jun;55(2):221–31

GROWTH & DEVELOPMENT

Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Benedetti JK, et al. **Ann Intern Med** 1999 Jul 6;131(1):14–20
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. Schacker T, et al. **J Infect Dis** 1998 Dec;178(6):1616–22

IMMUNOLOGY

The primary production of an infectious recombinant Herpes Simplex Virus vaccine. O'Keeffe R, et al. **Biotechnol Bioeng** 1998 Feb 5;57(3):262–71
The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. O'Keeffe RS, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):537–45
Herpes. Vaccines for HSV. Stanberry LR. **Dermatol Clin** 1998 Oct;16(4):811–6, xiv (27 ref.)
Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Sin JI, et al. **Eur J Immunol** 1998 Nov;28(11):3530–40
MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Reichstetter S, et al. **Hum Immunol** 1999 Jul;60(7):608–18
Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Parr MB, et al. **Immunology** 1998 Oct; 95(2):208–13
IgG and IgM antibodies of Herpes Simplex Virus type-1 and type-2 in 233 maternal and neonatal sera. Dong Z, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):69–70
Prevalence of herpes simplex type 2 antibodies and a clinical history of herpes in three different populations in Campinas City, Brazil. Carvalho M, et al. **Int J Infect Dis** 1998-99 Winter;3(2):94–8
Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. Ashley RL, et al. **J Clin Microbiol** 1999 May; 37(5):1632–3
Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera. Eis-Hübinger AM, et al. **J Clin Microbiol** 1999 May;37(5):1242–6
Limits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2. Schmid DS, et al. **J Clin Microbiol** 1999 Feb;37(2):376–9
Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. Grabowska A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1789–98
IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. Sin JI, et al. **J Immunol** 1999 Mar 1; 162(5):2912–21
Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. Obasi A, et al. **J Infect Dis** 1999 Jan;179(1):16–24
Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? García-Corbeira P, et al. **J Med Virol** 1999 Oct;59(2):194–7
Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. Zeitlin L, et al. **J Reprod Immunol** 1998 Oct; 40(1):93–101
Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. Blaney JE Jr, et al. **J Virol** 1998 Dec; 72(12):9567–74
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. Sin JI, et al. **J Virol** 1999 Jan;73(1):501–9
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group [see comments] Corey L, et al. **JAMA** 1999 Jul 28;282(4):331–40. Comment in: JAMA 1999 Jul 28;282(4):379–80.
Herpes simplex virus vaccines--why don't antibodies protect? [editorial; comment] Mascola JR. **JAMA** 1999 Jul 28;282(4):379–80. Comment on: JAMA 1999 Jul 28;282(4):331–40.
Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan. Hashido M, et al. **Microbiol Immunol** 1999; 43(2):177–80
A new subtraction technique for molecular cloning of rare antiviral antibody specificities from phage display libraries. Burioni R, et al. **Res Virol** 1998 Sep-Oct;149(5):327–30
Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Austin H, et al. **Sex Transm Dis** 1999 Jul;26(6):329–34
Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease [see comments] Diamond C, et al. **Sex Transm Dis** 1999 Apr;26(4):221–5. Comment in: Sex Transm Dis 1999 Apr;26(4):226–7.
Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Dobbins JG, et al. **Sex Transm Dis** 1999 Feb;26(2):67–74
Clinical misidentification of patients with first episode genital herpes: a note of caution [editorial; comment] Fife KH, et al. **Sex Transm Dis** 1999 Apr;26(4):226–7. Comment on: Sex Transm Dis 1999 Apr;26(4):221–5.
Prevention agenda for genital herpes. Handsfield HH, et al. **Sex Transm Dis** 1999 Apr;26(4):228–31
Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Arvaja M, et al. **Sex Transm Infect** 1999 Jun;75(3):168–71
Evaluation of a novel point of care test for antibodies to herpes simplex virus type 2 [letter] Ashley RL, et al. **Sex Transm Infect** 1998 Jun;74(3):228–9
Herpes simplex type 2 infection in a cohort aged 21 years. Eberhart-Phillips J, et al. **Sex Transm Infect** 1998 Jun; 74(3):216–8
Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Munday PE, et al. **Sex Transm Infect** 1998 Jun;74(3):175–8
Control of STDs--the role of prophylactic vaccines against herpes simplex virus. Stanberry LR. **Sex Transm Infect** 1998 Dec;74(6):391–4 (40 ref.)
Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Aurelian L, et al. **Vaccine** 1999 Apr 9;17(15–16):1951–63
Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Bernstein DI, et al. **Vaccine** 1999 Apr 9; 17(15–16):1964–9
Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. O'Hagan D, et al. **Vaccine** 1999 May 4;17(18):2229–36
A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Singh M, et al. **Vaccine** 1998 Nov;16(19):1822–7
The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Parr MB, et al. **Virology** 1999 Jun 5;258(2):282–94
[Antibodies against Herpes simplex virus type 2 among pregnant women in Norway] Eskild A, et al. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2323–6 (Eng. Abstr.) **(Nor)**

ISOLATION & PURIFICATION

Sequential peripartum herpes simplex virus type 2 disease in parents and their newborn mimicking intrafamily spread of common viruses. Klauber EV, et al. **Am J Perinatol** 1999;16(1):43–5
The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. O'Keeffe RS, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):537–45
Atypical presentation of herpes simplex virus in a patient with chronic lymphocytic leukemia. Brown TS, et al. **Cutis** 1999 Aug;64(2):123–5
Seroprevalence study of herpes simplex virus type 2 among pregnant women in Germany using a type-specific enzyme immunoassay. Enders G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):870–2
Herpetic salpingitis and fallopian tube prolapse. Lefrancq T, et al. **Histopathology** 1999 Jun;34(6):548–50
Detection of herpes simplex virus DNA in human

spermatozoa by in situ hybridization technique. Kotronias D, et al. **In Vivo** 1998 Jul-Aug;12(4):391-4
Detection of herpes simplex virus in genital specimens by type-specific polymerase chain reaction. Waldhuber MG, et al. **Int J STD AIDS** 1999 Feb;10(2):89-92
Fulminant herpes hepatitis in a healthy adult: a treatable disorder? Velasco M, et al. **J Clin Gastroenterol** 1999 Jun; 28(4):386-9
Typing of clinical herpes simplex virus type 1 and type 2 isolates with monoclonal antibodies. Liljeqvist JA, et al. **J Clin Microbiol** 1999 Aug;37(8):2717-8
Evaluation of a fully automated glycoprotein G-2 based assay for the detection of HSV-2 specific IgG antibodies in serum and plasma. Groen J, et al. **J Clin Virol** 1999 May; 12(3):193-200
Disseminated herpes simplex virus infection in a renal transplant patient as possible cause of repeated urinary extravasations. Gómez E, et al. **Nephron** 1999;82(1):59-64
Successful treatment of generalized primary herpes simplex type 2 infection during pregnancy. Anderson R, et al. **Scand J Infect Dis** 1999;31(2):201-2
Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. Wald A, et al. **Sex Transm Dis** 1999 Jan;26(1):1-3
[Virology, epidemiology and diagnosis of herpes genitalis] Chenot JF, et al. **Dtsch Med Wochenschr** 1999 Feb 12; 124(6):158-62 (31 ref.) **(Ger)**

METABOLISM

The murine homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies virus but not herpes simplex virus types 1 and 2. Shukla D, et al. **J Virol** 1999 May;73(5):4493-7

PATHOGENICITY

Induction of apoptosis in HEp-2 cells by infection with herpes simplex virus type 2. Koyama AH, et al. **Arch Virol** 1998;143(12):2435-41
Strategies to control the genital herpes epidemic. Schinazi RB. **Math Biosci** 1999 Jul;159(2):113-21
Progression of intravaginal infection by herpes simplex-2 in genetically athymic mice. Sanjuan NA. **Medicina (B Aires)** 1998;58(5 Pt 1):492-6

PHYSIOLOGY

NF-kappaB activation is responsible for the synergistic effect of herpes simplex virus type 2 infection on interferon-gamma-induced nitric oxide production in macrophages. Paludan SR, et al. **J Gen Virol** 1998 Nov; 79 (Pt 11):2785-93
Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity. Bour SP, et al. **J Virol** 1999 Jan;73(1):778-82
The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. Cocchi F, et al. **J Virol** 1998 Dec;72(12):9992-10002
The V domain of herpesvirus Ig-like receptor (HIgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D. Cocchi F, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15700-5
Herpes simplex virus entry is associated with tyrosine phosphorylation of cellular proteins. Qie L, et al. **Virology** 1999 Apr 10;256(2):220-7
[Fatal fulminating hepatitis due to Herpes simplex virus type 2 in a young immunocompetent female] Chauveau E, et al. **Med Trop (Mars)** 1999;59(1):58-60 (Eng. Abstr.) **(Fre)**

HERPESVIRUS 3, HUMAN

Multifocal varicella-zoster virus leukoencephalitis in a patient with AIDS: MR findings. Aygun N, et al. **AJNR Am J Neuroradiol** 1998 Nov-Dec;19(10):1897-9
Recent advances in varicella-zoster virus infection. Cohen JI, et al. **Ann Intern Med** 1999 Jun 1;130(11):922-32 (104 ref.)
Cerebral infarction associated with vasculitis due to varicella zoster virus in patients infected with the human immunodeficiency virus. Picard O, et al. **Biomed Pharmacother** 1997;51(10):449-54
Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. Bilgrami S, et al. **Bone Marrow Transplant** 1999 Mar;23(5):469-74
Varicella-zoster virus disease and epidemiology: seeking better control strategies--Part 1. Bentsi-Enchill A. **Can Commun Dis Rep** 1998 Dec 15;24(24):193-8 **(Eng, Fre)**
Varicella-zoster screening and management programs in healthcare facilities in Canada. Lussier N, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):562-3
Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Estrada-Parra S, et al. **Int J Immunopharmacol** 1998 Oct;20(10):521-35
Varicella-zoster virus infections in pregnancy. Sauerbrei A. **Intervirology** 1998;41(4-5):191-6
Varicella zoster virus. McCrary ML, et al. **J Am Acad Dermatol** 1999 Jul;41(1):1-14; quiz 15-6 (168 ref.)
Bullous erythema multiforme following herpes zoster and varicella-zoster virus infection. Weisman K, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):147-50
Proceedings of the 3rd International Conference on the Varicella-Zoster Virus. Palm Beach Gardens, Florida, USA. 9-11 March 1997. **J Infect Dis** 1998 Nov;178 Suppl 1:S1-112
VZV fulminant necrotizing encephalitis with concomitant EBV-related lymphoma and CMV ventriculitis: report of an AIDS case. Nebuloni M, et al. **J Neurovirol** 1998 Aug; 4(4):457-60
[Varicella-zoster virus meningo-encephalomyelitis without skin eruption] Sissoko D, et al. **Ann Biol Clin (Paris)** 1998 Mar-Apr;56(2):211-2 **(Fre)**
[Otorhinolaryngological manifestations of varicella-zoster virus] Bravo Dominguez O, et al. **Acta Otorrinolaringol Esp** 1999 Apr;50(3):225-7 (Eng. Abstr.) **(Spa)**
[Acute myocarditis caused by varicella virus] Noriega Peiró F, et al. **Rev Esp Cardiol** 1998 Aug;51(8):677-9 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Ida M, et al. **Antiviral Res** 1999 Jan;40(3):155-66
Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. Visse B, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S55-7
Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. Visse B, et al. **J Med Virol** 1999 Sep; 59(1):84-90
Synergistic anti-varicella-zoster virus activity of interferon-alpha 2a and acyclovir in corneal cells. Punda-Polić V, et al. **Zentralbl Bakteriol** 1999 Apr; 289(2):203-10

ENZYMOLOGY

Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. Visse B, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S55-7

GENETICS

Analysis of nucleotide sequence variations in herpes simplex virus types 1 and 2, and varicella-zoster virus. Chiba A, et al. **Acta Virol** 1998 Dec;42(6):401-7
Correlation of varicella-zoster virus copies and final visual acuities of acute retinal necrosis syndrome. Abe T, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Oct;236(10):747-52
The varicella-zoster virus (VZV) open-reading frame 29 protein acts as a modulator of a late VZV gene promoter. Boucaud D, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S34-8
Baculovirus expression, purification, and properties of varicella-zoster virus gE, gI, and the complex they form. Kimura H, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S13-5
Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. LaRussa P, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S64-6
Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids. Mallory S, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S22-6
Anatomy of the varicella-zoster virus open-reading frame 4 promoter. Michael EJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S27-33
Viral gene expression in rat trigeminal ganglia following neonatal infection with varicella-zoster virus. Brunell PA, et al. **J Med Virol** 1999 Jul;58(3):286-90
Analysis of strain variation of R1 repeated structure in varicella-zoster virus DNA by polymerase chain reaction. Yoshida M, et al. **J Med Virol** 1999 May;58(1):76-8
Rapid diagnosis of varicella zoster virus infection in acute facial palsy. Murakami S, et al. **Neurology** 1998 Oct; 51(4):1202-5
Rapid contamination with varicella-zoster virus DNA to the throat of a daycare attendee and environmental surfaces from a child with varicella. Asano Y, et al. **Pediatr Int** 1999 Apr;41(2):233-6
Varicella-zoster virus: less immutable than once thought. Grose C. **Pediatrics** 1999 May;103(5 Pt 1):1027-8
Transcript mapping and transregulatory behavior of varicella-zoster virus gene 21, a latency-associated gene. Xia D, et al. **Virology** 1999 Jun 5;258(2):304-13
[Case of varicella-zoster pneumonia with bronchioalveolar lavage confirmed by the detection of VZV DNA in the bronchial washing by the polymerase chain reaction] Saito S, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):346-50 (12 ref.) (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

Recurrent nodular scleritis associated with varicella zoster virus. Livir-Rallatos C, et al. **Am J Ophthalmol** 1998 Oct; 126(4):594-7
Computational and experimental investigation of flow and particle settling in a roller bottle bioreactor. Muzzio FJ, et al. **Biotechnol Bioeng** 1999 Apr 20;63(2):185-96
Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. Mo C, et al. **J Virol** 1999 May;73(5):4197-207
Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Satoh N, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):185-8

IMMUNOLOGY

A cost-effectiveness model for analyzing two varicella vaccination strategies. Gayman J. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S4-8
Varicella immunity: persistent serologic non-response to immunization. Katial RK, et al. **Ann Allergy Asthma Immunol** 1999 May;82(5):431-4
Seroprevalence of varicella antibodies among new house officers. Alagappan K, et al. **Ann Emerg Med** 1999 May; 33(5):516-9
Susceptibility to varicella-zoster infection in individuals 1 to 29 years of age in Mexico. Alvarez y Muñoz MT, et al. **Arch Med Res** 1999 Jan-Feb;30(1):60-3
Varicella-zoster virus immune evasion. Abendroth A, et al. **Immunol Rev** 1999 Apr;168:143-56 (123 ref.)
Seroconversion rates in healthcare workers using a latex agglutination assay after varicella virus vaccination. Weinstock DM, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):504-7
Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Schünemann S, et al. **Intervirology** 1998;41(2-3):98-102
Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE, et al. **J Immunol** 1999 Jan 1;162(1):560-7
A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Berger R, et al. **J Infect Dis** 1998 Nov; 178 Suppl 1:S99-103
Cytokine production in varicella-zoster virus-stimulated cultures of human blood lymphocytes. Hayward AR, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S95-8
Cellular immunity to varicella-zoster virus in patients with major depression [published erratum appears in J Infect Dis 1999 Mar;179(3):753] Irwin M, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S104-8
Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. Jenkins DE, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S39-42
Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. Jenkins DE, et al. **J Infect Dis** 1998 Oct;178(4):940-8
Varicella-zoster virus-specific cellular immunity in subjects given acyclovir after household chickenpox exposure. Kumagai T, et al. **J Infect Dis** 1999 Sep;180(3):834-7
Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. Sadzot-Delvaux C, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S43-7
Ability of yeast Ty-VLPs (virus-like particles) containing varicella-zoster virus (VZV)gE and assembly protein fragments to induce in vitro proliferation of human lymphocytes from VZV immune patients. Welsh MD, et al. **J Med Virol** 1999 Sep;59(1):78-83
The value of cerebrospinal fluid antiviral antibody in the diagnosis of neurologic disease produced by varicella zoster virus. Gilden DH, et al. **J Neurol Sci** 1998 Aug 14; 159(2):140-4
Detection of serum antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus 6 in patients with recurrent aphthous stomatitis. Ghodratnama F, et al. **J Oral Pathol Med** 1999 Jan;28(1):12-5
Expression of interleukin-2 receptor, CD25, on CD4 lymphocytes in response to varicella-zoster virus antigen among patients with malignancies immunized with live attenuated varicella vaccine. Oitani K. **Pediatr Int** 1999 Feb;41(1):32-6
Subsets of T-cells and in vitro cytokine production after measles and varicellae-zoster virus antigen stimulation in allogeneic BMT patients. Pauksen K, et al. **Scand J Infect Dis** 1999;31(1):43-9
Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Habermehl P, et al. **Vaccine** 1999 Feb 26;17(7-8):669-74
[Management of varicella-zoster virus infections. No systematic vaccination against varicella in France] Lorette G. **Presse Med** 1998 Jul 4-11;27(24):1237 **(Fre)**
[An adult case of peripheral facial nerve palsy following acute cerebellitis associated with high antibody titers against varicella-zoster virus] Ogata K, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1070-2 (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Enhancement of varicella-zoster virus detection in A-549 shell vials by use of freeze-thawed specimens, extended incubation, and "a centrifuged, not incubated" direct detection method. Brinker JP, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):555-8
Age-specific rates of serological immunity in patients with a negative history for varicella infection [letter] Nordin

J, et al. **Infect Control Hosp Epidemiol** 1998 Nov; 19(11):823–4

Varicella arthritis diagnosed by polymerase chain reaction. Chen MK, et al. **J Formos Med Assoc** 1999 Jul;98(7):519–21

Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella–zoster virus isolates from the United States and other parts of the world. LaRussa P, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S64–6

Detection of varicella–zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. Terada K, et al. **J Med Virol** 1998 Dec;56(4):359–63

Profound cerebrospinal fluid pleocytosis and Froin's Syndrome secondary to widespread necrotizing vasculitis in an HIV–positive patient with varicella zoster virus encephalomyelitis. Kleinschmidt–DeMasters BK, et al. **J Neurol Sci** 1998 Aug 14;159(2):213–8

Impact of cerebrospinal fluid PCR on the management of HIV–infected patients with varicella–zoster virus infection of the central nervous system. Iten A, et al. **J Neurovirol** 1999 Apr;5(2):172–80

Prevalence of varicella–zoster virus DNA in dissociated human trigeminal ganglion neurons and nonneuronal cells. LaGuardia JJ, et al. **J Virol** 1999 Oct;73(10):8571–7

Development of a fluorogenic polymerase chain reaction assay (TaqMan) for the detection and quantitation of varicella zoster virus. Hawrami K, et al. **J Virol Methods** 1999 Apr;79(1):33–40

Neonatal varicella despite maternal immunity [letter] Bendig JW, et al. **Lancet** 1998 Dec 19–26;352(9145):1985–6

Rapid diagnosis of varicella zoster virus infection in acute facial palsy. Murakami S, et al. **Neurology** 1998 Oct; 51(4):1202–5

Spread of varicella–zoster virus DNA to family members and environments from siblings with varicella in a household. Asano Y, et al. **Pediatrics** 1999 May;103(5):e61

Villitis of known origin: varicella and toxoplasma. Benirschke K, et al. **Placenta** 1999 Jul–Aug;20(5–6):395–9

Prenatal diagnosis of congenital varicella syndrome and detection of varicella–zoster virus in the fetus: a case report. Hartung J, et al. **Prenat Diagn** 1999 Feb;19(2):163–6

Latent Varicella–zoster virus in human dorsal root ganglia. Kennedy PG, et al. **Virology** 1999 Jun 5;258(2):451–4

[Investigation on sera prevalence rate of varicella and immunogenicity of varicella vaccine in healthy children] Zhou T, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct; 19(5):271–3 (Eng. Abstr.) **(Chi)**

[Virology, epidemiology and diagnosis of herpes genitalis] Chenot JF, et al. **Dtsch Med Wochenschr** 1999 Feb 12; 124(6):158–62 (31 ref.) **(Ger)**

METABOLISM

Distinct responses of the herpes simplex virus and varicella zoster virus immediate early promoters to the cellular transcription factors Brn–3a and Brn–3b. Brownlees J, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):451–61

Regulated nuclear localization of the varicella–zoster virus major regulatory protein, IE62. Kinchington PR, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S16–21

Varicella–zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin–dependent kinase. Ye M, et al. **J Virol** 1999 Feb;73(2):1320–30

PATHOGENICITY

Latency of varicella zoster virus; a persistently perplexing state. Kinchington PR. **Front Biosci** 1999 Feb 15;4:D200–11 (114 ref.)

Herpes zoster and its complications in Italy: an observational survey. di Luzio Paparatti U, et al. **J Infect** 1999 Mar; 38(2):116–20

Evidence of latent varicella–zoster virus in rat dorsal root ganglia. Annunziato P, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S48–51

PHYSIOLOGY

Varicella–zoster virus eye disease. Liesegang TJ. **Cornea** 1999 Sep;18(5):511–31 (203 ref.)

Latency of varicella zoster virus; a persistently perplexing state. Kinchington PR. **Front Biosci** 1999 Feb 15;4:D200–11 (114 ref.)

Baculovirus expression, purification, and properties of varicella–zoster virus gE, gI, and the complex they form. Kimura H, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S13–5

Varicella–zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. Olson JK, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S2–6

Intracellular transport of varicella–zoster glycoproteins. Wang Z, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S7–12

Induced expression and localization to nuclear–inclusion bodies of hsp70 in varicella–zoster virus–infected human diploid fibroblasts. Ohgitani E, et al. **Microbiol Immunol** 1998;42(11):755–60

In vitro activity of acetylsalicylic acid on replication of varicella–zoster virus. Primache V, et al. **New Microbiol** 1998 Oct;21(4):397–401

Varicella–zoster virus ORF57, unlike its pseudorabies virus UL3.5 homolog, is dispensable for viral replication in cell culture. Cox E, et al. **Virology** 1998 Oct 10;250(1):205–9

Expression of a uracil DNA glycosylase (UNG) inhibitor in mammalian cells: varicella–zoster virus can replicate in vitro in the absence of detectable UNG activity. Reddy SM, et al. **Virology** 1998 Nov 25;251(2):393–401

HERPESVIRUS 4, HUMAN

see related

FATIGUE SYNDROME, CHRONIC

Hypothyroidism presenting as acute cardiac tamponade with viral pericarditis. Gupta R, et al. **Am J Emerg Med** 1999 Mar;17(2):176–8

Lymphoproliferative disorder of fetal origin presenting as oligohydramnios. Fritsch M, et al. **Am J Surg Pathol** 1999 May;23(5):595–601

Epstein–Barr virus–associated polymorphic B–cell lymphoproliferative disorders in the lungs of children with AIDS: a report of two cases. Tao J, et al. **Am J Surg Pathol** 1999 May;23(5):560–6

Epstein–Barr virus related hemophagocytic syndrome in a T–cell rich B–cell lymphoma. Mitterer M, et al. **Ann Oncol** 1999 Feb;10(2):231–4

Epstein–Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Speck P, et al. **Arch Virol** 1999; 144(6):1123–37

Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan. Takeshita H, et al. **Auris Nasus Larynx** 1999 Jul;26(3):277–86

Post–transplant Epstein–Barr virus–associated meningoencephalitis and lymphoid interstitial pneumonitis [letter] Davis K, et al. **Bone Marrow Transplant** 1999 Aug; 24(4):443–4

Effect of material deprivation on Epstein–Barr virus infection in Hodgkin's disease in the West Midlands. Flavell K, et al. **Br J Cancer** 1999 May;80(3–4):604–8

Clonal change of infiltrating T–cells in children with familial hemophagocytic lymphohistiocytosis: possible association with Epstein–Barr virus infection. Ishii E, et al. **Cancer** 1999 Apr 1;85(7):1636–43

Analysis of cell–free Epstein–Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Lo KW, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1292–4

Suspected Brazilian purpuric fever in a toddler with overwhelming Epstein–Barr virus infection. Virata M, et al. **Clin Infect Dis** 1998 Nov;27(5):1238–40

Epstein–Barr virus and lymphoproliferative disease. Mosier DE. **Curr Opin Hematol** 1999 Jan;6(1):25–9 (59 ref.)

Image of the month. What is the etiology of these ulcers? Rudolph JA, et al. **Gastroenterology** 1999 Apr;116(4):788, 1018

Sustained transgene expression in vitro and in vivo using an Epstein–Barr virus replicon vector system combined with HVJ liposomes. Saeki Y, et al. **Gene Ther** 1998 Aug; 5(8):1031–7

Lymphoepithelioma–like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein–Barr virus infection. Wang HH, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1214–9

Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV–associated reactive and malignant lympho–proliferations. Berger C, et al. **Int J Cancer** 1999 May 5;81(3):371–5

Developing immunotherapeutic strategies for the control of Epstein–Barr virus–associated malignancies. Moss DJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S80–3 (27 ref.)

Synergistic effect of Epstein–Barr virus and tumor promoters on induction of lymphoma and carcinoma in nude mice. Liu Z, et al. **J Cancer Res Clin Oncol** 1998;124(10):541–8

Epstein–Barr virus: a possible accomplice in gastric oncogenesis [editorial; comment] Rugge M, et al. **J Clin Gastroenterol** 1999 Jul;29(1):3–5. Comment on: J Clin Gastroenterol 1999 Jul;29(1):39–43.

Severe cholestatic jaundice induced by Epstein–Barr virus infection in the elderly. Edoute Y, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):821–4

Natural history of primary Epstein–Barr virus infection in children of mothers infected with human immunodeficiency virus type 1. Jenson H, et al. **J Infect Dis** 1999 Jun;179(6):1395–404

Comments from the Editor–in–Chief [editorial] Arceci RJ. **J Pediatr Hematol Oncol** 1999 Jan–Feb;21(1):1–2

Massive splenomegaly and Epstein–Barr virus–associated infectious mononucleosis in a patient with Gaucher disease. Eapen M, et al. **J Pediatr Hematol Oncol** 1999 Jan–Feb; 21(1):47–9

Central nervous system T–cell lymphoproliferative disorder in a patient with chronic active Epstein–Barr virus infection. Ohga S, et al. **J Pediatr Hematol Oncol** 1999 Jan–Feb;21(1):42–6

Polysynovitis associated with acute Epstein–Barr virus infection [letter] McCarty DJ, et al. **J Rheumatol** 1998 Oct; 25(10):2039–40 (6 ref.)

Epstein–Barr virus induced renal leiomyoma. Krishnan R, et al. **J Urol** 1999 Jan;161(1):212

Association with the cellular export receptor CRM 1 mediates function and intracellular localization of Epstein–Barr virus SM protein, a regulator of gene expression. Boyle SM, et al. **J Virol** 1999 Aug;73(8):6872–81

Requirement for cell–to–cell contact in Epstein–Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. Chang Y, et al. **J Virol** 1999 Oct; 73(10):8857–66

Identification of a spliced gene from Kaposi's sarcoma–associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein–Barr virus. Glenn M, et al. **J Virol** 1999 Aug; 73(8):6953–63

Nasopharyngeal carcinoma. Vokes EE, et al. **Lancet** 1997 Oct 11;350(9084):1087–91 (26 ref.)

Fulminant Epstein–Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Feranchak AP, et al. **Liver Transpl Surg** 1998 Nov;4(6):469–76 (39 ref.)

Successful treatment of monoclonal, aggressive Epstein–Barr virus–associated B–cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia. Perkkiö M, et al. **Med Pediatr Oncol** 1999 Jun;32(6):447–9

Host response to EBV infection in X–linked lymphoproliferative disease results from mutations in an SH2–domain encoding gene [see comments] Coffey AJ, et al. **Nat Genet** 1998 Oct;20(2):129–35. Comment in: Nat Genet 1998 Oct;20(2):103–4.

Why commonplace encounters turn to fatal attraction [news; comment] Sadelain M, et al. **Nat Genet** 1998 Oct; 20(2):103–4. Comment on: Nat Genet 1998 Oct;20(2):129–35.

A case of Whipple's disease associated with acute Ebstein Barr virus hepatitis and Berger's disease [letter] Evrenkaya R, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):241–2

Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Hudson LB, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):642–4 (4 ref.)

CD95 (Fas) ligand expression of Epstein–Barr virus (EBV)–infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection. Ohshima K, et al. **Pathol Int** 1999 Jan;49(1):9–13

Clinicopathological study of severe chronic active Epstein–Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Ohshima K, et al. **Pathol Int** 1998 Dec; 48(12):934–43

Epstein–Barr virus polymerase chain reaction and serology in pediatric post–transplant lymphoproliferative disorder: three–year experience. Rogers BB, et al. **Pediatr Dev Pathol** 1998 Nov–Dec;1(6):480–6

Tubulointerstitial nephritis and uveitis in association with Epstein–Barr virus infection. Grefer J, et al. **Pediatr Nephrol** 1999 May;13(4):336–9

A first–generation packaging cell line for Epstein–Barr virus–derived vectors. Delecluse HJ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5188–93

Primary ocular Epstein–Barr virus–associated non–Hodgkin's lymphoma in a patient with AIDS: a clinicopathologic report. Mittra RA, et al. **Retina** 1999;19(1):45–50

Perinatal Epstein Barr virus infection in a premature infant. Andronikou S, et al. **Scand J Infect Dis** 1999;31(1):96–8

Epstein–Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Jarrett RF, et al. **Semin Hematol** 1999 Jul;36(3):260–9 (102 ref.)

Aspergillus fumigatus in sputum during acute EBV infection [letter; comment] Schmid ML, et al. **Thorax** 1999 Jul; 54(7):658. Comment on: Thorax 1998 Nov;53(11):975–8.

EBV–B cells as antigen presenting cells in characterization of the self/donor context of allorecognition by T lymphocytes. Drouet C, et al. **Transpl Immunol** 1998 Dec; 6(4):209–15

Epstein–Barr virus infection after kidney transplantation. Kaden J, et al. **Transpl Int** 1998;11 Suppl 1:S119–24

Kaposi sarcoma–associated herpesvirus/human herpesvirus type 8 and Epstein–Barr virus in immunosuppressed renal transplant recipients. Demirağ A, et al. **Transplant Proc** 1998 Nov;30(7):3166–7

Prospective study of Epstein–Barr virus chronic infection in renal transplant recipients. Lauzurica R, et al. **Transplant Proc** 1999 Sep;31(6):2339–40

B cells malignantly transformed by human immunodeficiency virus are polyclonal. Rodriguez–Alfageme C, et al. **Virology** 1998 Dec 5;252(1):34–8

[A cause of acute encephalitis: primary infection due to Epstein–Barr virus] Follet–Bouhamed C, et al. **Arch Pediatr** 1999 Mar;6(3):286–9 (Eng. Abstr.) **(Fre)**

[Orbital lymphoma and AIDS. Apropos of a case] Than–Trong T, et al. **J Fr Ophtalmol** 1999 May;22(5):594–8 (Eng. Abstr.) **(Fre)**

[Post–transplantation lymphomas and Epstein–Barr virus] Caillard S, et al. **Nephrologie** 1998;19(8):481–8 (100 ref.) (Eng. Abstr.) **(Fre)**

[Genital ulceration in the course of a primo–infection with Epstein–Barr virus (letter)] Gisserot O. **Presse Med** 1998 Oct 10;27(30):1528 **(Fre)**

[Preoperative classification of malignant stomach tumors] Totkas S, et al. **Chirurg** 1999 Jun;70(6):713–7 (Eng. Abstr.) **(Ger)**

[A case with chronic active EB virus infection accompanied with pulmonary candidiasis] Karino T, et al. **Kansenshogaku Zasshi** 1998 Dec;72(12):1306–10 (Eng. Abstr.) **(Jpn)**

[Laboratory diagnosis of viral infections. 7. Opportunistic infection by herpesviruses (human cytomegalovirus, Epstein–Barr virus, and human herpesvirus 8)] Okuno T. **Rinsho Byori** 1998 Nov;Suppl 108:98–104 (5 ref.) **(Jpn)**

[Epstein–Barr virus encephalitis] Fukaya S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):25–8 (20 ref.) **(Jpn)**

[EB virus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):126–8 (10 ref.) **(Jpn)**

[Infectious mononucleosis caused by Epstein–Barr virus] Ueda T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):188–91 (8 ref.) **(Jpn)**

[Epstein–Barr virus and rheumatic disease] Murakami K. **Ryumachi** 1998 Dec;38(6):849–59 (70 ref.) **(Jpn)**

CHEMISTRY

Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Caldwell RG, et al. **Immunity** 1998 Sep;9(3):405–11

Detection of human antibodies using "convergent" combinatorial peptide libraries or "mixotopes" designed from a nonvariable antigen: application to the EBV viral capsid antigen p18. Tranchand-Bunel D, et al. **J Pept Res** 1998 Dec;52(6):495–508

CLASSIFICATION

A novel Epstein–Barr virus–like virus, HV(MNE), in a Macaca nemestrina with mycosis fungoides. Rivadeneira ED, et al. **Blood** 1999 Sep 15;94(6):2090–101

A–type and B–type Epstein–Barr virus differ in their ability to spontaneously enter the lytic cycle. Buck M, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):441–5

Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Edwards RH, et al. **Virology** 1999 Aug 15;261(1):79–95

DRUG EFFECTS

Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein–Barr virus replication. Meerbach A, et al. **Antivir Chem Chemother** 1998 May;9(3):275–82

Inhibitory effects of monoacylated 2–O–beta–galactosylglycerols on Epstein–Barr virus activation: the significant role of the hexanoyl chain. Colombo D, et al. **Cancer Lett** 1999 Aug 23;143(1):1–4

Xanthones as inhibitors of Epstein–Barr virus activation. Ito C, et al. **Cancer Lett** 1998 Oct 23;132(1–2):113–7

Anti–tumor–promoting effects of phenylpropanoids on Epstein–Barr virus activation and two–stage mouse skin carcinogenesis. Ito C, et al. **Cancer Lett** 1999 Jul 19; 142(1):49–54

Anti–tumor–promoting effects of 8–substituted 7–methoxycoumarins on Epstein–Barr virus activation assay. Ito C, et al. **Cancer Lett** 1999 Apr 26;138(1–2):87–92

Detection of tumor promoters by early antigen expression of EB virus in Raji cells using a fluorescence microplate–reader. Ohmori K, et al. **Cancer Lett** 1998 Oct 23;132(1–2):51–9

Screening for biological activity and chemical composition of Euodia borbonica var. borbonica (Rutaceae), a medicinal plant in Reunion Island. Valenciennes E, et al. **J Ethnopharmacol** 1999 Mar;64(3):283–8

Structure–activity relationships of L–dioxolane uracil nucleosides as anti–Epstein Barr virus agents. Lin JS, et al. **J Med Chem** 1999 Jun 17;42(12):2212–7

Inhibition of Epstein–Barr virus replication by a benzimidazole L–riboside: novel antiviral mechanism of 5, 6–dichloro–2–(isopropylamino)–1–beta–L–ribofuranosyl–1H–benzimidazole. Zacny VL, et al. **J Virol** 1999 Sep; 73(9):7271–7

Evaluation of the effect of smokeless tobacco purified products and extracts on latent Epstein–Barr virus. Jenson HB, et al. **Toxicology** 1999 Mar 1;133(1):35–42

Preventing acute rejection, Epstein–Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid–free immunosuppressive protocol. Birkeland SA, et al. **Transplantation** 1999 May 15;67(9):1209–14

ENZYMOLOGY

The Epstein–Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Gustafson EA, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2923–31

Arginine butyrate–induced susceptibility to ganciclovir in an Epstein–Barr–virus–associated lymphoma. Mentzer SJ, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):114–23

GENETICS

Non–AIDS–related Kaposi sarcoma tissues do not contain DNA sequences of HHV–6, HHV–7, Epstein–Barr virus, cytomegalovirus and HSV [letter] Drago F, et al. **Acta Derm Venereol** 1998 Nov;78(6):485

Tissue distribution of Epstein–Barr virus genotypes in hosts coinfected by HIV. Triantos D, et al. **AIDS** 1998 Nov 12; 12(16):2141–6

Malignant lymphoma of the thyroid. A 30–year clinicopathologic experience and an evaluation of the presence of Epstein–Barr virus. Lam KY, et al. **Am J Clin Pathol** 1999 Aug;112(2):263–70

Methylation status of the Epstein–Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR–based analysis. Tao Q, et al. **Am J Pathol** 1999 Aug;155(2):619–25

The oncogenic 30 and 69 bp deletion variants of the EBV LMP–1 gene are common in HIV–negative lymphoproliferations, both malignant and benign. Barozzi P, et al. **Ann Oncol** 1999 Apr;10(4):467–9

Flow cytometric analysis of BHRF1 expression prohibiting apoptosis induced by radiation. Huang H, et al. **Ann Otol Rhinol Laryngol** 1999 May;108(5):481–4

A study on Epstein–Barr virus in erythema multiforme. Chen CL, et al. **Arch Dermatol Res** 1998 Aug;290(8):446–9

Regulation of the Epstein–Barr viral immediate early BRLF1 promoter through a distal NF1 site. Glaser G, et al. **Arch Virol** 1998;143(10):1967–83

Efficient gene delivery into epstein–barr virus (EBV)–transformed human B cells mediated by replication–defective herpes simplex virus–1 (HSV–1): A gene therapy model for EBV–related B cell malignancy. Suzuki T, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):686–90

Gene transfer in vitro and in vivo with Epstein–Barr virus–based episomal vector results in markedly high transient expression in rodent cells. Tomiyasu K, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):733–8

C–1027–induced alterations in Epstein–Barr viral DNA replication in latently infected cultured human Raji cells: relationship to DNA damage. McHugh MM, et al. **Biochemistry** 1999 May 25;38(21):6962–70

Purification of large quantities of high–molecular–weight Epstein–Barr viral and cellular genomic DNA from cultured human Raji cells. McHugh MM, et al. **Biotechniques** 1999 Feb;26(2):188–90, 192, 194

Paediatric Hodgkin's disease in Spain: association with Epstein–Barr virus strains carrying latent membrane protein–1 oncogene deletions and high frequency of dual infections. Santón A, et al. **Br J Haematol** 1998 Oct; 103(1):129–36

Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV–immortalized B cells despite induction of chromosomal breakage and loss. Jox A, et al. **Cancer Res** 1998 Nov 1;58(21):4930–9

Induction of lytic Epstein–Barr virus (EBV) infection in EBV–associated malignancies using adenovirus vectors in vitro and in vivo. Westphal EM, et al. **Cancer Res** 1999 Apr 1;59(7):1485–91

Phenylbutyrate induces cell differentiation and modulates Epstein–Barr virus gene expression in Burkitt's lymphoma cells. Bar–Ner M, et al. **Clin Cancer Res** 1999 Jun; 5(6):1509–16

EBV genes and B cell proliferation. Manet E, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):129–37 (59 ref.)

Epstein–Barr virus vectors for gene expression and transfer. Sclimenti CR, et al. **Curr Opin Biotechnol** 1998 Oct; 9(5):476–9 (40 ref.)

EBNA2 and c–myc in B cell immortalization by Epstein–Barr virus and in the pathogenesis of Burkitt's lymphoma. Zimber–Strobl U, et al. **Curr Top Microbiol Immunol** 1999; 246:315–20; discussion 321 (23 ref.)

The plasmid replicon of EBV consists of multiple cis–acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. Aiyar A, et al. **EMBO J** 1998 Nov 2;17(21):6394–403

Systemic delivery of an adenovirus expressing EBV–derived vIL–10 in mice infected with Schistosoma mansoni or Leishmania amazonensis: controversial effects on the development of pathological parameters. Verwaerde C, et al. **Eur Cytokine Netw** 1999 Jun;10(2):161–70

Successful transfer of ADA gene in vitro into human peripheral blood CD34+ cells by transfecting EBV–based episomal vectors. Satoh E, et al. **FEBS Lett** 1998 Dec 11; 441(1):39–42

An enhanced EBNA1 variant with reduced IR3 domain for long–term episomal maintenance and transgene expression of oriP–based plasmids in human cells. Wendelburg BJ, et al. **Gene Ther** 1998 Oct;5(10):1389–99

Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: a good supplement to the serologic screening. Sheen TS, et al. **Head Neck** 1998 Dec;20(8):732–8

High prevalence of a 30–base pair deletion in the Epstein–Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. Dirnhofer S, et al. **Hum Pathol** 1999 Jul;30(7):781–7

LMP–1, the Epstein–Barr virus–encoded oncogene with a B cell activating mechanism similar to CD40. Klein E, et al. **Immunol Lett** 1999 May 3;68(1):147–54 (33 ref.)

Nasopharyngeal carcinoma cell line (C666–1) consistently harbouring Epstein–Barr virus. Cheung ST, et al. **Int J Cancer** 1999 Sep 24;83(1):121–6

Comparative analysis of Epstein–Barr virus gene polymorphisms in nasal T/NK–cell lymphomas and normal nasal tissues: implications on virus strain selection in malignancy. Chiang AK, et al. **Int J Cancer** 1999 Jan 29; 80(3):356–64

Epstein–Barr virus genomes are found predominantly in IgA–positive B cells in the blood of healthy carriers. Ehlin–Henriksson B, et al. **Int J Cancer** 1999 Sep 24; 83(1):50–4

Epstein–barr virus in Hodgkin's disease: frequency of a 30–bp deletion in the latent membrane protein (LMP–1) oncogene in South African patients [letter] Essop MF, et al. **Int J Cancer** 1999 Aug 20;84(4):449–51

Expression of Epstein–Barr virus lytically related genes in African Burkitt's lymphoma: correlation with patient response to therapy. Labrecque LG, et al. **Int J Cancer** 1999 Mar 31;81(1):6–11

Epstein–Barr virus study in malignant lymphoma in Sjögren's syndrome. Hirose Y, et al. **Int J Hematol** 1999 Apr; 69(3):174–9

Nucleic acid sequence–based amplification, a new method for analysis of spliced and unspliced Epstein–Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. Brink AA, et al. **J Clin Microbiol** 1998 Nov;36(11):3164–9

Pretreatment with restriction enzyme or bovine serum albumin for effective PCR amplification of Epstein–Barr virus DNA in DNA extracted from paraffin–embedded gastric carcinoma tissue. Satoh Y, et al. **J Clin Microbiol** 1998 Nov;36(11):3423–5

Monitoring of epstein–barr virus DNA load in peripheral blood by quantitative competitive PCR. Stevens SJ, et al. **J Clin Microbiol** 1999 Sep;37(9):2852–7

Value of combined approach with thallium–201 single–photon emission computed tomography and Epstein–Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS–related primary CNS lymphoma. Antinori A, et al. **J Clin Oncol** 1999 Feb; 17(2):554–60

The major immunogenic epitopes of Epstein–Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV–associated cell lines. Chen MR, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):447–55

Kaposi's sarcoma–associated herpesvirus (human herpesvirus–8) encodes a homologue of the Epstein–Barr virus bZip protein EB1. Gruffat H, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):557–61

Definition of the transcription factors which bind the differentiation responsive element of the Epstein–Barr virus BZLF1 Z promoter in human epithelial cells. MacCallum P, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1501–12

Diversity of naturally occurring Epstein–Barr virus revealed by nucleotide sequence polymorphism in hypervariable domains in the BamHI K and N subgenomic regions. Triantos D, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2809–17

Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein–Barr virus–transformed lymphoid cells in latent and lytic stages of infection. Zetterberg H, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):457–66

Identification of transactivator and nuclear localization domains in the Epstein–Barr virus DNA polymerase accessory protein, BMRF1. Zhang Q, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):69–74

Differential expression and localization of EBER–1 and EBER–2 in Epstein–Barr virus–carrying cells. Teramoto N, et al. **J Hum Virol** 1998 Jul–Aug;1(5):307–13

EBV gene expression not altered in rheumatoid synovia despite the presence of EBV antigen–specific T cell clones. Edinger JW, et al. **J Immunol** 1999 Mar 15;162(6):3694–701

Carboxy terminal variants of Epstein–Barr virus–encoded latent membrane protein 1 during long–term human immunodeficiency virus infection: reliable markers for individual strain identification. Berger C, et al. **J Infect Dis** 1999 Jan;179(1):240–4

The molecular epidemiology and evolution of Epstein–Barr virus: sequence variation and genetic recombination in the latent membrane protein–1 gene. Walling DM, et al. **J Infect Dis** 1999 Apr;179(4):763–74

Epstein–Barr virus infection and its gene expression in gastric lymphoma of mucosa–associated lymphoid tissue. Xu WS, et al. **J Med Virol** 1998 Dec;56(4):342–50

The 2.2 A structure of a permanganate–sensitive DNA site bound by the Epstein–Barr virus origin binding protein, EBNA1. Bochkarev A, et al. **J Mol Biol** 1998 Dec 18; 284(5):1273–8 (24 ref.)

Epstein–Barr virus DNA in cerebrospinal fluid from an immunocompetent man with herpes simplex virus encephalitis. Portolani M, et al. **J Neurovirol** 1998 Aug; 4(4):461–4

Detection of Epstein–Barr virus (EBV) DNA and antigens in oral mucosa of renal transplant patients without clinical evidence of oral hairy leukoplakia (OHL). Ammatuna P, et al. **J Oral Pathol Med** 1998 Oct;27(9):420–7

Functional differences between BHRF1, the Epstein–Barr virus–encoded Bcl–2 homologue, and Bcl–2 in human epithelial cells. Dawson CW, et al. **J Virol** 1998 Nov; 72(11):9016–24

Amino acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of early lytic cycle genes and synergy with the Epstein–Barr virus R transactivator. Francis A, et al. **J Virol** 1999 Jun; 73(6):4543–51

Transcriptional activation signals found in the Epstein–Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV–like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15). Fuentes–Panana EM, et al. **J Virol** 1999 Jan;73(1):826–33

The Epstein–Barr virus lytic transactivator Zta interacts with the helicase–primase replication proteins. Gao Z, et al. **J Virol** 1998 Nov;72(11):8559–67

Epstein–Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. Greifenegger N, et al. **J Virol** 1998 Nov;72(11):9323–8

Epstein–barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains

prevalent in different geographic areas. Habeshaw G, et al. **J Virol** 1999 Feb;73(2):965–75

Residues 231 to 280 of the Epstein–Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation. Harada S, et al. **J Virol** 1998 Dec; 72(12):9948–54

Activated mouse Notch1 transactivates Epstein–Barr virus nuclear antigen 2–regulated viral promoters. Höfelmayr H, et al. **J Virol** 1999 Apr;73(4):2770–80

The Epstein–Barr virus (EBV) SM protein enhances pre-mRNA processing of the EBV DNA polymerase transcript. Key SC, et al. **J Virol** 1998 Nov;72(11):8485–92

Intron retention may regulate expression of Epstein–Barr virus nuclear antigen 3 family genes. Kienzle N, et al. **J Virol** 1999 Feb;73(2):1195–204

Epstein–Barr virus–encoded RK-BARF0 protein expression. Kienzle N, et al. **J Virol** 1999 Oct;73(10):8902–6

Regulation of Epstein–Barr virus promoters in oral epithelial cells and lymphocytes. Lagenaur LA, et al. **J Virol** 1999 Aug;73(8):6566–72

Epstein–Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. Marshall WL, et al. **J Virol** 1999 Jun;73(6):5181–5

Strong selective pressure for evolution of an Epstein–Barr virus LMP2B homologue in the rhesus lymphocryptovirus. Rivailler P, et al. **J Virol** 1999 Oct;73(10):8867–72

Repression of Epstein–Barr virus EBNA-1 gene transcription by pRb during restricted latency. Ruf IK, et al. **J Virol** 1999 Oct;73(10):7943–51

Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein–Barr virus replication gene mRNA. Semmes OJ, et al. **J Virol** 1998 Dec; 72(12):9526–34

Silencing of the Epstein–Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure. Sjöblom-Hallén A, et al. **J Virol** 1999 Apr; 73(4):2983–93

Visualization of alternative Epstein–Barr virus expression programs by fluorescent in situ hybridization at the cell level. Szeles A, et al. **J Virol** 1999 Jun;73(6):5064–9

An adenovirus-Epstein–Barr virus hybrid vector that stably transforms cultured cells with high efficiency. Tan BT, et al. **J Virol** 1999 Sep;73(9):7582–9

Detection of human papilloma virus and Epstein–Barr virus DNA in nasopharyngeal carcinoma by polymerase chain reaction. Tung YC, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1999 May; 15(5):256–62

Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein–Barr virus detected in Burkitt's lymphoma of Turkish children. Tacyildiz N, et al. **Leukemia** 1998 Nov;12(11):1796–805

DNA damage–associated cell cycle and cell death control is differentially modulated by caffeine in clones with p53 mutations. Takagi M, et al. **Leukemia** 1999 Jan;13(1):70–7

Cytotoxic granular protein expression, Epstein–Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Elenitoba-Johnson KS, et al. **Mod Pathol** 1998 Aug;11(8):754–61

Lymphoepithelioma-like carcinoma of the renal pelvis: a case report with immunohistochemical analysis and in situ hybridization for the Epstein–Barr viral genome. Fukunaga M, et al. **Mod Pathol** 1998 Dec;11(12):1252–6

Virus infection leads to localized hyperacetylation of histones H3 and H4 at the IFN-beta promoter. Parekh BS, et al. **Mol Cell** 1999 Jan;3(1):125–9

Multiple layers of cooperativity regulate enhanceosome-responsive RNA polymerase II transcription complex assembly. Ellwood K, et al. **Mol Cell Biol** 1999 Apr;19(4):2613–23

The linking regions of EBNA1 are essential for its support of replication and transcription. Mackey D, et al. **Mol Cell Biol** 1999 May;19(5):3349–59

Determination of Epstein–Barr virus (EBV) load by RT-PCR and cellular dilution. Orentas RJ. **Mol Cell Probes** 1998 Dec;12(6):427–30

Cloning and analysis of the Epstein–Barr virus glycoprotein 350 genes [published erratum appears in Mol Cells 1999 Feb 28;9(1):following 114] Chang SH, et al. **Mol Cells** 1998 Oct 31;8(5):585–93

Expression of Epstein–Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Hayes DP, et al. **Mol Pathol** 1999 Apr; 52(2):97–103

The effect of Epstein–Barr virus gene BHRF1 expression on radioresistance of nasopharyngeal carcinoma cells. Huang H, et al. **ORL J Otorhinolaryngol Relat Spec** 1998 Nov-Dec;60(6):329–33

Epstein–Barr virus plasmid model system for analyzing recombination in human cells. Phillips JE, et al. **Plasmid** 1999 May;41(3):198–206

The Epstein–Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Chen H, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9339–44

Epstein–Barr virus gene expression in post-transplant lymphoproliferative disorders. Rowe M, et al. **Springer Semin Immunopathol** 1998;20(3–4):389–403

Polymerase chain reaction and in situ hybridization of Epstein–Barr virus in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Barkholt L, et al. **Transpl Int** 1998;11(5):336–44

Specific expression of Epstein–Barr virus in cutaneous squamous cell carcinomas from heart transplant recipients. Ternesten-Bratel A, et al. **Transplantation** 1998 Dec 15; 66(11):1524–9

Rescue of the Epstein–Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Adamson AL, et al. **Virology** 1998 Nov 10;251(1):187–97

Characterisation of regulatory sequences at the Epstein–Barr virus BamHI W promoter. Bell A, et al. **Virology** 1998 Dec 5;252(1):149–61

Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Edwards RH, et al. **Virology** 1999 Aug 15;261(1):79–95

Human herpesvirus-8 glycoprotein B interacts with Epstein–Barr virus (EBV) glycoprotein 110 but fails to complement the infectivity of EBV mutants. Pertel PE, et al. **Virology** 1998 Nov 25;251(2):402–13

Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein–Barr virus RNA, EBER-1. Sharp TV, et al. **Virology** 1999 May 10;257(2):303–13

Additive effect of Sp1 and Sp3 in regulation of the ED-L1E promoter of the EBV LMP 1 gene in human epithelial cells. Tsai CN, et al. **Virology** 1999 Sep 1;261(2):288–94

The position of the ZEBRA activation domain does not influence its biological activity. Asković S, et al. **Virus Res** 1998 Oct;57(2):125–38

[The viral genome status studied under the conditions of a mixed infection in lymphoblastoid cells by adenovirus and the Epstein–Barr virus] Nosach LN, et al. **Tsitol Genet** 1998 Jul-Aug;32(4):82–8 (Eng. Abstr.) **(Rus)**

[Detection and characterization of gastric carcinoma associated with epstein-barr herpes virus] Gurtsevich VE, et al. **Vestn Ross Akad Med Nauk** 1999;(3):56–9 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Inhibitory effect of Epstein–Barr virus activation by Citrus fruits, a cancer chemopreventor. Iwase Y, et al. **Cancer Lett** 1999 May 24;139(2):227–36

Suppression of Epstein–Barr virus reactivation in lymphoblastoid cells cultured in simulated microgravity. Long JP, et al. **In Vitro Cell Dev Biol Anim** 1999 Jan; 35(1):49–54

Induction of interleukin-10 on activation of Epstein–Barr virus in EBV-infected B-cell lines. Sairenji T, et al. **Viral Immunol** 1998;11(4):221–31

Nitric oxide down-regulates Epstein–Barr virus reactivation in epithelial cell lines. Gao X, et al. **Virology** 1999 Jun 5; 258(2):375–81

[High inducibility of Epstein–Barr virus replication in B lymphocytes in Vogt-Koyanagi-Harada disease] Minoda H, et al. **Nippon Ganka Gakkai Zasshi** 1999 Apr; 103(4):289–96 (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Establishment and characterization of Epstein–Barr virus-specific human CD4+ T lymphocyte clones. Honda S, et al. **Acta Virol** 1998 Nov;42(5):307–13

Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Rooney CM, et al. **Ann Oncol** 1998;9 Suppl 5:S129–32

CD4(+) Epstein–Barr virus–specific cytotoxic T-lymphocytes from human umbilical cord blood. Sun Q, et al. **Cell Immunol** 1999 Aug 1;195(2):81–8

Detection of IgA against Epstein–Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein. Shu CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jun;62(6):350–5

The influence of Epstein–Barr virus seropositivity on the efficacy of intravenous immune globulin in children with immune thrombocytopenic purpura. Sturgill MG, et al. **Clin Pediatr (Phila)** 1999 Mar;38(3):171–3

The biology of Epstein–Barr virus: lessons learned from the virus and the host. Cohen JI. **Curr Opin Immunol** 1999 Aug;11(4):365–70 (51 ref.)

Detection of Epstein–Barr virus–specific antibodies by an automated enzyme immunoassay. Performance evaluation and cost analysis. Tang YW, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):549–54

T cell selection during the evolution of CD8+ T cell memory in vivo. Callan MF, et al. **Eur J Immunol** 1998 Dec;28(12):4382–90

Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein–Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Khanna R, et al. **Eur J Immunol** 1999 May;29(5):1587–97

Selective amino acid substitutions of a subdominant Epstein–Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein–Barr virus–associated malignancies. Micheletti F, et al. **Eur J Immunol** 1999 Aug;29(8):2579–89

Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Scotet E, et al. **Eur J Immunol** 1999 Mar;29(3):973–85

EBV persistence in memory B cells in vivo. Babcock GJ, et al. **Immunity** 1998 Sep;9(3):395–404

Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Caldwell RG, et al. **Immunity** 1998 Sep;9(3):405–11

Diminished recognition of HLA-A2 proteins lacking a cytoplasmic domain (CY) by A2-restricted, EBV-specific CTLs: possible role of the CY in TAP association. Cannon MJ, et al. **Immunogenetics** 1999 Apr;49(4):346–50

Epstein–Barr virus and cytomegalovirus infections cause false-positive results in IgM two-test protocol for early Lyme borreliosis [letter] Goossens HA, et al. **Infection** 1999 May-Jun;27(3):231

HLA-A alleles of patients with pyothorax-associated lymphoma: anti–Epstein–Barr virus (EBV) host immune responses during the development of EBV latent antigen–positive lymphomas. Kanno H, et al. **Int J Cancer** 1999 Aug 27;82(5):630–4

Evaluation of antibodies to the Epstein–Barr virus immediate early gene product ZEBRA by a new enzyme-linked immunosorbent assay. Yamauchi Y, et al. **Intervirology** 1998;41(6):278–84

Anorexia, OCD, and streptococcus [letter; comment] Henry MC, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar; 38(3):228–9. Comment on: J Am Acad Child Adolesc Psychiatry 1997 Aug;36(8):1128–33.

Fusions between Epstein–Barr viral nuclear antigen-1 of Epstein–Barr virus and the large T-antigen of simian virus 40 replicate their cognate origins. Aiyar A, et al. **J Biol Chem** 1998 Dec 4;273(49):33073–81

A functional link for major TCR expansions in healthy adults caused by persistent Epstein–Barr virus infection. Silins SL, et al. **J Clin Invest** 1998 Oct 15;102(8):1551–8

Development and evaluation of an Epstein–Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay based on the 18-kilodalton matrix protein for diagnosis of primary EBV infection. Chan KH, et al. **J Clin Microbiol** 1998 Nov;36(11):3359–61

Serodiagnosis of Epstein–Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion. Hinderer W, et al. **J Clin Microbiol** 1999 Oct; 37(10):3239–44

Evaluation of an Epstein–Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay using a synthetic convergent peptide library, or mixotope, for diagnosis of primary EBV infection. Tranchand-Bunel D, et al. **J Clin Microbiol** 1999 Jul;37(7):2366–8

Clinical relevance of serum immunoglobulin A antibodies to Epstein–Barr virus envelope glycoprotein gp350 in nasopharyngeal carcinoma patients [letter] Xu JW, et al. **J Clin Microbiol** 1998 Dec;36(12):3740

Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections. Schubert J, et al. **J Clin Virol** 1998 Dec;11(3):161–72

The major immunogenic epitopes of Epstein–Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. Chen MR, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):447–55

Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein–Barr virus–transformed lymphoid cells in latent and lytic stages of infection. Zetterberg H, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):457–66

Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. Couedel C, et al. **J Immunol** 1999 Jun 1; 162(11):6351–8

Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein–Barr virus latent membrane protein 1. Henriquez NV, et al. **J Immunol** 1999 Mar 15;162(6):3298–307

EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. Khanna R, et al. **J Immunol** 1999 Mar 1;162(5):3063–9

Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. Khatri VP, et al. **J Immunol** 1999 Jul 1;163(1):500–6

Virus-induced CD8+ T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: a mechanism for rescue from replicative senescence. Maini MK, et al. **J Immunol** 1999 Apr 15; 162(8):4521–6

A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. Tan LC, et al. **J Immunol** 1999 Feb 1;162(3):1827–35

EBV-induced expression and HLA-DR–restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. van Sechel AC, et al. **J Immunol** 1999 Jan 1;162(1):129–35

Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein–Barr virus infection. Helminen M, et al. **J Infect Dis** 1999 Aug;180(2):496–9

Restricted low-level human antibody responses against Epstein–Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. Meij P, et al. **J Infect Dis** 1999 May;179(5):1108–15

Antibody against the Epstein–Barr virus BHRF1 protein, a

homologue of Bcl-2, in patients with nasopharyngeal carcinoma. Liu MY, et al. **J Med Virol** 1998 Nov; 56(3):179–85

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. Dalod M, et al. **J Virol** 1999 Sep;73(9):7108–16

Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. Pepperl S, et al. **J Virol** 1998 Nov;72(11):8644–9

Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. Redchenko IV, et al. **J Virol** 1999 Jan;73(1):334–42

Immunology. Sinking surveillance's flagship [news; comment] Klein G, et al. **Nature** 1998 Oct 1;395(6701):441, 443–4. Comment on: Nature 1998 Oct 1;395(6701):462–9.

Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Ho S, et al. **Oral Oncol** 1998 Nov;34(6):491–5

Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation [see comments] Harwood JS, et al. **Pediatr Transplant** 1999 May;3(2):100–3. Comment in: Pediatr Transplant 1999 May;3(2):95–9.

Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? [editorial; comment] Webber SA. **Pediatr Transplant** 1999 May; 3(2):95–9. Comment on: Pediatr Transplant 1999 May;3(2):100–3.

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Khanna R, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10391–6

Immunoglobulin-secreting cells in cord blood: effects of Epstein-Barr virus and interleukin-4. Gudmundsson KO, et al. **Scand J Immunol** 1999 Jul;50(1):21–4

Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits. Chan SH, et al. **Singapore Med J** 1998 Jun; 39(6):263–5

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Faro A. **Springer Semin Immunopathol** 1998;20(3–4):425–36 (55 ref.)

Acute disseminated encephalomyelitis after renal transplantation in patients with positive Epstein-Barr virus antibody. Kim SC, et al. **Transplant Proc** 1998 Nov; 30(7):3139

Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Jackman WT, et al. **Vaccine** 1999 Feb 26;17(7–8):660–8

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Wilson AD, et al. **Vaccine** 1999 Mar 5; 17(9–10):1282–90

EBV specific CTL: a model for immune therapy. Rooney CM, et al. **Vox Sang** 1998;74 Suppl 2:497–8 (6 ref.)

[Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease] Kuljić-Kapulica N. **Srp Arh Celok Lek** 1998 Mar–Apr;126(3–4):97–100 (Eng. Abstr.) **(Sec)**

ISOLATION & PURIFICATION

Monomorphic agranular natural killer cell lymphoma/leukemia with no Epstein-Barr virus association. Matano S, et al. **Acta Haematol** 1999; 101(4):206–8

A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. Munch M, et al. **Acta Neurol Scand** 1998 Dec;98(6):395–9

Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Enblad G, et al. **Acta Oncol** 1999;38(4):425–9

Investigation of the relationship between Epstein-Barr virus and ordinary gastric carcinoma using the nested polymerase chain reaction. Durmaz R, et al. **Acta Virol** 1998 Dec; 42(6):359–63

Detection and genotyping of Epstein-Barr virus by polymerase chain reaction in tissues obtained from cases with Hodgkin's disease in Turkey. Durmaz R, et al. **Acta Virol** 1998 Dec;42(6):375–81

Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. Huh J, et al. **Am J Hematol** 1999 Mar; 60(3):205–14

Epstein-Barr virus detection in kidney biopsy specimens correlates with glomerular mesangial injury. Iwama H, et al. **Am J Kidney Dis** 1998 Nov;32(5):785–93

Acute monoarthritis from infectious mononucleosis. Berger RG, et al. **Am J Med** 1999 Aug;107(2):177–8

Nasopharyngeal carcinoma in two young brothers and its relationship with Epstein-Barr virus. Duque CS, et al. **Am J Otolaryngol** 1998 Sep–Oct;19(5):335–8

The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Stewart JP, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1336–41

Epstein-Barr virus-associated intravascular lymphomatosis within Kaposi's sarcoma in an AIDS patient. Hsiao CH, et al. **Am J Surg Pathol** 1999 Apr;23(4):482–7

Epstein-Barr virus-associated leiomyosarcoma of the thyroid in a child with congenital immunodeficiency: a case report. Tulbah A, et al. **Am J Surg Pathol** 1999 Apr;23(4):473–6

A comparison of epidemiologic, histologic, and virologic studies on Hodgkin's disease in western Kenya and Nagasaki, Japan. Kusuda M, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):801–7

Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Antinori A, et al. **Ann Neurol** 1999 Feb;45(2):259–61

EBER1 in situ hybridization as an adjuvant for diagnosis of recurrent nasopharyngeal carcinoma. Hsiao JR, et al. **Anticancer Res** 1998 Nov–Dec;18(6B):4585–9

EBER in situ hybridization differentiates carcinomas originating from the sinonasal region and the nasopharynx. Hwang TZ, et al. **Anticancer Res** 1998 Nov–Dec; 18(6B):4581–4

Biliary lymphoepithelioma-like carcinoma not associated with Epstein-Barr virus. Kim YB, et al. **Arch Pathol Lab Med** 1999 May;123(5):441–3

Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Saal JG, et al. **Arthritis Rheum** 1999 Jul;42(7):1485–96

Detection of human herpesvirus-8 and Epstein-Barr virus DNA in primary intraocular lymphomas [letter] Chan CC, et al. **Blood** 1999 Apr 15;93(8):2749–51

Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Lucas KG, et al. **Blood** 1998 Nov 15;92(10):3977–8

Interferon-gamma prevents apoptosis in Epstein-Barr virus-infected natural killer cell leukemia in an autocrine fashion. Mizuno S, et al. **Blood** 1999 May 15; 93(10):3494–504

Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Tepper CG, et al. **Blood** 1999 Sep 1;94(5):1727–37

Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. van Baarle D, et al. **Blood** 1999 Jun 1; 93(11):3949–55

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251–8 (42 ref.)

Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus. Kagami Y, et al. **Br J Haematol** 1998 Dec;103(3):669–77

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Maeda Y, et al. **Br J Haematol** 1999 Apr; 105(1):295–302

Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Sleckman BG, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec;7(12):1117–21

Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Tokunaga M, et al. **Cancer Epidemiol Biomarkers Prev** 1998 May;7(5):449–50

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Lo YM, et al. **Cancer Res** 1999 Mar 15;59(6):1188–91

Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Sbih-Lammali F, et al. **Cancer Res** 1999 Feb 15;59(4):924–30

Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Aguilar LK, et al. **Curr Opin Oncol** 1999 Mar;11(2):96–101 (57 ref.)

Epstein-Barr virus, human papillomavirus, and flow cytometric cell cycle kinetics in nasopharyngeal carcinoma and inverted papilloma among Egyptian patients. Kassim SK, et al. **Dis Markers** 1998 Oct;14(2):113–20

Scleroderma-like lesions and Epstein-Barr virus-associated B-cell lymphoma presenting with a huge splenomegaly [letter; comment] Sakai C, et al. **Eur J Haematol** 1999 Apr; 62(4):278–80. Comment on: Eur J Haematol 1997 Sep;59(3):194–6.

B-cell lymphoma associated with DiGeorge syndrome [letter] Sato T, et al. **Eur J Pediatr** 1999 Jul;158(7):609

Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Punwaney R, et al. **Head Neck** 1999 Jan; 21(1):21–9

Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association. Chan AC, et al. **Histopathology** 1999 Jan; 34(1):16–24

Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma. Kume T, et al. **Histopathology** 1999 Jun;34(6):502–9

p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Leung SY, et al. **Histopathology** 1998 Oct; 33(4):311–7

Polymerase chain reaction amplification of archival material for Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, and parvovirus B19 in children with bone marrow hemophagocytosis. Hoang MP, et al. **Hum Pathol** 1998 Oct;29(10):1074–7

HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Lazzi S, et al. **Hum Pathol** 1998 Nov;29(11):1285–9

Epstein-Barr virus-containing T-cell lymphoma and atherosclerotic abdominal aortic aneurysm in a young adult. Luo CY, et al. **Hum Pathol** 1999 Sep;30(9):1114–7

Expression of Epstein-Barr virus in mesopharyngeal and hypopharyngeal carcinomas [see comments] Shimakage M, et al. **Hum Pathol** 1999 Sep;30(9):1071–6. Comment in: Hum Pathol 1999 Sep;30(9):1001–3.

Epstein-Barr virus and cytomegalovirus in relation to testicular-cancer risk: a nested case-control study. Akre O, et al. **Int J Cancer** 1999 Jul 2;82(1):1–5

Epstein-barr virus in Hodgkin's disease: frequency of a 30-bp deletion in the latent membrane protein (LMP-1) oncogene in South African patients [letter] Essop MF, et al. **Int J Cancer** 1999 Aug 20;84(4):449–51

Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Gallagher A, et al. **Int J Cancer** 1999 Aug 20;84(4):442–8

Genetic analysis of sorted Hodgkin and Reed-Sternberg cells using comparative genomic hybridization. Ohshima K, et al. **Int J Cancer** 1999 Jul 19;82(2):250–5

Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Xu J, et al. **Int J Cancer** 1999 Aug 20;84(4):396–9

L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma. Obama K, et al. **Int J Hematol** 1999 Jun; 69(4):260–2

Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy [letter; comment] Iwatsuki K, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):283–4. Comment on: J Am Acad Dermatol 1998 Apr;38(4):574–9.

Epstein-Barr virus-associated gastric carcinoma and atrophic gastritis [see comments] Yanai H, et al. **J Clin Gastroenterol** 1999 Jul;29(1):39–43. Comment in: J Clin Gastroenterol 1999 Jul;29(1):3–5.

Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. Kuzushima K, et al. **J Clin Invest** 1999 Jul;104(2):163–71

Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation [letter] Beck R, et al. **J Clin Microbiol** 1999 Oct; 37(10):3430–1

Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. Buisson M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2709–14

Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. Kimura H, et al. **J Clin Microbiol** 1999 Jan;37(1):132–6

Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Limaye AP, et al. **J Clin Microbiol** 1999 Apr;37(4):1113–6

Pretreatment with restriction enzyme or bovine serum albumin for effective PCR amplification of Epstein-Barr virus DNA in DNA extracted from paraffin-embedded gastric carcinoma tissue. Satoh Y, et al. **J Clin Microbiol** 1998 Nov;36(11):3423–5

Presence of Epstein-Barr virus in lymphoepithelioma-like carcinoma of the middle ear. Leung SY, et al. **J Clin Pathol** 1998 Aug;51(8):602–5

Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. Chai C, et al. **J Cutan Pathol** 1999 May;26(5):242–7

Epstein-Barr virus-associated lymphoproliferative skin lesion with recurrent necrotic papulovesicles of the face. Jung DY, et al. **J Dermatol** 1999 Jul;26(7):448–51

Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. Babcock GJ, et al. **J Exp Med** 1999 Aug 16;190(4):567–76

Case report: hypoechoic submucosal nodules: a sign of Epstein-Barr virus-associated early gastric cancer [published erratum appears in J Gastroenterol Hepatol 1998 Oct;13(10):1080] Nishikawa J, et al. **J Gastroenterol Hepatol** 1998 Jun;13(6):585–90

Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. Maeda A, et al. **J Infect Dis** 1999 Apr;179(4):1012–5

Prevalence of type specific Epstein-Barr virus in the genital tract of genital herpes suspected patients. Kantakamalakul W, et al. **J Med Assoc Thai** 1999 Mar;82(3):263–7

Polymerase chain reaction study of Epstein-Barr virus in high risk group of nasopharyngeal carcinoma: a preliminary report. Luxamechanporn T, et al. **J Med Assoc Thai** 1999 Jun;82(6):593–7

High Epstein-Barr virus serum load and elevated titers of

anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. Drouet E, et al. **J Med Virol** 1999 Apr;57(4):383–9

Characterization of natural Epstein-Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma. Jenson HB, et al. **J Med Virol** 1999 Jan;57(1):36–46

Detection of Epstein-Barr virus in invasive breast cancers [see comments] Bonnet M, et al. **J Natl Cancer Inst** 1999 Aug 18;91(16):1376–81. Comment in: J Natl Cancer Inst 1999 Aug 18;91(16):1349–50.

Breast cancer: a new Epstein-Barr virus-associated disease? [editorial; comment] Magrath I, et al. **J Natl Cancer Inst** 1999 Aug 18;91(16):1349–50. Comment on: J Natl Cancer Inst 1999 Aug 18;91(16):1376–81.

Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. Tune CE, et al. **J Natl Cancer Inst** 1999 May 5;91(9):796–800

Primary EBV-associated cauda equina lymphoma [letter] Giobbia M, et al. **J Neurol** 1999 Aug;246(8):739–40

Epstein-Barr virus associated arthritis [letter] Huston GJ. **J Rheumatol** 1999 Jun;26(6):1422

PCR ELISA for the quantitative detection of Epstein-Barr virus genome. Bazzichi A, et al. **J Virol Methods** 1998 Sep; 74(1):15–20

Flow cytometric detection of EBV (EBER snRNA) using peptide nucleic acid probes. Just T, et al. **J Virol Methods** 1998 Aug;73(2):163–74

Detection of Epstein-Barr virus EBER sequence in post-transplant lymphoma patients with DNA dendrimers. Orentas RJ, et al. **J Virol Methods** 1999 Feb;77(2):153–63

Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. Stowe RP, et al. **J Virol Methods** 1998 Nov;75(1):83–91

Detection and quantification of cell-free Epstein-Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay. Zingg W, et al. **J Virol Methods** 1999 May; 79(2):141–8

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders [letter] Faye A, et al. **Lancet** 1998 Oct 17;352(9136):1285

Epstein-Barr virus involvement in T-cell malignancy: significance in adult T-cell leukemia. Ohtsubo H, et al. **Leuk Lymphoma** 1999 May;33(5–6):451–8 (71 ref.)

Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type. Buisson M, et al. **Leukemia** 1999 Feb;13(2):298–301

Hodgkin disease in children: clinicoepidemiologic and viral (Epstein-Barr virus) analyses. Cavdar AO, et al. **Med Pediatr Oncol** 1999 Jan;32(1):18–24

Brief report: Pediatric Burkitt lymphoma with concurrent chronic Epstein-Barr virus hepatitis. Preciado MV, et al. **Med Pediatr Oncol** 1999 Aug;33(2):134–6

Epstein-Barr virus and oral squamous cell carcinoma in patients without HIV infection: viral detection by polymerase chain reaction. González-Moles M, et al. **Microbios** 1998;96(383):23–31

Epstein-Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine [letter] Niesvizky R, et al. **N Engl J Med** 1999 Jul 1;341(1):55

Post-transplantation lymphoproliferative disorder of the T-cell/B-cell type: an unusual manifestation in a renal allograft. Wirnsberger GH, et al. **Oncol Rep** 1999 Jan–Feb; 6(1):29–32

Chronological changes in incidences of polymorphic reticulosis in Korea and Japan. Ohsawa M, et al. **Oncology** 1999 Apr;56(3):202–7

Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Atula T, et al. **Oral Oncol** 1998 Sep;34(5):391–5

EBER oligonucleotide RNA in situ hybridization in EBV associated neoplasms. Tornóczky T, et al. **Pathol Oncol Res** 1998;4(3):201–5

Epstein-Barr virus and CD21 expression in gastrointestinal tumors. Kim YS, et al. **Pathol Res Pract** 1998; 194(10):705–11

Poliomyelitis-like syndrome associated with Epstein-Barr virus infection. Wong M, et al. **Pediatr Neurol** 1999 Mar; 20(3):235–7

Failure in detection of Epstein-Barr virus and cytomegalovirus in specimen obtained by fine needle aspiration biopsy of thyroid in patients with subacute thyroiditis. Mori K, et al. **Tohoku J Exp Med** 1998 Sep; 186(1):13–7

Natural history of Epstein-Barr viral load in peripheral blood of pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disorder. Cacciarelli TV, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):488–9

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Green M, et al. **Transplantation** 1998 Dec 27;66(12):1641–4

Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients. Kogan DL, et al. **Transplantation** 1999 Apr 15; 67(7):1068–70

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. McDiarmid SV, et al. **Transplantation** 1998 Dec 27; 66(12):1604–11

The role of the Epstein-Barr virus in the oncogenesis of EBV(+) gastric carcinomas. Takano Y, et al. **Virchows Arch** 1999 Jan;434(1):17–22

Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Sugawara Y, et al. **Virology** 1999 Apr 10;256(2):196–202

[The relation between EB virus and Burkitt's lymphoma] Gao Z, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Apr;26(2):106–7 (Eng. Abstr.) **(Chi)**

[Association of epstein-barr virus with lymphoepithelioma-like carcinoma of the lung] Han A, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug; 26(4):222–4 (Eng. Abstr.) **(Chi)**

[The significance of detecting EB virus and its products in benign and malignant lymphoepithelial lesions of the salivary glands] Lin H, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Aug;26(4):225–8 (Eng. Abstr.) **(Chi)**

[Epstein-Barr virus infection and the expression of bcl-2 proto-oncogene in Hodgkin's disease] Liu C, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Jun;26(3):155–7 (Eng. Abstr.) **(Chi)**

[The significance of detecting Epstein-Barr virus BNLF1 fragment and its expression in Hodgkin's disease in the Guangdong area] Zeng W, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Feb;26(1):27–30 (Eng. Abstr.) **(Chi)**

[Hodgkin's disease and anaplastic large cell lymphoma in 1998] Delsol G, et al. **Ann Pathol** 1998 Oct;18(4):331–42 (40 ref.) **(Fre)**

[Smooth muscle mesentery associated with Epstein-Barr virus (EBV). Report of a case in a child with a liver transplant under FK506 regimen] Ferlicot S, et al. **Ann Pathol** 1999 Mar;19(1):46–9 (Eng. Abstr.) **(Fre)**

[Lymphoid hyperplasia associated with human immunodeficiency virus and Epstein-Barr virus; relationship with lymphomatous pathology] Raphaël M, et al. **Ann Pathol** 1998 Oct;18(4):325–30 (61 ref.) **(Fre)**

[Epstein-Barr virus and associated tumors] Raphaël M. **Ann Pathol** 1998;18(5 Suppl):74 **(Fre)**

[Implications of Epstein-Barr virus in pathology. Inflammatory pseudotumors (comment)] Voigt JJ, et al. **Ann Pathol** 1998 Dec;18(6):514–5. Comment on: Ann Pathol 1998 Feb;18(1):16–28. **(Fre)**

[Detection of Epstein-Barr virus in Malt type gastric malignant lymphoma using in situ hybridization] Ben Rejeb A, et al. **Clin Exp Pathol** 1999;47(2):101–5 (Eng. Abstr.) **(Fre)**

[Lymphoepithelioma-like carcinoma of the lung] Muraishi K, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul; 37(7):565–70 (Eng. Abstr.) **(Jpn)**

[Epstein-Barr virus, hemophagocytic syndrome and angiocentric lymphoma: a rare and fatal association] Ramírez Jiménez S, et al. **An Esp Pediatr** 1998 Oct; 49(4):401–4 **(Spa)**

METABOLISM

In situ RT-PCR detection of Epstein-Barr virus immediate-early transcripts in CD4+ and CD8+ T lymphocytes. Guan M, et al. **Anticancer Res** 1998 Sep–Oct; 18(5A):3171–80

Interleukin-12 expression in B cells by transformation with Epstein-Barr virus. Yoshimoto T, et al. **Biochem Biophys Res Commun** 1998 Nov 27;252(3):556–60

Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. Gires O, et al. **EMBO J** 1999 Jun 1;18(11):3064–73

A potential NES of the Epstein-Barr virus nuclear antigen 1 (EBNA1) does not confer shuttling. Fischer N, et al. **FEBS Lett** 1999 Mar 26;447(2–3):311–4

Epstein-Barr virus-encoded nuclear protein EBNA-3 interacts with the epsilon-subunit of the T-complex protein 1 chaperonin complex. Kashuba E, et al. **J Hum Virol** 1999 Jan–Feb;2(1):33–7

The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. Adamson AL, et al. **J Virol** 1999 Aug;73(8):6551–8

The C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus protein EB2 is required for its effect on RNA splicing and transport. Buisson M, et al. **J Virol** 1999 May;73(5):4090–100

Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. Cohen JI, et al. **J Virol** 1999 Sep; 73(9):7627–32

Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. Eliopoulos AG, et al. **J Virol** 1999 Feb;73(2):1023–35

The Epstein-Barr virus (EBV) SM protein enhances pre-mRNA processing of the EBV DNA polymerase transcript. Key SC, et al. **J Virol** 1998 Nov;72(11):8485–92

Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. Kube D, et al. **J Virol** 1999 Feb; 73(2):1630–6

Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. Radkov SA, et al. **J Virol** 1999 Jul;73(7):5688–97

Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein-Barr virus replication gene mRNA. Semmes OJ, et al. **J Virol** 1998 Dec; 72(12):9526–34

The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. Swenson JJ, et al. **J Virol** 1999 Aug;73(8):6540–50

Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. Takeshita H, et al. **J Virol** 1999 Jul;73(7):5548–55

Functional analysis of different LMP1 proteins isolated from Epstein-Barr virus-positive carriers. Fischer N, et al. **Virus Res** 1999 Mar;60(1):41–54

PATHOGENICITY

Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. Klein R, et al. **Am J Surg Pathol** 1999 Apr;23(4):477–81 (31 ref.)

Epstein-Barr virus in Hodgkin's disease. Chapman AL, et al. **Ann Oncol** 1998;9 Suppl 5:S5–16 (118 ref.)

Microsatellite instability, Epstein-Barr virus, mutation of type II transforming growth factor beta receptor and BAX in gastric carcinomas in Hong Kong Chinese. Leung SY, et al. **Br J Cancer** 1999 Feb;79(3–4):582–8

EBNA2 and c-myc in B cell immortalization by Epstein-Barr virus and in the pathogenesis of Burkitt's lymphoma. Zimber-Strobl U, et al. **Curr Top Microbiol Immunol** 1999; 246:315–20; discussion 321 (23 ref.)

Epstein-Barr virus infection and its gene expression in gastric lymphoma of mucosa-associated lymphoid tissue. Xu WS, et al. **J Med Virol** 1998 Dec;56(4):342–50

Detection of Epstein-Barr virus in oral scrapes in HIV infection, in hairy leukoplakia, and in healthy non-HIV-infected people. Scully C, et al. **J Oral Pathol Med** 1998 Nov;27(10):480–2

Functional differences between BHRF1, the Epstein-Barr virus-encoded Bcl-2 homologue, and Bcl-2 in human epithelial cells. Dawson CW, et al. **J Virol** 1998 Nov; 72(11):9016–24

Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. Greifenegger N, et al. **J Virol** 1998 Nov;72(11):9323–8

Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation. Harada S, et al. **J Virol** 1998 Dec; 72(12):9948–54

Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. Komano J, et al. **J Virol** 1998 Nov;72(11):9150–6

Epstein-Barr virus infection of human astrocyte cell lines. Menet A, et al. **J Virol** 1999 Sep;73(9):7722–33

Gene mutation responsible for fatal EBV complication discovered [news] McCarthy M. **Lancet** 1998 Oct 3; 352(9134):1125

Genomic organization of human B-ATF, a target for regulation by EBV and HTLV-1. Meyer NP, et al. **Mamm Genome** 1998 Oct;9(10):849–52

Evidence for a new transcript of the Epstein-Barr virus/C3d receptor (CR2, CD21) which is due to alternative exon usage. Barel M, et al. **Mol Immunol** 1998 Nov; 35(16):1025–31

Epstein-Barr-virus-induced interstitial nephritis in an HIV-positive patient with progressive renal failure. Frazão JM, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1849–52

Clinicopathological findings of virus-associated hemophagocytic syndrome in bone marrow: association with Epstein-Barr virus and apoptosis. Ohshima K, et al. **Pathol Int** 1999 Jun;49(6):533–40

Human herpesvirus-8 glycoprotein B interacts with Epstein-Barr virus (EBV) glycoprotein 110 but fails to complement the infectivity of EBV mutants. Pertel PE, et al. **Virology** 1998 Nov 25;251(2):402–13

The truncated form of the Epstein-Barr virus LMP-1 is dispensable or complimentable by the full-length form in virus infection and replication. Torii T, et al. **Virology** 1998 Nov 25;251(2):273–8

[Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma] Niedobitek G. **Pathologe** 1998 Sep;19(5):337–44 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Natural killer cell-derived large granular lymphocyte lymphoma of lung developed in a patient with hypersensitivity to mosquito bites and reactivated Epstein-Barr virus infection. Mizuki M, et al. **Am J Hematol** 1998 Dec;59(4):309–15

A cosmid system for the analysis of lytic replication of Epstein-Barr virus. Hung CH, et al. **Anal Biochem** 1999 Aug 1;272(2):277–80

Expression of latent and replicative-infection genes of Epstein-Barr virus in macrophage. Shimakage M, et al. **Arch Virol** 1999;144(1):157–66

Epstein-Barr virus and lymphoma. Ambinder RF, et al. **Cancer Treat Res** 1999;99:27–45 (130 ref.)

Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Müller A, et al. **Eur J Immunol** 1998 Nov; 28(11):3488–98

DNA global hypomethylation in EBV-transformed interphase nuclei. Habib M, et al. **Exp Cell Res** 1999 May

25;249(1):46–53
Epstein–Barr virus immortalization and latency. Rowe DT. **Front Biosci** 1999 Mar 15;4:D346–71 (263 ref.)
Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Dolcetti R, et al. **Int J Cancer** 1999 Jan 18; 80(2):240–9
The control of lytic replication of Epstein–Barr virus in B lymphocytes (Review). Schwarzmann F, et al. **Int J Mol Med** 1998 Jan;1(1):137–42 (44 ref.)
Elevated blood levels of soluble tumor necrosis factor receptors in nasopharyngeal carcinoma: correlation with humoral immune response to lytic replication of Epstein–Barr virus. Feng P, et al. **Int J Oncol** 1999 Jul; 15(1):167–72
Maternal and perinatal factors related to maternal–infant transmission of HIV–1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV–1 Infection (P2C2 HIV) Study Group. Pitt J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):462–70
A–type and B–type Epstein–Barr virus differ in their ability to spontaneously enter the lytic cycle. Buck M, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):441–5
Epstein–Barr virus infection and mitogen stimulation of normal B cells induces wild–type p53 without subsequent growth arrest or apoptosis. Pokrovskaja K, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):987–95
Epstein–Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild–type virus. Speck P, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2193–203
Nicotinamide–adenine dinucleotide phosphate oxidase assembly and activation in EBV–transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. Dusi S, et al. **J Immunol** 1998 Nov 1;161(9):4968–74
Expression of EBNA–1 mRNA is regulated by cell cycle during Epstein–Barr virus type I latency. Davenport MG, et al. **J Virol** 1999 Apr;73(4):3154–61
X–Linked agammaglobulinemia patients are not infected with Epstein–Barr virus: implications for the biology of the virus. Faulkner GC, et al. **J Virol** 1999 Feb;73(2):1555–64
Divergent requirements for the MAPK(ERK) signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein–Barr virus latency by phorbol esters. Fenton M, et al. **J Virol** 1999 Oct;73(10):8913–6
CD21–Dependent infection of an epithelial cell line, 293, by Epstein–Barr virus. Fingeroth JD, et al. **J Virol** 1999 Mar; 73(3):2115–25
The Epstein–Barr virus lytic transactivator Zta interacts with the helicase–primase replication proteins. Gao Z, et al. **J Virol** 1998 Nov;72(11):8559–67
Genetic evidence that EBNA–1 is needed for efficient, stable latent infection by Epstein–Barr virus. Lee MA, et al. **J Virol** 1999 Apr;73(4):2974–82
Epstein–Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression. Nishikawa J, et al. **J Virol** 1999 Feb;73(2):1286–92
EBP2, a human protein that interacts with sequences of the Epstein–Barr virus nuclear antigen 1 important for plasmid maintenance. Shire K, et al. **J Virol** 1999 Apr;73(4):2587–95
Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein–Barr virus. Spender LC, et al. **J Virol** 1999 Jun;73(6):4678–88
Cyno–EBV (EBV–related herpesvirus from cynomolgus macaques) induces rabbit malignant lymphomas and their tumor cell lines frequently show specific chromosomal abnormalities. Hayashi K, et al. **Lab Invest** 1999 Jul; 79(7):823–35
Reconsideration of senescence, immortalization and telomere maintenance of Epstein–Barr virus–transformed human B–lymphoblastoid cell lines. Sugimoto M, et al. **Mech Ageing Dev** 1999 Feb 1;107(1):51–60
The Epstein–Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor–associated proteins TRADD and receptor–interacting protein (RIP) but does not induce apoptosis or require RIP for NF–kappaB activation. Izumi KM, et al. **Mol Cell Biol** 1999 Aug;19(8):5759–67
Epstein–barr virus regulates c–MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Ruf IK, et al. **Mol Cell Biol** 1999 Mar;19(3):1651–60
The amino–terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein–Barr virus. Zerby D, et al. **Mol Cell Biol** 1999 Mar;19(3):1617–26
Interferon regulatory factor 2 represses the Epstein–Barr virus BamHI Q latency promoter in type III latency. Zhang L, et al. **Mol Cell Biol** 1999 Apr;19(4):3216–23
Relationship between IkappaBalpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV–infected lymphoblastoid cells. Asso–Bonnet M, et al. **Oncogene** 1998 Sep 24;17(12):1607–15
Regulation of interleukin–1beta transcription by Epstein–Barr virus involves a number of latent proteins via their interaction with RBP. Krauer KG, et al. **Virology** 1998 Dec 20;252(2):418–30
The truncated form of the Epstein–Barr virus LMP–1 is dispensable or complimentable by the full–length form in virus infection and replication. Torii T, et al. **Virology** 1998 Nov 25;251(2):273–8
The interaction of mitogen–activated protein kinases to Epstein–Barr virus activation in Akata cells. Satoh T, et al. **Virus Genes** 1999;18(1):57–64
[Role of Epstein–Barr virus in the pathogenesis of lymphogranulomatosis. Immunohistochemical and molecular–biological (hybridization in situ) research] Leenman EE, et al. **Arkh Patol** 1999 Jan–Feb;61(1):15–22 (Eng. Abstr.) **(Rus)**
[Molecular biological aspects of carcinogenesis associated with the Epstein–Barr virus] Afanas'eva TA, et al. **Mol Biol (Mosk)** 1998 Nov–Dec;32(6):940–7 (100 ref.) **(Rus)**

HERPESVIRUS 5, HUMAN see **CYTOMEGALOVIRUS**

HERPESVIRUS 6, HUMAN

see related
EXANTHEMA SUBITUM

Erythema elevatum diutinum in a patient with human herpesvirus 6 infection [letter] Drago F, et al. **Acta Derm Venereol** 1999 Jan;79(1):91–2
Herpesvirus–6 (HHV–6) encephalitis in a child presenting as a focal necrotic lesion. Matsumoto K, et al. **Acta Neurochir (Wien)** 1999;141(4):439–40
Preferential involvement of U–fibers in human herpesvirus 6–associated acute encephalopathy [letter] Kurachi Y, et al. **Ann Neurol** 1999 May;45(5):684
Human herpesviruses 6 and 7. New roles yet to be discovered? [editorial] Le Cleach L, et al. **Arch Dermatol** 1998 Sep;134(9):1155–7
Human herpesvirus 6 infection as a risk factor for the development of severe drug–induced hypersensitivity syndrome. Suzuki Y, et al. **Arch Dermatol** 1998 Sep; 134(9):1108–12
Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Tohyama M, et al. **Arch Dermatol** 1998 Sep;134(9):1113–7
Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. Bosi A, et al. **Bone Marrow Transplant** 1998 Aug;22(3):285–8
Integration of human herpesvirus 6 in a Burkitt's lymphoma cell line. Daibata M, et al. **Br J Haematol** 1998 Sep; 102(5):1307–13
Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Cole PD, et al. **Clin Infect Dis** 1998 Sep;27(3):653–4
Human herpesvirus 6: An emerging pathogen. Campadelli–Fiume G, et al. **Emerg Infect Dis** 1999 May–Jun;5(3):353–66 (105 ref.)
Lymphoblastoid cell lines with integrated human herpesvirus type 6. Daibata M, et al. **J Hum Virol** 1998 Nov–Dec; 1(7):475–81
Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. Cone RW, et al. **J Infect Dis** 1999 Feb;179(2):311–8
Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. Kositanont U, et al. **J Infect Dis** 1999 Jul;180(1):50–5
Interactions between beta–herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. Emery VC, et al. **J Med Virol** 1999 Mar;57(3):278–82
Human herpesvirus–6: neurologic implications of a newly–described viral pathogen [see comments] Kimberlin DW, et al. **J Neurovirol** 1998 Oct;4(5):474–85 (130 ref.). Comment in: J Neurovirol 1998 Oct;4(5):471–3.
Post transplant CD8+ gammadelta T–cell lymphoma associated with human herpes virus–6 infection. Lin WC, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):377–84 (40 ref.)
Encephalopathy associated with human herpesvirus 6 in a liver transplant recipient. Paterson DL, et al. **Liver Transpl Surg** 1999 Sep;5(5):454–5
Human herpesvirus 6. Dockrell DH, et al. **Mayo Clin Proc** 1999 Feb;74(2):163–70 (56 ref.)
Human Herpesvirus–6 (HHV–6) infection in multiple sclerosis: a preliminary report. Ablashi DV, et al. **Mult Scler** 1998 Dec;4(6):490–6
Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. Lanphear BP, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):792–5
Human herpesvirus 6 infection increases adhesion molecule expression in liver allografts. Lautenschlager I, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):479–80
Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Ratnamohan VM, et al. **Transplantation** 1998 Oct 15;66(7):877–82
[Human Herpesvirus 6: general information and infections in organ transplantations and hematopoietic stem cell grafts] Fontan J, et al. **Presse Med** 1999 Jan 23;28(3):149–56 (60 ref.) (Eng. Abstr.) **(Fre)**
[Serologic study of human herpesviruses 6 and 7 in lymphoma patients] Ongrádi J, et al. **Orv Hetil** 1999 Jun 27; 140(26):1457–9 (Eng. Abstr.) **(Hun)**
[Infantile T cell acute lymphoblastic leukemia complicated by thrombotic microangiopathy and human herpes virus 6 infection after allogeneic peripheral blood stem cell transplantation using CD34–positive cells] Hasegawa D, et al. **Rinsho Ketsueki** 1999 Jul;40(7):574–80 (Eng. Abstr.) **(Jpn)**
[HHV–6 infection, HHV–7 infection] Suga S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):48–50 (15 ref.) **(Jpn)**
[Comparative biology of human herpesviruses 6 and 7] Yamada M. **Uirusu** 1998 Jun;48(1):39–44 (46 ref.) **(Jpn)**
[HHV 6,7 and 8. Recently discovered herpesviruses explain the etiology of well–known diseases] Bergström T. **Lakartidningen** 1999 Jun 30;96(26–27):3161–5 (40 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Comparison of antiviral compounds against human herpesvirus 6 and 7. Yoshida M, et al. **Antiviral Res** 1998 Dec;40(1–2):73–84
The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. Ansari A, et al. **J Virol** 1999 Apr; 73(4):3284–91

ENZYMOLOGY

Active site mutants of human herpesvirus–6 proteinase. Tigue NJ, et al. **FEBS Lett** 1998 Dec 28;441(3):467–9
Autoprocessing and peptide substrates for human herpesvirus 6 proteinase. Tigue NJ, et al. **J Biol Chem** 1998 Oct 9; 273(41):26441–6

GENETICS

Non–AIDS–related Kaposi sarcoma tissues do not contain DNA sequences of HHV–6, HHV–7, Epstein–Barr virus, cytomegalovirus and HSV [letter] Drago F, et al. **Acta Derm Venereol** 1998 Nov;78(6):485
Inheritance of chromosomally integrated human herpesvirus 6 DNA. Daibata M, et al. **Blood** 1999 Sep 1;94(5):1545–9
Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Doniger J, et al. **Clin Microbiol Rev** 1999 Jul;12(3):367–82 (198 ref.)
Presence of human herpesvirus 6 DNA in cord blood cells [letter; comment] Daibata M, et al. **J Infect Dis** 1999 Apr; 179(4):1046–7. Comment on: J Infect Dis 1998 Aug;178(2):544–6.
Fine mapping of an apparently targeted latent human herpesvirus type 6 integration site in chromosome band 17p13.3. Morris C, et al. **J Med Virol** 1999 May;58(1):69–75
The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. Ansari A, et al. **J Virol** 1999 Apr; 73(4):3284–91
Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. Dominguez G, et al. **J Virol** 1999 Oct;73(10):8040–52
CD4 promoter transactivation by human herpesvirus 6. Flamand L, et al. **J Virol** 1998 Nov;72(11):8797–805
Comparison of the complete DNA sequences of human herpesvirus 6 variants A and B. Isegawa Y, et al. **J Virol** 1999 Oct;73(10):8053–63
Human herpesvirus 6 open reading frame U83 encodes a functional chemokine. Zou P, et al. **J Virol** 1999 Jul; 73(7):5926–33
Integration of human herpesvirus 6 genome in human chromosomes [letter; comment] Luppi M, et al. **Lancet** 1998 Nov 21;352(9141):1707–8. Comment on: Lancet 1998 Aug 15;352(9127):543–4.

GROWTH & DEVELOPMENT

Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA, et al. **J Infect Dis** 1998 Dec; 178(6):1783–6
Efficient propagation of human herpesvirus 6B in a T–cell line derived from a patient with adult T–cell leukemia/lymphoma. Zhou CF, et al. **Microbiol Immunol** 1999;43(5):425–36
Inhibition of human immunodeficiency virus 1 (HIV–1) by variant B of human herpesvirus 6 (HHV–6). Bonura F, et al. **New Microbiol** 1999 Jul;22(3):161–71

IMMUNOLOGY

Human herpes virus–6 seroprevalence and leukaemias: a case–control study. GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto). Gentile G, et al. **Br J Cancer** 1999 Jun;80(7):1103–6
Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls. Enbom M, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):545–9
Serological association of measles virus and human herpesvirus–6 with brain autoantibodies in autism. Singh VK, et al. **Clin Immunol Immunopathol** 1998 Oct; 89(1):105–8
Hypersensitivity syndrome due to 2 anticonvulsant drugs. Conilleau V, et al. **Contact Dermatitis** 1999 Sep;41(3):141–4
Serum IgG antibodies to human herpesvirus–6 (HHV–6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group. Dorrucci M, et al. **Eur J Epidemiol** 1999 Apr;15(4):317–22
Human herpesvirus 6 (HHV–6) causes severe thymocyte depletion in SCID–hu Thy/Liv mice. Gobbi A, et al.

HERPESVIRUS 6, HUMAN

J Exp Med 1999 Jun 21;189(12):1953–60

Detection of serum antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus 6 in patients with recurrent aphthous stomatitis. Ghodratnama F, et al. **J Oral Pathol Med** 1999 Jan;28(1):12–5

Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfected cultures. Asada H, et al. **J Virol** 1999 May; 73(5):4019–28

CD4 promoter transactivation by human herpesvirus 6. Flamand L, et al. **J Virol** 1998 Nov;72(11):8797–805

Selection and characterization of two specific monoclonal antibodies directed against the two variants of human herpesvirus–6. Robert C, et al. **Res Virol** 1998 Nov–Dec; 149(6):403–11

Comparison of seroprevalences of human herpesvirus–6 and –7 in healthy blood donors from nine countries. Krueger GR, et al. **Vox Sang** 1998;75(3):193–7

[Level of HHV–6A antibodies in symptomless HIV infection as well as in the course of AIDS] Ongrádi J, et al. **Orv Hetil** 1999 Aug 22;140(34):1881–5 (Eng. Abstr.) **(Hun)**

[Presence of antibodies to human herpesvirus type 6 and 7 in Hungarian children] Ongrádi J, et al. **Orv Hetil** 1999 Apr 25;140(17):935–40 (58 ref.) (Eng. Abstr.) **(Hun)**

ISOLATION & PURIFICATION

Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Berneman ZN, et al. **Ann Hematol** 1998 Dec;77(6):275–8 (59 ref.)

Fever and rash in a young boy. Golledge C. **Aust Fam Physician** 1999 Mar;28(3):271

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Maeda Y, et al. **Br J Haematol** 1999 Apr; 105(1):295–302

Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Wang FZ, et al. **Clin Infect Dis** 1999 Mar;28(3):562–8

Encephalitis in the first three years of life. **Commun Dis Rep CDR Wkly** 1998 Sep 25;8(39):343

Human herpesvirus–6 encephalitis after bone marrow transplantation: magnetic resonance imaging could identify the involved sites of encephalitis [letter] Tsujimura H, et al. **Eur J Haematol** 1998 Oct;61(4):284–5

Polymerase chain reaction amplification of archival material for Epstein–Barr virus, cytomegalovirus, human herpesvirus 6, and parvovirus B19 in children with bone marrow hemophagocytosis. Hoang MP, et al. **Hum Pathol** 1998 Oct;29(10):1074–7

Meningoencephalitis caused by human herpesvirus–6 in an immunocompetent adult patient: case report and review of the literature. Torre D, et al. **Infection** 1998 Nov–Dec; 26(6):402–4 (28 ref.)

Human herpesvirus 6 latently infects mononuclear cells but not liver tissue. Yoshikawa T, et al. **J Clin Pathol** 1999 Jan;52(1):65–7

Human herpesvirus–6 and sudden death in infancy: report of a case and review of the literature. Hoang MP, et al. **J Forensic Sci** 1999 Mar;44(2):432–7 (26 ref.)

Polymerase chain reaction analysis of human herpesvirus–6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis. Goldberg SH, et al. **J Neurovirol** 1999 Apr;5(2):134–9

Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy. Mock DJ, et al. **J Neurovirol** 1999 Aug;5(4):363–73

Serological screening for hepatitis B and C and human herpesvirus 6 in Norwegian patients with primary Sjögren's syndrome [letter] Iakimtchouk K, et al. **J Rheumatol** 1999 Sep;26(9):2065–6

Development of a dot blot neutralizing assay for HHV–6 and HHV–7 using specific monoclonal antibodies. Tsukazaki T, et al. **J Virol Methods** 1998 Aug;73(2):141–9

Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Kadakia MP. **Leuk Lymphoma** 1998 Oct;31(3–4):251–66 (130 ref.)

Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR–ELISA. Ohyashiki JH, et al. **Leuk Res** 1999 Jul; 23(7):625–30

Sudden unexpected death associated with HHV–6 in an adolescent with tuberous sclerosis. Wang J, et al. **Pediatr Neurol** 1999 Jul;21(1):488–91

Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Dockrell DH, et al. **Transplantation** 1999 Feb 15;67(3):399–403

METABOLISM

N– and C–terminal external domains of human herpesvirus–6 glycoprotein H affect a fusion–associated conformation mediated by glycoprotein L binding the N terminus. Anderson RA, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1485–94

The 41–kDa protein of human herpesvirus 6 specifically binds to viral DNA polymerase and greatly increases DNA synthesis. Lin K, et al. **Virology** 1998 Oct 10;250(1):210–9

PATHOGENICITY

The new herpesviruses: emerging pathogens of dermatological interest. Drago F, et al. **Arch Dermatol** 1999 Jan;135(1):71–5 (110 ref.)

The effect of human herpesvirus–6 (HHV–6) on cultured human neural cells: oligodendrocytes and microglia [see comments] Albright AV, et al. **J Neurovirol** 1998 Oct; 4(5):486–94. Comment in: J Neurovirol 1998 Oct;4(5):471–3.

Association of human herpesvirus–6 and multiple sclerosis: here we go again? [editorial; comment] Jacobson S. **J Neurovirol** 1998 Oct;4(5):471–3 (18 ref.). Comment on: J Neurovirol 1998 Oct;4(5):474–85. Comment on: J Neurovirol 1998 Oct;4(5):486–94. Comment on: J Neurovirol 1998 Oct;4(5):495–511.

Viral glycoproteins accumulate in newly formed annulate lamellae following infection of lymphoid cells by human herpesvirus 6. Cardinali G, et al. **J Virol** 1998 Dec; 72(12):9738–46

PHYSIOLOGY

Latent infection and reactivation of human herpesvirus 6 in two novel myeloid cell lines. Yasukawa M, et al. **Blood** 1999 Feb 1;93(3):991–9

Down–regulation of CXCR4 by human herpesvirus 6 (HHV–6) and HHV–7. Yasukawa M, et al. **J Immunol** 1999 May 1;162(9):5417–22

Induction of apoptosis in cord blood lymphocytes by HHV–6. Ichimi R, et al. **J Med Virol** 1999 May;58(1):63–8

Cytomegalovirus and human herpesvirus–6 trans–activate the HIV–1 long terminal repeat via multiple response regions in human fetal astrocytes [see comments] McCarthy M, et al. **J Neurovirol** 1998 Oct;4(5):495–511. Comment in: J Neurovirol 1998 Oct;4(5):471–3.

Viral glycoproteins accumulate in newly formed annulate lamellae following infection of lymphoid cells by human herpesvirus 6. Cardinali G, et al. **J Virol** 1998 Dec; 72(12):9738–46

Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. Luppi M, et al. **J Virol** 1999 Jan; 73(1):754–9

Trafficking to the plasma membrane of the seven–transmembrane protein encoded by human herpesvirus 6 U51 gene involves a cell–specific function present in T lymphocytes. Menotti L, et al. **J Virol** 1999 Jan;73(1):325–33

U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture. Rotola A, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13911–6

Intracellular transport and maturation pathway of human herpesvirus 6. Torrisi MR, et al. **Virology** 1999 May 10; 257(2):460–71

HERPESVIRUS 7, HUMAN

Pityriasis rosea is not associated with human herpesvirus 7. Kempf W, et al. **Arch Dermatol** 1999 Sep;135(9):1070–2

Human herpesviruses 6 and 7. New roles yet to be discovered? [editorial] Le Cleach L, et al. **Arch Dermatol** 1998 Sep;134(9):1155–7

Pityriasis rosea and herpesvirus 7: action or interaction? [letter; comment] Drago F, et al. **Dermatology** 1998; 197(3):275. Comment on: Dermatology 1998;196(2):275.

Human herpesvirus 7 and pityriasis rosea [letter] Watanabe T, et al. **J Invest Dermatol** 1999 Aug;113(2):288–9

Interactions between beta–herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. Emery VC, et al. **J Med Virol** 1999 Mar;57(3):278–82

Thrombocytopenia after human herpesvirus–7 infection in a patient with DiGeorge syndrome [letter] Sato A, et al. **J Pediatr Hematol Oncol** 1999 Mar–Apr;21(2):171–2

Tamplicon–7, a novel T–lymphotropic vector derived from human herpesvirus 7. Romi H, et al. **J Virol** 1999 Aug; 73(8):7001–7

Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations. van den Berg JS, et al. **Neurology** 1999 Mar 23;52(5):1077–9

Risk factors for the early acquisition of human herpesvirus 6 and human herpesvirus 7 infections in children. Lanphear BP, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):792–5

[Serologic study of human herpesviruses 6 and 7 in lymphoma patients] Ongrádi J, et al. **Orv Hetil** 1999 Jun 27; 140(26):1457–9 (Eng. Abstr.) **(Hun)**

[In vitro cytokine induction in leukocytes by human herpesvirus 7] Ongrádi J, et al. **Orv Hetil** 1999 Aug 29; 140(35):1935–9 (Eng. Abstr.) **(Hun)**

[HHV–6 infection, HHV–7 infection] Suga S. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):48–50 (15 ref.) **(Jpn)**

[Comparative biology of human herpesviruses 6 and 7] Yamada M. **Uirusu** 1998 Jun;48(1):39–44 (46 ref.) **(Jpn)**

[HHV 6,7 and 8. Recently discovered herpesviruses explain the etiology of well–known diseases] Bergström T. **Lakartidningen** 1999 Jun 30;96(26–27):3161–5 (40 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

Comparison of antiviral compounds against human herpesvirus 6 and 7. Yoshida M, et al. **Antiviral Res** 1998 Dec;40(1–2):73–84

GENETICS

Non–AIDS–related Kaposi sarcoma tissues do not contain DNA sequences of HHV–6, HHV–7, Epstein–Barr virus, cytomegalovirus and HSV [letter] Drago F, et al. **Acta Derm Venereol** 1998 Nov;78(6):485

Definition and distribution analysis of glycoprotein B gene alleles of human herpesvirus 7. Franti M, et al. **J Virol** 1998 Nov;72(11):8725–30

GROWTH & DEVELOPMENT

Propagation and characterization of human herpesvirus–7 (HHV–7) isolates in a continuous T–lymphoblastoid cell line (SupT1). Ablashi DV, et al. **J Virol Methods** 1998 Aug; 73(2):123–40

IMMUNOLOGY

Detection of human herpesvirus 7 (HHV–7) DNA in breast milk by polymerase chain reaction and prevalence of HHV–7 antibody in breast–fed and bottle–fed children. Fujisaki H, et al. **J Med Virol** 1998 Nov;56(3):275–9

Comparison of seroprevalences of human herpesvirus–6 and –7 in healthy blood donors from nine countries. Krueger GR, et al. **Vox Sang** 1998;75(3):193–7

[Presence of antibodies to human herpesvirus type 6 and 7 in Hungarian children] Ongrádi J, et al. **Orv Hetil** 1999 Apr 25;140(17):935–40 (58 ref.) (Eng. Abstr.) **(Hun)**

ISOLATION & PURIFICATION

Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy. Berneman ZN, et al. **Ann Hematol** 1998 Dec;77(6):275–8 (59 ref.)

Human herpesvirus 7 and lymphocytic leukaemia [letter] Daibata M, et al. **Br J Haematol** 1999 Mar;104(4):934

Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Maeda Y, et al. **Br J Haematol** 1999 Apr; 105(1):295–302

Encephalitis in the first three years of life. **Commun Dis Rep CDR Wkly** 1998 Sep 25;8(39):343

Detection of human herpesvirus 7 (HHV–7) DNA in breast milk by polymerase chain reaction and prevalence of HHV–7 antibody in breast–fed and bottle–fed children. Fujisaki H, et al. **J Med Virol** 1998 Nov;56(3):275–9

Propagation and characterization of human herpesvirus–7 (HHV–7) isolates in a continuous T–lymphoblastoid cell line (SupT1). Ablashi DV, et al. **J Virol Methods** 1998 Aug; 73(2):123–40

Development of a dot blot neutralizing assay for HHV–6 and HHV–7 using specific monoclonal antibodies. Tsukazaki T, et al. **J Virol Methods** 1998 Aug;73(2):141–9

PATHOGENICITY

Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. Secchiero P, et al. **Blood** 1998 Dec 15;92(12):4521–8

PHYSIOLOGY

Down–regulation of CXCR4 by human herpesvirus 6 (HHV–6) and HHV–7. Yasukawa M, et al. **J Immunol** 1999 May 1;162(9):5417–22

HERPESVIRUS 8, HUMAN see **HERPESVIRUS, KAPOSI SARCOMA–ASSOCIATED**

HERPESVIRUS INFECTIONS see **HERPESVIRIDAE INFECTIONS**

HERPESVIRUS, KAPOSI SARCOMA–ASSOCIATED

Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival [see comments] Brodt HR, et al. **AIDS** 1998 Aug 20;12(12):1475–81. Comment in: AIDS 1999 Feb 4;13(2):286.

Involvement of human interleukin–6 in systemic manifestations of human herpesvirus type 8–associated multicentric Castleman's disease [letter] Foussat A, et al. **AIDS** 1999 Jan 14;13(1):150–2

Complete regression of AIDS–related Kaposi's sarcoma–associated human herpesvirus–8 during therapy with indinavir [letter] Martinelli C, et al. **AIDS** 1998 Sep 10;12(13):1717–9

Increasing Kaposi's sarcoma–associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985. Olsen SJ, et al. **AIDS** 1998 Oct 1;12(14):1921–5

A biophenotypic human herpesvirus 8–associated primary bowel lymphoma [letter; comment] Beaty MW, et al. **Am J Surg Pathol** 1999 Aug;23(8):992–4. Comment on: Am J Surg Pathol 1997 Jun;21(6):719–24.

Herpes virus type 8–negative primary effusion lymphoma associated with PAX–5 gene rearrangement and hepatitis C virus: a case report and review of the literature.

Ichinohasama R, et al. **Am J Surg Pathol** 1998 Dec; 22(12):1528–37 (45 ref.)

No evidence of HHV–8 infection in patients with pemphigus vulgaris/foliaceus [letter; comment] Cathomas G, et al. **Arch Dermatol** 1998 Sep;134(9):1162. Comment on: Arch Dermatol 1997 Oct;133(10):1247–51.

Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T–cell phenotype. Said JW, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):257–60

Inflammatory reactivation and angiogenicity of Kaposi's sarcoma–associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome–associated Kaposi's sarcoma [comment] Mesri EA. **Blood** 1999 Jun 15;93(12):4031–3 (18 ref.). Comment on: Blood 1999 Jun 15;93(12):4034–43. Comment on: Blood 1999 Jun 15;93(12):4044–58.

Kaposi's sarcoma herpesvirus as a new paradigm for virus–induced oncogenesis. Whitby D, et al. **Curr Opin Oncol** 1998 Sep;10(5):405–12 (82 ref.)

Suppression of HHV–8 viremia by foscarnet in an HIV–infected patient with Kaposi's sarcoma and HHV–8 associated hemophagocytic syndrome. Löw P, et al. **Eur J Med Res** 1998 Oct 14;3(10):461–4

Accessibility of selenomethionine proteins by total chemical synthesis: structural studies of human herpesvirus–8 MIP–II. Shao W, et al. **FEBS Lett** 1998 Dec 11; 441(1):77–82

A complex immunodeficiency. Idiopathic CD4+ T–lymphocytopenia and hypogammaglobulinemia associated with HHV8 infection, Kaposi's sarcoma and gastric cancer [letter] Mazzucchelli I, et al. **Haematologica** 1999 Apr;84(4):378–80

Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Gessain A, et al. **Int J Cancer** 1999 Apr 12;81(2):189–92

CD4+ T–lymphocytopenia, Kaposi's sarcoma, HHV–8 infection, severe seborrheic dermatitis, and onychomycosis in a homosexual man without HIV infection [letter] García–Silva J, et al. **Int J Dermatol** 1999 Mar;38(3):231–3

Incidence of acquired immunodeficiency syndrome (AIDS)–related Kaposi's sarcoma in the Aquitaine Cohort, France, 1988–1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Dupon M, et al. **Int J Epidemiol** 1998 Dec;27(6):1078–82

Kaposi's sarcoma–associated herpesvirus infection in the lung in multicentric Castleman's disease [see comments] Hayashi M, et al. **Intern Med** 1999 Mar;38(3):279–82. Comment in: Intern Med 1999 Mar;38(3):221–2.

Consideration of host–viral interactions in the pathogenesis of Kaposi's sarcoma. Offermann MK. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S58–65 (69 ref.)

Kaposi's sarcoma–associated herpesvirus: a sexually transmissible infection? Grulich AE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):387–93

Human herpes–virus 8 seropositive patient with skin and graft Kaposi's sarcoma after lung transplantation. Sachsenberg–Studer EM, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):308–11

Classic Kaposi's sarcoma after multiple–partner heterosexual behavior in Central Africa. Simonart T, et al. **J Am Acad Dermatol** 1999 Oct;41(4):648–9

Chemokines activate Kaposi's sarcoma–associated herpesvirus G protein–coupled receptor in mammalian cells in culture [see comments] Gershengorn MC, et al. **J Clin Invest** 1998 Oct 15;102(8):1469–72. Comment in: J Clin Invest 1998 Oct 15;102(8):1467–8.

Transcriptional activation by the human herpesvirus–8–encoded interferon regulatory factor. Roan F, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2205–9

Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8 [see comments] Ariyoshi K, et al. **J Hum Virol** 1998 Mar–Apr;1(3):193–9 . Comment in: J Hum Virol 1998 Mar–Apr;1(3):185–6.

Unique properties of a second human herpesvirus 8–encoded interferon regulatory factor (vIRF–2). Burysek L, et al. **J Hum Virol** 1999 Jan–Feb;2(1):19–32

Seroprevalence of Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8 in several regions of Italy. Calabrò ML, et al. **J Hum Virol** 1998 Mar–Apr;1(3):207–13

HIV–1, HHV–8, and Kaposi's sarcoma [editorial; comment] Gallo RC. **J Hum Virol** 1998 Mar–Apr;1(3):185–6. Comment on: J Hum Virol 1998 Mar–Apr;1(3):193–9.

Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother–child pairs with KS. He J, et al. **J Infect Dis** 1998 Dec;178(6):1787–90

Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Smith NA, et al. **J Infect Dis** 1999 Sep;180(3):600–6

Cellular tropism and viral interleukin–6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Staskus KA, et al. **J Virol** 1999 May;73(5):4181–7

Human herpesvirus–8 infection in hemodialysis patients from northern Italy [letter] Luppi M, et al. **Kidney Int** 1999 Jan; 55(1):340

Lymphoid disorders associated with HHV–8/KSHV infection: facts and contentions. Gaidano G, et al. **Med Oncol** 1999 Apr;16(1):8–12

Human herpesvirus 8—let the transplantation physician beware [editorial; comment] Ho M. **N Engl J Med** 1998 Nov 5;339(19):1391–2. Comment on: N Engl J Med 1998 Nov 5;339(19):1358–63.

Human herpesvirus 8 and Kaposi's sarcoma—some answers, more questions [editorial; comment] Jaffe HW, et al. **N Engl J Med** 1999 Jun 17;340(24):1912–3. Comment on: N Engl J Med 1999 Jun 17;340(24):1863–71.

HHV8 status in Kaposi's sarcoma associated with multiple myeloma. Le Gars L, et al. **Rev Rhum Engl Ed** 1998 Dec; 65(12):788–90

Kaposi sarcoma–associated herpesvirus/human herpesvirus type 8 and Epstein–Barr virus in immunosuppressed renal transplant recipients. Demirağ A, et al. **Transplant Proc** 1998 Nov;30(7):3166–7

Transplantation–associated Kaposi's sarcoma: herpesvirus 8 transmission through renal allografts. Regamey N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):922–3

Human herpes virus–8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). Farge D, et al. **Transplantation** 1999 May 15;67(9):1236–42

[Human herpesvirus 8 (HHV–8): I. Characteristics and epidemiology] Boulanger E. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):643–50 (38 ref.) (Eng. Abstr.) **(Fre)**

[HHV–8 related diseases] Calvez V, et al. **Presse Med** 1998 Dec;27 Suppl 5:16 (Eng. Abstr.) **(Fre)**

[Kaposi's disease] Lebbé C. **Rev Prat** 1999 Apr 15;49(8):843–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Kaposiform HHV–8 negative acroangiodermatitis in chronic venous insufficiency] Krengel S, et al. **Hautarzt** 1999 Mar; 50(3):208–13 (Eng. Abstr.) **(Ger)**

[Painless, red–violet skin lesions during immunosuppression] Pfister M, et al. **Ther Umsch** 1998 Sep;55(9):583–5 (Eng. Abstr.) **(Ger)**

[HHV8 infection (Kaposi's sarcoma)] Tachikawa N. **Ryoikibetsu Shokogun Shiriza** 1999;(23 Pt 1):51–4 (6 ref.) **(Jpn)**

[HHV 6,7 and 8. Recently discovered herpesviruses explain the etiology of well–known diseases] Bergström T. **Lakartidningen** 1999 Jun 30;96(26–27):3161–5 (40 ref.) (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Study of human herpesvirus 8 (HHV–8) variants from Kaposi's sarcoma in France: is HHV–8 subtype A responsible for more agressive tumors? [letter; comment] Boralevi F, et al. **J Infect Dis** 1998 Nov;178(5):1546–7. Comment on: J Infect Dis 1998 Apr;177(4):1136–7.

Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Meng YX, et al. **Virology** 1999 Aug 15; 261(1):106–19

DRUG EFFECTS

Favourable effect of chemotherapy on clinical symptoms and human herpesvirus–8 DNA load in a patient with Kaposi's sarcoma presenting with fever and anemia. Prins JM, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):499–502

Activity of thalidomide in AIDS–related Kaposi's sarcoma and correlation with HHV8 titre. Fife K, et al. **Int J STD AIDS** 1998 Dec;9(12):751–5

Human herpesvirus 8–encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. Cannon JS, et al. **J Virol** 1999 Jun; 73(6):4786–93

Identification and rapid quantification of early– and late–lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. Zoeteweij JP, et al. **J Virol** 1999 Jul;73(7):5894–902

[Human herpesvirus 8 (HHV8). II. Pathogenic role and sensitivity to antiviral drugs] Boulanger E. **Ann Biol Clin (Paris)** 1999 Jan–Feb;57(1):19–28 (48 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Kaposi's sarcoma–associated herpesvirus (human herpesvirus–8) ORF54 encodes a functional dUTPase expressed in the lytic replication cycle. Kremmer E, et al. **J Gen Virol** 1999 May;80 (Pt 5):1305–10

GENETICS

Epidemiology of Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8. Schulz TF. **Adv Cancer Res** 1999;76:121–60 (172 ref.)

Kaposi's sarcoma–associated herpesvirus: epidemiology, virology, and molecular biology. Sarid R, et al. **Adv Virus Res** 1999;52:139–232 (395 ref.)

Variability and evolution of Kaposi's sarcoma–associated herpesvirus in Europe and Africa. International Collaborative Group. Cook PM, et al. **AIDS** 1999 Jul 9; 13(10):1165–76

Angiogenesis and hematopoiesis induced by Kaposi's sarcoma–associated herpesvirus–encoded interleukin–6 [see comments] Aoki Y, et al. **Blood** 1999 Jun 15;93(12):4034–43 . Comment in: Blood 1999 Jun 15;93(12):4031–3.

Activation of human herpesvirus 8 (HHV–8) thymidine kinase (TK) TATAA–less promoter by HHV–8 ORF50 gene product is SP1 dependent. Zhang L, et al. **DNA Cell Biol** 1998 Sep;17(9):735–42

Detection and sequence diversity of Kaposi's sarcoma–associated herpesvirus (KSHV)/human herpesvirus 8 (HHV–8) DNA. Murakami M, et al. **Eur J Dermatol** 1999 Jan–Feb;9(1):13–6

Human herpesvirus 8 (HHV–8) in familial Kaposi's sarcoma. Kempf W, et al. **Exp Dermatol** 1999 Feb;8(1):68–70

Big but weak: how many pathogenic genes does human herpesvirus–8 need to cause Kaposi's sarcoma? (Review). Sturzl M, et al. **Int J Oncol** 1999 Feb;14(2):287–9 (20 ref.)

American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Active transcription of human herpesvirus 8 cellular homologue genes and HIV–1 tat in various forms of Kaposi's sarcoma. Moore AY. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):458–9

HHV8–encoded vMIP–I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. Dairaghi DJ, et al. **J Biol Chem** 1999 Jul 30; 274(31):21569–74

Agonists and inverse agonists for the herpesvirus 8–encoded constitutively active seven–transmembrane oncogene product, ORF–74. Rosenkilde MM, et al. **J Biol Chem** 1999 Jan 8;274(2):956–61

Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. Pellett PE, et al. **J Clin Microbiol** 1999 May;37(5):1298–301

Further confirmation of the association of human herpesvirus 8 with Kaposi's sarcoma. Li N, et al. **J Cutan Pathol** 1998 Sep;25(8):413–9

Kaposi's sarcoma–associated herpesvirus (human herpesvirus–8) encodes a homologue of the Epstein–Barr virus bZip protein EB1. Gruffat H, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):557–61

Sequence analyses of human herpesvirus–8 strains from both African human immunodeficiency virus–negative and –positive childhood endemic Kaposi's sarcoma show a close relationship with strains identified in febrile children and high variation in the K1 glycoprotein. Kasolo FC, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3055–65

Induction of human herpesvirus–8 DNA replication and transcription by butyrate and TPA in BCBL–1 cells. Yu Y, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):83–90

Identification and characterization of human herpesvirus 8 open reading frame K9 viral interferon regulatory factor by a monoclonal antibody. Inagi R, et al. **J Hum Virol** 1999 Mar–Apr;2(2):63–71

Identification of a major latent nuclear antigen, LNA–1, in the human herpesvirus 8 genome. Kellam P, et al. **J Hum Virol** 1997 Nov–Dec;1(1):19–29

Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus–G protein–coupled receptor. Burger M, et al. **J Immunol** 1999 Aug 15;163(4):2017–22

Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. Whitby D, et al. **J Infect Dis** 1999 Jan;179(1):234–6

Distinct biology of Kaposi's sarcoma–associated herpesvirus from primary lesions and body cavity lymphomas. Friborg J Jr, et al. **J Virol** 1998 Dec;72(12):10073–82

Identification of a spliced gene from Kaposi's sarcoma–associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein–Barr virus. Glenn M, et al. **J Virol** 1999 Aug; 73(8):6953–63

Expression of the open reading frame 74 (G–protein–coupled receptor) gene of Kaposi's sarcoma (KS)–associated herpesvirus: implications for KS pathogenesis. Kirshner JR, et al. **J Virol** 1999 Jul;73(7):6006–14

Identification and characterization of Kaposi's sarcoma–associated herpesvirus K8.1 virion glycoprotein. Li M, et al. **J Virol** 1999 Feb;73(2):1341–9

Kaposi's sarcoma–associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein–Barr virus. Lin SF, et al. **J Virol** 1999 Mar;73(3):1909–17

Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma–associated herpesvirus reveals evidence for recombination and for two distinct types of open reading frame K15 alleles at the right–hand end. Poole LJ, et al. **J Virol** 1999 Aug;73(8):6646–60

A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma–associated herpesvirus. Sadler R, et al. **J Virol** 1999 Jul;73(7):5722–30

Characterization and cell cycle regulation of the major Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) latent genes and their promoter. Sarid R, et al. **J Virol** 1999 Feb;73(2):1438–46

Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma–associated herpesvirus/human herpesvirus 8. Searles RP, et al. **J Virol** 1999 Apr;73(4):3040–53

Kinetics of Kaposi's sarcoma–associated herpesvirus gene expression. Sun R, et al. **J Virol** 1999 Mar;73(3):2232–42

Identification of the immediate–early transcripts of Kaposi's sarcoma–associated herpesvirus. Zhu FX, et al. **J Virol** 1999 Jul;73(7):5556–67

High–level variability in the ORF–K1 membrane protein gene at the left end of the Kaposi's sarcoma–associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. Zong JC, et al. **J Virol** 1999 May;73(5):4156–70

Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma [published erratum appears in Lab Invest 1999 Jul;79(7):835] Teruya-Feldstein J, et al. **Lab Invest** 1998 Dec;78(12):1637-42

Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study. Stürzl M, et al. **Leukemia** 1999 Apr;13 Suppl 1:S110-2

Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Lagunoff M, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5704-9

Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Ballestas ME, et al. **Science** 1999 Apr 23;284(5414):641-4

Viral encoded cyclins. Cannell E, et al. **Semin Cancer Biol** 1999 Jun;9(3):221-9 (94 ref.)

KSHV strains: the origins and global spread of the virus. Hayward GS. **Semin Cancer Biol** 1999 Jun;9(3):187-99 (37 ref.)

The descent of human herpesvirus 8. McGeoch DJ, et al. **Semin Cancer Biol** 1999 Jun;9(3):201-9 (31 ref.)

The role of HHV-8 in Kaposi's sarcoma. Neipel F, et al. **Semin Cancer Biol** 1999 Jun;9(3):151-64 (82 ref.)

Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Hudnall SD, et al. **Transplantation** 1999 Mar 15;67(5):648-52

Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Talbot SJ, et al. **Virology** 1999 Apr 25;257(1):84-94

GROWTH & DEVELOPMENT

Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma [see comments] Monini P, et al. **Blood** 1999 Jun 15;93(12):4044-58. Comment in: Blood 1999 Jun 15;93(12):4031-3.

The chemokine kidnapping receptor of HHV8 [editorial; comment] Howard OM, et al. **J Clin Invest** 1998 Oct 15; 102(8):1467-8. Comment on: J Clin Invest 1998 Oct 15;102(8):1469-72.

Activation in vivo of retroperitoneal fibromatosis-associated herpesvirus, a simian homologue of human herpesvirus-8. Bosch ML, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):467-75

Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. Hudnall SD, et al. **J Infect Dis** 1998 Dec;178(6):1791-4

Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. Katano H, et al. **J Med Virol** 1999 Aug;58(4):394-401

IMMUNOLOGY

Prevalence of human herpesvirus 8 antibodies in human immunodeficiency virus type 1-infected homosexual men in Slovakia [letter] Mayer V, et al. **Acta Virol** 1998 Apr; 42(2):123-4

Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. Renwick N, et al. **AIDS** 1998 Dec 24;12(18):2481-8

The association of skin diseases with human herpesvirus 8 infection in HIV carriers. Na Ayuthaya PI, et al. **Arch Virol** 1998;143(10):1881-92

Human herpes virus 8 (HHV8) serology in allogeneic bone marrow transplant recipients. Rosenzwajg M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):351-4

Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease. Bélec L, et al. **Clin Infect Dis** 1999 Mar;28(3):678-9

HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. Dairaghi DJ, et al. **J Biol Chem** 1999 Jul 30; 274(31):21569-74

Human herpesvirus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. Cattani P, et al. **J Clin Microbiol** 1999 Apr;37(4):1150-3

Evaluation of BC-3 and BCP-1 cell lines in immunofluorescence assay to detect HHV-8 antibodies in Kaposi's sarcoma, multiple myeloma and other groups. Couty JP, et al. **J Clin Virol** 1999 May;12(3):221-31

Increased human herpesvirus 8 seroprevalence in young homosexual men who have multiple sex contacts with different partners. Blackbourn DJ, et al. **J Infect Dis** 1999 Jan;179(1):237-9

Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. Cannon JS, et al. **J Infect Dis** 1999 Sep; 180(3):824-8

Searching for human herpesvirus 8 antibodies in serum samples from patients infected with human immunodeficiency virus type 1 and blood donors from São Paulo, Brazil [letter] Caterino-de-Araujo A, et al. **J Infect Dis** 1999 Jun;179(6):1591-2

Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. Tedeschi R, et al. **J Infect Dis** 1999 Apr;179(4):1016-20

Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. Whitby D, et al. **J Infect Dis** 1999 Jan;179(1):234-6

Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. Zhang Xq, et al. **J Infect Dis** 1998 Nov;178(5):1488-91

High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. Andreoni M, et al. **J Natl Cancer Inst** 1999 Mar 3; 91(5):465-9

Human herpesvirus 8 and cancer [editorial; comment] Beral V, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1440-1. Comment on: J Natl Cancer Inst 1999 Sep 1;91(17):1468-74.

Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases [see comments] Rezza G, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1468-74. Comment in: J Natl Cancer Inst 1999 Sep 1;91(17):1440-1.

Characterization of monoclonal antibodies raised against the latent nuclear antigen of human herpesvirus 8. Kellam P, et al. **J Virol** 1999 Jun;73(6):5149-55

Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. Monini P, et al. **J Virol** 1999 May; 73(5):4029-41

Identification of human herpesvirus 8-specific cytotoxic T-cell responses. Osman M, et al. **J Virol** 1999 Jul; 73(7):6136-40

HHV-8 peripheral-blood viral load and the titer of antibodies against HHV-8 [letter] Campbell TB, et al. **N Engl J Med** 1999 Oct 14;341(16):1241-2

Human herpesvirus 8 and renal transplantation [letter; comment] Frances C, et al. **N Engl J Med** 1999 Apr 1; 340(13):1045; discussion 1046. Comment on: N Engl J Med 1998 Nov 5;339(19):1358-63.

Human herpesvirus 8 and renal transplantation [letter; comment] Rabkin CS, et al. **N Engl J Med** 1999 Apr 1; 340(13):1045-6. Comment on: N Engl J Med 1998 Nov 5;339(19):1358-63.

Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients [see comments] Regamey N, et al. **N Engl J Med** 1998 Nov 5; 339(19):1358-63. Comment in: N Engl J Med 1998 Nov 5;339(19):1391-2. Comment in: N Engl J Med 1999 Apr 1;340(13):1045; discussion 1046. Comment in: N Engl J Med 1999 Apr 1;340(13):1045-6.

Increasing probability of mother-to-child transmission of HHV-8 with increasing maternal antibody titer for HHV-8 [letter] Sitas F, et al. **N Engl J Med** 1999 Jun 17; 340(24):1923

Antibodies against human herpesvirus 8 in black South African patients with cancer [see comments] Sitas F, et al. **N Engl J Med** 1999 Jun 17;340(24):1863-71. Comment in: N Engl J Med 1999 Jun 17;340(24):1912-3.

Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Chatlynne LG, et al. **Semin Cancer Biol** 1999 Jun;9(3):175-85 (57 ref.)

Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8. Lang D, et al. **Virology** 1999 Jul 20;260(1):47-54

Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Zhu L, et al. **Virology** 1999 Apr 10; 256(2):381-92

[Human herpesvirus-8 in Hungarian blood donors and in patients with Kaposi sarcoma] Juhász A, et al. **Orv Hetil** 1998 Dec 13;139(50):3001-4 (Eng. Abstr.) **(Hun)**

ISOLATION & PURIFICATION

Association of body cavity-based lymphoma and human herpesvirus 8 in an HIV-seronegative male. Report of a case with immunocytochemical and molecular studies. San Miguel P, et al. **Acta Cytol** 1999 Mar-Apr;43(2):299-302

Kaposi's sarcoma-associated herpesvirus. Boshoff C, et al. **Adv Cancer Res** 1998;75:57-86 (175 ref.)

Parenteral transmission of Kaposi's sarcoma-associated herpesvirus [letter] Marcelin AG, et al. **AIDS** 1998 Dec 3;12(17):2351

Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. Min J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):51-5

Usefulness of molecular detection of human herpesvirus-8 in the diagnosis of Kaposi sarcoma by fine-needle aspiration. Alkan S, et al. **Am J Clin Pathol** 1999 Jan; 111(1):91-6

Human herpesvirus-8 (HHV-8) associated with small non-cleaved cell lymphoma in a child with AIDS. Leach CT, et al. **Am J Hematol** 1999 Mar;60(3):215-21

Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA. Bellos F, et al. **Ann Oncol** 1999 Mar;10(3):323-7

Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Bélec L, et al. **Blood** 1999 Jun 1;93(11):3643-53

HHV-8 is present in multiple myeloma patients. Berenson JR, et al. **Blood** 1999 May 15;93(10):3157-9; discussion 3164-6 (29 ref.)

Detection of human herpesvirus-8 and Epstein-Barr virus DNA in primary intraocular lymphomas [letter] Chan CC, et al. **Blood** 1999 Apr 15;93(8):2749-51

Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Chauhan D, et al. **Blood** 1999 Mar 1;93(5):1482-6

Absence of Kaposi's sarcoma--associated herpesvirus DNA sequences in multiple myeloma [letter] Corbellino M, et al. **Blood** 1999 Feb 1;93(3):1110-1

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Raje N, et al. **Blood** 1999 Mar 1;93(5):1487-95

Absence of a correlation between Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) and multiple myeloma [letter] Schönrich G, et al. **Blood** 1998 Nov 1;92(9):3474-5

Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. Tarte K, et al. **Blood** 1999 May 15;93(10):3159-63; discussion 3163-4 (41 ref.)

Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Tisdale JF, et al. **Blood** 1998 Oct 15;92(8):2681-7

Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients. Cull GM, et al. **Bone Marrow Transplant** 1999 Apr;23(8):759-61

The human herpesvirus-type 8 is not involved in malignant melanoma. Deichmann M, et al. **Br J Cancer** 1999 Apr; 80(1-2):67-9

The absence of HHV-8 DNA sequences in skin tumours other than Kaposi's sarcoma from AIDS patients and transplant recipients [letter; comment] Gil Mateo MP, et al. **Br J Dermatol** 1998 Nov;139(5):918-9. Comment on: Br J Dermatol 1997 May;136(5):803-4.

Progressive HHV-8-positive classic Kaposi's sarcoma: rapid response to interferon alpha-2a but persistence of HHV-8 DNA sequences in lesional skin. Pfrommer C, et al. **Br J Dermatol** 1998 Sep;139(3):516-9

Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA. Bellos F, et al. **Br J Haematol** 1998 Dec; 103(4):1192-7

Dendritic cells derived from bone marrow and CD34+ selected blood progenitor cells of myeloma patients, cultured in serum-free media, do not contain the Kaposi sarcoma herpesvirus genome. Mitterer M, et al. **Br J Haematol** 1998 Sep;102(5):1338-40

Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome [letter] Papo T, et al. **Br J Haematol** 1999 Mar;104(4):932-3

HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. Antinori A, et al. **Brain Pathol** 1999 Apr;9(2):199-208

New advances in multiple myeloma. Reece DE. **Curr Opin Hematol** 1998 Nov;5(6):460-4 (48 ref.)

Detection of HHV-8 DNA in a German patient with classical Kaposi's sarcoma may allow an estimation of the incubation period. Kowalzick L, et al. **Eur J Dermatol** 1998 Sep; 8(6):432-4

Detection and sequence diversity of Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) DNA. Murakami M, et al. **Eur J Dermatol** 1999 Jan-Feb;9(1):13-6

Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma arising in the subarachnoid space. Ely SA, et al. **Hum Pathol** 1999 Aug;30(8):981-4

Kaposi's sarcoma-associated herpesvirus in Kikuchi's disease. Huh J, et al. **Hum Pathol** 1998 Oct;29(10):1091-6

HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Lazzi S, et al. **Hum Pathol** 1998 Nov;29(11):1285-9

Absence of human herpes virus 8 in semen from healthy Danish donors. Kelsen J, et al. **Hum Reprod** 1999 Sep; 14(9):2274-6

Detection of human herpesvirus 8 in Korean Kaposi's sarcoma cases by polymerase chain reaction and in situ polymerase chain reaction. Jang HS, et al. **J Dermatol** 1999 Jul;26(7):434-41

Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. Wong SW, et al. **J Exp Med** 1999 Sep 20;190(6):827-40

Cellular localization of human herpesvirus 8 in nonneoplastic lymphadenopathies and chronic interstitial pneumonitis by in situ polymerase chain reaction studies. Trovato R, et al. **J Hum Virol** 1999 Jan-Feb;2(1):38-44

Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. Calabrò ML, et al. **J Infect Dis** 1999 Jun;179(6):1534-7

Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids. LaDuca JR, et al. **J Infect Dis** 1998 Dec; 178(6):1610-5

Localization of human herpesvirus type 8 (HHV-8) in the

Kaposi's sarcoma tissues and the semen specimens of HIV-1 infected and uninfected individuals by utilizing in situ polymerase chain reaction. Bobroski L, et al. **J Reprod Immunol** 1998 Dec;41(1-2):149-60

Purification of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) and analyses of the structural proteins. Wang YC, et al. **J Virol Methods** 1998 Aug; 73(2):219-28

Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma [published erratum appears in Lab Invest 1999 Jul;79(7):835] Teruya-Feldstein J, et al. **Lab Invest** 1998 Dec;78(12):1637-42

Lack of evidence of an association between HHV-8 and multiple myeloma [letter] Bouscary D, et al. **Leukemia** 1998 Nov;12(11):1840-1

Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Dotti G, et al. **Leukemia** 1999 May;13(5):664-70 (35 ref.)

Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Drexler HG, et al. **Leukemia** 1998 Oct; 12(10):1507-17 (46 ref.)

Absence of Kaposi's sarcoma-associated herpesvirus (KSHV) in bone marrow cells from Japanese myeloma patients [letter] Harada N, et al. **Leukemia** 1999 Sep; 13(9):1465-6

HHV-8 infection is specific for cell lines derived from primary effusion (body cavity-based) lymphomas. Uphoff CC, et al. **Leukemia** 1998 Nov;12(11):1806-9

Human herpes virus 8 (HHV-8) in Kaposi's sarcoma: lack of association with Bcl-2 and p53 protein expression. Kennedy MM, et al. **Mol Pathol** 1998 Jun;51(3):155-9

CD40 upregulation is independent of HHV-8 in the pathogenesis of Kaposi's sarcoma. Kennedy MM, et al. **Mol Pathol** 1999 Feb;52(1):32-6

HHV-8 is not associated with follicular dendritic cell tumours. Nayler SJ, et al. **Mol Pathol** 1998 Jun;51(3):168-70

Hypothesis. HHV-8 in multiple myeloma: is this the first paracrine model of human tumorigenesis and do Koch's postulates apply? O'Leary JJ, et al. **Mol Pathol** 1998 Aug; 51(4):201-3

An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS [letter] Zietz C, et al. **N Engl J Med** 1999 Jun 17;340(24):1923-4

Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Atula T, et al. **Oral Oncol** 1998 Sep;34(5):391-5

HHV-8 and multiple myeloma. Berenson JR, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):115-8 (25 ref.)

Human herpesvirus 8 in hematologic diseases. Mikala G, et al. **Pathol Oncol Res** 1999;5(1):73-9 (42 ref.)

Human herpesvirus 8 is not associated with Kawasaki disease [letter] Yoshikawa T, et al. **Pediatr Infect Dis J** 1998 Dec; 17(12):1179

Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Dupin N, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4546-51

Prevalence of infection with human herpesvirus 8/Kaposi's sarcoma herpesvirus in rural South Africa. Wilkinson D, et al. **S Afr Med J** 1999 May;89(5):554-7

Complete histological regression of Kaposi's sarcoma following treatment with protease inhibitors despite persistence of HHV-8 in lesions. Benfield TL, et al. **Scand J Infect Dis** 1998;30(6):613-5

The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Cesarman E, et al. **Semin Cancer Biol** 1999 Jun;9(3):165-74 (92 ref.)

Absence of Kaposi's sarcoma-associated virus (human herpesvirus-8) sequences in angiosarcoma. Lasota J, et al. **Virchows Arch** 1999 Jan;434(1):51-6

[New oncogenic viruses in human pathology] Brousset P, et al. **Ann Pathol** 1998;18(5 Suppl):76-7 **(Fre)**

METABOLISM

Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor. Geras-Raaka E, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):725-7

The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Sozzani S, et al. **Blood** 1998 Dec 1;92(11):4036-9

Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. Ellis M, et al. **EMBO J** 1999 Feb 1;18(3):644-53

Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. Mann DJ, et al. **EMBO J** 1999 Feb 1;18(3):654-63

Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. Burýšek L, et al. **J Virol** 1999 Sep;73(9):7334-42

Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. Wan X, et al. **J Virol** 1999 Oct;73(10):8268-78

Human herpesvirus-8 glycoprotein B interacts with Epstein-Barr virus (EBV) glycoprotein 110 but fails to complement the infectivity of EBV mutants. Pertel PE, et al. **Virology** 1998 Nov 25;251(2):402-13

PATHOGENICITY

The new herpesviruses: emerging pathogens of dermatological interest. Drago F, et al. **Arch Dermatol** 1999 Jan;135(1):71-5 (110 ref.)

Human herpesvirus-8 and relatives of patients with plasmocytic diseases [letter; comment] Jaccard A, et al. **Blood** 1998 Nov 1;92(9):3488. Comment on: Blood 1997 Dec 1;90(11):4278-82. Comment on: Blood 1998 Jun 1;91(11):4391-3.

The role of human herpesvirus-8, (HHV-8), in multiple myeloma pathogenesis. Vescio RA, et al. **Curr Top Microbiol Immunol** 1999;246:403-8; discussion 409 (27 ref.)

Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. Gaidano G, et al. **Genes Chromosomes Cancer** 1999 Jan; 24(1):16-23

Big but weak: how many pathogenic genes does human herpesvirus-8 need to cause Kaposi's sarcoma? (Review). Sturzl M, et al. **Int J Oncol** 1999 Feb;14(2):287-9 (20 ref.)

An attractive relation of human herpesvirus-8 with multicentric Castleman's disease [editorial; comment] Katano H, et al. **Intern Med** 1999 Mar;38(3):221-2 (10 ref.) . Comment on: Intern Med 1999 Mar;38(3):279-82.

The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. Endres MJ, et al. **J Exp Med** 1999 Jun 21;189(12):1993-8

Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. Moses AV, et al. **J Virol** 1999 Aug;73(8):6892-902

HHV-8 and multistep tumorigenesis [letter] Ensoli B, et al. **Trends Microbiol** 1999 Aug;7(8):310-2

Kaposi's sarcoma-associated herpesvirus: a new human tumor virus, but how? Schulz TF, et al. **Trends Microbiol** 1999 May;7(5):196-200

Evidence against KSHV infection in the pathogenesis of multiple myeloma. Olsen SJ, et al. **Virus Res** 1998 Oct; 57(2):197-202

[Human herpesvirus 8 (HHV8). II. Pathogenic role and sensitivity to antiviral drugs] Boulanger E. **Ann Biol Clin (Paris)** 1999 Jan-Feb;57(1):19-28 (48 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Boivin G, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):377-80

Role of the interferon regulatory factors (IRFs) in virus-mediated signaling and regulation of cell growth. Pitha PM, et al. **Biochimie** 1998 Aug-Sep;80(8-9):651-8 (50 ref.)

Human herpesvirus 8 and its role in the genesis of Kaposi's sarcoma. Ganem D. **Curr Clin Top Infect Dis** 1998; 18:237-51 (86 ref.)

Kaposi's sarcoma: breeding ground of herpesviridae - A tour de force over viral evolution (review). Sinkovics JG, et al. **Int J Oncol** 1999 Apr;14(4):615-46 (300 ref.)

Activation of cyclin A gene expression by the cyclin encoded by human herpesvirus-8. Duro D, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):549-55

HHV-8 infection and multiple myeloma. Sjak-Shie NN, et al. **J Leukoc Biol** 1999 Aug;66(2):357-60

Distinct biology of Kaposi's sarcoma-associated herpesvirus from primary lesions and body cavity lymphomas. Friborg J Jr, et al. **J Virol** 1998 Dec;72(12):10073-82

Human herpesvirus 8 and sarcoidosis [letter; comment] Di Alberti L, et al. **Lancet** 1998 May 23;351(9115):1589-90. Comment on: Lancet 1998 Feb 28;351(9103):679-80.

Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Dupin N, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4546-51

The enigmas of Kaposi's sarcoma. Gallo RC. **Science** 1998 Dec 4;282(5395):1837-9 (25 ref.)

Relationship of HHV8 replication and Kaposi's sarcoma after solid organ transplantation. Mendez JC, et al. **Transplantation** 1999 Apr 27;67(8):1200-1

Cancer (or lack thereof) and viruses [letter] Herndier B. **Trends Microbiol** 1999 Jul;7(7):269-70

Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Lukac DM, et al. **Virology** 1998 Dec 20;252(2):304-12

ULTRASTRUCTURE

Appearance of human herpesvirus 8 on electron microscopy [letter; comment] Orenstein JM, et al. **N Engl J Med** 1999 Jan 7;340(1):62-4. Comment on: N Engl J Med 1998 Aug 13;339(7):444-9.

HERPESVIRUS 1, MURINE see **MUROMEGALOVIRUS**

HERPESVIRUS PLATYRHINAE see **SIMPLEXVIRUS**

HERPESVIRUS 1, RANID

GENETICS

Genomic studies of the Lucké tumor herpesvirus (RaHV-1). Davison AJ, et al. **J Cancer Res Clin Oncol** 1999; 125(3-4):232-8

HERPESVIRUS SAIMIRI see **HERPESVIRUS 2, SAIMIRINE**

HERPESVIRUS 1, SAIMIRINE see **SIMPLEXVIRUS**

HERPESVIRUS 2, SAIMIRINE

Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86. Akari H, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):352-6

Assessment of Herpesvirus saimiri as a potential human gene therapy vector. Stevenson AJ, et al. **J Med Virol** 1999 Mar; 57(3):269-77

CHEMISTRY

Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6. Schulze-Gahmen U, et al. **Structure Fold Des** 1999 Mar 15;7(3):245-54

GENETICS

The gene product encoded by ORF 57 of herpesvirus saimiri regulates the redistribution of the splicing factor SC-35. Cooper M, et al. **J Gen Virol** 1999 May;80 (Pt 5):1311-6

Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Jung JU, et al. **Semin Cancer Biol** 1999 Jun; 9(3):231-9 (98 ref.)

IMMUNOLOGY

Successful in vitro immortalization of human intestinal mucosal lymphocytes with Herpesvirus saimiri. Martin-Villa JM, et al. **Tissue Antigens** 1998 Nov; 52(5):430-4

METABOLISM

Activation of the lck tyrosine-protein kinase by the binding of the tip protein of herpesvirus saimiri in the absence of regulatory tyrosine phosphorylation. Hartley DA, et al. **J Biol Chem** 1999 Jul 16;274(29):20056-9

Role of cellular tumor necrosis factor receptor-associated factors in NF-kappaB activation and lymphocyte transformation by herpesvirus Saimiri STP. Lee H, et al. **J Virol** 1999 May;73(5):3913-9

The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells. Lund TC, et al. **J Virol** 1999 Feb;73(2):1689-94

PHYSIOLOGY

Mechanisms of cell transformation by Herpesvirus saimiri. Tsygankov AY, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):973-83 (120 ref.)

Enhanced replication of M-tropic HIV-1 strains in Herpesvirus saimiri immortalised T-cells which express CCR5. Vella C, et al. **J Virol Methods** 1999 Apr;79(1):51-63

Herpesvirus saimiri strategies for T cell stimulation and transformation. Bröker BM, et al. **Med Microbiol Immunol (Berl)** 1999 Mar;187(3):127-36 (128 ref.)

HERPESVIRUS SIMIAE see **HERPESVIRUS 1, CERCOPITHECINE**

HERPESVIRUS 1, SUID

The distribution of calcitonin gene-related peptide in gastric vagal circuit of rats. Lee HS, et al. **Anat Histol Embryol** 1998 Oct;27(5):331-3

Life beyond eradication: veterinary viruses in basic science. Enquist LW. **Arch Virol Suppl** 1999;15:87-109 (67 ref.)

CNS innervation of vagal preganglionic neurons controlling peripheral airways: a transneuronal labeling study using pseudorabies virus. Hadziefendic S, et al. **J Auton Nerv Syst** 1999 May 28;76(2-3):135-45

A single social defeat transiently suppresses the anti-viral immune response in mice. de Groot J, et al. **J Neuroimmunol** 1999 Mar 1;95(1-2):143-51

Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. Jasmin L, et al. **J Neurosci** 1998 Dec 1;18(23):10016-29

Extended survival time following pseudorabies virus injection labels the suprapontine neural network controlling the bladder and urethra in the rat. Grill WM, et al. **Neurosci Lett** 1999 Jul 30;270(2):63-6

Pseudorabies virus early protein 0 trans-activates the TATA-associated promoter by stimulating the transcription initiation. Ho TY, et al. **Virus Res** 1999 May; 61(1):77-86

CHEMISTRY

Neuronal labeling in the rat brain and spinal cord from the ovary using viral transneuronal tracing technique. Gerendai I, et al. **Neuroendocrinology** 1998 Oct;68(4):244-56

HERPESVIRUS 1, SUID

Evidence for the internal location of actin in the pseudorabies virion. Wong ML, et al. **Virus Res** 1998 Aug;56(2):191–7

DRUG EFFECTS

Viral inactivation of human bone tissue using supercritical fluid extraction. Fages J, et al. **ASAIO J** 1998 Jul–Aug; 44(4):289–93

ENZYMOLOGY

Experimental infection of pigs with a thymidine kinase negative strain of pseudorabies virus. Ferrari M, et al. **Comp Immunol Microbiol Infect Dis** 1998 Oct;21(4):291–303

GENETICS

Analysis of the latency-associated transcript/UL1–3.5 gene cluster promoter complex of pseudorabies virus. Cheung AK, et al. **Arch Virol** 1999;144(2):381–91

Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. Smith GA, et al. **J Virol** 1999 Aug; 73(8):6405–14

Isolation of mutants of Aujeszky's disease virus with antigenically altered glycoprotein E by affinity chromatography using monoclonal antibodies. Morenkov OS, et al. **J Virol Methods** 1999 Jan;77(1):101–8

Pseudorabies virus (PRV) early protein 0 activates PRV gene transcription in combination with the immediate-early protein IE180 and enhances the infectivity of PRV genomic DNA. Ono E, et al. **Vet Microbiol** 1998 Oct;63(2–4):99–107

Characterisation of pseudorabies virus isolated from wild boar (Sus scrofa). Müller T, et al. **Vet Rec** 1998 Sep 19; 143(12):337–40

Analysis of the equalization of inverted repeats and neurovirulence using a pseudorabies virus mutant strain altered at the Ul/Ir junction. Boldogköi Z, et al. **Virus Genes** 1998;17(1):89–98

The left border of the genomic inversion of pseudorabies virus contains genes homologous to the UL46 and UL47 genes of herpes simplex virus type 1, but no UL45 gene. Bras F, et al. **Virus Res** 1999 Mar;60(1):29–40

Conversion of US3-encoded protein kinase gene from pseudorabies virus in a diploid gene located within inverted repeats by genetic recombination between the viral genome isomers. Fernández A, et al. **Virus Res** 1999 Jun; 61(2):125–35

Identification, expression, and characterization of the pseudorabies virus DNA-binding protein gene and gene product. Wu SL, et al. **Virus Res** 1998 Jul;56(1):1–9

IMMUNOLOGY

Indirect ELISAs based on recombinant and affinity-purified glycoprotein E of Aujeszky's disease virus to differentiate between vaccinated and infected animals. Morenkov OS, et al. **Acta Vet Hung** 1999;47(1):137–50

Antibody-induced endocytosis of viral glycoproteins and major histocompatibility complex class I on pseudorabies virus-infected monocytes. Favoreel HW, et al. **J Gen Virol** 1999 May;80 (Pt 5):1283–91

Distribution of B-cell epitopes on the pseudorabies virus glycoprotein B [published erratum appears in J Gen Virol 1999 Aug;80(Pt 8):2285] Zaripov MM, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):537–41

Recombinant porcine IFN-gamma potentiates the secondary IgG and IgA responses to an inactivated suid herpesvirus-1 vaccine and reduces postchallenge weight loss and fever in pigs. Vandenbroeck K, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):739–44

Differential regulation of Dk and Kk major histocompatibility complex class I proteins on the cell surface after infection of murine cells by pseudorabies virus. Sparks-Thissen RL, et al. **J Virol** 1999 Jul;73(7):5748–56

Herd factors affecting the selection and success of intervention strategies in the program for eradication of pseudorabies (Aujeszky's disease) virus from Illinois swine farms. Siegel AM, et al. **Prev Vet Med** 1999 Jun 11; 40(3–4):243–59

Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D. Haagmans BL, et al. **Vaccine** 1999 Mar 5;17(9–10):1264–71

Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. Hilgers LA, et al. **Vaccine** 1999 Jan 21;17(3):219–28

Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice. Katayama S, et al. **Vaccine** 1999 Jun 4; 17(20–21):2733–9

Time course of the porcine cellular and humoral immune responses in vivo against pseudorabies virus after inoculation and challenge: significance of in vitro antigenic restimulation. De Bruin MG, et al. **Vet Immunol Immunopathol** 1998 Sep 16;65(1):75–87

Effects of mild stress on the immune response against pseudorabies virus in mice. de Groot J, et al. **Vet Immunol Immunopathol** 1999 Feb 1;67(2):153–60

Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs. van Rooij EM, et al. **Vet Immunol Immunopathol** 1998 Nov 24;66(2):113–26

Use of muscle exudates for the detection of anti-gE antibodies to Aujeszky's disease virus. Le Potier MF, et al. **Vet Rec** 1998 Oct 3;143(14):385–7

ISOLATION & PURIFICATION

Isolation of mutants of Aujeszky's disease virus with antigenically altered glycoprotein E by affinity chromatography using monoclonal antibodies. Morenkov OS, et al. **J Virol Methods** 1999 Jan;77(1):101–8

Study of the persistence of Aujeszky's disease (pseudorabies) virus in peripheral blood mononuclear cells and tissues of experimentally infected pigs. Balasch M, et al. **Vet Microbiol** 1998 Jul;62(3):171–83

METABOLISM

Intracellular trafficking and localization of the pseudorabies virus Us9 type II envelope protein to host and viral membranes. Brideau AD, et al. **J Virol** 1999 May; 73(5):4372–84

The murine homolog (Mph) of human herpesvirus entry protein B (HveB) mediates entry of pseudorabies virus but not herpes simplex virus types 1 and 2. Shukla D, et al. **J Virol** 1999 May;73(5):4493–7

PATHOGENICITY

Pseudorabies virus-induced leukocyte trafficking into the rat central nervous system. Rassnick S, et al. **J Virol** 1998 Nov; 72(11):9181–91

Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. Smith GA, et al. **J Virol** 1999 Aug; 73(8):6405–14

Retrograde, transneuronal spread of pseudorabies virus in defined neuronal circuitry of the rat brain is facilitated by gE mutations that reduce virulence. Yang M, et al. **J Virol** 1999 May;73(5):4350–9

Molecular mechanisms of neurotropic herpesvirus invasion and spread in the CNS. Tirabassi RS, et al. **Neurosci Biobehav Rev** 1998 Oct;22(6):709–20

Potency of an experimental DNA vaccine against Aujeszky's disease in pigs. Gerdts V, et al. **Vet Microbiol** 1999 Mar 31;66(1):1–13

Pseudorabies virus (PRV) early protein 0 activates PRV gene transcription in combination with the immediate-early protein IE180 and enhances the infectivity of PRV genomic DNA. Ono E, et al. **Vet Microbiol** 1998 Oct;63(2–4):99–107

PHYSIOLOGY

Characterization of transsynaptic tracing with central application of pseudorabies virus. Chen S, et al. **Brain Res** 1999 Aug 14;838(1–2):171–83

The renal afferent pathways in the rat: a pseudorabies virus study. Weiss ML, et al. **Brain Res** 1998 Nov 23; 812(1–2):227–41

Retrograde transynaptic pseudorabies virus infection of central autonomic circuits in neonatal rats. Rinaman L, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):207–16

Neuroinvasiveness of pseudorabies virus injected intracerebrally is dependent on viral concentration and terminal field density. Card JP, et al. **J Comp Neurol** 1999 May 10;407(3):438–52

Central neuronal circuit innervating the lordosis-producing muscles defined by transneuronal transport of pseudorabies virus. Daniels D, et al. **J Neurosci** 1999 Apr 1;19(7):2823–33

Influence of cell surface glycoprotein gC produced by pseudorabies virus on cytopathic effect. Katayama S, et al. **J Vet Med Sci** 1998 Aug;60(8):905–9

Inhibition of virion maturation by simultaneous deletion of glycoproteins E, I, and M of pseudorabies virus. Brack AR, et al. **J Virol** 1999 Jul;73(7):5364–72

Glycoprotein gL-independent infectivity of pseudorabies virus is mediated by a gD-gH fusion protein. Klupp BG, et al. **J Virol** 1999 Apr;73(4):3014–22

Infection of Chinese hamster ovary cells by pseudorabies virus. Nixdorf R, et al. **J Virol** 1999 Oct;73(10):8019–26

Mutation of the YXXL endocytosis motif in the cytoplasmic tail of pseudorabies virus gE. Tirabassi RS, et al. **J Virol** 1999 Apr;73(4):2717–28

Tracing autonomic innervation of the rat pineal gland using viral transneuronal tracing. Larsen PJ. **Microsc Res Tech** 1999 Aug 15–Sep 1;46(4–5):296–304

Practical considerations for the use of pseudorabies virus in transneuronal studies of neural circuitry. Card JP. **Neurosci Biobehav Rev** 1998 Oct;22(6):685–94 (46 ref.)

Protection of fattening pigs against challenge with Aujeszky's disease virus after a successive intranasal/intramuscular vaccination. Labarque GG, et al. **Vet Q** 1999 Jun; 21(3):104–7

Varicella-zoster virus ORF57, unlike its pseudorabies virus UL3.5 homolog, is dispensable for viral replication in cell culture. Cox E, et al. **Virology** 1998 Oct 10;250(1):205–9

Role of the cytoplasmic tail of gE in antibody-induced redistribution of viral glycoproteins expressed on pseudorabies-virus-infected cells. Favoreel HW, et al. **Virology** 1999 Jun 20;259(1):141–7

Protein synthesis in pseudorabies virus-infected cells: decreased expression of protein kinase PKR, and effects of 2-aminopurine and adenine. Wong ML, et al. **Virus Res** 1998 Aug;56(2):199–206

HERPESVIRUS VARICELLAE see **HERPESVIRUS 3, HUMAN**

HERPESVIRUS 2, GALLID

PATHOGENICITY

Infectivity of Marek's disease agent after different treatments used in vaccine production. Kottaridis SD, et al. **Am J Vet Res** 1969 Oct;30(10):1851–5

HERPESVIRUS 2, HUMAN

DRUG EFFECTS

Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication. Sudo K, et al. **Antivir Chem Chemother** 1998 May;9(3):263–7

ISOLATION & PURIFICATION

Seroprevalence of herpes simplex virus-type 2 in African-American college women. Lewis LM, et al. **J Natl Med Assoc** 1999 Apr;91(4):210–2

HERPETOMONAS see **TRYPANOSOMATINA**

HERTZIAN WAVES see **RADIO WAVES**

HERVS see **ENDOGENOUS RETROVIRUSES**

HESPERIDIN

ADMINISTRATION & DOSAGE

Inhibitory effect of Hesperidin on tumour initiation and promotion in mouse skin. Berkarda B, et al. **Res Exp Med (Berl)** 1998 Aug;198(2):93–9

ANALOGS & DERIVATIVES

Antinociceptive and anti-inflammatory activity of a flavonoid isolated from Caralluma attenuata. Ramesh M, et al. **J Ethnopharmacol** 1998 Aug;62(1):63–6

PHARMACOLOGY

Effect of long-term treatment with a purified micronized flavonoid fraction on pancreatic mononuclear cell infiltration in diabetic BB rats. Guillot R, et al. **Pancreas** 1998 Oct;17(3):301–8

Colony stimulating factor-inducing activity of hesperidin [letter] Kawaguchi K, et al. **Planta Med** 1999 May; 65(4):365–6

Effect of a micronized purified flavonoid fraction on in vivo platelet functions in the rat. McGregor L, et al. **Thromb Res** 1999 May 15;94(4):235–40

HESPEROMYINAE

Hantavirus (Bunyaviridae) infections in rodents from Orange and San Diego counties, California. Bennett SG, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):75–84

Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Rojas-Martinez A, et al. **Cancer Gene Ther** 1998 Nov–Dec;5(6):365–70

Cotton rats (Sigmodon hispidus): an animal model to study the pathogenesis of measles virus infection. Niewiesk S. **Immunol Lett** 1999 Jan;65(1–2):47–50 (31 ref.)

Experimental infection of cotton rats with three naturally occurring Bartonella species. Kosoy MY, et al. **J Wildl Dis** 1999 Apr;35(2):275–84

Neuroendocrine (ECL cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Waldum HL, et al. **Lab Anim Sci** 1999 Jun;49(3):241–7

GENETICS

Extraordinary chromosomal polymorphism with 28 different karyotypes in the neotropical species Akodon cursor (Muridae, Sigmodontinae), one of the smallest diploid number in rodents (2n = 16, 15 and 14). Fagundes V, et al. **Hereditas** 1998;129(3):263–74

Allelic diversity at the Mhc-DQA locus in cotton rats (Sigmodon hispidus) and a comparison of DQA sequences within the family muridae (Mammalia: Rodentia). Pfau RS, et al. **Immunogenetics** 1999 Sep;49(10):886–93

IMMUNOLOGY

Indicators of immunotoxicity in populations of cotton rats (Sigmodon hispidus) inhabiting an abandoned oil refinery. McMurry ST, et al. **Ecotoxicol Environ Saf** 1999 Mar; 42(3):223–35

Allelic diversity at the Mhc-DQA locus in cotton rats (Sigmodon hispidus) and a comparison of DQA sequences within the family muridae (Mammalia: Rodentia). Pfau RS, et al. **Immunogenetics** 1999 Sep;49(10):886–93

MICROBIOLOGY

Isolation of Borrelia burgdorferi from Neotoma fuscipes, Peromyscus maniculatus, Peromyscus boylii, and Ixodes pacificus in Oregon. Burkot TR, et al. **Am J Trop Med Hyg** 1999 Mar;60(3):453–7

Dusky-footed wood rats (Neotoma fuscipes) as reservoirs of granulocytic Ehrlichiae (Rickettsiales: Ehrlichieae) in northern California. Nicholson WL, et al.

J Clin Microbiol 1999 Oct;37(10):3323-7

PARASITOLOGY

Short report: a focus of Leishmania mexicana near Tucson, Arizona. Kerr SF, et al. **Am J Trop Med Hyg** 1999 Sep; 61(3):378-9

[Eimeria species (Eucoccidida: Eimeriidae) found in the cotton rat Sigmodon hispidus in Costa Rica] Castro A, et al. **Rev Biol Trop** 1998 Jun;46(2):339-40 (Eng. Abstr.) **(Spa)**

VIROLOGY

Black Creek Canal Virus infection in Sigmodon hispidus in southern Florida. Glass GE, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):699-703

Replication of clinical measles virus strains in hispid cotton rats. Wyde PR, et al. **Proc Soc Exp Biol Med** 1999 May; 221(1):53-62

HESPEROMYINES see **HESPEROMYINAE**

HESW see **HIGH-ENERGY SHOCK WAVES**

HETASTARCH

Volume reduction of cord blood by Hetastarch for long-term stem cell banking. Kögler G, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S14-5

Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases. Adorno G, et al. **Clin Lab Haematol** 1998 Dec; 20(6):341-3

[A new hydroxyethyl starch for volume replacement: Elohes 6%] Medel J, et al. **Rev Esp Anestesiol Reanim** 1998 Nov; 45(9):389-96 (68 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. König E, et al. **Hum Reprod** 1998 Sep;13(9):2421-4

Effect of intravenous saline, albumin, or hydroxyethylstarch on blood volume during combined ultrafiltration and hemodialysis. van der Sande FM, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1303-8

Antioxidative resuscitation solution prevents leukocyte adhesion in the liver after hemorrhagic shock. Bauer C, et al. **J Trauma** 1999 May;46(5):886-93

Preoperative volume expansion improves tolerance to carotid artery cross-clamping during endarterectomy. Gross CE, et al. **Neurosurgery** 1998 Aug;43(2):222-6; discussion 226-8

[Changes in blood coagulation in treatment with hydroxyethyl starch] Sefrin P, et al. **Anaesthesiol Reanim** 1998;23(6):149-56 (Eng. Abstr.) **(Ger)**

[Topic on the theme "volume replacement". 6% HES 130/0.4 is the optimum combination (news)] Diwo SB. **Anaesthesist** 1998 Sep;47(9):815 **(Ger)**

[The maximum safe dosage of the low molecular weight hydroxyethyl starch, HESPANDAR (HES), estimated from HES induced changes in coagulation parameters and clinical bleeding] Saito Y, et al. **Masui** 1999 Mar; 48(3):238-43 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hydroxyethyl starch impairs in vitro coagulation. Niemi TT, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1104-9

Moderately severe anaphylactoid reaction to pentastarch (200/0.5) in a patient with acute severe asthma. Kannan S, et al. **Intensive Care Med** 1999 Feb;25(2):220-2

Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Deman A, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1517-20

Hydroxyethylstarch-associated transient acute renal failure after epidural anaesthesia for labour analgesia and Caesarean section [letter] Dickenamm MJ, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2706

CHEMISTRY

Effect of polytyrosine on the hydrophobicity of hydroxyethyl starch microspheres. Chadha H, et al. **Pharm Dev Technol** 1998 Nov;3(4):597-606

PHARMACOKINETICS

Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. Sirtl C, et al. **Br J Anaesth** 1999 Apr;82(4):510-5

Pulmonary capillary sieving of hetastarch is not altered by LPS-induced sepsis. Conhaim RL, et al. **J Trauma** 1999 May;46(5):800-8; discussion 808-10

PHARMACOLOGY

Compromised blood coagulation: an in vitro comparison of hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using thrombelastography. Jamnicki M, et al. **Anesth Analg** 1998 Nov;87(5):989-93

The effects of in vitro hemodilution with gelatin, hydroxyethyl starch, and lactated Ringer's solution on markers of coagulation: an analysis using SONOCLOT. Konrad C, et al. **Anesth Analg** 1999 Mar;88(3):483-8

Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Omar MN, et al. **Clin Biochem** 1999 Jun; 32(4):269-74

Effects of hydroxyethyl starch on blood coagulation profile. Türkan H, et al. **Eur J Anaesthesiol** 1999 Mar;16(3):156-9

Hydroxyethyl starch solution: is it a new alternative way of treatment in bacterial translocation? Tiras S, et al. **Int Surg** 1998 Jul-Sep;83(3):250-2

An international view of hydroxyethyl starches. Treib J, et al. **Intensive Care Med** 1999 Mar;25(3):258-68 (82 ref.)

Histology and ultrastructure of liver and kidney following blood exchange with ultrapurified, polymerised bovine hemoglobin in comparison with hydroxyethyl starch. Lipfert B, et al. **Lab Invest** 1999 May;79(5):573-82

Pharmacokinetics and pharmacodynamics of hydroxyethyl starch in hypovolemic pigs; a comparison of peripheral and intraosseous infusion. Kentner R, et al. **Resuscitation** 1999 Jan;40(1):37-44

Hydroxyethyl starch reduces the chemotaxis of white cells through endothelial cell monolayers. Hofbauer R, et al. **Transfusion** 1999 Mar;39(3):289-94

THERAPEUTIC USE

Peri-operative tolerance to large-dose 6% HES 200/0.5 in major urological procedures compared with 5% human albumin. Vogt N, et al. **Anaesthesia** 1999 Feb;54(2):121-7

Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group. Gan TJ, et al. **Anesth Analg** 1999 May;88(5):992-8

Early clinical experience with a newly formulated hydroxyethyl starch--Hextend [letter] Woolf RL, et al. **Br J Anaesth** 1999 Feb;82(2):299-300

Differential effects of serial hemodilution with hydroxyethyl starch, albumin, and 0.9% saline on whole blood coagulation. Tobias MD, et al. **J Clin Anesth** 1998 Aug; 10(5):366-71

Effects of hydroxyethyl-starch-bound deferoxamine on ischemia/reperfusion injury in chronic nerve compression. Marin PC, et al. **J Reconstr Microsurg** 1998 Oct; 14(7):485-90

Controlled resuscitation for uncontrolled hemorrhagic shock. Burris D, et al. **J Trauma** 1999 Feb;46(2):216-23

Hydroxyethyl starch: pharmaceutical and clinical profile. Boldt J. **Minerva Anestesiol** 1999 May;65(5):305-9 (25 ref.)

Lactated Ringer's solution versus hydroxyethyl starch for volume replacement in autologous blood donors with cardiovascular disease: a controlled, randomized trial. Kasper SM, et al. **Vox Sang** 1998;75(1):26-31

TOXICITY

Action of hydroxyethyl starch (HES) on the activity of plasmatic clotting factors. Langer R, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(2-3):103-16

HETE see **HYDROXYEICOSATETRAENOIC ACIDS**

5,12-HETE see **LEUKOTRIENE B4**

12-HETE see **12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID**

12-R-HETE see **12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID**

12-S-HETE see **12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID**

HETEROANTIBODIES see **ANTIBODIES, HETEROPHILE**

HETEROANTIGENS see **ANTIGENS, HETEROPHILE**

HETEROCEPHALUS see **MOLE RATS**

HETEROCHROMATIN

Cytosine methylation is not involved in the heterochromatization of the paternal genome of mealybug Planococcus citri. Buglia G, et al. **Chromosome Res** 1999; 7(1):71-3

A rare chromosome 5 heterochromatic variant derived from insertion of 9qh satellite 3 sequences. Doneda L, et al. **Chromosome Res** 1998 Aug;6(5):411-4

A novel repetitive sequence, termed the JNK repeat family, located on an extra heterochromatic region of chromosome 2R of Japanese rye. Nagaki K, et al. **Chromosome Res** 1999; 7(2):95-101

Extra euchromatic band in the qh region of chromosome 9. von Beust G, et al. **Fetal Diagn Ther** 1999 Jan-Feb; 14(1):35-7

In vivo chromatin accessibility correlates with gene silencing in Drosophila. Boivin A, et al. **Genetics** 1998 Dec; 150(4):1539-49

Dominant defects in Drosophila eye pigmentation resulting from a euchromatin-heterochromatin fusion gene. Rong YS, et al. **Genetics** 1998 Dec;150(4):1551-66

KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Krüppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Ryan RF, et al. **Mol Cell Biol** 1999 Jun;19(6):4366-78

A novel simple satellite DNA is colocalized with the Stalker retrotransposon in Drosophila melanogaster heterochromatin. Makunin IV, et al. **Mol Gen Genet** 1999 Mar;261(2):381-7

Polycomb silencing and the maintenance of stable chromatin states. Pirrotta V. **Results Probl Cell Differ** 1999;25:205-28 (110 ref.)

CHEMISTRY

Decondensation of pericentric heterochromatin alters the sequence of centromere separation in mouse cells. Vig BK, et al. **Chromosoma** 1998 Dec;107(6-7):417-23

DRUG EFFECTS

Reduced levels of poly(ADP-ribosyl)ation result in chromatin compaction and hypermethylation as shown by cell-by-cell computer-assisted quantitative analysis. de Capoa A, et al. **FASEB J** 1999 Jan;13(1):89-93

Targeted breakage of paracentromeric heterochromatin induces chromosomal instability. Smith LE, et al. **Mutagenesis** 1998 Sep;13(5):435-43

Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Fauth E, et al. **Mutat Res** 1999 Apr 6;440(2):147-56

GENETICS

Absence of pericentromeric heterochromatin (9qh-) in a patient with bilateral retinoblastoma. Sivakumaran TA, et al. **Acta Genet Med Gemellol (Roma)** 1997;46(4):193-8

Pericentromeric heteromorphism of human chromosome 18 as revealed by FISH-technique. Verma RS, et al. **Ann Genet** 1998;41(3):154-6

Characterization of sequences associated with position-effect variegation at pericentric sites in Drosophila heterochromatin. Cryderman DE, et al. **Chromosoma** 1998 Nov;107(5):277-85

Heterochromatin. Hennig W. **Chromosoma** 1999 Apr; 108(1):1-9 (83 ref.)

UASrpg can function as a heterochromatin boundary element in yeast. Bi X, et al. **Genes Dev** 1999 May 1;13(9):1089-101

Heterochromatic banding pattern in two Brazilian populations of Aedes aegypti. de Sousa R de C, et al. **Genetica** 1999;105(1):93-9

Pairing-dependent mislocalization of a Drosophila brown gene reporter to a heterochromatic environment. Sass GL, et al. **Genetics** 1999 Jun;152(2):595-604

Suppressors of position-effect variegation in Drosophila melanogaster affect expression of the heterochromatic gene light in the absence of a chromosome rearrangement. Clegg NJ, et al. **Genome** 1998 Aug;41(4):495-503

A FISH study of chromosome fusion in the ICF syndrome: involvement of paracentric heterochromatin but not of the centromeres themselves. Sumner AT, et al. **J Med Genet** 1998 Oct;35(10):833-5

Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division. Brown KE, et al. **Mol Cell** 1999 Feb;3(2):207-17

Dynamic organization of the beta-heterochromatin in the Drosophila melanogaster polytene X chromosome. Koryakov DE, et al. **Mol Gen Genet** 1999 Jan;260(6):503-9

Heterochromatic silencing of Drosophila heat shock genes acts at the level of promoter potentiation. Cryderman DE, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):3364-70

Revising the selfish DNA hypothesis: new evidence on accumulation of transposable elements in heterochromatin. Dimitri P, et al. **Trends Genet** 1999 Apr;15(4):123-4 (25 ref.)

[Variability of pericentromeric chromatin in chromosome 2 of ovarian nurse cells during inbreeding in Anopheles atroparvus V.Tiel] Burlak VA, et al. **Genetika** 1998 Jul; 34(7):992-5 (Eng. Abstr.) **(Rus)**

[Microcloning and characteristics of DNA from regions of the centromeric heterochromatin of Drosophila melanogaster polytene chromosomes] Rutsov NB, et al. **Genetika** 1999 Jan;35(1):55-61 (Eng. Abstr.) **(Rus)**

[Heterochromatin: molecular evolution and effects of gene location in Drosophila melanogaster] Gvozdev VA, et al. **Mol Biol (Mosk)** 1999 Jan-Feb;33(1):14-25 (67 ref.) **(Rus)**

[Disruption of polytenization of DNA from the euchromatin region of the Drosophila melanogaster X-chromosome, caused by euheterochromatin restructuring] Lavrov SA, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):992-7 **(Rus)**

METABOLISM

Histone H4 underacetylation in plant facultative heterochromatin. Buzek J, et al. **Biol Chem** 1998 Oct; 379(10):1235-41

Chromosomal localization and heterochromatin association of ribosomal RNA gene loci and silver-stained nucleolar organizer regions in salmonid fishes. Fujiwara A, et al. **Chromosome Res** 1998 Sep;6(6):463-71

DDP1, a single-stranded nucleic acid-binding protein of Drosophila, associates with pericentric heterochromatin and is functionally homologous to the yeast Scp160p, which

is involved in the control of cell ploidy. Cortés A, et al. **EMBO J** 1999 Jul 1;18(13):3820–33

Heterochromatin organization of a natural yeast telomere. Recruitment of Sir3p through interaction with histone H4 N terminus is required for the establishment of repressive structures. Venditti S, et al. **J Biol Chem** 1999 Jan 22; 274(4):1928–33

Phosphorylation of heterochromatin protein 1 by casein kinase II is required for efficient heterochromatin binding in Drosophila. Zhao T, et al. **J Biol Chem** 1999 May 21; 274(21):15095–100

[Role of nuclear matrix proteins in the formation of heterochromatin] Lobov IB, et al. **Tsitologiia** 1999; 41(7):562–73 (119 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Distribution of heterochromatin on the mitotic chromosomes of Musca domestica L. in relation to the activity of male-determining factors. Hediger M, et al. **Chromosoma** 1998 Sep;107(4):267–71

Amplification of telomeric DNA and the extent of karyotypic evolution. Pathak S, et al. **Cytobios** 1998;93(374):141–6

Heterochromatin islands and their dynamic reorganization: a hypothesis for three distinctive features of cellular aging. Imai S, et al. **Exp Gerontol** 1998 Sep;33(6):555–70 (64 ref.)

Polymorphisms for the size of heterochromatic regions allow sex-independent quantification of post-BMT chimerism targeting metaphase and interphase cells. Buño I, et al. **Haematologica** 1999 Feb;84(2):138–41

RADIATION EFFECTS

Microwave irradiation influences on the state of human cell nuclei. Shckorbatov YG, et al. **Bioelectromagnetics** 1998; 19(7):414–9

Nonrandom degradation of DNA in human leukemic cells during radiation-induced apoptosis. Dullea RG, et al. **Cancer Res** 1999 Aug 1;59(15):3712–8

Heterogeneity of Chinese hamster X chromosomes in X-ray-induced chromosomal aberrations. Xiao Y, et al. **Int J Radiat Biol** 1999 Apr;75(4):419–27

ULTRASTRUCTURE

Heterochromatin discrimination in Aegilops speltoides by simultaneous genomic in situ hybridization. Belyayev A, et al. **Chromosome Res** 1998 Nov;6(7):559–65

HETEROCHROMIC CYCLITIS see **IRIDOCYCLITIS**

HETEROCYCLIC ACIDS see **ACIDS, HETEROCYCLIC**

HETEROCYCLIC COMPOUNDS

Improvement of the performance of H2O2 oxidation at low working potential by incorporating TTF-TCNQ into a platinum wire electrode for glucose determination. Li QS, et al. **Biosens Bioelectron** 1999 Mar 15;14(3):327–34

ADMINISTRATION & DOSAGE

Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging. Wolansky LJ, et al. **Clin Imaging** 1998 Nov–Dec; 22(6):385–92

Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla. Loubeyre P, et al. **J Magn Reson Imaging** 1999 Mar;9(3):447–53

Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Fossheim SL, et al. **Magn Reson Imaging** 1999 Jan;17(1):83–9

ADVERSE EFFECTS

Acute renal failure after arteriography with a gadolinium-based contrast agent. Gemery J, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1277–8

Dietary mutagens and the risk of breast cancer [editorial; comment] Egan KM, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1687–9. Comment on: J Natl Cancer Inst 1998 Nov 18;90(22):1724–9.

Well-done meat intake and the risk of breast cancer [see comments] Zheng W, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1724–9. Comment in: J Natl Cancer Inst 1998 Nov 18;90(22):1687–9.

Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study [see comments] Augustsson K, et al. **Lancet** 1999 Feb 27; 353(9154):703–7. Comment in: Lancet 1999 Feb 27;353(9154):686–7.

Meat and cancer: a relation in search of a mechanism [comment] Forman D. **Lancet** 1999 Feb 27;353(9154):686–7 . Comment on: Lancet 1999 Feb 27;353(9154):703–7.

Case-control study on the role of heterocyclic amines in the etiology of upper aerodigestive cancers in Uruguay. De Stefani E, et al. **Nutr Cancer** 1998;32(1):43–8

[Present and future cancer risk assessment of carcinogenic heterocyclic amines in humans] Manabe S, et al. **Nippon Eiseigaku Zasshi** 1998 Oct;53(3):521–8 (46 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Capillary electrophoresis and capillary electrophoresis-electrospray-mass spectroscopy for the analysis of heterocyclic amines. Zhao Y, et al. **Electrophoresis** 1998 Sep;19(12):2213–9

Heterocyclic amines in process flavours, process flavour ingredients, bouillon concentrates and a pan residue. Solyakov A, et al. **Food Chem Toxicol** 1999 Jan;37(1):1–11

Factors determining dietary intakes of heterocyclic amines in cooked foods. Keating GA, et al. **Mutat Res** 1999 Jul 15;443(1-2):149–56 (30 ref.)

[Heterocyclic amines in cooked meat] Vikse R, et al. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):45–9 (38 ref.) (Eng. Abstr.) **(Nor)**

CHEMICAL SYNTHESIS

A novel synthesis of heterocyclic compounds containing coumarin moiety of potential antimicrobial activity. el-Fattah ME. **Arch Pharm Res** 1998 Dec;21(6):723–8

Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-Heteroaryl derivatives. Aitken RA, et al. **Arch Pharm (Weinheim)** 1998 Dec;331(12):405–11

Substituted pyrazoles as novel selective ligands for the human dopamine D4 receptor. Bourrain S, et al. **Bioorg Med Chem** 1998 Oct;6(10):1731–43

Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists. Cocuzza AJ, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1063–6

Combinatorial chemistry: from peptides and peptidomimetics to small organic and heterocyclic compounds. Nefzi A, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2273–8

Polymer supported bases in solution-phase synthesis. 2. A convenient method for N-alkylation reactions of weakly acidic heterocycles. Xu W, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1089–92

Recent advances in the solid phase synthesis of drug-like heterocyclic small molecules. Andres CJ, et al. **Comb Chem High Throughput Screen** 1999 Aug; 2(4):191–210 (57 ref.)

A solid phase approach to substituted pyrimidines and their conversion into condensed heterocycles for potential use in combinatorial chemistry. Srivastava SK, et al. **Comb Chem High Throughput Screen** 1999 Feb;2(1):33–7

Solid phase synthesis of heterocycles by cyclization/cleavage methodologies. van Maarseveen JH. **Comb Chem High Throughput Screen** 1998 Dec; 1(4):185–214 (67 ref.)

Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. Bryant LH Jr, et al. **J Magn Reson Imaging** 1999 Feb;9(2):348–52

Synthesis and enzymic evaluation of 4-mercapto-6-oxo-1, 4-azaphosphinane-2-carboxylic acid 4-oxide as an inhibitor of mammalian dihydroorotase. Manthey MK, et al. **J Med Chem** 1998 Nov 5;41(23):4550–5

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. Kukis DL, et al. **J Nucl Med** 1998 Dec; 39(12):2105–10

CHEMISTRY

Unusual amino acids. VIII. Asymmetric hydrogenation of some heteroaryl-N-Cbz and N-Boc aminocinnamic acid derivatives. Döbler C, et al. **Amino Acids** 1999;16(1):21–7

Peroxynitrite reacts with biological nitrogen-containing cyclic molecules by a radical pathway, as demonstrated by ultraweak luminescence coupled with ESR technique. Mouithys-Mickalad A, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):460–4

Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors. Dominguez C, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):925–30

Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1). McComsey DF, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1423–8

Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):307–12

Polymer supported bases in solution-phase synthesis. 2. A convenient method for N-alkylation reactions of weakly acidic heterocycles. Xu W, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1089–92

Studies on some N-bridged heterocycles derived from bis-[4-amino-5-mercapto-1,2,4-triazol-3-yl] alkanes. Holla BS, et al. **Farmaco** 1998 Aug–Sep;53(8–9):574–8

Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Curtet C, et al. **Invest Radiol** 1998 Oct;33(10):752–61

S19159, a modulator of neurite outgrowth produced by the ascomycete Preussia aemulans. II. Structure elucidation. Sato T, et al. **J Antibiot (Tokyo)** 1998 Nov;51(11):1047–50

Bond strength of acrylic resin to cobalt-chromium alloy treated with the Silicoater MD and Kevloc systems. Pesun S, et al. **J Can Dent Assoc** 1998 Dec;64(11):798–802

Modelling of adrenoceptor ligand targets based on novel medium- or macro-sized fused nitrogen heterocyclic systems. Griffith R, et al. **J Comput Aided Mol Des** 1999 Jan;13(1):69–78

Sulfonylamido derivatives of 2-aminophenoxathiin-10,10-dioxide and related compounds possess antifungal action due to the possible inhibition of lanosterol-14-alpha-demethylase. Supuran CT, et al. **J Enzyme Inhib** 1998 Jul;13(4):291–310

Studies of antibacterial activity of binuclear rhodium (II) complexes with heterocyclic nitrogen ligands. Bień M, et al. **J Inorg Biochem** 1999 Jan–Feb;73(1–2):49–55

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971–81

New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor. Dessolin J, et al. **J Med Chem** 1999 Jan 28;42(2):229–41

Bond strengths of silicoated and acrylic resin bonding systems to metal. Vojvodic D, et al. **J Prosthet Dent** 1999 Jan; 81(1):1–6

Guest exchange in an encapsulation complex: a supramolecular substitution reaction. Santamaria J, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8344–7

Characterization of ionized heterocyclic carbenes by ion-molecule reactions. Gerbaux P, et al. **Rapid Commun Mass Spectrom** 1999;13(17):1707–11

Illuminating single molecules in condensed matter. Moerner WE, et al. **Science** 1999 Mar 12;283(5408):1670–6 (75 ref.)

DIAGNOSTIC USE

MR imaging patterns of gadolinium retention within liver neoplasms. Peterson MS, et al. **Abdom Imaging** 1998 Nov–Dec;23(6):592–9

Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. Dousset V, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):223–7

Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. Bagga H, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1509–11 (7 ref.)

Gadolinium chelate-enhanced subtraction spoiled gradient-recalled echo MR imaging of hepatic tumors. Soyer P, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):79–82

Bilateral optic neuritis in a child diagnosed with Gd-enhanced MR imaging using fat-suppression technique. Okamoto K, et al. **Eur Radiol** 1999;9(4):731–3

Paramagnetic liposomes as magnetic resonance imaging contrast agents. Assessment of contrast efficacy in various liver models. Fossheim SL, et al. **Invest Radiol** 1998 Nov; 33(11):810–21

Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. Leimer M, et al. **J Nucl Med** 1998 Dec;39(12):2090–4

Assessment of iron oxide particles (AMI 227) and a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) in a tumor model implanted in rats. Loubeyre P, et al. **Magn Reson Imaging** 1999 May;17(4):627–31

Utilization of the nephrectomized mouse for determining threshold effects of MRI contrast agents. Wedeking P, et al. **Magn Reson Imaging** 1999 May;17(4):569–75

Gd-BOPTA: "the MRA contrast agent of choice"? Fellner F, et al. **Rontgenpraxis** 1999;52(2):51–8

IMMUNOLOGY

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle. Casey JL, et al. **Br J Cancer** 1998 Nov;78(10):1307–12

Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. DeNardo SJ, et al. **Hybridoma** 1999 Feb;18(1):13–21

METABOLISM

Substituted pyrazoles as novel selective ligands for the human dopamine D4 receptor. Bourrain S, et al. **Bioorg Med Chem** 1998 Oct;6(10):1731–43

PHARMACOKINETICS

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. DeNardo GL, et al. **Clin Cancer Res** 1999 Mar;5(3):533–41

PHARMACOLOGY

Comparative studies of new thienothiazine derivatives on heart and smooth muscle preparations of guinea pigs. Studenik C, et al. **Biol Pharm Bull** 1999 May;22(5):453–6

Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists. Cocuzza AJ, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1063–6

Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif. Hoekstra WJ, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1649–54

Structure-activity relationships (SAR) of some tetracyclic

heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):307–12

Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043. Fujie K, et al. **Eur J Pharmacol** 1999 Jun 11; 374(1):117–25

New members of the macrosphelides from Microsphaeropsis sp. FO–5050 IV. Fukami A, et al. **J Antibiot (Tokyo)** 1999 May;52(5):501–4

Sulfonylamido derivatives of 2–aminophenoxathiin–10,10–dioxide and related compounds possess antifungal action due to the possible inhibition of lanosterol–14–alpha–demethylase. Supuran CT, et al. **J Enzyme Inhib** 1998 Jul;13(4):291–310

Synthesis and structure–activity relationships of phenylenebis(methylene)–linked bis–azamacrocycles that inhibit HIV–1 and HIV–2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971–81

Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. Posner GH, et al. **J Med Chem** 1999 Jan 28;42(2):300–4

T134, a small–molecule CXCR4 inhibitor, has no cross–drug resistance with AMD3100, a CXCR4 antagonist with a different structure. Arakaki R, et al. **J Virol** 1999 Feb; 73(2):1719–23

Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. Egberink HF, et al. **J Virol** 1999 Aug; 73(8):6346–52

Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium–inducing phenotype by blockade of CXCR4. Esté JA, et al. **J Virol** 1999 Jul;73(7):5577–85

Aniracetam, 1–BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices. Pittaluga A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr; 359(4):272–9

Promising anti–HIV therapeutic strategy with a small molecule CXCR4 antagonist. Schols D. **Verh K Acad Geneeskd Belg** 1999;61(4):551–64

THERAPEUTIC USE

Synergistic therapy of breast cancer with Y–90–chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. Denardo SJ, et al. **Anticancer Res** 1998 Nov–Dec;18(6A):4011–8

Efficacy of RD3–0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Sudo K, et al. **Antimicrob Agents Chemother** 1999 Apr; 43(4):752–7

Efficacy and toxicity of 67Cu–2IT–BAT–Lym–1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). DeNardo GL, et al. **Clin Cancer Res** 1997 Jan;3(1):71–9

Treatment–related parameters predicting efficacy of Lym–1 radioimmunotherapy in patients with B–lymphocytic malignancies. Lamborn KR, et al. **Clin Cancer Res** 1997 Aug;3(8):1253–60

Response to treatment with yttrium 90–DOTA–lanreotide of a patient with metastatic gastrinoma. Leimer M, et al. **J Nucl Med** 1998 Dec;39(12):2090–4

Schizophrenia, psychotropic medication, and cataract. McCarty CA, et al. **Ophthalmology** 1999 Apr;106(4):683–7

TOXICITY

Re: Felix,K., Lin,S., Bornkamm,G.W. and Janz,S. (1998) tetravinyl–tetramethylcyclo–tetrasiloxane (tetravinyl D4) is a mutagen in Rat2lambdalacI fibroblasts. Carcinogenesis, 19, 315–320 [letter] Kulig K. **Carcinogenesis** 1999 Aug; 20(8):1653–4

Cancer chemopreventive mechanisms of tea against heterocyclic amine mutagens from cooked meat. Dashwood RH, et al. **Proc Soc Exp Biol Med** 1999 Apr; 220(4):239–43 (28 ref.)

HETEROCYCLIC COMPOUNDS, 1–RING

Total solid–phase synthesis of 1,4,7,10–tetraazacyclododecane–N,N',N'',N'''–tetraacetic acid–functionalized peptides for radioimmunotherapy. Peterson JJ, et al. **Bioconjug Chem** 1999 Mar–Apr; 10(2):316–20

CHEMICAL SYNTHESIS

Synthesis of 1,3–dithianes and 1,3–dithiolanes. Baker's yeast reduction and lipase–catalyzed resolution for synthesis of enantiopure derivatives. Anthonsen T, et al. **Acta Chem Scand** 1999 May;53(5):360–5

Direct synthesis of [DOTA–DPhe1]–octreotide and [DOTA–DPhe1,Tyr3]–octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Albert R, et al. **Bioorg Med Chem Lett** 1998 May 19; 8(10):1207–10

A 2–methyleneoxetane analog of orlistat demonstrating inhibition of porcine pancreatic lipase. Dollinger LM, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):977–8

Design, synthesis, and biological evaluation of novel non–piperazine analogues of 1–[2–(diphenylmethoxy)ethyl]– and 1–[2–[bis(4–fluorophenyl)methoxy]ethyl]–4–(3–phenylpropyl)piperazines as dopamine transporter inhibitors. Choi SW, et al. **J Med Chem** 1999 Sep 9; 42(18):3647–56

Antitumor activity of new derivatives of 1,3–diazaheterocycles. Krężel I. **Pharmazie** 1998 Sep; 53(9):614–7

CHEMISTRY

NMR studies of the metal–loading kinetics and acid–base chemistry of DOTA and butylamide–DOTA. Keire DA, et al. **Bioconjug Chem** 1999 May–Jun;10(3):454–63

TOXICITY

Mutagenicity tests of 4–phenyl–1,3–dithia–2–thioxo–cyclopent–4–ene. Sadanobu S, et al. **J Toxicol Sci** 1999 May;24(2):87–94

HETEROCYCLIC COMPOUNDS, 2–RING

CHEMICAL SYNTHESIS

Dimeric analogues of non–cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Spicer JA, et al. **Anticancer Drug Des** 1999 Jun;14(3):281–9

Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro. Davis MC, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):843–6

Synthesis and structure–activity relationships of phenylenebis(methylene)–linked bis–azamacrocycles that inhibit HIV–1 and HIV–2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971–81

PHARMACOLOGY

Dimeric analogues of non–cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents. Spicer JA, et al. **Anticancer Drug Des** 1999 Jun;14(3):281–9

Synthesis and structure–activity relationships of phenylenebis(methylene)–linked bis–azamacrocycles that inhibit HIV–1 and HIV–2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971–81

[Effects of a new excitotoxic amino acid, dysiherbaine, on cultured Müller cells] Minei R. **Nippon Ganka Gakkai Zasshi** 1999 Aug;103(8):584–90 (Eng. Abstr.) **(Jpn)**

HETEROCYCLIC COMPOUNDS, 3–RING

CHEMISTRY

Heterocyclic analogs of DNA minor groove alkylating agents. Baraldi PG, et al. **Curr Pharm Des** 1998 Jun; 4(3):249–76 (166 ref.)

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure–activity relationships. Strickland CL, et al. **J Med Chem** 1999 Jun 17;42(12):2125–35

PHARMACOLOGY

Reversal of P–glycoprotein–mediated multidrug resistance in vitro by AV200, a new ardeemin derivative. Méndez–Vidal C, et al. **Cancer Lett** 1998 Oct 23; 132(1–2):45–50

Characterization of antiallodynic actions of ALE–0540, a novel nerve growth factor receptor antagonist, in the rat. Owolabi JB, et al. **J Pharmacol Exp Ther** 1999 Jun; 289(3):1271–6

TOXICITY

Antitumor activity of 4,5,6,7–tetrathiocino (1,2–b: 3,4–b') diimidazolyl–1,3,8,10–tetrasubstituted–2,9–dithiones (R4–todit). Pani A, et al. **Anticancer Res** 1998 Nov–Dec; 18(6A):4429–34

HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS

PHARMACOLOGY

Effects of Ca2+ channel blockers on apomorphine, bromocriptine and morphine–induced locomotor activity in mice. Doğrul A, et al. **Eur J Pharmacol** 1999 Jan 8; 364(2–3):175–82

HETEROCYCLIC CPDS, BICYCLIC see **BICYCLO COMPOUNDS, HETEROCYCLIC**

HETEROCYCLIC COMPOUNDS, 1–RING

CHEMISTRY

Synthesis and physicochemical characterization of a novel precursor for covalently bound macromolecular MRI contrast agents. André JP, et al. **J Biol Inorg Chem** 1999 Jun;4(3):341–7

HETEROCYCLIC N–OXIDES see **CYCLIC N–OXIDES**

HETEROCYCLIC P–OXIDES see **CYCLIC P–OXIDES**

HETEROCYCLIC S–OXIDES see **CYCLIC S–OXIDES**

HETERODUPLEX ANALYSIS

see related
BASE PAIR MISMATCH
NUCLEIC ACID HETERODUPLEXES

HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1–infected individuals. Diaz RS, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1151–6

Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology. Clark ZE, et al. **Clin Chem** 1998 Nov; 44(11):2360–2

Heteroduplex analysis: a useful screening method for glycogen storage disease type Ia. Narita T, et al. **Diagn Mol Pathol** 1998 Apr;7(2):111–3

Comparison of enzyme mismatch cleavage and chemical cleavage of mismatch on a defined set of heteroduplexes. Deeble VJ, et al. **Genet Test** 1997–98;1(4):253–9

Denaturing HPLC–identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders. Liu WO, et al. **Genet Test** 1997–98;1(4):237–42

Accurate, high–throughput "snapshot" detection of hMLH1 mutations by two–dimensional DNA electrophoresis. Smith WM, et al. **Genet Test** 1998;2(1):43–53

Multiplex SSCP and heteroduplex analysis with Southern hybridization for large–scale mutation detection. Pogue R, et al. **Genomics** 1998 Nov 15;54(1):1–4

Surfactant protein B deficiency: clinical, histological and molecular evaluation. Williams GD, et al. **J Paediatr Child Health** 1999 Apr;35(2):214–20

The combination of heteroduplex analysis and protein truncation test for exact detection of the APC gene mutations. Tomka M, et al. **Neoplasma** 1998;45(6):345–8

METHODS

Heteroduplex cleavage analysis using S1 nuclease. Howard JT, et al. **Biotechniques** 1999 Jul;27(1):18–9

High–throughput screening for the detection of unknown mutations: improved productivity using heteroduplex analysis. Maynard JH, et al. **Biotechniques** 1998 Oct; 25(4):648–51

Evaluation of mutation screening by heteroduplex analysis in acute intermittent porphyria: comparison with denaturing gradient gel electrophoresis. Tchernitchko D, et al. **Clin Chim Acta** 1999 Jan;279(1–2):133–43

High resolution mapping DNAs by R–loop atomic force microscopy. Klinov DV, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4603–10

Generation of co–dominant PCR–based markers by duplex analysis on high resolution gels. Hauser MT, et al. **Plant J** 1998 Oct;16(1):117–25

HETERODUPLEXES, NUCLEIC ACID see **NUCLEIC ACID HETERODUPLEXES**

HETEROGENEOUS NUCLEAR RNA see **RNA, HETEROGENEOUS NUCLEAR**

HETEROGRAFT see **TRANSPLANTATION, HETEROLOGOUS**

HETEROGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

HETEROGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

HETEROLOGOUS ANTIBODIES see **ANTIBODIES, HETEROPHILE**

HETEROLOGOUS ANTIGENS see **ANTIGENS, HETEROPHILE**

HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR**

HETEROPHILE ANTIBODIES see **ANTIBODIES, HETEROPHILE**

HETEROPHILE ANTIGENS see **ANTIGENS, HETEROPHILE**

HETEROPHYES

HETEROPHYES see **HETEROPHYIDAE**

HETEROPHYIDAE

Two endemic foci of heterophyids and other intestinal fluke infections in southern and western coastal areas in Korea. Chai JY, et al. **Korean J Parasitol** 1998 Sep;36(3):155–61

ANATOMY & HISTOLOGY

Redescription of Phagicola pithecophagicola Faust, 1920 (Digenea: Heterophyidae), the type species of Phagicola Faust, 1920. Scholz T. **J Parasitol** 1999 Feb;85(1):111–4

GROWTH & DEVELOPMENT

Experimental host of Stellantchasmus falcatus. Wongsawad C, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):406–9

ISOLATION & PURIFICATION

Natural mass infection by heterophyid metacercariae in aquacultured Japanese eel in Taiwan. Ooi HK, et al. **Dis Aquat Organ** 1999 Jan 7;35(1):31–6

Occurrence of two heterophyid metacercariae Haplorchis and Haplorchoides in cyprinoid fish of some districts in Chiang Mai and Lumphun Province. Namue C, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):401–5

Experimental host of Stellantchasmus falcatus. Wongsawad C, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun;29(2):406–9

ULTRASTRUCTURE

Surface ultrastructure of juvenile and adult stages of Centrocestus armatus. Woo HC, et al. **J Helminthol** 1998 Sep;72(3):215–9

Surface ultrastructure of Metagonimus miyatai metacercariae and adults. Chai JY, et al. **Korean J Parasitol** 1998 Dec; 36(4):217–25

HETEROPNEUSTES see **CATFISH**

HETEROPTERA

ANATOMY & HISTOLOGY

Heteropteran ovaries: variations on the theme. Simiczyjew B, et al. **Folia Histochem Cytobiol** 1998;36(4):147–56 (51 ref.)

PHYSIOLOGY

Wing morph-related physiological differences in adults of temperate population of Pyrrhocoris apterus (L.) (Heteroptera: Pyrrhocoridae). Sula J, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Dec; 121(4):365–73

HETEROSEXUALITY

Cofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya. Rakwar J, et al. **AIDS** 1999 Apr 1; 13(5):607–14

Managing HIV among serodiscordant heterosexual couples: serostatus, stigma and sex. van der Straten A, et al. **AIDS Care** 1998 Oct;10(5):533–48

Heterosexual couples confronting the challenges of HIV infection. VanDevanter N, et al. **AIDS Care** 1999 Apr; 11(2):181–93

Maintenance of safe sex behavior by HIV-serodiscordant heterosexual couples. Skurnick JH, et al. **AIDS Educ Prev** 1998 Dec;10(6):493–505

Re: "Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992–1995" [letter; comment] Brody S, et al. **Am J Epidemiol** 1999 Aug 15;150(4):429–30. Comment on: Am J Epidemiol 1999 Jan 1;149(1):75–84.

Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Holly EA, et al. **Am J Epidemiol** 1999 Aug 15;150(4):375–89

Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992–1995. Mode of Transmission Validation Study Group [see comments] Klevens RM, et al. **Am J Epidemiol** 1999 Jan 1;149(1):75–84. Comment in: Am J Epidemiol 1999 Aug 15;150(4):429–30.

Male and female differences in reports of women's heterosexual initiation and aggression. Anderson PB, et al. **Arch Sex Behav** 1999 Jun;28(3):243–53

The relation between sexual orientation and penile size. Bogaert AF, et al. **Arch Sex Behav** 1999 Jun;28(3):213–21

Birth order and sibling sex ratio in homosexual and heterosexual non-white men. Bogaert AF. **Arch Sex Behav** 1998 Oct;27(5):467–73

Two variants of HIV-1 B serotype are transmitted heterosexually in São Paulo, Brazil. Casseb J, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1243–6

Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. Pedraza MA, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):120–5

Incidence and risk factors for heterosexually acquired HIV in an inner-city cohort of women: temporal association with pregnancy. Chirgwin KD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):295–9

Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research. Rompalo AM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):448–54

Epidemiologic evidence for time variation in HIV infectivity. Shiboski SC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):527–35

Heteronegativism? The attitudes of gay men and lesbians toward heterosexuals. White SM, et al. **J Homosex** 1999; 37(1):65–79

Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. Lin JS, et al. **J Infect Dis** 1998 Dec; 178(6):1707–12

Effect of chemokine receptor mutations on heterosexual human immunodeficiency virus transmission. Lockett SF, et al. **J Infect Dis** 1999 Sep;180(3):614–21

High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. Nelson KE, et al. **J Infect Dis** 1999 Aug;180(2):337–43

Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Smith NA, et al. **J Infect Dis** 1999 Sep;180(3):600–6

Structured models for heterosexual disease transmission. Kribs-Zaleta CM. **Math Biosci** 1999 Aug;160(1):83–108

Heterosexual HIV transmission and STD prevalence: predictions of a theoretical model. Renton AM, et al. **Sex Transm Infect** 1998 Oct;74(5):339–44

GENETICS

Epigenesis and sexual orientation: a report of five bisexual males. Bemporad JR. **J Am Acad Psychoanal** 1999 Summer; 27(2):221–37

PSYCHOLOGY

Heterosexual men's attitudes toward the female condom. Seal DW, et al. **AIDS Educ Prev** 1999 Apr;11(2):93–106

Predictors of increased condom use following HIV intervention with heterosexually active drug users. Kwiatkowski CF, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):57–62

A new analytic dyad: homosexual analyst, heterosexual patient. Phillips SH. **J Am Psychoanal Assoc** 1998; 46(4):1195–219

Gender differences related to heterosexual condom use: the influence of negotiation styles. Carter JA, et al. **J Sex Marital Ther** 1999 Jul-Sep;25(3):217–25

STATISTICS & NUMERICAL DATA

Heterosexual transmission of HIV in Scotland [letter; comment] Gilbart VL, et al. **Sex Transm Infect** 1998 Aug; 74(4):306–7. Comment on: Sex Transm Infect 1998 Feb;74(1):77.

HETEROSIS see **HYBRID VIGOR**

HETEROTOPIC TISSUE see **CHORISTOMA**

HETEROZYGOSITY, LOSS OF see **LOSS OF HETEROZYGOSITY**

HETEROZYGOTE

Pros and cons of genetic screening for breast cancer [editorial; comment] Lynch HT, et al. **Am Fam Physician** 1999 Jan 1;59(1):43–4, 46. Comment on: Am Fam Physician 1999 Jan 1;59(1):99–104, 106.

Screening for genetic risk of breast cancer [see comments] Rosenthal TC, et al. **Am Fam Physician** 1999 Jan 1; 59(1):99–104, 106 (23 ref.). Comment in: Am Fam Physician 1999 Jan 1;59(1):43–4, 46.

Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Sánchez-Quesada JL, et al. **Am J Cardiol** 1999 Sep 15; 84(6):655–9

Dietary oleic and palmitic acids and postprandial factor VII in middle-aged men heterozygous and homozygous for factor VII R353Q polymorphism. Sanders TA, et al. **Am J Clin Nutr** 1999 Feb;69(2):220–5

Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Ahmed A, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2598–9

Fetal hemoglobin expression in the compound heterozygous state for -117 (G-->A) Agamma HPFH and IVSII-745 (C-->G) beta+ thalassemia: a case study. Dedoussis GV, et al. **Am J Hematol** 1999 Jun;61(2):139–43

Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Allingham-Hawkins DJ, et al. **Am J Med Genet** 1999 Apr 2;83(4):322–5

Menstrual disorders and endocrine profiles in fragile X carriers prior to 40 years of age: a pilot study. Braat DD, et al. **Am J Med Genet** 1999 Apr 2;83(4):327–8

Compound heterozygosity for the Achondroplasia-hypochondroplasia FGFR3 mutations: prenatal diagnosis and postnatal outcome. Chitayat D, et al. **Am J Med Genet** 1999 Jun 11;84(5):401–5

Linear lesions reflecting lyonization in women heterozygous for IFAP syndrome (ichthyosis follicularis with atrichia and photophobia). König A, et al. **Am J Med Genet** 1999 Aug 6;85(4):365–8

Compound heterozygous female with fragile X syndrome. Linden MG, et al. **Am J Med Genet** 1999 Apr 2; 83(4):318–21

Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease [letter] Martiniuk F, et al. **Am J Med Genet** 1998 Aug 27;79(1):69–72

Heterozygous glycine substitution in the COL11A2 gene in the original patient with the Weissenbacher-Zweymüller syndrome demonstrates its identity with heterozygous OSMED (nonocular Stickler syndrome). Pihlajamaa T, et al. **Am J Med Genet** 1998 Nov 2;80(2):115–20

Risk of abnormal pregnancy outcome in carriers of balanced reciprocal translocations involving the Miller-Dieker syndrome (MDS) critical region in chromosome 17p13.3. Pollin TI, et al. **Am J Med Genet** 1999 Aug 6;85(4):369–75

Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier. Takacs I, et al. **Am J Med Genet** 1999 Jul 2;85(1):9–12

Twinning and premature ovarian failure in premutation fragile X carriers [letter] Vianna-Morgante AM. **Am J Med Genet** 1999 Apr 2;83(4):326

Selection for carriers of recessive diseases: a common phenomenon? Zlotogora J. **Am J Med Genet** 1998 Nov 16;80(3):266–8 (19 ref.)

Double heterozygosity for the codon beta 39 C-to-T nonsense mutation and a triplicate alpha-globin gene locus can cause "dominantly" inherited beta-thalassemia intermedia. Rhodes SL, et al. **Am J Med Sci** 1999 May; 317(5):341–5

Decreased renal Na-K-2Cl cotransporter abundance in mice with heterozygous disruption of the G(s)alpha gene. Ecelbarger CA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):F235–44

Normal lung function in subjects heterozygous for surfactant protein-B deficiency. Yusen RD, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):411–4

A new amyloidogenic transthyretin variant (Val122Ala) found in a compound heterozygous patient. Théberge R, et al. **Amyloid** 1999 Mar;6(1):54–8

Compound heterozygous hereditary coproporphyria with fluorescing teeth. Doss MO, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):680–2

Carrier detection by microsatellite analysis of Duchenne/Becker muscular dystrophy in Hungarian families. Bachrati CZ, et al. **Ann Hum Genet** 1998 Nov;62 (Pt 6):511–20

Increased risk for fetal loss in carriers of the factor V Leiden mutation. Meinardi JR, et al. **Ann Intern Med** 1999 May 4;130(9):736–9

Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Cossée M, et al. **Ann Neurol** 1999 Feb;45(2):200–6

Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Van Remmen H, et al. **Arch Biochem Biophys** 1999 Mar 1; 363(1):91–7

Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency. Matsunaga A, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):348–55

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. **Atherosclerosis** 1999 Jan;142(1):105–12

A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the alpha1(VI) collagen chain in an italian family affected by bethlem myopathy. Pepe G, et al. **Biochem Biophys Res Commun** 1999 May 19; 258(3):802–7

Diagnosis of mitochondrial disease: assessment of mitochondrial DNA heteroplasmy in blood. Taylor RW, et al. **Biochem Biophys Res Commun** 1998 Oct 29; 251(3):883–7

Aberrant DNA sequence pattern caused by a heterozygosity. Argyropoulos G, et al. **Biotechniques** 1999 Apr;26(4):604–6

Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Osato M, et al. **Blood** 1999 Mar 15;93(6):1817–24

Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Poort SR, et al. **Blood Coagul Fibrinolysis** 1998 Nov;9(8):761–4

Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Inskip HM, et al. **Br J Cancer** 1999 Mar;79(7-8):1304–7

Contribution of the glycoprotein Ia 807TT, methylene

tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Hessner MJ, et al. **Br J Haematol** 1999 Jul;106(1):237–9

Reproductive choices of haemophilia carriers. Tedgård U, et al. **Br J Haematol** 1999 Aug;106(2):421–6

Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Yang P, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):461–5

High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Ingvarsson S, et al. **Cancer Res** 1998 Oct 1;58(19):4421–5

Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Shigeta T, et al. **Cancer Res** 1999 Jun 1;59(11):2602–7

Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Jones JM, et al. **Cell Growth Differ** 1999 Apr;10(4):213–22

Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension [letter] Morse JH, et al. **Chest** 1999 Sep;116(3):847

Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see comments] Tuomainen TP, et al. **Circulation** 1999 Sep 21; 100(12):1274–9. Comment in: Circulation 1999 Sep 21;100(12):1260–3.

The molecular genetics of arrhythmias and sudden death [letter] Brooker JZ. **Clin Cardiol** 1999 Apr;22(4):323

Genetic analyses in homozygous and heterozygous variants of lactate dehydrogenase-B (H) subunit--LD-B Matsumoto I and II (LD-B W323R). Okumura N, et al. **Clin Chim Acta** 1999 Sep;287(1-2):163–71

Identification of compound heterozygous mutations (G188E/W382X) of lipoprotein lipase gene in a Japanese infant with hyperchylomicronemia: the G188E mutation was newly identified in Japanese. Takagi A, et al. **Clin Chim Acta** 1999 Jul;285(1-2):143–54

Carrier detection in Duchenne and Becker muscular dystrophy Argentine families. Baranzini SE, et al. **Clin Genet** 1998 Dec;54(6):503–11

Determination of the prevalence of cystic fibrosis in the United Arab Emirates by genetic carrier screening [letter] Frossard PM, et al. **Clin Genet** 1999 Jun;55(6):496–7

A novel DraI polymorphism in the 3' untranslated region of human glucose-6-phosphatase gene: useful for carrier detection and prenatal diagnosis of glycogen storage disease type Ia. Lam CW, et al. **Clin Genet** 1998 Jun;53(6):502–3

Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia. Winder AF, et al. **Clin Genet** 1998 Dec;54(6):497–502

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? [letter; comment] Xie HG. **Clin Pharmacol Ther** 1998 Nov;64(5):575. Comment on: Clin Pharmacol Ther 1998 Mar;63(4):422–7.

Prevention of insulin resistance and diabetes in mice heterozygous for GLUT4 ablation by transgenic complementation of GLUT4 in skeletal muscle. Tsao TS, et al. **Diabetes** 1999 Apr;48(4):775–82

Implications of compound heterozygous insulin receptor mutations in congenital muscle fibre type disproportion myopathy for the receptor kinase activation. Klein HH, et al. **Diabetologia** 1999 Feb;42(2):245–9

Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Lonardo A, et al. **Dig Dis Sci** 1998 Nov;43(11):2489–92 (46 ref.)

Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone. Yasufuku-Takano J, et al. **Endocrinology** 1999 May;140(5):2018–26

Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers [see comments] González C, et al. **Eur J Clin Invest** 1999 Jul;29(7):637–42 . Comment in: Eur J Clin Invest 1999 Jul;29(7):569–70.

Purine metabolism in female heterozygotes for hypoxanthine-guanine phosphoribosyltransferase deficiency. Puig JG, et al. **Eur J Clin Invest** 1998 Nov; 28(11):950–7

Meiotic segregation analysis by FISH investigations in sperm and spermatocytes of translocation heterozygotes [letter] Armstrong SJ, et al. **Eur J Hum Genet** 1998 Sep-Oct; 6(5):430–1

Heterozygous mutation in the pore of potassium channel gene KvLQT1 causes an apparently normal phenotype in long QT syndrome. Neyroud N, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):129–33

Lower frequency of Gaucher disease carriers among Tay-Sachs disease carriers. Peleg L, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):185–6

Altered responses to potassium in cerebellar neurons from weaver heterozygote mice. Fox AP, et al. **Exp Brain Res** 1998 Dec;123(3):298–306

Unusual macular findings in a known choroideremia carrier [letter] Majid MA, et al. **Eye** 1998;12 (Pt 4):740–1

Reproductive properties of heterozygous nu/+ mice. Boubelik M. **Folia Microbiol (Praha)** 1998;43(5):479–80

Essential defects of athymic nude mice affect also the nu/+ heterozygotes. Holub M, et al. **Folia Microbiol (Praha)** 1998;43(5):491–2

A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Wallace DF, et al. **Gastroenterology** 1999 Jun; 116(6):1409–12

The new heterozygosity theory of mate choice and the MHC. Brown JL. **Genetica** 1998-99;104(3):215–21 (87 ref.)

Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Grove J, et al. **Gut** 1998 Aug;43(2):262–6

Effects of a hair cell transcription factor, Brn-3.1, gene deletion on homozygous and heterozygous mouse cochleas in adulthood and aging. Keithley EM, et al. **Hear Res** 1999 Aug;134(1-2):71–6

Associative overdominance, heterozygosity and fitness. Pamilo P, et al. **Heredity** 1998 Oct;81 (Pt 4):381–9

One founder/one gene hypothesis in a new expanding population: Saguenay (Quebec, Canada). Heyer E. **Hum Biol** 1999 Feb;71(1):99–109

Evidence of an increased risk of hearing loss in heterozygous carriers in a Wolfram syndrome family. Ohata T, et al. **Hum Genet** 1998 Oct;103(4):470–4

Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online. Csokay B, et al. **Hum Mutat** 1999;14(1):92

Characterisation of 16 polymorphic markers in the NF2 gene: application to hemizygosity detection. Legoix P, et al. **Hum Mutat** 1999;13(4):290–3

Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. Scherer-Oppliger T, et al. **Hum Mutat** 1999;13(4):286–9

Trimodal distribution of HbS levels in sickle heterozygotes--an useful predictor of the alpha-genotype for population screening. Mukherjee MB, et al. **Indian J Med Res** 1998 Dec;108:285–90

Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Weissberg JB, et al. **Int J Radiat Oncol Biol Phys** 1998 Dec 1;42(5):1133–6

Fifteen-year follow-up of a heterozygous Fabry's disease patient associated with pre-excitation syndrome. Murata R, et al. **Intern Med** 1999 Jun;38(6):476–81

Comparison of cardiorespiratory reflexes in NK1 receptor knockout, heterozygous and wild-type mice in vivo. Butcher JW, et al. **J Auton Nerv Syst** 1998 Apr 30; 69(2-3):89–95

Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. Arai T, et al. **J Biol Chem** 1999 Jan 22;274(4):2366–71

Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. Periasamy M, et al. **J Biol Chem** 1999 Jan 22;274(4):2556–62

Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. Williams MD, et al. **J Biol Chem** 1998 Oct 23;273(43):28510–5

Growth hormone receptor mutations in children with idiopathic short stature. Sanchez JE, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4079–83

Moral concerns of different types of patients in clinical BRCA1/2 gene mutation testing. Goelen G, et al. **J Clin Oncol** 1999 May;17(5):1595–600

Intramammary infections in primiparous Holsteins: heritabilities and comparisons of bovine leukocyte adhesion deficiency carriers and noncarriers. Wanner JM, et al. **J Dairy Sci** 1998 Dec;81(12):3293–9

Molecular epidemiology of C9 deficiency heterozygotes with an Arg95Stop mutation of the C9 gene in Japan. Kira R, et al. **J Hum Genet** 1999;44(2):109–11

Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. Buseyne F, et al. **J Infect Dis** 1998 Oct;178(4):1019–23

Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. van Rij RP, et al. **J Infect Dis** 1999 Sep;180(3):854–7

Aberrant phenylalanine metabolism in phenylketonuria heterozygotes. Guldberg P, et al. **J Inherit Metab Dis** 1998 Jun;21(4):365–72

Accurate detection of Smith-Lemli-Opitz syndrome carriers by measurement of the rate of reduction of the ergosterol C-7 double bond in cultured skin fibroblasts. Honda M, et al. **J Inherit Metab Dis** 1998 Oct;21(7):761–8

Oral phenylalanine loading profiles in symptomatic and asymptomatic gene carriers with dopa-responsive dystonia due to dominantly inherited GTP cyclohydrolase deficiency. Hyland K, et al. **J Inherit Metab Dis** 1999 May; 22(3):213–5

Single-cell analysis of mitochondrial DNA in patients and a carrier of the tRNA(Leu)(UUR) gene mutation. Saitoh S, et al. **J Inherit Metab Dis** 1999 Jun;22(5):608–14

Phenylalanine and tyrosine metabolism in phenylketonuria heterozygotes: influence of different phenylalanine hydroxylase mutations. Spada M, et al. **J Inherit Metab Dis** 1998 Jun;21(3):236–9

Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation [published erratum appears in J Inherit Metab Dis 1998 Oct;21(7):783] van Kuilenburg AB, et al. **J Inherit Metab Dis** 1998 Jun; 21(3):280–4

Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. Eichhorn RF, et al. **J Intern Med** 1999 Jan;245(1):103–6

Compound heterozygosity for silent and dominant glycine substitution mutations in COL7A1 leads to a marked transient intracytoplasmic retention of procollagen VII and a moderately severe dystrophic epidermolysis bullosa phenotype [letter] Shimizu H, et al. **J Invest Dermatol** 1999 Sep;113(3):419–21

Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband. Argyropoulos G, et al. **J Lipid Res** 1998 Sep;39(9):1870–6

Sperm DNA analysis in a Friedreich ataxia premutation carrier suggests both meiotic and mitotic expansion in the FRDA gene. Delatycki MB, et al. **J Med Genet** 1998 Sep; 35(9):713–6

Men in breast cancer families: a preliminary qualitative study of awareness and experience. McAllister MF, et al. **J Med Genet** 1998 Sep;35(9):739–44

Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. Richard P, et al. **J Med Genet** 1999 Jul;36(7):542–5

Reassessment of biochemically determined Hunter syndrome carrier status by DNA testing. Timms KM, et al. **J Med Genet** 1998 Aug;35(8):646–9

Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history [see comments] Claus EB, et al. **J Natl Cancer Inst** 1998 Dec 2;90(23):1824–9. Comment in: J Natl Cancer Inst 1999 Jul 21;91(14):1250–1.

Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. Phillips KA, et al. **J Natl Cancer Inst** 1999 Mar 3;91(5):469–73

Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Stratton JF, et al. **J Natl Cancer Inst** 1999 Apr 7;91(7):626–8

Postpartum cerebral venous thrombosis, congenital protein C deficiency, and activated protein C resistance due to heterozygous factor V Leiden mutation [letter] Derex L, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):801–2

Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. Kim JH, et al. **J Neurooncol** 1998 Nov;40(2):101–6

Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. Fumagalli F, et al. **J Neurosci** 1999 Apr 1;19(7):2424–31

Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness. Green GE, et al. **JAMA** 1999 Jun 16;281(23):2211–6

One Lewis rat with homozygous defect of the serine proteinase inhibitor 2 (Spi-2) gene and two Lewis rats with heterozygous Spi-2 gene defect. Nakatsuji T. **Keio J Med** 1998 Sep;47(3):150–6

Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Hoogerwaard EM, et al. **Lancet** 1999 Jun 19;353(9170):2116–9

Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy [letter] Jacquemin E, et al. **Lancet** 1999 Jan 16;353(9148):210–1

Prevalence of Werner's syndrome heterozygotes in Japan [letter] Satoh M, et al. **Lancet** 1999 May 22;353(9166):1766

Heterozygote advantage of the MTHFR gene in patients with neural-tube defect and their relatives [letter] Weitkamp LR, et al. **Lancet** 1998 May 23;351(9115):1554–5

The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Maestri NE, et al. **Medicine (Baltimore)** 1998 Nov;77(6):389–97

Efficient identification of point mutations by automated DNA sequencing of artificial heterozygote samples. Staedtler F, et al. **Mol Biotechnol** 1998 Dec;10(3):269–72

Effect of ploidy and homozygosity on transgene expression in primary tobacco transformants and their androgenetic progenies. Beaujean A, et al. **Mol Gen Genet** 1998 Nov; 260(4):362–71

Electrical myotonia in heterozygous carriers of recessive myotonia congenita. Deymeer F, et al. **Muscle Nerve** 1999 Jan;22(1):123–5

Familial endometrial cancer in female carriers of MSH6 germline mutations [letter] Wijnen J, et al. **Nat Genet** 1999 Oct;23(2):142–4

Selective thrombolysis in a newborn with bilateral renal venous and cerebral thrombosis and heterozygous APC resistance. Klinge J, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3205–7

Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis. Lauronen L, et al. **Neurology** 1999 Jan 15;52(2):360–5

Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Hoogerwaard EM, et al. **Neuromuscul Disord** 1999 Jul;9(5):347–51

HETEROZYGOTE

Cardiac transplantation in a Duchenne muscular dystrophy carrier. Melacini P, et al. **Neuromuscul Disord** 1998 Dec; 8(8):585–90

An ultrastructural study of granule cell/Purkinje cell synapses in tottering (tg/tg), leaner (tg(la)/tg(la)) and compound heterozygous tottering/leaner (tg/tg(la)) mice. Rhyu IJ, et al. **Neuroscience** 1999 Mar;90(3):717–28

Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry's disease improved following implantation of a dual chamber pacemaker. Nakayama Y, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1114–5

Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease [see comments] Asonuma K, et al. **Pediatr Transplant** 1999 Aug; 3(3):201–5. Comment in: Pediatr Transplant 1999 Aug;3(3):169–70.

Neonatal hyperbilirubinemia in glucose–6–phosphate dehydrogenase–deficient heterozygotes. Kaplan M, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):68–74

Long–term psychological effects of carrier testing and prenatal diagnosis of haemophilia: comparison with a control group. Tedgård U, et al. **Prenat Diagn** 1999 May; 19(5):411–7

Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice. Shao C, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9230–5

Genotype–phenotype relationship in female carriers of the premutation and full mutation of FMR–1. Franke P, et al. **Psychiatry Res** 1998 Aug 17;80(2):113–27

Presymptomatic detection and treatment of Japanese carriers of the multiple endocrine neoplasia type 2A gene. Uchino S, et al. **Surg Today** 1999;29(9):862–7

Recurrent thromboembolism in two unrelated patients with double heterozygosity for factor V R506Q and factor II 20210G/A mutations [letter] Veyradier A, et al. **Thromb Haemost** 1998 Jul;80(1):201–2

Molecular characterization of HLA class I in Colombians carrying HLA–A2: high allelic diversity and frequency of heterozygotes at the HLA–B locus. Fleischhauer K, et al. **Tissue Antigens** 1999 Jun;53(6):519–26

[Influence of the sickle cell trait heterozygote on energy abilities] Bitanga E, et al. **Pathol Biol (Paris)** 1998 Jan; 46(1):46–52 (50 ref.) (Eng. Abstr.) **(Fre)**

[Pedigree analysis of childless families of reciprocal chromosome translocation carriers] Stasiewicz–Jarocka B, et al. **Ginekol Pol** 1998 Dec;69(12):1183–90 (Eng. Abstr.) **(Pol)**

[Combined hemostatic defects in family members of symptomatic carriers of Leiden mutations of factor V] Lewandowski K, et al. **Pol Arch Med Wewn** 1998 Mar; 99(3):211–7 (Eng. Abstr.) **(Pol)**

[Relation between the space flight–induced frequency of dominant lethal mutations and the level of allozyme heterozygosity in Drosophila melanogaster populations] Altukhov IuP, et al. **Dokl Akad Nauk** 1998 Aug; 361(5):709–11 **(Rus)**

[Allozyme heterozygosity, sexual maturation rate, and longevity] Altukhov IuP. **Genetika** 1998 Jul;34(7):908–19 (Eng. Abstr.) **(Rus)**

[Formation of the heterozygous tandem duplication in the process of conjugation recombination in Escherichia coli: study of the effect of mutations for the recQ, uvrD, and recJ genes] Sukhodolets VV. **Genetika** 1999 Apr; 35(4):450–8 (Eng. Abstr.) **(Rus)**

[Gene frequencies and heterozygosity of the population of Donetsk Province, Ukraine by the alleles of the ABO and Rhesus systems] Mukhin VN. **Tsitol Genet** 1999 May–Jun; 33(3):10–3 (Eng. Abstr.) **(Rus)**

[Newborn's heterozygocity for five blood groups and neonatal morbidity (letter)] Thumala MI, et al. **Rev Med Chil** 1998 Dec;126(12):1516–7 **(Spa)**

[Obstetric treatment of hemophilia carriers] Aguilar C, et al. **Sangre (Barc)** 1998 Oct;43(5):399–405 (71 ref.) **(Spa)**

HETEROZYGOTE DETECTION

Alpha–thalassemia carrier identification by DNA analysis in the screening for thalassemia. Galanello R, et al. **Am J Hematol** 1998 Dec;59(4):273–8

Mixed messages: presentation of information in cystic fibrosis–screening pamphlets. Loeben GL, et al. **Am J Hum Genet** 1998 Oct;63(4):1181–9

X chromosome inactivation in carriers of Barth syndrome. Orstavik KH, et al. **Am J Hum Genet** 1998 Nov; 63(5):1457–63

Prenatal diagnosis and carrier detection for a point mutation in UBE3A causing Angelman syndrome [letter] Tsai TF, et al. **Am J Hum Genet** 1998 Nov;63(5):1561–3

Parental attitudes regarding carrier testing in children at risk for fragile X syndrome. McConkie–Rosell A, et al. **Am J Med Genet** 1999 Jan 29;82(3):206–11

Low rate of venous thromboembolism in asymptomatic relatives of probands with factor V Leiden mutation [letter] Simioni P, et al. **Ann Intern Med** 1999 Mar 16;130(6):538

Detection of a new compound heterozygote (del G916/G1401A) for lipoprotein lipase deficiency and a comparativé haplotype analysis of the mutant lipoprotein lipase gene from Japanese patients [letter] Okubo M, et al. **Atherosclerosis** 1999 Jun;144(2):443–7

Absence of mutations in the ATM gene in forty–seven cases of sporadic breast cancer. Bebb DG, et al. **Br J Cancer** 1999 Aug;80(12):1979–81

Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Wang–Gohrke S, et al. **Br J Cancer** 1999 Sep;81(1):179–83

Failure to support the right–shift theory's hypothesis of a 'heterozygote advantage' for cognitive abilities. Cerone LJ, et al. **Br J Psychol** 1999 Feb;90 (Pt 1):109–23

Breast carcinoma in carriers of BRCA1 or BRCA2 mutations: implications of proposed distinct histologic phenotypes [editorial; comment] Phillips KA. **Cancer** 1998 Dec 1; 83(11):2251–4 (29 ref.). Comment on: Cancer 1998 Dec 1;83(11):2335–45.

Familial context of genetic testing for cancer susceptibility: moderating effect of siblings' test results on psychological distress one to two weeks after BRCA1 mutation testing. Smith KR, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Apr;8(4 Pt 2):385–92

Public health aspects of breast cancer gene testing in Canada. Part 1: risks and interventions [see comments] Elwood JM. **Chronic Dis Can** 1999;20(1):3–13. Comment in: Chronic Dis Can 1999 ;20(1):1–2.

Rapid and non–isotopic detection of intron 18 polymorphism of the factor VIII gene. Soares RP, et al. **Clin Chim Acta** 1999 Sep;287(1–2):157–61

Tissue–specific methylation differences in a fragile X premutation carrier. Tassone F, et al. **Clin Genet** 1999 May; 55(5):346–51

How do carriers of hemophilia and their spouses experience prenatal diagnosis by chorionic villus sampling? Tedgård U, et al. **Clin Genet** 1999 Jan;55(1):26–33

Thalassemia carrier screening and prenatal diagnosis among the British Columbia (Canada) population of Chinese descent. Yong KN, et al. **Clin Genet** 1999 Jan;55(1):20–5

Screening of CFTR mutations in an isolated population: identification of carriers and patients. Chiba–Falek O, et al. **Eur J Hum Genet** 1998 Mar–Apr;6(2):181–4

Repeated transmission of X–linked ocular albinism type 1 by a carrier oocyte donor. Burns WN, et al. **Fertil Steril** 1998 Dec;70(6):1169–72

A genealogical study of Alzheimer disease in the Saguenay region of Quebec. Vézina H, et al. **Genet Epidemiol** 1999; 16(4):412–25

Discovery of children's carrier status for recessive genetic disease: some ethical issues. Davis DS. **Genet Test** 1998; 2(4):323–7

Establishing criteria for a carrier detection panel: lessons from the Ashkenazi Jewish model. Gilbert F. **Genet Test** 1998;2(4):301–4 (23 ref.)

Tay–Sachs disease carrier screening: a model for prevention of genetic disease. Kaplan F. **Genet Test** 1998;2(4):271–92 (192 ref.)

Cystic fibrosis carrier population screening: a review. Rowley PT, et al. **Genet Test** 1997;1(1):53–9 (47 ref.)

Cystic fibrosis carrier screening practices in an ethnically diverse region: experience of the Genetic Network of the Empire State, Puerto Rico, and the U.S. Virgin Islands. Schwind EL, et al. **Genet Test** 1999;3(2):215–8

High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Shahrabani–Gargir L, et al. **Genet Test** 1998;2(4):293–6

Cystic fibrosis Delta F508 heterozygotes, smoking, and reproduction: studies of 9141 individuals from a general population sample. Dahl M, et al. **Genomics** 1998 May 15; 50(1):89–96

Circulating activated protein C in subjects with heterozygous Gln506–factor V. Petäjä J, et al. **Haemostasis** 1998 Jan–Feb; 28(1):31–6

Phenotypic variability in five cystic fibrosis patients compound heterozygous for the Y1092X mutation. De Braekeleer M, et al. **Hum Hered** 1998 May–Jun; 48(3):158–62

Genetic heterogeneity in familial hyperinsulinism [published erratum appears in Hum Mol Genet 1998 Sep;7(9):1527] Nestorowicz A, et al. **Hum Mol Genet** 1998 Jul; 7(7):1119–28

Cancer risk in mutation carriers of DNA–mismatch–repair genes. Aarnio M, et al. **Int J Cancer** 1999 Apr 12; 81(2):214–8

Molecular analysis in familial neurohypophyseal diabetes insipidus: early diagnosis of an asymptomatic carrier. Calvo B, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3351–4

Utility of genotyping in diagnosis of genetic haemochromatosis [editorial; comment] Crawford DH, et al. **J Gastroenterol Hepatol** 1999 May;14(5):401–2. Comment on: J Gastroenterol Hepatol 1999 May;14(5):427–30.

ERG phenotype of a dystrophin mutation in heterozygous female carriers of Duchenne muscular dystrophy. Fitzgerald KM, et al. **J Med Genet** 1999 Apr;36(4):316–22

Feasibility of DNA based methods for prenatal diagnosis and carrier detection of propionic acidaemia. Muro S, et al. **J Med Genet** 1999 May;36(5):412–4

An improved polymerase chain reaction (PCR) protocol for unambigous detection of growth hormone gene deletions. Mone CM, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug; 11(4):563–8

Screening for beta–thalassemia heterozygotes in pregnant women. Pafumi C, et al. **J Pediatr Endocrinol Metab** 1998; 11 Suppl 3:993

Identification of ataxia telangiectasia heterozygotes, a cancer–prone population, using the single–cell gel electrophoresis (Comet) assay. Djuzenova CS, et al. **Lab Invest** 1999 Jun;79(6):699–705

Accurate DNA–based diagnostic and carrier testing for X–linked adrenoleukodystrophy. Boehm CD, et al. **Mol Genet Metab** 1999 Feb;66(2):128–36

Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Li L, et al. **Mol Genet Metab** 1998 Aug;64(4):286–90

Biochemical phenotype and its relationship with genotype in hyperphenylalaninemia heterozygotes. Mallolas J, et al. **Mol Genet Metab** 1999 Jun;67(2):156–61

Late onset of renal and hepatic cysts in Pkd1–targeted heterozygotes [letter] Lu W, et al. **Nat Genet** 1999 Feb; 21(2):160–1

p53 compound heterozygosity in a severely affected child with Li–Fraumeni syndrome. Quesnel S, et al. **Oncogene** 1999 Jul 8;18(27):3970–8

Molecular confirmation of carriers for Lowe syndrome. Lin T, et al. **Ophthalmology** 1999 Jan;106(1):119–22

Adult–type metachromatic leukodystrophy with a compound heterozygote mutation showing character change and dementia. Fukutani Y, et al. **Psychiatry Clin Neurosci** 1999 Jun;53(3):425–8

Molecular genetic detection of female carriers of protan defects. Kainz PM, et al. **Vision Res** 1998 Nov; 38(21):3365–9

Increased plasma, serum and urinary 8–epi–prostaglandin F2 alpha in heterozygous hypercholesterolemia. Oguogho A, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):113–8

[Attitude of patients toward detection of hereditary disease. Heterozygote familial hypercholesterolemia] Andersen LK, et al. **Ugeskr Laeger** 1998 Oct 12;160(42):6075–81 (Eng. Abstr.) **(Dan)**

[Heterozygote detection for hemoglobinopathies: situation in the Netherlands as compared to the British (letter; comment)] Wierenga KJ, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):326–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):996–7. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):1019–22. **(Dut)**

[Splenic infarct in heterozygote sickle cell trait (Hb AS)] von Känel R, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1614–7 (Eng. Abstr.) **(Ger)**

METHODS

A program for the monte carlo evaluation of significance of the extended transmission/disequilibrium test [letter] Zhao JH, et al. **Am J Hum Genet** 1999 May;64(5):1484–5

Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Ashton–Prolla P, et al. **Am J Med Genet** 1999 Jun 11;84(5):420–4

Roles for biochemical and polymerase chain reaction technologies in diagnosis and control of bovine alpha–mannosidosis. Healy PJ, et al. **Aust Vet J** 1998 Oct; 76(10):699–700

Fabry disease: identification of novel alpha–galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Germain DP, et al. **Biochem Biophys Res Commun** 1999 Apr 21; 257(3):708–13

A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis. Hinks JL, et al. **Br J Haematol** 1999 Mar;104(4):915–8

An explanation for the different inhibitory characteristics of human serum butyrylcholinesterase phenotypes deriving from inhibition of atypical heterozygotes. Simeon–Rudolf V, et al. **Chem Biol Interact** 1999 May 14;119–120:159–64

Improved DNA sequencing accuracy and detection of heterozygous alleles using manganese citrate and different fluorescent dye terminators. Korch C, et al. **Genome Res** 1999 Jun;9(6):588–95

Determination of the carrier frequency of the common GJB2 (connexin–26) 35delG mutation in the Belgian population using an easy and reliable screening method. Storm K, et al. **Hum Mutat** 1999;14(3):263–6

A simple screening test for the detection of heterozygous beta thalassemia. Thool AA, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):423–6

Efficacy of cascade testing for fragile X syndrome. Wildhagen MF, et al. **J Med Screen** 1999;6(2):70–6

Haemophilia A carrier detection in the Free State and Northern Cape [letter] Vosloo WM, et al. **S Afr Med J** 1999 Jun;89(6):625–6

Usefulness of cyanide–nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. Finocchiaro R, et al. **Urol Res** 1998;26(6):401–5

[Update on a diagnostic test for choroideremia: the protein truncation test (PTT)] Beaufrere L, et al. **J Fr Ophtalmol** 1998 May;21(5):345–50 (Eng. Abstr.) **(Fre)**

[Analysis of Bcl I polymorphism of factor VIII gene in the molecular diagnosis of female hemophilia A carriers in families from northwestern Venezuela] Borjas–Fajardo L, et al. **Sangre (Barc)** 1999 Feb;44(1):19–23 (Eng. Abstr.) **(Spa)**

HEX A see **BETA–N–ACETYLHEXOSAMINIDASE**

HEX B see **BETA–N–ACETYLHEXOSAMINIDASE**

HEXABRACHION see **TENASCIN**

HEXACHLOROBENZENE

ADVERSE EFFECTS

Hexachlorobenzene and porphyria cutanea tarda [editorial; comment] Kim JJ, et al. **Arch Dermatol** 1999 Apr; 135(4):459–60. Comment on: Arch Dermatol 1999 Apr;135(4):400–4.

Health effects of chronic high exposure to hexachlorobenzene in a general population sample. Sala M, et al. **Arch Environ Health** 1999 Mar–Apr;54(2):102–9

Porphyrin status in aluminum foundry workers exposed to hexachlorobenzene and octachlorostyrene. Seldén AI, et al. **Arch Environ Health** 1999 Jul–Aug;54(4):248–53

Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. Zheng T, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May; 8(5):407–11

Case-control study on breast cancer and adipose tissue concentrations of congener specific polychlorinated biphenyls, DDE and hexachlorobenzene. Liljegren G, et al. **Eur J Cancer Prev** 1998 Apr;7(2):135–40

ANALYSIS

Porphyrin status in aluminum foundry workers exposed to hexachlorobenzene and octachlorostyrene. Seldén AI, et al. **Arch Environ Health** 1999 Jul–Aug;54(4):248–53

Hexachlorobenzene as a possible major contributor to the dioxin activity of human milk. van Birgelen AP. **Environ Health Perspect** 1998 Nov;106(11):683–8 (100 ref.)

BLOOD

Urinary porphyrin excretion in a human population highly exposed to hexachlorobenzene [see comments] Herrero C, et al. **Arch Dermatol** 1999 Apr;135(4):400–4. Comment in: Arch Dermatol 1999 Apr;135(4):459–60.

Distribution of PCB congeners, DDE, hexachlorobenzene, and methylsulfonyl metabolites of PCB and DDE among various fractions of human blood plasma. Norén K, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):408–14

Organochlorine in the serum of inhabitants living near an electrochemical factory. Sala M, et al. **Occup Environ Med** 1999 Mar;56(3):152–8

CHEMISTRY

Microbial hexachlorobenzene dechlorination under three reducing conditions. Chang BV, et al. **Chemosphere** 1998 Jun;36(13):2721–30

METABOLISM

Effect of alpha lipoic acid amide on hexachlorobenzene porphyria. Vilas GL, et al. **Biochem Mol Biol Int** 1999 May; 47(5):815–23

Thermogravimetric study of thermal decontamination of soils polluted by hexachlorobenzene, 4-chlorobiphenyl, naphthalene, or n-decane. Risoul V, et al. **J Hazard Mater** 1999 Feb 15;64(3):295–311

PHARMACOKINETICS

Tissue distribution of planar and non-planar chlorobiphenyls, 4,4'-DDE and hexachlorobenzene in sheep and lambs. Jan J, et al. **Chemosphere** 1999 May;38(11):2607–12

Digestive tract absorption of PCDD/Fs, PCBs, and HCB in humans: mass balances and mechanistic considerations. Schlummer M, et al. **Toxicol Appl Pharmacol** 1998 Sep; 152(1):128–37

PHARMACOLOGY

Hexachlorobenzene, a dioxin-type compound, increases malic enzyme gene transcription through a mechanism involving the thyroid hormone response element. Loaiza-Pérez AI, et al. **Endocrinology** 1999 Sep; 140(9):4142–51

Effect of hexachlorobenzene on NADPH-generating lipogenic enzymes and L-glycerol-3-phosphate dehydrogenase in brown adipose tissue. Alvarez L, et al. **J Endocrinol Invest** 1999 Jun;22(6):436–45

POISONING

[Effect of thyroid hormones on the modulation of genetic expression of liver cytosolic malic enzyme, in rats poisoned with hexachlorobenzene] Loaiza Perez AI, et al. **Acta Physiol Pharmacol Ther Latinoam** 1998;48(3):125–36 (Eng. Abstr.) **(Spa)**

TOXICITY

Sediment toxicity evaluation for hexachlorobenzene: spiked sediment tests with Leptocheirus plumulosus, Hyalella azteca, and Chironomus tentans. Fuchsman PC, et al. **Arch Environ Contam Toxicol** 1998 Nov;35(4):573–9

The TEF approach for hexachlorobenzene [letter; comment] Schwab BW. **Environ Health Perspect** 1999 Apr; 107(4):A183–4. Comment on: Environ Health Perspect 1998 Nov;106(11):683–8.

Polymorphonuclear phagocytosis and killing in workers occupationally exposed to hexachlorobenzene. Queiroz ML, et al. **Immunopharmacol Immunotoxicol** 1998 Aug; 20(3):447–54

Chromosomal linkage analysis of porphyria in mice induced by hexachlorobenzene-iron synergism: a model of sporadic porphyria cutanea tarda. Akhtar RA, et al. **Pharmacogenetics** 1998 Dec;8(6):485–94

Effects of hexachlorobenzene on phospholipid and porphyrin metabolism in Harderian glands: a time-course study in two strains of rats. Cochón AC, et al. **Toxicol Lett** 1999 Jun 1;106(2–3):129–36

[Effect of the thioctamide in relation to the hexachlorobenzene action] Vilas GL, et al. **Acta Physiol Pharmacol Ther Latinoam** 1998;48(3):137–45 (Eng. Abstr.) **(Spa)**

HEXACHLOROCYCLOHEXANE see **LINDANE**

HEXACHLOROPHENE

TOXICITY

In vitro kinetics of the rat brain succinate dehydrogenase inhibition by hexachlorophene. Lokanatha V, et al. **J Biochem Mol Toxicol** 1999;13(6):303–6

HEXADECADROL see **DEXAMETHASONE**

HEXADECANOATES see **PALMITATES**

HEXADECANOIC ACID see **PALMITIC ACID**

HEXADIENOIC ACID see **SORBIC ACID**

HEXADIMETHRINE

Stable cationic capillary coating with successive multiple ionic polymer layers for capillary electrophoresis. Katayama H, et al. **Anal Chem** 1998 Dec 15;70(24):5272–7

ANALYSIS

Thromboplastins, heparin, and polybrene [letter; comment] Carroll WE. **Am J Clin Pathol** 1999 Apr;111(4):565. Comment on: Am J Clin Pathol 1996 Oct;106(4):556. Comment on: Am J Clin Pathol 1998 Jun;109(6):764–8.

PHARMACOLOGY

Polybrene increases the efficiency of gene transfer by lipofection. Abe A, et al. **Gene Ther** 1998 May;5(5):708–11

Retroviral vector-mediated gene transfer into keratocytes: in vitro effects of polybrene and protamine sulfate. Seitz B, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Aug; 236(8):602–12

THERAPEUTIC USE

Recent experiences with hexadimethrine for neutralizing heparin after cardiopulmonary bypass. Cooney A, et al. **Anaesth Intensive Care** 1999 Jun;27(3):298–300

HEXADIMETHRINE BROMIDE see **HEXADIMETHRINE**

HEXAMETHYLENEIMINES see **AZEPINES**

HEXAMETHYLENETETRAMINE see **METHENAMINE**

HEXAMINE see **METHENAMINE**

HEXANES

Focal conduction block in n-hexane polyneuropathy [letter; comment] Bogucki A, et al. **Muscle Nerve** 1999 Mar; 22(3):425–6. Comment on: Muscle Nerve 1998 Jul;21(7):964–9.

ADVERSE EFFECTS

Preliminary in vivo report on the osteocompatibility of poly(anhydride-co-imides) evaluated in a tibial model. Ibim SE, et al. **J Biomed Mater Res** 1998 Winter; 43(4):374–9

[Occupational N-hexane neuropathy: clinical and neurophysiological investigation] Głuszcz-Zielińska A. **Med Pr** 1999;50(1):31–6 (Eng. Abstr.) **(Pol)**

[An outbreak of n-hexane-induced polyneuritis in a footwear factory (letter)] Mateos Ramos A, et al. **Aten Primaria** 1999 Jan;23(1):47–9 **(Spa)**

[Neuropathy by n-hexanes: a generalized disorder of the intermediate filaments] Jaumà S, et al. **Neurologia** 1998 Nov;13(9):417–21 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Crosslinked polyanhydrides for use in orthopedic applications: degradation behavior and mechanics. Muggli DS, et al. **J Biomed Mater Res** 1999 Aug;46(2):271–8

Atomic contributions to the optical rotation angle as a quantitative probe of molecular chirality. Kondru RK, et al. **Science** 1998 Dec 18;282(5397):2247–50

METABOLISM

Determination of n-hexane metabolites by liquid chromatography/mass spectrometry. 1. 2,5-hexanedione and other phase I metabolites in untreated and hydrolyzed urine samples by atmospheric pressure chemical ionization. Andreoli R, et al. **Rapid Commun Mass Spectrom** 1998; 12(19):1410–6

Determination of free and glucuronated hexane metabolites without prior hydrolysis by liquid- and gas-chromatography coupled with mass spectrometry. Manini P, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):225–31

PHARMACOKINETICS

Chemical changes during in vivo degradation of poly(anhydride-imide) matrices. Uhrich KE, et al. **Biomaterials** 1998 Nov;19(22):2045–50

PHARMACOLOGY

Poly(anhydride-co-imides): in vivo biocompatibility in a rat model. Ibim SM, et al. **Biomaterials** 1998 May; 19(10):941–51

POISONING

n-Hexane neuropathy caused by addictive inhalation: clinical and electrophysiological features. Kuwabara S, et al. **Eur Neurol** 1999;41(3):163–7

TOXICITY

Chronic inhalation carcinogenicity study of commercial hexane solvent in F-344 rats and B6C3F1 mice. Daughtrey W, et al. **Toxicol Sci** 1999 Mar;48(1):21–9

URINE

Determination of n-hexane metabolites by liquid chromatography/mass spectrometry. 2. Glucuronide-conjugated metabolites in untreated urine samples by electrospray ionization. Manini P, et al. **Rapid Commun Mass Spectrom** 1998;12(21):1615–24

HEXANOATES see **CAPROATES**

HEXANOIC ACIDS

Lymph node extraction of radiopaque nanoparticulates in the rabbit as measured in vivo with CT. Wolf GL, et al. **Acad Radiol** 1999 Jan;6(1):55–60

Genetic analysis of Drosophila sechellia specialization: oviposition behavior toward the major aliphatic acids of its host plant. Amlou M, et al. **Behav Genet** 1998 Nov; 28(6):455–64

Ring-opening bulk polymerization of epsilon-caprolactone and trimethylene carbonate catalyzed by lipase Novozym 435. Deng F, et al. **Int J Biol Macromol** 1999 Jun–Jul; 25(1–3):153–9

ADMINISTRATION & DOSAGE

Enteral infusion of sodium 2-ketoisocaproate in endotoxic rats [see comments] Hirokawa M, et al. **Crit Care Med** 1999 Feb;27(2):373–9. Comment in: Crit Care Med 1999 Feb;27(2):251–2.

PHARMACOLOGY

Specific and non-specific binding of long-chain fatty acids to firefly luciferase: cutoff at octanoate. Matsuki H, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):143–50

Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Imig JD, et al. **Br J Pharmacol** 1999 Jul; 127(6):1399–405

Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):851–3

THERAPEUTIC USE

Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1184–8

Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4099–103

Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec;30(8):4137–9

Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec;30(8):4153–5

Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4170–3

TOXICITY

Larval tolerance in the Drosophila melanogaster species complex toward the two toxic acids of the D. sechellia host plant. Amlou M, et al. **Hereditas** 1998;129(1):7–14

HEXANONES

HEXANONES

METABOLISM

Two distinct signaling pathways mediate DIF induction of prestalk gene expression in Dictyostelium. Verkerke-van Wijk I, et al. **Exp Cell Res** 1998 Nov 25;245(1):179-85

PHARMACOKINETICS

2,5-Hexanedione concentrations and morphological changes within the eye of albino rat. Bäckström B, et al. **Arch Toxicol** 1998 Sep;72(9):597-600

PHARMACOLOGY

2,5-Hexanedione concentrations and morphological changes within the eye of albino rat. Bäckström B, et al. **Arch Toxicol** 1998 Sep;72(9):597-600

TOXICITY

Neurotoxic effects of 2,5-hexanedione on normal and neurofilament-deficient quail. Hirai T, et al. **Toxicol Pathol** 1999 May-Jun;27(3):348-53

URINE

Determination of n-hexane metabolites by liquid chromatography/mass spectrometry. 1. 2,5-hexanedione and other phase I metabolites in untreated and hydrolyzed urine samples by atmospheric pressure chemical ionization. Andreoli R, et al. **Rapid Commun Mass Spectrom** 1998; 12(19):1410-6

HEXOKINASE

ANALYSIS

An improved assay for hexokinase activity in human tissue homogenates. Scheer WD, et al. **Anal Biochem** 1978 Dec; 91(2):451-63

ANTAGONISTS & INHIBITORS

Hypoglycaemic activity of alpha, alpha trehalose-6-phosphate. Oke JM, et al. **Afr J Med Med Sci** 1998 Sep-Dec;27(3-4):219-23

Trehalose-6-phosphate-potent anti-onchocerciatic agent. Oke JM, et al. **Afr J Med Med Sci** 1998 Sep-Dec; 27(3-4):225-8

In vitro and in vivo effects of heavy metals on mussel digestive gland hexokinase activity: the role of glutathione. Canesi L, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):261-8

BIOSYNTHESIS

mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. Feldhaus LM, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2475-85

BLOOD

Hexokinase, glucose-6-phosphate dehydrogenase and antioxidant enzymes in diabetic reticulocytes: effects of insulin and vanadate. Gupta BL, et al. **Biochem Mol Biol Int** 1998 Dec;46(6):1145-52

CHEMISTRY

Nonaggregating mutant of recombinant human hexokinase I exhibits wild-type kinetics and rod-like conformations in solution. Aleshin AE, et al. **Biochemistry** 1999 Jun 29; 38(26):8359-66

Viscoelastic properties of f-actin, microtubules, f-actin/alpha-actinin, and f-actin/hexokinase determined in microliter volumes with a novel nondestructive method. Wagner O, et al. **Biophys J** 1999 May;76(5):2784-96

Functional consequences of naturally occurring variants of human hexokinase II. Malkki M, et al. **Diabetologia** 1998 Oct;41(10):1205-9

Effect of glucose on the conformation of ADPMg(II) bound at the active site of yeast hexokinase PI. Maity H, et al. **Physiol Chem Phys Med NMR** 1998;30(1):49-62

DEFICIENCY

Hexokinase II-deficient mice. Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes. Heikkinen S, et al. **J Biol Chem** 1999 Aug 6; 274(32):22517-23

Chinese hamster ovary cells with reduced hexokinase activity maintain normal GDP-mannose levels. O'Rear JL, et al. **J Cell Biochem** 1999 Jan 1;72(1):56-66

GENETICS

Functional organization and evolution of mammalian hexokinases: mutations that caused the loss of catalytic activity in N-terminal halves of type I and type III isozymes. Tsai HJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):149-56

Heterogeneous nuclear ribonucleoprotein I (hnRNP-I/PTB) selectively binds the conserved 3' terminus of hepatitis C viral RNA. Chung RT, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):351-62

Nonaggregating mutant of recombinant human hexokinase I exhibits wild-type kinetics and rod-like conformations in solution. Aleshin AE, et al. **Biochemistry** 1999 Jun 29; 38(26):8359-66

Characterization of a hexokinase encoding cDNA of the parasitic nematode Hhaemonchus contortus. Schmitt-Wrede HP, et al. **Biochim Biophys Acta** 1999 Mar 19;1444(3):439-44

Expression, purification, and characterization of a recombinant erythroid-specific hexokinase isozyme. Bianchi M, et al. **Blood Cells Mol Dis** 1998 Dec; 24(4):401-11

Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Aloj L, et al. **Cancer Res** 1999 Sep 15; 59(18):4709-14

Stimulation of brain hexokinase gene expression by recombinant brain insulin-like growth factor in C6 glial cells. Sebastian S, et al. **Exp Cell Res** 1999 Jan 10; 246(1):243-7

Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Katabi MM, et al. **Hum Gene Ther** 1999 Jan 20;10(2):155-64

Insulin regulates expression of metabolic genes through divergent signaling pathways. Hall RK, et al. **J Basic Clin Physiol Pharmacol** 1999;10(2):119-33 (47 ref.)

Novel alleles of yeast hexokinase PII with distinct effects on catalytic activity and catabolite repression of SUC2. Hohmann S, et al. **Microbiology** 1999 Mar;145 (Pt 3):703-14

Human HKR isozyme: organization of the hexokinase I gene, the erythroid-specific promoter, and transcription initiation site. Murakami K, et al. **Mol Genet Metab** 1999 Jun; 67(2):118-30

Overexpression of Arabidopsis hexokinase in tomato plants inhibits growth, reduces photosynthesis, and induces rapid senescence. Dai N, et al. **Plant Cell** 1999 Jul;11(7):1253-66

Glucose metabolism during the final stage of human oocyte maturation: genetic expression of hexokinase, glucose phosphate isomerase and phosphofructokinase. el Mouatassim S, et al. **Zygote** 1999 Feb;7(1):45-50

METABOLISM

Insulin does not change the intracellular distribution of hexokinase in rat heart. Doenst T, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E558-67

Overexpression of hexokinase II increases insulinand exercise-stimulated muscle glucose uptake in vivo. Halseth AE, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E70-7

Allosteric regulation of type I hexokinase: A site-directed mutational study indicating location of the functional glucose 6-phosphate binding site in the N-terminal half of the enzyme. Sebastian S, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):203-10

Functional organization and evolution of mammalian hexokinases: mutations that caused the loss of catalytic activity in N-terminal halves of type I and type III isozymes. Tsai HJ. **Arch Biochem Biophys** 1999 Sep 1; 369(1):149-56

Effects of acute or prolonged exposure to human leptin on isolated human islet function. Lupi R, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):637-41

A mutation Ser213/Asn in the hexokinase 1 from Schizosaccharomyces pombe increases its affinity for glucose. Petit T, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):714-9

A comparative study by a single chromatographic procedure of glycolytic regulatory kinase isozymes in rat erythroid cells as a function of differentiation-maturation process. Jimeno P, et al. **Biochem Mol Biol Int** 1998 Sep; 45(6):1211-25

Light-induced photoactivation of hypericin affects the energy metabolism of human glioma cells by inhibiting hexokinase bound to mitochondria. Miccoli L, et al. **Cancer Res** 1998 Dec 15;58(24):5777-86

Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism. Vestergaard H. **Dan Med Bull** 1999 Feb;46(1):13-34 (293 ref.)

Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Virkamäki A, et al. **Diabetes** 1999 May;48(5):1101-7

Functional consequences of naturally occurring variants of human hexokinase II. Malkki M, et al. **Diabetologia** 1998 Oct;41(10):1205-9

Reg1p targets protein phosphatase 1 to dephosphorylate hexokinase II in Saccharomyces cerevisiae: characterizing the effects of a phosphatase subunit on the yeast proteome. Alms GR, et al. **EMBO J** 1999 Aug 2;18(15):4157-68

Cloning and biochemical characterisation of Aspergillus niger hexokinase--the enzyme is strongly inhibited by physiological concentrations of trehalose 6-phosphate. Panneman H, et al. **Eur J Biochem** 1998 Nov 15; 258(1):223-32

Mutations that confer resistance to 2-deoxyglucose reduce the specific activity of hexokinase from Myxococcus xanthus. Youderian P, et al. **J Bacteriol** 1999 Apr; 181(7):2225-35

Binding of rat brain hexokinase to recombinant yeast mitochondria: effect of environmental factors and the source of porin. Aflalo C, et al. **J Bioenerg Biomembr** 1998 Jun;30(3):245-55

Functional interaction between the N- and C-terminal halves of human hexokinase II. Ardehali H, et al. **J Biol Chem** 1999 Jun 4;274(23):15986-9

An unusual high-Km hexokinase is expressed in the mhAT3F hepatoma cell line. Rencurel F, et al. **J Biol Chem** 1998 Oct 2;273(40):26187-93

Analytical methods and stability assessment of liquid yeast derived sucrase. McIntosh KA, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1037-45

Interaction of bis(1-anilino-8-naphthalenesulfonate) with yeast hexokinase: a steady-state fluorescence study. Maity H, et al. **J Photochem Photobiol B** 1998 Dec;47(2-3):190-6

Hexokinase in astrocytes: kinetic and regulatory properties. Lai JC, et al. **Metab Brain Dis** 1999 Jun;14(2):125-33

Enzymatic properties of overexpressed human hexokinase fragments. Bianchi M, et al. **Mol Cell Biochem** 1998 Dec; 189(1-2):185-93

Three different forms of hexokinase are identified during Tuber borchii mycelium growth. Ceccaroli P, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):71-7

Effect of primary congenital hypothyroidism upon expression of genes mediating murine brain glucose uptake. Khan JY, et al. **Pediatr Res** 1999 May;45(5 Pt 1):718-25

Effect of glucose on the conformation of ADPMg(II) bound at the active site of yeast hexokinase PI. Maity H, et al. **Physiol Chem Phys Med NMR** 1998;30(1):49-62

Mannose inhibits Arabidopsis germination via a hexokinase-mediated step. Pego JV, et al. **Plant Physiol** 1999 Mar;119(3):1017-23

[Cooperation of membrane proteins and cytosolic proteins in metabolic regulation--involvement of binding of hexokinase to mitochondria in regulation of glucose metabolism and association and complex formation between membrane proteins and cytosolic proteins in regulation of active oxygen production] Ishibashi S. **Yakugaku Zasshi** 1999 Jan;119(1):16-34 (49 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The involvement of hexokinases in trehalose synthesis. Peixoto DN, et al. **Biochem Mol Biol Int** 1999 May; 47(5):873-80

Sugar regulation of gene expression in plants. Smeekens S. **Curr Opin Plant Biol** 1998 Jun;1(3):230-4 (45 ref.)

HEXOPRENALINE

ADMINISTRATION & DOSAGE

[beta 2-Adrenomimetics before and after extracorporeal lithotripsy] Pytel' IuA, et al. **Urol Nefrol (Mosk)** 1998 Sep-Oct;(5):3-6 (Eng. Abstr.) **(Rus)**

HEXOSAMINES

ANALYSIS

Differentiation of diastereomeric N-acetylhexosamine monosaccharides using ion trap tandem mass spectrometry. Desaire H, et al. **Anal Chem** 1999 May 15;71(10):1997-2002

BIOSYNTHESIS

Decreased hexosamine biosynthesis in GH-deficient dwarf rat muscle. reversal with GH, but not IGF-I, therapy. Robinson KA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E435-42

Geranylgeranylacetone, an anti-ulcer drug, stimulates hexosamine production in a rat gastric mucosal cell line through binding to a specific cytosolic protein. Hassan S, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):809-15

CHEMISTRY

Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Ogawa S, et al. **Bioorg Med Chem** 1998 Oct;6(10):1955-62

Incorporation of ammonium into intracellular UDP-activated N-acetylhexosamines and into carbohydrate structures in glycoproteins. Valley U, et al. **Biotechnol Bioeng** 1999 Aug 20;64(4):401-17

Conversion of N-sulfated glucosamine to N-sulfated mannosamine in an unsaturated heparin disaccharide by non-enzymatic, base-catalyzed C-2 epimerization during enzymatic oligosaccharide preparation. Yamada S, et al. **Carbohydr Res** 1998 Jul;309(3):261-8

METABOLISM

Improvement of interferon-gamma sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine. Gu X, et al. **Biotechnol Bioeng** 1998 Jun 20;58(6):642-8

Use of mannosamine for inducing the addition of outer arm N-acetylglucosamine onto N-linked oligosaccharides of recombinant proteins in insect cells. Donaldson M, et al. **Biotechnol Prog** 1999 Mar-Apr;15(2):168-73

Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Patti ME, et al.

Diabetes 1999 Aug;48(8):1562-71
Uptake of N-acetyl-D-mannosamine: an essential intermediate in polysialic acid biosynthesis by Escherichia coli K92 [published erratum appears in FEBS Lett 1999 Aug 13;456(3):417] Revilla-Nuin B, et al. **FEBS Lett** 1999 Apr 23;449(2-3):183-6
Convergent pathways for utilization of the amino sugars N-acetylglucosamine, N-acetylmannosamine, and N-acetylneuraminic acid by Escherichia coli. Plumbridge J, et al. **J Bacteriol** 1999 Jan;181(1):47-54

PHARMACOKINETICS

Engineering novel cell surface receptors for virus-mediated gene transfer. Lee JH, et al. **J Biol Chem** 1999 Jul 30; 274(31):21878-84

PHARMACOLOGY

In vivo modulation of the acidic N-glycans from rat liver dipeptidyl peptidase IV by N-propanoyl-D-mannosamine. Stehling P, et al. **Biochem Biophys Res Commun** 1999 Sep 16;263(1):76-80
Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Ogawa S, et al. **Bioorg Med Chem** 1998 Oct;6(10):1955-62

PHYSIOLOGY

Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Cooksey RC, et al. **Endocrinology** 1999 Mar;140(3):1151-7

HEXOSAMINIDASE see
BETA-N-ACETYLHEXOSAMINIDASE

HEXOSAMINIDASE A see
BETA-N-ACETYLHEXOSAMINIDASE

HEXOSAMINIDASE B see
BETA-N-ACETYLHEXOSAMINIDASE

HEXOSAMINIDASE ISOENZYMES see
BETA-N-ACETYLHEXOSAMINIDASE

HEXOSAMINIDASE ISOZYMES see
BETA-N-ACETYLHEXOSAMINIDASE

HEXOSAMINIDASES

see related
GANGLIOSIDOSES

BLOOD

Plasma chitotriosidase activity in patients with beta-thalassemia. Barone R, et al. **Blood Cells Mol Dis** 1999 Feb;25(1):1-8
Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). Czartoryska B, et al. **Clin Biochem** 1998 Jul;31(5):417-20

GENETICS

The human chitotriosidase gene. Nature of inherited enzyme deficiency. Boot RG, et al. **J Biol Chem** 1998 Oct 2; 273(40):25680-5

METABOLISM

Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Boot RG, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):687-94

HEXOSE MONOPHOSPHATE SHUNT see
PENTOSEPHOSPHATE PATHWAY

HEXOSE TRANSPORT PROTEINS see
MONOSACCHARIDE TRANSPORT PROTEINS

HEXOSEDIPHOSPHATASE see
FRUCTOSE-BISPHOSPHATASE

HEXOSEPHOSPHATE AMINOTRANSFERASE see
GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE (ISOMERIZING)

HEXOSEPHOSPHATE URIDYLYLTRANSFERASE see
UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE

HEXOSEPHOSPHATES

BIOSYNTHESIS

Activity of enzymes catalyzing formation of beta-L-fucosyl phosphate and GDP-beta-L-fucose in amphibian tissues and their application in chemo-enzymic synthesis of GDP-beta-L-fucose. Druzhinina TN, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):783-7

HEXOSES

Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? Murdan S, et al. **Eur J Pharm Sci** 1999 Jul;8(3):177-86

ADMINISTRATION & DOSAGE

Inverse toroidal vesicles: precursors of tubules in sorbitan monostearate organogels. Murdan S, et al. **Int J Pharm** 1999 Jun 10;183(1):47-9

ADVERSE EFFECTS

Human gastrointestinal tolerance to D-tagatose. Buemann B, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S71-7
Human tolerance to a single, high dose of D-tagatose. Buemann B, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S66-70
Comparative gastrointestinal tolerance of sucrose, lactitol, or D-tagatose in chocolate. Lee A, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S78-82
Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans. Saunders JP, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S57-65

ANALYSIS

The composition of NF-defined emulsifiers: sorbitan monolaurate, monopalmitate, monostearate, monooleate, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80. Brandner JD. **Drug Dev Ind Pharm** 1998 Nov;24(11):1049-54

BIOSYNTHESIS

Mechanisms and pathways from recent deoxysugar biosynthesis research. Johnson DA, et al. **Curr Opin Chem Biol** 1998 Oct;2(5):642-9 (42 ref.)

CHEMICAL SYNTHESIS

A convenient enzymatic procedure for the production of aldose-free D-tagatose. Haltrich D, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:295-9

CHEMISTRY

Interaction of a nonionic surfactant-based organogel with aqueous media. Murdan S, et al. **Int J Pharm** 1999 Apr 15;180(2):211-4
The effect of core-to-wall ratio and Span 80 concentration on the properties of ascorbic acid microcapsules. Vanichtanunkul D, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):753-9
Novel sorbitan monostearate organogels. Murdan S, et al. **J Pharm Sci** 1999 Jun;88(6):608-14
Water-in-sorbitan monostearate organogels (water-in-oil gels). Murdan S, et al. **J Pharm Sci** 1999 Jun;88(6):615-9

METABOLISM

Transport and utilization of hexoses and pentoses in the halotolerant yeast Debaryomyces hansenii. Nobre A, et al. **Appl Environ Microbiol** 1999 Aug;65(8):3594-8
Multiple effects of mercuric chloride on hexose transport in Xenopus oocytes. Barnes DM, et al. **Biochim Biophys Acta** 1999 Jul 15;1419(2):289-98
Hydrolysis of hexose pentaacetate esters in rat pancreatic islets. Vanhoutte C, et al. **Biochim Biophys Acta** 1998 Oct 21;1405(1-3):78-84
Hexose transporter expression and function in mammalian spermatozoa: cellular localization and transport of hexoses and vitamin C. Angulo C, et al. **J Cell Biochem** 1998 Nov 1;71(2):189-203
The detoxification of cumene hydroperoxide by the glutathione system of cultured astroglial cells hinges on hexose availability for the regeneration of NADPH. Kussmaul L, et al. **J Neurochem** 1999 Sep;73(3):1246-53
D-tagatose has low small intestinal digestibility but high large intestinal fermentability in pigs. Laerke HN, et al. **J Nutr** 1999 May;129(5):1002-9
Hexose metabolism in pancreatic islets: effect of D-glucose upon D-fructose metabolism. Scruel O, et al. **Mol Cell Biochem** 1999 Jul;197(1-2):209-16
Ectopic expression of a tobacco invertase inhibitor homolog prevents cold-induced sweetening of potato tubers. Greiner S, et al. **Nat Biotechnol** 1999 Jul;17(7):708-11
A male gametophyte-specific monosaccharide transporter in Arabidopsis. Truernit E, et al. **Plant J** 1999 Jan; 17(2):191-201
Transgenic tomato plants with decreased sucrose synthase are unaltered in starch and sugar accumulation in the fruit. Chengappa S, et al. **Plant Mol Biol** 1999 May;40(2):213-21
Hexose transport in growing petunia pollen tubes and characterization of a pollen-specific, putative monosaccharide transporter. Ylstra B, et al. **Plant Physiol** 1998 Sep;118(1):297-304
Effects of gliquidone on D-glucose metabolism in rat pancreatic islets depend on hexose concentration. Picton S, et al. **Res Commun Mol Pathol Pharmacol** 1998 Nov; 102(2):99-112

PHARMACOKINETICS

Disposition of D-[U-14C]tagatose in the rat. Saunders JP, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S46-56

PHARMACOLOGY

Impairment by hexoses of the utilization of maltose by Saccharomyces cerevisiae. Heredia CF. **Biochim Biophys Acta** 1998 Sep 16;1425(1):151-8
Effects of hexose sugars: glucose, fructose, galactose and mannose on wound healing in the rat. Kössi J, et al. **Eur Surg Res** 1999;31(1):74-82
Cladinose analogues of sixteen-membered macrolide antibiotics. VI. Synthesis of metabolically programmed, highly potent analogues of sixteen-membered macrolide antibiotics. Kurihara KI, et al. **J Antibiot (Tokyo)** 1998 Aug; 51(8):771-85
Stimulation by hexose esters of lactate production by rat erythrocytes: insensitivity to 3-O-methyl-D-glucose and inhibition by 2-deoxy-D-glucose and its tetraacetic ester. Ladrière L, et al. **Mol Cell Biochem** 1998 Jun; 183(1-2):175-82
Inhibitory effects of tetragalloylglucose and digalloylhamamelose on adhesion and in vitro invasion of mouse lung carcinoma cells. Saeki K, et al. **Planta Med** 1999 Apr;65(3):227-9
Soluble saccharides block the inhibition of agonist-induced human platelet aggregation observed after in vitro incubation of human platelet-rich plasma with porcine aortic endothelial cells. Magnusson S, et al. **Transpl Int** 1998;11(5):345-52

TOXICITY

L-Sorbose but not D-tagatose induces hemolysis of dog erythrocytes in vitro. Bär A, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S43-5
Effect of D-tagatose on liver weight and glycogen content of rats. Bär A, et al. **Regul Toxicol Pharmacol** 1999 Apr; 29(2 Pt 2):S11-28
90-Day oral toxicity study of D-tagatose in rats. Kruger CL, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S1-10
Developmental toxicity study of D-tagatose in rats. Kruger CL, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S29-35
Genotoxicity tests on D-tagatose. Kruger CL, et al. **Regul Toxicol Pharmacol** 1999 Apr;29(2 Pt 2):S36-42

HEXOSYLTRANSFERASES

Purification and enzymic properties of the fructosyltransferase of Streptococcus salivarius ATCC 25975. Song DD, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):285-91

ANALYSIS

Septal localization of penicillin-binding protein 1 in Bacillus subtilis. Pedersen LB, et al. **J Bacteriol** 1999 May; 181(10):3201-11

CHEMISTRY

Conserved sequence motifs in levansucrases and bifunctional beta-xylosidases and alpha-L-arabinases. Naumoff DG. **FEBS Lett** 1999 Apr 1;448(1):177-9
Disulfide bridges are not involved in penicillin-binding protein 1b dimerization in Escherichia coli. Chalut C, et al. **J Bacteriol** 1999 May;181(9):2970-2
Identification, purification, and characterization of transpeptidase and glycosyltransferase domains of Streptococcus pneumoniae penicillin-binding protein 1a. Di Guilmi AM, et al. **J Bacteriol** 1998 Nov;180(21):5652-9
Role of C-terminal domains in surface attachment of the fructosyltransferase of Streptococcus salivarius ATCC 25975. Rathsam C, et al. **J Bacteriol** 1998 Dec; 180(23):6400-3
Structural characterization of Acetobacter diazotropicus levansucrase by matrix-assisted laser desorption/ionization mass spectrometry: identification of an N-terminal blocking group and a free-thiol cysteine residue. Betancourt L, et al. **J Mass Spectrom** 1999 Mar;34(3):169-74
A conserved motif in the hexosyltransferases [letter] Henderson IR, et al. **Mol Microbiol** 1999 Jul;33(1):222
Structural model for family 32 of glycosyl-hydrolase enzymes. Pons T, et al. **Proteins** 1998 Nov 15;33(3):383-95

GENETICS

Levansucrase of Rahnella aquatilis ATCC33071. Gene cloning, expression, and levan formation. Song KB, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:506-11
Cloning, nucleotide sequence, and expression in Escherichia coli of levansucrase genes from the plant pathogens Pseudomonas syringae pv. glycinea and P. syringae pv. phaseolicola. Hettwer U, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3180-7
Expression of the extracellular levansucrase and invertase genes from Zymomonas mobilis in Escherichia coli cells. Yanase H, et al. **Biosci Biotechnol Biochem** 1998 Sep; 62(9):1802-5
Expression of a functional barley sucrose-fructan 6-fructosyltransferase in the methylotrophic yeast Pichia pastoris. Hochstrasser U, et al. **FEBS Lett** 1998 Dec 4; 440(3):356-60
Analysis of the length distribution of murein glycan strands

in ftsZ and ftsI mutants of E. coli. Ishidate K, et al. **FEMS Microbiol Lett** 1998 Nov 1;168(1):71–5

Transcriptional analysis of levU operon encoding saccharolytic enzymes and two apparent genes involved in amino acid biosynthesis in Zymomonas mobilis. Song KB, et al. **Gene** 1999 May 17;232(1):107–14

Identification and recombinant expression of a Mycobacterium avium rhamnosyltransferase gene (rtfA) involved in glycopeptidolipid biosynthesis. Eckstein TM, et al. **J Bacteriol** 1998 Nov;180(21):5567–73

Transcriptional analysis of the Staphylococcus aureus penicillin binding protein 2 gene. Pinho MG, et al. **J Bacteriol** 1998 Dec;180(23):6077–81

Application of pbp1A PCR in identification of penicillin-resistant Streptococcus pneumoniae. du Plessis M, et al. **J Clin Microbiol** 1999 Mar;37(3):628–32

An aureobasidin A resistance gene isolated from Aspergillus is a homolog of yeast AUR1, a gene responsible for inositol phosphorylceramide (IPC) synthase activity. Kuroda M, et al. **Mol Gen Genet** 1999 Mar;261(2):290–6

Production and cell surface anchoring of functional fusions between the SLH motifs of the Bacillus anthracis S-layer proteins and the Bacillus subtilis levansucrase. Mesnage S, et al. **Mol Microbiol** 1999 Feb;31(3):927–36

Cloning of the fructan biosynthesis pathway of Jerusalem artichoke. van der Meer IM, et al. **Plant J** 1998 Aug; 15(4):489–500

Three proteins involved in Caenorhabditis elegans vulval invagination are similar to components of a glycosylation pathway. Herman T, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):974–9

[Homologous locus of genomes of Bacillus subtilis and Bacillus stearothermophilus, containing levansucrase and levanase genes] Naumov DG. **Mol Biol (Mosk)** 1999 Mar–Apr;33(2):207–10 **(Rus)**

METABOLISM

Substitution of Asp-309 by Asn in the Arg-Asp-Pro (RDP) motif of Acetobacter diazotrophicus levansucrase affects sucrose hydrolysis, but not enzyme specificity. Batista FR, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):503–6

Synthesis of fructans by fructosyltransferase from the tuberous roots of Viguiera discolor (Asteraceae). Itaya NM, et al. **Braz J Med Biol Res** 1999 Apr;32(4):435–42

Structure of the enzymatically synthesized fructan inulin. Heyer AG, et al. **Carbohydr Res** 1998 Dec 15; 313(3–4):165–74

Disulfide bridges are not involved in penicillin-binding protein 1b dimerization in Escherichia coli. Chalut C, et al. **J Bacteriol** 1999 May;181(9):2970–2

Differential dependence of levansucrase and alpha-amylase secretion on SecA (Div) during the exponential phase of growth of Bacillus subtilis. Leloup L, et al. **J Bacteriol** 1999 Mar;181(6):1820–6

Mutational analysis of the Streptococcus pneumoniae bimodular class A penicillin-binding proteins. Paik J, et al. **J Bacteriol** 1999 Jun;181(12):3852–6

Role of C-terminal domains in surface attachment of the fructosyltransferase of Streptococcus salivarius ATCC 25975. Rathsam C, et al. **J Bacteriol** 1998 Dec; 180(23):6400–3

Localization of FtsI (PBP3) to the septal ring requires its membrane anchor, the Z ring, FtsA, FtsQ, and FtsL. Weiss DS, et al. **J Bacteriol** 1999 Jan;181(2):508–20

Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli. Vollmer W, et al. **J Biol Chem** 1999 Mar 5;274(10):6726–34

[Synthesis of novel fructo-oligosaccharides (FOS) by enzymatic reaction] Grizard D, et al. **C R Seances Soc Biol Fil** 1998;192(4):711–7 **(Fre)**

PHYSIOLOGY

Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. Denome SA, et al. **J Bacteriol** 1999 Jul; 181(13):3981–93

SECRETION

Levansucrase from Acetobacter diazotrophicus SRT4 is secreted via periplasm by a signal-peptide-dependent pathway. Hernández L, et al. **Curr Microbiol** 1999 Sep; 39(3):146–52

HEXOURONIC ACIDS see **HEXURONIC ACIDS**

HEXURONIC ACIDS

ANALYSIS

Sequencing of partially methyl-esterified oligogalacturonates by tandem mass spectrometry and its use to determine pectinase specificities. Körner R, et al. **Anal Chem** 1999 Apr 1;71(7):1421–7

Scarcity or complete lack of single rhamnose residues interspersed within the homogalacturonan regions of citrus pectin. Zhan D, et al. **Carbohydr Res** 1998 Jun; 308(3–4):373–80

CHEMICAL SYNTHESIS

Synthesis of the two monomethyl esters of the disaccharide 4-O-alpha-D-galacturonosyl-D-galacturonic acid and of precursors for the preparation of higher oligomers methyl uronated in definite sequences. Magaud D, et al. **Carbohydr Res** 1998 Dec 31;314(3–4):189–99

N alpha- and N epsilon-D-galacturonoyl-L-lysine amides: properties and possible occurrence in plant cell walls. Perrone P, et al. **Phytochemistry** 1998 Dec;49(7):1879–90

CHEMISTRY

Molecular motions of D-alpha-galacturonic acid (GA) and methyl-D-alpha-galacturonic acid methyl ester (MGAM) in the solid state-A proton NMR study. Tang HR, et al. **Solid State Nucl Magn Reson** 1998 Aug;12(1):21–30

METABOLISM

Unsaturated oligogalacturonic acids are generated by in vitro treatment of pectin with human faecal flora. Dongowski G, et al. **Carbohydr Res** 1998 Dec 31;314(3–4):237–44

Regulation of hexuronate utilization in Bacillus subtilis. Mekjian KR, et al. **J Bacteriol** 1999 Jan;181(2):426–33

The kdgRKAT operon of Bacillus subtilis: detection of the transcript and regulation by the kdgR and ccpA genes. Pujic P, et al. **Microbiology** 1998 Nov;144 (Pt 11):3111–8

HEYMANN NEPHRITIS see **GLOMERULONEPHRITIS**

HFRS see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HFRS VIRUS see **HANTAAN VIRUS**

HGF RECEPTOR see **PROTO-ONCOGENE PROTEINS C-MET**

HIATAL HERNIA see **HERNIA, HIATAL**

HIB see **HAEMOPHILUS INFLUENZAE TYPE B**

HIBERNATING GLAND see **BROWN FAT**

HIBERNATION

Nuclear bodies are usual constituents in tissues of hibernating dormice. Malatesta M, et al. **Anat Rec** 1999 Mar; 254(3):389–95

Protein kinase A from bat skeletal muscle: a kinetic study of the enzyme from a hibernating mammal. Holden CP, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):243–50

Secondary structure of antifreeze proteins from overwintering larvae of the beetle Dendroides canadensis. Li N, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):25–32

Gallopamil activity on asynergic viable myocardium in acute myocardial infarction: insights on stunned and hibernating myocardium. Natale E, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):431–7

Ultrastructural localization of nitric oxide synthase and endothelin in the renal and mesenteric arteries of the golden hamster: differences during and after arousal from hibernation. Saitongdee P, et al. **Endothelium** 1999; 6(3):197–207

Effects of hibernation and arousal from hibernation on mesenteric arterial responses of the golden hamster. Ralevic V, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):521–6

Sex steroid and prolactin profiles in male American black bears (Ursus americanus) during denning. Tsubota T, et al. **J Vet Med Sci** 1999 Jan;61(1):81–3

[The fine structure of the gustatory cells of the circumvallate, foliate and fungiform papillae in hibernating bats] Arcari ML, et al. **Acta Biomed Ateneo Parmense** 1996;67(1–2):5–31 (Eng. Abstr.) **(Ita)**

[Seasonal changes in the brain integrative activity in hibernating animals] Semenova TP, et al. **Dokl Akad Nauk** 1998 Dec;363(4):567–9 **(Rus)**

DRUG EFFECTS

Reduced epinephrine-stimulated lipolytic activity in male golden-mantled ground squirrel during hibernation: an in situ microdialysis study. Flechtner-Mors M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jul; 123(3):281–4

PHYSIOLOGY

Neuroprotective strategies in nature--novel clues for the treatment of stroke and trauma. Frerichs KU. **Acta Neurochir Suppl (Wien)** 1999;73:57–61

Differential regulation of uncoupling protein gene homologues in multiple tissues of hibernating ground squirrels. Boyer BB, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1232–8

Sleep after arousal from hibernation is not homeostatically regulated. Larkin JE, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R522–9

Dissimilarity of slow-wave activity enhancement by torpor and sleep deprivation in a hibernator. Strijkstra AM, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1110–7

Relativistic velocities and biological processes [letter; comment] Warmflash D. **Aviat Space Environ Med** 1998 Sep;69(9):918–9. Comment on: Aviat Space Environ Med 1997 Jun;68(6):538–41.

Regulation of ground squirrel Na+K+-ATPase activity by reversible phosphorylation during hibernation. MacDonald JA, et al. **Biochem Biophys Res Commun** 1999 Jan 19; 254(2):424–9

Comparisons of the effects of temperature on the liver fatty acid binding proteins from hibernator and nonhibernator mammals. Stewart JM, et al. **Biochem Cell Biol** 1998; 76(4):593–9

Effect of isoproterenol on the L-type Ca2+ current in cardiac cells from rats and hybernating ground squirrels. Kokoz YuM, et al. **Biosci Rep** 1999 Feb;19(1):17–25

Determination of striatal extracellular gamma-aminobutyric acid in non-hibernating and hibernating arctic ground squirrels using quantitative microdialysis. Osborne PG, et al. **Brain Res** 1999 Aug 21;839(1):1–6

The search for the hibernating myocardium--have we reached the limit? Ferrari R. **Cardiovasc Drugs Ther** 1999 Apr;13(2):137–43 (50 ref.)

The effects of hibernation on the myenteric plexus of the golden hamster small and large intestine. Toole L, et al. **Cell Tissue Res** 1999 Jun;296(3):479–87

Hibernation triggers and myocardial protection. Bolling SF, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II220–3; discussion II223–4

Opening of potassium channels: the common cardioprotective link between preconditioning and natural hibernation? Kevelaitis E, et al. **Circulation** 1999 Jun 15; 99(23):3079–85

Evolution of daily torpor and hibernation in birds and mammals: importance of body size. Geiser F. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):736–9 (37 ref.)

Uncoupling protein mRNA, mitochondrial GTP-binding, and T4 5'-deiodinase activity of brown adipose tissue in Daurian ground squirrel during hibernation and arousal. Liu XT, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):745–52

Isolation and partial characterization of an opioid-like 88 kDa hibernation-related protein. Horton ND, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):787–805

Hibernation induces expression of moesin in intestinal epithelial cells. Gorham DA, et al. **Cryobiology** 1998 Sep; 37(2):146–54

Spontaneous activity of preoptic neurons in slice preparations of the hypothalamus of European hamsters (Cricetus cricetus) and Wistar rats under different states of hypothermia. Hashimoto M, et al. **Cryobiology** 1998 Nov; 37(3):254–62

Comparison of K(+)-p-nitrophenyl phosphatase activity in the urinary bladder of the frog Rana esculenta during hibernation and active life. De Piceis Polver P, et al. **Eur J Histochem** 1999;43(1):55–62

Increase in liver pigmentation during natural hibernation in some amphibians. Barni S, et al. **J Anat** 1999 Jul;195 (Pt 1):19–25

Electron-immunocytochemical studies of perivascular nerves of mesenteric and renal arteries of golden hamsters during and after arousal from hibernation. Saitongdee P, et al. **J Anat** 1999 Jul;195 (Pt 1):121–30

Alterations in pulmonary surfactant after rapid arousal from torpor in the marsupial Sminthopsis crassicaudata. Lopatko OV, et al. **J Appl Physiol** 1999 Jun;86(6):1959–70

Effect of hibernation on responses of hamster vas deferens to sympathetic nerve stimulation and exogenous neurotransmitters. Knight GE, et al. **J Auton Nerv Syst** 1998 Nov 25;74(1):62–9

Immunocytochemical changes of cytoskeleton components and calmodulin in the frog cerebellum and optic tectum during hibernation. Pisu MB, et al. **J Chem Neuroanat** 1998 Aug;15(2):63–73

Rhythmicity of torpor in a marsupial hibernator, the mountain pygmy-possum (Burramys parvus), under natural and laboratory conditions. Körtner G, et al. **J Comp Physiol [B]** 1998 Dec;168(8):631–8

cAMP-dependent protein kinase from brown adipose tissue: temperature effects on kinetic properties and enzyme role in hibernating ground squirrels. MacDonald JA, et al. **J Comp Physiol [B]** 1998 Oct;168(7):513–25

Gene expression in the brain across the hibernation cycle. O'Hara BF, et al. **J Neurosci** 1999 May 15;19(10):3781–90

Major changes in the brain histamine system of the ground squirrel Citellus lateralis during hibernation. Sallmen T, et al. **J Neurosci** 1999 Mar 1;19(5):1824–35

Enhanced vasoconstrictor responses in renal and femoral arteries of the golden hamster during hibernation. Karoon P, et al. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):927–38

The kidney during hibernation and arousal from hibernation. A natural model of organ preservation during cold ischaemia and reperfusion. Zancanaro C, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1982–90

Neuronal activity in the mediobasal hypothalamus of hibernating jerboas (Jaculus orientalis). El Quezzani S, et al. **Neurosci Lett** 1999 Jan 22;260(1):13–6

Photoperiod modulates torpor and food intake in Siberian hamsters challenged with metabolic inhibitors. Stamper JL, et al. **Physiol Behav** 1999 Mar;66(1):113–8

Reversible depression of oxygen consumption in isolated liver mitochondria during hibernation. Martin SL, et al. **Physiol Biochem Zool** 1999 May-Jun;72(3):255–64

The physiology of hibernation among painted turtles: the

Eastern painted turtle Chrysemys picta picta. Ultsch GR, et al. **Physiol Biochem Zool** 1999 Jul–Aug;72(4):493–501

Suppression of protein synthesis in brain during hibernation involves inhibition of protein initiation and elongation. Frerichs KU, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14511–6

Preparing for inactivity: how insectivorous bats deposit a fat store for hibernation. Speakman JR, et al. **Proc Nutr Soc** 1999 Feb;58(1):123–31 (53 ref.)

[Opportunities and struggle in my study] Cai YP. **Sheng Li Ke Hsueh Chin Chan** 1996 Oct;27(4):289–93 **(Chi)**

[The Van't Hoff rule in studying various phases of hibernation of the squirrel Citellus undulatus Pallas. Physico-chemical route to cold adaptation] Kalabukhova TN. **Biofizika** 1998 Nov–Dec;43(6):1076–80 (Eng. Abstr.) **(Rus)**

[Absence of seasonal adaptive changes in the isoformic state and functional properties of actin-containing and thin filament proteins in skeletal muscles of hibernating squirrels] [letter] Lukoianova NA, et al. **Biofizika** 1998 Nov–Dec;43(6):1134–6 (Eng. Abstr.) **(Rus)**

[The myoglobin level in skeletal muscles of the hibernating Iakutiia ground squirrel Citellus undulatus] Postnikova GB, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May–Jun; 84(5–6):541–6 (Eng. Abstr.) **(Rus)**

HIBERNATION, ARTIFICIAL see **HYPOTHERMIA, INDUCED**

HIBERNATION, MYOCARDIAL see **MYOCARDIAL STUNNING**

HIBERNOMA see **LIPOMA**

HICCUP

CHEMICALLY INDUCED

Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Lauterbach EC. **Clin Neuropharmacol** 1999 Mar–Apr; 22(2):87–92 (61 ref.)

Persistent hiccups associated with intraarticular corticosteroid injection [letter] Gutierrez-Ureña S, et al. **J Rheumatol** 1999 Mar;26(3):760

Incidence and therapy of midazolam induced hiccups in paediatric anaesthesia. Marhofer P, et al. **Paediatr Anaesth** 1999;9(4):295–8

Perphenazine-induced hiccups [letter] Miyaoka H, et al. **Pharmacopsychiatry** 1999 Mar;32(2):81

Persistent hiccups induced by dexamethasone. Ross J, et al. **West J Med** 1999 Jan;170(1):51–2

[Drug-induced hiccup: a review of the France pharmacologic vigilance database] Bagheri H, et al. **Therapie** 1999 Jan–Feb;54(1):35–9 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Primary medullary haemorrhage with intractable hiccup [letter] Kumral E, et al. **J Neurol** 1998 Sep;245(9):620–2

DRUG THERAPY

Baclofen therapy for intractable hiccups in pancreatic carcinoma [letter] Marino RA. **Am J Gastroenterol** 1998 Oct;93(10):2000

Nimodipine treatment for intractable hiccups [letter] Hernández JL, et al. **Am J Med** 1999 May;106(5):600

The use of baclofen for treatment of chronic hiccups [letter] Oneschuk D. **J Pain Symptom Manage** 1999 Jul;18(1):4–5

Baclofen neurotoxicity in chronic haemodialysis patients with hiccups [letter] Peces R, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1896–7

[ETICS Study: Empirical therapy of idiopathic chronic singultus] Petroianu G, et al. **Z Gastroenterol** 1998 Jul; 36(7):559–66 (Eng. Abstr.) **(Ger)**

[Chronic hiccups in childhood: usefulness of baclofen] Ansó Olivan S, et al. **An Esp Pediatr** 1998 Oct;49(4):399–400 **(Spa)**

EPIDEMIOLOGY

[Drug-induced hiccup: a review of the France pharmacologic vigilance database] Bagheri H, et al. **Therapie** 1999 Jan–Feb;54(1):35–9 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Intractable hiccups and syncope in multiple sclerosis. Funakawa I, et al. **Acta Neurol Scand** 1998 Aug;98(2):136–9

Transient hiccups after posteroventral pallidotomy for Parkinson's disease [letter] de Bie RM, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):124–5

PHYSIOPATHOLOGY

[Persistent hiccup? Dysfunction of the inferior olivary complex (letter; comment)] Pérez del Molino A, et al. **Med Clin (Barc)** 1998 Oct 24;111(13):519. Comment on: Med Clin (Barc) 1998 Jan 17;110(1):22–4. **(Spa)**

THERAPY

Japanese electro-acustim in the treatment of chronic hiccups [letter; comment] Nichols TW Jr. **Am J Gastroenterol** 1999 Apr;94(4):1114–5. Comment on: Am J Gastroenterol 1998 Nov;93(11):2312–3.

Korean hand acupuncture in the treatment of chronic hiccups [letter] [see comments] Schlager A. **Am J Gastroenterol** 1998 Nov;93(11):2312–3. Comment in: Am J Gastroenterol 1999 Apr;94(4):1114–5.

Relief of chronic refractory hiccups with glossopharyngeal nerve block [letter; comment] Babacan A, et al. **Anesth Analg** 1998 Oct;87(4):980. Comment on: Anesth Analg 1997 Jan;84(1):229.

Idiopathic chronic hiccup (ICH): phrenic nerve block is not the way to go [letter; comment] Petroianu G. **Anesthesiology** 1998 Nov;89(5):1284–5. Comment on: Anesthesiology 1998 Feb;88(2):525–7.

Practice tips. Simple method for curing hiccups. Goldstein R. **Can Fam Physician** 1999 Jun;45:1459

[Stimulation of the root of the tongue can cure hiccup. 20 years of "unscientific" experience supports the thesis] Dernevik L. **Lakartidningen** 1998 Oct 7;95(41):4477–9 **(Swe)**

[Epilogue to the simple and effective, but unusual method to cure hiccup] Dernevik L. **Lakartidningen** 1999 Aug 25; 96(34):3542 **(Swe)**

HIDRADENITIS

CHEMICALLY INDUCED

A case report of neutrophilic eccrine hidradenitis in a patient receiving chemotherapy for acute myeloid leukaemia. Wong GC, et al. **Ann Acad Med Singapore** 1998 Nov; 27(6):860–3

DIAGNOSIS

[Neutrophilic disease] Wallach D. **Rev Prat** 1999 Feb 15; 49(4):356–8 **(Fre)**

ETIOLOGY

Neutrophilic eccrine hidradenitis induced by granulocyte colony-stimulating factor [letter] Bachmeyer C, et al. **Br J Dermatol** 1998 Aug;139(2):354–5

Lymphocytic autoimmune hidradenitis, cutaneous leucocytoclastic vasculitis and primary Sjögren's syndrome. Sais G, et al. **Br J Dermatol** 1998 Dec; 139(6):1073–6

PATHOLOGY

Neutrophilic dermatosis versus neutrophilic eccrine hidradenitis [letter; comment] Gross PR, et al. **N Engl J Med** 1999 Apr 29;340(17):1371. Comment on: N Engl J Med 1998 Dec 3;339(23):1687.

[Idiopathic plantar eccrinitis (letter)] Nagore Enguidanos E, et al. **An Esp Pediatr** 1998 Dec;49(6):648–9 (4 ref.) **(Spa)**

HIDRADENITIS SUPPURATIVA

A non responsive skin infection. Or is it? Golledge C. **Aust Fam Physician** 1999 Jul;28(7):727

COMPLICATIONS

Marjolin's ulcer occurring in hidradenitis suppurativa [letter] Lin MT, et al. **Plast Reconstr Surg** 1999 Apr;103(5):1541–3

[Widely disseminated ectopic acne] De Bruin-Weller MS, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1340–1 **(Dut)**

DIAGNOSIS

[Widely disseminated ectopic acne] De Bruin-Weller MS, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1340–1 **(Dut)**

[Comment on the contribution by D. Abeck, H.C. Korting, M. Mempel: "Pyoderma." (letter; comment)] Jemec GB. **Hautarzt** 1998 Nov;49(11):863–4. Comment on: Hautarzt 1998 Mar;49(3):243–52. **(Ger)**

DRUG THERAPY

Arthropathy associated with cystic acne, hidradenitis suppurativa, and perifollicultis capitis abscedens et suffodiens: treatment with isotretinoin. Libow LF, et al. **Cutis** 1999 Aug;64(2):87–90

Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. Boer J, et al. **J Am Acad Dermatol** 1999 Jan;40(1):73–6

Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. Jemec GB, et al. **J Am Acad Dermatol** 1998 Dec;39(6):971–4

Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa [letter] Jemec GB. **J Am Acad Dermatol** 1999 Oct;41(4):658

EPIDEMIOLOGY

Extent of surgery and recurrence rate of hidradenitis suppurativa. Ritz JP, et al. **Int J Colorectal Dis** 1998; 13(4):164–8

ETIOLOGY

Cigarette smoking as a triggering factor of hidradenitis suppurativa. König A, et al. **Dermatology** 1999;198(3):261–4

MICROBIOLOGY

Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. Brook I, et al. **J Med Microbiol** 1999 Jan; 48(1):103–5

PATHOLOGY

Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Mengesha YM, et al. **Pediatr Dermatol** 1999 Jul–Aug;16(4):292–6 (32 ref.)

PHYSIOPATHOLOGY

Hidradenitis suppurativa. Brown TJ, et al. **South Med J** 1998 Dec;91(12):1107–14 (103 ref.)

SURGERY

Perianal hidradenitis suppurativa: early surgical treatment gives good results in chronic or recurrent cases. Endo Y, et al. **Br J Dermatol** 1998 Nov;139(5):906–10

Colonoscopy-assisted colostomy--an alternative to laparotomy: report of two cases. Mukherjee A, et al. **Dis Colon Rectum** 1998 Nov;41(11):1458–60

Extent of surgery and recurrence rate of hidradenitis suppurativa. Ritz JP, et al. **Int J Colorectal Dis** 1998; 13(4):164–8

THERAPY

Prepubertal hidradenitis suppurativa: two case reports and review of the literature. Mengesha YM, et al. **Pediatr Dermatol** 1999 Jul–Aug;16(4):292–6 (32 ref.)

HIDRADENOMA see **ADENOMA, SWEAT GLAND**

HIDROCYSTOMA

DIAGNOSIS

[Black hidrocystoma of the free margin of the eyelid] d'Hermies F, et al. **J Fr Ophtalmol** 1999 May;22(5):599–601 (Eng. Abstr.) **(Fre)**

[An apocrine hidrocystoma of the scrotum. A case report] Flessati P, et al. **Minerva Chir** 1999 Jan–Feb;54(1–2):87–9 (7 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Multiple facial eccrine hidrocystomas: effective topical therapy with atropine [letter] Armstrong DK, et al. **Br J Dermatol** 1998 Sep;139(3):558–9

METABOLISM

Immunohistochemical analysis of cytokeratin expression in multiple eccrine hidrocystoma. Ohnishi T, et al. **J Cutan Pathol** 1999 Feb;26(2):91–4

Immunohistochemical analysis of cytokeratin expression in apocrine cystadenoma or hidrocystoma. Ohnishi T, et al. **J Cutan Pathol** 1999 Jul;26(6):295–300

PATHOLOGY

Multiple translucent facial papules. Apocrine hidrocystoma. Schleicher SM. **Arch Dermatol** 1998 Dec;134(12):1627–8, 1630–1

Pigmented hidrocystoma of the eccrine secretory coil in the vulva: clinicopathologic, immunohistochemical and ultrastructural studies. Kamishima T, et al. **J Cutan Pathol** 1999 Mar;26(3):145–9

HIDROSADENITIS see **HIDRADENITIS**

HIDROTIC ECTODERMAL DYSPLASIA see **ECTODERMAL DYSPLASIA**

HIERARCHY, SOCIAL

The renewal of aristocratic principles. Didić E. **Coll Antropol** 1999 Jun;23(1):265–72

Research notes on social order and subjectivity: individuals' experience of susto and fallen fontanelle in a rural community in central Mexico. Castro R, et al. **Cult Med Psychiatry** 1998 Jun;22(2):203–30

Teasing in hierarchical and intimate relations. Keltner D, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1231–47

Effects of social status after mixing on immune, metabolic, and endocrine responses in pigs. Tuchscherer M, et al. **Physiol Behav** 1998 Jun 1;64(3):353–60

Maternal effects on the development of social rank and immunity trade-offs in male laboratory mice (Mus musculus). Barnard CJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 7;265(1410):2087–93

Hierarchies and cliques in the social networks of health care professionals: implications for the design of dissemination strategies. West E, et al. **Soc Sci Med** 1999 Mar; 48(5):633–46

HIGH CARDIAC OUTPUT see **CARDIAC OUTPUT, HIGH**

HIGH CHAIRS see **INFANT EQUIPMENT**

HIGH-COST TECHNOLOGY see **TECHNOLOGY, HIGH-COST**

HIGH-DENSITY LIPOPROTEINS

HIGH-DENSITY LIPOPROTEINS see **LIPOPROTEINS, HDL**

HIGH-ENERGY SHOCK WAVES

see related
LITHOTRIPSY

Shock waves in vascular diseases: an in-vitro study. Belcaro G, et al. **Angiology** 1998 Oct;49(10):777-88

Evaluation of basal membrane antibody (immunoglobulin G) formation after high-energy shockwave application in rats. Sarica K, et al. **J Endourol** 1998 Dec;12(6):505-8

Control of cavitation activity by different shockwave pulsing regimes. Huber P, et al. **Phys Med Biol** 1999 Jun; 44(6):1427-37

[The mechanical effects of shock waves in extracorporeal shock wave treatment of calcific tendinitis--an in vitro model] Perlick L, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb;137(1):10-6 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Application of high energy shock waves to cancer treatment in combination with cisplatin and ATX-70. Maruyama M, et al. **Anticancer Res** 1999 May-Jun;19(3A):1989-93

Shoulder function after extracorporal shock wave therapy for calcific tendinitis. Rompe JD, et al. **J Shoulder Elbow Surg** 1998 Sep-Oct;7(5):505-9

HIGH-FREQUENCY JET VENTILATION

High frequency jet ventilation in trachea reconstructions--its advantages in our experience. Džuberová I, et al. **Acta Chir Hung** 1999;38(1):31-4

Rediscovering the obvious [letter; comment] Schapera A. **Anesth Analg** 1999 Jun;88(6):1427-8. Comment on: Anesth Analg 1998 Oct;87(4):915-20.

Evaluation of high-frequency jet ventilation in oxygenation through an artificial membrane lung. Matsuura Y, et al. **Artif Organs** 1992 Oct;16(5):504-9

Aspiration and transtracheal jet ventilation with different pressures and depths of chest compression [see comments] Jawan B, et al. **Crit Care Med** 1999 Jan;27(1):142-5. Comment in: Crit Care Med 1999 Jan;27(1):27-8.

Transesophageal echocardiographic assessment of right heart hemodynamics during high-frequency jet ventilation. Ihra G, et al. **J Clin Anesth** 1999 Feb;11(1):32-8

Cystic adenomatoid malformation of the lung: neonatal management of 21 cases. Waszak P, et al. **Pediatr Surg Int** 1999 Jul;15(5-6):326-31

Changes in parameters of mechanics of breathing during high-frequency jet ventilation: what is the cause? Calkovská A, et al. **Physiol Res** 1997;46(4):271-8

[Respiratory monitoring and high frequence jet ventilation (HFJV) in the treatment of severe chest injuries] Deng Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):521-2, 526 (Eng. Abstr.) **(Chi)**

[Salvage transtracheal ventilation (letter)] Boughezala S, et al. **Ann Fr Anesth Reanim** 1997;16(5):553 **(Fre)**

[High-frequency jet ventilation in thoracic surgery (letter)] Muñoz JF, et al. **Rev Esp Anestesiol Reanim** 1998 Oct; 45(8):353-4 **(Spa)**

INSTRUMENTATION

Jet ventilation in upper airway obstruction: description and model lung testing of a new jetting device [see comments] Garry B, et al. **Anesth Analg** 1998 Oct;87(4):915-20. Comment in: Anesth Analg 1999 Jun;88(6):1427-8.

Devices for difficult airway management in academic emergency departments: results of a national survey. Levitan RM, et al. **Ann Emerg Med** 1999 Jun;33(6):694-8

METHODS

Respiratory gas monitoring during high-frequency jet ventilation for tracheal resection using a double-lumen jet catheter. Klein U, et al. **Anesth Analg** 1999 Jan;88(1):224-6

Combined high-frequency ventilation (CHFV) in the treatment of acute lung injury--a case report. Ip-Yam PC, et al. **Ann Acad Med Singapore** 1998 May;27(3):437-41

The clinical characteristics at the onset of a severe asthma attack and the effects of high frequency jet ventilation for severe asthmatic patients. Goto E, et al. **Eur J Emerg Med** 1998 Dec;5(4):451-5

High-frequency jet ventilation using a helium-oxygen mixture. Tobias JD, et al. **Paediatr Anaesth** 1999;9(5):451-5

[High-frequency jet ventilation with a proximal injector in a case of surgery of the tracheal carina] Puebla G, et al. **Rev Esp Anestesiol Reanim** 1999 Apr;46(4):169-72 (Eng. Abstr.) **(Spa)**

HIGH-FREQUENCY OSCILLATION see **HIGH-FREQUENCY VENTILATION**

HIGH-FREQUENCY POSITIVE PRESSURE VENTILATION see **HIGH-FREQUENCY VENTILATION**

HIGH-FREQUENCY VENTILATION

Combined effects of high-frequency ventilation and surfactant treatment in experimental meconium aspiration syndrome. Calkovska A, et al. **Acta Anaesthesiol Scand** 1999 Feb;43(2):135-45

Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical, and high-frequency oscillatory ventilation in premature lambs with respiratory distress syndrome. Kinsella JP, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1220-7

Successful use of high frequency oscillatory ventilation for pneumomediastinum. Miyahara K, et al. **Ann Thorac Cardiovasc Surg** 1999 Feb;5(1):49-51

Meta-analysis of elective high frequency ventilation in preterm infants with respiratory distress syndrome. Cools F, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan; 80(1):F15-20

Multicentre trail of high frequency ventilation. Ukos Study Group [letter] Johnson A, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F160

Nasal high frequency ventilation in neonates with moderate respiratory insufficiency. van der Hoeven M, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F61-3

Independent and combined effects of inhaled nitric oxide, liquid perfluorochemical, and high-frequency oscillatory ventilation in premature lambs with respiratory distress syndrome. Kinsella JP, et al. **Chest** 1999 Jul;116(1 Suppl):15S-16S

Experiences with high-frequency oscillatory ventilation in premature infants with respiratory distress syndrome. Jeng MJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Sep; 61(9):531-7

New-born infants with severe hyaline membrane disease: radiological evaluation during high frequency oscillatory versus conventional ventilation. Helbich TH, et al. **Eur J Radiol** 1998 Oct;28(3):243-9

A prospective randomized comparison of conventional mechanical ventilation and very early high frequency oscillatory ventilation in extremely premature newborns with respiratory distress syndrome. Plavka R, et al. **Intensive Care Med** 1999 Jan;25(1):68-75

Effect of I/E ratio on mean alveolar pressure during high-frequency oscillatory ventilation. Pillow JJ, et al. **J Appl Physiol** 1999 Jul;87(1):407-14

High frequency percussive ventilation in pediatric patients with inhalation injury. Cortiella J, et al. **J Burn Care Rehabil** 1999 May-Jun;20(3):232-5

Use of high frequency oscillatory ventilation (HFOV) for respiratory distress syndrome (RDS). Stewart DL, et al. **J Ky Med Assoc** 1999 Jan;97(1):17-21

Randomized comparison of high-frequency ventilation with high-rate intermittent positive pressure ventilation in preterm infants with respiratory failure [see comments] Thome U, et al. **J Pediatr** 1999 Jul;135(1):39-46. Comment in: J Pediatr 1999 Jul;135(1):9-11.

High-frequency ventilation versus conventional ventilation: No winner-but no loser [editorial; comment] Truog WE. **J Pediatr** 1999 Jul;135(1):9-11 (10 ref.). Comment on: J Pediatr 1999 Jul;135(1):39-46.

Effect of frequency and tidal volume on pleural pressure in rabbits during high frequency ventilation. Hernaiz MI, et al. **Lung** 1999;177(1):21-36

Synergistic effects of high-frequency ventilation and inhaled nitric oxide in the treatment of hypoxemic respiratory failure in infancy [letter] Hoehn T, et al. **Pediatr Pulmonol** 1998 Sep;26(3):228-30

Pulmonary function in ventilated infants with bronchiolitis [letter; comment] Newth CJ, et al. **Pediatr Pulmonol** 1998 Dec;26(6):438-41. Comment on: Pediatr Pulmonol 1998 Jan;25(1):18-31.

Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits. Dijk PH, et al. **Pediatr Res** 1998 Nov;44(5):699-704

Prolonged preoperative stabilization using high-frequency oscillatory ventilation does not improve the outcome in neonates with congenital diaphragmatic hernia. Kamata S, et al. **Pediatr Surg Int** 1998 Oct;13(8):542-6

Treatment of respiratory failure with inhaled nitric oxide and high- frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia. Hoehn T, et al. **Respiration** 1998;65(6):477-80

[Kinetic therapy of severe meconium aspiration syndrome] Urlesberger B, et al. **Z Geburtshilfe Neonatol** 1998 Sep; 202(5):214-6 (Eng. Abstr.) **(Ger)**

[High-frequency oscillatory ventilation as salvage strategy in the newborn infant. Spanish multicenter study. I] Morcillo F, et al. **An Esp Pediatr** 1999 Mar;50(3):269-74 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Ventilator-associated lung injury decreases lung ability to clear edema in rats. Lecuona E, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):603-9

Skin breakdown in children and high-frequency oscillatory ventilation. Schmidt JE, et al. **Arch Phys Med Rehabil** 1998 Dec;79(12):1565-9

Comparison of pulmonary inflammatory mediators in preterm infants treated with intermittent positive pressure ventilation or high frequency oscillatory ventilation. Thome U, et al. **Pediatr Res** 1998 Sep;44(3):330-7

INSTRUMENTATION

Intratracheal pulmonary ventilation in neonatal respiratory failure [editorial; comment] Bancalari E. **Crit Care Med** 1999 Jan;27(1):18-9. Comment on: Crit Care Med 1999 Jan;27(1):109-12.

A new ventilator improves CO2 removal in newborn lambs with congenital diaphragmatic hernia [see comments] Schnitzer JJ, et al. **Crit Care Med** 1999 Jan;27(1):109-12 . Comment in: Crit Care Med 1999 Jan;27(1):18-9.

New tools in ventilatory support: high frequency ventilation, nitric oxide, tracheal gas insufflation, non-invasive ventilation. Biarent D. **Pediatr Pulmonol Suppl** 1999; 18:178-81 (25 ref.)

METHODS

High-frequency oscillation via a laryngeal mask airway [letter] Fraser J, et al. **Anaesthesia** 1999 Apr;54(4):404

Non-conventional respiratory support modalities applicable in the older child. High frequency ventilation and liquid ventilation. Kallas HJ. **Crit Care Clin** 1998 Oct;14(4):655-83 (245 ref.)

High-frequency ventilation [editorial; comment] MacIntyre NR. **Crit Care Med** 1998 Dec;26(12):1955-6 (8 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2073-7.

Partial liquid ventilation reduces pulmonary neutrophil accumulation in an experimental model of systemic endotoxemia and acute lung injury. Rotta AT, et al. **Crit Care Med** 1998 Oct;26(10):1707-15

Volume recruitment and oxygenation in pulmonary edema: a comparison between HFOV and CMV. Sznajder JI, et al. **J Crit Care** 1998 Sep;13(3):126-35

Phase analysis in high-frequency oscillation. Lee S, et al. **Med Eng Phys** 1998 Sep;20(6):452-7

Effects of mean and swing pressures on piston-type high-frequency oscillatory ventilation in rabbits with and without acute lung injury. Sakai T, et al. **Pediatr Pulmonol** 1999 May;27(5):328-35

High-frequency oscillatory ventilation in RSV bronchiolitis patients. Duval EL, et al. **Respir Med** 1999 Jun;93(6):435-40

[Combination therapy of high frequency oscillatory ventilation, NO inhalation and surfactant replacement in a child with acute respiratory distress syndrome] Merz U, et al. **Klin Padiatr** 1999 Mar-Apr;211(2):83-5 (Eng. Abstr.) **(Ger)**

[The use of high-frequency artificial ventilation of lungs in the surgery of the trachea] Glumcher FS. **Klin Khir** 1999; (4):38-41 (Eng. Abstr.) **(Rus)**

STANDARDS

Has high-frequency ventilation been inappropriately discarded in adult acute respiratory distress syndrome? [see comments] Herridge MS, et al. **Crit Care Med** 1998 Dec; 26(12):2073-7 (33 ref.). Comment in: Crit Care Med 1998 Dec;26(12):1955-6.

HIGH FREQUENCY WAVES see **RADIO WAVES**

HIGH GRAVITY see **HYPERGRAVITY**

HIGH MOBILITY GROUP PROTEINS

BIOSYNTHESIS

Expression and hormonal regulation of the Sox4 gene in mouse female reproductive tissues. Hunt SM, et al. **Biol Reprod** 1999 Aug;61(2):476-81

Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Abe N, et al. **Cancer Res** 1999 Mar 15;59(6):1169-74

Early expression of AMH in chicken embryonic gonads precedes testicular SOX9 expression. Oreal E, et al. **Dev Dyn** 1998 Aug;212(4):522-32

A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. Lefebvre V, et al. **EMBO J** 1998 Oct 1;17(19):5718-33

Induction of high mobility group-I(Y) protein by endotoxin and interleukin-1beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase. Pellacani A, et al. **J Biol Chem** 1999 Jan 15;274(3):1525-32

CHEMISTRY

Co-crystallization and preliminary crystallographic analysis of the high mobility group domain of HMG-D bound to DNA. Murphy FV 4th, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Sep;55 (Pt 9):1594-7

Flexing DNA: HMG-box proteins and their partners. Bianchi ME, et al. **Am J Hum Genet** 1998 Dec;63(6):1573-7 (25 ref.)

DNA bending induced by high mobility group proteins studied by fluorescence resonance energy transfer. Lorenz M, et al. **Biochemistry** 1999 Sep 14;38(37):12150-8

Differences in DNA recognition and conformational change activity between boxes A and B in HMG2 protein. Yoshioka Ki, et al. **Biochemistry** 1999 Jan 12;38(2):589-95

Reexamination of the high mobility group-1 protein for self-association and characterization of hydrodynamic properties. Ranatunga W, et al. **Biochim Biophys Acta** 1999 Jun 15;1432(1):1-12

Solution structure of the HMG protein NHP6A and its interaction with DNA reveals the structural determinants for non-sequence-specific binding. Allain FH, et al. **EMBO J** 1999 May 4;18(9):2563-79

Domain-domain interactions in high mobility group 1 protein (HMG1). Ramstein J, et al. **Eur J Biochem** 1999 Mar; 260(3):692-700

Architectural regulations and Hmg1 [news; comment] Wolffe AP. **Nat Genet** 1999 Jul;22(3):215-7. Comment on: Nat Genet 1999 Jul;22(3):276-80.

DEFICIENCY

The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice [see comments] Calogero S, et al. **Nat Genet** 1999 Jul;22(3):276-80. Comment in: Nat Genet 1999 Jul;22(3):215-7.

GENETICS

HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Tallini G, et al. **Adv Anat Pathol** 1999 Sep;6(5):237-46 (94 ref.)

Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene. Chase MB, et al. **Am J Hematol** 1999 Jan;60(1):27-35

Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. Pfeifer D, et al. **Am J Hum Genet** 1999 Jul;65(1):111-24

Campomelic syndrome and deletion of SOX9. Olney PN, et al. **Am J Med Genet** 1999 May 7;84(1):20-4

Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation. Inoue K, et al. **Ann Neurol** 1999 Sep;46(3):313-8

Identification of cDNAs for Sox-4, an HMG-Box protein, and a novel human homolog of yeast splicing factor SSF-1 differentially regulated during apoptosis induced by prostaglandin A2/delta12-PGJ2 in Hep3B cells. Ahn SG, et al. **Biochem Biophys Res Commun** 1999 Jun 24; 260(1):216-21

Isolation and characterization of a mouse SRY-related cDNA, mSox7. Taniguchi K, et al. **Biochim Biophys Acta** 1999 May 14;1445(2):225-31

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Chesi M, et al. **Blood** 1998 Nov 1;92(9):3025-34

Deletion of HMGI7 in uterine leiomyomas with ring chromosome 1. Polito P, et al. **Cancer Genet Cytogenet** 1999 Jan 15;108(2):107-9

Pleomorphic adenomas of the salivary glands: absence of HMGIY rearrangements. Rohen C, et al. **Cancer Genet Cytogenet** 1999 Jun;111(2):178-81

HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Giannini G, et al. **Cancer Res** 1999 May 15;59(10):2484-92

Sry and Sox9: mammalian testis-determining genes. Koopman P. **Cell Mol Life Sci** 1999 Jun;55(6-7):839-56 (187 ref.)

Sox4-deficiency syndrome in mice is an animal model for common trunk. Ya J, et al. **Circ Res** 1998 Nov 16; 83(10):986-94

Characterisation and mapping of the human SOX14 gene. Arsic N, et al. **Cytogenet Cell Genet** 1998;83(1-2):139-46

Temperature-dependent sex determination: upregulation of SOX9 expression after commitment to male development. Western PS, et al. **Dev Dyn** 1999 Mar;214(3):171-7

sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis. De Martino SP, et al. **Dev Genes Evol** 1999 Jun;209(6):357-62

DSP1 gene of Drosophila melanogaster encodes an HMG-domain protein that plays multiple roles in development. Mosrin-Huaman C, et al. **Dev Genet** 1998; 23(4):324-34

The Drosophila SOX-domain protein Dichaete is required for the development of the central nervous system midline. Soriano NS, et al. **Development** 1998 Oct;125(20):3989-96

Genetic basis of uterine leiomyoma: involvement of high mobility group protein genes. Van de Ven WJ. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):289-93 (22 ref.)

A novel downstream positive regulatory element mediating transcription of the human high mobility group (HMG) I-C gene. Chau K, et al. **FEBS Lett** 1999 Sep 3; 457(3):429-36

Further complexity of the human SOX gene family revealed by the combined use of highly degenerate primers and nested PCR. Cremazy F, et al. **FEBS Lett** 1998 Nov 6; 438(3):311-4

Plant chromosomal HMGI/Y proteins and histone H1 exhibit a protein domain of common origin. Krech AB, et al. **Gene** 1999 Apr 1;230(1):1-5

Selection of a cDNA clone for chicken high-mobility-group 1 (HMG1) protein through its unusually conserved 3'-untranslated region, and improved expression of recombinant HMG1 in Escherichia coli. Lee KB, et al. **Gene** 1998 Dec 28;225(1-2):97-105

Rearrangement of the neoplasia-associated gene HMGIC in synovia from patients with osteoarthritis. Broberg K, et al. **Genes Chromosomes Cancer** 1999 Mar;24(3):278-82

Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. Dal Cin P, et al. **Genes Chromosomes Cancer** 1999 Mar;24(3):286-9

HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Gattas GJ, et al. **Genes Chromosomes Cancer** 1999 Aug;25(4):316-22

The expression pattern of the Hmgic gene during development. Hirning-Folz U, et al. **Genes Chromosomes Cancer** 1998 Dec;23(4):350-7

HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Kazmierczak B, et al. **Genes Chromosomes Cancer** 1998 Dec;23(4):279-85

HMG1 is not rearranged by 13q12 aberrations in lipomas. Kazmierczak B, et al. **Genes Chromosomes Cancer** 1999 Mar;24(3):290-2

Is HMGIC rearranged due to cryptic paracentric inversion of 12q in karyotypically normal uterine leiomyomas? [letter] Weremowicz S, et al. **Genes Chromosomes Cancer** 1999 Feb;24(2):172-3

Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. Dolinski KJ, et al. **Genetics** 1999 Mar; 151(3):935-44

The Sox10(Dom) mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. Southard-Smith EM, et al. **Genome Res** 1999 Mar;9(3):215-25

Assignment of a new gene (LBH). Kazmierczak B, et al. **Genomics** 1999 Feb 15;56(1):136-7

LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. Petit MM, et al. **Genomics** 1999 May 1;57(3):438-41

The Sox-13 gene: structure, promoter characterization, and chromosomal localization. Roose J, et al. **Genomics** 1999 Apr 15;57(2):301-5

The SOX10/Sox10 gene from human and mouse: sequence, expression, and transactivation by the encoded HMG domain transcription factor. Pusch C, et al. **Hum Genet** 1998 Aug;103(2):115-23

Structural and functional characterization of the mouse Sox9 promoter: implications for campomelic dysplasia. Kanai Y, et al. **Hum Mol Genet** 1999 Apr;8(4):691-6

Novel missense mutation in the HMG box of SOX9 gene in a Japanese XY male resulted in campomelic dysplasia and severe defect in masculinization. Goji K, et al. **Hum Mutat** 1998;Suppl 1:S114-6

Mutation analysis of the SOX9 gene in a patient with campomelic dysplasia. Hageman RM, et al. **Hum Mutat** 1998;Suppl 1:S112-3

Expression of the HMGI(Y) gene in human colorectal cancer. Kim DH, et al. **Int J Cancer** 1999 Aug 20;84(4):376-80

HMG-17, a chromosomal non-histone protein, shows developmental regulation during organogenesis. Lehtonen S, et al. **Int J Dev Biol** 1998 Sep;42(6):775-82

Functional and structural studies of wild type SOX9 and mutations causing campomelic dysplasia. McDowall S, et al. **J Biol Chem** 1999 Aug 20;274(34):24023-30

Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. Xie WF, et al. **J Bone Miner Res** 1999 May;14(5):757-63

Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. Guldner HH, et al. **J Cell Sci** 1999 Mar;112 (Pt 5):733-47

Ultrastructural localization of beta-actin and amphoterin mRNA in cultured cells: application of tyramide signal amplification and comparison of detection methods. Punnonen EL, et al. **J Histochem Cytochem** 1999 Jan; 47(1):99-112

Regulation of the expression and activity by progestins of a member of the SOX gene family of transcriptional modulators. Graham JD, et al. **J Mol Endocrinol** 1999 Jun; 22(3):295-304

Diversification pattern of the HMG and SOX family members during evolution. Soullier S, et al. **J Mol Evol** 1999 May;48(5):517-27

The isolation and high-resolution chromosomal mapping of human SOX14 and SOX21; two members of the SOX gene family related to SOX1, SOX2, and SOX3. Malas S, et al. **Mamm Genome** 1999 Sep;10(9):934-7

Comparative analyses of the Dominant megacolon-SOX10 genomic interval in mouse and human. Southard-Smith EM, et al. **Mamm Genome** 1999 Jul;10(7):744-9

cDNA characterization and high resolution mapping of the human SOX20 gene. Vujić M, et al. **Mamm Genome** 1998 Dec;9(12):1059-61

Differential expression of the HMG box transcription factors XTcf-3 and XLef-1 during early xenopus development. Molenaar M, et al. **Mech Dev** 1998 Jul;75(1-2):151-4

High mobility group 1 (HMG1) protein in mouse preimplantation embryos. Spada F, et al. **Mech Dev** 1998 Aug;76(1-2):57-66

Two distinct subgroups of Group B Sox genes for transcriptional activators and repressors: their expression during embryonic organogenesis of the chicken. Uchikawa M, et al. **Mech Dev** 1999 Jun;84(1-2):103-20

The MATA locus of the dimorphic yeast Yarrowia lipolytica consists of two divergently oriented genes. Kurischko C, et al. **Mol Gen Genet** 1999 Aug;262(1):180-8

Capture of a genomic HMG domain sequence by the En/Spm-related transposable element Tpn1 in the Japanese morning glory. Takahashi S, et al. **Mol Gen Genet** 1999 Apr;261(3):447-51

Sox9 is required for cartilage formation. Bi W, et al. **Nat Genet** 1999 May;22(1):85-9

The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice [see comments] Calogero S, et al. **Nat Genet** 1999 Jul;22(3):276-80. Comment in: Nat Genet 1999 Jul;22(3):215-7.

MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans. Meneghini MD, et al. **Nature** 1999 Jun 24;399(6738):793-7

AT-hook motifs identified in a wide variety of DNA-binding proteins. Aravind L, et al. **Nucleic Acids Res** 1998 Oct 1;26(19):4413-21

The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Panagiotidis CA, et al. **Virology** 1999 Mar 30; 256(1):64-74

IMMUNOLOGY

High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis [see comments] Sobajima J, et al. **Gut** 1999 Jun;44(6):867-73. Comment in: Gut 1999 Jun;44(6):776-7.

[High mobility group protein HMG1/HMG2: clinical significance of the autoantibodies] Ozaki S. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):95-107 (40 ref.) **(Jpn)**

ISOLATION & PURIFICATION

High mobility group-like protein in bovine milk stimulates the proliferation of osteoblastic MC3T3-E1 cells. Yamamura J, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):113-7

The high mobility group domain protein Cmb1 of Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines. Fleck O, et al. **J Biol Chem** 1998 Nov 13;273(46):30398-405

Purification and assays for high mobility group HMG-I(Y) protein function. Reeves R, et al. **Methods Enzymol** 1999; 304:155-88

Identification of a novel Sry-related gene and its germ cell-specific expression. Osaki E, et al. **Nucleic Acids Res** 1999 Jun 15;27(12):2503-10

Isolation and separation of HMG proteins and histones H1 and H5 and core histones by column chromatography on phosphocellulose. Garg LC, et al. **Protein Expr Purif** 1998 Nov;14(2):155-9

METABOLISM

Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene. Chase MB, et al. **Am J Hematol** 1999 Jan;60(1):27-35

HMGIC expression patterns in non-small lung cancer and surrounding tissue. Rogalla P, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3327-30

Identification of the nuclear factor HMG2 as an activator for DFF nuclease activity. Toh SY, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):598-601

DNA bending induced by high mobility group proteins studied by fluorescence resonance energy transfer. Lorenz M, et al. **Biochemistry** 1999 Sep 14;38(37):12150-8

Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Vaisman A, et al. **Biochemistry** 1999 Aug 24;38(34):11026-39

Expression of reciprocal fusion transcripts of the HMGIC and LPP genes in parosteal lipoma. Petit MM, et al. **Cancer Genet Cytogenet** 1998 Oct 1;106(1):18-23

CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin. Kelley DE, et al. **Chromosoma** 1999 Apr;108(1):10-25

Regulation and role of Sox9 in cartilage formation. Healy C, et al. **Dev Dyn** 1999 May;215(1):69-78

Dynamic relocation of chromosomal protein HMG-17 in the nucleus is dependent on transcriptional activity. Hock R, et al. **EMBO J** 1998 Dec 1;17(23):6992-7001

The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. Yie J, et al. **EMBO J** 1999 Jun 1;18(11):3074-89

The HMG protein T160 colocalizes with DNA replication foci and is down-regulated during cell differentiation. Hertel L, et al. **Exp Cell Res** 1999 Aug 1;250(2):313-28

An HMG1-like protein facilitates Wnt signaling in Caenorhabditis elegans. Jiang LI, et al. **Genes Dev** 1999 Apr 1;13(7):877-89

The stabilized structural array of two HMG1/2-boxes endowed by a linker sequence between them is requisite for the effective binding of HMG1 with DNA. Saito K, et al. **J Biochem (Tokyo)** 1999 Feb;125(2):399-405

High mobility group proteins 1 and 2 can function as DNA-binding regulatory components for DNA-dependent protein kinase in vitro. Yumoto Y, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):519-27

The non-histone chromatin protein HMG1 protects linker DNA on the side opposite to that protected by linker histones. An W, et al. **J Biol Chem** 1998 Oct 9; 273(41):26289-91

The HMG-I(Y) A.T-hook peptide motif confers DNA-binding specificity to a structured chimeric protein. Banks GC, et al. **J Biol Chem** 1999 Jun 4;274(23):16536-44

The high mobility group domain protein Cmb1 of

Schizosaccharomyces pombe binds to cytosines in base mismatches and opposite chemically altered guanines. Fleck O, et al. **J Biol Chem** 1998 Nov 13;273(46):30398–405

Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. Jamieson ER, et al. **J Biol Chem** 1999 Apr 30;274(18):12346–54

A possible role for the high mobility group box transcription factor Tcf-4 in vertebrate gut epithelial cell differentiation. Lee YJ, et al. **J Biol Chem** 1999 Jan 15;274(3):1566–72

Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. Li J, et al. **J Biol Chem** 1998 Nov 20;273(47):30870–8

Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. Nagpal S, et al. **J Biol Chem** 1999 Aug 6;274(32):22563–8

High mobility group-I(Y) protein facilitates nuclear factor-kappaB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer. Perrella MA, et al. **J Biol Chem** 1999 Mar 26;274(13):9045–52

High mobility group protein 1 interacts specifically with the core domain of human TATA box-binding protein and interferes with transcription factor IIB within the pre-initiation complex. Sutrias-Grau M, et al. **J Biol Chem** 1999 Jan 15;274(3):1628–34

Constitutive phosphorylation of the acidic tails of the high mobility group 1 proteins by casein kinase II alters their conformation, stability, and DNA binding specificity. Wiśniewski JR, et al. **J Biol Chem** 1999 Jul 16; 274(29):20116–22

A small region in HMG I(Y) is critical for cooperation with NF-kappaB on DNA. Zhang XM, et al. **J Biol Chem** 1999 Jul 16;274(29):20235–43

Chromosomal proteins HMG-14 and HMG-17 are released from mitotic chromosomes and imported into the nucleus by active transport. Hock R, et al. **J Cell Biol** 1998 Dec 14;143(6):1427–36

Three distinct sub-nuclear populations of HMG-I protein of different properties revealed by co-localization image analysis. Amirand C, et al. **J Cell Sci** 1998 Dec;111 (Pt 23):3551–61

High-mobility group 1/2 proteins are essential for initiating rolling-circle-type DNA replication at a parvovirus hairpin origin. Cotmore SF, et al. **J Virol** 1998 Nov; 72(11):8477–84

Interactions of high mobility group box proteins with DNA and chromatin. Churchill ME, et al. **Methods Enzymol** 1999;304:99–133

Reconstitution of high mobility group 14/17 proteins into nucleosomes and chromatin. Postnikov YV, et al. **Methods Enzymol** 1999;304:133–55

Purification and assays for high mobility group HMG-I(Y) protein function. Reeves R, et al. **Methods Enzymol** 1999; 304:155–88

Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Munshi N, et al. **Mol Cell** 1998 Oct;2(4):457–67

MOM-4, a MAP kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in C. elegans. Shin TH, et al. **Mol Cell** 1999 Aug;4(2):275–80

Specific binding of high-mobility-group I (HMGI) protein and histone H1 to the upstream AT-rich region of the murine beta interferon promoter: HMGI protein acts as a potential antirepressor of the promoter. Bonnefoy E, et al. **Mol Cell Biol** 1999 Apr;19(4):2803–16

A novel DNA-binding protein bound to the mitochondrial inner membrane restores the null mutation of mitochondrial histone Abf2p in Saccharomyces cerevisiae. Cho JH, et al. **Mol Cell Biol** 1998 Oct;18(10):5712–23

Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. De Santa Barbara P, et al. **Mol Cell Biol** 1998 Nov;18(11):6653–65

Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes. Herrera JE, et al. **Mol Cell Biol** 1999 May;19(5):3466–73

Mechanism of regulatory target selection by the SOX high-mobility-group domain proteins as revealed by comparison of SOX1/2/3 and SOX9. Kamachi Y, et al. **Mol Cell Biol** 1999 Jan;19(1):107–20

The RAG-HMG1 complex enforces the 12/23 rule of V(D)J recombination specifically at the double-hairpin formation step. West RB, et al. **Mol Cell Biol** 1998 Nov; 18(11):6408–15

HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Zhang CC, et al. **Mol Endocrinol** 1999 Apr;13(4):632–43

Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Cavallo RA, et al. **Nature** 1998 Oct 8; 395(6702):604–8

Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Ohndorf UM, et al. **Nature** 1999 Jun 17;399(6737):708–12

The DNA-binding domain of human c-Abl tyrosine kinase promotes the interaction of a HMG chromosomal protein with DNA. David-Cordonnier MH, et al. **Nucleic Acids Res** 1999 Jun 1;27(11):2265–70

Directional binding of HMG-I(Y) on four-way junction DNA and the molecular basis for competitive binding with HMG-1 and histone H1. Hill DA, et al. **Nucleic Acids Res** 1999 May 15;27(10):2135–44

The DNA-binding specificity of SOX9 and other SOX proteins. Mertin S, et al. **Nucleic Acids Res** 1999 Mar 1; 27(5):1359–64

A dimer of the lymphoid protein RAG1 recognizes the recombination signal sequence and the complex stably incorporates the high mobility group protein HMG2. Rodgers KK, et al. **Nucleic Acids Res** 1999 Jul 15; 27(14):2938–46

Environmental signals controlling sexual development of the corn Smut fungus Ustilago maydis through the transcriptional regulator Prf1. Hartmann HA, et al. **Plant Cell** 1999 Jul;11(7):1293–306

The HMG-I/Y protein PF1 stimulates binding of the transcriptional activator GT-2 to the PHYA gene promoter. Martínez-García JF, et al. **Plant J** 1999 Apr; 18(2):173–83

Interactions between an HMG-1 protein and members of the Rel family. Brickman JM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10679–83

The mechanism of sequence non-specific DNA binding of HMG1/2-box B in HMG1 with DNA. Saito K, et al. **Protein Eng** 1999 Mar;12(3):235–42

HMG-1 as a late mediator of endotoxin lethality in mice. Wang H, et al. **Science** 1999 Jul 9;285(5425):248–51

The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Panagiotidis CA, et al. **Virology** 1999 Mar 30; 256(1):64–74

PHARMACOLOGY

High mobility group-like protein in bovine milk stimulates the proliferation of osteoblastic MC3T3-E1 cells. Yamamura J, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):113–7

Cooperative transcriptional activation by serum response factor and the high mobility group protein SSRP1. Spencer JA, et al. **J Biol Chem** 1999 May 28;274(22):15686–93

PHYSIOLOGY

Regulation and role of Sox9 in cartilage formation. Healy C, et al. **Dev Dyn** 1999 May;215(1):69–78

Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. Dolinski KJ, et al. **Genetics** 1999 Mar; 151(3):935–44

A role for the architectural transcription factors HMGI(Y) in cytokine gene transcription in T cells. Shannon MF, et al. **Immunol Cell Biol** 1998 Oct;76(5):461–6

High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains. Abdulkadir SA, et al. **J Leukoc Biol** 1998 Nov;64(5):681–91

Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. Arioka H, et al. **Jpn J Cancer Res** 1999 Jan;90(1):108–15

Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Bustin M. **Mol Cell Biol** 1999 Aug;19(8):5237–46 (130 ref.)

The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins. Orphanides G, et al. **Nature** 1999 Jul 15;400(6741):284–8

From head to toes: the multiple facets of Sox proteins. Wegner M. **Nucleic Acids Res** 1999 Mar 15;27(6):1409–20 (119 ref.)

SECRETION

Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Wang H, et al. **Surgery** 1999 Aug; 126(2):389–92

HIGH-MOLECULAR-WEIGHT KININOGEN see **KININOGEN, HIGH-MOLECULAR-WEIGHT**

HIGH PERFORMANCE COMPUTING see **COMPUTING METHODOLOGIES**

HIGH PRESSURE NERVOUS SYNDROME

see related
DECOMPRESSION SICKNESS
DIVING

DRUG THERAPY

The full expression of locomotor and motor hyperactivities induced by pressure requires both striatal dopaminergic and N-methyl-D-aspartate receptor activities in the rat. Darbin O, et al. **Neurosci Lett** 1999 Jun 4;267(3):149–52

METABOLISM

Crucial role of the 5-HT2C receptor, but not of the 5-HT2A receptor, in the down regulation of stimulated dopamine release produced by pressure exposure in freely moving rats. Kriem B, et al. **Brain Res** 1998 Jun 15;796(1-2):143–9

SURGERY

Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers. Walsh KP, et al. **Heart** 1999 Mar;81(3):257–61

HIGH-RISK PREGNANCY see **PREGNANCY, HIGH-RISK**

HIGH T4 SYNDROME see **EUTHYROID SICK SYNDROMES**

HIGHER NERVOUS ACTIVITY

Pavlov's conceptualization of voluntary movements within the framework of the theory of higher nervous activity. Windholz G. **Am J Psychol** 1998 Fall;111(3):435–43

[Development of instrumental technologies of assessment of higher mental functions in health and disease] Matveev EV, et al. **Med Tekh** 1999 Jan-Feb;(1):18–20 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[New approaches in correcting disorders of higher integrative brain functions in the pharmacotherapy of arterial hypertension with propranolol] Petrov VI, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):10–2 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Effects of cortical polarization on mental arithmetic. Pauli P, et al. **Brain Res Cogn Brain Res** 1998 Jul;7(1):49–56

Individual differences in memory and executive function abilities during normal aging. Mejia S, et al. **Int J Neurosci** 1998 Sep;95(3-4):271–84

Enhanced brain activity preceding voluntary movement in early blind humans. Lehtokoski A, et al. **Neurosci Lett** 1998 Sep 11;253(3):155–8

[The psychophysiological readiness of children for instruction in school] Makarenko NV, et al. **Fiziol Cheloveka** 1999 Mar-Apr;25(2):39–45 **(Rus)**

[The time distribution of the spike train activity of the neurons in the rabbit sensorimotor cortex during a rhythmic motor dominant] Bogdanov AV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):630–9 (Eng. Abstr.) **(Rus)**

[The typological characteristics of higher nervous activity in dogs and the maxima of the cross-correlation function between the electrical activities of the frontal cortex and the brain limbic systems] Chilingarian LI. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 May-Jun; 49(3):385–99 (Eng. Abstr.) **(Rus)**

[The neurochemical and behavioral indices of an acquired alcohol craving in rats under conditions of information loading] Dovedova EL, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar-Apr; 49(2):331–7 (Eng. Abstr.) **(Rus)**

[The interaction in the motor cortex of 2 foci of a "polarization" dominant] Kiazimova KM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):607–15 (Eng. Abstr.) **(Rus)**

[A coherence analysis of the electrical activity of the rabbit brain during the creation of a "polarization" hunger dominant] Liubimova IuV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):600–6 (Eng. Abstr.) **(Rus)**

[The motivational dominant and goal-directed behavior] Pavlygina RA. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug;48(4):581–90 (Eng. Abstr.) **(Rus)**

[Experimental studies of the capacity of ants for the addition and subtraction of small numbers] Reznikova ZhI, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan-Feb; 49(1):12–21 (Eng. Abstr.) **(Rus)**

[A coherence analysis of the electrical activity of the rabbit brain during a shift in the dominants] Roshchina GIa, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):616–22 (Eng. Abstr.) **(Rus)**

[The structure of the cortical-subcortical relationships of the cerebral electrical processes during a motor polarization dominant] Rusinova EV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):591–9 (Eng. Abstr.) **(Rus)**

[A method for performing a study and assessment of the individual neurodynamic properties of human higher nervous activity] Makarenko MV. **Fiziol Zh** 1999; 45(4):125–31 (Eng. Abstr.) **(Ukr)**

[Neurodynamic functions in older school-age pupils with different levels of development in the properties of their basic neural processes] Makarenko MV, et al. **Fiziol Zh** 1999;45(3):3–10 (Eng. Abstr.) **(Ukr)**

HILL-BURTON ACT see **FINANCING, GOVERNMENT**

HINDBRAIN see **RHOMBENCEPHALON**

HINDLIMB

Serotonin in an antigen-induced arthritis of the rabbit temporomandibular joint. Tominaga K, et al. **Arch Oral Biol** 1999 Jul;44(7):595–601

Effects of hindlimb suspension and androgen treatment on testosterone receptors in rat skeletal muscles. Bricout VA, et al. **Eur J Appl Physiol** 1999 Apr;79(5):443–8

Evaluation of the association between medial patellar luxation and hip dysplasia in cats. Smith GK, et al.

J Am Vet Med Assoc 1999 Jul 1;215(1):40–5
Pelvic limb paresis in a safari cat. Hankenson FC, et al. **Lab Anim Sci** 1998 Aug;48(4):325–9

ABNORMALITIES

Paired-related homeobox genes cooperate in handplate and hindlimb zeugopod morphogenesis. Lu MF, et al. **Dev Biol** 1999 Jan 1;205(1):145–57
Induction of mortality and malformation in Xenopus laevis embryos by water sources associated with field frog deformities [see comments] Burkhart JG, et al. **Environ Health Perspect** 1998 Dec;106(12):841–8. Comment in: Environ Health Perspect 1998 Dec;106(12):773–4.
Environmentally induced limb malformations in mink frogs (Rana septentrionalis). Gardiner DM, et al. **J Exp Zool** 1999 Jul 1;284(2):207–16
Exclusion of Jagged2 as a candidate for the legless gene. Bell SM, et al. **Mamm Genome** 1998 Sep;9(9):778–9
Effects of dietary roxarsone supplementation, lighting program, and season on the incidence of leg abnormalities in broiler chickens. Laster CP, et al. **Poult Sci** 1999 Feb; 78(2):197–203
The effect of trematode infection on amphibian limb development and survivorship [see comments] Johnson PT, et al. **Science** 1999 Apr 30;284(5415):802–4. Comment in: Science 1999 Apr 30;284(5415):731, 733.
A trematode parasite causes some frog deformities [news; comment] Kaiser J. **Science** 1999 Apr 30;284(5415):731,733 . Comment on: Science 1999 Apr 30;284(5415):802–4.
Morphological clues from multilegged frogs: are retinoids to blame? Sessions SK, et al. **Science** 1999 Apr 30; 284(5415):800–2

ANATOMY & HISTOLOGY

Representations of hindlimb digits in rat dorsal root ganglia. Prats-Galino A, et al. **J Comp Neurol** 1999 May 24; 408(1):137–45
Pelvic limb musculature in the emu Dromaius novaehollandiae (Aves: Struthioniformes: Dromaiidae): adaptations to high-speed running. Patak AE, et al. **J Morphol** 1998 Oct;238(1):23–37
Quantitative analysis of muscle fibre type and myosin heavy chain distribution in the frog hindlimb: implications for locomotory design. Lutz GJ, et al. **J Muscle Res Cell Motil** 1998 Oct;19(7):717–31

BLOOD SUPPLY

Reflection coefficient for albumin and capillary fluid permeability in cat calf muscle after traumatic injury. Kongstad L, et al. **Acta Physiol Scand** 1999 Apr; 165(4):369–77
Microsphere infusion reverses vasoconstrictor-mediated change in hindlimb oxygen uptake and energy status. Vincent MA, et al. **Acta Physiol Scand** 1998 Sep; 164(1):61–9
The morphogenesis of the arteries of the pelvic extremity. A comparative study of mammals with special reference to the tree shrew Tupaia belangeri (Tupaiidae, Scandentia, Mammalia). Funke C, et al. **Adv Anat Embryol Cell Biol** 1998;144:1–97 (115 ref.)
Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. Bless NM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L57–63
Microcirculatory perfusion deficits are not essential for remote parenchymal injury within the liver. Brock RW, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):G55–60
Exercise training enhances basic fibroblast growth factor-induced collateral blood flow. Yang HT, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):H2053–61
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease. Tanaka T, et al. **Biol Pharm Bull** 1999 Mar;22(3):257–60
Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo. Häbler H, et al. **Br J Pharmacol** 1999 Aug;127(7):1719–27
Venous drainage through bone marrow after replantation: an experimental study. Tanaka K, et al. **Br J Plast Surg** 1998 Dec;51(8):629–32
Prevention of limb loss in critical ischaemia by arterialization of the superficial venous system: an experimental study in dogs. Kopelman D, et al. **Cardiovasc Surg** 1998 Aug; 6(4):384–8
Mediation of calcitonin gene-related peptide in protection of ischemic preconditioning in rat hindlimbs. Zhou FW, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep;19(5):477–80
Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Shyu KG, et al. **Circulation** 1998 Nov 10;98(19):2081–7
Redox status of cytochrome a,a3: a noninvasive indicator of dysoxia in regional hypoxic or ischemic hypoxia [see comments] Guery BP, et al. **Crit Care Med** 1999 Mar; 27(3):576–82. Comment in: Crit Care Med 1999 Mar;27(3):469–71.
Skeletal muscle tissue oxygen pressure distribution during early reperfusion after prolonged ischaemia. Gustafsson U, et al. **Eur J Vasc Endovasc Surg** 1999 Jan;17(1):41–6
Sympathectomy decreases formalin-induced nociceptive responses independent of changes in peripheral blood flow. Fuchs PN, et al. **Exp Neurol** 1999 Jan;155(1):95–102
Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Morishita R, et al. **Hypertension** 1999 Jun;33(6):1379–84
Rat hindlimb muscle blood flow during level and downhill locomotion. Delp MD, et al. **J Appl Physiol** 1999 Feb; 86(2):564–8
Analysis of lower extremity embolic material after total knee arthroplasty in a canine model. Markel DC, et al. **J Arthroplasty** 1999 Feb;14(2):227–32
The effect of electro-acupuncture stimulation on the muscle blood flow of the hindlimb in anesthetized rats. Noguchi E, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):78–86
Intermittent pneumatic compression of legs increases microcirculation in distant skeletal muscle. Liu K, et al. **J Orthop Res** 1999 Jan;17(1):88–95
The role of bradykinin in the regulation of blood flow to hindlimb muscle groups of the anaesthetized cat. Poucher SM, et al. **J Physiol (Lond)** 1998 Jul 15;510 (Pt 2):643–50
Increased hindlimb leukocyte concentration in a chronic rodent model of venous hypertension. Hahn TL, et al. **J Surg Res** 1999 Jan;81(1):38–41
Hindlimb ischemia-reperfusion increases complement deposition and glycolysis. Wong MS, et al. **J Surg Res** 1999 Jul;85(1):130–5
Temporary arterial shunts to maintain limb perfusion after arterial injury: an animal study. Dawson DL, et al. **J Trauma** 1999 Jul;47(1):64–71
Cytokines contribute to early hepatic parenchymal injury and microvascular dysfunction after bilateral hindlimb ischemia. Lawlor DK, et al. **J Vasc Surg** 1999 Sep; 30(3):533–41
Low-dose basic fibroblast growth factor and vascular endothelial growth factor for angiogenesis in canine acute hindlimb insufficiency. Rakue H, et al. **Jpn Circ J** 1998 Dec;62(12):933–9
The use of lumbar sympathectomy for peripheral vascular disease (PVD) [letter] Claeys LG. **World J Surg** 1999 Sep; 23(9):981–3
[Effect of frostbite under hypoxia on microcirculatory perfusion in rats] Yan P, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):12–5 (Eng. Abstr.) **(Chi)**
[Topography of the major vessels of the pelvic cavity and pelvic limb in albino rats using phase x-ray] Iushkevich TV, et al. **Morfologiia** 1998;114(5):51–5 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Sympathectomy decreases formalin-induced nociceptive responses independent of changes in peripheral blood flow. Fuchs PN, et al. **Exp Neurol** 1999 Jan;155(1):95–102
The mechanism of the increasing action of TA-993, a new 1,5- benzothiazepine derivative, on limb blood flow in anesthetized dogs: selective suppression of sympathetic nerve activity. Kaburaki M, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1167–73

EMBRYOLOGY

Expression of tissue transglutaminase in the developing chicken limb is associated both with apoptosis and endochondral ossification. Thomázy VA, et al. **Cell Death Differ** 1999 Feb;6(2):146–54
T-box genes and the formation of vertebrate forelimb- and hindlimb specific pattern. Simon H. **Cell Tissue Res** 1999 Apr;296(1):57–66 (71 ref.)
Gap junction signalling mediated through connexin-43 is required for chick limb development. Makarenkova H, et al. **Dev Biol** 1999 Mar 15;207(2):380–92
Independent development of sensory and motor innervation patterns in embryonic chick hindlimbs. Wang G, et al. **Dev Biol** 1999 Apr 15;208(2):324–36
p63 is a p53 homologue required for limb and epidermal morphogenesis. Mills AA, et al. **Nature** 1999 Apr 22; 398(6729):708–13
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Yang A, et al. **Nature** 1999 Apr 22;398(6729):714–8
Role of Pitx1 upstream of Tbx4 in specification of hindlimb identity [see comments] Logan M, et al. **Science** 1999 Mar 12;283(5408):1736–9. Comment in: Science 1999 Mar 12;283(5408):1615–6.
New findings reveal how legs take wing [news; comment] Vogel G. **Science** 1999 Mar 12;283(5408):1615–6. Comment on: Science 1999 Mar 12;283(5408):1736–9.
Upregulation of cathepsin D expression in the dedifferentiating salamander limb regenerates and enhancement of its expression by retinoic acid. Ju BG, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):349–57

GROWTH & DEVELOPMENT

Notch-mediated segmentation and growth control of the Drosophila leg. Rauskolb C, et al. **Dev Biol** 1999 Jun 15; 210(2):339–50
Role of the Bicoid-related homeodomain factor Pitx1 in specifying hindlimb morphogenesis and pituitary development. Szeto DP, et al. **Genes Dev** 1999 Feb 15; 13(4):484–94
Postnatal limb bone growth in relation to live weight in pigs from birth to 84 days of age. Liu MF, et al. **J Anim Sci** 1999 Jul;77(7):1693–701

INJURIES

Management of rupture of the gastrocnemius and superficial digital flexor muscles with a modified Thomas splint-cast combination in a horse. Lescun TB, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1457–9
Injury to the growth plate after Pemberton osteotomy. Leet AI, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):169–76
Radiographic diagnosis: avulsion fracture of the caudal cruciate ligament. Soderstrom MJ, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec;39(6):536–8
Repair of complete dorsal fracture of the proximal phalanx in two horses. Dechant JE, et al. **Vet Surg** 1998 Sep-Oct; 27(5):445–9
[Effect of superoxide dismutase on membrane fluidity and functions of lymphocytes in traumatized mice] Luo Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov;13(4):309–11 (Eng. Abstr.) **(Chi)**

INNERVATION

Hindlimb motor neurons require Cu/Zn superoxide dismutase for maintenance of neuromuscular junctions. Flood DG, et al. **Am J Pathol** 1999 Aug;155(2):663–72
Independent development of sensory and motor innervation patterns in embryonic chick hindlimbs. Wang G, et al. **Dev Biol** 1999 Apr 15;208(2):324–36
The lumbar preganglionic sympathetic supply to rat tail and hindpaw. Rathner JA, et al. **J Auton Nerv Syst** 1998 Apr 30;69(2-3):127–31
Input-output connections of the "hindlimb" region of the inferior olive in cats. Apps R. **J Comp Neurol** 1998 Oct 5;399(4):513–29
Ultrastructural observations on the expression of axonin-1: implications for the fasciculation of sensory axons during axonal outgrowth into the chick hindlimb. Xue Y, et al. **J Comp Neurol** 1999 Jun 7;408(3):299–317
Synaptic activation of plateaus in hindlimb motoneurons of decerebrate cats. Bennett DJ, et al. **J Neurophysiol** 1998 Oct;80(4):2023–37
Short-term plasticity in hindlimb motoneurons of decerebrate cats. Bennett DJ, et al. **J Neurophysiol** 1998 Oct; 80(4):2038–45
Reciprocal interactions in the turtle hindlimb enlargement contribute to scratch rhythmogenesis. Currie SN, et al. **J Neurophysiol** 1999 Jun;81(6):2977–87
Activation patterns of hindlimb motor units in the awake rat and their relation to motoneuron intrinsic properties. Gorassini M, et al. **J Neurophysiol** 1999 Aug;82(2):709–17
Reduced glycogen phosphorylase activity in denervated hindlimb muscles of rat is related to muscle atrophy and fibre type. Wallis MG, et al. **Life Sci** 1999;64(4):221–8
Differential response of fast hindlimb extensor and flexor muscles to exercise in adult spinalized cats. Roy RR, et al. **Muscle Nerve** 1999 Feb;22(2):230–41
Response properties of hind limb single motor units in normal rats and after carrageenan-induced inflammation. Solano R, et al. **Neuroscience** 1999;90(4):1393–402

METABOLISM

Age-related changes in oxygen and nutrient uptake by hindquarters in newborn pigs during cold-induced shivering. Lossec G, et al. **Exp Physiol** 1998 Nov; 83(6):793–807
Distribution and binding kinetics of ciprofloxacin and ofloxacin in the hindlimb of the rat. Sanchez-Navarro A, et al. **Pharm Res** 1999 Apr;16(4):587–91

PATHOLOGY

Clinical course of an antigen-induced arthritis model in the rabbit temporomandibular joint. Tominaga K, et al. **J Oral Pathol Med** 1999 Jul;28(6):268–73

PHYSIOLOGY

Sarcomere length-joint angle relationships of seven frog hindlimb muscles. Lieber RL, et al. **Acta Anat (Basel)** 1992; 145(4):289–95
Clomethiazole (ZENDRA, CMZ) improves hind limb motor function and reduces neuronal damage after severe spinal cord injury in rat. Farooque M, et al. **Acta Neuropathol (Berl)** 1999 Jul;98(1):22–30
EMG activity of three rat hindlimb muscles during microgravity and hypergravity phase of parabolic flight. Leterme D, et al. **Aviat Space Environ Med** 1998 Nov; 69(11):1065–70
The effects of unilateral pyramidal tract section on hindlimb motor performance in the rat. Metz GA, et al. **Behav Brain Res** 1998 Nov;96(1-2):37–46
Adaptation of rat lateral gastrocnemius muscle motor units during hindlimb unloading. Leterme D, et al. **Eur J Appl Physiol** 1999 Mar;79(4):312–7
Hindlimb suspension reduces muscle regeneration. Mozdziak PE, et al. **Eur J Appl Physiol** 1998 Jul;78(2):136–40
Spatial organization of proprioception in the cat spinocerebellum. Purkinje cell responses to passive foot rotation. Perciavalle V, et al. **Eur J Neurosci** 1998 Jun; 10(6):1975–85
Kinetic and energetic patterns for hindlimb obstacle avoidance during cat locomotion. McFadyen BJ, et al. **Exp Brain Res** 1999 Apr;125(4):502–10
Comparison of morphine-induced effects on thermal nociception, mechanoreception, and hind limb flexion in

chronic spinal rats. Advokat C, et al. **Exp Clin Psychopharmacol** 1999 Aug;7(3):219–25

In vivo tendon forces correlate with activity level and remain bounded: evidence in a rabbit flexor tendon model. Malaviya P, et al. **J Biomech** 1998 Nov;31(11):1043–9

Biomechanical studies of the rabbit patellar tendon after removal of its one-fourth or a half. Yamamoto N, et al. **J Biomech Eng** 1999 Jun;121(3):323–9

Nerve-independence of limb regeneration in larval Xenopus laevis is related to the presence of mitogenic factors in early limb tissues. Filoni S, et al. **J Exp Zool** 1999 Jul 1; 284(2):188–96

Retention of hindlimb stepping ability in adult spinal cats after the cessation of step training. De Leon RD, et al. **J Neurophysiol** 1999 Jan;81(1):85–94

Force of limb withdrawals elicited by graded noxious heat compared with other behavioral measures of carrageenan-induced hyperalgesia and allodynia. Tabo E, et al. **J Neurosci Methods** 1998 Jun 1;81(1-2):139–49

Consistent repeated M- and H-Wave recording in the hind limb of rats. Cliffer KD, et al. **Muscle Nerve** 1998 Nov; 21(11):1405–13

Differential response of fast hindlimb extensor and flexor muscles to exercise in adult spinalized cats. Roy RR, et al. **Muscle Nerve** 1999 Feb;22(2):230–41

Sensitivity of neurons in somatosensory cortex (S1) to cutaneous stimulation of the hindlimb immediately following a sciatic nerve crush. Barbay S, et al. **Somatosens Mot Res** 1999;16(2):103–14

Fibroblast growth factor receptors regulate the ability for hindlimb regeneration in Xenopus laevis. D'Jamoos CA, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):388–97

Pattern formation in dissociated limb bud mesenchyme in vitro and in vivo. Ide H, et al. **Wound Repair Regen** 1998 Jul-Aug;6(4):398–402 (12 ref.)

PHYSIOPATHOLOGY

The impact of muscular dystrophy on limb bone growth and scaling in mice. Lammers AR, et al. **Acta Anat (Basel)** 1998; 162(4):199–208

Relationship between hind limb lameness and radiographic signs of bone spavin in Icelandic horses in Sweden. Axelsson M, et al. **Acta Vet Scand** 1998;39(3):349–57

Isometric torque about the knee joint generated by microstimulation of the cat L6 spinal cord. Tai C, et al. **IEEE Trans Rehabil Eng** 1999 Mar;7(1):46–55

One-year changes in hind limb kinematics, ground reaction forces and knee stability in an experimental model of osteoarthritis. Suter E, et al. **J Biomech** 1998 Jun; 31(6):511–7

SURGERY

Venous drainage through bone marrow after replantation: an experimental study. Tanaka K, et al. **Br J Plast Surg** 1998 Dec;51(8):629–32

Total hip arthroplasty in nine canine hind limb amputees: a retrospective study. Preston CA, et al. **Vet Surg** 1999 Sep-Oct;28(5):341–7

TRANSPLANTATION

Microchimerism following allogeneic vascularized bone marrow transplantation--its possible role in induction of posttransplantation tolerance. Durlik M, et al. **Ann Transplant** 1998;3(1):24–6

Reconstitution of lymphoid tissue after vascularized bone marrow transplantation. Lukomska B, et al. **Ann Transplant** 1996;1(1):67–9

Body distribution of syngeneic and allogeneic cells from vascularized bone marrow graft. Olszewski WL, et al. **Ann Transplant** 1998;3(1):20–2

Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. Muramatsu K, et al. **J Hand Surg [Am]** 1999 May; 24(3):586–93

Determination of hindlimb transplantation-induced vascular albumin leakage and leukocyte activation during the acute phase of rejection. Gudemez E, et al. **J Reconstr Microsurg** 1999 Feb;15(2):133–41

Development of a mouse limb transplantation model. Zhang F, et al. **Microsurgery** 1999;19(5):209–13

In vivo microscopic assessment of cremasteric microcirculation during hindlimb allograft rejection in rats. Ozer K, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1949–56

Composite tissue allografts in rats: IV. Graft-versus-host disease in recipients of vascularized bone marrow transplants. Ramsamooj R, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1365–71

Successful limb transplantation across a multi-minor barrier facilitated by preceding engraftment of T-cell-purged donor and recipient bone marrow. Hiotis SP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):692–3

Orthotopic hindlimb transplantation in the rat: a technically challenging but useful animal model for solid organ engraftment. Hiotis SP, et al. **Transplant Proc** 1999 May; 31(3):1567–8

Requirement of stromal cells in the bone marrow transplant for rapid lymphoid replenishment. Janczewska S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):696–9

ULTRASONOGRAPHY

The axolotl as an animal model for the comparison of 3-D ultrasound with plain film radiography. Kulbisky GP, et al. **Ultrasound Med Biol** 1999 Jul;25(6):969–75

Ultrasonographic examination of the distal limb of cattle. Tryon KA, et al. **Vet Clin North Am Food Anim Pract** 1999 Jul;15(2):275–300 (31 ref.)

HINDLIMB IMMOBILIZATION see **HINDLIMB SUSPENSION**

HINDLIMB SUSPENSION

Bone and hormonal changes induced by skeletal unloading in the mature male rat. Dehority W, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E62–9

Effects of hindlimb suspension on cytosolic Ca2+ and [3H]ryanodine binding in cardiac myocytes. Halet G, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1131–6

Transforming growth factor-beta2 mRNA level in unloaded bone analyzed by quantitative in situ hybridization. Zhang R, et al. **Calcif Tissue Int** 1999 Jun;64(6):522–6

Adaptation of rat lateral gastrocnemius muscle motor units during hindlimb unloading. Leterme D, et al. **Eur J Appl Physiol** 1999 Mar;79(4):312–7

Evolution of contractile and elastic properties of rat soleus muscle fibres under unloading conditions. Toursel T, et al. **Exp Physiol** 1999 Jan;84(1):93–107

Effects of ovariectomy and hindlimb unloading on skeletal muscle. Fisher JS, et al. **J Appl Physiol** 1998 Oct; 85(4):1316–21

Capillary changes with fenestrations in the contralateral soleus muscle of the rat following unilateral limb immobilization. Oki S, et al. **J Orthop Sci** 1999;4(1):28–31

The rat suspension model is also a good tool for inducing muscle hyperactivity. Allaf O, et al. **Pflugers Arch** 1999 Feb;437(3):504–7

[Comparative analysis of changes in rats organisms exposed to microgravity and head-down suspension] Il'in EA, et al. **Aviakosm Ekolog Med** 1998;32(6):43–50 (Eng. Abstr.) **(Rus)**

[Functional activity of rat pancreatic endocrine cells in weightlessness and in a suspended state] Grigor'ev AI, et al. **Dokl Akad Nauk** 1998 Nov;363(2):267–70 **(Rus)**

ADVERSE EFFECTS

Myogenin, MyoD, and myosin heavy chain isoform expression following hindlimb suspension. Mozdziak PE, et al. **Aviat Space Environ Med** 1999 May;70(5):511–6

Influence of centrifugation and hindlimb suspension on testosterone and corticosterone excretion in rats. Ortiz RM, et al. **Aviat Space Environ Med** 1999 May;70(5):499–504

[Role of growth hormone underproduction and support load deficit in development of muscle atrophy and osteopenia in tail-suspended rats] Kaplanskii AS, et al. **Aviakosm Ekolog Med** 1999;33(1):20–4 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Changes in CNTF receptor alpha expression in rat skeletal muscle during the recovery period after hindlimb suspension. Guillet C, et al. **Acta Physiol Scand** 1998 Jul; 163(3):273–8

Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Carlson CJ, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):R601–6

Myogenin, MyoD, and myosin heavy chain isoform expression following hindlimb suspension. Mozdziak PE, et al. **Aviat Space Environ Med** 1999 May;70(5):511–6

Influence of centrifugation and hindlimb suspension on testosterone and corticosterone excretion in rats. Ortiz RM, et al. **Aviat Space Environ Med** 1999 May;70(5):499–504

Femoral vein ligation increases bone mass in the hindlimb suspended rat [see comments] Bergula AP, et al. **Bone** 1999 Mar;24(3):171–7. Comment in: Bone 1999 Mar;24(3):161–2.

Effect of a 14-day hindlimb suspension on beta-adrenoreceptors in rats. Bouzeghrane F, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 May;123(1):95–102

Novel transitions in MHC isoforms: separate and combined effects of thyroid hormone and mechanical unloading. Caiozzo VJ, et al. **J Appl Physiol** 1998 Dec;85(6):2237–48

Interaction of hyperthyroidism and hindlimb suspension on skeletal myosin heavy chain expression. Haddad F, et al. **J Appl Physiol** 1998 Dec;85(6):2227–36

PGAM-M expression is regulated pretranslationally in hindlimb muscles and under altered loading conditions. Kell R, et al. **J Appl Physiol** 1999 Jan;86(1):236–42

Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration. Mokhtarian A, et al. **J Appl Physiol** 1999 Mar;86(3):924–31

Reversal of weightlessness-induced musculoskeletal losses with androgens: quantification by MRI. Wimalawansa SM, et al. **J Appl Physiol** 1999 Jun;86(6):1841–6

Nitric oxide synthase inhibition reduces muscle inflammation and necrosis in modified muscle use. Pizza FX, et al. **J Leukoc Biol** 1998 Oct;64(4):427–33

Effects of hindlimb suspension on contractile properties of young and old rat muscles and the impact of electrical stimulation on the recovery process. Mercier C, et al. **Mech Ageing Dev** 1999 Jan 15;106(3):305–20

Alteration of spinal cord IGF-I receptors and skeletal muscle IGF-I after hind-limb immobilization in the rat. Suliman IA, et al. **Neuroreport** 1999 Apr 26;10(6):1195–9

HINDUISM

see related

MEDICINE, AYURVEDIC

Health profile of two social groups living in a squatter settlement in Calcutta. Ray S, et al. **Coll Antropol** 1998 Jun;22(1):247–57

On borderline phenomena. Kapadia S. **Int J Psychoanal** 1998 Jun;79 (Pt 3):513–28

Hinduism and medical practice. Sinha PK. **J Med Assoc Ga** 1998 Nov;87(4):312–4

How do Jains get toxoplasma infection? [letter] Hall SM, et al. **Lancet** 1999 Aug 7;354(9177):486–7

Female gene flow stratifies Hindu castes [letter] Bamshad MJ, et al. **Nature** 1998 Oct 15;395(6703):651–2

HIP

consider also terms at COX-

Clostridium septicum osteomyelitis with intramedullary gas on CT and MR imaging. Kihiczak D, et al. **AJR Am J Roentgenol** 1999 May;172(5):1457–8

Back and hip extensor muscle function during therapeutic exercises. Arokoski JP, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):842–50

Radiology case of the month. Paraplegia and hip swelling. Heterotopic ossification of soft tissues. Neitzschman HR. **J La State Med Soc** 1998 Oct;150(10):461–2

A ballet dancer with chronic hip pain due to a lesser trochanter bony avulsion: the challenge of a differential diagnosis. Quarrier NF, et al. **J Orthop Sports Phys Ther** 1998 Sep;28(3):168–73

Evaluation of spine and hip bone density by DXA and QCT in thalassemic patients. Danesi L, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:961–2

Transient osteoporosis of the hip. Corr P, et al. **S Afr Med J** 1999 May;89(5):525

[Pain in the hip area accompanied by a fever] Veldman BA, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1425–9 (Eng. Abstr.) **(Dut)**

ANATOMY & HISTOLOGY

Influence of hip position and gender on active hip internal and external rotation. Simoneau GG, et al. **J Orthop Sports Phys Ther** 1998 Sep;28(3):158–64

Oreopithecus was a bipedal ape after all: evidence from the iliac cancellous architecture. Rook L, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8795–9

BLOOD SUPPLY

Doppler ultrasonography is a potential tool for the assessment of hip vascularity [letter; comment] Robben SG, et al. **J Ultrasound Med** 1999 Apr;18(4):320. Comment on: J Ultrasound Med 1998 May;17(5):275–80; quiz 281–2.

GROWTH & DEVELOPMENT

Development and growth of immature hips. Vrdoljak J, et al. **Coll Antropol** 1998 Jun;22(1):107–12

INJURIES

Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures. Study of Osteoporotic Fractures Research Group. Arden NK, et al. **Arthritis Rheum** 1999 Jul;42(7):1378–85

Spontaneous or traumatic premature closure of the tibial tubercle. Tonino AJ. **Int Orthop** 1999;23(1):71–2

Tensor fascia lata muscle tear: evaluation by MRI. Asinger DA, et al. **Iowa Orthop J** 1998;18:146–9

Traumatic hip dislocation in childhood. Hamilton PR, et al. **J Pediatr Orthop** 1998 Sep-Oct;18(5):691–4

MR imaging of sports injuries of the hip. Kneeland JB. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):105–15, viii (16 ref.)

INNERVATION

Nerve injuries in total hip arthroplasty. DeHart MM, et al. **J Am Acad Orthop Surg** 1999 Mar-Apr;7(2):101–11 (32 ref.)

PATHOLOGY

Development of a desmoid tumor at the site of a total hip replacement. Gebhart M, et al. **Acta Orthop Belg** 1999 Jun; 65(2):230–4 (24 ref.)

Hip arthroscopy in Legg-Calve-Perthes disease. Kuklo TR, et al. **Arthroscopy** 1999 Jan-Feb;15(1):88–92

Hip involvement in seropositive rheumatoid arthritis. Survivorship analysis with a 15-year follow-up. Lehtimäki MY, et al. **Scand J Rheumatol** 1998;27(6):406–9

PHYSIOLOGY

Relationship between bone mineral density of the proximal femur and strength of hip muscles in postmenopausal women. Tan J, et al. **Am J Phys Med Rehabil** 1998 Nov-Dec;77(6):477–82

The coordinated movement of the lumbo-pelvic-hip complex during running: a literature review. Schache AG, et al.

Gait Posture 1999 Sep;10(1):30–47 (138 ref.)
Variations of relative anteversion of the femoral neck during walking [published erratum appears in Surg Radiol Anat 1999;21(1):54] Quesnel T. **Surg Radiol Anat** 1998; 20(6):425–9

PHYSIOPATHOLOGY

Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. Bauer DC, et al. **J Bone Miner Res** 1999 Aug; 14(8):1404–10

RADIOGRAPHY

The pattern of bone mineral density in the proximal femur and radiographic signs of early joint degeneration. Bruno RJ, et al. **J Rheumatol** 1999 Mar;26(3):636–40
Influence of heterotopic ossification of the hip on bone densitometry: a study in spinal cord injured patients. Jaovisidha S, et al. **Spinal Cord** 1998 Sep;36(9):647–53
Heterotopic ossification of the hip and bone densitometry [letter] Papadaki PJ, et al. **Spinal Cord** 1999 Jun;37(6):453–4
[Radiological assessment of the hip after Mittelmeier and Parhofer- Mönch stem implantation] Grzegorzewski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(6):535–9 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

The pitfalls of planar three-phase bone scintigraphy in nontraumatic hip avascular osteonecrosis. Scheiber C, et al. **Clin Nucl Med** 1999 Jul;24(7):488–94

SURGERY

Response to local anaesthetic injection as a predictor of successful hip surgery. Odoom JE, et al. **Clin Radiol** 1999 Jul;54(7):430–3
Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery. de Andrade JR, et al. **Orthopedics** 1999 Jan;22(1 Suppl):s113–8
A novel technique for securing lumbar epidural catheters in children undergoing hip surgery [letter] Bliss A, et al. **Paediatr Anaesth** 1999;9(5):469–70
[Transgluteal approach to the hip by anterior hemimyotomy of the gluteus medius] Thomine JM, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):520–5 (Eng. Abstr.) **(Fre)**
[Possibilities of avoiding an intra-femoral increase in pressure during hip revision surgery] Porsch M, et al. **Biomed Tech (Berl)** 1999 May;44(5):142–5 (Eng. Abstr.) **(Ger)**
[Experimental-morphological and clinical basis of preventive methods for the intraoperative complications of the amputation of the lower extremity at the thigh level] Zaryts'kyi OB, et al. **Klin Khir** 1998;(7):28–30 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Doppler ultrasonography is a potential tool for the assessment of hip vascularity [letter; comment] Robben SG, et al. **J Ultrasound Med** 1999 Apr;18(4):320. Comment on: J Ultrasound Med 1998 May;17(5):275–80; quiz 281–2.
Pediatric hip sonography. Diagnosis and differential diagnosis. Harcke HT, et al. **Radiol Clin North Am** 1999 Jul;37(4):787–96 (23 ref.)
[Ultrasound diagnosis of iliopectineal bursitis--contribution to differential diagnosis of leg swelling] Forstner R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):408–11 (Eng. Abstr.) **(Ger)**

HIP CONTRACTURE

COMPLICATIONS

Hip abductor contracture as a biomechanical factor in the development of the so-called "idiopathic scoliosis". Explanation of the etiology. Karski T. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:87–94

ETIOLOGY

Predicting the outcome of adductor tenotomy. Cottalorda J, et al. **Int Orthop** 1998;22(6):374–9

SURGERY

Predicting the outcome of adductor tenotomy. Cottalorda J, et al. **Int Orthop** 1998;22(6):374–9

HIP DISLOCATION

COMPLICATIONS

Failed cementless total hip arthroplasty for osteoarthrosis due to hip dysplasia. A minimum five-year follow-up study. Kawamoto K, et al. **Bull Hosp Jt Dis** 1998;57(3):130–5
Irreducible fracture-dislocation of the hip: a severe injury with a poor prognosis [letter] Johnson EE. **J Orthop Trauma** 1999 Jan;13(1):67–9
Closed treatment of hip dislocation in Down syndrome. Greene WB. **J Pediatr Orthop** 1998 Sep-Oct;18(5):643–7
Severity of injuries associated with traumatic hip dislocation as a result of motor vehicle collisions. Hak DJ, et al. **J Trauma** 1999 Jul;47(1):60–3
[Indentation fractures of the femoral head complicating the traumatic dislocation of the hip. Treatment by intertrochanteric osteotomy] Mascard E, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):258–63 (Eng. Abstr.) **(Fre)**

CONGENITAL see HIP DISLOCATION, CONGENITAL

ETIOLOGY

Asymmetric bilateral traumatic hip dislocation. Loupasis G, et al. **Arch Orthop Trauma Surg** 1998;118(3):179–80
Dislocation after total hip arthroplasty. Yuan L, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):263–6
Posterior dislocation of the hip while playing basketball. Tennent TD, et al. **Br J Sports Med** 1998 Dec;32(4):342–3
Causes of and treatment protocol for instability of total hip replacement. Dorr LD, et al. **Clin Orthop** 1998 Oct; (355):144–51
Salvage of total hip instability with a constrained acetabular component. Goetz DD, et al. **Clin Orthop** 1998 Oct; (355):171–81
Relationship of femoral head and acetabular size to the prevalence of dislocation. Kelley SS, et al. **Clin Orthop** 1998 Oct;(355):163–70
Dislocation after total hip arthroplasty using the anterolateral abductor split approach. Mallory TH, et al. **Clin Orthop** 1999 Jan;(358):166–72
A finite element analysis of factors influencing total hip dislocation. Scifert CF, et al. **Clin Orthop** 1998 Oct; (355):152–62
Pseudosubluxation of the hip joint. A case report. Tornetta P 3rd, et al. **Clin Orthop** 1999 Jul;(364):160–3
Orthopedic problems in Lesch-Nyhan syndrome. Sponseller PD, et al. **J Pediatr Orthop** 1999 Sep-Oct;19(5):596–602
Developmental hip dysplasia in hereditary motor and sensory neuropathy type 1. van Erve RH, et al. **J Pediatr Orthop** 1999 Jan-Feb;19(1):92–6
[Hip dislocation in children with cerebral palsy--the result of illness or treatment error] Tarczyńska M, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:95–102 (Eng. Abstr.) **(Pol)**

PATHOLOGY

Avascular necrosis after treatment of DDH: the protective influence of the ossific nucleus. Segal LS, et al. **J Pediatr Orthop** 1999 Mar-Apr;19(2):177–84
Location of the femoral head in developmental dysplasia of the hip: three-dimensional evaluation by means of magnetic resonance image. Suzuki S, et al. **J Pediatr Orthop** 1999 Jan-Feb;19(1):88–91
[Remodeling of the acetabulum after experimental hip joint dislocation--an animal experiment study of the rabbit] Raab P, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec; 136(6):519–24 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Planning acetabular redirection osteotomies based on joint contact pressures. Hipp JA, et al. **Clin Orthop** 1999 Jul; (364):134–43
Muscular and neurologic function in patients with recurrent dislocation after total hip arthroplasty: a matched controlled study of 65 patients using dual-energy X-ray absorptiometry and postural stability tests. Hedlundh U, et al. **J Arthroplasty** 1999 Apr;14(3):319–25

PREVENTION & CONTROL

Capsular replacement with synthetic mesh: effectiveness in preventing postoperative dislocation after wide resection of proximal femoral tumors and prosthetic reconstruction. Masterson EL, et al. **J Arthroplasty** 1998 Dec;13(8):860–6
Ultrasound screening for hips at risk in developmental dysplasia. Is it worth it? Paton RW, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):255–8

RADIOGRAPHY

Reliability of radiological measurements in the assessment of hip dysplasia in adults. Nelitz M, et al. **Br J Radiol** 1999 Apr;72(856):331–4
Planning acetabular redirection osteotomies based on joint contact pressures. Hipp JA, et al. **Clin Orthop** 1999 Jul; (364):134–43
Adduction hip deformity following anterior dislocation of the hip. Faraj AA, et al. **Injury** 1998 Jun;29(5):375–6
Radiology case of the month. Growing pains. Slipped capital femoral epiphysis. Schruff L, et al. **J La State Med Soc** 1999 Apr;151(4):165–7
The predictive value of computed tomography in the treatment of developmental dysplasia of the hip. Mandel DM, et al. **J Pediatr Orthop** 1998 Nov-Dec;18(6):794–8
Bilateral traumatic hip dislocation in a child: a case report and review of the literature. Sahin V, et al. **J Trauma** 1999 Mar;46(3):500–4 (23 ref.)
[Study of cotyloid anteversion by coxometric measurement] Fabeck L, et al. **J Radiol** 1998 Aug;79(8):743–50 (Eng. Abstr.) **(Fre)**

SURGERY

Acetabular augmentation for the treatment of unstable total hip arthroplasties. Nicholl JE, et al. **Ann R Coll Surg Engl** 1999 Mar;81(2):127–32
The Salter innominate osteotomy for the treatment of developmental dysplasia of the hip in young adults. Böhm P, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):186–9
Bilateral traumatic dislocation of the hip: simultaneously one hip anterior and the other posterior. Kaleli T, et al. **Arch Orthop Trauma Surg** 1998;117(8):479–80
Reconstruction of dislocated hips in children with cerebral palsy [editorial] Spencer JD. **BMJ** 1999 Apr 17; 318(7190):1021–2
Early experience and results with the periacetabular osteotomy. The Mayo Clinic experience. Crockarell J Jr, et al. **Clin Orthop** 1999 Jun;(363):45–53
Complications of periacetabular osteotomy. Davey JP, et al. **Clin Orthop** 1999 Jun;(363):33–7
Salvage of total hip instability with a constrained acetabular component. Goetz DD, et al. **Clin Orthop** 1998 Oct; (355):171–81
A comparison of different surgical approaches for the periacetabular osteotomy. Hussell JG, et al. **Clin Orthop** 1999 Jun;(363):64–72 (16 ref.)
Technical complications of the Bernese periacetabular osteotomy. Hussell JG, et al. **Clin Orthop** 1999 Jun; (363):81–92
Periacetabular osteotomy through the Smith-Petersen approach. Matta JM, et al. **Clin Orthop** 1999 Jun; (363):21–32
Results of periacetabular osteotomy in patients with previous surgery for hip dysplasia. Mayo KA, et al. **Clin Orthop** 1999 Jun;(363):73–80
Surgical correction of acetabular dysplasia in the adult. A Boston experience. Murphy SB, et al. **Clin Orthop** 1999 Jun;(363):38–44
Anterior femoroacetabular impingement after periacetabular osteotomy. Myers SR, et al. **Clin Orthop** 1999 Jun; (363):93–9
Bernese periacetabular osteotomy. Siebenrock KA, et al. **Clin Orthop** 1999 Jun;(363):9–20
The periacetabular osteotomy. Minimum 2 year followup in more than 100 hips. Trumble SJ, et al. **Clin Orthop** 1999 Jun;(363):54–63
Drain entrapment and titanium to ceramic head deposition: two unique complications following closed reduction of a dislocated total hip arthroplasty. Luchetti WT, et al. **J Arthroplasty** 1998 Sep;13(6):713–7
Unsuccessful surgical treatment of hip dislocation in congenital sensory neuropathy with anhidrosis. A case report. Köster G, et al. **J Bone Joint Surg Br** 1999 Jan; 81(1):102–5
'Floating pelvis'. A combination of bilateral hip dislocation with a lumbar ligamentous disruption. Levine RG, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):309–11
Irreducible fracture-dislocation of the hip: a severe injury with a poor prognosis [letter] Johnson EE. **J Orthop Trauma** 1999 Jan;13(1):67–9
Finding patients after 40 years: a very long term follow-up study of the Colonna arthroplasty. Boardman DL, et al. **J Pediatr Orthop** 1999 Mar-Apr;19(2):169–76
Universal lower-extremity positioning device for the spica frame. Givon U, et al. **J Pediatr Orthop** 1999 May-Jun; 19(3):351
The effect of unilateral varus rotational osteotomy with or without pelvic osteotomy on the contralateral hip in patients with perinatal static encephalopathy. Gordon JE, et al. **J Pediatr Orthop** 1998 Nov-Dec;18(6):734–7
Iatrogenic avascular necrosis of the hip in young children: a long-term follow-up. Gore DR. **J Pediatr Orthop** 1999 Sep-Oct;19(5):635–40
Avascular necrosis after treatment of DDH: the protective influence of the ossific nucleus. Segal LS, et al. **J Pediatr Orthop** 1999 Mar-Apr;19(2):177–84
Complications of osteotomies in severe cerebral palsy. Stasikelis PJ, et al. **J Pediatr Orthop** 1999 Mar-Apr; 19(2):207–10
Cementless total hip replacement in patients with developmental dysplasia of the hip. Huo MH, et al. **J South Orthop Assoc** 1998 Fall;7(3):171–9
[Osteotomy of the proximal femur for correction of post-traumatic changes] Strecker W, et al. **Chirurg** 1998 Nov;69(11):1153–60 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Closed reduction of posterior hip dislocation [letter] Anderson R. **Am J Orthop** 1999 Jul;28(7):401
Closed reduction of posterior hip dislocation: the Rochester method. Stefanich RJ. **Am J Orthop** 1999 Jan;28(1):64–5
Causes of and treatment protocol for instability of total hip replacement. Dorr LD, et al. **Clin Orthop** 1998 Oct; (355):144–51
Maneuvers for reducing dislocated hips. A new technique and a literature review. Nordt WE 3rd. **Clin Orthop** 1999 Mar;(360):260–4
Whistler technique used to reduce traumatic dislocation of the hip in the emergency department setting. Walden PD, et al. **J Emerg Med** 1999 May-Jun;17(3):441–4
Reduction of posterior hip dislocations in the lateral position using traction-countertraction: safer for the surgeon? Dahners LE, et al. **J Orthop Trauma** 1999 Jun-Jul;

13(5):373–4
The East Baltimore Lift: a simple and effective method for reduction of posterior hip dislocations [letter] Robinson MK. **J Orthop Trauma** 1999 Aug;13(6):461
The East Baltimore Lift: a simple and effective method for reduction of posterior hip dislocations. Schafer SJ, et al. **J Orthop Trauma** 1999 Jan;13(1):56–7
The fate of untreated developmental dislocation of the hip: long-term follow-up of eleven patients. Crawford AH, et al. **J Pediatr Orthop** 1999 Sep–Oct;19(5):641–4
Closed treatment of hip dislocation in Down syndrome. Greene WB. **J Pediatr Orthop** 1998 Sep–Oct;18(5):643–7
Open anterior dislocation of the hip in a child. García Mata S, et al. **J Pediatr Orthop B** 1998 Jul;7(3):232–4
Bilateral traumatic hip dislocation in a child: a case report and review of the literature. Sahin V, et al. **J Trauma** 1999 Mar;46(3):500–4 (23 ref.)

ULTRASONOGRAPHY

Development and growth of immature hips. Vrdoljak J, et al. **Coll Antropol** 1998 Jun;22(1):107–12

VETERINARY

Relationship between degenerative joint disease and hip joint laxity by use of distraction index and Norberg angle measurement in a group of cats [published erratum appears in J Am Vet Med Assoc 1999 Mar 1;214(5):659] Langenbach A, et al. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1439–43
Evaluation of the association between medial patellar luxation and hip dysplasia in cats. Smith GK, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):40–5

HIP DISLOCATION, CONGENITAL

Analysis of radiographic measurements as prognostic indicators of treatment success in patients with developmental dysplasia of the hip. Rosen A, et al. **J Pediatr Orthop B** 1999 Apr;8(2):118–21
Common orthopedic problems of the newborn. Fernbach SA. **Nurs Clin North Am** 1998 Dec;33(4):583–94 (60 ref.)

CLASSIFICATION

A new modification of rotationplasty in a patient with proximal femoral focal deficiency Pappas type II. Hamel J, et al. **J Pediatr Orthop B** 1999 Jul;8(3):200–2
Developmental dysplasia of the hip: a new approach to incidence. Bialik V, et al. **Pediatrics** 1999 Jan;103(1):93–9

COMPLICATIONS

Rotational acetabular osteotomy for advanced osteoarthrosis secondary to dysplasia of the hip.Results at 6–11 years postoperatively. Yasunaga Y, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):253–7

DIAGNOSIS

Screening for developmental dysplasia of the hip. French LM, et al. **Am Fam Physician** 1999 Jul;60(1):177–84, 187–8 (57 ref.)
The importance of combined clinical and sonographic examination of instability of the neonatal hip. Rosenberg N, et al. **Int Orthop** 1998;22(3):185–8
Neonatal detection of developmental dysplasia of the hip (DDH) [letter] Hadlow V. **J Bone Joint Surg Br** 1999 Jul; 81(4):744
Neonatal detection of developmental dysplasia of the hip (DDH) [editorial] Jones D. **J Bone Joint Surg Br** 1998 Nov;80(6):943–5
Utility of MRI in detecting obstacles to reduction in developmental dysplasia of the hip: comparison with two-directional arthrography and correlation with intraoperative findings. Aoki K, et al. **J Orthop Sci** 1999; 4(4):255–63
Variability in measurement of acetabular index in normal and dysplastic hips, before and after reduction. Skaggs DL, et al. **J Pediatr Orthop** 1998 Nov–Dec;18(6):799–801
Developmental dysplasia of the hip: a spectrum of abnormality. Harcke HT. **Pediatrics** 1999 Jan;103(1):152
Screening for hip instability in neonates and infants [editorial] Lee EH. **Singapore Med J** 1998 Jul;39(7):288–9
[Hip dislocation. Organization of screening and follow-up] Abuamara S, et al. **Arch Pediatr** 1999 Jun;6(6):675–82 (14 ref.) (Eng. Abstr.) **(Fre)**
[Why and how to examine the newborns' hips?] Philippet B, et al. **Rev Med Liege** 1998 Aug;53(8):470–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Clinical and diagnostic imaging of labrum lesions in the hip joint] Hofmann S, et al. **Orthopade** 1998 Oct;27(10):681–9 (31 ref.) (Eng. Abstr.) **(Ger)**
[Magnetic resonance tomography in therapy follow-up after repositioning treatment of congenital hip dislocation (see comments)] Franke J, et al. **Z Orthop Ihre Grenzgeb** 1998 May-Jun;136(3):205–9 (Eng. Abstr.). Comment in: Z Orthop Ihre Grenzgeb 1998 May-Jun;136(3):195–6. **(Ger)**
[Magnetic resonance tomography in congenital hip dysplasia and dislocation (editorial; comment)] Niethard FU. **Z Orthop Ihre Grenzgeb** 1998 May-Jun;136(3):195–6. Comment on: Z Orthop Ihre Grenzgeb 1998 May-Jun;136(3):205–9. Comment on: Z Orthop Ihre Grenzgeb 1998 May-Jun;136(3):210–4. **(Ger)**
[Magnetic resonance tomography in diagnosis and therapy follow-up of patients with congenital hip dysplasia and hip dislocation (see comments)] Wirth T, et al. **Z Orthop Ihre Grenzgeb** 1998 May-Jun;136(3):210–4 (Eng. Abstr.). Comment in: Z Orthop Ihre Grenzgeb 1998 May-Jun;136(3):195–6. **(Ger)**
[Developmental dysplasia of the hip (editorial)] Antón Rodrigálvarez LM. **An Esp Pediatr** 1998 Oct;49(4):337–8 **(Spa)**

EPIDEMIOLOGY

Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Yoshimura N, et al. **Br J Rheumatol** 1998 Nov; 37(11):1193–7
The prognostic importance of the ossific nucleus in the treatment of congenital dysplasia of the hip. Luhmann SJ, et al. **J Bone Joint Surg Am** 1998 Dec;80(12):1719–27
Developmental dysplasia of the hip: a new approach to incidence. Bialik V, et al. **Pediatrics** 1999 Jan;103(1):93–9

ETHNOLOGY

Untreated acetabular dysplasia of the hip in the Navajo. A 34 year case series followup. Schwend RM, et al. **Clin Orthop** 1999 Jul;(364):108–16

ETIOLOGY

[Natural history of congenital hip luxation] Jiménez Collado J. **An R Acad Nac Med (Madr)** 1998;115(2):335–45 **(Spa)**

HISTORY

Trendelenburg's test: 1895 [classical article] Trendelenburg F. **Clin Orthop** 1998 Oct;(355):3–7

PATHOLOGY

Cartilage and labrum degeneration in the dysplastic hip generally originates in the anterosuperior weight-bearing area: an arthroscopic observation. Noguchi Y, et al. **Arthroscopy** 1999 Jul–Aug;15(5):496–506
Hip arthroscopy for acetabular dysplasia: a pipe dream? McCarthy JC, et al. **Orthopedics** 1998 Sep;21(9):977–9

PHYSIOPATHOLOGY

Computer modeling of the pathomechanics of spastic hip dislocation in children. Miller F, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):486–92
The contribution of the ossific nucleus to the structural stiffness of the capital femoral epiphysis: a porcine model for DDH. Segal LS, et al. **J Pediatr Orthop** 1999 Jul–Aug; 19(4):433–7
They cannot sit properly or move around: seating and mobility during treatment for developmental dysplasia of the hip in children. Cox SL, et al. **Pediatr Rehabil** 1998 Jul–Sep;2(3):129–34
[Labrum lesions and residual dysplasia of the hip joint. Definition and prospectives] Tschauner C, et al. **Orthopade** 1998 Nov;27(11):772–8 (56 ref.) (Eng. Abstr.) **(Ger)**
[Labrum lesions in residual dysplasia of the hip joint. Biomechanical considerations on pathogenesis and treatment] Tschauner C, et al. **Orthopade** 1998 Nov; 27(11):725–32 (32 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Simulation of acetabular coverage of femoral head using anteroposterior pelvic radiographs. Kojima A, et al. **Arch Orthop Trauma Surg** 1998;117(6–7):330–6
Untreated acetabular dysplasia of the hip in the Navajo. A 34 year case series followup. Schwend RM, et al. **Clin Orthop** 1999 Jul;(364):108–16
Development of bony acetabulum in newborns with developmental hip dysplasia. Vrdoljak J, et al. **Coll Antropol** 1998 Dec;22 Suppl:173–7
Anteversion of the acetabulum in developmental dysplasia of the hip: analysis with computed tomography. Kim SS, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):438–42
Acetabular development after Salter's innominate osteotomy for congenital dislocation of the hip: evaluation by three-dimensional quantitative method. Takashi S, et al. **J Pediatr Orthop** 1998 Nov–Dec;18(6):802–6
Rotational profile of lower extremities in bladder exstrophy patients with unapproximated pelvis: a clinical and radiologic study in children older than 7 years. Yazici M, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):531–5
Femorocoxometry: angles and segments characteristic of dysplastic and dysmorphic hip conditions in adult. Measurement using a femorocoxometer for standard or reduced (digitized) films. Lequesne MG. **Rev Rhum Engl Ed** 1999 Mar;66(3):136–42
Three-dimensional CT measurement of adult acetabular dysplasia: technique, preliminary results in normal subjects, and potential applications. Janzen DL, et al. **Skeletal Radiol** 1998 Jul;27(7):352–8
[The Donauspital-Stolzalpe concept (Danube Hospital, Vienna, Austria). Corrective osteotomy with selective labrum surgery following preoperative MRI arthrography] Tschauner C, et al. **Orthopade** 1998 Nov;27(11):765–71 (42 ref.) (Eng. Abstr.) **(Ger)**
[Decreased acetabular anteversion and femur neck antetorsion cause pain and arthrosis. I: Statistics and clinical sequelae] Tönnis D, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar–Apr;137(2):153–9 (Eng. Abstr.) **(Ger)**

REHABILITATION

They cannot sit properly or move around: seating and mobility during treatment for developmental dysplasia of the hip in children. Cox SL, et al. **Pediatr Rehabil** 1998 Jul–Sep;2(3):129–34

SURGERY

Three-dimensional displacement of the hip joint after triple pelvic osteotomy. A postmortem radiostereometric study. de Kleuver M, et al. **Acta Orthop Scand** 1998 Dec; 69(6):585–9
Treatment of congenital dislocated hip by arthroplasty with femoral shortening. Chareancholvanich K, et al. **Clin Orthop** 1999 Mar;(360):127–35
Acetabular reconstruction in developmental dysplasia of the hip: results of the acetabular reinforcement ring with hook. Gill TJ, et al. **J Arthroplasty** 1999 Feb;14(2):131–7
Total hip arthroplasty with insertion of the acetabular component without cement in hips with total congenital dislocation or marked congenital dysplasia. Anderson MJ, et al. **J Bone Joint Surg Am** 1999 Mar;81(3):347–54
Medial protrusio technique for placement of a porous-coated, hemispherical acetabular component without cement in a total hip arthroplasty in patients who have acetabular dysplasia. Dorr LD, et al. **J Bone Joint Surg Am** 1999 Jan; 81(1):83–92
The treatment of subluxation of the hip in children over the age of four years [letter; comment] Kiely N, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):371. Comment on: J Bone Joint Surg Br 1998 Sep;80(5):757–61.
Treatment of developmental dysplasia of the hip after failed open reduction. Hsieh SM, et al. **J Formos Med Assoc** 1998 Nov;97(11):763–9
Utility of MRI in detecting obstacles to reduction in developmental dysplasia of the hip: comparison with two-directional arthrography and correlation with intraoperative findings. Aoki K, et al. **J Orthop Sci** 1999; 4(4):255–63
Open reduction and varus-detorsion osteotomy with femoral shortening in treatment of congenital dislocation of the hip. Ohsako H, et al. **J Orthop Sci** 1998;3(6):304–9
Asymmetric hip deformity and subluxation in cerebral palsy: an analysis of surgical treatment. Abel MF, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):479–85
Fate of the psoas muscle after open reduction for developmental dislocation of the hip (DDH). Bassett GS, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):425–32
Separation of the proximal femoral epiphysis after derotation varus osteotomy of the femur. Lahoti O, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):662–4
Computer modeling of the pathomechanics of spastic hip dislocation in children. Miller F, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):486–92
Acetabular development after Salter's innominate osteotomy for congenital dislocation of the hip: evaluation by three-dimensional quantitative method. Takashi S, et al. **J Pediatr Orthop** 1998 Nov–Dec;18(6):802–6
Sonographic hip screening and early management of developmental dysplasia of the hip. Falliner A, et al. **J Pediatr Orthop B** 1999 Apr;8(2):112–7
A new modification of rotationplasty in a patient with proximal femoral focal deficiency Pappas type II. Hamel J, et al. **J Pediatr Orthop B** 1999 Jul;8(3):200–2
Cementless total hip replacement in patients with developmental dysplasia of the hip. Huo MH, et al. **J South Orthop Assoc** 1998 Fall;7(3):171–9
Nerve injury in the prosthetic management of the dysplastic hip. Cameron HU, et al. **Orthopedics** 1998 Sep;21(9):980–1
Hip challenges: what would you do? Dorr LD, et al. **Orthopedics** 1998 Sep;21(9):1055–8
Congenital dysplasia of the hip in adults. Is there still room for surgical correction? [editorial] Lequesne M. **Rev Rhum Engl Ed** 1999 Jan;66(1):4–8
[Causative ananlysis for redislocation after operative reduction of congenital dislocation of hip] Wang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):28–30 (Eng. Abstr.) **(Chi)**
[Incidence of arthrosis in the results of the treatment of coxarthrosis in the young adult with Chiari's osteotomy. Retrospective study of 52 hips with 10.5 years of follow-up] Hulet C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Feb; 84(1):41–50 (Eng. Abstr.) **(Fre)**
[The Bernese method of periacetabular osteotomy] Leunig M, et al. **Orthopade** 1998 Nov;27(11):743–50 (38 ref.) (Eng. Abstr.) **(Ger)**
[The Boston concept. peri-acetabular osteotomy with simultaneous arthrotomy via direct anterior approach] Millis MB, et al. **Orthopade** 1998 Nov;27(11):751–8 (Eng. Abstr.) **(Ger)**
[The Osaka concept. "Dome osteotomy" with of without labrum resection] Ohzono K, et al. **Orthopade** 1998 Nov; 27(11):759–64 (Eng. Abstr.) **(Ger)**
[Acetabular rotations y triple pelvic osteotomy by the Tönnis method] Tönnis D, et al. **Orthopade** 1998 Nov;

27(11):733–42 (30 ref.) (Eng. Abstr.) **(Ger)**

[Artificial hip replacement in young patients with hip dysplasia--long-term outcome after 10 years] Porsch M, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):548–53 (36 ref.) (Eng. Abstr.) **(Ger)**

[Artificial hip joint implantation in stiff-man syndrome] Rittmeister M, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct; 136(5):428–32 (Eng. Abstr.) **(Ger)**

[Decreased acetabular anteversion and femur neck antetorsion cause pain and arthrosis. 2: Etiology, diagnosis and therapy] Tönnis D, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar–Apr;137(2):160–7 (Eng. Abstr.) **(Ger)**

[Growth disorders of the acetabular roof after acetabuloplasty in congenital hip dysplasia] Weber M, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):525–33 (Eng. Abstr.) **(Ger)**

[Hip joint deformity caused by osteochondrosis in the course of treatment of congenital dysplasia of the hip] Pucher A. **Chir Narzadow Ruchu Ortop Pol** 1998;63(5):423–30 (Eng. Abstr.) **(Pol)**

THERAPY

[Hip dislocation. Organization of screening and follow-up] Abuamara S, et al. **Arch Pediatr** 1999 Jun;6(6):675–82 (14 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Ultrasound measurements of the newborn hip--comparison of two methods in 657 newborns [letter; comment] Graf R. **Acta Orthop Scand** 1998 Oct;69(5):550–1. Comment on: Acta Orthop Scand 1998 Feb;69(1):21–4.

Ultrasonography for evaluation of hip dysplasia. Methods and policy in neonates, infants, and older children. Terjesen T. **Acta Orthop Scand** 1998 Dec;69(6):653–62

Echosonogrametric diagnosis of developmental dysplasia of the hip. Vrdoljak J, et al. **Coll Antropol** 1998 Dec;22 Suppl:179–84

Ultrasonography and developmental dysplasia of the infant hip [see comments] Grissom LE, et al. **Curr Opin Pediatr** 1999 Feb;11(1):66–9 (19 ref.). Comment in: Curr Opin Pediatr 1999 Feb;11(1):65–6.

Ultrasonography in developmental hip dysplasia [letter; comment] Ozçelik A. **J Bone Joint Surg Br** 1999 Jan; 81(1):179. Comment on: J Bone Joint Surg Br 1998 Mar;80(2):321–4.

Sonographic hip screening and early management of developmental dysplasia of the hip. Falliner A, et al. **J Pediatr Orthop B** 1999 Apr;8(2):112–7

The 'black hole' sign: a visual ultrasonographic sign of hip dislocation. Warner JG, et al. **J R Coll Surg Edinb** 1998 Oct;43(5):333–5

[The congenital dislocation of the hip joint in ultrasound examination--frequency, diagnosis and treatment] Merk H, et al. **Klin Padiatr** 1999 Jan–Feb;211(1):18–21 (Eng. Abstr.) **(Ger)**

[Ultrasound hip joint screening in newborn infants. Correlation of anamnestic risk factors and hip dysplasia] Rühmann O, et al. **Klin Padiatr** 1999 May–Jun;211(3):141–8 (Eng. Abstr.) **(Ger)**

[Hip ultrasound screening within the scope of U3--initial experiences] Altenhofen L, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):501–7 (Eng. Abstr.) **(Ger)**

[[So-called congenital hip dislocation--development of incidence, diagnosis and therapy in the last 7 years] Falliner A, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov–Dec; 136(6):487–91 (Eng. Abstr.) **(Ger)**

[Initial results of the evaluation study of ultrasound hip screening in Germany] Günther KP, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov–Dec;136(6):508–12 (Eng. Abstr.) **(Ger)**

[An ultrasound hip screening program--middle term results of flexion-abduction orthosis therapy] Mittelmeier H, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):513–8 (Eng. Abstr.) **(Ger)**

[Ultrasound and clinical screening for hip dysplasia-dislocation (editorial)] Niethard FU. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):485–6 **(Ger)**

[Ultrasound neonatal screening: the effect of anamnestic risk factors on hip dysplasia] Rühmann O, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):492–500 (Eng. Abstr.) **(Ger)**

[Importance of use of ultrasound in the early diagnosis and treatment of hip joint developmental disorders] Todorović Lj. **Srp Arh Celok Lek** 1998 Sep–Oct;126(9–10):399–401 (10 ref.) (Eng. Abstr.) **(Scc)**

HIP DYSPLASIA, CANINE

DIAGNOSIS

Relationships between results of the Ortolani method of hip joint palpation and distraction index, Norberg angle, and hip score in dogs. Puerto DA, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):497–501

Recent information about hip dysplasia. Arnbjerg J. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):921–34 (39 ref.)

EPIDEMIOLOGY

Prevalency data regarding hip dysplasia in dogs needs clarification [news; comment] Smith GK. **J Am Vet Med Assoc** 1999 Jan 1;214(1):27–8. Comment on: J Am Vet Med Assoc 1998 Nov 1;213(9):1270–3.

[Epidemiologic and genetic studies of canine hip dysplasia in a population of Labrador retrievers: a study over 25 years] Ohlerth S, et al. **DTW Dtsch Tierarztl Wochenschr** 1998 Oct;105(10):378–83 (Eng. Abstr.) **(Ger)**

GENETICS

An outcrossed canine pedigree for linkage analysis of hip dysplasia. Todhunter RJ, et al. **J Hered** 1999 Jan–Feb; 90(1):83–92

Analysis of randomly amplified polymorphic DNA (RAPD) for identifying genetic markers associated with canine hip dysplasia. Wang X, et al. **J Hered** 1999 Jan–Feb; 90(1):99–103

RADIOGRAPHY

Comparison of ventrodorsal and dorsoventral radiographic projections for hip dysplasia diagnosis. Saunders JH, et al. **Vet Rec** 1999 Jul 24;145(4):109–10

Dorsolateral subluxation of hip joints in dogs measured in a weight-bearing position with radiography and computed tomography [see comments] Farese JP, et al. **Vet Surg** 1998 Sep–Oct;27(5):393–405. Comment in: Vet Surg 1999 Mar–Apr;28(2):117–9.

A radiographic stress technique for evaluation of coxofemoral joint laxity in dogs. Flückiger MA, et al. **Vet Surg** 1999 Jan–Feb;28(1):1–9

Revealing hip joint laxity through the use of a stress radiographic technique [letter] Harrod M, et al. **Vet Surg** 1999 Jul–Aug;28(4):297–9

A stress-radiographic method to evaluate dogs for passive hip laxity [letter; comment] Smith GK, et al. **Vet Surg** 1999 Mar–Apr;28(2):117–9. Comment on: Vet Surg 1998 Sep–Oct;27(5):393–405.

THERAPY

Recent information about hip dysplasia. Arnbjerg J. **Vet Clin North Am Small Anim Pract** 1999 Jul;29(4):921–34 (39 ref.)

HIP DYSPLASIA, CONGENITAL see **HIP DISLOCATION, CONGENITAL**

HIP FRACTURES

Residential status and risk of hip fracture. Norton R, et al. **Age Ageing** 1999 Mar;28(2):135–9

Medical consultation for the elderly patient with hip fracture. Ackermann RJ. **J Am Board Fam Pract** 1998 Sep–Oct; 11(5):366–77 (78 ref.)

Hip fracture outcomes and their prevention in Kanawha County, West Virginia. Pfister AK, et al. **W V Med J** 1999 Jul–Aug;95(4):170–4

[Per- and subtrochanteric femur fractures] Wagner S, et al. **Unfallchirurg** 1999 Mar;102(3):206–22 (17 ref.) **(Ger)**

BLOOD

Serum fructosamine level and the risk of hip fracture in elderly women: a case-cohort study within the study of osteoporotic fractures. Jamal SA, et al. **Am J Med** 1998 Dec;105(6):488–93

CHEMICALLY INDUCED

Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group [letter] Baltzan MA, et al. **Lancet** 1999 Apr 17;353(9161):1327

Increased number of hip fractures [letter; comment] Schwab M, et al. **Lancet** 1999 Jun 19;353(9170):2160. Comment on: Lancet 1999 Mar 6;353(9155):802–5.

CLASSIFICATION

Biomechanical evaluation of impaction fractures of the femoral head. Konrath GA, et al. **J Orthop Trauma** 1999 Aug;13(6):407–13

COMPLICATIONS

Pseudoaneurysm of the profunda femoris artery due to intertrochanteric fracture of the hip. Murphy PG, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):117–8

Pressure sores and tube feeding in patients with a fracture of the hip: a randomized clinical trial. Hartgrink HH, et al. **Clin Nutr** 1998 Dec;17(6):287–92

Is there a reduced risk of breast cancer among women with hip fractures? Ganry O, et al. **Eur J Epidemiol** 1999 Apr; 15(4):313–5

Increased prevalence of fall risk factors in older people following hip fracture. Sherrington C, et al. **Gerontology** 1998;44(6):340–4

Avascular necrosis of the femoral head after intertrochanteric fractures [corrected and republished in J Orthop Trauma 1999 Feb;13(2):134–7] Baixauli EJ, et al. **J Orthop Trauma** 1999 Jan;13(1):9–12

Irreducible fracture-dislocation of the hip: a severe injury with a poor prognosis [letter] Johnson EE. **J Orthop Trauma** 1999 Jan;13(1):67–9

Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. LeBoff MS, et al. **JAMA** 1999 Apr 28;281(16):1505–11

The prevalence of malnutrition in elderly hip fracture patients. Hanger HC, et al. **N Z Med J** 1999 Mar 26; 112(1084):88–90

[Indentation fractures of the femoral head complicating the traumatic dislocation of the hip. Treatment by intertrochanteric osteotomy] Mascard E, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):258–63 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Added value of bone mineral density in hip fracture risk scores. Burger H, et al. **Bone** 1999 Sep;25(3):369–74

A ballet dancer with chronic hip pain due to a lesser trochanter bony avulsion: the challenge of a differential diagnosis. Quarrier NF, et al. **J Orthop Sports Phys Ther** 1998 Sep;28(3):168–73

Comparison of MRI with subchondral fracture in the evaluation of extent of epiphyseal necrosis in the early stage of Legg-Calvé-Perthes disease. Song HR, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):70–5

MR imaging of sports injuries of the hip. Kneeland JB. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):105–15, viii (16 ref.)

Incomplete intertrochanteric fractures: imaging features and clinical management. Schultz E, et al. **Radiology** 1999 Apr; 211(1):237–40

DIET THERAPY

Smoking, antioxidant vitamins, and the risk of hip fracture. Melhus H, et al. **J Bone Miner Res** 1999 Jan;14(1):129–35

ECONOMICS

The economic impact of geriatric hip fractures. Youm T, et al. **Am J Orthop** 1999 Jul;28(7):423–8 (47 ref.)

Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935–7

Supplemental calcium for the prevention of hip fracture: potential health-economic benefits. Bendich A, et al. **Clin Ther** 1999 Jun;21(6):1058–72

EPIDEMIOLOGY

Incidence of hip fractures in Malmö, Sweden, 1992–1995. A trend-break. Rogmark C, et al. **Acta Orthop Scand** 1999 Feb;70(1):19–22

Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Guo Z, et al. **Am J Epidemiol** 1998 Nov 1;148(9):887–92

Hip fractures among infertile women. Hesdorffer DC, et al. **Am J Epidemiol** 1999 May 1;149(9):810–3

Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Høidrup S, et al. **Am J Epidemiol** 1999 Jun 1;149(11):993–1001

Ex-smokers and risk of hip fracture. Forsén L, et al. **Am J Public Health** 1998 Oct;88(10):1481–3

Significant changes in the surgical methods and length of hospital stay of hip fracture patients occurring over 10 years in Central Finland. Huusko T, et al. **Ann Chir Gynaecol** 1999;88(1):55–60

Characteristics of male hip fracture patients. Huuskonen J, et al. **Ann Chir Gynaecol** 1999;88(1):48–53

Dietary vitamin A intake and risk for hip fracture [letter] Sigurdsson G. **Ann Intern Med** 1999 Sep 7;131(5):392

Identification of incident fractures: the Geelong Osteoporosis Study [see comments] Pasco JA, et al. **Aust N Z J Med** 1999 Apr;29(2):203–6. Comment in: Aust N Z J Med 1999 Apr;29(2):185–7.

Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Hagino H, et al. **Bone** 1999 Mar;24(3):265–70

The changing picture of hip fractures: dramatic change in age distribution and no change in age-adjusted incidence within 10 years in Central Finland. Huusko TM, et al. **Bone** 1999 Mar;24(3):257–9

Epidemiological study of hip fracture in Shenyang, People's Republic of China. Yan L, et al. **Bone** 1999 Feb;24(2):151–5

Hip fractures to treble by the year 2030 [news] **Bull World Health Organ** 1999;77(5):449

Is geographic variation in hip fracture rates related to current or former region of residence? Lauderdale DS, et al. **Epidemiology** 1998 Sep;9(5):574–7

Risk factors associated with increased falls in a hip fracture population [letter] Stewart A, et al. **Gerontology** 1999 Jul–Aug;45(4):233

Hospital separation rates from osteoporotic and non-osteoporotic fractures in metropolitan and rural Australia. Peach HG, et al. **Injury** 1999 Mar;30(2):101–3

Incidence of hip fracture in Kuwait. Memon A, et al. **Int J Epidemiol** 1998 Oct;27(5):860–5

Falls among community-dwelling elderly in Japan. Aoyagi K, et al. **J Bone Miner Res** 1998 Sep;13(9):1468–74

Hip fracture prediction in elderly men and women: validation in the Rotterdam study. De Laet CE, et al. **J Bone Miner Res** 1998 Oct;13(10):1587–93

Amelioration of osteopenia and hypovitaminosis D by

1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. Sato Y, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):64–8

Occupation and risk of hip fracture. Suen LK. **J Public Health Med** 1998 Dec;20(4):428–33

Increased number of hip fractures [letter; comment] Gillet P, et al. **Lancet** 1999 Jun 19;353(9170):2160–1. Comment on: Lancet 1999 Mar 6;353(9155):802–5.

Hip fractures in Finland between 1970 and 1997 and predictions for the future [see comments] Kannus P, et al. **Lancet** 1999 Mar 6;353(9155):802–5. Comment in: Lancet 1999 Mar 6;353(9155):769–70. Comment in: Lancet 1999 Jun 19;353(9170):2160. Comment in: Lancet 1999 Jun 19;353(9170):2160–1.

Prediction of burden of hip fracture [comment] Martyn CN, et al. **Lancet** 1999 Mar 6;353(9155):769–70. Comment on: Lancet 1999 Mar 6;353(9155):802–5.

The potential effect on hip fracture incidence of mass screening for osteoporosis [see comments] Pocock NA, et al. **Med J Aust** 1999 May 17;170(10):486–8. Comment in: Med J Aust 1999 May 17;170(10):459–60.

Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study [see comments] Sanders KM, et al. **Med J Aust** 1999 May 17;170(10):467–70. Comment in: Med J Aust 1999 May 17;170(10):459–60.

Hospitalization for hip fractures among North Carolina's Medicare population. Schenck AP, et al. **N C Med J** 1999 May-Jun;60(3):149–51

The prevalence and impact of self-reported hip fracture in elderly community-dwelling women: the Women's Health and Aging Study. Hochberg MC, et al. **Osteoporos Int** 1998;8(4):385–9

Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Kanis J, et al. **Osteoporos Int** 1999;9(1):45–54

International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Schwartz AV, et al. **Osteoporos Int** 1999;9(3):242–53

A secular trend in hip fracture incidence in East Germany. Wildner M, et al. **Osteoporos Int** 1999;9(2):144–50

[The incidence of hip fractures in pre- and postmenopausal women in Panama] Chue de Coto E. **Rev Med Panama** 1997 Jan;22(1):30–8 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Vertebral and hip fractures in Japan [comment] Nakamura T, et al. **Bull World Health Organ** 1999;77(5):430–1. Comment on: Bull World Health Organ 1999 ;77(5):416–22.

ETIOLOGY

Cervical hip fractures do not occur in arthrotic joints. A clinicoradiographic study of 256 patients. Dretakis EK, et al. **Acta Orthop Scand** 1998 Aug;69(4):384–6

Insufficiency fracture of the femoral head in patients with severe osteoporosis--report of 2 cases. Hagino H, et al. **Acta Orthop Scand** 1999 Feb;70(1):87–9

Are osteoporotic fractures due to osteoporosis? Impacts of a frailty pandemic in an aging world. Elffors L. **Aging (Milano)** 1998 Jun;10(3):191–204 (116 ref.)

Plant-based diets and bone health: nutritional implications. Anderson JJ. **Am J Clin Nutr** 1999 Sep;70(3 Suppl):539S–542S (17 ref.)

Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Høidrup S, et al. **Am J Epidemiol** 1999 Jun 1;149(11):993–1001

Smoking, smoking cessation, and risk of hip fracture in women. Cornuz J, et al. **Am J Med** 1999 Mar;106(3):311–4

Do all hip fractures result from a fall? Youm T, et al. **Am J Orthop** 1999 Mar;28(3):190–4 (36 ref.)

Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Melhus H, et al. **Ann Intern Med** 1998 Nov 15; 129(10):770–8

Risk factors for osteoporotic hip fractures in Mexicans. Clark P, et al. **Arch Med Res** 1998 Autumn;29(3):253–7

Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: a prospective controlled hip fracture study with 206 consecutive patients. Parkkari J, et al. **Calcif Tissue Int** 1999 Sep;65(3):183–7

Body mass and fracture risk. A study of 330 patients. Bernstein J, et al. **Clin Orthop** 1999 Jul;(364):227–30

Fractures of the hip: does the type of fall really affect the site of fracture? Hopkinson-Woolley JA, et al. **Injury** 1998 Oct;29(8):585–7

Traumatic apophyseal avulsion of the greater trochanter: case report and review of the literature. Mbubaegbu CE, et al. **Injury** 1998 Oct;29(8):647–9 (11 ref.)

How well do investigators estimate results in advance? A methodological study from a multinational epidemiological survey on hip fracture risks. Allander E. **Int J Technol Assess Health Care** 1998 Fall;14(4):728–34

Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency. Bruce DG, et al. **J Am Geriatr Soc** 1999 Mar;47(3):354–9

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. Black DM, et al. **J Bone Miner Res** 1999 May;14(5):821–8

Detection of risk of falling and hip fracture in women referred for bone densitometry [letter] Durward G, et al. **Lancet** 1999 Jul 17;354(9174):220–1

Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Gabriel SE, et al. **Med Decis Making** 1999 Apr-Jun;19(2):141–8

Oestrogen deficiency: an important risk marker for fractures. Vij U. **Natl Med J India** 1999 May-Jun;12(3):119–20

Ultrasound measurements at the proximal phalanges in healthy women and patients with hip fractures. Alenfeld FE, et al. **Osteoporos Int** 1998;8(5):393–8

Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Garnero P, et al. **Osteoporos Int** 1998; 8(6):563–9

Lifetime risk of hip fractures is underestimated. Oden A, et al. **Osteoporos Int** 1998;8(6):599–603

Characteristics of falls and risk of hip fracture in elderly men. Schwartz AV, et al. **Osteoporos Int** 1998;8(3):240–6

The epidemiology of osteoporosis. Practical implications for patient care. Goddard D, et al. **Postgrad Med** 1998 Oct; 104(4):54–6, 65, 69–72 (27 ref.)

[Simultaneous bilateral hip fracture] Carstensen JP, et al. **Ugeskr Laeger** 1998 Oct 19;160(43):6216–7 (Eng. Abstr.) **(Dan)**

[Severe osteoporosis during glucocorticoid therapy] Aitio ML, et al. **Duodecim** 1995;111(20):1949–53 **(Fin)**

GENETICS

Vitamin D receptor genotype and the risk of bone fractures in women. Feskanich D, et al. **Epidemiology** 1998 Sep; 9(5):535–9

Apolipoprotein E polymorphism: A new genetic marker of hip fracture risk--The Study of Osteoporotic Fractures, Cauley JA, et al. **J Bone Miner Res** 1999 Jul;14(7):1175–81

METABOLISM

Low IGF-I levels in hip fracture patients. A comparison of 20 coxarthrotic and 23 hip fracture patients. Hedström M, et al. **Acta Orthop Scand** 1999 Apr;70(2):145–8

Protein supplements after osteoporotic hip fracture [letter; comment] Craig RM. **Ann Intern Med** 1998 Dec 15; 129(12):1076. Comment on: Ann Intern Med 1998 May 15;128(10):801–9.

Protein supplements after osteoporotic hip fracture [letter; comment] Kelly KG. **Ann Intern Med** 1998 Dec 15; 129(12):1075–6; discussion 1076. Comment on: Ann Intern Med 1998 May 15;128(10):801–9.

Changes of biochemical markers during fracture healing. Ohishi T, et al. **Arch Orthop Trauma Surg** 1998; 118(3):126–30

MORTALITY

Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935–7

Reproductive factors and fatal hip fractures. A Norwegian prospective study of 63,000 women. Jacobsen BK, et al. **J Epidemiol Community Health** 1998 Oct;52(10):645–50

Osteoporotic fractures in Cornwall [letter; comment] Pande I, et al. **Lancet** 1999 May 15;353(9165):1707. Comment on: Lancet 1999 Mar 13;353(9156):878–82.

Hip fracture in the elderly: the effect of anesthetic technique. Koval KJ, et al. **Orthopedics** 1999 Jan;22(1):31–4

[Hip fracture mortality (letter; comment)] Falch JA, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3674. Comment on: Tidsskr Nor Laegeforen 1998 Aug 10;118(18):2764–6. **(Nor)**

NURSING

Hip fracture. Caring for a fragile population. Yarnold BD. **Am J Nurs** 1999 Feb;99(2):36–40; quiz 41 (10 ref.)

PATHOLOGY

Bone density reduction in various measurement sites in men and women with osteoporotic fractures of spine and hip: the European quantitation of osteoporosis study. Kröger H, et al. **Calcif Tissue Int** 1999 Mar;64(3):191–9

Fractures of the hip: does the type of fall really affect the site of fracture? Hopkinson-Woolley JA, et al. **Injury** 1998 Oct;29(8):585–7

Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis. Bell KL, et al. **J Bone Miner Res** 1999 Jan;14(1):111–9

Proximal femur: assessment for osteoporosis with T2* decay characteristics at MR imaging. Link TM, et al. **Radiology** 1998 Nov;209(2):531–6

PHYSIOPATHOLOGY

Intramedullary versus extramedullary fixation of subtrochanteric fractures. A biomechanical study. Kummer FJ, et al. **Acta Orthop Scand** 1998 Dec;69(6):580–4

Sense of coherence, quality of life, and function among elderly hip fracture patients. Johansson I, et al. **Aging (Milano)** 1998 Oct;10(5):377–84

Bone loss after hip fracture is correlated to the postoperative degree of mobilisation. Zerahn B, et al. **Arch Orthop Trauma Surg** 1998;117(8):453–6

Bone mineral density, body mass index, and hip axis length in postmenopausal cretan women with cervical and trochanteric fractures. Dretakis EK, et al. **Calcif Tissue Int** 1999 Mar;64(3):257–8

Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur. Lochmüller EM, et al. **Osteoporos Int** 1998;8(6):591–8

Weight variability, weight change and the incidence of hip fracture: a prospective study of 39,000 middle-aged Norwegians. Meyer HE, et al. **Osteoporos Int** 1998; 8(4):373–8

How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Schott AM, et al. **Osteoporos Int** 1998;8(3):247–54

[Biomechanical observation on unstable intertrochanteric fracture fixed by 130 degrees angled-plate] Li F, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jun;35(6):340–3 (Eng. Abstr.) **(Chi)**

PREVENTION & CONTROL

Hip protectors and hip fractures [letter] Jäntti PO, et al. **Age Ageing** 1998 Nov;27(6):758–9

Vitamin K intake and hip fractures in women: a prospective study. Feskanich D, et al. **Am J Clin Nutr** 1999 Jan; 69(1):74–9

Protein intake and the risk of hip fracture in postmenopausal women [letter] Lavine JB. **Am J Clin Nutr** 1999 Aug; 70(2):303

Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Munger RG, et al. **Am J Clin Nutr** 1999 Jan;69(1):147–52

Comparison of force attenuation properties of four different hip protectors under simulated falling conditions in the elderly: an in vitro biomechanical study. Kannus P, et al. **Bone** 1999 Aug;25(2):229–35

Supplemental calcium for the prevention of hip fracture: potential health-economic benefits. Bendich A, et al. **Clin Ther** 1999 Jun;21(6):1058–72

Developing a strategy for the prevention of hip fractures in the elderly due to osteoporosis: the application of economics to the findings from a clinical trial. Phillips CJ, et al. **Int J Clin Pract** 1998 Jul-Aug;52(5):335–40 (29 ref.)

An economic evaluation of energy-absorbing flooring to prevent hip fractures. Zacker C, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):446–57

Effect on the femur of a new hip fracture preventive system using dropped-weight impact testing. Okuizumi H, et al. **J Bone Miner Res** 1998 Dec;13(12):1940–5

Oral contraceptives and risk of hip fractures [letter; comment] La Vecchia C, et al. **Lancet** 1999 Jul 24;354(9175):335–6 . Comment on: Lancet 1999 May 1;353(9163):1481–4.

Oral-contraceptive use and risk of hip fracture: a case-control study [see comments] Michaëlsson K, et al. **Lancet** 1999 May 1;353(9163):1481–4. Comment in: Lancet 1999 Jul 24;354(9175):335–6.

The hip fracture threat [editorial; comment] Morris HA, et al. **Med J Aust** 1999 May 17;170(10):459–60. Comment on: Med J Aust 1999 May 17;170(10):467–70. Comment on: Med J Aust 1999 May 17;170(10):486–8.

A qualitative investigation into the receptivity to hip protective underwear among staff and residents of residential institutions. Butler M, et al. **N Z Med J** 1998 Oct 9;111(1075):383–5

Separate and combined value of bone mass and gait speed measurements in screening for hip fracture risk: results from the EPIDOS study. Epidémiologie de l'Ostéoporose. Dargent-Molina P, et al. **Osteoporos Int** 1999;9(2):188–92

Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study Group. Michaëlsson K, et al. **Osteoporos Int** 1998; 8(6):540–6

Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Tanizawa T, et al. **Osteoporos Int** 1999; 9(2):163–70

[Costs of different intervention strategies to prevent hip fractures] Vestergaard P, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4400–5 (Eng. Abstr.) **(Dan)**

[Compliance in use of external protectors for hip fractures among the community elderly in Japan] Suzuki T, et al. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):40–4 (Eng. Abstr.) **(Jpn)**

[Time to take the regional program for prevention of injuries seriously. Reduced number of hip fractures is the most obvious benefit of the Falun project] Bjerre B, et al. **Lakartidningen** 1999 Apr 21;96(16):1982, 1985–6, 1988 (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Sense of coherence, quality of life, and function among elderly hip fracture patients. Johansson I, et al. **Aging (Milano)** 1998 Oct;10(5):377–84

Outcomes following acute hospital care for stroke or hip fracture: how useful is an assessment of anxiety or depression for older people? Bond J, et al. **Int J Geriatr Psychiatry** 1998 Sep;13(9):601–10

Mental distress and risk of hip fracture. Do broken hearts lead to broken bones? Forsén L, et al. **J Epidemiol Community Health** 1999 Jun;53(6):343–7

RADIOGRAPHY

Identification of incident fractures: the Geelong Osteoporosis Study [see comments] Pasco JA, et al. **Aust N Z J Med** 1999 Apr;29(2):203–6. Comment in: Aust N Z J Med 1999 Apr;29(2):185–7.

John Thomas sign: common distraction or useful pointer? [letter] Thomas MC, et al. **Med J Aust** 1998 Dec 7–21; 169(11–12):670

Trochanteric hip fracture: strong association with spinal trabecular bone mineral density measured with quantitative CT. Lang TF, et al. **Radiology** 1998 Nov;209(2):525–30

[Clinical and radiological assessment of proximally coated stems in growth in total hip replacement] Blacha J, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):333–40 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Low IGF-I levels in hip fracture patients. A comparison of 20 coxarthrotic and 23 hip fracture patients. Hedström M, et al. **Acta Orthop Scand** 1999 Apr;70(2):145–8

REHABILITATION

Outcomes of protocol-based and adaptation-based occupational therapy interventions for low-income elderly persons on a transitional unit. Spencer J, et al. **Am J Occup Ther** 1999 Mar–Apr;53(2):159–70

Cognitive status at admission: does it affect the rehabilitation outcome of elderly patients with hip fracture? Heruti RJ, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):432–6

Benefits of home health care after inpatient rehabilitation for hip fracture: health service use by Medicare beneficiaries, 1987–1992. Intrator O, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1195–9

Home-based multicomponent rehabilitation program for older persons after hip fracture: a randomized trial. Tinetti ME, et al. **Arch Phys Med Rehabil** 1999 Aug;80(8):916–22

Rehabilitation length of stay after hip fracture [letter] Cameron ID, et al. **Aust N Z J Med** 1998 Aug;28(4):480

Anaesthesia in orthogeriatric rehabilitation [letter; comment] Alladi VR. **Hosp Med** 1998 Oct;59(10):825. Comment on: Hosp Med 1998 Apr;59(4):274–6.

Functional outcomes of posthospital care for stroke and hip fracture patients under medicare. Kane RL, et al. **J Am Geriatr Soc** 1998 Dec;46(12):1525–33

Dynamic beat-to-beat QT-RR relationship during physiotherapy effort in elderly patients without primary heart disease. Arad M, et al. **Pacing Clin Electrophysiol** 1999 Aug;22(8):1240–4

The Sir John McNee bequest. England v. Australia: a comparison of management of fractures at the hip. Summary of a report on a period of elective study in Melbourne. Mitra S. **Trans Med Soc Lond** 1996–97; 113:94–100

[Accidental fall-induced, proximal femoral fracture in the elderly--etiology and rehabilitation] Herrmann R, et al. **Z Gerontol Geriatr** 1999 Feb;32(1):52–7 (Eng. Abstr.) **(Ger)**

SURGERY

RAB-plate vs Richards CHS plate for unstable trochanteric hip fractures--a randomized study of 233 patients with 1-year follow-up [letter; comment] Parker MJ. **Acta Orthop Scand** 1999 Feb;70(1):101–2. Comment on: Acta Orthop Scand 1998 Feb;69(1):25–8.

Postoperative mental impairment in hip fracture patients. A randomized study of reorientation measures in 223 patients. Strömberg L, et al. **Acta Orthop Scand** 1999 Jun;70(3):250–5

Dimon-Hughston osteotomy [letter; comment] Brackett B. **Am J Orthop** 1999 Apr;28(4):266. Comment on: Am J Orthop 1998 Sep;27(9):612–6.

Fixing intertrochanteric fractures [letter] Brackett B. **Am J Orthop** 1999 Aug;28(8):450

Clinical evaluation of the Alta hip bolt in peritrochanteric hip fractures [see comments] Rao JP, et al. **Am J Orthop** 1998 Sep;27(9):612–6. Comment in: Am J Orthop 1999 Apr;28(4):266.

Significant changes in the surgical methods and length of hospital stay of hip fracture patients occurring over 10 years in Central Finland. Huusko T, et al. **Ann Chir Gynaecol** 1999;88(1):55–60

The medical consultant's role in caring for patients with hip fracture [letter; comment] Zaveri KG. **Ann Intern Med** 1999 Jan 5;130(1):76–7. Comment on: Ann Intern Med 1998 Jun 15;128(12 Pt 1):1010–20.

The classic nail in the therapy of trochanteric fractures.A prospective, controlled study. Fritz T, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):308–14

Prospective randomized comparison of gliding nail and gamma nail in the therapy of trochanteric fractures. Fritz T, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):1–6

Spontaneous subcapital femoral neck fracture complicating a healed intertrochanteric fracture. Kanai H, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):271–5

Deep vein thrombosis in elderly Hong Kong Chinese with hip fractures detected with compression ultrasound and Doppler imaging: incidence and effect of low molecular weight heparin. Kew J, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):156–8

Ipsilateral fractures of the pelvis and the femur--floating hip? A retrospective analysis of 42 cases. Müller EJ, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):179–82

Volume kinetics of Ringer solution after surgery for hip fracture. Svensén C, et al. **Can J Anaesth** 1999 Feb; 46(2):133–41

A reinforced rigid fixation device for unstable intertrochanteric fractures. Baixauli F, et al. **Clin Orthop** 1999 Apr;(361):205–15

The compares a unipolar with a bipolar prosthesis of similar stem design [letter; comment] Calder S. **Clin Orthop** 1999 Feb;(359):259. Comment on: Clin Orthop 1998 Mar;(348):67–71.

Blood conservation in hip trauma. Schmidt AH, et al. **Clin Orthop** 1998 Dec;(357):68–73 (24 ref.)

Perioperative myocardial ischaemia in patients undergoing surgery for fractured hip randomized to incremental spinal, single-dose spinal or general anaesthesia. Juelsgaard P, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):656–63

Fixed nail plates versus sliding hip systems for the treatment of trochanteric femoral fractures: a meta analysis of 14 studies. Chinoy MA, et al. **Injury** 1999 Apr;30(3):157–63

A simple laser guide to reduce the screening time during the insertion of dynamic hip screws. Conn KS, et al. **Injury** 1998 Sep;29(7):539–41

Subtrochanteric missile fractures of the femur. Nikolić D, et al. **Injury** 1998 Dec;29(10):743–9

Failure of femoral head fixation: a cadaveric analysis of lag screw cut-out with the gamma locking nail and the AO dynamic hip screw [letter; comment] Parker MJ. **Injury** 1998 Sep;29(7):569. Comment on: Injury 1997 Jun-Jul;28(5–6):337–41.

Early failure of spiral blade using with an unreamed femoral nail: a case report. Qureshi F, et al. **Injury** 1999 Apr; 30(3):219–20

The AO/ASIF-proximal femoral nail (PFN): a new device for the treatment of unstable proximal femoral fractures. Simmermacher RK, et al. **Injury** 1999 Jun;30(5):327–32

Treatment of intertrochanteric fracture with the Gamma AP locking nail or by a compression hip screw--a randomised prospective trial. Park SR, et al. **Int Orthop** 1998; 22(3):157–60

Intraoperative type 1 proximal femoral fractures: influence on the stability of hydroxyapatite-coated femoral components. Falez F, et al. **J Arthroplasty** 1998 Sep; 13(6):653–9

Hemiarthroplasty in hip fracture care: effects of surgical volume on short-term outcome. Lavernia CJ. **J Arthroplasty** 1998 Oct;13(7):774–8

Avulsion fracture of the lesser trochanter as a result of a preliminary malignant tumor of bone. A report of four cases. Afra R, et al. **J Bone Joint Surg Am** 1999 Sep; 81(9):1299–304

Clinical results using the trochanter stabilizing plate (TSP): the modular extension of the dynamic hip screw (DHS) for internal fixation of selected unstable intertrochanteric fractures. Babst R, et al. **J Orthop Trauma** 1998 Aug; 12(6):392–9

Avascular necrosis of the femoral head after intertrochanteric fractures [corrected and republished article originally printed in J Orthop Trauma 1999 Jan;13(1):9–12] Baixauli EJ, et al. **J Orthop Trauma** 1999 Feb;13(2):134–7

Results of intertrochanteric femur fractures treated with a 135-degree sliding screw with a two-hole side plate. Bolhofner BR, et al. **J Orthop Trauma** 1999 Jan;13(1):5–8

Irreducible fracture-dislocation of the hip: a severe injury with a poor prognosis [letter] Johnson EE. **J Orthop Trauma** 1999 Jan;13(1):67–9

Irreducible fracture-dislocation of the hip: a severe injury with a poor prognosis [letter] Johnson EE. **J Orthop Trauma** 1999 Mar–Apr;13(3):228–9

The effects of nutritional status on outcome after hip fracture. Koval KJ, et al. **J Orthop Trauma** 1999 Mar–Apr; 13(3):164–9

Decompression and stable internal fixation of femoral neck fractures in children can affect the outcome. Cheng JC, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):338–43

Further uses of polymethylmethacrylate in orthopaedic surgery [letter; comment] Haddad FS, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):65–6. Comment on: J R Coll Surg Edinb 1998 Oct;43(5):360.

How best to fix a broken hip. Fractured Neck of Femur Health Outcomes Project Team. March LM, et al. **Med J Aust** 1999 May 17;170(10):489–94

Catatonia responsive to lorazepam: a case report. Rosenfeld MJ, et al. **Mov Disord** 1999 Jan;14(1):161–2

Hip fracture in the elderly: the effect of anesthetic technique. Koval KJ, et al. **Orthopedics** 1999 Jan;22(1):31–4

Incomplete intertrochanteric fractures: imaging features and clinical management. Schultz E, et al. **Radiology** 1999 Apr; 211(1):237–40

Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair [see comments] Carson JL, et al. **Transfusion** 1999 Jul; 39(7):694–700. Comment in: Transfusion 1999 Jul;39(7):665–9.

Early development of deep-vein thrombosis following hip fracture surgery: the role of venous wall thickening detected by B-mode ultrasonography. Cracowski JL, et al. **Vasc Med** 1998;3(4):269–74

[Ipsilateral hip and femoral shaft fractures: components of therapeutic choice] Laporte C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Mar; 85(1):24–32 (Eng. Abstr.) **(Fre)**

[Indentation fractures of the femoral head complicating the traumatic dislocation of the hip. Treatment by intertrochanteric osteotomy] Mascard E, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):258–63 (Eng. Abstr.) **(Fre)**

[Fracture of the great trochanter treated by dynamic hip screw plate: measure of impaction according to fracture type] Oger P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):539–45 (Eng. Abstr.) **(Fre)**

[Ender nailing of trochanteric fractures (report of 100 cases)] Ezzaouia K, et al. **Tunis Med** 1999 Feb;77(2):95–100 **(Fre)**

[Osteotomy of the proximal femur for correction of post-traumatic changes] Strecker W, et al. **Chirurg** 1998 Nov;69(11):1153–60 (28 ref.) (Eng. Abstr.) **(Ger)**

[Importance of blade geometry for stability of fixation with short intramedullary nailing systems for the proximal end of the femur (gliding nail)] Friedl W, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1224–6 (Eng. Abstr.) **(Ger)**

[The Richard classic nail (intramedullary hip screw, IMHS) as unreamed intramedullary nail in osteosynthesis treatment of pertrochanteric fractures] Weiss C, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1191–3 (Eng. Abstr.) **(Ger)**

[Long-term outcome of hip-operated geriatric patients] Hager K, et al. **Rehabilitation (Stuttg)** 1998 Aug; 37(3):128–33 (Eng. Abstr.) **(Ger)**

[Classic nail versus DHS. A prospective randomised study of fixation of trochanteric femur fractures] Hoffmann R, et al. **Unfallchirurg** 1999 Mar;102(3):182–90 (Eng. Abstr.) **(Ger)**

[Periprosthetic femur shaft fracture. Indications and outcome in 51 patients] Siegmeth A, et al. **Unfallchirurg** 1998 Dec; 101(12):901–6 (Eng. Abstr.) **(Ger)**

[Solution to the problem of extra-articular, femoral hip fracture by the "sliding screw-nail principle". Results of 2 different systems (classical nail and gamma nail)] Wagner R, et al. **Unfallchirurg** 1998 Dec;101(12):894–900 (Eng. Abstr.) **(Ger)**

[Clinical and radiological assessment of proximally coated stems in growth in total hip replacement] Blacha J, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):333–40 (Eng. Abstr.) **(Pol)**

[Selected aspects of treatment of trochanteric fractures by the Ender method] Niedziółka J, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(2):189–93 (Eng. Abstr.) **(Pol)**

[Comparing results of the treatment of fractures and osteotomies in the trochanteric femoral region with the osteosynthesis of Zespol method] Pizio ZJ. **Chir Narzadow Ruchu Ortop Pol** 1999;64(2):195–9 (Eng. Abstr.) **(Pol)**

[Hip Zespol fixator in osteosynthesis for trochanteric fracture] Przybyszewski J, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(1):39–44 (Eng. Abstr.) **(Pol)**

[Modified Ender nail in the treatment of unstable peritrochanteric fractures] Semenowicz J. **Chir Narzadow Ruchu Ortop Pol** 1999;64(2):181–7 (Eng. Abstr.) **(Pol)**

[Ender nails in the stabilization of trochanteric fractures of the femur in the elderly] Wójcik B, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(3):279–83 (Eng. Abstr.) **(Pol)**

[Surgery provides symptomatic relief in skeletal metastases] Nilsson J, et al. **Lakartidningen** 1999 Mar 3;96(9):1000–5 (Eng. Abstr.) **(Swe)**

THERAPY

Is preoperative tibial traction responsible for peroneal nerve palsy in patients with a fractured hip? Levi N. **Acta Orthop Belg** 1998 Sep;64(3):273–6

Long-term outcome in children with fractures of the proximal femur after high-energy trauma. Pape HC, et al. **J Trauma** 1999 Jan;46(1):58–64

The Mt. Tyndall incident. Braude D, et al. **Prehosp Emerg Care** 1999 Apr–Jun;3(2):167–9

[A reference program on hip fractures (letter)] Lauridsen UB. **Ugeskr Laeger** 1998 Dec 7;160(50):7280 **(Dan)**

[The treatment of middle-aged and elderly patients suffering from trochanteric fractures of the femur] Nikolenko VK, et al. **Voen Med Zh** 1998 Oct;319(10):49–57, 95 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Does combining the results from multiple bone sites measured by a new quantitative ultrasound device improve discrimination of hip fracture? Hans D, et al. **J Bone Miner Res** 1999 Apr;14(4):644–51

VETERINARY

Salter-Harris type III fracture of the proximal femoral physis in a puppy. Lipscomb VJ, et al. **Vet Rec** 1998 Nov 28; 143(22):616–7

HIP JOINT

Synovial chondromatosis associated with osteopoikilosis--a case report. Havitçioglu H, et al. **Acta Orthop Scand** 1998

Dec;69(6):649–50

RAB–plate vs Richards CHS plate for unstable trochanteric hip fractures—a randomized study of 233 patients with 1–year follow–up [letter; comment] Parker MJ. **Acta Orthop Scand** 1999 Feb;70(1):101–2. Comment on: Acta Orthop Scand 1998 Feb;69(1):25–8.

Radiographic absorptiometry of the phalanges as a screening instrument to detect osteoporosis of the hip. Versluis RG, et al. **Acta Radiol** 1999 Jul;40(4):418–21

Tendinosis and tears of gluteus medius and minimus muscles as a cause of hip pain: MR imaging findings. Kingzett–Taylor A, et al. **AJR Am J Roentgenol** 1999 Oct; 173(4):1123–6

Articular interposition of broken trochanteric wires. Fakih RR, et al. **Bull Hosp Jt Dis** 1998;57(2):108–10

Slipped capital femoral epiphysis after septic arthritis of the hip in an adolescent: report of a case. Marx RG, et al. **Can J Surg** 1999 Apr;42(2):145–8

Medial synovial entrapment syndrome of the hip in Chinese children. Peng MX, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Nov; 61(11):630–5

Hip bursitis in active polymyalgia rheumatica: report of a case [letter] Cantini F, et al. **Clin Exp Rheumatol** 1999 Jul–Aug;17(4):512–3

Idiopathic hip instability. An unrecognized cause of coxa saltans in the adult. Bellabarba C, et al. **Clin Orthop** 1998 Oct;(355):261–71

A preliminary report on the effectiveness of trunk targeting in achieving independent sitting balance in children with cerebral palsy. Butler PB. **Clin Rehabil** 1998 Aug; 12(4):281–93

Treatment of hip and knee problems in myelomeningocele. Greene WB. **Instr Course Lect** 1999;48:563–74 (49 ref.)

Intra–articular lipoma of the hip. A case report. Margheritini F, et al. **Int Orthop** 1998;22(5):328–9

Osteonecrosis of the hip in sickle–cell disease associated with tuberculous arthritis. A review of 15 cases. Varango G, et al. **Int Orthop** 1998;22(6):384–9

Fortuitous diagnosis of iliac osteomyelitis: septic arthritis of the hip in the neonate. Duffy TN, et al. **J Am Osteopath Assoc** 1998 Dec;98(12):689–92

Is diagnostic arthroscopy of the hip worthwhile? A prospective review of 328 adults investigated for hip pain. Baber YF, et al. **J Bone Joint Surg Br** 1999 Jul;81(4):600–3

Complications of arthroscopy of the hip. Griffin DR, et al. **J Bone Joint Surg Br** 1999 Jul;81(4):604–6

Tuberculous bursitis of the greater trochanter. Ihara K, et al. **J Orthop Sci** 1998;3(2):120–4

Idiopathic chondrolysis of the hip: long–term evolution. del Couz Garcia A, et al. **J Pediatr Orthop** 1999 Jul–Aug; 19(4):449–54

Knee pain as the initial symptom of slipped capital femoral epiphysis: an analysis of initial presentation and treatment. Matava MJ, et al. **J Pediatr Orthop** 1999 Jul–Aug; 19(4):455–60

Subluxation of the hip joint in multiple hereditary osteochondromatosis: report of two cases. Woodward MN, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):119–21

Recreational physical activity and the risk of osteoarthritis of the hip in elderly women. Lane NE, et al. **J Rheumatol** 1999 Apr;26(4):849–54

Ankylosed hips caused by heterotopic ossification after traumatic brain injury: a difficult problem. Sarafis KA, et al. **J Trauma** 1999 Jan;46(1):104–9

Lack of association of transient synovitis of the hip joint with human parvovirus B19 infection in children. Zeharia A, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):843–4

Painful hips in a patient on long–term steroid treatment. Lay JP, et al. **Postgrad Med J** 1998 Nov;74(877):693–4

[What is it? Bilateral sacroilitis and avascular necrosis of the left hip in Crohn's disease treated with corticoids] Fleurent D, et al. **J Radiol** 1998 Apr;79(4):351–2 (Eng. Abstr.) **(Fre)**

[Anterior snapping of the hip associated with the ilial psoas] Kouvalchouk JF, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Feb; 84(1):67–74 (Eng. Abstr.) **(Fre)**

[Direct communication between the lower urinary tract and the hip joint complicating acetabular fracture. A case report] Rafai M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):507–11 (Eng. Abstr.) **(Fre)**

[Hip pain: diagnostic direction] Revel M, et al. **Rev Prat** 1998 Jun 1;48(11):1243–8 (0 ref.) **(Fre)**

[Candida spondylitis. Case report and review of the literature] Andermahr J, et al. **Unfallchirurg** 1998 Dec;101(12):955–9 (27 ref.) (Eng. Abstr.) **(Ger)**

[Vacuum phenomenon in the hip joint: diagnostic value] Iordache S, et al. **Harefuah** 1998 Aug;135(3–4):108–9, 167 (Eng. Abstr.) **(Heb)**

[Differential epidural block for definitive diagnosis of snapping hip joint] Tokumine J, et al. **Masui** 1999 Feb; 48(2):185–8 (Eng. Abstr.) **(Jpn)**

[Osteoporosis of the hip: a precautionary warning (letter)] Riancho JA, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):277 **(Spa)**

ABNORMALITIES

Autosomal dominant (Beukes) premature degenerative osteoarthropathy of the hip joint maps to an 11–cM region on chromosome 4q35 [letter] Roby P, et al. **Am J Hum Genet** 1999 Mar;64(3):904–8

Asymmetric hip deformity and subluxation in cerebral palsy: an analysis of surgical treatment. Abel MF, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):479–85

ANATOMY & HISTOLOGY

An investigation of ethnic differences in bone mineral, hip axis length, calcium metabolism and bone turnover between West African and Caucasian adults living in the United Kingdom. Dibba B, et al. **Ann Hum Biol** 1999 May–Jun; 26(3):229–42

Predicting the position of the femoral head center. Sugano N, et al. **J Arthroplasty** 1999 Jan;14(1):102–7

Three–dimensional computational reconstruction of mixed anatomical tissues following histological preparation. Ferguson SJ, et al. **Med Eng Phys** 1999 Mar;21(2):111–7

[Preferential direction of collagen fibrils in the sub–chondral bone bone and the hip and shoulder joint] Vogt S, et al. **Anat Anz** 1999 Mar;181(2):181–9 (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

[Assessment of tissue microcirculation in patients with aseptic necrosis of femur heads in systemic lupus erythematosus (SLE)] Mach ES, et al. **Ter Arkh** 1999;71(1):57–60 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Immunohistochemical analysis of type–X–collagen expression in osteoarthritis of the hip joint. Boos N, et al. **J Orthop Res** 1999 Jul;17(4):495–502

CYTOLOGY

Cartilaginous differentiation in the joint capsule. Yutani Y, et al. **J Bone Miner Metab** 1999;17(1):7–10

IMMUNOLOGY

[The immunological aspects of a hip joint lesion in childhood] Bebeshko AV, et al. **Lik Sprava** 1999 Apr–May;(3):118–21 (Eng. Abstr.) **(Rus)**

INJURIES

MR imaging of sports injuries of the hip. Kneeland JB. **Magn Reson Imaging Clin N Am** 1999 Feb;7(1):105–15, viii (16 ref.)

[Labrum lesions from the viewpoint of arthroscopic hip surgery] Conn KS, et al. **Orthopade** 1998 Oct; 27(10):699–703 (Eng. Abstr.) **(Ger)**

INNERVATION

The "Aunt Minnie" ability—revisited [editorial] Johnson EW. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):305

[Sensory innervation of the hip joint capsule in dogs] Kinzel S, et al. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep;26(5):330–5 (Eng. Abstr.) **(Ger)**

METABOLISM

Beta 2–microglobulin amyloid deposition in hip revision arthroplasty tissues. Crawford R, et al. **Histopathology** 1998 Nov;33(5):479–84

Cartilaginous differentiation in the joint capsule. Yutani Y, et al. **J Bone Miner Metab** 1999;17(1):7–10

MICROBIOLOGY

Synovial actinomycosis of the hip: case report and review. Dom K, et al. **Acta Orthop Belg** 1999 Jun;65(2):242–4 (5 ref.)

Septic arthritis caused by Corynebacterium amycolatum following vascular graft sepsis. Clarke R, et al. **J Infect** 1999 Mar;38(2):126–7

On tuberculosis of the bones and joints [letter; comment] Olivé A, et al. **J Rheumatol** 1998 Nov;25(11):2284–5. Comment on: J Rheumatol 1998 Feb;25(2):391–3.

PATHOLOGY

MR arthrography of the adult acetabular capsular–labral complex: correlation with surgery and anatomy. Czerny C, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):345–9

Arthroscopy of the hip: 12 years of experience. Dorfmann H, et al. **Arthroscopy** 1999 Jan–Feb;15(1):67–72

Bone mineral density, body mass index, and hip axis length in postmenopausal cretan women with cervical and trochanteric fractures. Dretakis EK, et al. **Calcif Tissue Int** 1999 Mar;64(3):257–8

Amyloid arthropathy of the hip joint: MR demonstration of presumed amyloid lesions in 152 patients with long–term hemodialysis. Otake S, et al. **Eur Radiol** 1998;8(8):1352–6

Radiological case of the month. Dialysis related amyloid arthropathy. Nokes SR, et al. **J Ark Med Soc** 1999 May; 95(12):544–5

Analysis of routine histological evaluation of tissues removed during primary hip and knee arthroplasty. Lawrence T, et al. **J Bone Joint Surg Am** 1999 Jul;81(7):926–31

Utility of MRI in detecting obstacles to reduction in developmental dysplasia of the hip: comparison with two–directional arthrography and correlation with intraoperative findings. Aoki K, et al. **J Orthop Sci** 1999; 4(4):255–63

Wiberg's center–edge angle in patients with slipped capital femoral epiphysis. Kitadai HK, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):97–105

Relationship between lateral subluxation and widening of medial joint space in Legg–Calvé–Perthes disease. Song HR, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):637–42

Articular cartilage evaluation in osteoarthritis of the hip with MR imaging under continuous leg traction. Nishii T, et al. **Magn Reson Imaging** 1998 Oct;16(8):871–5

Septic arthritis versus transient synovitis at MR imaging: preliminary assessment with signal intensity alterations in bone marrow. Lee SK, et al. **Radiology** 1999 May; 211(2):459–65

Prevalence of hip osteoarthritis and acetabular dysplasia in Kamitonda: from a longitudinal population–based epidemiological study of rheumatic diseases in Japan [letter] Inoue K, et al. **Rheumatology (Oxford)** 1999 Aug; 38(8):793–4

Validity of Cyriax's concept capsular pattern for the diagnosis of osteoarthritis of hip and/or knee. Bijl D, et al. **Scand J Rheumatol** 1998;27(5):347–51

[Philosophy of total hip replacement] Lewalle J. **Acta Orthop Belg** 1998;64 Suppl 2:57–63 **(Fre)**

[MR arthrography of the labrum acetabulare—a radiological–anatomical correlation in 20 cadaveric hips] Brossmann J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):143–8 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Carry it on the bad side [letter] Rork PE. **Am J Orthop** 1999 Mar;28(3):186

Biomechanics of total hip arthroplasty. Lim LA, et al. **Anat Rec** 1999 Jun 15;257(3):110–6 (22 ref.)

Influence of skeletal site of origin and donor age on 1,25(OH)2D3–induced response of various osteoblastic markers in human osteoblastic cells. Martinez ME, et al. **Bone** 1999 Mar;24(3):203–9

Analysis of rising from a chair after total knee arthroplasty. Itokazu M, et al. **Bull Hosp Jt Dis** 1998;57(2):88–92

Psoas major and its controversial rotational action. Skyrme AD, et al. **Clin Anat** 1999;12(4):264–5

Test–retest reliabilty of isokinetic hip adductor and flexor muscle strength. Emery CA, et al. **Clin J Sport Med** 1999 Apr;9(2):79–85

Comparison between two devices for measuring hip joint motions. Bierma–Zeinstra SM, et al. **Clin Rehabil** 1998 Dec; 12(6):497–505

The effect of acetabular cup orientations on limiting hip rotation. Kummer FJ, et al. **J Arthroplasty** 1999 Jun; 14(4):509–13

Mechanical energetic processes during the giant swing exercise before dismounts and flight elements on the high bar and the uneven parallel bars. Arampatzis A, et al. **J Biomech** 1999 Aug;32(8):811–20

Hip joint forces in sheep. Bergmann G, et al. **J Biomech** 1999 Aug;32(8):769–77

Placing the trailing foot closer to an obstacle reduces flexion of the hip, knee, and ankle to increase the risk of tripping. Chou LS, et al. **J Biomech** 1998 Aug;31(8):685–91

Variation of rotation moment arms with hip flexion. Delp SL, et al. **J Biomech** 1999 May;32(5):493–501

Identification of passive elastic joint moments in the lower extremities. Riener R, et al. **J Biomech** 1999 May; 32(5):539–44

Active responses decrease impact forces at the hip and shoulder in falls to the side. Sabick MB, et al. **J Biomech** 1999 Sep;32(9):993–8

The role of the acetabular labrum and the transverse acetabular ligament in load transmission in the hip. Konrath GA, et al. **J Bone Joint Surg Am** 1998 Dec;80(12):1781–8

The effect of upper cervical or sacroiliac manipulation on hip flexion range of motion. Pollard H, et al. **J Manipulative Physiol Ther** 1998 Nov–Dec;21(9):611–6

Validity and reliability of measurements taken by the Peak 5 motion analysis system. Selfe J. **J Med Eng Technol** 1998 Sep–Oct;22(5):220–5

Quantitative determination of joint incongruity and pressure distribution during simulated gait and cartilage thickness in the human hip joint. von Eisenhart R, et al. **J Orthop Res** 1999 Jul;17(4):532–9

Age–related kinetic changes in normal pediatrics. Cupp T, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):475–8

Muscle control in elite alpine skiing. Berg HE, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):1065–7

Jumping for distance: control of the external force in squat jumps. Ridderikhoff A, et al. **Med Sci Sports Exerc** 1999 Aug;31(8):1196–204

An analysis of hip joint loading during walking, running, and skiing. van den Bogert AJ, et al. **Med Sci Sports Exerc** 1999 Jan;31(1):131–42

Hip moments during level walking, stair climbing, and exercise in individuals aged 55 years or older. Kirkwood RN, et al. **Phys Ther** 1999 Apr;79(4):360–70

Development of a ten–station, multi–axis hip joint simulator. Goldsmith AA, et al. **Proc Inst Mech Eng [H]** 1999; 213(4):311–6

Loads in hip disarticulation prostheses during normal daily use. Nietert M, et al. **Prosthet Orthot Int** 1998 Dec; 22(3):199–215

[Cadaver study of acetabular cup mobility in the healthy hip and prosthesis by monopodal pressure simulation] Vandenbussche E, et al.

Rev Chir Orthop Reparatrice Appar Mot 1999 May; 85(2):136–45 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Carry it on the bad side! Tan V, et al. **Am J Orthop** 1998 Oct;27(10):673–7

Measurement of clinical change caused by knee replacement. Conventional score or special change indexes? Barck AL. **Arch Orthop Trauma Surg** 1999;119(1–2):76–8

Hip endoprosthesis for in vivo measurement of joint force and temperature. Graichen F, et al. **J Biomech** 1999 Oct; 32(10):1113–7

Hip motion and moments during gait relate directly to proximal femoral bone mineral density in patients with hip osteoarthritis. Hurwitz DE, et al. **J Biomech** 1998 Oct; 31(10):919–25

The effects of simulated transverse, anterior column, and posterior column fractures of the acetabulum on the stability of the hip joint. Vrahas MS, et al. **J Bone Joint Surg Am** 1999 Jul;81(7):966–74

Intracapsular components do not change hip proprioception. Ishii Y, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):345–8

Treatment of iliopsoas syndrome with a hip rotation strengthening program; a retrospective case series. Johnston CA, et al. **J Orthop Sports Phys Ther** 1999 Apr; 29(4):218–24

Effect of hamstring and psoas lengthening on pelvic tilt in patients with spastic diplegic cerebral palsy. DeLuca PA, et al. **J Pediatr Orthop** 1998 Nov–Dec;18(6):712–8

Anteversion of the acetabulum in developmental dysplasia of the hip: analysis with computed tomography. Kim SS, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):438–42

Standing is a causative factor in osteonecrosis of the femoral head in growing rats. Mihara K, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):665–9

How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. Chen Z, et al. **Osteoporos Int** 1998;8(5):423–7

The interrater reliability of force measurements using a modified sphygmomanometer in elderly subjects. Kaegi C, et al. **Phys Ther** 1998 Oct;78(10):1095–103

The functional use of the reciprocal hip mechanism during gait for paraplegic patients walking in the Louisiana State University reciprocating gait orthosis. Dall PM, et al. **Prosthet Orthot Int** 1999 Aug;23(2):152–62

[Kinematics of the healthy and arthritic hip joint during walking. A study of 136 subjects] Dujardin F, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(8):689–99 (Eng. Abstr.) **(Fre)**

[The painful hip in childhood] Hahn H, et al. **Radiologe** 1999 Jun;39(6):478–82 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Hip pain. Garcia–Porrua C, et al. **Ann Rheum Dis** 1999 Mar; 58(3):148–9

The faux profil (oblique view) of the hip in the standing position. Contribution to the evaluation of osteoarthritis of the adult hip. Lequesne MG, et al. **Ann Rheum Dis** 1998 Nov;57(11):676–81

Are radiological joint space widths of normal hips asymmetrical? Reis P, et al. **Ann Rheum Dis** 1999 Apr; 58(4):246–9

Errors of computer–assisted migration analysis in conventional radiographs of femoral hip implants––an experimental study. Wirtz DC, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):50–6

Quantitative measurement of joint space narrowing progression in hip osteoarthritis: a longitudinal retrospective study of patients treated by total hip arthroplasty. Conrozier T, et al. **Br J Rheumatol** 1998 Sep; 37(9):961–8

Study of the joint space of the hip on supine and weight–bearing digital radiographs. Pessis E, et al. **Clin Radiol** 1999 Aug;54(8):528–32

Relationship between degenerative joint disease and hip joint laxity by use of distraction index and Norberg angle measurement in a group of cats [published erratum appears in J Am Vet Med Assoc 1999 Mar 1;214(5):659] Langenbach A, et al. **J Am Vet Med Assoc** 1998 Nov 15; 213(10):1439–43

The Charnley versus the Spectron hip prosthesis: radiographic evaluation of a randomized, prospective study of 2 different hip implants. Garellick G, et al. **J Arthroplasty** 1999 Jun;14(4):414–25

Differences in the rates of penetration determined from radiographic and shadowgraphic measurements of acetabular sockets. Hall RM, et al. **J Arthroplasty** 1998 Aug;13(5):570–5

Predictive value of early radiographic findings in cementless total hip arthroplasty femoral components: an 8– to 12–year follow–up. Khalily C, et al. **J Arthroplasty** 1998 Oct; 13(7):768–73

Validation of a functional method for the estimation of hip joint centre location. Leardini A, et al. **J Biomech** 1999 Jan;32(1):99–103

Accuracy of EBRA–FCA in the measurement of migration of femoral components of total hip replacement. Einzel–Bild–Röntgen–Analyse–femoral component analysis. Biedermann R, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):266–72

Retroversion of the acetabulum [letter] Bircher MD. **J Bone Joint Surg Br** 1999 Jul;81(4):743–4

The prediction of failure of the stem in THR by measurement of early migration using EBRA–FCA. Einzel–Bild–Roentgen–Analyse–femoral component analysis. Krismer M, et al. **J Bone Joint Surg Br** 1999 Mar; 81(2):273–80

Retroversion of the acetabulum. A cause of hip pain. Reynolds D, et al. **J Bone Joint Surg Br** 1999 Mar; 81(2):281–8

The influence of weight–bearing on the measurement of polyethylene wear in THA. Smith PN, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):259–65

Prediction of long–term polyethylene wear in total hip arthroplasty, based on early wear measurements made using digital image analysis. Pedersen DR, et al. **J Orthop Res** 1998 Sep;16(5):557–63

Normal radiographic values for cartilage thickness and physeal angle in the pediatric hip. Hughes LO, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):443–8

Acetabular development after Salter's innominate osteotomy for congenital dislocation of the hip: evaluation by three–dimensional quantitative method. Takashi S, et al. **J Pediatr Orthop** 1998 Nov–Dec;18(6):802–6

Accurate needle placement by the suction–bubble technique for hip arthrography. Yun AG, et al. **J Pediatr Orthop** 1999 Sep–Oct;19(5):632–4

Bilateral Legg–Calvé–Perthes disease: different from unilateral disease? Van den Bogaert G, et al. **J Pediatr Orthop B** 1999 Jul;8(3):165–8

The pattern of bone mineral density in the proximal femur and radiographic signs of early joint degeneration. Bruno RJ, et al. **J Rheumatol** 1999 Mar;26(3):636–40

Migration measurement of cementless acetabular components: value of clinical and radiographic data. Boehler M, et al. **Orthopedics** 1998 Aug;21(8):897–900

Femorocoxometry: angles and segments characteristic of dysplastic and dysmorphic hip conditions in adult. Measurement using a femorocoxometer for standard or reduced (digitized) films. Lequesne MG. **Rev Rhum Engl Ed** 1999 Mar;66(3):136–42

Synovial desmoplastic fibroblastoma of hip joint with bone erosion. Beggs I, et al. **Skeletal Radiol** 1999 Jul;28(7):402–6

Compensatory spinopelvic balance over the hip axis and better reliability in measuring lordosis to the pelvic radius on standing lateral radiographs of adult volunteers and patients. Jackson RP, et al. **Spine** 1998 Aug 15; 23(16):1750–67

Dorsolateral subluxation of hip joints in dogs measured in a weight–bearing position with radiography and computed tomography [see comments] Farese JP, et al. **Vet Surg** 1998 Sep–Oct;27(5):393–405. Comment in: Vet Surg 1999 Mar–Apr;28(2):117–9.

[Study of cotyloid anteversion by coxometric measurement] Fabeck L, et al. **J Radiol** 1998 Aug;79(8):743–50 (Eng. Abstr.) **(Fre)**

[Villonodular synovitis of the hip. Combined diagnostic imaging of a case] Genchi V, et al. **Radiol Med (Torino)** 1999 Mar;97(3):190–3 **(Ita)**

[Radiography assessment of the hip joint after the implantation of cementless ceramic cup and metal cup] Grzegorzewski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(5):431–5 (Eng. Abstr.) **(Pol)**

[Hip joint deformity caused by osteochondrosis in the course of treatment of congenital dysplasia of the hip] Pucher A. **Chir Narzadow Ruchu Ortop Pol** 1998;63(5):423–30 (Eng. Abstr.) **(Pol)**

SURGERY

Anterior flap for coverage following hip disarticulation for osteomyelitis. Vancabeke M, et al. **Acta Orthop Belg** 1999 Jun;65(2):223–5

Salvage of failed amputation about the hip in peripheral vascular disease by open wound care and nutritional support. Pinzur MS, et al. **Am J Orthop** 1998 Aug; 27(8):561–2

Hip arthroscopy for acetabular labral tears. Farjo LA, et al. **Arthroscopy** 1999 Mar;15(2):132–7

Surgical management of inflammatory arthritis of the adult hip and knee. Stuchin SA, et al. **Instr Course Lect** 1999; 48:93–109 (113 ref.)

Capsular replacement with synthetic mesh: effectiveness in preventing postoperative dislocation after wide resection of proximal femoral tumors and prosthetic reconstruction. Masterson EL, et al. **J Arthroplasty** 1998 Dec;13(8):860–6

Primary hybrid total hip replacement, performed with insertion of the acetabular component without cement and a precoat femoral component with cement. An average ten–year follow–up study. Clohisy JC, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):247–55

Proximal femoral osteotomy as the primary operation for young adults who have osteoarthrosis of the hip. D'Souza SR, et al. **J Bone Joint Surg Am** 1998 Oct;80(10):1428–38

The hemispherical Harris–Galante acetabular cup, inserted without cement. The results of an eight to eleven–year follow–up of one hundred and sixty–eight hips. Petersen MB, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):219–24

The treatment of subluxation of the hip in children over the age of four years [letter; comment] Kiely N, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):371. Comment on: J Bone Joint Surg Br 1998 Sep;80(5):757–61.

Effect of nonweight bearing on tibial bone density measured by QCT in patients with hip surgery. Ito M, et al. **J Bone Miner Metab** 1999;17(1):45–50

Length changes of the hamstrings and adductors resulting from derotational osteotomies of the femur. Schmidt DJ, et al. **J Orthop Res** 1999 Mar;17(2):279–85

Asymmetric hip deformity and subluxation in cerebral palsy: an analysis of surgical treatment. Abel MF, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):479–85

Complications of blade plate removal. Becker CE, et al. **J Pediatr Orthop** 1999 Mar–Apr;19(2):188–93

Results of hip arthrodesis in adolescents by using the cobra–head plate for internal fixation. Klemme WR, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):648–50

Hip arthrodesis using the AO modular external fixator. Tavares JO, et al. **J Pediatr Orthop** 1998 Sep–Oct; 18(5):651–6

Shortening of a unit rod protruding into the hip joint: case report and description of a surgical technique. Givon U, et al. **J Spinal Disord** 1999 Feb;12(1):74–6

Effects on acetabular development of resection of the labrum acetabulare (limbus) in the hip joint. Sannomiya T. **Kurume Med J** 1999;46(1):51–60

Adhesive capsulitis of the hip. Mont MA, et al. **Orthopedics** 1999 Mar;22(3):343–5

Treatment of fibrous dysplasia involving the proximal femur. Shih HN, et al. **Orthopedics** 1998 Dec;21(12):1263–6

Percutaneous radiofrequency destruction of the obturator nerve for treatment of pain caused by coxarthrosis. Akatov OV, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):278–80

[Treatment of aseptic acetabular loosening by reconstruction combining bone graft and Müller ring. Actuarial analysis over 11 years] Massin P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Feb; 84(1):51–60 (Eng. Abstr.) **(Fre)**

[Radiography assessment of the hip joint after the implantation of cementless ceramic cup and metal cup] Grzegorzewski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(5):431–5 (Eng. Abstr.) **(Pol)**

[Regional arterial infusion in patients after reconstructive–restorative operations of the hip joint] Shapovalov VM, et al. **Vestn Khir Im I I Grek** 1998; 157(3):56–7 (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Emergency physician–performed ultrasonography–guided hip arthrocentesis. Smith SW. **Acad Emerg Med** 1999 Jan; 6(1):84–6

Ultrasonography in developmental hip dysplasia [letter; comment] Ozçelik A. **J Bone Joint Surg Br** 1999 Jan; 81(1):179. Comment on: J Bone Joint Surg Br 1998 Mar;80(2):321–4.

Ultrasonography in the diagnosis of transient synovitis of the hip and Legg–Calvé–Perthes disease. Eggl H, et al. **J Pediatr Orthop B** 1999 Jul;8(3):177–80

The 'black hole' sign: a visual ultrasonographic sign of hip dislocation. Warner JG, et al. **J R Coll Surg Edinb** 1998 Oct;43(5):333–5

Ultrasonographic guidance for injections of local steroids in the native hip. Carson BW, et al. **J Ultrasound Med** 1999 Feb;18(2):159–60

Anterior joint capsule of the normal hip and in children with transient synovitis: US study with anatomic and histologic correlation. Robben SG, et al. **Radiology** 1999 Feb; 210(2):499–507

[Value of ultrasound in differential diagnosis of pediatric hip joint effusion (Perthes disease, C. fugax, epiphysiolysis coapitis femoris] Bosch R, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep–Oct;136(5):412–9 (Eng. Abstr.) **(Ger)**

HIP PROSTHESIS

see related

ARTHROPLASTY, REPLACEMENT, HIP

Histopathology of a well–functioning hydroxyapatite–coated femoral prosthesis after 52 months. Hardy DC, et al. **Acta Orthop Belg** 1999 Mar;65(1):72–82

Interface gap after implantation of a cemented femoral stem in pigs. Wang JS, et al. **Acta Orthop Scand** 1999 Jun; 70(3):234–9

A new technique for removing noncemented acetabular components in revision total hip arthroplasty. Markovich GD, et al. **Am J Orthop** 1999 Jan;28(1):35–7 (10 ref.)

Total hip disarticulation prosthesis with suction socket: report of two cases. Zaffer SM, et al. **Am J Phys Med Rehabil** 1999 Mar–Apr;78(2):160–2

Tennis after total hip arthroplasty. Mont MA, et al. **Am J Sports Med** 1999 Jan–Feb;27(1):60–4

Measurement of clinical change caused by knee replacement. Conventional score or special change indexes? Barck AL. **Arch Orthop Trauma Surg** 1999;119(1–2):76–8

Cementless Roy–Camille femoral component. Chen CH, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):85–8

Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Kienapfel H, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):296–302

Polyethylene wear from femoral bipolar neck–cup impingement as a cause of femoral prosthetic loosening.

Kobayashi S, et al. **Arch Orthop Trauma Surg** 1998; 117(6–7):390–1

Intrapelvic cyst formation after hip arthroplasty with a carbon fibre-reinforced polyethylene socket. Korkala O, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):113–5 (8 ref.)

Centralization of the femoral component in cemented hip arthroplasty using guided stem insertion. Köster G, et al. **Arch Orthop Trauma Surg** 1998;117(8):425–9

Improvement of the cement mantle of the acetabular component with bone cement spacers. A retrospective analysis of 200 cemented cups. Lichtinger TK, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):75–7

Complex cemented revision using polished stem and morselized allograft.Minimum 5-years' follow-up. Mikhail WE, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):288–91

Middle-term results of anatomic medullary locking total hip arthroplasty. Ohsawa S, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):14–20

Biocompatibility of silicon carbide in colony formation test in vitro. A promising new ceramic THR implant coating material. Santavirta S, et al. **Arch Orthop Trauma Surg** 1998; 118(1–2):89–91

Simulator trials to determine the wear of the combination aluminium oxide ceramic–carbon fibre reinforced plastic (CFRP) used as an insert in a hip socket. Scheller G, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):13–7

Errors of computer-assisted migration analysis in conventional radiographs of femoral hip implants--an experimental study. Wirtz DC, et al. **Arch Orthop Trauma Surg** 1999;119(1–2):50–6

Health related quality of life in patients with total hip or knee replacement. Shields RK, et al. **Arch Phys Med Rehabil** 1999 May;80(5):572–9

Nonlinear three-dimensional finite element analysis of newly designed cementless total hip stems. Ando M, et al. **Artif Organs** 1999 Apr;23(4):339–46

Mixed oxides prosthetic ceramic ball heads. Part 1: effect of the ZrO2 fraction on the wear of ceramic on polythylene joints. Affatato S, et al. **Biomaterials** 1999 May;20(10):971–5

Cytokine release in mononuclear cells of patients with Co–Cr hip prosthesis. Granchi D, et al. **Biomaterials** 1999 Jun; 20(12):1079–86

Polyethylene particles of a 'critical size' are necessary for the induction of cytokines by macrophages in vitro. Green TR, et al. **Biomaterials** 1998 Dec;19(24):2297–302

Unified wear model for highly crosslinked ultra-high molecular weight polyethylenes (UHMWPE). Muratoglu OK, et al. **Biomaterials** 1999 Aug;20(16):1463–70

Development of fatigue lifetime predictive test methods for hip implants: part I. Test methodology. Styles CM, et al. **Biomaterials** 1998 Jun;19(11–12):1057–65

Materials selection and design for orthopaedic implants with improved long-term performance. Vander Sloten J, et al. **Biomaterials** 1998 Aug;19(16):1455–9

The effect of titanium plasma-sprayed implants on trabecular bone healing in the goat. Vercaigne S, et al. **Biomaterials** 1998 Jun;19(11–12):1093–9

Surface roughness of debonded straight-tapered stems in cemented THA reduces subsidence but not cement damage. Verdonschot N, et al. **Biomaterials** 1998 Oct;19(19):1773–9

Development of bioactive bone cement and its clinical applications. Yamamuro T, et al. **Biomaterials** 1998 Aug; 19(16):1479–82

Clinical study on arthroplasties for osteoarthritic hip by quantitative gait analysis. Comparison between total hip arthroplasty and bipolar endoprosthetic arthroplasty. Isobe Y, et al. **Biomed Mater Eng** 1998;8(3–4):167–75

Quantitative measurement of joint space narrowing progression in hip osteoarthritis: a longitudinal retrospective study of patients treated by total hip arthroplasty. Conrozier T, et al. **Br J Rheumatol** 1998 Sep; 37(9):961–8

Evaluation of the allograft-prosthesis composite technique for proximal femoral reconstruction after resection of a primary bone tumour. McGoveran BM, et al. **Can J Surg** 1999 Feb;42(1):37–45

Changes in the femoral cortex as related to prosthetic stem. Toni A, et al. **Chir Organi Mov** 1998 Oct-Dec;83(4):323–35 **(Eng, Ita)**

Precoated femoral component in total hip arthroplasty. Results of 5- to 9-year followup. Brown EC 3rd, et al. **Clin Orthop** 1999 Jul;(364):153–9

The compares a unipolar with a bipolar prosthesis of similar stem design [letter; comment] Calder S. **Clin Orthop** 1999 Feb;(359):259. Comment on: Clin Orthop 1998 Mar;(348):67–71.

Cementless acetabular revision for aseptic failure of cemented hip arthroplasty. Chareancholvanich K, et al. **Clin Orthop** 1999 Apr;(361):140–9

Salvage of failed femoral megaprostheses with allograft prosthesis composites. Clarke HD, et al. **Clin Orthop** 1998 Nov;(356):222–9

Omnifit-HA stem in total hip arthroplasty. A 2- to 5-year followup. D'Lima DD, et al. **Clin Orthop** 1999 Jun; (363):163–9

Micromotion measurements with hip center and modular neck length alterations. Doehring TC, et al. **Clin Orthop** 1999 May;(362):230–9

The osseous response to corundum blasted implant surfaces in a canine hip model. Hacking SA, et al. **Clin Orthop** 1999 Jul;(364):240–53

Omnifit cementless total hip arthroplasty. A 10-year average followup. Hellman EJ, et al. **Clin Orthop** 1999 Jul; (364):164–74

Primary total hip arthroplasty with the AML total hip prosthesis. Kim YH, et al. **Clin Orthop** 1999 Mar; (360):147–58

Mueller roof reinforcement rings. Medium-term results. Korovessis P, et al. **Clin Orthop** 1999 May;(362):125–37

Mechanism of failure in hips with an uncemented, all polyethylene socket. Llinás A, et al. **Clin Orthop** 1999 May; (362):145–55

Localization of hyaluronan in pseudocapsule from total hip arthroplasty. Namba RS, et al. **Clin Orthop** 1999 Jun; (363):158–62

Maneuvers for reducing dislocated hips. A new technique and a literature review. Nordt WE 3rd. **Clin Orthop** 1999 Mar;(360):260–4

Effect of increasing temperature on the properties of four bone cements. Parks ML, et al. **Clin Orthop** 1998 Oct; (355):238–48

Minimum 10-year results of a tapered cementless hip replacement. Sakalkale DP, et al. **Clin Orthop** 1999 May; (362):138–44

Relationship of acetabular wear to osteolysis and loosening in total hip arthroplasty. Sochart DH. **Clin Orthop** 1999 Jun;(363):135–50

Analysis of prosthetic femoral heads retrieved at autopsy. Sychterz CJ, et al. **Clin Orthop** 1999 Jan;(358):223–34

Six-year results of a cementless stem with prophylaxis against heterotopic bone. Wurnig C, et al. **Clin Orthop** 1999 Apr; (361):150–8

Influence of orthopaedic metal and high-density detection on body composition as assessed by dual-energy X-ray absorptiometry. Madsen OR, et al. **Clin Physiol** 1999 May; 19(3):238–45

Spatial positioning of an hip stem solid model within the CT data set of the host bone [published erratum appears in Comput Methods Programs Biomed 1999 May;59(2):143–4] Viceconti M, et al. **Comput Methods Programs Biomed** 1999 Mar;58(3):219–26

Transosseous transposition of a pedicled rectus abdominis flap to cover hip wounds. Ross DA, et al. **Eur J Surg Oncol** 1998 Dec;24(6):610–1

Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Faulkner A, et al. **Health Technol Assess** 1998; 2(6):1–133 (128 ref.)

The Mennen plate: unsuitable for elderly femoral peri-prosthetic fractures. Kamineni S, et al. **Injury** 1999 May;30(4):257–60

Peri-prosthetic femoral shaft fractures treated with plate and cable fixation. Kamineni S, et al. **Injury** 1999 May; 30(4):261–8

Hip prothesis: an in vitro wear protocol based on a comparison between gravimetric and profilometric analysis. Affatato S, et al. **Int J Artif Organs** 1999; 22(4):226–9

Twelve years of cementless revision in retrospect. Wagner self-locking revision stem and acetabular reinforcement cage. **Int Orthop** 1999;23(1 Suppl):1–6

Coating titanium implants with bioglass and with hydroxyapatite. A comparative study in sheep. Lopez-Sastre S, et al. **Int Orthop** 1998;22(6):380–3

Problems with the Mennen plate when used for femoral fractures associated with implants. A report of 5 patients. Petersen VS. **Int Orthop** 1998;22(3):169–70

Use of reconstruction rings for the management of acetabular bone loss during revision hip surgery. Brady OH, et al. **J Am Acad Orthop Surg** 1999 Jan;7(1):1–7

Autonomic neuropeptides in the interface membrane of aseptic loose hip prostheses. Ahmed M, et al. **J Arthroplasty** 1999 Aug;14(5):594–602

Polyethylene wear in cases using femoral stems of similar geometry, but different metals, porous layer, and modularity. Bal BS, et al. **J Arthroplasty** 1998 Aug; 13(5):492–9

Tissue response to porous tantalum acetabular cups: a canine model. Bobyn JD, et al. **J Arthroplasty** 1999 Apr; 14(3):347–54

Successful salvage of a primary total knee arthroplasty infected with Candida parapsilosis. Brooks DH, et al. **J Arthroplasty** 1998 Sep;13(6):707–12 (15 ref.)

Periprosthetic acetabular fracture associated with extensive osteolysis. Chatoo M, et al. **J Arthroplasty** 1998 Oct; 13(7):843–5

Migration and failure of the Mecron screw-in acetabular prosthesis. Chell J, et al. **J Arthroplasty** 1998 Sep; 13(6):638–41

Results of cemented metal-backed acetabular components: a 10-year-average follow-up study. Chen FS, et al. **J Arthroplasty** 1998 Dec;13(8):867–73

In vitro stress shielding measurements can be affected by large errors. Cristofolini L, et al. **J Arthroplasty** 1999 Feb; 14(2):215–9

Reconstruction of the deficient acetabulum with an oblong prosthesis: three- to seven-year results. DeBoer DK, et al. **J Arthroplasty** 1998 Sep;13(6):674–80

Effects of acetabular abduction on cup wear rates in total hip arthroplasty. Del Schutte H Jr, et al. **J Arthroplasty** 1998 Sep;13(6):621–6

Bilateral total hip arthroplasty comparing hydroxyapatite coating to porous-coated fixation. Dorr LD, et al. **J Arthroplasty** 1998 Oct;13(7):729–36

Intraoperative type 1 proximal femoral fractures: influence on the stability of hydroxyapatite-coated femoral components. Falez F, et al. **J Arthroplasty** 1998 Sep; 13(6):653–9

Rheumatoid arthritis and hydroxyapatite-coated hip prostheses: five-year results. International ABG Study Group. Garcia Araujo C, et al. **J Arthroplasty** 1998 Sep; 13(6):660–7

Porous-coated cementless acetabular cups in revision surgery: a 6- to 11-year follow-up study. Garcia-Cimbrelo E. **J Arthroplasty** 1999 Jun;14(4):397–406

The Charnley versus the Spectron hip prosthesis: clinical evaluation of a randomized, prospective study of 2 different hip implants. Garellick G, et al. **J Arthroplasty** 1999 Jun; 14(4):407–13

The Charnley versus the Spectron hip prosthesis: radiographic evaluation of a randomized, prospective study of 2 different hip implants. Garellick G, et al. **J Arthroplasty** 1999 Jun;14(4):414–25

Differences in the rates of penetration determined from radiographic and shadowgraphic measurements of acetabular sockets. Hall RM, et al. **J Arthroplasty** 1998 Aug;13(5):570–5

Average 12-year outcome of a chrome-cobalt, beaded, bony ingrowth acetabular component [letter] Harris WH. **J Arthroplasty** 1998 Oct;13(7):846

Effect of acetabular component orientation on recurrent dislocation, pelvic osteolysis, polyethylene wear, and component migration. Kennedy JG, et al. **J Arthroplasty** 1998 Aug;13(5):530–4

Predictive value of early radiographic findings in cementless total hip arthroplasty femoral components: an 8- to 12-year follow-up. Khalily C, et al. **J Arthroplasty** 1998 Oct; 13(7):768–73

Clinical results of the midstem porous-coated anatomic uncemented femoral stem in primary total hip arthroplasty: a five- to nine-year prospective study. Knight JL, et al. **J Arthroplasty** 1998 Aug;13(5):535–45

An oblong revision cup for large acetabular defects: design rationale and two- to seven-year follow-up. Köster G, et al. **J Arthroplasty** 1998 Aug;13(5):559–69

The effect of acetabular cup orientations on limiting hip rotation. Kummer FJ, et al. **J Arthroplasty** 1999 Jun; 14(4):509–13

Wear of bipolar hip prostheses. Kusaba A, et al. **J Arthroplasty** 1998 Sep;13(6):668–73

Viability of the acetabular bone bed at revision surgery following cemented primary arthroplasty. Lamerigts NM, et al. **J Arthroplasty** 1998 Aug;13(5):524–9

Late failure of the polyethylene liner fixation in an uncemented total hip arthroplasty. Louwerse RT, et al. **J Arthroplasty** 1999 Apr;14(3):391–6 (16 ref.)

Drain entrapment and titanium to ceramic head deposition: two unique complications following closed reduction of a dislocated total hip arthroplasty. Luchetti WT, et al. **J Arthroplasty** 1998 Sep;13(6):713–7

Cartilage degeneration in relation to repetitive pressure: case study of a unilateral hip hemiarthroplasty patient. McGibbon CA, et al. **J Arthroplasty** 1999 Jan;14(1):52–8

Impaction allografting of the proximal femur using a Charnley-type stem: a cement mantle analysis. Masterson EL, et al. **J Arthroplasty** 1999 Jan;14(1):59–63

A comparison of collared and collarless femoral components in primary cemented total hip arthroplasty: a randomized clinical trial. Meding JB, et al. **J Arthroplasty** 1999 Feb; 14(2):123–30

A modified direct lateral approach in total hip arthroplasty: a comprehensive review. Mulliken BD, et al. **J Arthroplasty** 1998 Oct;13(7):737–47

Technique for a composite femoral intramedullary plug in cemented hip arthroplasty. Owens P, et al. **J Arthroplasty** 1999 Apr;14(3):369–71

Severe polyethylene wear in uncemented acetabular cup system components: a report of 5 cases. Patel J, et al. **J Arthroplasty** 1999 Aug;14(5):635–6

Temporal changes of periprosthetic bone density in patients with a modular noncemented femoral prosthesis. Rosenthall L, et al. **J Arthroplasty** 1999 Jan;14(1):71–6

Increased urinary crosslink levels in aseptic loosening of total hip arthroplasty. Schneider U, et al. **J Arthroplasty** 1998 Sep;13(6):687–92

Conversion of hemiarthroplasty to total hip arthroplasty: can groin pain be eliminated? Sharkey PF, et al. **J Arthroplasty** 1998 Sep;13(6):627–30

Factors influencing choice of implants in total hip arthroplasty and total knee arthroplasty: perspectives of surgeons and patients. Sharkey PF, et al. **J Arthroplasty** 1999 Apr;14(3):281–7

Five-year clinical and radiographic follow-up of the uncemented long-term stable fixation total hip arthroplasty. Sharkey PF, et al. **J Arthroplasty** 1998 Aug;13(5):546–51

Preliminary results of partial surface replacement of the femoral head in osteonecrosis. Siguier M, et al. **J Arthroplasty** 1999 Jan;14(1):45–51

Hybrid total hip arthroplasty in patients under the age of fifty: a five- to ten-year follow-up. Sporer SM, et al. **J Arthroplasty** 1998 Aug;13(5):485–91

Catastrophic progression of the disassembly of a modular acetabular component. Suh KT, et al. **J Arthroplasty** 1998 Dec;13(8):950–2

Examination of wear in Duraloc acetabular components: two- to five-year evaluation of Hylamer and Enduron

liners. Sychterz CJ, et al. **J Arthroplasty** 1998 Aug; 13(5):508–14

Porous cups with and without hydroxylapatite–tricalcium phosphate coating: 23 matched pairs evaluated with radiostereometry. Thanner J, et al. **J Arthroplasty** 1999 Apr;14(3):266–71

Intermediate clinical follow–up of a dual–radius acetabular component. Van Flandern GJ, et al. **J Arthroplasty** 1998 Oct;13(7):804–11

Effect of femoral head surface roughness on the wear of ultrahigh molecular weight polyethylene acetabular cups. Wang A, et al. **J Arthroplasty** 1998 Sep;13(6):615–20

Effect of modular head seating on the cement–stem interface strength of femoral prostheses. Weiss JM, et al. **J Arthroplasty** 1998 Oct;13(7):799–803

Deformation of the acetabular polyethylene liner and the backside gap. Yamaguchi M, et al. **J Arthroplasty** 1999 Jun;14(4):464–9

Lessons learned from loosening of the McKee–Farrar metal–on–metal total hip replacement. Zahiri CA, et al. **J Arthroplasty** 1999 Apr;14(3):326–32

Hip joint forces in sheep. Bergmann G, et al. **J Biomech** 1999 Aug;32(8):769–77

Hip endoprosthesis for in vivo measurement of joint force and temperature. Graichen F, et al. **J Biomech** 1999 Oct; 32(10):1113–7

Simulation of initial frontside and backside wear rates in a modular acetabular component with multiple screw holes. Kurtz SM, et al. **J Biomech** 1999 Sep;32(9):967–76

Backside nonconformity and locking restraints affect liner/shell load transfer mechanisms and relative motion in modular acetabular components for total hip replacement. Kurtz SM, et al. **J Biomech** 1998 May; 31(5):431–7

Microdamage accumulation in the cement layer of hip replacements under flexural loading. McCormack BA, et al. **J Biomech** 1999 May;32(5):467–75

Functional adaptation and ingrowth of bone vary as a function of hip implant stiffness. Sumner DR, et al. **J Biomech** 1998 Oct;31(10):909–17

The effect of hip stem material modulus on surface strain in human femora. Vail TP, et al. **J Biomech** 1998 Jul; 31(7):619–28

A parametric study of acetabular cup design variables using finite element analysis and statistical design of experiments. Mantell SC, et al. **J Biomech Eng** 1998 Oct;120(5):667–75

Effect of metal surface topography on mechanical bonding at simulated total hip stem–cement interfaces. Chen CQ, et al. **J Biomed Mater Res** 1999;48(4):440–6

Metal wear particle characterization from metal on metal total hip replacements: transmission electron microscopy study of periprosthetic tissues and isolated particles. Doorn PF, et al. **J Biomed Mater Res** 1998 Oct;42(1):103–11

Effect of protein lubrication on the wear properties of materials for prosthetic joints. Liao YS, et al. **J Biomed Mater Res** 1999;48(4):465–73

Potential thermal artifacts in hip joint wear simulators. Lu Z, et al. **J Biomed Mater Res** 1999;48(4):458–64

Effects of prosthesis surface roughness on the failure process of cemented hip implants after stem–cement debonding. Verdonschot N, et al. **J Biomed Mater Res** 1998 Dec 15; 42(4):554–9

The Harris Design–2 total hip replacement fixed with so–called second–generation cementing techniques. A ten to fifteen–year follow–up. Bourne RB, et al. **J Bone Joint Surg Am** 1998 Dec;80(12):1775–80

The Harris–Galante porous–coated acetabular component with screw fixation. An average ten–year follow–up study. Clohisy JC, et al. **J Bone Joint Surg Am** 1999 Jan; 81(1):66–73

Medial protrusio technique for placement of a porous–coated, hemispherical acetabular component without cement in a total hip arthroplasty in patients who have acetabular dysplasia. Dorr LD, et al. **J Bone Joint Surg Am** 1999 Jan; 81(1):83–92

Effect of circumferential plasma–spray porous coating on the rate of femoral osteolysis after total hip arthroplasty. Emerson RH Jr, et al. **J Bone Joint Surg Am** 1999 Sep; 81(9):1291–8

Effect of flexibility of the femoral stem on bone–remodeling and fixation of the stem in a canine total hip arthroplasty model without cement. Harvey EJ, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):93–107

Catastrophic failure of a cemented, collarless, polished, tapered cobalt–chromium femoral stem used with impaction bone–grafting. A report of two cases. Jazrawi LM, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):844–7 (22 ref.)

Charnley total hip arthroplasty in patients less than fifty years old. A twenty to twenty–five–year follow–up note [letter; comment] Kaufman JD. **J Bone Joint Surg Am** 1999 Mar; 81(3):437. Comment on: J Bone Joint Surg Am 1998 May;80(5):704–14.

Impaction allografting with cement for revision of the femoral component. A minimum four–year follow–up study with use of a precoated femoral stem. Leopold SS, et al. **J Bone Joint Surg Am** 1999 Aug;81(8):1080–92

A femoral component inserted without cement in total hip arthroplasty. A study of the Tri–Lock component with an average ten–year duration of follow–up [letter; comment] Love BR. **J Bone Joint Surg Am** 1999 Jul; 81(7):1044–5. Comment on: J Bone Joint Surg Am 1998 Jul;80(7):952–60.

The hemispherical Harris–Galante acetabular cup, inserted without cement. The results of an eight to eleven–year follow–up of one hundred and sixty–eight hips. Petersen MB, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):219–24

Comparison of fixation of the femoral component without cement and fixation with use of a bone–vacuum cementing technique for the prevention of fat embolism during total hip arthroplasty. A prospective, randomized clinical trial. Pitto RP, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):831–43

Wear in total hip and knee replacements. Schmalzried TP, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):115–36 (256 ref.)

Factors affecting aseptic failure of fixation after primary charnley total hip arthroplasty. Multivariate survival analysis [letter; comment] Sochart DH. **J Bone Joint Surg Am** 1998 Oct;80(10):1553–4. Comment on: J Bone Joint Surg Am 1997 Nov;79(11):1618–27.

The effects of surface roughness and polymethylmethacrylate precoating on the radiographic and clinical results of the Iowa hip prosthesis. A study of patients less than fifty years old. Sporer SM, et al. **J Bone Joint Surg Am** 1999 Apr; 81(4):481–92

Analysis of temporal wear patterns of porous–coated acetabular components: distinguishing between true wear and so–called bedding–in. Sychterz CJ, et al. **J Bone Joint Surg Am** 1999 Jun;81(6):821–30

Polyethylene wear after total hip arthroplasty: the effect of a modular femoral head with an extended flange–reinforced neck. Urquhart AG, et al. **J Bone Joint Surg Am** 1998 Nov; 80(11):1641–7

Proteins bound to polyethylene components in patients who have aseptic loosening after total joint arthroplasty. A preliminary report [see comments] Wooley PH, et al. **J Bone Joint Surg Am** 1999 May;81(5):616–23. Comment in: J Bone Joint Surg Am 1999 May;81(5):599–602.

The porous–coated anatomic total hip prosthesis, inserted without cement. A prospective study with a minimum of ten years of follow–up. Xenos JS, et al. **J Bone Joint Surg Am** 1999 Jan;81(1):74–82

Determination of Hounsfield value for CT–based design of custom femoral stems. Aamodt A, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):143–7

Femoral stem fixation [letter; comment] Harrington P. **J Bone Joint Surg Br** 1999 Mar;81(2):372. Comment on: J Bone Joint Surg Br 1998 Sep;80(5):754–6.

Subsidence of a non–polished stem in revisions of the hip using impaction allograft. Evaluation with radiostereometry and dual–energy X–ray absorptiometry. Kärrholm J, et al. **J Bone Joint Surg Br** 1999 Jan; 81(1):135–42

Induction of macrophage C–C chemokine expression by titanium alloy and bone cement particles. Nakashima Y, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):155–62

Cytokine levels in synovial fluid from hips with well–functioning or loose prostheses. Nivbrant B, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):163–6

The inadequacy of standard radiographs in detecting flaws in the cement mantle. Reading AD, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):167–70

Analysis of 118 second–generation metal–on–metal retrieved hip implants. Sieber HP, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):46–50

The influence of weight–bearing on the measurement of polyethylene wear in THA. Smith PN, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):259–65

Improving the detection of acetabular osteolysis using oblique radiographs. Southwell DG, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):289–95

Migration of the Duraloc cup at two years. Stöckl B, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):51–3

Hydroxyapatite–coated femoral stems. Histology and histomorphometry around five components retrieved at post mortem. Tonino AJ, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):148–54

An FEA–based protocol for the pre–clinical validation of custom–made hip implants. Viceconti M, et al. **J Med Eng Technol** 1998 Nov–Dec;22(6):257–62

Development of an extremely wear–resistant ultra high molecular weight polyethylene for total hip replacements. McKellop H, et al. **J Orthop Res** 1999 Mar;17(2):157–67

Effect of molecular weight, calcium stearate, and sterilization methods on the wear of ultra high molecular weight polyethylene acetabular cups in a hip joint simulator. McKellop HA, et al. **J Orthop Res** 1999 May;17(3):329–39

Retrograde nailing of femoral fractures distal to a Moore prosthesis. Ponzer S, et al. **J Orthop Trauma** 1998 Nov–Dec;12(8):588–91

Effect of activity levels on polyethylene wear in Charnley low–friction arthroplasty. Prakash U, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):193–6

Hip joint prosthesis design: effect of stem introducers. Mathias KJ, et al. **Med Eng Phys** 1998 Nov;20(8):620–4

Analysis of titanium induced CT artifacts in the development of biomechanical finite element models. Zannoni C, et al. **Med Eng Phys** 1998 Nov–Dec;20(9):653–9

Femoral fixation algorithm for what works. Mallory TH. **Orthopedics** 1998 Sep;21(9):965–7 (10 ref.)

A femoral component for hip replacement. Morrey BF. **Orthopedics** 1998 Sep;21(9):1011–2

Distal fixation with fully coated stems in femoral revision: a 16–year follow–up. Paprosky WG. **Orthopedics** 1998 Sep; 21(9):993–5

The acetabular component: an elliptical monoblock alternative. Sculco TP. **Orthopedics** 1998 Sep;21(9):973–4

A multi–station hip joint simulator study of the performance of 22 mm diameter zirconia–ultra–high molecular weight polyethylene total replacement hip joints. Goldsmith AA, et al. **Proc Inst Mech Eng [H]** 1999;213(2):77–90

Development of a ten–station, multi–axis hip joint simulator. Goldsmith AA, et al. **Proc Inst Mech Eng [H]** 1999; 213(4):311–6

An axisymmetric contact model of ultra high molecular weight polyethylene cups against metallic femoral heads for artificial hip joint replacements. Jin ZM, et al. **Proc Inst Mech Eng [H]** 1999;213(4):317–27

Press–fit acetabular cup fixation: principles and testing. Macdonald W, et al. **Proc Inst Mech Eng [H]** 1999; 213(1):33–9

Quantification of interdigitation at bone cement/cancellous bone interfaces in cemented femoral reconstructions. Maher SA, et al. **Proc Inst Mech Eng [H]** 1999;213(4):347–54

Type of motion and lubricant in wear simulation of polyethylene acetabular cup. Saikko V, et al. **Proc Inst Mech Eng [H]** 1999;213(4):301–10

Interleukin–11 (IL–11) in aseptic loosening of total hip replacement (THR). Xu JW, et al. **Scand J Rheumatol** 1998; 27(5):363–7

[Analysis of causes of revision after hip replacement] Liu S, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Jan;12(1):31–2 (Eng. Abstr.) **(Chi)**

[Philosophy of total hip replacement] Lewalle J. **Acta Orthop Belg** 1998;64 Suppl 2:57–63 **(Fre)**

[Failure of the polyethylene cups directly implanted into bone. A study of 32 Freeman cups after 9 years of followup (6–12 years)] Boisgard S, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(8):700–4 (Eng. Abstr.) **(Fre)**

[10–year survival of Zweymüller total prostheses in primary uncemented arthroplasty of the hip (see comments)] Delaunay C, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Sep; 84(5):421–32 (Eng. Abstr.). Comment in: Rev Chir Orthop Reparatrice Appar Mot 1998 Nov;84(8):759–61. **(Fre)**

["10–year followup of Zweymüller's total prosthesis in primary non–cemented hip arthroplasty" (letter; comment)] Jenny JY. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov;84(8):759–61. Comment on: Rev Chir Orthop Reparatrice Appar Mot 1998 Sep;84(50:421–32. **(Fre)**

[10–year actuarial analysis of a cohort of 156 total hip prostheses of a cemented polished aluminum/polyethylene alloy] Le Mouel S, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Jul; 84(4):338–45 (Eng. Abstr.) **(Fre)**

[Complete hip prosthesis before 50 years of age] Pidhorz L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84 Suppl 1:75–120 **(Fre)**

[Cadaver study of acetabular cup mobility in the healthy hip and prosthesis by monopodal pressure simulation] Vandenbussche E, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 May; 85(2):136–45 (Eng. Abstr.) **(Fre)**

[Ceramic cups for hip endoprostheses. 6: Cup design, inclination and antetorsion angle modify range of motion and impingement] Bader R, et al. **Biomed Tech (Berl)** 1999 Jul–Aug;44(7–8):212–9 (Eng. Abstr.) **(Ger)**

[Development and validation of a method for wear measurement of polyethylene hip acetabulum with metal backing using roentgen images] Gölzhäuser G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:66–7 **(Ger)**

[New instruments for preparation of the prosthesis socket and primary stability of the acetabular Press–fit cups] Pitto RP, et al. **Biomed Tech (Berl)** 1999 Apr;44(4):92–7 (Eng. Abstr.) **(Ger)**

[Effect of socket preparation on primary stability of an elliptical acetabular component] Pitto RP, et al. **Biomed Tech (Berl)** 1998 Sep;43(9):257–60 (Eng. Abstr.) **(Ger)**

[Primary stability of 2 acetabulum roof cups and an acetabulum reinforcement cup. Effect of osseous defects] Pitto RP, et al. **Biomed Tech (Berl)** 1998 Jul–Aug; 43(7–8):210–5 (Eng. Abstr.) **(Ger)**

[Effect of substance and length of intramedullary implant rods of special tumor prostheses on bone canal] Steinhauser E, et al. **Biomed Tech (Berl)** 1998;43 Suppl:378–9 **(Ger)**

[Ceramic cups for hip endoprostheses. 5: Consideration of designs] Willmann G, et al. **Biomed Tech (Berl)** 1998 Dec; 43(12):342–9 (21 ref.) (Eng. Abstr.) **(Ger)**

[A 12–year retrospective on the cement–free prosthesis. SL (Self–Locking) femur revision–prosthesis by Wagner] **Orthopade** 1999 Feb;28(2 Suppl):1–4 **(Ger)**

[Treatment of femoral neck fractures with duo cup prosthesis] Csuka E, et al. **Swiss Surg** 1999;5(2):55–61 (Eng. Abstr.) **(Ger)**

[Periprosthetic femur shaft fracture. Indications and outcome in 51 patients] Siegmeth A, et al. **Unfallchirurg** 1998 Dec; 101(12):901–6 (Eng. Abstr.) **(Ger)**

[Stress analysis of an anatomically–adapted femur shaft prosthesis (Lubinus SPII)] Alter P, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar–Apr;137(2):129–35 (Eng. Abstr.) **(Ger)**

[Intermediate–term results with the Mecron screw cup acetabulum–-a follow–up study] Bertram R, et al.

Z Orthop Ihre Grenzgeb 1998 Jul-Aug;136(4):317-20 (Eng. Abstr.) **(Ger)**

[Anatomic basis of the cemented femur shaft. A comparative study of straight and anatomic design] Breusch SJ, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec;136(6):554-9 (Eng. Abstr.) **(Ger)**

[Proximal fixation of hip endoprostheses with porous surface: results of 6 years] Decking J, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar-Apr;137(2):108-13 (Eng. Abstr.) **(Ger)**

[Experiences with a hydroxyapatite-coated, macroporous surface hip endoprosthesis] Kinner B, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar-Apr;137(2):114-21 (Eng. Abstr.) **(Ger)**

[Comparative static biomechanical studies of tripod surface structures of cementless endoprostheses] Mittelmeier W, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar-Apr;137(2):122-8 (Eng. Abstr.) **(Ger)**

[Destruction of the gliding inlay of a hip endoprosthesis caused by intra-articular cement particles] Scharmann K, et al. **Z Orthop Ihre Grenzgeb** 1999 Mar-Apr;137(2):145-7 (Eng. Abstr.) **(Ger)**

[Gliding polyethylene-PMMA combination as "wear model"] Scheller G, et al. **Z Orthop Ihre Grenzgeb** 1998 Nov-Dec; 136(6):566-7 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Different cup migration in rheumatoid arthritis and arthrosis: a radiographic analysis of 127 uncemented acetabular cups. Dominkus M, et al. **Acta Orthop Scand** 1998 Oct; 69(5):455-62

Gene expressions of antiinflammatory mediators in THR retrieved interfacial membranes. Nabac M, et al. **Acta Orthop Scand** 1999 Apr;70(2):149-54

Poor outcome of the PCA and Harris-Galante hip prostheses. Randomized study of 171 arthroplasties with 9-year follow-up. Thanner J, et al. **Acta Orthop Scand** 1999 Apr; 70(2):155-62

Polyethylene wear and calcar osteolysis. Joshi AB, et al. **Am J Orthop** 1999 Jan;28(1):45-8

Success rates of the TARA hip [letter; comment] Pritchett JW. **Am J Orthop** 1998 Oct;27(10):658. Comment on: Am J Orthop 1997 Feb;26(2):114-8.

Conservative versus surgical treatment for femoral fracture after total or hemiarthroplasty of hip. Kligman M, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):79-81

Sensitivity to metals in 40 patients with failed hip endoprosthesis. Milavec-Puretić V, et al. **Arch Orthop Trauma Surg** 1998;117(6-7):383-6

Dislocation after total hip arthroplasty. Yuan L, et al. **Arch Orthop Trauma Surg** 1999;119(5-6):263-6

Failed cementless total hip arthroplasty for osteoarthrosis due to hip dysplasia. A minimum five-year follow-up study. Kawamoto K, et al. **Bull Hosp Jt Dis** 1998;57(3):130-5

Risk factors for prosthetic joint infection: case-control study. Berbari EF, et al. **Clin Infect Dis** 1998 Nov;27(5):1247-54

Hematogenous infection of a total hip prosthesis due to Clostridium perfringens. Vogely HC, et al. **Clin Infect Dis** 1999 Jan;28(1):157-8

A critical look at cementless stems. Taper designs and when to use alternatives. Bourne RB, et al. **Clin Orthop** 1998 Oct;(355):212-23

Cemented femoral stem performance. Effects of proximal bonding, geometry, and neck length. Chang PB, et al. **Clin Orthop** 1998 Oct;(355):57-69

Loosening rates and bone lysis with rough finished and polished stems. Collis DK, et al. **Clin Orthop** 1998 Oct; (355):113-22

Failure of total hip arthroplasty with a precoated prosthesis. 4- to 11-year results. Dowd JE, et al. **Clin Orthop** 1998 Oct;(355):123-36

Salvage of total hip instability with a constrained acetabular component. Goetz DD, et al. **Clin Orthop** 1998 Oct; (355):171-81

Long-term results of cemented femoral stems with roughened precoated surfaces. Harris WH. **Clin Orthop** 1998 Oct;(355):137-43 (32 ref.)

Migration, stem shape, and surface finish in cemented total hip arthroplasty. Huiskes R, et al. **Clin Orthop** 1998 Oct; (355):103-12

Cementless femoral design concerns. Rationale for extensive porous coating. Nourbash PS, et al. **Clin Orthop** 1998 Oct; (355):189-99 (27 ref.)

Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Hanssen AD, et al. **Instr Course Lect** 1999;48:111-22 (141 ref.)

Results with a cementless alumina-coated cup with dual mobility. A twelve-year follow-up study. Farizon F, et al. **Int Orthop** 1998;22(4):219-24

A cement spacer for two-stage revision of infected implants of the hip joint. Leunig M, et al. **Int Orthop** 1998; 22(4):209-14

Infected total hip arthroplasty--the value of intraoperative histology. Pons M, et al. **Int Orthop** 1999;23(1):34-6

Comparison of the results of the Girdlestone pseudarthrosis with reimplantation of a total hip replacement. Schröder J, et al. **Int Orthop** 1998;22(4):215-8

Changes in bone mineral density adjacent to two biomechanically different types of cementless femoral stems in total hip arthroplasty. Zerahn B, et al. **Int Orthop** 1998; 22(4):225-9

The role of intraoperative Gram stain in revision total joint arthroplasty. Della Valle CJ, et al. **J Arthroplasty** 1999 Jun;14(4):500-4

Inguinal abscess: an unusual presentation of infection around total hip replacement. Nadeem RD, et al. **J Arthroplasty** 1999 Aug;14(5):630-2

Bacteriologic evidence of infection caused by coagulase-negative staphylococci in total hip replacement. Ringberg H, et al. **J Arthroplasty** 1998 Dec;13(8):935-8

Analysis of frozen sections of intraoperative specimens obtained at the time of reoperation after hip or knee resection arthroplasty for the treatment of infection. Della Valle CJ, et al. **J Bone Joint Surg Am** 1999 May;81(5):684-9

Metallosis due to impingement between the socket and the femoral neck in a metal-on-metal bearing total hip prosthesis. A case report. Iida H, et al. **J Bone Joint Surg Am** 1999 Mar;81(3):400-3

Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. Spangehl MJ, et al. **J Bone Joint Surg Am** 1999 May; 81(5):672-83

Osteolysis in association with a total hip arthroplasty with ceramic bearing surfaces. Yoon TR, et al. **J Bone Joint Surg Am** 1998 Oct;80(10):1459-68

Infections associated with dental procedures in total hip arthroplasty [letter] Jenny JY. **J Bone Joint Surg Br** 1999 Jul;81(4):745

Infections associated with dental procedures in total hip arthroplasty. LaPorte DM, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):56-9

An assessment of the histological criteria used to diagnose infection in hip revision arthroplasty tissues. Pandey R, et al. **J Clin Pathol** 1999 Feb;52(2):118-23

Migration measurement of cementless acetabular components: value of clinical and radiographic data. Boehler M, et al. **Orthopedics** 1998 Aug;21(8):897-900

Periacetabular osteolysis demands component removal. Cuckler J. **Orthopedics** 1999 Jun;22(6):575

Component removal is not mandatory in the presence of periacetabular osteolysis. Rosenberg AG. **Orthopedics** 1999 Jun;22(6):574

The role of acetabular component screw holes and/or screws in the development of pelvic osteolysis. Schmalzried TP, et al. **Proc Inst Mech Eng [H]** 1999;213(2):147-53

Severe metallosis in an isoelastic hip prosthesis. Thiagarajan P, et al. **Singapore Med J** 1998 Jul;39(7):324-5

[The causes of failure for hip and knee arthroplasties] Huiskes R. **Ned Tijdschr Geneeskd** 1998 Sep 12;142(37):2035-40 (9 ref.) (Eng. Abstr.) **(Dut)**

[Dissociation of a modular acetabular component in an uncemented total hip prosthesis. Effect of the modular design and anti-luxation rim. A case report] Blanco Blanco J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):302-5 (Eng. Abstr.) **(Fre)**

[Posterior position of acetabular component of a total hip prosthesis: possible cause of lower limb rotation problem] Curvale G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Nov; 84(7):653-6 (Eng. Abstr.) **(Fre)**

[Value and limits of determining serum cobalt levels in patients with metal on metal articulating prostheses] Gleizes V, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):217-25 (Eng. Abstr.) **(Fre)**

[Fatal fat embolism from an infected femoral shaft during surgical removal of a hip endoprosthesis] Uslu N, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jul; 34(7):447-9 **(Ger)**

CLASSIFICATION

Changes in bone mineral density adjacent to two biomechanically different types of cementless femoral stems in total hip arthroplasty. Zerahn B, et al. **Int Orthop** 1998; 22(4):225-9

ECONOMICS

The costs and benefits of primary total hip replacement. How likely are new prostheses to be cost-effective? Briggs A, et al. **Int J Technol Assess Health Care** 1998 Fall; 14(4):743-61

Comparison of the hospital cost of primary and revision total hip arthroplasty after cost containment. Iorio R, et al. **Orthopedics** 1999 Feb;22(2):185-9

[An estimate of the intramural costs of the placement of a total hip prosthesis] Okhuijsen SY, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1450-5 (Eng. Abstr.) **(Dut)**

MICROBIOLOGY

...or not to treat? [letter] van de Belt H, et al. **Nat Med** 1999 Apr;5(4):358-9

STANDARDS

Survivorship of rough-surfaced threaded acetabular cups. 382 consecutive primary Zweymüller cups followed for 0.2-12 years. Delaunay CP, et al. **Acta Orthop Scand** 1998 Aug;69(4):379-83

Fixation and metal release from the Tifit femoral stem prosthesis. 5-year follow-up of 64 cases. Kärrholm J, et al. **Acta Orthop Scand** 1998 Aug;69(4):369-78

Tribological tests cannot replace clinical trials [editorial; comment] Ohlin A. **Acta Orthop Scand** 1998 Oct; 69(5):441-2. Comment on: Acta Orthop Scand 1998 Oct;69(5):443-8. Comment on: Acta Orthop Scand 1998 Oct;69(5):449-54.

Low wear and friction in alumina/alumina total hip joints: a hip simulator study [see comments] Saikko V, et al. **Acta Orthop Scand** 1998 Oct;69(5):443-8. Comment in: Acta Orthop Scand 1998 Oct;69(5):441-2.

Metal release from total hip articulations in vitro: substantial from CoCr/CoCr, negligible from CoCr/PE and alumina/PE [see comments] Saikko V, et al. **Acta Orthop Scand** 1998 Oct;69(5):449-54. Comment in: Acta Orthop Scand 1998 Oct;69(5):441-2.

A new technique for morphologic measurement of the femur. Its application for Japanese patients with osteoarthrosis of the hip. Miura T, et al. **Bull Hosp Jt Dis** 1998;57(4):202-7

A critical look at cementless stems. Taper designs and when to use alternatives. Bourne RB, et al. **Clin Orthop** 1998 Oct;(355):212-23

Radiographic and histologic analysis of cemented double tapered femoral stems. Brumby SA, et al. **Clin Orthop** 1998 Oct;(355):229-37

Cemented femoral component surface finish mechanics. Crowninshield RD, et al. **Clin Orthop** 1998 Oct; (355):90-102

Importance of a thin cement mantle. Autopsy studies of eight hips. Kawate K, et al. **Clin Orthop** 1998 Oct;(355):70-6

Effects of design changes on cemented tapered femoral stem fixation. Middleton RG, et al. **Clin Orthop** 1998 Oct; (355):47-56

Pressurization and centralization enhance the quality and reproducibility of cement mantles. Noble PC, et al. **Clin Orthop** 1998 Oct;(355):77-89

Cementless femoral design concerns. Rationale for extensive porous coating. Nourbash PS, et al. **Clin Orthop** 1998 Oct; (355):189-99 (27 ref.)

Accuracy of EBRA-FCA in the measurement of migration of femoral components of total hip replacement. Einzel-Bild-Röntgen-Analyse-femoral component analysis. Biedermann R, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):266-72

The control of new prosthetic implants [editorial] Grigoris P, et al. **J Bone Joint Surg Br** 1998 Nov;80(6):941-3

The prediction of failure of the stem in THR by measurement of early migration using EBRA-FCA. Einzel-Bild-Roentgen-Analyse-femoral component analysis. Krismer M, et al. **J Bone Joint Surg Br** 1999 Mar; 81(2):273-80

An analysis of hylamer and polyethylene bearings from retrieved acetabular components. Collier JP, et al. **Orthopedics** 1998 Aug;21(8):865-71

Initial stability comparison of modular hip implants in synthetic femurs. Lee TQ, et al. **Orthopedics** 1998 Aug; 21(8):885-8

The estimation of acetabular cup wear volume from two-dimensional measurements: a comprehensive analysis. Derbyshire B. **Proc Inst Mech Eng [H]** 1998;212(4):281-91

The frictional behaviour of explanted PCA hip prostheses. Elfick AP, et al. **Proc Inst Mech Eng [H]** 1998;212(5):395-7

The association between rates of wear in retrieved acetabular components and the radius of the femoral head. Hall RM, et al. **Proc Inst Mech Eng [H]** 1998;212(5):321-6

Sliding wear studies of selected nitride coatings and their potential for long-term use in orthopaedic applications. Ward LP, et al. **Proc Inst Mech Eng [H]** 1998;212(4):303-15

SUPPLY & DISTRIBUTION

Population requirement for primary hip-replacement surgery: a cross-sectional study [see comments] Frankel S, et al. **Lancet** 1999 Apr 17;353(9161):1304-9. Comment in: Lancet 1999 Jun 19;353(9170):2161.

VETERINARY

Canine uncemented porous-coated anatomic total hip arthroplasty: results of a long-term prospective evaluation of 50 consecutive cases. Marcellin-Little DJ, et al. **Vet Surg** 1999 Jan-Feb;28(1):10-20

HIP PROSTHESIS IMPLANTATION see **ARTHROPLASTY, REPLACEMENT, HIP**

HIP REPLACEMENT, TOTAL see **ARTHROPLASTY, REPLACEMENT, HIP**

HIPAA see **HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT**

HIPPEL-LINDAU DISEASE

Pregnancy in von Hippel-Lindau disease. Grimbert P, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):110-1

Third International Meeting on von Hippel-Lindau disease. Zbar B, et al. **Cancer Res** 1999 May 1;59(9):2251-3

[von Hippel-Lindau disease] Kanno H, et al. **No To Shinkei** 1999 Jan;51(1):33-40 (30 ref.) **(Jpn)**

COMPLICATIONS

The hereditary forms of pancreatic neuroendocrine tumors. DeLellis RA. **Adv Anat Pathol** 1999 May;6(3):149-53

Postpartum cerebellar herniation in von Hippel-Lindau syndrome. Othmane IS, et al. **Am J Ophthalmol** 1999 Sep;

128(3):387–9
Clinical characteristics of ocular angiomatosis in von Hippel–Lindau disease and correlation with germline mutation. Webster AR, et al. **Arch Ophthalmol** 1999 Mar; 117(3):371–8
Pancreatic metastasis from renal cell carcinoma causing massive gastrointestinal bleeding in von Hippel–Lindau disease. Sugiyama M, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1199–201
Hepatic hemangioblastoma: an unusual presentation of von Hippel–Lindau disease. Hayasaka K, et al. **J Comput Assist Tomogr** 1999 Jul–Aug;23(4):565–6
Pheochromocytoma and clear–cell renal carcinoma in a child with von Hippel–Lindau disease: a patient report. Ferragut J, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug; 12(4):579–82
Management of hereditary pheochromocytoma in von Hippel–Lindau kindreds with partial adrenalectomy. Walther MM, et al. **J Urol** 1999 Feb;161(2):395–8
Clinical and genetic characterization of pheochromocytoma in von Hippel–Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. Walther MM, et al. **J Urol** 1999 Sep; 162(3 Pt 1):659–64
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel–Lindau disease and multiple endocrine neoplasia type 2. Eisenhofer G, et al. **N Engl J Med** 1999 Jun 17;340(24):1872–9
Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Libutti SK, et al. **Surgery** 1998 Dec; 124(6):1153–9
[Neuro–endocrine tumors and von Hippel–Lindau disease. 3 cases] Aubert–Petit G, et al. **Presse Med** 1999 Jun 26; 28(23):1231–4 (Eng. Abstr.) **(Fre)**
[Bilateral pheochromocytomas with von Hippel–Lindau's disease: a case report] Kubota Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Aug;89(8):726–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of spinal cord hemangioblastoma in von Hippel–Lindau disease] Nakashima H, et al. **No Shinkei Geka** 1999 Jun;27(6):533–40 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Gastrointestinal/genitourinary case of the day. von Hippel–Lindau disease. Chaoui AS, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):789, 793–4
Molecular diagnosis of inherited diseases [published erratum appears in Clin Chim Acta 1999 Apr;28(1–2):229] Murgia A, et al. **Clin Chim Acta** 1999 Feb;280(1–2):73–80 (16 ref.)
Von Hippel–Lindau disease: strategies in early detection (renal–, adrenal–, pancreatic masses). Hes FJ, et al. **Eur Radiol** 1999;9(4):598–610 (142 ref.)
Cerebellar hemangioblastoma as a late manifestation of sporadic von Hippel–Lindau disease. Kume H, et al. **J Urol** 1999 Mar;161(3):911–2
Images in clinical medicine. von Hippel–Lindau disease. Goldsmith DJ, et al. **N Engl J Med** 1999 Jun 17; 340(24):1880
[Von Hippel–Lindau disease––a multidisciplinary, underdiagnosed condition] Møller HU. **Ugeskr Laeger** 1999 Feb 15;161(7):969–70 **(Dan)**
[von Hippel–Lindau presenting as acute pancreatitis secondary to multiple pancreatic cysts (letter)] Klein I, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):102–3 **(Fre)**

GENETICS

An analysis of phenotypic variation in the familial cancer syndrome von Hippel–Lindau disease: evidence for modifier effects. Webster AR, et al. **Am J Hum Genet** 1998 Oct;63(4):1025–35
Functioning carotid paraganglioma in the von Hippel–Lindau syndrome [letter] Schimke RN, et al. **Am J Med Genet** 1998 Dec 28;80(5):533–4
VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Chan CC, et al. **Arch Ophthalmol** 1999 May;117(5):625–30
Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel–Lindau tumor suppressor gene loss of function. Krieg M, et al. **Blood** 1998 Nov 1;92(9):3388–93
Establishment of experimental conditions for the rapid detection of mutations in the von Hippel–Lindau gene by parallel temperature gradient gel electrophoresis. Hernández A, et al. **Electrophoresis** 1999 Jul;20(10):1958–61
Morphologic and genetic analysis of retinal angioma associated with massive gliosis in a patient with von Hippel–Lindau disease. Vortmeyer AO, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun;237(6):513–7
Germline mutations detected in the von Hippel–Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. Li C, et al. **Hum Mutat** 1998; Suppl 1:S31–3
Three novel mutations in the Von Hippel–Lindau tumour suppressor gene in Italian patients. Mandich P, et al. **Hum Mutat** 1998;Suppl 1:S268–70
Germline mutation profile of the VHL gene in von Hippel–Lindau disease and in sporadic hemangioblastoma. Olschwang S, et al. **Hum Mutat** 1998;12(6):424–30
Improved detection of germline mutations in the von Hippel–Lindau disease tumor suppressor gene. Stolle C, et al. **Hum Mutat** 1998;12(6):417–23
Differences in allelic distribution of two polymorphisms in the VHL–associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations. Duerr EM, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3207–11
Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. Brauch H, et al. **J Natl Cancer Inst** 1999 May 19;91(10):854–61
von Hippel–Lindau gene mutations in human and rodent renal tumors––association with clear cell phenotype [editorial; comment] Gnarra JR. **J Natl Cancer Inst** 1998 Nov 18;90(22):1685–7. Comment on: J Natl Cancer Inst 1998 Nov 18;90(22):1720–3.
Tracking von Hippel–Lindau mutations for patterns of disease [news] McCann J. **J Natl Cancer Inst** 1999 Jan 6; 91(1):12–4
aHIF: the missing link between HIF–1 and VHL? [editorial; comment] Neckers LM. **J Natl Cancer Inst** 1999 Jan 20; 91(2):106–7. Comment on: J Natl Cancer Inst 1999 Jan 20;91(2):143–51.
von Hippel–Lindau gene mutations in N–nitrosodimethylamine–induced rat renal epithelial tumors [see comments] Shiao YH, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1720–3. Comment in: J Natl Cancer Inst 1998 Nov 18;90(22):1685–7.
Clinical and genetic characterization of pheochromocytoma in von Hippel–Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. Walther MM, et al. **J Urol** 1999 Sep; 162(3 Pt 1):659–64
Development of high–grade renal cell carcinomas in rats independently of somatic mutations in the Tsc2 and VHL tumor suppressor genes. Toyokuni S, et al. **Jpn J Cancer Res** 1998 Aug;89(8):814–20
Efficacy of gene testing for von Hippel–Lindau disease. Martin RL, et al. **Med J Aust** 1998 Oct 19;169(8):422–4
Protective function of von Hippel–Lindau protein against impaired protein processing in renal carcinoma cells. Gorospe M, et al. **Mol Cell Biol** 1999 Feb;19(2):1289–300
The von Hippel–Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor–induced invasion and branching morphogenesis in renal carcinoma cells. Koochekpour S, et al. **Mol Cell Biol** 1999 Sep;19(9):5902–12
A PCR generated BsaJ I RFLP in the promoter of the von Hippel–Lindau disease (VHL) tumour suppressor gene. Geil L, et al. **Mol Cell Probes** 1998 Oct;12(5):343–4
The von Hippel–Lindau tumour suppressor protein: new perspectives. Ohh M, et al. **Mol Med Today** 1999 Jun; 5(6):257–63 (45 ref.)
Cancer. Many vessels, faulty gene [news; comment] Kaelin WG Jr. **Nature** 1999 May 20;399(6733):203–4. Comment on: Nature 1999 May 20;399(6733):271–5.
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel–Lindau disease [see comments] Kawahara N, et al. **Neurology** 1999 Jul 13;53(1):208–10. Comment in: Neurology 1999 Jul 13;53(1):7–8.
Von Hippel–Lindau disease: how does one gene cause multiple tumors? [editorial; comment] Roach ES. **Neurology** 1999 Jul 13;53(1):7–8. Comment on: Neurology 1999 Jul 13;53(1):208–10.
A clinical and molecular genetic analysis of solitary ocular angioma. Webster AR, et al. **Ophthalmology** 1999 Mar; 106(3):623–9
Structure of the VHL–ElonginC–ElonginB complex: implications for VHL tumor suppressor function. Stebbins CE, et al. **Science** 1999 Apr 16;284(5413):455–61
The VHL tumour–suppressor gene paradigm. Kaelin WG Jr, et al. **Trends Genet** 1998 Oct;14(10):423–6 (47 ref.)
[Von Hippel–Lindau disease and molecular genetic diagnosis] Jensen AM, et al. **Ugeskr Laeger** 1999 Feb 15;161(7):959–61 (Eng. Abstr.) **(Dan)**
[Von Hippel–Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel–Lindau Disease (GEFVH)] Richard S, et al. **Ann Endocrinol (Paris)** 1998;59(6):452–8 (45 ref.) (Eng. Abstr.) **(Fre)**
[Von Hippel–Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management] Richard S, et al. **Neurochirurgie** 1998 Nov; 44(4):258–66 (59 ref.) (Eng. Abstr.) **(Fre)**
[Retinal capillary angioma. Clinical and molecular genetic studies] Kreusel KM, et al. **Ophthalmologe** 1999 Feb; 96(2):71–6 (Eng. Abstr.) **(Ger)**
[Hippel–Lindau disease] Krzystolik K, et al. **Neurol Neurochir Pol** 1998 Sep–Oct;32(5):1119–33 (21 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Inflammatory cell infiltrate in a responding metastatic nodule after vaccine–based immunotherapy. Logan TF, et al. **Clin Exp Immunol** 1998 Dec;114(3):347–54

METABOLISM

Expression of vascular endothelial growth factor in von Hippel–Lindau syndrome–associated papillary cystadenoma of the epididymis. Leung SY, et al. **Hum Pathol** 1998 Nov;29(11):1322–4
aHIF: the missing link between HIF–1 and VHL? [editorial; comment] Neckers LM. **J Natl Cancer Inst** 1999 Jan 20; 91(2):106–7. Comment on: J Natl Cancer Inst 1999 Jan 20;91(2):143–51.
Protective function of von Hippel–Lindau protein against impaired protein processing in renal carcinoma cells. Gorospe M, et al. **Mol Cell Biol** 1999 Feb;19(2):1289–300

PATHOLOGY

Renal lesions in Von Hippel–Lindau disease: the benign, the malignant, the unknown. Salomé F, et al. **Eur Urol** 1998; 34(5):383–92
The neuropathology of selected neurocutaneous diseases. Nelson JS. **Semin Pediatr Neurol** 1995 Sep;2(3):192–9 (42 ref.)
[Von Hippel–Lindau disease: a hereditary disease that impacts multiple tissues] Richard S, et al. **Presse Med** 1998 Jun 20;27(22):1112–20 (61 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Epidural anesthesia for cesarean section in a patient with von Hippel–Lindau disease and multiple sclerosis. Wang A, et al. **Anesth Analg** 1999 May;88(5):1083–4

RADIOGRAPHY

Renal lesions in Von Hippel–Lindau disease: the benign, the malignant, the unknown. Salomé F, et al. **Eur Urol** 1998; 34(5):383–92

SURGERY

Management of renal cell carcinoma in von Hippel–Lindau disease. Hes FJ, et al. **Eur J Clin Invest** 1999 Jan; 29(1):68–75
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. Walther MM, et al. **J Urol** 1999 May;161(5):1475–9
[Multifocal hemangioblastoma in a young woman with Hippel–Lindau syndrome] Gumprecht H, et al. **Zentralbl Neurochir** 1998;59(3):181–4 (Eng. Abstr.) **(Ger)**

THERAPY

[Von Hippel–Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel–Lindau Disease (GEFVH)] Richard S, et al. **Ann Endocrinol (Paris)** 1998;59(6):452–8 (45 ref.) (Eng. Abstr.) **(Fre)**
[Guidelines for the maintenance of Hippel–Lindau disease in daily practice. French Society of Neurosurgery] Decq P. **Neurochirurgie** 1998 Nov;44(4):273–4 (Eng. Abstr.) **(Fre)**

HIPPOCAMPAL FORMATION see **HIPPOCAMPUS**

HIPPOCAMPAL MOSSY FIBERS see **MOSSY FIBERS, HIPPOCAMPAL**

HIPPOCAMPUS

see related

ENTORHINAL CORTEX

The chronic cell death with DNA fragmentation after post–ischaemic hypothermia in the gerbil hippocampus. Nakamura T, et al. **Acta Neurochir (Wien)** 1999; 141(4):407–12; discussion 412–3
Alterations of calcium/calmodulin–dependent protein kinase II activity in ischaemia–induced neuronal death and neuronal protection against ischaemia in the gerbil hippocampus. Uno H, et al. **Acta Neurochir (Wien)** 1999; 141(3):287–94
Does stress damage the brain? Bremner JD. **Biol Psychiatry** 1999 Apr 1;45(7):797–805 (93 ref.)
Hippocampal sclerosis revisited. Fisher PD, et al. **Brain Dev** 1998 Dec;20(8):563–73 (108 ref.)
Reduced hippocampal N–acetylaspartate without volume loss in schizophrenia. Deicken RF, et al. **Schizophr Res** 1999 Jun 22;37(3):217–23
[Influence of NMDA receptor stimulation in brain cortex and hippocampus on NO dependent cGMP synthase. Effect of ischemia on NO related biochemical processes during recirculation] Chalimoniuk M, et al. **Neurol Neurochir Pol** 1998 May–Jun;32(3):551–62 (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Uniform abnormalities in the hippocampus of five chronic schizophrenic men compared with age–matched controls. Luts A, et al. **Acta Psychiatr Scand** 1998 Jul;98(1):60–4
Regional changes in hippocampal T2 relaxation and volume: a quantitative magnetic resonance imaging study of hippocampal sclerosis. Woermann FG, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):656–64
Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice. Demyanenko GP, et al. **J Neurosci** 1999 Jun 15; 19(12):4907–20
Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin–2 gene deletion. Petitto JM, et al. **J Neurosci Res** 1999 May 15; 56(4):441–6
[The clinico–neuropsychological aspects of arteriovenous malformations of the hippocampus] Buklina SB, et al.

HIPPOCAMPUS

Zh Vopr Neirokhir Im N N Burdenko 1998 Oct-Dec; (4):18-20; discussion 20-1 (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

A quantitative MR study of the hippocampal formation, the amygdala, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. Mu Q, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):207-11

High-field, high-resolution MR imaging of the human indusium griseum. Nakada T. **AJNR Am J Neuroradiol** 1999 Mar;20(3):524-5

MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. Aylward EH, et al. **Am J Psychiatry** 1999 Apr;156(4):564-8

Neural plasticity and the development of sex differences. Juraska JM. **Annu Rev Sex Res** 1998;9:20-38 (61 ref.)

Hippocampal volume in patients with alcohol dependence. Agartz I, et al. **Arch Gen Psychiatry** 1999 Apr;56(4):356-63

Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Velakoulis D, et al. **Arch Gen Psychiatry** 1999 Feb;56(2):133-41

Segmentation of the hippocampus from brain MRI using deformable contours. Ghanei A, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):203-16

Normative volumetric data of the developing hippocampus in children based on magnetic resonance imaging. Pfluger T, et al. **Epilepsia** 1999 Apr;40(4):414-23

Stratum radiatum giant cells: a type of principal cell in the rat hippocampus. Gulyás AI, et al. **Eur J Neurosci** 1998 Dec;10(12):3813-22

Introduction: what is where in the medial temporal lobe? Amaral DG. **Hippocampus** 1999;9(1):1-6

Functional differentiation in the hippocampus. Moser MB, et al. **Hippocampus** 1998;8(6):608-19 (126 ref.)

Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7-24 (86 ref.)

Hippocampal layers on high resolution magnetic resonance images: real or imaginary? Wieshmann UC, et al. **J Anat** 1999 Jul;195 (Pt 1):131-5

Fiber system linking the mid-dorsolateral frontal cortex with the retrosplenial/presubicular region in the rhesus monkey. Morris R, et al. **J Comp Neurol** 1999 May 3;407(2):183-92

Projections from the lateral, basal, and accessory basal nuclei of the amygdala to the hippocampal formation in rat. Pikkarainen M, et al. **J Comp Neurol** 1999 Jan 11; 403(2):229-60

Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats. Rapp PR, et al. **J Comp Neurol** 1999 Jan 25;403(4):459-70

Volumetric MRI measurements of the tree shrew hippocampus. Ohl F, et al. **J Neurosci Methods** 1999 May 1;88(2):189-93

Determination of stereotaxic coordinates for the hippocampus in the domestic pig. Saito T, et al. **J Neurosci Methods** 1998 Mar 13;80(1):29-36

Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Golomb J, et al. **Learn Mem** 1994 May-Jun;1(1):45-54

MRI measurement of cell volume fraction in the perfused rat hippocampal slice. Buckley DL, et al. **Magn Reson Med** 1999 Sep;42(3):603-7

Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome [published erratum appears in Neurosci Lett 1998 Dec 24;258(3):190] Insausti AM, et al. **Neurosci Lett** 1998 Sep 11;253(3):175-8

Spatial learning and hippocampal volume in male deer mice: relations to age, testosterone and adrenal gland weight. Perrot-Sinal TS, et al. **Neuroscience** 1998 Oct;86(4):1089-99

Transcallosal approach to the third ventricle: normative morphometric data based on magnetic resonance imaging scans, with special reference to the fornix and forniceal insertion. Winkler PA, et al. **Neurosurgery** 1999 Aug; 45(2):309-17; discussion 317-9

Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Csernansky JG, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11406-11

MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. Convit A, et al. **Psychiatry Res** 1999 Apr 26;90(2):113-23

MR imaging of the hippocampus: measurement of T2 with four dual-echo techniques. Melhem ER, et al. **Radiology** 1998 Nov;209(2):551-5

Dinucleotide repeat polymorphism in the neurotrophin-3 gene and hippocampal volume in psychoses [letter] Kunugi H, et al. **Schizophr Res** 1999 Jun 22;37(3):271-3

Can neuronavigation contribute to standardization of selective amygdalohippocampectomy? Van Roost D, et al. **Stereotact Funct Neurosurg** 1997;69(1-4 Pt 2):239-42

BLOOD SUPPLY

Selective hippocampal damage to hypoxia after mild closed head injury in the rat. Katoh H, et al. **Acta Neurochir Suppl (Wien)** 1998;71:247-9

Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Latini S, et al. **Br J Pharmacol** 1999 Jun;127(3):729-39

Ischemia-induced neuronal cell loss is associated with loss of atypical angiotensin type-1 receptor expression in the gerbil hippocampal formation. Häuser W, et al. **Brain Res** 1999 Jan 30;817(1-2):34-44

Occlusion of the MCA by an intraluminal filament may cause disturbances in the hippocampal blood flow due to anomalies of circle of Willis and filament thickness. Ozdemir YG, et al. **Brain Res** 1999 Mar 20;822(1-2):260-4

Effect of seizures on cerebral hypoxic-ischemic lesions in immature rats. Towfighi J, et al. **Brain Res Dev Brain Res** 1999 Mar 12;113(1-2):83-95

The effect of hypothermia on the expression of neurotrophin mRNA in the hippocampus following transient cerebral ischemia in the rat. Boris-Möller F, et al. **Brain Res Mol Brain Res** 1998 Dec 10;63(1):163-73

Global cerebral ischemia due to cardiocirculatory arrest in mice causes neuronal degeneration and early induction of transcription factor genes in the hippocampus. Böttiger BW, et al. **Brain Res Mol Brain Res** 1999 Mar 5; 65(2):135-42

Role of the ryanodine receptor in ischemic brain damage--localized reduction of ryanodine receptor binding during ischemia in hippocampus CA1. Nozaki H, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):119-31 (74 ref.)

Hippocampal synaptic density and glutamate immunoreactivity following transient cerebral ischaemia in the chick. Horner CH, et al. **Eur J Neurosci** 1998 Dec; 10(12):3913-7

MR measurement of regional relative cerebral blood volume in epilepsy. Wu RH, et al. **J Magn Reson Imaging** 1999 Mar;9(3):435-40

Decreased hippocampal expression, but not functionality, of GABA(B) receptors after transient cerebral ischemia in rats. Francis J, et al. **J Neurochem** 1999 Jan;72(1):87-94

Bilateral decrease in interictal hippocampal blood flow in unilateral mesiotemporal epilepsy. Rougier A, et al. **J Neurosurg** 1999 Feb;90(2):282-8

Hippocampal ischemia in a patient who experienced transient global amnesia after undergoing cerebral angiography. Case illustration. Tanabe M, et al. **J Neurosurg** 1999 Aug; 91(2):347

Mild traumatic brain injury does not modify the cerebral blood flow profile of secondary forebrain ischemia in Wistar rats. Davis KL, et al. **J Neurotrauma** 1998 Aug; 15(8):615-25

Effects of certain cerebral circulation activating drugs on regional cerebral blood flow in rats. Izumo T, et al. **Methods Find Exp Clin Pharmacol** 1999 May;21(4):279-83

Quantitative analysis of peptide and protein changes in ischemic hippocampal tissue by HPLC. Wengenack TM, et al. **Methods Mol Biol** 1998;108:165-80

The effects of 17beta-estradiol on ischemia-induced neuronal damage in the gerbil hippocampus. Chen J, et al. **Neuroscience** 1998 Dec;87(4):817-22

Chronic stress exposure influences local cerebral blood flow in the rat hippocampus. Endo Y, et al. **Neuroscience** 1999; 93(2):551-5

Neurovascular relationships in hippocampal slices: physiological and anatomical studies of mechanisms underlying flow-metabolism coupling in intraparenchymal microvessels. Lovick TA, et al. **Neuroscience** 1999; 92(1):47-60

Failure of glutathione peroxidase to reduce transient ischemic injury in the rat hippocampal CA1 subfield. Yano T, et al. **Resuscitation** 1998 Oct-Nov;39(1-2):91-8

[The clinico-neuropsychological aspects of arteriovenous malformations of the hippocampus] Buklina SB, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Oct-Dec; (4):18-20; discussion 20-1 (Eng. Abstr.) **(Rus)**

CHEMISTRY

TEM investigations of biogenic magnetite extracted from the human hippocampus. Schultheiss-Grassi PP, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):212-6

Characterization of receptors for ciliary neurotrophic factor on rat hippocampal astrocytes. Alderson RF, et al. **Brain Res** 1999 Feb 13;818(2):236-51

The demonstration of immunoreactive dystrophin and its developmental expression in perivascular astrocytes. Jancsik V, et al. **Brain Res** 1999 Jun 12;831(1-2):200-5

Quantitative analysis of GABAergic neurons in the mouse hippocampus, with optical disector using confocal laser scanning microscope. Jinno S, et al. **Brain Res** 1998 Dec 14;814(1-2):55-70

Hippocampal microtubule-associated protein-2 alterations with contextual memory. Woolf NJ, et al. **Brain Res** 1999 Mar 6;821(1):241-9

Markers for neuronal degeneration in organotypic slice cultures. Noraberg J, et al. **Brain Res Brain Res Protoc** 1999 Jan;3(3):278-90

Metabotropic glutamate receptors are involved in calcium-induced LTP of AMPA and NMDA receptor-mediated responses in the rat hippocampus. Yang SN, et al. **Brain Res Bull** 1998 Aug;46(6):505-12

Antisense oligodeoxynucleotides against the muscarinic m2, but not m4, receptor supports its role as autoreceptors in the rat hippocampus. Kitaichi K, et al. **Brain Res Mol Brain Res** 1999 Apr 6;67(1):98-106

Measurement of NMDA receptor protein subunits in discrete hippocampal regions of kindled animals. Kraus JE, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):114-20

Synaptophysin immunohistochemistry densitometry measurement in resected human hippocampus: implication for the etiology of hippocampal sclerosis. Davies KG, et al. **Epilepsy Res** 1998 Nov;32(3):335-44

Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphé reveals differential GABAergic control in two animal tests of anxiety. Gonzalez LE, et al. **Eur J Neurosci** 1998 Dec; 10(12):3673-80

Hippocampal synaptic density and glutamate immunoreactivity following transient cerebral ischaemia in the chick. Horner CH, et al. **Eur J Neurosci** 1998 Dec; 10(12):3913-7

Clusters of GABAA receptors on cultured hippocampal cells correlate only partially with functional synapses. Kannenberg K, et al. **Eur J Neurosci** 1999 Apr; 11(4):1256-64

Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Okada M, et al. **Eur J Neurosci** 1999 Jan;11(1):1-9

Effects of the atypical antidepressant trimipramine on field potentials in the low Mg2+-model in guinea pig hippocampal slices. Langosch JM, et al. **Eur Neuropsychopharmacol** 1998 Aug;8(3):209-12

Progress in spanning the molecular and behavioral mechanisms of hippocampal function [editorial; comment] Eichenbaum H. **Hippocampus** 1999;9(2):100. Comment on: Hippocampus 1999 ;9(2):118-36.

Molecular studies define the primary structure of alpha1-antichymotrypsin (ACT) protease inhibitor in Alzheimer's disease brains. Comparison of act in hippocampus and liver. Hwang SR, et al. **J Biol Chem** 1999 Jan 15;274(3):1821-7

High-performance liquid chromatography with peroxyoxalate chemiluminescence determination of propentofylline concentrations in rat brain microdialysate. Hamachi Y, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 5;724(1):189-94

Increase in proportion of hippocampal spine synapses expressing neural cell adhesion molecule NCAM180 following long-term potentiation. Schuster T, et al. **J Neurobiol** 1998 Nov 15;37(3):359-72

Insulin causes a transient tyrosine phosphorylation of NR2A and NR2B NMDA receptor subunits in rat hippocampus. Christie JM, et al. **J Neurochem** 1999 Apr;72(4):1523-8

Activity-dependent phosphorylation of SNAP-25 in hippocampal organotypic cultures. Genoud S, et al. **J Neurochem** 1999 Apr;72(4):1699-706

A nuclear microscopic study of elemental changes in the rat hippocampus after kainate-induced neuronal injury. Ong WY, et al. **J Neurochem** 1999 Apr;72(4):1574-9

Endogenous pH shifts facilitate spreading depression by effect on NMDA receptors. Tong CK, et al. **J Neurophysiol** 1999 Apr;81(4):1988-91

A 29 kDa intracellular chloride channel p64H1 is associated with large dense-core vesicles in rat hippocampal neurons. Chuang JZ, et al. **J Neurosci** 1999 Apr 15;19(8):2919-28

The mammalian staufen protein localizes to the somatodendritic domain of cultured hippocampal neurons: implications for its involvement in mRNA transport. Kiebler MA, et al. **J Neurosci** 1999 Jan 1;19(1):288-97

The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. Lehre KP, et al. **J Neurosci** 1998 Nov 1;18(21):8751-7

Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. Mazarati AM, et al. **J Neurosci** 1998 Dec 1;18(23):10070-7

Opioid receptor subtype expression defines morphologically distinct classes of hippocampal interneurons. Svoboda KR, et al. **J Neurosci** 1999 Jan 1;19(1):85-95

Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. Vezzani A, et al. **J Neurosci** 1999 Jun 15;19(12):5054-65

Simultaneous determination of acetylcholine, choline and physostigmine in microdialysis samples from rat hippocampus by microbore liquid chromatography/electrochemistry on peroxidase redox polymer coated electrodes. Kehr J, et al. **J Neurosci Methods** 1998 Sep 1;83(2):143-50

Induction of hyperphosphorylated tau in living slices of rat hippocampal formation and subsequent detection using an ELISA. Mudher AK, et al. **J Neurosci Methods** 1999 Apr 1;88(1):15-25

Synaptic coexistence of AMPA and NMDA receptors in the rat hippocampus: a postembedding immunogold study. He Y, et al. **J Neurosci Res** 1998 Nov 15;54(4):444-9

Brain N-acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan-Feb;33(1):41-51 (126 ref.)

Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia [see comments] [published erratum appears in Lancet 1999 Jan 9;353(9147):154] Harrison PJ, et al. **Lancet** 1998 Nov 21;352(9141):1669-73 . Comment in: Lancet 1998 Nov 21;352(9141):1643.

Muscarinic receptor subtypes involved in hippocampal circuits. Rouse ST, et al. **Life Sci** 1999;64(6-7):501-9 (43 ref.)

Galanin receptors in the hippocampus and entorhinal cortex of aged Fischer 344 male rats. Planas B, et al. **Neurobiol Aging** 1998 Sep-Oct;19(5):427-35

Mapping brain networks engaged by, and changed by,

learning. Gall CM, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):14-36

LTP in CA1 of the adult rat hippocampus and voltage-activated calcium channels. Izumi Y, et al. **Neuroreport** 1998 Nov 16;9(16):3689-91

Developmental expression of GDNF, neurturin and their receptors in rat hippocampus. Lenhard T, et al. **Neuroreport** 1998 Sep 14;9(13):2927-31

Mineralocorticoid receptors regulate bcl-2 and p53 mRNA expression in hippocampus. McCullers DL, et al. **Neuroreport** 1998 Sep 14;9(13):3085-9

N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Mazarati AM, et al. **Neurosci Lett** 1999 Apr 23; 265(3):187-90

Cholinergic lesions of the rat brain by ibotenic acid and 192 IgG-saporin: effects on somatostatin, substance P and neuropeptide Y levels in the cerebral cortex and the hippocampus. Nag S, et al. **Neurosci Lett** 1998 Aug 14; 252(2):83-6

Imaging of the super high affinity binding sites for [3H]Ro15-4513 in rat hippocampus: comparison between in vitro and in vivo binding. Nakano T, et al. **Neurosci Lett** 1998 Jul 10;250(3):161-4

Immunocytochemical evidence for a distinct GFAP-negative subpopulation of astrocytes in the adult rat hippocampus. Walz W, et al. **Neurosci Lett** 1998 Dec 4;257(3):127-30

Nuclear magnetic resonance imaging measurements of water diffusion in the perfused hippocampal slice during N-methyl-D-aspartate-induced excitotoxicity. Bui JD, et al. **Neuroscience** 1999;93(2):487-90

High level of adenosine A1 receptor-like immunoreactivity in the CA2/CA3a region of the adult rat hippocampus. Ochiishi T, et al. **Neuroscience** 1999;93(3):955-67

Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. van der Zee EA, et al. **Prog Neurobiol** 1999 Aug;58(5):409-71 (620 ref.)

Coupling efficiency of brain beta-adrenergic receptors to Gs protein in suicide, alcoholism and control subjects. Gurguis GN, et al. **Psychopharmacology (Berl)** 1999 Jul;145(1):31-8

Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Schroeder H, et al. **Psychopharmacology (Berl)** 1999 Jul;145(1):61-6

Glutamatergic synaptic responses and long-term potentiation are impaired in the CA1 hippocampal area of calbindin D(28k)-deficient mice. Jouvenceau A, et al. **Synapse** 1999 Sep 1;33(3):172-80

CYTOLOGY

Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Futerman AH. **Acta Biochim Pol** 1998;45(2):469-78 (33 ref.)

Electrophysiology of hippocampal CA1 neurons after prenatal ethanol exposure. Krahl SE, et al. **Alcohol** 1999 Feb;17(2):125-31

Effects of the Aconitum alkaloid songorine on synaptic transmission and paired-pulse facilitation of CA1 pyramidal cells in rat hippocampal slices. Ameri A. **Br J Pharmacol** 1998 Oct;125(3):461-8

Synaptic reorganization in explanted cultures of rat hippocampus. Gutiérrez R, et al. **Brain Res** 1999 Jan 9; 815(2):304-16

Blockade of bepridil on IA and IK in acutely isolated hippocampal CA1 neurons. Hu H, et al. **Brain Res** 1998 Nov 2;809(2):149-54

High-threshold calcium channel activity in rat hippocampal neurones during hypoxia. Shkryl VM, et al. **Brain Res** 1999 Jul 3;833(2):319-28

Long-lasting structural changes in CA3 hippocampal and layer V motor cortical pyramidal neurons associated with self-stimulation rewarding experience: a quantitative Golgi study. Shankaranarayana Rao BS, et al. **Brain Res Bull** 1998 Sep 1;47(1):95-101

Developmental study of miniature IPSCs of CA3 hippocampal cells: modulation by midazolam. Rovira C, et al. **Brain Res Dev Brain Res** 1999 Apr 12;114(1):79-88

Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Bastianetto S, et al. **Brain Res Mol Brain Res** 1999 Mar 20;66(1-2):35-41

Spatial view cells in the primate hippocampus: allocentric view not head direction or eye position or place. Georges-François P, et al. **Cereb Cortex** 1999 Apr-May; 9(3):197-212

Variation in hippocampal neuron number with age and brain volume. Harding AJ, et al. **Cereb Cortex** 1998 Dec; 8(8):710-8

Association of the type 1 protein phosphatase PP1 with the A-kinase anchoring protein AKAP220. Schillace RV, et al. **Curr Biol** 1999 Mar 25;9(6):321-4

Cajal-Retzius cells, Reelin, and the formation of layers. Frotscher M. **Curr Opin Neurobiol** 1998 Oct;8(5):570-5 (49 ref.)

Regulation of back-propagating action potentials in hippocampal neurons. Johnston D, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):288-92 (34 ref.)

Hippocampal cell density and subcortical metabolism in temporal lobe epilepsy. Dlugos DJ, et al. **Epilepsia** 1999 Apr;40(4):408-13

Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. Foldvary N, et al. **Epilepsia** 1999 Jan;40(1):26-9

Halothane as a neuroprotectant during constant stimulation of the perforant path. Walker MC, et al. **Epilepsia** 1999 Mar;40(3):359-64

GABAergic cell types in the lizard hippocampus. Guirado S, et al. **Eur J Morphol** 1999 Apr;37(2-3):89-94

IPSPs elicited in CA1 pyramidal cells by putative basket cells in slices of adult rat hippocampus. Ali AB, et al. **Eur J Neurosci** 1999 May;11(5):1741-53

CaMKII-dependent phosphorylation of NR2A and NR2B is decreased in animals characterized by hippocampal damage and impaired LTP. Caputi A, et al. **Eur J Neurosci** 1999 Jan;11(1):141-8

Sustained activation of hippocampal pyramidal cells by 'space clamping' in a running wheel. Czurkó A, et al. **Eur J Neurosci** 1999 Jan;11(1):344-52

Stratum radiatum giant cells: a type of principal cell in the rat hippocampus. Gulyás AI, et al. **Eur J Neurosci** 1998 Dec;10(12):3813-22

BDNF and NT-4 differentiate two pathways in the modulation of neuropeptide protein levels in postnatal hippocampal interneurons. Marty S, et al. **Eur J Neurosci** 1999 May;11(5):1647-56

A purinergic component of the excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons of the rat hippocampus. Pankratov Y, et al. **Eur J Neurosci** 1998 Dec;10(12):3898-902

Effects of mesaconitine on [3H]noradrenaline uptake and neuronal excitability in rat hippocampus. Ameri A, et al. **Exp Brain Res** 1998 Aug;121(4):451-6

Sympathetic sprouting: no evidence for muscarinic modulation of noradrenaline release in hippocampal slices of rats with fimbria-fornix lesions. Jackisch R, et al. **Exp Brain Res** 1999 Jan;124(1):17-24

Regeneration and proliferation of embryonic and adult rat hippocampal neurons in culture [see comments] Brewer GJ. **Exp Neurol** 1999 Sep;159(1):237-47. Comment in: Exp Neurol 1999 Sep;159(1):248-9.

Neuronal subpopulations of developing rat hippocampus containing different calcium-binding proteins behave distinctively in trimethyltin-induced neurodegeneration. Geloso MC, et al. **Exp Neurol** 1998 Dec;154(2):645-53

NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Miyata T, et al. **Genes Dev** 1999 Jul 1;13(13):1647-52

Interleukin-1 induces lipid peroxidation and membrane changes in rat hippocampus: An age-related study. Murray CA, et al. **Gerontology** 1999 May-Jun;45(3):136-42

Head direction cells in the primate pre-subiculum. Robertson RG, et al. **Hippocampus** 1999;9(3):206-19

Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. Chyan YJ, et al. **J Biol Chem** 1999 Jul 30;274(31):21937-42

Microcontact printing for precise control of nerve cell growth in culture. Wheeler BC, et al. **J Biomech Eng** 1999 Feb;121(1):73-8

Patterned glass surfaces direct cell adhesion and process outgrowth of primary neurons of the central nervous system. Saneinejad S, et al. **J Biomed Mater Res** 1998 Oct; 42(1):13-9

Peptide surface modification of poly(tetrafluoroethylene-co-hexafluoropropylene) enhances its interaction with central nervous system neurons. Tong YW, et al. **J Biomed Mater Res** 1998 Oct; 42(1):85-95

Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons. Ethell IM, et al. **J Cell Biol** 1999 Feb 8; 144(3):575-86

Stereological estimation of the total number of neurons in the murine hippocampus using the optical disector. Abusaad I, et al. **J Comp Neurol** 1999 Jun 14;408(4):560-6

Spiny calretinin-immunoreactive neurons in the hilus and CA3 region of the rat hippocampus: local axon circuits, synaptic connections, and glutamic acid decarboxylase 65/67 mRNA expression. Martínez A, et al. **J Comp Neurol** 1999 Feb 22;404(4):438-48

Amyloid beta-peptide (1-40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA. Aksenov MY, et al. **J Mol Neurosci** 1998 Jun; 10(3):181-92

Aromatic alcohols as neuroprotectants. Uhr M, et al. **J Neural Transm Suppl** 1998;54:287-94

Role of moving growth cone-like "wave" structures in the outgrowth of cultured hippocampal axons and dendrites. Ruthel G, et al. **J Neurobiol** 1999 Apr;39(1):97-106

Neurite outgrowth from progeny of epidermal growth factor-responsive hippocampal stem cells is significantly less robust than from fetal hippocampal cells following grafting onto organotypic hippocampal slice cultures: effect of brain-derived neurotrophic factor. Shetty AK, et al. **J Neurobiol** 1999 Feb 15;38(3):391-413

Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. Guo Q, et al. **J Neurochem** 1999 Mar; 72(3):1019-29

Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42. Tekirian TL, et al. **J Neurochem** 1999 Oct;73(4):1584-9

Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. Verderio C, et al. **J Neurochem** 1999 Jul;73(1):372-9

Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line. Xiao N, et al. **J Neurochem** 1999 Jan;72(1):95-101

Functional GABAA receptor heterogeneity of acutely dissociated hippocampal CA1 pyramidal cells. Tietz EI, et al. **J Neurophysiol** 1999 Apr;81(4):1575-86

Effects of ibotenate hippocampal and extrahippocampal destruction on delayed-match and -nonmatch-to-sample behavior in rats. Hampson RE, et al. **J Neurosci** 1999 Feb 15;19(4):1492-507

Specific agrin isoforms induce cAMP response element binding protein phosphorylation in hippocampal neurons. Ji RR, et al. **J Neurosci** 1998 Dec 1;18(23):9695-702

GABAA receptor subunit composition and functional properties of Cl- channels with differential sensitivity to zolpidem in embryonic rat hippocampal cells. Maric D, et al. **J Neurosci** 1999 Jun 15;19(12):4921-37

Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. Palmer TD, et al. **J Neurosci** 1999 Oct 1; 19(19):8487-97

Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. Tanapat P, et al. **J Neurosci** 1999 Jul 15;19(14):5792-801

Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. Tatebayashi Y, et al. **J Neurosci** 1999 Jul 1;19(13):5245-54

Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. Vezzani A, et al. **J Neurosci** 1999 Jun 15;19(12):5054-65

Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. Xu D, et al. **J Neurosci** 1999 Jun 15;19(12):5026-33

Slow oscillations (</=1 Hz) mediated by GABAergic interneuronal networks in rat hippocampus. Zhang Y, et al. **J Neurosci** 1998 Nov 15;18(22):9256-68

Precocious axons and improved survival of rat hippocampal neurons on lysine-alanine polymer substrates. Brewer GJ, et al. **J Neurosci Methods** 1998 Nov 1;85(1):13-20

An on-line archive of reconstructed hippocampal neurons. Cannon RC, et al. **J Neurosci Methods** 1998 Oct 1; 84(1-2):49-54

A submersion method to induce hypoxic damage in organotypic hippocampal cultures. Frantseva MV, et al. **J Neurosci Methods** 1999 Jul 1;89(1):25-31

Astrocyte-conditioned saline supports embryonic rat hippocampal neuron differentiation in short-term cultures. Liu QY, et al. **J Neurosci Methods** 1998 Dec 31;86(1):71-7

Stereological estimation of total microglia number in mouse hippocampus. Long JM, et al. **J Neurosci Methods** 1998 Oct 1;84(1-2):101-8

No difference between estimated mean nuclear volumes of various types of neurons in the mouse brain obtained on either isotropic uniform random sections or conventional frontal or sagittal sections. Schmitz C, et al. **J Neurosci Methods** 1999 Apr 1;88(1):71-82

Microlithographic determination of axonal/dendritic polarity in cultured hippocampal neurons. Stenger DA, et al. **J Neurosci Methods** 1998 Aug 1;82(2):167-73

Regulation of hippocampal neuronal differentiation by the basic helix-loop-helix transcription factors HES-1 and MASH-1. Castella P, et al. **J Neurosci Res** 1999 May 1; 56(3):229-40

Neuroprotection by pigment epithelial-derived factor against glutamate toxicity in developing primary hippocampal neurons. DeCoster MA, et al. **J Neurosci Res** 1999 Jun 15;56(6):604-10

Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. Flavin MP, et al. **J Neurosci Res** 1999 Apr 1;56(1):54-9

Long-term survival of fetal porcine lateral ganglionic eminence cells in the hippocampus of rats. Jacoby DB, et al. **J Neurosci Res** 1999 Jun 15;56(6):581-94

Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. Luo JJ, et al. **J Neurosci Res** 1999 Mar 1;55(5):629-42

Evidence for mitochondrial control of neuronal polarity. Mattson MP, et al. **J Neurosci Res** 1999 Apr 1;56(1):8-20

Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus. Murakami N, et al. **J Neurotrauma** 1998 Nov;15(11):993-1003

Persistent depolarizing action of GABA in rat Cajal-Retzius cells. Mienville JM. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):809-17

Radix Salviae miltiorrhizae protects rat hippocampal neuron in culture from anoxic damage. Liu J, et al. **J Tradit Chin Med** 1998 Mar;18(1):49-54

Purification of human fetal hippocampal neurons by flow cytometry for transplantation. Chiu FC, et al. **Methods** 1998 Nov;16(3):260-7

Confocal imaging of microglial cell dynamics in hippocampal

slice cultures. Dailey ME, et al. **Methods** 1999 Jun; 18(2):222–30, 177

Microtubule-dependent recruitment of Staufen-green fluorescent protein into large RNA-containing granules and subsequent dendritic transport in living hippocampal neurons. Köhrmann M, et al. **Mol Biol Cell** 1999 Sep; 10(9):2945–53

B-50/GAP-43 potentiates cytoskeletal reorganization in raft domains. Aarts LH, et al. **Mol Cell Neurosci** 1999 Aug; 14(2):85–97

Widespread integration and survival of adult-derived neural progenitor cells in the developing optic retina. Takahashi M, et al. **Mol Cell Neurosci** 1998 Dec;12(6):340–8

When less says more: clues from a missing Alzheimer-associated protein [news] Perez RG, et al. **Mol Psychiatry** 1998 Sep;3(5):378–80

Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Guo Q, et al. **Nat Med** 1999 Jan;5(1):101–6

Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures. Hirai K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Nov;358(5):582–5

Age-related toxicity to lactate, glutamate, and beta-amyloid in cultured adult neurons. Brewer GJ. **Neurobiol Aging** 1998 Nov-Dec;19(6):561–8

Hippocampal neuron and synaptophysin-positive bouton number in aging C57BL/6 mice. Calhoun ME, et al. **Neurobiol Aging** 1998 Nov-Dec;19(6):599–606

Altered hippocampal kainate-receptor mRNA levels in temporal lobe epilepsy patients. Mathern GW, et al. **Neurobiol Dis** 1998 Sep;5(3):151–76

Ciliary neurotrophic factor protects hippocampal neurons from excitotoxic damage. Semkova I, et al. **Neurochem Int** 1999 Jul;35(1):1–10

Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors. Potter PE, et al. **Neuropharmacology** 1999 Apr;38(4):579–86

Observations on the relationship between verbal explicit and implicit memory and density of neurons in the hippocampus. Zaidel DW, et al. **Neuropsychologia** 1998 Oct;36(10):1049–62

Protein kinase C inhibitors block generation of anoxia-induced long-term potentiation. Hsu KS, et al. **Neuroreport** 1998 Oct 26;9(15):3525–9

Amyloid beta-protein impairs astrocyte-mediated differentiation of hippocampal neurons. Liu QY, et al. **Neuroreport** 1998 Sep 14;9(13):3059–63

Calcium-dependent alterations in dendritic architecture of hippocampal pyramidal neurons. Meberg PJ, et al. **Neuroreport** 1999 Feb 25;10(3):639–44

Chondroitin sulfate E promotes neurite outgrowth of rat embryonic day 18 hippocampal neurons. Clement AM, et al. **Neurosci Lett** 1999 Jul 16;269(3):125–8

Kainic acid-induced neuronal loss and glial changes in the hippocampal CA3 of p53-deficient mouse. Kitamura Y, et al. **Neurosci Lett** 1998 Oct 9;255(1):57–60

Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. May PC, et al. **Neurosci Lett** 1999 Mar 12;262(3):219–21

Vitamin E and beta-carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. Mitchell JJ, et al. **Neurosci Lett** 1999 Mar 26;263(2-3):189–92

Intracellular calcium and arachidonic acid increase SNAP-25 expression in cultured rat hippocampal explants, but not in cultured rat cerebellar explants. Sepúlveda CM, et al. **Neurosci Lett** 1998 Aug 14;252(2):127–30

Anoxia-evoked intracellular pH and Ca2+ concentration changes in cultured postnatal rat hippocampal neurons. Diarra A, et al. **Neuroscience** 1999;93(3):1003–16

Morphine reversed formalin-induced CA1 pyramidal cell suppression via an effect on septohippocampal neural processing. Khanna S, et al. **Neuroscience** 1999 Mar; 89(1):61–71

Identification of different putative neuronal subtypes in cultures of the superior region of the hippocampus using electrophysiological parameters. Mynlieff M. **Neuroscience** 1999;93(2):479–86

Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats. Wang P, et al. **Neuroscience** 1999 Jan;88(2):585–97

Multiple picrotoxinin effect on glycine channels in rat hippocampal neurons. Yoon KW, et al. **Neuroscience** 1998 Dec;87(4):807–15

Volume changes induced by osmotic stress in freshly isolated rat hippocampal neurons. Aitken PG, et al. **Pflugers Arch** 1998 Nov;436(6):991–8

Hippocampal neurogenesis in adult Old World primates. Gould E, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27; 96(9):5263–7

Effects of vasopressin and related peptides on neurons of the rat lateral septum and ventral hippocampus. Urban IJ. **Prog Brain Res** 1998;119:285–310 (168 ref.)

Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5. Zhao Y, et al. **Science** 1999 May 14;284(5417):1155–8

Maintenance of hippocampal cell numbers in young and aged rats submitted to chronic unpredictable stress. Comparison with the effects of corticosterone treatment. Sousa N, et al. **Stress** 1998 Dec;2(4):237–49

Effects of volatile anaesthetics on a high conductance calcium dependent potassium channel in cultured hippocampal neurons. McLarnon J, et al. **Toxicol Lett** 1998 Nov 23;100–101:271–6

[Anoxia-induced c-fos expression of cultured rat hippocampal neurons and effect of recombinant human interleukin-1 beta] Ding A, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov; 13(4):290–301 (Eng. Abstr.) **(Chi)**

[Structure and neuronal connections of the hippocampus] Ishizuka N. **No To Shinkei** 1998 Oct;50(10):881–92 (105 ref.) **(Jpn)**

[Proliferative activity and structure-functional organization of chromosomes in cells from the developing brain in respect to genetically determined excitability of the rat nervous system] Diuzhikova NA, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):93–8 (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Chan SA, et al. **Acta Neurochir (Wien)** 1998;140(2):175–80

The antioxidants vitamin E and beta-carotene protect against ethanol-induced neurotoxicity in embryonic rat hippocampal cultures. Mitchell JJ, et al. **Alcohol** 1999 Feb; 17(2):163–8

Development of rapid tolerance to ethanol-stimulated serotonin release in the ventral hippocampus. Bare DJ, et al. **Alcohol Clin Exp Res** 1998 Sep;22(6):1272–6

Chronic ethanol treatment leads to increased ornithine decarboxylase activity: implications for a role of polyamines in ethanol dependence and withdrawal. Davidson M, et al. **Alcohol Clin Exp Res** 1998 Sep; 22(6):1205–11

Effect of prenatal ethanol exposure on the developmental profile of the NMDA receptor subunits in rat forebrain and hippocampus. Hughes PD, et al. **Alcohol Clin Exp Res** 1998 Sep;22(6):1255–61

Alteration in the sensitivity of GABA(A) receptors to allosteric modulatory drugs in rat hippocampus after chronic intermittent ethanol treatment. Kang MH, et al. **Alcohol Clin Exp Res** 1998 Dec;22(9):2165–73

Glial cell loss in the hippocampus of alcoholics. Korbo L. **Alcohol Clin Exp Res** 1999 Jan;23(1):164–8

Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1 beta- and LPS-induced hippocampal pyramidal cell loss in vitro. Luthman J, et al. **Amino Acids** 1998;14(1-3):263–9

Effects of isoflurane, ketamine, and fentanyl/N2O on concentrations of brain and plasma catecholamines during near-complete cerebral ischemia in the rat. Miura Y, et al. **Anesth Analg** 1999 Apr;88(4):787–92

Halothane, but not the nonimmobilizers perfluoropentane and 1,2-dichlorohexafluorocyclobutane, depresses synaptic transmission in hippocampal CA1 neurons in rats. Taylor DM, et al. **Anesth Analg** 1999 Oct;89(4):1040–5

The effects of general anesthetics on excitatory and inhibitory synaptic transmission in area CA1 of the rat hippocampus in vitro. Wakasugi M, et al. **Anesth Analg** 1999 Mar; 88(3):676–80

Volatile anesthetics increase intracellular calcium in cerebrocortical and hippocampal neurons. Kindler CH, et al. **Anesthesiology** 1999 Apr;90(4):1137–45

PACAP protects hippocampal neurons against apoptosis: involvement of JNK/SAPK signaling pathway. Shioda S, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:111–7

Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Prickaerts J, et al. **Behav Brain Res** 1999 Jul;102(1-2):73–88

Scopolamine disruption of behavioral and hippocampal responses in appetitive trace classical conditioning. Seager MA, et al. **Behav Brain Res** 1999 Apr;100(1-2):143–51

Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. File SE, et al. **Behav Neurosci** 1998 Dec;112(6):1423–9

Postnatal choline supplementation in preweanling mice: sexually dimorphic behavioral and neurochemical effects. Ricceri L, et al. **Behav Neurosci** 1998 Dec;112(6):1387–92

Interaction between midazolam-induced anterograde amnesia and memory enhancement by treatments given hours later in hippocampus, entorrhinal cortex or posterior parietal cortex. Barros DM, et al. **Behav Pharmacol** 1998 Mar;9(2):163–7

The septum and the hippocampus differentially mediate anxiolytic effects of R(+)-8-OH-DPAT. Menard J, et al. **Behav Pharmacol** 1998 Mar;9(2):93–101

Glutamate release is involved in PAF-increased cyclic GMP levels in hippocampus. Calcerrada MC, et al. **Biochem Mol Biol Int** 1999 Mar;47(3):529–35

Reversal by flunarizine of the decrease in hippocampal acetylcholine release in pentylenetetrazole-kindled rats. Serra M, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):145–9

Chronic fluoxetine administration increases the serotonin N-acetyltransferase messenger RNA content in rat hippocampus. Uz T, et al. **Biol Psychiatry** 1999 Jan 15; 45(2):175–9

Differential inhibitory effects of thiopental, thiamylal and phenobarbital on both voltage-gated calcium channels and NMDA receptors in rat hippocampal slices. Zhan RZ, et al. **Br J Anaesth** 1998 Dec;81(6):932–9

Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Ameri A, et al. **Br J Pharmacol** 1999 Apr;126(8):1831–9

Nicotine administration stimulates the in vivo N-methyl-D-aspartate receptor/nitric oxide/cyclic GMP pathway in rat hippocampus through glutamate release. Fedele E, et al. **Br J Pharmacol** 1998 Nov;125(5):1042–8

Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy. Lücke A, et al. **Br J Pharmacol** 1998 May;124(2):370–6

Enhanced isoflurane suppression of excitatory synaptic transmission in the aged rat hippocampus. Ouanounou A, et al. **Br J Pharmacol** 1998 Jul;124(6):1075–82

Inhibition of NMDA-gated ion channels by the P2 purinoceptor antagonists suramin and reactive blue 2 in mouse hippocampal neurones. Peoples RW, et al. **Br J Pharmacol** 1998 May;124(2):400–8

Inhibition of excitatory amino acid-activated currents by trichloroethanol and trifluoroethanol in mouse hippocampal neurones. Peoples RW, et al. **Br J Pharmacol** 1998 Jul;124(6):1159–64

L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective. Priestley T, et al. **Br J Pharmacol** 1998 Aug;124(8):1767–73

Pharmacological characterization of nicotine-induced acetylcholine release in the rat hippocampus in vivo: evidence for a permissive dopamine synapse. Reid RT, et al. **Br J Pharmacol** 1999 Jul;127(6):1486–94

Persistent nicotinic blockade by chlorisondamine of noradrenergic neurons in rat brain and cultured PC12 cells. Reuben M, et al. **Br J Pharmacol** 1998 Nov;125(6):1218–27

Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Wu SP, et al. **Br J Pharmacol** 1998 Oct;125(4):826–32

alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Alkondon M, et al. **Brain Res** 1998 Nov 9;810(1-2):257–63

Block of (Na+,K+)ATPase with ouabain induces spreading depression-like depolarization in hippocampal slices. Balestrino M, et al. **Brain Res** 1999 Aug 14;838(1-2):37–44

Effects of enadoline on the development of pentylenetetrazol kindling, learning performance, and hippocampal morphology. Becker A, et al. **Brain Res** 1999 Mar 27; 823(1-2):191–7

Glucocorticoid receptor antagonists in the hippocampus modify the negative feedback following neural stimuli. Feldman S, et al. **Brain Res** 1999 Mar 6;821(1):33–7

Hydroxylamine blocks adenosine A1 receptor-mediated inhibition of synaptic transmission in rat hippocampus. Fowler JC, et al. **Brain Res** 1999 Jan 9;815(2):414–8

Epileptiform activity generated by endogenous acetylcholine during blockade of GABAergic inhibition in immature and adult rat hippocampus. Gruslin E, et al. **Brain Res** 1999 Jul 24;835(2):290–7

Psychosine blocks quisqualate-induced glutamate excitotoxicity in hippocampal CA sector neurons. Hodgson DM, et al. **Brain Res** 1998 Aug 17;802(1-2):1–8

Activation of NMDA receptors stimulates extracellular proteolysis of cell adhesion molecules in hippocampus. Hoffman KB, et al. **Brain Res** 1998 Nov 16;811(1-2):152–5

Effects of changes in glucose concentration on synaptic plasticity in hippocampal slices. Kamal A, et al. **Brain Res** 1999 Apr 10;824(2):238–42

Intrahippocampal D-cycloserine improves MK-801-induced memory deficits: radial-arm maze performance in rats. Kawabe K, et al. **Brain Res** 1998 Dec 14;814(1-2):226–30

Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro. Kawasaki H, et al. **Brain Res** 1998 Oct 5;807(1-2):125–34

Effects of T-588, a newly synthesized cognitive enhancer, on hippocampal CA1 neurons in rat brain tissue slices. Kimura T, et al. **Brain Res** 1999 Jun 12;831(1-2):175–83

Spermidine, a polyamine site agonist, attenuates working memory deficits caused by blockade of hippocampal muscarinic receptors and mGluRs in rats. Kishi A, et al. **Brain Res** 1998 May 18;793(1-2):311–4

Hippocampal damage induced by carbon monoxide poisoning and spreading depression is alleviated by chronic treatment with brain derived polypeptides. Koroleva VI, et al. **Brain Res** 1999 Jan 23;816(2):618–27

Chronic (-) deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Lakshmana MK, et al. **Brain Res** 1998 Jun 15;796(1-2):38–44

Excitatory effects of muscarine on septohippocampal neurons: involvement of M3 receptors. Liu W, et al. **Brain Res** 1998 Sep 14;805(1-2):220–33

Protection against amyloid beta peptide toxicity by zinc. Lovell MA, et al. **Brain Res** 1999 Mar 27;823(1-2):88–95

Chronic in vivo morphine administration facilitates primed-bursts-induced long-term potentiation of Schaffer collateral-CA1 synapses in hippocampal slices in vitro. Mansouri FA, et al. **Brain Res** 1999 Jan 9;815(2):419–23

Fibroblast growth factor-8 protects cultured rat hippocampal neurons from oxidative insult. Mark RJ, et al. **Brain Res** 1999 May 29;830(1):88–93

Kainic acid-induced inducible cyclooxygenase and c-Jun phosphorylation in the rat hippocampal formation. Matsuoka Y, et al. **Brain Res** 1999 Jul 31;836(1-2):213–7

Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Mattson MP, et al. **Brain Res** 1998 Oct 5;807(1-2):167-76

Contribution of cholinergic and gabaergic functions to memory processes in BALB/cANnCrlBR mice. Messier C, et al. **Brain Res** 1999 Feb 13;818(2):583-92

Hippocampal damage after injection of kainic acid into the rat entorhinal cortex. Miettinen R, et al. **Brain Res** 1998 Nov 30;813(1):9-17

Halothane depresses action potential conduction in hippocampal axons. Mikulec AA, et al. **Brain Res** 1998 Jun 15;796(1-2):231-8

Cortical spreading depression reduces paraventricular activation induced by hippocampal neostigmine injection. Monda M, et al. **Brain Res** 1999 Apr 3;824(1):119-24

Inhibition of major cationic inward currents prevents spreading depression-like hypoxic depolarization in rat hippocampal tissue slices. Müller M, et al. **Brain Res** 1998 Nov 23;812(1-2):1-13

Modulation of mechanically induced calcium waves in hippocampal astroglial cells. Inhibitory effects of alpha 1-adrenergic stimulation. Muyderman H, et al. **Brain Res** 1998 May 18;793(1-2):127-35

Occlusive responses to adenosine A1 receptor and muscarinic M2 receptor activation on hippocampal presynaptic terminals. Nikbakht MR, et al. **Brain Res** 1999 May 22; 829(1-2):193-6

5-(N-Ethyl-N-isopropyl)-amiloride, an Na(+)-H(+) exchange inhibitor, protects gerbil hippocampal neurons from ischemic injury. Phillis JW, et al. **Brain Res** 1999 Aug 21;839(1):199-202

Protein tyrosine kinase inhibitors reduce high-voltage activating calcium currents in CA1 pyramidal neurones from rat hippocampal slices. Potier B, et al. **Brain Res** 1999 Jan 23;816(2):587-97

Severe learning impairment caused by combined immunotoxic lesion of the cholinergic projections to the cortex and hippocampus in monkeys. Ridley RM, et al. **Brain Res** 1999 Jul 31;836(1-2):120-38

Behavioral effects of anti-muscarinic, anti-serotonergic, and anti-NMDA treatments: hippocampal and neocortical slow wave electrophysiology predict the effects on grooming in the rat. Robertson BJ, et al. **Brain Res** 1999 Aug 14; 838(1-2):234-40

Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Schaaf MJ, et al. **Brain Res** 1998 Nov 30;813(1):112-20

The effect of pentylenetetrazol kindling on synaptic mechanisms of interacting glutamatergic and opioid system in the hippocampus of rats. Schroeder H, et al. **Brain Res** 1998 Nov 16;811(1-2):40-6

Ascorbic acid is neuroprotective against global ischaemia in striatum but not hippocampus: histological and voltammetric data. Stamford JA, et al. **Brain Res** 1999 Jul 24;835(2):229-40

Ginkgo biloba extract EGb761 reduces the development of amphetamine-induced behavioral sensitization: effects on hippocampal type II corticosteroid receptors. Trovero F, et al. **Brain Res** 1999 Feb 6;818(1):135-9

Pregnenolone sulfate exacerbates NMDA-induced death of hippocampal neurons. Weaver CE Jr, et al. **Brain Res** 1998 Aug 24;803(1-2):129-36

Reversible attenuation of glutamatergic transmission in hippocampal CA1 neurons of rat brain slices following transient cerebral ischemia. Zhang L, et al. **Brain Res** 1999 Jun 19;832(1-2):31-9

The effects of chronic lead exposure on long-term depression in area CA1 and dentate gyrus of rat hippocampus in vitro. Zhao WF, et al. **Brain Res** 1999 Feb 6;818(1):153-9

Modulation of synaptic transmission by nicotine and nicotinic antagonists in hippocampus. Chiodini FC, et al. **Brain Res Bull** 1999 Apr;48(6):623-8

Tyrosine phosphorylation is increased in the rat hippocampus during the status epilepticus induced by pilocarpine. Funke MG, et al. **Brain Res Bull** 1998 Sep 1;47(1):87-93

Changes in hippocampal theta following intrahippocampal corticotropin-releasing hormone (CRH) infusions in the rat. Kortekaas R, et al. **Brain Res Bull** 1999 Apr;48(6):603-7

Branched-chain amino acid-induced hippocampal norepinephrine release is antagonized by picrotoxin: evidence for a central mode of action. Torigoe K, et al. **Brain Res Bull** 1999 Jul 1;49(4):281-4

Delayed neuronal loss after administration of intracerebroventricular kainic acid to preweanling rats. Montgomery EM, et al. **Brain Res Dev Brain Res** 1999 Jan 11;112(1):107-16

Flurothyl status epilepticus in developing rats: behavioral, electrographic histological and electrophysiological studies. Sperber EF, et al. **Brain Res Dev Brain Res** 1999 Aug 5;116(1):59-68

Isoform-specific translocation of protein kinase C following glutamate administration in primary hippocampal neurons. Buchner K, et al. **Brain Res Mol Brain Res** 1999 Feb 5; 64(2):222-35

Caspase-3-dependent neuronal death in the hippocampus following kainic acid treatment. Faherty CJ, et al. **Brain Res Mol Brain Res** 1999 Jun 18;70(1):159-63

Chronic amitriptyline treatment induces hippocampal NGFI-A, glucocorticoid receptor and mineralocorticoid receptor mRNA expression in rats. Johansson IM, et al. **Brain Res Mol Brain Res** 1998 Nov 12;62(1):92-5

NMDAR-2A subunit protein expression is reduced in the hippocampus of rats exposed to Pb2+ during development. Nihei MK, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1-2):42-9

Arachidonic acid induces a long-lasting facilitation of hippocampal synaptic transmission by modulating PKC activity and nicotinic ACh receptors. Nishizaki T, et al. **Brain Res Mol Brain Res** 1999 Jun 8;69(2):263-72

Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Zhuang S, et al. **Brain Res Mol Brain Res** 1998 Nov 20;62(2):141-9

Involvement of hippocampal NMDA receptors in retention of shuttle avoidance conditioning in rats. Roesler R, et al. **Braz J Med Biol Res** 1998 Dec;31(12):1601-4

Effects of diethylstilbestrol on mouse hippocampal evoked potentials in vitro. SanMartin S, et al. **Cell Mol Neurobiol** 1999 Dec;19(6):691-703

Altered dendritic maturation and loss of GABA immunoreactivity of hippocampal neurons after prenatal exposure to chloroquine. Dietzmann K, et al. **Clin Neuropathol** 1999 Jul-Aug;18(4):163-70

The influence of (+/-)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices. Langosch JM, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):545-9

An analysis of low level doses of cholinesterase inhibitors in cultured neurons and hippocampal slices of rats. Rocha ES, et al. **Drug Chem Toxicol** 1998;21 Suppl 1:191-200

Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Gu Q, et al. **Endocrinology** 1999 Feb;140(2):660-6

Electrophysiologic analysis of a chronic seizure model after unilateral hippocampal KA injection. Bragin A, et al. **Epilepsia** 1999 Sep;40(9):1210-21

Effects of new valproate derivatives on epileptiform discharges induced by pentylenetetrazole or low Mg2+ in rat entorhinal cortex-hippocampus slices. Armand V, et al. **Epilepsy Res** 1998 Nov;32(3):345-55

Selective loss of GABA neurons in area CA1 of the rat hippocampus after intraventricular kainate. Morin F, et al. **Epilepsy Res** 1998 Nov;32(3):363-9

Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Okada M, et al. **Epilepsy Res** 1999 Apr; 34(2-3):187-97

Effects of carbamazepine on hippocampal serotonergic system. Okada M, et al. **Epilepsy Res** 1998 Aug; 31(3):187-98

Radial astrocytes: toxic effects induced by antiepileptic drug in the developing rat hippocampus in vitro. Fennrich S, et al. **Eur J Cell Biol** 1998 Oct;77(2):142-50

GABA-dependent generation of ectopic action potentials in the rat hippocampus. Avoli M, et al. **Eur J Neurosci** 1998 Aug;10(8):2714-22

Facilitation of GABA release by arachidonic acid in rat hippocampal synaptosomes. Cunha RA, et al. **Eur J Neurosci** 1999 Jun;11(6):2171-4

Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats. Venero C, et al. **Eur J Neurosci** 1999 Jul;11(7):2465-73

Metyrapone alleviates ischemic neuronal damage in the gerbil hippocampus. Adachi N, et al. **Eur J Pharmacol** 1999 Jun 4;373(2-3):147-52

Frequency- and structure-dependent inhibition of normal and epileptiform activity by 6-benzoyldeltamine in rat hippocampal slices. Ameri A, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):279-88

Novel potent AMPA analogues differentially affect desensitisation of AMPA receptors in cultured hippocampal neurons. Banke TG, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):405-12

The role of group II metabotropic glutamate receptors in hippocampal CA1 long-term potentiation in vitro. Behnisch T, et al. **Eur J Pharmacol** 1998 Sep 4; 356(2-3):159-65

Nerve growth factor, ganglioside and vitamin E reverse glutamate cytotoxicity in hippocampal cells. Cunha GM, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):107-12

Gender-selective effects of ethanol dependence on NMDA receptor subunit expression in cerebral cortex, hippocampus and hypothalamus. Devaud LL, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):331-4

Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Gessa GL, et al. **Eur J Pharmacol** 1998 Aug 21; 355(2-3):119-24

Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats. Giovannini MG, et al. **Eur J Pharmacol** 1998 Jul 31;354(1):17-24

(1S,3R)-ACPD, a metabotropic glutamate receptor agonist, enhances damage after global ischaemia. Henrich-Noack P, et al. **Eur J Pharmacol** 1999 Jan 15;365(1):55-8

Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Kilbride J, et al. **Eur J Pharmacol** 1998 Sep 4; 356(2-3):149-57

Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. Kodama M, et al. **Eur J Pharmacol** 1999 Jun 11;374(1):11-9

Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination. Lledó A, et al. **Eur J Pharmacol** 1999 May 7;372(1):75-83

Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Magariños AM, et al. **Eur J Pharmacol** 1999 Apr 29;371(2-3):113-22

PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Maj R, et al. **Eur J Pharmacol** 1998 Oct 16;359(1):27-32

In vivo and in vitro evaluation of AMPA receptor antagonists in rat hippocampal neurones and cultured mouse cortical neurones. Mathiesen C, et al. **Eur J Pharmacol** 1998 Jul 24;353(2-3):159-67

Acute rise in corticosterone facilitates 5-HT(1A) receptor-mediated behavioural responses. Meijer OC, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):7-14

Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. O'Neill MJ, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):37-46

The behavioral effect of vasopressin in the ventral hippocampus is antagonized by an oxytocin receptor antagonist. Paban V, et al. **Eur J Pharmacol** 1998 Nov 20; 361(2-3):165-73

Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. Pizzi M, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):133-7

Kappa-opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension. Wright RC, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):57-61

Effects of nicotine, pilocarpine, and tetrahydroaminoacridine on hippocampal theta waves in freely moving rabbits. Yamamoto J. **Eur J Pharmacol** 1998 Oct 23;359(2-3):133-7

Missing action of carbamazepine on postsynaptic GABA-responses of hippocampal CA3-neurons (slice, guinea pig). Bonnet U, et al. **Eur Neuropsychopharmacol** 1998 Dec;8(4):353-6

Effects of lithium treatment on extracellular serotonin levels in the dorsal hippocampus and wet-dog shakes in the rat. Mørk A. **Eur Neuropsychopharmacol** 1998 Dec;8(4):267-72

Effect of the mono- and tetra-sialogangliosides, GM1 and GQ1b, on long-term potentiation in the CA1 hippocampal neurons of the guinea pig. Furuse H, et al. **Exp Brain Res** 1998 Dec;123(3):307-14

Glucocorticoid modulation of gp120-induced effects on calcium-dependent degenerative events in primary hippocampal and cortical cultures. Howard SA, et al. **Exp Neurol** 1999 Jul;158(1):164-70

Neuroprotective effects of alpha-lipoic acid and its positively charged amide analogue. Tirosh O, et al. **Free Radic Biol Med** 1999 Jun;26(11-12):1418-26

Effects of nerve growth factor on brain glutathione-related enzymes from aged rats. Cruz-Aguado R, et al. **Fundam Clin Pharmacol** 1998;12(5):538-45

Residual granule cells can maintain susceptibility of CA3 pyramidal cells to kainate-induced epileptiform discharges. Czéh B, et al. **Hippocampus** 1998;8(5):548-61

Loss of NADPH diaphorase-positive neurons in the hippocampal formation of chronic pilocarpine-epileptic rats. Hamani C, et al. **Hippocampus** 1999;9(3):303-13

Distribution and analysis of hippocampal theta-related cells in the pontine region of the urethane-anesthetized rat. Hanada Y, et al. **Hippocampus** 1999;9(3):288-302

Prenatal gonadal steroids affect adult spatial behavior, CA1 and CA3 pyramidal cell morphology in rats. Isgor C, et al. **Horm Behav** 1998 Oct;34(2):183-98

Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine. Bacciottini L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S63-4

Amyloid beta-peptide possesses a transforming growth factor-beta activity. Huang SS, et al. **J Biol Chem** 1998 Oct 16;273(42):27640-4

Regional and laminar specificity of kainate-stimulated cobalt uptake in the rat hippocampal formation. Toomim CS, et al. **J Comp Neurol** 1998 Dec 14;402(2):141-54

Effect of aromatic short-chain analogues of ceramide on axonal growth in hippocampal neurons. Van Overmeire I, et al. **J Med Chem** 1999 Jul 15;42(14):2697-705

Corticosterone treatment differentially affects adrenocorticoid receptors expression and binding in the hippocampus and spinal cord of the rat. Patacchioli FR, et al. **J Mol Neurosci** 1998 Aug;11(1):95-103

Streptozotocin increases free fatty acids and decreases phospholipids in rat brain. Müller D, et al. **J Neural Transm** 1998;105(10-12):1271-81

Neurite outgrowth from progeny of epidermal growth factor-responsive hippocampal stem cells is significantly less robust than from fetal hippocampal cells following grafting onto organotypic hippocampal slice cultures: effect of brain-derived neurotrophic factor. Shetty AK, et al. **J Neurobiol** 1999 Feb 15;38(3):391-413

Relationships among seizures, extracellular amino acid changes, and neurodegeneration induced by 4-aminopyridine in rat hippocampus: a microdialysis and electroencephalographic study. Peña F, et al. **J Neurochem** 1999 May;72(5):2006-14

Brain-derived neurotrophic factor (BDNF) modulates inhibitory, but not excitatory, transmission in the CA1 region of the hippocampus. Frerking M, et al. **J Neurophysiol** 1998 Dec;80(6):3383-6

VDCCs and NMDARs underlie two forms of LTP in CA1

hippocampus in vivo. Morgan SL, et al. **J Neurophysiol** 1999 Aug;82(2):736–40

GABA(B) receptor activation promotes seizure activity in the juvenile rat hippocampus. Motalli R, et al. **J Neurophysiol** 1999 Aug;82(2):638–47

Facilitation of miniature GABAergic currents by ruthenium red in neonatal rat hippocampal neurons. Sciancalepore M, et al. **J Neurophysiol** 1998 Nov;80(5):2316–22

Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. Alkondon M, et al. **J Neurosci** 1999 Apr 1;19(7):2693–705

Long-term potentiation in the hippocampal CA1 region of mice lacking cGMP-dependent kinases is normal and susceptible to inhibition of nitric oxide synthase. Kleppisch T, et al. **J Neurosci** 1999 Jan 1;19(1):48–55

Regulatory role and molecular interactions of a cell-surface heparan sulfate proteoglycan (N-syndecan) in hippocampal long-term potentiation. Lauri SE, et al. **J Neurosci** 1999 Feb 15;19(4):1226–35

Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. Leverenz JB, et al. **J Neurosci** 1999 Mar 15;19(6):2356–61

Adenosine: a mediator of interleukin-1beta-induced hippocampal synaptic inhibition. Luk WP, et al. **J Neurosci** 1999 Jun 1;19(11):4238–44

Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Misner DL, et al. **J Neurosci** 1999 Aug 15;19(16):6795–805

Metrifonate increases neuronal excitability in CA1 pyramidal neurons from both young and aging rabbit hippocampus. Oh MM, et al. **J Neurosci** 1999 Mar 1;19(5):1814–23

An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons. Schurr A, et al. **J Neurosci** 1999 Jan 1;19(1):34–9

Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. Sebret A, et al. **J Neurosci** 1999 Aug 15;19(16):7230–7

The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. Tovar KR, et al. **J Neurosci** 1999 May 15;19(10):4180–8

Semi-automated analysis of NMDA-mediated toxicity in digitised colour images from rat hippocampus. Manahan-Vaughan D, et al. **J Neurosci Methods** 1998 Jul 1;82(1):85–95

Septohippocampal adaptive GABAergic responses by AF64A treatment. Ayala-Grosso CA, et al. **J Neurosci Res** 1999 Jan 15;55(2):178–86

Effect of dexamethasone on elevated cytokine mRNA levels in chemical-induced hippocampal injury. Bruccoleri A, et al. **J Neurosci Res** 1999 Sep 15;57(6):916–26

GABA induces norepinephrine exocytosis from hippocampal noradrenergic axon terminals by a dual mechanism involving different voltage-sensitive calcium channels. Fassio A, et al. **J Neurosci Res** 1999 Aug 1;57(3):324–31

Interleukin-1beta, inducible nitric oxide synthase, and nuclear factor-kappaB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-gamma injection. Hartlage-Rübsamen M, et al. **J Neurosci Res** 1999 Aug 1;57(3):388–98

2-Deoxy-D-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. Lee J, et al. **J Neurosci Res** 1999 Jul 1;57(1):48–61

In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. Kohara A, et al. **J Pharm Pharmacol** 1998 Jul;50(7):795–801

Inhibition of nitric oxide synthase disrupts inhibitory gating of auditory responses in rat hippocampus. Adams CE, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):760–5

Cognition-enhancing drugs increase stimulated hippocampal theta rhythm amplitude in the urethane-anesthetized rat. Kinney GG, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):99–106

Inhibitory effect of ondansetron on glycine response of dissociated rat hippocampal neurons. Ye JH, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):104–11

Laminar difference in GABA uptake and GAT-1 expression in rat CA1. Engel D, et al. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):643–9

Age-dependent, steroid-specific effects of oestrogen on long-term potentiation in rat hippocampal slices. Ito K, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):209–20

Nicotine modifies the activity of ventral tegmental area dopaminergic neurons and hippocampal GABAergic neurons. Fisher JL, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):209–13

Cholinergic excitation induces activity-dependent electrophysiological and transcriptional responses in hippocampal slices. Friedman A, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):329–35

Vitamin E prevents apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Tagami M, et al. **Lab Invest** 1999 May;79(5):609–15

Phorbol ester effects at hippocampal synapses act independently of the gamma isoform of PKC. Goda Y, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):182–7

Determinants of BDNF-induced hippocampal synaptic plasticity: role of the Trk B receptor and the kinetics of neurotrophin delivery. Kang H, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):188–96

Intraseptal injection of scopolamine increases the effect of systemic diazepam on passive avoidance learning and emotionality in rats. Anglade F, et al. **Life Sci** 1999; 64(17):1553–61

Cannabinoids, hippocampal function and memory. Hampson RE, et al. **Life Sci** 1999;65(6-7):715–23 (71 ref.)

Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence. Fan GH, et al. **Mol Pharmacol** 1999 Jul; 56(1):39–45

Modulation of Ca2+/calmodulin-dependent protein kinase II activity by acute and chronic morphine administration in rat hippocampus: differential regulation of alpha and beta isoforms. Lou L, et al. **Mol Pharmacol** 1999 Mar; 55(3):557–63

Silent synapses: I can't hear you! Could you please speak aloud? [news; comment] Malgaroli A. **Nat Neurosci** 1999 Jan;2(1):3–5. Comment on: Nat Neurosci 1999 Jan;2(1):24–30.

How does xenon produce anaesthesia? [letter] Franks NP, et al. **Nature** 1998 Nov 26;396(6709):324

Aniracetam, 1-BCP and cyclothiazide differentially modulate the function of NMDA and AMPA receptors mediating enhancement of noradrenaline release in rat hippocampal slices. Pittaluga A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr; 359(4):272–9

Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Ivins KJ, et al. **Neurobiol Dis** 1998 Nov;5(5):365–78

Stimulators of the cAMP cascade reverse amnesia induced by intra-amygdala but not intrahippocampal KN-62 administration. Barros DM, et al. **Neurobiol Learn Mem** 1999 Jan;71(1):94–103

Effects of posttraining intrahippocampal injections of platelet-activating factor and PAF antagonists on memory. Teather LA, et al. **Neurobiol Learn Mem** 1998 Nov; 70(3):349–63

Interferon-gamma plus lipopolysaccharide induction of delayed neuronal apoptosis in rat hippocampus. Matsuoka Y, et al. **Neurochem Int** 1999 Feb;34(2):91–9

Neurotensin modulation of acetylcholine and GABA release from the rat hippocampus: an in vivo microdialysis study. Rakovska A, et al. **Neurochem Int** 1998 Oct;33(4):335–40

Inactivation of 5-HT1A and [3H]5-HT binding sites by N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) in rat brain. Subhash MN, et al. **Neurochem Res** 1998 Oct;23(10):1321–6

The influence of electric fields on the epileptiform bursts induced by high potassium in CA3 region of rat hippocampal slice. Duong DH, et al. **Neurol Res** 1998 Sep; 20(6):542–8

Neuroprotection by 21-aminosteroids: insights from latencies of anoxic terminal negativity in hippocampus slices of guinea pig. Hülsmann S, et al. **Neurol Res** 1999 Apr; 21(3):305–8

Propofol administration reduces hippocampal neuronal damage induced by kainic acid in rats. Lee SR, et al. **Neurol Res** 1999 Mar;21(2):225–8

Amobarbital effects on the posterior hippocampus during the intracarotid amobarbital test. Urbach H, et al. **Neurology** 1999 May 12;52(8):1596–602

NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Lee HK, et al. **Neuron** 1998 Nov; 21(5):1151–62

In vitro effect of angiotensin II on GABA release in rat hippocampus. Hadjivanova CH, et al. **Neuropeptides** 1998 Oct;32(5):431–4

Chronic treatment with oestradiol does not alter in vitro LTP in subfield CA1 of the female rat hippocampus. Barraclough DJ, et al. **Neuropharmacology** 1999 Jan; 38(1):65–71

GR 127935 and (+)-WAY 100135 do not affect TFMPP-induced inhibition of 5-HT synthesis in the midbrain and hippocampus of Wistar-Kyoto rats. Chaouloff F, et al. **Neuropharmacology** 1998 Sep; 37(9):1159–67

Antagonism of neuronal kainate receptors by lanthanum and gadolinium. Huettner JE, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1239–47

Reevaluation of ACEA 1021 as an antagonist at the strychnine-insensitive glycine site of the N-methyl-D-aspartate receptor. Lingenhöhl K, et al. **Neuropharmacology** 1998 Jun;37(6):729–37

ACPD-mediated slow-onset potentiation is associated with cell death in the rat CA1 region in vivo. Manahan-Vaughan D, et al. **Neuropharmacology** 1999 Apr; 38(4):487–94

Interaction between purinoceptor subtypes on hippocampal serotonergic transmission using in vivo microdialysis. Okada M, et al. **Neuropharmacology** 1999 May;38(5):707–15

Activation and desensitization properties of native and recombinant kainate receptors. Paternain AV, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1249–59

Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. Paton GS, et al. **Neuropharmacology** 1998 Sep;37(9):1123–30

Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones. Rammes G, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1299–320

A CaMKII inhibitor, KN-62, facilitates DHPG-induced LTD in the CA1 region of the hippocampus. Schnabel R, et al. **Neuropharmacology** 1999 Apr;38(4):605–8

The novel Na+/Ca2+ exchange inhibitor KB-R7943 protects CA1 neurons in rat hippocampal slices against hypoxic/hypoglycemic injury. Schröder UH, et al. **Neuropharmacology** 1999 Feb;38(2):319–21

Effects of 5-HT-releasing agents on the extracellular hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Scorza C, et al. **Neuropharmacology** 1999 Jul; 38(7):1055–61

LY339434, a GluR5 kainate receptor agonist. Small B, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1261–7

Blockade of NMDA channels in acutely isolated rat hippocampal neurons by the Na+/Ca2+ exchange inhibitor KB-R7943. Sobolevsky AI, et al. **Neuropharmacology** 1999 Aug;38(8):1235–42

Increased membrane cholesterol reduces the potentiation of GABA(A) currents by neurosteroids in dissociated hippocampal neurones. Sooksawate T, et al. **Neuropharmacology** 1998 Sep;37(9):1103–10

Modifications in brain cAMP- and calcium/calmodulin-dependent protein kinases induced by treatment with S-adenosylmethionine. Zanotti S, et al. **Neuropharmacology** 1998 Aug;37(8):1081–9

Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Brown ES, et al. **Neuropsychopharmacology** 1999 Oct;21(4):474–84 (121 ref.)

Increase of cellular hypoxic tolerance by erythromycin and other antibiotics. Huber R, et al. **Neuroreport** 1999 May 14;10(7):1543–6

Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors. Kiss JP, et al. **Neuroreport** 1999 Jan 18;10(1):81–6

NMDA antagonist displays anticonvulsant effect via NO synthesis inhibition in penicillin-treated rat hippocampal slices. Lu W, et al. **Neuroreport** 1998 Dec 21;9(18):4045–9

Effect of induced tolerance on biochemical disturbances in hippocampal slices from the gerbil during and after oxygen/glucose deprivation. Paschen W, et al. **Neuroreport** 1999 May 14;10(7):1417–21

Differential alcohol modulation of GABA(A) and NMDA receptors. Peoples RW, et al. **Neuroreport** 1999 Jan 18; 10(1):97–101

Serum deprivation-induced apoptosis in cultured hippocampi is prevented by kainate. Rivera S, et al. **Neuroreport** 1998 Dec 1;9(17):3949–53

Lithium treatment causes gliosis and modifies the morphology of hippocampal astrocytes in rats. Rocha E, et al. **Neuroreport** 1998 Dec 1;9(17):3971–4

Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. Saura J, et al. **Neuroreport** 1999 Jan 18;10(1):161–4

Selective suppression of forward and recurrent "rapid" inhibition by local application of picrotoxin in area CA1 of rat hippocampal slices. Bayazitov IT, et al. **Neurosci Behav Physiol** 1999 Mar-Apr;29(2):117–23

The effects of vasopressin on hippocampal slices from trained rats. Kudryashova IV, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):289–93

Electrophysiological actions of N-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-N-methyl-2-benzothiazola mine (R56865) on CA1 neurons of the rat hippocampal slice during hypoxia. Barbieri M, et al. **Neurosci Lett** 1999 Aug 6;270(3):161–4

Inhibition of apamin-sensitive calcium dependent potassium channels facilitate the induction of long-term potentiation in the CA1 region of rat hippocampus in vitro. Behnisch T, et al. **Neurosci Lett** 1998 Sep 4;253(2):91–4

5-HT1B antagonists modulate clearance of extracellular serotonin in rat hippocampus. Daws LC, et al. **Neurosci Lett** 1999 May 14;266(3):165–8

Corticosterone modifies muscarinic receptor immunoreactivity in rat hippocampus. Douma BR, et al. **Neurosci Lett** 1999 Jun 11;268(1):41–4

Frequency and synchrony of tetanically-induced, gamma-frequency population discharges in the rat hippocampal slice: the effect of diazepam and propofol. Fox JE, et al. **Neurosci Lett** 1998 Nov 27;257(2):101–4

Inhibition of nicotine-induced hippocampal norepinephrine release in rats by alpha-conotoxins MII and AuIB microinjected into the locus coeruleus. Fu Y, et al. **Neurosci Lett** 1999 May 7;266(2):113–6

Mossy fibre innervation is not required for the development of kainic acid toxicity in organotypic hippocampal slice cultures. Gatherer M, et al. **Neurosci Lett** 1998 Sep 4; 253(2):119–22

Enhancement by 1-oleoyl-2-docosahexaenoyl phosphatidylcholine of long-term potentiation in the rat hippocampal CA1 region. Izaki Y, et al. **Neurosci Lett** 1999 Jan 29;260(2):146–8

Effect of long-term elevated corticosteroid levels on field responses to synaptic stimulation, in the rat CA1 hippocampal area. Karten YJ, et al. **Neurosci Lett** 1999 Apr 9;265(1):41–4

Kainic acid-induced neuronal loss and glial changes in the hippocampal CA3 of p53-deficient mouse. Kitamura Y, et al. **Neurosci Lett** 1998 Oct 9;255(1):57-60

Excitatory effects of adenosine are not mediated by inhibition of GABAergic system in slices of superior colliculus and hippocampus from guinea pig. Kobayashi K, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):37-40

Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Koyama T, et al. **Neurosci Lett** 1999 Apr 9;265(1):33-6

Hippocampal slices from long-term streptozotocin-injected rats are prone to epileptiform responses. Margineanu DG, et al. **Neurosci Lett** 1998 Aug 21;252(3):183-6

Cholinergic and serotonergic alterations in the rat hippocampus following trimethyltin exposure and fetal neural transplantation. Roy A, et al. **Neurosci Lett** 1999 Jan 15;259(3):173-6

Nicotine-evoked nitric oxide release in the rat hippocampal slice. Smith DA, et al. **Neurosci Lett** 1998 Oct 23; 255(3):127-30

3-Nitropropionic acid induces ischemic tolerance in gerbil hippocampus in vivo. Sugino T, et al. **Neurosci Lett** 1999 Jan 4;259(1):9-12

Intracerebral administration of L-kynurenine decreases N-methyl-D-aspartate receptor-mediated production of cGMP in the cerebellum and hippocampus of unanaesthetized rats subjected to transcerebral microdialysis. Varnier G, et al. **Neurosci Lett** 1999 May 7;266(2):81-4

Effects of an interleukin-1beta analogue [Lys-D-Pro-Thr], on incomplete cerebral ischemia-induced inhibition of long-term potentiation in rat hippocampal neurons in vivo. Yoshioka M, et al. **Neurosci Lett** 1999 Feb 19;261(3):171-4

Kainic acid may enhance hippocampal NO generation of awake rats in a seizure stage-related fashion. Kashihara K, et al. **Neurosci Res** 1998 Nov;32(3):189-94

Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Nakai K, et al. **Neurosci Res** 1998 May; 31(1):23-9

Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone. Antonawich FJ, et al. **Neuroscience** 1999 Jan;88(1):319-25

Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy. Bouilleret V, et al. **Neuroscience** 1999 Mar;89(3):717-29

Impact of neonatal kainate treatment on hippocampal insulin-like growth factor receptors. Doré S, et al. **Neuroscience** 1999;91(3):1035-43

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Engber TM, et al. **Neuroscience** 1998 Dec;87(4):905-11

The mechanism gated by external potassium and sodium controls the resting conductance in hippocampal and cortical neurons. Filippov V, et al. **Neuroscience** 1999; 92(4):1231-42

Modulation of long-term potentiation induction in the hippocampus by N-methyl-D-aspartate-mediated presynaptic inhibition. Kato K, et al. **Neuroscience** 1999; 92(4):1261-72

Synaptic depression induced by pharmacological activation of metabotropic glutamate receptors in the perirhinal cortex in vitro. McCaffery B, et al. **Neuroscience** 1999;93(3):977-84

Neurosteroid regulation of inhibitory synaptic transmission in the rat hippocampus in vitro. Meyer JH, et al. **Neuroscience** 1999;90(4):1177-83

Up-regulation of Eph tyrosine kinase receptors after excitotoxic injury in adult hippocampus. Moreno-Flores MT, et al. **Neuroscience** 1999;91(1):193-201

Phencyclidine interferes with the hippocampal gating of nucleus accumbens neuronal activity in vivo. O'Donnell P, et al. **Neuroscience** 1998 Dec;87(4):823-30

Hippocampal dynorphin B injections impair spatial learning in rats: a kappa-opioid receptor-mediated effect. Sandin J, et al. **Neuroscience** 1998 Jul;85(2):375-82

Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro. Scharfman HE, et al. **Neuroscience** 1998 Oct;86(3):751-64

Ligand and subfield specificity of corticoid-induced neuronal loss in the rat hippocampal formation. Sousa N, et al. **Neuroscience** 1999;89(4):1079-87

A double dissociation within the hippocampus of dopamine D1/D5 receptor and beta-adrenergic receptor contributions to the persistence of long-term potentiation. Swanson-Park JL, et al. **Neuroscience** 1999;92(2):485-97

Effects of hippocampal kainic acid lesions on striatolimbic dopamine D1-, D2-, and D4-like receptors. Tarazi FI, et al. **Neuroscience** 1998 Nov;87(1):1-4

Hippocampal field CA1 interneuronal nociceptive responses: modulation by medial septal region and morphine. Zheng F, et al. **Neuroscience** 1999;93(1):45-55

Two phases of behavioral plasticity in rats following unilateral excitotoxic lesion of the hippocampus. Zou LB, et al. **Neuroscience** 1999;92(3):819-26

Alterations in synaptic transmission and plasticity in hippocampus by a complex PCB mixture, Aroclor 1254. Gilbert ME, et al. **Neurotoxicol Teratol** 1998 Jul-Aug; 20(4):383-9

Effects of gestational nicotine exposure on hippocampal morphology. Roy TS, et al. **Neurotoxicol Teratol** 1998 Jul-Aug;20(4):465-73

Effects of suramin on hippocampal apyrase activity and inhibitory avoidance learning of rats. Bonan CD, et al. **Pharmacol Biochem Behav** 1999 May;63(1):153-8

3H-L-glutamate binding and 3H-D-aspartate release from hippocampal tissue during the development of pentylenetetrazole kindling in rats. Schröeder H, et al. **Pharmacol Biochem Behav** 1999 Feb;62(2):349-52

Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Shankaran M, et al. **Pharmacol Biochem Behav** 1998 Dec;61(4):361-6

Potentiation of muscimol-induced long-term depression by benzodiazepines and prevention or reversal by pregnenolone sulfate. Akhondzadeh S, et al. **Pharmacol Res** 1998 Dec;38(6):441-8

Systemic chlorophenylpiperazine increases acetylcholine release from rat hippocampus-implication of 5-HT2C receptors. Zhelyazkova-Savova M, et al. **Pharmacol Res** 1999 Aug;40(2):165-70

An investigation of the possible interaction of clomethiazole with glutamate and ion channel sites as an explanation of its neuroprotective activity. Green AR, et al. **Pharmacol Toxicol** 1998 Aug;83(2):90-4

Effect of neurosteroids on glutamate binding sites and glutamate uptake in rat hippocampus. Leśkiewicz M, et al. **Pol J Pharmacol** 1998 Jul-Oct;50(4-5):355-60

Comparison of the effects of low and high concentrations of group I metabotropic receptor agonists on field potentials in the hippocampal CA1 region in vitro. Zahorodna A, et al. **Pol J Pharmacol** 1998 Jul-Oct; 50(4-5):291-8

Selective glutamate receptor antagonists can induce or prevent axonal sprouting in rat hippocampal slice cultures. McKinney RA, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11631-6

Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Murphy DD, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11412-7

Anticonvulsant effects of dipotassium clorazepate on hippocampal kindled seizures in rats. Amano K, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):459-62

Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Becker A, et al. **Psychopharmacology (Berl)** 1999 Jun;144(4):333-8

Are some of the effects of ethanol mediated through NPY? Ehlers CL, et al. **Psychopharmacology (Berl)** 1998 Sep; 139(1-2):136-44

Role of hippocampus in alcohol-induced memory impairment: implications from behavioral and immediate early gene studies. Ryabinin AE. **Psychopharmacology (Berl)** 1998 Sep;139(1-2):34-43 (111 ref.)

Differential behavioral effects of angiotensin II microinjected unilaterally into the CA1 hippocampal area. Belcheva I, et al. **Regul Pept** 1998 Jun 30;74(2-3):67-71

Nitric oxide production in the CA1 field of the gerbil hippocampus after transient forebrain ischemia : effects of 7-nitroindazole and NG-nitro-L-arginine methyl ester. Lei B, et al. **Stroke** 1999 Mar;30(3):669-77

Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors. Barton CL, et al. **Synapse** 1999 Jan;31(1):13-9

Ethanol exposure during the third trimester equivalent results in long-lasting decreased synaptic efficacy but not plasticity in the CA1 region of the rat hippocampus. Bellinger FP, et al. **Synapse** 1999 Jan;31(1):51-8

Norepinephrine promotes long-term potentiation in the adult rat hippocampus in vitro. Izumi Y, et al. **Synapse** 1999 Mar 1;31(3):196-202

Agonist- and antagonist-induced plasticity of rat 5-HT1A receptor in hippocampal cell culture. Nishi M, et al. **Synapse** 1999 Mar 1;31(3):186-95

Benzodiazepine tolerance at GABAergic synapses on hippocampal CA1 pyramidal cells. Zeng XJ, et al. **Synapse** 1999 Mar 15;31(4):263-77

Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine. Albuquerque EX, et al. **Toxicol Lett** 1998 Dec 28;102-103:211-8

Enhancement of CNS activity by thiopentone: comparison of nocifensive reflexes with hippocampal EEG. Archer DP, et al. **Toxicol Lett** 1998 Nov 23;100-101:85-8

Biologically-based dose-response model for neurotoxicity risk assessment. Slikker W Jr, et al. **Toxicol Lett** 1998 Dec 28;102-103:429-33

[Amyloidogenic peptides such as beta-amyloid, amylin and calcitonin strongly enhance the susceptibility of rat hippocampal neurons to excitatory amino acids in vivo] Morimoto K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct; 112 Suppl 1:83P-87P (Eng. Abstr.) **(Jpn)**

[Assessment of acute neurotoxic effect of exposure to certain organic solvents based on an analysis of bioelectric function of the rat cerebral cortex] Tomas T, et al. **Med Pr** 1998; 49(6):563-71 (Eng. Abstr.) **(Pol)**

[Effect of various dilutions of the potentiated antibodies to the brain-specific protein S-100 on the post-titanic potentiation in surviving hippocampal slices] Epshtein OI, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):317-20 **(Rus)**

[Effect of anticonvulsants lamotrigine and carbamazepine on the synaptic transmission in CA1 field of the rat hippocampal slices] Kalemenev SV, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):307-10 **(Rus)**

[Levels of monoaminergic neuromediators and their main metabolites in mouse hippocampus and brain stem after administration of adrenocorticotropic hormone (ACTH(4-10))] Shilova OB, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):350-2 **(Rus)**

[Long-term morphofunctional preservation of guinea pig hippocampal slices following short-term treatment with cyclooxygenase inhibitors] Pakhotin PI, et al. **Morfologiia** 1998;114(5):30-4 (Eng. Abstr.) **(Rus)**

[Effects of the chronic administration of midazolam on the rat hippocampus] Carassiti M, et al. **Rev Med Univ Navarra** 1998 Jan-Mar;42(1):18-28 (Eng. Abstr.) **(Spa)**

[The action of pilocarpine on the accommodation properties of isolated phasic neurons of the rat hippocampus] Luk'ianets' OO, et al. **Fiziol Zh** 1999;45(4):35-40 (Eng. Abstr.) **(Ukr)**

EMBRYOLOGY

The antioxidants vitamin E and beta-carotene protect against ethanol-induced neurotoxicity in embryonic rat hippocampal cultures. Mitchell JJ, et al. **Alcohol** 1999 Feb; 17(2):163-8

Ontogeny of estrogen sulfatase activity in ovine fetal hypothalamus, hippocampus, and brain stem. Purinton SC, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1647-52

Involvement of metabotropic glutamate receptors in taurine release in the adult and developing mouse hippocampus. Saransaari P, et al. **Amino Acids** 1999;16(2):165-79

Quantitative morphology of human hippocampus early neuron development. Zaidel DW. **Anat Rec** 1999 Jan; 254(1):87-91

Generation of reactive oxygen species, release of L-glutamate and activation of caspases are required for oxygen-induced apoptosis of embryonic hippocampal neurons in culture. Ishikawa Y, et al. **Brain Res** 1999 Apr 3;824(1):71-80

Delayed neuronal migration of protein kinase Cgamma immunoreactive cells in hippocampal CA1 area after 48 h of moderate hypoxemia in the near term ovine fetus. Braaksma MA, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):253-60

Altered dendritic maturation and loss of GABA immunoreactivity of hippocampal neurons after prenatal exposure to chloroquine. Dietzmann K, et al. **Clin Neuropathol** 1999 Jul-Aug;18(4):163-70

Target- and maturation-specific membrane-associated molecules determine the ingrowth of entorhinal fibers into the hippocampus. Skutella T, et al. **Dev Biol** 1999 Jul 15; 211(2):277-92

F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. Feinstein Y, et al. **Development** 1999 Aug;126(16):3637-48

Precocious development of parvalbumin-like immunoreactive interneurons in the hippocampal formation and entorhinal cortex of the fetal cynomolgus monkey. Berger B, et al. **J Comp Neurol** 1999 Jan 18;403(3):309-31

Purification of human fetal hippocampal neurons by flow cytometry for transplantation. Chiu FC, et al. **Methods** 1998 Nov;16(3):260-7

Effect of chronic prenatal ethanol exposure on nitric oxide synthase I and III proteins in the hippocampus of the near-term fetal guinea pig. Kimura KA, et al. **Neurotoxicol Teratol** 1999 May-Jun;21(3):251-9

Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5. Zhao Y, et al. **Science** 1999 May 14;284(5417):1155-8

ENZYMOLOGY

Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Nagy Z, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):346-54

Activation of PKC disrupts presynaptic inhibition by group II and group III metabotropic glutamate receptors and uncouples the receptor from GTP-binding proteins. Macek TA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:554-7

Pre-conditioning to global cerebral ischemia changes hippocampal acetylcholinesterase in the rat. Schetinger MR, et al. **Biochem Mol Biol Int** 1999 Mar;47(3):473-8

Chronic fluoxetine administration increases the serotonin N-acetyltransferase messenger RNA content in rat hippocampus. Uz T, et al. **Biol Psychiatry** 1999 Jan 15; 45(2):175-9

Net efflux of cysteine, glutathione and related metabolites from rat hippocampal slices during oxygen/glucose deprivation: dependence on gamma-glutamyl transpeptidase. Li X, et al. **Brain Res** 1999 Jan 2;815(1):81-8

Methylene blue inhibits hippocampal nitric oxide synthase activity in vivo. Volke V, et al. **Brain Res** 1999 May 1; 826(2):303-5

Amyloid beta-peptides inhibit Na+/K+-ATPase: tissue slices versus primary cultures. Bores GM, et al.

Brain Res Bull 1998 Jul 15;46(5):423–7

Comparisons of the densities of NADPHd reactive and nNOS immunopositive neurons in the hippocampus of three age groups of young nonhandled and handled rats. Veenman CL, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):229–43

Human c-Jun N-terminal kinase expression and activation in the nervous system. Kumagae Y, et al. **Brain Res Mol Brain Res** 1999 Apr 6;67(1):10–7

Involvement of a putative G-protein-coupled receptor and a branching pathway in argipressin (4–8) signal transduction in rat hippocampus. Qiao LY, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):15–20

Prenatal availability of choline alters the development of acetylcholinesterase in the rat hippocampus. Cermak JM, et al. **Dev Neurosci** 1999;21(2):94–104

Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. Konietzko U, et al. **EMBO J** 1999 Jun 15;18(12):3359–69

Rapid increase in PKA activity during long-term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in vivo. Jay TM, et al. **Eur J Neurosci** 1998 Oct;10(10):3302–6

Age-dependent differences in glutamate-induced phosphorylation systems in rat hippocampal slices. Angenstein F, et al. **Hippocampus** 1999;9(2):173–85

The passerine hippocampus is a site of high aromatase: inter- and intraspecies comparisons. Saldanha CJ, et al. **Horm Behav** 1998 Oct;34(2):85–97

Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis. Kishi T, et al. **J Biol Chem** 1999 Feb 12;274(7):4220–4

Quantitative analysis of neuronal nitric oxide synthase-immunoreactive neurons in the mouse hippocampus with optical disector. Jinno S, et al. **J Comp Neurol** 1999 Aug 2;410(3):398–412

Distribution of GABAergic cells and fibers in the hippocampal formation of the macaque monkey: an immunohistochemical and in situ hybridization study. Jongen-Rêlo AL, et al. **J Comp Neurol** 1999 May 31; 408(2):237–71

Regulation of myelin basic protein phosphorylation by mitogen-activated protein kinase during increased action potential firing in the hippocampus. Atkins CM, et al. **J Neurochem** 1999 Sep;73(3):1090–7

Activity-dependent phosphorylation of SNAP-25 in hippocampal organotypic cultures. Genoud S, et al. **J Neurochem** 1999 Apr;72(4):1699–706

Effects of calyculin A and okadaic acid on acetylcholine release and subcellular distribution in rat hippocampal formation. Issa AM, et al. **J Neurochem** 1999 Jan; 72(1):166–73

Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. Uz T, et al. **J Neurochem** 1999 Aug;73(2):693–9

Alterations in the balance of protein kinase/phosphatase activities parallel reduced synaptic strength during aging. Norris CM, et al. **J Neurophysiol** 1998 Sep;80(3):1567–70

Regulation and immunohistochemical localization of betagamma-stimulated adenylyl cyclases in mouse hippocampus. Baker LP, et al. **J Neurosci** 1999 Jan 1; 19(1):180–92

Modulation of synaptic GABAA receptor function by PKA and PKC in adult hippocampal neurons. Poisbeau P, et al. **J Neurosci** 1999 Jan 15;19(2):674–83

Induction of hyperphosphorylated tau in living slices of rat hippocampal formation and subsequent detection using an ELISA. Mudher AK, et al. **J Neurosci Methods** 1999 Apr 1;88(1):15–25

In vivo glutamate neurotoxicity is associated with reductions in calcium/calmodulin-dependent protein kinase II immunoreactivity. Babcock AM, et al. **J Neurosci Res** 1999 Apr 1;56(1):36–43

APE/Ref-1 responses to oxidative stress in aged rats. Edwards M, et al. **J Neurosci Res** 1998 Dec 1;54(5):635–8

Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. Ho L, et al. **J Neurosci Res** 1999 Aug 1;57(3):295–303

Phorbol ester effects at hippocampal synapses act independently of the gamma isoform of PKC. Goda Y, et al. **Learn Mem** 1996 Sep–Oct;3(2–3):182–7

NADPH-diaphorase histochemistry in the rat cerebral cortex and hippocampus: effect of electrolytic lesions of the nucleus basalis magnocellularis. Sabbatini M, et al. **Mech Ageing Dev** 1999 Mar 1;107(2):147–57

Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Markstein R, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):454–9

Effects of AF64A on gene expression of choline acetyltransferase (ChAT) in the septo-hippocampal pathway and striatum in vivo. Fan QI, et al. **Neurochem Res** 1999 Jan;24(1):15–24

Maitotoxin induces calpain but not caspase-3 activation and necrotic cell death in primary septo-hippocampal cultures. Zhao X, et al. **Neurochem Res** 1999 Mar;24(3):371–82

Involvement of calcium/calmodulin-dependent protein kinases in the setting of a molecular switch involved in hippocampal LTP. Bortolotto ZA, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):535–44

The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/calmodulin-dependent protein kinase II in the hippocampus of rat brain. Pilc A, et al. **Neuropharmacology** 1999 Apr;38(4):597–603

State-dependent impairment in object recognition after hippocampal NOS inhibition. Blokland A, et al. **Neuroreport** 1998 Dec 21;9(18):4205–8

Ribonuclease improves the state of hippocampal sections in the post-ischemic period. Kudryashov IE, et al. **Neurosci Behav Physiol** 1998 Jul–Aug;28(4):357–65

Beta-amyloid increases cathepsin D levels in hippocampus. Hoffman KB, et al. **Neurosci Lett** 1998 Jul 3;250(2):75–8

Group I metabotropic receptors down-regulate nitric oxide induced caspase-3 activity in rat hippocampal neurons. Maiese K, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):17–20

Expression of nitric oxide synthase in the developing rat hippocampus. Moritz GC, et al. **Neurosci Lett** 1999 Mar 26;263(2–3):89–92

Delayed neuronal cell death in the rat hippocampus is mediated by the mitogen-activated protein kinase signal transduction pathway. Ozawa H, et al. **Neurosci Lett** 1999 Feb 26;262(1):57–60

Both protein kinase G dependent and independent mechanisms are involved in the modulation of glutamate release by nitric oxide in rat hippocampal nerve terminals. Sequeira SM, et al. **Neurosci Lett** 1999 Feb 12; 261(1–2):29–32

Temporal bone surgery causes reduced nitric oxide synthase activity in the ipsilateral guinea pig hippocampus. Zheng Y, et al. **Neurosci Lett** 1999 Jan 8;259(2):130–2

Neurotrophin-induced activation of casein kinase 2 in rat hippocampal slices. Blanquet PR. **Neuroscience** 1998 Oct; 86(3):739–49

Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Kimonides VG, et al. **Neuroscience** 1999 Mar;89(2):429–36

Corticosterone and phenytoin reduce neuronal nitric oxide synthase messenger RNA expression in rat hippocampus. Reagan LP, et al. **Neuroscience** 1999;91(1):211–9

Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning. Shamloo M, et al. **Neuroscience** 1999;93(1):81–8

Effect of chronic prenatal ethanol exposure on nitric oxide synthase I and III proteins in the hippocampus of the near-term fetal guinea pig. Kimura KA, et al. **Neurotoxicol Teratol** 1999 May–Jun;21(3):251–9

Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Klann E, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):359–76 (94 ref.)

Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation. Shen K, et al. **Science** 1999 Apr 2;284(5411):162–6

GROWTH & DEVELOPMENT

Quantitative morphology of human hippocampus early neuron development. Zaidel DW. **Anat Rec** 1999 Jan; 254(1):87–91

Differential expression of rat brain synaptic proteins in development and aging. Shimohama S, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):394–8

Synaptogenesis in the postnatal rat fascia dentata is influenced by 5-HT1a receptor activation. Faber KM, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):245–52

Effect of seizures on cerebral hypoxic-ischemic lesions in immature rats. Towfighi J, et al. **Brain Res Dev Brain Res** 1999 Mar 12;113(1–2):83–95

NMDAR-2A subunit protein expression is reduced in the hippocampus of rats exposed to Pb2+ during development. Nihei MK, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1–2):42–9

The effects of a transient increase in temperature on cell generation and cell death in the hippocampus and amygdala of the wallaby, Setonix brachyurus (quokka). Kent AR, et al. **Exp Brain Res** 1998 Oct;122(3):301–8

Development of microglia in the postnatal rat hippocampus. Dalmau I, et al. **Hippocampus** 1998;8(5):458–74

Prenatal stress: consequences of glucocorticoids on hippocampal development and function. Takahashi LK. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):199–207 (80 ref.)

Reelin regulates the development and synaptogenesis of the layer-specific entorhino-hippocampal connections. Borrell V, et al. **J Neurosci** 1999 Feb 15;19(4):1345–58

Synaptogenesis via dendritic filopodia in developing hippocampal area CA1. Fiala JC, et al. **J Neurosci** 1998 Nov 1;18(21):8900–11

Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Golomb J, et al. **Learn Mem** 1994 May–Jun;1(1):45–54

Beta-alanine release from the adult and developing hippocampus is enhanced by ionotropic glutamate receptor agonists and cell-damaging conditions. Saransaari P, et al. **Neurochem Res** 1999 Mar;24(3):407–14

Linear modeling of mRNA expression levels during CNS development and injury. D'Haeseleer P, et al. **Pac Symp Biocomput** 1999;:41–52

Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Kornack DR, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5768–73

Age-related impairment in long-term potentiation in hippocampus: a role for the cytokine, interleukin-1 beta? Lynch MA. **Prog Neurobiol** 1998 Dec;56(5):571–89 (187 ref.)

IMMUNOLOGY

HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. Aisen PS, et al. **J Neurol Sci** 1998 Nov 26; 161(1):66–9

Prolonged and concomitant induction of astroglial immunoreactivity of interleukin-1beta and interleukin-6 in the rat hippocampus after transient global ischemia. Orzyłowska O, et al. **Neurosci Lett** 1999 Mar 19;263(1):72–6

INJURIES

Short-time predegenerated peripheral nerve grafts promote regrowth of injured hippocampal neurites. Lewin-Kowalik J, et al. **Acta Physiol Hung** 1997–98;85(3):259–68

Purified extracts from short-time-predegenerated rats' sciatic nerves promote the regrowth of injured hippocampal neurites. Lewin-Kowalik J, et al. **Acta Physiol Hung** 1997–98;85(4):325–34

Traumatic amnesia, repression, and hippocampus injury due to emotional stress, corticosteroids and enkephalins. Joseph R. **Child Psychiatry Hum Dev** 1998 Winter;29(2):169–85 (128 ref.)

Basic fibroblast growth factor reduces lactic acid-induced neuronal injury in rat hippocampal neurons [see comments] Himmelseher S, et al. **Crit Care Med** 1998 Dec; 26(12):2029–36. Comment in: Crit Care Med 1998 Dec;26(12):1947–8.

Is transient acidosis detrimental to the nervous system? [editorial; comment] Hsu CY, et al. **Crit Care Med** 1998 Dec;26(12):1947–8 (27 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2029–36.

Human FGF-1 gene delivery protects against quinolinate-induced striatal and hippocampal injury in neonatal rats. Hossain MA, et al. **Eur J Neurosci** 1998 Aug; 10(8):2490–9

Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain. Joashi UC, et al. **Eur J Neurosci** 1999 Jan;11(1):91–100

Retrograde amnesia for spatial information: a dissociation between intra and extramaze cues following hippocampus lesions in rats. Ramos JM. **Eur J Neurosci** 1998 Oct; 10(10):3295–301

Inhibition of collagen IV deposition promotes regeneration of injured CNS axons. Stichel CC, et al. **Eur J Neurosci** 1999 Feb;11(2):632–46

Effects of hippocampal lesions on striatolimbic ionotropic glutamatergic receptors. Tarazi FI, et al. **Neurosci Lett** 1998 Jun 26;250(1):13–6

METABOLISM

Phosphorylation of protein kinase C substrate proteins in rat hippocampal slices—effect of calpain inhibition. Domańska-Janik K, et al. **Acta Neurobiol Exp (Warsz)** 1998;58(4):247–52

An increase of hippocampal calretinin-immunoreactive neurons correlates with early febrile seizures in temporal lobe epilepsy. Blümcke I, et al. **Acta Neuropathol (Berl)** 1999 Jan;97(1):31–9

Synaptophysin immunoreactivity in temporal lobe epilepsy-associated hippocampal sclerosis. Looney MR, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):179–85

Immunoelectron microscopic study of c-Fos, c-Jun and heat shock protein after transient cerebral ischemia in gerbils. Tomimoto H, et al. **Acta Neuropathol (Berl)** 1999 Jan; 97(1):22–30

Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Müller-Vahl KR, et al. **Acta Psychiatr Scand** 1998 Dec;98(6):502–6

Proton MR spectroscopy in patients with complex partial seizures: single-voxel spectroscopy versus chemical-shift imaging. Hsu YY, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):643–51

Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Funato H, et al. **Am J Pathol** 1999 Jul;155(1):23–8

Regulation of GLUT-3 glucose transporter in the hippocampus of diabetic rats subjected to stress. Reagan LP, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E879–86

Activation of adenosine A2 receptors enhances high K(+)-evoked taurine release from rat hippocampus: a microdialysis study. Hada J, et al. **Amino Acids** 1998; 15(1–2):43–52

Development of full-length Trk B-immunoreactive structures in the hippocampal formation of the macaque monkey. Hayashi M, et al. **Anat Embryol (Berl)** 1999 Jun; 199(6):529–37

Septotemporal distribution of [3H]MK-801, [3H]AMPA and [3H]Kainate binding sites in the rat hippocampus. Martens U, et al. **Anat Embryol (Berl)** 1998 Sep;198(3):195–204

An immunocytochemical assay for activity-dependent redistribution of glutamate receptors from the postsynaptic plasma membrane. Lissin DV, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:550–3

Quantitative fluorescent RT-PCR measurements of postnatal calcium channel gene expression in rat hippocampal subfields. Pradhan SM, et al. **Ann N Y Acad Sci** 1999 Apr

30;868:228–32
Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Radcliffe KA, et al. **Ann N Y Acad Sci** 1999 Apr 30;868:591–610
Hippocampal N-methyl-D-aspartate receptor subunit mRNA levels in temporal lobe epilepsy patients. Mathern GW, et al. **Ann Neurol** 1999 Sep;46(3):343–58
Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Woermann FG, et al. **Ann Neurol** 1999 Mar;45(3):369–76
Long-term voluntary ethanol consumption affects neither spatial nor passive avoidance learning, nor hippocampal acetylcholine release in alcohol-preferring rats. Fadda F, et al. **Behav Brain Res** 1999 Aug;103(1):71–6
Reinforcement enhances hippocampal acetylcholine release in rats: an in vivo microdialysis study. Iso H, et al. **Behav Brain Res** 1999 Jun;101(2):207–13
Effects of environmental enrichment on cognitive function and hippocampal NGF in the non-handled rats. Pham TM, et al. **Behav Brain Res** 1999 Aug;103(1):63–70
Learning upregulates brain-derived neurotrophic factor messenger ribonucleic acid: a mechanism to facilitate encoding and circuit maintenance? Kesslak JP, et al. **Behav Neurosci** 1998 Aug;112(4):1012–9
The dendritic translocation of translin protein in the form of BC1 RNA protein particles in developing rat hippocampal neurons in primary culture. Kobayashi S, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):448–53
Differential expression of rat brain synaptic proteins in development and aging. Shimohama S, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):394–8
Tissue-specific differences in rat glucocorticoid receptor gene transcriptional regulation. McCormick JA, et al. **Biochem Soc Trans** 1998 Aug;26(3):S207
Intracerebroventricular injection of mu- and delta-opiate receptor antagonists block 60 Hz magnetic field-induced decreases in cholinergic activity in the frontal cortex and hippocampus of the rat. Lai H, et al. **Bioelectromagnetics** 1998;19(7):432–7
Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype [published erratum appears in Biol Psychiatry 1999 Jan 15;45(2):following 244] Callicott JH, et al. **Biol Psychiatry** 1998 Nov 15;44(10):941–50
Serotonin 1A receptor messenger RNA regulation in the hippocampus after acute stress. López JF, et al. **Biol Psychiatry** 1999 Apr 1;45(7):934–7
Involvement of K(+) channels in the inhibitory effects of adenosine on anoxia-induced [Ca(2+)](i) increase in cultured rat hippocampal CA1 neurons. Wan Q, et al. **Biol Signals Recept** 1999 Jul-Oct;8(4–5):309–15
Presynaptic and postsynaptic actions of halothane at glutamatergic synapses in the mouse hippocampus. Kirson ED, et al. **Br J Pharmacol** 1998 Aug;124(8):1607–14
Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Okada M, et al. **Br J Pharmacol** 1998 Jul;124(6):1277–85
Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Meguro K, et al. **Brain** 1999 Aug;122 (Pt 8):1519–31
Facilitation by arachidonic acid of acetylcholine release from the rat hippocampus. Almeida T, et al. **Brain Res** 1999 Apr 24;826(1):104–11
CO2/HCO3(-)-withdrawal from the bath medium of hippocampal slices: biphasic effect on intracellular pH and bioelectric activity of CA3-neurons. Bonnet U, et al. **Brain Res** 1998 Jun 15;796(1-2):161–70
Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats. Carta G, et al. **Brain Res** 1998 Oct 26;809(1):1–4
Effects of novelty and pain on behavior and hippocampal extracellular ACh levels in male and female rats. Ceccarelli I, et al. **Brain Res** 1999 Jan 9;815(2):169–76
Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Chandrasekaran K, et al. **Brain Res** 1998 Jun 15;796(1-2):13–9
Physical training modifies the age-related decrease of GAP-43 and synaptophysin in the hippocampal formation in C57BL/6J mouse. Chen YC, et al. **Brain Res** 1998 Sep 28;806(2):238–45
Noxious tooth pulp stimulation suppresses c-fos expression in the rat hippocampal formation. Funahashi M, et al. **Brain Res** 1999 May 8;827(1-2):215–20
Postmortem elevation in extracellular glutamate in the rat hippocampus when brain temperature is maintained at physiological levels: implications for the use of human brain autopsy tissues. Geddes JW, et al. **Brain Res** 1999 Jun 12; 831(1-2):104–12
Depletion of intracellular Ca2+ stores or lowering extracellular calcium alters intracellular Ca2+ changes during cerebral energy deprivation. Grøndahl TO, et al. **Brain Res** 1998 Jun 15;796(1-2):125–31
Chloride concentration in cultured hippocampal neurons increases during long-term exposure to ammonia through enhanced expression of an anion exchanger. Irie T, et al. **Brain Res** 1998 Sep 28;806(2):246–56
Enhanced localization of amyloid beta precursor protein in the rat hippocampus following long-term adrenalectomy. Islam A, et al. **Brain Res** 1998 Sep 21;806(1):108–12
Involvement of P2 purinoceptors and the nitric oxide pathway in [3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. Jurányi Z, et al. **Brain Res** 1999 Mar 27;823(1-2):183–90
Reverse transport of glutamate during depolarization in immature hippocampal slices. Katsumori H, et al. **Brain Res** 1999 Feb 20;819(1-2):160–4
Postnatal expressions of non-phosphorylated and phosphorylated neurofilament proteins in the rat hippocampus and the Timm-stained mossy fiber pathway. Mikuni N, et al. **Brain Res** 1998 Nov 16;811(1-2):1–9
Amygdala-kindled and electroconvulsive seizures alter hippocampal expression of the m1 and m3 muscarinic cholinergic receptor genes. Mingo NS, et al. **Brain Res** 1998 Nov 9;810(1-2):9–15
Restriction of environmental space attenuates locomotor activity and hippocampal acetylcholine release in male rats. Mitsushima D, et al. **Brain Res** 1998 Sep 14;805(1-2):207–12
The effects of median raphé electrical stimulation on serotonin release in the dorsal hippocampal formation of prenatally protein malnourished rats. Mokler DJ, et al. **Brain Res** 1999 Aug 14;838(1-2):95–103
Modulation of mechanically induced calcium waves in hippocampal astroglial cells. Inhibitory effects of alpha 1-adrenergic stimulation. Muyderman H, et al. **Brain Res** 1998 May 18;793(1-2):127–35
In vivo microdialysis measures of extracellular serotonin in the rat hippocampus during sleep-wakefulness. Park SP, et al. **Brain Res** 1999 Jul 3;833(2):291–6
Increased density of M1 receptors in the hippocampus of juvenile rats chronically deprived of NGF. Rosati AM, et al. **Brain Res** 1999 Jan 9;815(2):185–91
Mechanisms of ischemia-induced taurine release in mouse hippocampal slices. Saransaari P, et al. **Brain Res** 1998 Oct 5;807(1-2):118–24
Fibroblast growth factor receptor-1 expression in the cortex and hippocampus in Alzheimer's disease. Takami K, et al. **Brain Res** 1998 Aug 17;802(1-2):89–97
Ultrastructural localization of hippocampal TNF-alpha immunoreactive cells in rats following transient global ischemia. Tseng MT, et al. **Brain Res** 1999 Jun 26; 833(1):121–4
Effects of applied currents on spontaneous epileptiform activity induced by low calcium in the rat hippocampus. Warren RJ, et al. **Brain Res** 1998 Sep 28;806(2):186–95
Delayed induction of JunB precedes CA1 neuronal death after global ischemia in the gerbil. Whitfield PC, et al. **Brain Res** 1999 Feb 13;818(2):450–8
Immunohistochemical detection of oxidative DNA damage induced by ischemia-reperfusion insults in gerbil hippocampus in vivo. Won MH, et al. **Brain Res** 1999 Jul 31;836(1-2):70–8
Involvement of the glutamate transporter and the sodium-calcium exchanger in the hypoxia-induced increase in intracellular Ca2+ in rat hippocampal slices. Yamaguchi S, et al. **Brain Res** 1998 Dec 7;813(2):351–8
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Yamamoto-Sasaki M, et al. **Brain Res** 1999 Apr 10;824(2):300–3
Noradrenaline and serotonin levels in the guinea pig hippocampus following unilateral vestibular deafferentation. Zheng Y, et al. **Brain Res** 1999 Jul 31; 836(1-2):199–202
Modulation of 5-hydroxytryptamine release in hippocampal slices of rats: effects of fimbria-fornix lesions on 5-HT1B-autoreceptor and alpha2-heteroreceptor function. Jackisch R, et al. **Brain Res Bull** 1999 Jan 1;48(1):49–59
[Arg8]-vasopressin-induced increase in intracellular Ca2+ concentration in cultured rat hippocampal neurons. Mihara T, et al. **Brain Res Bull** 1999 Jul 15;49(5):343–7
Neurotrophin-like immunoreactivity in the human hippocampal formation. Quartu M, et al. **Brain Res Bull** 1999 Mar 1;48(4):375–82
Individual differences in behavioral reactivity: correlation with stress-induced norepinephrine efflux in the hippocampus of Sprague-Dawley rats. Rosario LA, et al. **Brain Res Bull** 1999 Apr;48(6):595–602
Intracerebroventricular infusion of CRF increases extracellular concentrations of norepinephrine in the hippocampus and cortex as determined by in vivo voltammetry. Zhang JJ, et al. **Brain Res Bull** 1998 Oct; 47(3):277–84
The specific dopamine uptake inhibitor GBR 12783 improves learning of inhibitory avoidance and increases hippocampal acetylcholine release. Nail-Boucherie K, et al. **Brain Res Cogn Brain Res** 1998 Oct;7(2):203–5
Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Chen B, et al. **Brain Res Mol Brain Res** 1999 Jun 18;70(1):45–53
The expression of voltage-dependent calcium channel beta subunits in human hippocampus. Day NC, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):259–69
Increased expression of voltage-activated calcium channels in cultured hippocampal neurons from mouse trisomy 16, a model for Down syndrome. Galdzicki Z, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):200–6
Measurement of NMDA receptor protein subunits in discrete hippocampal regions of kindled animals. Kraus JE, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):114–20
Hippocampal Myc and p53 expression following transient global ischemia. McGahan L, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):133–45
GABAA receptor beta 2 and beta 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. Mizukami K, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):268–72
Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Oliff HS, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1-2):147–53
Differentially expressed genes in hippocampal cell cultures in response to an excitotoxic insult by quinolinic acid. Seidel B, et al. **Brain Res Mol Brain Res** 1998 Oct 1; 60(2):296–300
Nitric oxide differentially affects the exocytotic and the carrier-mediated release of [3H] gamma-aminobutyric acid in rat hippocampal synaptosomes. Sequeira SM, et al. **Brain Res Mol Brain Res** 1998 Apr;55(2):337–40
Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion. Terrisse L, et al. **Brain Res Mol Brain Res** 1999 Jun 18;70(1):26–35
Highest trkB mRNA expression in the entorhinal cortex among hippocampal subregions in the adult rat: contrasting pattern with BDNF mRNA expression. Tokuyama W, et al. **Brain Res Mol Brain Res** 1998 Nov 20;62(2):206–15
Changes in proliferating cell nuclear antigen, a protein involved in DNA repair, in vulnerable hippocampal neurons following global cerebral ischemia. Tomasevic G, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):168–76
The modulatory role of nitric oxide in the regulation of proenkephalin and prodynorphin gene expressions induced by kainic acid in rat hippocampus. Won JS, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):76–83
Expression of recombinant NMDA receptors in hippocampal neurons by adenoviral-mediated gene transfer. Yamada N, et al. **Brain Res Mol Brain Res** 1999 May 7;68(1-2):169–80
Serotonin receptor subtype gene expression in the hippocampus of aged rats following chronic amitriptyline treatment. Yau JL, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):282–7
A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Zachrisson O, et al. **Brain Res Mol Brain Res** 1998 Oct 1;60(2):291–5
Platelet activating factor receptor expression is associated with neuronal apoptosis in an in vivo model of excitotoxicity. Bennett SA, et al. **Cell Death Differ** 1998 Oct;5(10):867–75
Metal ion and guanine nucleotide modulations of agonist interaction in G-protein-coupled serotonin1A receptors from bovine hippocampus. Harikumar KG, et al. **Cell Mol Neurobiol** 1998 Oct;18(5):535–53
Role of the ryanodine receptor in ischemic brain damage--localized reduction of ryanodine receptor binding during ischemia in hippocampus CA1. Nozaki H, et al. **Cell Mol Neurobiol** 1999 Feb;19(1):119–31 (74 ref.)
Detection of endogenous biotin in various tissues: novel functions in the hippocampus and implications for its use in avidin-biotin technology. Wang H, et al. **Cell Tissue Res** 1999 Jun;296(3):511–6
Proton chemical shift imaging of the hippocampus in patients with complex partial seizures. Hsu YY, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar;22(1):68–75
Over-expression of c-fos mRNA in the hippocampal neurons in Alzheimer's disease. Lu W, et al. **Chin Med J (Engl)** 1998 Jan;111(1):35–7
Involvement of intracellular Ca2+ stores in 3,4-diaminopyridine-evoked [3H]norepinephrine release. Huang HY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul; 17(4):302–5
Effects of ginsenoside Rg1 on c-fos gene expression and cAMP levels in rat hippocampus. Liu M, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Mar;17(2):171–4
Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Ishii K, et al. **Dement Geriatr Cogn Disord** 1998 Nov-Dec;9(6):317–22
Identification of CXorf1, a novel intronless gene in Xq27.3, expressed in human hippocampus. Redolfi E, et al. **DNA Cell Biol** 1998 Dec;17(12):1009–16
Defense of adrenocorticosteroid receptor expression in rat hippocampus: effects of stress and strain. Herman JP, et al. **Endocrinology** 1999 Sep;140(9):3981–91
Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Kawata Y, et al. **Epilepsy Res** 1999 Jul;35(3):173–82
Hippocampal AMPA and NMDA mRNA levels and subunit immunoreactivity in human temporal lobe epilepsy patients and a rodent model of chronic mesial limbic epilepsy. Mathern GW, et al. **Epilepsy Res** 1998 Sep;32(1-2):154–71
Transcripts of the transposon mariner are present in epileptic brain. Xie H, et al. **Epilepsy Res** 1998 Sep;32(1-2):140–53
Increased production of nitric oxide metabolites in the hippocampus under isoflurane anaesthesia in rats. Matsuoka H, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):216–24
GABAergic cell types in the lizard hippocampus. Guirado S, et al. **Eur J Morphol** 1999 Apr;37(2-3):89–94
Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose.

Brana C, et al. **Eur J Neurosci** 1999 Jul;11(7):2375–84

Learning-specific, time-dependent increases in hippocampal Ca2+/calmodulin-dependent protein kinase II activity and AMPA GluR1 subunit immunoreactivity. Cammarota M, et al. **Eur J Neurosci** 1998 Aug;10(8):2669–76

AMPA receptor subunits are differentially expressed in parvalbumin- and calretinin-positive neurons of the rat hippocampus. Catania MV, et al. **Eur J Neurosci** 1998 Nov; 10(11):3479–90

Neuroprotection of cultured foetal rat hippocampal cells against glucose deprivation: are GABAergic neurons less vulnerable or more sensitive to TCP protection? Chaudieu I, et al. **Eur J Neurosci** 1999 Jul;11(7):2413–21

Facilitation of GABA release by arachidonic acid in rat hippocampal synaptosomes. Cunha RA, et al. **Eur J Neurosci** 1999 Jun;11(6):2171–4

Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Okada M, et al. **Eur J Neurosci** 1999 Jan;11(1):1–9

Perturbation of the synaptic release machinery in hippocampal neurons by overexpression of SNAP-25 with the Semliki Forest virus vector. Owe-Larsson B, et al. **Eur J Neurosci** 1999 Jun;11(6):1981–7

Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats. Venero C, et al. **Eur J Neurosci** 1999 Jul;11(7):2465–73

The effect of serotonin depletion on motor activity habituation, and [3H]muscimol binding in the rat hippocampus. Bidzinski A, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):5–12

GABA receptors and benzodiazepine binding sites modulate hippocampal acetylcholine release in vivo. Moor E, et al. **Eur J Pharmacol** 1998 Oct 23;359(2–3):119–26

Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. O'Kane EM, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):17–25

Synergistic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists. Trillat AC, et al. **Eur J Pharmacol** 1998 Sep 18;357(2–3):179–84

Effects of the atypical antidepressant trimipramine on field potentials in the low Mg2+-model in guinea pig hippocampal slices. Langosch JM, et al. **Eur Neuropsychopharmacol** 1998 Aug;8(3):209–12

Hippocampal 5-HT and NE release in the transgenic rat TGR(mREN2)27 related to behavior on the elevated plus maze. Voigt JP, et al. **Eur Neuropsychopharmacol** 1999 Jun; 9(4):279–85

Biphasic changes in F3/contactin expression in the gerbil hippocampus after transient ischemia. Cho H, et al. **Exp Brain Res** 1998 Sep;122(2):227–34

Bcl-2, Bax, and Bcl-x expression in the CA1 area of the hippocampus following transient forebrain ischemia in the adult gerbil. Ferrer I, et al. **Exp Brain Res** 1998 Jul; 121(2):167–73

Kainic acid-induced activation of nuclear factor-kappaB in rat hippocampus. Matsuoka Y, et al. **Exp Brain Res** 1999 Jan;124(2):215–22

Modulation of mRNA expression of the neurotrophins of the nerve-growth-factor family and their receptors in the septum and hippocampus of rats after transient postnatal thyroxine treatment. II. Effects on p75 and trk receptor expression. Roskoden T, et al. **Exp Brain Res** 1999 Aug; 127(3):307–13

Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Zhang L, et al. **Exp Brain Res** 1999 Jun;126(4):509–16

The protein phosphatase inhibitor okadaic acid induces heat shock protein expression and neurodegeneration in rat hippocampus in vivo. Arias C, et al. **Exp Neurol** 1998 Oct; 153(2):242–54

Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Lidström AM, et al. **Exp Neurol** 1998 Dec;154(2):511–21

VASE-containing N-CAM isoforms are increased in the hippocampus in bipolar disorder but not schizophrenia. Vawter MP, et al. **Exp Neurol** 1998 Nov;154(1):1–11

High activity K+ channels in rat hippocampal neurones maintained in culture. Wann KT, et al. **Exp Physiol** 1999 May;84(3):501–14

Plasticity of hippocampal corticosteroid receptors during aging in the rat. Hassan AH, et al. **FASEB J** 1999 Jan; 13(1):115–22

AlphaCaMKII binding to the C-terminal tail of NMDA receptor subunit NR2A and its modulation by autophosphorylation. Gardoni F, et al. **FEBS Lett** 1999 Aug 13;456(3):394–8

Second form of gonadotropin-releasing hormone in mouse: immunocytochemistry reveals hippocampal and periventricular distribution. Gestrin ED, et al. **FEBS Lett** 1999 Apr 9;448(2–3):289–91

Differential discrimination of G-protein coupling of serotonin(1A) receptors from bovine hippocampus by an agonist and an antagonist. Harikumar KG, et al. **FEBS Lett** 1999 Sep 3;457(3):389–92

Gangliosides GM1 and GD1b are not polarized in mature hippocampal neurons. Shogomori H, et al. **FEBS Lett** 1999 Sep 17;458(2):107–11

Quinolinic acid and sigma receptor ligand: effect on pyramidal neurons of the CA1 sector of dorsal hippocampus following peripheral administration in rats. Beskid M, et al. **Folia Neuropathol** 1998;36(2):94–100

Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Nakamura E, et al. **Genes Cells** 1998 Dec;3(12):811–22

Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss. Friedman LK. **Hippocampus** 1998;8(5):511–25

Regulation of gamma-aminobutyric acid (GABA) transporters by extracellular GABA. Bernstein EM, et al. **J Biol Chem** 1999 Jan 8;274(2):889–95

A regulated secretory pathway in cultured hippocampal astrocytes. Calegari F, et al. **J Biol Chem** 1999 Aug 6; 274(32):22539–47

Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca2+/calmodulin-dependent protein kinases in cultured rat hippocampal neurons. Kasahara J, et al. **J Biol Chem** 1999 Mar 26;274(13):9061–7

Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. Liu YF. **J Biol Chem** 1998 Oct 30;273(44):28873–7

Interaction of NE-dlg/SAP102, a neuronal and endocrine tissue-specific membrane-associated guanylate kinase protein, with calmodulin and PSD-95/SAP90. A possible regulatory role in molecular clustering at synaptic sites. Masuko N, et al. **J Biol Chem** 1999 Feb 26;274(9):5782–90

Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death. Mukherjee PK, et al. **J Biol Chem** 1999 Mar 5;274(10):6493–8

Phosphorylation of myristoylated alanine-rich protein kinase C substrate by mitogen-activated protein kinase in cultured rat hippocampal neurons following stimulation of glutamate receptors. Ohmitsu M, et al. **J Biol Chem** 1999 Jan 1; 274(1):408–17

Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. Tamatani M, et al. **J Biol Chem** 1999 Mar 26; 274(13):8531–8

Differential expressions of glycine transporter 1 and three glutamate transporter mRNA in the hippocampus of gerbils with transient forebrain ischemia. Fujita H, et al. **J Cereb Blood Flow Metab** 1999 Jun;19(6):604–15

Ubiquitin stress response in postischemic hippocampal neurons under nontolerant and tolerant conditions. Ide T, et al. **J Cereb Blood Flow Metab** 1999 Jul;19(7):750–6

Insulin induces dephosphorylation of eukaryotic initiation factor 2alpha and restores protein synthesis in vulnerable hippocampal neurons after transient brain ischemia. Sullivan JM, et al. **J Cereb Blood Flow Metab** 1999 Sep; 19(9):1010–9

The reversible change of GluR2 RNA editing in gerbil hippocampus in course of ischemic tolerance. Yamaguchi K, et al. **J Cereb Blood Flow Metab** 1999 Apr;19(4):370–5

Expression of the myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein (MRP) in the prefrontal cortex and hippocampus of suicide victims. McNamara RK, et al. **J Clin Psychiatry** 1999;60 Suppl 2:21–6; discussion 40–1, 113–6

Expression of L1 and PSA during sprouting and regeneration in the adult hippocampal formation. Aubert I, et al. **J Comp Neurol** 1998 Sep 14;399(1):1–19

Up-regulation of GAD65 and GAD67 in remaining hippocampal GABA neurons in a model of temporal lobe epilepsy. Esclapez M, et al. **J Comp Neurol** 1999 Sep 27; 412(3):488–505

Spiny calretinin-immunoreactive neurons in the hilus and CA3 region of the rat hippocampus: local axon circuits, synaptic connections, and glutamic acid decarboxylase 65/67 mRNA expression. Martínez A, et al. **J Comp Neurol** 1999 Feb 22;404(4):438–48

Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus. Phillips LM, et al. **J Comp Neurol** 1999 Mar 15;405(3):322–33

Effect of propentofylline on hippocampal brain energy state and amyloid precursor protein concentration in a rat model of cerebral hypoperfusion. Plaschke K, et al. **J Neural Transm** 1998;105(8–9):1065–77

Kainate-elicited seizures induce mRNA encoding a CaMK-related peptide: a putative modulator of kinase activity in rat hippocampus. Vreugdenhil E, et al. **J Neurobiol** 1999 Apr;39(1):41–50

Effect of serine and ethanolamine administration on phospholipid-related compounds and neurotransmitter amino acids in the rabbit hippocampus. Buratta S, et al. **J Neurochem** 1998 Nov;71(5):2145–50

Insulin causes a transient tyrosine phosphorylation of NR2A and NR2B NMDA receptor subunits in rat hippocampus. Christie JM, et al. **J Neurochem** 1999 Apr;72(4):1523–8

Decreased hippocampal expression, but not functionality, of GABA(B) receptors after transient cerebral ischemia in rats. Francis J, et al. **J Neurochem** 1999 Jan;72(1):87–94

Increased expression of apolipoprotein D following experimental traumatic brain injury. Franz G, et al. **J Neurochem** 1999 Oct;73(4):1615–25

Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices. Hennings EC, et al. **J Neurochem** 1999 Sep;73(3):1043–50

Characterization of the phosphoinositide-linked dopamine receptor in a mouse hippocampal-neuroblastoma hybrid cell line. Jin LQ, et al. **J Neurochem** 1998 Nov; 71(5):1935–43

Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. Li QX, et al. **J Neurochem** 1999 Jun;72(6):2479–87

Extracellular glucose concentrations in the rat hippocampus measured by zero-net-flux: effects of microdialysis flow rate, strain, and age. McNay EC, et al. **J Neurochem** 1999 Feb;72(2):785–90

Prenatal ethanol exposure decreases GAP-43 phosphorylation and protein kinase C activity in the hippocampus of adult rat offspring. Perrone-Bizzozero NI, et al. **J Neurochem** 1998 Nov;71(5):2104–11

Magnetic resonance spectroscopy studies on changes in cerebral calcium and zinc and the energy state caused by excitotoxic amino acids. Thatcher NM, et al. **J Neurochem** 1999 Jun;72(6):2471–8

Differential regulation of hippocampal glucocorticoid receptors mRNA and fast feedback: relevance to post-traumatic stress disorder. Liberzon I, et al. **J Neuroendocrinol** 1999 Jan;11(1):11–7

Altered patterns of Ca2+/calmodulin-dependent protein kinase II and calcineurin immunoreactivity in the hippocampus of patients with temporal lobe epilepsy. Lie AA, et al. **J Neuropathol Exp Neurol** 1998 Nov; 57(11):1078–88

Synaptic activation of GABAA receptors induces neuronal uptake of Ca2+ in adult rat hippocampal slices. Autere AM, et al. **J Neurophysiol** 1999 Feb;81(2):811–6

Activation of neurotransmitter release in hippocampal nerve terminals during recovery from intracellular acidification. Trudeau LE, et al. **J Neurophysiol** 1999 Jun;81(6):2627–35

Kainate receptor-mediated responses in the CA1 field of wild-type and GluR6-deficient mice. Bureau I, et al. **J Neurosci** 1999 Jan 15;19(2):653–63

Suppression of postischemic hippocampal nerve growth factor expression by a c-fos antisense oligodeoxynucleotide. Cui JK, et al. **J Neurosci** 1999 Feb 15;19(4):1335–44

Post-transcriptional regulation of synaptic vesicle protein expression and the developmental control of synaptic vesicle formation. Daly C, et al. **J Neurosci** 1997 Apr 1; 17(7):2365–75

Effects of transforming growth factor-beta (isoforms 1-3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures. Harris-White ME, et al. **J Neurosci** 1998 Dec 15; 18(24):10366–74

Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. Katona I, et al. **J Neurosci** 1999 Jun 1; 19(11):4544–58

Optical detection of synaptically induced glutamate transport in hippocampal slices. Kojima S, et al. **J Neurosci** 1999 Apr 1;19(7):2580–8

Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. Mowla SJ, et al. **J Neurosci** 1999 Mar 15;19(6):2069–80

Identification of the Kv2.1 K+ channel as a major component of the delayed rectifier K+ current in rat hippocampal neurons. Murakoshi H, et al. **J Neurosci** 1999 Mar 1;19(5):1728–35

Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action. Opanashuk LA, et al. **J Neurosci** 1999 Jan 1;19(1):133–46

The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. Roberson ED, et al. **J Neurosci** 1999 Jun 1;19(11):4337–48

Oxygen/glucose deprivation in hippocampal slices: altered intraneuronal elemental composition predicts structural and functional damage. Taylor CP, et al. **J Neurosci** 1999 Jan 15;19(2):619–29

Mechanisms of calcium influx into hippocampal spines: heterogeneity among spines, coincidence detection by NMDA receptors, and optical quantal analysis. Yuste R, et al. **J Neurosci** 1999 Mar 15;19(6):1976–87

Citron binds to PSD-95 at glutamatergic synapses on inhibitory neurons in the hippocampus. Zhang W, et al. **J Neurosci** 1999 Jan 1;19(1):96–108

Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: major roles for glutamate and Na+-dependent Ca2+ release from mitochondria. Zhang Y, et al. **J Neurosci** 1999 May 1;19(9):3307–15

Turnover rates of the AMPA-type glutamate receptor GluR1 measured by transient gene expression. Horikawa HP, et al. **J Neurosci Methods** 1998 Oct 1;84(1-2):173–9

Quantitative analysis of gene expression in organotypic slice-explant cultures by particle-mediated gene transfer. Thomas A, et al. **J Neurosci Methods** 1998 Oct 1; 84(1-2):181–91

Functional expression of TrkA receptors in hippocampal neurons. Aibel L, et al. **J Neurosci Res** 1998 Nov 1; 54(3):424–31

Calcium-induced activation of the mitochondrial permeability transition in hippocampal neurons. Dubinsky JM, et al. **J Neurosci Res** 1998 Sep 15;53(6):728–41

AMPA receptor protein expression and function in astrocytes cultured from hippocampus. Fan D, et al. **J Neurosci Res** 1999 Aug 15;57(4):557–71

Antisense oligonucleotide to GABA(A) receptor gamma2

subunit induces limbic status epilepticus. Karle J, et al. **J Neurosci Res** 1998 Dec 15;54(6):863–9

Differential effects of Bcl-2 overexpression on hippocampal CA1 neurons and dentate granule cells following hypoxic ischemia in adult mice. Wang HD, et al. **J Neurosci Res** 1999 Jul 1;57(1):1–12

Native gamma-aminobutyric acid type A receptors from rat hippocampus, containing both alpha 1 and alpha 5 subunits, exhibit a single benzodiazepine binding site with alpha 5 pharmacological properties. Araujo F, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):989–97

Zinc and ifenprodil allosterically inhibit two separate polyamine-sensitive sites at N-methyl-D-aspartate receptor complex. Berger ML, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1584–91

Local alpha-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine. Fu Y, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):133–9

Laminar difference in GABA uptake and GAT-1 expression in rat CA1. Engel D, et al. **J Physiol (Lond)** 1998 Nov 1;512 (Pt 3):643–9

Effects of noradrenaline on intracellular pH in acutely dissociated adult rat hippocampal CA1 neurones. Smith GA, et al. **J Physiol (Lond)** 1998 Oct 15;512 (Pt 2):487–505

Inositol 1,3,4,5-tetrakisphosphate enhances long-term potentiation by regulating Ca2+ entry in rat hippocampus. Szinyei C, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):855–68

Imprinting of hippocampal metabolism of choline by its availability during gestation: implications for cholinergic neurotransmission. Blusztajn JK, et al. **J Physiol Paris** 1998 Jun-Aug;92(3–4):199–203

Brain N-acetyl aspartate concentrations measured by H MRS are reduced in adult male rats subjected to perinatal stress: preliminary observations and hypothetical implications for neurodevelopmental disorders. Poland RE, et al. **J Psychiatr Res** 1999 Jan-Feb;33(1):41–51 (126 ref.)

Training in the Morris water maze occludes the synergism between ACPD and arachidonic acid on glutamate release in synaptosomes prepared from rat hippocampus. McGahon B, et al. **Learn Mem** 1996 Nov-Dec;3(4):296–304

A biochemist's view of long-term potentiation. Roberson ED, et al. **Learn Mem** 1996 Jul-Aug;3(1):1–24 (168 ref.)

Modification of hippocampal synaptic proteins by nitric oxide-stimulated ADP ribosylation. Sullivan BM, et al. **Learn Mem** 1997 Jan-Feb;3(5):414–24

Quantitative 1H MRS in the evaluation of mesial temporal lobe epilepsy in vivo. Duc CO, et al. **Magn Reson Imaging** 1998 Oct;16(8):969–79

Water diffusion in the human hippocampus in epilepsy. Wieshmann UC, et al. **Magn Reson Imaging** 1999 Jan; 17(1):29–36

The effect of ouabain on water diffusion in the rat hippocampal slice measured by high resolution NMR imaging. Buckley DL, et al. **Magn Reson Med** 1999 Jan; 41(1):137–42

Localized proton MRS of the human hippocampus: metabolite concentrations and relaxation times. Choi CG, et al. **Magn Reson Med** 1999 Jan;41(1):204–7

Intercellular Transport-metabolic interactions in the nervous tissue developing under conditions of afferentation deficit (transplants in the anterior eye chamber). Zhuravleva ZN. **Membr Cell Biol** 1998;11(6):727–35

Autoradiographic measurements of protein synthesis in hippocampal slices from rats and guinea pigs. Lipton P, et al. **Methods** 1999 Jun;18(2):127–43

Preparation of cDNA from single cells and subcellular regions. Kacharmina JE, et al. **Methods Enzymol** 1999; 303:3–18

Quantitative analysis of peptide and protein changes in ischemic hippocampal tissue by HPLC. Wengenack TM, et al. **Methods Mol Biol** 1998;108:165–80

Are there differences between the secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity-dependent neuronal plasticity. Griesbeck O, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):262–75

Localization of the brain-specific high-affinity l-proline transporter in cultured hippocampal neurons: molecular heterogeneity of synaptic terminals. Crump FT, et al. **Mol Cell Neurosci** 1999 Jan;13(1):25–39

Aberrant presenilin-1 expression downregulates LDL receptor-related protein (LRP): is LRP central to Alzheimer's disease pathogenesis? Van Uden E, et al. **Mol Cell Neurosci** 1999 Aug;14(2):129–40

Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Chalimoniuk M, et al. **Mol Chem Neuropathol** 1998 Aug-Dec;35(1–3):77–95

A light and electron microscopic study of the metabotropic glutamate receptor mGluR1a in the normal and kainate-lesioned rat hippocampus. Ong WY, et al. **Mol Chem Neuropathol** 1998 Aug-Dec;35(1–3):173–86

No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Naylor L, et al. **Mol Med** 1998 Oct; 4(10):671–4

Antagonist pharmacology of metabotropic glutamate receptors coupled to phospholipase D activation in adult rat hippocampus: focus on (2R,1'S,2'R,3'S)-2-(2'-carboxy-3'-phenylcyclopropyl) glycine versus 3, 5-dihydroxyphenylglycine. Albani-Torregrossa S, et al. **Mol Pharmacol** 1999 Apr; 55(4):699–707

Kainate receptors coupled to G(i)/G(o) proteins in the rat hippocampus. Cunha RA, et al. **Mol Pharmacol** 1999 Aug; 56(2):429–33

Regulation of N-methyl-D-aspartate receptor function by constitutively active protein kinase C. Xiong ZG, et al. **Mol Pharmacol** 1998 Dec;54(6):1055–63

A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Edgar PF, et al. **Mol Psychiatry** 1999 Mar;4(2):173–8

Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Fatemi SH, et al. **Mol Psychiatry** 1999 Mar;4(2):145–54

A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation. Carrié A, et al. **Nat Genet** 1999 Sep;23(1):25–31

Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. Carroll RC, et al. **Nat Neurosci** 1999 May;2(5):454–60

Focal photolysis of caged glutamate produces long-term depression of hippocampal glutamate receptors [see comments] Kandler K, et al. **Nat Neurosci** 1998 Jun; 1(2):119–23. Comment in: Nat Neurosci 1998 Jun;1(2):89–90.

Casein kinase-II regulates NMDA channel function in hippocampal neurons. Lieberman DN, et al. **Nat Neurosci** 1999 Feb;2(2):125–32

Selective acquisition of AMPA receptors over postnatal development suggests a molecular basis for silent synapses. Petralia RS, et al. **Nat Neurosci** 1999 Jan;2(1):31–6

Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. Takumi Y, et al. **Nat Neurosci** 1999 Jul;2(7):618–24

Selective activation of Ca2+-activated K+ channels by co-localized Ca2+ channels in hippocampal neurons. Marrion NV, et al. **Nature** 1998 Oct 29;395(6705):900–5

Up-regulation of alpha1D Ca2+ channel subunit mRNA expression in the hippocampus of aged F344 rats. Herman JP, et al. **Neurobiol Aging** 1998 Nov-Dec;19(6):581–7

Enhanced release of norepinephrine in rat hippocampus during spontaneous alternation tests. Men D, et al. **Neurobiol Learn Mem** 1999 May;71(3):289–300

The hippocampal opioidergic system: a comparative immunocytochemical study in four rodents. Rácz B, et al. **Neurobiology (Bp)** 1998;6(4):429–41

The glutamate transporter, GLT-1, is expressed in cultured hippocampal neurons. Brooks-Kayal AR, et al. **Neurochem Int** 1998 Aug;33(2):95–100

Adenosine and dopamine receptor antagonist binding in the rat ventral and dorsal striatum: lack of changes after a neonatal bilateral lesion of the ventral hippocampus. Lillrank SM, et al. **Neurochem Int** 1999 Mar;34(3):235–44

Neurotensin modulation of acetylcholine and GABA release from the rat hippocampus: an in vivo microdialysis study. Rakovska A, et al. **Neurochem Int** 1998 Oct;33(4):335–40

Increases in levels of brain-derived neurotrophic factor mRNA and its promoters after transient forebrain ischemia in the rat brain. Tsukahara T, et al. **Neurochem Int** 1998 Aug;33(2):201–7

Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Kondo Y, et al. **Neurochem Res** 1999 Jan;24(1):9–13

Beta-alanine release from the adult and developing hippocampus is enhanced by ionotropic glutamate receptor agonists and cell-damaging conditions. Saransaari P, et al. **Neurochem Res** 1999 Mar;24(3):407–14

Mechanisms of D-aspartate release under ischemic conditions in mouse hippocampal slices. Saransaari P, et al. **Neurochem Res** 1999 Aug;24(8):1009–16

The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Yatin SM, et al. **Neurochem Res** 1999 Mar;24(3):427–35

The S100B protein inhibits phosphorylation of GFAP and vimentin in a cytoskeletal fraction from immature rat hippocampus. Ziegler DR, et al. **Neurochem Res** 1998 Oct; 23(10):1259–63

Changes in messenger ribonucleic acid species in gerbil brain perturbation. Kobayashi H, et al. **Neurol Med Chir (Tokyo)** 1998 Sep;38 Suppl:263–7

Subarachnoid blood infusion versus raised intracranial pressure: effects on the amino acid pattern in the extracellular fluid of the rabbit hippocampus. Runnerstam M, et al. **Neurol Res** 1999 Jun;21(4):404–8

Single synaptic events evoke NMDA receptor-mediated release of calcium from internal stores in hippocampal dendritic spines. Emptage N, et al. **Neuron** 1999 Jan; 22(1):115–24

NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Lee HK, et al. **Neuron** 1998 Nov; 21(5):1151–62

Variability of neurotransmitter concentration and nonsaturation of postsynaptic AMPA receptors at synapses in hippocampal cultures and slices [see comments] Liu G, et al. **Neuron** 1999 Feb;22(2):395–409. Comment in: Neuron 1999 Feb;22(2):206–7.

Candidate editases for GluR channels in single neurons of rat hippocampus and cerebellum. Köhr G, et al. **Neuropharmacology** 1998 Oct-Nov;37(10–11):1411–7

Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain. Healy DJ, et al. **Neuropsychopharmacology** 1999 Sep;21(3):341–51

Effects of barium on stimulus-induced rises in [K+]o in juvenile rat hippocampal area CA1. Gabriel S, et al. **Neuroreport** 1998 Aug 3;9(11):2583–7

Direct evidence of NO production in rat hippocampus and cortex using a new fluorescent indicator: DAF-2 DA. Kojima H, et al. **Neuroreport** 1998 Oct 26;9(15):3345–8

The mGluR stimulating GFAP phosphorylation in immature hippocampal slices has some properties of a group II receptor. Kommers T, et al. **Neuroreport** 1999 Jul 13; 10(10):2119–23

NMDA antagonist displays anticonvulsant effect via NO synthesis inhibition in penicillin-treated rat hippocampal slices. Lu W, et al. **Neuroreport** 1998 Dec 21;9(18):4045–9

In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus. Sandin J, et al. **Neuroreport** 1999 Jan 18; 10(1):71–6

Rapid decline in protein kinase Cgamma levels in the synaptosomal fraction of rat hippocampus after ischemic preconditioning. Shamloo M, et al. **Neuroreport** 1999 Apr 6;10(5):931–5

Immunohistochemical localization of redox factor-1 (Ref-1) in Alzheimer's hippocampus. Tan Z, et al. **Neuroreport** 1998 Aug 24;9(12):2749–52

Kindling induces an asymmetric enhancement of N-type Ca2+ channel density in the dendritic fields of the rat hippocampus. Bernstein GM, et al. **Neurosci Lett** 1999 Jun 25;268(3):155–8

Sensitivity of the rat hippocampal GABA(A) receptor alpha 4 subunit to electroshock seizures. Clark M. **Neurosci Lett** 1998 Jun 26;250(1):17–20

Activation of dihydropyridine sensitive Ca2+ channels in rat hippocampal neurons in culture by parathyroid hormone. Hirasawa T, et al. **Neurosci Lett** 1998 Nov 13; 256(3):139–42

Concurrent activation of hippocampal glycine and polyamine sites of the N-methyl-D-aspartate receptor synergistically reverses working memory deficits in rats. Kishi A, et al. **Neurosci Lett** 1998 Dec 4;257(3):131–4

Sensitization by prolonged glutathione depletion of kainic acid to potentiate DNA binding of the nuclear transcription factor activator protein-1 in murine hippocampus. Kitayama T, et al. **Neurosci Lett** 1999 Jul 16;269(3):157–60

Spatiotemporal changes in hippocampal NMDA receptor binding as a consequence of trimethyltin neurotoxicity in the rat. Koczyk D, et al. **Neurosci Lett** 1998 Jul 17; 251(1):29–32

Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions. Leanza G. **Neurosci Lett** 1998 Nov 20; 257(1):53–6

Kainic acid seizure suppression by neuropeptide Y is not correlated to immediate early gene mRNA levels in rats. Madsen TM, et al. **Neurosci Lett** 1999 Aug 13;271(1):21–4

Cataloging altered gene expression during rat hippocampal long-term potentiation by means of differential display. Matsuo R, et al. **Neurosci Lett** 1998 Mar 20;244(3):173–6

Increased NR1-NR2A/B coassembly as a mechanism for rat chronic hippocampal epilepsy. Mikuni N, et al. **Neurosci Lett** 1999 Jun 4;267(3):165–8

Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Reis DJ, et al. **Neurosci Lett** 1998 Jul 10;250(3):185–8

Age-related decline of F3/contactin in rat hippocampus. Shimazaki K, et al. **Neurosci Lett** 1998 Apr 3;245(2):117–20

Extracellular amino acids in the rat hippocampus during picrotoxin threshold seizures in chronic microdialysis experiments. Sierra-Paredes G, et al. **Neurosci Lett** 1998 May 22;248(1):53–6

Nicotine-evoked nitric oxide release in the rat hippocampal slice. Smith DA, et al. **Neurosci Lett** 1998 Oct 23; 255(3):127–30

Role of 5-HT2A receptors in the stress-induced down-regulation of brain-derived neurotrophic factor expression in rat hippocampus. Vaidya VA, et al. **Neurosci Lett** 1999 Feb 26;262(1):1–4

Rat embryonic hippocampal neurons express a new class A calcium channel variant. Vigues S, et al. **Neurosci Lett** 1998 Dec 11;258(1):37–40

Activation of gonadotropin-releasing hormone receptors induces a long-term enhancement of excitatory postsynaptic currents mediated by ionotropic glutamate receptors in the rat hippocampus. Yang SN, et al. **Neurosci Lett** 1999 Jan 22;260(1):33–6

Chronic amitriptyline administration increases serotonin transporter binding sites in the hippocampus of aged rats. Yau JL, et al. **Neurosci Lett** 1999 Feb 19;261(3):183–5

Taurine antagonizes calcium overload induced by glutamate or chemical hypoxia in cultured rat hippocampal neurons. Zhao P, et al. **Neurosci Lett** 1999 Jun 11;268(1):25–8

Proteolysis of neuronal cell adhesion molecule by the tissue plasminogen activator-plasmin system after kainate injection in the mouse hippocampus. Endo A, et al. **Neurosci Res** 1999 Jan;33(1):1–8

Expression of interleukin-1 genes and interleukin-1 receptors in the mouse brain after hippocampal injury. Gabellec MM,

et al. **Neurosci Res** 1999 Apr;33(4):251–60

Development of the GABA system in organotypic culture of hippocampal and cerebellar slices from a 67–kDa isoform of glutamic acid decarboxylase (GAD67)–deficient mice. Ji F, et al. **Neurosci Res** 1999 Mar;33(3):233–7

Neuronal degeneration and a decrease in laminin–like immunoreactivity is associated with elevated tissue–type plasminogen activator in the rat hippocampus after kainic acid injection. Nagai N, et al. **Neurosci Res** 1999 Feb; 33(2):147–54

Distribution of AP–2 subtypes in the adult mouse brain. Shimada M, et al. **Neurosci Res** 1999 Apr;33(4):275–80

Constitutive expression of cytoplasmic activator protein–1 with DNA binding activity and responsiveness to ionotropic glutamate signals in the murine hippocampus. Azuma Y, et al. **Neuroscience** 1999;92(4):1295–308

Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Bouron A, et al. **Neuroscience** 1999 Mar; 90(3):729–36

Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy. Bregola G, et al. **Neuroscience** 1999;92(3):1043–9

Benzodiazepine–mediated regulation of alpha1, alpha2, beta1–3 and gamma2 GABA(A) receptor subunit proteins in the rat brain hippocampus and cortex. Chen S, et al. **Neuroscience** 1999;93(1):33–44

Attenuation of hypoxic current by intracellular applications of ATP regenerating agents in hippocampal CA1 neurons of rat brain slices. Chung I, et al. **Neuroscience** 1998 Oct; 86(4):1101–7

Impact of neonatal kainate treatment on hippocampal insulin–like growth factor receptors. Doré S, et al. **Neuroscience** 1999;91(3):1035–43

Detection and quantification of hippocampal synaptophysin messenger RNA in schizophrenia using autoclaved, formalin–fixed, paraffin wax–embedded sections. Eastwood SL, et al. **Neuroscience** 1999;93(1):99–106

Hippocampal and cortical growth–associated protein–43 messenger RNA in schizophrenia. Eastwood SL, et al. **Neuroscience** 1998 Sep;86(2):437–48

The time–course of DNA fragmentation in the choroid plexus and the CA1 region following transient global ischemia in the rat brain. The effect of intra–ischemic hypothermia. Ferrand–Drake M, et al. **Neuroscience** 1999;93(2):537–49

Mitochondrial permeability transition induced DNA–fragmentation in the rat hippocampus following hypoglycemia. Ferrand–Drake M, et al. **Neuroscience** 1999; 90(4):1325–38

Psychophysiological stress induces heat shock cognate protein 70 messenger RNA in the hippocampus of rats. Fukudo S, et al. **Neuroscience** 1999;91(4):1205–8

Expression of nerve growth factor in astrocytes of the hippocampal CA1 area following transient forebrain ischemia. Gottlieb M, et al. **Neuroscience** 1999; 91(3):1027–34

Correlated long–term increase of brain–derived neurotrophic factor and Trk B proteins in enlarged granule cells of mouse hippocampus after kainic acid injection. Inoue T, et al. **Neuroscience** 1998 Oct;86(3):723–8

Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta–amyloid pathologies. Kelliher M, et al. **Neuroscience** 1999;92(2):499–513

Kinetics of sevoflurane action on GABA– and glycine–induced currents in acutely dissociated rat hippocampal neurons. Kira T, et al. **Neuroscience** 1998 Jul; 85(2):383–94

Distribution of voltage–dependent calcium channel beta subunits in the hippocampus of patients with temporal lobe epilepsy. Lie AA, et al. **Neuroscience** 1999;93(2):449–56

Regulation of nitric oxide synthase messenger RNA expression in the rat hippocampus by glucocorticoids. López–Figueroa MO, et al. **Neuroscience** 1998 Nov; 87(2):439–46

Increased expression of hippocampal cholinergic neurostimulating peptide–related components and their messenger RNAs in the hippocampus of aged senescence–accelerated mice. Matsukawa N, et al. **Neuroscience** 1999 Jan;88(1):79–92

Up–regulation of Eph tyrosine kinase receptors after excitotoxic injury in adult hippocampus. Moreno–Flores MT, et al. **Neuroscience** 1999;91(1):193–201

Selective inhibition of inositol 1,4,5–triphosphate–induced Ca2+ release in the CA1 region of the hippocampus in the ischemic gerbil. Nagata E, et al. **Neuroscience** 1999; 93(3):995–1001

A light and electron microscopic study of NG2 chondroitin sulfate proteoglycan–positive oligodendrocyte precursor cells in the normal and kainate–lesioned rat hippocampus. Ong WY, et al. **Neuroscience** 1999;92(1):83–95

Expression of neurotrophins in hippocampal interneurons immunoreactive for the neuropeptides somatostatin, neuropeptide–Y, vasoactive intestinal polypeptide and cholecystokinin. Pascual M, et al. **Neuroscience** 1999; 89(4):1089–101

The human immunodeficiency virus–1 envelope protein gp120 binds through its V3 sequence to the glycine site of N–methyl–D–aspartate receptors mediating noradrenaline release in the hippocampus. Pattarini R, et al. **Neuroscience** 1998 Nov;87(1):147–57

Developmental expression of alpha–synuclein in rat hippocampus and cerebral cortex. Petersen K, et al. **Neuroscience** 1999;91(2):651–9

Taurine release modified by nitric oxide–generating compounds in the developing and adult mouse hippocampus. Saransaari P, et al. **Neuroscience** 1999; 89(4):1103–11

Transient and persistent increases in protein phosphatase activity during long–term depression in the adult hippocampus in vivo. Thiels E, et al. **Neuroscience** 1998 Oct;86(4):1023–9

Cannabinoid CB1 receptors are localized primarily on cholecystokinin–containing GABAergic interneurons in the rat hippocampal formation. Tsou K, et al. **Neuroscience** 1999;93(3):969–75

Effects of transient cerebral ischemia on glial fibrillary acidic protein phosphorylation and immunocontent in rat hippocampus. Valentim LM, et al. **Neuroscience** 1999; 91(4):1291–7

Considerations in the determination by microdialysis of resting extracellular amino acid concentrations and release upon spinal cord injury. Xu GY, et al. **Neuroscience** 1998 Oct;86(3):1011–21

Expression of early hippocampal CA1 LTP does not lead to changes in AMPA–EPSC kinetics or sensitivity to cyclothiazide. Rammes G, et al. **Pflugers Arch** 1999 Jan; 437(2):191–6

Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Bitran D, et al. **Pharmacol Biochem Behav** 1998 Aug;60(4):879–87

The functions of ATP receptors in the hippocampus. Inoue K. **Pharmacol Res** 1998 Nov;38(5):323–31 (78 ref.)

Extracellular glutamate diffusion determines the occupancy of glutamate receptors at CA1 synapses in the hippocampus. Kullmann DM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):395–402 (57 ref.)

Role of brain allopregnanolone in the plasticity of gamma–aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Concas A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13284–9

Neurotrophic factors [activity–dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Guo Q, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4125–30

Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Liu H, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5286–91

Novelty acquisition is associated with induction of hippocampal long–term depression. Manahan–Vaughan D, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8739–44

Synaptically released glutamate reduces gamma–aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. Min MY, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9932–7

Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Pan Y, et al. **Proc Soc Exp Biol Med** 1999 Jun;221(2):118–25

Monitoring neuronal NO release in vivo in cerebellum, thalamus and hippocampus. Vincent SR, et al. **Prog Brain Res** 1998;118:27–35 (91 ref.)

In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Fedele E, et al. **Prog Neurobiol** 1999 May;58(1):89–120 (168 ref.)

Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex. Frechilla D, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Jul; 22(5):787–802

Comparison of Y–receptor subtype expression in the rat hippocampus. Parker RM, et al. **Regul Pept** 1998 Sep 25; 75–76:109–15

Divalent cations influencing neuropeptide Y receptor subtype binding in rat hippocampus and cortex membranes as well as in recombinant cells. Wieland HA, et al. **Regul Pept** 1998 Sep 25;75–76:263–9

Role of Ca2+ release from ryanodine stores in generation of NMDA–induced Ca2+ signal in rabbit hippocampus. Salińska E, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan;85(1):212–9

Nitric oxide production in the CA1 field of the gerbil hippocampus after transient forebrain ischemia : effects of 7–nitroindazole and NG–nitro–L–arginine methyl ester. Lei B, et al. **Stroke** 1999 Mar;30(3):669–77

Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Dean B, et al. **Synapse** 1999 Apr;32(1):67–9

Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Kullmann DM, et al. **Trends Neurosci** 1998 Jan;21(1):8–14 (57 ref.)

[Changes in gamma–amino–butyric acid and N–methyl–D–aspartic acid receptor–gated currents from freshly isolated hippocampal CA1 pyramidal neurons of hepatic encephalopathy rats] Zhang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):439–42 (Eng. Abstr.) **(Chi)**

[Effects of nicotine on expression of c–fos–like protein in hippocampal formation in mice] Sun J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Mar;31(2):75–7 (Eng. Abstr.) **(Chi)**

[Activation of glutamate uptake in rat hippocampal synaptosome by lead] Zhang H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):16–8 (Eng. Abstr.) **(Chi)**

[Effects of lead on the release of glutamate neurotransmitter in rat hippocampal slices] Zhang H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):285–7 (Eng. Abstr.) **(Chi)**

[Effects of new constituents L–6a and L–10 from leaves of Luffa cylinderica on learning, memory, and hippocampal somatostatin in rats] Qi SB, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):529–31 (Eng. Abstr.) **(Chi)**

[The expression of hsp70 and BCL–2 genes in hippocampus of the rats exposed to cerebral ischemia and reperfusion] Lu D, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):224–7 (Eng. Abstr.) **(Chi)**

[Blocker of Na+/Ca2+ exchanger, benzamil, decreases Ca2+ influx and enhances the ability of hippocampal neuron against hypoxia] Wang F, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):79 **(Chi)**

[The effect of wuto granules on the levels of excitatory amino acids in extracellular fluid of rat hippocampus following cerebral ischemia] Li J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):19–21 (Eng. Abstr.) **(Chi)**

[Studies on mechanism of the inhibition of Ca2+/CaM PKII activity induced by hypoxia in rat hippocampal slices] Pei L, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):61–6 (Eng. Abstr.) **(Chi)**

[Effect of adenosine on intracellular free calcium in cultured rat hippocampal CA1 neurons during anoxia] Wan Q, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):545–50 (Eng. Abstr.) **(Chi)**

[The decrease in the hippocampus of the neurosteroid pregnenolone sulfate is involved in memory deficit in the aged animal] Baulieu EE. **C R Acad Sci III** 1998 Feb–Mar; 321(2–3):223–7 **(Fre)**

[The morphochemical characteristics and plastic restructurings of the hippocampal neurons after rhythmic stimulation of an extremity in old rabbits] Kopytova FV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):123–6 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Magnetic resonance imaging and temporal lobe epilepsy. King D, et al. **Acta Neurol Scand** 1998 Oct;98(4):217–23 (70 ref.)

Blood–brain barrier damage in reperfusion following ischemia in the hippocampus of the Mongolian gerbil brain. Shinnou M, et al. **Acta Neurol Scand** 1998 Dec;98(6):406–11

Polyglutamine aggregates: a possible component of eosinophilic intracular inclusions in the hippocampal pyramidal neurons of a patient with amyotrophic lateral sclerosis [letter; comment] Altschuler EL. **Acta Neuropathol (Berl)** 1999 Jan;97(1):103–4. Comment on: Acta Neuropathol (Berl) 1997 May;93(5):532–6.

Synaptophysin immunoreactivity in temporal lobe epilepsy–associated hippocampal sclerosis. Looney MR, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):179–85

Neuritic degeneration in the hippocampus and amygdala in Parkinson's disease in relation to Alzheimer pathology. Mattila PM, et al. **Acta Neuropathol (Berl)** 1999 Aug; 98(2):157–64

Pyramidal neuron loss is matched by ghost tangle increase in Guam parkinsonism–dementia hippocampus. Schwab C, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):409–16

Hippocampal sclerosis with hypertrophy of end folium pyramidal cells. Thom M, et al. **Acta Neuropathol (Berl)** 1999 Jul;98(1):107–10

Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. Juottonen K, et al. **AJNR Am J Neuroradiol** 1999 Jan;20(1):139–44

Presence of sodium dodecyl sulfate–stable amyloid beta–protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Funato H, et al. **Am J Pathol** 1999 Jul;155(1):23–8

GluR2 antisense knockdown produces seizure behavior and hippocampal neurodegeneration during a critical window. Friedman LK, et al. **Ann N Y Acad Sci** 1999 Apr 30; 868:541–5

Does chronic activity–stress produce hippocampal atrophy and basal forebrain lesions? A preliminary analysis. Lambert KG, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:742–6

Hippocampal or neocortical lesions on magnetic resonance imaging do not necessarily indicate site of ictal onsets in partial epilepsy. Holmes MD, et al. **Ann Neurol** 1999 Apr; 45(4):461–5

Progressive hippocampal atrophy in chronic intractable temporal lobe epilepsy. O'Brien TJ, et al. **Ann Neurol** 1999 Apr;45(4):526–9

Ictal electroencephalographic localization in patients with hippocampal sclerosis [letter; comment] Wennberg R. **Ann Neurol** 1999 Jan;45(1):135–6. Comment on: Ann Neurol 1998 Jun;43(6):756–62.

Short echo time single–voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging–negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Woermann FG, et

al. **Ann Neurol** 1999 Mar;45(3):369–76

Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Barber R, et al. **Arch Neurol** 1999 Aug;56(8):961–5

Impairments in conditioned stimulus processing and conditioned responding after combined selective removal of hippocampal and neocortical cholinergic input. Baxter MG, et al. **Behav Neurosci** 1999 Jun;113(3):486–95

Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats. Maren S. **Behav Neurosci** 1999 Apr;113(2):283–90

A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives [letter] Senitz D. **Biol Psychiatry** 1999 Jun 1;45(11):1528–30

Cell biology of the hippocampal formation in schizophrenia. Weinberger DR. **Biol Psychiatry** 1999 Feb 15;45(4):395–402 (50 ref.)

Neurophysiological changes associated with selective neuronal damage in hippocampus following transient forebrain ischemia. Xu ZC, et al. **Biol Signals Recept** 1999 Jul–Oct;8(4–5):294–308

Hippocampal sclerosis and temporal lobe epilepsy: cause or consequence? [editorial; comment] Jefferys JG. **Brain** 1999 Jun;122 (Pt 6):1007–8. Comment on: Brain 1999 Jun;122 (Pt 6):1009–16.

Surgical outcome in patients with epilepsy and dual pathology. Li LM, et al. **Brain** 1999 May;122 (Pt 5):799–805

Forebrain ischaemia with CA1 cell loss impairs epileptogenesis in the tetanus toxin limbic seizure model [see comments] Milward AJ, et al. **Brain** 1999 Jun;122 (Pt 6):1009–16. Comment in: Brain 1999 Jun;122 (Pt 6):1007–8.

Effects of enadoline on the development of pentylenetetrazol kindling, learning performance, and hippocampal morphology. Becker A, et al. **Brain Res** 1999 Mar 27; 823(1–2):191–7

Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Bobinski M, et al. **Brain Res** 1998 Sep 14;805(1–2):267–9

Morphological changes in the hippocampal CA3 region induced by non-invasive glucocorticoid administration: a paradox. Magariños AM, et al. **Brain Res** 1998 Nov 2; 809(2):314–8

Topiramate reduces neuronal injury after experimental status epilepticus. Niebauer M, et al. **Brain Res** 1999 Aug 7; 837(1–2):263–9

Neuronal apoptosis studied by a sequential TUNEL technique: a method for tract-tracing. Hara A, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):140–6

A simple in vitro model of ischemia based on hippocampal slice cultures and propidium iodide fluorescence. Laake JH, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):173–84

Delayed neuronal loss after administration of intracerebroventricular kainic acid to preweanling rats. Montgomery EM, et al. **Brain Res Dev Brain Res** 1999 Jan 11;112(1):107–16

GABAA receptor beta 2 and beta 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. Mizukami K, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):268–72

Apoptosis of hippocampal neurons after amygdala kindled seizures. Zhang LX, et al. **Brain Res Mol Brain Res** 1998 Apr;55(2):198–208

Hippocampal neuronal death following deep hypothermic circulatory arrest in dogs: involvement of apoptosis. Kin H, et al. **Cardiovasc Surg** 1999 Aug;7(5):558–64

Research on nucleolar organizer regions of hippocampal neuron in Alzheimer's disease. Lu W, et al. **Chin Med J (Engl)** 1998 Mar;111(3):282–4

Parahippocampal pathology in Creutzfeldt-Jakob disease. Kaneko M, et al. **Clin Neuropathol** 1999 Jan–Feb;18(1):9–16

Amygdalo-subicular degeneration in a young adult with status epilepticus and choreoathetoid movements of acute onset. Yamashita M, et al. **Clin Neuropathol** 1999 Jan–Feb; 18(1):45–50

Pathogenesis of Alzheimer-related neuritic plaques: AT8 immunoreactive dystrophic neurites precede argyrophilic neurites in plaques of the entorhinal region, hippocampal formation, and amygdala. Yilmazer-Hanke DM. **Clin Neuropathol** 1998 Jul–Aug;17(4):194–8

Febrile convulsions and mesial temporal sclerosis. Lewis DV. **Curr Opin Neurol** 1999 Apr;12(2):197–201 (39 ref.)

Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type. Golebiowski M, et al. **Dement Geriatr Cogn Disord** 1999 Jul–Aug;10(4):284–8

Lack of genetic associations of alpha-1-antichymotrypsin polymorphism with alzheimer-type neuropathological changes or sporadic Alzheimer's disease. Sodeyama N, et al. **Dement Geriatr Cogn Disord** 1999 May–Jun;10(3):221–5

Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation. Yilmazer-Hanke DM, et al. **Dement Geriatr Cogn Disord** 1999 Mar–Apr;10(2):70–6

Prenatal stress reduces the effectiveness of the neurosteroid 3 alpha,5 alpha-THP to block kainic-acid-induced seizures. Frye CA, et al. **Dev Psychobiol** 1999 Apr; 34(3):227–34

Hemicranial volume deficits in patients with temporal lobe epilepsy with and without hippocampal sclerosis [published erratum appears in Epilepsia 1999 Aug;40(8):1175] Briellmann RS, et al. **Epilepsia** 1998 Nov;39(11):1174–81

Benign childhood epilepsy with centrotemporal spikes and hippocampal atrophy. Gelisse P, et al. **Epilepsia** 1999 Sep; 40(9):1312–5

Evidence of enhanced kindling and hippocampal neuronal injury in immature rats with neuronal migration disorders. Germano IM, et al. **Epilepsia** 1998 Dec;39(12):1253–60

Interictal epileptiform discharges in temporal lobe epilepsy due to hippocampal sclerosis versus medial temporal lobe tumors. Hamer HM, et al. **Epilepsia** 1999 Sep;40(9):1261–8

The neuropathology of hyperthermic seizures in the rat. Jiang W, et al. **Epilepsia** 1999 Jan;40(1):5–19

[11C]Flumazenil PET in patients with epilepsy with dual pathology. Juhász C, et al. **Epilepsia** 1999 May;40(5):566–74

Status epilepticus-induced neuronal injury and network reorganization. Sloviter RS. **Epilepsia** 1999;40 Suppl 1:S34–9; discussion S40–1 (59 ref.)

Prediction of presence of hippocampal sclerosis from intracarotid amobarbital procedure memory asymmetry scores and epilepsy on set age. Davies KG, et al. **Epilepsy Res** 1999 Feb;33(2–3):117–23

Effects of vigabatrin treatment on status epilepticus-induced neuronal damage and mossy fiber sprouting in the rat hippocampus. Pitkänen A, et al. **Epilepsy Res** 1999 Jan; 33(1):67–85

Hippocampal volumetry in children 6 years or younger: assessment of children with and without complex febrile seizures. Szabó CA, et al. **Epilepsy Res** 1999 Jan;33(1):1–9

Pyramidal neuron size in the hippocampus of schizophrenics correlates with total cell count and degree of cell disarray. Jönsson SA, et al. **Eur Arch Psychiatry Clin Neurosci** 1999; 249(4):169–73

Limbic P300s in temporal lobe epilepsy with and without Ammon's horn sclerosis. Grunwald T, et al. **Eur J Neurosci** 1999 Jun;11(6):1899–906

BCL-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Antonawich FJ, et al. **Exp Neurol** 1999 Mar; 156(1):130–7

Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease. Bi X, et al. **Exp Neurol** 1999 Aug;158(2):312–27

Development of commissural connections in the hippocampus of reeler mice: evidence of an inhibitory influence of Cajal-Retzius cells. Borrell V, et al. **Exp Neurol** 1999 Apr;156(2):268–82

The hippocampus of the reeler mutant mouse: fiber segregation in area CA1 depends on the position of the postsynaptic target cells. Deller T, et al. **Exp Neurol** 1999 Apr;156(2):254–67

Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Dietrich WD, et al. **Exp Neurol** 1999 Aug;158(2):444–50

Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Mandel RJ, et al. **Exp Neurol** 1999 Jan;155(1):59–64

Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. Tsuchiya K, et al. **Exp Neurol** 1999 Feb;155(2):187–94

Oral administration of (-)catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil. Inanami O, et al. **Free Radic Res** 1998 Oct;29(4):359–65

Relevance of temporal lobe white matter changes in hippocampal sclerosis. Magnetic resonance imaging and histology. Meiners LC, et al. **Invest Radiol** 1999 Jan; 34(1):38–45

Brain injury with prolonged seizures in children and adults. Moshé SL. **J Child Neurol** 1998 Oct;13 Suppl 1:S3–6; discussion S30–2

Declarative and procedural learning, quantitative measures of the hippocampus, and subcortical white alterations in Alzheimer's disease and ischaemic vascular dementia. Libon DJ, et al. **J Clin Exp Neuropsychol** 1998 Feb; 20(1):30–41

Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. Nakagawa Y, et al. **J Comp Neurol** 1999 Aug 30;411(3):390–8

Laminar boundaries persist in the hippocampal dentate molecular layer of the mutant Shaking Rat Kawasaki despite aberrant granule cell migration. Woodhams PL, et al. **J Comp Neurol** 1999 Jun 21;409(1):57–70

Stage-correlated distribution of type 1 and 2 dystrophic neurites in cortical and hippocampal plaques in Alzheimer's disease. Thal DR, et al. **J Hirnforsch** 1998;39(2):175–81

Glutaric aciduria type I: pathomechanisms of neurodegeneration. Ullrich K, et al. **J Inherit Metab Dis** 1999 Jun;22(4):392–403

Temporal lobe epilepsy caused by intrahippocampal calcified cysticercus: a case report. Chung CK, et al. **J Korean Med Sci** 1998 Aug;13(4):445–8

The effects of peripheral leukocytes on the hippocampal neuronal changes in transient global ischemia and unilateral cerebral hemispheric infarction. Lee HW, et al. **J Korean Med Sci** 1999 Jun;14(3):304–14

Early childhood MRI findings in complex partial seizures and hippocampal sclerosis. Risse JH, et al. **J Magn Reson Imaging** 1999 Jul;10(1):93–6

MR measurement of regional relative cerebral blood volume in epilepsy. Wu RH, et al. **J Magn Reson Imaging** 1999 Mar;9(3):435–40

Calbindin D28K gene transfer via herpes simplex virus amplicon vector decreases hippocampal damage in vivo following neurotoxic insults. Phillips RG, et al. **J Neurochem** 1999 Sep;73(3):1200–5

MRI temporal lobe volume measures and neuropsychologic function in Alzheimer's disease. Smith CD, et al. **J Neuroimaging** 1999 Jan;9(1):2–9

Site-specific control of T cell traffic in the brain: T cell entry to brainstem vs. hippocampus after local injection of IFN-gamma. Phillips LM, et al. **J Neuroimmunol** 1999 May 3;96(2):218–27

Corpora amylacea in hippocampal sclerosis [letter; comment] Leel-Ossy L. **J Neurol Neurosurg Psychiatry** 1998 Oct; 65(4):614. Comment on: J Neurol Neurosurg Psychiatry 1997 Oct;63(4):513–5.

Regional changes in hippocampal T2 relaxation and volume: a quantitative magnetic resonance imaging study of hippocampal sclerosis. Woermann FG, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):656–64

Retrograde temporal order amnesia resulting from damage to the fornix. Yasuno F, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):102–5

Influence of apolipoprotein E genotype on neuronal damage and apoE immunoreactivity in human hippocampus following global ischemia. Horsburgh K, et al. **J Neuropathol Exp Neurol** 1999 Mar;58(3):227–34

Neurotoxicity mediated by aberrant patterns of synaptic activity between rat hippocampal neurons in culture. McLeod JR Jr, et al. **J Neurophysiol** 1998 Nov; 80(5):2688–98

Electron microscopic evidence against apoptosis as the mechanism of neuronal death in global ischemia. Colbourne F, et al. **J Neurosci** 1999 Jun 1;19(11):4200–10

Modification of postsynaptic densities after transient cerebral ischemia: a quantitative and three-dimensional ultrastructural study. Martone ME, et al. **J Neurosci** 1999 Mar 15;19(6):1988–97

Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. Sheline YI, et al. **J Neurosci** 1999 Jun 15;19(12):5034–43

Loss of CA1 cells following global ischaemia correlates with spatial deficits in the circular platform task. Milani H, et al. **J Neurosci Methods** 1998 Mar 13;80(1):19–27

AP1 transcriptional factor activation and its relation to apoptosis of hippocampal CA1 pyramidal neurons after transient ischemia in gerbils. Domańska-Janik K, et al. **J Neurosci Res** 1999 Sep 15;57(6):840–6

Exacerbation of cortical and hippocampal CA1 damage due to posttraumatic hypoxia following moderate fluid-percussion brain injury in rats. Bramlett HM, et al. **J Neurosurg** 1999 Oct;91(4):653–9

Site-specific cleavage of 28S rRNA as a marker of traumatic brain injury. Fan L, et al. **J Neurotrauma** 1999 May; 16(5):357–64

Transient umbilical cord occlusion in late-gestation fetal sheep results in hippocampal damage but not in cerebral arteriovenous difference for nitrite, a stable end product of nitric oxide. Keunen H, et al. **J Soc Gynecol Investig** 1999 May–Jun;6(3):120–6

Hippocampal damage and duration of temporal-lobe epilepsy [letter] [published erratum appears in Lancet 1998 Oct 10;352(9135):1230] Bower S, et al. **Lancet** 1998 Jul 4; 352(9121):66–7

Excitatory neurons and schizophrenia [see comments] Butterworth RF. **Lancet** 1998 Nov 21;352(9141):1643. Comment in: Lancet 1998 Nov 21;352(9141):1669–73.

Prevention of ischemia-induced hippocampal neuronal damage by 2-deoxy-D-glucose in gerbils. Niwa M, et al. **Life Sci** 1999;64(18):PL193–8

DNA fragmentation and HSP72 gene expression by adenovirus-mediated gene transfer in postischemic gerbil hippocampus and ventricle. Kitagawa H, et al. **Metab Brain Dis** 1998 Sep;13(3):211–23

Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Young D, et al. **Nat Med** 1999 Apr;5(4):448–53

Cortisol levels during human aging predict hippocampal atrophy and memory deficits [see comments] [published erratum appears in Nat Neurosci 1998 Aug;1(4):329] Lupien SJ, et al. **Nat Neurosci** 1998 May;1(1):69–73. Comment in: Nat Neurosci 1998 May;1(1):3–4.

On the survival time of a tangled neuron in the hippocampal CA4 region in parkinsonism dementia complex of Guam. Schwab C, et al. **Neurobiol Aging** 1999 Jan–Feb;20(1):57–63

Morphological study of the entorhinal cortex, hippocampal formation, and basal ganglia in Rett syndrome patients. Leontovich TA, et al. **Neurobiol Dis** 1999 Apr;6(2):77–91

Disproportion in the distribution of gray and white matter: neuropsychological correlates. Baxendale SA, et al. **Neurology** 1999 Jan 15;52(2):248–52

Hippocampal malformation as a cause of familial febrile convulsions and subsequent hippocampal sclerosis [letter; comment] Davies KG, et al. **Neurology** 1999 May 12; 52(8):1717–8. Comment on: Neurology 1998 Apr;50(4):909–17.

HIPPOCAMPUS

Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Frisoni GB, et al. **Neurology** 1999 Jan 1;52(1):91–100

Amygdala atrophy and seizure outcome after temporal lobe epilepsy surgery. Ho SS, et al. **Neurology** 1998 Nov; 51(5):1502–4

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Jack CR Jr, et al. **Neurology** 1999 Apr 22;52(7):1397–403

Hippocampal damage and the onset of epilepsy [letter; comment] Janszky J, et al. **Neurology** 1999 May 12; 52(8):1718–20. Comment on: Neurology 1998 May;50(5):1377–82.

Quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy. Kuzniecky R, et al. **Neurology** 1999 Aug 11;53(3):496–501

Temporal lobe developmental malformations and hippocampal sclerosis: epilepsy surgical outcome. Kuzniecky R, et al. **Neurology** 1999 Feb;52(3):479–84

Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy [see comments] Mathern GW, et al. **Neurology** 1999 Feb; 52(3):453–72. Comment in: Neurology 1999 Feb;52(3):441–3.

The relation between dementia and direct involvement of the hippocampus and amygdala in PD [letter; comment] Samuel W. **Neurology** 1998 Nov;51(5):1517–8. Comment on: Neurology 1997 Dec;49(6):1570–6.

Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. Theodore WH, et al. **Neurology** 1999 Jan 1;52(1):132–6

The presence of FAC1 protein in Hirano bodies. Jordan-Sciutto K, et al. **Neuropathol Appl Neurobiol** 1998 Oct;24(5):359–66

Spatial memory deficits in patients with lesions to the right hippocampus and to the right parahippocampal cortex. Bohbot VD, et al. **Neuropsychologia** 1998 Nov; 36(11):1217–38

Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: an MR volumetry study in Alzheimer's disease [published erratum appears in Neuropsychologia 1999 Jan;37(1):123] Köhler S, et al. **Neuropsychologia** 1998 Sep;36(9):901–14

Contributions of prefrontal cortex to recognition memory: electrophysiological and behavioral evidence. Swick D, et al. **Neuropsychology** 1999 Apr;13(2):155–70

Intra- and interobserver variability of MRI-based volume measurements of the hippocampus and amygdala using the manual ray-tracing method. Achten E, et al. **Neuroradiology** 1998 Sep;40(9):558–66

Cellular changes in rat brain areas associated with neonatal hippocampal damage. Bernstein HG, et al. **Neuroreport** 1999 Aug 2;10(11):2307–11

Acute cell damage after low Mg2+-induced epileptiform activity in organotypic hippocampal slice cultures. Kovács R, et al. **Neuroreport** 1999 Feb 5;10(2):207–13

Stress, glucocorticoids and structural plasticity of the hippocampus. Fuchs E, et al. **Neurosci Biobehav Rev** 1998; 23(2):295–300 (77 ref.)

Memory deterioration in an oxidative stress model and its correlation with cytological changes on rat hippocampus CA1. Avila-Costa MR, et al. **Neurosci Lett** 1999 Jul 30; 270(2):107–9

Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome [published erratum appears in Neurosci Lett 1998 Dec 24;258(3):190] Insausti AM, et al. **Neurosci Lett** 1998 Sep 11;253(3):175–8

Degenerative terminals of the perforant pathway are human alpha-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease. Iseki E, et al. **Neurosci Lett** 1998 Dec 18;258(2):81–4

Cell cycle-related protein expression in vascular dementia and Alzheimer's disease. Smith MZ, et al. **Neurosci Lett** 1999 Aug 13;271(1):45–8

Postischemic hypothermia induced by eugenol protects hippocampal neurons from global ischemia in gerbils. Won MH, et al. **Neurosci Lett** 1998 Sep 25;254(2):101–4

Novel non-apoptotic morphological changes in neurons of the mouse hippocampus following transient hypoxic-ischemia. Fukuda T, et al. **Neurosci Res** 1999 Jan; 33(1):49–55

Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. De Jong GI, et al. **Neuroscience** 1999; 91(1):203–10

Two electrophysiologically distinct types of granule cells in epileptic human hippocampus. Dietrich D, et al. **Neuroscience** 1999;90(4):1197–206

Ultrastructural analysis of the progression of neurodegeneration in the septum following fimbria-fornix transection. Ginsberg SD, et al. **Neuroscience** 1998 Oct; 86(4):1259–72

The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Guan J, et al. **Neuroscience** 1999 Mar;89(3):649–59

Hippocampal cell loss in transient global cerebral ischemia in rats: a critical assessment. Herguido MJ, et al. **Neuroscience** 1999;93(1):71–80

Calbindin-D28k fails to protect hippocampal neurons against ischemia in spite of its cytoplasmic calcium buffering properties: evidence from calbindin-D28k knockout mice. Klapstein GJ, et al. **Neuroscience** 1998 Jul;85(2):361–73

Alterations of perisomatic GABA synapses on hippocampal CA1 inhibitory interneurons and pyramidal cells in the kainate model of epilepsy. Morin F, et al. **Neuroscience** 1999;93(2):457–67

A light and electron microscopic study of NG2 chondroitin sulfate proteoglycan-positive oligodendrocyte precursor cells in the normal and kainate-lesioned rat hippocampus. Ong WY, et al. **Neuroscience** 1999;92(1):83–95

No hippocampal neuron or synaptic bouton loss in learning-impaired aged beta-amyloid precursor protein-null mice. Phinney AL, et al. **Neuroscience** 1999; 90(4):1207–16

Neuronal apoptosis in sudden infant death syndrome. Waters KA, et al. **Pediatr Res** 1999 Feb;45(2):166–72

Activity-stress induces atrophy of apical dendrites of hippocampal pyramidal neurons in male rats. Lambert KG, et al. **Physiol Behav** 1998 Aug;65(1):43–9

Behavioral and neuroanatomical consequences of chronic ethanol intake and withdrawal. Lukoyanov NV, et al. **Physiol Behav** 1999 Apr;66(2):337–46

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Yrjänheikki J, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22; 95(26):15769–74

A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases. Muramori F, et al. **Psychiatry Clin Neurosci** 1998 Dec;52(6):593–9

Increased expression of Wnt-1 in schizophrenic brains. Miyaoka T, et al. **Schizophr Res** 1999 Jul 27;38(1):1–6

Hippocampal volume reduction in male schizophrenic patients. Whitworth AB, et al. **Schizophr Res** 1998 May 25;31(2-3):73–81

Amelioration of hippocampal neuronal damage after global ischemia by neuronal overexpression of BCL-2 in transgenic mice [see comments] Kitagawa K, et al. **Stroke** 1998 Dec;29(12):2616–21. Comment in: Stroke 1999 May;30(5):1154–6.

A transient brain ischemia- and bacterial endotoxin-induced glial iNOS expression and NO-induced neuronal apoptosis. Nomura Y. **Toxicol Lett** 1998 Dec 28;102-103:65–9

Stress: metaplastic effects in the hippocampus. Kim JJ, et al. **Trends Neurosci** 1998 Dec;21(12):505–9 (61 ref.)

[Role of Na+/Ca2+ exchange blocker in rat hippocampal injury during anoxia] Wan Q, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):205–8 (Eng. Abstr.) **(Chi)**

[Seizure activity and lesions of neuronal cells by intrahippocampal injection of guanidinosuccinic acid in rats] Pan JC, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):561–7 (Eng. Abstr.) **(Chi)**

[Hippocampal pathology in diffuse Lewy body disease] Iseki E, et al. **No To Shinkei** 1998 Oct;50(10):907–12 (11 ref.) **(Jpn)**

[Perforant pathway degeneration as a system degeneration: secondary hippocampal degeneration in Alzheimer-type dementia] Mizutani T. **No To Shinkei** 1998 Oct; 50(10):895–905 (40 ref.) **(Jpn)**

[Hippocampal pathology in dementia patients with amyotrophic lateral sclerosis] Okamoto K. **No To Shinkei** 1998 Oct;50(10):915–22 (27 ref.) **(Jpn)**

[Histologic examination of some hippocampus fields after experimental ischemia] Majewska T, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:39–43 (Eng. Abstr.) **(Pol)**

[Visual and volumetric analysis with magnetic resonance of hippocampus formations in a group of patients with clinical diagnosis of temporal lobe epilepsy] Rogacheski E, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):419–28 (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Distinct roles for sphingolipids and glycosphingolipids at different stages of neuronal development. Futerman AH. **Acta Biochim Pol** 1998;45(2):469–78 (33 ref.)

The effect of glutamate uptake inhibitors on hippocampal evoked potentials in vitro. el-Sherif Y, et al. **Acta Neurobiol Exp (Warsz)** 1999;59(2):89–97

Short-time predegenerated peripheral nerve grafts promote regrowth of injured hippocampal neurites. Lewin-Kowalik J, et al. **Acta Physiol Hung** 1997-98;85(3):259–68

Purified extracts from short-time-predegenerated rats' sciatic nerves promote the regrowth of injured hippocampal neurites. Lewin-Kowalik J, et al. **Acta Physiol Hung** 1997-98;85(4):325–34

Synaptic and extrasynaptic roles of glutamate in the mammalian hippocampus. Kullmann DM. **Acta Physiol Scand** 1999 Jun;166(2):79–83 (25 ref.)

Metabotropic glutamate receptors in the plasticity of excitatory responses in the hippocampus. Clinical impact. Merlin LR. **Adv Exp Med Biol** 1998;446:131–44 (70 ref.)

Avian hippocampus as a model to study spatial orientation-related synaptic plasticity. Wieraszko A. **Adv Exp Med Biol** 1998;446:107–29 (150 ref.)

Heart rate surges during REM sleep are associated with theta rhythm and PGO activity in cats. Rowe K, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R843–9

The effects of general anesthetics on excitatory and inhibitory synaptic transmission in area CA1 of the rat hippocampus in vitro. Wakasugi M, et al. **Anesth Analg** 1999 Mar; 88(3):676–80

Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Andrade R. **Ann N Y Acad Sci** 1998 Dec 15;861:190–203 (81 ref.)

Using olfaction to study memory. Eichenbaum H. **Ann N Y Acad Sci** 1998 Nov 30;855:657–69 (24 ref.)

Serotonin transporter function in vivo: assessment by chronoamperometry. Frazer A, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:217–29 (48 ref.)

Galanin inhibits performance on rodent memory tasks. McDonald MP, et al. **Ann N Y Acad Sci** 1998 Dec 21; 863:305–22 (59 ref.)

Age-associated memory impairment. Assessing the role of nitric oxide. Meyer RC, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:307–17 (62 ref.)

Modulation of acetylcholine and serotonin transmission by galanin. Relationship to spatial and aversive learning. Ogren SO, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:342–63 (77 ref.)

Amygdaloid and hippocampal beta-adrenoceptors in the olfactory bulbectomy syndrome: effects of desipramine. Richardson JS, et al. **Ann N Y Acad Sci** 1999 Jun 29; 877:764–8

Time-dependent effects of intrahippocampal galanin on spatial learning. Relationship to distribution and kinetics. Schött PA, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:454–6

Consequences of 5-HT re-uptake blockade on postsynaptic 5-HT1A receptor activation: an electrophysiological and neurochemical study in guinea pig dorsal raphe and hippocampus. Sprouse J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:272–3

5-HT1A agonist activity of pindolol: reversal of the inhibitory effects on cell firing in the dorsal raphe nucleus but not in the hippocampus by WAY-100,635. Sprouse J, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:274–5

Amphetamine injections into the nucleus accumbens enhance the reward of stimulation of the subiculum. Sweet KL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:828–30

Modulation of ventral tegmental area dopamine cell activity by the ventral subiculum and entorhinal cortex. Todd CL, et al. **Ann N Y Acad Sci** 1999 Jun 29;877:688–90

Emotional behavior in female rabbits: hippocampal EEG and neuroendocrine aspects. Fontani G, et al. **Arch Ital Biol** 1999 Aug;137(4):263–78

Hippocampal type 1 (movement-related) theta rhythm positively correlates with serotonergic activity. Gemma C, et al. **Arch Ital Biol** 1999 May;137(2-3):151–60

Ibotenate lesions of the hippocampus impair spatial learning but not contextual fear conditioning in mice. Cho YH, et al. **Behav Brain Res** 1999 Jan;98(1):77–87

Effects of amygdaloid lesions, hippocampal lesions, and buspirone on black-white exploration and food carrying in rats. Dringenberg HC, et al. **Behav Brain Res** 1998 Nov; 96(1-2):161–72

Lesions of the medial or lateral perforant path have different effects on hippocampal contributions to place learning and on fear conditioning to context. Ferbinteanu J, et al. **Behav Brain Res** 1999 May;101(1):65–84

Spatial memory, habituation, and reactions to spatial and nonspatial changes in rats with selective lesions of the hippocampus, the entorhinal cortex or the subiculum. Galani R, et al. **Behav Brain Res** 1998 Nov;96(1-2):1–12

A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study. Gerlai R. **Behav Brain Res** 1998 Sep; 95(1):91–101

Contextual learning and cue association in fear conditioning in mice: a strain comparison and a lesion study. Gerlai R. **Behav Brain Res** 1998 Oct;95(2):191–203

Intrahippocampal injections of cysteamine improve the retention of a bar-pressing task in mice. Guillou JL, et al. **Behav Brain Res** 1999 Aug;103(1):113–7

Reinforcement enhances hippocampal acetylcholine release in rats: an in vivo microdialysis study. Iso H, et al. **Behav Brain Res** 1999 Jun;101(2):207–13

The effect of excitotoxic hippocampal lesions on simple and conditional discrimination learning in the rat. Murray TK, et al. **Behav Brain Res** 1999 Feb 15;99(1):103–13

A quantitative autoradiographic comparison of binding to glutamate receptor sub-types in hippocampus and forebrain regions of a food-storing and a non-food-storing bird. Stewart MG, et al. **Behav Brain Res** 1999 Jan;98(1):89–94

Differential deficits in the Morris water maze following cytotoxic lesions of the anterior thalamus and fornix transection. Warburton EC, et al. **Behav Brain Res** 1999 Jan;98(1):27–38

Effects of hippocampal lesions on spatial operant discrimination in pigeons. Watanabe S. **Behav Brain Res** 1999 Aug;103(1):77–84

Fimbria-fornix cut affects spontaneous activity, two-way avoidance and delayed non matching to sample, but not latent inhibition. Weiner I, et al. **Behav Brain Res** 1998 Nov;96(1-2):59–70

Hippocampectomized rats are capable of homing by path integration. Alyan S, et al. **Behav Neurosci** 1999 Feb; 113(1):19–31

Neonatal monoaminergic depletion in mice (Mus musculus) improves performance of a novel odor discrimination task. Berger-Sweeney J, et al. **Behav Neurosci** 1998 Dec; 112(6):1318–26

Functional dissociation of the prefrontal cortex and the hippocampus in timing behavior. Dietrich A, et al.

Behav Neurosci 1998 Oct;112(5):1043–7
The hippocampus and transverse patterning guided by olfactory cues. Dusek JA, et al. **Behav Neurosci** 1998 Aug; 112(4):762–71
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning. Frankland PW, et al. **Behav Neurosci** 1998 Aug; 112(4):863–74
Intrahippocampal infusions of a metabotropic glutamate receptor antagonist block the memory of context-specific but not tone-specific conditioned fear. Frohardt RJ, et al. **Behav Neurosci** 1999 Feb;113(1):222–7
Effects of lesions to the hippocampus on contextual fear: evidence for a disruption of freezing and avoidance behavior but not context conditioning. Gisquet-Verrier P, et al. **Behav Neurosci** 1999 Jun;113(3):507–22
Cue control and head direction cells. Goodridge JP, et al. **Behav Neurosci** 1998 Aug;112(4):749–61
The opposite effects of cysteamine on the acquisition of two different tasks in mice are associated with bidirectional testing-induced changes in hippocampal adenylyl cyclase activity. Guillou JL, et al. **Behav Neurosci** 1998 Aug; 112(4):900–8
Lesions of the frontal cortex, hippocampus, and intralaminar thalamic nuclei have distinct effects on remembering in rats. Mair RG, et al. **Behav Neurosci** 1998 Aug; 112(4):772–92
Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats. Maren S. **Behav Neurosci** 1999 Apr;113(2):283–90
Monkeys with rhinal cortex damage or neurotoxic hippocampal lesions are impaired on spatial scene learning and object reversals. Murray EA, et al. **Behav Neurosci** 1998 Dec;112(6):1291–303
Contributions of the hippocampus, amygdala, and dorsal striatum to the response elicited by reward reduction. Salinas JA, et al. **Behav Neurosci** 1998 Aug;112(4):812–26
Aging and ischemia in gerbils impair spatial memory performance. Schwartz C, et al. **Behav Neurosci** 1998 Aug; 112(4):937–41
Mechanisms of reorientation and object localization by children: a comparison with rats. Wang RF, et al. **Behav Neurosci** 1999 Jun;113(3):475–85
Involvement of mechanisms dependent on NMDA receptors, nitric oxide and protein kinase A in the hippocampus but not in the caudate nucleus in memory. Quevedo J, et al. **Behav Pharmacol** 1997 Dec;8(8):713–7
Arachidonic acid as a messenger for the expression of long-term potentiation. Nishizaki T, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):446–9
Evidence that a novel metabotropic glutamate receptor mediates the induction of long-term potentiation at CA1 synapses in the hippocampus. Bortolotto ZA, et al. **Biochem Soc Trans** 1999 Feb;27(2):170–4
Statistical model of the hippocampal CA3 region II. The population framework: model of rhythmic activity in the CA3 slice. Barna G, et al. **Biol Cybern** 1998 Oct; 79(4):309–21
Statistical model of the hippocampal CA3 region. I. The single-cell module: bursting model of the pyramidal cell. Gröbler T, et al. **Biol Cybern** 1998 Oct;79(4):301–8
Forming independent components via temporal locking of reconstruction architectures: a functional model of the hippocampus. Lörincz A. **Biol Cybern** 1998 Sep; 79(3):263–75
A neural network solution to the transverse patterning problem depends on repetition of the input code. Wu X, et al. **Biol Cybern** 1998 Sep;79(3):203–13
Properties of slow, cumulative sodium channel inactivation in rat hippocampal CA1 pyramidal neurons. Mickus T, et al. **Biophys J** 1999 Feb;76(2):846–60
Memorizing and recalling spatial-temporal patterns in an oscillator model of the hippocampus. Borisyuk RM, et al. **Biosystems** 1998 Sep-Dec;48(1-3):3–10
Investigating spike backpropagation induced Ca2+ influx in models of hippocampal and cortical pyramidal neurons. Marsálek P, et al. **Biosystems** 1998 Sep-Dec;48(1-3):147–56
Gamma oscillations by synaptic inhibition in a homogeneous medium model of hippocampal interneurons. Olypher AV. **Biosystems** 1998 Sep-Dec;48(1-3):165–9
Simulation of CA3 region of hippocampus by kinetic models. Ventriglia F. **Biosystems** 1998 Sep-Dec;48(1-3):247–54
Improved protocol for a microsphere-adhesion assay on living tissue slices. Förster E, et al. **Biotechniques** 1999 Mar; 26(3):466–8, 470, 472
Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Ameri A, et al. **Br J Pharmacol** 1999 Apr;126(8):1831–9
Pharmacological modulation of GABA(A) receptor-mediated postsynaptic potentials in the CA1 region of the rat hippocampus. Manuel NA, et al. **Br J Pharmacol** 1998 Dec;125(7):1529–42
Rundown of somatodendritic N-methyl-D-aspartate (NMDA) receptor channels in rat hippocampal neurones: evidence for a role of the small GTPase RhoA. Nörenberg W, et al. **Br J Pharmacol** 1999 Jul;127(5):1060–3
Comparison of antagonist potencies at pre- and post-synaptic GABA(B) receptors at inhibitory synapses in the CA1 region of the rat hippocampus. Pozza MF, et al. **Br J Pharmacol** 1999 May;127(1):211–9
The role of the hippocampus in auditory processing studied by event-related electric potentials and magnetic fields in epilepsy patients before and after temporal lobectomy. Nishitani N, et al. **Brain** 1999 Apr;122 (Pt 4):687–707
Effects of hyperthermia and continuous hippocampal stimulation on the immature and adult brain. Sarkisian MR, et al. **Brain Dev** 1999 Jul;21(5):318–25
Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: dose-effect relationship. Balestrino M, et al. **Brain Res** 1999 Jan 16;816(1):124–30
Neonatal ventral hippocampal lesions attenuate the nucleus accumbens dopamine response to stress: an electrochemical study in the adult rat. Brake WG, et al. **Brain Res** 1999 Jun 12;831(1-2):25–32
Septocingulate and septohippocampal cholinergic pathways: involvement in working/episodic memory. Dougherty KD, et al. **Brain Res** 1998 Nov 9;810(1-2):59–71
Hydroxylamine blocks pre- but not postsynaptic adenosine A(1) receptor-mediated actions in rat hippocampus. Fowler JC, et al. **Brain Res** 1999 Aug 7;837(1-2):309–13
Anoxic decrease in potassium outward currents of hippocampal cultured neurons in absence and presence of dithionite. Gebhardt C, et al. **Brain Res** 1999 Aug 7; 837(1-2):270–6
Resistance of the hippocampus in the lactating rat to N-methyl-D-aspartate (NMDA)-mediated excitation is not due to a nonfunctional receptor system. Grove KL, et al. **Brain Res** 1998 Dec 14;814(1-2):157–63
Synaptic reorganization in explanted cultures of rat hippocampus. Gutiérrez R, et al. **Brain Res** 1999 Jan 9; 815(2):304–16
Reverse transport of glutamate during depolarization in immature hippocampal slices. Katsumori H, et al. **Brain Res** 1999 Feb 20;819(1-2):160–4
Brainstem carbachol injections in the urethane anesthetized rat produce hippocampal theta rhythm and cortical desynchronization: a comparison of pedunculopontine tegmental versus nucleus pontis oralis injections. Kinney GG, et al. **Brain Res** 1998 Nov 2;809(2):307–13
Altered mitochondrial oxidative phosphorylation in hippocampal slices of kainate-treated rats. Kunz WS, et al. **Brain Res** 1999 May 1;826(2):236–42
Spatial memory impairment in ventral subicular lesioned rats. Laxmi TR, et al. **Brain Res** 1999 Jan 16;816(1):245–8
A role of subicular and hippocampal afterdischarges in initiation of locomotor activity in rats. Ma J, et al. **Brain Res** 1998 May 18;793(1-2):112–8
Multiple single units and population responses during inhibitory gating of hippocampal auditory response in freely-moving rats. Moxon KA, et al. **Brain Res** 1999 Apr 17;825(1-2):75–85
A 'long-term-potentiation-like' facilitation of hippocampal synaptic transmission induced by the nootropic nefiracetam. Nishizaki T, et al. **Brain Res** 1999 May 1; 826(2):281–8
Diurnal modulation of long-term potentiation in the hamster hippocampal slice. Raghavan AV, et al. **Brain Res** 1999 Jul 3;833(2):311–4
The frequency of rat's hippocampal theta rhythm is related to the speed of locomotion. Slawińska U, et al. **Brain Res** 1998 Jun 15;796(1-2):327–31
The expression of mRNAs for hepatocyte growth factor/scatter factor, its receptor c-met, and one of its activators tissue-type plasminogen activator show a systematic relationship in the developing and adult cerebral cortex and hippocampus. Thewke DP, et al. **Brain Res** 1999 Mar 13;821(2):356–67
Modulation of synaptic transmission by nicotine and nicotinic antagonists in hippocampus. Chiodini FC, et al. **Brain Res Bull** 1999 Apr;48(6):623–8
The effect of intraseptal procaine injection of hippocampal theta in freely moving cat. Gołębiewski H, et al. **Brain Res Bull** 1999 Aug;49(6):407–12
Changes in hippocampal theta following intrahippocampal corticotropin-releasing hormone (CRH) infusions in the rat. Kortekaas R, et al. **Brain Res Bull** 1999 Apr;48(6):603–7
Different effects of unilateral and bilateral hippocampal lesions in rats on the performance of radial maze and odor-paired associate tasks. Li H, et al. **Brain Res Bull** 1999 Jan 1;48(1):113–9
The fasciculus retroflexus controls the integrity of REM sleep by supporting the generation of hippocampal theta rhythm and rapid eye movements in rats. Valjakka A, et al. **Brain Res Bull** 1998 Sep 15;47(2):171–84
Differential effects of chronic stress on memory processes in the tree shrew. Ohl F, et al. **Brain Res Cogn Brain Res** 1999 Jan;7(3):379–87
Inhibition of long-term potentiation in developing rat visual cortex but not hippocampus by in utero exposure to polychlorinated biphenyls. Altmann L, et al. **Brain Res Dev Brain Res** 1998 Oct 1;110(2):257–60
A comparison of the adenosine-mediated synaptic inhibition in the CA3 area of immature and adult rat hippocampus. Descombes S, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):51–9
GABAa receptor-mediated field potentials are enhanced in area CA1 following prenatal cocaine exposure. Little JZ, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):115–9
Regulation of extracellular potassium in the developing hippocampus. Stringer JL. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):97–103
GluR2 hippocampal knockdown reveals developmental regulation of epileptogenicity and neurodegeneration. Friedman LK, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):224–31
Electro-oscillographic correlation between dorsal raphe nucleus, neocortex and hippocampus during wakefulness before and after serotoninergic inactivation. Fonoff ET, et al. **Braz J Med Biol Res** 1999 Apr;32(4):469–72 (14 ref.)
Some temporal and parietal cortical connections converge in CA1 of the primate hippocampus. Rockland KS, et al. **Cereb Cortex** 1999 Apr-May;9(3):232–7
Carbamazepine facilitates effects of GABA on rat hippocampus slices. Zhang JD, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):230–3
The hippocampus: The shock of the new. Eichenbaum H. **Curr Biol** 1999 Jul 1;9(13):R482–4
Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Bortolotto ZA, et al. **Curr Opin Neurobiol** 1999 Jun;9(3):299–304 (64 ref.)
Hippocampus and context in classical conditioning. Holland PC, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):195–202 (75 ref.)
Synaptic plasticity in cortical systems. Klintsova AY, et al. **Curr Opin Neurobiol** 1999 Apr;9(2):203–8 (79 ref.)
Effects of estrogen in the CNS. Woolley CS. **Curr Opin Neurobiol** 1999 Jun;9(3):349–54 (44 ref.)
Synapse formation by hippocampal neurons from agrin-deficient mice. Serpinskaya AS, et al. **Dev Biol** 1999 Jan 1;205(1):65–78
Target- and maturation-specific membrane-associated molecules determine the ingrowth of entorhinal fibers into the hippocampus. Skutella T, et al. **Dev Biol** 1999 Jul 15; 211(2):277–92
The homing pigeon hippocampus and the development of landmark navigation. Strasser R, et al. **Dev Psychobiol** 1998 Dec;33(4):305–15
The effects of stress on memory and the hippocampus throughout the life cycle: implications for childhood development and aging. Bremner JD, et al. **Dev Psychopathol** 1998 Fall;10(4):871–85 (98 ref.)
Semaphorins III and IV repel hippocampal axons via two distinct receptors. Chédotal A, et al. **Development** 1998 Nov;125(21):4313–23
Physiological bases of the synchronized population spikes and slow wave of the magnetic field generated by a guinea-pig longitudinal CA3 slice preparation. Wu J, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 107(5):361–73
Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. Madani R, et al. **EMBO J** 1999 Jun 1;18(11):3007–12
Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Gu Q, et al. **Endocrinology** 1999 Feb;140(2):660–6
Evidence of enhanced kindling and hippocampal neuronal injury in immature rats with neuronal migration disorders. Germano IM, et al. **Epilepsia** 1998 Dec;39(12):1253–60
Interaction between superficial layers of the entorhinal cortex and the hippocampus in normal and epileptic temporal lobe. Gloveli T, et al. **Epilepsy Res** 1998 Sep;32(1-2):183–93 (81 ref.)
FAST and SLOW amygdala kindling rat strains: comparison of amygdala, hippocampal, piriform and perirhinal cortex kindling. McIntyre DC, et al. **Epilepsy Res** 1999 Jul; 35(3):197–209
Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Okada M, et al. **Epilepsy Res** 1999 Apr; 34(2-3):187–97
IPSPs elicited in CA1 pyramidal cells by putative basket cells in slices of adult rat hippocampus. Ali AB, et al. **Eur J Neurosci** 1999 May;11(5):1741–53
Glutamate-dependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Araque A, et al. **Eur J Neurosci** 1998 Jun;10(6):2129–42
A novel form of long-term depression in the CA1 area of the adult rat hippocampus independent of glutamate receptors activation. Berretta N, et al. **Eur J Neurosci** 1998 Sep;10(9):2957–63
Local inhibition of hippocampal nitric oxide synthase does not impair place learning in the Morris water escape task in rats. Blokland A, et al. **Eur J Neurosci** 1999 Jan; 11(1):223–32
Excitatory synaptic transmission and its modulation by PKC is unchanged in the hippocampus of GAP-43-deficient mice. Capogna M, et al. **Eur J Neurosci** 1999 Feb; 11(2):433–40
Platelet-activating factor receptor is not required for long-term potentiation in the hippocampal CA1 region. Kobayashi K, et al. **Eur J Neurosci** 1999 Apr;11(4):1313–6
Modulation by substance P of synaptic transmission in the mouse hippocampal slice. Kouznetsova M, et al. **Eur J Neurosci** 1998 Oct;10(10):3076–84
Calcium-dependent inactivation of the monosynaptic NMDA EPSCs in rat hippocampal neurons in culture. Medina I, et al. **Eur J Neurosci** 1999 Jul;11(7):2422–30
Short communication: hippocampal neuronal activity and imprinting in the behaving domestic chick. Nicol AU, et al. **Eur J Neurosci** 1998 Aug;10(8):2738–41
Survival and synaptogenesis of hippocampal neurons without NMDA receptor function in culture. Okabe S, et al. **Eur J Neurosci** 1998 Jun;10(6):2192–8
A purinergic component of the excitatory postsynaptic current mediated by P2X receptors in the CA1 neurons

of the rat hippocampus. Pankratov Y, et al. **Eur J Neurosci** 1998 Dec;10(12):3898–902

The effects of NMDA-induced retrohippocampal lesions on performance of four spatial memory tasks known to be sensitive to hippocampal damage in the rat. Pouzet B, et al. **Eur J Neurosci** 1999 Jan;11(1):123–40

Intracellular calcium stores modulate miniature GABA-mediated synaptic currents in neonatal rat hippocampal neurons. Savić N, et al. **Eur J Neurosci** 1998 Nov;10(11):3379–86

Reduced hippocampal LTP in mice lacking a presynaptic protein: complexin II. Takahashi S, et al. **Eur J Neurosci** 1999 Jul;11(7):2359–66

Astrocytes are required for the oscillatory activity in cultured hippocampal neurons. Verderio C, et al. **Eur J Neurosci** 1999 Aug;11(8):2793–800

Corticotrophin-releasing factor produces a long-lasting enhancement of synaptic efficacy in the hippocampus. Wang HL, et al. **Eur J Neurosci** 1998 Nov;10(11):3428–37

Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats. Giovannini MG, et al. **Eur J Pharmacol** 1998 Jul 31;354(1):17–24

Idiothetic input into object-place configuration as the contribution to memory of the monkey and human hippocampus: a review. Gaffan D. **Exp Brain Res** 1998 Nov;123(1–2):201–9 (64 ref.)

Dendrite classification in rat hippocampal neurons according to signal propagation properties. Observation by multichannel optical recording in cultured neuronal networks. Kawaguchi H, et al. **Exp Brain Res** 1998 Oct; 122(4):378–92

Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease. Behl C. **Exp Gerontol** 1998 Nov-Dec;33(7–8):689–96 (51 ref.)

Hippocampal neurochemical and electrophysiological measures from freely moving rats. Bronzino JD, et al. **Exp Neurol** 1999 Jan;155(1):150–5

Stress and the aging hippocampus. McEwen BS. **Front Neuroendocrinol** 1999 Jan;20(1):49–70 (155 ref.)

Tests used to assess the cognitive abilities of aged rats: their relation to each other and to hippocampal morphology and neurotrophin expression. McLay RN, et al. **Gerontology** 1999 May-Jun;45(3):143–55

GABAA receptor agonists modulate K+ currents in adult hippocampal glial cells in situ. Bekar LK, et al. **Glia** 1999 Apr;26(2):129–38

Mature hippocampal astrocytes exhibit functional metabotropic and ionotropic glutamate receptors in situ. Shelton MK, et al. **Glia** 1999 Mar;26(1):1–11

Introduction: what is where in the medial temporal lobe? Amaral DG. **Hippocampus** 1999;9(1):1–6

Plasticity of directional place fields in a model of rodent CA3. Brunel N, et al. **Hippocampus** 1998;8(6):651–65

NMDA receptor-independent LTP in basal versus apical dendrites of CA1 pyramidal cells in rat hippocampal slice. Cavus I, et al. **Hippocampus** 1998;8(4):373–9

Hippocampal system and declarative (relational) memory: summarizing the data from functional neuroimaging studies. Cohen NJ, et al. **Hippocampus** 1999;9(1):83–98 (52 ref.)

Lateralized fascia dentata lesion and blockade of one hippocampus: effect on spatial memory in rats. Czéh B, et al. **Hippocampus** 1998;8(6):647–50

Selective hippocampal lesions yield nonspatial memory impairments in rhesus monkeys. Doré FY, et al. **Hippocampus** 1998;8(4):323–9

Progress in spanning the molecular and behavioral mechanisms of hippocampal function [editorial; comment] Eichenbaum H. **Hippocampus** 1999;9(2):100. Comment on: Hippocampus 1999 ;9(2):118–36.

Discharge correlates of hippocampal complex spike neurons in behaving rats passively displaced on a mobile robot. Gavrilov VV, et al. **Hippocampus** 1998;8(5):475–90

Gene expression of growth-associated proteins, GAP-43 and SCG10, in the hippocampal formation of the macaque monkey: nonradioactive in situ hybridization study. Higo N, et al. **Hippocampus** 1998;8(5):533–47

Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Jouvenceau A, et al. **Hippocampus** 1998;8(6):627–37

Hippocampal modulation of cingulo-thalamic neuronal activity and discriminative avoidance learning in rabbits. Kang E, et al. **Hippocampus** 1998;8(5):491–510

Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. Kempermann G, et al. **Hippocampus** 1999; 9(3):321–32

Neural circuit analysis of spatial working memory: role of pre- and parasubiculum, medial and lateral entorhinal cortex. Kesner RP, et al. **Hippocampus** 1998;8(4):416–23

Conditioning, awareness, and the hippocampus. LaBar KS, et al. **Hippocampus** 1998;8(6):620–6 (75 ref.)

Hippocampal PET activations of memory encoding and retrieval: the HIPER model. Lepage M, et al. **Hippocampus** 1998;8(4):313–22

Is there a direct projection from perirhinal cortex to the hippocampus? [letter; comment] Liu P, et al. **Hippocampus** 1998;8(4):424–5. Comment on: Hippocampus 1997;7(6):643–55.

Hippocampectomy disrupts auditory trace fear conditioning and contextual fear conditioning in the rat. McEchron MD, et al. **Hippocampus** 1998;8(6):638–46

Differential modulation of a common memory retrieval network revealed by positron emission tomography. Maguire EA, et al. **Hippocampus** 1999;9(1):54–61

Functional differentiation in the hippocampus. Moser MB, et al. **Hippocampus** 1998;8(6):608–19 (126 ref.)

Synchronous modulation of perirhinal cortex neuronal activity during cholinergically mediated (type II) hippocampal theta. Muir GM, et al. **Hippocampus** 1998; 8(5):526–32

Age-related deficits on the radial maze and in fear conditioning: hippocampal processing and consolidation. Oler JA, et al. **Hippocampus** 1998;8(4):402–15

Representational organization in the aged hippocampus [see comments] Rapp PR. **Hippocampus** 1998;8(5):432–5. Comment in: Hippocampus 1998 ;8(5):438–43.

Reconciling Barnes et al. (1997) and Tanila et al. (1997a,b) [comment] Redish AD, et al. **Hippocampus** 1998; 8(5):438–43 (37 ref.). Comment on: Hippocampus 1998 ;8(5):432–5.

Medial temporal lobe activations in fMRI and PET studies of episodic encoding and retrieval. Schacter DL, et al. **Hippocampus** 1999;9(1):7–24 (86 ref.)

Comparison of the timing of hippocampal and subicular spatial signals: implications for path integration. Sharp PE. **Hippocampus** 1999;9(2):158–72

Gene-trapping to identify and analyze genes expressed in the mouse hippocampus. Steel M, et al. **Hippocampus** 1998; 8(5):444–57

Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5 [see comments] Steele RJ, et al. **Hippocampus** 1999;9(2):118–36. Comment in: Hippocampus 1999 ;9(2):100.

Bridging the gap: integrating cellular and functional magnetic resonance imaging studies of the hippocampus. Stern CE, et al. **Hippocampus** 1999;9(1):45–53 (103 ref.)

Intrinsic oscillations in CA3 hippocampal pyramids: physiological relevance to theta rhythm generation. Strata F. **Hippocampus** 1998;8(6):666–79

Unique features in the processing of spatial information by the aged hippocampus as shown by place cell recording studies: a response to Peter Rapp's commentary "Representational organization in the aged hippocampus". Tanila H. **Hippocampus** 1998;8(5):436–7

Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions [see comments] Vizi ES, et al. **Hippocampus** 1998;8(6):566–607 (384 ref.). Comment in: Hippocampus 1998 ;8(6):565.

Role of the hippocampal system in conditional motor learning: mapping antecedents to action. Wise SP, et al. **Hippocampus** 1999;9(2):101–17 (112 ref.)

Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Woolley CS. **Horm Behav** 1998 Oct;34(2):140–8 (47 ref.)

Learning-related effects and functional neuroimaging. Petersson KM, et al. **Hum Brain Mapp** 1999;7(4):234–43

Relationship of rectal & hippocampal temperature profiles to seizure activity in rats prone & resistant to hot water induced epilepsy. Ullal GR, et al. **Indian J Med Res** 1998 Dec;108:279–84

Immunolesion of the cholinergic basal forebrain: effects on functional properties of hippocampal and septal neurons. Bassant MH, et al. **Int J Dev Neurosci** 1998 Nov-Dec; 16(7–8):613–32 (109 ref.)

Postnatal maternal separation during the stress hyporesponsive period enhances the adrenocortical response to novelty in adult rats by affecting feedback regulation in the CA1 hippocampal field. Biagini G, et al. **Int J Dev Neurosci** 1998 Jun-Jul;16(3–4):187–97

Perception of species-specific vocalizations in rats: role of the cholinergic septo-hippocampal pathway and aging. Hörtnagl H, et al. **Int J Dev Neurosci** 1998 Nov-Dec; 16(7–8):715–27

Spatiotemporal pattern of the postnatal astrogliogenesis in the rat hippocampal formation. Setkowicz Z, et al. **Int J Dev Neurosci** 1999 Jun;17(3):215–24

Neurotoxicity assessment of selected organic solvents based on spontaneous and evoked cortical and hippocampal activity in rats. Tomas T, et al. **Int J Occup Med Environ Health** 1999;12(1):73–84

Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. Korkotian E, et al. **J Biol Chem** 1999 Jul 30;274(31):21673–8

Expressions of CCAAT/Enhancer-binding proteins beta and delta and their activities are intensified by cAMP signaling as well as Ca2+/calmodulin kinases activation in hippocampal neurons. Yukawa K, et al. **J Biol Chem** 1998 Nov 20;273(47):31345–51

Impairment of inhibitory synaptic transmission in mice lacking synapsin I. Terada S, et al. **J Cell Biol** 1999 May 31;145(5):1039–48

Conceptual processing during the conscious resting state. A functional MRI study. Binder JR, et al. **J Cogn Neurosci** 1999 Jan;11(1):80–95

H.M. revisited: relations between language comprehension, memory, and the hippocampal system. MacKay DG, et al. **J Cogn Neurosci** 1998 May;10(3):377–94

Interactive processing of sensory input and motor output in the human hippocampus. Tesche CD, et al. **J Cogn Neurosci** 1999 Jul;11(4):424–36

Evidence that nerve growth factor influences recent memory through structural changes in septohippocampal cholinergic neurons. Gustilo MC, et al. **J Comp Neurol** 1999 Mar 22;405(4):491–507

Rapid extension of axons into the CA3 region by adult-generated granule cells. Hastings NB, et al. **J Comp Neurol** 1999 Oct 11;413(1):146–54

Morphometric studies of the aged hippocampus: I. Volumetric analysis in behaviorally characterized rats. Rapp PR, et al. **J Comp Neurol** 1999 Jan 25;403(4):459–70

Perirhinal cortex projections to the amygdaloid complex and hippocampal formation in the rat. Shi CJ, et al. **J Comp Neurol** 1999 Apr 12;406(3):299–328

Temporal sequence compression by an integrate-and-fire model of hippocampal area CA3. August DA, et al. **J Comput Neurosci** 1999 Jan;6(1):71–90

Sub-regional hippocampal vulnerability in various animal models leading to cognitive dysfunction. Kadar T, et al. **J Neural Transm** 1998;105(8–9):987–1004

Attenuated extracellular dopamine levels after stress and amphetamine in the nucleus accumbens of rats with neonatal ventral hippocampal damage. Lillrank SM, et al. **J Neural Transm** 1999;106(2):183–96

The role of the hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands. Nazar M, et al. **J Neural Transm** 1999;106(5–6):369–81

Regulation of myelin basic protein phosphorylation by mitogen-activated protein kinase during increased action potential firing in the hippocampus. Atkins CM, et al. **J Neurochem** 1999 Sep;73(3):1090–7

Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal pathway lesions. Gilmor ML, et al. **J Neurochem** 1998 Dec;71(6):2411–20

Glutathione efflux induced by NMDA and kainate: implications in neurotoxicity? Wallin C, et al. **J Neurochem** 1999 Oct;73(4):1566–72

Right hippocampal contribution to visual memory: a presurgical and postsurgical study in patients with temporal lobe epilepsy. Gleissner U, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):665–9

Evidence for chloride ions as intracellular messenger substances in astrocytes. Bekar LK, et al. **J Neurophysiol** 1999 Jul;82(1):248–54

Group I mGluR activation causes voltage-dependent and -independent Ca2+ rises in hippocampal pyramidal cells. Bianchi R, et al. **J Neurophysiol** 1999 Jun;81(6):2903–13

Oxidative downmodulation of the transient K-current IA by intracellular arachidonic acid in rat hippocampal neurons. Bittner K, et al. **J Neurophysiol** 1999 Jul; 82(1):508–11

Glutamate controls the induction of GABA-mediated giant depolarizing potentials through AMPA receptors in neonatal rat hippocampal slices. Bolea S, et al. **J Neurophysiol** 1999 May;81(5):2095–102

Net interaction between different forms of short-term synaptic plasticity and slow-IPSPs in the hippocampus and auditory cortex. Buonomano DV, et al. **J Neurophysiol** 1998 Oct;80(4):1765–74

Effects of PKA and PKC on miniature excitatory postsynaptic currents in CA1 pyramidal cells. Carroll RC, et al. **J Neurophysiol** 1998 Nov;80(5):2797–800

Intrinsic theta-frequency membrane potential oscillations in hippocampal CA1 interneurons of stratum lacunosum-moleculare. Chapman CA, et al. **J Neurophysiol** 1999 Mar;81(3):1296–307

Long-term depression of temporoammonic-CA1 hippocampal synaptic transmission. Dvorak-Carbone H, et al. **J Neurophysiol** 1999 Mar;81(3):1036–44

Potassium conductance causing hyperpolarization of CA1 hippocampal neurons during hypoxia. Erdemli G, et al. **J Neurophysiol** 1998 Nov;80(5):2378–90

Lack of AMPA receptor desensitization during basal synaptic transmission in the hippocampal slice. Hjelmstad GO, et al. **J Neurophysiol** 1999 Jun;81(6):3096–9

Neuromodulation of dendritic action potentials. Hoffman DA, et al. **J Neurophysiol** 1999 Jan;81(1):408–11

Membrane dysfunction induced by in vitro ischemia in immature rat hippocampal CA1 neurons. Isagai T, et al. **J Neurophysiol** 1999 Apr;81(4):1866–71

Activity-dependent depression of GABAergic IPSCs in cultured hippocampal neurons. Jensen K, et al. **J Neurophysiol** 1999 Jul;82(1):42–9

Role of presynaptic L-type Ca2+ channels in GABAergic synaptic transmission in cultured hippocampal neurons. Jensen K, et al. **J Neurophysiol** 1999 Mar;81(3):1225–30

Blockade of hippocampal long-term potentiation by sustained tetanic stimulation near the recording site. Kauer JA. **J Neurophysiol** 1999 Feb;81(2):940–4

Rapid and slow swelling during hypoxia in the CA1 region of rat hippocampal slices. Kreisman NR, et al. **J Neurophysiol** 1999 Jul;82(1):320–9

High safety factor for action potential conduction along axons but not dendrites of cultured hippocampal and cortical neurons. Mackenzie PJ, et al. **J Neurophysiol** 1998 Oct;80(4):2089–101

Cell-specific alterations in synaptic properties of hippocampal CA1 interneurons after kainate treatment. Morin F, et al. **J Neurophysiol** 1998 Dec;80(6):2836–47

Nonlinear frequency-dependent synchronization in the developing hippocampus. Prida LM, et al.

J Neurophysiol 1999 Jul;82(1):202–8
Modulation of transmitter release by action potential duration at the hippocampal CA3–CA1 synapse. Qian J, et al. **J Neurophysiol** 1999 Jan;81(1):288–98
Serotonin modulates spike backpropagation and associated [Ca2+]i changes in the apical dendrites of hippocampal CA1 pyramidal neurons. Sandler VM, et al. **J Neurophysiol** 1999 Jan;81(1):216–24
Chronic changes in synaptic responses of entorhinal and hippocampal neurons after amino-oxyacetic acid (AOAA)-induced entorhinal cortical neuron loss. Scharfman HE, et al. **J Neurophysiol** 1998 Dec; 80(6):3031–46
Intraneuronal [Ca2+] changes induced by 2-deoxy-D-glucose in rat hippocampal slices. Tekkök S, et al. **J Neurophysiol** 1999 Jan;81(1):174–83
Endogenous pH shifts facilitate spreading depression by effect on NMDA receptors. Tong CK, et al. **J Neurophysiol** 1999 Apr;81(4):1988–91
Geometry of dendritic spines affects calcium dynamics in hippocampal neurons: theory and experiments. Volfovsky N, et al. **J Neurophysiol** 1999 Jul;82(1):450–62
Membrane potential and intracellular Ca2+ oscillations activated by mGluRs in hippocampal stratum oriens/alveus interneurons. Woodhall G, et al. **J Neurophysiol** 1999 Jan; 81(1):371–82
Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination. Anagnostaras SG, et al. **J Neurosci** 1999 Feb 1;19(3):1106–14
Reactive oxygen species mediate activity-dependent neuron-glia signaling in output fibers of the hippocampus. Atkins CM, et al. **J Neurosci** 1999 Sep 1;19(17):7241–8
Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. Bakshi VP, et al. **J Neurosci** 1998 Oct 15;18(20):8394–401
Synaptic modifications in cultured hippocampal neurons: dependence on spike timing, synaptic strength, and postsynaptic cell type. Bi GQ, et al. **J Neurosci** 1998 Dec 15;18(24):10464–72
Decreased G-protein-mediated regulation and shift in calcium channel types with age in hippocampal cultures. Blalock EM, et al. **J Neurosci** 1999 Oct 1;19(19):8674–84
Mechanisms of neural synchrony in the septohippocampal pathways underlying hippocampal theta generation. Bland BH, et al. **J Neurosci** 1999 Apr 15;19(8):3223–37
A mitogen-activated protein kinase cascade in the CA1/CA2 subfield of the dorsal hippocampus is essential for long-term spatial memory. Blum S, et al. **J Neurosci** 1999 May 1;19(9):3535–44
On the synchronizing mechanisms of tetanically induced hippocampal oscillations. Bracci E, et al. **J Neurosci** 1999 Sep 15;19(18):8104–13
Ceramide signaling downstream of the p75 neurotrophin receptor mediates the effects of nerve growth factor on outgrowth of cultured hippocampal neurons. Brann AB, et al. **J Neurosci** 1999 Oct 1;19(19):8199–206
Distinct functional types of associative long-term potentiation in neocortical and hippocampal pyramidal neurons. Buonomano DV. **J Neurosci** 1999 Aug 15; 19(16):6748–54
Mechanisms of induction and expression of long-term depression at GABAergic synapses in the neonatal rat hippocampus. Caillard O, et al. **J Neurosci** 1999 Sep 1; 19(17):7568–77
Cholinergic induction of theta-frequency oscillations in hippocampal inhibitory interneurons and pacing of pyramidal cell firing. Chapman CA, et al. **J Neurosci** 1999 Oct 1;19(19):8637–45
Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. Chen G, et al. **J Neurosci** 1999 Sep 15;19(18):7983–90
Arachidonic acid reciprocally alters the availability of transient and sustained dendritic K(+) channels in hippocampal CA1 pyramidal neurons. Colbert CM, et al. **J Neurosci** 1999 Oct 1;19(19):8163–71
Parallel information processing in the dorsal striatum: relation to hippocampal function. Devan BD, et al. **J Neurosci** 1999 Apr 1;19(7):2789–98
Interactions between hippocampus and medial septum during sharp waves and theta oscillation in the behaving rat. Dragoi G, et al. **J Neurosci** 1999 Jul 15;19(14):6191–9
Ultrastructural localization of full-length trkB immunoreactivity in rat hippocampus suggests multiple roles in modulating activity-dependent synaptic plasticity. Drake CT, et al. **J Neurosci** 1999 Sep 15;19(18):8009–26
Local presentation of substrate molecules directs axon specification by cultured hippocampal neurons. Esch T, et al. **J Neurosci** 1999 Aug 1;19(15):6417–26
Endogenous FGF-2 is important for cholinergic sprouting in the denervated hippocampus. Fagan AM, et al. **J Neurosci** 1997 Apr 1;17(7):2499–511
Homing in pigeons: the role of the hippocampal formation in the representation of landmarks used for navigation. Gagliardo A, et al. **J Neurosci** 1999 Jan 1;19(1):311–5
Head direction cells in rats with hippocampal or overlying neocortical lesions: evidence for impaired angular path integration. Golob EJ, et al. **J Neurosci** 1999 Aug 15; 19(16):7198–211
Defining affinity with the GABAA receptor. Jones MV, et al. **J Neurosci** 1998 Nov 1;18(21):8590–604
Slices have more synapses than perfusion-fixed hippocampus from both young and mature rats. Kirov SA, et al. **J Neurosci** 1999 Apr 15;19(8):2876–86
Interdependence of multiple theta generators in the hippocampus: a partial coherence analysis. Kocsis B, et al. **J Neurosci** 1999 Jul 15;19(14):6200–12
Mitochondrial depolarization is not required for neuronal apoptosis. Krohn AJ, et al. **J Neurosci** 1999 Sep 1; 19(17):7394–404
Reactivation of hippocampal cell assemblies: effects of behavioral state, experience, and EEG dynamics. Kudrimoti HS, et al. **J Neurosci** 1999 May 15; 19(10):4090–101
Excitotoxic septal lesions result in spatial memory deficits and altered flexibility of hippocampal single-unit representations. Leutgeb S, et al. **J Neurosci** 1999 Aug 1; 19(15):6661–72
Long-term effects of transcranial magnetic stimulation on hippocampal reactivity to afferent stimulation. Levkovitz Y, et al. **J Neurosci** 1999 Apr 15;19(8):3198–203
Enhancement of neurotransmitter release induced by brain-derived neurotrophic factor in cultured hippocampal neurons. Li YX, et al. **J Neurosci** 1998 Dec 15; 18(24):10231–40
Rapid, activation-induced redistribution of ionotropic glutamate receptors in cultured hippocampal neurons [published erratum appears in J Neurosci 1999 Apr 15;19(8):3275] Lissin DV, et al. **J Neurosci** 1999 Feb 15; 19(4):1263–72
Differential roles of Ca(2+)/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation. Liu J, et al. **J Neurosci** 1999 Oct 1;19(19):8292–9
Muscarinic receptor activity has multiple effects on the resting membrane potentials of CA1 hippocampal interneurons. McQuiston AR, et al. **J Neurosci** 1999 Jul 15;19(14):5693–702
Muscarinic receptor activity induces an afterdepolarization in a subpopulation of hippocampal CA1 interneurons. McQuiston AR, et al. **J Neurosci** 1999 Jul 15;19(14):5703–10
Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. McQuiston AR, et al. **J Neurosci** 1999 Apr 15;19(8):2887–96
Nitric oxide facilitates long-term potentiation, but not long-term depression. Malen PL, et al. **J Neurosci** 1997 Apr 1;17(7):2645–51
Temperature-dependent modulation of excitatory transmission in hippocampal slices is mediated by extracellular adenosine. Masino SA, et al. **J Neurosci** 1999 Mar 15;19(6):1932–9
Spatial- and task-dependent neuronal responses during real and virtual translocation in the monkey hippocampal formation. Matsumura N, et al. **J Neurosci** 1999 Mar 15; 19(6):2381–93
Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. Otmakhova NA, et al. **J Neurosci** 1999 Feb 15;19(4):1437–45
Differential modulation of synaptic transmission by calcium chelators in young and aged hippocampal CA1 neurons: evidence for altered calcium homeostasis in aging. Ouanounou A, et al. **J Neurosci** 1999 Feb 1;19(3):906–15
Tetanic stimulation leads to increased accumulation of Ca(2+)/calmodulin-dependent protein kinase II via dendritic protein synthesis in hippocampal neurons. Ouyang Y, et al. **J Neurosci** 1999 Sep 15;19(18):7823–33
Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. Pozzo-Miller LD, et al. **J Neurosci** 1999 Jun 15;19(12):4972–83
Hippocampal long-term potentiation preserves the fidelity of postsynaptic responses to presynaptic bursts. Selig DK, et al. **J Neurosci** 1999 Feb 15;19(4):1236–46
Three-dimensional structure and composition of CA3-->CA1 axons in rat hippocampal slices: implications for presynaptic connectivity and compartmentalization. Shepherd GM, et al. **J Neurosci** 1998 Oct 15;18(20):8300–10
Spatial firing properties of hippocampal CA1 populations in an environment containing two visually identical regions. Skaggs WE, et al. **J Neurosci** 1998 Oct 15;18(20):8455–66
Time-dependent reversal of long-term potentiation in area CA1 of the freely moving rat induced by theta pulse stimulation. Stäubli U, et al. **J Neurosci** 1999 Oct 1; 19(19):8712–9
Glutamate receptors mediate TTX-resistant synchronous activity in the rat hippocampus. Strowbridge BW. **J Neurosci** 1999 Jul 15;19(14):5758–67
On the mechanism of the gamma --> beta frequency shift in neuronal oscillations induced in rat hippocampal slices by tetanic stimulation. Traub RD, et al. **J Neurosci** 1999 Feb 1;19(3):1088–105
Transistor probes local potassium conductances in the adhesion region of cultured rat hippocampal neurons. Vassanelli S, et al. **J Neurosci** 1999 Aug 15;19(16):6767–73
Three-dimensional relationships between hippocampal synapses and astrocytes. Ventura R, et al. **J Neurosci** 1999 Aug 15;19(16):6897–906
Noninvasive measurements of the membrane potential and GABAergic action in hippocampal interneurons. Verheugen JA, et al. **J Neurosci** 1999 Apr 1;19(7):2546–55
Different contributions of the hippocampus and perirhinal cortex to recognition memory. Wan H, et al. **J Neurosci** 1999 Feb 1;19(3):1142–8
Path integration absent in scent-tracking fimbria-fornix rats: evidence for hippocampal involvement in "sense of direction" and "sense of distance" using self-movement cues. Whishaw IQ, et al. **J Neurosci** 1999 Jun 1;19(11):4662–73
Optic flow input to the hippocampal formation from the accessory optic system. Wylie DR, et al. **J Neurosci** 1999 Jul 1;19(13):5514–27
Adenosine release mediates cyanide-induced suppression of CA1 neuronal activity. Zhu PJ, et al. **J Neurosci** 1997 Apr 1;17(7):2355–64
A submersion method to induce hypoxic damage in organotypic hippocampal cultures. Frantseva MV, et al. **J Neurosci Methods** 1999 Jul 1;89(1):25–31
Thin slice CNS explants maintained on collagen-coated culture dishes. Parsley CP, et al. **J Neurosci Methods** 1998 Mar 13;80(1):65–74
Microcutting of living brain slices by a pulsed ultrafine water jet which allows simultaneous electrophysiological recordings (micromingotome). Speckmann EJ, et al. **J Neurosci Methods** 1998 Jul 1;82(1):53–8
SNAP-25 requirement for dendritic growth of hippocampal neurons. Grosse G, et al. **J Neurosci Res** 1999 Jun 1; 56(5):539–46
Induction of DNA fragmentation and HSP72 immunoreactivity by adenovirus-mediated gene transfer in normal gerbil hippocampus and ventricle. Kitagawa H, et al. **J Neurosci Res** 1998 Oct 1;54(1):38–45
Role of intracellular Ca(2+) stores shaping normal activity in brain. Nyitrai G, et al. **J Neurosci Res** 1999 Sep 15; 57(6):906–15
Recombinant plasma-type platelet-activating factor acetylhydrolase attenuates NMDA-induced hippocampal neuronal apoptosis. Ogden F, et al. **J Neurosci Res** 1998 Sep 15;53(6):677–84
Role for myelin-associated glycoprotein as a functional tenascin-R receptor. Yang H, et al. **J Neurosci Res** 1999 Mar 15;55(6):687–701
Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. Gold BG, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1202–10
Somatic amplification of distally generated subthreshold EPSPs in rat hippocampal pyramidal neurones. Andreasen M, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:85–100
Passive electrotonic properties of rat hippocampal CA3 interneurones. Chitwood RA, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):743–56
pH modulation of Ca2+ responses and a Ca2+-dependent K+ channel in cultured rat hippocampal neurones. Church J, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):119–32
Cell-attached measurements of the firing threshold of rat hippocampal neurones. Fricker D, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):791–804
Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. Hefft S, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):769–76
Post-tetanic potentiation of GABAergic IPSCs in cultured rat hippocampal neurones. Jensen K, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:71–84
Conduction velocities and membrane properties of different classes of rat septohippocampal neurons recorded in vitro. Jones GA, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):867–77
Bombesin-like peptides depolarize rat hippocampal interneurones through interaction with subtype 2 bombesin receptors. Lee K, et al. **J Physiol (Lond)** 1999 Aug 1;518 (Pt 3):791–802
N- and L-type calcium channel involvement in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells. Lenz RA, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):61–73
Multiple sites of action of neomycin, Mg2+ and spermine on the NMDA receptors of rat hippocampal CA1 pyramidal neurones. Lu WY, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):29–46
Block of rapid depolarization induced by in vitro energy depletion of rat dorsal vagal motoneurones. Martin RL. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:131–41
Photolytically released nitric oxide produces a delayed but persistent suppression of LTP in area CA1 of the rat hippocampal slice. Murphy KP, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):453–62
Requirement of rapid Ca2+ entry and synaptic activation of metabotropic glutamate receptors for the induction of long-term depression in adult rat hippocampus. Otani S, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):761–70
Rapid report: postsynaptic bursting is essential for 'Hebbian' induction of associative long-term potentiation at excitatory synapses in rat hippocampus. Pike FG, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):571–6
Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. Sobolevsky AI, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):47–60
Release-independent depression at pyramidal inputs onto specific cell targets: dual recordings in slices of rat cortex. Thomson AM, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:57–70
Long-term suppression of synaptic transmission by tetanization of a single pyramidal cell in the mouse hippocampus in vitro. Yanovsky Y, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):757–67

Cell-type specific expression of ATP-sensitive potassium channels in the rat hippocampus. Zawar C, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):327-41

Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors. Albuquerque EX, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):309-16

Age-related changes in rat hippocampal theta rhythms: a difference between type 1 and type 2 theta. Abe Y, et al. **J Vet Med Sci** 1999 May;61(5):543-8

Current studies on a working model of CaM kinase II in hippocampal long-term potentiation and memory. Fukunaga K, et al. **Jpn J Pharmacol** 1999 Jan;79(1):7-15 (39 ref.)

ATP receptors for the protection of hippocampal functions. Inoue K. **Jpn J Pharmacol** 1998 Dec;78(4):405-10 (43 ref.)

A specific role for group I mGluRs in hippocampal LTP and hippocampus-dependent spatial learning. Balschun D, et al. **Learn Mem** 1999 Mar-Apr;6(2):138-52

Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Bourtchouladze R, et al. **Learn Mem** 1998 Sep-Oct; 5(4-5):365-74

The role of dendritic action potentials and Ca2+ influx in the induction of homosynaptic long-term depression in hippocampal CA1 pyramidal neurons. Christie BR, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):160-9

Blockade of NR2B-containing NMDA receptors prevents BDNF enhancement of glutamatergic transmission in hippocampal neurons. Crozier RA, et al. **Learn Mem** 1999 May-Jun;6(3):257-66

Increase in syntaxin 1B mRNA in hippocampal and cortical circuits during spatial learning reflects a mechanism of trans-synaptic plasticity involved in establishing a memory trace. Davis S, et al. **Learn Mem** 1998 Sep-Oct; 5(4-5):375-90

Reduced K+ channel inactivation, spike broadening, and after-hyperpolarization in Kvbeta1.1-deficient mice with impaired learning. Giese KP, et al. **Learn Mem** 1998 Sep-Oct;5(4-5):257-73

Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Gottschalk WA, et al. **Learn Mem** 1999 May-Jun;6(3):243-56

Basal and apical synapses of CA1 pyramidal cells employ different LTP induction mechanisms. Haley JE, et al. **Learn Mem** 1996 Nov-Dec;3(4):289-95

CA1 long-term potentiation is diminished but present in hippocampal slices from alpha-CaMKII mutant mice. Hinds HL, et al. **Learn Mem** 1998 Sep-Oct;5(4-5):344-54

Long-lasting forms of synaptic potentiation in the mammalian hippocampus. Huang YY, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):74-85 (56 ref.)

Recruitment of long-lasting and protein kinase A-dependent long-term potentiation in the CA1 region of hippocampus requires repeated tetanization. Huang YY, et al. **Learn Mem** 1994 May-Jun;1(1):74-82

Hippocampal CA3 region predicts memory sequences: accounting for the phase precession of place cells. Jensen O, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):279-87

Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Jia Z, et al. **Learn Mem** 1998 Sep-Oct;5(4-5):331-43

Enhanced hippocampal CA1 LTP but normal spatial learning in inositol 1,4,5-trisphosphate 3-kinase(A)-deficient mice. Jun K, et al. **Learn Mem** 1998 Sep-Oct;5(4-5):317-30

Deficiency in induction but not expression of LTP in hippocampal slices from young rats. Liao D, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):138-49

Neuronal NT-3 is not required for synaptic transmission or long-term potentiation in area CA1 of the adult rat hippocampus. Ma L, et al. **Learn Mem** 1999 May-Jun; 6(3):267-75

Brief theta-burst stimulation induces a transcription-dependent late phase of LTP requiring cAMP in area CA1 of the mouse hippocampus. Nguyen PV, et al. **Learn Mem** 1997 Jul-Aug;4(2):230-43

Hippocampal EEG and unit activity responses to modulation of serotonergic median raphe neurons in the freely behaving rat. Nitz DA, et al. **Learn Mem** 1999 Mar-Apr; 6(2):153-67

Long-term potentiation and evidence for novel synaptic association in CA1 stratum oriens of rat hippocampus. Otani S, et al. **Learn Mem** 1995 Mar-Apr;2(2):101-6

Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Paylor R, et al. **Learn Mem** 1998 Sep-Oct;5(4-5):302-16

Lesions of the dorsal hippocampal formation interfere with background but not foreground contextual fear conditioning. Phillips RG, et al. **Learn Mem** 1994 May-Jun; 1(1):34-44

Examination of the role of cGMP in long-term potentiation in the CA1 region of the hippocampus. Selig DK, et al. **Learn Mem** 1996 Jul-Aug;3(1):42-8

The specific role of cGMP in hippocampal LTP. Son H, et al. **Learn Mem** 1998 Jul-Aug;5(3):231-45

Alterations in the expression of specific glutamate receptor subunits following hippocampal LTP in vivo. Thomas KL, et al. **Learn Mem** 1996 Sep-Oct;3(2-3):197-208

Properties of LTP induction in the CA3 region of the primate hippocampus. Urban NN, et al. **Learn Mem** 1996 Sep-Oct; 3(2-3):86-95

On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus [corrected and republished in Learn Mem 1999 Jan-Feb;6(1):63-76] Zhuo M, et al. **Learn Mem** 1998 Nov-Dec;5(6):467-80

On the respective roles of nitric oxide and carbon monoxide in long-term potentiation in the hippocampus [corrected and republished article originally printed in Learn Mem 1998 Nov-Dec;5(6):467-80] Zhuo M, et al. **Learn Mem** 1999 Jan-Feb;6(1):63-76

Cholinergic facilitation of trace eyeblink conditioning in aging rabbits. Disterhoft JF, et al. **Life Sci** 1999; 64(6-7):541-8 (66 ref.)

Non-linear analysis of the rhythmic activity in rodent brains. Alvarenga MY, et al. **Math Biosci** 1999 Mar 15; 157(1-2):287-302

Microstructures for studies of cultured neural networks. Maher MP, et al. **Med Biol Eng Comput** 1999 Jan; 37(1):110-8

Pacemaker neurons of the forebrain medical septal area and theta rhythm of the hippocampus. Vinogradova OS, et al. **Membr Cell Biol** 1998;11(6):715-25 (27 ref.)

Potential sources of intrinsic optical signals imaged in live brain slices. Andrew RD, et al. **Methods** 1999 Jun; 18(2):185-96, 179

Confocal imaging of microglial cell dynamics in hippocampal slice cultures. Dailey ME, et al. **Methods** 1999 Jun; 18(2):222-30, 177

Two-photon imaging in living brain slices. Mainen ZF, et al. **Methods** 1999 Jun;18(2):231-9, 181

Using hippocampal slices to study how aging alters ion regulation in brain tissue. Roberts EL Jr. **Methods** 1999 Jun;18(2):150-9

Study of cerebral energy metabolism using the rat hippocampal slice preparation. Schurr A, et al. **Methods** 1999 Jun;18(2):117-26

Astrocyte changes in aging cerebral cortex and hippocampus: a quantitative immunohistochemical study. Amenta F, et al. **Microsc Res Tech** 1998 Oct 1;43(1):29-33

Human neural stem cells on trial for Parkinson's disease [news] Fricker J. **Mol Med Today** 1999 Apr;5(4):144

Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Schmitz D, et al. **Mol Neurobiol** 1998 Winter;17(1-3):59-72 (85 ref.)

Stress, splicing, cortisol, and the aging hippocampus [news] Collier DA. **Mol Psychiatry** 1998 Jul;3(4):298

What is the biological significance of an age-related increase in IL-1beta in hippocampus? [news] Lynch MA. **Mol Psychiatry** 1999 Jan;4(1):15-8

A pinch of salt for NMDA receptors [news] Salter MW. **Mol Psychiatry** 1999 May;4(3):209-11

Neurogenesis in the adult human hippocampus [see comments] Eriksson PS, et al. **Nat Med** 1998 Nov; 4(11):1313-7. Comment in: Nat Med 1998 Nov;4(11):1207.

Reciprocal interactions between CA3 network activity and strength of recurrent collateral synapses. Bains JS, et al. **Nat Neurosci** 1999 Aug;2(8):720-6

Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues [see comments] Crestani F, et al. **Nat Neurosci** 1999 Sep;2(9):833-9. Comment in: Nat Neurosci 1999 Sep;2(9):780-2.

Conscious awareness, memory and the hippocampus [news; comment] Eichenbaum H. **Nat Neurosci** 1999 Sep; 2(9):775-6. Comment on: Nat Neurosci 1999 Sep;2(9):844-7.

Synaptic activation of kainate receptors on hippocampal interneurons [see comments] Frerking M, et al. **Nat Neurosci** 1998 Oct;1(6):479-86. Comment in: Nat Neurosci 1998 Oct;1(6):434-5.

Regulation of morphological postsynaptic silent synapses in developing hippocampal neurons. Liao D, et al. **Nat Neurosci** 1999 Jan;2(1):37-43

Modulation of a pacemaker current through Ca(2+)-induced stimulation of cAMP production. Lüthi A, et al. **Nat Neurosci** 1999 Jul;2(7):634-41

Cyclic AMP induces functional presynaptic boutons in hippocampal CA3-CA1 neuronal cultures [see comments] Ma L, et al. **Nat Neurosci** 1999 Jan;2(1):24-30. Comment in: Nat Neurosci 1999 Jan;2(1):3.

Dendritic Ih normalizes temporal summation in hippocampal CA1 neurons. Magee JC. **Nat Neurosci** 1999 Jun; 2(6):508-14

Silent synapses: I can't hear you! Could you please speak aloud? [news; comment] Malgaroli A. **Nat Neurosci** 1999 Jan;2(1):3-5. Comment on: Nat Neurosci 1999 Jan;2(1):24-30.

Reversal of synaptic vesicle docking at central synapses. Murthy VN, et al. **Nat Neurosci** 1999 Jun;2(6):503-7

Can molecules explain long-term potentiation? Sanes JR, et al. **Nat Neurosci** 1999 Jul;2(7):597-604 (122 ref.)

Presynaptic modulation of CA3 network activity [published erratum appears in Nat Neurosci 1998 Aug;1(4):331] Staley KJ, et al. **Nat Neurosci** 1998 Jul;1(3):201-9

A molecular correlate of memory and amnesia in the hippocampus [letter] Taubenfeld SM, et al. **Nat Neurosci** 1999 Apr;2(4):309-10

Afferent-specific innervation of two distinct AMPA receptor subtypes on single hippocampal interneurons. Tóth K, et al. **Nat Neurosci** 1998 Nov;1(7):572-8

Multiple forms of LTP in hippocampal CA3 neurons use a common postsynaptic mechanism. Yeckel MF, et al. **Nat Neurosci** 1999 Jul;2(7):625-33

Dendritic spine changes associated with hippocampal long-term synaptic plasticity [see comments] Engert F, et al. **Nature** 1999 May 6;399(6731):66-70. Comment in: Nature 1999 May 6;399(6731):19-21.

Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors. Pearce JM, et al. **Nature** 1998 Nov 5;396(6706):75-7

Neurobiology. A place for space and smells [news; comment] Rawlins JN. **Nature** 1999 Feb 18;397(6720):561, 563. Comment on: Nature 1999 Feb 18;397(6720):613-6.

Memory for places learned long ago is intact after hippocampal damage. Teng E, et al. **Nature** 1999 Aug 12; 400(6745):675-7

The global record of memory in hippocampal neuronal activity [see comments] Wood ER, et al. **Nature** 1999 Feb 18;397(6720):613-6. Comment in: Nature 1999 Feb 18;397(6720):561, 563.

Spatial exploration induces a persistent reversal of long-term potentiation in rat hippocampus [see comments] Xu L, et al. **Nature** 1998 Aug 27;394(6696):891-4. Comment in: Nature 1998 Aug 27;394(6696):834-5.

CREB activation mediates plasticity in cultured hippocampal neurons. Segal M, et al. **Neural Plast** 1998 Jul-Sep;6(3):1-7

Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Landfield PW, et al. **Neurobiol Aging** 1998 Sep-Oct;19(5):469-77

Age-dependent local modulation of hippocampal-evoked responses to perforant path stimulation. Levkovitz Y, et al. **Neurobiol Aging** 1998 Jul-Aug;19(4):317-24

Septo-hippocampal cholinergic and neurotrophin markers in age-induced cognitive decline. Sugaya K, et al. **Neurobiol Aging** 1998 Jul-Aug;19(4):351-61

Role of cannabinoid receptors in memory storage. Hampson RE, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):474-82 (72 ref.)

Synaptic plasticity in the CA1 area of the hippocampus of scrapie-infected mice. Johnston AR, et al. **Neurobiol Dis** 1998 Sep;5(3):188-95

Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Parent A, et al. **Neurobiol Dis** 1999 Feb; 6(1):56-62

Support for a bimodal role for type II adrenal steroid receptors in spatial memory. Conrad CD, et al. **Neurobiol Learn Mem** 1999 Jul;72(1):39-46

Memory for duration: role of hippocampus and medial prefrontal cortex. Jackson PA, et al. **Neurobiol Learn Mem** 1998 Nov;70(3):328-48

Cell-assembly coding in several memory processes. Sakurai Y. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):212-25

Molecular, cellular, and neuroanatomical substrates of place learning. Silva AJ, et al. **Neurobiol Learn Mem** 1998 Jul-Sep;70(1-2):44-61 (84 ref.)

Two different forms of long-term potentiation in the hippocampus. López-García JC. **Neurobiology (Bp)** 1998; 6(1):75-98 (112 ref.)

Structural basis of the cholinergic and serotonergic modulation of GABAergic neurons in the hippocampus. Gulyás AI, et al. **Neurochem Int** 1999 May;34(5):359-72 (102 ref.)

Modest cholinergic deafferentation fails to alter hippocampal G-proteins. McLaughlin M, et al. **Neurochem Int** 1999 Jul; 35(1):59-64

Differential effects of zinc on native GABA(A) receptor function in rat hippocampus and cerebellum. Schmid G, et al. **Neurochem Int** 1999 May;34(5):399-405

The functional neuroanatomy of episodic memory: the role of the frontal lobes, the hippocampal formation, and other areas. Desgranges B, et al. **Neuroimage** 1998 Aug; 8(2):198-213 (120 ref.)

Linear summation of excitatory inputs by CA1 pyramidal neurons. Cash S, et al. **Neuron** 1999 Feb;22(2):383-94

An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Chiang MY, et al. **Neuron** 1998 Dec;21(6):1353-61

Response of hippocampal synapses to natural stimulation patterns. Dobrunz LE, et al. **Neuron** 1999 Jan;22(1):157-66

The parahippocampal place area: recognition, navigation, or encoding? Epstein R, et al. **Neuron** 1999 May;23(1):115-25

Dendritic sodium spikes are variable triggers of axonal action potentials in hippocampal CA1 pyramidal neurons. Golding NL, et al. **Neuron** 1998 Nov;21(5):1189-200

Postsynaptically silent synapses in single neuron cultures [see comments] Gomperts SN, et al. **Neuron** 1998 Dec; 21(6):1443-51. Comment in: Neuron 1998 Dec;21(6):1226-7.

Characterization of elementary Ca2+ release signals in NGF-differentiated PC12 cells and hippocampal neurons. Koizumi S, et al. **Neuron** 1999 Jan;22(1):125-37

Relating hippocampal circuitry to function: recall of memory sequences by reciprocal dentate-CA3 interactions. Lisman JE. **Neuron** 1999 Feb;22(2):233-42 (78 ref.)

Silencing the controversy in LTP? [comment] Malinow R. **Neuron** 1998 Dec;21(6):1226-7 (12 ref.). Comment on: Neuron 1998 Dec;21(6):1443-51.

Activation of AMPA, kainate, and metabotropic receptors at hippocampal mossy fiber synapses: role of glutamate diffusion. Min MY, et al. **Neuron** 1998 Sep;21(3):561-70

Role of the carboxy-terminal region of the GluR epsilon2 subunit in synaptic localization of the NMDA receptor channel. Mori H, et al. **Neuron** 1998 Sep;21(3):571-80

Switch from facilitation to inhibition of excitatory synaptic

transmission by group I mGluR desensitization. Rodriguez-Moreno A, et al. **Neuron** 1998 Dec; 21(6):1477-86

Coordinated interactions between hippocampal ripples and cortical spindles during slow-wave sleep. Siapas AG, et al. **Neuron** 1998 Nov;21(5):1123-8

Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP. Wong ST, et al. **Neuron** 1999 Aug;23(4):787-98

Involvement of calcium/calmodulin-dependent protein kinases in the setting of a molecular switch involved in hippocampal LTP. Bortolotto ZA, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):535-44

Memory and the hippocampus in food-storing birds: a comparative approach. Clayton NS. **Neuropharmacology** 1998 Apr-May;37(4-5):441-52 (93 ref.)

The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Fitzjohn SM, et al. **Neuropharmacology** 1998 Dec;37(12):1445-58

Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (+/-)-MDL 73005EF and its enantiomers. Hajós-Korcsok E, et al. **Neuropharmacology** 1999 Feb;38(2):299-306

An investigation of the expression mechanism of LTP of AMPA receptor-mediated synaptic transmission at hippocampal CA1 synapses using failures analysis and dendritic recordings. Isaac JT, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1399-410

Learning of landmark stability and instability by hippocampal place cells. Jeffery KJ. **Neuropharmacology** 1998 Apr-May; 37(4-5):677-87

Induction of LTD in the adult hippocampus by the synaptic activation of AMPA/kainate and metabotropic glutamate receptors. Kemp N, et al. **Neuropharmacology** 1999 Apr; 38(4):495-504

A role for BDNF in the late-phase of hippocampal long-term potentiation. Korte M, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):553-9

Hippocampal contributions to cortical plasticity. Nadel L, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):431-9 (41 ref.)

Synapses in hippocampus occupy only 1-2% of cell membranes and are spaced less than half-micron apart: a quantitative ultrastructural analysis with discussion of physiological implications. Rusakov DA, et al. **Neuropharmacology** 1998 Apr-May;37(4-5):513-21

Characterisation of kainate receptor mediated whole-cell currents in rat cultured cerebellar granule cells. Savidge JR, et al. **Neuropharmacology** 1999 Mar;38(3):375-82

Protective effect of group I metabotropic glutamate receptor activation against hypoxic/hypoglycemic injury in rat hippocampal slices: timing and involvement of protein kinase C. Schröder UH, et al. **Neuropharmacology** 1999 Feb; 38(2):209-16

Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Seabrook GR, et al. **Neuropharmacology** 1999 Mar; 38(3):349-59

The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus. Vignes M, et al. **Neuropharmacology** 1998 Oct-Nov;37(10-11):1269-77

Selective spatial memory impairment after right unilateral temporal lobectomy. Nunn JA, et al. **Neuropsychologia** 1998 Sep;36(9):837-48

Serotonin and hippocampal neurogenesis. Gould E. **Neuropsychopharmacology** 1999 Aug;21(2 Suppl):46S-51S (64 ref.)

Disruption of latent inhibition in rats with postnatal hippocampal lesions. Grecksch G, et al. **Neuropsychopharmacology** 1999 Jun;20(6):525-32

Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage. Lipska BK, et al. **Neuropsychopharmacology** 1998 Dec;19(6):451-64

Astrocytes re-express nestin in deafferented target territories of the adult rat hippocampus. Brook GA, et al. **Neuroreport** 1999 Apr 6;10(5):1007-11

Focal hippocampal gain of NGF function elicits specific septal cholinergic reorganization. Brooks AI, et al. **Neuroreport** 1999 Feb 5;10(2):337-44

Interaction between paired-pulse facilitation and long-term potentiation in the projection from hippocampal area CA1 to the subiculum. Commins S, et al. **Neuroreport** 1998 Dec 21;9(18):4109-13

LTP in CA1 of the adult rat hippocampus and voltage-activated calcium channels. Izumi Y, et al. **Neuroreport** 1998 Nov 16;9(16):3689-91

Can the hippocampus tell time? The temporo-septal engram shift model. Lytton WW, et al. **Neuroreport** 1999 Aug 2; 10(11):2301-6

Facilitation of miniature GABAergic currents by chlorpromazine in cultured rat hippocampal cells. Mozrzymas JW, et al. **Neuroreport** 1999 Aug 2; 10(11):2251-4

Potentiation and depression following stimulus interruption in young rat hippocampi. Niu YP, et al. **Neuroreport** 1999 Apr 6;10(5):919-23

Hippocampal theta rhythm in anesthetized rats: role of AMPA glutamate receptors. Puma C, et al. **Neuroreport** 1999 Aug 2;10(11):2297-300

Unspecific long-term potentiation can evoke functional segregation in a model of area 17. Stetter M, et al. **Neuroreport** 1998 Aug 24;9(12):2697-702

Relationships between the epiphysis and hippocampus during formation of a stress response. Arushanyan EB, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):608-12

Synaptic plasticity in the hippocampus during afferent activation reproducing the pattern of the theta rhythm (theta plasticity). Kleshchevnikov AM. **Neurosci Behav Physiol** 1999 Mar-Apr;29(2):185-96 (76 ref.)

The effects of vasopressin on hippocampal slices from trained rats. Kudryashova IV, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):289-93

Conditioned reflex release of dopamine in the nucleus accumbens after disruption of the hippocampal formation in rats. Saul'skaya NB, et al. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):380-5

Kindling-like state occurring on periodic increases in the extracellular K+ concentration in field CA1 in rat hippocampal slices. Sem'yanov AV, et al. **Neurosci Behav Physiol** 1998 Sep-Oct;28(5):504-12

Differentiation of neurons in the locus ceruleus after allotransplantation into previously denervated white rat hippocampus. Svanidze IK, et al. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):349-53

Effects of hippocampectomy on the development and recovery of a conditioned reflex to time in rats. Vodolazhskaya MG. **Neurosci Behav Physiol** 1998 Sep-Oct;28(5):527-32

Intracellular studies of the interaction between paired-pulse facilitation and the delayed phase of long-term potentiation in the hippocampus. Voronin LL, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):347-54

Is learning blocked by saturation of synaptic weights in the hippocampus? Moser EI, et al. **Neurosci Biobehav Rev** 1999 May;23(5):661-72 (110 ref.)

Gamma frequency oscillations gate temporally coded afferent inputs in the rat hippocampal slice. Burchell TR, et al. **Neurosci Lett** 1998 Oct 23;255(3):151-4

Lack of effect of the novel anticonvulsant SB-204269 on voltage-dependent currents in neurones cultured from rat hippocampus. Caeser M, et al. **Neurosci Lett** 1999 Aug 13; 271(1):57-60

Expression of immediate early gene cyr61 during the differentiation of immortalized embryonic hippocampal neuronal cells. Chung KC, et al. **Neurosci Lett** 1998 Oct 23;255(3):155-8

The effects of single and multiple episodes of theta patterned or high frequency stimulation on synaptic transmission from hippocampal area CA1 to the subiculum in rats. Commins S, et al. **Neurosci Lett** 1999 Jul 30;270(2):99-102

Subcellular muscarinic enhancement of excitability and Ca2+-signals in CA1-dendrites in rat hippocampal slice. Egorov AV, et al. **Neurosci Lett** 1999 Feb 12; 261(1-2):77-80

Frequency and synchrony of tetanically-induced, gamma-frequency population discharges in the rat hippocampal slice: the effect of diazepam and propofol. Fox JE, et al. **Neurosci Lett** 1998 Nov 27;257(2):101-4

The modulation of excitatory synaptic transmission by adenosine in area CA1 of the rat hippocampus is temperature dependent. Grover LM, et al. **Neurosci Lett** 1999 Mar 26;263(2-3):77-80

Quantitative evidence for increase in galanin-immunoreactive terminals in the hippocampal formation following entorhinal cortex lesions in the adult rat. Harrison PS, et al. **Neurosci Lett** 1999 Apr 30; 266(1):41-4

Differences in the effects of zolpidem and diazepam on recurrent inhibition and long-term potentiation in rat hippocampal slices. Higashima M, et al. **Neurosci Lett** 1998 Apr 3;245(2):77-80

Intracerebral source localization of mental process-related potentials elicited prior to mental sweating response in humans. Homma S, et al. **Neurosci Lett** 1998 May 8; 247(1):25-8

Dimethyl sulfoxide increases latency of anoxic terminal negativity in hippocampal slices of guinea pig in vitro. Hülsmann S, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):1-4

Serotonin depolarizes hippocampal interneurones in the rat stratum oriens by interaction with 5HT2 receptors. Lee K, et al. **Neurosci Lett** 1999 Jul 23;270(1):56-8

Effects of age and sex on the water maze performance and hippocampal cholinergic fibers in rats. Lukoyanov NV, et al. **Neurosci Lett** 1999 Jul 16;269(3):141-4

Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid. Matsuoka Y, et al. **Neurosci Lett** 1998 Aug 14;252(2):119-22

Rat hippocampal neurons maintain their own GABAergic synaptic transmission in culture. Melnick IV, et al. **Neurosci Lett** 1999 Mar 12;262(3):151-4

Time course of transient expression of GDNF protein in rat granule cells of the bilateral dentate gyri after unilateral intrahippocampal kainic acid injection. Mikuni N, et al. **Neurosci Lett** 1999 Mar 12;262(3):215-8

Postsynaptic phospholipase C activity is required for the induction of homosynaptic long-term depression in rat hippocampus. Reyes-Harde M, et al. **Neurosci Lett** 1998 Aug 21;252(3):155-8

Differential expression of sialoglycoproteins in the rat hippocampus and its changes during aging. Sato Y, et al. **Neurosci Lett** 1999 Feb 26;262(1):49-52

Do hippocampal CA1 neurones of the adult rat possess a slow inwardly-rectifying chloride conductance? Stocca G, et al. **Neurosci Lett** 1999 Jan 15;259(3):186-90

Presynaptic involvement of nitric oxide in dopamine D1/D5 receptor-induced sustained enhancement of synaptic currents mediated by ionotropic glutamate receptors in the rat hippocampus. Yang SN. **Neurosci Lett** 1999 Jul 30; 270(2):87-90

Effects of an interleukin-1beta analogue [Lys-D-Pro-Thr], on incomplete cerebral ischemia-induced inhibition of long-term potentiation in rat hippocampal neurons in vivo. Yoshioka M, et al. **Neurosci Lett** 1999 Feb 19;261(3):171-4

Involvement of the adenosine neuromodulatory system in the benzodiazepine-induced depression of excitatory synaptic transmissions in rat hippocampal neurons in vitro. Narimatsu E, et al. **Neurosci Res** 1999 Jan;33(1):57-64

Desynchronization of carbachol-induced theta-like activities by alpha-adrenergic agents in guinea pig hippocampal slices. Natsume K, et al. **Neurosci Res** 1999 Mar; 33(3):179-86

Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Bakshi VP, et al. **Neuroscience** 1999; 92(1):113-21

Reversal of excitatory postsynaptic potential/spike potentiation in the CA1 area of the rat hippocampus. Bernard C, et al. **Neuroscience** 1998 Sep;86(2):431-6

Long-term synaptic changes induced by intracellular tetanization of CA3 pyramidal neurons in hippocampal slices from juvenile rats. Berretta N, et al. **Neuroscience** 1999;93(2):469-77

Thalamic excitation of hippocampal CA1 neurons: a comparison with the effects of CA3 stimulation. Bertram EH, et al. **Neuroscience** 1999;92(1):15-26

5-Hydroxytryptamine and glutamate modulate velocity and extent of intercellular calcium signalling in hippocampal astroglial cells in primary cultures. Blomstrand F, et al. **Neuroscience** 1999;88(4):1241-53

Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. Brezun JM, et al. **Neuroscience** 1999;89(4):999-1002

Development of multiple calcium channel types in cultured mouse hippocampal neurons. Chameau P, et al. **Neuroscience** 1999 May;90(2):383-8

Distinct expressions for synaptic potentiation induced by calcium through voltage-gated calcium and N-methyl-D-aspartate receptor channels in the hippocampal CA1 region. Chen HX, et al. **Neuroscience** 1998 Sep;86(2):415-22

Reduced Mg2+ blockade of synaptically activated N-methyl-D-aspartate receptor-channels in CA1 pyramidal neurons in kainic acid-lesioned rat hippocampus. Chen Y, et al. **Neuroscience** 1999;88(3):727-39

Effects of pH changes on calcium-mediated potentials in rat hippocampal neurons in vitro. Church J. **Neuroscience** 1999 Mar;89(3):731-42

Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus. Eijkenboom M, et al. **Neuroscience** 1999;91(4):1299-313

Restoration of decaying long-term potentiation in the hippocampal formation by stimulation of neuromodulatory nuclei in freely moving rats. Ezrokhi VL, et al. **Neuroscience** 1999;88(3):741-53

Possibility of multiquantal transmission at single inhibitory synapse in cultured rat hippocampal neurons. Fedulova SA, et al. **Neuroscience** 1999;92(4):1217-30

Fimbria-fornix transection and excitotoxicity produce similar neurodegeneration in the septum. Ginsberg SD, et al. **Neuroscience** 1999;88(4):1059-71

Effect of hypoxia on membrane potential and resting conductance in rat hippocampal neurons. Hyllienmark L, et al. **Neuroscience** 1999;91(2):511-7

Analysis of the tetanic and post-tetanic components of intradendritic Ca2+ signals in hippocampal CA1 neurons. Jäger T, et al. **Neuroscience** 1998 Sep;86(2):423-9

Postsynaptic targets of somatostatin-immunoreactive interneurons in the rat hippocampus. Katona I, et al. **Neuroscience** 1999 Jan;88(1):37-55

The entorhino-septo-supramammillary nucleus connection in the rat: morphological basis of a feedback mechanism regulating hippocampal theta rhythm. Leranth C, et al. **Neuroscience** 1999;88(3):701-18

Modulation of unitary glutamatergic synapses by neurotrophin-4/5 or brain-derived neurotrophic factor in hippocampal microcultures: presynaptic enhancement depends on pre-established paired-pulse facilitation. Lessmann V, et al. **Neuroscience** 1998 Sep;86(2):399-413

Enhancement of glutamate release uncovers spillover-mediated transmission by N-methyl-D-aspartate receptors in the rat hippocampus. Lozovaya NA, et al. **Neuroscience** 1999;91(4):1321-30

Masking of forskolin-induced long-term potentiation by adenosine accumulation in area CA1 of the rat hippocampus. Lu KT, et al. **Neuroscience** 1999 Jan; 88(1):69-78

Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine1A receptor activation. Lu KT, et al. **Neuroscience** 1998 Oct; 86(3):729-37

Muscarinic facilitation of the occurrence of depolarization-induced suppression of inhibition in rat

hippocampus. Martin LA, et al. **Neuroscience** 1999; 92(1):61–71

Glycosylation of proteins during a critical time window is necessary for the maintenance of long–term potentiation in the hippocampal CA1 region. Matthies H Jr, et al. **Neuroscience** 1999;91(1):175–83

Neurosteroid regulation of inhibitory synaptic transmission in the rat hippocampus in vitro. Meyer JH, et al. **Neuroscience** 1999;90(4):1177–83

Heparin injection into the adult rat hippocampus induces seizures in the absence of macroscopic abnormalities. Mudher AK, et al. **Neuroscience** 1999 Mar;89(2):329–33

Identification of different putative neuronal subtypes in cultures of the superior region of the hippocampus using electrophysiological parameters. Mynlieff M. **Neuroscience** 1999;93(2):479–86

Medial septal and median raphe innervation of vasoactive intestinal polypeptide–containing interneurons in the hippocampus. Papp EC, et al. **Neuroscience** 1999 May; 90(2):369–82

Differential induction of long–lasting potentiation of inhibitory postsynaptic potentials by theta patterned stimulation versus 100–Hz tetanization in hippocampal pyramidal cells in vitro. Perez Y, et al. **Neuroscience** 1999 Mar;90(3):747–57

Spatial learning and hippocampal volume in male deer mice: relations to age, testosterone and adrenal gland weight. Perrot–Sinal TS, et al. **Neuroscience** 1998 Oct;86(4):1089–99

The effects of radiofrequency lesion or transection of the fimbria–fornix on latent inhibition in the rat. Pouzet B, et al. **Neuroscience** 1999;91(4):1355–68

Effects of lesions to the glutamatergic afferents to the nucleus accumbens in the modulation of reactivity to spatial and non–spatial novelty in mice. Sargolini F, et al. **Neuroscience** 1999;93(3):855–67

Self–stimulation rewarding experience induced alterations in dendritic spine density in CA3 hippocampal and layer V motor cortical pyramidal neurons. Shankaranarayana Rao BS, et al. **Neuroscience** 1999;89(4):1067–77

Long–term depression of perforant path excitatory postsynaptic potentials following synchronous network bursting in area CA3 of immature hippocampus. Smith KL, et al. **Neuroscience** 1999 Mar;89(3):625–30

Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task. Stancampiano R, et al. **Neuroscience** 1999;89(4):1135–43

Dual intracellular recordings and computational models of slow inhibitory postsynaptic potentials in rat neocortical and hippocampal slices. Thomson AM, et al. **Neuroscience** 1999;92(4):1193–215

High–frequency population oscillations are predicted to occur in hippocampal pyramidal neuronal networks interconnected by axoaxonal gap junctions. Traub RD, et al. **Neuroscience** 1999;92(2):407–26

Evidence for an ephaptic feedback in cortical synapses: postsynaptic hyperpolarization alters the number of response failures and quantal content. Voronin LL, et al. **Neuroscience** 1999;92(2):399–405

Pretraining tetanic fimbrial stimulation impairs the expression but not the acquisition of contextual fear conditioning in mice. Vouimba RM, et al. **Neuroscience** 1999;93(3):869–76

Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats. Wilkerson A, et al. **Neuroscience** 1999 Mar;89(3):743–9

Dexamethasone selectively suppresses microglial trophic responses to hippocampal deafferentation. Woods AG, et al. **Neuroscience** 1999;91(4):1277–89

Brain dysfunction associated with an induction of nitric oxide synthase following an intracerebral injection of lipopolysaccharide in rats. Yamada K, et al. **Neuroscience** 1999 Jan;88(1):281–94

Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Zarei MM, et al. **Neuroscience** 1999;88(3):755–64

Two phases of behavioral plasticity in rats following unilateral excitotoxic lesion of the hippocampus. Zou LB, et al. **Neuroscience** 1999;92(3):819–26

Chronic developmental lead exposure and hippocampal long–term potentiation: biphasic dose–response relationship. Gilbert ME, et al. **Neurotoxicology** 1999 Feb; 20(1):71–82

Is the hippocampus a Kalman filter? Bousquet O, et al. **Pac Symp Biocomput** 1998;:657–68

The activity–dependent potentiation of the slow Ca2+–activated K+ current regulates synaptic efficacy in rat CA1 pyramidal neurons. Borde M, et al. **Pflugers Arch** 1999 Jan;437(2):261–6

Diazepam–treated female rats: flumazenil– and PK 11195–induced withdrawal in the hippocampus CA1. Sloan JW, et al. **Pharmacol Biochem Behav** 1998 Sep;61(1):121–30

Properties of fast endocytosis at hippocampal synapses. Kavalali ET, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Feb 28; 354(1381):337–46

Place cells, navigational accuracy, and the human hippocampus. O'Keefe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1998 Aug 29; 353(1373):1333–40

Mathematical model of the CA1 region of the rat hippocampus. Almeida AC, et al. **Phys Med Biol** 1998 Sep; 43(9):2631–46

Place cells can flexibly terminate and develop their spatial firing. A new theory for their function. Ludvig N. **Physiol Behav** 1999 Aug 1;67(1):57–67

Impaired learning and memory in OLETF rats without cholecystokinin (CCK)–A receptor. Nomoto S, et al. **Physiol Behav** 1999 Jul;66(5):869–72

Alteration of dopamine metabolites in CSF and behavioral impairments induced by neonatal hippocampal lesions. Wan RQ, et al. **Physiol Behav** 1998 Dec 1;65(3):429–36

Hippocampal, but not amygdala, activity at encoding correlates with long–term, free recall of nonemotional information. Alkire MT, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14506–10

Metabotropic glutamate receptor–initiated translocation of protein kinase p90rsk to polyribosomes: a possible factor regulating synaptic protein synthesis. Angenstein F, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):15078–83

Age–related defects in spatial memory are correlated with defects in the late phase of hippocampal long–term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Bach ME, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5280–5

Rolipram, a type IV–specific phosphodiesterase inhibitor, facilitates the establishment of long–lasting long–term potentiation and improves memory. Barad M, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):15020–5

Modulation of N–methyl–D–aspartate receptor function by glycine transport. Bergeron R, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15730–4

Prolonged activation of the N–methyl–D–aspartate receptor–Ca2+ transduction pathway causes spontaneous recurrent epileptiform discharges in hippocampal neurons in culture. DeLorenzo RJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14482–7

Bilirubin, formed by activation of heme oxygenase–2, protects neurons against oxidative stress injury. Doré S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2445–50

Ephrin–dependent growth and pruning of hippocampal axons. Gao PP, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4073–7

Human hippocampus associates information in memory. Henke K, et al. **Proc Natl Acad Sci U S A** 1999 May 11; 96(10):5884–9

Volatile anesthetics block actin–based motility in dendritic spines. Kaech S, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10433–7

Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Liu Y, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13266–71

Effect of reduced myristoylated alanine–rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background. McNamara RK, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14517–22

Activation of the genetically defined m1 muscarinic receptor potentiates N–methyl–D–aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Marino MJ, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11465–70

Memory and long–term potentiation (LTP) dissociated: normal spatial memory despite CA1 LTP elimination with Kv1.4 antisense. Meiri N, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):15037–42

Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Meucci O, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14500–5

Evidence of a role for cyclic ADP–ribose in long–term synaptic depression in hippocampus. Reyes–Harde M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4061–6

Basolateral amygdala noradrenergic influence enables enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. Roozendaal B, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11642–7

An apamin–sensitive Ca2+–activated K+ current in hippocampal pyramidal neurons. Stocker M, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4662–7

Segregating the functions of human hippocampus. Strange BA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30; 96(7):4034–9

Calexcitin transformation of GABAergic synapses: from excitation filter to amplifier. Sun MK, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7023–8

Perturbed dentate gyrus function in serotonin 5–HT2C receptor mutant mice. Tecott LH, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):15026–31

Cholecystokinin–8 protects central cholinergic neurons against fimbria–fornix lesion through the up–regulation of nerve growth factor synthesis. Tirassa P, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6473–7

Active summation of excitatory postsynaptic potentials in hippocampal CA3 pyramidal neurons. Urban NN, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11450–5

Glutamate and gamma–aminobutyric acid mediate a heterosynaptic depression at mossy fiber synapses in the hippocampus. Vogt KE, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1118–22

A selective role of calcineurin aalpha in synaptic depotentiation in hippocampus. Zhuo M, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4650–5

Low expression of the ClC–2 chloride channel during postnatal development: a mechanism for the paradoxical depolarizing action of GABA and glycine in the hippocampus. Mladinić M, et al. **Proc R Soc Lond B Biol Sci** 1999 Jun 22;266(1425):1207–13

Role of vasopressin in learning and memory in the hippocampus. Alescio–Lautier B, et al. **Prog Brain Res** 1998;119:501–21 (106 ref.)

Regulation of brain–derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Castrén E, et al. **Prog Brain Res** 1998;117:57–64 (28 ref.)

Nitric oxide as a retrograde messenger during long–term potentiation in hippocampus. Hawkins RD, et al. **Prog Brain Res** 1998;118:155–72 (137 ref.)

Differential effects of neonatal handling on anxiety, corticosterone response to stress, and hippocampal glucocorticoid and serotonin (5–HT)2A receptors in Lewis rats. Durand M, et al. **Psychoneuroendocrinology** 1998 May; 23(4):323–35

Hebbian synapses in cortical and hippocampal pathways. Skrebitsky VG, et al. **Rev Neurosci** 1998;9(4):243–64 (246 ref.)

Real–time tracking of memory formation in the human rhinal cortex and hippocampus [see comments] Fernández G, et al. **Science** 1999 Sep 3;285(5433):1582–5. Comment in: Science 1999 Sep 3;285(5433):1503–4.

New role found for the hippocampus [news] Helmuth L. **Science** 1999 Aug 27;285(5432):1339, 1341

Long–term depression in hippocampal interneurons: joint requirement for pre– and postsynaptic events. Laezza F, et al. **Science** 1999 Aug 27;285(5432):1411–4

Long–term potentiation––a decade of progress? Malenka RC, et al. **Science** 1999 Sep 17;285(5435):1870–4 (62 ref.)

Perspectives: neuroscience. Remembrance of things past [comment] Schacter DL, et al. **Science** 1999 Sep 3; 285(5433):1503–4. Comment on: Science 1999 Sep 3;285(5433):1582–5.

Nota bene: neuroscience. For time is the longest distance between two places. Smith O. **Science** 1999 Sep 3; 285(5433):1504

Estrogen: mechanisms for a rapid action in CA1 hippocampal neurons. Moss RL, et al. **Steroids** 1999 Jan–Feb; 64(1–2):14–21

Corticosterone peak is responsible for stress–induced elevation of glutamate in the hippocampus. Abrahám I, et al. **Stress** 1998 Jul;2(3):171–81

Differential participation of hippocampal formation in cocaine–induced cortical electroencephalographic desynchronization and penile erection in the rat. Chang AY, et al. **Synapse** 1998 Oct;30(2):140–9

Injections of N–methyl–D–aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Legault M, et al. **Synapse** 1999 Mar 15;31(4):241–9

Discrete local application of corticotropin–releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Page ME, et al. **Synapse** 1999 Sep 15;33(4):304–13

Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. Smith JE, et al. **Synapse** 1998 Nov; 30(3):318–28

Analysing hippocampal function in transgenic mice: an ethological perspective. Gerlai R, et al. **Trends Neurosci** 1999 Feb;22(2):47–51 (40 ref.)

Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. McBain CJ, et al. **Trends Neurosci** 1999 May;22(5):228–35 (61 ref.)

A model of hippocampal memory encoding and retrieval: GABAergic control of synaptic plasticity. Paulsen O, et al. **Trends Neurosci** 1998 Jul;21(7):273–8 (61 ref.)

Hippocampal synapses: do they talk to their neighbours? Rusakov DA, et al. **Trends Neurosci** 1999 Sep;22(9):382–8 (37 ref.)

The hippocampus as an associator of discontiguous events. Wallenstein GV, et al. **Trends Neurosci** 1998 Aug; 21(8):317–23 (61 ref.)

The representation of space and the hippocampus in rats, robots and humans. Burgess N, et al. **Z Naturforsch [C]** 1998 Jul–Aug;53(7–8):504–9

[Effect of ginsenosides on nucleolar organizer region of neuron and sprouting of mossy fibre terminals of hippocampus in rats] Wang J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):154–8 (Eng. Abstr.) **(Chi)**

[Effects of no precursor and donor on neuronal activity of rat hippocampal slices] Xue BJ, et al. **Sheng Li Hsueh Pao** 1997 Aug;49(4):375–81 (Eng. Abstr.) **(Chi)**

[Long–term depression of excitatory synapses in the cortex and hippocampus] Cohen I, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):121–4 (Eng. Abstr.) **(Fre)**

[Memory consolidation and the hippocampal system] Jaffard R, et al. **C R Acad Sci III** 1998 Feb–Mar;321(2–3):163–6 (18 ref.) **(Fre)**

[Homozygote mice deficient in serotonin 5–HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors] Trillat AC, et al. **C R Seances Soc Biol Fil** 1998; 192(6):1139–47 (Eng. Abstr.) **(Fre)**

[Changes in spatio–temporal patterns after long–term potentiation (LTP) in mouse hippocampal slices and effects of trichloroethylene on LTP] Ohta M. **Hokkaido Igaku Zasshi** 1998 Jul;73(4):365–78 (Eng. Abstr.) **(Jpn)**

[Signal transduction through ATP receptors in brain and the

development of new drugs] Inoue K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:36P–40P (15 ref.) (Eng. Abstr.) **(Jpn)**

[Structure and neuronal connections of the hippocampus] Ishizuka N. **No To Shinkei** 1998 Oct;50(10):881–92 (105 ref.) **(Jpn)**

[Hippocampal cholinergic neurostimulating peptide] Ojika K. **Seikagaku** 1998 Sep;70(9):1175–80 (18 ref.) **(Jpn)**

[Participation of the hippocampus in regulation of GABA release in the nucleus accumbens during emotional conditioning] Saul'skaia NB, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May–Jun; 84(5–6):443–9 (Eng. Abstr.) **(Rus)**

[Intracellular study of interaction of paired-pulse facilitation and late phase of hippocampal long-term potentiation] Voronin LL, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May–Jun;84(5–6):426–35 (Eng. Abstr.) **(Rus)**

[Long-term potentiation of the NMDA-dependent component of the EPSP in the hippocampus] Kleshchevnikov AM. **Usp Fiziol Nauk** 1998 Oct–Dec; 29(4):6–23 (97 ref.) (Eng. Abstr.) **(Rus)**

[The effect of destruction of the hippocampus and removal of the epiphysis on the circadian dynamics of mobility in stressed rats] Arushanian EB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov–Dec; 48(6):1065–72 (Eng. Abstr.) **(Rus)**

[The contrary effect of destruction of the dorsal hippocampus and of the suprachiasmatic nucleus of the hypothalamus on the rhythmic organization of behavior and on anxiety in rats] Arushanian EB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar–Apr; 49(2):264–70 (Eng. Abstr.) **(Rus)**

[Reciprocal suppression of the AMPA and NMDA components of the excitatory postsynaptic potentials in the CA1 area of the rat hippocampus in vitro] Bazhenov AV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Sep–Oct; 48(5):885–93 (Eng. Abstr.) **(Rus)**

[The generation of action potentials in the terminals of the Schaffer collaterals during long-term potentiation in the CA1 region of the hippocampus] Ezrokhi VL, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Jan–Feb; 49(1):127–31 (Eng. Abstr.) **(Rus)**

[Sexual and interhemispheric differences in the involvement of serotonin from the hippocampus and amygdaloid body in the processing of new and repeatedly presented information in rats] Molodtsova GF. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 May–Jun; 49(3):408–15 (Eng. Abstr.) **(Rus)**

[The enhancement of glutamate release in the nucleus accumbens of rats with a destroyed hippocampal formation during an emotional conditioned response] Saul'skaia NB, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar–Apr; 49(2):245–53 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Atropine-induced convulsions in the septohippocampal system. I. Effects of cannula position and sex. Herink J. **Acta Medica (Hradec Kralove)** 1998;41(3):131–4

Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Müller-Vahl KR, et al. **Acta Psychiatr Scand** 1998 Dec;98(6):502–6

Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Small SA, et al. **Ann Neurol** 1999 Apr; 45(4):466–72

Ictal electroencephalographic localization in patients with hippocampal sclerosis [letter; comment] Wennberg R. **Ann Neurol** 1999 Jan;45(1):135–6. Comment on: Ann Neurol 1998 Jun;43(6):756–62.

Stress and hippocampal plasticity. McEwen BS. **Annu Rev Neurosci** 1999;22:105–22 (111 ref.)

Posterior parietal cortex lesions severely disrupt spatial learning in DBA mice characterized by a genetic hippocampal dysfunction. Ammassari-Teule M, et al. **Behav Brain Res** 1998 Sep;95(1):85–90

Illness-induced context aversion learning in rats with lesions of the dorsal hippocampus. Aguado L, et al. **Behav Neurosci** 1998 Oct;112(5):1142–51

Impairments in conditioned stimulus processing and conditioned responding after combined selective removal of hippocampal and neocortical cholinergic input. Baxter MG, et al. **Behav Neurosci** 1999 Jun;113(3):486–95

Temporal discrimination learning in severe amnesic patients reveals an alteration in the timing of eyeblink conditioned responses. McGlinchey-Berroth R, et al. **Behav Neurosci** 1999 Feb;113(1):10–8

60 Hz magnetic fields and central cholinergic activity: effects of exposure intensity and duration. Lai H, et al. **Bioelectromagnetics** 1999;20(5):284–9

Neurophysiological changes associated with selective neuronal damage in hippocampus following transient forebrain ischemia. Xu ZC, et al. **Biol Signals Recept** 1999 Jul–Oct;8(4–5):294–308

Nitric oxide is involved in anoxic preconditioning neuroprotection in rat hippocampal slices. Centeno JM, et al. **Brain Res** 1999 Jul 31;836(1–2):62–9

Epileptiform activity induced by low Mg2+ in cultured rat hippocampal slices. Gutiérrez R, et al. **Brain Res** 1999 Jan 9;815(2):294–303

Characterization of neocortical and hippocampal synaptosomes from temporal lobe epilepsy patients. Hoogland G, et al. **Brain Res** 1999 Aug 7;837(1–2):55–66

Modulation of GABAA receptor-mediated inhibition by postsynaptic calcium in epileptic hippocampal neurons. Isokawa M. **Brain Res** 1998 Nov 9;810(1–2):241–50

Medial septum mediates the increase in post-ictal behaviors and hippocampal gamma waves after an electrically induced seizure. Ma J, et al. **Brain Res** 1999 Jun 26; 833(1):51–7

Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1–42). O'Hare E, et al. **Brain Res** 1999 Jan 2;815(1):1–10

Calcium and increase excitability promote tolerance against anoxia in hippocampal slices. Pérez-Pinzón MA, et al. **Brain Res** 1999 Jun 26;833(1):20–6

Involvement of NMDA receptors and voltage-dependent calcium channels on augmentation of long-term potentiation in hippocampal CA1 area of morphine dependent rats. Pourmotabbed A, et al. **Brain Res** 1998 Aug 31;804(1):125–34

A behavioral and immunohistochemical study on the development of perirhinal cortical kindling: a comparison with other types of limbic kindling. Sato T, et al. **Brain Res** 1998 Nov 16;811(1–2):122–32

Reduced signal complexity of intracellular recordings: a precursor for epileptiform activity? Widman G, et al. **Brain Res** 1999 Jul 31;836(1–2):156–63

The effect of hypothermia on the expression of neurotrophin mRNA in the hippocampus following transient cerebral ischemia in the rat. Boris-Möller F, et al. **Brain Res Mol Brain Res** 1998 Dec 10;63(1):163–73

The neurology of traumatic "dissociative" amnesia: commentary and literature review. Joseph R. **Child Abuse Negl** 1999 Aug;23(8):715–27 (140 ref.)

Hippocampal sleep spindles revisited: physiologic or epileptic activity? Malow BA, et al. **Clin Neurophysiol** 1999 Apr; 110(4):687–93

Experimental partial epileptogenesis. Bausch SB, et al. **Curr Opin Neurol** 1999 Apr;12(2):203–9 (81 ref.)

Prediction of surgical outcome by interictal epileptiform abnormalities during intracranial EEG monitoring in patients with extrahippocampal seizures. Bautista RE, et al. **Epilepsia** 1999 Jul;40(7):880–90

Hippocampal and entorhinal cortex high-frequency oscillations (100--500 Hz) in human epileptic brain and in kainic acid--treated rats with chronic seizures. Bragin A, et al. **Epilepsia** 1999 Feb;40(2):127–37

Nitric oxide and glutamate interaction in the control of cortical and hippocampal excitability. Ferraro G, et al. **Epilepsia** 1999 Jul;40(7):830–6

Prediction of postoperative seizure control by hippocampal event-related potentials. Grunwald T, et al. **Epilepsia** 1999 Mar;40(3):303–6

Consequences of cortical dysplasia during development in rats. Holmes GL, et al. **Epilepsia** 1999 May;40(5):537–44

Acute cellular alterations in the hippocampus after status epilepticus. Macdonald RL, et al. **Epilepsia** 1999;40 Suppl 1:S9–20; discussion S21–2 (65 ref.)

Interneurones are not so dormant in temporal lobe epilepsy: a critical reappraisal of the dormant basket cell hypothesis. Bernard C, et al. **Epilepsy Res** 1998 Sep;32(1–2):93–103 (61 ref.)

Properties of human glial cells associated with epileptic seizure foci. Bordey A, et al. **Epilepsy Res** 1998 Sep; 32(1–2):286–303

'Dormant' inhibitory neurons: do they exist and what is their functional impact? Jefferys JG, et al. **Epilepsy Res** 1998 Sep;32(1–2):104–13

Supragranular mossy fiber sprouting is not necessary for spontaneous seizures in the intrahippocampal kainate model of epilepsy in the rat. Longo BM, et al. **Epilepsy Res** 1998 Sep;32(1–2):172–82

Chronic electrode implantation entails epileptiform field potentials in rat hippocampal slices, similarly to amygdala kindling. Niespodziany I, et al. **Epilepsy Res** 1999 Aug; 36(1):69–74

Evidence of increased excitability in GEPR hippocampus preceding development of seizure susceptibility. Verma-Ahuja S, et al. **Epilepsy Res** 1998 Aug;31(3):161–73

Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Vreugdenhil M, et al. **Epilepsy Res** 1998 Sep; 32(1–2):309–20

Paired pulse suppression and facilitation in human epileptogenic hippocampal formation. Wilson CL, et al. **Epilepsy Res** 1998 Aug;31(3):211–30

Episodic corticosterone treatment accelerates kindling epileptogenesis and triggers long-term changes in hippocampal CA1 cells, in the fully kindled state. Karst H, et al. **Eur J Neurosci** 1999 Mar;11(3):889–98

Spreading depression determines acute cellular damage in the hippocampal slice during oxygen/glucose deprivation. Obeidat AS, et al. **Eur J Neurosci** 1998 Nov;10(11):3451–61

Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery. Sun B, et al. **Exp Neurol** 1998 Dec;154(2):691–5

High-frequency oscillations in human brain. Bragin A, et al. **Hippocampus** 1999;9(2):137–42

Hypoxia-induced loss of synaptic transmission is exacerbated in hippocampal slices of transgenic mice expressing C-terminal fragments of Alzheimer amyloid precursor protein. Ghribi O, et al. **Hippocampus** 1999;9(3):201–5

Hippocampal lesions interfere with Pavlovian negative occasion setting. Holland PC, et al. **Hippocampus** 1999; 9(2):143–57

Electrophysiological properties of rat hippocampal principal cells are unaltered by prenatal protein malnutrition. Rushmore J, et al. **Hippocampus** 1998;8(4):380–9

Prenatal stress: consequences of glucocorticoids on hippocampal development and function. Takahashi LK. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):199–207 (80 ref.)

Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats. Colbourne F, et al. **J Cereb Blood Flow Metab** 1999 Jul;19(7):742–9

Postischemic enhancements of N-methyl-D-aspartic acid (NMDA) and non-NMDA receptor-mediated responses in hippocampal CA1 pyramidal neurons. Mitani A, et al. **J Cereb Blood Flow Metab** 1998 Oct;18(10):1088–98

The effect of transient global ischemia on the interaction of Src and Fyn with the N-methyl-D-aspartate receptor and postsynaptic densities: possible involvement of Src homology 2 domains. Takagi N, et al. **J Cereb Blood Flow Metab** 1999 Aug;19(8):880–8

Transient amnesia after perimesencephalic haemorrhage: the role of enlarged temporal horns. Hop JW, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):590–3

HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. Aisen PS, et al. **J Neurol Sci** 1998 Nov 26; 161(1):66–9

Effect of entorhinal cortex lesion on hippocampal cholinergic system in rat in operant learning task as studied by in vivo brain microdialysis. Shinjo H, et al. **J Neurol Sci** 1998 Apr 15;157(1):13–8

Similar propagation of SD and hypoxic SD-like depolarization in rat hippocampus recorded optically and electrically. Aitken PG, et al. **J Neurophysiol** 1998 Sep; 80(3):1514–21

Extracellular chloride and the maintenance of spontaneous epileptiform activity in rat hippocampal slices. Hochman DW, et al. **J Neurophysiol** 1999 Jan;81(1):49–59

Neurotoxicity mediated by aberrant patterns of synaptic activity between rat hippocampal neurons in culture. McLeod JR Jr, et al. **J Neurophysiol** 1998 Nov; 80(5):2688–98

Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity. Tallent MK, et al. **J Neurophysiol** 1999 Apr;81(4):1626–35

Membrane dysfunction induced by in vitro ischemia in rat hippocampal CA1 pyramidal neurons. Tanaka E, et al. **J Neurophysiol** 1999 Apr;81(4):1872–80

Termination of epileptic afterdischarge in the hippocampus. Bragin A, et al. **J Neurosci** 1997 Apr 1;17(7):2567–79

Impaired K(+) homeostasis and altered electrophysiological properties of post-traumatic hippocampal glia. D'Ambrosio R, et al. **J Neurosci** 1999 Sep 15;19(18):8152–62

Spine loss and other persistent alterations of hippocampal pyramidal cell dendrites in a model of early-onset epilepsy. Jiang M, et al. **J Neurosci** 1998 Oct 15;18(20):8356–68

Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. Mazarati AM, et al. **J Neurosci** 1998 Dec 1;18(23):10070–7

Independent mechanisms of potassium clearance by astrocytes in gliotic tissue. Walz W, et al. **J Neurosci Res** 1999 Jun 15;56(6):595–603

Perinatal brain iron deficiency increases the vulnerability of rat hippocampus to hypoxic ischemic insult. Rao R, et al. **J Nutr** 1999 Jan;129(1):199–206

Temporally graded retrograde amnesia following separate and combined lesions of the perirhinal cortex and fornix in the rat. Wiig KA, et al. **Learn Mem** 1996 Nov–Dec; 3(4):313–25

ESR spectroscopy for analysis of hippocampal elimination of a nitroxide radical during kainic acid-induced seizure in rats. Ueda Y, et al. **Magn Reson Med** 1998 Sep; 40(3):491–3

Hypothyroidism-evoked shifts in hippocampal adrenergic receptors: implications to ischemia-induced hippocampal damage. Hemmings SJ, et al. **Mol Cell Biochem** 1998 Aug; 185(1–2):161–9

Stress and long-term synaptic depression [news] Rowan MJ, et al. **Mol Psychiatry** 1998 Nov;3(6):472–4

Memory deficits for implicit contextual information in amnesic subjects with hippocampal damage [see comments] Chun MM, et al. **Nat Neurosci** 1999 Sep;2(9):844–7. Comment in: Nat Neurosci 1999 Sep;2(9):775–6.

The missing link: a failure of fronto-hippocampal integration in schizophrenia [news; comment] Fletcher P. **Nat Neurosci** 1998 Aug;1(4):266–7. Comment on: Nat Neurosci 1998 Aug;1(4):318–323.

Impaired recruitment of the hippocampus during conscious recollection in schizophrenia [see comments] Heckers S, et al. **Nat Neurosci** 1998 Aug;1(4):318–23. Comment in: Nat Neurosci 1998 Aug;1(4):266–7.

Deficit of quantal release of GABA in experimental models of temporal lobe epilepsy [see comments] Hirsch JC, et al. **Nat Neurosci** 1999 Jun;2(6):499–500. Comment in: Nat Neurosci 1999 Jun;2(6):494–5.

The influence of electric fields on the epileptiform bursts induced by high potassium in CA3 region of rat hippocampal slice. Duong DH, et al. **Neurol Res** 1998 Sep; 20(6):542–8

Diffusion mapping applied to mesial temporal lobe epilepsy: preliminary observations. Hugg JW, et al. **Neurology** 1999 Jul 13;53(1):173–6

Acute cell damage after low Mg2+-induced epileptiform

activity in organotypic hippocampal slice cultures. Kovács R, et al. **Neuroreport** 1999 Feb 5;10(2):207–13
Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat. Royo NC, et al. **Neuroreport** 1999 Apr 26;10(6):1363–7
Beta-amyloid increases cathepsin D levels in hippocampus. Hoffman KB, et al. **Neurosci Lett** 1998 Jul 3;250(2):75–8
Effects of experimental hypercapnia on hippocampal long-term potentiation in anesthetized rats. Itoh Y, et al. **Neurosci Lett** 1999 Feb 5;260(3):201–3
NMDAR2 upregulation precedes mossy fiber sprouting in kainate rat hippocampal epilepsy. Mikuni N, et al. **Neurosci Lett** 1998 Oct 9;255(1):25–8
Bilateral intranigral NMDA infusion suppresses neuronal injury without affecting the duration of kainic acid-induced seizures in rats. Tanaka K, et al. **Neurosci Lett** 1998 Jul 17;251(1):69–71
Neural correlates of recognition memory with and without recollection in patients with Alzheimer's disease and healthy controls. Tendolkar I, et al. **Neurosci Lett** 1999 Mar 19;263(1):45–8
Changes in excitatory and inhibitory circuits of the rat hippocampus 12–14 months after complete forebrain ischemia. Arabadzisz D, et al. **Neuroscience** 1999; 92(1):27–45
Two electrophysiologically distinct types of granule cells in epileptic human hippocampus. Dietrich D, et al. **Neuroscience** 1999;90(4):1197–206
Changes in membrane properties of CA1 pyramidal neurons after transient forebrain ischemia in vivo. Gao TM, et al. **Neuroscience** 1999 Mar;90(3):771–80
Anticonvulsant actions of furosemide in vitro. Gutschmidt KU, et al. **Neuroscience** 1999;91(4):1471–81
Ventral subiculum regulates hypothalamo-pituitary-adrenocortical and behavioural responses to cognitive stressors. Herman JP, et al. **Neuroscience** 1998 Sep;86(2):449–59
Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression. Kamal A, et al. **Neuroscience** 1999 Mar;90(3):737–45
Electroshock seizures protect against apoptotic hippocampal cell death induced by adrenalectomy. Masco D, et al. **Neuroscience** 1999;91(4):1315–9
Increased intracellular Ca2+ concentration in the hippocampal CA1 area during global ischemia and reperfusion in the rat: a possible cause of delayed neuronal death. Nakamura T, et al. **Neuroscience** 1999 Jan; 88(1):57–67
Rapid preconditioning neuroprotection following anoxia in hippocampal slices: role of the K+ ATP channel and protein kinase C. Pérez-Pinzón MA, et al. **Neuroscience** 1999 Mar;89(2):453–9
Acceleration of ageing-related gliopathic changes and hippocampal dysfunction following intracerebroventricular infusion of cysteamine in adult rats. St-Jacques R, et al. **Neuroscience** 1999 Mar;90(3):1103–13
Diabetes mellitus preserves synaptic plasticity in hippocampal slices from middle-aged rats. Tekkök S, et al. **Neuroscience** 1999;91(1):185–91
Mice deficient in endothelial nitric oxide synthase exhibit a selective deficit in hippocampal long-term potentiation. Wilson RI, et al. **Neuroscience** 1999;90(4):1157–65
Neuroprotective effect of mild hypothermia cannot be explained in terms of a reduction of glutamate release during ischemia. Yamamoto H, et al. **Neuroscience** 1999; 91(2):501–9
Persistent block of CA1 synaptic function by prolonged hypoxia. Zhu PJ, et al. **Neuroscience** 1999 Mar;90(3):759–70
Depth electrode implantation in the length axis of the hippocampus for the presurgical evaluation of medial temporal lobe epilepsy: a computed tomography-based stereotactic insertion technique and its accuracy. Van Roost D, et al. **Neurosurgery** 1998 Oct;43(4):819–26; discussion 826–7
Development of cholinergic neurons in rat brain regions: dose-dependent effects of propylthiouracil-induced hypothyroidism. Sawin S, et al. **Neurotoxicol Teratol** 1998 Nov-Dec;20(6):627–35
Dissociation between specific personal episodes and other aspects of remote memory in a patient with hippocampal amnesia. Hirano M, et al. **Percept Mot Skills** 1998 Aug; 87(1):99–107
Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice. Cremer H, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13242–7
Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Liu H, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5286–91
Calbindin immunoreactivity in the hippocampal formation and neocortex of schizophrenics. Iritani S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):409–21
Interictal–ictal interactions and limbic seizure generation. Avoli M, et al. **Rev Neurol (Paris)** 1999 Jul;155(6–7):468–71 (17 ref.)
Facilitated NMDA receptor-mediated synaptic plasticity in the hippocampal CA1 area of dystrophin-deficient mice. Vaillend C, et al. **Synapse** 1999 Jul;33(1):59–70
[The role of adenosine in the early stage of anoxia of hippocampal slices and its mechanisms] Wan Q, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):102–5 (Eng. Abstr.) **(Chi)**
[Effects of fimbria–fornix lesion on the temporal discrimination revealed by peak interval procedure in rats] Hata T, et al. **Shinrigaku Kenkyu** 1998 Oct;69(4):304–9 (Eng. Abstr.) **(Jpn)**
[Increasing threshold of the epileptiform activity in the CA1 field of hippocampal slices of Krushinskii–Molodkina rats as protective adaptation mechanism] Sem'ianov AV, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May–Jun; 84(5–6):450–9 (Eng. Abstr.) **(Rus)**
[Long-lasting reduction of the threshold of epileptiform discharges induced by periodic removal of extracellular Mg2+ in slices of CA1 field of the rat hippocampus] Sem'ianov AV, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Dec;84(12):1438–42 **(Rus)**

RADIATION EFFECTS

Effects of prenatal gamma-irradiation on postnatal astrogliogenesis in the hippocampal formation of rat. Janeczko K, et al. **Brain Res** 1999 Jan 23;816(2):628–32
Weak ELF magnetic field effects on hippocampal rhythmic slow activity. Jenrow KA, et al. **Exp Neurol** 1998 Oct; 153(2):328–34
Neuron loss in the mouse hippocampus following prenatal injection of tritiated thymidine or saline. Schmitz C, et al. **Int J Dev Neurosci** 1999 Jun;17(3):185–90
Evidence for involvement of Bax and p53, but not caspases, in radiation-induced cell death of cultured postnatal hippocampal neurons. Johnson MD, et al. **J Neurosci Res** 1998 Dec 15;54(6):721–33

RADIOGRAPHY

Transient amnesia after perimesencephalic haemorrhage: the role of enlarged temporal horns. Hop JW, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):590–3

RADIONUCLIDE IMAGING

Correlation of hippocampal neuronal density and FDG-PET in mesial temporal lobe epilepsy. Foldvary N, et al. **Epilepsia** 1999 Jan;40(1):26–9
Muscarinic receptor loss and preservation of presynaptic cholinergic terminals in hippocampal sclerosis. Pennell PB, et al. **Epilepsia** 1999 Jan;40(1):38–46
Hippocampal PET activations of memory encoding and retrieval: the HIPER model. Lepage M, et al. **Hippocampus** 1998;8(4):313–22
Functional neuroanatomy of semantic memory: recognition of semantic associations. Ricci PT, et al. **Neuroimage** 1999 Jan;9(1):88–96

SECRETION

Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine. Bacciottini L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S63–4

SURGERY

Unco-parahippocampectomy for direct surgical treatment of downward transtentorial herniation. Mori K, et al. **Acta Neurochir (Wien)** 1998;140(12):1239–44
Intrahippocampal grafts containing cholinergic and serotonergic fetal neurons ameliorate spatial reference but not working memory in rats with fimbria-fornix/cingular bundle lesions. Balse E, et al. **Brain Res Bull** 1999 Jul 1; 49(4):263–72
Pig fetal septal neurons implanted into the hippocampus of aged or cholinergic deafferented rats grow axons and form cross-species synapses in appropriate target regions. Deacon T, et al. **Cell Transplant** 1999 Jan–Feb;8(1):111–29
Morris water maze analysis of 192-IgG-saporin-lesioned rats and porcine cholinergic transplants to the hippocampus. LeBlanc CJ, et al. **Cell Transplant** 1999 Jan–Feb; 8(1):131–42
Increased neocortical spiking and surgical outcome after selective amygdalo-hippocampectomy. Wennberg RA, et al. **Electroencephalogr Clin Neurophysiol Suppl** 1998; 48:105–11 (23 ref.)
Seizure frequency and duration of epilepsy are not risk factors for postoperative seizure outcome in patients with hippocampal sclerosis. Kilpatrick C, et al. **Epilepsia** 1999 Jul;40(7):899–903
Right hippocampal contribution to visual memory: a presurgical and postsurgical study in patients with temporal lobe epilepsy. Gleissner U, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):665–9
NGF prevents changes in rat brain glutathione-related enzymes following transection of the septohippocampal pathway. Cruz-Aguado R, et al. **Neurochem Int** 1999 Feb; 34(2):125–30
Retrolabyrinthine presigmoid transpetrosal approach for selective subtemporal amygdalohippocampectomy. Hori T, et al. **Neurol Med Chir (Tokyo)** 1999 Mar;39(3):214–24; discussion 224–5
Limbic ERPs predict verbal memory after left-sided hippocampectomy. Grunwald T, et al. **Neuroreport** 1998 Oct 26;9(15):3375–8
The potentiation of amphetamine-induced hyperlocomotion by fimbria-fornix lesions in rats is abolished by intrahippocampal grafts rich in serotonergic neurons. Balse E, et al. **Neurosci Lett** 1999 Apr 16;265(2):79–82
Can neuronavigation contribute to standardization of selective amygdalohippocampectomy? Van Roost D, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):239–42
[Short-term effects of septo-hippocampal pathway transsection and cerebrolysin effects on glutathione-related enzymes in the rat brain] Cruz R, et al. **Rev Neurol** 1998 Apr;26(152):551–4 (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Expression of L1 and PSA during sprouting and regeneration in the adult hippocampal formation. Aubert I, et al. **J Comp Neurol** 1998 Sep 14;399(1):1–19

ULTRASTRUCTURE

Alterations in the density of excrescences in CA3 neurons of hippocampus in rats subjected to self-stimulation experience. Shankaranarayana Rao BS, et al. **Brain Res** 1998 Sep 7;804(2):320–4
Synaptogenesis via dendritic filopodia in developing hippocampal area CA1. Fiala JC, et al. **J Neurosci** 1998 Nov 1;18(21):8900–11
Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. Wong TP, et al. **J Neurosci** 1999 Apr 1;19(7):2706–16
Large receptor reserve for cannabinoid actions in the central nervous system. Gifford AN, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):478–83
Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. Yang XC, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):544–9
Rat and human hippocampal alpha5 subunit-containing gamma-aminobutyric AcidA receptors have alpha5 beta3 gamma2 pharmacological characteristics. Sur C, et al. **Mol Pharmacol** 1998 Nov;54(5):928–33
Energy metabolism of synaptosomal subpopulations from different neuronal systems of rat hippocampus: effect of L-acetylcarnitine administration in vivo. Gorini A, et al. **Neurochem Res** 1999 May;24(5):617–24
Cell type and pathway dependence of synaptic AMPA receptor number and variability in the hippocampus. Nusser Z, et al. **Neuron** 1998 Sep;21(3):545–59
Synapses in hippocampus occupy only 1–2% of cell membranes and are spaced less than half-micron apart: a quantitative ultrastructural analysis with discussion of physiological implications. Rusakov DA, et al. **Neuropharmacology** 1998 Apr–May;37(4–5):513–21
Ultrastructural analysis of the progression of neurodegeneration in the septum following fimbria-fornix transection. Ginsberg SD, et al. **Neuroscience** 1998 Oct; 86(4):1259–72
Increased numerical density of synapses in CA3 region of hippocampus and molecular layer of motor cortex after self-stimulation rewarding experience. Rao BS, et al. **Neuroscience** 1999;91(3):799–803
Quantitative fine-structural analysis of olfactory cortical synapses. Schikorski T, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4107–12
[Delayed brain injury induced by Bordetella pertussis in rats] Chen X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(4):301–3 (Eng. Abstr.) **(Chi)**
[The role of certain sections of the central nervous system in the genesis of sudden death] Dubrovin IA, et al. **Sud Med Ekspert** 1999 Jul–Aug;42(4):19–21 (Eng. Abstr.) **(Rus)**

VIROLOGY

Rabies virus entry into cultured rat hippocampal neurons. Lewis P, et al. **J Neurocytol** 1998 Aug;27(8):559–73
Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Ehrengruber MU, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7041–6

HIPPOCRATIC OATH

Articulating the concept of palliative care: philosophical and theological perspectives. Janssens RM, et al. **J Palliat Care** 1999 Summer;15(2):38–44 (29 ref.)
Hippocrates and contemporary medicine. Fishman AP. **Trans Stud Coll Physicians Phila** 1998 Dec;20:41–50
[The Hippocratic Oath not sworn (letter)] Bock KD. **Internist (Berl)** 1999 Jul;40(7):819 **(Ger)**
[Technology and beneficence toward the patient] Sanz Ortiz J. **Med Clin (Barc)** 1999 Mar 20;112(10):380–3 **(Spa)**
[Analysis of the ethical principles in medical oaths used by medical schools of Argentina in relation to the Hippocratic Oath] Rancich AM, et al. **Medicina (B Aires)** 1998; 58(2):147–52 (Eng. Abstr.) **(Spa)**
[Hippocratic philosophy] Cruz-Coke R. **Rev Med Chil** 1999 May;127(5):611–4 (Eng. Abstr.) **(Spa)**
[The Hippocratic Oath (editorial)] Goic A. **Rev Med Chil** 1998 Oct;126(10):1151–2 (Eng. Abstr.) **(Spa)**

HIPPOTRAGINES see **ANTELOPES**

HIPPURATES

ANALYSIS

Assay of acetylsalicylic acid and three of its metabolites in human plasma and urine using non-aqueous capillary electrophoresis with reversed electroosmotic flow. Hansen SH, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1155-60

CHEMICAL SYNTHESIS

Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid. Jung YJ, et al. **Arch Pharm Res** 1998 Apr;21(2):174-8

METABOLISM

Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. James MO, et al. **Drug Metab Dispos** 1998 Nov;26(11):1134-43

Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Krivošíková Z, et al. **Physiol Res** 1998;47(3):177-83

PHARMACOKINETICS

Disposition of 4-methylbenzoylglycine in rat isolated perfused kidney and effects of hippurates on renal mitochondrial metabolism. Masereeuw R, et al. **J Pharm Pharmacol** 1998 Dec;50(12):1397-404

Differences in excretion of hippurate, as a metabolite of benzoate and as an administered species, in the single-pass isolated perfused rat kidney explained [published erratum appears in J Pharmacol Exp Ther 1999 Jun;289(3):following 1696] Geng W, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):597-606

PHARMACOLOGY

Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin. Dasgupta A, et al. **Ther Drug Monit** 1998 Dec;20(6):658-62

URINE

Validation of hippuric acid as a biomarker of toluene exposure. Duydu Y, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):1-8

Possible preferential metabolism of xylene isomers following occupational exposure to mixed xylenes. Miller MJ, et al. **Int Arch Occup Environ Health** 1999 Mar;72(2):89-97

Gas chromatography-electron-capture detection of urinary methylhippuric acid isomers as biomarkers of environmental exposure to xylene. Buratti M, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19; 723(1-2):95-104

Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. Loizou GD, et al. **Toxicol Sci** 1999 Apr;48(2):170-9

[The simultaneous determination of hippuric acid, o-, m-, p-methylhippuric acids, mandelic acid and phenylglyoxylic acid in urine by HPLC] Burrini C. **Med Lav** 1998 Sep-Oct; 89(5):404-11 (Eng. Abstr.) **(Ita)**

HIRSCHSPRUNG DISEASE

Total colonic aganglionosis. Jasonni V, et al. **Semin Pediatr Surg** 1998 Aug;7(3):174-80 (39 ref.)

Intestinal neuronal dysplasia. Puri P, et al. **Semin Pediatr Surg** 1998 Aug;7(3):181-6 (39 ref.)

COMPLICATIONS

Anencephaly-associated aganglionosis. Mathew A. **Am J Med Genet** 1998 Dec 28;80(5):518-20

Colonic atresia associated with Hirschsprung's disease: it is not a diagnostic challenge. Akgür FM, et al. **Eur J Pediatr Surg** 1998 Dec;8(6):378-9 (11 ref.)

Bilateral iris sector heterochromia with or without Hirschsprung's disease [letter] Lai JS, et al. **Eye** 1998;12 (Pt 6):1024-7

Acute appendicitis in neonates: complication or morbus sui generis? Stiefel D, et al. **Pediatr Surg Int** 1998 Nov; 14(1-2):122-3

Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes. Moore SW, et al. **Semin Pediatr Surg** 1998 Aug;7(3):156-61 (71 ref.)

Enterocolitis. Teitelbaum DH, et al. **Semin Pediatr Surg** 1998 Aug;7(3):162-9 (59 ref.)

DIAGNOSIS

Hirschsprung disease and other enteric dysganglionoses. Kapur RP. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):225-73 (307 ref.)

Anorectal manometry during the neonatal period: its specificity in the diagnosis of Hirschsprung's disease. Emir H, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):101-3

Preoperative enzymo-histochemical diagnosis of dysganglionoses associated with anorectal malformations (ARM) with recto-vestibular and recto-perineal fistula. Martucciello G, et al. **Eur J Pediatr Surg** 1999 Apr; 9(2):96-100

Aganglionosis of the appendix: is it reliable for diagnosis of total colonic aganglionosis? Shih TY, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):353-4

Organic causes of constipation in infants and children. Nowicki MJ, et al. **Pediatr Ann** 1999 May;28(5):293-300 (50 ref.)

The approach to common abdominal diagnoses in infants and children. Part II. Pearl RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1287-326, vii (130 ref.)

Diagnosis of Hirschsprung's disease [letter] Giles AP, et al. **Pediatr Dev Pathol** 1998 Nov-Dec;1(6):571-2

NADPH-diaphorase histochemical staining of suction rectal biopsies in the diagnosis of Hirschsprung's disease and allied disorders. Miyazaki E, et al. **Pediatr Surg Int** 1998 Sep; 13(7):464-7

EPIDEMIOLOGY

Congenital malformations and perinatal morbidity associated with intestinal neuronal dysplasia. Berger S, et al. **Pediatr Surg Int** 1998 Sep;13(7):474-9

ETIOLOGY

Hirschsprung disease and other enteric dysganglionoses. Kapur RP. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):225-73 (307 ref.)

Mast cells and gut nerve development: implications for Hirschsprung's disease and intestinal neuronal dysplasia. Kobayashi H, et al. **J Pediatr Surg** 1999 Apr;34(4):543-8

Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Takahashi M, et al. **Recent Results Cancer Res** 1998; 154:229-36 (22 ref.)

Hirschsprung's disease: a search for etiology. Puri P, et al. **Semin Pediatr Surg** 1998 Aug;7(3):140-7 (105 ref.)

[Megacolon in adults--the spectrum of underlying intestinal innervation disorders] Wedel T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:979-81 (Eng. Abstr.) **(Ger)**

[Endothelin B receptor system and Hirschsprung disease] Inoue M, et al. **Nippon Rinsho** 1998 Jul;56(7):1876-80 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The role of chronic colitis in the pathogenesis of Hirschsprung 's disease in children] Kolomeitsev PI, et al. **Khirurgiia (Mosk)** 1999;(6):56-9 (Eng. Abstr.) **(Rus)**

GENETICS

A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with Hirschsprung disease, cardiac defects, and autonomic dysfunction [letter] Hofstra RM, et al. **Am J Hum Genet** 1999 Jan;64(1):304-8

Mutations in the endothelin-receptor B gene in Hirschsprung disease in Sweden [letter] Svensson PJ, et al. **Clin Genet** 1999 Mar;55(3):215-7

Low frequency of RET mutations in Hirschsprung disease in Sweden. Svensson PJ, et al. **Clin Genet** 1998 Jul; 54(1):39-44

The Sox10(Dom) mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. Southard-Smith EM, et al. **Genome Res** 1999 Mar;9(3):215-25

Oncological implications of RET gene mutations in Hirschsprung's disease. Sijmons RH, et al. **Gut** 1998 Oct; 43(4):542-7

Phenotypic variation in a family with mutations in two Hirschsprung-related genes (RET and endothelin receptor B). Svensson PJ, et al. **Hum Genet** 1998 Aug;103(2):145-8

Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? [letter] Takahashi M, et al. **Hum Mutat** 1999;13(4):331-6

A Hirschsprung disease locus at 22q11? Kerstjens-Frederikse WS, et al. **J Med Genet** 1999 Mar;36(3):221-4

Hirschsprung disease, microcephaly, mental retardation, and characteristic facial features: delineation of a new syndrome and identification of a locus at chromosome 2q22-q23. Mowat DR, et al. **J Med Genet** 1998 Aug;35(8):617-23

Investigation of germline GFR alpha-1 mutations in Hirschsprung disease. Myers SM, et al. **J Med Genet** 1999 Mar;36(3):217-20

Histochemical and genetic analysis of colonic mucin glycoproteins in Hirschsprung's disease. Aslam A, et al. **J Pediatr Surg** 1999 Feb;34(2):330-3

Molecular biology for the pediatric surgeon. Boulanger SC, et al. **J Pediatr Surg** 1999 Jun;34(6):917-30

Mutational analysis of the endothelin-B receptor gene in Japanese Hirschsprung's disease. Inoue M, et al. **J Pediatr Surg** 1998 Aug;33(8):1206-8

Altered endothelin-3 and endothelin-B receptor mRNA expression in Hirschsprung's disease. Oue T, et al. **J Pediatr Surg** 1999 Aug;34(8):1257-60

Familial megacecum and colon in the rat: a new model of gastrointestinal neuromuscular dysfunction. Lipman NS, et al. **Lab Anim Sci** 1998 Jun;48(3):243-52

Genomic structure of the gene for the SH2 and pleckstrin homology domain-containing protein GRB10 and evaluation of its role in Hirschsprung disease. Angrist M, et al. **Oncogene** 1998 Dec 10;17(23):3065-70

A heterozygous frameshift mutation in the endothelin-3 (EDN-3) gene in isolated Hirschsprung's disease. Svensson PJ, et al. **Pediatr Res** 1999 May;45(5 Pt 1):714-7

Genetic aspects of Hirschsprung's disease. Kusafuka T, et al. **Semin Pediatr Surg** 1998 Aug;7(3):148-55 (97 ref.)

Hirschsprung's disease: genetic and functional associations of Down's and Waardenburg syndromes. Moore SW, et al. **Semin Pediatr Surg** 1998 Aug;7(3):156-61 (71 ref.)

Hirschsprung's disease in an adult patient with familial occurrence: report of a case. Nagashima T, et al. **Surg Today** 1998;28(9):943-7

Point nucleotidic changes in both the RET proto-oncogene and the endothelin-B receptor gene in a Hirschsprung disease patient associated with Down syndrome. Sakai T, et al. **Tohoku J Exp Med** 1999 Jan;187(1):43-7

[Genes and genetics in Hirschsprung's disease] Maas SM, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1352-6 (24 ref.) (Eng. Abstr.) **(Dut)**

[From monogenic to polygenic: model of Hirschsprung disease] Salomon R, et al. **Pathol Biol (Paris)** 1998 Nov; 46(9):705-7 (0 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

Treatment of Hirschsprung's disease [letter; comment] Swenson O. **J Pediatr Surg** 1998 Dec;33(12):1849. Comment on: J Pediatr Surg 1998 Jun;33(6):951.

METABOLISM

Both ET(A) and ET(B) receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ET(B) receptor-deficient rats (aganglionosis rats). Sasaki Y, et al. **Eur J Neurosci** 1998 Sep;10(9):2984-93

Histochemical and genetic analysis of colonic mucin glycoproteins in Hirschsprung's disease. Aslam A, et al. **J Pediatr Surg** 1999 Feb;34(2):330-3

Diagnosis of Hirschsprung's disease [letter] Giles AP, et al. **Pediatr Dev Pathol** 1998 Nov-Dec;1(6):571-2

Lack of a docking mechanism for neurotransmitter release in the aganglionic segment of bowel in patients with Hirschsprung's disease. Kakita Y, et al. **Pediatr Surg Int** 1998 Oct;13(8):581-3

PATHOLOGY

Rectal biopsy in the investigation of constipation. Ghosh A, et al. **Arch Dis Child** 1998 Sep;79(3):266-8

A correlative morphometric and clinical investigation of hypoganglionosis of the colon in children. Meier-Ruge WA, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):67-74

Functional and morphological examination of ganglionic and aganglionic distal gut from the lethal spotted mouse. Sandgren K, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):234-9

Ultrastructural features of nerve fascicles and basal lamina abnormalities in Hirschsprung's disease. Wedel T, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):75-82

Rectal biopsy for diagnosis of intestinal neuronal dysplasia in children: a prospective multicentre study on interobserver variation and clinical outcome. Koletzko S, et al. **Gut** 1999 Jun;44(6):853-61

Clinical quiz. Long-segment Hirschsprung's disease (total colonic aganglionosis). Tozzi A, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):546,559

Distribution of c-Kit immunopositive cells in normal human colon and in Hirschsprung's disease. Horisawa M, et al. **J Pediatr Surg** 1998 Aug;33(8):1209-14

Extrinsic nerve strands in the aganglionic segment of Hirschsprung's disease. Watanabe Y, et al. **J Pediatr Surg** 1998 Aug;33(8):1233-7

Morphological investigation of the enteric nervous system in Hirschsprung's disease and hypoganglionosis using whole-mount colon preparation. Watanabe Y, et al. **J Pediatr Surg** 1999 Mar;34(3):445-9

Whole-mount NADPH-diaphorase histochemistry is a reliable technique for the intraoperative evaluation of extent of aganglionosis. Nemeth L, et al. **Pediatr Surg Int** 1999;15(3-4):195-7

Altered intramuscular innervation and synapse formation in internal sphincter achalasia. Oue T, et al. **Pediatr Surg Int** 1999;15(3-4):192-4

Qualitative and quantitative analysis of synapses in Hirschsprung's disease. Wiedenmann B, et al. **Pediatr Surg Int** 1998 Sep;13(7):468-73

[Hirschsprung's disease: neurocristopathy of cell migration and differentiation (letter; comment)] Aguirre Garcia J. **Rev Gastroenterol Mex** 1998 Oct-Dec;63(4):250. Comment on: Rev Gastroenterol Mex 1997 Oct-Dec;62(4):287-92. **(Spa)**

PHYSIOPATHOLOGY

Autonomic dysfunction in children with Hirschsprung's disease. Staiano A, et al. **Dig Dis Sci** 1999 May;44(5):960-5

Functional and morphological examination of ganglionic and aganglionic distal gut from the lethal spotted mouse. Sandgren K, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):234-9

Intestinal transit time in children with intestinal neuronal malformations mimicking Hirschsprung's disease. Ure BM, et al. **Eur J Pediatr Surg** 1999 Apr;9(2):91-5

Endothelins, pseudo-obstruction and Hirschsprung's disease [comment] Milla PJ. **Gut** 1999 Feb;44(2):148-9. Comment on: Gut 1999 Feb;44(2):246-52.

Regulation of the enteric nervous system in the internal anal sphincter in Hirschsprung's disease. Tomita R.

HIRSCHSPRUNG DISEASE

Hepatogastroenterology 1999 Jan-Feb;46(25):215-9
Long-term outcome and colonic motility after the Duhamel procedure for Hirschsprung's disease. Baillie CT, et al. **J Pediatr Surg** 1999 Feb;34(2):325-9
Hypoganglionosis. Schärli AF, et al. **Semin Pediatr Surg** 1998 Aug;7(3):187-91
A role of peptidergic nerves in the internal anal sphincter of Hirschsprung's disease. Tomita R, et al. **Surgery** 1999 Jan;125(1):60-6

RADIOGRAPHY

Pediatric case of the day. Total colonic Hirschsprung's disease. Guidone P, et al. **AJR Am J Roentgenol** 1999 Sep; 173(3):815, 819-20
Clinical quiz. Long-segment Hirschsprung's disease (total colonic aganglionosis). Tozzi A, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):546,559
Allergic colitis: a mimic of Hirschsprung disease. Bloom DA, et al. **Pediatr Radiol** 1999 Jan;29(1):37-41

SURGERY

Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: a new gold standard. Georgeson KE, et al. **Ann Surg** 1999 May;229(5):678-82; discussion 682-3
Treatment of total colonic aganglionosis by a modified Martin procedure--a preliminary report. Ajuluchuku EU, et al. **Eur J Pediatr Surg** 1998 Oct;8(5):317-9
Redo operations of Hirschsprung's disease. Sarioğlu A, et al. **Int Surg** 1998 Oct-Dec;83(4):333-5
Longterm outcomes and quality of life after Z-shaped anastomosis for Hirschsprung's disease. Suita S, et al. **J Am Coll Surg** 1998 Dec;187(6):577-83
Clinical and manometric evaluation of postoperative fecal soiling in patients with Hirschsprung's disease. Hsu WM, et al. **J Formos Med Assoc** 1999 Jun;98(6):410-4
Perineal one-stage pull-through for Hirschsprung's disease. Albanese CT, et al. **J Pediatr Surg** 1999 Mar;34(3):377-80
Long-term outcome and colonic motility after the Duhamel procedure for Hirschsprung's disease. Baillie CT, et al. **J Pediatr Surg** 1999 Feb;34(2):325-9
Transanal endorectal pull-through for Hirschsprung's disease. De la Torre-Mondragón L, et al. **J Pediatr Surg** 1998 Aug;33(8):1283-6
Endosonographic study of anal sphincters in patients after surgery for Hirschsprung's disease. Kuwahara M, et al. **J Pediatr Surg** 1999 Mar;34(3):450-3
Transanal one-stage Soave procedure for infants with Hirschsprung's disease. Langer JC, et al. **J Pediatr Surg** 1999 Jan;34(1):148-51; discussion 152
Repeat pull-through surgery for complicated Hirschsprung's disease: indications, techniques, and results. Langer JC. **J Pediatr Surg** 1999 Jul;34(7):1136-41
Extra-anal mucosectomy: laparascopic-assisted endorectal pull-through using a prolapsing technique. Morikawa Y, et al. **J Pediatr Surg** 1998 Nov;33(11):1679-81
Posterior sagittal abdominoperineal pull-through: a new approach to definitive treatment of Hirschsprung's disease--initial experience. Niedzielski J. **J Pediatr Surg** 1999 Apr;34(4):572-6
Effects of anal invasive treatment and incontinence on mental health and psychosocial functioning of adolescents with Hirshsprung's disease and low anorectal anomalies [letter; comment] Peña A, et al. **J Pediatr Surg** 1998 Nov; 33(11):1732. Comment on: J Pediatr Surg 1998 Mar;33(3):468-75.
Primary Swenson pull-through compared with multiple-stage pull-through in the neonate. Santos MC, et al. **J Pediatr Surg** 1999 Jul;34(7):1079-81
Management and long-term follow-up of infants with total colonic aganglionosis. Tsuji H, et al. **J Pediatr Surg** 1999 Jan;34(1):158-61; discussion 162
Reoperation for Hirschsprung's disease. Weber TR, et al. **J Pediatr Surg** 1999 Jan;34(1):153-6; discussion 156-7
Repeat pull-through for Hirschsprung's disease. Wilcox DT, et al. **J Pediatr Surg** 1998 Oct;33(10):1507-9
Long-term outcome after Hirschsprung's disease: patients' perspectives. Yanchar NL, et al. **J Pediatr Surg** 1999 Jul; 34(7):1152-60
Modified Duhamel operation using a newly designed crushing clamp. Bahador A. **Pediatr Surg Int** 1999 Jul; 15(5-6):445-6
A male newborn with colonic atresia and total colonic aganglionosis. Siu KL, et al. **Pediatr Surg Int** 1999; 15(2):141-2
Neonatal Soave endorectal pull-through for Hirschsprung's disease. Sidler D, et al. **S Afr J Surg** 1999 May;37(2):47-9; discussion 49-50
One-stage neonatal reconstruction without stoma for Hirschsprung's disease. Bianchi A. **Semin Pediatr Surg** 1998 Aug;7(3):170-3
Laparoscopic pull-through procedure for Hirschsprung's disease. Jona JZ, et al. **Semin Pediatr Surg** 1998 Nov; 7(4):228-31
A laparoscopic pull-through operation for Hirschsprung's disease: report of two infant cases. Hirose R, et al. **Surg Today** 1999;29(4):371-4
Stone's enterostomy crushing clamp for modified Duhamel's procedure. Agarwala S, et al. **Trop Gastroenterol** 1998 Oct-Dec;19(4):164-6
Tube caecostomies--a fresh look in paediatric practice. Hesse AA, et al. **West Afr J Med** 1998 Oct-Dec;17(4):261-3
[Management of Hirschsprung's disease during the neonatal period] de Lagausie P, et al. **Ann Chir** 1998;52(10):1028-32 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Endosonographic study of anal sphincters in patients after surgery for Hirschsprung's disease. Kuwahara M, et al. **J Pediatr Surg** 1999 Mar;34(3):450-3

HIRSUTISM

see related
HYPERTRICHOSIS
The diagnosis and treatment of hirsutism. de Berker D. **Practitioner** 1999 Jun;243(1599):493-8, 501 (3 ref.)

BLOOD

Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism. Escobar-Morreale HF, et al. **Fertil Steril** 1998 Dec;70(6):1090-100
Transient hyperandrogenemia and its relation to ovulation. Martins JM, et al. **Fertil Steril** 1998 Oct;70(4):664-70

COMPLICATIONS

SAHA syndrome: female androgenetic alopecia and hirsutism. Camacho FM. **Exp Dermatol** 1999 Aug; 8(4):304-5

DIAGNOSIS

ACOG technical bulletin. Evaluation and treatment of hirsute women. Number 203 -- March 1995 (replaces no. 103, April 1987). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Jun;49(3):341-6
Prostate-specific antigen (PSA) in women. Yu H, et al. **J La State Med Soc** 1999 Apr;151(4):209-13 (54 ref.)
Is the free androgen index a useful clinical marker in male patients? Brannian JD, et al. **S D J Med** 1998 Dec; 51(12):449-51
[Updated aspects of hirsutism] Sirakov M. **Akush Ginekol (Sofiia)** 1998;37(2):49-52 (10 ref.) **(Bul)**

DRUG THERAPY

Finasteride treatment for one year in 35 hirsute patients. Bayram F, et al. **Exp Clin Endocrinol Diabetes** 1999; 107(3):195-7
Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Falsetti L, et al. **Fertil Steril** 1999 Jul; 72(1):41-6
Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fruzzetti F, et al. **Fertil Steril** 1999 Mar;71(3):445-51
Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Paoletti AM, et al. **Fertil Steril** 1999 Sep;72(3):448-53
Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Pazos F, et al. **Fertil Steril** 1999 Jan;71(1):122-8
Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Dahlgren E, et al. **Hum Reprod** 1998 Oct; 13(10):2706-11
ACOG technical bulletin. Evaluation and treatment of hirsute women. Number 203 -- March 1995 (replaces no. 103, April 1987). American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1995 Jun;49(3):341-6
Recurrence rate of hirsutism after 3 different antiandrogen therapies. Yücelten D, et al. **J Am Acad Dermatol** 1999 Jul;41(1):64-8
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. Moghetti P, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1250-4
A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. Venturoli S, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1304-10
Effect of finasteride in idiopathic hirsutism. Faloia E, et al. **J Endocrinol Invest** 1998 Nov;21(10):694-8
Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. Müderris II, et al. **J Endocrinol Invest** 1999 Mar;22(3):165-8
Fulminant liver failure associated with flutamide therapy for hirsutism [letter; comment] Andrade RJ, et al. **Lancet** 1999 Mar 20;353(9157):983. Comment on: Lancet 1997 Jan 18;349(9046):191-5.

ENZYMOLOGY

Results of the ACTH stimulation test in hirsute women. Erel CT, et al. **J Reprod Med** 1999 Mar;44(3):247-52

EPIDEMIOLOGY

Prevalence of idiopathic hirsutism. Carmina E. **Eur J Endocrinol** 1998 Oct;139(4):421-3

ETIOLOGY

Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. Fox R. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):63-8
Prevalence of idiopathic hirsutism. Carmina E. **Eur J Endocrinol** 1998 Oct;139(4):421-3
Hirsutism and weakness in a young woman. Archer TP, et al. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):165-6, 169-70
[Hirsutism. Polycystic ovaries with suspected metabolic syndrome] Zwimpfer J. **Schweiz Rundsch Med Prax** 1999 Jun 10;88(24):1093-5 **(Ger)**
[The clinical value of 3 alpha-androstanediol-glucuronide in hirsute women] Joura EA, et al. **Wien Klin Wochenschr** 1997 Dec 12;109(23):919-21 (Eng. Abstr.) **(Ger)**

GENETICS

Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. Vottero A, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1091-5
Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. Sawaya ME, et al. **J Cutan Med Surg** 1998 Jul;3(1):9-15
Glucocorticoid resistance in premature pubarche and adolescent hyperandrogenism. Witchel SF, et al. **Mol Genet Metab** 1999 Feb;66(2):137-41
[Non-classical 21-hydroxylase deficiency: clinico-hormonal discrepancies and intrafamilial phenotypic variability] Relimpio Astolfi F, et al. **Rev Clin Esp** 1999 Jun; 199(6):366-8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Analysis of gonadotropin pulsatility in hirsute women with normal menstrual cycles and in women with polycystic ovary syndrome. Minanni SL, et al. **Fertil Steril** 1999 Apr; 71(4):675-83
Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. Vottero A, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1091-5

RADIOTHERAPY

The removal of unwanted hair using a ruby laser. Gault DT, et al. **Br J Plast Surg** 1999 Apr;52(3):173-7

THERAPY

Hair removal in 40 hirsute women with an intense laser-like light source. Schroeter CA, et al. **Eur J Dermatol** 1999 Jul-Aug;9(5):374-9
Optical hair removal. Ort RJ, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):149-58 (42 ref.)
[Androgenetic alopecia, hirsutism and hypertrichosis] Trüeb RM, et al. **Ther Umsch** 1999 Apr;56(4):219-24 (21 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Corynebacterium bovis infection in immunocompetent hirsute mice [see comments] Gobbi A, et al. **Lab Anim Sci** 1999 Apr;49(2):209-11. Comment in: Lab Anim Sci 1999 Apr;49(2):132-3.

HIRUDIN

Bioengineering of a novel small diameter polyurethane vascular graft with covalently bound recombinant hirudin. Phaneuf MD, et al. **ASAIO J** 1998 Sep-Oct;44(5):M653-8
The influence of hirudin on plasma fibrinogen assays [letter] Dempfle CE, et al. **Thromb Haemost** 1998 Oct;80(4):716-7
Insertion of the Asp-Ser/Phe sequence in the P' position of hirutonin provides molecules having both antithrombin and disintegrin activity. Leblond L, et al. **Thromb Res** 1999 Feb 15;93(4):171-81

ADVERSE EFFECTS

Prolonged bleeding after cardiopulmonary bypass with recombinant hirudin in heart transplantation [letter] Kwapisz MM, et al. **Eur J Cardiothorac Surg** 1999 Aug; 16(2):256-7
Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Dickneite G, et al. **Thromb Haemost** 1998 Jul;80(1):192-8
[Allergy to heparin, heparinoids, and recombinant hirudin. Diagnostic and therapeutic alternatives] Jappe U, et al. **Hautarzt** 1999 Jun;50(6):406-11 (49 ref.) (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. Kleiman NS, et al. **Am Heart J** 1999 Jan; 137(1):12-23
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Bates SM, et al. **Am J Cardiol** 1998 Oct 22; 82(8B):12P-18P (64 ref.)
A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction

angina. Hirulog Angioplasty Study Investigators. Bittl JA, et al. **Am J Cardiol** 1998 Oct 22;82(8B):43P–49P
Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Bittl JA, et al. **Am J Cardiol** 1998 Oct 22; 82(8B):50P–56P
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)
Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. White HD. **Am J Cardiol** 1998 Oct 22; 82(8B):57P–62P
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. Yusuf S. **Am J Cardiol** 1999 Sep 2;84(5A):20M–25M
Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Bossavy JP, et al. **Arterioscler Thromb Vasc Biol** 1999 May; 19(5):1348–53
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. White HD, et al. **Aust N Z J Med** 1998 Aug;28(4):551–4
Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Greinacher A, et al. **Circulation** 1999 Aug 10;100(6):587–93
Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Greinacher A, et al. **Circulation** 1999 Jan 5–12;99(1):73–80
FDA panel votes against approval for bivalirudin [news] Piña I. **Circulation** 1999 Mar 16;99(10):1277
A recombinant prodrug type approach for triggered delivery of streptokinase. Wang H, et al. **J Controlled Release** 1999 May 1;59(1):119–22
Sites of elimination and pharmacokinetics of recombinant [131I]lepirudin in baboons. Meiring SM, et al. **J Pharm Sci** 1999 May;88(5):523–9
Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators [see comments] **Lancet** 1999 Feb 6;353(9151):429–38. Comment in: Lancet 1999 Feb 6;353(9151):423–4.
Antithrombotic stent coatings: hirudin/iloprost combination. Alt E, et al. **Semin Interv Cardiol** 1998 Sep-Dec; 3(3–4):177–83 (40 ref.)
Treatment of hirudin overdosage in a patient with chronic renal failure [letter] Bauersachs RM, et al. **Thromb Haemost** 1999 Feb;81(2):323–4
Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors. Gandossi E, et al. **Thromb Haemost** 1998 Nov; 80(5):840–4
Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y, et al. **Thromb Haemost** 1999 Feb;81(2):250–5
The antithrombotic effect of potent bifunctional thrombin inhibitors based on hirudin sequence, P551 and P532, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Yamashita T, et al. **Thromb Res** 1998 Jun 1;90(5):199–206
[Refludan. First line of treatment for type II heparin-induced thrombopenia] Camez A. **Presse Med** 1998 Jun;27 Suppl 2:28–30 (Eng. Abstr.) **(Fre)**
[Refludan: pharmacologic surveillance study] Winicki J. **Presse Med** 1998 Jun;27 Suppl 2:31–2 **(Fre)**
[Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia] **Chirurg** 1998 Nov;69(11 Suppl Massnahme):1–4 **(Ger)**
[Heparin-induced thrombocytopenia type II. Intra- and postoperative lepirudin treatment in acute ischemia of the extremities (see comments)] Schmidt O, et al. **Dtsch Med Wochenschr** 1998 Oct 9;123(41):1207–10 (Eng. Abstr.). Comment in: Dtsch Med Wochenschr 1999 Jan 22;124(3):67. **(Ger)**
[Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA--treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA] Laubenthal FC, et al. **Z Kardiol** 1999 Feb;88(2):141–6 (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

Synthesis and characterization of more potent analogues of hirudin fragment 1–47 containing non-natural amino acids. De Filippis V, et al. **Biochemistry** 1998 Sep 29; 37(39):13507–15

CHEMISTRY

Synthesis and characterization of more potent analogues of hirudin fragment 1–47 containing non-natural amino acids. De Filippis V, et al. **Biochemistry** 1998 Sep 29; 37(39):13507–15
Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH. Gietz U, et al. **Pharm Res** 1998 Sep;15(9):1456–62

GENETICS

Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. Riesbeck K, et al. **Circulation** 1998 Dec 15;98(24):2744–52
Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins. Rade JJ, et al. **Gene Ther** 1999 Mar;6(3):385–92

HISTORY

[Once upon a time there was hirudin...] Samama MM. **Presse Med** 1998 Jun;27 Suppl 2:5–6 **(Fre)**

IMMUNOLOGY

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Huhle G, et al. **Br J Haematol** 1999 Jul;106(1):195–201
Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Song X, et al. **Circulation** 1999 Oct 5;100(14):1528–32

METABOLISM

General numerical treatment of competitive binding kinetics: application to thrombin-dehydrothrombin-hirudin. KuzmicP. **Anal Biochem** 1999 Feb 1;267(1):17–23
Destabilase complexes--natural liposome produced by medicinal leeches Hirudo medicinalis. Nikonov GI, et al. **Fundam Clin Pharmacol** 1999;13(1):102–6
The platelet high affinity binding site for thrombin mimics hirudin, modulates thrombin-induced platelet activation, and is distinct from the glycoprotein Ib-IX-V complex. Hayes KL, et al. **J Biol Chem** 1999 Jan 8;274(2):972–80
Binding of hirudin to meizothrombin. Fischer BE, et al. **Protein Eng** 1998 Aug;11(8):715–21
Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins. Chen D, et al. **Transplantation** 1999 Feb 15;67(3):467–74

PHARMACOLOGY

Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Gerotziafas GT, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):571–80
Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor [letter; comment] Cella G, et al. **Circulation** 1999 Jun 29;99(25):3323. Comment on: Circulation 1998 Jan 27;97(3):251–6.
Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: potential implications for dosing of antithrombin agents. Thome LM, et al. **Circulation** 1998 Nov 24;98(21):2301–6
Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Steuer S, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:45–7
Evidence that heparin but not hirudin reduces PAI-1 expression in cultured human endothelial cells. Orbe J, et al. **Thromb Res** 1999 May 1;94(3):137–45

THERAPEUTIC USE

The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation. Anand SS. **Am J Cardiol** 1999 Sep 2;84(5A):13M–19M
Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Bates SM, et al. **Am J Cardiol** 1998 Oct 22; 82(8B):12P–18P (64 ref.)
Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Fox KA. **Am J Cardiol** 1999 Sep 2;84(5A):26M–31M (18 ref.)
Anticoagulants in acute coronary syndromes. Turpie AG. **Am J Cardiol** 1999 Sep 2;84(5A):2M–6M (14 ref.)
The GUSTO 2b and related studies. Global Use of Strategies to Open Occluded Coronary Arteries. Aylward P. **Aust N Z J Med** 1998 Aug;28(4):548–50
Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. White HD, et al. **Aust N Z J Med** 1998 Aug;28(4):551–4
Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits. Muñoz MC, et al. **Br J Haematol** 1999 Apr;105(1):117–21
r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons. van Wyk V, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):633–9
Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia. Bauer M, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):191–2
Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid. Sauer M, et al. **Med Pediatr Oncol** 1999 Jun;32(6):457–8
[Hirudin for heparin-induced thrombopenia: a new step forward (editorial)] Lecompte T. **Presse Med** 1998 Jun;27 Suppl 2:3–4 **(Fre)**
[Management of a suspicion of heparin-induced thrombopenia] Samama CM. **Presse Med** 1998 Jun;27 Suppl 2:18–21 (10 ref.) (Eng. Abstr.) **(Fre)**
[Once upon a time there was hirudin...] Samama MM. **Presse Med** 1998 Jun;27 Suppl 2:5–6 **(Fre)**
[Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia] **Chirurg** 1998 Nov;69(11 Suppl Massnahme):1–4 **(Ger)**
[The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins] López-Sendón J, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:76–89 (66 ref.) (Eng. Abstr.) **(Spa)**

HIRUDINEA see **LEECHES**

HISPANIC AMERICANS

Seatbelt use and belief in destiny among Hispanic and non-Hispanic drivers. Byrd T, et al. **Accid Anal Prev** 1999 Jan-Mar;31(1–2):63–5
Impacts of culture on driver knowledge and safety device usage among Hispanic farm workers. Stiles MC, et al. **Accid Anal Prev** 1999 May;31(3):235–41
Hispanic adolescent delinquency and the family: a discussion of sociocultural influences. Pabon E. **Adolescence** 1998 Winter;33(132):941–55
Is acculturation associated with sexual risk behaviours? An investigation of HIV-positive Latino men and women. Marks G, et al. **AIDS Care** 1998 Jun;10(3):283–95
Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Aronow WS, et al. **Am J Cardiol** 1999 Sep 1;84(5):611–2, A9
Presenting characteristics, treatment patterns, and clinical outcomes of non-black minorities in the National Registry of Myocardial Infarction 2. Canto JG, et al. **Am J Cardiol** 1998 Nov 1;82(9):1013–8
Development of sex-specific equations for estimating stature of frail elderly Hispanics living in the northeastern United States. Bermúdez OI, et al. **Am J Clin Nutr** 1999 May; 69(5):992–8
Prenatal purified protein derivative skin testing in a teaching clinic with a large Hispanic population. Medchill MT. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1579–83
Choroidal melanoma with oculodermal melanocytosis in Hispanic patients. Infante de German-Ribon R, et al. **Am J Ophthalmol** 1999 Aug;128(2):251–3
A comparison of the nutritional status and food security of drug-using and non-drug-using Hispanic women in Hartford, Connecticut. Himmelgreen DA, et al. **Am J Phys Anthropol** 1998 Nov;107(3):351–61
Trends in AIDS among Hispanics in the United States, 1991–1996. Klevens RM, et al. **Am J Public Health** 1999 Jul;89(7):1104–6
A study of tuberculosis among foreign-born Hispanic persons in the U.S. States bordering Mexico. Wells CD, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):834–7
National Highway Traffic Safety Administration (NHTSA) notes. An analysis of alcohol-related motor vehicle fatalities by ethnicity [see comments] Cheung F. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):550–1. Comment in: Ann Emerg Med 1999 Oct;34(4 Pt 1):551–3.
Methods and prevalence of ADL limitations in Hispanic and non-Hispanic white subjects in rural Colorado: the San Luis Valley Health and Aging Study. Hamman RF, et al. **Ann Epidemiol** 1999 May;9(4):225–35
Seeking the both/and of a nursing research proposal. Bent KN. **ANS Adv Nurs Sci** 1999 Mar;21(3):76–89
The Braden Scale for pressure ulcer risk: evaluating the predictive validity in Black and Latino/Hispanic elders. Lyder CH, et al. **Appl Nurs Res** 1999 May;12(2):60–8
Maternal blood lead level during pregnancy in South Central Los Angeles. Rothenberg SJ, et al. **Arch Environ Health** 1999 May-Jun;54(3):151–7
Renovasculopathies of hypertension in Hispanic residents of Dallas, Texas. Tracy RE, et al. **Arch Med Res** 1999 Jan-Feb;30(1):40–8
Postrehabilitation outcomes after spinal cord injury caused by firearms and motor vehicle crash among ethnically diverse groups. Waters RL, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1237–43
Optimal short forms of the Spanish WAIS (EIWA). Demsky Y, et al. **Assessment** 1998 Dec;5(4):361–4
The anatomic distribution of colorectal cancer in a New York City Puerto Rican group. Chattar-Cora D, et al. **Bol Asoc Med P R** 1998 Jul-Dec;90(7–12):126–9
Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts? Kaplan SA, et al. **Br J Urol** 1998 Dec;82(6):804–7
Mammography and Pap test screening among low-income

foreign-born Hispanic women in USA. Fernández MA, et al. **Cad Saude Publica** 1998;14 Suppl 3:133-47

A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups. Tortolero-Luna G, et al. **Cad Saude Publica** 1998;14 Suppl 3:149-59

Cancer among Hispanic children in California, 1988-1994: comparison with non-Hispanic white children. Glazer ER, et al. **Cancer** 1999 Sep 15;86(6):1070-9

The experience of having cancer in Latin America. Granda-Cameron C. **Cancer Nurs** 1999 Feb;22(1):51-7 (35 ref.)

Latinos and violence: mental health implications and strategies for clinicians. Vasquez MJ. **Cult Divers Ment Health** 1998;4(4):319-34

Prevalence of unilateral hearing loss in children: the National Health and Nutrition Examination Survey II and the Hispanic Health and Nutrition Examination Survey. Lee DJ, et al. **Ear Hear** 1998 Aug;19(4):329-32

Leadership is required for getting American minorities into research [editorial] Alderete JF. **Environ Health Perspect** 1998 Aug;106(8):A366-7

The association between acculturation and health practices among middle-aged and elderly Latinas. Cantero PJ, et al. **Ethn Dis** 1999 Spring-Summer;9(2):166-80

Is being Hispanic a risk factor for non-insulin dependent diabetes mellitus (NIDDM)? Chakraborty BM, et al. **Ethn Dis** 1999 Spring-Summer;9(2):278-83 (33 ref.)

Rubella outbreaks among Hispanics in North Carolina: lessons learned from a field investigation. Rangel MC, et al. **Ethn Dis** 1999 Spring-Summer;9(2):230-6

Age at migration and family dependency among older Mexican immigrants: recent evidence from the Mexican American EPESE. Angel RJ, et al. **Gerontologist** 1999 Feb; 39(1):59-65

Social relationships of Latino grandparent caregivers: a role theory perspective. Burnette D. **Gerontologist** 1999 Feb; 39(1):49-58

English language proficiency among older Hispanics in the United States. Mutchler JE, et al. **Gerontologist** 1999 Jun; 39(3):310-9

Inhibitors occur more frequently in African-American and Latino haemophiliacs [letter] Aledort LM, et al. **Haemophilia** 1998 Jan;4(1):68

AIDS protection and contraception among African American, Hispanic, and white women. Hines AM, et al. **Health Soc Work** 1998 Aug;23(3):186-94

Correlates of alcohol and drug use among low-income Hispanic immigrant childbearing women living in the USA. Lindenberg CS, et al. **Int J Nurs Stud** 1999 Feb;36(1):3-11

Relationship of low-density lipoprotein particle size and measures of adiposity. Rainwater DL, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23(2):180-9

Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. Wu Y, et al. **Int J Oncol** 1999 Jun;14(6):1021-37

Association between violent behaviors and substance use among Mexican-American and non-Hispanic white high school students. Grunbaum JA, et al. **J Adolesc Health** 1998 Sep;23(3):153-9

Skills training for pregnancy and AIDS prevention in Anglo and Latino youth [see comments] Hovell M, et al. **J Adolesc Health** 1998 Sep;23(3):139-49. Comment in: J Adolesc Health 1998 Sep;23(3):150-2.

Access to health care for Latina adolescents: a critical review. Rew L. **J Adolesc Health** 1998 Oct;23(4):194-204 (69 ref.)

Structural equation socialization model of substance use among Mexican-American and white non-Hispanic school dropouts. Swaim RC, et al. **J Adolesc Health** 1998 Sep; 23(3):128-38

Health practices of adult Hispanic women. Higgins PG, et al. **J Adv Nurs** 1999 May;29(5):1105-12

Risk factors for cardiovascular disease and diabetes in two groups of Hispanic Americans with differing dietary habits. Alexander H, et al. **J Am Coll Nutr** 1999 Apr;18(2):127-36

Hispanic grandmothers preserve cultural traditions and reduce foodborne illness by conducting safe cheese workshops. Bell RA, et al. **J Am Diet Assoc** 1999 Sep; 99(9):1114-6

Comparison of standard and portion-assisted responses to a brief fruit and vegetable food frequency questionnaire in a Hispanic WIC population. Cotugna N, et al. **J Am Diet Assoc** 1998 Dec;98(12):1462-4

Life-course events and experiences: association with fruit and vegetable consumption in 3 ethnic groups. Devine CM, et al. **J Am Diet Assoc** 1999 Mar;99(3):309-14

Child feeding strategies in low-income Latino households: focus group observations. Kaiser LL, et al. **J Am Diet Assoc** 1999 May;99(5):601-3

Indicators of nutritional risk in a rural elderly Hispanic and non-Hispanic white population: San Luis Valley Health and Aging Study. Marshall JA, et al. **J Am Diet Assoc** 1999 Mar;99(3):315-22

Effect of participation in congregate-site meal programs on the energy and nutrient intakes of Hispanic seniors. Neyman MR, et al. **J Am Diet Assoc** 1998 Dec; 98(12):1460-2

Comparison of energy and nutrient sources of elderly Hispanics and non-Hispanic whites in New Mexico. Pareo-Tubbeh SL, et al. **J Am Diet Assoc** 1999 May; 99(5):572-82

Aging versus disease: the opinions of older black, Hispanic, and non-Hispanic white Americans about the causes and treatment of common medical conditions. Goodwin JS, et al. **J Am Geriatr Soc** 1999 Aug;47(8):973-9

Subclinical hypothyroidism in a biethnic, urban community. Lindeman RD, et al. **J Am Geriatr Soc** 1999 Jun;47(6):703-9

Marital conflict, family processes, and boys' externalizing behavior in Hispanic American and European American families. Lindahl KM, et al. **J Clin Child Psychol** 1999 Mar; 28(1):12-24

The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche. Vuguin P, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2037-42

Pretesting Spanish-language educational radio messages to promote timely and complete infant immunization in California. de Nuncio ML, et al. **J Community Health** 1999 Aug;24(4):269-84

Listening to migrant voices: focus groups on health issues in south Georgia. Perilla JL, et al. **J Community Health Nurs** 1998;15(4):251-63

Are Latinos less satisfied with communication by health care providers? Morales LS, et al. **J Gen Intern Med** 1999 Jul; 14(7):409-17

Physician perceptions of barriers to care for inner-city Latino children with asthma. Lara M, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):27-44

Mini-Mental State Examination and Mattis Dementia Rating Scale performance differs in Hispanic and non-Hispanic Alzheimer's disease patients. Hohl U, et al. **J Int Neuropsychol Soc** 1999 May;5(4):301-7

Diabetes and hearing impairment in Mexican American adults: a population-based study. Ma F, et al. **J Laryngol Otol** 1998 Sep;112(9):835-9

Subtle and not-so-subtle insensitivity to ethnic diversity. Jackson BS. **J Nurs Adm** 1998 Dec;28(12):11-4

Severity of abuse before and during pregnancy for African American, Hispanic, and Anglo women. McFarlane J, et al. **J Nurse Midwifery** 1999 Mar-Apr;44(2):139-44

Calcium absorption and kinetics are similar in 7- and 8-year-old Mexican-American and Caucasian girls despite hormonal differences. Abrams SA, et al. **J Nutr** 1999 Mar; 129(3):666-71

Thematic instrument for measuring death anxiety in children (TIMDAC). Ireland M, et al. **J Pediatr Nurs** 1999 Feb; 14(1):28-37

Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors. Estrada AL. **J Psychoactive Drugs** 1998 Jul-Sep; 30(3):247-53

Components of self-reported oral health and general health in racial and ethnic groups. Atchison KA, et al. **J Public Health Dent** 1998 Fall;58(4):301-8

Characteristics of sexual abuse against pregnant Hispanic women by their male intimates. McFarlane J, et al. **J Womens Health** 1998 Aug;7(6):739-45

Growing Hispanic association serves increasing population [news] Marwick C. **JAMA** 1999 May 12;281(18):1687-8

The impact of language as a barrier to effective health care in an underserved urban Hispanic community. David RA, et al. **Mt Sinai J Med** 1998 Oct-Nov;65(5-6):393-7

Health problems of Asian and Latino immigrants. Flaskerud JH, et al. **Nurs Clin North Am** 1999 Jun;34(2):359-80 (118 ref.)

Predicting intentions to obtain a Pap smear among African American and Latina women: testing the theory of planned behavior. Jennings-Dozier K. **Nurs Res** 1999 Jul-Aug; 48(4):198-205

Grieving and death rituals of Latinos. Munet-Vilaró F. **Oncol Nurs Forum** 1998 Nov-Dec;25(10):1761-3 (16 ref.)

Patient education: reaching the Hispanic community. Surath Y, et al. **Oncol Nurs Forum** 1999 Jun;26(5):834

Literacy promotion for Hispanic families in a primary care setting: a randomized, controlled trial. Golova N, et al. **Pediatrics** 1999 May;103(5 Pt 1):993-7

The social ecology of addiction: race, risk, and resilience. Wallace JM Jr. **Pediatrics** 1999 May;103(5 Pt 2):1122-7 (41 ref.)

Risk factors for cardiovascular disease in Latina women. Juarbe TC. **Prog Cardiovasc Nurs** 1998 Spring;13(2):17-27 (93 ref.)

Health and quality of life within Colonias settlements along the United States and Mexico border. Davidhizar R, et al. **Public Health Nurs** 1999 Aug;16(4):301-6 (18 ref.)

Health education guides target Hispanic Americans [news] **Public Health Rep** 1999 May-Jun;114(3):206

Professional nursing support for culturally diverse family members of critically ill adults. Waters CM. **Res Nurs Health** 1999 Apr;22(2):107-17

Personal characteristics associated with injecting drug use among Latinas in the United States of America. Delva J, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):341-5

Sexual experiences and condom use of heterosexual, low-income African American and Hispanic youth practicing relative monogamy, serial monogamy, and nonmonogamy. Norris AE, et al. **Sex Transm Dis** 1999 Jan; 26(1):17-25

Ethnicity, alcohol, and acculturation. Gutmann MC. **Soc Sci Med** 1999 Jan;48(2):173-84

Latinas and sexually transmitted diseases: implications of recent research for prevention. Suarez ZE, et al. **Soc Work Health Care** 1998;28(1):1-19 (61 ref.)

Stroke in Hispanic veterans: a descriptive study. Reyes-Iglesias Y, et al. **South Med J** 1999 Jan;92(1):28-32

A new HLA-Cw*15 allele, Cw*1508, identified in the Peruvian population. Sanz L, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):391-3

Children, youth, and families: building on the cultural strengths of Hispanic and Latino communities [editorial; comment] Aceves J. **West J Med** 1999 Feb;170(2):73-4. Comment on: West J Med 1999 Feb;170(2):75-84.

Elevated asthma morbidity in Puerto Rican children: a review of possible risk and prognostic factors [see comments] Lara M, et al. **West J Med** 1999 Feb; 170(2):75-84 (63 ref.). Comment in: West J Med 1999 Feb;170(2):73-4.

Latino children's health and the family-community health promotion model. Mendoza FS, et al. **West J Med** 1999 Feb;170(2):85-92

Assessing physical activity among minority women: focus group results. Tortolero SR, et al. **Womens Health Issues** 1999 May-Jun;9(3):135-42

CLASSIFICATION

Is there a Hispanic race? [letter] Zubizarreta P. **Lancet** 1999 Aug 28;354(9180):780

EDUCATION

The Abuela Project: safe cheese workshops to reduce the incidence of Salmonella typhimurium from consumption of raw-milk fresh cheese. Bell RA, et al. **Am J Public Health** 1999 Sep;89(9):1421-4

Improving breast cancer control among Latinas: evaluation of a theory-based educational program. Mishra SI, et al. **Health Educ Behav** 1998 Oct;25(5):653-70

Multiple perspectives on nutrition education needs of low-income Hispanics. Palmeri D, et al. **J Community Health** 1998 Aug;23(4):301-16

Listening to Hispanic mothers: guidelines for teaching. Wilson AH, et al. **J Soc Pediatr Nurs** 1999 Jul-Sep; 4(3):125-7 (10 ref.)

Community-based Spanish language arthritis education program: a randomized trial. Lorig K, et al. **Med Care** 1999 Sep;37(9):957-63

GENETICS

CYP17 genotype and breast cancer risk. Weston A, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Oct;7(10):941-4

Genetics of atherosclerosis risk factors in Mexican Americans. MacCluer JW, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S59-65 (26 ref.)

Genetic and environmental influences on type 2 diabetes mellitus in Mexican Americans. Stern MP. **Nutr Rev** 1999 May;57(5 Pt 2):S66-70 (8 ref.)

Jarcho-Levin syndrome: two consecutive pregnancies in a Puerto Rican couple. Wong G, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):70-3

PSYCHOLOGY

Alcohol and AIDS-related sexual behavior among Hispanics: acculturation and gender differences. Hines AM, et al. **AIDS Educ Prev** 1998 Dec;10(6):533-47

Depressive symptomatology in first-degree family caregivers of Alzheimer disease patients: a cross-ethnic comparison. Harwood DG, et al. **Alzheimer Dis Assoc Disord** 1998 Dec; 12(4):340-6

Multiple mediators of the effects of acculturation status on delinquency for Mexican American adolescents. Samaniego RY, et al. **Am J Community Psychol** 1999 Apr; 27(2):189-210

The role of culture in psychiatric care [clinical conference] Ruiz P. **Am J Psychiatry** 1998 Dec;155(12):1763-5

The risks for late adolescence of early adolescent marijuana use. Brook JS, et al. **Am J Public Health** 1999 Oct; 89(10):1549-54

The effectiveness of the Reach for Health Community Youth Service learning program in reducing early and unprotected sex among urban middle school students. O'Donnell L, et al. **Am J Public Health** 1999 Feb; 89(2):176-81

Acculturation and breast cancer screening among Hispanic women in New York City. O'Malley AS, et al. **Am J Public Health** 1999 Feb;89(2):219-27

The experience of relapse to unsafe sexual behavior among HIV-positive, heterosexual, minority men. Sherman DW, et al. **Appl Nurs Res** 1999 May;12(2):91-100

Narratives of breast symptom discovery and cancer diagnosis: psychologic risk for advanced cancer at diagnosis. Facione NC, et al. **Cancer Nurs** 1998 Dec;21(6):430-40

The impact of cultural and familial context on behavioral and emotional problems of preschool Latino children. Weiss SJ, et al. **Child Psychiatry Hum Dev** 1999 Summer; 29(4):287-301

Responding to the mental health needs of Latino children and families through school-based services. Garrison EG, et al. **Clin Psychol Rev** 1999 Mar;19(2):199-219 (98 ref.)

Caries conditions among 2-5-year-old immigrant Latino children related to parents' oral health knowledge, opinions and practices. Watson MR, et al. **Community Dent Oral Epidemiol** 1999 Feb;27(1):8-15

Intimidades: confianza, gender, and hierarchy in the

construction of Latino-Latina therapeutic relationships. Bracero W. **Cult Divers Ment Health** 1998;4(4):264-77
Subtypes of ataques de nervios: the influence of coexisting psychiatric diagnosis. Salmán E, et al. **Cult Med Psychiatry** 1998 Jun;22(2):231-44
Latino beliefs about diabetes. Weller SC, et al. **Diabetes Care** 1999 May;22(5):722-8
Trends in situational norms and attitudes toward drinking among whites, blacks, and hispanics: 1984-1995. Caetano R, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):45-56
Gender, injury status and acculturation differences in performance of screening instruments for alcohol problems among US Hispanic emergency department patients. Cherpitel CJ. **Drug Alcohol Depend** 1999 Jan 7;53(2):147-57
Methadone-maintenance outcomes for Hispanic and African-American men and women. Mulvaney FD, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):11-8
Ethnic differences in cancer risk behaviors through the transition out of high school. Baranowski T, et al. **Ethn Dis** 1999 Winter;9(1):94-103
Do patients' ethnic and social factors influence the use of do-not-resuscitate orders? Thompson BL, et al. **Ethn Dis** 1999 Winter;9(1):132-9
Workplace discrimination and alcohol consumption: findings from the San Francisco Muni Health and Safety Study. Yen IH, et al. **Ethn Dis** 1999 Winter;9(1):70-80
Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995. Sclar DA, et al. **Harv Rev Psychiatry** 1999 May-Jun;7(1):29-36
Sex in the New World: an empowerment model for HIV prevention in Latina immigrant women. Gómez CA, et al. **Health Educ Behav** 1999 Apr;26(2):200-12
Self-regulating childhood asthma: a developmental model of family change. Zimmerman BJ, et al. **Health Educ Behav** 1999 Feb;26(1):55-71
Relation of family problems to patterns of delinquent involvement among urban youth. Gorman-Smith D, et al. **J Abnorm Child Psychol** 1998 Oct;26(5):319-33
Exploring lay definitions of asthma and interpersonal barriers to care in a predominantly Puerto Rican, inner-city community. Zayas LE, et al. **J Asthma** 1999 Sep; 36(6):527-37
A study of rural Latino women seeking cancer-detection examinations. Frank-Stromborg M, et al. **J Cancer Educ** 1998 Winter;13(4):231-41
Depression screening in a women's clinic: using automated Spanish- and English-language voice recognition. Muñoz RF, et al. **J Consult Clin Psychol** 1999 Aug;67(4):502-10
Stress-coping factors in adolescent substance use: test of ethnic and gender differences in samples of urban adolescents. Vaccaro D, et al. **J Drug Educ** 1998; 28(3):257-82
Factors affecting patient-physician communication for abused Latina and Asian immigrant women. Rodriguez MA, et al. **J Fam Pract** 1998 Oct;47(4):309-11
At risk on the cusp of old age: living arrangements and functional status among black, white and Hispanic adults. Waite LJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 May;54(3):S136-44
A multimodal support group with Hispanic traumatic brain injury survivors. Armengol CG. **J Head Trauma Rehabil** 1999 Jun;14(3):233-46
Norplant utilization in a Latina inner-city population. Ebacher R, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):85-99
Ethnicity and sex differences in university students' knowledge of AIDS, fear of AIDS, and homophobia. Waldner LK, et al. **J Homosex** 1999;37(3):117-33
The impact of socio-cultural and clinical factors on health-related quality of life reports among Hispanic and African-American cancer patients. Wan GJ, et al. **J Outcome Meas** 1999;3(3):200-15
Hispanic mothers' knowledge and care of their children with respiratory illnesses: a pilot study. Robledo L, et al. **J Pediatr Nurs** 1999 Aug;14(4):239-47
Los Cinco Grandes across cultures and ethnic groups: multitrait multimethod analyses of the Big Five in Spanish and English. Benet-Martínez V, et al. **J Pers Soc Psychol** 1998 Sep;75(3):729-50
Protective factors in adolescent health behavior. Jessor R, et al. **J Pers Soc Psychol** 1998 Sep;75(3):788-800
Pro-drinking messages and message environments for young adults: the case of alcohol industry advertising in African American, Latino, and Native American communities. Alaniz ML, et al. **J Public Health Policy** 1998;19(4):447-72
Responses to civilian war experiences: predictors of psychological functioning and coping. Michultka D, et al. **J Trauma Stress** 1998 Jul;11(3):571-7
Using qualitative methods to elicit recall of a critical time period. Hatch M, et al. **J Womens Health** 1999 Mar; 8(2):269-77
Interpreter use and satisfaction with interpersonal aspects of care for Spanish-speaking patients. Baker DW, et al. **Med Care** 1998 Oct;36(10):1461-70
Limitations of a structured psychiatric diagnostic instrument in assessing somatization among Latino patients in primary care. Villaseñor Y, et al. **Med Care** 1999 Jul;37(7):637-46
Translating the CAHPS 1.0 Survey Instruments into Spanish. Consumer Assessment of Health Plans Study. Weidmer B, et al. **Med Care** 1999 Mar;37(3 Suppl):MS89-96
MMPI-2 and MMPI-A research with U.S. Latinos: a bibliography. Corrales ML, et al. **Psychol Rep** 1998 Dec; 83(3 Pt 1):1027-33
Latin American, Asian, and American cultural differences in perceptions of spousal abuse. Gabler M, et al. **Psychol Rep** 1998 Oct;83(2):587-92
Factor structure and subtest differences on the Preschool Behavior Questionnaire in a Latino, African-American, Euro-American, and Asian preschool population. Johnson R, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):936-42
Public displays of affection among Asian and Latino heterosexual couples. Regan PC, et al. **Psychol Rep** 1999 Jun;84(3 Pt 2):1201-2
The sociosomatic course of depression and trauma: a cultural analysis of suffering and resilience in the life of a Puerto Rican woman [see comment] Jenkins JH, et al. **Psychosom Med** 1998 Jul-Aug;60(4):439-47. Comment on: Psychosom Med 1998 Jul-Aug;60(4):389-93.
Women's help-seeking patterns for depression. Van Hook MP. **Soc Work Health Care** 1999;29(1):15-34
Traditionalism in the prevention of substance misuse among Puerto Ricans. Cuadrado M, et al. **Subst Use Misuse** 1998 Dec;33(14):2737-55
Partner violence and sexual HIV-risk behaviors among women in an inner-city emergency department. El-Bassel N, et al. **Violence Vict** 1998 Winter;13(4):377-93
Violent pornography and abuse of women: theory to practice. Cramer E, et al. **Violence Vict** 1998 Winter;13(4):319-32
Sociodemographic predictors and cultural barriers to help-seeking behavior by Latina and Anglo American battered women. West CM, et al. **Violence Vict** 1998 Winter;13(4):361-75

STATISTICS & NUMERICAL DATA

Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Alexander M, et al. **Am Heart J** 1999 May;137(5):919-27
Physical and nonphysical partner abuse and other risk factors for low birth weight among full term and preterm babies: a multiethnic case-control study. Campbell J, et al. **Am J Epidemiol** 1999 Oct 1;150(7):714-26
Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. Gilliland FD, et al. **Am J Epidemiol** 1998 Oct 1;148(7):683-92
Relations of plasma fibrinogen level in children to measures of obesity, the (G-455-->A) mutation in the beta-fibrinogen promoter gene, and family history of ischemic heart disease: the Columbia University BioMarkers Study. Shea S, et al. **Am J Epidemiol** 1999 Oct 1;150(7):737-46
Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Stewart SL, et al. **Am J Epidemiol** 1999 Jun 1;149(11):1063-71
Delayed referral of black, Hispanic, and older patients with chronic renal failure. Ifudu O, et al. **Am J Kidney Dis** 1999 Apr;33(4):728-33
Human immunodeficiency virus-associated nephropathy in the Bronx: low prevalence in a predominantly Hispanic population. Mokrzycki MH, et al. **Am J Nephrol** 1998; 18(6):508-12
Predicting physical abuse against pregnant Hispanic women. McFarlane J, et al. **Am J Prev Med** 1998 Aug;15(2):134-8
The Latino mortality paradox: a test of the "salmon bias" and healthy migrant hypotheses. Abraido-Lanza AF, et al. **Am J Public Health** 1999 Oct;89(10):1543-8
Barriers to completion of health care proxies: an examination of ethnic differences. Morrison RS, et al. **Arch Intern Med** 1998 Dec 7-21;158(22):2493-7
Alcohol abuse and dependence in Latinos living in the United States: validation of the CAGE (4M) questions. Saitz R, et al. **Arch Intern Med** 1999 Apr 12;159(7):718-24
Motor vehicle occupant deaths among Hispanic and black children and teenagers. Baker SP, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1209-12
Access barriers to health care for Latino children. Flores G, et al. **Arch Pediatr Adolesc Med** 1998 Nov; 152(11):1119-25
Testing the epidemiologic paradox of low birth weight in Latinos. Fuentes-Afflick E, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):147-53
The relationship between asthma and obesity in urban minority children and adolescents. Gennuso J, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1197-200
Differences in breast cancer stage at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988-1993. Bentley JR, et al. **Breast Cancer Res Treat** 1998 Jul;50(1):1-9
Significant contributing causes of cancer deaths among Hispanics in Colorado, USA, 1983-1992. Sweitzer K, et al. **Cad Saude Publica** 1998;14 Suppl 3:187-91
Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non-Hispanic white women in New Mexico, 1973-1994. Adams-Cameron M, et al. **Cancer** 1999 Mar 1;85(5):1084-90
Racial inequality in active life among adult Americans. Hayward MD, et al. **Demography** 1999 Feb;36(1):77-91
Social environment and year of birth influence type 1 diabetes risk for African-American and Latino children. Lipton RB, et al. **Diabetes Care** 1999 Jan;22(1):78-85
Migrant populations and the incidence of type 1 diabetes mellitus: an overview of the literature with a focus on the Spanish-heritage countries in Latin America. Serrano-Ríos M, et al. **Diabetes Metab Res Rev** 1999 Mar-Apr; 15(2):113-32 (140 ref.)
Prenatal care, birth outcomes and newborn hospitalization costs: patterns among Hispanics in New Jersey. Reichman NE, et al. **Fam Plann Perspect** 1998 Jul-Aug;30(4):182-7, 200
Prevalence of proteinuria/microalbuminuria in an elderly urban, biethnic community. Lindeman RD, et al. **Geriatr Nephrol Urol** 1998;8(3):123-30
Concerns and dilemmas of Hispanic AIDS information seekers: Spanish-speaking callers to the CDC National AIDS hotline. Scott SA, et al. **Health Educ Behav** 1998 Aug;25(4):501-16
The demand for healthcare among racial/ethnic subpopulations. Freiman MP. **Health Serv Res** 1998 Oct; 33(4 Pt 1):867-90
Family, social, and cultural factors in pedestrian injuries among Hispanic children. Agran PF, et al. **Inj Prev** 1998 Sep;4(3):188-93
Estimated HIV risk among Hispanics in a national sample of drug users. Montoya ID, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):42-50
Sociodemographic correlates of virginity in seventh-grade black and Latino students. Raine TR, et al. **J Adolesc Health** 1999 May;24(5):304-12
Condom use by Hispanic and African-American adolescent girls who use hormonal contraception [see comments] Roye CF. **J Adolesc Health** 1998 Oct;23(4):205-11. Comment in: J Adolesc Health 1999 Jun;24(6):374-5.
Alcohol consumption is negatively associated with the prevalence of coronary heart disease in the New Mexico Elder Health Survey. Lindeman RD, et al. **J Am Geriatr Soc** 1999 Apr;47(4):396-401
The Latina Breast Cancer Control Study, year one: factors predicting screening mammography utilization by urban Latina women in Massachusetts. Laws MB, et al. **J Community Health** 1998 Aug;23(4):251-67
A trial to increase mammography utilization among Los Angeles Hispanic women. Fox SA, et al. **J Health Care Poor Underserved** 1998 Aug;9(3):309-21
Severity of spousal and intimate partner abuse to pregnant Hispanic women. Wiist WH, et al. **J Health Care Poor Underserved** 1998 Aug;9(3):248-61
Adolescent physical activity and inactivity vary by ethnicity: The National Longitudinal Study of Adolescent Health. Gordon-Larsen P, et al. **J Pediatr** 1999 Sep;135(3):301-6
Physician utilization by Hispanic elderly persons: national perspective. Burnette D, et al. **Med Care** 1999 Apr; 37(4):362-74
Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery [see comments] Hannan EL, et al. **Med Care** 1999 Jan; 37(1):68-77. Comment in: Med Care 1999 Jan;37(1):3-4.
Self-reported prevalence of diabetes among Hispanics--United States, 1994-1997. **MMWR Morb Mortal Wkly Rep** 1999 Jan 15;48(1):8-12
A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics. Harwood DG, et al. **Neurology** 1999 Feb;52(3):551-6
The risk of invasive cervical cancer among Hispanics: evidence for targeted preventive interventions. Howe SL, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):674-80
Domestic violence among patients at two rural health care clinics: prevalence and social correlates. Van Hightower NR, et al. **Public Health Nurs** 1998 Oct;15(5):355-62
Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation [see comments] Laumann EO, et al. **Sex Transm Dis** 1999 May;26(5):250-61. Comment in: Sex Transm Dis 1999 May;26(5):262-4.
The public health care of Central Americans in Houston. Eichenberger RK, et al. **Tex Med** 1999 Jun;95(6):55-62
Ischemic heart disease and stroke mortality in African-American, Hispanic, and non-Hispanic white men and women, 1985 to 1991. Karter AJ, et al. **West J Med** 1998 Sep;169(3):139-45
Contraceptive use among Latina women: social, cultural, and demographic correlates. Unger JB, et al. **Womens Health Issues** 1998 Nov-Dec;8(6):359-69

HISTAMETIZYN see **MECLIZINE**

HISTAMINASE see **AMINE OXIDASE (COPPER-CONTAINING)**

HISTAMINE

see related
HYPERSENSITIVITY, IMMEDIATE
RECEPTORS, HISTAMINE

[A method for the assay of histidine decarboxylase activity] Endo Y. **Nippon Yakurigaku Zasshi** 1998 Nov; 112(5):307-14 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Lecklin A, et al. **Brain Res** 1998 May 18;793(1-2):279-88
Comparison of the effects of cetirizine and ebastine on the skin response to histamine iontophoresis monitored with laser Doppler flowmetry. Leroy T, et al. **Dermatology** 1998; 197(2):146-51

HISTAMINE

Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. van der Veen MJ, et al. **Eur Respir J** 1999 Mar; 13(3):668-72

Inhibition of human basophil degranulation by successive histamine dilutions: results of a European multi-centre trial. Belon P, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S17-8

Skin cooling attenuates rat dorsal horn neuronal responses to intracutaneous histamine. Carstens E, et al. **Neuroreport** 1998 Dec 21;9(18):4145-9

ADVERSE EFFECTS

Histamine intolerance imitated a fish allergy [letter] Thewes M, et al. **Acta Derm Venereol** 1999 Jan;79(1):89

Histamine content does not influence the tolerance of wine in normal subjects. Kanny G, et al. **Allerg Immunol (Paris)** 1999 Feb;31(2):45-8

Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin. Weisshaar E, et al. **Arch Dermatol Res** 1998 Jun; 290(6):306-11

Participation of histamine H1 and H2 receptors in passive cutaneous anaphylaxis-induced scratching behavior in ICR mice. Inagaki N, et al. **Eur J Pharmacol** 1999 Feb 19; 367(2-3):361-71

A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine. Grant JA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2-4):339-40

Repeated hand urticaria due to contact with fishfood. Harvima RJ, et al. **Scand J Work Environ Health** 1999 Apr; 25(2):151-2

Erythrocytes and proinflammatory mediators in wound drainage. Mottl-Link S, et al. **Vox Sang** 1998;75(3):205-11

AGONISTS see HISTAMINE AGONISTS

ANALOGS & DERIVATIVES

Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties. Briganti F, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2043-8

N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists. Kramer K, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2583-8

Novel H3 receptor antagonists. Sulfonamide homologs of histamine. Wolin R, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2157-62

Degradation of histamine solutions used for bronchoprovocation. Marshik P, et al. **Chest** 1999 Jan; 115(1):194-9

Pharmacology and function of imidazole 4-acetic acid in brain. Tunnicliff G. **Gen Pharmacol** 1998 Oct;31(4):503-9 (89 ref.)

Pharmacology of Casimiroa edulis IV. Hypotensive effects of compounds isolated from methanolic extracts in rats and guinea pigs. Magos GA, et al. **J Ethnopharmacol** 1999 Jan; 64(1):35-44

Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine. De Esch IJ, et al. **J Med Chem** 1999 Apr 8;42(7):1115-22

Histaprodifen, methylhistaprodifen, and dimethylhistaprodifen are potent H1-receptor agonists in the pithed and in the anaesthetized rat. Malinowska B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jan; 359(1):11-6

ANALYSIS

Histamine content of peanuts. Frémont S, et al. **Allergy** 1999 May;54(5):528-9

Novel histamine measurement by HPLC analysis used to assay histidine decarboxylase inhibitory activity of shoyuflavones from soy sauce. Kinoshita E, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1488-91

Presence and localization of histidine decarboxylase enzyme (HDC) and histamine in Tetrahymena pyriformis. Hegyesi H, et al. **Cell Biol Int** 1998;22(7-8):493-7

Radio-enzymatic determination of histamine: interference by fluoride and possible activation of histamine methyl transferase. Bruce C, et al. **Clin Chim Acta** 1998 Aug 28; 276(2):157-62

Biogenic amines in foods: histamine and food processing. Bodmer S, et al. **Inflamm Res** 1999 Jun;48(6):296-300 (22 ref.)

Histamine content and mast cell number in tissues of mutant mice of (mi/mi) genotype. Dastych J, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S31-2

An attempt to disclose brain histamine localisation in portocaval shunted rats. Fogel WA, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S55-6

Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis. Lozeva V, et al. **Inflamm Res** 1999 Feb; 48(2):81-5

Determination of histamine in tissues using reversed phase-HPLC with post column fluorimetric detection. May S, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S94-5

Measurement of histamine release from human lung tissue ex vivo by microdialysis technique. Nissen D, et al. **Inflamm Res** 1998 Dec;47(12):501-5

Mast cells and histamine in intrauterine growth retardation--relation to the development of placental microvessels. Szukiewicz D, et al. **Inflamm Res** 1999 Apr; 48 Suppl 1:S41-2

Mast cell number, histamine concentration and placental vascular response to histamine in preeclampsia. Szukiewicz D, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S39-40

Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. Jacobi HH, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):768-72

Liquid chromatographic determination of histamine in fish, sauerkraut, and wine: interlaboratory study. Beljaars PR, et al. **J AOAC Int** 1998 Sep-Oct;81(5):991-8

Method optimization: determination of histamine in fish by capillary zone electrophoresis. Trenerry VC, et al. **J Capillary Electrophor** 1998 Jan-Apr;5(1-2):27-32

Histaminergic neurons in the sheep diencephalon. Tillet Y, et al. **J Comp Neurol** 1998 Oct 26;400(3):317-33

A method of computationally enhanced detection of chromatogram regions with apparent high relative agonist activity. Price JA. **J Pharmacol Toxicol Methods** 1998 Aug; 40(2):117-21

The distribution of histamine and serotonin in the barnacle's nervous system. Callaway JC, et al. **Microsc Res Tech** 1999 Jan 15-Feb 1;44(2-3):94-104

Histamine in the brain of insects: a review. Nässel DR. **Microsc Res Tech** 1999 Jan 15-Feb 1;44(2-3):121-36 (64 ref.)

Distribution of histamine in the CNS of different spiders. Schmid A, et al. **Microsc Res Tech** 1999 Jan 15-Feb 1; 44(2-3):81-93

Distribution of histamine in laying hen ovary. Paczoska-Eliasiewicz H, et al. **Zentralbl Veterinarmed A** 1998 Oct;45(8):491-7

ANTAGONISTS & INHIBITORS see HISTAMINE ANTAGONISTS

BIOSYNTHESIS

Monoamine- and histamine-synthesizing enzymes and neurotransmitters within neurons of adult human cardiac ganglia. Singh S, et al. **Circulation** 1999 Jan 26;99(3):411-9

Histamine synthesis, action and inactivation: is the balance disturbed in allergy? [editorial; comment] Clough GF, et al. **Clin Exp Allergy** 1999 Jan;29(1):9-11. Comment on: Clin Exp Allergy 1999 Jan;29(1):76-83.

Regulation of histamine synthesis in mouse CD4+ and CD8+ T lymphocytes. Kubo Y, et al. **Inflamm Res** 1999 Mar;48(3):149-53

Increase in histamine production by inflammatory exudate in the chronic phase of allergic inflammation in rats. Hirasawa N, et al. **Inflammation** 1998 Oct;22(5):471-82

Lack of histamine synthesis and down-regulation of H1 and H2 receptor mRNA levels by dexamethasone in cerebral endothelial cells. Karlstedt K, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):321-30

Halotolerant and halophilic histamine-forming bacteria isolated during the ripening of salted anchovies (Engraulis encrasicholus). Hernández-Herrero MM, et al. **J Food Prot** 1999 May;62(5):509-14

Uptake of precursor and synthesis of transmitter in a histaminergic photoreceptor. Morgan JR, et al. **J Neurosci** 1999 Feb 15;19(4):1217-25

BLOOD

Liposome entrapped allergen reduces plasma histamine in sensitized mice. Arora N, et al. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2-3):87-91

Biphasic elevation of plasma histamine induced by water immersion stress, and their sources in rats. Huang ZL, et al. **Eur J Pharmacol** 1998 Nov 6;360(2-3):139-46

Modulation of serum histamine releasing activity in chronic idiopathic urticaria. Zweiman B, et al. **Immunopharmacology** 1998 Jun;39(3):225-34

Blood histamine levels in patients with chronic lymphocytic leukemia. Belcheva A. **Inflamm Res** 1999 Apr;48 Suppl 1:S53-4

Histamine content of human eosinophil granulocytes. Elsner J, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S19-20

Prestorage leukofiltration of whole blood and SAGM blood prevents extracellular bioactive substance accumulation. Mynster T, et al. **Inflamm Res** 1999 Jul;48(7):363-8

Generation and subcellular distribution of histamine in human blood monocytes and monocyte subsets. Zwadlo-Klarwasser G, et al. **Inflamm Res** 1998 Nov; 47(11):434-9

Histamine phase shifts the hamster circadian pacemaker via an NMDA dependent mechanism. Meyer JL, et al. **J Biol Rhythms** 1998 Aug;13(4):288-95

In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Halmerbauer G, et al. **Pediatr Allergy Immunol** 1999 Feb;10(1):53-7

[Comparison of the levels of histamine, tryptase, and interleukin-6 for the investigation of anaphylactoid drug reactions] Sainte-Laudy J, et al. **Allerg Immunol (Paris)** 1998 Sep;30(7):209-11 (Eng. Abstr.) **(Fre)**

[Level of histamine in supernatants from the basophil activation test: applications to hymenoptera allergy and drug allergy--preliminary study] Tamim S, et al. **Allerg Immunol (Paris)** 1999 Feb;31(2):35-44 (Eng. Abstr.) **(Fre)**

[The histamine and serotonin levels in the blood plasma of diabetic patients] Shvets NV, et al. **Lik Sprava** 1999 Jan-Feb;(1):59-62 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Quantitative characterization of the binding of histamine by heparin. Rabenstein DL, et al. **Biochemistry** 1998 Oct 6; 37(40):14121-7

State of imidazole side chain of hen lysozyme modified with histamine and Japanese quail lysozyme. A study by immobilized metal ion affinity chromatography. Fukamizo T. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2239-41

Picture story. Mopping up histamine. Feng HP. **Nat Struct Biol** 1999 Jul;6(7):612

DIAGNOSTIC USE

Histamine provocation in young, awake children with bronchial asthma, using a fall in oxygenation as the only indicator of a bronchial reaction. Holmgren D, et al. **Acta Paediatr** 1999 May;88(5):545-9

Nasal challenge with histamine decreases nonspecific bronchial reactivity in workers exposed to respiratory irritants. Godnic-Cvar J, et al. **Am J Ind Med** 1999 Apr; 35(4):420-5

Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Nightingale JA, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1786-90

Comparison of forced oscillation with the conventional method for histamine bronchoprovocation testing in horses. Mazan MR, et al. **Am J Vet Res** 1999 Feb;60(2):174-80

Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Jenks PJ, et al. **Clin Exp Dermatol** 1999 Mar;24(2):112-7

Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine. Baroody FM, et al. **J Appl Physiol** 1999 Sep;87(3):1038-47

Both inhaled histamine and hypertonic saline increase airway reactivity in non-sensitised rabbits. Högman M, et al. **Respiration** 1999;66(4):349-54

GENETICS

Activity of a purified His-tagged 3C-like proteinase from the coronavirus infectious bronchitis virus. Tibbles KW, et al. **Virus Res** 1999 Apr;60(2):137-45

HISTORY

Histamine and the antiallergic antihistamines: a history of their discoveries. Emanuel MB. **Clin Exp Allergy** 1999 Jul; 29 Suppl 3:1-11; discussion 12

IMMUNOLOGY

Histamine--a major role in allergy? Bachert C. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:15-9 (18 ref.)

Production of monoclonal antibody against histamine and its application to immunohistochemical study in the stomach. Doi T, et al. **Histochem J** 1998 Jun;30(6):425-34

Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. Hosono M, et al. **J Nucl Med** 1999 Jul;40(7):1216-21

METABOLISM

Alcohol-histamine interactions. Zimatkin SM, et al. **Alcohol Alcohol** 1999 Mar-Apr;34(2):141-7 (50 ref.)

Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1-mediated histamine release from human nasal mucosa. Fujikura T, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1331-5

Ca2+ and protein kinase C signaling for histamine and sulfidoleukotrienes released from human cultured mast cells [published erratum appears in Biochem Biophys Res Commun 1999 Jun 7;259(2):503-4] Kimata M, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):895-900

Histamine, polyamines, and cancer. Medina MA, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1341-4 (42 ref.)

Quantitative characterization of the binding of histamine by heparin. Rabenstein DL, et al. **Biochemistry** 1998 Oct 6; 37(40):14121-7

Synthesis and antiallergic activity of pyridothienopyrimidines. Quintela JM, et al. **Bioorg Med Chem** 1998 Oct;6(10):1911-25

Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties. Briganti F, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2043-8

Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Granerus G, et al. **Br J Dermatol** 1998 Nov;139(5):858-61

Different contributions of voltage-sensitive Ca2+ channels to histamine-induced catecholamine release and tyrosine hydroxylase activation in bovine adrenal chromaffin cells. O'Farrell M, et al. **Cell Calcium** 1999 Mar;25(3):209-17

Determination of the inositol (1,4,5) trisphosphate requirement for histamine- and substance P-induced Ca2+ mobilisation in human U373 MG astrocytoma cells. Young KW, et al. **Cell Calcium** 1998 Jul;24(1):59-70

Effects of reserpine on ECL-cell ultrastructure and histamine compartmentalization in the rat stomach. Zhao CM, et al. **Cell Tissue Res** 1999 Jan;295(1):131-40

Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement. Brandes LJ, et al. **Clin Cancer Res** 1997 Aug;3(8):1357-61

Ovarian, uterine and brain mast cells in female rats: cyclic changes and contribution to tissue histamine. Aydin Y, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jun; 120(2):255-62

Local downregulation of enterochromaffin-like cell histamine formation in ulcer healing: a study in rats. Mei Q, et al. **Digestion** 1999;60(3):227-37

Estrogen receptor immunoreactivity is present in the majority of central histaminergic neurons: evidence for a new neuroendocrine pathway associated with luteinizing hormone-releasing hormone-synthesizing neurons in rats and humans. Fekete CS, et al. **Endocrinology** 1999 Sep; 140(9):4335-41

Brain histamine levels and neocortical slow-wave activity in rats with portacaval anastomosis. Lozeva V, et al. **Hepatology** 1999 Feb;29(2):340-6

Production of monoclonal antibody against histamine and its application to immunohistochemical study in the stomach. Doi T, et al. **Histochem J** 1998 Jun;30(6):425-34

Enteral histaminosis: Clinical implications. Amon U, et al. **Inflamm Res** 1999 Jun;48(6):291-5 (31 ref.)

The manipulation of brain histamine concentrations failed to modify voluntary alcohol intake by rats. Fogel WA, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S65-6

No sex difference in the urinary excretion of the histamine metabolite methylimidazoleacetic acid (MeImAA) when corrected for creatinine excretion. Granerus G, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S92-3

Histamine H3 receptor binding sites in rat cortex following L-histidine loading. Lozeva V, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S59-60

The involvement of the histamine degradation pathway by diamine oxidase in manifest gastrointestinal allergies. Raithel M, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S75-6

Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors: a relationship between its sensitivity and the density of H1 receptors. Ohuchi Y, et al. **Int J Mol Med** 1998 Feb;1(2):355-60

Histamine immunoreactive axons in the macaque retina. Gastinger MJ, et al. **Invest Ophthalmol Vis Sci** 1999 Feb; 40(2):487-95

Possible involvement of histamine in muscular fatigue in temporomandibular disorders: animal and human studies. Watanabe M, et al. **J Dent Res** 1999 Mar;78(3):769-75

Immunocytochemical localization of histamine in enterochromaffin-like (ECL) cells in rat oxyntic mucosa: a transmission electron microscopy study using monoclonal antibodies and conventional glutaraldehyde-based fixation. Fujiwara K, et al. **J Histochem Cytochem** 1999 Aug; 47(8):1031-8

Major changes in the brain histamine system of the ground squirrel Citellus lateralis during hibernation. Sallmen T, et al. **J Neurosci** 1999 Mar 1;19(5):1824-35

Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. Morisset S, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):590-6

Epithelium-dependent regulation of airways smooth muscle function. A histamine-nitric oxide pathway. Gourgoulianis K, et al. **Mediators Inflamm** 1998;7(6):409-11

Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Paesen GC, et al. **Mol Cell** 1999 May;3(5):661-71

Effects of the acute and chronic restraint stresses on the central histaminergic neuron system of Fischer rat. Ito C, et al. **Neurosci Lett** 1999 Mar 5;262(2):143-5

Prostaglandin E2 mediates activation of hypothalamic histamine by interleukin-1beta in rats. Kang M, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):88-93

Histamine content and secretion in basophils and mast cells. Dvorak AM. **Prog Histochem Cytochem** 1998; 33(3-4):III-IX, 169-320 (355 ref.)

Histamine release upon adenosine 5'-monophosphate (AMP) nasal provocation in allergic subjects. Polosa R, et al. **Thorax** 1999 Mar;54(3):230-3

Physiological significance of ECL-cell histamine. Andersson K, et al. **Yale J Biol Med** 1998 May-Aug;71(3-4):183-93 (80 ref.)

Histamine metabolism of gastric carcinoids in Mastomys natalensis. Kölby L, et al. **Yale J Biol Med** 1998 May-Aug; 71(3-4):207-15 (44 ref.)

The fate of released histamine: reception, response and termination. Rangachari PK. **Yale J Biol Med** 1998 May-Aug;71(3-4):173-82 (41 ref.)

[Histamine as a mediator of allergic inflammation (editorial)] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):232-5 (46 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOKINETICS

Aerosol recovery from large-volume reservoir delivery systems is highly dependent on the static properties of the reservoir. van der Veen MJ, et al. **Eur Respir J** 1999 Mar; 13(3):668-72

PHARMACOLOGY

Cis-urocanic acid down-regulates histamine-mediated activation of adenylate cyclase in the pig epidermis. Shimizu T, et al. **Acta Derm Venereol** 1998 Sep;78(5):348-50

Sensitization of rat gastrointestinal tract to acetylcholine and histamine produced by X-radiation. Janković SM, et al. **Acta Physiol Hung** 1997-98;85(3):215-30

Time course of the inflammatory response to histamine and allergen skin prick test in guinea-pigs. Evilevitch V, et al. **Acta Physiol Scand** 1999 Apr;165(4):409-13

Histaminergic activation of endogenous angiotensin II fails to inhibit alcohol intake in rats. Kraly FS, et al. **Alcohol** 1999 Jan;17(1):57-61

Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Petersen LJ, et al. **Allergy** 1999 Jun;54(6):607-11

Reactivities to serotonin and histamine in umbilical and placental vessels during the third trimester after normotensive pregnancies and pregnancies complicated by preeclampsia. Bertrand C, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):650-9

Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. Costello RW, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L709-14

Histamine sensitivity of mesenteric afferent nerves in the rat jejunum. Kreis ME, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G675-80

Minor role of a Ca2+-depleted sarcoplasmic reticulum in heterologous desensitization of smooth muscle to K+. Wardle RL, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1095-103

Effects of histamine and endothelin-1 on membrane potentials and ion currents in bovine tracheal smooth-muscle cells. Nara M, et al. **Am J Respir Cell Mol Biol** 1998 Nov;19(5):805-11

Acoustic rhinometry evaluation of nasal response to histamine and antigen in guinea pigs. Ohkawa C, et al. **Am J Rhinol** 1999 Jan-Feb;13(1):67-71

Histamine-induced adherence and migration of equine eosinophils. Foster AP, et al. **Am J Vet Res** 1998 Sep; 59(9):1153-9

Airway responses to histamine aerosol in clinically normal foods. Hoffman AM, et al. **Am J Vet Res** 1999 Aug; 60(8):965-8

Histamine-induced gastric acid secretion in horses. Kitchen DL, et al. **Am J Vet Res** 1998 Oct;59(10):1303-6

Nasal and bronchial histamine reactivity in patients with allergic rhinitis out of season. Kölbeck KG, et al. **Ann Allergy Asthma Immunol** 1999 Jan;82(1):55-60

Histamine enhances UVB-induced IL-6 production by human keratinocytes. Shinoda S, et al. **Arch Dermatol Res** 1998 Aug;290(8):429-34

Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Yanni JM, et al. **Arch Ophthalmol** 1999 May;117(5):643-7

Lack of significant alteration of histamine-induced response in aorta from diabetic rats induced by streptozocin. Wong KK. **Artery** 1997;22(6):287-92

Exploratory behaviour after intra-accumbens histamine and/or histamine antagonists injection in the rat. Orofino AG, et al. **Behav Brain Res** 1999 Jul;102(1-2):171-80

Effect of inflammatory mediators on the electrophysiology of the human oviduct. Downing SJ, et al. **Biol Reprod** 1999 Sep;61(3):657-64

I.v. lidocaine worsens histamine-induced bronchoconstriction in dogs. Hirota K, et al. **Br J Anaesth** 1999 Jan;82(1):87-9

Mechanism underlying histamine-induced desensitization of amylase secretion in rat parotid glands. Eguchi T, et al. **Br J Pharmacol** 1998 Aug;124(7):1523-33

A partial involvement of histamine in ultrasonically nebulized distilled water-induced bronchoconstriction in guinea-pigs. Fujimura M, et al. **Br J Pharmacol** 1998 Oct;125(4):902-8

Influence of TASP-V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans. Malis DD, et al. **Br J Pharmacol** 1999 Feb;126(4):989-96

Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells. Sharif NA, et al. **Br J Pharmacol** 1998 Nov;125(6):1336-44

Inhibitors of spasmogen-induced Ca2+ channel suppression in smooth muscle cells from small intestine. Unno T, et al. **Br J Pharmacol** 1998 Oct;125(4):667-74

Effects of histamine on MK-801-induced memory deficits in radial maze performance in rats. Chen Z, et al. **Brain Res** 1999 Aug 21;839(1):186-9

Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus. Kurose Y, et al. **Brain Res** 1999 May 15;828(1-2):115-8

Histamine causes Ca2+ entry via both a store-operated and a store-independent pathway in bovine adrenal chromaffin cells. Zerbes M, et al. **Cell Calcium** 1998 Jun;23(6):379-86

Histamine aggravated levothyroxine-induced cardiomyopathy in guinea pigs. Hu HJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):159-60

Transient and prolonged increase in endothelial permeability induced by histamine and thrombin: role of protein kinases, calcium, and RhoA. van Nieuw Amerongen GP, et al. **Circ Res** 1998 Nov 30;83(11):1115-23

Stimulation of central and systemic oxytocin release by histamine in the paraventricular hypothalamic nucleus: evidence for an interaction with norepinephrine. Bealer SL, et al. **Endocrinology** 1999 Mar;140(3):1158-64

Histaminergic and catecholaminergic interactions in the central regulation of vasopressin and oxytocin secretion. Knigge U, et al. **Endocrinology** 1999 Aug;140(8):3713-9

Hyperosmolar saline induces airway resistance changes and neuropeptide release: a comparison with the effect of capsaicin, potassium and histamine. Högman M, et al. **Eur J Clin Invest** 1999 Mar;29(3):264-9

Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy. Ma L, et al. **Eur J Pharmacol** 1998 Oct 23;359(2-3):191-200

Fenspiride inhibits histamine-induced responses in a lung epithelial cell line. Quartulli F, et al. **Eur J Pharmacol** 1998 May 8;348(2-3):297-304

Histamine effects on conjunctival fibroblasts from patients with vernal conjunctivitis. Leonardi A, et al. **Exp Eye Res** 1999 Jun;68(6):739-46

Heterogeneous responses of cell Ca2+ in human airway epithelium. Paradiso AM, et al. **Exp Lung Res** 1999 Jun; 25(4):277-90

Histoenzymatic investigations of the thyroid gland of guinea pig after the application of some receptor antagonists and histamine. Danowski J, et al. **Folia Histochem Cytobiol** 1999;37(2):69-70

Morphobiochemical studies on alpha-amylase secretion by parotid gland acini of guinea pigs after the application of exogenous histamine. Kmieć BL, et al. **Folia Histochem Cytobiol** 1999;37(2):101-2

Kinin and histamine stimulate Cl- secretion in gerbil middle ear epithelium: connection to otitis media. Furukawa M, et al. **Hear Res** 1999 Jun;132(1-2):109-16

Morphobiochemical investigations of the thyroid gland of the guinea pig after the application of some receptor antagonists and histamine. Danowski J, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S69-70

Histaminergic H2 receptor ligands modulate acetylcholine release in the ventral striatum. Philippu A, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S57-8

Mast cell number, histamine concentration and placental vascular response to histamine in preeclampsia. Szukiewicz D, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S39-40

Role of the endothelium in the vasorelaxing influence of histamine on isolated human subcutaneous resistance arteries. Van de Voorde J, et al. **Inflamm Res** 1999 Apr; 48 Suppl 1:S100-1

The red wine maximization test: drinking histamine rich wine induces a transient increase in plasma diamine oxidase activity in healthy volunteers [letter] Wantke F, et al. **Inflamm Res** 1999 Apr;48(4):169-70

Different reactions of aortic and venular endothelial cell monolayers to histamine on macromolecular permeability: role of cAMP, cytosolic Ca2+ and F-actin. Ikeda K, et al. **Inflammation** 1999 Feb;23(1):87-97

Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Sharif NA, et al. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2562-71

Ventilation distribution during histamine provocation [letter] Gourgoulianis KI, et al. **J Appl Physiol** 1998 Sep;85(3):1198

Effect of cardiogenic and noncardiogenic pulmonary edema on histamine responsiveness in sheep. Snapper JR, et al. **J Appl Physiol** 1998 Nov;85(5):1635-42

Biphasic responses of equine colonic vessel rings to vasoactive inflammatory mediators. Venugopalan CS, et al. **J Auton Pharmacol** 1998 Aug;18(4):231-7

Hormone-evoked elementary Ca2+ signals are not stereotypic, but reflect activation of different size channel clusters and variable recruitment of channels within a cluster. Thomas D, et al. **J Biol Chem** 1998 Oct 16; 273(42):27130-6

Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. van der Pouw Kraan TC, et al. **J Clin Invest** 1998 Nov 15;102(10):1866-73

Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling. Banu Y, et al. **J Exp Med** 1999 Feb 15;189(4):673-82

Short exposure of intestinal epithelial cells to TNF-alpha and histamine induces Mac-1-mediated neutrophil adhesion independent of protein synthesis. Miyata R, et al. **J Leukoc Biol** 1999 Sep;66(3):437-46

Redistribution of a 120 kDa phosphoprotein in the parietal cell associated with stimulation. Urushidani T, et al. **J Membr Biol** 1999 Apr 1;168(3):209-20

Probing the "active site" of diamine oxidase: structure-activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium. High A, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):490-501

On the mechanism of histaminergic inhibition of glutamate release in the rat dentate gyrus. Brown RE, et al. **J Physiol (Lond)** 1999 Mar 15;515 (Pt 3):777-86

Chloride-sensitive nature of the histamine-induced Ca2+ entry in cultured human aortic endothelial cells. Ono K, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):837-49

A synergistic interaction between histamine and vasoactive intestinal peptide (VIP) on cyclic AMP production in the chick pineal gland. Nowak JZ, et al. **J Physiol Pharmacol** 1998 Sep;49(3):377-86

Diazepam potentiates the positive inotropic effects of

histamine and forskolin in guinea-pig papillary muscles. Hara Y, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):375-9
The effect of tulobuterol tape on histamine-induced bronchoconstriction in conscious guinea pigs: long duration of action. Musoh K, et al. **Jpn J Pharmacol** 1999 Mar; 79(3):401-2
Cardiac histamine receptors: their pharmacological consequences and signal transduction pathways. Hattori Y. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):123-31 (113 ref.)
Pharmacological evaluation of an in vivo model of vestibular dysfunction in the rat. O'Neill AB, et al. **Methods Find Exp Clin Pharmacol** 1999 May;21(4):285-9
Superoxide dismutase restores impaired histamine-induced increases in venular macromolecular efflux during diabetes mellitus. Mayhan WG, et al. **Microcirculation** 1998; 5(2-3):211-8
Agonist-stimulated calcium entry in primary cultures of human cerebral microvascular endothelial cells. Li L, et al. **Microvasc Res** 1999 May;57(3):211-26
Inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in rat supraoptic neurons: involvement in histamine-induced enhancement of depolarizing afterpotentials. Li Z, et al. **Neuroscience** 1999;93(2):667-74
Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus. Takeshita Y, et al. **Neuroscience** 1998 Dec;87(4):797-805
Histamine-induced internalization of substance P receptors in myoepithelial cells of the guinea pig nasal glands. Shibano A, et al. **Peptides** 1998;19(8):1365-71
Mast cell histamine-induced calcium transients in cultured human peritoneal mesothelial cells. Bird SD, et al. **Perit Dial Int** 1998 Nov-Dec;18(6):626-36
Effects of calcium ions and substances affecting Ca2+ -related mechanisms on histamine-evoked stimulation of cyclic AMP formation in chick pineal gland. Zawilska JB, et al. **Pol J Pharmacol** 1998 Jul-Oct;50(4-5):307-14
Four-week exposure to diesel exhaust induces nasal mucosal hy; erresponsiveness to histamine in guinea pigs. Kobayashi T, et al. **Toxicol Sci** 1998 Sep;45(1):106-12
Dose-dependent increase of transcapillary diffusion of sodium fluorescein after histamine microinjections. Läuchli S, et al. **Vasa** 1999 May;28(2):79-83
Histamine affects growth of sheep ruminal epithelial cells kept in primary culture. Aschenbach JR, et al. **Zentralbl Veterinarmed A** 1998 Sep;45(6-7):411-6
[Machanism of the stimulatory effect of intracerebroventricular administration of histamine on gastatric acid secretion induced by pentagastrin in rats] Zhang J, et al. **Sheng Li Hsueh Pao** 1997 Aug;49(4):439-44 (Eng. Abstr.) **(Chi)**
[Peripheral mechanism of inhibitory effect of centrally administrated histamine on gastric acid secertion] Zhang ZF, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):551-6 (Eng. Abstr.) **(Chi)**
[Mechanism of inhibitory effects of ethanol on gallbladder contraction: differences in cases of histamine- and acetylcholine-induced contraction] Masui H, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1999 Feb; 34(1):49-62 (Eng. Abstr.) **(Jpn)**
[Changes in parameters of the systemic hemodynamics during combined action of humoral stimuli exerting various effects on arterial pressure] Evlakhov VI, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Sep;84(9):845-52 (Eng. Abstr.) **(Rus)**
[Inhibitory effect of astemizol in skin tests with histamine] Rodriguez Medina R, et al. **Rev Alerg Mex** 1999 Mar-Apr; 46(2):58-60 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Molecular biology and role of histamine in physiological and pathological reactions. A review. Novák I, et al. **Acta Biol Hung** 1997;48(4):385-94 (30 ref.)
Histaminergic influence on vestibular stimulation-induced locus coeruleus inhibition in rats. Nishiike S, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:15-8
NO and prostanoids: age dependence of hypercapniaand histamine-induced dilations of pig pial arterioles. Willis AP, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H299-307
Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Numata T, et al. **Ann Otol Rhinol Laryngol** 1999 May; 108(5):467-73
Mepyramine inhibits platelet activating factor-induced rabbit platelet aggregation: role of intracellular histamine. Zeng S, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):155-8
Development of the histaminergic neurons and expression of histidine decarboxylase mRNA in the zebrafish brain in the absence of all peripheral histaminergic systems. Eriksson KS, et al. **Eur J Neurosci** 1998 Dec; 10(12):3799-812
GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro. Stevens DR, et al. **Eur J Neurosci** 1999 Apr;11(4):1148-54
Endogenous histamine reduces plasma insulin-like growth factor I via H1 receptor-mediated pathway in the rat. Liao W, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):471-6
Involvement of protein kinase A in histamine-mediated inhibition of IL-2 mRNA expression in mouse splenocytes. Poluektova LY, et al. **Immunopharmacology** 1999 Feb; 41(2):77-87
Is histamine involved in milk ejection in goats? Eriksson L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S90-1
Is endogenous histamine involved in the contraction of the isolated trachea, evoked by muscarinic agonist? Korosec L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S37-8
Role of nitric oxide and histamine in the reflux-related gastric mucosal injury in the rat. Masini E, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S102-3
Central histaminergic neurons regulate rabbit tracheal tension through the cervical sympathetic nerve. Iwase M, et al. **J Auton Nerv Syst** 1998 Nov 25;74(1):23-32
A pair of reciprocally inhibitory histaminergic sensory neurons are activated within the same phase of ingestive motor programs in Aplysia. Evans CG, et al. **J Neurosci** 1999 Jan 15;19(2):845-58
Histamine excites rat cerebellar granule cells in vitro through H1 and H2 receptors. Li WC, et al. **J Physiol Paris** 1999 May-Jun;93(3):239-44
The key role of histamine in the development of atherosclerosis and coronary heart disease. Clemetson CA. **Med Hypotheses** 1999 Jan;52(1):1-8 (60 ref.)
Histamine and prostaglandins in schizophrenia: revisited. Heleniak E, et al. **Med Hypotheses** 1999 Jan;52(1):37-42 (59 ref.)
Picture story. Mopping up histamine. Feng HP. **Nat Struct Biol** 1999 Jul;6(7):612
From fruit flies to barnacles, histamine is the neurotransmitter of arthropod photoreceptors. Stuart AE. **Neuron** 1999 Mar; 22(3):431-3 (15 ref.)
Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanaesthetised rats with a single treatment of compound 48/80, a mast cell degranulator. Ohta Y, et al. **Pharmacol Res** 1999 Apr; 39(4):261-7
[Role of neuropeptides and "pain substances" in the formation of humoral mechanisms of experimental and postoperative pain] Nazyrova LA, et al. **Anesteziol Reanimatol** 1998 Sep-Oct;(5):21-3 (Eng. Abstr.) **(Rus)**
[Mathematical model of histamine bronchospasm] Kalinin OA, et al. **Biofizika** 1999 Mar-Apr;44(2):350-5 (Eng. Abstr.) **(Rus)**

POISONING

Scombrotoxic (histamine) fish poisoning in the United Kingdom: 1987 to 1996. Scoging A. **Commun Dis Public Health** 1998 Sep;1(3):204-5
[Confirmation of collective histamine poisoning origin by rapid high pressure liquid chromatography] Chianéa D, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):578-9 **(Fre)**

SECRETION see HISTAMINE RELEASE

THERAPEUTIC USE

Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation. Johansson S, et al. **Anticancer Res** 1999 May-Jun;19(3A):1961-9
Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Greelish JP, et al. **Nat Med** 1999 Apr;5(4):439-43
[Therapeutic effectiveness of histaglobin preparations in patients with allergic rhinitis and chronic urticaria] Gushchin IS, et al. **Ter Arkh** 1999;71(3):57-62 (Eng. Abstr.) **(Rus)**

TOXICITY

Respective role of lipoxygenase and nitric oxide-synthase pathways in plasma histamine-induced macromolecular leakage in conscious hamsters. Gimeno G, et al. **Br J Pharmacol** 1999 Apr;126(8):1801-9

HISTAMINE AGENTS

PHARMACOLOGY

The use of low-dose histamine therapy in otolaryngology. King WP. **Ear Nose Throat J** 1999 May;78(5):366-70

THERAPEUTIC USE

The use of low-dose histamine therapy in otolaryngology. King WP. **Ear Nose Throat J** 1999 May;78(5):366-70

HISTAMINE AGONISTS

ADMINISTRATION & DOSAGE

Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Lecklin A, et al. **Brain Res** 1998 May 18;793(1-2):279-88

CHEMICAL SYNTHESIS

N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists. Kramer K, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2583-8

PHARMACOLOGY

Prevention by (R)-alpha-methylhistamine of ethanol-induced gastric mucosal lesions in rats: importance of adherent mucus gel layer. Morini G, et al. **Acta Biomed Ateneo Parmense** 1996;67(3-4):71-8
Effects of betahistine on vestibular receptors of the frog. Botta L, et al. **Acta Otolaryngol (Stockh)** 1998 Jul; 118(4):519-23
Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971. Hey JA, et al. **Arzneimittelforschung** 1998 Sep;48(9):881-8
In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-alpha-methyl-histamine and its prodrug BP 2.94 in the dog. Mazenot C, et al. **Br J Pharmacol** 1999 Jan; 126(1):264-8
Nitric oxide synthase inhibition by dimaprit and dimaprit analogues. Paquay JB, et al. **Br J Pharmacol** 1999 May; 127(2):331-4
Direct evidence for histamine H3 receptor-mediated inhibition of norepinephrine release from sympathetic terminals of guinea pig myocardium. Luo XX, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep;17(5):425-8
Agonist and antagonist effects of histamine H3 receptor ligands on 5-HT3 receptor-mediated ion currents in NG108-15 cells. Allen MC. **Eur J Pharmacol** 1998 Nov 20;361(2-3):261-8
In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Jansen FP, et al. **Eur J Pharmacol** 1998 Dec 4;362(2-3):149-55
Modulatory effect of imetit, a histamine H3 receptor agonist, on C-fibers, cholinergic fibers and mast cells in rabbit lungs in vitro. Nemmar A, et al. **Eur J Pharmacol** 1999 Apr 23; 371(1):23-30
Effects of histamine H2 receptor agonists and antagonists on the isolated guinea pig gallbladder. Coruzzi G, et al. **Fundam Clin Pharmacol** 1999;13(1):84-90
Histamine H3-receptor stimulation is unable to modulate noradrenaline release by the isolated rat heart during ischaemia-reperfusion. Mazenot C, et al. **Fundam Clin Pharmacol** 1999;13(4):455-60
Histamine receptor-independent muscle relaxation elicited by a series of histamine H2-receptor agonists on the isolated guinea pig duodenum: a study into the mechanism of action. Coruzzi G, et al. **Gen Pharmacol** 1998 Oct;31(4):643-51
Analysis of the effects of histaminergic compounds on experimental nociception and body temperature in mice. Freeman P, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S61-2
Histamine H2-receptor modulation in two mouse models of seizure susceptibility. Seeley NA, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S67-8
Histamine H3 activation depresses cardiac function in experimental sepsis. Li X, et al. **J Appl Physiol** 1998 Nov; 85(5):1693-701
Ca2+/calmodulin-mediated regulation of agonist-induced sequestration of Gq protein-coupled histamine H1 receptors in human U373 MG astrocytoma cells. Hishinuma S, et al. **J Neurochem** 1998 Dec;71(6):2626-33
Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. McLeod RL, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):43-50
Differential effect of histamine 3 receptor-active agents on brain, but not peritoneal, mast cell activation. Roźniecki JJ, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1427-35
Further study on the effects of histamine H2 receptor agonist and antagonists on restraint-induced antinociception in mice. Wong JC. **Methods Find Exp Clin Pharmacol** 1999 Jul-Aug;21(6):403-7
Histaprodifen, methylhistaprodifen, and dimethylhistaprodifen are potent H1-receptor agonists in the pithed and in the anaesthetized rat. Malinowska B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jan; 359(1):11-6
Betahistine increases vestibular blood flow. Dziadziola JK, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):400-5
Effect of the H1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats. Rossi R, et al. **Physiol Behav** 1999 May;66(3):517-21
Effect of histamine H2 and H3 receptor modulation in the septum on post-training memory processing. Flood JF, et al. **Psychopharmacology (Berl)** 1998 Dec;140(3):279-84
The fate of released histamine: reception, response and termination. Rangachari PK. **Yale J Biol Med** 1998 May-Aug;71(3-4):173-82 (41 ref.)
[The effects of betahistine on the function of equilibrium system] Kubiczkowa J. **Otolaryngol Pol** 1997;51 Suppl 25:230-9 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

What happens when doctors stop prescribing temazepam? Use of alternative therapies. Gilhooly TC, et al. **Br J Gen Pract** 1998 Sep;48(434):1601-2
Therapeutic potential of histamine H3 receptor agonists and antagonists. Leurs R, et al. **Trends Pharmacol Sci** 1998 May; 19(5):177-83 (97 ref.)
[Treatment of vertigo with betahistine and its clinical and electrophysiological evaluation] Wasilewska H, et al. **Neurol Neurochir Pol** 1999 Jan-Feb;33(1):63-9 (Eng.

Abstr.) **(Pol)**
[The effects of betahistine on the function of equilibrium system] Kubiczkowa J. **Otolaryngol Pol** 1997;51 Suppl 25:230–9 (Eng. Abstr.) **(Pol)**
[The use of betaserk in patients with cochlear–vestibular disorders] Kadymov MI, et al. **Vestn Otorinolaringol** 1998; (5):49–50 (Eng. Abstr.) **(Rus)**

HISTAMINE H1 AGONISTS see **HISTAMINE AGONISTS**

HISTAMINE H2 AGONISTS see **HISTAMINE AGONISTS**

HISTAMINE H3 AGONISTS see **HISTAMINE AGONISTS**

HISTAMINE ANTAGONISTS

Antihistamines: back to the future. Preface. Holgate ST. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:iii
Antihistamines: back to the future. Summary of the conclusions. BSACI. British Society for Allergy and Clinical Immunology. Holgate ST, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:iv–vi
Biological properties of a venom extract from the sea anemone, Bunodosoma cavernata. Eno AE, et al. **Toxicon** 1998 Dec;36(12):2013–20

ADMINISTRATION & DOSAGE

An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. Markman M, et al. **J Cancer Res Clin Oncol** 1999 Jul;125(7):427–9
Combined action of thioperamide plus scopolamine, diphenhydramine, or methysergide on memory in mice. Molinengo L, et al. **Pharmacol Biochem Behav** 1999 Jun; 63(2):221–7

ADVERSE EFFECTS

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Hindmarch I, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:133–42 (42 ref.)
Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Routledge PA, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:240–6; discussion 247–50
Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Taglialatela M, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:182–9 (38 ref.)
Why are non-sedating antihistamines non-sedating? Timmerman H. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:13–8 (23 ref.)
Arrhythmogenic mechanisms of non-sedating antihistamines. Yap YG, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:174–81 (47 ref.)
QT lengthening and arrhythmias associated with fexofenadine [letter; comment] Giraud T. **Lancet** 1999 Jun 12;353(9169):2072–3. Comment on: Lancet 1999 Mar 20;353(9157):980.

ANALYSIS

Development of a sensitive and quantitative analytical method for 1H-4-substituted imidazole histamine H3-receptor antagonists utilizing high-performance liquid chromatography and dabsyl derivatization. Handley MK, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1–2):239–49

CHEMICAL SYNTHESIS

New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Ali SM, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1133–8
4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor. Aslanian R, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2263–8
Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines. Piwinski JJ, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3469–74
General construction pattern of histamine H3-receptor antagonists: change of a paradigm. Stark H, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2011–6
From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists. Tozer MJ, et al. **Bioorg Med Chem Lett** 1999 Jul 5; 9(13):1825–30
Novel H3 receptor antagonists. Sulfonamide homologs of histamine. Wolin R, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2157–62
Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. Ali SM, et al. **J Med Chem** 1999 Mar 11;42(5):903–9
4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity. Krause M, et al. **J Med Chem** 1998 Oct 8;41(21):4171–6
Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity. Sasse A, et al. **J Med Chem** 1999 Feb 25; 42(4):593–600
Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. Tedford CE, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1160–8
Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. Yates SL, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1151–9

CHEMISTRY

Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Kaminski JJ, et al. **Bioorg Med Chem** 1999 Jul; 7(7):1413–23

HISTORY

Histamine and the antiallergic antihistamines: a history of their discoveries. Emanuel MB. **Clin Exp Allergy** 1999 Jul; 29 Suppl 3:1–11; discussion 12

METABOLISM

The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Renwick AG. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:116–24 (81 ref.)

PHARMACOLOGY

Cardiovascular safety of fexofenadine HCl. Pratt CM, et al. **Am J Cardiol** 1999 May 15;83(10):1451–4 (23 ref.)
Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Paolieri F, et al. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):601–7
Synthesis of potent non-imidazole histamine H3-receptor antagonists. Ganellin CR, et al. **Arch Pharm (Weinheim)** 1998 Dec;331(12):395–404
Exploratory behaviour after intra-accumbens histamine and/or histamine antagonists injection in the rat. Orofino AG, et al. **Behav Brain Res** 1999 Jul;102(1–2):171–80
Thioperamide, a histamine H3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Itoh E, et al. **Biol Psychiatry** 1999 Feb 15;45(4):475–81
Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Kaminski JJ, et al. **Bioorg Med Chem** 1999 Jul; 7(7):1413–23
The effects of histamine H3-receptor antagonists on amygdaloid kindled seizures in rats. Kakinoki H, et al. **Brain Res Bull** 1998 Jul 15;46(5):461–5
8-(N,N-diethylamino)-n-octyl-3,4,5-trimethoxybenzoate reduced [Ca2+]i elevation induced by histamine, serotonin, and glutamate in cultured calf basilar artery smooth muscle cells. Wang B, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May;19(3):251–3
Non-H1-receptor effects of antihistamines. Church MK. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:39–48 (75 ref.)
Beyond the histamine receptor: effect of antihistamines on mast cells. Cuss FM. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:54–9 (40 ref.)
Effect of antihistamines on epithelial cells. Devalia JL, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:64–8; discussion 69–71 (20 ref.)
New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Yanai K, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:29–36; discussion 37–8
Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Russell T, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):612–21
Cerebral ischemia reperfusion-induced vasogenic brain edema formation in rats: effect of an intracellular histamine receptor antagonist. Németh L, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):216–9
Agonist and antagonist effects of histamine H3 receptor ligands on 5-HT3 receptor-mediated ion currents in NG108-15 cells. Allen MC. **Eur J Pharmacol** 1998 Nov 20;361(2-3):261–8
In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Jansen FP, et al. **Eur J Pharmacol** 1998 Dec 4;362(2-3):149–55
Role of histamine H1 and H2 receptor antagonists in the prevention of intimal thickening. Miyazawa N, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):53–9
Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats. Munzar P, et al. **Eur J Pharmacol** 1998 Dec 18;363(2-3):93–101
High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. Tedford CE, et al. **Eur J Pharmacol** 1998 Jun 26; 351(3):307–11
Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion. Tanaka S, et al. **Gut** 1998 Sep;43(3):334–41
Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine. Bacciottini L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S63–4
Morphobiochemical investigations of the thyroid gland of the guinea pig after the application of some receptor antagonists and histamine. Danowski J, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S69–70
Histamine H2-receptor modulation in two mouse models of seizure susceptibility. Seeley NA, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S67–8
Human corneal epithelial cell functional responses to inflammatory agents and their antagonists. Sharif NA, et al. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2562–71
Interactions of new and conventional H3-antagonists with non-histaminergic receptors involved in neurogenic and myogenic contractile responses of guinea-pig ileum. Barocelli E, et al. **J Auton Pharmacol** 1999 Feb;19(1):7–17
Sodium butyrate induces alkaline phosphatase gene expression in human hepatoma cells. Khan KN, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):156–62
Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice. Fischer W, et al. **J Neural Transm** 1998;105(6-7):587–99
Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. Ligneau X, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):658–66
Differential effect of histamine 3 receptor-active agents on brain, but not peritoneal, mast cell activation. Roznicki JJ, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1427–35
Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Hough LB, et al. **Life Sci** 1999;64(5):PL79–86
Ciproxifan and chemically related compounds are highly potent and selective histamine H3-receptor antagonists. Kathmann M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):623–7
PAF- and histamine-receptor antagonists lessen allergen-induced hearing impairment in guinea pigs. Masuyama K, et al. **Prostaglandins Other Lipid Mediat** 1998 Jul;56(4):239–44
Effect of histamine H2 and H3 receptor modulation in the septum on post-training memory processing. Flood JF, et al. **Psychopharmacology (Berl)** 1998 Dec;140(3):279–84
Thioperamide, a histamine H3 receptor antagonist, suppresses NPY-but not dynorphin A-induced feeding in rats. Itoh E, et al. **Regul Pept** 1998 Sep 25;75–76:373–6
The fate of released histamine: reception, response and termination. Rangachari PK. **Yale J Biol Med** 1998 May-Aug;71(3-4):173–82 (41 ref.)
[The role of the histaminergic receptor in the vestibular habituation: an experimental study] Kaźmierczak H, et al. **Otolaryngol Pol** 1998;52(4):447–50 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Ohsawa H, et al. **Am Heart J** 1998 Dec;136(6):1081–7
Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Kimata H. **Ann Allergy Asthma Immunol** 1999 Mar; 82(3):293–5
Assessment of antihistamine efficacy and potency. Howarth PH. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:87–97 (44 ref.)
Clinical assessment of antihistamines in rhinitis. Scadding GK. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:77–81 (23 ref.)
Consumption of antihistamines and antiasthmatics in Hungary during 1992–1996. Szemere PA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):335–7
Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Passani MB, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):725–33 (96 ref.)
Effects of histamine H3 receptor ligands in experimental models of anxiety and depression. Pérez-García C, et al. **Psychopharmacology (Berl)** 1999 Feb;142(2):215–20
Therapeutic potential of histamine H3 receptor agonists and antagonists. Leurs R, et al. **Trends Pharmacol Sci** 1998 May; 19(5):177–83 (97 ref.)
[Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies] Yoshinuma M. **J Cardiol** 1999 Feb; 33(2):81–8 (Eng. Abstr.) **(Jpn)**

HISTAMINE H1 ANTAGONISTS

see related
ANTI-ALLERGIC AGENTS
BRONCHODILATOR AGENTS
HYPERSENSITIVITY, IMMEDIATE

Second-generation antihistamines: a comparative review [see comments] Slater JW, et al. **Drugs** 1999 Jan;57(1):31–47. Comment in: Drugs 1999 Jun;57(6):1033–4.
[Fefoxenadine] Bindslev-Jensen C. **Ugeskr Laeger** 1998 Oct 26;160(44):6372–5 (15 ref.) **(Dan)**
[Cetirizine] Groschner K, et al. **Dtsch Med Wochenschr** 1998 Dec 11;123(50):1523–4 (0 ref.) **(Ger)**

ADMINISTRATION & DOSAGE

A double-blind, single-dose, crossover comparison of

cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Grant JA, et al. **Allergy** 1999 Jul; 54(7):700–7

Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Casale TB, et al. **Allergy Asthma Proc** 1999 May-Jun;20(3):193–8

Ipratropium bromide nasal spray 0.03% provides additional relief from rhinorrhea when combined with terfenadine in perennial rhinitis patients; a randomized, double-blind, active-controlled trial. Finn AF Jr, et al. **Am J Rhinol** 1998 Nov-Dec;12(6):441–9

Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis. Hampel FC Jr, et al. **Am J Rhinol** 1999 Jan-Feb;13(1):55–62

Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. Berger WE, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):535–41

In vitro release and diffusion studies of promethazine hydrochloride from polymeric dermatological bases using cellulose membrane and hairless mouse skin. Babar A, et al. **Drug Dev Ind Pharm** 1999 Feb;25(2):235–40

Simultaneous assessment of the hemodynamic, cardiomechanical, and electrophysiological effects of terfenadine on the in vivo canine model. Usui T, et al. **Heart Vessels** 1998;13(2):49–57

The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. Sussman GL, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):100–6

Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis. Golden SJ, et al. **J Am Osteopath Assoc** 1999 Jul;99(7 Suppl):S7–12 (35 ref.)

Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis. Stern M, et al. **J Int Med Res** 1998 Dec;26(6):292–303

Prolonged release of drug from O/w emulsion and residence in rat nasal cavity. Aikawa K, et al. **Pharm Dev Technol** 1998 Nov;3(4):461–9

[Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine] Dupin O, et al. **J Fr Ophtalmol** 1998 Jan; 21(1):12–8 (Eng. Abstr.) **(Fre)**

[Alomide eyedrops in the treatment of allergic conjunctivitis and keratoconjunctivitis] Maichuk IuF, et al. **Vestn Oftalmol** 1998 Jul-Aug;114(4):43–4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Anaphylactic reaction due to diphenhydramine. Barranco P, et al. **Allergy** 1998 Aug;53(8):814

Dioxopromethazine-induced photoallergic contact dermatitis followed by persistent light reaction. Schauder S. **Am J Contact Dermat** 1998 Sep;9(3):182–7

Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis. Khurana V, et al. **Am J Med** 1999 Jan;106(1):118–9

Cardiovascular safety of second-generation antihistamines. Barbey JT, et al. **Am J Rhinol** 1999 May-Jun;13(3):235–43

Central nervous system effects of H1-receptor antagonists in the elderly. Simons FE, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):157–60

Central effects of the H1-antihistamine, cetirizine [letter; comment] Donnelly F, et al. **Aviat Space Environ Med** 1999 Jan;70(1):89. Comment on: Aviat Space Environ Med 1998 Feb;69(2):166–71.

Loratadine in the high performance aerospace environment. Hansen GR. **Aviat Space Environ Med** 1999 Sep; 70(9):919–24

Antihistamine drug withdrawn by manufacturer [news] Gottlieb S. **BMJ** 1999 Jul 3;319(7201):7

Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. de Abajo FJ, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):307–13

Terfenadine and risk of acute liver disease. Myers MW, et al. **Br J Clin Pharmacol** 1998 Sep;46(3):251–3

QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine. Delauche-Cavallier MC, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:206–11

Cardiovascular profile of loratadine. Hey JA, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:197–9 (16 ref.)

Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Kay GG, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:147–50 (19 ref.)

The systemic safety of fexofenadine HCl. Mason J, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:163–70; discussion 171–3 (19 ref.)

A review of the cardiac systemic side-effects of antihistamines: ebastine. Moss AJ, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:200–5 (14 ref.)

Cardiovascular safety of fexofenadine HCl. Pratt C, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:212–6

CNS effects of histamine H1 antagonists. Rihoux JP, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:143–6 (15 ref.)

The non-cardiac systemic side-effects of antihistamines: ebastine. Roberts DJ, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:151–5 (16 ref.)

Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies. Rosenzweig P, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:156–62

Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Simons FE. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:125–32 (61 ref.)

The current cardiac safety situation with antihistamines. Yap YG, et al. **Clin Exp Allergy** 1999 Mar;29 Suppl 1:15–24 (56 ref.)

Second-generation antihistamines: the risk of ventricular arrhythmias. DuBuske LM. **Clin Ther** 1999 Feb; 21(2):281–95 (58 ref.)

Comparative tolerability of second generation antihistamines. Horak F, et al. **Drug Saf** 1999 May;20(5):385–401 (162 ref.)

Treating allergic rhinitis in pregnancy. Safety considerations. Mazzotta P, et al. **Drug Saf** 1999 Apr;20(4):361–75 (54 ref.)

Cardiotoxicity of second-generation antihistamines [letter; comment] Roberts DJ. **Drugs** 1999 Jun;57(6):1033–4. Comment on: Drugs 1999 Jan;57(1):31–47.

Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine. Stone BM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):338

Prolonged nocturnal penile tumescence caused by epinastine. Yamanaka M, et al. **Int J Urol** 1999 Mar;6(3):162–3

Pros and cons of the use of antihistamines in managing allergic rhinitis. Day J. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S395–9 (53 ref.)

Point-counterpoint. Antihistamines--safer than you might think [comment] Shear NH. **J Cutan Med Surg** 1998 Jul; 3(1):23–4. Comment on: J Cutan Med Surg 1998 Jul;3(1):21–3.

Point-counterpoint. Antihistamines and the risks they pose [see comments] Wexler D. **J Cutan Med Surg** 1998 Jul; 3(1):21–3. Comment in: J Cutan Med Surg 1998 Jul;3(1):23–4.

Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. Crowson AN, et al. **J Cutan Pathol** 1999 Feb;26(2):95–9

Cinnarizine-induced cholestasis [letter] Colle I, et al. **J Hepatol** 1999 Mar;30(3):553

QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter] [see comments] Pinto YM, et al. **Lancet** 1999 Mar 20;353(9157):980. Comment in: Lancet 1999 Jun 12;353(9169):2072–3.

Causality assessment of adverse drug effects: when is rechallenge ethically acceptable? [letter] Po AL, et al. **Lancet** 1999 Aug 21;354(9179):683

Infantile spasms associated with a histamine H1 antagonist. Yasuhara A, et al. **Neuropediatrics** 1998 Dec;29(6):320–1

[Edema tendency, dyspnea and hypertension in the treatment with mirtazapine (Remeron)] Jensen JB. **Ugeskr Laeger** 1999 May 3;161(18):2699 **(Dan)**

[Dexchlorpheniramine-induced acute hepatitis: a case with positive rechallenge] Remy AJ, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):831–2 **(Fre)**

[The influence of antihistamine agents on reaction time] Rapiejko P, et al. **Otolaryngol Pol** 1997;51 Suppl 25:226–9 (Eng. Abstr.) **(Pol)**

ANALYSIS

Simultaneous determination of pyridoxine hydrochloride and doxylamine succinate from tablets by ion pair reversed-phase high-performance liquid chromatography (RP-HPLC). Argekar AP, et al. **Drug Dev Ind Pharm** 1999 Aug;25(8):945–50

Determination of pseudoephedrine hydrochloride and carbinoxamine maleate in combination drug formulation by liquid chromatography. Mansour AM. **J AOAC Int** 1998 Sep-Oct;81(5):958–62

Quantitation of efletirizine in human plasma and urine using automated solid-phase extraction and column-switching high-performance liquid chromatography. Coe RA, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jul 9;730(2):239–47

Determination of astemizole, terfenadine and flunarizine hydrochloride by ternary complex formation with eosin and lead(II). Kelani K, et al. **J Pharm Biomed Anal** 1999 Jan;18(6):985–92

BLOOD

Simultaneous determination of diphenhydramine, its N-oxide metabolite and their deuterium-labeled analogues in ovine plasma and urine using liquid chromatography/electrospray tandem mass spectrometry. Kumar S, et al. **J Mass Spectrom** 1998 Dec;33(12):1171–81

CHEMICAL SYNTHESIS

Synthesis and antiplatelet, antiinflammatory, and antiallergic activities of substituted 3-chloro-5,8-dimethoxy-1,4-naphthoquinone and related compounds. Huang LJ, et al. **Bioorg Med Chem** 1998 Dec; 6(12):2261–9

Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors. Bucholtz EC, et al. **J Med Chem** 1999 Aug 12;42(16):3041–54

CHEMISTRY

Stereochemical studies of the isomerization of novel 2-alkyl-9-phenyl-2,3,4,4a- and 2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridines. Upton C, et al. **J Pharm Pharmacol** 1998 Aug;50(8):829–35

ISOLATION & PURIFICATION

Application of heparin to chiral separations of antihistamines by capillary electrophoresis. Jin Y, et al. **Electrophoresis** 1998 Sep;19(12):2119–23

Separation of promethazine and thioridazine using capillary electrophoresis with end-column amperometric detection. Wang R, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22;721(2):327–32

METABOLISM

Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells. Sharif NA, et al. **Br J Pharmacol** 1998 Nov;125(6):1336–44

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Cvetkovic M, et al. **Drug Metab Dispos** 1999 Aug;27(8):866–71

In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Imai T, et al. **Drug Metab Dispos** 1999 Aug;27(8):942–6

H1 antihistamines, cytochrome P450 and multidrug resistance: is there a link? Rihoux JP, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S71–2 (8 ref.)

Transport characteristics of diphenhydramine in human intestinal epithelial Caco-2 cells: contribution of pH-dependent transport system. Mizuuchi H, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):388–92

Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Yasuda SU, et al. **Pharmacotherapy** 1999 Apr;19(4):447–51

PHARMACOKINETICS

Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Petersen LJ, et al. **Allergy** 1999 Jun;54(6):607–11

Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Ohtani H, et al. **Biopharm Drug Dispos** 1999 Mar;20(2):101–6

Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Robbins DK, et al. **Biopharm Drug Dispos** 1998 Oct;19(7):455–63

Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Simons FE. **Clin Exp Allergy** 1999 Mar; 29 Suppl 1:3–8 (19 ref.)

Clinical pharmacology of new histamine H1 receptor antagonists. Simons FE, et al. **Clin Pharmacokinet** 1999 May;36(5):329–52 (164 ref.)

Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Jones BC, et al. **Drug Metab Dispos** 1998 Sep;26(9):875–82

Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. Kumar S, et al. **Drug Metab Dispos** 1999 Feb;27(2):297–302

Pharmacokinetic aspects of second-generation H1 antihistamines: a reply to Philpot [letter] Estes KS, et al. **Int J Clin Pharmacol Ther** 1999 Jun;37(6):310–2

Reply to Gonzalez and Estes [letter; comment] Philpot E. **Int J Clin Pharmacol Ther** 1999 Apr;37(4):207–8. Comment on: Int J Clin Pharmacol Ther 1998 May;36(5):292–300.

The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. Sussman GL, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):100–6

Semi-automated solid-phase extraction procedure for the high-performance liquid chromatographic determination of alinastine in biological fluids. Corta E, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 30; 727(1-2):131–8

Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. Pesco-Koplowitz L, et al. **J Clin Pharmacol** 1999 Jan;39(1):76–85

Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. Stern RH, et al. **J Clin Pharmacol** 1998 Aug;38(8):753–7

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method. Mesnil F, et al. **J Pharmacokinet Biopharm** 1998 Apr;26(2):133–61

Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Raeissi SD, et al. **Pharm Res** 1999 May;16(5):625–32

Effect of venlafaxine on the pharmacokinetics of terfenadine. Amchin J, et al. **Psychopharmacol Bull** 1998;34(3):383–9

[Effect of carbon tetrachloride-induced hepatic injury on stereoselective N-demethylation of chlorpheniramine by rat hepatic cytochrome P450 2C11 isozyme] Nomura A, et al. **Yakugaku Zasshi** 1998 Aug;118(8):317–23 (Eng. Abstr.) **(Jpn)**

[Effect of beta-glycyrrhizinate on eye mucosa absorption of drugs] Odaka A, et al. **Yakugaku Zasshi** 1999 Jul; 119(7):502–9 (Eng. Abstr.) **(Jpn)**

[Second generation topical antihistaminics] Pietrzkowicz M,

et al. **Pol Merkuriusz Lek** 1999 May;6(35):277–80 (59 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Yanni JM, et al. **Arch Ophthalmol** 1999 May;117(5):643–7

Selectivity of oxomemazine for the M1 muscarinic receptors. Lee SW, et al. **Arch Pharm Res** 1994 Dec;17(6):443–51

Effects of inhaled KAA-276, a selective histamine H1 receptor antagonist, on antigen- and histamine-induced bronchoconstriction in animals. Kobayashi T, et al. **Arzneimittelforschung** 1998 Aug;48(8):826–31

Mechanisms of non-drowsiness after oral administration of TMK688, a novel antiallergic drug. Shizawa T, et al. **Arzneimittelforschung** 1998 Oct;48(10):979–84

Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine. Suzuki T, et al. **Behav Pharmacol** 1997 Dec;8(8):718–24

Influence of the antiallergic drug oxatomide and derivatives on membrane structures: relation with inhibition of calcium influx in rat basophilic leukemia cells. Paulussen JJ, et al. **Biochem Pharmacol** 1999 Mar 1;57(5):503–10

Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. Chaufour S, et al. **Br J Clin Pharmacol** 1999 May; 47(5):515–20

A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Hindmarch I, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):200–6

Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Crumb WJ Jr. **Br J Pharmacol** 1999 Feb;126(3):575–80

A partial involvement of histamine in ultrasonically nebulized distilled water-induced bronchoconstriction in guinea-pigs. Fujimura M, et al. **Br J Pharmacol** 1998 Oct;125(4):902–8

Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells. Sharif NA, et al. **Br J Pharmacol** 1998 Nov;125(6):1336–44

Differential ontogenetic patterns of levocabastine-sensitive neurotensin NT2 receptors and of NT1 receptors in the rat brain revealed by in situ hybridization. Lépée-Lorgeoux I, et al. **Brain Res Dev Brain Res** 1999 Mar 12; 113(1-2):115–31

Mepyramine inhibits platelet activating factor-induced rabbit platelet aggregation: role of intracellular histamine. Zeng S, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):155–8

Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Ciprandi G, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:49–53 (30 ref.)

H1-receptor antagonists: effects on leukocytes, myth or reality? De Vos C. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:60–3 (21 ref.)

Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Simons FE. **Clin Exp Allergy** 1999 Mar; 29 Suppl 1:3–8 (19 ref.)

The low potential for drug interactions with zanamivir. Daniel MJ, et al. **Clin Pharmacokinet** 1999;36 Suppl 1:41–50

Clinical pharmacology of new histamine H1 receptor antagonists. Simons FE, et al. **Clin Pharmacokinet** 1999 May;36(5):329–52 (164 ref.)

Comparison of the effects of cetirizine and ebastine on the skin response to histamine iontophoresis monitored with laser Doppler flowmetry. Leroy T, et al. **Dermatology** 1998; 197(2):146–51

Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Jones BC, et al. **Drug Metab Dispos** 1998 Sep;26(9):875–82

Mutagenic and antimutagenic evaluation of the juice of the leaves of Bryophyllum calycinum (Kalanchoe pinnata), a plant with antihistamine activity. Umbuzeiro-Valent G, et al. **Environ Mol Mutagen** 1999;33(4):325–7

Effects of the antihistaminergic drugs diphenhydramine and zolantidine on vestibular-induced hypothalamic neuronal activity in the guinea pig. Inokuchi A, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S22–6

Membrane stabilization in harvested vein graft storage: effects on adhesion molecule expression and nitric oxide synthesis. Vural KM, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):150–5

Variations among non-sedating antihistamines: are there real differences? Mattila MJ, et al. **Eur J Clin Pharmacol** 1999 Apr;55(2):85–93 (72 ref.)

Combined histamine H1/H2 receptor antagonists: part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures. Schulze FR, et al. **Eur J Pharm Sci** 1998 Jul;6(3):177–86

Combined histamine H1/H2 receptor antagonists: part II. Pharmacological hybrids with pheniramine- and tiotidine-like substructures. Wolf C, et al. **Eur J Pharm Sci** 1998 Jul;6(3):187–96

Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel. Chachin M, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):457–60

The induction of a prolonged increase in microvascular permeability by human mast cell chymase. He S, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):91–8

Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Sugimoto Y, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):1–5

Effects of epinastine hydrochloride on cholinergic neuro-effector transmission in canine tracheal smooth muscle. Takahashi N, et al. **Eur J Pharmacol** 1998 Sep 25; 358(1):55–61

Histoenzymatic investigations of the thyroid gland of guinea pig after the application of some receptor antagonists and histamine. Danowski J, et al. **Folia Histochem Cytobiol** 1999;37(2):69–70

The effect of tranilast on experimental proliferative vitreoretinopathy. Ito S, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Aug;237(8):691–6

Suppressive effects of antihistaminic and/or anti-PAF agents on passive anaphylactic shock in mice sensitized with allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum. Kimura S, et al. **Immunol Invest** 1998 Dec;27(6):379–93

H1- and H2-receptor antagonists prevent histamine release in allergic patients after the administration of midazolam-ketamine. A randomized controlled study. Kimura K, et al. **Inflamm Res** 1999 Mar;48(3):128–32

Daily variations of serum diamine oxidase and the influence of H1 and H2 blockers: a critical approach to routine diamine oxidase assessment. Wantke F, et al. **Inflamm Res** 1998 Oct;47(10):396–400

A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine. Grant JA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):339–40

Hypothetical mechanisms of action of an H1-antihistamine in asthma. Rihoux JP, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):380–3 (32 ref.)

Hydroxyzine inhibits neurogenic bladder mast cell activation. Minogiannis P, et al. **Int J Immunopharmacol** 1998 Oct; 20(10):553–63

The clinical pharmacology of brompheniramine in children. Simons FE, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):223–6

Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine. Baroody FM, et al. **J Appl Physiol** 1999 Sep;87(3):1038–47

Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Zhou Z, et al. **J Cardiovasc Electrophysiol** 1999 Jun;10(6):836–43

Terfenadine block of sodium current in canine atrial myocytes. Lu Y, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):507–13

Antihistaminic and anticholinergic activity of barberry fruit (Berberis vulgaris) in the guinea-pig ileum. Shamsa F, et al. **J Ethnopharmacol** 1999 Feb;64(2):161–6

Antihistamines. Wroblewski BA. **J Head Trauma Rehabil** 1998 Feb;13(1):83–5

Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. Khalifa M, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):858–65

Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. Nishio M, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):293–300

No development of tolerance to analgesia by repeated administration of H1 antagonists. Ghelardini C, et al. **Life Sci** 1998;63(22):PL 317–22

Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Dringenberg HC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Oct; 358(4):423–9

Enhanced learning by posttrial injection of H1-but not H2-histaminergic antagonists into the nucleus basalis magnocellularis region. Privou C, et al. **Neurobiol Learn Mem** 1999 May;71(3):308–24

Central nervous system effects of the novel antiallergic agent HSR-609 and typical antiallergic agents using behavioral and electroencephalographic analyses in dogs. Kakiuchi M, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Oct; 18(5):189–99

Physiological and behavioral effects of an antivertigo antihistamine in adults. Lauter JL, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):707–32

Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. Lamberg TS, et al. **Pharmacol Toxicol** 1999 Apr;84(4):165–9

Influence of antazoline on the anticonvulsant activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Swiąder M, et al. **Pol J Pharmacol** 1999 Jan-Feb;51(1):104

Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Amsellem C, et al. **Pulm Pharmacol Ther** 1998;11(4):245–52

Effects of antihistamines on fenfluramine-induced depletion of indoles in the brain of rats. Yeh SY. **Synapse** 1999 Jun 15;32(4):301–11

Effects of antihistamines on 3, 4-methylenedioxymethamphetamine-induced depletion of serotonin in rats. Yeh SY, et al. **Synapse** 1999 Sep 1; 33(3):207–17

Effect of the anti-motion-sickness medication cinnarizine on central nervous system oxygen toxicity. Arieli R, et al. **Undersea Hyperb Med** 1999 Summer;26(2):105–9

[Functional neuropharmacology in the human brain using positron emission tomography: PET imaging of impaired cognitive performance induced by sedative antihistamines] Yanai K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:48P–52P (Eng. Abstr.) **(Jpn)**

[Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis] Arcimowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):363–7 (Eng. Abstr.) **(Pol)**

[The antiallergic and anti-inflammatory effects of the second generation of antihistamines] Grzelewska-Rzymowska I, et al. **Pol Merkuriusz Lek** 1998 May;4(23):277–80 (51 ref.) (Eng. Abstr.) **(Pol)**

[The effect of new H1-receptor antagonists on cardiovascular system] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):360–2 (34 ref.) (Eng. Abstr.) **(Pol)**

POISONING

Neuroleptic malignant syndrome associated with diphenhydramine and diprophyllin overdose in a depressed patient [letter] Park-Matsumoto YC, et al. **J Neurol Sci** 1999 Jan 1;162(1):108–9

[Accidental cetirizine poisoning in a four-year-old boy] Hansen JJ, et al. **Ugeskr Laeger** 1998 Oct 5;160(41):5946–7 (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Bachert C, et al. **Allergy** 1998 Oct;53(10):969–75

A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multicentre Study Group. Bousquet J, et al. **Allergy** 1999 Jun;54(6):562–8

Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Ciprandi G, et al. **Allergy** 1999 Apr; 54(4):358–65

Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. Giede-Tuch C, et al. **Allergy** 1998 Sep;53(9):857–62

A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Grant JA, et al. **Allergy** 1999 Jul; 54(7):700–7

Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Horak F, et al. **Allergy** 1998 Sep;53(9):849–56

In vivo and ex vivo inhibitory effects of loratadine on histamine release in patients with allergic rhinitis. Miadonna A, et al. **Allergy** 1998 Dec;53(12):1183–8

Efficacy of an antiallergic drug on otitis media with effusion in association with allergic rhinitis. An experimental study. Suzuki M, et al. **Ann Otol Rhinol Laryngol** 1999 Jun; 108(6):554–8

Action spectrum and response to antihistamine use in solar pruritus [letter] Sassmannshausen J, et al. **Arch Dermatol** 1999 Sep;135(9):1122–3

Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy of seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe. Kremer B, et al. **Arzneimittelforschung** 1998 Sep; 48(9):924–30

Dimethindene maleate in the treatment of sunburn. A double-blind, placebo-controlled pilot study. Schaffler K, et al. **Arzneimittelforschung** 1999 Apr;49(4):374–9

Angioedema/anaphylaxis [letter; comment] Tong KH. **Aust Fam Physician** 1999 Jul;28(7):652. Comment on: Aust Fam Physician 1997 Dec;26(12):1419–20. Comment on: Aust Fam Physician 1999 Jul;28(7):697.

Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites. Fan HW, et al. **BMJ** 1999 May 29;318(7196):1451–2

Antihistamine decongestant medication improves which one of the following symptoms in children with common colds? Sleep status. **Can Fam Physician** 1998 Oct;44:2089, 2096–7 **(Eng, Fre)**

Terbutaline-induced desensitization of human cardiac beta 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Poller U, et al. **Cardiovasc Res** 1998 Oct;40(1):211–22

Rapid symptom relief in rhinitis. Bousquet J. **Clin Exp Allergy** 1999 Mar;29 Suppl 1:25–9

Antihistamines in severe/chronic rhinitis. Bousquet J. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:49–53 (23 ref.)

Optimizing treatment options. Naclerio RM. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:54–9

Antihistamines in urticaria. Ring J, et al. **Clin Exp Allergy** 1999 Mar;29 Suppl 1:31–7

Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Simons FE. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:98–104 (30 ref.)

The effectiveness of antihistamines in reducing the severity

HISTAMINE H1 ANTAGONISTS

of runny nose and sneezing: a meta-analysis. D'Agostino RB Sr, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):579–96

Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation. Ricard N, et al. **Clin Ther** 1999 Jan;21(1):268–77

Preventing an adverse drug event [editorial; comment] Goodman LJ. **Crit Care Med** 1999 Sep;27(9):2027–8. Comment on: Crit Care Med 1999 Sep;27(9):1732–7.

Antihistamine prophylaxis permits rapid vancomycin infusion [see comments] Renz CL, et al. **Crit Care Med** 1999 Sep; 27(9):1732–7. Comment in: Crit Care Med 1999 Sep;27(9):2027–8.

Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Sabbah A, et al. **Curr Med Res Opin** 1998;14(3):161–70

Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Richard C, et al. **Eur J Ophthalmol** 1998 Oct–Dec; 8(4):207–16

Ketotifen in prevention of indomethacin-induced gastropathy. Narendranathan M, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):76–7

Influence of histamine H1+H2 receptor antagonists on abdominal infections following minimally invasive versus conventional surgery: studies in large samples of rats following the new concept of clinic modelling randomised trials (CMRT). Celik I, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S51–2

Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine. Stone BM, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):338

Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. Corren J, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):574–80

Pros and cons of the use of antihistamines in managing allergic rhinitis. Day J. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 2):S395–9 (53 ref.)

Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. Lieberman P. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S400–4 (39 ref.)

Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. Persi L, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):591–4

Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. Simons FE. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):433–40

Same drug, different outcomes in the environmental exposure unit [letter; comment] Stone BD. **J Allergy Clin Immunol** 1999 Apr;103(4):715. Comment on: J Allergy Clin Immunol 1998 May;101(5):638–45.

Use of cyproheptadine to control urine spraying and masturbation in a cat. Schwartz S. **J Am Vet Med Assoc** 1999 Feb 1;214(3):369–71, 351–2

Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. Akhondzadeh S, et al. **J Clin Pharm Ther** 1999 Feb;24(1):49–52

Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. Dubertret L, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):16–24

Intranasal steroids or antihistamines for allergic rhinitis? Grimm KJ. **J Fam Pract** 1999 Mar;48(3):170–1

The effect of cetirizine on symptoms and signs of nasal polyposis. Haye R, et al. **J Laryngol Otol** 1998 Nov; 112(11):1042–6

Antihistamines in the management of allergic pruritus in dogs and cats. Scott DW, et al. **J Small Anim Pract** 1999 Aug; 40(8):359–64

Beneficial effects of diphenhydramine in dystonia. Grañana N, et al. **Medicina (B Aires)** 1999;59(1):38–42

Causes of chronic persistent cough in adult patients: the results of a systematic management protocol. Marchesani F, et al. **Monaldi Arch Chest Dis** 1998 Oct;53(5):510–4

The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes. Privou C, et al. **Neuropharmacology** 1998 Aug; 37(8):1019–32

Managing allergic rhinitis [news] Brown CS, et al. **Nurse Pract** 1999 May;24(5):107–11, 115–7, 120

Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen. Ueno M, et al. **Pharmacology** 1998 Oct;57(4):206–14

Effects of histamine H1 antagonist dithiaden on acetic acid-induced colitis in rats. Nosál'ová V, et al. **Physiol Res** 1999;48(1):65–72

Experimentally induced nasal hypersecretion does not reduce the efficacy of intranasal levocabastine. Borum S, et al. **Rhinology** 1998 Dec;36(4):153–5

What you need to know--medications for rhinitis--uses and abuses. Soh KB. **Singapore Med J** 1999 Feb;40(2):120–2

Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. Okonkwo CA, et al. **Trans R Soc Trop Med Hyg** 1999 May–Jun;93(3):306–11

Inhibition of antigen-induced cutaneous responses of ponies with insect hypersensitivity by the histamine-1 receptor antagonist chlorpheniramine. Foster AP, et al. **Vet Rec** 1998 Aug 15;143(7):189–93

[Anti-histamines] Bonneau JC, et al. **Allerg Immunol (Paris)** 1999 Apr;31(4):106–8 (5 ref.) (Eng. Abstr.) **(Fre)**

[Antiallergy drugs and respiratory diseases in children] Donato L, et al. **Arch Pediatr** 1999;6 Suppl 1:98S–104S (12 ref.) (Eng. Abstr.) **(Fre)**

[Antihistaminics. I] Reider N, et al. **Hautarzt** 1998 Aug; 49(8):674–81 (67 ref.) **(Ger)**

[Antihistaminics. II] Reider N, et al. **Hautarzt** 1998 Sep; 49(9):734–42; quiz 472 (0 ref.) **(Ger)**

[The efficacy of cetirizine in the treatment of perennial allergic rhinitis] Pacor ML, et al. **Recenti Prog Med** 1999 Jun;90(6):325–6 (Eng. Abstr.) **(Ita)**

[Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis] Arcimowicz M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):363–7 (Eng. Abstr.) **(Pol)**

[Clinical efficacy and safety of levocarbastine++ in the therapy in children suffering from seasonal allergic rhinitis and conjunctivitis who are less than 12 year of age] Kurzawa R, et al. **Pol Merkuriusz Lek** 1998 May; 4(23):269–72 (Eng. Abstr.) **(Pol)**

[IgE mediated food allergy: pathomechanism, clinical picture and perspectives of new therapy] Romański B. **Pol Merkuriusz Lek** 1998 Dec;5(30):379–83 (Eng. Abstr.) **(Pol)**

[Current antihistamine preparations] **Ter Arkh** 1998;70(7):88 **(Rus)**

[Ebastine in the treatment of seasonal allergic rhinitis] Il'ina NI, et al. **Ter Arkh** 1998;70(9):79–81 (Eng. Abstr.) **(Rus)**

[Anti-recurrence treatment of polypous rhinosinusitis] Kondrat'ev VA, et al. **Vestn Otorinolaringol** 1999;(4):39 (3 ref.) (Eng. Abstr.) **(Rus)**

[Ketotifen (Zaditen and K-Asthma): a drug with sales disproportionate to its demonstrated effectiveness] Pérez-Padilla JR. **Gac Med Mex** 1999 Mar–Apr; 135(2):165–70 (67 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Terfenadine induces toxicity in cultured cerebellar neurons: a role for glutamate receptors. Diaz-Trelles R, et al. **Amino Acids** 1999;16(1):59–70

Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Ohtani H, et al. **Biopharm Drug Dispos** 1999 Mar;20(2):101–6

Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome. Weissenburger J, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:190–6

A review and investigation into the mechanistic basis of the genotoxicity of antihistamines. Snyder RD. **Mutat Res** 1998 Nov;411(3):235–48 (57 ref.)

Effects of induction and inhibition of cytochromes P450 on the hepatotoxicity of methapyrilene. Ratra GS, et al. **Toxicol Sci** 1998 Nov;46(1):185–96

Methapyrilene hepatotoxicity is associated with oxidative stress, mitochondrial disfunction and is prevented by the Ca2+ channel blocker verapamil. Ratra GS, et al. **Toxicology** 1998 Sep 15;130(2–3):79–93

URINE

Simultaneous determination of diphenhydramine, its N-oxide metabolite and their deuterium-labeled analogues in ovine plasma and urine using liquid chromatography/electrospray tandem mass spectrometry. Kumar S, et al. **J Mass Spectrom** 1998 Dec;33(12):1171–81

HISTAMINE H2 ANTAGONISTS

see related
ANTI-ULCER AGENTS

ADMINISTRATION & DOSAGE

Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Rinaldi V, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):163–8

High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Kahrilas PJ, et al. **Am J Gastroenterol** 1999 Jan;94(1):92–7

Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. Vakil N, et al. **Am J Gastroenterol** 1999 May; 94(5):1197–9

Food but not a chemically defined diet interferes with maintenance of intragastric pH at a predefined level using continuous pH-stat-adjusted intravenous infusion of ranitidine in healthy volunteers. Thomson AB, et al. **Dig Dis Sci** 1999 Sep;44(9):1858–64

Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Jeppesen PB, et al. **Gut** 1998 Dec; 43(6):763–9

The outcome of reflux oesophagitis: does drug-induced remission mean cure? [comment] Savarino V, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):475–7 (20 ref.) . Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):470–4.

Outcome of erosive/ulcerative reflux oesophagitis in 181 consecutive patients 5 years after diagnosis [see comments] Zeitoun P, et al. **Ital J Gastroenterol Hepatol** 1998 Oct; 30(5):470–4. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):475–7.

Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients. Cossu ML, et al. **Obes Surg** 1999 Feb;9(1):36–9

[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication] Kanayama S. **Nippon Rinsho** 1999 Jan;57(1):153–6 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections] Kihira K, et al. **Nippon Rinsho** 1999 Jan;57(1):148–52 (Eng. Abstr.) **(Jpn)**

[Long-term endoscopic follow-up for peptic ulcer patients after eradication of H. pylori; comparison with the maintainance therapy by H2-blocker] Shirai T, et al. **Nippon Rinsho** 1999 Jan;57(1):157–61 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Adverse events of HP eradication: long-term negative consequences of HP eradication. Koster ED. **Acta Gastroenterol Belg** 1998 Jul–Sep;61(3):350–1 (10 ref.)

Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Smith AD, et al. **Am J Gastroenterol** 1999 May;94(5):1209–13

Cimetidine-induced climacteric symptoms in a young man maintained on chronic hemodialysis. Bastani B, et al. **Am J Nephrol** 1998;18(6):538–40

A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. Hanisch EW, et al. **Am J Surg** 1998 Nov;176(5):453–7

Complete atrioventricular block and cardiac arrest following intravenous famotidine administration. Schoenwald PK, et al. **Anesthesiology** 1999 Feb;90(2):623–6

Latex anaphylaxis causing heart block: role of ranitidine. Patterson LJ, et al. **Can J Anaesth** 1999 Aug;46(8):776–8

Does acid suppression by antacids and H2 receptor antagonists increase the incidence of atrophic gastritis in patients with or without H. pylori gastritis? Carter M, et al. **J Clin Gastroenterol** 1999 Sep;29(2):183–7

Central nervous system reactions associated with famotidine: report of five cases. Odeh M, et al. **J Clin Gastroenterol** 1998 Oct;27(3):253–4

Famotidine-induced acute interstitial nephritis. Hirayama K, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2636–8

[Biochemical and immunohistological changes in the gastric mucosa of rats with long-term administration of histamine H2-receptor antagonist] Tsutsumi J, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Dec;95(12):1333–42 (Eng. Abstr.) **(Jpn)**

[Drug-induced thrombocytopenia] Higuchi W, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):311–3 (6 ref.) **(Jpn)**

[Ebrotidine-induced acute hepatitis (letter) Rausell V, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):28 (10 ref.) **(Spa)**

[Toxic hepatitis caused by ebrotidine (letter)] Castellote J, et al. **Med Clin (Barc)** 1998 Nov 21;111(17):676 **(Spa)**

ANALYSIS

Simultaneous high-performance liquid chromatographic analysis for famotidine, ranitidine HCl, cimetidine, and nizatidine in commercial products. Ho C, et al. **Drug Dev Ind Pharm** 1999 Mar;25(3):379–85

BLOOD

Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients. Cossu ML, et al. **Obes Surg** 1999 Feb;9(1):36–9

CHEMICAL SYNTHESIS

Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles. Katsura Y, et al. **Bioorg Med Chem Lett** 1998 Jun 2;8(11):1307–12

CHEMISTRY

Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine. Frick A, et al. **Eur J Pharm Biopharm** 1998 Nov;46(3):313–9

SAR studies on H2 antagonists containing alkylamino substituted 1,2, 5-thiadiazole 1-oxide moieties. Di Stilo A, et al. **Farmaco** 1998 Aug–Sep;53(8–9):536–40

Investigation of classification methods for the prediction of activity in diverse chemical libraries. Dixon SL, et al. **J Comput Aided Mol Des** 1999 Sep;13(5):533–45

ECONOMICS

Using multiple pharmacoeconomic methods to conduct a cost-effectiveness analysis of histamine H2-receptor antagonists. McCoy S, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S8–12

METABOLISM

Cimetidine transport in brush-border membrane vesicles from rat small intestine. Piyapolrungroj N, et al.

J Pharmacol Exp Ther 1999 Apr;289(1):346–53

Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Bayliss MK, et al. **Xenobiotica** 1999 Mar;29(3):253–68

PHARMACOKINETICS

Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:25–9

Cimetidine sulfoxidation in small intestinal microsomes. Lu X, et al. **Drug Metab Dispos** 1998 Sep;26(9):940–2

Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine. Frick A, et al. **Eur J Pharm Biopharm** 1998 Nov;46(3):313–9

Pharmacokinetics of famotidine in patients with cystic fibrosis. Maish WA, et al. **J Clin Pharmacol** 1998 Nov; 38(11):1010–6

Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. Lee K, et al. **J Pharm Sci** 1999 Jul;88(7):680–7

Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. Collett A, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):171–8

Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Bayliss MK, et al. **Xenobiotica** 1999 Mar;29(3):253–68

Pharmacokinetics of a new histamine H2-receptor antagonist, Z-300, in rat and dog. Sugimoto T, et al. **Xenobiotica** 1999 Apr;29(4):425–33

PHARMACOLOGY

Interdigestive antroduodenal motility and gastric acid secretion. Gielkens HA, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):27–33

Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. Kovacs TO, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):959–67

Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Orr WC, et al. **Aliment Pharmacol Ther** 1998 Oct; 12(10):1033–8

Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis. Ottlecz A, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):875–81

The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Peters FT, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):921–6

The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Mikawa K, et al. **Anesth Analg** 1999 Jul;89(1):218–24

Interaction of the new histamine H2-receptor antagonist pibutidine hydrochloride with canine cloned H2-receptor expressed cells. Kaku S, et al. **Arzneimittelforschung** 1999 Jan;49(1):67–71

Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine. Suzuki T, et al. **Behav Pharmacol** 1997 Dec;8(8):718–24

Novel angucycline compound with both antigastrin- and gastric mucosal protective-activities. Uesato S, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):1969–72

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Martínez C, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):369–76

Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Mathôt RA, et al. **Clin Pharmacol Ther** 1999 Aug;66(2):140–51

Effect of omeprazole, lansoprazole, and ranitidine on the DNA synthesis of mononuclear cells [see comments] Peddicord TE, et al. **Crit Care Med** 1999 Jan;27(1):90–4. Comment in: Crit Care Med 1999 Jan;27(1):13–4.

Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic. Rendić S. **Croat Med J** 1999 Sep;40(3):357–67 (97 ref.)

Up-regulation of H2 receptor and adenylate cyclase in rabbit parietal cells during prolonged treatment with H2-receptor antagonists. Takeuchi K, et al. **Dig Dis Sci** 1999 Aug; 44(8):1703–9

Is there an interaction between H2-antagonists and alcohol? Fraser AG. **Drug Metabol Drug Interact** 1998;14(3):123–45 (112 ref.)

An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin. Purkins L, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):431–3

The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. Niopas I, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):399–404

Combined histamine H1/H2 receptor antagonists: part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures. Schulze FR, et al. **Eur J Pharm Sci** 1998 Jul;6(3):177–86

Combined histamine H1/H2 receptor antagonists: part II. Pharmacological hybrids with pheniramine- and tiotidine-like substructures. Wolf C, et al. **Eur J Pharm Sci** 1998 Jul;6(3):187–96

SAR studies on H2 antagonists containing alkylamino substituted 1,2, 5-thiadiazole 1-oxide moieties. Di Stilo A, et al. **Farmaco** 1998 Aug-Sep;53(8–9):536–40

Histoenzymatic investigations of the thyroid gland of guinea pig after the application of some receptor antagonists and histamine. Danowski J, et al. **Folia Histochem Cytobiol** 1999;37(2):69–70

Effects of histamine H2 receptor agonists and antagonists on the isolated guinea pig gallbladder. Coruzzi G, et al. **Fundam Clin Pharmacol** 1999;13(1):84–90

Effects of cimetidine and pentagastrin on surgical repair of gastric mucosa. Giovanoni M, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):574–83

Inhibitory effects of H2-receptor antagonists on platelet function in vitro. Nakamura K, et al. **Hum Exp Toxicol** 1999 Aug;18(8):487–92

H1- and H2-receptor antagonists prevent histamine release in allergic patients after the administration of midazolam-ketamine. A randomized controlled study. Kimura K, et al. **Inflamm Res** 1999 Mar;48(3):128–32

Histaminergic H2 receptor ligands modulate acetylcholine release in the ventral striatum. Philippu A, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S57–8

Daily variations of serum diamine oxidase and the influence of H1 and H2 blockers: a critical approach to routine diamine oxidase assessment. Wantke F, et al. **Inflamm Res** 1998 Oct;47(10):396–400

Effect of histamine-2 receptor antagonists on blood alcohol levels: a meta-analysis. Weinberg DS, et al. **J Gen Intern Med** 1998 Sep;13(9):594–9

Adaptation of gastric mucosa to stress. Effect of ranitidine. Ernst H, et al. **J Physiol Pharmacol** 1998 Sep;49(3):405–19

Correlation of the end-tidal PCO2 during laparoscopic surgery with the pH of the gastric juice. Baraka A, et al. **J Soc Laparoendosc Surg** 1998 Apr-Jun;2(2):163–7

Histamine H2-receptor antagonism of T-593, an anti-ulcer agent: studies on aminopyrine accumulation in isolated canine gastric mucosal cells. Inoie M, et al. **Jpn J Pharmacol** 1998 Nov;78(3):313–22

Stimulant effect of nitric oxide generator and roxatidine on mucin biosynthesis of rat gastric oxyntic mucosa. Ichikawa T, et al. **Life Sci** 1999;65(4):PL41–6

Further study on the effects of histamine H2 receptor agonist and antagonists on restraint-induced antinociception in mice. Wong JC. **Methods Find Exp Clin Pharmacol** 1999 Jul-Aug;21(6):403–7

Enhanced learning by posttrial injection of H1-but not H2-histaminergic antagonists into the nucleus basalis magnocellularis region. Privou C, et al. **Neurobiol Learn Mem** 1999 May;71(3):308–24

Histamine H2 receptor antagonism by T-593: studies on cAMP generation in Hepa cells expressing histamine H2 receptor. Tashiro T, et al. **Pharmacology** 1999 Jul; 59(1):1–10

Effect of pibutidine hydrochloride on nitric oxide production in rat gastric mucosa. Kiuchi Y, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jun;100(3):273–82

Methicillin-resistant Staphylococcus aureus proliferation in the rat gut is influenced by gastric acid inhibition and the administration of antibiotics. Yoshida Y. **Surg Today** 1999; 29(4):327–37

[Characteristics of T-593, a novel antiulcer agent, and each of its enantiomers on pharmacodynamics] Arai H, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):107–16 (Eng. Abstr.) **(Jpn)**

[Effect of T-593 on gastric bleeding and lesions induced by indomethacin and water-immersion stress in rats: improving effect of T-593 on reduced gastric mucosal blood flow in rats] Arai H, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):117–24 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Is it justified to give antisecretory drugs before an endoscopy in case of symptoms suggestive of gastro-oesophageal reflux disease? Société Royale Belge de Gastro-entérolgie. Galmiche JP, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec; 61(4):438–49 (55 ref.)

Effects of cimetidine on broiler fattening and on stress-induced gizzard erosion in chicken. Grabarević Z, et al. **Acta Vet Hung** 1999;47(2):233–41

Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. Bate CM, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):41–7

Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Catalano F, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):59–62

Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. Dobrilla G, et al. **Aliment Pharmacol Ther** 1998 Jan;12(1):63–8

Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Martin RM, et al. **Aliment Pharmacol Ther** 1998 Aug;12(8):797–805

An evaluation of increasing doses of ranitidine for treatment of heartburn. Pappa KA, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):475–81

H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study. Prach AT, et al. **Aliment Pharmacol Ther** 1998 Sep;12(9):873–80

Clinical economics review: functional (non-ulcer) dyspepsia. Tebaldi M, et al. **Aliment Pharmacol Ther** 1998 Jan; 12(1):11–9 (98 ref.)

A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Creagan ET, et al. **Am J Clin Oncol** 1998 Oct;21(5):475–8

Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Festen HP, et al. **Am J Gastroenterol** 1999 Apr;94(4):931–6

Famotidine in the management of schizophrenia. Martinez MC. **Ann Pharmacother** 1999 Jun;33(6):742–7 (14 ref.)

Importance of pH control in the management of GERD. Hunt RH. **Arch Intern Med** 1999 Apr 12;159(7):649–57 (75 ref.)

Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity. Onodera S, et al. **Arzneimittelforschung** 1999 Jun; 49(6):519–26

Acid suppression therapy. Tavenor T. **Can J Gastroenterol** 1998 Jul-Aug;12(5):320–1 (0 ref.)

The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Thomson AB, et al. **Can J Gastroenterol** 1998 Nov-Dec;12(8):551–6 (37 ref.)

Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Kelly MD, et al. **Cancer** 1999 Apr 15;85(8):1658–63

Effect of H2-blockers on serum calcium and phosphorus in hemodialysis patients on calcium carbonate therapy [letter] Kushihata S, et al. **Clin Nephrol** 1998 Sep;50(3):198–9

Stress ulcer prevention and histamine-2-receptor antagonists: leaps of faith or back to the drawing board? [editorial; comment] Freedman MD. **Crit Care Med** 1999 Jan; 27(1):13–4. Comment on: Crit Care Med 1999 Jan;27(1):90–4.

National survey of stress ulcer prophylaxis [see comments] Lam NP, et al. **Crit Care Med** 1999 Jan;27(1):98–103. Comment in: Crit Care Med 1999 Jan;27(1):16–7.

Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease. Tytgat GN. **Dig Surg** 1999; 16(1):1–6 (20 ref.)

Does the rapid healing of duodenal ulcers mean longer remissions? Ahmed W, et al. **East Mediterr Health J** 1998 Dec;4(3):554–9

Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Gschwantler M, et al. **Eur J Gastroenterol Hepatol** 1998 Jul;10(7):579–82

Effect of cimetidine on development of gastric cancer in rats after gastrojejunostomy. Hortemo GS, et al. **Eur J Surg** 1999 Mar;165(3):259–61

Ranitidine reduced clinically important gastrointestinal bleeding in patients who required mechanical ventilation. Hinds CJ, et al. **Gut** 1999 Jan;44(1):10–1

Cost effectiveness of treatment for gastro-oesophageal reflux [letter; comment] Laheij RJ, et al. **Gut** 1998 Nov; 43(5):728–9; discussion 729–30. Comment on: Gut 1998 Jan;42(1):13–6.

Chemoprevention of colorectal cancer. Langman M, et al. **Gut** 1998 Oct;43(4):578–85 (118 ref.)

Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Kanda Y, et al. **Hematol Oncol** 1998 Mar;16(1):33–7

Influence of histamine H1+H2 receptor antagonists on abdominal infections following minimally invasive versus conventional surgery: studies in large samples of rats following the new concept of clinic modelling randomised trials (CMRT). Celik I, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S51–2

Cimetidine: an inhibitor or promoter of tumor growth? [letter] Sasson AR, et al. **Int J Cancer** 1999 May 31; 81(5):835–8

Antacids vs. antacids plus non-prescription ranitidine for heartburn during pregnancy. Rayburn W, et al. **Int J Gynaecol Obstet** 1999 Jul;66(1):35–7

Cimetidine and obesity: conflicting evidence [letter; comment] Andersen T, et al. **Int J Obes Relat Metab Disord** 1999 May;23(5):550–1. Comment on: Int J Obes Relat Metab Disord 1998 Nov;22(11):1041–5.

Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes [see comments] Støa-Birketvedt G, et al. **Int J Obes Relat Metab Disord** 1998 Nov;22(11):1041–5. Comment in: Int J Obes Relat Metab Disord 1999 May;23(5):550–1.

Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. Lazzaroni M, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S73–8 (39 ref.)

Novel therapeutic approaches to the management of Helicobacter pylori infection. Montague S, et al.

Ital J Gastroenterol Hepatol 1998 Oct;30 Suppl 3:S334–8 (35 ref.)

Audit of reflux oesophagitis at 4 years. Pace F, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):355–60

Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Scarpignato C, et al. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S63–72 (113 ref.)

A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Yeomans ND. **Ital J Gastroenterol Hepatol** 1999;31 Suppl 1:S89–92 (26 ref.)

Cimetidine therapy for recalcitrant warts in adults: is it any better than placebo? Rogers CJ, et al. **J Am Acad Dermatol** 1999 Jul;41(1):123–7

Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. Takahashi N, et al. **J Am Soc Nephrol** 1999 May;10(5):1090–4

Clinicopathological study of background gastric mucosa during long-term conservative maintenance therapy for intractable peptic ulcer. Nimura H, et al. **J Gastroenterol** 1999 Feb;34(1):18–27

Successful medical treatment of peptic pyloric stenosis: Dr Sippy revisited. Khandekar S, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):354–7

The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Andrade SE, et al. **Med Care** 1999 Apr;37(4):424–30

On the biological treatment of autistic disorder [letter] Sher L. **Med Hypotheses** 1999 May;52(5):489

Gastro-oesophageal reflux disease. de Carle DJ. **Med J Aust** 1998 Nov 16;169(10):549–54 (30 ref.)

Gastroduodenal bleeding after discontinuation of H2-receptor antagonists in hemodialysis patients [letter] Fiorini F, et al. **Nephron** 1998 Sep;80(1):118

The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes. Privou C, et al. **Neuropharmacology** 1998 Aug; 37(8):1019–32

National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions. Juul KV, et al. **Scand J Gastroenterol** 1998 Sep;33(9):928–32

Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Qvigstad G, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1244–8

Duodenal ulcer perforation: have H2 receptor blockers reduced mortality? Perakath B, et al. **Trop Gastroenterol** 1999 Jan–Mar;20(1):53–4

Impact of ranitidine on prognosis after simple closure of perforated duodenal ulcer. Singh K, et al. **Trop Gastroenterol** 1999 Apr–Jun;20(2):90–2

[Medical treatment of gastroesophageal reflux by H2 receptor antagonists] Scarpignato C, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1 Pt 2):S78–89 (113 ref.) **(Fre)**

[A common disease: heartburn. Self-medication with low-dose H2-receptor antagonists] **Internist (Berl)** 1998 Nov;39(11 Suppl Selbstmedi):1–4 **(Ger)**

[99mTc pertechnetate scintigraphy and premedication for the search for ectopic gastric mucosa in Meckel's diverticulum] Rampin L, et al. **Minerva Chir** 1998 Nov;53(11):877–82 (Eng. Abstr.) **(Ita)**

[Recent progress in the drug therapy for gastrointestinal bleeding] Nakajima S, et al. **Nippon Rinsho** 1998 Sep; 56(9):2291–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Comparison of the therapeutic effects and acid suppression of H2-receptor antagonist and proton pump inhibitor in patients with gastric body ulcer--a prospective controlled trial] Takeyama Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 May;96(5):502–10 (Eng. Abstr.) **(Jpn)**

[Histological study on healing of cryocautery-induced rat gastric ulcer treated with T-593] Doi Y, et al. **Nippon Yakurigaku Zasshi** 1999 Mar;113(3):167–76 (Eng. Abstr.) **(Jpn)**

[Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation] Mori Y, et al. **Nippon Yakurigaku Zasshi** 1998 Dec; 112(6):381–93 (Eng. Abstr.) **(Jpn)**

[Famotidine (quamatel) for treatment of ulcer disease] Bogachev RS, et al. **Khirurgiia (Mosk)** 1999;(1):34 **(Rus)**

[Antisecretory effects of quamatel and gastrocepin in duodenal ulcer: comparison with intragastric pH-metry] Sheptulin AA, et al. **Klin Med (Mosk)** 1998;76(8):38–40 (Eng. Abstr.) **(Rus)**

[The effect of histamine H2 receptor blockers on reparative processes in the gastric mucosa of patients with gastric peptic ulcer] Alekseenko SA, et al. **Ter Arkh** 1999; 71(2):23–6 (Eng. Abstr.) **(Rus)**

[Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group] Gallo S, et al. **Rev Gastroenterol Mex** 1998 Jan–Mar; 63(1):11–6 (Eng. Abstr.) **(Spa)**

TOXICITY

Twenty-four-month oral carcinogenicity study of ebrotidine in rats. Romero A, et al. **Teratog Carcinog Mutagen** 1998; 18(6):263–77

URINE

Rapid characterization of urinary metabolites of pibutidine hydrochloride in humans by liquid chromatography/electrospray ionization tandem mass spectrometry. Kato K, et al. **Rapid Commun Mass Spectrom** 1999;13(15):1626–32

HISTAMINE BINDING SITES see **RECEPTORS, HISTAMINE**

HISTAMINE LIBERATION see **HISTAMINE RELEASE**

HISTAMINE METHYLTRANSFERASE see **HISTAMINE N-METHYLTRANSFERASE**

HISTAMINE N-METHYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Metoprine-induced thirst and diuresis in Wistar rats. Lecklin A, et al. **Acta Physiol Scand** 1999 Mar;165(3):325–33

GENETICS

Expression of histidine decarboxylase messenger RNA and histamine N-methyltransferase messenger RNA in nasal allergy [see comments] Hirata N, et al. **Clin Exp Allergy** 1999 Jan;29(1):76–83. Comment in: Clin Exp Allergy 1999 Jan;29(1):9–11.

METABOLISM

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Weinshilboum RM, et al. **Annu Rev Pharmacol Toxicol** 1999;39:19–52 (157 ref.)

Radio-enzymatic determination of histamine: interference by fluoride and possible activation of histamine methyl transferase. Bruce C, et al. **Clin Chim Acta** 1998 Aug 28; 276(2):157–62

Effects of the acute and chronic restraint stresses on the central histaminergic neuron system of Fischer rat. Ito C, et al. **Neurosci Lett** 1999 Mar 5;262(2):143–5

HISTAMINE-PRODUCING CELL-STIMULATING FACTOR see **GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

HISTAMINE H1 RECEPTOR ANTAGONISTS see **HISTAMINE H1 ANTAGONISTS**

HISTAMINE H2 RECEPTOR ANTAGONISTS see **HISTAMINE H2 ANTAGONISTS**

HISTAMINE H1 RECEPTOR BLOCKADERS see **HISTAMINE H1 ANTAGONISTS**

HISTAMINE H2 RECEPTOR BLOCKADERS see **HISTAMINE H2 ANTAGONISTS**

HISTAMINE RECEPTORS see **RECEPTORS, HISTAMINE**

HISTAMINE H1 RECEPTORS see **RECEPTORS, HISTAMINE H1**

HISTAMINE H2 RECEPTORS see **RECEPTORS, HISTAMINE H2**

HISTAMINE H3 RECEPTORS see **RECEPTORS, HISTAMINE H3**

HISTAMINE RELEASE

see related
COMPOUND 48-80

Predictive capacity of histamine release for the diagnosis of drug allergy. Demoly P, et al. **Allergy** 1999 May; 54(5):500–6

Chlamydia pneumoniae and possible relationship to asthma. Serum immunoglobulins and histamine release in patients and controls. Larsen FO, et al. **APMIS** 1998 Oct; 106(10):928–34

Enhanced basophil histamine release and neutrophil chemotactic activity predispose grain dust-induced airway obstruction. Park H, et al. **Clin Exp Allergy** 1999 Apr; 29(4):543–9

Adenosine induces histamine release from human bronchoalveolar lavage mast cells. Forsythe P, et al. **Clin Sci (Colch)** 1999 Apr;96(4):349–55

Measurement of histamine release in intact human skin by microdialysis technique. Clinical and experimental findings. Petersen LJ. **Dan Med Bull** 1998 Sep;45(4):383–401 (303 ref.)

Modulation of serum histamine releasing activity in chronic idiopathic urticaria. Zweiman B, et al. **Immunopharmacology** 1998 Jun;39(3):225–34

Structure-activity relationship of polyphenols on inhibition of chemical mediator release from rat peritoneal exudate cells. Yamada K, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar;35(3):169–74

Pilot study on histamine release from basophils of atopic individuals with low specific IgE serum levels against cascin. Amon U, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S43–4

The basophil histamine release test in the diagnosis of atopic bronchial asthma in children. Botulińska E, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S45–6

Randomised study comparing a non-ionic with an ionic contrast medium in patients with malignancies: first answer with a new diagnostic approach. Celik I, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S47–8

Measurement of histamine release from human lung tissue ex vivo by microdialysis technique. Nissen D, et al. **Inflamm Res** 1998 Dec;47(12):501–5

Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry. Comparison with histamine release. Sainte-Laudy J, et al. **Inflamm Res** 1998 Oct; 47(10):401–8

IgE-binding and histamine-release capabilities of the main carbohydrate component isolated from the major allergen of olive tree pollen, Ole e 1. Batanero E, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):147–53

Complement dependence of histamine release in chronic urticaria. Ferrer M, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):169–72

Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. Pierkes M, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):326–32

Anti-Fc(epsilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. Sabroe RA, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):651–8

Relationship between histamine and physiological changes during the early response to nasal antigen provocation. Baroody FM, et al. **J Appl Physiol** 1999 Feb;86(2):659–68

Effect of immunotherapy on allergen-specific production of sulphidoleukotriene and histamine. Ferrer M, et al. **J Investig Allergol Clin Immunol** 1998 Sep–Oct;8(5):277–80

The identification and characterization of umbilical cord blood-derived human basophils. Kepley CL, et al. **J Leukoc Biol** 1998 Oct;64(4):474–83

Activation of sensory nerves participates in stress-induced histamine release from mast cells in rats. Huang ZL, et al. **Neurosci Lett** 1999 Aug 6;270(3):181–4

In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Halmerbauer G, et al. **Pediatr Allergy Immunol** 1999 Feb;10(1):53–7

Histamine content and secretion in basophils and mast cells. Dvorak AM. **Prog Histochem Cytochem** 1998; 33(3-4):III–IX, 169–320 (355 ref.)

[Level of histamine in supernatants from the basophil activation test: applications to hymenoptera allergy and drug allergy--preliminary study] Tamim S, et al. **Allerg Immunol (Paris)** 1999 Feb;31(2):35–44 (Eng. Abstr.) **(Fre)**

[A case of cold urticaria with histamine release by a possible skin intrinsic mechanism] Kaneko S, et al. **Arerugi** 1999 May;48(5):554–7 **(Jpn)**

DRUG EFFECTS

Histamine release and contrast media-induced renal vasoconstriction. Drescher P, et al. **Acad Radiol** 1998 Nov; 5(11):785–9

In vivo and ex vivo inhibitory effects of loratadine on histamine release in patients with allergic rhinitis. Miadonna A, et al. **Allergy** 1998 Dec;53(12):1183–8

Tannin inhibits histamine release. Zuberbier T, et al. **Allergy** 1999 Aug;54(8):898–900

Influence of ozone and nitrogen dioxide on histamine and interleukin formation in a human nasal mucosa culture system. Schierhorn K, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):1013–9

ATP modulates anti-IgE-induced release of histamine from human lung mast cells. Schulman ES, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):530–7

The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Levy JH, et al. **Anesth Analg** 1999 Aug; 89(2):290–5

Histamine releasability after adenosine challenge in subjects with allergic and non-allergic rhinitis: possible implications for mast cell priming. Polosa R, et al. **Ann Ital Med Int** 1999 Apr–Jun;14(2):86–93

Substance P- and antigen-induced release of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by different mechanisms in vitro. Furutani K, et al. **Arch Dermatol Res** 1999 Jul–Aug;291(7–8):466–73

Structure-requirements of isocoumarins, phthalides, and stilbenes from Hydrangeae Dulcis Folium for inhibitory activity on histamine release from rat peritoneal mast cells. Matsuda H, et al. **Bioorg Med Chem** 1999 Jul;7(7):1445–50

Prostaglandins inhibit secretion of histamine and pancreastatin from isolated rat stomach ECL cells. Lindström E, et al. **Br J Pharmacol** 1998 Jul;124(6):1307–13

Antiallergic agent from natural sources. Structures and

inhibitory effect of histamine release of naphthopyrone glycosides from seeds of Cassia obtusifolia L. Kitanaka S, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1650–2

The effects of anti-asthma drugs on mediator release from cultured human mast cells [see comments] Shichijo M, et al. **Clin Exp Allergy** 1998 Oct;28(10):1228–36. Comment in: Clin Exp Allergy 1998 Oct;28(10):1171–3.

Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Theoharides TC, et al. **Dig Dis Sci** 1999 Aug;44(8 Suppl):87S–93S

The ex vivo effect of the herbal medicine sho-saiko-to on histamine release from rat mast cells. Matsumoto T, et al. **Eur Arch Otorhinolaryngol** 1998;255(7):359–64

In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Jansen FP, et al. **Eur J Pharmacol** 1998 Dec 4;362(2–3):149–55

Modulatory effect of imetit, a histamine H3 receptor agonist, on C-fibers, cholinergic fibers and mast cells in rabbit lungs in vitro. Nemmar A, et al. **Eur J Pharmacol** 1999 Apr 23; 371(1):23–30

Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats. Ogawa K, et al. **Eur J Pharmacol** 1999 Jun 18; 374(2):285–91

Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Sugimoto Y, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):1–5

Granulocyte-macrophage colony-stimulating factor enhances interleukin-1beta stimulated histamine release in the preovulatory rat ovary. Tamura K, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):207–13

Effects of beta3-adrenoceptor agonist SR 58611A on gastric acid secretion and histamine release in the dog: comparison with ritodrine. Bertini S, et al. **Gen Pharmacol** 1998 Oct; 31(4):625–31

Tumor necrosis factor alpha (TNF-alpha) modulates rat mast cell reactivity. Olejnik AK, et al. **Immunol Lett** 1998 Dec; 64(2–3):167–71

Neurotensin stimulation of mast cell secretion is receptor-mediated, pertussis-toxin sensitive and requires activation of phospholipase C. Barrocas AM, et al. **Immunopharmacology** 1999 Feb;41(2):131–7

Ultraviolet B (UVB) light-induced histamine release from rat peritoneal mast cells and its augmentation by certain phenothiazine compounds. Mio M, et al. **Immunopharmacology** 1999 Jan;41(1):55–63

Prostanoid DP receptor activation inhibits anti-IgE induced histamine release from rat peritoneal mast cells. Chan CL, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S29–30

Mercuric chloride releases preformed mediators from mast cells of the mouse and rat. Dastych J, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S33–4

The effect of adenosine and its analogues on histamine release from mast cells. Dexter EJ, et al. **Inflamm Res** 1999 Apr; 48 Suppl 1:S7–8

Effects of free radical scavengers on histamine release from human basophils stimulated by immunological and non-immunological secretagogues. Gibbs BF, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S13–4

Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Gibbs BF, et al. **Inflamm Res** 1999 Feb;48(2):86–93

H1- and H2-receptor antagonists prevent histamine release in allergic patients after the administration of midazolam-ketamine. A randomized controlled study. Kimura K, et al. **Inflamm Res** 1999 Mar;48(3):128–32

Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells. Larsson L, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S9–10

Nitric oxide does not affect histamine release from rat peritoneal mast cells. Lau HY, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S27–8

The effect of some anti-inflammatory drugs on histamine and serotonin release from rat peritoneal mast cells. Lipnik-Stangelj M, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S21–2

Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Odum L, et al. **Inflamm Res** 1998 Dec;47(12):488–92

The effect of captopril on histamine release from purified rat mast cells. Wawrocka-Pawlak M, et al. **Inflamm Res** 1999 May;48(5):262–4

Ozone-induced release of histamine in human nasal mucosa of smokers and nonsmokers in organ culture. Schierhorn K, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):333–4

Inhibitory effect of ginsenoside on the mediator release in the guinea pig lung mast cells activated by specific antigen-antibody reactions. Ro JY, et al. **Int J Immunopharmacol** 1998 Nov;20(11):625–41

Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor. Bheekha-Escura R, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):937–43

The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. Wantke F, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):642–8

Histamine release induced by immobilization, gentle handling and decapitation from mast cells and its inhibition by nedocromil in rats. Huang ZL, et al. **Jpn J Pharmacol** 1999 Jul;80(3):255–62

Inhibitory effects of Sasa senanensis Rehder extract (SE) on calcium-ionophore A23187-induced histamine release from rat peritoneal exudate cells. Okazaki M, et al. **Jpn J Pharmacol** 1999 Apr;79(4):489–92

Acetaldehyde induces histamine release from purified rat peritoneal mast cells. Koivisto T, et al. **Life Sci** 1999; 64(3):183–90

Effect of tetracosahexaenoic acid on the content and release of histamine, and eicosanoid production in MC/9 mouse mast cell. Ishihara K, et al. **Lipids** 1998 Nov;33(11):1107–14

Effects of antiallergic drugs on histamine release from rat peritoneal mast cells induced by bradykinin. Sugimoto Y, et al. **Methods Find Exp Clin Pharmacol** 1998 Jul-Aug; 20(6):457–62

Effect of NMDA receptor ligands on mast cell histamine release, a reappraisal. Daeffler L, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):512–8

Histamine and tumor necrosis factor-alpha production from purified rat brain mast cells mediated by substance P. Cocchiara R, et al. **Neuroreport** 1999 Feb 25;10(3):575–8

Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415–20 (39 ref.)

Enhancement by reproterol of the ability of disodium cromoglycate to stabilize rat mastocytes. Eleno N, et al. **Pulm Pharmacol Ther** 1999;12(1):55–60

Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells [published erratum appears in Wien Klin Wochenschr 1998 Sep 4;110(16):585] [see comments] Schedle A, et al. **Wien Klin Wochenschr** 1998 Jul 31;110(13–14):467–72. Comment in: Wien Klin Wochenschr 1998 Jul 31;110(13–14):455–8.

[Search for a threshold to distinguish between locoregional and systemic reactions using the histamine liberation value and the LTC4 level] Collin N, et al. **Allerg Immunol (Paris)** 1999 Jan;31(1):7–10 (Eng. Abstr.) **(Fre)**

[The effect of nedocromil sodium on spontaneous production of histamine releasing factor (HRF) by mononuclear blood cells in patients with nonatopic bronchial asthma] Grzelewska-Rzymowska I, et al. **Pneumonol Alergol Pol** 1997;65(11–12):775–82 (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Induction of histamine release in parasitized individuals by somatic and cuticular antigens from Onchocerca volvulus. González-Muñoz M, et al. **Am J Trop Med Hyg** 1999 Jun; 60(6):974–9

Eosinophils activate mast cells to release histamine. Piliponsky AM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):202–3

Clinical manifestations of the release of histamine and other inflammatory mediators. Naclerio R. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S382–5 (42 ref.)

Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. Befus AD, et al. **J Immunol** 1999 Jul 15;163(2):947–53

Extracellular signal-regulated kinases regulate leukotriene C4 generation, but not histamine release or IL-4 production from human basophils. Miura K, et al. **J Immunol** 1999 Apr 1;162(7):4198–206

IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. Yamaguchi M, et al. **J Immunol** 1999 May 1;162(9):5455–65

Comparison of basophil histamine releasability between atopic and nonatopic asthmatics. Son JW, et al. **J Korean Med Sci** 1999 Apr;14(2):153–8

Comparative study of histamine release from skin mast cells dispersed from atopic, ascaris-sensitive and healthy dogs. Brazis P, et al. **Vet Immunol Immunopathol** 1998 Nov 6; 66(1):43–51

[An attempt to block histamine release from basophils granulocytes with antibodies obtained as a result of long-term immunization] Szymaniak L. **Ann Acad Med Stetin** 1998;44:45–64 (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Differential effect of ebselen on compound 48/80- and anti-IgE-induced histamine release from rat peritoneal mast cells. Tchoumkeu-Nzouessa GC, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1525–8

Histamine response and local cooling in the human skin: involvement of H1- and H2-receptors. Grossmann M, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):216–22

Nerve-induced histamine release is of little importance in psoriatic skin. Krogstad AL, et al. **Br J Dermatol** 1998 Sep;139(3):403–9

Mast cells of the bovine trachea: staining characteristics, dispersion techniques and response to secretagogues. Harris WH, et al. **Can J Vet Res** 1999 Jan;63(1):5–12

Strain differences in histamine release from peritoneal mast cells in rats. Sugimoto Y, et al. **Gen Pharmacol** 1998 Oct; 31(4):613–6

Granulocyte-macrophage colony-stimulating factor and interleukin-3 cause basophil histamine release by a common pathway: downregulation by sodium. Tedeschi A, et al. **Immunology** 1999 Feb;96(2):164–70

Memory improvement by post-trial injection of lidocaine into the tuberomammillary nucleus, the source of neuronal histamine. Frisch C, et al. **Neurobiol Learn Mem** 1999 Sep; 72(2):69–77

Potentiation and suppression of the histamine response by raising and lowering the temperature in canine visceral polymodal receptors in vitro. Mizumura K, et al. **Neurosci Lett** 1999 Apr 30;266(1):9–12

Autoregulation of histamine release in medulla oblongata via H3-receptors in rabbits. Kanamaru M, et al. **Neurosci Res** 1998 May;31(1):53–60

RADIATION EFFECTS

Ultraviolet B (UVB) light-induced histamine release from rat peritoneal mast cells and its augmentation by certain phenothiazine compounds. Mio M, et al. **Immunopharmacology** 1999 Jan;41(1):55–63

HISTAPYRIDAMINE see **PHENIRAMINE**

HISTIDASE see **HISTIDINE AMMONIA-LYASE**

HISTIDINE

Roles of the N- and C-terminal domains of carnitine palmitoyltransferase I isoforms in malonyl-CoA sensitivity of the enzymes: insights from expression of chimaeric proteins and mutation of conserved histidine residues. Swanson ST, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):513–9

Site-directed mutagenesis of the quinoprotein glucose dehydrogenase of Escherichia coli; the role of His262 in PQQ binding and determination of substrate specificity. Cozier GE, et al. **Biochem Soc Trans** 1998 Aug;26(3):S270

Chemical modification of histidine residues in human 'electron transferring flavoprotein' (ETF). Parker A, et al. **Biochem Soc Trans** 1998 Aug;26(3):S272

Functions of His107 in the catalytic mechanism of human glutathione S-transferase hGSTM1a-1a. Patskovsky YV, et al. **Biochemistry** 1999 Jan 26;38(4):1193–202

Replacement of terminal cysteine with histidine in the metallothionein alpha and beta domains maintains its binding capacity [published erratum appears in Eur J Biochem 1999 Feb;259(3):961] Romero-Isart N, et al. **Eur J Biochem** 1999 Jan;259(1–2):519–27

His84 rather than His35 is the active site histidine in the corrinoid protein MrtA of the energy conserving methyltransferase complex from Methanobacterium thermoautotrophicum. Sauer K, et al. **FEBS Lett** 1998 Oct 9;436(3):401–2

Use of heme-protein complexes by the Yersinia enterocolitica HemR receptor: histidine residues are essential for receptor function. Bracken CS, et al. **J Bacteriol** 1999 Oct; 181(19):6063–72

The aspartyl replacement of the active site histidine in histidine-containing protein, HPr, of the Escherichia coli Phosphoenolpyruvate:Sugar phosphotransferase system can accept and donate a phosphoryl group. Spontaneous dephosphorylation of acyl-phosphate autocatalyzes an internal cyclization. Napper S, et al. **J Biol Chem** 1999 Jul 30;274(31):21776–82

Localization of critical histidyl residues required for vinblastine-induced tubulin polymerization and for microtubule assembly. Rai SS, et al. **J Biol Chem** 1998 Nov 20;273(47):31131–7

Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain. No evidence for a non-heme metal requirement for catalysis. Rodriguez-Crespo I, et al. **J Biol Chem** 1999 Jul 30; 274(31):21617–24

Isolation and stability of histidine-tagged proteins produced in plants via potyvirus gene vectors. Dolja VV, et al. **Virology** 1998 Dec 5;252(1):269–74

Histidine codons appended to the gene encoding the RPO22 subunit of vaccinia virus RNA polymerase facilitate the isolation and purification of functional enzyme and associated proteins from virus-infected cells. Katsafanas GC, et al. **Virology** 1999 Jun 5;258(2):469–79

ADMINISTRATION & DOSAGE

Folate requirement of growing kittens to prevent elevated formiminoglutamic acid excretion following histidine loading. Yu S, et al. **J Nutr** 1998 Dec;128(12 Suppl):2606S–2608S

Superior myocardial protection with a new histidine-buffered crystalloid cardioplegic solution in clinical trial. Takeuchi K, et al. **Thorac Cardiovasc Surg** 1999 Jun;47(3):148–52

[Histidine buffered cardioplegic solution (HBS) provides effective myocardial preservation with wider safety margin in patients with prolonged ischemia] Takeuchi K, et al. **Kyobu Geka** 1999 Jun;52(6):467–70 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

An enzyme-linked immunosorbent assay for the association of the catalytic domain of diphthamide-specific ribosyltransferases to eukaryotic elongation factor-2. Prentice GA, et al. **Anal Biochem** 1999 Aug 1;272(2):216–23

HISTIDINE

Introduction of histidine analogs leads to enhanced proton transfer in carbonic anhydrase V. Earnhardt JN, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):264–70

The roles of Glu–327 and His–446 in the bisphosphatase reaction of rat liver 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase probed by NMR spectroscopic and mutational analyses of the enzyme in the transient phosphohistidine intermediate complex. Okar DA, et al. **Biochemistry** 1999 Apr 6; 38(14):4471–9

Effects of L–histidine and its structural analogues on human N–myristoyltransferase activity and importance of EEVEH amino acid sequence for enzyme activity. Raju RV, et al. **Biochemistry** 1998 Oct 20;37(42):14928–36

Phosphofurylalanine, a stable analog of phosphohistidine. Schenkels C, et al. **Bioorg Med Chem Lett** 1999 May 17; 9(10):1443–6

Inhibition of copper–induced LDL oxidation by vitamin C is associated with decreased copper–binding to LDL and 2–oxo–histidine formation. Retsky KL, et al. **Free Radic Biol Med** 1999 Jan;26(1–2):90–8

Function of the N–acetyl–L–histidine system in the vertebrate eye. Evidence in support of a role as a molecular water pump. Baslow MH. **J Mol Neurosci** 1998 Jun; 10(3):193–208

Interaction between surface active drug (FK906:rennin inhibitor) and cyclodextrins in aqueous solution. Kitamura S, et al. **J Pharm Sci** 1999 Mar;88(3):327–30

Determination of 2–oxohistidine by amino acid analysis. Lewisch SA, et al. **Methods Enzymol** 1999;300:120–4

High energy exchange: proteins that make or break phosphoramidate bonds. Robinson VL, et al. **Structure Fold Des** 1999 Mar 15;7(3):R47–53 (24 ref.)

ANALYSIS

Crystallization of a complex between a novel C–terminal transmitter, HPt domain, of the anaerobic sensor kinase ArcB and the chemotaxis response regulator CheY. Kato M, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jan 1; 54 (Pt 1):140–2

Mass spectrometric analysis of catechol–histidine adducts from insect cuticle. Kerwin JL, et al. **Anal Biochem** 1999 Mar 15;268(2):229–37

Purification and characterization of a histidine–rich glycoprotein that binds cadmium from the blood plasma of the bivalve Mytilus edulis. Nair PS, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):8–14

Isotachophoretic determination of 3–methylhistidine. Kvasnička F. **J Chromatogr A** 1999 Apr 9;838(1–2):191–5

Analysis of essential histidine residues of maize branching enzymes by chemical modification and site–directed mutagenesis. Funane K, et al. **J Protein Chem** 1998 Oct; 17(7):579–90

BIOSYNTHESIS

Buchnera aphidicola (Aphid endosymbiont) contains genes encoding enzymes of histidine biosynthesis. Clark MA, et al. **Curr Microbiol** 1998 Nov;37(5):356–8

A histidine gene cluster of the hyperthermophile Thermotoga maritima: sequence analysis and evolutionary significance. Thoma R, et al. **Extremophiles** 1998 Nov;2(4):379–89

Efficient expression, purification and crystallisation of two hyperthermostable enzymes of histidine biosynthesis. Thoma R, et al. **FEBS Lett** 1999 Jul 2;454(1–2):1–6

Histidine operon deattenuation in dnaA mutants of Salmonella typhimurium correlates with a decrease in the gene dosage ratio between tRNA(His) and histidine biosynthetic loci. Blanc–Potard AB, et al. **J Bacteriol** 1999 May;181(9):2938–41

Regulation of expression of the Lactococcus lactis histidine operon. Delorme C, et al. **J Bacteriol** 1999 Apr; 181(7):2026–37

Histidinol phosphate phosphatase, catalyzing the penultimate step of the histidine biosynthesis pathway, is encoded by ytvP (hisJ) in Bacillus subtilis. le Coq D, et al. **J Bacteriol** 1999 May;181(10):3277–80

Isolation and characterization of a histidine biosynthetic gene in Arabidopsis encoding a polypeptide with two separate domains for phosphoribosyl–ATP pyrophosphohydrolase and phosphoribosyl–AMP cyclohydrolase. Fujimori K, et al. **Plant Physiol** 1998 Sep;118(1):275–83

An aminoacyl–tRNA synthetase paralog with a catalytic role in histidine biosynthesis. Sissler M, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8985–90

Characterization of the histidine mutants of Kluyveromyces lactis. Zonneveld BJ, et al. **Yeast** 1999 Mar 30;15(5):377–84

BLOOD

High–performance liquid chromatographic method for rapid and highly sensitive determination of histidine using postcolumn fluorescence detection with o–phthaldialdehyde. Tateda N, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 6;718(2):235–41

CHEMISTRY

Recombinant His–tagged DNA polymerase. I. Cloning, purification and partial characterization of Thermus thermophilus recombinant DNA polymerase. Dąbrowski S, et al. **Acta Biochim Pol** 1998;45(3):653–60

Recombinant His–tagged DNA polymerase. II. Cloning and purification of Thermus aquaticus recombinant DNA polymerase (Stoffel fragment). Dąbrowski S, et al. **Acta Biochim Pol** 1998;45(3):661–7

Structure of the histidine–containing phosphotransfer (HPt) domain of the anaerobic sensor protein ArcB complexed with the chemotaxis response regulator CheY. Kato M, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jul;55 (Pt 7):1257–63

Spontaneous alpha–N–6–phosphogluconoylation of a "His tag" in Escherichia coli: the cause of extra mass of 258 or 178 Da in fusion proteins. Geoghegan KF, et al. **Anal Biochem** 1999 Feb 1;267(1):169–84

Purification of recombinant proteins by chemical removal of the affinity tag. Rais–Beghdadi C, et al. **Appl Biochem Biotechnol** 1998 Aug;74(2):95–103

Properties of the His57–Asp102 dyad of rat trypsin D189S in the zymogen, activated enzyme, and alpha1–proteinase inhibitor complexed forms. Kaslik G, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):254–64

Histidine–tailed microperoxidase–10: a pH–dependent ligand switch. Cheek J, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):195–8

Mass spectrometric determination of a novel modification of the N–terminus of histidine–tagged proteins expressed in bacteria. Yan Z, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):271–82

The histidine–rich protamine from ostrich and tinamou sperm. A link between reptile and bird protamines. Ausió J, et al. **Biochemistry** 1999 Jan 5;38(1):180–4

Substitutions at histidine 74 and aspartate 278 alter ligand binding and allostery in lactose repressor protein. Barry JK, et al. **Biochemistry** 1999 Mar 23;38(12):3579–90

Galactose mutarotase: purification, characterization, and investigations of two important histidine residues. Beebe JA, et al. **Biochemistry** 1998 Oct 20;37(42):14989–97

Heteronuclear NMR and crystallographic studies of wild–type and H187Q Escherichia coli uracil DNA glycosylase: electrophilic catalysis of uracil expulsion by a neutral histidine 187. Drohat AC, et al. **Biochemistry** 1999 Sep 14;38(37):11876–86

Role of D1–His190 in the proton–coupled oxidation of tyrosine YZ in manganese–depleted photosystem II. Hays AM, et al. **Biochemistry** 1999 Sep 14;38(37):11851–65

Combinatorial optimization of the DNA cleaving Ni(II) x Xaa–Xaa–His metallotripeptide domain. Huang X, et al. **Biochemistry** 1999 Feb 16;38(7):2160–6

Backbone dynamics of azurin in solution: slow conformational change associated with deprotonation of histidine 35. Kalverda AP, et al. **Biochemistry** 1999 Sep 28;38(39):12690–7

Evaluation of the role of His447 in the reaction catalyzed by cholesterol oxidase. Kass IJ, et al. **Biochemistry** 1998 Dec 22;37(51):17990–8000

Role of proximal His93 in nitric oxide binding to metmyoglobin. Application of continuum solvation in Monte Carlo protein simulations. Keserü GM, et al. **Biochemistry** 1999 May 18;38(20):6614–22

UV resonance Raman studies of alpha–nitrosyl hemoglobin derivatives: relation between the alpha 1–beta 2 subunit interface interactions and the Fe–histidine bonding of alpha heme. Nagatomo S, et al. **Biochemistry** 1999 Jul 27; 38(30):9659–66

Hydrogen bonding interaction between the primary quinone acceptor QA and a histidine side chain in photosystem II as revealed by Fourier transform infrared spectroscopy. Noguchi T, et al. **Biochemistry** 1999 Jan 5;38(1):399–403

The roles of Glu–327 and His–446 in the bisphosphatase reaction of rat liver 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase probed by NMR spectroscopic and mutational analyses of the enzyme in the transient phosphohistidine intermediate complex. Okar DA, et al. **Biochemistry** 1999 Apr 6; 38(14):4471–9

His...Asp catalytic dyad of ribonuclease A: conformational stability of the wild–type, D121N, D121A, and H119A enzymes. Quirk DJ, et al. **Biochemistry** 1998 Dec 22; 37(51):17958–64

Role of His159 in yeast enolase catalysis. Vinarov DA, et al. **Biochemistry** 1999 Sep 14;38(37):12138–49

Active site characterization of the exo–N–acetyl–beta–D–glucosaminidase from thermotolerant Bacillus sp. NCIM 5120: involvement of tryptophan, histidine and carboxylate residues in catalytic activity. Amutha B, et al. **Biochim Biophys Acta** 1999 Mar 14;1427(1):121–32

Systematic mutations of highly conserved His49 and carboxyl–terminal of recombinant porcine liver NADH–cytochrome b5 reductase solubilized domain. Kimura S, et al. **Biochim Biophys Acta** 1999 Mar 19; 1430(2):290–301

Essential histidyl residues at the active site(s) of sucrose–phosphate synthase from Prosopis juliflora. Sinha AK, et al. **Biochim Biophys Acta** 1998 Nov 10; 1388(2):397–404

Bifunctional phosphoramidite reagents for the introduction of histidyl and dihistidyl residues into oligonucleotides. Smith TH, et al. **Bioconjug Chem** 1999 Jul–Aug; 10(4):647–52

Modification of histidine residues by 4,5–epoxy–2–alkenals. Zamora R, et al. **Chem Res Toxicol** 1999 Jul;12(7):654–60

Chiroptical rhythmicity, Part 2: Evidence for signal transduction by stereoselective ion pair formation at the membrane/water interface. Ghebremariam B, et al. **Enantiomer** 1999;4(2):131–9

The lactose transporter of Staphylococcus aureus––overexpression, purification and characterization of the histidine–tagged domains IIC and IIB. Kowolik CM, et al. **Eur J Biochem** 1998 Oct 15;257(2):389–94

Chemical modification of NADP–isocitrate dehydrogenase from Cephalosporium acremonium evidence of essential histidine and lysine groups at the active site. Olano J, et al. **Eur J Biochem** 1999 May;261(3):640–9

Physical state of L–histidine after freeze–drying and long–term storage. Osterberg T, et al. **Eur J Pharm Sci** 1999 Aug;8(4):301–8

Natural agonist enhancing bis–His zinc–site in transmembrane segment V of the tachykinin NK3 receptor. Rosenkilde MM, et al. **FEBS Lett** 1998 Nov 13;439(1–2):35–40

Site–selective control of the reactivity of surface–exposed histidine residues in designed four–helix–bundle catalysts. Broo KS, et al. **Fold Des** 1998;3(4):303–12

The structure and function of the histidine–containing phosphotransfer (HPt) signaling domain of the Escherichia coli ArcB sensor. Matsushika A, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):440–5

Hydroxide rather than histidine is coordinated to the heme in five–coordinate ferric Scapharca inaequivalvis hemoglobin. Das TK, et al. **J Biol Chem** 1999 Jan 29; 274(5):2916–9

The structure and unusual pH dependence of plastocyanin from the fern Dryopteris crassirhizoma. The protonation of an active site histidine is hindered by pi–pi interactions. Kohzuma T, et al. **J Biol Chem** 1999 Apr 23; 274(17):11817–23

Nickel–catalyzed N–terminal oxidative deamination in peptides containing histidine at position 2 coupled with sulfite oxidation. Levine J, et al. **J Biol Chem** 1999 Feb 19;274(8):4848–57

Receptor recognition by histidine 16 of human epidermal growth factor via hydrogen–bond donor/acceptor interactions. Nandagopal K, et al. **J Cell Biochem** 1999 Jan 1;72(1):16–24

Inhibition of adhesion and induction of epithelial cell invasion by HAV–containing E–cadherin–specific peptides. Noë V, et al. **J Cell Sci** 1999 Jan;112 (Pt 1):127–35

Selective adsorption of poly–His tagged glutaryl acylase on tailor–made metal chelate supports. Armisén P, et al. **J Chromatogr A** 1999 Jul 2;848(1–2):61–70

Influence of chemical modification of cysteine and histidine side chains upon subunit reassembly of alpha crystallin. Pal J, et al. **J Protein Chem** 1998 Oct;17(7):617–32

Kinetic and mutagenic evidence for the role of histidine residues in the Lycopersicon esculentum 1–aminocyclopropane–1–carboxylic acid oxidase. Tayeh MA, et al. **J Protein Chem** 1999 Jan;18(1):55–68

The anti–angiogenic agent fumagillin covalently modifies a conserved active–site histidine in the Escherichia coli methionine aminopeptidase. Lowther WT, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12153–7

Catalytic role of the active site histidine of porcine pancreatic phospholipase A2 probed by the variants H48Q, H48N and H48K. Janssen MJ, et al. **Protein Eng** 1999 Jun; 12(6):497–503

Evidence for a copper–coordinated histidine–tyrosine cross–link in the active site of cytochrome oxidase. Buse G, et al. **Protein Sci** 1999 May;8(5):985–90

Exploring protein interiors: the role of a buried histidine in the KH module fold. Fraternali F, et al. **Proteins** 1999 Mar 1;34(4):484–96

Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu–opioid receptor in binding of mu–selective ligands. Xu H, et al. **Synapse** 1999 Apr; 32(1):23–8

GENETICS

Characterization of the membrane quinoprotein glucose dehydrogenase from Escherichia coli and characterization of a site–directed mutant in which histidine–262 has been changed to tyrosine. Cozier GE, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):639–47

Site–directed mutagenesis of histidine 245 in firefly luciferase: a proposed model of the active site. Branchini BR, et al. **Biochemistry** 1998 Nov 3;37(44):15311–9

Photoaffinity labeling with the activator IMP and site–directed mutagenesis of histidine 995 of carbamoyl phosphate synthetase from Escherichia coli demonstrate that the binding site for IMP overlaps with that for the inhibitor UMP. Bueso J, et al. **Biochemistry** 1999 Mar 30; 38(13):3910–7

The distal cavity structure of carbonyl horseradish peroxidase as probed by the resonance Raman spectra of His 42 Leu and Arg 38 Leu mutants. Feis A, et al. **Biochemistry** 1998 Sep 29;37(39):13575–81

Effect of pH on formation of a nativelike intermediate on the unfolding pathway of a Lys 73 --> His variant of yeast iso–1–cytochrome c. Godbole S, et al. **Biochemistry** 1999 Jan 5;38(1):487–95

Site–directed mutagenesis of charged and potentially proton–carrying residues in the beta subunit of the proton–translocating nicotinamide nucleotide transhydrogenase from Escherichia coli. Characterization of the beta H91, beta D392, and beta K424 mutants. Hu X, et al. **Biochemistry** 1999 Feb 2;38(5):1652–8

(S)–Mandelate dehydrogenase from Pseudomonas putida: mutations of the catalytic base histidine–274 and chemical

rescue of activity. Lehoux IE, et al. **Biochemistry** 1999 Aug 3;38(31):9948–55

Effects of mutations of the alpha His45 residue of Vibrio harveyi luciferase on the yield and reactivity of the flavin peroxide intermediate. Li H, et al. **Biochemistry** 1999 Apr 6;38(14):4409–15

Mutagenesis studies of the FeSII protein of Azotobacter vinelandii: roles of histidine and lysine residues in the protection of nitrogenase from oxygen damage. Lou J, et al. **Biochemistry** 1999 Apr 27;38(17):5563–71

The functional role of positively charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a His-tagged recombinant alpha-bungarotoxin. Rosenthal JA, et al. **Biochemistry** 1999 Jun 15;38(24):7847–55

Structural consequences of the B5 histidine —> tyrosine mutation in human insulin characterized by X-ray crystallography and conformational analysis. Tang L, et al. **Biochemistry** 1999 Sep 14;38(37):12041–51

Mutagenesis of histidinol dehydrogenase reveals roles for conserved histidine residues. Teng H, et al. **Biochemistry** 1999 Jun 1;38(22):7363–71

Positive selection vectors to generate fused genes for the expression of his-tagged proteins. Van Reeth T, et al. **Biotechniques** 1998 Nov;25(5):898–904

A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Nakagawa S, et al. **Br J Cancer** 1999 Feb;79(3–4):589–94

Posttranslational deamidation of proteins: the case of hemoglobin J Sardegna [alpha50(CD8)His-->Asn-->Asp]. Paleari R, et al. **Clin Chem** 1999 Jan;45(1):21–8

His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype. Duc HH, et al. **Eur J Hum Genet** 1998 Nov-Dec;6(6):616–23

Independent occurrence of the novel Arg2163 to His mutation in the factor VIII gene in three unrelated families with haemophila A with different phenotypes. Mutations in brief no. 126. Online. Theophilus BD, et al. **Hum Mutat** 1998;11(4):334

Mutagenesis of active-site histidines of Listeria monocytogenes phosphatidylinositol-specific phospholipase C: effects on enzyme activity and biological function. Bannam T, et al. **Infect Immun** 1999 Jan; 67(1):182–6

The roles of two amino acid residues in the active site of L-lactate monooxygenase. Mutation of arginine 187 to methionine and histidine 240 to glutamine. Sanders SA, et al. **J Biol Chem** 1999 Aug 6;274(32):22289–95

Mutation at histidine 338 of gp91(phox) depletes FAD and affects expression of cytochrome b558 of the human NADPH oxidase. Yoshida LS, et al. **J Biol Chem** 1998 Oct 23;273(43):27879–86

Probing transmembrane topology of the high-affinity Sodium/Glucose cotransporter (SGLT1) with histidine-tagged mutants. Lin J, et al. **J Membr Biol** 1999 Aug 1;170(3):243–52

Isolation and characterization of a histidine biosynthetic gene in Arabidopsis encoding a polypeptide with two separate domains for phosphoribosyl-ATP pyrophosphohydrolase and phosphoribosyl-AMP cyclohydrolase. Fujimori K, et al. **Plant Physiol** 1998 Sep;118(1):275–83

IMMUNOLOGY

Specific detection by flow cytometry of histidine-tagged ligands bound to their receptors using a tag-specific monoclonal antibody. Wilken HC, et al. **J Immunol Methods** 1999 Jun 24;226(1–2):139–45

METABOLISM

Introduction of histidine analogs leads to enhanced proton transfer in carbonic anhydrase V. Earnhardt JN, et al. **Arch Biochem Biophys** 1999 Jan 15;361(2):264–70

Metmyoglobin/fluoride: effect of distal histidine protonation on the association and dissociation rate constants. Merryweather J, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):359–68

The roles of histidine residues at the starch-binding site in streptococcal-binding activities of human salivary amylase. Tseng CC, et al. **Arch Oral Biol** 1999 Feb;44(2):119–27

Identification of a histidine acid phosphatase (phyA)-like gene in Arabidopsis thaliana. Mullaney EJ, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):252–5

Role of the His273 located in the sixth transmembrane domain of the angiotensin II receptor subtype AT2 in ligand-receptor interaction. Turner CA, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):704–7

Electron paramagnetic resonance measurements of the ferrous mononuclear site of phthalate dioxygenase substituted with alternate divalent metal ions: direct evidence for ligation of two histidines in the copper(II)-reconstituted protein. Coulter ED, et al. **Biochemistry** 1999 Aug 24;38(34):11062–72

Effects on substrate reduction of substitution of histidine-195 by glutamine in the alpha-subunit of the MoFe protein of Azotobacter vinelandii nitrogenase. Dilworth MJ, et al. **Biochemistry** 1998 Dec 15;37(50):17495–505

Use of a novel histidyl modifier to probe for residues on Tris-treated photosystem II membrane fragments that may bind functional manganese. Ghirardi ML, et al. **Biochemistry** 1998 Sep 29;37(39):13567–74

His68 and His141 are critical contributors to the intersubunit catalytic site of adenylosuccinate lyase of Bacillus subtilis. Lee TT, et al. **Biochemistry** 1999 Jan 5;38(1):22–32

Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Liu ST, et al. **Biochemistry** 1999 Jul 20;38(29):9373–8

Replacement of the proximal histidine iron ligand by a cysteine or tyrosine converts heme oxygenase to an oxidase. Liu Y, et al. **Biochemistry** 1999 Mar 23;38(12):3733–43

Involvement of histidine 190 on the D1 protein in electron/proton transfer reactions on the donor side of photosystem II. Mamedov F, et al. **Biochemistry** 1998 Oct 6;37(40):14245–56

Structure of a histidine ligand in the photosynthetic oxygen-evolving complex as studied by light-induced fourier transform infrared difference spectroscopy. Noguchi T, et al. **Biochemistry** 1999 Aug 3;38(31):10187–95

Effects of L-histidine and its structural analogues on human N-myristoyltransferase activity and importance of EEVEH amino acid sequence for enzyme activity. Raju RV, et al. **Biochemistry** 1998 Oct 20;37(42):14928–36

Identification of two important heme site residues (cysteine 75 and histidine 77) in CooA, the CO-sensing transcription factor of Rhodospirillum rubrum. Shelver D, et al. **Biochemistry** 1999 Mar 2;38(9):2669–78

Role of His159 in yeast enolase catalysis. Vinarov DA, et al. **Biochemistry** 1999 Sep 14;38(37):12138–49

Involvement of essential cysteine and histidine residues in the activity of isolated glutaminase from tumour cells. Campos JA, et al. **Biochim Biophys Acta** 1998 Dec 8; 1429(1):275–83

Inhibitory effects in vitro of S-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-glutathione, a proposed metabolite of L-histidine, on gamma-glutamyltransferase activity. Shimizu H, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):112–8

Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase. Doorn JA, et al. **Chem Biol Interact** 1999 May 14;119-120:235–41

The role of distal histidine in peroxidase activity of myoglobin--transient-kinetics study of the reaction of H2O2 with wild-type and distal-histidine-mutanted recombinant human myoglobin [published erratum appears in Eur J Biochem 1999 Apr;261(2):591] Khan KK, et al. **Eur J Biochem** 1998 Nov 1;257(3):547–55

Association of His117 in the D2 protein of photosystem II with a chlorophyll that affects excitation-energy transfer efficiency to the reaction center. Lince MT, et al. **Eur J Biochem** 1998 Sep 15;256(3):595–602

Purification of a serine and histidine phosphorylated mitochondrial nucleoside diphosphate kinase from Pisum sativum. Struglics A, et al. **Eur J Biochem** 1999 Jun; 262(3):765–73

Overexpression of nucleoside diphosphate kinases induces neurite outgrowth and their substitution to inactive forms leads to suppression of nerve growth factor- and dibutyryl cyclic AMP-induced effects in PC12D cells. Ishijima Y, et al. **FEBS Lett** 1999 Feb 19;445(1):155–9

Possible role for ligand binding of histidine 81 in the second transmembrane domain of the rat prostaglandin F2alpha receptor. Rehwald M, et al. **FEBS Lett** 1999 Jan 29; 443(3):357–62

The role of a conserved histidine residue, His324, in Trigonopsis variabilis D-amino acid oxidase. Lin LL, et al. **FEMS Microbiol Lett** 1999 Jul 15;176(2):443–8

Toxicity of copper, cobalt, and nickel salts is dependent on histidine metabolism in the yeast Saccharomyces cerevisiae. Pearce DA, et al. **J Bacteriol** 1999 Aug;181(16):4774–9

trans-acting factors affecting carbon catabolite repression of the hut operon in Bacillus subtilis. Zalieckas JM, et al. **J Bacteriol** 1999 May;181(9):2883–8

Proton-relay system of carboxypeptidase Y as a sole catalytic site: studies on mutagenic replacement of his 397. Jung G, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):446–50

On the active site of Old Yellow Enzyme. Role of histidine 191 and asparagine 194. Brown BJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32753–62

Lysine 58 and histidine 66 at the C-terminal alpha-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. Chakravarty L, et al. **J Biol Chem** 1998 Nov 6;273(45):29641–7

Zinc coordination and substrate catalysis within the neuropeptide processing enzyme endopeptidase EC 3.4.24.15. Identification of active site histidine and glutamate residues. Cummins PM, et al. **J Biol Chem** 1999 Jun 4;274(23):16003–9

EPR characterization of axial bond in metal center of native and cobalt-substituted guanylate cyclase. Makino R, et al. **J Biol Chem** 1999 Mar 19;274(12):7714–23

Effects of the location of distal histidine in the reaction of myoglobin with hydrogen peroxide. Matsui T, et al. **J Biol Chem** 1999 Jan 29;274(5):2838–44

Reaction mechanism of fructose-2,6-bisphosphatase. A mutation of nucleophilic catalyst, histidine 256, induces an alteration in the reaction pathway. Mizuguchi H, et al. **J Biol Chem** 1999 Jan 22;274(4):2166–75

Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. Silvente-Poirot S, et al. **J Biol Chem** 1999 Aug 13;274(33):23191–7

The active site of Escherichia coli UDP-N-acetylglucosamine acyltransferase. Chemical modification and site-directed mutagenesis. Wyckoff TJ, et al. **J Biol Chem** 1999 Sep 17;274(38):27047–55

DNA-histidine complex formation in isoelectric histidine buffers. Stellwagen NC, et al. **J Chromatogr A** 1999 Apr 9;838(1–2):179–89

The degradation of L-histidine and trans- and cis-urocanic acid by bacteria from skin and the role of bacterial cis-urocanic acid isomerase. Hug DH, et al. **J Photochem Photobiol B** 1999 May;50(1):66–73

Histidine-tagging and purification of tobacco etch potyvirus helper component protein. Blanc S, et al. **J Virol Methods** 1999 Jan;77(1):11–5

Histidine-phosphorylation of succinyl CoA synthetase from Trypanosoma brucei. Hunger-Glaser I, et al. **Mol Biochem Parasitol** 1999 May 15;100(1):43–52

Differential sensitivity of voltage-gated potassium channels Kv1.5 and Kv1.2 to acidic pH and molecular identification of pH sensor. Steidl JV, et al. **Mol Pharmacol** 1999 May; 55(5):812–20

Compilation and characterization of Arabidopsis thaliana response regulators implicated in His-Asp phosphorelay signal transduction. Imamura A, et al. **Plant Cell Physiol** 1999 Jul;40(7):733–42

Histidine-containing phosphotransfer (HPt) signal transducers implicated in His-to-Asp phosphorelay in Arabidopsis. Suzuki T, et al. **Plant Cell Physiol** 1998 Dec; 39(12):1258–68

Signalling pathways in two-component phosphorelay systems. Perraud AL, et al. **Trends Microbiol** 1999 Mar; 7(3):115–20 (38 ref.)

[His-Asp phosphotransfer signal transduction] Mizuno T. **Tanpakushitsu Kakusan Koso** 1999 Mar;44(4 Suppl):412–20 (16 ref.) **(Jpn)**

[Modulatory effects of various factors of muscular origin on the function of the motor nerve endings] Drabkina TM, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Jan; 85(1):149–58 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Stereoselective blood-brain barrier transport of histidine in rats. Yamakami J, et al. **Brain Res** 1998 Nov 23; 812(1–2):105–12

PHARMACOLOGY

Protective effect of histidine on MPP+-induced hydroxyl radical generation in rat striatum. Obata T, et al. **Brain Res** 1999 Jan 30;817(1–2):206–8

Effect of histidine on myocardial mitochondria and platelet aggregation during thrombotic cerebral ischemia in rats. Li SQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep; 19(5):493–6

Histamine H3 receptor binding sites in rat cortex following L-histidine loading. Lozeva V, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S59–60

Protective effect of histidine on iron (II)-induced hydroxyl radical generation in rat hearts. Obata T, et al. **J Physiol Paris** 1999 May-Jun;93(3):213–8

Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand. Suginaka R, et al. **Jpn J Cancer Res** 1998 Sep;89(9):947–53

Protective effect of histidine on hydroxyl radical generation induced by potassium-depolarization in rat myocardium. Obata T, et al. **Jpn J Pharmacol** 1999 Jul;80(3):217–22

Effect of carnosine and its components on free-radical reactions. Klebanov GI, et al. **Membr Cell Biol** 1998; 12(1):89–99

PHYSIOLOGY

Possible roles for His 208 in the active-site region of chloroplast carbonic anhydrase from Pisum sativum. Björkbacka H, et al. **Arch Biochem Biophys** 1999 Jan 1; 361(1):17–24

Role of His-224 in the anomalous pH dependence of human stromelysin-1. Holman CM, et al. **Biochemistry** 1999 Jan 12;38(2):677–81

Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A. Omburo GA, et al. **Cell Signal** 1998 Jul;10(7):491–7

Evidence for the role of His-142 of protein 1C in the acid-induced disassembly of foot-and-mouth disease virus capsids. Ellard FM, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1911–8

Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor. Choi YB, et al. **Neuron** 1999 May; 23(1):171–80

THERAPEUTIC USE

Improved functional recovery of ischemic rat hearts due to singlet oxygen scavengers histidine and carnosine. Lee JW, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):113–21

HISTIDINE AMMONIA-LYASE

BIOSYNTHESIS

Regulation of histidase gene expression by glucagon,

HISTIDINE AMMONIA-LYASE

hydrocortisone and protein-free/high carbohydrate diet in the rat. Aleman G, et al. **Life Sci** 1998;63(18):1663-72

CHEMISTRY

Crystallization and preliminary X-ray studies of Pseudomonas putida histidine ammonium-lyase. Teo B, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1;54 (Pt 4):681-3

Crystal structure of histidine ammonia-lyase revealing a novel polypeptide modification as the catalytic electrophile. Schwede TF, et al. **Biochemistry** 1999 Apr 27;38(17):5355-61

Homogenization and crystallization of histidine ammonia-lyase by exchange of a surface cysteine residue. Schwede TF, et al. **Protein Eng** 1999 Feb;12(2):151-3

GENETICS

Hepatic histidase gene expression responds to protein rehabilitation in undernourished growing rats. Tovar AR, et al. **J Nutr** 1998 Oct;128(10):1631-5

METABOLISM

Hepatic histidase gene expression responds to protein rehabilitation in undernourished growing rats. Tovar AR, et al. **J Nutr** 1998 Oct;128(10):1631-5

HISTIDINE CARBOXY-LYASE see **HISTIDINE DECARBOXYLASE**

HISTIDINE DECARBOXYLASE

ANALYSIS

Immunolocalization of gastrin-dependent histidine decarboxylase activity in rat gastric mucosa during feeding. Ohning GV, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G660-7

Presence and localization of histidine decarboxylase enzyme (HDC) and histamine in Tetrahymena pyriformis. Hegyesi H, et al. **Cell Biol Int** 1998;22(7-8):493-7

[A method for the assay of histidine decarboxylase activity] Endo Y. **Nippon Yakurigaku Zasshi** 1998 Nov; 112(5):307-14 (30 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Novel histamine measurement by HPLC analysis used to assay histidine decarboxylase inhibitory activity of shoyuflavones from soy sauce. Kinoshita E, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1488-91

BIOSYNTHESIS

Modulation of histidine decarboxylase activity and cytokine synthesis in human leukemic cell lines: relationship with basophilic and/or megakaryocytic differentiation. Dy M, et al. **Exp Hematol** 1999 Aug;27(8):1295-305

Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. Conti P, et al. **FASEB J** 1998 Dec;12(15):1693-700

Histidine decarboxylase expression in human monocytes, macrophages and macrophage subsets. Belke K, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):353-4

Mast cell-/basophil-specific transcriptional regulation of human L-histidine decarboxylase gene by CpG methylation in the promoter region. Kuramasu A, et al. **J Biol Chem** 1998 Nov 20;273(47):31607-14

BLOOD

Increase of histidine decarboxylase in human monocytes during macrophage colony stimulating factor induced in vitro phagocytic differentiation. László V, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S85-6

Detection of histidine decarboxylase in peripheral blood leukocytes by flow cytometry. Szeberényi JB, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S87-9

CHEMISTRY

Multiple forms of rat stomach histidine decarboxylase may reflect posttranslational activation of the enzyme. Dartsch C, et al. **Regul Pept** 1998 Oct 16;77(1-3):33-41

GENETICS

Expression of histidine decarboxylase messenger RNA and histamine N-methyltransferase messenger RNA in nasal allergy [see comments] Hirata N, et al. **Clin Exp Allergy** 1999 Jan;29(1):76-83. Comment in: Clin Exp Allergy 1999 Jan;29(1):9-11.

Development of the histaminergic neurons and expression of histidine decarboxylase mRNA in the zebrafish brain in the absence of all peripheral histaminergic systems. Eriksson KS, et al. **Eur J Neurosci** 1998 Dec; 10(12):3799-812

IL-3-induced coexpression of histidine decarboxylase, IL-4 and IL-6 mRNA by murine basophil precursors. Schneider E, et al. **Exp Hematol** 1999 Jun;27(6):1010-8

Activation of human histidine decarboxylase gene promoter activity by gastrin is mediated by two distinct nuclear factors. Raychowdhury R, et al. **J Biol Chem** 1999 Jul 23; 274(30):20961-9

Control of histidine decarboxylase gene expression in enterochromaffin-like cells. Dimaline R, et al. **Yale J Biol Med** 1998 May-Aug;71(3-4):195-205 (56 ref.)

METABOLISM

Intracisternal TRH analog increases gastrin release and corpus histidine decarboxylase activity in rats. Song M, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G901-8

The pest regions containing C-termini of mammalian ornithine decarboxylase and histidine decarboxylase play different roles in protein degradation. Olmo MT, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):269-72

Multiple forms of histidine decarboxylase may reflect posttranslational activation. Dartsch C, et al. **Biochem Soc Trans** 1998 Nov;26(4):S377

Induction by interleukin-1, tumor necrosis factor and lipopolysaccharides of histidine decarboxylase in the stomach and prolonged accumulation of gastric acid. Endo Y, et al. **Br J Pharmacol** 1998 Oct;125(4):842-8

Membrane targeting and binding of the 74-kDa form of mouse L-histidine decarboxylase via its carboxyl-terminal sequence. Suzuki S, et al. **FEBS Lett** 1998 Oct 16; 437(1-2):44-8

Possible involvement of histamine in muscular fatigue in temporomandibular disorders: animal and human studies. Watanabe M, et al. **J Dent Res** 1999 Mar;78(3):769-75

Increase in histidine decarboxylase activity in tissues of mice bearing Colon-26 tumor cells. Takeuchi Y, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):92-8

Novel aspects of gastrin-induced activation of histidine decarboxylase in rat stomach ECL cells. Chen D, et al. **Regul Pept** 1998 Oct 16;77(1-3):169-75

Histidine decarboxylase in rat stomach ECL cells: relationship between enzyme activity and different molecular forms. Dartsch C, et al. **Regul Pept** 1999 May 31;81(1-3):41-8

Rat stomach ECL-cell histidine decarboxylase activity is suppressed by ergocalciferol but unaffected by parathyroid hormone and calcitonin. Gagnemo-Persson R, et al. **Regul Pept** 1999 Feb 5;79(2-3):131-9

Ontogeny of ECL cells in the rat. Sundler F. **Yale J Biol Med** 1998 May-Aug;71(3-4):155-61 (24 ref.)

HISTIDINE-SPECIFIC TRNA see **RNA, TRANSFER, HIS**

HISTIDINE-TRNA LIGASE

DEFICIENCY

[High resolution CT of the lung in Jo-1 syndrome: rapidly progressive fibrosis as a sequela of histidyl-tRNA synthetase deficiency syndrome] Gries C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):450-2 **(Ger)**

IMMUNOLOGY

Pulmonary fibrosis in polymyositis with the Jo-1 syndrome: an unusual mode of presentation. Kiely JL, et al. **Respir Med** 1998 Sep;92(9):1167-9

METABOLISM

Histidyl-tRNA synthetase. Freist W, et al. **Biol Chem** 1999 Jun;380(6):623-46 (264 ref.)

HISTIDINOL

PHARMACOLOGY

Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice. Al-Shabanah OA, et al. **Pharmacol Res** 1998 Sep;38(3):225-30

THERAPEUTIC USE

L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Badary OA. **Exp Nephrol** 1999 Jul-Aug; 7(4):323-7

HISTIDINOL-PHOSPHATASE

GENETICS

Histidinol phosphate phosphatase, catalyzing the penultimate step of the histidine biosynthesis pathway, is encoded by ytvP (hisJ) in Bacillus subtilis. le Coq D, et al. **J Bacteriol** 1999 May;181(10):3277-80

HISTIDINOL PHOSPHATE PHOSPHATASE see **HISTIDINOL-PHOSPHATASE**

HISTIDOL see **HISTIDINOL**

HISTIDYL T RNA SYNTHETASE see **HISTIDINE-TRNA LIGASE**

HISTIOCYTES

Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Nguyen TN, et al. **Diagn Cytopathol** 1998 Aug;19(2):89-93

1998 Annual Histiocyte Society Abstracts, 14th Annual meeting. Kyoto, Japan, 30 September-2 October 1998. **Med Pediatr Oncol** 1999 Mar;32(3):234-45

CYTOLOGY

Lack of heat shock response triggers programmed cell death in a rat histiocytic cell line. Sreedhar AS, et al. **FEBS Lett** 1999 Aug 6;456(2):339-42

Anitschkow myocytes or cardiac histiocytes in human hearts. Stehbens WE, et al. **Pathology** 1999 May;31(2):98-101

DRUG EFFECTS

Histiocyte reaction in rabbit femurs to UHMWPE, metal, and ceramic particles in different sizes. Kubo T, et al. **J Biomed Mater Res** 1999 Jun 15;45(4):363-9

METABOLISM

Lack of heat shock response triggers programmed cell death in a rat histiocytic cell line. Sreedhar AS, et al. **FEBS Lett** 1999 Aug 6;456(2):339-42

PATHOLOGY

Transthoracic fine-needle aspiration cytology of inflammatory pseudotumor, fibrohistiocytic type: a case report with immunohistochemical studies. Bakhos R, et al. **Diagn Cytopathol** 1998 Sep;19(3):216-20

Combined clear and granular cell leiomyoma of soft tissue: evidence of transformation to a histiocytic phenotype. Dobashi Y, et al. **Histopathology** 1999 Jun;34(6):526-31

Phenotypic characterization of histiocytes infiltrating a leiomyofibrosarcoma. Whyte A, et al. **J Comp Pathol** 1999 Feb;120(2):177-86

Origin of histiocyte-like cells and multinucleated giant cells in malignant fibrous histiocytoma: neoplastic or reactive? Hatano H, et al. **Pathol Int** 1999 Jan;49(1):14-22

Histiocytoid cardiomyopathy: three new cases and a review of the literature. Shehata BM, et al. **Pediatr Dev Pathol** 1998 Jan-Feb;1(1):56-69 (45 ref.)

ULTRASTRUCTURE

Subacute inflammatory polyneuropathy: two cases with plasmacytoid histiocytes in the endoneurium. Vital C, et al. **Ultrastruct Pathol** 1998 Sep-Oct;22(5):377-83

HISTIOCYTIC LYMPHOMA see **LYMPHOMA, LARGE-CELL**

HISTIOCYTIC LYMPHOMA, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

HISTIOCYTIC LYMPHOMA, NODULAR see **LYMPHOMA, LARGE-CELL, FOLLICULAR**

HISTIOCYTIC NECROTIZING LYMPHADENITIS

The histopathology of cutaneous lesions of Kikuchi's disease (necrotizing lymphadenitis): a report of five cases. Spies J, et al. **Am J Surg Pathol** 1999 Sep;23(9):1040-7

[Necrotizing lymphadenitis] Asano S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):326-9 (18 ref.) **(Jpn)**

[Histiocytic necrotizing lymphadenitis: Kikuchi-Fujimoto disease. Apropos of 6 cases] Lorenzo Hernández A, et al. **An Med Interna** 1999 Jun;16(6):301-4 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Kikuchi lymphadenitis and AIDS [letter; comment] Ereño C. **Histopathology** 1999 Mar;34(3):273. Comment on: Histopathology 1998 Sep;33(3):248-54.

Kikuchi's histiocytic necrotizing lymphadenitis driven by activated cytolytic T-cells: an example associated with systemic scleroderma [letter] Laeng RH, et al. **Histopathology** 1999 Apr;34(4):373-4

Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. Mathew LG, et al. **Indian Pediatr** 1998 Aug;35(8):775-7

Kikuchi disease associated with Still disease. Cousin F, et al. **Int J Dermatol** 1999 Jun;38(6):464-7

Histiocytic necrotizing lymphadenitis (Kikuchi's disease) with aseptic meningitis. Sato Y, et al. **J Neurol Sci** 1999 Mar 1;163(2):187-91 (13 ref.)

Kikuchi's disease with leukocytoclastic vasculitis in a 10-year-old girl. Kawai H, et al. **Pediatr Int** 1999 Jun; 41(3):323-6

Kikuchi's disease with multisystemic involvement and adverse reaction to drugs. Sierra ML, et al. **Pediatrics** 1999 Aug;104(2):e24

[A case of subacute necrotizing lymphadenitis complicated with brachial plexus neuritis] Sugiyama A, et al. **Rinsho Shinkeigaku** 1998 Oct-Nov;38(10-11):941-4 (Eng. Abstr.) **(Jpn)**

[Subacute necrotizing lymphadenitis associated with mononeuritis multiplex. A case report] Tsuboi Y, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):465-7 (Eng. Abstr.) **(Jpn)**

[Kikuchi disease in an acquired immunodeficiency syndrome patient (letter)] Abad A, et al.

Enferm Infecc Microbiol Clin 1999 Apr;17(4):193–4 **(Spa)**

DIAGNOSIS

Three cases of Kikuchi–Fujimoto disease [letter] Santoro LF, et al. **Haematologica** 1999 May;84(5):465–6

Kikuchi lymphadenitis and AIDS [letter; comment] Ereño C. **Histopathology** 1999 Mar;34(3):273. Comment on: Histopathology 1998 Sep;33(3):248–54.

Kikuchi's disease: a benign cause of pyrexia of unknown origin with lymphadenopathy. Murali NS, et al. **J Indian Med Assoc** 1998 Mar;96(3):90–1

Kikuchi–Fujimoto's syndrome masquerading as tuberculosis. Jayaraj SM, et al. **J Laryngol Otol** 1999 Jan;113(1):82–4

[Kikuchi's lymphadenitis--a new disease in Finland?] Rauhala A, et al. **Duodecim** 1995;111(22):2165–9 **(Fin)**

[Cutaneous-lymph node Kikuchi-Fujimoto disease] Letawe C, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):26–8 (Eng. Abstr.) **(Fre)**

[Kikuchi–Fusimoto disease: the differential diagnosis of cervical lymphadenitis with recurrent attacks of fever] Kosch M, et al. **Dtsch Med Wochenschr** 1999 Feb 26; 124(8):213–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Kikuchi's disease (letter; comment)] Chocarro Martínez A, et al. **An Med Interna** 1999 Apr;16(4):208. Comment on: An Med Interna 1998 Jul;15(7):367–9. **(Spa)**

ENZYMOLOGY

Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Facchetti F, et al. **Am J Pathol** 1999 Jan;154(1):145–52

ETIOLOGY

Kikuchi disease in systemic lupus erythematosus: clinical features and literature review. Chen YH, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1998 Sep;31(3):187–92 (28 ref.)

IMMUNOLOGY

Kikuchi's histiocytic necrotizing lymphadenitis driven by activated cytolytic T-cells: an example associated with systemic scleroderma [letter] Laeng RH, et al. **Histopathology** 1999 Apr;34(4):373–4

Perforin and Fas pathways of cytotoxic T-cells in histiocytic necrotizing lymphadenitis. Ohshima K, et al. **Histopathology** 1998 Nov;33(5):471–8

Antibodies to the DEK protein in Kikuchi's disease [letter] Arnaudo JP, et al. **J Rheumatol** 1998 Sep;25(9):1861–2

PATHOLOGY

Apoptotic cell death in Kikuchi's disease: a TEM study. Iguchi H, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:250–3

Histiocytic necrotizing lymphadenitis (Kikuchi–Fujimoto disease): continuing diagnostic difficulties [see comments] Menasce LP, et al. **Histopathology** 1998 Sep;33(3):248–54 . Comment in: Histopathology 1999 Mar;34(3):273.

Pseudolymphomatous phase of Kikuchi–Fujimoto disease. Pai SA, et al. **Indian J Cancer** 1998 Sep;35(3):119–28

Histiocytic necrotizing lymphadenitis (Kikuchi's disease): the necrotic appearance of the lymph node cells is caused by apoptosis. Ura H, et al. **J Dermatol** 1999 Jun;26(6):385–9

Kikuchi's disease of the neck (histiocytic necrotizing lymphadenitis). Bhat NA, et al. **J Laryngol Otol** 1998 Sep; 112(9):898–900 (22 ref.)

Fatal Kikuchi–Fujimoto disease in transplant recipients: a case report. Tsai MK, et al. **Transplant Proc** 1998 Nov; 30(7):3137–8

[Kikuchi–Fujimoto disease of the neck] Li W, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Jul; 11(7):334–6 (17 ref.) **(Chi)**

[Kikuchi–Fujimoto subacute necrotizing lymphadenitis: two histologic forms observed in the same patient] el Mezni F, et al. **Ann Pathol** 1998 Nov;18(5):422–4 (Eng. Abstr.) **(Fre)**

[A 17-year-old woman with fever and cervical adenopathies (clinico-pathologic conference)] Oristrell J, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):428–35 **(Spa)**

PHYSIOPATHOLOGY

[Kikuchi disease] Meyer O. **Ann Med Interne (Paris)** 1999 Apr;150(3):199–204 (49 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Cross-sectional imaging of Kikuchi disease. Miller WT Jr, et al. **J Comput Assist Tomogr** 1999 Jul–Aug;23(4):548–51

VIROLOGY

Kaposi's sarcoma-associated herpesvirus in Kikuchi's disease. Huh J, et al. **Hum Pathol** 1998 Oct;29(10):1091–6

HISTIOCYTOMA see **DERMATOFIBROMA**

HISTIOCYTOMA, FIBROUS

Malignant fibrous histiocytoma of the stomach during pregnancy: a case report. Wiersema AM, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):71–3

Primary malignant fibrous histiocytoma of spleen. Mallipudi BV, et al. **Eur J Surg Oncol** 1998 Oct;24(5):448–9 (07 ref.)

Malignant fibrous histiocytoma of the rectum. Singh DR, et al. **Eur J Surg Oncol** 1999 Aug;25(4):447–8

Malignant fibrous histiocytoma of the gallbladder. Tomono H, et al. **Hepatogastroenterology** 1998 Sep–Oct; 45(23):1468–72

Malignant fibrous histiocytoma (MFH). A comparison of MFH in man and animals. A critical review. Schneider P, et al. **Histol Histopathol** 1999 Jul;14(3):845–60 (143 ref.)

Benign fibrous histiocytoma of the floor of the mouth. Hong KH, et al. **Otolaryngol Head Neck Surg** 1999 Sep; 121(3):330–3

CHEMISTRY

Immunohistochemical and histochemical characterization of the mucosubstances of odontogenic myxoma: histogenesis and differential diagnosis. Zhao M, et al. **Pathol Res Pract** 1999;195(6):391–7

CLASSIFICATION

[Fibrohistiocytic skin lesions] Zelger B. **Verh Dtsch Ges Pathol** 1998;82:290–300 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Pathologic odontoid fracture and benign fibrous histiocytoma of bone. Peicha G, et al. **Eur Spine J** 1999;8(2):161–3

Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia. Kenan S, et al. **Skeletal Radiol** 1998 Aug;27(8):463–7 (15 ref.)

[A case of fibrous histiocytoma of the appendix with twisted stalk] Fujishima N, et al. **Nippon Geka Gakkai Zasshi** 1998 Dec;99(12):865–7 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Malignant fibrous histiocytoma presenting as cystic pancreatic mass. Liu DM, et al. **Abdom Imaging** 1999 May–Jun;24(3):299–300

Primary malignant fibrous histiocytoma of the liver: imaging features of five surgically confirmed cases. Yu JS, et al. **Abdom Imaging** 1999 Jul–Aug;24(4):386–91

Retroperitoneal malignant fibrous histiocytoma. Répássy DL, et al. **Acta Chir Hung** 1998;37(3–4):271–9

Malignant fibrous histiocytoma of the jejunum [letter] Rasero M, et al. **Eur Radiol** 1999;9(6):1236–7

Renal fibrohistiocytic sarcoma. Three cases and a review of the literature. Haddad FS, et al. **J Med Liban** 1998 Nov–Dec;46(6):335–42 (50 ref.)

Haematoma-like primary intracranial malignant fibrous histiocytoma in a 5-year-old girl. Ozhan S, et al. **Neuroradiology** 1999 Jul;41(7):523–5

Test and Teach. Number Ninety: Part 1. Plexiform fibrohistiocytic tumor. Ng WK, et al. **Pathology** 1998 Aug; 30(3):257–8, 314–5

Fibrous histiocytoma and fibrous tissue tumors of the orbit. Dalley RW. **Radiol Clin North Am** 1999 Jan;37(1):185–94

Malignant fibrous histiocytoma of the trachea. Vinod SK, et al. **Respirology** 1999 Sep;4(3):271–4 (23 ref.)

Diagnosis: atypical fibroxanthoma or not? Evaluating spindle cell malignancies on sun damaged skin: a practical approach. Heintz PW, et al. **Semin Cutan Med Surg** 1999 Mar;18(1):78–83

Malignant fibrous histiocytoma of bone: conventional X-ray and MR imaging features. Link TM, et al. **Skeletal Radiol** 1998 Oct;27(10):552–8

[Farmer with osteomalacia?] Schlumpf U, et al. **Schweiz Med Wochenschr** 1998 Aug 22;128(34):1267 **(Ger)**

[Primary intracerebral malignant fibrous histiocytoma with adhesion to a dura: a case report] Fujiwara K, et al. **No Shinkei Geka** 1998 Sep;26(9):837–44 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Malignant fibrous histiocytoma on the chest wall (letter)] Martín Díaz E, et al. **Arch Bronconeumol** 1998 Oct; 34(9):467–8 **(Spa)**

ENZYMOLOGY

Expression of cathepsins in dermal fibrous tumors: an immunohistochemical study. Thewes M, et al. **Eur J Dermatol** 1998 Mar;8(2):86–9

Identification and characterization of a novel UDP-GalNAc:GlcAbeta-R alpha1,4-N-acetylgalactosaminyltransferase from a human sarcoma cell line. Kitagawa H, et al. **Glycobiology** 1999 Jul;9(7):697–703

ETIOLOGY

The development of a malignant fibrous histiocytoma after treatment for advanced testicular seminoma. Shinohara N, et al. **BJU Int** 1999 Feb;83(3):355–6

GENETICS

Diaphyseal medullary stenosis with malignant fibrous histiocytoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21–22. Martignetti JA, et al. **Am J Hum Genet** 1999 Mar;64(3):801–7

Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Mairal A, et al. **Cancer Genet Cytogenet** 1999 Jun;111(2):134–8

Identification of a ring chromosome in a myxoid malignant fibrous histiocytoma with chromosome microdissection and fluorescence in situ hybridization. Meloni-Ehrig AM, et al. **Cancer Genet Cytogenet** 1999 Feb;109(1):81–5

Cytogenetic findings in a malignant fibrous histiocytoma of the breast [letter] Pandis N, et al. **Cancer Genet Cytogenet** 1999 Jan 1;108(1):87–9

Plexiform fibrohistiocytic tumor with a clonal cytogenetic anomaly. Redlich GC, et al. **Cancer Genet Cytogenet** 1999 Jan 15;108(2):141–3

Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization. Sakabe T, et al. **Cancer Res** 1999 Feb 1;59(3):511–5

Assessment of genomic imbalances in malignant fibrous histiocytomas by comparative genomic hybridization. Hinze R, et al. **Int J Mol Med** 1999 Jan;3(1):75–9

Molecular biological observations in some rare neoplasms: DNA ploidy and cell cycle data in liposarcoma and malignant fibrous histiocytoma. Lüdemann M, et al. **Langenbecks Arch Surg** 1999 Apr;384(2):209–15

Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations. Rieske P, et al. **Mol Pathol** 1999 Apr;52(2):64–7

Clonal composition of malignant fibrous histiocytoma: analysis by PCR-based assay of the human androgen receptor gene (HUMARA). Fujita MQ, et al. **Oncology** 1998 Nov–Dec;55(6):600–6

IMMUNOLOGY

A case of interleukin-6-producing malignant fibrous histiocytoma originating in the heart. Deguchi H, et al. **Jpn J Clin Oncol** 1999 Aug;29(8):382–6

METABOLISM

Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Abdiu A, et al. **Eur J Cancer** 1998 Dec;34(13):2094–100

Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Fukuda T, et al. **Pathol Int** 1998 Oct;48(10):757–62

p53 protein immunoreactivity in fibrohistiocytic tumors of the skin. Lee CS, et al. **Pathology** 1998 Aug;30(3):272–5

nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors. Lee CS, et al. **Pathology** 1999 May;31(2):123–6

MORTALITY

Malignant fibrous histiocytoma of the extremity. Salo JC, et al. **Cancer** 1999 Apr 15;85(8):1765–72

PATHOLOGY

Logistic regression analysis of high grade spindle cell neoplasms. A fine needle aspiration cytologic study. Liu K, et al. **Acta Cytol** 1999 Jul–Aug;43(4):593–600

CD34 and factor XIIIa-positive microvascular dendritic cells and the family of fibrohistiocytic mesenchymal tumors [letter; comment] Silverman JS, et al. **Am J Dermatopathol** 1998 Oct;20(5):533–6 (39 ref.). Comment on: Am J Dermatopathol 1996 Jun;18(3):283–8. Comment on: Am J Dermatopathol 1998 Jun;20(3):317–22.

Giant cell atypical fibroxanthoma: does it really exist? [letter; comment] Zelger BG, et al. **Am J Dermatopathol** 1999 Feb; 21(1):108–10. Comment on: Am J Dermatopathol 1997 Apr;19(2):174–9.

Plexiform fibrohistiocytic tumor: clinicopathologic analysis of 22 cases. Remstein ED, et al. **Am J Surg Pathol** 1999 Jun;23(6):662–70

Infiltrative subcutaneous malignant fibrous histiocytoma: a comparative study with deep malignant fibrous histiocytoma and an observation of biologic behavior. Fanburg-Smith JC, et al. **Ann Diagn Pathol** 1999 Feb; 3(1):1–10

A novel human malignant fibrous histiocytoma cell line of the heart (MFH-H) with secretion of hematopoietic growth factors. Reinecke P, et al. **Anticancer Res** 1999 May–Jun;19(3A):1901–7

Subcutaneous nodule of the lower extremity. Biedermann TM, et al. **Arch Dermatol** 1999 Sep;135(9):1113, 1116

Bleeding nodule on the forehead. Holmes S, et al. **Arch Dermatol** 1999 Sep;135(9):1115, 1118

Malignant fibrous histiocytoma of the conjunctiva. Allaire GS, et al. **Arch Ophthalmol** 1999 May;117(5):685–7

Identification of a ring chromosome in a myxoid malignant fibrous histiocytoma with chromosome microdissection and fluorescence in situ hybridization. Meloni-Ehrig AM, et al. **Cancer Genet Cytogenet** 1999 Feb;109(1):81–5

Cytogenetic findings in a malignant fibrous histiocytoma of the breast [letter] Pandis N, et al. **Cancer Genet Cytogenet** 1999 Jan 1;108(1):87–9

Histopathologic and immunohistochemical diagnosis of benign and malignant fibrous and fibrohistiocytic tumors of the skin. Kamino H, et al. **Dermatol Clin** 1999 Jul; 17(3):487–505, vii (53 ref.)

Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Hafner J, et al. **Dermatology** 1999;198(1):29–32

Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Abdiu A, et al. **Eur J Cancer** 1998 Dec;34(13):2094–100

Recurring atypical ("pseudosarcomatous") cutaneous fibrous histiocytoma. Adamski H, et al. **Eur J Dermatol** 1998 Mar; 8(2):122–4

Malignant fibrous histiocytoma with myofibroblastic differentiation of the vulva in an adolescent female. Grisaru D, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug; 79(2):219–21

Primary extraskeletal osteosarcoma of the penis with a malignant fibrous histiocytoma-like component [letter] Bacetić D, et al. **Histopathology** 1998 Aug;33(2):185–6

Pigmented atypical fibroxanthoma. Diaz-Cascajo C, et al. **Histopathology** 1998 Dec;33(6):537–41

Malignant fibrous histiocytoma in a child's hand [letter] Lim SC, et al. **Histopathology** 1998 Aug;33(2):191–2

Atypical fibroxanthoma with granular cells [letter; comment] Orosz Z. **Histopathology** 1998 Jul;33(1):88–9. Comment on: Histopathology 1997 May;30(5):495–7. Comment on: Histopathology 1997 Nov;31(5):481–2.

Myxoid dermatofibroma. Zelger BG, et al. **Histopathology** 1999 Apr;34(4):357–64

Orbital fibrous histiocytoma: case report and literature review. Ulloa TK, et al. **J Am Optom Assoc** 1999 Apr; 70(4):253–60 (22 ref.)

Aneurysmal fibrous histiocytoma: an unusual variant of cutaneous fibrous histiocytoma. McKenna DB, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):238–40

Plexiform fibrohistiocytic tumor of the foot. Wilkin MM, et al. **J Foot Ankle Surg** 1999 Mar-Apr;38(2):135–8

Fibrous histiocytoma of the larynx. Saleem M, et al. **J Laryngol Otol** 1998 Dec;112(12):1205–7 (12 ref.)

Origin of histiocyte-like cells and multinucleated giant cells in malignant fibrous histiocytoma: neoplastic or reactive? Hatano H, et al. **Pathol Int** 1999 Jan;49(1):14–22

Primary giant cell malignant fibrous histocytoma of the lung: a case report. Kimizuka G, et al. **Pathol Int** 1999 Apr; 49(4):342–6

Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Michal M. **Pathol Res Pract** 1998;194(8):529–33

Benign fibrous histiocytoma of the nasal septum. Basak S, et al. **Rhinology** 1998 Sep;36(3):133–5

Intrahepatic cholangiocarcinoma with extensive sarcomatous change: report of a case. Matsuo S, et al. **Surg Today** 1999; 29(6):560–3

Prognostic relevance of histologic grading, the cell cycle-associated antigen Ki-S1 and cell cycle regulators in malignant fibrous histiocytomas: a multivariate analysis. Brinck U, et al. **Verh Dtsch Ges Pathol** 1998;82:232–8

[Histopathological and clinical aspects of benign cutaneous fibrous histiocytoma: increased rate of recurrent histiocytomas with a proliferative tendency] Ledergerber JD, et al. **Pathologe** 1999 Mar;20(2):110–4 (Eng. Abstr.) **(Ger)**

[Fibrohistiocytic skin lesions] Zelger B. **Verh Dtsch Ges Pathol** 1998;82:290–300 (Eng. Abstr.) **(Ger)**

[Gastric xanthogranuloma (inflammatory malignant fibrohistiocytoma). Case report and literature review] Lespi PJ. **Acta Gastroenterol Latinoam** 1998;28(4):309–10 (7 ref.) (Eng. Abstr.) **(Spa)**

[Intrascrotal malignant fibrous histiocytoma] Medina Pérez M, et al. **Arch Esp Urol** 1999 May;52(4):393–5 (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

CT features of calcifications in abdominal malignant fibrous histiocytoma. Ko SF, et al. **Clin Imaging** 1998 Nov-Dec; 22(6):408–13

[Pulmonary malignant fibrous histiocytoma (inflammatory type) showing intracavitary fungus ball-like shadow] Kobayashi T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Feb;37(2):156–60 (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

Tc-99m DTPA uptake in malignant fibrous histiocytoma masquerading as a phantom kidney. Kosuda S, et al. **Clin Nucl Med** 1999 Mar;24(3):200–1

RADIOTHERAPY

Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Pollack A, et al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1; 42(3):563–72

[Plastic reconstruction of the irradiated thoracic wall] Vogt PM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:507–11 (Eng. Abstr.) **(Ger)**

SECONDARY

Primary meningeal malignant fibrous histiocytoma with cerebrospinal dissemination and pulmonary metastasis. Akimoto J, et al. **Acta Neurochir (Wien)** 1998; 140(11):1191–6 (20 ref.)

Malignant fibrous histiocytoma metastases to the small intestine and colon presenting as an intussusception. Kanoh T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2594–5 (10 ref.)

Primary malignant fibrous histiocytoma of the ascending colon: report of a case. Udaka T, et al. **Surg Today** 1999; 29(2):160–4 (22 ref.)

Cardiac metastasis of a malignant fibrous histiocytoma occupying the right ventricle and infiltrating the myocardium. Wankmüller H, et al. **Ultraschall Med** 1998 Jun;19(3):139–41

SURGERY

Malignant fibrous histiocytoma of the hand: multimodal therapy and extensor tendon reconstruction. Lohman R, et al. **Ann Plast Surg** 1998 Nov;41(5):544–9

Cardiac autotransplant for surgical treatment of a malignant neoplasm. Reardon MJ, et al. **Ann Thorac Surg** 1999 Jun; 67(6):1793–5

Cardiac explantation and autotransplantation. Wagner S, et al. **AORN J** 1999 Jul;70(1):99–100, 102, 104–7; quiz 108–12 (13 ref.)

Malignant fibrous histiocytoma of the pancreas: a case report with genetic analysis. Bastian D, et al. **Cancer** 1999 Jun 1;85(11):2352–8 (49 ref.)

Resection of malignant fibrous histiocytoma invading the thoracic aorta. Takamori S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Sep;46(9):825–8

Cost analysis of three different surgical procedures for treatment of a pelvic tumour. Bruns J, et al. **Langenbecks Arch Surg** 1998 Oct;383(5):359–63

Malignant bone tumors of the chest wall. Liptay MJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):278–84

[Posterior thoracic reconstruction with latissimus dorsi flap after partial amputation of the latissimus dorsi muscle for sarcoma of the back. Report of four cases] Payement G, et al. **Ann Chir Plast Esthet** 1998 Apr;43(2):189–94 (Eng. Abstr.) **(Fre)**

[Retroperitoneal malignant fibrous histiocytoma] Csata S, et al. **Orv Hetil** 1999 Feb 14;140(7):359–62 (Eng. Abstr.) **(Hun)**

[A case of primary cardiac malignant fibrous histiocytoma] Baba T, et al. **Kyobu Geka** 1998 Sep;51(10):849–52 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Sonographic findings of malignant fibrous histiocytoma of the mesentery-report of two cases. Shibuya T, et al. **Eur J Ultrasound** 1998 Dec;8(3):207–12 (11 ref.)

ULTRASTRUCTURE

Clonal composition of malignant fibrous histiocytoma: analysis by PCR-based assay of the human androgen receptor gene (HUMARA). Fujita MQ, et al. **Oncology** 1998 Nov-Dec;55(6):600–6

VETERINARY

Malignant fibrous histiocytoma of the deep peri-articular tissue of the stifle in a dog. Booth MJ, et al. **J S Afr Vet Assoc** 1998 Dec;69(4):163–8

Pathologic and prognostic characteristics of splenomegaly in dogs due to fibrohistiocytic nodules: 98 cases. Spangler WL, et al. **Vet Pathol** 1998 Nov;35(6):488–98

HISTIOCYTOSIS

The histiocytoses. Jaffe R. **Clin Lab Med** 1999 Mar; 19(1):135–55 (79 ref.)

The histiocytoses: the fall of the Tower of Babel. Arceci RJ. **Eur J Cancer** 1999 May;35(5):747–67; discussion 767–9 (230 ref.)

1998 Annual Histiocyte Society Abstracts, 14th Annual meeting. Kyoto, Japan, 30 September-2 October 1998. **Med Pediatr Oncol** 1999 Mar;32(3):234–45

The histiocytoses of infancy. Huang F, et al. **Semin Perinatol** 1999 Aug;23(4):319–31 (97 ref.)

[Histiocytosis] D'Antonio A, et al. **Pediatr Med Chir** 1998 Nov-Dec;20(6):381–5 (29 ref.) (Eng. Abstr.) **(Ita)**

[Histiocytic cytophagic panniculitis, Weber-Christian disease and nodular fat necrosis] Kitamura K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):397–9 (5 ref.) **(Jpn)**

BLOOD

Histiocytic sarcoma of the spleen associated with hypoalbuminemia, hypo gamma-globulinemia and thrombocytopenia as a possibly unique clinical entity--report of three cases. Kimura H, et al. **Leuk Lymphoma** 1998 Sep;31(1-2):217–24

CLASSIFICATION

Emergence of a new entity, the macrophagic myofasciitis. GERMMAD Study Group of the French Association Against Myopathies. Study and Research Group on Acquired Dysimmunity-related Muscle Disease [editorial] Chérin P, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):541–2

COMPLICATIONS

Solitary crystal-storing histiocytosis of the tongue in a patient with rheumatoid arthritis and polyclonal hypergammaglobulinemia. Bosman C, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):920–4

Crystal-storing histiocytosis and immunocytoma associated with multifocal fibrosclerosis. Garc-ia JF, et al. **Histopathology** 1998 Nov;33(5):459–64

Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). Tritos NA, et al. **J Intern Med** 1998 Dec;244(6):529–35

Neurological manifestations of Erdheim-Chester disease. Wright RA, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan; 66(1):72–5

[Urinary complications of Erdheim-Chester disease] Karsenty G, et al. **Presse Med** 1999 Apr 10;28(14):738–40 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Fine needle aspiration cytology of dermatopathic lymphadenitis. Sudilovsky D, et al. **Acta Cytol** 1998 Nov-Dec;42(6):1341–6

A pseudo-tumoral form of Kikuchi's disease in children: a case report and review of the literature. Lerosey Y, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):1–6 (41 ref.)

Neurological manifestations of Erdheim-Chester disease. Wright RA, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan; 66(1):72–5

Histiocytic-phagocytic infiltrates in the liver of an infant: a case clinically simulating perinatal hemochromatosis. Senger C, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug; 29(2):215–20

A train driver with painful legs. Oliveira L, et al. **Lancet** 1999 Jun 12;353(9169):2034

A patient with diabetes insipidus and periorbital swellings; Erdheim-Chester disease. van der Lee I, et al. **Neth J Med** 1999 Aug;55(2):76–9

DRUG THERAPY

Cytophagic histiocytic panniculitis improved by combined CHOP and cyclosporin A treatment [see comments] Ito M, et al. **Intern Med** 1999 Mar;38(3):296–301. Comment in: Intern Med 1999 Mar;38(3):224–5.

Cytophagic histiocytic panniculitis--what is the best therapy? [editorial; comment] Okamura T, et al. **Intern Med** 1999 Mar;38(3):224–5 (11 ref.). Comment on: Intern Med 1999 Mar;38(3):296–301.

METABOLISM

Mucicarminophilic histiocytosis (benign signet-ring cells) and hyperplastic mesothelial cells: two mimics of metastatic carcinoma within a single lymph node. Groisman GM, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):282–4

PATHOLOGY

Fine needle aspiration cytology of dermatopathic lymphadenitis. Sudilovsky D, et al. **Acta Cytol** 1998 Nov-Dec;42(6):1341–6

Mucicarminophilic histiocytosis (benign signet-ring cells) and hyperplastic mesothelial cells: two mimics of metastatic carcinoma within a single lymph node. Groisman GM, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):282–4

Multicentric reticulohistiocytosis in a child. Havill S, et al. **Australas J Dermatol** 1999 Feb;40(1):44–6

Erdheim-Chester disease: a case report. Park YK, et al. **J Korean Med Sci** 1999 Jun;14(3):323–6

Evidence for a hybrid macrophage phenotype in erythrophagocytic histiocytosis. Bosman C, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):31–7

HISTIOCYTOSIS, GENERALIZED see **LETTERER-SIWE DISEASE**

HISTIOCYTOSIS, LANGERHANS-CELL

Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Howarth DM, et al. **Cancer** 1999 May 15;85(10):2278–90

Comments from the Editor-in-Chief [editorial] Arceci RJ. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):1–2

COMPLICATIONS

Multisystem Langerhans cell histiocytosis [letter; comment] Vázquez JA, et al. **Acta Paediatr** 1999 Mar;88(3):349–50. Comment on: Acta Paediatr 1998 Jan;87(1):112–4.

Nodular Langerhans cell histiocytosis of the liver in an adult with colonic adenocarcinoma [letter] Cavazza A, et al. **Histopathology** 1999 Mar;34(3):273–5

Labyrinthine involvement in Langerhans' cell histiocytosis. Nanduri VR, et al. **Int J Pediatr Otorhinolaryngol** 1998 Nov 15;46(1-2):109–15 (18 ref.)

Cerebral Erdheim-Chester disease: report of two cases with progressive cerebellar syndrome with dentate abnormalities on magnetic resonance imaging. Pautas E, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):597–9

Visual loss with Langerhans cell histiocytosis: multifocal central nervous system involvement. Job OM, et al. **J Neuroophthalmol** 1999 Mar;19(1):49–53

Diabetes insipidus in Langerhans' cell histiocytosis: report of a case. Wu HT, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 May; 15(5):302–6

Concurrent Langerhans cell histiocytosis and neuroblastoma. Fischer A, et al. **Med Pediatr Oncol** 1999 Mar;32(3):223–4

Liver involvement in Langerhans' cell histiocytosis: a study of nine cases. Kaplan KJ, et al. **Mod Pathol** 1999 Apr; 12(4):370–8

Simultaneous occurrence of Hodgkin's disease, nodal Langerhans' cell histiocytosis and multiple myeloma IgA(kappa). Ibarrola de Andrés C, et al. **Virchows Arch** 1999 Mar;434(3):259–62

[Association of Langerhans-cell histiocytosis and acute monocytic leukemia (letter)] Misery L, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):732–3 **(Fre)**

[Vulvar and gingival ulcers and skull tumors] Morand JJ, et al. **Rev Med Interne** 1998 Dec;19(12):931–4 **(Fre)**

CONGENITAL

[Congenital self-healing histiocytosis] García Arias M, et al. **An Esp Pediatr** 1998 Sep;49(3):297–8 (6 ref.) **(Spa)**

DIAGNOSIS

Langerhans' cell histiocytosis as a cause of periportal abnormal signal intensity on MRI. Kim M, et al. **Abdom Imaging** 1999 Jul–Aug;24(4):373–7

Pulmonary Langerhans'cell granulomatosis (histiocytosis X): clinical analysis of 8 cases. Callebaut W, et al. **Acta Clin Belg** 1998 Oct;53(5):337–43

Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans' cell histiocytosis. Calming U, et al. **Acta Paediatr** 1998 Oct; 87(10):1085–7

Langerhans cell histiocytosis. Herzog KM, et al. **Adv Anat Pathol** 1998 Nov;5(6):347–58 (101 ref.)

Langerhans' cell histiocytosis [letter] Devine JC, et al. **Br J Oral Maxillofac Surg** 1998 Aug;36(4):318

Limp as unusual presentation of Langerhans' cell histiocytosis. Bodart E, et al. **Eur J Pediatr** 1999 May; 158(5):384–6

Langerhans cell histiocytosis of the cervical spine: case report of an unusual location. Geusens E, et al. **Eur Radiol** 1998; 8(7):1142–4

Imaging findings in Langerhans'cell histiocytosis of the liver and the spleen in an adult. Mampaey S, et al. **Eur Radiol** 1999;9(1):96–8

Langerhans' cells histiocytosis. Sellari-Franceschini S, et al. **Int J Pediatr Otorhinolaryngol** 1999 Apr 25;48(1):83–7

Pagetoid self-healing Langerhans cell histiocytosis in an infant. Hashimoto K, et al. **Pediatr Dermatol** 1999 Mar–Apr;16(2):121–7

Langerhans' cell histiocytosis and juvenile xanthogranuloma of the orbit. Clinicopathologic, CT, and MR imaging features. Hidayat AA, et al. **Radiol Clin North Am** 1998 Nov;36(6):1229–40, xii (68 ref.)

Juvenile xanthogranuloma versus Langerhans cell histiocytosis (histiocytosis X). Lazova R, et al. **Semin Cutan Med Surg** 1999 Mar;18(1):71–7

[Langerhans-cell histiocytosis] Willems PWJM, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1583–4 **(Dut)**

[Langerhans-cell histiocytosis and Erdheim-Chester disease: probably not a fortuitous association] Boralevi F, et al. **Ann Dermatol Venereol** 1998 May;125(5):335–8 (Eng. Abstr.) **(Fre)**

[Langerhans-cell histiocytosis and medullary fibrosis (letter)] Piguet C, et al. **Arch Pediatr** 1998 Sep;5(9):1045–6 **(Fre)**

[What is it? Histiocytosis X] Cisse R, et al. **J Radiol** 1999 Feb;80(2):157–9 **(Fre)**

[Cystic pulmonary metastasis simulating a diagnosis of histiocytosis X] Essadki O, et al. **J Radiol** 1998 Sep; 79(9):886–8 (Eng. Abstr.) **(Fre)**

[Vulvar and gingival ulcers and skull tumors] Morand JJ, et al. **Rev Med Interne** 1998 Dec;19(12):931–4 **(Fre)**

[An old story of cutaneous fistula] Morisset M, et al. **Rev Med Interne** 1999;20 Suppl 2:251s–255s **(Fre)**

[Langerhans-cell histiocytosis of the penis] Seseke F, et al. **Urologe A** 1999 Jan;38(1):42–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Erdheim Chester disease: autonomous entity or expression of Langerhans cell histiocytosis? Report of a case] Popolizio T, et al. **Radiol Med (Torino)** 1999 May; 97(5):422–4 **(Ita)**

[Histiocytosis of Langerhans cells in the lung: case report] Nalepa P, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):377–8 (Eng. Abstr.) **(Pol)**

[Langerhans cell histiocytosis in anogenital region] Neto MS, et al. **Rev Assoc Med Bras** 1998 Oct–Dec;44(4):344–6 (Eng. Abstr.) **(Por)**

[Bone pain and dyspnea in a young woman] Hernández-Mezquita MA, et al. **Rev Clin Esp** 1998 Sep; 198(9):627–9 **(Spa)**

DRUG THERAPY

Disseminated Langerhans cell histocytosis in children: treatment outcome. Kusumakumary P, et al. **Am J Clin Oncol** 1999 Apr;22(2):180–3

Low-dose oral etoposide monotherapy in adult Langerhans cell histiocytosis. Helmbold P, et al. **Arch Dermatol** 1998 Oct;134(10):1275–8

Cladribine activity in adult langerhans-cell histiocytosis. Saven A, et al. **Blood** 1999 Jun 15;93(12):4125–30

Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH) [letter] Lopes LF, et al. **Med Pediatr Oncol** 1999 Apr; 32(4):315

Use of indomethacin in Langerhans cell histiocytosis. Munn SE, et al. **Med Pediatr Oncol** 1999 Apr;32(4):247–9

Etoposide and Langerhans cell histiocytosis: second malignancies, a second look [editorial; comment] Felix CA, et al. **Pediatr Hematol Oncol** 1999 May–Jun;16(3):183–5. Comment on: Pediatr Hematol Oncol 1999 May–Jun;16(3):251–6.

Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis [see comments] Kager L, et al. **Pediatr Hematol Oncol** 1999 May–Jun;16(3):251–6 (19 ref.) . Comment in: Pediatr Hematol Oncol 1999 May–Jun;16(3):183–5.

[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide] Lair G, et al. **Rev Med Interne** 1998 Mar;19(3):196–8 (Eng. Abstr.) **(Fre)**

ETIOLOGY

B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Shimazaki C, et al. **Br J Haematol** 1999 Mar;104(4):672–9

Pulmonary Langerhans' cell histiocytosis following autologous haemopoietic progenitor cell transplantation. Soler N, et al. **Respir Med** 1998 Oct;92(10):1253–5

[Physiopathology of langerhans-cell histiocytosis] Boralevi F, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):856–9 (24 ref.) **(Fre)**

[Pathogenesis of adult pulmonary Langerhans-cell histiocytosis] Tazi A, et al. **Rev Mal Respir** 1999 Apr; 16(2):151–9 (Eng. Abstr.) **(Fre)**

GENETICS

Ataxia, ocular telangiectasia, chromosome instability, and Langerhans cell histiocytosis in a patient with an unknown breakage syndrome. Di Rocco M, et al. **J Med Genet** 1999 Feb;36(2):159–60

Hereditary Langerhans cell histiocytosis: instances of apparent vertical transmission [letter] de Chadarévian JP, et al. **Med Pediatr Oncol** 1998 Dec;31(6):559

Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Sullivan KE, et al. **Pediatr Res** 1998 Oct; 44(4):465–8

[Langerhans cell histiocytosis and myelomonocytic leukemia: a non-fortuitous association] Baikian B, et al. **Ann Dermatol Venereol** 1999 May;126(5):409–11 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Expression of Fas ligand in Langerhans' cell histiocytosis: A case report of a boy with multisystem involvement. Peng CT, et al. **Am J Hematol** 1999 Aug;61(4):256–61

Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Sullivan KE, et al. **Pediatr Res** 1998 Oct; 44(4):465–8

METABOLISM

Bcl-2 expression in Langerhans'cell histiocytosis. Savell VH Jr, et al. **Pediatr Dev Pathol** 1998 May–Jun;1(3):210–5

PATHOLOGY

Fine needle aspiration cytology of Langerhans cell histiocytosis of the thyroid. A case report. Dey P, et al. **Acta Cytol** 1999 May–Jun;43(3):429–31

Langerhans cell histiocytosis. Herzog KM, et al. **Adv Anat Pathol** 1998 Nov;5(6):347–58 (101 ref.)

Erdheim–Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Egan AJ, et al. **Am J Surg Pathol** 1999 Jan; 23(1):17–26 (24 ref.)

Nail and scalp lesions in a man with diabetes insipidus. Langerhans cell histiocytosis (LCH). Munro CS, et al. **Arch Dermatol** 1998 Nov;134(11):1477–8, 1480–1

Langerhans cell histiocytosis localized to the eyelid. Chikama T, et al. **Arch Ophthalmol** 1998 Oct;116(10):1375–7

Pathologic quiz case 2: Langerhans cell histiocytosis (LCH) of the temporal bone. Bauer PW, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1395, 1397

Presence of circulating abnormal CD34+ progenitors in adult Langerhans cell histiocytosis. Misery L, et al. **Clin Exp Immunol** 1999 Jul;117(1):177–82

Brain stem infiltration by mixed Langerhans cell histiocytosis and Chester–Erdheim disease: more than just an isolated case? Vital C, et al. **Clin Exp Pathol** 1999;47(2):71–6

Pure cutaneous relapsing langerhans cell histiocytosis in an adult. Baldo A, et al. **Eur J Dermatol** 1998 Oct–Nov; 8(7):501–2

Pancreatic hamartoma with Langerhans cell histiocytosis in a draining lymph node [letter] Wu SS, et al. **Histopathology** 1998 Nov;33(5):485–7

Langerhans cell histocytosis--a clinicopathological spectrum. Jayaram N, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):331–5

Cutaneous Langerhans cell histiocytosis of the genitalia in the elderly: a report of three cases. Meehan SA, et al. **J Cutan Pathol** 1998 Aug;25(7):370–4

Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. Tazi A, et al. **J Immunol** 1999 Sep 15;163(6):3511–5

Cerebral Erdheim–Chester disease: report of two cases with progressive cerebellar syndrome with dentate abnormalities on magnetic resonance imaging. Pautas E, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):597–9

Multifocal Langerhans' cell histiocytosis involving the orbit. LaBorwit SE, et al. **J Pediatr Ophthalmol Strabismus** 1998 Jul–Aug;35(4):234–6

Cerebral localization of Langerhans cell histiocytosis: MRI--neuropathologic correlations [letter] Colombo N, et al. **Neuroradiology** 1999 Jul;41(7):548–9

Langerhans cell histiocytosis of the stomach with atypical morphological features. Terracciano L, et al. **Pathol Int** 1999 Jun;49(6):553–6

A preadolescent with polydipsia and polyuria [clinical conference] Huhn SL, et al. **Pediatr Neurosurg** 1998 Feb; 28(2):91–5

Langerhans cell histiocytosis. Chauffaille M de L, et al. **Rev Paul Med** 1998 Jan–Feb;116(1):1625–8

Langerhans' cell histiocytosis of the spine: use of MRI in guiding biopsy. Kaplan GR, et al. **Skeletal Radiol** 1998 Dec; 27(12):673–6

Langerhans cell histiocytosis of the vulva: an ultrastructural study. Prignano F, et al. **Ultrastruct Pathol** 1999 Mar–Apr; 23(2):127–32

[Dynamic studies of Langerhans cell histiocytosis cells. Their contribution to the current concept of the disease. Report of a series of 38 cases] Nezelof C, et al. **Bull Acad Natl Med** 1999;183(4):815–22; discussion 822–4 (Eng. Abstr.) **(Fre)**

[Oral manifestations of Lpngerhans' cell histiocytosis. Therapeutic strategies involving oral and maxillofacial surgery] Schultze A, et al. **Mund Kiefer Gesichtschir** 1999 May;3(3):158–64 (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Spontaneous regression of orbital Langerhans cell granulomatosis in a three-year-old girl. Smith JH, et al. **Am J Ophthalmol** 1999 Jul;128(1):119–21

Endocrinological aspects of Langerhans cell histiocytosis complicated with diabetes insipidus. Lin KD, et al. **J Endocrinol Invest** 1998 Jul–Aug;21(7):428–33

Langerhans' cell histiocytosis of the spine. Analysis of twenty-three cases. Yeom JS, et al. **Spine** 1999 Aug 15; 24(16):1740–9

[Physiopathology of langerhans-cell histiocytosis] Boralevi F, et al. **Ann Dermatol Venereol** 1998 Nov;125(11):856–9 (24 ref.) **(Fre)**

[Current status of clinical knowledge, physiopathology, and treatment of Langerhans histiocytosis (histiocytosis X)] Geissmann F, et al. **Arch Pediatr** 1999;6 Suppl 2:414s–416s (8 ref.) **(Fre)**

RADIOGRAPHY

Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Mogulkoc N, et al. **Chest** 1999 May;115(5):1452–5

Severe bone involvement with Langerhans cell histiocytosis. Köseoğlu V, et al. **J Pediatr** 1998 Nov;133(5):711

Langerhans' cell histiocytosis of the spine. Analysis of twenty-three cases. Yeom JS, et al. **Spine** 1999 Aug 15; 24(16):1740–9

[Intestinal Langerhans cell histiocytosis: computerized tomography findings in a case] Ferrozzi F, et al. **Radiol Med (Torino)** 1999 Apr;97(4):315–7 **(Ita)**

SURGERY

[An emergency operation in pulmonary histiocytosis X] Kozhukharov S. **Khirurgiia (Sofiia)** 1998;51(2):43–4 **(Bul)**

[Oral manifestations of Lpngerhans' cell histiocytosis. Therapeutic strategies involving oral and maxillofacial surgery] Schultze A, et al. **Mund Kiefer Gesichtschir** 1999 May;3(3):158–64 (Eng. Abstr.) **(Ger)**

[Treatment concepts in osseous manifestations of Langerhans cell histiocytosis] Nebelung W, et al. **Z Orthop Ihre Grenzgeb** 1999 May–Jun;137(3):236–43 (Eng. Abstr.) **(Ger)**

THERAPY

Pulmonary embolism caused by acrylic cement: a rare complication of percutaneous vertebroplasty. Padovani B, et al. **AJNR Am J Neuroradiol** 1999 Mar;20(3):375–7

Successful induction therapy of natural killer/cytotoxic T-lymphocyte cells in the treatment of Langerhans' cell histiocytosis [letter] Hirose M, et al. **Int J Hematol** 1999 Jun;69(4):272–3

[Current status of clinical knowledge, physiopathology, and treatment of Langerhans histiocytosis (histiocytosis X)] Geissmann F, et al. **Arch Pediatr** 1999;6 Suppl 2:414s–416s (8 ref.) **(Fre)**

VIROLOGY

Human cytomegalovirus infection in foci of Langerhans cell histiocytosis [published erratum appears in Virchows Arch 1999 Jul;435(1):77] Kawakubo Y, et al. **Virchows Arch** 1999 Feb;434(2):109–15

HISTIOCYTOSIS, LIPID see **NIEMANN-PICK DISEASE**

HISTIOCYTOSIS, MALIGNANT

[Malignant histiocytosis (histiocytic medullary reticulosis)] Takai K. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):368–71 (15 ref.) **(Jpn)**

COMPLICATIONS

[Failure of treatment with 2-chlorodeoxyadenosine in the course of hairy cell leukemia associated with malignant histiocytosis (letter)] Jullien V, et al. **Rev Med Interne** 1999 Mar;20(3):287–8 **(Fre)**

DRUG THERAPY

[Failure of treatment with 2-chlorodeoxyadenosine in the course of hairy cell leukemia associated with malignant histiocytosis (letter)] Jullien V, et al. **Rev Med Interne** 1999 Mar;20(3):287–8 **(Fre)**

GENETICS

Genetic and immunological parameters governing in vivo susceptibility/resistance to retrovirally induced murine malignant histiocytosis. Panoskaltsis-Mortari A, et al. **J Leukoc Biol** 1998 Oct;64(4):441–50

PATHOLOGY

Indeterminate-cell histiocytosis: immunophenotypic and cytogenetic findings in an infant. Martin Flores-Stadler E, et al. **Med Pediatr Oncol** 1999 Apr;32(4):250–4

VETERINARY

Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Visonneau S, et al. **Clin Cancer Res** 1997 Oct;3(10):1789–97

Primary malignant histiocytosis of the brain in a dog. Chandra AM, et al. **J Comp Pathol** 1999 Jul;121(1):77–82

Pathologic and prognostic characteristics of splenomegaly in dogs due to fibrohistiocytic nodules: 98 cases. Spangler WL, et al. **Vet Pathol** 1998 Nov;35(6):488–98

Characterization of a canine CD44 specific monoclonal antibody. Alldinger S, et al. **Zentralbl Veterinarmed A** 1999 Feb;46(1):19–32

VIROLOGY

Genetic and immunological parameters governing in vivo susceptibility/resistance to retrovirally induced murine malignant histiocytosis. Panoskaltsis-Mortari A, et al. **J Leukoc Biol** 1998 Oct;64(4):441–50

HISTIOCYTOSIS, NON-LANGERHANS-CELL

Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma [letter; comment] Imashuku S, et al. **Cancer** 1999 May 15; 85(10):2298–300. Comment on: Cancer 1998 May 15;82(10):1963–72.

Two separate episodes of hemophagocytic syndrome at a two-year interval in an apparently immunocompetent male. Ohno T, et al. **Int J Hematol** 1999 Feb;69(2):101–4

An Asian variant of intravascular lymphomatosis: an updated review of malignant histiocytosis-like B-cell lymphoma [published erratum appears in Leuk Lymphoma 1999 Jun;34(1-2):following 206] Murase T, et al. **Leuk Lymphoma** 1999 May;33(5-6):459–73 (98 ref.)

Hemophagocytic lymphohistiocytosis. Lim ME, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):154–5

[Virus-associated hemophagocytic syndrome. Diagnosis and treatment] Faurschou M, et al. **Ugeskr Laeger** 1998 Oct 19;160(43):6198–200 (25 ref.) (Eng. Abstr.) **(Dan)**

[Familial lymphohistiocytic hemophagocytosis: apropos of a case] Zermani R, et al. **Tunis Med** 1998 Mar;76(3):54–6 **(Fre)**

[Current concept of hemophagocytic syndrome] Kawa K. **Rinsho Ketsueki** 1999 Feb;40(2):81–2 **(Jpn)**

[Virus-associated hemophagocytic syndrome] Kawaguchi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):365–7 (7 ref.) **(Jpn)**

[Bacteria-associated hemophagocytic syndrome] Kawaguchi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):362–4 (10 ref.) **(Jpn)**

[Autoimmune-associated hemophagocytic syndrome] Kumakura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):358–61 (7 ref.) **(Jpn)**

[Virus-associated hemophagocytic syndrome] Nakamura Y. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):166–70 (15 ref.) **(Jpn)**

[Acute lupus hemophagocytic syndrome] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):352–4 (13 ref.) **(Jpn)**

[Malignancy-associated hemophagocytic syndrome] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):355–7 (17 ref.) **(Jpn)**

COMPLICATIONS

Hemophagocytic syndrome associated with fulminant ulcerative colitis and presumed acute pancreatitis. Kanaji S, et al. **Am J Gastroenterol** 1998 Oct;93(10):1956–9

Fatal virus-associated hemophagocytic syndrome associated with coexistent chronic active hepatitis B and acute hepatitis C virus infection. Faurschou M, et al. **Am J Hematol** 1999 Jun;61(2):135–8

Epstein-Barr virus related hemophagocytic syndrome in a T-cell rich B-cell lymphoma. Mitterer M, et al. **Ann Oncol** 1999 Feb;10(2):231–4

Haemophagocytic syndrome in a patient with dermatomyositis [letter] Yasuda S, et al. **Br J Rheumatol** 1998 Dec;37(12):1357–8

Xanthoma disseminatum: a case with hepatic involvement, diabetes insipidus and type IIb hyperlipidaemia. Woollons A, et al. **Clin Exp Dermatol** 1998 Nov;23(6):277–80

Encephalopathy associated with haemophagocytic lymphohistiocytosis following rotavirus infection. Takahashi S, et al. **Eur J Pediatr** 1999 Feb;158(2):133–7 (23 ref.)

Development of acute lymphoblastic leukemia following hemophagocytic lymphohistiocytosis: is it secondary leukemia? [letter] Suzuki T, et al. **Int J Hematol** 1999 Jul; 70(1):58–9

Anaemia and thrombocytopenia due to haemophagocytosis in a 7-month-old boy with galactosialidosis. Olcay L, et al. **J Inherit Metab Dis** 1998 Aug;21(6):679–80

Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. Duval M, et al. **J Pediatr** 1999 Feb;134(2):236–9

Aplastic anemia after Mycoplasma pneumoniae infection: a report of two cases. Stéphan JL, et al. **J Pediatr Hematol Oncol** 1999 Jul-Aug;21(4):299–302

Nasal angiocentric lymphoma with hemophagocytic syndrome. Han JY, et al. **Korean J Intern Med** 1999 Jul; 14(2):41–6

Hemophagocytic syndrome in a patient with Hashimoto's thyroiditis and membranous nephritis [letter] Taniguchi Y, et al. **Nephron** 1999 Feb;81(2):246–7

Hemophagocytic syndrome presenting as acute hepatic failure in two infants: clinical overlap with neonatal hemochromatosis. Parizhskaya M, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):360–6

[Hemophagocytic syndrome and hemorrhagic fever with renal syndrome (letter)] Baty V, et al. **Presse Med** 1998 Oct 17;27(31):1577 **(Fre)**

[Hemophagocytic syndrome complicating seronegative rheumatoid polyarthritis: a differential diagnosis of Still's disease? (letter)] Abad S, et al. **Rev Med Interne** 1998 May; 19(5):361–2 **(Fre)**

[Peripheral T-cell lymphoma 9 months after hemophagocytic syndrome with a favorable outcome after splenectomy (letter)] Aubriet S, et al. **Rev Med Interne** 1999 Aug; 20(8):718–9 **(Fre)**

[Febrile pancytopenia in the course of AIDS: a hemophagocytic syndrome (letter)] Fiszbin M, et al. **Rev Med Interne** 1998 Sep;19(9):673–5 (14 ref.) **(Fre)**

[Collagen diseases and hemophagocytic syndrome] Okada J. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):905–9 (14 ref.) **(Jpn)**

[Case of hereditary spherocytosis complicated by human parvovirus B19-associated hemophagocytosis syndrome and aplastic crisis] Sano F, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):127–9 **(Jpn)**

[Epstein-Barr virus, hemophagocytic syndrome and angiocentric lymphoma: a rare and fatal association] Ramirez Jiménez S, et al. **An Esp Pediatr** 1998 Oct; 49(4):401–4 **(Spa)**

[Hemophagocytic syndrome associated with tuberculosis in a patient infected with the human immunodeficiency virus (letter)] García C, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):43–4 **(Spa)**

DIAGNOSIS

Hepato-splenic gammadelta T-cell lymphoma: a rare entity mimicking the hemophagocytic syndrome. Nosari A, et al. **Am J Hematol** 1999 Jan;60(1):61–5

Chromobacterium violaceum sepsis accompanied by bacteria-associated hemophagocytic syndrome in a Japanese man [letter] Hiraoka N, et al. **Arch Intern Med** 1999 Jul 26;159(14):1623–4

Multicentric reticulohistiocytosis: a mimic of gout and rheumatoid arthritis. Horvath JR, et al. **Cleve Clin J Med** 1999 Mar;66(3):166–72

Haemophagocytic lymphohistiocytosis in children. Hallahan AR, et al. **J Paediatr Child Health** 1999 Feb;35(1):55–9

Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. Duval M, et al. **J Pediatr** 1999 Feb;134(2):236–9

Liver and spleen MRI findings in virus-associated hemophagocytic syndrome in a patient with acute lymphocytic leukemia. Zilkha A, et al. **Pediatr Radiol** 1998 Dec;28(12):920–2

Cutaneous nodules in a patient with polyarthritis. Handa R, et al. **Postgrad Med J** 1999 Feb;75(880):111–3

[Langerhans-cell histiocytosis and Erdheim-Chester disease: probably not a fortuitous association] Boralevi F, et al. **Ann Dermatol Venereol** 1998 May;125(5):335–8 (Eng. Abstr.) **(Fre)**

[Recurrent febrile organomegaly] Lecomte F, et al. **Rev Med Interne** 1998;19 Suppl 2:301s–302s **(Fre)**

[Xanthoma disseminatum with marked mucocutaneous involvement] Tietge UJ, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1337–42 (19 ref.) (Eng. Abstr.) **(Ger)**

[Non-Langerhans-cell histocytosis] Burgdorf WH, et al. **Hautarzt** 1998 Jul;49(7):600–13; quiz 612 (24 ref.) **(Ger)**

[Hemophagocytic syndrome in a patient with anemia and liver pathology] D'Angelo G. **Recenti Prog Med** 1998 Nov; 89(11):573–4 (Eng. Abstr.) **(Ita)**

[The hemophagocytic syndrome in childhood: apropos 4 cases] Astigarraga Aguirre I, et al. **An Esp Pediatr** 1998 Sep;49(3):289–93 (29 ref.) **(Spa)**

[Hemophagocytic syndromes] Herrero Hernández A, et al. **An Esp Pediatr** 1998 Sep;49(3):230–6 (84 ref.) **(Spa)**

DRUG THERAPY

Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens. Chen JS, et al. **Br J Haematol** 1998 Dec;103(3):756–62

Prolonged gastrointestinal dysmotility in a patient with hemophagocytic lymphohistiocytosis treated with vincristine. Tomomasa T, et al. **Dig Dis Sci** 1999 Sep; 44(9):1755–7

Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. Löw P, et al. **Eur J Med Res** 1998 Oct 14;3(10):461–4

Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. Takahashi T, et al. **Int J Hematol** 1998 Oct; 68(3):333–6

[Successful treatment with CPT-11 and adriamycin for hemophagocytic syndrome associated with intravascular lymphomatosis] Ise M, et al. **Rinsho Ketsueki** 1998 Nov; 39(11):1131–6 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

[Lymphoma-associated hemophagocytic syndrome in Japan] Takahashi N, et al. **Rinsho Ketsueki** 1999 Jul;40(7):542–9 (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation. Sato M, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1219–22

Haemophagocytosis in early congenital syphilis. Pohl M, et al. **Eur J Pediatr** 1999 Jul;158(7):553–5

Hemophagocytosis by leukemic blasts in a case of acute megakaryoblastic leukemia with t(16;21)(p11;q22). Imashuku S, et al. **Int J Hematol** 1999 Jul;70(1):36–9

Multicentric reticulohistiocytosis associated with recurrent breast carcinoma. Valencia IC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):864–6

The spectrum of reactive hemophagocytic syndrome in systemic lupus erythematosus. Papo T, et al. **J Rheumatol** 1999 Apr;26(4):927–30

Severe chronic active Epstein-Barr virus infection accompanied by virus-associated hemophagocytic syndrome, cerebellar ataxia and encephalitis. Yamashita S, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):449–52

Hemophagocytosis: a potential complication in small bowel transplantation. Muiesan P, et al. **Transplantation** 1998 Sep 27;66(6):794–6

-Hemophagocytic syndrome associated with strongyloidiasis in a child treated for acute lymphoblastic leukemia (letter)- Smedts Walters H, et al. **Arch Pediatr** 1998 Mar;5(3):346–7 **(Fre)**

[Primary chronic ulcerative jejunoileitis complicated by hemophagocytic syndrome] Galoo E, et al. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6-7):783–7 (Eng. Abstr.) **(Fre)**

[Pancytopenia and pulmonary tuberculosis. Significance of a hemophagocytic syndrome] François B, et al. **Rev Mal Respir** 1998 Oct;15(5):668–70 (Eng. Abstr.) **(Fre)**

[Hemophagocytic syndrome associated with tuberculosis and mycoplasma infection in two patients] Oyaizu H, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Sep;36(9):787–92 (Eng. Abstr.) **(Jpn)**

[Case of diabetes mellitus succumbing to multiple organ failure due to hemophagocytic syndrome complicating mucormycosis] Makino C, et al. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):133–4 **(Jpn)**

[Hemophagocytic syndrome in autoimmune disease] Kumakura S, et al. **Rinsho Ketsueki** 1999 Feb;40(2):99–102 **(Jpn)**

[Hemophagocytic syndrome in a patient with rheumatoid arthritis] Yamanouchi J, et al. **Ryumachi** 1998 Oct; 38(5):731–4 (Eng. Abstr.) **(Jpn)**

GENETICS

Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Dufourcq-Lagelouse R, et al. **Am J Hum Genet** 1999 Jan; 64(1):172–9

Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Ohadi M, et al. **Am J Hum Genet** 1999 Jan;64(1):165–71

The breakpoints of a constitutional inversion of chromosome 9 associated with haemophagocytic lymphohistiocytosis are not linked to the disease gene. Aricò M, et al. **Br J Haematol** 1999 Jan;104(1):108–10

Chester-Erdheim disease: a neoplastic disorder. Chetritt J, et al. **Hum Pathol** 1999 Sep;30(9):1093-6

Genetic basis of hemophagocytic lymphohistiocytosis syndrome (Review). Dufourcq-Lagelouse R, et al. **Int J Mol Med** 1999 Aug;4(2):127-33 (63 ref.)

[Genetic defects in control of T cell activation evolving in a syndrome of lymphohistiocytic activation] Dufourcq-Lagelouse R, et al. **Arch Pediatr** 1999;6 Suppl 2:417s-419s **(Fre)**

[Diagnosis and pathogenesis of primary (familial) hemophagocytic lymphohistiocytosis] Ishii E, et al. **Rinsho Ketsueki** 1999 Feb;40(2):83-7 **(Jpn)**

[Treatment of familial hemophagocytic lymphohistiocytosis] Sako M. **Rinsho Ketsueki** 1999 Feb;40(2):88-91 (13 ref.) **(Jpn)**

[Familial hemophagocytic lymphohistiocytosis] Tsunamoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):347-51 (17 ref.) **(Jpn)**

IMMUNOLOGY

Th1/Th2 milieu in adult hemophagocytic syndrome. Tsuda H, et al. **Acta Haematol** 1999;101(3):157-60

Up-regulation of adhesion and MHC molecules on splenic monocyte/macrophages in adult haemophagocytic syndrome. Keréveur A, et al. **Br J Haematol** 1999 Mar; 104(4):871-7

Haemophagocytic syndrome in a patient with dermatomyositis [letter] Yasuda S, et al. **Br J Rheumatol** 1998 Dec;37(12):1357-8

[Characteristics of hemophagocytic lymphohistiocytosis in childhood in Japan] Hibi S, et al. **Rinsho Ketsueki** 1999 Feb;40(2):92-5 **(Jpn)**

[Pathogenesis of hemophagocytic syndrome (HPS)--regarding cytokine] Shiraishi K, et al. **Rinsho Ketsueki** 1999 Feb;40(2):103-7 **(Jpn)**

METABOLISM

Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Takada H, et al. **Br J Haematol** 1999 Jul;106(1):182-9

MICROBIOLOGY

Chromobacterium violaceum sepsis accompanied by bacteria-associated hemophagocytic syndrome in a Japanese man [letter] Hiraoka N, et al. **Arch Intern Med** 1999 Jul 26;159(14):1623-4

PATHOLOGY

Pathological case of the month. Neuropathology of familial hemophagocytic lymphohistiocytosis. Vasishta RK, et al. **Arch Pediatr Adolesc Med** 1999 May;153(5):545-7

Multiple cutaneous reticulohistiocytosis [letter] McKenna DB, et al. **Br J Dermatol** 1998 Sep;139(3):544-6 (9 ref.)

Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. Fadeel B, et al. **Br J Haematol** 1999 Aug; 106(2):406-15

Chester-Erdheim disease: a neoplastic disorder. Chetritt J, et al. **Hum Pathol** 1999 Sep;30(9):1093-6

Clonal dissemination of T-lymphocytes in scid mice from familial hemophagocytic lymphohistiocytosis. Ishii E, et al. **Med Pediatr Oncol** 1999 Mar;32(3):201-8

Clinicopathological findings of virus-associated hemophagocytic syndrome in bone marrow: association with Epstein-Barr virus and apoptosis. Ohshima K, et al. **Pathol Int** 1999 Jun;49(6):533-40

Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Ohshima K, et al. **Pathol Int** 1998 Dec; 48(12):934-43

Marked histiocytosis in the portal tract in a patient with reactive hemophagocytic syndrome: An autopsy case. Terada T, et al. **Pathol Int** 1999 Jul;49(7):672-5

[Lymphoma associated hemophagocytic syndrome with plasmacytosis in the bone marrow and hypergammaglobulinemia] Ikewaki J, et al. **Rinsho Ketsueki** 1998 Dec;39(12):1175-9 (Eng. Abstr.) **(Jpn)**

[An autopsy case of intravascular malignant lymphomatosis with hemophagocytic syndrome, mental confusion and liver dysfunction] Onishi Y, et al. **Rinsho Ketsueki** 1998 Aug;39(8):586-92 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Clinicopathological characteristics of adult patients with lymphoma-associated hemophagocytic syndrome in Japan] Takahashi N, et al. **Rinsho Ketsueki** 1999 Feb;40(2):96-8 **(Jpn)**

RADIOGRAPHY

Multicentric reticulohistiocytosis in a child: radiologic findings and clinical correlation. Friedman PD, et al. **Can Assoc Radiol J** 1998 Dec;49(6):378-80

[Diagnostic imaging...] Serratrice J, et al. **Rev Med Interne** 1999;20 Suppl 2:239s-241s **(Fre)**

[Xanthogranulomatous cholecystitis. Findings with computerized tomography in two cases] Catalano O, et al. **Radiol Med (Torino)** 1999 Apr;97(4):321-2 **(Ita)**

THERAPY

Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Jan-Inge Henter for the Histiocyte Society. Imashuku S, et al. **Blood** 1999 Mar 15; 93(6):1869-74

Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis. Chan KW, et al. **Bone Marrow Transplant** 1998 Aug;22(3):301-2

A case of hemophagocytic lymphohistiocytosis with prolonged remission after syngeneic bone marrow transplantation. Hasegawa D, et al. **Bone Marrow Transplant** 1999 Aug;24(4):425-7

Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan. Imashuku S, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):569-72

Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis. Schwinger W, et al. **Bone Marrow Transplant** 1998 Aug;22(4):393-6

Successful engraftment of unrelated cord blood stem cells for familial erythrophagocytic lymphohistiocytosis. Kinki Cord Blood Bank. Tanaka Y, et al. **Bone Marrow Transplant** 1998 Sep;22(5):511-3

Haemophagocytic lymphohistiocytosis in children. Hallahan AR, et al. **J Paediatr Child Health** 1999 Feb;35(1):55-9

The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Matsumoto Y, et al. **Ther Apher** 1998 Nov;2(4):300-4

[Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation] Dürken M, et al. **Klin Padiatr** 1998 Jul-Aug;210(4):180-4 (Eng. Abstr.) **(Ger)**

[Treatment of familial hemophagocytic lymphohistiocytosis] Sako M. **Rinsho Ketsueki** 1999 Feb;40(2):88-91 (13 ref.) **(Jpn)**

[Treatment for adult hemophagocytic syndrome] Takami Y. **Rinsho Ketsueki** 1999 Feb;40(2):108-11 **(Jpn)**

ULTRASONOGRAPHY

Abdominal ultrasound findings in children with hemophagocytic lymphohistiocytosis. Chateil J, et al. **Eur Radiol** 1999;9(3):474-7

VIROLOGY

Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Jan-Inge Henter for the Histiocyte Society. Imashuku S, et al. **Blood** 1999 Mar 15; 93(6):1869-74

Virus-associated haemophagocytic syndrome caused by rubella in an adult. Takenaka H, et al. **Br J Dermatol** 1998 Nov;139(5):877-80

Clonal change of infiltrating T-cells in children with familial hemophagocytic lymphohistiocytosis: possible association with Epstein-Barr virus infection. Ishii E, et al. **Cancer** 1999 Apr 1;85(7):1636-43

Polymerase chain reaction amplification of archival material for Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, and parvovirus B19 in children with bone marrow hemophagocytosis. Hoang MP, et al. **Hum Pathol** 1998 Oct;29(10):1074-7

[Epstein-Barr virus, hemophagocytic syndrome and angiocentric lymphoma: a rare and fatal association] Ramirez Jiménez S, et al. **An Esp Pediatr** 1998 Oct; 49(4):401-4 **(Spa)**

HISTIOCYTOSIS, SEA-BLUE see **SEA-BLUE HISTIOCYTE SYNDROME**

HISTIOCYTOSIS, SINUS

[Rosai-Dorfman disease] Kobayashi H. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):333-4 (11 ref.) **(Jpn)**

COMPLICATIONS

Acute renal failure in a patient with Rosai-Dorfman disease. Lai FM, et al. **Am J Kidney Dis** 1999 Sep;34(3):e12

Rosai-Dorfman disease presenting as a pituitary tumour. Kelly WF, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):133-7

Rosai-Dorfman disease (extranodal sinus histiocytosis) in a patient with HIV. Perry BP, et al. **Ear Nose Throat J** 1998 Oct;77(10):855-8

Sinus histiocytosis with massive lymphadenopathy involving the orbit: reversal of compressive optic neuropathy after chemotherapy. Goldberg S, et al. **J Neuroophthalmol** 1998 Dec;18(4):270-5

Bilateral eyelid edema: an uncommon presentation of Rosai-Dorfman disease. Pelletier CR, et al. **Ophthal Plast Reconstr Surg** 1999 Jan;15(1):52-5

Sinus histiocytosis: A rare cause of progressive pediatric cervical adenopathy. Lasak JM, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):765-9

DIAGNOSIS

Importance of Papanicolaou-stained smears and immunocytochemistry in the diagnosis of Rosai-Dorfman disease [letter] Viguer JM, et al. **Acta Cytol** 1999 Mar-Apr; 43(2):328-30

Sinus histiocytosis presenting as bilateral epibulbar masses. Ireland KC, et al. **Am J Ophthalmol** 1999 Mar;127(3):360-1

Rosai-Dorfman disease with primary cutaneous manifestations--a case report. Huang HY, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):589-93 (16 ref.)

Rosai-Dorfman disease (extranodal sinus histiocytosis) in a patient with HIV. Perry BP, et al. **Ear Nose Throat J** 1998 Oct;77(10):855-8

Subconjunctival mass in Rosai-Dorfman disease. Fernandez FJ, et al. **Eur J Ophthalmol** 1998 Oct-Dec;8(4):263-4

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Unal OF, et al. **Int J Pediatr Otorhinolaryngol** 1998 Jul 10;44(2):173-6

Rosai-Dorfman disease presenting multiple intracranial lesions with unique findings on magnetic resonance imaging. Case report. Udono H, et al. **J Neurosurg** 1999 Aug;91(2):335-9 (29 ref.)

Sinus histiocytosis: A rare cause of progressive pediatric cervical adenopathy. Lasak JM, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):765-9

Isolated intracranial Rosai-Dorfman disease: case report and literature review. Huang HY, et al. **Pathol Int** 1998 May; 48(5):396-402 (25 ref.)

[Sinus histiocytosis (Destombes-Rosai-Dorfman disease) revealed by extranodal spinal involvement] Bernard F, et al. **Arch Pediatr** 1999 Feb;6(2):173-7 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Importance of Papanicolaou-stained smears and immunocytochemistry in the diagnosis of Rosai-Dorfman disease [letter] Viguer JM, et al. **Acta Cytol** 1999 Mar-Apr; 43(2):328-30

Acute renal failure in a patient with Rosai-Dorfman disease. Lai FM, et al. **Am J Kidney Dis** 1999 Sep;34(3):e12

Rosai-Dorfman's disease of the breast [letter; comment] Soares FA, et al. **Am J Surg Pathol** 1999 Mar;23(3):359-60 . Comment on: Am J Surg Pathol 1997 Jun;21(6):664-8.

Sinus histiocytosis with massive lymphadenopathy: a case of multiple dural involvement. Sakai K, et al. **Brain Tumor Pathol** 1998;15(2):63-9

Fine needle aspiration (FNA) cytology of Rosai Dorfman disease. Deshpande V, et al. **Cytopathology** 1998 Oct; 9(5):329-35

Cutaneous Rosai-Dorfman disease presenting as pustular and acneiform lesions. Ang P, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):335-7

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): case report with nodal and diffuse muco-cutaneous involvement. Innocenzi D, et al. **J Cutan Pathol** 1998 Nov;25(10):563-7

Nasal manifestation of extranodal Rosai-Dorfman disease--diagnosis and management. Ku PK, et al. **J Laryngol Otol** 1999 Mar;113(3):275-80

[Destomebes-Rosaï-Dorfman syndrome (apropos of a case)] Khayat O, et al. **Tunis Med** 1998 Nov;76(11):421-3 **(Fre)**

[Intracranial location of a case of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) mimicking meningioma] Losi L, et al. **Pathologica** 1998 Aug;90(4):403-7 (16 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Sinus histiocytosis with massive lymphadenopathy. Multiple skull involvements. Park YK, et al. **J Korean Med Sci** 1998 Aug;13(4):423-7

SURGERY

Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) of the pancreas: first case report. Esquivel J, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1202-5

[Anesthesia in a patient with Rosai-Dorfman disease (letter)] Ortiz JR, et al. **Rev Esp Anestesiol Reanim** 1998 Dec; 45(10):443-4 **(Spa)**

HISTIOCYTOSIS X see **HISTIOCYTOSIS, LANGERHANS-CELL**

HISTOCOMPATIBILITY

Effect of HLA mismatching and antibody status on "homovital" aortic valve homograft performance. Smith JD, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S212-5

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Kawano Y, et al. **Blood** 1998 Nov 1;92(9):3123-30

Feasibility of finding an unrelated bone marrow donor on international registries for New Zealand patients. Velickovic ZM, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):291-4

Survival after large ABO-incompatible blood transfusion [letter] Ti LK, et al. **Can J Anaesth** 1998 Sep;45(9):916

Changing paternity and the risk of preterm delivery in the subsequent pregnancy. Li DK. **Epidemiology** 1999 Mar; 10(2):148-52

Effectiveness of rotor off fraction in allogeneic murine bone marrow transplantation with complete disparity of major histocompatibility. Jeong DC, et al. **Exp Hematol** 1999 Jul; 27(7):1219-25

European Federation for Immunogenetics 13th Conference.

Heraklion, Crete, Greece, April 13–17, 1999. Abstracts. **Hum Immunol** 1999;60 Suppl 1:S1–121

The American Society for Histocompatibility and Immunogenetics 24th annual meeting. Vancouver, British Columbia, Canada. October 10–15, 1998. Abstracts. **Hum Immunol** 1998;59 Suppl 1:1–170

The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1195–200

Cell adhesion and histocompatibility in sponges. Fernández-Busquets X, et al. **Microsc Res Tech** 1999 Feb 15;44(4):204–18 (160 ref.)

The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Sheldon S, et al. **Transplantation** 1999 Aug 27;68(4):515–9

Use of HLA- and HPA--matched platelets in alloimmunized patients. Kekomäki R. **Vox Sang** 1998;74 Suppl 2:359–63 (47 ref.)

DRUG EFFECTS

Transplantation of anergic histoincompatible bone marrow allografts [see comments] Guinan EC, et al. **N Engl J Med** 1999 Jun 3;340(22):1704–14. Comment in: N Engl J Med 1999 Jun 3;340(22):1754–6.

GENETICS

Transplantation of Fu/HC-incompatible zooids in Botryllus schlosseri results in chimerism. Rinkevich B, et al. **Biol Bull** 1998 Oct;195(2):98–106

HLA-identical sibling renal transplantation--a 21-yr single-center experience. de Mattos AM, et al. **Clin Transplant** 1999 Apr;13(2):158–67

Thymic transplantation across an MHC class I barrier in swine. Haller GW, et al. **J Immunol** 1999 Oct 1; 163(7):3785–92

Mouse male sterility and histoincompatibility (mshi) maps between the D10Mit51/168/212 cluster and D10Mit213. Rule MC, et al. **Mamm Genome** 1999 May;10(5):447–50

IMMUNOLOGY

Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection. Scott I, et al. **Blood** 1998 Dec 15;92(12):4864–71

HLA-C and HLA-DQB1 compatibility in unrelated cord blood transplants. Elia L, et al. **Haematologica** 1999 Jun; 84(6):530–4

Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4. Hall BM, et al. **J Immunol** 1998 Nov 15; 161(10):5147–56

Thymic transplantation across an MHC class I barrier in swine. Haller GW, et al. **J Immunol** 1999 Oct 1; 163(7):3785–92

Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Dickinson AM, et al. **Transplantation** 1998 Oct 15;66(7):857–63

Serum cytokine levels after HLA-identical bone marrow transplantation. Liem LM, et al. **Transplantation** 1998 Oct 15;66(7):863–71

HISTOCOMPATIBILITY ANTIGEN DNA PROBES see **DNA PROBES, HLA**

HISTOCOMPATIBILITY ANTIGENS

ADMINISTRATION & DOSAGE

Allopeptide-mediated expression of endothelial Fas-ligand (CD95L) in long-term tolerized heterotopic rat heart grafts. Fändrich F, et al. **Transplant Proc** 1999 May; 31(3):1558–9

Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts. Perez J, et al. **Transplant Proc** 1999 May;31(3):1560

ANALYSIS

Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas. Papaccio G, et al. **J Endocrinol** 1999 Mar;160(3):389–400

BIOSYNTHESIS

Inhibitory effect of alpha(1,2) fucosyltransferase recombinant adenoviral vector on alpha Gal expression. Nagasaka T, et al. **Transplant Proc** 1998 Nov;30(7):3837–8

CHEMISTRY

Comparative organization and function of the major histocompatibility complex of domesticated cattle. Lewin HA, et al. **Immunol Rev** 1999 Feb;167:145–58 (90 ref.)

Localization of immunogenic and tolerogenic epitopes in the RT1.A1 alloantigen. Wang M, et al. **Transplant Proc** 1999 May;31(3):1517–8

GENETICS

Applicability of SSCP analysis for MHC genotyping: fingerprinting of Ovar-DRB1 exon 2 alleles from Finnish and Russian breeds. Kostia S, et al. **Anim Genet** 1998 Dec; 29(6):453–5

AIRS-PCR for the canine DLA-DQA1 F141L polymorphism. Venta PJ, et al. **Anim Genet** 1998 Dec; 29(6):475

Isolation and characterization of a novel human gene (HFB30) which encodes a protein with a RING finger motif. Ueki N, et al. **Biochim Biophys Acta** 1999 May 14; 1445(2):232–6

Gene conversion of major histocompatibility complex genes is associated with CpG-rich regions. Högstrand K, et al. **Immunogenetics** 1999 May;49(5):446–55

Cis-acting regulation of splenic Art2 gene expression in inbred mouse strains. Sardinha DF, et al. **Immunogenetics** 1999 Jul;49(7–8):700–3

Nucleotide sequences of three distinct complementary DNA clones encoding rat class II major histocompatibility complex RT1.D beta-chain proteins. Tian L, et al. **Immunogenetics** 1999 Jul;49(7–8):735–7

RT1-U: identification of a novel, active, class Ib alloantigen of the rat MHC. Leong LY, et al. **J Immunol** 1999 Jan 15;162(2):743–52

Analysis of MHC class II and class IV restriction fragment length polymorphism in chicken lines divergently selected for multitrait immune response. Weigend S, et al. **Poult Sci** 1999 Jul;78(7):973–82

Characterisation of four non-human primate Mhc-DQB1 alleles. de Groot NG, et al. **Tissue Antigens** 1998 Nov; 52(5):497–9

DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Wagner JL, et al. **Tissue Antigens** 1998 Oct;52(4):397–401

Expression of soluble allo-MHC class I antigen in vivo suppresses IL-2 production by allo-reactive helper T cells. Geissler EK, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):742–3

Gene order of the RT1.M region of the rat MHC exemplifies interspecies conservation with the mouse. Lambracht-Washington D, et al. **Transplant Proc** 1999 May;31(3):1515–6

Expression of the T-cell differentiation antigen RT6.2 in T-cell lines is correlated with hypomethylation of the RT6 promoter. Rothenburg S, et al. **Transplant Proc** 1999 May; 31(3):1624–5

Evidence that allelic variations in the main RT6 promoter modulate transcriptional activity. Rothenburg S, et al. **Transplant Proc** 1999 May;31(3):1626–8

Sequence analysis of the genomic interval between the Rps18 and RT1-A genes in the RT1u haplotype. Walter L, et al. **Transplant Proc** 1999 May;31(3):1513–4

Characterization of RT1.B alleles from serologically identical and different RT1.B/D haplotypes. Wedekind D, et al. **Transplant Proc** 1999 May;31(3):1522

Potential of gene transfer for the induction of specific unresponsiveness to alloantigens in vivo. Wood KJ. **Transplant Proc** 1999 Feb-Mar;31(1–2A):19S–20S (16 ref.)

IMMUNOLOGY

Mechanism of complement-dependent haemolysis via the lectin pathway: role of the complement regulatory proteins. Suankratay C, et al. **Clin Exp Immunol** 1999 Sep; 117(3):442–8

Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. Silla S, et al. **Eur Cytokine Netw** 1999 Jun;10(2):181–90

Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Mazza G, et al. **Immunol Rev** 1998 Jun;163:187–96 (34 ref.)

Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. Blazar BR, et al. **J Immunol** 1999 Jun 1;162(11):6368–77

Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. Ciubotariu R, et al. **J Immunol** 1998 Nov 15; 161(10):5193–202

Serial TCR engagement and down-modulation by peptide:MHC molecule ligands: relationship to the quality of individual TCR signaling events. Itoh Y, et al. **J Immunol** 1999 Feb 15;162(4):2073–80

Cutting edge: alloimmune responses against major and minor histocompatibility antigens: distinct division kinetics and requirement for CD28 costimulation. Song HK, et al. **J Immunol** 1999 Mar 1;162(5):2467–71

A composite graft of islet plus donor lymph node cells induced donor specific tolerance in a "low responder" rat combination with class I MHC disparity. Maeda A, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):749–50

Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Mhoyan A, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1189–91

Immune nonresponsiveness to cardiac allografts by intrathymic inoculation of donor class I allopeptides is associated with high levels of transcripts for Th2 cytokines in the graft. Shirwan H, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):123–4

Potential of gene transfer for the induction of specific unresponsiveness to alloantigens in vivo. Wood KJ. **Transplant Proc** 1999 Feb-Mar;31(1–2A):19S–20S (16 ref.)

Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Chowdhury NC, et al. **Transplantation** 1998 Oct 27;66(8):1059–66

ISOLATION & PURIFICATION

RT1-U: identification of a novel, active, class Ib alloantigen of the rat MHC. Leong LY, et al. **J Immunol** 1999 Jan 15;162(2):743–52

METABOLISM

Mouse R16.1 is a thiol-dependent arginine-specific ADP-ribosyltransferase. Hara N, et al. **Eur J Biochem** 1999 Jan;259(1–2):289–94

Interaction of the p23/p198 protein with ErbB-3. Yoo JY, et al. **Gene** 1999 Mar 18;229(1–2):215–21

Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected] [published erratum appears in Immunity 1998 Dec;9(6):891] Boniface JJ, et al. **Immunity** 1998 Oct; 9(4):459–66

Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Sykulev Y, et al. **Immunity** 1998 Oct;9(4):475–83

Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide. Takahashi K, et al. **Mol Immunol** 1998 Dec;35(17):1081–7

The immunological synapse: a molecular machine controlling T cell activation [see comments] Grakoui A, et al. **Science** 1999 Jul 9;285(5425):221–7. Comment in: Science 1999 Jul 9;285(5425):207–8.

Dancing the immunological two-step [comment] Malissen B. **Science** 1999 Jul 9;285(5425):207–8. Comment on: Science 1999 Jul 9;285(5425):221–7.

PHYSIOLOGY

Comparative organization and function of the major histocompatibility complex of domesticated cattle. Lewin HA, et al. **Immunol Rev** 1999 Feb;167:145–58 (90 ref.)

Coordinate involvement of invasin and Yop proteins in a Yersinia pseudotuberculosis-specific class I-restricted cytotoxic T cell-mediated response. Falgarone G, et al. **J Immunol** 1999 Mar 1;162(5):2875–83

HISTOCOMPATIBILITY ANTIGENS CLASS I

A high resolution HLA class I and class II matching method for bone marrow donor selection. Argüello JR, et al. **Bone Marrow Transplant** 1998 Sep;22(6):527–34

Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. Noakes KL, et al. **FEBS Lett** 1999 Jun 18;453(1–2):95–9

Modulation of Ly49A receptors on mature cells to changes in major histocompatibility complex class I molecules. Khoo NK, et al. **Immunology** 1998 Sep;95(1):126–31

m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. Cretney E, et al. **J Exp Med** 1999 Aug 2;190(3):435–44

Pure red-cell aplasia [letter; comment] Zimmer J, et al. **N Engl J Med** 1999 Jun 24;340(25):2004–5. Comment on: N Engl J Med 1999 Jan 28;340(4):278–84.

HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. Cox ST, et al. **Tissue Antigens** 1999 Jan;53(1):41–50

Allele-specific and peptide-dependent recognition of swine leukocyte antigen class I by human cytotoxic T-cell clones. Xu XC, et al. **Transplantation** 1999 Aug 27;68(4):473–9

ADMINISTRATION & DOSAGE

In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density. Motta I, et al. **Eur J Immunol** 1998 Nov;28(11):3685–95

Allopeptide-mediated expression of endothelial Fas-ligand (CD95L) in long-term tolerized heterotopic rat heart grafts. Fändrich F, et al. **Transplant Proc** 1999 May; 31(3):1558–9

Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts. Perez J, et al. **Transplant Proc** 1999 May;31(3):1560

Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein. Stepkowski SM, et al. **Transplant Proc** 1999 May;31(3):1557

ANALYSIS

HLA antigens in lyophilised corneal lenticules. Tabandeh H, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):653–7

Soluble HLA-G: purification from eukaryotic transfected cells and detection by a specific ELISA. Fournel S, et al. **Am J Reprod Immunol** 1999 Jul;42(1):22–9

Quantitative assessment of human leukocyte antigen-G protein in amniotic fluid by a double-determinant

enzyme-linked immunosorbent assay using anti-human leukocyte antigen-G-specific antibody '87G'. Hamai Y, et al. **Am J Reprod Immunol** 1999 Apr;41(4):293-5

First trimester human endovascular trophoblast cells express both HLA-C and HLA-G. Pröll J, et al. **Am J Reprod Immunol** 1999 Jul;42(1):30-6

A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. van der Heeft E, et al. **Anal Chem** 1998 Sep 15;70(18):3742-51

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674-7

Lack of class I major histocompatibility antigens on trophoblast of periimplantation blastocysts and term placenta in the pig. Ramsoondar JJ, et al. **Biol Reprod** 1999 Feb;60(2):387-97

Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection. Scott I, et al. **Blood** 1998 Dec 15;92(12):4864-71

Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Dolo V, et al. **Cancer Res** 1998 Oct 1;58(19):4468-74

Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Flad T, et al. **Cancer Res** 1998 Dec 15;58(24):5803-11

Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Seliger B, et al. **Clin Cancer Res** 1996 Aug;2(8):1427-33

Biology in pictures. Gut reaction. **Curr Biol** 1998 Dec 17-31; 8(25):R901

Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLA-G*01012 allele. Castro MJ, et al. **Eur J Immunogenet** 1998 Aug;25(4):311-5

Immune selection in murine tumors. A study of MCA induced sarcomas in normal and immunodeficient mice. Engel AM, et al. **Folia Microbiol (Praha)** 1998;43(5):483-6

MHC expression in syngeneic and allogeneic retinal cell transplants in the rat. Larsson J, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):82-5

Characterizing the antigenic profile of the human trachea: implications for tracheal transplantation. Shaari CM, et al. **Head Neck** 1998 Sep;20(6):522-7

Detection and characterization of HLA class I molecules in the supernatant of an hepatocarcinoma cell line and of EBV-transformed B cell lines. Datema G, et al. **Hum Immunol** 1999 May;60(5):435-41

Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. Mangasarian A, et al. **J Virol** 1999 Mar;73(3):1964-73

Contribution of mass spectrometry to contemporary immunology. de Jong A. **Mass Spectrom Rev** 1998 Sep-Oct;17(5):311-35 (127 ref.)

Does a low level of expression of HLA molecules engender autoimmunity? [editorial; comment] Raulet DH. **N Engl J Med** 1999 Jan 28;340(4):314-5. Comment on: N Engl J Med 1999 Jan 28;340(4):278-84.

Constitutive and visna virus induced expression of class I and II major histocompatibility complex antigens in the central nervous system of sheep and their role in the pathogenesis of visna lesions. Bergsteinsdóttir K, et al. **Neuropathol Appl Neurobiol** 1998 Jun;24(3):224-32

Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions. Magyarosy E, et al. **Pathol Oncol Res** 1999;5(1):32-5

HLA-G and pregnancy. Le Bouteiller P. **Rev Rhum Engl Ed** 1998 Nov;65(11):608-10 (21 ref.)

Detection of soluble HLA-G molecules in plasma and amniotic fluid. Rebmann V, et al. **Tissue Antigens** 1999 Jan; 53(1):14-22

Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Suzuki S, et al. **Tohoku J Exp Med** 1998 Jul;185(3):223-6

Natural killer cell reactivity and HLA-G in recurrent spontaneous abortion. Emmer PM, et al. **Transplant Proc** 1999 Jun;31(4):1838-40

Induction of HLA-G-specific human CD8+ T cell lines by stimulation across a polymorphism of HLA-G. Horuzsko A, et al. **Transplant Proc** 1999 Jun;31(4):1860-3

HLA class I expression on peripheral blood lymphocytes and hepatocytes after liver transplantation. Minguela A, et al. **Transplant Proc** 1999 Sep;31(6):2466-8

[Association of class I HLA antigens with invasive meningococcal disease] Holub M, et al. **Cas Lek Cesk** 1998 Oct 5;137(19):598-600 (Eng. Abstr.) **(Cze)**

BIOSYNTHESIS

Expression, purification, crystallization and crystallographic characterization of the human MHC class I related protein MICA. Bauer S, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):451-3

Regulation of major histocompatibility complex and TAP gene products in preimplantation mouse stage embryos. Cooper JC, et al. **Am J Reprod Immunol** 1998 Sep; 40(3):165-71

Expression of porcine major histocompatibility antigens in cardiac tissue. Mirzaie M, et al. **APMIS** 1998 Oct; 106(10):935-40

Differential expression of Ped gene candidates in preimplantation mouse embryos. Wu L, et al. **Biol Reprod** 1998 Oct;59(4):941-52

Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Martayan A, et al. **Br J Cancer** 1999 May; 80(5-6):639-49

Interferon yield and MHC antigen expression of human medulloblastoma cells and its suppression during dibutyryl cyclic AMP-induced differentiation: do medulloblastoma cells derive from bipotent neuronal and glial progenitors? Park KC, et al. **Cell Mol Neurobiol** 1998 Oct;18(5):497-507

Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Nagaraju K, et al. **Clin Immunol** 1999 Aug;92(2):161-9

Expression and temperature-dependent regulation of the beta2-microglobulin (Cyca-B2m) gene in a cold-blooded vertebrate, the common carp (Cyprinus carpio L.). Rodrigues PN, et al. **Dev Immunol** 1998;5(4):263-75

Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes. Nilsen EM, et al. **Eur J Immunol** 1999 Jan;29(1):168-79

IFN-alpha super-induction of HLA class I expression by a variant thymoma cell line involves nuclear translocation of Rel complexes. Travers H, et al. **Eur J Immunol** 1998 Nov;28(11):3792-9

Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Zimmer J, et al. **Eur J Immunol** 1999 Apr;29(4):1286-91

Cytokine regulation of expression of class I MHC antigens. Raval A, et al. **Exp Mol Med** 1998 Mar 31;30(1):1-13 (115 ref.)

Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Chu W, et al. **Hum Immunol** 1998 Jul;59(7):435-42

The metalloproteinase-mediated pathway is essential for generation of soluble HLA class I proteins by activated cells in vitro: proposed mechanism for soluble HLA release in transplant rejection. DeVito-Haynes LD, et al. **Hum Immunol** 1998 Jul;59(7):426-34

Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. Graeb C, et al. **Hum Immunol** 1998 Jul; 59(7):415-25

Differential expression of major histocompatibility complex class Ia, Ib, and II molecules on monocytes-derived dendritic and macrophagic cells. Laupèze B, et al. **Hum Immunol** 1999 Jul;60(7):591-7

Two distinct forms of soluble MHC class I molecules synthesized by different mechanisms in normal rat cells in vitro. Zhai Y, et al. **Hum Immunol** 1998 Jul;59(7):404-14

Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Zwirner NW, et al. **Hum Immunol** 1999 Apr;60(4):323-30

The pathway for processing leader-derived peptides that regulate the maturation and expression of Qa-1b. Bai A, et al. **Immunity** 1998 Sep;9(3):413-21

Modulation of major histocompatibility complex antigen expression by human immunodeficiency virus-2 gp36. Chen YH, et al. **Immunol Lett** 1999 Jun 1;68(2-3):415-7

HLA and cancer: from research to clinical impact. Ruiz-Cabello F, et al. **Immunol Today** 1998 Dec; 19(12):539-42 (15 ref.)

HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Mallet V, et al. **Int Immunol** 1999 Jun;11(6):889-98

The effect of staphylococcal enterotoxin B on thyrocyte HLA molecule expression. Fierabracci A, et al. **J Autoimmun** 1999 Jun;12(4):305-14

Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z, et al. **J Exp Clin Cancer Res** 1998 Sep;17(3):251-8

Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. Bennett EM, et al. **J Immunol** 1999 May 1;162(9):5049-52

Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. Kovalev G, et al. **J Immunol** 1999 Jun 15;162(12):7555-62

Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. Pacasova R, et al. **J Immunol** 1999 May 1;162(9):5190-6

Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). Coral S, et al. **J Immunother** 1999 Jan;22(1):16-24

A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. Perry VH. **J Neuroimmunol** 1998 Oct 1;90(2):113-21 (74 ref.)

Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type-1. Song GY, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):1-7

Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. Chu W, et al. **J Reprod Immunol** 1999 Jan;42(1):1-15

Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells. Ljunggren G, et al. **J Reprod Immunol** 1998 Jul;38(2):123-38

Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway. Gao J, et al. **J Virol** 1999 Feb;73(2):1411-8

Differential regulation of Dk and Kk major histocompatibility complex class I proteins on the cell surface after infection of murine cells by pseudorabies virus. Sparks-Thissen RL, et al. **J Virol** 1999 Jul;73(7):5748-56

HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma. Yano T, et al. **Lung Cancer** 1998 Jun;20(3):185-90

Modification of HLA expression on peripheral lymphocytes and monocytes during aging. Le Morvan C, et al. **Mech Ageing Dev** 1998 Nov 16;105(3):209-20

HLA antigens in Iranian patients with B-cell chronic lymphocytic leukemia. Moazzeni SM, et al. **Pathol Oncol Res** 1999;5(2):142-5

Cell surface expression of HLA-E molecules on PBMC from a TAP1-deficient patient. Furukawa H, et al. **Tissue Antigens** 1999 Mar;53(3):292-5

Induction of swine major histocompatibility complex class I molecules on porcine endothelium by tumor necrosis factor-alpha reduces lysis by human natural killer cells. Kwiatkowski P, et al. **Transplantation** 1999 Jan 27; 67(2):211-8

Monophosphoryl lipid A (MPL) upregulates major histocompatibility complex (MHC) class I expression by increasing interferon-gamma (IFN-gamma). Cho CH, et al. **Yonsei Med J** 1999 Feb;40(1):20-5

BLOOD

Human leukocyte antigens associated with hyperthyroid Graves ophthalmology in Japanese patients. Ohtsuka K, et al. **Am J Ophthalmol** 1998 Dec;126(6):805-10

Soluble HLA class I antigens in plasma of patients with malignant melanoma. Westhoff U, et al. **Anticancer Res** 1998 Sep-Oct;18(5B):3789-92

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Ghio M, et al. **Blood** 1999 Mar 1;93(5):1770-7

Specific sHLA in healthy donors and donor-specific sHLA in renal transplant patients. Borelli SD, et al. **Hum Immunol** 1999 May;60(5):430-4

Soluble HLA-I in rheumatic diseases. Wolf RE, et al. **Hum Immunol** 1998 Oct;59(10):644-9

Serum concentrations of soluble human leukocyte class I antigens and of the soluble intercellular adhesion molecule-1 in endometriosis: relationship with stage and non-pigmented peritoneal lesions. De Placido G, et al. **Hum Reprod** 1998 Nov;13(11):3206-10

HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Kakizaki S, et al. **J Hepatol** 1999 May;30(5):794-800

Expression profiles of I and sialosyl-I antigens on blood cells: the sialosyl-I antigen is expressed along the monocytic differentiation. Muroi K, et al. **Leuk Res** 1998 Nov; 22(11):1029-36

Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype. Puppo F, et al. **Tissue Antigens** 1999 Mar; 53(3):253-62

Detection of soluble HLA-G levels in maternal serum can be predictive for a successful pregnancy. Athanassakis I, et al. **Transplant Proc** 1999 Jun;31(4):1834-7

CHEMISTRY

Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Martin WL, et al. **Biochemistry** 1999 Sep 28; 38(39):12639-47

CH/pi interactions in the crystal structure of class I MHC antigens and their complexes with peptides. Umezawa Y, et al. **Bioorg Med Chem** 1998 Dec;6(12):2507-15

Photophysical analysis of class I major histocompatibility complex protein assembly using a xanthene-derivatized beta2-microglobulin. Gakamsky DM, et al. **Biophys J** 1999 Mar;76(3):1552-60

The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences. Agrawal B, et al. **Cancer Res** 1998 Nov 15;58(22):5151-6

Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Gambacorti-Passerini C, et al. **Clin Cancer Res** 1997 May;3(5):675-83

Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK. **Clin Transpl** 1997;:317-35

Enhanced sensitivity for sequence determination of major histocompatibility complex class I peptides by membrane preconcentration-capillary electrophoresis-microspray-tandem mass spectrometry. Naylor S, et al. **Electrophoresis** 1998 Sep;19(12):2207-12

Knowledge-based structure prediction of MHC class I bound

peptides: a study of 23 complexes. Schueler-Furman O, et al. **Fold Des** 1998;3(6):549-64

Monitoring of soluble HLA class I size variants after liver transplantation [see comments] Rebmann V, et al. **Hum Immunol** 1999 May;60(5):424-9. Comment in: Hum Immunol 1999 May;60(5):401-2.

Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Li P, et al. **Immunity** 1999 May; 10(5):577-84

Recognition surfaces of MHC class I. Jones EY, et al. **Immunol Rev** 1998 Jun;163:121-8 (45 ref.)

Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. O'Callaghan CA, et al. **Immunol Rev** 1998 Jun;163:129-38 (49 ref.)

TAP association influences the conformation of nascent MHC class I molecules. Owen BA, et al. **J Immunol** 1999 Apr 15;162(8):4677-84

N-Hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities. Bianco A, et al. **J Pept Sci** 1998 Dec;4(8):471-8

The monoclonal antibody HCA2 recognises a broadly shared epitope on selected classical as well as several non-classical HLA class I molecules. Seitz C, et al. **Mol Immunol** 1998 Sep;35(13):819-27

Use of BONSAI decision trees for the identification of potential MHC class I peptide epitope motifs. Savoie CJ, et al. **Pac Symp Biocomput** 1999;:182-9

Structure and function of a membrane-bound murine MHC class I molecule. Celia H, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5634-9

Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Sánchez LM, et al. **Science** 1999 Mar 19;283(5409):1914-9

Localization of immunogenic and tolerogenic epitopes in the RT1.A1 alloantigen. Wang M, et al. **Transplant Proc** 1999 May;31(3):1517-8

Domain structure, intracellular trafficking, and beta2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus. Senkevich TG, et al. **Virology** 1998 Oct 25;250(2):397-407

CLASSIFICATION

A new taxonomy of mammalian MHC class I molecules. Hughes AL, et al. **Immunol Today** 1999 Jan;20(1):22-6

DRUG EFFECTS

Antigen presentation by MHC class I and its regulation by interferon gamma. Früh K, et al. **Curr Opin Immunol** 1999 Feb;11(1):76-81 (52 ref.)

GENETICS

The role of class I and class II HLA antigens in primary open angle glaucoma (POAG). Ferreri G, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):17-9

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. Tang J, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):317-24

On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. Verhoef K, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1553-9

The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Ota M, et al. **Am J Hum Genet** 1999 May;64(5):1406-10

Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. Santin AD, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):1020-5

Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. Moreau P, et al. **Am J Reprod Immunol** 1998 Sep;40(3):136-44

HLA-G polymorphisms: ethnic differences and implications for potential molecule function. van der Ven K, et al. **Am J Reprod Immunol** 1998 Sep;40(3):145-57 (54 ref.)

Analysis of human leukocyte antigen-G polymorphism including intron 4 in Japanese couples with habitual abortion [see comments] Yamashita T, et al. **Am J Reprod Immunol** 1999 Feb;41(2):159-63. Comment in: Am J Reprod Immunol 1999 Feb;41(2):117-20.

A PCR-RSP Csp6I site in the canine DLA-DQA1 gene. Venta PJ, et al. **Anim Genet** 1999 Feb;30(1):67

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674-7

HFE gene mutation and transferrin saturation in very low birthweight infants. Maier RF, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F144-5

The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Gonzalez S, et al. **Arthritis Rheum** 1999 May;42(5):1010-6

Molecular analyses of five new chimpanzee MHC class I alleles: implications for differences between evolutional mechanisms of HLA-A, -B, and -C loci. Matsui M, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):46-52

Cloning of a new gene (FB19) within HLA class I region. Totaro A, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):555-7

Expanded genomic organization of conserved mammalian MHC class I-related genes, human MR1 and its murine ortholog. Yamaguchi H, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):558-64

Frequencies in the Japanese population of HFE gene mutations. Sohda T, et al. **Biochem Genet** 1999 Feb; 37(1-2):63-8

Defective induction of the transcription factor interferon-stimulated gene factor-3 and interferon alpha insensitivity in human trophoblast cells. Cross JC, et al. **Biol Reprod** 1999 Feb;60(2):312-21

Identification of two major histocompatibility complex class Ib genes, Q7 and Q9, as the Ped gene in the mouse. Wu L, et al. **Biol Reprod** 1999 May;60(5):1114-9

No association between factor V Leiden and C282Y mutation in the hereditary hemochromatosis gene [letter; comment] Le Maréchal C, et al. **Blood** 1999 Jun 1;93(11):4024-5. Comment on: Blood 1998 Aug 15;92(4):1461-2.

The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Levy JE, et al. **Blood** 1999 Jul 1;94(1):9-11

HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Mura C, et al. **Blood** 1999 Apr 15; 93(8):2502-5

Alternate splicing produces a soluble form of the hereditary hemochromatosis protein HFE. Jeffrey GP, et al. **Blood Cells Mol Dis** 1999 Feb;25(1):61-7

Celtic origin of the C282Y mutation of hemochromatosis. Lucotte G. **Blood Cells Mol Dis** 1998 Dec;24(4):433-8

Frequency of the C282Y mutation of hemochromatosis in five French populations. Mercier G, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):165-6

Hemochromatosis in Ireland and HFE. Ryan E, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):428-32

Class I typing by PCR-SSP in Olomouc. Drábek J, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S23-6

Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells. Fox BA, et al. **Cancer Gene Ther** 1998 Sep-Oct; 5(5):307-12

Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Paul P, et al. **Cancer Res** 1999 Apr 15;59(8):1954-60

Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Beckman LE, et al. **Carcinogenesis** 1999 Jul;20(7):1231-3

Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women [see comments] Roest M, et al. **Circulation** 1999 Sep 21; 100(12):1268-73. Comment in: Circulation 1999 Sep 21;100(12):1260-3.

Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see comments] Tuomainen TP, et al. **Circulation** 1999 Sep 21; 100(12):1274-9. Comment in: Circulation 1999 Sep 21;100(12):1260-3.

Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Hiraki A, et al. **Clin Cancer Res** 1999 Apr;5(4):933-6

Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Datz C, et al. **Clin Chem** 1998 Dec;44(12):2429-32

Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Mangasser-Stephan K, et al. **Clin Chem** 1999 Oct; 45(10):1875-8

Simple multiplex PCR for the simultaneous detection of the C282Y and H63D hemochromatosis (HFE) gene mutations. Stott MK, et al. **Clin Chem** 1999 Mar;45(3):426-8

Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population. Weckmann AL, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):91-4

Expression of MhcCyca class I and class II molecules in the early life history of the common carp (Cyprinus carpio L.) Rodrigues PN, et al. **Dev Comp Immunol** 1998 Sep-Dec; 22(5-6):493-506

Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM [letter] Dubois-Laforgue D, et al. **Diabetes Care** 1998 Aug;21(8):1371-2

Hereditary haemochromatosis mutations (HFE) in patients with Type II diabetes mellitus [letter] Braun J, et al. **Diabetologia** 1998 Aug;41(8):983-4

Generation of a transcription map distal to HLA-F. Goldwurm S, et al. **Eur J Hum Genet** 1998 Sep-Oct; 6(5):475-86

Generation of a transcription map of a 1 Mbase region containing the HFE gene (6p22). Totaro A, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):105-13

Phylogenetic analysis of primate MIC (PERB11) sequences suggests that the representation of the gene family differs in different primates: comparison of MIC (PERB11) and C4. Cattley SK, et al. **Eur J Immunogenet** 1999 Apr-Jun; 26(2-3):233-8

DNA typing for BoLA class I using sequence-specific primers (PCR-SSP). Ellis SA, et al. **Eur J Immunogenet** 1998 Oct;25(5):365-70

HLA-G and classical HLA class I transcripts in various components of the adult human eye. Robert PY, et al. **Eur J Immunogenet** 1999 Aug;26(4):271-4

Definition of new alleles of MIC-A using sequencing-based typing. Yao Z, et al. **Eur J Immunogenet** 1999 Apr-Jun; 26(2-3):225-32

HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Krausa P, et al. **Exp Clin Immunogenet** 1999;16(1):17-25

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Moirand R, et al. **Gastroenterology** 1999 Feb;116(2):372-7

A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Wallace DF, et al. **Gastroenterology** 1999 Jun; 116(6):1409-12

Overexpression of chicken interferon regulatory factor-1 (Ch-IRF-1) induces constitutive expression of MHC class I antigens but does not confer virus resistance to a permanent chicken fibroblast cell line. Zoeller B, et al. **Gene** 1998 Nov 19;222(2):269-78

Mutation analysis of the HLA-H gene in French hemochromatosis patients, and genetic counseling in families. Mercier G, et al. **Genet Couns** 1998;9(3):181-6

The present status of the 'carrier hypothesis' for chemosensory recognition of genetic individuality. Singh PB. **Genetica** 1998-99;104(3):231-3 (22 ref.)

Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Grove J, et al. **Gut** 1998 Aug;43(2):262-6

HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload [letter] Remacha AF, et al. **Haematologica** 1999 Mar;84(3):284-5

Inherited HFE-unrelated hemochromatosis in Italian families. Camaschella C, et al. **Hepatology** 1999 May; 29(5):1563-4

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105-9

Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Beutler AS, et al. **Hum Gene Ther** 1999 Jan 1;10(1):95-101

Polymorphisms in the HFE gene. Douabin V, et al. **Hum Hered** 1999 Jan;49(1):21-6

Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. Moreau P, et al. **Hum Immunol** 1998 Dec;59(12):751-7

Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. de Villiers JN, et al. **Hum Mol Genet** 1999 Aug;8(8):1517-22

A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Merryweather-Clarke AT, et al. **Hum Mutat** 1999; 13(2):154-9

Variability in the expression of trophectodermal markers beta-human chorionic gonadotrophin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst. Jurisicova A, et al. **Hum Reprod** 1999 Jul;14(7):1852-8

Positive selection of an H2-M3 restricted T cell receptor. Berg RE, et al. **Immunity** 1999 Jul;11(1):33-43

Shapes of MHC restriction. Garboczi DN, et al. **Immunity** 1999 Jan;10(1):1-7

Evolution of the Mhc class I region: the framework hypothesis. Amadou C. **Immunogenetics** 1999 Apr; 49(4):362-7

Selection in favor of the Ped fast haplotype occurs between mid-gestation and birth. Exley GE, et al. **Immunogenetics** 1999 Jul;49(7-8):653-9

MICA haplotypic diversity. Fodil N, et al. **Immunogenetics** 1999 Jun;49(6):557-60

Identification of the Tapasin gene in the chicken major histocompatibility complex. Frangoulis B, et al. **Immunogenetics** 1999 Apr;49(4):328-37

A new polymorphism in the human HFE gene. HJohler T, et al. **Immunogenetics** 1999 Aug;49(9):823-4

CTL and sequence analyses of MHC class IB antigens Qa1(c) (H2-T23(r)) and Qa1(d) (H2-T23(f)). Hermel E, et al. **Immunogenetics** 1999 Jul;49(7-8):712-7

Re-examination of HLA-G polymorphism in African Americans. Ishitani A, et al. **Immunogenetics** 1999 Aug; 49(9):808-11

MIC-A polymorphism in Japanese and a MIC-A-MIC-B null haplotype. Komatsu-Wakui M, et al. **Immunogenetics** 1999 Jul;49(7-8):620-8

A new polymorphism in the HLA-F gene (67Ala[GCC] to Ala[GCG]). Kunishima S, et al. **Immunogenetics** 1999 Feb; 49(2):147-8

Characterization of the MICA polymorphism by sequence-specific oligonucleotide probing. Mendoza-Rincon J, et al. **Immunogenetics** 1999 Jun; 49(6):471-8

Population study of allelic diversity in the human MHC class I-related MIC-A gene. Petersdorf EW, et al. **Immunogenetics** 1999 Jul;49(7-8):605-12

Alternate splice variants of the hemochromatosis gene Hfe.

Rhodes DA, et al. **Immunogenetics** 1999 Apr;49(4):357–9
Physical mapping between the S and HLA-E genes in the human MHC class I region: construction of a BAC, PAC, and cosmid contig. Shiina T, et al. **Immunogenetics** 1998 Nov-Dec;48(6):402–7
Multiple class I loci expressed by the quail Mhc. Shiina T, et al. **Immunogenetics** 1999 May;49(5):456–60
Gene organization of the quail major histocompatibility complex (MhcCoja) class I gene region. Shiina T, et al. **Immunogenetics** 1999 May;49(5):384–94
Sequencing-based typing of MICA reveals 33 alleles: a study on linkage with classical HLA genes. Visser CJ, et al. **Immunogenetics** 1999 Jun;49(6):561–6
MIC-A allele profiles and HLA class I associations in Behçet's disease. Wallace GR, et al. **Immunogenetics** 1999 Jul;49(7-8):613–7
Characterization of a harbor seal class I major histocompatability complex cDNA clone. Zhong JF, et al. **Immunogenetics** 1998 Nov-Dec;48(6):422–4
The functionality of HLA-G is emerging. Le Bouteiller P, et al. **Immunol Rev** 1999 Feb;167:233–44 (64 ref.)
Genome sequencing analysis of the 1.8 Mb entire human MHC class I region. Shiina T, et al. **Immunol Rev** 1999 Feb;167:193–9 (56 ref.)
Disease-protected major histocompatibility complex Ea-transgenic non-obese diabetic (NOD) mice show interleukin-4 production not seen in susceptible Ea-transgenic and non-transgenic NOD mice. Brenden N, et al. **Immunology** 1998 Sep;95(1):1–7
Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Pappo J, et al. **Infect Immun** 1999 Jan; 67(1):337–41
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Moreau P, et al. **Int Immunol** 1999 May;11(5):803–11
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Cormier JN, et al. **Int J Cancer** 1999 Mar 1;80(5):781–90
Expression of HLA G in human tumors is not a frequent event. Real LM, et al. **Int J Cancer** 1999 May 17; 81(4):512–8
Immunogenetic analysis of Buerger's disease in India. Jaini R, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S283–5
MICA gene polymorphism in Takayasu's arteritis and Buerger's disease. Kimura A, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S107–13; discussion S115
Interaction of a nuclear factor derived from the trophoblast cell line BeWo with the HLA-G gene. Kimura T, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):67–8
Association of MICA gene and HLA-B*5101 with Behçet's disease in Greece. Yabuki K, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):1921–6
Allelic variation in the intron 2 and 3 of the MICA gene. Yao Z, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar; 13(1):47–50
HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. de la Salle H, et al. **J Clin Invest** 1999 Mar;103(5):R9–R13
A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. Brissot P, et al. **J Hepatol** 1999 Apr;30(4):588–93
Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. Pratiwi R, et al. **J Hepatol** 1999 Jul;31(1):39–46
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. Sánchez M, et al. **J Hepatol** 1998 Nov;29(5):725–8
Little evidence of HLA-G mRNA polymorphism in Caucasian or Afro-Caribbean populations. Bainbridge DR, et al. **J Immunol** 1999 Aug 15;163(4):2023–7
Human class I supertypes and CTL repertoires extend to chimpanzees. Bertoni R, et al. **J Immunol** 1998 Oct 15; 161(8):4447–55
Thymic transplantation across an MHC class I barrier in swine. Haller GW, et al. **J Immunol** 1999 Oct 1; 163(7):3785–92
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. Hendel H, et al. **J Immunol** 1999 Jun 1;162(11):6942–6
Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. Ishioka GY, et al. **J Immunol** 1999 Apr 1;162(7):3915–25
Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. Pacasova R, et al. **J Immunol** 1999 May 1;162(9):5190–6
Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. Riegert P, et al. **J Immunol** 1998 Oct 15;161(8):4066–77
Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. Keet IP, et al. **J Infect Dis** 1999 Aug;180(2):299–309
Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. Himmelmann A, et al. **J Lab Clin Med** 1999 Mar; 133(3):229–36 (51 ref.)
Frequency of the HFE C282Y and H63D mutations in distinct ethnic groups living in Spain [letter; comment] Baiget M, et al. **J Med Genet** 1998 Aug;35(8):701. Comment on: J Med Genet 1997 Apr;34(4):275–8.
High frequency of the haemochromatosis C282Y mutation in Hungary could argue against a Celtic origin of the mutation [letter; comment] Tordai A, et al. **J Med Genet** 1998 Oct;35(10):878–9. Comment on: J Med Genet 1997 Apr;34(4):275–8.
Coevolution of PERB11 (MIC) and HLA class I genes with HERV-16 and retroelements by extended genomic duplication. Kulski JK, et al. **J Mol Evol** 1999 Jul; 49(1):84–97
Genomic organization around the centromeric end of the HLA class I region: large-scale sequence analysis. Yamazaki M, et al. **J Mol Evol** 1999 Mar;48(3):317–27
Reciprocal regulation of HFE and NNamp2 gene expression by iron in human intestinal cells. Han O, et al. **J Nutr** 1999 Jan;129(1):98–104
Molecular cloning of bottle-nosed dolphin (Tursiops truncatus) MHC class I cDNA. Shirai K, et al. **J Vet Med Sci** 1998 Oct;60(10):1093–6
Transfusion with blood from people with HFE gene mutations [letter] Ania BJ, et al. **Lancet** 1999 Jul 31; 354(9176):430
Haemochromatosis gene C282Y homozygotes in an elderly male population [letter] Willis G, et al. **Lancet** 1999 Jul 17;354(9174):221–2
Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens [letter] Larghero J, et al. **Leukemia** 1999 Aug;13(8):1295–6
Hereditary haemochromatosis: diagnosis and management in the gene era. Olynyk JK. **Liver** 1999 Apr;19(2):73–80 (81 ref.)
Hereditary hemochromatosis in liver transplantation. Fiel MI, et al. **Liver Transpl Surg** 1999 Jan;5(1):50–6
Update on hereditary hemochromatosis and the HFE gene. Brandhagen DJ, et al. **Mayo Clin Proc** 1999 Sep; 74(9):917–21 (25 ref.)
Analysis of HLA association in susceptibility to infection with Cryptococcus neoformans var. gattii in a Papua New Guinean population. Van Dam MG, et al. **Med Mycol** 1998 Jun;36(3):185–8
HLA-H: a pseudogene with increased variation due to balancing selection at neighboring loci. Grimsley C, et al. **Mol Biol Evol** 1998 Dec;15(12):1581–8
Reduced phosphorylation of p50 is responsible for diminished NF-kappaB binding to the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells. Kushner DB, et al. **Mol Cell Biol** 1999 Mar;19(3):2169–79
Augmentation of therapeutic antitumor immunity by B16F10 melanoma cells transfected by interferon-gamma and allogeneic MHC class I cDNAs. Lim YS, et al. **Mol Cells** 1998 Oct 31;8(5):629–36
Search for a human homologue of the mouse Ped gene. Cao W, et al. **Mol Hum Reprod** 1999 Jun;5(6):541–7
The expression pattern of the Qa-2 antigen in mouse preimplantation embryos and its correlation with the Ped gene phenotype. McElhinny AS, et al. **Mol Hum Reprod** 1998 Oct;4(10):966–71
Lymphoid specificity of a copy number-related expression of the H2-Kb transgene. Hatina J, et al. **Mol Immunol** 1999 Jan;36(1):73–80
A population-based study of the clinical expression of the hemochromatosis gene [see comments] Olynyk JK, et al. **N Engl J Med** 1999 Sep 2;341(10):718–24. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.
Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene [see comments] Pietrangelo A, et al. **N Engl J Med** 1999 Sep 2; 341(10):725–32. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.
Clinical implications of the hemochromatosis gene [editorial; comment] Tavill AS. **N Engl J Med** 1999 Sep 2; 341(10):755–7. Comment on: N Engl J Med 1999 Sep 2;341(10):718–24. Comment on: N Engl J Med 1999 Sep 2;341(10):725–32.
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis [letter] Jeffrey GP, et al. **Nat Genet** 1999 Aug;22(4):325–6
Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Corriveau RA, et al. **Neuron** 1998 Sep;21(3):505–20
Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)
Diversification, expression, and gamma delta T cell recognition of evolutionarily distant members of the MIC family of major histocompatibility complex class I-related molecules. Steinle A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12510–5
The regulation of HLA class I expression: is HLA-G the odd one out? Gobin SJ, et al. **Semin Cancer Biol** 1999 Feb; 9(1):55–9 (18 ref.)
High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Cabrera T, et al. **Tissue Antigens** 1998 Aug;52(2):114–23
Improvement of HLA class I and class II PCR-SSP typing by using timed-release activity of DNA polymerase. Chen DF, et al. **Tissue Antigens** 1998 Jun;51(6):645–8
HLA and alveolar echinococcosis. Eiermann TH, et al. **Tissue Antigens** 1998 Aug;52(2):124–9
Polymorphism of TAPASIN and its linkage disequilibria with HLA class II genes in the Japanese population. Furukawa H, et al. **Tissue Antigens** 1998 Sep;52(3):279–81
Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. Hiby SE, et al. **Tissue Antigens** 1999 Jan;53(1):1–13
DLA-DRB1 polymorphisms in dogs defined by sequence-specific oligonucleotide probes (SSOP). Kennedy LJ, et al. **Tissue Antigens** 1999 Feb;53(2):184–9
HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Koopman LA, et al. **Tissue Antigens** 1998 Jun;51(6):623–36
HLA class I and class II of the Nivkhi, an indigenous population carrying HTLV-I in Sakhalin, Far Eastern Russia. Lou H, et al. **Tissue Antigens** 1998 Nov;52(5):444–51
Characterization of the HLA class I genotypes of a Venezuelan Amerindian group by molecular methods. Martínez-Arends A, et al. **Tissue Antigens** 1998 Jul; 52(1):51–6
Selective co-evolution of the D6S TNFa microsatellite region with HLA class I and II loci. Moghaddam PH, et al. **Tissue Antigens** 1998 Sep;52(3):213–9
High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population--implications for haemochromatosis. Murphy S, et al. **Tissue Antigens** 1998 Nov;52(5):484–8
Tissue distribution of the mRNA for a rhesus monkey major histocompatibility class Ib molecule, Mamu-AG. Slukvin II, et al. **Tissue Antigens** 1999 Mar;53(3):282–91
HLA-E polymorphism in patients with recurrent spontaneous abortion. Steffensen R, et al. **Tissue Antigens** 1998 Dec;52(6):569–72
Towards a molecular phototyping system for allelic variants of MICA, encoded by polymorphisms in exons 2, 3 and 4 of MHC class I chain-related genes. Stephens HA, et al. **Tissue Antigens** 1999 Feb;53(2):167–74
Sequencing-based typing reveals six novel MHC class I chain-related gene B (MICB) alleles. Visser CJ, et al. **Tissue Antigens** 1998 Jun;51(6):649–52
HLA-G genetic polymorphism in 57 Portuguese white families studied by PCR-RFLP and PCR-SSOP. Alvarez M, et al. **Transplant Proc** 1999 Jun;31(4):1829–31
Expression of HLA-E in transgenic mice. Boulouis HJ, et al. **Transplant Proc** 1999 Jun;31(4):1868–70
Preliminary study on the expression of HLA-G mRNA in normal placenta and placenta with RSA after immunotherapy. Fan L, et al. **Transplant Proc** 1999 Jun; 31(4):1854–6
Expression of soluble allo-MHC class I antigen in vivo suppresses IL-2 production by allo-reactive helper T cells. Geissler EK, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):742–3
Transcriptional regulation of HLA-G. Gobin SJ, et al. **Transplant Proc** 1999 Jun;31(4):1857–9
HLA-G gene polymorphism in the normal population and in recurrent spontaneous abortion in Hungary. Pénzes M, et al. **Transplant Proc** 1999 Jun;31(4):1832–3
Iron overload: molecular clues to its cause. Kühn LC. **Trends Biochem Sci** 1999 May;24(5):164–6 (24 ref.)
The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Poland GA, et al. **Vaccine** 1998 Nov; 16(19):1869–71
[The hemochromatosis gene (HFE). Molecular analysis--diagnostic applications] Ferec C, et al. **Transfus Clin Biol** 1998 Aug;5(4):283–9 (Eng. Abstr.) **(Fre)**
[DNA typing of class I HLA alleles] Kulcsárová E, et al. **Bratisl Lek Listy** 1998 Nov;99(11):597–600 (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

Activating and inhibitory NK cell receptors. Lanier LL. **Adv Exp Med Biol** 1998;452:13–8 (57 ref.)
Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Yewdell JW, et al. **Adv Immunol** 1999;73:1–77 (216 ref.)
Peripheral blood mononuclear cells from women with recurrent abortion exhibit an aberrant reaction to release cytokines upon the direct contact of human leukocyte antigen-G-expressing cells. Hamai Y, et al. **Am J Reprod Immunol** 1998 Dec;40(6):408–13
Monoclonal antibodies against maternal major histocompatibility complex class I molecules induce rapid abortion in mice. Knezevic N, et al. **Am J Reprod Immunol** 1999 Mar;41(3):217–23
Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. Moreau P, et al. **Am J Reprod Immunol** 1998 Sep;40(3):136–44
Unique biochemical properties of human leukocyte antigen-E allow for a highly specific function in immune recognition. Weiss EH, et al. **Am J Reprod Immunol** 1998 Sep; 40(3):177–82
Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Park MH, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):526–9
Donor-specific tolerance induction in composite tissue allografts. Foster RD, et al. **Am J Surg** 1998 Nov; 176(5):418–21

Serology versus ARMS-PCR in prospective HLA-class I typing for bone marrow transplantation. Usichenko T, et al. **Ann Hematol** 1998 Sep;77(3):97-100

Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products. Itescu S, et al. **Ann Transplant** 1997;2(1):14-20

High MHC class I expression correlates with slow growth in UV-induced skin carcinomas in hairless mice. Svane IM, et al. **APMIS** 1998 Nov;106(11):1101-7

Journey beyond immunology. Regulation of receptor internalization by major histocompatibility complex class I (MHC-I) and effect of peptides derived from MHC-I. Stagsted J. **APMIS Suppl** 1998;85:1-40 (553 ref.)

Mutation "hot spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Chen WN, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):757-61

Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation. Silva CL, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):591-5

Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells. Schirmbeck R, et al. **Biol Chem** 1999 Mar; 380(3):285-91 (90 ref.)

Real-time analysis of cell surface HLA class I interactions. Morgan CL, et al. **Biosens Bioelectron** 1998 Nov 1; 13(10):1099-105

Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Serody JS, et al. **Blood** 1999 Jan 1;93(1):43-50

The cytoplasmic and the transmembrane domains are not sufficient for class I MHC signal transduction. Gur H, et al. **Cell Immunol** 1999 Feb 1;191(2):105-16

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Hiltbold EM, et al. **Cell Immunol** 1999 Jun 15;194(2):143-9

Inhibition of NK cells by murine CMV-encoded class I MHC homologue m144. Kubota A, et al. **Cell Immunol** 1999 Feb 1;191(2):145-51

Normal epithelial cells modulating HLA class I surface molecules are susceptible to lysis mediated by CD3(+) and CD3(-) "nonspecific" killer cells. Semino C, et al. **Cell Immunol** 1998 Dec 15;190(2):183-90

Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327-33 (42 ref.)

Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells. Pellat-Deceunynck C, et al. **Clin Cancer Res** 1999 Mar; 5(3):705-9

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Scheibenbogen C, et al. **Clin Cancer Res** 1997 Feb;3(2):221-6

Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Větvička V, et al. **Clin Exp Immunol** 1999 Feb;115(2):229-35

Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK. **Clin Transpl** 1997;:317-35

The role of MHC class II molecules in susceptibility and resistance to autoimmunity. McDevitt HO. **Curr Opin Immunol** 1998 Dec;10(6):677-81 (31 ref.)

Genes regulating MHC class I processing of antigen. van Endert PM. **Curr Opin Immunol** 1999 Feb;11(1):82-8 (64 ref.)

Interactions of LIRs, a family of immunoreceptors expressed in myeloid and lymphoid cells, with viral and cellular MHC class I antigens. Borges L, et al. **Curr Top Microbiol Immunol** 1999;244:123-36 (49 ref.)

Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Braud VM, et al. **Curr Top Microbiol Immunol** 1999;244:85-95 (30 ref.)

A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **Curr Top Microbiol Immunol** 1999; 244:115-22 (39 ref.)

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. Vidalin O, et al. **DNA Cell Biol** 1999 Aug;18(8):611-21

Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. De Lerma Barbaro A, et al. **Eur J Immunol** 1999 Feb;29(2):499-511

Intrathymic deletion of MHC class I-restricted cytotoxic T cell precursors by constitutive cross-presentation of exogenous antigen. Merkenschlager M, et al. **Eur J Immunol** 1999 May;29(5):1477-86

Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Plebanski M, et al. **Eur J Immunol** 1998 Dec;28(12):4345-55

Major histocompatibility class I molecules present Urtica dioica agglutinin, a superantigen of vegetal origin, to T lymphocytes. Rovira P, et al. **Eur J Immunol** 1999 May; 29(5):1571-80

The Qa-1b molecule binds to a large subpopulation of murine NK cells. Salcedo M, et al. **Eur J Immunol** 1998 Dec; 28(12):4356-61

Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Schirmbeck R, et al. **Eur J Immunol** 1998 Dec;28(12):4149-61

Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Stoltze L, et al. **Eur J Immunol** 1998 Dec; 28(12):4029-36

Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Ulbrecht M, et al. **Eur J Immunol** 1999 Feb;29(2):537-47

MHC-I-induced apoptosis in human B-lymphoma cells is dependent on protein tyrosine and serine/threonine kinases. Pedersen AE, et al. **Exp Cell Res** 1999 Aug 25; 251(1):128-34

Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Furukawa H, et al. **Hum Immunol** 1999 Jan;60(1):32-40

Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Jiang S, et al. **Hum Immunol** 1998 Nov;59(11):690-9

Anti-HLA antibodies interfere in the detection of soluble HLA class I molecules. Koelman CA, et al. **Hum Immunol** 1999 May;60(5):414-23

Implication of soluble and membrane HLA class I and serum IL-10 in liver graft acceptance. Minguela A, et al. **Hum Immunol** 1999 Jun;60(6):500-9

Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative caucasian patients with ankylosing spondylitis. Yabuki K, et al. **Hum Immunol** 1999 Jan; 60(1):83-6

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Cohen GB, et al. **Immunity** 1999 Jun;10(6):661-71

Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Leibson PJ. **Immunity** 1998 Sep;9(3):289-94 (50 ref.)

Residue 3 of beta2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody. Ladasky JJ, et al. **Immunogenetics** 1999 Apr;49(4):312-20

Differential cytotoxic T-lymphocyte (CTL) responses in HIV-1 immunised sibling chimpanzees with shared MHC haplotypes. Balla-Jhagjhoorsingh S, et al. **Immunol Lett** 1999 Mar;66(1-3):61-7

Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. Evans DT, et al. **Immunol Lett** 1999 Mar;66(1-3):53-9

Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. Garcia AM, et al. **Immunol Lett** 1999 Apr 15;67(3):167-77

Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Collins EJ, et al. **Immunol Rev** 1998 Jun;163:151-60 (66 ref.)

Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Cosman D, et al. **Immunol Rev** 1999 Apr;168:177-85 (71 ref.)

A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Früh K, et al. **Immunol Rev** 1999 Apr;168:157-66 (76 ref.)

Cytomegaloviral control of MHC class I function in the mouse. Hengel H, et al. **Immunol Rev** 1999 Apr;168:167-76 (65 ref.)

Recognition surfaces of MHC class I. Jones EY, et al. **Immunol Rev** 1998 Jun;163:121-8 (45 ref.)

The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Tanaka K, et al. **Immunol Rev** 1998 Jun;163:161-76 (127 ref.)

HLA-G: a tolerance molecule from the major histocompatibility complex. Carosella ED, et al. **Immunol Today** 1999 Feb;20(2):60-2 (22 ref.)

The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses. Micheletti F, et al. **Immunology** 1999 Mar;96(3):411-5

Ethanol impairs major histocompatibility complex (MHC) class II molecule-mediated but not MHC class I molecule-mediated T cell response in alcohol-consuming mice. Chang MP, et al. **Immunopharmacol Immunotoxicol** 1999 Feb;21(1):65-87

Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Barnard JP, et al. **Infect Immun** 1999 Feb; 67(2):562-7

Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells. Bermudez LE, et al. **Infect Immun** 1999 Jun;67(6):3108-11

Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Carbonetti NH, et al. **Infect Immun** 1999 Feb;67(2):602-7

Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. Fayen J, et al. **Int Immunol** 1998 Sep;10(9):1347-58

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Le Gal FA, et al. **Int Immunol** 1999 Aug; 11(8):1351-6

The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protcin displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Vitale M, et al. **Int Immunol** 1999 Jan; 11(1):29-35

Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes. Nguyen T, et al. **Int J Cancer** 1999 May 17;81(4):607-15

HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. Posch PE, et al. **J Biomed Sci** 1998 Sep-Oct; 5(5):321-31 (102 ref.)

Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis. Yonamine Y, et al. **J Clin Immunol** 1999 Jan; 19(1):77-85

Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. Furukawa H, et al. **J Clin Invest** 1999 Mar; 103(5):755-8

Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. Raghavan M. **J Clin Invest** 1999 Mar;103(5):595-6

Donor MHC and adhesion molecules in transplant arteriosclerosis. Shi C, et al. **J Clin Invest** 1999 Feb; 103(4):469-74

Ultrastructure of murine tumour cell lines defective in MHC class I expression before and after interferon-gamma treatment. Hosaka Y, et al. **J Electron Microsc (Tokyo)** 1998;47(5):495-503

The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. Chang CS, et al. **J Exp Med** 1999 Feb 1;189(3):483-91

Development of CD8alpha/alpha and CD8alpha/beta T cells in major histocompatibility complex class I-deficient mice. Das G, et al. **J Exp Med** 1999 Sep 20;190(6):881-4

Effects of complementarity determining region mutations on the affinity of an alpha/beta T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing. Manning TC, et al. **J Exp Med** 1999 Feb 1;189(3):461-70

Selection and expansion of CD8alpha/alpha(1) T cell receptor alpha/beta(1) intestinal intraepithelial lymphocytes in the absence of both classical major histocompatibility complex class I and nonclassical CD1 molecules. Park SH, et al. **J Exp Med** 1999 Sep 20; 190(6):885-90

A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. Rajagopalan S, et al. **J Exp Med** 1999 Apr 5; 189(7):1093-100

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. Regnault A, et al. **J Exp Med** 1999 Jan 18;189(2):371-80

An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. Tilloy F, et al. **J Exp Med** 1999 Jun 21;189(12):1907-21

Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). Vance RE, et al. **J Exp Med** 1998 Nov 16;188(10):1841-8

Role of class I major histocompatibility complex-restricted and -unrestricted suppression of human immunodeficiency virus type 1 replication by CD8+ T lymphocytes. Ohashi T, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):209-16

Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. Kerman RH, et al. **J Heart Lung Transplant** 1998 Aug;17(8):789-94

Dual MHC class I and class II restriction of a single T cell receptor: distinct modes of tolerance induction by two classes of autoantigens. Arsov I, et al. **J Immunol** 1999 Feb 15;162(4):2008-15

Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. Avril T, et al. **J Immunol** 1999 May 15;162(10):5902-9

Human class I supertypes and CTL repertoires extend to chimpanzees. Bertoni R, et al. **J Immunol** 1998 Oct 15; 161(8):4447-55

Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. Bian H, et al. **J Immunol** 1999 Jul 15;163(2):1010-8

Peptide affinity and concentration affect the sensitivity of M3-restricted CTLs induced in vitro. Byers DE, et al. **J Immunol** 1999 Sep 15;163(6):3022-8

The alloreactive T cell response against the class Ib molecule H2-M3 is specific for high affinity peptides. Dabhi VM, et al. **J Immunol** 1998 Nov 15;161(10):5171-8

Human anti-porcine T cell response: blocking with anti-class I antibody leads to hyporesponsiveness and a switch in cytokine production. DerSimonian H, et al. **J Immunol** 1999 Jun 15;162(12):6993-7001

Thymic transplantation across an MHC class I barrier in swine. Haller GW, et al. **J Immunol** 1999 Oct 1; 163(7):3785–92

Peripheral tolerance to class I mismatched renal allografts in miniature swine: donor antigen–activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity. Ierino FL, et al. **J Immunol** 1999 Jan 1; 162(1):550–9

Induction of HLA class I–restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. Kim SK, et al. **J Immunol** 1999 Jun 1;162(11):6855–66

Cutting edge: requirement of class I signal sequence–derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone. Martinozzi S, et al. **J Immunol** 1999 May 15; 162(10):5662–5

Selective induction of protective MHC class I–restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. Murphey-Corb M, et al. **J Immunol** 1999 Jan 1;162(1):540–9

Priming MHC-I–restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Wild J, et al. **J Immunol** 1999 Aug 15; 163(4):1880–7

The use of human leucocyte antigen class I transgenic mice to investigate human immune function. Faulkner L, et al. **J Immunol Methods** 1998 Dec 1;221(1-2):1–16 (83 ref.)

Different in vivo tolerogenicity of MHC class I peptides. Fändrich F, et al. **J Leukoc Biol** 1999 Jan;65(1):16–27

Expanded cohorts of maternal CD8+ T-cells specific for paternal MHC class I accumulate during pregnancy. Zhou M, et al. **J Reprod Immunol** 1998 Oct;40(1):47–62

Cytotoxic T lymphocytes directed against donor HLA class I antigens on airway epithelial cells are present in bronchoalveolar lavage fluid from lung transplant recipients during acute rejection. Nakajima J, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):565–71

Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. Doan T, et al. **J Virol** 1999 Jul;73(7):6166–70

Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian–human immunodeficiency virus–infected rhesus monkeys. Egan MA, et al. **J Virol** 1999 Jul;73(7):5466–72

Detection of simian immunodeficiency virus Gag–specific CD8(+) T lymphocytes in semen of chronically infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I–peptide complex. Jordan HL, et al. **J Virol** 1999 May;73(5):4508–12

Proliferation and MHC–unrestricted bystander lysis by virus–specific cytotoxic T cells following antigen self–presentation. Staege MS, et al. **Med Microbiol Immunol (Berl)** 1998 Jun;187(1):17–21

Effects of sairei–to and tokishakuyaku–san on cytokine release from peripheral blood mononuclear cells upon recognition of HLA–G protein in the treatment of recurrent abortion. Fujii T, et al. **Methods Find Exp Clin Pharmacol** 1999 May;21(4):261–4

Extracellular processing and presentation of a 69–mer synthetic polypeptide to MHC class I–restricted T cells. Eberl G, et al. **Mol Immunol** 1999 Feb;36(2):103–12

Lymphoid specificity of a copy number–related expression of the H2–Kb transgene. Hatina J, et al. **Mol Immunol** 1999 Jan;36(1):73–80

Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen–specific cytotoxic T lymphocytes in patients with graft–versus–host disease. Mutis T, et al. **Nat Med** 1999 Jul;5(7):839–42

Identification of an MHC class I–restricted autoantigen in type 1 diabetes by screening an organ–specific cDNA library [see comments] Wong FS, et al. **Nat Med** 1999 Sep; 5(9):1026–31. Comment in: Nat Med 1999 Sep;5(9):992–3.

Cytotoxic T–cell immunity to virus–infected non–haematopoietic cells requires presentation of exogenous antigen [see comments] Sigal LJ, et al. **Nature** 1999 Mar 4;398(6722):77–80. Comment in: Nature 1999 Mar 4;398(6722):26–7.

Proto–oncogene PML controls genes devoted to MHC class I antigen presentation. Zheng P, et al. **Nature** 1998 Nov 26;396(6709):373–6

Relation of natural killer cell line NK–92–mediated cytolysis (NK–92–lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Komatsu F, et al. **Oncol Res** 1998;10(10):483–9

Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer. Arosarena OA, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):665–71

From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Krebs S, et al. **Pharm Acta Helv** 1998 Dec;73(4):173–81 (53 ref.)

Susceptibility of MHC class I expressing extravillous trophoblast cell lines to killing by natural killer cells. Zdravkovic M, et al. **Placenta** 1999 Jul–Aug;20(5–6):431–40

Broad tumor–associated expression and recognition by tumor–derived gamma delta T cells of MICA and MICB. Groh V, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8; 96(12):6879–84

Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I–restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Misko IS, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2279–84

The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Story CM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8516–21

Direct binding of purified HLA class I antigens by soluble NKG2/CD94 C–type lectins from natural killer cells. Ding Y, et al. **Scand J Immunol** 1999 May;49(5):459–65

Activation of NK cells and T cells by NKG2D, a receptor for stress–inducible MICA [see comments] Bauer S, et al. **Science** 1999 Jul 30;285(5428):727–9. Comment in: Science 1999 Jul 30;285(5428):645–6.

HLA–G expression: immune privilege for tumour cells? Cabestre FA, et al. **Semin Cancer Biol** 1999 Feb;9(1):27–36 (49 ref.)

HLA–G: a new opening for HLA. Dausset J, et al. **Semin Cancer Biol** 1999 Feb;9(1):1

How do NK cells sense the expression of HLA–G class Ib molecules? López–Botet M, et al. **Semin Cancer Biol** 1999 Feb;9(1):19–26 (70 ref.)

The role of peptide presentation in the physiological function of HLA–G. Münz C, et al. **Semin Cancer Biol** 1999 Feb; 9(1):47–54 (35 ref.)

The immunotolerance role of HLA–G. Rouas–Freiss N, et al. **Semin Cancer Biol** 1999 Feb;9(1):3–12 (40 ref.)

HLA–G and HLA–C at the feto–maternal interface: lessons learned from pathogenic viruses. Schust DJ, et al. **Semin Cancer Biol** 1999 Feb;9(1):37–46 (71 ref.)

High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). Argüello JR, et al. **Tissue Antigens** 1998 Jul;52(1):57–66

Mutations of the beta2–microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Benitez R, et al. **Tissue Antigens** 1998 Dec;52(6):520–9

Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Bresciani A, et al. **Tissue Antigens** 1998 Jul;52(1):44–50

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Cabrera T, et al. **Tissue Antigens** 1998 Aug;52(2):114–23

HLA–G protein expression is not induced during malignant transformation. Pangault C, et al. **Tissue Antigens** 1999 Apr; 53(4 Pt 1):335–46

The reduction of HLA class I expression on platelets: a potential approach in the management of HLA–alloimmunized refractory patients. Novotný VM, et al. **Transfus Med Rev** 1999 Apr;13(2):95–105 (60 ref.)

Antibodies to private and public HLA class I epitopes in platelet recipients. Zimmermann R, et al. **Transfusion** 1999 Jul;39(7):772–80

Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Zhai Y, et al. **Transpl Immunol** 1998 Sep;6(3):169–75

HLA–G mediates protection from natural killer cytolysis: implications in immune tolerance. Carosella ED, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):1192–3

Comparison of serologic HLA class I results in a bone marrow donor registry with results obtained by DNA methods. Chang YW, et al. **Transplant Proc** 1998 Nov; 30(7):3486–7

Indirect allorecognition is involved in both acute and chronic allograft rejection. Fluck N, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):842–3

Discrepancies between serology– and sequence–based typing of HLA class I alleles among unrelated donor/recipient pairs. Gimferrer I, et al. **Transplant Proc** 1999 Sep; 31(6):2579–80

Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Magee JC, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):1194

Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Mhoyan A, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):1189–91

Development of anti–HLA–antibodies against intra–CREG–mismatches in renal transplant recipients. Papassavas AC, et al. **Transplant Proc** 1999 Feb–Mar; 31(1-2):757–9

Synergy of class I and class II MHC deficiency (C1D and C2D) islets and early short–term suppression in achieving long–term islet graft survival and tolerance induction. Pittman K, et al. **Transplant Proc** 1999 Feb–Mar; 31(1-2):635–6

Role of HLA–G in maternal–fetal immune tolerance. Rouas–Freiss N, et al. **Transplant Proc** 1999 Feb–Mar; 31(1-2):724–5

Maintenance of acquired thymic tolerance to rat islet allografts by regulatory/suppressor T cells. Saborio DV, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):897

HLA–G expression protects porcine endothelial cells from xenogeneic cytotoxicity mediated by human natural killer cells. Sasaki H, et al. **Transplant Proc** 1999 Feb–Mar; 31(1-2):953–4

Immune nonresponsiveness to cardiac allografts by intrathymic inoculation of donor class I allopeptides is associated with high levels of transcripts for Th2 cytokines in the graft. Shirwan H, et al. **Transplant Proc** 1999 Feb–Mar;31(1-2):123–4

MHC structure and function. Thorsby E. **Transplant Proc** 1999 Feb–Mar;31(1-2):713–6 (28 ref.)

The humoral immune response against an HLA class I allodeterminant correlates with the HLA–DR phenotype of the responder. Fuller TC, et al. **Transplantation** 1999 Jul 27;68(2):173–82

T–cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas. Kelly KE, et al. **Transplantation** 1998 Sep 27;66(6):764–71

HLA–G expression protects porcine endothelial cells against natural killer cell–mediated xenogeneic cytotoxicity. Sasaki H, et al. **Transplantation** 1999 Jan 15;67(1):31–7

Predominant expression of T helper 2 cytokines and altered expression of T helper 1 cytokines in long–term allograft survival induced by intrathymic immune modulation with donor class I major histocompatibility complex peptides. Shirwan H, et al. **Transplantation** 1998 Dec 27; 66(12):1802–9

Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. SivaSai KS, et al. **Transplantation** 1999 Apr 27; 67(8):1094–8

Induction of MHC class I–restricted CTL response by DNA immunization with ubiquitin–influenza virus nucleoprotein fusion antigens. Fu TM, et al. **Vaccine** 1998 Nov; 16(18):1711–7

MHC class I– and class II–restricted processing and presentation of microencapsulated antigens. Men Y, et al. **Vaccine** 1999 Mar 5;17(9–10):1047–56

Delayed progression of murine AIDS in C57BL/6 mice pre–immunized with a highly antigenic 10–mer peptide encoded by the murine AIDS defective virus gag p12 gene. Mizuochi T, et al. **Vaccine** 1998 Dec;16(20):2026–30

Bovine lymphocyte antigen–A11––specific peptide motif as a means to identify cytotoxic T–lymphocyte epitopes of bovine herpesvirus 1. Hegde NR, et al. **Viral Immunol** 1999; 12(2):149–61

Endosomal/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus. Zúñiga MC, et al. **Virology** 1999 Sep 1; 261(2):180–92

ISOLATION & PURIFICATION

Soluble HLA–G: purification from eukaryotic transfected cells and detection by a specific ELISA. Fournel S, et al. **Am J Reprod Immunol** 1999 Jul;42(1):22–9

Monomorphic HLA class I–(non–A, non–B) expression on Ewing's tumor cell lines, modulation by TNF–alpha and IFN–gamma. Borowski A, et al. **Immunobiology** 1999 Feb; 200(1):1–20

METABOLISM

Degradation of cell proteins and the generation of MHC class I–presented peptides. Rock KL, et al. **Annu Rev Immunol** 1999;17:739–79 (211 ref.)

Thimet oligopeptidase and the stability of MHC class I epitopes in macrophage cytosol. Portaro FC, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):596–601

Anomalous diffusion of major histocompatibility complex class I molecules on HeLa cells determined by single particle tracking. Smith PR, et al. **Biophys J** 1999 Jun; 76(6):3331–44

Vitiligo melanocytes in long–term culture show normal constitutive and cytokine–induced expression of intercellular adhesion molecule–1 and major histocompatibility complex class I and class II molecules. Hedley SJ, et al. **Br J Dermatol** 1998 Dec;139(6):965–73

Lipofection indirectly increases expression of endogenous major histocompatibility complex class I molecules on tumor cells. Fox BA, et al. **Cancer Gene Ther** 1998 Sep–Oct; 5(5):307–12

Mapping of HLA class I binding motifs in forty–four fusion proteins involved in human cancers. Gambacorti–Passerini C, et al. **Clin Cancer Res** 1997 May;3(5):675–83

Antigen presentation: coming out gracefully. Lehner PJ, et al. **Curr Biol** 1998 Aug 27;8(17):R605–8 (27 ref.)

Natural killer cell activation and inhibition by receptors for MHC class I. López–Botet M, et al. **Curr Opin Immunol** 1999 Jun;11(3):301–7 (75 ref.)

HLA expression at the maternal–fetal interface. Hutter H, et al. **Dev Immunol** 1998;6(3–4):197–204 (57 ref.)

A cytomegalovirus glycoprotein re–routes MHC class I complexes to lysosomes for degradation. Reusch U, et al. **EMBO J** 1999 Feb 15;18(4):1081–91

Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. Schoenhals GJ, et al. **EMBO J** 1999 Feb 1; 18(3):743–53

Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2–A and the activating receptor CD94/NKG2–C to HLA–E. Valés–Gómez M, et al. **EMBO J** 1999 Aug 2;18(15):4250–60

The human natural killer lymphocyte receptors for MHC class I molecules. Bensussan A. **Eur Cytokine Netw** 1998 Dec;9(4):577–83 (73 ref.)

Immunohistological diagnosis of myocarditis. Potential role

of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Wojnicz R, et al. **Eur Heart J** 1998 Oct;19(10):1564–72

The N-terminal region of tapasin is required to stabilize the MHC class I loading complex. Bangia N, et al. **Eur J Immunol** 1999 Jun;29(6):1858–70

The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Navarro F, et al. **Eur J Immunol** 1999 Jan;29(1):277–83

Differing MHC class I requirements for induction and propagation of experimental systemic lupus erythematosus. Singer DS, et al. **Eur J Immunol** 1999 Jul;29(7):2259–68

Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. Svensson M, et al. **Eur J Immunol** 1999 Jan;29(1):180–8

Partial purification and characterization of a novel murine factor that augments the expression of class I MHC antigens on tumor cells. Puri N, et al. **Exp Mol Med** 1998 Jun 30; 30(2):93–9

Up-regulation of the expression of major histocompatibility complex class I antigens by plasmid DNA transfection in non-hematopoietic cells. Park JH, et al. **FEBS Lett** 1998 Sep 25;436(1):55–60

Activation and peripheral expansion of murine T-cell receptor gamma delta intraepithelial lymphocytes. Guehler SR, et al. **Gastroenterology** 1999 Feb;116(2):327–34

Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. Moreau P, et al. **Hum Immunol** 1998 Dec;59(12):751–7

Soluble CD8 stabilizes the HLA class I molecule by promoting beta2M exchange: analysis in real-time. Morgan CL, et al. **Hum Immunol** 1999 May;60(5):442–9

Expression of class I human leukocyte antigen (HLA) and beta2-microglobulin is associated with decidualization of human endometrial stromal cells. Komatsu T, et al. **Hum Reprod** 1998 Aug;13(8):2246–51

Shapes of MHC restriction. Garboczi DN, et al. **Immunity** 1999 Jan;10(1):1–7

Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Hanke T, et al. **Immunity** 1999 Jul;11(1):67–77

Modulation of HLA class I antigen and ICAM-2 on endothelial cells after in vitro infection with human cytomegalovirus. Shahgasempour S, et al. **Immunol Cell Biol** 1998 Jun;76(3):217–21

Simian virus 40 infection via MHC class I molecules and caveolae. Norkin LC. **Immunol Rev** 1999 Apr;168:13–22 (55 ref.)

Exploitation of major histocompatibility complex class I molecules and caveolae by simian virus 40. Parton RG, et al. **Immunol Rev** 1999 Apr;168:23–31 (70 ref.)

The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Piguet V, et al. **Immunol Rev** 1999 Apr;168:51–63 (112 ref.)

Elevated major histocompatibility complex class I expression protects T cells from antibody- and macrophage-mediated deletion. Orlikowsky T, et al. **Immunology** 1998 Nov; 95(3):437–42

Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. Gatfield J, et al. **Int Immunol** 1998 Nov; 10(11):1665–72

Natural killing of MHC class I(-) lymphoblasts by NK cells from long-term bone marrow culture requires effector cell expression of Ly49 receptors. Lindberg J, et al. **Int Immunol** 1999 Aug;11(8):1239–46

Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. Arosa FA, et al. **J Biol Chem** 1999 Jun 11;274(24):16917–22

26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. Ben-Shahar S, et al. **J Biol Chem** 1999 Jul 30;274(31):21963–72

Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing. Li S, et al. **J Biol Chem** 1999 Mar 26;274(13):8649–54

Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. Allan DS, et al. **J Exp Med** 1999 Apr 5;189(7):1149–56

The majority of H2-M3 is retained intracellularly in a peptide-receptive state and traffics to the cell surface in the presence of N-formylated peptides. Chiu NM, et al. **J Exp Med** 1999 Aug 2;190(3):423–34

Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. Haurum JS, et al. **J Exp Med** 1999 Jul 5;190(1):145–50

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. Romero P, et al. **J Exp Med** 1998 Nov 2; 188(9):1641–50

Antibody-induced endocytosis of viral glycoproteins and major histocompatibility complex class I on pseudorabies virus-infected monocytes. Favoreel HW, et al. **J Gen Virol** 1999 May;80 (Pt 5):1283–91

Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. Agrawal S, et al. **J Immunol** 1999 Feb 1;162(3):1223–6

Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. Amoscato AA, et al. **J Immunol** 1998 Oct 15;161(8):4023–32

Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. Andersen MH, et al. **J Immunol** 1999 Oct 1;163(7):3812–8

MHC class I-restricted presentation of maleylated protein binding to scavenger receptors. Bansal P, et al. **J Immunol** 1999 Apr 15;162(8):4430–7

Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. Brooks AG, et al. **J Immunol** 1999 Jan 1;162(1):305–13

Orientation of the Ig domains of CD8 alpha beta relative to MHC class I. Devine L, et al. **J Immunol** 1999 Jan 15; 162(2):846–51

Three different MHC class I molecules bind the same CTL epitope of the influenza virus in a primate species with limited MHC class I diversity. Evans DT, et al. **J Immunol** 1999 Apr 1;162(7):3970–7

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. Ferris RL, et al. **J Immunol** 1999 Feb 1;162(3):1324–32

Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs. Hauser C, et al. **J Immunol** 1999 Jul 1;163(1):330–6

Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. Ishii T, et al. **J Immunol** 1999 Feb 1;162(3):1303–9

MHC class I molecules compete in the endoplasmic reticulum for access to transporter associated with antigen processing. Knittler MR, et al. **J Immunol** 1998 Dec 1;161(11):5967–77

Intracellular rate-limiting steps in MHC class I antigen processing. Montoya M, et al. **J Immunol** 1999 Aug 15; 163(4):1914–22

TAP association influences the conformation of nascent MHC class I molecules. Owen BA, et al. **J Immunol** 1999 Apr 15;162(8):4677–84

Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. Selby M, et al. **J Immunol** 1999 Jan 15;162(2):669–76

Stochastic acquisition of Qa1 receptors during the development of fetal NK cells in vitro accounts in part but not in whole for the ability of these cells to distinguish between class I-sufficient and class I-deficient targets. Toomey JA, et al. **J Immunol** 1999 Sep 15;163(6):3176–84

Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma. White J, et al. **J Immunol** 1999 Mar 1;162(5):2671–6

Antigen secreted from noncytosolic Listeria monocytogenes is processed by the classical MHC class I processing pathway. Zwickey HL, et al. **J Immunol** 1999 Jun 1; 162(11):6341–50

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Colonna M, et al. **J Leukoc Biol** 1999 Sep; 66(3):375–81 (61 ref.)

Granulocyte-macrophage colony-stimulating factor modulates tapasin expression in human neutrophils. El Ouakfaoui S, et al. **J Leukoc Biol** 1999 Feb;65(2):205–10

The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary hemochromatosis. Lebrón JA, et al. **J Mol Biol** 1999 Jun 18;289(4):1109–18

The expression pattern of the Qa-2 antigen in mouse preimplantation embryos and its correlation with the Ped gene phenotype. McElhinny AS, et al. **Mol Hum Reprod** 1998 Oct;4(10):966–71

Differential association of beta2-microglobulin mutants with MHC class I heavy chains and structural analysis demonstrate allele-specific interactions. Shields MJ, et al. **Mol Immunol** 1999 Jun;36(9):561–73

Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)

Natural killer cells fertile with receptors for HLA-G? [see comments] Lanier LL. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5343–5. Comment in: Proc Natl Acad Sci U S A 1999 May 11;96(10):5674–9.

Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Salter-Cid L, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5434–9

Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Waheed A, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1579–84

Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I. Young HE, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):63–71

A trigger of natural (and other) killers [news; comment] Hagmann M. **Science** 1999 Jul 30;285(5428):645, 647. Comment on: Science 1999 Jul 30;285(5428):727–9. Comment on: Science 1999 Jul 30;285(5428):730–2.

Biotinylation of class I MHC molecules abrogates recognition by W6/32 antibody. Malik P, et al. **Tissue Antigens** 1999 Jun;53(6):576–9

Analysis of HLA-G expression in tumor cell lines. Frumento G, et al. **Transplant Proc** 1999 Jun;31(4):1847–8

Expression and regulation of HLA-G in human glioma cell lines. Maier S, et al. **Transplant Proc** 1999 Jun;31(4):1849–53

Interactions formed by truncated transporter associated with antigen-processing polypeptides. Newitt S, et al. **Transplant Proc** 1999 May;31(3):1519–21

HLA-G expression on porcine endothelial cells protects partially against direct human NK cytotoxicity but not against ADCC. Seebach JD, et al. **Transplant Proc** 1999 Jun;31(4):1864–5

[Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression] Wu XX, et al. **Hinyokika Kiyo** 1998 Sep;44(9):621–6 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides. Saborio DV, et al. **Cell Transplant** 1999 Jul-Aug;8(4):375–81

The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. Roy CN, et al. **J Biol Chem** 1999 Mar 26;274(13):9022–8

Mechanism of acquired thymic tolerance induced by a single major histocompatibility complex class I peptide with the dominant epitope: differential analysis of regulatory cytokines in the lymphoid and intragraft compartments. Oluwole SF, et al. **Transplantation** 1999 Aug 15; 68(3):418–29

PHYSIOLOGY

Human leukocyte antigen-G: new roles for old? [editorial; comment] Clark DA. **Am J Reprod Immunol** 1999 Feb; 41(2):117–20. Comment on: Am J Reprod Immunol 1999 Feb;41(2):153–8. Comment on: Am J Reprod Immunol 1999 Feb;41(2):159–63.

The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them [see comments] Hamai Y, et al. **Am J Reprod Immunol** 1999 Feb;41(2):153–8. Comment in: Am J Reprod Immunol 1999 Feb;41(2):117–20.

Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer. Yamada A, et al. **Cancer Immunol Immunother** 1999 May-Jun;48(2-3):147–52

Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. Griffiths E, et al. **Cancer Res** 1998 Oct 15;58(20):4682–7

MHC class I molecules on CD4 T cells regulate receptor-mediated activation signals. Wang ZQ, et al. **Cell Immunol** 1999 Apr 10;193(1):108–14

Functions of nonclassical MHC and non-MHC-encoded class I molecules. Braud VM, et al. **Curr Opin Immunol** 1999 Feb;11(1):100–8 (85 ref.)

Short peptides sensitize target cells to CTL specific for the MHC class Ib molecule, H2-M3. Dabhi VM, et al. **Eur J Immunol** 1998 Nov;28(11):3773–82

Soluble MHC antigens and olfactory recognition of genetic individuality: the mechanism. Pearse-Pratt R, et al. **Genetica** 1998-99;104(3):223–30 (13 ref.)

Placental HLA-G protein expression in vivo: where and what for? Le Bouteiller P, et al. **Hum Reprod Update** 1999 May-Jun;5(3):223–33 (101 ref.)

Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. Paz P, et al. **Immunity** 1999 Aug; 11(2):241–51

The functionality of HLA-G is emerging. Le Bouteiller P, et al. **Immunol Rev** 1999 Feb;167:233–44 (64 ref.)

Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Bian H, et al. **Int Immunol** 1998 Sep;10(9):1315–23

Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. Canaday DH, et al. **J Immunol** 1999 Jan 1;162(1):372–9

IL-7 up-regulates IL-4 production by splenic NK1.1+ and NK1.1- MHC class I-like/CD1-dependent CD4+ T cells. Hameg A, et al. **J Immunol** 1999 Jun 15;162(12):7067–74

T cell responses to Gram-negative intracellular bacterial pathogens: a role for CD8+ T cells in immunity to Salmonella infection and the involvement of MHC class Ib molecules. Lo WF, et al. **J Immunol** 1999 May 1; 162(9):5398–406

HLA class I-mediated induction of cell proliferation involves cyclin E-mediated inactivation of Rb function and induction of E2F activity. Nath N, et al. **J Immunol** 1999 May 1;162(9):5351–8

An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection. Holterman AX, et al. **J Virol** 1999 Mar; 73(3):2058–63

Recycling MHC class I molecules and endosomal peptide loading. Grommé M, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10326–31

Class I MHC molecules on hematopoietic cells can support intrathymic positive selection of T cell receptor transgenic T cells. Zerrahn J, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11470–5

Choriocarcinoma cell line resistance to NK lysis mainly involves an HLA–G–independent mechanism. Avril T, et al. **Transplant Proc** 1999 Jun;31(4):1866–7

Sulfation–dependent down–regulation of interferon–gamma–induced major histocompatibility complex class I and II and intercellular adhesion molecule–1 expression on tubular and endothelial cells by glycosaminoglycans. Yard BA, et al. **Transplantation** 1998 Nov 15;66(9):1244–50

HISTOCOMPATIBILITY ANTIGENS CLASS II

A high resolution HLA class I and class II matching method for bone marrow donor selection. Argüello JR, et al. **Bone Marrow Transplant** 1998 Sep;22(6):527–34

The distribution and ultrastructure of class II MHC–positive cells in human dental pulp. Ohshima H, et al. **Cell Tissue Res** 1999 Jan;295(1):151–8

Coding sequences of the MHC II beta chain of homozygous rainbow trout (Oncorhynchus mykiss). Ristow SS, et al. **Dev Comp Immunol** 1999 Jan–Feb;23(1):51–60

Modulation by epitope–specific antibodies of class II MHC–restricted presentation of the tetanus toxin antigen. Watts C, et al. **Immunol Rev** 1998 Aug;164:11–6 (22 ref.)

Iterative stepwise discriminant analysis: a meta–algorithm for detecting quantitative sequence motifs. Mallios RR. **J Comput Biol** 1998 Winter;5(4):703–11

Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal. Ceman S, et al. **J Exp Med** 1998 Dec 7;188(11):2139–49

H2–M3–restricted T cells in bacterial infection: rapid primary but diminished memory responses. Kerksiek KM, et al. **J Exp Med** 1999 Jul 19;190(2):195–204

A Lewis(y) epitope mimicking peptide induces anti–Lewis(y) immune responses in rabbits and mice. Lou Q, et al. **J Pept Res** 1999 Mar;53(3):252–60

Syncytium–inhibiting monoclonal antibodies produced against human T–cell lymphotropic virus type 1–infected cells recognize class II major histocompatibility complex molecules and block by protein crowding. Hildreth JE. **J Virol** 1998 Dec;72(12):9544–52

HLA–DRB1*01 and DRB1*04 alleles in Sardinian rheumatoid arthritis patients. Carcassi C, et al. **Tissue Antigens** 1999 Jan;53(1):97–100

ANALYSIS

Differential epidermal expression of the invariant chain in allergic and irritant contact dermatitis. Emilson A, et al. **Acta Derm Venereol** 1998 Nov;78(6):402–7

HLA antigens in lyophilised corneal lenticules. Tabandeh H, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):653–7

Dexamethasone inhibits IFNgamma–induced MHC class II expression of intestinal epithelial cells independently of the TGF–beta1 regulatory pathway. Ruemmele FM, et al. **Aliment Pharmacol Ther** 1999 May;13(5):595–601

Longitudinal study of lymphocyte subsets and major histocompatibility complex–class II expressing cells in mammary glands of sows. Magnusson U. **Am J Vet Res** 1999 May;60(5):546–8

HLA–DM is expressed on the cell surface and colocalizes with HLA–DR and invariant chain in human Langerhans cells. Andersson T, et al. **Arch Dermatol Res** 1998 Dec; 290(12):674–80

Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Semple JW, et al. **Blood** 1999 Jan 15;93(2):713–20

Dynamic expression changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. Rocha M, et al. **Clin Cancer Res** 1996 May;2(5):811–20

MHC expression in syngeneic and allogeneic retinal cell transplants in the rat. Larsson J, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):82–5

Characterizing the antigenic profile of the human trachea: implications for tracheal transplantation. Shaari CM, et al. **Head Neck** 1998 Sep;20(6):522–7

HLA–DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. Catálfamo M, et al. **Int Immunol** 1999 Feb; 11(2):269–77

Endothelial cell class II major histocompatibility complex molecule expression in stereotactic brain biopsies of patients with acute inflammatory/demyelinating conditions. van der Maesen K, et al. **J Neuropathol Exp Neurol** 1999 Apr; 58(4):346–58

Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. Dababneh A, et al. **J Rheumatol** 1998 Nov; 25(11):2140–5

Contribution of mass spectrometry to contemporary immunology. de Jong A. **Mass Spectrom Rev** 1998 Sep–Oct;17(5):311–35 (127 ref.)

Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot–Marie–Tooth type 1 and hereditary neuropathy with liability to pressure palsies. Stoll G, et al. **Muscle Nerve** 1998 Nov;21(11):1419–27

Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane. Tokumoto M, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2210–5 (28 ref.)

Constitutive and visna virus induced expression of class I and II major histocompatibility complex antigens in the central nervous system of sheep and their role in the pathogenesis of visna lesions. Bergsteinsdóttir K, et al. **Neuropathol Appl Neurobiol** 1998 Jun;24(3):224–32

CD4(+) T cells eliminate MHC class II–negative cancer cells in vivo by indirect effects of IFN–gamma. Mumberg D, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8633–8

Selective modulation of B–cell activation markers CD86 and I–Ak on murine draining lymph node cells following allergen or irritant treatment. Gerberick GF, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):142–51

Chronic rejection of major histocompatibility complex class II–disparate skin grafts after anti–CD3 therapy: a model of antibody–independent transplant vasculopathy. Le Moine A, et al. **Transplantation** 1998 Dec 15;66(11):1537–44

BIOSYNTHESIS

Cordyceps sinensis increases the expression of major histocompatibility complex class II antigens on human hepatoma cell line HA22T/VGH cells. Chiu JH, et al. **Am J Chin Med** 1998;26(2):159–70

Macrophage expression of class II major histocompatibility complex gene products in Paracoccidioides brasiliensis–infected mice. Bocca AL, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):280–7

Expression of porcine major histocompatibility antigens in cardiac tissue. Mirzaie M, et al. **APMIS** 1998 Oct; 106(10):935–40

Up–regulation of intercellular adhesion molecule–1 (ICAM–1), endothelial leucocyte adhesion molecule–1 (ELAM–1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1–ribonucleoprotein. Okawa–Takatsuji M, et al. **Clin Exp Immunol** 1999 Apr;116(1):174–80

Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Nagaraju K, et al. **Clin Immunol** 1999 Aug;92(2):161–9

Altered expression of immune–related antigens by neuronophages does not improve neuronal survival after severe lesion of the facial nerve in rats. Angelov DN, et al. **Glia** 1998 Oct;24(2):155–71

Differential expression of major histocompatibility complex class Ia, Ib, and II molecules on monocytes–derived dendritic and macrophagic cells. Laupéze B, et al. **Hum Immunol** 1999 Jul;60(7):591–7

A novel monoclonal antibody against rat LFA–1: blockade of LFA–1 and CD4 augments class II MHC expression on T cells. Arnold PY, et al. **Hybridoma** 1998 Aug; 17(4):331–8

Fibronectin–binding protein I of Streptococcus pyogenes promotes T cell–independent proliferation of murine B lymphocytes and enhances the expression of MHC class II molecules on antigen–presenting cells. Medina E, et al. **Int Immunol** 1998 Nov;10(11):1657–64

CIITA–induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter–bound multi–protein complexes. Villard J, et al. **Int Immunol** 1999 Mar;11(3):461–9

Mice lacking the transcription factor CIITA--a second look. Williams GS, et al. **Int Immunol** 1998 Dec;10(12):1957–67

The effect of staphylococcal enterotoxin B on thyrocyte HLA molecule expression. Fierabracci A, et al. **J Autoimmun** 1999 Jun;12(4):305–14

Photohapten TCSA painting plus UVA irradiation of murine skin augments the expression of MHC class II molecules and CD86 on Langerhans cells. Nishijima T, et al. **J Dermatol Sci** 1999 Apr;19(3):202–7

Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules. Forquet F, et al. **J Immunol** 1999 Mar 15; 162(6):3408–16

TNF–alpha suppresses IFN–gamma–induced MHC class II expression in HT1080 cells by destabilizing class II trans–activator mRNA. Han Y, et al. **J Immunol** 1999 Aug 1;163(3):1435–40

Reduced IL–4–, lipopolysaccharide–, and IFN–gamma–induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP–binding domain. Itoh–Lindstrom Y, et al. **J Immunol** 1999 Sep 1;163(5):2425–31

Protection from radiation–induced colitis requires MHC class II antigen expression by cells of hemopoietic origin. Marguerat S, et al. **J Immunol** 1999 Oct 1;163(7):4033–40

IFN–gamma down–regulates MHC expression and antigen processing in a human B cell line. O'Neil D, et al. **J Immunol** 1999 Jan 15;162(2):791–8

Discoordinate expression of invariant chain and MHC class II genes in class II transactivator–transfected fibroblasts defective for RFX5. Peijnenburg A, et al. **J Immunol** 1999 Jul 15;163(2):794–801

Murine cytomegalovirus infection down–regulates MHC class II expression on macrophages by induction of IL–10. Redpath S, et al. **J Immunol** 1999 Jun 1;162(11):6701–7

IL–1 beta inhibits IFN–gamma–induced class II MHC expression by suppressing transcription of the class II transactivator gene. Rohn W, et al. **J Immunol** 1999 Jan 15;162(2):886–96

Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette–Guérin involves class II transactivator and depends on the Nramp1 gene. Wojciechowski W, et al. **J Immunol** 1999 Sep 1;163(5):2688–96

MHC class II–dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. Poncet P, et al. **J Leukoc Biol** 1999 Jul; 66(1):105–12

An autologous self–antigen differentially regulates expression of I–A glycoproteins and B7 costimulatory molecules on CD4– CD8– T helper cells. Walker MR, et al. **J Leukoc Biol** 1999 Jul;66(1):120–6

Cell surface expression of MHC molecules in glioma cells infected with herpes simplex virus type–1. Song GY, et al. **J Neuroimmunol** 1999 Jan 1;93(1–2):1–7

Cytokine induced modulation of MHC class I and class II molecules on human cervical epithelial cells. Ljunggren G, et al. **J Reprod Immunol** 1998 Jul;38(2):123–38

Human parainfluenza virus type 3 up–regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1– and CIITA–independent pathway. Gao J, et al. **J Virol** 1999 Feb;73(2):1411–8

HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma. Yano T, et al. **Lung Cancer** 1998 Jun;20(3):185–90

HLA antigens in Iranian patients with B–cell chronic lymphocytic leukemia. Moazzeni SM, et al. **Pathol Oncol Res** 1999;5(2):142–5

Differential expression of major histocompatibility complex class II variants in cells infiltrating the meth A sarcoma. Busund L, et al. **Scand J Immunol** 1999 May;49(5):501–5

Differential regulation of HLA–DQ expression by keratinocytes and Langerhans cells in normal and premalignant cervical epithelium. Mota FF, et al. **Tissue Antigens** 1998 Sep;52(3):286–93

Estradiol inhibits allograft–inducible major histocompatibility complex class II antigen expression and transplant arteriosclerosis in the absence of immunosuppression. Saito S, et al. **Transplantation** 1998 Dec 15;66(11):1424–31

Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease. Hewicker–Trautwein M, et al. **Vet Immunol Immunopathol** 1999 Mar 1;67(4):341–57

Invariant chain expression in colon neoplasms. Jiang Z, et al. **Virchows Arch** 1999 Jul;435(1):32–6

BLOOD

Human leukocyte antigens associated with hyperthyroid Graves ophthalmology in Japanese patients. Ohtsuka K, et al. **Am J Ophthalmol** 1998 Dec;126(6):805–10

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Ghio M, et al. **Blood** 1999 Mar 1;93(5):1770–7

HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. Guédez Y, et al. **Circulation** 1999 Jun 1; 99(21):2784–90

CHEMISTRY

Kinetic isomers of a class II MHC–peptide complex. Schmitt L, et al. **Biochemistry** 1998 Dec 15;37(50):17371–80

Tetrapeptide derived inhibitors of complexation of a class II MHC: fully unnatural ligands. Jones AB, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2115–8

Crystal structure of MHC class II–associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. Gunčar G, et al. **EMBO J** 1999 Feb 15;18(4):793–803

Structure of a trimeric domain of the MHC class II–associated chaperonin and targeting protein Ii. Jasanoff A, et al. **EMBO J** 1998 Dec 1;17(23):6812–8

One of two unstructured domains of Ii becomes ordered in complexes with MHC class II molecules. Jasanoff A, et al. **Immunity** 1999 Jun;10(6):761–8

MHC multimerization, antigen expression and the induction of APC amnesia in the developing immune response. Lake RA, et al. **Immunol Cell Biol** 1999 Feb;77(1):99–104 (41 ref.)

Mutations in MHC class II dimer of dimers contact residues: effects on antigen presentation. Nydam T, et al. **Int Immunol** 1998 Aug;10(8):1237–49

Molecular modeling of hen egg lysozyme HEL[52–61] peptide binding to I–Ak MHC class II molecule. Weber P, et al. **Int Immunol** 1998 Dec;10(12):1753–64

Cutting edge: a single, essential hydrogen bond controls the stability of peptide–MHC class II complexes. McFarland BJ, et al. **J Immunol** 1999 Oct 1;163(7):3567–71

Conformational isomers of a class II MHC–peptide complex in solution. Schmitt L, et al. **J Mol Biol** 1999 Feb 12; 286(1):207–18

Synthesis and kinetics of cyclization of MHC class II–derived cyclic peptide vaccine for diabetes. Berezhkovskiy L, et al. **J Pept Res** 1999 Aug;54(2):112–9

Catalysis of peptide dissociation from class II MHC–peptide complexes. Schmitt L, et al. **Proc Natl Acad Sci U S A**

1999 Jun 8;96(12):6581-6

DRUG EFFECTS

Tetrapeptide derived inhibitors of complexation of a class II MHC: the peptide backbone is not inviolate. Jones AB, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2109-14

DR (MHC class II) ligands: an approach to rheumatoid arthritis therapeutics. Hanson GJ. **Curr Pharm Des** 1998 Oct;4(5):397-402 (57 ref.)

Downregulation of class II antigen expression by FGF-heparin complexes is due primarily to heparin effect. Hackshaw KV, et al. **Res Commun Mol Pathol Pharmacol** 1998 Aug; 101(2):99-114 (45 ref.)

GENETICS

The role of class I and class II HLA antigens in primary open angle glaucoma (POAG). Ferreri G, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):17-9

Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. Santin AD, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):1020-5

HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype. Aron Y, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1464-8

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arnett FC, et al. **Arthritis Rheum** 1999 Feb;42(2):268-74

Influence of HLA-DPB1 mismatches on MLR responses: the role of high resolution HLA class II typing and MLC in unrelated donor selection for BMT. Penzes M, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S34-7

Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Hiraki A, et al. **Clin Cancer Res** 1999 Apr;5(4):933-6

Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population. Weckmann AL, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):91-4

Coding sequences of the MHC II beta chain of homozygous rainbow trout (Oncorhynchus mykiss). Ristow SS, et al. **Dev Comp Immunol** 1999 Jan-Feb;23(1):51-60

Expression of MhcCyca class I and class II molecules in the early life history of the common carp (Cyprinus carpio L.) Rodrigues PN, et al. **Dev Comp Immunol** 1998 Sep-Dec; 22(5-6):493-506

Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Liu J, et al. **Diabetes** 1999 Mar;48(3):469-77

Family studies and human leukocyte antigen class II typing in Indian probands with seizures in association with single small enhancing computed tomography lesions. Jain S, et al. **Epilepsia** 1999 Feb;40(2):232-8

Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Beutler AS, et al. **Hum Gene Ther** 1999 Jan 1;10(1):95-101

Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes. Guo W, et al. **Hum Immunol** 1999 Apr; 60(4):312-22

Characterization and distribution of Mhc-DPB1 alleles in chimpanzee and rhesus macaque populations. Otting N, et al. **Hum Immunol** 1998 Oct;59(10):656-64

Studies on associations between human leukocyte antigen (HLA) class II alleles and antiphospholipid antibodies in Danish and Czech women with recurrent miscarriages. Christiansen OB, et al. **Hum Reprod** 1998 Dec; 13(12):3326-31

CREB regulates MHC class II expression in a CIITA-dependent manner. Moreno CS, et al. **Immunity** 1999 Feb;10(2):143-51

The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Allcock RJ, et al. **Immunogenetics** 1999 Jul;49(7-8):660-5

Evidence for an additional cattle DQA locus, BoLA-DQA5. Gelhaus A, et al. **Immunogenetics** 1999 Apr;49(4):321-7

Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene. Peijnenburg A, et al. **Immunogenetics** 1999 Apr;49(4):338-45

Identification and sequence analysis of an Mhc class II B gene in a marsupial (Monodelphis domestica). Stone WH, et al. **Immunogenetics** 1999 May;49(5):461-3

Nucleotide sequences of three distinct complementary DNA clones encoding rat class II major histocompatibility complex RT1.D beta-chain proteins. Tian L, et al. **Immunogenetics** 1999 Jul;49(7-8):735-7

Characterization of Mhc-DRB allelic diversity in white-tailed deer (Odocoileus virginianus) provides insight into Mhc-DRB allelic evolution within Cervidae. Van Den Bussche RA, et al. **Immunogenetics** 1999 May;49(5):429-37

Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Pappo J, et al. **Infect Immun** 1999 Jan; 67(1):337-41

Mice lacking the transcription factor CIITA--a second look. Williams GS, et al. **Int Immunol** 1998 Dec;10(12):1957-67

Class II major histocompatibility complex typing across the ethnic barrier in pemphigoid gestationis. A study in Mexicans. Garcia-Gonzalez E, et al. **Int J Dermatol** 1999 Jan;38(1):46-51

HLA-B27 subtypes and HLA class II alleles in Japanese patients with anterior uveitis. Konno Y, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1838-44

Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study [see comments] Heward JM, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3394-7. Comment in: J Clin Endocrinol Metab 1998 Oct;83(10):3391-3.

A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. Gregori S, et al. **J Immunol** 1999 Jun 1;162(11):6630-40

Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. Hermans IF, et al. **J Immunol** 1999 Jul 1;163(1):77-81

Thymic positive selection and peripheral activation of islet antigen-specific T cells: separation of two diabetogenic steps by an I-A(g7) class II MHC beta-chain mutant. Kanagawa O, et al. **J Immunol** 1998 Nov 1;161(9):4489-92

BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge. Kenty G, et al. **J Immunol** 1999 Jul 1; 163(1):232-41

IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. Le Moine A, et al. **J Immunol** 1999 Oct 1;163(7):3778-84

Alterations in CD4-binding regions of the MHC class II molecule I-Ek do not impede CD4+ T cell development. Yelon D, et al. **J Immunol** 1999 Feb 1;162(3):1348-58

Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. Keet IP, et al. **J Infect Dis** 1999 Aug;180(2):299-309

Evolution of Mhc-DRB introns: implications for the origin of primates. Kupfermann H, et al. **J Mol Evol** 1999 Jun; 48(6):663-74

Experimental autoimmune encephalomyelitis induced in B6.C-H-2bm12 mice by myelin oligodendrocyte glycoprotein: effect of MHC class II mutation on immunodominant epitope selection and fine epitope specificity of encephalitogenic T cells. Mendel I, et al. **J Neuroimmunol** 1999 Apr 1;96(1):9-20

Immunogenetics of uveitis in leprosy. Joko S, et al. **Jpn J Ophthalmol** 1999 Mar-Apr;43(2):97-102

Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Tjernström F, et al. **Lupus** 1999;8(2):103-8

Major histocompatibility complex (MHC) class II polymorphism and paternity in the monogamous Hypogeomys antimena, the endangered, largest endemic Malagasy rodent. Sommer S, et al. **Mol Ecol** 1999 Aug; 8(8):1259-72

Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Tai AK, et al. **Mol Immunol** 1999 May;36(7):447-60

Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression. Murphy SP, et al. **Mol Reprod Dev** 1998 Sep;51(1):1-12

Differential expression of MHC class II molecules by microglia and neoplastic astroglia: relevance for the escape of astrocytoma cells from immune surveillance. Tran CT, et al. **Neuropathol Appl Neurobiol** 1998 Aug;24(4):293-301

Analysis of MHC class II and class IV restriction fragment length polymorphism in chicken lines divergently selected for multitrait immune response. Weigend S, et al. **Poult Sci** 1999 Jul;78(7):973-82

Mice lacking all conventional MHC class II genes. Madsen L, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10338-43

HLA genotyping of 5,000- and 6,000-year-old ancient bones in Japan. Anzai T, et al. **Tissue Antigens** 1999 Jul;54(1):53-8

Improvement of HLA class I and class II PCR-SSP typing by using timed-release activity of DNA polymerase. Chen DF, et al. **Tissue Antigens** 1998 Jun;51(6):645-8

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Cotler SJ, et al. **Tissue Antigens** 1998 Nov;52(5):435-43

HLA and alveolar echinococcosis. Eiermann TH, et al. **Tissue Antigens** 1998 Aug;52(2):124-9

Polymorphism of TAPASIN and its linkage disequilibria with HLA class II genes in the Japanese population. Furukawa H, et al. **Tissue Antigens** 1998 Sep;52(3):279-81

Distribution of HLA class II alleles among Spanish patients with pemphigus vulgaris. González-Escribano MF, et al. **Tissue Antigens** 1998 Sep;52(3):275-8

HLA class I and class II of the Nivkhi, an indigenous population carrying HTLV-I in Sakhalin, Far Eastern Russia. Lou H, et al. **Tissue Antigens** 1998 Nov;52(5):444-51

HLA class II polymorphism in a Gabonese Banzabi population. Migot-Nabias F, et al. **Tissue Antigens** 1999 Jun;53(6):580-5

Selective co-evolution of the D6STNFa microsatellite region with HLA class I and II loci. Moghaddam PH, et al. **Tissue Antigens** 1998 Sep;52(3):213-9

Association of HLA class II alleles with different subgroups of diabetes mellitus in Eastern India identify different associations with IDDM and malnutrition-related diabetes. Sanjeevi CB, et al. **Tissue Antigens** 1999 Jul;54(1):83-7

Polymorphisms of HLA class II genes in Japanese patients with pemphigus vulgaris. Yamashina Y, et al. **Tissue Antigens** 1998 Jul;52(1):74-7

HLA class II alleles in Japanese patients with inflammatory bowel disease. Yoshitake S, et al. **Tissue Antigens** 1999 Apr; 53(4 Pt 1):350-8

Protection of murine systemic lupus erythematosus by an I-E alpha-chain transgene. Izui S, et al. **Transplant Proc** 1998 Dec;30(8):4122-3

Transfer of swine major histocompatibility complex class II genes into autologous bone marrow cells of baboons for the induction of tolerance across xenogeneic barriers. Ierino FL, et al. **Transplantation** 1999 Apr 27;67(8):1119-28

[Variations under genetic control of onchocerca infection as a function of clinical profile in the endemic center of Cameroon] Donfack J, et al. **Bull Soc Pathol Exot** 1999 May;92(2):85-90 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines. Ostrand-Rosenberg S, et al. **Adv Exp Med Biol** 1998;451:259-64

Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules. Unanue ER. **Am J Pathol** 1999 Mar;154(3):651-64 (75 ref.)

Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Hoekstra FM, et al. **Ann Thorac Surg** 1998 Dec; 66(6):2022-6

A novel macrophage receptor enhances MHC II-peptide loading and surface expression of a hapten-protein conjugate. Weaver DJ Jr, et al. **Biol Cell** 1998 Sep; 90(5):427-38

Humoral immune response to equine chorionic gonadotropin in ewes: association with major histocompatibility complex and interference with subsequent fertility. Roy F, et al. **Biol Reprod** 1999 Jul;61(1):209-18

Incomplete T-cell immune reconstitution in two major histocompatibility complex class II-deficiency/bare lymphocyte syndrome patients after HLA-identical sibling bone marrow transplantation. Godthelp BC, et al. **Blood** 1999 Jul 1;94(1):348-58

Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Serody JS, et al. **Blood** 1999 Jan 1;93(1):43-50

The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. van Vugt MJ, et al. **Blood** 1999 Jul 15; 94(2):808-17

An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes? Gerlier D, et al. **C R Acad Sci III** 1998 Jan;321(1):19-24 (23 ref.)

Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Hiltbold EM, et al. **Cancer Res** 1998 Nov 15;58(22):5066-70

Hyperacute rejection from antibody against class II HLA antigens. Ghasemian SR, et al. **Clin Transplant** 1998 Dec; 12(6):569-71

Toxicity of major histocompatibility complex class II specific monoclonal antibodies: audietur et altera pars. Toral IJ, et al. **Croat Med J** 1999 Sep;40(3):353-6

Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Liu J, et al. **Diabetes** 1999 Mar;48(3):469-77

Spontaneous T-cell proliferation in the non-obese diabetic mouse to a peptide from the unique class II MHC molecule, I-Ag7, which is also protective against the development of autoimmune diabetes. Xu XJ, et al. **Diabetologia** 1999 May;42(5):560-5

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. Vidalin O, et al. **DNA Cell Biol** 1999 Aug;18(8):611-21

Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Kita M, et al. **Endocrinology** 1999 Mar;140(3):1392-8

Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. De Lerma Barbaro A, et al. **Eur J Immunol** 1999 Feb;29(2):499-511

Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. Filaci G, et al. **Eur J Immunol** 1998 Dec; 28(12):3968-79

An endogenously processed self peptide and the corresponding exogenous peptide bound to the same MHC class II molecule could be distinct ligands for TCR with different kinetic stability. Gyotoku T, et al. **Eur J Immunol** 1998 Dec;28(12):4050-61

Peptide length-dependent TCR antagonism on class II HLA-restricted responses of peripheral blood mononuclear cells and T cell clones. Matsushita S, et al. **Eur J Immunol** 1999 Feb;29(2):431-6

Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class II molecules. Mommaas AM, et al. **Eur J Immunol** 1999 Feb;29(2):571–80

CIIV, MIIC and other compartments for MHC class II loading. Neefjes J. **Eur J Immunol** 1999 May;29(5):1421–5

Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2–DMa gene. Russell HI, et al. **Eur J Immunol** 1999 Mar;29(3):905–11

Inhibition of thymocyte positive selection by natural MHC: peptide ligands. Tourne S, et al. **Eur J Immunol** 1999 Feb; 29(2):394–402

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Fujii S, et al. **Hum Immunol** 1998 Oct;59(10):607–14

Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. Hua ZX, et al. **Hum Pathol** 1998 Dec;29(12):1441–6

Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. Viret C, et al. **Immunity** 1999 May;10(5):559–68

Differential MHC expression requirements for positive selection of separate TCR Vb families. Brenden N, et al. **Immunogenetics** 1999 Jan;49(1):1–6

A clustered subset of MHC class II molecules [letter; comment] Horejsi V, et al. **Immunol Today** 1998 Oct; 19(10):486. Comment on: Immunol Today 1998 Apr;19(4):192–3.

On the intrathymic intercellular transfer of self-determinants. Viret C, et al. **Immunol Today** 1999 Jan;20(1):8–10 (20 ref.)

Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Carrasco-Marin E, et al. **Immunology** 1998 Nov; 95(3):314–21

Peptide-binding motifs of the mixed haplotype Abetaz/Aalphad major histocompatibility complex class II molecule: a restriction element for auto-reactive T cells in (NZBxNZW)F1 mice. Mine M, et al. **Immunology** 1998 Dec;95(4):577–84

Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Moldenhauer G, et al. **Immunology** 1999 Mar;96(3):473–84

A mutational analysis of the Abetaz/Aalphad major histocompatibility complex class II molecule that restricts autoreactive T cells in (NZBxNZW)F1 mice. The critical influence of alanine at position 69 in the Aalphad chain. Sai T, et al. **Immunology** 1999 Mar;96(3):325–32

The Ii41 isoform of invariant chain mediates both positive and negative selection events in T-cell receptor transgenic mice. Wright RJ, et al. **Immunology** 1998 Nov;95(3):309–13

Ethanol impairs major histocompatibility complex (MHC) class II molecule-mediated but not MHC class I molecule-mediated T cell response in alcohol-consuming mice. Chang MP, et al. **Immunopharmacol Immunotoxicol** 1999 Feb;21(1):65–87

Peptide specificity, HLA class II restriction, and T-cell subsets of the T-cell clones specific to either Cry j 1 or Cry j 2, the major allergens of Japanese cedar (Cryptomeria japonica) pollen. Sone T, et al. **Int Arch Allergy Immunol** 1999 Jul;119(3):185–96

The nature of the subset of MHC class II molecules carrying the CDw78 epitopes. Drbal K, et al. **Int Immunol** 1999 Apr;11(4):491–8

Peptide dependency of alloreactive CD4+ T cell responses. Mendiratta SK, et al. **Int Immunol** 1999 Mar;11(3):351–60

In vitro positive selection and anergy induction of class II-restricted TCR transgenic thymocytes by a cortical thymic epithelial cell line. Nelson AJ, et al. **Int Immunol** 1998 Sep;10(9):1335–46

Mutations in MHC class II dimer of dimers contact residues: effects on antigen presentation. Nydam T, et al. **Int Immunol** 1998 Aug;10(8):1237–49

Characterization of the interaction of a TCR alpha chain variable domain with MHC II I-A molecules. Qadri A, et al. **Int Immunol** 1999 Jun;11(6):967–77

IgA production in MHC class II-deficient mice is primarily a function of B-1a cells. Snider DP, et al. **Int Immunol** 1999 Feb;11(2):191–8

Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Griffiths GL, et al. **Int J Cancer** 1999 Jun 11;81(6):985–92

Immunopathology of pineal glands from horses with uveitis. Kalsow CM, et al. **Invest Ophthalmol Vis Sci** 1999 Jun; 40(7):1611–5

A conformationally-constrained MHC class II I-Ag7-derived peptide protects NOD mice from the development of diabetes. Dunsavage MB, et al. **J Autoimmun** 1999 Jun;12(4):233–42

A secreted form of the major histocompatibility complex class II-associated invariant chain inhibiting T cell activation. Eynon EE, et al. **J Biol Chem** 1999 Sep 10; 274(37):26266–71

Functional early endosomes are required for maturation of major histocompatibility complex class II molecules in human B lymphoblastoid cells. Pond L, et al. **J Biol Chem** 1999 Jun 18;274(25):18049–54

The overlooked "nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. Altomonte M, et al. **J Cell Physiol** 1999 Jun;179(3):251–6 (51 ref.)

Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. Murphy B, et al. **J Clin Invest** 1999 Mar;103(6):859–67

Donor MHC and adhesion molecules in transplant arteriosclerosis. Shi C, et al. **J Clin Invest** 1999 Feb; 103(4):469–74

Characterization of the I-E(d)--restricted peptide recognized by an anti-idiotypic CD4+ T cell line. Masaki H, et al. **J Clin Lab Immunol** 1997;49(1):1–14

Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. Casares S, et al. **J Exp Med** 1999 Aug 16;190(4):543–53

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. Ermak TH, et al. **J Exp Med** 1998 Dec 21; 188(12):2277–88

Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. Inaba K, et al. **J Exp Med** 1998 Dec 7; 188(11):2163–73

Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. Pingel S, et al. **J Exp Med** 1999 Apr 5;189(7):1111–20

Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response. Ridgway WM, et al. **J Exp Med** 1998 Dec 21;188(12):2267–75

Molecular requirements for T cell recognition by a major histocompatibility complex class II-restricted T cell receptor: the involvement of the fourth hypervariable loop of the Valpha domain. Thatte J, et al. **J Exp Med** 1999 Feb 1;189(3):509–20

CD4 T cells and their role in antitumor immune responses [comment] Toes RE, et al. **J Exp Med** 1999 Mar 1; 189(5):753–6. Comment on: J Exp Med 1999 Mar 1;189(5):757–65. Comment on: J Exp Med 1999 Mar 1;189(5):767–77. Comment on: J Exp Med 1999 Mar 1;189(5):871–6.

Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. Zhong G, et al. **J Exp Med** 1999 Jun 21;189(12):1931–8

Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. Leipner C, et al. **J Hum Virol** 1999 Mar–Apr;2(2):102–14

Dual MHC class I and class II restriction of a single T cell receptor: distinct modes of tolerance induction by two classes of autoantigens. Arsov I, et al. **J Immunol** 1999 Feb 15;162(4):2008–15

Normal thymic selection of TCR transgenic CD4 T cells, but impaired survival in the periphery despite the presence of selecting MHC molecules. Barthlott T, et al. **J Immunol** 1998 Oct 15;161(8):3992–9

Large protein fragments as substrates for endocytic antigen capture by MHC class II molecules. Castellino F, et al. **J Immunol** 1998 Oct 15;161(8):4048–57

Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. Maecker HT, et al. **J Immunol** 1998 Dec 15;161(12):6532–6

Requirement for efficient interactions between CD4 and MHC class II molecules for survival of resting CD4+ T lymphocytes in vivo and for activation-induced cell death. Maroto R, et al. **J Immunol** 1999 May 15;162(10):5973–80

Differential responses of invariant V alpha 24J alpha Q T cells and MHC class II-restricted CD4+ T cells to dexamethasone. Milner JD, et al. **J Immunol** 1999 Sep 1; 163(5):2522–9

Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. Mora C, et al. **J Immunol** 1999 Apr 15;162(8):4576–88

The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. Panjwani N, et al. **J Immunol** 1999 Aug 15;163(4):1936–42

Negative selection of immature thymocytes by a few peptide-MHC complexes: differential sensitivity of immature and mature T cells. Peterson DA, et al. **J Immunol** 1999 Mar 15;162(6):3117–20

Human choriocarcinoma-derived JEG-3 cells transfected with murine MHC class II Aq expression vectors present antigen to Aq-restricted murine T-cell hybridoma. Arvola M, et al. **J Reprod Immunol** 1999 Jan;42(1):17–30

gamma delta+ T cells regulate major histocompatibility complex class II(IA and IE)-dependent susceptibility to coxsackievirus B3-induced autoimmune myocarditis. Huber SA, et al. **J Virol** 1999 Jul;73(7):5630–6

Expression of major histocompatibility class II antigens on polymorphonuclear neutrophils in patients with Wegener's granulomatosis. Hänsch GM, et al. **Kidney Int** 1999 May; 55(5):1811–8

Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Tai AK, et al. **Mol Immunol** 1999 May;36(7):447–60

Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Tomazin R, et al. **Nat Med** 1999 Sep;5(9):1039–43

Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor. Hare BJ, et al. **Nat Struct Biol** 1999 Jun;6(6):574–81

Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer. Arosarena OA, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):665–71

A pediatrician's view. Mechanism of the immune response [editorial] Altemeier WA 3rd, et al. **Pediatr Ann** 1999 Aug; 28(8):480–1

From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Krebs S, et al. **Pharm Acta Helv** 1998 Dec;73(4):173–81 (53 ref.)

The lack of consensus for I-A(g7)-peptide binding motifs: is there a requirement for anchor amino acid side chains? Carrasco-Marin E, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8621–6

Mice lacking all conventional MHC class II genes. Madsen L, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10338–43

A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11. Pearson CI, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):197–202

An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Rees W, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9781–6

Immunohistochemical localization of B7 costimulating molecules and major histocompatibility complex class II antigen in pulmonary sarcoidosis. Kaneko Y, et al. **Respiration** 1999;66(4):343–8

Requirement for diverse, low-abundance peptides in positive selection of T cells. Barton GM, et al. **Science** 1999 Jan 1;283(5398):67–70

A new look at MHC and autoimmune disease. Ridgway WM, et al. **Science** 1999 Apr 30;284(5415):749,751

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Wang RF, et al. **Science** 1999 May 21;284(5418):1351–4

Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Cotler SJ, et al. **Tissue Antigens** 1998 Nov;52(5):435–43

Immune tolerance to self-MHC class II antigens after bone marrow transplantation. Hess A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):688–9

Synergy of class I and class II MHC deficiency (C1D and C2D) islets and early short-term suppression in achieving long-term islet graft survival and tolerance induction. Pittman K, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):635–6

Generation and characterization of xenospecific human suppressor T cells. Suciu-Foca N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):968–9

T-cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas. Kelly KE, et al. **Transplantation** 1998 Sep 27;66(6):764–71

Interferon-gamma is necessary for initiating the acute rejection of major histocompatibility complex class II-disparate skin allografts. Ring GH, et al. **Transplantation** 1999 May 27;67(10):1362–5

Anti-major histocompatibility complex class II treatment prevents graft rejection in the hamster-to-rat cardiac xenograft [see comments] Saxton NE, et al. **Transplantation** 1999 Jun 27;67(12):1599–606. Comment in: Transplantation 1999 Jun 27;67(12):1515–6.

Anti-MHC-II preventing graft rejection [comment] Vanhove B. **Transplantation** 1999 Jun 27;67(12):1515–6. Comment on: Transplantation 1999 Jun 27;67(12):1599–606.

Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Vella JP, et al. **Transplantation** 1999 Jun 27; 67(12):1523–32

MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Men Y, et al. **Vaccine** 1999 Mar 5;17(9–10):1047–56

Increased MHC class II and CD25 expression on lymphocytes in the absence of persistent lymphocytosis in cattle experimentally infected with bovine leukemia virus. Isaacson JA, et al. **Vet Immunol Immunopathol** 1998 Jul 31;64(3):235–48

Specific and nonspecific immune stimulation of MHC-II-deficient mice results in chronic HSV-1 infection of the trigeminal ganglia following ocular challenge. Ghiasi H, et al. **Virology** 1999 Jun 5;258(2):208–16

[HLA-peptide complex and immunity-related diseases] Matsushita S. **Rinsho Byori** 1999 Jun;47(6):511–8 (26 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Kinetic isomers of a class II MHC-peptide complex. Schmitt L, et al. **Biochemistry** 1998 Dec 15;37(50):17371–80

Class II MHC quantitative binding motifs derived from a large molecular database with a versatile iterative stepwise discriminant analysis meta-algorithm. Mallios RR. **Bioinformatics** 1999 Jun;15(6):432–9

Tetrapeptide derived inhibitors of complexation of a class II MHC: the peptide backbone is not inviolate. Jones AB, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2109–14

Tetrapeptide derived inhibitors of complexation of a class II MHC: fully unnatural ligands. Jones AB, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2115–8

Vitiligo melanocytes in long-term culture show normal

constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Hedley SJ, et al. **Br J Dermatol** 1998 Dec;139(6):965-73

Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo. Xiang J, et al. **Cancer Gene Ther** 1998 Sep-Oct;5(5):313-20

Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Grohmann U, et al. **Cancer Immunol Immunother** 1999 Jul; 48(4):195-203

Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses. Lebowitz MS, et al. **Cell Immunol** 1999 Mar 15;192(2):175-84

Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Harfouch-Hammoud E, et al. **Diabetes** 1999 Oct;48(10):1937-47

Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Wojnicz R, et al. **Eur Heart J** 1998 Oct;19(10):1564-72

Fate of MHC class II molecules in human dendritic cells. Hanau D, et al. **Eur J Dermatol** 1999 Jan-Feb;9(1):7-12 (32 ref.)

Vesicles bearing MHC class II molecules mediate transfer of antigen from antigen-presenting cells to CD4+ T cells. Arnold PY, et al. **Eur J Immunol** 1999 Apr;29(4):1363-73

N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, et al. **Eur J Immunol** 1999 Jan;29(1):189-95

Endogenous and exogenous forms of the same antigen are processed from different pools to bind MHC class II molecules in endocytic compartments. Bonifaz LC, et al. **Eur J Immunol** 1999 Jan;29(1):119-31

CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Léveillé C, et al. **Eur J Immunol** 1999 Jan;29(1):65-74

Retinal pigment epithelial cells are heterogeneous in their expression of MHC-II after stimulation with interferon-gamma. Casella AM, et al. **Exp Eye Res** 1999 Apr;68(4):423-30

Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes. Guo W, et al. **Hum Immunol** 1999 Apr; 60(4):312-22

A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. de Saint-Vis B, et al. **Immunity** 1998 Sep;9(3):325-36

High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Kersh GJ, et al. **Immunity** 1998 Dec;9(6):817-26

Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Nakagawa TY, et al. **Immunity** 1999 Feb;10(2):207-17

Formation of a highly peptide-receptive state of class II MHC. Rabinowitz JD, et al. **Immunity** 1998 Nov; 9(5):699-709

Cathepsin S required for normal MHC class II peptide loading and germinal center development. Shi GP, et al. **Immunity** 1999 Feb;10(2):197-206

Platelet-activating factor plays a role in the mechanism of major histocompatibility complex in T lymphocytes. Nikbakht-Sangari M, et al. **Immunol Invest** 1999 Jul; 28(4):223-33

Conserved T-cell receptor class II major histocompatibility complex contact detected in a T-lymphocyte population. Feng M, et al. **Immunology** 1998 Oct;95(2):185-92

Kinetics and intracellular pathways required for major histocompatibility complex II-peptide loading and surface expression of a fluorescent hapten-protein conjugate in murine macrophage. Weaver DJ Jr, et al. **Immunology** 1999 Apr;96(4):557-68

Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes. Forestier C, et al. **Infect Immun** 1999 Aug; 67(8):4048-54

An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class II alphabeta dimers and facilitates highly efficient peptide loading. Barton GM, et al. **Int Immunol** 1998 Aug; 10(8):1159-65

A minimal level of MHC class II expression is sufficient to abrogate autoreactivity. de Bont ES, et al. **Int Immunol** 1999 Aug;11(8):1295-306

MHC class II and invariant chain biosynthesis and transport during maturation of human precursor dendritic cells. Engering AJ, et al. **Int Immunol** 1998 Nov;10(11):1713-23

Characterization of the interaction of a TCR alpha chain variable domain with MHC II I-A molecules. Qadri A, et al. **Int Immunol** 1999 Jun;11(6):967-77

Molecular modeling of hen egg lysozyme HEL[52-61] peptide binding to I-Ak MHC class II molecule. Weber P, et al. **Int Immunol** 1998 Dec;10(12):1753-64

Trafficking of the Igalpha/Igbeta heterodimer with membrane Ig and bound antigen to the major histocompatibility complex class II peptide-loading compartment. Brown BK, et al. **J Biol Chem** 1999 Apr 16;274(16):11439-46

Direct transport of newly synthesized HLA-DR from the trans-Golgi network to major histocompatibility complex class II containing compartments (MIICS) demonstrated using a novel tyrosine-sulfated chimera. Davidson HW. **J Biol Chem** 1999 Sep 17;274(38):27315-22

Peptide loading in the endoplasmic reticulum accelerates trafficking of peptide:MHC class II complexes in B cells. Morkowski S, et al. **J Biomed Sci** 1999 Jan;6(1):53-63

Actin microfilaments control the MHC class II antigen presentation pathway in B cells. Barois N, et al. **J Cell Sci** 1998 Jul;111 (Pt 13):1791-800

Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus. Phillips LM, et al. **J Comp Neurol** 1999 Mar 15;405(3):322-33

Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. Hamad AR, et al. **J Exp Med** 1998 Nov 2; 188(9):1633-40

pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH. Hausmann DH, et al. **J Exp Med** 1999 Jun 7;189(11):1723-34

A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain. Ashman JB, et al. **J Immunol** 1999 Sep 1;163(5):2704-12

Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. Burrows GG, et al. **J Immunol** 1998 Dec 1;161(11):5987-96

MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. Cheng PC, et al. **J Immunol** 1999 Jun 15;162(12):7171-80

In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities. Chmielowski B, et al. **J Immunol** 1999 Jan 1;162(1):95-105

CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. Chu RS, et al. **J Immunol** 1999 Aug 1;163(3):1188-94

MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. Deck MB, et al. **J Immunol** 1999 Apr 15;162(8):4740-4

MHC class II engagement in brain endothelial cells induces protein kinase A-dependent IL-6 secretion and phosphorylation of cAMP response element-binding protein. Etienne S, et al. **J Immunol** 1999 Oct 1; 163(7):3636-41

Selection and function of CD4+ T lymphocytes in transgenic mice expressing mutant MHC class II molecules deficient in their interaction with CD4. Gilfillan S, et al. **J Immunol** 1998 Dec 15;161(12):6629-37

A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. Gregori S, et al. **J Immunol** 1999 Jun 1;162(11):6630-40

Isolation and quantitation of a minor determinant of hen egg white lysozyme bound to I-Ak by using peptide-specific immunoaffinity. Gugasyan R, et al. **J Immunol** 1998 Dec 1;161(11):6074-83

Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes. McFarland BJ, et al. **J Immunol** 1999 Oct 1;163(7):3567-71

Antigen recognition influences transendothelial migration of CD4+ T cells. Marelli-Berg FM, et al. **J Immunol** 1999 Jan 15;162(2):696-703

Differential responses of invariant V alpha 24J alpha Q T cells and MHC class II-restricted CD4+ T cells to dexamethasone. Milner JD, et al. **J Immunol** 1999 Sep 1; 163(5):2522-9

Coreceptor-independent T cell activation in mice expressing MHC class II molecules mutated in the CD4 binding domain. Mostaghel EA, et al. **J Immunol** 1998 Dec 15; 161(12):6559-66

Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. Natarajan SK, et al. **J Immunol** 1999 Apr 1;162(7):4030-6

MHC class II-dependent NK1.1+ gammadelta T cells are induced in mice by Salmonella infection. Nishimura H, et al. **J Immunol** 1999 Feb 1;162(3):1573-81

The HSC73 molecular chaperone: involvement in MHC class II antigen presentation. Panjwani N, et al. **J Immunol** 1999 Aug 15;163(4):1936-42

Phagosomes are fully competent antigen-processing organelles that mediate the formation of peptide:class II MHC complexes. Ramachandra L, et al. **J Immunol** 1999 Mar 15;162(6):3263-72

Cutting edge: trimolecular interaction of TCR with MHC class II and bacterial superantigen shows a similar affinity to MHC:peptide ligands. Redpath S, et al. **J Immunol** 1999 Jul 1;163(1):6-10

T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] Shirai M, et al. **J Immunol** 1999 Jan 1; 162(1):568-76

Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. Soos JM, et al. **J Immunol** 1998 Dec 1;161(11):5959-66

Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules. Thayer WP, et al. **J Immunol** 1999 Feb 1;162(3):1502-9

Th cells and Th2 responses can develop in the absence of MHC class II-CD4 interactions. Wack A, et al. **J Immunol** 1999 Aug 1;163(3):1162-9

Regulation of B cell receptor-mediated MHC class II antigen processing by FcgammaRIIB1. Wagle NM, et al. **J Immunol** 1999 Mar 1;162(5):2732-40

Invariant chain can bind MHC class II at a site other than the peptide binding groove. Wilson NA, et al. **J Immunol** 1998 Nov 1;161(9):4777-84

The orientation and nature of the interaction between beef insulin-specific TCRs and the insulin/class II MHC complex. Wither JE, et al. **J Immunol** 1999 Feb 15; 162(4):2113-22

Alterations in CD4-binding regions of the MHC class II molecule I-Ek do not impede CD4+ T cell development. Yelon D, et al. **J Immunol** 1999 Feb 1;162(3):1348-58

ED2-positive perivascular phagocytes produce interleukin-1beta during delayed neuronal loss in the facial nucleus of the rat. Angelov DN, et al. **J Neurosci Res** 1998 Dec 15;54(6):820-7

Quantitative analysis of major histocompatibility complex class II-positive cells in posterior segment of Royal College of Surgeons rat eyes. Akaishi K, et al. **Jpn J Ophthalmol** 1998 Sep-Oct;42(5):357-62

IFN-gamma and LPS differentially modulate class II MHC and B7-1 expression on murine renal tubular epithelial cells. Banu N, et al. **Kidney Int** 1999 Jun;55(6):2250-63

TGF-beta1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells. Banu N, et al. **Kidney Int** 1999 Sep; 56(3):985-94

Early endosomes are required for major histocompatiblity complex class II transport to peptide-loading compartments. Brachet V, et al. **Mol Biol Cell** 1999 Sep; 10(9):2891-904

A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Masternak K, et al. **Nat Genet** 1998 Nov; 20(3):273-7

Dynamics of microglial activation in the spinal cord after cerebral infarction are revealed by expression of MHC class II antigen. Schmitt AB, et al. **Neuropathol Appl Neurobiol** 1998 Jun;24(3):167-76

In-vitro methods to decrease MHC class II-positive cells in retinal pigment epithelium cell grafts. Enzmann V, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):145-53

Down-regulation of MHC class II expression on bovine retinal pigment epithelial cells by cytokines. Enzmann V, et al. **Ophthalmic Res** 1999;31(4):256-66

Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation. van Rensen AJ, et al. **Pharm Res** 1999 Feb; 16(2):198-204

Thermodynamics of T cell receptor binding to peptide-MHC: evidence for a general mechanism of molecular scanning. Boniface JJ, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11446-51

HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Serradell L, et al. **Tissue Antigens** 1999 May;53(5):447-58

PHYSIOLOGY

Requirement of I-E molecule for thymocyte apoptosis induced by staphylococcal enterotoxin B in vivo. Lin YS, et al. **Cell Immunol** 1999 Apr 10;193(1):71-9

CD4+ T cell responses in mice lacking MHC class II molecules specifically on B cells. Williams GS, et al. **Eur J Immunol** 1998 Nov;28(11):3763-72

Direct and indirect antigen recognition: the pathways to allograft immune rejection. Benichou G. **Front Biosci** 1999 May 15;4:D476-80 (30 ref.)

The role of the invariant chain in mucosal immunity. Barrera CA, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):85-93 (88 ref.)

Survival of naive CD4 T cells: roles of restricting versus selecting MHC class II and cytokine milieu. Boursalian TE, et al. **J Immunol** 1999 Apr 1;162(7):3795-801

Involvement of MIIC-like late endosomes in B cell receptor-mediated antigen processing in murine B cells. Drake JR, et al. **J Immunol** 1999 Jan 15;162(2):1150-5

Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules. Forquet F, et al. **J Immunol** 1999 Mar 15; 162(6):3408-16

Antigen recognition influences transendothelial migration of CD4+ T cells. Marelli-Berg FM, et al. **J Immunol** 1999 Jan 15;162(2):696-703

I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. Noorchashm H, et al. **J Immunol** 1999 Jul 15;163(2):743-50

Autoantigen-independent deletion of diabetogenic CD4+

thymocytes by protective MHC class II molecules. Schmidt D, et al. **J Immunol** 1999 Apr 15;162(8):4627–36

Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain. Simonsen A, et al. **J Immunol** 1999 Sep 1; 163(5):2540–8

Engagement of B cell receptor regulates the invariant chain-dependent MHC class II presentation pathway. Zimmermann VS, et al. **J Immunol** 1999 Mar 1; 162(5):2495–502

Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. Njenga MK, et al. **J Neuropathol Exp Neurol** 1999 Jan;58(1):78–91

Sulfation-dependent down-regulation of interferon-gamma-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans. Yard BA, et al. **Transplantation** 1998 Nov 15;66(9):1244–50

HISTOCOMPATIBILITY ANTIGENS, MINOR see **MINOR HISTOCOMPATIBILITY ANTIGENS**

HISTOCOMPATIBILITY COMPLEX see **MAJOR HISTOCOMPATIBILITY COMPLEX**

HISTOCOMPATIBILITY LOCI, MINOR see **MINOR HISTOCOMPATIBILITY LOCI**

HISTOCOMPATIBILITY TESTING

HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. Prasad VK, et al. **Biol Blood Marrow Transplant** 1999; 5(2):77–85

Molecular typing of HLA class I and class II for a transplantation programme. Bendukidze N, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S31–3

Confirmatory typing results of the National Polish Bone Marrow Donors Registry. Bogunia-Kubik K, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S45–6

Implication of molecular analysis of HLA-A*02 subtyping for unrelated bone-marrow donor selection. Cecuk-Jelicic E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S27–30

Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. Greinix HT, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S53–6

Influence of HLA-DPB1 mismatches on MLR responses: the role of high resolution HLA class II typing and MLC in unrelated donor selection for BMT. Pénzes M, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S34–7

An HLA matched donor! An HLA matched donor? What do you mean by: HLA matched donor? van Rood JJ, et al. **Bone Marrow Transplant** 1998 Jul;22 Suppl 1:S83

Transplantation for adrenoleukodystrophy with HLA-A and B nonidentical paternal marrow: report of one case. Lin HC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul-Aug;39(4):260–3

Evaluation of a novel mononuclear cell isolation procedure for serological HLA typing. Schlenke P, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):808–13

The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Kotb M, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):83–9

Current methodologies of human leukocyte antigen typing utilized for bone marrow donor selection. Little AM, et al. **Curr Opin Hematol** 1998 Nov;5(6):419–28 (77 ref.)

Assignment of HLA-antigens in CREGs facilitates the detection of acceptable mismatches in highly sensitized patients. Papassavas AC, et al. **Hum Immunol** 1998 Sep; 59(9):587–96

Saliva as DNA source for HLA typing. Terasaki P, et al. **Hum Immunol** 1998 Sep;59(9):597–8

The significance of HLA matching in cardiac transplantation. Ketheesan N, et al. **J Heart Lung Transplant** 1999 Mar; 18(3):226–30

Peripheral tolerance to class I mismatched renal allografts in miniature swine: donor antigen-activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity. Ierino FL, et al. **J Immunol** 1999 Jan 1; 162(1):550–9

HLA-A, -B, -C genotyping and expression in human nonlymphoid tumor cell lines. Delfino L, et al. **J Immunother** 1999 Jan;22(1):7–15

Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. Singhal S, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):287–94 (37 ref.)

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Eiermann TH. **N Engl J Med** 1999 Mar 11;340(10):809; discussion 810–1. Comment on: N Engl J Med 1998 Oct 22;339(17):1177–85.

Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch. Bittencourt MC, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2059–64

Transmission of psoriatic arthritis by allogeneic bone marrow transplantation for chronic myelogenous leukaemia from an HLA-identical donor [letter] Daikeler T, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):89–90

Improvement of HLA class I and class II PCR-SSP typing by using timed-release activity of DNA polymerase. Chen DF, et al. **Tissue Antigens** 1998 Jun;51(6):645–8

Probability of finding HLA-matched unrelated marrow donors for Koreans and Japanese from the Korean and Japan Marrow Donor Programs. Oh HB, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):347–9

Influence of an historically positive crossmatch on cadaveric renal transplantation. Bryan CF, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):225–7

Correlation of pretransplant allosensitization with severity of rejection biopsy. Clark J, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):751–2

Influence of positive crossmatch in the outcome of liver transplantation. Dagher L, et al. **Transplant Proc** 1999 Sep; 31(6):2363

Effects of HLA matching on the results of kidney transplantation (81 case reports). De-Lin G, et al. **Transplant Proc** 1998 Nov;30(7):3498–9

Prognostic value of crossmatch in liver transplantation. Gugenheim J, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):552–3

New methods to detect donor-type DNA in HLA-DRB1-matched living-related liver transplant recipients. Kita Y, et al. **Transplant Proc** 1998 Nov; 30(7):3493–5

Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mofetil and cyclosporine. Kupin W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):744–5

Effect of HLA-A and -DPB1 matching in corneal transplantation. Morita N, et al. **Transplant Proc** 1998 Nov; 30(7):3491–2

Effect of HLA matching on liver graft survival. Muro M, et al. **Transplant Proc** 1999 Sep;31(6):2477–9

Effect of mismatched combinations of HLA-A antigens on graft survival in the transplanted kidney. Ogahara S, et al. **Transplant Proc** 1998 Nov;30(7):3500–1

Acute rejection and the flow cytometry crossmatch. O'Malley KJ, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1216–7

Is HLA matching worth the effort? Collaborative Transplant Study. Opelz G, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):717–20

Cadaver kidney graft outcome in relation to ischemia time and HLA match. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1998 Dec;30(8):4294–6

Donor specific CDC lymphocyte crossmatch and five year allograft survival. Sharma RK, et al. **Transplant Proc** 1998 Nov;30(7):2966

Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Takaya S, et al. **Transplant Proc** 1999 Aug;31(5):2028–31

Allocation of cadaver kidneys according to HLA-DR matching alone would result in optimal graft outcome in most recipients. Vereerstraeten P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):739–41

The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Andresdottir MB, et al. **Transplantation** 1999 Sep 15;68(5):623–7

Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Bryan CF, et al. **Transplantation** 1998 Dec 27;66(12):1827–32

HLA-DR matched transfusions: development of donor-specific T- and B-cell antibodies and renal allograft outcome. Christiaans MH, et al. **Transplantation** 1999 Apr 15;67(7):1029–35

Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch? Kerman RH, et al. **Transplantation** 1998 Dec 27;66(12):1833–4

Kidney transplantation without a final crossmatch. Matas AJ, et al. **Transplantation** 1998 Dec 27;66(12):1835–6

[Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings] Morimoto T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):631–9 (Eng. Abstr.) **(Jpn)**

[Biophysical parity of a donor with a recipient that represents their metabolic parity is suggested as a criterion of histocompatibility] Piruzian LA, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):100–5 (35 ref.) **(Rus)**

[Polymorphism of the HLA-DRB1 04 gene in inhabitants of Tuva] Sartakova ML, et al. **Genetika** 1998 Jul; 34(7):973–8 (Eng. Abstr.) **(Rus)**

HISTORY

Progress in the determination of histocompatibility. 1965 [classical article] Billingham RE, et al. **ASAIO J** 1999 Jan-Feb;45(1):4–9

METHODS

Comparison of serological and molecular (PCR-SSP) techniques of HLA-DR typing in clinical laboratory routine. Woszczek G, et al. **Ann Transplant** 1997;2(1):39–42

Nested polymerase chain reaction with sequence-specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-matched individuals. Carter AS, et al. **Blood** 1999 Aug 15;94(4):1471–7

Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Petersdorf EW, et al. **Blood** 1998 Nov 15;92(10):3515–20

Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection. Scott I, et al. **Blood** 1998 Dec 15;92(12):4864–71

A high resolution HLA class I and class II matching method for bone marrow donor selection. Argüello JR, et al. **Bone Marrow Transplant** 1998 Sep;22(6):527–34

Serological versus molecular HLA-DR typing of cadaveric donors in conditions of Regional Tissue Typing Laboratory. Cermaková Z, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S47–8

Class I typing by PCR-SSP in Olomouc. Drábek J, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S23–6

Our experiences with 1D-IEF in selection of bone marrow donors. Matejková E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S20–2

Flow cytometry cross-match before kidney transplantation in relation to early postransplant rejection. Slavcev A, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S114–5

Optimisation of HLA-B27 testing by association of flow cytometry and DNA typing. Bonnaud G, et al. **Clin Rheumatol** 1999;18(1):23–7

Utilization of crossmatch techniques for renal transplantation. Harmer AW. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):687–90 (22 ref.)

Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. McCarthy JF, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):197–200

Molecular matching in allogeneic bone marrow transplantation. Little AM, et al. **Eur J Immunogenet** 1999 Feb;26(1):35–41 (85 ref.)

High resolution genetic typing of the class II HLA-DRB1 locus using group-specific amplification and SSO-hybridisation in microplates. Allen M, et al. **Hereditas** 1998;129(2):161–7

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Hum Immunol** 1999 Apr;60(4):347–60

Microchimerism of maternal origin persists into adult life. Maloney S, et al. **J Clin Invest** 1999 Jul;104(1):41–7

DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. Frohn C, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):155–60

Optimization and comparison of the MTT assay and the 3H-TdR assay for the detection of IL-2 in helper T cell precursor assays. Russell CA, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):165–75

High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. Kicklighter EJ, et al. **J Immunother** 1999 May;22(3):219–28

Matching donors and recipients. Marino IR, et al. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S115–9

Correlation between allograft survival and chimeric state after bone marrow infusion in rat small bowel transplantation. Bakonyi Neto A, et al. **Pediatr Transplant** 1999 Feb;3(1):67–73

The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I [see comments] Fleming DR, et al. **Pediatr Transplant** 1998 Nov;2(4):299–304. Comment in: Pediatr Transplant 1998 Nov;2(4):250–3.

High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). Argüello JR, et al. **Tissue Antigens** 1998 Jul;52(1):57–66

HLA-C high resolution typing: analysis of exons 2 and 3 by sequence based typing and detection of polymorphisms in exons 1-5 by sequence specific primers. Delfino L, et al. **Tissue Antigens** 1998 Sep;52(3):251–9

Identification of an HLA-C variant allele, Cw*0805, by sequencing based typing. Dunn PP, et al. **Tissue Antigens** 1998 Dec;52(6):587–9

Virtual DNA analysis--a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Helmberg W, et al. **Tissue Antigens** 1998 Jun;51(6):587–92

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Hurley CK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):394–406 (88 ref.)

New high resolution typing strategy for HLA-A locus alleles based on dye terminator sequencing of haplotypic group-specific PCR-amplicons of exon 2 and exon 3. Kurz B, et al. **Tissue Antigens** 1999 Jan;53(1):81–96

Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tonks S, et al. **Tissue Antigens** 1999 Feb;53(2):175–83

A reliable and efficient high resolution typing method for HLA-C using sequence-based typing. van der Vlies SA, et al. **Tissue Antigens** 1998 Dec;52(6):558–68

Detection of HLA-A*24 null alleles by DNA typing methods. Williams F, et al. **Tissue Antigens** 1998 Sep; 52(3):208–12

Discrepancies between serology- and sequence-based typing of HLA class I alleles among unrelated donor/recipient

pairs. Gimferrer I, et al. **Transplant Proc** 1999 Sep; 31(6):2579–80

Flow cytometry crossmatch and kidney graft outcome. Piazza A, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):314–6

IgA class antibodies and flow cytometric cross-matching in renal transplantation. Doran TJ, et al. **Transplantation** 1999 Jan 27;67(2):309–14

The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies. Sumitran-Karuppan S. **Transplantation** 1999 Aug 27; 68(4):502–9

Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies. Susskind B, et al. **Transplantation** 1998 Dec 27;66(12):1823–6

Clinical aspects and typing of platelet alloantigens. Kroll H, et al. **Vox Sang** 1998;74 Suppl 2:345–54 (120 ref.)

[Serological typing of HLA] Tanaka H. **Rinsho Byori** 1999 May;Suppl 110:107–12 (5 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

The sixth quality control exercise of the Central European tissue typing laboratories. Fischer G, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S14–6

Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Bone Marrow Transplant** 1999 Jul;24(2):119–21

Results of evaluation of the quality of HLA typing in the Czech Republic. Ivasková E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S17–9

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Hurley CK, et al. **Hum Immunol** 1999 Apr;60(4):347–60

A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Hurley CK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):394–406 (88 ref.)

VETERINARY

Method of lymphocytotoxic crossmatch test for feline renal transplantation. Kuwahara Y, et al. **J Vet Med Sci** 1999 May;61(5):481–5

HISTOCYTOCHEMISTRY

Glycohistochemical investigation of canine and feline zonae pellucidae of preantral and antral oocytes. Parillo F, et al. **Acta Histochem** 1999 Apr;101(2):127–46

Histochemical study of hyaluronate in alcoholic liver disease. Urashima S, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):56S–60S

Structural organization of lymphatics in the monkey esophagus as revealed by enzyme-histochemistry. Shimoda H. **Arch Histol Cytol** 1998 Dec;61(5):439–50

Fontana-Masson--stained tissue from culture-proven mycoses. Kimura M, et al. **Arch Pathol Lab Med** 1998 Dec; 122(12):1107–11

Improved detection reliability of beta-galactosidase in histological preparations. Cheng G, et al. **Biotechniques** 1999 Sep;27(3):438–40

Cytochemical localization of vanadium(III) in blood cells of ascidian Phallusia mammillata Cuvier, and its relevance to hematic cell lineage determination. Nette G, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Feb;122(2):231–7

28th National Congress of the Italian Society of Histochemistry. Camerino, Italy, June 2–4, 1999. Abstracts. **Eur J Histochem** 1999;43 Suppl 2:5–73

Histochemistry on the threshold of the third millennium. In memory of Maffo Vialli and Giovanni Prenna. Pavia, Italy, June 18–19, 1997. **Eur J Histochem** 1998;42 Spec No:5–76

Computer morphometry for quantitative measurement of liver fibrosis: comparison with Knodell's score, colorimetry and conventional description reports. Lin XZ, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):75–80

Introduction to histochemical studies on human fetal brain development. Ulfig N. **Microsc Res Tech** 1999 Jun 15; 45(6):339–40

[Proceedings of the 3rd committee meeting of INSERM-Anatomy and Cytopathology and INSERM-Genetics. Paris, France, 8–10 December 1998] **Ann Pathol** 1998;18(5 Suppl):1–115 **(Fre)**

INSTRUMENTATION

Virtual microscopy: high resolution digital photomicrography as a tool for light microscopy simulation. Felten CL, et al. **Hum Pathol** 1999 Apr; 30(4):477–83

METHODS

A simple image analysis method for evaluating cell binding to derivatized beads. Latham VH, et al. **Acta Histochem** 1999 Jul;101(3):263–70

Molecular probes in histochemistry and cytochemistry [editorial] Van Noorden CJ. **Acta Histochem** 1998 Nov; 100(4):337 (0 ref.)

Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Murayama H, et al. **Am J Pathol** 1999 Sep;155(3):877–85

Quantitative cytochemistry of succinic dehydrogenase activity in rat mitochondria. Fattoretti P, et al. **Anal Quant Cytol Histol** 1998 Dec;20(6):521–5

Chemical dehydration of specimens with 2,2-dimethoxypropane (DMP) for paraffin processing of animal tissues: practical and economic advantages over dehydration in ethanol. Conway K, et al. **Biotech Histochem** 1999 Jan;74(1):20–6

Beyond plant lectin histochemistry: preparation and application of markers to visualize the cellular capacity for protein-carbohydrate recognition. Gabius HJ, et al. **Biotech Histochem** 1998 Sep;73(5):263–77 (79 ref.)

Laser scanning microscopy in enzyme histochemistry. Visualization of cerium-based and dab-based primary reaction products of phosphatases, oxidases and peroxidases by reflectance and transmission laser scanning microscopy. Halbhuber KJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Jul;44(5):807–26

The application of thermodynamic principles to histochemical and morphometric tissue research: principles and practical outline with focus on the glycosciences. Kayser K, et al. **Cell Tissue Res** 1999 Jun;296(3):443–55 (91 ref.)

A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Diwu Z, et al. **Chem Biol** 1999 Jul;6(7):411–8

High-resolution cytometry of FISH dots in interphase cell nuclei. Kozubek M, et al. **Cytometry** 1999 Aug 1; 36(4):279–93

Scavenger function of leukocytes phagocytosing apoptotic cells: analysis and quantitation by flow cytometry. Galati G, et al. **Eur J Histochem** 1997;41 Suppl 2:75–6

Biparametric analysis of DNA and Ag-NOR content for ploidy and kinetics. Grigolato PG, et al. **Eur J Histochem** 1997;41 Suppl 2:129–30

Measurement of antigen expression in early apoptotic cells. Renò F, et al. **Eur J Histochem** 1997;41 Suppl 2:83–4

Histochemical staining of chromium with 2-(8-quinolylazo)-4,5-di-p-tolylimidazole. Sumi Y, et al. **Eur J Histochem** 1998;42(4):271–6

Abstracts of papers presented at a Symposium on the theme 'Progress in Basic, Applied and Diagnostic Histochemistry'. Prague, 10–12 December 1997. **Histochem J** 1998 Nov;30(11):829–48

Improved cytochemical methods for demonstrating cell death using LR White as an embedding medium. Al-Hazzaa AA, et al. **Histochem J** 1998 Dec; 30(12):897–902

A quantitative histochemical study of alkaline phosphatase activity in isolated rat duodenal epithelial cells. Mozes S, et al. **Histochem J** 1998 Aug;30(8):583–9

Fixing Indian ink on resection margins [letter] Salerno A. **Histopathology** 1998 Sep;33(3):284

Current cytochemical techniques for the investigation of peroxisomes. A review. Fahimi HD, et al. **J Histochem Cytochem** 1999 Oct;47(10):1219–32 (135 ref.)

Lectin-gold localization of fucose residues in human gastric mucosa. Madrid JF, et al. **J Histochem Cytochem** 1998 Nov; 46(11):1311–20

Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. Schnell SA, et al. **J Histochem Cytochem** 1999 Jun;47(6):719–30

Detection of pathological zinc accumulation in neurons: methods for autopsy, biopsy, and cultured tissue. Suh SW, et al. **J Histochem Cytochem** 1999 Jul;47(7):969–72

Cerium-based histochemical demonstration of oxidative stress in taurocholate-induced acute pancreatitis in rats. A confocal laser scanning microscopic study. Telek G, et al. **J Histochem Cytochem** 1999 Sep;47(9):1201–12

Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. Van Driel BE, et al. **J Histochem Cytochem** 1999 May; 47(5):575–82 (50 ref.)

Microwave staining of enteric neurons using cuprolinic blue (Quinolinic phthalocyanin) combined with enzyme histochemistry and peroxidase immunohistochemistry. Van Ginneken CJ, et al. **J Histochem Cytochem** 1999 Jan; 47(1):13–22

Cytochemical methods for the detection of apoptosis. Willingham MC. **J Histochem Cytochem** 1999 Sep; 47(9):1101–10 (54 ref.)

Effects of a triple enzyme digestion method on a diamine reaction for glycosaminoglycans of the rat aorta in electron microscopy. Ueda H, et al. **J Vet Med Sci** 1998 Nov; 60(11):1169–74

Problems and artifacts of microwave accelerated procedures in neurohistotechnology and resolutions. Horobin RW. **Methods** 1998 Jun;15(2):101–6 (27 ref.)

Studying neuronal peptide release and secretory granule dynamics with green fluorescent protein. Levitan ES. **Methods** 1998 Oct;16(2):182–7

Histology and histochemistry of the aging cerebral cortex: an overview. Peinado MA. **Microsc Res Tech** 1998 Oct 1;43(1):1–7 (104 ref.)

An easy and quick stain for the demonstration of Helicobacter pylori [letter] Ramos CV. **Mod Pathol** 1998 Sep;11(9):914

[Multiple histochemical methods in the diagnosis of Wilson's disease. (Presentation of 74 cases and review of the literature)] Lecca S, et al. **Pathologica** 1998 Dec;90(6):771–5 (31 ref.) (Eng. Abstr.) **(Ita)**

[Method of combined cytochemical staining of cells of the granulocyte and lymphoid series] Pigarevskii PV, et al. **Morfologiia** 1999;116(4):68–70 **(Rus)**

STANDARDS

[Celiac disease. Minimal diagnostic requirements for histopathological diagnosis. Italian Group of Gastrointestinal Pathology] Chiarelli S, et al. **Pathologica** 1998 Dec;90(6):809–13 (8 ref.) **(Ita)**

TRENDS

How rational histochemistry produced order out of chaos in the "amorphous ground substance" (with a little help from biochemistry, biophysics etc.). Scott JE. **Eur J Histochem** 1998;42 Spec No:29–34 (17 ref.)

[Molecular histopathology?!] Stanta G. **Pathologica** 1998 Dec; 90(6):821–3 (5 ref.) **(Ita)**

HISTOCYTOLOGICAL PREPARATION TECHNIQUES

Thin-layer cytology meets viral hybrid capture. Leiman G. **Adv Anat Pathol** 1999 May;6(3):161–4

Polymerase chain reaction to detect Mycobacterium tuberculosis in histologic specimens. Salian NV, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1150–5

Lack of asbestos contamination of paraffin. Dodson RF, et al. **Arch Pathol Lab Med** 1998 Dec;122(12):1103–6

Sectioning human bone [letter; comment] Smith S, et al. **Br J Biomed Sci** 1998 Jun;55(2):162. Comment on: Br J Biomed Sci 1997 Jun;54(2):88–90.

Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Aubele M, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):94–102

Fluorescence in situ hybridization on G-banded chromosome preparations mounted with Eukitt in a retrospective study and in routine diagnostics [letter; comment] Liehr T, et al. **Cancer Genet Cytogenet** 1998 Nov;107(1):85–6. Comment on: Cancer Genet Cytogenet 1997 Oct 1;98(1):9–15.

Fine needle aspiration cytology of the breast using the Cytospin method. Howat AJ, et al. **Cytopathology** 1999 Feb;10(1):50–3

Classification of bovine muscle fibres by different histochemical techniques. Picard B, et al. **Histochem J** 1998 Jul;30(7):473–9

The dark side of the gastric biopsy. Cassaro M, et al. **Hum Pathol** 1999 Jul;30(7):741–4

Effect of formalin fixation and epitope retrieval techniques on antibody 34betaE12 immunostaining of prostatic tissues [see comments] Varma M, et al. **Mod Pathol** 1999 May; 12(5):472–8. Comment in: Mod Pathol 1999 May;12(5):443–4.

Immunohistochemical retrieval of the principal HIV antigens p24, gp41, and gp120 in formalin fixed tissue: an investigation using HIV infected lymphoblasts and postmortem brain tissue from AIDS cases. Morrison HL, et al. **Mol Pathol** 1998 Aug;51(4):227–31

Correlative light and backscattered electron microscopy of bone--Part I: Specimen preparation methods. Goldman HM, et al. **Scanning** 1999 Jan–Feb;21(1):40–3

A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Lee JY, et al. **Virchows Arch** 1998 Oct;433(4):305–9

[Early nuclear modifications related to cellular activation: from histology to molecular cytopathology (1967–1997)] Pompidou A. **Bull Acad Natl Med** 1999;183(1):143–55; discussion 156–8 (68 ref.) (Eng. Abstr.) **(Fre)**

[Guidelines for preparation of uterine surgical specimen] Horn LC, et al. **Pathologe** 1999 Jan;20(1):9–14 (Eng. Abstr.) **(Ger)**

STANDARDS

Performance optimization of the ThinPrep processor: effect of microscope slides. Lapen DC, et al. **Diagn Cytopathol** 1998 Nov;19(5):388–91

HISTOLOGICAL TECHNIQUES

Simple method to isolate the intact duct system of the rat submandibular gland. Sato A, et al. **Anat Rec** 1999 Jan; 254(1):74–5

Fluorescence activated cell sorting: a reliable method in tissue engineering of a bioprosthetic heart valve. Hoerstrup SP, et al. **Ann Thorac Surg** 1998 Nov;66(5):1653–7

Comparison of three methods for estimation of bone resorption following ovariectomy in the distal femur and the proximal tibia of the rat. Baldock PA, et al. **Bone** 1999 Jun;24(6):597–602

Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Ratto C, et al. **Dis Colon Rectum** 1999 Feb;42(2):143–54; discussion 154–8

Determining the human origin of fragments of burnt bone:

a comparative study of histological, immunological and DNA techniques. Cattaneo C, et al. **Forensic Sci Int** 1999 Jun 28;102(2-3):181-91

Enhanced visualization of parathyroid tissue by infusion of a visible dye conjugated to an antiparathyroid antibody. King RC, et al. **Head Neck** 1999 Mar;21(2):111-5

Applications of the microbiopsy technique in non-cervical cytology: where cytology and histology meet. Mravunac M, et al. **Histopathology** 1998 Aug;33(2):174-82

Three-dimensional computational reconstruction of mixed anatomical tissues following histological preparation. Ferguson SJ, et al. **Med Eng Phys** 1999 Mar;21(2):111-7

[The NADP-diaphorase reaction as a neurohistologic method] Radionova IuV, et al. **Ontogenez** 1998 Nov-Dec; 29(6):463-4 (Eng. Abstr.) **(Rus)**

ECONOMICS

Analysis of routine histological evaluation of tissues removed during primary hip and knee arthroplasty. Lawrence T, et al. **J Bone Joint Surg Am** 1999 Jul;81(7):926-31

INSTRUMENTATION

A further modified tissue homogenizer. Emery RC, et al. **Anal Biochem** 1978 Nov;91(1):340-2

A technique for section thickness evaluation for microphotometry and image analysis of sectioned nuclei. Cabrini RL, et al. **Anal Cell Pathol** 1998;17(2):125-30

[Image segmentation and 3D presentation of histological objects] Dramm P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:36 **(Ger)**

[A device for demonstrating micropreparations "histoskop"] Krylov PA, et al. **Arkh Patol** 1999 Jan-Feb;61(1):53-4 (Eng. Abstr.) **(Rus)**

[Histologic tissue processing in an automated microwave histoprocessor] Zubkova TV, et al. **Arkh Patol** 1999 May-Jun;61(3):48-9 (Eng. Abstr.) **(Rus)**

STANDARDS

Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections. Steinbeck RG, et al. **Eur J Cancer** 1999 May; 35(5):787-95

Tuberculosis of bones and joints: diagnostic approaches. Mousa HA. **Int Orthop** 1998;22(4):245-6

[Undiagnosed microinvasive carcinomas of the prostate] Berner A, et al. **Tidsskr Nor Laegeforen** 1998 Sep 20; 118(22):3408-12 (Eng. Abstr.) **(Nor)**

TRENDS

In vitro maintenance of isolated hair follicles: current status and future development. Philpott M. **Exp Dermatol** 1999 Aug;8(4):317-9 (25 ref.)

[What will the future bring in cutaneous histopathology? (editorial)] Grosshans E. **Ann Dermatol Venereol** 1999 May; 126(5):396-8 **(Fre)**

HISTOLOGY

EDUCATION

An ethnographic, controlled study of the use of a computer-based histology atlas during a laboratory course. Lehmann HP, et al. **J Am Med Inform Assoc** 1999 Jan-Feb; 6(1):38-52

[Ways of optimizing the teaching of cellular bases of immune reactions in the course of general histology for students of medical universities] Bykov VL. **Morfologiia** 1999; 115(2):73-5 **(Rus)**

[Clinical trends and use of current technology in teaching histology, cytology and embryology] Taskaev II, et al. **Morfologiia** 1998;114(5):112-4 **(Rus)**

HISTORY

[Work of the Leningrad section of the All-Russian Scientific Society of Anatomists, Histologists and Embryologists in 1991-1998] Sudzilovskii FV, et al. **Morfologiia** 1999; 115(3):99-101 **(Rus)**

METHODS see HISTOLOGICAL TECHNIQUES

HISTOLOGY, COMPARATIVE

EDUCATION

Graduate education in microscopic anatomy [see comments] Askew DS, et al. **Anat Rec** 1998 Oct;253(5):143-6. Comment in: Anat Rec 1998 Oct;253(5):127-8.

METHODS

Guidelines for the development of comparative pathology. Kaiser HE, et al. **In Vivo** 1998 Nov-Dec;12(6):639-42 (46 ref.)

HISTOMONIASIS see PROTOZOAN INFECTIONS

HISTONE DEACETYLASE

ANTAGONISTS & INHIBITORS

Activation of the MAP kinase cascade by histone deacetylase inhibitors is required for the stimulation of choline acetyltransferase gene promoter. Espinos E, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):118-24

Neuronal apoptosis induced by histone deacetylase inhibitors. Salminen A, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1-2):203-6

Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Glick RD, et al. **Cancer Res** 1999 Sep 1; 59(17):4392-9

Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Huang H, et al. **Cancer Res** 1999 Jun 15;59(12):2981-8

Histone deacetylase inhibitors as potential anti-skin cancer agents. Saunders N, et al. **Cancer Res** 1999 Jan 15; 59(2):399-404

Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Sowa Y, et al. **Cancer Res** 1999 Sep 1; 59(17):4266-70

Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Wang J, et al. **Cancer Res** 1999 Jun 15; 59(12):2766-9

Transient inhibition of histone deacetylase activity overcomes silencing in the mating-type region in fission yeast. Olsson TGS, et al. **Curr Genet** 1999 Mar;35(2):82-7

A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Niki T, et al. **Hepatology** 1999 Mar; 29(3):858-67

Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. Xiao H, et al. **J Cell Biochem** 1999 Jun 1; 73(3):291-302

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. Suzuki T, et al. **J Med Chem** 1999 Jul 29;42(15):3001-3

Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase [letter; comment] Samid D. **J Natl Cancer Inst** 1999 Mar 3;91(5):475-6. Comment on: J Natl Cancer Inst 1998 Nov 4;90(21):1621-5.

Trichostatin A up-regulates human papillomavirus type 11 upstream regulatory region-E6 promoter activity in undifferentiated primary human keratinocytes. Zhao W, et al. **J Virol** 1999 Jun;73(6):5026-33

Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Kosugi H, et al. **Leukemia** 1999 Sep;13(9):1316-24

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Cameron EE, et al. **Nat Genet** 1999 Jan;21(1):103-7

CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Chariot A, et al. **Oncogene** 1999 Jul 8;18(27):4007-14

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Kim YB, et al. **Oncogene** 1999 Apr 15;18(15):2461-70

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Saito A, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13; 96(8):4592-7

[Discovery of cell cycle inhibitors and their application to molecular biology] Yoshida M. **Jpn J Antibiot** 1999 Feb; 52(2):172-3 **(Jpn)**

[New approaches of differentiation-inducing therapy for leukemia] Kosugi H, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):480-3 (14 ref.) **(Jpn)**

CHEMISTRY

Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Kölle D, et al. **Biochemistry** 1999 May 25; 38(21):6769-73

Purification and characterization of chicken erythrocyte histone deacetylase 1. Sun JM, et al. **Biochemistry** 1999 May 4;38(18):5939-47

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Finnin MS, et al. **Nature** 1999 Sep 9;401(6749):188-93

DRUG EFFECTS

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase [see comments] Warrell RP Jr, et al. **J Natl Cancer Inst** 1998 Nov 4;90(21):1621-5. Comment in: J Natl Cancer Inst 1999 Mar 3;91(5):475-6.

GENETICS

Cloning and characterization of the murine histone deacetylase (HDAC3). Mahlknecht U, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):482-90

Histone acetylases and deacetylases in cell proliferation. Kouzarides T. **Curr Opin Genet Dev** 1999 Feb;9(1):40-8 (81 ref.)

Assignment of the histone deacetylase gene (Hdac3) to mouse chromosome 18B3 by in situ hybridization. Mahlknecht U, et al. **Cytogenet Cell Genet** 1999;84(3-4):192-3

Histone deacetylase mRNA temporally and spatially regulated in its expression in sea urchin embryos. Nemer M. **Dev Growth Differ** 1998 Dec;40(6):583-90

phd1+, a histone deacetylase gene of Schizosaccharomyces pombe, is required for the meiotic cell cycle and resistance to trichostatin A. Kim YB, et al. **FEBS Lett** 1998 Oct 2; 436(2):193-6

Molecular cloning of Drosophila melanogaster cDNAs that encode a novel histone deacetylase dHDAC3. Johnson CA, et al. **Gene** 1998 Oct 9;221(1):127-34

Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Nomura T, et al. **Genes Dev** 1999 Feb 15;13(4):412-23

Human histone deacetylase 2, HDAC2 (Human RPD3), is localized to 6q21 by radiation hybrid mapping. Betz R, et al. **Genomics** 1998 Sep 1;52(2):245-6

Genomic organization and chromosomal localization of the human histone deacetylase 3 gene. Mahlknecht U, et al. **Genomics** 1999 Mar 1;56(2):197-202

Identification and mapping of human histone acetylation modifier gene homologues. Randhawa GS, et al. **Genomics** 1998 Jul 15;51(2):262-9

A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. Fischle W, et al. **J Biol Chem** 1999 Apr 23;274(17):11713-20

Cloning and characterization of the mouse histone deacetylase-2 gene. Zeng Y, et al. **J Biol Chem** 1998 Oct 30;273(44):28921-30

Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum. Joshi MB, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):11-9

Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Gelmetti V, et al. **Mol Cell Biol** 1998 Dec;18(12):7185-91

Three proteins define a class of human histone deacetylases related to yeast Hda1p. Grozinger CM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4868-73

BRCA1 interacts with components of the histone deacetylase complex. Yarden RI, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4983-8

ISOLATION & PURIFICATION

Purification and characterization of chicken erythrocyte histone deacetylase 1. Sun JM, et al. **Biochemistry** 1999 May 4;38(18):5939-47

Biochemical methods for analysis of histone deacetylases. Kölle D, et al. **Methods** 1998 Aug;15(4):323-31

METABOLISM

Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide derived from histone-H4. Nare B, et al. **Anal Biochem** 1999 Feb 15; 267(2):390-6

MBP-1 physically associates with histone deacetylase for transcriptional repression. Ghosh AK, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):405-9

Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Kölle D, et al. **Biochemistry** 1999 May 25; 38(21):6769-73

Roles of histone acetyltransferases and deacetylases in gene regulation. Kuo MH, et al. **Bioessays** 1998 Aug; 20(8):615-26 (84 ref.)

The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Stiegler P, et al. **Cancer Res** 1998 Nov 15;58(22):5049-52

The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Zhang Y, et al. **Cell** 1998 Oct 16;95(2):279-89

The regulation of gene activity by histones and the histone deacetylase RPD3. Suka N, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:391-9 (58 ref.)

Histone deacetylase directs the dominant silencing of transcription in chromatin: association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase. Wade PA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:435-45 (72 ref.)

The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. Brehm A, et al. **EMBO J** 1999 May 4;18(9):2449-58

Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. Koipally J, et al. **EMBO J** 1999 Jun 1;18(11):3090-100

A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in Drosophila development. Chen G, et al. **Genes Dev** 1999 Sep 1; 13(17):2218-30

Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Zhang Y, et al. **Genes Dev** 1999 Aug 1;13(15):1924-35

A general requirement for the Sin3-Rpd3 histone deacetylase complex in regulating silencing in Saccharomyces cerevisiae. Sun ZW, et al. **Genetics** 1999 Jul;152(3):921-32

WD repeats of the p48 subunit of chicken chromatin assembly factor-1 required for in vitro interaction with chicken histone deacetylase-2. Ahmad A, et al. **J Biol Chem** 1999

Jun 4;274(23):16646–53
Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/cut homolog, is associated with histone deacetylation. Li S, et al. **J Biol Chem** 1999 Mar 19;274(12):7803–15
Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. Verdel A, et al. **J Biol Chem** 1999 Jan 22;274(4):2440–5
Maternal histone deacetylase is accumulated in the nuclei of Xenopus oocytes as protein complexes with potential enzyme activity. Ryan J, et al. **J Cell Sci** 1999 Jul;112 (Pt 14):2441–52
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. Radkov SA, et al. **J Virol** 1999 Jul;73(7):5688–97
Biochemical methods for analysis of histone deacetylases. Kölle D, et al. **Methods** 1998 Aug;15(4):323–31
Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum. Joshi MB, et al. **Mol Biochem Parasitol** 1999 Mar 15;99(1):11–9
NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Xue Y, et al. **Mol Cell** 1998 Dec;2(6):851–61
E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Iavarone A, et al. **Mol Cell Biol** 1999 Jan; 19(1):916–22
Functional analysis of the SIN3-histone deacetylase RPD3-RbAp48-histone H4 connection in the Xenopus oocyte. Vermaak D, et al. **Mol Cell Biol** 1999 Sep; 19(9):5847–60
RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex. Bach I, et al. **Nat Genet** 1999 Aug; 22(4):394–9
Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Tong JK, et al. **Nature** 1998 Oct 29; 395(6705):917–21
Repression of the mouse M-lysozyme gene involves both hindrance of enhancer factor binding to the methylated enhancer and histone deacetylation. Ammerpohl O, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5256–60
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Dhordain P, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4645–51
A non-isotopic assay for histone deacetylase activity. Hoffmann K, et al. **Nucleic Acids Res** 1999 May 1; 27(9):2057–8
CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Hsieh JJ, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):23–8
Histone deacetylases: complex transducers of nuclear signals [see comments] Johnson CA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):179–88 (80 ref.). Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.
Histone deacetylases: transcriptional repression with SINers and NuRDs. Ayer DE. **Trends Cell Biol** 1999 May; 9(5):193–8 (66 ref.)

PHYSIOLOGY

Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line. Takami Y, et al. **J Biol Chem** 1999 Aug 20; 274(34):23977–90
Role of histone deacetylases in acute leukemia. Fenrick R, et al. **J Cell Biochem Suppl** 1998;30–31:194–202 (35 ref.)
Histone deacetylase 1 can repress transcription by binding to Sp1. Doetzlhofer A, et al. **Mol Cell Biol** 1999 Aug; 19(8):5504–11
Transcriptional repression by XPc1, a new Polycomb homolog in Xenopus laevis embryos, is independent of histone deacetylase. Strouboulis J, et al. **Mol Cell Biol** 1999 Jun;19(6):3958–68
MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex [see comments] Ng HH, et al. **Nat Genet** 1999 Sep;23(1):58–61. Comment in: Nat Genet 1999 Sep;23(1):5–6.
CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Chariot A, et al. **Oncogene** 1999 Jul 8;18(27):4007–14
Histone acetylation in signal transduction by growth regulatory signals [see comments] Magnaghi-Jaulin L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):197–203 (105 ref.) Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165–7.

HISTONE H1 KINASE, M-PHASE-SPECIFIC see **MATURATION-PROMOTING FACTOR**

HISTONE KINASE see **PROTAMINE KINASE**

HISTONE KINASE P34(CDC2) see **PROTEIN P34CDC2**

HISTONE-LYSINE N-METHYLTRANSFERASE

GENETICS

Expression, purification, and characterization of recombinant ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit nepsilon-methyltransferase. Zheng Q, et al. **Protein Expr Purif** 1998 Oct;14(1):104–12

ISOLATION & PURIFICATION

Expression, purification, and characterization of recombinant ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit nepsilon-methyltransferase. Zheng Q, et al. **Protein Expr Purif** 1998 Oct;14(1):104–12

HISTONES

A novel DNA-binding protein bound to the mitochondrial inner membrane restores the null mutation of mitochondrial histone Abf2p in Saccharomyces cerevisiae. Cho JH, et al. **Mol Cell Biol** 1998 Oct;18(10):5712–23

ADMINISTRATION & DOSAGE

A new efficient method for transfection of neonatal cardiomyocytes using histone H1 in combination with DOSPER liposomal transfection reagent. Kott M, et al. **Somat Cell Mol Genet** 1998 Jul;24(4):257–61

ANALYSIS

Differential silver-staining sodium dodecyl sulfate-polyacrylamide gel electrophoresis: a nonisotopic method for characterizing gel-separated histone-DNA complexes. Carter GJ, et al. **Anal Biochem** 1998 Oct 1; 263(1):79–84
Developmentally regulated loss and reappearance of immunoreactive somatic histone H1 on chromatin of bovine morula-stage nuclei following transplantation into oocytes. Bordignon V, et al. **Biol Reprod** 1999 Jul;61(1):22–30
Techniques for sorting X and Y spermatozoa may adversely affect histone-associated regions in human spermatozoa [letter; comment] Gardiner-Garden M. **Hum Reprod** 1999 May;14(5):1403–4. Comment on: Hum Reprod 1998 Sep;13(9):2367–70.
Identification and characterization of a calreticulin-binding nuclear protein as histone (H1), an autoantigen in systemic lupus erythematosus. Treves S, et al. **Lupus** 1998; 7(7):479–87
Histone stoichiometry and DNA circularization in archaeal nucleosomes. Bailey KA, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):532–6

BIOSYNTHESIS

Quantitative analysis of histone H1 degrees protein synthesis in HTC cells. Cuisset L, et al. **Eur J Biochem** 1999 May; 261(3):593–9
Immunoexpression of testis-specific histone 2B in human spermatozoa and testis tissue. van Roijen HJ, et al. **Hum Reprod** 1998 Jun;13(6):1559–66
Prediction of human oral cancer radiation responsiveness by histone (H3) mRNA in situ hybridization: a preliminary report. Donoff RB, et al. **J Oral Maxillofac Surg** 1998 Dec; 56(12):1410–6
Overproduction of histone H1 variants in vivo increases basal and induced activity of the mouse mammary tumor virus promoter. Gunjan A, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):3355–63

BLOOD

T-lymphocyte long-term cultures have a constant histone variant pattern during aging. Sourlingas TG, et al. **Exp Gerontol** 1999 Jan;34(1):59–67

CHEMISTRY

Purification of histone core octamers and 2.15 A X-ray analysis of crystals in KCl/phosphate. Lambert SJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):1048–51
Ultraviolet laser footprinting of histone H1(0)-four-way junction DNA complexes. Angelov D, et al. **Biochemistry** 1999 Aug 31;38(35):11333–9
Self-association of linker histone H5 and of its globular domain: evidence for specific self-contacts. Carter GJ, et al. **Biochemistry** 1998 Sep 8;37(36):12477–88
Structure and function of the core histone N-termini: more than meets the eye. Hansen JC, et al. **Biochemistry** 1998 Dec 22;37(51):17637–41 (58 ref.)
hSWI/SNF disrupts interactions between the H2A N-terminal tail and nucleosomal DNA. Lee KM, et al. **Biochemistry** 1999 Jun 29;38(26):8423–9
DNA recognition and nucleosome organization. Travers A, et al. **Biopolymers** 1997;44(4):423–33 (70 ref.)
Chromatin structure: linking structure to function with histone H1. Widom J. **Curr Biol** 1998 Nov 5;8(22):R788–91 (11 ref.)
Histones and nucleosomes in Archaea and Eukarya: a comparative analysis. Pereira SL, et al. **Extremophiles** 1998 Aug;2(3):141–8 (46 ref.)
Parasin I, an antimicrobial peptide derived from histone H2A in the catfish, Parasilurus asotus. Park IY, et al. **FEBS Lett** 1998 Oct 23;437(3):258–62
Molecular dynamics simulation of interaction of histone-like protein of mycobacterium tuberculosis (Hlpmt) and histone of clostridium pasteurianum (DBHclopa) with 35 based paired GC rich U-bend DNA. Kothekar V, et al. **J Biomol Struct Dyn** 1998 Oct;16(2):223–35
Effect of in vivo histone hyperacetylation on the state of chromatin fibers. Krajewski WA. **J Biomol Struct Dyn** 1999 Apr;16(5):1097–106
Phosphorylation-induced rearrangement of the histone H3 NH2-terminal domain during mitotic chromosome condensation. Sauvé DM, et al. **J Cell Biol** 1999 Apr 19; 145(2):225–35
Nucleosome dynamics. Protein and DNA contributions in the chiral transition of the tetrasome, the histone (H3-H4)2 tetramer-DNA particle. Alilat M, et al. **J Mol Biol** 1999 Aug 27;291(4):815–41
Nucleosome dynamics. III. Histone tail-dependent fluctuation of nucleosomes between open and closed DNA conformations. Implications for chromatin dynamics and the linking number paradox. A relaxation study of mononucleosomes on DNA minicircles. De Lucia F, et al. **J Mol Biol** 1999 Jan 22;285(3):1101–19
NF-Y histone fold alpha1 helices help impart CCAAT specificity. Zemzoumi K, et al. **J Mol Biol** 1999 Feb 19; 286(2):327–37
Selective isopeptide bond formation: coupling ubiquitin(67–76) with histone 2A(114–128) by use of the transfer active ester condensation technique. Wang P, et al. **J Pept Res** 1999 Jun;53(6):673–7
Genetic dissection of histone function. Smith MM, et al. **Methods** 1998 Aug;15(4):269–81 (76 ref.)
Base-pair resolution mapping of nucleosome positions using site-directed hydroxy radicals. Flaus A, et al. **Methods Enzymol** 1999;304:251–63
Localization of specific histone regions on nucleosomal DNA by cross-linking. Usachenko SI, et al. **Methods Enzymol** 1999;304:264–78
Histones and histone-like DNA-binding proteins: correlations between structural differences, properties and functions. Li JY, et al. **Microbiology** 1999 Jan;145 (Pt 1):1–2
The SWI/SNF complex creates loop domains in DNA and polynucleosome arrays and can disrupt DNA-histone contacts within these domains. Bazett-Jones DP, et al. **Mol Cell Biol** 1999 Feb;19(2):1470–8
Analysis of primary structural determinants that distinguish the centromere-specific function of histone variant Cse4p from histone H3. Keith KC, et al. **Mol Cell Biol** 1999 Sep; 19(9):6130–9
Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide. Rojas JR, et al. **Nature** 1999 Sep 2;401(6748):93–8
Histone Sequence Database: sequences, structures, post-translational modifications and genetic loci. Makalowska I, et al. **Nucleic Acids Res** 1999 Jan 1; 27(1):323–4
The location of the linker histone on the nucleosome. Travers A. **Trends Biochem Sci** 1999 Jan;24(1):4–7 (34 ref.)
[Chromatin compactification using a model system of DNA-protein complexes] Chikhirzhina EV, et al. **Tsitologiia** 1998;40(10):883–8 (Eng. Abstr.) **(Rus)**

GENETICS

Differentiation of Fusarium subglutinans f. sp. pini by histone gene sequence data. Steenkamp ET, et al. **Appl Environ Microbiol** 1999 Aug;65(8):3401–6
Analysis of DNA compaction profile and intracellular contents of archaeal histones from Pyrococcus kodakaraensis KOD1. Higashibata H, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):416–24
Allelic polymorphism of histone H1.a in duck erythrocytes. Kowalski A, et al. **Biochem Genet** 1998 Jun;36(5–6):183–91
Ultraviolet laser footprinting of histone H1(0)-four-way junction DNA complexes. Angelov D, et al. **Biochemistry** 1999 Aug 31;38(35):11333–9
Selective expression of specific histone H4 genes reflects distinctions in transcription factor interactions with divergent H4 promoter elements. van der Meijden CM, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):82–100
The human H2A and H2B histone gene complement. Albig W, et al. **Biol Chem** 1999 Jan;380(1):7–18
Regulation of the sea urchin early H2A histone gene expression depends on the modulator element and on sequences located near the 3' end. Palla F, et al. **Biol Chem** 1999 Feb;380(2):159–65
High-level expression of human histone H4 in E. coli. Burnett VL, et al. **Biotechniques** 1999 Jan;26(1):30–2, 34
Drosophila virilis has atypical kinds and arrangements of histone repeats. Schienman JE, et al. **Chromosoma** 1998 Dec;107(8):529–39
Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Kotelnikov V, et al. **Clin Cancer Res** 1997 May;3(5):669–73
A His2AvDGFP fusion gene complements a lethal His2AvD mutant allele and provides an in vivo marker for Drosophila chromosome behavior. Clarkson M, et al. **DNA Cell Biol** 1999 Jun;18(6):457–62
Mutations in both the structured domain and N-terminus of histone H2B bypass the requirement for Swi-Snf in yeast. Recht J, et al. **EMBO J** 1999 Jan 4;18(1):229–40
Regulated transcription of the histone H2B genes of

Trypanosoma brucei. García-Salcedo JA, et al. **Eur J Biochem** 1999 Sep;264(3):717-23

Conserved sequence elements in human main type-H1 histone gene promoters: their role in H1 gene expression. Meergans T, et al. **Eur J Biochem** 1998 Sep 1;256(2):436-46

Structure and expression of the highly repetitive histone H1-related sperm chromatin proteins from winter flounder. Watson CE, et al. **Eur J Biochem** 1999 Jun;262(2):258-67

Leishmania major: histone H1 gene expression from the sw3 locus. Belli S, et al. **Exp Parasitol** 1999 Feb;91(2):151-60

Histones and nucleosomes in Archaea and Eukarya: a comparative analysis. Pereira SL, et al. **Extremophiles** 1998 Aug;2(3):141-8 (46 ref.)

Several highly divergent histone H3 genes are present in the hypotrichous ciliate Stylonychia lemnae. Bernhard D. **FEMS Microbiol Lett** 1999 Jun 1;175(1):45-50

Plant chromosomal HMGI/Y proteins and histone H1 exhibit a protein domain of common origin. Krech AB, et al. **Gene** 1999 Apr 1;230(1):1-5

Differential expression of linker histone variants in Euplotes crassus. Ray S, et al. **Gene** 1999 Apr 29;231(1-2):15-20

Multiple SSAP binding sites constitute the stage-specific enhancer of the sea urchin late H1beta gene. Edelmann L, et al. **Gene Expr** 1998;7(3):133-47

Cell-cycle-specific transcription termination within the human histone H3.3 gene is correlated with specific protein-DNA interactions. Taylor A, et al. **Genet Res** 1997 Apr;69(2):101-10

Sth1p, a Saccharomyces cerevisiae Snf2p/Swi2p homolog, is an essential ATPase in RSC and differs from Snf/Swi in its interactions with histones and chromatin-associated proteins. Du J, et al. **Genetics** 1998 Nov;150(3):987-1005

Isolation and preliminary characterization of histone H1.b allelic variants from quail erythrocytes. Pałyga J, et al. **Genome** 1998 Oct;41(5):709-19

Molecular analysis and chromosome mapping of the H2A, H3 and H4 histone genes from the malaria vector Anopheles gambiae. Reynaud E, et al. **Insect Mol Biol** 1998 Nov;7(4):385-91

Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Handa K, et al. **Int J Cancer** 1999 Jun 21;84(3):225-33

Biosynthesis of osteogenic growth peptide via alternative translational initiation at AUG85 of histone H4 mRNA. Bab I, et al. **J Biol Chem** 1999 May 14;274(20):14474-81

Identification and mutation of phosphorylation sites in a linker histone. Phosphorylation of macronuclear H1 is not essential for viability in tetrahymena. Mizzen CA, et al. **J Biol Chem** 1999 May 21;274(21):14533-6

PIPPin is a brain-specific protein that contains a cold-shock domain and binds specifically to H1 degrees and H3.3 mRNAs. Nastasi T, et al. **J Biol Chem** 1999 Aug 20; 274(34):24087-93

Multiple interactions of the transcription factor YY1 with human histone H4 gene regulatory elements. Last TJ, et al. **J Cell Biochem** 1999 Mar 15;72(4):507-16

HiNF-D (CDP-cut/CDC2/cyclin A/pRB-complex) influences the timing of IRF-2-dependent cell cycle activation of human histone H4 gene transcription at the G1/S phase transition. Aziz F, et al. **J Cell Physiol** 1998 Dec;177(3):453-64

The genomic organization of the histone clusters on human 6p21.3. Ahn J, et al. **Mamm Genome** 1999 Jul;10(7):768-70

Interactions of transcriptional regulators with histones. Edmondson DG, et al. **Methods** 1998 Aug;15(4):355-64

Genetic dissection of histone function. Smith MM, et al. **Methods** 1998 Aug;15(4):269-81 (76 ref.)

Incongruence in the diploid B-genome species complex of Glycine (Leguminosae) revisited: histone H3-D alleles versus chloroplast haplotypes. Doyle JJ, et al. **Mol Biol Evol** 1999 Mar;16(3):354-62

A role for transcriptional repressors in targeting the yeast Swi/Snf complex. Dimova D, et al. **Mol Cell** 1999 Jul; 4(1):75-83

Virus infection leads to localized hyperacetylation of histones H3 and H4 at the IFN-beta promoter. Parekh BS, et al. **Mol Cell** 1999 Jan;3(1):125-9

Stem-loop binding protein facilitates 3'-end formation by stabilizing U7 snRNP binding to histone pre-mRNA. Dominski Z, et al. **Mol Cell Biol** 1999 May;19(5):3561-70

Role for a YY1-binding element in replication-dependent mouse histone gene expression. Eliassen KA, et al. **Mol Cell Biol** 1998 Dec;18(12):7106-18

Temporal activation of the sea urchin late H1 gene requires stage-specific phosphorylation of the embryonic transcription factor SSAP. Li Z, et al. **Mol Cell Biol** 1999 May;19(5):3684-95

Two Xenopus proteins that bind the 3'end of histone mRNA: implications for translational control of histone synthesis during oogenesis. Wang ZF, et al. **Mol Cell Biol** 1999 Jan; 19(1):835-45

Induction of reproductive organ-preferential histone genes by wounding or methyl jasmonate. Kim SA, et al. **Mol Cells** 1998 Dec 31;8(6):669-77

Expression of mRNA and protein of nucleoproteins during human spermiogenesis. Steger K, et al. **Mol Hum Reprod** 1998 Oct;4(10):939-45

Localization and quantitative expression of mRNAs encoding the testis-specific histone TH2B, the phosphoprotein p19, the transition proteins 1 and 2 during pubertal development and throughout the spermatogenic cycle of the rat. Marret C, et al. **Mol Reprod Dev** 1998 Sep;51(1):22-35

Conditional deletion of Xist disrupts histone macroH2A localization but not maintenance of X inactivation [letter] Csankovszki G, et al. **Nat Genet** 1999 Aug;22(4):323-4

Early activated replication origins within the cell cycle-regulated histone H4 genes in Physarum. Bénard M, et al. **Nucleic Acids Res** 1999 May 15;27(10):2091-8

Histone Sequence Database: sequences, structures, post-translational modifications and genetic loci. Makalowska I, et al. **Nucleic Acids Res** 1999 Jan 1; 27(1):323-4

Both the 5S rRNA gene and the AT-rich flanks of xenopus laevis oocyte-type 5S rDNA repeat are required for histone H1-dependent repression of transcription of pol III-type genes in in vitro reconstituted chromatin. Tomaszewski R, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5596-601

Identification of AP-2 as an interactive target of Rb and a regulator of the G1/S control element of the hamster histone H3.2 promoter. Wu F, et al. **Nucleic Acids Res** 1998 Nov 1;26(21):4837-45

Isolation and molecular characterization of gibberellin-regulated H1 and H2B histone cDNAs in the leaf of the gibberellin-deficient tomato. van den Heuvel KJ, et al. **Plant Mol Biol** 1999 Mar;39(5):883-90

Male gametic cell-specific expression of H2A and H3 histone genes. Xu H, et al. **Plant Mol Biol** 1999 Feb;39(3):607-14

The partial sequence of the Plasmodium falciparum histone H4 gene. Beauchamps P, et al. **Res Microbiol** 1997 Mar-Apr;148(3):201-3

IMMUNOLOGY

Antigen specificity of antihistone antibodies in systemic sclerosis. Hasegawa M, et al. **Ann Rheum Dis** 1998 Aug; 57(8):470-5

Apoptosis in serum of patients with solid tumours. Holdenrieder S, et al. **Anticancer Res** 1999 Jul-Aug; 19(4A):2721-4

Anti-[(H2A/2B)-DNA]] IgG supports the diagnosis of procainamide-induced arthritis or pleuritis. Lau CC, et al. **Arthritis Rheum** 1999 Jun;42(6):1300-1

A comparison of the anti-histone and Apop-Tag technique for demonstrating apoptosis with option for silver enhancement. Al-hazzaa AA, et al. **Cell Biol Int** 1998; 22(4):271-6

Antigenicity of the Leishmania infantum histones H2B and H4 during canine visceral cutaneous leishmaniasis. Soto M, et al. **Clin Exp Immunol** 1999 Feb;115(2):342-9

Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Shen GQ, et al. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):321-34 (93 ref.)

Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. Kubo M, et al. **J Invest Dermatol** 1999 May;112(5):711-5

[Natural antihistone antibodies: their possible role in genesis of radiation injuries] Abakushin DN, et al. **Radiats Biol Radioecol** 1998 Jul-Aug;38(4):560-4 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Purification of histone core octamers and 2.15 A X-ray analysis of crystals in KCl/phosphate. Lambert SJ, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):1048-51

Mobility of acetylated histones in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Georgieva EI, et al. **Anal Biochem** 1999 May 1;269(2):399-402

Changes in the protein pattern of H1 histones associated with apoptotic DNA fragmentation. Kratzmeier M, et al. **Biochem J** 1999 Jan 15;337 (Pt 2):319-27

Structural and functional analysis of chromatin assembled from defined histones. Nightingale KP, et al. **Methods** 1998 Aug;15(4):343-53

Protein image hybridization: mapping and positioning DNA-protein contacts along DNA. Belikov S, et al. **Methods Enzymol** 1999;304:600-12

Assembly of defined nucleosomal and chromatin arrays from pure components. Carruthers LM, et al. **Methods Enzymol** 1999;304:19-35

Chromatin immunoprecipitation assays in acetylation mapping of higher eukaryotes. Crane-Robinson C, et al. **Methods Enzymol** 1999;304:533-47

Analysis of nucleosome positioning in mammalian cells. Hager GL, et al. **Methods Enzymol** 1999;304:626-38

Nucleoprotein gel assays for nucleosome positioning and mobility. Pennings S. **Methods Enzymol** 1999;304:298-312

Chromatin assembly in Xenopus extracts. Tremethick DJ. **Methods Enzymol** 1999;304:50-63

Isolation and separation of HMG proteins and histones H1 and H5 and core histones by column chromatography on phosphocellulose. Garg LC, et al. **Protein Expr Purif** 1998 Nov;14(2):155-9

METABOLISM

Differential silver-staining sodium dodecyl sulfate-polyacrylamide gel electrophoresis: a nonisotopic method for characterizing gel-separated histone-DNA complexes. Carter GJ, et al. **Anal Biochem** 1998 Oct 1; 263(1):79-84

Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide derived from histone-H4. Nare B, et al. **Anal Biochem** 1999 Feb 15; 267(2):390-6

Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Lea MA, et al. **Anticancer Res** 1999 May-Jun; 19(3A):1971-6

Interaction of Nickel(II) with histones: in vitro binding of nickel(II) to the core histone tetramer. Bal W, et al. **Arch Biochem Biophys** 1999 Apr 15;364(2):161-6

Influence of DNA binding on the degradation of oxidized histones by the 20S proteasome. Ullrich O, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):211-6

The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene. Hu JF, et al. **Biochem Biophys Res Commun** 1998 Oct 20; 251(2):403-8

LBP-p40 binds DNA tightly through associations with histones H2A, H2B, and H4. Kinoshita K, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):277-82

Promotion of antigen-specific antibody production in murine B cells by a moderate increase in histone acetylation. Kohge T, et al. **Biochem Pharmacol** 1998 Nov 15; 56(10):1359-64

Linker histones stabilize the intrinsic salt-dependent folding of nucleosomal arrays: mechanistic ramifications for higher-order chromatin folding. Carruthers LM, et al. **Biochemistry** 1998 Oct 20;37(42):14776-87

The site of binding of linker histone to the nucleosome does not depend upon the amino termini of core histones. An W, et al. **Biochimie** 1999 Jul;81(7):727-32

Linker histone binding to superhelical DNA: electrophoretic and filter binding studies. Ivanchenko M, et al. **Biochimie** 1998 Dec;80(12):1031-4

How do linker histones mediate differential gene expression? Crane-Robinson C. **Bioessays** 1999 May;21(5):367-71 (21 ref.)

Histone H4 underacetylation in plant facultative heterochromatin. Buzek J, et al. **Biol Chem** 1998 Oct; 379(10):1235-41

DNA recognition and nucleosome organization. Travers A, et al. **Biopolymers** 1997;44(4):423-33 (70 ref.)

Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Chen H, et al. **Cell** 1999 Sep 3;98(5):675-86

ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF. Hamiche A, et al. **Cell** 1999 Jun 25;97(7):833-42

Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer. Längst G, et al. **Cell** 1999 Jun 25;97(7):843-52

Histone octamer transfer by a chromatin-remodeling complex. Lorch Y, et al. **Cell** 1999 Feb 5;96(3):389-92

Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Wei Y, et al. **Cell** 1999 Apr 2;97(1):99-109

Interactions of Nickel(II) with histones: interactions of Nickel(II) with CH3CO-Thr-Glu-Ser-His-His-Lys-NH2, a peptide modeling the potential metal binding site in the "C-Tail" region of histone H2A. Bal W, et al. **Chem Res Toxicol** 1998 Sep;11(9):1014-23

A novel histone variant localized in nucleoli of higher plant cells. Tanaka I, et al. **Chromosoma** 1999 Jul;108(3):190-9

Trypsin digestion of histones inhibited by glucose [letter] Jobst K, et al. **Clin Chim Acta** 1998 Aug 28;276(2):187-9

Structure of the yeast histone acetyltransferase Hat1: insights into substrate specificity and implications for the Gcn5-related N-acetyltransferase superfamily. Dutnall RN, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:501-7 (51 ref.)

In vivo functions of histone acetylation/deacetylation in Tup1p repression and Gcn5p activation. Edmondson DG, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:459-68

TBP-associated factors in the PCAF histone acetylase complex. Kotani T, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:493-9 (53 ref.)

Signaling to chromatin through histone modifications: how clear is the signal? Mizzen C, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:469-81 (109 ref.)

The regulation of gene activity by histones and the histone deacetylase RPD3. Suka N, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:391-9 (58 ref.)

Chromatin modification: how to put a HAT on the histones. Travers A. **Curr Biol** 1999 Jan 14;9(1):R23-5

Gene activation by histone and factor acetyltransferases. Berger SL. **Curr Opin Cell Biol** 1999 Jun;11(3):336-41 (53 ref.)

Histone H1: location and role. Thomas JO. **Curr Opin Cell Biol** 1999 Jun;11(3):312-7 (51 ref.)

Chromatin assembly: biochemical identities and genetic redundancy. Adams CR, et al. **Curr Opin Genet Dev** 1999 Apr;9(2):185-90 (45 ref.)

Histone acetylation and cancer. Archer SY, et al. **Curr Opin Genet Dev** 1999 Apr;9(2):171-4 (32 ref.)

Histone ubiquitination and chromatin remodeling in mouse spermatogenesis. Baarends WM, et al. **Dev Biol** 1999 Mar 15;207(2):322-33

The importin beta/importin 7 heterodimer is a functional nuclear import receptor for histone H1. Jäkel S, et al. **EMBO J** 1999 May 4;18(9):2411-23

A developmental switch in H4 acetylation upstream of Xist plays a role in X chromosome inactivation. O'Neill LP, et al. **EMBO J** 1999 May 17;18(10):2897-907

Mutations in both the structured domain and N-terminus of

histone H2B bypass the requirement for Swi-Snf in yeast. Recht J, et al. **EMBO J** 1999 Jan 4;18(1):229-40

Effect of PTU treatment on histone acetylation pattern in the developing rat brain. Lakshmy R, et al. **Endocr Res** 1999 Feb;25(1):77-85

Histone H3 phosphorylation in human monocytes and during HL-60 cell differentiation. Juan G, et al. **Exp Cell Res** 1999 Jan 10;246(1):212-20

Epigenetic regulation of gelsolin expression in human breast cancer cells. Mielnicki LM, et al. **Exp Cell Res** 1999 May 25;249(1):161-76

The histone H1(0) contains multiple sequence elements for nuclear targeting. Schwamborn K, et al. **Exp Cell Res** 1998 Oct 10;244(1):206-17

Linker histones: paradigm lost but questions remain. Belikov S, et al. **FEBS Lett** 1998 Dec 18;441(2):161-4 (44 ref.)

Specific binding of glucosaminylmuramyl peptides to histones. Golovina T, et al. **FEBS Lett** 1999 Jul 2; 454(1-2):152-6

Basic homopolyamino acids, histones and protamines are potent antagonists of angiogenin binding to ribonuclease inhibitor. Moenner M, et al. **FEBS Lett** 1999 Jan 29; 443(3):303-7

Atomic force microscopy sees nucleosome positioning and histone H1-induced compaction in reconstituted chromatin. Sato MH, et al. **FEBS Lett** 1999 Jun 11; 452(3):267-71

Histone H4 acetylation during interleukin-2 stimulation of mouse T cells. Taplick J, et al. **FEBS Lett** 1998 Oct 9; 436(3):349-52

Repressor elements in the coding region of the human histone H4 gene interact with the transcription factor CDP/cut. Last TJ, et al. **Gene** 1998 Oct 23;221(2):267-77

Multiple SSAP binding sites constitute the stage-specific enhancer of the sea urchin late H1beta gene. Edelmann L, et al. **Gene Expr** 1998;7(3):133-47

Tip60 acetylates six lysines of a specific class in core histones in vitro. Kimura A, et al. **Genes Cells** 1998 Dec; 3(12):789-800

In vitro assembly of the CENP-B/alpha-satellite DNA/core histone complex: CENP-B causes nucleosome positioning. Yoda K, et al. **Genes Cells** 1998 Aug;3(8):533-48

Cell cycle-regulated histone acetylation required for expression of the yeast HO gene. Krebs JE, et al. **Genes Dev** 1999 Jun 1;13(11):1412-21

Euchromatic domains in plant chromosomes as revealed by H4 histone acetylation and early DNA replication. Vyskot B, et al. **Genome** 1999 Apr;42(2):343-50

H4 acetylation, XIST RNA and replication timing are coincident and define x;autosome boundaries in two abnormal X chromosomes. Keohane AM, et al. **Hum Mol Genet** 1999 Feb;8(2):377-83

Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Lea MA, et al. **Int J Oncol** 1999 Aug;15(2):347-52

The non-histone chromatin protein HMG1 protects linker DNA on the side opposite to that protected by linker histones. An W, et al. **J Biol Chem** 1998 Oct 9; 273(41):26289-91

Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. Chadee DN, et al. **J Biol Chem** 1999 Aug 27; 274(35):24914-20

Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. Goto H, et al. **J Biol Chem** 1999 Sep 3;274(36):25543-9

Histone H1 dephosphorylation is mediated through a radiation-induced signal transduction pathway dependent on ATM. Guo CY, et al. **J Biol Chem** 1999 Jun 25; 274(26):18715-20

Activation of the apoptotic endonuclease DFF40 (caspase-activated DNase or nuclease). Oligomerization and direct interaction with histone H1. Liu X, et al. **J Biol Chem** 1999 May 14;274(20):13836-40

Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. Nagpal S, et al. **J Biol Chem** 1999 Aug 6;274(32):22563-8

Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. Schiltz RL, et al. **J Biol Chem** 1999 Jan 15;274(3):1189-92

In vitro binding of H1 histone subtypes to nucleosomal organized mouse mammary tumor virus long terminal repeat promotor. Talasz H, et al. **J Biol Chem** 1998 Nov 27;273(48):32236-43

Heterochromatin organization of a natural yeast telomere. Recruitment of Sir3p through interaction with histone H4 N terminus is required for the establishment of repressive structures. Venditti S, et al. **J Biol Chem** 1999 Jan 22; 274(4):1928-33

Dynamics of histone acetylation in Chlamydomonas reinhardtii. Waterborg JH. **J Biol Chem** 1998 Oct 16; 273(42):27602-9

Nucleosomes bind to cell surface proteoglycans. Watson K, et al. **J Biol Chem** 1999 Jul 30;274(31):21707-13

Localization of histone H1 binding sites within the nucleosome by UV-induced H1-DNA crosslinking in vivo. Belikov S, et al. **J Biomol Struct Dyn** 1998 Aug;16(1):35-9

Age-dependent deamidation of H1(0) histones in chromatin of mammalian tissues. Lindner H, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):182-6

Regulation and regulatory parameters of histone modifications. Davie JR, et al. **J Cell Biochem Suppl** 1998; 30-31:203-13 (64 ref.)

Phosphorylation-induced rearrangement of the histone H3 NH2-terminal domain during mitotic chromosome condensation. Sauvé DM, et al. **J Cell Biol** 1999 Apr 19; 145(2):225-35

Active transgenes in zebrafish are enriched in acetylated histone H4 and dynamically associate with RNA Pol II and splicing complexes. Collas P, et al. **J Cell Sci** 1999 Apr;112 (Pt 7):1045-54

Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation. Van Hooser A, et al. **J Cell Sci** 1998 Dec;111 (Pt 23):3497-506

Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus. Borowski P, et al. **J Clin Virol** 1999 Jun;13(1-2):61-9

Histone-mediated transfer and expression of the HIV-1 tat gene in Jurkat cells. Demirhan I, et al. **J Hum Virol** 1998 Nov-Dec;1(7):430-40

Lymphoid transcription of the murine CD21 gene is positively regulated by histone acetylation. Zabel MD, et al. **J Immunol** 1999 Sep 1;163(5):2697-703

Heparin in plasma samples causes nonspecific binding to histones on Western blots. Alcantara FF, et al. **J Immunol Methods** 1999 Jun 24;226(1-2):11-8

The bromodomain of Gcn5p interacts in vitro with specific residues in the N terminus of histone H4. Ornaghi P, et al. **J Mol Biol** 1999 Mar 19;287(1):1-7

Histone H1o ribosomal RNA synthesis and cell differentiation. Flickinger RA. **J Theor Biol** 1999 Feb 21; 196(4):521-5

Interactions of transcriptional regulators with histones. Edmondson DG, et al. **Methods** 1998 Aug;15(4):355-64

Preparation/analysis of chromatin replicated in vivo and in isolated nuclei. Chang L, et al. **Methods Enzymol** 1999; 304:76-99

Targeted cross-linking and DNA cleavage within model chromatin complexes. Lee KM, et al. **Methods Enzymol** 1999;304:231-51

Histone acetyltransferases: preparation of substrates and assay procedures. Mizzen CA, et al. **Methods Enzymol** 1999; 304:675-96

DNA-protein cross-linking applications for chromatin studies in vitro and in vivo. Pruss D, et al. **Methods Enzymol** 1999;304:516-33

Localization of specific histone regions on nucleosomal DNA by cross-linking. Usachenko SI, et al. **Methods Enzymol** 1999;304:264-78

Analysis of modulators of chromatin structure in Drosophila. Varga-Weisz PD, et al. **Methods Enzymol** 1999;304:742-57

The nuclear actin-related protein of Saccharomyces cerevisiae, Act3p/Arp4, interacts with core histones. Harata M, et al. **Mol Biol Cell** 1999 Aug;10(8):2595-605

Measurement of poly(ADP-ribose) glycohydrolase activity by high resolution polyacrylamide gel electrophoresis: specific inhibition by histones and nuclear matrix proteins. Pacheco-Rodriguez G, et al. **Mol Cell Biochem** 1999 Mar; 193(1-2):13-8

The SWI/SNF complex creates loop domains in DNA and polynucleosome arrays and can disrupt DNA-histone contacts within these domains. Bazett-Jones DP, et al. **Mol Cell Biol** 1999 Feb;19(2):1470-8

Specific binding of high-mobility-group I (HMGI) protein and histone H1 to the upstream AT-rich region of the murine beta interferon promoter: HMGI protein acts as a potential antirepressor of the promoter. Bonnefoy E, et al. **Mol Cell Biol** 1999 Apr;19(4):2803-16

Esa1p is an essential histone acetyltransferase required for cell cycle progression. Clarke AS, et al. **Mol Cell Biol** 1999 Apr;19(4):2515-26

Analysis of primary structural determinants that distinguish the centromere-specific function of histone variant Cse4p from histone H3. Keith KC, et al. **Mol Cell Biol** 1999 Sep; 19(9):6130-9

Synergistic transcriptional activation by TATA-binding protein and hTAFII28 requires specific amino acids of the hTAFII28 histone fold. Lavigne AC, et al. **Mol Cell Biol** 1999 Jul;19(7):5050-60

The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Madisen L, et al. **Mol Cell Biol** 1998 Nov;18(11):6281-92

Persistent interactions of core histone tails with nucleosomal DNA following acetylation and transcription factor binding. Mutskov V, et al. **Mol Cell Biol** 1998 Nov; 18(11):6293-304

Functional analysis of the SIN3-histone deacetylase RPD3-RbAp48-histone H4 connection in the Xenopus oocyte. Vermaak D, et al. **Mol Cell Biol** 1999 Sep; 19(9):5847-60

Follicle-stimulating hormone promotes histone H3 phosphorylation on serine-10. DeManno DA, et al. **Mol Endocrinol** 1999 Jan;13(1):91-105

Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells [published erratum appears in Nat Genet 1999 Jun;22(2):209] Coffee B, et al. **Nat Genet** 1999 May;22(1):98-101

Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation [see comments] Wade PA, et al. **Nat Genet** 1999 Sep;23(1):62-6. Comment in: Nat Genet 1999 Sep;23(1):5-6.

DNA methylation models histone acetylation [letter] Eden S, et al. **Nature** 1998 Aug 27;394(6696):842

Repression of the mouse M-lysozyme gene involves both hindrance of enhancer factor binding to the methylated enhancer and histone deacetylation. Ammerpohl O, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5256-60

Specific local histone-DNA sequence contacts facilitate high-affinity, non-cooperative nucleosome binding of both adf-1 and GAGA factor. Gao J, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5394-401

Directional binding of HMG-I(Y) on four-way junction DNA and the molecular basis for competitive binding with HMG-1 and histone H1. Hill DA, et al. **Nucleic Acids Res** 1999 May 15;27(10):2135-44

Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Kögel D, et al. **Oncogene** 1998 Nov 19;17(20):2645-54

Histone modification governs the cell cycle regulation of a replication-independent chromatin assembly pathway in Saccharomyces cerevisiae. Altheim BA, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1345-50

GCN5-dependent histone H3 acetylation and RPD3-dependent histone H4 deacetylation have distinct, opposing effects on IME2 transcription, during meiosis and during vegetative growth, in budding yeast. Burgess SM, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6835-40

The tail domain of lamin Dm0 binds histones H2A and H2B. Goldberg M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2852-7

Enhanced transcription factor access to arrays of histone H3/H4 tetramer.DNA complexes in vitro: implications for replication and transcription. Tse C, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12169-73

Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. Ullrich O, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6223-8

How chromatin changes its shape [news] Hagmann M. **Science** 1999 Aug 20;285(5431):1200-1, 1203

Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Sassone-Corsi P, et al. **Science** 1999 Aug 6;285(5429):886-91

Histone acetyltransferase complexes [see comments] Grant PA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):169-77 (95 ref.). Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

Histone deacetylases: complex transducers of nuclear signals [see comments] Johnson CA, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):179-88 (80 ref.). Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

Histone acetylation in signal transduction by growth regulatory signals [see comments] Magnaghi-Jaulin L, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):197-203 (105 ref.) . Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

DNA replication in the 1-cell mouse embryo: stimulatory effect of histone acetylation. Aoki E, et al. **Zygote** 1999 May;7(2):165-72

[Histone-like TAFs within the PCAF histone acetylase complex] Nakatani Y. **Tanpakushitsu Kakusan Koso** 1998 Nov;43(14):2079-86 (20 ref.) **(Jpn)**

[Inhibition of nuclear histone proteolysis by nucleotides] Tiulenev VI, et al. **Ukr Biokhim Zh** 1998 Nov-Dec; 70(6):43-7 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Histones evoke thymocyte death in vitro; histone-binding immunoglobulins decrease their cytotoxicity. Abakushin DN, et al. **Biochemistry (Mosc)** 1999 Jun;64(6):693-8

Effects of histone and diolein on the structure of phosphatidylcholine/phosphatidylserine or phosphatidylcholine/phosphatidylglycerol bilayers. Goldberg EM, et al. **Eur J Biochem** 1998 Dec 1; 258(2):722-8

Modulation of nuclear matrix protein phosphorylation by histones: possible involvement of NM-associated protein kinase CK2 activity. Tawfic S, et al. **J Cell Biochem** 1999 Feb 1;72(2):242-50

PHYSIOLOGY

Transcriptional inhibitory role of the tail domains of histone (H3 x H4)2 tetramers. Hernández F, et al. **Arch Biochem Biophys** 1998 Oct 1;358(1):98-103

The core histone N-terminal domains are required for multiple rounds of catalytic chromatin remodeling by the SWI/SNF and RSC complexes. Logie C, et al. **Biochemistry** 1999 Feb 23;38(8):2514-22

Histones as extracellular messengers: effects on growth hormone secretion. Brown OA, et al. **Cell Biol Int** 1997 Dec;21(12):787-92

Stochastic nucleosome positioning in a yeast chromatin region is not dependent on histone H1. Puig S, et al. **Curr Microbiol** 1999 Sep;39(3):168-72

Regulation and regulatory parameters of histone modifications. Davie JR, et al. **J Cell Biochem Suppl** 1998; 30-31:203-13 (64 ref.)

Histone proteins in vivo: cell-cycle-dependent physiological effects of exogenous linker histones incorporated into Physarum polycephalum. Thiriet C, et al. **Methods** 1999 Feb;17(2):140-50

Assembly of defined nucleosomal and chromatin arrays from pure components. Carruthers LM, et al. **Methods Enzymol** 1999;304:19-35

Preparation of nucleosome core particle from recombinant histones. Luger K, et al. **Methods Enzymol** 1999;304:3–19
Location and function of linker histones [news] Vignali M, et al. **Nat Struct Biol** 1998 Dec;5(12):1025–8
Regions of variant histone His2AvD required for Drosophila development. Clarkson MJ, et al. **Nature** 1999 Jun 17; 399(6737):694–7

RADIATION EFFECTS

Poly-ADP-ribosylation of histone proteins of human kidney T1-cells in vitro following gamma-irradiation. Sharan RN, et al. **Indian J Biochem Biophys** 1998 Apr;35(2):97–102

THERAPEUTIC USE

Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. Kaliyaperumal A, et al. **J Immunol** 1999 May 15; 162(10):5775–83

ULTRASTRUCTURE

Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Bednar J, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14173–8

HISTOPLASMA

Molecular and cellular determinants of immunity to Histoplasma capsulatum. Deepe GS Jr, et al. **Res Immunol** 1998 May-Jun;149(4–5):397–406; discussion 509–10 (60 ref.)

CLASSIFICATION

Phylogenetic relationships of varieties and geographical groups of the human pathogenic fungus Histoplasma capsulatum Darling. Kasuga T, et al. **J Clin Microbiol** 1999 Mar;37(3):653–63
Relatedness analyses of Histoplasma capsulatum isolates from Mexican patients with AIDS-associated histoplasmosis by using histoplasmin electrophoretic profiles and randomly amplified polymorphic DNA patterns. Reyes-Montes MR, et al. **J Clin Microbiol** 1999 May;37(5):1404–8

DRUG EFFECTS

Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP. Milewski S, et al. **Med Mycol** 1998 Jun; 36(3):177–80

ENZYMOLOGY

The URA5 gene is necessary for histoplasma capsulatum growth during infection of mouse and human cells. Retallack DM, et al. **Infect Immun** 1999 Feb;67(2):624–9

GENETICS

Transcript splicing is essential for functional Histoplasma capsulatum URA5 expression. Retallack DM, et al. **Gene** 1999 Apr 16;230(2):181–5
Histoplasma capsulatum strain variation in both H antigen production and beta-glucosidase activity and overexpression of HAG1 from a telomeric linear plasmid. Fisher KL, et al. **Infect Immun** 1999 Jul;67(7):3312–6
Molecular cloning, characterization, and expression of the M antigen of Histoplasma capsulatum. Zancopé-Oliveira RM, et al. **Infect Immun** 1999 Apr;67(4):1947–53
Genome size, complexity, and ploidy of the pathogenic fungus Histoplasma capsulatum. Carr J, et al. **J Bacteriol** 1998 Dec;180(24):6697–703
Phylogenetic relationships of varieties and geographical groups of the human pathogenic fungus Histoplasma capsulatum Darling. Kasuga T, et al. **J Clin Microbiol** 1999 Mar;37(3):653–63
Genetic analysis of Histoplasma capsulatum strains isolated from clinical specimens in thailand by a PCR-based random amplified polymorphic DNA method. Poonwan N, et al. **J Clin Microbiol** 1998 Oct;36(10):3073–6
Characterization of a single group I intron in the 18S rRNA gene of the pathogenic fungus Histoplasma capsulatum. Lasker BA, et al. **Med Mycol** 1998 Aug;36(4):205–12
Cloning and sequence analysis of Histoplasma capsulatum glucosamine-6-phosphate synthase gene fragment. Sachadyn P, et al. **Mycopathologia** 1998;142(2):67–70
Ribosomal genes of Histoplasma capsulatum var. duboisii and var. farciminosum. Okeke CN, et al. **Mycoses** 1998 Nov; 41(9–10):355–62
Isolation of a Histoplasma capsulatum cDNA that complements a mitochondrial NAD(+)-isocitrate dehydrogenase subunit 1-deficient mutant of Saccharomyces cerevisiae. Johnson CH, et al. **Yeast** 1999 Jun 30;15(9):799–804

GROWTH & DEVELOPMENT

The URA5 gene is necessary for histoplasma capsulatum growth during infection of mouse and human cells. Retallack DM, et al. **Infect Immun** 1999 Feb;67(2):624–9

IMMUNOLOGY

Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. Strasser JE, et al. **J Immunol** 1999 May 15;162(10):6148–54
Prevalence of antibodies to Histoplasma capsulatum among Dutch speleologists [letter] van Roosmalen MS, et al. **J Infect** 1998 Sep;37(2):200–1
Macrophages in host defense against Histoplasma capsulatum. Newman SL. **Trends Microbiol** 1999 Feb;7(2):67–71 (44 ref.)

ISOLATION & PURIFICATION

Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up. Gómez BL, et al. **J Clin Microbiol** 1999 Mar;37(3):675–80
Histoplasma capsulatum antigen detection: comparison of the performance characteristics of a new inhibition immunoassay to those of an established antibody sandwich immunoassay [letter; comment] Wheat J. **J Clin Microbiol** 1999 Jul;37(7):2387. Comment on: J Clin Microbiol 1997 Oct;35(10):2618–22.
Oral histoplasmosis: a case report. Mead GE, et al. **J Infect** 1998 Jul;37(1):73–5
Disseminated histoplasmosis in an infant with acquired immunodeficiency syndrome. Wang H, et al. **J Infect** 1998 Nov;37(3):298–301
African histoplasmosis: report of four cases from north-eastern Nigeria. Khalil MA, et al. **Mycoses** 1998 Sep-Oct;41(7–8):293–5
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1998. A 19-year-old man with the acquired immunodeficiency syndrome and persistent fever [clinical conference] **N Engl J Med** 1998 Dec 17;339(25):1835–43

METABOLISM

An homologue of the human 100-kDa protein (p100) is differentially expressed by Histoplasma capsulatum during infection of murine macrophages. Porta A, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):605–13

PATHOGENICITY

Outbreak of histoplasmosis among cavers attending the National Speleological Society Annual Convention, Texas, 1994. Ashford DA, et al. **Am J Trop Med Hyg** 1999 Jun; 60(6):899–903

HISTOPLASMIN

ANALYSIS

Relatedness analyses of Histoplasma capsulatum isolates from Mexican patients with AIDS-associated histoplasmosis by using histoplasmin electrophoretic profiles and randomly amplified polymorphic DNA patterns. Reyes-Montes MR, et al. **J Clin Microbiol** 1999 May;37(5):1404–8

DIAGNOSTIC USE

Epidemiologic surveys of histoplasmin and paracoccidioidin sensitivity in Brazil. Fava S di C, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun;40(3):155–64
[Cutaneous sensitivity to histoplasmin in a Martinique hospitalized population (see comments)] Verneuil L, et al. **Ann Dermatol Venereol** 1999 May;126(5):405–7 (Eng. Abstr.). Comment in: Ann Dermatol Venereol 1999 May;126(5):401–3. **(Fre)**

GENETICS

Histoplasma capsulatum strain variation in both H antigen production and beta-glucosidase activity and overexpression of HAG1 from a telomeric linear plasmid. Fisher KL, et al. **Infect Immun** 1999 Jul;67(7):3312–6

HISTOPLASMOSIS

Pharyngo-laryngeal histoplasmosis: one case in an immunocompetent child. Coiffier T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Oct 2;45(2):177–81 (18 ref.)
[Exotic pulmonary mycoses] Dupont B. **Rev Pneumol Clin** 1998 Dec;54(6):301–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[American pulmonary histoplasmosis caused by Histoplasma capsulatum] Guigay J, et al. **Rev Pneumol Clin** 1998 Dec; 54(6):311–20 (56 ref.) (Eng. Abstr.) **(Fre)**
[Progressive disseminated histoplasmosis] Nagai M. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):369–71 (8 ref.) **(Jpn)**
[Pulmonary histoplasmosis] Suzaki A, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):372–4 (14 ref.) **(Jpn)**
[Disseminated histoplasmosis in AIDS patients. A study of 2 cases and review of the Spanish literature] Benito N, et al. **Enferm Infecc Microbiol Clin** 1998 Aug-Sep; 16(7):316–21 (58 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Acute renal failure in a patient with AIDS: histoplasmosis-induced granulomatous interstitial nephritis. Ahuja TS, et al. **Am J Kidney Dis** 1998 Jul;32(2):E3
Severe anal ulceration secondary to Histoplasma capsulatum in a patient with HIV disease. Winburn GB, et al. **Am Surg** 1999 Apr;65(4):321–2
Chronic pulmonary histoplasmosis in a patient with a recent history of tuberculosis and persistent round lung lesions. Pometta R, et al. **Eur J Clin Microbiol Infect Dis** 1999 Mar;18(3):229–31
Fluconazole in the therapy of multiple osteomyelitis in African histoplasmosis. Onwuasoigwe O. **Int Orthop** 1999; 23(2):82–4
Recurrent histoplasmosis of the wrist: a case report. Care SB, et al. **J Hand Surg [Am]** 1998 Nov;23(6):1112–4
Disseminated histoplasmosis in an infant with acquired immunodeficiency syndrome. Wang H, et al. **J Infect** 1998 Nov;37(3):298–301
Disseminated histoplasmosis causing reversible gaze palsy and optic neuropathy. Perry JD, et al. **J Neuroophthalmol** 1999 Jun;19(2):140–3
Acute disseminated histoplasmosis and endocarditis. Scapellato PG, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan-Feb;40(1):19–22
Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Hansen KE, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):193–9 (22 ref.)
Potential association between calcified thoracic lymphadenopathy due to previous Histoplasma capsulatum infection and pulmonary Mycobacterium avium complex disease. Chan ED, et al. **South Med J** 1999 Jun;92(6):572–6
Disseminated histoplasmosis and Wegener's granulomatosis. Manepalli AN, et al. **South Med J** 1998 Dec;91(12):1156–8
Coexistence of histoplasma granulomas and Warthin's tumor in the submaxillary salivary gland. Udoji WC. **Tenn Med** 1999 May;92(5):175–6

DIAGNOSIS

Acute renal failure in a patient with AIDS: histoplasmosis-induced granulomatous interstitial nephritis. Ahuja TS, et al. **Am J Kidney Dis** 1998 Jul;32(2):E3
Ophthaproblem. Ocular histoplasmosis syndrome. Sharma S. **Can Fam Physician** 1999 Aug;45:1869, 1879
Evaluation of a western blot test in an outbreak of acute pulmonary histoplasmosis. Pizzini CV, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):20–3
Dark spots in late-phase indocyanine green angiographic studies in a patient with presumed ocular histoplasmosis syndrome. Weinberger AW, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun;237(6):524–6
Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up. Gómez BL, et al. **J Clin Microbiol** 1999 Mar;37(3):675–80
Histoplasma capsulatum antigen detection: comparison of the performance characteristics of a new inhibition immunoassay to those of an established antibody sandwich immunoassay [letter; comment] Wheat J. **J Clin Microbiol** 1999 Jul;37(7):2387. Comment on: J Clin Microbiol 1997 Oct;35(10):2618–22.
Oral histoplasmosis: a case report. Mead GE, et al. **J Infect** 1998 Jul;37(1):73–5
Clinical quiz. Histoplasma capsulatum. Carvalho Galvão L, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):320,345
Histoplasmosis mimicking vasculitis of the central nervous system. Stone JH, et al. **J Rheumatol** 1998 Aug;25(8):1644–8
Perianal ulcer [letter; comment] Meis JF, et al. **Lancet** 1999 May 29;353(9167):1881. Comment on: Lancet 1999 Mar 13;353(9156):894.
Central nervous system histoplasmosis mimicking a brain tumor: difficulties in diagnosis and treatment. Klein CJ, et al. **Mayo Clin Proc** 1999 Aug;74(8):803–7
Serodiagnosis of histoplasmosis, paracoccidioidomycosis and penicilliosis marneffei; current status and future trends. Hamilton AJ. **Med Mycol** 1998 Dec;36(6):351–64 (148 ref.)
African histoplasmosis: report of four cases from north-eastern Nigeria. Khalil MA, et al. **Mycoses** 1998 Sep-Oct;41(7–8):293–5
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1998. A 19-year-old man with the acquired immunodeficiency syndrome and persistent fever [clinical conference] **N Engl J Med** 1998 Dec 17;339(25):1835–43
Oral histoplasmosis as an indicator of HIV infection. Economopoulou P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):203–6 (24 ref.)
Pulmonary histoplasmosis in a Japanese male: report of a case. Endo S, et al. **Surg Today** 1998;28(12):1316–8
[Papular exanthema in systemic histoplasmosis and HIV infection] Schöfer H, et al. **Hautarzt** 1998 Jul;49(7):581–5 (Eng. Abstr.) **(Ger)**
[Disseminated histoplasmosis within the scope of immune deficiency with suspected HIV infection. HIV infection CDC stage C3. Disseminated histoplasmosis] Guex AC. **Schweiz Rundsch Med Prax** 1999 May 12;88(20):917–9 **(Ger)**
[Progressive disseminated histoplasmosis in AIDS patients] Fernández Andreu CM, et al. **Rev Cubana Med Trop** 1996; 48(3):163–6 (Eng. Abstr.) **(Spa)**
[Cutaneous histoplasmosis in nine patients with AIDS] Orozco-Topete RL, et al. **Rev Invest Clin** 1998 Nov-Dec; 50(6):525–8 (Eng. Abstr.) **(Spa)**

HISTOPLASMOSIS

DRUG THERAPY

Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Connolly P, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):322–8

Activities of sordarins in murine histoplasmosis. Graybill JR, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1716–8

Disseminated histoplasmosis successfully treated with liposomal amphotericin B following azathioprine therapy in a patient from a nonendemic area. Poveda F, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):357–9

Fluconazole in the therapy of multiple osteomyelitis in African histoplasmosis. Onwuasoigwe O. **Int Orthop** 1999; 23(2):82–4

Detection of the 70-kilodalton histoplasma capsulatum antigen in serum of histoplasmosis patients: correlation between antigenemia and therapy during follow-up. Gómez BL, et al. **J Clin Microbiol** 1999 Mar;37(3):675–80

Central nervous system histoplasmosis mimicking a brain tumor: difficulties in diagnosis and treatment. Klein CJ, et al. **Mayo Clin Proc** 1999 Aug;74(8):803–7

Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP. Milewski S, et al. **Med Mycol** 1998 Jun; 36(3):177–80

African histoplasmosis: report of two patients treated with amphotericin B and ketoconazole. Akpuaka FC, et al. **Mycoses** 1998 Nov;41(9–10):363–4 (12 ref.)

Case report. Successful therapy of disseminated histoplasmosis in AIDS with liposomal amphotericin B [letter] Rieg GK, et al. **Mycoses** 1999 Apr;42(1–2):117–20

[Effect of cyclophosphamide in experimental histoplasmosis in the rat] Gago JG, et al. **Rev Argent Microbiol** 1998 Oct–Dec;30(4):185–9 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Outbreak of histoplasmosis among cavers attending the National Speleological Society Annual Convention, Texas, 1994. Ashford DA, et al. **Am J Trop Med Hyg** 1999 Jun; 60(6):899–903

Evaluation of a western blot test in an outbreak of acute pulmonary histoplasmosis. Pizzini CV, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):20–3

Histoplasmosis and Paracoccidioidomycosis in northwestern Argentina III. Epidemiological survey in Vipos, La Toma, and Choromoro – Trancas, Tucumán, Argentina. van Gelderen de Komaid A, et al. **Eur J Epidemiol** 1999 Apr; 15(4):383–8

Prevalence of antibodies to Histoplasma capsulatum among Dutch speleologists [letter] van Roosmalen MS, et al. **J Infect** 1998 Sep;37(2):200–1

Epidemiologic surveys of histoplasmin and paracoccidioidin sensitivity in Brazil. Fava S di C, et al. **Rev Inst Med Trop Sao Paulo** 1998 May–Jun;40(3):155–64

Epidemiology of histoplasmosis in the French West Indies (Martinique). Garsaud P, et al. **Trans R Soc Trop Med Hyg** 1999 May–Jun;93(3):264–7

[Investigation on the epidemiology of Histoplasma capsulatum infection in Nanjing district] Zhao B, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Aug; 19(4):215–7 (Eng. Abstr.) **(Chi)**

[Histoplasmosis caused by Histoplasma capsulatum: an endemic infection in the French Antilles (comment)] Cabié A. **Ann Dermatol Venereol** 1999 May;126(5):401–3. Comment on: Ann Dermatol Venereol 1999 May;126(5):405–7. **(Fre)**

[Cutaneous sensitivity :o histoplasmin in a Martinique hospitalized population (see comments)] Verneuil L, et al. **Ann Dermatol Venereol** 1999 May;126(5):405–7 (Eng. Abstr.). Comment in: Ann Dermatol Venereol 1999 May;126(5):401–3. **(Fre)**

ETIOLOGY

Acute pulmonary histoplasmosis in bridge workers: a persistent problem. Jones TF, et al. **Am J Med** 1999 Apr; 106(4):480–2

Disseminated histoplasmosis 19 years after renal transplantation. Jha V, et al. **Clin Nephrol** 1999 Jun; 51(6):373–8 (38 ref.)

IMMUNOLOGY

Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Wu-Hsieh BA, et al. **Infect Immun** 1998 Nov;66(11):5520–6

Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. Allendörfer R, et al. **J Immunol** 1999 Jun 15;162(12):7389–96

Molecular and cellular determinants of immunity to Histoplasma capsulatum. Deepe GS Jr, et al. **Res Immunol** 1998 May–Jun;149(4–5):397–406; discussion 509–10 (60 ref.)

Macrophages in host defense against Histoplasma capsulatum. Newman SL. **Trends Microbiol** 1999 Feb;7(2):67–71 (44 ref.)

MICROBIOLOGY

Phylogenetic relationships of varieties and geographical groups of the human pathogenic fungus Histoplasma capsulatum Darling. Kasuga T, et al. **J Clin Microbiol** 1999 Mar;37(3):653–63

Genetic analysis of Histoplasma capsulatum strains isolated from clinical specimens in thailand by a PCR-based random amplified polymorphic DNA method. Poonwan N, et al. **J Clin Microbiol** 1998 Oct;36(10):3073–6

Relatedness analyses of Histoplasma capsulatum isolates from Mexican patients with AIDS-associated histoplasmosis by using histoplasmin electrophoretic profiles and randomly amplified polymorphic DNA patterns. Reyes-Montes MR, et al. **J Clin Microbiol** 1999 May;37(5):1404–8

[Cerebral miliary granulomatosis with Histoplasma capsulatum in an HIV seronegative patient] Hadi M, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):231–3 (Eng. Abstr.) **(Fre)**

PATHOLOGY

Clinical conference on management dilemmas: progressive pneumonia in a patient receiving long-term steroid therapy [clinical conference] Schnader J, et al. **Chest** 1999 Jan; 115(1):260–6

Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Wu-Hsieh BA, et al. **Infect Immun** 1998 Nov;66(11):5520–6

Images in clinical medicine. Cerebral histoplasmosis. Tabbal SD, et al. **N Engl J Med** 1999 Apr 15;340(15):1176

[Histopathological and immunohistochemical characteristics of cutaneous and oral mucosa lesions in disseminated histoplasmosis associated with acquired immunodeficiency syndrome (AIDS)] D'Avila SC, et al. **Rev Soc Bras Med Trop** 1998 Nov–Dec;31(6):539–47 (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Histoplasmosis of the wrist: a case report [letter] Houtman PM, et al. **Rheumatology (Oxford)** 1999 Sep;38(9):906–7

SURGERY

[Inflammatory pseudotumor of the lung in hilus lymph node histoplasmosis] Frey A, et al. **Chirurg** 1998 Oct; 69(10):1101–4 (Eng. Abstr.) **(Ger)**

VETERINARY

Use of corticosteroids for treating dogs with airway obstruction secondary to hilar lymphadenopathy caused by chronic histoplasmosis: 16 cases (1979–1997). Schulman RL, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1345–8

Histoplasmosis in the skin and gingiva in a dog. Kagawa Y, et al. **J Vet Med Sci** 1998 Jul;60(7):863–5

HISTORICAL COHORT STUDIES see **COHORT STUDIES**

HISTORIOGRAPHY

On writing medical history. Joy RJ, et al. **Ann Diagn Pathol** 1997 Dec;1(2):130–7 (67 ref.)

Where is the postcolonial history of medicine? Essay review. Anderson W. **Bull Hist Med** 1998 Fall;72(3):522–30

The Oral History Program: II. Personal views of health sciences librarianship and the Medical Library Association. McKenzie D, et al. **Bull Med Libr Assoc** 1998 Jul; 86(3):366–76

Controversies in the history of dentistry. Curtis EK. **J Am Coll Dent** 1999 Summer;66(2):57–9

Assessing historical research in the behavioral and social sciences: A symposium. Introduction. Burnham JC. **J Hist Behav Sci** 1999 Summer;35(3):225–6

Assessing research in the history of sociology and anthropology. Kuklick H. **J Hist Behav Sci** 1999 Summer; 35(3):227–37

Assessing research in the history of psychology: past, present, and future. Samelson F. **J Hist Behav Sci** 1999 Summer; 35(3):247–55

A quarter century of the history of psychiatry. Scull A. **J Hist Behav Sci** 1999 Summer;35(3):239–46

From African health and influenza pandemics to disease in Russia: the medical history of K. David Patterson. Pyle GF. **Soc Sci Med** 1999 Apr;48(8):1047–51

["History of Medicine" rubrics in our scientific journal (editorial)] Pocard M. **Ann Chir** 1998;52(2):123 **(Fre)**

[On the 10th anniversary of the death of Erwin H. Ackerknecht (1906–1988)] Walser HH. **Gesnerus** 1998; 55(3–4):175–82 **(Ger)**

HISTORY OF DENTISTRY

Controversies in the history of dentistry. Curtis EK. **J Am Coll Dent** 1999 Summer;66(2):57–9

Canada's historic contribution to the evolution of the dental profession in North America. Lang MR. **J Can Dent Assoc** 1999 Apr;65(4):208–10

It takes determination to be a dentist [editorial] Albert SB. **N Y State Dent J** 1999 Jan;65(1):3–5

The dentition of Abraham's people. Why Abraham left Mesopotamia [see comments] Neiburger EJ, et al. **N Y State Dent J** 1998 Nov;64(9):25–9. Comment in: N Y State Dent J 1999 Feb;65(2):9.

Pre-endodontics [letter; comment] Neiburger EJ. **N Y State Dent J** 1999 Feb;65(2):9. Comment on: N Y State Dent J 1998 Nov;64(9):25–9. Comment on: N Y State Dent J 1998 Nov;64(9):34–6.

Dentistry and medical dominance. Adams T. **Soc Sci Med** 1999 Feb;48(3):407–20

[Iconography--the monogrammist HF. "The tooth crusher" (news)] Neumeister M. **Schweiz Monatsschr Zahnmed** 1998; 108(10):1010, 1032 **(Fre, Ger)**

[Hungarian Medical Journal 100 years ago: Dentistry at the time of Hippocrates] Abonyi J. **Orv Hetil** 1998 Nov 15; 139(46):2789–90 **(Hun)**

[Mining and dentistry] Hunstadbråten K. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4691–2 (Eng. Abstr.) **(Nor)**

[Origins of dental science and art] Canut Brusola JA. **An R Acad Nac Med (Madr)** 1998;Spec No:23–6 **(Spa)**

[50 years of stomatology in Spain: its odontology and stomatology colleges. A philosophy to be studied with warmth and without passion] Coscolín Fuertes E. **An R Acad Nac Med (Madr)** 1998;Spec No:27–30 **(Spa)**

[Evolution of stomatology and neuro-occlusal rehabilitation from 1940 until today] Gálvez Rodríguez JL. **An R Acad Nac Med (Madr)** 1998;Spec No:37–43 **(Spa)**

[First initiations of odontology-stomatology education] Goiriena de Gandarias J. **An R Acad Nac Med (Madr)** 1998; Spec No:59–77 **(Spa)**

[Lecture of Professor Pedro Laín Entralgo, Academician of the National Royal Academy of Medicine] Laín Entralgo P. **An R Acad Nac Med (Madr)** 1998;Spec No:129–37 **(Spa)**

HISTORY OF MEDICINE

History of medicine: the metamorphosis of scientific medicine in the ever-present past. Cruse JM. **Am J Med Sci** 1999 Sep;318(3):171–80

A web of words: The 1998 Kenneth F. Russell memorial lecture. Beasley AW. **Aust N Z J Surg** 1998 Apr; 69(4):252–7

Teaching the history of medicine in cyberspace. Jones KW, et al. **Bull Hist Med** 1998 Winter;72(4):734–43

The story of a medical lifetime, told in a stamp [news] Jay V. **CMAJ** 1998 Oct 20;159(8):911

Learning medical history in Oslo: training for medical practice. Larsen O. **Croat Med J** 1999 Mar;40(1):29–33

Study of the history of medicine in Georgia. Shengelia R. **Croat Med J** 1999 Mar;40(1):38–41

Teaching history of medicine in the perspective of "medical humanities". von Engelhardt D. **Croat Med J** 1999 Mar; 40(1):1–7

Importance of philosophy of science to the history of medical thinking. Zalewski Z. **Croat Med J** 1999 Mar;40(1):8–13

Teaching history of medicine at Russian medical schools: past, present, and future. Zhuravleva TV, et al. **Croat Med J** 1999 Mar;40(1):25–8

Dr Ivan Pintar and his contribution to the development of history of medicine in Slovenia. Zupanic Slavec Z. **Croat Med J** 1999 Mar;40(1):34–7

The end of medical history? Hampton JR. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):366–75

Praise for profiles. Smith T. **Nat Struct Biol** 1999 Feb;6(2):113

A brief survey of the history of medicine in Tunisia. Ammar S. **Tunis Med** 1998 Oct;76(10):317–23

[Development of European medicine to the time of Vesalius (16th century)] Smrčka V, et al. **Cas Lek Cesk** 1999 Jan 25;138(3):87–8 (Eng. Abstr.) **(Cze)**

[Memories of the Institute of Medical History at the 1st School of Medicine] Rozsivalová E. **Sb Lek** 1998; 99(1):63–76 **(Cze)**

[The muse of medicine] Appelboom T. **Rev Med Brux** 1999 Apr;20(2):A121–2 **(Fre)**

[On the Tunisian Medical Society of History of Medicine and Pharmacy. Notes and recollections] Mabrouk R. **Tunis Med** 1998 Oct;76(10):306–10 (Eng. Abstr.) **(Fre)**

[Memorial dates in the history of medicine in 1999] **Klin Med (Mosk)** 1999;77(3):68–9 **(Rus)**

[50 years of the Society of Historians of Medicine of Russia] Lisitsyn IuP, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):45–6 **(Rus)**

[The 50th anniversary of the St. Petersburg Scientific Society of Historians of Medicine] Selivanov VI. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):47 **(Rus)**

[Asklepios redivivus--or the art of snake interpretation] Fichtelius KE. **Lakartidningen** 1998 Sep 23;95(39):4226–7 **(Swe)**

HISTORY OF MEDICINE, ANCIENT

The metaphorical and mythical use of the kidney in antiquity. Maio G. **Am J Nephrol** 1999;19(2):101–6

The future of the realm: medicine and divination in ancient Syro-Mesopotamia. Mujais S. **Am J Nephrol** 1999; 19(2):133–9

Edema in the Corpus Hippocraticum. Touwaide A, et al. **Am J Nephrol** 1999;19(2):155–8

Dental pathology in ancient Mesopotamia. Pangas JC. **Bull Hist Med** 1999 Summer;73(2):197–207

Part 1. European science and surgery from 500 BC–AD 1500. Rew DA. **Eur J Surg Oncol** 1999 Apr;25(2):199–204

Ancient evidence for the origin and early development of chronobiology and biometeorology in Bulgaria. Kostova EK, et al. **Folia Med (Plovdiv)** 1999;41(1):25–8

Medicine in ancient Egypt. Shafik A. **J Invest Surg** 1998 Sep–Oct;11(5):291–3

Aesculapius: a modern tale. Stanton JA. **JAMA** 1999 Feb 3;281(5):476–7
Cult of Asclepius [letter] Kellie SM. **Lancet** 1999 Sep 18; 354(9183):1038
The beginnings of medicine. Tierney J. **Med Health R I** 1998 Oct;81(10):339
Hippocrates. The father of spine surgery. Marketos SG, et al. **Spine** 1999 Jul 1;24(13):1381–7
Ancient Egyptian medicine. Nunn JF. **Trans Med Soc Lond** 1996–97;113:57–68
Hippocrates and contemporary medicine. Fishman AP. **Trans Stud Coll Physicians Phila** 1998 Dec;20:41–50
[Medicine in Tunisia under the Hafsid dynasty] Ammar S, et al. **Tunis Med** 1998 Oct;76(10):356–9 **(Ara)**
[Multiple births in ancient medical texts] Dasen V. **Gesnerus** 1998;55(3–4):183–204 (Eng. Abstr.) **(Fre)**
[Medicine in ancient Egypt] Blázovics A, et al. **Orv Hetil** 1999 Jun 27;140(26):1471–5 **(Hun)**
[Science, customs and social life in the classical world] Latronico N. **Minerva Pediatr** 1998 Nov;50(11):479–96 **(Ita)**
[The oldest "medicine". Wine and health--from Nippur to the Osterbro study] Hagen A. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4758–61 **(Nor)**
[Surgery in ancient civilization of Asia] Mirskiĭ MB. **Khirurgiia (Mosk)** 1999;(8):68–71 **(Rus)**
[Old slavonic medicine] Mirskiĭ MB. **Klin Med (Mosk)** 1999; 77(2):65–7 **(Rus)**

HISTORY OF MEDICINE, MEDIEVAL

Pre-Columbian medicine and the kidney. Peña JC. **Am J Nephrol** 1999;19(2):148–54
Medieval notions of cancer: malignancy and metaphor. Demaitre L. **Bull Hist Med** 1998 Winter;72(4):609–37
Hildegard of Bingen and the greening of medieval medicine. Sweet V. **Bull Hist Med** 1999 Fall;73(3):381–403
Ut Dicunt Medici: medical knowledge and theological debates in the second half of the thirteenth century. Ziegler J. **Bull Hist Med** 1999 Summer;73(2):208–37
Part I. European science and surgery from 500 BC–AD 1500. Rew DA. **Eur J Surg Oncol** 1999 Apr;25(2):199–204
Evaluation of the Bulgarian medicine in the ninth century. Kuvandzhiev G. **Folia Med (Plovdiv)** 1998;40(4):82–5
On the official medical doctrine in Bulgaria after establishment of Christianity as a state religion. Kuvandzhiev G. **Folia Med (Plovdiv)** 1998;40(4):86–91
Isaac Ibn Suleiman al Israili (end IXth–beginning Xth century AD) (end of IIIrd and first half of IVth century of the Hegira). Ammar S. **Tunis Med** 1998 Oct;76(10):324–6
[In the times of the "Fatimids of Mehdia" "the encyclopedist physician Abu Salt Oumia el Andalussi"] Tamboura B, et al. **Tunis Med** 1998 Oct;76(10):333–5 (Eng. Abstr.) **(Spa)**

HISTORY OF MEDICINE, MODERN

Nehushtan: Iberia, Humpty Dumpty, and modern medicine. Goihman-Yahr M. **Int J Dermatol** 1999 Jan;38(1):26–8
Progress in medical knowledge is never straightforward. Wood C. **Lancet** 1999 Apr 10;353(9160):1279

HISTORY OF MEDICINE, RENAISSANCE see **HISTORY OF MEDICINE, MEDIEVAL**

HISTORY OF MEDICINE, 15TH CENT.

Gabriele Zerbi's De cautelis medicorum and the tradition of medical prudence. Linden DE. **Bull Hist Med** 1999 Spring;73(1):19–37
[Mohammed Ibn Othman As-Siqilly and his work "el Moukhtassar el Farissi"] Asli FO. **Tunis Med** 1998 Oct; 76(10):286–9 (Eng. Abstr.) **(Fre)**

HISTORY OF MEDICINE, 16TH CENT.

Part II. Europe and surgery from AD 1500 to 1800; the modern world is shaped. Rew DA. **Eur J Surg Oncol** 1999 Jun;25(3):311–6
[Medical and surgical books printed in the New Spain and their authors during the 1st two centuries of colonial culture (1570–1692)] Rodriguez-Sala ML. **Gac Med Mex** 1998 Sep-Oct;134(5):587–608 **(Spa)**

HISTORY OF MEDICINE, 17TH CENT.

Part II. Europe and surgery from AD 1500 to 1800; the modern world is shaped. Rew DA. **Eur J Surg Oncol** 1999 Jun;25(3):311–6
[Place of the works of Aziza Othmana in the history of medicine in Tunisia] Essaddam H. **Tunis Med** 1998 Oct; 76(10):290–2 (Eng. Abstr.) **(Fre)**
[Medical and surgical books printed in the New Spain and their authors during the 1st two centuries of colonial culture (1570–1692)] Rodriguez-Sala ML. **Gac Med Mex** 1998 Sep-Oct;134(5):587–608 **(Spa)**

HISTORY OF MEDICINE, 18TH CENT.

Part II. Europe and surgery from AD 1500 to 1800; the modern world is shaped. Rew DA. **Eur J Surg Oncol** 1999 Jun;25(3):311–6
Nosology, mortality, and disease theory in the eighteenth century. DeLacy M. **J Hist Med Allied Sci** 1999 Apr; 54(2):261–84
[Medicine and enlightenment in New Spain] de Micheli A. **Gac Med Mex** 1998 May-Jun;134(3):343–9 (Eng. Abstr.) **(Spa)**

HISTORY OF MEDICINE, 19TH CENT.

Medical progress in all its gory. Cooper C. **Lancet** 1998 Oct 3;352(9134):1160
Dentistry and medical dominance. Adams T. **Soc Sci Med** 1999 Feb;48(3):407–20
[Epidemics and colonial medicine in West Africa] Becker C, et al. **Sante** 1998 Nov-Dec;8(6):411–6 (Eng. Abstr.) **(Fre)**
[Medicine in Tunisia from the French Protectorate to the contemporary era] Ammar S. **Tunis Med** 1998 Oct; 76(10):295–301 (Eng. Abstr.) **(Fre)**
[Memorable dates in the history of medicine in 1999] **Klin Med (Mosk)** 1999;77(2):67–72 **(Rus)**
[Medicine in Tunisia in the 19th Century] Zitouna MM, et al. **Tunis Med** 1998 Oct;76(10):338–9 (Eng. Abstr.) **(Spa)**

HISTORY OF MEDICINE, 20TH CENT.

That was the century that was: historical perspectives on medical life at the fin de siècle. Maulitz RC. **Ann Intern Med** 1999 Jul 6;131(1):75–8
Clinical investigation in the 20th century: the ascendancy of numerical reasoning. Vandenbroucke JP. **Lancet** 1998; :SII12–6
175th anniversary lecture. Medical journals and the shaping of medical knowledge [published erratum appears in Lancet 1999 Mar 6;353(9155):848] Vandenbroucke JP. **Lancet** 1998 Dec 19–26;352(9145):2001–6 (23 ref.)
Dentistry and medical dominance. Adams T. **Soc Sci Med** 1999 Feb;48(3):407–20
[Epidemics and colonial medicine in West Africa] Becker C, et al. **Sante** 1998 Nov-Dec;8(6):411–6 (Eng. Abstr.) **(Fre)**
[Medicine in Tunisia from the French Protectorate to the contemporary era] Ammar S. **Tunis Med** 1998 Oct; 76(10):295–301 (Eng. Abstr.) **(Fre)**
[Fight against acute infectious diseases in Poland in the first year of independence (1918–1919)] Więckowska E. **Przegl Epidemiol** 1999;53(1–2):211–20 (Eng. Abstr.) **(Pol)**
[Memorable dates in the history of medicine in 1999] **Klin Med (Mosk)** 1999;77(2):67–72 **(Rus)**

HISTORY OF NURSING

We are diminished by one. Just one nurse, with a remarkable dedication. McCabe B. **Am J Nurs** 1999 Jul;99(7):25
Ninety-nine years later [editorial] Mason DJ. **Am J Nurs** 1999 Jan;99(1 Pt 1):7
Horsemen of the Apocalypse: lessons from the Gulf War. Boyle JS, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):30–41 (34 ref.)
Revisiting and rethinking the rewriting of nursing history. D'Antonio P. **Bull Hist Med** 1999 Summer;73(2):268–90
Nursing history: repositories and the Web [letter; comment] Szabunia M, et al. **Image J Nurs Sch** 1998;30(2):109–10. Comment on: Image J Nurs Sch 1997;29(4):355–9.
First-rate scholarship by LeVasseur [letter; comment] Walker C. **Image J Nurs Sch** 1999;31(1):9–10. Comment on: Image J Nurs Sch 1998;30(3):281–5.
History. Delete or save? Woolley AS. **J Prof Nurs** 1998 Sep-Oct;14(5):263
Refuge and rescue. Jewish nurse refugees and the International Council of Nurses, 1947–1965. Brush BL. **Nurs Hist Rev** 1999;7:113–25
Entering the professional domain. The making of the modern nurse in 17th century France. Nelson S. **Nurs Hist Rev** 1999;7:171–87
[The first nurses on the American continent] Quijano-Pitman F. **Gac Med Mex** 1999 Jan-Feb;135(1):77–8 **(Spa)**
["Murphy's button" became salvation for the nurse's assitant miss Johanna] Berggren A. **Lakartidningen** 1999 Jan 6; 96(1–2):75 **(Swe)**

HISTRIONIC PERSONALITY DISORDER

DIAGNOSIS

The hysterical personality disorder: a phenomenological approach. Sigmund D, et al. **Psychopathology** 1998 Nov-Dec;31(6):318–30

PSYCHOLOGY

Implicit and self-attributed dependency needs in dependent and histrionic personality disorders. Bornstein RF. **J Pers Assess** 1998 Aug;71(1):1–14

HIV

see related
RECEPTORS, HIV
REVERSE TRANSCRIPTASE INHIBITORS

Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. Benson EM, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):105–13
Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 in fetal lymphoid organs: implications for pathogenesis in utero. Kitchen SG, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):143–8
Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Doan S, et al. **Am J Ophthalmol** 1999 Aug;128(2):250–1
HIV/AIDS mental health training for health care providers: an evaluation of three models. Neff JA, et al. **Am J Orthopsychiatry** 1999 Apr;69(2):240–6
HIV/SIV enteropathy. Zeitz M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:139–48 (48 ref.)
Origins and evolution of AIDS viruses. Sharp PM, et al. **Biol Bull** 1999 Jun;196(3):338–42 (27 ref.)
VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brenneman DE, et al. **Brain Res** 1999 Aug 14; 838(1–2):27–36
Cardiac and autonomic evaluation in a pediatric population with human immunodeficiency virus. Plein D, et al. **Clin Cardiol** 1999 Jan;22(1):33–6
HIV. McKnight A. **Curr Biol** 1999 Apr 8;9(7):R234
HIV: The deadly passenger in dendritic cells. Rowland-Jones SL. **Curr Biol** 1999 Apr 8;9(7):R248–50 (11 ref.)
Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. Evans JT, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1479–89
9th International Conference on Human Retrovirology HTLV and Related Viruses. Kagoshima, Japan, April 5–9, 1999. Abstracts.. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):A1–88
Antiretroviral therapy for HIV infection: a review of current medications and therapies. Bright DC. **J Am Optom Assoc** 1999 Jun;70(6):355–83 (288 ref.)
Sarcoidosis-related anterior uveitis in a patient with human immunodeficiency virus. Lee AK, et al. **J Am Optom Assoc** 1999 Jun;70(6):384–90
Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. Piratvisuth T, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):146–9
A personal perspective on HIV-AIDS research. Gallo RC. **J Hum Virol** 1999 Jan-Feb;2(1):8–18
Changes in circulating levels of HIV, CD4, and tissue expression of HIV in a patient with recent-onset ulcerative colitis treated by surgery. Case report. Silver S, et al. **J Hum Virol** 1999 Jan-Feb;2(1):52–7
Venom anyone? Researchers tweak "bad" compounds into good medicines [news] Volkers N. **J Natl Cancer Inst** 1999 Apr 21;91(8):667–8
Development of HIV encephalitis in AIDS and TNF-alpha regulatory elements. Sato-Matsumura KC, et al. **J Neuroimmunol** 1998 Nov 2;91(1–2):89–92
Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. Gasnault J, et al. **J Neurovirol** 1999 Aug;5(4):421–9
SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells. Barbouche R, et al. **J Pept Sci** 1998 Dec;4(8):479–85
Thoracic computed tomography of patients infected with the human immunodeficiency virus: relevance for the course of disease. Knollmann FD, et al. **J Thorac Imaging** 1999 Jul;14(3):185–93
Bovine immunodeficiency virus and analogies with human immunodeficiency virus. Straub OC, et al. **Leukemia** 1999 Apr;13 Suppl 1:S106–9
Casual household transmission of human immunodeficiency virus. Razel M. **Med Hypotheses** 1998 Aug;51(2):115–24
The importance of doing HIV research in developing countries. Morris L, et al. **Nat Med** 1998 Nov;4(11):1228–9
Due process or French farce? [editorial] **Nature** 1999 Feb 18;397(6720):545
Anomalies in French blood inquiry over 'misleading' report [news] Butler D. **Nature** 1999 Mar 4;398(6722):3
Dating the origin of HIV-1 subtypes [letter] Goudsmit J, et al. **Nature** 1999 Jul 22;400(6742):325–6
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Schifitto G, et al. **Neurology** 1999 Jul 22;53(2):391–6
Follow-up essential for positive home HIV test results [news] **Oncology (Huntingt)** 1999 Jan;13(1):81
French AIDS research pioneers to testify in trial of ministers [news] Balter M. **Science** 1999 Feb 12;283(5404):910–1
Effect of heating human sera at a temperature necessary to deactivate human immunodeficiency virus on measurement of free phenytoin, free valproic acid, and free carbamazepine concentrations. Dasgupta A, et al. **Ther Drug Monit** 1999 Aug;21(4):421–5
B cells malignantly transformed by human immunodeficiency virus are polyclonal. Rodriguez-Alfageme C, et al. **Virology** 1998 Dec 5;252(1):34–8
[Viral vasculitis not related to HBV, HCV and HIV] Lortholary O, et al. **Pathol Biol (Paris)** 1999 Mar; 47(3):248–51 (38 ref.) (Eng. Abstr.) **(Fre)**
[Risk of accidental contamination by the human immunodeficiency virus (HIV): review and management] Conquy S, et al. **Prog Urol** 1999 Apr;9(2):330–41 (Eng. Abstr.) **(Fre)**
[HIV research: the interim report from Chicago (news)] **Dtsch Med Wochenschr** 1999 Mar 19;124(11):A7 **(Ger)**

[HIV and glycosylation] Nakata M, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2567-73 (25 ref.) **(Jpn)**

CHEMISTRY

Analysis of HIV by entropy evolution rate. Sato K, et al. **Amino Acids** 1998;14(4):343-52

Towards the structure of the human immunodeficiency virus: divide and conquer. Wilk T, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):231-43 (97 ref.)

Structural similarities between influenza virus matrix protein M1 and human immunodeficiency virus matrix and capsid proteins: an evolutionary link between negative-stranded RNA viruses and retroviruses. Harris A, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):863-9

Structural biology of HIV. Turner BG, et al. **J Mol Biol** 1999 Jan 8;285(1):1-32 (321 ref.)

Viral gene screen. Netting J. **Sci Am** 1999 Aug;281(2):31-2

CLASSIFICATION

HIV vaccine development: a subtype E-specific strategy. Brown AE, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):377-82 (30 ref.)

[A new type of HIV (news)] De Giuseppe R. **Recenti Prog Med** 1998 Dec;89(12):686 **(Ita)**

DRUG EFFECTS

Higher antiviral activity of antiretroviral regimens including protease inhibitors [letter] de Mendoza C, et al. **AIDS** 1999 May 28;13(8):998-9

Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications [editorial] Friedman SR, et al. **AIDS** 1998 Nov 12;12(16):2089-93 (37 ref.)

HIV suppression and risk of drug resistance mutations [letter] Phillips AN, et al. **AIDS** 1998 Oct 1;12(14):1930

The need for microbicides: why aren't women's groups more involved in the fight against AIDS? Wainberg MA. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):405-6

Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients. Zanussi S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20; 15(2):97-103

HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. Pomerantz RJ. **Am Fam Physician** 1999 May 15;59(10):2855

Protease inhibitors--worldwide use? [news] **Am J Nurs** 1999 Jun;99(6):17

In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Tuntland T, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):198-206

Pharmacologic considerations for therapeutic success with antiretroviral agents. Fletcher CV. **Ann Pharmacother** 1999 Sep;33(9):989-95 (35 ref.)

Gynecomastia with stavudine treatment in an HIV-positive patient [letter] Melbourne KM, et al. **Ann Pharmacother** 1998 Oct;32(10):1108

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Daelemans D, et al. **Antivir Chem Chemother** 1999 Jan;10(1):1-14 (131 ref.)

Isolation and characterization of the fungal metabolite 3-O-methylviridicatin as an inhibitor of tumour necrosis factor alpha-induced human immunodeficiency virus replication. Heguy A, et al. **Antivir Chem Chemother** 1998 Mar;9(2):149-55

A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Colgrove R, et al. **Antiviral Res** 1999 Feb;41(1):45-56 (45 ref.)

Recent developments in HIV protease inhibitor therapy. Molla A, et al. **Antiviral Res** 1998 Jul;39(1):1-23 (98 ref.)

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Balzarini J. **Biochem Pharmacol** 1999 Jul 1;58(1):1-27 (219 ref.)

Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand. Patel NM, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):931-4

Blocking HIV co-receptors by chemokines. Virelizier JL. **Dev Biol Stand** 1999;97:105-9 (15 ref.)

Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. Kurowski M, et al. **Eur J Med Res** 1999 Mar 26;4(3):101-4

Ethanol treatment of tendon allografts: a potential HIV inactivating procedure. Anastasescou M, et al. **Int Orthop** 1998;22(4):252-4

Feglymycin, a novel inhibitor of the replication of the human immunodeficiency virus. Fermentation, isolation and structure elucidation. Vértesy L, et al. **J Antibiot (Tokyo)** 1999 Apr;52(4):374-82

Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus. Jung D, et al. **J Clin Pharmacol** 1998 Nov;38(11):1021-4

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. Jung D, et al. **J Clin Pharmacol** 1998 Nov;38(11):1057-62

Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine. Medina DJ, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2361-7

What's new in HIV. Morris-Jones S, et al. **J Infect** 1999 Mar;38(2):i-ii

How I encourage my patients to take their antiretroviral therapy regularly. Walsh J. **J Infect** 1999 Mar;38(2):ii

Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. Yang F, et al. **J Mol Biol** 1999 May 7;288(3):403-12

The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. Austin DJ, et al. **J Theor Biol** 1998 Oct 7;194(3):313-39

HIV drug resistance testing shows promise [news] Stephenson J. **JAMA** 1999 Jan 27;281(4):309-10

Adherence to HAART in HIV [letter] [see comments] Lazzarini L, et al. **Lancet** 1999 Mar 6;353(9155):841. Comment in: Lancet 1999 Jun 5;353(9168):1974.

Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Ding AA, et al. **Math Biosci** 1999 Aug;160(1):63-82

New drug makes host cell machinery unavailable to HIV [news] Senior K. **Mol Med Today** 1999 Jun;5(6):234-5

Nailing down another HIV target [news; comment] Richman DD. **Nat Med** 1998 Nov;4(11):1232-3. Comment on: Nat Med 1998 Nov;4(11):1302- 7.

The use of HIV resistance assays--random or randomised? [editorial] Loveday C, et al. **Sex Transm Infect** 1999 Jun; 75(3):140-1

Resistance--clinical significance and diagnostics. Puchhammer-Stöckl E. **Wien Med Wochenschr** 1998; 148(23-24):556-9 (28 ref.)

[HIV 1998: eradication dreams?] Vernazza PL. **Schweiz Med Wochenschr** 1998 Dec 26;128(51-52):2019-22 (0 ref.) **(Ger)**

[Incorporation of the test of resistance to antiretroviral drugs in clinical practice (editorial)] Soriano V, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):412-5 **(Spa)**

[Tests to detect resistance to antiretroviral agents in clinical practice] Seriano Vázquez V, et al. **Rev Clin Esp** 1999 Mar; 199(3):179-83 (21 ref.) **(Spa)**

ENZYMOLOGY

Human DNA polymerases and retroviral reverse transcriptases: selectivity in respect to dNTPs modified at triphosphate residues. Victorova LS, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):1031-2

GENETICS

The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. Cozzi Lepri A, et al. **AIDS** 1998 Sep 10;12(13):1639-43

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. Race E, et al. **AIDS** 1998 Aug 20;12(12):1465-74

High frequency of the 3'A mutation of the SDF-1 gene in Cambodia [letter] Rousset D, et al. **AIDS** 1999 Feb 25; 13(3):420-1

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Daelemans D, et al. **Antivir Chem Chemother** 1999 Jan;10(1):1-14 (131 ref.)

Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense. Player MR, et al. **Antivir Chem Chemother** 1998 May;9(3):225-31

The ins and outs of HIV Rev. Hope TJ. **Arch Biochem Biophys** 1999 May 15;365(2):186-91 (66 ref.)

Further characterization of HIV RNA synthesis early after cell-to-cell transmission infection. Kok TW, et al. **Arch Virol** 1998;143(10):1911-26

Specificity in the binding of aminoglycosides to HIV-RRE RNA. Cho J, et al. **Biochemistry** 1999 Jun 29; 38(26):8548-54

HIV. Genetic effects on immunity immunity to infection. Web alert. Greaves DR. **Curr Opin Immunol** 1998 Aug; 10(4):377-8

Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting. Pérez-Olmeda M, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):448-9

MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes. Lodge R, et al. **Gene Ther** 1998 May;5(5):655-64

HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Dragoni F, et al. **Haematologica** 1999 Jun;84(6):525-9

Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal. Götte M, et al. **J Biol Chem** 1999 Apr 16;274(16):11159-69

Variations in HIV-RNA viral load and CD4 counts of infants and children receiving antiretroviral drug therapy [letter] Sever JL, et al. **J Clin Virol** 1999 Jan;12(1):71-4

A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. Shinohara K, et al. **J Gen Virol** 1999 May;80 (Pt 5):1231-40

Sequence requirements for incorporation of human immunodeficiency virus gag-beta-galactosidase fusion proteins into virus-like particles. Wang CT, et al. **J Med Virol** 1999 Oct;59(2):180-8

Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. Isel C, et al. **J Mol Biol** 1999 Jul 30;290(5):929-41

Codon bias and mutability in HIV sequences. Stephens CR, et al. **J Mol Evol** 1999 Apr;48(4):390-7

The 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. Butsch M, et al. **J Virol** 1999 Jun; 73(6):4847-55

Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. Herrmann CH, et al. **J Virol** 1998 Dec;72(12):9881-8

Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes. Pérez-Gracia T, et al. **Liver** 1999 Aug;19(4):288-93

The differential infectivity and staged progression models for the transmission of HIV. Hyman JM, et al. **Math Biosci** 1999 Feb;155(2):77-109

Integration complexes derived from HIV vectors for rapid assays in vitro. Hansen MS, et al. **Nat Biotechnol** 1999 Jun; 17(6):578-82

Intra-tRNA distance measurements for nucleocapsid proteindependent tRNA unwinding during priming of HIV reverse transcription. Chan B, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):459-64

HIV evolutionary genetics [comment] Rodrigo AG. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10559-61 (25 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10752-7. Comment on: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10758-63.

Linkage disequilibrium test implies a large effective population number for HIV in vivo [see comments] Rouzine IM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10758-63. Comment in: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10559-61.

Lentiviral vectors--the promise of gene therapy within reach? Amado RG, et al. **Science** 1999 Jul 30; 285(5428):674-6

Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Miyoshi H, et al. **Science** 1999 Jan 29;283(5402):682-6

Gene therapy. Treating with HIV. Sikorski R, et al. **Science** 1998 Nov 20;282(5393):1438

HIV strain analysis debuts in murder trial [news] Vogel G. **Science** 1998 Oct 30;282(5390):851,853

[New biological monitoring of HIV infection] Morand-Joubert L. **Rev Prat** 1998 Mar 1;48(5):472-7 **(Fre)**

GROWTH & DEVELOPMENT

Ongoing HIV dissemination during HAART. Grossman Z, et al. **Nat Med** 1999 Oct;5(10):1099-104

IMMUNOLOGY

First AIDS vaccine trial in Africa [news] **Am J Nurs** 1999 Jun;99(6):17

Increase in the immunogenicity of HIV peptide antigens by chemical linkage to polytuftsin (TKPR40). Gokulan K, et al. **DNA Cell Biol** 1999 Aug;18(8):623-30

Human immunodeficiency virus and the hematopoietic repertoire: implications for gene therapy. Panoskaltsis N, et al. **Front Biosci** 1999 May 1;4:D457-67 (110 ref.)

A mathematical analysis of the spread of HIV/AIDS in Japan [published erratum appears in IMA J Math Appl Med Biol 1999 Mar;16(1):111-2] Kakehashi M. **IMA J Math Appl Med Biol** 1998 Dec;15(4):299-311

HIV-induced immunopathogenesis. Shearer GM. **Immunity** 1998 Nov;9(5):587-93 (59 ref.)

Proceedings of the 2nd International Summit Meeting on Immunological Correlates of Protection from HIV Infection and Disease. Oxford, United Kingdom, 17-20 April 1998. **Immunol Lett** 1999 Mar;66(1-3):1-228

Immune correlates of protection from HIV and AIDS - more answers but yet more questions. Heeney JL, et al. **Immunol Today** 1999 Jun;20(6):247-51

Lysis of HIV envelope glycoprotein-expressing cells by CD4+ T lymphocytes from chimpanzees [letter] Ohnimus H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):207-13

Central serous chorioretinopathy and HIV. Spalding JM. **J Am Optom Assoc** 1999 Jun;70(6):391-8

The challenge of immune control of immunodeficiency virus [comment] Richman D. **J Clin Invest** 1999 Sep;104(6):677-8 . Comment on: J Clin Invest 1999 Sep;104(6):R13-18.

Differential effects of CD28 costimulation on HIV production by CD4+ cells. Barker E, et al. **J Immunol** 1998 Dec 1;161(11):6223-7

Up-regulation of CCR2 chemokine receptor expression and increased susceptibility to the multitropic HIV strain 89.6 in monocytes exposed to glucocorticoid hormones. Penton-Rol G, et al. **J Immunol** 1999 Sep 15;163(6):3524-9

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. Bernard NF, et al. **J Infect Dis** 1999 Mar;179(3):538-47

Impaired phagocyte oxidative capacity in human immunodeficiency virus-infected children. Hayani KC, et al. **J Infect Dis** 1999 Mar;179(3):584-9

Presence of circulating CTL induced by infection with

wild-type or attenuated SIV and their correlation with protection from pathogenic SHIV challenge. Vogel TU, et al. **J Med Primatol** 1998 Apr-Jun;27(2-3):65-72

Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. Woodberry T, et al. **J Virol** 1999 Jul;73(7):5320-5

Anti-CD34+ Fabs generated against hematopoietic stem cells in HIV-derived combinatorial immunoglobulin library suggest antigen-selected autoantibodies. Rubinstein DB, et al. **Mol Immunol** 1998 Oct;35(14-15):955-64

T-cell induced pathogenesis in HIV: bystander effects and latent infection. Krakauer DC, et al. **Proc R Soc Lond B Biol Sci** 1999 May 22;266(1423):1069-75

Research of antigen and antibodies from retroviruses, CMV and HBV among prisoners of the penitentiary complex of the region of Campinas, SP, Brazil. Osti NM, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):209-13

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Hanke T, et al. **Vaccine** 1999 Feb 12;17(6):589-96

ISOLATION & PURIFICATION

Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care [letter] Dickinson BP, et al. **AIDS** 1998 Oct 22;12(15):2075-6

The conundrum of early HIV infection [editorial; comment] Siwek J, et al. **Am Fam Physician** 1999 Aug;60(2):417-8. Comment on: Am Fam Physician 1999 Aug;60(2):535-42, 545-6.

Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Twigg HL, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1439-44

Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II (HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results. Carneiro-Proietti AB, et al. **Haemophilia** 1998 Jan; 4(1):47-50

HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Lazzi S, et al. **Hum Pathol** 1998 Nov;29(11):1285-9

Dr. P. C. Sen Memorial Award Paper. A study of HIV infection in thalassaemia patients of rural Bengal. Sur D, et al. **Indian J Public Health** 1998 Jul-Sep;42(3):81-7

Effect of a single bout of acute exercise on plasma human immunodeficiency virus RNA levels. Roubenoff R, et al. **J Appl Physiol** 1999 Apr;86(4):1197-201

Effect of splenectomy on T-cell subsets and plasma HIV viral titers in HIV-infected patients. Bernard NF, et al. **J Hum Virol** 1998 Jul-Aug;1(5):338-45

Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women [see comments] Palefsky JM, et al. **J Natl Cancer Inst** 1999 Feb 3;91(3):226-36. Comment in: J Natl Cancer Inst 1999 Feb 3;91(3):200-1.

Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing. Lefrère JJ, et al. **J Virol Methods** 1999 Jun;80(1):33-44

Indian welfare minister orders compulsory HIV testing for children in care [news] Sharma DC. **Lancet** 1999 Jan 30; 353(9150):390

Human immunodeficiency virus-rich multinucleated giant cells in the colon: a case report with transmission electron microscopy, immunohistochemistry, and in situ hybridization. Lewin-Smith M, et al. **Mod Pathol** 1999 Jan; 12(1):75-81

Chromosomal proviral sequences of human immunodeficiency virus in multiple thymic cell types in a patient with acquired immunodeficiency syndrome and massive thymic hyperplasia. Fisher RG, et al. **Pediatr Infect Dis J** 1998 Nov;17(11):1050-2

Plasma hypercoagulability is correlated to plasma HIV load [letter] Karmochkine M, et al. **Thromb Haemost** 1998 Jul; 80(1):208-9

HIV in leprosy patients. Burns SM. **Trop Doct** 1999 Apr; 29(2):126-7

Magnetoliposomes may be useful for elimination of HIV from infected individuals. Babincová M, et al. **Z Naturforsch [C]** 1998 Sep-Oct;53(9-10):935-6

[DuPont-Pharma Laboratories. Sustiva (news)] **Allerg Immunol (Paris)** 1998 Nov;30(9):302 **(Fre)**

[Lymphoid hyperplasia associated with human immunodeficiency virus and Epstein-Barr virus; relationship with lymphomatous pathology] Raphaël M, et al. **Ann Pathol** 1998 Oct;18(4):325-30 (61 ref.) **(Fre)**

[A method of isothermal gene amplification] David F, et al. **C R Acad Sci III** 1998 Nov;321(11):909-14 (Eng. Abstr.) **(Fre)**

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412-5 (Eng. Abstr.) **(Fre)**

METABOLISM

Altered expression of CD4, CD54, CD62L, and CCR5 in primary lymphocytes productively infected with the human immunodeficiency virus. Marodon G, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):161-71

The ins and outs of HIV Rev. Hope TJ. **Arch Biochem Biophys** 1999 May 15;365(2):186-91 (66 ref.)

Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Soda Y, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):313-21

Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. Selig L, et al. **J Virol** 1999 Jan; 73(1):592-600

Activation of Ste20 by Nef from human immunodeficiency virus induces cytoskeletal rearrangements and downstream effector functions in Saccharomyces cerevisiae. Plemenitas A, et al. **Virology** 1999 Jun 5;258(2):271-81

PATHOGENICITY

Mechanism of HIV pathogenesis: role of superantigens in disease. Torres BA, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):188S-192S (58 ref.)

Role of human immunodeficiency virus in primary pulmonary hypertension--case reports. Pellicelli AM, et al. **Angiology** 1998 Dec;49(12):1005-11

Pathology of human immunodeficiency virus infection: noninfectious conditions. Klassen MK, et al. **Ann Diagn Pathol** 1997 Oct;1(1):57-64 (58 ref.)

HIV: a new role for Nef in the spread of HIV. Harris M. **Curr Biol** 1999 Jun 17;9(12):R459-61 (12 ref.)

Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine [see comments] Alioum A, et al. **Epidemiology** 1998 Nov;9(6):605-12. Comment in: Epidemiology 1998 Nov;9(6):590-3.

Temporal trends in the progression of human immunodeficiency virus disease in a cohort of drug users. Webber MP, et al. **Epidemiology** 1998 Nov;9(6):613-7

HIV as the cause of AIDS and associated diseases [comment] Galéa P, et al. **Genetica** 1998;104(2):133-42 (113 ref.). Comment on: Genetica 1998 ;104(2):85-132.

HIV nef: the mother of all evil? Peter F. **Immunity** 1998 Oct;9(4):433-7 (49 ref.)

Does HIV cause depletion of CD4+ T cells in vivo by the induction of apoptosis? Jaworowski A, et al. **Immunol Cell Biol** 1999 Feb;77(1):90-8 (107 ref.)

A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. Shinohara K, et al. **J Gen Virol** 1999 May;80 (Pt 5):1231-40

Long-term non-progression in HIV infection: definitions and epidemiological issues. Easterbrook PJ. **J Infect** 1999 Mar; 38(2):71-3 (13 ref.)

Long-term non-progression in HIV infection: clinico pathological issues. Rowland-Jones S. **J Infect** 1999 Mar; 38(2):67-70 (26 ref.)

T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. Miller CJ, et al. **J Infect Dis** 1999 May;179 Suppl 3:S413-7

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. Ten Haaft P, et al. **J Virol** 1998 Dec;72(12):10281-5

An HIV-resistant allele is exceptionally frequent in New Guinean highlanders [letter] Su B, et al. **JAMA** 1998 Dec 2;280(21):1830

Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. Tan WY, et al. **Math Biosci** 1999 Mar 1;156(1-2):69-94

HIV-1 envelope determinants for cell tropism and chemokine receptor use. Hoffman TL, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):57-65 (106 ref.)

The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Wodarz D, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 22;265(1411):2149-58

Researchers urged not to inject virulent HIV strain into chimps [news; comment] Cohen J. **Science** 1999 Feb 19; 283(5405):1090-1. Comment on: Science 1999 Feb 19;283(5405):1117-8.

Virulent HIV strains, chimpanzees, and trial vaccines [letter] [see comments] Prince AM, et al. **Science** 1999 Feb 19; 283(5405):1117-8. Comment in: Science 1999 Feb 19;283(5405):1090-1.

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Fleming DT, et al. **Sex Transm Infect** 1999 Feb;75(1):3-17 (81 ref.)

PHYSIOLOGY

HIV entry and tropism. When one receptor is not enough. Berger EA. **Adv Exp Med Biol** 1998;452:151-7 (39 ref.)

HIV transmission and immune protection at mucosal surfaces. Neutra MR. **Adv Exp Med Biol** 1998;452:169-75 (60 ref.)

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. Foudraine NA, et al. **AIDS** 1998 Aug 20;12(12):1513-9

Dichotomous effects of macrophage-derived chemokine on HIV infection [letter] Moriuchi H, et al. **AIDS** 1999 May 28;13(8):994-6

The role of dendritic cells in the infection of CD4+ T cells with the human immunodeficiency virus: use of dendritic cells from individuals homozygous for the delta32CCR5 allele as a model. Dybul M, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1109-13

The numerous effector functions of Nef. Marsh JW. **Arch Biochem Biophys** 1999 May 15;365(2):192-8 (150 ref.)

Endogenous salivary inhibitors of human immunodeficiency virus. Shugars DC, et al. **Arch Oral Biol** 1999 Jun; 44(6):445-53 (68 ref.)

The world of HIV and disease, and some new approaches to block it. Gallo R. **Bull Mem Acad R Med Belg** 1998; 153(7-9):339-42

HIV: a new role for Nef in the spread of HIV. Harris M. **Curr Biol** 1999 Jun 17;9(12):R459-61 (12 ref.)

Blocking HIV co-receptors by chemokines. Virelizier JL. **Dev Biol Stand** 1999;97:105-9 (15 ref.)

Restricted replication of non-syncytium-inducing HIV in Th1 and Th2 lymphocytes. Poli G, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):95-6 (10 ref.)

Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Poli G. **Eur J Clin Invest** 1999 Aug; 29(8):723-32 (126 ref.)

Transgenic mice expressing human HIV receptors become persistently recipient of HIV DNA after injection with infected human cell lines. Simeoni L, et al. **Folia Microbiol (Praha)** 1998;43(5):525-6

Anti-apoptotic strategies of lymphotropic viruses. Meinl E, et al. **Immunol Today** 1998 Oct;19(10):474-9 (55 ref.)

Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Wolday D, et al. **Infect Immun** 1999 Oct;67(10):5258-64

Potential risk of enhancing survival of infected cells [letter; comment] LeGrand EK. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1698. Comment on: J Am Vet Med Assoc 1998 Oct 1;213(7):991-2.

Human immunodeficiency virus induction of corticotropin in lymphoid cells. Hashemi FB, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4373-81

Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. Cicala C, et al. **J Immunol** 1999 Jul 1;163(1):420-6

HIV coreceptors. Dimitrov DS, et al. **J Membr Biol** 1998 Nov 15;166(2):75-90 (111 ref.)

Dynamics of macrophage and T cell infection by HIV. Wodarz D, et al. **J Theor Biol** 1999 Jan 7;196(1):101-13

Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. Herrmann CH, et al. **J Virol** 1998 Dec;72(12):9881-8

Potential use of a caspase against HIV. Finkel TH. **JAMA** 1999 Sep 15;282(11):1021-2

Strategies used by human immunodeficiency virus that allow persistent viral replication. Desrosiers RC. **Nat Med** 1999 Jul;5(7):723-5 (43 ref.)

The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Wodarz D, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 22;265(1411):2149-58

Host-fungal interactions in HIV infection. Levitz SM. **Res Immunol** 1998 May-Jun;149(4-5):489-93; discussion 516-7 (50 ref.)

HIV's early home and inner life [news] Balter M. **Science** 1998 Nov 27;282(5394):1630-1

Can IL-2 smoke out HIV reservoirs? [news] WIlliams N. **Science** 1998 Nov 20;282(5393):1394-5

The role of chemokine receptors in HIV infection. Rowland-Jones S. **Sex Transm Infect** 1999 Jun;75(3):148-51 (40 ref.)

Is the AIDS incubation time changing? A back-calculation approach. Deuffic S, et al. **Stat Med** 1999 May 15; 18(9):1031-47

The gut-associated lymphoid tissue: a major site of HIV replication and CD4 cell loss. Kraehenbuhl JP. **Trends Microbiol** 1998 Nov;6(11):419-20; discussion 420-1

Noncytolytic HIV immunity. Slifka MK. **Trends Microbiol** 1999 Apr;7(4):143

Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist. Schols D. **Verh K Acad Geneeskd Belg** 1999;61(4):551-64

[Latent infection in exposed high-risk persons (news)] Volkert R. **Dtsch Med Wochenschr** 1999 Mar 19;124(11):A8 **(Ger)**

[HIV infection. Virus resistance: development and prevention] Link R, et al. **Med Monatsschr Pharm** 1999 Mar;22(3):86-8 **(Ger)**

[Cell tropism of HIV] Koyanagi Y. **Uirusu** 1998 Dec; 48(2):153-61 (56 ref.) **(Jpn)**

RADIATION EFFECTS

Sterilization of HIV with irradiation: relevance to infected bone allografts. Campbell DG, et al. **Aust N Z J Surg** 1999 Jul;69(7):517-21

ULTRASTRUCTURE

Towards the structure of the human immunodeficiency virus: divide and conquer. Wilk T, et al. **Curr Opin Struct Biol** 1999 Apr;9(2):231-43 (97 ref.)

HIV ANTIBODIES

see related

AIDS SERODIAGNOSIS

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. Jiang S, et al. **J Virol** 1998 Dec;72(12):10213-7

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. Parren PW, et al. **J Virol** 1998 Dec;72(12):10270-4

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Spenlehauer C, et al. **J Virol** 1998 Dec; 72(12):9855-64

ANALYSIS

Compartmentalization of the IgG immune response to HIV-1 in breast milk. Becquart P, et al. **AIDS** 1999 Jul 30; 13(11):1323-31

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Carotenuto P, et al. **AIDS** 1998 Sep 10; 12(13):1591-600

Detection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection. Rich JD, et al. **AIDS** 1998 Dec 3;12(17):2345-50

Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Vardinon N, et al. **Am J Kidney Dis** 1999 Jul;34(1):146-9

Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients. Chia WK, et al. **Br J Haematol** 1998 Dec;103(4):1014-22

A simple saliva-based test for detecting antibodies to human immunodeficiency virus. Schramm W, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):577-80

Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2. Ng KP, et al. **Int J STD AIDS** 1999 Jun;10(6):401-4

Sensitive enzyme immunoassay of antibodies to HIV-1 p17 antigen using indirectly immobilized recombinant p17 for diagnosis of HIV-1 infection. Ishikawa S, et al. **J Clin Lab Anal** 1998;12(6):343-50

Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and western blot assays using serum, gingival-crevicular transudate, and urine samples. Martinez PM, et al. **J Clin Microbiol** 1999 Apr;37(4):1100-6

Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. Raux M, et al. **J Immunol Methods** 1999 Jan 1;222(1-2):111-24

CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection [letter] Williams SB, et al. **J Infect Dis** 1999 May;179(5):1310-2

[Immunoenzyme system for detection of antibodies in their complexes with HIV-1 antigens] Abelian AV, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):189-92 **(Rus)**

[Evaluation of indirect immunofluorescence as a supplementary test for the diagnosis of HIV-1 infection] Ceballos A, et al. **Rev Argent Microbiol** 1998 Apr-Jun; 30(2):59-63 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines. Coëffier E, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1023-34

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. Montefiori DC, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):689-98

Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1341-3

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. Salmon-Céron D, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):633-45

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. Tartaglia J, et al. **AIDS Res Hum Retroviruses** 1998 Oct; 14 Suppl 3:S291-8 (58 ref.)

The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Sasaki S, et al. **Anticancer Res** 1998 Sep-Oct; 18(5D):3907-15 (77 ref.)

Selective alterations of the antibody response to HIV-1. Juompan L, et al. **Appl Biochem Biotechnol** 1998 Oct; 75(1):139-50 (81 ref.)

Increase in the immunogenicity of HIV peptide antigens by chemical linkage to polytuftsin (TKPR40). Gokulan K, et al. **DNA Cell Biol** 1999 Aug;18(8):623-30

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):93-103

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. Ferko B, et al. **J Infect Dis** 1998 Nov; 178(5):1359-68

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. Loomis-Price LD, et al. **J Infect Dis** 1998 Nov;178(5):1306-16

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. Richmond JF, et al. **J Virol** 1998 Nov;72(11):9092-100

Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies. Vu HM, et al. **J Virol** 1999 Jan; 73(1):746-50

Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. Giraud A, et al. **J Virol Methods** 1999 Apr;79(1):75-84

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma [see comments] Igarashi T, et al. **Nat Med** 1999 Feb;5(2):211-6. Comment in: Nat Med 1999 Feb;5(2):142-4.

HIV-1 neutralizing antibodies: how full is the bottle? [news; comment] Moore JP, et al. **Nat Med** 1999 Feb;5(2):142-4 . Comment on: Nat Med 1999 Feb;5(2):204-10. Comment on: Nat Med 1999 Feb;5(2):211-6.

Neutralizing antibodies in Brazilian sera against three strains of human immunodeficiency virus type 1 (HIV-1). Machado AA, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov-Dec;39(6):319-22

AIDS vaccines. Glimmerings of hope from the bottom of the well [news] Cohen J. **Science** 1999 Jul 30; 285(5428):656-7

Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Fernández IM, et al. **Vaccine** 1998 Dec; 16(20):1936-40

Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Lundholm P, et al. **Vaccine** 1999 Apr 9;17(15-16):2036-42

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Mrsny RJ, et al. **Vaccine** 1999 Mar 17; 17(11-12):1425-33

The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM, et al. **Virology** 1998 Nov 10; 251(1):59-70

BLOOD

Diagnosis of HIV-1/2 dual infection using dilution analysis of type-specific antibody [letter] Ariyoshi K, et al. **AIDS** 1998 Dec 24;12(18):2504-5

Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing [letter] Diaz RS, et al. **AIDS** 1999 Jul 30;13(11):1417-8

Decline of anti-DP107 antibody associated with clinical progression [letter] Hattori T, et al. **AIDS** 1998 Aug 20; 12(12):1557-9

HIV-1 group O virus infection in Abidjan, Côte d'Ivoire [letter] Nkengasong J, et al. **AIDS** 1998 Aug 20; 12(12):1565-6

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy [letter] Rice PS, et al. **AIDS** 1999 Apr 16; 13(6):729-31

HIV incidence among repeat HIV testers with sexually transmitted diseases in Italy. STD Surveillance Working Group. Suligoi B, et al. **AIDS** 1999 May 7;13(7):845-50

Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):43-50

Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. Metlas R, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):671-7

Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. Popper SJ, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1157-62

HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice. Scott DE, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1263-9

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117-24; discussion 125-6 (43 ref.)

Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Ciesielski CA, et al. **Am J Med** 1997 May 19;102(5B):115-6 (11 ref.)

The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of HIV infection: its expression and purification in E. coli by use of a translation initiation site within HIV-1 env gene. Han B, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):607-17

Evaluation of screening kits for the detection of anti-human immunodeficiency virus type 1 and 2 (HIV-1/2) antibodies. Chin LT, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Aug;28(3):179-92

Incidence of human immunodeficiency virus antibody in a prenatal population at a community hospital. Alexander TS, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):140-1

HIV antibody tests and viral load--more unanswered questions and a further plea for clarification. Papadopulos-Eleopulos E, et al. **Curr Med Res Opin** 1998; 14(3):185-6

Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cameron PU, et al. **Cytometry** 1998 Sep 1;33(1):83-8

Antibodies against peripheral myelin glycolipids in people with HIV infection. Petratos S, et al. **Immunol Cell Biol** 1998 Dec;76(6):535-41

Increasing prevalence of HIV antibody among blood donors monitored over 9 years in one blood bank. Rose D, et al. **Indian J Med Res** 1998 Aug;108:42-4

Screening for human immunodeficiency virus type 1 and 2 in a Turkish blood donor population. Altuglu I, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):202-4

Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):259-65

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):315-20

Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen. Hashida S, et al. **J Clin Lab Anal** 1998;12(6):329-36

Use of indirectly immobilized recombinant p17 antigen for detection of antibodies to HIV-1 by enzyme immunoassay. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(1):9-18

Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. Arai H, et al. **J Clin Microbiol** 1999 Feb;37(2):367-70

Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2. Vallari AS, et al. **J Clin Microbiol** 1998 Dec;36(12):3657-61

Isoelectricfocusing and reverse blotting as a diagnostic tool in pediatric HIV infection. del Bono V, et al. **J Clin Virol** 1998 Dec;11(3):203-10

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine [see comments] Zagury JF, et al. **J Hum Virol** 1998 May-Jun;1(4):282-92. Comment in: J Hum Virol 1998 May-Jun;1(4):249-50.

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. Scala G, et al. **J Immunol** 1999 May 15; 162(10):6155-61

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. Cecilia D, et al. **J Infect Dis** 1999 Jun;179(6):1365-74

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. Mazzoli S, et al. **J Infect Dis** 1999 Sep;180(3):871-5

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection. Heeney JL, et al. **J Med Primatol** 1998 Apr-Jun;27(2-3):50-8

Simple/rapid test devices for anti-HIV screening: do they come up to the mark? Giles RE, et al. **J Med Virol** 1999 Sep;59(1):104-9

False negativity by an anti-HIV assay kit (IMx 8B32) and evaluation of its replacement (IMx 8C98). Parry JV, et al. **J Med Virol** 1998 Oct;56(2):138-44

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943-51

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM, et al. **J Virol** 1998 Dec;72(12):9656-67

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. VanCott TC, et al. **J Virol** 1999 Jun;73(6):4640-50

Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II. van Binsbergen J, et al. **J Virol Methods** 1998 Dec; 76(1-2):59-71

Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Dobbins JG, et al. **Sex Transm Dis** 1999 Feb;26(2):67-74

A prime-boost regime that combines Montanide ISA720 and

Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9. Raya NE, et al. **Vaccine** 1999 Jun 4;17(20-21):2646-50

The importance of simple/rapid assays in HIV testing. **Wkly Epidemiol Rec** 1998 Oct 16;73(42):321-6 **(Eng, Fre)**

[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)] Yerly S, et al. **Schweiz Med Wochenschr** 1999 Feb 27; 129(8):319-22 (Eng. Abstr.) **(Ger)**

[Evaluation of a new screening assay kit for the combined detection of HIV p24 antigen and antibody--comparison of the performance of the new kit and HIV antibody assay kits] Hayashi T, et al. **Kansenshogaku Zasshi** 1999 Jul; 73(7):681-8 (Eng. Abstr.) **(Jpn)**

[The establishment of screening system for HIV and Chlamydia trachomatis antibodies among pregnant women in Nagasaki] Yamamoto T, et al. **Nippon Koshu Eisei Zasshi** 1999 Apr;46(4):304-10 **(Jpn)**

[The organization of the work to determine antibodies to the human immunodeficiency virus in the Republic of Byelarus] Meleshko LA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):63-4 (Eng. Abstr.) **(Rus)**

[Anonymous serological screening for HIV infection in umbilical cord blood by the pooled-batch system] Ochoa Sangrador C, et al. **An Esp Pediatr** 1999 Jun;50(6):603-6 (Eng. Abstr.) **(Spa)**

[The detection of antibodies against HIV-1 24-kd protein. A clinico-serological correlation] Diaz Torres H, et al. **Rev Cubana Med Trop** 1996;48(3):188-91 (Eng. Abstr.) **(Spa)**

[The determination of antibodies to the human immunodeficiency virus type 1 (HIV-1) in samples of dried blood on filter paper] Pérez Guevara MT, et al. **Rev Cubana Med Trop** 1998;50(2):93-5 (Eng. Abstr.) **(Spa)**

[The serological diagnosis of HIV-1 in samples of dried blood on filter paper by the HIV-1 DAVIH Dot system] Sánchez RG, et al. **Rev Cubana Med Trop** 1998;50(3):221-2 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. Fontenot JD, et al. **AIDS** 1998 Aug 20;12(12):1413-8

Structural studies of HIV-1 protease-inhibiting antibodies. Lescar J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:3-6

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6-8

Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. Metlas R, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):266-70

Backbone and C beta assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide [letter] Tugarinov V, et al. **J Biomol NMR** 1999 Feb;13(2):193-4

Structural basis of the gp120 superantigen-binding site on human immunoglobulins. Karray S, et al. **J Immunol** 1998 Dec 15;161(12):6681-8

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V, et al. **Nat Struct Biol** 1999 Apr; 6(4):331-5

GENETICS

Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. Kunert R, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1; 14(13):1115-28

Intrabodies to human immunodeficiency virus type 1 [comment] Paillard F. **Hum Gene Ther** 1999 Jun 10; 10(9):1425-7. Comment on: Hum Gene Ther 1999 Jun 10;10(9):1453-67.

IMMUNOLOGY

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Kaul R, et al. **AIDS** 1999 Jan 14; 13(1):23-9

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **AIDS** 1999 Jan 14;13(1):31-9

Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS, et al. **AIDS** 1999 Jan 14;13(1):89-96

Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. Brand D, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1369-77

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. Gorse GJ, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):921-30

Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. Hioe CE, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):523-31

Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. Joag SV, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):391-4

Inhibition of the anti-V3 loop response to a recombinant gp120SF2 vaccine by preexisting monoclonal antibody. Keller MA, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):855-60

Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype. McNicholl JM, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1457-71

Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. Metlas R, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):671-7

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. Quinnan GV Jr, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):561-70

Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. Schønning K, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1451-6

DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Asakura Y, et al. **Biol Chem** 1999 Mar; 380(3):375-9

Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry. Millar AL, et al. **Eur J Biochem** 1998 Nov 15;258(1):164-9

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. Juompan L, et al. **FASEB J** 1998 Nov;12(14):1473-80

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies [see comments] Mhashilkar AM, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1453-67. Comment in: Hum Gene Ther 1999 Jun 10;10(9):1425-7.

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A, et al. **Hybridoma** 1999 Apr;18(2):149-57

Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. Mühlbacher M, et al. **Immunobiology** 1999 Jun;200(2):295-305

Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45. Chen YH, et al. **Immunol Lett** 1999 Aug 3;69(2):253-7

Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1). Laisney IL, et al. **Immunol Lett** 1999 Apr 15;67(3):185-92

Antibody neutralization of HIV-1 and the potential for vaccine design. Sattentau QJ, et al. **Immunol Lett** 1999 Mar; 66(1-3):143-9 (116 ref.)

Three-dimensional conformation of the epitopes of human superoxide dismutase-2 recognized by antibody against HIV-1p17. Kato T, et al. **Int J Mol Med** 1998 Jan;1(1):63-6

Salivary sIgA response in HIV-1 infection. Skott P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):73-80

Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies [letter] Kohler H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):315-6

Antibodies to the CD4-binding site of HIV-1 gp120 in patients infected by variants belonging to the M or O group [letter] Turbica I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):95-7

Anti-HIV-1 seroreactivity and HIV transmission route[R1]. The HEC/FIOCRUZ AIDS Clinical Research Group. Bongertz V, et al. **J Clin Virol** 1999 Jan;12(1):27-36

Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. Björling E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1987-93

Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire. de Haard JJ, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2883-94

Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. Jackson NA, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):225-36

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP, et al. **J Infect Dis** 1999 May;179(5):1264-7

Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. Lathey JL, et al. **J Infect Dis** 1999 Aug;180(2):344-50

Neutralization of HIV-1 subtypes: implications for vaccine formulations. Smith TL, et al. **J Med Virol** 1998 Nov; 56(3):264-8

NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies. Tsang P, et al. **J Mol Recognit** 1997 Nov-Dec;10(6):256-61

Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins. Krsmanovic V, et al. **J Pept Res** 1998 Nov;52(5):410-20

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. Tyler DS, et al. **J Surg Res** 1998 Oct;79(2):115-20

Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. Beddows S, et al. **J Virol** 1999 Feb;73(2):1740-5

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Cheng-Mayer C, et al. **J Virol** 1999 Jul;73(7):5294-300

Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase. Ishikawa T, et al. **J Virol** 1999 May;73(5):4475-80

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Mascola JR, et al. **J Virol** 1999 May;73(5):4009-18

Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. Schønning K, et al. **J Virol** 1999 Oct;73(10):8364-70

Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. Zhang PF, et al. **J Virol** 1999 Jun;73(6):5225-30

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. Zolla-Pazner S, et al. **J Virol** 1999 May;73(5):4042-51

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27-38

Selecting antibodies that block the HIV-1 coreceptor [news] Dorrell S. **Mol Med Today** 1998 Dec;4(12):507

Selection and characterization of two specific monoclonal antibodies directed against the two variants of human herpesvirus-6. Robert C, et al. **Res Virol** 1998 Nov-Dec; 149(6):403-11

Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Llorente M, et al. **Scand J Immunol** 1999 Sep;50(3):270-9

Fusion-competent vaccines: broad neutralization of primary isolates of HIV [see comments] LaCasse RA, et al. **Science** 1999 Jan 15;283(5400):357-62. Comment in: Science 1999 Jan 15;283(5400):336-7.

HIV vaccines. Magic of the occult? [see comments] Montefiori D, et al. **Science** 1999 Jan 15;283(5400):336-7 . Comment in: Science 1999 Jan 15;283(5400):357-62.

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Pinter A, et al. **Vaccine** 1998 Nov; 16(19):1803-11

[A functional model of the central epitope of the V3 loop of HIV-1 gp120 when complexed with antibodies] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Nov-Dec; 32(6):1062-74 **(Rus)**

ISOLATION & PURIFICATION

Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Bos OJ, et al. **Biologicals** 1998 Dec;26(4):267-76

Sero-prevalence of HIV antibodies in tuberculosis patients in Ile-Ife, Nigeria. Onipede AO, et al. **East Afr Med J** 1999 Mar;76(3):127-32

Comparison of three assays for HIV antibodies detection in urine to be applied to epidemiological setting. Carducci A, et al. **Eur J Epidemiol** 1999 Jul;15(6):545-8

A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits. Galéa P, et al. **Vaccine** 1999 Mar 17;17(11-12):1454-61

METABOLISM

A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. Jiang S, et al. **J Virol Methods** 1999 Jun;80(1):85-96

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V, et al. **Nat Struct Biol** 1999 Apr; 6(4):331-5

HIV ANTIBODIES

PHARMACOLOGY

Conformational aspects of HIV-1 integrase inhibition by a peptide derived from the enzyme central domain and by antibodies raised against this peptide. Maroun RG, et al. **Eur J Biochem** 1999 Feb;260(1):145-55

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6-8

Inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Jun;18(3):235-41

Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Apr;18(2):139-47

Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120 C1 or C4 region. Kröpelin M, et al. **Immunol Lett** 1998 Aug; 63(1):19-25

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. Frankel SS, et al. **J Virol** 1998 Dec;72(12):9788-94

THERAPEUTIC USE

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. Stiehm ER, et al. **J Infect Dis** 1999 Mar;179(3):567-75

URINE

Urine-based test to detect HIV antibodies [news] **Am Fam Physician** 1998 Oct 1;58(5):1222

Comparison of three assays for HIV antibodies detection in urine to be applied to epidemiological setting. Carducci A, et al. **Eur J Epidemiol** 1999 Jul;15(6):545-8

HIV ANTIBODY POSITIVITY see **HIV SEROPOSITIVITY**

HIV ANTIGENS

Use of indirectly immobilized recombinant p17 antigen for detection of antibodies to HIV-1 by enzyme immunoassay. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(1):9-18

Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. Nyambi PN, et al. **J Virol** 1998 Nov;72(11):9384-91

[Immunoenzyme system for detection of antibodies in their complexes with HIV-1 antigens] Abelian AV, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):189-92 **(Rus)**

ANALYSIS

Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. Orendi JM, et al. **J Infect Dis** 1998 Nov;178(5):1279-87

Immunohistochemical retrieval of the principal HIV antigens p24, gp41, and gp120 in formalin fixed tissue: an investigation using HIV infected lymphoblasts and postmortem brain tissue from AIDS cases. Morrison HL, et al. **Mol Pathol** 1998 Aug;51(4):227-31

BLOOD

[Evaluation of a new screening assay kit for the combined detection of HIV p24 antigen and antibody—comparison of the performance of the new kit and HIV antibody assay kits] Hayashi T, et al. **Kansenshogaku Zasshi** 1999 Jul; 73(7):681-8 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2. Skott P, et al. **Viral Immunol** 1999;12(1):79-88

GENETICS

Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. Birk M, et al. **AIDS** 1998 Oct 22; 12(15):1973-81

Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. Goudsmit J, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1483-6

Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission. Hahn T, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):875-88

The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. Price DA, et al. **J Mol Med** 1998 Sep;76(10):699-708 (91 ref.)

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943-51

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Spenlehauer C, et al. **J Virol** 1998 Dec; 72(12):9855-64

IMMUNOLOGY

Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. Popper SJ, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1157-62

The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of HIV infection: its expression and purification in E. coli by use of a translation initiation site within HIV-1 env gene. Han B, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):607-17

Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Hart DJ, et al. **Biol Psychiatry** 1999 Mar 15;45(6):704-14

Increase in the immunogenicity of HIV peptide antigens by chemical linkage to polytuftsin (TKPR40). Gokulan K, et al. **DNA Cell Biol** 1999 Aug;18(8):623-30

Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Apr;18(2):139-47

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A, et al. **Hybridoma** 1999 Apr;18(2):149-57

Evaluation of the affinity measurement of anti-HIV-1 p17 monoclonal antibody by BIAcore. Ota A, et al. **Hybridoma** 1998 Oct;17(5):471-7

Modulation of major histocompatibility complex antigen expression by human immunodeficiency virus-2 gp36. Chen YH, et al. **Immunol Lett** 1999 Jun 1;68(2-3):415-7

The implications of antigenic diversity for vaccine development. Zolla-Pazner S, et al. **Immunol Lett** 1999 Mar;66(1-3):159-64 (49 ref.)

Three-dimensional conformation of the epitopes of human superoxide dismutase-2 recognized by antibody against HIV-1p17. Kato T, et al. **Int J Mol Med** 1998 Jan;1(1):63-6

Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen. Hashida S, et al. **J Clin Lab Anal** 1998;12(6):329-36

Sensitive enzyme immunoassay of antibodies to HIV-1 p17 antigen using indirectly immobilized recombinant p17 for diagnosis of HIV-1 infection. Ishikawa S, et al. **J Clin Lab Anal** 1998;12(6):343-50

Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. Björling E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1987-93

Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. Harrer T, et al. **J Immunol** 1998 Nov 1; 161(9):4875-81

Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. Lynch JA, et al. **J Infect Dis** 1998 Oct;178(4):1040-6

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. Rinaldo Jr CR, et al. **J Infect Dis** 1999 Feb;179(2):329-36

Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death. Aladdin H, et al. **Scand J Immunol** 1999 Aug; 50(2):223-7

Fusion-competent vaccines: broad neutralization of primary isolates of HIV [see comments] LaCasse RA, et al. **Science** 1999 Jan 15;283(5400):357-62. Comment in: Science 1999 Jan 15;283(5400):336-7.

HIV vaccines. Magic of the occult? [see comments] Montefiori D, et al. **Science** 1999 Jan 15;283(5400):336-7 . Comment in: Science 1999 Jan 15;283(5400):357-62.

The role of anchor residues in the binding of peptides to HLA-A*1101 molecules. Chujoh Y, et al. **Tissue Antigens** 1998 Dec;52(6):501-9

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, et al. **Vaccine** 1999 Jan; 17(1):64-71

METABOLISM

Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix. Wilson SA, et al. **Biochem J** 1999 Aug 15;342 (Pt 1):97-103

HEED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. Peytavi R, et al. **J Biol Chem** 1999 Jan 15;274(3):1635-45

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. Ferris RL, et al. **J Immunol** 1999 Feb 1;162(3):1324-32

Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. Cimarelli A, et al. **J Virol** 1999 Jul; 73(7):5388-401

PHYSIOLOGY

Formation and release of virus-like particles by HIV-1 matrix protein [letter] Wang JJ, et al. **AIDS** 1999 Feb 4; 13(2):281-3

Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. Ono A, et al. **J Virol** 1999 May;73(5):4136-44

Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. Kootstra NA, et al. **Virology** 1999 Jan 20;253(2):170-80

HIV-ASSOCIATED ANTIBODIES see **HIV ANTIBODIES**

HIV-ASSOCIATED ANTIGENS see **HIV ANTIGENS**

HIV-ASSOCIATED COGNITIVE MOTOR COMPLEX see **AIDS DEMENTIA COMPLEX**

HIV-ASSOCIATED ENTEROPATHY see **HIV ENTEROPATHY**

HIV-ASSOCIATED NEPHROPATHY see **AIDS-ASSOCIATED NEPHROPATHY**

HIV CORE PROTEIN P24

ANALYSIS

HIV-1 (p24)-positive multinucleated giant cells in HIV-associated lymphoepithelial lesion of the parotid gland. A report of two cases. Vicandi B, et al. **Acta Cytol** 1999 Mar-Apr;43(2):247-51

Similar proviral load but increased HIV-1 p24 in the intestinal mucosa compared to the peripheral blood in HIV-infected patients. Schmidt W, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:276-9

HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Bell JE, et al. **Brain** 1998 Nov;121 (Pt 11):2043-52

[Determination of HIV protein 24 in feces of Triatoma infestans fed with blood from AIDS patients] Nuzzo SF, et al. **Rev Saude Publica** 1998 Oct;32(5):464-6 (Eng. Abstr.) **(Por)**

BIOSYNTHESIS

Dissolved oxygen concentration affects the accumulation of HIV-1 recombinant proteins in Escherichia coli. Qoronfleh MW. **Appl Biochem Biotechnol** 1999 May;80(2):107-20

CD8+ lymphocyte-mediated suppression of human immunodeficiency virus type 1 expression in human brain cells. Lokensgard JR, et al. **Immunol Lett** 1999 Apr 15; 67(3):257-61

Effect of immune activation induced by Cryptosporidium parvum whole antigen on in vitro human immunodeficiency virus type 1 infection. Xiao L, et al. **J Infect Dis** 1999 Aug;180(2):559-63

BLOOD

Ultrasensitive immune complex transfer enzyme immunoassay of HIV-1 p24 antigen with less serum interference using 2,4-dinitrophenyl-anti-HIV-1 p24 IgG and indirectly immobilized (anti-2,4-dinitrophenyl group) Fab. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(3):126-32

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27-38

Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II. van Binsbergen J, et al. **J Virol Methods** 1998 Dec; 76(1-2):59-71

Multicenter evaluation of a new rapid automated human immunodeficiency virus antigen detection assay. Weber B, et al. **J Virol Methods** 1999 Mar;78(1-2):61-70

A comparison of immunocomplex-dissociated serum HIV-1 p24 antigenemia and plasma HIV-1 viral load: assessment of 3,129 paired assays. Manfredi R, et al. **New Microbiol** 1999 Jul;22(3):269-75

[Cost-benefit analysis of screening strategies by human immunodeficiency virus in French blood donors] Djossou F, et al. **Transfus Clin Biol** 1999 Jun;6(3):180-8 (Eng. Abstr.) **(Fre)**

[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)] Yerly S, et al. **Schweiz Med Wochenschr** 1999 Feb 27; 129(8):319-22 (Eng. Abstr.) **(Ger)**

[Investigation of a new p24 antigen detection system by the chemiluminescence-enzyme-immuno-assay] Sakai A, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):205-12 (Eng. Abstr.) **(Jpn)**

[Value of quantification of p24 antigen in plasma as a prognostic marker of survival in a cohort of 251 HIV-positive patients] Rubio Caballero M, et al. **An Med Interna** 1998 Dec;15(12):647-9 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. Berthet-Colominas C, et al. **EMBO J** 1999 Mar 1; 18(5):1124-36

GENETICS

Interpatient genetic variability of HIV-1 group O. Janssens W, et al. **AIDS** 1999 Jan 14;13(1):41-8

IMMUNOLOGY

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **AIDS** 1999 Jan 14;13(1):31-9

Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. Pontesilli O, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):973-81

Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Welfle K, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):120-31

Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cameron PU, et al. **Cytometry** 1998 Sep 1;33(1):83-8

Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. Wagner R, et al. **J Immunol** 1999 Mar 15;162(6):3727-34

Stepwise transformation of a cholera toxin and a p24 (HIV-1) epitope into D-peptide analogs. Kramer A, et al. **Protein Eng** 1998 Oct;11(10):941-8

Specific immune response to human immunodeficiency virus (HIV)-1 in patients assessed through the production of interferon-gamma and interleukin-4 in HIV-1 p24-activated whole blood cultures: relationship with the viral load in plasma. Hober D, et al. **Scand J Immunol** 1999 Jul;50(1):83-90

[The detection of antibodies against HIV-1 24-kd protein. A clinico-serological correlation] Díaz Torres H, et al. **Rev Cubana Med Trop** 1996;48(3):188-91 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

A simple and robust method for the complete dissociation of HIV-1 p24 and other antigens from immune complexes in serum and plasma samples. Steindl F, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):143-51

[Purification of the natural 24kd (P24) of the type-1 human immunodeficiency virus (HIV-1) using immunoaffinity] Grana Sánchez R, et al. **Rev Cubana Med Trop** 1996; 48(2):98-101 (Eng. Abstr.) **(Spa)**

METABOLISM

Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24. Jason J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20; 15(2):173-81

Studies on binding of HIV-1 p24gag peptide to HLA-Cw3+ cells. Kość A, et al. **Immunol Lett** 1998 Dec;64(2-3):57-62

Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24. Bristow R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):334-6

Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. Liang C, et al. **J Virol** 1999 Jul;73(7):6147-51

Interaction of the capsid protein p24 (HIV-1) with sequence-derived peptides: influence on p24 dimerization. Hilpert K, et al. **Virology** 1999 Feb 1;254(1):6-10

THERAPEUTIC USE

Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. Benson EM, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):105-13

HIV DEMENTIA see **AIDS DEMENTIA COMPLEX**

HIV ENCEPHALOPATHY see **AIDS DEMENTIA COMPLEX**

HIV ENHANCER

see related
HIV LONG TERMINAL REPEAT
NF-KAPPA B

Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site. Verhoef K, et al. **J Virol** 1999 Feb;73(2):1331-40

HIV ENTEROPATHY

COMPLICATIONS

Evaluation of diarrhea in HIV-infected patients. Simon D. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):857-67 (34 ref.)

DIAGNOSIS

Comparison of duodenal with jejunal biopsy and aspirate in chronic human immunodeficiency virus-related diarrhea. Bini EJ, et al. **Am J Gastroenterol** 1998 Oct;93(10):1837-40

Endoscopic approach to HIV-associated diarrhea: how far is far enough? [editorial; comment] Bini EJ. **Am J Gastroenterol** 1999 Mar;94(3):556-9. Comment on: Am J Gastroenterol 1999 Mar;94(3):596-602.

A prospective study of endoscopy in HIV-associated diarrhea [see comments] Kearney DJ, et al. **Am J Gastroenterol** 1999 Mar;94(3):596-602. Comment in: Am J Gastroenterol 1999 Mar;94(3):556-9.

Diagnostic yield and cost-effectiveness of endoscopy in chronic human immunodeficiency virus-related diarrhea. Bini EJ, et al. **Gastrointest Endosc** 1998 Oct;48(4):354-61

MICROBIOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):869-88 (80 ref.)

PARASITOLOGY

Small intestine pathogens in AIDS: conventional and opportunistic. Koch J, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):869-88 (80 ref.)

PATHOLOGY

HIV enteropathy: comparative morphometry of the jejunal mucosa of HIV infected patients resident in the United Kingdom and Uganda. Batman PA, et al. **Gut** 1998 Sep; 43(3):350-5

PHYSIOPATHOLOGY

Correlation of intestinal structure and function in HIV infection. Reka S, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):841-56 (77 ref.)

HIV ENVELOPE PROTEIN GP41

BIOSYNTHESIS

Dissolved oxygen concentration affects the accumulation of HIV-1 recombinant proteins in Escherichia coli. Qoronfleh MW. **Appl Biochem Biotechnol** 1999 May;80(2):107-20

Expression of Chlamydia psittaci- and human immunodeficiency virus-derived antigens on the cell surface of Lactobacillus fermentum BR11 as fusions to bspA. Turner MS, et al. **Infect Immun** 1999 Oct; 67(10):5486-9

BLOOD

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments] Kilby JM, et al. **Nat Med** 1998 Nov; 4(11):1302-7. Comment in: Nat Med 1998 Nov;4(11):1232-3.

CHEMISTRY

Site-specific deuterium order parameters and membrane-bound behavior of a peptide fragment from the intracellular domain of HIV-1 gp41. Koenig BW, et al. **Biochemistry** 1999 May 11;38(19):6327-34

Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model. Shu W, et al. **Biochemistry** 1999 Apr 27;38(17):5378-85

Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs. Mobley PW, et al. **Biochim Biophys Acta** 1999 Apr 14;1418(1):1-18

The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids. Curtain C, et al. **Eur Biophys J** 1999;28(5):427-36

Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1. Implications on viral fusion mechanism. Chang DK, et al. **J Biol Chem** 1999 Feb 26;274(9):5299-309

Determination of the equilibrium micelle-inserting position of the fusion peptide of gp41 of human immunodeficiency virus type 1 at amino acid resolution by exchange broadening of amide proton resonances. Chang DK, et al. **J Biomol NMR** 1998 Nov;12(4):549-52

Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. Debnath AK, et al. **J Med Chem** 1999 Aug 26;42(17):3203-9

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. Jiang S, et al. **J Virol** 1998 Dec;72(12):10213-7

Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. Weng Y, et al. **J Virol** 1998 Dec; 72(12):9676-82

The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. Kim EM, et al. **Mol Cells** 1999 Jun 30;9(3):281-5

The paramyxovirus fusion protein forms an extremely stable core trimer: structural parallels to influenza virus haemagglutinin and HIV-1 gp41. Lamb RA, et al. **Mol Membr Biol** 1999 Jan-Mar;16(1):11-9

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Chan DC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15613-7

Conformational mapping of a viral fusion peptide in structure-promoting solvents using circular dichroism and electrospray mass spectrometry. Waring AJ, et al. **Proteins** 1998;Suppl 2:38-49

DRUG EFFECTS

Development of an in vitro assay system for screening of gp41 inhibitory compounds. Ryu JR, et al. **Mol Cells** 1998 Dec 31;8(6):717-23

GENETICS

Molecular characterization of the envelope transmembrane glycoprotein of 13 new human immunodeficiency virus type 1 group O strains from six different African countries. Bibollet-Ruche F, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1281-5

Phylogeny of HIV type 1 group O isolates based on env gene sequences. Mas A, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):769-73

Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes. Pritsker M, et al. **Biochemistry** 1999 Aug 31;38(35):11359-71

Enhanced HIV-1 envelope-tumor protection by a recombinant vaccinia virus expressing anchored HIV-1 gp120 lacking gp41. Lie H, et al. **Int J Mol Med** 1999 Apr;3(4):397-400

Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. Weng Y, et al. **J Virol** 1998 Dec; 72(12):9676-82

IMMUNOLOGY

Decline of anti-DP107 antibody associated with clinical progression [letter] Hattori T, et al. **AIDS** 1998 Aug 20; 12(12):1557-9

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. Cavacini LA, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1271-80

Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. Mühlbacher M, et al. **Immunobiology** 1999 Jun;200(2):295-305

Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45. Chen YH, et al. **Immunol Lett** 1999 Aug 3;69(2):253-7

A common epitope on gp41, IFN-alpha and IFN-beta induces protective activity [letter] Chen YH, et al. **Immunol Today** 1998 Dec;19(12):586-7

The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. Buratti E, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2709-16

T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. Su SB, et al. **J Immunol** 1999 May 15; 162(10):5924-30

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):93-103

Solid-phase synthesis and on-resin cyclization of a disulfide bond peptide and lactam analogues corresponding to the major antigenic site of HIV gp41 protein. Limal D, et al. **J Pept Res** 1998 Aug;52(2):121-9

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. Jiang S, et al. **J Virol** 1998 Dec;72(12):10213-7

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. Park EJ, et al. **J Virol** 1999 Jul;73(7):5707-13

Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. McInerney TL, et al. **Vaccine** 1999 Mar 17; 17(11-12):1359-68

Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees. Rovinski B, et al. **Virology** 1999 May 10;257(2):438-48

METABOLISM

The C domain of HIV-1 gp41 binds the putative cellular receptor protein P62. Chen YH, et al. **AIDS** 1999 Jun 18; 13(9):1021-4

T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Su SB, et

al. **Blood** 1999 Jun 1;93(11):3885–92

Antigenic characterization of HIV-1 gp41 binding proteins. Chen YH, et al. **Immunol Lett** 1998 Jun;62(2):75–9

Differential binding of IgG and of a HIV gp41 peptide by the B chain and A chain globular head sequences of C1q, respectively. Kojouharova MS, et al. **J Immunol** 1998 Oct 15;161(8):4325–31

Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. Berlioz-Torrent C, et al. **J Virol** 1999 Feb;73(2):1350–61

Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. Merat R, et al. **J Virol** 1999 Jul;73(7):5698–706

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. Muñoz-Barroso I, et al. **J Virol** 1999 Jul;73(7):6089–92

A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. Jiang S, et al. **J Virol Methods** 1999 Jun;80(1):85–96

The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. Kim EM, et al. **Mol Cells** 1999 Jun 30;9(3):281–5

A 60 kD heat-shock protein-like molecule interacts with the HIV transmembrane glycoprotein gp41. Speth C, et al. **Mol Immunol** 1999 Jun;36(9):619–28

Rate and severity of HIV-associated dementia (HAD): correlations with Gp41 and iNOS. Adamson DC, et al. **Mol Med** 1999 Feb;5(2):98–109

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Chan DC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15613–7

[Interaction of peptides of human immunodeficiency viral proteins with continuous cell lines of varying origin] Khromykh LM, et al. **Mol Biol (Mosk)** 1998 Sep-Oct; 32(5):863–8 **(Rus)**

PHARMACOLOGY

Role of lentiviral lytic polypeptide I (LLP-I) in the selective cytotoxicity of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1-producing cells. Kubota S, et al. **Antivir Chem Chemother** 1999 May; 10(3):121–7

Human immunodeficiency virus glycoproteins 160 and 41 alter sleep and brain temperature of rats. Gemma C, et al. **J Neuroimmunol** 1999 Jun 1;97(1–2):94–101

Involvement of adenylate cyclase and p70(S6)-kinase activation in IL-10 up-regulation in human monocytes by gp41 envelope protein of human immunodeficiency virus type 1. Barcova M, et al. **Pflugers Arch** 1999 Mar; 437(4):538–46

PHYSIOLOGY

Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine-based signal and favors cell-to-cell viral transmission. Deschambeault J, et al. **J Virol** 1999 Jun;73(6):5010–7

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. Ji H, et al. **J Virol** 1999 Oct;73(10):8578–86

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. Salzwedel K, et al. **J Virol** 1999 Mar;73(3):2469–80

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments] Kilby JM, et al. **Nat Med** 1998 Nov; 4(11):1302–7. Comment in: Nat Med 1998 Nov;4(11):1232–3.

THERAPEUTIC USE

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments] Kilby JM, et al. **Nat Med** 1998 Nov; 4(11):1302–7. Comment in: Nat Med 1998 Nov;4(11):1232–3.

Nailing down another HIV target [news; comment] Richman DD. **Nat Med** 1998 Nov;4(11):1232–3. Comment on: Nat Med 1998 Nov;4(11):1302– 7.

TOXICITY

Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity. Adamson DC, et al. **J Neurosci** 1999 Jan 1;19(1):64–71

HIV ENVELOPE PROTEIN GP120

see related

PEPTIDE T

Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand. MacQueen KM, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1; 21(3):243–51

ANALYSIS

Expression and detection of macrophage-tropic HIV-1 gp120 in the brain using conformation-dependent antibodies. Altmeyer R, et al. **Virology** 1999 Jul 5; 259(2):314–23

BIOSYNTHESIS

Effect of promoters and signal sequences on the production of secreted HIV-1 gp120 protein in the baculovirus system. Golden A, et al. **Protein Expr Purif** 1998 Oct;14(1):8–12

[HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis] Chen Y, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):120–6 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Analysis of the V3 loop sequences from 12 HIV type 1-infected patients from Colombia, South America. Navas MC, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1141–4

Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana. Sagoe KW, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):775–9

Synthesis of an N-glucoasparagine analog as a building block for a V3-loop glycopeptide from gp120 of HIV-I. Schäfer A, et al. **Carbohydr Res** 1998 Dec;313(2):107–16

The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. Losman B, et al. **FEBS Lett** 1999 Jul 2;454(1–2):47–52

Specific interaction of conformational polypeptides derived from HIV gp120 with human T lymphocyte CD4 receptor. Liu M, et al. **Immunol Lett** 1998 Aug;63(1):27–32

Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). Kwong PD, et al. **J Biol Chem** 1999 Feb 12;274(7):4115–23

Backbone and C beta assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide [letter] Tugarinov V, et al. **J Biomol NMR** 1999 Feb;13(2):193–4

Global and local structural properties of the principal neutralizing determinant of the HIV-1 envelope protein gp120. Andrianov AM. **J Biomol Struct Dyn** 1999 Feb; 16(4):931–53

Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. Li H, et al. **J Mol Biol** 1998;283(1):179–91

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. Barbouche R, et al. **J Pept Res** 1998 Oct;52(4):283–8

Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. Ferrer M, et al. **J Pept Res** 1999 Jul;54(1):32–42

Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection. Dettin M, et al. **J Pept Sci** 1998 Nov;4(7):436–48

"Hidden" dUTPase sequence in human immunodeficiency virus type 1 gp120. Abergel C, et al. **J Virol** 1999 Jan; 73(1):751–3

Nuclear magnetic resonance analysis of solution conformations in C4–V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies. Vu HM, et al. **J Virol** 1999 Jan; 73(1):746–50

Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins. Biller M, et al. **J Virol Methods** 1998 Dec; 76(1–2):87–100

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V, et al. **Nat Struct Biol** 1999 Apr; 6(4):331–5

Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120. Weliky DP, et al. **Nat Struct Biol** 1999 Feb;6(2):141–5

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Wang WK, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4558–62

Molecular dynamics study of the proposed beta-hairpin form of the switch domain from HIV1 gp120 alone and complexed with an inhibitor of CD4 binding. Graf von Stosch A, et al. **Proteins** 1999 Feb 1;34(2):197–205

HIV gp120: double lock strategy foils host defences. Sattentau QJ. **Structure** 1998 Aug 15;6(8):945–9 (27 ref.)

Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Stanfield R, et al. **Structure Fold Des** 1999 Feb 15;7(2):131–42

[Spatial structure of the rp142 peptide containing the immunodominant epitope of the HIV-1 gp120 protein. A theoretical study] Andrianov AM, et al. **Biofizika** 1999 Jan-Feb;44(1):10–7 (Eng. Abstr.) **(Rus)**

[Analysis of the immunologic heterogeneity of HIV-1. II. Effect of amino acid residues, flanking the C-terminus of the central tetrapeptide loop V3 of gp120] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):729–34 **(Rus)**

[Analysis of the immunologic heterogeneity of HIV-1: I. "Arginine-glutamine trigger" in the fourth position of the central tetrapeptide of the V3 loop of gp120] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):717–28 **(Rus)**

[A functional model of the central epitope of the V3 loop of HIV-1 gp120 when complexed with antibodies] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Nov-Dec; 32(6):1062–74 **(Rus)**

CLASSIFICATION

Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. Nkengasong JN, et al. **AIDS** 1998 Aug 20;12(12):1405–12

Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. Candotti D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):309–14

V3 serotyping of HIV-1 infection: correlation with genotyping and limitations. Plantier JC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):432–41

DRUG EFFECTS

Suppression of PrP(Sc)- and HIV-1 gp120 induced neuronal cell death by sulfated colominic acid. Ushijima H, et al. **J Neurovirol** 1999 Jun;5(3):289–99

Role of curdlan sulfate in the production of beta-chemokines and interleukin-16. Naito T, et al. **Med Microbiol Immunol (Berl)** 1998 Jun;187(1):43–8

GENETICS

HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A, et al. **AIDS** 1999 Jul 30; 13(11):1305–11

Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. Nkengasong JN, et al. **AIDS** 1998 Aug 20;12(12):1405–12

V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection [letter] Vallejo A, et al. **AIDS** 1999 Mar 11; 13(4):532–4

Characterization of the V3 region of HIV type 1 isolates from Morocco. Abid M, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1387–9

HIV type 1 sequences with GGC substitution in injecting drug users in Greece. Adwan G, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):679–80

Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. Alaeus A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):889–94

A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda. Buonaguro L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1287–9

HIV type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal, and Western Cape Provinces of South Africa. Engelbrecht S, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):325–8

Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. Goudsmit J, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1483–6

Characterization of V3 loop sequences from HIV type 1 subtype B in South Korea: predominance of the GPGS motif. Kim EY, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):681–6

Subtypes of HIV type 1 circulating in India: partial envelope sequences. Maitra A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):941–4

Phylogeny of HIV type 1 group O isolates based on env gene sequences. Mas A, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):769–73

Characterization of HIV type 1 gp120 V3 region sequences from Ugandan infants. Mellquist JL, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1391–5

Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. Oggioni MR, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):451–9

Genetic characterization of the V3 loop sequences of 21 HIV type 1 Spanish isolates from hemophilia patients. Ortiz M, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1487–90

Phylogenetic examination of HIV type 1 glycoprotein 120-V3 sequences in patients from rural Georgia. Roth WW, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):399–403

Genetic characterization of viral quasispecies in blood and cervical secretions of HIV-1- and HIV-2-infected women. Sankalé JL, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1473–81

Analysis of sequence diversity in the C2-V3 regions of the external glycoproteins of HIV type 1 in Singapore. Se-Thoe SY, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1601–4

Independent evolution of HIV type 1 in different brain regions. Shapshak P, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):811–20

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. Stamatatos L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1129-39

Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies. Toriyoshi H, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1109-20

A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. Van Harmelen JH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):395-8

VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brenneman DE, et al. **Brain Res** 1999 Aug 14; 838(1-2):27-36

Biodiversity and bioseparation of HIV-1 envelope glycoproteins. Shao Y, et al. **Crit Rev Oncog** 1999; 10(1-2):1-16 (50 ref.)

Enhanced HIV-1 envelope-tumor protection by a recombinant vaccinia virus expressing anchored HIV-1 gp120 lacking gp41. Lie H, et al. **Int J Mol Med** 1999 Apr;3(4):397-400

Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. Chen YM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):393-402

Dependencies of substitution steps number on Hamming distance are identical for one-parameter discrete models of both direct and parallel genetic diversity. Shchelkanov MY, et al. **J Biomol Struct Dyn** 1998 Aug;16(1):133-8

Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates. Gartner S, et al. **J Hum Virol** 1997 Nov-Dec;1(1):3-18

Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. Shaheen F, et al. **J Hum Virol** 1999 May-Jun;2(3):154-66

Diversification of subtype E human immunodeficiency virus type 1 env in heterosexual seroconverters from Northern Thailand. Wang Z, et al. **J Infect Dis** 1998 Nov; 178(5):1507-11

Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. Neilson JR, et al. **J Virol** 1999 May;73(5):4393-403

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. Ping LH, et al. **J Virol** 1999 Aug;73(8):6271-81

Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. Sato H, et al. **J Virol** 1999 May;73(5):3551-9

Significance of plasma and peripheral blood mononuclear cell derived HIV-1 sequences in establishing epidemiologic linkage between two individuals multiply exposed to HIV-1. Song JZ, et al. **Microb Pathog** 1999 Jun; 26(6):287-98

Effect of promoters and signal sequences on the production of secreted HIV-1 gp120 protein in the baculovirus system. Golden A, et al. **Protein Expr Purif** 1998 Oct;14(1):8-12

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Mrsny RJ, et al. **Vaccine** 1999 Mar 17; 17(11-12):1425-33

Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. Prljić J, et al. **Vaccine** 1999 Mar 17;17(11-12):1462-7

Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Martinez MA, et al. **Virology** 1999 Apr 10;256(2):180-7

[Subtype and sequence analysis of the C2-V3 region of gp120 genes among HIV-1 strains in Hubei province] Li YW, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug;18(4):217-9 (Eng. Abstr.) **(Chi)**

[Subtype and sequence analysis of the C2-V3 region of gp120 genes among HIV-1 strains in Sichuan province] Qin G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):39-42 (Eng. Abstr.) **(Chi)**

[Sequence analysis on HIV1 env V3 rigion from HIV1 infected intravenous drug users in Ruili city, Yunnan] Wang B, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct;19(5):297-300 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. Bartlett JA, et al. **AIDS** 1998 Jul 30; 12(11):1291-300

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. Belshe RB, et al. **AIDS** 1998 Dec 24; 12(18):2407-15

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. Churdboonchart V, et al. **AIDS** 1998 Aug 20;12(12):1521-7

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. Berman PW. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S277-89 (78 ref.)

Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines. Coëffier E, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1023-34

B7 cosignal potentiates apoptosis of uninfected CD4+ T lymphocytic cell lines primed by HIV envelope proteins. Coito C, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10; 15(6):509-21

Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. Gilljam G, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1; 15(10):899-907

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. Gorse GJ, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):921-30

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Gorse GJ, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):115-32

Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. Hioe CE, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):523-31

Inhibition of the anti-V3 loop response to a recombinant gp120SF2 vaccine by preexisting monoclonal antibody. Keller MA, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):855-60

Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype. McNicholl JM, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1457-71

Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. Metlas R, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):671-7

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. Quinnan GV Jr, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):561-70

Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. Schønning K, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1451-6

HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice. Scott DE, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1263-9

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. Stamatatos L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1129-39

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY, et al. **Biol Chem** 1999 Mar; 380(3):353-64

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F, et al. **Biol Chem** 1999 Mar;380(3):341-52

A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1. Zhang A, et al. **Biol Chem** 1999 Mar; 380(3):365-74

A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Deng X, et al. **Blood** 1999 Aug 15;94(4):1165-73

Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120 [published erratum appears in Eur J Immunol 1996 Feb;29(2):725] Bitton N, et al. **Eur J Immunol** 1998 Dec;28(12):4177-87

Antagonistic activity of HIV-1 T helper peptides flanked by an unrelated carrier protein. Fenoglio D, et al. **Eur J Immunol** 1999 May;29(5):1448-55

Dendritic cells from HIV-1-infected patients naturally express HIV-1 gp120 V3 loop-derived peptide ligands. Fernandez MH, et al. **Eur J Immunol** 1998 Oct; 28(10):3144-53

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. Juompan L, et al. **FASEB J** 1998 Nov;12(14):1473-80

Impact of chimeric immune receptor extracellular protein domains on T cell function. Patel SD, et al. **Gene Ther** 1999 Mar;6(3):412-9

Human monoclonal antibodies to MN-24 peptide of gp 120 HIV-1. Sidorova E. **Hum Antibodies** 1999;9(2):107-10

Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Marasco WA, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1627-42

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A, et al. **Hybridoma** 1999 Apr;18(2):149-57

Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Apr;18(2):139-47

The role of HIV gp120 in the disruption of the immune system. Dalgleish AG, et al. **Immunol Lett** 1999 Mar; 66(1-3):81-7

Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1). Laisney IL, et al. **Immunol Lett** 1999 Apr 15;67(3):185-92

The role of the viral glycoprotein in HIV-1 persistence. McKeating JA, et al. **Immunol Lett** 1999 Jan;65(1-2):63-70 (110 ref.)

The effect of epitope variation on the profile of cytotoxic T lymphocyte responses to the HIV envelope glycoprotein. Kmieciak D, et al. **Int Immunol** 1998 Dec;10(12):1789-99

Evaluation of the serologic response against two consensus V3 loop peptides from human immunodeficiency virus-1 in Cuban patients. Miguez J, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):221-5

Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. Metlas R, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):266-70

Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies [letter] Kohler H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):315-6

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):315-20

Antibodies to the CD4-binding site of HIV-1 gp120 in patients infected by variants belonging to the M or O group [letter] Turbica I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):95-7

Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. Jackson NA, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):225-36

A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. Rodriguez D, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):217-23

Epitope-specific antibody and suppression of autoantibody responses against a hybrid self protein. Lohnas GL, et al. **J Immunol** 1998 Dec 15;161(12):6518-25

HIV-1 envelope gp120 inhibits the monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation. Wang JM, et al. **J Immunol** 1998 Oct 15;161(8):4309-17

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. Evans TG, et al. **J Infect Dis** 1999 Aug;180(2):290-8

Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D. Jones GJ, et al. **J Infect Dis** 1999 Mar; 179(3):558-66

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. Sitz KV, et al. **J Infect Dis** 1999 Apr;179(4):817-24

CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection [letter] Williams SB, et al. **J Infect Dis** 1999 May;179(5):1310-2

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection. Heeney JL, et al. **J Med Primatol** 1998 Apr-Jun;27(2-3):50-8

CD4/GP120mac251 interaction induces phospholipase A2 (PLA2) activation in cynomolgus monkey lymphocytes. Mavoungou E, et al. **J Med Primatol** 1998 Aug; 27(4):193-201

Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera. Lawoko AL, et al. **J Med Virol** 1999 Oct;59(2):169-79

Neutralization of HIV-1 subtypes: implications for vaccine formulations. Smith TL, et al. **J Med Virol** 1998 Nov; 56(3):264-8

NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies. Tsang P, et al. **J Mol Recognit** 1997 Nov-Dec;10(6):256-61

Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins. Krsmanovic V, et al. **J Pept Res** 1998 Nov;52(5):410-20

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. Cleland JL, et al. **J Pharm Sci** 1998 Dec;87(12):1489-95

Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. Beddows S, et al. **J Virol** 1999 Feb;73(2):1740-5

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. Buge SL, et al. **J Virol** 1999 Sep;73(9):7430-40

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Cheng-Mayer C, et al. **J Virol** 1999 Jul;73(7):5294-300

Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. Etemad-Moghadam B, et al. **J Virol** 1999 Oct;73(10):8873-9

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. Park EJ, et al. **J Virol** 1999 Jul;73(7):5707-13

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Spenlehauer C, et al. **J Virol** 1998 Dec; 72(12):9855-64

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM, et al. **J Virol** 1998 Dec;72(12):9656-67

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. VanCott TC, et al. **J Virol** 1999 Jun;73(6):4640-50

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. Verschoor EJ, et al. **J Virol** 1999 Apr; 73(4):3292-300

Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies. Vu HM, et al. **J Virol** 1999 Jan; 73(1):746-50

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. Zolla-Pazner S, et al. **J Virol** 1999 May;73(5):4042-51

The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients. Gerencer M, et al. **Microb Pathog** 1998 Nov; 25(5):253-66

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V, et al. **Nat Struct Biol** 1999 Apr; 6(4):331-5

Structure/antigenicity relationship of cyclic and linear peptides mimicking the V3 loop of HIV2 envelope glycoprotein. Belhadj Jrad B, et al. **Res Virol** 1998 Nov-Dec;149(6):363-73

Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Llorente M, et al. **Scand J Immunol** 1999 Sep;50(3):270-9

Lack of developmental neurotoxicity of MN rgp 120/HIV-1 administered subcutaneously to neonatal rats. Bussiere JL, et al. **Toxicol Sci** 1999 Mar;48(1):90-9

Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes. Chang JS, et al. **Vaccine** 1999 Mar 17;17(11-12):1540-8

The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Moore A, et al. **Vaccine** 1999 Jun 4;17(20-21):2517-27

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Pinter A, et al. **Vaccine** 1998 Nov; 16(19):1803-11

A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Dimitrov DS, et al. **Virology** 1999 Jun 20; 259(1):1-6

The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM, et al. **Virology** 1998 Nov 10; 251(1):59-70

Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Sugiura W, et al. **Virology** 1999 Feb 15;254(2):257-67

[Effect of HIV envelope glycoprotein on the induction of immune dysregulation in HIV infection] Sekigawa I, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Feb;21(1):11-9 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection] Lee S, et al. **Ryumachi** 1998 Oct; 38(5):747-51 (33 ref.) **(Jpn)**

[Human monoclonal antibodies to synthetic viral peptides] Borisova TK, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):172-4 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission. Hayakawa T, et al. **J Med Virol** 1998 Dec;56(4):327-31

METABOLISM

The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate. Jagodzinski PP, et al. **Acta Biochim Pol** 1998;45(3):799-804

The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. Blanco J, et al. **AIDS** 1999 May 28;13(8):909-17

Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. Fontenot JD, et al. **AIDS** 1998 Aug 20;12(12):1413-8

Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies. Golding H, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):149-59

Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope. Lallos LB, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):895-7

Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages [published erratum appears in AIDS Res Hum Retroviruses 1999 Mar 20;15(5):493] Rabehi L, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1605-15

Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. Verrier F, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):731-43

Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry. Zhang X, et al. **Antisense Nucleic Acid Drug Dev** 1998 Dec;8(6):441-50

Characterization of the noncovalent complex of human immunodeficiency virus glycoprotein 120 with its cellular receptor CD4 by matrix-assisted laser desorption/ionization mass spectrometry. Borchers C, et al. **Biochemistry** 1999 Sep 7;38(36):11734-40

Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Zhang W, et al. **Biochemistry** 1999 Jul 20; 38(29):9405-16

Synthetic neoglycolipids for biological applications: correlation between their structures and their interactions with membrane proteins. Rico-Lattes I, et al. **Biochimie** 1998 May-Jun;80(5-6):483-7 (18 ref.)

A CD4-independent interaction of human immunodeficiency virus-1 gp120 with CXCR4 induces their cointernalization, cell signaling, and T-cell chemotaxis. Missé D, et al. **Blood** 1999 Apr 15;93(8):2454-62

Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Cashion MF, et al. **Brain Res** 1999 Mar 20; 822(1-2):26-33

Glucocorticoids interact with gp120 in causing neurotoxicity in striatal cultures. Iyer AM, et al. **Brain Res** 1998 Oct 19;808(2):305-9

Adsorptive endocytosis of HIV-1gp120 by blood-brain barrier is enhanced by lipopolysaccharide. Banks WA, et al. **Exp Neurol** 1999 Mar;156(1):165-71

A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding. Howie SE, et al. **FASEB J** 1999 Mar;13(3):503-11

Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120 C1 or C4 region. Kröpelin M, et al. **Immunol Lett** 1998 Aug; 63(1):19-25

Specific interaction of conformational polypeptides derived from HIV gp120 with human T lymphocyte CD4 receptor. Liu M, et al. **Immunol Lett** 1998 Aug;63(1):27-32

New brominated and halogen-less derivatives and structure-activity relationship of azaphilones inhibiting gp120-CD4 binding. Matsuzaki K, et al. **J Antibiot (Tokyo)** 1998 Nov;51(11):1004-11

Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1. Kozak SL, et al. **J Biol Chem** 1999 Aug 13;274(33):23499-507

A convenient oxidation of natural glycosphingolipids to their "ceramide acids" for neoglycoconjugation. Bovine serum albumin-glycosylceramide acid conjugates as investigative probes for HIV gp120 coat protein-glycosphingolipid interactions. Mylvaganam M, et al. **J Biol Chem** 1999 Jul 16;274(29):20725-32

Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo [see comments] Glushakova S, et al. **J Clin Invest** 1999 Sep; 104(5):R7-R11. Comment in: J Clin Invest 1999 Sep;104(5):531.

Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one [comment] Rollins BJ. **J Clin Invest** 1999 Sep;104(5):531-2. Comment on: J Clin Invest 1999 Sep;104(5):R7-R11.

Mutations in the env gene of human immunodeficiency virus type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells. Dumonceaux J, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1975-82

T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis. Iyengar S, et al. **J Immunol** 1999 May 15;162(10):6263-7

Structural basis of the gp120 superantigen-binding site on human immunoglobulins. Karray S, et al. **J Immunol** 1998 Dec 15;161(12):6681-8

Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma. White J, et al. **J Immunol** 1999 Mar 1;162(5):2671-6

Characterization of lectin-mediated brain uptake of HIV-1 GP120. Banks WA, et al. **J Neurosci Res** 1998 Nov 15; 54(4):522-9

SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells. Barbouche R, et al. **J Pept Sci** 1998 Dec;4(8):479-85

New insights into the interaction between the gp120 and the HIV receptor in human sperm (human.sperm/gp120/galactoglycerolipid/antigalactosylceramide/seminolip id/spermatogonia). Brogi A, et al. **J Reprod Immunol** 1998 Dec;41(1-2):213-31

Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. Doranz BJ, et al. **J Virol** 1999 Apr;73(4):2752-61

Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. Esser MT, et al. **J Virol** 1999 May;73(5):4360-71

Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. Ferrer M, et al. **J Virol** 1999 Jul;73(7):5795-802

CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. Genoud S, et al. **J Virol** 1999 Feb;73(2):1645-8

Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. Hung CS, et al. **J Virol** 1999 Oct;73(10):8216-26

Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. Kato K, et al. **J Virol** 1999 Jul;73(7):5520-6

Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. Merat R, et al. **J Virol** 1999 Jul;73(7):5698-706

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. Muñoz-Barroso I, et al. **J Virol** 1999 Jul;73(7):6089-92

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Olson WC, et al. **J Virol** 1999 May;73(5):4145-55

Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. Vicenzi E, et al. **J Virol** 1999 Sep; 73(9):7515-23

Effects of wheatgerm agglutinin and aging on the regional brain uptake of HIV-1GP120. Banks WA, et al. **Life Sci** 1999;65(1):81-9

The human immunodeficiency virus-1 envelope protein gp120 binds through its V3 sequence to the glycine site of N-methyl-D-aspartate receptors mediating noradrenaline release in the hippocampus. Pattarini R, et al. **Neuroscience** 1998 Nov;87(1):147-57

Tyrosine phosphorylation induced by C4 peptide constructs from HIV Gp120. Liu M, et al. **Peptides** 1999;20(2):185-91

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Wang WK, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4558-62

HIV-1 attachment: another look. Ugolini S, et al. **Trends Microbiol** 1999 Apr;7(4):144-9 (62 ref.)

Enhanced human immunodeficiency virus infection in macrophages by high-molecular-weight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor. Jagodzinski PP, et al. **Viral Immunol** 1999;12(1):23-33

HIV and SIV gp120 binding does not predict coreceptor function. Baik SS, et al. **Virology** 1999 Jul 5;259(2):267-73

Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate. Lee MK, et al. **Virology** 1999 May 10;257(2):290-6

Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop. Sato H, et al. **Virology** 1999 May 10;257(2):491-501

[HIV and glycosylation] Nakata M, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2567-73 (25 ref.) **(Jpn)**

[Interaction of peptides of human immunodeficiency viral proteins with continuous cell lines of varying origin] Khromykh LM, et al. **Mol Biol (Mosk)** 1998 Sep-Oct; 32(5):863-8 **(Rus)**

PHARMACOLOGY

HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. Annunziata P, et al. **AIDS** 1998 Dec 24;12(18):2377-85

The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in

primary macrophage cultures. Seddiki N, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):381–90

HIV–1 gp120 induces the activation of both c–fos and c–jun immediate–early genes in HEL megakaryocytic cells. Gibellini D, et al. **Br J Haematol** 1999 Jan;104(1):81–6

Evidence for a synergistic effect of the HIV–1 envelope protein gp120 and brain–derived neurotrophic factor (BDNF) leading to enhanced expression of somatostatin neurons in aggregate cultures derived from the human fetal cortex. Barnea A, et al. **Brain Res** 1999 Jan 9;815(2):349–57

Glucocorticoid modulation of gp120–induced effects on calcium–dependent degenerative events in primary hippocampal and cortical cultures. Howard SA, et al. **Exp Neurol** 1999 Jul;158(1):164–70

HIV/gp120 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas–L upregulation. Accornero P, et al. **FEBS Lett** 1998 Oct 9; 436(3):461–5

Inhibition of tyrosine kinase activation blocks the down–regulation of CXC chemokine receptor 4 by HIV–1 gp120 in CD4+ T cells. Su SB, et al. **J Immunol** 1999 Jun 15;162(12):7128–32

Chronic systemic administration of tumor necrosis factor alpha and HIV gp120: effects on adult rodent brain and blood–brain barrier. Petito CK, et al. **J Neurovirol** 1999 Jun;5(3):314–8

V3 loop–derived peptide SPC3 inhibits infection of CD4– and galactosylceramide– cells by LAV–2/B. Moulard M, et al. **J Pept Res** 1999 Jun;53(6):647–55

Involvement of interleukin–1beta in the mechanism of human immunodeficiency virus type 1 (HIV–1) recombinant protein gp120–induced apoptosis in the neocortex of rat. Bagetta G, et al. **Neuroscience** 1999;89(4):1051–66

Chemokines and activated macrophages in HIV gp120–induced neuronal apoptosis. Kaul M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8212–6

PHYSIOLOGY

Inhibition of HIV type 1 infectivity by coexpression of a wild–type and a defective glycoprotein 120. Lund OS, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1445–50

Substance abuse and HIV–gp120: are opiates protective? Stefano GB. **Arch Immunol Ther Exp (Warsz)** 1999; 47(2):99–106 (101 ref.)

Cell surface display of human immunodeficiency virus type 1 gp120 on Escherichia coli by using ice nucleation protein. Kwak YD, et al. **Clin Diagn Lab Immunol** 1999 Jul; 6(4):499–503

Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. Nagashunmugam T, et al. **J Infect Dis** 1998 Dec; 178(6):1635–41

V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. Chan SY, et al. **J Virol** 1999 Mar;73(3):2350–8

Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV–1) entry: evidence for CD4–induced interactions between HIV–1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). Hammache D, et al. **J Virol** 1999 Jun;73(6):5244–8

Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. Ohagen A, et al. **J Virol** 1999 Feb;73(2):897–906

T–tropic human immunodeficiency virus type 1 (HIV–1)–derived V3 loop peptides directly bind to CXCR–4 and inhibit T–tropic HIV–1 infection. Sakaida H, et al. **J Virol** 1998 Dec;72(12):9763–70

HIV–1 envelope determinants for cell tropism and chemokine receptor use. Hoffman TL, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):57–65 (106 ref.)

Induction of matrix metalloproteinase–2 in human immunodeficiency virus–1 glycoprotein 120 transgenic mouse brains. Marshall DC, et al. **Neurosci Lett** 1998 Sep 25;254(2):97–100

Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage–operated Ca2+ channels in human immunodeficiency virus type 1 gp120–mediated increases in intracellular Ca2+ in human neurons and astrocytes. Holden CP, et al. **Neuroscience** 1999;91(4):1369–78

Stable exposure of the coreceptor–binding site in a CD4–independent HIV–1 envelope protein. Hoffman TL, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6359–64

Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Shimizu N, et al. **Virology** 1999 Jul 5;259(2):324–33

TOXICITY

Mobilization of intracellular calcium stores participates in the rise of [Ca2+]i and the toxic actions of the HIV coat protein GP120. Medina I, et al. **Eur J Neurosci** 1999 Apr; 11(4):1167–78

The contribution of various NOS gene products to HIV–1 coat protein (gp120)–mediated retinal ganglion cell injury. Dreyer EB, et al. **Invest Ophthalmol Vis Sci** 1999 Apr; 40(5):983–9

Mechanisms of prionSc– and HIV–1 gp120 induced neuronal cell death. Schröder HC, et al. **Neurotoxicology** 1998 Aug–Oct;19(4–5):683–8 (30 ref.)

Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Meucci O, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14500–5

HIV envelope protein gp120 induces neuropeptide Y receptor–mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Kim J, et al. **Regul Pept** 1998 Sep 25;75–76:201–5

HIV ENVELOPE PROTEIN GP160

BIOSYNTHESIS

[HIV–1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis] Chen Y, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):120–6 (Eng. Abstr.) **(Chi)**

CHEMISTRY

A multi–mode chromatographic method for the comparison of the N–glycosylation of a recombinant HIV envelope glycoprotein (gp160s–MN/LAI) purified by two different processes. Taverna M, et al. **J Biotechnol** 1999 Feb 5; 68(1):37–48

GENETICS

Interpatient genetic variability of HIV–1 group O. Janssens W, et al. **AIDS** 1999 Jan 14;13(1):41–8

Gene gun DNA vaccination with Rev–independent synthetic HIV–1 gp160 envelope gene using mammalian codons. Vinner L, et al. **Vaccine** 1999 Apr 23;17(17):2166–75

IMMUNOLOGY

Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. Brand D, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1369–77

Antibody–dependent cellular cytotoxicity in HIV type 1–infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. Cox JH, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):847–54

Lack of in vitro anti–gp160 antibody production is a correlate of nonprogression among HIV type 1–infected individuals. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1341–3

Recombinant vaccinia viruses expressing an immunodominant epitope of HIV–1 envelope protein within an influenza hemagglutinin cassette predominantly prime epitope–specific CD8(+) CTL. Chiba M, et al. **Arch Virol** 1999;144(8):1469–85

Construction and characterization of recombinant VLPs and Semliki–Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F, et al. **Biol Chem** 1999 Mar;380(3):341–52

Immunostimulatory CpG motifs trigger a T helper–1 immune response to human immunodeficiency virus type–1 (HIV–1) gp 160 envelope proteins. Deml L, et al. **Clin Chem Lab Med** 1999 Mar;37(3):199–204

Longitudinal study of antibody reactivity against HIV–1 envelope and a peptide representing a conserved site on Gp41 in HIV–1–infected patients. Mühlbacher M, et al. **Immunobiology** 1999 Jun;200(2):295–305

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV–1 infection: evaluation of the T cell proliferative response. Ratto–Kim S, et al. **J Infect Dis** 1999 Feb; 179(2):337–44

Proliferative responses to human immunodeficiency virus type 1 (HIV–1) gp120 peptides in HIV–1–infected individuals immunized with HIV–1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. Sitz KV, et al. **J Infect Dis** 1999 Apr;179(4):817–24

Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1–immunosuppressive tat and gp160 proteins. Lachgar A, et al. **J Virol** 1999 Feb; 73(2):1447–52

Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. Giraud A, et al. **J Virol Methods** 1999 Apr;79(1):75–84

Immunisation with gp160 in HIV–1 infection [letter] Fiala C, et al. **Lancet** 1999 Sep 11;354(9182):948; discussion 949

Immunisation with gp160 in HIV–1 infection [letter] Pontesilli O, et al. **Lancet** 1999 Sep 11;354(9182):948–9

Therapeutic immunisation with recombinant gp160 in HIV–1 infection: a randomised double–blind placebo–controlled trial. Nordic VAC–04 Study Group [see comments] Sandström E, et al. **Lancet** 1999 May 22;353(9166):1735–42 . Comment in: Lancet 1999 May 22;353(9166):1723–4.

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Belyakov IM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4512–7

A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T–cell responses to a covalently linked carrier protein. Oscherwitz J, et al. **Vaccine** 1999 May 14;17(19):2392–9

A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T–cell epitope in HIV–infected chimpanzees and humans. Nehete PN, et al. **Viral Immunol** 1998;11(3):147–58

METABOLISM

Intracellular degradation of the HIV–1 envelope glycoprotein. Evidence for, and some characteristics of, an endoplasmic reticulum degradation pathway. Courageot J, et al. **Eur J Biochem** 1999 Mar;260(2):482–9

The extracellular processing of HIV–1 envelope glycoprotein gp160 by human plasmin. Okumura Y, et al. **FEBS Lett** 1999 Jan 8;442(1):39–42

Occurrence of an HIV–1 gp160 endoproteolytic activity in low–density vesicles and evidence for a distinct density distribution from endogenously expressed furin and PC7/LPC convertases. Wouters S, et al. **FEBS Lett** 1999 Jul 30;456(1):97–102

Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. Pöhlmann S, et al. **J Gen Virol** 1999 May;80 (Pt 5):1241–51

Replication–competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH–independent pathway. Boritz E, et al. **J Virol** 1999 Aug;73(8):6937–45

Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope–mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. Chabot DJ, et al. **J Virol** 1999 Aug;73(8):6598–609

Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. Merat R, et al. **J Virol** 1999 Jul;73(7):5698–706

Processing and routage of HIV glycoproteins by furin to the cell surface. Moulard M, et al. **Virus Res** 1999 Mar; 60(1):55–65

PHARMACOLOGY

Human immunodeficiency virus glycoproteins 160 and 41 alter sleep and brain temperature of rats. Gemma C, et al. **J Neuroimmunol** 1999 Jun 1;97(1–2):94–101

PHYSIOLOGY

HIV–1 gp160 decreases the K+ voltage–gated current from Jurkat E6.1 T cells by up–phosphorylation. Dellis O, et al. **FEBS Lett** 1999 Jan 25;443(2):187–91

THERAPEUTIC USE

Long–term immunotherapy in HIV infection, combined with short–term antiretroviral treatment. Bratt G, et al. **Int J STD AIDS** 1999 Aug;10(8):514–21

HIV GAG GENE PRODUCT P24 see **HIV CORE PROTEIN P24**

HIV INFECTIONS

see related
LYMPHOMA, AIDS–RELATED

Epidemiology, clinical characteristics and natural history of vertically transmitted human immunodeficiency virus–1 infection in Japan. Akagi K. **Acta Paediatr Jpn** 1998 Oct; 40(5):496–502

Role of chemokine receptors in HIV–1 infection and pathogenesis. Ross TM, et al. **Adv Virus Res** 1999;52:233–67 (151 ref.)

Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV–discordant couples wishing to have children. Kim LU, et al. **AIDS** 1999 Apr 16;13(6):645–51

The changing pattern of admissions to a London hospital of patients with HIV: 1988–1997. Royal Free Centre for HIV Medicine. Mocroft A, et al. **AIDS** 1999 Jul 9; 13(10):1255–61

HIV/AIDS, orphans, and access to school education in a community of Kampala, Uganda [letter] Müller O, et al. **AIDS** 1999 Jan 14;13(1):146–7

Complications of surgery in HIV–infected patients [editorial] Rose DN, et al. **AIDS** 1998 Dec 3;12(17):2243–51 (119 ref.)

The acceptability of a computer HIV/AIDS risk assessment to not–in–treatment drug users. Williams ML, et al. **AIDS Care** 1998 Dec;10(6):701–11

Continuing medical education versus clinic–based STD and HIV education interventions for primary care service providers: replication and extension. Neff JA, et al. **AIDS Educ Prev** 1998 Oct;10(5):417–32

Amphetamine use and its correlates among youths living with HIV. Rotheram–Borus MJ, et al. **AIDS Educ Prev** 1999 Jun;11(3):232–42

Internet resource for physicians who treat patients with HIV [news] **Am Fam Physician** 1999 Feb 15;59(4):746

The changing spectrum of HIV care. Reyes EM, et al. **Am Fam Physician** 1999 Feb 1;59(3):545–8

AAP policy on children with HIV–infected parents. American Academy of Pediatrics [news] Rose VL. **Am Fam Physician** 1999 Apr 1;59(7):2022–3

Evidence that Par–4 participates in the pathogenesis of HIV encephalitis. Kruman II, et al. **Am J Pathol** 1999 Jul; 155(1):39–46

Overview of HIV infection. Temesgen Z.

Ann Allergy Asthma Immunol 1999 Jul;83(1):1-5; quiz 6-7 (33 ref.)
As originally published in 1989: human immunodeficiency virus and the cardiac surgeon: a survey of attitudes. Updated in 1999. Frater RW. **Ann Thorac Surg** 1999 Apr; 67(4):1203-4
Disease progression in HIV-positive women with moderate to severe immunosuppression: the role of depression. Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Vedhara K, et al. **Behav Med** 1999 Spring;25(1):43-7
Infection with HIV-1. Graham BS. **BMJ** 1998 Nov 7; 317(7168):1297-301 (37 ref.)
Are we winning the battle against the human immunodeficiency virus [editorial] Sullivan AK, et al. **Br J Hosp Med** 1998 Nov 19-Dec 9;58(10):486-8
The thoracic surgeon's role in the management of patients with HIV infection and AIDS. DiMaio JM, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):97-111 (42 ref.)
Current concepts in human immunodeficiency virus infection and AIDS. Schwartz SA, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):295-305 (56 ref.)
Tropical infectious diseases in human immunodeficiency virus-infected patients. Karp CL, et al. **Clin Infect Dis** 1999 May;28(5):947-63; quiz 964-5 (120 ref.)
7th German AIDS Conference. Essen, 2-6 June 1999. Abstracts. **Eur J Med Res** 1999 Jun 2;4 Suppl 1:1-74 **(Eng, Ger)**
HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Dragoni F, et al. **Haematologica** 1999 Jun;84(6):525-9
Progression of HIV in haemophilia. Ragni MV. **Haemophilia** 1998 Jul;4(4):601-9 (63 ref.)
Effects of cognitive-behavioral interventions on quality of life in persons with HIV. Eller LS. **Int J Nurs Stud** 1999 Jun;36(3):223-33
4th Annual meeting of the British HIV Association (BHIVA). Oxford, 27-29 March 1998. Abstracts. **Int J STD AIDS** 1998 Oct;9(10):623-44
Frequency of alcohol use and its association with STD/HIV-related risk practices, attitudes and knowledge among an African-American community-recruited sample. Morrison TC, et al. **Int J STD AIDS** 1998 Oct;9(10):608-12
HIV/STD: the women to blame? Knowledge and attitudes among STD clinic attendees in the second decade of HIV/AIDS. Rakwar J, et al. **Int J STD AIDS** 1999 Aug; 10(8):543-7
The clinical load of HIV and AIDS for genitourinary physicians. Shahmanesh M, et al. **Int J STD AIDS** 1998 Oct;9(10):567-70
9th International Conference on Human Retrovirology HTLV and Related Viruses. Kagoshima, Japan, April 5-9, 1999. Abstracts.. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):A1-88
Predictors and risk-taking consequences of drug use among HIV-infected women. Novotná L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):502-7
Critique of research review of attitudes to HIV/AIDS [comment] [see comments] Bennett JA. **J Adv Nurs** 1999 Mar;29(3):770-1. Comment on: J Adv Nurs 1998 Apr;27(4):752-9. Comment in: J Adv Nurs 1999 Jun;29(6):1532-3.
The care of HIV-infected persons: a specialty? [editorial; comment] Carmichael JK. **J Am Board Fam Pract** 1999 Mar-Apr;12(2):178-80. Comment on: J Am Board Fam Pract 1999 Mar-Apr;12(2):115-9.
Sexual practices in a cohort of US women with and without human immunodeficiency virus. HERS Study. HIV Epidemiology Research Study. Zierler S, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):79-83
Healthy pets, healthy people. Wong SK, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):335-8
HIV pioneer stands up for patients' rights. Gardner N. **J Ark Med Soc** 1999 Jul;96(2):52-3
Searching for HIV/AIDS information on the World Wide Web. Mann CE. **J Assoc Nurses AIDS Care** 1999 Mar-Apr; 10(2):79-81
Designing a short-term process evaluation of a wellness center serving persons with HIV/AIDS. Sharts-Hopko NC, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb; 10(1):71-5
Dentists and HIV [letter] McCarthy GM, et al. **J Can Dent Assoc** 1999 Jun;65(6):314, 316
Sexual behavior and AIDS-related knowledge among community college students in Orange County, California. Shapiro J, et al. **J Community Health** 1999 Feb;24(1):29-43
Poor women living with HIV: self-identified needs. Bunting SM, et al. **J Community Health Nurs** 1999;16(1):41-52
A comparison of HIV/AIDS knowledge among high school freshmen and senior students. Hancock T, et al. **J Community Health Nurs** 1999;16(3):151-63
Paediatric HIV infection: a brief review. Bhattacharya MK, et al. **J Indian Med Assoc** 1998 Sep;96(9):279-81
Searching for human herpesvirus 8 antibodies in serum samples from patients infected with human immunodeficiency virus type 1 and blood donors from São Paulo, Brazil [letter] Caterino-de-Araujo A, et al. **J Infect Dis** 1999 Jun;179(6):1591-2
Factors related to family therapists' breaking confidence when clients disclose high-risks-to-HIV/AIDS sexual behaviors. Pais S, et al. **J Marital Fam Ther** 1998 Oct; 24(4):457-72
Evolution of medical services for HIV/AIDS in Thailand. Kunanusont C, et al. **J Med Assoc Thai** 1999 May; 82(5):425-34
International comparison of medical students' perceptions of HIV infection and AIDS. Najem GR, et al. **J Natl Med Assoc** 1998 Dec;90(12):765-74
Nigerian university students' knowledge, perceptions, and behaviours about HIV/AIDS: are these students at risk? Harding AK, et al. **J R Soc Health** 1999 Mar;119(1):23-31
General practice and patient Y. Singh S. **J R Soc Med** 1999 Feb;92(2):94
Caring for children orphaned by AIDS [editorial] Moy R. **J Trop Pediatr** 1999 Apr;45(2):64-5
From the Centers for Disease Control and Prevention. Trends in HIV-related sexual risk behaviors among high school students--selected US cities, 1991-1997. **JAMA** 1999 Jul 21;282(3):228-30
Euthanasia and end-of-life care [letter; comment] Colebunders R, et al. **JAMA** 1999 Apr 28;281(16):1488. Comment on: JAMA 1999 Jan 13;281(2):163-8.
An asymptomatic 41-year-old man with HIV infection, 1 year later. Delbanco T, et al. **JAMA** 1999 Sep 22-29; 282(12):1176
Disability discrimination in America: HIV/AIDS and other health conditions. Gostin LO, et al. **JAMA** 1999 Feb 24; 281(8):745-52
Lessons outside the lecture hall. Reirden DH. **JAMA** 1999 Sep 1;282(9):820-1
Knowledge, attitude and behaviour towards AIDS among educated youth in Lahore, Pakistan. Raza MI, et al. **JPMA J Pak Med Assoc** 1998 Jun;48(6):179-82
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Des Jarlais DC, et al. **Lancet** 1999 May 15; 353(9165):1657-61
HIV/AIDS information overload [letter; comment] Green CW. **Lancet** 1999 Jan 30;353(9150):412. Comment on: Lancet 1998 Dec 5;352(9143):1866.
US Court rules HIV infection confers disability [news] McCarthy M. **Lancet** 1998 Jul 4;352(9121):45
Jonathan Mann's mantle [letter; comment] Schusky RW. **Lancet** 1998 Dec 19-26;352(9145):2025. Comment on: Lancet 1998 Sep 12;352(9131):889.
Popular drama prompts interest in HIV in Japan [news] Watts J. **Lancet** 1998 Dec 5;352(9143):1840
A novel mouse model of HIV-1 disease. Jolicoeur P, et al. **Leukemia** 1999 Apr;13 Suppl 1:S78-80
Training medical students about HIV/AIDS? [letter] Abdullah AS, et al. **Med Educ** 1999 Jun;33(6):472-3
HIV/AIDS and human rights in prison. The Costa Rican experience. Valerio Monge CJ. **Med Law** 1998; 17(2):197-210
Bio-ethical and legal issues in relation to HIV/AIDS: the Uganda experience. Yusuf NK. **Med Law** 1998;17(4):619-24
Trends in HIV-related sexual risk behaviors among high school students--selected U.S. cities, 1991-1997. **MMWR Morb Mortal Wkly Rep** 1999 Jun 4;48(21):440-3
Bragdon v. Abbott: the Americans with Disabilities Act and HIV infection [letter; comment] Greely HT. **N Engl J Med** 1999 Apr 15;340(15):1213-4. Comment on: N Engl J Med 1998 Oct 22;339(17):1255-9.
Poxvirus dilemmas [letter; comment] Hooper C. **N Engl J Med** 1998 Dec 31;339(27):2027-8. Comment on: N Engl J Med 1998 Aug 20;339(8):556-9.
Bragdon v. Abbott: the Americans with Disabilities Act and HIV infection [letter; comment] Neiburger EJ. **N Engl J Med** 1999 Apr 15;340(15):1213; discussion 1213-4 . Comment on: N Engl J Med 1998 Oct 22;339(17):1255-9.
Teens & AIDS. The education gap. Levinson RK. **N J Med** 1999 Jul;96(7):29-31
Knowledge, attitudes and behaviour towards HIV infection among family planning clinic attendees: changes between 1991 and 1997 [see comments] Elliot N, et al. **N Z Med J** 1999 Apr 9;112(1085):121-3. Comment in: N Z Med J 1999 May 28;112(1088):191.
The importance of doing HIV research in developing countries. Morris L, et al. **Nat Med** 1998 Nov;4(11):1228-9
Successful pregnancy in an adolescent with perinatally acquired human immunodeficiency virus. Crane S, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):711 (2 ref.)
Factors associated with Mexico City dentists' willingness to treat AIDS/HIV-positive patients. Irigoyen M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):169-74
Factors associated with utilization of care for oral lesions in HIV disease. Mascarenhas AK, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):708-13
Oral testimonies: the other face of the HIV story. Santiago LE. **P R Health Sci J** 1998 Dec;17(4):375-80
Redefining empowerment and sexual negotiation for women living with HIV. Zorrilla CD, et al. **P R Health Sci J** 1998 Sep;17(3):253-6
Disclosure of illness status to children and adolescents with HIV infection. American Academy of Pediatrics Committee on Pediatrics AIDS. **Pediatrics** 1999 Jan; 103(1):164-6
Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. **Pediatrics** 1999 May; 103(5 Pt 1):1057-60
Unexpected non-HIV causes of death in children born to HIV-infected mothers. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. Starc TJ, et al. **Pediatrics** 1999 Jul;104(1):e6
Planning for children whose parents are dying of HIV/AIDS. American Academy of Pediatrics. Committee on Pediatric AIDS, 1998-1999. Wilfert C, et al. **Pediatrics** 1999 Feb;103(2):509-11
HIV infection and AIDS. Shearer WT. **Prim Care** 1998 Dec; 25(4):759-74 (75 ref.)
A practical method for simultaneously determining the effective burst sizes and cycle times of viruses. Spouge JL, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7017-22
HIV and people with serious mental illness: the public sector's role in reducing HIV risk and improving care. Sullivan G, et al. **Psychiatr Serv** 1999 May;50(5):648-52 (44 ref.)
Simian immunodeficiency virus as a model of human HIV disease. Geretti AM. **Rev Med Virol** 1999 Jan-Mar; 9(1):57-67 (82 ref.)
Prevalence and clinical presentations of arthritis in HIV-positive patients seen at a rheumatology department in Congo-Brazzaville. Bileckot R, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):549-54
All about AIDS [news] Jones JS. **S Afr Med J** 1999 Jun; 89(6):583
Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau. Norrgren H, et al. **Scand J Infect Dis** 1998; 30(4):323-9
Human immunodeficiency virus infection in pregnancy. Minkoff HL. **Semin Perinatol** 1998 Aug;22(4):293-308 (112 ref.)
Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Hershow RC, et al. **Sex Transm Dis** 1998 Nov; 25(10):527-32
Family responses to HIV/AIDS in Mexico. Castro R, et al. **Soc Sci Med** 1998 Nov;47(10):1473-84
The role of the supervisor in training social workers treating HIV infected persons in a hospital. Itzhaky H, et al. **Soc Work Health Care** 1999;29(1):57-74 (32 ref.)
The role of social work in HIV/AIDS clinical trials. Williams JK, et al. **Soc Work Health Care** 1999;29(1):35-56 (19 ref.)
Drug use and HIV risks among migrant workers on the DelMarVa Peninsula. Inciardi JA, et al. **Subst Use Misuse** 1999 Mar-Apr;34(4-5):653-66
The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status. Stenbacka M, et al. **Subst Use Misuse** 1998 Dec; 33(14):2819-34
MedBytes. Franke J. **Tex Med** 1998 Dec;94(12):19
Child labour [news] **Trop Doct** 1999 Jan;29(1):57-8
Infection of rabbits with R29 strain of bovine immunodeficiency virus: virulence, immunosuppression, and progressive mesenteric lymphadenopathy. Kalvatchev Z, et al. **Viral Immunol** 1998;11(3):159-66
[Anesthesiologic aspects in patients with HIV infections] Laursen SB, et al. **Ugeskr Laeger** 1999 Mar 22; 161(12):1744-6 (23 ref.) (Eng. Abstr.) **(Dan)**
[Infectious diseases in 1998] Bricaire F. **Rev Med Interne** 1999 Apr;20(4):365-8 **(Fre)**
[Maternal HIV infection and the anthropometric characteristics of children at birth in Burkina Faso. DITRAME Study Group] Sombié I, et al. **Sante** 1999 May-Jun;9(3):173-7 (Eng. Abstr.) **(Fre)**
[Latent infection in exposed high-risk persons (news)] Volkert R. **Dtsch Med Wochenschr** 1999 Mar 19;124(11):A8 **(Ger)**
[Mental and physical impairment, socio-economic resources and care strategies in people with HIV infection] Mancinelli S, et al. **Ann Ig** 1998 May-Jun;10(3):189-99 (Eng. Abstr.) **(Ita)**
[Hepatitis associated with HIV] Nishiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):117-9 (15 ref.) **(Jpn)**
[Basic results of studying the problem of "AIDS" since 1997] Pokrovskii VI, et al. **Vopr Virusol** 1998 Nov-Dec; 43(6):244-7 **(Rus)**
[Basic results of studies on the problem of AIDS in 1996] Pokrovskii VI, et al. **Vopr Virusol** 1998 Jul-Aug; 43(4):148-51 **(Rus)**
[The legal status of Russian HIV-infected persons] D'iachenko AP. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):100-2 (Eng. Abstr.) **(Rus)**
[HIV infection in aged patients (editorial)] Rodríguez Pascual C. **An Med Interna** 1999 Jun;16(6):271-2 **(Spa)**
[Evaluation of the quality of life in patients with HIV and AIDS infection] Badia X, et al. **Med Clin (Barc)** 1999 May 29;112(19):739-44 (65 ref.) **(Spa)**
[Duration of HIV infection, plasma viremia and CD4+ lymphocyte count (letter; comment)] Cuende y Alberto Alba JI. **Med Clin (Barc)** 1998 Nov 28;111(18):717-8. Comment on: Med Clin (Barc) 1998 Apr 25;110(14):529-31. **(Spa)**
[The 2nd International Seminar on HIV/AIDS Infection in Cuba (editorial)] Tápanes R, et al. **Rev Cubana Med Trop** 1995;47(2):81-2 **(Spa)**

BLOOD

Serum immunoreactive erythropoietin levels and associated

factors amongst HIV-infected children. Allen UD, et al. **AIDS** 1998 Oct 1;12(14):1785-91

Bound leptin is regulated by tumour necrosis factor-alpha in HIV-infected patients: a potential mediator of wasting? [letter] Ockenga J, et al. **AIDS** 1998 Nov 12;12(16):2233-5

Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. Olivero OA, et al. **AIDS** 1999 May 28;13(8):919-25

Detection of high nerve growth factor serum levels in AIDS-related and -unrelated Kaposi's sarcoma patients. Pica F, et al. **AIDS** 1998 Oct 22;12(15):2025-9

Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. Polo S, et al. **AIDS** 1999 Mar 11; 13(4):447-54

Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals. Derdeyn CA, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1063-71

Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. Regamey N, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):803-10

Quantitation of 8 human herpesviruses in peripheral blood of human immunodeficiency virus-infected patients and healthy blood donors by polymerase chain reaction. Hoang MP, et al. **Am J Clin Pathol** 1999 May;111(5):655-9

Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Jahoor F, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E205-11

The acute-phase protein response to human immunodeficiency virus infection in human subjects. Jahoor F, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1092-8

The relationship between asymptomatic human immunodeficiency virus infection and the prevalence and severity of anemia in pregnant Malawian women. van den Broek NR, et al. **Am J Trop Med Hyg** 1998 Dec; 59(6):1004-7

Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. Martinez-Brú C, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):601-8

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Mueller BU, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3187-92

Monitoring adherence to HIV therapy [letter] Tuldrà A, et al. **Arch Intern Med** 1999 Jun 28;159(12):1376-7

Comparison of early events during infection of human and chimpanzee peripheral blood mononuclear cells with HIV-1. Pischinger K, et al. **Arch Virol** 1998; 143(11):2065-76

Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection. Phuapradit W, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):288-92

Immunophenotypic analysis of peripheral blood mononuclear cells undergoing in vitro apoptosis after isolation from human immunodeficiency virus-infected children. McCloskey TW, et al. **Blood** 1998 Dec 1;92(11):4230-7

Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Müller F, et al. **Blood** 1998 Nov 15;92(10):3721-9

IL-6 receptor (CD126/IL-6R) expression is increased on monocytes and B lymphocytes in HIV infection. van der Meijden M, et al. **Cell Immunol** 1998 Dec 15;190(2):156-66

Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects. Kelleher AD, et al. **Clin Exp Immunol** 1999 Jan;115(1):147-52

Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Di Marzio L, et al. **Clin Immunol** 1999 Jul;92(1):103-10

Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. Meroni L, et al. **Clin Immunol** 1999 Sep;92(3):276-84

Pharmacokinetics of zidovudine in infants: a population analysis across studies. Mirochnick M, et al. **Clin Pharmacol Ther** 1999 Jul;66(1):16-24

Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls. Lenkei R, et al. **Cytometry** 1998 Oct 1;33(2):115-22

CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression. Perfetto SP, et al. **Cytometry** 1998 Oct 1;33(2):133-7

Carotenoid status of pregnant women with and without HIV infection in Malawi. Lan Y, et al. **East Afr Med J** 1999 Mar;76(3):133-7

Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. Vandamme AM, et al. **Eur J Clin Invest** 1999 May;29(5):445-52

HIV influence on hematopoiesis at the initial stage of infection. Spada C, et al. **Eur J Haematol** 1998 Oct; 61(4):255-60

Evaluation of serum and urinary estrogen levels in male patients with HIV-infection. Teichmann J, et al. **Eur J Med Res** 1998 Nov 17;3(11):533-7

Different effect of 1,25-dihydroxyvitamin D3 on replication of Mycobacterium avium in monocyte-derived macrophages from human immunodeficiency virus-infected subjects and healthy controls. Haug CJ, et al. **Immunol Lett** 1998 Sep;63(2):107-12

Isolation and transduction of CD34+ cells from small quantities of peripheral blood from HIV-1-infected patients not treated with hemopoietic growth factors. Adams GB, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):1-8

Detection and enumeration of HIV-1-producing cells by ELISPOT (enzyme-linked immunospot) assay. Corne P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):442-7

Eosinophil involvement and serum IgE level in HIV-1-infected children. Onorato J, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):245-7

Effect of a single bout of acute exercise on plasma human immunodeficiency virus RNA levels. Roubenoff R, et al. **J Appl Physiol** 1999 Apr;86(4):1197-201

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. Veldkamp AI, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 30; 727(1-2):151-7

Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. McDermott JL, et al. **J Clin Microbiol** 1999 Jul;37(7):2361-5

Reproducibility and performance of the second-generation branched-DNA assay in routine quantification of human immunodeficiency virus type 1 RNA in plasma. Murphy DG, et al. **J Clin Microbiol** 1999 Mar;37(3):812-4

Anonymous unlinked testing as a sentinel approach: experience in Germany. Siedler A, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:25S-27S

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. Hockett RD, et al. **J Exp Med** 1999 May 17; 189(10):1545-54

Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. Ahmed SD, et al. **J Infect** 1998 Nov; 37(3):248-51

Measurement of plasma HIV viral load--clinical applications. Churchill D, et al. **J Infect** 1999 May;38(3):147-50 (38 ref.)

Protein levels of interleukin-12 p70 holomer, its p40 chain and interferon-gamma during advancing HIV infection. Rockstroh JK, et al. **J Infect** 1998 Nov;37(3):282-6

Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. Broström C, et al. **J Infect Dis** 1999 Jun;179(6):1542-8

In vivo cytokine and neuroendocrine responses to endotoxin in human immunodeficiency virus-infected subjects. da Silva B, et al. **J Infect Dis** 1999 Jul;180(1):106-15

Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. Luque AE, et al. **J Infect Dis** 1999 Jun; 179(6):1405-9

Elevated concentrations of plasma alpha-melanocyte stimulating hormone are associated with reduced disease progression in HIV-infected patients. Airaghi L, et al. **J Lab Clin Med** 1999 Mar;133(3):309-15

Impaired metoclopramide-induced pituitary prolactin release in men with human immunodeficiency virus infection. Parra A, et al. **J Lab Clin Med** 1999 Jan;133(1):70-4

Glycocalicin levels in the plasma of HIV+ patients: an indicator of platelet turnover. Williams SB, et al. **J Lab Clin Med** 1998 Oct;132(4):303-7

Redox and activation status of monocytes from human immunodeficiency virus-infected patients: relationship with viral load. Elbim C, et al. **J Virol** 1999 Jun;73(6):4561-6

Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. Voulgaropoulou F, et al. **J Virol** 1999 Apr;73(4):3497-504

Hyperkalemia in patients infected with the human immunodeficiency virus: involvement of a systemic mechanism. Caramelo C, et al. **Kidney Int** 1999 Jul; 56(1):198-205

Monocyte expression of adhesion molecules in HIV-infected patients: variations according to disease stage and possible pathogenic role. Pillet S, et al. **Lab Invest** 1999 Jul; 79(7):815-22

Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy [letter] Bernard L, et al. **Lancet** 1998 Nov 28;352(9142):1757-8

Interleukin-2 restores natural killer activity inhibited by sera from HIV+ hemophilic patients. Vulcano M, et al. **Medicina (B Aires)** 1999;59(2):162-6

Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Read JS, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):134-42

Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients. Catania A, et al. **Peptides** 1998;19(6):1099-104

Plasma vitamins A and E in HIV-positive patients. Constans J, et al. **Subcell Biochem** 1998;30:145-55 (49 ref.)

Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results. Cardoso MS, et al. **Transfusion** 1998 Oct;38(10):905-7

Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Murthy KK, et al. **Transfusion** 1999 Jul;39(7):688-93

[Hemostasis and human immunodeficiency virus (HIV) infection] Toulon P. **Ann Biol Clin (Paris)** 1998 Mar-Apr; 56(2):153-60 (46 ref.) (Eng. Abstr.) **(Fre)**

[Lipoprotein profile of patients infected with HIV in Côte d'Ivoire] Djessou P, et al. **Bull Soc Pathol Exot** 1999 May; 92(2):107-8 (Eng. Abstr.) **(Fre)**

[The detection of viral hepatitis markers in HIV-infected patients] Kishtanova NA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):36-7 (Eng. Abstr.) **(Rus)**

[Autoantibodies to the thrombocytes and erythrocytes in HIV-infected patients] Kravchenko AV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):78-80 (Eng. Abstr.) **(Rus)**

[The use of a method for the quantitative determination of HIV-1 RNA for assessing the severity and prognosis of the development of the disease] Smol'skaia TT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):57-9 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Cinque P, et al. **AIDS** 1998 Jul 30; 12(11):1327-32

Cerebrospinal fluid S-100b concentrations in patients with HIV infection [letter] Green AJ, et al. **AIDS** 1999 Jan 14; 13(1):139-40

Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. Andersson LM, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1065-9

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Mueller BU, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3187-92

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Moyle GJ, et al. **Clin Infect Dis** 1999 Feb;28(2):403-4

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. Tashima KT, et al. **J Infect Dis** 1999 Sep;180(3):862-4

Interpretation of high levels of HIV-1 RNA in the cerebrospinal fluid (CSF) using amplicor HIV-1 monitor test. Honderlick P, et al. **Pathol Biol (Paris)** 1999 May; 47(5):560-2

CHEMICALLY INDUCED

[CD4+-T-cells are the predominant source of HIV-1 and HIV-2 production in asymptomatic people and AIDS patients with opportunistic infections] van der Ende ME, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230 **(Dut)**

CLASSIFICATION

Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. Kassa E, et al. **AIDS** 1999 Feb 25;13(3):381-9

Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. Vanhems P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1; 21(2):99-106

Revision of HIV center medical staging scale. McCain NL, et al. **J Assoc Nurses AIDS Care** 1998 Sep-Oct;9(5):19-23

Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Scott-Lennox JA, et al. **Med Care** 1999 Sep;37(9):908-25

COMPLICATIONS

Patient-controlled epidural analgesia for postherpetic neuralgia in an HIV-infected patient as a therapeutic ambulatory modality. Kang FC, et al. **Acta Anaesthesiol Sin** 1998 Dec;36(4):235-9

Primary pulmonary hypertension in a patient with HIV infection. Conraads VM, et al. **Acta Cardiol** 1998; 53(6):367-9

Fine needle aspiration of solid tumors in HIV-positive patients [letter] Gattuso P, et al. **Acta Cytol** 1999 May-Jun; 43(3):510-2

Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature. Muñoz-Pérez MA, et al. **Acta Derm Venereol** 1999 Mar; 79(2):153-5 (19 ref.)

Lichen amyloidosis in an HIV-infected Patient. A case report and review of the literature [letter] Vaghjimal A, et al. **Acta Derm Venereol** 1998 Sep;78(5):399 (6 ref.)

Toward a clearer understanding of the link between viral infection of the heart and dilated cardiomyopathy. Saffitz

JE. **Adv Anat Pathol** 1999 May;6(3):154–60
Spectrum of clinical diseases in HIV-infected adults at the Lagos University Teaching Hospital: a five-year experience [1992–1996]. Akinsete I, et al. **Afr J Med Med Sci** 1998 Sep-Dec;27(3–4):147–51
Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. Alexander CS, et al. **AIDS** 1999 May 28;13(8):981–5
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses [letter] Antón P, et al. **AIDS** 1999 Mar 11;13(4):524–5
Plasma HIV viral load in relation to season and to Plasmodium falciparum parasitaemia [letter] Ariyoshi K, et al. **AIDS** 1999 Jun 18;13(9):1145–6
Acute hepatitis in HIV-infected patients during ritonavir treatment [letter] Arribas JR, et al. **AIDS** 1998 Sep 10; 12(13):1722–4
Prevalence and underestimation of pain in HIV-infected patients by physicians: a cross-sectional study in a day care hospital [letter] Bernard N, et al. **AIDS** 1999 Feb 4; 13(2):293–5
Ketoacidosis associated with protease inhibitor therapy [letter] Besson C, et al. **AIDS** 1998 Jul 30;12(11):1399–400
Sweet's syndrome in an HIV-infected patient [letter] Bevilacqua S, et al. **AIDS** 1999 Apr 16;13(6):728–9
New HIV cases attributable to syphilis in the USA: estimates from a simplified transmission model. Chesson HW, et al. **AIDS** 1999 Jul 30;13(11):1387–96
Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. Del Amo J, et al. **AIDS** 1999 Jul 9;13(10):1151–8 (91 ref.)
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Dieleman JP, et al. **AIDS** 1999 Mar 11;13(4):473–8
Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease [letter] Foussat A, et al. **AIDS** 1999 Jan 14;13(1):150–2
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs [editorial] Gonzalez A, et al. **AIDS** 1998 Dec 24;12(18):2365–7
Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997 [letter] Holtzer CD, et al. **AIDS** 1998 Oct 1;12(14):1931–3
Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count [letter] Husak R, et al. **AIDS** 1999 Feb 25;13(3):432–3
HIV prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996. Judd A, et al. **AIDS** 1999 May 7;13(7):833–7
High variability of cytomegalovirus glycoprotein B gene and frequent multiple infections in HIV-infected patients with low CD4 T-cell count [letter] Meyer-König U, et al. **AIDS** 1998 Nov 12;12(16):2228–30
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. Mocroft A, et al. **AIDS** 1999 May 28;13(8):943–50
Treatment of oral candidiasis: a study to determine the clinical response of sodium benzoate compared with nystatin suspension [letter] Moshi AH, et al. **AIDS** 1998 Nov 12;12(16):2237–8
Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients [letter; comment] Orlando G, et al. **AIDS** 1999 Feb 25;13(3):424–5. Comment on: AIDS 1998 Aug 20;12(12):1459–64.
Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-I theory of lipodystrophy? [letter] Padberg J, et al. **AIDS** 1999 Feb 4;13(2):284–5
Reply: Treatment of tuberculosis in HIV-infected patients [letter] Pozniak AL, et al. **AIDS** 1999 Jul 30;13(11):1431–2
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. Renwick N, et al. **AIDS** 1998 Dec 24;12(18):2481–8
Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. Simpson DM, et al. **AIDS** 1998 Dec 24;12(18):2425–32
Marked hypertriglyceridaemia associated with ritonavir therapy [letter] Sullivan AK, et al. **AIDS** 1998 Jul 30; 12(11):1393–4
Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. Taha TE, et al. **AIDS** 1998 Sep 10;12(13):1699–706
Serum antibodies to dietary antigens in patients with HIV-1 infection [letter] Wahnschaffe U, et al. **AIDS** 1998 Aug 20;12(12):1553–5
Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. Woitas RP, et al. **AIDS** 1999 Jul 30;13(11):1313–22
The validation of statements by IDUs based on the analysis of blood traces on their used syringes. Menoyo C, et al. **AIDS Care** 1998 Aug;10(4):409–14
Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients. Snijders F, et al. **AIDS Care** 1998 Oct;10(5):629–37
High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. Egan JF, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):699–705
Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. Min J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):51–5
Multifocal hepatic steatosis in HIV infection. Monill JM, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):839
Intractable pruritus in HIV infection: immunologic characterization. Milazzo F, et al. **Allergy** 1999 Mar; 54(3):266–72
An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161–4 (46 ref.)
Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Leigh BR, et al. **Am J Clin Oncol** 1998 Oct; 21(5):479–81
Coexistence of allergic contact dermatitis and granuloma annulare in an HIV-1-infected patient: A casual association? [letter] Muñoz-Pérez MA, et al. **Am J Contact Dermat** 1999 Jun;10(2):100–1
HIV-associated eosinophilic folliculitis in an infant. Ramdial PK, et al. **Am J Dermatopathol** 1999 Jun;21(3):241–6
Risk factors for rebleeding and mortality from acute upper gastrointestinal hemorrhage in human immunodeficiency virus infection. Bini EJ, et al. **Am J Gastroenterol** 1999 Feb;94(2):358–63
Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)
Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Bagasra O, et al. **Am J Hematol** 1998 Nov;59(3):199–207
Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Moore RD. **Am J Hematol** 1999 Feb;60(2):116–20
Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. Mylonakis E, et al. **Am J Hematol** 1999 Feb;60(2):164–6
Renal manifestations of concurrent systemic lupus erythematosus and HIV infection. Chang BG, et al. **Am J Kidney Dis** 1999 Mar;33(3):441–9
Nephrotic range proteinuria and hematuria in a white bisexual male. Paueksakon P, et al. **Am J Kidney Dis** 1999 Mar;33(3):607–12 (27 ref.)
The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Dobs AS, et al. **Am J Med** 1999 Aug;107(2):126–32
Plasmacytoma in HIV disease: two case reports and review of the literature. Theodossiou C, et al. **Am J Med Sci** 1998 Nov;316(5):351–3
HIV-related pain. Hughes AM, et al. **Am J Nurs** 1999 Jun; 99(6):20
Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Minkoff HL, et al. **Am J Obstet Gynecol** 1999 Apr; 180(4):824–36
Trichomoniasis in pregnant human immunodeficiency virus-infected and human immunodeficiency virus-uninfected congolese women: prevalence, risk factors, and association with low birth weight. Sutton MY, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):656–62
Human immunodeficiency virus-associated vision loss: electroretinogram attenuation. Donahue SP. **Am J Ophthalmol** 1998 Nov;126(5):729–31
Schizophrenia and major affective disorder among Medicaid recipients with HIV/AIDS in New Jersey. Walkup J, et al. **Am J Public Health** 1999 Jul;89(7):1101–3
Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients. Weis SE, et al. **Am J Public Health** 1999 Jan; 89(1):73–5
Meeting primary oral health care needs of HIV-infected women [editorial; comment] Zabos GP. **Am J Public Health** 1999 Jun;89(6):818–9 (7 ref.). Comment on: Am J Public Health 1999 Jun;89(6):834–9.
Clinical and biological characteristics of human immunodeficiency virus-infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Follézou JY, et al. **Am J Trop Med Hyg** 1999 Sep; 61(3):420–4
Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus. Molina R, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):51–3
In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Nigro L, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):142–5
Abdominal surgery in human immunodeficiency virus (HIV) infected patients--early local experience. Foo E, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):759–62
Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: a measure of current immune suppression. Multicenter Hemophilia Cohort Study. Engels EA, et al. **Ann Intern Med** 1999 Aug 17;131(4):256–64
The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Goldie SJ, et al. **Ann Intern Med** 1999 Jan 19;130(2):97–107
Human immunodeficiency virus-related vasculitis. Clinical presentation of and therapeutic approach to eight cases. Gisselbrecht M, et al. **Ann Med Interne (Paris)** 1998 Nov; 149(7):398–405
The mechanism of diarrhea in HIV is based on an impaired epithelial barrier function that could be induced by a specific cytokine pattern. Stockmann M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:267–70
Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma [letter] Tavio M, et al. **Ann Oncol** 1998 Aug; 9(8):923
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Boivin G, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):377–80
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Lopez-Ribot JL, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2932–7
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Lopez-Ribot JL, et al. **Antimicrob Agents Chemother** 1999 Jul; 43(7):1621–30
Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal? Wolters LM, et al. **Antiviral Res** 1999 May;42(1):71–6
The changing spectrum of the cutaneous manifestation of HIV disease [letter; comment] Colebunders R, et al. **Arch Dermatol** 1999 Apr;135(4):471. Comment on: Arch Dermatol 1998 Oct;134(10):1290–2.
The changing spectrum of the cutaneous manifestations of HIV disease [editorial; comment] [see comments] Costner M, et al. **Arch Dermatol** 1998 Oct;134(10):1290–2. Comment on: Arch Dermatol 1998 Oct;134(10):1208–12. Comment in: Arch Dermatol 1999 Apr;135(4):471.
Nail changes in patients infected with human immunodeficiency virus. A prospective controlled study [see comments] Cribier B, et al. **Arch Dermatol** 1998 Oct; 134(10):1216–20. Comment in: Arch Dermatol 1999 Jun;135(6):715–6.
Butyl nitrite-induced acrocyanosis in an HIV-infected patient [letter] Hoegl L, et al. **Arch Dermatol** 1999 Jan; 135(1):90–1
Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine [see comments] Spira R, et al. **Arch Dermatol** 1998 Oct; 134(10):1208–12. Comment in: Arch Dermatol 1998 Oct;134(10):1290–2.
CMV coinfection and disease progression in vertically acquired HIV infection [letter] Mentzer D, et al. **Arch Dis Child** 1999 Aug;81(2):189
GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates. Woelfle J, et al. **Arch Dis Child** 1999 May;80(5):429–32
Isolated, chronic, epilepsia partialis continua in an HIV-infected patient. Bartolomei F, et al. **Arch Neurol** 1999 Jan;56(1):111–4
Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Pascual-Sedano B, et al. **Arch Neurol** 1999 May;56(5):609–12
Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Tagliati M, et al. **Arch Neurol** 1999 Jan;56(1):84–9
Bilateral bacterial keratitis after laser in situ keratomileusis in a patient with human immunodeficiency virus infection. Hovanesian JA, et al. **Arch Ophthalmol** 1999 Jul; 117(7):968–70
HIV-related occlusive vasculitis. Roth DB, et al. **Arch Ophthalmol** 1999 May;117(5):696–8
Pattern of early visual field loss in HIV-infected patients. Sample PA, et al. **Arch Ophthalmol** 1999 Jun;117(6):755–60
Pre-AIDS physical disability: data from the AIDS Time-Oriented Health Outcome Study [see comments] O'Dell MW, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1200–5. Comment in: Arch Phys Med Rehabil 1999 Apr;80(4):473.
Oral candidiasis in children with immune suppression: clinical appearance and therapeutic considerations. Flaitz CM, et al. **ASDC J Dent Child** 1999 May-Jun;66(3):161–6, 154
A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma. Newell M, et al. **Aust N Z J Med** 1998 Dec;28(6):777–83
Surgery in patients with HIV infection: indications and outcome. Eriguchi M, et al. **Biomed Pharmacother** 1997; 51(10):474–9
Two cases of cytomegalovirus infection revealed by hearing loss in HIV-infected patients. Meynard JL, et al. **Biomed Pharmacother** 1997;51(10):461–3
Drug reactions to contrimoxazole in HIV infection: possibly not due to the hydroxylamine metabolites of sulphamethoxazole [letter] ter Hofstede HJ, et al. **Br J Clin Pharmacol** 1999 May;47(5):571–3

HLA-Cw*0602 and HIV-associated psoriasis. Mallon E, et al. **Br J Dermatol** 1998 Sep;139(3):527–33
Cutaneous mucinoses and HIV infection. Rongioletti F, et al. **Br J Dermatol** 1998 Dec;139(6):1077–80 (23 ref.)
Major surgery seems not to influence HIV disease progression in haemophilia patients. Astermark J, et al. **Br J Haematol** 1998 Oct;103(1):10–4
Micronutrients and the pathogenesis of human immunodeficiency virus infection. Semba RD, et al. **Br J Nutr** 1999 Mar;81(3):181–9 (99 ref.)
The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Brocklehurst P, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):836–48 (58 ref.)
Osteomyelitis of the mandible in HIV infection [letter] Chindia ML. **Br J Oral Maxillofac Surg** 1999 Apr;37(2):154
Acute bacterial infections and HIV disease. Gilks CF. **Br Med Bull** 1998;54(2):383–93 (48 ref.)
HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Bell JE, et al. **Brain** 1998 Nov;121 (Pt 11):2043–52
Treatment for common STDs may not always reduce the spread of HIV [news] **Bull World Health Organ** 1999; 77(4):361
Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. Strong J, et al. **Can J Neurol Sci** 1998 Aug;25(3):254–6
Is HIV infection a cofactor for cervical squamous cell neoplasia? Mandelblatt JS, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jan;8(1):97–106
Haematologic features of the human immunodeficiency virus (HIV) infection in adult Zimbabweans. Adewuyi JO, et al. **Cent Afr J Med** 1999 Feb;45(2):26–30
Seroprevalence of human immunodeficiency virus type 1 infection in childhood malignancy in Zimbabwe. Chitsike I, et al. **Cent Afr J Med** 1998 Oct;44(10):242–5
The relationship between malaria and HIV. Tswana SA, et al. **Cent Afr J Med** 1999 Feb;45(2):43–5
Thoracic empyema in HIV-infected patients [letter; comment] Riquet M, et al. **Chest** 1999 Apr;115(4):1219–20 . Comment on: Chest 1998 Mar;113(3):732–8.
Pericardial involvement in human immunodeficiency virus infection. Silva-Cardoso J, et al. **Chest** 1999 Feb; 115(2):418–22
Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Barbaro G, et al. **Circulation** 1999 Aug 31;100(9):933–9
Cardiac and autonomic evaluation in a pediatric population with human immunodeficiency virus. Plein D, et al. **Clin Cardiol** 1999 Jan;22(1):33–6
CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. Daniel V, et al. **Clin Exp Immunol** 1999 Mar;115(3):477–84
The role of sulphasalazine in African patients with HIV-associated seronegative arthritis [letter] Adebajo AO, et al. **Clin Exp Rheumatol** 1998 Sep-Oct;16(5):629
Vasculitis and oral and genital ulcers: Behçet's syndrome or HIV infection? [letter] Olivé A, et al. **Clin Exp Rheumatol** 1999 Jan-Feb;17(1):124
Photo quiz. Aberrant fat deposition (benign lipomatosis) in association with highly active antiretroviral therapy. Azmeh W, et al. **Clin Infect Dis** 1999 Feb;28(2):239, 351
Genital ulcers: etiology, clinical diagnosis, and associated human immunodeficiency virus infection in Kingston, Jamaica. Behets FM, et al. **Clin Infect Dis** 1999 May; 28(5):1086–90
Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J. **Clin Infect Dis** 1998 Nov;27(5):1309–10
Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Cinque P, et al. **Clin Infect Dis** 1998 Aug;27(2):303–9
Pulmonary tuberculosis due to Mycobacterium microti in a human immunodeficiency virus-infected patient. Foudraine NA, et al. **Clin Infect Dis** 1998 Dec;27(6):1543–4
Primary meningococcal conjunctivitis in a human immunodeficiency virus-infected adult. Garcia-Lechuz JM, et al. **Clin Infect Dis** 1998 Dec;27(6):1556–7
Campylobacter upsaliensis-associated diarrhea in human immunodeficiency virus-infected patients. Jenkin GA, et al. **Clin Infect Dis** 1998 Oct;27(4):816–21
Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment. Mitsuyasu R. **Clin Infect Dis** 1999 Jul;29(1):35–43 (77 ref.)
Human immunodeficiency virus infection, anemia, and survival. Moore RD. **Clin Infect Dis** 1999 Jul;29(1):44–9 (29 ref.)
Superior vena cava syndrome secondary to syphilitic aneurysm of the ascending aorta in a human immunodeficiency virus-infected patient. Olmos JM, et al. **Clin Infect Dis** 1998 Nov;27(5):1331–2
Acute human immunodeficiency virus infection with severe respiratory and renal failure. Onuchic MH, et al. **Clin Infect Dis** 1998 Dec;27(6):1537–8
Photo quiz. Pulmonary tuberculosis. Roghmann MC. **Clin Infect Dis** 1998 Nov;27(5):1137, 1318–9
Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Zylberberg H, et al. **Clin Infect Dis** 1998 Nov;27(5):1255–8
Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. Nitu IC, et al. **Clin Lab Haematol** 1999 Apr; 21(2):139–41
TORCH testing in HIV-infected women. Helfgott A. **Clin Obstet Gynecol** 1999 Mar;42(1):149–62; quiz 174–5 (69 ref.)
Detection and significance of splenomegaly on chest radiographs of HIV-infected outpatients. Zambetti EF, et al. **Clin Radiol** 1999 Jan;54(1):34–7
Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. Hankins C, et al. **CMAJ** 1999 Jan 26;160(2):185–91
Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus [see comments] Bédos JP, et al. **Crit Care Med** 1999 Jun;27(6):1109–15. Comment in: Crit Care Med 1999 Jun;27(6):1043–4.
Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations. Johnson RA. **Curr Clin Top Infect Dis** 1999; 19:252–86 (210 ref.)
FUO and AIDS. Sepkowitz KA. **Curr Clin Top Infect Dis** 1999;19:1–15 (54 ref.)
Pathogenesis and pathophysiology of anemia in HIV infection. Bain BJ. **Curr Opin Hematol** 1999 Mar;6(2):89–93 (28 ref.)
Human immunodeficiency virus infection and female lower genital tract malignancy. Kuhn L, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):35–9 (33 ref.)
Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Schwartz JA, et al. **Depress Anxiety** 1999;9(2):70–4
Update on the cutaneous manifestations of HIV infection. Clinical and pathologic features. Aftergut K, et al. **Dermatol Clin** 1999 Jul;17(3):445–71, vii (188 ref.)
Sexually transmitted diseases in HIV-positive patients. Ormond P, et al. **Dermatol Clin** 1998 Oct;16(4):853–7, xvi (52 ref.)
Cutaneous reaction to ultraviolet irradiation in human-immunodeficiency-virus-infected patients. A case-control study. Aubin F, et al. **Dermatology** 1999; 198(3):256–60
HIV-Associated eosinophilic folliculitis and follicular mucinosis. Buezo GF, et al. **Dermatology** 1998; 197(2):178–80
Is there a relation between risk groups or initial CD4 T cell counts and prevalence of seborrheic dermatitis in HIV-infected patients? Schaub NA, et al. **Dermatology** 1999;198(2):126–9
HIV-1 and the developing central nervous system. Tardieu M. **Dev Med Child Neurol** 1998 Dec;40(12):843–6 (28 ref.)
Does HIV status influence the anatomy of anal fistulas? Manookian CM, et al. **Dis Colon Rectum** 1998 Dec; 41(12):1529–33
Prospective study of healing time after hemorrhoidectomy: influence of HIV infection, acquired immunodeficiency syndrome, and anal wound infection. Morandi E, et al. **Dis Colon Rectum** 1999 Sep;42(9):1140–4
Regression of rectal stenosis secondary to neoplasm in an HIV1-positive patient with gancyclovir antiviral therapy: report of a case. Sobhani I, et al. **Dis Colon Rectum** 1998 Nov;41(11):1454–7
Anorectal disease in HIV-infected patients. Yuhan R, et al. **Dis Colon Rectum** 1998 Nov;41(11):1367–70
HIV-associated lymphoma: report of three cases. Mwangi JW. **East Afr Med J** 1999 Mar;76(3):176–7
Sero-prevalence of HIV antibodies in tuberculosis patients in Ile-Ife, Nigeria. Onipede AO, et al. **East Afr Med J** 1999 Mar;76(3):127–32
Epidemiology of Streptococcus pneumoniae infections at the Edinburgh City Hospital: 1980–95. Kalima P, et al. **Epidemiol Infect** 1999 Apr;122(2):251–7
Incidence of Chlamydia pneumoniae infection in vertically HIV-1 infected children. Cosentini R, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):720–3
Streptococcus bovis bacteremia in patients infected with the human immunodeficiency virus: case reports and literature review. Manfredi R, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):148–50 (4 ref.)
Brucellosis in patients infected with the human immunodeficiency virus. Moreno S, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):319–26 (5 ref.)
Porphyria cutanea tarda associated with human immunodeficiency virus infection. Drobacheff C, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):492–6
Candida onychomycosis in HIV infection. Tosti A, et al. **Eur J Dermatol** 1998 Apr-May;8(3):173–4
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Soriano V, et al. **Eur J Epidemiol** 1999 Jan;15(1):1–4
The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Haydon GH, et al. **Eur J Gastroenterol Hepatol** 1998 Jun; 10(6):485–9
Cytokine profile of HIV-positive Kaposi's sarcoma derived cells in vitro. Brockmeyer NH, et al. **Eur J Med Res** 1999 Mar 26;4(3):95–100
Cases of HIV-associated characteristic periodontal diseases. Pistorius A, et al. **Eur J Med Res** 1999 Mar 26;4(3):121–5 (32 ref.)
Unusual neurological manifestations of primary human immunodeficiency virus infection. Hassin-Baer S, et al. **Eur J Neurol** 1998 Jul;5(4):369–73
Genital tuberculosis in a HIV infected woman: a case report. Giannacopoulos KCh, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):227–9
Corneal endothelial precipitates in HIV- and CMV-positive patients without concomitant ocular disease [letter] Miedziak AI, et al. **Eye** 1998;12 (Pt 4):743–5
HIV-1-infection in the CNS. A pathogenesis of some neurological syndromes in the light of recent investigations. Rafałowska J. **Folia Neuropathol** 1998;36(4):211–6 (49 ref.)
Pulmonary hypertension associated with human immunodeficiency virus infection. Report of two cases and review of the literature. Fiorencis R, et al. **G Ital Cardiol** 1998 Dec;28(12):1404–8 (24 ref.)
A 37-year-old patient with human immunodeficiency virus (HIV) disease. Nair S, et al. **Gastroenterology** 1999 Aug; 117(2):296
Risk factors for recurrent bleeding and mortality in human immunodeficiency virus infected patients with acute lower GI hemorrhage. Bini EJ, et al. **Gastrointest Endosc** 1999 Jun;49(6):748–53
Posttraumatic stress disorder in response to HIV infection. Kelly B, et al. **Gen Hosp Psychiatry** 1998 Nov;20(6):345–52
Testosterone as a treatment for fatigue in HIV+ men. Wagner GJ, et al. **Gen Hosp Psychiatry** 1998 Jul; 20(4):209–13
Pancreatic dysfunction and its association with fat malabsorption in HIV infected children. Carroccio A, et al. **Gut** 1998 Oct;43(4):558–63
Verrucous carcinoma of the vulva in a patient infected with the human immunodeficiency virus. Massad LS, et al. **Gynecol Oncol** 1999 May;73(2):315–8
Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factors. Del Pozo MA, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1695–701
Inflammatory pseudotumor of the liver in a patient with human immunodeficiency virus infection. Tai YS, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1760–3
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Benhamou Y, et al. **Hepatology** 1999 Oct; 30(4):1054–8
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Colin JF, et al. **Hepatology** 1999 Apr;29(4):1306–10
HIV-associated lymphoepithelial cysts and lesions: morphological and immunohistochemical study of the lymphoid cells. Chetty R. **Histopathology** 1998 Sep; 33(3):222–9
Leg pain and swelling in an HIV-infected drug abuser. Formica R, et al. **Hosp Pract (Off Ed)** 1998 Oct 15; 33(10):195–7
Upper body lipomas in an HIV-infected man. Meza AD, et al. **Hosp Pract (Off Ed)** 1999 Apr 15;34(4):130, 135
Clinical features & HIV progression as observed longitudinally in a cohort of injecting drug users in Manipur. Agarwal AK, et al. **Indian J Med Res** 1998 Aug; 108:51–7
Long-term central venous catheter infection in HIV-infected and cancer patients: a multicenter cohort study. Astagneau P, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):494–8
Pneumonia in the patient with HIV infection. Bartlett JG. **Infect Dis Clin North Am** 1998 Sep;12(3):807–20, xi (26 ref.)
Chronic plasma cell endometritis in hysterectomy specimens of HIV-infected women: a retrospective analysis. Kerr-Layton JA, et al. **Infect Dis Obstet Gynecol** 1998; 6(4):186–90
Painful hyperaesthesia caused by protease inhibitors? [letter] Colebunders R, et al. **Infection** 1998 Jul-Aug;26(4):250–1
Nelfinavir associated with peripheral neuropathy in an HIV-infected patient [letter] Grunke M, et al. **Infection** 1998 Jul-Aug;26(4):252
Oral health behaviour and the prevalence of oral manifestations of HIV infection in a group of HIV positive adults. Marcenes W, et al. **Int Dent J** 1998 Dec;48(6):557–62
Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Friedler S, et al. **Int J Dermatol** 1999 Feb;38(2):111–8 (24 ref.)
Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. Temmerman M, et al. **Int J Gynaecol Obstet** 1999 May;65(2):171–81
Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus. Ambati BK, et al. **Int J Infect Dis** 1998-99 Winter;3(2):70–5
Typhoid fever and HIV infection: a rare disease association in industrialized countries. Manfredi R, et al.

Int J Infect Dis 1998-99 Winter;3(2):105-8
Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Sirisanthana T, et al. **Int J Infect Dis** 1998 Jul-Sep;3(1):48-53 (58 ref.)
Benign parotid hypertrophy on +HIV patients: limited late failures after external radiation. Beitler JJ, et al.
Int J Radiat Oncol Biol Phys 1999 Sep 1;45(2):451-5
The role of splenic irradiation in treating HIV-associated immune thrombocytopenia. Blauth J, et al.
Int J Radiat Oncol Biol Phys 1999 Sep 1;45(2):457-60
Gynaecomastia associated with saquinavir therapy. Donovan B, et al. **Int J STD AIDS** 1999 Jan;10(1):49-50
Short-term follow up of cervical squamous intraepithelial lesions associated with HIV and human papillomavirus infections in Africa. La Ruche G, et al.
Int J STD AIDS 1999 Jun;10(6):363-8
Primary effusion lymphoma and Kaposi's sarcoma in an HIV-infected man. Lankester KJ, et al.
Int J STD AIDS 1998 Oct;9(10):616-8
Blue nails are a sign of HIV infection. Leppard B.
Int J STD AIDS 1999 Jul;10(7):479-82
Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management. Mansourati FF, et al. **Int J STD AIDS** 1999 Jan;10(1):51-6
Lipodystrophy despite anabolic steroids [letter] O'Mahony C, et al. **Int J STD AIDS** 1998 Oct;9(10):619
Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group. Petruckevitch A, et al.
Int J STD AIDS 1999 Jan;10(1):38-42
Disorders of fat distribution in HIV infection. Shaw AJ, et al. **Int J STD AIDS** 1998 Oct;9(10):595-9
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine. Shaw AJ, et al. **Int J STD AIDS** 1999 Jun;10(6):417-8
The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study. Elliott AM, et al. **Int J Tuberc Lung Dis** 1999 Mar; 3(3):239-47
Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire. Grant AD, et al. **Int J Tuberc Lung Dis** 1998 Nov; 2(11):926-34
Mycobacterium kansasii infection in a Paris suburb: comparison of disease presentation and outcome according to human immunodeficiency virus status. Groupe d'Etude Des Mycobactéries de la Seine-Saint-Denis. Lortholary O, et al. **Int J Tuberc Lung Dis** 1999 Jan;3(1):68-73
Tuberculous pleural effusions in HIV-positive patients [letter] Post FA, et al. **Int J Tuberc Lung Dis** 1998 Nov; 2(11):941
Serum vitamin A levels during tuberculosis and human immunodeficiency virus infection. Rwangabwoba JM, et al. **Int J Tuberc Lung Dis** 1998 Sep;2(9):771-3
Multidrug-resistant tuberculous meningitis in a health care worker [letter] Silber E, et al. **Int J Tuberc Lung Dis** 1998 Sep;2(9):774
Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center. Plummer DJ, et al.
Invest Ophthalmol Vis Sci 1999 Feb;40(2):435-42
Low prevalence of HTLV-I/II infection among HIV-1-infected injecting drug users in Russia [letter] Bobkova MR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):354
Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study. Daar ES, et al.
J Acquir Immune Defic Syndr 1999 Aug 1;21(4):317-25
Chronic diarrhea and weight loss in HIV-infected patients [letter; comment] Ehrenpreis E.
J Acquir Immune Defic Syndr 1999 Aug 1;21(4):351-3. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1998 Sep 1;19(1):34-9.
Antiviral therapy for HIV patients with renal insufficiency. Jayasekara D, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):384-95 (92 ref.)
Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):259-65
HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. Mahoney EM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):333-7
Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. Rabkin CS, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S31-3
Insulin resistance in HIV protease inhibitor-associated diabetes. Yarasheski KE, et al.
J Acquir Immune Defic Syndr 1999 Jul 1;21(3):209-16
CCR5, vertical transmission of HIV-1, and disease progression. European Collaborative Study [letter] Bailey AJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):211-2
Substance users and protease inhibitors: do barriers exist? [letter] Michaels S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):212-3
Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. Navin TR, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):154-9
Effect of coinfection with hepatitis G virus on HIV disease progression in hemophilic men [letter; comment] Sabin CA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):546-8. Comment on: J Acquir Immune Defic Syndr Hum Retrovirol 1998 Mar 1;17(3):209-13.
A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. Ssali FN, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 15;19(5):484-9
Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. Stratton P, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):179-86
Cervical dysplasia on cervicovaginal Papanicolaou smear among HIV-1-infected pregnant and nonpregnant women. Women and Infants Transmission Study. Stratton P, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Mar 1;20(3):300-7
Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. Telzak EE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):513-8
Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay. Tumbarello M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 15;19(5):490-7
A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group. Walmsley SL, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 15;19(5):498-505
Transcending the physical: spiritual aspects of pain in patients with HIV and/or cancer. Newshan G. **J Adv Nurs** 1998 Dec;28(6):1236-41 (38 ref.)
The fatigue experience: persons with HIV infection. Rose L, et al. **J Adv Nurs** 1998 Aug;28(2):295-304
Nongenital dermatologic disease in HIV-infected women. Barton JC, et al. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):938-48
Contact dermatitis in subjects infected with HIV type 1. Bellegrandi S, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):777-9
Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. Lim HW, et al. **J Am Acad Dermatol** 1998 Dec;39(6):956-9
Oral health care issues in HIV disease: developing a core curriculum for primary care physicians. Sifri R, et al.
J Am Board Fam Pract 1998 Nov-Dec;11(6):434-44
Prevalence of congenital cardiovascular malformations in children of human immunodeficiency virus-infected women: the prospective P2C2 HIV Multicenter Study. P2C2 HIV Study Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Lai WW, et al.
J Am Coll Cardiol 1998 Nov 15;32(6):1749-55
HIV-associated parotid lymphoepithelial cysts. Mandel L, et al. **J Am Dent Assoc** 1999 Apr;130(4):528-32
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients [editorial] Chronister CL, et al.
J Am Optom Assoc 1998 Nov;69(11):695-8 (18 ref.)
Sarcoidosis-related anterior uveitis in a patient with human immunodeficiency virus. Lee AK, et al.
J Am Optom Assoc 1999 Jun;70(6):384-90
Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. Cheng JT, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1566-74
HIV-associated nephropathy: outcome and prognosis factors. Groupe d'Etudes Néphrologiques d'Ile de France. Laradi A, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2327-35 (34 ref.)
Nurses decrease barriers to health care by "hyperlinking" multiple-diagnosed women living with HIV/AIDS into care. Andersen MD, et al. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):55-65
A symptom review: nausea and vomiting in HIV. Capili B, et al. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):47-56 (44 ref.)
Special population: HIV/AIDS among the deaf and hard of hearing. Gaskins S. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):75-8 (18 ref.)
Quality of life and self-care management strategies of PLWAs with chronic diarrhea. Henry SB, et al.
J Assoc Nurses AIDS Care 1999 Mar-Apr;10(2):46-54
Hepatitis A and HIV: a clinical review of disease and strategies for prevention. Kwong JJ.
J Assoc Nurses AIDS Care 1999 Mar-Apr;10(2):31-6 (20 ref.)
Supraventricular tachycardia in a human immunodeficiency virus-infected man [published erratum appears in J Cardiol 1999 Mar;33(3):189] Cheng TO. **J Cardiol** 1999 Jan; 33(1):21-6
Moyamoya syndrome in a patient with congenital human immunodeficiency virus infection. Hsiung GY, et al.
J Child Neurol 1999 Apr;14(4):268-70
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. Kirkpatrick WR, et al. **J Clin Microbiol** 1998 Oct;36(10):3007-12
Indigenous disseminated Penicillium marneffei infection in the state of Manipur, India: report of four autochthonous cases. Singh PN, et al. **J Clin Microbiol** 1999 Aug; 37(8):2699-702
Coexistent gastric MALT lymphoma and Kaposi sarcoma in an HIV positive patient. Chetty R, et al.
J Clin Pathol 1999 Apr;52(4):313-6
The gingival plasma cell infiltrate in HIV-positive patients with periodontitis is disorganized. Myint M, et al.
J Clin Periodontol 1999 Jun;26(6):358-65
Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. Rabkin JG, et al. **J Clin Psychopharmacol** 1999 Feb; 19(1):19-27
Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. Puig L, et al. **J Cutan Pathol** 1999 May;26(5):227-31
Detection of human herpesvirus 8 in Korean Kaposi's sarcoma cases by polymerase chain reaction and in situ polymerase chain reaction. Jang HS, et al. **J Dermatol** 1999 Jul;26(7):434-41
Acquired trichomegaly of the eyelashes in a child with human immunodeficiency virus infection [letter] Patrizi A, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):89-91
Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. Sendi PP, et al. **J Eval Clin Pract** 1999 Aug;5(3):283-95
Oral manifestations of human immunodeficiency virus-infected patients in Taiwan. Chiang CP, et al.
J Formos Med Assoc 1998 Sep;97(9):600-5
Bacteremia and fungemia in patients with advanced human immunodeficiency virus (HIV) infection in Taiwan. Hung CC, et al. **J Formos Med Assoc** 1998 Oct;97(10):690-7
Ultrasound-guided percutaneous transthoracic needle aspiration biopsy for diagnosis of pulmonary lesions in advanced HIV infection. Hung CC, et al.
J Formos Med Assoc 1999 Mar;98(3):195-200
Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. Nagai K, et al. **J Gastroenterol** 1999 Apr;34(2):275-81
Molecular analysis of GB virus C/hepatitis G virus in HIV-1-positive intravenous drug users in Belgium. Liu HF, et al. **J Hum Virol** 1999 Mar-Apr;2(2):115-20
Prevalence of hepatitis G virus RNA in human immunodeficiency virus type 1-positive intravenous drug users. Zehender G, et al. **J Hum Virol** 1998 Jan-Feb; 1(2):96-100
Diagnostic usefulness of percutaneous liver biopsy in HIV-infected patients with fever of unknown origin. García-Ordóñez MA, et al. **J Infect** 1999 Mar;38(2):94-8
Tuberculosis in HIV-infected persons with special emphasis on sub-Saharan Africa. Harries AD. **J Infect** 1998 Nov; 37(3):205-9 (31 ref.)
Mycobacterium kansasii and human immunodeficiency virus co-infection in London. Klein JL, et al. **J Infect** 1998 Nov; 37(3):252-9
Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. Meynard JL, et al. **J Infect** 1999 May;38(3):176-81
Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. Mwachari C, et al. **J Infect** 1998 Jul; 37(1):48-53
Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis? Reus S, et al. **J Infect** 1998 Jul;37(1):84-6
The tuberculosis pandemic--which way now? Zumla A, et al. **J Infect** 1999 Mar;38(2):74-9 (41 ref.)
Sexually transmitted disease acquisition among women infected with human immunodeficiency virus type 1. Bersoff-Matcha SJ, et al. **J Infect Dis** 1998 Oct; 178(4):1174-7
Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. Cohen CR, et al. **J Infect Dis** 1998 Nov;178(5):1352-8
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. Dore GJ, et al.
J Infect Dis 1999 Sep;180(3):607-13
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. Jacobson JM, et al. **J Infect Dis** 1999 Jul;180(1):61-7
Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1. Jenson H, et al.
J Infect Dis 1999 Jun;179(6):1395-404
Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. Kaplan JE, et al. **J Infect Dis** 1998 Oct; 178(4):1126-32
Characterization of intestinal disease associated with human

immunodeficiency virus infection and response to antiretroviral therapy. Kotler DP. **J Infect Dis** 1999 May; 179 Suppl 3:S454–6 (15 ref.)

Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. Kuhn L, et al. **J Infect Dis** 1999 Jan;179(1):52–8

The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. Laskus T, et al. **J Infect Dis** 1998 Oct;178(4):1189–92

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus–positive hemophiliacs and should be treated as an opportunistic infection. Lesens O, et al. **J Infect Dis** 1999 May;179(5):1254–8

Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1 [published erratum appears in J Infect Dis 1999 Apr;179(4):1053] Menu E, et al. **J Infect Dis** 1999 Jan;179(1):44–51

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. Mertz KJ, et al. **J Infect Dis** 1998 Dec;178(6):1795–8

Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus–infected men. Schacker T, et al. **J Infect Dis** 1998 Dec;178(6):1616–22

Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. Wanke CA, et al. **J Infect Dis** 1998 Nov;178(5):1369–72

Hypocalcaemia in HIV infection and AIDS. Kuehn EW, et al. **J Intern Med** 1999 Jan;245(1):69–73

Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. Rowe A, et al. **J Invest Dermatol** 1999 Mar;112(3):284–9

In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients. Schaller M, et al. **J Invest Dermatol** 1999 Mar;112(3):383–6

Sonographic and MR findings of an extensive, HIV-related prostatic abscess. Bertschinger K, et al. **J Magn Reson Imaging** 1999 Mar;9(3):488–90

Nonadherence in tuberculosis treatment among HIV patients attending Bamrasnaradura Hospital, Nonthaburi. Tansuphasawadikul S, et al. **J Med Assoc Thai** 1998 Dec; 81(12):964–9

Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. Bourlet T, et al. **J Med Virol** 1999 Aug; 58(4):373–7

Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Devereux H, et al. **J Med Virol** 1998 Dec;56(4):316–20

Influence of CD4+ lymphocyte counts on GB virus C/hepatitis G virus carriership in HIV-positive individuals. Goubau P, et al. **J Med Virol** 1999 Apr;57(4):367–9

GBV-C/HGV coinfection in HIV-1-positive men: frequent detection of viral RNA in blood plasma but absence from seminal fluid plasma. Hollingsworth RC, et al. **J Med Virol** 1998 Dec;56(4):321–6

High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. Nerurkar VR, et al. **J Med Virol** 1998 Oct; 56(2):123–7

Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. Sabin CA, et al. **J Med Virol** 1999 Jul;58(3):280–5

Human herpesvirus 8 and cancer [editorial; comment] Beral V, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1440–1. Comment on: J Natl Cancer Inst 1999 Sep 1;91(17):1468–74.

Old and new issues in cervical cancer control [editorial; comment] Critchlow CW, et al. **J Natl Cancer Inst** 1999 Feb 3;91(3):200–1. Comment on: J Natl Cancer Inst 1999 Feb 3;91(3):226–36. Comment on: J Natl Cancer Inst 1999 Feb 3;91(3):252–8.

Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. Reitz MS Jr, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1453–8 (100 ref.)

Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome–related diseases [see comments] Rezza G, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1468–74. Comment in: J Natl Cancer Inst 1999 Sep 1;91(17):1440–1.

Neuropsychological functioning in HIV-positive African-American women with a history of drug use. Mason KI, et al. **J Natl Med Assoc** 1998 Nov;90(11):665–74

Non-lymphomatous brain tumors in HIV-1 infection: a review. Büttner A, et al. **J Neurooncol** 1999 Jan;41(1):81–8 (46 ref.)

Lack of association between Borna disease virus infection and neurological disorders among HIV-infected individuals. Bachmann S, et al. **J Neurovirol** 1999 Apr; 5(2):190–5

Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. Dubois V, et al. **J Neurovirol** 1998 Oct;4(5):539–44

Enterovirus associated neurological disease in an HIV-1 infected man. Dyer JR, et al. **J Neurovirol** 1998 Oct; 4(5):569–71

Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system. Iten A, et al. **J Neurovirol** 1999 Apr;5(2):172–80

Review: neuronal injury in HIV infection. Petito CK, et al. **J Neurovirol** 1999 Aug;5(4):327–41

HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. Margiotta V, et al. **J Oral Pathol Med** 1999 Apr;28(4):173–7

Oral lesions in children with perinatally acquired human immunodeficiency virus infection. Nicolatou O, et al. **J Oral Pathol Med** 1999 Feb;28(2):49–53

Detection of Epstein-Barr virus in oral scrapes in HIV infection, in hairy leukoplakia, and in healthy non-HIV-infected people. Scully C, et al. **J Oral Pathol Med** 1998 Nov;27(10):480–2

Oral manifestations of HIV infection in a group of predominantly ethnic Chinese. Tsang PC, et al. **J Oral Pathol Med** 1999 Mar;28(3):122–7

Neuropathic pain after anti-HIV gene therapy successfully treated with gabapentin [letter] Vadivelu N, et al. **J Pain Symptom Manage** 1999 Mar;17(3):155–6

Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. Stockheim JA, et al. **J Pediatr** 1999 Mar;134(3):368–70 (8 ref.)

Endocrine dysfunction in children with HIV-1 infection. Chiarelli F, et al. **J Pediatr Endocrinol Metab** 1999 Jan–Feb; 12(1):17–26 (86 ref.)

Cyclosporine for rectoperineal fistula in a human immunodeficiency virus–infected child. Caselli D, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):333–5

Clinical quiz. Mycobacterium avium-intracellurare. Del Rosario MA. **J Pediatr Gastroenterol Nutr** 1999 Apr; 28(4):434, 441

Human immunodeficiency virus infection associated arthritis: clinical characteristics. Berman A, et al. **J Rheumatol** 1999 May;26(5):1158–62

Osteonecrosis and human immunodeficiency virus infection [letter; comment] Koeger AC. **J Rheumatol** 1999 Mar; 26(3):752–3. Comment on: J Rheumatol 1997 Mar;24(3):601–4.

Spondyloarthropathy and human immunodeficiency virus infection in Zambia. Njobvu P, et al. **J Rheumatol** 1998 Aug;25(8):1553–9

Residential detoxification for substance abusers with HIV/AIDS. Walden House Detoxification Program. Sargent R, et al. **J Subst Abuse Treat** 1999 Jan;16(1):87–95

Common health problems in HIV-infected travelers to the (sub)tropics. Simons FM, et al. **J Travel Med** 1999 Jun; 6(2):71–5

Low birthweight in infants born to African HIV-infected women: relationship with maternal body weight during pregnancy: Pregnancy and HIV Study Group (EGE). Castetbon K, et al. **J Trop Pediatr** 1999 Jun;45(3):152–7

No evidence of vertical transmission of HTLV-I and HTLV-II in children at high risk for HIV-1 infection from São Paulo, Brazil. Caterino-de-Araujo A, et al. **J Trop Pediatr** 1999 Feb;45(1):42–7

Upper airway obstruction in an HIV-1 infected child with acute Epstein-Barr virus infection [letter] Weber HC, et al. **J Trop Pediatr** 1999 Apr;45(2):119–20

Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. Curi MA, et al. **J Vasc Surg** 1999 Apr;29(4):608–16

Arterial aneurysms in patients infected with human immunodeficiency virus: a distinct clinicopathology entity? Nair R, et al. **J Vasc Surg** 1999 Apr;29(4):600–7

The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. Goldie SJ, et al. **JAMA** 1999 May 19;281(19):1822–9

Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain [letter; comment] Kaptchuk TJ. **JAMA** 1999 Apr 14;281(14):1270; discussion 1271–2. Comment on: JAMA 1998 Nov 11;280(18):1590–5.

Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain [letter; comment] King SA. **JAMA** 1999 Apr 14;281(14):1271–2. Comment on: JAMA 1998 Nov 11;280(18):1590–5.

Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS [see comments] Shlay JC, et al. **JAMA** 1998 Nov 11;280(18):1590–5. Comment in: JAMA 1999 Apr 14;281(14):1270; discussion 1271–2. Comment in: JAMA 1999 Apr 14;281(14):1270–1; discussion 1271–2. Comment in: JAMA 1999 Apr 14;281(14):1271–2.

Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain [letter; comment] Ulett GA. **JAMA** 1999 Apr 14;281(14):1270–1; discussion 1271–2. Comment on: JAMA 1998 Nov 11;280(18):1590–5.

Prevalence of hepatitis B, C and HIV virus infection among beta thalassaemia major patients [letter] Shamsi T, et al. **JPMA J Pak Med Assoc** 1998 Mar;48(3):87

Rhinosinusitis and atopy in patients infected with HIV. Garcia-Rodriguez JF, et al. **Laryngoscope** 1999 Jun; 109(6):939–44

Recrudescence of treated neurosyphilis in a patient with human immunodeficiency virus. Dibbern DA Jr, et al. **Mayo Clin Proc** 1999 Jan;74(1):53–6

Meningioma in four patients with human immunodeficiency virus infection. Khurshid A, et al. **Mayo Clin Proc** 1999 Mar;74(3):253–7

Dermatologic manifestations in HIV-infected patients: a primary care perspective. Samet JH, et al. **Mayo Clin Proc** 1999 Jul;74(7):658–60

Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Ampel NM. **Med Mycol** 1999 Aug;37(4):245–50

Myelodysplastic syndrome in an HIV-1-infected infant. van den Berg H, et al. **Med Pediatr Oncol** 1999 May;32(5):385

Nailfold capillary microscopy in human immunodeficiency virus–infected patients: a case-control study. Aubin F, et al. **Microvasc Res** 1999 Sep;58(2):197–9

Oral manifestations of HIV disease. Sirois DA. **Mt Sinai J Med** 1998 Oct-Nov;65(5–6):322–32 (59 ref.)

Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency virus–infected patient observed over a period of 6 years. Hoegl L, et al. **Mycoses** 1998 Sep-Oct;41(7–8):335–8

Dilated cardiomyopathy in HIV-infected patients [letter; comment] Chariot P, et al. **N Engl J Med** 1999 Mar 4; 340(9):732; discussion 733–5. Comment on: N Engl J Med 1998 Oct 15;339(16):1093–9. Comment on: N Engl J Med 1998 Oct 15;339(16):1153–5.

Dilated cardiomyopathy in HIV-infected patients [letter; comment] Flotats A, et al. **N Engl J Med** 1999 Mar 4; 340(9):733–4. Comment on: N Engl J Med 1998 Oct 15;339(16):1093–9.

Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1–infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Kovacs A, et al. **N Engl J Med** 1999 Jul 8;341(2):77–84

Dilated cardiomyopathy in HIV-infected patients [letter; comment] Malnick S, et al. **N Engl J Med** 1999 Mar 4; 340(9):732–3; discussion 733–4. Comment on: N Engl J Med 1998 Oct 15;339(16):1093–9.

Fat distribution in AIDS [letter; comment] Teplitsky V, et al. **N Engl J Med** 1999 Mar 25;340(12):969–70. Comment on: N Engl J Med 1998 Oct 29;339(18):1296. Comment on: N Engl J Med 1998 Oct 29;339(18):1297.

Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Peraldi MN, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1578–85

The heterogeneity of glomerulonephritis associated with HIV [letter] Rivera M, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):244–5

HIV infection presenting with Fournier's gangrene. Roca B, et al. **Neth J Med** 1998 Oct;53(4):168–71

Primary intracranial neoplasms in patients with HIV. Blumenthal DT, et al. **Neurology** 1999 May 12; 52(8):1648–51

A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Kieburtz K, et al. **Neurology** 1998 Dec; 51(6):1682–8

Distinct light microscopic changes in HIV-associated nemaline myopathy [letter; comment] Miró O, et al. **Neurology** 1999 Jul 13;53(1):241–2. Comment on: Neurology 1998 Feb;50(2):529–31.

HIV and HCV [letter; comment] Geiger D. **Nurse Pract** 1999 Apr;24(4):16. Comment on: Nurse Pract 1998 Dec;23(12):78, 81.

Cervical dysplasia in women with HIV [news] Goodman L, et al. **Nurse Pract** 1999 Aug;24(8):79–80, 82, 84–5 (39 ref.)

Metabolic complications of HIV disease. Swindells S. **Nurse Pract** 1999 Feb;24(2):125–6, 129 (13 ref.)

Tuberculosis, HIV infection, and malnutrition: an infernal trio in central Africa [editorial] Perronne C. **Nutrition** 1999 Apr;15(4):321–2 (12 ref.)

Cancers in children infected with the human immunodeficiency virus. Mueller BU. **Oncologist** 1999; 4(4):309–17 (100 ref.)

Lower genital tract neoplasia in women with HIV infection. Abercrombie PD, et al. **Oncology (Huntingt)** 1998 Dec; 12(12):1735–9; discussion 1742, 1745, 1747 (50 ref.)

Elective surgery and the patient with human immunodeficiency virus [editorial] Schipper AM. **Ophthal Plast Reconstr Surg** 1999 May;15(3):151–2

HIV infection and AIDS. Lloyd A. **P N G Med J** 1996 Sep; 39(3):174–80 (2 ref.)

Predictors of the severity of acute pancreatitis in patients with HIV infection or AIDS. Parithivel VS, et al. **Pancreas** 1999 Aug;19(2):133–6

T cell responses in coinfection with Onchocerca volvulus and the human immunodeficiency virus type 1. Sentongo E, et al. **Parasite Immunol** 1998 Sep;20(9):431–9

Neurologic complications of HIV infections in children. Zuckerman GB, et al. **Pediatr Ann** 1998 Oct;27(10):635–9

Mucocutaneous manifestations in children with HIV infection and AIDS. El Hachem M, et al. **Pediatr Dermatol** 1998 Nov-Dec;15(6):429–34

Varicella and zoster in children with human immunodeficiency virus infection. Derryck A, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):931–3

Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human

immunodeficiency virus infection. Hagerty SL, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):929–30

Effect of superimposed infections on viral replication in human immunodeficiency virus type 1–infected children. Marchisio P, et al. **Pediatr Infect Dis J** 1998 Aug; 17(8):755–7

Characteristics of acute pneumonia in human immunodeficiency virus–infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):872–80

Primary acquired toxoplasmosis in a five-year-old child with perinatal human immunodeficiency virus type 1 infection. Sobanjo A, et al. **Pediatr Infect Dis J** 1999 May;18(5):476–8

Stroke in pediatric HIV infection [letter] Legido A, et al. **Pediatr Neurol** 1999 Aug;21(2):588

Stroke and seizures as the presenting signs of pediatric HIV infection. Visudtibhan A, et al. **Pediatr Neurol** 1999 Jan; 20(1):53–6

Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Starc TJ, et al. **Pediatrics** 1999 Aug; 104(2):e14

Clozapine treatment of HIV-associated psychosis--too much bone marrow toxicity? Dettling M, et al. **Pharmacopsychiatry** 1998 Jul;31(4):156–7

Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Varriale P, et al. **Pharmacotherapy** 1999 Jul;19(7):881–4 (26 ref.)

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Vazquez JA. **Pharmacotherapy** 1999 Jan;19(1):76–87 (122 ref.)

HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)

The olfactory loss that accompanies an HIV infection. Hornung DE, et al. **Physiol Behav** 1998 Jun 15;64(4):549–56

HIV infection and seizures. Garg RK. **Postgrad Med J** 1999 Jul;75(885):387–90 (22 ref.)

Primary pulmonary hypertension associated with human immunodeficiency virus infection. Golpe R, et al. **Postgrad Med J** 1998 Jul;74(873):400–4 (47 ref.)

HIV envelope protein gp120 induces neuropeptide Y receptor–mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Kim J, et al. **Regul Pept** 1998 Sep 25;75–76:201–5

Tuberculosis and HIV infection: a global perspective. Murray JF. **Respiration** 1998;65(5):335–42 (45 ref.)

ABR and HIV-induced impairment of the central nervous system. Serafini G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(2):87–90

The neuropathology of adult HIV infection. Bell JE. **Rev Neurol (Paris)** 1998 Dec;154(12):816–29 (143 ref.)

Cardiac involvement in human immunodeficiency virus infection. Cardoso JS. **Rev Port Cardiol** 1999 Feb; 18(2):217–20 (22 ref.)

Characteristics of septic arthritis in human immunodeficiency virus–infected haemophiliacs versus other risk groups. Barzilai A, et al. **Rheumatology (Oxford)** 1999 Feb; 38(2):139–42

Virus-associated vasculitides [editorial] Guillevin L. **Rheumatology (Oxford)** 1999 Jul;38(7):588–90

Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Leder K, et al. **Scand J Infect Dis** 1998;30(4):331–8 (42 ref.)

Changes in small intestinal structure and function in HIV-infected patients with chronic diarrhoea. Oktedalen O, et al. **Scand J Infect Dis** 1998;30(5):459–63

Effects of HIV co-infection and chemotherapy on the urinary levels of nitric oxide metabolites in patients with pulmonary tuberculosis. Schön T, et al. **Scand J Infect Dis** 1999;31(2):123–6

Chronic cough in patients with HIV infection. Wong KH, et al. **Scand J Infect Dis** 1998;30(3):227–9

The enigmas of Kaposi's sarcoma. Gallo RC. **Science** 1998 Dec 4;282(5395):1837–9 (25 ref.)

Nutritional management of patients with AIDS-related anorexia. Kotler DP. **Semin Gastrointest Dis** 1998 Oct; 9(4):189–99 (47 ref.)

Sexually transmitted infections in women infected with the human immunodeficiency virus. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Capps L, et al. **Sex Transm Dis** 1998 Sep;25(8):443–7

Lower genital tract infections among HIV-infected and high-risk uninfected women: findings of the Women's Interagency HIV Study (WIHS). Greenblatt RM, et al. **Sex Transm Dis** 1999 Mar;26(3):143–51

Etiology of genital ulcer disease and its relationship to HIV infection [editorial; comment] Morse SA. **Sex Transm Dis** 1999 Jan;26(1):63–5. Comment on: Sex Transm Dis 1999 Jan;26(1):55–62.

Acute pulmonary embolism in patients with HIV disease. Howling SJ, et al. **Sex Transm Infect** 1999 Feb;75(1):25–9

A study of anal intraepithelial neoplasia in HIV positive homosexual men. Lacey HB, et al. **Sex Transm Infect** 1999 Jun;75(3):172–7

Local treatment of a chronic leg ulcer with GM-CSF in a patient with HIV infection [letter] Mastroianni A, et al. **Sex Transm Infect** 1999 Jun;75(3):203–4

Toxoplasma gondii antibody in pregnant women with and without HIV infection. Chintana T, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):383–6

HIV in leprosy patients. Burns SM. **Trop Doct** 1999 Apr; 29(2):126–7

Fungal keratitis as an indicator of HIV infection in Africa. Mselle J. **Trop Doct** 1999 Jul;29(3):133–5

Retinal manifestations of HIV-1 and HIV-2 infections among hospital patients in The Gambia, west Africa. Jaffar S, et al. **Trop Med Int Health** 1998 Oct; 3(10):783–7

[Acral erythema and HIV infection] Barzegar C, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):595–7 (Eng. Abstr.) **(Fre)**

[Acute myelocytic leukemia in immunodeficiency virus infection] Pulik M, et al. **Ann Med Interne (Paris)** 1998 Dec;149(8):475–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Placental infection in Rwanda: comparison an HIV infected population and a control population] Hofman V, et al. **Ann Pathol** 1998 Dec;18(6):466–72 (Eng. Abstr.) **(Fre)**

[Hematologic abnormalities and immunodepression in HIV/AIDS- related pulmonary tuberculosis] Hane AA, et al. **Bull Soc Pathol Exot** 1999 Jul;92(3):161–3 (Eng. Abstr.) **(Fre)**

[Neurologic manifestations associated with HIV infections at the Bobo-Dioulasso Hospital Center (Burkina Faso)] Millogo A, et al. **Bull Soc Pathol Exot** 1999 Feb;92(1):23–6 (Eng. Abstr.) **(Fre)**

[Prevalence of HIV infection in dialysis patients: results of a national multicenter study] Poignet JL, et al. **Nephrologie** 1999;20(3):159–63 (Eng. Abstr.) **(Fre)**

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412–5 (Eng. Abstr.) **(Fre)**

[Vasculitis during human acquired immunodeficiency virus infection] Gisselbrecht M. **Pathol Biol (Paris)** 1999 Mar; 47(3):245–7 (16 ref.) (Eng. Abstr.) **(Fre)**

[Disseminated infestation of Enterocytozooon bieneusi a an HIV-infected patient] Rabaud C, et al. **Pathol Biol (Paris)** 1999 May;47(5):576–8 (Eng. Abstr.) **(Fre)**

[HIV arthritis: an entity apart from HIV infection (letter)] Bileckot R, et al. **Presse Med** 1998 May 2–9;27(17):806–7 **(Fre)**

[Portal thrombosis and anticardiolipin antibodies association in an HIV-2 infected patient (letter)] Bouchard O, et al. **Presse Med** 1998 Jun 6;27(20):965 **(Fre)**

[5th Conference on Opportunistic Retrovirus Infections in HIV: contribution of anti-retroviral combinations] Granier F, et al. **Presse Med** 1998 Apr 4;27(13):622–3 **(Fre)**

[Myocardial infarct induced by antiproteases. Report of a case (letter)] Khellaf M, et al. **Presse Med** 1998 Dec 5; 27(38):1955–6 **(Fre)**

[Mitral papillary fibroelastoma in a HIV infected patient] Paraf F, et al. **Presse Med** 1999 May 15;28(18):962–4 (Eng. Abstr.) **(Fre)**

[Lung cancer in patients infected with human immunodeficiency virus. Clinical course and therapeutic implications] Peyrade F, et al. **Presse Med** 1998 Feb 7; 27(5):198–201 (Eng. Abstr.) **(Fre)**

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809–14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Chylothorax as a complication of Kaposi sarcoma (letter)] Vandenbos F, et al. **Presse Med** 1998 Jul 4–11;27(24):1218 **(Fre)**

[Polymyositis in a HIV infected patient (letter)] Vandenbos F, et al. **Presse Med** 1999 Feb 6;28(5):231 **(Fre)**

[Factors associated with survival in Kaposi's sarcoma in patients infected with the human immunodeficiency virus. Clinical Epidemiological Group for AIDS in Aquitaine] Cazorla C, et al. **Rev Epidemiol Sante Publique** 1999 Apr; 47(2):109–17 (Eng. Abstr.) **(Fre)**

[Prevalence of nocardiosis in an area of endemic tuberculosis] Koffi N, et al. **Rev Mal Respir** 1998 Oct;15(5):643–7 (Eng. Abstr.) **(Fre)**

[Parotitis due to Mycobacterium and HIV infection (letter)] Benharrats I, et al. **Rev Med Interne** 1998 Sep;19(9):676–7 **(Fre)**

[Hodgkin's disease in patients infected with the human immunodeficiency virus] Costello R, et al. **Rev Med Interne** 1998 Aug;19(8):558–64 (69 ref.) (Eng. Abstr.) **(Fre)**

[Adenocarcinoma of unknown primary site with thoracic localization and HIV: four case reports] Courtot H, et al. **Rev Med Interne** 1999 Mar;20(3):272–6 (Eng. Abstr.) **(Fre)**

[A very, very short of breath HIV-infected patient] Mégarbane B, et al. **Rev Med Interne** 1999;20 Suppl 2:256s–259s **(Fre)**

[Interactions between the human immunodeficiency virus and hepatitis C virus] Pol S, et al. **Rev Med Interne** 1998 Dec; 19(12):885–91 (48 ref.) (Eng. Abstr.) **(Fre)**

[Kaposi's disease] Lebbé C. **Rev Prat** 1999 Apr 15;49(8):843–7 (42 ref.) (Eng. Abstr.) **(Fre)**

[Long-term HIV infection and dialysis dependent renal failure in analgesic nephropathy] Müller V, et al. **Ther Umsch** 1998 Sep;55(9):555–7 (Eng. Abstr.) **(Ger)**

[Endocrine involvement in HIV infections] Luckhaus J. **Zentralbl Gynakol** 1999;121(1):30–2 (41 ref.) (Eng. Abstr.) **(Ger)**

[Therapeutic problems with HIV-infected tuberculous spondylitis patients in the South African Republic] Riskó Z. **Orv Hetil** 1999 Mar 28;140(13):711–3 (Eng. Abstr.) **(Hun)**

[Liver changes in HIV/AIDS] Telegdy L, et al. **Orv Hetil** 1999 Apr 11;140(15):811–4 (36 ref.) (Eng. Abstr.) **(Hun)**

[Mycobacterium tuberculosis drug resistance in patients with HIV and pulmonary tuberculosis infections in Rome: 1987–1996] Palmieri F, et al. **Ann Ital Med Int** 1998 Jul–Sep;13(3):139–45 (Eng. Abstr.) **(Ita)**

[Improvement of lipodystrophy associated with protease inhibitors (news)] **Boll Chim Farm** 1999 Apr;138(4):192–3 **(Ita)**

[Effective splenectomy in a patient with HIV-associated thrombocytopenia] Kato Y, et al. **Rinsho Ketsueki** 1998 Nov;39(11):1137–9 (Eng. Abstr.) **(Jpn)**

[Viral infectious diseases of the retina] Azumi A, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):336–8 (7 ref.) **(Jpn)**

[Cardiovascular morbidity in children with human immunodeficiency virus infection] Nogueira G, et al. **Acta Med Port** 1998 Dec;11(12):1051–7 (Eng. Abstr.) **(Por)**

[Reiter's syndrome and human immunodeficiency virus infection] de Mello e Silva AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1998 Jul–Aug; 53(4):202–4 (24 ref.) (Eng. Abstr.) **(Por)**

[Usefulness of routine investigation of fungal infections through bronchoscopy in HIV-infected and non-HIV-infected patients in a general hospital, reference to AIDS] Lazzarini-de-Oliveira LC, et al. **Rev Soc Bras Med Trop** 1999 May–Jun;32(3):255–61 (Eng. Abstr.) **(Por)**

[Visceral leishmaniasis and HIV infection in differential diagnosis of fever conditions] Rugol' LV, et al. **Klin Med (Mosk)** 1998;76(9):68–9 (5 ref.) **(Rus)**

[First case in Russia of coinfection of visceral leishmaniasis and HIV-infection] Konstantinova TN, et al. **Ter Arkh** 1998;70(11):31–3 **(Rus)**

[Thrombotic thrombocytopenic purpura associated with HIV infection (letter)] Bayo Poleo R, et al. **An Med Interna** 1999 Apr;16(4):210–1 **(Spa)**

[Tuberculosis and HIV infection. Clinical characteristics and diagnosis] Lado Lado FL, et al. **An Med Interna** 1998 Aug; 15(8):415–20 (Eng. Abstr.) **(Spa)**

[Nutritional status of patients with HIV-AIDS infection (editorial)] López-Herce JA. **An Med Interna** 1998 Dec; 15(12):623–6 (58 ref.) **(Spa)**

[Lumbosacral and meningeal polyradicular disease in a patient with HIV infection (letter)] Parra Ródenas JV, et al. **An Med Interna** 1999 Aug;16(8):435–6 **(Spa)**

[Characteristics of the carriers of antibodies to hepatitis C virus with normal transaminases levels in HIV infected patients] Ramos Paesa C, et al. **An Med Interna** 1998 Sep; 15(9):459–63 (Eng. Abstr.) **(Spa)**

[Viremia levels of the chronic hepatitis c virus in HIV infected patients, clinical implications] Ramos Paesa C, et al. **An Med Interna** 1998 Sep;15(9):464–9 (Eng. Abstr.) **(Spa)**

[Primary tuberculous psoas abscess in a patient with HIV infection (letter)] Salcedo M, et al. **An Med Interna** 1999 Aug;16(8):437–8 **(Spa)**

[Evolution of the nutritional status of patients with HIV-AIDS. Effects of socioeconomic situation and dietetic counseling] Sánchez Alvarez MC, et al. **An Med Interna** 1998 Dec;15(12):627–32 (Eng. Abstr.) **(Spa)**

[Fungemia in patients with HIV infection] Santos J, et al. **An Med Interna** 1998 Oct;15(10):523–7 (Eng. Abstr.) **(Spa)**

[Left-sided endocarditis in patients with HIV infection] Valencia Ortega ME, et al. **An Med Interna** 1999 Apr; 16(4):171–4 (Eng. Abstr.) **(Spa)**

[Kikuchi disease in an acquired immunodeficiency syndrome patient (letter)] Abad A, et al. **Enferm Infecc Microbiol Clin** 1999 Apr;17(4):193–4 **(Spa)**

[Cavitated pulmonary lesions in a patient with human immunodeficiency virus infection] Cañizares R, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):141–2 **(Spa)**

[PCR in the diagnosis of focal cerebral lesions in HIV infected patients] Pujol-Riqué M, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):29–35 (82 ref.) **(Spa)**

[Fulminant sepsis by Listeria monocytogenes in a patient with coinfection by human immunodeficiency virus (letter)] Ricart C, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):147–8 **(Spa)**

[Initial infection by human immunodeficiency virus accompanied by disseminated mycobacteriosis (letter)] Sáez L, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):381–2 **(Spa)**

[Myocarditis by Toxoplasma in a patient with human immunodeficiency virus infection (letter)] Segura JC, et al. **Enferm Infecc Microbiol Clin** 1999 Apr;17(4):200–1 **(Spa)**

[Nitric oxide levels in cephalorhachidian + + fluid in patients with HIV infection (letter)] Velasco JJ, et al. **Enferm Infecc Microbiol Clin** 1999 May;17(5):252–3 **(Spa)**

[HIV infection in mental disease: a new group with risk behaviors (editorial)] Ayuso Mateos JL. **Med Clin (Barc)** 1998 Sep 19;111(8):292–3 **(Spa)**

[Tuberculosis trends in Barcelona (1987–1995). Impact of the human immunodeficiency virus and control measures] Caylà JA, et al. **Med Clin (Barc)** 1998 Nov 14; 111(16):608–15 (Eng. Abstr.) **(Spa)**

[Myelopathy and human immunodeficiency virus infection] Lleó A, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):423–7 (86 ref.) **(Spa)**

[Liver transplantation in patients infected with the human immunodeficiency virus: the difficult challenge of a new stage (editorial)] Torre-Cisneros J, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):215–8 (33 ref.) **(Spa)**

[Febrile picture with disseminated ulcers and plantar lesions] de Argila Fernández-Durán D, et al. **Rev Clin Esp** 1998 Aug;198(8):539–40 **(Spa)**

[Primary cavity-based lymphoma and HIV infection] Valencia Ortega ME, et al. **Rev Clin Esp** 1999 Feb; 199(2):73–7 (Eng. Abstr.) **(Spa)**

[Pseudomonas aeruginosa as a pathogen in patients with human immunodeficiency virus infection] Vidal Marsal F, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 2:37–43 (36 ref.) **(Spa)**

[Utility of bronchoalveolar lavage in the diagnosis of respiratory infection in HIV patients] Aliaga L, et al. **Rev Med Univ Navarra** 1997 Oct–Dec;41(4):217–23 (Eng. Abstr.) **(Spa)**

[Neurophysiological parameters and CD4 lymphocyte count in patients infected by human immunodeficiency virus] Aznar-Bueno C, et al. **Rev Neurol** 1998 Nov;27(159):789–92 (Eng. Abstr.) **(Spa)**

[Use of health services and progression of AIDS in persons with HIV infection in Belo Horizonte (Minas Gerais), Brazil] Acurcio F de A, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):331–40 (Eng. Abstr.) **(Spa)**

CONGENITAL

Neurodevelopmental outcomes of Ugandan infants with HIV infection: an application of growth curve analysis. Drotar D, et al. **Health Psychol** 1999 Mar;18(2):114–21

Growth of children according to maternal and child HIV, immunological and disease characteristics: a prospective cohort study in Kinshasa, Democratic Republic of Congo. Bailey RC, et al. **Int J Epidemiol** 1999 Jun;28(3):532–40

Mother-to-child transmission of human immunodeficiency virus (HIV) in Ireland: a prospective study. Nourse CB, et al. **Ir J Med Sci** 1998 Jul–Sep;167(3):145–8

Moyamoya syndrome in a patient with congenital human immunodeficiency virus infection. Hsiung GY, et al. **J Child Neurol** 1999 Apr;14(4):268–70

Cyclosporine for rectoperineal fistula in a human immunodeficiency virus-infected child. Caselli D, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):333–5

Cryptosporidium-induced gastric obstruction in a child with congenital HIV infection: case report and review of the literature. Moon A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):108–11 (23 ref.)

Diagnosis disclosure by family caregivers to children who have perinatally acquired HIV disease: when the time comes [see comments] Ledlie SW. **Nurs Res** 1999 May–Jun; 48(3):141–9. Comment in: Nurs Res 1999 May–Jun;48(3):119.

Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature. Rohrer T, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):382–6 (27 ref.)

DIAGNOSIS

Spectrum of clinical diseases in HIV-infected adults at the Lagos University Teaching Hospital: a five-year experience [1992–1996]. Akinsete I, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):147–51

Selective versus universal antenatal HIV testing: epidemiological and implementational factors in policy choice. Ades AE, et al. **AIDS** 1999 Feb 4;13(2):271–8

HIV testing and counseling among men attending sexually transmitted disease clinics in Pune, India: changes in condom use and sexual behavior over time. Bentley ME, et al. **AIDS** 1998 Oct 1;12(14):1869–77

Attitude of pregnant women towards HIV testing in Abidjan, Côte d'Ivoire and Bobo-Dioulasso, Burkina Faso. DITRAME Study Group (ANRS 049 Clinical Trial). Diminution de la Transmission Mère Enfant du VIH. Agence Nationale de Recherches sur le SIDA. Cartoux M, et al. **AIDS** 1998 Dec 3;12(17):2337–44

Acceptability of voluntary HIV testing by pregnant women in developing countries: an international survey. Ghent International Working Group on Mother-to-Child Transmission of HIV: Cartoux M, et al. **AIDS** 1998 Dec 24;12(18):2489–93

Serological testing algorithms for the diagnosis of HIV infection [editorial] Dax EM. **AIDS** 1999 Jan 14;13(1):133–4

Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d'Ivoire. Nkengasong JN, et al. **AIDS** 1999 Jan 14;13(1):109–17

Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study. Simonds RJ, et al. **AIDS** 1998 Aug 20;12(12):1545–9

What do pregnant women think about the HIV test? A qualitative study. Boyd FM, et al. **AIDS Care** 1999 Feb; 11(1):21–9

Feasibility of named antenatal HIV screening in an inner city population. Dennison B, et al. **AIDS Care** 1998 Jun; 10(3):259–65

Acceptability of voluntary HIV testing with counselling in a rural village in Kagera, Tanzania. Killewo JZ, et al. **AIDS Care** 1998 Aug;10(4):431–9

Hope and resilience in suicide ideation and behavior of gay and bisexual men following notification of HIV infection. Siegel K, et al. **AIDS Educ Prev** 1999 Feb;11(1):53–64

A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors. Axelrod JH, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):759–67

Urine-based test to detect HIV antibodies [news] **Am Fam Physician** 1998 Oct 1;58(5):1222

HIV testing for all pregnant women [news] **Am Fam Physician** 1999 Feb 1;59(3):701, 704

How to recognize and treat acute HIV syndrome [see comments] Perlmutter BL, et al. **Am Fam Physician** 1999 Aug;60(2):535–42, 545–6 (24 ref.). Comment in: Am Fam Physician 1999 Aug;60(2):413–4, 417. Comment in: Am Fam Physician 1999 Aug;60(2):417–8.

HIV screening [news] Rose VL. **Am Fam Physician** 1999 Sep 1;60(3):1023

FDA warning on HIV tests purchased on the Internet [news] Rose VL. **Am Fam Physician** 1999 Sep 1;60(3):1026, 1029

The conundrum of early HIV infection [editorial; comment] Siwek J, et al. **Am Fam Physician** 1999 Aug;60(2):417–8. Comment on: Am Fam Physician 1999 Aug;60(2):535–42, 545–6.

Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Chen Y, et al. **Am Heart J** 1999 Mar;137(3):516–21 (49 ref.)

Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Vardinon N, et al. **Am J Kidney Dis** 1999 Jul;34(1):146–9

Legal considerations in screening pregnant women for human immunodeficiency virus. Grimes RM, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):259–64 (24 ref.)

Universal HIV screening at a major metropolitan TB clinic: HIV prevalence and high-risk behaviors among TB patients. Weis SE, et al. **Am J Public Health** 1999 Jan; 89(1):73–5

Identification of human immunodeficiency virus-infected individuals by delayed type hypersensitivity skin testing. Metersky ML, et al. **Ann Clin Lab Sci** 1998 Sep–Oct; 28(5):272–9

Misdiagnosis of HIV infection [letter] Goodman C, et al. **Ann Intern Med** 1999 Oct 5;131(7):547; discussion 547–8

Rapid testing for HIV: why so fast? [news] Kane B. **Ann Intern Med** 1999 Sep 21;131(6):481–3

Misdiagnosis of HIV infection [letter] Palmas W. **Ann Intern Med** 1999 Oct 5;131(7):546–7; discussion 547–8

Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Rich JD, et al. **Ann Intern Med** 1999 Jan 5;130(1):37–9

HIV testing in pregnant women [letter; comment] Wong JG. **Ann Intern Med** 1998 Dec 15;129(12):1075. Comment on: Ann Intern Med 1998 May 1;128(9):760–7.

Generalized exanthem with palmoplantar involvement and genital ulcerations. Acute primary HIV infection. Porras-Luque JI, et al. **Arch Dermatol** 1998 Oct; 134(10):1279, 1282

A population with short delay from diagnosis of human immunodeficiency virus to medical care [letter; comment] Guenter CD, et al. **Arch Intern Med** 1999 Apr 12; 159(7):758–9. Comment on: Arch Intern Med 1998 Apr 13;158(7):734–40.

Chronic renal insufficiency [letter; comment] Hirsch RL. **Arch Intern Med** 1999 Apr 12;159(7):757. Comment on: Arch Intern Med 1998 Sep 14;158(16):1743–52.

Antenatal HIV testing: assessment of a routine voluntary approach. Simpson WM, et al. **BMJ** 1999 Jun 19; 318(7199):1660–1

HIV testing and prevention issues for women attending termination assessment clinics. Bergenstrom A, et al. **Br J Fam Plann** 1999 Apr;25(1):3–8

Women's knowledge and attitudes, and the acceptability of voluntary antenatal HIV testing. Duffy TA, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):849–54

Each of the following statements about human immunodeficiency virus (HIV) in pregnancy is true. **Can Fam Physician** 1999 Aug;45:1872, 1880 **(Eng, Fre)**

Routine prenatal HIV screening program launched. Ketchum P. **Can Fam Physician** 1999 Mar;45:700–2, 708–9 **(Eng, Fre)**

Non-nominal HIV surveillance: preserving privacy while tracking an epidemic. Patrick DM, et al. **Can J Public Health** 1999 May–Jun;90(3):164–7

Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Vassilopoulos D, et al. **Cleve Clin J Med** 1998 Sep;65(8):436–41 (33 ref.)

Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Aziz N, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):755–61

Compulsory HIV tests [letter; comment] Dunn RW. **CMAJ** 1999 May 4;160(9):1286–7. Comment on: CMAJ 1998 Oct 20;159(8):942–7.

Talking about HIV [letter; comment] Keystone D. **CMAJ** 1998 Oct 20;159(8):920–1. Comment on: CMAJ 1998 Jun 2;158(11):1449–57.

False-positive results in antenatal HIV screening [letter; comment] Magee LA, et al. **CMAJ** 1999 May 4;160(9):1285 . Comment on: CMAJ 1998 Jun 2;158(11):1449–57.

Routine prenatal screening for HIV in a low-prevalence setting [see comments] Patrick DM, et al. **CMAJ** 1998 Oct 20;159(8):942–7. Comment in: CMAJ 1999 May 4;160(9):1286–7.

Ontario joins prenatal HIV-screening movement [news] Silversides A. **CMAJ** 1999 Jan 26;160(2):173–4

Results of a survey of diagnosed HIV infections prevalent in 1996 in England and Wales. Molesworth AM. **Commun Dis Public Health** 1998 Dec;1(4):271–5

Newly diagnosed HIV infections among pregnant women and their partners [letter; comment] Puro V, et al. **Eur J Epidemiol** 1998 Jul;14(5):521–2. Comment on: Eur J Epidemiol 1997 Jun;13(4):373–8.

Screening infertile couples for HIV infection [letter; comment] Abusheikha N, et al. **Fertil Steril** 1998 Oct; 70(4):785–6. Comment on: Fertil Steril 1997 Nov;68(5):820–5.

Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada. Teitel JM, et al. **Haemophilia** 1998 Sep;4(5):731–8

Primary care of HIV infection [see comments] Bartlett JA, et al. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):53–6, 61–4, 67–9; discussion 69–71. Comment in: Hosp Pract (Off Ed) 1999 Apr 15;34(4):62.

Occupational exposure and voluntary human immunodeficiency virus testing: a survey of Maryland hospitals. Solomon L, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):430–2

Determinants of antepartum human immunodeficiency virus testing in a non-Medicaid obstetric population. Cardonick E, et al. **Infect Dis Obstet Gynecol** 1998;6(5):209–13

Mucocutaneous manifestations of HIV infection: a retrospective analysis of 145 cases in a Chinese population in Malaysia. Jing W, et al. **Int J Dermatol** 1999 Jun; 38(6):457–63

Evaluation of 2 techniques of HIV pre-test counselling for pregnant women in west Africa. DITRAME Study Group. Cartoux M, et al. **Int J STD AIDS** 1999 Mar;10(3):199–201

Human immunodeficiency virus and hepatitis B virus infection in pregnancy: diagnostic potential of viral genome detection. Berger A, et al. **Intervirology** 1998;41(4–5):201–7 (38 ref.)

Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. Tansuphasawadikul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):326–32

Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. Vanhems P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1; 21(2):99–106

Acute varicella zoster with postherpetic hyperhidrosis as the initial presentation of HIV infection. Chopra KF, et al. **J Am Acad Dermatol** 1999 Jul;41(1):119–21

HIV home tests can be inaccurate [news] **J Am Osteopath Assoc** 1999 Jul;99(7):355

The complexities of HIV testing mount [news] Zuger A. **J Ark Med Soc** 1999 Jan;95(8):334

On-line coupling of polymerase chain reaction and capillary electrophoresis for automatic DNA typing and HIV-1 diagnosis. Zhang N, et al. **J Chromatogr B Biomed Sci Appl** 1998 Aug 28;714(1):3–11

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target. de Baar MP, et al. **J Clin Microbiol** 1999 Jun;37(6):1813–8

Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. Panteleeff DD, et al. **J Clin Microbiol** 1999 Feb;37(2):350–3

Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. Sun R, et al. **J Clin Microbiol** 1998 Oct; 36(10):2964–9

Evaluation of epidemiological and serological predictors of human immunodeficiency virus type-1 (HIV-1) infection among high risk professional blood donors with western blot indeterminate results. Chattopadhya D, et al. **J Clin Virol** 1998 Jul 24;11(1):39–49

Isoelectricfocusing and reverse blotting as a diagnostic tool in pediatric HIV infection. del Bono V, et al. **J Clin Virol** 1998 Dec;11(3):203–10

Amplicor HIV monitor, NASBA HIV-1 RNA QT and quantiplex HIV RNA version 2.0 viral load assays: a Canadian evaluation. Prud'homme IT, et al. **J Clin Virol** 1998 Dec;11(3):189–202

Anonymous testing of HIV infection in pregnant women. Gupta MK, et al. **J Commun Dis** 1998 Jun;30(2):121–2

Syphilis in an HIV infected patient misdiagnosed as leprosy. Fonseca E, et al. **J Cutan Pathol** 1999 Jan;26(1):51–4

Hepatitis C in the patient with human immunodeficiency virus infection. Spengler U, et al. **J Hepatol** 1998 Dec; 29(6):1023-30 (84 ref.)

Clinical presentation of HIV infection in patients aged 50 years or older. Ena J, et al. **J Infect** 1998 Nov;37(3):213-6

Antenatal screening for HIV in the UK: what is to be done? [editorial] [see comments] Nicoll A. **J Med Screen** 1998; 5(4):170-1 (31 ref.). Comment in: J Med Screen 1999;6(2):111-2.

Antenatal screening for HIV in the UK [letter; comment] Ray S. **J Med Screen** 1999;6(2):111-2. Comment on: J Med Screen 1998;5(4):170-1.

Performance of antenatal HIV screening strategies in the UK: correction [letter] Tookey P, et al. **J Med Screen** 1998; 5(4):214

Performance of antenatal HIV screening strategies in the United Kingdom [published erratum appears in J Med Screen 1998;5(4):214] Tookey PA, et al. **J Med Screen** 1998; 5(3):133-6

Simple/rapid test devices for anti-HIV screening: do they come up to the mark? Giles RE, et al. **J Med Virol** 1999 Sep;59(1):104-9

False negativity by an anti-HIV assay kit (IMx 8B32) and evaluation of its replacement (IMx 8C98). Parry JV, et al. **J Med Virol** 1998 Oct;56(2):138-44

Neurobehavioral correlates of perceived mental and motor slowness in HIV infection and AIDS. Lopez OL, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):343-50

Forty-six-year-old man with unexplained hematuria, proteinuria, and pulmonary infiltrates: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine. Lee S, et al. **J Okla State Med Assoc** 1998 Oct;91(7):399-405

Oral mucosal leishmaniasis as a presenting feature of HIV infection and its management. Chaudhry Z, et al. **J Oral Pathol Med** 1999 Jan;28(1):43-6

Human immunodeficiency virus prevalence in women at delivery using unlinked anonymous testing of newborns in the Malaysian setting. Amar HS, et al. **J Paediatr Child Health** 1999 Feb;35(1):63-6

Patterns of presentation of human immunodeficiency virus type 1-infected children to the paediatric surgeon. Grant HW. **J Pediatr Surg** 1999 Feb;34(2):251-4

The dilemma of antenatal HIV testing: what goes on in the European Community? Hudson CN, et al. **J R Soc Med** 1999 Jun;92(6):273-6

HIV and the returning expatriate. Jones ME. **J Travel Med** 1999 Jun;6(2):99-106 (47 ref.)

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27-38

Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II. van Binsbergen J, et al. **J Virol Methods** 1998 Dec; 76(1-2):59-71

Multicenter evaluation of a new rapid automated human immunodeficiency virus antigen detection assay. Weber B, et al. **J Virol Methods** 1999 Mar;78(1-2):61-70

HIV screening launched in Ireland [news] Birchard K. **Lancet** 1997 Oct 11;350(9084):1084

Spain offers free HIV tests to pregnant women [news] Bosch X. **Lancet** 1999 Aug 28;354(9180):754

Sepsis with multiple organ dysfunction. De Socio GV, et al. **Lancet** 1998 May 23;351(9115):1552

Should assays drive science or vice versa? [letter; comment] Johnston MI, et al. **Lancet** 1997 Oct 11;350(9084):1108. Comment on: Lancet 1997 Jul 26;305(9073):230-1.

Voluntary blood tests for Canadian doctors? [news] Kondro W. **Lancet** 1998 Oct 10;352(9135):1205

Antenatal screening for HIV in Australia: time to revise policies? Ziegler JB. **Med J Aust** 1999 Aug 16;171(4):201-3

Immunohistochemical retrieval of the principal HIV antigens p24, gp41, and gp120 in formalin fixed tissue: an investigation using HIV infected lymphoblasts and postmortem brain tissue from AIDS cases. Morrison HL, et al. **Mol Pathol** 1998 Aug;51(4):227-31

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5-1999. A 37-year-old man with fever and diffuse lymphadenopathy [clinical conference] **N Engl J Med** 1999 Feb 18;340(7):545-54

Acute HIV infection among patients tested for mononucleosis [letter] Rosenberg ES, et al. **N Engl J Med** 1999 Mar 25; 340(12):969

HIV homes tests. **N J Med** 1999 Aug;96(8):14

Roche integrates HIV therapeutics and diagnostics [news] Robertson D. **Nat Biotechnol** 1998 Sep;16(9):815

A comparison of immunocomplex-dissociated serum HIV-1 p24 antigenemia and plasma HIV-1 viral load: assessment of 3,129 paired assays. Manfredi R, et al. **New Microbiol** 1999 Jul;22(3):269-75

Laboratory diagnosis of HIV infection in Papua New Guinea. Babona DV, et al. **P N G Med J** 1996 Sep;39(3):200-4 (5 ref.)

Clinical manifestations of HIV infection in Melanesian adults. Seaton A, et al. **P N G Med J** 1996 Sep;39(3):181-2

Index of suspicion. Case 3. Diagnosis: HIV infection. Stille CJ. **Pediatr Rev** 1999 Mar;20(3):103, 105-6

HIV service provision and training needs in outpatient mental health settings. Satriano J, et al. **Psychiatr Q** 1999 Spring; 70(1):63-74

Troublesome diagnosis in two children born to HIV-1 infected mothers. Liberatore D, et al. **Rev Argent Microbiol** 1998 Jul-Sep;30(3):143-6

HIV testing not for self-doers [news] **S Afr Med J** 1998 Sep; 88(9):1062

The association of false-positive rapid plasma reagin results and HIV infection. Joyanes P, et al. **Sex Transm Dis** 1998 Nov;25(10):569-71

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Albert JM, et al. **Stat Med** 1998 Nov 15;17(21):2435-62

Incorporating correlations between measurements into the estimation of age-related reference ranges. Wade AM, et al. **Stat Med** 1998 Sep 15;17(17):1989-2002

Primary HIV infection diagnosed in South Africa masquerading as another tropical disease. Pendle S, et al. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):425-7

HIV in leprosy patients. Burns SM. **Trop Doct** 1999 Apr; 29(2):126-7

Childhood tuberculosis score chart when HIV infection is common [letter; comment] Graham SM. **Trop Doct** 1999 Jul;29(3):187-9. Comment on: Trop Doct 1998 Jul;28(3):155-60.

Local evaluation of a rapid HIV assay for use in developing countries. Zaw M, et al. **Trop Med Int Health** 1999 Mar; 4(3):216-21

New tests for detecting HIV infection. Woehrle TA, et al. **West J Med** 1998 Dec;169(6):371-2

Wisconsin statutes regarding HIV testing in primary care: frequent questions and answers. Vergeront JM, et al. **WMJ** 1998 Dec;97(11):47-51 (1 ref.)

Meeting the challenge of early identification of HIV infection in primary care. Vergeront JM, et al. **WMJ** 1998 Dec; 97(11):52-61 (6 ref.)

[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1129-33 (Eng. Abstr.) **(Dut)**

[Vertical HIV-1-transmission. II. HIV-diagnosis in a child] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2724-8 (33 ref.) (Eng. Abstr.) **(Dut)**

[Disseminated cutaneous leishmaniasis revealing human immunodeficiency virus infection] Durand I, et al. **Ann Dermatol Venereol** 1998 Apr;125(4):268-70 (Eng. Abstr.) **(Fre)**

[Diagnostic case. Primary HIV infection] Noacco G, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):525-6 **(Fre)**

[Clinical importance of the quantification of HIV-1 RNA in cerebrospinal fluid for the diagnosis of HIV encephalitis] Bossi P, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):423-5 (Eng. Abstr.) **(Fre)**

[Use in Mozambique of WHO diagnostic strategies in HIV infection] Louis FJ, et al. **Sante** 1999 Mar-Apr;9(2):111-4 (Eng. Abstr.) **(Fre)**

[Muscle pain after travel to the tropics (letter; comment)] Gudemann D. **Dtsch Med Wochenschr** 1999 May 7; 124(18):575. Comment on: Dtsch Med Wochenschr 1998 Oct 9;123(41):1201-6. **(Ger)**

[HIV infection as an occupational disease in a hospital physician. Decision of the Federal Social Court 18 November 1997] Rieger HJ. **Dtsch Med Wochenschr** 1998 Nov 27;123(48):1461 **(Ger)**

[Hepatitis B and HIV: the role of the family physician] Bucklitsch M, et al. **Fortschr Med** 1999 Apr 20;117(11):33 **(Ger)**

[Clinical and histopathological characterization of oral leukoplakia in patients with HIV infection] Schmidt-Westhausen AM, et al. **Mund Kiefer Gesichtschir** 1999 Mar;3(2):73-7 (Eng. Abstr.) **(Ger)**

[Results and complications of fiber bronchoscopy in HIV positive patients] Steiner S, et al. **Pneumologie** 1998 Dec; 52(12):694-9 (Eng. Abstr.) **(Ger)**

[Red fingers] Speich R. **Schweiz Med Wochenschr** 1998 Nov 7;128(45):1789 **(Ger)**

[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)] Yerly S, et al. **Schweiz Med Wochenschr** 1999 Feb 27; 129(8):319-22 (Eng. Abstr.) **(Ger)**

[Exertional dyspnea in HIV infection] Krautheim A. **Schweiz Rundsch Med Prax** 1998 Nov 4;87(45):1512-5 **(Ger)**

[Testing for HIV infection in pregnant women at the obstetric centers in Italy] D'Ubaldo C, et al. **Minerva Ginecol** 1999 Jan-Feb;51(1-2):7-14 (Eng. Abstr.) **(Ita)**

[The symptoms in HIV disease: prevalence and control (editorial)] Fantoni M, et al. **Recenti Prog Med** 1999 Apr; 90(4):217-21 (16 ref.) **(Ita)**

[The diagnosis of new cases of HIV infection: a reversal of the trend?] Manfredi R, et al. **Recenti Prog Med** 1999 Apr; 90(4):202-5 (Eng. Abstr.) **(Ita)**

[The principles of pre-epidemic diagnosis in the epidemiological surveillance system for HIV infection] Borovskii IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):10-1 (Eng. Abstr.) **(Rus)**

[The testing policy for HIV infection in Ukraine] Kobyshcha Iu. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):65-7 (Eng. Abstr.) **(Rus)**

[A retrospective study of the expediency of performing the immunoblot in conducting expert diagnosis at a center for the prevention and control of AIDS] Matveeva EM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):62-3 (Eng. Abstr.) **(Rus)**

[The clinical course of HIV infection in children who were parenterally infected] Popova IA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):75-8 (Eng. Abstr.) **(Rus)**

[The theory and practice of using in-house control in screening and verification studies for the diagnosis of HIV infection] Shevelev BI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):60-1 (Eng. Abstr.) **(Rus)**

[Mucocutaneous manifestations in acute HIV infection. 3 case reports] Barnadas MA, et al. **An Med Interna** 1998 Dec; 15(12):650-3 (Eng. Abstr.) **(Spa)**

[Evaluation of indirect immunofluorescence as a supplementary test for the diagnosis of HIV-1 infection] Ceballos A, et al. **Rev Argent Microbiol** 1998 Apr-Jun; 30(2):59-63 (Eng. Abstr.) **(Spa)**

[7 new cases of HIV-2 infection recognized in Madrid in 1996 and 1997] Machuca A, et al. **Rev Clin Esp** 1998 Oct; 198(10):660-4 (Eng. Abstr.) **(Spa)**

[Burkitt leukemia as the presenting form of acquired immunodeficiency syndrome. Description of 2 cases (letter)] Gracia A, et al. **Sangre (Barc)** 1999 Jun;44(3):242-3 **(Spa)**

DIET THERAPY

Outcome measures for nutritional research in HIV/AIDS. Keithley JK, et al. **Nutrition** 1999 Jul-Aug;15(7-8):638-40

DRUG THERAPY

Safe and effective use of combination antiretroviral treatment. Colebunders R, et al. **Acta Clin Belg** 1999 Apr; 54(2):55-60

Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children. **Acta Paediatr** 1999 Feb;88(2):228-32

Protease inhibitors in antiviral therapy of paediatric HIV disease [letter] Manfredi R, et al. **Acta Paediatr** 1998 Jul; 87(7):814-6

Lactoferrin. Antiviral activity of lactoferrin. Swart PJ, et al. **Adv Exp Med Biol** 1998;443:205-13

Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Wang HK, et al. **Adv Exp Med Biol** 1998; 439:191-225 (99 ref.)

Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight? The European Collaborative Study. **AIDS** 1999 Jan 14; 13(1):119-24

A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. **AIDS** 1998 Oct 1;12(14):F151-60

4th International Congress on Drug Therapy in HIV infection. Glasgow, United Kingdom, 8-12 November 1998. Abstracts. **AIDS** 1998 Nov;12 Suppl 4:S1-113

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. **AIDS** 1999 Apr 1;13(5):565-73

Place of antiretroviral drugs in the treatment of HIV-infected people in Africa. International AIDS Society. **AIDS** 1999 Feb 4;13(2):IAS1-3 (0 ref.)

Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children. **AIDS** 1999 May 28;13(8):927-33

Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee [editorial] **AIDS** 1998 Jul 30;12(11):1259-65 (19 ref.)

How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee. **AIDS** 1999 Jul 9;13(10):1241-7

Lipodystrophy associated with nevirapine-containing antiretroviral therapies [letter] Aldeen T, et al. **AIDS** 1999 May 7;13(7):865-7

Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. Allard JP, et al. **AIDS** 1998 Sep 10;12(13):1653-9

The impact of highly active antiretroviral therapy on HIV-related hospitalizations in 17 county hospitals in Catalonia, Spain. Catalonian County Hospitals HIV Infection Study Group [letter] Altés J, et al. **AIDS** 1999 Jul 30;13(11):1418-9

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. Altice FL, et al. **AIDS** 1999 May 28;13(8):957-62

Delayed HIV-1 seroconversion after antiretroviral therapy [letter] Apetrei C, et al. **AIDS** 1998 Oct 1;12(14):1935-6

Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy [letter] Barreiro PM, et al. **AIDS** 1999 Mar 11;13(4):525-6

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. Bayoumi AM, et al. **AIDS** 1998 Aug 20;12(12):1503-12

Impaired glucose tolerance, beta cell function and lipid

metabolism in HIV patients under treatment with protease inhibitors. Behrens G, et al. **AIDS** 1999 Jul 9;13(10):F63–70

Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. Bellman PC. **AIDS** 1998 Jul 30;12(11):1333–40

Ketoacidosis associated with protease inhibitor therapy [letter] Besson C, et al. **AIDS** 1998 Jul 30;12(11):1399–400

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. Bisset LR, et al. **AIDS** 1998 Nov 12;12(16):2115–23

Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. Böhler T, et al. **AIDS** 1999 May 7;13(7):779–89

Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. Bouscarat F, et al. **AIDS** 1998 Jul 30;12(11):1267–73

Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy [letter] Boyraz-Ikiz HD, et al. **AIDS** 1999 May 7;13(7):867

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. Bratt G, et al. **AIDS** 1998 Nov 12;12(16):2193–202

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial] Brinkman K, et al. **AIDS** 1998 Oct 1;12(14):1735–44 (108 ref.)

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. Brodie SB, et al. **AIDS** 1998 Dec 24;12(18):2433–7

Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Cameron DW, et al. **AIDS** 1999 Feb 4;13(2):213–24

Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy [letter] Canani RB, et al. **AIDS** 1999 May 28;13(8):1005–6

T cell changes after combined nucleoside analogue therapy in HIV primary infection. Carcelain G, et al. **AIDS** 1999 Jun 18;13(9):1077–81

Lamivudine for chronic hepatitis B and HIV co-infection [letter] Carton JA, et al. **AIDS** 1999 May 28;13(8):1002–3

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. Casado JL, et al. **AIDS** 1998 Jul 30;12(11):F131–5

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Chêne G, et al. **AIDS** 1998 Dec 3;12(17):2313–20

Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. Chougnet C, et al. **AIDS** 1998 Dec 24;12(18):2397–406

Immunologic and virologic response of HIV-2 infection to antiretroviral therapy [letter] Clark NM, et al. **AIDS** 1998 Dec 24;12(18):2506–7

A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. Cohen C, et al. **AIDS** 1998 Aug 20;12(12):1495–502

Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. Cohen Stuart JW, et al. **AIDS** 1998 Nov 12;12(16):2155–9

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). Cohen Stuart JW, et al. **AIDS** 1999 May 7;13(7):F53–8

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. Craig C, et al. **AIDS** 1998 Sep 10;12(13):1611–8

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. d'Arminio Monforte A, et al. **AIDS** 1998 Sep 10;12(13):1631–7

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine [editorial] De Boer RJ, et al. **AIDS** 1998 Sep 10;12(13):1567–70 (49 ref.)

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. Deeks SG, et al. **AIDS** 1999 Apr 16; 13(6):F35–43

Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells [letter] Degen O, et al. **AIDS** 1998 Sep 10;12(13):1715–6

Higher antiviral activity of antiretroviral regimens including protease inhibitors [letter] de Mendoza C, et al. **AIDS** 1999 May 28;13(8):998–9

Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection [editorial] Deresinski SC. **AIDS** 1999 Apr 16;13(6):633–43 (136 ref.)

Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine [letter] De Wit S, et al. **AIDS** 1999 May 7;13(7):864–5

Predictors of undetectable HIV plasma viral load in 250 HIV-positive women receiving care [letter] Dickinson BP, et al. **AIDS** 1998 Oct 22;12(15):2075–6

Substituting nevirapine for protease inhibitors because of intolerance [letter] Dieleman JP, et al. **AIDS** 1999 Jul 30; 13(11):1423–4

Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge [letter] Di Martino V, et al. **AIDS** 1999 Jul 30;13(11):1421–3

Indinavir and thrombocytopenia [letter] Durand JM. **AIDS** 1999 Jan 14;13(1):148–9

Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? [letter] Eriksson U, et al. **AIDS** 1998 Oct 22;12(15):2079–80

Abacavir rechallenge has to be avoided in case of hypersensitivity reaction [letter] Escaut L, et al. **AIDS** 1999 Jul 30;13(11):1419–20

HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy [letter] Evison J, et al. **AIDS** 1999 Apr 16; 13(6):732–4

Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients [letter; comment] Fätkenheuer G, et al. **AIDS** 1998 Jul 30; 12(11):1402–3. Comment on: AIDS 1998 Jun 18;12(9):1111.

Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy [letter] Fischer T, et al. **AIDS** 1999 Apr 1;13(5):628–9

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee [letter] Flandre P. **AIDS** 1999 Feb 25;13(3):430–1

Deep venous thrombosis and megestrol in patients with HIV infection [letter] Force L, et al. **AIDS** 1999 Jul 30; 13(11):1425–6

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. Foudraine NA, et al. **AIDS** 1998 Aug 20;12(12):1513–9

Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications [editorial] Friedman SR, et al. **AIDS** 1998 Nov 12;12(16):2089–93 (37 ref.)

Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. Gallant JE, et al. **AIDS** 1999 Feb 4;13(2):225–9

Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy [letter] Galli M, et al. **AIDS** 1998 Dec 24;12(18):2500–2

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Garcia F, et al. **AIDS** 1999 Jul 30;13(11):F79–86

Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA, et al. **AIDS** 1999 May 28;13(8):963–9

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. Gervasoni C, et al. **AIDS** 1999 Mar 11;13(4):465–71

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team [letter] Gill MJ. **AIDS** 1998 Jul 30; 12(11):1400–2

Lest we forget: neuropsychiatry and the new generation anti-HIV drugs [editorial] Gonzalez A, et al. **AIDS** 1998 Dec 24;12(18):2365–7

Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. Green LA, et al. **AIDS** 1998 Oct 22;12(15):1983–90

Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors [letter] Gripshover BM, et al. **AIDS** 1998 Dec 24;12(18):2513–4

Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy [letter] Grubert TA, et al. **AIDS** 1999 Jul 30;13(11):1430–1

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. Hall CS, et al. **AIDS** 1999 Jul 9;13(10):1207–12

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. Harrigan PR, et al. **AIDS** 1999 May 28; 13(8):F59–62

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Haubrich RH, et al. **AIDS** 1999 Jun 18;13(9):1099–107

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. Hengge UR, et al. **AIDS** 1998 Dec 3;12(17):F225–34

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients [letter] Hewitt RG, et al. **AIDS** 1999 May 7;13(7):868–9

High incidence of nevirapine-associated rash in HIV-infected Chinese [letter] Ho TT, et al. **AIDS** 1998 Oct 22;12(15):2082–3

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. Hoetelmans RM, et al. **AIDS** 1998 Dec 3;12(17):F211–6

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. Hoetelmans RM, et al. **AIDS** 1998 Jul 30;12(11):F111–5

One world, one hope: the cost of providing antiretroviral therapy to all nations. Hogg RS, et al. **AIDS** 1998 Nov 12;12(16):2203–9

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. Hughes MD, et al. **AIDS** 1998 Oct 1;12(14):1823–32

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. Ibáñez A, et al. **AIDS** 1999 Jun 18;13(9):1045–9

Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals. Ioannidis JP, et al. **AIDS** 1998 Dec 24;12(18):2417–23

High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy [letter] Jubault V, et al. **AIDS** 1998 Dec 3;12(17):2358–9

Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir [letter] Karmochkine M, et al. **AIDS** 1998 Dec 24;12(18):2499

Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. Kaufmann GR, et al. **AIDS** 1998 Sep 10;12(13):1625–30

Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T-cell count? Keita-Perse O, et al. **AIDS** 1998 Oct 22;12(15):F175–9

Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. Kirk O, et al. **AIDS** 1998 Oct 22;12(15):2031–9

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. Kirk O, et al. **AIDS** 1999 Jan 14;13(1):F9–16

Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy. Kostense S, et al. **AIDS** 1998 Dec 24; 12(18):F235–40

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. Kuritzkes DR, et al. **AIDS** 1999 Apr 16;13(6):685–94

Combination antiretroviral therapy for HIV infection: policies and practices [letter] Lansky A, et al. **AIDS** 1998 Aug 20;12(12):1552–3

Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. Lillo FB, et al. **AIDS** 1999 May 7;13(7):791–6

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study [see comments] Lorenzi P, et al. **AIDS** 1998 Dec 24;12(18):F241–7. Comment in: AIDS 1998 Dec 24;12(18):2495–7.

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17–21

Lipodystrophy in patients naive to HIV protease inhibitors [letter] Madge S, et al. **AIDS** 1999 Apr 16;13(6):735–7

HIV-associated non-mycobacterial sepsis-bacteraemia, before and during the highly active antiretroviral therapy era [letter] Manfredi R, et al. **AIDS** 1999 Jul 9;13(10):1274–6

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. Martin C, et al. **AIDS** 1999 Jul 9;13(10):1227–32

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. Martínez E, et al. **AIDS** 1999 May 7;13(7):805–10

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease [letter] Maserati R, et al. **AIDS** 1999 May 7;13(7):870–1

Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. Mastroianni CM, et al. **AIDS** 1999 May 28; 13(8):883–90

Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy [letter] Mastroianni CM, et al. **AIDS** 1998 Oct 1;12(14):1939–40

CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy [letter] Meroni L, et al. **AIDS** 1999 Apr 1;13(5):621–2

Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors [letter] Meyer D, et al. **AIDS** 1999 Jun 18;13(9):1147–8

Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. Mezzaroma I, et al. **AIDS** 1999 Jul 9;13(10):1187–93

Opportunistic infections occurring during highly active antiretroviral treatment. Michelet C, et al. **AIDS** 1998 Oct 1;12(14):1815–22

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. Mitsuyasu RT, et al. **AIDS** 1998 Jul 30;12(11):F103–9

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team. Mobley JE, et al. **AIDS** 1999 Jul 30; 13(11):F87–93

Predictors of a viral response and subsequent virological

treatment failure in patients with HIV starting a protease inhibitor. Mocroft A, et al. **AIDS** 1998 Nov 12; 12(16):2161–7

Rebound of plasma HIV viral load following prolonged suppression with combination therapy [letter] Montaner JS, et al. **AIDS** 1998 Jul 30;12(11):1398–9

Reversal of abnormalities of neutrophil adhesion molecule expression in HIV infection following protease inhibitor therapy [letter] Moore DA, et al. **AIDS** 1998 Oct 22; 12(15):2083–4

Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy. Mueller BU, et al. **AIDS** 1998 Oct 22; 12(15):F191–6

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. Murray JS, et al. **AIDS** 1999 May 7;13(7):797–804 (24 ref.)

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Musoke P, et al. **AIDS** 1999 Mar 11;13(4):479–86

Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland [letter] Nadal D, et al. **AIDS** 1998 Dec 3;12(17):2356–7

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. Neumann AU, et al. **AIDS** 1999 Apr 16;13(6):677–83

Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen [see comments] Notermans DW, et al. **AIDS** 1998 Aug 20; 12(12):1483–90. Comment in: AIDS 1999 Feb 25;13(3):429–30.

Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients [letter; comment] Orlando G, et al. **AIDS** 1999 Feb 25;13(3):424–5. Comment on: AIDS 1998 Aug 20;12(12):1459–64.

Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert [letter] Otero MJ, et al. **AIDS** 1999 May 28;13(8):1004–5

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. Paul S, et al. **AIDS** 1999 Feb 25;13(3):415–8

HIV suppression and risk of drug resistance mutations [letter] Phillips AN, et al. **AIDS** 1998 Oct 1;12(14):1930

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. Piketty C, et al. **AIDS** 1999 Jul 30;13(11):F71–7

Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. Pilcher CD, et al. **AIDS** 1999 Jul 30;13(11):1337–42

Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. Poggi C, et al. **AIDS** 1999 Jul 9;13(10):1213–20

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Raboud JM, et al. **AIDS** 1998 Sep 10;12(13):1619–24

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. Race E, et al. **AIDS** 1998 Aug 20;12(12):1465–74

Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. Rae S, et al. **AIDS** 1998 Nov 12;12(16):2185–92

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. Raffi F, et al. **AIDS** 1998 Oct 22;12(15):1999–2005

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. Renaud M, et al. **AIDS** 1999 Apr 16;13(6):669–76

Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients [letter] Revankar SG, et al. **AIDS** 1998 Dec 24;12(18):2511–3

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Revicki DA, et al. **AIDS** 1999 May 7;13(7):851–8

A stochastic model for primary HIV infection: optimal timing of therapy. Ribeiro RM, et al. **AIDS** 1999 Feb 25; 13(3):351–7

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy [letter] Rice PS, et al. **AIDS** 1999 Apr 16; 13(6):729–31

Combined stavudine and lamivudine during pregnancy [letter] Ristola M, et al. **AIDS** 1999 Feb 4;13(2):285

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. Roubenoff R, et al. **AIDS** 1999 Jul 30;13(11):1373–5

Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES [letter] Rusconi S, et al. **AIDS** 1999 Jun 18;13(9):1144–5

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, et al. **AIDS** 1999 Feb 25;13(3):359–65

Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? Schechter M, et al. **AIDS** 1999 Jan 14; 13(1):97–102

Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease [letter] Schürmann D, et al. **AIDS** 1998 Nov 12;12(16):2232–3

Combination antiretroviral therapy during pregnancy [editorial; comment] Scott GB, et al. **AIDS** 1998 Dec 24; 12(18):2495–7. Comment on: AIDS 1998 Dec 24;12(18):F241–7.

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. Sendi PP, et al. **AIDS** 1999 Jun 18;13(9):1115–22

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. Shevitz AH, et al. **AIDS** 1999 Jul 30;13(11):1351–7

The effect of protease inhibitors on weight and body composition in HIV-infected patients. Silva M, et al. **AIDS** 1998 Sep 10;12(13):1645–51

Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. Simpson DM, et al. **AIDS** 1998 Dec 24;12(18):2425–32

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. Sperling RS, et al. **AIDS** 1998 Oct 1;12(14):1805–13

HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. Staszewski S, et al. **AIDS** 1998 Oct 22;12(15):1991–7

Rebound of HIV-1 viral load after suppression to very low levels [letter] Staszewski S, et al. **AIDS** 1998 Dec 3; 12(17):2360

Virological response to protease inhibitor therapy in an HIV clinic cohort. Staszewski S, et al. **AIDS** 1999 Feb 25; 13(3):367–73

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. Staszewski S, et al. **AIDS** 1999 May 28;13(8):951–6

Poor penetration of the male genital tract by HIV-1 protease inhibitors [letter] Taylor S, et al. **AIDS** 1999 May 7; 13(7):859–60

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. Tebas P, et al. **AIDS** 1999 Feb 4;13(2):F23–8

Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency. Thuret I, et al. **AIDS** 1999 Jan 14;13(1):81–7

Agranulocytosis induced by abacavir [letter] Tikhomirov V, et al. **AIDS** 1999 Jul 30;13(11):1420–1

Interaction between ritonavir and levothyroxine [letter] Tseng A, et al. **AIDS** 1998 Nov 12;12(16):2235–6

Highly active antiretroviral therapy among drug users in Amsterdam: self-perceived reasons for not receiving therapy [letter] van der Werf MJ, et al. **AIDS** 1999 Jul 9;13(10):1280–1

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. Walli R, et al. **AIDS** 1998 Oct 22;12(15):F167–73

Adherence to combination antiretroviral therapy assessed by anonymous patient self-report [letter] Walsh JC, et al. **AIDS** 1998 Dec 3;12(17):2361–3

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. Weverling GJ, et al. **AIDS** 1998 Jul 30;12(11):F117–22

Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity [see comments] Wilkinson D, et al. **AIDS** 1998 Sep 10;12(13):1675–82. Comment in: AIDS 1998 Sep 10;12(13):1571–80.

HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. Woods ML 2nd, et al. **AIDS** 1998 Aug 20;12(12):1491–4

Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? [letter; comment] Wu H, et al. **AIDS** 1999 Feb 25; 13(3):429–30. Comment on: AIDS 1998 Aug 20;12(12):1483–90.

Changing attitudes towards antiretroviral treatment of HIV infection: a prospective study in a sample of Dutch general practitioners. Reedijk M, et al. **AIDS Care** 1999 Apr; 11(2):141–5

Medication adherence strategies for drug abusers with HIV/AIDS. Sorensen JL, et al. **AIDS Care** 1998 Jun; 10(3):297–312

Use of protease inhibitors among persons with AIDS in Los Angeles County. Sorvillo F, et al. **AIDS Care** 1999 Apr; 11(2):147–55

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. Adams GB, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):551–9

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. Churchill DR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1181–9

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. Cook J, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):499–508

Downregulation of the expression of the main immunoglobulin V(H) family in HIV-infected patients: modulation by triple combination therapy [letter] David D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):315–6

Elusive realities: a perspective on the Chicago retrovirus meeting. Harris PJ. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1149–50

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. Haslett PA, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1169–79

Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection. Hengel RL, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):435–43

Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. Kaufmann GR, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20; 15(11):963–72

Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). Lori F, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):619–24

Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations. Nokta M, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):255–64

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. Noormohamed FH, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1047–52

Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children. Principi N, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1653–9

Treatment of HIV infection with cytoreductive agents. Smith C, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10; 14(15):1305–13

Once-daily drug for persons with HIV [news] **Am Fam Physician** 1998 Dec;58(9):2174–5

Abacavir for treatment of HIV infection [news] **Am Fam Physician** 1999 Mar 1;59(5):1329

How to recognize and treat acute HIV syndrome [see comments] Perlmutter BL, et al. **Am Fam Physician** 1999 Aug;60(2):535–42, 545–6 (24 ref.). Comment in: Am Fam Physician 1999 Aug;60(2):413–4, 417. Comment in: Am Fam Physician 1999 Aug;60(2):417–8.

HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. Pomerantz RJ. **Am Fam Physician** 1999 May 15;59(10):2855

Availability of updated HIV treatment guidelines [news] Rose VL. **Am Fam Physician** 1999 Aug;60(2):678

Once-daily nonnucleoside reverse-transcriptase inhibitor approved [news] **Am J Health Syst Pharm** 1998 Dec 1; 55(23):2458

Using a pharmacist's progress-note form to manage HIV pharmacotherapy. Geletko S, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):420–1

Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)

Amprenavir approved for HIV treatment [news] Miller SL. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1057–8

Compliance issues in the treatment of HIV infection. Tseng AL. **Am J Health Syst Pharm** 1998 Sep 1;55(17):1817–24 (35 ref.)

Simultaneous use of two protease inhibitors in HIV infection. Varav H, et al. **Am J Health Syst Pharm** 1999 Feb 1; 56(3):273–6 (29 ref.)

Renal insufficiency induced by ritonavir in HIV-infected patients [letter] Bochet MV, et al. **Am J Med** 1998 Nov; 105(5):457

Herbs' benefits and risks [letter] Badten K. **Am J Nurs** 1999 Jul;99(7):14

Ethics and HIV trials [letter; comment] Simonds RJ, et al. **Am J Public Health** 1999 Feb;89(2):255–6. Comment on: Am J Public Health 1998 Apr;88(4):547–8.

Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Naccache JM, et al. **Am J Respir Crit Care Med** 1999 Jun; 159(6):2009–13

New developments in the treatment of HIV disease: An overview. Hovanessian HC. **Ann Emerg Med** 1999 May; 33(5):546–55 (71 ref.)

Myocardial infarction in HIV-infected men receiving protease inhibitors [letter] Flynn TE, et al. **Ann Intern Med** 1999 Oct 5;131(7):548

Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Gulick RM, et al. **Ann Intern Med** 1999 Mar 16; 130(6):510–4

Beyond HIV viral load testing [news] Kane B. **Ann Intern Med** 1999 Oct 19;131(8):637–8

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV–1 disease progression: results from the EuroSIDA study. Miller V, et al. **Ann Intern Med** 1999 Apr 6;130(7):570–7

Characteristics of primary HIV infection [letter; comment] Silvers AA. **Ann Intern Med** 1999 Jan 5;130(1):80–1. Comment on: Ann Intern Med 1998 Apr 15;128(8):613–20.

"Buffalo humps" associated with protease inhibitors [letter; comment] Stricker RB, et al. **Ann Intern Med** 1999 Feb 2;130(3):241–2. Comment on: Ann Intern Med 1998 Jul 15;129(2):164.

Translating clinical trial results into practice: the effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV–infected pregnant women. Turner BJ, et al. **Ann Intern Med** 1999 Jun 15;130(12):979–86

Salvage treatment against human immunodeficiency virus. Battegay M, et al. **Ann Med** 1999 Aug;31(4):253–60 (36 ref.)

Pharmacologic considerations for therapeutic success with antiretroviral agents. Fletcher CV. **Ann Pharmacother** 1999 Sep;33(9):989–95 (35 ref.)

The use of combination antiretroviral therapy in HIV–infected patients. Holtzer CD, et al. **Ann Pharmacother** 1999 Feb;33(2):198–209

Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. Rublein JC, et al. **Ann Pharmacother** 1999 Sep;33(9):899–905

Nonprescription and alternative medication use by individuals with HIV disease. Smith SR, et al. **Ann Pharmacother** 1999 Mar;33(3):294–300

Focal hepatic lesions on magnetic resonance imaging induced by trimethoprim/sulfamethoxazole in HIV infection [letter] Takahashi T, et al. **Ann Pharmacother** 1999 Sep; 33(9):1007–8

Significant interactions with new antiretrovirals and psychotropic drugs. Tseng AL, et al. **Ann Pharmacother** 1999 Apr;33(4):461–73 (83 ref.)

Indinavir–fluconazole interaction [letter; comment] Bellibas SE. **Antimicrob Agents Chemother** 1999 Feb;43(2):432–3. Comment on: Antimicrob Agents Chemother 1998 Feb;42(2):223–7.

A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus–infected patients. Piscitelli SC, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):647–50

Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus–infected patients. Robbins BL, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2656–60

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV–infected adults. Sadler BM, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1686–92

Intracellular nucleotides of (–)–2',3'–deoxy–3'–thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Solas C, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2989–95

Single–dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Wang LH, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1708–15

Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Daelemans D, et al. **Antivir Chem Chemother** 1999 Jan;10(1):1–14 (131 ref.)

Anti–human immunodeficiency virus drug combination strategies. Vandamme AM, et al. **Antivir Chem Chemother** 1998 May;9(3):187–203 (149 ref.)

A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple–drug HIV therapy for the evolution of antiviral resistance. Colgrove R, et al. **Antiviral Res** 1999 Feb;41(1):45–56 (45 ref.)

The role of non–nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV–1 infection. De Clercq E. **Antiviral Res** 1998 Jun;38(3):153–79 (137 ref.)

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Evans TG, et al. **Antiviral Res** 1998 Oct;39(3):163–73

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI–272, an inhibitor of HIV–1 protease, in patients with AIDS or symptomatic HIV infection. Humphrey RW, et al. **Antiviral Res** 1999 Feb;41(1):21–33

Resistance mutations selected in vivo under therapy with anti–HIV drug HBY 097 differ from resistance pattern selected in vitro. Rübsamen–Waigmann H, et al. **Antiviral Res** 1999 May;42(1):15–24

Antiviral treatment for human immunodeficiency virus patients co–infected with hepatitis B virus: combined effect for both infections, an obtainable goal? Wolters LM, et al. **Antiviral Res** 1999 May;42(1):71–6

The changing spectrum of the cutaneous manifestation of HIV disease [letter; comment] Colebunders R, et al. **Arch Dermatol** 1999 Apr;135(4):471. Comment on: Arch Dermatol 1998 Oct;134(10):1290–2.

Carnitine stands on its own in HIV infection treatment [letter; comment] Famularo G, et al. **Arch Intern Med** 1999 May 24;159(10):1143–4. Comment on: Arch Intern Med 1998 Nov 9;158(20):2257–64.

Monitoring adherence to HIV therapy [letter] Tuldrà A, et al. **Arch Intern Med** 1999 Jun 28;159(12):1376–7

Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Valdez H, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1771–6

Hepatic mitochondrial toxicity from nucleoside analog therapy [letter; comment] Finkle HI. **Arch Pathol Lab Med** 1999 Mar;123(3):189. Comment on: Arch Pathol Lab Med 1998 Apr;122(4):342–5.

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Balzarini J. **Biochem Pharmacol** 1999 Jul 1;58(1):1–27 (219 ref.)

Chemokine receptors––future therapeutic targets for HIV? Proudfoot AE, et al. **Biochem Pharmacol** 1999 Mar 1; 57(5):451–63 (123 ref.)

HIV disease treatment in the era of HAART. Bonfanti P, et al. **Biomed Pharmacother** 1999 Mar;53(2):93–105 (124 ref.)

Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR–undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements? [editorial] Mathé G. **Biomed Pharmacother** 1999 Mar;53(2):57–62 (24 ref.)

Data of pre–clinical and early clinical trials of acriflavine and hydroxy–methyl–ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics. Mathé G, et al. **Biomed Pharmacother** 1998;52(9):391–6 (34 ref.)

Hypothetical reasons of the HIV1–AIDS "tritherapy" failure. A challenging model [editorial] [see comments] Mathé G. **Biomed Pharmacother** 1997;51(10):413–6 (39 ref.). Comment in: Biomed Pharmacother 1997 ;51(10):417–26.

Antiretroviral therapy: 'the state of the art'. Montaner JS, et al. **Biomed Pharmacother** 1999 Mar;53(2):63–72 (41 ref.)

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Shafer RW, et al. **Biomed Pharmacother** 1999 Mar; 53(2):73–86 (105 ref.)

Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Sloand EM, et al. **Blood** 1999 Aug 1;94(3):1021–7

Protease inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival [letter] Buss N, et al. **BMJ** 1999 Jan 9;318(7176):122

Risk of HIV related Kaposi's sarcoma and non–Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Ledergerber B, et al. **BMJ** 1999 Jul 3;319(7201):23–4

Development of autoantibodies and factor VIII inhibitor in an HIV–infected haemophiliac following treatment with combination anti–retroviral therapy [letter] Evans GD, et al. **Br J Haematol** 1998 Sep;102(5):1382–3

Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection. Inui K, et al. **Brain Dev** 1999 Sep; 21(6):416–9

Hope for HIV patients. News from the 12th International Conference on HIV and AIDS [news] Elliott EB. **Can Fam Physician** 1999 Mar;45:829–31

Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Badley AD, et al. **Cell Death Differ** 1999 May;6(5):420–32

Atherogenic dyslipidemia in HIV–infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Périard D, et al. **Circulation** 1999 Aug 17; 100(7):700–5

Drug monitoring of antiretroviral therapy for HIV–1 infection: method validation and results of a pilot study. Moyer TP, et al. **Clin Chem** 1999 Sep;45(9):1465–76

Recombinant human gamma interferon in human immunodeficiency virus–infected children: safety, CD4(+)–lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211). Shearer WT, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):311–5

IL–10 in HIV infection: increasing serum IL–10 levels with disease progression––down–regulatory effect of potent anti–retroviral therapy. Stylianou E, et al. **Clin Exp Immunol** 1999 Apr;116(1):115–20

Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV–infected subjects with highly active anti–retroviral therapy (HAART) or HAART + IL–2. Zanussi S, et al. **Clin Exp Immunol** 1999 Jun; 116(3):486–92

Acetyl–L–carnitine administration increases insulin–like growth factor 1 levels in asymptomatic HIV–1–infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Di Marzio L, et al. **Clin Immunol** 1999 Jul;92(1):103–10

Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV–1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells [see comments] Kaushal S, et al. **Clin Immunol** 1999 Jul;92(1):14–24. Comment in: Clin Immunol 1999 Jul;92(1):1–2.

Chronic active hepatitis B exacerbations in human immunodeficiency virus–infected patients following development of resistance to or withdrawal of lamivudine. Bessesen M, et al. **Clin Infect Dis** 1999 May;28(5):1032–5

Acyclovir–resistant herpes zoster in human immunodeficiency virus–infected patients: results of foscarnet therapy. Breton G, et al. **Clin Infect Dis** 1998 Dec;27(6):1525–7

Clinical experience and choice of drug therapy for human immunodeficiency virus disease [see comments] Brosgart CL, et al. **Clin Infect Dis** 1999 Jan;28(1):14–22. Comment in: Clin Infect Dis 1999 Jan;28(1):23–5.

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus–related tuberculosis. Burman WJ, et al. **Clin Infect Dis** 1999 Mar;28(3):419–29; quiz 430 (108 ref.)

Factors that predict incomplete virological response to protease inhibitor–based antiretroviral therapy. Clough LA, et al. **Clin Infect Dis** 1999 Jul;29(1):75–81; discussion 82–4

The incidence and spectrum of AIDS–defining illnesses in persons treated with antiretroviral drugs [see comments] Forrest DM, et al. **Clin Infect Dis** 1998 Dec;27(6):1379–85 . Comment in: Clin Infect Dis 1998 Dec;27(6):1386–7.

An open–label pilot study of the efficacy and tolerability of once–daily didanosine versus twice–daily didanosine. Keiser P, et al. **Clin Infect Dis** 1998 Aug;27(2):400–1

Treatment of human immunodeficiency virus 1–infected infants and children with the protease inhibitor nelfinavir mesylate. Krogstad P, et al. **Clin Infect Dis** 1999 May; 28(5):1109–18

Prospective follow–up of 67 indinavir–experienced human immunodeficiency virus–infected and AIDS patients treated with the ritonavir/saquinavir combination. Lallemand F, et al. **Clin Infect Dis** 1999 May;28(5):1184–5

Shock and cerebral infarct after rifampin re–exposure in a patient infected with human immunodeficiency virus. Martínez E, et al. **Clin Infect Dis** 1998 Nov;27(5):1329–30

What is the relevance of antiretroviral therapy that does not include protease inhibitors? [editorial; comment] Miller LG, et al. **Clin Infect Dis** 1998 Dec;27(6):1386–7. Comment on: Clin Infect Dis 1998 Dec;27(6):1379–85.

Effect of oral beta–carotene supplementation on plasma human immunodeficiency virus (HIV) RNA levels and CD4+ cell counts in HIV–infected patients. Nimmagadda AP, et al. **Clin Infect Dis** 1998 Nov;27(5):1311–3

Time for a new paradigm––optimal management of patients with human immunodeficiency virus infection and AIDS [editorial; comment] Robbins GK. **Clin Infect Dis** 1999 Jan; 28(1):23–5. Comment on: Clin Infect Dis 1999 Jan;28(1):14–22.

Longer–term immunologic effects and side effects of successful antiretroviral therapy. Schooley RT. **Clin Infect Dis** 1999 Jul;29(1):12–8 (49 ref.)

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus–infected patients: protease inhibitors, non–nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Tavel JA, et al. **Clin Infect Dis** 1999 Mar;28(3):643–76 (99 ref.)

Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Tseng A, et al. **Clin Infect Dis** 1998 Oct;27(4):908–9

Rapidly evolving hepatitis C virus–related cirrhosis in a human immunodeficiency virus–infected patient receiving triple antiretroviral therapy. Zylberberg H, et al. **Clin Infect Dis** 1998 Nov;27(5):1255–8

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Barry M, et al. **Clin Pharmacokinet** 1999 Apr; 36(4):289–304 (101 ref.)

Improved survival among HIV–infected patients after initiation of triple–drug antiretroviral regimens [see comments] Hogg RS, et al. **CMAJ** 1999 Mar 9; 160(5):659–65. Comment in: CMAJ 1999 Mar 9;160(5):669–70.

New–onset diabetes mellitus associated with protease inhibitor therapy in an HIV–positive patient: case report and review. Lee EC, et al. **CMAJ** 1999 Jul 27;161(2):161–4 (27 ref.)

HIV clinical trials are not enough [editorial; comment] Millson ME, et al. **CMAJ** 1999 Mar 9;160(5):669–70. Comment on: CMAJ 1999 Mar 9;160(5):659–65.

New ethical obligations accompany new HIV drugs, conference told. Silversides A. **CMAJ** 1999 Jul 27; 161(2):187

Protease inhibitors raising quality–of–life issues for HIV patients. Silversides A. **CMAJ** 1999 Mar 23;160(6):894

Rationale and design of the Tanzania Vitamin and HIV Infection Trial. Fawzi WW, et al. **Control Clin Trials** 1999 Feb;20(1):75–90

Antiretroviral chemotherapy. Saag MS, et al. **Curr Clin Top Infect Dis** 1998;18:154–79 (77 ref.)

Advances and future challenges in non–Hodgkin's lymphoma. Klencke B, et al. **Curr Opin Oncol** 1998 Sep; 10(5):422–7 (37 ref.)

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV–infected patients on highly active antiretroviral therapy (HAART). Vigouroux C, et al. **Diabetes Metab** 1999 Sep;25(3):225–32

Drug interactions of HIV protease inhibitors. Malaty LI, et

al. **Drug Saf** 1999 Feb;20(2):147–69 (93 ref.)
A risk–benefit assessment of HIV protease inhibitors. Moyle GJ, et al. **Drug Saf** 1999 Apr;20(4):299–321 (94 ref.)
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Moyle GJ, et al. **Drug Saf** 1998 Dec;19(6):481–94 (67 ref.)
Efavirenz. Adkins JC, et al. **Drugs** 1998 Dec;56(6):1055–64; discussion 1065–6 (34 ref.)
Complexity of human immunodeficiency virus management in developing countries [editorial; comment] White AD, et al. **Epidemiology** 1998 Nov;9(6):593–5. Comment on: Epidemiology 1998 Nov;9(6):590–3.
Efficacy vs impact of human immunodeficiency virus–related drug therapies [editorial; comment] [see comments] Zierler S. **Epidemiology** 1998 Nov;9(6):590–3. Comment on: Epidemiology 1998 Nov;9(6):605–12. Comment in: Epidemiology 1998 Nov;9(6):593–5.
Human immunodeficiency virus mutation and changes in CD4 T-cell levels during antiretroviral therapy [editorial] Battegay M. **Eur J Clin Microbiol Infect Dis** 1998 May; 17(5):301–3
Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Cabié A, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):812–3
Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Mirete G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):810–1
Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting. Pérez–Olmeda M, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):448–9
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type–1 nucleoside reverse–transcriptase inhibitors. Venturi G, et al. **Eur J Clin Microbiol Infect Dis** 1999 Apr; 18(4):274–82
Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV–infected patient heavily exposed to nucleoside analogues. Villalba N, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):372–5
The chemokine family. Potential therapeutic targets from allergy to HIV infection. Proudfoot AE. **Eur J Dermatol** 1998 Apr–May;8(3):147–57 (111 ref.)
Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy [letter] Cauda R, et al. **Eur J Haematol** 1999 Aug;63(2):134–5
Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Jung C, et al. **Eur J Med Res** 1998 Sep 17;3(9):439–42
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV–infected patients refractory to standard triple therapy. Reiser M, et al. **Eur J Med Res** 1999 Feb 25;4(2):54–8
Failure of double protease inhibitor therapy as a salvage therapy for HIV–infected patients resistant to conventional triple therapy. Rockstroh JK, et al. **Eur J Med Res** 1999 Jul 28;4(7):271–4
Treatment of AIDS–related complications. 12th World–AIDS–Conference, June 1998, Geneva. Tossing G. **Eur J Med Res** 1998 Sep 17;3(9):449–52
Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus–infected children [letter] Funk M, et al. **Eur J Pediatr** 1999 Jan;158(1):86–7
Human immunodeficiency virus and hepatitis B virus co–infection in two siblings: viral loads markedly reduced by triple–therapy including lamivudine [letter] Horneff G, et al. **Eur J Pediatr** 1999 Aug;158(8):687–8
When do HIV–infected persons start with antiretroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines. Reedijk M, et al. **Fam Pract** 1998 Dec;15(6):525–8
Antisense activity of an anti–HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols. Bonora GM, et al. **Farmaco** 1998 Oct–Nov; 53(10–11):634–7
Resistance to HIV protease inhibitors. Condra JH. **Haemophilia** 1998 Jul;4(4):610–5 (24 ref.)
HIV treatment—a rational approach to the use of antiretroviral agents. Vella S. **Haemophilia** 1998 Jul; 4(4):616–8 (10 ref.)
AZT trials and tribulations. Crouch RA, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):26–34 (32 ref.)
Science in the service of healing. Grady C. **Hastings Cent Rep** 1998 Nov–Dec;28(6):34–8 (19 ref.)
Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Kelly JA, et al. **Health Psychol** 1998 Jul;17(4):310–9 (100 ref.)
Access and use of medications in HIV disease. Smith SR, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):123–44
Primary care of HIV infection [see comments] Bartlett JA, et al. **Hosp Pract (Off Ed)** 1998 Dec 15;33(12):53–6, 61–4, 67–9; discussion 69–71. Comment in: Hosp Pract (Off Ed) 1999 Apr 15;34(4):62.
Restoration of the immune system with anti–retroviral therapy. Autran B, et al. **Immunol Lett** 1999 Mar; 66(1–3):207–11 (9 ref.)
Antigen–specific T–lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV–1 infection. Pontesilli O, et al. **Immunol Lett** 1999 Mar;66(1–3):213–7
HIV infection: how effective is drug combination treatment? Grossman Z, et al. **Immunol Today** 1998 Nov;19(11):528–32 (22 ref.)
Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Silverman NS, et al. **Infect Dis Obstet Gynecol** 1998;6(6):237–43
Zidovudine. Sperling R. **Infect Dis Obstet Gynecol** 1998; 6(5):197–203 (27 ref.)
Preliminary experiences with ritonavir in children with advanced HIV infection. Horneff G, et al. **Infection** 1999 Mar–Apr;27(2):103–7
Randomized, double–blind, placebo–controlled trial of the immune modulator WF10 in patients with advanced AIDS. Raffanti SP, et al. **Infection** 1998 Jul–Aug;26(4):202–7
Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross–toxicity with indinavir [letter] Vandercam B, et al. **Infection** 1998 Sep–Oct;26(5):313
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. Been–Tiktak AM, et al. **Int J Antimicrob Agents** 1999 Jan; 11(1):13–21
Adverse drug reactions (ADRs) in patients with HIV infection. A prospective study. González–Martín G, et al. **Int J Clin Pharmacol Ther** 1999 Jan;37(1):34–40
Efavirenz in the management of HIV infection. Gazzard BG. **Int J Clin Pract** 1999 Jan–Feb;53(1):60–4
HIV: mother to child transmission, current knowledge and on–going studies. Giaquinto C, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S161–5 (22 ref.)
T cell regeneration in HIV–infected subjects under highly active antiretroviral therapy (review). Fleury S, et al. **Int J Mol Med** 1999 Jul;4(1):91–7 (69 ref.)
Changing cost of English HIV service provision 1996–1997. NPMS Steering Group. National Prospective Monitoring System. **Int J STD AIDS** 1999 Jun;10(6):357–62
Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy. Beck EJ, et al. **Int J STD AIDS** 1998 Sep;9(9):512–7
HIV infection and pregnancy. de Ruiter A, et al. **Int J STD AIDS** 1998 Nov;9(11):647–54; quiz 655 (34 ref.)
Antiretroviral uptake in Australia: medical, attitudinal and cultural correlates. Ezzy DM, et al. **Int J STD AIDS** 1998 Oct;9(10):579–86
The role of proteinases in the treatment of HIV infection. Gazzard B. **Int J STD AIDS** 1998;9 Suppl 1:28–31 (20 ref.)
HIV surveillance must keep pace with advances in antiretroviral therapy [editorial; comment] Goldberg D, et al. **Int J STD AIDS** 1998 Oct;9(10):559–60. Comment on: Int J STD AIDS 1998 Oct;9(10):561–6.
Coronary artery disease occurring with protease inhibitor therapy. Sullivan AK, et al. **Int J STD AIDS** 1998 Nov; 9(11):711–2
A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Honda M, et al. **Intern Med** 1999 Mar; 38(3):302–3
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Bassetti S, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):114–9
Ritonavir combination therapy restores intestinal function in children with advanced HIV disease. Canani RB, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):307–12
Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case–control study. Cauda R, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):20–5
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV–1–infected patients. Chien JW, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):277–80
Changes in body habitus and serum lipid abnormalities in HIV–positive women on highly active antiretroviral therapy (HAART). Dong KL, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):107–13
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two–drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. Friedland GH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):281–92
Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection [letter] Grunke M, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):424–6
Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study [letter] Jahnke N, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):347–8
Antiviral therapy for HIV patients with renal insufficiency. Jayasekara D, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):384–95 (92 ref.)
Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. Kravcik S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):371–5
Lipid abnormalities during saquinavir soft–gel–based highly active antiretroviral therapy [letter] Moyle GJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):423–4
Escalating multiple–dose safety and tolerance study of oral WR 6026 in HIV–infected subjects: AIDS clinical trials group 173. Petty BG, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):26–32
Immune function and phenotype before and after highly active antiretroviral therapy. Søndergaard SR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):376–83
Protease inhibitor use among a community sample of people with HIV disease. Bing EG, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):474–80
Lack of tumors in infants with perinatal HIV–1 exposure and fetal/neonatal exposure to zidovudine. Hanson IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):463–7
Short–term effects of large–dose vitamin A supplementation on viral load and immune response in HIV–infected women. Humphrey JH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):44–51
Decay of HIV–1 DNA in patients receiving suppressive antiretroviral therapy. Izopet J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):478–83
Factors associated with HIV–infected patients' recognition and use of HIV medications. Jeffe DB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):350–60
Protease inhibitor–based therapy is associated with decreased HIV–related health care costs in men treated at a Veterans Administration hospital. Keiser P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):28–33
Phase II, randomized, open–label, community–based trial to compare the safety and activity of combination therapy with recombinant interferon–alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91–253 Study Team. Krown SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):245–54
Clinical trials using HIV–1 RNA–based primary endpoints: statistical analysis and potential biases. Marschner IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):220–7
Substance users and protease inhibitors: do barriers exist? [letter] Michaels S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):212–3
Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV–infected individuals with anemia of chronic disease [letter] Mylonakis E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):306–7
Analysis of HIV–1 reverse transcriptase gene mutations in infected children treated with zidovudine. Orlandi P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):230–7
Prophylaxis for opportunistic infections among HIV–infected patients receiving medical care. Sackoff J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):387–92
Concomitant therapy with subcutaneous interleukin–2 and zidovudine plus didanosine in patients with early stage HIV infection. Simonelli C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):20–7
Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. van Roon EN, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):290–4
Six–hour trimethoprim–sulfamethoxazole–graded challenge in HIV–infected patients. Demoly P, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):1033–6
Resolution of recalcitrant hand warts in an HIV–infected patient treated with potent antiretroviral therapy. Spach DH, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):818–21
Changing treatment regimens for HIV infection: impact on referral patterns and training needs of family physicians [see comments] Brandon W. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):115–9. Comment in: J Am Board Fam Pract 1999 Mar–Apr;12(2):178–80.
Antiretroviral therapy for HIV infection: a review of current medications and therapies. Bright DC. **J Am Optom Assoc** 1999 Jun;70(6):355–83 (288 ref.)
Are HIV–infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy? Easterbrook PJ, et al. **J Antimicrob Chemother** 1999 Mar; 43(3):379–88
Pharmacokinetics, safety and anti–human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine [letter] Luzzati R, et al. **J Antimicrob Chemother** 1998 Oct;42(4):565–6
Chicago ANAC nurses find mock drug trial informative—and fun! Despotes J, et al. **J Assoc Nurses AIDS Care** 1999 Jul–Aug;10(4):85–7
Improved gastrointestinal tolerance and palatability of didanosine in adults by the use of pediatric power formulation. Dodge RT, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):27–31

Adherence to combination therapy in persons living with HIV: balancing the hardships and the blessings. Erlen JA, et al. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):75-84

Clinicians' antiretroviral medications guide. Martin JE, et al. **J Assoc Nurses AIDS Care** 1998 Sep-Oct;9(5):84-6

Lipid abnormalities associated with protease inhibitors. Melroe NH, et al. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):22-30

Thalidomide: the past, present, and future. Porche D. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):82-4

Patient's adherence to antiretroviral medications to control HIV disease [letter] Raper J. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):96-7

Patient appraisal of mandarin orange didanosine: implications for adherence and well-being. Reynolds NR, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):35-41

Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. Aukrust P, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):145-50

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Yanovski JA, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1925-31

The ethics of placebo-controlled trials for perinatal transmission of HIV in developing countries [see comments] Clark PA. **J Clin Ethics** 1998 Summer; 9(2):156-66. Comment in: J Clin Ethics 1998 Summer;9(2):99-107.

Deconstructing equity, autonomy, and ethical analysis [comment] Howe EG. **J Clin Ethics** 1998 Summer; 9(2):99-107. Comment on: J Clin Ethics 1998 Summer;9(2):156-66. Comment on: J Clin Ethics 1998 Summer;9(2):167-72.

The "best proven therapeutic method" standard in clinical trials in technologically developing countries [see comments] Levine RJ. **J Clin Ethics** 1998 Summer; 9(2):167-72. Comment in: J Clin Ethics 1998 Summer;9(2):99-107.

Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. Bucy RP, et al. **J Clin Invest** 1999 May 15; 103(10):1391-8

Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. McDermott JL, et al. **J Clin Microbiol** 1999 Jul;37(7):2361-5

Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. Thibault V, et al. **J Clin Microbiol** 1999 Sep;37(9):3013-6

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. Moyle GJ, et al. **J Clin Pharmacol** 1998 Aug;38(8):736-43

Variations in HIV-RNA viral load and CD4 counts of infants and children receiving antiretroviral drug therapy [letter] Sever JL, et al. **J Clin Virol** 1999 Jan;12(1):71-4

Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. Désormeaux A, et al. **J Drug Target** 1998;6(1):1-15 (105 ref.)

Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. Carrieri MP, et al. **J Epidemiol Community Health** 1999 Jan;53(1):4-8

Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. Zhang L, et al. **J Exp Med** 1999 Sep 6; 190(5):725-32

Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. Nagai K, et al. **J Gastroenterol** 1999 Apr;34(2):275-81

When should we delay highly active antiretroviral therapy? [editorial; comment] Bangsberg DR, et al. **J Gen Intern Med** 1999 Jul;14(7):446-8. Comment on: J Gen Intern Med 1999 Jul;14(7):395-401.

Delays in protease inhibitor use in clinical practice [see comments] Fairfield KM, et al. **J Gen Intern Med** 1999 Jul;14(7):395-401. Comment in: J Gen Intern Med 1999 Jul;14(7):446-8.

Adherence to combination antiretroviral therapies in HIV patients of low health literacy [see comments] Kalichman SC, et al. **J Gen Intern Med** 1999 May;14(5):267-73. Comment in: J Gen Intern Med 1999 May;14(5):315-7.

HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. Stone VE, et al. **J Gen Intern Med** 1998 Sep;13(9):586-93

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Locarnini S, et al. **J Hepatol** 1999 Mar;30(3):536-50 (127 ref.)

Post-HAART therapy research [editorial] Gallo RC. **J Hum Virol** 1998 Jan-Feb;1(2):67-8

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). Gray CM, et al. **J Immunol** 1999 Feb 1;162(3):1780-8

What's new in HIV. Morris-Jones S, et al. **J Infect** 1999 Mar;38(2):i-ii

Can alprostadil improve liver failure in HIV-infected patients with severe acute viral hepatitis? Reus S, et al. **J Infect** 1998 Jul;37(1):84-6

How I encourage my patients to take their antiretroviral therapy regularly. Walsh J. **J Infect** 1999 Mar;38(2):ii

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load. Arnó A, et al. **J Infect Dis** 1999 Jul; 180(1):56-60

Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. Aukrust P, et al. **J Infect Dis** 1999 Jan;179(1):74-82

Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. Bartlett JA, et al. **J Infect Dis** 1998 Dec; 178(6):1803-5

Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. Bartlett JA, et al. **J Infect Dis** 1998 Oct; 178(4):1170-3

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. Carr A, et al. **J Infect Dis** 1998 Oct; 178(4):992-9

Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. Dam Nielsen S, et al. **J Infect Dis** 1998 Nov;178(5):1299-305

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Deeks SG, et al. **J Infect Dis** 1999 Jun; 179(6):1375-81

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. Dore GJ, et al. **J Infect Dis** 1999 Sep;180(3):607-13

Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. Dworkin MS, et al. **J Infect Dis** 1999 Sep;180(3):621-5

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection [letter] Fialaire P, et al. **J Infect Dis** 1999 Aug;180(2):574-5

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. Hirsch M, et al. **J Infect Dis** 1999 Sep;180(3):659-65

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. Kleim JP, et al. **J Infect Dis** 1999 Mar;179(3):709-13

Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. Kully C, et al. **J Infect Dis** 1999 Mar;179(3):705-8

Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. Lindbäck S, et al. **J Infect Dis** 1999 Jun;179(6):1549-52

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Miller MD, et al. **J Infect Dis** 1999 Jan;179(1):92-100

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. Miller V, et al. **J Infect Dis** 1999 Aug;180(2):530-3

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Molina JM, et al. **J Infect Dis** 1999 Aug;180(2):351-8

Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations [letter] Monno L, et al. **J Infect Dis** 1999 Aug;180(2):568-71

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. Moodley J, et al. **J Infect Dis** 1998 Nov;178(5):1327-33

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Murphy RL, et al. **J Infect Dis** 1999 May;179(5):1116-23

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. Murphy RL, et al. **J Infect Dis** 1999 Apr;179(4):808-16

Interleukin-12 enhancement of antigen-specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection. Nagy-Agren SE, et al. **J Infect Dis** 1999 Feb;179(2):493-6

Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children. Palumbo PE, et al. **J Infect Dis** 1999 Mar;179(3):576-83

Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo, Brazil. Pilcher CD, et al. **J Infect Dis** 1999 May;179(5):1259-63

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. Pontesilli O, et al. **J Infect Dis** 1999 Jul;180(1):76-86

Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. Spiegel HM, et al. **J Infect Dis** 1999 Aug;180(2):359-68

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. Tashima KT, et al. **J Infect Dis** 1999 Sep;180(3):862-4

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Vittinghoff E, et al. **J Infect Dis** 1999 Mar;179(3):717-20

CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. Wilkinson J, et al. **J Infect Dis** 1999 Jul;180(1):68-75

Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. Yerly S, et al. **J Infect Dis** 1999 Sep;180(3):850-3

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Young B, et al. **J Infect Dis** 1998 Nov; 178(5):1497-501

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. Zaunders JJ, et al. **J Infect Dis** 1999 Aug; 180(2):320-9

Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. Andreoni M, et al. **J Med Virol** 1998 Dec; 56(4):332-6

The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load. Jordan WC. **J Natl Med Assoc** 1998 Oct;90(10):622-4

CNS as an HIV-1 reservoir; BBB and drug delivery. Kerza-Kwiatecki AP, et al. **J Neurovirol** 1999 Apr; 5(2):113-4

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. McKinney RE Jr, et al. **J Pediatr** 1998 Oct;133(4):500-8

Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. Sleasman JW, et al. **J Pediatr** 1999 May;134(5):597-606

Antiretroviral treatment and travel to developing countries. Colebunders R, et al. **J Travel Med** 1999 Mar;6(1):27-31 (19 ref.)

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6721-8

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. Shafer RW, et al. **J Virol** 1999 Jul;73(7):6197-202

From the Centers for Disease Control and Prevention. Availability of updated HIV treatment guidelines. **JAMA** 1999 Jul 21;282(3):230

Use of antiretroviral therapy by intravenous drug users with HIV [letter; comment] Anderson JF. **JAMA** 1999 Feb 24; 281(8):699; discussion 700-1. Comment on: JAMA 1998 Aug 12;280(6):547-9.

Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia [letter; comment] Clay PG, et al. **JAMA** 1999 Jan 13;281(2):130; discussion 131. Comment on: JAMA 1998 Mar 25;279(12):930-7.

Does use of potent antiretroviral therapy differ by health care setting? [letter; comment] Fessel J, et al. **JAMA** 1999 May 12;281(18):1696-7. Comment on: JAMA 1998 Nov 4;280(17):1497-503.

Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia [letter; comment] Haubrich R, et al. **JAMA** 1999 Jan 13;281(2):130-1. Comment on: JAMA 1998 Mar 25;279(12):930-7.

An asymptomatic 41-year-old man with HIV infection [clinical conference] Makadon HJ. **JAMA** 1999 Feb 24; 281(8):739-44

Use of antiretroviral therapy by intravenous drug users with HIV [letter; comment] Mannheimer SB, et al. **JAMA** 1999

Feb 24;281(8):699; discussion 700–1. Comment on: JAMA 1998 Aug 12;280(6):544–6. Comment on: JAMA 1998 Aug 12;280(6):547–9.
Maintenance antiretroviral treatment in HIV infection. Mayers D. **JAMA** 1999 Feb 10;281(6):497–8
Use of antiretroviral therapy by intravenous drug users with HIV [letter; comment] Michaels SH, et al. **JAMA** 1999 Feb 24;281(8):699–700; discussion 700–1. Comment on: JAMA 1998 Aug 12;280(6):544–6.
Induction/maintenance treatment regimens for HIV. Montaner JS. **JAMA** 1999 May 12;281(18):1680–2
Use of antiretroviral therapy by intravenous drug users with HIV [letter; comment] Murri R, et al. **JAMA** 1999 Feb 24;281(8):700–1. Comment on: JAMA 1998 Aug 12;280(6):544–6.
HIV researchers air new findings [news] Stephenson J. **JAMA** 1999 Mar 10;281(10):883–5
HIV drug resistance testing shows promise [news] Stephenson J. **JAMA** 1999 Jan 27;281(4):309–10
Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures [letter] Tack PC, et al. **JAMA** 1999 Mar 24–31; 281(12):1085–6
Improving patient compliance with HIV treatment regimens [letter; comment] Ungvarski PJ. **JAMA** 1998 Nov 25; 280(20):1745–6. Comment on: JAMA 1998 Jun 24;279(24):1977–83.
Association of the CCR5delta32 mutation with improved response to antiretroviral therapy [letter] Valdez H, et al. **JAMA** 1999 Aug 25;282(8):734
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia [letter; comment] Weinstein B. **JAMA** 1999 Jan 13;281(2):131. Comment on: JAMA 1998 Mar 25;279(12):957–9.
HIV-treatment guidelines [news] **Lancet** 1999 May 15; 353(9165):1682
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group [see comments] **Lancet** 1999 Jun 12;353(9169):2014–25. Comment in: Lancet 1999 Jun 12;353(9169):1984–90.
Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. **Lancet** 1999 Jun 12; 353(9169):2061–4
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group [see comments] Anglaret X, et al. **Lancet** 1999 May 1;353(9163):1463–8. Comment in: Lancet 1999 Jul 24;354(9175):333; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):333–4; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):334; discussion 335.
Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals [letter] Babl FE, et al. **Lancet** 1999 Apr 10;353(9160):1243–4
Huge percentage of women volunteer for zidovudine project [news] Baleta A. **Lancet** 1999 Jan 16;353(9148):219
Antiretroviral treatment [letter; comment] Boelaert JR, et al. **Lancet** 1998 Oct 10;352(9135):1224–5. Comment on: Lancet 1998 Jun 20;351(9119):1825.
CD38/CD8 expression and HAART failure [letter; comment] Caselli D, et al. **Lancet** 1999 Mar 6;353(9155):840–1. Comment on: Lancet 1998 Dec 12;352(9144):1905–6.
Sexual dysfunction with protease inhibitors [letter; comment] Colebunders R, et al. **Lancet** 1999 May 22;353(9166):1802 . Comment on: Lancet 1999 Mar 6;353(9155):810–1.
Lipodystrophy in HIV-1-infected patients [letter] Domingo P, et al. **Lancet** 1999 Sep 4;354(9181):868
Early treatment of HIV-1 infection [letter; comment] Fauci A, et al. **Lancet** 1998 Dec 12;352(9144):1935; discussion 1936. Comment on: Lancet 1998 Sep 19;352(9132):982–3.
Withdrawal of prophylaxis against Pneumocystis carinii pneumonia [comment] Feinberg J. **Lancet** 1999 Apr 17; 353(9161):1287. Comment on: Lancet 1999 Apr 17;353(9161):1293–8.
Pooch protease paunch [letter] Gill MJ, et al. **Lancet** 1999 Jun 12;353(9169):2078
Estimation of missing values [letter] Herxenberg LA, et al. **Lancet** 1999 Aug 21;354(9179):686
Access to treatment for HIV in developing countries [letter; comment] Kroes AC, et al. **Lancet** 1999 Jan 9;353(9147):153 . Comment on: Lancet 1998 Oct 24;352(9137):1379–80.
Adherence to HAART in HIV [letter] [see comments] Lazzarini L, et al. **Lancet** 1999 Mar 6;353(9155):841. Comment in: Lancet 1999 Jun 5;353(9168):1974.
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Ledergerber B, et al. **Lancet** 1999 Mar 13;353(9156):863–8
Riboflavine and severe lactic acidosis [letter] Luzzati R, et al. **Lancet** 1999 Mar 13;353(9156):901–2
Lipid lowering therapy in patients with HIV infection [letter; comment] McBride M, et al. **Lancet** 1998 Nov 28; 352(9142):1782–3. Comment on: Lancet 1998 Sep 26;352(9133):1031–2.
HIV-1 peripheral neuropathy and combination antiretroviral therapy [letter] Markus R, et al. **Lancet** 1998 Dec 12; 352(9144):1906–7
Lipodystrophy in HIV-1-infected patients [letter] Mercié P, et al. **Lancet** 1999 Sep 4;354(9181):867–8
Early treatment of HIV-1 infection [letter; comment] Milazzo F, et al. **Lancet** 1998 Dec 12;352(9144):1936. Comment on: Lancet 1998 Sep 19;352(9132):982–3.
Better salvage therapy for HIV-1 infection still needed [news] Montaner J, et al. **Lancet** 1999 May 29; 353(9167):1857
Progress in HIV-1 therapy continues on upward track [news] Montaner J, et al. **Lancet** 1999 Feb 13;353(9152):565
Antiretroviral treatment in 1998. Montaner JS, et al. **Lancet** 1998 Dec 12;352(9144):1919–22 (55 ref.)
Early treatment of HIV-1 infection [letter; comment] Montella F, et al. **Lancet** 1998 Dec 12;352(9144):1935–6. Comment on: Lancet 1998 Sep 19;352(9132):982–3.
Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients [letter; comment] Murri R, et al. **Lancet** 1999 Jun 5;353(9168):1974. Comment on: Lancet 1999 Mar 6;353(9155):841.
Possible interaction between sildenafil and HIV combination therapy [letter] [see comments] Nandwani R, et al. **Lancet** 1999 Mar 6;353(9155):840. Comment in: Lancet 1999 Jun 12;353(9169):2071–2.
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study [letter] Plana M, et al. **Lancet** 1998 Oct 10;352(9135):1194–5
Liposuction for protease-inhibitor-associated lipodystrophy [letter] Ponce-de-Leon S, et al. **Lancet** 1999 Apr 10; 353(9160):1244
Helsinki Declaration and Thailand [letter; comment] Suwanjandee J, et al. **Lancet** 1999 Jul 24;354(9175):343. Comment on: Lancet 1999 Apr 17;353(9161):1285.
Amsterdam Duration of Antiretroviral Medication (ADAM) study [letter; comment] Torres RA, et al. **Lancet** 1998 Oct 3;352(9134):1149. Comment on: Lancet 1998 Jul 18;352(9123):185–90.
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy [letter] [see comments] Viganó A, et al. **Lancet** 1998 Dec 12; 352(9144):1905–6. Comment in: Lancet 1999 Mar 6;353(9155):840–1.
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group [see comments] Weverling GJ, et al. **Lancet** 1999 Apr 17; 353(9161):1293–8. Comment in: Lancet 1999 Apr 17;353(9161):1287.
Lipid lowering therapy in patients with HIV infection [letter; comment] Wierzbicki AS, et al. **Lancet** 1998 Nov 28; 352(9142):1782. Comment on: Lancet 1998 Sep 26;352(9133):1031–2.
Strategies for cohort sampling under the Cox proportional hazards model, application to an AIDS clinical trial. Kim S, et al. **Lifetime Data Anal** 1999 Jun;5(2):149–72
Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Ding AA, et al. **Math Biosci** 1999 Aug;160(1):63–82
Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. Tan WY, et al. **Math Biosci** 1999 Mar 1;156(1–2):69–94
Use of combination antiretroviral therapy in pregnant women with HIV disease. Newshan G, et al. **MCN Am J Matern Child Nurs** 1998 Nov–Dec; 23(6):307–12; quiz 313 (22 ref.)
HIV disease progression in Australia in the time of combination antiretroviral therapies [see comments] Correll PK, et al. **Med J Aust** 1998 Nov 2;169(9):469–72. Comment in: Med J Aust 1998 Nov 2;169(9):456–7. Comment in: Med J Aust 1999 Mar 15;170(6):285.
Should research ethics change at the border? [editorial; comment] [see comments] McNeill PM. **Med J Aust** 1998 Nov 16;169(10):509–10. Comment on: Med J Aust 1998 Nov 16;169(10):545–8. Comment in: Med J Aust 1999 Aug 2;171(3):167–8.
HIV disease progression in Australia in the time of combination antiretroviral therapies [letter; comment] Spragg GS. **Med J Aust** 1999 Mar 15;170(6):285. Comment on: Med J Aust 1998 Nov 2;169(9):469–72.
"You've gotta have HAART" [editorial; comment] Stewart GJ. **Med J Aust** 1998 Nov 2;169(9):456–7. Comment on: Med J Aust 1998 Nov 2;169(9):469–72.
Three new drugs for HIV infection. **Med Lett Drugs Ther** 1998 Dec 4;40(1041):114–6
Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Baum SE, et al. **Mil Med** 1999 Sep;164(9):609–12
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. **MMWR Morb Mortal Wkly Rep** 1998 Oct 30; 47(RR-20):1–58
Blocking HIV-1 infection with intrakines [news] Dorrell S. **Mol Med Today** 1999 Mar;5(3):97
New drug makes host cell machinery unavailable to HIV [news] Senior K. **Mol Med Today** 1999 Jun;5(6):234–5
Parkinsonism with HIV infection. Mirsattari SM, et al. **Mov Disord** 1998 Jul;13(4):684–9
HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Hoegl L, et al. **Mycoses** 1998 Sep-Oct;41(7-8):321–5
Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection [letter] Arranz Caso JA, et al. **N Engl J Med** 1999 Oct 14; 341(16):1239–40
Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor [see comments] Carr A, et al. **N Engl J Med** 1998 Oct 29;339(18):1296. Comment in: N Engl J Med 1999 Mar 25;340(12):969–70.
Therapeutic strategies for HIV infection--time to think hard [editorial; comment] Cooper DA, et al. **N Engl J Med** 1998 Oct 29;339(18):1319–21. Comment on: N Engl J Med 1998 Oct 29;339(18):1261–8. Comment on: N Engl J Med 1998 Oct 29;339(18):1269–76.
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study [see comments] Furrer H, et al. **N Engl J Med** 1999 Apr 29;340(17):1301–6. Comment in: N Engl J Med 1999 Apr 29;340(17):1356–8.
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy [see comments] Furtado MR, et al. **N Engl J Med** 1999 May 27;340(21):1614–22. Comment in: N Engl J Med 1999 May 27;340(21):1672–4.
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see comments] Havlir DV, et al. **N Engl J Med** 1998 Oct 29; 339(18):1261–8. Comment in: N Engl J Med 1998 Oct 29;339(18):1319–21.
Does Pneumocystis carinii prophylaxis still need to be lifelong? [editorial; comment] Masur H, et al. **N Engl J Med** 1999 Apr 29;340(17):1356–8. Comment on: N Engl J Med 1999 Apr 29;340(17):1301–6.
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team [see comments] Pialoux G, et al. **N Engl J Med** 1998 Oct 29;339(18):1269–76 . Comment in: N Engl J Med 1998 Oct 29;339(18):1319–21.
Residual HIV-1 disease in the era of highly active antiretroviral therapy [editorial; comment] Pomerantz RJ. **N Engl J Med** 1999 May 27;340(21):1672–4. Comment on: N Engl J Med 1999 May 27;340(21):1605–13. Comment on: N Engl J Med 1999 May 27;340(21):1614–22.
Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient [letter] Velasco M, et al. **N Engl J Med** 1999 Jun 3;340(22):1765–6
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy [see comments] Zhang H, et al. **N Engl J Med** 1998 Dec 17; 339(25):1803–9. Comment in: N Engl J Med 1998 Dec 17;339(25):1846–8.
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy [see comments] Zhang L, et al. **N Engl J Med** 1999 May 27;340(21):1605–13. Comment in: N Engl J Med 1999 May 27;340(21):1672–4.
Roche integrates HIV therapeutics and diagnostics [news] Robertson D. **Nat Biotechnol** 1998 Sep;16(9):815
South Africa: setting the wrong example [editorial] **Nat Med** 1999 Jan;5(1):1
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy [see comments] Chun TW, et al. **Nat Med** 1999 Jun;5(6):651–5. Comment in: Nat Med 1999 Jun;5(6):609–11. Comment in: Nat Med 1999 Jun;5(6):611–2.
Latent reservoirs of HIV infection: flushing with IL-2? [news; comment] Cooper DA, et al. **Nat Med** 1999 Jun; 5(6):611–2. Comment on: Nat Med 1999 Jun;5(6):651–5.
HIV-1 entry inhibitors and virus emergence [letter] D'Aquila RT, et al. **Nat Med** 1999 Oct;5(10):1091
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [see comments] Finzi D, et al. **Nat Med** 1999 May;5(5):512–7. Comment in: Nat Med 1999 Jun;5(6):609–11.
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Fleury S, et al. **Nat Med** 1998 Jul;4(7):794–801
Ongoing HIV dissemination during HAART. Grossman Z, et al. **Nat Med** 1999 Oct;5(10):1099–104
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments] Kilby JM, et al. **Nat Med** 1998 Nov; 4(11):1302–7. Comment in: Nat Med 1998 Nov;4(11):1232–3.
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments] Pitcher CJ, et al. **Nat Med** 1999 May;5(5):518–25. Comment in: Nat Med 1999 May;5(5):483–4.
Call to buy nevirapine for developing countries [news] Renault B, et al. **Nat Med** 1999 Oct;5(10):1093
Nailing down another HIV target [news; comment] Richman DD. **Nat Med** 1998 Nov;4(11):1232–3. Comment on: Nat Med 1998 Nov;4(11):1302– 7.
HIV-1 and HAART: a time to cure, a time to kill [news; comment] Saag MS, et al. **Nat Med** 1999 Jun;5(6):609–11

. Comment on: Nat Med 1999 May;5(5):512–7. Comment on: Nat Med 1999 Jun;5(6):651–5.
Renal tolerance of indinavir in HIV-positive patients [letter] Guery B, et al. **Nephron** 1999;82(1):72
Gaining ground in progressive multifocal leukoencephalopathy [editorial; comment] Dolin R. **Neurology** 1999 Feb;52(3):440–1. Comment on: Neurology 1999 Feb;52(3):623–5.
Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Sacktor NC, et al. **Neurology** 1999 May 12;52(8):1640–7
Structural determinants of HIV-1 reverse transcriptase stereoselectivity towards (beta)-L-deoxy- and dideoxy-pyrimidine nucleoside triphosphates: molecular basis for the combination of L-dideoxynucleoside analogs with non-nucleoside inhibitors in anti HIV chemotherapy. Maga G, et al. **Nucleosides Nucleotides** 1999 Apr-May; 18(4–5):795–805
State of the art: antiretroviral and prophylactic treatments in HIV/AIDS. Porche DJ. **Nurs Clin North Am** 1999 Mar; 34(1):95–112 (37 ref.)
Adherence to highly active antiretroviral therapy. Williams AB. **Nurs Clin North Am** 1999 Mar;34(1):113–29 (88 ref.)
Postsexual exposure prophylaxis [news] Klaus BD, et al. **Nurse Pract** 1998 Aug;23(8):70, 72–3
A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection [news] Wolbach J, et al. **Nurse Pract** 1999 Jun;24(6):81–2, 87–90, 92 (27 ref.)
Therapy for HIV: restoring the balance? [editorial] Macallan DC. **Nutrition** 1999 Jul-Aug;15(7–8):590–1
Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Schwenk A, et al. **Nutrition** 1999 Jun;15(6):453–7
Phase III results of second-generation HIV protease inhibitor reported [news] **Oncology (Huntingt)** 1998 Nov;12(11):1616
AIDS drugs effective against most common HIV strain [news] **Oncology (Huntingt)** 1999 Mar;13(3):392
Reduction of HIV-associated oral lesions after highly active antiretroviral therapy [letter] Aguirre JM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):114–5
Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Diz Dios P, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):437–41
Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection. Hagerty SL, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):929–30
A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir. Pelton SI, et al. **Pediatr Infect Dis J** 1999 Jul; 18(7):650–2
Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Purswani M, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):512–6
Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature. Rohrer T, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):382–6 (27 ref.)
Early experience with protease inhibitors in human immunodeficiency virus-infected children. Sáez-Llorens X, et al. **Pediatr Infect Dis J** 1998 Aug;17(8):728–38 (90 ref.)
Ureteral obstruction secondary to indinavir in the pediatric HIV population. Noble CB, et al. **Pediatr Radiol** 1998 Aug; 28(8):627–9
Antiretroviral therapy and medical management of pediatric HIV infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. **Pediatrics** 1998 Oct; 102(4 Pt 2):999–1085 (267 ref.)
Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team. Kline MW, et al. **Pediatrics** 1999 May;103(5):e62
A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Kline MW, et al. **Pediatrics** 1999 Apr;103(4):e47
Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Raskino C, et al. **Pediatrics** 1999 Sep;104(3):e32
Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Carver PL, et al. **Pharm Res** 1999 May;16(5):718–24
Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge? Koopmans PP, et al. **Pharm World Sci** 1998 Dec; 20(6):253–7 (43 ref.)
Indinavir concentrations and antiviral effect. Acosta EP, et al. **Pharmacotherapy** 1999 Jun;19(6):708–12
Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colony-stimulating factor therapy. Engles-Horton LL, et al. **Pharmacotherapy** 1999 Mar;19(3):356–62
Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Piscitelli SC, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1212–6
Human immunodeficiency virus protease inhibitors. Rana KZ, et al. **Pharmacotherapy** 1999 Jan;19(1):35–59 (205 ref.)
Integrating molecular diagnostic and flow cytometric reporting for improved longitudinal monitoring of HIV patients. Asare AL, et al. **Proc AMIA Symp** 1998;:952–6
Therapy planning as constraint satisfaction: a computer-based antiretroviral therapy advisor for the management of HIV. Smith DS, et al. **Proc AMIA Symp** 1998;:627–31
New developments in the biology and treatment of HIV. Bushman F, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11041–2
Latent reservoirs of HIV: obstacles to the eradication of virus. Chun TW, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):10958–61
Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. David D, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15; 95(19):11348–53
Development of HIV protease inhibitors: a survey. Ren S, et al. **Prog Drug Res** 1998;51:1–31 (63 ref.)
Why is the efficacy of HAART so durable? [editorial] Griffiths PD. **Rev Med Virol** 1999 Jan-Mar;9(1):1–2
Use of antiviral agents in pregnant women with HIV infection [letter] Nash E, et al. **S Afr Med J** 1999 Jul; 89(7):704
Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Ullum H, et al. **Scand J Immunol** 1999 May;49(5):539–47
A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients. Roca B, et al. **Scand J Infect Dis** 1998;30(4):426–8
Stevens-Johnson syndrome caused by indinavir. Teira R, et al. **Scand J Infect Dis** 1998;30(6):634–5
HIV. French-led therapy fund kicks off in Africa [news] Balter M. **Science** 1999 May 14;284(5417):1101
Can IL-2 smoke out HIV reservoirs? [news] WIlliams N. **Science** 1998 Nov 20;282(5393):1394–5
HIV drug resistance: genotypic assays and their possible applications. Ballard AL, et al. **Sex Transm Infect** 1998 Aug;74(4):243–8 (16 ref.)
Commentary: resistance testing--a clinical perspective. Gazzard BG, et al. **Sex Transm Infect** 1999 Jun;75(3):141–2
The use of HIV resistance assays--random or randomised? [editorial] Loveday C, et al. **Sex Transm Infect** 1999 Jun; 75(3):140–1
Is nucleoside analogue monotherapy sufficient for treatment of HBV infection? Lessons from HIV [editorial] Pillay D, et al. **Sex Transm Infect** 1999 Apr;75(2):87–8
Positive attitude towards antiretroviral therapy after 6 months of treatment in a sample of Dutch HIV infected people [letter] Reedijk M, et al. **Sex Transm Infect** 1999 Jun;75(3):204
Early lipodystrophy occurring during post-exposure prophylaxis [letter] Spenatto N, et al. **Sex Transm Infect** 1998 Dec;74(6):455
British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Taylor GP, et al. **Sex Transm Infect** 1999 Apr;75(2):90–7 (55 ref.)
Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. Acosta BS, et al. **South Med J** 1999 Apr;92(4):421–3
Estimating the proportion of treatment effect explained by a surrogate marker [letter] Flandre P, et al. **Stat Med** 1999 Jan 15;18(1):107–9
Economic issues and antiretroviral therapy in developing countries. Forsythe S, et al. **Trans R Soc Trop Med Hyg** 1999 Jan-Feb;93(1):1–3
Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist. Schols D. **Verh K Acad Geneeskd Belg** 1999;61(4):551–64
Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands. Medrano L, et al. **Virus Genes** 1999;18(3):203–10
HIV related skin diseases clear with combination therapy. Conant MA. **West J Med** 1998 Oct;169(4):225–6
Resistance--clinical significance and diagnostics. Puchhammer-Stöckl E. **Wien Med Wochenschr** 1998; 148(23–24):556–9 (28 ref.)
[Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs] Jensen-Fangel S, et al. **Ugeskr Laeger** 1999 Mar 22;161(12):1751–4 (Eng. Abstr.) **(Dan)**
[Experiences with antiretroviral combination therapy] Justesen US, et al. **Ugeskr Laeger** 1999 Mar 22; 161(12):1747–51 (Eng. Abstr.) **(Dan)**
[Antiretroviral treatment (editorial)] Nielsen HI. **Ugeskr Laeger** 1999 Mar 22;161(12):1731 **(Dan)**
[A changed pattern of opportunistic infections and malignancies in HIV-seropositive patients after the introduction of intensive anti-HIV-combination therapy] Borleffs JC, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31; 142(44):2395–9 (16 ref.) (Eng. Abstr.) **(Dut)**
[Glucose tolerance test for tracing of mitochondrial toxicity from nucleoside analogs] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2231–2 **(Dut)**
[Increased serum level of naive CD8+-T-cells during intensive antiretroviral therapy] Cohen Stuart JW, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230–1 **(Dut)**
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors] Dieleman JP, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26;142(52):2856–60 (Eng. Abstr.) **(Dut)**
[Team care: a necessity for a child with HIV infection] Geelen SP, et al. **Ned Tijdschr Geneeskd** 1999 Aug 14; 143(33):1681–5 (Eng. Abstr.) **(Dut)**
[AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment] Notermans DW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1909–12 (48 ref.) (Eng. Abstr.) **(Dut)**
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-1 infection, preliminary results] Reijers MH, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230 **(Dut)**
[Modification or stopping of the initial antiretroviral combination therapy with protease-inhibitors: incidence and reasons] van Roon EN, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2231 **(Dut)**
[FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment] **Allerg Immunol (Paris)** 1998 Oct;30(8):268–70 **(Fre)**
[DuPont-Pharma Laboratories. Sustiva (news)] **Allerg Immunol (Paris)** 1998 Nov;30(9):302 **(Fre)**
[Factors predictive of early virologic response after a first treatment with an protease inhibitor in the course of HIV infection] Frottier J, et al. **Bull Acad Natl Med** 1998; 182(5):981–92; discussion 992–5 (Eng. Abstr.) **(Fre)**
[AIDS: the myth of Sisyphus (editorial)] Jaubert D. **Med Trop (Mars)** 1999;59(1):31–2 **(Fre)**
[Experience with nevirapine taken once daily in 93 HIV-infected patients] Allavena C, et al. **Pathol Biol (Paris)** 1999 May;47(5):563–5 (Eng. Abstr.) **(Fre)**
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor] Mouroux M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):549–52 (Eng. Abstr.) **(Fre)**
[Antiretroviral therapy of HIV infections. New recommendations by the International AIDS Society] Allouch H. **Presse Med** 1998 Nov 7;27(34):1739–41 **(Fre)**
[Observance, adherence, compliance ...different words for better therapeutic results] Baril L. **Presse Med** 1998 Dec; 27 Suppl 5:13–4 (Eng. Abstr.) **(Fre)**
[Value of zalcitabine in antiretroviral protocols] Cassuto JP. **Presse Med** 1998 Sep 26;27(28):1460–2 **(Fre)**
[The role of nelfinavir in the triple-therapy of HIV infection] Coulaud JP. **Presse Med** 1999 Feb 20;28(7):368–70 **(Fre)**
[Initial antiretroviral prescriptions in patients with HIV. Second semester 1994-second semester 1996] Courtial-Destembert S, et al. **Presse Med** 1998 May 23–30; 27(19):905–8 (Eng. Abstr.) **(Fre)**
[Anterior uveitis in HIV-infected patients. 3 cases in patients treated with an antiprotease] Fournier S, et al. **Presse Med** 1998 May 16;27(18):844–8 (Eng. Abstr.) **(Fre)**
[Therapeutic attitude to HIV infection: uncertain and variable scientific attitudes. 1998 national survey of physicians prescribing antiretroviral drugs] Landman R, et al. **Presse Med** 1999 May 1–8;28(17):899–907 (Eng. Abstr.) **(Fre)**
[Discontinuation of antiretroviral treatment containing a protease inhibitor. Failure and tolerance] Michelet C. **Presse Med** 1999 Feb 27;28(8):402–4 **(Fre)**
[The role of stavudine in antiretroviral therapy] Molina JM. **Presse Med** 1998 Oct 31;27(33):1708–9 **(Fre)**
[Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients] Piroth L, et al. **Presse Med** 1999 Feb 27;28(8):381–7 (Eng. Abstr.) **(Fre)**
[The concept of therapeutic management: exemplary implementation of antiretroviral treatments (editorial)] Rozenbaum W. **Presse Med** 1998 May 23–30;27(19):919–20 (Eng. Abstr.) **(Fre)**
[Apropos of antiretroviral therapy of HIV infection (interview by H. Allouch)] Sobel A. **Presse Med** 1998 Nov 7;27(34):1741–4 **(Fre)**
[Immunologic reconstruction after antiretroviral treatment] Tubiana R, et al. **Presse Med** 1999 Feb 27;28(8):424–8 (Eng. Abstr.) **(Fre)**
[Apropos of antiretroviral therapy of HIV infections (interview by H. Allouch)] Yeni P. **Presse Med** 1998 Nov 7;27(34):1741–4 **(Fre)**
[Treatment of complicated renal colic in patients treated with indinavir: value of double J stents] Van Glabeke E, et al. **Prog Urol** 1999 Jun;9(3):470–3 (Eng. Abstr.) **(Fre)**
[Nevirapine (Viramune): a new HIV inhibitor] De Wit S, et al. **Rev Med Brux** 1999 Apr;20(2):95–9 (12 ref.) (Eng. Abstr.) **(Fre)**
[Diabetes mellitus associated with protease inhibitors in HIV infected patients (letter)] Bardonnet K, et al. **Rev Med Interne** 1998 Sep;19(9):675–6 **(Fre)**
[Advances in the therapy of HIV infection and implications for clinical research (editorial)] Morlat P.

Rev Med Interne 1999 Mar;20(3):217–9 (24 ref.) **(Fre)**
[Strategies for the use of anti-retroviral agents in HIV infection (1997). Extracts from the 4th Dormont Report] **Rev Pneumol Clin** 1998 Feb;54(1):9–16 (24 ref.) **(Fre)**
[A new drug in HIV infections authorized (news)] **Dtsch Med Wochenschr** 1999 Sep 10;124(36):A20 **(Ger)**
[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection] Fischer T, et al. **Dtsch Med Wochenschr** 1998 Dec 11;123(50):1512–6 (Eng. Abstr.) **(Ger)**
[New trends in HIV (news)] Volkert R. **Dtsch Med Wochenschr** 1998 Sep 18;123(38):A7 **(Ger)**
[HIV therapy in women begins earlier (news)] Wehr A. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):A10 **(Ger)**
[HIV drugs: no solution for psychosocial problems (news)] Weismann H. **Dtsch Med Wochenschr** 1998 Dec 18; 123(51–52):A12 **(Ger)**
[An unusual hemorrhagic variant of Stevens-Johnson syndrome in an HIV-infected patient] Schmid MH, et al. **Hautarzt** 1999 Jan;50(1):52–5 (Eng. Abstr.) **(Ger)**
[An important task even in the HAART era (High Activity Anti-Retroviral Therapy). Infection management in HIV-patients] **Internist (Berl)** 1999 Mar;40(3 Suppl Infektions):1–4 **(Ger)**
[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions] Fätkenheuer G, et al. **Internist (Berl)** 1998 Sep;39(9):927–34 (37 ref.) **(Ger)**
[HIV infection. Virus resistance: development and prevention] Link R, et al. **Med Monatsschr Pharm** 1999 Mar;22(3):86–8 **(Ger)**
[HIV 1998: eradication dreams?] Vernazza PL. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2019–22 (0 ref.) **(Ger)**
[Indinavir-associated lipodystrophy] Krautheim A. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):285–7 **(Ger)**
[Antiretroviral therapy in children] Jakob-Sölder B. **Wien Med Wochenschr** 1998;148(23–24):539–46 (59 ref.) (Eng. Abstr.) **(Ger)**
[Antiretroviral drugs 1998/1999] Rieger A. **Wien Med Wochenschr** 1998;148(23–24):567–76 (115 ref.) (Eng. Abstr.) **(Ger)**
[Guidelines for implementing antiretroviral therapy] Sarcletti M, et al. **Wien Med Wochenschr** 1998;148(23–24):530–8 (32 ref.) (Eng. Abstr.) **(Ger)**
[Reducing perinatal transmission by antiretroviral therapy] Schmied B. **Wien Med Wochenschr** 1998;148(23–24):550–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Therapies in HIV infection] Zangerle R. **Wien Med Wochenschr** 1998;148(23–24):525–6 **(Ger)**
[Antiretroviral therapy 1998/1999: what is our current status?--Avoiding therapy failure instead of expecting it] Zangerle R. **Wien Med Wochenschr** 1998;148(23–24):527–9 (32 ref.) (Eng. Abstr.) **(Ger)**
[Antiretroviral therapy in childhood] Feiterna-Sperling C. **Zentralbl Gynakol** 1999;121(1):35–6 (7 ref.) (Eng. Abstr.) **(Ger)**
[The use of HIV-1 protease inhibitors. Their effects on AIDS-correlated outpatient and hospitalization activities. A catchment area study] Resta F, et al. **Recenti Prog Med** 1998 Dec;89(12):623–4 (Eng. Abstr.) **(Ita)**
[Recent advances in the treatment of HIV infection/AIDS] Matsushita S. **Gan To Kagaku Ryoho** 1999 Jul;26(8):1033–9 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Advances in the treatment of severe refractory infections. 1) HIV infections] Oka S. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2240–4 (2 ref.) **(Jpn)**
[Progress in the chemotherapy of HIV-infection and AIDS (according to the materials of the Symposium "Highly Active Antiretrovirus Therapy")] Galegov GA. **Antibiot Khimioter** 1999;44(1):36–8 **(Rus)**
[Achievements in drug therapy of HIV infection and AIDS, presented at the 12th International Conference on AIDS] Galegov GA. **Vopr Virusol** 1998 Nov-Dec;43(6):285–6 **(Rus)**
[New approaches to the chemotherapy of HIV infection] Karamova EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):84–6 (Eng. Abstr.) **(Rus)**
[The successes and problems in the treatment of HIV infection: a biochemist's view] Kraevskiĭ AA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):82–4 (Eng. Abstr.) **(Rus)**
[In old age ... AIDS. Is it worth to initiate antiretroviral treatment? Review of 37 patients more than 60 years of age] de Górgolas M, et al. **An Med Interna** 1999 Jun; 16(6):273–6 (Eng. Abstr.) **(Spa)**
[Clinical and immuno-virologic efficacy of the expanded access use of protease inhibitors for HIV-1 advanced disease] Gómez-Vera J, et al. **An Med Interna** 1999 May; 16(5):218–24 (Eng. Abstr.) **(Spa)**
[Virologic levels for HIV before and after the introduction of protease inhibitors (letter)] Molinero M, et al. **An Med Interna** 1998 Sep;15(9):508–9 **(Spa)**
[Antiretroviral treatment in 1999: from uncertainty to hopefulness (editorial)] Pujol de la Llave E. **An Med Interna** 1999 May;16(5):215–7 (47 ref.) **(Spa)**
[Large, atypical accumumlation of adipose tissue in a patient with human immunodeficiency virus infection] García de la Llana F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):431–2 **(Spa)**
[HIV-1 protease inhibitors. Why, when, and how? (editorial)] Gatell JM. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):393–4 **(Spa)**
[Adherence to very active antiretroviral treatment: impact of individualized assessment] Knobel H, et al. **Enferm Infecc Microbiol Clin** 1999 Feb;17(2):78–81 (Eng. Abstr.) **(Spa)**
[Reecommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)] Moreno S, et al. **Enferm Infecc Microbiol Clin** 1998 Oct;16(8):374–6 **(Spa)**
[AZT and 3TC treatment in a pregnant woman with HIV infection (letter)] Pardo MJ, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):358–9 **(Spa)**
[Antiretroviral treatment (letter; comment)] Pardo Serrano FJ, et al. **Med Clin (Barc)** 1998 Nov 14;111(16):637–8. Comment on: Med Clin (Barc) 1998 Jan 31;110(3):109–16. Comment on: Med Clin (Barc) 1998 Jul 4;111(4):137–41. **(Spa)**
[Drug interactions in patients infected with the human immunodeficiency virus] Jiménez-Nácher I, et al. **Rev Clin Esp** 1998 Nov;198(11):765–8 (14 ref.) **(Spa)**
[Clinical and economic impact of new antiretroviral treatments (editorial)] Moreno Guillén S, et al. **Rev Clin Esp** 1999 Feb;199(2):53–4 **(Spa)**
[Tests to detect resistance to antiretroviral agents in clinical practice] Seriano Vázquez V, et al. **Rev Clin Esp** 1999 Mar; 199(3):179–83 (21 ref.) **(Spa)**
[Admissions and mortality in a HIV unit before and after protease inhibitors (letter)] Soriano V, et al. **Rev Clin Esp** 1998 Oct;198(10):715 **(Spa)**
[Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus (letter)] Soriano Vázquez V, et al. **Rev Clin Esp** 1998 Sep;198(9):634–5 **(Spa)**
[Drug injection method risky for transmission of blood-borne diseases: are we careful enough?] Bravo Portela MJ, et al. **Rev Esp Salud Publica** 1998 Jul-Aug;72(4):289–301 (63 ref.) (Eng. Abstr.) **(Spa)**
[Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine] López-Martínez C, et al. **Rev Invest Clin** 1998 Jul-Aug; 50(4):335–9 (Eng. Abstr.) **(Spa)**
[Treatment of HIV infections--an update. The easy work is done--the difficult is still to be done] Sönnerborg A, et al. **Lakartidningen** 1998 Oct 14;95(42):4562–4 (9 ref.) **(Swe)**
[Current treatment of HIV infection] Blaxhult A, et al. **Nord Med** 1998 Nov;113(9):290–2, 296 (Eng. Abstr.) **(Swe)**

ECONOMICS

Evolution of socioeconomic impact assessments of HIV/AIDS. Forsythe S, et al. **AIDS** 1998;12 Suppl 2:S47–55
Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA, et al. **AIDS** 1999 May 28;13(8):963–9
Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. Ratcliffe J, et al. **AIDS** 1998 Jul 30;12(11):1381–8
Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. Sculpher MJ, et al. **AIDS** 1998 Jul 30;12(11):1371–80
The cost of home-based care for HIV/AIDS patients in Zimbabwe. Hansen K, et al. **AIDS Care** 1998 Dec; 10(6):751–9
Medications used for paediatric HIV infection in the USA, 1991–1992. Hsia DC. **AIDS Care** 1998 Dec;10(6):761–70
Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. Cook J, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):499–508
HHS awards $479 million in grants for HIV/AIDS care and support services [news] **Am Fam Physician** 1999 Feb 1; 59(3):518
HHS announces $710 million in grants for HIV/AIDS care [news] Sweeney R, et al. **Am Fam Physician** 1999 May 1;59(9):2403
Cost effectiveness of Streetworks' needle exchange program of Edmonton. Jacobs P, et al. **Can J Public Health** 1999 May-Jun;90(3):168–71
Blood money [letter; comment] Massel D. **CMAJ** 1999 Jul 27;161(2):129. Comment on: CMAJ 1999 Mar 9;160(5):699–700.
Changing cost of English HIV service provision 1996–1997. NPMS Steering Group. National Prospective Monitoring System. **Int J STD AIDS** 1999 Jun;10(6):357–62
New study showed average costs of care for HIV in managed care were lower for patients with undetectable viral loads [news] **J Assoc Nurses AIDS Care** 1999 Mar-Apr; 10(2):87–8
New study shows average per patient cost of HIV care in managed care setting stabilized in 1997 [news] **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):79
Cost of preventing HIV infection after sexual exposure. Lindbloom EJ, et al. **J Fam Pract** 1998 Oct;47(4):251–2
Financial issues in defining levels for HIV/AIDS research. Eastaugh SR. **J Health Care Finance** 1998 Fall;25(1):19–25
Relationship between ambulatory care accessibility and hospitalization for persons with advanced HIV disease. Laine C, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):313–27
Shared care in HIV and AIDS: shifting care or shifting costs? Cartledge JD, et al. **J R Coll Physicians Lond** 1998 Jul-Aug;32(4):376–9
Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Shapiro MF, et al. **JAMA** 1999 Jun 23–30; 281(24):2305–15
US Senate moves to broaden HIV-1 payment [news] Droste TM. **Lancet** 1998 Oct 3;352(9134):1128
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Marseille E, et al. **Lancet** 1999 Sep 4;354(9181):803–9
US bill aids HIV-1-infected haemophiliacs [news] Rovner J. **Lancet** 1998 Nov 14;352(9140):1610
How good are US studies of HIV costs of care? Rabeneck L, et al. **Med Care** 1999 Aug;37(8):748–59 (35 ref.)
Insurance and inpatient utilization for HIV: better answers, still further questions [editorial; comment] Wu AW. **Med Care** 1999 Apr;37(4):325–8. Comment on: Med Care 1999 Mar;37(3):220–7.
Implicit valuation of a blood-exclusion decision. Kaplan EH. **Med Decis Making** 1999 Apr-Jun;19(2):207–13
Finding funding for China's HIV research [news] Watanabe ME. **Nat Med** 1999 Apr;5(4):364–5
Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Stringer JS, et al. **Obstet Gynecol** 1999 Jul;94(1):34–40
Cheaper to manage HIV than to treat AIDS--the Medscheme experience. Cowlin J. **S Afr Med J** 1999 Jan; 89(1):34–5
Affordable management of HIV infection in the private sector. Regensberg LD, et al. **S Afr Med J** 1998 Aug; 88(8):945, 948
The costing of HIV/AIDS--without a clue? van der Linde I. **S Afr Med J** 1999 Jan;89(1):33–4
How to assess an article on economic evaluation. Sculpher M, et al. **Sex Transm Infect** 1998 Jun;74(3):223–7 (22 ref.)
Demograghic and socio-economic determinants of community and hospital services costs for people with HIV/AIDS in London. Kupek E, et al. **Soc Sci Med** 1999 May;48(10):1433–40
[Cost effectiveness of the treatment of HIV infection (letter)] Amato Neto V, et al. **Rev Soc Bras Med Trop** 1998 Nov-Dec;31(6):581–2 **(Por)**

ENZYMOLOGY

Expression of inducible nitric oxide synthase in duodenal tissue of HIV-infected patients. Bauer U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:307–10
Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. Rostasy K, et al. **Ann Neurol** 1999 Aug;46(2):207–16
Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Hosono O, et al. **Clin Immunol** 1999 Jun;91(3):283–95
Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus-1 infection. Strovel JW, et al. **Mod Pathol** 1998 Oct;11(10):957–62
Serum pancreatic enzymes in human immunodeficiency virus-infected children. A collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. Carroccio A, et al. **Scand J Gastroenterol** 1998 Sep; 33(9):998–1001
Macroamylasemia in HIV infection. Eleccion CB, et al. **Tex Med** 1998 Dec;94(12):77–9

EPIDEMIOLOGY

Peripheral facial paralysis (PFP) and HIV infection in Togo. Balogou AK, et al. **Acta Neurol Scand** 1998 Sep;98(3):200–3
Child survival in children born to HIV-2 infected women in Guinea-Bissau, West Africa. Norrgren H, et al. **Acta Trop** 1999 Apr 30;72(3):309–15
Bloodborne viral infection in Irish injecting drug users. Smyth BP, et al. **Addiction** 1998 Nov;93(11):1649–56
High rates of drug use, but low rates of HIV risk behaviours among injecting drug users during incarceration in Dutch prisons. van Haastrecht HJ, et al. **Addiction** 1998 Sep; 93(9):1417–25
HIV seroprevalence in women of childbearing age in Benin City, Nigeria. Offor E, et al. **Afr J Reprod Health** 1997 Sep;1(2):36–40
Migration, ethnicity and environment: HIV risk factors for women on the sugar cane plantations of the Dominican Republic. Brewer TH, et al. **AIDS** 1998 Oct 1; 12(14):1879–87
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. Broers B, et al. **AIDS** 1998 Oct 22;12(15):2059–66
HIV and AIDS in Asia--the current state of affairs. Brown T. **AIDS** 1999 Jul 30;13(11):9–10
HIV-1 seroprevalence among childbearing women in

northern Thailand: monitoring a rapidly evolving epidemic. Bunnell RE, et al. **AIDS** 1999 Mar 11;13(4):509–15

The HIV/AIDS epidemic in eastern Europe: recent patterns and trends and their implications for policy-making [editorial] Dehne KL, et al. **AIDS** 1999 May 7;13(7):741–9 (38 ref.)

HIV-1 subtypes in Santiago, Chile [letter] Desgranges C, et al. **AIDS** 1998 Aug 20;12(12):1563–5

Estimation of HIV-1 prevalence in the population of Abidjan by adjustment of the prevalence observed in antenatal centres [letter; comment] Desgrées du Loû A, et al. **AIDS** 1999 Mar 11;13(4):526–7. Comment on: AIDS 1998 Oct 1;12(14):1861–7.

Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing [letter] Diaz RS, et al. **AIDS** 1999 Jul 30;13(11):1417–8

Estimating HIV incidence from age-specific prevalence data: comparison with concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe. Gregson S, et al. **AIDS** 1998 Oct 22;12(15):2049–58

Stable antenatal HIV-1 seroprevalence with high population mobility and marked seroprevalence variation among sentinel sites within Nairobi, Kenya. Jackson DJ, et al. **AIDS** 1999 Apr 1;13(5):583–9

The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. Jones N, et al. **AIDS** 1998 Nov 12;12(16):2177–84

HIV prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996. Judd A, et al. **AIDS** 1999 May 7;13(7):833–7

Human T-cell leukaemia/lymphoma virus type I infection in West African patients with clinical AIDS [letter] Kanmogné G, et al. **AIDS** 1998 Nov 12;12(16):2239

Age of male circumcision and risk of prevalent HIV infection in rural Uganda. Kelly R, et al. **AIDS** 1999 Feb 25; 13(3):399–405

Reductions in risk behaviour provide the most consistent explanation for declining HIV-1 prevalence in Uganda. Kilian AH, et al. **AIDS** 1999 Feb 25;13(3):391–8

HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. Kilmarx PH, et al. **AIDS** 1998 Oct 1;12(14):1889–98

Poverty and prognosis of HIV infection in Switzerland. Swiss HIV Cohort Study [letter] Ledergerber B, et al. **AIDS** 1998 Oct 1;12(14):1933–4

Decline in sexually transmitted disease prevalence in female Bolivian sex workers: impact of an HIV prevention project. Levine WC, et al. **AIDS** 1998 Oct 1;12(14):1899–906

HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. Liitsola K, et al. **AIDS** 1998 Oct 1;12(14):1907–19

HIV seroprevalence and HIV-1 subtype E among pregnant women in Vientiane, Laos [letter] Loue S, et al. **AIDS** 1998 Jul 30;12(11):1403

Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? Meda N, et al. **AIDS** 1999 Jul 30;13(11):1397–405

Incidence of HIV infection in homosexual men attending a sexually transmitted disease clinic in London measured by a novel unlinked anonymous method [letter] Miller E, et al. **AIDS** 1999 Jan 14;13(1):143–4

HIV risk behavioral surveillance: a methodology for monitoring behavioral trends. Mills S, et al. **AIDS** 1998;12 Suppl 2:S37–46

The relationship of HIV prevalence in pregnant women to that in women of reproductive age: a validated method for adjustment [see comments] Nicoll A, et al. **AIDS** 1998 Oct 1;12(14):1861–7. Comment in: AIDS 1999 Mar 11;13(4):526–7.

HIV-1 group O virus infection in Abidjan, Côte d'Ivoire [letter] Nkengasong J, et al. **AIDS** 1998 Aug 20; 12(12):1565–6

Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. Norrgren H, et al. **AIDS** 1999 Apr 16;13(6):701–7

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. Paul S, et al. **AIDS** 1999 Feb 25;13(3):415–8

Cofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya. Rakwar J, et al. **AIDS** 1999 Apr 1; 13(5):607–14

Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. Rizzardini G, et al. **AIDS** 1998 Dec 24;12(18):2387–96

Tribute to Jonathan Mann. Ryder RW, et al. **AIDS** 1998 Oct 22;12(15):ii–v

HIV incidence among repeat HIV testers with sexually transmitted diseases in Italy. STD Surveillance Working Group. Suligoi B, et al. **AIDS** 1999 May 7;13(7):845–50

Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). Tabet SR, et al. **AIDS** 1998 Oct 22;12(15):2041–8

Predictors of visits to commercial sex workers by male attendees at sexually transmitted disease clinics in southern Vietnam. Thuy NT, et al. **AIDS** 1999 Apr 16;13(6):719–25

Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome [editorial] Wanke CA. **AIDS** 1999 Jul 30; 13(11):1287–93 (57 ref.)

Continued explosive rise in HIV prevalence among pregnant women in rural South Africa [letter] Wilkinson D, et al. **AIDS** 1999 Apr 16;13(6):740

UNAIDS/WHO global AIDS statistics. **AIDS Care** 1999 Apr;11(2):253–64

A qualitative investigation into an HIV outbreak among injection drug users in Vancouver, British Columbia. Harvey E, et al. **AIDS Care** 1998 Jun;10(3):313–21

Prevalence of HIV infection among hospital patients in north west Tanzania. Kwesigabo G, et al. **AIDS Care** 1999 Feb; 11(1):87–93

Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. Candotti D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):309–14

HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1-infected individuals. Diaz RS, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1151–6

Long-term nonprogression in HIV infection: methodological issues and scientific priorities. Report of an international European community-National Institutes of Health Workshop, The Royal Society, London, England, November 27–29, 1995. Scientific Coordinating Committee. Easterbrook PJ, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1211–28

Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. Ellenberger DL, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):3–9

Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. Kato K, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1; 15(13):1157–68

Characterization of V3 loop sequences from HIV type 1 subtype B in South Korea: predominance of the GPGS motif. Kim EY, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):681–6

Molecular phylogenetic analysis of human immunodeficiency virus type 1 strains obtained from Korean patients: env gene sequences. Kim YB, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):303–7

Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1299–303

Molecular epidemiological analysis of human immunodeficiency virus type 1 in Newfoundland, Canada. Montpetit ML, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1205–9

HIV-1 incidence among opiate users in northern Thailand. Celentano DD, et al. **Am J Epidemiol** 1999 Mar 15; 149(6):558–64

Re: "Invited commentary: le mystère de Montréal" [letter; comment] Fisher DG, et al. **Am J Epidemiol** 1998 Oct 1; 148(7):714–5; discussion 715–7. Comment on: Am J Epidemiol 1997 Dec 15;146(12):1003–6; discussion 1007–10.

Re: "High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study" [letter; comment] Garfein RS, et al. **Am J Epidemiol** 1999 Aug 1;150(3):325–6. Comment on: Am J Epidemiol 1997 Dec 15;146(12):994–1002.

Re: "Invited commentary: le mystère de Montréal" [letter; comment] Hahn J, et al. **Am J Epidemiol** 1998 Oct 1; 148(7):714; discussion 715–6. Comment on: Am J Epidemiol 1997 Dec 15;146(12):1003–6; discussion 1007–10.

Re: "High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study" [letter; comment] Lowndes CM, et al. **Am J Epidemiol** 1998 Oct 1;148(7):713–4; discussion 716–7. Comment on: Am J Epidemiol 1997 Dec 15;146(12):994–1002.

Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Moorman AC, et al. **Ann Epidemiol** 1999 Aug; 9(6):349–57

HIV infection in children: the widening gap between developing and industrialized countries. Coulter JB. **Ann Trop Paediatr** 1998 Sep;18 Suppl:S15–20 (15 ref.)

HIV/AIDS surveillance system and reported cases of human immunodeficiency virus infection and acquired immunodeficiency syndrome in Japan (1983–1993). Miyazaki M, et al. **Asia Pac J Public Health** 1995;8(3):162–6

HIV and HCV prevalence among trawler crew. MacDonald M, et al. **Aust N Z J Public Health** 1998 Dec;22(7):829–31

US considers name based tracking for HIV positive patients [news] Ciment J. **BMJ** 1999 Jan 9;318(7176):75

United nations estimates of HIV prevalence in Zambia under attack. Moszynski P. **BMJ** 1999 Aug 7;319(7206):338

Impact of HIV infection and AIDS on prevalence of type 2 diabetes in South Africa in 2010 [letter] Panz VR, et al. **BMJ** 1999 May 15;318(7194):1351A

Authors' words foster stigmatisation of commercial sex workers in India [letter; comment] Patnaik P, et al. **BMJ** 1999 Jun 5;318(7197):1559. Comment on: BMJ 1999 Jan 16;318(7177):162–3.

The growing challenge of HIV/AIDS in developing countries. Grant AD, et al. **Br Med Bull** 1998;54(2):369–81 (62 ref.)

AIDS shortens life and dents economic growth across Africa [news] **Bull World Health Organ** 1999;77(1):95

Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India. Brabin L, et al. **Bull World Health Organ** 1998;76(3):277–87

Non-nominal HIV surveillance: preserving privacy while tracking an epidemic. Patrick DM, et al. **Can J Public Health** 1999 May-Jun;90(3):164–7

Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis [see comments] Riantawan P, et al. **Chest** 1999 Jul;116(1):97–103. Comment in: Chest 1999 Jul;116(1):3–5.

Global control and Leishmania HIV co-infection. Desjeux P. **Clin Dermatol** 1999 May-Jun;17(3):317–25 (13 ref.)

Sexually transmitted disease (STD) and acquired immunodeficiency syndrome (AIDS) in South East Asia. Ismail R. **Clin Dermatol** 1999 Mar-Apr;17(2):127–35; discussion 105–6

Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Moss WJ, et al. **Clin Infect Dis** 1999 Jul;29(1):106–12

Incidence of tuberculosis among reported AIDS cases in Quebec from 1979 to 1996. Brassard P, et al. **CMAJ** 1999 Jun 29;160(13):1838–42

The global impact of HIV infection and disease. Nicoll A, et al. **Commun Dis Public Health** 1999 Jun;2(2):85–95 (54 ref.)

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Aug 27; 9(35):317–8

Cumulative reports of HIV infections in the UK exceed 37,000. **Commun Dis Rep CDR Wkly** 1999 Jan 29;9(5):37

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Jan 29;9(5):45–6, 48

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Jun 25; 9(26):235–6

AIDS and HIV infection in the United Kingdom: monthly report [published erratum appears in Commun Dis Rep CDR Wkly 1998 Oct 23;8(43):388] **Commun Dis Rep CDR Wkly** 1998 Sep 25;8(39):351–2

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1998 Aug 28; 8(35):315–6

AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1998 Oct 23; 8(43):385–8

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Jul 30; 9(31):277–80

Mood disorders in HIV infection. Treisman G, et al. **Depress Anxiety** 1998;7(4):178–87 (59 ref.)

Drug and alcohol consumption and sexual risk behaviour among young adults: results from a national survey. Castilla J, et al. **Drug Alcohol Depend** 1999 Aug 2;56(1):47–53

Situation analysis of HIV/AIDS epidemic in sub-Saharan Africa. Balint GA. **East Afr Med J** 1998 Dec;75(12):684–6

Perception of risk, sexual behaviour and STD/HIV prevalence in western Kenya. Wools KK, et al. **East Afr Med J** 1998 Dec;75(12):679–83

The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Crampin AC, et al. **Epidemiol Infect** 1998 Oct;121(2):381–6

Non-participation bias in unlinked anonymous HIV-prevalence surveys in England and Wales. Duong T, et al. **Epidemiol Infect** 1999 Apr;122(2):267–72

Risk factors for monoinfections and coinfections with HIV, hepatitis B and hepatitis C viruses in northern Spanish prisoners. Pallás J, et al. **Epidemiol Infect** 1999 Aug; 123(1):95–102

The Health Belief Model and HIV risk behaviours: a causal model analysis among Anglos, African-Americans and Mexican-Americans. Neff JA, et al. **Ethn Health** 1998 Nov; 3(4):283–99

Lack of HIV infection in Albanians immigrated into southern Italy in 1997 [letter] Chironna M, et al. **Eur J Epidemiol** 1999 Jul;15(6):591–2

Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners: preponderance of parenteral transmission. Massad E, et al. **Eur J Epidemiol** 1999 May;15(5):439–45

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Santana Rodriguez OE, et al. **Eur J Epidemiol** 1998 Sep;14(6):555–61

Reaching homosexual men for HIV surveillance through a gay magazine. Wiessing LG, et al. **Eur J Epidemiol** 1999 May;15(5):429–37

Overview of HIV and AIDS: biology and epidemiology of the virus. Klein RS, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):751–67 (80 ref.)

A mathematical analysis of the spread of HIV/AIDS in Japan [published erratum appears in IMA J Math Appl Med Biol 1999 Mar;16(1):111–2] Kakehashi M. **IMA J Math Appl Med Biol** 1998 Dec;15(4):299–311

A two-type model for the Cuban national programme on HIV/AIDS. Lounes R, et al. **IMA J Math Appl Med Biol** 1999 Jun;16(2):143–54

Incidence of HIV infection & its predictors in blood donors in Delhi. Kapur S, et al. **Indian J Med Res** 1998 Aug; 108:45–50

Seroprevalence of HIV infection among jail inmates in

Orissa. Pal BB, et al. **Indian J Med Res** 1999 Jun; 109:199–201

Increasing prevalence of HIV-2 and dual HIV-1-2 infections among high risk group hospital admitted patients in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Nov;52(11):479–84

Increasing prevalence of dual HIV-1-2 infections among voluntary blood donors in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Dec;52(12):548–52

Incidence of HIV risk and prevention of infection in health care settings. Ram S, et al. **Indian J Med Sci** 1998 Jun; 52(6):239–43

Lack of association of gestational trophoblastic diseases (GTD) with syphilis and AIDS. Swapna E, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):277–9

New, emerging and re-emerging infectious diseases [editorial] Bansal RD, et al. **Indian J Public Health** 1997 Apr-Jun;41(2):35

Reconstruction of human immunodeficiency virus (HIV) sub-epidemics in Italian regions. Barcherini S, et al. **Int J Epidemiol** 1999 Feb;28(1):122–9

Estimation of injecting drug users in the City of Edinburgh, Scotland, and number infected with human immunodeficiency virus. Davies AG, et al. **Int J Epidemiol** 1999 Feb;28(1):117–21

Socioeconomic geographical links to human immunodeficiency virus seroprevalence among childbearing women in Montreal, 1989–1993. Hankins C, et al. **Int J Epidemiol** 1998 Aug;27(4):691–7

Human immunodeficiency virus (HIV) infection in parenteral drug users: evolution of the epidemic over 10 years. Valencian Epidemiology and Prevention of HIV Disease Study Group. Hernández-Aguado I, et al. **Int J Epidemiol** 1999 Apr;28(2):335–40

Completeness of HIV reporting in Louisiana, USA [letter; comment] Klevens RM, et al. **Int J Epidemiol** 1998 Dec; 27(6):1105. Comment on: Int J Epidemiol 1997 Dec;26(6):1352–8.

Pregnancy, body weight and human immunodeficiency virus infection in African women: a prospective cohort study in Kigali (Rwanda), 1992–1994. Pregnancy and HIV Study Group (EGE). Ladner J, et al. **Int J Epidemiol** 1998 Dec; 27(6):1072–7

Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV. Madge S, et al. **Int J Epidemiol** 1998 Dec;27(6):1068–71

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Prins M, et al. **Int J Epidemiol** 1999 Jun;28(3):541–9

Seroprevalence of syphilis, human immunodeficiency virus type-1, and hepatitis B virus infections among pregnant women in Turkey. Nas T, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):171–2

Human immunodeficiency virus infection in pregnant women in Nigeria. Sagay AS, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):183–4

Creating alliances for disease management in industrial settings: a case study of HIV/AIDS in workers in South African gold mines. Williams B, et al. **Int J Occup Environ Health** 1998 Oct-Dec;4(4):257–64 (50 ref.)

HIV infection and asymptomatic sexually transmitted infections in a rural South African community. Colvin M, et al. **Int J STD AIDS** 1998 Sep;9(9):548–50

Survey of risk behaviour and HIV prevalence in an English prison. Edwards A, et al. **Int J STD AIDS** 1999 Jul; 10(7):464–6

Behavioural risk factors for HIV/AIDS in a low-HIV prevalence Muslim nation: Bangladesh. Gibney L, et al. **Int J STD AIDS** 1999 Mar;10(3):186–94

HIV/AIDS in Bangladesh: a national surveillance. Islam M, et al. **Int J STD AIDS** 1999 Jul;10(7):471–4

Paediatric HIV infection in the Republic of Ireland and the need for antenatal screening. Nourse C, et al. **Int J STD AIDS** 1998 Oct;9(10):587–90

Education attainment as a predictor of HIV risk in rural Uganda: results from a population-based study. Smith J, et al. **Int J STD AIDS** 1999 Jul;10(7):452–9

Routine reporting or sentinel surveys for HIV/AIDS surveillance in resource-poor settings: experience in South Africa, 1991–97. Stuart JM, et al. **Int J STD AIDS** 1999 May;10(5):328–30

HIV infection among patients with sexually transmitted diseases in rural South Africa. Wilkinson D, et al. **Int J STD AIDS** 1998 Dec;9(12):736–9

HIV infection and related risk behaviours in a disadvantaged youth institution of São Paulo, Brazil. Zanetta DM, et al. **Int J STD AIDS** 1999 Feb;10(2):98–104

Mycobacterial disease in South African gold miners in the era of HIV infection. Churchyard GJ, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):791–8

Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991–1995. Connolly C, et al. **Int J Tuberc Lung Dis** 1998 Nov;2(11):919–25

Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana [see comments] Kenyon TA, et al. **Int J Tuberc Lung Dis** 1999 Jan;3(1):4–11. Comment in: Int J Tuberc Lung Dis 1999 Jan;3(1):1–3.

TB and HIV in Bolivia [letter] Ollé-Goig JE, et al. **Int J Tuberc Lung Dis** 1998 Sep;2(9):775–6

HIV infection among patients with tuberculosis in Kenya [letter] van Gorkom J, et al. **Int J Tuberc Lung Dis** 1999 Aug;3(8):741–2

Global overview of HIV/AIDS--a challenge for nurses. Anderson S. **Int Nurs Rev** 1998 Nov-Dec;45(6):175–8, 186

The HIV/AIDS epidemic in Malawi. Kachapila L. **Int Nurs Rev** 1998 Nov-Dec;45(6):179–81

Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group. Machuca A, et al. **Intervirology** 1999;42(1):37–42

Prevalence of HIV-1 among recent arrestees in Los Angeles County, California: serial cross-sectional study, 1991–1995. Carpenter CL, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):172–7

Incident HIV infection in a high-risk, homosexual, male cohort in Rio de Janeiro, Brazil. Harrison LH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):408–12

Increase of HIV-1 subtype A in Central African Republic. Müller-Trutwin MC, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):164–71

HIV monitoring in Vietnam: system, methodology, and results of sentinel surveillance. Nguyen TH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):338–46

Risk of HIV infection in oral contraceptive pill users: a meta-analysis [published erratum appears in J Acquir Immune Defic Syndr 1999 Aug 15;21(5):428] Wang CC, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):51–8

HIV-1, HTLV-I, and HTLV-II in a semiurban population in East Gabon [letter] Bertherat E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):430–2

HIV prevalence in pregnant women in Europe: differences in assessment methods and prevalence levels across countries. Cazein F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):296–305

Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. Chen YM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):393–402

Incidence and risk factors for heterosexually acquired HIV in an inner-city cohort of women: temporal association with pregnancy. Chirgwin KD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):295–9

HIV infection and disturbances of vaginal flora during pregnancy. Taha TE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):52–9

Primary subtype C HIV-1 infection in Harare, Zimbabwe. Tien PC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):147–53

Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. van Roon EN, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):290–4

HIV seroincidence and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996. STD Clinic HIV Seroincidence Study Group. Weinstock H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):506–12

Sociodemographic and behavioral characteristics of African-American women with HIV and AIDS in Los Angeles County, 1990–1997. Wohl AR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):413–20

Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group [see comments] Klein RS, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):93–8. Comment in: J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):26–8.

Arkansas HIV/AIDS Report. **J Ark Med Soc** 1998 Oct; 95(5):209–11

Human immunodeficiency virus type 2 [news] **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):76–8

HIV/AIDS in migrant and seasonal farm workers. Aranda-Naranjo B, et al. **J Assoc Nurses AIDS Care** 1998 Sep-Oct;9(5):80–3

Mandatory name reporting of HIV infection. Bloomer S. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):80–1

Bridging the gap: 12th World AIDS conference update. Porche D, et al. **J Assoc Nurses AIDS Care** 1998 Nov-Dec; 9(6):82–5

The continuing epidemic [letter; comment] Hardie J. **J Can Dent Assoc** 1998 Nov;64(10):678, 680. Comment on: J Can Dent Assoc 1998 Jun;64(6):426–30.

Prevalence of HIV and hepatitis C markers among a cadaver population in Milan. Cattaneo C, et al. **J Clin Pathol** 1999 Apr;52(4):267–70

Evolution of the HIV epidemic in Kaliningrad, Russia. Mashkilleyson N, et al. **J Clin Virol** 1999 Jan;12(1):37–42

Epidemiology of HIV and AIDS in Bahrain. al-Haddad MK, et al. **J Commun Dis** 1997 Dec;29(4):321–8

Trend of HIV incidence rates among drug users in an HIV epicenter in northern Thailand (1989–1997). Sawanpanyalert P, et al. **J Epidemiol** 1999 Apr;9(2):114–20

HIV/AIDS in Pakistan: the context and magnitude of an emerging threat. Hyder AA, et al. **J Epidemiol Community Health** 1998 Sep;52(9):579–85 (33 ref.)

Tuberculosis infection and disease among schoolchildren: the influence of the HIV epidemic and of other factors. Villalbí JR, et al. **J Epidemiol Community Health** 1999 Feb; 53(2):112–7

HIV infection among dental patients. Lakshmi N, et al. **J Indian Med Assoc** 1998 Sep;96(9):278

Early mortality of undiagnosed but prevalent (in 1983–1984) HIV infection in Lothian injectors who tested hepatitis B surface antigen positive (group A) or negative but were high risk for blood-borne virus transmission (group B) in 1983–1984. Gore SM, et al. **J Infect** 1998 Sep;37(2):166–72

Epidemiology and outcome of HIV infection in North-East Scotland (1985–1997). Mackenzie AR, et al. **J Infect** 1999 Mar;38(2):107–10

HIV and tuberculosis co-infection in an inner London hospital--a prospective anonymized seroprevalence study. Marshall BG, et al. **J Infect** 1999 May;38(3):162–6

Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients >/=15 years old, Bangkok. Archibald LK, et al. **J Infect Dis** 1999 Jul;180(1):87–92

Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya. Lavreys L, et al. **J Infect Dis** 1999 Aug;180(2):330–6

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. Mertz KJ, et al. **J Infect Dis** 1998 Dec;178(6):1795–8

An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. Mertz KJ, et al. **J Infect Dis** 1998 Oct; 178(4):1060–6

Infection with human immunodeficiency virus, an epidemic out of control: personal reflections. Sande MA. **J Infect Dis** 1999 Mar;179 Suppl 2:S387–90 (12 ref.)

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Vittinghoff E, et al. **J Infect Dis** 1999 Mar;179(3):717–20

Adult AIDS and symptomatic HIV patients at Sawanpracharak Hospital. Santibhavank P, et al. **J Med Assoc Thai** 1999 Jun;82(6):536–44

Human immunodeficiency virus infection in Haiti. Pierre JA, et al. **J Natl Med Assoc** 1999 Mar;91(3):165–70 (31 ref.)

Meningitis in a community with a high prevalence of tuberculosis and HIV infection. Silber E, et al. **J Neurol Sci** 1999 Jan 1;162(1):20–6

Secular trends in the prevalence of HIV infection among a population of males with hemophilia, 1988–1997: the Oklahoma Hemophilia Surveillance System. Cowan LD, et al. **J Okla State Med Assoc** 1999 Sep;92(9):462–7

Human immunodeficiency virus prevalence in women at delivery using unlinked anonymous testing of newborns in the Malaysian setting. Amar HS, et al. **J Paediatr Child Health** 1999 Feb;35(1):63–6

Prevalence of HIV-associated periodontitis and chronic periodontitis in a southeastern US study group. McKaig RG, et al. **J Public Health Dent** 1998 Fall;58(4):294–300

The challenge of HIV/AIDS in Sub-Saharan Africa. Gilks CF. **J R Coll Physicians Lond** 1999 Mar-Apr;33(2):180–4

From the Centers for Disease Control and Prevention. Cluster of HIV-positive young women--New York, 1997–1998. **JAMA** 1999 Jul 7;282(1):20–1

From the Centers for Disease Control and Prevention. HIV postexposure prophylaxis registry closing. **JAMA** 1999 Apr 7;281(13):1167

Confidential Spanish registry of HIV-infected individuals [news] Bosch X. **JAMA** 1999 Mar 17;281(11):977

Admission trends in a rural South African hospital during the early years of the HIV epidemic. Floyd K, et al. **JAMA** 1999 Sep 15;282(11):1087–91

Trends in perinatal transmission of HIV/AIDS in the United States [see comments] Lindegren ML, et al. **JAMA** 1999 Aug 11;282(6):531–8. Comment in: JAMA 1999 Aug 11;282(6):577–9.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection [see comments] Little SJ, et al. **JAMA** 1999 Sep 22-29;282(12):1142–9. Comment in: JAMA 1999 Sep 22-29;282(12):1177–9.

The global HIV/AIDS epidemic [news] Satcher D. **JAMA** 1999 Apr 28;281(16):1479

Inmates in Irish prisons face drug abuse and disease [news] Birchard K. **Lancet** 1999 Aug 28;354(9180):753

An African perspective on the threat of tuberculosis and HIV/AIDS--can despair be turned to hope? Chintu C, et al. **Lancet** 1999 Mar 20;353(9157):997

India has the largest number of people infected with HIV [news] Kumar S. **Lancet** 1999 Jan 2;353(9146):48

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Kvåle G. **Lancet** 1999 May 1;353(9163):1522–3; discussion 1523–4. Comment on: Lancet 1995 Aug 26;346(8974):530–6. Comment on: Lancet 1999 Feb 13;353(9152):513–5. Comment on: Lancet 1999 Feb 13;353(9152):525–35.

A new design of stochastic partnership models for epidemics of sexually transmitted diseases with stages. Mode CJ, et al. **Math Biosci** 1999 Mar 1;156(1-2):95-122

A computer exploration of some properties of non-linear stochastic partnership models for sexually transmitted diseases with stages. Sleeman CK, et al. **Math Biosci** 1999 Mar 1;156(1-2):123-45

HIV prevalence at reception into Australian prisons, 1991-1997 [comment] McDonald AM, et al. **Med J Aust** 1999 Jul 5;171(1):18-21. Comment on: Med J Aust 1999 Jul 5;171(1):7-8.

Risks for HIV infection among persons residing in rural areas and small cities--selected sites, southern United States, 1995-1996 [published erratum appears in MMWR Morb Mortal Wkly Rep 1998 Dec 25;47(50):1107] **MMWR Morb Mortal Wkly Rep** 1998 Nov 20;47(45):974-8

HIV postexposure prophylaxis registry closing. **MMWR Morb Mortal Wkly Rep** 1999 Mar 12;48(9):194-5

Cluster of HIV-positive young women--New York, 1997-1998. **MMWR Morb Mortal Wkly Rep** 1999 May 28; 48(20):413-6

AIDS--New Zealand [news] **N Z Dent J** 1998 Dec; 94(418):163

HIV infection in women in New Zealand [news] **N Z Med J** 1998 Aug 28;111(1072):329

China faces increased spread of HIV [news] Watanabe M. **Nat Med** 1998 Nov;4(11):1216

Southern Africa's 'Holocaust': is HIV infection uncontrollable? Walker AR. **Natl Med J India** 1999 May-Jun;12(3):132-3

Is it over yet? Hope or hype: status of the HIV/AIDS pandemic. Miramontes HM, et al. **Nurs Outlook** 1998 Jul-Aug;46(4):155-6 (22 ref.)

Implications of HIV and hepatitis C coinfection [news] [see comments] Klaus BD, et al. **Nurse Pract** 1998 Dec; 23(12):78, 81. Comment in: Nurse Pract 1999 Apr;24(4):16.

Paediatric HIV infection. Friesen H. **P N G Med J** 1996 Sep;39(3):183-9 (7 ref.)

HIV infections in obstetrics and gynaecology. Mola G. **P N G Med J** 1996 Sep;39(3):190-5 (8 ref.)

HIV and AIDS [editorial] Verma N. **P N G Med J** 1996 Sep;39(3):163

New epidemiological problem in Poland: vertical transmission of human immunodeficiency virus. Lech MM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):459-62

HIV infection linked to substance use among hospitalized patients with severe mental illness. McKinnon K, et al. **Psychiatr Serv** 1998 Oct;49(10):1269

Tuberculosis among foreign-born residents of southern Florida, 1995. Granich RM, et al. **Public Health Rep** 1998 Nov-Dec;113(6):552-6

Cross-matching TB and AIDS registries: TB patients with HIV co-infection, United States, 1993-1994. Moore M, et al. **Public Health Rep** 1999 May-Jun;114(3):269-77

HIV/AIDS research priorities among aboriginal people in Canada. **Rev Panam Salud Publica** 1999 Mar;5(3):207-9

Making AIDS a notifiable disease--is it an appropriate policy for South Africa? Abdool Karim SS. **S Afr Med J** 1999 Jun;89(6):609-11

HIV surveillance in South Africa [letter; comment] Ash G. **S Afr Med J** 1999 Apr;89(4):357-9. Comment on: S Afr Med J 1998 Oct;88(10):1316-20.

HIV surveillance in South Africa [letter] Colvin M, et al. **S Afr Med J** 1998 Sep;88(9):1046

National HIV surveillance in South Africa--1993-1995 [see comments] Küstner HG, et al. **S Afr Med J** 1998 Oct; 88(10):1316-20. Comment in: S Afr Med J 1999 Apr;89(4):357-9.

The South African HIV epidemic, reflected by nine provincial epidemics, 1990-1996. Swanevelder JP, et al. **S Afr Med J** 1998 Oct;88(10):1320-5

On World AIDS Day, a shadow looms over southern Africa [news] Balter M. **Science** 1998 Dec 4;282(5395):1790-1

HIV in Scotland--the challenge ahead. Goldberg D, et al. **Scott Med J** 1998 Dec;43(6):168-72

Herpes in the time of AIDS: a comparison of the epidemiology of HIV-1 and HSV-2 in young men in northern Thailand. Dobbins JG, et al. **Sex Transm Dis** 1999 Feb;26(2):67-74

HIV surveillance: a dynamic, not static, process to assure accurate local data. Griffin RG, et al. **Sex Transm Dis** 1999 May;26(5):291-5

The association of false-positive rapid plasma reagin results and HIV infection. Joyanes P, et al. **Sex Transm Dis** 1998 Nov;25(10):569-71

Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, and HIV infection among drug users attending an STD/HIV prevention and needle-exchange program in Quebec City, Canada. Poulin C, et al. **Sex Transm Dis** 1999 Aug;26(7):410-20

The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India [see comments] Risbud A, et al. **Sex Transm Dis** 1999 Jan;26(1):55-62. Comment in: Sex Transm Dis 1999 Jan;26(1):63-5.

Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy [see comments] Spina M, et al. **Sex Transm Dis** 1998 Oct;25(9):451-4. Comment in: Sex Transm Dis 1998 Oct;25(9):455-6.

Sexual practices and prevalence of HIV, HTLV-I/II, and Treponema pallidum among clandestine female sex workers in Lima, Peru. Trujillo L, et al. **Sex Transm Dis** 1999 Feb; 26(2):115-8

HIV infection among homosexual/bisexual males attending genitourinary clinics in Scotland. Goldberg D, et al. **Sex Transm Infect** 1998 Jun;74(3):185-8

Oral examination: a screening tool for HIV infection? Robinson PG, et al. **Sex Transm Infect** 1998 Oct;74(5):345-8

Prospective cohort study of female sex workers and the risk of HIV infection in Alicante, Spain (1986-96). Vioque J, et al. **Sex Transm Infect** 1998 Aug;74(4):284-8

Sexual regimes and sexual networking: the risk of an HIV/AIDS epidemic in Bangladesh. Caldwell B, et al. **Soc Sci Med** 1999 Apr;48(8):1103-16

HIV-related sexual risk assessment among Asian/Pacific Islander American women: an inductive model. Chin D. **Soc Sci Med** 1999 Jul;49(2):241-51

A test to detect replication in HIV serological data labelled by birth date based on the number of matching pairs in a sample. Greenhalgh D, et al. **Stat Med** 1999 Jul 15; 18(13):1641-56

Naming names. TDH implements HIV/STD reporting changes. Franke J. **Tex Med** 1999 Apr;95(4):14-5

HIV-2 status in southern India. Kannangai R, et al. **Trans R Soc Trop Med Hyg** 1999 Jan-Feb;93(1):30-1

The tuberculosis pandemic: implications for health in the tropics. Zumla A, et al. **Trans R Soc Trop Med Hyg** 1999 Mar-Apr;93(2):113-7

Voluntary screening for HIV: 1997 World AIDS Day experience in a rural mission hospital in Cameroon [letter] Amoaku E. **Trop Doct** 1998 Oct;28(4):248-9

Epidemiology and clinical profile of HIV/AIDS in Pakistan. Baqi S, et al. **Trop Doct** 1999 Jul;29(3):144-8

HIV infection in Dharam, Nepal [letter] Bhattacharya SK, et al. **Trop Doct** 1999 Apr;29(2):117-8

HIV and syphilis serostatus of antenatals in traditional Maasai pasturalist communities in Kajiado District, Kenya: 1989-1992. Valadez JJ, et al. **Trop Doct** 1999 Apr, 29(2):94-8

Utilizing an epidemiological profile for HIV prevention community planning in West Virginia. Foglia G, et al. **W V Med J** 1998 Nov-Dec;94(6):320-5

Drug use, sexual behaviour and HIV risk of the homeless in Port-of-Spain, Trinidad. Reid SD. **West Indian Med J** 1999 Jun;48(2):57-60

At-risk behaviors with regard to HIV and addiction among women in prison. Guyon L, et al. **Women Health** 1999; 29(3):49-66

Epidemiological surveillance for the spread of HIV infection. Foreword [editorial] Piot P. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):3-4 **(Eng, Rus)**

[Epidemiological analysis of HIV infection status in the population at high risk] Wang D, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Apr; 19(2):81-3 (Eng. Abstr.) **(Chi)**

[A cohort study of HIV infection among intravenous drug users in Ruili and other two counties in Yunnan Province, China, 1992-1995] Zheng X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Oct; 18(5):259-62 (Eng. Abstr.) **(Chi)**

[A changed pattern of opportunistic infections and malignancies in HIV-seropositive patients after the introduction of intensive anti-HIV-combination therapy] Borleffs JC, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31; 142(44):2395-9 (16 ref.) (Eng. Abstr.) **(Dut)**

[Increase of reported HIV-1 infections in children in Netherlands, 1982-1997: more vertical transmission and a greater proportion of other than Dutch children] de Kleer IM, et al. **Ned Tijdschr Geneeskd** 1999 Aug 14; 143(33):1696-700 (Eng. Abstr.) **(Dut)**

[Surveillance of AIDS and HIV infections in Amsterdam, 1997] van den Hoek JA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26;142(52):2861-5 (Eng. Abstr.) **(Dut)**

[Panophthalmitis and results of HIV tests. Experience at the Cocody University Hospital Center in Abidjan, Ivory Coast] Ahnoux-Zabsonre A, et al. **J Fr Ophtalmol** 1998 Apr;21(4):283-6 (Eng. Abstr.) **(Fre)**

[Salmonellosis in HIV infection in a hospital setting in Gabon] Okome-Kouakou M, et al. **Med Trop (Mars)** 1999; 59(1):46-50 (Eng. Abstr.) **(Fre)**

[Prevalence of HIV infection in dialysis patients: results of a national multicenter study] Poignet JL, et al. **Nephrologie** 1999;20(3):159-63 (Eng. Abstr.) **(Fre)**

[Severe community-acquired bacterial pneumonia from Streptococcus pneumonia in HIV-infected patients: epidemiology and prognostic features of mortality] Mégarbane B, et al. **Pathol Biol (Paris)** 1999 May; 47(5):422-9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of clinical epidemiology to the management of HIV infections] Morlat P, et al. **Rev Med Interne** 1999 Aug;20(8):681-92 (50 ref.) (Eng. Abstr.) **(Fre)**

[Comorbidities in the addicted patient] Meiler A, et al. **Rev Med Suisse Romande** 1998 Sep;118(9):747-50 **(Fre)**

[Early decline in an epidemic: evolution of the prevalences of HIV, hepatitis B, hepatitis C and aminotransferases in intravenous drug abusers in Strasbourg between 1980 and 1990] Will T. **Rev Med Suisse Romande** 1999 Apr; 119(4):329-34 (Eng. Abstr.) **(Fre)**

[Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992-1996] Pillonel J, et al. **Transfus Clin Biol** 1998 Oct;5(5):305-12 (Eng. Abstr.) **(Fre)**

[AIDS--the forgotten pandemic?] Bartens W. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):A7-8 **(Ger)**

[Risk of infection by needle-stick injury] Goebel FD, et al. **Internist (Berl)** 1999 Jan;40(1):117-8 **(Ger)**

[The number of people in Germany living with HIV infection has reached a new high (news)] **Pharm Unserer Zeit** 1999 May;28(3):158-9 **(Ger)**

[Epidemiology and transmission of HIV infection] Rockstroh JK. **Pharm Unserer Zeit** 1999 Mar;28(2):95-101 (19 ref.) **(Ger)**

[Sexual behaviors and the HIV/AIDS risk in the general population: the methodological aspects of a national study within the context of a European Concerted Action] Renzi C, et al. **Ann Ig** 1999 Mar-Apr;11(2):83-94 (Eng. Abstr.) **(Ita)**

[The survey of HIV infection among clients of foreign female prostitutes in Tokyo Metropolitan] Ichikawa S, et al. **Nippon Koshu Eisei Zasshi** 1999 Aug;46(8):638-43 (Eng. Abstr.) **(Jpn)**

[Epidemiological study on HIV/AIDS in Cambodia seroprevalence of HIV/STD among commercial sex workers] Ohshige K, et al. **Nippon Koshu Eisei Zasshi** 1999 Jan;46(1):61-70 (Eng. Abstr.) **(Jpn)**

[The clinico-epidemiological characteristics of HIV infection in 93 adults in the Republic of Moldova] Cojocaru S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):269-74 (Eng. Abstr.) **(Rum)**

[The clinico-epidemiological aspects of HIV infection in 167 children nonmaternally infected who have died with a diagnosis of AIDS] Cojocaru S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Jul-Sep; 43(3):139-45 (Eng. Abstr.) **(Rum)**

[HIV-infection in St. Petersburg] Rakhmanova AG, et al. **Klin Med (Mosk)** 1998;76(9):57-9 **(Rus)**

[The characteristics of the epidemic process of HIV infection in the Armed Forces] Zmushko EI, et al. **Voen Med Zh** 1998 Aug;319(8):44-7 **(Rus)**

[Increase in the serotypical heterogeneity in HIV-1 in Svetlogorsk focus 1 year after the start of an epidemic] Shchelkanov MIu, et al. **Vopr Virusol** 1999 Jul-Aug; 44(4):174-7 (Eng. Abstr.) **(Rus)**

[HIV infection in Russia in 1998] **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):38 (Eng. Abstr.) **(Rus)**

[The development of HIV infection in the Far-Eastern region of the Russian Federation] Bogach VV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):13-6 (Eng. Abstr.) **(Rus)**

[HIV infection in the penitentiaries of Ukraine] Gunchenko A, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):31-3 (Eng. Abstr.) **(Rus)**

[The epidemiological characteristics of HIV infection in Turkmenistan] Illiev SKh, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):19-21 (Eng. Abstr.) **(Rus)**

[The molecular epidemiological characteristics of the HIV-1 variants circulating among injection drug addicts on the territory of the CIS Nations] Karamov EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):39-41 (Eng. Abstr.) **(Rus)**

[The determinants of the spread of HIV among injection drug addicts in Ukraine] Kobyshcha Iu. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):34-6 (Eng. Abstr.) **(Rus)**

[An analysis of an outbreak of HIV infection in the city of Svetlogorsk, the Republic of Byelarus, among persons using injected narcotics] Kostikova LI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):18-9 (Eng. Abstr.) **(Rus)**

[Children, adolescents and HIV infection] Kuznetsova VV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):112-3 (Eng. Abstr.) **(Rus)**

[The epidemic situation in relation to HIV infection in the Volga River region] Nosov NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):24-6 (Eng. Abstr.) **(Rus)**

[The characteristics of HIV infection during a sharp activation of the epidemic process in Rostov Province] Saukhat SR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):23-4 (Eng. Abstr.) **(Rus)**

[The epidemic situation in relation to HIV infection in Ukraine (1987-1997)] Shcherbinskaia AM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):26-9 (Eng. Abstr.) **(Rus)**

[The clinico-epidemiological characteristics of HIV infection and AIDS in Ukraine] Vovk AD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):29-31 (Eng. Abstr.) **(Rus)**

[Hospital detoxification unit: 4-year experience. Treatment and infections] Gutiérrez del Rio C, et al. **An Med Interna** 1998 Oct;15(10):528-30 (Eng. Abstr.) **(Spa)**

[Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain] Alfonso Gil R, et al. **Gac Sanit** 1999 Jan-Feb;13(1):16-21 (Eng. Abstr.) **(Spa)**

[Prevalence of human immunodeficiency virus and risk behaviours among opioid users seen in an emergency room] Pérez González K, et al. **Gac Sanit** 1999 Jan-Feb;13(1):7-15 (Eng. Abstr.) **(Spa)**

[The epidemiological surveillance of human immunodeficiency virus (HIV) infection in a hospital

population of Catalonia. Collaborators in the VIHHOSP project] Blanch C, et al. **Med Clin (Barc)** 1998 Dec 5; 111(19):731–5 (Eng. Abstr.) **(Spa)**

[Prevalence of human immunodeficiency virus infection and behaviors associated with its transmission among parenteral drug users selected on the street] Rodés A, et al. **Med Clin (Barc)** 1998 Oct 3;111(10):372–7 (Eng. Abstr.) **(Spa)**

[HIV seroprevalence in patients seen at sexually-transmitted disease and family planning centers in Spain, 1995–1996. AIDS Programs of the Autonomic Communities and Network of sexually-transmitted disease, HIV and family planning centers] **Rev Esp Salud Publica** 1999 Jan–Feb; 73(1):25–34 (Eng. Abstr.) **(Spa)**

[Prevalence of tuberculosis and HIV infections among participants in an intravenous drug user risk-control program] Alvarez Rodriguez M, et al. **Rev Esp Salud Publica** 1999 May–Jun;73(3):375–81 (Eng. Abstr.) **(Spa)**

[AIDS and sexually transmitted diseases in the Americas (letter)] **Rev Panam Salud Publica** 1999 Sep;6(3):215–9 (Eng. Abstr.) **(Spa)**

[Beginning of the end of HIV? (editorial)] Britton S. **Nord Med** 1998 Nov;113(9):286 **(Swe)**

ETHNOLOGY

Alleles that may influence HIV-1 pathogenesis in Chinese subjects [letter] Shieh B, et al. **AIDS** 1999 Feb 25; 13(3):421–4

Changing HIV infection rates and risk in an African-American community cohort. Brunswick AF, et al. **AIDS Care** 1998 Jun;10(3):267–81

Is acculturation associated with sexual risk behaviours? An investigation of HIV-positive Latino men and women. Marks G, et al. **AIDS Care** 1998 Jun;10(3):283–95

Ethnic minorities and their vulnerability to AIDS in a border state of India. Thomas J, et al. **AIDS Care** 1999 Feb; 11(1):45–60

Condom use in sexual exchange relationships among young single adults in Ghana. Ankomah A. **AIDS Educ Prev** 1998 Aug;10(4):303–16

Elevated frequencies of the mutant allele delta32 at the CCR5 gene in Ashkenazic Jews. Lucotte G, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):1–2

Sexual partnering and risk of HIV/STD among Aboriginals. Calzavara LM, et al. **Can J Public Health** 1999 May–Jun; 90(3):186–91

Mutant chemokine receptor (CCR-5) and its relevance to HIV infection in Arabs [letter] al-Sheikh IH, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):183–5

HLA antigens associated with susceptibility/resistance to HIV-1 infection. Rohowsky-Kochan C, et al. **Hum Immunol** 1998 Dec;59(12):802–15

HIV and hepatitis B surveillance in First Nations alcohol and drug treatment centers in British Columbia, Canada. Martin JD, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:280–4

Estimated HIV risk among Hispanics in a national sample of drug users. Montoya ID, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):42–50

Spirituality, psychological well-being, and HIV symptoms for African Americans living with HIV disease. Coleman CL, et al. **J Assoc Nurses AIDS Care** 1999 Jan–Feb; 10(1):42–50

Two cultures, one epidemic. Hall CM, et al. **J Assoc Nurses AIDS Care** 1999 Jul–Aug;10(4):19–26

Integrating Buddhism and HIV prevention in U.S. southeast Asian communities. Loue S, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):100–21 (107 ref.)

Human immunodeficiency virus/acquired immunodeficiency syndrome crisis. Dennis GC. **J Natl Med Assoc** 1998 Nov; 90(11):643–4

Oral manifestations of HIV infection in a group of predominantly ethnic Chinese. Tsang PC, et al. **J Oral Pathol Med** 1999 Mar;28(3):122–7

Do blacks believe that HIV/AIDS is a government conspiracy against them? Klonoff EA, et al. **Prev Med** 1999 May;28(5):451–7

ETIOLOGY

Drug scene roles and HIV risk. Friedman SR, et al. **Addiction** 1998 Sep;93(9):1403–16

Sexually transmitted diseases and risk of HIV infection in men attending a sexually transmitted diseases clinic in Dakar, Senegal. Thior I, et al. **Afr J Reprod Health** 1997 Sep;1(2):26–35

Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Bell DM. **Am J Med** 1997 May 19;102(5B):9–15 (56 ref.)

Failures of zidovudine postexposure prophylaxis. Jochimsen EM. **Am J Med** 1997 May 19;102(5B):52–5; discussion 56–7 (20 ref.)

Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Pinto LA, et al. **Am J Med** 1997 May 19;102(5B):21–4 (31 ref.)

Depression, suicidality, and HIV [letter] Nandakumar R. **Am J Psychiatry** 1999 May;156(5):801–2

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Berger EA, et al. **Annu Rev Immunol** 1999;17:657–700 (230 ref.)

Chemokine receptors in HIV-1 and SIV infection. Choe H. **Arch Pharm Res** 1998 Dec;21(6):634–9 (38 ref.)

Medical students, their electives, and HIV [editorial; comment] Wilkinson D, et al. **BMJ** 1999 Jan 16; 318(7177):139–40. Comment on: **BMJ** 1999 Jan 16;318(7177):158–60. Comment on: **BMJ** 1999 Jan 16;318(7177):161–2.

Krever 2008 [editorial] [see comments] Schechter MT, et al. **CMAJ** 1999 Apr 20;160(8):1179–80. Comment in: **CMAJ** 1999 Aug 24;161(4):366–7.

Link between HIV risk and other STDs debated at forum. Silversides A. **CMAJ** 1999 Apr 6;160(7):1048

HIV pathogenesis: mechanisms of susceptibility and disease progression. Simonsen JN, et al. **Curr Opin Microbiol** 1998 Aug;1(4):423–9 (70 ref.)

Assessment of behavioural risk factors associated with HIV infection among youth in Moshi rural district, Tanzania. Tengia-Kessy A, et al. **East Afr Med J** 1998 Sep; 75(9):528–32

Risk of human immunodeficiency virus infection and genital ulcer disease among persons attending a sexually transmitted disease clinic in Italy. Corona R, et al. **Epidemiol Infect** 1998 Dec;121(3):623–30

Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Wenzel T, et al. **Haemostasis** 1998 Mar–Apr;28(2):106–10

Chemokines and chemokine receptors: role in HIV infection. Kalinkovich A, et al. **Immunol Lett** 1999 Jun 1; 68(2–3):281–7 (84 ref.)

Relationship of national highway with injecting drug abuse and HIV in rural Manipur, India. Sarkar K, et al. **Indian J Public Health** 1997 Apr–Jun;41(2):49–51

Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. Des Jarlais DC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):67–72

Temporal trends in HIV risk behaviors of out-of-treatment injection drug users and injection drug users who smoke crack. Semaan S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):274–81

Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. Unutmaz D, et al. **J Exp Med** 1999 Jun 7;189(11):1735–46

cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. Cole SW, et al. **J Immunol** 1999 Feb 1;162(3):1392–400

T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis. Iyengar S, et al. **J Immunol** 1999 May 15;162(10):6263–7

CCR5 genotype and HIV-1 infection in perinatally-exposed infants. Mas A, et al. **J Infect** 1999 Jan;38(1):9–11

Determinants of the natural history of human immunodeficiency virus type 1 infection. Phair JP. **J Infect Dis** 1999 Mar;179 Suppl 2:S384–6 (34 ref.)

Do alcohol and cocaine abuse alter the course of HIV-associated dementia complex? Tyor WR, et al. **J Leukoc Biol** 1999 Apr;65(4):475–81 (116 ref.)

Blood transfusions and the risk of intermediate- or high-grade non-Hodgkin's lymphoma. Nelson RA, et al. **J Natl Cancer Inst** 1998 Nov 18;90(22):1742–3

Drug use and HIV risks among African-American, Mexican-American, and Puerto Rican drug injectors. Estrada AL. **J Psychoactive Drugs** 1998 Jul–Sep; 30(3):247–53

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. Huang L, et al. **J Virol** 1998 Nov;72(11):8952–60

Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. Kitchen SG, et al. **J Virol** 1998 Nov; 72(11):9054–60

An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Richter A, et al. **Med Decis Making** 1999 Apr–Jun;19(2):167–79

How HIV-1 lentivirus causes immune deficiency disease. Habeshaw JA, et al. **Med Hypotheses** 1999 Jan;52(1):59–67 (33 ref.)

Did Parisians catch HIV from 'monkey glands'? [letter] Short RV. **Nature** 1999 Apr 22;398(6729):657

Experimental study of the possible implications of some apoptosis mechanisms in the pathogenesis of HIV infection. 1. In vitro apoptotic death of peripheral blood lymphocytes. Topârceanu F, et al. **Rom J Virol** 1997 Jan–Dec;48(1–4):51–9

Gender differences in risk behaviors among HIV+ persons with an IDU history. The link between partner characteristics and women's higher drug-sex risks. The Manif 2000 Study Group. Gollub EL, et al. **Sex Transm Dis** 1998 Oct;25(9):483–8

HIV/AIDS in nonurban Alabama: risk activities and access to services among HIV-infected persons. Beltrami JF, et al. **South Med J** 1999 Jul;92(7):677–83

HIV risk behaviors associated with the injection process: multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Needle RH, et al. **Subst Use Misuse** 1998 Oct;33(12):2403–23

[Genetic variability in the pathogenesis of HIV infection (news)] **Recenti Prog Med** 1999 May;90(5):298–9 **(Ita)**

[The possible role of immunogenetic factors in the pathogenesis of HIV infection] Volianskii IuL, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):49–52 (42 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children [letter] Amoroso A, et al. **AIDS** 1999 May 7;13(7):863–4

HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32 [letter] Heiken H, et al. **AIDS** 1999 Mar 11;13(4):529–30

An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3'A allele [letter] Kuipers H, et al. **AIDS** 1999 Feb 25;13(3):433–4

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells. Scheuring UJ, et al. **AIDS** 1999 Feb 4;13(2):167–75

Alleles that may influence HIV-1 pathogenesis in Chinese subjects [letter] Shieh B, et al. **AIDS** 1999 Feb 25; 13(3):421–4

Comparison of complete env gene sequences from individuals with symptomatic primary HIV type 1 infection. Ataman-Onal Y, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1035–9

Association between a defective CCR-5 gene and progression to disease in HIV infection. Balfe P, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1229–34

Elevated frequencies of the mutant allele delta32 at the CCR5 gene in Ashkenazic Jews. Lucotte G, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):1–2

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. Tang J, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):317–24

Normal telomere lengths in naive and memory CD4+ T cells in HIV type 1 infection: a mathematical interpretation. Wolthers KC, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1053–62

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection. Zamarchi R, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):337–44

Host genes and infectious diseases. HIV, other pathogens, and a public health perspective. McNicholl JM, et al. **Am J Prev Med** 1999 Feb;16(2):141–54 (131 ref.)

The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load. Si Mohamed A, et al. **Antiviral Res** 1998 Jul; 39(1):47–53

Cloning of a long HIV-1 readthrough transcript and detection of an increased level of early growth response protein-1 (Egr-1) mRNA in chronically infected U937 cells. Dron M, et al. **Arch Virol** 1999;144(1):19–28

Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity [letter] Quirino T, et al. **Biomed Pharmacother** 1999 Jun;53(5–6):286–7

Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Magierowska M, et al. **Blood** 1999 Feb 1;93(3):936–41

Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting. Pérez-Olmeda M, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun;18(6):448–9

CCR5 genotype and human immunodeficiency virus type 1 infection in perinatally exposed infants. Villalba N, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):389–91

HLA antigens associated with susceptibility/resistance to HIV-1 infection. Rohowsky-Kochan C, et al. **Hum Immunol** 1998 Dec;59(12):802–15

CCR5 genotype and resistance to vertical transmission of HIV-1. Philpott S, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):189–93

Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. Hendel H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):381–6

CXCR4 polymorphisms and HIV-1 pathogenesis [letter] Martin MP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):430

Atopy, anergic status, and cytokine expression in HIV-infected subjects. Empson M, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):833–42

The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. Bowles NE, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):857–65

Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. Banda NK, et al. **J Hematother** 1998 Aug;7(4):319–31

In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. Arya SK, et al. **J Hum Virol** 1999 May–Jun;2(3):133–8

Correlation of tumor suppressor P53 RNA expression with human immunodeficiency virus disease in rapid and slow progressors. McLinden RJ, et al. **J Hum Virol** 1997 Nov–Dec;1(1):30–6

Telomere dynamics in monkeys: increased cell turnover in macaques infected with chimeric simian-human immunodeficiency viruses. Shibata R, et al. **J Med Primatol** 1999 Feb;28(1):1-10

Frequencies of SDF-1 chemokine, CCR-5, and CCR-2 chemokine receptor gene alleles conferring resistance to human immunodeficiency virus type 1 and AIDS in Kuwaitis. Voevodin A, et al. **J Med Virol** 1999 May; 58(1):54-8

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. Grovit-Ferbas K, et al. **J Virol** 1998 Nov;72(11):8650-8

Association of the CCR5delta32 mutation with improved response to antiretroviral therapy [letter] Valdez H, et al. **JAMA** 1999 Aug 25;282(8):734

Modulation of cell surface protein expression by infection with HIV-1. Speth C, et al. **Leukemia** 1999 Apr;13 Suppl 1:S99-105 (85 ref.)

Application of random amplified polymorphic DNA PCR for genomic analysis of HIV-1-infected individuals. Aikhionbare FO, et al. **Mutat Res** 1998 Nov;406(1):25-31

HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy [see comments] Corder EH, et al. **Nat Med** 1998 Oct;4(10):1182-4. Comment in: Nat Med 1998 Dec;4(12):1344.

Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Mummidi S, et al. **Nat Med** 1998 Jul; 4(7):786-93

Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro. Veal GJ, et al. **Nucleic Acids Res** 1998 Dec 15; 26(24):5670-5

Genetic determinants of HIV-1 infection and its manifestations. Kaslow RA, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):299-307 (62 ref.)

Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Gonzalez-Cadavid NF, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14938-43

Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Liu H, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4581-5

Survival with HIV infection: good luck or good breeding? Rowland-Jones SL. **Trends Genet** 1998 Sep;14(9):343-5 (36 ref.)

Transmission of human immunodeficiency type 1 viruses with intersubtype recombinant long terminal repeat sequences. Blackard JT, et al. **Virology** 1999 Feb 15;254(2):220-5

HIV-1 subtype B in Honduras. Renjifo B, et al. **Virus Res** 1999 Apr;60(2):191-7

[Are prehistoric epidemics reflected in the genetic variability of Danes and in current pathogenesis of HIV infections?] Eugen-Olsen J, et al. **Ugeskr Laeger** 1998 Dec 21; 160(52):7585-8 (22 ref.) **(Dan)**

HISTORY

Hemophilia: a story of success--disaster and the perseverance of the human spirit, Part 2. Dubin CS. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):88-92

IMMUNOLOGY

Antibody responses to the herpes simplex virus type 2 glycoprotein G in sera of human immunodeficiency virus-infected patients in Slovakia. Bystrická M, et al. **Acta Virol** 1998 Nov;42(5):319-24

Prevalence of human herpesvirus 8 antibodies in human immunodeficiency virus type 1-infected homosexual men in Slovakia [letter] Mayer V, et al. **Acta Virol** 1998 Apr; 42(2):123-4

HIV entry and tropism. When one receptor is not enough. Berger EA. **Adv Exp Med Biol** 1998;452:151-7 (39 ref.)

HIV transmission and immune protection at mucosal surfaces. Neutra MR. **Adv Exp Med Biol** 1998;452:169-75 (60 ref.)

Immune control of HIV-1 replication. Walker BD, et al. **Adv Exp Med Biol** 1998;452:159-67 (32 ref.)

T cell dynamics in HIV-1 infection. Clark DR, et al. **Adv Immunol** 1999;73:301-27 (97 ref.)

How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee. **AIDS** 1999 Jul 9;13(10):1241-7

Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. Andersson J, et al. **AIDS** 1999 Jul 30;13(11):1295-303

Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients [letter] Ankri A, et al. **AIDS** 1999 Jul 9;13(10):1282-3

Compartmentalization of the IgG immune response to HIV-1 in breast milk. Becquart P, et al. **AIDS** 1999 Jul 30; 13(11):1323-31

HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. Bernard NF, et al. **AIDS** 1998 Nov 12;12(16):2125-39

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. Bisset LR, et al. **AIDS** 1998 Nov 12;12(16):2115-23

Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. Blanco J, et al. **AIDS** 1999 Apr 1;13(5):547-55

Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. Böhler T, et al. **AIDS** 1999 May 7;13(7):779-89

T cell changes after combined nucleoside analogue therapy in HIV primary infection. Carcelain G, et al. **AIDS** 1999 Jun 18;13(9):1077-81

Persistent T cell and B cell activities in the duodenal mucosa of AIDS patients. Carol M, et al. **AIDS** 1998 Oct 1; 12(14):1763-9

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Carotenuto P, et al. **AIDS** 1998 Sep 10; 12(13):1591-600

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Chêne G, et al. **AIDS** 1998 Dec 3;12(17):2313-20

Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. Chougnet C, et al. **AIDS** 1998 Dec 24;12(18):2397-406

Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study. Cone RW, et al. **AIDS** 1998 Dec 3; 12(17):2253-60

Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. Conge AM, et al. **AIDS** 1998 Aug 20;12(12):1437-49

Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells [letter] Degen O, et al. **AIDS** 1998 Sep 10;12(13):1715-6

Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection [editorial] Deresinski SC. **AIDS** 1999 Apr 16;13(6):633-43 (136 ref.)

Immune activation and plasma viral load in HIV-infected African individuals [letter] Dyer JR, et al. **AIDS** 1999 Jul 9;13(10):1283-5

Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is related to CMV serostatus [letter] Evans TG, et al. **AIDS** 1999 Jun 18;13(9):1139-41

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Garcia F, et al. **AIDS** 1999 Jul 30;13(11):F79-86

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. Giorgi JV, et al. **AIDS** 1998 Oct 1;12(14):1833-44

Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. Grassi F, et al. **AIDS** 1999 May 7;13(7):759-66

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Haubrich RH, et al. **AIDS** 1999 Jun 18;13(9):1099-107

Evaluation of guidelines for initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected individuals. Ioannidis JP, et al. **AIDS** 1998 Dec 24;12(18):2417-23

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Kaul R, et al. **AIDS** 1999 Jan 14; 13(1):23-9

Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy. Kostense S, et al. **AIDS** 1998 Dec 24; 12(18):F235-40

Vaccination and HIV-1 replication during highly active antiretroviral therapy [letter] Kroon FP, et al. **AIDS** 1999 Jan 14;13(1):135-6

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. Kroon FP, et al. **AIDS** 1998 Dec 3;12(17):F217-23

Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. Kubar J, et al. **AIDS** 1998 Nov 12;12(16):2147-53

Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Kupfer B, et al. **AIDS** 1999 Jun 18;13(9):1025-8

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Larsson M, et al. **AIDS** 1999 May 7;13(7):767-77

HIV-specific cytotoxic T lymphocyte precursors exist in a CD28-CD8+ T cell subset and increase with loss of CD4 T cells. Lewis DE, et al. **AIDS** 1999 Jun 18;13(9):1029-33

Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. Lieberman J, et al. **AIDS** 1999 May 28;13(8):891-9

Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. Martinon F, et al. **AIDS** 1999 Feb 4;13(2):185-94

CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy [letter] Meroni L, et al. **AIDS** 1999 Apr 1;13(5):621-2

CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS [letter] Meyer L, et al. **AIDS** 1999 Apr 1;13(5):624-6

Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. Mezzaroma I, et al. **AIDS** 1999 Jul 9;13(10):1187-93

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **AIDS** 1999 Jan 14;13(1):31-9

Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. Monari C, et al. **AIDS** 1999 Apr 16;13(6):653-60

Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. Norrgren H, et al. **AIDS** 1999 Apr 16;13(6):701-7

Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. Ortigão-de-Sampaio MB, et al. **AIDS** 1998 Oct 1;12(14):F145-50

HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail to develop a Bacillus Calmette-Guérin scar [letter] Ota MO, et al. **AIDS** 1999 May 28;13(8):996-8

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. Pakker NG, et al. **AIDS** 1999 Feb 4;13(2):203-12

HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. Patki AH, et al. **AIDS** 1999 Jul 9;13(10):1177-85

Unscheduled cyclin B expression and p34 cdc2 activation in T lymphocytes from HIV-infected patients. Piedimonte G, et al. **AIDS** 1999 Jul 9;13(10):1159-64

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. Renaud M, et al. **AIDS** 1999 Apr 16;13(6):669-76

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy [letter] Rice PS, et al. **AIDS** 1999 Apr 16; 13(6):729-31

Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. Rizzardini G, et al. **AIDS** 1998 Dec 24;12(18):2387-96

Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. Roos MT, et al. **AIDS** 1998 Oct 1;12(14):1745-51

Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals [letter] Shapira-Nahor O, et al. **AIDS** 1998 Sep 10;12(13):1731-3

Small differences in CD4+ T-cell production may go unnoticed [letter] Shapiro HM, et al. **AIDS** 1999 Feb 4; 13(2):290-1

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. Staszewski S, et al. **AIDS** 1999 May 28;13(8):951-6

Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS, et al. **AIDS** 1999 Jan 14;13(1):89-96

Natural immunity and HIV disease progression. Ullum H, et al. **AIDS** 1999 Apr 1;13(5):557-63

Thymus volume correlates with the progression of vertical HIV infection. Vigano' A, et al. **AIDS** 1999 Apr 1; 13(5):F29-34

Lack of protection against HIV-1 infection among women with HIV-2 infection. Wiktor SZ, et al. **AIDS** 1999 Apr 16;13(6):695-9

Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. Williams PL, et al. **AIDS** 1999 Jun 18;13(9):1035-44

Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group. Zou W, et al. **AIDS** 1999 Mar 11;13(4):455-63

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. Adams GB, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):551-9

C1 inhibitor function and anti-C1 inhibitor autoantibodies in patients with HIV type 1 infection [letter; comment] Beretta A, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):95-6. Comment on: AIDS Res Hum Retroviruses 1997 Jul 1;13(10):813-4.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. Betts MR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1219-28

Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. Bucy RP. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):223-7

Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers. Buseyne F, et al. **AIDS Res Hum Retroviruses** 1998 Nov

1;14(16):1435–44

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. Cavacini LA, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1271–80

Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):43–50

Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. Cox JH, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):847–54

Virology and immunology of acute HIV type 1 infection. Daar ES. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S229–34 (80 ref.)

Downregulation of the expression of the main immunoglobulin V(H) family in HIV-infected patients: modulation by triple combination therapy [letter] David D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):315–6

The role of dendritic cells in the infection of CD4+ T cells with the human immunodeficiency virus: use of dendritic cells from individuals homozygous for the delta32CCR5 allele as a model. Dybul M, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1109–13

HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced beta-chemokine production. Fowke KR, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20; 14(17):1521–30

Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. Gilljam G, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1; 15(10):899–907

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. Haslett PA, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1169–79

Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. Hioe CE, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S247–54 (69 ref.)

Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. Kaufmann GR, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20; 15(11):963–72

Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. Kundu SK, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1669–78

Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. Lopalco L, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1079–85

Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). Lori F, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):619–24

Comparison of seven quantitative assays to assess lymphocyte cell death during HIV infection: measurement of induced apoptosis in anti-Fas-treated Jurkat cells and spontaneous apoptosis in peripheral blood mononuclear cells from children infected with HIV. McCloskey TW, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1413–22

In vivo expansion coincident with excessive in vitro cell death within the memory subset of CD8+ T cells in HIV type 1 infection. Mugnaini EN, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):265–72

Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations. Nokta M, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):255–64

Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. Pontesilli O, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):973–81

Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. Popper SJ, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1157–62

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. Quinnan GV Jr, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):561–70

CD8+ lymphocytes in pregnancy and HIV infection: characterization of CD8+ subpopulations and CD8+ noncytotoxic antiviral activity. Rich KC, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):665–70

Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. Rinaldo CR Jr, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1423–33

Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1341–3

Encouraging vaccine results from primate models of HIV type 1 infection. Schultz A. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S261–3 (33 ref.)

Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion. Xiao L, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1201–8

Expression of a novel Nef epitope on the surface of HIV type 1-infected cells. Yamada T, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1001–9

Transgenic mouse model of ethanol as a cofactor in HIV disease. Prakash O, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):266S–268S (39 ref.)

Mechanism of HIV pathogenesis: role of superantigens in disease. Torres BA, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):188S–192S (58 ref.)

Intractable pruritus in HIV infection: immunologic characterization. Milazzo F, et al. **Allergy** 1999 Mar; 54(3):266–72

The role of skin dendritic cells in the initiation of human immunodeficiency virus infection. Blauvelt A. **Am J Med** 1997 May 19;102(5B):16–20 (31 ref.)

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117–24; discussion 125–6 (43 ref.)

Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Ciesielski CA, et al. **Am J Med** 1997 May 19;102(5B):115–6 (11 ref.)

Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Pinto LA, et al. **Am J Med** 1997 May 19;102(5B):21–4 (31 ref.)

Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. Johnson JL, et al. **Am J Respir Crit Care Med** 1998 Dec;158(6):1790–6

Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Wewers MD, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1543–9

Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):160–4

Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):212–6

Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: a measure of current immune suppression. Multicenter Hemophilia Cohort Study. Engels EA, et al. **Ann Intern Med** 1999 Aug 17;131(4):256–64

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Miller V, et al. **Ann Intern Med** 1999 Apr 6;130(7):570–7

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Tasker SA, et al. **Ann Intern Med** 1999 Sep 21;131(6):430–3

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Haase AT. **Annu Rev Immunol** 1999;17:625–56 (158 ref.)

Cartesian coordinate analysis of viral burden and CD4+ T-cell count in human immunodeficiency virus type-1 infection. Reichelderfer PS, et al. **Antiviral Res** 1998 Jun; 38(3):181–94

CD26-processed RANTES(3–68), but not intact RANTES, has potent anti-HIV-1 activity [published erratum appears in Antiviral Res 1999 Jan;40(3):189–90] Schols D, et al. **Antiviral Res** 1998 Oct;39(3):175–87

Placental antibody transfer: influence of maternal HIV infection and placental malaria. de Moraes-Pinto MI, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov; 79(3):F202–5

Carnitine stands on its own in HIV infection treatment [letter; comment] Famularo G, et al. **Arch Intern Med** 1999 May 24;159(10):1143–4. Comment on: Arch Intern Med 1998 Nov 9;158(20):2257–64.

T-cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection. Schneider C, et al. **Arch Neurol** 1999 Jan;56(1):79–83

Autoantibodies in human immunodeficiency virus-infected patients with and without concurrent hepatitis C infection. Montero A, et al. **Arthritis Rheum** 1998 Nov;41(11):2077–9

Disappointment in the search for an HIV vaccine [news] **Aust Fam Physician** 1999 Jul;28(7):736

Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals. Banda NK, et al. **Biol Blood Marrow Transplant** 1999;5(3):162–72

Potentialization of IL-2 effects on immune cells by oyster extract (JCOE) in normal and HIV-infected individuals. Achour A, et al. **Biomed Pharmacother** 1997;51(10):427–9

B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Tähtinen M, et al. **Biomed Pharmacother** 1997;51(10):480–7

CD8 T-cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells–T-cell interaction. Agostini C, et al. **Blood** 1999 Feb 15;93(4):1277–86

Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Aiuti A, et al. **Blood** 1999 Jul 1;94(1):62–73

Sensitivity of CD4+ peripheral blood T cells toward spontaneous and CD95 (APO-1/Fas)-induced apoptosis in pediatric human immunodeficiency virus infection [letter] Böhler T, et al. **Blood** 1999 Sep 1;94(5):1829–33

The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Canque B, et al. **Blood** 1999 Jun 1;93(11):3866–75

Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Lee B, et al. **Blood** 1999 Feb 15;93(4):1145–56

The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Marshall JD, et al. **Blood** 1999 Aug 1; 94(3):1003–11

Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Sloand EM, et al. **Blood** 1999 Aug 1;94(3):1021–7

Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Tan R, et al. **Blood** 1999 Mar 1;93(5):1506–10

Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Wolthers KC, et al. **Blood** 1999 Feb 1;93(3):1011–9

Human herpes virus 8 (HHV8) serology in allogeneic bone marrow transplant recipients. Rosenzwajg M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):351–4

Paraproteins and monoclonal expansion of CD3+CD8+ CD56–CD57+ T lymphocytes in a patient with HIV infection. Smith P, et al. **Br J Haematol** 1999 Apr; 105(1):85–7

Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Westby M, et al. **Br J Haematol** 1998 Sep;102(5):1187–96

Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Cashion MF, et al. **Brain Res** 1999 Mar 20; 822(1–2):26–33

Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Kinoshita S, et al. **Cell** 1998 Nov 25;95(5):595–604

Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Badley AD, et al. **Cell Death Differ** 1999 May;6(5):420–32

Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children. Stricker K, et al. **Cell Death Differ** 1998 Mar; 5(3):222–30

Single cell analysis of antigen-specific T cell responses in HIV-infected individuals. Byl B, et al. **Cell Immunol** 1999 Mar 15;192(2):107–12

Qualitative immunoglobulin abnormalities in HIV-positive patients: long-term follow-up. Pontet F, et al. **Clin Chem Lab Med** 1998 Jun;36(7):493–6

Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures. Aziz N, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):755–61

Increased expression of regeneration and tolerance factor in individuals with human immunodeficiency virus infection. DuChateau BK, et al. **Clin Diagn Lab Immunol** 1999 Mar; 6(2):193–8

Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Kroon FP, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):352–5

Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals. Meddows-Taylor S, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):345–51

Immunohematological reference ranges for adult Ethiopians. Tsegaye A, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):410–4

Levels of proinflammatory cytokines in plasma after pneumococcal immunization in human immunodeficiency virus type 1-infected patients. Valdez H, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):427–8

Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Weinberg A, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):804–7

Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients. Witt DJ, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):369–76

Hypersensitivity reactions to drugs in HIV-infected patients. Allergic evaluation and desensitization. Moreno-Ancillo A, et al. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:57–60 (45 ref.)

Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Bürgisser P, et al. **Clin Exp Immunol** 1999 Mar;115(3):458–63

CD8+ T cell-mediated enhancement of tumour necrosis factor-alpha (TNF-alpha) production and HIV-1

LTR-driven gene expression in human monocytic cells is pertussis toxin-sensitive. Copeland KF, et al. **Clin Exp Immunol** 1999 Jun;116(3):479–85

CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes. Daniel V, et al. **Clin Exp Immunol** 1999 Mar;115(3):477–84

Viral load and CD69 molecule expression on freshly isolated and cultured mitogen-stimulated lymphocytes of children with perinatal HIV-1 infection. De Martino M, et al. **Clin Exp Immunol** 1999 Sep;117(3):513–6

Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals. Galiani MD, et al. **Clin Exp Immunol** 1999 Mar;115(3):472–6

Anti-phospholipid antibodies and CD5+ B cells in HIV infection. Grünewald T, et al. **Clin Exp Immunol** 1999 Mar; 115(3):464–71

Alterations in blood leucocyte adhesion molecule profiles in HIV-1 infection. Hayes PJ, et al. **Clin Exp Immunol** 1999 Aug;117(2):331–4

Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection. Jobe O, et al. **Clin Exp Immunol** 1999 Jun;116(3):474–8

Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Kumar A, et al. **Clin Exp Immunol** 1999 Jul;117(1):84–91

Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. Kumar A, et al. **Clin Exp Immunol** 1998 Oct;114(1):78–86

Neutrophil adhesion molecules in HIV disease. Moore DA, et al. **Clin Exp Immunol** 1998 Oct;114(1):73–7

Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Nielsen SD, et al. **Clin Exp Immunol** 1998 Oct;114(1):66–72

Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection. Steiner K, et al. **Clin Exp Immunol** 1999 Mar;115(3):451–7

IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Stylianou E, et al. **Clin Exp Immunol** 1999 Apr;116(1):115–20

Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Tedla N, et al. **Clin Exp Immunol** 1999 Jul; 117(1):92–9

Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Vanham G, et al. **Clin Exp Immunol** 1999 Aug; 117(2):335–42

Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Hildreth JEK, et al. **Clin Immunol** 1999 Feb;90(2):203–12

Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Hosono O, et al. **Clin Immunol** 1999 Jun;91(3):283–95

Primary HIV infection of infants: the effects of somatic growth on lymphocyte and virus dynamics [see comments] Krogstad P, et al. **Clin Immunol** 1999 Jul;92(1):25–33. Comment in: Clin Immunol 1999 Jul;92(1):3–5.

Costimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV. Lewis DE, et al. **Clin Immunol** 1999 Mar;90(3):302–12

The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes. Plaeger S, et al. **Clin Immunol** 1999 Feb;90(2):238–46

C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Prohászka Z, et al. **Clin Immunol** 1999 Feb; 90(2):247–55

Autoantibodies to leukocyte alphaMbeta2 integrin glycoproteins in HIV infection. Rubinstein DB, et al. **Clin Immunol** 1999 Mar;90(3):352–9

Influenza, influenza virus vaccine, and human immunodeficiency virus infection [editorial; comment] Couch RB. **Clin Infect Dis** 1999 Mar;28(3):548–51. Comment on: Clin Infect Dis 1999 Mar;28(3):541–7.

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response [see comments] Fuller JD, et al. **Clin Infect Dis** 1999 Mar; 28(3):541–7. Comment in: Clin Infect Dis 1999 Mar;28(3):548–51.

Longer-term immunologic effects and side effects of successful antiretroviral therapy. Schooley RT. **Clin Infect Dis** 1999 Jul;29(1):12–8 (49 ref.)

HIV. Genetic effects on immunity immunity to infection. Web alert. Greaves DR. **Curr Opin Immunol** 1998 Aug; 10(4):377–8

Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cameron PU, et al. **Cytometry** 1998 Sep 1;33(1):83–8

Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Hultin LE, et al. **Cytometry** 1998 Oct 1;33(2):123–32

New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Krol A, et al. **Drug Alcohol Depend** 1999 Apr 1;54(2):145–54

Dysregulation of interleukin-2 receptor beta and interleukin-2 receptor gamma expression during HIV infection. David D, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):97–101 (38 ref.)

Impairment of HIV polymorphonuclear leukocyte transmigration across T84 cell monolayers: an alternative mechanisms for increased intestinal bacterial infections in AIDS? Hofman P, et al. **Eur Cytokine Netw** 1999 Sep; 10(3):373–82

Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Torres Y, et al. **Eur J Clin Invest** 1998 Nov;28(11):930–6

False-positive tests for syphilis associated with human immunodeficiency virus and hepatitis B virus infection among intravenous drug abusers. Valencian Study Group on HIV Epidemiology. Hernández-Aguado I, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):784–7

Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group. Dorrucci M, et al. **Eur J Epidemiol** 1999 Apr;15(4):317–22

Antiphosphatidylserine antibodies in HIV-1+ patients bind apoptotic T cells in vitro. Cafforio P, et al. **Eur J Histochem** 1997;41 Suppl 2:65–6

Flow cytometric evaluation of CD38, CD45 RO and CD45 RA in HIV-infected children. Caselli D, et al. **Eur J Histochem** 1997;41 Suppl 2:193–4

Lack of correlation between HLA-DR and CD25 "activation" related antigens on CD16+ NK cells in HIV infection. Lucia MB, et al. **Eur J Histochem** 1997;41 Suppl 2:31–2

Surface P-glycoprotein expression on peripheral lymphocyte subpopulations from HIV-infected patients. Lucia MB, et al. **Eur J Histochem** 1997;41 Suppl 2:33–4

Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons. Boullier S, et al. **Eur J Immunol** 1999 Jan; 29(1):90–9

Dendritic cells from HIV-1-infected patients naturally express HIV-1 gp120 V3 loop-derived peptide ligands. Fernandez MH, et al. **Eur J Immunol** 1998 Oct; 28(10):3144–53

Phagocytosis of Escherichia coli and Staphylococcus aureus by neutrophils of human immunodeficiency virus-infected patients. Schaumann R, et al. **Eur J Med Res** 1998 Dec 16;3(12):546–8

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. Juompan L, et al. **FASEB J** 1998 Nov;12(14):1473–80

Intestinal macrophages display reduced permissiveness to human immunodeficiency virus 1 and decreased surface CCR5. Li L, et al. **Gastroenterology** 1999 May; 116(5):1043–53

Increased CD4-positive monocytes in HIV-infected haemophilic patients. Riera N, et al. **Haemophilia** 1998 Sep; 4(5):725–30

Human immunodeficiency virus infection in haemophiliacs in Taiwan: the importance of CD4 lymphocyte count in the progression to acquired immunodeficiency syndrome. Shen MC, et al. **Haemophilia** 1998 Mar;4(2):115–21

CD8 T cells in HIV infection: mechanisms of immunity. Yang OO. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):105–8, 111–2, 115–7 passim (5 ref.)

The human uniqueness of HIV: innate immunity and the viral Tat protein. Rodman TC, et al. **Hum Immunol** 1999 Aug; 60(8):631–9

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A, et al. **Hybridoma** 1999 Apr;18(2):149–57

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Poignard P, et al. **Immunity** 1999 Apr;10(4):431–8

HIV-induced immunopathogenesis. Shearer GM. **Immunity** 1998 Nov;9(5):587–93 (59 ref.)

Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. Mühlbacher M, et al. **Immunobiology** 1999 Jun;200(2):295–305

Antibodies against peripheral myelin glycolipids in people with HIV infection. Petratos S, et al. **Immunol Cell Biol** 1998 Dec;76(6):535–41

Proceedings of the 2nd International Summit Meeting on Immunological Correlates of Protection from HIV Infection and Disease. Oxford, United Kingdom, 17–20 April 1998. **Immunol Lett** 1999 Mar;66(1-3):1–228

Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure. Akridge R, et al. **Immunol Lett** 1999 Mar;66(1-3):15–9

Restoration of the immune system with anti-retroviral therapy. Autran B, et al. **Immunol Lett** 1999 Mar; 66(1-3):207–11 (9 ref.)

A role for mucosal immunity in resistance to HIV infection. Clerici M, et al. **Immunol Lett** 1999 Mar;66(1-3):21–5

The role of HIV gp120 in the disruption of the immune system. Dalgleish AG, et al. **Immunol Lett** 1999 Mar; 66(1-3):81–7

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Daniel V, et al. **Immunol Lett** 1999 Aug 3;69(2):283–9

Antigen presenting cell function in HIV-1 infected patients. Fidler SJ, et al. **Immunol Lett** 1999 Mar;66(1-3):129–34

Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Giorgi JV, et al. **Immunol Lett** 1999 Mar;66(1-3):105–10

Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Gougeon ML, et al. **Immunol Lett** 1999 Mar;66(1-3):97–103

Different effect of 1,25-dihydroxyvitamin D3 on replication of Mycobacterium avium in monocyte-derived macrophages from human immunodeficiency virus-infected subjects and healthy controls. Haug CJ, et al. **Immunol Lett** 1998 Sep;63(2):107–12

Soluble tumor necrosis factor receptor type II (sTNFRII) in HIV-infected patients: relationship with the plasma level of HIV-1 RNA. Hober D, et al. **Immunol Lett** 1999 Apr 1;67(2):91–4

CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Köchli C, et al. **Immunol Lett** 1999 Feb;65(3):197–201

The role of the viral glycoprotein in HIV-1 persistence. McKeating JA, et al. **Immunol Lett** 1999 Jan;65(1-2):63–70 (110 ref.)

Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15. Naora H, et al. **Immunol Lett** 1999 Jun 1; 68(2-3):359–67

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Nixon DF, et al. **Immunol Lett** 1999 Mar;66(1-3):219–28

Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Plummer FA, et al. **Immunol Lett** 1999 Mar; 66(1-3):27–34

Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Pontesilli O, et al. **Immunol Lett** 1999 Mar;66(1-3):213–7

Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Rosenberg ES, et al. **Immunol Lett** 1999 Mar;66(1-3):89–93

Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Sapp M, et al. **Immunol Lett** 1999 Mar;66(1-3):121–8

Evolutionary dynamics of HIV-induced subversion of the immune response. Wodarz D, et al. **Immunol Rev** 1999 Apr; 168:75–89 (118 ref.)

Thymic involution and HIV progression [letter] Beltz L. **Immunol Today** 1999 Sep;20(9):429 (9 ref.)

Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Bofill M, et al. **Immunol Today** 1999 Jun;20(6):258–61 (29 ref.)

Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Akimoto H, et al. **Immunology** 1998 Oct;95(2):214–8

The effects of HIV viral load on the phagocytic activity of monocytes activated with lipopolysaccharide from oral microorganisms. Baqui AA, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):421–38

Kala Azar and HIV [editorial] Shahi SK, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):269–70

Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection. Cornely OA, et al. **Infection** 1999 Mar-Apr;27(2):92–6

An enlarged subpopulation of T lymphocytes bearing two distinct gammadelta TCR in an HIV-positive patient. Taupin JL, et al. **Int Immunol** 1999 Apr;11(4):545–52

Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. Wesch D, et al. **Int Immunol** 1998 Aug;10(8):1067–75

Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. Silvestris F, et al. **Int J Clin Lab Res** 1998; 28(4):215–25

CD4 count and CD4% in African HIV-infected people [letter; comment] Anglaret X, et al. **Int J Epidemiol** 1998 Oct;27(5):928–9. Comment on: Int J Epidemiol 1997 Dec;26(6):1367–72.

Contribution of zinc to reduce CD4+ risk factor for 'severe' infection relapse in aging: parallelism with HIV. Mocchegiani E, et al. **Int J Immunopharmacol** 1999 Apr; 21(4):271–81

CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study [see comments] Denny TN, et al. **Int J Infect Dis** 1998 Apr-Jun; 2(4):186–92. Comment in: Int J Infect Dis 1998 Apr-Jun;2(4):182–5.

Evaluation of the serologic response against two consensus V3 loop peptides from human immunodeficiency virus-1 in Cuban patients. Miguez J, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):221–5

T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy (review). Fleury S, et al.

Int J Mol Med 1999 Jul;4(1):91–7 (69 ref.)
Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Poccia F, et al. **Int J Mol Med** 1998 Feb;1(2):409–13 (62 ref.)
Protein kinase C regulates NO–cGMP pathway in muscarinic receptor activation by HIV+–IgA. Sales ME, et al. **Int J Mol Med** 1999 Jun;3(6):633–7
Immunological predictors of HIV-related survival. Baillargeon J, et al. **Int J STD AIDS** 1999 Jul;10(7):467–70
Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2. Ng KP, et al. **Int J STD AIDS** 1999 Jun;10(6):401–4
Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). Anastos K, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):141–7
Evidence for a local synthesis of beta-chemokines within the genital tract of both HIV-1-infected and uninfected women [letter] Fiore JR, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):255–7
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. Gisslén M, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):271–6
HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. Mahoney EM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):333–7
Immune function and phenotype before and after highly active antiretroviral therapy. Søndergaard SR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):376–83
Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. Weisman Z, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):157–63
Activation and proliferation of CD8+ T cells in lymphoid tissues of HIV-1-infected individuals in the absence of the high-affinity IL-2 receptor. Brinchmann JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):332–8
Growth hormone in immune reconstitution. Chappel S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):423–31 (132 ref.)
Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. Hendel H, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):381–6
Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. Ioannidis JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):129–36
Stability of cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiology Research Study Group. Klein RS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):238–44
Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). Lambert JS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):451–61
CXCR4 polymorphisms and HIV-1 pathogenesis [letter] Martin MP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):430
Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. Navin TR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):154–9
Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research. Rompalo AM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):448–54
Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV. Talesnik E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):471–7
Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. van der Ryst E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):238–44
Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients. Demoly P, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):1033–6
Atopy, anergic status, and cytokine expression in HIV-infected subjects. Empson M, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):833–42
Monitoring cellular immune function in HIV infection by the delayed hypersensitivity skin test: alternative to the CD4 T-cell count? [editorial; comment] Shearer WT. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):26–8. Comment on: J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):93–8.
Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. Patton LL, et al. **J Am Dent Assoc** 1999 Sep;130(9):1313–22 (66 ref.)
Stress and HIV disease progression: psychoneuroimmunological framework. Robinson FP, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):21–31 (56 ref.)
Chemokine receptors and chemokines in HIV infection [published erratum appears in J Clin Immunol 1998 Nov;18(6):441] Garzino-Demo A, et al. **J Clin Immunol** 1998 Jul;18(4):243–55 (159 ref.)
Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. Lin SJ, et al. **J Clin Immunol** 1998 Sep;18(5):335–45
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. Bucy RP, et al. **J Clin Invest** 1999 May 15; 103(10):1391–8
Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection [published erratum appears in J Clin Invest 1999 Mar;103(6):921] Haynes BF, et al. **J Clin Invest** 1999 Feb;103(4):453–60
What immunity can protect against HIV infection [editorial; comment] Letvin NL. **J Clin Invest** 1998 Nov 1; 102(9):1643–4. Comment on: J Clin Invest 1998 Nov 1;102(9):1758–65.
Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi [see comments] Rowland-Jones SL, et al. **J Clin Invest** 1998 Nov 1;102(9):1758–65. Comment in: J Clin Invest 1998 Nov 1;102(9):1643–4.
Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I. González C, et al. **J Clin Lab Anal** 1999;13(2):59–64
CD8 lymphocytes in HIV infection: helpful and harmful. Famularo G, et al. **J Clin Lab Immunol** 1997;49(1):15–32 (97 ref.)
The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus. Lehmann DF, et al. **J Clin Pharmacol** 1999 May;39(5):533–7
Anti-HIV-1 seroreactivity and HIV transmission route[R1]. The HEC/FIOCRUZ AIDS Clinical Research Group. Bongertz V, et al. **J Clin Virol** 1999 Jan;12(1):27–36
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. Zhang L, et al. **J Exp Med** 1999 Sep 6; 190(5):725–32
Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire. de Haard JJ, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2883–94
Role of class I major histocompatibility complex-restricted and -unrestricted suppression of human immunodeficiency virus type 1 replication by CD8+ T lymphocytes. Ohashi T, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):209–16
Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. Banda NK, et al. **J Hematother** 1998 Aug;7(4):319–31
Effect of splenectomy on T-cell subsets and plasma HIV viral titers in HIV-infected patients. Bernard NF, et al. **J Hum Virol** 1998 Jul-Aug;1(5):338–45
Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects. Moss RB, et al. **J Hum Virol** 1998 Jan-Feb;1(2):77–81
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease. Nicastri E, et al. **J Hum Virol** 1998 Jan-Feb;1(2):90–5
Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections. Sarr AD, et al. **J Hum Virol** 1999 Jan-Feb; 2(1):45–51
Changes in circulating levels of HIV, CD4, and tissue expression of HIV in a patient with recent-onset ulcerative colitis treated by surgery. Case report. Silver S, et al. **J Hum Virol** 1999 Jan-Feb;2(1):52–7
IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. Bailer RT, et al. **J Immunol** 1999 Jun 15;162(12):7534–42
Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection. Brander C, et al. **J Immunol** 1999 Apr 15;162(8):4796–800
Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Calarota SA, et al. **J Immunol** 1999 Aug 15;163(4):2330–8
Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. Chougnet C, et al. **J Immunol** 1999 Aug 1;163(3):1666–73
Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. Ensoli F, et al. **J Immunol** 1999 May 15;162(10):6268–77
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). Gray CM, et al. **J Immunol** 1999 Feb 1;162(3):1780–8
Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. Hengel RL, et al. **J Immunol** 1999 Sep 15; 163(6):3539–48
Biased TCR repertoire in HIV-1-infected patients due to clonal expansion of HIV-1-reverse transcriptase-specific CTL clones. Kolowos W, et al. **J Immunol** 1999 Jun 15; 162(12):7525–33
Complement receptor 1 (CD35) on human reticulocytes: normal expression in systemic lupus erythematosus and HIV-infected patients. Lach-Trifilieff E, et al. **J Immunol** 1999 Jun 15;162(12):7549–54
Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. McDyer JF, et al. **J Immunol** 1999 Mar 15;162(6):3711–7
C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease. Peritt D, et al. **J Immunol** 1999 Jun 15;162(12):7563–8
Detection of HIV-1-specific CTLs in the semen of HIV-infected individuals. Quayle AJ, et al. **J Immunol** 1998 Oct 15;161(8):4406–10
Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. Ruiz ME, et al. **J Immunol** 1998 Oct 15;161(8):4169–76
Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. Sousa AE, et al. **J Immunol** 1999 Mar 15;162(6):3718–26
Clonal dominance patterns of CD8 T cells in relation to disease progression in HIV-infected children. Than S, et al. **J Immunol** 1999 Mar 15;162(6):3680–6
HIV-1 envelope gp120 inhibits the monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation. Wang JM, et al. **J Immunol** 1998 Oct 15;161(8):4309–17
Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. Wasik TJ, et al. **J Immunol** 1999 Apr 1; 162(7):4355–64
CD4+ T cell enumeration in HIV infection with limited resources. Sherman GG, et al. **J Immunol Methods** 1999 Jan 1;222(1-2):209–17
Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? Gompels MM, et al. **J Infect** 1999 Mar;38(2):111–5
Long-term non-progression in HIV infection: clinico pathological issues. Rowland-Jones S. **J Infect** 1999 Mar; 38(2):67–70 (26 ref.)
Cytomegalovirus retinitis, human immunodeficiency virus antibody positivity and normal T helper cell numbers. Thomson RM, et al. **J Infect** 1998 Sep;37(2):186–8
HIV-1 Infection, Mucosal Immunity and Pathogenesis. Conference proceedings. Bethesda, Maryland, USA. 11–13 September 1997. **J Infect Dis** 1999 May;179 Suppl 3:S391–498
Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. Abadi J, et al. **J Infect Dis** 1999 Sep; 180(3):915–9
Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. Aukrust P, et al. **J Infect Dis** 1999 Jan;179(1):74–82
Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. Aziz N, et al. **J Infect Dis** 1999 Apr;179(4):843–8
CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor. Barker E. **J Infect Dis** 1999 May;179 Suppl 3:S485–8 (17 ref.)
Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP, et al. **J Infect Dis** 1999 May;179(5):1264–7
A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. Cecilia D, et al. **J Infect Dis** 1999 Jun;179(6):1365–74
Impaired phagocyte oxidative capacity in human immunodeficiency virus-infected children. Hayani KC, et al. **J Infect Dis** 1999 Mar;179(3):584–9
Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. Hosaka N, et al. **J Infect Dis** 1998 Oct;178(4):1030–9
Human immunodeficiency virus type 1 and mucosal humoral defense. Janoff EN, et al. **J Infect Dis** 1999 May;179 Suppl 3:S475–9 (21 ref.)
The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California. Kemper CA, et al. **J Infect Dis** 1998 Oct;

178(4):1177–80
Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. Kresina TF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S392–6 (4 ref.)
The effect of route of immunization on mucosal immunity and protection. Lehner T, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S489–92 (19 ref.)
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. Loomis-Price LD, et al. **J Infect Dis** 1998 Nov;178(5):1306–16
Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. Lynch JA, et al. **J Infect Dis** 1998 Oct;178(4):1040–6
In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. Maas JJ, et al. **J Infect Dis** 1998 Oct;178(4):1024–9
Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. Merrill DP, et al. **J Infect Dis** 1999 Feb;179(2):345–51
CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. Meyer L, et al. **J Infect Dis** 1999 Sep;180(3):920–4
Effect of human immunodeficiency virus type 1 on intracellular activation and superoxide production by neutrophils. Muñoz JF, et al. **J Infect Dis** 1999 Jul; 180(1):206–10
Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. Musey LK, et al. **J Infect Dis** 1999 Aug;180(2):278–84
Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. Orendi JM, et al. **J Infect Dis** 1998 Nov;178(5):1279–87
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. Pontesilli O, et al. **J Infect Dis** 1999 Jul;180(1):76–86
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. Sei S, et al. **J Infect Dis** 1999 Sep;180(3):626–40
Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. Spiegel HM, et al. **J Infect Dis** 1999 Aug;180(2):359–68
The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. Sulkowski MS, et al. **J Infect Dis** 1998 Dec;178(6):1642–8
All-trans retinoic acid inhibition of anti-CD3-induced T cell apoptosis in human immunodeficiency virus infection mostly concerns CD4 T lymphocytes and is mediated via regulation of CD95 ligand expression. Szondy Z, et al. **J Infect Dis** 1998 Nov;178(5):1288–98
Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production. Triozzi PL, et al. **J Infect Dis** 1999 Jan; 179(1):245–8
Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis: comments and conference summary. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S397–400
Persistent expansion, in a human immunodeficiency virus-infected person, of V beta-restricted CD4+CD8+ T lymphocytes that express cytotoxicity-associated molecules and are committed to produce interferon-gamma and tumor necrosis factor-alpha. Weiss L, et al. **J Infect Dis** 1998 Oct;178(4):1158–62
CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. Wilkinson J, et al. **J Infect Dis** 1999 Jul;180(1):68–75
CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection [letter] Williams SB, et al. **J Infect Dis** 1999 May;179(5):1310–2
Generation of CD28- cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism accounting for the increased number of CD8+CD28- T cells in HIV-1-infected patients. Fiorentini S, et al. **J Leukoc Biol** 1999 May;65(5):641–8
Chemokine immunobiology in HIV-1 pathogenesis. Lee B, et al. **J Leukoc Biol** 1999 May;65(5):552–65 (192 ref.)
Production of monoclonal antibody to CD4 antigen and development of reagent for CD4+ lymphocyte enumeration. Kasinrerk W, et al. **J Med Assoc Thai** 1998 Nov;81(11):879–92
Functional antibody response to human cytomegalovirus in immunocompetent and HIV-1 infected individuals with antibodies that inhibit virus penetration into cells and intercellular transmission of viral infection. Alberola J, et al. **J Med Microbiol** 1999 Oct;48(10):947–54
Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera. Lawoko AL, et al. **J Med Virol** 1999 Oct;59(2):169–79
Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission. Mazza C, et al. **J Med Virol** 1999 May;58(1):59–62
The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. Price DA, et al. **J Mol Med** 1998 Sep;76(10):699–708 (91 ref.)
Cocaine opens the blood-brain barrier to HIV-1 invasion. Zhang L, et al. **J Neurovirol** 1998 Dec;4(6):619–26
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. Sleasman JW, et al. **J Pediatr** 1999 May;134(5):597–606
Occurrence of anti-thyroid autoantibodies in children vertically infected with HIV-1. Fundarò C, et al. **J Pediatr Endocrinol Metab** 1998 Nov-Dec;11(6):745–50
Changes in immune activation markers during pregnancy and postpartum. Burns DN, et al. **J Reprod Immunol** 1999 Mar; 42(2):147–65
Human serum beta2-microglobulin levels: correlation with total serum IgG and placental IgG transfer in HIV-infected and non-HIV infected individuals. de Moraes-Pinto MI, et al. **J Reprod Immunol** 1999 Mar;42(2):167–74
A stochastic model for early HIV-1 population dynamics. Tuckwell HC, et al. **J Theor Biol** 1998 Dec 21; 195(4):451–63
The disappearing CD4(+)T cells in HIV infection: a case of over-stimulation? Wick D. **J Theor Biol** 1999 Apr 21; 197(4):507–16
Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. Amado RG, et al. **J Virol** 1999 Aug;73(8):6361–9
Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. Beddows S, et al. **J Virol** 1999 Feb;73(2):1740–5
Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. Fais S, et al. **J Virol** 1999 Aug;73(8):6453–9
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. Hay CM, et al. **J Virol** 1999 Jul;73(7):5509–19
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6721–8
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6715–20
Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. Kitchen SG, et al. **J Virol** 1998 Nov; 72(11):9054–60
HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication. Mackewicz CE, et al. **J Virol** 1998 Dec;72(12):10165–70
CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. Moir S, et al. **J Virol** 1999 Oct;73(10):7972–80
Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. Ostrowski MA, et al. **J Virol** 1999 Aug;73(8):6430–5
Resistance against syncytium-inducing human immunodeficiency virus type 1 (HIV-1) in selected CD4(+) T cells from an HIV-1-infected nonprogressor: evidence of a novel pathway of resistance mediated by a soluble factor(s) that acts after virus entry. Saha K, et al. **J Virol** 1999 Sep;73(9):7891–8
Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees. Santra S, et al. **J Virol** 1999 Aug;73(8):7065–9
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM, et al. **J Virol** 1998 Dec;72(12):9656–67
Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. Wilson CC, et al. **J Virol** 1999 May;73(5):3975–85
Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. Woodberry T, et al. **J Virol** 1999 Jul;73(7):5320–5
Potential use of a caspase against HIV. Finkel TH. **JAMA** 1999 Sep 15;282(11):1021–2
HIV researchers air new findings [news] Stephenson J. **JAMA** 1999 Mar 10;281(10):883–5
CD38/CD8 expression and HAART failure [letter; comment] Caselli D, et al. **Lancet** 1999 Mar 6;353(9155):840–1. Comment on: Lancet 1998 Dec 12;352(9144):1905–6.
Immunisation with gp160 in HIV-1 infection [letter] Fiala C, et al. **Lancet** 1999 Sep 11;354(9182):948; discussion 949
Lack of sex difference in CD4 to HIV-1 RNA viral load ratio [letter] Moore RD, et al. **Lancet** 1999 Feb 6; 353(9151):463–4
HAART and host: balancing the response to HIV-1. Highly active antiretroviral therapy [news] Morris K. **Lancet** 1998 Nov 21;352(9141):1686
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study [letter] Plana M, et al. **Lancet** 1998 Oct 10;352(9135):1194–5
Immunisation with gp160 in HIV-1 infection [letter] Pontesilli O, et al. **Lancet** 1999 Sep 11;354(9182):948–9
HIV infection: where have all the T cells gone? Rowland-Jones S. **Lancet** 1999 Jul 3;354(9172):5–7
A model of primary HIV-1 infection. Murray JM, et al. **Math Biosci** 1998 Dec 15;154(2):57–85
HIV pathogenesis: gp120-antibody complexes bind CD4 and kill T4 cells--immunotoxin therapy should prevent the progression of HIV to AIDS. Chaplin JW. **Med Hypotheses** 1999 Feb;52(2):133–46 (126 ref.)
Human immunodeficiency virus in breast milk. Kennedy SB 4th. **Med Hypotheses** 1998 Jul;51(1):75–7
Cardiopulmonary and CD4 cell changes in response to exercise training in early symptomatic HIV infection. Perna FM, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):973–9
The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients. Gerencer M, et al. **Microb Pathog** 1998 Nov; 25(5):253–66
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort [see comments] Learmont JC, et al. **N Engl J Med** 1999 Jun 3;340(22):1715–22. Comment in: N Engl J Med 1999 Jun 3;340(22):1756–7.
Latent reservoirs of HIV infection: flushing with IL-2? [news; comment] Cooper DA, et al. **Nat Med** 1999 Jun; 5(6):611–2. Comment on: Nat Med 1999 Jun;5(6):651–5.
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Fleury S, et al. **Nat Med** 1998 Jul;4(7):794–801
Dangerous T-cell amnesia [news; comment] Gorochov G. **Nat Med** 1999 May;5(5):483–4. Comment on: Nat Med 1999 May;5(5):518–25.
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans [see comments] Hellerstein M, et al. **Nat Med** 1999 Jan;5(1):83–9. Comment in: Nat Med 1999 Jan;5(1):27–8.
Is an HIV vaccine possible? [news; comment] McMichael AJ, et al. **Nat Med** 1999 Jun;5(6):612–4. Comment on: Nat Med 1999 May;5(5):526–34. Comment on: Nat Med 1999 Jun;5(6):643–50.
Unraveling the strands of HIV's web [news; comment] Pantaleo G. **Nat Med** 1999 Jan;5(1):27–8. Comment on: Nat Med 1999 Jan;5(1):29–3. Comment on: Nat Med 1999 Jan;5(1):34–41. Comment on: Nat Med 1999 Jan;5(1):83–9.
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments] Pitcher CJ, et al. **Nat Med** 1999 May;5(5):518–25. Comment in: Nat Med 1999 May;5(5):483–4.
HIV-1 and HAART: a time to cure, a time to kill [news; comment] Saag MS, et al. **Nat Med** 1999 Jun;5(6):609–11 . Comment on: Nat Med 1999 May;5(5):512–7. Comment on: Nat Med 1999 Jun;5(6):651–5.
Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Walker RE, et al. **Nat Med** 1998 Jul; 4(7):852–6
Changes in thymic function with age and during the treatment of HIV infection [see comments] Douek DC, et al. **Nature** 1998 Dec 17;396(6712):690–5. Comment in: Nature 1998 Dec 17;396(6712):630–1.
Chemokine control of HIV-1 infection [letter] Mellado M, et al. **Nature** 1999 Aug 19;400(6746):723–4
T cell responses in coinfection with Onchocerca volvulus and the human immunodeficiency virus type 1. Sentongo E, et al. **Parasite Immunol** 1998 Sep;20(9):431–9
Immunizations for the immunocompromised child. McFarland E. **Pediatr Ann** 1999 Aug;28(8):487–96 (32 ref.)
Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression. Esposito S, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):847–9
CD28 expression in pediatric human immunodeficiency virus infection. Niehues T, et al. **Pediatr Res** 1998 Aug; 44(2):265–8
Human immunodeficiency virus status and delayed-type hypersensitivity skin testing in Ugandan children. Mandalakas AM, et al. **Pediatrics** 1999 Feb;103(2):E21
HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Markham RB, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12568–73
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Penn ML, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;

96(2):663–8
Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Stranford SA, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1030–5
Why is the efficacy of HAART so durable? [editorial] Griffiths PD. **Rev Med Virol** 1999 Jan–Mar;9(1):1–2
Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death. Aladdin H, et al. **Scand J Immunol** 1999 Aug; 50(2):223–7
Specific immune response to human immunodeficiency virus (HIV)-1 in patients assessed through the production of interferon-gamma and interleukin-4 in HIV-1 p24-activated whole blood cultures: relationship with the viral load in plasma. Hober D, et al. **Scand J Immunol** 1999 Jul;50(1):83–90
Production of interleukin-4, interferon (IFN)-gamma and IFN-alpha in human immunodeficiency virus-1 infection: an imbalance of type 1 and type 2 cytokines may reduce the synthesis of IFN-alpha. Hober D, et al. **Scand J Immunol** 1998 Oct;48(4):436–42
Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339–46 (80 ref.)
Increased CD4+ T-lymphocyte senescence fraction in advanced human immunodeficiency virus type 1 infection. Nichols WS, et al. **Scand J Immunol** 1999 Mar;49(3):302–6
Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Ullum H, et al. **Scand J Immunol** 1999 May;49(5):539–47
The effects of CD40 ligation on peripheral blood mononuclear cell interleukin-12 and interleukin-15 production and on monocyte CD14 surface antigen expression in human immunodeficiency virus-positive patients. Zanussi S, et al. **Scand J Immunol** 1999 Mar; 49(3):286–92
Low levels of IgG antibodies against pneumocystis carinii among HIV-infected patients. Laursen AL, et al. **Scand J Infect Dis** 1998;30(5):495–9
Testing a model: effects of pain on immunity in HIV+ and HIV- participants. Eller LS. **Sch Inq Nurs Pract** 1998 Fall; 12(3):191–214; discussion 215–20
T cell production slowed, not exhausted? [news] Balter M. **Science** 1999 Jan 15;283(5400):305–6
HLA and HIV-1: heterozygote advantage and B*35–Cw*04 disadvantage [see comments] Carrington M, et al. **Science** 1999 Mar 12;283(5408):1748–52. Comment in: Science 1999 Jul 2;285(5424):11.
Deficient cellular immunity--finding and fixing the defects. Greenberg PD, et al. **Science** 1999 Jul 23;285(5427):546–51 (58 ref.)
The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections. Rosenberg YJ, et al. **Semin Immunol** 1999 Apr;11(2):139–54 (113 ref.)
Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Rojanasuphot S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):443–50
Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. Le Corfec E, et al. **Stat Med** 1999 Jul 30;18(14):1803–17; discussion 1819
Noncytolytic HIV immunity. Slifka MK. **Trends Microbiol** 1999 Apr;7(4):143
Evaluation of a quantitative determination of CD4 and CD8 molecules as an alternative to CD4+ and CD8+ T lymphocyte counts in Africans. Diagbouga S, et al. **Trop Med Int Health** 1999 Feb;4(2):79–84
Local impairment of immunoreactivity in HIV-infected women with HPV-related squamous intraepithelial lesions of the cervix. Barberis MC, et al. **Tumori** 1998 Jul–Aug; 84(4):489–92
A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits. Galéa P, et al. **Vaccine** 1999 Mar 17;17(11–12):1454–61
The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. Gómez CE, et al. **Vaccine** 1999 May 4;17(18):2311–9
Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Johnson D, et al. **Vaccine** 1999 Jun 4; 17(20–21):2583–7
Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review). Menéndez-Arias L, et al. **Viral Immunol** 1998;11(4):167–81 (81 ref.)
Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus [published erratum appears in Viral Immunol 1999;12(1):89] Nehete PN, et al. **Viral Immunol** 1998;11(3):119–29
A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans. Nehete PN, et al. **Viral Immunol** 1998;11(3):147–58
Correlation of clinical parameters and immunological function with human immunodeficiency virus plasma viremia in children. Peters VB, et al. **Viral Immunol** 1999; 12(2):139–48
Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Buseyne F, et al. **Virology** 1998 Oct 25;250(2):316–24
Differential regulation of CC chemokine gene expression in human immunodeficiency virus-infected myeloid cells. Génin P, et al. **Virology** 1999 Sep 1;261(2):205–15
Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees. Rovinski B, et al. **Virology** 1999 May 10;257(2):438–48
Host-pathogen relationship: evasion from control [editorial] Dierich MP. **Wien Klin Wochenschr** 1999 Jun 4; 111(11):417–8
Dynamics of immune escape in HIV infection. Wodarz D, et al. **Wien Klin Wochenschr** 1999 Jun 4;111(11):419–27 (46 ref.)
[Increase of circulating CD3+CD4-CD8-CD19+ cells in the latent phase of HIV-1 infection] Nozaki-Renard J, et al. **C R Seances Soc Biol Fil** 1998;192(5):1007–15 (Eng. Abstr.) **(Fre)**
[Are antiphospholipid antibodies thrombogenic in the course of human immunodeficiency virus infection?] Cailleux N, et al. **J Mal Vasc** 1999 Feb;24(1):53–6 (Eng. Abstr.) **(Fre)**
[Portal thrombosis and anticardiolipin antibodies association in an HIV-2 infected patient (letter)] Bouchard O, et al. **Presse Med** 1998 Jun 6;27(20):965 **(Fre)**
[Latent adrenal gland insufficiency in a HIV-infected patient with phospholipid antibodies (letter)] Faller JP, et al. **Presse Med** 1999 Sep 11;28(26):1419 **(Fre)**
[Influence of HIV-related immunodeficiency on the histopathology of chronic hepatitis C] Roger PM, et al. **Presse Med** 1998 Oct 24;27(32):1617–20 (Eng. Abstr.) **(Fre)**
[Metabolic changes induced by protease inhibitors. Expert Workshop of the Curatorium on Immune Deficiency, Munich, 15–17 October 1998, Weimar] **Dtsch Med Wochenschr** 1998 Dec 11;123(50 Suppl Stoffwech):1–6 **(Ger)**
[Intermittent therapy ought to strengthen the immune system (news)] Volkert R. **Dtsch Med Wochenschr** 1999 Mar 19; 124(11):A8 **(Ger)**
[How to increase immune response in HIV-infected patients] Gürtler L. **Fortschr Med** 1998 Nov 30;116(33):6 **(Ger)**
[Level of HHV-6A antibodies in symptomless HIV infection as well as in the course of AIDS] Ongrádi J, et al. **Orv Hetil** 1999 Aug 22;140(34):1881–5 (Eng. Abstr.) **(Hun)**
[Effect of HIV envelope glycoprotein on the induction of immune dysregulation in HIV infection] Sekigawa I, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Feb;21(1):11–9 (38 ref.) (Eng. Abstr.) **(Jpn)**
[Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection] Lee S, et al. **Ryumachi** 1998 Oct; 38(5):747–51 (33 ref.) **(Jpn)**
[The immune response in HIV infection and associated diseases of the female genitalia] Lakatosh VP, et al. **Lik Sprava** 1998 Oct–Nov;(7):25–36 (63 ref.) **(Rus)**
[A pulmonary cellular immunity study in HIV patients] Fernández Fabrellas E, et al. **An Med Interna** 1999 Jan; 16(1):21–4 (Eng. Abstr.) **(Spa)**
[Which are the vaccines that human immunodeficiency virus infected patients must receive?] Valencia Ortega ME, et al. **An Med Interna** 1998 Aug;15(8):439–42 (36 ref.) (Eng. Abstr.) **(Spa)**
[Antibodies against Toxoplasma gondii in patients with HIV in Yucatan] Góngora-Biachi RA, et al. **Rev Invest Clin** 1998 Sep–Oct;50(5):419–22 (Eng. Abstr.) **(Spa)**

METABOLISM

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. Gervasoni C, et al. **AIDS** 1999 Mar 11;13(4):465–71
Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure [letter] Guardiola JM, et al. **AIDS** 1998 Jul 30;12(11):1395
Effect of malabsorption on nutritional status and resting energy expenditure in HIV-infected patients. Jiménez-Expósito MJ, et al. **AIDS** 1998 Oct 22; 12(15):1965–72
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. Martínez E, et al. **AIDS** 1999 May 7;13(7):805–10
Comparison of zidovudine phosphorylation in lymph nodes and peripheral blood mononuclear cells in HIV-infected patients. DATRI 012 Study Group [letter] Peter K, et al. **AIDS** 1998 Sep 10;12(13):1729–31
The influence of nutritional and metabolic status on progression from asymptomatic HIV infection to AIDS-defining diagnosis. Sharpstone D, et al. **AIDS** 1999 Jul 9;13(10):1221–6
Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. Shevitz AH, et al. **AIDS** 1999 Jul 30;13(11):1351–7
Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. Kumar D, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1073–7
Production of interferon-gamma by lung lymphocytes in HIV-infected individuals. Twigg HL 3rd, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L256–62
Promiscuous chemokine receptors and their redundant ligands play an enigmatic role during HIV-1 infection. Kunkel SL. **Am J Respir Cell Mol Biol** 1999 May; 20(5):859–60
Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl]cytosine in human immunodeficiency virus-infected patients. Cundy KC, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):271–7
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Hughes W, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):609–15
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Kumar PN, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):603–8
Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients. Wintergerst U, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):699–701
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Zhou XJ, et al. **Antimicrob Agents Chemother** 1999 Jan;43(1):121–8
The effect of increasing gastric pH upon the bioavailability of orally-administered foscarnet. Barditch-Crovo PA, et al. **Antiviral Res** 1998 Jun;38(3):209–12
Saliva collection technique for cytologic, microbiologic and viral evaluation in pediatric HIV infection. Flaitz CM, et al. **ASDC J Dent Child** 1998 Sep–Oct;65(5):318–24, 355
Clinico-immunopathological alterations of lymph nodes from human immunodeficiency virus-infected patients in northern Thailand. Bhoopat L, et al. **Asian Pac J Allergy Immunol** 1999 Jun;17(2):85–92
Metabolic aspects of HIV: associated wasting. Melchior JC. **Biomed Pharmacother** 1997;51(10):455–60 (52 ref.)
Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Gallicano KD, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):168–79
Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Cashion MF, et al. **Brain Res** 1999 Mar 20; 822(1–2):26–33
Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1. Savarino A, et al. **Cell Biochem Funct** 1999 Mar; 17(1):47–55
Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. Piscitelli SC, et al. **Clin Pharmacol Ther** 1998 Nov; 64(5):492–8
Detection of P-glycoprotein efflux activity on peripheral blood lymphocyte subsets from HIV+ patients. Lucia MB, et al. **Eur J Histochem** 1997;41 Suppl 2:195–6
Expression of CD69 on T-cells from HIV-1-infected children and adolescents increases with increasing viral load. Böhler T, et al. **Eur J Pediatr** 1999 Aug;158(8):638–44
Sugar transport and glut transporter expression in a variety of human immunodeficiency virus-1 (HIV-1) chronically infected target cell lines. Caro C, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1031–8
HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection. Fantini J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):221–9
Increased intracellular accumulation of macrophage inflammatory protein 1beta and its decreased secretion correlate with advanced HIV disease. Tartakovsky B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):420–2
HIV infection and signal transduction. Bovolenta C, et al. **J Biol Regul Homeost Agents** 1998 Jul–Sep;12(3):63–6 (56 ref.)
HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. Conaldi PG, et al. **J Clin Invest** 1998 Dec 15;102(12):2041–9
Does valproate pose a threat to human immunodeficiency virus-infected patients? [letter] Hardy MA, et al. **J Clin Psychopharmacol** 1999 Apr;19(2):189–90
Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. Boven LA, et al. **J Immunol** 1999 Apr 1;162(7):4319–27
Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. Kagnoff MF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S444–7 (11 ref.)
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. Moodley J, et al. **J Infect Dis** 1998 Nov;178(5):1327–33
Impaired phagocyte oxidative capacity in patients with human immunodeficiency virus infection. Pitrak DL, et al. **J Lab Clin Med** 1998 Oct;132(4):284–93
Chemokine receptor (CCR5) expression in human kidneys

and in the HIV infected macaque [see comments] Eitner F, et al. **Kidney Int** 1998 Dec;54(6):1945–54. Comment in: Kidney Int 1998 Dec;54(6):2243–4.

Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Meyerhoff DJ, et al. **Neurology** 1999 Mar 23;52(5):995–1003

Chemokine receptor mRNA expression at the in vitro blood–brain barrier during HIV infection. Shaw KT, et al. **Neuroreport** 1999 Jan 18;10(1):53–6

Glutathione redox disturbances in human immunodeficiency virus infection: immunologic and therapeutic consequences [editorial] Aukrust P, et al. **Nutrition** 1999 Feb;15(2):165–7 (32 ref.)

Whole body protein turnover in children with human immunodeficiency virus (HIV) infection. Henderson RA, et al. **Nutrition** 1999 Mar;15(3):189–94

Host–cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Flores O, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22; 96(13):7208–13

Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase. Gladyshev VN, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):835–9

The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Amzazi S, et al. **Virology** 1998 Dec 5;252(1):96–105

[Fat distribution anomalies and other metabolic disorders in patients under antiretroviral therapy] Baril L. **Presse Med** 1998 Dec;27 Suppl 5:10–1 (Eng. Abstr.) **(Fre)**

[Nitric oxide levels in cephalorhachidian + + fluid in patients with HIV infection (letter)] Velasco JJ, et al. **Enferm Infecc Microbiol Clin** 1999 May;17(5):252–3 **(Spa)**

MICROBIOLOGY

Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. Juffermans NP, et al. **AIDS** 1998 Sep 10;12(13):1661–6

Genotypic changes in DNA fingerprinting patterns of Mycobacterium tuberculosis strains from HIV-positive persons in Sardinia. Sechi LA, et al. **AIDS** 1998 Oct 22; 12(15):2084–6

Bone marrow biopsy and blood culture in evaluating HIV patients [letter; comment] Levin M. **Am J Med** 1998 Nov; 105(5):457–8. Comment on: Am J Med 1998 Feb;104(2):123–8.

Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Korting HC, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2038–42

Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Schuman P, et al. **Clin Infect Dis** 1998 Nov;27(5):1161–7

No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1 infected patients. Wilcox CM, et al. **Gut** 1999 Jan;44(1):101–5

Enteric pathogens in southern Indian HIV-infected patients with & without diarrhoea. Mukhopadhya A, et al. **Indian J Med Res** 1999 Mar;109:85–9

Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Hawken MP, et al. **Int J Tuberc Lung Dis** 1999 Aug;3(8):646–50 (26 ref.)

The effect of immunodeficiency on cutaneous delayed-type hypersensitivity testing in HIV-infected women without anergy: implications for tuberculin testing. HER Study Group. HIV Epidemiology Research. Klein RS, et al. **Int J Tuberc Lung Dis** 1999 Aug;3(8):681–8

Low rate of Clostridium difficile colonization in ambulatory and hospitalized HIV-infected patients in a hospital unit: a prospective survey. Mainardi JL, et al. **J Infect** 1998 Sep; 37(2):108–11

[Epidemiology of yeast colonization and oropharyngeal infection other than Candida albicans in patients with HIV infection] Masiá Canuto MM, et al. **Med Clin (Barc)** 1999 Feb 20;112(6):211–4 (Eng. Abstr.) **(Spa)**

MORTALITY

Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival [see comments] Brodt HR, et al. **AIDS** 1998 Aug 20;12(12):1475–81. Comment in: AIDS 1999 Feb 4;13(2):286.

Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count [letter] Husak R, et al. **AIDS** 1999 Feb 25;13(3):432–3

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. Mocroft A, et al. **AIDS** 1999 May 28;13(8):943–50

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **AIDS** 1999 Jan 14;13(1):31–9

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. Sendi PP, et al. **AIDS** 1999 Jun 18;13(9):1115–22

ICU admission in patients infected with the human immunodeficiency virus – a multicentre survey. Gill JK, et al. **Anaesthesia** 1999 Aug;54(8):727–32

The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. French R, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):827–35

Morbidity and mortality related to human immunodeficiency virus in Canadian men and women, 1987–94. Weber AE, et al. **Can J Public Health** 1999 Mar–Apr;90(2):127–32

Human immunodeficiency virus infection, anemia, and survival. Moore RD. **Clin Infect Dis** 1999 Jul;29(1):44–9 (29 ref.)

As HIV related deaths fall, increased numbers need treatment. **Commun Dis Rep CDR Wkly** 1998 Nov 27; 8(48):421

Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Okongo M, et al. **Int J Epidemiol** 1998 Aug;27(4):698–702

CD4+ lymphocytes and tuberculin skin test as survival predictors in pulmonary tuberculosis HIV-infected patients. Serrat C, et al. **Int J Epidemiol** 1998 Aug; 27(4):703–12

Immunological predictors of HIV-related survival. Baillargeon J, et al. **Int J STD AIDS** 1999 Jul;10(7):467–70

Current estimates of and future projections for adult deaths attributed to HIV infection in Zimbabwe. Robinson NJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):187–94

Gender and survival after AIDS in Rio de Janeiro, Brazil. Santoro-Lopes G, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):403–7

Steady state assumptions in DALYs: effect on estimates of HIV impact. Hyder AA, et al. **J Epidemiol Community Health** 1999 Jan;53(1):43–5

The three leading causes of death in African Americans: barriers to reducing excess disparity and to improving health behaviors. Feldman RH, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):45–71

Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study. Battegay M, et al. **J Intern Med** 1998 Dec; 244(6):479–87

Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality. Graham WJ, et al. **Lancet** 1999 Mar 6;353(9155):836–9

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Mocroft A, et al. **Lancet** 1998 Nov 28;352(9142):1725–30

Heroin, HIV and harm in New York and Sydney [letter] Maher LS, et al. **Med J Aust** 1999 Aug 2;171(3):163, 165

Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Baum SE, et al. **Mil Med** 1999 Sep;164(9):609–12

A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus–infected and uninfected children in Tanzania. Fawzi WW, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):127–33

The natural history of human immunodeficiency virus 1 infection in Haitian infants. Jean SS, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):58–63

Mortality in a cohort of children born to HIV-1 infected women from Durban, South Africa. Bobat R, et al. **S Afr Med J** 1999 Jun;89(6):646–8

Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death. Aladdin H, et al. **Scand J Immunol** 1999 Aug; 50(2):223–7

Interval-censored survival data with informative examination times: parametric models and approximate inference. Farrington CP, et al. **Stat Med** 1999 May 30;18(10):1235–48

Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment. Fugelstad A, et al. **Subst Use Misuse** 1998 Dec;33(14):2803–17

Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Harries AD, et al. **Trans R Soc Trop Med Hyg** 1998 May–Jun;92(3):343–7

Mortality attributed to malaria versus HIV/AIDS in Africa [letter] Müller O. **Trans R Soc Trop Med Hyg** 1999 Mar–Apr;93(2):222

[HIV infections: mortality reduced only in developed countries (news)] Wehr A. **Dtsch Med Wochenschr** 1999 May 7;124(18):A8–9 **(Ger)**

[Causes of death (1983–1997) in patients infected with human immunodeficiency virus by contaminated blood coagulation factor products: report of the clinical study group on prevention and treatments of HIV infection] Fukutake K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):550–5 (Eng. Abstr.) **(Jpn)**

[Mortality descriptors in HIV inpatients] Thuler LC, et al. **Rev Saude Publica** 1998 Dec;32(6):572–8 (Eng. Abstr.) **(Por)**

[Mortality in a cohort of intravenous drug users before the introduction of potent HIV therapy (see comments)] Muga R, et al. **Med Clin (Barc)** 1999 May 29;112(19):721–5 (Eng. Abstr.). Comment in: Med Clin (Barc) 1999 May 29;112(19):736–7. **(Spa)**

[Admissions and mortality in a HIV unit before and after protease inhibitors (letter)] Soriano V, et al. **Rev Clin Esp** 1998 Oct;198(10):715 **(Spa)**

NURSING

HIV & AIDS. Are you biased? Bormann J, et al. **Am J Nurs** 1999 Sep;99(9):38–9

Bringing the World together to fight HIV/AIDS. **Int Nurs Rev** 1998 Nov–Dec;45(6):169–72

Nurses intensify worldwide efforts to ensure HIV/AIDS care for all [news] **Int Nurs Rev** 1998 Jul–Aug;45(4):104

Global overview of HIV/AIDS—a challenge for nurses. Anderson S. **Int Nurs Rev** 1998 Nov–Dec;45(6):175–8, 186

The HIV/AIDS epidemic in Malawi. Kachapila L. **Int Nurs Rev** 1998 Nov–Dec;45(6):179–81

Nurses are the key to effective HIV/AIDS prevention and care. Stallknecht K. **Int Nurs Rev** 1998 Nov–Dec; 45(6):173–4

Teaching about HIV/AIDS: the lessons learned. Wyness MA, et al. **Int Nurs Rev** 1998 Nov–Dec;45(6):182–6

Reducing HIV/AIDS for nursing personnel [news] **J Adv Nurs** 1999 Feb;29(2):277

Are you protecting yourself? [news] **J Adv Nurs** 1999 Feb; 29(2):281

Nurses intensify world-wide efforts to ensure HIV/AIDS care for all [news] **J Adv Nurs** 1998 Dec;28(6):1177

Burnout and AIDS care-related factors in HIV community clinical nurse specialists in the North of England. Hayter M. **J Adv Nurs** 1999 Apr;29(4):984–93

Validation of the quality of life scale: living with HIV. Holzemer WL, et al. **J Adv Nurs** 1998 Sep;28(3):622–30

Attitudes to HIV/AIDS [letter] Välimäki M, et al. **J Adv Nurs** 1999 Jun;29(6):1532–3

HIV/AIDS in migrant and seasonal farm workers. Aranda-Naranjo B, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):80–3

Improved gastrointestinal tolerance and palatability of didanosine in adults by the use of pediatric power formulation. Dodge RT, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):27–31

Grappling with global concerns in the search for an HIV vaccine. Grady C. **J Assoc Nurses AIDS Care** 1999 Jan–Feb;10(1):17–20

Sharing the dance toward the next century [editorial] Highsmith C. **J Assoc Nurses AIDS Care** 1999 Mar–Apr; 10(2):20–1

Revision of HIV center medical staging scale. McCain NL, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):19–23

Clinicians' antiretroviral medications guide. Martin JE, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):84–6

HIV/AIDS units: is there still a need? [editorial] Morrison C. **J Assoc Nurses AIDS Care** 1998 Nov–Dec;9(6):16–8

Management of occupational exposures to HIV: updated guidelines for postexposure prophylaxis. Centers of Disease Control and Prevention. Porche D, et al. **J Assoc Nurses AIDS Care** 1999 Jan–Feb;10(1):66–70

Reviewing the literature. Sharts-Hopko NC. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):87–9 (4 ref.)

Group sex in gay men: its meaning and HIV prevention implications [letter; comment] Simmons P. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):90–1. Comment on: J Assoc Nurses AIDS Care 1998 May–Jun;9(3):59–71.

Reflecting our past—looking toward our future [editorial] Sowell R. **J Assoc Nurses AIDS Care** 1999 Jan–Feb; 10(1):15–6

Practice what we preach? HIV knowledge, beliefs, and behaviors of adolescents and adolescent peer educators. Villarruel AM, et al. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):61–72

The impact of an HIV/AIDS training course for baccalaureate nursing students. Carney JS, et al. **J Nurs Educ** 1999 Jan;38(1):39–41

Current issues in the midwifery management of women living with HIV/AIDS. MacLaren A, et al. **J Nurse Midwifery** 1998 Nov–Dec;43(6):502–25 (156 ref.)

A program of acquired immune deficiency syndrome education for nurses in Romania. Simon C, et al. **J Pediatr Oncol Nurs** 1999 Apr;16(2):68–73

Home care: addressing the needs of people living with AIDS and their caregivers. Baker S. **Nurs Clin North Am** 1999 Mar;34(1):201–12 (43 ref.)

The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49–70 (90 ref.)

Evaluating alternative treatments for HIV infection. Freeman EM, et al. **Nurs Clin North Am** 1999 Mar;34(1):147–62 (69 ref.)

Primary care and case management of persons with HIV/AIDS. Kirton CA, et al. **Nurs Clin North Am** 1999 Mar;34(1):71–94 (27 ref.)

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213–25 (11 ref.)

Grief work of HIV positive persons and their survivors. Mallinson RK. **Nurs Clin North Am** 1999 Mar;34(1):163–77 (43 ref.)

Palliative care: pain and symptom management in persons with HIV/AIDS. Newshan G, et al. **Nurs Clin North Am** 1999 Mar;34(1):131–45 (62 ref.)

Moving beyond fear: lessons learned through a longitudinal

review of the literature regarding health care providers and the care of people with HIV/AIDS. Sherman DW, et al. **Nurs Clin North Am** 1999 Mar;34(1):1-48 (117 ref.)
The care of women with AIDS: special needs and considerations. Sowell RL, et al. **Nurs Clin North Am** 1999 Mar;34(1):179-99 (147 ref.)
Adherence to highly active antiretroviral therapy. Williams AB. **Nurs Clin North Am** 1999 Mar;34(1):113-29 (88 ref.)
Long-term nonprogressors with HIV disease. Barroso J. **Nurs Res** 1999 Sep-Oct;48(5):242-9
HIV and HCV [letter; comment] Geiger D. **Nurse Pract** 1999 Apr;24(4):16. Comment on: Nurse Pract 1998 Dec;23(12):78, 81.

PARASITOLOGY

Clinical analysis and parasite genetic diversity in human immunodeficiency virus/Chagas' disease coinfections in Brazil. Perez-Ramirez L, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):198-206
Enteric pathogens in southern Indian HIV-infected patients with & without diarrhoea. Mukhopadhya A, et al. **Indian J Med Res** 1999 Mar;109:85-9
Cryptosporidium and HIV. Agarwal A, et al. **J Indian Med Assoc** 1998 Sep;96(9):276-7
Opportunistic protozoa in stool samples from HIV-infected patients. Punpoowong B, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):31-4

PATHOLOGY

HIV-1 (p24)-positive multinucleated giant cells in HIV-associated lymphoepithelial lesion of the parotid gland. A report of two cases. Vicandi B, et al. **Acta Cytol** 1999 Mar-Apr;43(2):247-51
Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome [editorial] Wanke CA. **AIDS** 1999 Jul 30; 13(11):1287-93 (57 ref.)
Correlates of apoptosis of CD4+ and CD8+ T cells in tonsillar tissue in HIV type 1 infection. Røsok BI, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1635-43
Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Engelson ES, et al. **Am J Clin Nutr** 1999 Jun; 69(6):1162-9
Renal pathology and HIV infection in Thailand. Praditpornsilpa K, et al. **Am J Kidney Dis** 1999 Feb; 33(2):282-6
Thrombotic microangiopathy in the HIV-2-infected macaque. Eitner F, et al. **Am J Pathol** 1999 Aug; 155(2):649-61
Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Twigg HL, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1439-44
Similar proviral load but increased HIV-1 p24 in the intestinal mucosa compared to the peripheral blood in HIV-infected patients. Schmidt W, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:276-9
Human immunodeficiency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodeficiency syndrome dementia complex. Rostasy K, et al. **Ann Neurol** 1999 Aug;46(2):207-16
Neuropathology of human immunodeficiency virus 1 infection. Significance of studying in forensic autopsy cases at Dar es Salaam, Tanzania. Kibayashi K, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):519-23
The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency [editorial] Mathé G. **Biomed Pharmacother** 1998;52(10):413-20 (49 ref.)
The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Canque B, et al. **Blood** 1999 Jun 1;93(11):3866-75
Lymphomas and reactive lymphoid lesions in HIV infection. Bain BJ. **Blood Rev** 1998 Sep;12(3):154-62 (77 ref.)
Case of the month: May 1998--a patient with HIV infection and multiple cranial neuritis. Kenyon LC, et al. **Brain Pathol** 1998 Oct;8(4):815-6
HIV infection and the dynamic interplay between the thymus and the peripheral T cell pool [editorial; comment] Haynes BF. **Clin Immunol** 1999 Jul;92(1):3-5. Comment on: Clin Immunol 1999 Jul;92(1):25-33.
Fine needle aspiration (FNA) in HIV+ patients [comment] Buley ID. **Cytopathology** 1998 Aug;9(4):219-21 (3 ref.). Comment on: Cytopathology 1998 Aug;9(4):222-9. Comment on: Cytopathology 1998 Aug;9(4):230-9.
Fine needle aspiration (FNA) in HIV+ patients: results from a series of 655 aspirates [see comments] Ellison E, et al. **Cytopathology** 1998 Aug;9(4):222-9. Comment in: Cytopathology 1998 Aug;9(4):219-21.
Diagnostic utility of fine needle aspiration (FNA) cytology in HIV-infected patients with lymphadenopathy [see comments] Reid AJ, et al. **Cytopathology** 1998 Aug; 9(4):230-9. Comment in: Cytopathology 1998 Aug;9(4):219-21.
Relationship between erythema of the proximal nailfold in HIV-infected patients and hepatitis C virus infection. Courvoisier S, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):596-7
CD16+CD56+CD8+ natural killer (NK) cells are decreased during HIV infection. Lucia MB, et al. **Eur J Histochem** 1997;41 Suppl 2:197-8
Apoptotic features of peripheral blood granulocytes and monocytes during primary, acute HIV infection. Cossarizza A, et al. **Exp Cell Res** 1999 Feb 25;247(1):304-11
Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. Palefsky JM. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S42-8 (28 ref.)
Body shape changes in HIV-infected patients [letter] Lo JC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):307-8
Measurement of body composition in people with HIV/AIDS: a comparison of bioelectrical impedance and skinfold anthropometry with dual-energy x-ray absorptiometry. Batterham MJ, et al. **J Am Diet Assoc** 1999 Sep;99(9):1109-11
Potential risk of enhancing survival of infected cells [letter; comment] LeGrand EK. **J Am Vet Med Assoc** 1998 Dec 15;213(12):1698. Comment on: J Am Vet Med Assoc 1998 Oct 1;213(7):991-2.
The spectrum of mucocutaneous manifestations during the evolutionary phases of HIV disease: an emerging Indian scenario. Singh A, et al. **J Dermatol** 1999 May; 26(5):294-304
Findings and benefit of liver biopsies in 46 patients infected with human immunodeficiency virus. Piratvisuth T, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):146-9
Chronically HIV-1-infected monocytic cells induce apoptosis in cocultured T cells. Chen H, et al. **J Immunol** 1998 Oct 15;161(8):4257-67
Activation-associated necrosis in human immunodeficiency virus infection. Borthwick NJ, et al. **J Infect Dis** 1999 Feb; 179(2):352-60
HIV-1-induced neuronal injury in the developing brain. Epstein LG, et al. **J Leukoc Biol** 1999 Apr;65(4):453-7 (63 ref.)
The SIV-infected rhesus monkey model for HIV-associated dementia and implications for neurological diseases. Rausch DM, et al. **J Leukoc Biol** 1999 Apr;65(4):466-74 (74 ref.)
Telomere dynamics in monkeys: increased cell turnover in macaques infected with chimeric simian-human immunodeficiency viruses. Shibata R, et al. **J Med Primatol** 1999 Feb;28(1):1-10
Synovial non-Hodgkin's lymphoma in a human immunodeficiency virus infected patient. Peeva E, et al. **J Rheumatol** 1999 Mar;26(3):696-8
Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. Tyler DS, et al. **J Surg Res** 1998 Oct;79(2):115-20
Nailfold capillary microscopy in human immunodeficiency virus-infected patients: a case-control study. Aubin F, et al. **Microvasc Res** 1999 Sep;58(2):197-9
Chemokines, renal disease, and HIV infection. Wenzel UO, et al. **Nephron** 1999 Jan;81(1):5-16 (108 ref.)
Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Salvan AM, et al. **Pediatr Res** 1998 Nov;44(5):755-62
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Zhang ZQ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5169-72
Increased CD4+ T-lymphocyte senescence fraction in advanced human immunodeficiency virus type 1 infection. Nichols WS, et al. **Scand J Immunol** 1999 Mar;49(3):302-6
Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Constans J, et al. **Thromb Haemost** 1998 Dec;80(6):1015-7
The Warthin-Finkeldey-type giant cell in HIV infection, what is it? Orenstein JM. **Ultrastruct Pathol** 1998 Jul-Aug; 22(4):293-303

PHYSIOPATHOLOGY

Similar birthweight in children born to HIV-2 infected and HIV-negative women in Guinea-Bissau [letter] Norrgren H, et al. **Acta Paediatr** 1998 Jul;87(7):816-7
Is age a negative prognostic indicator in HIV infection or AIDS? Keller MJ, et al. **Aging (Milano)** 1999 Feb; 11(1):35-8
The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. Cozzi Lepri A, et al. **AIDS** 1998 Sep 10;12(13):1639-43
Impaired fertility in HIV-1-infected pregnant women: a clinic-based survey in Abidjan, Côte d'Ivoire, 1997. Desgrées du Loû A, et al. **AIDS** 1999 Mar 11;13(4):517-21
The estimated impact of the CCR-5 delta32 gene deletion on HIV disease progression varies with study design. Oslo HIV Cohort Study Group. Eskild A, et al. **AIDS** 1998 Dec 3;12(17):2271-4
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. Fahey JL, et al. **AIDS** 1998 Sep 10;12(13):1581-90
Taste and smell complaints in HIV-infected patients. Heald AE, et al. **AIDS** 1998 Sep 10;12(13):1667-74
Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. Kassa E, et al. **AIDS** 1999 Feb 25;13(3):381-9
Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study. Lyles RH, et al. **AIDS** 1999 Feb 25;13(3):341-9
Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland [letter] Nadal D, et al. **AIDS** 1998 Dec 3;12(17):2356-7
Involvement of hormonal circadian secretion in the growth of HIV-infected children. Rondanelli M, et al. **AIDS** 1998 Oct 1;12(14):1845-50
Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. Roubenoff R, et al. **AIDS** 1999 Feb 4;13(2):231-9
Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. Shikuma CM, et al. **AIDS** 1999 Jul 30;13(11):1359-65
A prospective study of HIV disease progression in female and male drug users. Webber MP, et al. **AIDS** 1999 Feb 4;13(2):257-62
Association between a defective CCR-5 gene and progression to disease in HIV infection. Balfe P, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1229-34
Unraveling the mechanisms of neurotoxicity in HIV type 1-associated dementia: inhibition of neuronal synaptic transmission by macrophage secretory products. Xiong H, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):57-63
Body composition in HIV-infected children: relations with disease progression and survival. Fontana M, et al. **Am J Clin Nutr** 1999 Jun;69(6):1282-6
Hypermetabolism and progression of HIV infection [letter] Garcia Luna PP, et al. **Am J Clin Nutr** 1999 Aug; 70(2):299-300; discussion 301
Relative influences of sex, race, environment, and HIV infection on body composition in adults. Kotler DP, et al. **Am J Clin Nutr** 1999 Mar;69(3):432-9
Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Bagasra O, et al. **Am J Hematol** 1998 Nov;59(3):199-207
Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Mattana J, et al. **Am J Med Sci** 1999 Apr;317(4):232-7
The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Diaz PT, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):272-7
Association between exercise and HIV disease progression in a cohort of homosexual men. Mustafa T, et al. **Ann Epidemiol** 1999 Feb;9(2):127-31
The mechanism of diarrhea in HIV is based on an impaired epithelial barrier function that could be induced by a specific cytokine pattern. Stockmann M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:267-70
HIV/SIV enteropathy. Zeitz M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:139-48 (48 ref.)
Microglia as mediators of inflammatory and degenerative diseases. González-Scarano F, et al. **Annu Rev Neurosci** 1999;22:219-40 (134 ref.)
Pre-AIDS physical disability: data from the AIDS Time-Oriented Health Outcome Study [see comments] O'Dell MW, et al. **Arch Phys Med Rehabil** 1998 Oct; 79(10):1200-5. Comment in: Arch Phys Med Rehabil 1999 Apr;80(4):473.
Role of cysteine and glutathione in signal transduction, immunopathology and cachexia. Dröge W, et al. **Biofactors** 1998;8(1-2):97-102 (23 ref.)
HIV infection of fetal human astrocytes: the potential role of a receptor-mediated endocytic pathway. Hao HN, et al. **Brain Res** 1999 Mar 27;823(1-2):24-32
Neuropathogenesis of HIV-1 infection. Outstanding questions. Vitkovic L, et al. **C R Acad Sci III** 1998 Dec; 321(12):1015-21 (37 ref.)
Postural reflexes in patients with HIV-1 infection. Beckley DJ, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 109(5):402-8
Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Lyles CM, et al. **Eur J Epidemiol** 1999 Feb;15(2):99-108
Kinetics of indium-111-labelled platelets in HIV-infected patients with and without associated thrombocytopaenia. Van Wyk V, et al. **Eur J Haematol** 1999 May;62(5):332-5
Unusual neurological manifestations of primary human immunodeficiency virus infection. Hassin-Baer S, et al. **Eur J Neurol** 1998 Jul;5(4):369-73
Anthropometric indicators of human immunodeficiency virus infection in infants with early and late symptoms in the first months of life. Agostoni C, et al. **Eur J Pediatr** 1998 Oct;157(10):811-3
Growth of children according to maternal and child HIV, immunological and disease characteristics: a prospective cohort study in Kinshasa, Democratic Republic of Congo. Bailey RC, et al. **Int J Epidemiol** 1999 Jun;28(3):532-40
Ritonavir combination therapy restores intestinal function in children with advanced HIV disease. Canani RB, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):307-12
Psychoactive drug use and progression of HIV infection. Des Jarlais DC. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):272-4 (9 ref.)
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. Hanson IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr

15;20(5):463-7

Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. Kemper CA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):367-72

Studies of body composition and fat distribution in HIV-infected and control subjects. Kotler DP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):228-37

A prospective study of tuberculosis and HIV disease progression. Munsiff SS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):361-6

Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. Haug CJ, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3832-8

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users [letter; comment] Bonacini M. **J Hepatol** 1999 Feb;30(2):347-8. Comment on: J Hepatol 1998 Jun;28(6):945-50.

Evolution of human immunodeficiency virus type 1 in relation to disease progression in children. Strunnikova N, et al. **J Hum Virol** 1998 Mar-Apr;1(3):224-39

Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. Emery VC, et al. **J Infect Dis** 1999 Sep;180(3):695-701

Decreased expression of zeta molecules by T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. Geertsma MF, et al. **J Infect Dis** 1999 Sep;180(3):649-58

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. Kaufmann GR, et al. **J Infect Dis** 1998 Dec;178(6):1812-5

Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. Keet IP, et al. **J Infect Dis** 1999 Aug;180(2):299-309

Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. Otten RA, et al. **J Infect Dis** 1999 Sep;180(3):673-84

Telomere dynamics in HIV-1 infected and uninfected chimpanzees measured by an improved method based on high-resolution two-dimensional calibration of DNA sizes. Feng YR, et al. **J Med Primatol** 1998 Oct;27(5):258-65

The fatigue experience for women with human immunodeficiency virus. Lee KA, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Mar-Apr; 28(2):193-200

Hemodialysis access: influence of the human immunodeficiency virus on patency and infection rates. Curi MA, et al. **J Vasc Surg** 1999 Apr;29(4):608-16

Function of the thymus in HIV-infected adults. Poulin JF, et al. **JAMA** 1999 Jul 21;282(3):219

Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Mummidi S, et al. **Nat Med** 1998 Jul; 4(7):786-93

Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats. Wang P, et al. **Neuroscience** 1999 Jan;88(2):585-97

Bioelectrical impedance analysis in human immunodeficiency virus-infected patients: comparison of single frequency with multifrequency, spectroscopy, and other novel approaches [see comments] Paton NI, et al. **Nutrition** 1998 Sep;14(9):658-66. Comment in: Nutrition 1998 Sep;14(9):707-8.

HIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus). Langley RJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14355-60

Progression to AIDS: the effects of stress, depressive symptoms, and social support. Leserman J, et al. **Psychosom Med** 1999 May-Jun;61(3):397-406

Exocrine pancreatic function and fat malabsorption in human immunodeficiency virus-infected patients. Carroccio A, et al. **Scand J Gastroenterol** 1999 Jul;34(7):729-34

Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Pernet P, et al. **Scand J Gastroenterol** 1999 Jan;34(1):29-34

[Anesthesia in the HIV positive or AIDS patient] Balabaud-Pichon V, et al. **Ann Fr Anesth Reanim** 1999 May;18(5):509-29 (114 ref.) (Eng. Abstr.) **(Fre)**

[Pathophysiology of HIV-1 infection of the nervous system and AIDS- related dementia] Seilhean D, et al. **Rev Neurol (Paris)** 1998 Dec;154(12):830-42 (201 ref.) **(Fre)**

[Some aspects of the pathogenesis of HIV infection] Eremin VF, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):933-9 (53 ref.) **(Rus)**

[Discriminative value for AIDS case of erythrocyte sedimentation rate, immunoglobulins IgA and IgM, and beta 2-microglobulin in combination with the CD4+ lymphocyte count] Pérez de Oteyza C, et al. **An Med Interna** 1998 Aug;15(8):411-4 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Croatian blood transfusion service in prevention of HIV spread during the war. Vuk T, et al. **Acta Med Croatica** 1998;52(4-5):221-2

Retesting of bone donors 2 months after donation guarantees sufficient safety of bone allografts. Hirn MY, et al. **Acta Orthop Scand** 1998 Dec;69(6):566-9

Zidovudine treatment prevents vertical transmission of human immunodeficiency virus-1 independently of viral load [letter] Alonso Arias R, et al. **Acta Paediatr** 1998 Nov; 87(11):1208-9

Strengthening STD/HIV/AIDS work in the framework of sexual-reproductive health/family planning projects. 29 January 1998, Heidelberg. Dehne KL. **Afr J Reprod Health** 1998 Apr;2(1):90-4

HIV/AIDS prevention-related social skills and knowledge among adolescents in Sierra Leone, West Africa. Lahai-Momoh JC, et al. **Afr J Reprod Health** 1997 Mar; 1(1):37-44

The condom conundrum: barriers to condom use among commercial sex workers in Durban, South Africa. Varga CA. **Afr J Reprod Health** 1997 Mar;1(1):74-88

AIDS vaccine research in Asia: needs and opportunities. Report from a UNAIDS/WHO/NIID meeting Tokyo, 28-30 October 1998. **AIDS** 1999 Jul 30;13(11):UNAIDS 1-UNAIDS 13

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. Bartlett JA, et al. **AIDS** 1998 Jul 30; 12(11):1291-300

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. Belshe RB, et al. **AIDS** 1998 Dec 24; 12(18):2407-15

HIV testing and counseling among men attending sexually transmitted disease clinics in Pune, India: changes in condom use and sexual behavior over time. Bentley ME, et al. **AIDS** 1998 Oct 1;12(14):1869-77

Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases. Chamot E, et al. **AIDS** 1999 May 28; 13(8):971-9

Partner notification in newly diagnosed HIV-positive patients [letter; comment] Elliott SA, et al. **AIDS** 1998 Aug 20;12(12):1559-60. Comment on: AIDS 1998 Jan 1;12(1):95-102.

Is HIV/STD control in Jamaica making a difference? Figueroa JP, et al. **AIDS** 1998;12 Suppl 2:S89-98

Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. Fontanet AL, et al. **AIDS** 1998 Oct 1;12(14):1851-9

Acute porphyria following commencement of indinavir [letter] Fox PA, et al. **AIDS** 1999 Apr 1;13(5):622-3

The message not heard: myth and reality in discussions about syringe exchange [letter] Friedman SR, et al. **AIDS** 1999 Apr 16;13(6):738-9

Field experiences: measuring capacity building efforts in HIV/AIDS prevention programmes. Kotellos KA, et al. **AIDS** 1998;12 Suppl 2:S109-17

Social marketing sexually transmitted disease and HIV prevention: a consumer-centered approach to achieving behaviour change. Lamptey PR, et al. **AIDS** 1998;12 Suppl 2:S1-9

Decline in sexually transmitted disease prevalence in female Bolivian sex workers: impact of an HIV prevention project. Levine WC, et al. **AIDS** 1998 Oct 1;12(14):1899-906

Beyond the dichotomy: linking HIV prevention with care. MacNeil JM, et al. **AIDS** 1998;12 Suppl 2:S19-26

Applying social, behavioral and evaluation research to developing country HIV prevention programs. MacNeil JM, et al. **AIDS** 1998;12 Suppl 2:S99-108

Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility [editorial] Marks G, et al. **AIDS** 1999 Feb 25;13(3):297-306 (119 ref.)

Low and stable HIV infection rates in Senegal: natural course of the epidemic or evidence for success of prevention? Meda N, et al. **AIDS** 1999 Jul 30;13(11):1397-405

Public attitudes towards needle exchange programs [letter] Quinn SC. **AIDS** 1999 Jul 30;13(11):1428-9

Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. Ratcliffe J, et al. **AIDS** 1998 Jul 30;12(11):1381-8

AVERT: a user-friendly model to estimate the impact of HIV/sexually transmitted disease prevention interventions on HIV transmission. Rehle TM, et al. **AIDS** 1998;12 Suppl 2:S27-35

Sexual behaviours, perception of risk of HIV infection, and factors associated with attending HIV post-test counselling in Ethiopia. Sahlu T, et al. **AIDS** 1999 Jul 9;13(10):1263-72

Use of highly sensitive assays for the evaluation of post-exposure HIV prophylaxis [letter] Schockmel GA, et al. **AIDS** 1998 Sep 10;12(13):1726-7

Increased protected sex and abstinence among Namibian youth following a HIV risk-reduction intervention: a randomized, longitudinal study. Stanton BF, et al. **AIDS** 1998 Dec 24;12(18):2473-80

Sexual transmission of HIV: infectiousness and prevention. Vernazza PL, et al. **AIDS** 1999 Feb 4;13(2):155-66 (150 ref.)

Lack of protection against HIV-1 infection among women with HIV-2 infection. Wiktor SZ, et al. **AIDS** 1999 Apr 16;13(6):695-9

Transgender HIV prevention: a qualitative needs assessment. Bockting WO, et al. **AIDS Care** 1998 Aug;10(4):505-25

HIV testing for HIV prevention: a comparative analysis of policies in Britain, Hungary and Sweden. Danziger R. **AIDS Care** 1998 Oct;10(5):563-70

Self-management health education for chronic HIV infection. Gifford AL, et al. **AIDS Care** 1999 Feb; 11(1):115-30

Health service utilization in London's African migrant communities: implications for HIV prevention. McMunn AM, et al. **AIDS Care** 1998 Aug;10(4):453-62

Community pharmacist perspectives on HIV/AIDS and interventions for injection drug users in Canada. Myers T, et al. **AIDS Care** 1998 Dec;10(6):689-700

Factors associated with changes in sex behaviour among drug users in Puerto Rico. Robles RR, et al. **AIDS Care** 1998 Jun;10(3):329-38

HIV infection among foreign people involved in HIV-related risk activities and attending an HIV reference centre in Rome: the possible role of counselling in reducing risk behaviour. Spizzichino L, et al. **AIDS Care** 1998 Aug; 10(4):473-80

HIV/AIDS risks among Native American drug users: key findings from focus group interviews and implications for intervention strategies. Baldwin JA, et al. **AIDS Educ Prev** 1999 Aug;11(4):279-92

HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences. Broome KM, et al. **AIDS Educ Prev** 1999 Aug;11(4):293-306

Condom use as a dependent variable: measurement issues relevant to HIV prevention programs. Crosby RA. **AIDS Educ Prev** 1998 Dec;10(6):548-57 (52 ref.)

Factors influencing attitudes within AIDS service organizations toward the use of research-based HIV prevention interventions. DiFranceisco W, et al. **AIDS Educ Prev** 1999 Feb;11(1):72-86

This is my story: a descriptive analysis of a peer education HIV/STD risk reduction program for women living in housing developments. Downing M, et al. **AIDS Educ Prev** 1999 Jun;11(3):243-61

Physicians' transmission prevention assessment and counseling practices with their HIV positive patients. Gerbert B, et al. **AIDS Educ Prev** 1999 Aug;11(4):307-20

Barriers to social services for HIV-infected urban migrators. Montoya ID, et al. **AIDS Educ Prev** 1998 Aug;10(4):366-79

Effects of an HIV risk reduction project on sexual risk behavior of low-income STD patients. O'Leary A, et al. **AIDS Educ Prev** 1998 Dec;10(6):483-92

"Lifepoint": a case study in using social science community identification data to guide the implementation of a needle exchange program. Somlai AM, et al. **AIDS Educ Prev** 1999 Jun;11(3):187-202

Participatory action research for sustaining individual and community change: a model of HIV prevention education. Stevens PE, et al. **AIDS Educ Prev** 1998 Oct;10(5):387-402

The Women and Infants Demonstration Project: an integrated approach to AIDS prevention and research. Terry MA, et al. **AIDS Educ Prev** 1999 Apr;11(2):107-21

An evaluation of the use of drama to communicate HIV/AIDS information. Valente TW, et al. **AIDS Educ Prev** 1999 Jun;11(3):203-11

Knowledge of HIV/AIDS among health care workers in China. Wu Z, et al. **AIDS Educ Prev** 1999 Aug;11(4):353-63

Prime-boost immunization strategies against HIV. Barnett SW, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S299-309 (106 ref.)

HIV vaccine development for the world: an idea whose time has come? Berkley S. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S191-6 (18 ref.)

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. Berman PW. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S277-89 (78 ref.)

Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. Foresman L, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10; 14(12):1035-43

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. Francis DP, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S325-31 (14 ref.)

Preventive HIV type 1 vaccine clinical trials: a regulatory perspective. Goldenthal KL, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S333-40 (58 ref.)

Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. Joag SV, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):391-4

Active and passive immunization against HIV type 1 infection in chimpanzees. Murthy KK, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S271-6 (36 ref.)

Candidate vaccines protect macaques against primate

immunodeficiency viruses. Stott J, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S265–70 (54 ref.)

Replication-defective HIV as a vaccine candidate. Tung FY, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1247–52

Rationale for the testing and use of a partially effective HIV vaccine. Vermund SH. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S321–3 (23 ref.)

The need for microbicides: why aren't women's groups more involved in the fight against AIDS? Wainberg MA. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):405–6

The role of government in controlling the HIV epidemic [letter] Gordon N. **Am Fam Physician** 1999 Jun;59(11):2983

U.S. Public Health Service updates guidelines for HIV prophylaxis in health care workers. Morey SS. **Am Fam Physician** 1998 Dec;58(9):2165–8

HIV patients receiving HAART therapy can still transmit the virus. Highly active antiretroviral chemotherapy. Pomerantz RJ. **Am Fam Physician** 1999 May 15;59(10):2855

An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors. Zule WA, et al. **Am J Drug Alcohol Abuse** 1999 Feb;25(1):1–23

Triple therapy prevents HIV but not HCV transmission after needlestick injury [letter] Fabris P, et al. **Am J Gastroenterol** 1999 Jul;94(7):1990–1

Syringe sales by pharmacies reviewed as HIV-prevention strategy [news] **Am J Health Syst Pharm** 1999 Jan 1; 56(1):16

Report updates recommendations for health workers exposed to HIV [news] **Am J Health Syst Pharm** 1998 Sep 1; 55(17):1755

Prophylaxis after nonoccupational exposure to HIV. Dong BJ. **Am J Health Syst Pharm** 1999 May 15;56(10):1011–5; quiz 1016 (35 ref.)

Protocol for initial evaluation of occupational exposure to HIV and initiation of antiretroviral prophylaxis. Shinohara YT, et al. **Am J Health Syst Pharm** 1998 Sep 15; 55(18):1921–4

Human Immunodeficiency Virus Postexposure Management of Healthcare Workers. Symposium proceedings. Atlanta, Georgia, USA. March 4–5, 1996. **Am J Med** 1997 May 19;102(5B):1–126

Emergency medical services. Arndt SD. **Am J Med** 1997 May 19;102(5B):104–5 (09 ref.)

Efficacy of zidovudine in preventing HIV transmission from mother to infant. Balsley J. **Am J Med** 1997 May 19; 102(5B):45–6

Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. Bamberger JD, et al. **Am J Med** 1999 Mar;106(3):323–6 (22 ref.)

Legal and ethical issues in revising human immunodeficiency virus postexposure protocols. Barnes M. **Am J Med** 1997 May 19;102(5B):111–2; discussion 113–4 (05 ref.)

Zidovudine safety and tolerance among uninfected healthcare workers: a brief update. Beekmann SE, et al. **Am J Med** 1997 May 19;102(5B):63–4

Human immunodeficiency virus postexposure management of healthcare workers: report of a workshop. Bell DM, et al. **Am J Med** 1997 May 19;102(5B):1–3

Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)

Perspectives of healthcare workers. Cohen J, et al. **Am J Med** 1997 May 19;102(5B):102–3

Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)

Principles of clinical pharmacology in postexposure prophylaxis. Flexner CW. **Am J Med** 1997 May 19; 102(5B):32–8 (32 ref.)

Editorial note in March 1997: combination chemotherapy [editorial] Gerberding JL, et al. **Am J Med** 1997 May 19; 102(5B):83–4

Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Gerberding JL. **Am J Med** 1997 May 19;102(5B):85–9 (07 ref.)

Postexposure chemoprophylaxis against HIV: what are the implications for people with AIDS and the organizations that serve them? Hodel D. **Am J Med** 1997 May 19; 102(5B):106–10 (10 ref.)

Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis. Ippolito G, et al. **Am J Med** 1997 May 19;102(5B):58–62

Failures of zidovudine postexposure prophylaxis. Jochimsen EM. **Am J Med** 1997 May 19;102(5B):52–5; discussion 56–7 (20 ref.)

Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis. Khurana V, et al. **Am J Med** 1999 Jan;106(1):118–9

Issues complicating the implementation of postexposure prophylaxis. L'Ecuyer PB, et al. **Am J Med** 1997 May 19; 102(5B):90–4 (50 ref.)

Candidate antiretroviral agents for use in postexposure prophylaxis. Saag MS. **Am J Med** 1997 May 19; 102(5B):25–31 (38 ref.)

Toxicity of antiretroviral agents. Struble KA, et al. **Am J Med** 1997 May 19;102(5B):65–7; discussion 68–9 (00 ref.)

The use of human immunodeficiency virus postexposure prophylaxis after successful artificial insemination. Bloch M, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):760–1

Bloodless cesarean delivery and perinatal transmission of the human immunodeficiency virus [letter; comment] Ghidini A, et al. **Am J Obstet Gynecol** 1999 May;180(5):1308–9. Comment on: Am J Obstet Gynecol 1998 Sep;179(3 Pt 1):708–14.

A brief HIV intervention for adolescents and young adults. Rotheram-Borus MJ, et al. **Am J Orthopsychiatry** 1998 Oct;68(4):553–64

Tympano-ossicular allografts and HIV transmission. Janssens de Varebeke S, et al. **Am J Otol** 1998 Nov;19(6):704–8

Development and testing of an HIV-risk screening instrument for use in health care settings. Gerbert B, et al. **Am J Prev Med** 1998 Aug;15(2):103–13

Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Kalichman SC. **Am J Prev Med** 1998 Aug; 15(2):120–7

Comparison of simulated patient and didactic methods of teaching HIV risk assessment to medical residents. Madan AK, et al. **Am J Prev Med** 1998 Aug;15(2):114–9

Community-level HIV intervention in 5 cities: final outcome data from the CDC AIDS Community Demonstration Projects [see comments] **Am J Public Health** 1999 Mar; 89(3):336–45. Comment in: Am J Public Health 1999 Mar;89(3):299–301.

The protective effect of condoms and nonoxynol-9 against HIV infection: a response to Wittkowski and colleagues [letter; comment] Feldblum PJ, et al. **Am J Public Health** 1999 Jan;89(1):108–10. Comment on: Am J Public Health 1998 Apr;88(4):590–6.

Human rights is a US problem, too: the case of women and HIV [comment] Gollub EL. **Am J Public Health** 1999 Oct; 89(10):1479–82. Comment on: Am J Public Health 1999 Oct;89(10):1514–21.

Community-level interventions are needed to prevent new HIV infections [editorial; comment] Kelly JA. **Am J Public Health** 1999 Mar;89(3):299–301 (20 ref.). Comment on: Am J Public Health 1999 Mar;89(3):336–45.

Zidovudine and reduction of vertical transmission of HIV in Africa. ANRS 049 Trial Group [letter] Msellati P, et al. **Am J Public Health** 1999 Jun;89(6):947–8

Fertility implications of reduced breast-feeding by HIV/AIDS-Infected mothers in developing countries [letter] Stecklov G. **Am J Public Health** 1999 May; 89(5):780–1, 784–5

Prevention of sexually transmitted diseases: the need for social and behavioral science expertise in public health departments [editorial; comment] Van Devanter N. **Am J Public Health** 1999 Jun;89(6):815–8 (38 ref.). Comment on: Am J Public Health 1999 Jun;89(6):899–902.

Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997. Weinhardt LS, et al. **Am J Public Health** 1999 Sep; 89(9):1397–405

Mandatory HIV testing of infants and rates of follow-up care [letter] Wilson TE, et al. **Am J Public Health** 1999 Oct;89(10):1583

Name-based reporting of HIV infection [letter] Wortley PM, et al. **Am J Public Health** 1999 Aug;89(8):1271–3

Provider-to-patient HIV transmission: how to keep it exceedingly rare [editorial; comment] Gerberding J. **Ann Intern Med** 1999 Jan 5;130(1):64–5. Comment on: Ann Intern Med 1999 Jan 5;130(1):1–6.

Antiinfectives update: focus on treatment and prevention of viral and associated infections. McNicholl IR, et al. **Ann Pharmacother** 1999 May;33(5):607–14 (67 ref.)

Understanding women's risk of HIV infection in Thailand through critical hermeneutics. Ruangjiratain S, et al. **ANS Adv Nurs Sci** 1998 Dec;21(2):42–51 (28 ref.)

Clinical progress and the future of HIV exceptionalism. Bayer R. **Arch Intern Med** 1999 May 24;159(10):1042–8 (45 ref.)

Early effects of a school-based human immunodeficiency virus infection and sexual risk prevention intervention. Siegel DM, et al. **Arch Pediatr Adolesc Med** 1998 Oct; 152(10):961–70

A survey of potential risk factors for HIV transmission through dental practice in Japan. Aizawa F, et al. **Asia Pac J Public Health** 1998;10(1):21–8

A bleach program for inmates in NSW: an HIV prevention strategy. Dolan KA, et al. **Aust N Z J Public Health** 1998 Dec;22(7):838–40

Sterilization of HIV with irradiation: relevance to infected bone allografts. Campbell DG, et al. **Aust N Z J Surg** 1999 Jul;69(7):517–21

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Le Buanec H, et al. **Biomed Pharmacother** 1998;52(10):431–5

Vaginal viricides-another way to tackle HIV transmission. Berger A. **BMJ** 1998 Oct 17;317(7165):1053

Surgeons' and occupational health departments' awareness of guidelines on post-exposure prophylaxis for staff exposed to HIV: telephone survey. Duff SE, et al. **BMJ** 1999 Jul 17;319(7203):162–3

Medical student electives and infectious diseases. Risk of hepatitis C is greater than HIV [letter] Green ST. **BMJ** 1999 Apr 24;318(7191):1146

Post-exposure prophylaxis against HIV infection is hard to supply for expatriate staff [letter; comment] Logie A. **BMJ** 1998 Oct 17;317(7165):1084. Comment on: BMJ 1998 Apr 11;316(7138):1158–60.

Medical student electives and infectious diseases. Zidovudine alone is not recommended prophylaxis [letter] Meadway J. **BMJ** 1999 Apr 24;318(7191):1145–6

Provision of health advice for UK medical students planning to travel overseas for their elective study period: questionnaire survey [see comments] Moss PJ, et al. **BMJ** 1999 Jan 16;318(7177):161–2. Comment in: BMJ 1999 Jan 16;318(7177):139–40.

Doctor in india arrested over irregularities trial of vaccine [news] Mudur G. **BMJ** 1999 May 15;318(7194):1308A

Universal HIV screening of pregnant women in England: cost effectiveness analysis. Postma MJ, et al. **BMJ** 1999 Jun 19;318(7199):1656–60

Can social cognitive models contribute to the effectiveness of HIV-preventive behavioural interventions? A brief review of the literature and a reply to Joffe (1996; 1997) and Fife-Schaw (1997) [comment] Abraham C, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):297–310 (73 ref.). Comment on: Br J Med Psychol 1996 Sep;69 (Pt 3):169–90. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):65–73. Comment on: Br J Med Psychol 1997 Mar;70 (Pt 1):75–83.

The world of HIV and disease, and some new approaches to block it. Gallo R. **Bull Mem Acad R Med Belg** 1998; 153(7–9):339–42

Research on needle exchange: redefining the agenda. Hantman JA. **Bull N Y Acad Med** 1995 Winter; 72(2):397–412

When science and politics collide: the federal response to needle-exchange programs. Lurie P. **Bull N Y Acad Med** 1995 Winter;72(2):380–96

Treatment for common STDs may not always reduce the spread of HIV [news] **Bull World Health Organ** 1999; 77(4):361

Shorter short-course treatment protects some infants from HIV [news] **Bull World Health Organ** 1999;77(4):362

Two cultures, two levels of AIDS risk. Wang MS, et al. **Bull World Health Organ** 1999;77(3):278–80

Chemoprophylaxis after definite occupational exposure to human immunodeficiency virus (HIV). **Can Fam Physician** 1998 Nov;44:2388, 2401–3 **(Eng, Fre)**

Each of the following statements about human immunodeficiency virus (HIV) in pregnancy is true. **Can Fam Physician** 1999 Aug;45:1872, 1880 **(Eng, Fre)**

Needle-stick injuries and HIV infection [editorial] Hurwitz JJ. **Can J Ophthalmol** 1999 Jun;34(4):189–90 **(Eng, Fre)**

Needle-stick injuries and HIV infection: a surgeon's personal experience and review of postexposure prophylaxis. St. Paul's Ocular AIDS Group. Hurwitz JJ, et al. **Can J Ophthalmol** 1999 Jun;34(4):195–203

Cost effectiveness of Streetworks' needle exchange program of Edmonton. Jacobs P, et al. **Can J Public Health** 1999 May-Jun;90(3):168–71

Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe. Machekano R, et al. **Cent Afr J Med** 1998 Apr;44(4):98–102

Abstinence and safer sex HIV risk-reduction interventions for African-American adolescents. Braverman PK. **Clin Pediatr (Phila)** 1999 Mar;38(3):184–7 (0 ref.)

New expanded guidelines for preventing HIV [news] **CMAJ** 1999 Jul 27;161(2):122

Routine prenatal screening for HIV in a low-prevalence setting [see comments] Patrick DM, et al. **CMAJ** 1998 Oct 20;159(8):942–7. Comment in: CMAJ 1999 May 4;160(9):1286–7.

Krever 2008 [editorial] [see comments] Schechter MT, et al. **CMAJ** 1999 Apr 20;160(8):1179–80. Comment in: CMAJ 1999 Aug 24;161(4):366–7.

Are HIV lookbacks worthwhile? Outcome of an exercise to notify patients treated by an HIV infected health care worker. Incident Management Teams [see comments] Donnelly M, et al. **Commun Dis Public Health** 1999 Jun; 2(2):126–9. Comment in: Commun Dis Public Health 1999 Jun;2(2):79–81.

The global impact of HIV infection and disease. Nicoll A, et al. **Commun Dis Public Health** 1999 Jun;2(2):85–95 (54 ref.)

Lookback in angst [editorial; comment] Weller I. **Commun Dis Public Health** 1999 Jun;2(2):79–81. Comment on: Commun Dis Public Health 1999 Jun;2(2):126–9. Comment on: Commun Dis Public Health 1999 Jun;2(2):130–6. Comment on: Commun Dis Public Health 1999 Jun;2(2):137–40.

Revised guidance to reduce risks to patients from health care workers exposed to HIV infection. **Commun Dis Rep CDR Wkly** 1999 Jan 1;9(1):1, 4

Preparing for HIV vaccines that induce cytotoxic T lymphocytes [editorial] McMichael A. **Curr Opin Immunol** 1998 Aug;10(4):379–81

Methadone treatment in Spain, 1994. Domingo-Salvany A, et al. **Drug Alcohol Depend** 1999 Aug 2;56(1):61–6

Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine. Desai KN, et al. **Epidemiol Infect** 1999 Aug;123(1):65–88

Temporal trends in reasons for and result of HIV-testing among women in Rome, Italy. Puro V, et al. **Eur J Epidemiol** 1998 Jul;14(5):433–7

The balance of positive and negative effects of specific messages in the evaluation of interventions for preventing HIV infection. Spadea T, et al. **Eur J Epidemiol** 1999 Feb; 15(2):109–17

HIV postexposure prophylaxis. German-Austrian recommendations. Deutsche AIDS-Gesellschaft (DAIG) and Osterreichische AIDS- Gesellschaft (OAG). Brodt H. **Eur J Med Res** 1998 Oct 14;3(10):485-500

Protection against HIV infection for medical trainees outside the United States. Markle WH. **Fam Med** 1999 Jul-Aug; 31(7):495-500

Condom use and HIV risk behaviors among U.S. adults: data from a national survey. Anderson JE, et al. **Fam Plann Perspect** 1999 Jan-Feb;31(1):24-8

Dual-method use among an ethnically diverse group of women at risk of HIV infection. Riehman KS, et al. **Fam Plann Perspect** 1998 Sep-Oct;30(5):212-7

Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Bai X, et al. **Gene Ther** 1998 Jul;5(7):984-94

Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins. Fraisier C, et al. **Gene Ther** 1998 Jul;5(7):946-54

Sex in the New World: an empowerment model for HIV prevention in Latina immigrant women. Gómez CA, et al. **Health Educ Behav** 1999 Apr;26(2):200-12

Collaborative research to prevent HIV among male prison inmates and their female partners. Grinstead OA, et al. **Health Educ Behav** 1999 Apr;26(2):225-38

"Out-of-the-mainstream" youth as partners in collaborative research: exploring the benefits and challenges. Harper GW, et al. **Health Educ Behav** 1999 Apr;26(2):250-65

The collaboration process in HIV prevention and evaluation in an urban American Indian clinic for women. Klein D, et al. **Health Educ Behav** 1999 Apr;26(2):239-49

Targeting "risky" gender ideologies: constructing a community-driven, theory-based HIV prevention intervention for youth. Laub C, et al. **Health Educ Behav** 1999 Apr;26(2):185-99

Collaborative community research consortium: a model for HIV prevention. Sanstad KH, et al. **Health Educ Behav** 1999 Apr;26(2):171-84

Organizing community research partnerships in the struggle against AIDS. Schensul JJ. **Health Educ Behav** 1999 Apr; 26(2):266-83 (47 ref.)

A collaborative evaluation of a needle exchange program for youth. Weiker RL, et al. **Health Educ Behav** 1999 Apr; 26(2):213-24

Risk for HIV infection among bisexual men seeking HIV-prevention services and risks posed to their female partners. Kalichman SC, et al. **Health Psychol** 1998 Jul; 17(4):320-7

Reinforcement value of unsafe sex as a predictor of condom use and continued HIV/AIDS risk behavior among gay and bisexual men. Kelly JA, et al. **Health Psychol** 1998 Jul;17(4):328-35

Linking injection drug users to medical services: role of street outreach referrals. Greenberg JB, et al. **Health Soc Work** 1998 Nov;23(4):298-309

HIV prevention case management: current practice and future directions. Purcell DW, et al. **Health Soc Work** 1998 Nov;23(4):282-9

Empowerment evaluation as a social work strategy. Secret M, et al. **Health Soc Work** 1999 May;24(2):120-7

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Poignard P, et al. **Immunity** 1999 Apr;10(4):431-8

Proceedings of the 2nd International Summit Meeting on Immunological Correlates of Protection from HIV Infection and Disease. Oxford, United Kingdom, 17-20 April 1998. **Immunol Lett** 1999 Mar;66(1-3):1-228

HIV-1 DNA vaccines. Fomsgaard A. **Immunol Lett** 1999 Jan;65(1-2):127-31 (36 ref.)

Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. D'Amico R, et al. **Infect Control Hosp Epidemiol** 1999 Jun; 20(6):428-30

HIV vaccines. Frey SE. **Infect Dis Clin North Am** 1999 Mar; 13(1):95-112 (162 ref.)

Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Brenner BG, et al. **Infect Dis Obstet Gynecol** 1999;7(1-2):80-90 (82 ref.)

Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. Witter FR, et al. **Int J Gynaecol Obstet** 1999 May;65(2):165-70

Vertical transmission of human immunodeficiency virus type 1: frequency and correlation of transmission (review). Li Q, et al. **Int J Mol Med** 1998 Mar;1(3):589-91 (29 ref.)

Reduction of mother-to-child transmission of HIV infection: non-pharmaceutical interventions and their implementation. Gibb DM. **Int J STD AIDS** 1998;9 Suppl 1:19-21

Brief behavioural skills building intervention for female controlled methods of STD-HIV prevention: outcomes of a randomized clinical field trial. Kalichman SC, et al. **Int J STD AIDS** 1999 Mar;10(3):174-81

HIV prevention and the positive population. King-Spooner S. **Int J STD AIDS** 1999 Mar;10(3):141-50 (92 ref.)

Circumcision and HIV infection: review of the literature and meta-analysis. Van Howe RS. **Int J STD AIDS** 1999 Jan; 10(1):8-16 (79 ref.)

Bringing the World together to fight HIV/AIDS. **Int Nurs Rev** 1998 Nov-Dec;45(6):169-72

Nurses intensify worldwide efforts to ensure HIV/AIDS care for all [news] **Int Nurs Rev** 1998 Jul-Aug;45(4):104

HIV/AIDS: a South African perspective. Nzimande PN. **Int Nurs Rev** 1998 Nov-Dec;45(6):162

Nurses are the key to effective HIV/AIDS prevention and care. Stallknecht K. **Int Nurs Rev** 1998 Nov-Dec; 45(6):173-4

Seroprevalence of HIV among female sex workers in Bangkok: evidence of ongoing infection risk after the "100% condom program" was implemented. Kilmarx PH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):313-6

Adequacy of prenatal care and prescription of zidovudine to prevent perinatal HIV transmission. Lansky A, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):223-7

Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program [letter] Naef MR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):349-51

Obstacles to needle exchange participation in Rhode Island. Rich JD, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):396-400

Prevention of mother-to-child transmission of HIV in Thailand: physicians' attitudes on zidovudine use, pregnancy termination, and willingness to provide care. Stringer JS, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):217-22

Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. Hays RB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):164-71

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand. Markowitz LE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):488-94

Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. Scheer S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):172-8

Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. Thapinta D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):308-14

Drug abuse treatment as HIV prevention: changes in social drug use patterns might also reduce risk. Iguchi MY. **J Addict Dis** 1998;17(4):9-18

The effects of partner insistence of condom usage on perceptions of the partner, the relationship, and the experience. Hocking JE, et al. **J Adolesc** 1999 Jun; 22(3):355-67

Determinants of condom use to prevent HIV infection among youth in Ghana. Adih WK, et al. **J Adolesc Health** 1999 Jan;24(1):63-72

Use of Western-based HIV risk-reduction interventions targeting adolescents in an African setting. Fitzgerald AM, et al. **J Adolesc Health** 1999 Jul;25(1):52-61

HIV prevention in street youth. Walters AS. **J Adolesc Health** 1999 Sep;25(3):187-98 (67 ref.)

Preventing the high-risk sexual behavior of adolescents: focus on HIV/AIDS transmission, unintended pregnancy, or both? Whaley AL. **J Adolesc Health** 1999 Jun; 24(6):376-82 (49 ref.)

Reducing HIV/AIDS for nursing personnel [news] **J Adv Nurs** 1999 Feb;29(2):277

Are you protecting yourself? [news] **J Adv Nurs** 1999 Feb; 29(2):281

Mildmay AIDS Centre, Uganda [news] **J Adv Nurs** 1999 Jan;29(1):4

Attitudes of university students towards HIV/AIDS. Serlo KL, et al. **J Adv Nurs** 1999 Feb;29(2):463-70

Reproductive health needs: comparing women at high, drug-related risk of HIV with a national sample. Armstrong KA, et al. **J Am Med Womens Assoc** 1999 Spring;54(2):65-70, 78

Prevention of perinatal transmission of HIV in Arkansas. Darville T, et al. **J Ark Med Soc** 1998 Nov;95(6):239-41

Viral screening and assisted conception treatment--the Bourn Hall experience. Abusheikha N, et al. **J Assist Reprod Genet** 1999 Jul;16(6):337-9

Grappling with global concerns in the search for an HIV vaccine. Grady C. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):17-20

Women and the prevention of HIV infection: an integrative review of the literature. Mallory C, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):51-63 (56 ref.)

Updated estimates of condom effectiveness. Pinkerton SD, et al. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):88-9

Bridging the gap: 12th World AIDS conference update. Porche D, et al. **J Assoc Nurses AIDS Care** 1998 Nov-Dec; 9(6):82-5

Management of occupational exposures to HIV: updated guidelines for postexposure prophylaxis. Centers of Disease Control and Prevention. Porche D, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):66-70

HIV/AIDS risk in the college population: modifying the culture in a private religious university. Sharts-Hopko NC, et al. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):72-9

Group sex in gay men: its meaning and HIV prevention implications [letter; comment] Simmons P. **J Assoc Nurses AIDS Care** 1998 Sep-Oct;9(5):90-1. Comment on: J Assoc Nurses AIDS Care 1998 May-Jun;9(3):59-71.

HIV, pregnancy, and zidovudine: what do women know? Vitiello MA, et al. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):41-7

The 1998 Lindberg Award. Comparison of glycerol preservation with cryopreservation methods on HIV-1 inactivation. van Baare J, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):494-500

When the unthinkable happens: post-exposure prophylaxis of HIV-contaminated percutaneous injuries. Petty TL. **J Can Dent Assoc** 1999 May;65(5):293-4

Chemokine receptors and chemokines in HIV infection [published erratum appears in J Clin Immunol 1998 Nov;18(6):441] Garzino-Demo A, et al. **J Clin Immunol** 1998 Jul;18(4):243-55 (159 ref.)

AIDS vaccine development: let a thousand flowers bloom. Oxford JS, et al. **J Clin Pathol** 1998 Oct;51(10):725-30 (37 ref.)

Linking clients from HIV antibody counseling and testing to prevention services. Marx R, et al. **J Community Health** 1999 Jun;24(3):201-14

Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. Thompson AS, et al. **J Community Health** 1998 Dec;23(6):419-40

Exposure to a community-level HIV prevention intervention: who gets the message. Walls CT, et al. **J Community Health** 1998 Aug;23(4):281-99

HIV infection in U.S. correctional systems: its effect on the community. Leh SK. **J Community Health Nurs** 1999; 16(1):53-63 (18 ref.)

A randomized trial of a brief HIV risk reduction counseling intervention for women. Belcher L, et al. **J Consult Clin Psychol** 1998 Oct;66(5):856-61

Psychosocial factors associated with the stages of change for condom use among women at risk for HIV and STDs: implications for intervention development. Stark MJ, et al. **J Consult Clin Psychol** 1998 Dec;66(6):967-78

Increasing assertiveness skills to reduce HIV risk among women living with a severe and persistent mental illness. Weinhardt LS, et al. **J Consult Clin Psychol** 1998 Aug; 66(4):680-4

Emergency department management of occupational exposures to HIV-infected fluids. Torbati SS, et al. **J Emerg Med** 1999 Mar-Apr;17(2):261-4

Association between condom use and HIV infection: a randomised study of self reported condom use measures. Weir SS, et al. **J Epidemiol Community Health** 1999 Jul; 53(7):417-22

Elective cesarean delivery to prevent vertical transmission of HIV. DuBard CA, et al. **J Fam Pract** 1999 Jul; 48(7):493-4

Cost of preventing HIV infection after sexual exposure. Lindbloom EJ, et al. **J Fam Pract** 1998 Oct;47(4):251-2

Integrating Buddhism and HIV prevention in U.S. southeast Asian communities. Loue S, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):100-21 (107 ref.)

An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. D'Aunno T, et al. **J Health Soc Behav** 1999 Jun;40(2):175-92

HIV vaccines and prevention in a world without Mary Lou Clements-Mann and Jonathan Mann. Levine MM, et al. **J Hum Virol** 1999 Jan-Feb;2(1):58-60

Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. Fiscus SA, et al. **J Infect Dis** 1999 Jul;180(1):99-105

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. Stiehm ER, et al. **J Infect Dis** 1999 Mar;179(3):567-75

Needle myringotomy: a useful technique with the increased prevalence of the human immunodeficiency virus. Thorp MA. **J Laryngol Otol** 1998 Sep;112(9):865-6

Medical screening: the next five years. Haddow P. **J Med Screen** 1999;6(2):58-9

Human immunodeficiency virus/acquired immunodeficiency syndrome crisis. Dennis GC. **J Natl Med Assoc** 1998 Nov; 90(11):643-4

Understanding HIV-related risk among persons with a severe and persistent mental illness: insights from qualitative inquiry. Gordon CM, et al. **J Nerv Ment Dis** 1999 Apr; 187(4):208-16

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. Barbouche R, et al. **J Pept Res** 1998 Oct;52(4):283-8

Female injecting drug users: human immunodeficiency virus risk behavior and intervention needs. Brown EJ. **J Prof Nurs** 1998 Nov-Dec;14(6):361-9

Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. Booth RE, et al. **J Psychoactive Drugs** 1998 Jul-Sep; 30(3):269-78

Effectiveness of HIV risk reduction initiatives among out-of-treatment non-injection drug users. Cottler LB, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):279-90

Editors' introduction: HIV/AIDS interventions for out-of-treatment drug users. Inciardi JA, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):225-9

Efficacy and effectiveness issues in the NIDA Cooperative Agreement: interventions for out-of-treatment drug users. National Institute on Drug Abuse. Rhodes F, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):261-8

Postscript: where do we go from here? Sloboda Z, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):307-14

Theoretical models used to guide NIDA's cooperative agreement research and intervention efforts. National Institute on Drug Abuse. Stevens SJ, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):231-8

HIV prevention protocols: adaptation to evolving trends in drug use. Wechsberg WM, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):291-8

Modulation of integrin function inhibits HIV transmission to epithelial cells and fertilization. Davidson JB, et al. **J Reprod Immunol** 1998 Dec;41(1-2):271-90 (91 ref.)

The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1-2):261-70 (21 ref.)

Short-term impact of safer choices: a multicomponent, school-based HIV, other STD, and pregnancy prevention program. Coyle K, et al. **J Sch Health** 1999 May; 69(5):181-8

Dental precautions for travelers [letter] Florence E, et al. **J Travel Med** 1998 Sep;5(3):159-

Are preventive HIV interventions at airports effective? Gehring TM, et al. **J Travel Med** 1998 Dec;5(4):205-9

HIV and the returning expatriate. Jones ME. **J Travel Med** 1999 Jun;6(2):99-106 (47 ref.)

T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. Sakaida H, et al. **J Virol** 1998 Dec;72(12):9763-70

Observations from the CDC. The urgent need for new HIV/STD prevention options for women. Irwin K, et al. **J Womens Health** 1998 Nov;7(9):1081-6 (27 ref.)

Reduction in recidivism of incarcerated women through primary care, peer counseling, and discharge planning. Vigilante KC, et al. **J Womens Health** 1999 Apr;8(3):409-15

JAMA Patient Page. HIV/AIDS. **JAMA** 1999 Aug 11; 282(6):606

From the Centers for Disease Control and Prevention. Prenatal discussion of HIV testing and maternal HIV testing--14 states, 1996-1997. **JAMA** 1999 Jun 23-30; 281(24):2278-9

Rapid HIV screening during labor [letter; comment] Balano K, et al. **JAMA** 1998 Nov 18;280(19):1664. Comment on: JAMA 1998 Jun 3;279(21):1743-4.

Postexposure prophylaxis following HIV exposure [letter; comment] Barry MA. **JAMA** 1999 Apr 14;281(14):1269; discussion 1270. Comment on: JAMA 1998 Nov 25;280(20):1769-73.

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Culnane M, et al. **JAMA** 1999 Jan 13;281(2):151-7

Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. Henderson DK. **JAMA** 1999 Mar 10;281(10):931-6 (63 ref.)

Postexposure prophylaxis following HIV exposure [letter; comment] Kahn JG, et al. **JAMA** 1999 Apr 14; 281(14):1269-70. Comment on: JAMA 1998 Nov 25;280(20):1769-73.

Anonymous HIV testing and medical care [letter; comment] Levi J. **JAMA** 1999 Jun 23-30;281(24):2282-3. Comment on: JAMA 1998 Oct 28;280(16):1416-20.

Postexposure prophylaxis after nonoccupational HIV exposure: clinical, ethical, and policy considerations [see comments] Lurie P, et al. **JAMA** 1998 Nov 25; 280(20):1769-73. Comment in: JAMA 1999 Apr 14;281(14):1269; discussion 1270. Comment in: JAMA 1999 Apr 14;281(14):1269-70.

Can perinatal HIV infection be eliminated in the United States? [editorial; comment] Mofenson LM. **JAMA** 1999 Aug 11;282(6):577-9. Comment on: JAMA 1999 Aug 11;282(6):531-8.

Perinatal HIV prevention. Stephenson J. **JAMA** 1999 Aug 18;282(7):625

Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint. Stringer JS, et al. **JAMA** 1999 May 26; 281(20):1946-9

HIV vaccine trial in Africa [news] Voelker R. **JAMA** 1999 Mar 10;281(10):889

Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration [see comments] [published erratum appears in Lancet 1999 May 15;353(9165):1714] **Lancet** 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Mar 27;353(9158):1030-1. Comment in: Lancet 1999 Jun 26;353(9171):2240. Comment in: Lancet 1999 Jun 26;353(9171):2240-1.

A positive response to perinatal HIV [editorial] **Lancet** 1999 Feb 13;353(9152):511

South Africa to redouble efforts to control the spread of HIV [news] Baleta A. **Lancet** 1999 Sep 4;354(9181):844

Needle-exchange programmes are not the answer [letter; comment] Bellm J. **Lancet** 1999 Mar 13;353(9156):930. Comment on: Lancet 1996 Aug 3;348(9023):324. Comment on: Lancet 1999 Jan 2;353(946):49.

6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Dabis F, et al. **Lancet** 1999 Mar 6; 353(9155):786-92

IOM recommends routine HIV tests in pregnancy [news] Droste TM. **Lancet** 1998 Oct 17;352(9136):1294

Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality. Graham WJ, et al. **Lancet** 1999 Mar 6;353(9155):836-9

Preventing HIV infection: lessons from Mwanza and Rakai [comment] [see comments] Hitchcock P, et al. **Lancet** 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35. Comment in: Lancet 1999 May 1;353(9163):1522; discussion 1523-4. Comment in: Lancet 1999 May 1;353(9163):1522-3; discussion 1523-4. Comment in: Lancet 1999 May 1;353(9163):1523-4.

Elective caesarean section for prevention of vertical transmission of HIV-1 infection [comment] [see comments] Hudson CN. **Lancet** 1999 Mar 27;353(9158):1030-1. Comment on: Lancet 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Jun 26;353(9171):2241.

"Inactive" polymer is active against sexually transmitted diseases [news] Larkin M. **Lancet** 1999 Jul 31;354(9176):399

Australian HIV vaccines trial to begin in the next few months [news] Loff B, et al. **Lancet** 1999 Apr 10;353(9160):1251

Low-cost drug cuts perinatal HIV-transmission rate [news] McCarthy M. **Lancet** 1999 Jul 24;354(9175):309

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Matthys F, et al. **Lancet** 1999 May 1; 353(9163):1523-4. Comment on: Lancet 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35.

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Nicoll A, et al. **Lancet** 1999 May 1; 353(9163):1522; discussion 1523-4. Comment on: Lancet 1995 Aug 26;346(8974):530-6. Comment on: Lancet 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35.

Rapid assessment, injecting drug use, and public health. Rhodes T, et al. **Lancet** 1999 Jul 3;354(9172):65-8 (32 ref.)

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group [see comments] Sandström E, et al. **Lancet** 1999 May 22;353(9166):1735-42 . Comment in: Lancet 1999 May 22;353(9166):1723-4.

Prevention better than cure? [news] Stevenson P. **Lancet** 1999 Jan 16;353(9148):217

Audio-computer interviewing to measure HIV-risk behaviour [letter] Taylor A, et al. **Lancet** 1999 Aug 21; 354(9179):678-9

Japan tackles sexually transmitted diseases [news] Watts J. **Lancet** 1999 Jul 31;354(9176):405

Men in India respond to HIV-1 education [news] Wunsch H. **Lancet** 1998 Oct 3;352(9134):1124

Implicit valuation of a blood-exclusion decision. Kaplan EH. **Med Decis Making** 1999 Apr-Jun;19(2):207-13

An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Richter A, et al. **Med Decis Making** 1999 Apr-Jun;19(2):167-79

HIV vaccines--promise and directions. Kent SJ. **Med J Aust** 1999 Aug 2;171(3):124-5

Antenatal screening for HIV in Australia: time to revise policies? Ziegler JB. **Med J Aust** 1999 Aug 16;171(4):201-3

Human immunodeficiency virus (HIV) education and HIV risk behavior: a survey of rapid deployment troops. Nannis ED, et al. **Mil Med** 1998 Oct;163(10):672-6

Prenatal discussion of HIV testing and maternal HIV testing--14 states, 1996-1997. **MMWR Morb Mortal Wkly Rep** 1999 May 21;48(19):401-4

HIV testing among populations at risk for HIV infection--nine states, November 1995-December 1996. **MMWR Morb Mortal Wkly Rep** 1998 Dec 25; 47(50):1086-91

Recommendations for occupational exposures to HIV. Paul SM, et al. **N J Med** 1999 Jan;96(1):41-6

Protecting the health of medical students on electives. **N Z Med J** 1999 Jul 23;112(1092):264-5

HIV vaccines--and the winner is... [news] Birmingham K. **Nat Med** 1998 Jul;4(7):753

South Africa plans home-grown HIV vaccine [news] Birmingham K. **Nat Med** 1999 Mar;5(3):252

IAVI advances AIDS vaccine research...International AIDS Vaccine Initiative [news] Dove A. **Nat Med** 1999 Jan;5(1):5

Vaccine reactions [letter; comment] Francis DP, et al. **Nat Med** 1998 Jul;4(7):746. Comment on: Nat Med 1998 May;4(5 Suppl):495-8.

Vaccine reactions [letter; comment] Mascola JR, et al. **Nat Med** 1998 Jul;4(7):746. Comment on: Nat Med 1998 May;4(5 Suppl):495-8.

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys [see comments] Shibata R, et al. **Nat Med** 1999 Feb;5(2):204-10. Comment in: Nat Med 1999 Feb;5(2):142-4.

Beijing HIV vaccine meeting to go ahead [news] Watanabe M. **Nat Med** 1999 Oct;5(10):1097

Vaccine reactions [letter; comment] Yamazaki S. **Nat Med** 1998 Jul;4(7):746. Comment on: Nat Med 1998 May;4(5):540.

Drug could slash rate of perinatal HIV [news] **Nature** 1999 Jul 22;400(6742):304

South Africa stands firm on AIDS drug...[news] [see comments] Cherry M. **Nature** 1999 Mar 4;398(6722):8. Comment in: Nature 1999 Apr 15;398(6728):555.

The complex realities of primary prevention for HIV infection in a "just do it" world. Bradley-Springer LA. **Nurs Clin North Am** 1999 Mar;34(1):49-70 (90 ref.)

Occupational exposure to HIV: considerations for postexposure prophylaxis and prevention. McClinsey SC. **Nurs Clin North Am** 1999 Mar;34(1):213-25 (11 ref.)

Is it over yet? Hope or hype: status of the HIV/AIDS pandemic. Miramontes HM, et al. **Nurs Outlook** 1998 Jul-Aug;46(4):155-6 (22 ref.)

Postsexual exposure prophylaxis [news] Klaus BD, et al. **Nurse Pract** 1998 Aug;23(8):70, 72-3

Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Stringer JS, et al. **Obstet Gynecol** 1999 Jul;94(1):34-40

PHS recommendations for the management of health-care worker exposures to HIV--Part 2. **Oncology (Huntingt)** 1998 Oct;12(10):1447-9, 1453-4, 1457 passim

PHS guidelines for the management of health-care worker exposures to HIV--Part 1. **Oncology (Huntingt)** 1998 Sep; 12(9):1331-2, 1335-6, 1339 passim

Assessment of HIV/AIDS knowledge, attitudes and behaviour of high school students in Papua New Guinea. Friesen H, et al. **P N G Med J** 1996 Sep;39(3):208-13

HIV and AIDS [editorial] Verma N. **P N G Med J** 1996 Sep;39(3):163

Joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. American Academy of Pediatrics. American College of Obstetricians and Gynecologists. **Pediatrics** 1999 Jul;104(1 Pt 1):128

A STD/HIV prevention trial among adolescents in managed care. Boekeloo BO, et al. **Pediatrics** 1999 Jan;103(1):107-15

Increasing use of the female condom through video instruction. Zimmers E, et al. **Percept Mot Skills** 1999 Jun; 88(3 Pt 2):1071-7

Closing the condom gap. **Popul Rep H** 1999 Apr;(9):1-35

Do blacks believe that HIV/AIDS is a government conspiracy against them? Klonoff EA, et al. **Prev Med** 1999 May;28(5):451-7

Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Potash MJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13865-8

HIV/AIDS prevention through changing risky sexual behavior among heterosexual college students: a 1990's bibliography. Livingston MM. **Psychol Rep** 1998 Dec;83(3 Pt 1):781-2

Knowledge of laws regulating issues related to HIV and AIDS: development of the HIV/AIDS and the law scale. Paniagua FA, et al. **Psychol Rep** 1999 Jun;84(3 Pt 2):1345-53

Trial marriage: Florida's experience in consolidating HIV/AIDS, STD, and TB programs. Wroten JE, et al. **Public Health Rep** 1999 Jan-Feb;114(1):74-80

Integrating women's perspectives on prenatal human immunodeficiency virus screening: toward a socially just policy. Mawn B. **Res Nurs Health** 1998 Dec;21(6):499-509

The mother-to-child HIV transmission debate [letter; comment] Beyers N, et al. **S Afr Med J** 1999 Feb;89(2):104, 106. Comment on: S Afr Med J 1998 Oct;88(10):1283.

AIDS and informed consent [letter; comment] Edge B. **S Afr Med J** 1999 Mar;89(3):218, 220. Comment on: S Afr Med J 1998 Dec;88(12):1535-6.

The mother-to-child HIV transmission debate [letter; comment] Hussey G, et al. **S Afr Med J** 1999 Feb; 89(2):103-4. Comment on: S Afr Med J 1998 Oct;88(10):1304-6.

The mother-to-child HIV transmission debate [letter; comment] Joubert JR, et al. **S Afr Med J** 1999 Feb;89(2):106 . Comment on: S Afr Med J 1998 Oct;88(10):1283.

Preventing perinatal vertical HIV transmission in South Africa [letter; comment] [see comments] van de Wal BW. **S Afr Med J** 1998 Oct;88(10):1283. Comment on: S Afr Med J 1998 Apr;88(4):431-2. Comment on: S Afr Med J 1998 Apr;88(4):432-3. Comment on: S Afr Med J 1998 Apr;88(4):434-6. Comment in: S Afr Med J 1999 Feb;89(2):104, 106. Comment in: S Afr Med J 1999 Feb;89(2):106.

SAMA Committee wants free AZT for rape survivors [news] van der Linde I. **S Afr Med J** 1999 Jun;89(6):584

UNAIDS and BMS to combat AIDS [news] van der Linde I. **S Afr Med J** 1999 Jun;89(6):585

HIV. French-led therapy fund kicks off in Africa [news] Balter M. **Science** 1999 May 14;284(5417):1101

Confronting the HIV pandemic [editorial] Nathanson N, et al. **Science** 1999 Jun 4;284(5420):1619

AIDS vaccine trials in chimpanzees [letter; comment] Prince AM, et al. **Science** 1998 Dec 18;282(5397):2195-6. Comment on: Science 1998 Jun 19;280(5371):1875-80.

Risk assessment to improve targeting of HIV counseling and testing services for STD clinic patients. Chen Z, et al. **Sex Transm Dis** 1998 Nov;25(10):539-43

Gender differences in risk behaviors among HIV+ persons with an IDU history. The link between partner characteristics and women's higher drug-sex risks. The Manif 2000 Study Group. Gollub EL, et al.

Sex Transm Dis 1998 Oct;25(9):483–8

HIV surveillance: a dynamic, not static, process to assure accurate local data. Griffin RG, et al. **Sex Transm Dis** 1999 May;26(5):291–5

Sexual activity, substance use, and HIV/STD knowledge among detained male adolescents with multiple versus first admissions. Harwell TS, et al. **Sex Transm Dis** 1999 May; 26(5):265–71

Disclosure of HIV status to sexual partners: predictors and temporal patterns. Niccolai LM, et al. **Sex Transm Dis** 1999 May;26(5):281–5

Sexual experiences and condom use of heterosexual, low-income African American and Hispanic youth practicing relative monogamy, serial monogamy, and nonmonogamy. Norris AE, et al. **Sex Transm Dis** 1999 Jan; 26(1):17–25

Learning from success: global priorities for HIV prevention--Thomas Parran Award Lecture. Piot P. **Sex Transm Dis** 1999 May;26(5):244–9

HIV testing and prevention: family planning clinic attenders in London [letter] Bergenström A, et al. **Sex Transm Infect** 1999 Apr;75(2):130

Monetary incentives: a useful strategy for enhancing enrollment and promoting participation in HIV/STD risk reduction interventions [editorial; comment] Diclemente R, et al. **Sex Transm Infect** 1998 Aug;74(4):239–40. Comment on: Sex Transm Infect 1998 Aug;74(4):253–55.

Post-exposure prophylaxis (PEP) after non-occupational risk of HIV infection [letter] Kinghorn GR, et al. **Sex Transm Infect** 1998 Aug;74(4):304

Beyond the biomedical and behavioural: towards an integrated approach to HIV prevention in the southern African mining industry. Campbell C, et al. **Soc Sci Med** 1999 Jun;48(11):1625–39

The social impact of HIV testing: a comparative analysis of Britain and Sweden. Danziger R. **Soc Sci Med** 1999 Feb; 48(3):293–300 (40 ref.)

Implications of social class and race for urban public health policy making: a case study of HIV/AIDS and TB policy in Washington, DC. Dievler A, et al. **Soc Sci Med** 1999 Apr;48(8):1095–102

A tale of two (low prevalence) cities: social movement organisations and the local policy response to HIV/AIDS. Petchey R, et al. **Soc Sci Med** 1998 Nov;47(9):1197–208

HIV vaccine development: a subtype E-specific strategy. Brown AE, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):377–82 (30 ref.)

Opening the AIDS door [editorial; comment] Kidson C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):427–8. Comment on: Southeast Asian J Trop Med Public Health 1998 Sep;29(3):429–42.

From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in Northern Thailand [see comments] Thaineua V, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):429–42. Comment in: Southeast Asian J Trop Med Public Health 1998 Sep;29(3):427–8.

Semi-parametric models for mismeasured exposure information in vaccine trials. Golm GT, et al. **Stat Med** 1998 Oct 30;17(20):2335–52

Group testing in presence of classification errors. Gupta D, et al. **Stat Med** 1999 May 15;18(9):1049–68

A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. Longini IM Jr, et al. **Stat Med** 1999 Jan 15;18(1):53–68

Behavior changes among crack-using rural and urban women. McCoy HV, et al. **Subst Use Misuse** 1999 Mar-Apr;34(4–5):667–84

The Tennessee HIV Pregnancy Screening Act of 1997. Moore WL Jr. **Tenn Med** 1999 Apr;92(4):141–2

Voluntary screening for HIV: 1997 World AIDS Day experience in a rural mission hospital in Cameroon [letter] Amoaku E. **Trop Doct** 1998 Oct;28(4):248–9

HIV infection in Dharam, Nepal [letter] Bhattacharya SK, et al. **Trop Doct** 1999 Apr;29(2):117–8

Methods and meanings in anthropological, epidemiological and clinical encounters: the case of sexually transmitted disease and human immunodeficiency virus control and prevention in India [see comments] Lambert H. **Trop Med Int Health** 1998 Dec;3(12):1002–10 (38 ref.). Comment in: Trop Med Int Health 1998 Dec;3(12):993–5.

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, et al. **Vaccine** 1999 Jan; 17(1):64–71

Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Wagner R, et al. **Vaccine** 1999 Mar 26;17(13–14):1706–10 (18 ref.)

Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Putkonen P, et al. **Virology** 1998 Oct 25;250(2):293–301

Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing. Busch MP. **Vox Sang** 1998; 74 Suppl 2:147–54 (79 ref.)

Interactions between science, government and media on selection and testing of donors. Sazama K. **Vox Sang** 1998; 74 Suppl 2:503–6 (24 ref.)

Donor selection: the exclusion of high risk donors? van den Burg PJ, et al. **Vox Sang** 1998;74 Suppl 2:499–502 (22 ref.)

Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. **Wkly Epidemiol Rec** 1998 Oct 9; 73(41):313–20

The acceptability of the female condom among substance-using women in Washington, DC. Klein H, et al. **Women Health** 1999;29(3):97–114

[Antiviral chemoprophylaxis following sexual exposure to HIV (letter)] **Ugeskr Laeger** 1998 Oct 19;160(43):6224–5 **(Dan)**

[Therapeutic options for HIV-infection should lead to increased utilization of HIV tests (letter; comment)] Boer K. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1395–6. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):598–9. **(Dut)**

[Therapeutic options for HIV infection should lead to increased utilization of HIV tests (see comments)] Coutinho RA, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):598–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1395–6. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1396–7. **(Dut)**

[Therapeutic options for HIV-infections should lead to increased utilization of HIV tests (letter; comment)] Kleiverda G, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26; 143(26):1396–7. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):598–9. **(Dut)**

[Vertical HIV-I-transmission. Risk and prevention in pregnancy (letter; comment)] Mulder B, et al. **Ned Tijdschr Geneeskd** 1999 Feb 20;143(8):434–6. Comment on: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2720–4. **(Dut)**

[Jaundice with free bilirubin following preventive anti-retroviral therapy after sexual aggression] Questel F, et al. **Presse Med** 1999 Jan 9;28(1):8–10 (Eng. Abstr.) **(Fre)**

[Risk of accidental contamination by the human immunodeficiency virus (HIV): review and management] Conquy S, et al. **Prog Urol** 1999 Apr;9(2):330–41 (Eng. Abstr.) **(Fre)**

[Knowledge, beliefs and attitudes of inmates towards AIDS and HIV infection: a survey in a Marseille penitentiary center] Delorme C, et al. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):229–38 (Eng. Abstr.) **(Fre)**

[Perinatal HIV transmission prophylaxis in the Liege region] Jacquet Y, et al. **Rev Med Liege** 1998 Aug;53(8):475–8 (Eng. Abstr.) **(Fre)**

[Management of professional exposures to blood and other biological liquids contaminated with hepatitis B and C and HIV] Dubey BR, et al. **Rev Med Suisse Romande** 1999 Jul;119(7):587–92 (9 ref.) **(Fre)**

[Cost-benefit analysis of screening strategies by human immunodeficiency virus in French blood donors] Djossou F, et al. **Transfus Clin Biol** 1999 Jun;6(3):180–8 (Eng. Abstr.) **(Fre)**

[RKI "Current version of prophylactic drug therapy after occupational HIV-exposure". Consensus conference 21 November 1997 in Munich] **Chirurg** 1998 Jul;69(7):suppl 224–6 (0 ref.) **(Ger)**

[German-Austrian recommendations for post-exposure prophylaxis after HIV infection (letter)] Seuffer RH. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):373 **(Ger)**

[Vertical transmission: healthy children--a new UNAIDS initiative (news)] Volkert R. **Dtsch Med Wochenschr** 1998 Sep 18;123(38):A9 **(Ger)**

[HIV post-exposure prophylaxis after sexual risk contact (editorial; comment)] Battegay M, et al. **Schweiz Med Wochenschr** 1999 Feb 27;129(8):311–3. Comment on: Schweiz Med Wochenschr 1999 Feb 27;129(8):314–8. **(Ger)**

[HIV infection in the child: is there hope on the horizon?] Nadal D. **Schweiz Med Wochenschr** 1999 Jan 12; 129(1–2):30–3 **(Ger)**

[Post-exposure HIV prevention: eligibility of patients recently infected by sexual exposure (see comments)] Sudre P, et al. **Schweiz Med Wochenschr** 1999 Feb 27;129(8):314–8 (Eng. Abstr.). Comment in: Schweiz Med Wochenschr 1999 Feb 27;129(8):311–3. **(Ger)**

[Post-exposure prevention of HIV infection] Möst J. **Wien Med Wochenschr** 1998;148(23–24):547–9 (5 ref.) (Eng. Abstr.) **(Ger)**

[HIV prevention for migrant prostitutes] Nitschke-Ozbay H. **Zentralbl Gynakol** 1999;121(1):36–41 (5 ref.) (Eng. Abstr.) **(Ger)**

[A day-after cure of HIV infection?] Aavitsland P. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4495 **(Nor)**

[Trends in HIV/AIDS-related knowledge, attitudes, and practices in a Rio de Janeiro slum population] Fernandes JC. **Cad Saude Publica** 1998 Jul-Sep;14(3):575–81 (Eng. Abstr.) **(Por)**

[Assessment of the effectiveness of medical instruments sterilization by electrochemically activated solutions and computer modeling of the dynamics of hospital infections] Bakhir VM, et al. **Med Tekh** 1999 Mar-Apr;(2):14–6 (Eng. Abstr.) **(Rus)**

[Surfactants as agents for the individual prevention of HIV/AIDS] Krivorutchenko IuL. **Mikrobiol Z** 1999 Jan-Feb;61(1):95–103 (65 ref.) (Eng. Abstr.) **(Rus)**

[Work with youth--the basis of educational programs aimed at the prevention of HIV infection] Agafonova OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):119–20 (Eng. Abstr.) **(Rus)**

[The road will be mastered by the walker] Agapova VM. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):108–10 (Eng. Abstr.) **(Rus)**

[The prevention of HIV infection and STDs among injection drug addicts in Ukraine] Andrushchak LI. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):86–9 (Eng. Abstr.) **(Rus)**

[A decrease in harm: a new concept for Russian public health] Burrows D, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):107–8 (Eng. Abstr.) **(Rus)**

[The educating and informing of the population on HIV/AIDS problems in the Republic of Byelarus] Bykova VM. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):110–1 (Eng. Abstr.) **(Rus)**

[The role of public organizations in the prevention of HIV infection in Russia] Dement'eva LA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):114–6 (Eng. Abstr.) **(Rus)**

[The prevention of HIV infection in abusers of psychoactive substances as a social behavioral problem] Dolzhanskaia NA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):98–100 (Eng. Abstr.) **(Rus)**

[A comparative study of the level of knowledge of schoolchildren about HIV infection and AIDS] Kopnina EO, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):116–7 (Eng. Abstr.) **(Rus)**

[The role of educational programs on the prevention of HIV infection and the development of a healthy life style for adolescents] Mamchik TA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):113–4 (Eng. Abstr.) **(Rus)**

[The prevalence of the intravenous use of psychoactive preparations in Nizhegorod Province and the possible ways to prevent HIV infection among the users] Moshkovich GF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):21–3 (Eng. Abstr.) **(Rus)**

[The acceptance of a strategy for decreasing the risk of contracting an HIV infection among drug abusers] Nosov NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):96–7 (Eng. Abstr.) **(Rus)**

[Emergency measures to control the spread of diseases caused by the human immunodeficiency virus] Onishchenko GG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):5–9 (Eng. Abstr.) **(Rus)**

[The clean syringe and HIV infection. A clean syringe can be obtained by any drug addict in a bus stationed in places of active drug trading] Ostrovskii DV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):118–9 (Eng. Abstr.) **(Rus)**

[The forms and analysis of the results of work in preventing HIV infection among youth] Shorokhov SSW, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):89–91 (Eng. Abstr.) **(Rus)**

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240–1 **(Spa)**

[A new strategy in the fight against HIV/AIDS is needed. Inaccurate information is a waste of both money and energy (see comments)] Christenson B, et al. **Lakartidningen** 1998 Nov 18;95(47):5300–2. Comment in: Lakartidningen 1998 Dec 16;95(51–52):5863–4. **(Swe)**

[Preventive work against HIV/AIDS has been successful in Sweden. But the global transmission is still unchanged] Haglind P. **Lakartidningen** 1998 Nov 18;95(47):5267–9 (17 ref.) **(Swe)**

[The HIV/AIDS strategy is continuously re-evaluated (letter; comment)] Strandell A, et al. **Lakartidningen** 1998 Dec 16;95(51–52):5863–4. Comment on: Lakartidningen 1998 Nov 18;95(47):5300–2. **(Swe)**

[Promising experiments with DNA vaccine against HIV. A complete eradication of the virus is a formidable task] Wahren B. **Lakartidningen** 1999 Feb 17;96(7):722–5 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Prevalence of unprotected sex among men with AIDS in Los Angeles County, California 1995–1997. Simon PA, et al. **AIDS** 1999 May 28;13(8):987–90

Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study. Wilson TE, et al. **AIDS** 1999 Apr 1;13(5):591–8

Facing the challenge: household responses to HIV/AIDS in Mumbai, India. Bharat S, et al. **AIDS Care** 1999 Feb; 11(1):31–44

Women who are HIV infected: the role of religious activity in psychosocial adjustment. Biggar H, et al. **AIDS Care** 1999 Apr;11(2):195–9

'In an important way, I did die': uncertainty and revival in persons living with HIV or AIDS. Brashers DE, et al. **AIDS Care** 1999 Apr;11(2):201–19

Whose health is it? The views of injecting drug users with HIV infection and their professional carers. Carretero MD, et al. **AIDS Care** 1998 Jun;10(3):323–8

AIDS-related illness trajectories in Mexico: findings from a qualitative study in two marginalized communities. Castro R, et al. **AIDS Care** 1998 Oct;10(5):583–98

Do people with HIV/AIDS disclose their HIV-positivity to dentists? Charbonneau A, et al. **AIDS Care** 1999 Feb; 11(1):61–70

Subjective HIV attribution theories, coping and psychological functioning among homosexual men with HIV. Clement U, et al. **AIDS Care** 1998 Jun;10(3):355–63

The relative importance of factors which influence order of injecting with a shared needle and syringe. Crisp BR, et al. **AIDS Care** 1998 Dec;10(6):713–21

Social support and unsupportive social interactions: their association with depression among people living with HIV. Ingram KM, et al. **AIDS Care** 1999 Jun;11(3):313–29

HIV risk behaviours among male-to-female transgenders in comparison with homosexual or bisexual males and heterosexual females. Nemoto T, et al. **AIDS Care** 1999 Jun;11(3):297–312

Measuring the stress associated with caring for clients with HIV/AIDS. Niven CA, et al. **AIDS Care** 1999 Apr; 11(2):171–80

Close relationships and safer sex among HIV-infected men with haemophilia. Norman LR, et al. **AIDS Care** 1998 Jun; 10(3):339–54

Nature and consequences of stressful life events in homosexual HIV-positive men: a review. Nott KH, et al. **AIDS Care** 1999 Apr;11(2):235–43

HIV risk behaviours of current sex workers attending syringe exchange: the experiences of women in five US cities. Paone D, et al. **AIDS Care** 1999 Jun;11(3):269–80

The moral universe of injecting drug users in the era of AIDS: sharing injecting equipment and the protection of moral standing. Plumridge E, et al. **AIDS Care** 1998 Dec; 10(6):723–33

AIDS diagnosis and depression in the Multicenter AIDS Cohort Study: the ameliorating impact of pet ownership. Siegel JM, et al. **AIDS Care** 1999 Apr;11(2):157–70

Young people and HIV in Cambodia: meanings, contexts and sexual cultures. Tarr CM, et al. **AIDS Care** 1999 Jun; 11(3):375–84

Heterosexual couples confronting the challenges of HIV infection. VanDevanter N, et al. **AIDS Care** 1999 Apr; 11(2):181–93

Sexual HIV risk behaviour among men who have sex with both men and women. Weatherburn P, et al. **AIDS Care** 1998 Aug;10(4):463–71

HIV-related attitudes and risk behavior of young adolescent mothers. Brown LK, et al. **AIDS Educ Prev** 1998 Dec; 10(6):565–73

Do actions speak louder than words? Perceived peer influences on needle sharing and cleaning in a sample of injection drug users. Hawkins WE, et al. **AIDS Educ Prev** 1999 Apr;11(2):122–31

Traumatic stress in HIV-infected women. Kimerling R, et al. **AIDS Educ Prev** 1999 Aug;11(4):321–30

Knowledge, attitudes, beliefs, and practices about HIV/AIDS in Kuwait. al-Owaish R, et al. **AIDS Educ Prev** 1999 Apr;11(2):163–73

Hope and resilience in suicide ideation and behavior of gay and bisexual men following notification of HIV infection. Siegel K, et al. **AIDS Educ Prev** 1999 Feb;11(1):53–64

HIV risk behaviors, intentions, and perceptions among Namibian youth as assessed by a theory-based questionnaire. Stanton BF, et al. **AIDS Educ Prev** 1999 Apr;11(2):132–49

An HIV-positive patient who avoids treatment. Legg JJ, et al. **Am Fam Physician** 1999 Jun;59(11):3252, 3257

An AIDS patient's right to refuse life-sustaining treatment. Majette GR. **Am Fam Physician** 1998 Dec;58(9):2161–4 (46 ref.)

Disclosing diagnosis to children with HIV [news] Rose VL. **Am Fam Physician** 1999 Apr 15;59(8):2367

Play development in children with HIV infection: a pilot study. Parks RA, et al. **Am J Occup Ther** 1998 Sep; 52(8):672–5

Measuring desire for death among patients with HIV/AIDS: the schedule of attitudes toward hastened death. Rosenfeld B, et al. **Am J Psychiatry** 1999 Jan;156(1):94–100

Dental care access and use among HIV-infected women [see comments] Shiboski CH, et al. **Am J Public Health** 1999 Jun;89(6):834–9. Comment in: Am J Public Health 1999 Jun;89(6):818–9.

The will to live among HIV-infected patients. Tsevat J, et al. **Ann Intern Med** 1999 Aug 3;131(3):194–8

Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Meyer JM, et al. **Biol Psychiatry** 1998 Oct 15;44(8):791–4

HIV stress in primary school teachers in Zambia. Baggaley R, et al. **Bull World Health Organ** 1999;77(3):284–7

Proxy, health, and personal care preferences: implications for end-of-life care. Aikman PJ, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):200–10

The perception of discrimination in the HIV policy among Czech gay men. Procházka I, et al. **Cent Eur J Public Health** 1998 Aug;6(3):192–4

Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group [see comments] Hankins C, et al. **CMAJ** 1998 Dec 1; 159(11):1359–65. Comment in: CMAJ 1998 Dec 1;159(11):1373–4.

Understanding the intention of dentists to provide dental care to HIV+ and AIDS patients. Godin G, et al. **Community Dent Oral Epidemiol** 1999 Jun;27(3):221–7

Suicide, euthanasia and AIDS. Mishara BL. **Crisis** 1998; 19(2):87–96 (49 ref.)

Posttraumatic stress disorder in response to HIV infection. Kelly B, et al. **Gen Hosp Psychiatry** 1998 Nov;20(6):345–52

Influence of HIV-infection on the Karnofsky score and general social functioning in patients with hemophilia. Wenzel T, et al. **Haemostasis** 1998 Mar-Apr;28(2):106–10

Measuring self-efficacy in the context of HIV risk reduction: research challenges and recommendations. Forsyth AD, et al. **Health Psychol** 1998 Nov;17(6):559–68 (91 ref.)

Negative HIV-specific expectancies and AIDS-related bereavement as predictors of symptom onset in asymptomatic HIV-positive gay men. Reed GM, et al. **Health Psychol** 1999 Jul;18(4):354–63

Tolerance, compliance and psychological consequences of post-exposure prophylaxis in health-care workers. de la Tribonnière X, et al. **Int J STD AIDS** 1998 Oct;9(10):591–4

Antiretroviral uptake in Australia: medical, attitudinal and cultural correlates. Ezzy DM, et al. **Int J STD AIDS** 1998 Oct;9(10):579–86

Sexual functioning in ambulatory men with HIV/AIDS. Newshan G, et al. **Int J STD AIDS** 1998 Nov;9(11):672–6

Trends in HIV-related consultation in Dutch general practice. Ros CC, et al. **Int J STD AIDS** 1999 May; 10(5):294–9

Transsexual orientation in HIV risk behaviours in an adult male prison. Stephens T, et al. **Int J STD AIDS** 1999 Jan; 10(1):28–31

Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. Swindells S, et al. **Int J STD AIDS** 1999 Jun; 10(6):383–91

HIV knowledge, beliefs and sexual behavior of male heterosexual drug users and non-drug users attending an HIV testing clinic in Israel. Soskolne V, et al. **Isr J Psychiatry Relat Sci** 1998;35(4):307–17

Factors associated with HIV-infected patients' recognition and use of HIV medications. Jeffe DB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):350–60

Effect of race on insurance coverage and health service use for HIV-infected gay men. Kass N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):85–92

Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. Sheon AR, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):519–26

Assessment of HIV risk. Chawarski MC, et al. **J Addict Dis** 1998;17(4):49–59

Knowledge, attitudes and behaviours related to HIV and AIDS among chinese adolescents in hong kong. Davis C, et al. **J Adolesc** 1998 Dec;21(6):657–65

Changes in incarcerated adolescents' human immunodeficiency virus knowledge and selected behaviors from 1988 to 1996. Lanier MM, et al. **J Adolesc Health** 1999 Sep;25(3):182–6

AIDS in southern Thailand: stories of krengjai and social connections. Bechtel GA, et al. **J Adv Nurs** 1999 Feb; 29(2):471–5

Validation of the quality of life scale: living with HIV. Holzemer WL, et al. **J Adv Nurs** 1998 Sep;28(3):622–30

People with HIV/AIDS: who cares? Robinson N. **J Adv Nurs** 1998 Oct;28(4):771–8 (65 ref.)

Dimensions of health-related quality of life in persons living with HIV disease. Sousa KH, et al. **J Adv Nurs** 1999 Jan; 29(1):178–87

The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients. Perretta P, et al. **J Affect Disord** 1998 Sep;50(2–3):215–24

HIV update: misinformation persists [editorial] Meskin LH. **J Am Dent Assoc** 1999 Sep;130(9):1260, 1262

Ethnic differences in body image attitudes and perceptions among women infected with human immunodeficiency virus. Clark RA, et al. **J Am Diet Assoc** 1999 Jun; 99(6):735–7

The expressed needs of a group of HIV-infected gay men subsequent to hospital care. Cederfjäll C, et al. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):66–74

Spirituality, psychological well-being, and HIV symptoms for African Americans living with HIV disease. Coleman CL, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb; 10(1):42–50

Barriers to self-care in a cohort of low-income white women living with HIV/AIDS. Leenerts MH. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):22–36

Depressive symptoms and HIV disease. Moneyham L. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):93–4

Health-related quality of life in HIV disease: achieving a balance. Murdaugh C. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):59–71

Stress and HIV disease progression: psychoneuroimmunological framework. Robinson FP, et al. **J Assoc Nurses AIDS Care** 1999 Jan-Feb;10(1):21–31 (56 ref.)

Stories of violence and shame [editorial] Sowell RL. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):15–6

Practice what we preach? HIV knowledge, beliefs, and behaviors of adolescents and adolescent peer educators. Villarruel AM, et al. **J Assoc Nurses AIDS Care** 1998 Sep-Oct;9(5):61–72

Depression predicts procedural but not episodic memory in HIV-1 infection. Kalechstein AD, et al. **J Clin Exp Neuropsychol** 1998 Aug;20(4):529–35

The difficulties of women living with HIV infection. Gray JJ. **J Psychosoc Nurs Ment Health Serv** 1999 May; 37(5):39–43

HIV-risk behaviors in adolescent substance abusers. Deas-Nesmith D, et al. **J Subst Abuse Treat** 1999 Mar; 16(2):169–72

Victimization experiences and HIV infection in women: associations with serostatus, psychological symptoms, and health status. Kimerling R, et al. **J Trauma Stress** 1999 Jan;12(1):41–58

Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV-related resources between HIV-infected women and men. Davidson AJ, et al. **Med Care** 1998 Dec;36(12):1676–84

Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Scott-Lennox JA, et al. **Med Care** 1999 Sep;37(9):908–25

Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Sacktor NC, et al. **Neurology** 1999 May 12;52(8):1640–7

Grief work of HIV positive persons and their survivors. Mallinson RK. **Nurs Clin North Am** 1999 Mar;34(1):163–77 (43 ref.)

Moving beyond fear: lessons learned through a longitudinal review of the literature regarding health care providers and the care of people with HIV/AIDS. Sherman DW, et al. **Nurs Clin North Am** 1999 Mar;34(1):1–48 (117 ref.)

The care of women with AIDS: special needs and considerations. Sowell RL, et al. **Nurs Clin North Am** 1999 Mar;34(1):179–99 (147 ref.)

Computerized information and support for patients with breast cancer or HIV infection. Rolnick SJ, et al. **Nurs Outlook** 1999 Mar-Apr;47(2):78–83

Long-term nonprogressors with HIV disease. Barroso J. **Nurs Res** 1999 Sep-Oct;48(5):242–9

The effect of a social support boosting intervention on stress, coping, and social support in caregivers of children with HIV/AIDS [letter; comment] Eldredge D. **Nurs Res** 1998 Nov-Dec;47(6):307–8. Comment on: Nurs Res 1998 Mar-Apr;47(2):79–86.

Relationships between work and HIV/AIDS status. Vitry-Henry L, et al. **Occup Med (Lond)** 1999 Feb; 49(2):115–6

The olfactory loss that accompanies an HIV infection. Hornung DE, et al. **Physiol Behav** 1998 Jun 15;64(4):549–56

Cognitive-behavioral group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. Lee MR, et al. **Psychiatr Serv** 1999 Jul; 50(7):948–52

Fatigue in HIV illness: relationship to depression, physical limitations, and disability. Ferrando S, et al. **Psychosom Med** 1998 Nov-Dec;60(6):759–64

Progression to AIDS: the effects of stress, depressive symptoms, and social support. Leserman J, et al. **Psychosom Med** 1999 May-Jun;61(3):397–406

Pain and depression in HIV illness. Evans S, et al. **Psychosomatics** 1998 Nov-Dec;39(6):528–35

Integrating women's perspectives on prenatal human immunodeficiency virus screening: toward a socially just policy. Mawn B. **Res Nurs Health** 1998 Dec;21(6):499–509

Should AIDS be notifiable? [editorial] Colvin M. **S Afr Med J** 1999 Feb;89(2):147–8

Pre-test counselling for HIV--short and friendly please [letter] Mankazana M. **S Afr Med J** 1999 Jan;89(1):11–2

Revisiting how the Chronic Illness Trajectory Framework can be applied for persons living with HIV/AIDS. Nokes KM. **Sch Inq Nurs Pract** 1998 Spring;12(1):27–31

HIV and youths in Singapore--knowledge, attitudes and willingness to work with HIV-infected persons. Lim VK, et al. **Singapore Med J** 1999 Jun;40(6):410–5

Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrument. Witteveen PO, et al. **Support Care Cancer** 1999 Mar;7(2):64–70

Sexual risk behavior changes among HIV+ and HIV-female injecting drug users over 4 years. Dolezal C, et al. **Women Health** 1998;27(4):1–17

Women HIV sexual risk takers: related behaviors, interpersonal issues, and attitudes. Harlow LL, et al. **Womens Health** 1998 Winter;4(4):407–39 (85 ref.)

[Team care: a necessity for a child with HIV infection] Geelen SP, et al. **Ned Tijdschr Geneeskd** 1999 Aug 14; 143(33):1681–5 (Eng. Abstr.) **(Dut)**

[Dementia and human inmmunodeficiency virus infection] Gray F. **Rev Neurol (Paris)** 1998;154 Suppl 2:S91–8 (72 ref.) (Eng. Abstr.) **(Fre)**

[HIV drugs: no solution for psychosocial problems (news)] Weismann H. **Dtsch Med Wochenschr** 1998 Dec 18; 123(51–52):A12 **(Ger)**

[HIV infection: the psychological indices at different stages of the disease] Uliukin IM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):104–6 (Eng. Abstr.) **(Rus)**

[Perception of risk for infection with the human immunodeficiency virus] Vuković D, et al. **Srp Arh Celok Lek** 1998 Nov-Dec;126(11–12):446–9 (Eng. Abstr.) **(Scc)**

RADIOGRAPHY

Thoracic computed tomography of patients infected with the human immunodeficiency virus: relevance for the course

of disease. Knollmann FD, et al. **J Thorac Imaging** 1999 Jul;14(3):185–93

RADIONUCLIDE IMAGING

Radioaerosol scintigraphy in infants and children born to mothers with HIV disease. Pediatric Pulmonary and Cardiovascular Complications (of Vertically Transmitted Human Immunodeficiency Virus) Study Group. Alderson PO, et al. **Radiology** 1999 Mar;210(3):815–22

RADIOTHERAPY

Sterilization of HIV with irradiation: relevance to infected bone allografts. Campbell DG, et al. **Aust N Z J Surg** 1999 Jul;69(7):517–21

REHABILITATION

Assisting persons living with HIV/AIDS to return to work: programmatic steps for AIDS service organizations. Brooks RA, et al. **AIDS Educ Prev** 1999 Jun;11(3):212–23

Meeting the challenge of early identification of HIV infection in primary care. Vergeront JM, et al. **WMJ** 1998 Dec; 97(11):52–61 (6 ref.)

SURGERY

Primary dural leiomyosarcoma in a patient infected with human immunodeficiency virus: case report. Bejjani GK, et al. **Neurosurgery** 1999 Jan;44(1):199–202

THERAPY

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. Churdboonchart V, et al. **AIDS** 1998 Aug 20;12(12):1521–7

Prolonged CD8+ T-cell expansions after adoptive transfer of syngeneic lymphocytes between HIV-discordant identical twins [letter] Tan R, et al. **AIDS** 1998 Nov 12; 12(16):2240–1

Patient satisfaction with HIV service provision in NPMS hospitals: the development of a standard satisfaction questionnaire. NPMS Steering Group. Beck EJ, et al. **AIDS Care** 1999 Jun;11(3):331–43

Predictors of outpatient medical appointment attendance among persons with HIV. Catz SL, et al. **AIDS Care** 1999 Jun;11(3):361–73

Associations of clinical parameters with health-related quality of life in hospitalized persons with HIV disease. Globe DR, et al. **AIDS Care** 1999 Feb;11(1):71–86

Barriers to care among persons living with HIV/AIDS in urban and rural areas. Heckman TG, et al. **AIDS Care** 1998 Jun;10(3):365–75

The integration of informal care, case management and community-based services for persons with HIV/AIDS. London AS, et al. **AIDS Care** 1998 Aug;10(4):481–503

Reluctance amongst nurses and doctors to care for and treat patients with HIV/AIDS. McCann TV. **AIDS Care** 1999 Jun;11(3):355–9

Reducing financial barriers to HIV-related medical care: does the Ryan White CARE Act make a difference? Marx R, et al. **AIDS Care** 1998 Oct;10(5):611–6

Is access to medical care associated with receipt of HIV testing and counselling? Mosen DM, et al. **AIDS Care** 1998 Oct;10(5):617–28

Factors associated with HIV-infected women's delay in seeking medical care. Raveis VH, et al. **AIDS Care** 1998 Oct;10(5):549–62

Managing HIV among serodiscordant heterosexual couples: serostatus, stigma and sex. van der Straten A, et al. **AIDS Care** 1998 Oct;10(5):533–48

Complementary therapies & HIV infection. Evans BM. **Am J Nurs** 1999 Feb;99(2):42–5 (10 ref.)

Factors associated with refusal to treat HIV-infected patients: the results of a national survey of dentists in Canada. McCarthy GM, et al. **Am J Public Health** 1999 Apr;89(4):541–5

Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Moorman AC, et al. **Ann Epidemiol** 1999 Aug; 9(6):349–57

Optimizing care for persons with HIV infection. Society of General Internal Medicine AIDS Task Force. Hecht FM, et al. **Ann Intern Med** 1999 Jul 20;131(2):136–43 (63 ref.)

Clinical progress and the future of HIV exceptionalism. Bayer R. **Arch Intern Med** 1999 May 24;159(10):1042–8 (45 ref.)

Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients [see comments] Fairfield KM, et al. **Arch Intern Med** 1998 Nov 9;158(20):2257–64. Comment in: Arch Intern Med 1999 May 24;159(10):1143–4.

A population with short delay from diagnosis of human immunodeficiency virus to medical care [letter; comment] Guenter CD, et al. **Arch Intern Med** 1999 Apr 12; 159(7):758–9. Comment on: Arch Intern Med 1998 Apr 13;158(7):734–40.

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Le Buanec H, et al. **Biomed Pharmacother** 1998;52(10):431–5

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy. Zagury D, et al. **Biomed Pharmacother** 1999 Mar;53(2):90–2

General practice and the care of children with HIV infection: 6 month prospective interview study [see comments] Boulton M, et al. **BMJ** 1999 Jul 24;319(7204):232–5. Comment in: BMJ 1999 Jul 24;319(7204):207–8.

Children with HIV: the challenge for general practice [editorial; comment] Kidd M. **BMJ** 1999 Jul 24; 319(7204):207–8. Comment on: BMJ 1999 Jul 24;319(7204):232–5.

Homeopathy in HIV infection: a trial report of double-blind placebo controlled study. Rastogi DP, et al. **Br Homeopath J** 1999 Apr;88(2):49–57

The role of the GP in the care of people with HIV and AIDS [letter; comment] Dunford A. **Br J Gen Pract** 1998 Aug;48(433):1526–7. Comment on: Br J Gen Pract 1998 May;48(430):1233–6.

Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides. Müller H, et al. **Clin Exp Immunol** 1999 Jul;117(1):76–83

Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Zanussi S, et al. **Clin Exp Immunol** 1999 Jun; 116(3):486–92

A comprehensive plan for managed care of patients infected with human immunodeficiency virus. Bartlett JG, et al. **Clin Infect Dis** 1999 Jul;29(1):50–5

Human immunodeficiency virus infection, Part I. Horowitz HW, et al. **Dis Mon** 1998 Oct;44(10):545–606 (233 ref.)

Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infected individuals. Law P, et al. **Exp Hematol** 1999 Jan;27(1):147–54

Gene therapy approaches to HIV-infection: immunological strategies: use of T bodies and universal receptors to redirect cytolytic T-cells. Bitton N, et al. **Front Biosci** 1999 Apr 1;4:D386–93 (95 ref.)

Human immunodeficiency virus and the hematopoietic repertoire: implications for gene therapy. Panoskaltsis N, et al. **Front Biosci** 1999 May 1;4:D457–67 (110 ref.)

Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. BouHamdan M, et al. **Gene Ther** 1999 Apr; 6(4):660–6

High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector. Fraisier C, et al. **Gene Ther** 1998 Dec;5(12):1665–76

The emerging needs of persons living with haemophilia and HIV/AIDS in British Columbia. Taylor G. **Haemophilia** 1999 Jan;5(1):1–8 (16 ref.)

Board specialty and treatment of HIV infection [letter; comment] Dodge WT. **Hosp Pract (Off Ed)** 1999 Apr 15; 34(4):62. Comment on: Hosp Pract (Off Ed) 1998 Dec 15;33(12):53–6, 61–4, 67–9; discussion 69–71.

A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Cooper D, et al. **Hum Gene Ther** 1999 May 20; 10(8):1401–21

Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Marasco WA, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1627–42

Intrabodies to human immunodeficiency virus type 1 [comment] Paillard F. **Hum Gene Ther** 1999 Jun 10; 10(9):1425–7. Comment on: Hum Gene Ther 1999 Jun 10;10(9):1453–67.

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Wong-Staal F, et al. **Hum Gene Ther** 1998 Nov 1;9(16):2407–25

Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Shearer GM, et al. **Immunol Today** 1999 Feb;20(2):66–71 (49 ref.)

Evaluating the process of tailoring the global HIV/AIDS practice guidelines for use in developing countries. Wabitsch R, et al. **Int J Qual Health Care** 1998 Apr; 10(2):147–54

Access to and utilization of primary care services among HIV-infected women. Palacio H, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):293–300

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study). Gringeri A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):358–70

'What drugs could I give my child?' [news] **J Adv Nurs** 1998 Dec;28(6):1180

Identifying providers of care to individuals with human immunodeficiency virus for a mail survey using a prescription tracking database. Bach PB, et al. **J Clin Epidemiol** 1999 Feb;52(2):147–50

Relationship between ambulatory care accessibility and hospitalization for persons with advanced HIV disease. Laine C, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):313–27

Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. Levine BL, et al. **J Hematother** 1998 Oct;7(5):437–48

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Calarota SA, et al. **J Immunol** 1999 Aug 15;163(4):2330–8

Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. Amiel C, et al. **J Infect Dis** 1999 Jan;179(1):83–91

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. Ratto-Kim S, et al. **J Infect Dis** 1999 Feb; 179(2):337–44

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. Sei S, et al. **J Infect Dis** 1999 Sep;180(3):626–40

Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production. Triozzi PL, et al. **J Infect Dis** 1999 Jan; 179(1):245–8

Health care professionals and treatment of HIV-positive patients. Is there an affirmative duty to treat under common law, the Rehabilitation Act, or the Americans with Disabilities Act? White CC. **J Leg Med** 1999 Mar; 20(1):67–113 (309 ref.)

A preliminary study of African-American physician involvement in the care of HIV-infected patients. Rawlings MK, et al. **J Natl Med Assoc** 1999 Jun;91(6):343–8

Terminal HIV disease and extreme poverty: a review of 307 home care files. Daneault S, et al. **J Palliat Care** 1999 Spring;15(1):6–12

Shared care in HIV and AIDS: shifting care or shifting costs? Cartledge JD, et al. **J R Coll Physicians Lond** 1998 Jul-Aug;32(4):376–9

Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. Amado RG, et al. **J Virol** 1999 Aug;73(8):6361–9

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. Shapiro MF, et al. **JAMA** 1999 Jun 23–30; 281(24):2305–15

Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998. UK NGO AIDS Consortium Working Group on Access to Treatment for HIV in Developing Countries [see comments] **Lancet** 1998 Oct 24;352(9137):1379–80 (0 ref.) . Comment in: Lancet 1999 Jan 9;353(9147):153.

British HIV Association guidelines [letter; comment] Hay P, et al. **Lancet** 1998 Oct 10;352(9135):1226. Comment on: Lancet 1998 Jul 25;352(9124):314–6.

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Levy Y, et al. **Lancet** 1999 Jun 5;353(9168):1923–9

Further clues emerge for strategies to attack HIV [news] McCarthy M. **Lancet** 1999 Jan 9;353(9147):125

British HIV Association guidelines [letter; comment] Montaner JS, et al. **Lancet** 1998 Oct 10;352(9135):1226–7 . Comment on: Lancet 1998 Jul 25;352(9124):314–6.

HAART and host: balancing the response to HIV-1. Highly active antiretroviral therapy [news] Morris K. **Lancet** 1998 Nov 21;352(9141):1686

Variation in inpatient resource use in the treatment of HIV: do the privately insured receive more care? [see comments] Joyce GF, et al. **Med Care** 1999 Mar;37(3):220–7. Comment in: Med Care 1999 Apr;37(4):325–8.

HIV pathogenesis: gp120-antibody complexes bind CD4 and kill T4 cells--immunotoxin therapy should prevent the progression of HIV to AIDS. Chaplin JW. **Med Hypotheses** 1999 Feb;52(2):133–46 (126 ref.)

Could bone marrow transplantation cure AIDS?: review. Hužička I. **Med Hypotheses** 1999 Mar;52(3):247–57 (75 ref.)

Restoring interleukin 2 production in AIDS patients [news] Dorrell S. **Mol Med Today** 1998 Dec;4(12):508

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium [see comments] Bozzette SA, et al. **N Engl J Med** 1998 Dec 24;339(26):1897–904. Comment in: N Engl J Med 1998 Dec 24;339(26):1926–8. Comment in: N Engl J Med 1999 May 13;340(19):1512–3.

Caring for people with human immunodeficiency virus infection [editorial; comment] [see comments] Steinbrook R. **N Engl J Med** 1998 Dec 24;339(26):1926–8. Comment on: N Engl J Med 1998 Dec 24;339(26):1897–904. Comment in: N Engl J Med 1999 May 13;340(19):1512–3.

Is an HIV vaccine possible? [news; comment] McMichael AJ, et al. **Nat Med** 1999 Jun;5(6):612–4. Comment on: Nat Med 1999 May;5(5):526–34. Comment on: Nat Med 1999 Jun;5(6):643–50.

Evaluating alternative treatments for HIV infection. Freeman EM, et al. **Nurs Clin North Am** 1999 Mar;34(1):147–62 (69 ref.)

The era of managed care: the struggle of cost containment and compassionate, effective care of persons with HIV/AIDS. Gallagher DM. **Nurs Clin North Am** 1999 Mar;34(1):227–35 (8 ref.)

A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Fawzi WW, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):127–33

Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV. Dieterich DT, et al. **Semin Liver Dis** 1999;19 Suppl 1:87–94 (63 ref.)

Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Schedel I, et al. **Vaccine** 1999 Apr 9; 17(15-16):1837-45

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Ugen KE, et al. **Vaccine** 1998 Nov;16(19):1818-21

Improving community care for persons with the acquired immunodeficiency syndrome in Jamaica. Bain BC. **West Indian Med J** 1998 Dec;47 Suppl 4:37-9

Magnetoliposomes may be useful for elimination of HIV from infected individuals. Babincová M, et al. **Z Naturforsch [C]** 1998 Sep-Oct;53(9-10):935-6

[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1129-33 (Eng. Abstr.) **(Dut)**

[Comparison of infectious complications of long-term and short-term central venous catheterization] Guiguet M, et al. **Presse Med** 1999 Sep 4;28(25):1347-51 (Eng. Abstr.) **(Fre)**

[Observing in HIV infections] Vittecocq D. **Presse Med** 1998 Nov 14;27(35):1818-9 **(Fre)**

[Contribution of clinical epidemiology to the management of HIV infections] Morlat P, et al. **Rev Med Interne** 1999 Aug;20(8):681-92 (50 ref.) (Eng. Abstr.) **(Fre)**

[Intermittent therapy ought to strengthen the immune system (news)] Volkert R. **Dtsch Med Wochenschr** 1999 Mar 19; 124(11):A8 **(Ger)**

[Perioperative therapy of HIV infections] Müller FP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1107-10 (Eng. Abstr.) **(Ger)**

[Immunotherapy of HIV infection] Harrer T. **Wien Med Wochenschr** 1998;148(23-24):560-6 (105 ref.) (Eng. Abstr.) **(Ger)**

[Position of the Scientific Medical Council on the antitumor studies conducted in Hungary on the Newcastle disease virus] **Orv Hetil** 1998 Nov 29;139(48):2903-5 **(Hun)**

[Rational treatment of HIV infection] Kimura T. **Nippon Naika Gakkai Zasshi** 1999 Feb 20;88 Suppl:61-4 (0 ref.) **(Jpn)**

[Impact of HIV infection in hospital environment] Martinez Avilés P, et al. **An Med Interna** 1998 Dec;15(12):633-7 (Eng. Abstr.) **(Spa)**

[The effect of human immunodeficiency virus infection on the consumption of hospital resources. A correlation with the degree of immunodeficiency] Rovira Daudi E, et al. **An Med Interna** 1999 Jan;16(1):8-14 (Eng. Abstr.) **(Spa)**

[AIDS or HIV infection? The health care implications (editorial)] Casabona J. **Med Clin (Barc)** 1999 Mar 13; 112(9):335-6 (14 ref.) **(Spa)**

[Should we include seropositive patients in autotransfusion programs?] Herranz Marti MJ, et al. **Sangre (Barc)** 1998 Aug;43(4):317-20 (32 ref.) **(Spa)**

[Hemopoietic cells from human embryonic liver in the treatment of HIV/AIDS] Pylypchak OM. **Lik Sprava** 1998 Dec;(8):116-8 (Eng. Abstr.) **(Ukr)**

TRANSMISSION

Bone bank service in Finland. Experience of bacteriologic, serologic and clinical results of the Turku Bone Bank 1972-1995 [see comments] Aho AJ, et al. **Acta Orthop Scand** 1998 Dec;69(6):559-65. Comment in: Acta Orthop Scand 1998 Dec;69(6):557-8.

Bank bone, infections and HIV [editorial; comment] Aspenberg P. **Acta Orthop Scand** 1998 Dec;69(6):557-8. Comment on: Acta Orthop Scand 1998 Dec;69(6):559-65.

Zidovudine treatment prevents vertical transmission of human immunodeficiency virus-1 independently of viral load [letter] Alonso Arias R, et al. **Acta Paediatr** 1998 Nov; 87(11):1208-9

Vertical infection of human immunodeficiency virus as an imported infectious disease. Takayama N, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):510-4

Vertical transmission of human immunodeficiency virus type 1 in Japan, 1989-1997: presence of two subtypes B and E with subtype E predominance. National Cooperative Study Investigators on Vertical Transmission of HIV-1. Yoshino N, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):503-9

Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children. **AIDS** 1999 May 28;13(8):927-33

IAS position paper on prevention of HIV 1 mother-to-child transmission. International Aids Society. **AIDS** 1999 Jul 30;13(11):5-9

Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study. **AIDS** 1999 Jul 30;13(11):1377-85

Spread of HIV infection in a rural area of Tanzania. Boerma JT, et al. **AIDS** 1999 Jul 9;13(10):1233-40

Molecular analysis of HIV-1 relatedness in a case of viral transmission during a bloody fight between two adults [letter] Brambilla A, et al. **AIDS** 1998 Oct 1;12(14):1928-30

Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Carpenter LM, et al. **AIDS** 1999 Jun 18;13(9):1083-9

New HIV cases attributable to syphilis in the USA: estimates from a simplified transmission model. Chesson HW, et al. **AIDS** 1999 Jul 30;13(11):1387-96

Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? Cohen CR, et al. **AIDS** 1999 Feb 25;13(3):327-32

Mother-to-child transmission of HIV: implications of variation in maternal infectivity. Dunn DT, et al. **AIDS** 1998 Nov 12;12(16):2211-6

Sexual risk behaviour among gay men in a relationship. Elford J, et al. **AIDS** 1999 Jul 30;13(11):1407-11

What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective [editorial] Hu DJ, et al. **AIDS** 1999 May 28;13(8):873-81 (120 ref.)

Self-reported sexual behaviour and HIV risk taking among men who have sex with men in Fortaleza, Brazil. Kerr-Pontes LR, et al. **AIDS** 1999 Apr 16;13(6):709-17

Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Kupfer B, et al. **AIDS** 1999 Jun 18;13(9):1025-8

Two successive HIV contaminations from subjects in the window period [letter] Laperche S, et al. **AIDS** 1998 Jul 30;12(11):1397-8

Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility [editorial] Marks G, et al. **AIDS** 1999 Feb 25;13(3):297-306 (119 ref.)

Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. Mock PA, et al. **AIDS** 1999 Feb 25;13(3):407-14

Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV [editorial; comment] Newell ML, et al. **AIDS** 1998 Sep 10; 12(13):1571-80 (24 ref.). Comment on: AIDS 1998 Sep 10;12(13):1675-82.

Lack of demonstrable association between use of a cervicovaginal mucosal irritant and HIV infection in female commercial sex workers in Thailand [letter] Palanuvej T, et al. **AIDS** 1998 Nov 12;12(16):2230-1

Who may be engaging in high-risk sex due to medical treatment advances? [letter] Remien RH, et al. **AIDS** 1998 Aug 20;12(12):1560-1

Oral sex and HIV transmission [letter] Robinson EK, et al. **AIDS** 1999 Apr 16;13(6):737-8 (16 ref.)

Social network dynamics and HIV transmission. Rothenberg RB, et al. **AIDS** 1998 Aug 20;12(12):1529-36

Oral transmission of HIV [editorial] Rothenberg RB, et al. **AIDS** 1998 Nov 12;12(16):2095-105 (126 ref.)

Sexual behaviours, perception of risk of HIV infection, and factors associated with attending HIV post-test counselling in Ethiopia. Sahlu T, et al. **AIDS** 1999 Jul 9;13(10):1263-72

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. Schechter MT, et al. **AIDS** 1999 Apr 16;13(6):F45-51

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. Sperling RS, et al. **AIDS** 1998 Oct 1;12(14):1805-13

Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. Tachet A, et al. **AIDS** 1999 May 7;13(7):823-31

Mother-to-child transmission of HIV-1: the 'all mucosal' hypothesis as a predominant mechanism of transmission [editorial] Van de Perre P. **AIDS** 1999 Jun 18;13(9):1133-8

Occupational risk of HIV infection among western health care professionals posted in AIDS endemic areas. de Graaf R, et al. **AIDS Care** 1998 Aug;10(4):441-52

A model to explain the relationship between sexual abuse and HIV risk among women. Miller M. **AIDS Care** 1999 Feb;11(1):3-20

Partner notification with HIV-infected drug users: results of formative research. Rogers SJ, et al. **AIDS Care** 1998 Aug;10(4):415-29

Relationship of HIV testing and high-risk behaviors among clients in methadone maintenance treatment. Grella CE, et al. **AIDS Educ Prev** 1998 Oct;10(5):403-16

Sexual and drug use behaviors among women crack users: implications for prevention. Logan TK, et al. **AIDS Educ Prev** 1998 Aug;10(4):327-40

Genital infection of female chimpanzees with human immunodeficiency virus type 1. Girard M, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1357-67

Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. Goudsmit J, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1483-6

Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission. Hahn T, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):875-88

Domestic transmission of HIV type 1 subtype G strains in Taiwan. Lee CN, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1137-40

HIV type 1 transmission probabilities: estimates from epidemiological studies. Mastro TD, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S223-7 (50 ref.)

Horizontal transmission of human immunodeficiency virus type 1 from father to child. Salvatori F, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1679-85

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection. Zamarchi R, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):337-44

Women inmates' risky sex and drug behaviors: are they related? Cotten-Oldenburg NU, et al. **Am J Drug Alcohol Abuse** 1999 Feb;25(1):129-49

Readmissions to drug abuse treatment and HIV risk behavior. McCusker J, et al. **Am J Drug Alcohol Abuse** 1998 Nov; 24(4):523-40

Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Vittinghoff E, et al. **Am J Epidemiol** 1999 Aug 1;150(3):306-11

AIDS & HIV: evidence of actual exposure--Majca v. Beekil. Sinclair PS. **Am J Law Med** 1998;24(4):513-4

Human Immunodeficiency Virus Postexposure Management of Healthcare Workers. Symposium proceedings. Atlanta, Georgia, USA. March 4-5, 1996. **Am J Med** 1997 May 19;102(5B):1-126

Efficacy of zidovudine in preventing HIV transmission from mother to infant. Balsley J. **Am J Med** 1997 May 19; 102(5B):45-6

Human immunodeficiency virus postexposure management of healthcare workers: report of a workshop. Bell DM, et al. **Am J Med** 1997 May 19;102(5B):1-3

Provider-to-patient transmission [news] **Am J Nurs** 1999 May;99(5):17

The use of human immunodeficiency virus postexposure prophylaxis after successful artificial insemination. Bloch M, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):760-1

Bloodless cesarean delivery and perinatal transmission of the human immunodeficiency virus [letter; comment] Ghidini A, et al. **Am J Obstet Gynecol** 1999 May;180(5):1308-9. Comment on: Am J Obstet Gynecol 1998 Sep;179(3 Pt 1):708-14.

Tympano-ossicular allografts and HIV transmission. Janssens de Varebeke S, et al. **Am J Otol** 1998 Nov;19(6):704-8

Sexual and mother-to-child transmission of the human immunodeficiency virus type 1: a review. Chermann JC. **Am J Reprod Immunol** 1998 Sep;40(3):183-6 (46 ref.)

Vertical transmission of HIV: parameters which might affect infection of placental trophoblasts by HIV-1: a review. Biomed Group on the Study of in Utero Transmission of HIV 1. Moussa M, et al. **Am J Reprod Immunol** 1999 May; 41(5):312-9 (82 ref.)

Reliability of the timeline follow-back sexual behavior interview. Weinhardt LS, et al. **Ann Behav Med** 1998 Winter;20(1):25-30

Provider-to-patient HIV transmission: how to keep it exceedingly rare [editorial; comment] Gerberding J. **Ann Intern Med** 1999 Jan 5;130(1):64-5. Comment on: Ann Intern Med 1999 Jan 5;130(1):1-6.

Probable transmission of HIV from an orthopedic surgeon to a patient in France [see comments] Lot F, et al. **Ann Intern Med** 1999 Jan 5;130(1):1-6. Comment in: Ann Intern Med 1999 Jan 5;130(1):64-5.

The early natural history of vertically transmitted HIV-1 infection in African children from Durban, South Africa. Bobat R, et al. **Ann Trop Paediatr** 1998 Sep;18(3):187-96

Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Kashuba AD, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1817-26 (141 ref.)

Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Baron S, et al. **Arch Intern Med** 1999 Feb 8;159(3):303-10

A survey of potential risk factors for HIV transmission through dental practice in Japan. Aizawa F, et al. **Asia Pac J Public Health** 1998;10(1):21-8

Timing and mechanism of perinatal human immunodeficiency virus-1 infection. Phuapradit W. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):293-7 (46 ref.)

Commission set up to deal with HIV infected doctors in Spain [news] Bosch X. **BMJ** 1998 Oct 10;317(7164):970

Breast feeding reduces morbidity. The risk of HIV transmission requires risk assessment--not a shift to formula feeds [editorial; comment] Latham MC. **BMJ** 1999 May 15;318(7194):1303-4. Comment on: BMJ 1999 May 15;318(7194):1316-20.

Short course antiretroviral regimens to reduce maternal transmission of HIV [editorial] Wilkinson D, et al. **BMJ** 1999 Feb 20;318(7182):479-80

HIV testing and prevention issues for women attending termination assessment clinics. Bergenstrom A, et al. **Br J Fam Plann** 1999 Apr;25(1):3-8

HIV and sexually transmitted disease. Weber J. **Br Med Bull** 1998;54(3):717-29 (28 ref.)

Two variants of HIV-1 B serotype are transmitted heterosexually in São Paulo, Brazil. Casseb J, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1243-6

Reducing HIV transmission [news] Elliott EB. **Can Fam Physician** 1999 Feb;45:519-20

AIDS related knowledge and sexual behaviour among commercial farm residents in Zimbabwe. Chikovore J, et al. **Cent Afr J Med** 1999 Jan;45(1):7-10

Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Ippolito G, et al. **Clin Infect Dis** 1999 Feb; 28(2):365-83 (122 ref.)

Risk of HIV transmission [letter; comment] Tessman I. **Clin Pediatr (Phila)** 1998 Sep;37(9):581. Comment on: Clin Pediatr (Phila) 1998 Mar;37(3):175-8.

New expanded guidelines for preventing HIV [news] **CMAJ** 1999 Jul 27;161(2):122

Link between HIV risk and other STDs debated at forum. Silversides A. **CMAJ** 1999 Apr 6;160(7):1048

The impact of a split-second error. Thompson SK. **CMAJ** 1999 May 4;160(9):1351

Canada's drug problem: time to get serious [letter; comment] Voth EA. **CMAJ** 1999 Feb 23;160(4):477, 479. Comment on: CMAJ 1998 Sep 8;159(5):451-4.

Are HIV lookbacks worthwhile? Outcome of an exercise to notify patients treated by an HIV infected health care worker. Incident Management Teams [see comments] Donnelly M, et al. **Commun Dis Public Health** 1999 Jun; 2(2):126-9. Comment in: Commun Dis Public Health 1999 Jun;2(2):79-81.

Targets for antenatal HIV testing announced. **Commun Dis Rep CDR Wkly** 1999 Aug 20;9(34):297, 300

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Sep 24; 9(39):353-4

AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1998 Oct 23; 8(43):385-8

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1998 Aug 28; 8(35):315-6

HIV infected women and genital health. Barton SE. **Curr Opin Obstet Gynecol** 1998 Oct;10(5):375-8 (16 ref.)

Sexually transmitted diseases and HIV. A female perspective. Horgan M, et al. **Dermatol Clin** 1998 Oct;16(4):847-51, xv-xvi

Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California. Gleghorn AA, et al. **Drug Alcohol Depend** 1998 Aug 1; 51(3):219-27

Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1. Menu E, et al. **Early Pregnancy** 1997 Dec;3(4):245-58 (130 ref.)

CCR5 genotype and human immunodeficiency virus type 1 infection in perinatally exposed infants. Villalba N, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):389-91

Risk to the health care worker of HIV infection and how to minimize It. Cheung RJ, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):769-82 (110 ref.)

AIDS treatment advances and behavioral prevention setbacks: preliminary assessment of reduced perceived threat of HIV-AIDS. Kalichman SC, et al. **Health Psychol** 1998 Nov;17(6):546-50

Mother-to-child transmission of human immunodeficiency virus in Italy: temporal trends and determinants of infection. The Italian Collaborative Study on HIV infection in pregnancy. **Hum Reprod** 1999 Jan;14(1):242-6

Dr. P. C. Sen Memorial Award Paper. A study of HIV infection in thalassaemia patients of rural Bengal. Sur D, et al. **Indian J Public Health** 1998 Jul-Sep;42(3):81-7

Institutional liability for needlestick injury [letter] Tereskerz PM, et al. **Infect Control Hosp Epidemiol** 1998 Oct; 19(10):737

A review of statistical methods for estimating the risk of vertical human immunodeficiency virus transmission. Dunn DT. **Int J Epidemiol** 1998 Dec;27(6):1064-7 (26 ref.)

Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi. Ioannidis JP, et al. **Int J Epidemiol** 1999 Aug;28(4):769-75

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Prins M, et al. **Int J Epidemiol** 1999 Jun;28(3):541-9

HIV: mother to child transmission, current knowledge and on-going studies. Giaquinto C, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S161-5 (22 ref.)

Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Lee MJ, et al. **Int J Gynaecol Obstet** 1998 Dec;63(3):247-52

Sexually transmitted diseases and human immunodeficiency virus infection: cause, effect, or both? [editorial; comment] Cohen MS, et al. **Int J Infect Dis** 1998 Jul-Sep;3(1):1-4. Comment on: Int J Infect Dis 1998 Jul-Sep;3(1):5-11.

Host factors that affect sexual transmission of HIV [editorial; comment] Cohen OJ, et al. **Int J Infect Dis** 1998 Apr-Jun; 2(4):182-5 (38 ref.). Comment on: Int J Infect Dis 1998 Apr-Jun;2(4):186-95.

CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study [see comments] Denny TN, et al. **Int J Infect Dis** 1998 Apr-Jun; 2(4):186-92. Comment in: Int J Infect Dis 1998 Apr-Jun;2(4):182-5.

Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study [see comments] Perez G, et al. **Int J Infect Dis** 1998 Jul-Sep;3(1):5-11. Comment in: Int J Infect Dis 1998 Jul-Sep;3(1):1-4.

Otitis media in children with vertically-acquired HIV infection: the Great Ormond Street Hospital experience. Shapiro NL, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):69-75

HIV infection and pregnancy. de Ruiter A, et al. **Int J STD AIDS** 1998 Nov;9(11):647-54; quiz 655 (34 ref.)

Changing patterns of HIV transmission and better targeting for intervention strategies. Donisi A, et al. **Int J STD AIDS** 1998 Dec;9(12):740-3

HIV/AIDS in Bangladesh. an assessment of biomedical risk factors for transmission. Gibney L, et al. **Int J STD AIDS** 1999 May;10(5):338-46 (83 ref.)

Network structural dynamics and infectious disease propagation. Potterat JJ, et al. **Int J STD AIDS** 1999 Mar; 10(3):182-5

Perinatal transmission--successful interventions. Where do we go from here? Wilfert CM, et al. **Int J STD AIDS** 1998; 9 Suppl 1:22-7

Mother-to-child transmission of human immunodeficiency virus (HIV) in Ireland: a prospective study. Nourse CB, et al. **Ir J Med Sci** 1998 Jul-Sep;167(3):145-8

Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: results of the 1996 National Household Survey on Drug Abuse. Anderson JE, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):148-56

Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):259-65

Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. Pedraza MA, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):120-5

CCR5, vertical transmission of HIV-1, and disease progression. European Collaborative Study [letter] Bailey AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):211-2

Neonatal characteristics and outcome in a cohort of infants born to HIV-1-infected African women from Durban, South Africa [letter] Bobat R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):408-9

Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group. Pitt J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):462-70

Epidemiologic evidence for time variation in HIV infectivity. Shiboski SC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):527-35

Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. Stratton P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):179-86

Changes in HIV risk behaviors among cocaine-using methadone patients. Magura S, et al. **J Addict Dis** 1998; 17(4):71-90

Stimulant abuse treatment as HIV prevention. Shoptaw S, et al. **J Addict Dis** 1998;17(4):19-32

Substance use and risky sexual behavior among homeless and runaway youth. Bailey SL, et al. **J Adolesc Health** 1998 Dec;23(6):378-88

HIV update: misinformation persists [editorial] Meskin LH. **J Am Dent Assoc** 1999 Sep;130(9):1260, 1262

Prevention of perinatal transmission of HIV in Arkansas. Darville T, et al. **J Ark Med Soc** 1998 Nov;95(6):239-41

Transmission of an azole-resistant isogenic strain of Candida albicans among human immunodeficiency virus-infected family members with oropharyngeal candidiasis. Müller FM, et al. **J Clin Microbiol** 1999 Oct;37(10):3405-8

Elective cesarean delivery to prevent vertical transmission of HIV. DuBard CA, et al. **J Fam Pract** 1999 Jul; 48(7):493-4

Milk-borne transmission of HIV. Characterization of productively infected cells in breast milk and interactions between milk and saliva. Southern SO. **J Hum Virol** 1998 Jul-Aug;1(5):328-37

Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. McDyer JF, et al. **J Immunol** 1999 Mar 15;162(6):3711-7

Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. Wasik TJ, et al. **J Immunol** 1999 Apr 1; 162(7):4355-64

Early mortality of undiagnosed but prevalent (in 1983-1984) HIV infection in Lothian injectors who tested hepatitis B surface antigen positive (group A) or negative but were high risk for blood-borne virus transmission (group B) in 1983-1984. Gore SM, et al. **J Infect** 1998 Sep;37(2):166-72

HIV-1 Infection, Mucosal Immunity and Pathogenesis. Conference proceedings. Bethesda, Maryland, USA. 11-13 September 1997. **J Infect Dis** 1999 May;179 Suppl 3:S391-498

Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. Beyrer C, et al. **J Infect Dis** 1999 Jan;179(1):59-67

Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. Fultz PN, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S418-21

Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. Hocini H, et al. **J Infect Dis** 1999 May;179 Suppl 3:S448-53 (35 ref.)

Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. ARIEL Project Investigators [published erratum appears in J Infect Dis 1999 Jun;179(6):1593] Jin X, et al. **J Infect Dis** 1998 Nov;178(5):1317-26

Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. Perinatal AIDS Collaborative Transmission Study. Kuhn L, et al. **J Infect Dis** 1999 Jan;179(1):52-8

Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. Lathey JL, et al. **J Infect Dis** 1999 Aug;180(2):344-50

Effect of chemokine receptor mutations on heterosexual human immunodeficiency virus transmission. Lockett SF, et al. **J Infect Dis** 1999 Sep;180(3):614-21

Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1 [published erratum appears in J Infect Dis 1999 Apr;179(4):1053] Menu E, et al. **J Infect Dis** 1999 Jan;179(1):44-51

T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV. Miller CJ, et al. **J Infect Dis** 1999 May;179 Suppl 3:S413-7

High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. Nelson KE, et al. **J Infect Dis** 1999 Aug;180(2):337-43

Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. Neutra MR. **J Infect Dis** 1999 May;179 Suppl 3:S441-3 (16 ref.)

Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. Overbaugh J, et al. **J Infect Dis** 1999 May;179 Suppl 3:S401-4 (11 ref.)

Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. Papaevangelou V, et al. **J Infect Dis** 1998 Oct; 178(4):1047-52

Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. Semba RD, et al. **J Infect Dis** 1999 Jul;180(1):93-8

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431-5 (33 ref.)

Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. Smith PD, et al. **J Infect Dis** 1999 May;179 Suppl 3:S436-40 (20 ref.)

Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? Van de Perre P. **J Infect Dis** 1999 May;179 Suppl 3:S405-7 (17 ref.)

A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness [see comments] Wilkinson DA, et al. **J Infect Dis** 1998 Oct;178(4):1163-6. Comment in: J Infect Dis 1999 May;179(5):1310-2.

Health care professionals and treatment of HIV-positive patients. Is there an affirmative duty to treat under common law, the Rehabilitation Act, or the Americans with Disabilities Act? White CC. **J Leg Med** 1999 Mar; 20(1):67-113 (309 ref.)

Antenatal screening for HIV in the UK: what is to be done? [editorial] [see comments] Nicoll A. **J Med Screen** 1998; 5(4):170-1 (31 ref.). Comment in: J Med Screen 1999;6(2):111-2.

Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission. Hayakawa T, et al. **J Med Virol** 1998 Dec;56(4):327-31

Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission. Mazza C, et al. **J Med Virol** 1999 May;58(1):59-62

HIV risk differences between African-American and white men who have sex with men. Heckman TG, et al. **J Natl Med Assoc** 1999 Feb;91(2):92-100

Occupational exposure to HIV: experience at a tertiary care center. Swotinsky RB, et al. **J Occup Environ Med** 1998 Dec;40(12):1102-9

Occurrence of anti-thyroid autoantibodies in children vertically infected with HIV-1. Fundarò C, et al. **J Pediatr Endocrinol Metab** 1998 Nov-Dec;11(6):745-50

Developing surveillance for HIV transmission and risk behaviours among high-risk groups in a central London health district. Nardone A, et al. **J Public Health Med** 1999 Jun;21(2):208-14

Proceedings of the Ares Serono Foundation Workshop on HIV-1 and Gametes. Siena, Italy, October 14-17, 1997. **J Reprod Immunol** 1998 Dec;41(1-2):1-377

HIV and germinal cells: how close an association? Alexander NJ. **J Reprod Immunol** 1998 Dec;41(1-2):17-26 (62 ref.)

Transmission of HIV to the placenta, fetus and mother and implications of gametic infection. Douglas GC, et al. **J Reprod Immunol** 1998 Dec;41(1-2):321-9 (48 ref.)

Sperm as infection-potentiating cofactors in HIV transmission. Scofield VL. **J Reprod Immunol** 1998 Dec; 41(1-2):359-72 (58 ref.)

Update on vertical HIV transmission. Groginsky E, et al. **J Reprod Med** 1998 Aug;43(8):637-46 (72 ref.)

Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. Pasquier C, et al. **J Virol** 1998 Nov;72(11):8493-501

JAMA Patient Page. HIV/AIDS. **JAMA** 1999 Aug 11; 282(6):606

When is breastfeeding not best? The dilemma facing HIV-infected women in resource-poor settings [editorial; comment] Fowler MG, et al. **JAMA** 1999 Aug 25; 282(8):781-3. Comment on: JAMA 1999 Aug 25;282(8):744-9.

Trends in perinatal transmission of HIV/AIDS in the United States [see comments] Lindegren ML, et al. **JAMA** 1999 Aug 11;282(6):531-8. Comment in: JAMA 1999 Aug 11;282(6):577-9.

HIV transmission through breastfeeding: a study in Malawi [see comments] Miotti PG, et al. **JAMA** 1999 Aug 25; 282(8):744-9. Comment in: JAMA 1999 Aug 25;282(8):781-3.

Can perinatal HIV infection be eliminated in the United States? [editorial; comment] Mofenson LM. **JAMA** 1999 Aug 11;282(6):577-9. Comment on: JAMA 1999 Aug 11;282(6):531-8.

Perinatal HIV prevention. Stephenson J. **JAMA** 1999 Aug 18;282(7):625

Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: the case for restraint. Stringer JS, et al. **JAMA** 1999 May 26; 281(20):1946-9

Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures [letter] Tack PC, et al. **JAMA** 1999 Mar 24-31; 281(12):1085-6

Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration [see comments] [published erratum appears in Lancet 1999 May 15;353(9165):1714] **Lancet** 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Mar 27;353(9158):1030-1. Comment in: Lancet 1999 Jun 26;353(9171):2240. Comment in: Lancet 1999 Jun 26;353(9171):2240-1.

Science, ethics, and the future of research into maternal infant transmission of HIV-1. Perinatal HIV Intervention Research in Developing Countries Workshop participants [see comments] **Lancet** 1999 Mar 6;353(9155):832-5 (23 ref.) . Comment in: Lancet 1999 May 29;353(9167):1878; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1878-9; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879-80; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1880-1.

Prevention of vertical HIV-1 transmission [letter; comment] Anderson JR, et al. **Lancet** 1999 Jun 26;353(9171):2240-1 . Comment on: Lancet 1999 Mar 27;353(9158):1035-9.

Concern voiced over "dry sex" practices in South Africa [news] Baleta A. **Lancet** 1998 Oct 17;352(9136):1292

Perinatal HIV-1 transmission discussed in Geneva [news; comment] Bradbury J, et al. **Lancet** 1998 Jul 4;352(9121):39 . Comment on: Lancet 1998 Aug 29;352(9129):737.

Court order for HIV-1 test for baby. Brahams D. **Lancet** 1999 Sep 11;354(9182):884

Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable [comment] Cohen OJ, et al. **Lancet** 1999 Aug 28;354(9180):697-8. Comment on: Lancet 1999 Aug 28;354(9180):729-33.

Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group [see comments] Coutsoudis A, et al. **Lancet** 1999 Aug 7;354(9177):471-6. Comment in: Lancet 1999 Aug 7;354(9177):442-3.

6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Dabis F, et al. **Lancet** 1999 Mar 6; 353(9155):786-92

HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers [letter] Descamps V, et al. **Lancet** 1999 May 29;353(9167):1855-6

IOM recommends routine HIV tests in pregnancy [news] Droste TM. **Lancet** 1998 Oct 17;352(9136):1294

Tackling mother-to-child HIV in Côte d'Ivoire [news] Feinmann J. **Lancet** 1997 Oct 11;350(9084):1084

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Foëx B. **Lancet** 1999 May 29;353(9167):1879; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Late postnatal mother-to-child transmission of HIV-1 [letter; comment] Glynn JR, et al. **Lancet** 1998 Nov 14; 352(9140):1630. Comment on: Lancet 1998 Aug 22;352(9128):597-600.

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Golden B, et al. **Lancet** 1999 Jul 10;354(9173):158-9. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission? Goldenberg RL, et al. **Lancet** 1998 Dec 12;352(9144):1927-30

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Greco DB. **Lancet** 1999 May 29;353(9167):1880-1. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Guay LA, et al. **Lancet** 1999 Sep 4; 354(9181):795-802

Elective caesarean section for prevention of vertical transmission of HIV-1 infection [comment] [see comments] Hudson CN. **Lancet** 1999 Mar 27;353(9158):1030-1. Comment on: Lancet 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Jun 26;353(9171):2241.

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Isturiz RE. **Lancet** 1999 May 29;353(9167):1879-80; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Urethral Trichomonas vaginalis infection and HIV-1 transmission [letter] Jackson DJ, et al. **Lancet** 1997 Oct 11;350(9084):1076

Inquiries launched after Australian girl contracts HIV from blood transfusion [news] Loff B, et al. **Lancet** 1999 Jul 31; 354(9176):404

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Lurie P, et al. **Lancet** 1999 May 29;353(9167):1878-9; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Marseille E, et al. **Lancet** 1999 Sep 4;354(9181):803-9

Infant feeding and HIV-1 transmission [see comments] Newell ML. **Lancet** 1999 Aug 7:354(9177):442-3. Comment in: Lancet 1999 Aug 7;354(9177):471-6.

Nosocomial child-to-child transmission of HIV [letter] Nielsen H, et al. **Lancet** 1998 Nov 7;352(9139):1520

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Omene JA. **Lancet** 1999 May 29;353(9167):1878; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group [see comments] Shaffer N, et al. **Lancet** 1999 Mar 6;353(9155):773-80. Comment in: Lancet 1999 Jul 10;354(9173):156; discussion 157-8. Comment in: Lancet 1999 Jul 10;354(9173):158.

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Pediatric AIDS Clinical Trials Group 076 Study Group [letter; comment] Shapiro DE, et al. **Lancet** 1999 Jul 10;354(9173):156; discussion 157-8. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Prevention of vertical HIV-1 transmission [letter; comment] Shields JW. **Lancet** 1999 Jun 26;353(9171):2241. Comment on: Lancet 1999 Mar 6,353(9155):766-7. Comment on: Lancet 1999 Mar 27:353(9158):1030-1.

Prevention of vertical HIV-1 transmission [letter; comment] Skinner J, et al. **Lancet** 1999 Jun 26;353(9171):2240. Comment on: Lancet 1999 Mar 27;353(9158):1035-9.

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Wiktor SZ, et al. **Lancet** 1999 Mar 6;353(9155):781-5

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Wilson D. **Lancet** 1999 Jul 10;354(9173):156-8. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Wolffers I. **Lancet** 1999 Jul 10;354(9173):158. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Transmission of antiretroviral-drug-resistant HIV-1 variants [see comments] Yerly S, et al. **Lancet** 1999 Aug 28; 354(9180):729-33. Comment in: Lancet 1999 Aug 28;354(9180):697-8.

The differential infectivity and staged progression models for the transmission of HIV. Hyman JM, et al. **Math Biosci** 1999 Feb;155(2):77-109

The inter-relation of maternal immune competence, HIV-1 viral load, and nutritional status in preventing vertical transmission: an alternative to chemoprophylaxis? Moran PJ, et al. **Med Hypotheses** 1998 Nov;51(5):389-97

Casual household transmission of human immunodeficiency virus. Razel M. **Med Hypotheses** 1998 Aug;51(2):115-24

HIV transmission in a prison system in an Australian State [see comments] Dolan KA, et al. **Med J Aust** 1999 Jul 5;171(1):14-7. Comment in: Med J Aust 1999 Jul 5;171(1):7-8.

Should research ethics change at the border? [letter; comment] Lurie P, et al. **Med J Aust** 1999 Aug 2; 171(3):167-8. Comment on: Med J Aust 1998 Nov 16;169(10):509-10.

The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not [letter; comment] Sullivan LG. **Med J Aust** 1999 Aug 2; 171(3):165-6. Comment on: Med J Aust 1999 Mar 1;170(5):220-1.

The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group [see comments] **N Engl J Med** 1999 Apr 1;340(13):977-87. Comment in: N Engl J Med 1999 Apr 1;340(13):1032-3. Comment in: N Engl J Med 1999 Jul 15;341(3):205; discussion 206-7. Comment in: N Engl J Med 1999 Jul 15;341(3):205-6; discussion 206-7. Comment in: N Engl J Med 1999 Jul 15;341(3):206-7.

Mode of delivery and the risk of vertical transmission of HIV-1 [letter; comment] Beckerman KP, et al. **N Engl J Med** 1999 Jul 15;341(3):205-6; discussion 206-7 . Comment on: N Engl J Med 1999 Apr 1;340(13):977-87.

Short courses of zidovudine and perinatal transmission of HIV [letter; comment] Feiterna-Sperling C, et al. **N Engl J Med** 1999 Apr 1;340(13):1040-1; discussion 1042-3. Comment on: N Engl J Med 1998 Nov 12;339(20):1409-14.

Short courses of zidovudine and perinatal transmission of HIV [letter; comment] Fiscus SA, et al. **N Engl J Med** 1999 Apr 1;340(13):1040-1; discussion 1042-3. Comment on: N Engl J Med 1998 Nov 12;339(20):1409-14.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group [see comments] Garcia PM, et al. **N Engl J Med** 1999 Aug 5;341(6):394-402 . Comment in: N Engl J Med 1999 Aug 5;341(6):441-3.

Mode of delivery and the risk of vertical transmission of HIV-1 [letter; comment] Gelber RD, et al. **N Engl J Med** 1999 Jul 15;341(3):206-7. Comment on: N Engl J Med 1999 Apr 1;340(13):977-87.

Potential for the transmission of HIV-1 despite highly active antiretroviral therapy [editorial; comment] Haase AT, et al. **N Engl J Med** 1998 Dec 17;339(25):1846-8. Comment on: N Engl J Med 1998 Dec 17;339(25):1803-9.

Mode of delivery and the risk of vertical transmission of HIV-1 [letter; comment] Landers DV, et al. **N Engl J Med** 1999 Jul 15;341(3):205; discussion 206-7. Comment on: N Engl J Med 1999 Apr 1;340(13):977-87.

Short (and shorter) courses of zidovudine [editorial; comment] McIntosh K. **N Engl J Med** 1998 Nov 12; 339(20):1467-8. Comment on: N Engl J Med 1998 Nov 12;339(20):1409-14.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team [see comments] Mofenson LM, et al. **N Engl J Med** 1999 Aug 5;341(6):385-93. Comment in: N Engl J Med 1999 Aug 5;341(6):441-3.

Elective cesarean delivery to reduce the transmission of HIV [editorial; comment] Riley LE, et al. **N Engl J Med** 1999 Apr 1;340(13):1032-3. Comment on: N Engl J Med 1999 Apr 1;340(13):977-87.

Reducing the risk of maternal-infant transmission of HIV by attacking the virus [editorial; comment] Rogers MF, et al. **N Engl J Med** 1999 Aug 5;341(6):441-3. Comment on: N Engl J Med 1999 Aug 5;341(6):385-93. Comment on: N Engl J Med 1999 Aug 5;341(6):394-402.

Short courses of zidovudine and perinatal transmission of HIV [letter; comment] Shaffer N, et al. **N Engl J Med** 1999 Apr 1;340(13):1042-3. Comment on: N Engl J Med 1998 Nov 12;339(20):1409-14.

Bragdon v. Abbott: the Americans with Disabilities Act and HIV infection [letter; comment] Tessman I. **N Engl J Med** 1999 Apr 15;340(15):1212-3; discussion 1213-4. Comment on: N Engl J Med 1998 Oct 22;339(17):1255-9.

Short courses of zidovudine and perinatal transmission of HIV [letter; comment] Thomas P, et al. **N Engl J Med** 1999 Apr 1;340(13):1041; discussion 1042-3. Comment on: N Engl J Med 1998 Nov 12;339(20):1409-14.

Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus [see comments] Wade NA, et al. **N Engl J Med** 1998 Nov 12;339(20):1409-14. Comment in: N Engl J Med 1998 Nov 12;339(20):1467-8. Comment in: N Engl J Med 1999 Apr 1;340(13):1040-1; discussion 1042-3. Comment in: N Engl J Med 1999 Apr 1;340(13):1041; discussion 1042-3. Comment in: N Engl J Med 1999 Apr 1;340(13):1041-2; discussion 1042-3. Comment in: N Engl J Med 1999 Apr 1;340(13):1042-3.

Donating blood and the perceived risk of HIV infection [letter; comment] Siebers R. **N Z Med J** 1999 May 28; 112(1088):191. Comment on: N Z Med J 1999 Apr 9;112(1085):121-3.

Due process or French farce? [editorial] **Nature** 1999 Feb 18;397(6720):545

Scientists defend French ex-ministers in blood trial [news] Butler D. **Nature** 1999 Feb 18;397(6720):548

Former Pasteur head defends politicians [news] Butler D. **Nature** 1999 Feb 25;397(6721):635

Diagnosis disclosure by family caregivers to children who have perinatally acquired HIV disease: when the time comes [see comments] Ledlie SW. **Nurs Res** 1999 May-Jun; 48(3):141-9. Comment in: Nurs Res 1999 May-Jun;48(3):119.

Breast-feeding, mastitis, and HIV transmission: nutritional implications. Semba RD, et al. **Nutr Rev** 1999 May;57(5

Pt 1):146–53 (100 ref.)

PHS recommendations for the management of health-care worker exposures to HIV--Part 2. **Oncology (Huntingt)** 1998 Oct;12(10):1447–9, 1453–4, 1457 passim

AIDS drugs effective against most common HIV strain [news] **Oncology (Huntingt)** 1999 Mar;13(3):392

Paediatric HIV infection. Friesen H. **P N G Med J** 1996 Sep;39(3):183–9 (7 ref.)

HIV infections in obstetrics and gynaecology. Mola G. **P N G Med J** 1996 Sep;39(3):190–5 (8 ref.)

Effective HIV/AIDS strategies, policies and programs for the correctional centre system. Munro D. **P N G Med J** 1996 Sep;39(3):230–3 (0 ref.)

New epidemiological problem in Poland: vertical transmission of human immunodeficiency virus. Lech MM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):459–62

Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression. Esposito S, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):847–9

The natural history of human immunodeficiency virus 1 infection in Haitian infants. Jean SS, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):58–63

Risks of human immunodeficiency virus transmission from artificial insemination from an infected donor. Mayer KH. **Pediatr Infect Dis J** 1999 Mar;18(3):310–1

Issues related to human immunodeficiency virus transmission in schools, child care, medical settings, the home, and community. American Academy of Pediatrics. Committee of Pediatric AIDS and Committee on Infectious Diseases. **Pediatrics** 1999 Aug;104(2 Pt 1):318–24 (53 ref.)

Factors associated with nonuse of condoms in heterosexual men and women attending an HIV testing clinic in Israel. Soskolne V, et al. **Public Health Rev** 1998;26(2):175–87

Troublesome diagnosis in two children born to HIV-1 infected mothers. Liberatore D, et al. **Rev Argent Microbiol** 1998 Jul–Sep;30(3):143–6

Research of antigen and antibodies from retroviruses, CMV and HBV among prisoners of the penitentiary complex of the region of Campinas, SP, Brazil. Osti NM, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul–Aug;40(4):209–13

HIV/STD transmission in gold-mining areas of Bolívar State, Venezuela: interventions for diagnosis, treatment, and prevention. Faas L, et al. **Rev Panam Salud Publica** 1999 Jan;5(1):58–65

The mother-to-child HIV transmission debate [letter; comment] Beyers N, et al. **S Afr Med J** 1999 Feb;89(2):104, 106. Comment on: S Afr Med J 1998 Oct;88(10):1283.

Breast is still best [letter] Chopra M. **S Afr Med J** 1999 May; 89(5):490

The mother-to-child HIV transmission debate [letter; comment] Hussey G, et al. **S Afr Med J** 1999 Feb; 89(2):103–4. Comment on: S Afr Med J 1998 Oct;88(10):1304–6.

The mother-to-child HIV transmission debate [letter; comment] Joubert JR, et al. **S Afr Med J** 1999 Feb;89(2):106 . Comment on: S Afr Med J 1998 Oct;88(10):1283.

Use of antiviral agents in pregnant women with HIV infection [letter] Nash E, et al. **S Afr Med J** 1999 Jul; 89(7):704

Free drug short course for needle stick injuries [news] van der Linde I. **S Afr Med J** 1998 Sep;88(9):1062–3

Confronting AIDS--a plea for a national dried milk formula. Woods DL. **S Afr Med J** 1998 Aug;88(8):948–9

Cheap treatment cuts HIV transmission [news] Cohen J. **Science** 1999 Feb 12;283(5404):916–7

Uses and abuses of Tuskegee. Fairchild AL, et al. **Science** 1999 May 7;284(5416):919–21

HIV strain analysis debuts in murder trial [news] Vogel G. **Science** 1998 Oct 30;282(5390):851,853

Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy [see comments] Spina M, et al. **Sex Transm Dis** 1998 Oct;25(9):451–4. Comment in: Sex Transm Dis 1998 Oct;25(9):455–6.

From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Fleming DT, et al. **Sex Transm Infect** 1999 Feb;75(1):3–17 (81 ref.)

Heterosexual transmission of HIV in Scotland [letter; comment] Gilbart VL, et al. **Sex Transm Infect** 1998 Aug; 74(4):306–7. Comment on: Sex Transm Infect 1998 Feb;74(1):77.

Doing a shotgun: a drug use practice and its relationship to sexual behaviors and infection risk. Perlman DC, et al. **Soc Sci Med** 1999 May;48(10):1441–8

HIV/AIDS in nonurban Alabama: risk activities and access to services among HIV-infected persons. Beltrami JF, et al. **South Med J** 1999 Jul;92(7):677–83

Opening the AIDS door [editorial; comment] Kidson C. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):427–8. Comment on: Southeast Asian J Trop Med Public Health 1998 Sep;29(3):429–42.

From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in Northern Thailand [see comments] Thaineua V, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):429–42. Comment in: Southeast Asian J Trop Med Public Health 1998 Sep;29(3):427–8.

Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: bayesian estimation using a mixture. Chouquet C, et al. **Stat Med** 1999 Apr 15;18(7):815–33

Semi-parametric models for mismeasured exposure information in vaccine trials. Golm GT, et al. **Stat Med** 1998 Oct 30;17(20):2335–52

The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments [see comments] Bourgois P. **Subst Use Misuse** 1998 Sep;33(11):2323–51. Comment in: Subst Use Misuse 1998 Sep;33(11):2353–5. Comment in: Subst Use Misuse 1998 Sep;33(11):2357–9. Comment in: Subst Use Misuse 1998 Sep;33(11):2361–3. Comment in: Subst Use Misuse 1998 Sep;33(11):2365–8.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Courtwright DT. **Subst Use Misuse** 1998 Sep;33(11):2353–5. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–4.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Fielding NG. **Subst Use Misuse** 1998 Sep;33(11):2361–3. Comment on: Subst Use Misuse 1998 Sep;33(11):2361–3.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Johnson TP. **Subst Use Misuse** 1998 Sep;33(11):2365–8. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–51.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Latkin CA. **Subst Use Misuse** 1998 Sep; 33(11):2375–82

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Leshner AI. **Subst Use Misuse** 1998 Sep;33(11):2369–74

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Lilja J, et al. **Subst Use Misuse** 1998 Sep;33(11):2357–9. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–51.

Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Purgus R, et al. **Transplantation** 1998 Nov 27;66(10):1384–6

Zidovudine against mother-to-child HIV transmission [letter; comment] Colebunders R, et al. **Trop Med Int Health** 1999 Mar;4(3):237–8. Comment on: Trop Med Int Health 1998 Sep;3(9):689–90.

Zidovudine to prevent mother-to-infant HIV transmission in developing countries: a view from Thailand [letter; comment] Kumphitak A, et al. **Trop Med Int Health** 1999 Mar;4(3):236–7; discussion 237–8. Comment on: Trop Med Int Health 1998 Sep;3(9):689–90.

Partner violence and sexual HIV-risk behaviors among women in an inner-city emergency department. El-Bassel N, et al. **Violence Vict** 1998 Winter;13(4):377–93

Drug use and syphilis. Co-factors for HIV transmission among commercial sex workers in Guyana. Persaud NE, et al. **West Indian Med J** 1999 Jun;48(2):52–6

[New preventive possibilities in HIV infection] Nielsen JO. **Nord Med** 1998 Nov;113(9):287–9 (Eng. Abstr.) **(Dan)**

[Vertical HIV-1-transmission. I. Risk and prevention in pregnancy (see comments)] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12;142(50):2720–4 (27 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2720–4. **(Dut)**

[Antiretroviral therapy and prevention of maternal-fetal transmission of HIV-1. Current and future strategies] Monpoux F, et al. **Arch Pediatr** 1999 May;6(5):556–65 (70 ref.) (Eng. Abstr.) **(Fre)**

[Guidelines in accidental injury of a caretaker in contact with a blood product in the framework of HIV infection] Daher M, et al. **J Med Liban** 1998 May–Jun;46(3):156–9 **(Fre)**

[Influence of irradiation on the risk of HIV virus transmission by bone allograft] Hernigou P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):493–500 (Eng. Abstr.) **(Fre)**

[Perinatal HIV transmission prophylaxis in the Liege region] Jacquet Y, et al. **Rev Med Liege** 1998 Aug;53(8):475–8 (Eng. Abstr.) **(Fre)**

[Vertical transmission: healthy children--a new UNAIDS initiative (news)] Volkert R. **Dtsch Med Wochenschr** 1998 Sep 18;123(38):A9 **(Ger)**

[Long-term observation on children. HIV-positive pregnant women: AZT therapy to be continued] Gürtler L. **Fortschr Med** 1999 Mar 20;117(8):6 **(Ger)**

[Post-exposure prophylaxis. What to do when nosocomial infection by HBV, HCV or HIV is suspected?] Gürtler L. **Fortschr Med** 1999 Jan 30;117(3):18–20 **(Ger)**

[Nosocomial hepatitis B virus, hepatitis C virus and HIV infections by infectious medial personnel] Hasselhorn HM, et al. **Gesundheitswesen** 1998 Oct;60(10):545–51 (38 ref.) (Eng. Abstr.) **(Ger)**

[Transmission of infectious diseases during imprisonment--results of a study and introduction of a model project for infection prevention in Lower Saxony] Keppler K, et al. **Gesundheitswesen** 1999 Apr;61(4):207–13 (Eng. Abstr.) **(Ger)**

[Epidemiology and transmission of HIV infection] Rockstroh JK. **Pharm Unserer Zeit** 1999 Mar;28(2):95–101 (19 ref.) **(Ger)**

[The probability of transmission of the human immunodeficiency virus] Spadea T, et al. **Epidemiol Prev** 1999 Apr–Jun;23(2):77–83 (53 ref.) (Eng. Abstr.) **(Ita)**

[Maternal-fetal transmission of HCV. Role of HIV as a risk factor] Catalano D, et al. **Minerva Ginecol** 1999 Apr; 51(4):117–9 (Eng. Abstr.) **(Ita)**

[Maternal viral and gestational risk factors in vertical transmission of HIV-1 infection] Greco P, et al. **Minerva Ginecol** 1998 Nov;50(11):449–54 (Eng. Abstr.) **(Ita)**

[The influence of authorization to oral contraceptive on HIV infection among university students] Arakawa O, et al. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):204–15 **(Jpn)**

[Laboratory diagnosis of viral infections. 9. Viral infections related to blood transfusion and organ transplantation] Miyamoto A, et al. **Rinsho Byori** 1998 Nov;Suppl 108:111–5 (6 ref.) **(Jpn)**

[Latent AIDS in young children of mothers who were HIV-negative in the first trimester of pregnancy] Cunha M, et al. **Acta Med Port** 1998 Jul;11(7):691–5 (Eng. Abstr.) **(Por)**

[The behavioral risk factors for contracting HIV infection in the intravenous administration of narcotics in abusers of psychoactive substances in the city of Rostov-on-Don] Saukhat SR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):97–8 (Eng. Abstr.) **(Rus)**

[HIV infection in children perinatally infected] Voronin EE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):16–8 (Eng. Abstr.) **(Rus)**

[Intravenous drug use and transmission of AIDS (editorial)] Suvaković V. **Srp Arh Celok Lek** 1998 Nov–Dec; 126(11–12):417–22 **(Scc)**

[Transmission of acquired immunodeficiency syndrome among intravenous drug abusers in Belgrade] Suvaković V, et al. **Srp Arh Celok Lek** 1998 Nov–Dec; 126(11–12):437–45 (Eng. Abstr.) **(Scc)**

[The persistence of risky conduct for HIV transmission among intravenous drug users in Madrid, Seville, and Valencia. The Working Group of the Médicos del Mundo for the Monitoring of HIV Infection and the Risk Practices of Intravenous Drug Users (see comments)] Bravo MJ, et al. **Gac Sanit** 1999 Mar–Apr;13(2):109–18 (Eng. Abstr.). Comment in: Gac Sanit 1999 Mar–Apr;13(2):79–81. **(Spa)**

[AIDS patients with an unclassified risk factor for HIV] Martinez Alonso JL, et al. **Gac Sanit** 1999 Mar–Apr; 13(2):119–25 (Eng. Abstr.) **(Spa)**

[Intrafamilial transmission of the human immunodeficiency virus associated with palliative care (letter)] Prados MD, et al. **Med Clin (Barc)** 1998 Oct 10;111(11):437–8 **(Spa)**

[Prevalence of human immunodeficiency virus infection and behaviors associated with its transmission among parenteral drug users selected on the street] Rodés A, et al. **Med Clin (Barc)** 1998 Oct 3;111(10):372–7 (Eng. Abstr.) **(Spa)**

[The standardization of the criteria for the prevention of occupational postexposure to the human immunodeficiency virus] Haro Pérez AM, et al. **Rev Clin Esp** 1999 Apr; 199(4):233–8 (89 ref.) **(Spa)**

[Vertical transmission rate of the immunodeficiency virus: determinant factors and comparison of results] Sanz Aliaga SA, et al. **Rev Clin Esp** 1998 Sep;198(9):571–9 (58 ref.) (Eng. Abstr.) **(Spa)**

URINE

Urine antibody tests: new insights into the dynamics of HIV-1 infection. Urnovitz HB, et al. **Clin Chem** 1999 Sep; 45(9):1602–13

Evaluation of serum and urinary estrogen levels in male patients with HIV-infection. Teichmann J, et al. **Eur J Med Res** 1998 Nov 17;3(11):533–7

Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection. Herman RA, et al. **Pharmacotherapy** 1999 Jun;19(6):734–40

Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Noormohamed SE, et al. **Ren Fail** 1998 Jul;20(4):627–33

VIROLOGY

Bilateral optic neuritis in acute human immunodeficiency virus infection. Larsen M, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):737–8

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. Delta Coordinating Committee and Delta Virology Committee. **AIDS** 1999 Jan 14;13(1):57–65

HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A, et al. **AIDS** 1999 Jul 30; 13(11):1305–11

Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom? [letter] Aizawa S, et al. **AIDS** 1999 Jul 9;13(10):1278–9

Similar rate of disease progression among individuals infected

with HIV-1 genetic subtypes A-D. Alaeus A, et al. **AIDS** 1999 May 28;13(8):901-7

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. Alexander CS, et al. **AIDS** 1999 May 28;13(8):981-5

Diagnosis of HIV-1/2 dual infection using dilution analysis of type-specific antibody [letter] Ariyoshi K, et al. **AIDS** 1998 Dec 24;12(18):2504-5

Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. Birk M, et al. **AIDS** 1998 Dec 24;12(18):2369-75

Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis [editorial] Brack-Werner R. **AIDS** 1999 Jan 14;13(1):1-22 (216 ref.)

Molecular analysis of HIV-1 relatedness in a case of viral transmission during a bloody fight between two adults [letter] Brambilla A, et al. **AIDS** 1998 Oct 1;12(14):1928-30

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. Bratt G, et al. **AIDS** 1998 Nov 12;12(16):2193-202

Immunologic and virologic response of HIV-2 infection to antiretroviral therapy [letter] Clark NM, et al. **AIDS** 1998 Dec 24;12(18):2506-7

Selective vertical transmission of HIV-1 antiretroviral resistance mutations. Colgrove RC, et al. **AIDS** 1998 Dec 3;12(17):2281-8

HIV-1 subtypes and plasma RNA quantification [letter] Damond F, et al. **AIDS** 1999 Feb 4;13(2):286-8

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. de Jong JJ, et al. **AIDS** 1999 Jan 14;13(1):75-80

HIV-1 subtypes in Santiago, Chile [letter] Desgranges C, et al. **AIDS** 1998 Aug 20;12(12):1563-5

The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic [letter] Devereux H, et al. **AIDS** 1999 Jan 14;13(1):142

Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women largely treated with antiretroviral agents [letter] Di Stefano M, et al. **AIDS** 1999 May 28;13(8):992-4

Immune activation and plasma viral load in HIV-infected African individuals [letter] Dyer JR, et al. **AIDS** 1999 Jul 9;13(10):1283-5

Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. Eron JJ, et al. **AIDS** 1998 Oct 22;12(15):F181-9

Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women [letter] Fiore JR, et al. **AIDS** 1999 Apr 1;13(5):626-7

Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. Furrer H, et al. **AIDS** 1998 Jul 30; 12(11):1341-6

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. Harrigan PR, et al. **AIDS** 1999 May 28; 13(8):F59-62

What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective [editorial] Hu DJ, et al. **AIDS** 1999 May 28;13(8):873-81 (120 ref.)

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. Ibáñez A, et al. **AIDS** 1999 Jun 18;13(9):1045-9

Interpatient genetic variability of HIV-1 group O. Janssens W, et al. **AIDS** 1999 Jan 14;13(1):41-8

High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy [letter] Jubault V, et al. **AIDS** 1998 Dec 3;12(17):2358-9

Vaccination and HIV-1 replication during highly active antiretroviral therapy [letter] Kroon FP, et al. **AIDS** 1999 Jan 14;13(1):135-6

Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. Lieberman J, et al. **AIDS** 1999 May 28;13(8):891-9

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17-21

High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population [letter] Loveday C, et al. **AIDS** 1999 Apr 1;13(5):627-8

Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients [letter] Magiorkinis E, et al. **AIDS** 1999 Jul 9;13(10):1276-8

HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions. El Messaoudi K, et al. **AIDS** 1999 Feb 25;13(3):333-9

Improved estimates for HIV-1 clearance rate and intracellular delay [letter] Mittler JE, et al. **AIDS** 1999 Jul 30;13(11):1415-7

Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. Mock PA, et al. **AIDS** 1999 Feb 25;13(3):407-14

Rebound of plasma HIV viral load following prolonged suppression with combination therapy [letter] Montaner JS, et al. **AIDS** 1998 Jul 30;12(11):1398-9

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. Neumann AU, et al. **AIDS** 1999 Apr 16;13(6):677-83

Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. Nkengasong JN, et al. **AIDS** 1998 Aug 20;12(12):1405-12

Use of dried whole blood spots for quantification of HIV-1 RNA [letter] O'Shea S, et al. **AIDS** 1999 Apr 1;13(5):630-1

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Palmer S, et al. **AIDS** 1999 Apr 16; 13(6):661-7

In vivo HIV-1 replicative capacity in early and advanced infection. Phillips AN, et al. **AIDS** 1999 Jan 14;13(1):67-73

Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent. Rae S, et al. **AIDS** 1998 Nov 12;12(16):2185-92

Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. Renwick N, et al. **AIDS** 1998 Dec 24;12(18):2481-8

Introduction of HIV drug-resistance testing in clinical practice [editorial] Rodriguez-Rosado R, et al. **AIDS** 1999 Jun 18;13(9):1007-14 (47 ref.)

High frequency of the 3'A mutation of the SDF-1 gene in Cambodia [letter] Rousset D, et al. **AIDS** 1999 Feb 25; 13(3):420-1

Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. Ruiz L, et al. **AIDS** 1999 Jan 14;13(1):F1-8

Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES [letter] Rusconi S, et al. **AIDS** 1999 Jun 18;13(9):1144-5

Sex differences in HIV-1 viral load and TNF-alpha plasmatic level? [letter] Savès M, et al. **AIDS** 1999 Jul 30; 13(11):1414-5

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. Schmit JC, et al. **AIDS** 1998 Oct 22; 12(15):2007-15

Rebound of HIV-1 viral load after suppression to very low levels [letter] Staszewski S, et al. **AIDS** 1998 Dec 3; 12(17):2360

Virological response to protease inhibitor therapy in an HIV clinic cohort. Staszewski S, et al. **AIDS** 1999 Feb 25; 13(3):367-73

Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS, et al. **AIDS** 1999 Jan 14;13(1):89-96

Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. Tachet A, et al. **AIDS** 1999 May 7;13(7):823-31

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. Tamalet C, et al. **AIDS** 1998 Oct 1;12(14):F161-6

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. Tebas P, et al. **AIDS** 1999 Feb 4;13(2):F23-8

Tissue distribution of Epstein-Barr virus genotypes in hosts coinfected by HIV. Triantos D, et al. **AIDS** 1998 Nov 12; 12(16):2141-6

V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection [letter] Vallejo A, et al. **AIDS** 1999 Mar 11; 13(4):532-4

Sexual transmission of HIV: infectiousness and prevention. Vernazza PL, et al. **AIDS** 1999 Feb 4;13(2):155-66 (150 ref.)

Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. Vidal C, et al. **AIDS** 1998 Jul 30;12(11):1285-9

Selection of HIV-1 genotypes by cultivation in different primary cells. von Briesen H, et al. **AIDS** 1999 Feb 25; 13(3):307-15

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. Weverling GJ, et al. **AIDS** 1998 Jul 30;12(11):F117-22

Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? [letter; comment] Wu H, et al. **AIDS** 1999 Feb 25; 13(3):429-30. Comment on: AIDS 1998 Aug 20;12(12):1483-90.

HIV type 1 sequences with GGC substitution in injecting drug users in Greece. Adwan G, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):679-80

nef sequences of primary HIV type 1 isolates from northern India. Ahmad KM, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1491-3

Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. Alacus A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):889-94

Molecular characterization of the envelope transmembrane glycoprotein of 13 new human immunodeficiency virus type 1 group O strains from six different African countries. Bibollet-Ruche F, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1281-5

HIV type 1 gag D/env G recombinants in Russia. Bobkov A, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20; 14(17):1597-9

Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. Bruisten SM, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1053-8

A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda. Buonaguro L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1287-9

Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. Candotti D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):309-14

HIV type 1 subtypes in Guangxi Province, China, 1996. Chen J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):81-4

Primary intestinal epithelial cells can be infected with laboratory-adapted strain HIV type 1 NDK but not with clinical primary isoiates. Chenine AL, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1235-8

Virology and immunology of acute HIV type 1 infection. Daar ES. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S229-34 (80 ref.)

HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1-infected individuals. Diaz RS, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1151-6

Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon. Dittmar MT, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):707-12

Human immunodeficiency virus type 1 subtypes B and C detected in New Zealand. Dwyer DE, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1105-8

Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. Ellenberger DL, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):3-9

HIV type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal, and Western Cape Provinces of South Africa. Engelbrecht S, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):325-8

Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. Goudsmit J, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1483-6

HIV type 1 C2V3 env diversity among Belgian individuals. Heyndrickx L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1291-6

Genetic characterization of the nef gene from human immunodeficiency virus type 1 group M strains representing genetic subtypes A, B, C, E, F, G, and H. Jubier-Maurin V, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):23-32

Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. Kato K, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1; 15(13):1157-68

Characterization of V3 loop sequences from HIV type 1 subtype B in South Korea: predominance of the GPGS motif. Kim EY, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):681-6

Molecular phylogenetic analysis of human immunodeficiency virus type 1 strains obtained from Korean patients: env gene sequences. Kim YB, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):303-7

HIV type 1 infection in lymphoid tissue: natural history and model systems. Kitchen SG, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S235-9 (54 ref.)

HIV type 1 subtypes of nonhemophiliac patients in Japan. Kitsutani PT, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1099-103

HIV type 1 env subtype E in Cambodia. Kusagawa S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):91-4

Virtually full-length sequences of HIV type 1 subtype J reference strains. Laukkanen T, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):293-7

Domestic transmission of HIV type 1 subtype G strains in Taiwan. Lee CN, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1137-40

Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1299-303

Subtypes of HIV type 1 circulating in India: partial envelope sequences. Maitra A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):941-4

HIV type 1 genetic variability in the northern part of Cameroon. Mboudjeka I, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):951-6

Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. Min J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):51-5

Genetic heterogeneity of HIV type 1 subtypes in Kimpese, rural Democratic Republic of Congo. Mokili JL, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):655-64

Molecular epidemiological analysis of human immunodeficiency virus type 1 in Newfoundland, Canada. Montpetit ML, et al. **AIDS Res Hum Retroviruses** 1998

Sep 1;14(13):1205–9
DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G. Naghavi MH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):485–8
Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. Nasioulas G, et al. **AIDS Res Hum Retroviruses** 1999 May 20; 15(8):745–58
Analysis of the V3 loop sequences from 12 HIV type 1–infected patients from Colombia, South America. Navas MC, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1141–4
Molecular epidemiology of an HIV-1 subtype A subcluster among injection drug users in the Southern Ukraine. Novitsky VA, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1079–85
Full-length genomic sequence of an HIV type 1 subtype G from Kinshasa. Oelrichs RB, et al.
AIDS Res Hum Retroviruses 1999 Apr 10;15(6):585–9
Genetic characterization of the V3 loop sequences of 21 HIV type 1 Spanish isolates from hemophilia patients. Ortiz M, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1487–90
The subtypes of HIV type 1 in Greece. Papa A, et al.
AIDS Res Hum Retroviruses 1998 Sep 20;14(14):1297–8
Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. Pieniazek D, et al.
AIDS Res Hum Retroviruses 1999 Apr 10;15(6):603–8
Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. Quiñones-Mateu ME, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):73–9
Molecular epidemiology of HIV type 1 isolates from the Czech Republic: identification of an env E subtype case. Quiñones-Mateu ME, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):85–9
Quantitative intracellular kinetics of HIV type 1. Reddy B, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):273–83
Cell-associated viral RNA expression during acute infection with HIV type 1. Riggs NL, et al.
AIDS Res Hum Retroviruses 1998 Sep 1;14(13):1141–9
Genetic analysis of human immunodeficiency virus type 1 strains in Kenya: a comparison using phylogenetic analysis and a combinatorial melting assay. Robbins KE, et al.
AIDS Res Hum Retroviruses 1999 Mar 1;15(4):329–35
Phylogenetic examination of HIV type 1 glycoprotein 120–V3 sequences in patients from rural Georgia. Roth WW, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):399–403
9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells. Sadaie MR, et al.
AIDS Res Hum Retroviruses 1999 Feb 10;15(3):239–45
Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1–only seropositives in Ghana. Sagoe KW, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):775–9
Genetic characterization of viral quasispecies in blood and cervical secretions of HIV-1– and HIV-2–infected women. Sankalé JL, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1473–81
Analysis of sequence diversity in the C2–V3 regions of the external glycoproteins of HIV type 1 in Singapore. Se-Thoe SY, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1601–4
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):65–9
Independent evolution of HIV type 1 in different brain regions. Shapshak P, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):811–20
The presence and absence of histocompatibility antigens in HIV type 1 produced by autologous blood-derived macrophages and peripheral blood lymphoblasts. Tsai WP, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):33–41
A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. Van Harmelen JH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):395–8
No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects. Visco-Comandini U, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):609–17
High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. Walther-Jallow L, et al.
AIDS Res Hum Retroviruses 1999 Jul 20;15(11):957–62
Quantitation of 8 human herpesviruses in peripheral blood of human immunodeficiency virus–infected patients and healthy blood donors by polymerase chain reaction. Hoang MP, et al. **Am J Clin Pathol** 1999 May;111(5):655–9
Risk factors for HIV-1 shedding in semen. Speck CE, et al. **Am J Epidemiol** 1999 Sep 15;150(6):622–31
Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Twigg HL, et al. **Am J Respir Crit Care Med** 1999 May; 159(5 Pt 1):1439–44
Role of human immunodeficiency virus in primary pulmonary hypertension--case reports. Pellicelli AM, et al. **Angiology** 1998 Dec;49(12):1005–11
Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Haase AT. **Annu Rev Immunol** 1999;17:625–56 (158 ref.)
Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):253–8
Viral loads in dual infection with HIV-1 and cytomegalovirus. Boriskin YS, et al. **Arch Dis Child** 1999 Feb;80(2):132–6
Nitric oxide inhibits HIV-1 replication in human astrocytoma cells. Persichini T, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):200–2
Producer cell-dependent requirement of the Nef protein for efficient entry of HIV-1 into cells. Tokunaga K, et al.
Biochem Biophys Res Commun 1998 Sep 29;250(3):565–8
The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency [editorial] Mathé G. **Biomed Pharmacother** 1998;52(10):413–20 (49 ref.)
Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Ylisastigui L, et al.
Biomed Pharmacother 1998;52(10):447–53
Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. Chelucci C, et al. **Blood** 1999 Sep 1; 94(5):1590–600
GATA-1 transcription factor transactivates the promoter for CCR5, a coreceptor for human immunodeficiency virus type 1 entry [letter] Moriuchi M, et al. **Blood** 1999 Feb 15;93(4):1433–5
Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients. Witt DJ, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):369–76
CD8+ T cell-mediated enhancement of tumour necrosis factor-alpha (TNF-alpha) production and HIV-1 LTR-driven gene expression in human monocytic cells is pertussis toxin-sensitive. Copeland KF, et al.
Clin Exp Immunol 1999 Jun;116(3):479–85
Viral load and CD69 molecule expression on freshly isolated and cultured mitogen-stimulated lymphocytes of children with perinatal HIV-1 infection. De Martino M, et al.
Clin Exp Immunol 1999 Sep;117(3):513–6
Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection. Jobe O, et al.
Clin Exp Immunol 1999 Jun;116(3):474–8
Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J.
Clin Infect Dis 1998 Nov;27(5):1309–10
Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Ahuja TS, et al. **Clin Nephrol** 1999 Jan;51(1):40–4
HIV: The deadly passenger in dendritic cells. Rowland-Jones SL. **Curr Biol** 1999 Apr 8;9(7):R248–50 (11 ref.)
HIV-2 and T cell recognition. Whittle HC, et al.
Curr Opin Immunol 1998 Aug;10(4):382–7 (66 ref.)
HIV-1 subtype F in single and dual infections in Puerto Rico: A potential sentinel site for monitoring novel genetic HIV variants in North America [letter] Flores I, et al.
Emerg Infect Dis 1999 May-Jun;5(3):481–3
Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. Pieniazek D, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):649–56
Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Ramos A, et al.
Emerg Infect Dis 1999 Jan-Feb;5(1):65–74
Induction of the heat-shock response by antiviral prostaglandins in human cells infected with human immunodeficiency virus type 1. de Marco A, et al.
Eur J Biochem 1998 Sep 1;256(2):334–41
Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. Vandamme AM, et al. **Eur J Clin Invest** 1999 May;29(5):445–52
Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes. Holguin A, et al.
Eur J Clin Microbiol Infect Dis 1999 Apr;18(4):256–9
Transgenic mice expressing human HIV receptors become persistently recipient of HIV DNA after injection with infected human cell lines. Simeoni L, et al.
Folia Microbiol (Praha) 1998;43(5):525–6
Increasing prevalence of dual HIV-1–2 infections among voluntary blood donors in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Dec;52(12):548–52
Corneal, anterior segment, and adnexal manifestations of human immunodeficiency virus. Acharya NR, et al.
Int Ophthalmol Clin 1998 Fall;38(4):161–77 (189 ref.)
HIV-1 reactivation in resting peripheral blood mononuclear cells of infected adults upon in vitro CD4 cross-linking by ligands of the CDR2-loop in extracellular domain 1. Briant L, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):9–19
Decreased peripheral circulation of HIV-infected cells in a subset of long-term nonprogressors. The French ALT Study Group [letter] Candotti D, et al.
J Acquir Immune Defic Syndr 1999 Jul 1;21(3):253–5
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1–infected patients. Chien JW, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):277–80
Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study. Daar ES, et al.
J Acquir Immune Defic Syndr 1999 Aug 1;21(4):317–25
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. Gisslén M, et al.
J Acquir Immune Defic Syndr 1999 Aug 1;21(4):271–6
Increase of HIV-1 subtype A in Central African Republic. Müller-Trutwin MC, et al.
J Acquir Immune Defic Syndr 1999 Jun 1;21(2):164–71
Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. Pedraza MA, et al.
J Acquir Immune Defic Syndr 1999 Jun 1;21(2):120–5
Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. Weisman Z, et al.
J Acquir Immune Defic Syndr 1999 Jun 1;21(2):157–63
Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. Chen YM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 1;19(4):393–402
HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid. Eggers CC, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Mar 1;20(3):259–64
Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. Ioannidis JP, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):129–36
Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. Kitayaporn D, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1;19(3):289–95
Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. Marschner IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):220–7
HIV-1 dynamics in children. Melvin AJ, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 15;20(5):468–73
Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia. Menu E, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 15;20(5):481–7
Introduction of HIV-1 subtype A in the French West Indies [letter] Ouka M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1;19(3):308–10
Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil [letter] Pinto ME, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1;19(3):310–2
V3 serotyping of HIV-1 infection: correlation with genotyping and limitations. Plantier JC, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 15;20(5):432–41
Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research. Rompalo AM, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 15;20(5):448–54
Primary subtype C HIV-1 infection in Harare, Zimbabwe. Tien PC, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):147–53
The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. Bowles NE, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):857–65
Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. Patton LL, et al.
J Am Dent Assoc 1999 Sep;130(9):1313–22 (66 ref.)
New study showed average costs of care for HIV in managed care were lower for patients with undetectable viral loads [news] **J Assoc Nurses AIDS Care** 1999 Mar-Apr; 10(2):87–8
Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo. de Baar MP, et al. **J Clin Microbiol** 1999 Jan;37(1):63–7
Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. Dyer JR, et al.
J Clin Microbiol 1999 Feb;37(2):447–9
Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. Gomes P, et al.
J Clin Microbiol 1999 Feb;37(2):453–6
Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays. Raboud JM, et

al. **J Clin Microbiol** 1998 Nov;36(11):3369–71

Evaluation of the Nuclisens HIV-1 QT assay for quantitation of human immunodeficiency virus type 1 RNA levels in plasma. Segondy M, et al. **J Clin Microbiol** 1998 Nov; 36(11):3372–4

Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. Segondy M, et al. **J Clin Microbiol** 1998 Nov;36(11):3392–5

Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. Zazzi M, et al. **J Clin Microbiol** 1999 Feb;37(2):333–8

Variations in HIV-RNA viral load and CD4 counts of infants and children receiving antiretroviral drug therapy [letter] Sever JL, et al. **J Clin Virol** 1999 Jan;12(1):71–4

Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. Bukrinskaya A, et al. **J Exp Med** 1998 Dec 7;188(11):2113–25

Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. Bogers WM, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2895–903

Effect of splenectomy on T-cell subsets and plasma HIV viral titers in HIV-infected patients. Bernard NF, et al. **J Hum Virol** 1998 Jul-Aug;1(5):338–45

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients. Fontaine E, et al. **J Hum Virol** 1998 Nov-Dec; 1(7):451–6

Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates. Gartner S, et al. **J Hum Virol** 1997 Nov-Dec;1(1):3–18

Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease. Nicastri E, et al. **J Hum Virol** 1998 Jan-Feb;1(2):90–5

Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections. Sarr AD, et al. **J Hum Virol** 1999 Jan-Feb; 2(1):45–51

Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. Shaheen F, et al. **J Hum Virol** 1999 May-Jun;2(3):154–66

Changes in circulating levels of HIV, CD4, and tissue expression of HIV in a patient with recent-onset ulcerative colitis treated by surgery. Case report. Silver S, et al. **J Hum Virol** 1999 Jan-Feb;2(1):52–7

Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. Sugiura W, et al. **J Hum Virol** 1999 May-Jun;2(3):146–53

IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. Bailer RT, et al. **J Immunol** 1999 Jun 15;162(12):7534–42

A simple and robust method for the complete dissociation of HIV-1 p24 and other antigens from immune complexes in serum and plasma samples. Steindl F, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):143–51

Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. Balotta C, et al. **J Infect Dis** 1999 Aug; 180(2):285–9

Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification. Berger C, et al. **J Infect Dis** 1999 Jan;179(1):240–4

Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. Buseyne F, et al. **J Infect Dis** 1998 Oct;178(4):1019–23

Human immunodeficiency virus type 1 subtypes differ in disease progression. Kanki PJ, et al. **J Infect Dis** 1999 Jan; 179(1):68–73

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. Koot M, et al. **J Infect Dis** 1999 Jan;179(1):254–8

Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. Kully C, et al. **J Infect Dis** 1999 Mar;179(3):705–8

Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. Lefrère JJ, et al. **J Infect Dis** 1999 Apr; 179(4):783–9

Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. Lefrère JJ, et al. **J Infect Dis** 1999 Aug; 180(2):526–9

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Miller MD, et al. **J Infect Dis** 1999 Jan;179(1):92–100

Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. Overbaugh J, et al. **J Infect Dis** 1999 May;179 Suppl 3:S401–4 (11 ref.)

Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy. Romano L, et al. **J Infect Dis** 1999 Feb;179(2):361–6

The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. Sulkowski MS, et al. **J Infect Dis** 1998 Dec;178(6):1642–8

Chemokine immunobiology in HIV-1 pathogenesis. Lee B, et al. **J Leukoc Biol** 1999 May;65(5):552–65 (192 ref.)

Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. Rappaport J, et al. **J Leukoc Biol** 1999 Apr;65(4):458–65 (66 ref.)

Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. Candotti D, et al. **J Med Virol** 1999 Jul;58(3):256–63

Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count. Kupfer B, et al. **J Med Virol** 1998 Nov;56(3):259–63

GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. Lefrère JJ, et al. **J Med Virol** 1999 Sep; 59(1):32–7

Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance. Puchhammer-Stöckl E, et al. **J Med Virol** 1999 Mar; 57(3):283–9

High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus. Rey D, et al. **J Med Virol** 1999 Jan;57(1):75–9

Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. Koralnik IJ, et al. **J Neurovirol** 1999 Aug;5(4):430–5

Localization of human herpesvirus type 8 (HHV-8) in the Kaposi's sarcoma tissues and the semen specimens of HIV-1 infected and uninfected individuals by utilizing in situ polymerase chain reaction. Bobroski L, et al. **J Reprod Immunol** 1998 Dec;41(1-2):149–60

Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. Byrn RA, et al. **J Reprod Immunol** 1998 Dec;41(1-2):161–76

Assisted conception in HIV discordant couples: evaluation of semen processing techniques in reducing HIV viral load. Chrystie IL, et al. **J Reprod Immunol** 1998 Dec; 41(1-2):301–6

Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. Merigan TC. **J Reprod Immunol** 1998 Dec;41(1-2):177–85

Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. Pudney J, et al. **J Reprod Immunol** 1998 Dec;41(1-2):105–25 (29 ref.)

The case against an association between HIV-1 and sperm: molecular evidence. Quayle AJ, et al. **J Reprod Immunol** 1998 Dec;41(1-2):127–36 (20 ref.)

HIV in testis: quantitative histology and HIV localization in germ cells. Shevchuk MM, et al. **J Reprod Immunol** 1998 Dec;41(1-2):69–79

Natural endogenous reverse transcription of HIV-1. Zhang H, et al. **J Reprod Immunol** 1998 Dec;41(1-2):255–60 (11 ref.)

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. Tyler DS, et al. **J Surg Res** 1998 Oct;79(2):115–20

Dynamics of macrophage and T cell infection by HIV. Wodarz D, et al. **J Theor Biol** 1999 Jan 7;196(1):101–13

Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. Bagnarelli P, et al. **J Virol** 1999 May;73(5):3764–77

R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus. Berkowitz RD, et al. **J Virol** 1999 Sep;73(9):7817–22

Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. Dorrell L, et al. **J Virol** 1999 Feb;73(2):1708–14

Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Esté JA, et al. **J Virol** 1999 Jul;73(7):5577–85

Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. Fais S, et al. **J Virol** 1999 Aug;73(8):6453–9

Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. Frank I, et al. **J Virol** 1999 Apr; 73(4):3449–54

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. Grovit-Ferbas K, et al. **J Virol** 1998 Nov;72(11):8650–8

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. Ji H, et al. **J Virol** 1999 Oct;73(10):8578–86

Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients. Karlsson AC, et al. **J Virol** 1999 Jul;73(7):6191–6

Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. Kirchhoff F, et al. **J Virol** 1999 Jul;73(7):5497–508

Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. Lewin SR, et al. **J Virol** 1999 Jul;73(7):6099–103

CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. Moir S, et al. **J Virol** 1999 Oct;73(10):7972–80

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. Mosier DE, et al. **J Virol** 1999 May;73(5):3544–50

Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. Mwaengo DM, et al. **J Virol** 1998 Nov;72(11):8976–87

Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. Neilson JR, et al. **J Virol** 1999 May;73(5):4393–403

Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. Novitsky VA, et al. **J Virol** 1999 May;73(5):4427–32

Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. Pasquier C, et al. **J Virol** 1998 Nov;72(11):8493–501

Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. Peeters M, et al. **J Virol** 1999 Sep;73(9):7368–75

Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. Quiñones-Mateu ME, et al. **J Virol** 1998 Nov;72(11):9002–15

Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. Sato H, et al. **J Virol** 1999 May;73(5):3551–9

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. Shafer RW, et al. **J Virol** 1999 Jul;73(7):6197–202

Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon. Takehisa J, et al. **J Virol** 1999 Aug;73(8):6810–20

Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. Yang X, et al. **J Virol** 1999 Apr; 73(4):3460–6

Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? Zhang YJ, et al. **J Virol** 1999 Apr;73(4):3443–8

Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. Zhang YJ, et al. **J Virol** 1998 Nov;72(11):9337–44

Effect of potentially interfering substances on the measurement of HIV-1 viral load by the bDNA assay. Alonso R, et al. **J Virol Methods** 1999 Mar;78(1-2):149–52

An international collaborative study on the detection of an HIV-1 genotype B field isolate by nucleic acid amplification techniques. Bootman J, et al. **J Virol Methods** 1999 Mar;78(1-2):21–34

Isolation of HIV-1 RNA from plasma: evaluation of seven different methods for extraction (part two). Fransen K, et al. **J Virol Methods** 1998 Dec;76(1-2):153–7

Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. Koch N, et al. **J Virol Methods** 1999 Jun; 80(1):25–31

Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus type 1 in South Africa. van Harmelen J, et al. **J Virol Methods** 1999 Mar;78(1-2):51–9

Techniques for the evaluation of nucleic acid amplification technology performance with specimens containing interfering substances: efficacy of boom methodology for extraction of HIV-1 RNA. Witt DJ, et al. **J Virol Methods** 1999 Apr;79(1):97–111

HIV-1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22-29; 282(12):1135–41. Comment in: **JAMA** 1999 Sep 22-29;282(12):1177–9.

A new HIV-1 group: abstract and commentary. Delwart E. **JAMA** 1998 Dec 9;280(22):1960

Reduced antiretroviral drug susceptibility among patients with primary HIV infection [see comments] Little SJ, et al. **JAMA** 1999 Sep 22-29;282(12):1142–9. Comment in:

JAMA 1999 Sep 22-29;282(12):1177-9.
Primary HIV-1 resistance: a new phase in the epidemic? [editorial; comment] Pomerantz RJ. **JAMA** 1999 Sep 22-29; 282(12):1177-9. Comment on: JAMA 1999 Sep 22-29;282(12):1135-41. Comment on: JAMA 1999 Sep 22-29;282(12):1142-9.
Sex differences in HIV-1 viral load and progression to AIDS [see comments] Farzadegan H, et al. **Lancet** 1998 Nov 7; 352(9139):1510-4. Comment in: Lancet 1999 Feb 13;353(9152):589; discussion 590-1. Comment in: Lancet 1999 Feb 13;353(9152):589-90; discussion 590-1. Comment in: Lancet 1999 Feb 13;353(9152):590-1.
Sex differences in HIV-1 viral load and progression to AIDS [letter; comment] Foulkes MA, et al. **Lancet** 1999 Feb 13; 353(9152):590-1. Comment on: Lancet 1998 Nov 7;352(9139):1510-4.
Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study [letter; comment] Junghans C, et al. **Lancet** 1999 Feb 13;353(9152):589; discussion 590-1 . Comment on: Lancet 1998 Nov 7;352(9139):1510-4.
Lack of sex difference in CD4 to HIV-1 RNA viral load ratio [letter] Moore RD, et al. **Lancet** 1999 Feb 6; 353(9151):463-4
Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals [letter; comment] Moroni M. **Lancet** 1999 Feb 13;353(9152):589-90; discussion 590-1. Comment on: Lancet 1998 Nov 7;352(9139):1510-4.
Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation [letter] Patterson BK, et al. **Lancet** 1999 Jan 16;353(9148):211-2
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy [letter] [see comments] Viganó A, et al. **Lancet** 1998 Dec 12; 352(9144):1905-6. Comment in: Lancet 1999 Mar 6;353(9155):840-1.
Relationship of hepatitis C viremia to HIV state and to infection by specific hepatitis C genotypes. Pérez-Gracia T, et al. **Liver** 1999 Aug;19(4):288-93
Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. Tan WY, et al. **Math Biosci** 1999 Mar 1;156(1-2):69-94
Significance of plasma and peripheral blood mononuclear cell derived HIV-1 sequences in establishing epidemiologic linkage between two individuals multiply exposed to HIV-1. Song JZ, et al. **Microb Pathog** 1999 Jun; 26(6):287-98
The distribution of HIV-1 subtypes in Fukuoka, Japan. Chijiwa K, et al. **Microbiol Immunol** 1999;43(3):271-8
Naturally attenuated HIV--lessons for AIDS vaccines and treatment [editorial; comment] Collins KL, et al. **N Engl J Med** 1999 Jun 3;340(22):1756-7. Comment on: N Engl J Med 1999 Jun 3;340(22):1715-22.
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1 [letter] Greenough TC, et al. **N Engl J Med** 1999 Jan 21;340(3):236-7
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort [see comments] Learmont JC, et al. **N Engl J Med** 1999 Jun 3;340(22):1715-22. Comment in: N Engl J Med 1999 Jun 3;340(22):1756-7.
Control of HIV despite the discontinuation of antiretroviral therapy [letter] Lisziewicz J, et al. **N Engl J Med** 1999 May 27;340(21):1683-4
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [see comments] Finzi D, et al. **Nat Med** 1999 May;5(5):512-7. Comment in: Nat Med 1999 Jun;5(6):609-11.
Dangerous T-cell amnesia [news; comment] Gorochov G. **Nat Med** 1999 May;5(5):483-4. Comment on: Nat Med 1999 May;5(5):518-25.
Evaluation of three different commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels. Aschbacher R, et al. **New Microbiol** 1999 Jan; 22(1):1-9
Virological aspects of human immunodeficiency virus infection. Catton MG. **P N G Med J** 1996 Sep;39(3):166-73 (7 ref.)
Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. Cunningham CK, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):30-5
Effect of superimposed infections on viral replication in human immunodeficiency virus type 1-infected children. Marchisio P, et al. **Pediatr Infect Dis J** 1998 Aug; 17(8):755-7
HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Marzio G, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13519-24
Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339-46 (80 ref.)
HIV's early home and inner life [news] Balter M. **Science** 1998 Nov 27;282(5394):1630-1 .
The role of chemokine receptors in HIV infection. Rowland-Jones S. **Sex Transm Infect** 1999 Jun;75(3):148-51 (40 ref.)
Design of HIV viral dynamics studies. Marschner IC. **Stat Med** 1998 Nov 15;17(21):2421-34
Estimation of HIV dynamic parameters. Wu H, et al. **Stat Med** 1998 Nov 15;17(21):2463-85
Correlation of clinical parameters and immunological function with human immunodeficiency virus plasma viremia in children. Peters VB, et al. **Viral Immunol** 1999; 12(2):139-48
Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. Andersson S, et al. **Virology** 1999 Sep 30;262(2):312-20
Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Brambilla A, et al. **Virology** 1999 Jul 5;259(2):349-68
Role of the leukocyte function antigen-1 conformational state in the process of human immunodeficiency virus type 1-mediated syncytium formation and virus infection. Fortin JF, et al. **Virology** 1999 Apr 25;257(1):228-38
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. McCutchan FE, et al. **Virology** 1999 Feb 15; 254(2):226-34
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Martínez MA, et al. **Virology** 1999 Apr 10;256(2):180-7
B cells malignantly transformed by human immunodeficiency virus are polyclonal. Rodriguez-Alfageme C, et al. **Virology** 1998 Dec 5;252(1):34-8
LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Quiñones-Mateu ME, et al. **Virus Res** 1998 Sep;57(1):11-20
[AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment] Notermans DW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1909-12 (48 ref.) (Eng. Abstr.) **(Dut)**
[Another look at the AIDS virus] Burny A. **Bull Mem Acad R Med Belg** 1998;153(2):139-43 **(Fre)**
[Resistance to antiretroviral agents: mechanism and study methods] Bossi P, et al. **Presse Med** 1998 Dec;27 Suppl 5:18-9 (Eng. Abstr.) **(Fre)**
[An unusual cause of ambiguous HIV-1 western blot pattern (letter)] Gérôme P, et al. **Presse Med** 1999 Jul 3-10; 28(24):1293-4 **(Fre)**
[Antibodies against cytomegalovirus and risk of hepatitis C (letter)] Moncharmont P, et al. **Presse Med** 1998 Apr 4; 27(13):617 **(Fre)**
[Interactions between the human immunodeficiency virus and hepatitis C virus] Pol S, et al. **Rev Med Interne** 1998 Dec; 19(12):885-91 (48 ref.) (Eng. Abstr.) **(Fre)**
[New biological monitoring of HIV infection] Morand-Joubert L. **Rev Prat** 1998 Mar 1;48(5):472-7 **(Fre)**
[New HIV-1 variant discovered in Cameroon (news)] Kowalski A. **Dtsch Med Wochenschr** 1998 Nov 20; 123(47):A7 **(Ger)**
[HIV infection. Virus resistance: development and prevention] Link R, et al. **Med Monatsschr Pharm** 1999 Mar;22(3):86-8 **(Ger)**
[Genetic characteristics of variants of human immunodeficiency virus type 1, causing an epidemic among substance abusers in Commonwealth of Independent States countries] Bobkov AF, et al. **Vopr Virusol** 1998 Nov-Dec; 43(6):253-6 (Eng. Abstr.) **(Rus)**
[Biological properties of primary HIV-1 isolates with varying serotype] Pashkova TA, et al. **Vopr Virusol** 1998 Nov-Dec; 43(6):256-61 (Eng. Abstr.) **(Rus)**
[Serological properties of HIV-1 isolates from the focus of an epidemic in the Gomel region of the Belarus Republic (1996)] Shchelkanov MIu, et al. **Vopr Virusol** 1998 Sep-Oct; 43(5):220-9 (Eng. Abstr.) **(Rus)**
[A recombinant HIV-1 strain causing an epidemic among injection drug addicts in Kaliningrad] Korovina GI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):47-9 (Eng. Abstr.) **(Rus)**
[The HTHIV27 highly productive continuous cell line and its use for solving the fundamental and applied problems of HIV infection] Miller GG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):52-7 (Eng. Abstr.) **(Rus)**
[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment] Villegas Castrejón H, et al. **Ginecol Obstet Mex** 1999 May;67:196-206 (35 ref.) (Eng. Abstr.) **(Spa)**
[The biological characterization of HIV-1 isolated in patients with a rapid clinical evolution] Lobaina Barthelemy L, et al. **Rev Cubana Med Trop** 1998;50(2):96-9 (Eng. Abstr.) **(Spa)**

HIV INTEGRASE

ANALYSIS

Analysis of the three enzymatic activities of HIV-1 integrase in vitro using minigels for detection of the reaction products. Sayasith K, et al. **Anal Biochem** 1999 Apr 10; 269(1):189-92

ANTAGONISTS & INHIBITORS see HIV INTEGRASE INHIBITORS

CHEMISTRY

HIV-1 integrase: structural organization, conformational changes, and catalysis. Asante-Appiah E, et al. **Adv Virus Res** 1999;52:351-69 (67 ref.)
HIV integrase structure and function. Esposito D, et al. **Adv Virus Res** 1999;52:319-33 (65 ref.)
Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Wlodawer A. **Adv Virus Res** 1999;52:335-50 (48 ref.)
The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Greenwald J, et al. **Biochemistry** 1999 Jul 13;38(28):8892-8
Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Yi J, et al. **Biochemistry** 1999 Jun 29;38(26):8458-68
Molecular dynamics studies on the HIV-1 integrase catalytic domain. Lins RD, et al. **Biophys J** 1999 Jun;76(6):2999-3011
Structural determinants of metal-induced conformational changes in HIV-1 integrase. Asante-Appiah E, et al. **J Biol Chem** 1998 Dec 25;273(52):35078-87
Brownian and essential dynamics studies of the HIV-1 integrase catalytic domain. Weber W, et al. **J Biomol Struct Dyn** 1998 Dec;16(3):733-45
Solution structure of the His12 --> Cys mutant of the N-terminal zinc binding domain of HIV-1 integrase complexed to cadmium. Cai M, et al. **Protein Sci** 1998 Dec; 7(12):2669-74
Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. Eijkelenboom AP, et al. **Proteins** 1999 Sep 1;36(4):556-64

DRUG EFFECTS

Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters. Desideri N, et al. **Antivir Chem Chemother** 1998 Nov;9(6):497-509
Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Hong H, et al. **Antivir Chem Chemother** 1998 Nov;9(6):461-72
Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. Zhu K, et al. **J Virol** 1999 Apr;73(4):3309-16

GENETICS

Dissecting the role of the N-terminal domain of human immunodeficiency virus integrase by trans-complementation analysis. van den Ent FM, et al. **J Virol** 1999 Apr;73(4):3176-83
Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase. Kalpana GV, et al. **Virology** 1999 Jul 5;259(2):274-85
A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions. Kulkosky J, et al. **Virology** 1999 Mar 1;255(1):77-85

IMMUNOLOGY

Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. Haas G, et al. **AIDS** 1998 Aug 20; 12(12):1427-36
Conformational aspects of HIV-1 integrase inhibition by a peptide derived from the enzyme central domain and by antibodies raised against this peptide. Maroun RG, et al. **Eur J Biochem** 1999 Feb;260(1):145-55
Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. Kitamura Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):105-14
Generation of HIV-1/HIV-2 cross-reactive peptide antisera by small sequence changes in HIV-1 reverse transcriptase and integrase immunizing peptides. Klutch M, et al. **J Biomed Sci** 1998;5(3):192-202
Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase. Ishikawa T, et al. **J Virol** 1999 May;73(5):4475-80

METABOLISM

HIV-1 integrase: structural organization, conformational changes, and catalysis. Asante-Appiah E, et al. **Adv Virus Res** 1999;52:351-69 (67 ref.)
Inhibitors of human immunodeficiency virus integrase. Pommier Y, et al. **Adv Virus Res** 1999;52:427-58 (148 ref.)
Comparison of enzymatic activities of the HIV-1 and HFV integrases to their U5 LTR substrates. Oh YT, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):621-9
The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Greenwald J, et al. **Biochemistry** 1999 Jul 13;38(28):8892-8
Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase. Yi J, et al. **Biochemistry** 1999 Jun 29;38(26):8458-68
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. Esposito D, et al. **EMBO J** 1998 Oct 1; 17(19):5832-43
High affinity interaction of HIV-1 integrase with specific and non-specific single-stranded short oligonucleotides. Caumont A, et al. **FEBS Lett** 1999 Jul 16;455(1-2):154-8
Multiple integrase functions are required to form the native

HIV INTEGRASE

structure of the human immunodeficiency virus type I intasome. Chen H, et al. **J Biol Chem** 1999 Jun 11; 274(24):17358–64

Chicoric acid analogues as HIV-1 integrase inhibitors. Lin Z, et al. **J Med Chem** 1999 Apr 22;42(8):1401–14

Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. Reddy MV, et al. **J Med Chem** 1999 Jun 3;42(11):1901–7

Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. Carteau S, et al. **J Virol** 1999 Aug;73(8):6670–9

Activity of recombinant HIV-1 integrase on mini-HIV DNA. Cherepanov P, et al. **Nucleic Acids Res** 1999 May 15;27(10):2202–10

Solution structure of the His12 —> Cys mutant of the N-terminal zinc binding domain of HIV-1 integrase complexed to cadmium. Cai M, et al. **Protein Sci** 1998 Dec; 7(12):2669–74

Application of electrospray ionization mass spectrometry for studying human immunodeficiency virus protein complexes. Loo JA, et al. **Proteins** 1998;Suppl 2:28–37

Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase. Kalpana GV, et al. **Virology** 1999 Jul 5;259(2):274–85

Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein. Pluymers W, et al. **Virology** 1999 Jun 5;258(2):327–32

PHYSIOLOGY

HIV integrase structure and function. Esposito D, et al. **Adv Virus Res** 1999;52:319–33 (65 ref.)

HIV INTEGRASE INHIBITORS

see related
ANTIVIRAL AGENTS

Inhibitors of human immunodeficiency virus integrase. Pommier Y, et al. **Adv Virus Res** 1999;52:427–58 (148 ref.)

Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. Artico M, et al. **J Med Chem** 1998 Oct 8;41(21):3948–60

CHEMICAL SYNTHESIS

Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters. Desideri N, et al. **Antivir Chem Chemother** 1998 Nov;9(6):497–509

Thiazolothiazepine inhibitors of HIV-1 integrase. Neamati N, et al. **J Med Chem** 1999 Aug 26;42(17):3334–41

CHEMISTRY

Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. Jing N, et al. **J Biol Chem** 1998 Dec 25;273(52):34992–9

IMMUNOLOGY

Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. Kitamura Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):105–14

ISOLATION & PURIFICATION

Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Hazuda D, et al. **Antivir Chem Chemother** 1999 Mar;10(2):63–70

Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Hong H, et al. **Antivir Chem Chemother** 1998 Nov;9(6):461–72

Lamellarin alpha 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. Reddy MV, et al. **J Med Chem** 1999 Jun 3;42(11):1901–7

PHARMACOLOGY

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Robinson WE Jr. **Antiviral Res** 1998 Aug; 39(2):101–11

Inhibition of HIV integrase by novel nucleotides bearing tricyclic bases. Zhang J, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1887–90

Conformational aspects of HIV-1 integrase inhibition by a peptide derived from the enzyme central domain and by antibodies raised against this peptide. Maroun RG, et al. **Eur J Biochem** 1999 Feb;260(1):145–55

Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. King PJ, et al. **J Med Chem** 1999 Feb 11;42(3):497–509

Chicoric acid analogues as HIV-1 integrase inhibitors. Lin Z, et al. **J Med Chem** 1999 Apr 22;42(8):1401–14

Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. Zhu K, et al. **J Virol** 1999 Apr;73(4):3309–16

Effect of acyclic nucleoside phosphonates on the HIV-1 integrase in vitro. Abu Sheika G, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):849–51

Synthesis of oligonucleotide-intercalator conjugates capable to inhibit HIV-1 DNA integration. Gottikh MB, et al. **Nucleosides Nucleotides** 1999 Jun-Jul;18(6-7):1645–6

Potential inhibitors of HIV integrase. Mathé C, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4-5):681–2

[The anti-HIV action of chicoric acid (news)] De Giuseppe R. **Recenti Prog Med** 1998 Dec;89(12):686 **(Ita)**

HIV LONG-TERM SURVIVORS

Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Carotenuto P, et al. **AIDS** 1998 Sep 10; 12(13):1591–600

'In an important way, I did die': uncertainty and revival in persons living with HIV or AIDS. Brashers DE, et al. **AIDS Care** 1999 Apr;11(2):201–19

Association between a defective CCR-5 gene and progression to disease in HIV infection. Balfe P, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1229–34

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. Betts MR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1219–28

Long-term nonprogression in HIV infection: methodological issues and scientific priorities. Report of an international European community-National Institutes of Health Workshop, The Royal Society, London, England, November 27–29, 1995. Scientific Coordinating Committee. Easterbrook PJ, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1211–28

Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1341–3

Isolation of HIV type 1 from long-term nonprogressors in Herpesvirus saimiri-immortalized T cells [letter] Vella C, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1145–7

No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects. Visco-Comandini U, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):609–17

Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Barker E, et al. **Blood** 1998 Nov 1;92(9):3105–14

Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Magierowska M, et al. **Blood** 1999 Feb 1;93(3):936–41

Long-term survival in a patient with AIDS and hereditary haemochromatosis [letter] Nielsen P, et al. **Eur J Haematol** 1999 Sep;63(3):202–4

Decreased peripheral circulation of HIV-infected cells in a subset of long-term nonprogressors. The French ALT Study Group [letter] Candotti D, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):253–5

HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study. Visco-Comandini U, et al. **J Hum Virol** 1998 Jul-Aug;1(5):320–7

Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. Balla-Jhagjhoorsingh SS, et al. **J Immunol** 1999 Feb 15; 162(4):2308–14

Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. Harrer T, et al. **J Immunol** 1998 Nov 1; 161(9):4875–81

Long-term non-progression in HIV infection: definitions and epidemiological issues. Easterbrook PJ. **J Infect** 1999 Mar; 38(2):71–3 (13 ref.)

Long-term non-progression in HIV infection: clinico pathological issues. Rowland-Jones S. **J Infect** 1999 Mar; 38(2):67–70 (26 ref.)

Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. Balotta C, et al. **J Infect Dis** 1999 Aug; 180(2):285–9

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP, et al. **J Infect Dis** 1999 May;179(5):1264–7

Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. Broström C, et al. **J Infect Dis** 1999 Jun;179(6):1542–8

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. Pontesilli O, et al. **J Infect Dis** 1998 Oct;178(4):1008–18

Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. Candotti D, et al. **J Med Virol** 1999 Jul;58(3):256–63

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. Grovit-Ferbas K, et al. **J Virol** 1998 Nov;72(11):8650–8

Survival with HIV infection: good luck or good breeding? Rowland-Jones SL. **Trends Genet** 1998 Sep;14(9):343–5 (36 ref.)

Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus [published erratum appears in Viral Immunol 1999;12(1):89] Nehete PN, et al. **Viral Immunol** 1998;11(3):119–29

Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Brambilla A, et al. **Virology** 1999 Jul 5;259(2):349–68

[Long-term HIV infection and dialysis dependent renal failure in analgesic nephropathy] Müller V, et al. **Ther Umsch** 1998 Sep;55(9):555–7 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Behavioral research on AIDS--protease inhibitors and the new millennium: comment on Kelly, Otto-Salaj, Sikkema, Pinkerton, and Bloom (1998). Ferrando S. **Health Psychol** 1998 Jul;17(4):307–9

Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Kelly JA, et al. **Health Psychol** 1998 Jul;17(4):310–9 (100 ref.)

Long-term nonprogressors with HIV disease. Barroso J. **Nurs Res** 1999 Sep-Oct;48(5):242–9

HIV LONG TERMINAL REPEAT

see related
GENE PRODUCTS, NEF
GENE PRODUCTS, TAT
HIV ENHANCER
TRANSCRIPTION FACTOR, SP1

Nucleosomes and regulation of gene expression. Structure of the HIV-1 5'LTR. Widlak P, et al. **Acta Biochim Pol** 1998;45(1):209–19 (28 ref.)

Transient Tat activation of the HIVLAV/Lai-1 LTR by primary HIV-1 phenotypic variants in HeLaT4LTRbeta-gal cells. Nilsen MV, et al. **APMIS** 1999 May;107(5):485–92

Comparison of enzymatic activities of the HIV-1 and HFV integrases to their U5 LTR substrates. Oh YT, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):621–9

Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA. Long KS, et al. **Biochemistry** 1999 Aug 3;38(31):10059–69

Proximity of a Tat peptide to the HIV-1 TAR RNA loop region determined by site-specific photo-cross-linking. Wang Z, et al. **Bioconjug Chem** 1999 May-Jun;10(3):512–9

Activation of the human immunodeficiency virus-1 long terminal repeat by respiratory burst oxidants of neutrophils. Klebanoff SJ, et al. **Blood** 1999 Jan 1;93(1):350–6

Dual activity of pyrrolidine dithiocarbamate on kappa B-dependent gene expression in U937 cells: I. Regulation by the phorbol ester TPA. Watanabe K, et al. **Cell Signal** 1999 Jul;11(7):479–89

CD8+ T cell-mediated enhancement of tumour necrosis factor-alpha (TNF-alpha) production and HIV-1 LTR-driven gene expression in human monocytic cells is pertussis toxin-sensitive. Copeland KF, et al. **Clin Exp Immunol** 1999 Jun;116(3):479–85

Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. Bieniasz PD, et al. **EMBO J** 1998 Dec 1;17(23):7056–65

Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Adelson ME, et al. **Eur J Biochem** 1999 Sep;264(3):806–15

Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. Litovchick A, et al. **FEBS Lett** 1999 Feb 19;445(1):73–9

Transcriptional activation of NF-kappa B activity by Epstein-Barr virus (EBV) LMP1 as a selective therapeutic strategy for EBV-associated diseases. Wu CJ, et al. **Gene Ther** 1998 Jul;5(7):905–12

Activation of transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat by the vasoactive intestinal peptide (VIP). Gilles A, et al. **Ital J Biochem** 1998 Jun;47(2):101–10

Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. Al-Harthi L, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1; 21(3):194–202

Prostaglandin E2 Up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways. Dumais N, et al. **J Biol Chem** 1998 Oct 16; 273(42):27306–14

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target. de Baar MP, et al. **J Clin Microbiol** 1999 Jun;37(6):1813–8

Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1

replication. Honda Y, et al. **J Exp Med** 1998 Oct 5; 188(7):1255–65

Lactobacilli and vaginal host defense: activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF–kappaB. Klebanoff SJ, et al. **J Infect Dis** 1999 Mar;179(3):653–60

Expression of human immunodeficiency virus long terminal repeat–coupled genes in early cleaving embryos. Kiessling AA. **J Reprod Immunol** 1998 Dec;41(1–2):95–104

CAT–transfected epithelial cells provide evidence for a CD4 independent pathway of HIV infection. Tan X, et al. **J Reprod Immunol** 1998 Dec;41(1–2):307–19

Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat–cyclin T complexes. Bieniasz PD, et al. **J Virol** 1999 Jul;73(7):5777–86

The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle. Das AT, et al. **J Virol** 1998 Nov;72(11):9217–23

Cell cycle– and Vpr–mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T–cell lines. Gummuluru S, et al. **J Virol** 1999 Jul;73(7):5422–30

Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA–box–dependent manner. Suñé C, et al. **Mol Cell Biol** 1999 Jul;19(7):4719–28

ZFX transactivation of the HIV–1 LTR is cell specific and depends on core enhancer and TATA box sequences. Gazin C. **Nucleic Acids Res** 1999 May 15;27(10):2156–64

Visualizing tertiary folding of RNA and RNA–protein interactions by a tethered iron chelate: analysis ofHIV–1 Tat–TAR complex. Huq I, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):1084–93

Recruitment of cyclin T1/P–TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Bieniasz PD, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7791–6

Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Wimmer J, et al. **Virology** 1999 Mar 1;255(1):182–9

LTR and tat variability of HIV–1 isolates from patients with divergent rates of disease progression. Quiñones–Mateu ME, et al. **Virus Res** 1998 Sep;57(1):11–20

DRUG EFFECTS

Proteolytic fragments of anti–HIV and anti–tumor proteins MAP30 and GAP31 are biologically active. Huang PL, et al. **Biochem Biophys Res Commun** 1999 Sep 7; 262(3):615–23

Inhibitors of protein–RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. Mei HY, et al. **Biochemistry** 1998 Oct 6;37(40):14204–12

Inhibition of HIV–1 Tat–TAR interaction by diphenylfuran derivatives: effects of the terminal basic side chains. Gelus N, et al. **Bioorg Med Chem** 1999 Jun;7(6):1089–96

Modified (PNA, 2'–O–methyl and phosphoramidate) anti–TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV–1 reverse transcription. Boulmé F, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5492–500

GENETICS

Effect of insulin–like growth factor I on HIV type 1 long terminal repeat–driven chloramphenicol acetyltransferase expression. Germinario RJ, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):829–36

No association of HIV type 1 long terminal repeat sequence pattern with long–term nonprogression and in vivo viral replication levels in European subjects. Visco–Comandini U, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):609–17

The antisense sequence of the HIV–1 TAR stem–loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates. Pérez–Ruiz M, et al. **Antisense Nucleic Acid Drug Dev** 1999 Feb;9(1):33–42

Cloning of a long HIV–1 readthrough transcript and detection of an increased level of early growth response protein–1 (Egr–1) mRNA in chronically infected U937 cells. Dron M, et al. **Arch Virol** 1999;144(1):19–28

Poly (ADP–ribose) polymerase is involved in PMA–induced activation of HIV–1 in U1 cells by modulating the LTR function. Kameoka M, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):285–9

A novel mutant loxP containing part of long terminal repeat of HIV–1 in spacer region: presentation of possible target site for antiviral strategy using site–specific recombinase. Lee Y, et al. **Biochem Biophys Res Commun** 1998 Dec 30; 253(3):588–93

Molecular basis of HIV–1 TAR RNA specific recognition by an acridine tat–antagonist. Gelus N, et al. **Bioorg Med Chem** 1999 Jun;7(6):1075–9

A clinical trial of retroviral–mediated transfer of a rev–responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus–1–infected children. Kohn DB, et al. **Blood** 1999 Jul 1;94(1):368–71

Stimulation of Tat–associated kinase–independent transcriptional elongation from the human immunodeficiency virus type–1 long terminal repeat by a cellular enhancer. West MJ, et al. **EMBO J** 1999 Mar 1; 18(5):1378–86

Purification of RBF–2, a transcription factor with specificity for the most conserved cis–element of naturally occurring HIV–1 LTRs. Estable MC, et al. **J Biomed Sci** 1999 Sep–Oct;6(5):320–32

A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat–mediated transcription of a fusion gene composed of the long terminal repeat of HIV–1 and a gene for luciferase. Koseki S, et al. **J Controlled Release** 1998 Apr 30;53(1–3):159–73

HIV–1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans–acting–response regulatory motif. Kundu M, et al. **J Hum Virol** 1999 Mar–Apr;2(2):72–80

Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2–86 binding to sequences between –120 and –20 in promoter transactivation. Yurochko AD, et al. **J Hum Virol** 1999 Mar–Apr;2(2):81–90

Transiently transfected and stably integrated HIV–1 LTR responds differentially to the silencing activity of the Krüppel–associated box (KRAB) transcriptional repressor domain. Rossi C, et al. **J Med Virol** 1999 Jul;58(3):264–72

Role of the human and murine cyclin T proteins in regulating HIV–1 tat–activation. Kwak YT, et al. **J Mol Biol** 1999 Apr 23;288(1):57–69

Cytomegalovirus and human herpesvirus–6 trans–activate the HIV–1 long terminal repeat via multiple response regions in human fetal astrocytes [see comments] McCarthy M, et al. **J Neurovirol** 1998 Oct;4(5):495–511. Comment in: J Neurovirol 1998 Oct;4(5):471–3.

Mapping of a protein–RNA kissing hairpin interface: Rom and Tar–Tar*. Comolli LR, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4688–95

Transmission of human immunodeficiency type 1 viruses with intersubtype recombinant long terminal repeat sequences. Blackard JT, et al. **Virology** 1999 Feb 15;254(2):220–5

PHYSIOLOGY

Involvement of protein–DNA interaction in adeno–associated virus Rep78–mediated inhibition of HIV–1. Kokorina NA, et al. **J Hum Virol** 1998 Nov–Dec; 1(7):441–50

An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. Helga–Maria C, et al. **J Virol** 1999 May;73(5):4127–35

Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Fujinaga K, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1285–90

HIV MAJOR CORE PROTEIN P24 see **HIV CORE PROTEIN P24**

HIV NEGATIVE REGULATORY ELEMENT see **HIV LONG TERMINAL REPEAT**

HIV NF–KAPPA B–BINDING SITE see **HIV ENHANCER**

HIV NON–PROGRESSORS see **HIV LONG–TERM SURVIVORS**

HIV–3'–ORF GENES see **GENES, NEF**

HIV–3'–ORF PROTEIN see **GENE PRODUCTS, NEF**

HIV P24 ANTIGEN see **HIV CORE PROTEIN P24**

HIV PEPTIDE T see **PEPTIDE T**

HIV PROTEASE

Epitope–based assay to determine the efficiency of cleavage by HIV–1 protease. Serio D, et al. **Biotechniques** 1999 Feb; 26(2):242–4, 246

ANALYSIS

Use of a phosphotyrosine–antibody pair as a general detection method in homogeneous time–resolved fluorescence: application to human immunodeficiency viral protease. Cummings RT, et al. **Anal Biochem** 1999 Apr 10; 269(1):79–93

ANTAGONISTS & INHIBITORS see HIV PROTEASE INHIBITORS

BIOSYNTHESIS

An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir. Melnick L, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3256–65

CHEMICAL SYNTHESIS

Monitoring of solid phase peptide synthesis by FT–IR spectroscopy. Henkel B, et al. **J Pept Sci** 1998 Dec; 4(8):461–70

CHEMISTRY

Rapid X–ray diffraction analysis of HIV–1 protease–inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme. Munshi S, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1053–60

Counteracting HIV–1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Ala PJ, et al. **Biochemistry** 1998 Oct 27;37(43):15042–9

Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV–1 protease? Towler EM, et al. **Biochemistry** 1998 Dec 8; 37(49):17137–44

Small dipeptide–based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition–state mimic. Kiso Y, et al. **Biopolymers** 1999;51(1):59–68 (32 ref.)

Effect of substrate residues on the P2' preference of retroviral proteinases. Boross P, et al. **Eur J Biochem** 1999 Sep; 264(3):921–9

Structural and kinetic analysis of drug resistant mutants of HIV–1 protease. Mahalingam B, et al. **Eur J Biochem** 1999 Jul;263(1):238–45

Peptidomimetic inhibitors complexed with HIV–1 protease: crystallisation for X–ray diffraction studies. Dohnálek J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:9–11

Structural studies of HIV–1 protease–inhibiting antibodies. Lescar J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:3–6

Transverse 1H cross relaxation in 1H–15N correlated 1H CPMG experiments. Ishima R, et al. **J Magn Reson** 1999 Mar;137(1):289–92

X–ray structure and conformational dynamics of the HIV–1 protease in complex with the inhibitor SDZ283–910: agreement of time–resolved spectroscopy and molecular dynamics simulations. Ringhofer S, et al. **J Mol Biol** 1999 Mar 5;286(4):1147–59

The structural stability of the HIV–1 protease. Todd MJ, et al. **J Mol Biol** 1998 Oct 23;283(2):475–88

Artificial neural network method for predicting HIV protease cleavage sites in protein. Cai YD, et al. **J Protein Chem** 1998 Oct;17(7):607–15

Autoprocessing of HIV–1 protease is tightly coupled to protein folding. Louis JM, et al. **Nat Struct Biol** 1999 Sep; 6(9):868–75

A cooperative folding unit in HIV–1 protease. Implications for protein stability and occurrence of drug–induced mutations. Wallqvist A, et al. **Protein Eng** 1998 Nov; 11(11):999–1005

Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP–130 complexed with proteases from HIV–1, FIV, and EIAV. Kervinen J, et al. **Protein Sci** 1998 Nov;7(11):2314–23

Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV–1 protease. Rick SW, et al. **Protein Sci** 1998 Aug;7(8):1750–6

Methodology for protein–ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system. Dominy BN, et al. **Proteins** 1999 Aug 15; 36(3):318–31

Structure–based ligand design by dynamically assembling molecular building blocks at binding site. Liu H, et al. **Proteins** 1999 Sep 1;36(4):462–70

Exhaustive docking of molecular fragments with electrostatic solvation. Majeux N, et al. **Proteins** 1999 Oct 1;37(1):88–105

Predicting structural effects in HIV–1 protease mutant complexes with flexible ligand docking and protein side–chain optimization. Schaffer L, et al. **Proteins** 1998 Nov 1;33(2):295–310

The effect of inhibitor binding on the structural stability and cooperativity of the HIV–1 protease. Todd MJ, et al. **Proteins** 1999 Aug 1;36(2):147–56

DRUG EFFECTS

Screening of compounds interacting with HIV–1 proteinase using optical biosensor technology. Markgren PO, et al. **Anal Biochem** 1998 Dec 15;265(2):340–50

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV–infected adults. Sadler BM, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1686–92

Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV–1 protease. Ulysse LG, et al. **Bioorg Med Chem Lett** 1998 Nov 17;8(22):3281–6

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Gruber A, et al. **Immunopharmacology** 1999 Apr; 41(3):227–34

Non–active site changes elicit broad–based cross–resistance of the HIV–1 protease to inhibitors. Olsen DB, et al. **J Biol Chem** 1999 Aug 20;274(34):23699–701

Quantitative structure–activity relationships of some HIV–protease inhibitors. Gupta SP, et al. **J Enzyme Inhib** 1999;14(2):109–23

GENETICS

Clinical benefits of resistance assay for HIV–specific protease inhibitors: when to check and in whom? [letter] Aizawa

S, et al. **AIDS** 1999 Jul 9;13(10):1278–9
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. Craig C, et al. **AIDS** 1998 Sep 10;12(13):1611–8
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. Keulen W, et al. **AIDS** 1999 Jul 30;13(11):1343–9
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17–21
Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. Brown AJ, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):247–53
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):65–9
The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance [published erratum appears in AIDS Res Hum Retroviruses 1999 Jul 1;15(10):949] Vaillancourt M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):355–63
Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):253–8
Thioredoxin fusion/HIV-1 protease coexpression system for production of soluble human IL6 in E. coli cytoplasm. Han BG, et al. **Biochem Mol Biol Int** 1998 Nov;46(4):839–46
Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Ala PJ, et al. **Biochemistry** 1998 Oct 27;37(43):15042–9
Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Ridky TW, et al. **Biochemistry** 1998 Sep 29;37(39):13835–45
GFP:HIV-1 protease production and packaging with a T4 phage expression-packaging processing system. Mullaney JM, et al. **Biotechniques** 1998 Dec;25(6):1008–12
Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination. Lallemand F, et al. **Clin Infect Dis** 1999 May;28(5):1184–5
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Mahalingam B, et al. **Eur J Biochem** 1999 Jul;263(1):238–45
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. Bossi P, et al. **J Clin Microbiol** 1999 Sep;37(9):2910–2
Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. Koch N, et al. **J Clin Microbiol** 1999 May;37(5):1595–7
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations [letter] Monno L, et al. **J Infect Dis** 1999 Aug;180(2):568–71
Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Young B, et al. **J Infect Dis** 1998 Nov; 178(5):1497–501
Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. Cherry E, et al. **J Mol Biol** 1998 Nov 20;284(1):43–56
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. Dulioust A, et al. **J Virol** 1999 Jan; 73(1):850–4
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. Kiernan RE, et al. **J Virol** 1998 Dec;72(12):9621–7
Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. Rouzine IM, et al. **J Virol** 1999 Oct;73(10):8167–78
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. Shafer RW, et al. **J Virol** 1999 Jul;73(7):6197–202
HIV-1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22–29; 282(12):1135–41. Comment in: JAMA 1999 Sep 22–29;282(12):1177–9.
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Zazzi M, et al. **Mol Biotechnol** 1998 Aug;10(1):1–8
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Shafer RW, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):348–52
Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Rosin CD, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1369–74
Molecular mechanics analysis of drug-resistant mutants of HIV protease. Weber IT, et al. **Protein Eng** 1999 Jun; 12(6):469–74
Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Xie D, et al. **Protein Sci** 1999 Aug; 8(8):1702–7
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor] Mouroux M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):549–52 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease. Haas G, et al. **AIDS** 1998 Aug 20; 12(12):1427–36
Structural studies of HIV-1 protease-inhibiting antibodies. Lescar J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:3–6
Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6–8

ISOLATION & PURIFICATION

Cloning, isolation, expression and mutagenesis studies on the human immuno-deficiency virus type 1 (HIV-1) protease. Garner JC, et al. **Biochem Soc Trans** 1998 Aug;26(3):S287

METABOLISM

Inhibitory constituents against HIV-1 protease from Agastache rugosa. Min BS, et al. **Arch Pharm Res** 1999 Feb;22(1):75–7
Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors. Hilgeroth A, et al. **Arch Pharm (Weinheim)** 1999 Jan;332(1):3–5
Cysteine nitrosylation inactivates the HIV-1 protease. Persichini T, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):575–6
Cloning, isolation, expression and mutagenesis studies on the human immuno-deficiency virus type 1 (HIV-1) protease. Garner JC, et al. **Biochem Soc Trans** 1998 Aug;26(3):S287
A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors. Gupta SP, et al. **Bioorg Med Chem** 1998 Nov; 6(11):2185–92
4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme. Ellsworth EL, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2019–24
Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Ghosh AK, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):979–82
Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. Rodgers JD, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):715–20
Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Dunn BM, et al. **Biopolymers** 1999;51(1):69–77
Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Kiso Y, et al. **Biopolymers** 1999;51(1):59–68 (32 ref.)
Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Min BS, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1607–12
Effect of substrate residues on the P2' preference of retroviral proteinases. Boross P, et al. **Eur J Biochem** 1999 Sep; 264(3):921–9
Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. Baraz L, et al. **FEBS Lett** 1998 Dec 28;441(3):419–26
Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism. Louis JM, et al. **J Biol Chem** 1999 Aug 13;274(33):23437–42
Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. Paulus C, et al. **J Biol Chem** 1999 Jul 30;274(31):21539–43
Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations. McCarrick MA, et al. **J Comput Aided Mol Des** 1999 Mar;13(2):109–21
Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. Bouras A, et al. **J Med Chem** 1999 Mar 25; 42(6):957–62
Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities. Kaltenbach RF 3rd, et al. **J Med Chem** 1998 Dec 3;41(25):5113–7
Occluded molecular surface analysis of ligand-macromolecule contacts: application to HIV-1 protease-inhibitor complexes. Pattabiraman N. **J Med Chem** 1999 Sep 23;42(19):3821–34
Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. Pastor M, et al. **J Mol Graph Model** 1997 Dec;15(6):364–71, 389
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. Davis DA, et al. **J Virol** 1999 Feb;73(2):1156–64
Unraveling the strands of HIV's web [news; comment] Pantaleo G. **Nat Med** 1999 Jan;5(1):27–8. Comment on: Nat Med 1999 Jan;5(1):29–3. Comment on: Nat Med 1999 Jan;5(1):34–41. Comment on: Nat Med 1999 Jan;5(1):83–9.
Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein [see comments] Vocero-Akbani AM, et al. **Nat Med** 1999 Jan;5(1):29–33. Comment in: Nat Med 1999 Jan;5(1):27–8.
Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Louis JM, et al. **Nat Struct Biol** 1999 Sep; 6(9):868–75
Inhibitory effects of Sudanese plant extracts on HIV-1 replication and HIV-1 protease. Hussein G, et al. **Phytother Res** 1999 Feb;13(1):31–6
Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Rosin CD, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1369–74
Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers. Bagossi P, et al. **Protein Eng** 1998 Jun;11(6):439–45
Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations. Lee CY, et al. **Protein Eng** 1998 Jun;11(6):429–37
Production of chemokines CTAPIII and NAP/2 by digestion of recombinant ubiquitin-CTAPIII with yeast ubiquitin C-terminal hydrolase and human immunodeficiency virus protease. Mildner AM, et al. **Protein Expr Purif** 1999 Jul; 16(2):347–54
Structure-based ligand design by dynamically assembling molecular building blocks at binding site. Liu H, et al. **Proteins** 1999 Sep 1;36(4):462–70
Application of electrospray ionization mass spectrometry for studying human immunodeficiency virus protein complexes. Loo JA, et al. **Proteins** 1998;Suppl 2:28–37
The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease. Todd MJ, et al. **Proteins** 1999 Aug 1;36(2):147–56
[HIV-1 proteinase mutant with an altered region of the active center] Dergousova NI, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):678–85 **(Rus)**

PHYSIOLOGY

Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA. Hermida-Matsumoto L, et al. **J Virol** 1999 Mar;73(3):1902–8
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. Kiernan RE, et al. **J Virol** 1998 Dec;72(12):9621–7

HIV PROTEASE INHIBITORS

Mutagenic activity and DNA adduct formation by 1, 2-epoxy-3-(p-nitrophenoxy)propane, an HIV-1 protease inhibitor and GST substrate. Said B, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):844–7
Resistance to HIV protease inhibitors. Condra JH. **Haemophilia** 1998 Jul;4(4):610–5 (24 ref.)
HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Kaul DR, et al. **Pharmacotherapy** 1999 Mar;19(3):281–98 (115 ref.)

ADMINISTRATION & DOSAGE

Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Hilts AE, et al. **Am J Health Syst Pharm** 1998 Dec 1;55(23):2528–33 (38 ref.)
Simultaneous use of two protease inhibitors in HIV infection. Varav H, et al. **Am J Health Syst Pharm** 1999 Feb 1; 56(3):273–6 (29 ref.)
Switching HIV-1 protease inhibitor therapy: which? When? And why? [letter] Guardiola JM, et al. **Arch Intern Med** 1999 Jan 25;159(2):194–5
Monitoring adherence to HIV therapy [letter] Tuldrà A, et al. **Arch Intern Med** 1999 Jun 28;159(12):1376–7
Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Mayer KH, et al. **Clin Infect Dis** 1999 Jun;28(6):1252–9
Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Gieschke R, et al. **Clin Pharmacokinet** 1999 Jul;37(1):75–86
Transferrin trojan horses as a rational approach for the biological delivery of therapeutic peptide domains. Ali SA, et al. **J Biol Chem** 1999 Aug 20;274(34):24066–73
Delays in protease inhibitor use in clinical practice [see comments] Fairfield KM, et al. **J Gen Intern Med** 1999 Jul;14(7):395–401. Comment in: J Gen Intern Med 1999 Jul;14(7):446–8.
Risk of new AIDS diseases in people on triple therapy [letter] Miller V, et al. **Lancet** 1999 Feb 6;353(9151):463
Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Carver PL, et al. **Pharm Res** 1999 May;16(5):718–24
[Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs] Jensen-Fangel S, et al. **Ugeskr Laeger** 1999 Mar 22;161(12):1751–4 (Eng. Abstr.) **(Dan)**
[Experiences with antiretroviral combination therapy] Justesen US, et al. **Ugeskr Laeger** 1999 Mar 22; 161(12):1747–51 (Eng. Abstr.) **(Dan)**
[The new saquinavir formulation SGC (Soft Gel Capsule)] Katlama C. **Presse Med** 1999 Apr 17;28(15):815–8 (24 ref.) **(Fre)**

ADVERSE EFFECTS

Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy [letter]

Aldeen T, et al. **AIDS** 1998 Sep 10;12(13):1719–20

Acute hepatitis in HIV-infected patients during ritonavir treatment [letter] Arribas JR, et al. **AIDS** 1998 Sep 10; 12(13):1722–4

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Behrens G, et al. **AIDS** 1999 Jul 9;13(10):F63–70

Ketoacidosis associated with protease inhibitor therapy [letter] Besson C, et al. **AIDS** 1998 Jul 30;12(11):1399–400

Changes in renal function associated with indinavir. Boubaker K, et al. **AIDS** 1998 Dec 24;12(18):F249–54

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. Brodie SB, et al. **AIDS** 1998 Dec 24;12(18):2433–7

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Dieleman JP, et al. **AIDS** 1999 Mar 11;13(4):473–8

Substituting nevirapine for protease inhibitors because of intolerance [letter] Dieleman JP, et al. **AIDS** 1999 Jul 30; 13(11):1423–4

Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge [letter] Di Martino V, et al. **AIDS** 1999 Jul 30;13(11):1421–3

Indinavir and thrombocytopenia [letter] Durand JM. **AIDS** 1999 Jan 14;13(1):148–9

Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? [letter] Eriksson U, et al. **AIDS** 1998 Oct 22;12(15):2079–80

Acute porphyria following commencement of indinavir [letter] Fox PA, et al. **AIDS** 1999 Apr 1;13(5):622–3

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. Gervasoni C, et al. **AIDS** 1999 Mar 11;13(4):465–71

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team [letter] Gill MJ. **AIDS** 1998 Jul 30; 12(11):1400–2

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients [letter] Hewitt RG, et al. **AIDS** 1999 May 7;13(7):868–9

Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir [letter] Karmochkine M, et al. **AIDS** 1998 Dec 24;12(18):2499

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. Martinez E, et al. **AIDS** 1999 May 7;13(7):805–10

Protease inhibitor-associated hyperinsulinaemia [letter] Martinez E, et al. **AIDS** 1998 Oct 22;12(15):2077–9

Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors [letter] Meyer D, et al. **AIDS** 1999 Jun 18;13(9):1147–8

Atorvastatin for protease inhibitor-related hyperlipidaemia [letter] Murillas J, et al. **AIDS** 1999 Jul 30;13(11):1424–5

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. Roubenoff R, et al. **AIDS** 1999 Jul 30;13(11):1373–5

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy [letter] Saint-Marc T, et al. **AIDS** 1999 May 28; 13(8):1000–2

Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease [letter] Schürmann D, et al. **AIDS** 1998 Nov 12;12(16):2232–3

Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma [letter] Schwartz JD, et al. **AIDS** 1999 Feb 4;13(2):283–4

Marked hypertriglyceridaemia associated with ritonavir therapy [letter] Sullivan AK, et al. **AIDS** 1998 Jul 30; 12(11):1393–4

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. Walli R, et al. **AIDS** 1998 Oct 22;12(15):F167–73

Ureteric obstruction in HIV patients undergoing indinavir therapy [letter; comment] Yanez MH. **AJR Am J Roentgenol** 1999 May;172(5):1452. Comment on: AJR Am J Roentgenol 1998 Sep;171(3):717–20.

Acute paranoid reaction to saquinavir. Finlayson JA, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):2016–7

Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone [letter] Mauss S, et al. **Ann Intern Med** 1999 Aug 17; 131(4):313–4

Impaired glucose tolerance and protease inhibitors [letter] Walli R, et al. **Ann Intern Med** 1998 Nov 15;129(10):837–8

Hyperlipidemia associated with protease inhibitor therapy. Echevarria KL, et al. **Ann Pharmacother** 1999 Jul–Aug; 33(7–8):859–63

Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors [letter] Olivé A, et al. **Ann Rheum Dis** 1998 Dec;57(12):749

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Sadler BM, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1686–92

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. Humphrey RW, et al. **Antiviral Res** 1999 Feb;41(1):21–33

Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Trainor LD, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):256–9

Protease inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival [letter] Buss N, et al. **BMJ** 1999 Jan 9;318(7176):122

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Périard D, et al. **Circulation** 1999 Aug 17; 100(7):700–5

Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient. Antony SJ. **Clin Infect Dis** 1998 Oct;27(4):911–2

Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Benveniste O, et al. **Clin Infect Dis** 1999 May;28(5):1180–1

Ritonavir, triglycerides, and pancreatitis. Perry RC, et al. **Clin Infect Dis** 1999 Jan;28(1):161–2

Indinavir-induced nephropathy. Grabe DW, et al. **Clin Nephrol** 1999 Mar;51(3):181–3

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194–6 (8 ref.)

New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. Lee EC, et al. **CMAJ** 1999 Jul 27;161(2):161–4 (27 ref.)

Protease inhibitors raising quality-of-life issues for HIV patients. Silversides A. **CMAJ** 1999 Mar 23;160(6):894

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Vigouroux C, et al. **Diabetes Metab** 1999 Sep;25(3):225–32

A risk-benefit assessment of HIV protease inhibitors. Moyle GJ, et al. **Drug Saf** 1999 Apr;20(4):299–321 (94 ref.)

Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Mirete G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):810–1

Urolithiasis and the protease inhibitor indinavir. Hermieu J, et al. **Eur Urol** 1999;35(3):239–41

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Stanworth SJ, et al. **Haemophilia** 1998 Mar;4(2):109–14

Painful hyperaesthesia caused by protease inhibitors? [letter] Colebunders R, et al. **Infection** 1998 Jul–Aug;26(4):250–1

Nelfinavir associated with peripheral neuropathy in an HIV-infected patient [letter] Grunke M, et al. **Infection** 1998 Jul–Aug;26(4):252

Hyperlipidemia under treatment with proteinase inhibitors. Segerer S, et al. **Infection** 1999 Mar–Apr;27(2):77–81

Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir [letter] Vandercam B, et al. **Infection** 1998 Sep–Oct;26(5):313

Gynaecomastia associated with saquinavir therapy. Donovan B, et al. **Int J STD AIDS** 1999 Jan;10(1):49–50

Renal calculi developing de novo in a patient taking saquinavir [letter] Green ST, et al. **Int J STD AIDS** 1998 Sep;9(9):555

Lipodystrophy despite anabolic steroids [letter] O'Mahony C, et al. **Int J STD AIDS** 1998 Oct;9(10):619

Coronary artery disease occurring with protease inhibitor therapy. Sullivan AK, et al. **Int J STD AIDS** 1998 Nov; 9(11):711–2

A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Honda M, et al. **Intern Med** 1999 Mar; 38(3):302–3

Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy [letter] Moyle GJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):423–4

Insulin resistance in HIV protease inhibitor-associated diabetes. Yarasheski KE, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):209–16

Nelfinavir-induced urticaria and successful desensitization. Demoly P, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):875–6

Striae formation in two HIV-positive persons receiving protease inhibitors. Darvay A, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):467–9 (13 ref.)

Protease inhibitor-induced lipodystrophy. Williamson K, et al. **J Am Acad Dermatol** 1999 Apr;40(4):635–6

Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients [editorial] Chronister CL, et al. **J Am Optom Assoc** 1998 Nov;69(11):695–8 (18 ref.)

Lipid abnormalities associated with protease inhibitors. Melroe NH, et al. **J Assoc Nurses AIDS Care** 1999 Mar–Apr;10(2):22–30

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Yanovski JA, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1925–31

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction [editorial] Greenblatt DJ, et al. **J Clin Psychopharmacol** 1999 Aug;19(4):293–6 (51 ref.)

Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors. Smith K, et al. **J Cutan Med Surg** 1999 Apr;3(4):211–7

Urolithiasis associated with protease inhibitors. Sundaram CP, et al. **J Endourol** 1999 May;13(4):309–12

Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. Kohan AD, et al. **J Urol** 1999 Jun;161(6):1765–8

Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals [letter] Babl FE, et al. **Lancet** 1999 Apr 10;353(9160):1243–4

ApoE genotype and protease-inhibitor-associated hyperlipidaemia [letter; comment] Behrens G, et al. **Lancet** 1999 Jul 3;354(9172):76. Comment on: Lancet 1999 May 15;353(9165):1678.

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Carr A, et al. **Lancet** 1999 Jun 19;353(9170):2093–9

Sexual dysfunction with protease inhibitors [letter; comment] Colebunders R, et al. **Lancet** 1999 May 22;353(9166):1802 . Comment on: Lancet 1999 Mar 6;353(9155):810–1.

Lipodystrophy in HIV-1-infected patients [letter] Domingo P, et al. **Lancet** 1999 Sep 4;354(9181):868

Lipid lowering therapy in patients with HIV infection [letter; comment] McBride M, et al. **Lancet** 1998 Nov 28; 352(9142):1782–3. Comment on: Lancet 1998 Sep 26;352(9133):1031–2.

Sexual dysfunction with protease inhibitors [letter] [see comments] Martinez E, et al. **Lancet** 1999 Mar 6; 353(9155):810–1. Comment in: Lancet 1999 May 22;353(9166):1802.

Lipodystrophy in HIV-1-infected patients [letter] Mercié P, et al. **Lancet** 1999 Sep 4;354(9181):867–8

Liposuction for protease-inhibitor-associated lipodystrophy [letter] Ponce-de-Leon S, et al. **Lancet** 1999 Apr 10; 353(9160):1244

Itraconazole and HIV protease inhibitors: an important interaction [letter] MacKenzie-Wood AR, et al. **Med J Aust** 1999 Jan 4;170(1):46–7

Alopecia associated with indinavir therapy [letter] Bouscarat F, et al. **N Engl J Med** 1999 Aug 19;341(8):618

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor [see comments] Carr A, et al. **N Engl J Med** 1998 Oct 29;339(18):1296. Comment in: N Engl J Med 1999 Mar 25;340(12):969–70.

Renal atrophy associated with long-term treatment with indinavir [letter] [published erratum appears in N Engl J Med 1999 Mar 25;340(12):976] Hanabusa H, et al. **N Engl J Med** 1999 Feb 4;340(5):392–3

Spontaneous bleeding associated with the use of the protease inhibitor ritonavir in a hemophiliac patient with human immunodeficiency virus infection. Hagerty SL, et al. **Pediatr Infect Dis J** 1998 Oct;17(10):929–30

Ureteral obstruction secondary to indinavir in the pediatric HIV population. Noble CB, et al. **Pediatr Radiol** 1998 Aug; 28(8):627–9

Adhesive capsulitis of the shoulder induced by protease inhibitor therapy. Three new cases [letter; comment] Léone J, et al. **Rev Rhum Engl Ed** 1998 Dec;65(12):800–1. Comment on: Rev Rhum Engl Ed 1998 Jan;65(1):72–4.

Stevens-Johnson syndrome caused by indinavir. Teira R, et al. **Scand J Infect Dis** 1998;30(6):634–5

[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors] Dieleman JP, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26;142(52):2856–60 (Eng. Abstr.) **(Dut)**

["Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors] Milpied-Homsi B, et al. **Ann Dermatol Venereol** 1999 Mar;126(3):254–6 (Eng. Abstr.) **(Fre)**

[Nephrotoxicity of ritonavir] Deray G, et al. **Presse Med** 1998 Nov 14;27(35):1801–3 (Eng. Abstr.) **(Fre)**

[Anterior uveitis in HIV-infected patients. 3 cases in patients treated with an antiprotease] Fournier S, et al. **Presse Med** 1998 May 16;27(18):844–8 (Eng. Abstr.) **(Fre)**

[Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients] Hermieu JF, et al. **Prog Urol** 1999 Jun;9(3):537–40 (Eng. Abstr.) **(Fre)**

[Diabetes mellitus associated with protease inhibitors in HIV infected patients (letter)] Bardonnet K, et al. **Rev Med Interne** 1998 Sep;19(9):675–6 **(Fre)**

[Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy] Schwietert M, et al. **Dtsch Med Wochenschr** 1999 Jan 22;124(3):45–8 (Eng. Abstr.) **(Ger)**

[Improvement of lipodystrophy associated with protease inhibitors (news)] **Boll Chim Farm** 1999 Apr;138(4):192–3 **(Ita)**

[Metabolic disorders due to HIV-1 protease inhibitors (editorial)] Liguori M, et al. **Recenti Prog Med** 1998 Dec; 89(12):652–3 (14 ref.) **(Ita)**

[Large, atypical accumulation of adipose tissue in a patient with human immunodeficiency virus infection] García de la Llana F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):431–2 **(Spa)**

[Portal thrombosis in a female patient treated with protease inhibitors (letter)] Locutura J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):359 **(Spa)**

[Diabetes mellitus and protease inhibitors. A complication to take into account (letter)] Rodríguez Arrondo F, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):801 (8 ref.) **(Spa)**

[Potential opiate withdrawal syndrome after ritonavir administration in a patient treated with methadone (letter)] Jiménez-Lerma JM, et al. **Rev Clin Esp** 1999 Mar; 199(3):188–9 **(Spa)**

[Indinavir-induced anuria (letter)] Lacambra Calvet C, et al. **Rev Clin Esp** 1999 Mar;199(3):189 **(Spa)**

ANALYSIS

Identification of drug metabolites in biological matrices by intelligent automated liquid chromatography/tandem mass spectrometry. Lopez LL, et al.
Rapid Commun Mass Spectrom 1998;12(22):1756-60

BLOOD

Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human serum by high-performance liquid chromatography. Frappier S, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 4;714(2):384-9

Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. Hugen PW, et al.
J Chromatogr B Biomed Sci Appl 1999 Apr 30; 727(1-2):139-49

Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. van Heeswijk RP, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20;719(1-2):159-68

Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Poirier JM, et al. **Ther Drug Monit** 1999 Aug;21(4):404-10

CEREBROSPINAL FLUID

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. Martin C, et al. **AIDS** 1999 Jul 9;13(10):1227-32

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy. Moyle GJ, et al. **Clin Infect Dis** 1999 Feb;28(2):403-4

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex. Aweeka F, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Jan 1;20(1):39-43

CHEMICAL SYNTHESIS

Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746. Franchetti P, et al. **Antivir Chem Chemother** 1998 Jul;9(4):303-9

Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors. Hilgeroth A, et al.
Arch Pharm (Weinheim) 1999 Jan;332(1):3-5

A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors. Gupta SP, et al. **Bioorg Med Chem** 1998 Nov; 6(11):2185-92

Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors. Baker CT, et al.
Bioorg Med Chem Lett 1998 Dec 15;8(24):3631-6

Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Ghosh AK, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):979-82

Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Ghosh AK, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):687-90

Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones. Janakiraman MN, et al. **Bioorg Med Chem Lett** 1998 May 19; 8(10):1237-42

A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor. Kimura T, et al.
Bioorg Med Chem Lett 1999 Mar 22;9(6):803-6

Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases. Kurihara S, et al.
Bioorg Med Chem Lett 1999 Apr 19;9(8):1179-84

The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. Patel M, et al.
Bioorg Med Chem Lett 1998 May 5;8(9):1077-82

The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. Patel M, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):823-8

Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand. Patel NM, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):931-4

Design and synthesis of novel conformationally restricted HIV protease inhibitors. Salituro FG, et al.
Bioorg Med Chem Lett 1998 Dec 15;8(24):3637-42

Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease. Ulysse LG, et al.
Bioorg Med Chem Lett 1998 Nov 17;8(22):3281-6

Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties. Vara Prasad JV, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1481-6

Endothiopeptide inhibitors of HIV-1 protease. Yao S, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):699-704

Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Kiso Y, et al. **Biopolymers** 1999;51(1):59-68 (32 ref.)

Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors [published erratum appears in Chem Biol 1998 Nov;5(11):R312] Rodgers JD, et al. **Chem Biol** 1998 Oct; 5(10):597-608

Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. Alterman M, et al. **J Med Chem** 1999 Sep 23; 42(19):3835-44

Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. Bouras A, et al. **J Med Chem** 1999 Mar 25; 42(6):957-62

Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. De Lucca GV, et al. **J Med Chem** 1999 Jan 14;42(1):135-52

Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities. Kaltenbach RF 3rd, et al. **J Med Chem** 1998 Dec 3;41(25):5113-7

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. Mimoto T, et al. **J Med Chem** 1999 May 20;42(10):1789-802

Artificial neural network method for predicting HIV protease cleavage sites in protein. Cai YD, et al.
J Protein Chem 1998 Oct;17(7):607-15

De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule. De Lucca GV, et al. **Pharm Biotechnol** 1998;11:257-84 (71 ref.)

Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Rosin CD, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1369-74

CHEMISTRY

Rapid X-ray diffraction analysis of HIV-1 protease-inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme. Munshi S, et al.
Acta Crystallogr D Biol Crystallogr 1998 Sep 1;54 (Pt 5):1053-60

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Ala PJ, et al. **Biochemistry** 1998 Oct 27;37(43):15042-9

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Martin JL, et al.
Biochemistry 1999 Jun 22;38(25):7978-88

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands. Chen X, et al.
Bioorg Med Chem Lett 1998 Dec 15;8(24):3531-6

4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme. Ellsworth EL, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2019-24

Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Ghosh AK, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):979-82

Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases. Kurihara S, et al.
Bioorg Med Chem Lett 1999 Apr 19;9(8):1179-84

Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand. Randad RS, et al.
Bioorg Med Chem Lett 1998 Dec 15;8(24):3537-42

NMR and topochemical studies of peptidomimetic HIV-1 protease inhibitors containing a cis-epoxide amide isostere. Ro S, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2423-6

Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. Rodgers JD, et al.
Bioorg Med Chem Lett 1998 Apr 7;8(7):715-20

Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease. Shultz MD, et al.
Bioorg Med Chem Lett 1999 Aug 16;9(16):2431-6

Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Dunn BM, et al.
Biopolymers 1999;51(1):69-77

Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Kiso Y, et al. **Biopolymers** 1999;51(1):59-68 (32 ref.)

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Thaisrivongs S, et al.
Biopolymers 1999;51(1):51-8 (50 ref.)

Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies. Dohnálek J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:9-11

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al.
Gen Physiol Biophys 1998 Jun;17 Suppl 1:6-8

Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study. Hilgeroth A, et al.
J Comput Aided Mol Des 1999 May;13(3):233-42

Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations. McCarrick MA, et al.
J Comput Aided Mol Des 1999 Mar;13(2):109-21

Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. Debnath AK. **J Med Chem** 1999 Jan 28; 42(2):249-59

X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations. Ringhofer S, et al. **J Mol Biol** 1999 Mar 5;286(4):1147-59

Structure-based prediction of binding affinities and molecular design of peptide ligands. Luque I, et al.
Methods Enzymol 1998;295:100-27

Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations. Lee CY, et al. **Protein Eng** 1998 Jun;11(6):429-37

Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease. Trylska J, et al.
Protein Sci 1999 Jan;8(1):180-95

ISOLATION & PURIFICATION

Inhibitory constituents against HIV-1 protease from Agastache rugosa. Min BS, et al. **Arch Pharm Res** 1999 Feb;22(1):75-7

Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins. Lee TG, et al.
Biochem Biophys Res Commun 1998 Dec 30;253(3):604-8

Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Min BS, et al.
Chem Pharm Bull (Tokyo) 1998 Oct;46(10):1607-12

Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. el-Mekkawy S, et al.
Phytochemistry 1998 Nov;49(6):1651-7

METABOLISM

Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Kiriyama A, et al.
Antimicrob Agents Chemother 1999 Mar;43(3):549-56

Mutagenic activity and DNA adduct formation by 1, 2-epoxy-3-(p-nitrophenoxy)propane, an HIV-1 protease inhibitor and GST substrate. Said B, et al.
Biochem Biophys Res Commun 1999 Aug 11;261(3):844-7

4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme. Ellsworth EL, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2019-24

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Kumar GN, et al. **Drug Metab Dispos** 1999 Jan;27(1):86-91

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Kumar GN, et al. **Drug Metab Dispos** 1999 Aug;27(8):902-8

Mechanism, structure-activity studies, and potential applications of glutathione S-transferase-catalyzed cleavage of sulfonamides. Zhao Z, et al.
Drug Metab Dispos 1999 Sep;27(9):992-8

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Washington CB, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1;19(3):203-9

Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein. Paulus C, et al. **J Biol Chem** 1999 Jul 30;274(31):21539-43

Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations. McCarrick MA, et al.
J Comput Aided Mol Des 1999 Mar;13(2):109-21

Occluded molecular surface analysis of ligand-macromolecule contacts: application to HIV-1 protease-inhibitor complexes. Pattabiraman N.
J Med Chem 1999 Sep 23;42(19):3821-34

Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. Pastor M, et al. **J Mol Graph Model** 1997 Dec;15(6):364-71, 389

The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Lin JH, et al. **Pharm Biotechnol** 1998; 11:233-55 (28 ref.)

Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations. Lee CY, et al. **Protein Eng** 1998 Jun;11(6):429-37

The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease. Todd MJ, et al.
Proteins 1999 Aug 1;36(2):147-56

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Molla A, et al. **Virology** 1998 Oct 25;250(2):255-62

PHARMACOKINETICS

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir [letter] Burger DM, et al. **AIDS** 1998 Oct 22; 12(15):2080-2

Indinavir pharmacokinetics in haemodialysis-dependent

end-stage renal failure [letter] Guardiola JM, et al. **AIDS** 1998 Jul 30;12(11):1395

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. Hoetelmans RM, et al. **AIDS** 1998 Jul 30;12(11):F111-5

Nelfinavir and nevirapine interaction? [letter; comment] Mulcahy F, et al. **AIDS** 1998 Dec 3;12(17):2361. Comment on: **AIDS** 1998 Jul 9;12(10):1163-7. Comment on: **AIDS** 1998 Jul 9;12(10):1243-4.

Poor penetration of the male genital tract by HIV-1 protease inhibitors [letter] Taylor S, et al. **AIDS** 1999 May 7; 13(7):859-60

Pharmacokinetic interaction between saquinavir and cyclosporine [letter] Brinkman K, et al. **Ann Intern Med** 1998 Dec 1;129(11):914-5

Effect of fluoxetine on pharmacokinetics of ritonavir. Ouellet D, et al. **Antimicrob Agents Chemother** 1998 Dec; 42(12):3107-12

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. Humphrey RW, et al. **Antiviral Res** 1999 Feb;41(1):21-33

Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases. Kurihara S, et al. **Bioorg Med Chem Lett** 1999 Apr 19;9(8):1179-84

Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties. Vara Prasad JV, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1481-6

Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Kiriyama A, et al. **Biopharm Drug Dispos** 1999 May;20(4):199-205

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Nannan Panday VR, et al. **Cancer Chemother Pharmacol** 1999;43(6):516-9

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Barry M, et al. **Clin Pharmacokinet** 1999 Apr; 36(4):289-304 (101 ref.)

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Gieschke R, et al. **Clin Pharmacokinet** 1999 Jul;37(1):75-86

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents [published erratum appears in Clin Pharmacokinet 1998 Dec;35(6):473] Hsu A, et al. **Clin Pharmacokinet** 1998 Oct;35(4):275-91 (129 ref.)

Pharmacokinetic interaction between ritonavir and clarithromycin. Ouellet D, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):355-62

Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. Kurowski M, et al. **Eur J Med Res** 1999 Mar 26;4(3):101-4

The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Bawdon RE. **Infect Dis Obstet Gynecol** 1998; 6(6):244-6

The effect of azithromycin on the pharmacokinetics of indinavir. Foulds G, et al. **J Clin Pharmacol** 1999 Aug; 39(8):842-6

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Gutmann H, et al. **Mol Pharmacol** 1999 Aug;56(2):383-9

Factors impacting the delivery of therapeutic levels of pyrone-based HIV protease inhibitors. Padbury GE, et al. **Pharm Biotechnol** 1998;11:211-32 (46 ref.)

Hydrophobicity of HIV protease inhibitors by immobilized artificial membrane chromatography: application and significance to drug transport [published erratum appears in Pharm Res 1998 Dec;15(12):1911] Stewart BH, et al. **Pharm Res** 1998 Sep;15(9):1401-6

Indinavir concentrations and antiviral effect. Acosta EP, et al. **Pharmacotherapy** 1999 Jun;19(6):708-12

Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ion-pair reversed-phase high-performance liquid chromatography. Li W, et al. **Ther Drug Monit** 1999 Jun;21(3):360-6

PHARMACOLOGY

Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom? [letter] Aizawa S, et al. **AIDS** 1999 Jul 9;13(10):1278-9

Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. Birk M, et al. **AIDS** 1998 Dec 24;12(18):2369-75

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Palmer S, et al. **AIDS** 1999 Apr 16; 13(6):661-7

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. Piketty C, et al. **AIDS** 1999 Jul 30;13(11):F71-7

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, et al. **AIDS** 1999 Feb 25;13(3):359-65

Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans [letter] Ye JM, et al. **AIDS** 1998 Nov 12;12(16):2236-7

Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. Brown AJ, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):247-53

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):65-9

The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance [published erratum appears in AIDS Res Hum Retroviruses 1999 Jul 1;15(10):949] Vaillancourt M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):355-63

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Mayers DL. **Am J Med** 1997 May 19;102(5B):70-5 (55 ref.)

Protease inhibitors--worldwide use? [news] **Am J Nurs** 1999 Jun;99(6):17

Screening of compounds interacting with HIV-1 proteinase using optical biosensor technology. Markgren PO, et al. **Anal Biochem** 1998 Dec 15;265(2):340-50

Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Olkkola KT, et al. **Anesthesiology** 1999 Sep;91(3):681-5

Resistance to human immunodeficiency virus type 1 protease inhibitors. Boden D, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2775-83 (97 ref.)

Lack of ritonavir antifungal effect in vitro [letter] Diz P, et al. **Antimicrob Agents Chemother** 1999 Apr;43(4):997

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Hsu A, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2784-91

Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Korting HC, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2038-42

An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir. Melnick L, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3256-65

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Patick AK, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2637-44

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Sham HL, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3218-24

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Srinivas RV, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3157-62

Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):253-8

Recent developments in HIV protease inhibitor therapy. Molla A, et al. **Antiviral Res** 1998 Jul;39(1):1-23 (98 ref.)

A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro. Moussazadeh M, et al. **Antiviral Res** 1999 Jul;42(3):177-87

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Robinson WE Jr. **Antiviral Res** 1998 Aug; 39(2):101-11

Lipopeptides as dimerization inhibitors of HIV-1 protease. Schramm HJ, et al. **Biol Chem** 1999 May;380(5):593-6

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands. Chen X, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3531-6

Tricyclic ureas: a new class of HIV-1 protease inhibitors. Han W, et al. **Bioorg Med Chem Lett** 1998 Dec 15; 8(24):3615-20

Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Sloand EM, et al. **Blood** 1999 Aug 1;94(3):1021-7

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Ouellet D, et al. **Br J Clin Pharmacol** 1998 Aug;46(2):111-6

Inhibitory effects of constituents from Cynomorium songaricum and related triterpene derivatives on HIV-1 protease. Ma C, et al. **Chem Pharm Bull (Tokyo)** 1999 Feb; 47(2):141-5

Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Min BS, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1607-12

The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors. Monod M, et al. **Dermatology** 1999;198(4):412-4

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Kumar GN, et al. **Drug Metab Dispos** 1999 Aug;27(8):902-8

Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor. Nishime JA, et al. **Drug Metab Dispos** 1999 Sep;27(9):972-6

Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Gass RJ, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):741-7

Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. Baraz L, et al. **FEBS Lett** 1998 Dec 28;441(3):419-26

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6-8

Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Daniel V, et al. **Immunol Lett** 1999 Aug 3;69(2):283-9

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Gruber A, et al. **Immunopharmacology** 1999 Apr; 41(3):227-34

Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. Olsen DB, et al. **J Biol Chem** 1999 Aug 20;274(34):23699-701

HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Berkhout B. **J Biomed Sci** 1999 Sep-Oct;6(5):298-305 (59 ref.)

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Walter H, et al. **J Clin Virol** 1999 Jun;13(1-2):71-80

Quantitative structure-activity relationships of some HIV-protease inhibitors. Gupta SP, et al. **J Enzyme Inhib** 1999;14(2):109-23

Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors. Gupta SP, et al. **J Enzyme Inhib** 1998 Sep;13(6):399-407

A search for anti-viral properties in Panamanian medicinal plants. The effects on HIV and its essential enzymes. Matsuse IT, et al. **J Ethnopharmacol** 1999 Jan;64(1):15-22

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. Cassone A, et al. **J Infect Dis** 1999 Aug;180(2):448-53

Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. Debnath AK. **J Med Chem** 1999 Jan 28; 42(2):249-59

Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. Friedler A, et al. **J Mol Biol** 1999 Mar 19;287(1):93-101

Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. Rosin CD, et al. **J Mol Biol** 1999 Mar 19;287(1):77-92

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. von Moltke LL, et al. **J Pharm Sci** 1998 Oct;87(10):1184-9

Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. de la Carriere LC, et al. **J Virol** 1999 Apr;73(4):3455-9

Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. Martinez-Picado J, et al. **J Virol** 1999 May;73(5):3744-52

HIV-1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22-29; 282(12):1135-41. Comment in: JAMA 1999 Sep 22-29;282(12):1177-9.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection [see comments] Little SJ, et al. **JAMA** 1999 Sep 22-29;282(12):1142-9. Comment in: JAMA 1999 Sep 22-29;282(12):1177-9.

Ergotism related to concurrent administration of ergotamine tartrate and indinavir [letter] Rosenthal E, et al. **JAMA** 1999 Mar 17;281(11):987

Testing time as resistant HIV-1 faces next wave of attack [news] Mellors J. **Lancet** 1999 Jul 10;354(9173):135

Fat accumulation and HIV-1 protease inhibitors [letter; comment] Stricker RB, et al. **Lancet** 1998 Oct 24; 352(9137):1392. Comment on: Lancet 1998 Sep 5;352(9130):821-2.

Protease inhibitors enhance levodopa effects in Parkinson's disease [letter] Caparros-Lefebvre D, et al. **Mov Disord** 1999 May;14(3):535

Inhibitory effects of Sudanese plant extracts on HIV-1 replication and HIV-1 protease. Hussein G, et al. **Phytother Res** 1999 Feb;13(1):31-6

Inhibitory effect of triterpenes from Crataegus pinatifida on HIV-1 protease [letter] Min BS, et al. **Planta Med** 1999 May;65(4):374-5

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. André P, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):13120-4

Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Potash MJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13865-8

Coevolutionary analysis of resistance-evading peptidomimetic inhibitors of HIV-1 protease. Rosin CD, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1369-74

JE-2147: a dipeptide protease inhibitor (PI) that potently

inhibits multi-PI-resistant HIV-1. Yoshimura K, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8675-80

Exhaustive docking of molecular fragments with electrostatic solvation. Majeux N, et al. **Proteins** 1999 Oct 1;37(1):88-105

[HIV protease inhibitors: drug interactions] Gérard Y, et al. **Rev Med Interne** 1999 Feb;20(2):141-50 (47 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Indinavir overdose [letter] Burkhart KK, et al. **J Toxicol Clin Toxicol** 1998;36(7):747

THERAPEUTIC USE

Safe and effective use of combination antiretroviral treatment. Colebunders R, et al. **Acta Clin Belg** 1999 Apr; 54(2):55-60

Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy [letter] Barreiro PM, et al. **AIDS** 1999 Mar 11;13(4):525-6

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. Bayoumi AM, et al. **AIDS** 1998 Aug 20;12(12):1503-12

Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors [letter] Beauverie P, et al. **AIDS** 1998 Dec 24;12(18):2510-1

Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. Bellman PC. **AIDS** 1998 Jul 30;12(11):1333-40

Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Cameron DW, et al. **AIDS** 1999 Feb 4;13(2):213-24

Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy [letter] Canani RB, et al. **AIDS** 1999 May 28;13(8):1005-6

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. Casado JL, et al. **AIDS** 1998 Jul 30;12(11):F131-5

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Chêne G, et al. **AIDS** 1998 Dec 3;12(17):2313-20

Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. Chougnet C, et al. **AIDS** 1998 Dec 24;12(18):2397-406

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). Cohen Stuart JW, et al. **AIDS** 1999 May 7;13(7):F53-8

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. Craig C, et al. **AIDS** 1998 Sep 10;12(13):1611-8

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. d'Arminio Monforte A, et al. **AIDS** 1998 Sep 10;12(13):1631-7

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. Deeks SG, et al. **AIDS** 1999 Apr 16; 13(6):F35-43

Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter] De Luca A, et al. **AIDS** 1998 Oct 1;12(14):1937-8

Higher antiviral activity of antiretroviral regimens including protease inhibitors [letter] de Mendoza C, et al. **AIDS** 1999 May 28;13(8):998-9

Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine [letter] De Wit S, et al. **AIDS** 1999 May 7;13(7):864-5

Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients [letter; comment] Fätkenheuer G, et al. **AIDS** 1998 Jul 30; 12(11):1402-3. Comment on: AIDS 1998 Jun 18;12(9):1111.

Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy [letter] Fischer T, et al. **AIDS** 1999 Apr 1;13(5):628-9

Costs of HIV medical care in the era of highly active antiretroviral therapy. Gebo KA, et al. **AIDS** 1999 May 28;13(8):963-9

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. Giorgi JV, et al. **AIDS** 1998 Oct 1;12(14):1833-44

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. Hall CS, et al. **AIDS** 1999 Jul 9;13(10):1207-12

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. Hengge UR, et al. **AIDS** 1998 Dec 3;12(17):F225-34

Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy [letter] Jiménez-Expósito MJ, et al. **AIDS** 1999 Jan 14;13(1):152-3

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? John M, et al. **AIDS** 1998 Dec 3;12(17):2289-93

High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy [letter] Jubault V, et al. **AIDS** 1998 Dec 3;12(17):2358-9

Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. Kaufmann GR, et al. **AIDS** 1998 Sep 10;12(13):1625-30

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. Kirk O, et al. **AIDS** 1999 Jan 14;13(1):F9-16

Vaccination and HIV-1 replication during highly active antiretroviral therapy [letter] Kroon FP, et al. **AIDS** 1999 Jan 14;13(1):135-6

Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors [letter] Le Moing V, et al. **AIDS** 1998 Jul 30;12(11):1395-7

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17-21

Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy [letter] Martínez E, et al. **AIDS** 1999 Jan 14;13(1):147-8

Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. Martinon F, et al. **AIDS** 1999 Feb 4;13(2):185-94

Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy [letter] Mastroianni CM, et al. **AIDS** 1998 Oct 1;12(14):1939-40

CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy [letter] Meroni L, et al. **AIDS** 1999 Apr 1;13(5):621-2

Opportunistic infections occurring during highly active antiretroviral treatment. Michelet C, et al. **AIDS** 1998 Oct 1;12(14):1815-22

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. Mitsuyasu RT, et al. **AIDS** 1998 Jul 30;12(11):F103-9

Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. Mocroft A, et al. **AIDS** 1998 Nov 12; 12(16):2161-7

Reversal of abnormalities of neutrophil adhesion molecule expression in HIV infection following protease inhibitor therapy [letter] Moore DA, et al. **AIDS** 1998 Oct 22; 12(15):2083-4

Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland [letter] Nadal D, et al. **AIDS** 1998 Dec 3;12(17):2356-7

Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy? [letter] Padberg J, et al. **AIDS** 1999 Feb 4;13(2):284-5

Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. Pezzotti P, et al. **AIDS** 1999 Feb 4;13(2):249-55

Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. Race E, et al. **AIDS** 1998 Aug 20;12(12):1465-74

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. Renaud M, et al. **AIDS** 1999 Apr 16;13(6):669-76

Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. Ruiz L, et al. **AIDS** 1999 Jan 14;13(1):F1-8

Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? Schechter M, et al. **AIDS** 1999 Jan 14; 13(1):97-102

The effect of protease inhibitors on weight and body composition in HIV-infected patients. Silva M, et al. **AIDS** 1998 Sep 10;12(13):1645-51

Rebound of HIV-1 viral load after suppression to very low levels [letter] Staszewski S, et al. **AIDS** 1998 Dec 3; 12(17):2360

Virological response to protease inhibitor therapy in an HIV clinic cohort. Staszewski S, et al. **AIDS** 1999 Feb 25; 13(3):367-73

Tuberculosis treatment practices in the era of protease inhibitors: a provider survey [letter] Sundaram V, et al. **AIDS** 1999 Jan 14;13(1):149-50

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. Tebas P, et al. **AIDS** 1999 Feb 4;13(2):F23-8

Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency. Thuret I, et al. **AIDS** 1999 Jan 14;13(1):81-7

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. Weverling GJ, et al. **AIDS** 1998 Jul 30;12(11):F117-22

Use of protease inhibitors among persons with AIDS in Los Angeles County. Sorvillo F, et al. **AIDS Care** 1999 Apr; 11(2):147-55

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. Adams GB, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):551-9

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. Churchill DR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1181-9

Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2. Regamey N, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):803-10

Amprenavir approved for HIV treatment [news] Miller SL. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1057-8

Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant [see comments] Davis JL, et al. **Am J Ophthalmol** 1999 Mar;127(3):283-7. Comment in: Am J Ophthalmol 1999 Mar;127(3):327-8.

Nelfinavir mesylate: a protease inhibitor. Pai VB, et al. **Ann Pharmacother** 1999 Mar;33(3):325-39 (64 ref.)

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Evans TG, et al. **Antiviral Res** 1998 Oct;39(3):163-73

Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Valdez H, et al. **Arch Intern Med** 1999 Aug 9-23;159(15):1771-6

Cytomegalovirus retinitis in transition [letter] Tay-Kearney ML, et al. **Aust N Z J Ophthalmol** 1999 Feb;27(1):89

HIV disease treatment in the era of HAART. Bonfanti P, et al. **Biomed Pharmacother** 1999 Mar;53(2):93-105 (124 ref.)

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Shafer RW, et al. **Biomed Pharmacother** 1999 Mar; 53(2):73-86 (105 ref.)

Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients [see comments] van den Horn GJ, et al. **Br J Ophthalmol** 1998 Sep;82(9):988-90. Comment in: Br J Ophthalmol 1998 Sep;82(9):981-2.

AIDS update 1999: viral reservoirs and immune-based therapies. Isada CM, et al. **Cleve Clin J Med** 1999 May; 66(5):267-9 (3 ref.)

Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects. Kelleher AD, et al. **Clin Exp Immunol** 1999 Jan;115(1):147-52

Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clough LA, et al. **Clin Infect Dis** 1999 Jul;29(1):75-81; discussion 82-4

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Krogstad P, et al. **Clin Infect Dis** 1999 May; 28(5):1109-18

Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination. Lallemand F, et al. **Clin Infect Dis** 1999 May;28(5):1184-5

Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Schluger NW. **Clin Infect Dis** 1999 Jan;28(1):130-5 (13 ref.)

Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. Tacconelli E, et al. **Clin Infect Dis** 1998 Oct; 27(4):901-2

Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Tantisiriwat W, et al. **Clin Infect Dis** 1999 May;28(5):1152-4

Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Tavel JA, et al. **Clin Infect Dis** 1999 Mar;28(3):643-76 (99 ref.)

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine. Michelet C, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):661-71

Protease inhibitors, diabetes mellitus and blood lipids. Meyer L, et al. **Diabetes Metab** 1998 Dec;24(6):547-9

Drug interactions of HIV protease inhibitors. Malaty LI, et al. **Drug Saf** 1999 Feb;20(2):147-69 (93 ref.)

A risk-benefit assessment of HIV protease inhibitors. Moyle GJ, et al. **Drug Saf** 1999 Apr;20(4):299-321 (94 ref.)

Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Reiser M, et al. **Eur J Med Res** 1999 Feb 25;4(2):54-8

Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. Rockstroh JK, et al. **Eur J Med Res** 1999 Jul 28;4(7):271-4

Cicatrization of cytomegalovirus retinitis following introduction of highly active anti-retroviral therapy: uveitis as a possible indicator of good ocular prognosis. Herbort CP, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Oct; 236(10):795-7

Does protease inhibitor treatment induce increased bleeding tendency in haemophilia? [letter] Mandalaki T, et al.

Haemophilia 1998 Sep;4(5):766–7

Behavioral research on AIDS--protease inhibitors and the new millennium: comment on Kelly, Otto-Salaj, Sikkema, Pinkerton, and Bloom (1998). Ferrando S.
Health Psychol 1998 Jul;17(4):307–9

Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Kelly JA, et al.
Health Psychol 1998 Jul;17(4):310–9 (100 ref.)

Restoration of the immune system with anti-retroviral therapy. Autran B, et al. **Immunol Lett** 1999 Mar; 66(1–3):207–11 (9 ref.)

Apoptosis and the CD95 system in HIV disease: impact of highly active anti-retroviral therapy (HAART). Gougeon ML, et al. **Immunol Lett** 1999 Mar;66(1–3):97–103

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Nixon DF, et al. **Immunol Lett** 1999 Mar;66(1–3):219–28

Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Pontesilli O, et al. **Immunol Lett** 1999 Mar;66(1–3):213–7

Preliminary experiences with ritonavir in children with advanced HIV infection. Horneff G, et al. **Infection** 1999 Mar-Apr;27(2):103–7

The role of proteinases in the treatment of HIV infection. Gazzard B. **Int J STD AIDS** 1998;9 Suppl 1:28–31 (20 ref.)

Rethinking about the role of antiretroviral regimens for HIV-related chronic diarrhoea [letter; comment] Famularo G, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):445–6 . Comment on: Ital J Gastroenterol Hepatol 1997 Dec;29(6):577–8.

Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor [letter] Nigro L, et al.
Ital J Gastroenterol Hepatol 1999 Jan-Feb;31(1):85–6

Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. Catucci M, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):203–8

Immune function and phenotype before and after highly active antiretroviral therapy. Søndergaard SR, et al.
J Acquir Immune Defic Syndr 1999 Aug 15;21(5):376–83

Protease inhibitor use among a community sample of people with HIV disease. Bing EG, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 15;20(5):474–80

Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. Keiser P, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Jan 1;20(1):28–33

Negative result of cytomegalovirus blood culture with restoration of CD4+ T-cell reactivity to cytomegalovirus after HAART in an HIV-1-infected patient [letter] Li TS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):514–5

Substance users and protease inhibitors: do barriers exist? [letter] Michaels S, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Feb 1;20(2):212–3

Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV-infected individuals with anemia of chronic disease [letter] Mylonakis E, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Nov 1;19(3):306–7

Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. Spach DH, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):818–21

Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. Bossi P, et al.
J Clin Microbiol 1999 Sep;37(9):2910–2

Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. Koch N, et al. **J Clin Microbiol** 1999 May;37(5):1595–7

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. Moyle GJ, et al.
J Clin Pharmacol 1998 Aug;38(8):736–43

HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. Stone VE, et al.
J Gen Intern Med 1998 Sep;13(9):586–93

What's new in HIV. Morris-Jones S, et al. **J Infect** 1999 Mar;38(2):i–ii

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Deeks SG, et al. **J Infect Dis** 1999 Jun; 179(6):1375–81

Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. Dworkin MS, et al.
J Infect Dis 1999 Sep;180(3):621–5

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection [letter] Fialaire P, et al.
J Infect Dis 1999 Aug;180(2):574–5

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, et al. **J Infect Dis** 1999 Jun;179(6):1356–64

Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo, Brazil. Pilcher CD, et al.
J Infect Dis 1999 May;179(5):1259–63

The effectiveness of combined saquinavir and ketoconazole treatment in reducing HIV viral load. Jordan WC.
J Natl Med Assoc 1998 Oct;90(10):622–4

Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. Sleasman JW, et al. **J Pediatr** 1999 May;134(5):597–606

Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. Dulioust A, et al. **J Virol** 1999 Jan; 73(1):850–4

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6721–8

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. Shafer RW, et al.
J Virol 1999 Jul;73(7):6197–202

Association of the CCR5delta32 mutation with improved response to antiretroviral therapy [letter] Valdez H, et al.
JAMA 1999 Aug 25;282(8):734

HIV and AIDS. Gap between biology and reality in AIDS. Carr A, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV16 (5 ref.)

Progress in HIV-1 therapy continues on upward track [news] Montaner J, et al. **Lancet** 1999 Feb 13;353(9152):565

Some state space models of HIV pathogenesis under treatment by anti-viral drugs in HIV-infected individuals. Tan WY, et al. **Math Biosci** 1999 Mar 1;156(1–2):69–94

Use of combination antiretroviral therapy in pregnant women with HIV disease. Newshan G, et al.
MCN Am J Matern Child Nurs 1998 Nov-Dec; 23(6):307–12; quiz 313 (22 ref.)

Amprenavir: a new HIV protease inhibitor.
Med Lett Drugs Ther 1999 Jul 16;41(1057):64–6

Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Baum SE, et al.
Mil Med 1999 Sep;164(9):609–12

HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Hoegl L, et al. **Mycoses** 1998 Sep-Oct;41(7–8):321–5

Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient [letter] Velasco M, et al.
N Engl J Med 1999 Jun 3;340(22):1765–6

Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Fleury S, et al. **Nat Med** 1998 Jul;4(7):794–801

Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome. Dellow E, et al.
Nephrol Dial Transplant 1999 Mar;14(3):744–7

State of the art: antiretroviral and prophylactic treatments in HIV/AIDS. Porche DJ. **Nurs Clin North Am** 1999 Mar; 34(1):95–112 (37 ref.)

HIV drug now approved for use with protease inhibitors [published erratum appears in Nurse Pract 1998 Oct;23(10):89] **Nurse Pract** 1998 Oct;23(10):89

Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients. Schwenk A, et al.
Nutrition 1999 Jun;15(6):453–7

Phase III results of second-generation HIV protease inhibitor reported [news] **Oncology (Huntingt)** 1998 Nov;12(11):1616

Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Diz Dios P, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Apr;87(4):437–41

Growth hormone exerts potent anabolic effects in an adolescent with human immunodeficiency virus wasting. Dreimane D, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):167–9

Early experience with protease inhibitors in human immunodeficiency virus-infected children. Sáez-Llorens X, et al. **Pediatr Infect Dis J** 1998 Aug;17(8):728–38 (90 ref.)

Antiretroviral therapy and medical management of pediatric HIV infection and 1997 USPHS/IDSA report on the prevention of opportunistic infections in persons infected with human immunodeficiency virus. **Pediatrics** 1998 Oct; 102(4 Pt 2):999–1085 (267 ref.)

Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Nijhuis M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14441–6

Development of HIV protease inhibitors: a survey. Ren S, et al. **Prog Drug Res** 1998;51:1–31 (63 ref.)

Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Ullum H, et al. **Scand J Immunol** 1999 May;49(5):539–47

Complete histological regression of Kaposi's sarcoma following treatment with protease inhibitors despite persistence of HHV-8 in lesions. Benfield TL, et al.
Scand J Infect Dis 1998;30(6):613–5

HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Blanche P, et al.
Scand J Infect Dis 1998;30(6):615–6

Continued therapy with HIV-1 protease inhibitors, despite previous hypersensitivity reactions, through coadministration of prednisone. Prins JM, et al.
Scand J Infect Dis 1998;30(6):612–3

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Sheikh AM, et al.
Transplantation 1999 Jul 27;68(2):307–9

[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1129–33 (Eng. Abstr.) **(Dut)**

[Modification or stopping of the initial antiretroviral combination therapy with protease-inhibitors: incidence and reasons] van Roon EN, et al.
Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2231 **(Dut)**

[Factors predictive of early virologic response after a first treatment with an protease inhibitor in the course of HIV infection] Frottier J, et al. **Bull Acad Natl Med** 1998; 182(5):981–92; discussion 992–5 (Eng. Abstr.) **(Fre)**

[Incidence and evaluation of viral retinitis in patients infected with the HIV virus and treated with HIV protease inhibitors] Labetoulle M, et al. **J Fr Ophtalmol** 1998 Oct; 21(8):567–76 (Eng. Abstr.) **(Fre)**

[Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients] Bobin S, et al.
Pathol Biol (Paris) 1998 Jun;46(6):418–9 (Eng. Abstr.) **(Fre)**

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412–5 (Eng. Abstr.) **(Fre)**

[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor] Mouroux M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):549–52 (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of ocular viral infections in AIDS patients] Guex-Crosier Y. **Rev Med Suisse Romande** 1998 Nov;118(11):941–7 (15 ref.) (Eng. Abstr.) **(Fre)**

[HIV infections: mortality reduced only in developed countries (news)] Wehr A. **Dtsch Med Wochenschr** 1999 May 7;124(18):A8–9 **(Ger)**

[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions] Fätkenheuer G, et al.
Internist (Berl) 1998 Sep;39(9):927–34 (37 ref.) **(Ger)**

[The use of HIV-1 protease inhibitors. Their effects on AIDS-correlated outpatient and hospitalization activities. A catchment area study] Resta F, et al.
Recenti Prog Med 1998 Dec;89(12):623–4 (Eng. Abstr.) **(Ita)**

[Granular lymphocyte-proliferative disorder following initiation of protease inhibitor therapy in a patient with acquired immunodeficiency syndrome] Tanaka K, et al.
Kansenshogaku Zasshi 1999 Jul;73(7):702–6 (Eng. Abstr.) **(Jpn)**

[Combined polychemotherapy of patients with chronic hepatitis C] Nikitin IG, et al. **Klin Med (Mosk)** 1999; 77(5):24–6 **(Rus)**

[New approaches to the chemotherapy of HIV infection] Karamova EV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan-Feb;(1):84–6 (Eng. Abstr.) **(Rus)**

[Clinical and immuno-virologic efficacy of the expanded access use of protease inhibitors for HIV-1 advanced disease] Gómez-Vera J, et al. **An Med Interna** 1999 May; 16(5):218–24 (Eng. Abstr.) **(Spa)**

[Survival of patients with AIDS treated with protease inhibitors] Martínez Avilés P, et al. **An Med Interna** 1999 May;16(5):225–8 (Eng. Abstr.) **(Spa)**

[Virologic levels for HIV before and after the introduction of protease inhibitors (letter)] Molinero M, et al.
An Med Interna 1998 Sep;15(9):508–9 **(Spa)**

[Antiretroviral treatment in 1999: from uncertainty to hopefulness (editorial)] Pujol de la Llave E.
An Med Interna 1999 May;16(5):215–7 (47 ref.) **(Spa)**

[HIV-1 protease inhibitors. Why, when, and how? (editorial)] Gatell JM. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):393–4 **(Spa)**

[Prevention of opportunistic infections in the protease inhibitor era] Viciana P, et al.
Enferm Infecc Microbiol Clin 1998;16 Suppl 1:1–10 (51 ref.) (Eng. Abstr.) **(Spa)**

[Admissions and mortality in a HIV unit before and after protease inhibitors (letter)] Soriano V, et al.
Rev Clin Esp 1998 Oct;198(10):715 **(Spa)**

URINE

Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Trainor LD, et al.
Arch Pathol Lab Med 1998 Mar;122(3):256–9

Indinavir crystallization and urolithiasis. Grases F, et al.
Int Urol Nephrol 1999;31(1):23–9

HIV PROTEINASE see **HIV PROTEASE**

HIV RECEPTORS

HIV RECEPTORS see **RECEPTORS, HIV**

HIV-RELATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

HIV-RELATED OPPORTUNISTIC INFECTIONS see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

HIV REV GENE PRODUCT see **GENE PRODUCTS, REV**

HIV REV-RESPONSIVE ELEMENT see **GENES, ENV**

HIV SEROCONVERSION see **HIV SEROPOSITIVITY**

HIV SERODIAGNOSIS see **AIDS SERODIAGNOSIS**

HIV SERONEGATIVITY

see related
HIV SEROPOSITIVITY

Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Carpenter LM, et al. **AIDS** 1999 Jun 18;13(9):1083-9

HIV serostatus of sexual partners of HIV-positive and HIV-negative homosexual men in Sydney [letter] Grulich AE, et al. **AIDS** 1998 Dec 24;12(18):2508

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy [letter] Rice PS, et al. **AIDS** 1999 Apr 16; 13(6):729-31

Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). Tabet SR, et al. **AIDS** 1998 Oct 22;12(15):2041-8

Coping among HIV negative and HIV positive female injection drug users. Brook DW, et al.
AIDS Educ Prev 1999 Jun;11(3):262-73

Psychosocial correlates of unprotected anal sex in a cohort of gay men attending an HIV-negative support group. Dilley JW, et al. **AIDS Educ Prev** 1998 Aug;10(4):317-26

Maintenance of safe sex behavior by HIV-serodiscordant heterosexual couples. Skurnick JH, et al.
AIDS Educ Prev 1998 Dec;10(6):493-505

Syphilitic lymphadenopathy. Histology and human immunodeficiency virus status. Farhi DC, et al.
Am J Clin Pathol 1999 Sep;112(3):330-4

Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Germani Y, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):1008-14

Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Bloch KC, et al.
Ann Intern Med 1998 Nov 1;129(9):698-704

The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. Barozzi P, et al. **Ann Oncol** 1999 Apr;10(4):467-9

A randomized controlled clinical trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and -seronegative homosexual men [published erratum appears in Arch Gen Psychiatry 1999 Aug;56(8):693] Goodkin K, et al.
Arch Gen Psychiatry 1999 Jan;56(1):52-9

Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Feldman C, et al. **Chest** 1999 Jul;116(1):107-14

Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Johnson JG, et al. **Compr Psychiatry** 1999 Jan-Feb; 40(1):31-4

Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Aznar JA, et al. **Haemophilia** 1998 Jan;4(1):21-4

An unusual haemarthrosis in an HIV-seronegative haemophilia A patient. Ménart C, et al. **Haemophilia** 1998 Sep;4(5):752-4

Health status and satisfaction of asymptomatic HIV-positive haemophiliacs in Kyushu, Japan. Tanaka S, et al.
Haemophilia 1999 Jan;5(1):56-62

Influence of HIV status and age on cognitive representations of others. Carstensen LL, et al. **Health Psychol** 1998 Nov; 17(6):494-503

A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Eckert LO, et al. **Infect Dis Obstet Gynecol** 1999;7(3):158-64

Simian-virus-40 footprints in human lymphoproliferative disorders of HIV- and HIV+ patients. Martini F, et al. **Int J Cancer** 1998 Dec 9;78(6):669-74

CD4+ T-lymphocytopenia, Kaposi's sarcoma, HHV-8 infection, severe seborrheic dermatitis, and onychomycosis in a homosexual man without HIV infection [letter] García-Silva J, et al. **Int J Dermatol** 1999 Mar;38(3):231-3

Sexual practices in a cohort of US women with and without human immunodeficiency virus. HERS Study. HIV Epidemiology Research Study. Zierler S, et al.
J Am Med Womens Assoc 1999 Spring;54(2):79-83

Primary epidural non-Hodgkin's lymphoma with cervical location in an HIV-negative child: case report. Köseoğlu V, et al. **J Child Neurol** 1998 Oct;13(10):520-2

The prognostic factors of cryptococcal meningitis in HIV-negative patients. Lu CH, et al. **J Hosp Infect** 1999 Aug;42(4):313-20

Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. Krone MR, et al. **J Infect Dis** 1998 Oct;178(4):978-82

HIV-related gender biases among malnourished children in Abidjan, Côte D'Ivoire. Beau JP, et al. **J Trop Pediatr** 1999 Jun;45(3):169-71

From the Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. **JAMA** 1998 Nov 25; 280(20):1736

Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma [published erratum appears in Lab Invest 1999 Jul;79(7):835] Teruya-Feldstein J, et al. **Lab Invest** 1998 Dec;78(12):1637-42

Comparison between human immunodeficiency virus positive and negative patients with tuberculosis in Southern Brazil. Henn L, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun; 94(3):377-81

The prevalence of herpes family virus DNA in the conjunctiva of patients positive and negative for human immunodeficiency virus using the polymerase chain reaction. Lee-Wing MW, et al. **Ophthalmology** 1999 Feb; 106(2):350-4

Atypical mycobacterial pulmonary disease and bronchial obstruction in HIV-negative children. Dore ND, et al.
Pediatr Pulmonol 1998 Dec;26(6):380-8

Transplacental transmission of hepatitis C virus in HIV-negative mothers. Agha S, et al. **Res Virol** 1998 Jul-Aug;149(4):229-34

Influence of HIV positive status on sexual behavior among males. Ventura-Filipe EM, et al. **Rev Saude Publica** 1998 Dec;32(6):503-13

Intestinal microsporidiosis in a HIV-seronegative patient. Svenungsson B, et al. **Scand J Infect Dis** 1998;30(3):314-6

Cryptosporidium infection in HIV-seropositive and seronegative populations in southern Thailand. Uga S, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):100-4

Cryptococcosis in HIV negative patients: findings on chest radiography. Roebuck DJ, et al. **Thorax** 1998 Jul; 53(7):554-7

Microsporidiosis in HIV-seronegative patients in Mali. Desportes-Livage I, et al. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):423-4

Detection of HIV-1 RNA in two consecutive blood donations screened negative for HIV antibodies. Burin des Roziers N, et al. **Vox Sang** 1998;75(4):298-302

[Cytomegalovirus colonic pseudo-tumor in an HIV-negative man (letter)] Vaillant E, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):974-5 **(Fre)**

[Cerebral miliary granulomatosis with Histoplasma capsulatum in an HIV seronegative patient] Hadi M, et al. **Rev Neurol (Paris)** 1999 Mar;155(3):231-3 (Eng. Abstr.) **(Fre)**

[Diagnostic imaging of current pulmonary tuberculosis. Clinical significance of the presentation patterns and particular aspects in HIV-positive and HIV-negative subjects] Diotallevi P, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):55-61 (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

[A report on 8 seronegative converted HIV/AIDS patients with traditional Chinese medicine] Lu WB, et al.
Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1997 May; 17(5):271-3 (Eng. Abstr.) **(Chi)**

GENETICS

Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in west Africa. Kokkotou E, et al.
J Hum Virol 1998 Nov-Dec;1(7):469-74.

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. Bernard NF, et al. **J Infect Dis** 1999 Mar;179(3):538-47

Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. Goh WC, et al. **J Infect Dis** 1999 Mar; 179(3):548-57

IMMUNOLOGY

Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects. Nicastri E, et al. **AIDS** 1999 Jul 30;13(11):1333-6

HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail to develop a Bacillus Calmette-Guérin scar [letter] Ota MO, et al. **AIDS** 1999 May 28;13(8):996-8

Role of peripheral blood mononuclear cell subsets of seronegative donors in HIV replication: suppression by CD8+ and CD16+ cells and enhancement by CD14+ monocytes [letter] Alfano M, et al.
AIDS Res Hum Retroviruses 1999 Mar 20;15(5):489-91

Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. Lopalco L, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1079-85

Human immunodeficiency virus V3 peptide-reactive antibodies are present in normal HIV-negative sera. Metlas R, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):671-7

Cardiac autoimmunity in HIV related heart muscle disease. Currie PF, et al. **Heart** 1998 Jun;79(6):599-604

Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Juffermans NP, et al. **Infect Immun** 1999 Aug;67(8):4295-7

Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). Anastos K, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):141-7

Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. Leigh JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):373-80

Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. Raux M, et al. **J Immunol Methods** 1999 Jan 1;222(1-2):111-24

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. Bernard NF, et al. **J Infect Dis** 1999 Mar;179(3):538-47

Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. Goh WC, et al. **J Infect Dis** 1999 Mar; 179(3):548-57

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. Mazzoli S, et al. **J Infect Dis** 1999 Sep;180(3):871-5

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, et al. **Vaccine** 1999 Jan; 17(1):64-71

PHYSIOLOGY

Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Dolezal C, et al.
Am J Drug Alcohol Abuse 1999 May;25(2):281-303

Classifying individuals based on predictors of random effects. Multicenter AIDS Cohort Study. Lyles RH, et al.
Stat Med 1999 Jan 15;18(1):35-52

HIV SEROPOSITIVITY

see related
HIV SERONEGATIVITY
HIV SEROPREVALENCE

How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee. **AIDS** 1999 Jul 9;13(10):1241-7

Delayed HIV-1 seroconversion after antiretroviral therapy [letter] Apetrei C, et al. **AIDS** 1998 Oct 1;12(14):1935-6

Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Carpenter LM, et al. **AIDS** 1999 Jun 18;13(9):1083-9

HIV serostatus of sexual partners of HIV-positive and HIV-negative homosexual men in Sydney [letter] Grulich AE, et al. **AIDS** 1998 Dec 24;12(18):2508

HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. Kilmarx PH, et al. **AIDS** 1998 Oct 1;12(14):1889-98

Coping among HIV negative and HIV positive female injection drug users. Brook DW, et al.
AIDS Educ Prev 1999 Jun;11(3):262-73

Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Germani Y, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):1008-14

Growth in the first two years of uninfected children born to HIV-1 seropositive mothers. Agostoni C, et al.
Arch Dis Child 1998 Aug;79(2):175-8

Focal epithelial hyperplasia in an HIV positive man. An illustrated case and review of the literature. Marvan E, et al. **Aust Dent J** 1998 Oct;43(5):305-10 (36 ref.)

Double gloving and a glove perforation indication system during the dental treatment of HIV-positive patients: are they necessary? Avery CM, et al. **Br Dent J** 1999 Jan 9; 186(1):27-9

HIV retinopathy at seroconversion [letter] Finlayson J, et al. **Br J Ophthalmol** 1998 Nov;82(11):1339-40

Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Feldman C, et al. **Chest** 1999 Jul;116(1):107-14

Human immunodeficiency virus-related risk behavior among Italian psychiatric inpatients. Grassi L, et al.
Compr Psychiatry 1999 Mar-Apr;40(2):126-30

Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Wolf BW, et al. **Food Chem Toxicol** 1998 Dec; 36(12):1085-94

Spinal epidural haematoma in haemophilia A. Schmitz A, et al. **Haemophilia** 1998 Jan;4(1):51-5

Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Stanworth SJ, et al. **Haemophilia** 1998 Mar;4(2):109–14

Health status and satisfaction of asymptomatic HIV-positive haemophiliacs in Kyushu, Japan. Tanaka S, et al. **Haemophilia** 1999 Jan;5(1):56–62

Influence of HIV status and age on cognitive representations of others. Carstensen LL, et al. **Health Psychol** 1998 Nov; 17(6):494–503

Streptococcus pneumoniae septic arthritis and osteomyelitis in an HIV-seropositive patient. Oliker R, et al. **Heart Lung** 1999 Jan–Feb;28(1):74–6

A matched prospective study of human immunodeficiency virus serostatus, human papillomavirus DNA, and cervical lesions detected by cytology and colposcopy. Eckert LO, et al. **Infect Dis Obstet Gynecol** 1999;7(3):158–64

Simian-virus-40 footprints in human lymphoproliferative disorders of HIV- and HIV+ patients. Martini F, et al. **Int J Cancer** 1998 Dec 9;78(6):669–74

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Prins M, et al. **Int J Epidemiol** 1999 Jun;28(3):541–9

Determinants of survival in HIV-positive patients. Baillargeon J, et al. **Int J STD AIDS** 1999 Jan;10(1):22–7

Cerebral vasculitis and haemorrhage in a HIV positive intravenous drug abuser. Bane A, et al. **Ir Med J** 1999 May–Jun;92(4):340

The law and ethics in relation to dentists treating HIV-positive patients: report on a recent U.S. Supreme Court case. Graham PE, et al. **J Can Dent Assoc** 1999 Jan; 65(1):27–30

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. Jung D, et al. **J Clin Pharmacol** 1999 Aug;39(8):800–4

Asymptomatic HIV under the ADA: the invisible, yet legitimate disability. Davis CS. **J Contemp Health Law Policy** 1998 Fall;15(1):357–400 (0 ref.)

Immediate placement of an endosseous root-form implant in an HIV-positive patient: report of a case. Rajnay ZW, et al. **J Periodontol** 1998 Oct;69(10):1167–71

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Lole KS, et al. **J Virol** 1999 Jan;73(1):152–60

A case of unpaired anterior cerebral artery occlusion producing akinetic mutism [letter] Oomman A, et al. **Neurol India** 1999 Jun;47(2):157–8

Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Meyerhoff DJ, et al. **Neurology** 1999 Mar 23;52(5):995–1003

Factors associated with Mexico City dentists' willingness to treat AIDS/HIV-positive patients. Irigoyen M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):169–74

Apoptosis-associated proteins in oral lymphomas from HIV-positive patients. Regezi JA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Aug;86(2):196–202

HIV-risk behaviour and knowledge about HIV/AIDS among patients with schizophrenia. Grassi L, et al. **Psychol Med** 1999 Jan;29(1):171–9

Influence of HIV positive status on sexual behavior among males. Ventura-Filipe EM, et al. **Rev Saude Publica** 1998 Dec;32(6):503–13

Knowledge of HIV-positivity had no impact on AIDS survival time among Danish AIDS patients 1980–95. Jensen L, et al. **Scand J Infect Dis** 1998;30(3):231–6

Death of a vaccine? [news] Ezzell C. **Sci Am** 1999 Jul; 281(1):27

Sexual behaviour and risk assessment of HIV seroconvertors among urban male factory workers in Zimbabwe. Ray S, et al. **Soc Sci Med** 1998 Nov;47(10):1431–43

Progression to AIDS in relation to clinical factors and clotting product consumption. A 14-year follow-up of a cohort of 52 Dutch HIV-1-infected haemophilic patients. Roosendaal G, et al. **Vox Sang** 1998;75(4):261–6

[Changes of knowledge of HIV-positivity before development of AIDS among Danish patients with AIDS 1988–1997] Smith E, et al. **Ugeskr Laeger** 1999 May 31; 161(22):3281–5 (Eng. Abstr.) **(Dan)**

["Safe sex" among HIV-positive heterosexual couples] Weis NM, et al. **Ugeskr Laeger** 1999 Jun 14;161(24):3666–9 (Eng. Abstr.) **(Dan)**

[Tracing infants born to HIV positive mothers (letter)] Hervé F, et al. **Arch Pediatr** 1999 Aug;6(8):902–3 **(Fre)**

[Interaction of psychological and social factors in the care of AIDS virus carriers] Santiago Delefosse M. **Encephale** 1998 Nov–Dec;24(6):497–502 (Eng. Abstr.) **(Fre)**

[Orbital lymphoma and AIDS. Apropos of a case] Than-Trong T, et al. **J Fr Ophtalmol** 1999 May;22(5):594–8 (Eng. Abstr.) **(Fre)**

[Osteoarticular Mycobacterium xenopi infection] Ollagnier E, et al. **Presse Med** 1998 May 2–9;27(17):800–3 (Eng. Abstr.) **(Fre)**

[Hodgkin's disease in patients infected with the human immunodeficiency virus] Costello R, et al. **Rev Med Interne** 1998 Aug;19(8):558–64 (69 ref.) (Eng. Abstr.) **(Fre)**

[Endobronchial tuberculosis presenting as an obstructive tumor in an HIV-1-positive patient. Apropos of a case and review of the literature] Saadoun R, et al. **Rev Med Interne** 1998 May;19(5):344–7 (9 ref.) (Eng. Abstr.) **(Fre)**

[Zulu people and Isangoma people--HIV and tuberculosis (see comments)] Eilertsen L, et al. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1798–800. Comment in: Tidsskr Nor Laegeforen 1999 Jun 10;119(15):2240. **(Nor)**

[Endoscopic cholangiography in HIV+ patient. A clinical approach (editorial; comment)] Varsky CG. **Acta Gastroenterol Latinoam** 1998;28(3):271–2. Comment on: Acta Gastroenterol Latinoam 1998 ;28(3):237–41. **(Spa)**

[How to reduce the prevalence of HIV-positive blood donors] León G, et al. **Invest Clin** 1998 Dec;39(4):307–21 (Eng. Abstr.) **(Spa)**

[Should we include seropositive patients in autotransfusion programs?] Herranz Marti MJ, et al. **Sangre (Barc)** 1998 Aug;43(4):317–20 (32 ref.) **(Spa)**

[Serious accusations against HIV-positive persons (letter)] Bäckekihl U. **Lakartidningen** 1999 Sep 8;96(36):3759–60 **(Swe)**

BLOOD

Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks. Stoss M, et al. **Arzneimittelforschung** 1999 Apr; 49(4):366–73

Serum malondialdehyde in HIV-seropositive children negatively correlates with CD4+ lymphocytes count. Jareño EJ, et al. **Biofactors** 1998;8(1–2):129–32

A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis. Janier M, et al. **Dermatology** 1999;198(4):362–9

Viral markers in a blood donor population. Mwangi JW. **East Afr Med J** 1999 Jan;76(1):35–7

Effect of d-fenfluramine on the lymphocyte response of HIV+ humans. Mathews HL, et al. **Int J Immunopharmacol** 1998 Dec;20(12):751–63

Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Christeff N, et al. **Nutrition** 1999 Jul–Aug;15(7–8):534–9

CEREBROSPINAL FLUID

Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Kelder W, et al. **Ann Neurol** 1998 Nov;44(5):831–5

LTB4 and LTC4 are absent in the cerebrospinal fluid of human immunodeficiency virus type 1-seropositive persons with toxoplasmic encephalitis: evidence for inhibition of 5-lipoxygenase by Toxoplasma gondii. Mayatepek E, et al. **J Infect Dis** 1999 Mar;179(3):714–6

Interpretation of high levels of HIV-1 RNA in the cerebrospinal fluid (CSF) using amplicor HIV-1 monitor test. Honderlick P, et al. **Pathol Biol (Paris)** 1999 May; 47(5):560–2

CLASSIFICATION

Classifying individuals based on predictors of random effects. Multicenter AIDS Cohort Study. Lyles RH, et al. **Stat Med** 1999 Jan 15;18(1):35–52

COMPLICATIONS

Auto-amputation of the penis in HIV infected patient [letter] Bakare RA, et al. **Afr J Med Med Sci** 1998 Mar–Jun; 27(1–2):137

Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy [letter] Aldeen T, et al. **AIDS** 1998 Sep 10;12(13):1719–20

Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy [see comments] Heard I, et al. **AIDS** 1998 Aug 20; 12(12):1459–64. Comment in: AIDS 1999 Feb 25;13(3):424–5.

Response to: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy, by Heard et al. AIDS 1998, 12:1459–1464 [letter] Hoff C. **AIDS** 1999 Jun 18; 13(9):1149–50

Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. Touloumi G, et al. **AIDS** 1998 Sep 10;12(13):1691–7

Syphilitic lymphadenopathy. Histology and human immunodeficiency virus status. Farhi DC, et al. **Am J Clin Pathol** 1999 Sep;112(3):330–4

Detecting disseminated Mycobacterium avium complex infections in HIV-positive patients. The usefulness of bone marrow trephine biopsy specimens, aspirate cultures, and blood cultures. Hussong J, et al. **Am J Clin Pathol** 1998 Dec;110(6):806–9

Epibulbar allergic granulomatous nodules in a human immunodeficiency virus-positive patient. Godfrey DG, et al. **Am J Ophthalmol** 1998 Dec;126(6):844–6

Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Smith JA, et al. **Am J Ophthalmol** 1999 Feb;127(2):164–9

Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Rabkin JG, et al. **Am J Psychiatry** 1999 Jan;156(1):101–7

Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Murray J, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):733–40

Prevalence of sinonasal symptoms in patients with HIV infection. Porter JP, et al. **Am J Rhinol** 1999 May–Jun; 13(3):203–8

Human papillomavirus-associated penile squamous cell carcinoma in HIV-positive patients. Poblet E, et al. **Am J Surg Pathol** 1999 Sep;23(9):1119–23

Breast cancer and HIV: what do we know? Guth AA. **Am Surg** 1999 Mar;65(3):209–11 (24 ref.)

Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors [letter] Mauss S, et al. **Ann Intern Med** 1999 Jan 19;130(2):162–3

Tuberculous meningitis and co-infection with HIV. Topley JM, et al. **Ann Trop Paediatr** 1998 Dec;18(4):261–6

Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Keung AC, et al. **Antimicrob Agents Chemother** 1999 May; 43(5):1230–3

Red nodule on the forearm of an HIV-positive man. Isolated cutaneous Mycobacterium avium-intracellulare infection. Taylor CR, et al. **Arch Dermatol** 1998 Oct;134(10):1279–80, 1282–3

Oral cavity and oropharyngeal tumors in human immunodeficiency virus-positive patients: acute response to radiation therapy. Kao GD, et al. **Arch Otolaryngol Head Neck Surg** 1999 Aug;125(8):873–6

Cerebral infarction associated with vasculitis due to varicella zoster virus in patients infected with the human immunodeficiency virus. Picard O, et al. **Biomed Pharmacother** 1997;51(10):449–54

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa--laboratory parameters. van Staden AM, et al. **Cent Afr J Med** 1998 Oct; 44(10):246–50

AIDS-related Kaposi's sarcoma is a clonal neoplasm. Rabkin CS, et al. **Clin Cancer Res** 1995 Mar;1(3):257–60

Incidence of human immunodeficiency virus antibody in a prenatal population at a community hospital. Alexander TS, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):140–1

Episodic spontaneous hyperhidrosis hypothermia in human immunodeficiency virus-positive patients. Okechukwu CN, et al. **Clin Infect Dis** 1999 Jul;29(1):210

Photo quiz. Benign lymphoepithelial cysts. Samandari T. **Clin Infect Dis** 1998 Oct;27(4):687, 884–5

Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Weissman SB, et al. **Clin Infect Dis** 1999 Jul;29(1):223–4

Motor neuron disease and HIV-1 infection in a 30-year-old HIV-positive heroin abuser: a causal relationship? Galassi G, et al. **Clin Neuropathol** 1998 May–Jun;17(3):131–5 (23 ref.)

Increased risk of wound complications and poor healing following laparotomy in HIV-seropositive and AIDS patients. Davis PA, et al. **Dig Surg** 1999;16(1):60–7

Perianal diseases in HIV-positive patients compared with a seronegative population. Nadal SR, et al. **Dis Colon Rectum** 1999 May;42(5):649–54

Health-related service utilization and HIV risk behaviors among HIV infected injection drug users and crack smokers. Booth RE, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1–2):69–78

Reaching and enrolling drug users for HIV prevention: a multi-site analysis. Cunningham-Williams RM, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):1–10

Predictors of increased condom use following HIV intervention with heterosexually active drug users. Kwiatkowski CF, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):57–62

Rosai-Dorfman disease (extranodal sinus histiocytosis) in a patient with HIV. Perry BP, et al. **Ear Nose Throat J** 1998 Oct;77(10):855–8

Management of benign lymphoepithelial lesions of the parotid gland in human immunodeficiency virus-positive patients. Kooper DP, et al. **Eur Arch Otorhinolaryngol** 1998; 255(8):427–9

Nutritional status of adult inpatients in Bujumbura, Burundi (impact of HIV infection). Niyongabo T, et al. **Eur J Clin Nutr** 1999 Jul;53(7):579–82

HIV seroprevalence in disseminated tuberculosis and chronic diarrhea. Merchant RH, et al. **Indian Pediatr** 1998 Sep; 35(9):883–7

Oral health behaviour and the prevalence of oral manifestations of HIV infection in a group of HIV positive adults. Marcenes W, et al. **Int Dent J** 1998 Dec;48(6):557–62

Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. Boonchai W, et al. **Int J Dermatol** 1999 May;38(5):348–50

Gynaecological conditions associated with HIV infection in women who are partners of HIV-positive Thai blood donors. Rugpao S, et al. **Int J STD AIDS** 1998 Nov; 9(11):677–82

Effect of receptive oral sex and smoking on the incidence of hairy leukoplakia in HIV-positive gay men. Shiboski CH, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1; 21(3):236–42

HIV-1 seroprevalence in Zambian patients with acute

diarrhea: a community-based study. Baboo KS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):160–3

High prevalence of insomnia in an outpatient population with HIV infection. Rubinstein ML, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):260–5

Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group. Sullivan PS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):266–73

Use of noninvasive electroacupuncture for the treatment of HIV-related peripheral neuropathy: a pilot study. Galantino ML, et al. **J Altern Complement Med** 1999 Apr; 5(2):135–42

Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings. Christensen LA, et al. **J Am Acad Audiol** 1998 Aug;9(4):292–8

Striae formation in two HIV-positive persons receiving protease inhibitors. Darvay A, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):467–9 (13 ref.)

Central serous chorioretinopathy and HIV. Spalding JM. **J Am Optom Assoc** 1999 Jun;70(6):391–8

Characterization of plantar verrucae among individuals with human immunodeficiency virus. Meberg R, et al. **J Am Podiatr Med Assoc** 1998 Sep;88(9):442–5

Detection of HIV seropositivity during an outbreak of Japanese encephalitis in Manipur. Neogi DK, et al. **J Commun Dis** 1998 Jun;30(2):113–6

Pneumococcal pneumonia associated with perianal herpes simplex virus type 2 in a HIV seropositive patient [letter] Clarke S, et al. **J Eur Acad Dermatol Venereol** 1998 Nov; 11(3):257–8

Sexually transmitted diseases in 1161 HIV-positive patients: a 38-month prospective study in southern Spain. Muñoz-Pérez MA, et al. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):221–6

Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. Kimura M, et al. **J Infect Dis** 1999 May;179(5):1297–300

Differential association of HIV-related neuropsychological impairment with semantic versus repetition priming. Jasiukaitis P, et al. **J Int Neuropsychol Soc** 1999 Jul; 5(5):434–41

Use of PCR to detect mycoplasma DNA in respiratory tract specimens from adult HIV-positive patients. Cultrera R, et al. **J Med Microbiol** 1998 Nov;47(11):983–6

Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women. Uberti-Foppa C, et al. **J Med Virol** 1998 Oct;56(2):133–7

Subacute painful lumbosacral polyradiculoneuropathy in immunocompromised patients. Steiner I, et al. **J Neurol Sci** 1999 Jan 1;162(1):91–3

Alveolar bone levels in AIDS and HIV seropositive patients and in control subjects. Persson RE, et al. **J Periodontol** 1998 Sep;69(9):1056–61

HIV-related gender biases among malnourished children in Abidjan, Côte D'Ivoire. Beau JP, et al. **J Trop Pediatr** 1999 Jun;45(3):169–71

Comparison between human immunodeficiency virus positive and negative patients with tuberculosis in Southern Brazil. Henn L, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun; 94(3):377–81

Methadone is poorly removed by haemodialysis [letter] Furlan V, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):254–5

Computerized and traditional stroop task dysfunction in HIV-1 infection. Hinkin CH, et al. **Neuropsychology** 1999 Apr;13(2):306–16

Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Christeff N, et al. **Nutrition** 1999 Jul-Aug;15(7–8):534–9

Tuberculosis, human immunodeficiency virus infection, and malnutrition in Burundi. Niyongabo T, et al. **Nutrition** 1999 Apr;15(4):289–93

Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Spitzer M. **Obstet Gynecol Surv** 1999 Feb;54(2):131–7 (51 ref.)

Punctate outer retinal toxoplasmosis in an HIV-positive child. Moraes HV Jr. **Ocul Immunol Inflamm** 1999 Jun; 7(2):93–5

The risk of serious odontogenic infections in HIV-positive patients: a pilot study. Miller EJ Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):406–9

Psoriasis associated with human immunodeficiency virus in an infant. McAleer P, et al. **Pediatr Dermatol** 1999 Mar-Apr;16(2):144–5

Two cases of cerebral aneurysms in HIV+ children. Fulmer BB, et al. **Pediatr Neurosurg** 1998 Jan;28(1):31–4 (15 ref.)

A 10-year-old boy, HIV positive, develops progressive weakness [clinical conference] George T, et al. **Pediatr Neurosurg** 1999 Apr;30(4):211–7

HIV risk factors among people with severe mental illness in urban and rural areas. Brunette MF, et al. **Psychiatr Serv** 1999 Apr;50(4):556–8

Psychiatric patients and HIV. Chung JY, et al. **Psychiatr Serv** 1999 Apr;50(4):487

NMS and HIV [letter] Horwath E, et al. **Psychiatr Serv** 1999 Apr;50(4):564

Unusual extracranial complications of otitis media in a young HIV patient: retropharyngeal and Mouret's abscess. Mevio E, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998; 119(3):199–201

HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Kelly PM, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):287–93

[Intestinal invagination and HIV infection] Halkic N, et al. **Ann Chir** 1999;53(6):531–4 **(Fre)**

[Chronic sinusitis in patients infected by HIV: therapeutic strategies] Castillo L, et al. **Ann Otolaryngol Chir Cervicofac** 1999 Jun;116(3):162–6 (Eng. Abstr.) **(Fre)**

[Should infertility be treated in couples where one of the partners is HIV seropositive?] Auroux M. **Contracept Fertil Sex** 1999 Feb;27(2):118–20 **(Fre)**

[For or against infertility treatment in couples where one partner is HIV seropositive] Plachot M. **Contracept Fertil Sex** 1999 Feb;27(2):120–1 **(Fre)**

[Giant anovulvar condyloma acuminata revealing hiv-1 seropositivity in a Centrafrican patient] Sepou A, et al. **Med Trop (Mars)** 1998;58(4):378–80 (Eng. Abstr.) **(Fre)**

[Primary pulmonary hypertension in an HIV-seropositive patient (letter)] Lambiotte F, et al. **Presse Med** 1999 Mar 20;28(11):582 **(Fre)**

[Septicemia due to Corynebacterium aquaticum in an HIV-seropositive patient with an implantable chamber catheter (letter)] Vasseur E, et al. **Presse Med** 1998 Oct 3;27(29):1476–7 **(Fre)**

[Knee replacement arthroplasty in hemophilia: results, complications and predictive elements of their occurrence] Vastel L, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Sep; 85(5):458–65 (Eng. Abstr.) **(Fre)**

(Facial palsy relevant to HIV seropositivity (letter)] Youssov K, et al. **Rev Neurol (Paris)** 1998 Apr;154(3):258 **(Fre)**

[Treatment for infertility in HIV positive couples--psychosomatic and ethical considerations] Siedentopf F, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:50–2 **(Ger)**

[Candida albicans morphotypes and in vitro adhesivity to cells of the human oral mucosa in HIV-positive and AIDS patients after exposure of blastospores to fluconazole. II] Spadari E, et al. **Minerva Stomatol** 1998 Jul-Aug; 47(7–8):293–7 (Eng. Abstr.) **(Ita)**

[Diagnostic imaging of current pulmonary tuberculosis. Clinical significance of the presentation patterns and particular aspects in HIV-positive and HIV-negative subjects] Diotallevi P, et al. **Radiol Med (Torino)** 1998 Jul-Aug;96(1-2):55–61 (Eng. Abstr.) **(Ita)**

[Endoscopic cholangiography in biliary tract diseases in HIV+ patients (see comments)] Curràs A, et al. **Acta Gastroenterol Latinoam** 1998;28(3):237–41 (Eng. Abstr.). Comment in: Acta Gastroenterol Latinoam 1998 ;28(3):269–70. Comment in: Acta Gastroenterol Latinoam 1998 ;28(3):271–2. **(Spa)**

[Endoscopic cholangiography in an HIV+ patient. A cholangiographic approach (editorial; comment)] Zagalsky DH. **Acta Gastroenterol Latinoam** 1998;28(3):269. Comment on: Acta Gastroenterol Latinoam 1998 ;28(3):237–41. **(Spa)**

[Acute pancreatitis due to amphotericin B in an HIV-positive patient (letter)] Catalán I, et al. **An Med Interna** 1999 Jan; 16(1):47–8 **(Spa)**

[Anorectal Hodgkin disease in an HIV-infected patient (letter)] Márquez-Moreno AJ, et al. **Med Clin (Barc)** 1999 May 1;112(15):598–9 **(Spa)**

[Bronchiectasia in HIV-positive patients] Monteverde A, et al. **Medicina (B Aires)** 1999;59(1):67–70 (Eng. Abstr.) **(Spa)**

[Meningitis in subjects with human immunodeficiency virus infection] Silva-Rosas C, et al. **Neurologia** 1999 Feb; 14(2):62–6 (Eng. Abstr.) **(Spa)**

[Gastric necrosis due to vasculitis in an HIV+ patient (letter)] Alcántara Gijón F, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):152–3 (6 ref.) **(Spa)**

[Anorectal diseases in HIV-positive patients. A prospective study] Sánchez Valdez G, et al. **Rev Gastroenterol Mex** 1998 Apr-Jun;63(2):89–92 (Eng. Abstr.) **(Spa)**

CONGENITAL

[Care for the Cuban child born to an HIV-seropositive mother] González Núñez I, et al. **Rev Cubana Med Trop** 1995;47(3):201, 203–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. Ishikawa K, et al. **AIDS** 1998 Aug 20;12(12):1419–25

Testing for HIV in California: volume and seropositivity in private versus public sites [letter] Johnson A, et al. **AIDS** 1998 Dec 24;12(18):2508–10

Relationship of HIV testing and high-risk behaviors among clients in methadone maintenance treatment. Grella CE, et al. **AIDS Educ Prev** 1998 Oct;10(5):403–16

HIV testing in substance abusers. Samet JH, et al. **Am J Drug Alcohol Abuse** 1999 May;25(2):269–80

Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Snyder DC, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):178–85

Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Kelen GD, et al. **Ann Emerg Med** 1999 Feb; 33(2):147–55

Think HIV: why physicians should lower their threshold for HIV testing. Freedberg KA, et al. **Arch Intern Med** 1999 Sep 27;159(17):1994–2000 (69 ref.)

Successful use of levonorgestrel intrauterine system in a HIV positive woman. Cooling H. **Br J Fam Plann** 1999 Apr; 25(1):25–6

Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants. Abrams EJ, et al. **Bull N Y Acad Med** 1995 Winter;72(2):443–53

Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe. Machekano R, et al. **Cent Afr J Med** 1998 Apr;44(4):98–102

Photo quiz. HIV seroconversion illness. Pendle S. **Clin Infect Dis** 1999 Mar;28(3):527, 677

Widespread HIV antibody testing of pregnant women--how accurate? [editorial] Melchreit R. **Conn Med** 1998 Oct; 62(10):621–2

Long-term effects of HIV counseling and testing for women: behavioral and psychological consequences are limited at 18 months posttest. Ickovics JR, et al. **Health Psychol** 1998 Sep;17(5):395–402

Self-efficacy and disclosure of HIV-positive serostatus to sex partners. Kalichman SC, et al. **Health Psychol** 1999 May;18(3):281–7

Number of pregnancies, outcome expectancies, and social norms among HIV-infected young women. Murphy DA, et al. **Health Psychol** 1998 Sep;17(5):470–5

A descriptive analysis of students seeking HIV antibody testing at a university health service [see comments] Anastasi MC, et al. **J Am Coll Health** 1999 Jul;48(1):13–9 . Comment in: J Am Coll Health 1999 Jul;48(1):3–6.

Partner notification and focused intervention as a means of identifying HIV-positive patients. Jordan WC, et al. **J Natl Med Assoc** 1998 Sep;90(9):542–6

'Delayed HIV sero-conversion' in an Indian male [letter] Kura MM, et al. **Natl Med J India** 1998 Jul-Aug; 11(4):201–2

Follow-up essential for positive home HIV test results [news] **Oncology (Huntingt)** 1999 Jan;13(1):81

[Therapeutic options for HIV infection should lead to increased utilization of HIV tests (see comments)] Coutinho RA, et al. **Ned Tijdschr Geneeskd** 1999 Mar 20; 143(12):598–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1395–6. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1396–7. **(Dut)**

[Photosensitivity as presenting sign of HIV infection. Control with triple antiretroviral therapy] Schreckenberg C, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):516–8 (Eng. Abstr.) **(Fre)**

[White-noise field campimetry in HIV+ patients] Hettesheimer H, et al. **Ophthalmologe** 1999 Jul;96(7):437–42 (Eng. Abstr.) **(Ger)**

[A patient with rapidly progressing renal failure, florid syphilis and positive HIV serology] Räz HR, et al. **Schweiz Med Wochenschr** 1998 Nov 21;128(47):1850–6 (Eng. Abstr.) **(Ger)**

[Can one predict the prognosis of HIV infection?] Furrer H, et al. **Schweiz Rundsch Med Prax** 1998 Oct 7; 87(41):1361–7 (42 ref.) **(Ger)**

[Testing for HIV infection in pregnant women at the obstetric centers in Italy] D'Ubaldo C, et al. **Minerva Ginecol** 1999 Jan-Feb;51(1-2):7–14 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy [letter] Aldeen T, et al. **AIDS** 1998 Sep 10;12(13):1719–20

Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. Andersson J, et al. **AIDS** 1998 Jul 30;12(11):F123–9

Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors [letter] Beauverie P, et al. **AIDS** 1998 Dec 24;12(18):2510–1

Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy [see comments] Heard I, et al. **AIDS** 1998 Aug 20; 12(12):1459–64. Comment in: AIDS 1999 Feb 25;13(3):424–5.

Response to: Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy, by Heard et al. AIDS 1998, 12:1459–1464 [letter] Hoff C. **AIDS** 1999 Jun 18; 13(9):1149–50

Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy [letter] Mayo J, et al. **AIDS** 1998 Sep 10;12(13):1720–2

Gynecomastia with stavudine treatment in an HIV-positive patient [letter] Melbourne KM, et al. **Ann Pharmacother** 1998 Oct;32(10):1108

The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and

CMV-seropositive patients. Jung D, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):255-9

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Gieschke R, et al. **Clin Pharmacokinet** 1999 Jul;37(1):75-86

Protease inhibitors, diabetes mellitus and blood lipids. Meyer L, et al. **Diabetes Metab** 1998 Dec;24(6):547-9

Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor [letter] Nigro L, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):85-6

Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings. Christensen LA, et al. **J Am Acad Audiol** 1998 Aug;9(4):292-8

Severe paronychia due to zidovudine-induced neutropenia in a neonate. Russo F, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):322-4

Protease inhibitor-induced lipodystrophy. Williamson K, et al. **J Am Acad Dermatol** 1999 Apr;40(4):635-6

Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. Jung D, et al. **J Clin Pharmacol** 1998 Nov;38(11):1057-62

Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus. Jung D, et al. **J Clin Pharmacol** 1998 Nov;38(11):1021-4

Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. Séréni D, et al. **J Clin Pharmacol** 1999 Jan;39(1):47-54

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, et al. **J Infect Dis** 1999 Jun;179(6):1356-64

Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. Kohan AD, et al. **J Urol** 1999 Jun;161(6):1765-8

Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. Reiter WJ, et al. **J Urol** 1999 Apr;161(4):1082-4

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators [see comments] Detels R, et al. **JAMA** 1998 Nov 4; 280(17):1497-503. Comment in: JAMA 1999 May 12;281(18):1696-7.

ApoE genotype and protease-inhibitor-associated hyperlipidaemia [letter; comment] Behrens G, et al. **Lancet** 1999 Jul 3;354(9172):76. Comment on: Lancet 1999 May 15;353(9165):1678.

Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Sacktor NC, et al. **Neurology** 1999 May 12;52(8):1640-7

Providing AZT in pregnancy--if not now then when? [letter] Matchaba P. **S Afr Med J** 1999 Apr;89(4):357

[Edema of the lower extremities in a HIV seropositive patient: secondary effect of ritonavir? (letter)] Dol L, et al. **Presse Med** 1999 Jan 16;28(2):75 **(Fre)**

[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc (letter)] Rey D, et al. **Presse Med** 1998 Feb 28;27(8):360 **(Fre)**

[Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients] Hermieu JF, et al. **Prog Urol** 1999 Jun;9(3):537-40 (Eng. Abstr.) **(Fre)**

[Clinical case of the month. Apropos of pancytopenia in a seropositive patient] Daniel C, et al. **Rev Med Liege** 1998 Dec;53(12):732-4 (Eng. Abstr.) **(Fre)**

[Antiretroviral therapy in pregnant women with HIV] Niemiec KT, et al. **Ginekol Pol** 1998 Nov;69(11):820-6 (34 ref.) (Eng. Abstr.) **(Pol)**

[Dynamics of immunoglobulin production in non infected children born from HIV-1 infected mothers: effect of zidovudine] Resino S, et al. **Med Clin (Barc)** 1999 May 1;112(15):568-71 (Eng. Abstr.) **(Spa)**

[Optimization of antiretroviral treatment: new forms of the use of indinavir (letter)] Valencia Ortega ME, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):77-8 **(Spa)**

ENZYMOLOGY

Abnormalities of serum amylase and lipase in HIV-positive patients. Argiris A, et al. **Am J Gastroenterol** 1999 May; 94(5):1248-52

Elevated adenosine deaminase activity in patients with HIV and tuberculous peritonitis. Sathar MA, et al. **Eur J Gastroenterol Hepatol** 1999 Mar;11(3):337-41

EPIDEMIOLOGY

The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis. Hendriks JC, et al. **AIDS** 1998 Aug 20;12(12):1537-44

Cultures of sexual adventurism as markers of HIV seroconversion: a case control study in a cohort of Sydney gay men. Kippax S, et al. **AIDS Care** 1998 Dec;10(6):677-88

Correlates of HIV seropositivity and HIV testing among out-of-treatment drug users. Collier K, et al. **Am J Drug Alcohol Abuse** 1998 Aug;24(3):377-93

HIV testing in substance abusers. Samet JH, et al. **Am J Drug Alcohol Abuse** 1999 May;25(2):269-80

Suicide attempts among seropositive women in New York City [letter] Simoni JM, et al. **Am J Psychiatry** 1998 Nov; 155(11):1631-2

Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Bloch KC, et al. **Ann Intern Med** 1998 Nov 1;129(9):698-704

Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Brodine SK, et al. **Ann Intern Med** 1999 Oct 5;131(7):502-6

Factors associated with gonorrhoea in men aware of being positive for HIV infection: case-control study. Sadiq ST, et al. **BMJ** 1998 Oct 17;317(7165):1052-3

Do women with HIV infection consult with their GPs? [letter; comment] Moss TR, et al. **Br J Gen Pract** 1998 Aug;48(433):1525-6. Comment on: Br J Gen Pract 1998 Jun;48(431):1329-30.

HIV epidemic in Punjab, India: time trends over a decade. Sehgal S. **Bull World Health Organ** 1998;76(5):509-13

Incidence of human immunodeficiency virus antibody in a prenatal population at a community hospital. Alexander TS, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):140-1

Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Johnson JG, et al. **Compr Psychiatry** 1999 Jan-Feb; 40(1):31-4

HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old. Carneiro M, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):83-6

HIV seroprevalence in disseminated tuberculosis and chronic diarrhea. Merchant RH, et al. **Indian Pediatr** 1998 Sep; 35(9):883-7

Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Coovadia HM, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):844-51 (60 ref.)

HIV-1 seroprevalence in Zambian patients with acute diarrhea: a community-based study. Baboo KS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):160-3

HIV seropositivity rates in outreach-based counseling and testing services: program evaluation. DiFranceisco W, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):282-8

Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. Elliott AJ, et al. **J Clin Psychiatry** 1999 Apr;60(4):226-31

Long-term non-progression in HIV infection: definitions and epidemiological issues. Easterbrook PJ. **J Infect** 1999 Mar; 38(2):71-3 (13 ref.)

Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. Kositanont U, et al. **J Infect Dis** 1999 Jul;180(1):50-5

Infrequent detection of TT virus infection in intravenous drug users, prostitutes, and homosexual men. MacDonald DM, et al. **J Infect Dis** 1999 Mar;179(3):686-9

Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. Martin HL Jr, et al. **J Infect Dis** 1998 Oct;178(4):1053-9

HIV infection in dialysis centers in Italy: a nationwide multicenter study. Barbiano di Belgiojoso G, et al. **J Nephrol** 1998 Sep-Oct;11(5):249-54

Seroconversion issues among out-of-treatment injection drug users. Fisher DG, et al. **J Psychoactive Drugs** 1998 Jul-Sep; 30(3):299-305

Substance use disorders and the risk of HIV infection in gay men. Ryan CM, et al. **J Stud Alcohol** 1999 Jan;60(1):70-7

HIV-related gender biases among malnourished children in Abidjan, Côte D'Ivoire. Beau JP, et al. **J Trop Pediatr** 1999 Jun;45(3):169-71

Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group [see comments] Bindman AB, et al. **JAMA** 1998 Oct 28;280(16):1416-20. Comment in: JAMA 1999 Jun 23-30;281(24):2282-3.

HIV risk factors among people with severe mental illness in urban and rural areas. Brunette MF, et al. **Psychiatr Serv** 1999 Apr;50(4):556-8

Psychiatric patients and HIV. Chung JY, et al. **Psychiatr Serv** 1999 Apr;50(4):487

Survey of the prevalence of HIV infection in an antenatal population in South Dakota [letter; comment] Helmbrecht GD. **S D J Med** 1998 Oct;51(10):392; discussion 393. Comment on: S D J Med 1998 Jul;51(7):229-32.

Survey of the prevalence of HIV infection in an antenatal population in South Dakota [letter; comment] Travers H. **S D J Med** 1998 Oct;51(10):391-2; discussion 393. Comment on: S D J Med 1998 Jul;51(7):229-32.

Pre-AIDS mortality and morbidity among injection drug users in Amsterdam and Baltimore: an ecological comparison. van Ameijden EJ, et al. **Subst Use Misuse** 1999 May;34(6):845-65

[Prevalence of HIV infection in dialysis patients: results of a national multicenter study] Poignet JL, et al. **Nephrologie** 1999;20(3):159-63 (Eng. Abstr.) **(Fre)**

[Diagnostic and therapeutic concepts of HPV infection in HIV-positive women] Küppers V, et al. **Zentralbl Gynakol** 1999;121(1):27-30 (5 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

A social psychological perspective on HIV/AIDS and gay or homosexually active Asian men. Sanitioso R. **J Homosex** 1999;36(3-4):69-85

GENETICS

Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers [letter] Ometto L, et al. **AIDS** 1999 May 7;13(7):871-2

HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Krausa P, et al. **Exp Clin Immunogenet** 1999;16(1):17-25

Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. van Rij RP, et al. **J Infect Dis** 1998 Dec;178(6):1806-11

Diversification of subtype E human immunodeficiency virus type 1 env in heterosexual seroconverters from Northern Thailand. Wang Z, et al. **J Infect Dis** 1998 Nov; 178(5):1507-11

IMMUNOLOGY

Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. Andersson J, et al. **AIDS** 1998 Jul 30;12(11):F123-9

Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Sabin CA, et al. **AIDS** 1998 Jul 30; 12(11):1347-52

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. Janoff EN, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):837-45

Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Busch MP, et al. **Am J Med** 1997 May 19;102(5B):117-24; discussion 125-6 (43 ref.)

Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Ciesielski CA, et al. **Am J Med** 1997 May 19;102(5B):115-6 (11 ref.)

Evaluation of IgE-sensitization to fungi in HIV-positive patients with eczematous skin reactions. Nissen D, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):153-9

Serum malondialdehyde in HIV-seropositive children negatively correlates with CD4+ lymphocytes count. Jareño EJ, et al. **Biofactors** 1998;8(1-2):129-32

B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Tähtinen M, et al. **Biomed Pharmacother** 1997;51(10):480-7

Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Rizzardi GP, et al. **Clin Exp Immunol** 1998 Oct;114(1):61-5

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Boyer JD, et al. **Clin Immunol** 1999 Jan;90(1):100-7

Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus-positive subjects in the United States after a five-dose schedule of Mycobacterium vaccae vaccine. von Reyn CF, et al. **Clin Infect Dis** 1998 Dec;27(6):1517-20

Determination of T-lymphocyte subsets in a north African population (Tunisia): establishment of normal ranges and results in HIV-infected individuals. Feki S, et al. **Dis Markers** 1998 Nov;14(3):161-4

The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. Cozzi Lepri A, et al. **Epidemiol Infect** 1998 Oct;121(2):369-76

Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Chassin D, et al. **Eur J Immunol** 1999 Jan;29(1):196-202

Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients. Dalod M, et al. **Eur J Immunol** 1999 Jan; 29(1):38-44

Salivary defence factor concentrations in relation to oral and general parameters in HIV positive patients. Grimoud AM, et al. **Eur J Oral Sci** 1998 Dec;106(6):979-85

HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Krausa P, et al. **Exp Clin Immunogenet** 1999;16(1):17-25

Cardiac autoimmunity in HIV related heart muscle disease. Currie PF, et al. **Heart** 1998 Jun;79(6):599-604

Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Tomiyama H, et al. **Hum Immunol** 1999 Mar;60(3):177-86

'Naïve' and 'memory' CD4+ T-cells and T-cell receptor (TCR) V beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. King DJ, et al. **Immunol Lett** 1999 Mar;66(1-3):199-206

Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Juffermans NP, et al. **Infect Immun** 1999 Aug;67(8):4295-7

CD80 expression is decreased in hyperplastic lymph nodes

of HIV+ patients. Legendre C, et al. **Int Immunol** 1998 Dec;10(12):1847–51

The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Waibale P, et al. **Int J Epidemiol** 1999 Apr;28(2):341–6

The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Hoffman R, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):127–31

Moderate and high intensity exercise training in HIV-1 seropositive individuals: a randomized trial. Terry L, et al. **Int J Sports Med** 1999 Feb;20(2):142–6

Activation and proliferation of CD8+ T cells in lymphoid tissues of HIV-1-infected individuals in the absence of the high-affinity IL-2 receptor. Brinchmann JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):332–8

Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. Leigh JE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):373–80

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):315–20

Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. Watts DH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):455–62

Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. Fehniger TA, et al. **J Immunol** 1998 Dec 1;161(11):6433–8

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. Scala G, et al. **J Immunol** 1999 May 15; 162(10):6155–61

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. B Moss R, et al. **J Infect Dis** 1999 Sep;180(3):641–8

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. Mazzoli S, et al. **J Infect Dis** 1999 Sep;180(3):871–5

Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants. Plaeger S, et al. **J Infect Dis** 1999 Jun;179(6):1388–94

Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3. Sabin CA, et al. **J Infect Dis** 1998 Oct;178(4):1166–9

Maintenance of high-avidity rubella-specific IgG antibody and titres in recent HIV seroconvertors and in patients progressing to the AIDS-related complex and AIDS. Thomas HI, et al. **J Med Virol** 1999 Jul;58(3):273–9

Religiosity is associated with affective and immune status in symptomatic HIV-infected gay men. Woods TE, et al. **J Psychosom Res** 1999 Feb;46(2):165–76

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. Dalod M, et al. **J Virol** 1999 Sep;73(9):7108–16

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943–51

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [see comments] Brodie SJ, et al. **Nat Med** 1999 Jan;5(1):34–41. Comment in: Nat Med 1999 Jan;5(1):27–8.

Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals. Arany I, et al. **Sex Transm Infect** 1998 Oct; 74(5):349–53

The reference range of CD4+ and CD8+ T-lymphocytes in healthy non-infected infants born to HIV-1 seropositive mothers; a preliminary study at Siriraj Hospital. Likanonsakul S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):453–63

[Increase of circulating CD3+CD4-CD8-CD19+ cells in the latent phase of HIV-1 infection] Nozaki-Renard J, et al. **C R Seances Soc Biol Fil** 1998;192(5):1007–15 (Eng. Abstr.) **(Fre)**

[Dynamics of immunoglobulin production in non infected children born from HIV-1 infected mothers: effect of zidovudine] Resino S, et al. **Med Clin (Barc)** 1999 May 1;112(15):568–71 (Eng. Abstr.) **(Spa)**

METABOLISM

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. Maas JJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):254–9

The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. Jung D, et al. **J Clin Pharmacol** 1999 May;39(5):505–12

Orally administered dextran sulfate is absorbed in HIV-positive individuals. Hiebert LM, et al. **J Lab Clin Med** 1999 Feb;133(2):161–70

MICROBIOLOGY

An outbreak of methicillin-resistant Staphylococcus aureus (MRSA) infection in HIV-seropositive persons. Smith NP, et al. **Int J STD AIDS** 1998 Dec;9(12):726–30

Non-albicans oral candidosis in HIV-positive patients. Cartledge JD, et al. **J Antimicrob Chemother** 1999 Mar; 43(3):419–22

Mycoplasma penetrans and other mycoplasmas in urine of human immunodeficiency virus-positive children. Hussain AI, et al. **J Clin Microbiol** 1999 May;37(5):1518–23

Identification of Candida dubliniensis in a prospective study of patients in the United States. Jabra-Rizk MA, et al. **J Clin Microbiol** 1999 Feb;37(2):321–6

[Genotype, serotype and sensitivity to fluconazole of Candida albicans strains isolated from HIV-positive patients] Bastide JM, et al. **Bull Acad Natl Med** 1999;183(2):289–302; discussion 302–3 (Eng. Abstr.) **(Fre)**

[Candida albicans: the relationship between morphotypes and in-vitro adhesivity to the oral mucosa cells of HIV-positive and AIDS patients. I] Malighetti V, et al. **Minerva Stomatol** 1998 Sep;47(9):351–9 (Eng. Abstr.) **(Ita)**

MORTALITY

Bone marrow macrophage iron grade and survival of HIV-seropositive patients. de Monyé C, et al. **AIDS** 1999 Feb 25;13(3):375–80

Mortality risk in selenium-deficient HIV-positive children. Campa A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):508–13

Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. Katzenstein DA, et al. **J Infect Dis** 1999 Jun;179(6):1382–7

Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3. Sabin CA, et al. **J Infect Dis** 1998 Oct;178(4):1166–9

[AIDS and HIV infections in 1997] Szata W. **Przegl Epidemiol** 1999;53(1-2):171–9 (Eng. Abstr.) **(Pol)**

[Value of quantification of p24 antigen in plasma as a prognostic marker of survival in a cohort of 251 HIV-positive patients] Rubio Caballero M, et al. **An Med Interna** 1998 Dec;15(12):647–9 (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda [letter] Elliott AM, et al. **Lancet** 1999 Sep 18; 354(9183):1000–1

PATHOLOGY

Adenoid enlargement and CD4 counts in HIV-positive patients [letter] Fleckenstein JL. **AJNR Am J Neuroradiol** 1999 Jun-Jul;20(6):1186–7

Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Logani S, et al. **Am J Surg Pathol** 1999 Jun;23(6):656–61 (11 ref.)

Proposed CD4(+) T-cell criteria for staging human immunodeficiency virus-infected Chinese adults. Kam KM, et al. **Clin Immunol Immunopathol** 1998 Oct;89(1):11–22

Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Serraino D, et al. **Int J Cancer** 1999 Jul 30;82(3):334–7

Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. Massad LS, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):33–41

HIV-associated primary CNS lymorbidity and utility of brain biopsy. Skolasky RL, et al. **J Neurol Sci** 1999 Feb 1; 163(1):32–8

PHYSIOPATHOLOGY

Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion Study. Cozzi Lepri A, et al. **AIDS** 1998 Jul 30;12(11):1353–60

Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Yarasheski KE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E577–83

Neurotological auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations. Castello E, et al. **Ann Otol Rhinol Laryngol** 1998 Dec;107(12):1054–60

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa: anthropometric and dietary profile. Dannhauser A, et al. **Eur J Clin Nutr** 1999 Mar; 53(3):165–73

Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. Watts DH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):455–62

Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. Koziel H, et al. **J Clin Invest** 1998 Oct 1;102(7):1332–44

PSYCHOLOGY

Socially desirable response tendency as a correlate of accuracy of self-reported HIV serostatus for HIV seropositive injection drug users. Latkin CA, et al. **Addiction** 1998 Aug;93(8):1191–7

Child feeding practices of HIV-positive mothers in Cape Town, South Africa [letter] Kuhn L, et al. **AIDS** 1999 Jan 14;13(1):144–6

Personal social networks and HIV status among women on methadone. el-Bassel N, et al. **AIDS Care** 1998 Dec; 10(6):735–49

HIV serostatus disclosure among gay and bisexual men in four American cities: general patterns and relation to sexual practices. Wolitski RJ, et al. **AIDS Care** 1998 Oct; 10(5):599–610

An investigation of the effects of HIV on the sex lives of infected individuals. Cranson DA, et al. **AIDS Educ Prev** 1998 Dec;10(6):506–22

Experiences of 100 men who have sex with men using the Reality condom for anal sex. Gibson S, et al. **AIDS Educ Prev** 1999 Feb;11(1):65–71

Training community members to conduct survey interviews: notes from a study of seropositive women. Simoni JM, et al. **AIDS Educ Prev** 1999 Feb;11(1):87–8

Reducing HIV risk-associated sexual behavior among African American adolescents: testing the generality of intervention effects. Jemmott JB 3rd, et al. **Am J Community Psychol** 1999 Apr;27(2):161–87

Youth living with HIV as peer leaders. Luna GC, et al. **Am J Community Psychol** 1999 Feb;27(1):1–23

Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Dolezal C, et al. **Am J Drug Alcohol Abuse** 1999 May;25(2):281–303

Characteristics of persons with mental retardation and HIV/AIDS infection in a statewide Medicaid population. Walkup J, et al. **Am J Ment Retard** 1999 Jul;104(4):356–63

Mandatory HIV testing of newborns. The impact on women. Frank S, et al. **Am J Nurs** 1998 Oct;98(10):49–51

Impact of a patient-centered, computer-based health information/support system [see comments] Gustafson DH, et al. **Am J Prev Med** 1999 Jan;16(1):1–9. Comment in: Am J Prev Med 1999 Jan;16(1):43–5. Comment in: Am J Prev Med 1999 Jan;16(1):46–7.

The experience of relapse to unsafe sexual behavior among HIV-positive, heterosexual, minority men. Sherman DW, et al. **Appl Nurs Res** 1999 May;12(2):91–100

A randomized controlled clinical trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and -seronegative homosexual men [published erratum appears in Arch Gen Psychiatry 1999 Aug;56(8):693] Goodkin K, et al. **Arch Gen Psychiatry** 1999 Jan;56(1):52–9

The family health project: a multidisciplinary longitudinal investigation of children whose mothers are HIV infected. Family Health Project Research Group. **Clin Psychol Rev** 1998 Nov;18(7):839–56

Depression in cancer and HIV infection: research findings and implications of effective antidepressant treatment. Petitto JM, et al. **Depress Anxiety** 1998;8 Suppl 1:80–4 (42 ref.)

Health-related service utilization and HIV risk behaviors among HIV infected injection drug users and crack smokers. Booth RE, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1-2):69–78

Predictors of increased condom use following HIV intervention with heterosexually active drug users. Kwiatkowski CF, et al. **Drug Alcohol Depend** 1999 Mar 1;54(1):57–62

Long-term effects of HIV counseling and testing for women: behavioral and psychological consequences are limited at 18 months posttest. Ickovics JR, et al. **Health Psychol** 1998 Sep;17(5):395–402

Self-efficacy and disclosure of HIV-positive serostatus to sex partners. Kalichman SC, et al. **Health Psychol** 1999 May;18(3):281–7

Avoidance as a predictor of the biological course of HIV infection over a 7-year period in gay men. Mulder CL, et al. **Health Psychol** 1999 Mar;18(2):107–13

Role of relationship context in influencing college students' responsiveness to HIV prevention videos. Sanderson CA. **Health Psychol** 1999 May;18(3):295–300

HIV prevention and the positive population. King-Spooner S. **Int J STD AIDS** 1999 Mar;10(3):141–50 (92 ref.)

Personality characteristics of treatment-seeking HIV+ pregnant drug dependent women. Svikis DS, et al. **J Addict Dis** 1998;17(3):91–111

Repetition of the mother-infant dyad and the process of dying in the psychotherapy of an HIV-positive man. Des Rosiers P. **J Am Acad Psychoanal** 1999 Summer; 27(2):191–203

Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. Bower JE, et al. **J Consult Clin Psychol** 1998 Dec;66(6):979–86

Status passages: the experience of HIV-positive gay men.

Lewis J. **J Homosex** 1999;37(3):87–115
Evaluating anxiety and depression in HIV-infected patients. Savard J, et al. **J Pers Assess** 1998 Dec;71(3):349–67
Treatment of depression in HIV-infected patients. Cazzullo CL, et al. **J Psychiatry Neurosci** 1998 Nov;23(5):293–7
Anxiety and depression among HIV-infected heterosexuals--a report from India. Chandra PS, et al. **J Psychosom Res** 1998 Nov;45(5):401–9
Religiosity is associated with affective and immune status in symptomatic HIV-infected gay men. Woods TE, et al. **J Psychosom Res** 1999 Feb;46(2):165–76
Widespread horror over killing of AIDS activist in South Africa [news] Baleta A. **Lancet** 1999 Jan 9;353(9147):130
Psychosocial characteristics of pregnant and nonpregnant HIV-seropositive women. Swartz HA, et al. **Psychiatr Serv** 1998 Dec;49(12):1612–4
Executive functioning and compliance in HIV patients. Mann LS, et al. **Psychol Rep** 1999 Feb;84(1):319–22
Description and validation of a measure of received support specific to HIV. Renwick R, et al. **Psychol Rep** 1999 Apr; 84(2):663–73
Cognitive-behavioral stress management buffers decreases in dehydroepiandrosterone sulfate (DHEA-S) and increases in the cortisol/DHEA-S ratio and reduces mood disturbance and perceived stress among HIV-seropositive men. Cruess DG, et al. **Psychoneuroendocrinology** 1999 Jul; 24(5):537–49
Stressful events, pessimism, natural killer cell cytotoxicity, and cytotoxic/suppressor T cells in HIV+ black women at risk for cervical cancer. Byrnes DM, et al. **Psychosom Med** 1998 Nov-Dec;60(6):714–22
The uses of culture in the making of AIDS neurosis in Japan. Miller E. **Psychosom Med** 1998 Jul-Aug;60(4):402–9 (23 ref.)
Delivering mental health care to HIV-positive individuals. A comparison of two models. Gomez MF, et al. **Psychosomatics** 1999 Jul-Aug;40(4):321–4
Suicidal ideation, suicide attempts, and HIV infection. Kelly B, et al. **Psychosomatics** 1998 Sep-Oct;39(5):405–15
Illness behavior, emotional stress and psychosocial factors among asymptomatic HIV-infected patients. Grassi L, et al. **Psychother Psychosom** 1999;68(1):31–8
Combined effects of HIV-infection status and psychosocial vulnerability on mental health in homosexual men. Dickey WC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Jan; 34(1):4–11
Assessment of satisfaction with the communication process during consultation of cancer patients with potentially curable disease, cancer patients on palliative care, and HIV-positive patients. Petrasch S, et al. **Wien Med Wochenschr** 1998;148(21):491–9
[Treatment for infertility in HIV positive couples--psychosomatic and ethical considerations] Siedentopf F, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:50–2 **(Ger)**

REHABILITATION

Pre-AIDS physical disability [letter; comment] Brown A, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):473. Comment on: Arch Phys Med Rehabil 1998 Oct;79(10):1200–5.
[Predictors of behavioural disorders and consultation-liaison psychiatry in patients with HIV disorders] Ochoa E, et al. **Actas Esp Psiquiatr** 1999 Mar-Apr;27(2):97–102 (Eng. Abstr.) **(Spa)**

THERAPY

Low dose oral interferon alpha 2a in HIV-1 seropositive patients: a double-blind, placebo-controlled trial. Wright SE, et al. **Biotherapy** 1998;11(4):229–34
Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. Bratt G, et al. **Int J STD AIDS** 1999 Aug;10(8):514–21
Treatment of human immunodeficiency virus-positive patients with complementary and alternative medicine: a survey of practitioners. Calabrese C, et al. **J Altern Complement Med** 1998 Fall;4(3):281–7
Elective surgery and the HIV-positive patient: medical, legal, and ethical issues. Clarke SR, et al. **J La State Med Soc** 1999 May;151(5):245–9 (17 ref.)
Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Hillyer CD, et al. **Transfus Med Rev** 1999 Jan; 13(1):1–17 (174 ref.)
Family-centered care for HIV positive women. Solomon L. **Zentralbl Gynakol** 1999;121(1):25–7 (0 ref.)
[Current position on the care of HIV-seropositive pregnancies] Funke AM. **Zentralbl Gynakol** 1999; 121(1):33–4 (14 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Physicians' transmission prevention assessment and counseling practices with their HIV positive patients. Gerbert B, et al. **AIDS Educ Prev** 1999 Aug;11(4):307–20
Maintenance of safe sex behavior by HIV-serodiscordant heterosexual couples. Skurnick JH, et al. **AIDS Educ Prev** 1998 Dec;10(6):493–505
Bisexuality and HIV risk: experiences in Canada and the United States. Doll L, et al. **Annu Rev Sex Res** 1997; 8:102–47 (154 ref.)
Management of HIV serodiscordant couples. The clinician point of view. Coll O, et al. **Contracept Fertil Sex** 1999 Jun;27(6):399–404
HIV sexual risk behavior following bereavement in gay men. Mayne TJ, et al. **Health Psychol** 1998 Sep;17(5):403–11
Number of pregnancies, outcome expectancies, and social norms among HIV-infected young women. Murphy DA, et al. **Health Psychol** 1998 Sep;17(5):470–5
Gynaecological conditions associated with HIV infection in women who are partners of HIV-positive Thai blood donors. Rugpao S, et al. **Int J STD AIDS** 1998 Nov; 9(11):677–82
Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. Katzenstein DA, et al. **J Infect Dis** 1999 Jun;179(6):1382–7
Effect of chemokine receptor mutations on heterosexual human immunodeficiency virus transmission. Lockett SF, et al. **J Infect Dis** 1999 Sep;180(3):614–21
Decreased CD8 cell-mediated viral suppression and other immunologic characteristics of women who transmit human immunodeficiency virus to their infants. Plaeger S, et al. **J Infect Dis** 1999 Jun;179(6):1388–94
Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. Shaffer N, et al. **J Infect Dis** 1999 Mar;179(3):590–9
Partner notification and focused intervention as a means of identifying HIV-positive patients. Jordan WC, et al. **J Natl Med Assoc** 1998 Sep;90(9):542–6
Denying effective antiretroviral drugs to HIV-positive pregnant women--the national government's flawed decision [editorial] Lurie M, et al. **S Afr Med J** 1999 Jun; 89(6):621–3
Providing AZT in pregnancy--if not now then when? [letter] Matchaba P. **S Afr Med J** 1999 Apr;89(4):357
[Neurological complications of HIV-1 infection in an infant born to a seropositive mother] Tardieu M. **Rev Neurol (Paris)** 1998 Dec;154(12):850–5 (24 ref.) **(Fre)**
[Evaluation of the law of communicable disease control: compulsory isolation can reduce the high-risk behavior of HIV-positive individuals] Sylvan S, et al. **Lakartidningen** 1999 Jul 14;96(28–29):3244–7 (Eng. Abstr.) **(Swe)**

URINE

A validated method for the determination of paracetamol and its glucuronide and sulphate metabolites in the urine of HIV+/AIDS patients using wavelength-switching UV detection. Di Girolamo A, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):1191–7

VIROLOGY

Distribution of measles virus in the central nervous system of HIV-seropositive children. McQuaid S, et al. **Acta Neuropathol (Berl)** 1998 Dec;96(6):637–42
Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. Ishikawa K, et al. **AIDS** 1998 Aug 20;12(12):1419–25
Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Sabin CA, et al. **AIDS** 1998 Jul 30; 12(11):1347–52
Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. Xiao L, et al. **AIDS** 1998 Sep 10;12(13):F137–43
Serologic and genetic characterization of HIV type 1 subtypes on Reunion Island. Brengel-Pesce K, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):787–92
Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. Janoff EN, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):837–45
Optimization of polymerase chain reaction for detection of HIV type 2 DNA. Walther L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1151–6
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Brodine SK, et al. **Ann Intern Med** 1999 Oct 5;131(7):502–6
Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Brindeiro R, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1674–80
Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Chassin D, et al. **Eur J Immunol** 1999 Jan;29(1):196–202
'Naïve' and 'memory' CD4+ T-cells and T-cell receptor (TCR) V beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. King DJ, et al. **Immunol Lett** 1999 Mar;66(1–3):199–206
HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. Tanuri A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):60–6
Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. Calabrò ML, et al. **J Infect Dis** 1999 Jun;179(6):1534–7
Direct human papillomavirus (HPV) sequencing method yields a novel HPV in a human immunodeficiency virus-positive Quebec woman and distinguishes a new HPV clade. Feoli-Fonseca JC, et al. **J Infect Dis** 1998 Nov;178(5):1492–6
Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. Mostad SB, et al. **J Infect Dis** 1998 Oct;178(4):983–91
Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. Sterling TR, et al. **J Infect Dis** 1999 Sep;180(3):666–72
Diversification of subtype E human immunodeficiency virus type 1 env in heterosexual seroconverters from Northern Thailand. Wang Z, et al. **J Infect Dis** 1998 Nov; 178(5):1507–11
Detection of HIV-1 in seminal plasma and seminal cells of HIV-1 seropositive men. Dulioust E, et al. **J Reprod Immunol** 1998 Dec;41(1–2):27–40
Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. Muciaccia B, et al. **J Reprod Immunol** 1998 Dec;41(1–2):81–93
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943–51
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. Ping LH, et al. **J Virol** 1999 Aug;73(8):6271–81
Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. Poss M, et al. **J Virol** 1999 Jul;73(7):5255–64
Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood. Singh A, et al. **J Virol** 1999 Aug; 73(8):6680–90
Human immunodeficiency virus-rich multinucleated giant cells in the colon: a case report with transmission electron microscopy, immunohistochemistry, and in situ hybridization. Lewin-Smith M, et al. **Mod Pathol** 1999 Jan; 12(1):75–81
The prevalence of herpes family virus DNA in the conjunctiva of patients positive and negative for human immunodeficiency virus using the polymerase chain reaction. Lee-Wing MW, et al. **Ophthalmology** 1999 Feb; 106(2):350–4
[Serotypical stratification of HIV-1 in populations of intravenous drug users in the south/southwestern Ukraine] Shchelkanov MIu, et al. **Vopr Virusol** 1998 Jul-Aug; 43(4):176–82 (Eng. Abstr.) **(Rus)**

HIV SEROPREVALENCE

Spectrum of clinical diseases in HIV-infected adults at the Lagos University Teaching Hospital: a five-year experience [1992–1996]. Akinsete I, et al. **Afr J Med Med Sci** 1998 Sep-Dec;27(3–4):147–51
HIV seroprevalence in women of childbearing age in Benin City, Nigeria. Offor E, et al. **Afr J Reprod Health** 1997 Sep;1(2):36–40
Sexually transmitted diseases and risk of HIV infection in men attending a sexually transmitted diseases clinic in Dakar, Senegal. Thior I, et al. **Afr J Reprod Health** 1997 Sep;1(2):26–35
Estimating HIV incidence from age-specific prevalence data: comparison with concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe. Gregson S, et al. **AIDS** 1998 Oct 22;12(15):2049–58
Testing for HIV in California: volume and seropositivity in private versus public sites [letter] Johnson A, et al. **AIDS** 1998 Dec 24;12(18):2508–10
Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. Larsen O, et al. **AIDS** 1998 Sep 10;12(13):1707–14
The relationship of HIV prevalence in pregnant women to that in women of reproductive age: a validated method for adjustment [see comments] Nicoll A, et al. **AIDS** 1998 Oct 1;12(14):1861–7. Comment in: AIDS 1999 Mar 11;13(4):526–7.
Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants. Abrams EJ, et al. **Bull N Y Acad Med** 1995 Winter;72(2):443–53
Cost effectiveness of Streetworks' needle exchange program of Edmonton. Jacobs P, et al. **Can J Public Health** 1999 May-Jun;90(3):168–71
Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Analo HI, et al. **Cent Afr J Med** 1998 May; 44(5):130–4
Seroprevalence of human immunodeficiency virus type 1 infection in childhood malignancy in Zimbabwe. Chitsike I, et al. **Cent Afr J Med** 1998 Oct;44(10):242–5
Contemporary treatment of tuberculosis in HIV prevalent countries in sub-Saharan Africa. Nuwaha F. **East Afr Med J** 1998 Jun;75(6):358–63 (41 ref.)
Sero-prevalence of HIV antibodies in tuberculosis patients in Ile-Ife, Nigeria. Onipede AO, et al. **East Afr Med J** 1999 Mar;76(3):127–32
Assessment of behavioural risk factors associated with HIV infection among youth in Moshi rural district, Tanzania. Tengia-Kessy A, et al. **East Afr Med J** 1998 Sep;

75(9):528–32
Non-participation bias in unlinked anonymous HIV-prevalence surveys in England and Wales. Duong T, et al. **Epidemiol Infect** 1999 Apr;122(2):267–72
Methods for estimating HIV prevalence: A comparison of extrapolation from surveys on infection rate and risk behaviour with back-calculation for the Netherlands. Houweling H, et al. **Eur J Epidemiol** 1998 Oct;14(7):645–52
Trends in HIV seroprevalence, AIDS and prevention policy among intravenous drug users and men who have sex with men, before and after 1990 in Austria. Piribauer F, et al. **Eur J Epidemiol** 1998 Oct;14(7):635–43
Increasing prevalence of HIV antibody among blood donors monitored over 9 years in one blood bank. Rose D, et al. **Indian J Med Res** 1993 Aug;108:42–4
Incidence of HIV risk and prevention of infection in health care settings. Ram S, et al. **Indian J Med Sci** 1998 Jun; 52(6):239–43
Seroprevalence of HIV, HBV, and syphilis and associated risk behaviours in male transvestites (Hijras) in Karachi, Pakistan. Baqi S, et al. **Int J STD AIDS** 1999 May; 10(5):300–4
Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986–1992). Bogaerts J, et al. **Int J STD AIDS** 1998 Nov; 9(11):706–10
HIV/AIDS in Bangladesh: an assessment of biomedical risk factors for transmission. Gibney L, et al. **Int J STD AIDS** 1999 May;10(5):338–46 (83 ref.)
HIV-1 seroprevalence in Zambian patients with acute diarrhea: a community-based study. Baboo KS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):160–3
HIV seroprevalence and risk factors among clients of female and male prostitutes. Elifson KW, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):195–200
Seroepidemiology of HIV, HBV, HCV and treponemal infections. Kaur H, et al. **J Commun Dis** 1998 Mar; 30(1):29–31
Anonymous unlinked testing as a sentinel approach: experience in Germany. Siedler A, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:25S–27S
HIV and tuberculosis co-infection in an inner London hospital--a prospective anonymized seroprevalence study. Marshall BG, et al. **J Infect** 1999 May;38(3):162–6
Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. Mertz KJ, et al. **J Infect Dis** 1998 Dec;178(6):1795–8
Human immunodeficiency virus prevalence in women at delivery using unlinked anonymous testing of newborns in the Malaysian setting. Amar HS, et al. **J Paediatr Child Health** 1999 Feb;35(1):63–6
HIV serostatus and risk behaviors in a multisite sample of drug users. Deren S, et al. **J Psychoactive Drugs** 1998 Jul-Sep;30(3):239–45
HIV-related gender biases among malnourished children in Abidjan, Côte D'Ivoire. Beau JP, et al. **J Trop Pediatr** 1999 Jun;45(3):169–71
Increasing seroprevalence of HIV among high-risk hospitalized patients in Mumbai [letter] Kamat HA, et al. **Natl Med J India** 1999 May-Jun;12(3):139–40
Seroprevalence of blood borne transmissible diseases in trauma orthopaedic surgical patients. Sánchez LP, et al. **P R Health Sci J** 1998 Jun;17(2):113–6
Uses and abuses of Tuskegee. Fairchild AL, et al. **Science** 1999 May 7;284(5416):919–21
Human immunodeficiency virus seroprevalence and condom use among female sex workers in Italy [see comments] Spina M, et al. **Sex Transm Dis** 1998 Oct;25(9):451–4. Comment in: Sex Transm Dis 1998 Oct;25(9):455–6.
HIV infection and sexually transmitted diseases in a referral STD centre in south India. Thappa DM, et al. **Sex Transm Infect** 1999 Jun;75(3):191
Pooled testing for HIV prevalence estimation: exploiting the dilution effect. Zenios SA, et al. **Stat Med** 1998 Jul 15; 17(13):1447–67
HIV seroprevalence across the rural/urban continuum. McCoy CB, et al. **Subst Use Misuse** 1999 Mar-Apr; 34(4–5):595–615
Seroprevalence of hepatitis B and C, and human immunodeficiency type 1 viruses in a rural population from the Republic of Equatorial Guinea. Basaras M, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):250–2
Evaluation of the Eiken latex agglutination test for anti-Toxoplasma antibodies and seroprevalence of Toxoplasma infection among factory workers in Addis Ababa, Ethiopia. Woldemichael T, et al. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):401–3
Local understandings of adult diarrhoeal disease and its treatment in an area of high HIV-seroprevalence in Zambia. Ndubani P, et al. **Trop Med Int Health** 1998 Oct; 3(10):783–7
[Early decline in an epidemic: evolution of the prevalences of HIV, hepatitis B, hepatitis C and aminotransferases in intravenous drug abusers in Strasbourg between 1980 and 1990] Will T. **Rev Med Suisse Romande** 1999 Apr; 119(4):329–34 (Eng. Abstr.) **(Fre)**
[Epidemiological study on HIV/AIDS in Cambodia seroprevalence of HIV/STD among commercial sex workers] Ohshige K, et al. **Nippon Koshu Eisei Zasshi** 1999 Jan;46(1):61–70 (Eng. Abstr.) **(Jpn)**
[HIV infection in the health care are of Leon. Incidence from 1983–1997] Alcoba M, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):19–23 (Eng. Abstr.) **(Spa)**
[Risk behaviours and seroprevalence to HIV, HBV and HCV in patients of the AIDS information and prevention center in Valencia, Spain] Alfonso Gil R, et al. **Gac Sanit** 1999 Jan-Feb;13(1):16–21 (Eng. Abstr.) **(Spa)**
[Prevalence of human immunodeficiency virus and risk behaviours among opioid users seen in an emergency room] Pérez González K, et al. **Gac Sanit** 1999 Jan-Feb;13(1):7–15 (Eng. Abstr.) **(Spa)**
[HIV seroprevalence in patients seen at sexually-transmitted disease and family planning centers in Spain, 1995–1996. AIDS Programs of the Autonomic Communities and Network of sexually-transmitted disease, HIV and family planning centers] **Rev Esp Salud Publica** 1999 Jan-Feb; 73(1):25–34 (Eng. Abstr.) **(Spa)**

TRENDS

Low seroincidence and decrease in seroprevalence of HIV among female prostitutes in Madrid [letter] Ballesteros J, et al. **AIDS** 1999 Jun 18;13(9):1143–4
Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Des Jarlais DC, et al. **Am J Public Health** 1998 Dec; 88(12):1801–6
A two-type model for the Cuban national programme on HIV/AIDS. Lounes R, et al. **IMA J Math Appl Med Biol** 1999 Jun;16(2):143–54
Increasing prevalence of dual HIV-1-2 infections among voluntary blood donors in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Dec;52(12):548–52
Seroprevalence of HIV among female sex workers in Bangkok: evidence of ongoing infection risk after the "100% condom program" was implemented. Kilmarx PH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):313–6
The Swiss Network of Dermatology Policlinics HIV prevalence study: rationale, characteristics and results (1990–1996). Paget WJ, et al. **Soz Praventivmed** 1999; 44(1):1–7

HIV SPI-BINDING SITE see **HIV LONG TERMINAL REPEAT**

HIV TAT PROTEIN see **GENE PRODUCTS, TAT**

HIV TRANS-ACTING RESPONSIVE REGION see **HIV LONG TERMINAL REPEAT**

HIV TRANSACTING TRANSCRIPTION PROTEIN see **GENE PRODUCTS, TAT**

HIV TRANSMEMBRANE PROTEIN GP41 see **HIV ENVELOPE PROTEIN GP41**

HIV VACCINES see **AIDS VACCINES**

HIV VIF GENE PRODUCT see **GENE PRODUCTS, VIF**

HIV VPR GENE PRODUCT see **GENE PRODUCTS, VPR**

HIV VPU GENE PRODUCT see **GENE PRODUCTS, VPU**

HIV WASTING DISEASE see **HIV WASTING SYNDROME**

HIV WASTING SYNDROME

COMPLICATIONS

Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial [see comments] Strawford A, et al. **JAMA** 1999 Apr 14;281(14):1282–90. Comment in: JAMA 1999 Apr 14;281(14):1326–7.

DIAGNOSIS

Evaluation and treatment of weight loss in adults with HIV disease. Williams B, et al. **Am Fam Physician** 1999 Sep 1; 60(3):843–54, 857–60 (25 ref.)
Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa--laboratory parameters. van Staden AM, et al. **Cent Afr J Med** 1998 Oct; 44(10):246–50
Working group session report: HIV/AIDS working group. Mathews WC. **J Nutr** 1999 Jan;129(1S Suppl):311S–312S

DRUG THERAPY

Effect of indinavir on HIV-related wasting. Carbonnel F, et al. **AIDS** 1998 Oct 1;12(14):1777–84
Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial. Kelly P, et al. **AIDS** 1999 Mar 11; 13(4):495–500
The impact of body composition analysis in HIV-infected patients: quantifying therapeutic effects [editorial; comment] Ockenga J, et al. **AIDS** 1999 Feb 4;13(2):279–80 . Comment on: AIDS 1999 Feb 4;13(2):241–8.
Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. Paton NI, et al. **AIDS** 1999 Jul 9;13(10):1195–202
Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy [see comments] Van Loan MD, et al. **AIDS** 1999 Feb 4; 13(2):241–8. Comment in: AIDS 1999 Feb 4;13(2):279–80.
Testosterone-patch-induced psychotic mania [letter] Weiss EL, et al. **Am J Psychiatry** 1999 Jun;156(6):969
Androgen therapy in AIDS wasting. Dobs AS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):379–90 (63 ref.)
Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Grinspoon S, et al. **Clin Infect Dis** 1999 Mar;28(3):634–6
Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures. Segal DM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):215–9
Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. Strawford A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):137–46
HCFA mandates Medicaid reimbursement for AIDS wasting drug [news] **J Assoc Nurses AIDS Care** 1999 Jul-Aug; 10(4):95
Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. Sattler FR, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1268–76
Testosterone replacement therapy for HIV-related wasting: abstract and commentary. Dieterich DT. **JAMA** 1998 Dec 9;280(22):1959–60
Is there a role for androgenic anabolic steroids in medical practice? [editorial; comment] Dobs AS. **JAMA** 1999 Apr 14;281(14):1326–7. Comment on: JAMA 1999 Apr 14;281(14):1275–81. Comment on: JAMA 1999 Apr 14;281(14):1282–90.
Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial [see comments] Strawford A, et al. **JAMA** 1999 Apr 14;281(14):1282–90. Comment in: JAMA 1999 Apr 14;281(14):1326–7.
Treatments for wasting in patients with the acquired immunodeficiency syndrome. Corcoran C, et al. **N Engl J Med** 1999 Jun 3;340(22):1740–50 (78 ref.)
Growth hormone exerts potent anabolic effects in an adolescent with human immunodeficiency virus wasting. Dreimane D, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):167–9

ETIOLOGY

[Nutritional status of patients with HIV-AIDS infection (editorial)] López-Herce JA. **An Med Interna** 1998 Dec; 15(12):623–6 (58 ref.) **(Spa)**

GENETICS

Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Llovera M, et al. **Int J Mol Med** 1998 Jul;2(1):69–73
Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Gonzalez-Cadavid NF, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14938–43

METABOLISM

Bound leptin is regulated by tumour necrosis factor-alpha in HIV-infected patients: a potential mediator of wasting? [letter] Ockenga J, et al. **AIDS** 1998 Nov 12;12(16):2233–5
Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy [see comments] Van Loan MD, et al. **AIDS** 1999 Feb 4; 13(2):241–8. Comment in: AIDS 1999 Feb 4;13(2):279–80.
Metabolic aspects of HIV: associated wasting. Melchior JC. **Biomed Pharmacother** 1997;51(10):455–60 (52 ref.)
Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. Grinspoon S, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4251–6
Wasting in cancer. Tisdale MJ. **J Nutr** 1999 Jan;129(1S Suppl):243S–246S (46 ref.)
The wasting syndrome in AIDS: mechanisms and implications [editorial; comment] Grunfeld C. **Nutrition** 1998 Nov-Dec;14(11–12):867–8. Comment on: Nutrition 1998 Nov-Dec;14(11–12):853–63.
Sir David Cuthbertson Prize Medal Lecture. Metabolic abnormalities and wasting in human immunodeficiency virus infection. Macallan DC. **Proc Nutr Soc** 1998 Aug; 57(3):373–80 (48 ref.)

PHYSIOPATHOLOGY

The impact of body composition analysis in HIV-infected patients: quantifying therapeutic effects [editorial; comment] Ockenga J, et al. **AIDS** 1999 Feb 4;13(2):279–80

. Comment on: AIDS 1999 Feb 4;13(2):241–8.
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Yarasheski KE, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E577–83
Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. Grinspoon S, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):201–6
Wasting in HIV infection and AIDS. Macallan DC. **J Nutr** 1999 Jan;129(1S Suppl):238S–242S (17 ref.)
The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. Testa MA, et al. **J Nutr** 1999 Jan;129(1S Suppl):282S–289S
Role of cytokines in AIDS wasting [see comments] Chang HR, et al. **Nutrition** 1998 Nov-Dec;14(11–12):853–63 (172 ref.). Comment in: Nutrition 1998 Nov-Dec;14(11–12):867–8.
The wasting syndrome in AIDS: mechanisms and implications [editorial; comment] Grunfeld C. **Nutrition** 1998 Nov-Dec;14(11–12):867–8. Comment on: Nutrition 1998 Nov-Dec;14(11–12):853–63.

THERAPY

Evaluation and treatment of weight loss in adults with HIV disease. Williams B, et al. **Am Fam Physician** 1999 Sep 1; 60(3):843–54, 857–60 (25 ref.)
Working group session report: HIV/AIDS working group. Mathews WC. **J Nutr** 1999 Jan;129(1S Suppl):311S–312S
Home parenteral nutrition in acquired immunodeficiency syndrome patients [editorial] Melchior JC, et al. **Nutrition** 1999 Jan;15(1):68–9 (21 ref.)

URINE

Isolation, characterization, and distribution of a 24-kDa proteoglycan in the urine of cachectic cancer and AIDS patients. Figueroa JE, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):642–6

VIROLOGY

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa--laboratory parameters. van Staden AM, et al. **Cent Afr J Med** 1998 Oct; 44(10):246–50

HIV-1

see related

ACQUIRED IMMUNODEFICIENCY SYNDROME

High molecular mass dextran sulfate increases expression of HIV-1 coreceptor CCR-5 in macrophage-monocytes in culture. Jagodzinski PP, et al. **Acta Biochim Pol** 1998; 45(1):241–4
Cutaneous T-cell lymphoma and human immunodeficiency virus infection: 2 cases and a review of the literature. Muñoz-Pérez MA, et al. **Acta Derm Venereol** 1999 Mar; 79(2):153–5 (19 ref.)
Bilateral optic neuritis in acute human immunodeficiency virus infection. Larsen M, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):737–8
Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Italian Register for HIV Infection in Children. **Acta Paediatr** 1999 Feb;88(2):228–32
Zidovudine treatment prevents vertical transmission of human immunodeficiency virus-1 independently of viral load [letter] Alonso Arias R, et al. **Acta Paediatr** 1998 Nov; 87(11):1208–9
Prevalence of human herpesvirus 8 antibodies in human immunodeficiency virus type 1-infected homosexual men in Slovakia [letter] Mayer V, et al. **Acta Virol** 1998 Apr; 42(2):123–4
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. **AIDS** 1998 Oct 1;12(14):F151–60
IAS position paper on prevention of HIV 1 mother-to-child transmission. International Aids Society. **AIDS** 1999 Jul 30;13(11):5–9
An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. **AIDS** 1999 Apr 1;13(5):565–73
Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children. **AIDS** 1999 May 28;13(8):927–33
Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. Andersson J, et al. **AIDS** 1999 Jul 30;13(11):1295–303
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses [letter] Antón P, et al. **AIDS** 1999 Mar 11;13(4):524–5
Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy [letter] Barreiro PM, et al. **AIDS** 1999 Mar 11;13(4):525–6
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. Bellman PC. **AIDS** 1998 Jul 30;12(11):1333–40
Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. Blanco J, et al. **AIDS** 1999 Apr 1;13(5):547–55
Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. Bouscarat F, et al. **AIDS** 1998 Jul 30;12(11):1267–73
HIV-1 seroprevalence among childbearing women in northern Thailand: monitoring a rapidly evolving epidemic. Bunnell RE, et al. **AIDS** 1999 Mar 11;13(4):509–15
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Cameron DW, et al. **AIDS** 1999 Feb 4;13(2):213–24
Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy [letter] Canani RB, et al. **AIDS** 1999 May 28;13(8):1005–6
Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. Carotenuto P, et al. **AIDS** 1998 Sep 10; 12(13):1591–600
Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Carpenter LM, et al. **AIDS** 1999 Jun 18;13(9):1083–9
Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. Casado JL, et al. **AIDS** 1998 Jul 30;12(11):F131–5
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Cinque P, et al. **AIDS** 1998 Jul 30; 12(11):1327–32
Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? Cohen CR, et al. **AIDS** 1999 Feb 25;13(3):327–32
Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. Conge AM, et al. **AIDS** 1998 Aug 20;12(12):1437–49
Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. d'Arminio Monforte A, et al. **AIDS** 1998 Sep 10;12(13):1631–7
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine [editorial] De Boer RJ, et al. **AIDS** 1998 Sep 10;12(13):1567–70 (49 ref.)
Impaired fertility in HIV-1-infected pregnant women: a clinic-based survey in Abidjan, Côte d'Ivoire, 1997. Desgrées du Loû A, et al. **AIDS** 1999 Mar 11;13(4):517–21
Estimation of HIV-1 prevalence in the population of Abidjan by adjustment of the prevalence observed in antenatal centres [letter; comment] Desgrées du Loû A, et al. **AIDS** 1999 Mar 11;13(4):526–7. Comment on: AIDS 1998 Oct 1;12(14):1861–7.
The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic [letter] Devereux H, et al. **AIDS** 1999 Jan 14;13(1):142
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Dieleman JP, et al. **AIDS** 1999 Mar 11;13(4):473–8
Substituting nevirapine for protease inhibitors because of intolerance [letter] Dieleman JP, et al. **AIDS** 1999 Jul 30; 13(11):1423–4
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. Fahey JL, et al. **AIDS** 1998 Sep 10;12(13):1581–90
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women [letter] Fiore JR, et al. **AIDS** 1999 Apr 1;13(5):626–7
Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy [letter] Fischer T, et al. **AIDS** 1999 Apr 1;13(5):628–9
Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. Fontenot JD, et al. **AIDS** 1998 Aug 20;12(12):1413–8
Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. French N, et al. **AIDS** 1998 Sep 10;12(13):1683–9
Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. Furrer H, et al. **AIDS** 1998 Jul 30; 12(11):1341–6
Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients. Gallant JE, et al. **AIDS** 1999 Feb 4;13(2):225–9
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. Gervasoni C, et al. **AIDS** 1999 Mar 11;13(4):465–71
Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. Giorgi JV, et al. **AIDS** 1998 Oct 1;12(14):1833–44
Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy [letter] Grubert TA, et al. **AIDS** 1999 Jul 30;13(11):1430–1
HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32 [letter] Heiken H, et al. **AIDS** 1999 Mar 11;13(4):529–30
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. Hoetelmans RM, et al. **AIDS** 1998 Jul 30;12(11):F111–5
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. Hoetelmans RM, et al. **AIDS** 1998 Dec 3;12(17):F211–6
The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. Hoffman IF, et al. **AIDS** 1999 Mar 11;13(4):487–94
Stable antenatal HIV-1 seroprevalence with high population mobility and marked seroprevalence variation among sentinel sites within Nairobi, Kenya. Jackson DJ, et al. **AIDS** 1999 Apr 1;13(5):583–9
Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy [letter] Jiménez-Expósito MJ, et al. **AIDS** 1999 Jan 14;13(1):152–3
High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy [letter] Jubault V, et al. **AIDS** 1998 Dec 3;12(17):2358–9
Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. Kaufmann GR, et al. **AIDS** 1998 Sep 10;12(13):1625–30
HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. Kilmarx PH, et al. **AIDS** 1998 Oct 1;12(14):1889–98
Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. Kirk O, et al. **AIDS** 1999 Jan 14;13(1):F9–16
HIV seroprevalence and HIV-1 subtype E among pregnant women in Vientiane, Laos [letter] Loue S, et al. **AIDS** 1998 Jul 30;12(11):1403
Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. Martin C, et al. **AIDS** 1999 Jul 9;13(10):1227–32
Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir [letter] Martinelli C, et al. **AIDS** 1998 Sep 10;12(13):1717–9
Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy [letter] Martinez E, et al. **AIDS** 1999 Jan 14;13(1):147–8
Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy [letter] Mastroianni CM, et al. **AIDS** 1998 Oct 1;12(14):1939–40
Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. Mastroianni CM, et al. **AIDS** 1999 May 28; 13(8):883–90
Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa [letter] Mbopi Keou FX, et al. **AIDS** 1999 Mar 11;13(4):536–7
Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. Mezzaroma I, et al. **AIDS** 1999 Jul 9;13(10):1187–93
Opportunistic infections occurring during highly active antiretroviral treatment. Michelet C, et al. **AIDS** 1998 Oct 1;12(14):1815–22
Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. Mitsuyasu RT, et al. **AIDS** 1998 Jul 30;12(11):F103–9
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Musoke P, et al. **AIDS** 1999 Mar 11;13(4):479–86
Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients [letter] Nevez G, et al. **AIDS** 1999 Mar 11;13(4):535–6
Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d'Ivoire. Nkengasong JN, et al. **AIDS** 1999 Jan 14;13(1):109–17
Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. Olivero OA, et al. **AIDS** 1999 May 28;13(8):919–25
Analysis of the CC chemokine receptor 5 m303 mutation in infants born to HIV-1-seropositive mothers [letter] Ometto L, et al. **AIDS** 1999 May 7;13(7):871–2
Impact of highly active antiretroviral therapy on clinical evolution of genital warts in HIV-infected patients [letter] Orlando G, et al. **AIDS** 1999 Feb 4;13(2):291–3
HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail to develop a Bacillus Calmette-Guérin scar [letter] Ota MO, et al. **AIDS** 1999 May 28;13(8):996–8
Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. Polo S, et al. **AIDS** 1999 Mar 11; 13(4):447–54
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Raboud JM, et al. **AIDS** 1998 Sep 10;12(13):1619–24
Cofactors for the acquisition of HIV-1 among heterosexual men: prospective cohort study of trucking company workers in Kenya. Rakwar J, et al. **AIDS** 1999 Apr 1; 13(5):607–14
Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. Ratcliffe J, et al. **AIDS** 1998 Jul 30;12(11):1381–8
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults.

Abacavir Phase 2 Clinical Team. Saag MS, et al. **AIDS** 1998 Nov 12;12(16):F203–9

Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. Saah AJ, et al. **AIDS** 1998 Nov 12; 12(16):2107–13

Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Sabin CA, et al. **AIDS** 1998 Jul 30; 12(11):1347–52

Use of highly sensitive assays for the evaluation of post-exposure HIV prophylaxis [letter] Schockmel GA, et al. **AIDS** 1998 Sep 10;12(13):1726–7

Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals [letter] Shapira-Nahor O, et al. **AIDS** 1998 Sep 10;12(13):1731–3

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. Sperling RS, et al. **AIDS** 1998 Oct 1;12(14):1805–13

Rebound of HIV-1 viral load after suppression to very low levels [letter] Staszewski S, et al. **AIDS** 1998 Dec 3; 12(17):2360

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Staszewski S, et al. **AIDS** 1998 Nov 12;12(16):F197–202

Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. Taha TE, et al. **AIDS** 1998 Sep 10;12(13):1699–706

Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. Tebas P, et al. **AIDS** 1999 Feb 4;13(2):F23–8

Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia. Multicenter Hemophilia Cohort Study. Touloumi G, et al. **AIDS** 1998 Sep 10;12(13):1691–7

Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection. Vidal C, et al. **AIDS** 1998 Jul 30;12(11):1285–9

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. Weverling GJ, et al. **AIDS** 1998 Jul 30;12(11):F117–22

HIV-related attitudes and risk behavior of young adolescent mothers. Brown LK, et al. **AIDS Educ Prev** 1998 Dec; 10(6):565–73

Condom use as a dependent variable: measurement issues relevant to HIV prevention programs. Crosby RA. **AIDS Educ Prev** 1998 Dec;10(6):548–57 (52 ref.)

Alcohol and AIDS-related sexual behavior among Hispanics: acculturation and gender differences. Hines AM, et al. **AIDS Educ Prev** 1998 Dec;10(6):533–47

Effects of an HIV risk reduction project on sexual risk behavior of low-income STD patients. O'Leary A, et al. **AIDS Educ Prev** 1998 Dec;10(6):483–92

Evaluation of an AIDS training program for traditional healers in the Central African Republic. Somsé P, et al. **AIDS Educ Prev** 1998 Dec;10(6):558–64

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. Adams GB, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):551–9

Comparison of complete env gene sequences from individuals with symptomatic primary HIV type 1 infection. Ataman-Onal Y, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1035–9

Association between a defective CCR-5 gene and progression to disease in HIV infection. Balfe P, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1229–34

An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. Carruth LM, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1021–34

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. Cook J, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):499–508

Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein. Corallini A, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1561–71

High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. Egan JF, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):699–705

Genital infection of female chimpanzees with human immunodeficiency virus type 1. Girard M, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1357–67

Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. Kaufmann GR, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20; 15(11):963–72

Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. Kunert R, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1; 14(13):1115–28

In vivo expansion coincident with excessive in vitro cell death within the memory subset of CD8+ T cells in HIV type 1 infection. Mugnaini EN, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):265–72

Quantification of RNA in HIV type 1 subtypes D and G by NucliSens and Amplicor assays in Abidjan, Ivory Coast. Nkengasong JN, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):495–8

Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. Pontesilli O, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):973–81

Cell-associated viral RNA expression during acute infection with HIV type 1. Riggs NL, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1141–9

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. Stamatatos L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1129–39

HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. Tang J, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):317–24

High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. Walther-Jallow L, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):957–62

Expression of a novel Nef epitope on the surface of HIV type 1-infected cells. Yamada T, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1001–9

Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. Zheng L, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20; 15(11):1011–20

HIV-1 incidence among opiate users in northern Thailand. Celentano DD, et al. **Am J Epidemiol** 1999 Mar 15; 149(6):558–64

Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Bagasra O, et al. **Am J Hematol** 1998 Nov;59(3):199–207

Urine testing for HIV-1 [news] **Am J Nurs** 1998 Oct; 98(10):25

Provider-to-patient transmission [news] **Am J Nurs** 1999 May;99(5):17

Sexual and mother-to-child transmission of the human immunodeficiency virus type 1: a review. Chermann JC. **Am J Reprod Immunol** 1998 Sep;40(3):183–6 (46 ref.)

Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):160–4

Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):212–6

AIDS-related information, opinions and attitudes among high school pupils in the Reggio Emilia area (Italy). Stampi S, et al. **Ann Ig** 1998 Sep-Dec;10(5–6):315–23

Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Dimitrakopoulos AN, et al. **Ann Intern Med** 1999 Feb 2;130(3):226–30

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Miller V, et al. **Ann Intern Med** 1999 Apr 6;130(7):570–7

Characteristics of primary HIV infection [letter; comment] Silvers AA. **Ann Intern Med** 1999 Jan 5;130(1):80–1. Comment on: Ann Intern Med 1998 Apr 15;128(8):613–20.

Good and bad news at the AIDS Conference [news] **Ann Oncol** 1998 Sep;9(9):925

Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load. Kersten MJ, et al. **Ann Oncol** 1998 Oct;9(10):1135–8

The early natural history of vertically transmitted HIV-1 infection in African children from Durban, South Africa. Bobat R, et al. **Ann Trop Paediatr** 1998 Sep;18(3):187–96

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Haase AT. **Annu Rev Immunol** 1999;17:625–56 (158 ref.)

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Hughes W, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):609–15

Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Kashuba AD, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1817–26 (141 ref.)

Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Kiriyama A, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):549–56

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Kumar PN, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):603–8

Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. Ngo LY, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1516–9

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Para MF, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1373–8

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E. **Antiviral Res** 1998 Jun;38(3):153–79 (137 ref.)

CD26-processed RANTES(3–68), but not intact RANTES, has potent anti-HIV-1 activity [published erratum appears in Antiviral Res 1999 Jan;40(3):189–90] Schols D, et al. **Antiviral Res** 1998 Oct;39(3):175–87

Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal? Wolters LM, et al. **Antiviral Res** 1999 May;42(1):71–6

Growth in the first two years of uninfected children born to HIV-1 seropositive mothers. Agostoni C, et al. **Arch Dis Child** 1998 Aug;79(2):175–8

Viral loads in dual infection with HIV-1 and cytomegalovirus. Boriskin YS, et al. **Arch Dis Child** 1999 Feb;80(2):132–6

Pattern of early visual field loss in HIV-infected patients. Sample PA, et al. **Arch Ophthalmol** 1999 Jun;117(6):755–60

Neuropathology of human immunodeficiency virus 1 infection. Significance of studying in forensic autopsy cases at Dar es Salaam, Tanzania. Kibayashi K, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):519–23

Diffuse infiltrative lymphocytosis syndrome in a patient with anti-52-kd Ro/SSA and human immunodeficiency virus type 1. Hansen A, et al. **Arthritis Rheum** 1999 Mar; 42(3):578–80

Maternal and umbilical cord serum zidovudine levels in human immunodeficiency virus infection. Phuapradit W, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):288–92

Timing and mechanism of perinatal human immunodeficiency virus-1 infection. Phuapradit W. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):293–7 (46 ref.)

HIV-1 Tat protein is poly(ADP-ribosyl)ated in vitro. Kameoka M, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):90–4

Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins. Lee TG, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):604–8

Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. Rajamohan F, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):419–24

The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of HIV infection: its expression and purification in E. coli by use of a translation initiation site within HIV-1 env gene. Han B, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):607–17

HIV-1 Nef protein causes death in stressed yeast cells due to determinants near the N-terminus and elsewhere in Nef. Macreadie I, et al. **Biochem Mol Biol Int** 1998 Oct; 46(2):277–86

Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic. Zhang W, et al. **Biochemistry** 1999 Jul 20; 38(29):9405–16

Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs. Mobley PW, et al. **Biochim Biophys Acta** 1999 Apr 14;1418(1):1–18

Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Welfle K, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):120–31

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Le Buanec H, et al. **Biomed Pharmacother** 1998;52(10):431–5

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Shafer RW, et al. **Biomed Pharmacother** 1999 Mar; 53(2):73–86 (105 ref.)

Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Ylisastigui L, et al. **Biomed Pharmacother** 1998;52(10):447–53

NMR and topochemical studies of peptidomimetic HIV-1 protease inhibitors containing a cis-epoxide amide isostere. Ro S, et al. **Bioorg Med Chem Lett** 1998 Sep 22;8(18):2423–6

Endothiopeptide inhibitors of HIV-1 protease. Yao S, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):699–704

Low dose oral interferon alpha 2a in HIV-1 seropositive patients: a double-blind, placebo-controlled trial. Wright SE, et al. **Biotherapy** 1998;11(4):229–34

Sensitivity of CD4+ peripheral blood T cells toward spontaneous and CD95 (APO-1/Fas)-induced apoptosis in pediatric human immunodeficiency virus infection [letter] Böhler T, et al. **Blood** 1999 Sep 1;94(5):1829–33

The susceptibility to X4 and R5 human immunodeficiency virus-1 strains of dendritic cells derived in vitro from CD34(+) hematopoietic progenitor cells is primarily determined by their maturation stage. Canque B, et al. **Blood** 1999 Jun 1;93(11):3866–75

Human immunodeficiency virus type 1 Vpr alters bone marrow cell function. Kulkosky J, et al. **Blood** 1999 Mar 15;93(6):1906–15

Immunophenotypic analysis of peripheral blood mononuclear cells undergoing in vitro apoptosis after isolation from human immunodeficiency virus-infected children. McCloskey TW, et al. **Blood** 1998 Dec 1;92(11):4230–7

Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in

human immunodeficiency virus-1-infected individuals. Magierowska M, et al. **Blood** 1999 Feb 1;93(3):936-41

Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection. Wolthers KC, et al. **Blood** 1999 Feb 1;93(3):1011-9

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection [letter] Churchill DR, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):518-9

Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Regazzi MB, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):379-82

HLA-Cw*0602 and HIV-associated psoriasis. Mallon E, et al. **Br J Dermatol** 1998 Sep;139(3):527-33

HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. Gibellini D, et al. **Br J Haematol** 1999 Jan;104(1):81-6

Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Cashion MF, et al. **Brain Res** 1999 Mar 20; 822(1-2):26-33

Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants. Abrams EJ, et al. **Bull N Y Acad Med** 1995 Winter;72(2):443-53

Neuropathogenesis of HIV-1 infection. Outstanding questions. Vitkovic L, et al. **C R Acad Sci III** 1998 Dec; 321(12):1015-21 (37 ref.)

Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Acurcio F de A, et al. **Cad Saude Publica** 1998 Oct-Dec; 14(4):811-20

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Nannan Panday VR, et al. **Cancer Chemother Pharmacol** 1999;43(6):516-9

Synthesis of an N-glucoasparagine analog as a building block for a V3-loop glycopeptide from gp120 of HIV-1. Schäfer A, et al. **Carbohydr Res** 1998 Dec;313(2):107-16

Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1. Savarino A, et al. **Cell Biochem Funct** 1999 Mar; 17(1):47-55

Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children. Stricker K, et al. **Cell Death Differ** 1998 Mar; 5(3):222-30

Functional activity of alveolar and peripheral cells in patients with human acquired immunodeficiency syndrome and pulmonary tuberculosis. Bonecini-Almeida M da G, et al. **Cell Immunol** 1998 Dec 15;190(2):112-20

Seroprevalence of human immunodeficiency virus type 1 infection in childhood malignancy in Zimbabwe. Chitsike I, et al. **Cent Afr J Med** 1998 Oct;44(10):242-5

Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa--laboratory parameters. van Staden AM, et al. **Cent Afr J Med** 1998 Oct; 44(10):246-50

Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Moyer TP, et al. **Clin Chem** 1999 Sep;45(9):1465-76

Urine antibody tests: new insights into the dynamics of HIV-1 infection. Urnovitz HB, et al. **Clin Chem** 1999 Sep; 45(9):1602-13

Angiocentric CD3(+) T-cell infiltrates in human immunodeficiency virus type 1-associated central nervous system disease in children. Katsetos CD, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):105-14

Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals. Meddows-Taylor S, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):345-51

Current concepts in human immunodeficiency virus infection and AIDS. Schwartz SA, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):295-305 (56 ref.)

Immunohematological reference ranges for adult Ethiopians. Tsegaye A, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):410-4

Levels of proinflammatory cytokines in plasma after pneumococcal immunization in human immunodeficiency virus type 1-infected patients. Valdez H, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):427-8

Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Bürgisser P, et al. **Clin Exp Immunol** 1999 Mar;115(3):458-63

Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals. Galiani MD, et al. **Clin Exp Immunol** 1999 Mar;115(3):472-6

Anti-phospholipid antibodies and CD5+ B cells in HIV infection. Grünewald T, et al. **Clin Exp Immunol** 1999 Mar; 115(3):464-71

Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection. Jobe O, et al. **Clin Exp Immunol** 1999 Jun;116(3):474-8

Tumour necrosis factor (TNF) and TNF-related molecules in HIV-1+ individuals: relationship with in vitro Th1/Th2-type response. Rizzardi GP, et al. **Clin Exp Immunol** 1998 Oct;114(1):61-5

Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery. Sousa AE, et al. **Clin Exp Immunol** 1999 May;116(2):307-15

Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes. Tedla N, et al. **Clin Exp Immunol** 1999 Jul; 117(1):92-9

Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Di Marzio L, et al. **Clin Immunol** 1999 Jul;92(1):103-10

Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Hosono O, et al. **Clin Immunol** 1999 Jun;91(3):283-95

Kinetics of lymphocyte apoptosis in macaques infected with different simian immunodeficiency viruses or simian/human immunodeficiency hybrid viruses. Reinberger S, et al. **Clin Immunol** 1999 Jan;90(1):141-6

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Bessesen M, et al. **Clin Infect Dis** 1999 May;28(5):1032-5

Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clough LA, et al. **Clin Infect Dis** 1999 Jul;29(1):75-81; discussion 82-4

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Krogstad P, et al. **Clin Infect Dis** 1999 May; 28(5):1109-18

Entamoeba gingivalis in human immunodeficiency virus type 1-infected patients with periodontal disease. Lucht E, et al. **Clin Infect Dis** 1998 Sep;27(3):471-3

Unethical study of the natural history of cryptococcal meningitis in 1997 [letter; comment] Restrepo A, et al. **Clin Infect Dis** 1999 Jun;28(6):1341-2. Comment on: Clin Infect Dis 1998 Feb;26(2):284-9.

Longer-term immunologic effects and side effects of successful antiretroviral therapy. Schooley RT. **Clin Infect Dis** 1999 Jul;29(1):12-8 (49 ref.)

Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Ahuja TS, et al. **Clin Nephrol** 1999 Jan;51(1):40-4

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194-6 (8 ref.)

Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Sheehan MT, et al. **Clin Nephrol** 1998 Sep;50(3):188-93 (39 ref.)

AIDS and HIV-1 infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1998 Oct 23; 8(43):385-8

AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Sep 24; 9(39):353-4

Management of HIV serodiscordant couples. The clinician point of view. Coll O, et al. **Contracept Fertil Sex** 1999 Jun;27(6):399-404

Human immunodeficiency virus disease in the era of HAART: a reevaluation of the mucocutaneous manifestations. Johnson RA. **Curr Clin Top Infect Dis** 1999; 19:252-86 (210 ref.)

Host genetic influences on HIV-1 pathogenesis. Michael NL. **Curr Opin Immunol** 1999 Aug;11(4):466-74 (129 ref.)

Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Hultin LE, et al. **Cytometry** 1998 Oct 1;33(2):123-32

Regression of rectal stenosis secondary to neoplasm in an HIV1-positive patient with gancyclovir antiviral therapy: report of a case. Sobhani I, et al. **Dis Colon Rectum** 1998 Nov;41(11):1454-7

A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma [published erratum appears in Drug Saf 1999 Jun;20(6):473] Nasti G, et al. **Drug Saf** 1999 May; 20(5):403-25 (92 ref.)

Efavirenz. Adkins JC, et al. **Drugs** 1998 Dec;56(6):1055-64; discussion 1065-6 (34 ref.)

Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management. Bowen EF. **Drugs** 1999 May;57(5):735-41 (24 ref.)

Insights into the mechanisms of vertical transmission of HIV-1. BIOMED2 Working Group on the in utero transmission of HIV-1. Menu E, et al. **Early Pregnancy** 1997 Dec;3(4):245-58 (130 ref.)

Postural reflexes in patients with HIV-1 infection. Beckley DJ, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 109(5):402-8

Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1. Vidal F, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):473-7

CCR5 genotype and human immunodeficiency virus type 1 infection in perinatally exposed infants. Villalba N, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):389-91

Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Lyles CM, et al. **Eur J Epidemiol** 1999 Feb;15(2):99-108

Kinetics of indium-111-labelled platelets in HIV-infected patients with and without associated thrombocytopaenia. Van Wyk V, et al. **Eur J Haematol** 1999 May;62(5):332-5

Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals. André P, et al. **Eur J Immunol** 1999 Apr;29(4):1076-85

Expression of CD69 on T-cells from HIV-1-infected children and adolescents increases with increasing viral load. Böhler T, et al. **Eur J Pediatr** 1999 Aug;158(8):638-44

Human immunodeficiency virus and hepatitis B virus co-infection in two siblings: viral loads markedly reduced by triple-therapy including lamivudine [letter] Horneff G, et al. **Eur J Pediatr** 1999 Aug;158(8):687-8

Interleukin-15 enhances HIV-1-driven polyclonal B-cell response in vitro. Kacani L, et al. **Exp Clin Immunogenet** 1999;16(3):162-72

A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding. Howie SE, et al. **FASEB J** 1999 Mar;13(3):503-11

HIV-1-infection in the CNS. A pathogenesis of some neurological syndromes in the light of recent investigations. Rafalowska J. **Folia Neuropathol** 1998;36(4):211-6 (49 ref.)

Pulmonary hypertension associated with human immunodeficiency virus infection. Report of two cases and review of the literature. Fiorencis R, et al. **G Ital Cardiol** 1998 Dec;28(12):1404-8 (24 ref.)

Overview of HIV and AIDS: biology and epidemiology of the virus. Klein RS, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):751-67 (80 ref.)

Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Bai X, et al. **Gene Ther** 1998 Jul;5(7):984-94

Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. BouHamdan M, et al. **Gene Ther** 1999 Apr; 6(4):660-6

The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor. Li XY, et al. **Genes Dev** 1998 Oct 1;12(19):2992-6

No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1 infected patients. Wilcox CM, et al. **Gut** 1999 Jan;44(1):101-5

Neurodevelopmental outcomes of Ugandan infants with HIV infection: an application of growth curve analysis. Drotar D, et al. **Health Psychol** 1999 Mar;18(2):114-21

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Wong-Staal F, et al. **Hum Gene Ther** 1998 Nov 1;9(16):2407-25

HLA antigens associated with susceptibility/resistance to HIV-1 infection. Rohowsky-Kochan C, et al. **Hum Immunol** 1998 Dec;59(12):802-15

Enhanced survival and potent expansion of the natural killer cell population of HIV-infected individuals by exogenous interleukin-15. Naora H, et al. **Immunol Lett** 1999 Jun 1; 68(2-3):359-67

Novel mechanism for the impairment of cell proliferation in HIV-1 infection. Bofill M, et al. **Immunol Today** 1999 Jun;20(6):258-61 (29 ref.)

Increasing prevalence of HIV-2 and dual HIV-1-2 infections among high risk group hospital admitted patients in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Nov;52(11):479-84

Dysregulated production of interleukin-8 in individuals infected with human immunodeficiency virus type 1 and Mycobacterium tuberculosis. Meddows-Taylor S, et al. **Infect Immun** 1999 Mar;67(3):1251-60

Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. Harrer T, et al. **Infection** 1998 Nov-Dec;26(6):368-74

Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. Wesch D, et al. **Int Immunol** 1998 Aug;10(8):1067-75

Sugar transport and glut transporter expression in a variety of human immunodeficiency virus-1 (HIV-1) chronically infected target cell lines. Caro C, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1031-8

Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. Silvestris F, et al. **Int J Clin Lab Res** 1998; 28(4):215-25

Pregnancy, body weight and human immunodeficiency virus infection in African women: a prospective cohort study in Kigali (Rwanda), 1992-1994. Pregnancy and HIV Study Group (EGE). Ladner J, et al. **Int J Epidemiol** 1998 Dec; 27(6):1072-7

Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Okongo M, et al. **Int J Epidemiol** 1998 Aug;27(4):698-702

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe? Prins M, et al. **Int J Epidemiol** 1999 Jun;28(3):541-9

Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. Temmerman M, et al. **Int J Gynaecol Obstet** 1999

May;65(2):171–81

Vertical transmission of human immunodeficiency virus type 1: frequency and correlation of transmission (review). Li Q, et al. **Int J Mol Med** 1998 Mar;1(3):589–91 (29 ref.)

Moderate and high intensity exercise training in HIV-1 seropositive individuals: a randomized trial. Terry L, et al. **Int J Sports Med** 1999 Feb;20(2):142–6

Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986–1992). Bogaerts J, et al. **Int J STD AIDS** 1998 Nov; 9(11):706–10

Gynaecomastia associated with saquinavir therapy. Donovan B, et al. **Int J STD AIDS** 1999 Jan;10(1):49–50

Preventive HIV-1 vaccines: where are we going? Kent SJ. **Int J STD AIDS** 1998 Dec;9(12):715–9 (45 ref.)

Gynaecological conditions associated with HIV infection in women who are partners of HIV-positive Thai blood donors. Rugpao S, et al. **Int J STD AIDS** 1998 Nov; 9(11):677–82

Education attainment as a predictor of HIV risk in rural Uganda: results from a population-based study. Smith J, et al. **Int J STD AIDS** 1999 Jul;10(7):452–9

Multidrug-resistant tuberculous meningitis in a health care worker [letter] Silber E, et al. **Int J Tuberc Lung Dis** 1998 Sep;2(9):774

Retinal microvasculopathy in human immunodeficiency type 1 (HIV)-infected children. Tejada P, et al. **Int Ophthalmol** 1997–98;21(6):319–21

A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Honda M, et al. **Intern Med** 1999 Mar; 38(3):302–3

The contribution of various NOS gene products to HIV-1 coat protein (gp120)-mediated retinal ganglion cell injury. Dreyer EB, et al. **Invest Ophthalmol Vis Sci** 1999 Apr; 40(5):983–9

Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center. Plummer DJ, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):435–42

Isolation and transduction of CD34+ cells from small quantities of peripheral blood from HIV-1-infected patients not treated with hemopoietic growth factors. Adams GB, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):1–8

Prevalence of HIV-1 among recent arrestees in Los Angeles County, California: serial cross-sectional study, 1991–1995. Carpenter CL, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):172–7

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study. Daar ES, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):317–25

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. Friedland GH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):281–92

Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. Gisslén M, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):271–6

Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. Jacobson LP, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S34–41

Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. Massad LS, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):33–41

CCR5 genotype and resistance to vertical transmission of HIV-1. Philpott S, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):189–93

Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. Vanhems P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1; 21(2):99–106

Risk of HIV infection in oral contraceptive pill users: a meta-analysis [published erratum appears in J Acquir Immune Defic Syndr 1999 Aug 15;21(5):428] Wang CC, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):51–8

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1–infected patients with and without AIDS dementia complex. Aweeka F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):39–43

HIV-1 seroprevalence in Zambian patients with acute diarrhea: a community-based study. Baboo KS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):160–3

CCR5, vertical transmission of HIV-1, and disease progression. European Collaborative Study [letter] Bailey AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):211–2

Cytokine profiles in a cohort of long-term survivors of transfusion-acquired HIV-1 infection [letter] Blasdall SA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):97

Neonatal characteristics and outcome in a cohort of infants born to HIV-1-infected African women from Durban, South Africa [letter] Bobat R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):408–9

Detection and enumeration of HIV-1-producing cells by ELISPOT (enzyme-linked immunospot) assay. Corne P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):442–7

HIV-1-induced perturbations of glycosphingolipid metabolism are cell-specific and can be detected at early stages of HIV-1 infection. Fantini J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):221–9

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1–infected patients (the EURIS study). Gringeri A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):358–70

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. Hanson IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):463–7

Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. Ioannidis JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):129–36

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. Maas JJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):254–9

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand. Markowitz LE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):488–94

Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine. Orlandi P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):230–7

Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group. Pitt J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):462–70

Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research. Rompalo AM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):448–54

Increased intracellular accumulation of macrophage inflammatory protein 1beta and its decreased secretion correlate with advanced HIV disease. Tartakovsky B, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):420–2

Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. van der Ryst E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):238–44

Comparison of gynecologic history and laboratory results in HIV-positive women with CD4+ lymphocyte counts between 200 and 500 cells/microl and below 100 cells/microl. Watts DH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):455–62

Determinants of condom use to prevent HIV infection among youth in Ghana. Adih WK, et al. **J Adolesc Health** 1999 Jan;24(1):63–72

Eosinophil involvement and serum IgE level in HIV-1-infected children. Onorato J, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):245–7

Contact dermatitis in subjects infected with HIV type 1. Bellegrandi S, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):777–9

Immunologic and viral markers of HIV-1 disease progression: implications for dentistry. Patton LL, et al. **J Am Dent Assoc** 1999 Sep;130(9):1313–22 (66 ref.)

Characteristics of AIDS in older patients: a follow-up study [letter; comment] Allison-Ottey S, et al. **J Am Geriatr Soc** 1999 Jun;47(6):764–5. Comment on: J Am Geriatr Soc 1998 Feb;46(2):153–6.

Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients [editorial] Chronister CL, et al. **J Am Optom Assoc** 1998 Nov;69(11):695–8 (18 ref.)

Captopril prevents nephropathy in HIV-transgenic mice. Bird JE, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1441–7

Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). Kwong PD, et al. **J Biol Chem** 1999 Feb 12;274(7):4115–23

HEED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. Peytavi R, et al. **J Biol Chem** 1999 Jan 15;274(3):1635–45

Molecular modeling of HIV-1 coreceptor CCR5 and exploring of conformational space of its extracellular domain in molecular dynamics simulation. Efremov RG, et al. **J Biomol Struct Dyn** 1998 Aug;16(1):77–90

The 1998 Lindberg Award. Comparison of glycerol preservation with cryopreservation methods on HIV-1 inactivation. van Baare J, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):494–500

The continuing epidemic [letter; comment] Hardie J. **J Can Dent Assoc** 1998 Nov;64(10):678, 680. Comment on: J Can Dent Assoc 1998 Jun;64(6):426–30.

On-line coupling of polymerase chain reaction and capillary electrophoresis for automatic DNA typing and HIV-1 diagnosis. Zhang N, et al. **J Chromatogr B Biomed Sci Appl** 1998 Aug 28;714(1):3–11

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Yanovski JA, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1925–31

Slowed information processing in HIV-1 disease. The Multicenter AIDS Cohort Study (MACS). Llorente AM, et al. **J Clin Exp Neuropsychol** 1998 Feb;20(1):60–72

HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. Conaldi PG, et al. **J Clin Invest** 1998 Dec 15;102(12):2041–9

Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. Koziel H, et al. **J Clin Invest** 1998 Oct 1;102(7):1332–44

Cellular dysmetabolism: the dark side of HIV-1 infection. Famularo G, et al. **J Clin Lab Immunol** 1996;48(3):123–32 (53 ref.)

Evaluation of epidemiological and serological predictors of human immunodeficiency virus type-1 (HIV-1) infection among high risk professional blood donors with western blot indeterminate results. Chattopadhya D, et al. **J Clin Virol** 1998 Jul 24;11(1):39–49

Increased soft tissue in the posterior cervical and upper back area of patients on HIV-1 protease inhibitors. Smith K, et al. **J Cutan Med Surg** 1999 Apr;3(4):211–7

Sexually transmitted diseases in 1161 HIV-positive patients: a 38-month prospective study in southern Spain. Muñoz-Pérez MA, et al. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):221–6

Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. Zhang L, et al. **J Exp Med** 1999 Sep 6; 190(5):725–32

When should we delay highly active antiretroviral therapy? [editorial; comment] Bangsberg DR, et al. **J Gen Intern Med** 1999 Jul;14(7):446–8. Comment on: J Gen Intern Med 1999 Jul;14(7):395–401.

Delays in protease inhibitor use in clinical practice [see comments] Fairfield KM, et al. **J Gen Intern Med** 1999 Jul;14(7):395–401. Comment in: J Gen Intern Med 1999 Jul;14(7):446–8.

Pathogenesis of simian immunodeficiency virus infection. Whetter LE, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1557–68 (137 ref.)

Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. Banda NK, et al. **J Hematother** 1998 Aug;7(4):319–31

Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8 [see comments] Ariyoshi K, et al. **J Hum Virol** 1998 Mar-Apr;1(3):193–9 . Comment in: J Hum Virol 1998 Mar-Apr;1(3):185–6.

HIV-1, HHV-8, and Kaposi's sarcoma [editorial; comment] Gallo RC. **J Hum Virol** 1998 Mar-Apr;1(3):185–6. Comment on: J Hum Virol 1998 Mar-Apr;1(3):193–9.

Stimulation of bystander T-cell proliferation by tumor necrosis factor produced by HIV-1-infected macrophages. Godard CM, et al. **J Hum Virol** 1998 May-Jun;1(4):257–66

Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-infected and uninfected hemophilia patients. Kantor R, et al. **J Hum Virol** 1998 May-Jun; 1(4):299–301

Role of the CCR5 delta 32 allele in resisance to HIV-1 infection in west Africa. Kokkotou E, et al. **J Hum Virol** 1998 Nov-Dec;1(7):469–74

Molecular analysis of GB virus C/hepatitis G virus in HIV-1-positive intravenous drug users in Belgium. Liu HF, et al. **J Hum Virol** 1999 Mar-Apr;2(2):115–20

Milk-borne transmission of HIV. Characterization of productively infected cells in breast milk and interactions between milk and saliva. Southern SO. **J Hum Virol** 1998 Jul-Aug;1(5):328–37

Evolution of human immunodeficiency virus type 1 in relation to disease progression in children. Strunnikova N, et al. **J Hum Virol** 1998 Mar-Apr;1(3):224–39

Prevalence of hepatitis G virus RNA in human immunodeficiency virus type 1-positive intravenous drug users. Zehender G, et al. **J Hum Virol** 1998 Jan-Feb; 1(2):96–100

Chronically HIV-1-infected monocytic cells induce apoptosis in cocultured T cells. Chen H, et al. **J Immunol** 1998 Oct 15;161(8):4257–67

cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection.

Cole SW, et al. **J Immunol** 1999 Feb 1;162(3):1392–400

Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. Ruiz ME, et al. **J Immunol** 1998 Oct 15;161(8):4169–76

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load. Arnó A, et al. **J Infect Dis** 1999 Jul; 180(1):56–60

Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification. Berger C, et al. **J Infect Dis** 1999 Jan;179(1):240–4

Sexually transmitted disease acquisition among women infected with human immunodeficiency virus type 1. Bersoff-Matcha SJ, et al. **J Infect Dis** 1998 Oct; 178(4):1174–7

Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. Beyrer C, et al. **J Infect Dis** 1999 Jan;179(1):59–67

Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age. Buseyne F, et al. **J Infect Dis** 1998 Oct;178(4):1019–23

Detection of human herpesvirus 8 in cervicovaginal secretions and seroprevalence in human immunodeficiency virus type 1-seropositive and -seronegative women. Calabrò ML, et al. **J Infect Dis** 1999 Jun;179(6):1534–7

Searching for human herpesvirus 8 antibodies in serum samples from patients infected with human immunodeficiency virus type 1 and blood donors from São Paulo, Brazil [letter] Caterino-de-Araujo A, et al. **J Infect Dis** 1999 Jun;179(6):1591–2

Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. Cohen CR, et al. **J Infect Dis** 1998 Nov;178(5):1352–8

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. Davey RT Jr, et al. **J Infect Dis** 1999 Apr;179(4):849–58

Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. Fultz PN, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S418–21

Decreased expression of zeta molecules by T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. Geertsma MF, et al. **J Infect Dis** 1999 Sep;180(3):649–58

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. Giorgi JV, et al. **J Infect Dis** 1999 Apr;179(4):859–70

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. Hirsch M, et al. **J Infect Dis** 1999 Sep;180(3):659–65

Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. Iversen AK, et al. **J Infect Dis** 1998 Nov;178(5):1334–42

Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1. Jenson H, et al. **J Infect Dis** 1999 Jun;179(6):1395–404

Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. Keet IP, et al. **J Infect Dis** 1999 Aug;180(2):299–309

Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. Kositanont U, et al. **J Infect Dis** 1999 Jul;180(1):50–5

The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. Laskus T, et al. **J Infect Dis** 1998 Oct;178(4):1189–92

Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya. Lavreys L, et al. **J Infect Dis** 1999 Aug;180(2):330–6

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, et al. **J Infect Dis** 1999 Jun;179(6):1356–64

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. Loomis-Price LD, et al. **J Infect Dis** 1998 Nov;178(5):1306–16

Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. Luque AE, et al. **J Infect Dis** 1999 Jun; 179(6):1405–9

Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans. Mann DL, et al. **J Infect Dis** 1998 Dec;178(6):1799–802

Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. Martin HL Jr, et al. **J Infect Dis** 1998 Oct;178(4):1053–9

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. Moodley J, et al. **J Infect Dis** 1998 Nov;178(5):1327–33

Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. Mostad SB, et al. **J Infect Dis** 1998 Oct;178(4):983–91

Interactions of viruses and microparticles with apical plasma membranes of M cells: implications for human immunodeficiency virus transmission. Neutra MR. **J Infect Dis** 1999 May;179 Suppl 3:S441–3 (16 ref.)

Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. Overbaugh J, et al. **J Infect Dis** 1999 May;179 Suppl 3:S401–4 (11 ref.)

Determinants of the natural history of human immunodeficiency virus type 1 infection. Phair JP. **J Infect Dis** 1999 Mar;179 Suppl 2:S384–6 (34 ref.)

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. Rinaldo Jr CR, et al. **J Infect Dis** 1999 Feb;179(2):329–36

No evidence for an effect of the CCR5 delta32/+ and CCR2b 641/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. Schinkel J, et al. **J Infect Dis** 1999 Apr;179(4):825–31

Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. Sei S, et al. **J Infect Dis** 1999 Sep;180(3):626–40

Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. Semba RD, et al. **J Infect Dis** 1999 Jul;180(1):93–8

Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. Sterling TR, et al. **J Infect Dis** 1999 Sep;180(3):666–72

Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production. Triozzi PL, et al. **J Infect Dis** 1999 Jan; 179(1):245–8

Transmission of human immunodeficiency virus type 1 through breast-feeding: how can it be prevented? Van de Perre P. **J Infect Dis** 1999 May;179 Suppl 3:S405–7 (17 ref.)

The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy [published erratum appears in J Infect Dis 1999 Mar;179(3):754] Van Dyke RB, et al. **J Infect Dis** 1999 Feb;179(2):319–28

Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis: comments and conference summary. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S397–400

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. Wit FW, et al. **J Infect Dis** 1999 Apr;179(4):790–8

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. Wu H, et al. **J Infect Dis** 1999 Apr;179(4):799–807

Infection of T cell subsets by HIV-1 and the effects of interleukin-12. Salgame P, et al. **J Interferon Cytokine Res** 1998 Jul;18(7):521–8

Thiazolothiazepine inhibitors of HIV-1 integrase. Neamati N, et al. **J Med Chem** 1999 Aug 26;42(17):3334–41

Prevalence of GBV-C/hepatitis G virus RNA and E2 antibody among subjects infected with human immunodeficiency virus type 1 after parenteral or sexual exposure. Bourlet T, et al. **J Med Virol** 1999 Aug; 58(4):373–7

Influence of HIV-1 infection on GBV-C infection in multiply infected haemophilic patients. Devereux H, et al. **J Med Virol** 1998 Dec;56(4):316–20

Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. Emery VC, et al. **J Med Virol** 1999 Mar;57(3):278–82

GBV-C/HGV coinfection in HIV-1-positive men: frequent detection of viral RNA in blood plasma but absence from seminal fluid plasma. Hollingsworth RC, et al. **J Med Virol** 1998 Dec;56(4):321–6

Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission. Mazza C, et al. **J Med Virol** 1999 May;58(1):59–62

High prevalence of GB virus C/hepatitis G virus infection among homosexual men infected with human immunodeficiency virus type 1: evidence for sexual transmission. Nerurkar VR, et al. **J Med Virol** 1998 Oct; 56(2):123–7

Frequencies of SDF-1 chemokine, CCR-5, and CCR-2 chemokine receptor gene alleles conferring resistance to human immunodeficiency virus type 1 and AIDS in Kuwaitis. Voevodin A, et al. **J Med Virol** 1999 May; 58(1):54–8

Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors. Friedler A, et al. **J Mol Biol** 1999 Mar 19;287(1):93–101

Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein. Geyer M, et al. **J Mol Biol** 1999 May 28;289(1):123–38

HIV-1 rev nuclear export signal binding peptides isolated by phage display. Jensen A, et al. **J Mol Biol** 1998; 283(1):245–54

Binding properties of the human immunodeficiency virus type 1 nucleocapsid protein p7 to a model RNA: elucidation of the structural determinants for function. Urbaneja MA, et al. **J Mol Biol** 1999 Mar 19;287(1):59–75

Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. Haughey NJ, et al. **J Neurochem** 1999 Oct;73(4):1363–74

HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. Maggirwar SB, et al. **J Neurochem** 1999 Aug;73(2):578–86

Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. Fine SM, et al. **J Neuroimmunol** 1999 Mar 1;95(1-2):55–64

Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease). Roullet E. **J Neurol** 1999 Apr;246(4):237–43 (55 ref.)

HIV-associated PML presenting as epilepsia partialis continua. Ferrari S, et al. **J Neurol Sci** 1998 Dec 11; 161(2):180–4

Non-lymphomatous brain tumors in HIV-1 infection: a review. Büttner A, et al. **J Neurooncol** 1999 Jan;41(1):81–8 (46 ref.)

Human immunodeficiency virus type 1 Tat protein stimulates inducible nitric oxide synthase expression and nitric oxide production in microglial cultures. Polazzi E, et al. **J Neuropathol Exp Neurol** 1999 Aug;58(8):825–31

Apathy, depression, and cognitive performance in HIV-1 infection. Castellon SA, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer;10(3):320–9

Enterovirus associated neurological disease in an HIV-1 infected man. Dyer JR, et al. **J Neurovirol** 1998 Oct; 4(5):569–71

CNS as an HIV-1 reservoir; BBB and drug delivery. Kerza-Kwiatecki AP, et al. **J Neurovirol** 1999 Apr; 5(2):113–4

Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. Koralnik IJ, et al. **J Neurovirol** 1999 Aug;5(4):430–5

Cocaine opens the blood-brain barrier to HIV-1 invasion. Zhang L, et al. **J Neurovirol** 1998 Dec;4(6):619–26

Human immunodeficiency virus prevalence in women at delivery using unlinked anonymous testing of newborns in the Malaysian setting. Amar HS, et al. **J Paediatr Child Health** 1999 Feb;35(1):63–6

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. McKinney RE Jr, et al. **J Pediatr** 1998 Oct;133(4):500–8

Adrenal suppression in children with the human immunodeficiency virus treated with megestrol acetate. Stockheim JA, et al. **J Pediatr** 1999 Mar;134(3):368–70 (8 ref.)

Occurrence of anti-thyroid autoantibodies in children vertically infected with HIV-1. Fundarò C, et al. **J Pediatr Endocrinol Metab** 1998 Nov-Dec;11(6):745–50

Patterns of presentation of human immunodeficiency virus type 1-infected children to the paediatric surgeon. Grant HW. **J Pediatr Surg** 1999 Feb;34(2):251–4

Proceedings of the Ares Serono Foundation Workshop on HIV-1 and Gametes. Siena, Italy, October 14-17, 1997. **J Reprod Immunol** 1998 Dec;41(1-2):1–377

The debate on the presence of HIV-1 in human gametes. Baccetti B, et al. **J Reprod Immunol** 1998 Dec;41(1-2):41–67 (48 ref.)

Localization of human herpesvirus type 8 (HHV-8) in the Kaposi's sarcoma tissues and the semen specimens of HIV-1 infected and uninfected individuals by utilizing in situ polymerase chain reaction. Bobroski L, et al. **J Reprod Immunol** 1998 Dec;41(1-2):149–60

Changes in immune activation markers during pregnancy and postpartum. Burns DN, et al. **J Reprod Immunol** 1999 Mar; 42(2):147–65

Assisted conception in HIV discordant couples: evaluation of semen processing techniques in reducing HIV viral load. Chrystie IL, et al. **J Reprod Immunol** 1998 Dec; 41(1-2):301–6

The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1-2):261–70 (21 ref.)

Microscopic evidence against HIV-1 infection of germ cells or attachment to sperm. Pudney J, et al. **J Reprod Immunol** 1998 Dec;41(1-2):105–25 (29 ref.)

The case against an association between HIV-1 and sperm: molecular evidence. Quayle AJ, et al.

J Reprod Immunol 1998 Dec;41(1-2):127-36 (20 ref.)

Short-term impact of safer choices: a multicomponent, school-based HIV, other STD, and pregnancy prevention program. Coyle K, et al. **J Sch Health** 1999 May; 69(5):181-8

No evidence of vertical transmission of HTLV-I and HTLV-II in children at high risk for HIV-1 infection from São Paulo, Brazil. Caterino-de-Araujo A, et al. **J Trop Pediatr** 1999 Feb;45(1):42-7

Upper airway obstruction in an HIV-1 infected child with acute Epstein-Barr virus infection [letter] Weber HC, et al. **J Trop Pediatr** 1999 Apr;45(2):119-20

Induction of AIDS in rhesus monkeys by a recombinant simian immunodeficiency virus expressing nef of human immunodeficiency virus type 1. Alexander L, et al. **J Virol** 1999 Jul;73(7):5814-25

Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. Dettenhofer M, et al. **J Virol** 1999 Feb;73(2):1460-7

The presence of human immunodeficiency virus type 1 Vpr correlates with a decrease in the frequency of mutations in a plasmid shuttle vector. Jowett JB, et al. **J Virol** 1999 Sep;73(9):7132-7

CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. Moir S, et al. **J Virol** 1999 Oct;73(10):7972-80

Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. Takahashi M, et al. **J Virol** 1999 Sep;73(9):7812-6

Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia. Zheng J, et al. **J Virol** 1999 Oct;73(10):8256-67

An HIV autopsy--characterization of zidovudine-resistant subtype E HIV-1 from autopsy tissue suggests the route of infection and an alternative protocol of therapy [published erratum appears in Keio J Med 1999 Jun;38(2):108] Negishi M, et al. **Keio J Med** 1999 Mar; 48(1):44-52

HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection [see comments] Winston JA, et al. **Kidney Int** 1999 Mar;55(3):1036-40 (32 ref.). Comment in: Kidney Int 1999 Mar;55(3):1123-4.

Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee. **Lancet** 1999 Jun 12; 353(9169):2061-4

Science, ethics, and the future of research into maternal infant transmission of HIV-1. Perinatal HIV Intervention Research in Developing Countries Workshop participants [see comments] **Lancet** 1999 Mar 6;353(9155):832-5 (23 ref.) . Comment in: Lancet 1999 May 29;353(9167):1878; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1878-9; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1879-80; discussion 1880. Comment in: Lancet 1999 May 29;353(9167):1880-1.

Home HIV kits unreliable [news] **Lancet** 1999 Jul 3; 354(9172):55

Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. The European Mode of Delivery Collaboration [see comments] [published erratum appears in Lancet 1999 May 15;353(9165):1714] **Lancet** 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Mar 27;353(9158):1030-1. Comment in: Lancet 1999 Jun 26;353(9171):2240. Comment in: Lancet 1999 Jun 26;353(9171):2240-1.

Prevention of vertical HIV-1 transmission [letter; comment] Anderson JR, et al. **Lancet** 1999 Jun 26;353(9171):2240-1 . Comment on: Lancet 1999 Mar 27;353(9158):1035-9.

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group [see comments] Anglaret X, et al. **Lancet** 1999 May 1;353(9163):1463-8. Comment in: Lancet 1999 Jul 24;354(9175):333; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):333-4; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):334; discussion 335.

Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals [letter] Babl FE, et al. **Lancet** 1999 Apr 10;353(9160):1243-4

Co-trimoxazole in HIV-1 infection [letter; comment] Badri M, et al. **Lancet** 1999 Jul 24;354(9175):334-5. Comment on: Lancet 1999 May 1;353(9163):1469-75.

Concern voiced over "dry sex" practices in South Africa [news] Baleta A. **Lancet** 1998 Oct 17;352(9136):1292

Antiretroviral treatment [letter; comment] Boelaert JR, et al. **Lancet** 1998 Oct 10;352(9135):1224-5. Comment on: Lancet 1998 Jun 20;351(9119):1825.

Co-trimoxazole in HIV-1 infection [letter; comment] Boeree MJ, et al. **Lancet** 1999 Jul 24;354(9175):334; discussion 335 . Comment on: Lancet 1999 May 1;353(9163):1463-8. Comment on: Lancet 1999 May 1;353(9163):1469-75.

Perinatal HIV-1 transmission discussed in Geneva [news; comment] Bradbury J, et al. **Lancet** 1998 Jul 4;352(9121):39 . Comment on: Lancet 1998 Aug 29;352(9129):737.

Court order for HIV-1 test for baby. Brahams D. **Lancet** 1999 Sep 11;354(9182):884

Co-trimoxazole in HIV-1 infection [letter; comment] Brindle R. **Lancet** 1999 Jul 24;354(9175):333-4; discussion 335. Comment on: Lancet 1999 May 1;353(9163):1463-8. Comment on: Lancet 1999 May 1;353(9163):1469-75.

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Carr A, et al. **Lancet** 1999 Jun 19;353(9170):2093-9

Sexual dysfunction with protease inhibitors [letter; comment] Colebunders R, et al. **Lancet** 1999 May 22;353(9166):1802 . Comment on: Lancet 1999 Mar 6;353(9155):810-1.

Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group [see comments] Coutsoudis A, et al. **Lancet** 1999 Aug 7;354(9177):471-6. Comment in: Lancet 1999 Aug 7;354(9177):442-3.

HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers [letter] Descamps V, et al. **Lancet** 1999 May 29;353(9167):1855-6

Lipodystrophy in HIV-1-infected patients [letter] Domingo P, et al. **Lancet** 1999 Sep 4;354(9181):868

US Senate moves to broaden HIV-1 payment [news] Droste TM. **Lancet** 1998 Oct 3;352(9134):1128

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Dunne MW, et al. **Lancet** 1999 Sep 11;354(9182):891-5

Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda [letter] Elliott AM, et al. **Lancet** 1999 Sep 18; 354(9183):1000-1

Early treatment of HIV-1 infection [letter; comment] Fauci A, et al. **Lancet** 1998 Dec 12;352(9144):1935; discussion 1936. Comment on: Lancet 1998 Sep 19;352(9132):982-3.

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Foëx B. **Lancet** 1999 May 29;353(9167):1879; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Pooch protease paunch [letter] Gill MJ, et al. **Lancet** 1999 Jun 12;353(9169):2078

Late postnatal mother-to-child transmission of HIV-1 [letter; comment] Glynn JR, et al. **Lancet** 1998 Nov 14; 352(9140):1630. Comment on: Lancet 1998 Aug 22;352(9128):597-600.

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load [letter; comment] Golden B, et al. **Lancet** 1999 Jul 10;354(9173):158-9. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Choriodecidual inflammation: a potentially preventable cause of perinatal HIV-1 transmission? Goldenberg RL, et al. **Lancet** 1998 Dec 12;352(9144):1927-30

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Greco DB. **Lancet** 1999 May 29;353(9167):1880-1. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Guay LA, et al. **Lancet** 1999 Sep 4; 354(9181):795-802

British HIV Association guidelines [letter; comment] Hay P, et al. **Lancet** 1998 Oct 10;352(9135):1226. Comment on: Lancet 1998 Jul 25;352(9124):314-6.

Elective caesarean section for prevention of vertical transmission of HIV-1 infection [comment] [see comments] Hudson CN. **Lancet** 1999 Mar 27;353(9158):1030-1. Comment on: Lancet 1999 Mar 27;353(9158):1035-9. Comment in: Lancet 1999 Jun 26;353(9171):2241.

Co-trimoxazole in HIV-1 infection [letter; comment] Hudson CP, et al. **Lancet** 1999 Jul 24;354(9175):333; discussion 335 . Comment on: Lancet 1999 May 1;353(9163):1463-8.

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Isturiz RE. **Lancet** 1999 May 29;353(9167):1879-80; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Urethral Trichomonas vaginalis infection and HIV-1 transmission [letter] Jackson DJ, et al. **Lancet** 1997 Oct 11;350(9084):1076

Should assays drive science or vice versa? [letter; comment] Johnston MI, et al. **Lancet** 1997 Oct 11;350(9084):1108. Comment on: Lancet 1997 Jul 26;305(9073):230-1.

Voluntary blood tests for Canadian doctors? [news] Kondro W. **Lancet** 1998 Oct 10;352(9135):1205

India has the largest number of people infected with HIV [news] Kumar S. **Lancet** 1999 Jan 2;353(9146):48

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Kvåle G. **Lancet** 1999 May 1;353(9163):1522-3; discussion 1523-4. Comment on: Lancet 1995 Aug 26;346(8974):530-6. Comment on: Lancet 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35.

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Ledergerber B, et al. **Lancet** 1999 Mar 13;353(9156):863-8

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Levy Y, et al. **Lancet** 1999 Jun 5;353(9168):1923-9

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Lurie P, et al. **Lancet** 1999 May 29;353(9167):1878-9; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Riboflavine and severe lactic acidosis [letter] Luzzati R, et al. **Lancet** 1999 Mar 13;353(9156):901-2

AIDS doctors push for live-virus vaccine trials [news] McCarthy M. **Lancet** 1997 Oct 11;350(9084):1082

HIV-1 peripheral neuropathy and combination antiretroviral therapy [letter] Markus R, et al. **Lancet** 1998 Dec 12; 352(9144):1906-7

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Marseille E, et al. **Lancet** 1999 Sep 4;354(9181):803-9

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Matthys F, et al. **Lancet** 1999 May 1; 353(9163):1523-4. Comment on: Lancet 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35.

Lipodystrophy in HIV-1-infected patients [letter] Mercié P, et al. **Lancet** 1999 Sep 4;354(9181):867-8

Early treatment of HIV-1 infection [letter; comment] Milazzo F, et al. **Lancet** 1998 Dec 12;352(9144):1936. Comment on: Lancet 1998 Sep 19;352(9132):982-3.

Risk of new AIDS diseases in people on triple therapy [letter] Miller V, et al. **Lancet** 1999 Feb 6;353(9151):463

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Mocroft A, et al. **Lancet** 1998 Nov 28;352(9142):1725-30

Progress in HIV-1 therapy continues on upward track [news] Montaner J, et al. **Lancet** 1999 Feb 13;353(9152):565

Better salvage therapy for HIV-1 infection still needed [news] Montaner J, et al. **Lancet** 1999 May 29; 353(9167):1857

British HIV Association guidelines [letter; comment] Montaner JS, et al. **Lancet** 1998 Oct 10;352(9135):1226-7 . Comment on: Lancet 1998 Jul 25;352(9124):314-6.

Early treatment of HIV-1 infection [letter; comment] Montella F, et al. **Lancet** 1998 Dec 12;352(9144):1935-6. Comment on: Lancet 1998 Sep 19;352(9132):982-3.

Lack of sex difference in CD4 to HIV-1 RNA viral load ratio [letter] Moore RD, et al. **Lancet** 1999 Feb 6; 353(9151):463-4

New results may help design effective HIV-1 vaccine [news] Morris K. **Lancet** 1999 Feb 6;353(9151):471

HAART and host: balancing the response to HIV-1. Highly active antiretroviral therapy [news] Morris K. **Lancet** 1998 Nov 21;352(9141):1686

Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients [letter; comment] Murri R, et al. **Lancet** 1999 Jun 5;353(9168):1974. Comment on: Lancet 1999 Mar 6;353(9155):841.

Infant feeding and HIV-1 transmission [see comments] Newell ML. **Lancet** 1999 Aug 7;354(9177):442-3. Comment in: Lancet 1999 Aug 7;354(9177):471-6.

Preventing HIV-1: lessons from Mwanza and Rakai [letter; comment] Nicoll A, et al. **Lancet** 1999 May 1; 353(9163):1522; discussion 1523-4. Comment on: Lancet 1995 Aug 26;346(8974):530-6. Comment on: Lancet 1999 Feb 13;353(9152):513-5. Comment on: Lancet 1999 Feb 13;353(9152):525-35.

Science, ethics, and future of research into maternal-infant transmission of HIV-1 [letter; comment] Omene JA. **Lancet** 1999 May 29;353(9167):1878; discussion 1880. Comment on: Lancet 1999 Mar 6;353(9155):832-5.

Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation [letter] Patterson BK, et al. **Lancet** 1999 Jan 16;353(9148):211-2

A neonate with haemorrhagic ascites. Pillay T, et al. **Lancet** 1999 Sep 11;354(9182):914

Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study [letter] Plana M, et al. **Lancet** 1998 Oct 10;352(9135):1194-5

Liposuction for protease-inhibitor-associated lipodystrophy [letter] Ponce-de-Leon S, et al. **Lancet** 1999 Apr 10; 353(9160):1244

Rapid assessment, injecting drug use, and public health. Rhodes T, et al. **Lancet** 1999 Jul 3;354(9172):65-8 (32 ref.)

US bill aids HIV-1-infected haemophiliacs [news] Rovner J. **Lancet** 1998 Nov 14;352(9140):1610

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Schneider MM, et al. **Lancet** 1999 Jan 16;353(9148):201-3

Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Pediatric AIDS Clinical Trials Group 076 Study Group [letter; comment] Shapiro DE, et al. **Lancet** 1999 Jul 10;354(9173):156; discussion 157-8. Comment on: Lancet 1999 Mar 6;353(9155):773-80.

Prevention of vertical HIV-1 transmission [letter; comment] Shields JW. **Lancet** 1999 Jun 26;353(9171):2241. Comment on: Lancet 1999 Mar 6;353(9155):766-7. Comment on: Lancet 1999 Mar 27:353(9158):1030-1.

Prevention of vertical HIV-1 transmission [letter; comment] Skinner J, et al. **Lancet** 1999 Jun 26;353(9171):2240. Comment on: Lancet 1999 Mar 27;353(9158):1035-9.

Amsterdam Duration of Antiretroviral Medication (ADAM) study [letter; comment] Torres RA, et al. **Lancet** 1998 Oct 3;352(9134):1149. Comment on: Lancet 1998 Jul 18;352(9123):185-90.

Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected

children. Highly active antiretroviral therapy [letter] [see comments] Viganó A, et al. **Lancet** 1998 Dec 12; 352(9144):1905–6. Comment in: Lancet 1999 Mar 6;353(9155):840–1.

Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group [see comments] Wawer MJ, et al. **Lancet** 1999 Feb 13;353(9152):525–35. Comment in: Lancet 1999 Feb 13;353(9152):513–5. Comment in: Lancet 1999 May 1;353(9163):1522; discussion 1523–4. Comment in: Lancet 1999 May 1;353(9163):1522–3; discussion 1523–4. Comment in: Lancet 1999 May 1;353(9163):1523–4.

Efficacy of trimethoprim–sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV–1–infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial [published erratum appears in Lancet 1999 Jun 12;353(9169):2078] [see comments] Wiktor SZ, et al. **Lancet** 1999 May 1;353(9163):1469–75. Comment in: Lancet 1999 Jul 24;354(9175):333–4; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):334; discussion 335. Comment in: Lancet 1999 Jul 24;354(9175):334–5.

Effect of zidovudine on perinatal HIV–1 transmission and maternal viral load [letter; comment] Wilson D. **Lancet** 1999 Jul 10;354(9173):156–8. Comment on: Lancet 1999 Mar 6;353(9155):773–80.

Effect of zidovudine on perinatal HIV–1 transmission and maternal viral load [letter; comment] Wolffers I. **Lancet** 1999 Jul 10;354(9173):158. Comment on: Lancet 1999 Mar 6;353(9155):773–80.

Men in India respond to HIV–1 education [news] Wunsch H. **Lancet** 1998 Oct 3;352(9134):1124

A novel mouse model of HIV–1 disease. Jolicoeur P, et al. **Leukemia** 1999 Apr;13 Suppl 1:S78–80

The inter–relation of maternal immune competence, HIV–1 viral load, and nutritional status in preventing vertical transmission: an alternative to chemoprophylaxis? Moran PJ, et al. **Med Hypotheses** 1998 Nov;51(5):389–97

Myelodysplastic syndrome in an HIV–1–infected infant. van den Berg H, et al. **Med Pediatr Oncol** 1999 May;32(5):385

Cardiopulmonary and CD4 cell changes in response to exercise training in early symptomatic HIV infection. Perna FM, et al. **Med Sci Sports Exerc** 1999 Jul;31(7):973–9

Anti–HIV–1 activity of an ionically modified porous polypropylene membrane determined by filtration of a viral suspension. Owada T, et al. **Microbiol Immunol** 1999; 43(2):141–51

Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus–1 infection. Strovel JW, et al. **Mod Pathol** 1998 Oct;11(10):957–62

Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Fackler OT, et al. **Mol Cell** 1999 Jun;3(6):729–39

Blocking HIV–1 infection with intrakines [news] Dorrell S. **Mol Med Today** 1999 Mar;5(3):97

Selecting antibodies that block the HIV–1 coreceptor [news] Dorrell S. **Mol Med Today** 1998 Dec;4(12):507

Application of random amplified polymorphic DNA PCR for genomic analysis of HIV–1–infected individuals. Aikhionbare FO, et al. **Mutat Res** 1998 Nov;406(1):25–31

The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta–analysis of 15 prospective cohort studies. The International Perinatal HIV Group [see comments] **N Engl J Med** 1999 Apr 1;340(13):977–87. Comment in: N Engl J Med 1999 Apr 1;340(13):1032–3. Comment in: N Engl J Med 1999 Jul 15;341(3):205; discussion 206–7. Comment in: N Engl J Med 1999 Jul 15;341(3):205–6; discussion 206–7. Comment in: N Engl J Med 1999 Jul 15;341(3):206–7.

Mode of delivery and the risk of vertical transmission of HIV–1 [letter; comment] Beckerman KP, et al. **N Engl J Med** 1999 Jul 15;341(3):205–6; discussion 206–7 . Comment on: N Engl J Med 1999 Apr 1;340(13):977–87.

Therapeutic strategies for HIV infection--time to think hard [editorial; comment] Cooper DA, et al. **N Engl J Med** 1998 Oct 29;339(18):1319–21. Comment on: N Engl J Med 1998 Oct 29;339(18):1261–8. Comment on: N Engl J Med 1998 Oct 29;339(18):1269–76.

The AIDS epidemic--considerations for the 21st century. Fauci AS. **N Engl J Med** 1999 Sep 30;341(14):1046–50

Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV–1–infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study [see comments] Furrer H, et al. **N Engl J Med** 1999 Apr 29;340(17):1301–6. Comment in: N Engl J Med 1999 Apr 29;340(17):1356–8.

Mode of delivery and the risk of vertical transmission of HIV–1 [letter; comment] Gelber RD, et al. **N Engl J Med** 1999 Jul 15;341(3):206–7. Comment on: N Engl J Med 1999 Apr 1;340(13):977–87.

Cytomegalovirus infection and HIV–1 disease progression in infants born to HIV–1–infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. Kovacs A, et al. **N Engl J Med** 1999 Jul 8;341(2):77–84

Mode of delivery and the risk of vertical transmission of HIV–1 [letter; comment] Landers DV, et al. **N Engl J Med** 1999 Jul 15;341(3):205; discussion 206–7. Comment on: N Engl J Med 1999 Apr 1;340(13):977–87.

AIDS--New Zealand [news] **N Z Dent J** 1998 Dec; 94(418):163

HIV–1 entry inhibitors and virus emergence [letter] D'Aquila RT, et al. **Nat Med** 1999 Oct;5(10):1091

Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma [see comments] Igarashi T, et al. **Nat Med** 1999 Feb;5(2):211–6. Comment in: Nat Med 1999 Feb;5(2):142–4.

Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV–1 disease progression. Mummidi S, et al. **Nat Med** 1998 Jul; 4(7):786–93

Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys [see comments] Shibata R, et al. **Nat Med** 1999 Feb;5(2):204–10. Comment in: Nat Med 1999 Feb;5(2):142–4.

Structure of a human DNA repair protein UBA domain that interacts with HIV–1 Vpr. Dieckmann T, et al. **Nat Struct Biol** 1998 Dec;5(12):1042–7

Chemokine control of HIV–1 infection [letter] Mellado M, et al. **Nature** 1999 Aug 19;400(6746):723–4

Cerebral metabolite abnormalities correlate with clinical severity of HIV–1 cognitive motor complex. Chang L, et al. **Neurology** 1999 Jan 1;52(1):100–8

Paroxysmal dyskinesias in patients with HIV infection. Mirsattari SM, et al. **Neurology** 1999 Jan 1;52(1):109–14

Dual infective pathology in patients with cryptococcal meningitis. Silber E, et al. **Neurology** 1998 Oct;51(4):1213–5

Computerized and traditional stroop task dysfunction in HIV–1 infection. Hinkin CH, et al. **Neuropsychology** 1999 Apr;13(2):306–16

The nef protein of the human immunodeficiency virus type 1 (HIV–1) inhibits a large–conductance potassium channel in human glial cells. Kort JJ, et al. **Neurosci Lett** 1998 Jul 17;251(1):1–4

The human immunodeficiency virus–1 envelope protein gp120 binds through its V3 sequence to the glycine site of N–methyl–D–aspartate receptors mediating noradrenaline release in the hippocampus. Pattarini R, et al. **Neuroscience** 1998 Nov;87(1):147–57

Visualizing tertiary folding of RNA and RNA–protein interactions by a tethered iron chelate: analysis of HIV–1 Tat–TAR complex. Huq I, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):1084–93

Diagnosis disclosure by family caregivers to children who have perinatally acquired HIV disease: when the time comes [see comments] Ledlie SW. **Nurs Res** 1999 May–Jun; 48(3):141–9. Comment in: Nurs Res 1999 May–Jun;48(3):119.

Implications of HIV and hepatitis C coinfection [news] [see comments] Klaus BD, et al. **Nurse Pract** 1998 Dec; 23(12):78, 81. Comment in: Nurse Pract 1999 Apr;24(4):16.

A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV–1 infection [news] Wolbach J, et al. **Nurse Pract** 1999 Jun;24(6):81–2, 87–90, 92 (27 ref.)

T cell responses in coinfection with Onchocerca volvulus and the human immunodeficiency virus type 1. Sentongo E, et al. **Parasite Immunol** 1998 Sep;20(9):431–9

Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1–exposed infants. Cunningham CK, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):30–5

Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression. Esposito S, et al. **Pediatr Infect Dis J** 1998 Sep;17(9):847–9

The natural history of human immunodeficiency virus 1 infection in Haitian infants. Jean SS, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):58–63

Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1–infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Read JS, et al. **Pediatr Infect Dis J** 1999 Feb;18(2):134–42

Primary acquired toxoplasmosis in a five–year–old child with perinatal human immunodeficiency virus type 1 infection. Sobanjo A, et al. **Pediatr Infect Dis J** 1999 May;18(5):476–8

Stroke in pediatric HIV infection [letter] Legido A, et al. **Pediatr Neurol** 1999 Aug;21(2):588

Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Salvan AM, et al. **Pediatr Res** 1998 Nov;44(5):755–62

Human immunodeficiency virus status and delayed–type hypersensitivity skin testing in Ugandan children. Mandalakas AM, et al. **Pediatrics** 1999 Feb;103(2):E21

Tyrosine phosphorylation induced by C4 peptide constructs from HIV Gp120. Liu M, et al. **Peptides** 1999;20(2):185–91

HIV infection and AIDS. Shearer WT. **Prim Care** 1998 Dec; 25(4):759–74 (75 ref.)

Stable transduction of quiescent CD34(+)CD38(–) human hematopoietic cells by HIV–1–based lentiviral vectors. Case SS, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):2988–93

Polymorphism in RANTES chemokine promoter affects HIV–1 disease progression. Liu H, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4581–5

Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Meucci O, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14500–5

Peptide inhibitors of HIV–1 protease and viral infection of peripheral blood lymphocytes based on HIV–1 Vif. Potash MJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13865–8

Molecular dynamics study of the proposed beta–hairpin form of the switch domain from HIV1 gp120 alone and complexed with an inhibitor of CD4 binding. Graf von Stosch A, et al. **Proteins** 1999 Feb 1;34(2):197–205

Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector. Marcello A, et al. **Res Virol** 1998 Nov–Dec;149(6):419–31

Tuberculosis and HIV infection: a global perspective. Murray JF. **Respiration** 1998;65(5):335–42 (45 ref.)

Troublesome diagnosis in two children born to HIV–1 infected mothers. Liberatore D, et al. **Rev Argent Microbiol** 1998 Jul–Sep;30(3):143–6

Abdominal tuberculous abscesses in AIDS patients: percutaneous treatment. Rendón Unceta P, et al. **Rev Esp Enferm Dig** 1999 Jun;91(6):439–46 **(Eng, Spa)**

Detection of mycoplasmas in urethral swabs from HIV–1 infected patients and control individuals using culture techniques and polymerase chain reaction. da Cunha RA, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan–Feb;40(1):1–5

Cardiac involvement in human immunodeficiency virus infection. Cardoso JS. **Rev Port Cardiol** 1999 Feb; 18(2):217–20 (22 ref.)

Characteristics of septic arthritis in human immunodeficiency virus–infected haemophiliacs versus other risk groups. Barzilai A, et al. **Rheumatology (Oxford)** 1999 Feb; 38(2):139–42

Mortality in a cohort of children born to HIV–1 infected women from Durban, South Africa. Bobat R, et al. **S Afr Med J** 1999 Jun;89(6):646–8

Relationship between interleukin–5 production and variations in eosinophil counts during HIV infection in West Africa: influence of Mycobacterium tuberculosis infection. Diagbouga S, et al. **Scand J Immunol** 1999 Feb;49(2):203–9

Production of interleukin–4, interferon (IFN)–gamma and IFN–alpha in human immunodeficiency virus–1 infection: an imbalance of type 1 and type 2 cytokines may reduce the synthesis of IFN–alpha. Hober D, et al. **Scand J Immunol** 1998 Oct;48(4):436–42

Increased CD4+ T–lymphocyte senescence fraction in advanced human immunodeficiency virus type 1 infection. Nichols WS, et al. **Scand J Immunol** 1999 Mar;49(3):302–6

Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus–1 infection. Nielsen H, et al. **Scand J Infect Dis** 1998; 30(6):597–601

Continued therapy with HIV–1 protease inhibitors, despite previous hypersensitivity reactions, through coadministration of prednisone. Prins JM, et al. **Scand J Infect Dis** 1998;30(6):612–3

Short–term risk for AIDS–indicator diseases predicted by plasma HIV–1 RNA and CD4+ lymphocytes. Romeu J, et al. **Scand J Infect Dis** 1999;31(1):37–42

Serum levels of Fas/Apo–1 and Bcl–2 in children with HIV–1 infection. Torre D, et al. **Scand J Infect Dis** 1998; 30(6):565–8

HLA and HIV–1: heterozygote advantage and B*35–Cw*04 disadvantage [see comments] Carrington M, et al. **Science** 1999 Mar 12;283(5408):1748–52. Comment in: Science 1999 Jul 2;285(5424):11.

The enigmas of Kaposi's sarcoma. Gallo RC. **Science** 1998 Dec 4;282(5395):1837–9 (25 ref.)

Genetic acceleration of AIDS progression by a promoter variant of CCR5. Martin MP, et al. **Science** 1998 Dec 4; 282(5395):1907–11

Herpes in the time of AIDS: a comparison of the epidemiology of HIV–1 and HSV–2 in young men in northern Thailand. Dobbins JG, et al. **Sex Transm Dis** 1999 Feb;26(2):67–74

Etiology of genital ulcer disease and its relationship to HIV infection [editorial; comment] Morse SA. **Sex Transm Dis** 1999 Jan;26(1):63–5. Comment on: Sex Transm Dis 1999 Jan;26(1):55–62.

HIV–1 and other sexually transmitted infections in a cohort of female sex workers in Chiang Rai, Thailand. Limpakarnjanarat K, et al. **Sex Transm Infect** 1999 Feb; 75(1):30–5

Prevalence of HIV–1 among attenders at sexually transmitted disease clinics: analyses according to country of birth. McGarrigle CA, et al. **Sex Transm Infect** 1998 Dec; 74(6):415–20

The reference range of CD4+ and CD8+ T–lymphocytes in healthy non–infected infants born to HIV–1 seropositive mothers; a preliminary study at Siriraj Hospital. Likanonsakul S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):453–63

Incorporating correlations between measurements into the estimation of age–related reference ranges. Wade AM, et al. **Stat Med** 1998 Sep 15;17(17):1989–2002

Pediatric oncology and AIDS: therapeutic lessons of relevance to generic drug use. Rodman J. **Transplant Proc** 1999 May;31(3A Suppl):13S–15S (18 ref.)

Long–term nonprogressive human immunodeficiency virus–1 infection in a kidney allograft recipient. Purgus R, et al. **Transplantation** 1998 Nov 27;66(10):1384–6

HIV and syphilis serostatus of antenatals in traditional Maasai pasturalist communities in Kajiado District, Kenya: 1989–1992. Valadez JJ, et al. **Trop Doct** 1999 Apr; 29(2):94–8

Retinal manifestations of HIV-1 and HIV-2 infections among hospital patients in The Gambia, west Africa. Jaffar S, et al. **Trop Med Int Health** 1999 Jul;4(7):487–92

Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes. Chang JS, et al. **Vaccine** 1999 Mar 17;17(11–12):1540–8

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Mrsny RJ, et al. **Vaccine** 1999 Mar 17; 17(11–12):1425–33

Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. Prljić J, et al. **Vaccine** 1999 Mar 17;17(11–12):1462–7

Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Schedel I, et al. **Vaccine** 1999 Apr 9; 17(15–16):1837–45

Relationship between immunoclinical status and prevalence of viral sexually transmitted diseases among human immunodeficiency virus–1 seropositive patients in Ghana. Brandful JA, et al. **Viral Immunol** 1999;12(2):131–7

Transmission of human immunodeficiency type 1 viruses with intersubtype recombinant long terminal repeat sequences. Blackard JT, et al. **Virology** 1999 Feb 15;254(2):220–5

HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. Dornadula G, et al. **Virology** 1999 Jan 5;253(1):10–6

Differential regulation of CC chemokine gene expression in human immunodeficiency virus–infected myeloid cells. Génin P, et al. **Virology** 1999 Sep 1;261(2):205–15

In vitro assembly properties of wild-type and cyclophilin-binding defective human immunodeficiency virus capsid proteins in the presence and absence of cyclophilin A. Grättinger M, et al. **Virology** 1999 Apr 25; 257(1):247–60

HIV-1 Nef plays an essential role in two independent processes in CD4 down-regulation: dissociation of the CD4-p56(lck) complex and targeting of CD4 to lysosomes. Kim YH, et al. **Virology** 1999 Apr 25;257(1):208–19

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Molla A, et al. **Virology** 1998 Oct 25;250(2):255–62

HIV-1 infection induces differentiation of immature neural cells through autocrine tumor necrosis factor and nitric oxide production. Obregón E, et al. **Virology** 1999 Sep 1; 261(2):193–204

Intracellular trafficking and interactions of the HIV-1 Tat protein. Stauber RH, et al. **Virology** 1998 Dec 5; 252(1):126–36

Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein. Wang Z, et al. **Virology** 1999 May 10;257(2):502–10

Epidemiological surveillance for the spread of HIV infection. Foreword [editorial] Piot P.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):3–4 **(Eng, Rus)**

[HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis] Chen Y, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1997 Apr; 19(2):120–6 (Eng. Abstr.) **(Chi)**

[FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment]
Allerg Immunol (Paris) 1998 Oct;30(8):268–70 **(Fre)**

[In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS] Leissner P, et al. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):167–73 (31 ref.) (Eng. Abstr.) **(Fre)**

[Antiretroviral therapy and prevention of maternal-fetal transmission of HIV-1. Current and future strategies] Monpoux F, et al. **Arch Pediatr** 1999 May;6(5):556–65 (70 ref.) (Eng. Abstr.) **(Fre)**

[Pediatric AIDS: epidemiological, clinical and prognostic aspects in Abidjan, Ivory Coast (letter)] Niangué-Beugré NM, et al. **Arch Pediatr** 1999 Mar;6(3):342–3 **(Fre)**

[Cancer in patients infected with the human immunodeficiency virus. The unusual aspects] Peyrade F, et al. **Presse Med** 1999 Apr 17;28(15):809–14 (39 ref.) (Eng. Abstr.) **(Fre)**

[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc (letter)] Rey D, et al.
Presse Med 1998 Feb 28;27(8):360 **(Fre)**

[Prevalence and incidence of cytomegalovirus infection in patients infected with HIV-1. SEROCO group] Robain M, et al. **Presse Med** 1998 Jun 6;27(20):949–53 (Eng. Abstr.) **(Fre)**

[Endobronchial tuberculosis presenting as an obstructive tumor in an HIV-1-positive patient. Apropos of a case and review of the literature] Saadoun R, et al.
Rev Med Interne 1998 May;19(5):344–7 (9 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasound aspects of abdominal involvement in adults with HIV infections in the Ivory Coast: apropos of 146 cases] N'Zi PK, et al. **Sante** 1999 Mar–Apr;9(2):85–8 (Eng. Abstr.) **(Fre)**

[A new drug in HIV infections authorized (news)]
Dtsch Med Wochenschr 1999 Sep 10;124(36):A20 **(Ger)**

[Hyperkalemia after trimethoprim or pentamidine. Until now, a little noticed side effect of antimicrobial therapeutic measures in AIDS patients] Gabriëls G, et al.
Dtsch Med Wochenschr 1998 Nov 6;123(45):1351–5 (25 ref.) **(Ger)**

[Riddle of HIV-1 origin solved (news)] Volkert R.
Dtsch Med Wochenschr 1999 Mar 19;124(11):A7 **(Ger)**

[Diagnosis of pneumocystis carinii pneumonia in AIDS patients] Armbruster C, et al. **Wien Klin Wochenschr** 1998 Sep 18;110(17):604–7 (Eng. Abstr.) **(Ger)**

[Sexual behaviors and the HIV/AIDS risk in the general population: the methodological aspects of a national study within the context of a European Concerted Action] Renzi C, et al. **Ann Ig** 1999 Mar–Apr;11(2):83–94 (Eng. Abstr.) **(Ita)**

[The probability of transmission of the human immunodeficiency virus] Spadea T, et al.
Epidemiol Prev 1999 Apr–Jun;23(2):77–83 (53 ref.) (Eng. Abstr.) **(Ita)**

[Maternal viral and gestational risk factors in vertical transmission of HIV-1 infection] Greco P, et al.
Minerva Ginecol 1998 Nov;50(11):449–54 (Eng. Abstr.) **(Ita)**

[The symptoms in HIV disease: prevalence and control (editorial)] Fantoni M, et al. **Recenti Prog Med** 1999 Apr; 90(4):217–21 (16 ref.) **(Ita)**

[The diagnosis of new cases of HIV infection: a reversal of the trend?] Manfredi R, et al. **Recenti Prog Med** 1999 Apr; 90(4):202–5 (Eng. Abstr.) **(Ita)**

[AIDS and opportunistic visceral mycoses. A diagnostic and therapeutic update] Manfredi R. **Recenti Prog Med** 1998 Dec;89(12):657–67 (100 ref.) (Eng. Abstr.) **(Ita)**

[The use of HIV-1 protease inhibitors. Their effects on AIDS-correlated outpatient and hospitalization activities. A catchment area study] Resta F, et al.
Recenti Prog Med 1998 Dec;89(12):623–4 (Eng. Abstr.) **(Ita)**

[HIV/AIDS research. The current status and future prospects] Nagai Y. **Arerugi** 1998 Nov;47(11):1160–2 (0 ref.) **(Jpn)**

[Anti-HIV-1 genes; genetic restriction of AIDS pathogenesis by gene variants] Tashiro K, et al. **Nippon Rinsho** 1999 Apr;57(4):967–74 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Causes of death (1983–1997) in patients infected with human immunodeficiency virus by contaminated blood coagulation factor products: report of the clinical study group on prevention and treatments of HIV infection] Fukutake K, et al. **Rinsho Ketsueki** 1999 Jul;40(7):550–5 (Eng. Abstr.) **(Jpn)**

[Possible pathogenic role of IL-16 on SLE: with reference to HIV-1 infection] Lee S, et al. **Ryumachi** 1998 Oct; 38(5):747–51 (33 ref.) **(Jpn)**

[Cardiovascular morbidity in children with human immunodeficiency virus infection] Nogueira G, et al.
Acta Med Port 1998 Dec;11(12):1051–7 (Eng. Abstr.) **(Por)**

[The treatment of cytomegalovirus retinitis in human immunodeficiency virus infection] Rabadão E, et al.
Acta Med Port 1999 Apr–Jun;12(4–6):203–7 (35 ref.) (Eng. Abstr.) **(Por)**

[An evaluation of the relationship between intestinal parasitoses and the risk factors for HIV in AIDS patients] Cimerman S, et al. **Rev Soc Bras Med Trop** 1999 Mar–Apr; 32(2):181–5 (Eng. Abstr.) **(Por)**

[Malnutrition and hypovitaminosis A in AIDS patients] Silveira SA, et al. **Rev Soc Bras Med Trop** 1999 Mar–Apr; 32(2):119–24 (Eng. Abstr.) **(Por)**

[The clinico-epidemiological aspects of HIV infection in 167 children nonmaternally infected who have died with a diagnosis of AIDS] Cojocaru S, et al.
Bacteriol Virusol Parazitol Epidemiol 1998 Jul–Sep; 43(3):139–45 (Eng. Abstr.) **(Rum)**

[The clinico-epidemiological characteristics of HIV infection in 93 adults in the Republic of Moldova] Cojocaru S, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct–Dec; 43(4):269–74 (Eng. Abstr.) **(Rum)**

[CMV retinitis--"the lightning that announces a storm"] Gafencu O, et al. **Oftalmologia** 1998;45(4):14–20 (Eng. Abstr.) **(Rum)**

[The immune response in HIV infection and associated diseases of the female genitalia] Lakatosh VP, et al.
Lik Sprava 1998 Oct–Nov;(7):25–36 (63 ref.) **(Rus)**

[Surfactants as agents for the individual prevention of HIV/AIDS] Krivorutchenko IuL. **Mikrobiol Z** 1999 Jan–Feb;61(1):95–103 (65 ref.) (Eng. Abstr.) **(Rus)**

[Viral lesions of the eye in human immunodeficiency virus infection] Krasnov MM, et al. **Vestn Oftalmol** 1998 Sep–Oct;114(5):35–9 (Eng. Abstr.) **(Rus)**

[The characteristics of the epidemic process of HIV infection in the Armed Forces] Zmushko EI, et al.
Voen Med Zh 1998 Aug;319(8):44–7 **(Rus)**

[HIV infection in Russia in 1998]
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):38 (Eng. Abstr.) **(Rus)**

[Work with youth--the basis of educational programs aimed at the prevention of HIV infection] Agafonova OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):119–20 (Eng. Abstr.) **(Rus)**

[The road will be mastered by the walker] Agapova VM. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):108–10 (Eng. Abstr.) **(Rus)**

[The prevention of HIV infection and STDs among injection drug addicts in Ukraine] Andrushchak LI.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):86–9 (Eng. Abstr.) **(Rus)**

[The development of HIV infection in the Far-Eastern region of the Russian Federation] Bogach VV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):13–6 (Eng. Abstr.) **(Rus)**

[The principles of pre-epidemic diagnosis in the epidemiological surveillance system for HIV infection] Borovskiĭ IV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):10–1 (Eng. Abstr.) **(Rus)**

[A decrease in harm: a new concept for Russian public health] Burrows D, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):107–8 (Eng. Abstr.) **(Rus)**

[The educating and informing of the population on HIV/AIDS problems in the Republic of Byelarus] Bykova VM. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):110–1 (Eng. Abstr.) **(Rus)**

[The role of public organizations in the prevention of HIV infection in Russia] Dement'eva LA.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):114–6 (Eng. Abstr.) **(Rus)**

[The legal status of Russian HIV-infected persons] D'iachenko AP. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):100–2 (Eng. Abstr.) **(Rus)**

[The prevention of HIV infection in abusers of psychoactive substances as a social behavioral problem] Dolzhanskaia NA. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):98–100 (Eng. Abstr.) **(Rus)**

[The structure of the secondary diseases in HIV-infected patients in Russia] Ermak TN, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):80–2 (Eng. Abstr.) **(Rus)**

[The characteristics of the course of tuberculosis in HIV-infected patients and prophylactic measures] Frolova OP, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):67–9 (Eng. Abstr.) **(Rus)**

[HIV infection in the penitentiaries of Ukraine] Gunchenko A, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):31–3 (Eng. Abstr.) **(Rus)**

[The epidemiological characteristics of HIV infection in Turkmenistan] Illiev SKh, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):19–21 (Eng. Abstr.) **(Rus)**

[New approaches to the chemotherapy of HIV infection] Karamova EV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):84–6 (Eng. Abstr.) **(Rus)**

[The detection of viral hepatitis markers in HIV-infected patients] Kishtanova NA.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):36–7 (Eng. Abstr.) **(Rus)**

[The testing policy for HIV infection in Ukraine] Kobyshcha Iu. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):65–7 (Eng. Abstr.) **(Rus)**

[The determinants of the spread of HIV among injection drug addicts in Ukraine] Kobyshcha Iu.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):34–6 (Eng. Abstr.) **(Rus)**

[A comparative study of the level of knowledge of schoolchildren about HIV infection and AIDS] Kopnina EO, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):116–7 (Eng. Abstr.) **(Rus)**

[An analysis of an outbreak of HIV infection in the city of Svetlogorsk, the Republic of Byelarus, among persons using injected narcotics] Kostikova LI, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):18–9 (Eng. Abstr.) **(Rus)**

[The successes and problems in the treatment of HIV infection: a biochemist's view] Kraevskiĭ AA.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb;(1):82–4 (Eng. Abstr.) **(Rus)**

[Autoantibodies to the thrombocytes and erythrocytes in HIV-infected patients] Kravchenko AV, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):78–80 (Eng. Abstr.) **(Rus)**

[Burkitt's lymphosarcoma in a child with HIV infection] Kuznetsova VV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):71–3 (Eng. Abstr.) **(Rus)**

[Children, adolescents and HIV infection] Kuznetsova VV.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):112–3 (Eng. Abstr.) **(Rus)**

[The characteristics of the course of Leishmania and Pneumocystis opportunistic infections in immunosuppressed laboratory animals] Lysenko AIa.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):69–71 (Eng. Abstr.) **(Rus)**

[The role of educational programs on the prevention of HIV infection and the development of a healthy life style for adolescents] Mamchik TA, et al.
Zh Mikrobiol Epidemiol Immunobiol 1999 Jan–Feb; (1):113–4 (Eng. Abstr.) **(Rus)**

[A retrospective study of the expediency of performing the immunoblot in conducting expert diagnosis at a center for the prevention and control of AIDS] Matveeva EM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):62–3 (Eng. Abstr.) **(Rus)**

[The spread of AIDS among homosexuals in the

Commonwealth of Independent States and Baltic countries] Mekkelsen H. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):11-3 (Eng. Abstr.) **(Rus)**

[The prevalence of the intravenous use of psychoactive preparations in Nizhegorod Province and the possible ways to prevent HIV infection among the users] Moshkovich GF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):21-3 (Eng. Abstr.) **(Rus)**

[The epidemic situation in relation to HIV infection in the Volga River region] Nosov NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):24-6 (Eng. Abstr.) **(Rus)**

[The acceptance of a strategy for decreasing the risk of contracting an HIV infection among drug abusers] Nosov NN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):96-7 (Eng. Abstr.) **(Rus)**

[Emergency measures to control the spread of diseases caused by the human immunodeficiency virus] Onishchenko GG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):5-9 (Eng. Abstr.) **(Rus)**

[The clean syringe and HIV infection. A clean syringe can be obtained by any drug addict in a bus stationed in places of active drug trading] Ostrovskii DV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):118-9 (Eng. Abstr.) **(Rus)**

[The clinical course of HIV infection in children who were parenterally infected] Popova IA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):75-8 (Eng. Abstr.) **(Rus)**

[Secondary diseases in HIV-infected patients] Rossa NA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):74-5 (Eng. Abstr.) **(Rus)**

[The characteristics of HIV infection during a sharp activation of the epidemic process in Rostov Province] Saukhat SR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):23-4 (Eng. Abstr.) **(Rus)**

[The behavioral risk factors for contracting HIV infection in the intravenous administration of narcotics in abusers of psychoactive substances in the city of Rostov-on-Don] Saukhat SR, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):97-8 (Eng. Abstr.) **(Rus)**

[The epidemic situation in relation to HIV infection in Ukraine (1987-1997)] Shcherbinskaia AM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):26-9 (Eng. Abstr.) **(Rus)**

[The theory and practice of using in-house control in screening and verification studies for the diagnosis of HIV infection] Shevelev BI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):60-1 (Eng. Abstr.) **(Rus)**

[The forms and analysis of the results of work in preventing HIV infection among youth] Shorokhov SSW, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):89-91 (Eng. Abstr.) **(Rus)**

[HIV infection: the psychological indices at different stages of the disease] Uliukin IM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):104-6 (Eng. Abstr.) **(Rus)**

[The possible role of immunogenetic factors in the pathogenesis of HIV infection] Volianskii IuL, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):49-52 (42 ref.) (Eng. Abstr.) **(Rus)**

[HIV infection in children perinatally infected] Voronin EE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):16-8 (Eng. Abstr.) **(Rus)**

[The clinico-epidemiological characteristics of HIV infection and AIDS in Ukraine] Vovk AD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):29-31 (Eng. Abstr.) **(Rus)**

[Perinatal infection with the human immunodeficiency virus] Milošević S. **Med Pregl** 1998 Jul-Aug;51(7-8):325-8 (8 ref.) (Eng. Abstr.) **(Scr)**

[Human immunodeficiency virus (HIV) infection. The effectiveness of different diagnostic sequences in suspected pulmonary infection] Cortés Blanco A, et al. **An Med Interna** 1999 Jan;16(1):15-20 (Eng. Abstr.) **(Spa)**

[A pulmonary cellular immunity study in HIV patients] Fernández Fabrellas E, et al. **An Med Interna** 1999 Jan; 16(1):21-4 (Eng. Abstr.) **(Spa)**

[A tuberculous liver abscess in HIV (letter)] Fernández Muinelo M, et al. **An Med Interna** 1999 Feb;16(2):105-6 (10 ref.) **(Spa)**

[An oral ulcer due to cytomegalovirus in a patient with the acquired immunodeficiency syndrome (letter)] Mendiburu Belzunegui L, et al. **An Med Interna** 1999 Jan;16(1):53 (10 ref.) **(Spa)**

[The effect of human immunodeficiency virus infection on the consumption of hospital resources. A correlation with the degree of immunodeficiency] Rovira Daudi E, et al. **An Med Interna** 1999 Jan;16(1):8-14 (Eng. Abstr.) **(Spa)**

[The setting of pediatric AIDS] Lucas Tomás M. **An R Acad Nac Med (Madr)** 1998;115(4):937-51; discussion 951-6 **(Spa)**

[Cavitated pulmonary lesions in a patient with human immunodeficiency virus infection] Cañizares R, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):141-2 **(Spa)**

[Hypertriglyceridemia during active intercurrent infections in HIV-infected patients] Montero A, et al. **Gac Med Mex** 1999 Jan-Feb;135(1):5-9 (Eng. Abstr.) **(Spa)**

[The persistence of risky conduct for HIV transmission among intravenous drug users in Madrid, Seville, and Valencia. The Working Group of the Médicos del Mundo for the Monitoring of HIV Infection and the Risk Practices of Intravenous Drug Users (see comments)] Bravo MJ, et al. **Gac Sanit** 1999 Mar-Apr;13(2):109-18 (Eng. Abstr.). Comment in: Gac Sanit 1999 Mar-Apr;13(2):79-81. **(Spa)**

[The users of centers for AIDS information and prevention in the Comunidad Valenciana, Spain: a study based on cluster analysis] González Aracil J, et al. **Gac Sanit** 1999 Mar-Apr;13(2):102-8 (Eng. Abstr.) **(Spa)**

[AIDS prevention among adolescents in school: a systematic review of the efficacy of interventions] Juárez O, et al. **Gac Sanit** 1999 Mar-Apr;13(2):150-62 (67 ref.) (Eng. Abstr.) **(Spa)**

[AIDS patients with an unclassified risk factor for HIV] Martínez Alonso JL, et al. **Gac Sanit** 1999 Mar-Apr; 13(2):119-25 (Eng. Abstr.) **(Spa)**

[Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: the clinical, neuroimaging, virological and evolutive characteristics in 35 patients] Asensi V, et al. **Med Clin (Barc)** 1999 Sep 4; 113(6):210-4 (Eng. Abstr.) **(Spa)**

[The epidemiological surveillance of human immunodeficiency virus (HIV) infection in a hospital population of Catalonia. Collaborators in the VIHHOSP project] Blanch C, et al. **Med Clin (Barc)** 1998 Dec 5; 111(19):731-5 (Eng. Abstr.) **(Spa)**

[Tuberculosis in AIDS patients: the contribution of an analysis of the restriction fragment length polymorphism of Mycobacterium tuberculosis isolates] Camarena JJ, et al. **Med Clin (Barc)** 1998 Dec 5;111(19):721-4 (Eng. Abstr.) **(Spa)**

[The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients] Cartón JA, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):205-9 (Eng. Abstr.) **(Spa)**

[AIDS or HIV infection? The health care implications (editorial)] Casabona J. **Med Clin (Barc)** 1999 Mar 13; 112(9):335-6 (14 ref.) **(Spa)**

[AIDS: more and better life? (editorial; comment)] Castilla J. **Med Clin (Barc)** 1999 Jul 10;113(5):171-2 (18 ref.). Comment on: Med Clin (Barc) 1999 Jul 10;113(5):169-70. **(Spa)**

[The mechanisms of Mycobacterium tuberculosis disease and the implications for its prevention in patients with HIV infection] Díez Ruiz-Navarro M, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):150-5 (57 ref.) **(Spa)**

[The clinical impact of symptomatic visceral leishmaniasis on HIV-1 infection (letter)] Macías J, et al. **Med Clin (Barc)** 1999 Feb 6;112(4):157 **(Spa)**

[Absence of changes in viral plasma of the human immunodeficiency virus after the application of the delayed cutaneous hypersensitivity test (letter)] Pachón J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):77 **(Spa)**

[AZT and 3TC treatment in a pregnant woman with HIV infection (letter)] Pardo MJ, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):358-9 **(Spa)**

[Pulmonary cavitation lesions in patients infected with the human immunodeficiency virus: an analysis of a series of 78 cases] Rodríguez Arrondo F, et al. **Med Clin (Barc)** 1998 Dec 5;111(19):725-30 (Eng. Abstr.) **(Spa)**

[Evolution of the prevalence of HIV-1 infection in drug addicts in the Community of Madrid (1985-1986)] Sopelana P, et al. **Med Clin (Barc)** 1998 Sep 12;111(7):257-8 (Eng. Abstr.) **(Spa)**

[Liver transplantation in patients infected with the human immunodeficiency virus: the difficult challenge of a new stage (editorial)] Torre-Cisneros J, et al. **Med Clin (Barc)** 1999 Sep 4;113(6):215-8 (33 ref.) **(Spa)**

[Meningitis in subjects with human immunodeficiency virus infection] Silva-Rosas C, et al. **Neurologia** 1999 Feb; 14(2):62-6 (Eng. Abstr.) **(Spa)**

[Bordetella bronchiseptica pneumonia and the acquired immunodeficiency syndrome (letter)] Abad A, et al. **Rev Clin Esp** 1999 May;199(5):330-1 (10 ref.) **(Spa)**

[Macrolide prophylaxis in patients with HIV-1 infection or other forms of immunosuppression] García Alcaide F, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 1:59-65 (40 ref.) **(Spa)**

[The cost effectiveness of the study of the familial contacts of tuberculosis patients coinfected with the human immunodeficiency virus] García Ordóñez MA, et al. **Rev Clin Esp** 1999 May;199(5):275-9 (Eng. Abstr.) **(Spa)**

[The standardization of the criteria for the prevention of occupational postexposure to the human immunodeficiency virus] Haro Pérez AM, et al. **Rev Clin Esp** 1999 Apr; 199(4):233-8 (89 ref.) **(Spa)**

[Drug interactions in patients infected with the human immunodeficiency virus] Jiménez-Nácher I, et al. **Rev Clin Esp** 1998 Nov;198(11):765-8 (14 ref.) **(Spa)**

[Dissociated cholestasis in patients with HIV-1 infection. Prevalence and diagnostic value of liver biopsy] Macías Sánchez J, et al. **Rev Clin Esp** 1999 Feb;199(2):81-3 (Eng. Abstr.) **(Spa)**

[Cerebral lesions in a patient with human immunodeficiency virus infection and prior tuberculous meningitis] Merino Muñoz D, et al. **Rev Clin Esp** 1998 Nov;198(11):775-6 (9 ref.) **(Spa)**

[Gastric leishmaniasis associated with human immunodeficiency virus infection (letter)] Santos Gil I, et al. **Rev Clin Esp** 1999 May;199(5):332 **(Spa)**

[Non-bacteremic ecthyma gangrenosum in a patient with human immunodeficiency virus infection (letter)] Tornero C, et al. **Rev Clin Esp** 1999 May;199(5):332-3 (10 ref.) **(Spa)**

[Progressive disseminated histoplasmosis in AIDS patients] Fernández Andreu CM, et al. **Rev Cubana Med Trop** 1996; 48(3):163-6 (Eng. Abstr.) **(Spa)**

[Esophageal candidiasis in AIDS patients. A clinical and microbiological study] Flores de Apodaca Verdura Z, et al. **Rev Cubana Med Trop** 1998;50(2):110-4 (Eng. Abstr.) **(Spa)**

[A chromatographic analysis of the Mycobacterium tuberculosis strains isolated from an outbreak in HIV patients in Cuba] Mederos LM, et al. **Rev Cubana Med Trop** 1998;50(2):120-3 (Eng. Abstr.) **(Spa)**

[Hemopoietic cells from human embryonic liver in the treatment of HIV/AIDS] Pylypchak OM. **Lik Sprava** 1998 Dec;(8):116-8 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Worthylake DK, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):85-92

Crystallization of the dimerization-initiation site of genomic HIV-1 RNA: preliminary crystallographic results. Yusupov M, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):281-4

The HIV-1 Rev protein. Pollard VW, et al. **Annu Rev Microbiol** 1998;52:491-532 (237 ref.)

RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Arold S, et al. **Biochemistry** 1998 Oct 20;37(42):14683-91

Backbone dynamics of the N-terminal domain of the HIV-1 capsid protein and comparison with the G94D mutant conferring cyclosporin resistance/dependence. Campos-Olivas R, et al. **Biochemistry** 1999 Aug 10; 38(32):10262-71

Probing the topography of HIV-1 nucleocapsid protein with the alkylating agent N-ethylmaleimide. Chertova EN, et al. **Biochemistry** 1998 Dec 22;37(51):17890-7

Structural investigation on the requirement of CCHH zinc finger type in nucleocapsid protein of human immunodeficiency virus 1. Ramboarina S, et al. **Biochemistry** 1999 Jul 27;38(30):9600-7

Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model. Shu W, et al. **Biochemistry** 1999 Apr 27;38(17):5378-85

Solution structure and orientation of the transmembrane anchor domain of the HIV-1-encoded virus protein U by high-resolution and solid-state NMR spectroscopy. Wray V, et al. **Biochemistry** 1999 Apr 20;38(16):5272-82

Structure and function of HIV-1 and SIV Tat proteins based on carboxy-terminal truncations, chimeric Tat constructs, and NMR modeling. Baier-Bitterlich G, et al. **Biomed Pharmacother** 1998;52(10):421-30

Time-resolved fluorescence investigation of the human immunodeficiency virus type 1 nucleocapsid protein: influence of the binding of nucleic acids. Bombarda E, et al. **Biophys J** 1999 Mar;76(3):1561-70

The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids. Curtain C, et al. **Eur Biophys J** 1999;28(5):427-36

Solution structures of human immunodeficiency virus type 1 (HIV-1) and moloney murine leukemia virus (MoMLV) capsid protein major-homology-region peptide analogs by NMR spectroscopy. Clish CB, et al. **Eur J Biochem** 1998 Oct 1;257(1):69-77

Occurrence of an HIV-1 gp160 endoproteolytic activity in low-density vesicles and evidence for a distinct density distribution from endogenously expressed furin and PC7/LPC convertases. Wouters S, et al. **FEBS Lett** 1999 Jul 30;456(1):97-102

Specific interaction of conformational polypeptides derived from HIV gp120 with human T lymphocyte CD4 receptor. Liu M, et al. **Immunol Lett** 1998 Aug;63(1):27-32

Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1. Implications on viral fusion mechanism. Chang DK, et al. **J Biol Chem** 1999 Feb 26;274(9):5299-309

Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. Péloponèse JM Jr, et al. **J Biol Chem** 1999 Apr 23;274(17):11473-8

Determination of the equilibrium micelle-inserting position of the fusion peptide of gp41 of human immunodeficiency virus type 1 at amino acid resolution by exchange broadening of amide proton resonances. Chang DK, et al. **J Biomol NMR** 1998 Nov;12(4):549-52

Global and local structural properties of the principal neutralizing determinant of the HIV-1 envelope protein gp120. Andrianov AM. **J Biomol Struct Dyn** 1999 Feb; 16(4):931-53

Structural model of the HIV-1 Tat(46-58)-TAR complex. Seewald MJ, et al. **J Biomol Struct Dyn** 1998 Dec; 16(3):683-92

A multi-mode chromatographic method for the comparison of the N-glycosylation of a recombinant HIV envelope glycoprotein (gp160s-MN/LAI) purified by two different

processes. Taverna M, et al. **J Biotechnol** 1999 Feb 5; 68(1):37-48

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients [see comments] Gringeri A, et al. **J Hum Virol** 1998 May-Jun; 1(4):293-8. Comment in: J Hum Virol 1998 May-Jun;1(4):249-50.

Identification of a nuclear transport inhibitory signal (NTIS) in the basic domain of HIV-1 Vif protein. Friedler A, et al. **J Mol Biol** 1999 Jun 11;289(3):431-7

Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. Ferrer M, et al. **J Pept Res** 1999 Jul;54(1):32-42

1H NMR conformational study on N-terminal nonapeptide sequences of HIV-1 Tat protein: a contribution to structure-activity relationships. Mrestani-Klaus C, et al. **J Pept Sci** 1998 Sep;4(6):400-10

"Hidden" dUTPase sequence in human immunodeficiency virus type 1 gp120. Abergel C, et al. **J Virol** 1999 Jan; 73(1):751-3

Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. Wilk T, et al. **J Virol** 1999 Mar;73(3):1931-40

Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins. Biller M, et al. **J Virol Methods** 1998 Dec; 76(1-2):87-100

Direct quantitation of HIV by flow cytometry using branched DNA signal amplification. Van Cleve M, et al. **Mol Cell Probes** 1998 Aug;12(4):243-7

A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V, et al. **Nat Struct Biol** 1999 Apr; 6(4):331-5

Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Meyerhoff DJ, et al. **Neurology** 1999 Mar 23;52(5):995-1003

Tat, a human immunodeficiency virus-1-derived protein, augments excitotoxic hippocampal injury in neonatal rats. Wang P, et al. **Neuroscience** 1999 Jan;88(2):585-97

Sensitive in vitro analysis of HIV-1 Rev multimerization. Brice PC, et al. **Nucleic Acids Res** 1999 May 15; 27(10):2080-5

Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Craig HM, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11229-34

A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Druillennec S, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4886-91

Viral protein R of HIV-1. Bukrinsky M, et al. **Rev Med Virol** 1999 Jan-Mar;9(1):39-49 (83 ref.)

Assembly and analysis of conical models for the HIV-1 core. Ganser BK, et al. **Science** 1999 Jan 1;283(5398):80-3

[Spatial structure of the rp142 peptide containing the immunodominant epitope of the HIV-1 gp120 protein. A theoretical study] Andrianov AM, et al. **Biofizika** 1999 Jan-Feb;44(1):10-7 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Vertical transmission of human immunodeficiency virus type 1 in Japan, 1989-1997: presence of two subtypes B and E with subtype E predominance. National Cooperative Study Investigators on Vertical Transmission of HIV-1. Yoshino N, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):503-9

HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. Abebe A, et al. **AIDS** 1999 Jul 30; 13(11):1305-11

HIV-1 subtypes in Santiago, Chile [letter] Desgranges C, et al. **AIDS** 1998 Aug 20;12(12):1563-5

HIV-1 group O virus infection in Abidjan, Côte d'Ivoire [letter] Nkengasong J, et al. **AIDS** 1998 Aug 20; 12(12):1565-6

Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. Nkengasong JN, et al. **AIDS** 1998 Aug 20;12(12):1405-12

Molecular characterization of the envelope transmembrane glycoprotein of 13 new human immunodeficiency virus type 1 group O strains from six different African countries. Bibollet-Ruche F, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1281-5

Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. Björndal A, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):647-53

Serologic and genetic characterization of HIV type 1 subtypes on Reunion Island. Brengel-Pesce K, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):787-92

Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. Candotti D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):309-14

HIV type 1 subtypes in Guangxi Province, China, 1996. Chen J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):81-4

Human immunodeficiency virus type 1 subtypes B and C detected in New Zealand. Dwyer DE, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1105-8

Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. Ellenberger DL, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):3-9

Genetic characterization of the nef gene from human immunodeficiency virus type 1 group M strains representing genetic subtypes A, B, C, E, F, G, and H. Jubier-Maurin V, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):23-32

Characterization of V3 loop sequences from HIV type 1 subtype B in South Korea: predominance of the GPGS motif. Kim EY, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):681-6

HIV type 1 subtypes of nonhemophiliac patients in Japan. Kitsutani PT, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1099-103

HIV type 1 env subtype E in Cambodia. Kusagawa S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):91-4

Genetic and serologic characterization of HIV type 1 prevailing in Myanmar (Burma). Kusagawa S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1379-85

Virtually full-length sequences of HIV type 1 subtype J reference strains. Laukkanen T, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):293-7

Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1299-303

Subtypes of HIV type 1 circulating in India: partial envelope sequences. Maitra A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):941-4

Genetic heterogeneity of HIV type 1 subtypes in Kimpese, rural Democratic Republic of Congo. Mokili JL, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):655-64

DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G. Naghavi MH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):485-8

Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. Nasioulas G, et al. **AIDS Res Hum Retroviruses** 1999 May 20; 15(8):745-58

The subtypes of HIV type 1 in Greece. Papa A, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1297-8

Impact of HIV type 1 subtype variation on viral RNA quantitation. Parekh B, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):133-42

Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. Quiñones-Mateu ME, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):73-9

Molecular epidemiology of HIV type 1 isolates from the Czech Republic: identification of an env E subtype case. Quiñones-Mateu ME, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):85-9

Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana. Sagoe KW, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):775-9

Two variants of HIV-1 B serotype are transmitted heterosexually in São Paulo, Brazil. Casseb J, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1243-6

HIV-1 subtype F in single and dual infections in Puerto Rico: A potential sentinel site for monitoring novel genetic HIV variants in North America [letter] Flores I, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):481-3

Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. Pieniazek D, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):649-56

Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):259-65

Increase of HIV-1 subtype A in Central African Republic. Müller-Trutwin MC, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):164-71

Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. Kitayaporn D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):289-95

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):315-20

Predominance of CCR5-dependent HIV-1 subtype E isolates in Cambodia. Menu E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):481-7

Further characterization of HIV-1 isolates from Ho Chi Minh City, Vietnam [letter] Nguyen TH, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):93-5

Introduction of HIV-1 subtype A in the French West Indies [letter] Ouka M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):308-10

Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil [letter] Pinto ME, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):310-2

V3 serotyping of HIV-1 infection: correlation with genotyping and limitations. Plantier JC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):432-41

HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. Tanuri A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):60-6

Primary subtype C HIV-1 infection in Harare, Zimbabwe. Tien PC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):147-53

Antibodies to the CD4-binding site of HIV-1 gp120 in patients infected by variants belonging to the M or O group [letter] Turbica I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):95-7

Application of dried blood spot specimens for serologic subtyping of human immunodeficiency virus type 1 in Thailand. Chanbancherd P, et al. **J Clin Microbiol** 1999 Mar;37(3):804-6

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target. de Baar MP, et al. **J Clin Microbiol** 1999 Jun;37(6):1813-8

Discrimination of subtype B and non-subtype B strains of human immunodeficiency virus type 1 by serotyping: correlation with genotyping. Murphy G, et al. **J Clin Microbiol** 1999 May;37(5):1356-60

Human immunodeficiency virus type 1 subtypes differ in disease progression. Kanki PJ, et al. **J Infect Dis** 1999 Jan; 179(1):68-73

Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1 [published erratum appears in J Infect Dis 1999 Apr;179(4):1053] Menu E, et al. **J Infect Dis** 1999 Jan;179(1):44-51

High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. Nelson KE, et al. **J Infect Dis** 1999 Aug;180(2):337-43

Human immunodeficiency viruses type 1 subtypes circulating in Sspain. Holguín A, et al. **J Med Virol** 1999 Oct; 59(2):189-93

An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). Gao F, et al. **J Virol** 1998 Dec;72(12):10234-41

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Lole KS, et al. **J Virol** 1999 Jan;73(1):152-60

Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. Quiñones-Mateu ME, et al. **J Virol** 1998 Nov;72(11):9002-15

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. Zolla-Pazner S, et al. **J Virol** 1999 May;73(5):4042-51

Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus type 1 in South Africa. van Harmelen J, et al. **J Virol Methods** 1999 Mar;78(1-2):51-9

A new HIV-1 group: abstract and commentary. Delwart E. **JAMA** 1998 Dec 9;280(22):1960

Different HIV-1 strains found in semen and blood [news] Birchard K. **Lancet** 1998 Oct 24;352(9137):1363

The distribution of HIV-1 subtypes in Fukuoka, Japan. Chijiwa K, et al. **Microbiol Immunol** 1999;43(3):271-8

Ups and downs on the road to an HIV vaccine [news] Senior K. **Mol Med Today** 1999 Apr;5(4):141-2

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort [see comments] Learmont JC, et al. **N Engl J Med** 1999 Jun 3;340(22):1715-22. Comment in: N Engl J Med 1999 Jun 3;340(22):1756-7.

Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes [see comments] Gao F, et al. **Nature** 1999 Feb 4;397(6718):436-41. Comment in: Nature 1999 Feb 4;397(6718):385-6.

From Pan to pandemic [news; comment] Weiss RA, et al. **Nature** 1999 Feb 4;397(6718):385-6. Comment on: Nature 1999 Feb 4;397(6718):436-41.

AIDS virus traced to chimp subspecies [news] [see comments] Cohen J. **Science** 1999 Feb 5;283(5403):772-3. Comment in: Science 1999 Apr 2;284(5411):50.

Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. McCutchan FE, et al. **Virology** 1999 Feb 15; 254(2):226-34

[New HIV-1 variant discovered in Cameroon (news)] Kowalski A. **Dtsch Med Wochenschr** 1998 Nov 20; 123(47):A7 **(Ger)**

[Serotypical stratification of HIV-1 in populations of intravenous drug users in the south/southwestern Ukraine] Shchelkanov MIu, et al. **Vopr Virusol** 1998 Jul-Aug; 43(4):176-82 (Eng. Abstr.) **(Rus)**

[Serological properties of HIV-1 isolates from the focus of an epidemic in the Gomel region of the Belarus Republic (1996)] Shchelkanov MIu, et al. **Vopr Virusol** 1998 Sep-Oct; 43(5):220-9 (Eng. Abstr.) **(Rus)**

[HIV-1 subtypes in Russia in 1987-1988] Bobkov AF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):43-5

(Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate. Jagodzinski PP, et al. **Acta Biochim Pol** 1998;45(3):799-804

Lactoferrin. Antiviral activity of lactoferrin. Swart PJ, et al. **Adv Exp Med Biol** 1998;443:205-13

Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom? [letter] Aizawa S, et al. **AIDS** 1999 Jul 9;13(10):1278-9

Interleukin-2 treatment of microglia has no effect on in vitro HIV infection [letter; comment] Albright AV, et al. **AIDS** 1999 Mar 11;13(4):527-8. Comment on: AIDS 1998 May 28;12(8):F59-64.

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. Alexander CS, et al. **AIDS** 1999 May 28;13(8):981-5

Bacterial lipopolysaccharide is a potent inhibitor of HIV-1 replication in T lymphocytes and macrophages [letter] Alfano M, et al. **AIDS** 1998 Sep 10;12(13):1724-6

Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. Birk M, et al. **AIDS** 1998 Dec 24;12(18):2369-75

Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. Böhler T, et al. **AIDS** 1999 May 7;13(7):779-89

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. Bratt G, et al. **AIDS** 1998 Nov 12;12(16):2193-202

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). Cohen Stuart JW, et al. **AIDS** 1999 May 7;13(7):F53-8

Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection [editorial] Deresinski SC. **AIDS** 1999 Apr 16;13(6):633-43 (136 ref.)

Detection of multiple drug-resistance-associated pol mutations in cervicovaginal secretions from women largely treated with antiretroviral agents [letter] Di Stefano M, et al. **AIDS** 1999 May 28;13(8):992-4

Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. Eron JJ, et al. **AIDS** 1998 Oct 22;12(15):F181-9

Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. Lillo FB, et al. **AIDS** 1999 May 7;13(7):791-6

High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population [letter] Loveday C, et al. **AIDS** 1999 Apr 1;13(5):627-8

Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients [letter] Magiorkinis E, et al. **AIDS** 1999 Jul 9;13(10):1276-8

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. Murray JS, et al. **AIDS** 1999 May 7;13(7):797-804 (24 ref.)

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Palmer S, et al. **AIDS** 1999 Apr 16; 13(6):661-7

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. Piketty C, et al. **AIDS** 1999 Jul 30;13(11):F71-7

Introduction of HIV drug-resistance testing in clinical practice [editorial] Rodriguez-Rosado R, et al. **AIDS** 1999 Jun 18;13(9):1007-14 (47 ref.)

Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES [letter] Rusconi S, et al. **AIDS** 1999 Jun 18;13(9):1144-5

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, et al. **AIDS** 1999 Feb 25;13(3):359-65

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. Schmit JC, et al. **AIDS** 1998 Oct 22; 12(15):2007-15

Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine [letter] Viani RM, et al. **AIDS** 1999 Jul 9;13(10):1273-4

Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. Brown AJ, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):247-53

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. Churchill DR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1181-9

Elusive realities: a perspective on the Chicago retrovirus meeting. Harris PJ. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1149-50

Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. Okamoto M, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1239-45

Phosphorylation of triciribine is necessary for activity against HIV type 1. Ptak RG, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1315-22

Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):861-7

9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells. Sadaie MR, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):239-45

The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in primary macrophage cultures. Seddiki N, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):381-90

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):65-9

Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1. Tachedjian G, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1059-64

Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. Vázquez-Rosales G, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1191-200

Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. Xu Y, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):419-27

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Mayers DL. **Am J Med** 1997 May 19;102(5B):70-5 (55 ref.)

Candidate antiretroviral agents for use in postexposure prophylaxis. Saag MS. **Am J Med** 1997 May 19; 102(5B):25-31 (38 ref.)

Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1. Achour A, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2482-91

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Borkow G, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):259-63

Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Buckheit RW Jr, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1827-34

Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. de Muys JM, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1835-44

A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). García Lerma J, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):264-70

A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Howett MK, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):314-21

Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Miller V, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3123-9

Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells. Okamoto M, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):492-7

Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Palmer S, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2046-50

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Patick AK, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2637-44

Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. Tachedjian G, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):3038-43

Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):253-8

In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters. Uchida H, et al. **Antimicrob Agents Chemother** 1999 Jun;43(6):1487-90

Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry. Zhang X, et al. **Antisense Nucleic Acid Drug Dev** 1998 Dec;8(6):441-50

Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Beadle JR, et al. **Antivir Chem Chemother** 1998 Jan;9(1):33-40

Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication. Buckheit RW Jr, et al. **Antivir Chem Chemother** 1999 May;10(3):115-9

PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms. Buckheit RW Jr, et al. **Antivir Chem Chemother** 1999 Jan;10(1):23-32

Synthesis and anti-human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon-3-yl esters. Desideri N, et al. **Antivir Chem Chemother** 1998 Nov;9(6):497-509

1,2,5-Benzothiadiazepine and pyrrolo[2,1-d]-[1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Di Santo R, et al. **Antivir Chem Chemother** 1998 Mar;9(2):127-37

Role of lentiviral lytic polypeptide I (LLP-I) in the selective cytotoxicity of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1-producing cells. Kubota S, et al. **Antivir Chem Chemother** 1999 May; 10(3):121-7

In vitro evaluation and characterization of newly designed alkylamidophospholipid analogues as anti-human immunodeficiency virus type 1 agents. Kucera LS, et al. **Antivir Chem Chemother** 1998 Mar;9(2):157-65

Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). McGuigan C, et al. **Antivir Chem Chemother** 1998 Nov; 9(6):473-9

Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro. Moog C, et al. **Antivir Chem Chemother** 1998 Nov;9(6):491-6

Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro. Mori H, et al. **Antivir Chem Chemother** 1999 Jan; 10(1):15-21

Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative. Okamoto M, et al. **Antivir Chem Chemother** 1999 Mar; 10(2):71-7

In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Peghini PA, et al. **Antivir Chem Chemother** 1998 Mar;9(2):117-26

3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine (YHI-1) selectively inhibits human immunodeficiency virus type 1. Premanathan M, et al. **Antivir Chem Chemother** 1998 Sep;9(5):423-30

Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation. Renoud-Grappin M, et al. **Antivir Chem Chemother** 1998 May;9(3):205-23

Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. Shao X, et al. **Antivir Chem Chemother** 1998 Mar;9(2):167-76

Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Silvestri R, et al. **Antivir Chem Chemother** 1998 Mar;9(2):139-48

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Taylor DL, et al. **Antivir Chem Chemother** 1999 Mar;10(2):79-86

Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues. Velázquez S, et al. **Antivir Chem Chemother** 1998 Nov; 9(6):481-9

Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents. Burstein ME, et al. **Antiviral Res** 1999 Apr;41(3):135-44

Synthesis and anti-HIV activity of some novel arylphosphate and H-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine. Cardona VM, et al. **Antiviral Res** 1999 Jul;42(3):189-96

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Evans TG, et al. **Antiviral Res** 1998 Oct;39(3):163-73

Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro. Konopka K, et al. **Antiviral Res** 1999 Jul;42(3):197-209

A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro. Moussazadeh M, et al. **Antiviral Res** 1999 Jul;42(3):177-87

L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Robinson WE Jr. **Antiviral Res** 1998 Aug;

39(2):101-11
Inhibition of human immunodeficiency virus type (HIV-1) replication by some diversely functionalized spirocyclopropyl derivatives. Witvrouw M, et al. **Arch Pharm (Weinheim)** 1999 May;332(5):163-6
Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Fujiwara M, et al. **Arch Virol** 1998;143(10):2003-10
Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Klimkait T, et al. **Arch Virol** 1998;143(11):2109-31
Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Ventura M, et al. **Arch Virol** 1999;144(3):513-23
Viral inactivation of human bone tissue using supercritical fluid extraction. Fages J, et al. **ASAIO J** 1998 Jul-Aug; 44(4):289-93
Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Huang PL, et al. **Biochem Biophys Res Commun** 1999 Sep 7; 262(3):615-23
Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1. Rajamohan F, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):453-8
A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Tamamura H, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):877-82
Mechanism of anti-HIV activity of succinylated human serum albumin. Kuipers ME, et al. **Biochem Pharmacol** 1999 Apr 15;57(8):889-98
Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Watson K, et al. **Biochem Pharmacol** 1999 Apr 1;57(7):775-83
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Arion D, et al. **Biochemistry** 1998 Nov 10;37(45):15908-17
Effects of IFN alpha on late stages of HIV-1 replication cycle. Dianzani F, et al. **Biochimie** 1998 Aug-Sep; 80(8-9):745-54
HIV-1 genotypic resistance: automated sequence analysis and interpretation. Goujon CP, et al. **Bioinformatics** 1998; 14(10):886-7
Inactivation of intracellular and non-enveloped viruses by a non-ionic naphthalene endoperoxide. Dewilde A, et al. **Biol Chem** 1998 Nov;379(11):1377-9
Anti-HIV-1 activity of herbs in Labiatae. Yamasaki K, et al. **Biol Pharm Bull** 1998 Aug;21(8):829-33
Phenylarsine oxide inhibits ex vivo HIV-1 expression. Arbault S, et al. **Biomed Pharmacother** 1997;51(10):430-8
Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR-undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements? [editorial] Mathé G. **Biomed Pharmacother** 1999 Mar;53(2):57-62 (24 ref.)
Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. Van Derpoorten K, et al. **Biomed Pharmacother** 1997; 51(10):464-8
Molecular basis of HIV-1 TAR RNA specific recognition by an acridine tat-antagonist. Gelus N, et al. **Bioorg Med Chem** 1999 Jun;7(6):1075-9
Inhibition of HIV-1 Tat-TAR interaction by diphenylfuran derivatives: effects of the terminal basic side chains. Gelus N, et al. **Bioorg Med Chem** 1999 Jun;7(6):1089-96
Biologically active oligodeoxyribonucleotides. Part 11: The least phosphate-modification of quadruplex-forming hexadeoxyribonucleotide TGGGAG, bearing 3-and 5-end-modification, with anti-HIV-1 activity. Koizumi M, et al. **Bioorg Med Chem** 1998 Dec;6(12):2469-75
Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Tamamura H, et al. **Bioorg Med Chem** 1998 Jul; 6(7):1033-41
Interaction of tRNA-derivatives and oligonucleotide primers with AZT-resistant mutants of HIV-1 reverse transcriptase. Zakharova OD, et al. **Bioorg Med Chem** 1998 Nov;6(11):2041-9
Synthesis of a cosalane analog with an extended polyanionic pharmacophore conferring enhanced potency as an anti-HIV agent. Cushman M, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):833-6
Anti-HIV pronucleotides: decomposition pathways and correlation with biological activities. Egron D, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1045-50
Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mao C, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2213-8
Synthesis of [(2S, 3S)-bis(hydroxylmethyl)pyrrolidin-1-yl] purine and pyrimidine nucleosides as potential antiviral agents. Oohashi T, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1187-8
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Sahlberg C, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1511-6
Anti-AIDS agents. 32. Synthesis and anti-HIV activity of betulin derivatives. Sun IC, et al. **Bioorg Med Chem Lett** 1998 May 19;8(10):1267-72
Anti-AIDS agents. 33. Synthesis and anti-HIV activity of mono-methyl substituted 3',4'-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues. Xie L, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2151-6
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI. Xu ZQ, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2179-84
Alloantigen-stimulated anti-HIV activity. Pinto LA, et al. **Blood** 1998 Nov 1;92(9):3346-54
A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication. Kashiwase H, et al. **Chemotherapy** 1999 Jan-Feb; 45(1):48-55
Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives. Pandeya SN, et al. **Chemotherapy** 1999 May-Jun;45(3):192-6
Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Mayer KH, et al. **Clin Infect Dis** 1999 Jun;28(6):1252-9
Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection. Nyland SB, et al. **DNA Cell Biol** 1999 Apr;18(4):285-91
Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Balani SK, et al. **Drug Metab Dispos** 1999 Jan; 27(1):41-5
Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Vandamme AM, et al. **Drugs** 1999 Mar;57(3):337-61 (214 ref.)
Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Mahalingam B, et al. **Eur J Biochem** 1999 Jul;263(1):238-45
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Venturi G, et al. **Eur J Clin Microbiol Infect Dis** 1999 Apr; 18(4):274-82
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Reiser M, et al. **Eur J Med Res** 1999 Feb 25;4(2):54-8
Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus-infected children [letter] Funk M, et al. **Eur J Pediatr** 1999 Jan;158(1):86-7
Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols. Bonora GM, et al. **Farmaco** 1998 Oct-Nov; 53(10-11):634-7
Synthesis and HIV-1 inhibitory properties of new tetrahydrobenzoquinazolinedione and tetrahydrobenzocycloheptenuracil derivatives and of their thioxo analogues. Macchia M, et al. **Farmaco** 1999 Apr 30;54(4):242-7
Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles. Merino I, et al. **Farmaco** 1999 Apr 30;54(4):255-64
Evaluation of anti-HIV activity of 5-(2-phenyl-3'-indolal)-2-thiohydantoin. Suzen S, et al. **Farmaco** 1998 Jul 30;53(7):525-7
Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. Feng JY, et al. **FASEB J** 1999 Sep;13(12):1511-7
Inhibition of HIV-1 replication by a two-strand system (FTFOs) targeted to the polypurine tract. Hiratou T, et al. **FEBS Lett** 1999 Jul 30;456(1):186-90
Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha. Xin X, et al. **FEBS Lett** 1999 Aug 27;457(2):219-22
Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. Zhang X, et al. **FEBS Lett** 1999 Sep 17;458(2):151-6
Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro. Stone AL, et al. **Glycoconj J** 1998 Jul;15(7):697-712
Resistance to HIV protease inhibitors. Condra JH. **Haemophilia** 1998 Jul;4(4):610-5 (24 ref.)
HIV treatment--a rational approach to the use of antiretroviral agents. Vella S. **Haemophilia** 1998 Jul; 4(4):616-8 (10 ref.)
Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Apr;18(2):139-47
Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes. Pardridge WM, et al. **Immunol Lett** 1998 Nov;64(1):45-7
Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-alpha-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells. Traber KE, et al. **Int Immunol** 1999 Feb;11(2):143-50
Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Puddu P, et al. **Int J Biochem Cell Biol** 1998 Sep;30(9):1055-62
Inhibition of HIV-1 replication by chimeric phosphorothioate oligodeoxynucleotides applied in free solution. Lund OS, et al. **Intervirology** 1998;41(2-3):63-8
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. Chien JW, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):277-80
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. Margolis D, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):362-70
Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures. Segal DM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):215-9
LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. Nibbs RJ, et al. **J Biol Chem** 1999 Jun 18;274(25):17478-83
Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. Pelemans H, et al. **J Biol Chem** 1998 Dec 18; 273(51):34234-9
HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Berkhout B. **J Biomed Sci** 1999 Sep-Oct;6(5):298-305 (59 ref.)
Modeling of the interaction between new ethidium derivatives and TAR RNA of HIV-1. Terreux R, et al. **J Chem Inf Comput Sci** 1999 Mar-Apr;39(2):413-9
Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. Fenard D, et al. **J Clin Invest** 1999 Sep;104(5):611-8
The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. Menten P, et al. **J Clin Invest** 1999 Aug;104(4):R1-5
Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Walter H, et al. **J Clin Virol** 1999 Jun;13(1-2):71-80
A search for anti-viral properties in Panamanian medicinal plants. The effects on HIV and its essential enzymes. Matsuse IT, et al. **J Ethnopharmacol** 1999 Jan;64(1):15-22
The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains [see comments] Alfano M, et al. **J Exp Med** 1999 Sep 6; 190(5):597-605. Comment in: J Exp Med 1999 Sep 6;190(5):591-5.
Translational effects of peptide antagonists of Tat protein of human immunodeficiency virus type 1. Choudhury I, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):777-82
Sensitivity of human immunodeficiency virus infection to various alpha, beta and gamma chemokines. Greco G, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2369-73
Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Locarnini S, et al. **J Hepatol** 1999 Mar;30(3):536-50 (127 ref.)
Effect of beta-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages. Jiang Y, et al. **J Hum Virol** 1999 May-Jun;2(3):123-32
Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. Hengel RL, et al. **J Immunol** 1999 Sep 15; 163(6):3539-48
Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro. Vassiliadou N, et al. **J Immunol** 1999 Jun 15;162(12):7510-8
Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. Amiel C, et al. **J Infect Dis** 1999 Jan;179(1):83-91
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Deeks SG, et al. **J Infect Dis** 1999 Jun; 179(6):1375-81
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Miller MD, et al. **J Infect Dis** 1999 Jan;179(1):92-100
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Murphy RL, et al. **J Infect Dis** 1999 May;179(5):1116-23
Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. Parkin NT, et al. **J Infect Dis** 1999 Sep;180(3):865-70
Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy. Romano L, et al. **J Infect Dis** 1999 Feb;179(2):361-6
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group

229. Schapiro JM, et al. **J Infect Dis** 1999 Jan;179(1):249–53

Novel 1,1,3–trioxo–2H,4H–thieno[3,4–e][1,2,4]thiadiazine derivatives as non–nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. Arranz E, et al. **J Med Chem** 1998 Oct 8; 41(21):4109–17

Lamellarin alpha 20–sulfate, an inhibitor of HIV–1 integrase active against HIV–1 virus in cell culture. Reddy MV, et al. **J Med Chem** 1999 Jun 3;42(11):1901–7

Anti–AIDS agents. 34. Synthesis and structure–activity relationships of betulin derivatives as anti–HIV agents. Sun IC, et al. **J Med Chem** 1998 Nov 5;41(23):4648–57

Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti–HIV–1 agents that target the viral nucleocapsid protein zinc fingers. Turpin JA, et al. **J Med Chem** 1999 Jan 14;42(1):67–86

Anti–AIDS agents. 37. Synthesis and structure–activity relationships of (3'R,4'R)–(+)–cis–khellactone derivatives as novel potent anti–HIV agents. Xie L, et al. **J Med Chem** 1999 Jul 15;42(14):2662–72

Saquinavir delays the emergence of zidovudine resistance in HIV–1 seropositive patients treated with combination therapy. Andreoni M, et al. **J Med Virol** 1998 Dec; 56(4):332–6

Unintegrated HIV–1 circular 2–LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. Panther LA, et al. **J Med Virol** 1999 Jun;58(2):165–73

The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type–1 (Pediatric AIDS Clinical Trials Group Protocol 076). McSherry GD, et al. **J Pediatr** 1999 Jun;134(6):717–24

Anti–HIV activity and mechanism of action of macrocyclic diamide SRR–SB3. Mahmood N, et al. **J Pharm Pharmacol** 1998 Dec;50(12):1339–42

T134, a small–molecule CXCR4 inhibitor, has no cross–drug resistance with AMD3100, a CXCR4 antagonist with a different structure. Arakaki R, et al. **J Virol** 1999 Feb; 73(2):1719–23

Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. Dulioust A, et al. **J Virol** 1999 Jan; 73(1):850–4

Enhancement of human immunodeficiency virus type 1 infection by the CC–chemokine RANTES is independent of the mechanism of virus–cell fusion. Gordon CJ, et al. **J Virol** 1999 Jan;73(1):684–94

Comparative fitness of multi–dideoxynucleoside–resistant human immunodeficiency virus type 1 (HIV–1) in an In vitro competitive HIV–1 replication assay. Kosalaraksa P, et al. **J Virol** 1999 Jul;73(7):5356–63

Opposite effects of SDF–1 on human immunodeficiency virus type 1 replication. Maréchal V, et al. **J Virol** 1999 May; 73(5):3608–15

Replicative fitness of protease inhibitor–resistant mutants of human immunodeficiency virus type 1. Martinez–Picado J, et al. **J Virol** 1999 May;73(5):3744–52

Highly potent RANTES analogues either prevent CCR5–using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4–using variants. Mosier DE, et al. **J Virol** 1999 May;73(5):3544–50

Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. Murakami T, et al. **J Virol** 1999 Sep;73(9):7489–96

Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. Quan Y, et al. **J Virol** 1999 Aug;73(8):6700–7

Interleukin–16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. Truong MJ, et al. **J Virol** 1999 Aug;73(8):7008–13

Enhanced inhibition of human immunodeficiency virus type 1 by Met–stromal–derived factor 1beta correlates with down–modulation of CXCR4. Yang OO, et al. **J Virol** 1999 Jun;73(6):4582–9

HIV–1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22–29; 282(12):1135–41. Comment in: JAMA 1999 Sep 22–29;282(12):1177–9.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection [see comments] Little SJ, et al. **JAMA** 1999 Sep 22–29;282(12):1142–9. Comment in: JAMA 1999 Sep 22–29;282(12):1177–9.

Primary HIV–1 resistance: a new phase in the epidemic? [editorial; comment] Pomerantz RJ. **JAMA** 1999 Sep 22–29; 282(12):1177–9. Comment on: JAMA 1999 Sep 22–29;282(12):1135–41. Comment on: JAMA 1999 Sep 22–29;282(12):1142–9.

A new source of resistance to HIV drugs. Wainberg MA. **JAMA** 1999 Jun 16;281(23):2169–70

ApoE genotype and protease–inhibitor–associated hyperlipidaemia [letter; comment] Behrens G, et al. **Lancet** 1999 Jul 3;354(9172):76. Comment on: Lancet 1999 May 15;353(9165):1678.

Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy [letter] Bernard L, et al. **Lancet** 1998 Nov 28;352(9142):1757–8

In–vivo anti–CD3–induced HIV–1 viraemia [letter] Brinkman K, et al. **Lancet** 1998 Oct 31;352(9138):1446

Transmission of drug–resistant strains of HIV–1: unfortunate, but inevitable [comment] Cohen OJ, et al. **Lancet** 1999 Aug 28;354(9180):697–8. Comment on: Lancet 1999 Aug 28;354(9180):729–33.

6–month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double–blind placebo–controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère–Enfant. Dabis F, et al. **Lancet** 1999 Mar 6; 353(9155):786–92

Testing time as resistant HIV–1 faces next wave of attack [news] Mellors J. **Lancet** 1999 Jul 10;354(9173):135

Short–course zidovudine for prevention of perinatal infection [see comments] Mofenson LM. **Lancet** 1999 Mar 6; 353(9155):766–7. Comment in: Lancet 1999 Jun 26;353(9171):2241.

HIV–1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy [letter] Natarajan V, et al. **Lancet** 1999 Jan 9; 353(9147):119–20

Short–course zidovudine for perinatal HIV–1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group [see comments] Shaffer N, et al. **Lancet** 1999 Mar 6;353(9155):773–80. Comment in: Lancet 1999 Jul 10;354(9173):156; discussion 157–8. Comment in: Lancet 1999 Jul 10;354(9173):158.

Short–course oral zidovudine for prevention of mother–to–child transmission of HIV–1 in Abidjan, Côte d'Ivoire: a randomised trial. Wiktor SZ, et al. **Lancet** 1999 Mar 6;353(9155):781–5

Transmission of antiretroviral–drug–resistant HIV–1 variants [see comments] Yerly S, et al. **Lancet** 1999 Aug 28; 354(9180):729–33. Comment in: Lancet 1999 Aug 28;354(9180):697–8.

Cysteine, glutathione (GSH) and zinc and copper ions together are effective, natural, intracellular inhibitors of (AIDS) viruses. Sprietsma JE. **Med Hypotheses** 1999 Jun; 52(6):529–38 (100 ref.)

Role of curdlan sulfate in the production of beta–chemokines and interleukin–16. Naito T, et al. **Med Microbiol Immunol (Berl)** 1998 Jun;187(1):43–8

Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Crandall KA, et al. **Mol Biol Evol** 1999 Mar;16(3):372–82

Suppression of replication of multidrug–resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. Gao WY, et al. **Mol Pharmacol** 1999 Mar;55(3):535–40

Persistence of HIV–1 transcription in peripheral–blood mononuclear cells in patients receiving potent antiretroviral therapy [see comments] Furtado MR, et al. **N Engl J Med** 1999 May 27;340(21):1614–22. Comment in: N Engl J Med 1999 May 27;340(21):1672–4.

Residual HIV–1 disease in the era of highly active antiretroviral therapy [editorial; comment] Pomerantz RJ. **N Engl J Med** 1999 May 27;340(21):1672–4. Comment on: N Engl J Med 1999 May 27;340(21):1605–13. Comment on: N Engl J Med 1999 May 27;340(21):1614–22.

Quantifying residual HIV–1 replication in patients receiving combination antiretroviral therapy [see comments] Zhang L, et al. **N Engl J Med** 1999 May 27;340(21):1605–13. Comment in: N Engl J Med 1999 May 27;340(21):1672–4.

Effect of interleukin–2 on the pool of latently infected, resting CD4+ T cells in HIV–1–infected patients receiving highly active anti–retroviral therapy [see comments] Chun TW, et al. **Nat Med** 1999 Jun;5(6):651–5. Comment in: Nat Med 1999 Jun;5(6):609–11. Comment in: Nat Med 1999 Jun;5(6):611–2.

HIV–1 and HAART: a time to cure, a time to kill [news; comment] Saag MS, et al. **Nat Med** 1999 Jun;5(6):609–11 . Comment on: Nat Med 1999 May;5(5):512–7. Comment on: Nat Med 1999 Jun;5(6):651–5.

MRP4: A previously unidentified factor in resistance to nucleoside–based antiviral drugs. Schuetz JD, et al. **Nat Med** 1999 Sep;5(9):1048–51

Closing in on HIV drug resistance [news] Larder BA, et al. **Nat Struct Biol** 1999 Feb;6(2):103–6

The mechanism of actinomycin D–mediated inhibition of HIV–1 reverse transcription. Jeeninga RE, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5472–9

Synthesis and anti–HIV activity of different novel nonclassical nucleosides. Elgemeie GE, et al. **Nucleosides Nucleotides** 1999 Jan;18(1):113–23

Synthesis and biological application of a new heterodinucleotide with both anti–HSV and anti–HIV activity. Franchetti P, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):989–90

ddC– and 3TC–bis(SATE) monophosphate prodrugs overcome cellular resistance mechanisms to HIV–1 associated with cytidine kinase deficiency. Gröschel B, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):921–6

Effects of cycloSal–d4TMP derivatives in H9 cells with induced AZT resistance phenotype. Gröschel B, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):933–6

Antiviral activity of magnesium and magnesium/poly r(A–U) combinations against two RNA viruses. Jamison J, et al. **Nucleosides Nucleotides** 1999 Jun–Jul;18(6–7):1221–2

Antisense oligodeoxynucleotide complementary to CXCR4 mRNA block replication of HIV–1 in COS cells. Kusunoki A, et al. **Nucleosides Nucleotides** 1999 Jun–Jul; 18(6–7):1705–8

Antiviral activity and resistance profile of phosphazid—a novel prodrug of AZT. Machado J, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):901–6

Synthesis, lipophilicity and anti–HIV activity of a new brominated analog of zidovudine. Motura M, et al. **Nucleosides Nucleotides** 1999 Mar;18(3):337–51

Resistance profiles of (+)2'–deoxy–3'–oxa–4'–thiocytidine and (–)2'–deoxy–3'–oxa–4'–thio–5–fluorocytidine. Richard N, et al. **Nucleosides Nucleotides** 1999 Apr–May; 18(4–5):773–8

AIDS drugs effective against most common HIV strain [news] **Oncology (Huntingt)** 1999 Mar;13(3):392

Hydroxyurea to inhibit human immunodeficiency virus–1 replication. Romanelli F, et al. **Pharmacotherapy** 1999 Feb; 19(2):196–204 (39 ref.)

Inhibitory effects of Sudanese plant extracts on HIV–1 replication and HIV–1 protease. Hussein G, et al. **Phytother Res** 1999 Feb;13(1):31–6

Antiviral activities against HSV–1, HCMV, and HIV–1 of rhamnan sulfate from Monostroma latissimum [letter] Lee JB, et al. **Planta Med** 1999 Jun;65(5):439–41

A small–molecule, nonpeptide CCR5 antagonist with highly potent and selective anti–HIV–1 activity. Baba M, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5698–703

A mimic of HIV–1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Druillennec S, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4886–91

Lysozyme and RNases as anti–HIV components in beta–core preparations of human chorionic gonadotropin. Lee–Huang S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):2678–81

An anti–CD45RO immunotoxin eliminates T cells latently infected with HIV–1 in vitro. McCoig C, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11482–5

Interleukin 18 stimulates HIV type 1 in monocytic cells. Shapiro L, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12550–5

National Institute of Virology report on testing of Virodene by the NIV [letter] Sequeira WL, et al. **S Afr Med J** 1999 Feb;89(2):108–9

Outsmarting HIV drug resistance [news; comment] Balter M. **Science** 1998 Nov 27;282(5394):1623, 1625. Comment on: Science 1998 Nov 27;282(5394):1669–75.

Structure of a covalently trapped catalytic complex of HIV–1 reverse transcriptase: implications for drug resistance [see comments] Huang H, et al. **Science** 1998 Nov 27; 282(5394):1669–75. Comment in: Science 1998 Nov 27;282(5394):1623, 1625.

Selection of drug–resistant HIV [published erratum appears in trends Microbiol 1999 Jul;7(7):302] Harrigan PR, et al. **Trends Microbiol** 1999 Mar;7(3):120–3 (32 ref.)

Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV–1 pol. Günthard HF, et al. **Virology** 1999 Jun 20;259(1):154–65

[Amsterdam duration of antiretroviral medication (ADAM)––study: induction–suppression treatment in HIV–I infection, preliminary results] Reijers MH, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230 **(Dut)**

[IFN–tau, a new interferon type I with antiretroviral activity] Clayette P, et al. **Pathol Biol (Paris)** 1999 May;47(5):553–9 (Eng. Abstr.) **(Fre)**

[Discontinuation of antiretroviral treatment containing a protease inhibitor. Failure and tolerance] Michelet C. **Presse Med** 1999 Feb 27;28(8):402–4 **(Fre)**

[Discontinuing protease inhibitor treatment of HIV–1 patients for intolerance. Longitudinal study of 309 patients] Piroth L, et al. **Presse Med** 1999 Feb 27;28(8):381–7 (Eng. Abstr.) **(Fre)**

[HIV: resistance and cross–resistance as the crux (news)] **Dtsch Med Wochenschr** 1999 Apr 9;124(14):A28 **(Ger)**

[HIV: fusion inhibitors as the new therapeutic approach (news)] **Dtsch Med Wochenschr** 1999 Sep 10; 124(36):A19–20 **(Ger)**

[Recent challenges and progress in AIDS therapy––emergence of drug resistant HIV–1 variants] Mitsuya H. **Rinsho Ketsueki** 1999 Apr;40(4):249–54 (20 ref.) **(Jpn)**

[Study of the inhibiting effect of the molecular complex yeast RNA–tilorone on HIV–1 reproduction in vitro] Karpov AV, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):433–5 **(Rus)**

[Tandem bifunctional derivatives of short oligonucleotides––inhibitors of replication of the human immunodeficiency virus in cell culture] Pliasunova OA, et al. **Mol Biol (Mosk)** 1998 Nov–Dec;32(6):1085–90 **(Rus)**

[Human immunodeficiency virus and resistance] Coórdoba J, et al. **Rev Esp Quimioter** 1998 Jun;11(2):152–6 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Continuous and discontinuous changes in the unit cell of HIV–1 reverse transcriptase crystals on dehydration. Esnouf RM, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):938–53

HIV–1 integrase: structural organization, conformational changes, and catalysis. Asante–Appiah E, et al. **Adv Virus Res** 1999;52:351–69 (67 ref.)

Crystal structures of catalytic core domains of retroviral integrases and role of divalent cations in enzymatic activity. Wlodawer A. **Adv Virus Res** 1999;52:335–50 (48 ref.)

Selective vertical transmission of HIV–1 antiretroviral resistance mutations. Colgrove RC, et al. **AIDS** 1998 Dec

3;12(17):2281–8

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. de Jong JJ, et al. **AIDS** 1999 Jan 14;13(1):75–80

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Larder BA, et al. **Antimicrob Agents Chemother** 1999 Aug; 43(8):1961–7

An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Chamorro C, et al. **Antivir Chem Chemother** 1998 Sep;9(5):413–22

Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure. Tanaka H, et al. **Antivir Chem Chemother** 1998 Jul;9(4):325–32

Comparison of enzymatic activities of the HIV-1 and HFV integrases to their U5 LTR substrates. Oh YT, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):621–9

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Ala PJ, et al. **Biochemistry** 1998 Oct 27;37(43):15042–9

Actinomycin D inhibition of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase and nucleocapsid protein. Davis WR, et al. **Biochemistry** 1998 Oct 6; 37(40):14213–21

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Martin JL, et al. **Biochemistry** 1999 Jun 22;38(25):7978–88

Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance. Vaccaro JA, et al. **Biochemistry** 1998 Oct 6; 37(40):14189–94

A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors. Gupta SP, et al. **Bioorg Med Chem** 1998 Nov; 6(11):2185–92

Inhibitory effects of constituents from Cynomorium songaricum and related triterpene derivatives on HIV-1 protease. Ma C, et al. **Chem Pharm Bull (Tokyo)** 1999 Feb; 47(2):141–5

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Kumar GN, et al. **Drug Metab Dispos** 1999 Jan;27(1):86–91

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Mahalingam B, et al. **Eur J Biochem** 1999 Jul;263(1):238–45

Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli – two tags tie it up. Maier G, et al. **Eur J Biochem** 1999 Apr; 261(1):10–8

Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. Isaguliants MG, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):232–6

Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies. Dohnálek J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:9–11

Structural studies of HIV-1 protease-inhibiting antibodies. Lescar J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:3–6

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6–8

Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. Catucci M, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):203–8

Structural determinants of metal-induced conformational changes in HIV-1 integrase. Asante-Appiah E, et al. **J Biol Chem** 1998 Dec 25;273(52):35078–87

Activation/attenuation model for RNase H. A one-metal mechanism with second-metal inhibition. Keck JL, et al. **J Biol Chem** 1998 Dec 18;273(51):34128–33

Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. Powell MD, et al. **J Biol Chem** 1999 Jul 9;274(28):19885–93

Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Schuurman R, et al. **J Clin Microbiol** 1999 Jul;37(7):2291–6

Quantitative structure-activity relationships of some HIV-protease inhibitors. Gupta SP, et al. **J Enzyme Inhib** 1999;14(2):109–23

Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors. Gupta SP, et al. **J Enzyme Inhib** 1998 Sep;13(6):399–407

Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. Sugiura W, et al. **J Hum Virol** 1999 May-Jun;2(3):146–53

IFN-gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. Sewell AK, et al. **J Immunol** 1999 Jun 15;162(12):7075–9

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Young B, et al. **J Infect Dis** 1998 Nov; 178(5):1497–501

Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. Artico M, et al. **J Med Chem** 1998 Oct 8;41(21):3948–60

Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. De Lucca GV, et al. **J Med Chem** 1999 Jan 14;42(1):135–52

Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. Bahar I, et al. **J Mol Biol** 1999 Jan 22;285(3):1023–37

Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. Boyer PL, et al. **J Mol Biol** 1999 Mar 5;286(4):995–1008

Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. Ding J, et al. **J Mol Biol** 1998 Dec 11;284(4):1095–111

Compression of the DNA minor groove is responsible for termination of DNA synthesis by HIV-1 reverse transcriptase. Lavigne M, et al. **J Mol Biol** 1999 Jan 22; 285(3):977–95

Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. Rosin CD, et al. **J Mol Biol** 1999 Mar 19;287(1):77–92

The structural stability of the HIV-1 protease. Todd MJ, et al. **J Mol Biol** 1998 Oct 23;283(2):475–88

Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. Pastor M, et al. **J Mol Graph Model** 1997 Dec;15(6):364–71, 389

Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase. Ishikawa T, et al. **J Virol** 1999 May;73(5):4475–80

Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. Kiernan RE, et al. **J Virol** 1998 Dec;72(12):9621–7

Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. Olivares I, et al. **J Virol** 1999 Aug;73(8):6293–8

Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase. Petit C, et al. **J Virol** 1999 Jun;73(6):5079–88

RNase H requirements for the second strand transfer reaction of human immunodeficiency virus type 1 reverse transcription. Smith CM, et al. **J Virol** 1999 Aug; 73(8):6573–81

Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. Zhu K, et al. **J Virol** 1999 Apr;73(4):3309–16

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. Demeter LM, et al. **J Virol Methods** 1998 Nov;75(1):93–104

Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Louis JM, et al. **Nat Struct Biol** 1999 Sep; 6(9):868–75

Activity of recombinant HIV-1 integrase on mini-HIV DNA. Cherepanov P, et al. **Nucleic Acids Res** 1999 May 15;27(10):2202–10

A role for RNA helicase A in post-transcriptional regulation of HIV type 1. Li J, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):709–14

Characterization of a folding intermediate from HIV-1 ribonuclease H. Kern G, et al. **Protein Sci** 1998 Oct; 7(10):2164–74

Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. Eijkelenboom AP, et al. **Proteins** 1999 Sep 1;36(4):556–64

Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Schaffer L, et al. **Proteins** 1998 Nov 1;33(2):295–310

The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease. Todd MJ, et al. **Proteins** 1999 Aug 1;36(2):147–56

Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages. Bossi P, et al. **Res Virol** 1998 Nov-Dec;149(6):355–61

Outsmarting HIV drug resistance [news; comment] Balter M. **Science** 1998 Nov 27;282(5394):1623, 1625. Comment on: Science 1998 Nov 27;282(5394):1669–75.

An open and closed case for all polymerases. Doublié S, et al. **Structure Fold Des** 1999 Feb 15;7(2):R31–5 (22 ref.)

Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase. Kalpana GV, et al. **Virology** 1999 Jul 5;259(2):274–85

Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein. Pluymers W, et al. **Virology** 1999 Jun 5;258(2):327–32

[HIV-1 proteinase mutant with an altered region of the active center] Dergousova NI, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):678–85 **(Rus)**

GENETICS

Detection and treatment of twinning: an improvement and new results. Dumas P, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1179–87

Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Fouchier RA, et al. **Adv Virus Res** 1999;52:275–99 (113 ref.)

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. Delta Coordinating Committee and Delta Virology Committee. **AIDS** 1999 Jan 14;13(1):57–65

Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. Alaeus A, et al. **AIDS** 1999 May 28;13(8):901–7

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. Alexander CS, et al. **AIDS** 1999 May 28;13(8):981–5

Molecular analysis of HIV-1 relatedness in a case of viral transmission during a bloody fight between two adults [letter] Brambilla A, et al. **AIDS** 1998 Oct 1;12(14):1928–30

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. Deeks SG, et al. **AIDS** 1999 Apr 16; 13(6):F35–43

Performance of an ultrasensitive assay to test undetectable viral load specimens using the branched DNA assay [letter] de Mendoza C, et al. **AIDS** 1998 Sep 10;12(13):1727–9

What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective [editorial] Hu DJ, et al. **AIDS** 1999 May 28;13(8):873–81 (120 ref.)

Interpatient genetic variability of HIV-1 group O. Janssens W, et al. **AIDS** 1999 Jan 14;13(1):41–8

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. Keulen W, et al. **AIDS** 1999 Jul 30;13(11):1343–9

Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children. Kim LU, et al. **AIDS** 1999 Apr 16;13(6):645–51

HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad. Liitsola K, et al. **AIDS** 1998 Oct 1;12(14):1907–19

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17–21

Recruitment of the TATA-binding protein to the HIV-1 promoter is a limiting step for Tat transactivation. Majello B, et al. **AIDS** 1998 Oct 22;12(15):1957–64

Use of dried whole blood spots for quantification of HIV-1 RNA [letter] O'Shea S, et al. **AIDS** 1999 Apr 1;13(5):630–1

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. Palmer S, et al. **AIDS** 1999 Apr 16; 13(6):661–7

A stochastic model for primary HIV infection: optimal timing of therapy. Ribeiro RM, et al. **AIDS** 1999 Feb 25; 13(3):351–7

Detection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection. Rich JD, et al. **AIDS** 1998 Dec 3;12(17):2345–50

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, et al. **AIDS** 1999 Feb 25;13(3):359–65

Alleles that may influence HIV-1 pathogenesis in Chinese subjects [letter] Shieh B, et al. **AIDS** 1999 Feb 25; 13(3):421–4

Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study. Simonds RJ, et al. **AIDS** 1998 Aug 20;12(12):1545–9

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. Tamalet C, et al. **AIDS** 1998 Oct 1;12(14):F161–6

V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection [letter] Vallejo A, et al. **AIDS** 1999 Mar 11; 13(4):532–4

Selection of HIV-1 genotypes by cultivation in different primary cells. von Briesen H, et al. **AIDS** 1999 Feb 25; 13(3):307–15

Characterization of the V3 region of HIV type 1 isolates from Morocco. Abid M, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1387–9

HIV type 1 sequences with GGC substitution in injecting drug users in Greece. Adwan G, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):679–80

nef sequences of primary HIV type 1 isolates from northern India. Ahmad KM, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1491–3

Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay. Alaeus A, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):889–94

HIV type 1 subtypes in Malaysia, determined with serologic

assays: 1992–1996. Beyrer C, et al.
AIDS Res Hum Retroviruses 1998 Dec 20;14(18):1687–91
Molecular characterization of the envelope transmembrane glycoprotein of 13 new human immunodeficiency virus type 1 group O strains from six different African countries. Bibollet-Ruche F, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1281–5
HIV type 1 gag D/env G recombinants in Russia. Bobkov A, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20; 14(17):1597–9
Genetic subtyping and V3 serotyping of HIV type 1 isolates in Congo. Candotti D, et al.
AIDS Res Hum Retroviruses 1999 Feb 10;15(3):309–14
HIV type 1 subtypes in Guangxi Province, China, 1996. Chen J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):81–4
HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1–infected individuals. Diaz RS, et al.
AIDS Res Hum Retroviruses 1999 Sep 1;15(13):1151–6
Genetic analysis of human immunodeficiency virus in Abidjan, Ivory Coast reveals predominance of HIV type 1 subtype A and introduction of subtype G. Ellenberger DL, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):3–9
HIV type 1 V3 domain serotyping and genotyping in Gauteng, Mpumalanga, KwaZulu-Natal, and Western Cape Provinces of South Africa. Engelbrecht S, et al.
AIDS Res Hum Retroviruses 1999 Mar 1;15(4):325–8
Effect of insulin-like growth factor I on HIV type 1 long terminal repeat–driven chloramphenicol acetyltransferase expression. Germinario RJ, et al.
AIDS Res Hum Retroviruses 1999 Jun 10;15(9):829–36
Impact of sexual versus parenteral transmission events on the evolution of the gag and env genes of HIV type 1. Goudsmit J, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1483–6
Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission. Hahn T, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):875–88
HIV type 1 C2V3 env diversity among Belgian individuals. Heyndrickx L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1291–6
Genetic characterization of the nef gene from human immunodeficiency virus type 1 group M strains representing genetic subtypes A, B, C, E, F, G, and H. Jubier-Maurin V, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):23–32
Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. Kato K, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1; 15(13):1157–68
Characterization of V3 loop sequences from HIV type 1 subtype B in South Korea: predominance of the GPGS motif. Kim EY, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):681–6
Molecular phylogenetic analysis of human immunodeficiency virus type 1 strains obtained from Korean patients: env gene sequences. Kim YB, et al.
AIDS Res Hum Retroviruses 1999 Feb 10;15(3):303–7
Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. Kundu SK, et al.
AIDS Res Hum Retroviruses 1998 Dec 20;14(18):1669–78
HIV type 1 env subtype E in Cambodia. Kusagawa S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):91–4
Virtually full-length sequences of HIV type 1 subtype J reference strains. Laukkanen T, et al.
AIDS Res Hum Retroviruses 1999 Feb 10;15(3):293–7
Phylogeny of HIV type 1 group O isolates based on env gene sequences. Mas A, et al.
AIDS Res Hum Retroviruses 1999 May 20;15(8):769–73
HIV type 1 genetic variability in the northern part of Cameroon. Mboudjeka I, et al.
AIDS Res Hum Retroviruses 1999 Jul 20;15(11):951–6
Dual transmission of subtype A and D HIV type 1 viruses from a Ugandan woman to her infant. Mellquist JL, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):217–21
Characterization of HIV type 1 gp120 V3 region sequences from Ugandan infants. Mellquist JL, et al.
AIDS Res Hum Retroviruses 1998 Oct 10;14(15):1391–5
Genetic heterogeneity of HIV type 1 subtypes in Kimpese, rural Democratic Republic of Congo. Mokili JL, et al.
AIDS Res Hum Retroviruses 1999 May 1;15(7):655–64
Molecular epidemiological analysis of human immunodeficiency virus type 1 in Newfoundland, Canada. Montpetit ML, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1205–9
DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G. Naghavi MH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):485–8
Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. Nasioulas G, et al. **AIDS Res Hum Retroviruses** 1999 May 20; 15(8):745–58
Analysis of the V3 loop sequences from 12 HIV type 1–infected patients from Colombia, South America. Navas MC, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1141–4
Molecular epidemiology of an HIV-1 subtype A subcluster among injection drug users in the Southern Ukraine. Novitsky VA, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1079–85
Full-length genomic sequence of an HIV type 1 subtype G from Kinshasa. Oelrichs RB, et al.
AIDS Res Hum Retroviruses 1999 Apr 10;15(6):585–9
A novel subtype A/G/J recombinant full-length HIV type 1 genome from Burkina Faso. Oelrichs RB, et al.
AIDS Res Hum Retroviruses 1998 Nov 1;14(16):1495–500
Complete sequence of an infectious molecular clone derived from a Spanish HIV type I isolate. Olivares I, et al.
AIDS Res Hum Retroviruses 1998 Dec 20;14(18):1649–51
Genetic characterization of the V3 loop sequences of 21 HIV type 1 Spanish isolates from hemophilia patients. Ortiz M, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1487–90
Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children. Principi N, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1653–9
Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. Quiñones-Mateu ME, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):73–9
Molecular epidemiology of HIV type 1 isolates from the Czech Republic: identification of an env E subtype case. Quiñones-Mateu ME, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):85–9
Genetic analysis of human immunodeficiency virus type 1 strains in Kenya: a comparison using phylogenetic analysis and a combinatorial melting assay. Robbins KE, et al.
AIDS Res Hum Retroviruses 1999 Mar 1;15(4):329–35
Phylogenetic examination of HIV type 1 glycoprotein 120–V3 sequences in patients from rural Georgia. Roth WW, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1; 15(4):399–403
Genetic characterization of viral quasispecies in blood and cervical secretions of HIV-1– and HIV-2–infected women. Sankalé JL, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1473–81
Analysis of sequence diversity in the C2–V3 regions of the external glycoproteins of HIV type 1 in Singapore. Se-Thoe SY, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1601–4
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, et al.
AIDS Res Hum Retroviruses 1999 Jan 1;15(1):65–9
Independent evolution of HIV type 1 in different brain regions. Shapshak P, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):811–20
Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. van der Groen G, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S211–21 (77 ref.)
A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. Van Harmelen JH, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):395–8
On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. Verhoef K, et al.
AIDS Res Hum Retroviruses 1998 Nov 20;14(17):1553–9
The human immunodeficiency virus type I Tat protein potentiates ethanol-induced neutrophil functional impairment in transgenic mice. Prakash O, et al.
Alcohol Clin Exp Res 1998 Dec;22(9):2043–9
Interactions of HIV-1 TAR RNA with Tat-derived peptides discriminated by on-line acoustic wave detector. Furtado LM, et al. **Anal Chem** 1999 Mar 15;71(6):1167–75
Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Brodine SK, et al. **Ann Intern Med** 1999 Oct 5;131(7):502–6
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Larder BA, et al. **Antimicrob Agents Chemother** 1999 Aug; 43(8):1961–7
Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity. Hammann C, et al.
Antisense Nucleic Acid Drug Dev 1999 Feb;9(1):25–31
Oligonucleotide-mediated inhibition of genomic RNA dimerization of HIV-1 strains MAL and LAI: a comparative analysis. Lodmell JS, et al.
Antisense Nucleic Acid Drug Dev 1998 Dec;8(6):517–29
The antisense sequence of the HIV-1 TAR stem-loop structure covalently linked to the hairpin ribozyme enhances its catalytic activity against two artificial substrates. Pérez-Ruiz M, et al.
Antisense Nucleic Acid Drug Dev 1999 Feb;9(1):33–42
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro. Rübsamen-Waigmann H, et al.
Antiviral Res 1999 May;42(1):15–24
Transient Tat activation of the HIVLAV/Lai-1 LTR by primary HIV-1 phenotypic variants in HeLaT4LTRbeta-gal cells. Nilsen MV, et al. **APMIS** 1999 May;107(5):485–92
Dissolved oxygen concentration affects the accumulation of HIV-1 recombinant proteins in Escherichia coli. Qoronfleh MW. **Appl Biochem Biotechnol** 1999 May;80(2):107–20
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Götte M, et al.
Arch Biochem Biophys 1999 May 15;365(2):199–210 (118 ref.)
Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Rana TM, et al.
Arch Biochem Biophys 1999 May 15;365(2):175–85 (99 ref.)
The human immunodeficiency virus-1 Tat protein increases cell proliferation, alters sensitivity to zinc chelator–induced apoptosis, and changes Sp1 DNA binding in HeLa cells. Seve M, et al. **Arch Biochem Biophys** 1999 Jan 15; 361(2):165–72
Poly (ADP-ribose) polymerase is involved in PMA-induced activation of HIV-1 in U1 cells by modulating the LTR function. Kameoka M, et al.
Biochem Biophys Res Commun 1999 Aug 19;262(1):285–9
A novel mutant loxP containing part of long terminal repeat of HIV-1 in spacer region: presentation of possible target site for antiviral strategy using site-specific recombinase. Lee Y, et al. **Biochem Biophys Res Commun** 1998 Dec 30; 253(3):588–93
Multiple centrosome formation induced by the expression of Vpr gene of human immunodeficiency virus. Minemoto Y, et al. **Biochem Biophys Res Commun** 1999 May 10; 258(2):379–84
Controlling human immunodeficiency virus type 1 gene expression by unnatural peptides. Huq I, et al.
Biochemistry 1999 Apr 20;38(16):5172–7
Variant effects of non-native kissing-loop hairpin palindromes on HIV replication and HIV RNA dimerization: role of stem-loop B in HIV replication and HIV RNA dimerization. Laughrea M, et al.
Biochemistry 1999 Jan 5;38(1):226–34
Characterization of the solution conformations of unbound and Tat peptide-bound forms of HIV-1 TAR RNA. Long KS, et al. **Biochemistry** 1999 Aug 3;38(31):10059–69
Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. Mei HY, et al. **Biochemistry** 1998 Oct 6;37(40):14204–12
Monomer-dimer equilibrium constants of RNA in the dimer initiation site of human immunodeficiency virus type 1. Shubsda MF, et al. **Biochemistry** 1999 Aug 3; 38(31):10147–57
RNA recognition and regulation of HIV-1 gene expression by viral factor Tat. Naryshkin NA, et al.
Biochemistry (Mosc) 1998 May;63(5):489–503 (98 ref.)
Repression of the human immunodeficiency virus type 1 promoter by the human KRAB domain results in inhibition of virus production. Herchenröder O, et al.
Biochim Biophys Acta 1999 May 14;1445(2):216–23
Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Mestre B, et al. **Biochim Biophys Acta** 1999 Apr 14;1445(1):86–98
HIV-1 genotypic resistance: automated sequence analysis and interpretation. Goujon CP, et al. **Bioinformatics** 1998; 14(10):886–7
PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101–4
B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Tähtinen M, et al. **Biomed Pharmacother** 1997;51(10):480–7
Quantitation of mixed-base populations of HIV-1 variants by automated DNA sequencing with BODIPY dye-labeled primers. Metzker ML, et al. **Biotechniques** 1998 Sep; 25(3):446–7, 450–2, 454, passim
Epitope-based assay to determine the efficiency of cleavage by HIV-1 protease. Serio D, et al. **Biotechniques** 1999 Feb; 26(2):242–4, 246
Activation of the human immunodeficiency virus-1 long terminal repeat by respiratory burst oxidants of neutrophils. Klebanoff SJ, et al. **Blood** 1999 Jan 1;93(1):350–6
A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1–infected children. Kohn DB, et al. **Blood** 1999 Jul 1;94(1):368–71
Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Kundu RK, et al. **Blood** 1999 Jul 1; 94(1):275–82
X-rays-induced secretion of cellular factor(s) that enhance(s) HIV-1 promoter transcription in various non-irradiated transfected cell lines. Faure E.
Cell Mol Biol (Noisy-le-grand) 1998 Dec;44(8):1275–92
Dual activity of pyrrolidine dithiocarbamate on kappa B-dependent gene expression in U937 cells: I. Regulation by the phorbol ester TPA. Watanabe K, et al.
Cell Signal 1999 Jul;11(7):479–89
Localization of HTLV-1 and HIV-1 proviral sequences in chromosomes of persistently infected cells. Glukhova LA, et al. **Chromosome Res** 1999;7(3):177–83
CD8+ T cell-mediated enhancement of tumour necrosis factor-alpha (TNF-alpha) production and HIV-1 LTR-driven gene expression in human monocytic cells is pertussis toxin-sensitive. Copeland KF, et al.
Clin Exp Immunol 1999 Jun;116(3):479–85
Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes. Toossi Z, et al.

Clin Exp Immunol 1999 Aug;117(2):324–30

HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Garber ME, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:371–80

Biodiversity and bioseparation of HIV-1 envelope glycoproteins. Shao Y, et al. **Crit Rev Oncog** 1999; 10(1–2):1–16 (50 ref.)

The origins of AIDS. Dixon B. **Curr Biol** 1999 Mar 25; 9(6):R192

HIV-1 Tat: coping with negative elongation factors. Garber ME, et al. **Curr Opin Immunol** 1999 Aug;11(4):460–5 (40 ref.)

HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. Boyer JD, et al. **Dev Biol Stand** 1998;95:147–53

Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. Bryder K, et al. **DNA Cell Biol** 1999 Mar; 18(3):219–25

Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Vandamme AM, et al. **Drugs** 1999 Mar;57(3):337–61 (214 ref.)

High performance DNA sequencing, and the detection of mutations and polymorphisms, on the Clipper sequencer. Yager TD, et al. **Electrophoresis** 1999 Jun;20(6):1280–300

Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. Bieniasz PD, et al. **EMBO J** 1998 Dec 1;17(23):7056–65

hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing. Caputi M, et al. **EMBO J** 1999 Jul 15;18(14):4060–7

Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. Esposito D, et al. **EMBO J** 1998 Oct 1; 17(19):5832–43

Structural basis for the specificity of the initiation of HIV-1 reverse transcription. Isel C, et al. **EMBO J** 1999 Feb 15; 18(4):1038–48

A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-1 transcription. Parada CA, et al. **EMBO J** 1999 Jul 1;18(13):3688–701

Stimulation of Tat-associated kinase-independent transcriptional elongation from the human immunodeficiency virus type-1 long terminal repeat by a cellular enhancer. West MJ, et al. **EMBO J** 1999 Mar 1; 18(5):1378–86

HIV-1 subtype F in single and dual infections in Puerto Rico: A potential sentinel site for monitoring novel genetic HIV variants in North America [letter] Flores I, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):481–3

Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Ramos A, et al. **Emerg Infect Dis** 1999 Jan-Feb;5(1):65–74

Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli – two tags tie it up. Maier G, et al. **Eur J Biochem** 1999 Apr; 261(1):10–8

Human immunodeficiency virus mutation and changes in CD4 T-cell levels during antiretroviral therapy [editorial] Battegay M. **Eur J Clin Microbiol Infect Dis** 1998 May; 17(5):301–3

Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Venturi G, et al. **Eur J Clin Microbiol Infect Dis** 1999 Apr; 18(4):274–82

Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues. Villalba N, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):372–5

Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Chassin D, et al. **Eur J Immunol** 1999 Jan;29(1):196–202

Micronuclei formation and aneuploidy induced by Vpr, an accessory gene of human immunodeficiency virus type 1. Shimura M, et al. **FASEB J** 1999 Apr;13(6):621–37

Binding of oligopyrimidines to the RNA hairpin responsible for the ribosome gag-pol frameshift in HIV-1. Aupeix K, et al. **FEBS Lett** 1999 Apr 23;449(2–3):169–74

Identification and cloning of a novel cellular protein Naf1, Nef-associated factor 1, that increases cell surface CD4 expression. Fukushi M, et al. **FEBS Lett** 1999 Jan 8; 442(1):83–8

Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. Isaguliants MG, et al. **FEBS Lett** 1999 Mar 26; 447(2–3):232–6

Isolation of efficient antivirals: genetic suppressor elements against HIV-1. Dunn SJ, et al. **Gene Ther** 1999 Jan; 6(1):130–7

High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector. Fraisier C, et al. **Gene Ther** 1998 Dec;5(12):1665–76

Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Richardson JH, et al. **Gene Ther** 1998 May;5(5):635–44

The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Garber ME, et al. **Genes Dev** 1998 Nov 15;12(22):3512–27

Population dynamics of HIV-1 inferred from gene sequences. Grassly NC, et al. **Genetics** 1999 Feb;151(2):427–38

Efficient transduction of human lymphocytes and CD34+ cells via human immunodeficiency virus-based gene transfer vectors. Douglas J, et al. **Hum Gene Ther** 1999 Apr 10;10(6):935–45

Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. Ragheb JA, et al. **Hum Gene Ther** 1999 Jan 1;10(1):103–12

HIV-1 DNA vaccines. Fomsgaard A. **Immunol Lett** 1999 Jan;65(1–2):127–31 (36 ref.)

HIV-1 Tat: a polypeptide for all seasons. Rubartelli A, et al. **Immunol Today** 1998 Dec;19(12):543–5 (26 ref.)

Human immunodeficiency virus type-1 transcription: role of the 5'-untranslated leader region (review). Al-Harthi L, et al. **Int J Mol Med** 1998 May;1(5):875–81 (71 ref.)

Enhanced HIV-1 envelope-tumor protection by a recombinant vaccinia virus expressing anchored HIV-1 gp120 lacking gp41. Lie H, et al. **Int J Mol Med** 1999 Apr;3(4):397–400

Host cell-dependent replication of HIV-1 gag MA, CA, and NC mutants are independent of the functions of Vif and Vpu. Shimano R, et al. **Int J Mol Med** 1999 Jan;3(1):91–4

Molecular variants of HIV-1 and their impact on vaccine development. Quinn TC. **Int J STD AIDS** 1998;9 Suppl 1:2

Human immunodeficiency virus and hepatitis B virus infection in pregnancy: diagnostic potential of viral genome detection. Berger A, et al. **Intervirology** 1998;41(4–5):201–7 (38 ref.)

Inhibition of HIV-1 replication by chimeric phosphorothioate oligodeoxynucleotides applied in free solution. Lund OS, et al. **Intervirology** 1998;41(2–3):63–8

Activation of transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat by the vasoactive intestinal peptide (VIP). Gilles A, et al. **Ital J Biochem** 1998 Jun;47(2):101–10

Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients. Chien JW, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):277–80

Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. Al-Harthi L, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1; 21(3):194–202

Increase of HIV-1 subtype A in Central African Republic. Müller-Trutwin MC, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):164–71

Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. Chen YM, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):393–402

Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. Izopet J, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):478–83

Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. Marschner IC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):220–7

Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. Peeters M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):115–21

American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Active transcription of human herpesvirus 8 cellular homologue genes and HIV-1 tat in various forms of Kaposi's sarcoma. Moore AY. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):458–9

The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. Bowles NE, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):857–65

Isolation and initial characterization of GBF, a novel DNA-binding zinc finger protein that binds to the GC-rich binding sites of the HIV-1 promoter. Suzuki T, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):389–95

The transcriptional inhibitors, actinomycin D and alpha-amanitin, activate the HIV-1 promoter and favor phosphorylation of the RNA polymerase II C-terminal domain. Cassé C, et al. **J Biol Chem** 1999 Jun 4; 274(23):16097–106

Identification of limiting steps for efficient trans-activation of HIV-1 promoter by Tat in Saccharomyces cerevisiae. Daviet L, et al. **J Biol Chem** 1998 Oct 23;273(43):28219–28

Prostaglandin E2 Up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways. Dumais N, et al. **J Biol Chem** 1998 Oct 16; 273(42):27306–14

Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells. Monnet C, et al. **J Biol Chem** 1999 Feb 5;274(6):3789–96

Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. Quinto I, et al. **J Biol Chem** 1999 Jun 18; 274(25):17567–72

Overlapping cis sites used for splicing of HIV-1 env/nef and rev mRNAs. Swanson AK, et al. **J Biol Chem** 1998 Dec 18;273(51):34551–7

Real-time kinetics of HIV-1 Rev-Rev response element interactions. Definition of minimal binding sites on RNA and protein and stoichiometric analysis. Van Ryk DI, et al. **J Biol Chem** 1999 Jun 18;274(25):17452–63

The nature of human immunodeficiency virus type 1 strand transfers. Yu H, et al. **J Biol Chem** 1998 Oct 23; 273(43):28384–91

HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. Berkhout B. **J Biomed Sci** 1999 Sep-Oct;6(5):298–305 (59 ref.)

Activation of a cryptic splice donor in human immunodeficiency virus type-1. Borg KT, et al. **J Biomed Sci** 1999 Jan;6(1):45–52

Organization of HIV-1 pol is critical for Pol polyprotein processing. Chang YY, et al. **J Biomed Sci** 1999 Sep-Oct; 6(5):333–41

Purification of RBF-2, a transcription factor with specificity for the most conserved cis-element of naturally occurring HIV-1 LTRs. Estable MC, et al. **J Biomed Sci** 1999 Sep-Oct;6(5):320–32

HIV-1 Rev promotes the nuclear export of unspliced and singly spliced RNAs in a mammalian cell-free export system. Huffman KM, et al. **J Biomed Sci** 1999 May-Jun; 6(3):194–205

Dimer initiation sequence of HIV-1Lai genomic RNA: NMR solution structure of the extended duplex. Girard F, et al. **J Biomol Struct Dyn** 1999 Jun;16(6):1145–57

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Winters MA, et al. **J Clin Invest** 1998 Nov 15;102(10):1769–75

Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. Bossi P, et al. **J Clin Microbiol** 1999 Sep;37(9):2910–2

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target. de Baar MP, et al. **J Clin Microbiol** 1999 Jun;37(6):1813–8

Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. Fischer M, et al. **J Clin Microbiol** 1999 May; 37(5):1260–4

Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays. Ginocchio CC, et al. **J Clin Microbiol** 1999 Apr;37(4):1210–2

Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy. Koch N, et al. **J Clin Microbiol** 1999 May;37(5):1595–7

Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. Martinez-Picado J, et al. **J Clin Microbiol** 1999 Sep;37(9):2943–51

Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Schuurman R, et al. **J Clin Microbiol** 1999 Jul;37(7):2291–6

Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. Vahey M, et al. **J Clin Microbiol** 1999 Aug;37(8):2533–7

Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. Yang C, et al. **J Clin Microbiol** 1999 Aug; 37(8):2581–6

Mutations in the env gene of human immunodeficiency virus type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells. Dumonceaux J, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1975–82

Co-expression of a trans-dominant negative mutant of the human immunodeficiency virus type 1 (HIV-1) Rev protein affects the Rev-dependent splicing pattern and expression of HIV-1 RNAs. Szilvay AM, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1965–74

Manganese cations increase the mutation rate of human immunodeficiency virus type 1 ex vivo. Vartanian JP, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1983–6

Histone-mediated transfer and expression of the HIV-1 tat gene in Jurkat cells. Demirhan I, et al. **J Hum Virol** 1998 Nov-Dec;1(7):430–40

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients. Fontaine E, et al. **J Hum Virol** 1998 Nov-Dec; 1(7):451–6

Gp120 sequence variation in brain and in T-lymphocyte human immunodeficiency virus type 1 primary isolates. Gartner S, et al. **J Hum Virol** 1997 Nov-Dec;1(1):3–18

Transduction of CD34+ cells by a vesicular stomach virus protein G (VSV-G) pseudotyped HIV-1 vector. Stable gene expression in progeny cells, including dendritic cells. Li X, et al. **J Hum Virol** 1998 Jul-Aug;1(5):346–52

Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can

interfere with processing and viral replication. Morin N, et al. **J Hum Virol** 1998 Mar-Apr;1(3):240-7

Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx. Philippon V, et al. **J Hum Virol** 1999 May-Jun;2(3):167-74

Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. Shaheen F, et al. **J Hum Virol** 1999 May-Jun;2(3):154-66

HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study. Visco-Comandini U, et al. **J Hum Virol** 1998 Jul-Aug;1(5):320-7

Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a Mac-1-positive host cell population. Doherty TM, et al. **J Immunol** 1999 Aug 1;163(3):1506-15

Functional gene transfer of HIV DNA by an HIV receptor-independent mechanism. Spetz AL, et al. **J Immunol** 1999 Jul 15;163(2):736-42

A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer. Al-Harthi L, et al. **J Infect Dis** 1998 Nov;178(5):1343-51

Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. Kagnoff MF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S444-7 (11 ref.)

Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. Kully C, et al. **J Infect Dis** 1999 Mar;179(3):705-8

Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1 [published erratum appears in J Infect Dis 1999 Apr;179(4):1053] Menu E, et al. **J Infect Dis** 1999 Jan;179(1):44-51

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Miller MD, et al. **J Infect Dis** 1999 Jan;179(1):92-100

Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations [letter] Monno L, et al. **J Infect Dis** 1999 Aug;180(2):568-71

Genotypic resistance and the treatment of HIV-1 infection in Espirito Santo, Brazil. Pilcher CD, et al. **J Infect Dis** 1999 May;179(5):1259-63

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Schapiro JM, et al. **J Infect Dis** 1999 Jan;179(1):249-53

Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. van Rij RP, et al. **J Infect Dis** 1998 Dec;178(6):1806-11

Diversification of subtype E human immunodeficiency virus type 1 env in heterosexual seroconverters from Northern Thailand. Wang Z, et al. **J Infect Dis** 1998 Nov; 178(5):1507-11

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Young B, et al. **J Infect Dis** 1998 Nov; 178(5):1497-501

Chimeric SHIV that causes CD4+ T cell loss and AIDS in rhesus macaques. Joag SV, et al. **J Med Primatol** 1998 Apr-Jun;27(2-3):59-64

Molecular genotyping of HIV-1 in 61 patients with AIDS from Lomé, Togo. Davies FJ, et al. **J Med Virol** 1999 Jan; 57(1):25-30

Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. Müller-Breitkreutz K, et al. **J Med Virol** 1998 Nov; 56(3):239-45

Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle. Bouillé P, et al. **J Mol Biol** 1999 Jan 22;285(3):945-54

Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins. Cherry E, et al. **J Mol Biol** 1998 Nov 20;284(1):43-56

Exploring three-dimensional structures of the HIV-1 RNA/tRNALys3 initiation complex. Elgavish T, et al. **J Mol Biol** 1999 Jan 15;285(2):449-53

Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. Forget J, et al. **J Mol Biol** 1998 Dec 11;284(4):915-23

Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation. Ivanov D, et al. **J Mol Biol** 1999 Apr 23;288(1):41-56

Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. Kwak YT, et al. **J Mol Biol** 1999 Apr 23;288(1):57-69

Synergistic stimulation of HIV-1 rev-dependent export of unspliced mRNA to the cytoplasm by hnRNP A1. Najera I, et al. **J Mol Biol** 1999 Feb 5;285(5):1951-64

Three-dimensional folding of an RNA hairpin required for packaging HIV-1. Pappalardo L, et al. **J Mol Biol** 1998 Oct 2;282(4):801-18

Virtues of being faithful: can we limit the genetic variation in human immunodeficiency virus? Drosopoulos WC, et al. **J Mol Med** 1998 Aug;76(9):604-12 (83 ref.)

Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef. Ambrosini E, et al. **J Neurosci Res** 1999 Mar 1; 55(5):569-77

Replication of different clones of human immunodeficiency virus type 1 in primary fetal human astrocytes: enhancement of viral gene expression by Nef. Bencheikh M, et al. **J Neurovirol** 1999 Apr;5(2):115-24

Brain-derived HIV-1 tat sequences from AIDS patients with dementia show increased molecular heterogeneity. Bratanich AC, et al. **J Neurovirol** 1998 Aug;4(4):387-93

Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir. Byrn RA, et al. **J Reprod Immunol** 1998 Dec;41(1-2):161-76

Expression of human immunodeficiency virus long terminal repeat-coupled genes in early cleaving embryos. Kiessling AA. **J Reprod Immunol** 1998 Dec;41(1-2):95-104

Use of PCR to measure HIV viral changes in drug-resistant genes in genital fluids. Merigan TC. **J Reprod Immunol** 1998 Dec;41(1-2):177-85

Natural endogenous reverse transcription of HIV-1. Zhang H, et al. **J Reprod Immunol** 1998 Dec;41(1-2):255-60 (11 ref.)

Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. Bagnarelli P, et al. **J Virol** 1999 May;73(5):3764-77

Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. Berkhout B, et al. **J Virol** 1999 Feb;73(2):1138-45

Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. Browning CM, et al. **J Virol** 1999 Jun;73(6):5191-5

Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. Carteau S, et al. **J Virol** 1999 Aug;73(8):6670-9

The role of Pr55(gag) in the annealing of tRNA3Lys to human immunodeficiency virus type 1 genomic RNA. Cen S, et al. **J Virol** 1999 May;73(5):4485-8

Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. Chen M, et al. **J Virol** 1999 Apr;73(4):3236-45

Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1. Clever JL, et al. **J Virol** 1999 Jan;73(1):101-9

Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. Cui Y, et al. **J Virol** 1999 Jul;73(7):6171-6

A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection. Das AT, et al. **J Virol** 1999 Jan;73(1):81-91

The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle. Das AT, et al. **J Virol** 1998 Nov;72(11):9217-23

Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. de la Carrière LC, et al. **J Virol** 1999 Apr;73(4):3455-9

A third-generation lentivirus vector with a conditional packaging system. Dull T, et al. **J Virol** 1998 Nov; 72(11):8463-71

An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). Gao F, et al. **J Virol** 1998 Dec;72(12):10234-41

Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. Gasmi M, et al. **J Virol** 1999 Mar;73(3):1828-34

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. Grovit-Ferbas K, et al. **J Virol** 1998 Nov;72(11):8650-8

Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. Gummuluru S, et al. **J Virol** 1999 Jul;73(7):5422-30

Genetic analysis of a unique human immunodeficiency virus type 1 (HIV-1) with a primer binding site complementary to tRNAMet supports a role for U5-PBS stem-loop RNA structures in initiation of HIV-1 reverse transcription. Kang SM, et al. **J Virol** 1999 Mar;73(3):1818-27

Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients. Karlsson AC, et al. **J Virol** 1999 Jul;73(7):6191-6

Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. Kiernan RE, et al. **J Virol** 1998 Dec;72(12):9621-7

Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. Kirchhoff F, et al. **J Virol** 1999 Jul;73(7):5497-508

The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. Kirchhoff F, et al. **J Virol** 1999 Oct;73(10):8371-83

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943-51

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Lole KS, et al. **J Virol** 1999 Jan;73(1):152-60

High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. Mochizuki H, et al. **J Virol** 1998 Nov;72(11):8873-83

Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. Morris A, et al. **J Virol** 1999 Oct; 73(10):8720-31

Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. Mwaengo DM, et al. **J Virol** 1998 Nov;72(11):8976-87

Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. Neilson JR, et al. **J Virol** 1999 May;73(5):4393-403

Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. Novitsky VA, et al. **J Virol** 1999 May;73(5):4427-32

Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. Pasquier C, et al. **J Virol** 1998 Nov;72(11):8493-501

Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. Peeters M, et al. **J Virol** 1999 Sep;73(9):7368-75

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. Ping LH, et al. **J Virol** 1999 Aug;73(8):6271-81

Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. Poss M, et al. **J Virol** 1999 Jul;73(7):5255-64

Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. Power C, et al. **J Virol** 1998 Nov;72(11):9045-53

Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. Quiñones-Mateu ME, et al. **J Virol** 1998 Nov;72(11):9002-15

Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA. Rong L, et al. **J Virol** 1998 Nov; 72(11):9353-8

Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. Rouzine IM, et al. **J Virol** 1999 Oct;73(10):8167-78

Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. Sato H, et al. **J Virol** 1999 May;73(5):3551-9

Control of human immunodeficiency virus type 1 RNA metabolism: role of splice sites and intron sequences in unspliced viral RNA subcellular distribution. Séguin B, et al. **J Virol** 1998 Dec;72(12):9503-13

Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. Shafer RW, et al. **J Virol** 1999 Jul;73(7):6197-202

Mutational analysis of the human immunodeficiency virus type 1 Vif protein. Simon JH, et al. **J Virol** 1999 Apr; 73(4):2675-81

Polyvalent Rev decoys act as artificial Rev-responsive elements. Symensma TL, et al. **J Virol** 1999 May; 73(5):4341-9

Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon. Takehisa J, et al. **J Virol** 1999 Aug;73(8):6810-20

Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. Ulich C, et al. **J Virol** 1999 Mar;73(3):2499-508

Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site. Verhoef K, et al. **J Virol** 1999 Feb;73(2):1331-40

Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. Welker R, et al. **J Virol** 1998 Nov;72(11):8833-40

Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. Weng Y, et al. **J Virol** 1998 Dec; 72(12):9676-82

Lentivirus vectors using human and simian immunodeficiency virus elements. White SM, et al. **J Virol** 1999 Apr;73(4):2832-40

Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems. Wu T, et al. **J Virol** 1999 Jun;73(6):4794-805

Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions

with the nucleoprotein reverse transcription complex. Wu X, et al. **J Virol** 1999 Mar;73(3):2126–35
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. Yuste E, et al. **J Virol** 1999 Apr;73(4):2745–51
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. Zufferey R, et al. **J Virol** 1998 Dec; 72(12):9873–80
Minimizing DNA recombination during long RT-PCR. Fang G, et al. **J Virol Methods** 1998 Dec;76(1–2):139–48
Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. Koch N, et al. **J Virol Methods** 1999 Jun; 80(1):25–31
HIV-1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22–29; 282(12):1135–41. Comment in: JAMA 1999 Sep 22–29;282(12):1177–9.
Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures [letter] Tack PC, et al. **JAMA** 1999 Mar 24–31; 281(12):1085–6
Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease. Liu XH, et al. **Kidney Int** 1999 Feb; 55(2):554–61
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [see comments] Durant J, et al. **Lancet** 1999 Jun 26;353(9171):2195–9. Comment in: Lancet 1999 Jun 26;353(9171):2173–4.
Time to genotype for selection of antiretroviral regimens in previously treated patients? [comment] Falloon J. **Lancet** 1999 Jun 26;353(9171):2173–4. Comment on: Lancet 1999 Jun 26;353(9171):2195–9.
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Foudraine NA, et al. **Lancet** 1998 May 23; 351(9115):1547–51
Effect of mutations in NC7 on endogenous reverse transcription in HIV-1. Hsu M, et al. **Leukemia** 1999 Apr; 13 Suppl 1:S113–5
Regulation of gene expression by HTLV-I Tax protein. Bex F, et al. **Methods** 1998 Sep;16(1):83–94 (174 ref.)
Significance of plasma and peripheral blood mononuclear cell derived HIV-1 sequences in establishing epidemiologic linkage between two individuals multiply exposed to HIV-1. Song JZ, et al. **Microb Pathog** 1999 Jun; 26(6):287–98
Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. Crandall KA, et al. **Mol Biol Evol** 1999 Mar;16(3):372–82
Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). da Silva J, et al. **Mol Biol Evol** 1998 Oct; 15(10):1259–68
Changes in ds/dn in the HIV-1 env gene [letter] Nielsen R. **Mol Biol Evol** 1999 May;16(5):711–4
The mid-depth method and HIV-1: a practical approach for testing hypotheses of viral epidemic history. Pybus OG, et al. **Mol Biol Evol** 1999 Jul;16(7):953–9
Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Bieniasz PD, et al. **Mol Cell Biol** 1999 Jul;19(7):4592–9
Tat activates human immunodeficiency virus type 1 transcriptional elongation independent of TFIIH kinase. Chen D, et al. **Mol Cell Biol** 1999 Apr;19(4):2863–71
Reciprocal modulatory interaction between human immunodeficiency virus type 1 Tat and transcription factor NFAT1. Macián F, et al. **Mol Cell Biol** 1999 May; 19(5):3645–53
Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. Suñé C, et al. **Mol Cell Biol** 1999 Jul;19(7):4719–28
Direct quantitation of HIV by flow cytometry using branched DNA signal amplification. Van Cleve M, et al. **Mol Cell Probes** 1998 Aug;12(4):243–7
Naturally attenuated HIV--lessons for AIDS vaccines and treatment [editorial; comment] Collins KL, et al. **N Engl J Med** 1999 Jun 3;340(22):1756–7. Comment on: N Engl J Med 1999 Jun 3;340(22):1715–22.
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1 [letter] Greenough TC, et al. **N Engl J Med** 1999 Jan 21;340(3):236–7
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort [see comments] Learmont JC, et al. **N Engl J Med** 1999 Jun 3;340(22):1715–22. Comment in: N Engl J Med 1999 Jun 3;340(22):1756–7.
PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Fang G, et al. **Nat Med** 1999 Feb;5(2):239–42
HIV-1 A-rich RNA loop mimics the tRNA anticodon structure. Puglisi EV, et al. **Nat Struct Biol** 1998 Dec; 5(12):1033–6
HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV-induced neurological disease. Mayne M, et al. **Neuroimmunomodulation** 1998 May-Aug; 5(3–4):184–92
An abnormally long HIV-1 env DNA PCR product due to altered sequences of primer binding sites. Boriskin YS, et al. **New Microbiol** 1999 Jan;22(1):59–62
ZFX transactivation of the HIV-1 LTR is cell specific and depends on core enhancer and TATA box sequences. Gazin C. **Nucleic Acids Res** 1999 May 15;27(10):2156–64
The mechanism of actinomycin D-mediated inhibition of HIV-1 reverse transcription. Jeeninga RE, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5472–9
The ability of the HIV-1 AAUAAA signal to bind polyadenylation factors is controlled by local RNA structure. Klasens BI, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):446–54
FBI-1, a factor that binds to the HIV-1 inducer of short transcripts (IST), is a POZ domain protein. Morrison DJ, et al. **Nucleic Acids Res** 1999 Mar 1;27(5):1251–62
Synthesis of oligonucleotide-intercalator conjugates capable to inhibit HIV-1 DNA integration. Gottikh MB, et al. **Nucleosides Nucleotides** 1999 Jun-Jul;18(6–7):1645–6
Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Bieniasz PD, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7791–6
The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Chen H, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15270–4
Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands [see comments] Dickinson LA, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12890–5. Comment in: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12739–41.
Association of HIV-1 Tat with the cellular protein, Puralpha, is mediated by RNA. Gallia GL, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11572–7
The molecular clock of HIV-1 unveiled through analysis of a known transmission history [see comments] Leitner T, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14; 96(19):10752–7. Comment in: Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10559–61.
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Loeb LA, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1492–7
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Markham RB, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12568–73
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Nijhuis M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14441–6
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Penn ML, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19; 96(2):663–8
Purified histone acetyltransferase complexes stimulate HIV-1 transcription from preassembled nucleosomal arrays. Steger DJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27; 95(22):12924–9
Chemicals that footprint DNA: hitting HIV-1 in the minor groove [comment]] Tutter A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12739–41 (26 ref.). Comment on: Proc Natl Acad Sci U S A 1998 Oct 27;95(22):12890–5.
Effect of promoters and signal sequences on the production of secreted HIV-1 gp120 protein in the baculovirus system. Golden A, et al. **Protein Expr Purif** 1998 Oct;14(1):8–12
Expression and purification of HIV-I p15NC protein in Escherichia coli. Ozturk DH, et al. **Protein Expr Purif** 1998 Oct;14(1):54–64
Dimerization of HIV-1 genomic RNA of subtypes A and B: RNA loop structure and magnesium binding. Jossinet F, et al. **RNA** 1999 Sep;5(9):1222–34
The use of polymerase chain reaction in plasma pools for the concomitant detection of hepatitis C virus and HIV type 1 RNA. Yerly S, et al. **Transfusion** 1998 Oct; 38(10):908–14
Selection of drug-resistant HIV [published erratum appears in trends Microbiol 1999 Jul;7(7):302] Harrigan PR, et al. **Trends Microbiol** 1999 Mar;7(3):120–3 (32 ref.)
Construction of attenuated HIV-1 accessory gene immunization cassettes. Ayyavoo V, et al. **Vaccine** 1998 Nov;16(19):1872–9
Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. Bagarazzi ML, et al. **Vaccine** 1998 Nov; 16(19):1836–41
Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Lundholm P, et al. **Vaccine** 1999 Apr 9;17(15–16):2036–42
DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Ugen KE, et al. **Vaccine** 1998 Nov;16(19):1818–21
IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Xin KQ, et al. **Vaccine** 1999 Feb 26;17(7–8):858–66
Limitation of Tat-associated transcriptional processivity in HIV-infected PBMC. Adams M, et al. **Virology** 1999 May 10;257(2):397–405
Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. Andersson S, et al. **Virology** 1999 Sep 30;262(2):312–20
The native structure of the human immunodeficiency virus type 1 RNA genome is required for the first strand transfer of reverse transcription. Berkhout B, et al. **Virology** 1998 Sep 30;249(2):211–8
Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Brambilla A, et al. **Virology** 1999 Jul 5;259(2):349–68
Effect of Rev on the intranuclear localization of HIV-1 unspliced RNA. Favaro JP, et al. **Virology** 1998 Sep 30; 249(2):286–96
Effect of rev on the cytoplasmic localization of intron-containing human immunodeficiency virus type 1 RNA. Favaro JP, et al. **Virology** 1999 Mar 15;255(2):237–49
Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. Günthard HF, et al. **Virology** 1999 Jun 20;259(1):154–65
Identification of a human immunodeficiency virus type 1 that stably uses tRNALys1,2 rather than tRNALys,3 for initiation of reverse transcription. Kang SM, et al. **Virology** 1999 Apr 25;257(1):95–105
A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions. Kulkosky J, et al. **Virology** 1999 Mar 1;255(1):77–85
Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex. Liu Y, et al. **Virology** 1999 Mar 15;255(2):337–46
Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. McCutchan FE, et al. **Virology** 1999 Feb 15; 254(2):226–34
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Martinez MA, et al. **Virology** 1999 Apr 10;256(2):180–7
Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques. Narayan SV, et al. **Virology** 1999 Mar 30;256(1):54–63
High diversity of HIV-1 subtype F strains in Central Africa. Triques K, et al. **Virology** 1999 Jun 20;259(1):99–109
Complementarity between 3' terminal nucleotides of tRNA and primer binding site is a major determinant for selection of the tRNA primer used for initiation of HIV-1 reverse transcription. Yu Q, et al. **Virology** 1999 Feb 1;254(1):160–8
Identification of a functionally important amino acid residue near to the amino-terminus of the human immunodeficiency virus type 1 Vif protein. Boyce M, et al. **Virus Genes** 1999;19(1):15–22
Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses. Iida S, et al. **Virus Genes** 1999;18(2):183–7
Mutational analysis of human immunodeficiency virus type 1 vif gene. Sakai K, et al. **Virus Genes** 1999;18(2):179–81
LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Quiñones-Mateu ME, et al. **Virus Res** 1998 Sep;57(1):11–20
HIV-1 subtype B in Honduras. Renjifo B, et al. **Virus Res** 1999 Apr;60(2):191–7
Growth properties of HSIVnef: HIV-1 containing the nef gene from pathogenic molecular clone SIVmac239. Yoon K, et al. **Virus Res** 1998 Sep;57(1):27–34
[Subtype and sequence analysis of the C2-V3 region of gp120 genes among HIV-1 strains in Hubei province] Li YW, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug;18(4):217–9 (Eng. Abstr.) **(Chi)**
[Subtype and sequence analysis of the C2-V3 region of gp120 genes among HIV-1 strains in Sichuan province] Qin G, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):39–42 (Eng. Abstr.) **(Chi)**
[Sequence analysis on HIV1 env V3 rigion from HIV1 infected intravenous drug users in Ruili city, Yunnan] Wang B, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct;19(5):297–300 (Eng. Abstr.) **(Chi)**
[Genetic subtyping of HIV-1 strains by heteroduplex mobility assay] Yu H, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Aug; 18(4):201–4 (Eng. Abstr.) **(Chi)**
[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor] Mouroux M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):549–52 (Eng. Abstr.) **(Fre)**
[Genetic variability in the pathogenesis of HIV infection (news)] **Recenti Prog Med** 1999 May;90(5):298–9 **(Ita)**
[Evaluation of a PCR assay commercial kit for quantification of human immunodeficiency virus type-1 RNA] Kawata K, et al. **Kansenshogaku Zasshi** 1998 Oct;72(10):1041–5 (Eng. Abstr.) **(Jpn)**
[Recombinant human immunodeficiency viruses] Bobkov AF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):45–7 (Eng. Abstr.) **(Rus)**
[The molecular epidemiological characteristics of the HIV-1 variants circulating among injection drug addicts on the territory of the CIS Nations] Karamov EV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):39–41 (Eng. Abstr.) **(Rus)**
[The use of a method for the quantitative determination of HIV-1 RNA for assessing the severity and prognosis of the development of the disease] Smol'skaia TT, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):57–9 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

HIV-1 infectivity and host range modification by cathepsin

D present in human vaginal secretions. El Messaoudi K, et al. **AIDS** 1999 Feb 25;13(3):333–9

Selection of HIV-1 genotypes by cultivation in different primary cells. von Briesen H, et al. **AIDS** 1999 Feb 25; 13(3):307–15

HIV-1: fifteen proteins and an RNA. Frankel AD, et al. **Annu Rev Biochem** 1998;67:1–25 (134 ref.)

Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. Bermejo M, et al. **Eur J Immunol** 1998 Oct; 28(10):3192–204

Antioxidant defenses influence HIV-1 replication and associated cytopathic effects. Sandstrom PA, et al. **Free Radic Biol Med** 1998 Jun;24(9):1485–91

HIV-1 reactivation in resting peripheral blood mononuclear cells of infected adults upon in vitro CD4 cross-linking by ligands of the CDR2-loop in extracellular domain 1. Briant L, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):9–19

HIV-1 dynamics in children. Melvin AJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):468–73

T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis. Iyengar S, et al. **J Immunol** 1999 May 15;162(10):6263–7

The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. McKinney DM, et al. **J Immunol** 1999 Jul 15;163(2):861–7

Signaling through the lymphotoxin-beta receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF-alpha. Marshall WL, et al. **J Immunol** 1999 May 15;162(10):6016–23

USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. Moriuchi M, et al. **J Immunol** 1999 May 15; 162(10):5986–92

A novel factor produced by placental cells with activity against HIV-1. Sharma UK, et al. **J Immunol** 1998 Dec 1;161(11):6406–12

Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. Orendi JM, et al. **J Infect Dis** 1998 Nov;178(5):1279–87

The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. Borsetti A, et al. **J Virol** 1998 Nov;72(11):9313–7

The 5' and 3' TAR elements of human immunodeficiency virus exert effects at several points in the virus life cycle. Das AT, et al. **J Virol** 1998 Nov;72(11):9217–23

Human immunodeficiency virus type 1 Vpr modifies cell proliferation via multiple pathways. Yamaguchi T, et al. **Microbiol Immunol** 1999;43(5):437–47

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [see comments] Finzi D, et al. **Nat Med** 1999 May;5(5):512–7. Comment in: Nat Med 1999 Jun;5(6):609–11.

Inhibition of human immunodeficiency virus 1 (HIV-1) by variant B of human herpesvirus 6 (HHV-6). Bonura F, et al. **New Microbiol** 1999 Jul;22(3):161–71

A comparison of immunocomplex-dissociated serum HIV-1 p24 antigenemia and plasma HIV-1 viral load: assessment of 3,129 paired assays. Manfredi R, et al. **New Microbiol** 1999 Jul;22(3):269–75

Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes. Ibrahim J, et al. **Virus Res** 1999 Apr;60(2):159–69

[The HTHIV27 highly productive continuous cell line and its use for solving the fundamental and applied problems of HIV infection] Miller GG, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb;(1):52–7 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Delayed HIV-1 seroconversion after antiretroviral therapy [letter] Apetrei C, et al. **AIDS** 1998 Oct 1;12(14):1935–6

Compartmentalization of the IgG immune response to HIV-1 in breast milk. Becquart P, et al. **AIDS** 1999 Jul 30; 13(11):1323–31

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. Belshe RB, et al. **AIDS** 1998 Dec 24; 12(18):2407–15

Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. Birk M, et al. **AIDS** 1998 Oct 22; 12(15):1973–81

Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study. Cone RW, et al. **AIDS** 1998 Dec 3; 12(17):2253–60

Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing [letter] Diaz RS, et al. **AIDS** 1999 Jul 30;13(11):1417–8

Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. Foudraine NA, et al. **AIDS** 1999 Feb 4;13(2):177–84

HLA-A*1101-restricted cytotoxic T lymphocyte recognition of HIV-1 Pol protein [letter] Fukada K, et al. **AIDS** 1999 Jul 30;13(11):1413–4

Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy [letter] Galli M, et al. **AIDS** 1998 Dec 24;12(18):2500–2

Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. Grassi F, et al. **AIDS** 1999 May 7;13(7):759–66

Identification of a novel HLA-A24-restricted cytotoxic T-lymphocyte epitope derived from HIV-1 Gag protein [letter] Ikeda-Moore Y, et al. **AIDS** 1998 Oct 22; 12(15):2073–4

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Kaul R, et al. **AIDS** 1999 Jan 14; 13(1):23–9

CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS. Kvale D, et al. **AIDS** 1999 Feb 4;13(2):195–201

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Larsson M, et al. **AIDS** 1999 May 7;13(7):767–77

Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Mofenson LM, et al. **AIDS** 1999 Jan 14;13(1):31–9

Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. Norrgren H, et al. **AIDS** 1999 Apr 16;13(6):701–7

Four novel cytotoxic T-lymphocyte epitopes in the highly conserved major homology region of HIV-1 Gag, restricted through B*4402, B*1801, A*2601, B*70 (B*1509) [letter] Ogg GS, et al. **AIDS** 1998 Aug 20;12(12):1561–3

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. Pakker NG, et al. **AIDS** 1999 Feb 4;13(2):203–12

Distinct recognition of closely-related HIV-1 and HIV-2 cytotoxic T-cell epitopes presented by HLA-B*2703 and B*2705 [letter] Rowland-Jones S, et al. **AIDS** 1998 Jul 30; 12(11):1391–3

Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS, et al. **AIDS** 1999 Jan 14;13(1):89–96

Cytotoxic T lymphocyte recognition of HLA-B*5101-restricted HIV-1 Rev epitope which is naturally processed in HIV-1-infected cells [letter] Tomiyama H, et al. **AIDS** 1999 May 7;13(7):861–3

Natural immunity and HIV disease progression. Ullum H, et al. **AIDS** 1999 Apr 1;13(5):557–63

Lack of protection against HIV-1 infection among women with HIV-2 infection. Wiktor SZ, et al. **AIDS** 1999 Apr 16;13(6):695–9

An investigation of the effects of HIV on the sex lives of infected individuals. Cranson DA, et al. **AIDS Educ Prev** 1998 Dec;10(6):506–22

Maintenance of safe sex behavior by HIV-serodiscordant heterosexual couples. Skurnick JH, et al. **AIDS Educ Prev** 1998 Dec;10(6):493–505

C1 inhibitor function and anti-C1 inhibitor autoantibodies in patients with HIV type 1 infection [letter; comment] Beretta A, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):95–6. Comment on: AIDS Res Hum Retroviruses 1997 Jul 1;13(10):813–4.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. Betts MR, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1219–28

Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. Brand D, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1369–77

Immune clearance of HIV type 1 replication-active cells: a model of two patterns of steady state HIV infection. Bucy RP. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):223–7

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. Cavacini LA, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1271–80

Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. Challita-Eid PM, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1617–24

Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. Cox JH, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):847–54

Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. Foresman L, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10; 14(12):1035–43

HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced beta-chemokine production. Fowke KR, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20; 14(17):1521–30

Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. Gilljam G, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1; 15(10):899–907

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. Gorse GJ, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):921–30

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Gorse GJ, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):115–32

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. Haslett PA, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1169–79

Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection. Hengel RL, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):435–43

Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. Hioe CE, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):523–31

Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments. Ho WZ, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20; 14(17):1573–80

Accumulation of specific amino acid substitutions in HLA-B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes. Kawana A, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1099–107

The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes. Koopman G, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):365–73

Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype. McNicholl JM, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1457–71

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. Montefiori DC, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):689–98

Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. Oggioni MR, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):451–9

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. Quinnan GV Jr, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):561–70

Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. Rinaldo CR Jr, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1423–33

Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals. Rusconi S, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10;14(15):1341–3

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. Salmon-Céron D, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):633–45

Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120. Schønning K, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1451–6

HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice. Scott DE, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1263–9

Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. Spruth M, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):533–43

Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies. Toriyoshi H, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1109–20

The presence and absence of histocompatibility antigens in HIV type 1 produced by autologous blood-derived macrophages and peripheral blood lymphoblasts. Tsai WP, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):33–41

Partial resistance to infection by R5X4 primary HIV type 1 isolates in an exposed-uninfected individual homozygous for CCR5 32-base pair deletion. Xiao L, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1201–8

Failure of SIVmac to be neutralized in macrophage cultures

is unique to SIVmac and not observed with neutralization of SHIV or HIV-1. Zhuge W, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1045-51

Transgenic mouse model of ethanol as a cofactor in HIV disease. Prakash O, et al. **Alcohol Clin Exp Res** 1998 Aug; 22(5 Suppl):266S-268S (39 ref.)

The search for a potent DNA vaccine against AIDS: the enhancement of immunogenicity by chemical and genetic adjuvants. Sasaki S, et al. **Anticancer Res** 1998 Sep-Oct; 18(5D):3907-15 (77 ref.)

Cartesian coordinate analysis of viral burden and CD4+ T-cell count in human immunodeficiency virus type-1 infection. Reichelderfer PS, et al. **Antiviral Res** 1998 Jun; 38(3):181-94

Selective alterations of the antibody response to HIV-1. Juompan L, et al. **Appl Biochem Biotechnol** 1998 Oct; 75(1):139-50 (81 ref.)

Recombinant vaccinia viruses expressing an immunodominant epitope of HIV-1 envelope protein within an influenza hemagglutinin cassette predominantly prime epitope-specific CD8(+) CTL. Chiba M, et al. **Arch Virol** 1999;144(8):1469-85

The association of skin diseases with human herpesvirus 8 infection in HIV carriers. Na Ayuthaya PI, et al. **Arch Virol** 1998;143(10):1881-92

DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Asakura Y, et al. **Biol Chem** 1999 Mar; 380(3):375-9

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY, et al. **Biol Chem** 1999 Mar; 380(3):353-64

Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F, et al. **Biol Chem** 1999 Mar;380(3):341-52

A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1. Zhang A, et al. **Biol Chem** 1999 Mar; 380(3):365-74

Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder. Hart DJ, et al. **Biol Psychiatry** 1999 Mar 15;45(6):704-14

Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity. Persson RH, et al. **Biologicals** 1998 Dec;26(4):255-65

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Gilbert PB, et al. **Biometrics** 1998 Sep;54(3):799-814

A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Deng X, et al. **Blood** 1999 Aug 15;94(4):1165-73

Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Lee B, et al. **Blood** 1999 Feb 15;93(4):1145-56

Homeopathy in HIV infection: a trial report of double-blind placebo controlled study. Rastogi DP, et al. **Br Homeopath J** 1999 Apr;88(2):49-57

HIV infection of placental macrophages: effect on the secretion of HIV stimulatory cytokines. Plaud-Valentin M, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Jun;45(4):423-31

A simple saliva-based test for detecting antibodies to human immunodeficiency virus. Schramm W, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):577-80

Immunohematological reference ranges for adult Ethiopians. Tsegaye A, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):410-4

Heterophile antibodies to bovine and caprine proteins causing false-positive human immunodeficiency virus type 1 and other enzyme-linked immunosorbent assay results. Willman JH, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):615-6

Viral load and CD69 molecule expression on freshly isolated and cultured mitogen-stimulated lymphocytes of children with perinatal HIV-1 infection. De Martino M, et al. **Clin Exp Immunol** 1999 Sep;117(3):513-6

Alterations in blood leucocyte adhesion molecule profiles in HIV-1 infection. Hayes PJ, et al. **Clin Exp Immunol** 1999 Aug;117(2):331-4

Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Lu Y, et al. **Clin Exp Immunol** 1999 Feb;115(2):335-41

Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Medrano FJ, et al. **Clin Exp Immunol** 1998 Dec;114(3):403-7

Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides. Müller H, et al. **Clin Exp Immunol** 1999 Jul;117(1):76-83

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Boyer JD, et al. **Clin Immunol** 1999 Jan;90(1):100-7

Antibody-dependent cell-mediated cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Hildreth JEK, et al. **Clin Immunol** 1999 Feb;90(2):203-12

Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Patterson BK, et al. **Clin Immunol** 1999 Jun;91(3):254-62

Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Xin KQ, et al. **Clin Immunol** 1999 Jul;92(1):90-6

T lymphocyte responses in HIV-1 infection: implications for vaccine development. Brander C, et al. **Curr Opin Immunol** 1999 Aug;11(4):451-9 (106 ref.)

Cross-clade T cell recognition of HIV.1. Gotch F. **Curr Opin Immunol** 1998 Aug;10(4):388-92 (34 ref.)

HIV pathogenesis: mechanisms of susceptibility and disease progression. Simonsen JN, et al. **Curr Opin Microbiol** 1998 Aug;1(4):423-9 (70 ref.)

Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects. Cameron PU, et al. **Cytometry** 1998 Sep 1;33(1):83-8

HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response. Boyer JD, et al. **Dev Biol Stand** 1998;95:147-53

Determination of T-lymphocyte subsets in a north African population (Tunisia): establishment of normal ranges and results in HIV-infected individuals. Feki S, et al. **Dis Markers** 1998 Nov;14(3):161-4

Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine. Desai KN, et al. **Epidemiol Infect** 1999 Aug;123(1):65-88

Isolation and identification of naturally modified C-C chemokines MCP-1, MCP-2 and RANTES: effects of posttranslational modifications on receptor usage, chemotactic and anti-HIV-1 activity. Proost P, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):73-5 (17 ref.)

Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry. Millar AL, et al. **Eur J Biochem** 1998 Nov 15;258(1):164-9

Evidence for a role of T-helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium-inducing phenotype. Torres Y, et al. **Eur J Clin Invest** 1998 Nov;28(11):930-6

Antiphosphatidylserine antibodies in HIV-1+ patients bind apoptotic T cells in vitro. Cafforio P, et al. **Eur J Histochem** 1997;41 Suppl 2:65-6

Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Chassin D, et al. **Eur J Immunol** 1999 Jan;29(1):196-202

Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients. Dalod M, et al. **Eur J Immunol** 1999 Jan; 29(1):38-44

Antagonistic activity of HIV-1 T helper peptides flanked by an unrelated carrier protein. Fenoglio D, et al. **Eur J Immunol** 1999 May;29(5):1448-55

Dendritic cells from HIV-1-infected patients naturally express HIV-1 gp120 V3 loop-derived peptide ligands. Fernandez MH, et al. **Eur J Immunol** 1998 Oct; 28(10):3144-53

Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-gamma of fusin/CXCR4. Galli G, et al. **Eur J Immunol** 1998 Oct;28(10):3280-90

Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection. Jin X, et al. **Eur J Immunol** 1998 Nov; 28(11):3564-76

Effects of human immunodeficiency virus type 1 on CD4 lymphocyte subset activation. Masci AM, et al. **Eur J Immunol** 1999 Jun;29(6):1879-89

Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. Juompan L, et al. **FASEB J** 1998 Nov;12(14):1473-80

Construction of single-chain antibodies that bind an overlapping epitope of HIV-1 Nef. Chang AH, et al. **FEBS Lett** 1998 Dec 18;441(2):307-12

Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR. Pinti M, et al. **FEBS Lett** 1999 Sep 17;458(2):209-14

Intestinal macrophages display reduced permissiveness to human immunodeficiency virus 1 and decreased surface CCR5. Li L, et al. **Gastroenterology** 1999 May; 116(5):1043-53

Structural studies of HIV-1 protease-inhibiting antibodies. Lescar J, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:3-6

Anti-HIV proteinase monoclonal antibody F11.2.32 that inhibits enzyme activity. Stouracova R, et al. **Gen Physiol Biophys** 1998 Jun;17 Suppl 1:6-8

Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Marasco WA, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1627-42

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies [see comments] Mhashilkar AM, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1453-67. Comment in: Hum Gene Ther 1999 Jun 10;10(9):1425-7.

Intrabodies to human immunodeficiency virus type 1 [comment] Paillard F. **Hum Gene Ther** 1999 Jun 10; 10(9):1425-7. Comment on: Hum Gene Ther 1999 Jun 10;10(9):1453-67.

The human uniqueness of HIV: innate immunity and the viral Tat protein. Rodman TC, et al. **Hum Immunol** 1999 Aug; 60(8):631-9

Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Tomiyama H, et al. **Hum Immunol** 1999 Mar;60(3):177-86

Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide. Ota A, et al. **Hybridoma** 1999 Apr;18(2):149-57

Inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Jun;18(3):235-41

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Cohen GB, et al. **Immunity** 1999 Jun;10(6):661-71

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Poignard P, et al. **Immunity** 1999 Apr;10(4):431-8

Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. Mühlbacher M, et al. **Immunobiology** 1999 Jun;200(2):295-305

Interactions of HIV-1 with antigen-presenting cells. Hewson T, et al. **Immunol Cell Biol** 1999 Aug;77(4):289-303 (182 ref.)

Cellular immunity and target cell susceptibility in persons with repeated HIV-1 exposure. Akridge R, et al. **Immunol Lett** 1999 Mar;66(1-3):15-9

Differential cytotoxic T-lymphocyte (CTL) responses in HIV-1 immunised sibling chimpanzees with shared MHC haplotypes. Balla-Jhagjhoorsingh S, et al. **Immunol Lett** 1999 Mar;66(1-3):61-7

Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45. Chen YH, et al. **Immunol Lett** 1999 Aug 3;69(2):253-7

A role for mucosal immunity in resistance to HIV infection. Clerici M, et al. **Immunol Lett** 1999 Mar;66(1-3):21-5

Antigen presenting cell function in HIV-1 infected patients. Fidler SJ, et al. **Immunol Lett** 1999 Mar;66(1-3):129-34

HIV-1 DNA vaccines. Fomsgaard A. **Immunol Lett** 1999 Jan;65(1-2):127-31 (36 ref.)

Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Giorgi JV, et al. **Immunol Lett** 1999 Mar;66(1-3):105-10

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Heeney J, et al. **Immunol Lett** 1999 Mar; 66(1-3):189-95

Soluble tumor necrosis factor receptor type II (sTNFRII) in HIV-infected patients: relationship with the plasma level of HIV-1 RNA. Hober D, et al. **Immunol Lett** 1999 Apr 1;67(2):91-4

Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1). Laisney IL, et al. **Immunol Lett** 1999 Apr 15;67(3):185-92

Suppression of human immunodeficiency virus type 1 replication by a soluble factor produced by CD8+ lymphocytes from HIV-2-infected baboons. Locher CP, et al. **Immunol Lett** 1999 Mar;66(1-3):151-7

The role of the viral glycoprotein in HIV-1 persistence. McKeating JA, et al. **Immunol Lett** 1999 Jan;65(1-2):63-70 (110 ref.)

Rational reconstitution of the immune repertoire in AIDS with autologous, antigen-specific, in vitro-expanded CD4 lymphocytes. Manca F, et al. **Immunol Lett** 1999 Mar; 66(1-3):117-20

Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Nixon DF, et al. **Immunol Lett** 1999 Mar;66(1-3):219-28

Subpopulations of peripheral blood dendritic cells show differential susceptibility to infection with a lymphotropic strain of HIV-1. Patterson S, et al. **Immunol Lett** 1999 Mar; 66(1-3):111-6

Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Plummer FA, et al. **Immunol Lett** 1999 Mar; 66(1-3):27-34

Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Pontesilli O, et al. **Immunol Lett** 1999 Mar;66(1-3):213-7

Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Rosenberg ES, et al. **Immunol Lett** 1999 Mar;66(1-3):89-93

Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Rowland-Jones SL, et al. **Immunol Lett** 1999 Mar; 66(1-3):9-14

Lysis of CD4+ T cells expressing HIV-1 gag peptides by gag-specific CD8+ cytotoxic T cells. Salerno-Gonçalves R, et al. **Immunol Lett** 1998 Dec;64(2-3):71-7

Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Sapp M, et al. **Immunol Lett** 1999 Mar;66(1-3):121-8

Antibody neutralization of HIV-1 and the potential for

vaccine design. Sattentau QJ, et al. **Immunol Lett** 1999 Mar; 66(1-3):143-9 (116 ref.)

The implications of antigenic diversity for vaccine development. Zolla-Pazner S, et al. **Immunol Lett** 1999 Mar;66(1-3):159-64 (49 ref.)

HIV's evasion of the cellular immune response. Collins KL, et al. **Immunol Rev** 1999 Apr;168:65-74 (68 ref.)

Evolutionary dynamics of HIV-induced subversion of the immune response. Wodarz D, et al. **Immunol Rev** 1999 Apr; 168:75-89 (118 ref.)

HIV-1 tat: immunosuppression via TGF-beta1 induction [letter] Reinhold D, et al. **Immunol Today** 1999 Aug; 20(8):384-5 (10 ref.)

B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Jakubik JJ, et al. **Immunology** 1999 Apr;96(4):612-9

Cross-reactive HIV-1-specific CTL in recent seroconverters from Pune, India. Paranjape RS, et al. **Indian J Med Res** 1998 Aug;108:35-41

Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. D'Amico R, et al. **Infect Control Hosp Epidemiol** 1999 Jun; 20(6):428-30

HIV vaccines. Frey SE. **Infect Dis Clin North Am** 1999 Mar; 13(1):95-112 (162 ref.)

Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Brenner BG, et al. **Infect Dis Obstet Gynecol** 1999;7(1-2):80-90 (82 ref.)

CD80 expression is decreased in hyperplastic lymph nodes of HIV+ patients. Legendre C, et al. **Int Immunol** 1998 Dec;10(12):1847-51

The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Waibale P, et al. **Int J Epidemiol** 1999 Apr;28(2):341-6

Effect of d-fenfluramine on the lymphocyte response of HIV+ humans. Mathews HL, et al. **Int J Immunopharmacol** 1998 Dec;20(12):751-63

Screening for human immunodeficiency virus type 1 and 2 in a Turkish blood donor population. Altuglu I, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):202-4

Evaluation of the serologic response against two consensus V3 loop peptides from human immunodeficiency virus-1 in Cuban patients. Miguez J, et al. **Int J Infect Dis** 1998 Apr-Jun;2(4):221-5

Three-dimensional conformation of the epitopes of human superoxide dismutase-2 recognized by antibody against HIV-1p17. Kato T, et al. **Int J Mol Med** 1998 Jan;1(1):63-6

Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. Bratt G, et al. **Int J STD AIDS** 1999 Aug;10(8):514-21

Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2. Ng KP, et al. **Int J STD AIDS** 1999 Jun;10(6):401-4

Evidence for a local synthesis of beta-chemokines within the genital tract of both HIV-1-infected and uninfected women [letter] Fiore JR, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):255-7

Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1; 21(4):259-65

Salivary sIgA response in HIV-1 infection. Skott P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):73-80

Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. Weisman Z, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):157-63

Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. Kitamura Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):105-14

Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. Louisirirotchanakul S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):315-20

Striae formation in two HIV-positive persons receiving protease inhibitors. Darvay A, et al. **J Am Acad Dermatol** 1999 Sep;41(3 Pt 1):467-9 (13 ref.)

Backbone and C beta assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide [letter] Tugarinov V, et al. **J Biomol NMR** 1999 Feb;13(2):193-4

Chemokine receptors and chemokines in HIV infection [published erratum appears in J Clin Immunol 1998 Nov;18(6):441] Garzino-Demo A, et al. **J Clin Immunol** 1998 Jul;18(4):243-55 (159 ref.)

The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. Belyakov IM, et al. **J Clin Invest** 1998 Dec 15;102(12):2072-81

Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection [published erratum appears in J Clin Invest 1999 Mar;103(6):921] Haynes BF, et al. **J Clin Invest** 1999 Feb;103(4):453-60

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy [see comments] Ortiz GM, et al. **J Clin Invest** 1999 Sep;104(6):R13-8. Comment in: J Clin Invest 1999 Sep;104(6):677-8.

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi [see comments] Rowland-Jones SL, et al. **J Clin Invest** 1998 Nov 1;102(9):1758-65. Comment in: J Clin Invest 1998 Nov 1;102(9):1643-4.

Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen. Hashida S, et al. **J Clin Lab Anal** 1998;12(6):329-36

Sensitive enzyme immunoassay of antibodies to HIV-1 p17 antigen using indirectly immobilized recombinant p17 for diagnosis of HIV-1 infection. Ishikawa S, et al. **J Clin Lab Anal** 1998;12(6):343-50

Use of indirectly immobilized recombinant p17 antigen for detection of antibodies to HIV-1 by enzyme immunoassay. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(1):9-18

Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. Arai H, et al. **J Clin Microbiol** 1999 Feb;37(2):367-70

Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2. Vallari AS, et al. **J Clin Microbiol** 1998 Dec;36(12):3657-61

Anti-HIV-1 seroreactivity and HIV transmission route[R1]. The HEC/FIOCRUZ AIDS Clinical Research Group. Bongertz V, et al. **J Clin Virol** 1999 Jan;12(1):27-36

HIV-1 variation diminishes CD4 T lymphocyte recognition. Harcourt GC, et al. **J Exp Med** 1998 Nov 16; 188(10):1785-93

The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. Buratti E, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2709-16

Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire. de Haard JJ, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2883-94

Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions. Jackson NA, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):225-36

Role of class I major histocompatibility complex-restricted and -unrestricted suppression of human immunodeficiency virus type 1 replication by CD8+ T lymphocytes. Ohashi T, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):209-16

A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. Rodriguez D, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):217-23

In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. Arya SK, et al. **J Hum Virol** 1999 May-Jun;2(3):133-8

Tat toxoid: its potential role as an HIV vaccine [editorial; comment] Lambert J. **J Hum Virol** 1998 May-Jun; 1(4):249-50. Comment on: J Hum Virol 1998 May-Jun;1(4):282-92. Comment on: J Hum Virol 1998 May-Jun;1(4):293-8.

Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects. Moss RB, et al. **J Hum Virol** 1998 Jan-Feb;1(2):77-81

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine [see comments] Zagury JF, et al. **J Hum Virol** 1998 May-Jun;1(4):282-92. Comment in: J Hum Virol 1998 May-Jun;1(4):249-50.

IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. Bailer RT, et al. **J Immunol** 1999 Jun 15;162(12):7534-42

Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. Balla-Jhagjhoorsingh SS, et al. **J Immunol** 1999 Feb 15; 162(4):2308-14

Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. Boven LA, et al. **J Immunol** 1999 Apr 1;162(7):4319-27

A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. Bovolenta C, et al. **J Immunol** 1999 Jan 1;162(1):323-30

Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. Boykins RA, et al. **J Immunol** 1999 Jul 1;163(1):15-20

Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection. Brander C, et al. **J Immunol** 1999 Apr 15;162(8):4796-800

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Calarota SA, et al. **J Immunol** 1999 Aug 15;163(4):2330-8

DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. Caselli E, et al. **J Immunol** 1999 May 1;162(9):5631-8

Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. Chougnet C, et al. **J Immunol** 1999 Aug 1;163(3):1666-73

Infection of HIV-1 transgenic mice with Mycobacterium avium induces the expression of infectious virus selectively from a Mac-1-positive host cell population. Doherty TM, et al. **J Immunol** 1999 Aug 1;163(3):1506-15

Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. Ensoli F, et al. **J Immunol** 1999 May 15;162(10):6268-77

Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. Fehniger TA, et al. **J Immunol** 1998 Dec 1;161(11):6433-8

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. Ferris RL, et al. **J Immunol** 1999 Feb 1;162(3):1324-32

IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. Gherardi MM, et al. **J Immunol** 1999 Jun 1;162(11):6724-33

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). Gray CM, et al. **J Immunol** 1999 Feb 1;162(3):1780-8

Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. Hadida F, et al. **J Immunol** 1999 Aug 1;163(3):1105-9

Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. Harrer T, et al. **J Immunol** 1998 Nov 1; 161(9):4875-81

HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. Koedel U, et al. **J Immunol** 1999 Aug 1;163(3):1237-45

Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms. Kovalev G, et al. **J Immunol** 1999 Jun 15;162(12):7555-62

TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. Lane BR, et al. **J Immunol** 1999 Oct 1;163(7):3653-61

Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. Lefevre EA, et al. **J Immunol** 1999 Aug 1; 163(3):1119-22

The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. McKinney DM, et al. **J Immunol** 1999 Jul 15;163(2):861-7

Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. Mata M, et al. **J Immunol** 1999 Aug 1;163(3):1449-56

Induction of HIV-1 replication by allogeneic stimulation. Moriuchi H, et al. **J Immunol** 1999 Jun 15;162(12):7543-8

C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease. Peritt D, et al. **J Immunol** 1999 Jun 15;162(12):7563-8

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. Scala G, et al. **J Immunol** 1999 May 15; 162(10):6155-61

Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. Sousa AE, et al. **J Immunol** 1999 Mar 15;162(6):3718-26

Inhibition of tyrosine kinase activation blocks the down-regulation of CXC chemokine receptor 4 by HIV-1 gp120 in CD4+ T cells. Su SB, et al. **J Immunol** 1999 Jun 15;162(12):7128-32

T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. Su SB, et al. **J Immunol** 1999 May 15; 162(10):5924-30

In vitro analysis of complement-dependent HIV-1 cell infection using a model system. Tacnet-Delorme P, et al. **J Immunol** 1999 Apr 1;162(7):4088-93

Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. van der Burg SH, et al. **J Immunol** 1999 Jan 1;162(1):152-60

Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. Wagner R, et al. **J Immunol** 1999 Mar 15;162(6):3727-34

HIV-1 envelope gp120 inhibits the monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation. Wang JM, et al. **J Immunol** 1998 Oct 15;161(8):4309-17

A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling

through homing receptors. Wang L, et al. **J Immunol** 1999 Jan 1;162(1):268–76

Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. Wasik TJ, et al. **J Immunol** 1999 Apr 1; 162(7):4355–64

HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. Weiss JM, et al. **J Immunol** 1999 Sep 1;163(5):2953–9

HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. Wilson CC, et al. **J Immunol** 1999 Mar 1;162(5):3070–8

Complement-mediated anti-HIV-1 effect induced by human IgM monoclonal antibody against ganglioside GM2. Wu X, et al. **J Immunol** 1999 Jan 1;162(1):533–9

Processing, secretion, and anti-HIV-1 activity of IL-16 with or without a signal peptide in CD4+ T cells. Zhou P, et al. **J Immunol** 1999 Jul 15;163(2):906–12

Activation-induced resistance of human macrophages to HIV-1 infection in vitro. Zybarth G, et al. **J Immunol** 1999 Jan 1;162(1):400–6

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):93–103

Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. Raux M, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):111–24

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. B Moss R, et al. **J Infect Dis** 1999 Sep;180(3):641–8

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP, et al. **J Infect Dis** 1999 May;179(5):1264–7

A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. Cecilia D, et al. **J Infect Dis** 1999 Jun;179(6):1365–74

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. Evans TG, et al. **J Infect Dis** 1999 Aug;180(2):290–8

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. Ferko B, et al. **J Infect Dis** 1998 Nov; 178(5):1359–68

Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. Goh WC, et al. **J Infect Dis** 1999 Mar; 179(3):548–57

Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. Hosaka N, et al. **J Infect Dis** 1998 Oct;178(4):1030–9

Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D. Jones GJ, et al. **J Infect Dis** 1999 Mar; 179(3):558–66

The effect of route of immunization on mucosal immunity and protection. Lehner T, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S489–92 (19 ref.)

Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. Lynch JA, et al. **J Infect Dis** 1998 Oct;178(4):1040–6

In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. Maas JJ, et al. **J Infect Dis** 1998 Oct;178(4):1024–9

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. Mazzoli S, et al. **J Infect Dis** 1999 Sep;180(3):871–5

Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy. Merrill DP, et al. **J Infect Dis** 1999 Feb;179(2):345–51

Effect of human immunodeficiency virus type 1 on intracellular activation and superoxide production by neutrophils. Muñoz JF, et al. **J Infect Dis** 1999 Jul; 180(1):206–10

Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. Musey LK, et al. **J Infect Dis** 1999 Aug;180(2):278–84

Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. Pontesilli O, et al. **J Infect Dis** 1998 Oct;178(4):1008–18

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. Pontesilli O, et al. **J Infect Dis** 1999 Jul;180(1):76–86

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. Sitz KV, et al. **J Infect Dis** 1999 Apr;179(4):817–24

Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. Spiegel HM, et al. **J Infect Dis** 1999 Aug;180(2):359–68

Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. Zolla-Pazner S, et al. **J Infect Dis** 1998 Nov;178(5):1502–6

Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. Kim JJ, et al. **J Interferon Cytokine Res** 1999 Jan; 19(1):77–84

Elective surgery and the HIV-positive patient: medical, legal, and ethical issues. Clarke SR, et al. **J La State Med Soc** 1999 May;151(5):245–9 (17 ref.)

Orally administered dextran sulfate is absorbed in HIV-positive individuals. Hiebert LM, et al. **J Lab Clin Med** 1999 Feb;133(2):161–70

Generation of CD28- cells from long-term-stimulated CD8+CD28+ T cells: a possible mechanism accounting for the increased number of CD8+CD28- T cells in HIV-1-infected patients. Fiorentini S, et al. **J Leukoc Biol** 1999 May;65(5):641–8

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection. Heeney JL, et al. **J Med Primatol** 1998 Apr-Jun;27(2–3):50–8

Simple/rapid test devices for anti-HIV screening: do they come up to the mark? Giles RE, et al. **J Med Virol** 1999 Sep;59(1):104–9

Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera. Lawoko AL, et al. **J Med Virol** 1999 Oct;59(2):169–79

Neutralization of HIV-1 subtypes: implications for vaccine formulations. Smith TL, et al. **J Med Virol** 1998 Nov; 56(3):264–8

The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. Price DA, et al. **J Mol Med** 1998 Sep;76(10):699–708 (91 ref.)

NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies. Tsang P, et al. **J Mol Recognit** 1997 Nov-Dec;10(6):256–61

High levels in serum, but no signs of intrathecal synthesis of anti-sulfatide antibodies in HIV-1 infected individuals with or without central nervous system complications. Gisslén M, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):153–6

HIV-1 tat protein induces the production of interleukin-8 by human brain-derived endothelial cells. Hofman FM, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):28–39

Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. Kolb SA, et al. **J Neuroimmunol** 1999 Jan 1;93(1–2):172–81

Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. Gorry P, et al. **J Neurovirol** 1998 Aug;4(4):377–86

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response. Cleland JL, et al. **J Pharm Sci** 1998 Dec;87(12):1489–95

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. Tyler DS, et al. **J Surg Res** 1998 Oct;79(2):115–20

Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. Amado RG, et al. **J Virol** 1999 Aug;73(8):6361–9

Human herpesvirus 6 infects dendritic cells and suppresses human immunodeficiency virus type 1 replication in coinfected cultures. Asada H, et al. **J Virol** 1999 May; 73(5):4019–28

Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. Beddows S, et al. **J Virol** 1999 Feb;73(2):1740–5

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. Cheng-Mayer C, et al. **J Virol** 1999 Jul;73(7):5294–300

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. Dalod M, et al. **J Virol** 1999 Sep;73(9):7108–16

Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. Dorrell L, et al. **J Virol** 1999 Feb;73(2):1708–14

Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. Dyer WB, et al. **J Virol** 1999 Jan;73(1):436–43

Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys. Egan MA, et al. **J Virol** 1999 Jul;73(7):5466–72

Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. Etemad-Moghadam B, et al. **J Virol** 1999 Oct;73(10):8873–9

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. Frankel SS, et al. **J Virol** 1998 Dec;72(12):9788–94

Differential effects of human immunodeficiency virus isolates on beta-chemokine and gamma interferon production and on cell proliferation. Greco G, et al. **J Virol** 1999 Feb; 73(2):1528–34

Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. Hay CM, et al. **J Virol** 1999 Jul;73(7):5509–19

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. Jiang S, et al. **J Virol** 1998 Dec;72(12):10213–7

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6715–20

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6721–8

Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. Kent SJ, et al. **J Virol** 1998 Dec;72(12):10180–8

Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteins. Lachgar A, et al. **J Virol** 1999 Feb; 73(2):1447–52

Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: in vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS. Lapenta C, et al. **J Virol** 1998 Dec;72(12):10323–7

Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Lewis J, et al. **J Virol** 1998 Nov;72(11):8943–51

Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus. Lewis MG, et al. **J Virol** 1999 Feb;73(2):1262–70

HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication. Mackewicz CE, et al. **J Virol** 1998 Dec;72(12):10165–70

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Mascola JR, et al. **J Virol** 1999 May;73(5):4009–18

Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. Nyambi PN, et al. **J Virol** 1998 Nov;72(11):9384–91

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. Ogg GS, et al. **J Virol** 1999 Jan; 73(1):797–800

Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. Ostrowski MA, et al. **J Virol** 1999 Aug;73(8):6430–5

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. Park EJ, et al. **J Virol** 1999 Jul;73(7):5707–13

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. Parren PW, et al. **J Virol** 1998 Dec;72(12):10270–4

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. Richmond JF, et al. **J Virol** 1998 Nov;72(11):9092–100

Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. Robert-Guroff M, et al. **J Virol** 1998 Dec;72(12):10275–80

Resistance against syncytium-inducing human immunodeficiency virus type 1 (HIV-1) in selected CD4(+) T cells from an HIV-1-infected nonprogressor: evidence of a novel pathway of resistance mediated by a soluble factor(s) that acts after virus entry. Saha K, et al. **J Virol** 1999 Sep;73(9):7891–8

Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees. Santra S, et al. **J Virol** 1999 Aug;73(8):7065–9

Stoichiometry of monoclonal antibody neutralization of

T-cell line-adapted human immunodeficiency virus type 1. Schønning K, et al. **J Virol** 1999 Oct;73(10):8364–70

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. Spenlehauer C, et al. **J Virol** 1998 Dec; 72(12):9855–64

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM, et al. **J Virol** 1998 Dec;72(12):9656–67

CD4(+) T-lymphocyte depletion in human lymphoid tissue ex vivo is not induced by noninfectious human immunodeficiency virus type 1 virions. Sylwester AW, et al. **J Virol** 1998 Nov;72(11):9345–7

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. VanCott TC, et al. **J Virol** 1999 Jun;73(6):4640–50

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. Verschoor EJ, et al. **J Virol** 1999 Apr; 73(4):3292–300

Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. Wilson CC, et al. **J Virol** 1999 May;73(5):3975–85

Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. Zhang PF, et al. **J Virol** 1999 Jun;73(6):5225–30

Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV. Zolla-Pazner S, et al. **J Virol** 1999 May;73(5):4042–51

Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. Giraud A, et al. **J Virol Methods** 1999 Apr;79(1):75–84

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27–38

Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II. van Binsbergen J, et al. **J Virol Methods** 1998 Dec; 76(1-2):59–71

Immunisation with gp160 in HIV-1 infection [letter] Fiala C, et al. **Lancet** 1999 Sep 11;354(9182):948; discussion 949

Therapeutic vaccines for preventing AIDS: their use with HAART [comment] Hoff R, et al. **Lancet** 1999 May 22; 353(9166):1723–4. Comment on: Lancet 1999 May 22;353(9166):1735–42.

Immunisation with gp160 in HIV-1 infection [letter] Pontesilli O, et al. **Lancet** 1999 Sep 11;354(9182):948–9

HIV infection: where have all the T cells gone? Rowland-Jones S. **Lancet** 1999 Jul 3;354(9172):5–7

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group [see comments] Sandström E, et al. **Lancet** 1999 May 22;353(9166):1735–42. Comment in: Lancet 1999 May 22;353(9166):1723–4.

Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use. Hayami M, et al. **Leukemia** 1999 Apr;13 Suppl 1:S42–7

A model of primary HIV-1 infection. Murray JM, et al. **Math Biosci** 1998 Dec 15;154(2):57–85

The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients. Gerencer M, et al. **Microb Pathog** 1998 Nov; 25(5):253–66

Ups and downs on the road to an HIV vaccine [news] Senior K. **Mol Med Today** 1999 Apr;5(4):141–2

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells [see comments] Brodie SJ, et al. **Nat Med** 1999 Jan;5(1):34–41. Comment in: Nat Med 1999 Jan;5(1):27–8.

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [see comments] Cafaro A, et al. **Nat Med** 1999 Jun;5(6):643–50. Comment in: Nat Med 1999 Jun;5(6):612–4.

Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans [see comments] Hellerstein M, et al. **Nat Med** 1999 Jan;5(1):83–9. Comment in: Nat Med 1999 Jan;5(1):27–8.

Vaccine reactions [letter; comment] Mascola JR, et al. **Nat Med** 1998 Jul;4(7):746. Comment on: Nat Med 1998 May;4(5 Suppl):495–8.

HIV-1 neutralizing antibodies: how full is the bottle? [news; comment] Moore JP, et al. **Nat Med** 1999 Feb;5(2):142–4 Comment on: Nat Med 1999 Feb;5(2):204–10. Comment on: Nat Med 1999 Feb;5(2):211–6.

Unraveling the strands of HIV's web [news; comment] Pantaleo G. **Nat Med** 1999 Jan;5(1):27–8. Comment on: Nat Med 1999 Jan;5(1):29–3. Comment on: Nat Med 1999 Jan;5(1):34–41. Comment on: Nat Med 1999 Jan;5(1):83–9.

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments] Pitcher CJ, et al. **Nat Med** 1999 May;5(5):518–25. Comment in: Nat Med 1999 May;5(5):483–4.

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Belyakov IM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4512–7

HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Schrager JA, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8167–72

Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Stranford SA, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1030–5

Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Wang CY, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10367–72

Neutralizing antibodies in Brazilian sera against three strains of human immunodeficiency virus type 1 (HIV-1). Machado AA, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov-Dec;39(6):319–22

Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death. Aladdin H, et al. **Scand J Immunol** 1999 Aug; 50(2):223–7

Specific immune response to human immunodeficiency virus (HIV)-1 in patients assessed through the production of interferon-gamma and interleukin-4 in HIV-1 p24-activated whole blood cultures: relationship with the viral load in plasma. Hober D, et al. **Scand J Immunol** 1999 Jul;50(1):83–90

Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Llorente M, et al. **Scand J Immunol** 1999 Sep;50(3):270–9

Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Ullum H, et al. **Scand J Immunol** 1999 May;49(5):539–47

Fusion-competent vaccines: broad neutralization of primary isolates of HIV [see comments] LaCasse RA, et al. **Science** 1999 Jan 15;283(5400):357–62. Comment in: Science 1999 Jan 15;283(5400):336–7.

HIV vaccines. Magic of the occult? [see comments] Montefiori D, et al. **Science** 1999 Jan 15;283(5400):336–7. Comment in: Science 1999 Jan 15;283(5400):357–62.

Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: bayesian estimation using a mixture. Chouquet C, et al. **Stat Med** 1999 Apr 15;18(7):815–33

Dynamics of co-infection with M. Tuberculosis and HIV-1. Kirschner D. **Theor Popul Biol** 1999 Feb;55(1):94–109

The role of anchor residues in the binding of peptides to HLA-A*1101 molecules. Chujoh Y, et al. **Tissue Antigens** 1998 Dec;52(6):501–9

Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Hillyer CD, et al. **Transfus Med Rev** 1999 Jan; 13(1):1–17 (174 ref.)

Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees. Bagarazzi ML, et al. **Vaccine** 1998 Nov; 16(19):1836–41

A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Caver TE, et al. **Vaccine** 1999 Mar 17;17(11-12):1567–72

Induction of HIV-1 IIIb neutralizing antibodies in BALB/c mice by a chimaeric peptide consisting of a T-helper cell epitope of Semliki Forest virus and a B-cell epitope of HIV. Fernández IM, et al. **Vaccine** 1998 Dec; 16(20):1936–40

A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits. Galéa P, et al. **Vaccine** 1999 Mar 17;17(11-12):1454–61

The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. Gómez CE, et al. **Vaccine** 1999 May 4;17(18):2311–9

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Gonzalo RM, et al. **Vaccine** 1999 Feb 26; 17(7-8):887–92

DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Lee AH, et al. **Vaccine** 1999 Feb 5;17(5):473–9

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Pinter A, et al. **Vaccine** 1998 Nov; 16(19):1803–11

A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9. Raya NE, et al. **Vaccine** 1999 Jun 4;17(20-21):2646–50

Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, et al. **Vaccine** 1999 Jan; 17(1):64–71

DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Ugen KE, et al. **Vaccine** 1998 Nov;16(19):1818–21

IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Xin KQ, et al. **Vaccine** 1999 Feb 26;17(7-8):858–66

Epitope mapping of rat neutralizing monoclonal antibody against human immunodeficiency virus type-1 by a phage peptide library: comparison with ELISA using synthetic peptides. Ichiyama K, et al. **Viral Immunol** 1999;12(1):57–66

Enhanced human immunodeficiency virus infection in macrophages by high-molecular-weight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor. Jagodzinski PP, et al. **Viral Immunol** 1999;12(1):23–33

A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans. Nehete PN, et al. **Viral Immunol** 1998;11(3):147–58

Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus [published erratum appears in Viral Immunol 1999;12(1):89] Nehete PN, et al. **Viral Immunol** 1998;11(3):119–29

Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Buseyne F, et al. **Virology** 1998 Oct 25;250(2):316–24

Isolation and partial characterization of a lentivirus from talapoin monkeys (Myopithecus talapoin). Osterhaus AD, et al. **Virology** 1999 Jul 20;260(1):116–24

The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LA1 on the immunogenicity of the envelope protein. Peet NM, et al. **Virology** 1998 Nov 10; 251(1):59–70

Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Putkonen P, et al. **Virology** 1998 Oct 25;250(2):293–301

The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Riggs NL, et al. **Virology** 1999 Jun 5;258(2):203–7

Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees. Rovinski B, et al. **Virology** 1999 May 10;257(2):438–48

Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Sugiura W, et al. **Virology** 1999 Feb 15;254(2):257–67

A specific T-cell subset with CD4+/CD38- markers derived from HIV-1 carriers induces apoptosis in healthy donor-derived T-lymphocytes. Kameoka M, et al. **Virus Res** 1998 Jul;56(1):115–22

[Antigenicity of nine synthetic peptides of human immunodeficiency virus] Mao P, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):105–7 (Eng. Abstr.) **(Chi)**

[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)] Yerly S, et al. **Schweiz Med Wochenschr** 1999 Feb 27; 129(8):319–22 (Eng. Abstr.) **(Ger)**

[Candida albicans: the relationship between morphotypes and in-vitro adhesivity to the oral mucosa cells of HIV-positive and AIDS patients. I] Malighetti V, et al. **Minerva Stomatol** 1998 Sep;47(9):351–9 (Eng. Abstr.) **(Ita)**

[Immunoenzyme system for detection of antibodies in their complexes with HIV-1 antigens] Abelian AV, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):189–92 **(Rus)**

[Analysis of the immunologic heterogeneity of HIV-1. II. Effect of amino acid residues, flanking the C-terminus of the central tetrapeptide loop V3 of gp120] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):729–34 **(Rus)**

[Analysis of the immunologic heterogeneity of HIV-1: I. "Arginine-glutamine trigger" in the fourth position of the central tetrapeptide of the V3 loop of gp120] Shchelkanov MIu, et al. **Mol Biol (Mosk)** 1998 Jul-Aug;32(4):717–28 **(Rus)**

[Increase in the serotypical heterogeneity in HIV-1 in Svetlogorsk focus 1 year after the start of an epidemic] Shchelkanov MIu, et al. **Vopr Virusol** 1999 Jul-Aug; 44(4):174–7 (Eng. Abstr.) **(Rus)**

[Acute pancreatitis due to amphotericin B in an HIV-positive patient (letter)] Catalán I, et al. **An Med Interna** 1999 Jan; 16(1):47–8 **(Spa)**

[Evaluation of indirect immunofluorescence as a supplementary test for the diagnosis of HIV-1 infection] Ceballos A, et al. **Rev Argent Microbiol** 1998 Apr-Jun; 30(2):59–63 (Eng. Abstr.) **(Spa)**

[Care for the Cuban child born to an HIV-seropositive mother] González Núñez I, et al. **Rev Cubana Med Trop** 1995;47(3):201, 203–8 (Eng. Abstr.) **(Spa)**

[Gastric necrosis due to vasculitis in an HIV+ patient (letter)] Alcántara Gijón F, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):152–3 (6 ref.) **(Spa)**

ISOLATION & PURIFICATION

Diagnosis of HIV-1/2 dual infection using dilution analysis of type-specific antibody [letter] Ariyoshi K, et al. **AIDS** 1998 Dec 24;12(18):2504–5

Inaccurate HIV-1 viral load quantification by three major commercially available methods [letter] Oelrichs RB, et al. **AIDS** 1999 Apr 16;13(6):727–8

Estimates of the virological benefit of antiretroviral therapy

are both assay- and analysis-dependent. Rae S, et al. **AIDS** 1998 Nov 12;12(16):2185-92

CD4 T cells remain the major source of HIV-1 during end stage disease. van der Ende ME, et al. **AIDS** 1999 Jun 18;13(9):1015-9

Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. Bruisten SM, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10;14(12):1053-8

A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda. Buonaguro L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1287-9

Primary intestinal epithelial cells can be infected with laboratory-adapted strain HIV type 1 NDK but not with clinical primary isolates. Chenine AL, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1235-8

HIV type 1 C2V3 env diversity among Belgian individuals. Heyndrickx L, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1291-6

HIV type 1 infection in lymphoid tissue: natural history and model systems. Kitchen SG, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S235-9 (54 ref.)

Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. Kumar D, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1073-7

Domestic transmission of HIV type 1 subtype G strains in Taiwan. Lee CN, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1137-40

Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. Lukashov VV, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1299-303

Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. Min J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):51-5

Molecular epidemiological analysis of human immunodeficiency virus type 1 in Newfoundland, Canada. Montpetit ML, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1205-9

The subtypes of HIV type 1 in Greece. Papa A, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1297-8

Isolation of HIV type 1 from long-term nonprogressors in Herpesvirus saimiri-immortalized T cells [letter] Vella C, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10; 15(12):1145-7

Coexistence of allergic contact dermatitis and granuloma annulare in an HIV-1-infected patient: A casual association? [letter] Muñoz-Pérez MA, et al. **Am J Contact Dermat** 1999 Jun;10(2):100-1

Risk factors for HIV-1 shedding in semen. Speck CE, et al. **Am J Epidemiol** 1999 Sep 15;150(6):622-31

Comparison of intraocular to plasma HIV-1 viral burden in patients with cytomegalovirus retinitis. Ciulla TA, et al. **Am J Ophthalmol** 1999 Feb;127(2):221-3

Vertical transmission of HIV: parameters which might affect infection of placental trophoblasts by HIV-1: a review. Biomed Group on the Study of in Utero Transmission of HIV 1. Moussa M, et al. **Am J Reprod Immunol** 1999 May; 41(5):312-9 (82 ref.)

Clinical and biological characteristics of human immunodeficiency virus-infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Follézou JY, et al. **Am J Trop Med Hyg** 1999 Sep; 61(3):420-4

Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Rich JD, et al. **Ann Intern Med** 1999 Jan 5;130(1):37-9

Similar proviral load but increased HIV-1 p24 in the intestinal mucosa compared to the peripheral blood in HIV-infected patients. Schmidt W, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:276-9

Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Keung AC, et al. **Antimicrob Agents Chemother** 1999 May; 43(5):1230-3

The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load. Si Mohamed A, et al. **Antiviral Res** 1998 Jul; 39(1):47-53

Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals. Banda NK, et al. **Biol Blood Marrow Transplant** 1999;5(3):162-72

PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Schottstedt V, et al. **Biologicals** 1998 Jun;26(2):101-4

Combinations of three or four HIV virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbers [comment] Mathé G, et al. **Biomed Pharmacother** 1997;51(10):417-26. Comment on: Biomed Pharmacother 1997 ;51(10):413-6.

Adaptation of the fluorogenic 5'-nuclease chemistry to a PCR-based reverse transcriptase assay. Maudru T, et al. **Biotechniques** 1998 Dec;25(6):972-5

CD8 T-cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cell interaction. Agostini C, et al. **Blood** 1999 Feb 15;93(4):1277-86

Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Tan R, et al. **Blood** 1999 Mar 1;93(5):1506-10

HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Bell JE, et al. **Brain** 1998 Nov;121 (Pt 11):2043-52

Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Vassilopoulos D, et al. **Cleve Clin J Med** 1998 Sep;65(8):436-41 (33 ref.)

Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Tantisiriwat W, et al. **Clin Infect Dis** 1999 May;28(5):1152-4

HIV antibody tests and viral load--more unanswered questions and a further plea for clarification. Papadopulos-Eleopulos E, et al. **Curr Med Res Opin** 1998; 14(3):185-6

Long-term stability of human immunodcficiency virus viral load and infectivity in whole blood. Vandamme AM, et al. **Eur J Clin Invest** 1999 May;29(5):445-52

Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes. Holguín A, et al. **Eur J Clin Microbiol Infect Dis** 1999 Apr;18(4):256-9

HIV influence on hematopoiesis at the initial stage of infection. Spada C, et al. **Eur J Haematol** 1998 Oct; 61(4):255-60

Flow cytometry in situ polymerase chain reaction as an innovative approach to HIV-1 proviral DNA detection. Gibellini D, et al. **Eur J Histochem** 1998;42(2):137-41 (16 ref.)

Seroprevalence of HIV infection among jail inmates in Orissa. Pal BB, et al. **Indian J Med Res** 1999 Jun; 109:199-201

Increasing prevalence of dual HIV-1-2 infections among voluntary blood donors in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Dec;52(12):548-52

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. Kravcik S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):371-5

Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. Pedraza MA, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):120-5

Survival of HIV-1 in syringes. Abdala N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):73-80

Hepatitis G virus RNA is common in AIDS patients' plasma but is not associated with abnormal liver function tests or other clinical syndromes. Woolley I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):408-12

Application of dried blood spot specimens for serologic subtyping of human immunodeficiency virus type 1 in Thailand. Chanbancherd P, et al. **J Clin Microbiol** 1999 Mar;37(3):804-6

Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo. de Baar MP, et al. **J Clin Microbiol** 1999 Jan;37(1):63-7

Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. Dyer JR, et al. **J Clin Microbiol** 1999 Feb;37(2):447-9

Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. Erali M, et al. **J Clin Microbiol** 1999 Mar;37(3):792-5

Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays. Ginocchio CC, et al. **J Clin Microbiol** 1999 Apr;37(4):1210-2

Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma. Kirstein LM, et al. **J Clin Microbiol** 1999 Aug;37(8):2428-33

Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. Lyles CM, et al. **J Clin Microbiol** 1998 Dec;36(12):3647-52

Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. Michael NL, et al. **J Clin Microbiol** 1999 Aug;37(8):2557-63

Reproducibility and performance of the second-generation branched-DNA assay in routine quantification of human immunodeficiency virus type 1 RNA in plasma. Murphy DG, et al. **J Clin Microbiol** 1999 Mar;37(3):812-4

Rapid method for screening dried blood samples on filter paper for human immunodeficiency virus type 1 DNA. Panteleeff DD, et al. **J Clin Microbiol** 1999 Feb;37(2):350-3

Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays. Raboud JM, et al. **J Clin Microbiol** 1998 Nov;36(11):3369-71

Improved Mg2+-based reverse transcriptase assay for detection of primate retroviruses. Sears JF, et al. **J Clin Microbiol** 1999 Jun;37(6):1704-8

Evaluation of the Nuclisens HIV-1 QT assay for quantitation of human immunodeficiency virus type 1 RNA levels in plasma. Segondy M, et al. **J Clin Microbiol** 1998 Nov; 36(11):3372-4

Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy. Segondy M, et al. **J Clin Microbiol** 1998 Nov;36(11):3392-5

Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. Sun R, et al. **J Clin Microbiol** 1998 Oct; 36(10):2964-9

Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1. Triques K, et al. **J Clin Microbiol** 1999 Jan;37(1):110-6

Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. Yang C, et al. **J Clin Microbiol** 1999 Aug; 37(8):2581-6

Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. Zazzi M, et al. **J Clin Microbiol** 1999 Feb;37(2):333-8

Amplicor HIV monitor, NASBA HIV-1 RNA QT and quantiplex HIV RNA version 2.0 viral load assays: a Canadian evaluation. Prud'homme IT, et al. **J Clin Virol** 1998 Dec;11(3):189-202

Detection of human immunodeficiency virus type 1 after infection of unstimulated peripheral blood mononuclear cells. Shapiro SZ, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):857-61

Human immunodeficiency virus type 1 in faeces and serum: evidence against independently evolving subpopulations. van der Hoek L, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2455-9

Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. Berry N, et al. **J Hum Virol** 1998 Nov-Dec; 1(7):457-68

Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples. Constantine NT, et al. **J Hum Virol** 1997 Nov-Dec;1(1):45-51

Detection of HIV-1-specific CTLs in the semen of HIV-infected individuals. Quayle AJ, et al. **J Immunol** 1998 Oct 15;161(8):4406-10

A simple and robust method for the complete dissociation of HIV-1 p24 and other antigens from immune complexes in serum and plasma samples. Steindl F, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):143-51

Measurement of plasma HIV viral load--clinical applications. Churchill D, et al. **J Infect** 1999 May;38(3):147-50 (38 ref.)

HIV-1 viral load testing. Clarke JR, et al. **J Infect** 1999 May; 38(3):141-6 (32 ref.)

HIV and tuberculosis co-infection in an inner London hospital--a prospective anonymized seroprevalence study. Marshall BG, et al. **J Infect** 1999 May;38(3):162-6

Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. Balotta C, et al. **J Infect Dis** 1999 Aug; 180(2):285-9

Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. Bartlett JA, et al. **J Infect Dis** 1998 Dec; 178(6):1803-5

Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP, et al. **J Infect Dis** 1999 May;179(5):1264-7

Longitudinal quantification of human immunodeficiency virus type 1 DNA and RNA in long-term nonprogressors. Broström C, et al. **J Infect Dis** 1999 Jun;179(6):1542-8

Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. Hart CE, et al. **J Infect Dis** 1999 Apr;179(4):871-82

Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. Shaffer N, et al. **J Infect Dis** 1999 Mar;179(3):590-9

Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Taoufik Y, et al. **J Infect Dis** 1998 Dec;178(6):1816-20

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. Tashima KT, et al. **J Infect Dis** 1999 Sep;180(3):862-4

Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. Yerly S, et al. **J Infect Dis** 1999 Sep;180(3):850-3

RANTES stimulates cell-mediated transmission of HIV-1 infection. Abbate I, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):345-50

Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: potential approach towards prevention of viral transmission. Hayakawa T, et al. **J Med Virol** 1998 Dec;56(4):327-31

Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance. Puchhammer-Stöckl E, et al. **J Med Virol** 1999 Mar; 57(3):283-9

Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. Barbouche R, et al. **J Pept Res** 1998 Oct;52(4):283-8

Detection of HIV-1 in seminal plasma and seminal cells of HIV-1 seropositive men. Dulioust E, et al. **J Reprod Immunol** 1998 Dec;41(1-2):27-40

Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. Muciaccia B, et al. **J Reprod Immunol** 1998 Dec;41(1-2):81-93

HIV in testis: quantitative histology and HIV localization in germ cells. Shevchuk MM, et al. **J Reprod Immunol** 1998 Dec;41(1-2):69-79

Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. Parren PW, et al. **J Virol** 1998 Dec;72(12):10270-4

Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. Voulgaropoulou F, et al. **J Virol** 1999 Apr;73(4):3497-504

An international collaborative study on the detection of an HIV-1 genotype B field isolate by nucleic acid amplification techniques. Bootman J, et al. **J Virol Methods** 1999 Mar;78(1-2):21-34

Isolation of HIV-1 RNA from plasma: evaluation of seven different methods for extraction (part two). Fransen K, et al. **J Virol Methods** 1998 Dec;76(1-2):153-7

A novel and innovative quantitative kinetic software for virological colorimetric assays. Giacomini M, et al. **J Virol Methods** 1998 Aug;73(2):201-9

Critical level and detection limit: performance measures for PCR-based assays. Markert-Hahn C, et al. **J Virol Methods** 1998 Oct;74(2):139-48

Restriction fragment length polymorphism analysis for rapid gag subtype determination of human immunodeficiency virus type 1 in South Africa. van Harmelen J, et al. **J Virol Methods** 1999 Mar;78(1-2):51-9

Multicenter evaluation of a new rapid automated human immunodeficiency virus antigen detection assay. Weber B, et al. **J Virol Methods** 1999 Mar;78(1-2):61-70

Techniques for the evaluation of nucleic acid amplification technology performance with specimens containing interfering substances: efficacy of boom methodology for extraction of HIV-1 RNA. Witt DJ, et al. **J Virol Methods** 1999 Apr;79(1):97-111

Rapid HIV screening during labor [letter; comment] Balano K, et al. **JAMA** 1998 Nov 18;280(19):1664. Comment on: JAMA 1998 Jun 3;279(21):1743-4.

Sex differences in HIV-1 viral load and progression to AIDS [see comments] Farzadegan H, et al. **Lancet** 1998 Nov 7; 352(9139):1510-4. Comment in: Lancet 1999 Feb 13;353(9152):589; discussion 590-1. Comment in: Lancet 1999 Feb 13;353(9152):589-90; discussion 590-1. Comment in: Lancet 1999 Feb 13;353(9152):590-1.

Sex differences in HIV-1 viral load and progression to AIDS [letter; comment] Foulkes MA, et al. **Lancet** 1999 Feb 13; 353(9152):590-1. Comment on: Lancet 1998 Nov 7;352(9139):1510-4.

Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study [letter; comment] Junghans C, et al. **Lancet** 1999 Feb 13;353(9152):589; discussion 590-1. Comment on: Lancet 1998 Nov 7;352(9139):1510-4.

Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian cohort of HIV-1 positive individuals [letter; comment] Moroni M. **Lancet** 1999 Feb 13;353(9152):589-90; discussion 590-1. Comment on: Lancet 1998 Nov 7;352(9139):1510-4.

Nosocomial child-to-child transmission of HIV [letter] Nielsen H, et al. **Lancet** 1998 Nov 7;352(9139):1520

Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting [see comments] Roth WK, et al. **Lancet** 1999 Jan 30;353(9150):359-63. Comment in: Lancet 1999 Apr 24;353(9162):1441.

Human immunodeficiency virus in breast milk. Kennedy SB 4th. **Med Hypotheses** 1998 Jul;51(1):75-7

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group [see comments] Garcia PM, et al. **N Engl J Med** 1999 Aug 5;341(6):394-402. Comment in: N Engl J Med 1999 Aug 5;341(6):441-3.

Potential for the transmission of HIV-1 despite highly active antiretroviral therapy [editorial; comment] Haase AT, et al. **N Engl J Med** 1998 Dec 17;339(25):1846-8. Comment on: N Engl J Med 1998 Dec 17;339(25):1803-9.

Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see comments] Havlir DV, et al. **N Engl J Med** 1998 Oct 29; 339(18):1261-8. Comment in: N Engl J Med 1998 Oct 29;339(18):1319-21.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team [see comments] Mofenson LM, et al. **N Engl J Med** 1999 Aug 5;341(6):385-93. Comment in: N Engl J Med 1999 Aug 5;341(6):441-3.

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team [see comments] Pialoux G, et al. **N Engl J Med** 1998 Oct 29;339(18):1269-76. Comment in: N Engl J Med 1998 Oct 29;339(18):1319-21.

Reducing the risk of maternal-infant transmission of HIV by attacking the virus [editorial; comment] Rogers MF, et al. **N Engl J Med** 1999 Aug 5;341(6):441-3. Comment on: N Engl J Med 1999 Aug 5;341(6):385-93. Comment on: N Engl J Med 1999 Aug 5;341(6):394-402.

Acute HIV infection among patients tested for mononucleosis [letter] Rosenberg ES, et al. **N Engl J Med** 1999 Mar 25; 340(12):969

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy [see comments] Zhang H, et al. **N Engl J Med** 1998 Dec 17; 339(25):1803-9. Comment in: N Engl J Med 1998 Dec 17;339(25):1846-8.

Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Childs EA, et al. **Neurology** 1999 Feb;52(3):607-13

Evaluation of three different commercial procedures for quantifying human immunodeficiency virus type-1 RNA levels. Aschbacher R, et al. **New Microbiol** 1999 Jan; 22(1):1-9

Interpretation of high levels of HIV-1 RNA in the cerebrospinal fluid (CSF) using amplicor HIV-1 monitor test. Honderlick P, et al. **Pathol Biol (Paris)** 1999 May; 47(5):560-2

Unusual presentation and course of HIV-1 progressive encephalopathy. Angelini L, et al. **Pediatr Neurol** 1999 Apr; 20(4):301-4

Integrating molecular diagnostic and flow cytometric reporting for improved longitudinal monitoring of HIV patients. Asare AL, et al. **Proc AMIA Symp** 1998;:952-6

A simple relationship between viral load and survival time in HIV-1 infection. Arnaout RA, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11549-53

Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Gonzalez-Cadavid NF, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14938-43

Multiplex detection of four pathogenic retroviruses using molecular beacons. Vet JA, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6394-9

Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Zhang ZQ, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5169-72

Biological properties of interferon-alpha produced Ex vivo by whole blood of patients infected by human immunodeficiency virus-1. Chehadeh W, et al. **Scand J Immunol** 1999 Jun;49(6):660-6

Detecting undetected HIV-1 variants in African children using degenerate polymerase chain reaction and sequence analyses. Nanteza M, et al. **Trans R Soc Trop Med Hyg** 1998 May-Jun;92(3):294-5

Detection of HIV-1 RNA in two consecutive blood donations screened negative for HIV antibodies. Burin des Roziers N, et al. **Vox Sang** 1998;75(4):298-302

Detection of HIV-1 infection in dried blood spots from a 12-year-old ABO bedside test card. Strobel E, et al. **Vox Sang** 1998;75(4):303-5

[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1129-33 (Eng. Abstr.) **(Dut)**

[AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment] Notermans DW, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1909-12 (48 ref.) (Eng. Abstr.) **(Dut)**

[CD4+-T-cells are the predominant source of HIV-1 and HIV-2 production in asymptomatic people and AIDS patients with opportunistic infections] van der Ende ME, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230 **(Dut)**

[Infection with Mycobacterium genavense in 2 HIV-seropositive patients in Amsterdam (letter; comment)] Van der Ven AJ, et al. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2537-8. Comment on: Ned Tijdschr Geneeskd 1998 Apr 25;142(17):970-2. Comment on: Ned Tijdschr Geneeskd 1998 Jul 11;142(28):1629. Comment on: Ned Tijdschr Geneeskd 1998 Sep 26;142(39):2165-6. **(Dut)**

[Clinical importance of the quantification of HIV-1 RNA in cerebrospinal fluid for the diagnosis of HIV encephalitis] Bossi P, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):423-5 (Eng. Abstr.) **(Fre)**

[Genetic characteristics of variants of human immunodeficiency virus type 1, causing an epidemic among substance abusers in Commonwealth of Independent States countries] Bobkov AF, et al. **Vopr Virusol** 1998 Nov-Dec; 43(6):253-6 (Eng. Abstr.) **(Rus)**

[Optimization of HIV diagnosis using the RT-PCR (gag) method with various dilutions of cDNA and $MgCl_2$ molarity] Subašić D, et al. **Med Arh** 1999;53(2):73-6 (Eng. Abstr.) **(Scr)**

[The biological characterization of HIV-1 isolated in patients with a rapid clinical evolution] Lobaina Barthelemy L, et al. **Rev Cubana Med Trop** 1998;50(2):96-9 (Eng. Abstr.) **(Spa)**

METABOLISM

RANTES upregulation by HIV-1-infected cells: lack of correlation with viral replication and induction of interferon [letter] Abbate I, et al. **AIDS** 1999 Feb 4; 13(2):288-90

The C domain of HIV-1 gp41 binds the putative cellular receptor protein P62. Chen YH, et al. **AIDS** 1999 Jun 18; 13(9):1021-4

HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells. Milani D, et al. **AIDS** 1998 Jul 30;12(11):1275-84

Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies. Golding H, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20;15(2):149-59

Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24. Jason J, et al. **AIDS Res Hum Retroviruses** 1999 Jan 20; 15(2):173-81

Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope. Lallos LB, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):895-7

Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Rana TM, et al. **Arch Biochem Biophys** 1999 May 15;365(2):175-85 (99 ref.)

Epithelin/granulin growth factors: extracellular cofactors for HIV-1 and HIV-2 Tat proteins. Trinh DP, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):299-306

Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Watson K, et al. **Biochem Pharmacol** 1999 Apr 1;57(7):775-83

A proposed mechanism for the induction of activator protein 1 (AP-1) binding by HIV-1 negative factor(Nef) in the macrophage cell line RAW267.4 cells. Biggs T, et al. **Biochem Soc Trans** 1998 Aug;26(3):S263

Proximity of a Tat peptide to the HIV-1 TAR RNA loop region determined by site-specific photo-cross-linking. Wang Z, et al. **Bioconjug Chem** 1999 May-Jun;10(3):512-9

Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Lachgar A, et al. **Biomed Pharmacother** 1998;52(10):436-9

HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Garber ME, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:371-80

TIP30, a cofactor for HIV-1 Tat-activated transcription, is homologous to short-chain dehydrogenases/reductases [letter] Baker ME. **Curr Biol** 1999 Jul 1;9(13):R471

A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Bresnahan PA, et al. **Curr Biol** 1998 Nov 5; 8(22):1235-8

A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Greenberg M, et al. **Curr Biol** 1998 Nov 5;8(22):1239-42

The synthesis of platelet-activating factor modulates chemotaxis of monocytes induced by HIV-1 Tat. Del Sorbo L, et al. **Eur J Immunol** 1999 May;29(5):1513-21

The HIV-1 Vpr co-activator induces a conformational change in TFIIB. Agostini I, et al. **FEBS Lett** 1999 May 7;450(3):235-9

Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. Baraz L, et al. **FEBS Lett** 1998 Dec 28;441(3):419-26

Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies. Demirhan I, et al. **FEBS Lett** 1999 Feb 19;445(1):53-6

The extracellular processing of HIV-1 envelope glycoprotein gp160 by human plasmin. Okumura Y, et al. **FEBS Lett** 1999 Jan 8;442(1):39-42

The tat protein of HIV-1 induces galectin-3 expression. Fogel S, et al. **Glycobiology** 1999 Apr;9(4):383-7

Antigenic characterization of HIV-1 gp41 binding proteins. Chen YH, et al. **Immunol Lett** 1998 Jun;62(2):75-9

Human cyclophilin has a significantly higher affinity for HIV-1 recombinant p55 than p24. Bristow R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):334-6

Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. Bachand F, et al. **J Biol Chem** 1999 Mar 26;274(13):9083-91

Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. Blanpain C, et al. **J Biol Chem** 1999 Jul 2;274(27):18902-8

Maturation-induced conformational changes of HIV-1 capsid protein and identification of two high affinity sites for cyclophilins in the C-terminal domain. Endrich MM, et al. **J Biol Chem** 1999 Feb 26;274(9):5326-32

A new nucleoporin-like protein interacts with both HIV-1 Rev nuclear export signal and CRM-1. Farjot G, et al. **J Biol Chem** 1999 Jun 11;274(24):17309-17

Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function. Howard OM, et al. **J Biol Chem** 1999 Jun 4;274(23):16228-34

Real-time kinetics of HIV-1 Rev-Rev response element interactions. Definition of minimal binding sites on RNA and protein and stoichiometric analysis. Van Ryk DI, et al. **J Biol Chem** 1999 Jun 18;274(25):17452-63

Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. Yang X, et al. **J Biol Chem** 1998 Nov 6;273(45):29879-87

HIV-1 Rev promotes the nuclear export of unspliced and singly spliced RNAs in a mammalian cell-free export system. Huffman KM, et al. **J Biomed Sci** 1999 May-Jun; 6(3):194–205

Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways. Jenkins Y, et al. **J Cell Biol** 1998 Nov 16;143(4):875–85

Structure-based design of ligands for protein basic domains: application to the HIV-1 Tat protein. Filikov AV, et al. **J Comput Aided Mol Des** 1998 May;12(3):229–40

A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. Burns JM, et al. **J Exp Med** 1998 Nov 16;188(10):1917–27

The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. Kino T, et al. **J Exp Med** 1999 Jan 4;189(1):51–62

Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. Xu XN, et al. **J Exp Med** 1999 May 3;189(9):1489–96

Mutations in the env gene of human immunodeficiency virus type 1 NDK isolates and the use of African green monkey CXCR4 as a co-receptor in COS-7 cells. Dumonceaux J, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1975–82

Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1. Pöhlmann S, et al. **J Gen Virol** 1999 May;80 (Pt 5):1241–51

Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. Ferris RL, et al. **J Immunol** 1999 Feb 1;162(3):1324–32

Differential binding of IgG and of a HIV gp41 peptide by the B chain and A chain globular head sequences of C1q, respectively. Kojouharova MS, et al. **J Immunol** 1998 Oct 15;161(8):4325–31

Flow cytometric quantification of HIV-1 Tat protein in tat-transfected Jurkat T cell lines [published erratum appears in J Immunol Methods 1999 Apr 22;224(1-2):209–10] Gibellini D, et al. **J Immunol Methods** 1998 Dec 1;221(1-2):107–17

A human cell line constitutively expressing HIV-1 Gag and Gag-Pol gene products. Wang CT, et al. **J Med Virol** 1999 Jan;57(1):17–24

Induction of activator protein 1 (AP-1) in macrophages by human immunodeficiency virus type-1 NEF is a cell-type-specific response that requires both hck and MAPK signaling events. Biggs TE, et al. **J Mol Biol** 1999 Jul 2;290(1):21–35

Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. Forget J, et al. **J Mol Biol** 1998 Dec 11;284(4):915–23

Glycolipids as potential binding sites for HIV: topology in the sperm plasma membrane in relation to the regulation of membrane fusion. Gadella BM, et al. **J Reprod Immunol** 1998 Dec;41(1-2):233–53

CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. Hoxie JA, et al. **J Reprod Immunol** 1998 Dec;41(1-2):197–211 (56 ref.)

Ikappakappa mediates NF-kappaB activation in human immunodeficiency virus-infected cells. Asin S, et al. **J Virol** 1999 May;73(5):3893–903

Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. Berlioz-Torrent C, et al. **J Virol** 1999 Feb;73(2):1350–61

Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. Bieniasz PD, et al. **J Virol** 1999 Jul;73(7):5777–86

Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway. Boritz E, et al. **J Virol** 1999 Aug;73(8):6937–45

Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. Chabot DJ, et al. **J Virol** 1999 Aug;73(8):6598–609

Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. Cimarelli A, et al. **J Virol** 1999 Jul; 73(7):5388–401

Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. Davis DA, et al. **J Virol** 1999 Feb;73(2):1156–64

Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5. Dejucq N, et al. **J Virol** 1999 Sep;73(9):7842–7

Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. Demarchi F, et al. **J Virol** 1999 Aug; 73(8):7080–6

Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. Esser MT, et al. **J Virol** 1999 May;73(5):4360–71

Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. Ferrer M, et al. **J Virol** 1999 Jul;73(7):5795–802

Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction. Fujiwara M, et al. **J Virol** 1999 May;73(5):3603–7

CCR5-Mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains. Genoud S, et al. **J Virol** 1999 Feb;73(2):1645–8

Simian immunodeficiency virus and human immunodeficiency virus type 1 nef proteins show distinct patterns and mechanisms of Src kinase activation. Greenway AL, et al. **J Virol** 1999 Jul;73(7):6152–8

Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. Hrimech M, et al. **J Virol** 1999 May;73(5):4101–9

Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. Kato K, et al. **J Virol** 1999 Jul;73(7):5520–6

CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection. Klasse PJ, et al. **J Virol** 1999 Sep;73(9):7453–66

A bipartite membrane-binding signal in the human immunodeficiency virus type 1 matrix protein is required for the proteolytic processing of Gag precursors in a cell type-dependent manner. Lee YM, et al. **J Virol** 1998 Nov; 72(11):9061–8

Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. Liang C, et al. **J Virol** 1999 Jul;73(7):6147–51

Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. Merat R, et al. **J Virol** 1999 Jul;73(7):5698–706

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. Muñoz-Barroso I, et al. **J Virol** 1999 Jul;73(7):6089–92

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Olson WC, et al. **J Virol** 1999 May;73(5):4145–55

Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. Ono A, et al. **J Virol** 1999 May;73(5):4136–44

The amino-terminal region of Vpr from human immunodeficiency virus type 1 forms ion channels and kills neurons. Piller SC, et al. **J Virol** 1999 May;73(5):4230–8

Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate. Ramanathan Y, et al. **J Virol** 1999 Jul;73(7):5448–58

Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. Reeves JD, et al. **J Virol** 1999 Sep;73(9):7795–804

Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA. Rong L, et al. **J Virol** 1998 Nov; 72(11):9353–8

Control of human immunodeficiency virus type 1 RNA metabolism: role of splice sites and intron sequences in unspliced viral RNA subcellular distribution. Séguin B, et al. **J Virol** 1998 Dec;72(12):9503–13

Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood. Singh A, et al. **J Virol** 1999 Aug; 73(8):6680–90

The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. Trkola A, et al. **J Virol** 1999 Aug;73(8):6370–9

Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation. Vicenzi E, et al. **J Virol** 1999 Sep; 73(9):7515–23

DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism. Willetts KE, et al. **J Virol** 1999 Feb;73(2):1682–8

Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. Worgall S, et al. **J Virol** 1999 Jul;73(7):5865–74

A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. Jiang S, et al. **J Virol Methods** 1999 Jun;80(1):85–96

The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. Truant R, et al. **Mol Cell Biol** 1999 Feb;19(2):1210–7

The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. Kim EM, et al. **Mol Cells** 1999 Jun 30;9(3):281–5

A 60 kD heat-shock protein-like molecule interacts with the HIV transmembrane glycoprotein gp41. Speth C, et al. **Mol Immunol** 1999 Jun;36(9):619–28

Cytokine modulation of HIV-1 chemokine receptor expression [letter; comment] Landay AL, et al. **Nat Med** 1999 Jun;5(6):592–3. Comment on: Nat Med 1999 Mar;5(3):344–6.

Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5 [published erratum appears in Nat Med 1999 May;5(5):590] Lapham CK, et al. **Nat Med** 1999 Mar; 5(3):303–8

RNA bulge entropies in the unbound state correlate with peptide binding strengths for HIV-1 and BIV TAR RNA because of improved conformational access. Lustig B, et al. **Nucleic Acids Res** 1998 Nov 15;26(22):5212–7

Nuclear and nucleolar targeting of human ribosomal protein S25: common features shared with HIV-1 regulatory proteins. Kubota S, et al. **Oncogene** 1999 Feb 18; 18(7):1503–14

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Chan DC, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15613–7

Dimerization of HIV-1 genomic RNA of subtypes A and B: RNA loop structure and magnesium binding. Jossinet F, et al. **RNA** 1999 Sep;5(9):1222–34

HIV-1 attachment: another look. Ugolini S, et al. **Trends Microbiol** 1999 Apr;7(4):144–9 (62 ref.)

Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Schafer JR, et al. **Vaccine** 1998 Nov;16(19):1880–4

Expression and detection of macrophage-tropic HIV-1 gp120 in the brain using conformation-dependent antibodies. Altmeyer R, et al. **Virology** 1999 Jul 5; 259(2):314–23

HIV and SIV gp120 binding does not predict coreceptor function. Baik SS, et al. **Virology** 1999 Jul 5;259(2):267–73

Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Edinger AL, et al. **Virology** 1998 Sep 30;249(2):367–78

Effect of Rev on the intranuclear localization of HIV-1 unspliced RNA. Favaro JP, et al. **Virology** 1998 Sep 30; 249(2):286–96

Inhibition of cellular glycoprotein incorporation into human immunodeficiency virus-like particles by coexpression of additional cellular interaction partner. Henriksson P, et al. **Virology** 1998 Nov 10;251(1):16–21

A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions. Johnson JE, et al. **Virology** 1998 Nov 25; 251(2):244–52

Identification of determinants of interaction between CXCR4 and gp120 of a dual-tropic HIV-1DH12 isolate. Lee MK, et al. **Virology** 1999 May 10;257(2):290–6

SH3-Domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Manninen A, et al. **Virology** 1998 Oct 25;250(2):273–82

Virological importance of the protease-cleavage site in human immunodeficiency virus type 1 Nef is independent of both intravirion processing and CD4 down-regulation. Pandori M, et al. **Virology** 1998 Nov 25;251(2):302–16

Tagging the human immunodeficiency virus gag protein with green fluorescent protein. Minimal evidence for colocalisation with actin. Perrin-Tricaud C, et al. **Virology** 1999 Mar 1;255(1):20–5

Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop. Sato H, et al. **Virology** 1999 May 10;257(2):491–501

Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. Stauber RH, et al. **Virology** 1998 Nov 10;251(1):38–48

Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. Tiganos E, et al. **Virology** 1998 Nov 10; 251(1):96–107

The cellular kinase binding motifs (PxxP and RR) in human immunodeficiency virus type 1 Nef protein are dispensable for producer-cell-dependent enhancement of viral entry. Tokunaga K, et al. **Virology** 1999 May 10;257(2):285–9

Processing and routage of HIV glycoproteins by furin to the cell surface. Moulard M, et al. **Virus Res** 1999 Mar; 60(1):55–65

PATHOGENICITY

HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. Annunziata P, et al. **AIDS** 1998 Dec 24;12(18):2377–85

The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. Blanco J, et al. **AIDS** 1999 May 28;13(8):909–17

HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions. El Messaoudi K, et al. **AIDS** 1999 Feb 25;13(3):333–9

Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. Rizzardini

G, et al. **AIDS** 1998 Dec 24;12(18):2387–96

Adaptation to promiscuous usage of CC and CXC–chemokine coreceptors in vivo correlates with HIV–1 disease progression. Xiao L, et al. **AIDS** 1998 Sep 10;12(13):F137–43

Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. Arthur LO, et al. **AIDS Res Hum Retroviruses** 1998 Oct; 14 Suppl 3:S311–9

Primary intestinal epithelial cells can be infected with laboratory–adapted strain HIV type 1 NDK but not with clinical primary isolates. Chenine AL, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1235–8

Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. Hibbitts S, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):989–1000

Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5–dependent HIV type 1 isolates. Pesenti E, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):983–7

Chemokine receptors as HIV–1 coreceptors: roles in viral entry, tropism, and disease. Berger EA, et al. **Annu Rev Immunol** 1999;17:657–700 (230 ref.)

Proteolytic activity in infected and noninfected insect cells: degradation of HIV–1 Pr55gag particles. Cruz PE, et al. **Biotechnol Bioeng** 1999 Oct 20;65(2):133–43

Nef harbors a major determinant of pathogenicity for an AIDS–like disease induced by HIV–1 in transgenic mice. Hanna Z, et al. **Cell** 1998 Oct 16;95(2):163–75

Host control of HIV–1 parasitism in T cells by the nuclear factor of activated T cells. Kinoshita S, et al. **Cell** 1998 Nov 25;95(5):595–604

Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL–10 in CD4–positive lymphocytes. Patterson BK, et al. **Clin Immunol** 1999 Jun;91(3):254–62

Cell–surface expression of CD4 reduces HIV–1 infectivity by blocking Env incorporation in a Nef– and Vpu–inhibitable manner. Lama J, et al. **Curr Biol** 1999 Jun 17;9(12):622–31

Heterozygous defect in HIV–1 coreceptor CCR5 and chemokine production. Yang JY, et al. **Cytokine** 1999 Jan; 11(1):1–7

Evidence for a role of T–helper type 2 cytokines in the acquisition of human immunodeficiency virus syncytium–inducing phenotype. Torres Y, et al. **Eur J Clin Invest** 1998 Nov;28(11):930–6

Long–term stability of human immunodeficiency virus viral load and infectivity in whole blood. Vandamme AM, et al. **Eur J Clin Invest** 1999 May;29(5):445–52

Effects of human immunodeficiency virus type 1 on CD4 lymphocyte subset activation. Masci AM, et al. **Eur J Immunol** 1999 Jun;29(6):1879–89

The N–linked glycan of the V3 region of HIV–1 gp120 and CXCR4–dependent multiplication of a human immunodeficiency virus type 1 lymphocyte–tropic variant. Losman B, et al. **FEBS Lett** 1999 Jul 2;454(1–2):47–52

Modeling the dynamics of HIV–1 and CD4 and CD8 lymphocytes [published erratum appears in IEEE Eng Med Biol Mag 1999 May–Jun;18(3):126] de Souza FM. **IEEE Eng Med Biol Mag** 1999 Jan–Feb;18(1):21–4

Interactions of HIV–1 with antigen–presenting cells. Hewson T, et al. **Immunol Cell Biol** 1999 Aug;77(4):289–303 (182 ref.)

Role of beta–chemokines in HIV–1 infection of dendritic cells maturing from CD34+ stem cells. Wang H, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):179–88

Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV–1: syncytium–inducing variants seem rare among subtype C HIV–1 viruses. Peeters M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):115–21

Identification of three major phosphorylation sites within HIV–1 capsid. Role of phosphorylation during the early steps of infection. Cartier C, et al. **J Biol Chem** 1999 Jul 2;274(27):19434–40

Transient exposure to HIV–1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. Nath A, et al. **J Biol Chem** 1999 Jun 11; 274(24):17098–102

Exposure to bacterial products renders macrophages highly susceptible to T–tropic HIV–1. Moriuchi M, et al. **J Clin Invest** 1998 Oct 15;102(8):1540–50

The B–oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M–tropic HIV–1 strains [see comments] Alfano M, et al. **J Exp Med** 1999 Sep 6; 190(5):597–605. Comment in: J Exp Med 1999 Sep 6;190(5):591–5.

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. Hockett RD, et al. **J Exp Med** 1999 May 17; 189(10):1545–54

Cytokine signals are sufficient for HIV–1 infection of resting human T lymphocytes. Unutmaz D, et al. **J Exp Med** 1999 Jun 7;189(11):1735–46

Enhancement of human immunodeficiency virus type 1 infectivity by Nef is producer cell–dependent. Tokunaga K, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2447–53

Cutting edge: a short polypeptide domain of HIV–1–Tat protein mediates pathogenesis. Boykins RA, et al. **J Immunol** 1999 Jul 1;163(1):15–20

CCR5 genotype and HIV–1 infection in perinatally–exposed infants. Mas A, et al. **J Infect** 1999 Jan;38(1):9–11

HIV–1 Infection, Mucosal Immunity and Pathogenesis. Conference proceedings. Bethesda, Maryland, USA. 11–13 September 1997. **J Infect Dis** 1999 May;179 Suppl 3:S391–498

CD8+ cell–derived anti–human immunodeficiency virus inhibitory factor. Barker E. **J Infect Dis** 1999 May;179 Suppl 3:S485–8 (17 ref.)

Cofactors for human immunodeficiency virus entry into primary macrophages. Collman RG, et al. **J Infect Dis** 1999 May;179 Suppl 3:S422–6

Human immunodeficiency virus type 1 and mucosal humoral defense. Janoff EN, et al. **J Infect Dis** 1999 May;179 Suppl 3:S475–9 (21 ref.)

Conversion rate towards a syncytium–inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. Koot M, et al. **J Infect Dis** 1999 Jan;179(1):254–8

Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. Kresina TF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S392–6 (4 ref.)

Mucosal dendritic cells and immunodeficiency viruses. Pope M. **J Infect Dis** 1999 May;179 Suppl 3:S427–30 (24 ref.)

Endogenous mucosal antiviral factors of the oral cavity. Shugars DC. **J Infect Dis** 1999 May;179 Suppl 3:S431–5 (33 ref.)

Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. Smith PD, et al. **J Infect Dis** 1999 May;179 Suppl 3:S436–40 (20 ref.)

Co–infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S457–60 (18 ref.)

HIV–1–induced neuronal injury in the developing brain. Epstein LG, et al. **J Leukoc Biol** 1999 Apr;65(4):453–7 (63 ref.)

Chemokine immunobiology in HIV–1 pathogenesis. Lee B, et al. **J Leukoc Biol** 1999 May;65(5):552–65 (192 ref.)

Molecular pathway involved in HIV–1–induced CNS pathology: role of viral regulatory protein, Tat. Rappaport J, et al. **J Leukoc Biol** 1999 Apr;65(4):458–65 (66 ref.)

In vitro infection of primate PBMC with simian/human immunodeficiency virus, SHIV(SF33A): correlation to in vivo outcome. Harouse JM, et al. **J Med Primatol** 1998 Apr–Jun;27(2–3):81–6

Role of HIV–1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T–cell count. Kupfer B, et al. **J Med Virol** 1998 Nov;56(3):259–63

Characterization of human immunodeficiency virus type–1 (HIV–1) particles that express protease–reverse transcriptase fusion proteins. Cherry E, et al. **J Mol Biol** 1998 Nov 20;284(1):43–56

Biological and conformational studies on analogues of a synthetic peptide enhancing HIV–1 infection. Dettin M, et al. **J Pept Sci** 1998 Nov;4(7):436–48

Human immunodeficiency virus induces a dual regulation of Bcl–2, resulting in persistent infection of CD4(+) T– or monocytic cell lines. Aillet F, et al. **J Virol** 1998 Dec; 72(12):9698–705

CCR5– and CXCR4–utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. Berkowitz RD, et al. **J Virol** 1998 Dec;72(12):10108–17

R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4–type pathogenicity in human thymus. Berkowitz RD, et al. **J Virol** 1999 Sep;73(9):7817–22

Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian–human immunodeficiency virus (SHIV–HXBc2). Cayabyab M, et al. **J Virol** 1999 Feb; 73(2):976–84

Polarized human immunodeficiency virus budding in lymphocytes involves a tyrosine–based signal and favors cell–to–cell viral transmission. Deschambeault J, et al. **J Virol** 1999 Jun;73(6):5010–7

Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu–PBL–SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. Fais S, et al. **J Virol** 1999 Aug;73(8):6453–9

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. Frankel SS, et al. **J Virol** 1998 Dec;72(12):9788–94

Tat protein induces human immunodeficiency virus type 1 (HIV–1) coreceptors and promotes infection with both macrophage–tropic and T–lymphotropic HIV–1 strains. Huang L, et al. **J Virol** 1998 Nov;72(11):8952–60

Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. Kitchen SG, et al. **J Virol** 1998 Nov; 72(11):9054–60

Human lymphoblastoid CD4(+) T cells become permissive to macrophage–tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: in vivo dynamics of CD4(+) T–cell differentiation in pathogenesis of AIDS. Lapenta C, et al. **J Virol** 1998 Dec;72(12):10323–7

An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. Madani N, et al. **J Virol** 1998 Dec;72(12):10251–5

Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. Mwaengo DM, et al. **J Virol** 1998 Nov;72(11):8976–87

Level of ICAM–1 surface expression on virus producer cells influences both the amount of virion–bound host ICAM–1 and human immunodeficiency virus type 1 infectivity. Paquette JS, et al. **J Virol** 1998 Nov;72(11):9329–36

Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. Pedroza–Martins L, et al. **J Virol** 1998 Dec; 72(12):9441–52

Neuronal death induced by brain–derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. Power C, et al. **J Virol** 1998 Nov;72(11):9045–53

Vaccine protection against a heterologous, non–syncytium–inducing, primary human immunodeficiency virus. Robert–Guroff M, et al. **J Virol** 1998 Dec;72(12):10275–80

T–tropic human immunodeficiency virus type 1 (HIV–1)–derived V3 loop peptides directly bind to CXCR–4 and inhibit T–tropic HIV–1 infection. Sakaida H, et al. **J Virol** 1998 Dec;72(12):9763–70

CD4(+) T–lymphocyte depletion in human lymphoid tissue ex vivo is not induced by noninfectious human immunodeficiency virus type 1 virions. Sylwester AW, et al. **J Virol** 1998 Nov;72(11):9345–7

Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane–targeting signal: analysis of its role in enhancement of viral infectivity. Welker R, et al. **J Virol** 1998 Nov;72(11):8833–40

Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. Zhang L, et al. **J Virol** 1998 Nov;72(11):9307–12

Use of coreceptors other than CCR5 by non–syncytium–inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. Zhang YJ, et al. **J Virol** 1998 Nov;72(11):9337–44

How HIV–1 lentivirus causes immune deficiency disease. Habeshaw JA, et al. **Med Hypotheses** 1999 Jan;52(1):59–67 (33 ref.)

HIV–1 and chemokines in the brain: location, location––location? [news] Tran PB, et al. **Mol Psychiatry** 1999 May;4(3):203–5, 202

Evidence for a newly discovered cellular anti–HIV–1 phenotype [see comments] Simon JH, et al. **Nat Med** 1998 Dec;4(12):1397–400. Comment in: Nat Med 1998 Dec;4(12):1368–9.

When accessories turn out to be essential [news; comment] Trono D. **Nat Med** 1998 Dec;4(12):1368–9. Comment on: Nat Med 1998 Dec;4(12):1397–400. Comment on: Nat Med 1998 Dec;4(12):1401–8.

HIV type 1 envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Hoffman TL, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11360–5

HIV type–1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus). Langley RJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14355–60

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Harouse JM, et al. **Science** 1999 Apr 30;284(5415):816–9

AIDS vaccine trials in chimpanzees [letter; comment] Prince AM, et al. **Science** 1998 Dec 18;282(5397):2195–6. Comment on: Science 1998 Jun 19;280(5371):1875–80.

HIV–1 attachment: another look. Ugolini S, et al. **Trends Microbiol** 1999 Apr;7(4):144–9 (62 ref.)

The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type–1 depends on the macrophage activation state. Amzazi S, et al. **Virology** 1998 Dec 5;252(1):96–105

Role of the leukocyte function antigen–1 conformational state in the process of human immunodeficiency virus type 1–mediated syncytium formation and virus infection. Fortin JF, et al. **Virology** 1999 Apr 25;257(1):228–38

Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV–1 particles containing mutant nucleocapsid zinc–coordinating sequences. Gorelick RJ, et al. **Virology** 1999 Mar 30;256(1):92–104

Derivation and biological characterization of a molecular clone of SHIV(KU–2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Liu ZQ, et al. **Virology** 1999 Aug 1;260(2):295–307

[Vertical HIV–I–transmission. I. Risk and prevention in pregnancy (see comments)] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12;142(50):2720–4 (27 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Dec 12;142(50):2720–4. **(Dut)**

[Vertical HIV–I–transmission. II. HIV–diagnosis in a child] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2724–8 (33 ref.) (Eng. Abstr.) **(Dut)**

[A recombinant HIV–1 strain causing an epidemic among injection drug addicts in Kaliningrad] Korovina GI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):47–9 (Eng. Abstr.) **(Rus)**

[The hepatitis C virus: after the track of the human

immunodeficiency virus (editorial)] Pérez-Olmeda M, et al. **Rev Clin Esp** 1999 Jan;199(1):5-7 (42 ref.) **(Spa)**

PHYSIOLOGY

Immune control of HIV-1 replication. Walker BD, et al. **Adv Exp Med Biol** 1998;452:159-67 (32 ref.)

Role of chemokine receptors in HIV-1 infection and pathogenesis. Ross TM, et al. **Adv Virus Res** 1999;52:233-67 (151 ref.)

Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study. **AIDS** 1999 Jul 30;13(11):1377-85

Cerebrospinal fluid and plasma HIV-1 RNA stability at 4 degrees C [letter] Ahmad M, et al. **AIDS** 1999 Jul 9; 13(10):1281-2

Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients [letter] Ankri A, et al. **AIDS** 1999 Jul 9;13(10):1282-3

Plasma HIV viral load in relation to season and to Plasmodium falciparum parasitaemia [letter] Ariyoshi K, et al. **AIDS** 1999 Jun 18;13(9):1145-6

Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis [editorial] Brack-Werner R. **AIDS** 1999 Jan 14;13(1):1-22 (216 ref.)

T cell changes after combined nucleoside analogue therapy in HIV primary infection. Carcelain G, et al. **AIDS** 1999 Jun 18;13(9):1077-81

Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. Churdboonchart V, et al. **AIDS** 1998 Aug 20;12(12):1521-7

HIV-1 subtypes and plasma RNA quantification [letter] Damond F, et al. **AIDS** 1999 Feb 4;13(2):286-8

Immune activation and plasma viral load in HIV-infected African individuals [letter] Dyer JR, et al. **AIDS** 1999 Jul 9;13(10):1283-5

Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee [letter] Flandre P. **AIDS** 1999 Feb 25;13(3):430-1

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Garcia F, et al. **AIDS** 1999 Jul 30;13(11):F79-86

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. Hall CS, et al. **AIDS** 1999 Jul 9;13(10):1207-12

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. Harrigan PR, et al. **AIDS** 1999 May 28; 13(8):F59-62

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. Haubrich RH, et al. **AIDS** 1999 Jun 18;13(9):1099-107

Human astrocytes inhibit HIV-1 expression in monocyte-derived macrophages by secreted factors. Hori K, et al. **AIDS** 1999 May 7;13(7):751-8

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. Ibáñez A, et al. **AIDS** 1999 Jun 18;13(9):1045-9

Vaccination and HIV-1 replication during highly active antiretroviral therapy [letter] Kroon FP, et al. **AIDS** 1999 Jan 14;13(1):135-6

Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. Kupfer B, et al. **AIDS** 1999 Jun 18;13(9):1025-8

Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. Lieberman J, et al. **AIDS** 1999 May 28;13(8):891-9

Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. Maas J, et al. **AIDS** 1998 Dec 3; 12(17):2275-80

Improved estimates for HIV-1 clearance rate and intracellular delay [letter] Mittler JE, et al. **AIDS** 1999 Jul 30;13(11):1415-7

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team. Mobley JE, et al. **AIDS** 1999 Jul 30; 13(11):F87-93

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. Neumann AU, et al. **AIDS** 1999 Apr 16;13(6):677-83

Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen [see comments] Notermans DW, et al. **AIDS** 1998 Aug 20; 12(12):1483-90. Comment in: AIDS 1999 Feb 25;13(3):429-30.

Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. Ortigão-de-Sampaio MB, et al. **AIDS** 1998 Oct 1;12(14):F145-50

HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. Patki AH, et al. **AIDS** 1999 Jul 9;13(10):1177-85

In vivo HIV-1 replicative capacity in early and advanced infection. Phillips AN, et al. **AIDS** 1999 Jan 14;13(1):67-73

Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. Pilcher CD, et al. **AIDS** 1999 Jul 30;13(11):1337-42

Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. Poggi C, et al. **AIDS** 1999 Jul 9;13(10):1213-20

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. Renaud M, et al. **AIDS** 1999 Apr 16;13(6):669-76

Host protein incorporation is conserved among diverse HIV-1 subtypes [letter] Roberts BD, et al. **AIDS** 1999 Feb 25;13(3):425-7

Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. Roos MT, et al. **AIDS** 1998 Oct 1;12(14):1745-51

Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. Ruiz L, et al. **AIDS** 1999 Jan 14;13(1):F1-8

Sex differences in HIV-1 viral load and TNF-alpha plasmatic level? [letter] Saves M, et al. **AIDS** 1999 Jul 30; 13(11):1414-5

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells. Scheuring UJ, et al. **AIDS** 1999 Feb 4;13(2):167-75

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. Staprans S, et al. **AIDS** 1999 Jun 18;13(9):1051-61

Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. Tachet A, et al. **AIDS** 1999 May 7;13(7):823-31

Mother-to-child transmission of HIV-1: the 'all mucosal' hypothesis as a predominant mechanism of transmission [editorial] Van de Perre P. **AIDS** 1999 Jun 18;13(9):1133-8

Sexual transmission of HIV: infectiousness and prevention. Vernazza PL, et al. **AIDS** 1999 Feb 4;13(2):155-66 (150 ref.)

Formation and release of virus-like particles by HIV-1 matrix protein [letter] Wang JJ, et al. **AIDS** 1999 Feb 4; 13(2):281-3

Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. Williams PL, et al. **AIDS** 1999 Jun 18;13(9):1035-44

Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? [letter; comment] Wu H, et al. **AIDS** 1999 Feb 25; 13(3):429-30. Comment on: AIDS 1998 Aug 20;12(12):1483-90.

Role of peripheral blood mononuclear cell subsets of seronegative donors in HIV replication: suppression by CD8+ and CD16+ cells and enhancement by CD14+ monocytes [letter] Alfano M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):489-91

A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors. Axelrod JH, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):759-67

Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. Björndal A, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):647-53

Extracellular HIV type 1 Tat protein induces CD69 expression through NF-kappaB activation: possible correlation with cell surface Tat-binding proteins. Blázquez MV, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1209-18

Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):43-50

Structural requirements for the cytotoxicity of the N-terminal region of HIV type 1 Nef. Curtain CC, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1543-51

Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon. Dittmar MT, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):707-12

Inhibition of human immunodeficiency virus type 1 replication by the K10-K42 peptide of GAP31 is due to induction of rapid but nonspecific precipitation of viral and nonviral proteins. Fink PD, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):429-34

Differences in HIV replication in CD4+ lymphocytes are not related to beta-chemokine production. Greco G, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1407-11

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. Janoff EN, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):837-45

Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1. Kort JJ. **AIDS Res Hum Retroviruses** 1998 Oct 10; 14(15):1329-39

Restricted HIV type 1 replication under serum-free culture conditions in human monocyte-derived macrophages. Kreutz M, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1581-8

Inhibition of HIV type 1 infectivity by coexpression of a wild-type and a defective glycoprotein 120. Lund OS, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1445-50

The nef gene controls syncytium formation in primary human lymphocytes and macrophages infected by HIV type 1. Meylan PR, et al. **AIDS Res Hum Retroviruses** 1998 Nov 20;14(17):1531-42

Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations. Nokta M, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):255-64

Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages [published erratum appears in AIDS Res Hum Retroviruses 1999 Mar 20;15(5):493] Rabehi L, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20;14(18):1605-15

Quantitative intracellular kinetics of HIV type 1. Reddy B, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):273-83

Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes. Robbins PA, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1; 14(16):1397-406

Replication-defective HIV as a vaccine candidate. Tung FY, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20; 14(14):1247-52

Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. Verrier F, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):731-43

No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects. Visco-Comandini U, et al. **AIDS Res Hum Retroviruses** 1999 May 1; 15(7):609-17

Unraveling the mechanisms of neurotoxicity in HIV type 1-associated dementia: inhibition of neuronal synaptic transmission by macrophage secretory products. Xiong H, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):57-63

Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Jabs DA, et al. **Am J Ophthalmol** 1998 Dec; 126(6):817-22

CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor. Park IW, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):864-71

Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Cammack N. **Antivir Chem Chemother** 1999 Mar;10(2):53-62 (94 ref.)

Cloning of a long HIV-1 readthrough transcript and detection of an increased level of early growth response protein-1 (Egr-1) mRNA in chronically infected U937 cells. Dron M, et al. **Arch Virol** 1999;144(1):19-28

Active HIV-1 redistribution and replication in the brain with HIV encephalitis. Gatanaga H, et al. **Arch Virol** 1999; 144(1):29-43

Comparison of early events during infection of human and chimpanzee peripheral blood mononuclear cells with HIV-1. Pischinger K, et al. **Arch Virol** 1998; 143(11):2065-76

Impaired CD45-associated tyrosine phosphatase activity during HIV-1 infection: implications for CD3 and CD4 receptor signalling. Guntermann C, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):69-77

Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation. Guntermann C, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):429-35

Nitric oxide inhibits HIV-1 replication in human astrocytoma cells. Persichini T, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):200-2

Direct visualization of HIV-1 entry: mechanisms and role of cell surface receptors. Stauber RH, et al. **Biochem Biophys Res Commun** 1999 May 19;258(3):695-702

Producer cell-dependent requirement of the Nef protein for efficient entry of HIV-1 into cells. Tokunaga K, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):565-8

Control of the histone-acetyltransferase activity of Tip60 by the HIV-1 transactivator protein, Tat. Creaven M, et al. **Biochemistry** 1999 Jul 6;38(27):8826-30

The human immunodeficiency virus type 1 Vpu protein enhances membrane permeability. González ME, et al. **Biochemistry** 1998 Sep 29;37(39):13710-9

Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes. Pritsker M, et al. **Biochemistry** 1999 Aug 31;38(35):11359-71

RNA recognition and regulation of HIV-1 gene expression by viral factor Tat. Naryshkin NA, et al. **Biochemistry (Mosc)** 1998 May;63(5):489-503 (98 ref.)

Dehydrogenase activity of infected cells and biological properties of HIV-1 variants. Shchelkanov MY, et al. **Biochemistry (Mosc)** 1999 Apr;64(4):431-6

Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model [editorial] [see comments] Mathé G. **Biomed Pharmacother** 1997;51(10):413-6 (39 ref.). Comment in: Biomed Pharmacother 1997 ;51(10):417-26.

The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency [editorial] Mathé G. **Biomed Pharmacother** 1998;52(10):413-20 (49 ref.)

Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. Aiuti A, et al. **Blood** 1999 Jul 1;94(1):62-73

The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Barillari G, et al. **Blood** 1999 Jul 15;94(2):663-72

Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have

remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Barker E, et al. **Blood** 1998 Nov 1;92(9):3105–14

Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. Chelucci C, et al. **Blood** 1999 Sep 1; 94(5):1590–600

Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndrome-related lymphoma cells and enhances their adhesion to endothelial cells. Chirivi RG, et al. **Blood** 1999 Sep 1;94(5):1747–54

Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Hori K, et al. **Blood** 1999 Mar 15;93(6):1843–50

Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Mengozzi M, et al. **Blood** 1999 Mar 15;93(6):1851–7

A CD4-independent interaction of human immunodeficiency virus-1 gp120 with CXCR4 induces their cointernalization, cell signaling, and T-cell chemotaxis. Missé D, et al. **Blood** 1999 Apr 15;93(8):2454–62

GATA-1 transcription factor transactivates the promoter for CCR5, a coreceptor for human immunodeficiency virus type 1 entry [letter] Moriuchi M, et al. **Blood** 1999 Feb 15;93(4):1433–5

Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Zauli G, et al. **Blood** 1999 Feb 1;93(3):1000–10

Regulated expression of HIV-1 Rev function in mammalian cell lines. Swenarchuk L, et al. **Can J Microbiol** 1999 Jun; 45(6):480–90

Micronuclei formation with chromosome breaks and gene amplification caused by Vpr, an accessory gene of human immunodeficiency virus. Shimura M, et al. **Cancer Res** 1999 May 15;59(10):2259–64

Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Farzan M, et al. **Cell** 1999 Mar 5;96(5):667–76

Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Piguet V, et al. **Cell** 1999 Apr 2;97(1):63–73

Effect of ethanol on monocytic function in human immunodeficiency virus type 1 infection. Chen H, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):790–8

Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211). Shearer WT, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):311–5

Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients. Witt DJ, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):369–76

Enhancement of HIV-1 replication in human macrophages is induced by CD8+ T cell soluble factors. Copeland KF, et al. **Clin Exp Immunol** 1998 Oct;114(1):87–93

Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J. **Clin Infect Dis** 1998 Nov;27(5):1309–10

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response [see comments] Fuller JD, et al. **Clin Infect Dis** 1999 Mar; 28(3):541–7. Comment in: Clin Infect Dis 1999 Mar;28(3):548–51.

Effect of oral beta-carotene supplementation on plasma human immunodeficiency virus (HIV) RNA levels and CD4+ cell counts in HIV-infected patients. Nimmagadda AP, et al. **Clin Infect Dis** 1998 Nov;27(5):1311–3

Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Granelli-Piperno A, et al. **Curr Biol** 1999 Jan 14; 9(1):21–9

Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Lama J, et al. **Curr Biol** 1999 Jun 17;9(12):622–31

Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Ross TM, et al. **Curr Biol** 1999 Jun 17;9(12):613–21

A trans-receptor mechanism for infection of CD4-negative cells by human immunodeficiency virus type 1. Speck RF, et al. **Curr Biol** 1999 May 20;9(10):547–50

Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Adelson ME, et al. **Eur J Biochem** 1999 Sep;264(3):806–15

Human chemokine receptors CCR5, CCR3 and CCR2B share common polarity motif in the first extracellular loop with other human G-protein coupled receptors implications for HIV-1 coreceptor function. Efremov R, et al. **Eur J Biochem** 1999 Aug;263(3):746–56

Granulocyte colony-stimulating factor (G-CSF) may stimulate HIV-replication during cytostatic chemotherapy [letter] Weiner SM, et al. **Eur J Haematol** 1998 Nov; 61(5):354–5

Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Lapenta C, et al. **Eur J Immunol** 1999 Apr;29(4):1202–8

Induction of interleukin-15 production by HIV-1 nef protein: a role in the proliferation of uninfected cells. Quaranta MG, et al. **Exp Cell Res** 1999 Jul 10;250(1):112–21

Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Shostak LD, et al. **Exp Cell Res** 1999 Aug 25;251(1):156–65

Establishment of persistent infection with HIV-1 abrogates the caspase-3-dependent apoptotic signaling pathway in U937 cells. Tanaka Y, et al. **Exp Cell Res** 1999 Mar 15; 247(2):514–24

Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins. Fraisier C, et al. **Gene Ther** 1998 Jul;5(7):946–54

Inhibitory mechanism of anti-P30-52 monoclonal antibody against human immunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells. Ota A, et al. **Hybridoma** 1999 Jun;18(3):235–41

Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Speth C, et al. **Immunobiology** 1998 Jul;199(1):152–62

CD8+ lymphocyte-mediated suppression of human immunodeficiency virus type 1 expression in human brain cells. Lokensgard JR, et al. **Immunol Lett** 1999 Apr 15; 67(3):257–61

HIV-1 infectability of CD4+ lymphocytes with relation to beta-chemokines and the CCR5 coreceptor. Paxton WA, et al. **Immunol Lett** 1999 Mar;66(1-3):71–5

Chemokine receptors and HIV-1: the fusion of two major research fields. Horuk R. **Immunol Today** 1999 Feb; 20(2):89–94 (51 ref.)

Cell-dependent functional roles of HIV-1 Nef for virus replication (review). Adachi A, et al. **Int J Mol Med** 1999 Apr;3(4):427–30 (30 ref.)

Cell-dependent function of HIV-1 Vif for virus replication (Review). Inubushi R, et al. **Int J Mol Med** 1999 May; 3(5):473–6 (11 ref.)

The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (Review). Weeks BS. **Int J Mol Med** 1998 Feb;1(2):361–6 (54 ref.)

Failure of HIV-1 to infect human oocytes directly. Baccetti B, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15; 21(5):355–61

Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. Calistri A, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):90–8

Inappropriate model-fitting methods may lead to significant underestimates of viral decay rates in HIV dynamic studies [letter] Wu H, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):426–8

Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase. Kitamura Y, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):105–14

Interleukin-10 enhances tumor necrosis factor-alpha activation of HIV-1 transcription in latently infected T cells. Rabbi MF, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):321–31

Role of post-transcriptional modifications of primer tRNALys,3 in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription. Auxilien S, et al. **J Biol Chem** 1999 Feb 12;274(7):4412–20

Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome. Chen H, et al. **J Biol Chem** 1999 Jun 11; 274(24):17358–64

Regulation of carboxyl-terminal domain phosphatase by HIV-1 tat protein. Marshall NF, et al. **J Biol Chem** 1998 Nov 27;273(48):31726–30

Processing of an HIV replication intermediate by the human DNA replication enzyme FEN1. Rumbaugh JA, et al. **J Biol Chem** 1998 Oct 30;273(44):28740–5

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. Siciliano SJ, et al. **J Biol Chem** 1999 Jan 22;274(4):1905–13

Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo [see comments] Glushakova S, et al. **J Clin Invest** 1999 Sep; 104(5):R7–R11. Comment in: J Clin Invest 1999 Sep;104(5):531.

Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one [comment] Rollins BJ. **J Clin Invest** 1999 Sep;104(5):531–2. Comment on: J Clin Invest 1999 Sep;104(5):R7–R11.

Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. Bukrinskaya A, et al. **J Exp Med** 1998 Dec 7;188(11):2113–25

Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. Honda Y, et al. **J Exp Med** 1998 Oct 5; 188(7):1255–65

Viral dynamics of acute HIV-1 infection. Little SJ, et al. **J Exp Med** 1999 Sep 20;190(6):841–50

Expression of the c-myc proto-oncogene is essential for HIV-1 infection in activated T cells. Sun Y, et al. **J Exp Med** 1999 May 3;189(9):1391–8

Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV-1 entry coreceptor in primary T lymphocytes [comment] Wang JM, et al. **J Exp Med** 1999 Sep 6;190(5):591–5 (40 ref.). Comment on: J Exp Med 1999 Sep 6;190(5):597–605.

Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. Bogers WM, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2895–903

Involvement of protein-DNA interaction in adeno-associated virus Rep78-mediated inhibition of HIV-1. Kokorina NA, et al. **J Hum Virol** 1998 Nov-Dec; 1(7):441–50

Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease. Nicastri E, et al. **J Hum Virol** 1998 Jan-Feb;1(2):90–5

Interferon downregulates CXCR4 (fusin) gene expression in peripheral blood mononuclear cells. Shirazi Y, et al. **J Hum Virol** 1998 Jan-Feb;1(2):69–76

Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. Barillari G, et al. **J Immunol** 1999 Aug 15;163(4):1929–35

Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. Secchiero P, et al. **J Immunol** 1999 Feb 15; 162(4):2427–31

HIV-1 nef expression inhibits the activity of a Ca2+-dependent K+ channel involved in the control of the resting potential in CEM lymphocytes. Zegarra-Moran O, et al. **J Immunol** 1999 May 1;162(9):5359–66

Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. Amiel C, et al. **J Infect Dis** 1999 Jan;179(1):83–91

CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor. Barker E. **J Infect Dis** 1999 May;179 Suppl 3:S485–8 (17 ref.)

Enhanced production of tumor necrosis factor-alpha and interleukin-6 due to prolonged response to lipopolysaccharide in human macrophages infected in vitro with human immunodeficiency virus type 1. Bergamini A, et al. **J Infect Dis** 1999 Apr;179(4):832–42

Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. Gottfredsson M, et al. **J Infect Dis** 1999 Aug;180(2):534–7

Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. Hashemi FB, et al. **J Infect Dis** 1999 Apr;179(4):924–30

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. Kaufmann GR, et al. **J Infect Dis** 1998 Dec;178(6):1812–5

Lactobacilli and vaginal host defense: activation of the human immunodeficiency virus type 1 long terminal repeat, cytokine production, and NF-kappaB. Klebanoff SJ, et al. **J Infect Dis** 1999 Mar;179(3):653–60

Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. Lathey JL, et al. **J Infect Dis** 1999 Aug;180(2):344–50

Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. Lefrère JJ, et al. **J Infect Dis** 1999 Aug; 180(2):526–9

Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. Letendre SL, et al. **J Infect Dis** 1999 Aug;180(2):310–9

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses [published erratum appears in J Infect Dis 1999 May;179(5):1315] Markowitz M, et al. **J Infect Dis** 1999 Mar;179(3):527–37

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. Miller V, et al. **J Infect Dis** 1999 Aug;180(2):530–3

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus. Molina JM, et al. **J Infect Dis** 1999 Aug;180(2):351–8

Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. Nagashunmugam T, et al. **J Infect Dis** 1998 Dec; 178(6):1635–41

Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC

chemokines. Poccia F, et al. **J Infect Dis** 1999 Sep; 180(3):858–61

Effect of immune activation induced by Cryptosporidium parvum whole antigen on in vitro human immunodeficiency virus type 1 infection. Xiao L, et al. **J Infect Dis** 1999 Aug;180(2):559–63

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. Zaunders JJ, et al. **J Infect Dis** 1999 Aug; 180(2):320–9

Chemokine receptors and the molecular basis for human immunodeficiency virus type 1 entry into peripheral hematopoietic stem cells and their progeny. Zhao SF, et al. **J Infect Dis** 1998 Dec;178(6):1623–34

IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. Wang J, et al. **J Leukoc Biol** 1998 Nov; 64(5):642–9

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971–81

Growth characteristics of T-cell tropic HIV-1 vpu gene mutants in human peripheral blood mononuclear cells. Iida S, et al. **J Med Invest** 1999 Feb;46(1–2):43–7

In vitro HIV-1 infection in Macaca nemestrina PBMCs is blocked at a step beyond reverse transcription. Kimball LE, et al. **J Med Primatol** 1998 Apr–Jun;27(2–3):99–103

Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. Candotti D, et al. **J Med Virol** 1999 Jul;58(3):256–63

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. Panther LA, et al. **J Med Virol** 1999 Jun;58(2):165–73

Replication of different clones of human immunodeficiency virus type 1 in primary fetal human astrocytes: enhancement of viral gene expression by Nef. Bencheikh M, et al. **J Neurovirol** 1999 Apr;5(2):115–24

Cytomegalovirus and human herpesvirus-6 trans-activate the HIV-1 long terminal repeat via multiple response regions in human fetal astrocytes [see comments] McCarthy M, et al. **J Neurovirol** 1998 Oct;4(5):495–511. Comment in: J Neurovirol 1998 Oct;4(5):471–3.

CAT-transfected epithelial cells provide evidence for a CD4 independent pathway of HIV infection. Tan X, et al. **J Reprod Immunol** 1998 Dec;41(1–2):307–19

A stochastic model for early HIV-1 population dynamics. Tuckwell HC, et al. **J Theor Biol** 1998 Dec 21; 195(4):451–63

Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. Albright AV, et al. **J Virol** 1999 Jan;73(1):205–13

An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. An DS, et al. **J Virol** 1999 Sep;73(9):7671–7

Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. Bartz SR, et al. **J Virol** 1999 Mar;73(3):1956–63

Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. Bogerd HP, et al. **J Virol** 1998 Nov;72(11):8627–35

The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. Borsetti A, et al. **J Virol** 1998 Nov;72(11):9313–7

Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. Brelot A, et al. **J Virol** 1999 Apr;73(4):2576–86

Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. Bukovsky AA, et al. **J Virol** 1999 Aug;73(8):7087–92

Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. Burniston MT, et al. **J Virol** 1999 Oct;73(10):8527–40

In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. Campbell S, et al. **J Virol** 1999 Mar;73(3):2270–9

Vpu increases susceptibility of human immunodeficiency virus type 1–infected cells to fas killing. Casella CR, et al. **J Virol** 1999 Jan;73(1):92–100

V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. Chan SY, et al. **J Virol** 1999 Mar;73(3):2350–8

trans-dominant interference with human immunodeficiency virus type 1 replication and transmission in CD4(+) cells by an envelope double mutant. Chen SS, et al. **J Virol** 1999 Oct;73(10):8290–302

High-level replication of human immunodeficiency virus in thymocytes requires NF-kappaB activation through interaction with thymic epithelial cells. Chêne L, et al. **J Virol** 1999 Mar;73(3):2064–73

Thymocyte-thymic epithelial cell interaction leads to high-level replication of human immunodeficiency virus exclusively in mature CD4(+) CD8(−) CD3(+) thymocytes: a critical role for tumor necrosis factor and interleukin-7. Chêne L, et al. **J Virol** 1999 Sep; 73(9):7533–42

Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. Dettenhofer M, et al. **J Virol** 1999 Jun;73(6):4696–704

Shift of clinical human immunodeficiency virus type I isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Esté JA, et al. **J Virol** 1999 Jul;73(7):5577–85

The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site. Feng YX, et al. **J Virol** 1999 May;73(5):4251–6

Human immunodeficiency virus type 1 derived from cocultures of immature dendritic cells with autologous T cells carries T-cell-specific molecules on its surface and is highly infectious. Frank I, et al. **J Virol** 1999 Apr; 73(4):3449–54

The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. Gerondelis P, et al. **J Virol** 1999 Jul;73(7):5803–13

Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. Glushakova S, et al. **J Virol** 1999 May; 73(5):3968–74

Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. Gorry PR, et al. **J Virol** 1999 Jan;73(1):352–61

Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein. Hamm TE, et al. **J Virol** 1999 Jul;73(7):5741–7

Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). Hammache D, et al. **J Virol** 1999 Jun;73(6):5244–8

An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. Helga-Maria C, et al. **J Virol** 1999 May;73(5):4127–35

HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. Hindmarsh P, et al. **J Virol** 1999 Apr;73(4):2994–3003

Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract. Hladik F, et al. **J Virol** 1999 Jul;73(7):5833–42

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. Huang L, et al. **J Virol** 1998 Nov;72(11):8952–60

Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. Hung CS, et al. **J Virol** 1999 Oct;73(10):8216–26

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. Ji H, et al. **J Virol** 1999 Oct;73(10):8578–86

Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism. Kato K, et al. **J Virol** 1999 Jul;73(7):5520–6

Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. Kaye JF, et al. **J Virol** 1999 Apr; 73(4):3023–31

Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. Kiernan RE, et al. **J Virol** 1999 Jun;73(6):4728–37

Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. Kolchinsky P, et al. **J Virol** 1999 Oct;73(10):8120–6

Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. Korin YD, et al. **J Virol** 1999 Aug;73(8):6526–32

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. Kosalaraksa P, et al. **J Virol** 1999 Jul;73(7):5356–63

Association of Nef with the human immunodeficiency virus type 1 core. Kotov A, et al. **J Virol** 1999 Oct; 73(10):8824–30

Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes. Lee YM, et al. **J Virol** 1999 Jul; 73(7):5654–62

Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. Lewin SR, et al. **J Virol** 1999 Jul;73(7):6099–103

Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site. Liang C, et al. **J Virol** 1999 Aug; 73(8):7014–20

Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. Liu B, et al. **J Virol** 1999 Apr; 73(4):2901–8

Targeting human immunodeficiency virus (HIV) type 2 integrase protein into HIV type 1. Liu H, et al. **J Virol** 1999 Oct;73(10):8831–6

Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes. Ludwig E, et al. **J Virol** 1999 Oct;73(10):8279–89

Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. Luzuriaga K, et al. **J Virol** 1999 Jan;73(1):362–7

HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication. Mackewicz CE, et al. **J Virol** 1998 Dec;72(12):10165–70

RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells. Martinand C, et al. **J Virol** 1999 Jan;73(1):290–6

Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. Naif HM, et al. **J Virol** 1999 Jun;73(6):4866–81

Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. Ohagen A, et al. **J Virol** 1999 Feb;73(2):897–906

Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein. Ott DE, et al. **J Virol** 1999 Jan;73(1):19–28

Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting. Paillart JC, et al. **J Virol** 1999 Apr; 73(4):2604–12

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. Park EJ, et al. **J Virol** 1999 Jul;73(7):5707–13

Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. Pedroza-Martins L, et al. **J Virol** 1998 Dec; 72(12):9441–52

Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. Poss M, et al. **J Virol** 1999 Jul;73(7):5255–64

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. Salzwedel K, et al. **J Virol** 1999 Mar;73(3):2469–80

Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. Schubert U, et al. **J Virol** 1999 Feb;73(2):887–96

Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1. Segura I, et al. **J Virol** 1999 Jun;73(6):5207–13

Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. Sharma PL, et al. **J Virol** 1999 Oct; 73(10):8448–56

Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. Shen H, et al. **J Virol** 1999 Jan;73(1):728–37

An orphan G protein-coupled receptor, GPR1, acts as a coreceptor to allow replication of human immunodeficiency virus types 1 and 2 in brain-derived cells. Shimizu N, et al. **J Virol** 1999 Jun;73(6):5231–9

Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. Simon JH, et al. **J Virol** 1999 Apr;73(4):2667–74

Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. Sutton RE, et al. **J Virol** 1999 May; 73(5):3649–60

Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions. Suzuki Y, et al. **J Virol** 1999 Jan;73(1):316–24

Dissecting the role of the N-terminal domain of human immunodeficiency virus integrase by trans-complementation analysis. van den Ent FM, et al. **J Virol** 1999 Apr;73(4):3176–83

A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus. Verhoef K, et al. **J Virol** 1999 Apr;73(4):2781-9

Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. Yang X, et al. **J Virol** 1999 Apr; 73(4):3460-6

Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. Yi Y, et al. **J Virol** 1999 Sep;73(9):7117-25

Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. Zhang YJ, et al. **J Virol** 1998 Nov;72(11):9337-44

Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? Zhang YJ, et al. **J Virol** 1999 Apr;73(4):3443-8

Nucleoporins nup98 and nup214 participate in nuclear export of human immunodeficiency virus type 1 Rev. Zolotukhin AS, et al. **J Virol** 1999 Jan;73(1):120-7

Effect of potentially interfering substances on the measurement of HIV-1 viral load by the bDNA assay. Alonso R, et al. **J Virol Methods** 1999 Mar;78(1-2):149-52

Enhanced replication of M-tropic HIV-1 strains in Herpesvirus saimiri immortalised T-cells which express CCR5. Vella C, et al. **J Virol Methods** 1999 Apr;79(1):51-63

Modulation of cell surface protein expression by infection with HIV-1. Speth C, et al. **Leukemia** 1999 Apr;13 Suppl 1:S99-105 (85 ref.)

Influence of delayed viral production on viral dynamics in HIV-1 infected patients. Mittler JE, et al. **Math Biosci** 1998 Sep;152(2):143-63

Using physical-chemistry-based substitution models in phylogenetic analyses of HIV-1 subtypes. Koshi JM, et al. **Mol Biol Evol** 1999 Feb;16(2):173-9

HIV Tat represses transcription of the beta 2-microglobulin promoter. Carroll IR, et al. **Mol Immunol** 1998 Dec; 35(18):1171-8

Benzodiazepines, glia, and HIV-1 neuropathogenesis. Lokensgard JR, et al. **Mol Neurobiol** 1998 Aug;18(1):23-33 (69 ref.)

HIV-1 and chemokines in the brain: location, location--location? [news] Tran PB, et al. **Mol Psychiatry** 1999 May;4(3):203-5, 202

HIV-1 Nef protein: An invitation to a kill [news; comment] Cullen BR. **Nat Med** 1999 Sep;5(9):985-6. Comment on: Nat Med 1999 Sep;5(9):997-1003.

CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue [see comments] Grivel JC, et al. **Nat Med** 1999 Mar;5(3):344-6 . Comment in: Nat Med 1999 Jun;5(6):592-3.

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments] Kilby JM, et al. **Nat Med** 1998 Nov; 4(11):1302-7. Comment in: Nat Med 1998 Nov;4(11):1232-3.

HIV-1 entry inhibitors: evading the issue [news] Michael NL, et al. **Nat Med** 1999 Jul;5(7):740-2

Local people threaten chimp sanctuary [news] Novak K. **Nat Med** 1999 Jul;5(7):718

Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev [published erratum appears in Nat Med 1999 Jul;5(7):849] Reddy TR, et al. **Nat Med** 1999 Jun;5(6):635-42

HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages [see comments] Swingler S, et al. **Nat Med** 1999 Sep;5(9):997-103. Comment in: Nat Med 1999 Sep;5(9):985-6.

Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein [see comments] Vocero-Akbani AM, et al. **Nat Med** 1999 Jan;5(1):29-33 . Comment in: Nat Med 1999 Jan;5(1):27-8.

Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Wang Y, et al. **Nat Med** 1999 Sep;5(9):1004-9

Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Peterson PK, et al. **Neuropharmacology** 1999 Feb; 38(2):273-8

Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system. Rohr O, et al. **Nucleic Acids Res** 1999 Aug 15;27(16):3291-9

Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro. Veal GJ, et al. **Nucleic Acids Res** 1998 Dec 15; 26(24):5670-5

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides. Brodin P, et al. **Nucleosides Nucleotides** 1999 Jun-Jul; 18(6-7):1717-8

Virological aspects of human immunodeficiency virus infection. Catton MG. **P N G Med J** 1996 Sep;39(3):166-73 (7 ref.)

Effect of superimposed infections on viral replication in human immunodeficiency virus type 1-infected children. Marchisio P, et al. **Pediatr Infect Dis J** 1998 Aug; 17(8):755-7

A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir. Pelton SI, et al. **Pediatr Infect Dis J** 1999 Jul; 18(7):650-2

Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Romanelli F, et al. **Pharmacotherapy** 1999 Feb; 19(2):196-204 (39 ref.)

Genetic determinants of HIV-1 infection and its manifestations. Kaslow RA, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):299-307 (62 ref.)

Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription. Chen D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2728-33

Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Flores O, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22; 96(13):7208-13

Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase. Gladyshev VN, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):835-9

Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Hoffman TL, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6359-64

Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Kaul M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8212-6

HIV type-1 infection of the cotton rat (Sigmodon fulviventer and S. hispidus). Langley RJ, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14355-60

HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Marzio G, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13519-24

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Meyer PR, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13471-6

The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Puri A, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14435-40

Coalescent estimates of HIV-1 generation time in vivo. Rodrigo AG, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2187-91

A practical method for simultaneously determining the effective burst sizes and cycle times of viruses. Spouge JL, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7017-22

HIV-1 Gag shares a signature motif with annexin (Anx7), which is required for virus replication. Srivastava M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2704-9

Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Wahl SM, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12574-9

Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Wang WK, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4558-62

Constitutive cell surface association between CD4 and CCR5. Xiao X, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22; 96(13):7496-501

Susceptibility of human lymphoblastoid B-cell line CE to HIV1 infection. Valli MB, et al. **Res Virol** 1998 Sep-Oct; 149(5):307-9

Viral protein R of HIV-1. Bukrinsky M, et al. **Rev Med Virol** 1999 Jan-Mar;9(1):39-49 (83 ref.)

Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339-46 (80 ref.)

The role of nucleocapsid of HIV-1 in virus assembly. Dawson L, et al. **Virology** 1998 Nov 10;251(1):141-57

A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Dimitrov DS, et al. **Virology** 1999 Jun 20; 259(1):1-6

HIV-1 gag proteins: diverse functions in the virus life cycle. Freed EO. **Virology** 1998 Nov 10;251(1):1-15 (179 ref.)

Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences. Gorelick RJ, et al. **Virology** 1999 Mar 30;256(1):92-104

Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. Kootstra NA, et al. **Virology** 1999 Jan 20;253(2):170-80

U937 cells overexpressing bcl-xl are resistant to human immunodeficiency virus-1-induced apoptosis and human immunodeficiency virus-1 replication. Marshall WL, et al. **Virology** 1999 Mar 30;256(1):1-7

Mapping of HIV-1 determinants of apoptosis in infected T cells. Rapaport E, et al. **Virology** 1998 Dec 20;252(2):407-17

Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Shimizu N, et al. **Virology** 1999 Jul 5;259(2):324-33

Gag protein from human immunodeficiency virus type 1 assembles in the absence of cyclophilin A. Streblow DN, et al. **Virology** 1998 Dec 5;252(1):228-34

Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid. Wiegers K, et al. **Virology** 1999 Apr 25;257(1):261-74

Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Wimmer J, et al. **Virology** 1999 Mar 1;255(1):182-9

Inhibition of HIV/SIV replication by dominant negative Gag mutants. Shimano R, et al. **Virus Genes** 1999;18(3):197-201

[Another look at the AIDS virus] Burny A. **Bull Mem Acad R Med Belg** 1998;153(2):139-43 **(Fre)**

[Increase of circulating CD3+CD4-CD8-CD19+ cells in the latent phase of HIV-1 infection] Nozaki-Renard J, et al. **C R Seances Soc Biol Fil** 1998;192(5):1007-15 (Eng. Abstr.) **(Fre)**

[HIV-1 integration and viral replication] Masuda T. **Uirusu** 1998 Jun;48(1):19-25 (38 ref.) **(Jpn)**

[Biological properties of primary HIV-1 isolates with varying serotype] Pashkova TA, et al. **Vopr Virusol** 1998 Nov-Dec; 43(6):256-61 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Human immunodeficiency virus (HIV) inactivation of banked bone by gamma irradiation. Salai M, et al. **Ann Transplant** 1997;2(1):55-6

X-rays-induced secretion of cellular factor(s) that enhance(s) HIV-1 promoter transcription in various non-irradiated transfected cell lines. Faure E. **Cell Mol Biol (Noisy-le-grand)** 1998 Dec;44(8):1275-92

Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. Breuer-McHam J, et al. **J Am Acad Dermatol** 1999 Jan;40(1):48-60

[Influence of irradiation on the risk of HIV virus transmission by bone allograft] Hernigou P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):493-500 (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Further evidence for hexagonal organization of HIV gag protein in prebudding assemblies and immature virus-like particles. Nermut MV, et al. **J Struct Biol** 1998 Oct; 123(2):143-9

HIV-1-ASSOCIATED COGNITIVE MOTOR COMPLEX see **AIDS DEMENTIA COMPLEX**

HIV-1 CORE PROTEIN P24 see **HIV CORE PROTEIN P24**

HIV-1 ENVELOPE PROTEIN GP41 see **HIV ENVELOPE PROTEIN GP41**

HIV-1 ENVELOPE PROTEIN GP120 see **HIV ENVELOPE PROTEIN GP120**

HIV-1 ENVELOPE PROTEIN GP160 see **HIV ENVELOPE PROTEIN GP160**

HIV-1 INTEGRASE see **HIV INTEGRASE**

HIV-1 PROTEASE see **HIV PROTEASE**

HIV-1 REVERSE TRANSCRIPTASE

ANALYSIS

Colorimetric capture assay for human-immunodeficiency-virus-1 reverse transcriptase activity. Rytting AS, et al. **Biotechnol Appl Biochem** 1999 Jun;29 (Pt 3):241-50

Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase. Nissley DV, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13905-10

ANTAGONISTS & INHIBITORS

Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. Vázquez-Rosales G, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1191-200

A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). García Lerma J, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):264-70

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Hughes W, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):609-15

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Kumar PN, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):603-8

Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Miller V, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3123-9

Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12

and other antiretroviral agents in acutely and chronically infected cells. Okamoto M, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):492–7

Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues. Velázquez S, et al. **Antivir Chem Chemother** 1998 Nov; 9(6):481–9

Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Ventura M, et al. **Arch Virol** 1999;144(3):513–23

Nitric oxide inhibits the HIV-1 reverse transcriptase activity. Persichini T, et al. **Biochem Biophys Res Commun** 1999 May 19;258(3):624–7

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Arion D, et al. **Biochemistry** 1998 Nov 10;37(45):15908–17

Conformational study of the HIV-1 reverse transcriptase inhibitor 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Lawtrakul L, et al. **Biol Chem** 1999 Feb; 380(2):265–7

Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Vig R, et al. **Bioorg Med Chem** 1998 Oct;6(10):1789–97

Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mao C, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2213–8

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2. Milton J, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2623–8 (11 ref.)

Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz. Mutlib AE, et al. **Drug Metab Dispos** 1999 Sep; 27(9):1045–56

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E. **Farmaco** 1999 Jan-Feb;54(1-2):26–45 (157 ref.)

Mechanistic studies show that (–)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. Feng JY, et al. **FASEB J** 1999 Sep;13(12):1511–7

The connection domain is implicated in metalloporphyrin binding and inhibition of HIV reverse transcriptase. Argyris EG, et al. **J Biol Chem** 1999 Jan 15;274(3):1549–56

A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. Morris MC, et al. **J Biol Chem** 1999 Aug 27; 274(35):24941–6

Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. Suo Z, et al. **J Biol Chem** 1998 Oct 16;273(42):27250–8

A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. Rao GS, et al. **J Biomol Struct Dyn** 1998 Oct; 16(2):347–54

Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication. Arranz E, et al. **J Med Chem** 1998 Oct 8; 41(21):4109–17

Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. Eriksson MA, et al. **J Med Chem** 1999 Mar 11;42(5):868–81

5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. Mai A, et al. **J Med Chem** 1999 Feb 25; 42(4):619–27

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. Ren J, et al. **J Med Chem** 1999 Sep 23; 42(19):3845–51

Synthesis and biological evaluation of 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. Shi J, et al. **J Med Chem** 1999 Mar 11;42(5):859–67

Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. Smith RH Jr, et al. **J Med Chem** 1998 Dec 17;41(26):5272–86

Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. Velázquez S, et al. **J Med Chem** 1998 Nov 5;41(23):4636–47

Cross-strand purine-pyrimidine stack and sheared purine.pyrimidine pairing in the human HIV-1 reverse transcriptase inhibitors. Chou SH, et al. **J Mol Biol** 1999 Jan 8;285(1):41–8

Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Baum SE, et al. **Mil Med** 1999 Sep;164(9):609–12

Modified (PNA, 2'-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Boulmé F, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5492–500

Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase. Hnatyszyn O, et al. **Phytother Res** 1999 May;13(3):206–9

HIV reverse transcriptase inhibitors of natural origin. Matthée G, et al. **Planta Med** 1999 Aug;65(6):493–506 (137 ref.)

[Diagnosis and treatment of ocular viral infections in AIDS patients] Guex-Crosier Y. **Rev Med Suisse Romande** 1998 Nov;118(11):941–7 (15 ref.) (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. Morris MC, et al. **J Biol Chem** 1999 Aug 27; 274(35):24941–6

CHEMISTRY

Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. Esnouf RM, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):938–53

Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Brindeiro R, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1674–80

Mechanistic studies comparing the incorporation of (+) and (–) isomers of 3TCTP by HIV-1 reverse transcriptase. Feng JY, et al. **Biochemistry** 1999 Jan 5;38(1):55–63

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Ren J, et al. **Biochemistry** 1998 Oct 13;37(41):14394–403

Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme. Tasara T, et al. **Biochemistry** 1999 Feb 2;38(5):1633–42

Docking experiments in the flexible non-nucleoside inhibitor binding pocket of HIV-1 reverse transcriptase. Titmuss SJ, et al. **Bioorg Med Chem** 1999 Jun;7(6):1163–70

Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Sarafianos SG, et al. **Chem Biol** 1999 May;6(5):R137–46 (68 ref.)

Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli – two tags tie it up. Maier G, et al. **Eur J Biochem** 1999 Apr; 261(1):10–8

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. Pelemans H, et al. **J Biol Chem** 1998 Dec 18; 273(51):34234–9

Residues in the alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. Powell MD, et al. **J Biol Chem** 1999 Jul 9;274(28):19885–93

Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. Ding J, et al. **J Mol Biol** 1998 Dec 11;284(4):1095–111

Cross-linking localization of a HIV-1 reverse transcriptase peptide involved in the binding of primer tRNALys3. Dufour E, et al. **J Mol Biol** 1999 Jan 29;285(4):1339–46

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Hsiou Y, et al. **J Mol Biol** 1998 Nov 27;284(2):313–23

Enhanced impairment of chain elongation by inhibitors of HIV reverse transcriptase in cell-free reactions yielding longer DNA products. Quan Y, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5692–8

Field-based similarity forcing in energy minimization and molecular matching. Blinn JR, et al. **Pac Symp Biocomput** 1999;:415–25

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Sarafianos SG, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10027–32

Major subdomain rearrangement in HIV-1 reverse transcriptase simulated by molecular dynamics. Madrid M, et al. **Proteins** 1999 May 15;35(3):332–7

Outsmarting HIV drug resistance [news; comment] Balter M. **Science** 1998 Nov 27;282(5394):1623, 1625. Comment on: Science 1998 Nov 27;282(5394):1669–75.

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance [see comments] Huang H, et al. **Science** 1998 Nov 27; 282(5394):1669–75. Comment in: Science 1998 Nov 27;282(5394):1623, 1625.

Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands. Medrano L, et al. **Virus Genes** 1999;18(3):203–10

GENETICS

Selective vertical transmission of HIV-1 antiretroviral resistance mutations. Colgrove RC, et al. **AIDS** 1998 Dec 3;12(17):2281–8

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. de Jong JJ, et al. **AIDS** 1999 Jan 14;13(1):75–80

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. Keulen W, et al. **AIDS** 1999 Jul 30;13(11):1343–9

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. Lorenzi P, et al. **AIDS** 1999 Feb 4;13(2):F17–21

High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population [letter] Loveday C, et al. **AIDS** 1999 Apr 1;13(5):627–8

Identification of reverse transcriptase mutations associated with HIV-1 drug resistance mainly against non-nucleoside reverse transcriptase inhibitors in treatment-naive patients [letter] Magiorkinis E, et al. **AIDS** 1999 Jul 9;13(10):1276–8

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. Tamalet C, et al. **AIDS** 1998 Oct 1;12(14):F161–6

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Larder BA, et al. **Antimicrob Agents Chemother** 1999 Aug; 43(8):1961–7

A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (–)-beta-2',3'-dideoxy-3'-thiacytidine. Smith RA, et al. **Antimicrob Agents Chemother** 1999 Aug; 43(8):2077–80

Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase. Tachedjian G, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):3038–43

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Balzarini J. **Biochem Pharmacol** 1999 Jul 1;58(1):1–27 (219 ref.)

Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate. Tramontano E, et al. **Biochem Pharmacol** 1998 Dec 15;56(12):1583–9

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Arion D, et al. **Biochemistry** 1998 Nov 10;37(45):15908–17

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Feng JY, et al. **Biochemistry** 1999 Jul 20;38(29):9440–8

Studies on the effects of truncating alpha-helix E' of p66 human immunodeficiency virus type 1 reverse transcriptase on template-primer binding and fidelity of DNA synthesis. Menéndez-Arias L. **Biochemistry** 1998 Nov 24; 37(47):16636–44

Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme. Tasara T, et al. **Biochemistry** 1999 Feb 2;38(5):1633–42

Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance. Vaccaro JA, et al. **Biochemistry** 1998 Oct 6; 37(40):14189–94

Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli – two tags tie it up. Maier G, et al. **Eur J Biochem** 1999 Apr; 261(1):10–8

Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. Isaguliants MG, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):232–6

Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. Catucci M, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):203–8

Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine. Orlandi P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):230–7

Vertical-scanning mutagenesis of a critical tryptophan in the minor groove binding track of HIV-1 reverse transcriptase. Molecular nature of polymerase-nucleic acid interactions. Beard WA, et al. **J Biol Chem** 1998 Nov 13; 273(46):30435–42

Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Schuurman R, et al. **J Clin Microbiol** 1999 Jul;37(7):2291–6

Manganese cations increase the mutation rate of human immunodeficiency virus type 1 ex vivo. Vartanian JP, et

al. **J Gen Virol** 1999 Aug;80 (Pt 8):1983–6
Fast genotypic detection of drug resistance mutations in the HIV–1 reverse transcriptase gene of treatment–naive patients. Fontaine E, et al. **J Hum Virol** 1998 Nov–Dec; 1(7):451–6
Identification of insertion mutations in HIV–1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. Sugiura W, et al. **J Hum Virol** 1999 May–Jun;2(3):146–53
Codon 215 mutations in human immunodeficiency virus–infected pregnant women. Swiss Collaborative HIV and Pregnancy' Study. Kully C, et al. **J Infect Dis** 1999 Mar;179(3):705–8
Human immunodeficiency virus type 1 expressing the lamivudine–associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Miller MD, et al. **J Infect Dis** 1999 Jan;179(1):92–100
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations [letter] Monno L, et al. **J Infect Dis** 1999 Aug;180(2):568–71
Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Young B, et al. **J Infect Dis** 1998 Nov; 178(5):1497–501
Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV–1 drug resistance. Puchhammer–Stöckl E, et al. **J Med Virol** 1999 Mar; 57(3):283–9
Analysis of amino insertion mutations in the fingers subdomain of HIV–1 reverse transcriptase. Boyer PL, et al. **J Mol Biol** 1999 Mar 5;286(4):995–1008
Characterization of human immunodeficiency virus type–1 (HIV–1) particles that express protease–reverse transcriptase fusion proteins. Cherry E, et al. **J Mol Biol** 1998 Nov 20;284(1):43–56
Second–site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. Olivares I, et al. **J Virol** 1999 Aug;73(8):6293–8
Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine–selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine–selected Met184Val. Sharma PL, et al. **J Virol** 1999 Oct; 73(10):8448–56
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV–1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. Demeter LM, et al. **J Virol Methods** 1998 Nov;75(1):93–104
Genetic polymorphism near HIV–1 reverse transcriptase resistance–associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. Koch N, et al. **J Virol Methods** 1999 Jun; 80(1):25–31
HIV–1 drug resistance in newly infected individuals [see comments] Boden D, et al. **JAMA** 1999 Sep 22–29; 282(12):1135–41. Comment in: JAMA 1999 Sep 22–29;282(12):1177–9.
A new source of resistance to HIV drugs. Wainberg MA. **JAMA** 1999 Jun 16;281(23):2169–70
Long–read direct infrared sequencing of crude PCR products for prediction of resistance to HIV–1 reverse transcriptase and protease inhibitors. Zazzi M, et al. **Mol Biotechnol** 1998 Aug;10(1):1–8
A mechanism of AZT resistance: an increase in nucleotide–dependent primer unblocking by mutant HIV–1 reverse transcriptase. Meyer PR, et al. **Mol Cell** 1999 Jul; 4(1):35–43
The influence of 3TC–resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency. Hamburgh ME, et al. **Nucleic Acids Res** 1998 Oct 1;26(19):4389–94
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Shafer RW, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):348–52
Hybrid Ty1/HIV–1 elements used to detect inhibitors and monitor the activity of HIV–1 reverse transcriptase. Nissley DV, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10; 95(23):13905–10
Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages. Bossi P, et al. **Res Virol** 1998 Nov–Dec;149(6):355–61
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Martinez MA, et al. **Virology** 1999 Apr 10;256(2):180–7

IMMUNOLOGY

Cytotoxic T–cell responses to HIV–1 reverse transcriptase, integrase and protease. Haas G, et al. **AIDS** 1998 Aug 20; 12(12):1427–36
Antagonistic activity of HIV–1 T helper peptides flanked by an unrelated carrier protein. Fenoglio D, et al. **Eur J Immunol** 1999 May;29(5):1448–55
Generation of HIV–1/HIV–2 cross–reactive peptide antisera by small sequence changes in HIV–1 reverse transcriptase and integrase immunizing peptides. Klutch M, et al. **J Biomed Sci** 1998;5(3):192–202
Biased TCR repertoire in HIV–1–infected patients due to clonal expansion of HIV–1–reverse transcriptase–specific CTL clones. Kolowos W, et al. **J Immunol** 1999 Jun 15; 162(12):7525–33
The importance of pairwise interactions between peptide residues in the delineation of TCR specificity. Leggatt GR, et al. **J Immunol** 1998 Nov 1;161(9):4728–35
IFN–gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV–1 reverse transcriptase. Sewell AK, et al. **J Immunol** 1999 Jun 15;162(12):7075–9
Identification of a conserved universal Th epitope in HIV–1 reverse transcriptase that is processed and presented to HIV–specific CD4+ T cells by at least four unrelated HLA–DR molecules. van der Burg SH, et al. **J Immunol** 1999 Jan 1;162(1):152–60
Recognition of HIV–derived B and T cell epitopes displayed on filamentous phages. De Berardinis P, et al. **Vaccine** 1999 Mar 17;17(11–12):1434–41
Cytotoxic T–lymphocyte responses to HIV–1 reverse transcriptase (review). Menéndez–Arias L, et al. **Viral Immunol** 1998;11(4):167–81 (81 ref.)

METABOLISM

Structure–based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Sudbeck EA, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3225–33
HIV–1 reverse transcription: a brief overview focused on structure–function relationships among molecules involved in initiation of the reaction. Götte M, et al. **Arch Biochem Biophys** 1999 May 15;365(2):199–210 (118 ref.)
HIV–1 reverse transcriptase is capable of elongating derivatives of sequence specific noncomplementary oligodeoxynucleotides. Martyanov IV, et al. **Biochem Mol Biol Int** 1998 Aug;45(5):857–64
Actinomycin D inhibition of DNA strand transfer reactions catalyzed by HIV–1 reverse transcriptase and nucleocapsid protein. Davis WR, et al. **Biochemistry** 1998 Oct 6; 37(40):14213–21
Explanation of pre–steady–state kinetics and decreased burst amplitude of HIV–1 reverse transcriptase at sites of modified DNA bases with an additional, nonproductive enzyme–DNA–nucleotide complex. Furge LL, et al. **Biochemistry** 1999 Apr 13;38(15):4818–25
Kinetic analysis of the effect of HIV nucleocapsid protein (NCp) on internal strand transfer reactions. Raja A, et al. **Biochemistry** 1999 Apr 20;38(16):5178–84
The effect of template RNA structure on elongation by HIV–1 reverse transcriptase. Klasens BI, et al. **Biochim Biophys Acta** 1999 Mar 19;1444(3):355–70
Biochemical characterization of recombinant HIV–1 reverse transcriptase (rRT) as a glycyrrhizin–binding protein and the CK–II–mediated stimulation of rRT activity potently inhibited by glycyrrhetinic acid derivative. Harada S, et al. **Biol Pharm Bull** 1998 Dec;21(12):1282–5
Effects of trace metal compounds on HIV–1 reverse transcriptase: an in vitro study. Sabbioni E, et al. **Biol Trace Elem Res** 1999 May;68(2):107–19
Interaction of tRNA–derivatives and oligonucleotide primers with AZT–resistant mutants of HIV–1 reverse transcriptase. Zakharova OD, et al. **Bioorg Med Chem** 1998 Nov;6(11):2041–9
A dipyrido [2,3–b:3',2'–f]azepine analog of the HIV–1 reverse transcriptase inhibitor nevirapine. Dyatkin AB, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2169–72
Recognition of 2'–deoxyisoguanosine triphosphate by HIV–1 reverse transcriptase and mammalian cellular DNA polymerases. Lutz MJ, et al. **Bioorg Med Chem Lett** 1998 Mar 3;8(5):499–504
In vitro anti–human immunodeficiency virus (HIV) activity of the chromanone derivative, 12–oxocalanolide A, a novel NNRTI. Xu ZQ, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2179–84
Probing interactions between HIV–1 reverse transcriptase and its DNA substrate with backbone–modified nucleotides. Marx A, et al. **Chem Biol** 1999 Feb;6(2):111–6
Nonlinear pharmacokinetics of efavirenz (DMP–266), a potent HIV–1 reverse transcriptase inhibitor, in rats and monkeys. Balani SK, et al. **Drug Metab Dispos** 1999 Jan; 27(1):41–5
Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. Isaguliants MG, et al. **FEBS Lett** 1999 Mar 26; 447(2–3):232–6
Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV–1. Druillennec S, et al. **J Biol Chem** 1999 Apr 16;274(16):11283–8
Functional analysis of amino acid residues constituting the dNTP binding pocket of HIV–1 reverse transcriptase. Harris D, et al. **J Biol Chem** 1998 Dec 11;273(50):33624–34
Involvement of HIV–I nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro. Lener D, et al. **J Biol Chem** 1998 Dec 11;273(50):33781–6
Mutational analysis of Tyr–318 within the non–nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase. Pelemans H, et al. **J Biol Chem** 1998 Dec 18; 273(51):34234–9
DNA secondary structure effects on DNA synthesis catalyzed by HIV–1 reverse transcriptase. Suo Z, et al. **J Biol Chem** 1998 Oct 16;273(42):27259–67
NMR structure of the chimeric hybrid duplex r(gcaguggc).r(gcca)d(CTGC) comprising the tRNA–DNA junction formed during initiation of HIV–1 reverse transcription. Szyperski T, et al. **J Biomol NMR** 1999 Apr; 13(4):343–55
IFN–gamma exposes a cryptic cytotoxic T lymphocyte epitope in HIV–1 reverse transcriptase. Sewell AK, et al. **J Immunol** 1999 Jun 15;162(12):7075–9
Crystallographic analysis of the binding modes of thiazoloisoindolinone non–nucleoside inhibitors to HIV–1 reverse transcriptase and comparison with modeling studies. Ren J, et al. **J Med Chem** 1999 Sep 23; 42(19):3845–51
Structure and functional implications of the polymerase active site region in a complex of HIV–1 RT with a double–stranded DNA template–primer and an antibody Fab fragment at 2.8 A resolution. Ding J, et al. **J Mol Biol** 1998 Dec 11;284(4):1095–111
Cross–linking localization of a HIV–1 reverse transcriptase peptide involved in the binding of primer tRNALys3. Dufour E, et al. **J Mol Biol** 1999 Jan 29;285(4):1339–46
Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. Gutiérrez–Rivas M, et al. **J Mol Biol** 1999 Jul 16;290(3):615–25
Recombination during reverse transcription: an evaluation of the role of the nucleocapsid protein. Negroni M, et al. **J Mol Biol** 1999 Feb 12;286(1):15–31
Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. de la Carrière LC, et al. **J Virol** 1999 Apr;73(4):3455–9
RNase H requirements for the second strand transfer reaction of human immunodeficiency virus type 1 reverse transcription. Smith CM, et al. **J Virol** 1999 Aug; 73(8):6573–81
Effect of mutations in NC7 on endogenous reverse transcription in HIV–1. Hsu M, et al. **Leukemia** 1999 Apr; 13 Suppl 1:S113–5
Closing in on HIV drug resistance [news] Larder BA, et al. **Nat Struct Biol** 1999 Feb;6(2):103–6
Molecular basis for the enantioselectivity of HIV–1 reverse transcriptase: role of the 3'–hydroxyl group of the L–(beta)–ribose in chiral discrimination between D– and L–enantiomers of deoxy– and dideoxy–nucleoside triphosphate analogs. Maga G, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):972–8
Structural determinants of HIV–1 reverse transcriptase stereoselectivity towards (beta)–L–deoxy– and dideoxy–pyrimidine nucleoside triphosphates: molecular basis for the combination of L–dideoxynucleoside analogs with non–nucleoside inhibitors in anti HIV chemotherapy. Maga G, et al. **Nucleosides Nucleotides** 1999 Apr–May; 18(4–5):795–805
Unblocking of chain–terminated primer by HIV–1 reverse transcriptase through a nucleotide–dependent mechanism. Meyer PR, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13471–6
Lamivudine (3TC) resistance in HIV–1 reverse transcriptase involves steric hindrance with beta–branched amino acids. Sarafianos SG, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10027–32

PHYSIOLOGY

Second–site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. Olivares I, et al. **J Virol** 1999 Aug;73(8):6293–8

HIV–1 REVERSE TRANSCRIPTASE P51 see **HIV–1 REVERSE TRANSCRIPTASE**

HIV–1 REVERSE TRANSCRIPTASE P66 see **HIV–1 REVERSE TRANSCRIPTASE**

HIV–2

Similar birthweight in children born to HIV–2 infected and HIV–negative women in Guinea–Bissau [letter] Norrgren H, et al. **Acta Paediatr** 1998 Jul;87(7):816–7
Child survival in children born to HIV–2 infected women in Guinea–Bissau, West Africa. Norrgren H, et al. **Acta Trop** 1999 Apr 30;72(3):309–15
Auto–amputation of the penis in HIV infected patient [letter] Bakare RA, et al. **Afr J Med Med Sci** 1998 Mar–Jun; 27(1–2):137
Improved detection of HIV–2 proviral DNA in dually seroreactive individuals by PCR. Ishikawa K, et al. **AIDS** 1998 Aug 20;12(12):1419–25
Declining HIV–2 prevalence and incidence among men in a community study from Guinea–Bissau. Larsen O, et al. **AIDS** 1998 Sep 10;12(13):1707–14
Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Côte d'Ivoire. Nkengasong JN, et al. **AIDS** 1999 Jan 14;13(1):109–17
HIV–negative infants born to HIV–1 but not HIV–2–positive mothers fail to develop a Bacillus Calmette–Guérin scar [letter] Ota MO, et al. **AIDS** 1999 May 28;13(8):996–8
Antibodies to the HIV type 2 core protein p26 and Vpx: association with disease progression. Popper SJ, et al.

AIDS Res Hum Retroviruses 1998 Sep 1;14(13):1157-62
High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. Walther-Jallow L, et al.
AIDS Res Hum Retroviruses 1999 Jul 20;15(11):957-62
Thrombotic microangiopathy in the HIV-2-infected macaque. Eitner F, et al. **Am J Pathol** 1999 Aug; 155(2):649-61
The use of a chimera HIV-1/HIV-2 envelope protein for immunodiagnosis of HIV infection: its expression and purification in E. coli by use of a translation initiation site within HIV-1 env gene. Han B, et al.
Biochem Mol Biol Int 1998 Oct;46(3):607-17
Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Ylisastigui L, et al.
Biomed Pharmacother 1998;52(10):447-53
Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infection. Jobe O, et al.
Clin Exp Immunol 1999 Jun;116(3):474-8
AIDS and HIV infection in the United Kingdom: monthly report. **Commun Dis Rep CDR Wkly** 1999 Sep 24; 9(39):353-4
Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Akimoto H, et al.
Immunology 1998 Oct;95(2):214-8
Increasing prevalence of HIV-2 and dual HIV-1-2 infections among high risk group hospital admitted patients in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Nov;52(11):479-84
Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group. Machuca A, et al.
Intervirology 1999;42(1):37-42
Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8 [see comments] Ariyoshi K, et al. **J Hum Virol** 1998 Mar-Apr;1(3):193-9 . Comment in: J Hum Virol 1998 Mar-Apr;1(3):185-6.
Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections. Sarr AD, et al. **J Hum Virol** 1999 Jan-Feb; 2(1):45-51
Detection of JC virus in two African cases of progressive multifocal leukoencephalopathy including identification of JCV type 3 in a Gambian AIDS patient. Stoner GL, et al. **J Med Microbiol** 1998 Aug;47(8):733-42
Human immunodeficiency virus prevalence in women at delivery using unlinked anonymous testing of newborns in the Malaysian setting. Amar HS, et al.
J Paediatr Child Health 1999 Feb;35(1):63-6
Clinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau. Norrgren H, et al. **Scand J Infect Dis** 1998; 30(4):323-9
HIV-2 status in southern India. Kannangai R, et al.
Trans R Soc Trop Med Hyg 1999 Jan-Feb;93(1):30-1
Retinal manifestations of HIV-1 and HIV-2 infections among hospital patients in The Gambia, west Africa. Jaffar S, et al. **Trop Med Int Health** 1999 Jul;4(7):487-92
[Pediatric AIDS: epidemiological, clinical and prognostic aspects in Abidjan, Ivory Coast (letter)] Niangué-Beugré NM, et al. **Arch Pediatr** 1999 Mar;6(3):342-3 **(Fre)**
[Epidemiologic and clinical features of HIV-2 infection in Abidjan, Ivory Coast (letter)] Eholie SP, et al.
Med Trop (Mars) 1998;58(2):204-5 **(Fre)**
[Portal thrombosis and anticardiolipin antibodies association in an HIV-2 infected patient (letter)] Bouchard O, et al.
Presse Med 1998 Jun 6;27(20):965 **(Fre)**
[Ultrasound aspects of abdominal involvement in adults with HIV infections in the Ivory Coast: apropos of 146 cases] N'Zi PK, et al. **Sante** 1999 Mar-Apr;9(2):85-8 (Eng. Abstr.) **(Fre)**
[HIV-2 infection in the world. A geographical perspective] Remy G. **Sante** 1998 Nov-Dec;8(6):440-6 (Eng. Abstr.) **(Fre)**
[7 new cases of HIV-2 infection recognized in Madrid in 1996 and 1997] Machuca A, et al. **Rev Clin Esp** 1998 Oct; 198(10):660-4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

High-resolution solution NMR structure of the minimal active domain of the human immunodeficiency virus type-2 nucleocapsid protein. Kodera Y, et al. **Biochemistry** 1998 Dec 22;37(51):17704-13
Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles. Höhne M, et al. **Virology** 1999 Aug 15;261(1):70-8

CLASSIFICATION

Similar HIV-1 subtype A V3 loop sequences are found in dual HIV-1/HIV-2 and HIV-1-only seropositives in Ghana. Sagoe KW, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):775-9
Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. Pieniazek D, et al. **Emerg Infect Dis** 1998 Oct-Dec;4(4):649-56

DRUG EFFECTS

1,2,5-Benzothiadiazepine and pyrrolo[2,1-d]-[1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Di Santo R, et al. **Antivir Chem Chemother** 1998 Mar;9(2):127-37
Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). McGuigan C, et al. **Antivir Chem Chemother** 1998 Nov; 9(6):473-9
Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro. Moog C, et al. **Antivir Chem Chemother** 1998 Nov;9(6):491-6
Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Silvestri R, et al.
Antivir Chem Chemother 1998 Mar;9(2):139-48
Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. Van Derpoorten K, et al. **Biomed Pharmacother** 1997; 51(10):464-8
Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives. Pandeya SN, et al. **Chemotherapy** 1999 May-Jun;45(3):192-6
Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells. Fenard D, et al.
J Clin Invest 1999 Sep;104(5):611-8
V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B. Moulard M, et al. **J Pept Res** 1999 Jun;53(6):647-55

GENETICS

Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast. Pieniazek D, et al.
AIDS Res Hum Retroviruses 1999 Apr 10;15(6):603-8
Genetic characterization of viral quasispecies in blood and cervical secretions of HIV-1- and HIV-2-infected women. Sankalé JL, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1473-81
Optimization of polymerase chain reaction for detection of HIV type 2 DNA. Walther L, et al.
AIDS Res Hum Retroviruses 1998 Sep 1;14(13):1151-6
Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx. Philippon V, et al. **J Hum Virol** 1999 May-Jun;2(3):167-74
Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. Browning CM, et al. **J Virol** 1999 Jun;73(6):5191-5
Molecular characterization of human immunodeficiency virus (HIV)-1 and -2 in individuals from guinea-bissau with single or dual infections: predominance of a distinct HIV-1 subtype A/G recombinant in West Africa. Andersson S, et al. **Virology** 1999 Sep 30;262(2):312-20
Truncation of the human immunodeficiency virus-type-2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles. Höhne M, et al. **Virology** 1999 Aug 15;261(1):70-8
Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses. Iida S, et al.
Virus Genes 1999;18(2):183-7

IMMUNOLOGY

Immunologic and virologic response of HIV-2 infection to antiretroviral therapy [letter] Clark NM, et al. **AIDS** 1998 Dec 24;12(18):2506-7
Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. Norrgren H, et al. **AIDS** 1999 Apr 16;13(6):701-7
Distinct recognition of closely-related HIV-1 and HIV-2 cytotoxic T-cell epitopes presented by HLA-B*2703 and B*2705 [letter] Rowland-Jones S, et al. **AIDS** 1998 Jul 30; 12(11):1391-3
Lack of protection against HIV-1 infection among women with HIV-2 infection. Wiktor SZ, et al. **AIDS** 1999 Apr 16;13(6):695-9
Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY, et al. **Biol Chem** 1999 Mar; 380(3):353-64
Homeopathy in HIV infection: a trial report of double-blind placebo controlled study. Rastogi DP, et al.
Br Homeopath J 1999 Apr;88(2):49-57
A simple saliva-based test for detecting antibodies to human immunodeficiency virus. Schramm W, et al.
Clin Diagn Lab Immunol 1999 Jul;6(4):577-80
HIV-2 and T cell recognition. Whittle HC, et al.
Curr Opin Immunol 1998 Aug;10(4):382-7 (66 ref.)
Modulation of major histocompatibility complex antigen expression by human immunodeficiency virus-2 gp36. Chen YH, et al. **Immunol Lett** 1999 Jun 1;68(2-3):415-7
Suppression of human immunodeficiency virus type 1 replication by a soluble factor produced by CD8+ lymphocytes from HIV-2-infected baboons. Locher CP, et al. **Immunol Lett** 1999 Mar;66(1-3):151-7
Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Rowland-Jones SL, et al. **Immunol Lett** 1999 Mar; 66(1-3):9-14
Screening for human immunodeficiency virus type 1 and 2 in a Turkish blood donor population. Altuglu I, et al.
Int J Infect Dis 1998 Apr-Jun;2(4):202-4
Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2. Ng KP, et al. **Int J STD AIDS** 1999 Jun;10(6):401-4
Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. Arai H, et al. **J Clin Microbiol** 1999 Feb;37(2):367-70
Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2. Vallari AS, et al.
J Clin Microbiol 1998 Dec;36(12):3657-61
Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. Björling E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1987-93
Simple/rapid test devices for anti-HIV screening: do they come up to the mark? Giles RE, et al. **J Med Virol** 1999 Sep;59(1):104-9
Zeta chain of the T-cell receptor interacts with nef of simian immunodeficiency virus and human immunodeficiency virus type 2. Howe AY, et al. **J Virol** 1998 Dec; 72(12):9827-34
Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27-38
Strongly enhanced sensitivity of a direct anti-HIV-1/-2 assay in seroconversion by incorporation of HIV p24 ag detection: a new generation vironostika HIV Uni-Form II. van Binsbergen J, et al. **J Virol Methods** 1998 Dec; 76(1-2):59-71
Structure/antigenicity relationship of cyclic and linear peptides mimicking the V3 loop of HIV2 envelope glycoprotein. Belhadj Jrad B, et al. **Res Virol** 1998 Nov-Dec;149(6):363-73
Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8. Hillyer CD, et al. **Transfus Med Rev** 1999 Jan; 13(1):1-17 (174 ref.)
[Antigenicity of nine synthetic peptides of human immunodeficiency virus] Mao P, et al.
Chung Hua Nei Ko Tsa Chih 1997;36(2):105-7 (Eng. Abstr.) **(Chi)**

ISOLATION & PURIFICATION

Diagnosis of HIV-1/2 dual infection using dilution analysis of type-specific antibody [letter] Ariyoshi K, et al.
AIDS 1998 Dec 24;12(18):2504-5
Optimization of polymerase chain reaction for detection of HIV type 2 DNA. Walther L, et al.
AIDS Res Hum Retroviruses 1998 Sep 1;14(13):1151-6
AIDS and HIV infection in the United Kingdom: monthly report [published erratum appears in Commun Dis Rep CDR Wkly 1998 Oct 23;8(43):388]
Commun Dis Rep CDR Wkly 1998 Sep 25;8(39):351-2
Isolation & preliminary characterization of two HIV-2 strains from Pune, India. Kulkarni SS, et al.
Indian J Med Res 1999 Apr;109:123-30
Seroprevalence of HIV infection among jail inmates in Orissa. Pal BB, et al. **Indian J Med Res** 1999 Jun; 109:199-201
Increasing prevalence of dual HIV-1-2 infections among voluntary blood donors in Mumbai (Bombay). Kamat HA, et al. **Indian J Med Sci** 1998 Dec;52(12):548-52
Human immunodeficiency virus type 2 [news]
J Assoc Nurses AIDS Care 1999 Jan-Feb;10(1):76-8
Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. Berry N, et al. **J Hum Virol** 1998 Nov-Dec; 1(7):457-68
Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples. Constantine NT, et al.
J Hum Virol 1997 Nov-Dec;1(1):45-51
HIV and tuberculosis co-infection in an inner London hospital--a prospective anonymized seroprevalence study. Marshall BG, et al. **J Infect** 1999 May;38(3):162-6
Multiplex detection of four pathogenic retroviruses using molecular beacons. Vet JA, et al.
Proc Natl Acad Sci U S A 1999 May 25;96(11):6394-9
[CD4+-T-cells are the predominant source of HIV-1 and HIV-2 production in asymptomatic people and AIDS patients with opportunistic infections] van der Ende ME, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2230 **(Dut)**

METABOLISM

Epithelin/granulin growth factors: extracellular cofactors for HIV-1 and HIV-2 Tat proteins. Trinh DP, et al.
Biochem Biophys Res Commun 1999 Mar 16;256(2):299-306
CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. Hoxie JA, et al.
J Reprod Immunol 1998 Dec;41(1-2):197-211 (56 ref.)
Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. Bieniasz PD, et al.
J Virol 1999 Jul;73(7):5777-86
Primary human immunodeficiency virus type 2 (HIV-2)

isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. Reeves JD, et al. **J Virol** 1999 Sep;73(9):7795-804

Processing and routage of HIV glycoproteins by furin to the cell surface. Moulard M, et al. **Virus Res** 1999 Mar; 60(1):55-65

PATHOGENICITY

Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. Otten RA, et al. **J Infect Dis** 1999 Sep;180(3):673-84

When accessories turn out to be essential [news; comment] Trono D. **Nat Med** 1998 Dec;4(12):1368-9. Comment on: Nat Med 1998 Dec;4(12):1397-400. Comment on: Nat Med 1998 Dec;4(12):1401-8.

Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses. Reimann KA, et al. **Virology** 1999 Mar 30; 256(1):15-21

PHYSIOLOGY

Plasma HIV viral load in relation to season and to Plasmodium falciparum parasitaemia [letter] Ariyoshi K, et al. **AIDS** 1999 Jun 18;13(9):1145-6

HIV type 2 can bind to CD8 molecules but does not infect CD8+ T cells [letter] Ichiyama K, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):687-8

Isolation & preliminary characterization of two HIV-2 strains from Pune, India. Kulkarni SS, et al. **Indian J Med Res** 1999 Apr;109:123-30

Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. Gomes P, et al. **J Clin Microbiol** 1999 Feb;37(2):453-6

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. Bridger GJ, et al. **J Med Chem** 1999 Sep 23;42(19):3971-81

Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. Kaye JF, et al. **J Virol** 1999 Apr; 73(4):3023-31

Targeting human immunodeficiency virus (HIV) type 2 integrase protein into HIV type 1. Liu H, et al. **J Virol** 1999 Oct;73(10):8831-6

Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. Mörner A, et al. **J Virol** 1999 Mar;73(3):2343-9

Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1. Segura I, et al. **J Virol** 1999 Jun;73(6):5207-13

An orphan G protein-coupled receptor, GPR1, acts as a coreceptor to allow replication of human immunodeficiency virus types 1 and 2 in brain-derived cells. Shimizu N, et al. **J Virol** 1999 Jun;73(6):5231-9

Virological aspects of human immunodeficiency virus infection. Catton MG. **P N G Med J** 1996 Sep;39(3):166-73 (7 ref.)

A practical method for simultaneously determining the effective burst sizes and cycle times of viruses. Spouge JL, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7017-22

Chemokine receptors and their crucial role in human immunodeficiency virus infection: major breakthroughs in HIV research. Kristiansen TB, et al. **Scand J Immunol** 1998 Oct;48(4):339-46 (80 ref.)

Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Edinger AL, et al. **Virology** 1999 Aug 1;260(2):211-21 (129 ref.)

[Astrocytes and lentivirus infection in an experimental models of macaque infected with SIVmac251] Guillemin G, et al. **C R Seances Soc Biol Fil** 1998;192(1):179-86 (Eng. Abstr.) **(Fre)**

HIV-2 ENVELOPE PROTEIN GP120 see **HIV ENVELOPE PROTEIN GP120**

HIV-2 ENVELOPE PROTEIN GP160 see **HIV ENVELOPE PROTEIN GP160**

HIV-2 INTEGRASE see **HIV INTEGRASE**

HIV-1 REVERSE TRANSCRIPTASE

CHEMISTRY

Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. Bahar I, et al. **J Mol Biol** 1999 Jan 22;285(3):1023-37

GENETICS

Structural basis for the specificity of the initiation of HIV-1 reverse transcription. Isel C, et al. **EMBO J** 1999 Feb 15; 18(4):1038-48

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Winters MA, et al. **J Clin Invest** 1998 Nov 15;102(10):1769-75

Compression of the DNA minor groove is responsible for termination of DNA synthesis by HIV-1 reverse transcriptase. Lavigne M, et al. **J Mol Biol** 1999 Jan 22; 285(3):977-95

METABOLISM

Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. Kiernan RE, et al. **J Virol** 1999 Jun;73(6):4728-37

HIVES see **URTICARIA**

HK3 KALLIKREIN see **PROSTATE-SPECIFIC ANTIGEN**

HL-60 CELLS

Commitment of neutrophilic differentiation and proliferation of HL-60 cells coincides with expression of transferrin receptor. Effect of granulocyte colony stimulating factor on differentiation and proliferation. Kanayasu-Toyoda T, et al. **J Biol Chem** 1999 Sep 3;274(36):25471-80

CHEMISTRY

Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation. Choi SY, et al. **Br J Pharmacol** 1999 Feb; 126(4):1050-6

Temperature dependence of voltage-gated H+ currents in human neutrophils, rat alveolar epithelial cells, and mammalian phagocytes. DeCoursey TE, et al. **J Gen Physiol** 1998 Oct;112(4):503-22

Chimeric amplicons containing the c-myc gene in HL60 cells. Mangano R, et al. **Oncogene** 1998 Nov 26; 17(21):2771-7

Deficient post-translational processing of Rap 1A in variant HL-60 cells. Scheele JS, et al. **Oncogene** 1998 Oct 29; 17(17):2211-23

CYTOLOGY

Increased agitation intensity increases CD13 receptor surface content and mRNA levels, and alters the metabolism of HL60 cells cultured in stirred tank bioreactors. McDowell CL, et al. **Biotechnol Bioeng** 1998 Oct 20;60(2):239-50

Effects of methocel A15LV, polyethylene glycol, and polyvinyl alcohol on CD13 and CD33 receptor surface content and metabolism of HL60 cells cultured in stirred tank bioreactors. McDowell CL, et al. **Biotechnol Bioeng** 1998 Oct 20;60(2):251-8

Acidic environment causes apoptosis by increasing caspase activity. Park HJ, et al. **Br J Cancer** 1999 Aug; 80(12):1892-7

Comparison of methods based on annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Del Bino G, et al. **Cell Prolif** 1999 Feb;32(1):25-37

Changes in mitochondrial mass, membrane potential, and cellular adenosine triphosphate content during the cell cycle of human leukemic (HL-60) cells. Sweet S, et al. **J Cell Physiol** 1999 Jul;180(1):91-6

Ubiquitin-proteasome system is involved in induction of LFA-1/ICAM-1-dependent adhesion of HL-60 cells. Katagiri K, et al. **J Leukoc Biol** 1999 Jun;65(6):778-85

DRUG EFFECTS

All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation. Freund A, et al. **Ann Oncol** 1999 Mar;10(3):335-8

Non-steroidal antiestrogens induce apoptosis in HL60 and MOLT3 leukemic cells; involvement of reactive oxygen radicals and protein kinase C. Hayon T, et al. **Anticancer Res** 1999 May-Jun;19(3A):2089-93

Effect of citrus flavonoids on HL-60 cell differentiation. Kawaii S, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):1261-9

Induction of differentiation in human promyelocytic leukemia cell line HL60 by a new type of polyenes, falconensone A and its derivatives. Takahashi N, et al. **Arch Biochem Biophys** 1998 Dec 1;360(1):113-20

Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Mills KI, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):294-300

Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells. Okajima F, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):491-500

Proanthocyanidins from barley bran potentiate retinoic acid-induced granulocytic and sodium butyrate-induced monocytic differentiation of HL60 cells. Tamagawa K, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1483-7

Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells. Aoyama M, et al. **Blood** 1998 Oct 15;92(8):2863-70

Alteration of actin organization by jaspamide inhibits ruffling, but not phagocytosis or oxidative burst, in HL-60 cells and human monocytes. Fabian I, et al. **Blood** 1999 Jun 1; 93(11):3994-4005

Phosphorylated forms of activated caspases are present in cytosol from HL-60 cells during etoposide-induced apoptosis. Martins LM, et al. **Blood** 1998 Nov 1; 92(9):3042-9

Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells. Côme MG, et al. **Br J Cancer** 1999 Mar;79(7-8):1090-7

Induction of granulocytic differentiation in acute promyelocytic leukemia cells (HL-60) by 2-(allylthio) pyrazine. Kong G, et al. **Cancer Lett** 1999 Sep 20;144(1):1-8

Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Bertagnolo V, et al. **Cancer Res** 1999 Feb 1;59(3):542-6

Geranylgeranylacetone induces apoptosis in HL-60 cells. Okada S, et al. **Cell Struct Funct** 1999 Jun;24(3):161-8

Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity. Schirmer M, et al. **Exp Hematol** 1998 Dec;26(13):1223-8

Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. Wu HL, et al. **Int J Cancer** 1999 Jun 11;81(6):923-9

The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. Xia Z, et al. **J Biochem Mol Toxicol** 1999;13(6):338-47

beta-hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells through a mechanism different from those of Fas and etoposide. Hashimoto S, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):17-23

The role of STAT3 in granulocyte colony-stimulating factor-induced enhancement of neutrophilic differentiation of Me2SO-treated HL-60 cells. GM-CSF inhibits the nuclear translocation of tyrosine-phosphorylated STAT3. Yamaguchi T, et al. **J Biol Chem** 1999 May 28; 274(22):15575-81

Cobalt chloride-induced signaling in endothelium leading to the augmented adherence of sickle red blood cells and transendothelial migration of monocyte-like HL-60 cells is blocked by PAF-receptor antagonist. Sultana C, et al. **J Cell Physiol** 1999 Apr;179(1):67-78

Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. Mo H, et al. **J Nutr** 1999 Apr;129(4):804-13

Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. Chan SC, et al. **J Pept Sci** 1998 Nov;4(7):413-25

Acridones as inducers of HL-60 cell differentiation. Kawaii S, et al. **Leuk Res** 1999 Mar;23(3):263-9

Staurosporine enhanced benzamide riboside-induced apoptosis in human multidrug-resistant promyelocytic leukemia cells (HL-60/VCR) in vitro. Hunáková L, et al. **Neoplasma** 1998;45(4):204-9

Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Amir H, et al. **Nutr Cancer** 1999;33(1):105-12

Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells. Ware JH, et al. **Nutr Cancer** 1999;33(2):174-7

Steroidal saponins from the aerial parts of Dracaena draco and their cytostatic activity on HL-60 cells. Mimaki Y, et al. **Phytochemistry** 1999 Mar;50(5):805-13

[Cytotoxicity and genotoxicity of methyl tert-butyl ether and its metabolite to human leukemia cells] Tang G, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):334-7 (Eng. Abstr.) **(Chi)**

[Studies on purging leukemic cells by photosensitizer PSD-007 laser photoradiation in vitro] Liang X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):199-202 (Eng. Abstr.) **(Chi)**

[Anticancer susceptibility test method using general-purpose dissolved oxygen meter] Arai J, et al. **Hum Cell** 1998 Sep; 11(3):175-8 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation. Marchisio M, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):346-51

Phospholipase D development during differentiation of human promyelocytic leukemic HL60 cells. Ohguchi K, et al. **Biochim Biophys Acta** 1999 Jul 30;1439(2):215-27 (94 ref.)

Phosphoinositide 3-kinase activity is essential for all-trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Bertagnolo V, et al. **Cancer Res** 1999 Feb 1;59(3):542-6

Alterations in glycosyltransferases during myeloid and monocytoid differentiation of HL-60 cells. Liu AH, et al. **Cell Biol Int** 1998;22(7-8):545-50

Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines. Uesugi Y, et al. **Eur J Haematol** 1999 Apr;62(4):239-45

Isolation and characterization of a variant HL60 cell line defective in the activation of the NADPH oxidase by

phorbol myristate acetate. Tardif M, et al. **J Immunol** 1998 Dec 15;161(12):6885-95

IMMUNOLOGY

Soluble CD14(1-152) confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay. Yu W, et al. **J Immunol** 1998 Oct 15;161(8):4244-51

METABOLISM

Downregulation of mRNA expression of Edg-3, a putative sphingosine 1-phosphate receptor coupled to Ca2+ signaling, during differentiation of HL-60 leukemia cells. Sato K, et al. **Biochem Biophys Res Commun** 1998 Dec 18;253(2):253-6

Response of cytosolic calcium, cyclic AMP, and cyclic GMP in dimethylsulfoxide-differentiated HL-60 cells to modulated low frequency electric currents. Sontag W, et al. **Bioelectromagnetics** 1998;19(8):452-8

Serum increases the CD13 receptor expression, reduces the transduction of fluid-mechanical forces, and alters the metabolism of HL60 cells cultured in agitated bioreactors. McDowell CL, et al. **Biotechnol Bioeng** 1998 Oct 20; 60(2):259-68

Decreasing extracellular pH increases CD13 receptor surface content and alters the metabolism of HL60 cells cultured in stirred tank bioreactors. McDowell CL, et al. **Biotechnol Prog** 1998 Jul-Aug;14(4):567-72

Inhibition of p34cdc2 dephosphorylation in DNA damage- and topoisomerase II inactivation-induced G2 arrests in HL-60 cells. Sugimoto K, et al. **Br J Haematol** 1999 Jun; 105(3):720-9

HL-60 cells degrade alpha-actinin to produce a fragment that promotes monocyte/macrophage maturation. Masri M, et al. **Exp Hematol** 1999 Feb;27(2):345-52

Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells. Wada H, et al. **Exp Hematol** 1999 Jan;27(1):99-109

Crucial role of apopain in the peroxynitrite-induced apoptotic DNA fragmentation. Virag L, et al. **Free Radic Biol Med** 1998 Dec;25(9):1075-82

The effect of pyrimidine nucleosides on adenosine-induced apoptosis in HL-60 cells. Kim KT, et al. **J Cancer Res Clin Oncol** 1998;124(9):471-7

Tumour suppressor protein p53 released by nuclease digestion increases at the onset of rat liver regeneration. Miró F, et al. **J Hepatol** 1999 Aug;31(2):306-14

Decreased phosphorylation of a low molecular weight protein by cGMP-dependent protein kinase in variant HL-60 cells resistant to nitric oxide- and cGMP-induced differentiation. Scheele JS, et al. **Mol Cell Biochem** 1998 Aug;185(1-2):111-21

[Does the universal "signal transduction pathway of differentiation" exist? Comparison of different cell differentiation experimental models with differentiation of HL-60 cells in response to 1,25-dihydroxyvitamin D3] Marcinkowska E. **Postepy Hig Med Dosw** 1999; 53(2):305-13 (32 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Changes in expression of the 44-kilodalton outer surface membrane antigen (p44 kD) for monitoring progression of infection and antimicrobial susceptibility of the human granulocytic ehrlichiosis (HGE) agent in HL-60 cells. Hsieh T, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):351-5

PATHOLOGY

Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. Deuel TF, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):192-6

Cupric nitrilotriacetate induces oxidative DNA damage and apoptosis in human leukemia HL-60 cells. Ma Y, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):568-75

[Suppression of transforming growth factor beta 1 on malignant phenotype in HL-60 cells] Song L, et al. **Chung Hua I Hsueh Tsa Chih** 1997 May;77(5):348-50 (Eng. Abstr.) **(Chi)**

[Effects of lithium chloride and harringtonine on the differentiation, proliferation and c-myc proto-oncogene expression of HL-60 cells] Li W, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):151-3 (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

Acidic environment causes apoptosis by increasing caspase activity. Park HJ, et al. **Br J Cancer** 1999 Aug; 80(12):1892-7

Spectral karyotypic study of the HL-60 cell line: detection of complex rearrangements involving chromosomes 5, 7, and 16 and delineation of critical region of deletion on 5q31.1. Liang JC, et al. **Cancer Genet Cytogenet** 1999 Sep; 113(2):105-9

Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities. Côme MG, et al. **Int J Cancer** 1999 May 17;81(4):580-7

Induction of cell-membrane porosity by ultrasound [letter] Tachibana K, et al. **Lancet** 1999 Apr 24;353(9162):1409

ULTRASTRUCTURE

Microscopic observations of the different morphological changes caused by anti-bacterial peptides on Klebsiella pneumoniae and HL-60 leukemia cells. Chan SC, et al. **J Pept Sci** 1998 Nov;4(7):413-25

Co-localization of mitochondrial and double minute DNA in the nuclei of HL-60 cells but not normal cells. Hirano T, et al. **Mutat Res** 1999 Apr 6;425(2):195-204

HLA ANTIGENS

Correlation of thymic pathology with HLA in myasthenia gravis. Machens A, et al. **Clin Immunol** 1999 Jun; 91(3):296-301

Nomenclature for factors of the HLA system, update January 1998. Marsh SG. **Eur J Immunogenet** 1998 Aug;25(4):321

Nomenclature for factors of the HLA system, update February 1998. Marsh SG. **Eur J Immunogenet** 1998 Aug; 25(4):323

Nomenclature for factors of the HLA system, update March 1998. Marsh SG. **Eur J Immunogenet** 1998 Aug;25(4):325-6

Nomenclature for Factors of the HLA System, update September 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 Jan;60(1):88-9

Environmentally-induced malignant pleural mesothelioma and HLA distribution in Turkey. Karakoca Y, et al. **Int J Tuberc Lung Dis** 1998 Dec;2(12):1017-22

HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication. Mackewicz CE, et al. **J Virol** 1998 Dec;72(12):10165-70

Immunogenetics. Defence by diversity [news] Hill AV. **Nature** 1999 Apr 22;398(6729):668-9

Nomenclature for factors of the HLA system, update March 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1998 Jun; 51(6):681-3

Nomenclature for factors of the HLA system, update January 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Jul;54(1):106-7

Nomenclature for factors of the HLA system, update February 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Jul;54(1):108-9

Nomenclature for factors of the HLA system, update March 1999. Marsh for the WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Jul;54(1):110-1

The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Sheldon S, et al. **Transplantation** 1999 Aug 27;68(4):515-9

The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies. Sumitran-Karuppan S. **Transplantation** 1999 Aug 27; 68(4):502-9

[Physiopathological and therapeutic study of collagen diseases based on results of clinical tests--collagen diseases and human leukocyte antigens] Takeuchi F. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2453-60 (5 ref.) **(Jpn)**

[Transformation B (III) and A (II) blood groups into AB (IV) during transplantation of the bone marrow from HLA-identical sibs of A (II) and A (III) groups] Zotikov EA, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):569-71 **(Rus)**

[HLA: past, present and future] Rubio Vela T, et al. **An Med Interna** 1998 Sep;15(9):501-5 (76 ref.) **(Spa)**

ANALYSIS

Soluble HLA-G: purification from eukaryotic transfected cells and detection by a specific ELISA. Fournel S, et al. **Am J Reprod Immunol** 1999 Jul;42(1):22-9

Quantitative assessment of human leukocyte antigen-G protein in amniotic fluid by a double-determinant enzyme-linked immunosorbent assay using anti-human leukocyte antigen-G-specific antibody 87G. Hamai Y, et al. **Am J Reprod Immunol** 1999 Apr;41(4):293-5

First trimester human endovascular trophoblast cells express both HLA-C and HLA-G. Pröll J, et al. **Am J Reprod Immunol** 1999 Jul;42(1):30-6

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674-7

Thyrotoxic periodic paralysis in Mexican mestizo patients: a clinical, biochemical and HLA-serological study. Nellen H, et al. **Arch Med Res** 1999 Jan-Feb;30(1):74-6

DNA typing of maternal HLA in congenital complete heart block: comparison with systemic lupus erythematosus and primary Sjögren's syndrome. Colombo G, et al. **Arthritis Rheum** 1999 Aug;42(8):1757-64

Genetic analysis of HLA- and HPA-typing in idiopathic (autoimmune) thrombocytopenic purpura patients treated with cepharanthin. Nomura S, et al. **Autoimmunity** 1999; 30(2):99-105

Regulation of T cell response to leishmania antigens by determinants of histocompatibility leukocyte class I and II molecules. Bacellar O, et al. **Braz J Med Biol Res** 1998 Dec;31(12):1575-81

Antigens of the major histocompatibility system in ischemic heart disease and idiopathic dilated cardiomyopathy. Osa A, et al. **Clin Cardiol** 1999 Apr;22(4):292-6

Association between type 1 diabetes age of onset and HLA among sibling pairs. Valdes AM, et al. **Diabetes** 1999 Aug; 48(8):1658-61

Human leukocyte antigens as genetic markers in colorectal carcinoma. Chatzipetrou MA, et al. **Dis Colon Rectum** 1999 Jan;42(1):66-70

Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLA-G*01012 allele. Castro MJ, et al. **Eur J Immunogenet** 1998 Aug;25(4):311-5

Polymerase chain reaction based human leucocyte antigen genotyping for the investigation of suspected gastrointestinal biopsy contamination. Bateman AC, et al. **Gut** 1999 Aug;45(2):259-63

Human leucocytic antigens (HLA) in breast cancer. Biswal BM, et al. **Indian J Med Sci** 1998 May;52(5):177-83

HLA-G and pregnancy. Le Bouteiller P. **Rev Rhum Engl Ed** 1998 Nov;65(11):608-10 (21 ref.)

Detection of soluble HLA-G molecules in plasma and amniotic fluid. Rebmann V, et al. **Tissue Antigens** 1999 Jan; 53(1):14-22

Natural killer cell reactivity and HLA-G in recurrent spontaneous abortion. Emmer PM, et al. **Transplant Proc** 1999 Jun;31(4):1838-40

Induction of HLA-G-specific human CD8+ T cell lines by stimulation across a polymorphism of HLA-G. Horuzsko A, et al. **Transplant Proc** 1999 Jun;31(4):1860-3

Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. Puppo F, et al. **Transplant Proc** 1999 Jun;31(4):1841-3

The impact of recurrent glomerulonephritis on graft survival in recipients of human histocompatibility leucocyte antigen-identical living related donor grafts. Andresdottir MB, et al. **Transplantation** 1999 Sep 15;68(5):623-7

[Distribution of transplantation HLA antigens in children and adolescents with meningitis of various etiology] Feizullaeva NA. **Probl Tuberk** 1999;(2):43-4 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Major histocompatibility complex expression on human, male germ cells: a review. Fiszer D, et al. **Am J Reprod Immunol** 1998 Sep;40(3):172-6 (34 ref.)

Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Chu W, et al. **Hum Immunol** 1998 Jul;59(7):435-42

The metalloproteinase-mediated pathway is essential for generation of soluble HLA class I proteins by activated cells in vitro: proposed mechanism for soluble HLA release in transplant rejection. DeVito-Haynes LD, et al. **Hum Immunol** 1998 Jul;59(7):426-34

HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Mallet V, et al. **Int Immunol** 1999 Jun;11(6):889-98

Antiproliferative effect of calcitriol on human prostatic cancer cell lines: unrelated to the expression of major histocompatibility complex antigens or intercellular adhesion molecule-1 (ICAM-1). Yu DM, et al. **Int J Urol** 1998 Nov;5(6):595-600

Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. Bennett EM, et al. **J Immunol** 1999 May 1;162(9):5049-52

Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. Pacasova R, et al. **J Immunol** 1999 May 1;162(9):5190-6

Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. Chu W, et al. **J Reprod Immunol** 1999 Jan;42(1):1-15

HLA expression on immature and mature human germ cells. Hutter H, et al. **J Reprod Immunol** 1998 Jul;38(2):101-22 (99 ref.)

Fetomaternal HLA differences and the onset and course of rheumatoid arthritis. Hazes JM. **Rev Rhum Engl Ed** 1998 Nov;65(11):611-3 (27 ref.)

Cell surface expression of HLA-E molecules on PBMC from a TAP1-deficient patient. Furukawa H, et al. **Tissue Antigens** 1999 Mar;53(3):292-5

Expression of HLA class I antigens in transporter associated with antigen processing (TAP)-deficient mutant cell lines. Young NT, et al. **Tissue Antigens** 1998 Oct;52(4):368-73

BLOOD

Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia. Arcese W, et al. **Bone Marrow Transplant** 1999 Mar;23(6):549-54

Soluble HLA: a review of the literature. McDonald JC, et al. **Hum Immunol** 1998 Jul;59(7):387-403 (205 ref.)

Soluble HLA-I in rheumatic diseases. Wolf RE, et al. **Hum Immunol** 1998 Oct;59(10):644-9

Blood groups association with HLA -A, -B and -C antigens among Bahrainis [letter] Mukhtar A. **Minerva Med** 1999 Mar;90(3):97

Lack of association between human leukocyte antigens and anti-Hu syndrome in patients with small-cell lung cancer [letter; comment] [published erratum appears in Neurology 1999 Jun 10;52(9):1952] Tanaka M, et al. **Neurology** 1999

Jan 15;52(2):431. Comment on: Neurology 1998 Feb;50(2):565–6.

Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype. Puppo F, et al. **Tissue Antigens** 1999 Mar; 53(3):253–62

Detection of soluble HLA-G levels in maternal serum can be predictive for a successful pregnancy. Athanassakis I, et al. **Transplant Proc** 1999 Jun;31(4):1834–7

Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Bornhäuser M, et al. **Transplantation** 1999 Jul 15;68(1):87–8

[Histocompatibility antigens in multiple sclerosis in children] Efimenko VN, et al. **Lik Sprava** 1998 Aug;(6):67–9 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Soluble HLA in human body fluids. Aultman D, et al. **Hum Immunol** 1999 Mar;60(3):239–44

CHEMISTRY

The analysis of peptide affinity and its binding kinetics to DR1DW1 major histocompatibility complex protein. Berezhkovskiy LM. **Biophys Chem** 1999 Mar 29; 77(2–3):183–94

Molecular forms of soluble HLA in body fluids: potential determinants of body odor cues. Wobst B, et al. **Genetica** 1998–99;104(3):275–83

Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. O'Callaghan CA, et al. **Immunol Rev** 1998 Jun;163:129–38 (49 ref.)

CLASSIFICATION

HLA and HPA typing in idiopathic thrombocytopenic purpura patients treated with Kami-kihi-to. Matsuzaki T, et al. **Am J Chin Med** 1998;26(2):191–8

HLA evidence for the lack of genetic heterogeneity in Basques. Comas D, et al. **Ann Hum Genet** 1998 Mar;62 (Pt 2):123–32

Nomenclature for factors of the HLA system, update March 1999. Marsh SG. **Eur J Immunogenet** 1999 Aug;26(4):319

Nomenclature for factors of the HLA system, update January 1999. Marsh SG. **Eur J Immunogenet** 1999 Aug;26(4):315

Nomenclature for factors of the HLA system, update February 1999. Marsh SG. **Eur J Immunogenet** 1999 Aug; 26(4):317

Nomenclature for factors of the HLA system, update April 1998. Marsh SG. **Eur J Immunogenet** 1998 Oct;25(5):379

Nomenclature for factors of the HLA system, update July 1998. Marsh SG. **Eur J Immunogenet** 1998 Oct;25(5):383

Nomenclature for factors of the HLA system, update March 1998. Marsh SG. **Hum Immunol** 1998 Jul;59(7):456–8

Nomenclature for factors of the HLA system, update April 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1998 Oct; 59(10):677

Nomenclature for factors of the HLA system, update May/June 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1998 Oct;59(10):678

Nomenclature for factors of the HLA system, update March 1999. WHO Nomenclature Committee for factors of the HLA system. Marsh SG. **Hum Immunol** 1999 Jul;60(7):627

Nomenclature for factors of the HLA system, update January 1999. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 May; 60(5):450

Nomenclature for factors of the HLA system, update February 1999. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 May;60(5):451

HLA typing in patients with multiple evanescent white dot syndrome (MEWDS). Borruat FX, et al. **Ocul Immunol Inflamm** 1998 Mar;6(1):39–41

Nomenclature for factors of the HLA system, 1998. Bodmer JG, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 2):407–46

Nomenclature for factors of the HLA system, update July 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1998 Oct; 52(4):405–6

Nomenclature for factors of the HLA system, update September 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1998 Dec;52(6):592–3

Nomenclature for factors of the HLA system, update April 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1998 Sep; 52(3):300

Nomenclature for factors of the HLA system, update May/June 1998. Marsh SG. **Tissue Antigens** 1998 Sep; 52(3):301

Nomenclature for factors of the HLA system, update October 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Feb; 53(2):207

Nomenclature for factors of the HLA system, update November 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Feb;53(2):208–9

Nomenclature for factors of the HLA system, update December 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Tissue Antigens** 1999 Feb;53(2):210–1

Predicting graft-versus-host disease in HLA-identical bone marrow transplant: a comparison of T-cell frequency analysis and a human skin explant model. Dickinson AM, et al. **Transplantation** 1998 Oct 15;66(7):857–63

Serum cytokine levels after HLA-identical bone marrow transplantation. Liem LM, et al. **Transplantation** 1998 Oct 15;66(7):863–71

GENETICS

Goodpasture's syndrome associated with multiple sclerosis. Henderson RD, et al. **Acta Neurol Scand** 1998 Aug; 98(2):134–5

Psoriasis linkage in the HLA region [letter; comment] Leder RO, et al. **Am J Hum Genet** 1999 Mar;64(3):895–6. Comment on: Am J Hum Genet 1998 Jul;63(1):191–9.

The predisposition to type 1 diabetes linked to the human leukocyte antigen complex includes at least one non-class II gene. Lie BA, et al. **Am J Hum Genet** 1999 Mar; 64(3):793–800

Genetic correlation in otosclerosis. Singhal SK, et al. **Am J Otolaryngol** 1999 Mar–Apr;20(2):102–5

Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. Moreau P, et al. **Am J Reprod Immunol** 1998 Sep;40(3):136–44

HLA-G polymorphisms: ethnic differences and implications for potential molecule function. van der Ven K, et al. **Am J Reprod Immunol** 1998 Sep;40(3):145–57 (54 ref.)

Analysis of human leukocyte antigen-G polymorphism including intron 4 in Japanese couples with habitual abortion [see comments] Yamashita T, et al. **Am J Reprod Immunol** 1999 Feb;41(2):159–63. Comment in: Am J Reprod Immunol 1999 Feb;41(2):117–20.

Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Newman Taylor AJ, et al. **Am J Respir Crit Care Med** 1999 Aug; 160(2):435–8

Haemochromatosis case detection by genetic testing: a new era. Kilpatrick ES, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):674–7

HLA evidence for the lack of genetic heterogeneity in Basques. Comas D, et al. **Ann Hum Genet** 1998 Mar;62 (Pt 2):123–32

Surnames, HLA genes and ancient migrations in the Po Valley (Italy). Guglielmino CR, et al. **Ann Hum Genet** 1998 May;62 (Pt 3):261–9

HFE gene mutation and transferrin saturation in very low birthweight infants. Maier RF, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F144–5

Association of HLA alleles and clinical features in patients with synovitis of recent onset. El-Gabalawy HS, et al. **Arthritis Rheum** 1999 Aug;42(8):1696–705

Juvenile arthritis: genetic update. Albert ED, et al. **Baillieres Clin Rheumatol** 1998 May;12(2):209–18 (34 ref.)

Frequencies in the Japanese population of HFE gene mutations. Sohda T, et al. **Biochem Genet** 1999 Feb; 37(1–2):63–8

Defective induction of the transcription factor interferon-stimulated gene factor-3 and interferon alpha insensitivity in human trophoblast cells. Cross JC, et al. **Biol Reprod** 1999 Feb;60(2):312–21

No association between factor V Leiden and C282Y mutation in the hereditary hemochromatosis gene [letter; comment] Le Maréchal C, et al. **Blood** 1999 Jun 1;93(11):4024–5. Comment on: Blood 1998 Aug 15;92(4):1461–2.

The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Levy JE, et al. **Blood** 1999 Jul 1;94(1):9–11

HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Mura C, et al. **Blood** 1999 Apr 15; 93(8):2502–5

Alternate splicing produces a soluble form of the hereditary hemochromatosis protein HFE. Jeffrey GP, et al. **Blood Cells Mol Dis** 1999 Feb;25(1):61–7

Celtic origin of the C282Y mutation of hemochromatosis. Lucotte G. **Blood Cells Mol Dis** 1998 Dec;24(4):433–8

Frequency of the C282Y mutation of hemochromatosis in five French populations. Mercier G, et al. **Blood Cells Mol Dis** 1998 Jun;24(2):165–6

Hemochromatosis in Ireland and HFE. Ryan E, et al. **Blood Cells Mol Dis** 1998 Dec;24(4):428–32

Feasibility of finding an unrelated bone marrow donor on international registries for New Zealand patients. Velickovic ZM, et al. **Bone Marrow Transplant** 1999 Feb; 23(3):291–4

Pregnancy-associated autoimmune neonatal thrombocytopenia: role of maternal HLA genotype. Gandemer V, et al. **Br J Haematol** 1999 Mar;104(4):878–85

HLA antigens in familial Behçet's disease in Ireland [letter] Sant SM, et al. **Br J Rheumatol** 1998 Nov;37(11):1250–1

Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Hildesheim A, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Nov;7(11):1035–41

Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation. Meyer GC, et al. **Cancer Gene Ther** 1999 May-Jun;6(3):282–8

Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Paul P, et al. **Cancer Res** 1999 Apr 15;59(8):1954–60

Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Beckman LE, et al. **Carcinogenesis** 1999 Jul;20(7):1231–3

Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women [see comments] Roest M, et al. **Circulation** 1999 Sep 21; 100(12):1268–73. Comment in: Circulation 1999 Sep 21;100(12):1260–3.

Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see comments] Tuomainen TP, et al. **Circulation** 1999 Sep 21; 100(12):1274–9. Comment in: Circulation 1999 Sep 21;100(12):1260–3.

Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Hiraki A, et al. **Clin Cancer Res** 1999 Apr;5(4):933–6

Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Datz C, et al. **Clin Chem** 1998 Dec;44(12):2429–32

Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Mangasser-Stephan K, et al. **Clin Chem** 1999 Oct; 45(10):1875–8

Simple multiplex PCR for the simultaneous detection of the C282Y and H63D hemochromatosis (HFE) gene mutations. Stott MK, et al. **Clin Chem** 1999 Mar;45(3):426–8

HLA class II homozygosity confers susceptibility to common variable immunodeficiency (CVID). De La Concha EG, et al. **Clin Exp Immunol** 1999 Jun;116(3):516–20

HLA associations in a family with autoimmune phenomena [letter] Hübscher O, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):262

HLA-identical sibling renal transplantation--a 21-yr single-center experience. de Mattos AM, et al. **Clin Transplant** 1999 Apr;13(2):158–67

Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM [letter] Dubois-Laforgue D, et al. **Diabetes Care** 1998 Aug;21(8):1371–2

Inverse relationship between GAD65 antibody levels and severe retinopathy in younger type 1 diabetic patients. Agardh D, et al. **Diabetes Res Clin Pract** 1998 Apr; 40(1):9–14

Hereditary haemochromatosis mutations (HFE) in patients with Type II diabetes mellitus [letter] Braun J, et al. **Diabetologia** 1998 Aug;41(8):983–4

Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status. Dolžan V, et al. **Eur J Endocrinol** 1999 Aug; 141(2):132–9

The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Kikuchi I, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):859–63

Generation of a transcription map distal to HLA-F. Goldwurm S, et al. **Eur J Hum Genet** 1998 Sep-Oct; 6(5):475–86

Generation of a transcription map of a 1 Mbase region containing the HFE gene (6p22). Totaro A, et al. **Eur J Hum Genet** 1998 Mar-Apr;6(2):105–13

Nomenclature for factors of the HLA system, 1998. Bodmer JG, et al. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):81–116

Molecular matching in allogeneic bone marrow transplantation. Little AM, et al. **Eur J Immunogenet** 1999 Feb;26(1):35–41 (85 ref.)

Nomenclature for factors of the HLA system, update December 1998. Marsh SG. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):247

Nomenclature for factors of the HLA system, update October 1998. Marsh SG. **Eur J Immunogenet** 1999 Apr-Jun; 26(2-3):243

Nomenclature for factors of the HLA system, update November 1998. Marsh SG. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):245–6

Nomenclature for factors of the HLA system, update September 1998. Marsh SG. **Eur J Immunogenet** 1998 Dec; 25(6):427

Nomenclature for factors of the HLA system, update August 1998. Marsh SG. **Eur J Immunogenet** 1998 Dec;25(6):425

HLA-G and classical HLA class I transcripts in various components of the adult human eye. Robert PY, et al. **Eur J Immunogenet** 1999 Aug;26(4):271–4

Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Saltini C, et al. **Eur Respir J** 1998 Dec;12(6):1463–75 (123 ref.)

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Moirand R, et al. **Gastroenterology** 1999 Feb;116(2):372–7

A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Wallace DF, et al. **Gastroenterology** 1999 Jun; 116(6):1409–12

Mutation analysis of the HLA-H gene in French

hemochromatosis patients, and genetic counseling in families. Mercier G, et al. **Genet Couns** 1998;9(3):181–6
Effect of inbreeding avoidance on Hardy–Weinberg expectations: examples of neutral and selected loci. Robertson A, et al. **Genet Epidemiol** 1999;17(3):165–73
Four ubiquitously expressed genes, RD (D6S45)–SKI2W (SKIV2L)–DOM3Z–RP1 (D6S60E), are present between complement component genes factor B and C4 in the class III region of the HLA. Yang Z, et al. **Genomics** 1998 Nov 1;53(3):338–47
Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Grove J, et al. **Gut** 1998 Aug;43(2):262–6
Familial hairy cell leukemia: a HLA-linked disease or farmers-linked disease? [letter] Casado LF, et al. **Haematologica** 1998 Aug;83(8):751–2 (11 ref.)
HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload [letter] Remacha AF, et al. **Haematologica** 1999 Mar;84(3):284–5
Human leukocyte antigen class II and III alleles and severity of hepatitis C virus–related chronic liver disease. Asti M, et al. **Hepatology** 1999 Apr;29(4):1272–9
Inherited HFE–unrelated hemochromatosis in Italian families. Camaschella C, et al. **Hepatology** 1999 May; 29(5):1563–4
Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Piperno A, et al. **Hepatology** 1998 Oct;28(4):1105–9
Parental HLA genes, hormone level and offspring sex ratios: a reply to James' letter [letter; comment] Astolfi P, et al. **Hum Hered** 1998 Sep–Oct;48(5):293–4. Comment on: Hum Hered 1997 Jan–Feb;47(1):60.
Polymorphisms in the HFE gene. Douabin V, et al. **Hum Hered** 1999 Jan;49(1):21–6
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. Enlund F, et al. **Hum Hered** 1999 Jan;49(1):2–8
Nomenclature for factors of the HLA System, 1998. Bodmer JG, et al. **Hum Immunol** 1999 Apr;60(4):361–95
Reconstruction of the block matching profiles. Ketheesan N, et al. **Hum Immunol** 1999 Feb;60(2):171–6
Nomenclature for factors of the HLA system, update October 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 Mar; 60(3):268
Nomenclature for factors of the HLA System, update November 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 Mar;60(3):269–70
Nomenclature for factors of the HLA System, update December 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 Mar;60(3):271
Nomenclature for factors of the HLA system, update July 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1998 Nov; 59(11):748–9
Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. Moreau P, et al. **Hum Immunol** 1998 Dec;59(12):751–7
HLA antigens associated with susceptibility/resistance to HIV-1 infection. Rohowsky-Kochan C, et al. **Hum Immunol** 1998 Dec;59(12):802–15
Saliva as DNA source for HLA typing. Terasaki P, et al. **Hum Immunol** 1998 Sep;59(9):597–8
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. de Villiers JN, et al. **Hum Mol Genet** 1999 Aug;8(8):1517–22
A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Merryweather-Clarke AT, et al. **Hum Mutat** 1999; 13(2):154–9
Variability in the expression of trophectodermal markers beta-human chorionic gonadotrophin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst. Jurisicova A, et al. **Hum Reprod** 1999 Jul;14(7):1852–8
Influence of human leukocyte antigen and tumour necrosis factor genes on the development of pre-eclampsia. Kilpatrick DC. **Hum Reprod Update** 1999 Mar–Apr; 5(2):94–102 (98 ref.)
Studies of HLA, fertility and mate choice in a human isolate. Ober C. **Hum Reprod Update** 1999 Mar–Apr;5(2):103–7 (39 ref.)
A new polymorphism in the human HFE gene. H]ohler T, et al. **Immunogenetics** 1999 Aug;49(9):823–4
Re-examination of HLA-G polymorphism in African Americans. Ishitani A, et al. **Immunogenetics** 1999 Aug; 49(9):808–11
A new polymorphism in the HLA-F gene (67Ala[GCC] to Ala[GCG]). Kunishima S, et al. **Immunogenetics** 1999 Feb; 49(2):147–8
Alternate splice variants of the hemochromatosis gene Hfe. Rhodes DA, et al. **Immunogenetics** 1999 Apr;49(4):357–9
Physical mapping between the S and HLA-E genes in the human MHC class I region: construction of a BAC, PAC, and cosmid contig. Shiina T, et al. **Immunogenetics** 1998 Nov–Dec;48(6):402–7
The sequence and organization of the mouse valyl-tRNA synthetase gene G7a/Bat6 located in the MHC class III region. Snoek M, et al. **Immunogenetics** 1999 May; 49(5):468–70
Sequencing-based typing of MICA reveals 33 alleles: a study on linkage with classical HLA genes. Visser CJ, et al. **Immunogenetics** 1999 Jun;49(6):561–6
Ancestral and recombinant 16-locus HLA haplotypes in the Hutterites. Weitkamp LR, et al. **Immunogenetics** 1999 Jun; 49(6):491–7
The functionality of HLA-G is emerging. Le Bouteiller P, et al. **Immunol Rev** 1999 Feb;167:233–44 (64 ref.)
Disease-protected major histocompatibility complex Ea-transgenic non-obese diabetic (NOD) mice show interleukin-4 production not seen in susceptible Ea-transgenic and non-transgenic NOD mice. Brenden N, et al. **Immunology** 1998 Sep;95(1):1–7
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Moreau P, et al. **Int Immunol** 1999 May;11(5):803–11
Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Jiménez P, et al. **Int J Cancer** 1999 Sep 24;83(1):91–7
Expression of HLA G in human tumors is not a frequent event. Real LM, et al. **Int J Cancer** 1999 May 17; 81(4):512–8
Immunogenetic analysis of Takayasu arteritis in Indian patients. Mehra NK, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S127–32; discussion S133
Interaction of a nuclear factor derived from the trophoblast cell line BeWo with the HLA-G gene. Kimura T, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):67–8
Contribution of molecular genetics to gastroenterology: the case of coeliac disease [comment] Biagi F, et al. **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):202–4 (24 ref.) . Comment on: Ital J Gastroenterol Hepatol 1999 Apr;31(3):198–201.
Comparison of viral load and human leukocyte antigen statistical and neural network predictive models for the rate of HIV-1 disease progression across two cohorts of homosexual men. Ioannidis JP, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):129–36
Skin cancer in Australian heart transplant recipients. Ong CS, et al. **J Am Acad Dermatol** 1999 Jan;40(1):27–34
Historical recombinant sites in extended HLA haplotypes. D'Alfonso S, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):8–13
Analysis of HLA-DRB1-related alleles in Japanese patients with lung cancer--relationship to genetic susceptibility and resistance to lung cancer. Tokumoto H. **J Cancer Res Clin Oncol** 1998;124(9):511–6
Human leukocyte antigen polymorphisms in the Taiwanese population. Shen SW, et al. **J Formos Med Assoc** 1999 Jan; 98(1):11–8
A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. Brissot P, et al. **J Hepatol** 1999 Apr;30(4):588–93
Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. Pratiwi R, et al. **J Hepatol** 1999 Jul;31(1):39–46
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. Sánchez M, et al. **J Hepatol** 1998 Nov;29(5):725–8
Little evidence of HLA-G mRNA polymorphism in Caucasian or Afro-Caribbean populations. Bainbridge DR, et al. **J Immunol** 1999 Aug 15;163(4):2023–7
New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. Hendel H, et al. **J Immunol** 1999 Jun 1;162(11):6942–6
Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. Pacasova R, et al. **J Immunol** 1999 May 1;162(9):5190–6
Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. Smythe JA, et al. **J Immunol** 1999 Sep 15;163(6):3239–49
HLA-A, -B, -C genotyping and expression in human nonlymphoid tumor cell lines. Delfino L, et al. **J Immunother** 1999 Jan;22(1):7–15
Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. Lekstrom-Himes JA, et al. **J Infect Dis** 1999 May; 179(5):1077–85
Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. Lynch JA, et al. **J Infect Dis** 1998 Oct;178(4):1040–6
Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. Lombardi ML, et al. **J Invest Dermatol** 1999 Jul;113(1):107–10
Cloning of the hereditary hemochromatosis gene: implications for pathogenesis, diagnosis, and screening. Himmelmann A, et al. **J Lab Clin Med** 1999 Mar; 133(3):229–36 (51 ref.)
Frequency of the HFE C282Y and H63D mutations in distinct ethnic groups living in Spain [letter; comment] Baiget M, et al. **J Med Genet** 1998 Aug;35(8):701. Comment on: J Med Genet 1997 Apr;34(4):275–8.
High frequency of the haemochromatosis C282Y mutation in Hungary could argue against a Celtic origin of the mutation [letter; comment] Tordai A, et al. **J Med Genet** 1998 Oct;35(10):878–9. Comment on: J Med Genet 1997 Apr;34(4):275–8.
Human leucocyte antigen frequencies [letter; comment] Naman RE. **J Med Liban** 1998 Jan–Feb;46(1):52–4. Comment on: J Med Liban 1997;45(2):78–83.
Reciprocal regulation of HFE and NNamp2 gene expression by iron in human intestinal cells. Han O, et al. **J Nutr** 1999 Jan;129(1):98–104
HLA associations of seropositive rheumatoid arthritis in a Cree and Ojibway population. Oen K, et al. **J Rheumatol** 1998 Dec;25(12):2319–23
Genetic linkage analysis of multicase families with fibromyalgia syndrome. Yunus MB, et al. **J Rheumatol** 1999 Feb;26(2):408–12
Transfusion with blood from people with HFE gene mutations [letter] Ania BJ, et al. **Lancet** 1999 Jul 31; 354(9176):430
Haemochromatosis gene C282Y homozygotes in an elderly male population [letter] Willis G, et al. **Lancet** 1999 Jul 17;354(9174):221–2
Hereditary haemochromatosis: diagnosis and management in the gene era. Olynyk JK. **Liver** 1999 Apr;19(2):73–80 (81 ref.)
Hereditary hemochromatosis in liver transplantation. Fiel MI, et al. **Liver Transpl Surg** 1999 Jan;5(1):50–6
Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Gotoh K, et al. **Lung Cancer** 1998 May;20(2):117–25
Update on hereditary hemochromatosis and the HFE gene. Brandhagen DJ, et al. **Mayo Clin Proc** 1999 Sep; 74(9):917–21 (25 ref.)
HLA-H: a pseudogene with increased variation due to balancing selection at neighboring loci. Grimsley C, et al. **Mol Biol Evol** 1998 Dec;15(12):1581–8
Search for a human homologue of the mouse Ped gene. Cao W, et al. **Mol Hum Reprod** 1999 Jun;5(6):541–7
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Hicklin DJ, et al. **Mol Med Today** 1999 Apr;5(4):178–86 (50 ref.)
Does HLA type predispose some individuals to cancer? Little AM, et al. **Mol Med Today** 1999 Aug;5(8):337–42
The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [see comments] Burlingham WJ, et al. **N Engl J Med** 1998 Dec 3;339(23):1657–64. Comment in: N Engl J Med 1998 Dec 3;339(23):1700–2. Comment in: N Engl J Med 1999 Apr 29;340(17):1369–70.
A population-based study of the clinical expression of the hemochromatosis gene [see comments] Olynyk JK, et al. **N Engl J Med** 1999 Sep 2;341(10):718–24. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.
The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [letter; comment] Opelz G. **N Engl J Med** 1999 Apr 29;340(17):1369–70. Comment on: N Engl J Med 1998 Dec 3;339(23):1657–64.
Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene [see comments] Pietrangelo A, et al. **N Engl J Med** 1999 Sep 2; 341(10):725–32. Comment in: N Engl J Med 1999 Sep 2;341(10):755–7.
Transplantation tolerance--the search continues [editorial; comment] Sanfilippo F. **N Engl J Med** 1998 Dec 3; 339(23):1700–2. Comment on: N Engl J Med 1998 Dec 3;339(23):1657–64.
Clinical implications of the hemochromatosis gene [editorial; comment] Tavill AS. **N Engl J Med** 1999 Sep 2; 341(10):755–7. Comment on: N Engl J Med 1999 Sep 2;341(10):718–24. Comment on: N Engl J Med 1999 Sep 2;341(10):725–32.
Type 2 diabetes, nephropathy and HLA [letter; comment] Thompson CF. **N Z Med J** 1999 Feb 12;112(1081):41. Comment on: N Z Med J 998 Aug 14;111(1071):294–6.
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis [letter] Jeffrey GP, et al. **Nat Genet** 1999 Aug;22(4):325–6
Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)
Slipped capital femoral epiphysis in identical twins: HLA predisposition. Bednarz PA, et al. **Orthopedics** 1998 Dec; 21(12):1291–3 (7 ref.)
Molecular genetic evidence for the human settlement of the Pacific: analysis of mitochondrial DNA, Y chromosome and HLA markers. Hagelberg E, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jan 29; 354(1379):141–52
High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe puumala virus-induced nephropathia epidemica. Kanerva M, et al. **Scand J Infect Dis** 1998;30(5):532–4
The regulation of HLA class I expression: is HLA-G the odd one out? Gobin SJ, et al. **Semin Cancer Biol** 1999 Feb; 9(1):55–9 (18 ref.)
Genetic analysis of ossification of the posterior longitudinal ligament. Matsunaga S, et al. **Spine** 1999 May 15; 24(10):937–8; discussion 939
The origin of Cretan populations as determined by characterization of HLA alleles. Arnaiz-Villena A, et al. **Tissue Antigens** 1999 Mar;53(3):213–26

The PCR-SSP Manager computer program: a tool for maintaining sequence alignments and automatically updating the specificities of PCR-SSP primers and primer mixes. Bunce M, et al. **Tissue Antigens** 1998 Aug; 52(2):158-74

HLA-Cw alleles associated with HLA extended haplotypes and C2 deficiency. Clavijo OP, et al. **Tissue Antigens** 1998 Sep;52(3):282-5

HLA region microsatellite polymorphisms in juvenile arthritis. Feichtlbauer P, et al. **Tissue Antigens** 1998 Sep; 52(3):220-9

Microsatellites in the HLA region: 1998 update. Foissac A, et al. **Tissue Antigens** 1998 Oct;52(4):318-52 (352 ref.)

Polymorphism of TAPASIN and its linkage disequilibria with HLA class II genes in the Japanese population. Furukawa H, et al. **Tissue Antigens** 1998 Sep;52(3):279-81

Distribution of HLA class II alleles among Spanish patients with pemphigus vulgaris. González-Escribano MF, et al. **Tissue Antigens** 1998 Sep;52(3):275-8

Virtual DNA analysis--a new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Helmberg W, et al. **Tissue Antigens** 1998 Jun;51(6):587-92

Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. Hiby SE, et al. **Tissue Antigens** 1999 Jan;53(1):1-13

HLA class II polymorphism in a Gabonese Banzabi population. Migot-Nabias F, et al. **Tissue Antigens** 1999 Jun;53(6):580-5

Selective co-evolution of the D6S7NFa microsatellite region with HLA class I and II loci. Moghaddam PH, et al. **Tissue Antigens** 1998 Sep;52(3):213-9

High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population--implications for haemochromatosis. Murphy S, et al. **Tissue Antigens** 1998 Nov;52(5):484-8

Probability of finding HLA-matched unrelated marrow donors for Koreans and Japanese from the Korean and Japan Marrow Donor Programs. Oh HB, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):347-9

Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Ohta H, et al. **Tissue Antigens** 1999 Jul; 54(1):91-7

HLA polymorphisms in Italian bone marrow donors: a regional analysis. Rendine S, et al. **Tissue Antigens** 1998 Aug;52(2):135-46

Distribution of HLA gene and haplotype frequencies in Taiwan: a comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese. Shaw CK, et al. **Tissue Antigens** 1999 Jan;53(1):51-64

HLA-E polymorphism in patients with recurrent spontaneous abortion. Steffensen R, et al. **Tissue Antigens** 1998 Dec;52(6):569-72

HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tan FK, et al. **Tissue Antigens** 1999 Jan;53(1):74-80

HLA-G genetic polymorphism in 57 Portuguese white families studied by PCR-RFLP and PCR-SSOP. Alvarez M, et al. **Transplant Proc** 1999 Jun;31(4):1829-31

Expression of HLA-E in transgenic mice. Boulouis HJ, et al. **Transplant Proc** 1999 Jun;31(4):1868-70

Preliminary study on the expression of HLA-G mRNA in normal placenta and placenta with RSA after immunotherapy. Fan L, et al. **Transplant Proc** 1999 Jun; 31(4):1854-6

Transcriptional regulation of HLA-G. Gobin SJ, et al. **Transplant Proc** 1999 Jun;31(4):1857-9

Influence of cryopreservation on antigen expression and immunogenicity of human vascular endothelial cells. Ono M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):985-7

HLA-G gene polymorphism in the normal population and in recurrent spontaneous abortion in Hungary. Pénzes M, et al. **Transplant Proc** 1999 Jun;31(4):1832-3

Iron overload: molecular clues to its cause. Kühn LC. **Trends Biochem Sci** 1999 May;24(5):164-6 (24 ref.)

Association of human leucocyte antigen phenotype with vaccine efficacy in patients receiving vaginal mucosal immunization for recurrent urinary tract infection. Hopkins WJ, et al. **Vaccine** 1999 Jan;17(2):169-71

[Determination of HLA class I and II alleles in the village of Dielmo] Dieye A, et al. **Dakar Med** 1996;41(1):25-9 (Eng. Abstr.) **(Fre)**

[The hemochromatosis gene (HFE). Molecular analysis--diagnostic applications] Ferec C, et al. **Transfus Clin Biol** 1998 Aug;5(4):283-9 (Eng. Abstr.) **(Fre)**

[Frequency distribution patterns of HLA antigens, genes, and haplotypesin the migrant population of northwestern Russia in relation to time of residence in the region and sex differentiation] Pereverzeva VV, et al. **Genetika** 1999 Apr; 35(4):504-8 (Eng. Abstr.) **(Rus)**

[HLA haplotypes in young myocardial infarct patients (a family study)] Kuz'mina AA, et al. **Ter Arkh** 1998; 70(8):33-7 (Eng. Abstr.) **(Rus)**

[Genes, polymorphism and function of the HLA gene region] Buc M. **Bratisl Lek Listy** 1998 Aug-Sep;99(8-9):447-53 (Eng. Abstr.) **(Slo)**

HISTORY

The HLA adventure. Dausset J. **Transplant Proc** 1999 Feb-Mar;31(1-2):22-4

Medawar Prize Lecture, 15 July 1998. The contribution of human subjects to experimental transplantation: the HLA story. Rapaport FT. **Transplant Proc** 1999 Feb-Mar; 31(1-2):60-6

IMMUNOLOGY

Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study. Saah AJ, et al. **AIDS** 1998 Nov 12; 12(16):2107-13

Peripheral blood mononuclear cells from women with recurrent abortion exhibit an aberrant reaction to release cytokines upon the direct contact of human leukocyte antigen-G-expressing cells. Hamai Y, et al. **Am J Reprod Immunol** 1998 Dec;40(6):408-13

Molecular and immunologic aspects of the nonclassical HLA class I antigen HLA-G: evidence for an important role in the maternal tolerance of the fetal allograft. Moreau P, et al. **Am J Reprod Immunol** 1998 Sep;40(3):136-44

Unique biochemical properties of human leukocyte antigen-E allow for a highly specific function in immune recognition. Weiss EH, et al. **Am J Reprod Immunol** 1998 Sep; 40(3):177-82

Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Piyasirisilp S, et al. **Ann Neurol** 1999 May;45(5):595-600

Effect of HLA mismatching and antibody status on "homovital" aortic valve homograft performance. Smith JD, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S212-5

An update on HLA association of Mi-2 autoantibodies: the association with a tryptophan at position 9 of the HLA-DRbeta chain is strong but not absolute. Mierau R, et al. **Arthritis Rheum** 1999 Jul;42(7):1552-3

HLAs and risk of acute graft-vs.-host disease after marrow transplantation from an HLA-identical sibling. Martin PJ, et al. **Biol Blood Marrow Transplant** 1998;4(3):128-33

Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Petersdorf EW, et al. **Blood** 1998 Nov 15;92(10):3515-20

HLA-mismatched family donor transplants: a novel strategy as curative therapy for patients with hematologic disorders. McGuirk JP, et al. **Cancer J Sci Am** 1998 Sep-Oct; 4(5):278-86 (134 ref.)

Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327-33 (42 ref.)

T cell response pattern to glutamic acid decarboxylase 65 (GAD65) peptides of newly diagnosed type 1 diabetic patients sharing susceptible HLA haplotypes. Rharbaoui F, et al. **Clin Exp Immunol** 1999 Jul;117(1):30-7

HLA-peptide tetrameric complexes. Ogg GS, et al. **Curr Opin Immunol** 1998 Aug;10(4):393-6 (18 ref.)

HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Sette A, et al. **Curr Opin Immunol** 1998 Aug;10(4):478-82

Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Braud VM, et al. **Curr Top Microbiol Immunol** 1999;244:85-95 (30 ref.)

HLA-specific and non-HLA-specific human NK receptors. Moretta A, et al. **Curr Top Microbiol Immunol** 1999; 244:69-84 (84 ref.)

Transplantation immunology--the role of human leucocyte antigen in allorecognition. Vartdal F, et al. **Curr Top Pathol** 1999;92:1-18 (64 ref.)

High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. Group for the Study of Protective Maternal HLA Antibodies in the Clinical Course of HDN. Neppert J, et al. **Eur J Haematol** 1999 Aug;63(2):120-5

Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. Montoya L, et al. **Eur J Immunogenet** 1998 Oct; 25(5):329-37

The Qa-1b molecule binds to a large subpopulation of murine NK cells. Salcedo M, et al. **Eur J Immunol** 1998 Dec; 28(12):4356-61

Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Ulbrecht M, et al. **Eur J Immunol** 1999 Feb;29(2):537-47

Human T cell recognition of the Mycobacterium leprae LSR antigen: epitopes and HLA restriction. Oftung F, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):151-9

A case of aortitis syndrome and IgA nephropathy: possible role of human leukocyte antigens in both diseases. Kanahara K, et al. **Hiroshima J Med Sci** 1999 Mar; 48(1):25-9

The presentation of self and allogeneic MHC peptides to T lymphocytes. Benichou G, et al. **Hum Immunol** 1998 Sep; 59(9):540-8 (44 ref.)

HLA and susceptibility to cervical neoplasia. Krul EJ, et al. **Hum Immunol** 1999 Apr;60(4):337-42

Independent contributions of HLA epitopes and killer inhibitory receptor expression to the functional alloreactive specificity of natural killer cells. Young NT, et al. **Hum Immunol** 1998 Nov;59(11):700-12

The major histocompatibility complex: an important factor in every stage of pregnancy from preimplantation to birth? Part I. Christiansen OB. **Hum Reprod Update** 1999 Mar-Apr;5(2):91-3 (8 ref.)

Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Leibson PJ. **Immunity** 1998 Sep;9(3):289-94 (50 ref.)

Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Mazza G, et al. **Immunol Rev** 1998 Jun;163:187-96 (34 ref.)

Intramolecular and intermolecular spreading during the course of organ allograft rejection. Suciu-Foca N, et al. **Immunol Rev** 1998 Aug;164:241-6 (42 ref.)

HLA-G: a tolerance molecule from the major histocompatibility complex. Carosella ED, et al. **Immunol Today** 1999 Feb;20(2):60-2 (22 ref.)

Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Shearer GM, et al. **Immunol Today** 1999 Feb;20(2):66-71 (49 ref.)

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Le Gal FA, et al. **Int Immunol** 1999 Aug; 11(8):1351-6

The association between the HLA antigens and Takayasu's arteritis in Thai patients. Charoenwongse P, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S117-20

Profiling of human leukocyte antigens in Eales' disease. Biswas J, et al. **Int Ophthalmol** 1997-98;21(5):277-81

HLA-derived peptides as novel immunomodulatory therapeutics. Murphy B, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1346-55 (78 ref.)

HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. Posch PE, et al. **J Biomed Sci** 1998 Sep-Oct; 5(5):321-31 (102 ref.)

HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. Zanni MP, et al. **J Clin Invest** 1998 Oct 15; 102(8):1591-8

A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. Dolstra H, et al. **J Exp Med** 1999 Jan 18;189(2):301-8

A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. Rajagopalan S, et al. **J Exp Med** 1999 Apr 5; 189(7):1093-100

Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. Moazami N, et al. **J Heart Lung Transplant** 1998 Sep;17(9):876-80

Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. Stringham JC, et al. **J Heart Lung Transplant** 1999 Feb; 18(2):160-5

Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. Bian H, et al. **J Immunol** 1999 Jul 15;163(2):1010-8

Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. Ishioka GY, et al. **J Immunol** 1999 Apr 1;162(7):3915-25

Induction of HLA class I-restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections. Kim SK, et al. **J Immunol** 1999 Jun 1;162(11):6855-66

Cutting edge: requirement of class I signal sequence-derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone. Martinozzi S, et al. **J Immunol** 1999 May 15; 162(10):5662-5

Expanded cohorts of maternal CD8+ T-cells specific for paternal MHC class I accumulate during pregnancy. Zhou M, et al. **J Reprod Immunol** 1998 Oct;40(1):47-62

Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. Smith MA, et al. **J Thorac Cardiovasc Surg** 1998 Nov; 116(5):812-20

Effects of sairei-to and tokishakuyaku-san on cytokine release from peripheral blood mononuclear cells upon recognition of HLA-G protein in the treatment of recurrent abortion. Fujii T, et al. **Methods Find Exp Clin Pharmacol** 1999 May;21(4):261-4

NIMA (non-inherited maternal antigens) versus NIPA (non-inherited paternal antigens) and tolerance of human kidney graft [editorial] Dupont E. **Nephrol Dial Transplant** 1999 Mar;14(3):547-8

Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Vella JP, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2027-32

Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain. Pina MA, et al. **Neuroepidemiology** 1999;18(4):203-9

Bacteria-specific T cells response. What role for HLA molecules? Breban M. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):37S-39S (13 ref.)

HLA-G expression: immune privilege for tumour cells? Cabestre FA, et al. **Semin Cancer Biol** 1999 Feb;9(1):27-36 (49 ref.)

HLA-G: a new opening for HLA. Dausset J, et al. **Semin Cancer Biol** 1999 Feb;9(1):1

How do NK cells sense the expression of HLA-G class Ib molecules? López-Botet M, et al. **Semin Cancer Biol** 1999

Feb;9(1):19–26 (70 ref.)
The role of peptide presentation in the physiological function of HLA-G. Münz C, et al. **Semin Cancer Biol** 1999 Feb; 9(1):47–54 (35 ref.)
The immunotolerance role of HLA-G. Rouas-Freiss N, et al. **Semin Cancer Biol** 1999 Feb;9(1):3–12 (40 ref.)
HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses. Schust DJ, et al. **Semin Cancer Biol** 1999 Feb;9(1):37–46 (71 ref.)
Probability of finding HLA-matched unrelated marrow donors for Koreans and Japanese from the Korean and Japan Marrow Donor Programs. Oh HB, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):347–9
HLA-G protein expression is not induced during malignant transformation. Pangault C, et al. **Tissue Antigens** 1999 Apr; 53(4 Pt 1):335–46
A single amino acid change makes the peptide specificity of B*3910 unrelated to B*3901 and closer to a group of HLA-B proteins including the malaria-protecting allotype HLA-B53. Yagüe J, et al. **Tissue Antigens** 1998 Nov; 52(5):416–21
Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Vamvakas EC. **Transfus Med Rev** 1998 Oct;12(4):258–70
Prevalence of HLA sensitization in female apheresis donors. Densmore TL, et al. **Transfusion** 1999 Jan;39(1):103–6
An association between antibodies specific for endothelial cells and renal transplant failure. Perrey C, et al. **Transpl Immunol** 1998 Jun;6(2):101–6
One-way donor-recipient HLA-matching as a risk factor for graft-versus-host disease in living-related liver transplantation. Kiuchi T, et al. **Transpl Int** 1998;11 Suppl 1:S383–4
Mismatch-specific anti-HLA antibody production following aorta transplants. Mirelli M, et al. **Transpl Int** 1998;11 Suppl 1:S444–7
A novel strategy for the detection and definition of HLA-specific antibodies in patients awaiting renal transplantation. Worthington JE, et al. **Transpl Int** 1998;11 Suppl 1:S372–6
Anti-HLA antibodies transduce proliferative signals in endothelial cells and smooth muscle cells. Bian H, et al. **Transplant Proc** 1999 Jun;31(4):1924
Negative response to noninherited maternal antigens confirmed by ELISA. Bishara A, et al. **Transplant Proc** 1999 Jun;31(4):1879–80
HLA-G mediates protection from natural killer cytolysis: implications in immune tolerance. Carosella ED, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1192–3
Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation. Jaramillo A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):185–6
Transfer of HLA antigens from stimulatory B cells to alloreactive T lymphocytes: a novel mechanism of "allospecific" autoregulation. Liu K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):726–7
Detection of anti-HLA antibodies by enzyme-linked immunosorbent assay, fluorescence activated cell sorter and microlymphocytotoxicity testing: a comparison of sensitivities and suggestions for standardization of ELISA. Loewenthal R, et al. **Transplant Proc** 1999 Jun;31(4):1918–9
Role of HLA-G in maternal-fetal immune tolerance. Rouas-Freiss N, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):724–5
HLA-G expression protects porcine endothelial cells from xenogeneic cytotoxicity mediated by human natural killer cells. Sasaki H, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):953–4
Only a limited set of HLA epitopes is associated with organ graft loss. Segers A, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):721–3
Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin. Urra JM, et al. **Transplant Proc** 1998 Dec; 30(8):4177–9
Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Jaramillo A, et al. **Transplantation** 1999 Apr 27;67(8):1155–61
HLA antibodies present in the sera of sensitized patients awaiting renal transplant are also reactive to swine leukocyte antigens. Naziruddin B, et al. **Transplantation** 1998 Oct 27;66(8):1074–80
Impact of transfusions and acute rejection on posttransplantation donor antigen-specific responses in two study populations. Cooperative Clinical Trial in Transplantation Research Group. Reinsmoen NL, et al. **Transplantation** 1999 Mar 15;67(5):697–702
HLA-G expression protects porcine endothelial cells against natural killer cell-mediated xenogeneic cytotoxicity. Sasaki H, et al. **Transplantation** 1999 Jan 15;67(1):31–7
Endothelial cell activation by sera containing HLA antibodies is mediated by interleukin-1. Smith JD, et al. **Transplantation** 1998 Nov 15;66(9):1229–37
Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. McDermott AB, et al. **Vaccine** 1999 Jan 28;17(4):330–9
Use of HLA- and HPA--matched platelets in alloimmunized patients. Kekomäki R. **Vox Sang** 1998;74 Suppl 2:359–63 (47 ref.)
The treatment of blood components with ultraviolet-B irradiation. Pamphilon DH. **Vox Sang** 1998;74 Suppl 2:15–9 (9 ref.)
[HLA-G-related repeat abortions with histological characteristics of organ rejection (letter)] Rabreau M, et al. **Presse Med** 1999 Jan 9;28(1):17 **(Fre)**
[Class I and II major histocompatibility complex molecules (HLA system). Antigenic presentation and cellular implications of this presentation] Tamouza R, et al. **Rev Prat** 1998 Nov 15;48(18):2045–50 **(Fre)**
[Labile blood products from donors immunized against the HLA system. Apropos of a case of transfusional pulmonary edema] Fruchart MF, et al. **Transfus Clin Biol** 1998 Dec; 5(6):381–4 (Eng. Abstr.) **(Fre)**
[Histocompatibility antigens in pregnant women with preeclampsia and in their husbands] Wiktor H, et al. **Ginekol Pol** 1998 Dec;69(12):937–42 (Eng. Abstr.) **(Pol)**
[HLA antigens and ocular pathology] Gafencu O, et al. **Oftalmologia** 1998;42(2):4–8 (10 ref.) (Eng. Abstr.) **(Rum)**
[Population study of antibodies to some potential pathogens of spondyloarthopathies: the study of the Chukotka population] Guseva IA, et al. **Klin Med (Mosk)** 1999; 77(5):27–31 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Soluble HLA-G: purification from eukaryotic transfected cells and detection by a specific ELISA. Fournel S, et al. **Am J Reprod Immunol** 1999 Jul;42(1):22–9
Soluble HLA in human body fluids. Aultman D, et al. **Hum Immunol** 1999 Mar;60(3):239–44

METABOLISM

The presence and absence of histocompatibility antigens in HIV type 1 produced by autologous blood-derived macrophages and peripheral blood lymphoblasts. Tsai WP, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):33–41
Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. Valés-Gómez M, et al. **EMBO J** 1999 Aug 2;18(15):4250–60
HLA-G and classical HLA class I transcripts in various components of the adult human eye. Robert PY, et al. **Eur J Immunogenet** 1999 Aug;26(4):271–4
The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Navarro F, et al. **Eur J Immunol** 1999 Jan;29(1):277–83
IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: a mechanism for its antitumor activity? Yue FY, et al. **Eur J Immunol** 1999 Jun;29(6):1762–73
Specific binding of nuclear factors to the HLA-G gene promoter correlates with a lack of HLA-G transcripts in first trimester human fetal liver. Moreau P, et al. **Hum Immunol** 1998 Dec;59(12):751–7
Modulation of HLA class I antigen and ICAM-2 on endothelial cells after in vitro infection with human cytomegalovirus. Shahgasempour S, et al. **Immunol Cell Biol** 1998 Jun;76(3):217–21
T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. Burton MD, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):255–61
Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. Allan DS, et al. **J Exp Med** 1999 Apr 5;189(7):1149–56
Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. Brooks AG, et al. **J Immunol** 1999 Jan 1;162(1):305–13
HLA-A, -B, -C genotyping and expression in human nonlymphoid tumor cell lines. Delfino L, et al. **J Immunother** 1999 Jan;22(1):7–15
The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary hemochromatosis. Lebrón JA, et al. **J Mol Biol** 1999 Jun 18;289(4):1109–18
Recurrent Miller Fisher syndrome: clinical and laboratory features and HLA antigens. Chida K, et al. **J Neurol Sci** 1999 Jun 1;165(2):139–43
Heterogeneous patterns of constitutive and heat shock induced expression of HLA-linked HSP70-1 and HSP70-2 heat shock genes in human melanoma cell lines. Dressel R, et al. **Melanoma Res** 1998 Dec;8(6):482–92
Interaction of the hemochromatosis gene product HFE with transferrin receptor modulates cellular iron metabolism. Eisenstein RS. **Nutr Rev** 1998 Dec;56(12):356–8 (15 ref.)
Natural killer cells fertile with receptors for HLA-G? [see comments] Lanier LL. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5343–5. Comment in: Proc Natl Acad Sci U S A 1999 May 11;96(10):5674–9.
Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Salter-Cid L, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5434–9
Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Waheed A, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1579–84
Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Mamitsuka H. **Proteins** 1998 Dec 1;33(4):460–74
Analysis of HLA-G expression in tumor cell lines. Frumento G, et al. **Transplant Proc** 1999 Jun;31(4):1847–8
Expression and regulation of HLA-G in human glioma cell lines. Maier S, et al. **Transplant Proc** 1999 Jun;31(4):1849–53
HLA-G expression on porcine endothelial cells protects partially against direct human NK cytotoxicity but not against ADCC. Seebach JD, et al. **Transplant Proc** 1999 Jun;31(4):1864–5

PHARMACOLOGY

The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. Roy CN, et al. **J Biol Chem** 1999 Mar 26;274(13):9022–8

PHYSIOLOGY

Human leukocyte antigen-G: new roles for old? [editorial; comment] Clark DA. **Am J Reprod Immunol** 1999 Feb; 41(2):117–20. Comment on: Am J Reprod Immunol 1999 Feb;41(2):153–8. Comment on: Am J Reprod Immunol 1999 Feb;41(2):159–63.
The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them [see comments] Hamai Y, et al. **Am J Reprod Immunol** 1999 Feb;41(2):153–8. Comment in: Am J Reprod Immunol 1999 Feb;41(2):117–20.
Evolution of HLA class II molecules: Allelic and amino acid site variability across populations. Salamon H, et al. **Genetics** 1999 May;152(1):393–400
Soluble HLA antigens and their peptides as immunoregulators and monitoring devices. Claas FH, et al. **Hum Immunol** 1999 May;60(5):398–400
Placental HLA-G protein expression in vivo: where and what for? Le Bouteiller P, et al. **Hum Reprod Update** 1999 May-Jun;5(3):223–33 (101 ref.)
The functionality of HLA-G is emerging. Le Bouteiller P, et al. **Immunol Rev** 1999 Feb;167:233–44 (64 ref.)
Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children. Yamamoto AM, et al. **J Autoimmun** 1998 Dec; 11(6):643–50
HLA class I-mediated induction of cell proliferation involves cyclin E-mediated inactivation of Rb function and induction of E2F activity. Nath N, et al. **J Immunol** 1999 May 1;162(9):5351–8
Choriocarcinoma cell line resistance to NK lysis mainly involves an HLA-G-independent mechanism. Avril T, et al. **Transplant Proc** 1999 Jun;31(4):1866–7

HLA-A ANTIGENS

Hematopoietic stem-cell transplantation for acute leukemia [letter; comment] Eiermann TH. **N Engl J Med** 1999 Mar 11;340(10):809; discussion 810–1. Comment on: N Engl J Med 1998 Oct 22;339(17):1177–85.

ANALYSIS

Transplantation for adrenoleukodystrophy with HLA-A and B nonidentical paternal marrow: report of one case. Lin HC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul-Aug;39(4):260–3
Oral lichen planus and HLA A. Ognjenović M, et al. **Coll Antropol** 1998 Dec;22 Suppl:89–92
HLA characterization in adult asymptomatic cyst passers of Entamoeba histolytica/E. dispar. Valdez E, et al. **Parasitol Res** 1999 Oct;85(10):833–6

BLOOD

[The role of HLA antigens in predicting the active course of multiple myeloma] Zaraiskiĭ MI, et al. **Ter Arkh** 1998; 70(7):42–6 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. Kicklighter EJ, et al. **J Immunother** 1999 May;22(3):219–28
Fluorotyping of HLA-A by sequence-specific priming and fluorogenic probing. Slateva K, et al. **Tissue Antigens** 1998 Nov;52(5):462–72

GENETICS

Nested polymerase chain reaction with sequence-specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-matched individuals. Carter AS, et al. **Blood** 1999 Aug 15;94(4):1471–7
DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Prasad VK, et al. **Blood** 1999 Jan 1;93(1):399–409
Implication of molecular analysis of HLA-A*02 subtyping for unrelated bone-marrow donor selection. Cecuk-Jelicić E, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S27–30
HLA-A, B antigens and their linkage with HLA-DR among blood donors in Taiwan. Tsai SJ, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Aug;28(3):157–66
HLA antigens and haplotypes in IgA-deficient Brazilian

paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281-5
HLA-A*28 allele frequencies in the five major U.S. ethnic groups. Hsu E, et al. **Hum Immunol** 1999 Feb;60(2):159-67
The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis. Seeger FH, et al. **Immunogenetics** 1999 Jun;49(6):571-6
MIC-A allele profiles and HLA class I associations in Behçet's disease. Wallace GR, et al. **Immunogenetics** 1999 Jul;49(7-8):613-7
A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Fujie T, et al. **Int J Cancer** 1999 Jan 18;80(2):169-72
HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas. Kanno H, et al. **Int J Cancer** 1999 Aug 27;82(5):630-4
Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Nukaya I, et al. **Int J Cancer** 1999 Jan 5;80(1):92-7
Familial versus sporadic longevity and MHC markers. Henon N, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar; 13(1):27-31
Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. Men Y, et al. **J Immunol** 1999 Mar 15;162(6):3566-73
Differences in gene conversion rates among exons between HLA-A and HLA-B loci. Inutsuka H. **Kurume Med J** 1999;46(1):79-82
Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. Middleton D, et al. **Neurosci Lett** 1999 Mar 5;262(2):140-2
HLA class I allele distributions in six Pacific/Asian populations: evidence of selection at the HLA-A locus. Bugawan TL, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):311-9
A DNA-based detection and screening system for identifying HLA class I expression variants by sequence-specific primers. Bunce M, et al. **Tissue Antigens** 1999 May; 53(5):498-506
Sequence of HLA-A*6808. Cox ST, et al. **Tissue Antigens** 1999 Jun;53(6):597-600
HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. Cox ST, et al. **Tissue Antigens** 1999 Jan;53(1):41-50
HLA-A*9, a probable secondary susceptibility marker to ankylosing spondylitis in Basque patients. de Juan MD, et al. **Tissue Antigens** 1999 Feb;53(2):161-6
Characterization of a novel HLA-A*24 allele containing an HLA-A*03 sequence motif. Drábek J, et al. **Tissue Antigens** 1999 Jul;54(1):98-101
Novel HLA-A and HLA-B alleles. Hurley CK, et al. **Tissue Antigens** 1998 Jul;52(1):84-7
Molecular analysis of HLA class I alleles in the Mexican Seri Indians: implications for their origin. Infante E, et al. **Tissue Antigens** 1999 Jul;54(1):35-42
New high resolution typing strategy for HLA-A locus alleles based on dye terminator sequencing of haplotypic group-specific PCR-amplicons of exon 2 and exon 3. Kurz B, et al. **Tissue Antigens** 1999 Jan;53(1):81-96
A null HLA-A*68 allele in a bone marrow donor. Laforet M, et al. **Tissue Antigens** 1999 Jun;53(6):573-5
Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Ono T, et al. **Tissue Antigens** 1998 Dec;52(6):539-42
HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). Ozawa A, et al. **Tissue Antigens** 1999 Mar;53(3):263-8
HLA-A,-B,-DRB1 allele and haplotype frequencies in 510 Koreans. Park MH, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):386-90
Fluorotyping for HLA-A by sequence-specific priming and fluorogenic probing. Slateva K, et al. **Tissue Antigens** 1998 Nov;52(5):462-72
Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tonks S, et al. **Tissue Antigens** 1999 Feb;53(2):175-83
Allele resolution of HLA-A using oligonucleotide probes in a two-stage typing strategy. Williams F, et al. **Tissue Antigens** 1999 Jul;54(1):59-68
Detection of HLA-A*24 null alleles by DNA typing methods. Williams F, et al. **Tissue Antigens** 1998 Sep; 52(3):208-12
HLA epitopes for kidney allocation. Lee PC, et al. **Transplant Proc** 1998 Nov;30(7):3496-7
Sequencing of two HLA-A blank alleles: implications in unrelated bone marrow donor matching. Zanone-Ramseier R, et al. **Transplantation** 1999 May 27;67(10):1336-41

IMMUNOLOGY

HLA-A*1101-restricted cytotoxic T lymphocyte recognition of HIV-1 Pol protein [letter] Fukada K, et al. **AIDS** 1999 Jul 30;13(11):1413-4
Identification of a novel HLA-A24-restricted cytotoxic T-lymphocyte epitope derived from HIV-1 Gag protein [letter] Ikeda-Moore Y, et al. **AIDS** 1998 Oct 22; 12(15):2073-4
A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Yazaki M, et al. **Bone Marrow Transplant** 1999 Jul; 24(2):129-37
The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Hogan KT, et al. **Cancer Res** 1998 Nov 15; 58(22):5144-50
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Irvine KR, et al. **Cancer Res** 1999 Jun 1;59(11):2536-40
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Parkhurst MR, et al. **Cancer Res** 1998 Nov 1;58(21):4895-901
Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Yang D, et al. **Cancer Res** 1999 Aug 15;59(16):4056-63
Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2 dimers, monomers, and monovalent F(ab). Mahoney RJ, et al. **Hum Immunol** 1999 Jun;60(6):492-9
Assignment of HLA-antigens in CREGs facilitates the detection of acceptable mismatches in highly sensitized patients. Papassavas AC, et al. **Hum Immunol** 1998 Sep; 59(9):587-96
Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Kikuchi M, et al. **Int J Cancer** 1999 May 5;81(3):459-66
Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Nukaya I, et al. **Int J Cancer** 1999 Jan 5;80(1):92-7
A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Oiso M, et al. **Int J Cancer** 1999 May 5;81(3):387-94
Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Skipper JC, et al. **Int J Cancer** 1999 Aug 27;82(5):669-77
Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. Harrer T, et al. **J Immunol** 1998 Nov 1; 161(9):4875-81
Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. Suzuki K, et al. **J Immunol** 1999 Sep 1;163(5):2783-91
Expression of the SART-1 antigens in uterine cancers. Matsumoto H, et al. **Jpn J Cancer Res** 1998 Dec; 89(12):1292-5
The role of anchor residues in the binding of peptides to HLA-A*1101 molecules. Chujoh Y, et al. **Tissue Antigens** 1998 Dec;52(6):501-9
Identification of an HLA-A11 serological variant and its characterization by sequencing based typing. Morrell G, et al. **Tissue Antigens** 1999 Jun;53(6):591-4
A human monoclonal antibody against HLA-Cw1 and a human monoclonal antibody against an HLA-A locus determinant derived from a single uniparous female. Mulder A, et al. **Tissue Antigens** 1998 Oct;52(4):393-6
HLA-A and -B alleles in cornea donors as risk factors for graft rejection. Creemers PC, et al. **Transpl Immunol** 1999 Mar;7(1):15-8
A retrospective evaluation of HLA-A, B and -DRB1 matching in liver transplantation. Poli F, et al. **Transpl Int** 1998;11 Suppl 1:S347-9
Effect of HLA-A and -DPB1 matching in corneal transplantation. Morita N, et al. **Transplant Proc** 1998 Nov; 30(7):3491-2
Effect of mismatched combinations of HLA-A antigens on graft survival in the transplanted kidney. Ogahara S, et al. **Transplant Proc** 1998 Nov;30(7):3500-1
Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):781

METABOLISM

Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Giacomini P, et al. **Cancer Res** 1999 Jun 1;59(11):2657-67
Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. Micheletti F, et al. **Eur J Immunol** 1999 Aug;29(8):2579-89
The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines. Shields MJ, et al. **J Biol Chem** 1998 Oct 23;273(43):28010-8
Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition. Collins EJ, et al. **J Immunol** 1999 Jan 1;162(1):331-7
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). Gray CM, et al. **J Immunol** 1999 Feb 1;162(3):1780-8

HLA-A1 ANTIGEN

BIOSYNTHESIS

Enhanced expression of HLA class I molecules in human hepatocellular carcinoma cells transduced with gamma-interferon gene. Qian S, et al. **Chin Med J (Engl)** 1998 Apr;111(4):319-22

GENETICS

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257-74 (171 ref.)
HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. Ozawa A, et al. **J Dermatol** 1998 Sep;25(9):573-81
Baculoviral expressed HLA class I heavy chains used to screen a synthetic peptide library for allele-specific peptide binding motifs. Smith MH, et al. **Mol Immunol** 1998 Nov; 35(16):1033-43

IMMUNOLOGY

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s). Imro MA, et al. **Cancer Res** 1999 May 15;59(10):2287-91
Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K, et al. **Cancer Res** 1999 Sep 15;59(18):4642-50
Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Maeurer MJ, et al. **Clin Cancer Res** 1996 Jan;2(1):87-95
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Marchand M, et al. **Int J Cancer** 1999 Jan 18;80(2):219-30
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y, et al. **J Immunol** 1998 Dec 15;161(12):6985-92

HLA-A2 ANTIGEN

ANALYSIS

Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Maeurer MJ, et al. **Clin Cancer Res** 1996 Apr;2(4):641-52

BIOSYNTHESIS

The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Riggs NL, et al. **Virology** 1999 Jun 5;258(2):203-7

CHEMISTRY

CH/pi interactions in the crystal structure of class I MHC antigens and their complexes with peptides. Umezawa Y, et al. **Bioorg Med Chem** 1998 Dec;6(12):2507-15
Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Ding YH, et al. **Immunity** 1999 Jul;11(1):45-56
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. Bieganowska K, et al. **J Immunol** 1999 Feb 1; 162(3):1765-71
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. Yee C, et al. **J Immunol** 1999 Feb 15;162(4):2227-34
Crystal structures of HLA-A*0201 complexed with antigenic peptides with either the amino- or carboxyl-terminal group substituted by a methyl group. Bouvier M, et al. **Proteins** 1998 Oct 1;33(1):97-106
Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. Fleischhauer K, et al. **Tissue Antigens** 1999 Jun;53(6):519-26

CLASSIFICATION

Rapid HLA class I DNA typing using microtiter plate-reverse hybridization assay (MRHA) by simple thermoregulation: high-resolution subtyping of the HLA-A2 and -B40 antigen groups. Moribe T, et al. **Hum Immunol** 1999 Jun;60(6):539-49
High-resolution HLA-A*0201 subtyping using directed heteroduplex analysis. Kicklighter EJ, et al. **J Immunother** 1999 May;22(3):219-28

GENETICS

Association of the HLA-A2 allele with an earlier age of onset of Alzheimer's disease. Combarros O, et al. **Acta Neurol Scand** 1998 Aug;98(2):140-1

HLA-A2 ANTIGEN

HLA A2 allele is associated with age at onset of Alzheimer's disease. Ballerini C, et al. **Ann Neurol** 1999 Mar; 45(3):397–400

Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas; lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2. Ofuji S, et al. **Anticancer Res** 1998 Sep–Oct; 18(5B):3639–44

Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains. Simmonds RE, et al. **Blood** 1999 Jul 15;94(2):632–41

Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Ressing ME, et al. **Eur J Immunol** 1999 Apr;29(4):1292–303

Role of the interferon-stimulated response element in HLA-B downregulation in human melanoma cell lines. Griffioen M, et al. **Immunogenetics** 1999 Apr;49(4):287–94

The peptide-binding motif of HLA-A*0217. Savoie CJ, et al. **Immunogenetics** 1999 Jun;49(6):567–70

HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. Ozawa A, et al. **J Dermatol** 1998 Sep;25(9):573–81

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. Pittet MJ, et al. **J Exp Med** 1999 Sep 6; 190(5):705–15

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. Wang Z, et al. **J Exp Med** 1999 Jul 19; 190(2):205–15

Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2KbnullDbnull double knockout mice. Ureta-Vidal A, et al. **J Immunol** 1999 Sep 1;163(5):2555–60

Baculoviral expressed HLA class I heavy chains used to screen a synthetic peptide library for allele-specific peptide binding motifs. Smith MH, et al. **Mol Immunol** 1998 Nov; 35(16):1033–43

Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. Fleischhauer K, et al. **Tissue Antigens** 1999 Jun;53(6):519–26

Identification of HLA-A*0224: implications for PCR-SSP HLA typing. Guttridge MG, et al. **Tissue Antigens** 1999 Feb;53(2):190–3

Novel HLA-A and HLA-B alleles in South American Indians. Marcos CY, et al. **Tissue Antigens** 1999 May; 53(5):476–85

Characterization of a novel HLA-A2 variant, A*02012, in the Southern Thai-Muslim population. Scheltinga SA, et al. **Tissue Antigens** 1999 May;53(5):507–9

HISTORY

Soluble HLA antigens: how it all started. van Rood JJ, et al. **Hum Immunol** 1999 May;60(5):412–3

IMMUNOLOGY

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Brossart P, et al. **Blood** 1999 Jun 15; 93(12):4309–17

Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Butterfield LH, et al. **Cancer Res** 1999 Jul 1;59(13):3134–42

A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Molldrem JJ, et al. **Cancer Res** 1999 Jun 1; 59(11):2675–81

An antigen-targeted approach to adoptive transfer therapy of cancer. Valmori D, et al. **Cancer Res** 1999 May 1; 59(9):2167–73

Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368–376. Valmori D, et al. **Cancer Res** 1999 Aug 15;59(16):4050–5

Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K, et al. **Cancer Res** 1999 Sep 15;59(18):4642–50

Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro. Fujie T, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2425–30

707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma. Takahashi T, et al. **Clin Cancer Res** 1997 Aug;3(8):1363–70

Recognition of HLA-DR1/DRB1*0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-5 A1. Löffler D, et al. **Eur J Immunogenet** 1998 Oct;25(5):339–47

HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. Lewis JW, et al. **Eur J Immunol** 1998 Oct;28(10):3214–20

Diminished recognition of HLA-A2 proteins lacking a cytoplasmic domain (CY) by A2-restricted, EBV-specific CTLs: possible role of the CY in TAP association. Cannon MJ, et al. **Immunogenetics** 1999 Apr;49(4):346–50

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. D'Souza S, et al. **Int J Cancer** 1998 Dec 9;78(6):699–706

HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. Burlingham WJ, et al. **J Immunol** 1998 Dec 15;161(12):6705–14

Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. Harrer T, et al. **J Immunol** 1998 Nov 1; 161(9):4875–81

Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y, et al. **J Immunol** 1998 Dec 15;161(12):6985–92

An HLA-A2 polyepitope vaccine for melanoma immunotherapy. Mateo L, et al. **J Immunol** 1999 Oct 1; 163(7):4058–63

Alloreactivity as a source of high avidity peptide-specific human CTL. Münz C, et al. **J Immunol** 1999 Jan 1; 162(1):25–34

HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. Reynolds SR, et al. **J Immunol** 1998 Dec 15;161(12):6970–6

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] Valmori D, et al. **J Immunol** 1998 Dec 15; 161(12):6956–62

Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in hepatitis B virus X antigen. Chung MK, et al. **J Immunother** 1999 Jul; 22(4):279–87

Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. Woodberry T, et al. **J Virol** 1999 Jul;73(7):5320–5

Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization. Dela Cruz CS, et al. **Vaccine** 1999 Jun 4;17(20–21):2479–92

METABOLISM

Human p53(264–272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Petersen TR, et al. **Cancer Lett** 1999 Apr 1;137(2):183–91

Selective formation of Gsalpha-MHC I complexes after desensitization of human platelets with iloprost. Ferreira P, et al. **Eur J Biochem** 1999 Jan;259(1–2):167–74

Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Forero L, et al. **Hum Immunol** 1998 Jul;59(7):443–50

TCR binding to peptide-MHC stabilizes a flexible recognition interface. Willcox BE, et al. **Immunity** 1999 Mar;10(3):357–65

T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. Wyer JR, et al. **Immunity** 1999 Feb;10(2):219–25

CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Bixby DL, et al. **Int J Cancer** 1998 Dec 9; 78(6):685–94

Changes in the fine specificity of gp100(209–217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. Clay TM, et al. **J Immunol** 1999 Feb 1;162(3):1749–55

Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. Hausmann S, et al. **J Immunol** 1999 May 1;162(9):5389–97

The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber. Davison E, et al. **J Virol** 1999 May;73(5):4513–7

The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Story CM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8516–21

Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Schafer JR, et al. **Vaccine** 1998 Nov;16(19):1880–4

PHYSIOLOGY

Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein. Escobar P, et al. **Clin Exp Immunol** 1999 May;116(2):214–9

THERAPEUTIC USE

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Murphy GP, et al. **Prostate** 1999 Jan 1;38(1):73–8

HLA-A3 ANTIGEN

GENETICS

The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Allcock RJ, et al. **Immunogenetics** 1999 Jul;49(7–8):660–5

Complete cDNA coding sequence of a new HLA-A3 subtype (A*0304) with a new HLA polymorphism at exon 3. Santos S, et al. **Immunogenetics** 1999 Apr;49(4):360–1

IMMUNOLOGY

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Posthuma EF, et al. **Blood** 1999 Jun 1;93(11):3863–5

Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Kawashima I, et al. **Cancer Res** 1999 Jan 15;59(2):431–5

Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Kawashima I, et al. **Int J Cancer** 1998 Nov 9;78(4):518–24

Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. Chang KM, et al. **J Immunol** 1999 Jan 15; 162(2):1156–64

Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. Kawakami Y, et al. **J Immunol** 1998 Dec 15;161(12):6985–92

Alloreactivity as a source of high avidity peptide-specific human CTL. Münz C, et al. **J Immunol** 1999 Jan 1; 162(1):25–34

HLA-B ANTIGENS

ANALYSIS

Primary association of HLA-B51 with Behçet's disease in Ireland [letter; comment] Benezra D. **Br J Ophthalmol** 1998 Jun;82(6):715. Comment on: Br J Ophthalmol 1997 Aug;81(8):649–53.

Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Tanzarella S, et al. **Cancer Res** 1999 Jun 1;59(11):2668–74

Transplantation for adrenoleukodystrophy with HLA-A and B nonidentical paternal marrow: report of one case. Lin HC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul–Aug;39(4):260–3

Oral lichen planus and HLA B. Ognjenović M, et al. **Coll Antropol** 1998 Dec;22 Suppl:93–6

HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Harcombe AA, et al. **Int J Cardiol** 1999 Jan;68(1):31–7

Differences between HLA-B44 and HLA-B60 in patients with smear-positive pulmonary tuberculosis and exposed controls [letter] Bothamley GH. **J Infect Dis** 1999 Apr; 179(4):1051–2

HLA characterization in adult asymptomatic cyst passers of Entamoeba histolytica/E. dispar. Valdez E, et al. **Parasitol Res** 1999 Oct;85(10):833–6

BIOSYNTHESIS

Is the expression of classical HLA class I antigens on trophoblast of importance for human pregnancy? Christiansen OB, et al. **Am J Reprod Immunol** 1998 Sep; 40(3):158–64

BLOOD

[The role of HLA antigens in predicting the active course of multiple myeloma] Zaraiskii MI, et al. **Ter Arkh** 1998; 70(7):42–6 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Peptide motif of HLA-B*1510. Seeger FH, et al. **Immunogenetics** 1999 Oct;49(11–12):996–9

HLA-B15 peptide ligands are preferentially anchored at their C termini. Prilliman KR, et al. **J Immunol** 1999 Jun 15; 162(12):7277–84

Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. Fleischhauer K, et al. **Tissue Antigens** 1999 Jun;53(6):519–26

CLASSIFICATION

Nomenclature for factors of the HLA system, update May/June 1998. Marsh SG. **Eur J Immunogenet** 1998 Oct; 25(5):381

Rapid HLA class I DNA typing using microtiter plate-reverse hybridization assay (MRHA) by simple thermoregulation: high-resolution subtyping of the HLA-A2 and -B40 antigen groups. Moribe T, et al. **Hum Immunol** 1999 Jun;60(6):539–49

Comparative analysis of HLA-B 8101 by serology, isoelectric

focusing, and sequence-based typing. Skerrett D, et al. **Hum Immunol** 1999 Feb;60(2):168-70
Identification of a novel HLA-B*51 variant: HLA-B*5112. Tamouza R, et al. **Tissue Antigens** 1998 Nov;52(5):489-91

GENETICS

Nested polymerase chain reaction with sequence-specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-matched individuals. Carter AS, et al. **Blood** 1999 Aug 15;94(4):1471-7
DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Prasad VK, et al. **Blood** 1999 Jan 1;93(1):399-409
HLA-A, B antigens and their linkage with HLA-DR among blood donors in Taiwan. Tsai SJ, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Aug;28(3):157-66
HLA antigens and haplotypes in IgA-deficient Brazilian paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281-5
Molecular, serological and population studies of the alleles and products of HLA-B*41. Darke C, et al. **Exp Clin Immunogenet** 1999;16(3):139-49
Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. Heo DS, et al. **Hum Gene Ther** 1998 Sep 20; 9(14):2031-8
HLA-B22 diversity including a novel B54 variant (B*5507) in the Korean population. Lee KW, et al. **Hum Immunol** 1999 Aug;60(8):731-7
MIC-A allele profiles and HLA class I associations in Behçet's disease. Wallace GR, et al. **Immunogenetics** 1999 Jul;49(7-8):613-7
Immunogenetic analysis of Buerger's disease in India. Jaini R, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S283-5
Association of clinical manifestations with HLA-B alleles in Takayasu arteritis. Kitamura H, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S121-6
Association of MICA gene and HLA-B*5101 with Behçet's disease in Greece. Yabuki K, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):1921-6
Familial versus sporadic longevity and MHC markers. Henon N, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar; 13(1):27-31
A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. Dolstra H, et al. **J Exp Med** 1999 Jan 18;189(2):301-8
Cloning, structure, and function of two rainbow trout Bf molecules. Sunyer JO, et al. **J Immunol** 1998 Oct 15; 161(8):4106-14
Differences in gene conversion rates among exons between HLA-A and HLA-B loci. Inutsuka H. **Kurume Med J** 1999;46(1):79-82
Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Griffioen M, et al. **Mol Immunol** 1998 Sep;35(13):829-35
Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. Middleton D, et al. **Neurosci Lett** 1999 Mar 5;262(2):140-2
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage [see comments] Carrington M, et al. **Science** 1999 Mar 12;283(5408):1748-52. Comment in: Science 1999 Jul 2;285(5424):11.
Characterization of a new HLA-B*38 allele (B*3803) in a Spanish Caucasian individual which is closely related to the Oriental B*38021 and B*39021 alleles. Balas A, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):374-7
Characterization and distribution of HLA-B*5002 in a Spanish population sample. Balas A, et al. **Tissue Antigens** 1998 Aug;52(2):183-6
Characterization of a new HLA-B18 allele, B*1806, which lacks expression of the Bw6 epitope. Balas A, et al. **Tissue Antigens** 1998 Dec;52(6):579-82
A DNA-based detection and screening system for identifying HLA class I expression variants by sequence-specific primers. Bunce M, et al. **Tissue Antigens** 1999 May; 53(5):498-506
HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. Cox ST, et al. **Tissue Antigens** 1999 Jan;53(1):41-50
Aberrant splicing of intron 1 creates a novel null HLA-B*1501 allele. Curran MD, et al. **Tissue Antigens** 1999 Mar;53(3):244-52
Molecular, serological and population studies on a novel HLA-B allele--HLA-B*5002. Darke C, et al. **Tissue Antigens** 1998 Jun;51(6):666-70
HLA-B*4703: sequence confirmation, serology and distribution. Darke C, et al. **Tissue Antigens** 1999 Jun; 53(6):586-90
Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. Fleischhauer K, et al. **Tissue Antigens** 1999 Jun;53(6):519-26
Evolutionary relationships between HLA-B alleles as indicated by an analysis of intron sequences. Gomez-Casado E, et al. **Tissue Antigens** 1999 Feb; 53(2):153-60
Association of HLA-B51 subtypes and Behçet's disease in Spain. González-Escribano MF, et al. **Tissue Antigens** 1998 Jul;52(1):78-80
Identification, sequencing and serology of HLA-B*3527. Guttridge MG, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):383-5
Novel HLA-A and HLA-B alleles. Hurley CK, et al. **Tissue Antigens** 1998 Jul;52(1):84-7
Molecular analysis of HLA class I alleles in the Mexican Seri Indians: implications for their origin. Infante E, et al. **Tissue Antigens** 1999 Jul;54(1):35-42
Diversity of HLA-B17 alleles and haplotypes in East Asians and a novel Cw6 allele (Cw*0604) associated with B*5701. Inoue T, et al. **Tissue Antigens** 1999 Jun;53(6):534-44
Contribution of TAP genes to genetic predisposition for diffuse panbronchiolitis. Keicho N, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):366-73
Characterization of a new HLA-B39 allele, B*3913, in a Brazilian Caucasian. Maertens R, et al. **Tissue Antigens** 1998 Dec;52(6):583-6
Novel HLA-A and HLA-B alleles in South American Indians. Marcos CY, et al. **Tissue Antigens** 1999 May; 53(5):476-85
Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Ono T, et al. **Tissue Antigens** 1998 Dec;52(6):539-42
HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). Ozawa A, et al. **Tissue Antigens** 1999 Mar;53(3):263-8
HLA-A,-B,-DRB1 allele and haplotype frequencies in 510 Koreans. Park MH, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):386-90
HLA-B locus sequence-based typing. Pozzi S, et al. **Tissue Antigens** 1999 Mar;53(3):275-81
Role of HLA-B and C alleles in development of psoriasis in patients from North India. Rani R, et al. **Tissue Antigens** 1998 Jun;51(6):618-22
Significant association of HLA-B and HLA-DRB1 alleles with cleft lip with or without cleft palate. Sakata Y, et al. **Tissue Antigens** 1999 Feb;53(2):147-52
A novel HLA allele, HLA-B*5113, identified in the Kolla Amerindians of North-West Argentina. Scott I, et al. **Tissue Antigens** 1999 Feb;53(2):194-7
Identification of a novel HLA-B*51 variant: HLA-B*5112. Tamouza R, et al. **Tissue Antigens** 1998 Nov;52(5):489-91
Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tonks S, et al. **Tissue Antigens** 1999 Feb;53(2):175-83
The South Amerindian allotype HLA-B*3909 has the largest known similarity in peptide specificity and common natural ligands with HLA-B27. Yagüe J, et al. **Tissue Antigens** 1999 Mar;53(3):227-36
Typing of HLA-B*15 alleles using sequence-specific primers. Yu N, et al. **Tissue Antigens** 1998 Sep;52(3):260-9
HLA epitopes for kidney allocation. Lee PC, et al. **Transplant Proc** 1998 Nov;30(7):3496-7

IMMUNOLOGY

Cytotoxic T lymphocyte recognition of HLA-B*5101-restricted HIV-1 Rev epitope which is naturally processed in HIV-1-infected cells [letter] Tomiyama H, et al. **AIDS** 1999 May 7;13(7):861-3
Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Sobao Y, et al. **Arthritis Rheum** 1999 Jan;42(1):175-81
Direct alloreactivity by human cytotoxic T lymphocytes can Be inhibited by altered peptide ligand antagonism. Burrows SR, et al. **Blood** 1999 Feb 1;93(3):1020-4
Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2 dimers, monomers, and monovalent F(ab). Mahoney RJ, et al. **Hum Immunol** 1999 Jun;60(6):492-9
Assignment of HLA-antigens in CREGs facilitates the detection of acceptable mismatches in highly sensitized patients. Papassavas AC, et al. **Hum Immunol** 1998 Sep; 59(9):587-96
Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules. Tomiyama H, et al. **Hum Immunol** 1999 Mar;60(3):177-86
The role of the amino acids associated with the HLA-Bw4/Bw6 epitope in peptide binding to HLA-B5, B35 CREG molecules. Sobao Y, et al. **Immunogenetics** 1999 Aug;49(9):819-22
Characterization and distribution of HLA-B*5002 in a Spanish population sample. Balas A, et al. **Tissue Antigens** 1998 Aug;52(2):183-6
Identification, sequencing and serology of HLA-B*3527. Guttridge MG, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):383-5
Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Herman J, et al. **Tissue Antigens** 1999 Feb;53(2):111-21
On the nature of "HLA-B42" alloantibodies. Specific reagents for HLA-Cw*17? Herrero MJ, et al. **Tissue Antigens** 1998 Jul;52(1):92-5
A single amino acid change makes the peptide specificity of B*3910 unrelated to B*3901 and closer to a group of HLA-B proteins including the malaria-protecting allotype HLA-B53. Yagüe J, et al. **Tissue Antigens** 1998 Nov; 52(5):416-21
HLA-A and -B alleles in cornea donors as risk factors for graft rejection. Creemers PC, et al. **Transpl Immunol** 1999 Mar;7(1):15-8
A retrospective evaluation of HLA-A, B and -DRB1 matching in liver transplantation. Poli F, et al. **Transpl Int** 1998;11 Suppl 1:S347-9
Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):781

METABOLISM

Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Giacomini P, et al. **Cancer Res** 1999 Jun 1;59(11):2657-67
Peptide motif of the class I molecule HLA-B*1503. Prilliman KR, et al. **Immunogenetics** 1999 Feb;49(2):144-6
HLA-B down-regulation in human melanoma is mediated by sequences located downstream of the transcription-initiation site. Griffioen M, et al. **Int J Cancer** 1999 Feb 9;80(4):573-80
HLA-B15 peptide ligands are preferentially anchored at their C termini. Prilliman KR, et al. **J Immunol** 1999 Jun 15; 162(12):7277-84
The South Amerindian allotype HLA-B*3909 has the largest known similarity in peptide specificity and common natural ligands with HLA-B27. Yagüe J, et al. **Tissue Antigens** 1999 Mar;53(3):227-36

HLA-B7 ANTIGEN

GENETICS

The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Allcock RJ, et al. **Immunogenetics** 1999 Jul;49(7-8):660-5
Role of the interferon-stimulated response element in HLA-B downregulation in human melanoma cell lines. Griffioen M, et al. **Immunogenetics** 1999 Apr;49(4):287-94

IMMUNOLOGY

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. Bartlett JA, et al. **AIDS** 1998 Jul 30; 12(11):1291-300
B7 cosignal potentiates apoptosis of uninfected CD4+ T lymphocytic cell lines primed by HIV envelope proteins. Coito C, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10; 15(6):509-21
Recently activated T cells are costimulation-dependent in vitro. Marelli-Berg FM, et al. **Cell Immunol** 1999 Jul 10; 195(1):18-27
The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. McAdam AJ, et al. **Immunol Rev** 1998 Oct;165:231-47 (96 ref.)
Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. Chang KM, et al. **J Immunol** 1999 Jan 15; 162(2):1156-64

METABOLISM

The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Maeda A, et al. **Br J Haematol** 1998 Sep;102(5):1257-62

PHARMACOLOGY

Purified truncated recombinant HLA-B7 molecules abrogate cell function in alloreactive cytotoxic T lymphocytes by apoptosis induction. Hansen B, et al. **Transplantation** 1998 Dec 27;66(12):1818-22

THERAPEUTIC USE

Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Gleich LL, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1097-104

HLA-B8 ANTIGEN

GENETICS

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257-74 (171 ref.)
Myasthenia gravis and tumor necrosis factor beta polymorphisms: linkage disequilibrium but no association beyond HLA-B8. Manz MG, et al. **J Neuroimmunol** 1998 Oct 1;90(2):187-91

IMMUNOLOGY

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Posthuma EF, et al. **Blood** 1999 Jun 1;93(11):3863-5
Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity. Lio D, et al. **Cytokines Cell Mol Ther** 1997 Dec;3(4):217-24

HLA-B8 ANTIGEN

(67 ref.)
Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Misko IS, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2279–84

HLA-B27 ANTIGEN

Arthritis and HLA-B27 in native North American tribes. Walsh B, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):319–25 (46 ref.)
Aerobic fitness and physical activity in patients with HLA-B27 positive juvenile spondyloarthropathy that is inactive or in remission. Hebestreit H, et al. **J Rheumatol** 1998 Aug;25(8):1626–33
The –308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. McGarry F, et al. **J Rheumatol** 1999 May;26(5):1110–6
[25 years HLA B27—report on the "B27 and Beyond" NIH Conference] Braun J, et al. **Z Rheumatol** 1999 Apr; 58(2):104–8 **(Ger)**

ANALYSIS

Is HLA B27 a true marker of axial involvement in psoriatic arthropathy? Mazzanti G, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:71–2
Occurrence of HLA-B27 tissue antigen in patients with purulent arthritis caused by Staphylococcus aureus or beta-haemolytic streptococci. Valtonen JM, et al. **Ann Med** 1998 Aug;30(4):375–8
Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Dodds EM, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):85–92
Whipple's syndrome (uveitis, B27-negative spondylarthropathy, meningitis, and lymphadenopathy) associated with Arthrobacter sp. infection. Bodaghi B, et al. **Ophthalmology** 1998 Oct;105(10):1891–6
HLA B27 and respiratory involvement in axial spondylarthropathies. A retrospective study in 107 male patients. Eulry F, et al. **Rev Rhum Engl Ed** 1998 Oct; 65(10):560–6
HLA-B*27 typing by group-specific hybridization in microtiter plates. Wagner T, et al. **Tissue Antigens** 1998 Aug;52(2):175–8

BIOSYNTHESIS

Correlation of cecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease. Onderdonk AB, et al. **Infect Immun** 1998 Dec;66(12):6022–3

BLOOD

HLA-B27 and the seronegative spondyloarthropathies. Reveille JD. **Am J Med Sci** 1998 Oct;316(4):239–49 (132 ref.)
Drug-induced pancytopenia in a patient with juvenile HLA-B27-associated spondylarthritis: comment on the article by Leipold et al [letter; comment] Schmidt KL. **Arthritis Rheum** 1998 Oct;41(10):1899–900. Comment on: Arthritis Rheum 1997 Oct;40(10):1896–8.
Coexistence of primary biliary cirrhosis and isolated B27-associated peripheral enthesitis [letter; comment] Ballardini P, et al. **Clin Exp Rheumatol** 1998 Sep–Oct; 16(5):624–6. Comment on: Clin Exp Rheumatol 1997 Nov–Dec;15(6):708–9.
Detection of HLA-B27 alleles by group-specific amplification and time-resolved fluorometry. Välimaa L, et al. **J Immunol Methods** 1998 Oct 1;219(1–2):131–7

CHEMISTRY

Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. Allen RL, et al. **J Immunol** 1999 May 1;162(9):5045–8

CLASSIFICATION

[HLA-B27 molecular subtypes and spondylarthropathies (editorial)] Tieng V, et al. **Pathol Biol (Paris)** 1998 Dec; 46(10):737–40 (Eng. Abstr.) **(Fre)**

GENETICS

Arthritis in HLA-B27 transgenic animals. Taurog JD. **Am J Med Sci** 1998 Oct;316(4):250–6 (43 ref.)
The immunogenetics of the seronegative spondyloarthropathies. al-Khoniyz W, et al. **Baillieres Clin Rheumatol** 1998 Nov;12(4):567–88 (136 ref.)
Identifying genes that cause disease: HLA-B27, the paradigm, the promise, the perplexity. Martin TM, et al. **Br J Ophthalmol** 1998 Dec;82(12):1354–5
Optimisation of HLA-B27 testing by association of flow cytometry and DNA typing. Bonnaud G, et al. **Clin Rheumatol** 1999;18(1):23–7
Low frequency of HLA-B27 and scarcity of ankylosing spondylitis in a Zairean Bantu population. Mbayo K, et al. **Clin Rheumatol** 1998;17(4):309–10
Immunogenetics, HLA-B27 and spondyloarthropathies. González S, et al. **Curr Opin Rheumatol** 1999 Jul; 11(4):257–64 (58 ref.)
Functional characterization and exon 2-intron 2-exon 3 gene sequence of HLA-B*2712 as found in a British family. Hemmatpour SK, et al. **Eur J Immunogenet** 1998 Dec; 25(6):395–402
Inflammatory disease in HLA-B27 transgenic rats. Taurog JD, et al. **Immunol Rev** 1999 Jun;169:209–23 (83 ref.)
HLA-B27 subtypes and HLA class II alleles in Japanese patients with anterior uveitis. Konno Y, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1838–44
HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. Brooks JM, et al. **J Immunol** 1998 Nov 15;161(10):5252–9
Differential expression and regulation of a human transgene, HLA-B27, in mouse placental and embryonic cell lines. Hunt JS, et al. **Mol Hum Reprod** 1998 Aug;4(8):817–25
The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy. López-Larrea C, et al. **Mol Med Today** 1998 Dec;4(12):540–9 (49 ref.)
Genes in the spondyloarthropathies. Wordsworth P. **Rheum Dis Clin North Am** 1998 Nov;24(4):845–63 (48 ref.)
Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Armas JB, et al. **Tissue Antigens** 1999 Mar;53(3):237–43
HLA-B*27 subtyping by PCR-RFLP in Spanish patients with ankylosing spondylitis. Fraile A, et al. **Tissue Antigens** 1998 Nov;52(5):492–6
TAP polymorphism is not associated with ankylosing spondylitis and complications with acute anterior uveitis in HLA-B27-positive Japanese. Konno Y, et al. **Tissue Antigens** 1998 Nov;52(5):478–83
Novel polymorphism detected in exon 1 of HLA-B*2713. Seurynck K, et al. **Tissue Antigens** 1998 Aug;52(2):187–9
HLA-B*27 typing by group-specific hybridization in microtiter plates. Wagner T, et al. **Tissue Antigens** 1998 Aug;52(2):175–8

IMMUNOLOGY

Distinct recognition of closely-related HIV-1 and HIV-2 cytotoxic T-cell epitopes presented by HLA-B*2703 and B*2705 [letter] Rowland-Jones S, et al. **AIDS** 1998 Jul 30; 12(11):1391–3
The pathogenesis of HLA-B27 arthritis: role of HLA-B27 in bacterial defense. Ikeda M, et al. **Am J Med Sci** 1998 Oct;316(4):257–63 (38 ref.)
Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies. Sobao Y, et al. **Arthritis Rheum** 1999 Jan;42(1):175–81
Humoral immune response to Klebsiella capsular polysaccharides in HLA-B27-positive patients with acute anterior uveitis and ankylosing spondylitis. Sahly H, et al. **Autoimmunity** 1998;28(4):209–15
Immunogenetics, HLA-B27 and spondyloarthropathies. González S, et al. **Curr Opin Rheumatol** 1999 Jul; 11(4):257–64 (58 ref.)
Spondyloarthropathies [editorial] Khan MA. **Curr Opin Rheumatol** 1999 Jul;11(4):233–4 (5 ref.)
Peptide binding alpha1alpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice. Khare SD, et al. **Hum Immunol** 1999 Feb;60(2):116–26
Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative caucasian patients with ankylosing spondylitis. Yabuki K, et al. **Hum Immunol** 1999 Jan; 60(1):83–6
Invasion by Salmonella typhimurium induces increased expression of the LMP, MECL, and PA28 proteasome genes and changes in the peptide repertoire of HLA-B27. Maksymowych WP, et al. **Infect Immun** 1998 Oct; 66(10):4624–32
Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Rath HC, et al. **Infect Immun** 1999 Jun;67(6):2969–74
Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. Dulphy N, et al. **J Immunol** 1999 Apr 1;162(7):3830–9
High T cell epitope sharing between two HLA-B27 subtypes (B*2705 and B*2709) differentially associated to ankylosing spondylitis. García-Peydró M, et al. **J Immunol** 1999 Aug 15;163(4):2299–305
The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. Paradela A, et al. **J Immunol** 1998 Nov 15;161(10):5481–90
Antibody response to Klebsiella pneumoniae 60 kDa protein in familial and sporadic ankylosing spondylitis: role of HLA-B27 and characterization as a GroEL-like protein. Cancino-Díaz ME, et al. **J Rheumatol** 1998 Sep; 25(9):1756–64
Host-microbe interaction in reactive arthritis: does HLA-B27 have a direct effect? [editorial; comment] Granfors K. **J Rheumatol** 1998 Sep;25(9):1659–61. Comment on: J Rheumatol 1998 Sep;25(9):1765–71.
Animal models of human leukocyte antigen B27-linked arthritides [published erratum appears in Rheum Dis Clin North Am 1998 Feb;25(1):preceding Preface] Khare SD, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):883–94, xi–xii (66 ref.)
Pathogenesis of human leukocyte antigen B27-positive arthritis. Information from clinical materials. Märker-Hermann E, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):865–81, xi (82 ref.)
Ankylosing spondylitis. Clinical features. van der Linden S, et al. **Rheum Dis Clin North Am** 1998 Nov;24(4):663–76, vii (40 ref.)
Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Armas JB, et al. **Tissue Antigens** 1999 Mar;53(3):237–43
Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization. Dela Cruz CS, et al. **Vaccine** 1999 Jun 4;17(20–21):2479–92
[From the HLA-B27 molecule to spondylarthropathy] Toubert A. **Rev Med Interne** 1999;20 Suppl 1:29S–30S **(Fre)**

METABOLISM

Quantitative analysis of HLA-B27 by flow cytometry using CD3 gating in seronegative spondylarthropathies. Lee YH, et al. **Clin Exp Rheumatol** 1999 Mar–Apr;17(2):191–5
The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. Paradela A, et al. **J Immunol** 1998 Nov 15;161(10):5481–90
Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein. Poenaru S, et al. **J Med Chem** 1999 Jul 1; 42(13):2318–31
Binding of rationally designed non-natural peptides to the human leukocyte antigen HLA-B*2705. Krebs S, et al. **J Pept Sci** 1998 Sep;4(6):378–88
Structure-based design of nonnatural ligands for the HLA-B27 protein. Dédier S, et al. **J Recept Signal Transduct Res** 1999 Jan–Jul;19(1–4):645–57
Differential expression and regulation of a human transgene, HLA-B27, in mouse placental and embryonic cell lines. Hunt JS, et al. **Mol Hum Reprod** 1998 Aug;4(8):817–25
Long-range effects in protein—ligand interactions mediate peptide specificity in the human major histocompatibilty antigen HLA-B27 (B*2701). Krebs S, et al. **Protein Sci** 1999 Jul;8(7):1393–9
The South Amerindian allotype HLA-B*3909 has the largest known similarity in peptide specificity and common natural ligands with HLA-B27. Yagüe J, et al. **Tissue Antigens** 1999 Mar;53(3):227–36
Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Schafer JR, et al. **Vaccine** 1998 Nov;16(19):1880–4

PHYSIOLOGY

HLA-B27 and other predisposing factors in spondyloarthropathies. Khare SD, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):282–91 (73 ref.)
Cytotoxic T-cell-mediated response against Yersinia pseudotuberculosis in HLA-B27 transgenic rat. Falgarone G, et al. **Infect Immun** 1999 Aug;67(8):3773–9
HLA-B27 does not affect invasion of arthritogenic bacteria into human cells [see comments] Ortiz-Alvarez O, et al. **J Rheumatol** 1998 Sep;25(9):1765–71. Comment in: J Rheumatol 1998 Sep;25(9):1659–61.
Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Peterson RL, et al. **Lab Invest** 1998 Dec;78(12):1503–12

THERAPEUTIC USE

Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Thurau SR, et al. **Immunol Lett** 1999 Jun 1;68(2–3):205–12

HLA-B35 ANTIGEN

CHEMISTRY

Decamer-like conformation of a nona-peptide bound to HLA-B*3501 due to non-standard positioning of the C terminus. Menssen R, et al. **J Mol Biol** 1999 Jan 15; 285(2):645–53

GENETICS

HLA-B35 frequency variations correlate with malaria infection in Sardinia. Contu L, et al. **Tissue Antigens** 1998 Nov;52(5):452–61
Novel HLA-A and HLA-B alleles in South American Indians. Marcos CY, et al. **Tissue Antigens** 1999 May; 53(5):476–85

IMMUNOLOGY

Accumulation of specific amino acid substitutions in HLA-B35-restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte epitopes. Kawana A, et al. **AIDS Res Hum Retroviruses** 1999 Aug 10;15(12):1099–107
Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Khanna R, et al. **Eur J Immunol** 1999 May;29(5):1587–97
HLA-A and -B alleles in cornea donors as risk factors for graft rejection. Creemers PC, et al. **Transpl Immunol** 1999 Mar;7(1):15–8
Induction of long-term heart graft survival in HLA class I transgenic mice by intrathymic injection of HLA class I peptides. Ando Y, et al. **Transplant Proc** 1998 Nov; 30(7):3890–1

HLA-BR ANTIGENS see HLA-DR ANTIGENS

HLA-BW35 see HLA-B35 ANTIGEN

HLA-C ANTIGENS

ANALYSIS

First trimester human endovascular trophoblast cells express both HLA-C and HLA-G. Pröll J, et al. **Am J Reprod Immunol** 1999 Jul;42(1):30-6

HLA-Cw*0602 and HIV-associated psoriasis. Mallon E, et al. **Br J Dermatol** 1998 Sep;139(3):527-33

BIOSYNTHESIS

Is the expression of classical HLA class I antigens on trophoblast of importance for human pregnancy? Christiansen OB, et al. **Am J Reprod Immunol** 1998 Sep; 40(3):158-64

Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Martayan A, et al. **Br J Cancer** 1999 May; 80(5-6):639-49

Studies on binding of HIV-1 p24gag peptide to HLA-Cw3+ cells. Kość A, et al. **Immunol Lett** 1998 Dec;64(2-3):57-62

BLOOD

HLA-C and HLA-DQB1 compatibility in unrelated cord blood transplants. Elia L, et al. **Haematologica** 1999 Jun; 84(6):530-4

CHEMISTRY

Structure of human histocompatibility leukocyte antigen (HLA)-Cw4, a ligand for the KIR2D natural killer cell inhibitory receptor. Fan QR, et al. **J Exp Med** 1999 Jul 5;190(1):113-23

GENETICS

The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Gonzalez S, et al. **Arthritis Rheum** 1999 May;42(5):1010-6

Nested polymerase chain reaction with sequence-specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-matched individuals. Carter AS, et al. **Blood** 1999 Aug 15;94(4):1471-7

HLA-C locus alleles in patients with psoriatic arthritis (PsA). Gladman DD, et al. **Hum Immunol** 1999 Mar;60(3):259-61

Evidence for an HLA-C-like locus in the orangutan Pongo pygmaeus. Adams EJ, et al. **Immunogenetics** 1999 Sep; 49(10):865-71

HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. Ozawa A, et al. **J Dermatol** 1998 Sep;25(9):573-81

The transmembrane sequence of human histocompatibility leukocyte antigen (HLA)-C as a determinant in inhibition of a subset of natural killer cells. Davis DM, et al. **J Exp Med** 1999 Apr 19;189(8):1265-74

Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. Castelli C, et al. **J Immunol** 1999 Feb 1;162(3):1739-48

DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. Frohn C, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):155-60

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage [see comments] Carrington M, et al. **Science** 1999 Mar 12;283(5408):1748-52. Comment in: Science 1999 Jul 2;285(5424):11.

Correction of HLA-Cw*0501 and identification of HLA-Cw*0711. Baurain JF, et al. **Tissue Antigens** 1999 May;53(5):510-2

A DNA-based detection and screening system for identifying HLA class I expression variants by sequence-specific primers. Bunce M, et al. **Tissue Antigens** 1999 May; 53(5):498-506

Characterization of a novel HLA-Cw*04 variant in a Laotian family: HLA-Cw*0406. Carbonnelle E, et al. **Tissue Antigens** 1999 Jun;53(6):601-3

HLA-Cw alleles associated with HLA extended haplotypes and C2 deficiency. Clavijo OP, et al. **Tissue Antigens** 1998 Sep;52(3):282-5

HLA-A, -B, -C polymorphism in a UK Ashkenazi Jewish potential bone marrow donor population. Cox ST, et al. **Tissue Antigens** 1999 Jan;53(1):41-50

Identification of a new variant, HLA-Cw*1507, differing from Cw*1502 only at the KIR-related dimorphism of codons 77 and 80. Day S, et al. **Tissue Antigens** 1999 May; 53(5):513-5

HLA-C high resolution typing: analysis of exons 2 and 3 by sequence based typing and detection of polymorphisms in exons 1-5 by sequence specific primers. Delfino L, et al. **Tissue Antigens** 1998 Sep;52(3):251-9

Identification of an HLA-C variant allele, Cw*0805, by sequencing based typing. Dunn PP, et al. **Tissue Antigens** 1998 Dec;52(6):587-9

Diversity of HLA-B17 alleles and haplotypes in East Asians and a novel Cw6 allele (Cw*0604) associated with B*5701. Inoue T, et al. **Tissue Antigens** 1999 Jun;53(6):534-44

Role of HLA-B and C alleles in development of psoriasis in patients from North India. Rani R, et al. **Tissue Antigens** 1998 Jun;51(6):618-22

Identification of a novel HLA-C allele, Cw*0406, in a Singapore Malay. Ren EC, et al. **Tissue Antigens** 1999 Feb; 53(2):198-200

A new HLA-Cw*15 allele, Cw*1508, identified in the Peruvian population. Sanz L, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):391-3

Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tonks S, et al. **Tissue Antigens** 1999 Feb;53(2):175-83

A reliable and efficient high resolution typing method for HLA-C using sequence-based typing. van der Vlies SA, et al. **Tissue Antigens** 1998 Dec;52(6):558-68

IMMUNOLOGY

Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Nagler A, et al. **Cytokines Cell Mol Ther** 1998 Sep;4(3):161-7

Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Snyder GA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3864-9

Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Valés-Gómez M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24; 95(24):14326-31

HLA-G and HLA-C at the feto-maternal interface: lessons learned from pathogenic viruses. Schust DJ, et al. **Semin Cancer Biol** 1999 Feb;9(1):37-46 (71 ref.)

On the nature of "HLA-B42" alloantibodies. Specific reagents for HLA-Cw*17? Herrero MJ, et al. **Tissue Antigens** 1998 Jul;52(1):92-5

A human monoclonal antibody against HLA-Cw1 and a human monoclonal antibody against an HLA-A locus determinant derived from a single uniparous female. Mulder A, et al. **Tissue Antigens** 1998 Oct;52(4):393-6

Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus [published erratum appears in Viral Immunol 1999;12(1):89] Nehete PN, et al. **Viral Immunol** 1998;11(3):119-29

METABOLISM

Lack of association between childhood common acute lymphoblastic leukaemia and an HLA-C locus dimorphism influencing the specificity of natural killer cells. Ghodsi K, et al. **Br J Haematol** 1998 Sep;102(5):1279-83

Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors [published erratum appears in Immunity 1998 Dec;9(6):892] Valés-Gómez M, et al. **Immunity** 1998 Sep;9(3):337-44

Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Maenaka K, et al. **Structure** 1999 Apr 15;7(4):391-8

HLA-D ANTIGENS

Human leukocyte antigen-associated susceptibility to pulmonary tuberculosis: molecular analysis of class II alleles by DNA amplification and oligonucleotide hybridization in Mexican patients. Terán-Escandón D, et al. **Chest** 1999 Feb;115(2):428-33

Nomenclature for Factors of the HLA system, update August 1998. WHO Nomenclature Committee for Factors of the HLA System. Marsh SG. **Hum Immunol** 1999 Jan;60(1):87

[Primary immunologic deficiency by deficiency of HLA class II antigens: nine new Tunisian cases] Bejaoui M, et al. **Arch Pediatr** 1998 Oct;5(10):1089-93 (Eng. Abstr.) **(Fre)**

ANALYSIS

HLA-DM is expressed on the cell surface and colocalizes with HLA-DR and invariant chain in human Langerhans cells. Andersson T, et al. **Arch Dermatol Res** 1998 Dec; 290(12):674-80

HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. Catálfamo M, et al. **Int Immunol** 1999 Feb; 11(2):269-77

HLA-DMA and HLA-DMB genotyping in patients with systemic lupus erythematosus. Yen JH, et al. **J Rheumatol** 1999 Sep;26(9):1930-3

BIOSYNTHESIS

Impaired expression of MHC class II molecules in response to interferon-gamma (IFN-gamma) on human thymoma neoplastic epithelial cells. Inoue M, et al. **Clin Exp Immunol** 1999 Jul;117(1):1-7

Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. Dimitriadou V, et al. **J Leukoc Biol** 1998 Dec;64(6):791-9

BLOOD

HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Kakizaki S, et al. **J Hepatol** 1999 May;30(5):794-800

CHEMISTRY

Crystal structure of mouse H2-M. Fremont DH, et al. **Immunity** 1998 Sep;9(3):385-93

The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Mosyak L, et al. **Immunity** 1998 Sep; 9(3):377-83

Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM. Busch R, et al. **J Biol Chem** 1998 Oct 16;273(42):27557-64

Conserved structural features between HLA-DO beta and -DR beta. Thibodeau J, et al. **Mol Immunol** 1998 Sep; 35(13):885-93

Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Rötzschke O, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7445-50

GENETICS

Immunogenetics of insulin-dependent diabetes mellitus. Kida K, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):3-7 (39 ref.)

HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Kwon OJ, et al. **Arch Neurol** 1999 May;56(5):555-60

Successful related umbilical cord blood transplantation for graft failure following T cell-depleted non-identical bone marrow transplantation in a child with major histocompatibility complex class II deficiency. Bonduel M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):437-40

Implication of HLA-DMA alleles in corsican IDDM. Cucchi-Mouillot P, et al. **Dis Markers** 1998 Nov; 14(3):135-41

Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Raddrizzani L, et al. **Eur J Immunol** 1999 Feb; 29(2):660-8

Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2-DMa gene. Russell HI, et al. **Eur J Immunol** 1999 Mar;29(3):905-11

Searching for the needle in the haystack: another candidate needle in autoimmune hepatitis? [editorial; comment] Manns MP, et al. **Gastroenterology** 1999 Sep;117(3):728-32 . Comment on: Gastroenterology 1999 Sep;117(3):645-52.

Impact of the MHC-encoded HLA-DMA, DMB, and LMP2 gene polymorphisms on kidney graft outcome. Chevrier D, et al. **Hum Immunol** 1998 Oct;59(10):650-5

HLA class II immunogenetics of IDDM in Yemenite Jews. Israel S, et al. **Hum Immunol** 1998 Nov;59(11):728-33

HLA DRB1, DMA, and DMB gene polymorphisms in rheumatoid arthritis. Reviron D, et al. **Hum Immunol** 1999 Mar;60(3):245-9

Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. West JE, et al. **Hum Immunol** 1999 Mar;60(3):255-8

Isolation and mapping of the rabbit DM genes. Hermel E, et al. **Immunogenetics** 1999 Apr;49(4):295-302

Mhc class I and non-class I gene organization in the proximal H2-M region of the mouse. Jones EP, et al. **Immunogenetics** 1999 Mar;49(3):183-95

Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA. Quan V, et al. **Immunogenetics** 1999 Oct; 49(11-12):957-63

Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases. Nishimura Y, et al. **Int Rev Immunol** 1998;17(5-6):229-62 (82 ref.)

Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):443-8

New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. Hendel H, et al. **J Immunol** 1999 Jun 1;162(11):6942-6

HLA-DMA and HLA-DMB genotyping in patients with rheumatic diseases. Yen JH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 May; 15(5):263-7

Positive association of the HLA DMB1*0101-0101 genotype with rheumatoid arthritis. Perdriger A, et al. **Rheumatology (Oxford)** 1999 May;38(5):448-52

Limited polymorphism in the HLA-DOA gene. Naruse TK, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):359-65

IMMUNOLOGY

Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification. Murad KL, et al. **Blood** 1999 Sep 15; 94(6):2135-41

Acquired immunoparalysis in paediatric intensive care: prospective observational study. Peters M, et al. **BMJ** 1999 Sep 4;319(7210):609-10

Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Raddrizzani L, et al. **Eur J Immunol** 1999 Feb; 29(2):660-8

Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2-DMa gene. Russell HI, et al. **Eur J Immunol** 1999 Mar;29(3):905-11

Identification of autoantigen epitopes in MHC class II transgenic mice. Sønderstrup G, et al. **Immunol Rev** 1998 Aug;164:129-38 (33 ref.)

HLA-D ANTIGENS

H-2M molecules, like MHC class II molecules, are targeted to parasitophorous vacuoles of Leishmania-infected macrophages and internalized by amastigotes of L. amazonensis and L. mexicana. Antoine JC, et al. **J Cell Sci** 1999 Aug;112 (Pt 15):2559-70

Analysis of HLA association in susceptibility to infection with Cryptococcus neoformans var. gattii in a Papua New Guinean population. Van Dam MG, et al. **Med Mycol** 1998 Jun;36(3):185-8

Positive association of the HLA DMB1*0101-0101 genotype with rheumatoid arthritis. Perdriger A, et al. **Rheumatology (Oxford)** 1999 May;38(5):448-52

ISOLATION & PURIFICATION

HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Wu Z, et al. **Clin Exp Immunol** 1999 Apr; 116(1):62-9

Cellular distribution of a mixed MHC class II heterodimer between DRalpha and a chimeric DObeta chain. Samaan A, et al. **Int Immunol** 1999 Jan;11(1):99-111

METABOLISM

Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. Wubbolts R, et al. **J Cell Sci** 1999 Mar;112 (Pt 6):785-95

Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases. Lem L, et al. **J Immunol** 1999 Jan 1;162(1):523-32

Unexpected reactivities of T cells selected by a single MHC-peptide ligand. Singh N, et al. **J Immunol** 1999 Oct 1;163(7):3583-91

HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Serradell L, et al. **Tissue Antigens** 1999 May;53(5):447-58

PHYSIOLOGY

HLA-DM - an endosomal and lysosomal chaperone for the immune system. Vogt AB, et al. **Trends Biochem Sci** 1999 Apr;24(4):150-4 (48 ref.)

HLA-D-RELATED ANTIGENS see **HLA-DR ANTIGENS**

HLA-DC ANTIGENS see **HLA-DQ ANTIGENS**

HLA DNA PROBES see **DNA PROBES, HLA**

HLA-DP ANTIGENS

Generation of HLA-DP transgenic pigs for the study of xenotransplantation. Tu CF, et al. **Int Surg** 1999 Apr-Jun; 84(2):176-82

[DPB 1 *0501-associated opticomyelitis and atopic myelitis: novel disease entities] Kira J. **Rinsho Shinkeigaku** 1999 Jan; 39(1):19-20 (4 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets. Gaschet J, et al. **Bone Marrow Transplant** 1998 Aug;22(4):385-92

Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011 [letter] Müller N, et al. **Schizophr Res** 1998 Jun 22;32(1):69-71

HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. Ito H, et al. **Tissue Antigens** 1998 Aug;52(2):179-82

CHEMISTRY

Immunosuppressory mini-regions of HLA-DP and HLA-DR. Szewczuk Z, et al. **Mol Immunol** 1999 Jun; 36(8):525-33

CLASSIFICATION

Nomenclature for factors of the HLA system, update August 1998. WHO Nomenclature Committee for Factors of the HLA system. Marsh SG. **Tissue Antigens** 1998 Dec; 52(6):590-1

GENETICS

Analysis of MHC encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis. Foley PJ, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):1009-14

Influence of HLA-DPB1 mismatches on MLR responses: the role of high resolution HLA class II typing and MLC in unrelated donor selection for BMT. Pénzes M, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S34-7

HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Yamasaki K, et al. **Brain** 1999 Sep;122 (Pt 9):1689-96

Occurrence rates of HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo. Buc M, et al. **Eur J Dermatol** 1998 Jan-Feb;8(1):13-5

HLA-DPB1 alleles in house dust mite allergic patients. O'Brien RM, et al. **Eur J Immunogenet** 1999 Aug; 26(4):281-4

A study of HLA-DPB1 phenotypes reveals DPB1*6301 in a rural population from Cameroon. Poulton KV, et al. **Eur J Immunogenet** 1998 Oct;25(5):375-7

A novel strategy for unambiguous DPB1 typing. Varney MD, et al. **Eur J Immunogenet** 1998 Oct;25(5):371-4

HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Potolicchio I, et al. **Eur J Immunol** 1999 Jul;29(7):2140-7

Application of RSCA for the typing of HLA-DPB1. Ramon DS, et al. **Hum Immunol** 1998 Nov;59(11):734-47

Associations of MHC class II alleles with insulin-dependent diabetes mellitus (IDDM) in patients from North India. Rani R, et al. **Hum Immunol** 1999 Jun;60(6):524-31

Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Varney MD, et al. **Hum Immunol** 1999 Jun;60(6):532-8

Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. Wang Z, et al. **J Immunol** 1999 Aug 1; 163(3):1647-53

Response to hepatitis B vaccine: multiple HLA genes are involved. Desombere I, et al. **Tissue Antigens** 1998 Jun; 51(6):593-604

HLA-DR-DQ alleles and HLA-DP alleles are independently associated with susceptibility to different stages of post-schistosomal hepatic fibrosis in the Chinese population. Hirayama K, et al. **Tissue Antigens** 1999 Mar; 53(3):269-74

HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. Ito H, et al. **Tissue Antigens** 1998 Aug;52(2):179-82

HLA DPA1/DPB1 genotype and haplotype frequencies, and linkage disequilibria in Nigeria, Liberia, and Gabon. May J, et al. **Tissue Antigens** 1998 Sep;52(3):199-207

DPB1*7601, a novel DPB1 variant in the Caucasoid population. Rozemuller EH, et al. **Tissue Antigens** 1998 Jun;51(6):663-5

Three new DP alleles identified in sub-Saharan Africa: DPB1*7401, DPA1*02013, and DPA1*0302. Steiner LL, et al. **Tissue Antigens** 1998 Jun;51(6):653-7

Four new DP alleles identified in a study of 500 unrelated bone marrow donor-recipient pairs. Steiner LL, et al. **Tissue Antigens** 1999 Feb;53(2):201-6

Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. Voorter C, et al. **Tissue Antigens** 1998 Aug;52(2):190-2

Identification of a new DPB1 allele (DPB1*7901) by sequence-based typing. Voorter C, et al. **Tissue Antigens** 1998 Aug;52(2):193-5

Expression of HLA-DP antigen on peripheral blood mononuclear cells of HLA-DP transgenic pigs. Tu CF, et al. **Transplant Proc** 1998 Nov;30(7):3502-3

IMMUNOLOGY

Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. van de Corput L, et al. **Blood** 1999 Jan 1;93(1):251-9

Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation. Ibisch C, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1153-9

HLA-DPbeta residue 69 plays a crucial role in allorecognition. Díaz G, et al. **Tissue Antigens** 1998 Jul; 52(1):27-36

Effect of HLA-A and -DPB1 matching in corneal transplantation. Morita N, et al. **Transplant Proc** 1998 Nov; 30(7):3491-2

METABOLISM

HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Potolicchio I, et al. **Eur J Immunol** 1999 Jul;29(7):2140-7

PHYSIOLOGY

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. Taylor GM, et al. **Br J Cancer** 1999 Jul;80(9):1405-11

HLA-DQ ANTIGENS

ANALYSIS

Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Bittencourt PL, et al. **Am J Gastroenterol** 1999 Jul;94(7):1906-13

HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Stokkers PC, et al. **Gut** 1999 Sep; 45(3):395-401

In vitro expansion of T-cell-receptor Valpha2.3(+) CD4(+) T lymphocytes in HLA-DR17(3), DQ2(+) individuals upon stimulation with Mycobacterium tuberculosis. Esin S, et al. **Infect Immun** 1999 Aug;67(8):3800-9

HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy. Vaughan RW, et al. **Tissue Antigens** 1998 Aug;52(2):130-4

[HLA-DQA1 genes involved in genetic susceptibility to rheumatic fever and rheumatic heart disease in southern Hans] Gu J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May; 36(5):308-11 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Differential regulation of HLA-DQ expression by keratinocytes and Langerhans cells in normal and premalignant cervical epithelium. Mota FF, et al. **Tissue Antigens** 1998 Sep;52(3):286-93

BLOOD

HLA-C and HLA-DQB1 compatibility in unrelated cord blood transplants. Elia L, et al. **Haematologica** 1999 Jun; 84(6):530-4

[PCR determination of an association between class II HLA and pemphigus vulgaris] Glorio RR, et al. **Medicina (B Aires)** 1999;59(1):28-32 (Eng. Abstr.) **(Spa)**

CHEMISTRY

The P9 pocket of HLA-DQ2 (non-Aspbeta57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspbeta57 MHC class II molecules. Quarsten H, et al. **Int Immunol** 1998 Aug;10(8):1229-36

GENETICS

HLA-DRB and HLA-DQB loci in the genetic susceptibility to develop glaucoma in Mexicans. Gil-Carrasco F, et al. **Am J Ophthalmol** 1999 Sep;128(3):297-300

No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. de Vries N, et al. **Arthritis Rheum** 1999 Aug;42(8):1621-7

Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Rider LG, et al. **Arthritis Rheum** 1999 Jun;42(6):1285-90

HLA-DQA1, -DQB1 polymorphism distribution in Chinese women with pregnancy induced hypertension in Shanghai area. Mao Y, et al. **Chin Med J (Engl)** 1998 Feb; 111(2):163-5

The HLA-DQ associations with Graves' disease in Chinese children. Wong GW, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):493-5

Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). The Childhood Diabetes in Finland Study Group. Sabbah E, et al. **Clin Exp Immunol** 1999 Apr;116(1):78-83

Relationship between HLA-DQ and -DR genotypes and clinical characteristics in a French population of Type 1 diabetic patients. Zevaco-Mattei C, et al. **Diabet Med** 1999 Mar;16(3):201-6

Transmission of DQ haplotypes to patients with type 1 diabetes. Kawasaki E, et al. **Diabetes** 1998 Dec; 47(12):1971-3

Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Horton V, et al. **Diabetologia** 1999 May;42(5):608-16

Occurrence rates of HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo. Buc M, et al. **Eur J Dermatol** 1998 Jan-Feb;8(1):13-5

HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Amirzargar A, et al. **Eur J Immunogenet** 1998 Aug; 25(4):297-301

Strong association between DQA1/DQB1 genotype and early-onset IDDM in Chinese: the association is with alleles rather than specific residues. Chang YW, et al. **Eur J Immunogenet** 1998 Aug;25(4):273-80

Cis-trans complementation of DQA1-DQB1 genes are modulated by DQ alleles: an immunogenetics analysis of DQ association with the down-regulatory function of CD8 cells in trichosanthin-induced immunosuppression. Chou KY, et al. **Eur J Immunogenet** 1999 Feb;26(1):5-13

Negative association between type 1 diabetes and HLA DQB1*0602-DQA1*0102 is attenuated with age at onset. Swedish Childhood Diabetes Study Group. Graham J, et al. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):117-27

HLA-DQA1 alleles and the presence of Helicobacter pylori antibodies. Karhukorpi J, et al. **Eur J Immunogenet** 1999 Feb;26(1):15-7

Distributions of HLA-DRB1/DQB1 alleles and haplotypes in the north-eastern Thai population: indicative of a distinct Thai population with Chinese admixtures in the central Thais. Romphruk AV, et al. **Eur J Immunogenet** 1999 Apr-Jun;26(2-3):129-33

HLA-DR/DQ interaction in patients with erosive rheumatoid arthritis presenting articular and extraarticular disease manifestations. Seidl C, et al. **Eur J Immunogenet** 1999 Feb;26(1):19-27

Multiple sclerosis: association to HLA DQalpha in a tropical population. Arcos-Burgos M, et al. **Exp Clin Immunogenet** 1999;16(3):131-8

HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Krausa P, et al. **Exp Clin Immunogenet** 1999;16(1):17-25

Genotyping for DQA1 and PM loci in urine using PCR-based amplification: effects of sample volume, storage temperature, preservatives, and aging on DNA extraction and typing. Vu NT, et al. **Forensic Sci Int** 1999 May 31; 102(1):23-34

Association of HLA-DR and -DQ alleles with idiopathic achalasia. Verne GN, et al. **Gastroenterology** 1999 Jul; 117(1):26-31

Different binding of NF-Y transcriptional factor to DQA1 promoter variants. Indovina P, et al. **Hum Immunol** 1998 Dec;59(12):758-67

HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish population. Krokowski M, et al. **Hum Immunol** 1998 Jul;59(7):451-5

Combinations of HLA DR and DQ molecules determine the susceptibility to insulin-dependent diabetes mellitus in Koreans. Park YS, et al. **Hum Immunol** 1998 Dec; 59(12):794-801

Genetic differences in HLA-DQA1* and DQB1* allelic distributions between celiac and control children in Santiago, Chile. Pérez-Bravo F, et al. **Hum Immunol** 1999 Mar;60(3):262-7

Associations of MHC class II alleles with insulin-dependent diabetes mellitus (IDDM) in patients from North India. Rani R, et al. **Hum Immunol** 1999 Jun;60(6):524-31

An endogenous retroviral long terminal repeat at the HLA-DQB1 gene locus confers susceptibility to rheumatoid arthritis. Seidl C, et al. **Hum Immunol** 1999 Jan;60(1):63-8

HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. van der Horst-Bruinsma IE, et al. **Hum Immunol** 1999 Feb;60(2):152-8

Thirteen Mhc-DQA1 alleles from two populations of baboons. Alberts SC. **Immunogenetics** 1999 Aug; 49(9):825-7

An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Zanelli E, et al. **Immunogenetics** 1998 Nov-Dec;48(6):394-401

HLA class II transgenic mice as models of human diseases. Taneja V, et al. **Immunol Rev** 1999 Jun;169:67-79 (101 ref.)

The same HLA-DQ alleles determine either susceptibility or resistance to different coxsackievirus-mediated autoimmune diseases. Luppi P, et al. **J Biol Regul Homeost Agents** 1999 Jan-Mar;13(1):14-26

Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure. Arif S, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1056-60

The presence or absence of a retroviral long terminal repeat influences the genetic risk for type 1 diabetes conferred by human leukocyte antigen DQ haplotypes. Belgian Diabetes Registry. Donner H, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1404-8

Sequence analysis of the diabetes-protective human leukocyte antigen-DQB1*0602 allele in unaffected, islet cell antibody-positive first degree relatives and in rare patients with type 1 diabetes. Pugliese A, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1722-8

DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. Yu L, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):328-35

Short ragweed allergen induces eosinophilic lung disease in HLA-DQ transgenic mice. Chapoval SP, et al. **J Clin Invest** 1999 Jun;103(12):1707-17

Effects of heparin on polymerase chain reaction for blood white cells. Yokota M, et al. **J Clin Lab Anal** 1999; 13(3):133-40

HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. Ozawa A, et al. **J Dermatol** 1998 Sep;25(9):573-81

Polymarker, HLA-DQA1, and D1S80 allele frequency data in Chamorro and Filipino populations from Guam. Budowle B, et al. **J Forensic Sci** 1998 Nov;43(6):1195-8

Gene and genotype frequencies for HLA-DQA1 in Caucasians and Mulattoes in Brazil. Soares-Vieira JA, et al. **J Forensic Sci** 1999 Sep;44(5):1051-2

Preferential transmission of maternal allele . with DQA1*0301-DQB1*0302 haplotype to affected offspring in families with type 1 diabetes. Sasaki T, et al. **J Hum Genet** 1999;44(5):318-22

Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice. Krco CJ, et al. **J Immunol** 1999 Aug 1; 163(3):1661-5

Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. Lombardi ML, et al. **J Immunother** 1998 Nov;21(6):435-9

HLA-DQ alleles and human papillomavirus DNA in adult-onset laryngeal papillomatosis. Aaltonen L, et al. **J Infect Dis** 1999 Mar;179(3):682-5

Association of Chlamydia trachomatis heat-shock protein 60 antibody and HLA class II DQ alleles. Gaur LK, et al. **J Infect Dis** 1999 Jul;180(1):234-7

Celiac disease in relation to immunologic serum markers, trace elements, and HLA-DR and DQ antigens in Swedish children with Down syndrome. Hansson T, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):286-92

Hepatitis B third-generation vaccines: improved response and conventional vacciae non-response--evidence for genetic basis in humans. McDermott AB, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:9-11

Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. Sim H, et al. **J Viral Hepat** 1998 Jul;5(4):249-53

Immunogenetics of episcleritis in leprosy. Joko S, et al. **Jpn J Ophthalmol** 1998 Sep-Oct;42(5):431-6

HLA DQA1 genotyping of Chinese in Taiwan by PCR-RFLP. Lo FS, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Aug; 14(8):458-63

Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Tjernström F, et al. **Lupus** 1999;8(2):103-8

Molecular genetic diversity and evolution at the MHC DQB locus in four species of pinnipeds. Hoelzel AR, et al. **Mol Biol Evol** 1999 May;16(5):611-8

Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes. She JX, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8116-9

HLA DR2 and DQ1 frequency among narcoleptic patients in Hong Kong Chinese. Wing YK, et al. **Psychiatry Clin Neurosci** 1998 Oct;52(5):523-7

Recombinant retrovirus vectors for the expression of MHC class II heterodimers. Shimada H, et al. **Surg Today** 1999; 29(6):533-41

HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Bateman AC, et al. **Tissue Antigens** 1998 Jul;52(1):67-73

Response to hepatitis B vaccine: multiple HLA genes are involved. Desombere I, et al. **Tissue Antigens** 1998 Jun; 51(6):593-604

Intronic sequence motifs of HLA-DQB1 are shared between humans, apes and Old World monkeys, but a retroviral LTR element (DQLTR3) is human specific. Donner H, et al. **Tissue Antigens** 1999 Jun;53(6):551-8

A novel DRB3 allele (DRB3*0208), a new allelic variant of DRB1*1502 (DRB1*15023) and two new DQB1 (DQB1*03012 and DQB1*0614) alleles. Hashemi-Tavoularis S, et al. **Tissue Antigens** 1998 Sep; 52(3):294-9

HLA-DR-DQ alleles and HLA-DP alleles are independently associated with susceptibility to different stages of post-schistosomal hepatic fibrosis in the Chinese population. Hirayama K, et al. **Tissue Antigens** 1999 Mar; 53(3):269-74

Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Langö-Warensjö A, et al. **Tissue Antigens** 1998 Oct;52(4):374-80

Microsatellite single nucleotide polymorphisms in the HLA-DQ region. Lin L, et al. **Tissue Antigens** 1998 Jul; 52(1):9-18

Identification of a novel DQB1 allele DBQ1*0616. Luo M, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):381-2

Identification of a novel HLA-DQA1 allele (DQA1*0106) by sequence-based DQA1 typing. Luo M, et al. **Tissue Antigens** 1999 Jun;53(6):595-6

High-resolution sequence typing of HLA-DQA1 and -DQB1 exon 2 DNA with taxonomy-based sequence analysis (TBSA) allele assignment. Luo M, et al. **Tissue Antigens** 1999 Jul;54(1):69-82

Distribution of insulin-dependent diabetes mellitus (IDDM)-related HLA alleles correlates with the difference in IDDM incidence in four populations of the Eastern Baltic region. Nejentsev S, et al. **Tissue Antigens** 1998 Nov; 52(5):473-7

Associations between HLA class II alleles in a North Indian population. Rani R, et al. **Tissue Antigens** 1998 Jul; 52(1):37-43

HLA-DRB1*0403 is associated with dominant protection against IDDM in the general Dutch population and subjects with high-risk DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype. Roep BO, et al. **Tissue Antigens** 1999 Jul; 54(1):88-90

HLA-DR, DQ nucleotide sequence polymorphisms in the Pasiegos (Pas valleys, Northern Spain) and comparison of the allelic and haplotypic frequencies with those of other European populations. Sánchez-Velasco P, et al. **Tissue Antigens** 1999 Jan;53(1):65-73

HLA-DR and -DQ gene polymorphism in Latvian patients with insulin-dependent diabetes mellitus. Shtauvere A, et al. **Tissue Antigens** 1998 Oct;52(4):385-8

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Spurkland A, et al. **Tissue Antigens** 1999 May;53(5):459-69

Molecular analysis and polymorphism of the DLA-DQB genes. Wagner JL, et al. **Tissue Antigens** 1998 Sep; 52(3):242-50

Nucleotide sequencing reveals a novel DQB1-06 allele (DQB1*06013) with a silent mutation at codon 137. White JM, et al. **Tissue Antigens** 1998 Aug;52(2):196-8

Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory. Matsuki N, et al. **Vaccine** 1999 Mar 5;17(9-10):1161-8

[A study of correlation between essential hypertension and HLA-DQA1 alleles] Sun N, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1998 Oct 10;15(5):288-90 (Eng. Abstr.) **(Chi)**

[Clinical characteristics and main diagnostic points of latent autoimmune diabetes mellitus in adults] Pan X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Mar;36(3):159-64 (Eng. Abstr.) **(Chi)**

[DNA typing for HLA-DR and HLA-DQ alleles in Chinese patients with rheumatoid arthritis] Yuan G, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):234-7 (Eng. Abstr.) **(Chi)**

[Sequence of HLA-DQA1 promoter region in the Han people] Qiu C, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Oct; 19(5):347-52 (Eng. Abstr.) **(Chi)**

[Polymorphism of HLA-DQA1,-DQB1 genes in Uygur and Kazak ethnic groups and comprehensive analysis of 25 related populations] Zhang XN, et al. **I Chuan Hsueh Pao** 1998;25(3):193-8 (Eng. Abstr.) **(Chi)**

[HLA-markers and diabetic retinopathy in the Senegalese population] Cisse A, et al. **Dakar Med** 1998;43(1):29-33 (Eng. Abstr.) **(Fre)**

[HLA-DR:DQ genotypes and insulin-dependent diabetes in Senegal] Cisse A, et al. **Dakar Med** 1996;41(2):75-8 (Eng. Abstr.) **(Fre)**

[Polymorphism of HLA-DQA1 and DQB1 genes in the Moscow population and in patients with diabetes mellitus types 1 and 2] Demurov LM, et al. **Mol Biol (Mosk)** 1998 Nov-Dec;32(6):964-9 **(Rus)**

[Identification of HLA DQA1 alleles by hybridization with oligonucleotide microchips] Shik VV, et al. **Mol Biol (Mosk)** 1998 Sep-Oct;32(5):813-22 **(Rus)**

[Frequency of loci of HLA-DRB1* and -DQB1* alleles in the Slovak population] Fazekašová H, et al. **Bratisl Lek Listy** 1998 Nov;99(11):601-4 (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

Autoimmune hemolytic anemia and HLA-DQ6 [letter] Nomura S, et al. **Autoimmunity** 1998;28(1):57-8

Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. van de Corput L, et al. **Blood** 1999 Jan 1;93(1):251-9

Generation of humanized mice susceptible to peptide-induced inflammatory heart disease. Bachmaier K, et al. **Circulation** 1999 Apr 13;99(14):1885-91

Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Kowalski ML, et al. **Clin Exp Allergy** 1998 Sep;28(9):1153-8

Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Liu J, et al. **Diabetes** 1999 Mar;48(3):469-77

The interrelationship between hepatitis C virus and HLA [comment] Donaldson PT. **Eur J Clin Invest** 1999 Apr; 29(4):280-3. Comment on: Eur J Clin Invest 1999 Apr;29(4):337-43.

NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice. Abraham RS, et al. **Hum Immunol** 1999 Jul;60(7):583-90

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Alric L, et al. **Hum Immunol** 1999 Jun;60(6):516-23

An HLA-DRB1*0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice. Das P, et al. **Hum Immunol** 1999 Jul;60(7):575-82

HLA-DR and -DQ associations with melioidosis. Dharakul T, et al. **Hum Immunol** 1998 Sep;59(9):580-6

Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Kwok WW, et al. **Hum Immunol** 1999 Jul; 60(7):619-26

MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Reichstetter S, et al. **Hum Immunol** 1999 Jul;60(7):608-18

Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Boyton RJ, et al. **Int Immunol** 1998 Dec;10(12):1765-76

Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Taneja V, et al. **Int Immunol** 1998 Oct;10(10):1449-57

HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization: a model for human relapsing polychondritis. Bradley DS, et al. **J Immunol** 1998 Nov 1;161(9):5046-53

Structural aspects of the interaction between heterogeneic human papillomavirus type 1 E4-specific T cell receptors and the same peptide/HLA-DQ8 complex. Steele JC, et al. **J Immunol** 1998 Nov 1;161(9):4745-52

Structural basis for HLA-DQ binding by the streptococcal superantigen SSA. Sundberg E, et al. **Nat Struct Biol** 1999 Feb;6(2):123-9

A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11. Pearson CI, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):197-202

Identification of a novel HLA-DQA1 allele (DQA1*0106) by sequence-based DQA1 typing. Luo M, et al. **Tissue Antigens** 1999 Jun;53(6):595-6

HLA restriction patterns of gliadin- and astrovirus-specific CD4+ T cells isolated in parallel from the small intestine of celiac disease patients. Molberg O, et al. **Tissue Antigens** 1998 Nov;52(5):407-15

Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory. Matsuki N, et al. **Vaccine** 1999 Mar

HLA-DQ ANTIGENS

5;17(9-10):1161-8

ISOLATION & PURIFICATION

Jejuna of patients with insulin-dependent diabetes mellitus (IDDM) show signs of immune activation. Savilahti E, et al. **Clin Exp Immunol** 1999 Apr;116(1):70-7

METABOLISM

A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation? Biagi F, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):945-50

Increased HLA-DQ2-affinity of a synthetic gliadin peptide by acid-induced deamidation of glutamine residues. Terreaux C, et al. **Bioorg Med Chem Lett** 1998 Aug 4; 8(15):2039-44

Naturally processed peptides from HLA-DQ7 (alpha1*0501-beta1*0301): influence of both alpha and beta chain polymorphism in the HLA-DQ peptide binding specificity. Khalil-Daher I, et al. **Eur J Immunol** 1998 Nov; 28(11):3840-9

HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. Quarsten H, et al. **Eur J Immunol** 1999 Aug;29(8):2506-14

Different binding of NF-Y transcriptional factor to DQA1 promoter variants. Indovina P, et al. **Hum Immunol** 1998 Dec;59(12):758-67

The P9 pocket of HLA-DQ2 (non-Aspbeta57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspbeta57 MHC class II molecules. Quarsten H, et al. **Int Immunol** 1998 Aug;10(8):1229-36

Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. Ettinger RA, et al. **J Immunol** 1998 Dec 1; 161(11):6439-45

Impaired binding of a DQ2 and DQ8-binding HSV VP16 peptide to a DQA1*0501/DQB1*0302 trans class II heterodimer. Reichstetter S, et al. **Tissue Antigens** 1999 Jan; 53(1):101-5

PHYSIOLOGY

Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T cell receptor in mouse hybridoma cells. Vollmer J, et al. **J Invest Dermatol** 1999 Aug;113(2):175-81

Different role of human HLA-DR and -DQ molecules in xenogeneic transplantation using transgenic mice. Sireci G, et al. **Transplantation** 1999 Jul 27;68(2):317-9

HLA-DR ANTIGENS

Lack of association between HLA DRB1* alleles and RS3PE syndrome [letter] Toussirot E, et al. **Ann Rheum Dis** 1998 Jul;57(7):442

Association of HLA shared epitope with joint damage progression in rheumatoid arthritis. Valenzuela A, et al. **Hum Immunol** 1999 Mar;60(3):250-4

A "case control" study on the rôle of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PCR.SSO). Bonfil JJ, et al. **J Clin Periodontol** 1999 Feb;26(2):77-84

Repeat donor HLA-DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA-DR alloantibodies? Fuller A, et al. **Transplantation** 1999 Aug 27;68(4):589-91

ANALYSIS

Differential epidermal expression of the invariant chain in allergic and irritant contact dermatitis. Emilson A, et al. **Acta Derm Venereol** 1998 Nov;78(6):402-7

Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Bittencourt PL, et al. **Am J Gastroenterol** 1999 Jul;94(7):1906-13

Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease. Oberhuber G, et al. **Am J Surg Pathol** 1999 Aug;23(8):970-6

Influence of non-inherited maternal HLA-DR antigens on susceptibility to rheumatoid arthritis. van der Horst-Bruinsma IE, et al. **Ann Rheum Dis** 1998 Nov; 57(11):672-5

Comparison of serological and molecular (PCR-SSP) techniques of HLA-DR typing in clinical laboratory routine. Woszczek G, et al. **Ann Transplant** 1997;2(1):39-42

HLA-DR expression is a significant prognostic factor in laryngeal cancer. A morphometric study. Sikorska B, et al. **APMIS** 1999 Apr;107(4):383-8

HLA-DM is expressed on the cell surface and colocalizes with HLA-DR and invariant chain in human Langerhans cells. Andersson T, et al. **Arch Dermatol Res** 1998 Dec; 290(12):674-80

Immunohistochemical localizations of class II antigens and nerve fibers in human carious teeth: HLA-DR immunoreactivity in Schwann cells. Yoshiba N, et al. **Arch Histol Cytol** 1998 Oct;61(4):343-52

BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Delforge M, et al. **Blood** 1999 Jan 1;93(1):284-92

Oral lichen planus and HLA DR. Ognjenović M, et al. **Coll Antropol** 1998 Dec;22 Suppl:97-101

CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. Rea IM, et al. **Exp Gerontol** 1999 Jan;34(1):79-93

HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Stokkers PC, et al. **Gut** 1999 Sep; 45(3):395-401

Phenotypic changes in neutrophils after rhG-CSF administration in non-Hodgkin's lymphoma patients undergoing PBSC transplantation or conventional chemotherapy [letter] Carulli G, et al. **Haematologica** 1999 Mar;84(3):281-3

Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Balazs C, et al. **Horm Metab Res** 1998 Aug;30(8):496-9

In vitro expansion of T-cell-receptor Valpha2.3(+) CD4(+) T lymphocytes in HLA-DR17(3), DQ2(+) individuals upon stimulation with Mycobacterium tuberculosis. Esin S, et al. **Infect Immun** 1999 Aug;67(8):3800-9

Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules. Van Overtvelt L, et al. **Infect Immun** 1999 Aug;67(8):4033-40

HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. Catálfamo M, et al. **Int Immunol** 1999 Feb; 11(2):269-77

Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Mutti L, et al. **Int J Cancer** 1998 Dec 9;78(6):740-9

A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. McDonnell GV, et al. **J Neurol Sci** 1999 May 1; 165(1):77-83

Increased HLA-DR and CD44 antigen expression in the gut: evidence of extraarticular immunological activity in rheumatoid arthritis. Abuzakouk M, et al. **J Rheumatol** 1999 Sep;26(9):1869-76

A retrospective study using nail clippings of rheumatoid susceptible alleles of HLA-DRB1 as a prognostic factor in early rheumatoid arthritis. Tanaka N, et al. **J Rheumatol** 1999 Apr;26(4):767-72

HLA-DR antigen expression in squamous epithelial dysplasia and squamous cell carcinoma of the esophagus: an immunohistochemical study. Sumiyoshi K, et al. **Oncol Rep** 1999 Mar-Apr;6(2):301-6

HLA characterization in adult asymptomatic cyst passers of Entamoeba histolytica/E. dispar. Valdez E, et al. **Parasitol Res** 1999 Oct;85(10):833-6

Relation between weak HLA-DR expression on human breast milk macrophages and cow milk allergy (CMA) in suckling infants. Järvinen KM, et al. **Pediatr Res** 1999 Jan; 45(1):76-81

TGF-beta 1 inhibits HLA-DR and beta 2-microglobulin expression in HeLa cells induced with r-IFN. Li Y, et al. **Transplant Proc** 1999 Aug;31(5):2143-5

HLA-DR matched transfusions: development of donor-specific T- and B-cell antibodies and renal allograft outcome. Christiaans MH, et al. **Transplantation** 1999 Apr 15;67(7):1029-35

[Modification of T-cell activation marker expression by peripheral blood lymphocytes of persons living in radiation polluted territories] Baeva EV, et al. **Radiats Biol Radioecol** 1998 Nov-Dec;38(6):893-9 (Eng. Abstr.) **(Rus)**

[The HLA-DR phenotype in Croatian children with gluten enteropathy] Jurčić Z, et al. **Lijec Vjesn** 1998 Sep; 120(9):273-7 (Eng. Abstr.) **(Scr)**

BIOSYNTHESIS

Modulation of HLA-DR antigen and ICAM-1 molecule expression on airway epithelial cells by sodium nedocromil. Sacco O, et al. **Ann Allergy Asthma Immunol** 1999 Jul; 83(1):49-54

HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ditschkowski M, et al. **Ann Surg** 1999 Feb;229(2):246-54

T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC). O'Keeffe J, et al. **Clin Exp Immunol** 1999 Aug;117(2):269-76

Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Layton AM, et al. **Exp Dermatol** 1998 Aug;7(4):191-7

Differential surface expression of HLA-DRB1 and HLA-DRB4 among peripheral blood cells of DR4 positive individuals. Czerwony G, et al. **Hum Immunol** 1999 Jan; 60(1):1-9

Modulation of major histocompatibility complex protein expression by human gamma interferon mediated by cysteine proteinase-adhesin polyproteins of Porphyromonas gingivalis. Yun PL, et al. **Infect Immun** 1999 Jun;67(6):2986-95

Expression of epithelial markers in nocturnal asthma. Kraft M, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):376-81

Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas [see comments] Fullen DR, et al. **J Cutan Pathol** 1998 Nov;25(10):553-8. Comment in: J Cutan Pathol 1999 May;26(5):263-4.

Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. Zheng Z, et al. **J Exp Clin Cancer Res** 1998 Sep;17(3):251-8

Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. Hmama Z, et al. **J Immunol** 1998 Nov 1; 161(9):4882-93

Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. Le Roy E, et al. **J Virol** 1999 Aug;73(8):6582-9

Modification of HLA expression on peripheral lymphocytes and monocytes during aging. Le Morvan C, et al. **Mech Ageing Dev** 1998 Nov 16;105(3):209-20

The effect of interleukin-10 and transforming growth factor beta-1 on HLA-DR expression in colonic epithelial cells. Zimmerman MJ, et al. **Mediators Inflamm** 1998;7(1):7-11

Outer membrane vesicles of Porphyromonas gingivalis inhibit IFN-gamma-mediated MHC class II expression by human vascular endothelial cells. Srisatjaluk R, et al. **Microb Pathog** 1999 Aug;27(2):81-91

Conjunctival epithelium expression of HLA-DR in dry eye patients. Tsubota K, et al. **Ophthalmologica** 1999; 213(1):16-9

Inhibition of HLA-DR expression on activated human blood eosinophils by transforming growth factor-beta1. Luttmann W, et al. **Scand J Immunol** 1998 Dec;48(6):667-71

Contribution of the expression of ICAM-1, HLA-DR and IL-2R to the diagnosis of acute rejection in renal allograft aspirative cytology. Ribeiro-David DS, et al. **Transpl Int** 1998;11 Suppl 1:S19-25

[Immunohistochemical study of HLA-DR expression in superficial epithelium and in lamina propria of colonic mucosa in children with Crohn's disease and nonspecific ulcerative colitis] Rodrigues M, et al. **Arq Gastroenterol** 1998 Apr-Jun;35(2):143-51 (Eng. Abstr.) **(Por)**

BLOOD

HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ditschkowski M, et al. **Ann Surg** 1999 Feb;229(2):246-54

Can HLA-DR explain the varying frequency of synovitis in polymyalgia rheumatica? Comment on the article by Salvarani et al [letter; comment] González-Gay MA, et al. **Arthritis Rheum** 1999 Jul;42(7):1561-2. Comment on: Arthritis Rheum 1998 Jul;41(7):1221-6.

Association between reduced human leukocyte antigen (HLA)-DR expression on blood monocytes and increased plasma level of interleukin-10 in patients with severe burns. Sachse C, et al. **Clin Chem Lab Med** 1999 Mar;37(3):193-8

Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Forsblom CM, et al. **Diabetologia** 1998 Nov;41(11):1253-62

Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients. Ferrarini AM, et al. **Mult Scler** 1998 Jun; 4(3):174-7

The influence of a partially HLA-matched blood transfusion on the disease activity of rheumatoid arthritis. van der Horst-Bruinsma IE, et al. **Rheumatology (Oxford)** 1999 Jan; 38(1):53-8

Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Flohé S, et al. **Shock** 1999 Jul;12(1):17-24

Effects of laparoscopic and conventional (open) cholecystectomy on human leukocyte antigen-DR expression in peripheral blood monocytes: correlations with immunologic status. Carlei F, et al. **World J Surg** 1999 Jan;23(1):18-22

[PCR determination of an association between class II HLA and pemphigus vulgaris] Glorio RR, et al. **Medicina (B Aires)** 1999;59(1):28-32 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Definition of the alpha 2 region of HLA-DR molecules involved in CD4 binding. Gaubin M, et al. **Hum Immunol** 1999 Apr;60(4):273-81

Immunosuppressory mini-regions of HLA-DP and HLA-DR. Szewczuk Z, et al. **Mol Immunol** 1999 Jun; 36(8):525-33

Conserved structural features between HLA-DO beta and -DR beta. Thibodeau J, et al. **Mol Immunol** 1998 Sep; 35(13):885-93

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices [see comments] Sturniolo T, et al. **Nat Biotechnol** 1999 Jun;17(6):555-61. Comment in: Nat Biotechnol 1999 Jun;17(6):533-4.

The role of beta-pleated sheet DRB1 differences in acute rejection after cadaveric renal transplant. Adorno D, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):730-3

CLASSIFICATION

Nomenclature for factors of the HLA system, update May/June 1998. Marsh SG. **Eur J Immunogenet** 1998 Oct; 25(5):381

A new categorization of HLA DR alleles on a functional

basis. Ou D, et al. **Hum Immunol** 1998 Oct;59(10):665–76
Nomenclature for factors of the HLA system, update August 1998. WHO Nomenclature Committee for Factors of the HLA system. Marsh SG. **Tissue Antigens** 1998 Dec; 52(6):590–1

DRUG EFFECTS

The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Sebok B, et al. **Eur J Dermatol** 1998 Jan–Feb; 8(1):29–32
Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. Chen W, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):322–7

GENETICS

Improvement of sensitivity in HLA-DRB1 typing by semi-nested PCR-RFLP. Inoue S, et al. **Acta Med Okayama** 1998 Dec;52(6):289–96
Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study. Sotgiu S, et al. **Acta Neurol Scand** 1998 Nov;98(5):314–7
Tracing the origin of HLA-DRB1 alleles by microsatellite polymorphism. Bergström TF, et al. **Am J Hum Genet** 1999 Jun;64(6):1709–18
HLA-DRB and HLA-DQB loci in the genetic susceptibility to develop glaucoma in Mexicans. Gil-Carrasco F, et al. **Am J Ophthalmol** 1999 Sep;128(3):297–300
Schizophrenia and the HLA-DRB1 gene in the Japanese population. Sasaki T, et al. **Am J Psychiatry** 1999 May; 156(5):771–3
Hepatitis C virus and autoimmune manifestations [editorial] Indiveri F. **Ann Ital Med Int** 1998 Oct–Dec;13(4):191–3
Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia [letter] Vandenbroeck K, et al. **Ann Neurol** 1998 Nov;44(5):841–2
Genotyping for disease associated HLA DR beta 1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation. Crilly A, et al. **Ann Rheum Dis** 1999 Feb;58(2):114–7
HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Salvarani C, et al. **Ann Rheum Dis** 1999 May;58(5):303–8
HLA-DRB1 alleles associated with susceptibility or resistance to rheumatoid arthritis, articular deformities, and disability in Mexican Americans. del Rincón I, et al. **Arthritis Rheum** 1999 Jul;42(7):1329–38
Cross-restriction of a T cell clone to HLA-DR alleles associated with rheumatoid arthritis: clues to arthritogenic peptide motifs. Hawke S, et al. **Arthritis Rheum** 1999 May; 42(5):1040–50
Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Levesque MC, et al. **Arthritis Rheum** 1999 Mar;42(3):569–73 (32 ref.)
Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Rider LG, et al. **Arthritis Rheum** 1999 Jun;42(6):1285–90
Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Thomson W, et al. **Arthritis Rheum** 1999 Apr;42(4):757–62
Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Hiroi S, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):332–9
A binding protein to the DNase I hypersensitive site II in HLA-DR alpha gene was identified as NF90. Sakamoto S, et al. **Biochemistry** 1999 Mar 16;38(11):3355–61
Analysis of the human HLA-DRA gene upstream region: evidence for a stem-loop array directed by nuclear factors. Mischiati C, et al. **Biochimie** 1999 Mar;81(3):219–28
Nested polymerase chain reaction with sequence-specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism in DR-matched individuals. Carter AS, et al. **Blood** 1999 Aug 15;94(4):1471–7
Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Dorak MT, et al. **Blood** 1999 Jul 15;94(2):694–700
T-cell expansions with conserved T-cell receptor beta chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Grunewald J, et al. **Blood** 1998 Nov 15;92(10):3737–44
DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Prasad VK, et al. **Blood** 1999 Jan 1;93(1):399–409
HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Jee SH, et al. **Br J Dermatol** 1998 Dec; 139(6):978–83
Serum dehydroepiandrosterone sulphate levels in patients with early rheumatoid arthritis: positive association with C-reactive protein, but not with HLA-DR genotype [letter] Giltay EJ, et al. **Br J Rheumatol** 1998 Nov; 37(11):1254–6
Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group. Saruhan-Direskeneli G. **Br J Rheumatol** 1998 Oct;37(10):1126–8
Ovine MHC class II DRB1 alleles associated with resistance or susceptibility to development of bovine leukemia virus-induced ovine lymphoma. Nagaoka Y, et al. **Cancer Res** 1999 Feb 15;59(4):975–81
HLA-DRB1 genes in 5 rheumatic disease multi-case families. Tian X, et al. **Chin Med J (Engl)** 1998 Mar;111(3):208–10
HLA-A, B antigens and their linkage with HLA-DR among blood donors in Taiwan. Tsai SJ, et al. **Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih** 1995 Aug;28(3):157–66
Genetic markers in clinically well defined patients with ulcerative colitis (UC). Bouma G, et al. **Clin Exp Immunol** 1999 Feb;115(2):294–300
HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin antibodies in Japanese patients with systemic lupus erythematosus. Hashimoto H, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):423–7
DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjögren's syndrome genetic susceptibility. Jean S, et al. **Clin Exp Rheumatol** 1998 Nov–Dec;16(6):725–8
Is there an indication for HLA-DR typing for individual patients with rheumatoid arthritis? van Jaarsveld CH, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):483–8 (46 ref.)
Relationship between HLA-DQ and -DR genotypes and clinical characteristics in a French population of Type 1 diabetic patients. Zevaco-Mattei C, et al. **Diabet Med** 1999 Mar;16(3):201–6
Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Horton V, et al. **Diabetologia** 1999 May;42(5):608–16
Lack of association between juvenile myoclonic epilepsy and HLA-DR13. Le Hellard S, et al. **Epilepsia** 1999 Jan; 40(1):117–9
TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Swider C, et al. **Eur Cytokine Netw** 1999 Jun;10(2):143–6
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection [see comments] Lechmann M, et al. **Eur J Clin Invest** 1999 Apr;29(4):337–43. Comment in: Eur J Clin Invest 1999 Apr;29(4):280–3.
Occurrence rates of HLA-DRB1, HLA-DQB1, and HLA-DPB1 alleles in patients suffering from vitiligo. Buc M, et al. **Eur J Dermatol** 1998 Jan–Feb;8(1):13–5
HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Amirzargar A, et al. **Eur J Immunogenet** 1998 Aug; 25(4):297–301
HLA antigens and haplotypes in IgA-deficient Brazilian paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281–5
Heterogeneity of HLA-DR2 haplotypes in Caucasoid Americans, African Americans, Chinese Americans, Native Americans and Xiamen Chinese. Lee A, et al. **Eur J Immunogenet** 1999 Aug;26(4):275–80
Complete cDNA sequence of the HLA-DRB1*09012 allele. Martínez-Quiles N, et al. **Eur J Immunogenet** 1998 Aug; 25(4):307–9
Distributions of HLA-DRB1/DQB1 alleles and haplotypes in the north-eastern Thai population: indicative of a distinct Thai population with Chinese admixtures in the central Thais. Romphruk AV, et al. **Eur J Immunogenet** 1999 Apr–Jun;26(2–3):129–33
HLA-DR/DQ interaction in patients with erosive rheumatoid arthritis presenting articular and extraarticular disease manifestations. Seidl C, et al. **Eur J Immunogenet** 1999 Feb;26(1):19–27
The distribution of HLA-DRB alleles in ulcerative colitis patients in Turkey. Uyar FA, et al. **Eur J Immunogenet** 1998 Aug;25(4):293–6
Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kDa alpha-crystallin antigen of Mycobacterium tuberculosis. Agrewala JN, et al. **Eur J Immunol** 1999 Jun;29(6):1753–61
HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5 and DQB1 polymorphism detected by PCR-SSP in a semi-urban HIV-positive Ugandan population. Krausa P, et al. **Exp Clin Immunogenet** 1999;16(1):17–25
Association of HLA-DR and -DQ alleles with idiopathic achalasia. Verne GN, et al. **Gastroenterology** 1999 Jul; 117(1):26–31
The (gt)n(ga)m containing intron 2 of HLA-DRB alleles binds a zinc-dependent protein and forms non B-DNA structures. Mäueler W, et al. **Gene** 1999 Jan 8;226(1):9–23
High resolution genetic typing of the class II HLA-DRB1 locus using group-specific amplification and SSO-hybridisation in microplates. Allen M, et al. **Hereditas** 1998;129(2):161–7
Combinations of HLA DR and DQ molecules determine the susceptibility to insulin-dependent diabetes mellitus in Koreans. Park YS, et al. **Hum Immunol** 1998 Dec; 59(12):794–801
Associations of MHC class II alleles with insulin-dependent diabetes mellitus (IDDM) in patients from North India. Rani R, et al. **Hum Immunol** 1999 Jun;60(6):524–31
HLA DRB1, DMA, and DMB gene polymorphisms in rheumatoid arthritis. Reviron D, et al. **Hum Immunol** 1999 Mar;60(3):245–9
The DRB1 Val86/Val86 genotype associates with multiple sclerosis in Australian patients. Teutsch SM, et al. **Hum Immunol** 1999 Aug;60(8):715–22
HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. van der Horst-Bruinsma IE, et al. **Hum Immunol** 1999 Feb;60(2):152–8
The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Allcock RJ, et al. **Immunogenetics** 1999 Jul;49(7–8):660–5
HLA-DR53 molecules are associated with susceptibility to celiac disease and selectively bind gliadin-derived peptides. Clot F, et al. **Immunogenetics** 1999 Aug;49(9):800–7
Complete cDNA sequences of the DRB6 gene from humans and chimpanzees: a possible model of a stop codon readingthrough mechanism in primates. Moreno-Pelayo MA, et al. **Immunogenetics** 1999 Sep;49(10):843–50
An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Zanelli E, et al. **Immunogenetics** 1998 Nov–Dec;48(6):394–401
Phylogenetic history of hominoid DRB loci and alleles inferred from intron sequences. Bergström TF, et al. **Immunol Rev** 1999 Feb;167:351–65
Monomorphism and polymorphism at Mhc DRB loci in domestic and wild ruminants. Mikko S, et al. **Immunol Rev** 1999 Feb;167:169–78 (60 ref.)
HLA class II transgenic mice as models of human diseases. Taneja V, et al. **Immunol Rev** 1999 Jun;169:67–79 (101 ref.)
Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Taneja V, et al. **Int Immunol** 1998 Oct;10(10):1449–57
Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. Quiralte J, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):685–9
HLA-DR antigen and HLA-DRB1 genotyping with nonobstructive azoospermia in Japan. Tsujimura A, et al. **J Androl** 1999 Jul–Aug;20(4):545–50
The role of DRB1 amino acid residue differences on donor-specific antibody production and acute rejection after cadaveric renal transplant. Adorno D, et al. **J Biol Regul Homeost Agents** 1999 Jan–Mar;13(1):32–6
HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. Chen QY, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3182–6
DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. Yu L, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):328–35
Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Barrett S, et al. **J Hepatol** 1999 Jun;30(6):979–83
Cutting edge: phorbol ester induction of IFN-gamma receptors leads to enhanced DR alpha gene expression. Sakamoto S, et al. **J Immunol** 1999 Apr 15;162(8):4381–4
The role of protein kinase C signaling in activated DRA transcription. Setterblad N, et al. **J Immunol** 1998 Nov 1; 161(9):4819–24
Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. Lombardi ML, et al. **J Immunother** 1998 Nov;21(6):435–9
High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains. Abdulkadir SA, et al. **J Leukoc Biol** 1998 Nov;64(5):681–91
HLA-DRB1 and tumor necrosis factor gene polymorphisms in Japanese patients with multiple sclerosis. Ma JJ, et al. **J Neuroimmunol** 1998 Dec 1;92(1–2):109–12
A genetic marker associated with non-response to recombinant hepatitis B vaccine by indigenous Australian children [letter] Sullivan JS, et al. **J Paediatr Child Health** 1999 Aug;35(4):412–3
Celiac disease in relation to immunologic serum markers, trace elements, and HLA-DR and DQ antigens in Swedish children with Down syndrome. Hansson T, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):286–92
HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. Meyer JM, et al. **J Rheumatol** 1999 May;26(5):1024–34
Association of (Q)R/KRAA positive HLA-DRB1 alleles with disease progression in early active and severe rheumatoid arthritis. Seidl C, et al. **J Rheumatol** 1999 Apr; 26(4):773–6
Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. McDermott AB, et al. **J Viral Hepat** 1998 Nov;5 Suppl 2:9–11
Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. Sim H, et al. **J Viral Hepat** 1998 Jul;5(4):249–53
Immunogenetics of episcleritis in leprosy. Joko S, et al. **Jpn J Ophthalmol** 1998 Sep–Oct;42(5):431–6
Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Tjernström F, et al. **Lupus** 1999;8(2):103–8
Heat shock proteins, HLA-DR and rheumatoid arthritis [letter; comment] Rich T, et al. **Nat Med** 1998 Nov; 4(11):1210–1. Comment on: Nat Med 1996 Mar;2(3):279–80. Comment on: Nat Med 1996 Mar;2(3):306–10.
Association between HLA-DRB1*15 and Japanese patients

with rheumatoid arthritis complicated by renal involvement. Tokunaga NK, et al. **Nephron** 1999 Feb; 81(2):165–71

Pars planitis: clinical features and class II HLA associations. Raja SC, et al. **Ophthalmology** 1999 Mar;106(3):594–9

HLA DR2 and DQ1 frequency among narcoleptic patients in Hong Kong Chinese. Wing YK, et al. **Psychiatry Clin Neurosci** 1998 Oct;52(5):523–7

The homozygote of HLA-DRB1*0901, not its heterozygote, is associated with rheumatoid arthritis in Japanese. Wakitani S, et al. **Scand J Rheumatol** 1998;27(5):381–2

Evidence supporting an association between the DRB1 gene and schizophrenia in Japanese. Arinami T, et al. **Schizophr Res** 1998 Jul 27;32(2):81–6

A transmission/disequilibrium study of the DRB1*04 gene locus on chromosome 6p21.3 with schizophrenia. Wright P, et al. **Schizophr Res** 1998 Jul 27;32(2):75–80

Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Weyand CM, et al. **Springer Semin Immunopathol** 1998;20(1–2):5–22

Extended tumour necrosis factor/HLA-DR haplotypes and asthma in an Australian population sample. Moffatt MF, et al. **Thorax** 1999 Sep;54(9):757–61

Fluorotyping of HLA-DRB by sequence-specific priming and fluorogenic probing. Albis-Camps M, et al. **Tissue Antigens** 1999 Mar;53(3):301–7

Sequence of HLA-DRB1*0431 allele. Bettens F, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):378–80

The nature of polymorphism of the HLA-DRB intron sequences is lineage specific. Blasczyk R, et al. **Tissue Antigens** 1998 Jul;52(1):19–26

Sequence of DRB1*08031 is incorrect [comment] Buyse IM, et al. **Tissue Antigens** 1998 Jun;51(6):676–7. Comment on: Tissue Antigens 1997 Sep;50(3):291–302.

Identification of novel DRB1*13 (DRB1*1333), DRB1*04 (DRB1*0426) and DRB5* (DRB5*0109) alleles. Buyse IM, et al. **Tissue Antigens** 1998 Jun;51(6):658–62

HLA-DRB1*01 and DRB1*04 alleles in Sardinian rheumatoid arthritis patients. Carcassi C, et al. **Tissue Antigens** 1999 Jan;53(1):97–100

Response to hepatitis B vaccine: multiple HLA genes are involved. Desombere I, et al. **Tissue Antigens** 1998 Jun; 51(6):593–604

A novel DRB3 allele (DRB3*0208), a new allelic variant of DRB1*1502 (DRB1*15023) and two new DQB1 (DQB1*03012 and DQB1*0614) alleles. Hashemi-Tavoularis S, et al. **Tissue Antigens** 1998 Sep; 52(3):294–9

HLA-DR-DQ alleles and HLA-DP alleles are independently associated with susceptibility to different stages of post-schistosomal hepatic fibrosis in the Chinese population. Hirayama K, et al. **Tissue Antigens** 1999 Mar; 53(3):269–74

Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: sequencing based typing of HLA-DRB genes. Kotsch K, et al. **Tissue Antigens** 1999 May;53(5):486–97

Description of a new DRB1*11 allele (DRB1*1132). Loiseau P, et al. **Tissue Antigens** 1998 Oct;52(4):402–4

A novel HLA-DR12 allele (DRB1*1206) found in a Korean B-cell line. Maeng CY, et al. **Tissue Antigens** 1999 May; 53(5):516–8

Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Ono T, et al. **Tissue Antigens** 1998 Dec;52(6):539–42

Identification of a novel DRB1-allele (DRB1*0106) by sequence-based typing. Palou E, et al. **Tissue Antigens** 1999 Mar;53(3):308–10

HLA-A,-B,-DRB1 allele and haplotype frequencies in 510 Koreans. Park MH, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):386–90

Can HLA-DRB1 typing have prognostic value in patients with undifferentiated chronic arthritis? [letter] Pazdur J, et al. **Tissue Antigens** 1998 Jun;51(6):678–80

Associations between HLA class II alleles in a North Indian population. Rani R, et al. **Tissue Antigens** 1998 Jul; 52(1):37–43

Diversity of HLA-DR2 in North Indians: the changed scenario after the discovery of DRB1*1506. Rani R, et al. **Tissue Antigens** 1998 Aug;52(2):147–52

HLA-DRB1*0403 is associated with dominant protection against IDDM in the general Dutch population and subjects with high-risk DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype. Roep BO, et al. **Tissue Antigens** 1999 Jul; 54(1):88–90

Significant association of HLA-B and HLA-DRB1 alleles with cleft lip with or without cleft palate. Sakata Y, et al. **Tissue Antigens** 1999 Feb;53(2):147–52

HLA-DR, DQ nucleotide sequence polymorphisms in the Pasiegos (Pas valleys, Northern Spain) and comparison of the allelic and haplotypic frequencies with those of other European populations. Sánchez-Velasco P, et al. **Tissue Antigens** 1999 Jan;53(1):65–73

HLA-DR and -DQ gene polymorphism in Latvian patients with insulin-dependent diabetes mellitus. Shtauvere A, et al. **Tissue Antigens** 1998 Oct;52(4):385–8

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Spurkland A, et al. **Tissue Antigens** 1999 May;53(5):459–69

The role of beta-pleated sheet DRB1 differences in acute rejection after cadaveric renal transplant. Adorno D, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):730–3

New methods to detect donor-type DNA in HLA-DRB1-matched living-related liver transplant recipients. Kita Y, et al. **Transplant Proc** 1998 Nov; 30(7):3493–5

Interferon gamma-induced expression of HLA-DR and LFA-3 was enhanced by cryopreservation. Lee MC, et al. **Transplant Proc** 1998 Nov;30(7):2964–5

Nitric oxide upregulates HLA-DR in human vascular endothelial cells. Simonson MS, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):737–8

Transfer of porcine MHC DRalpha into IEalpha-deficient murine bone marrow results in reduced IE-restricted Vbeta usage. Emery DW, et al. **Transplantation** 1998 Oct 27; 66(8):1081–8

The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Fuller TC, et al. **Transplantation** 1999 Jul 27;68(2):173–82

Molecular analysis of HLA-DR gene expression induced by IFN-gamma in malignant melanoma cell lines. Lee JL, et al. **Yonsei Med J** 1999 Feb;40(1):30–9

Lack of association between HLA-DRB1 alleles of the major histocompatibility complex and p-ANCA status or clinical characteristics in patients with ulcerative colitis. Folwaczny C, et al. **Z Gastroenterol** 1999 Feb;37(2):133–40

[Study on the relationship between primary Sjögren syndrome and HLA-DRbeta gene] Wang J, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun;36(6):398–401 (Eng. Abstr.) **(Chi)**

[HLA-DRB1 alleles genotyping in patients with rheumatoid arthritis in Chinese] Zhao Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):112–5 (Eng. Abstr.) **(Chi)**

[Analysis of HLA-DRB1 allele in patients with chronic bronchitis] Peng Z, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):346–8 (Eng. Abstr.) **(Chi)**

[HLA-markers and diabetic retinopathy in the Senegalese population] Cisse A, et al. **Dakar Med** 1998;43(1):29–33 (Eng. Abstr.) **(Fre)**

[Insulin-dependent diabetes in Senegal: HLA-DR combinations according to age of onset and sex] Cisse A, et al. **Dakar Med** 1998;43(1):54–6 (Eng. Abstr.) **(Fre)**

[HLA-DR:DQ genotypes and insulin-dependent diabetes in Senegal] Cisse A, et al. **Dakar Med** 1996;41(2):75–8 (Eng. Abstr.) **(Fre)**

[HLA class II typing: determination of the allelic subtypes of HLA-DR*13 and DRB1*11 using PCR-SSP] Dieye A, et al. **Dakar Med** 1996;41(1):31–5 (Eng. Abstr.) **(Fre)**

[Identification of HLA-DR alleles for susceptibility to rheumatoid polyarthritis in Senegal] Dieye A, et al. **Dakar Med** 1997;42(2):111–3 (Eng. Abstr.) **(Fre)**

[Susceptibility to neuro-malaria and HLA-DR alleles in Senegal] Ndiaye M, et al. **Dakar Med** 1998;43(1):25–8 (Eng. Abstr.) **(Fre)**

[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis] Bourcier T, et al. **J Fr Ophtalmol** 1998 Mar;21(3):209–13 (Eng. Abstr.) **(Fre)**

[Simple and rapid detection of HLA-DRB polymorphism from forensic samples] Kimura T, et al. **Nippon Hoigaku Zasshi** 1998 Aug;52(4):238–44 (Eng. Abstr.) **(Jpn)**

[Polymorphism of the HLA-DRB1 04 gene in inhabitants of Tuva] Sartakova ML, et al. **Genetika** 1998 Jul; 34(7):973–8 (Eng. Abstr.) **(Rus)**

[Comparative analysis of Ayrshire and Black Pied cattle breeds by histocompatibility markers] Udina IG, et al. **Genetika** 1998 Dec;34(12):1668–74 (Eng. Abstr.) **(Rus)**

[Frequency of loci of HLA-DRB1* and -DQB1* alleles in the Slovak population] Fazekašová H, et al. **Bratisl Lek Listy** 1998 Nov;99(11):601–4 (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

MHC class II and negative regulators of hematopoiesis. Deeg HJ, et al. **Arch Immunol Ther Exp (Warsz)** 1998; 46(5):285–91 (46 ref.)

Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Mu H, et al. **Arthritis Rheum** 1999 Mar;42(3):438–42

Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Thomson W, et al. **Arthritis Rheum** 1999 Apr;42(4):757–62

Isolation and identification of apoptosis inducing nucleosides from CD57(+)HLA-DRbright natural suppressor cell line. Mori T, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):416–22

Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blair A, et al. **Blood** 1998 Dec 1;92(11):4325–35

Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Dorak MT, et al. **Blood** 1999 Jul 15;94(2):694–700

CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Yasukawa M, et al. **Blood** 1998 Nov 1;92(9):3355–61

Triggering HLA-DR molecules on human peripheral monocytes induces their death. Thibeault A, et al. **Cell Immunol** 1999 Feb 25;192(1):79–85

Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Kowalski ML, et al. **Clin Exp Allergy** 1998 Sep;28(9):1153–8

Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185–199 in the endosomal compartment. Demotz S, et al. **Clin Exp Immunol** 1998 Nov;114(2):228–35

Knee and/or hip joint destruction in rheumatoid arthritis is associated with HLA-DRB1*0405 in Japanese patients. Wakitani S, et al. **Clin Rheumatol** 1998;17(6):485–8

Class I peptides involved in the indirect pathway of allorecognition. Takemoto SK. **Clin Transpl** 1997;:317–35

The interrelationship between hepatitis C virus and HLA [comment] Donaldson PT. **Eur J Clin Invest** 1999 Apr; 29(4):280–3. Comment on: Eur J Clin Invest 1999 Apr;29(4):337–43.

Recognition of HLA-DR1/DRB1*0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-5 A1. Löffler D, et al. **Eur J Immunogenet** 1998 Oct;25(5):339–47

T cell reactivity to DR*0401- and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes. Lohmann T, et al. **Exp Clin Endocrinol Diabetes** 1999; 107(3):166–71

Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Alric L, et al. **Hum Immunol** 1999 Jun;60(6):516–23

Multiple epitopes of HLA-DRB1*0411 are recognized by T-cell clones originated from individuals carrying other DR4 subtypes. Araujo HA, et al. **Hum Immunol** 1998 Sep; 59(9):561–70

An HLA-DRB1*0402 derived peptide (HV3 65–79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice. Das P, et al. **Hum Immunol** 1999 Jul;60(7):575–82

HLA-DR and -DQ associations with melioidosis. Dharakul T, et al. **Hum Immunol** 1998 Sep;59(9):580–6

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Fujii S, et al. **Hum Immunol** 1998 Oct;59(10):607–14

A new categorization of HLA DR alleles on a functional basis. Ou D, et al. **Hum Immunol** 1998 Oct;59(10):665–76

The DRB1 Val86/Val86 genotype associates with multiple sclerosis in Australian patients. Teutsch SM, et al. **Hum Immunol** 1999 Aug;60(8):715–22

Biased T-cell receptor usage is associated with allelic variation in the MHC class II peptide binding groove. Yassine-Diab B, et al. **Immunogenetics** 1999 Jun; 49(6):532–40

Down modulation of MHC surface molecules on B cells by suppressive immune complexes obtained from chronic intestinal schistosomiasis patients. Rezende SA, et al. **Immunol Lett** 1998 Jun;62(2):67–73

The optimization of helper T lymphocyte (HTL) function in vaccine development. Alexander J, et al. **Immunol Res** 1998;18(2):79–92 (145 ref.)

Identification of Streptococcus mutans PAc peptide motif binding with human MHC class II molecules (DRB1*0802, *1101, *1401 and *1405). Senpuku H, et al. **Immunology** 1998 Nov;95(3):322–30

Relationship between the expression of HLA-DR antigen and the effectiveness of preoperative hyperthermo-chemo-radiotherapy in oesophageal cancer. Kuwano H, et al. **Int J Hyperthermia** 1998 Sep-Oct; 14(5):435–44

HLA-DRB1 motifs and heat shock proteins in rheumatoid arthritis. Auger I, et al. **Int Rev Immunol** 1998; 17(5–6):263–71 (23 ref.)

The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Hingorani M, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):392–9

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes [see comments] Chaux P, et al. **J Exp Med** 1999 Mar 1;189(5):767–78. Comment in: J Exp Med 1999 Mar 1;189(5):753–6.

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11 [see comments] Manici S, et al. **J Exp Med** 1999 Mar 1;189(5):871–6. Comment in: J Exp Med 1999 Mar 1;189(5):753–6.

Sodium dodecyl sulfate-resistant HLA-DR "superdimer" bands are in some cases class II heterodimers bound to antibody. Hitzel C, et al. **J Immunol** 1999 Apr 15; 162(8):4671–6

Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. Nagvekar N, et al. **J Immunol** 1999 Apr 1;162(7):4079–87

EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. van Sechel AC, et al. **J Immunol** 1999 Jan 1;162(1):129–35

Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Falcioni F, et al. **Nat Biotechnol** 1999 Jun;17(6):562–7

Evaluation of HLA-DR expression and T-lymphocyte

infiltration in osteosarcoma. Trieb K, et al. **Pathol Res Pract** 1998;194(10):679–84

Analysis of the T-cell receptors utilized for allogeneic HLA-DR recognition: comparison of different responder-cell donors possessing an identical HLA-DR allele. Obata F, et al. **Scand J Immunol** 1998 Oct; 48(4):364–70

HLA restriction patterns of gliadin- and astrovirus-specific CD4+ T cells isolated in parallel from the small intestine of celiac disease patients. Molberg O, et al. **Tissue Antigens** 1998 Nov;52(5):407–15

Beneficial and detrimental human leucocyte antigen (HLA)-DR mismatches are not reflected by a differential effect of immunosuppressive drugs on the in vitro alloimmune response. van Beelen E, et al. **Transpl Immunol** 1999 Mar;7(1):59–63

A retrospective evaluation of HLA-A, B and -DRB1 matching in liver transplantation. Poli F, et al. **Transpl Int** 1998;11 Suppl 1:S347–9

Experience with the Wujciak-Opelz allocation system in a single center: an increase in HLA-DR mismatching and in early occurring acute rejection episodes [see comments] Vereerstraeten P, et al. **Transpl Int** 1998;11(5):378–81. Comment in: Transpl Int 1999;12(1):74.

Indirect allorecognition of donor HLA-DR peptides in chronic rejection of heart allografts. Suciu-Foca N, et al. **Transplant Proc** 1998 Dec;30(8):3999–4000

Allocation of cadaver kidneys according to HLA-DR matching alone would result in optimal graft outcome in most recipients. Vereerstraeten P, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):739–41

Point mutation of a rubella virus E1 protein T-cell epitope by substitution of single amino acid reversed the restrictive HLA-DR polymorphism: a possible mechanism maintaining HLA polymorphism. Ou D, et al. **Viral Immunol** 1998;11(2):93–102

[Antigenicity of fresh, cryopreserved, or liquid-medium-preserved human parathyroid adenomas] Martin L, et al. **Pathol Biol (Paris)** 1998 May;46(5):315–8 (Eng. Abstr.) **(Fre)**

[The influence of laparoscopic cholecystectomy vs laparotomy on the monocyte antigen expression (HLA-DR)] Schietroma M, et al. **Ann Ital Chir** 1998 Sep-Oct;69(5):619–23; discussion 623–6 (Eng. Abstr.) **(Ita)**

[Interferon therapy in chronic hepatitis C and cellular immunity] Nikitin IG, et al. **Klin Med (Mosk)** 1999; 77(6):33–7 **(Rus)**

[Immunologic correctors in combined treatment of paratonsillitis] Aref'eva NA, et al. **Vestn Otorinolaringol** 1999;(2):42–5 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Cellular distribution of a mixed MHC class II heterodimer between DRalpha and a chimeric DObeta chain. Samaan A, et al. **Int Immunol** 1999 Jan;11(1):99–111

METABOLISM

Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Overmyer M, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):383–92

Monocyte human leukocyte antigen-DR expression correlates with intrapulmonary shunting after major trauma. Giannoudis PV, et al. **Am J Surg** 1999 Jun; 177(6):454–9

Lack of correlation between HLA-DR and CD25 "activation" related antigens on CD16+ NK cells in HIV infection. Lucia MB, et al. **Eur J Histochem** 1997;41 Suppl 2:31–2

Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory ocular surface disorders. Brignole F, et al. **Exp Eye Res** 1998 Dec;67(6):687–97

The (gt)n(ga)m containing intron 2 of HLA-DRB alleles binds a zinc-dependent protein and forms non B-DNA structures. Mäueler W, et al. **Gene** 1999 Jan 8;226(1):9–23

Definition of the alpha 2 region of HLA-DR molecules involved in CD4 binding. Gaubin M, et al. **Hum Immunol** 1999 Apr;60(4):273–81

Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, et al. **Hum Immunol** 1998 Dec;59(12):783–93

Human collagen II peptide 256–271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Diab BY, et al. **Immunogenetics** 1999 Jan;49(1):36–44

Amidolytic and peptidolytic activities of immunoglobulin G present in sera from patients with rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus. Matsuura K, et al. **Immunology** 1998 Sep;95(1):26–30

Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Moldenhauer G, et al. **Immunology** 1999 Mar;96(3):473–84

Binding of random copolymers of three amino acids to class II MHC molecules. Fridkis-Hareli M, et al. **Int Immunol** 1999 May;11(5):635–41

Monitoring of immunotherapy by measuring monocyte HLA-DR expression and stimulated TNFalpha production during sepsis after liver transplantation [letter] Denzel C, et al. **Intensive Care Med** 1998 Dec;24(12):1343–4

Interferon-gamma induces apoptosis and expression of inflammation-related proteins in Chang conjunctival cells. De Saint Jean M, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2199–212

Regulation of human leukocyte antigen expression in human conjunctival epithelium. Tsubota K, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):28–34

Direct transport of newly synthesized HLA-DR from the trans-Golgi network to major histocompatibility complex class II containing compartments (MIICS) demonstrated using a novel tyrosine-sulfated chimera. Davidson HW. **J Biol Chem** 1999 Sep 17;274(38):27315–22

Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts. Huby RD, et al. **J Biol Chem** 1999 Aug 6;274(32):22591–6

Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. Fridkis-Hareli M, et al. **J Immunol** 1999 Apr 15; 162(8):4697–704

Sodium dodecyl sulfate-resistant HLA-DR "superdimer" bands are in some cases class II heterodimers bound to antibody. Hitzel C, et al. **J Immunol** 1999 Apr 15; 162(8):4671–6

Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases. Lem L, et al. **J Immunol** 1999 Jan 1;162(1):523–32

Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals. Reijonen H, et al. **J Immunol** 1999 Aug 1;163(3):1674–81

Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. van der Burg SH, et al. **J Immunol** 1999 Jan 1;162(1):152–60

New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries. Jung C, et al. **J Immunol Methods** 1998 Oct 1;219(1-2):139–49

Modulation of ICAM-1, VCAM-1 and HLA-DR by cytokines and steroids on HUVECs and human brain endothelial cells. Dufour A, et al. **J Neurol Sci** 1998 May 7;157(2):117–21

Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium. Diebold Y, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):517–31

Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. Yazawa T, et al. **J Pathol** 1999 Jan;187(2):191–9

Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. Rantala I, et al. **Kidney Int** 1999 Jun;55(6):2274–80

The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Mack WP, et al. **Ophthal Plast Reconstr Surg** 1999 Jul;15(4):260–71

The effect of interferon-gamma and tumor necrosis factor-alpha on the expression of ICAM-1 and HLA-DR molecules on cells of a human germ cell neoplasm and their susceptibility to lysis by lymphokine-activated killer cells. Eisenthal A, et al. **Pathobiology** 1998;66(5):205–8

IL-6 cerebrospinal fluid levels are related to laryngeal IgA and epithelial HLA-DR response in sudden infant death syndrome. Vege A, et al. **Pediatr Res** 1999 Jun;45(6):803–9

Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Fridkis-Hareli M, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12528–31

PHYSIOLOGY

CD40- and HLA-DR-mediated cell death pathways share a lot of similarities but differ in their use of ADP-ribosyltransferase activities. Léveillé C, et al. **Int Immunol** 1999 May;11(5):719–30

HLA-class II-associated control of antigen recognition by T cells in leprosy: a prominent role for the 30/31-kDa antigens. Thole JE, et al. **J Immunol** 1999 Jun 1; 162(11):6912–8

Different role of human HLA-DR and -DQ molecules in xenogeneic transplantation using transgenic mice. Sireci G, et al. **Transplantation** 1999 Jul 27;68(2):317–9

HLA-DR1 ANTIGEN

ANALYSIS

HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Harcombe AA, et al. **Int J Cardiol** 1999 Jan;68(1):31–7

BIOSYNTHESIS

Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Frayser M, et al. **Protein Expr Purif** 1999 Feb;15(1):105–14

CHEMISTRY

A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Zarutskie JA, et al. **Biochemistry** 1999 May 4;38(18):5878–87

Salt bridge residues between I-Ak dimer of dimers alpha-chains modulate antigen presentation. Yadati S, et al. **Immunol Lett** 1999 Mar 15;67(1):47–55

Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. Natarajan SK, et al. **J Immanol** 1999 Mar 15; 162(6):3463–70

Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Frayser M, et al. **Protein Expr Purif** 1999 Feb;15(1):105–14

GENETICS

HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish population. Krokowski M, et al. **Hum Immunol** 1998 Jul;59(7):451–5

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. Wang RF, et al. **J Exp Med** 1999 May 17; 189(10):1659–68

IMMUNOLOGY

The relative abundance of two measles virus fusion protein peptide-DR1 complexes expressed by B cells is independent of the form of the antigen. Demotz S. **Cell Immunol** 1999 May 1;193(2):202–8

Recognition of HLA-DR1/DRB1*0101 molecules presenting HLA-A2 derived peptides by a human recombinant antibody, Fab-5 A1. Löffler D, et al. **Eur J Immunogenet** 1998 Oct;25(5):339–47

Association between HLA-DR1 and -DR3 antigens and unexplained repeated miscarriage. Christiansen OB, et al. **Hum Reprod Update** 1999 May-Jun;5(3):249–55

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells [see comments] Pieper R, et al. **J Exp Med** 1999 Mar 1;189(5):757–66. Comment in: J Exp Med 1999 Mar 1;189(5):753–6.

T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. Hill M, et al. **J Neuroimmunol** 1999 Jun 1; 97(1-2):146–53

Rheumatoid factor and antikeratin antibody are independent from presence of DR4 or DR1 in rheumatoid arthritis. Cantagrel A, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):20–3

METABOLISM

A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Zarutskie JA, et al. **Biochemistry** 1999 May 4;38(18):5878–87

N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, et al. **Eur J Immunol** 1999 Jan;29(1):189–95

Role of the T cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes. Andersen PS, et al. **Immunity** 1999 Apr;10(4):473–83

A site for CD4 binding in the beta 1 domain of the MHC class II protein HLA-DR1. Brogdon J, et al. **J Immunol** 1998 Nov 15;161(10):5472–80

Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. Natarajan SK, et al. **J Immunol** 1999 Mar 15; 162(6):3463–70

Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain. Simonsen A, et al. **J Immunol** 1999 Sep 1; 163(5):2540–8

Molecular docking of superantigens with class II major histocompatibility complex proteins. Olson MA, et al. **J Mol Recognit** 1997 Nov-Dec;10(6):277–89

HLA-DR2 ANTIGEN

ANALYSIS

Two cases of HLA-DR2-negative hypersomnia manifesting sleep-onset rapid eye movement periods in the multiple sleep latency test. Yoshida Y, et al. **Psychiatry Clin Neurosci** 1999 Apr;53(2):295–7

CHEMISTRY

Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. Smith KJ, et al. **J Exp Med** 1998 Oct 19;188(8):1511–20

GENETICS

Chromosome 6p-encoded HLA-DR2 determination discriminates migraine without aura from migraine with aura. Martelletti P, et al. **Hum Immunol** 1999 Jan; 60(1):69–74

Immunogenetic analysis of Buerger's disease in India. Jaini

HLA-DR2 ANTIGEN

R, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S283–5

Polymorphism and distribution of HLA-DR2 alleles and haplotypes in a Greek population. Constantinidou N, et al. **Tissue Antigens** 1998 Aug;52(2):153–7

Diversity of HLA-DR2 in North Indians: the changed scenario after the discovery of DRB1*1506. Rani R, et al. **Tissue Antigens** 1998 Aug;52(2):147–52

IMMUNOLOGY

A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. ten Bosch GJ, et al. **Blood** 1999 Aug 1;94(3):1038–45

Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Wallström E, et al. **Eur J Immunol** 1998 Oct; 28(10):3329–35

HLA-DR3 ANTIGEN

ANALYSIS

HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy. Vaughan RW, et al. **Tissue Antigens** 1998 Aug;52(2):130–4

GENETICS

Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Schenker M, et al. **Diabetologia** 1999 Jun;42(6):671–7

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257–74 (171 ref.)

Evidence for oligogenic inheritance of type 1 diabetes in a large Bedouin Arab family. Verge CF, et al. **J Clin Invest** 1998 Oct 15;102(8):1569–75

IMMUNOLOGY

Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity. Lio D, et al. **Cytokines Cell Mol Ther** 1997 Dec;3(4):217–24 (67 ref.)

Association between HLA-DR1 and -DR3 antigens and unexplained repeated miscarriage. Christiansen OB, et al. **Hum Reprod Update** 1999 May-Jun;5(3):249–55

METABOLISM

HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Serradell L, et al. **Tissue Antigens** 1999 May;53(5):447–58

HLA-DR4 ANTIGEN

A "case control" study on the rôle of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PCR.SSO). Bonfil JJ, et al. **J Clin Periodontol** 1999 Feb;26(2):77–84

ANALYSIS

HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Harcombe AA, et al. **Int J Cardiol** 1999 Jan;68(1):31–7

Hepatitis C virus infection presenting as rheumatoid arthritis. Why not? [letter] Rivera J, et al. **J Rheumatol** 1999 Sep; 26(9):2062–3

BIOSYNTHESIS

Differential surface expression of HLA-DRB1 and HLA-DRB4 among peripheral blood cells of DR4 positive individuals. Czerwony G, et al. **Hum Immunol** 1999 Jan; 60(1):1–9

BLOOD

Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Forsblom CM, et al. **Diabetologia** 1998 Nov;41(11):1253–62

CHEMISTRY

Molecular dynamics simulations of HLA-DR4 (DRB1*0405) complexed with analogue peptide: conformational changes in the putative T-cell receptor binding regions. Toh H, et al. **Protein Eng** 1998 Nov;11(11):1027–32

GENETICS

Shared rheumatoid epitope as a risk factor in determining outcome in rheumatoid arthritis. Hedger SC, et al. **Aust N Z J Med** 1999 Apr;29(2):234–8

HLA genotype and increased risk of skin cancer [letter; comment] Howell WM, et al. **Br J Dermatol** 1998 Dec; 139(6):1111. Comment on: Br J Dermatol 1998 Apr;138(4):627–30.

Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Schenker M, et al. **Diabetologia** 1999 Jun;42(6):671–7

Distant interactions between dimorphisms in HLA-DR4 radically affect recognition of defined peptides by a specific T cell clone. Matsuo H, et al. **Int Immunol** 1999 May; 11(5):835–43

[DNA typing for HLA-DR and HLA-DQ alleles in Chinese patients with rheumatoid arthritis] Yuan G, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):234–7 (Eng. Abstr.) **(Chi)**

[HLA-DRB1 alleles genotyping in patients with rheumatoid arthritis in Chinese] Zhao Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):112–5 (Eng. Abstr.) **(Chi)**

[Study on the association of HLA-DR4 with IDDM susceptibility in a Chinese population] Qiu C, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Feb; 19(1):54–9 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

LMP2 polymorphisms and spondyloarthropathies [letter] Maksymowych W. **Ann Rheum Dis** 1999 Jun;58(6):386–7

T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Cope AP, et al. **Arthritis Rheum** 1999 Jul;42(7):1497–507

Multiple epitopes of HLA-DRB1*0411 are recognized by T-cell clones originated from individuals carrying other DR4 subtypes. Araujo HA, et al. **Hum Immunol** 1998 Sep; 59(9):561–70

MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW, et al. **Int J Mol Med** 1998 Jan; 1(1):157–62

Rheumatoid factor and antikeratin antibody are independent from presence of DR4 or DR1 in rheumatoid arthritis. Cantagrel A, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):20–3

METABOLISM

HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Serradell L, et al. **Tissue Antigens** 1999 May;53(5):447–58

PHYSIOLOGY

HLA-DR4 influences glial activity in Alzheimer's disease hippocampus. Aisen PS, et al. **J Neurol Sci** 1998 Nov 26; 161(1):66–9

HLA-DR7 ANTIGEN

GENETICS

Genetics and specific immune response in allergy to birch pollen and food: evidence of a strong, positive association between atopy and the HLA class II allele HLA-DR7. Sénéchal H, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):395–401

HLA-DW ANTIGENS see **HLA-D ANTIGENS**

HLA-MB ANTIGENS see **HLA-DQ ANTIGENS**

HLA-MT ANTIGENS see **HLA-DR ANTIGENS**

HLA-PL ANTIGENS see **HLA-DP ANTIGENS**

HLA-SB ANTIGENS see **HLA-DP ANTIGENS**

HLA TYPING see **HISTOCOMPATIBILITY TESTING**

HLY FACTORS see **HEMOLYSIN FACTORS**

HMG-COA REDUCTASE INHIBITORS see **HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS**

HMG COA REDUCTASES see **HYDROXYMETHYLGLUTARYL COA REDUCTASES**

HMG PROTEINS see **HIGH MOBILITY GROUP PROTEINS**

HMN DISTAL TYPE I see **CHARCOT-MARIE DISEASE**

HMN PROXIMAL TYPE I see **WERDNIG-HOFFMANN DISEASE**

HMO see **HEALTH MAINTENANCE ORGANIZATIONS**

HMSN see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE I see **CHARCOT-MARIE DISEASE**

HMSN TYPE II see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE III see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE IV see **REFSUM DISEASE**

HMSN TYPE V see **SPASTIC PARAPLEGIA, HEREDITARY**

HMSN TYPE VI see **OPTIC ATROPHY, HEREDITARY**

HMSN TYPE VII see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HN PROTEIN

ANALYSIS

Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. Fujioka H, et al. **J Exp Med** 1998 Oct 5;188(7):1223–9

CHEMISTRY

Anomeric specificity and protein-substrate interactions support the 3D model for the hemagglutinin-neuraminidase from sendai virus. Bellini T, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):401–5

GENETICS

Sequence analysis of F, SH, and HN genes among mumps virus strains in Japan. Kashiwagi Y, et al. **Arch Virol** 1999; 144(3):593–9

Strain-specific differences in the effect of influenza A virus neuraminidase on vector-expressed hemagglutinin. Kaverin NV, et al. **Arch Virol** 1999;144(4):781–6

Functional characterization of bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins expressed by adenovirus recombinants. Mittal SK, et al. **Intervirology** 1998;41(6):253–60

Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidasegene in wild-type strains of mumps virus is the most relevant marker of virulence. Grazia Cusi M, et al. **J Clin Microbiol** 1998 Dec; 36(12):3743–4

Amino acid substitutions in a conserved region in the stalk of the Newcastle disease virus HN glycoprotein spike impair its neuraminidase activity in the globular domain. Wang Z, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):749–53

Effect of inserting paramyxovirus simian virus 5 gene junctions at the HN/L gene junction: analysis of accumulation of mRNAs transcribed from rescued viable viruses. He B, et al. **J Virol** 1999 Aug;73(8):6228–34

Mutational analysis of heptad repeats in the membrane-proximal region of Newcastle disease virus HN protein. Stone-Hulslander J, et al. **J Virol** 1999 May; 73(5):3630–7

Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. Takimoto T, et al. **J Virol** 1998 Dec;72(12):9747–54

New clues to the emergence of flu pandemics [news] Claas EC, et al. **Nat Med** 1998 Oct;4(10):1122–3

Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion. Deng R, et al. **Virology** 1999 Jan 5; 253(1):43–54

Immune responses and protection induced by DNA vaccines encoding bovine parainfluenza virus type 3 glycoproteins. van Drunen Littel-van den Hurk S, et al. **Virology** 1999 Jul 20;260(1):35–46

The attachment protein of Hendra virus has high structural similarity but limited primary sequence homology compared with viruses in the genus Paramyxovirus. Yu M, et al. **Virology** 1998 Nov 25;251(2):227–33

IMMUNOLOGY

Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Schirrmacher V, et al. **Adv Exp Med Biol** 1998;451:251–7 (43 ref.)

Pathotyping isolates of Newcastle disease virus using antipeptide antibodies to pathotype-specific regions of their fusion and hemagglutinin-neuraminidase proteins. Scanlon DB, et al. **Arch Virol** 1999;144(1):55–72

Comparative characteristics of the Israeli Newcastle disease virus field strains by means of a wide panel of monoclonal antibodies against hemagglutinin-neuraminidase glycoprotein. Panshin A, et al. **Comp Immunol Microbiol Infect Dis** 1999 Apr;22(2):103–24

Evaluation of the hemagglutination-inhibition assay using a baculovirus-expressed hemagglutinin-neuraminidase protein for detection of Newcastle disease virus antibodies. Heckert RA, et al. **J Vet Diagn Invest** 1999 Jan;11(1):99–102

Heat inactivation of the neuraminidase and haemagglutinin estimated in the agglutination-separation reactions using red blood cells sensitized with Newcastle disease virus. Graves IL. **Vet Res** 1999 Jul-Aug;30(4):383–92

METABOLISM

Alternative mechanisms of interaction between homotypic and heterotypic parainfluenza virus HN and F proteins.

Tong S, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):107–15
Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. Takimoto T, et al. **J Virol** 1998 Dec;72(12):9747–54
Fusion of sendai virus with liposome depends on only F protein, but not HN protein. Mizuguchi H, et al. **Virus Res** 1999 Feb;59(2):191–201

PHYSIOLOGY

Involvement of the cytoplasmic domain of the hemagglutinin–neuraminidase protein in assembly of the paramyxovirus simian virus 5. Schmitt AP, et al. **J Virol** 1999 Oct;73(10):8703–12

HOARSENESS

CHEMICALLY INDUCED

Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Agertoft L, et al. **Eur Respir J** 1998 Jul;12(1):130–5

CLASSIFICATION

[Objective description of voice quality using the hoarseness diagram] Fröhlich M, et al. **HNO** 1998 Jul;46(7):684–9 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Painless aortic dissection presenting as hoarseness of voice: cardiovocal syndrome: Ortner's syndrome. Khan IA, et al. **Am J Emerg Med** 1999 Jul;17(4):361–3
Hoarseness. Garrett CG, et al. **Med Clin North Am** 1999 Jan; 83(1):115–23, ix

ETIOLOGY

Pharyngolaryngeal morbidity with the intubating laryngeal mask airway [letter; comment] Brimacombe J, et al. **Anaesthesia** 1998 Dec;53(12):1231. Comment on: Anaesthesia 1998 Jul;53(7):645–9.
Hoarse voice and fine-bore nasogastric tubes [letter] Nelson PD, et al. **Anaesthesia** 1999 Apr;54(4):407
Hoarseness after cardiac surgery. Inada T, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):455–9
[The immobile vocal cord] Hulshoff AC, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1897–901 (Eng. Abstr.) **(Dut)**
[Acid esophago-pharyngeal reflux as etiology of hoarseness] Micklefield GH, et al. **Laryngorhinootologie** 1998 Sep; 77(9):496–9 (Eng. Abstr.) **(Ger)**
[Hoarseness. Etiology, diagnosis and therapy] Grevers G. **Med Monatsschr Pharm** 1998 Nov;21(11):330–5 **(Ger)**

PSYCHOLOGY

Does hoarseness of voice from recurrent nerve paralysis after esophagectomy for carcinoma influence patient quality of life? Baba M, et al. **J Am Coll Surg** 1999 Mar;188(3):231–6

SURGERY

Autologous transplantation of fascia into the vocal fold: a new phonosurgical technique for glottal incompetence. Tsunoda K, et al. **Laryngoscope** 1999 Mar;109(3):504–8

THERAPY

Approaches to the patient with hoarseness. Hiott JC. **J S C Med Assoc** 1998 Dec;94(12):546–7

HOBBIES

Maternal occupational and hobby chemical exposures as risk factors for neural tube defects. Shaw GM, et al. **Epidemiology** 1999 Mar;10(2):124–9
A breathless accountant who blew up balloons. Thomeer M, et al. **Lancet** 1999 Jul 10;354(9173):124
Abnormal liver function tests following inadvertent inhalation of volatile hydrocarbons. Pyatt JR, et al. **Postgrad Med J** 1998 Dec;74(878):747–8

STATISTICS & NUMERICAL DATA

Homebuilt aircraft crashes. Hasselquist A, et al. **Aviat Space Environ Med** 1999 Jun;70(6):543–7
Civilian parachute injuries: 10 years on and no lessons learned. Dawson M, et al. **Injury** 1998 Oct;29(8):573–5

HOCK see **HINDLIMB**

HOCKEY

Winning the Stanley Cup Final Series is related to incurring fewer penalties for violent behavior [see comments] McCaw ST, et al. **Tex Med** 1999 Apr;95(4):66–9. Comment in: Tex Med 1999 Apr;95(4):70.
Professional ice hockey and violence in American society [comment] Moore HA. **Tex Med** 1999 Apr;95(4):70. Comment on: Tex Med 1999 Apr;95(4):66–9.

INJURIES

Commotio cordis: sudden cardiac death in athletes. Futterman LG, et al. **Am J Crit Care** 1999 Jul;8(4):270–2
Intercollegiate ice hockey injuries: a causal analysis. Ferrara MS, et al. **Clin J Sport Med** 1999 Jan;9(1):30–3
Delayed splenic rupture in an amateur hockey player. Flik K, et al. **Clin J Sport Med** 1998 Oct;8(4):309–10
Prospective analysis of ice hockey injuries at the Junior A level over the course of one season. Pinto M, et al. **Clin J Sport Med** 1999 Apr;9(2):70–4
How many concussions are too many? Kent H. **CMAJ** 1999 Mar 23;160(6):884
Spinal cord injuries in ice hockey in Finland and Sweden from 1980 to 1996. Mölsä JJ, et al. **Int J Sports Med** 1999 Jan;20(1):64–7
Sudden death of a young hockey player: case report of commotio cordis. Deady B, et al. **J Emerg Med** 1999 May-Jun;17(3):459–62
Unusual fracture of distal third of the clavicle in a hockey player: case report and a new approach to treatment. López JM, et al. **Knee Surg Sports Traumatol Arthrosc** 1999; 7(2):132–4
Comparison of injury patterns in elite hockey players using ice versus in-line skates. Hutchinson MR, et al. **Med Sci Sports Exerc** 1998 Sep;30(9):1371–3
Youth ice hockey tournament injuries: rates and patterns compared to season play. Roberts WO, et al. **Med Sci Sports Exerc** 1999 Jan;31(1):46–51
Self-esteem and injury in competitive field hockey players. Kolt GS, et al. **Percept Mot Skills** 1998 Aug;87(1):353–4
Hockey. Kahn J. **Phys Med Rehabil Clin N Am** 1999 Feb; 10(1):1–17 (36 ref.)

PHYSIOLOGY

Bone mineral density and body composition of the United States Olympic women's field hockey team. Sparling PB, et al. **Br J Sports Med** 1998 Dec;32(4):315–8

PSYCHOLOGY

Trait aggressiveness and hockey penalties: predicting hot tempers on the ice. Bushman BJ, et al. **J Appl Psychol** 1998 Dec;83(6):969–74
Strategic decisions of ice hockey coaches as a function of game location. Dennis PW, et al. **J Sports Sci** 1999 Apr; 17(4):263–8
Explanatory style among elite ice hockey athletes. Davis H 4th, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):1075–80
Cohesion predicts success in junior ice hockey. Salminen S, et al. **Percept Mot Skills** 1998 Oct;87(2):649–50

STATISTICS & NUMERICAL DATA

High prevalence of bronchial hyperresponsiveness and asthma in ice hockey players. Leuppi JD, et al. **Eur Respir J** 1998 Jul;12(1):13–6

HODGKIN DISEASE

see related
REED-STERNBERG CELLS

Hodgkin's disease of the esophagus: report of a case. Loeb DS, et al. **Am J Gastroenterol** 1999 Feb;94(2):520–2
Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. Loge JH, et al. **Ann Oncol** 1999 Jan; 10(1):71–7
An overview of the Fourth International Symposium on Hodgkin's Disease. Recent advances in basic and clinical research. Parsa-Parsi R, et al. **Ann Oncol** 1998;9 Suppl 5:S1–3
Hodgkin's disease following extranodal marginal zone B-cell lymphoma in remission. Shimizu K, et al. **Int J Hematol** 1999 Feb;69(2):96–100 (22 ref.)
The contribution of multiple data sources to a clinical audit of lymphoma in a teaching hospital. Paltiel O, et al. **Int J Qual Health Care** 1998 Aug;10(4):303–9
Hodgkin's disease: classification and differential diagnosis. Harris NL. **Mod Pathol** 1999 Feb;12(2):159–75 (124 ref.)
Hodgkin's lymphomas: classification, diagnosis, and grading [see comments] Harris NL. **Semin Hematol** 1999 Jul; 36(3):220–32 (96 ref.). Comment in: Semin Hematol 1999 Jul;36(3):217–8.
Introduction: Hodgkin's lymphoma--pathology, pathogenesis, and treatment [editorial; comment] Jaffe ES. **Semin Hematol** 1999 Jul;36(3):217–9. Comment on: Semin Hematol 1999 Jul;36(3):220–32.
Hodgkin's disease. Callaghan M. **Semin Oncol Nurs** 1998 Nov;14(4):262–72 (70 ref.)
Acquired immunodeficiency syndrome-related lymphoma. Roth EL. **Semin Oncol Nurs** 1998 Nov;14(4):284–92 (43 ref.)
Lymphomas of the anterior mediastinum. Glick RD, et al. **Semin Pediatr Surg** 1999 May;8(2):69–77 (60 ref.)
[Late complications after treatment of Hodgkin's disease] Lund MB, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):933–7 (Eng. Abstr.) **(Nor)**
[Hodgkin's disease and non-Hodgkin lymphomas] Ojeda Gutiérrez E. **Rev Clin Esp** 1999 Apr;199 Suppl 1:44–51 (40 ref.) **(Spa)**
[Hodgkin's disease. An old disease with a new face (editorial)] Giraldo P, et al. **Sangre (Barc)** 1998 Jun;43(3):171–3 **(Spa)**

BLOOD

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Sarris AH, et al. **Ann Oncol** 1999 Apr; 10(4):433–40
Integration of human herpesvirus 6 genome in human chromosomes [letter; comment] Luppi M, et al. **Lancet** 1998 Nov 21;352(9141):1707–8. Comment on: Lancet 1998 Aug 15;352(9127):543–4.

CHEMICALLY INDUCED

Incidence rates of lymphomas and environmental measurements of phenoxy herbicides: ecological analysis and case-control study. Fontana A, et al. **Arch Environ Health** 1998 Nov-Dec;53(6):384–7

CLASSIFICATION

World Health Organization Classification of lymphomas: a work in progress. Jaffe ES, et al. **Ann Oncol** 1998;9 Suppl 5:S25–30 (31 ref.)
Clinicopathological evaluation of the Revised European-American Classification of Lymphoid Neoplasms (REAL) in Japan. Isobe K, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):143–9
Prognostic factors in advanced Hodgkin's disease--can they guide therapeutic decisions? [editorial; comment] Brice P. **N Engl J Med** 1998 Nov 19;339(21):1547–9. Comment on: N Engl J Med 1998 Nov 19;339(21):1506–14.
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease [see comments] Hasenclever D, et al. **N Engl J Med** 1998 Nov 19;339(21):1506–14. Comment in: N Engl J Med 1998 Nov 19;339(21):1547–9. Comment in: N Engl J Med 1999 Apr 22;340(16):1288–9; discussion 1289–90. Comment in: N Engl J Med 1999 Apr 22;340(16):1289–90.
Prognostic score for Hodgkin's disease [letter; comment] Jack FR, et al. **N Engl J Med** 1999 Apr 22;340(16):1288–9; discussion 1289–90. Comment on: N Engl J Med 1998 Nov 19;339(21):1506–14.
Prognostic score for Hodgkin's disease [letter; comment] Watine J. **N Engl J Med** 1999 Apr 22;340(16):1289–90. Comment on: N Engl J Med 1998 Nov 19;339(21):1506–14.
[Main principles and diagnostic criteria for revision of the european-american classification of lymphoid neoplasms (T-cell lymphomas and Hodgkin's disease] Probatova NA, et al. **Arkh Patol** 1998 Jul-Aug;60(4):61–71 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin's disease. Peltola J, et al. **Acta Neurol Scand** 1998 Nov; 98(5):360–3
Recurrent lymphocytic pleural effusion after intravenous immunoglobulin [letter] Bolanos-Meade J, et al. **Am J Hematol** 1999 Mar;60(3):248–9
Intestinal involvement in Hodgkin's disease causing perforation [letter] Geetha N, et al. **Am J Med** 1999 Aug; 107(2):185–6
Hodgkin's and Castleman's disease in a patient with systemic mastocytosis. Saletti P, et al. **Ann Hematol** 1999 Feb; 78(2):97–100
Rare syndromes in Hodgkin's disease. Cavalli F. **Ann Oncol** 1998;9 Suppl 5:S109–13 (26 ref.)
Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis. Munro R, et al. **Ann Rheum Dis** 1998 Sep;57(9):513–7
Hodgkin's disease presenting with a bronchoesophageal fistula. Kassis ES, et al. **Ann Thorac Surg** 1998 Oct; 66(4):1409–10
Surgical treatment of tracheomediastinal fistula from recurrent Hodgkin's lymphoma. Tse DG, et al. **Ann Thorac Surg** 1999 Mar;67(3):832–4
Malignancy-associated remission of systemic lupus erythematosus maintained by autologous peripheral blood stem cell transplantation. Schachna L, et al. **Arthritis Rheum** 1998 Dec;41(12):2271–2
Polypoid endobronchial Hodgkin's disease with pneumomediastinum. Kim KI, et al. **Br J Radiol** 1999 Apr; 72(856):392–4
Hodgkin's lymphoma in a pregnant patient with acquired immunodeficiency syndrome. Okechukwu CN, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):410–1 (6 ref.)
A case of Listeria murray/grayi bacteremia in a patient with advanced Hodgkin's disease. Todeschini G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):808–10
Dyskeratosis congenita associated with Hodgkin's disease. Baykal C, et al. **Eur J Dermatol** 1998 Sep;8(6):385–7
Nephrotic syndrome as paraneoplastic syndrome of Hodgkin disease [letter] Utsch B, et al. **Eur J Pediatr** 1999 Sep; 158(9):768
Plasmodium falciparum: drug-resistant malaria complicating leukemias and lymphomas in children. Nirmala, et al. **Exp Parasitol** 1999 Sep;93(1):33–7
Sweet's syndrome associated with Hodgkin's disease. Suvajdzić N, et al. **Haematologia (Budap)** 1998;29(2):157–8
Cholestasis secondary to Hodgkin's disease: report of 2 cases of vanishing bile duct syndrome. de Medeiros BC, et al. **Haematologica** 1998 Nov;83(11):1038–40

Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin [letter] Pérez Equiza E, et al. **Haematologica** 1999 Jan; 84(1):93–4

Isolated nasopharyngeal Hodgkin's disease presenting as nasal obstruction. Malis DD, et al. **Int J Clin Pract** 1998 Jul–Aug; 52(5):343–6 (28 ref.)

Hodgkin's disease survivors more fatigued than the general population. Loge JH, et al. **J Clin Oncol** 1999 Jan; 17(1):253–61

Comment on the paper: Batchelor TT, Platten M, Palmer–Toy DE, Hunter GJ, Lev MH, Dalmau J, Hochberg FH: Chorea as a paraneoplastic complication of Hodgkin's disease. Journal of Neuro–Oncology 36: 185–190, 1998 [letter; comment] Heckmann JG, et al. **J Neurooncol** 1999 Jan;41(1):95–6. Comment on: J Neurooncol 1998 Jan;36(2):185–90.

Teaching cases from the Royal Marsden and St Mary's Hospitals case 19: pancytopenia following Hodgkin's disease. Arnold J, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):201–2

Images in clinical medicine. Chylous effusion in Hodgkin's disease. Bishop PC, et al. **N Engl J Med** 1998 Nov 19; 339(21):1515

Extrahepatic Hodgkin's disease with intrahepatic cholestasis: report of two cases. Yalçin S, et al. **Oncology** 1999 Jul; 57(1):83–5

Simultaneous occurrence of Hodgkin's disease, nodal Langerhans' cell histiocytosis and multiple myeloma IgA(kappa). Ibarrola de Andrés C, et al. **Virchows Arch** 1999 Mar;434(3):259–62

[Cutaneous lymphoma manifesting as pigmented, purpuric capillaries] Lipsker D, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):321–6 (Eng. Abstr.) **(Fre)**

[Hodgkin's disease in patients infected with the human immunodeficiency virus] Costello R, et al. **Rev Med Interne** 1998 Aug;19(8):558–64 (69 ref.) (Eng. Abstr.) **(Fre)**

[Clinical case of the month. The association of Hodgkin's disease and nephrotic syndrome] Baron F, et al. **Rev Med Liege** 1998 Nov;53(11):651–3 (Eng. Abstr.) **(Fre)**

[Late treatment related complications of Hodgkin's disease] Henry–Amar M, et al. **Rev Prat** 1998 May 15;48(10):1092–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Hodgkin's disease associated with a Kaposi's sarcoma and tuberculosis of hematopoietic organs] Laatiri MA, et al. **Tunis Med** 1998 Dec;76(12):481–3 **(Fre)**

[A case of surgical treatment for thymic Hodgkin's disease with tracheo–bronchial stenosis] Ichimanda M, et al. **Kyobu Geka** 1999 Aug;52(9):793–5 (Eng. Abstr.) **(Jpn)**

[Association of untreated lymphogranulomatosis and severe myocarditis] Nechaev VM, et al. **Klin Med (Mosk)** 1998; 76(12):61–3 **(Rus)**

[Multiple organ failure in patients with hemoblastosis during long–term follow–up of treatment] Loseva MI, et al. **Ter Arkh** 1999;71(7):39–42 (Eng. Abstr.) **(Rus)**

[Acute hepatic failure and Hodgkin's disease] Tornero C, et al. **An Med Interna** 1998 Dec;15(12):654–5 (Eng. Abstr.) **(Spa)**

[Anorectal Hodgkin disease in an HIV–infected patient (letter)] Márquez–Moreno AJ, et al. **Med Clin (Barc)** 1999 May 1;112(15):598–9 **(Spa)**

DIAGNOSIS

Mediastinal large B–cell lymphoma vs classic Hodgkin lymphoma [editorial; comment] Chadburn A, et al. **Am J Clin Pathol** 1999 Aug;112(2):155–8 (40 ref.). Comment on: Am J Clin Pathol 1999 Aug;112(2):241–7.

Intestinal involvement in Hodgkin's disease causing perforation [letter] Geetha N, et al. **Am J Med** 1999 Aug; 107(2):185–6

Management of abdominal lymphoproliferative diseases in the era of laparoscopy. Silecchia G, et al. **Am J Surg** 1999 Apr;177(4):325–30

Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study. Nguyen PL, et al. **Am J Surg Pathol** 1999 Jan;23(1):27–33

Differential diagnosis between classic Hodgkin's lymphoma, T–cell–rich B–cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Rüdiger T, et al. **Am J Surg Pathol** 1998 Oct;22(10):1184–91 (31 ref.)

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Rüdiger T, et al. **Ann Oncol** 1998; 9 Suppl 5:S31–8 (27 ref.)

Case of the month: not–so–obvious uses of the autopsy. Autopsy Committee of the College of American Pathologists. Collins KA, et al. **Arch Intern Med** 1998 Dec 7–21;158(22):2429–30

Osseous Hodgkin disease. Ostrowski ML, et al. **Cancer** 1999 Mar 1;85(5):1166–78

Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry. Perez–Jaffe LA, et al. **Diagn Cytopathol** 1999 Apr; 20(4):219–23

Hodgkin's lymphoma: an isolated case of involvement of the ureter. Tozzini A, et al. **Eur Radiol** 1999;9(2):344–6

Hodgkin's disease during pregnancy: diagnostic and therapeutic management. Anselmo AP, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):102–5

Utility of CD15, CD30 & CD45 in the immunohistochemical diagnosis of Hodgkin's disease by antigen retrieval method. Arici DS, et al. **Indian J Med Res** 1999 Jan;109:33–7

Case records of the Department of Medicine University of Mississippi Medical Center. Hodgkin's, medullar sclerosis type [clinical conference] Robbins MA, et al. **J Miss State Med Assoc** 1998 Nov;39(11):407–11

Syncytial variant of nodular sclerosing Hodgkin lymphoma. Pai NB, et al. **Lymphology** 1999 Jun;32(2):75–9

75–year–old man with fever, weight loss, and diarrhea. Denktas AE, et al. **Mayo Clin Proc** 1998 Oct;73(10):983–6

Henoch–Schönlein purpura associated with segmental and focal proliferative glomerulonephritis in a patient with Hodgkin's disease. Blanco P, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):179–80

Hodgkin's disease presenting as a parasternal chest wall mass. Stolk MF, et al. **Neth J Med** 1999 Jun;54(6):239–41

Unilateral proptosis in an immunocompetent man as the initial clinical manifestation of systemic Hodgkin disease. Klapper SR, et al. **Ophthalmology** 1999 Feb;106(2):338–41

Laparoscopic evaluation of lymphoma. Johna S, et al. **Semin Surg Oncol** 1998 Oct–Nov;15(3):176–82 (31 ref.)

Role of laparoscopy for Hodgkin's and non–Hodgkin's lymphoma. Walsh RM, et al. **Semin Surg Oncol** 1999 Jun; 16(4):284–92 (34 ref.)

CD30 differential staining is useful in classifying lymphomas intermediate between Hodgkin's disease and anaplastic large cell (Ki1) lymphoma. Schmidt U, et al. **Tumori** 1998 Nov–Dec;84(6):695–700

[Radiology case of the month. Pulmonary hypertrophic osteoarthropathy in the course of Hodgkin's disease] Desnoulez L, et al. **Arch Pediatr** 1998 Nov;5(11):1253–5 **(Fre)**

[Erythema nodosum and cutaneous vasculitis revealing Hodgkin's disease. Apropos of 2 case reports] Blanco P, et al. **Rev Med Interne** 1999 Feb;20(2):160–3 (Eng. Abstr.) **(Fre)**

[Histopathological diagnosis of Hodgkin's disease] Delsol G. **Rev Prat** 1998 May 15;48(10):1060–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[The rare differential diagnosis of a mediastinal space–occupying lesion] Bohle W, et al. **Dtsch Med Wochenschr** 1999 Mar 5;124(9):245–7 (9 ref.) (Eng. Abstr.) **(Ger)**

[Lymphomas presenting as Tietze's syndrome: a report of 4 clinical cases] Cocco R, et al. **Ann Ital Med Int** 1999 Apr–Jun;14(2):118–23 (20 ref.) (Eng. Abstr.) **(Ita)**

[And is research on the prognosis of Hodgkin's still justified?] Gobbi PG. **Recenti Prog Med** 1999 Apr;90(4):189–92 (13 ref.) **(Ita)**

[Difficulties in diagnosis and therapy in a case of brain inflammatory process in patient with Hodgkin's disease] Bilińska M, et al. **Neurol Neurochir Pol** 1998 May–Jun; 32(3):677–87 (Eng. Abstr.) **(Pol)**

[Diagnostic problems in cases of neck tumors] Kubiczkowa J, et al. **Otolaryngol Pol** 1997;51 Suppl 25:16–9 (Eng. Abstr.) **(Pol)**

[Hodgkin's disease in two children of mother treated with nitrogranulogen] Armata J, et al. **Pol Merkuriusz Lek** 1998 May;4(23):273–4 (Eng. Abstr.) **(Pol)**

[Hodgkin's disease in the thyroid gland] Jamski J, et al. **Przegl Lek** 1998;55(5):288–9 (Eng. Abstr.) **(Pol)**

[Young woman with upper right lobe condensation] de Frutos Arribas JF, et al. **Rev Clin Esp** 1998 Dec; 198(12):833–4 **(Spa)**

DRUG THERAPY

Advanced stage and unfavorable Hodgkin's disease in the Chinese–a 20–year experience. Chim CS, et al. **Am J Hematol** 1999 Jul;61(3):159–63

A case of primary refractory Hodgkin's disease treated successfully with paclitaxel [letter] Kallab AM, et al. **Am J Hematol** 1999 Mar;60(3):248

Successful salvage treatment for relapse after autologous stem cell transplantation in a patient with Hodgkin's disease––a case report. Kaiser U, et al. **Ann Hematol** 1999 Jan; 78(1):33–5

Prevalence of co–morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non–Hodgkin's lymphoma, 1993–1996. van Spronsen DJ, et al. **Ann Hematol** 1999 Jul;78(7):315–9

ESHAP is an active regimen for relapsing Hodgkin's disease. Aparicio J, et al. **Ann Oncol** 1999 May;10(5):593–5

Long–term toxicity of the treatment of Hodgkin's disease. Armitage JO. **Ann Oncol** 1998;9 Suppl 5:S133–6 (28 ref.)

New drugs in the treatment of Hodgkin's disease. Borchmann P, et al. **Ann Oncol** 1998;9 Suppl 5:S103–8 (52 ref.)

Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Canellos GP. **Ann Oncol** 1998;9 Suppl 5:S91–6 (61 ref.)

BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Diehl V, et al. **Ann Oncol** 1998;9 Suppl 5:S67–71 (16 ref.)

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G–CSF. Errante D, et al. **Ann Oncol** 1999 Feb;10(2):189–95

The case for and against high–dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission. Goldstone AH. **Ann Oncol** 1998;9 Suppl 5:S83–5 (3 ref.)

Molecular basis of targeted chemotherapy: novel concepts with special reference to the treatment of Hodgkin's disease. Grunicke HH. **Ann Oncol** 1998;9 Suppl 5:S125–8 (29 ref.)

Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Loeffler M, et al. **Ann Oncol** 1998;9 Suppl 5:S73–8 (10 ref.)

Pediatric Hodgkin's disease: treatment in the late 1990s. Schellong G. **Ann Oncol** 1998;9 Suppl 5:S115–9 (28 ref.)

Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives. Wolf J, et al. **Ann Oncol** 1998;9 Suppl 5:S79–82 (11 ref.)

Effect of Epstein–Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Murray PG, et al. **Blood** 1999 Jul 15;94(2):442–7

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Rodriguez J, et al. **Blood** 1999 Jun 1;93(11):3632–6

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Tesch H, et al. **Blood** 1998 Dec 15;92(12):4560–7

High dose therapy for Hodgkin's disease. Bhidayasiri R, et al. **Blood Rev** 1999 Mar;13(1):45–50 (39 ref.)

High–dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN, et al. **Br J Cancer** 1999 Oct;81(3):476–83

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Bonfante V, et al. **Br J Haematol** 1998 Nov;103(2):533–5

Endogenous thrombopoietin serum levels during multicycle chemotherapy. Engel C, et al. **Br J Haematol** 1999 Jun; 105(3):832–8

The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Gerres L, et al. **Cancer** 1998 Nov 15;83(10):2217–22

Uracil mustard revisited. Kennedy BJ, et al. **Cancer** 1999 May 15;85(10):2265–72 (51 ref.)

Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy. Cantin G, et al. **Cancer Chemother Pharmacol** 1999;43(6):503–6

HIV–associated lymphoma: report of three cases. Mwangi JW. **East Afr Med J** 1999 Mar;76(3):176–7

A limited role for VEEP (vincristine, etoposide, epirubicin, prednisolone) chemotherapy in childhood Hodgkin's disease. Shankar AG, et al. **Eur J Cancer** 1998 Dec; 34(13):2058–63

Hodgkin's disease during pregnancy: diagnostic and therapeutic management. Anselmo AP, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):102–5

Life threatening lung toxicity induced by low doses of bleomycin in a patient with Hodgkin's disease [letter] Real E, et al. **Haematologica** 1999 Jul;84(7):667–8

Vinorelbine in the treatment of lymphoma. Rule S, et al. **Hematol Oncol** 1998 Sep;16(3):101–5

Response of colony stimulating factor in cancer chemotherapy induced myelosuppression––a case report. Gupta AK, et al. **Indian J Med Sci** 1998 Apr;52(4):161–2

The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in–field disease control. Mendenhall NP, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):551–61

Feelings of oncology patients about being nursed in protective isolation as a consequence of cancer chemotherapy treatment. Campbell T. **J Adv Nurs** 1999 Aug;30(2):439–47

MOPP versus ABVD and low–dose versus high–dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta–analysis by clinicians [letter; comment] Andrieu JM, et al. **J Clin Oncol** 1999 Feb;17(2):730–4. Comment on: J Clin Oncol 1998 Mar;16(3):818–29.

Lymphocyte–predominant Hodgkin's disease: how little therapy is enough? [editorial; comment] Aster JC. **J Clin Oncol** 1999 Mar;17(3):744–6. Comment on: J Clin Oncol 1999 Mar;17(3):776–83.

BEACOPP, a new dose–escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced–stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Diehl V, et al. **J Clin Oncol** 1998 Dec;16(12):3810–21

The administration of 10 microg/kg granulocyte colony–stimulating factor (G–CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. D'Hondt L, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):105–9

Anti–CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease. Hartmann F, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):385–92

Feasibility of ESHAP + G–CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single–center study of 22 patients. Petit J, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):119–27

DIZE (dexamethasone, idarubicin, and continuous infusion

of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Reiser M, et al. **Leuk Lymphoma** 1998 Oct; 31(3-4):359-66

ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients. Saletti P, et al. **Leuk Lymphoma** 1999 Apr;33(3-4):313-9

Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Tormo M, et al. **Leuk Lymphoma** 1999 Jun; 34(1-2):137-42

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Zinzani PL, et al. **Leuk Lymphoma** 1999 Feb;32(5-6):553-9

Childhood stage IV Hodgkin disease: therapeutic results of the Polish pediatric leukemia/lymphoma study group. Armata J, et al. **Med Pediatr Oncol** 1999 Oct;33(4):382-7

High incidence of treatment failure with vincristine, etoposide, epirubicin, and prednisolone chemotherapy with successful salvage in childhood Hodgkin disease. Ekert H, et al. **Med Pediatr Oncol** 1999 Apr;32(4):255-8

Gonadal function in young patients successfully treated for Hodgkin disease. Papadakis V, et al. **Med Pediatr Oncol** 1999 May;32(5):366-72

Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects. Cutuli B, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1513-8

Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin). Kavan P, et al. **Pediatr Hematol Oncol** 1999 Mar-Apr; 16(2):141-8

MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Osaka M, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6428-33

Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Front D, et al. **Radiology** 1999 Feb;210(2):487-91

[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells] Mayer J, et al. **Cas Lek Cesk** 1998 Oct 5;137(19):590-7 (Eng. Abstr.) **(Cze)**

[The meta-analysis of clinical studies on chemotherapy alone compared to a combination of chemotherapy plus radiotherapy in the treatment of Hodgkin's disease] Baumann M, et al. **Strahlenther Onkol** 1998 Oct; 174(10):544-6 **(Ger)**

[Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991] Slanina J, et al. **Strahlenther Onkol** 1999 Apr;175(4):154-61 (Eng. Abstr.) **(Ger)**

[The management of Hodgkin's disease with chemotherapy or combined modality treatment] Tsushita K, et al. **Gan To Kagaku Ryoho** 1998 Dec;25(14):2202-9 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical effect of idarubicin on malignant lymphoma] Urabe A, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1275-82 (Eng. Abstr.) **(Jpn)**

[A trial for peripheral blood stem cell harvest by combination of G-CSF with ABVD regimen in the management of Hodgkin's disease] Suzuki A, et al. **Rinsho Ketsueki** 1999 Jan;40(1):16-21 (Eng. Abstr.) **(Jpn)**

[Difficulties in diagnosis and therapy in a case of brain inflammatory process in patient with Hodgkin's disease] Bilińska M, et al. **Neurol Neurochir Pol** 1998 May-Jun; 32(3):677-87 (Eng. Abstr.) **(Pol)**

ECONOMICS

[National health insurance refused high dose chemotherapy. "Death sentence" based on financial considerations?] Knauer RH. **Fortschr Med** 1998 Jul 20;116(20-21):48-9 **(Ger)**

ENZYMOLOGY

Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Izban KF, et al. **Am J Pathol** 1999 May;154(5):1439-47

EPIDEMIOLOGY

A comparison of epidemiologic, histologic, and virologic studies on Hodgkin's disease in western Kenya and Nagasaki, Japan. Kusuda M, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):801-7

Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. van Spronsen DJ, et al. **Ann Hematol** 1999 Jul;78(7):315-9

Incidence rates of lymphomas and environmental measurements of phenoxy herbicides: ecological analysis and case-control study. Fontana A, et al. **Arch Environ Health** 1998 Nov-Dec;53(6):384-7

Seasonal variation in the incidence of Hodgkin's disease. Douglas S, et al. **Br J Haematol** 1998 Dec;103(3):653-62

Childbearing and the risk of Hodgkin's disease. Lambe M, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Sep; 7(9):831-4

The rise in incidence of lymphomas in Europe 1985-1992. Cartwright R, et al. **Eur J Cancer** 1999 Apr;35(4):627-33

Incidence and time trends in Hodgkin's disease: from parts of the United Kingdom (1984-1993). Cartwright R, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):367-77

Hodgkin disease in children: clinicoepidemiologic and viral (Epstein-Barr virus) analyses. Cavdar AO, et al. **Med Pediatr Oncol** 1999 Jan;32(1):18-24

Hodgkin's disease in Turkish children: clinical characteristics and treatment results of 210 patients. Büyükpamukçu M, et al. **Pediatr Hematol Oncol** 1999 Mar-Apr;16(2):119-29

[Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center] Arranz R, et al. **Sangre (Barc)** 1998 Jun;43(3):179-84 (25 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. Taylor GM, et al. **Br J Cancer** 1999 Jul;80(9):1405-11

Lymphomatoid papulosis followed by Hodgkin's disease. Silva MM, et al. **Int J Dermatol** 1998 Jul;37(7):541-3

Hodgkin's disease, work, and the environment. A review. McCunney RJ. **J Occup Environ Med** 1999 Jan;41(1):36-46 (80 ref.)

Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Chan WC. **Semin Hematol** 1999 Jul;36(3):242-52 (83 ref.)

Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Jarrett RF, et al. **Semin Hematol** 1999 Jul;36(3):260-9 (102 ref.)

Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Stein H, et al. **Semin Hematol** 1999 Jul;36(3):233-41 (78 ref.)

GENETICS

Apoptosis-related genes and proteins in Hodgkin's disease. Lauritzen AF, et al. **APMIS** 1999 Jul;107(7):636-44

EBNA-1 gene sequences in Brazilian and American patients with Hodgkin's disease. Chang KL, et al. **Blood** 1999 Jul 1;94(1):244-50

Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Jox A, et al. **Blood** 1999 Jun 1;93(11):3964-72

Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Montesinos-Rongen M, et al. **Blood** 1999 Sep 1; 94(5):1755-60

Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Wihlborg C, et al. **Br J Haematol** 1999 Feb;104(2):346-9

Prospective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy. Sawada M, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Aug;7(8):711-7

Chromosome aberrations in adult Hodgkin disease in a Danish population-based study. Pedersen RK, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):128-32

Molecular cloning of a gene on chromosome 19q12 coding for a novel intracellular protein: analysis of expression in human and mouse tissues and in human tumor cells, particularly Reed-Sternberg cells in Hodgkin disease. Van Leuven F, et al. **Genomics** 1998 Dec 15;54(3):511-20

Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Falzetti D, et al. **Haematologica** 1999 Apr;84(4):298-305

High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. Dirnhofer S, et al. **Hum Pathol** 1999 Jul;30(7):781-7

Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells. Hasse U, et al. **J Natl Cancer Inst** 1999 Sep 15;91(18):1581-3

Hodgkin's disease: immunoglobulin heavy and light chain gene rearrangements revealed in single Hodgkin/Reed-Sternberg cells. Deng F, et al. **Mol Pathol** 1999 Feb;52(1):37-41

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Cabannes E, et al. **Oncogene** 1999 May 20;18(20):3063-70

[The factors of hereditary predisposition to lymphogranulomatosis] Zaretskaia IuM, et al. **Ter Arkh** 1998;70(7):53-7 (Eng. Abstr.) **(Rus)**

HISTORY

Thomas Hodgkin remembered. Kass AM. **Cancer Treat Rev** 1999 Jun;25(3):133-43

The management of Hodgkin's disease. Lister A. **Cancer Treat Rev** 1999 Jun;25(3):157-9

A new look at the original cases of Hodgkin's disease. Poston RN. **Cancer Treat Rev** 1999 Jun;25(3):151-5

The BNLI: past and present. British National Lymphoma Investigation. Hudson BV. **Clin Oncol (R Coll Radiol)** 1998; 10(4):212-8

Antiquity of Epstein-Barr virus, Sjögren's syndrome, and Hodgkin's disease--historical concordance and discordance [letter] Altshuler EL. **J Natl Cancer Inst** 1999 Sep 1;91(17):1512-3

IMMUNOLOGY

Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin disease. Izban KF, et al. **Am J Clin Pathol** 1998 Nov;110(5):599-606

Immune escape mechanisms in Hodgkin's disease. Poppema S, et al. **Ann Oncol** 1998;9 Suppl 5:S21-4 (44 ref.)

Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. Kanavaros P, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1209-16

Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Jox A, et al. **Blood** 1999 Jun 1;93(11):3964-72

Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Teruya-Feldstein J, et al. **Blood** 1999 Apr 15;93(8):2463-70

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Klimka A, et al. **Br J Cancer** 1999 Jun;80(8):1214-22

The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Konjević G, et al. **Br J Haematol** 1999 Jan;104(1):144-51

Cytokine deregulation in hematological malignancies: clinical and biological implications. Kurzrock R. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2581-4 (31 ref.)

Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. Kapp U, et al. **J Exp Med** 1999 Jun 21;189(12):1939-46

Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. Kube D, et al. **J Virol** 1999 Feb; 73(2):1630-6

The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours. Luciani MG, et al. **Mol Pathol** 1998 Oct; 51(5):273-6

Hodgkin's disease in a child with hyperimmunoglobulin E syndrome. Lin SJ, et al. **Pediatr Hematol Oncol** 1998 Sep-Oct;15(5):451-4

Immune reactions in classical Hodgkin's lymphoma. Poppema S, et al. **Semin Hematol** 1999 Jul;36(3):253-9 (64 ref.)

CD30: expression and function in health and disease. Horie R, et al. **Semin Immunol** 1998 Dec;10(6):457-70 (124 ref.)

METABOLISM

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. van den Berg A, et al. **Am J Pathol** 1999 Jun;154(6):1685-91

Hodgkin's disease expressing follicular dendritic cell marker CD21 without any other B-cell marker: a clinicopathologic study of nine cases. Nakamura S, et al. **Am J Surg Pathol** 1999 Apr;23(4):363-76

Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Dürkop H, et al. **Blood** 1999 Jan 15;93(2):617-23

Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study. Nuutinen J, et al. **Br J Cancer** 1999 May;80(3-4):513-8

Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Hsu PL, et al. **Cancer Res** 1998 Dec 1;58(23):5507-13

Expression of MPM2, p53 and Bcl2 proteins in Hodgkin's disease. Dzięciol J, et al. **Folia Histochem Cytobiol** 1999; 37(2):147-8

Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Chu WS, et al. **Hum Pathol** 1999 Sep;30(9):1065-70

Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse. Beham-Schmid C, et al. **J Pathol** 1998 Dec; 186(4):383-9

Expression of Fas and Fas ligand in Hodgkin's disease. Metkar SS, et al. **Leuk Lymphoma** 1999 May;33(5-6):521-30

Expression of membrane-associated macrophage colony-stimulating factor (M-CSF) in Hodgkin's disease and other hematologic malignancies. Zheng GG, et al. **Leuk Lymphoma** 1999 Jan;32(3-4):339-44

Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression. Ohshima K, et al. **Pathol Int** 1999 Jun;49(6):506-12

CD95 ligand is expressed in Reed-Sternberg cells of Hodgkin's disease. Sakuma I, et al. **Pathol Int** 1999 Feb; 49(2):103-9

[Molecular biology aspects of Hodgkin's disease] Mačák J. **Vnitr Lek** 1998 Jun;44(6):370-2 (12 ref.) (Eng. Abstr.) **(Cze)**

MORTALITY

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Sarris AH, et al. **Ann Oncol** 1999 Apr; 10(4):433-40

Increased survival in patients diagnosed with Hodgkin's disease in Tasmania, 1972-1992. Strickland AH, et al. **Aust N Z J Med** 1998 Oct;28(5):609-14

Increased mortality after successful treatment for Hodgkin's disease. Hudson MM, et al. **J Clin Oncol** 1998 Nov; 16(11):3592-600

Apoptotic index as a prognostic factor in Hodgkin's disease. Benharroch D, et al. **Leuk Lymphoma** 1999 Apr; 33(3-4):351-9

Outcome in Hodgkin's disease: a 20-year cohort of patients. Ranaghan L, et al. **Ulster Med J** 1998 Nov;67(2):91-8

NURSING

Detecting Hodgkin's disease. Thompson KA. **Am J Nurs** 1999 May;99(5):61-4

Feelings of oncology patients about being nursed in protective isolation as a consequence of cancer chemotherapy treatment. Campbell T. **J Adv Nurs** 1999 Aug;30(2):439-47

PARASITOLOGY

[Hodgkin's disease with concurrent infection of toxoplasmosis] Yu Z, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jan;35(1):33-4 (Eng. Abstr.) **(Chi)**

PATHOLOGY

Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. Chim CS, et al. **Am J Hematol** 1999 Jul;61(3):159-63

Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. Klein R, et al. **Am J Surg Pathol** 1999 Apr;23(4):477-81 (31 ref.)

Composite B-cell and T-cell lymphoma arising 24 years after nodular lymphocyte predominant Hodgkin's disease. Hancock JC, et al. **Ann Diagn Pathol** 1999 Feb;3(1):23-34 (51 ref.)

Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Franklin J, et al. **Ann Oncol** 1998;9 Suppl 5:S39-44 (30 ref.)

The many faces of Hodgkin's disease around the world: what have we learned from its pathology? Harris NL. **Ann Oncol** 1998;9 Suppl 5:S45-56 (112 ref.)

Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Küppers R, et al. **Ann Oncol** 1998;9 Suppl 5:S17-20 (36 ref.)

Protocol for the examination of specimens from patients with Hodgkin's disease: a basis for checklists. Cancer Committee, College of American Pathologists. Compton CC, et al. **Arch Pathol Lab Med** 1999 Jan;123(1):75-80

Specific skin lesions occurring in a patient with Hodgkin's lymphoma. Pagliaro JA, et al. **Australas J Dermatol** 1999 Feb;40(1):41-3

Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Carbone A, et al. **Blood** 1999 Apr 1;93(7):2319-26

Reed-Sternberg cell genome expression supports a B-cell lineage. Cossman J, et al. **Blood** 1999 Jul 15;94(2):411-6

Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Jundt F, et al. **Blood** 1999 Sep 15;94(6):2065-71

Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Kim SH, et al. **Blood** 1998 Dec 1;92(11):4287-95

Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease. Vockerodt M, et al. **Blood** 1998 Oct 15;92(8):2899-907

Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin's disease. Kornacker M, et al. **Br J Haematol** 1999 Aug;106(2):528-31

Hodgkin disease with subsequent transformation to CD30 positive non-hodgkin lymphoma in six patients. Mori N, et al. **Cancer** 1999 Feb 15;85(4):970-9

Hodgkin's disease: biology and origin of Hodgkin and Reed-Sternberg cells. Stein HS, et al. **Cancer Treat Rev** 1999 Jun;25(3):161-8 (45 ref.)

An unusual presentation of fine needle aspiration (FNA) cytology from the syncytial variant of nodular sclerosing Hodgkin's disease. Stephen MR, et al. **Cytopathology** 1998 Aug;9(4):271-6

Involvement of the urogenital tract in patients with five or more separate malignant neoplasms. Case and review. Rohde D, et al. **Eur Urol** 1998 Dec;34(6):512-7 (31 ref.)

Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Peters AM, et al. **Exp Hematol** 1999 May;27(5):868-74

Genetic analysis of sorted Hodgkin and Reed-Sternberg cells using comparative genomic hybridization. Ohshima K, et al. **Int J Cancer** 1999 Jul 19;82(2):250-5

Expression of cyclin D2 and D3 in lymphoid lesions. Teramoto N, et al. **Int J Cancer** 1999 May 17;81(4):543-50

Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Ha CS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15; 43(2):329-34

Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: role of the germinal center in B-cell lymphomagenesis. Küppers R. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S74-9 (47 ref.)

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease [see comments] Diehl V, et al. **J Clin Oncol** 1999 Mar; 17(3):776-83. Comment in: J Clin Oncol 1999 Mar;17(3):744-6.

Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. Ng AK, et al. **J Clin Oncol** 1999 Jan; 17(1):241-52

Mycosis fungoides and cutaneous Hodgkin's disease in the same patient: a case report. Geldenhuys L, et al. **J Cutan Pathol** 1999 Jul;26(6):311-4

Regarding laparoscopic staging for Hodgkin's disease [letter; comment] Baccarani U, et al. **J Laparoendosc Adv Surg Tech A** 1998 Aug;8(4):247-8. Comment on: J Laparoendosc Adv Surg Tech A 1997 Dec;7(6):353-5.

Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells. Hasse U, et al. **J Natl Cancer Inst** 1999 Sep 15;91(18):1581-3

Apoptotic index as a prognostic factor in Hodgkin's disease. Benharroch D, et al. **Leuk Lymphoma** 1999 Apr; 33(3-4):351-9

Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment. Dhodapkar MV, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):35-43 (53 ref.)

Clinicopathological evaluation of the Revised European-American Classification of Lymphoid Neoplasms (REAL) in Japan. Isobe K, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):143-9

Hodgkin's disease type Richter's syndrome in chronic lymphocytic leukemia [letter] Juneja S, et al. **Leukemia** 1999 May;13(5):826-7

Reappearance of Hodgkin disease after 32 years: relapse or new disease? Sharma A, et al. **Med Pediatr Oncol** 1999 Mar;32(3):231

Prognostic importance of magnetic resonance imaging in bone marrow involvement of Hodgkin disease. Varan A, et al. **Med Pediatr Oncol** 1999 Apr;32(4):267-71

Quantitative measurement of telomerase activity in lymphadenopathy: correlation with histologic features and human immunodeficiency virus-1 infection. Strovel JW, et al. **Mod Pathol** 1998 Oct;11(10):957-62

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma [see comments] Bräuninger A, et al. **N Engl J Med** 1999 Apr 22;340(16):1239-47. Comment in: N Engl J Med 1999 Apr 22;340(16):1280-2.

Clonality of Reed-Sternberg cells in Hodgkin's disease [letter; comment] Hummel M, et al. **N Engl J Med** 1999 Feb 4;340(5):394-5. Comment on: N Engl J Med 1995 Oct 5;333(14):901-6.

A common B-cell precursor in composite lymphomas [letter] Kerl K, et al. **N Engl J Med** 1999 Sep 2;341(10):764-5

Precursors of Hodgkin's disease and B-cell lymphomas [editorial; comment] Manis JP. **N Engl J Med** 1999 Apr 22;340(16):1280-2. Comment on: N Engl J Med 1999 Apr 22;340(16):1239-47.

Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Chan WC. **Semin Hematol** 1999 Jul;36(3):242-52 (83 ref.)

Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Stein H, et al. **Semin Hematol** 1999 Jul;36(3):233-41 (78 ref.)

[Hodgkin's disease with epithelioid granulomatous reaction] Mačák J, et al. **Cesk Patol** 1998 Jul;34(3):89-93 (Eng. Abstr.) **(Cze)**

[Cutaneous lymphoma manifesting as pigmented, purpuric capillaries] Lipsker D, et al. **Ann Dermatol Venereol** 1999 Apr;126(4):321-6 (Eng. Abstr.) **(Fre)**

[Hodgkin's disease and anaplastic large cell lymphoma in 1998] Delsol G, et al. **Ann Pathol** 1998 Oct;18(4):331-42 (40 ref.) **(Fre)**

[Intramedullary spinal cord metastasis and leptomeningeal involvement in Hodgkin's disease. Case report and review of the literature] Jardin F, et al. **Rev Med Interne** 1999 Mar;20(3):267-71 (30 ref.) (Eng. Abstr.) **(Fre)**

[Staging of Hodgkins's disease] Brice P. **Rev Prat** 1998 May 15;48(10):1070-4 (8 ref.) (Eng. Abstr.) **(Fre)**

[Case of immunocytoma 4 years after and immunoblastic lymphoma 6 years after complete remission of Hodgkin's disease] Sugai N, et al. **Nippon Naika Gakkai Zasshi** 1999 Aug 10;88(8):1515-7 **(Jpn)**

[Autopsy case of intravascular lymphomatosis with pancreatic carcinoma] Komada F, et al. **Rinsho Ketsueki** 1999 May;40(5):423-6 (Eng. Abstr.) **(Jpn)**

[Malignant lymphoproliferative lesions of the trachea] Kharchenko VP, et al. **Arkh Patol** 1998 Nov-Dec; 60(6):52-6 (31 ref.) (Eng. Abstr.) **(Rus)**

[Primary non-Hodgkin's lymphoma of the esophagus following Hodgkin's disease (letter)] Fernández-Llamazares J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):356-7 (10 ref.) **(Spa)**

[Pulmonary infiltrates in a 46-year-old man recipient of an allogeneic transplant of bone marrow (clinico-pathologic conference)] Sierra J, et al. **Med Clin (Barc)** 1999 Jun 26; 113(3):109-14 **(Spa)**

[Discordant lymphoma: a report of 2 new cases and a review of the literature] Azaceta Reinares G, et al. **Rev Clin Esp** 1998 Nov;198(11):749-51 (11 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. del Cañizo C, et al. **Bone Marrow Transplant** 1999 May;23(9):901-5

The effects of cardiotoxic chemotherapy on blood pressure in patients with lymphoma. Ratcliffe MA, et al. **Clin Lab Haematol** 1998 Dec;20(6):353-6

Epstein-barr virus in Hodgkin's disease: frequency of a 30-bp deletion in the latent membrane protein (LMP-1) oncogene in South African patients [letter] Essop MF, et al. **Int J Cancer** 1999 Aug 20;84(4):449-51

Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. Schmiegelow ML, et al. **J Pediatr Hematol Oncol** 1998 Sep-Oct;20(5):429-30

Basic fibroblast growth factor and fibrosis in Hodgkin's disease. Ohshima K, et al. **Pathol Res Pract** 1999; 195(3):149-55

[Physiopathology of Hodgkin's disease] Gaulard P, et al. **Rev Prat** 1998 May 15;48(10):1065-9 (26 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group. Flechtner H, et al. **Ann Oncol** 1998;9 Suppl 5:S147-54 (52 ref.)

Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Abrahamsen AF, et al. **Eur J Cancer** 1998 Nov; 34(12):1865-70

RADIOGRAPHY

Tuberculosis versus lymphomas in the abdominal lymph nodes: evaluation with contrast-enhanced CT. Yang ZG, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):619-23

Primary pulmonary Hodgkin's disease: CT findings in three patients. Cartier Y, et al. **Clin Radiol** 1999 Mar;54(3):182-4

Pleural effusions in lymphoblastic lymphoma: a diagnostic alternative. Chaignaud BE, et al. **J Pediatr Surg** 1998 Sep; 33(9):1355-7

[Computed tomography of lymphoma in adults. The Study Group of Lymphoma in Adults] Dupas B, et al. **J Radiol** 1998 Dec;79(12):1469-77 (Eng. Abstr.) **(Fre)**

[Anorectal Hodgkin disease in an HIV-infected patient (letter)] Márquez-Moreno AJ, et al. **Med Clin (Barc)** 1999 May 1;112(15):598-9 **(Spa)**

RADIONUCLIDE IMAGING

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Bangerter M, et al. **Ann Oncol** 1998 Oct; 9(10):1117-22

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. Krause T, et al. **Ann Oncol** 1999 Jan;10(1):79-85

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Jerusalem G, et al. **Blood** 1999 Jul 15;94(2):429-33

Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Kotzerke J, et al. **Eur J Nucl Med** 1999 Jan;26(1):31-8

Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Cremerius U, et al. **Nucl Med Commun** 1998 Nov; 19(11):1055-63

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Jerusalem G, et al. **Nucl Med Commun** 1999 Jan;20(1):13-20

Hodgkin's disease: internal mammary lymph nodes relapse diagnosed by gallium-67 scintigraphy. Ruíz Hernández G, et al. **Nuklearmedizin** 1999 Apr;38(3):90-4

Functional imaging of Hodgkin's disease with FDG-PET and gallium-67. Willkomm P, et al. **Nuklearmedizin** 1998; 37(7):251-3

Hodgkin disease: use of Tl-201 to monitor mediastinal involvement after treatment. Fletcher BD, et al. **Radiology** 1998 Nov;209(2):471-5

Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Front D, et al. **Radiology** 1999 Feb;210(2):487-91

[The value of gallium scintigraphy after the therapy of Hodgkin's disease] Staar S. **Strahlenther Onkol** 1998 Dec; 174(12):640-1 **(Ger)**

RADIOTHERAPY

Left lower lobe radiation pneumonitis in patients with early stage Hodgkin's disease: a reminder [letter] Zissin R, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):1127

Meningioma after radiotherapy for Hodgkin's disease. Deutsch M, et al. **Am J Clin Oncol** 1999 Aug;22(4):361–3

Acute myocardial infarction after irradiation for Hodgkin's disease: a not so unusual case [letter] [published erratum appears in Ann Emerg Med 1999 Mar;33(3):358] Spektor M, et al. **Ann Emerg Med** 1999 Jan;33(1):124–5

Long-term toxicity of the treatment of Hodgkin's disease. Armitage JO. **Ann Oncol** 1998;9 Suppl 5:S133–6 (28 ref.)

The role of radiotherapy for early stage Hodgkin's disease: limitations and perspectives. Cosset JM, et al. **Ann Oncol** 1998;9 Suppl 5:S57–62 (37 ref.)

Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease. Hoppe RT. **Ann Oncol** 1998;9 Suppl 5:S87–90 (14 ref.)

Radiotherapy in early stage Hodgkin's disease: principles and results of recent clinical trials. Noordijk EM. **Ann Oncol** 1998;9 Suppl 5:S63–5 (15 ref.)

Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Shafford EA, et al. **Br J Cancer** 1999 May;80(5–6):808–14

Mediastinal irradiation: A risk factor for atherosclerosis of the internal thoracic arteries. Renner SM, et al. **Can J Cardiol** 1999 May;15(5):597–600

Radiotherapy considerations in patients with Hodgkin's disease who receive mediastinal radiotherapy and anthracycline-containing chemotherapy. Plowman PN. **Clin Oncol (R Coll Radiol)** 1998;10(6):384–91

Brachial plexus neuropathy following mantle radiotherapy. Wadd NJ, et al. **Clin Oncol (R Coll Radiol)** 1998; 10(6):399–400

Small cell anaplastic carcinoma of the oesophagus following mantle field radiotherapy for mediastinal Hodgkin's lymphoma: first case report [letter] Graadt van Roggen JF, et al. **Eur J Cancer** 1998 Aug;34(9):1469

Long-term results of 60 patients with pathologic stage I & IIA Hodgkin's disease treated with exclusive mantle radiation therapy. Enrici RM, et al. **Eur J Haematol** 1999 Aug;63(2):126–33

Thyroid volume is progressively reduced as a sequela of neck irradiation for childhood Hodgkin's disease [letter] Bossi G, et al. **Haematologica** 1998 Aug;83(8):754–6

Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Ha CS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15; 43(2):329–34

The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control. Mendenhall NP, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):551–61

Second cancer among long-term survivors from Hodgkin's disease. Nyandoto P, et al. **Int J Radiat Oncol Biol Phys** 1998 Sep 1;42(2):373–8

Long-term follow-up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital. Shah AB, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 1;44(4):867–77

Results of the 1988–1989 Patterns of Care Study process survey for Hodgkin's disease. Smitt MC, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15;43(2):335–9

MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians [letter; comment] Andrieu JM, et al. **J Clin Oncol** 1999 Feb;17(2):730–4. Comment on: J Clin Oncol 1998 Mar;16(3):818–29.

Mantle irradiation alone for clinical stage I–II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. Wirth A, et al. **J Clin Oncol** 1999 Jan;17(1):230–40

Radiation-induced esophageal carcinoma 30 years after mediastinal irradiation: case report and review of the literature. Micke O, et al. **Jpn J Clin Oncol** 1999 Mar; 29(3):164–70 (43 ref.)

Treatment of stage I and II Hodgkin's disease with NOVP (mitoxantrone, vincristine, vinblastine, prednisone) and radiotherapy. Tormo M, et al. **Leuk Lymphoma** 1999 Jun; 34(1–2):137–42

ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Zinzani PL, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):553–9

Childhood stage IV Hodgkin disease: therapeutic results of the Polish pediatric leukemia/lymphoma study group. Armata J, et al. **Med Pediatr Oncol** 1999 Oct;33(4):382–7

Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects. Cutuli B, et al. **Oncol Rep** 1998 Nov–Dec;5(6):1513–8

Thyroid dysfunction in children receiving neck irradiation for Hodgkin's disease. Atahan IL, et al. **Radiat Med** 1998 Sep–Oct;16(5):359–61

Response during radiotherapy may be associated with outcome in mediastinal Hodgkin's disease. Movsas B, et al. **Radiat Oncol Investig** 1998;6(5):216–25

Prognostic factors affecting disease-free survival in patients with Hodgkin's disease stages IA and IIA treated initially with radiotherapy alone in a single centre during 1973 to 1992. Bessell EM, et al. **Radiother Oncol** 1998 Oct; 49(1):15–9

Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Reinders JG, et al. **Radiother Oncol** 1999 Apr;51(1):35–42

Dose distribution throughout the body from radiotherapy for Hodgkin's disease in childhood. Shamsaldin A, et al. **Radiother Oncol** 1998 Oct;49(1):85–90

Radiation therapy in Hodgkin's lymphoma. Ng AK, et al. **Semin Hematol** 1999 Jul;36(3):290–302 (133 ref.)

Comparison of conventional and virtual simulation for radiation treatment planning of malignant lymphoma. Dinges S, et al. **Strahlenther Onkol** 1998 Oct;174 Suppl 2:28–30

[Breast cancer after radiation treatment for Hodgkin disease] Camps MJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3; 142(40):2205–8 (Eng. Abstr.) **(Dut)**

[Preservation of ovarian function in 2 young women with Hodgkin disease by laparoscopic transposition of the ovaries prior to abdominal irradiation] Tinga DJ, et al. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):308–12 (Eng. Abstr.) **(Dut)**

[Ostial stenosis of the common trunk of the left coronary artery 20 years after mediastinal irradiation] Bensaid J, et al. **Ann Cardiol Angeiol (Paris)** 1998 Dec;47(10):732–4 (Eng. Abstr.) **(Fre)**

[the role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives] Cosset JM, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):112–8 (Eng. Abstr.) **(Fre)**

[The role of radiotherapy in the management of advanced Hodgkin's disease] Cowen D. **Cancer Radiother** 1999 Mar–Apr;3(2):119–28 (Eng. Abstr.) **(Fre)**

[A quality control program for radiotherapy in Hodgkin's disease] Hennequin C, et al. **Cancer Radiother** 1999 Mar–Apr;3(2):187–90 (Eng. Abstr.) **(Fre)**

[Radiotherapy for leukemias and lymphomas in children] Lévy-Piedbois C, et al. **Cancer Radiother** 1999 Mar–Apr; 3(2):181–6 (Eng. Abstr.) **(Fre)**

[Late-onset pleurisy: a rare complication of thoracic radiotherapy (letter)] Durupt S, et al. **Presse Med** 1998 Apr 25;27(16):762 **(Fre)**

[Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years] Dörffel W, et al. **Klin Padiatr** 1998 Jul–Aug;210(4):212–9 (Eng. Abstr.) **(Ger)**

[The meta-analysis of clinical studies on chemotherapy alone compared to a combination of chemotherapy plus radiotherapy in the treatment of Hodgkin's disease] Baumann M, et al. **Strahlenther Onkol** 1998 Oct; 174(10):544–6 **(Ger)**

[Second malignancies after the therapy of Hodgkin's disease: the Freiburg collective 1940 to 1991] Slanina J, et al. **Strahlenther Onkol** 1999 Apr;175(4):154–61 (Eng. Abstr.) **(Ger)**

[Fatal coronary heart disease in a young woman 20 years after radiotherapy for Hodgkin disease] Skulstad H, et al. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1431–2 (Eng. Abstr.) **(Nor)**

[Total irradiation of the liver in treating patients with lymphogranulomatosis] Balashov AT, et al. **Ter Arkh** 1998; 70(7):57–9 (Eng. Abstr.) **(Rus)**

SURGERY

Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Ketterer N, et al. **Am J Med** 1999 Feb;106(2):191–7

Regarding laparoscopic staging for Hodgkin's disease [letter; comment] Baccarani U, et al. **J Laparoendosc Adv Surg Tech A** 1998 Aug;8(4):247–8. Comment on: J Laparoendosc Adv Surg Tech A 1997 Dec;7(6):353–5.

Role of laparoscopy for Hodgkin's and non-Hodgkin's lymphoma. Walsh RM, et al. **Semin Surg Oncol** 1999 Jun; 16(4):284–92 (34 ref.)

Advanced primary Hodgkin's disease of the spleen cured by surgical resection: report of a case. Midorikawa Y, et al. **Surg Today** 1999;29(4):367–70

[A case of surgical treatment for thymic Hodgkin's disease with tracheo-bronchial stenosis] Ichimanda M, et al. **Kyobu Geka** 1999 Aug;52(9):793–5 (Eng. Abstr.) **(Jpn)**

THERAPY

Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Abrahamsen AF, et al. **Acta Oncol** 1999; 38(4):511–5

Treatment of grey zone lymphomas. Fisher RI. **Ann Oncol** 1998;9 Suppl 5:S121–3 (12 ref.)

Primary refractory Hodgkin's disease. Horning SJ. **Ann Oncol** 1998;9 Suppl 5:S97–101 (20 ref.)

Hodgkin's disease: quality of life in future trials. Kaasa S, et al. **Ann Oncol** 1998;9 Suppl 5:137–45 (63 ref.)

Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Rooney CM, et al. **Ann Oncol** 1998;9 Suppl 5:S129–32

Problems in Hodgkin's disease management. Aisenberg AC. **Blood** 1999 Feb 1;93(3):761–79 (216 ref.)

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. del Cañizo C, et al. **Bone Marrow Transplant** 1999 May;23(9):901–5

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S, et al. **Bone Marrow Transplant** 1998 Oct;22(7):625–30

Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. Ketterer N, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1309–15

Use of selected CD34+ cells in the treatment of relapsed Hodgkin's lymphoma (letter). Lakota J. **Bone Marrow Transplant** 1999 Sep;24(6):697–9

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Lancet JE, et al. **Bone Marrow Transplant** 1998 Aug;22(3):265–71

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Reece DE, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1131–8

Autologous stem cell transplantation for malignant lymphomas. Reményi P, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S104–6

Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Seropian S, et al. **Bone Marrow Transplant** 1999 Mar; 23(6):599–605

Non-invasive ventilatory support in the management of respiratory failure after autologous peripheral blood stem cell transplantation [letter] Sica S, et al. **Bone Marrow Transplant** 1999 Mar;23(5):527

Fulminant hepatic failure caused by adenovirus infection following bone marrow transplantation for Hodgkin's disease. Somervaille TC, et al. **Bone Marrow Transplant** 1999 Jul;24(1):99–101

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Ketterer N, et al. **Br J Haematol** 1998 Oct; 103(1):235–42

Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis. Perry AR, et al. **Br J Haematol** 1999 Apr;105(1):280–7

Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Salloum E, et al. **Cancer Invest** 1999; 17(3):171–80

Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Ran S, et al. **Cancer Res** 1998 Oct 15; 58(20):4646–53

Hodgkin's disease – new treatment strategies toward the cure of patients. Jox A, et al. **Cancer Treat Rev** 1999 Jun; 25(3):169–76 (36 ref.)

Natural killer cell activity in Hodgkin's disease patients undergoing radiation therapy or chemotherapy and radiation therapy. Pinel MI, et al. **Clin Lab Haematol** 1998 Oct;20(5):303–6

Hodgkin's disease and non-Hodgkin's lymphoma. Bociek RG, et al. **Curr Opin Hematol** 1999 Jul;6(4):205–15 (126 ref.)

Advances in the management of Hodgkin's and non-Hodgkin's lymphoma. Davis TA, et al. **Curr Opin Hematol** 1998 Jul;5(4):259–63 (18 ref.)

Issues in the treatment of Hodgkin's disease. Wolf J, et al. **Curr Opin Oncol** 1998 Sep;10(5):396–402 (26 ref.)

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. Greil R, et al. **Eur J Cancer** 1999 May;35(5):698–706

Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Tsang RW, et al. **Eur J Cancer** 1999 Jan; 35(1):73–8

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study [see comments] Brusamolino E, et al. **Haematologica** 1998 Sep;83(9):812–23 . Comment in: Haematologica 1998 Sep;83(9):769–70.

Hodgkin's disease and the risk of acute leukemia in successfully treated patients [editorial; comment] Valagussa P, et al. **Haematologica** 1998 Sep;83(9):769–70. Comment on: Haematologica 1998 Sep;83(9):812–23.

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. André M, et al. **J Clin Oncol** 1999 Jan;17(1):222–9

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. Baker KS, et al. **J Clin Oncol** 1999 Mar; 17(3):825–31

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Lazarus HM, et al. **J Clin Oncol** 1999 Feb;17(2):534–45

Laparotomy versus no laparotomy in the management of

early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. Ng AK, et al. **J Clin Oncol** 1999 Jan; 17(1):241-52

Measurement and biological correlates of antibody bioactivity during antibody immunotherapies. Hagg DS, et al. **J Immunol Methods** 1998 Oct 1;219(1-2):7-21

Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Delain M, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):305-13

Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Oddou S, et al. **Leuk Lymphoma** 1998 Sep;31(1-2):187-94

Hodgkin's disease presenting as a parasternal chest wall mass. Stolk MF, et al. **Neth J Med** 1999 Jun;54(6):239-41

NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network. **Oncology (Huntingt)** 1999 May;13(5A):78-110

Acute spontaneous pneumomediastinum in a child with Hodgkin's disease and pulmonary fibrosis. Briassoulis G, et al. **Pediatr Hematol Oncol** 1999 Mar-Apr;16(2):175-80

Acute lymphoblastic leukemia occurring as a second malignancy: report of a case and review of literature. Geetha N, et al. **Pediatr Hematol Oncol** 1999 May-Jun; 16(3):267-70 (10 ref.)

Pulmonary Langerhans' cell histiocytosis following autologous haemopoietic progenitor cell transplantation. Soler N, et al. **Respir Med** 1998 Oct;92(10):1253-5

Treatment of early-stage Hodgkin's disease. Advani RH, et al. **Semin Hematol** 1999 Jul;36(3):270-81 (82 ref.)

Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches. Engert A, et al. **Semin Hematol** 1999 Jul;36(3):282-9 (33 ref.)

Treatment of pediatric Hodgkin's lymphoma. Hudson MM, et al. **Semin Hematol** 1999 Jul;36(3):313-23 (54 ref.)

High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Laurence AD, et al. **Semin Hematol** 1999 Jul;36(3):303-12 (44 ref.)

Radiation therapy in Hodgkin's lymphoma. Ng AK, et al. **Semin Hematol** 1999 Jul;36(3):290-302 (133 ref.)

Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Marshall NA, et al. **Semin Oncol** 1999 Feb;26(1):67-73 (41 ref.)

[Prognostic factors and treatment of localized Hodgkin's disease] Carde P, et al. **Rev Prat** 1998 May 15; 48(10):1075-81 (26 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of resistant forms and recurrence of Hodgkin's disease] Diviné M, et al. **Rev Prat** 1998 May 15; 48(10):1087-91 (21 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors and treatment of advanced Hodgkin's disease] Fermé C. **Rev Prat** 1998 May 15;48(10):1082-6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Late treatment related complications of Hodgkin's disease] Henry-Amar M, et al. **Rev Prat** 1998 May 15;48(10):1092-7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of Hodgkin's disease. Optimization over 4 study generations] Diehl V, et al. **Internist (Berl)** 1998 Sep; 39(9):917-26 (25 ref.) **(Ger)**

[Hodgkin's disease] Aoyagi M, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):217-30 (73 ref.) **(Jpn)**

[Late complications after treatment of Hodgkin's disease] Lund MB, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10; 119(7):933-7 (Eng. Abstr.) **(Nor)**

[The late results of the combined therapy of patients in 2nd-stage lymphogranulomatosis] Demina EA, et al. **Ter Arkh** 1998;70(7):49-53 (Eng. Abstr.) **(Rus)**

VETERINARY

Hypereosinophilic syndrome with Hodgkin's-like lymphoma in a ferret. Blomme EA, et al. **J Comp Pathol** 1999 Feb; 120(2):211-7

VIROLOGY

Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Enblad G, et al. **Acta Oncol** 1999;38(4):425-9

Detection and genotyping of Epstein-Barr virus by polymerase chain reaction in tissues obtained from cases with Hodgkin's disease in Turkey. Durmaz R, et al. **Acta Virol** 1998 Dec;42(6):375-81

Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Chu PG, et al. **Am J Pathol** 1999 Sep; 155(3):941-7

A comparison of epidemiologic, histologic, and virologic studies on Hodgkin's disease in western Kenya and Nagasaki, Japan. Kusuda M, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):801-7

Epstein-Barr virus in Hodgkin's disease. Chapman AL, et al. **Ann Oncol** 1998;9 Suppl 5:S5-16 (118 ref.)

Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands. Flavell K, et al. **Br J Cancer** 1999 May;80(3-4):604-8

Hepatitis G virus in patients with Hodgkin's lymphoma [letter] Persico M, et al. **Br J Haematol** 1998 Dec; 103(4):1206-7

Paediatric Hodgkin's disease in Spain: association with Epstein-Barr virus strains carrying latent membrane protein-1 oncogene deletions and high frequency of dual infections. Santón A, et al. **Br J Haematol** 1998 Oct; 103(1):129-36

Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Sleckman BG, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec;7(12):1117-21

Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Dolcetti R, et al. **Int J Cancer** 1999 Jan 18; 80(2):240-9

Epstein-barr virus in Hodgkin's disease: frequency of a 30-bp deletion in the latent membrane protein (LMP-1) oncogene in South African patients [letter] Essop MF, et al. **Int J Cancer** 1999 Aug 20;84(4):449-51

Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Gallagher A, et al. **Int J Cancer** 1999 Aug 20;84(4):442-8

Epstein-Barr virus study in malignant lymphoma in Sjögren's syndrome. Hirose Y, et al. **Int J Hematol** 1999 Apr; 69(3):174-9

Diagnosis of measles viral pneumonia in a patient with Hodgkin's disease by reverse transcription-polymerase chain reaction of serum. Mori S, et al. **Int J Hematol** 1998 Oct;68(3):327-31

Multiple primary cancers and HPV infection: are they related? Hennig EM, et al. **J Exp Clin Cancer Res** 1999 Mar;18(1):53-4

High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. Drouet E, et al. **J Med Virol** 1999 Apr;57(4):383-9

Self-reported infectious mononucleosis and 6 cancers: a population-based, case-control study. Levine R, et al. **Scand J Infect Dis** 1998;30(3):211-4

[Epstein-Barr virus infection and the expression of bcl-2 proto-oncogene in Hodgkin's disease] Liu C, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Jun;26(3):155-7 (Eng. Abstr.) **(Chi)**

[The significance of detecting Epstein-Barr virus BNLF1 fragment and its expression in Hodgkin's disease in the Guangdong area] Zeng W, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1997 Feb;26(1):27-30 (Eng. Abstr.) **(Chi)**

[Serologic study of human herpesviruses 6 and 7 in lymphoma patients] Ongrádi J, et al. **Orv Hetil** 1999 Jun 27; 140(26):1457-9 (Eng. Abstr.) **(Hun)**

[Role of Epstein-Barr virus in the pathogenesis of lymphogranulomatosis. Immunohistochemical and molecular-biological (hybridization in situ) research] Leenman EE, et al. **Arkh Patol** 1999 Jan-Feb;61(1):15-22 (Eng. Abstr.) **(Rus)**

[Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease] Kuljić-Kapulica N. **Srp Arh Celok Lek** 1998 Mar-Apr;126(3-4):97-100 (Eng. Abstr.) **(Scc)**

HOE-766 see **BUSERELIN**

HOE-33258

CHEMISTRY

Theoretical studies employing an ab initio and molecular modeling combination method on the DNA binding of bis-benzimidazoles designed for bioreductive activation. Sapse AM, et al. **J Biomol Struct Dyn** 1998 Oct; 16(2):253-63

DNA minor groove recognition by bis-benzimidazole analogues of Hoechst 33258: insights into structure-DNA affinity relationships assessed by fluorescence titration measurements. Bostock-Smith CE, et al. **Nucleic Acids Res** 1999 Apr 1;27(7):1619-24

METABOLISM

DNA-drug interaction measurements using surface plasmon resonance. Bischoff G, et al. **J Biomol Struct Dyn** 1998 Oct;16(2):187-203

Controlling gene expression in living cells through small molecule-RNA interactions. Werstuck G, et al. **Science** 1998 Oct 9;282(5387):296-8

HOG CHOLERA

BLOOD

Phenotypic analysis of peripheral leukocytes in piglets infected with classical swine fever virus. Markowska-Daniel I, et al. **Res Vet Sci** 1999 Aug; 67(1):53-7

DIAGNOSIS

Comparison of a reverse transcription-polymerase chain reaction assay and virus isolation for the detection of classical swine fever virus. Vydelingum S, et al. **Rev Sci Tech** 1998 Dec;17(3):674-81

An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). van Rijn PA, et al. **Vaccine** 1999 Feb 5;17(5):433-40

An RT-PCR assay for the specific detection of classical swine fever virus in clinical samples. Díaz de Arce H, et al. **Vet Res** 1998 Sep-Oct;29(5):431-40

[Comparison of laboratory diagnostic methods for the detection of infection with the virus of classical swine fever in the early inspection phase: an experimental study] Kaden V, et al. **Berl Munch Tierarztl Wochenschr** 1999 Feb; 112(2):52-7 (Eng. Abstr.) **(Ger)**

[Methods of laboratory diagnosis of hog cholera] Nepoklonov EA, et al. **Vopr Virusol** 1998 Jul-Aug; 43(4):152-8 (54 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Prostaglandin A1 inhibits replication of classical swine fever virus. Freitas TR, et al. **Mem Inst Oswaldo Cruz** 1998 Nov-Dec;93(6):815-8

ECONOMICS

The involvement of the agriculture industry and government in animal disease emergencies and the funding of compensation in western Europe. Horst HS, et al. **Rev Sci Tech** 1999 Apr;18(1):30-7 (8 ref.)

EPIDEMIOLOGY

Classical swine fever in Sardinia: epidemiology of recent outbreaks. Lowings P, et al. **Epidemiol Infect** 1999 Jun; 122(3):553-9

Monte Carlo simulation of virus introduction into the Netherlands. Horst HS, et al. **Prev Vet Med** 1999 Jul 20; 41(2-3):209-29

Comparative sequence analysis of classical swine fever virus isolates from the epizootic in The Netherlands in 1997-1998. Widjojoatmodjo MN, et al. **Vet Microbiol** 1999 May;66(4):291-9

Incidence of classical swine fever (CSF) in wild boar in a densely populated area indicating CSF virus persistence as a mechanism for virus perpetuation. Kern B, et al. **Zentralbl Veterinarmed [B]** 1999 Feb;46(1):63-7

[Classical swine fever in wild boars in Switzerland] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1999;141(4):185-90 (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Bouma A, et al. **Vet Microbiol** 1999 Apr 1;66(2):101-14

Virus antigen expression and alterations in peripheral blood mononuclear cell subpopulations after classical swine fever virus infection. Lee WC, et al. **Vet Microbiol** 1999 Jun 1; 67(1):17-29

PHYSIOPATHOLOGY

[Classical swine fever] Büttner M, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Sep; 26(5):278-86 (54 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Classical swine fever virus: discrimination between vaccine strains and European field viruses by restriction endonuclease cleavage of PCR amplicons. Vilček S, et al. **Acta Vet Scand** 1998;39(3):395-400

EpiMAN-SF: a decision-support system for managing swine fever epidemics. Stärk KD, et al. **Rev Sci Tech** 1998 Dec; 17(3):682-90 (20 ref.)

Oral immunisation of swine with a classical swine fever vaccine (Chinese strain) and transmission studies in rabbits and sheep. Chenut G, et al. **Vet Microbiol** 1999 Feb 12; 64(4):265-76

[The non-vaccination policy (letter)] van Logtestijn JG, et al. **Tijdschr Diergeneeskd** 1999 Mar 1;124(5):160-1 **(Dut)**

[Practical implementation of control measures against highly contagious animal diseases in the territory of the European Union exemplified by classical swine fever] Winkenwerder W, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct; 111(10):393-6 (Eng. Abstr.) **(Ger)**

TRANSMISSION

Transmission of classical swine fever virus by artificial insemination. de Smit AJ, et al. **Vet Microbiol** 1999 Jul 1;67(4):239-49

VIROLOGY

Immunohistochemical and ultrastructural evidence of hog cholera virus infection of megakaryocytes in bone marrow and spleen. Gómez-Villamandos JC, et al. **J Comp Pathol** 1998 Aug;119(2):111-9

Comparative detection of classical swine fever virus in striated muscle from experimentally infected pigs by reverse transcription polymerase chain reaction, cell culture isolation and immunohistochemistry. Thür B, et al. **J Virol Methods** 1998 Sep;74(1):47-56

Application of genetic methods to study the relationship between classical swine fever outbreaks. Vilček S, et al. **Res Vet Sci** 1998 Jul-Aug;65(1):89-90

HOG CHOLERA VIRUS

CLASSIFICATION

Classical swine fever virus: discrimination between vaccine strains and European field viruses by restriction endonuclease cleavage of PCR amplicons. Vilček S, et al. **Acta Vet Scand** 1998;39(3):395–400

[Classical swine fever in wild boars in Switzerland] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1999;141(4):185–90 (Eng. Abstr.) **(Ger)**

GENETICS

Cytopathogenic and noncytopathogenic RNA replicons of classical swine fever virus. Moser C, et al. **J Virol** 1999 Sep;73(9):7787–94

Application of a computer program for genetic typing of classical swine fever virus isolates from Germany. Greiser-Wilke I, et al. **J Virol Methods** 1998 Nov; 75(2):141–50

Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase. van Gennip HG, et al. **J Virol Methods** 1999 Mar; 78(1–2):117–28

Genetic variation in the 5' end and NS5B regions of classical swine fever virus genome among Japanese isolates. Harasawa R, et al. **Microbiol Immunol** 1999;43(4):373–9

Application of genetic methods to study the relationship between classical swine fever outbreaks. Vilček S, et al. **Res Vet Sci** 1998 Jul–Aug;65(1):89–90

Comparative sequence analysis of classical swine fever virus isolates from the epizootic in The Netherlands in 1997–1998. Widjojoatmodjo MN, et al. **Vet Microbiol** 1999 May;66(4):291–9

Genetic analysis of pestiviruses at the 3' end of the genome. Vilcek S, et al. **Virus Genes** 1999;18(2):107–14

Molecular cloning and nucleotide sequence of 3'-terminal region of classical swine fever virus LPC vaccine strain. Wong ML, et al. **Virus Genes** 1998;17(3):213–8

[Genetic characteristics of the KC vaccine strain of hog cholera virus: comparative analysis of the primary sequence of surface glycoprotein E(rns), E1, and E2 genes] Grebennikova TV, et al. **Mol Gen Mikrobiol Virusol** 1999; (2):34–40 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Transmission of classical swine fever virus by artificial insemination. de Smit AJ, et al. **Vet Microbiol** 1999 Jul 1;67(4):239–49

IMMUNOLOGY

In vivo effect on pig chromosomes of high dosage vaccine against classic swine fever. Genghini R, et al. **Mutat Res** 1998 Dec 3;422(2):357–65

An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). van Rijn PA, et al. **Vaccine** 1999 Feb 5;17(5):433–40

Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Bouma A, et al. **Vet Microbiol** 1999 Apr 1;66(2):101–14

Oral immunisation of swine with a classical swine fever vaccine (Chinese strain) and transmission studies in rabbits and sheep. Chenut G, et al. **Vet Microbiol** 1999 Feb 12; 64(4):265–76

[Use of monoclonal antibodies for studying the classical hog cholera virus] Nepoklonov EA, et al. **Vopr Virusol** 1999 Mar–Apr;44(2):54–60 (38 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Classical swine fever in Sardinia: epidemiology of recent outbreaks. Lowings P, et al. **Epidemiol Infect** 1999 Jun; 122(3):553–9

Comparative detection of classical swine fever virus in striated muscle from experimentally infected pigs by reverse transcription polymerase chain reaction, cell culture isolation and immunohistochemistry. Thür B, et al. **J Virol Methods** 1998 Sep;74(1):47–56

Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase. van Gennip HG, et al. **J Virol Methods** 1999 Mar; 78(1–2):117–28

Comparison of a reverse transcription-polymerase chain reaction assay and virus isolation for the detection of classical swine fever virus. Vydelingum S, et al. **Rev Sci Tech** 1998 Dec;17(3):674–81

An RT-PCR assay for the specific detection of classical swine fever virus in clinical samples. Diaz de Arce H, et al. **Vet Res** 1998 Sep–Oct;29(5):431–40

Incidence of classical swine fever (CSF) in wild boar in a densely populated area indicating CSF virus persistence as a mechanism for virus perpetuation. Kern B, et al. **Zentralbl Veterinarmed [B]** 1999 Feb;46(1):63–7

[Comparison of laboratory diagnostic methods for the detection of infection with the virus of classical swine fever in the early inspection phase: an experimental study] Kaden V, et al. **Berl Munch Tierarztl Wochenschr** 1999 Feb; 112(2):52–7 (Eng. Abstr.) **(Ger)**

[Detection of the hog cholera virus using the polymerase chain reaction] Semenikhin VI, et al. **Mol Gen Mikrobiol Virusol** 1999;(1):27–30 (Eng. Abstr.) **(Rus)**

[Methods of laboratory diagnosis of hog cholera] Nepoklonov EA, et al. **Vopr Virusol** 1998 Jul–Aug; 43(4):152–8 (54 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Phenotypic analysis of peripheral leukocytes in piglets infected with classical swine fever virus. Markowska-Daniel I, et al. **Res Vet Sci** 1999 Aug; 67(1):53–7

PHYSIOLOGY

Immunohistochemical and ultrastructural evidence of hog cholera virus infection of megakaryocytes in bone marrow and spleen. Gómez-Villamandos JC, et al. **J Comp Pathol** 1998 Aug;119(2):111–9

Porcine cells persistently infected with classical swine fever virus protected from pestivirus-induced cytopathic effect. Mittelholzer C, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2981–7

Localization of pestiviral envelope proteins E(rns) and E2 at the cell surface and on isolated particles. Weiland F, et al. **J Gen Virol** 1999 May;80 (Pt 5):1157–65

Establishment of a serum-free culture cell line, CPK-NS, which is useful for assays of classical swine fever virus. Sakoda Y, et al. **J Virol Methods** 1998 Nov;75(1):59–68

Prostaglandin A1 inhibits replication of classical swine fever virus. Freitas TR, et al. **Mem Inst Oswaldo Cruz** 1998 Nov–Dec;93(6):815–8

Virus antigen expression and alterations in peripheral blood mononuclear cell subpopulations after classical swine fever virus infection. Lee WC, et al. **Vet Microbiol** 1999 Jun 1; 67(1):17–29

ULTRASTRUCTURE

Immunohistochemical and ultrastructural evidence of hog cholera virus infection of megakaryocytes in bone marrow and spleen. Gómez-Villamandos JC, et al. **J Comp Pathol** 1998 Aug;119(2):111–9

HOG-NOSED SKUNKS see **SKUNKS**

HOGNESS BOX see **TATA BOX**

HOLIDAYS

Attempted suicide and major public holidays in Europe: findings from the WHO/EURO Multicentre Study on Parasuicide [see comments] Jessen G, et al. **Acta Psychiatr Scand** 1999 Jun;99(6):412–8. Comment in: Acta Psychiatr Scand 1999 Jun;99(6):397–8.

Contacting GP surgeries over Christmas. I will be in my surgery on Christmas day if ministers and researchers are at work too [letter] Tanner B. **BMJ** 1999 Aug 21; 319(7208):513; discussion 514

Contacting GP surgeries over Christmas. Study was ill-considered and sensationalist [letter] Young G. **BMJ** 1999 Aug 21;319(7208):513–4

Safer sex at holiday centres: providing contraceptive services to seasonal workers. Hennink M, et al. **Br J Fam Plann** 1999 Jul;25(2):45–54

Weight control during the holidays: highly consistent self-monitoring as a potentially useful coping mechanism. Baker RC, et al. **Health Psychol** 1998 Jul;17(4):367–70

How can obese weight controllers minimize weight gain during the high risk holiday season? By self-monitoring very consistently. Boutelle KN, et al. **Health Psychol** 1999 Jul;18(4):364–8

The dangers of taking 'T in the country'. Kerr GW, et al. **Scott Med J** 1998 Aug;43(4):107–8

[Report from the medical tent at three rock festivals. Lots of music, great fun and very little drunkeness] Forrest RD. **Lakartidningen** 1999 Jun 9;96(23):2874–6 (Eng. Abstr.) **(Swe)**

HISTORY

Labor Day and the war on workers. Rosner D, et al. **Am J Public Health** 1999 Sep;89(9):1319–21

PSYCHOLOGY

Season's greetings: adults' social contacts at the holiday season. Fingerman KL, et al. **Psychol Aging** 1999 Jun; 14(2):192–205

HOLISTIC HEALTH

Barbara Dossey, RN, MS on holistic nursing, Florence Nightingale, and healing rituals [interview by Bonnie Horrigan] Dossey B. **Altern Ther Health Med** 1999 Jan; 5(1):78–86

Michael Murray, ND a natural approach to health [interview by Bonnie Horrigan] [see comments] Murray M. **Altern Ther Health Med** 1999 Mar;5(2):76–84. Comment in: Altern Ther Health Med 1999 Jul;5(4):18; discussion 20, 22. Comment in: Altern Ther Health Med 1999 Jul;5(4):18–9; discussion 20, 22.

The Osher Center for Integrative Medicine at UCSF: healing the whole person with 'relationship-centered' medicine. Muscat M. **Altern Ther Health Med** 1999 Mar;5(2):36–7

Parkinson's disease. A holistic approach. Barker S, et al. **Am J Nurs** 1998 Nov;98(11):48A–48G; quiz 48G–48H (27 ref.)

A change of heart. Leighton C. **Am J Nurs** 1998 Oct; 98(10):33–7

Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Ehman JW, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1803–6

Knowledge and intuition. Hassed C. **Aust Fam Physician** 1999 May;28(5):505–6

The body is the shadow of the soul. Hassed C. **Aust Fam Physician** 1999 Jun;28(6):613–4 (11 ref.)

Niches. Holy-stic health [news] Blecher MB. **Hosp Health Netw** 1999 Feb;73(2):22

Holistic help. No pain, big gain. Douglass K. **Hosp Health Netw** 1998 Oct 20;72(20):38–40

Upstarts. Send in the clown [news] Santoro J. **Hosp Health Netw** 1999 Apr;73(4):14

Holistic doctoral education for holistic nursing [letter] Heinrich KT. **Image J Nurs Sch** 1998;30(4):308–9

Health-within-illness: concept development through research and practice. Moch SD. **J Adv Nurs** 1998 Aug; 28(2):305–10 (38 ref.)

Inclusive spirituality [editorial; comment] [see comments] Thomason CL, et al. **J Fam Pract** 1999 Feb;48(2):96–7. Comment on: J Fam Pract 1999 Feb;48(2):98–104. Comment in: J Fam Pract 1999 May;48(5):389. Comment in: J Fam Pract 1999 Jul;48(7):501–3.

Social and political dis-ease. Frankford DM. **J Health Polit Policy Law** 1999 Feb;24(1):181–96 (19 ref.)

Promoting holistic child development: a collaborative school health approach. Haynes NM. **J Sch Health** 1998 Nov; 68(9):381–3 (9 ref.)

Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. MacKeigan LD, et al. **Med Decis Making** 1999 Apr–Jun;19(2):113–21

Models of intervention in menopause: proposal of a holistic or integral model. Olazábal Ulacia JC, et al. **Menopause** 1999 Fall;6(3):264–72 (50 ref.)

A journey into wholistic medicine [editorial] Mills JW. **Pa Med** 1999 Jun;102(6):6

Holistic pediatrics: a research agenda. Kemper KJ, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):902–9

Biological filtering and ecological machinery for self-purification and bioremediation in aquatic ecosystems: towards a holistic view. Ostroumov SA. **Riv Biol** 1998; 91(2):221–32

The meaning of 'holistic' [letter] Zaaijman JT. **S Afr Med J** 1999 May;89(5):500

The holistic health movement in the San Francisco Bay area: some preliminary observations. Baer HA, et al. **Soc Sci Med** 1998 Nov;47(10):1495–501

A holistic approach to the economic evaluation of health programs using institutionalist methodology. Jan S. **Soc Sci Med** 1998 Nov;47(10):1565–72

Complementary/alternative and conventional medicine. Rodgers-Johnson PE. **West Indian Med J** 1998 Dec; 47(4):162–4

[Person, body, cadaver, and back] Carlino A. **Rev Med Suisse Romande** 1998 Dec;118(12):1035–41 **(Fre)**

[The provoking dimension of pain. From somatoform pain disorder to a phenomenological approach to illness] Célis-Gennart M. **Rev Med Suisse Romande** 1999 Apr; 119(4):273–80 (17 ref.) **(Fre)**

[A model for holistically thinking male and female dentists (news)] **Schweiz Monatsschr Zahnmed** 1998;108(9):892–3 **(Ger)**

[Holistic support of mother and child in the puerprium or: mother is more than "not a patient"] Barz S, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:41–2 **(Ger)**

[Bioethics and internal medicine] Soldini M. **Clin Ter** 1998 Sep–Oct;149(5):365–8 (Eng. Abstr.) **(Ita)**

[Homeopathy or "viagra" (letter)] Cortada Villuendas LM. **Aten Primaria** 1998 Dec;22(10):668 **(Spa)**

HOLISTIC NURSING

Nursing the patient within. Folsom D. **Am J Nurs** 1999 Jul; 99(7):80

The ecologies of community caring. Bent KN. **ANS Adv Nurs Sci** 1999 Jun;21(4):29–36

Sailing beyond: nursing theory and the person. Drevdahl D. **ANS Adv Nurs Sci** 1999 Jun;21(4):1–13

The challenges of a care information system reflecting holistic nursing care. Büssing A, et al. **Comput Nurs** 1998 Nov–Dec;16(6):311–7; quiz 318–9

A review of spirituality as applied to nursing. Narayanasamy A. **Int J Nurs Stud** 1999 Apr;36(2):117–25 (38 ref.)

Story telling as a tool for providing holistic care to women. Banks-Wallace J. **MCN Am J Matern Child Nurs** 1999 Jan–Feb;24(1):20–4 (28 ref.)

Psychoneuroimmunology and preterm birth. A holistic model for obstetrical nursing practice and research. Ruiz RJ, et al. **MCN Am J Matern Child Nurs** 1999 Sep–Oct; 24(5):230–5; quiz 236

EDUCATION

Holistic doctoral education for holistic nursing [letter] Heinrich KT. **Image J Nurs Sch** 1998;30(4):308–9

HOLISTIC NURSING

METHODS

As uniquely trained holistic caregivers, DOs have duty to overweight patients [editorial; comment] Perkins RC. **J Am Osteopath Assoc** 1999 Jul;99(7):357. Comment on: J Am Osteopath Assoc 1999 Jul;99(7):358–65. Comment on: J Am Osteopath Assoc 1999 Jul;99(7):366–70.

ORGANIZATION & ADMINISTRATION

Healing the mind–body and nursing specialty splits. Conference regarding the "Blended" role in psychiatric/mental health nursing. June 5, 1998—University of Massachusetts, Lowell. Hoff LA, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Oct; 36(10):38–44

HOLMES–ADIE SYNDROME see **ADIE'S SYNDROME**

HOLMIUM

BLOOD

Metal–ion speciation in blood plasma incorporating the bisphosphonate, 1–hydroxy–4–aminopropylydenediphosphonate (APD), in therapeutic radiopharmaceuticals. Zeevaart JR, et al. **J Inorg Biochem** 1999 Apr;73(4):265–72

PHARMACOKINETICS

Biodistribution and kinetics of holmium–166–chitosan complex (DW–166HC) in rats and mice. Suzuki YS, et al. **J Nucl Med** 1998 Dec;39(12):2161–6

THERAPEUTIC USE

Treatment of multifocal Bowen's disease with a specially designed radioactive skin patch [letter] Chung HS, et al. **Br J Dermatol** 1998 Nov;139(5):938–9

Holmium–166 poly lactic acid microspheres applicable for intra–arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Nijsen JF, et al. **Eur J Nucl Med** 1999 Jul;26(7):699–704

HOLOCAUST

see related
CONCENTRATION CAMPS

Holocaust victims are discharged into the community [news] Siegel–Itzkovich J. **BMJ** 1999 Jan 16;318(7177):146

Holocaust survivors hospitalized for life: the Israeli experience. Terno P, et al. **Compr Psychiatry** 1998 Nov–Dec;39(6):364–7

Listening psychoanalytically to the Shoah half a century on. Wilgowicz P. **Int J Psychoanal** 1999 Jun;80 (Pt 3):429–38

Chronic pain in Holocaust survivors. Yaari A, et al. **J Pain Symptom Manage** 1999 Mar;17(3):181–7

Book review essay: mentalizing negative spaces in the wake of the Holocaust. Spero MH. **Psychoanal Q** 1998 Oct; 67(4):698–713

Resilience in child survivors of the Holocaust: toward the concept of resilience. Valent P. **Psychoanal Rev** 1998 Aug; 85(4):517–35 (33 ref.)

Holocaust survivors' perspectives on the euthanasia debate. Leichtentritt RD, et al. **Soc Sci Med** 1999 Jan;48(2):185–96

HISTORY

Care of the medical ethos: reflections on Social Darwinism, racial hygiene, and the Holocaust. Barondess JA. **Ann Intern Med** 1998 Dec 1;129(11):891–8

The Nuremberg doctors' trial in historical context. Marrus MR. **Bull Hist Med** 1999 Spring;73(1):106–23

Psychological mechanisms of violent behavior against children. Tomkiewicz S. **Child Abuse Negl** 1998 Oct; 22(10):947–57

PSYCHOLOGY

The American Indian Holocaust: healing historical unresolved grief. Brave Heart MY, et al. **Am Indian Alsk Native Ment Health Res** 1998;8(2):56–78 (90 ref.)

Posttraumatic stress disorder in children of Holocaust survivors [letter; comment] Sigal J. **Am J Psychiatry** 1999 Aug;156(8):1295. Comment on: Am J Psychiatry 1998 Jun;155(6):841–3.

Countertransference and life–and–death issues in group psychotherapy with child Holocaust survivors. Tauber Y, et al. **Am J Psychother** 1998 Summer;52(3):301–12

Psychodynamic–supportive group therapy model for elderly Holocaust survivors. Müller U, et al. **Int J Group Psychother** 1998 Oct;48(4):461–75 (41 ref.)

Amnestic state in a Holocaust survivor patient: psychogenic versus neurological basis. Durst R, et al. **Isr J Psychiatry Relat Sci** 1999;36(1):47–54

Diagnosis of Holocaust survivors and their children. Kellermann NP. **Isr J Psychiatry Relat Sci** 1999;36(1):55–64 (38 ref.)

Case series: PTSD symptoms in adolescent survivors of "ethnic cleansing." Results from a 1–year follow–up study. Becker DF, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jun;38(6):775–81

Reflections on countertransference in psychoanalytic work with child survivors of the Shoah. Gampel Y. **J Am Acad Psychoanal** 1998 Fall;26(3):343–68

Group belonging and mourning as factors in resilience in second generation of Holocaust survivors. Fogelman E. **Psychoanal Rev** 1998 Aug;85(4):537–49

Trauma and identity through two generations of the Holocaust. Hogman F. **Psychoanal Rev** 1998 Aug; 85(4):551–78

Long–term effects of the Holocaust: empirical evidence for resilience in the first, second, and third generation. Sigal JJ. **Psychoanal Rev** 1998 Aug;85(4):579–85

The psychiatric after–effects of the Holocaust on the second generation [editorial] Levav I, et al. **Psychol Med** 1998 Jul; 28(4):755–60

HOLOENZYMES

ANALYSIS

Quantitation of RNA polymerase II and its transcription factors in an HeLa cell: little soluble holoenzyme but significant amounts of polymerases attached to the nuclear substructure. Kimura H, et al. **Mol Cell Biol** 1999 Aug; 19(8):5383–92

CHEMISTRY

UDP–galactose 4–epimerase from Kluyveromyces fragilis: reconstitution of holoenzyme structure after dissociation with parachloromercuribenzoate. Majumdar S, et al. **Eur J Biochem** 1998 Oct 15;257(2):427–33

GENETICS

A mutation in region 1.1 of sigma70 affects promoter DNA binding by Escherichia coli RNA polymerase holoenzyme. Bowers CW, et al. **EMBO J** 1999 Feb 1;18(3):709–16

METABOLISM

Recruitment of the RNA polymerase II holoenzyme and its implications in gene regulation. Barberis A, et al. **Biol Chem** 1998 Dec;379(12):1397–405 (82 ref.)

A mutation in region 1.1 of sigma70 affects promoter DNA binding by Escherichia coli RNA polymerase holoenzyme. Bowers CW, et al. **EMBO J** 1999 Feb 1;18(3):709–16

Differential inhibition of transcription from sigma70– and sigma32–dependent promoters by rifampicin. Węgrzyn A, et al. **FEBS Lett** 1998 Nov 27;440(1–2):172–4

Sequences in sigmaN determining holoenzyme formation and properties. Gallegos MT, et al. **J Mol Biol** 1999 May 14; 288(4):539–53

In vitro selection of sequence contexts which enhance bypass of abasic sites and tetrahydrofuran by T4 DNA polymerase holoenzyme. Hatahet Z, et al. **J Mol Biol** 1999 Mar 5; 286(4):1045–57

Mg2+ induces conformational changes in the catalytic subunit of phosphorylase kinase, whether by itself or as part of the holoenzyme complex. Wilkinson DA, et al. **J Protein Chem** 1999 Feb;18(2):157–64

Interactions of protein kinase CK2beta subunit within the holoenzyme and with other proteins. Kusk M, et al. **Mol Cell Biochem** 1999 Jan;191(1–2):51–8

Histone acetyltransferase and protein kinase activities copurify with a putative Xenopus RNA polymerase I holoenzyme self–sufficient for promoter–dependent transcription. Albert AC, et al. **Mol Cell Biol** 1999 Jan; 19(1):796–806

An activator binding module of yeast RNA polymerase II holoenzyme. Lee YC, et al. **Mol Cell Biol** 1999 Apr; 19(4):2967–76

Characterisation of holoenzyme lacking sigmaN regions I and II. Cannon W, et al. **Nucleic Acids Res** 1999 Jun 15; 27(12):2478–86

Simultaneous formation of functional leading and lagging strand holoenzyme complexes on a small, defined DNA substrate. Berdis AJ, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11128–33

Efficient recruitment of TFIIB and CBP–RNA polymerase II holoenzyme by an interferon–beta enhanceosome in vitro. Kim TK, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12191–6

HOLOGRAPHY

High sensitive multiresolution analysis of low–contrast radiologic images based on the digital pseudocoherent holographic interferometry method. Akhmetshin AM. **J Digit Imaging** 1999 May;12(2 Suppl 1):197–8

Ternary pseudorandom encoding of Fourier transform holograms [published erratum appears in J Opt Soc Am A Opt Image Sci Vis 1999 May;16(5):1089] Cohn RW, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 Jan;16(1):71–84

METHODS

A holographic sensor based on a rationally designed synthetic polymer. Mayes AG, et al. **J Mol Recognit** 1998 Winter; 11(1–6):168–74

In–line holography and phase–contrast microtomography with high energy x–rays. Spanne P, et al. **Phys Med Biol** 1999 Mar;44(3):741–9

HOLOPROSENCEPHALY

Holoprosencephaly: a defect in brain patterning. Golden JA. **J Neuropathol Exp Neurol** 1998 Nov;57(11):991–9 (96 ref.)

CHEMICALLY INDUCED

Cyclopamine–induced holoprosencephaly and associated craniofacial malformations in the golden hamster: anatomic and molecular events. Coventry S, et al. **Pediatr Dev Pathol** 1998 Jan–Feb;1(1):29–41

COMPLICATIONS

Unusually prolonged survival and childhood–onset epilepsy in a case of alobar holoprosencephaly. Veneselli E, et al. **Childs Nerv Syst** 1999 May;15(5):274–7

[Holoprosencephaly with neurogenic hypernatremia] Cuisset JM, et al. **Arch Pediatr** 1999 Jan;6(1):43–5 (7 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Aventriculi associated with holoprosencephaly. Nuri Sener R. **Comput Med Imaging Graph** 1998 Jul–Aug;22(4):345–7

Mediobasal and mantle defect of the prosencephalon: lobar holoprosencephaly, schizencephaly and diabetes insipidus. Sztriha L, et al. **Neuropediatrics** 1998 Oct;29(5):272–5

[Holoprosencephaly with neurogenic hypernatremia] Cuisset JM, et al. **Arch Pediatr** 1999 Jan;6(1):43–5 (7 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Ectopic bone morphogenetic proteins 5 and 4 in the chicken forebrain lead to cyclopia and holoprosencephaly. Golden JA, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2439–44

GENETICS

Isolation of a 370 kb YAC fragment spanning a translocation breakpoint at 3p14.1 associated with holoprosencephaly. Petek E, et al. **Clin Genet** 1998 Nov;54(5):406–12

Holoprosencephaly: a paradigm for the complex genetics of brain development. Roessler E, et al. **J Inherit Metab Dis** 1998 Aug;21(5):481–97 (129 ref.)

Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd–paired. Brown SA, et al. **Nat Genet** 1998 Oct;20(2):180–3

Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Wallis DE, et al. **Nat Genet** 1999 Jun;22(2):196–8

[Neural tube defects and holoprosencephaly] Shiota K, et al. **No To Shinkei** 1999 Aug;51(8):659–66 (26 ref.) **(Jpn)**

PATHOLOGY

Syntelencephaly associated with connected transhemispheric cleft of focal cortical dysplasia. Fujimoto S, et al. **Pediatr Neurol** 1999 May;20(5):387–9

ULTRASONOGRAPHY

Holoprosencephaly in a Klinefelter fetus [letter] Armbruster–Moraes E, et al. **Am J Med Genet** 1999 Aug 27;85(5):511–2

First trimester sonographic diagnosis of holoprosencephaly. Tongsong T, et al. **Int J Gynaecol Obstet** 1999 Aug; 66(2):165–9

Prenatal diagnosis of alobar holoprosencephaly at 10 weeks of gestation. Turner CD, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):360–2

First–trimester ultrasound diagnosis of holoprosencephaly: three case reports. Wong HS, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):356–9

HOLOTHUROIDEA see **SEA CUCUMBERS**

HOLTER MONITORING see **ELECTROCARDIOGRAPHY, AMBULATORY**

HOLTZMAN INKBLOT TEST

STATISTICS & NUMERICAL DATA

The effects of violent media on adolescent inkblot responses: implications for clinical and forensic assessments. Hess TH, et al. **J Clin Psychol** 1999 Apr;55(4):439–45

HOME ACCIDENTS see **ACCIDENTS, HOME**

HOME BLOOD GLUCOSE MONITORING see **BLOOD GLUCOSE SELF–MONITORING**

HOME CARE AGENCIES

[Home–oxygen therapy and QOL support for the in the home setting patient] Saito N. **Gan To Kagaku Ryoho** 1998 Dec; 25 Suppl 4:511–4 (Eng. Abstr.) **(Jpn)**

[What 100 HPN patients taught us] Watanabe M, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:515–8 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Home health. Keeping the lights on [news] **Hosp Health Netw** 1998 Nov 5;72(21):18

Unhappy landings. Health care feels the fallout from Washington's 1997 balanced budget. Blecher MB.

Hosp Health Netw 1998 Nov 20;72(22):24–6, 28, 3

ORGANIZATION & ADMINISTRATION

A physician/advanced practice nurse home visiting program. Morgan MF. **N J Med** 1999 Sep;96(9):51–3

STATISTICS & NUMERICAL DATA

Home care. Anybody home? [news] **Hosp Health Netw** 1998 Sep 20;72(18):12

HOME CARE AIDES see **HOME HEALTH AIDES**

HOME CARE, NON-PROFESSIONAL see **HOME NURSING**

HOME CARE SERVICES

Elderly people at home disabled by chronic obstructive pulmonary disease. Yohannes AM, et al. **Age Ageing** 1998 Jul;27(4):523–5

Telephone monitoring after early discharge for cardiac surgery patients. Savage LS, et al. **Am J Crit Care** 1999 May;8(3):154–9 (14 ref.)

Factors influencing compliance with home exercise programs among patients with upper-extremity impairment. Chen CY, et al. **Am J Occup Ther** 1999 Mar–Apr;53(2):171–80

The need for a home hygiene policy and guidelines on home hygiene. Beumer R, et al. **Ann Ig** 1999 Jan–Feb;11(1):11–26

Stem cell transplant at home: glimpse of the future [editorial; comment] Reed E, et al. **Ann Oncol** 1999 May;10(5):493–4
Comment on: Ann Oncol 1999 May;10(5):511–7.

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies [see comments] Westermann AM, et al. **Ann Oncol** 1999 May;10(5):511–7
. Comment in: Ann Oncol 1999 May;10(5):493–4.

Effectiveness of home exercise on pain and disability from osteoarthritis of the knee: a randomised controlled trial. O'Reilly SC, et al. **Ann Rheum Dis** 1999 Jan;58(1):15–9

Home-based multicomponent rehabilitation program for older persons after hip fracture: a randomized trial. Tinetti ME, et al. **Arch Phys Med Rehabil** 1999 Aug;80(8):916–22

Home health care: a new challenge for clinical engineers. Anderson JT. **Biomed Instrum Technol** 1999 Mar–Apr; 33(2):121–4

Home treatment with recombinant activated factor VII: results from one centre. Ingerslev J, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S107–10

Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Stewart AJ, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S93–5

A randomised trial of hospital versus home administered enemas for flexible sigmoidoscopy. Lund JN, et al. **BMJ** 1998 Oct 31;317(7167):1201

Provision of oxygen at home. Rees PJ, et al. **BMJ** 1998 Oct 3;317(7163):935–8 (0 ref.)

Shifting care: GP opinions of hospital at home. Hood S, et al. **Br J Gen Pract** 1999 Mar;49(440):221–2

Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Sutanto A, et al. **Bull World Health Organ** 1999; 77(2):119–26

Domiciliary oxygen and smoking: an explosive combination. Muehlberger T, et al. **Burns** 1998 Nov;24(7):658–60

Frequency, causes, and outcome of home ventilator failure. Srinivasan S, et al. **Chest** 1998 Nov;114(5):1363–7

Home oxygen therapy for chronic lung disease in very low-birth-weight infants. Chang JH, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul–Aug;39(4):237–41

The home management of preterm premature ruptured membranes. Bartfield MC, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):503–14 (38 ref.)

Psychosocial impact of high-risk pregnancy: hospital and home care. Heaman M. **Clin Obstet Gynecol** 1998 Sep; 41(3):626–39 (52 ref.)

Computer network home care demonstration: a randomized trial in persons living with AIDS. Flatley-Brennan P. **Comput Biol Med** 1998 Sep;28(5):489–508

What does a home mean and when does it cease to be a home? Home as a setting for rehabilitation and care. Tamm M. **Disabil Rehabil** 1999 Feb;21(2):49–55 (33 ref.)

Rehabilitation in the home versus the hospital: the importance of context. von Koch L, et al. **Disabil Rehabil** 1998 Oct; 20(10):367–72

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Seremetis S, et al. **Haemophilia** 1999 Jan;5(1):9–16

A telemanagement system for home follow-up of respiratory patients. Morlion B, et al. **IEEE Eng Med Biol Mag** 1999 Jul–Aug;18(4):71–9

The use of the SelfCARE(D) as a screening tool for depression in the clients of local authority home care services--a preliminary study. Banerjee S, et al. **Int J Geriatr Psychiatry** 1998 Oct;13(10):695–9

Methodology of home planning within interdisciplinary team. Bouveron-Bonnevialle C, et al. **Int J Rehabil Res** 1998 Mar;21(1):97–101

Relationships between family dynamics of Finnish child-rearing families, factors causing strain and received support. Hakulinen T, et al. **J Adv Nurs** 1999 Feb; 29(2):407–15

Narcotic theft [letter] Kakaiya R, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):181

Special fraud alert. **J Ark Med Soc** 1999 Feb;95(9):380–3

Functional status of elderly home care users: do subjects, informal and professional caregivers agree? Santos-Eggimann B, et al. **J Clin Epidemiol** 1999 Mar; 52(3):181–6

Assessing community attitude towards home-based care for people with AIDS (PWAs) in Kenya. Olenja JM. **J Community Health** 1999 Jun;24(3):187–99

Postpartum home visits: infant outcomes. Frank-Hanssen MA, et al. **J Community Health Nurs** 1999;16(1):17–28

Maternal and infant health problems after normal childbirth: a randomised controlled study in Zambia. Ransjö-Arvidson AB, et al. **J Epidemiol Community Health** 1998 Jun; 52(6):385–91

Older persons' preferences for site of treatment in acute illness. Fried TR, et al. **J Gen Intern Med** 1998 Aug; 13(8):522–7

Going home: community reentry of light care nursing facility residents age 65 and over. Chapin R, et al. **J Health Care Finance** 1998 Winter;25(2):35–48

Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. Do AN, et al. **J Infect Dis** 1999 Feb;179(2):442–8

Right ventricular impairment in patients with chronic respiratory failure on home oxygen therapy--non-invasive assessment using a new Doppler index. Yamaguchi K, et al. **J Int Med Res** 1998 Oct-Nov;26(5):239–47

An early intervention program for adolescent mothers: a nursing demonstration project. Koniak-Griffin D, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):51–9

Home visits: strategies to protect the breastfeeding newborn at risk. Locklin MP, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):33–40

A randomized, controlled trial of nurse home visiting to vulnerable families with newborns. Armstrong KL, et al. **J Paediatr Child Health** 1999 Jun;35(3):237–44

The interaction between family physicians and palliative care consultants in the delivery of palliative care: clinical and educational issues. Brenneis C, et al. **J Palliat Care** 1998 Autumn;14(3):58–61 (21 ref.)

Terminal HIV disease and extreme poverty: a review of 307 home care files. Daneault S, et al. **J Palliat Care** 1999 Spring;15(1):6–12

Integration of pain education in home care. Ferrell BR, et al. **J Palliat Care** 1998 Autumn;14(3):62–8

Palliative care education for community-based family physicians: the development of a program, the evaluation, and its consequences. Hall P, et al. **J Palliat Care** 1998 Autumn;14(3):69–74

Congruence between patients' and family caregivers' perceptions of symptom distress in patients with terminal cancer. Kristjanson LJ, et al. **J Palliat Care** 1998 Autumn; 14(3):24–32

Home care for children with life-threatening illness. Liben S, et al. **J Palliat Care** 1998 Autumn;14(3):33–8 (36 ref.)

Nursing interventions for newly diagnosed older cancer patients facing terminal illness. McCorkle R, et al. **J Palliat Care** 1998 Autumn;14(3):39–45

Home care: images and reflections [editorial] Roy DJ. **J Palliat Care** 1998 Autumn;14(3):3–5

Community education in palliative medicine. Shvartzman P, et al. **J Palliat Care** 1998 Autumn;14(3):75–8 (26 ref.)

Assessment and management of patients who refuse life-prolonging treatments [letter; comment] Thorns A, et al. **J Palliat Care** 1998 Autumn;14(3):102–3. Comment on: J Palliat Care 1998 Spring;14(1):18–24.

Psychosocial needs of patients and families. Vachon ML. **J Palliat Care** 1998 Autumn;14(3):49–56 (43 ref.)

Telespirometry for home monitoring of pulmonary function [letter] Izbicki G, et al. **J R Soc Med** 1999 Mar;92(3):154–5

Home telecare. Ruggiero C, et al. **J Telemed Telecare** 1999; 5(1):11–7 (17 ref.)

The value of targeted case management during transitional care [editorial; comment] Boling PA. **JAMA** 1999 Feb 17; 281(7):656–7. Comment on: JAMA 1999 Feb 17;281(7):613–20.

Care paths. A new approach to high-risk maternal-child home visitation. Lowry LM, et al. **MCN Am J Matern Child Nurs** 1998 Nov-Dec;23(6):322–8

Fully automated health monitoring system in the home. Tamura T, et al. **Med Eng Phys** 1998 Nov;20(8):573–9

Features for a B-ISDN telemedicine system and its application. Choi J, et al. **Medinfo** 1998;9 Pt 1:307–10

A study on development of a home health care support information system. Inada H, et al. **Medinfo** 1998;9 Pt 1:269–71

Home telecare system integrated with periodic health reminder and medical record & multimedia health information. Yoo T, et al. **Medinfo** 1998;9 Pt 1:265–8

Networking rural health resources. The woman who cried wolf. Ferenz L, et al. **N C Med J** 1998 Nov-Dec; 59(6):354–6

Adult domiciliary oxygen therapy: position statement of the Thoracic Society of Australia and New Zealand. Young IH, et al. **N Z Med J** 1999 Jan 22;112(1080):15–8

Home care: addressing the needs of people living with AIDS and their caregivers. Baker S. **Nurs Clin North Am** 1999 Mar;34(1):201–12 (43 ref.)

Discharge planning and home follow-up of the elderly patient with heart failure. Campbell RL, et al. **Nurs Clin North Am** 1998 Sep;33(3):497–513 (12 ref.)

Putting infection control principles into practice in home care. Friedman MM, et al. **Nurs Clin North Am** 1999 Jun; 34(2):463–82 (22 ref.)

Urinary incontinence among elderly persons who live at home: a literature review. Steeman E, et al. **Nurs Clin North Am** 1998 Sep;33(3):441–55 (63 ref.)

Anticipating blood transfusions in the home: a safe and efficient approach. O'Gara K, et al. **Oncol Nurs Forum** 1999 Jun;26(5):832–3

Effect of number of home exercises on compliance and performance in adults over 65 years of age. Henry KD, et al. **Phys Ther** 1999 Mar;79(3):270–7

Designing HeartCare: custom computerized home care for patients recovering from CABG surgery. Brennan PF, et al. **Proc AMIA Symp** 1998;:381–5

Direct and buffering effects of social support on depressive symptoms of the elderly with home help. Hashimoto K, et al. **Psychiatry Clin Neurosci** 1999 Feb;53(1):95–100

Home intervention for in utero drug-exposed infants. Butz AM, et al. **Public Health Nurs** 1998 Oct;15(5):307–18

Predictors of elders' and family caregivers' use of formal home services. Houde SC. **Res Nurs Health** 1998 Dec; 21(6):533–43

Service delivery challenges of nursing research in home health care. Madigan EA, et al. **Res Nurs Health** 1999 Aug; 22(4):349–53

Starting home nebulizer therapy: patients' expectations and subsequent outcome at 2 months. Simpson AJ, et al. **Respir Med** 1998 Aug;92(8):1000–2

Full polysomnography in the home. Fry JM, et al. **Sleep** 1998 Sep 15;21(6):635–42

Home treatment of COPD exacerbations. Postma DS, et al. **Thorax** 1999 Aug;54 Suppl 2:S8–13 (39 ref.)

Quality-of-life in technology-dependent children receiving home care, and their families--a qualitative study. Baumgardner DJ, et al. **WMJ** 1998 Sep;97(8):51–5

[Home enteral and parenteral nutrition] Ginies JL. **Arch Pediatr** 1999;6 Suppl 2:147s–148s **(Fre)**

[Instrumental management of chronic respiratory insufficiency: contribution of long-term therapeutic assistance at home] Muir JF, et al. **Bull Acad Natl Med** 1998;182(6):1139–56; discussion 1156–8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Attitude of general practitioners facing patients at the end of life in home care] Noel K, et al. **Presse Med** 1999 Apr 3;28(13):692–4 (Eng. Abstr.) **(Fre)**

[Home management of chronic respiratory insufficiency. Oxygen inhalation therapy] Chaouat A, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S186–7 **(Fre)**

[Hygiene and disinfection best practices for home assisted respiratory care] Gautier V. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S141–2 **(Fre)**

[Home management of chronic respiratory insufficiency. Non-invasive ventilation at home] Ordronneau J, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S185–6 **(Fre)**

[Characteristics of patients with domiciliary equipment for chronic respiratory diseases in Martinique] Chenu E, et al. **Rev Pneumol Clin** 1998 Oct;54(5):245–50 (Eng. Abstr.) **(Fre)**

[Community integrated living with reliable care in the service home: the status of young handicapped patients in a model project "House at Weinberg" in Stuttgart] Gerngross-Haas G. **Rehabilitation (Stuttg)** 1999 May;38(2):100–6 (Eng. Abstr.) **(Ger)**

[Management of dementia patients and their relatives: report from the routine practice of a family physician] Michel E. **Ther Umsch** 1999 Feb;56(2):104–8 (Eng. Abstr.) **(Ger)**

[Problems in training home care nurses] Aakanuma T. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:561–4 (Eng. Abstr.) **(Jpn)**

[Terminal home care "Ikigai no Yoake--The real aim of our life"--case report] Funato T, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:579–84 (Eng. Abstr.) **(Jpn)**

[Life supports for terminal cancer patients] Kifune M, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:656–60 (Eng. Abstr.) **(Jpn)**

[Relation with patients and caregiver in home enteral nutrition (HEN)--from a pharmacist's point of view] Kimura M. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:569–71 (Eng. Abstr.) **(Jpn)**

[The current situation surrounding pharmacies and pharmacists] Kushida K. **Gan To Kagaku Ryoho** 1998 Dec; 25 Suppl 4:572–5 (Eng. Abstr.) **(Jpn)**

[Three patients with terminal gastric cancer who achieved good QOL through home hospice care] Muto Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:665–8 (Eng. Abstr.) **(Jpn)**

[Current status of cancer pain control in home hospice care--assessment by family members] Okuyama H, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:605–9 (Eng. Abstr.) **(Jpn)**

[Death at home: home care for terminal cancer patients] Sakuyama T, et al. **Gan To Kagaku Ryoho** 1998 Dec;25

Suppl 4:675–8 (Eng. Abstr.) **(Jpn)**

[Benefits and problems of "home care score"—discussion of deviation from home care] Shibuya R, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:640–5 (Eng. Abstr.) **(Jpn)**

[Home medical treatment for a distant patients with terminal cancer—close teamwork with a regional visiting nurse station] Shioya A, et al. **Gan To Kagaku Ryoho** 1998 Dec; 25 Suppl 4:586–8 (Eng. Abstr.) **(Jpn)**

[Role of the visiting nurse in pain control for the terminal cancer patient at home] Uemura Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:611–4 (Eng. Abstr.) **(Jpn)**

[MRSA infection concured and exsited and the examination of a home cases] Yasunaga A, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:595–8 (Eng. Abstr.) **(Jpn)**

[Evaluation of home-oxygen-therapy for old tuberculosis cases, especially emphasis on the medical support for more comfortable life] Kuraoka T, et al. **Kekkaku** 1998 Dec; 73(12):747–9 (Eng. Abstr.) **(Jpn)**

[The health and welfare system for elderly in France] Sauvaget C, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul; 45(7):664–74 (Eng. Abstr.) **(Jpn)**

[Combination care of a patient with Joseph's disease local community] Seiriki S, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):572–7 **(Jpn)**

[Effect of home visit dental health services] Takazawa M, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):915–20 **(Jpn)**

[Characteristics of home care patients with intractable neurological diseases (Nanbyo) in Tokyo] Ushikubo M, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul;45(7):653–63 (Eng. Abstr.) **(Jpn)**

[Continuous ambulatory peritoneal dialysis for therapy of late-stage kidney failure] Nakayama M, et al. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1329–34 (11 ref.) **(Jpn)**

[Home hemodialysis for therapy of late-stage kidney failure] Saito A. **Nippon Naika Gakkai Zasshi** 1998 Jul 10; 87(7):1323–8 (9 ref.) **(Jpn)**

[Home mechanical ventilation as a treatment of the sequelae of tuberculosis surgery] Prats Soro E, et al. **An Med Interna** 1998 Jan;16(1):35–7 (12 ref.) (Eng. Abstr.) **(Spa)**

[Effects of portable liquid oxygen therapy on walking] Arnedillo Muñoz A, et al. **Arch Bronconeumol** 1999 Feb; 35(2):60–3 (Eng. Abstr.) **(Spa)**

[The results of the operation of a monitoring unit for home oxygen therapy] Carrera M, et al. **Arch Bronconeumol** 1999 Jan;35(1):33–8 (Eng. Abstr.) **(Spa)**

[Better at home: a continuous health care program for patients with advanced chronic respiratory disease] Güell R, et al. **Arch Bronconeumol** 1998 Dec;34(11):541–6 (Eng. Abstr.) **(Spa)**

[Continuous oxygen therapy in interstitial lung diseases (letter; comment)] Rodriguez Becerra E, et al. **Arch Bronconeumol** 1998 Dec;34(11):565–6. Comment on: Arch Bronconeumol 1998 Feb;34(2):87–94. **(Spa)**

[Evacuative paracentesis at home (letter; comment)] Millet Sampedro M, et al. **Aten Primaria** 1999 Feb 15;23(2):100–1 . Comment on: Aten Primaria 1998 Jun 30;22(2):109–11. **(Spa)**

[Domiciliary intravenous antibiotic therapy] Hazas J, et al. **Enferm Infecc Microbiol Clin** 1998 Dec;16(10):465–70 (Eng. Abstr.) **(Spa)**

[Evaluation of the cost of home enteral nutrition in relation to different access routes] Castillo Rabaneda RM, et al. **Nutr Hosp** 1998 Nov-Dec;13(6):320–4 (Eng. Abstr.) **(Spa)**

[Satisfaction and capacitation in pediatric home care enteral nutrition] Moreno Villares JM, et al. **Nutr Hosp** 1998 Sep-Oct;13(5):240–7 **(Spa)**

[Twisted study on home care—final reply (letter)] Strang P, et al. **Lakartidningen** 1999 Sep 1;96(35):3650 **(Swe)**

[Psychosocial factors are limiting the possibility of dying at home] Thorén-Todoulos E. **Lakartidningen** 1999 Feb 3; 96(5):472–5 (Eng. Abstr.) **(Swe)**

CLASSIFICATION

Twenty care components: an educational strategy to teach nursing science. Saba VK, et al. **Medinfo** 1998;9 Pt 2:756–9

ECONOMICS

The cost of home-based care for HIV/AIDS patients in Zimbabwe. Hansen K, et al. **AIDS Care** 1998 Dec; 10(6):751–9

Physician reimbursement issues in home health care [letter; comment] Ackermann RJ, et al. **Am Fam Physician** 1999 Jul;60(1):53–4. Comment on: Am Fam Physician 1998 Nov 1;58(7):1608–14.

Medicare-financed home health care [editorial; comment] Marziano ML, et al. **Am Fam Physician** 1998 Nov 1; 58(7):1542, 1545. Comment on: Am Fam Physician 1998 Nov 1;58(7):1608–14.

Impact of home health care on health care costs and hospitalization frequency in patients with heart failure. Wilson JR, et al. **Am J Cardiol** 1999 Feb 15;83(4):615–7, A10

Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer [see comments] Witteveen PO, et al. **Ann Oncol** 1999 Feb;10(2):161–5. Comment in: Ann Oncol 1999 Feb;10(2):135–6.

Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Mann WC, et al. **Arch Fam Med** 1999 May-Jun;8(3):210–7

Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective? Heaney LG, et al. **BMJ** 1999 Jul 3;319(7201):19–23

Cost-effectiveness analysis of a home-based social work intervention for children and adolescents who have deliberately poisoned themselves. Results of a randomised controlled trial. Byford S, et al. **Br J Psychiatry** 1999 Jan; 174:56–62

Home-based versus hospital-based care for serious mental illness. Controlled cost-effectiveness study over four years. Knapp M, et al. **Br J Psychiatry** 1998 Jun;172:506–12

Home is where the health care is [letter; comment] Montalto M. **CMAJ** 1999 Aug 24;161(4):365–6. Comment on: CMAJ 1999 Apr 20;160(8):1151–5.

Debating the benefits of home care [letter; comment] Mullens JE. **CMAJ** 1998 Oct 20;159(8):918–9. Comment on: CMAJ 1998 Jul 28;159(2):135–6.

The health and cost effects of substituting home care for inpatient acute care: a review of the evidence [see comments] Soderstrom L, et al. **CMAJ** 1999 Apr 20; 160(8):1151–5 (36 ref.). Comment in: CMAJ 1999 Aug 24;161(4):365–6.

Economies of scope and home healthcare [comment] Kass DI. **Health Serv Res** 1998 Oct;33(4 Pt 1):947–51. Comment on: Health Serv Res 1997 Aug;32(3):313–24.

MediCaring: development and test marketing of a supportive care benefit for older people [see comments] Lynn J, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1058–64. Comment in: J Am Geriatr Soc 1999 Sep;47(9):1153–4.

Comprehensive home care after hospitalization of elderly patients [letter] Edes T. **JAMA** 1999 Sep 22-29; 282(12):1129

Long-term care at home [letter] Somers AR. **N Engl J Med** 1999 Sep 23;341(13):1005

Home-based management can achieve intensification cost-effectively in type I diabetes. Dougherty G, et al. **Pediatrics** 1999 Jan;103(1):122–8

Home health care cuts [letter] Bradberry A. **Tex Med** 1998 Oct;94(10):12–3

[Medico-social management of severe respiratory insufficiency. Role of Associations] Voisin C. **Bull Acad Natl Med** 1998;182(6):1159–71; discussion 1172 (25 ref.) (Eng. Abstr.) **(Fre)**

[The problems of nursing and medical expenses in end-stage home therapy] Kobayashi S, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:527–30 (Eng. Abstr.) **(Jpn)**

[Is home care really more expensive? A report on costs of care is questioned] Strang P, et al. **Lakartidningen** 1999 Aug 11;96(32–33):3424–5 **(Swe)**

LEGISLATION & JURISPRUDENCE

HIPPA law on Medicare home health care plans causes confusion [letter] Hamilton GH. **WMJ** 1998 Nov;97(10):6

ORGANIZATION & ADMINISTRATION

Home telemedicine: merging the old and new ways [editorial] Jerant AF. **Am Fam Physician** 1999 Sep 15;60(4):1096, 1098

Home health care [see comments] Montauk SL. **Am Fam Physician** 1998 Nov 1;58(7):1608–14 (9 ref.). Comment in: Am Fam Physician 1999 Jul;60(1):53–4.

The U.S. home infusion market. Monk-Tutor MR. **Am J Health Syst Pharm** 1998 Oct 1;55(19):2019–25

Exercise—it's never too late: the strong-for-life program. Jette AM, et al. **Am J Public Health** 1999 Jan;89(1):66–72

The Resource Mothers Program for Maternal Phenylketonuria. St James PS, et al. **Am J Public Health** 1999 May;89(5):762–4

Nursing intervention to increase the duration of breastfeeding. Pugh LC, et al. **Appl Nurs Res** 1998 Nov; 11(4):190–4

Eligibility criteria improve children's access to long term ventilation at home [letter; comment] Snelling S. **BMJ** 1999 Jun 19;318(7199):1699. Comment on: BMJ 1999 Jan 30;318(7179):295–9.

Home care clients, providers and costs. Alcock D, et al. **Can J Public Health** 1998 Sep-Oct;89(5):297–300

How many visits by health professionals are needed to make a difference in low birthweight? A dose-response study of the Toronto Healthiest Babies Possible program. Desjardins E, et al. **Can J Public Health** 1999 Jul-Aug; 90(4):224–8

Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home [see comments] Mercadante S. **Cancer** 1999 Apr 15;85(8):1849–58. Comment in: Cancer 1999 Apr 15;85(8):1645–8, iii.

Intensive, integrated, in-home psychiatric services. The catalyst to enhancing outpatient intervention. Woolston JL, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul; 7(3):615–33, x

House calls in Lebanon: reflections on personal experience. Sarru E, et al. **Fam Pract** 1998 Dec;15(6):571–5

Home-based multidisciplinary diagnosis and treatment of inner-city elders with dementia. Edwards DF, et al. **Gerontologist** 1999 Aug;39(4):483–8

Designing a home health care system for Alaska Natives in Anchorage. Mala TA, et al. **Int J Circumpolar Health** 1998; 57 Suppl 1:675–8

Care process and satisfaction analysis of a transmural home care program. Smeenk FW, et al. **Int J Nurs Stud** 1998 Jun;35(3):146–54

Effectiveness of preventive in-home geriatric assessment in well functioning, community-dwelling older people: secondary analysis of a randomized trial. Büla CJ, et al. **J Am Geriatr Soc** 1999 Apr;47(4):389–95

Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. Campbell AJ, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):850–3

The ten-year experience of the Palo Alto Veterans Affairs Home-Based Primary Care Program [letter] Quaglietti SE, et al. **J Am Geriatr Soc** 1999 Apr;47(4):496–7

Drug prevention with high risk families and young children. Hahn EJ, et al. **J Drug Educ** 1998;28(4):327–45

Home care by and for relatives of MS patients. Duijnstee MS, et al. **J Neurosci Nurs** 1998 Dec;30(6):356–60 (18 ref.)

Preventing adverse outcomes: a population focus. Ervin NE, et al. **J Nurs Care Qual** 1999 Aug;13(6):25–31

Palliative care services in the community: what do family doctors want? Higginson I. **J Palliat Care** 1999 Summer; 15(2):21–5

Pall-Connect: a support network for community physicians. Schroder C, et al. **J Palliat Care** 1998 Autumn;14(3):98–101

Home telecare in the United States. Kinsella A. **J Telemed Telecare** 1998;4(4):195–200 (27 ref.)

A feasibility study of video-based home telecare for clients with spinal cord injuries. Phillips VL, et al. **J Telemed Telecare** 1998;4(4):219–23

Nurse and patient reactions to a developmental home telecare system. Whitten P, et al. **J Telemed Telecare** 1998; 4(3):152–60

The potential for telemedicine in home nursing. Wootton R, et al. **J Telemed Telecare** 1998;4(4):214–8

Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial [see comments] Naylor MD, et al. **JAMA** 1999 Feb 17; 281(7):613–20. Comment in: JAMA 1999 Feb 17;281(7):656–7. Comment in: ACP J Club 1999 Sep-Oct;131(2):32.

Home-care of the dying. Qureshi R. **JPMA J Pak Med Assoc** 1999 Jan;49(1):20–2 (8 ref.)

Homecare online: a new twist on house calls. Kiel JM. **MD Comput** 1999 Jul-Aug;16(4):21–2

A physician/advanced practice nurse home visiting program. Morgan MF. **N J Med** 1999 Sep;96(9):51–3

Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Herrmann RP, et al. **Oncol Nurs Forum** 1998 Sep;25(8):1427–32

Family-level services in oncology nursing: facts, fallacies, and realities revisited. Lewis FM. **Oncol Nurs Forum** 1998 Sep;25(8):1378–88

Reconstructing organizational culture: a process using multiple perspectives. Cameron G, et al. **Public Health Nurs** 1999 Apr;16(2):96–101

Implementing nurse home visitation programs. Hanks CA, et al. **Public Health Nurs** 1999 Aug;16(4):235–45

Changes in the work and motivation of staff delivering home care services in Finland. Laamanen R, et al. **Public Health Nurs** 1999 Feb;16(1):60–71

[Terminal and palliative care at home] Saint-Laurent-Gagnon T. **Arch Pediatr** 1999;6 Suppl 2:142s–143s **(Fre)**

[Measurement of patient satisfaction admitted to the home care services of Vaud] Dubois A, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):637–46 **(Fre)**

[Medical evaluation of a home care program in Vaud. Results after one year] Pégada JE, et al. **Rev Med Suisse Romande** 1999 Aug;119(8):629–35 **(Fre)**

[Home care in psychiatry] Moldavsky D, et al. **Harefuah** 1998 Aug;135(3–4):127–30 (18 ref.) **(Heb)**

[Strategies for the development of the quality of integrated home care] Becchi MA, et al. **Minerva Med** 1998 Oct; 89(10):385–93 (Eng. Abstr.) **(Ita)**

[Training of personnel for work in home medical care and social welfare] Kikuno Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:651–5 (Eng. Abstr.) **(Jpn)**

[Role of the home health care/visiting nurse in industry: possibilities for visiting nurse station and industry cooperation] Takiguchi M. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:551–5 (Eng. Abstr.) **(Jpn)**

[History of society for family group activity for patients receiving home visiting care] Yoshizumi R, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:646–50 (Eng. Abstr.) **(Jpn)**

[Proposals for the development of home care (editorial)] Gené Badia J, et al. **Aten Primaria** 1999 Mar 15;23(4):183–4, 186 **(Spa)**

STANDARDS

Oryx and performance measurement in home care. Andrusko-Furphy KT. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2299–301

Implementation of safe practices for parenteral nutrition formulations. American Society Parenteral and Enteral Nutrition. Kumpf VJ. **Am J Health Syst Pharm** 1999 Apr

15;56(8):815-7
ASHP guidelines: minimum standard for home care pharmacies. American Society of Health-System Pharmacists. McKinnon B, et al. **Am J Health Syst Pharm** 1999 Apr 1;56(7):629-38
Use of pharmacists' cognitive services in home health care assessment. Reese L, et al. **Am J Health Syst Pharm** 1999 May 1;56(9):884-6
Benefits of home health care after inpatient rehabilitation for hip fracture: health service use by Medicare beneficiaries, 1987-1992. Intrator O, et al. **Arch Phys Med Rehabil** 1998 Oct;79(10):1195-9
Prenatal and infancy home visitation by nurses: recent findings. Olds DL, et al. **Future Child** 1999 Spring-Summer; 9(1):44-65, 190-1
Waste watch. Home's where the harm is. Starobin N. **Hosp Health Netw** 1998 Nov 20;72(22):48
Elderly community residents' evaluative criteria and preferences for formal and informal in-home services. Wielink G, et al. **Int J Aging Hum Dev** 1999;48(1):17-33
Quality medical management of the geriatric population using practice guidelines, physician-managed home health services, and continuous quality-improvement management strategies. Reaves LA, et al. **J Am Osteopath Assoc** 1999 May;99(5):265-9 (32 ref.)
A tale of two walls [editorial; comment] Day H, et al. **J Gen Intern Med** 1998 Oct;13(10):718-9 (15 ref.). Comment on: J Gen Intern Med 1998 Oct;13(10):705-9.
Eligibility for home care certification: what clinicians should know [see comments] Wachtel TJ, et al. **J Gen Intern Med** 1998 Oct;13(10):705-9 (24 ref.). Comment in: J Gen Intern Med 1998 Oct;13(10):718-9.
Data-driven quality improvement for HMO patients: one agency's experience with OASIS and OBQI. Adams CE, et al. **J Nurs Adm** 1998 Oct;28(10):20-5
A randomised controlled trial of home-based rehabilitation versus outpatient-based rehabilitation for patients suffering from chronic schizophrenia. Sellwood W, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 May;34(5):250-3
The complexity of everyday ethics in home health care: an analysis of social workers' decisions regarding frail elders' autonomy. Healy TC. **Soc Work Health Care** 1998; 27(4):19-37
[Strategies for the development of the quality of integrated home care] Becchi MA, et al. **Minerva Med** 1998 Oct; 89(10):385-93 (Eng. Abstr.) **(Ita)**
[Usefulness of home visits in the control and evaluation of the appropriate use of home continuous oxygen therapy] Farrero E, et al. **Arch Bronconeumol** 1998 Sep;34(8):374-8 (Eng. Abstr.) **(Spa)**
[Functional social support perceived by patients in a program of home care in rural and urban settings] Alamo Martell MC, et al. **Aten Primaria** 1999 Jun 15;24(1):26-31 (Eng. Abstr.) **(Spa)**
[Physicians are needed in palliative home care. Quality of home care should be equivalent to hospital care] Strang P. **Lakartidningen** 1999 Feb 3;96(5):438-9 **(Swe)**
[The expert evaluation of the quality of the treatment and diagnostic process in home hospitals] RLuden' VV. **Lik Sprava** 1999 Mar;(2):142-50 (Eng. Abstr.) **(Ukr)**

STATISTICS & NUMERICAL DATA

Injuries in home health care workers: an analysis of occupational morbidity from a state compensation database. Meyer JD, et al. **Am J Ind Med** 1999 Mar;35(3):295-301
How commonly are children hospitalized for asthma eligible for care in alternative settings? McConnochie KM, et al. **Arch Pediatr Adolesc Med** 1999 Jan;153(1):49-55
Which physicians make home visits and why? A survey. Bergeron R, et al. **CMAJ** 1999 Aug 24;161(4):369-73
Compliance and medication knowledge among elderly Japanese home-care recipients. Okuno J, et al. **Eur J Clin Pharmacol** 1999 Apr;55(2):145-9
Morbidity of homebound versus inpatient elderly psychiatric patients [see comments] Pasternak R, et al. **Int Psychogeriatr** 1998 Jun;10(2):117-25. Comment in: Int Psychogeriatr 1999 Mar;11(1):105-6.
Long-term oxygen therapy on the island of Crete, Greece. Tzanakis N, et al. **Monaldi Arch Chest Dis** 1998 Oct; 53(5):533-6
Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients. Emanuel EJ, et al. **N Engl J Med** 1999 Sep 23; 341(13):956-63
[Oxygen therapy in children] Pin I, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S144-5 **(Fre)**
[The resources of the social network of single person households during acute illness. Basic data for home care planning in an influenza epidemic] Wettstein A, et al. **Soz Praventivmed** 1999;44(3):107-16 (Eng. Abstr.) **(Ger)**
[Patient management in geriatric psychiatry by ambulatory care services. Results of an empirical analysis] Klostermann M, et al. **Z Gerontol Geriatr** 1998 Dec;31(6):426-37 (Eng. Abstr.) **(Ger)**

SUPPLY & DISTRIBUTION

Their home is their castle: learning to do in-home family therapy. Synder W, et al. **Fam Process** 1999 Summer; 38(2):229-42

TRENDS

There's no place like home: the home health care alternative [news] Gundersen L. **Ann Intern Med** 1999 Oct 19; 131(8):639-40
Monitoring changes in home health care: a comparison of two national surveys. Mullner RM, et al. **J Med Syst** 1999 Feb;23(1):21-6
Death at home: challenges for families and directions for the future. Stajduhar KI, et al. **J Palliat Care** 1998 Autumn; 14(3):8-14 (76 ref.)
[Ambulatory nursing-care related social work] Jansen B. **Z Gerontol Geriatr** 1998 Oct;31(5):319-24 (15 ref.) (Eng. Abstr.) **(Ger)**
[Home oxygen therapy. What future awaits it?] Sebastián Ariño A, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:95-7 (24 ref.) **(Spa)**

UTILIZATION

Regional variations in the use of home care services in Ontario, 1993/95. Coyte PC, et al. **CMAJ** 1999 Aug 24; 161(4):376-80
Long-term admissions to home health agencies: a life table analysis. Freedman VA. **Gerontologist** 1999 Feb;39(1):16-24
Who dies at home? Determinants of site of death for community-based long-term care patients. Fried TR, et al. **J Am Geriatr Soc** 1999 Jan;47(1):25-9
Barriers and facilitators to use of services following intensive family preservation services. Staudt M. **J Behav Health Serv Res** 1999 Feb;26(1):39-49
A study of the relationship of caregiving appraisal to depressive symptomatology and home care utilization. Schwarz KA. **J Community Health Nurs** 1999;16(2):95-108
Where do cancer patients die? Ten-year trends in the place of death of cancer patients in England. Higginson IJ, et al. **Palliat Med** 1998 Sep;12(5):353-63
Alternative measures of resource consumption in home care episodes. Madigan EA, et al. **Public Health Nurs** 1999 Jun; 16(3):198-204
[Comparisons of home care utilization between insured and not-insured patients] Liu HL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jun; 15(6):382-95 (Eng. Abstr.) **(Chi)**
[Study of the elderly in long form care facilities and home services] Kobayashi M. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):199-203 **(Jpn)**
[Home care service utilization by severely mentally and physically handicapped persons] Yamawaki A, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):499-511 (Eng. Abstr.) **(Jpn)**

HOME CARE SERVICES, HOSPITAL-BASED

What is the paradigm: hospital or home health care for pressure ulcers? O'Brien SP, et al. **Am Surg** 1999 Apr; 65(4):303-6
Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure [see comments] Stewart S, et al. **Arch Intern Med** 1999 Feb 8;159(3):257-61. Comment in: ACP J Club 1999 Jul-Aug;131(1):6.
Residential and home-based postacute rehabilitation of individuals with traumatic brain injury: a case control study. Willer B, et al. **Arch Phys Med Rehabil** 1999 Apr; 80(4):399-406
General practitioner involvement in hospital in the home. The hospital's view. Montalto M, et al. **Aust Fam Physician** 1998 Sep;27(9):811-5
Full polysomnography in the home: has it come of age? [editorial; comment] Millman RP. **Chest** 1999 Jan; 115(1):6-7. Comment on: Chest 1999 Jan;115(1):114-22.
Portable computerized polysomnography in attended and unattended settings [see comments] Mykytyn IJ, et al. **Chest** 1999 Jan;115(1):114-22. Comment in: Chest 1999 Jan;115(1):6-7.
Transitional care: hospital to home. Hall WJ, et al. **Clin Geriatr Med** 1998 Nov;14(4):799-812 (45 ref.)
Shared responsibility for ongoing rehabilitation: a new approach to home-based therapy after stroke. Baskett JJ, et al. **Clin Rehabil** 1999 Feb;13(1):23-33
Home continuous passive motion machine versus professional physical therapy following total knee replacement. Worland RL, et al. **J Arthroplasty** 1998 Oct;13(7):784-7
Eighteen years of home care: from assistance by phone to a complete service within the health care system. De Conno F, et al. **J Palliat Care** 1998 Autumn;14(3):91-3
The effectiveness of hospital at home compared with in-patient hospital care: a systematic review. Shepperd S, et al. **J Public Health Med** 1998 Sep;20(3):344-50 (20 ref.)
Telehealth: bringing health care to the point of living [editorial; comment] Brennan PF. **Med Care** 1999 Feb; 37(2):115-6. Comment on: Med Care 1999 Feb;37(2):117-25.
The effectiveness of videophones in home healthcare for the elderly [see comments] Nakamura K, et al. **Med Care** 1999 Feb;37(2):117-25. Comment in: Med Care 1999 Feb;37(2):115-6.
Hospital in the home: a randomised controlled trial [see comments] Caplan GA, et al. **Med J Aust** 1999 Feb 15; 170(4):156-60. Comment in: Med J Aust 1999 Feb 15;170(4):148-9. Comment in: ACP J Club 1999 Jul-Aug;131(1):7.
Hospital in the home: a randomised controlled trial [letter] Dickson HG, et al. **Med J Aust** 1999 Jul 19;171(2):109-10
Home-based treatment of cellulitis with twice-daily cefazolin. Leder K, et al. **Med J Aust** 1998 Nov 16; 169(10):519-22
Hospital in the home: take the evidence and run [editorial; comment] Montalto M. **Med J Aust** 1999 Feb 15; 170(4):148-9. Comment on: Med J Aust 1999 Feb 15;170(4):156-60.
Hospital in the home: a randomised controlled trial [letter] Thomas JA. **Med J Aust** 1999 Jul 19;171(2):110-1
Telematic system for monitoring of asthma severity in patients' homes. Finkelstein J, et al. **Medinfo** 1998;9 Pt 1:272-6
Telematics in the neonatal ICU and beyond: improving care, communication and information sharing. Gray J, et al. **Medinfo** 1998;9 Pt 1:294-7
Effectiveness of RSV-IVIG in premature infants: success in the home [letter; comment] Hayes C, et al. **Pediatrics** 1999 Mar;103(3):698-9. Comment on: Pediatrics 1998 Feb;101(2):320-1.
Length of stay, jaundice, and the hospital readmission [letter; comment] Izsak J. **Pediatrics** 1999 Mar;103(3):699-700. Comment on: Pediatrics 1997 Jul;100(1):72-4.
[Long-term oxygen therapy in chronic respiratory insufficiency] Emborg J, et al. **Ugeskr Laeger** 1998 Nov 30;160(49):7135-8 (Eng. Abstr.) **(Dan)**
["If only I had known it earlier"--the best time to bring a terminal cancer patient back home] Dochi K, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:531-4 (Eng. Abstr.) **(Jpn)**
[Pain management of private hospital in home care] Hashimoto Y. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:545-8 (Eng. Abstr.) **(Jpn)**
[Experience of 7 cases with home parenteral nutrition in our hospital] Kubo F, et al. **Gan To Kagaku Ryoho** 1998 Dec; 25 Suppl 4:709-12 (Eng. Abstr.) **(Jpn)**
[Pain management in home hospice care] Sakai T, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:539-43 (Eng. Abstr.) **(Jpn)**
[Experience of cancer home chemotherapy with cooperation between hospital and clinic] Sawada K, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:625-30 (Eng. Abstr.) **(Jpn)**
[Terminal care of the cancer patient at home--patient and family spending the last moments together] Sekiya Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:684-8 (Eng. Abstr.) **(Jpn)**
[Medical cooperation between the in-home medical care and family physician] Shino S, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:599-601 (Eng. Abstr.) **(Jpn)**
[Analysis of the factors involving in the success or failure of home infusion therapy (HIT)] Sumioka N, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:701-4 (Eng. Abstr.) **(Jpn)**
[A case of elderly home care after surgical treatment for gastric cancer--elderly patient with decubitus] Takamura S, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:679-83 (Eng. Abstr.) **(Jpn)**
[The role of home visiting nurse in the terminal care of cancer--from cooperation with other social resources] Takasuna H. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:631-9 (Eng. Abstr.) **(Jpn)**
[Roles and problems of nurses taking care of terminally-ill patients at home] Takeda U. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:557-60 (Eng. Abstr.) **(Jpn)**
[Our experience of home parenteral nutrition (HPN) for digestive disease patients] Umetsu W, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:713-7 (Eng. Abstr.) **(Jpn)**
[Support for and problems associated with the highly health care-dependent, single-living elderly] Watanabe M, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:661-4 (Eng. Abstr.) **(Jpn)**
[Significance of percutaneous endoscopic gastrostomy (PEG) in home medical care] Yokota H, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:521-6 (Eng. Abstr.) **(Jpn)**
[Transition in home care service in our hospital] Yoshizawa A, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:535-8 (Eng. Abstr.) **(Jpn)**
[Mechanical ventilation for amyotrophic lateral sclerosis--Making a comparison between hospital and home care] Saito T. **Rinsho Shinkeigaku** 1999 Jan; 39(1):70-1 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Home hospitalization for patients with acute illnesses] Roubicek J, et al. **Rev Panam Salud Publica** 1999 Sep; 6(3):172-6 (Eng. Abstr.) **(Spa)**
[Hospital-based advanced home-care, models from Ekenäs, Finland] Wikström U, et al. **Nord Med** 1998 Dec; 113(10):346-9 (Eng. Abstr.) **(Swe)**

ECONOMICS

Hospital at home. Costings were inadequate [letter; comment] Lilford RJ, et al. **BMJ** 1998 Dec 12;317(7173):1651-2. Comment on: BMJ 1998 Jun 13;316(7147):1802-6.
All the hazards of home. O'Donnell K, et al. **Hosp Health Netw** 1998 Nov 20;72(22):26
[Is home care really more expensive? A report on costs of care is questioned] Strang P, et al. **Lakartidningen** 1999 Aug 11;96(32-33):3424-5 **(Swe)**

HOME CARE SERVICES, HOSPITAL-BASED

LEGISLATION & JURISPRUDENCE

[Legal social status of management with portable liquid oxygen devices in Germany] Mitlehner W, et al. **Pneumologie** 1999 Feb;53(2):83–7 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Hospital at home. For people with severe mental illness, results are encouraging [letter; comment] Cleary M, et al. **BMJ** 1998 Dec 12;317(7173):1651. Comment on: **BMJ** 1998 Jun 13;316(7147):1761–2.

Acceptability of early discharge, hospital at home schemes. Treatments that can be safely and acceptably managed at home need to be defined [letter; comment] Montalto M, et al. **BMJ** 1998 Dec 12;317(7173):1652. Comment on: **BMJ** 1998 Jun 13;316(7147):1786–91. Comment on: **BMJ** 1998 Jun 13;316(7147):1796–801.

Acceptability of early discharge, hospital at home schemes. Care in community hospitals is another alternative [letter; comment] Seamark DA, et al. **BMJ** 1998 Dec 12; 317(7173):1652–3. Comment on: **BMJ** 1998 Jun 13;316(7147):1786–91. Comment on: **BMJ** 1998 Jun 13;316(7147):1796–801.

Hospital at home. Schemes evolve gradually [letter; comment] Sims J, et al. **BMJ** 1998 Dec 12;317(7173):1651 . Comment on: **BMJ** 1998 Jun 13;316(7147):1761–2.

Home hospital program: a pilot study. Leff B, et al. **J Am Geriatr Soc** 1999 Jun;47(6):697–702

Closure of an in-hospital palliative home care service. McNeil CA, et al. **J Palliat Care** 1998 Autumn;14(3):84–90

Expertise in caring: a source of power. Smith LL, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Sep;36(9):31–7

[Marketing research on the organization of paid medical services in home hospitals] Ruden' VV. **Lik Sprava** 1998 Aug;(6):173–6 **(Ukr)**

STANDARDS

Improving nursing documentation for private-duty home health care. Borchers EL. **J Nurs Care Qual** 1999 Jun; 13(5):24–43; quiz 91–2

STATISTICS & NUMERICAL DATA

Variations in diagnostic and therapeutic intensity between home and conventional hospitalization. Oterino-de-la-Fuente D, et al. **Int J Qual Health Care** 1998 Aug;10(4):331–8

TRENDS

Future directions: alternative approaches to traditional hospital care-home hospital. Leff B, et al. **Clin Geriatr Med** 1998 Nov;14(4):851–61 (45 ref.)

HOME CHILDBIRTH

Home births: an unresolved debate [editorial] Murphy JF. **Ir Med J** 1998 Oct-Nov;91(5):156

Home births and antenatal care: the G.P. perspective. O'Connell T, et al. **Ir Med J** 1998 Oct-Nov;91(5):174–5

[Advise to pregnant women on the question of "home childbirth--yes or no?" What are the criteria for a planned home delivery?] Heimrath W. **Fortschr Med** 1999 Mar 10; 117(7):20–2 **(Ger)**

ECONOMICS

The cost-effectiveness of home birth. Anderson RE, et al. **J Nurse Midwifery** 1999 Jan-Feb;44(1):30–5

MORTALITY

Perinatal death associated with planned home birth in Australia. Home births are not justified in Australia [letter; comment] Sullivan P. **BMJ** 1999 Feb 27;318(7183):605–6; discussion 606. Comment on: **BMJ** 1998 Aug 8;317(7155):384–8.

Perinatal death associated with planned home birth in Australia. Study prompts several questions [letter; comment] Tracy SK. **BMJ** 1999 Feb 27;318(7183):606. Comment on: **BMJ** 1998 Aug 8;317(7155):384–8.

The role of (traditional) birth attendants with midwifery skills in the reduction of maternal mortality [editorial] Walraven G, et al. **Trop Med Int Health** 1999 Aug;4(8):527–9

NURSING

Outcomes of intended home births in nurse-midwifery practice: a prospective descriptive study. Zeidenstein L. **J Nurse Midwifery** 1999 Jan-Feb;44(1):80–1

HOME HEALTH AGENCIES see **HOME CARE AGENCIES**

HOME HEALTH AIDES

STATISTICS & NUMERICAL DATA

Injuries in home health care workers: an analysis of occupational morbidity from a state compensation database. Meyer JD, et al. **Am J Ind Med** 1999 Mar;35(3):295–301

HOME HEALTH CARE AGENCIES see **HOME CARE AGENCIES**

HOME HEMODIALYSIS see **HEMODIALYSIS, HOME**

HOME INFUSION THERAPY

see related
PARENTERAL NUTRITION, HOME

Multidisciplinary approach to improving pediatric home infusion. Johnson KA, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):473–4

Home intravenous antibiotic therapy for patients with infective endocarditis. Huminer D, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):330–4

Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Andes D, et al. **Infect Dis Clin North Am** 1998 Dec;12(4):849–60, vi (40 ref.)

Outpatient parenteral antibiotic therapy in the management of community-acquired lower respiratory infections. Brown RB. **Infect Dis Clin North Am** 1998 Dec; 12(4):921–33, vii (53 ref.)

Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Deery HG 2nd. **Infect Dis Clin North Am** 1998 Dec;12(4):935–49, vii (50 ref.)

Practical considerations of outpatient infusion therapy in the HIV arena. Lutz B, et al. **Infect Dis Clin North Am** 1998 Dec;12(4):951–61 (30 ref.)

Patient selection in outpatient parenteral antimicrobial therapy. Nolet BR. **Infect Dis Clin North Am** 1998 Dec; 12(4):835–47, v–vi (58 ref.)

Outpatient antibiotic therapy in long-term care facilities. Petrak RM. **Infect Dis Clin North Am** 1998 Dec; 12(4):995–1008 (33 ref.)

Evolution of outpatient parenteral antibiotic therapy. Poretz DM. **Infect Dis Clin North Am** 1998 Dec;12(4):827–34 (67 ref.)

Outpatient intravenous antibiotic therapy for endocarditis. Rehm SJ. **Infect Dis Clin North Am** 1998 Dec; 12(4):879–901, vi (59 ref.)

Outpatient parenteral antimicrobial therapy for osteomyelitis. Tice AD. **Infect Dis Clin North Am** 1998 Dec;12(4):903–19 (78 ref.)

Outpatient parenteral antibiotic therapy for fever and neutropenia. Tice AD. **Infect Dis Clin North Am** 1998 Dec; 12(4):963–77, viii (63 ref.)

Practice guidelines for community-based parenteral anti-infective therapy. Williams DN, et al. **Infect Dis Clin North Am** 1998 Dec;12(4):1009–21, viii–ix (40 ref.)

The feasibility and advisability of administering home blood transfusions to the terminally ill patient. Singer Y, et al. **J Palliat Care** 1998 Autumn;14(3):46–8

[Ambulatory vs. inpatient intravenous antibiotic therapy in mucoviscidosis patients--a controlled study] Klettke U, et al. **Pneumologie** 1999 Jan;53(1):31–6 (Eng. Abstr.) **(Ger)**

[Analysis of the factors involving in the success or failure of home infusion therapy (HIT)] Sumioka N, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:701–4 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Adverse effects of outpatient parenteral antibiotic therapy. Hoffman-Terry ML, et al. **Am J Med** 1999 Jan;106(1):44–9

Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy. Tokars JI, et al. **Ann Intern Med** 1999 Sep 7;131(5):340–7

Infection control and outpatient parenteral antibiotic therapy. Wade BH, et al. **Infect Dis Clin North Am** 1998 Dec; 12(4):979–94 (43 ref.)

ECONOMICS

Home drug infusion therapy. A literature update. Balinsky W, et al. **Int J Technol Assess Health Care** 1998 Summer; 14(3):535–43 (37 ref.)

METHODS

Outpatient parenteral antimicrobial therapy technology. Mortlock NJ, et al. **Infect Dis Clin North Am** 1998 Dec; 12(4):861–78, vi (44 ref.)

STANDARDS

Experience of a home infusion organization with a performance measurement company. Cain DA. **Am J Health Syst Pharm** 1999 May 1;56(9):911–2

Development and preliminary outcomes of a program for administering antimicrobials by i.v. push in home care. Nowobilski-Vasilios A, et al. **Am J Health Syst Pharm** 1999 Jan 1;56(1):76–9

Quality assurance and outcomes in outpatient parenteral antibiotic therapy. Kunkel MJ. **Infect Dis Clin North Am** 1998 Dec;12(4):1023–34, ix (14 ref.)

Safety, efficacy, and acceptability of home intravenous therapy administered by parents of pediatric oncology patients. Hooker L, et al. **Med Pediatr Oncol** 1999 Jun; 32(6):421–6

HOME NURSING

Home observation for asymptomatic coin ingestion: acceptance and outcomes. The New York State Poison Control Center Coin Ingestion Study Group. Conners GP, et al. **Acad Emerg Med** 1999 Mar;6(3):213–7

Community-based survey of paediatric diarrhoeal morbidity and home treatment practices in Finland. Rautanen T, et al. **Acta Paediatr** 1998 Sep;87(9):986–90

Fatigue in mothers of infants discharged to the home on apnea monitors. Williams PD, et al. **Appl Nurs Res** 1999 May;12(2):69–77

Shared responsibility for ongoing rehabilitation: a new approach to home-based therapy after stroke. Baskett JJ, et al. **Clin Rehabil** 1999 Feb;13(1):23–33

Predictors of institutionalization for people with dementia living at home with a carer. Hope T, et al. **Int J Geriatr Psychiatry** 1998 Oct;13(10):682–90

Meaning in caring: reconceptualizing the nurse-family carer relationship in community practice. Kellett UM, et al. **J Adv Nurs** 1999 Mar;29(3):697–703

Grandma eats like a bird: helping caregivers improve the nutrition of older persons at home [news] Vozenilek G. **J Am Diet Assoc** 1998 Dec;98(12):1405

Management of pneumonia in the nursing home [letter; comment] Twersky J, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):913–4. Comment on: J Am Geriatr Soc 1998 Dec;46(12):1538–44.

Vascular dementia versus dementia of Alzheimer's type: do they have differential effects on caregivers' burden? Vetter PH, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Mar; 54(2):S93–8

The Caregiver Quality of Life Index-Cancer (CQOLC) Scale: revalidation in a home hospice setting. Weitzner MA, et al. **J Palliat Care** 1999 Summer;15(2):13–20

Well-being of families with healthy and technology-assisted infants in the home: a comparative study. Stephenson C. **J Pediatr Nurs** 1999 Jun;14(3):164–76

Children with cystic fibrosis benefit from massage therapy. Hernandez-Reif M, et al. **J Pediatr Psychol** 1999 Apr; 24(2):175–81

Disability and chronic illness: the role of the family carer [editorial] Schofield H, et al. **Med J Aust** 1998 Oct 19; 169(8):405–6

Telematic evolution of day-hospital in oncology. Maceratini R, et al. **Medinfo** 1998;9 Pt 1:302–6

Mechanical ventilation in chronic respiratory insufficiency: report on an Italian nationwide survey. The Italian Telethon Committee and the AIPO Study Group on Pulmonary Rehabilitation and Intensive Care. Gasperini M, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):394–9

Home-based rehabilitation for patients with chronic obstructive pulmonary disease. Wijkstra PJ, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):450–3

The loneliness of the long-term care giver. Levine C. **N Engl J Med** 1999 May 20;340(20):1587–90

Identifying the concerns of informal carers in palliative care. Payne S, et al. **Palliat Med** 1999 Jan;13(1):37–44

Agreement among raters in assessment of physiologic waveforms recorded by a cardiorespiratory monitor for home use. Collaborative Home Infant Monitoring Evaluation (CHIME) Study Group. Corwin MJ, et al. **Pediatr Res** 1998 Nov;44(5):682–90

How does home management of asthma exacerbations by parents of inner-city children differ from NHLBI guideline recommendations? National Heart, Lung, and Blood Institute. Warman KL, et al. **Pediatrics** 1999 Feb; 103(2):422–7

Baby CareLink: development and implementation of a WWW-based system for neonatal home telemedicine. Gray J, et al. **Proc AMIA Symp** 1998;:351–5

Nationwide telecare for diabetics: a pilot implementation of the HOLON architecture. Jones PC, et al. **Proc AMIA Symp** 1998;:346–50

Defining elder care. Lee JA. **Psychol Rep** 1999 Apr; 84(2):625–6

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS, et al. **Thromb Haemost** 1998 Dec; 80(6):912–8

A home blood transfusion programme for beta-thalassaemia patients. Madgwick KV, et al. **Transfus Med** 1999 Jun; 9(2):135–8

[Femoral neck fractures in children younger than 4 years: shorter hospital stays with the aid of traction at home (letter; comment)] Spelde AG, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1970. Comment on: Ned Tijdschr Geneeskd 1998 Jun 6;142(23):1324–7. **(Dut)**

[Acceptance and long-term results of home mechanical ventilation in various thoracic diseases] Schucher B, et al. **Med Klin** 1999 Apr;94(1 Spec No):22–6 (Eng. Abstr.) **(Ger)**

[Management of dementia patients and their relatives: report from the routine practice of a family physician] Michel E. **Ther Umsch** 1999 Feb;56(2):104–8 (Eng. Abstr.) **(Ger)**

[Invasive ventilation in pediatric patients discharged from intensive care to continuous home care] Carpino V, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):70–3 **(Ita)**

[Cardiorespiratory monitoring in hospital and at home] Carnelli V, et al. **Pediatr Med Chir** 1998 Nov-Dec; 20(6):361–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Study of the validity of ADL assessment by Minsei-iin of bed ridden elderly cared for at home] Tajima K, et al.

Nippon Koshu Eisei Zasshi 1998 Jul;45(7):612–8 (Eng. Abstr.) **(Jpn)**
[Home mechanical ventilation for the treatment of respiratory insufficiency] Kimura K. **Nippon Naika Gakkai Zasshi** 1999 Jan 10;88(1):89–93 (10 ref.) **(Jpn)**
[A study of the degree of burden and subjective sense of well being in care-givers involved in home care] Kawamoto R, et al. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):35–9 (Eng. Abstr.) **(Jpn)**
[Factors predicting return home of hospitalized aged patients] Sabartés O, et al. **An Med Interna** 1999 Aug;16(8):407–14 (Eng. Abstr.) **(Spa)**
[Health and social problems of caregivers of patients with dementia] Valles Fernández MN, et al. **Aten Primaria** 1998 Nov 15;22(8):481–5 (Eng. Abstr.) **(Spa)**
[Nursing care in the home and in conventional hospitalization] Oterino de la Fuente D, et al. **Rev Esp Salud Publica** 1998 Nov–Dec;72(6):517–27 (Eng. Abstr.) **(Spa)**

ECONOMICS

Medicaid eligibility workers discuss Medicaid estate planning for nursing home care. Walker L, et al. **Gerontologist** 1999 Apr;39(2):201–8
The economic value of informal caregiving. Arno PS, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):182–8
The valuation of informal care in economic appraisal. A consideration of individual choice and societal costs of time. Brouwer WB, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):147–60
Cost comparisons between family-based care and nursing home care for dementia. Chiu L, et al. **J Adv Nurs** 1999 Apr;29(4):1005–12

EDUCATION

Dementia carer education and patient behaviour disturbance. Coen RF, et al. **Int J Geriatr Psychiatry** 1999 Apr; 14(4):302–6
Improving community care for persons with the acquired immunodeficiency syndrome in Jamaica. Bain BC. **West Indian Med J** 1998 Dec;47 Suppl 4:37–9

MANPOWER

[Resources for home nursing care: willingness to undertake care by persons not involved in nursing services] Fuchs J. **Gesundheitswesen** 1998 Jul;60(7):392–8 (Eng. Abstr.) **(Ger)**

METHODS

Efficacy of home cervical traction therapy. Swezey RL, et al. **Am J Phys Med Rehabil** 1999 Jan–Feb;78(1):30–2
An intercultural comparison of home case management of acute diarrhea in Mexico: implications for program planners. Martinez H, et al. **Arch Med Res** 1998 Winter; 29(4):351–60
Parental report of pediatric tracheostomy care. Bahng SC, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1367–9
[Long-term oxygen inhalation therapy and home artificial respiration for chronic pulmonary heart disease] Köhler D, et al. **Internist (Berl)** 1999 Jul;40(7):756–63 (62 ref.) **(Ger)**
[Quality of life of various patient groups during home mechanical ventilation] Hein H, et al. **Med Klin** 1999 Apr; 94(1 Spec No):99–101 (Eng. Abstr.) **(Ger)**
[Invasive and non-invasive home ventilation—changes between 1982 and 1996] Raffenberg M, et al. **Med Klin** 1999 Apr;94(1 Spec No):18–21 (Eng. Abstr.) **(Ger)**
[Sleep-phase-related home therapy in congenital central hypoventilation syndrome (CCHS)] Schäfer C, et al. **Med Klin** 1999 Apr;94(1 Spec No):15–7 (Eng. Abstr.) **(Ger)**
[Brain syndrome and home ventilation—diagnosis, therapy and consequences] Winterholler M, et al. **Med Klin** 1999 Apr;94(1 Spec No):62–5 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Parents with mental illness. Is there help for their adolescent children? [news] Rimington H, et al. **Aust Fam Physician** 1998 Nov;27(11):987–8
A model for improving medication use in home health care patients. Brown NJ, et al. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec;38(6):696–702
Home care by and for relatives of MS patients. Duijnstee MS, et al. **J Neurosci Nurs** 1998 Dec;30(6):356–60 (18 ref.)
[Fracture of the femur neck in children younger than 4 years: shorter hospital stays with the aid of traction at home (letter; comment)] Hegge HG, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2166–7. Comment on: Ned Tijdschr Geneeskd 1998 Jun 6;142(23):1324–7. **(Dut)**
[Memisa and home care for AIDS patients in Zambia (see comments)] Reijer PJ. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):162–5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):701–2. **(Dut)**
[Memisa and home nursing of AIDS patients in Zambia (letter; comment)] Zaaijer LN. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):701–2. Comment on: Ned Tijdschr Geneeskd 1999 Jan 16;143(3):162–5. **(Dut)**

PSYCHOLOGY

Breakdowns on the path of chronic illness: opportunities for learning. Swartz R, et al. **Adv Ren Replace Ther** 1998 Oct; 5(4):315–23
Caring for relatives with serious mental illness at home: the experiences of family carers in Hong Kong. Ip GS, et al. **Arch Psychiatr Nurs** 1998 Oct;12(5):288–94
The impact of new demands for assistance on caregiver depression: tests using an inception cohort. Given CW, et al. **Gerontologist** 1999 Feb;39(1):76–85
Children-in-law in caregiving families. Peters-Davis ND, et al. **Gerontologist** 1999 Feb;39(1):66–75
Care and care alike. Speer TL. **Hosp Health Netw** 1998 Oct 5;72(19):36–9, 3
Family caregiving in dementia: prediction of caregiver burden 12 months after relocation to group-living care. Elmståhl S, et al. **Int Psychogeriatr** 1998 Jun;10(2):127–46
Assessment of caregiver's competence in dealing with the burden of caregiving for a dementia patient: a Short Sense of Competence Questionnaire (SSCQ) suitable for clinical practice [letter] Vernooij-Dassen MJ, et al. **J Am Geriatr Soc** 1999 Feb;47(2):256–7
Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Neumann PJ, et al. **Med Care** 1999 Jan;37(1):27–32
Patterns of burden in wives who care for husbands with dementia. Winslow BW, et al. **Nurs Clin North Am** 1999 Jun;34(2):275–87 (31 ref.)
Caregiving effectiveness in families managing complex technology at home: replication of a model [see comments] Smith CE. **Nurs Res** 1999 May–Jun;48(3):120–8. Comment in: Nurs Res 1999 May–Jun;48(3):119.
Employment, child care, and mental health of mothers caring for children assisted by technology. Thyen U, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1235–42
Predictors of bereavement outcome for family carers of cancer patients. Kelly B, et al. **Psychooncology** 1999 May–Jun;8(3):237–49
Social and clinical factors influencing the choice of coping strategies in relatives of patients with schizophrenia: results of the BIOMED I study. Magliano L, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Sep;33(9):413–9
Burden on the families of patients with schizophrenia: results of the BIOMED I study. Magliano L, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Sep;33(9):405–12
Measuring both negative and positive reactions to giving care to cancer patients: psychometric qualities of the Caregiver Reaction Assessment (CRA). Nijboer C, et al. **Soc Sci Med** 1999 May;48(9):1259–69
[Family nursing and occupational therapy in Charles Dickens' "David Copperfield"] Reker T. **Psychiatr Prax** 1998 Sep;25(5):260–1 **(Ger)**
[Management of dementia patients: the family as corner stone] Faes J, et al. **Ther Umsch** 1999 Feb;56(2):114–7 (Eng. Abstr.) **(Ger)**
[Family care of patients with dementia: differential significance of specific stress dimensions for the well-being of caregivers and the stability of the home nursing situation] Schacke C, et al. **Z Gerontol Geriatr** 1998 Oct;31(5):355–61 (Eng. Abstr.) **(Ger)**
[The factor structure of coping strategies and their effects on burnout among primary caregivers of impaired elderly persons] Okabayashi H, et al. **Shinrigaku Kenkyu** 1999 Feb; 69(6):486–93 (Eng. Abstr.) **(Jpn)**

STANDARDS

Long-term care research: demand, payment, and outcomes [editorial; comment] Siu AL. **Health Serv Res** 1998 Oct; 33(4 Pt 1):783–5. Comment on: Health Serv Res 1998 Oct;33(4 Pt 1):835–65.
The nursing home at night: effects of an intervention on noise, light, and sleep. Schnelle JF, et al. **J Am Geriatr Soc** 1999 Apr;47(4):430–8

STATISTICS & NUMERICAL DATA

Stress in carers of the elderly. A controlled study of patients attending a Sydney family medical practice. Payda C, et al. **Aust Fam Physician** 1999 Mar;28(3):233–7
Home mechanical ventilation: demographics and user perspectives. Goldstein RS. **Monaldi Arch Chest Dis** 1998 Oct;53(5):560–3

TRENDS

[Nursing care in social change. Effects of nursing care insurance on the status of the disabled] Klie T. **Z Gerontol Geriatr** 1998 Dec;31(6):387–91 (Eng. Abstr.) **(Ger)**
[The local community as a life environment for the elderly—on the future role of the community in supporting the elderly] Ziller H. **Z Gerontol Geriatr** 1998 Dec; 31(6):392–7 (Eng. Abstr.) **(Ger)**

UTILIZATION

Consistency between preference and use of long-term care among caregivers of stroke survivors. Chiu L, et al. **Public Health Nurs** 1998 Oct;15(5):379–86

HOME PARENTERAL NUTRITION see **PARENTERAL NUTRITION, HOME**

HOME RANGE see **HOMING BEHAVIOR**

HOME REMEDIES see **MEDICINE, TRADITIONAL**

HOME TOTAL PARENTERAL NUTRITION see **PARENTERAL NUTRITION, HOME TOTAL**

HOMEBOUND PERSONS

Inappropriate medication prescribing in homebound older adults. Golden AG, et al. **J Am Geriatr Soc** 1999 Aug; 47(8):948–53
Effectiveness of behavioral therapy to treat incontinence in homebound older adults. McDowell BJ, et al. **J Am Geriatr Soc** 1999 Mar;47(3):309–18
Dental care for homebpund and geriatric patients [letter] Phillips DE. **J Can Dent Assoc** 1999 Apr;65(4):194; 223
Hand-grip dynamometry provides a valid indication of upper extremity strength impairment in home care patients. Bohannon RW. **J Hand Ther** 1998 Oct–Dec;11(4):258–60
Factors affecting QOL of the home-bound elderly disabled. Takemasa S. **Kobe J Med Sci** 1998 Jun;44(3):99–114
Evaluation of the use of a pain diary in chronic cancer pain patients at home. de Wit R, et al. **Pain** 1999 Jan;79(1):89–99
[Public health nurses' disaster responses for intractable neurological patients at home] Iwasaki Y, et al. **Nippon Koshu Eisei Zasshi** 1999 Jan;46(1):71–80 (Eng. Abstr.) **(Jpn)**
[Effect of home visit dental health services] Takazawa M, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):915–20 **(Jpn)**

CLASSIFICATION

Increasing our knowledge of the homebound elderly [letter; comment] Bédard M. **Int Psychogeriatr** 1999 Mar; 11(1):105–6. Comment on: Int Psychogeriatr 1998 Jun;10(2):117–25.

PSYCHOLOGY

Cognitive-behavioral intervention for homebound caregivers of persons with dementia. Chang BL. **Nurs Res** 1999 May–Jun;48(3):173–82
[The importance of the 'frailty-concept' in geriatric assessment] (editorial)] Slaets JP. **Tijdschr Gerontol Geriatr** 1998 Dec;29(6):276–8 **(Dut)**

STATISTICS & NUMERICAL DATA

Increasing our knowledge of the homebound elderly [letter; comment] Bédard M. **Int Psychogeriatr** 1999 Mar; 11(1):105–6. Comment on: Int Psychogeriatr 1998 Jun;10(2):117–25.
[Homebound elderly in a Japanese community: related factors and change of mobility] Imuta H, et al. **Nippon Koshu Eisei Zasshi** 1998 Sep;45(9):883–92 (Eng. Abstr.) **(Jpn)**

HOMELESS CHILDREN see **HOMELESS YOUTH**

HOMELESS PERSONS

Effectiveness of a specialized vs. traditional AIDS education program attended by homeless and drug-addicted women alone or with supportive persons. Nyamathi A, et al. **AIDS Educ Prev** 1998 Oct;10(5):433–46
Modified therapeutic community for homeless mentally ill chemical abusers: emerging subtypes. De Leon G, et al. **Am J Drug Alcohol Abuse** 1999 Aug;25(3):495–515
Services for mentally ill homeless persons: street-level integration. Rowe M, et al. **Am J Orthopsychiatry** 1998 Jul;68(3):490–6
Mandated tuberculosis screening in a community of homeless people. Rendleman NJ. **Am J Prev Med** 1999 Aug; 17(2):108–13
Service system integration, access to services, and housing outcomes in a program for homeless persons with severe mental illness. Rosenheck R, et al. **Am J Public Health** 1998 Nov;88(11):1610–5
Health, health promotion, and homelessness. Power R, et al. **BMJ** 1999 Feb 27;318(7183):590–2 (32 ref.)
Development of housing programs to aid in the treatment of tuberculosis in homeless individuals: a pilot study. LoBue PA, et al. **Chest** 1999 Jan;115(1):218–23
Bringing health care to the homeless [news] Lechky O. **CMAJ** 1999 Jul 13;161(1):13
Bartonella quintana in body lice collected from homeless persons in Russia [letter] Rydkina EB, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):176–8
Sleep patterns of sheltered battered women. Humphreys JC, et al. **Image J Nurs Sch** 1999;31(2):139–43
Service learning in a homeless clinic [editorial; comment] Fournier AM. **J Gen Intern Med** 1999 Apr;14(4):258–9. Comment on: J Gen Intern Med 1999 Apr;14(4):211–6.
Experiences and attitudes of residents and students influence voluntary service with homeless populations [see comments] O'toole TP, et al. **J Gen Intern Med** 1999 Apr; 14(4):211–6. Comment in: J Gen Intern Med 1999 Apr;14(4):258–9.
Health status, needs, and health care barriers among the homeless. Wojtusik L, et al. **J Health Care Poor Underserved** 1998 May;9(2):140–52
Healing without housing: the Open Door Community's

medical clinic. Loring EN. **J Med Assoc Ga** 1999 Feb; 88(1):21–2

Interpersonal violence and the pregnant homeless woman. Robrecht LC, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov–Dec;27(6):684–91 (32 ref.)

Focus on the homeless family [news] **J Psychosoc Nurs Ment Health Serv** 1999 Apr;37(4):15

Outcome of a controlled trial of the effectiveness of intensive case management for chronic public inebriates. Cox GB, et al. **J Stud Alcohol** 1998 Sep;59(5):523–32

Dynamic Recovery: comparative study of therapeutic communities in homeless shelters for men. Liberty HJ, et al. **J Subst Abuse Treat** 1998 Sep–Oct;15(5):401–23

Modified therapeutic community for homeless mentally ill chemical abusers. Sociodemographic and psychological profiles. Sacks S, et al. **J Subst Abuse Treat** 1998 Nov–Dec; 15(6):545–54

The Montefiore community children's project: a controlled study of cognitive and emotional problems of homeless mothers and children. San Agustin M, et al. **J Urban Health** 1999 Mar;76(1):39–50

The homeless as a vulnerable population. Strehlow AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):261–74 (50 ref.)

Homelessness and mental illness: a story of failure [editorial] Drake RE, et al. **Psychiatr Serv** 1999 May;50(5):589

The community health nursing implications of the self-reported health status of a local homeless population. Reichenbach EM, et al. **Public Health Nurs** 1998 Dec; 15(6):398–405

Differences in personal, cognitive, psychological, and social factors associated with drug and alcohol use and nonuse by homeless women. Nyamathi A, et al. **Res Nurs Health** 1998 Dec;21(6):525–32

[Pneumonia among the homeless] Kashiyama T, et al. **Kansenshogaku Zasshi** 1999 Aug;73(8):717–21 (Eng. Abstr.) **(Jpn)**

[Characteristics of the medical status and living conditions of the homeless registered as tuberculosis patients in Nagoya City] Yamanaka K, et al. **Kekkaku** 1999 Feb; 74(2):99–105 (Eng. Abstr.) **(Jpn)**

[Alcoholic problem among homeless people around Shibuya Station] Tanimoto S, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1998 Dec; 33(6):718–26 (Eng. Abstr.) **(Jpn)**

[Organization of antituberculous work with homeless in Saint Petersburg] Grishko AN, et al. **Probl Tuberk** 1999;(3):8–10 (2 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Using clinical and criminal involvement factors to explain homelessness among clients of a psychiatric probation and parole service. Solomon P, et al. **Psychiatr Q** 1999 Spring; 70(1):75–87

[Death in the milieu of homeless persons. A comparative retrospective analysis of an autopsy sample of different regional population structures (Middle Hessia/Hamburg)] Risse M, et al. **Arch Kriminol** 1998 Sep–Oct;202(3–4):95–9 (Eng. Abstr.) **(Ger)**

[Medical management of homeless persons] Leidel I, et al. **Gesundheitswesen** 1998 Aug;60 Suppl 1:S41–6 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

The "modest needs" homeless family. Arrigo BA. **Adm Policy Ment Health** 1998 Nov;26(2):137–47

Residential treatment for dually diagnosed homeless veterans: a comparison of program types. Kasprow WJ, et al. **Am J Addict** 1999 Winter;8(1):34–43

A risk-amplification model of victimization and depressive symptoms among runaway and homeless adolescents. Whitbeck LB, et al. **Am J Community Psychol** 1999 Apr; 27(2):273–96

Surviving poverty: stress and coping in the lives of housed and homeless mothers. Banyard VL, et al. **Am J Orthopsychiatry** 1998 Jul;68(3):479–89

Predictors of homelessness among participants in a substance abuse treatment program. Kingree JB, et al. **Am J Orthopsychiatry** 1999 Apr;69(2):261–6

Psychosocial stressors among sheltered homeless children: relationship to behavior problems and depressive symptoms. Zima BT, et al. **Am J Orthopsychiatry** 1999 Jan;69(1):127–33

Mental disorder among homeless and poor people: a comparison of assessment methods. Bellavia CW, et al. **Community Ment Health J** 1999 Feb;35(1):57–67

Gender differences in homeless persons with schizophrenia and substance abuse. Brunette M, et al. **Community Ment Health J** 1998 Dec;34(6):627–42

The impact of assertive community treatment on the social relationships of people who are homeless and mentally ill. Calsyn RJ, et al. **Community Ment Health J** 1998 Dec; 34(6):579–93

A comparison of consumer and provider preferences for research on homeless veterans. Cohen CI, et al. **Community Ment Health J** 1999 Jun;35(3):273–80

Respite from stress and other service needs of homeless families. Kissman K. **Community Ment Health J** 1999 Jun; 35(3):241–9

The helping alliance in case management for homeless persons with severe mental illness. Klinkenberg WD, et al. **Community Ment Health J** 1998 Dec;34(6):569–78

Lifetime prevalence of mental disorders among homeless people in a southeast city in Brazil. Heckert U, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(3):150–5

Tailoring and individualizing housing programs for homeless persons with chronic mental illness [clinical conference] Reilly EC, et al. **Harv Rev Psychiatry** 1999 Sep–Oct; 7(3):166–71

Cancer screening in homeless women: attitudes and behaviors. Long HL, et al. **J Health Care Poor Underserved** 1998 Aug;9(3):276–92

Homeless mothers and depression: misdirected policy. Bogard CJ, et al. **J Health Soc Behav** 1999 Mar;40(1):46–62

It takes a village and time... a collaborative case study. Dunbar B, et al. **J Psychosoc Nurs Ment Health Serv** 1998 Nov;36(11):43–5

Street outreach for homeless persons with serious mental illness: is it effective? Lam JA, et al. **Med Care** 1999 Sep; 37(9):894–907

A perspective on voluntary and involuntary outreach services for the homeless mentally ill. Tsemberis S, et al. **New Dir Ment Health Serv** 1999 Summer;(82):9–19

Outreach workers' experiences in a homeless outreach project: issues of boundaries, ethics and staff safety. Fisk D, et al. **Psychiatr Q** 1999 Fall;70(3):231–46

Overcoming service barriers for homeless persons with serious psychiatric disorders. Calloway MO, et al. **Psychiatr Serv** 1998 Dec;49(12):1568–72

Homeless veterans' satisfaction with residential treatment. Kasprow WJ, et al. **Psychiatr Serv** 1999 Apr;50(4):540–5

The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments [see comments] Bourgois P. **Subst Use Misuse** 1998 Sep;33(11):2323–51. Comment in: Subst Use Misuse 1998 Sep;33(11):2353–5. Comment in: Subst Use Misuse 1998 Sep;33(11):2357–9. Comment in: Subst Use Misuse 1998 Sep;33(11):2361–3. Comment in: Subst Use Misuse 1998 Sep;33(11):2365–8.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Courtwright DT. **Subst Use Misuse** 1998 Sep;33(11):2353–5. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–4.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Fielding NG. **Subst Use Misuse** 1998 Sep;33(11):2361–3. Comment on: Subst Use Misuse 1998 Sep;33(11):2361–3.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Johnson TP. **Subst Use Misuse** 1998 Sep;33(11):2365–8. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–51.

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Latkin CA. **Subst Use Misuse** 1998 Sep; 33(11):2375–82

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois. Leshner AI. **Subst Use Misuse** 1998 Sep;33(11):2369–74

Comments on "The moral economies of homeless heroin addicts: confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments," by Phillippe Bourgois [comment] Lilja J, et al. **Subst Use Misuse** 1998 Sep;33(11):2357–9. Comment on: Subst Use Misuse 1998 Sep;33(11):2323–51.

Perceived factors influencing the initiation of drug and alcohol use among homeless women and reported consequences of use. Nyamathi A, et al. **Women Health** 1999;29(2):99–114

In search of sanctuary: addressing issues of domestic violence and homelessness at shelters. Krishnan SP, et al. **Womens Health Issues** 1998 Sep–Oct;8(5):310–6

[Homeless and mentally ill. Review of recent research and results on a doubly disadvantaged minority] Kellinghaus C, et al. **Fortschr Neurol Psychiatr** 1999 Mar;67(3):108–21 (140 ref.) (Eng. Abstr.) **(Ger)**

[A survey of the psychosocial situation of homeless men in Frankfurt am Main] Leder T, et al. **Nervenarzt** 1999 Jul; 70(7):650–6 (Eng. Abstr.) **(Ger)**

[Mental illness in homeless men and women in Munich] Fichter M, et al. **Psychiatr Prax** 1999 Mar;26(2):76–84 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Farrell M, et al. **Addict Behav** 1998 Nov–Dec;23(6):909–18

The "modest needs" homeless family. Arrigo BA. **Adm Policy Ment Health** 1998 Nov;26(2):137–47

Homeless people & mental health. Walker C. **Am J Nurs** 1998 Nov;98(11):26–32; quiz 33 (8 ref.)

Prevalence of mental health and substance use disorders among homeless and low-income housed mothers. Bassuk EL, et al. **Am J Psychiatry** 1998 Nov;155(11):1561–4

Mortality among homeless shelter residents in New York City. Barrow SM, et al. **Am J Public Health** 1999 Apr; 89(4):529–34

Who are "the homeless"? Reconsidering the stability and composition of the homeless population. Phelan JC, et al. **Am J Public Health** 1999 Sep;89(9):1334–8 (36 ref.)

Improving access to disability benefits among homeless persons with mental illness: an agency-specific approach to services integration. Rosenheck R, et al. **Am J Public Health** 1999 Apr;89(4):524–8

Predictors of homelessness among families in New York City: from shelter request to housing stability. Shinn M, et al. **Am J Public Health** 1998 Nov;88(11):1651–7

Drug access among homeless men in Toronto. Hwang SW, et al. **CMAJ** 1999 Apr 6;160(7):1021

Homelessness and its relation to the mental health and behavior of low-income school-age children. Buckner JC, et al. **Dev Psychol** 1999 Jan;35(1):246–57

Alcoholism in homeless men in the mid-nineties: results from the Bavarian Public Health Study on homelessness. Fichter M, et al. **Eur Arch Psychiatry Clin Neurosci** 1999; 249(1):34–44

Deaths among homeless people in Istanbul. Altun G, et al. **Forensic Sci Int** 1999 Jan 11;99(2):143–7

Aging and homelessness. Cohen CI. **Gerontologist** 1999 Feb; 39(1):5–14

Homeless patients with hepatocellular carcinoma in Osaka City, Japan. Sakai Y, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1106–10

City health dilemma on pavement dwellers [editorial] Biswas R, et al. **Indian J Public Health** 1998 Oct–Dec;42(4):98–9

Medicaid and service use among homeless adults. Glied S, et al. **Inquiry** 1998–99 Winter;35(4):380–8

Social support and service use among homeless persons with serious mental illness. Lam JA, et al. **Int J Soc Psychiatry** 1999 Spring;45(1):13–28

Spot sputum screening: evaluation of an intervention in two homeless shelters. Kimerling ME, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):613–9

Street talk: knowledge and attitudes about tuberculosis and tuberculosis control among homeless adults. Peterson Tulsky J, et al. **Int J Tuberc Lung Dis** 1999 Jun;3(6):528–33

Prevalence of skin disease in a cohort of shelter-based homeless men. Stratigos AJ, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 1):197–202

Health care needs and services utilization among sheltered and unsheltered Michigan homeless [letter] Douglass RL, et al. **J Health Care Poor Underserved** 1999 Feb;10(1):5–18

Utilization of health care services among subgroups of urban homeless and housed poor. O'Toole TP, et al. **J Health Polit Policy Law** 1999 Feb;24(1):91–114

The homeless crisis and health care [news] **J Psychosoc Nurs Ment Health Serv** 1998 Oct;36(10):9

Correlates of protracted homelessness in a sample of dually diagnosed psychiatric inpatients. Leal D, et al. **J Subst Abuse Treat** 1999 Mar;16(2):143–7

Retention of homeless clients in substance abuse treatment. Findings from the National Institute on Alcohol Abuse and Alcoholism Cooperative Agreement Program. Orwin RG, et al. **J Subst Abuse Treat** 1999 Jul–Sep;17(1–2):45–66

Disease patterns of the homeless in Tokyo. Takano T, et al. **J Urban Health** 1999 Mar;76(1):73–84

Homelessness and psychiatric admission rates through the criminal justice system [letter] James DV, et al. **Lancet** 1999 Apr 3;353(9159):1158

Utilization of mental health and substance abuse services among homeless adults in Los Angeles. Koegel P, et al. **Med Care** 1999 Mar;37(3):306–17

Chronic Bartonella quintana bacteremia in homeless patients. Brouqui P, et al. **N Engl J Med** 1999 Jan 21;340(3):184–9

Housing placement and subsequent days homeless among formerly homeless adults with mental illness. Goldfinger SM, et al. **Psychiatr Serv** 1999 May;50(5):674–9

Prediction of homelessness within three months of discharge among inpatients with schizophrenia. Olfson M, et al. **Psychiatr Serv** 1999 May;50(5):667–73

Differential patterns of mental disorders among the homeless in Madrid (Spain) and Los Angeles (USA). Muñoz M, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Oct; 33(10):514–20

Drug use, sexual behaviour and HIV risk of the homeless in Port-of-Spain, Trinidad. Reid SD. **West Indian Med J** 1999 Jun;48(2):57–60

[A survey of the psychosocial situation of homeless men in Frankfurt am Main] Leder T, et al. **Nervenarzt** 1999 Jul; 70(7):650–6 (Eng. Abstr.) **(Ger)**

HOMELESS YOUTH

Public perceptions of, and reactions to, street children. le Roux J, et al. **Adolescence** 1998 Winter;33(132):901–13

Is the street child phenomenon synonymous with deviant behavior? le Roux J, et al. **Adolescence** 1998 Winter; 33(132):915–25

Causes and characteristics of the street child phenomenon: a global perspective. le Roux J, et al. **Adolescence** 1998 Fall;33(131):683–8

Prevalence and correlates of survival sex among runaway and homeless youth. Greene JM, et al. **Am J Public Health** 1999 Sep;89(9):1406–9

Alternative medicine use by homeless youth. Breuner CC, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1071–5

Street children: a comparative perspective. Lalor KJ. **Child Abuse Negl** 1999 Aug;23(8):759–70

The impact of home background on the decision of children to run away: the case of Yaounde City street children in Cameroon. Matchinda B. **Child Abuse Negl** 1999 Mar; 23(3):245-55

Hepatitis B virus infection among street youths in Montreal. Roy E, et al. **CMAJ** 1999 Sep 21;161(6):689-93

Medical care of children who are homeless or in foster care. Simms MD. **Curr Opin Pediatr** 1998 Oct;10(5):486-90 (35 ref.)

"Out-of-the-mainstream" youth as partners in collaborative research: exploring the benefits and challenges. Harper GW, et al. **Health Educ Behav** 1999 Apr;26(2):250-65

Substance use and risky sexual behavior among homeless and runaway youth. Bailey SL, et al. **J Adolesc Health** 1998 Dec;23(6):378-88

Pregnancy among three national samples of runaway and homeless youth. Greene JM, et al. **J Adolesc Health** 1998 Dec;23(6):370-7

HIV prevention in street youth. Walters AS. **J Adolesc Health** 1999 Sep;25(3):187-98 (67 ref.)

Editor's choice: the plight of a people dispossessed: caring for street children in the mountains of Bulgaria. Barrett K. **J Pediatr Nurs** 1999 Aug;14(4):213-21

The Montefiore community children's project: a controlled study of cognitive and emotional problems of homeless mothers and children. San Agustin M, et al. **J Urban Health** 1999 Mar;76(1):39-50

Health and access to care: perspectives of homeless youth in Baltimore City, U.S.A. Ensign J, et al. **Soc Sci Med** 1998 Dec;47(12):2087-99

PSYCHOLOGY

Psychological characteristics of South African street children. le Roux J, et al. **Adolescence** 1998 Winter; 33(132):891-9

A risk-amplification model of victimization and depressive symptoms among runaway and homeless adolescents. Whitbeck LB, et al. **Am J Community Psychol** 1999 Apr; 27(2):273-96

A proactive approach to youth who run. English ND, et al. **Child Abuse Negl** 1999 Jul;23(7):693-8

Behavior problems and traumatic events of unaccompanied refugee minors. Sourander A. **Child Abuse Negl** 1998 Jul; 22(7):719-27

IQ scores among homeless older adolescents: characteristics of intellectual performance and associations with psychosocial functioning. Rohde P, et al. **J Adolesc** 1999 Jun;22(3):319-28

Service utilization among homeless and runaway youth in Los Angeles, California: rates and reasons [corrected and republished article originally printed in J Adolesc Health 1999 Mar;24(3):190-200] De Rosa CJ, et al. **J Adolesc Health** 1999 Jun;24(6):449-58

Hope as seen through the eyes of homeless children. Herth K. **J Adv Nurs** 1998 Nov;28(5):1053-62

Gay, lesbian, and bisexual youth risks for emotional, physical, and social problems: results from a community-based survey. Lock J, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar; 38(3):297-304

Homeless and matched housed adolescents: a comparative study of psychopathology. McCaskill PA, et al. **J Clin Child Psychol** 1998 Oct;27(3):306-19

Social network characteristics associated with risky behaviors among runaway and homeless youth. Ennett ST, et al. **J Health Soc Behav** 1999 Mar;40(1):63-78

Homeless youth in London: I. Childhood antecedents and psychiatric disorder. Craig TK, et al. **Psychol Med** 1998 Nov;28(6):1379-88

The impact of living on the streets on latency children's friendships. Rohde LA, et al. **Rev Saude Publica** 1998 Jun; 32(3):273-80

STATISTICS & NUMERICAL DATA

A survey of food problems experienced by Toronto street youth. Antoniades M, et al. **Can J Public Health** 1998 Nov-Dec;89(6):371-5

Street children--a preliminary study. Senanayake MP, et al. **Ceylon Med J** 1998 Dec;43(4):191-3

Association between drug use patterns and HIV risks among homeless, runaway, and street youth in northern California. Gleghorn AA, et al. **Drug Alcohol Depend** 1998 Aug 1; 51(3):219-27

Missing children. Lewit EM, et al. **Future Child** 1998 Summer-Fall;8(2):141-51 (35 ref.)

Service utilization among homeless and runaway youth in Los Angeles, California: rates and reasons [corrected and republished in J Adolesc Health 1999 Jun;24(6):449-58] De Rosa CJ, et al. **J Adolesc Health** 1999 Mar;24(3):190-200

Mortality among street youth [letter] [see comments] Roy E, et al. **Lancet** 1998 Jul 4;352(9121):32. Comment in: Lancet 1998 Aug 29;352(9129):743.

Comparing suicide attempters, suicide ideators, and nonsuicidal homeless and runaway adolescents. Yoder KA. **Suicide Life Threat Behav** 1999 Spring;29(1):25-36

HOMEMAKER-HOME HEALTH AIDES see **HOME HEALTH AIDES**

HOMEOBOX PROTEINS see **HOMEODOMAIN PROTEINS**

HOMEOBOX SEQUENCE see **GENES, HOMEOBOX**

HOMEODOMAIN PROTEINS

Drosophila engrailed can substitute for mouse Engrailed1 function in mid-hindbrain, but not limb development. Hanks MC, et al. **Development** 1998 Nov;125(22):4521-30

ANALYSIS

A single rostrocaudal colonization of the rodent intestine by enteric neuron precursors is revealed by the expression of Phox2b, Ret, and p75 and by explants grown under the kidney capsule or in organ culture. Young HM, et al. **Dev Biol** 1998 Oct 1;202(1):67-84

The murine Cdx1 gene product localises to the proliferative compartment in the developing and regenerating intestinal epithelium. Subramanian V, et al. **Differentiation** 1998 Nov; 64(1):11-8

The pattern of Distal-less expression in the mouthparts of crustaceans, myriapods and insects: new evidence for a gnathobasic mandible and the common origin of Mandibulata. Scholtz G, et al. **Int J Dev Biol** 1998 Sep; 42(6):801-10

Evidence for the presence of the tissue-specific transcription factor Pit-1 in lancelet larvae. Candiani S, et al. **J Comp Neurol** 1998 Oct 26;400(3):310-6

Expression of the medaka (Oryzias latipes) Ol-Rx3 paired-like gene in two diencephalic derivatives, the eye and the hypothalamus. Desehet K, et al. **Mech Dev** 1999 May;83(1-2):179-82

ANTAGONISTS & INHIBITORS

RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex. Bach I, et al. **Nat Genet** 1999 Aug; 22(4):394-9

BIOSYNTHESIS

The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle. Morgan MJ, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):245-50

The fourth member of the FHL family of LIM proteins is expressed exclusively in the testis. Morgan MJ, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):251-5

Age-related changes in thyroid hormone responsive protein (THRP) expression in cerebral tissue of rats. Mooradian AD, et al. **Brain Res** 1998 May 18;793(1-2):302-4

Differential expression of Islet-1 in neural crest-derived ganglia: Islet-1 + dorsal root ganglion cells are post-mitotic and Islet-1 + sympathetic ganglion cells are still cycling. Avivi C, et al. **Brain Res Dev Brain Res** 1999 Jun 8;115(1):89-92

Expression of Pax-3 in the lateral neural plate is dependent on a Wnt-mediated signal from posterior nonaxial mesoderm. Bang AG, et al. **Dev Biol** 1999 Aug 15; 212(2):366-80

Opposite effects of FGF and BMP-4 on embryonic blood formation: roles of PV.1 and GATA-2. Xu RH, et al. **Dev Biol** 1999 Apr 15;208(2):352-61

Patterns of paired-related homeobox genes PRX1 and PRX2 suggest involvement in matrix modulation in the developing chick vascular system. Bergwerff M, et al. **Dev Dyn** 1998 Sep;213(1):59-70

Anterior structural defects by misexpression of Xgbx-2 in early Xenopus embryos are associated with altered expression of cell adhesion molecules. King MW, et al. **Dev Dyn** 1998 Aug;212(4):563-79

Ectopic expression of hoxb2 after retinoic acid treatment or mRNA injection: disruption of hindbrain and craniofacial morphogenesis in zebrafish embryos. Yan YL, et al. **Dev Dyn** 1998 Dec;213(4):370-85

Novel regulation of the homeotic gene Scr associated with a crustacean leg-to-maxilliped appendage transformation. Abzhanov A, et al. **Development** 1999 Mar;126(6):1121-8

Prospero distinguishes sibling cell fate without asymmetric localization in the Drosophila adult external sense organ lineage. Manning L, et al. **Development** 1999 May; 126(10):2063-71

Expression of the LIM-homeobox gene LH2 generates immortalized steel factor-dependent multipotent hematopoietic precursors. Pinto do O P, et al. **EMBO J** 1998 Oct 1;17(19):5744-56

Endothelial cells express a novel, tumor necrosis factor-alpha-regulated variant of HOXA9. Patel CV, et al. **J Biol Chem** 1999 Jan 15;274(3):1415-22

Myocyte enhancer factor 2C and Nkx2-5 up-regulate each other's expression and initiate cardiomyogenesis in P19 cells. Skerjanc IS, et al. **J Biol Chem** 1998 Dec 25; 273(52):34904-10

Expression of the members of the Ptx family of transcription factors in human pituitary adenomas. Pellegrini-Bouiller I, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2212-20

Colony integration and the expression of the Hox gene, Cnox-2, in Hydractinia symbiolongicarpus (Cnidaria: Hydrozoa). Cartwright P, et al. **J Exp Zool** 1999 Apr 15; 285(1):57-62

Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, et al. **J Neurobiol** 1998 Sep 15;36(4):559-71

Lhx9: a novel LIM-homeodomain gene expressed in the developing forebrain. Rétaux S, et al. **J Neurosci** 1999 Jan 15;19(2):783-93

Checkpoints in thymocytopoiesis in aging: expression of the recombination activating genes RAG-1 and RAG-2. Yehuda AB, et al. **Mech Ageing Dev** 1998 May 15; 102(2-3):239-47

Modulation of Hedgehog target gene expression by the Fused serine-threonine kinase in wing imaginal discs. Alves G, et al. **Mech Dev** 1998 Nov;78(1-2):17-31

Transcriptional control of Drosophila bicoid by Serendipity delta: cooperative binding sites, promoter context, and co-evolution. Ruez C, et al. **Mech Dev** 1998 Nov; 78(1-2):125-34

Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients. Gennarelli M, et al. **Neuromuscul Disord** 1999 Jun;9(4):215-9

Active suppression of interneuron programs within developing motor neurons revealed by analysis of homeodomain factor HB9 [see comments] Thaler J, et al. **Neuron** 1999 Aug;23(4):675-87. Comment in: Neuron 1999 Aug;23(4):626-7.

The tissue-specific transcription factor Pit-1 is expressed in the spinal cord of the lancelet, Branchiostoma lanceolatum. Candiani S, et al. **Neurosci Lett** 1999 Jan 22;260(1):25-8

A novel Drosophila paired-like homeobox gene related to Caenorhabditis elegans unc-4 is expressed in subsets of postmitotic neurons and epidermal cells. Tabuchi K, et al. **Neurosci Lett** 1998 Nov 20;257(1):49-52

Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. Care A, et al. **Oncogene** 1999 Mar 18; 18(11):1993-2001

[Gene expression of Is-1 gene in adult motor neurons] Li T, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):270 **(Chi)**

CHEMISTRY

Topology of the thyroid transcription factor 1 homeodomain-DNA complex. Scaloni A, et al. **Biochemistry** 1999 Jan 5;38(1):64-72

Smoluchowski dynamics of the vnd/NK-2 homeodomain from Drosophila melanogaster: first-order mode-coupling approximation. La Penna G, et al. **Biopolymers** 1999 Mar; 49(3):235-54

Structure of a HoxB1-Pbx1 heterodimer bound to DNA: role of the hexapeptide and a fourth homeodomain helix in complex formation. Piper DE, et al. **Cell** 1999 Feb 19; 96(4):587-97

Co-operative DNA binding by GAGA transcription factor requires the conserved BTB/POZ domain and reorganizes promoter topology. Katsani KR, et al. **EMBO J** 1999 Feb 1;18(3):698-708

The nuclear localization signal (NLS) of PDX-1 is part of the homeodomain and represents a novel type of NLS. Hessabi B, et al. **Eur J Biochem** 1999 Jul;263(1):170-7

Cloning, characterization, and mapping of the mouse homeobox gene Hmx1. Yoshiura K, et al. **Genomics** 1998 May 15;50(1):61-8

1H, 13C and 15N assignment of the Isl-1 homeodomain. Ippel JH, et al. **J Biomol NMR** 1998 Aug;12(2):357-9

15N-edited three-dimensional NOESY-HMQC with water flipback: enhancement of weak labile 1H resonances of protein side chains contacting DNA. Gruschus JM, et al. **J Magn Reson** 1998 Nov;135(1):87-92

Engrailed homeodomain-DNA complex at 2.2 A resolution: a detailed view of the interface and comparison with other engrailed structures. Fraenkel E, et al. **J Mol Biol** 1998 Nov 27;284(2):351-61

The three-dimensional structure of the vnd/NK-2 homeodomain-DNA complex by NMR spectroscopy. Gruschus JM, et al. **J Mol Biol** 1999 Jun 11;289(3):529-45

The solution structure of the homeodomain of the rat insulin-gene enhancer protein isl-1. Comparison with other homeodomains. Ippel H, et al. **J Mol Biol** 1999 May 14; 288(4):689-703

NMR studies of the pbx1 TALE homeodomain protein free in solution and bound to DNA: proposal for a mechanism of HoxB1-Pbx1-DNA complex assembly. Jabet C, et al. **J Mol Biol** 1999 Aug 20;291(3):521-30

Definition of the transcriptional activation domains of three human HOX proteins depends on the DNA-binding context. Viganò MA, et al. **Mol Cell Biol** 1998 Nov; 18(11):6201-12

Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Wallis DE, et al. **Nat Genet** 1999 Jun;22(2):196-8

Structural basis of Hox specificity [news] Wilson DS, et al. **Nat Struct Biol** 1999 Apr;6(4):297-300

Structure of a DNA-bound Ultrabithorax-Extradenticle homeodomain complex [see comments] Passner JM, et al. **Nature** 1999 Feb 25;397(6721):714-9. Comment in: Nature 1999 Feb 25;397(6721):649, 651.

The Homeodomain Resource: sequences, structures and genomic information. Banerjee-Basu S, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):336-7

Crystal structure of the MATa1/MATalpha2 homeodomain heterodimer in complex with DNA containing an A-tract. Li T, et al. **Nucleic Acids Res** 1998 Dec 15;26(24):5707-18

Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis.

Kenny DA, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11257–62

Cloning of Mix-related homeodomain proteins using fast retrieval of gel shift activities, (FROGS), a technique for the isolation of DNA-binding proteins. Mead PE, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11251–6

Arm-domain interactions in proteins: a review [editorial] Schleif R. **Proteins** 1999 Jan 1;34(1):1–3

GENETICS

Monodactylous limbs and abnormal genitalia are associated with hemizygosity for the human 2q31 region that includes the HOXD cluster. Del Campo M, et al. **Am J Hum Genet** 1999 Jul;65(1):104–10

Deletions in HOXD13 segregate with an identical, novel foot malformation in two unrelated families. Goodman F, et al. **Am J Hum Genet** 1998 Oct;63(4):992–1000

Association of MSX1 and TGFB3 with nonsyndromic clefting in humans. Lidral AC, et al. **Am J Hum Genet** 1998 Aug;63(2):557–68

Mutation analysis of LMX1B gene in nail–patella syndrome patients. McIntosh I, et al. **Am J Hum Genet** 1998 Dec; 63(6):1651–8

A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription-factor gene. Sohocki MM, et al. **Am J Hum Genet** 1998 Nov;63(5):1307–15

Beta-catenin directly induces expression of the Siamois gene, and can initiate signaling indirectly via a membrane-tethered form. Nelson RW, et al. **Ann N Y Acad Sci** 1998 Oct 23;857:86–98

Evolution of chordate hox gene clusters. Ruddle FH, et al. **Ann N Y Acad Sci** 1999 May 18;870:238–48

HOXC5 and HOXC8 expression are selectively turned on in human cervical cancer cells compared to normal keratinocytes. Alami Y, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):738–45

Human CART1, a paired-class homeodomain protein, activates transcription through palindromic binding sites. Cai RL. **Biochem Biophys Res Commun** 1998 Sep 18; 250(2):305–11

Hox gene complexity in medaka fish may Be similar to that in pufferfish rather than zebrafish. Kurosawa G, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):66–70

Characterization of cis-elements required for the transcriptional activation of the rae28/mph1 gene in F9 cells. Motaleb MA, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):509–15

Analysis of a human cDNA containing a tissue-specific alternatively spliced LIM domain. Putilina T, et al. **Biochem Biophys Res Commun** 1998 Nov 18;252(2):433–9

Human ZHX1: cloning, chromosomal location, and interaction with transcription factor NF-Y. Yamada K, et al. **Biochem Biophys Res Commun** 1999 Aug 11; 261(3):614–21

The Cdx-1 and Cdx-2 homeobox genes in the intestine. Freund JN, et al. **Biochem Cell Biol** 1998;76(6):957–69 (144 ref.)

Hepatocyte nuclear factor 6: organization and chromosomal assignment of the rat gene and characterization of its promoter. Rastegar M, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):565–9

Transcriptional autorepression of Msx1 gene is mediated by interactions of Msx1 protein with a multi-protein transcriptional complex containing TATA-binding protein, Sp1 and cAMP-response-element-binding protein-binding protein (CBP/p300). Shetty S, et al. **Biochem J** 1999 May 1;339 (Pt 3):751–8

cDNA cloning and expression of rat homeobox gene, Hex, and functional characterization of the protein. Tanaka T, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):111–7

Sequence characterisation and expression of homeobox HOX A7 in the multi-potential erythroleukaemic cell line TF-1. McIlhatton MA, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2–3):329–33

Molecular cloning of LMO41, a new human LIM domain gene. Racevskis J, et al. **Biochim Biophys Acta** 1999 Apr 14;1445(1):148–53

A zebrafish Six4 homologue with early expression in head mesoderm. Seo HC, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2–3):427–31

A common theme for LIM homeobox gene function across phylogeny? Hobert O, et al. **Biol Bull** 1998 Dec; 195(3):377–80 (12 ref.)

Origin of the metazoan bodyplan: characterization and functional testing of the promoter of the homeobox gene EmH-3 from the freshwater sponge Ephydatia muelleri in mouse 3T3 cells. Coutinho CC, et al. **Biol Chem** 1998 Oct;379(10):1243–51

Characterization of HOX gene expression during myelopoiesis: role of HOX A5 in lineage commitment and maturation. Fuller JF, et al. **Blood** 1999 May 15; 93(10):3391–400

Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. Yagi OK, et al. **Br J Cancer** 1999 Feb;79(3–4):440–4

Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Saadane N, et al. **Br J Pharmacol** 1999 Jul;127(5):1165–76

Regulated expression of the homeobox gene, rPtx2, in the developing rat. Lindberg C, et al. **Brain Res Dev Brain Res** 1998 Oct 1;110(2):215–26

The mouse homeodomain protein OTX2 regulates NCAM promoter activity. Nguyen Ba-Charvet KT, et al. **Brain Res Mol Brain Res** 1999 Apr 20;67(2):292–5

NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Raza-Egilmez SZ, et al. **Cancer Res** 1998 Oct 1;58(19):4269–73

Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice. Tamai Y, et al. **Cancer Res** 1999 Jun 15;59(12):2965–70

Breaking colinearity in the mouse HoxD complex. Kondo T, et al. **Cell** 1999 Apr 30;97(3):407–17

Squid hnRNP protein promotes apical cytoplasmic transport and localization of Drosophila pair-rule transcripts. Lall S, et al. **Cell** 1999 Jul 23;98(2):171–80

Structure of a HoxB1-Pbx1 heterodimer bound to DNA: role of the hexapeptide and a fourth homeodomain helix in complex formation. Piper DE, et al. **Cell** 1999 Feb 19; 96(4):587–97

Giant eyes in Xenopus laevis by overexpression of XOptx2. Zuber ME, et al. **Cell** 1999 Aug 6;98(3):341–52

Genetic elements regulating HES-1 induction in Wnt-1-transformed PC12 cells. Issack PS, et al. **Cell Growth Differ** 1998 Oct;9(10):827–36

Altered expression of helix-loop-helix transcriptional regulators and cyclin D1 in Wnt-1-transformed PC12 cells. Issack PS, et al. **Cell Growth Differ** 1998 Oct;9(10):837–45

The murine Hoxb1 3' RAIDR5 enhancer contains multiple regulatory elements. Thompson JR, et al. **Cell Growth Differ** 1998 Dec;9(12):969–81

Do 5'Hoxd genes play a role in initiating or maintaining A-P polarizing signals in the limb? Mackem S, et al. **Cell Tissue Res** 1999 Apr;296(1):27–31 (43 ref.)

Polymorphic variants within the homeobox gene MSX1: a candidate gene for developmental disorders. Hollway GE, et al. **Clin Genet** 1998 Aug;54(2):152–4

Embryonic asymmetry: the left side gets all the best genes. King T, et al. **Curr Biol** 1999 Jan 14;9(1):R18–22

The nieuwkoid gene characterizes and mediates a Nieuwkoop-center-like activity in the zebrafish. Koos DS, et al. **Curr Biol** 1998 Nov 5;8(22):1199–206

Linkage mapping of Lims1l, the murine homolog of the human LIM domain gene PINCH, to mouse chromosome 10. Abu-Hayyeh S, et al. **Cytogenet Cell Genet** 1998; 82(1–2):46–8

Assignment1 of the human Stra13 gene (STRA13) to chromosome 3p26 by in situ hybridization. Antonevich T, et al. **Cytogenet Cell Genet** 1999;85(3–4):254–5

Assignment of SHOX2 (alias OG12X and SHOT) to human chromosome bands 3q25-->q26.1 by in situ hybridization. De Baere E, et al. **Cytogenet Cell Genet** 1998;82(3–4):228–9

Comparative gene mapping: cytogenetic localization of PROC, EN1, ALPI, TNP1, and IL1B in cattle and sheep reveals a conserved rearrangement relative to the human genome. Lòpez-Corrales NL, et al. **Cytogenet Cell Genet** 1998;83(1–2):35–8

Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. Shimada Y, et al. **Cytogenet Cell Genet** 1998;83(3–4):232–5

Lack of regulation in the heart forming region of avian embryos. Ehrman LA, et al. **Dev Biol** 1999 Mar 1; 207(1):163–75

Forced expression of the homeobox-containing gene Pem blocks differentiation of embryonic stem cells. Fan Y, et al. **Dev Biol** 1999 Jun 15;210(2):481–96

Patterning of Caenorhabditis elegans posterior structures by the Abdominal-B homolog, egl-5. Ferreira HB, et al. **Dev Biol** 1999 Mar 1;207(1):215–28

Regionalized organizing activity of the neural tube revealed by the regulation of lmx1 in the otic vesicle. Giraldez F. **Dev Biol** 1998 Nov 1;203(1):189–200

Notochord regulates cardiac lineage in zebrafish embryos. Goldstein AM, et al. **Dev Biol** 1998 Sep 15;201(2):247–52

Tinman function is essential for vertebrate heart development: elimination of cardiac differentiation by dominant inhibitory mutants of the tinman-related genes, XNkx2-3 and XNkx2-5. Grow MW, et al. **Dev Biol** 1998 Dec 1;204(1):187–96

Ascidian tail formation requires caudal function. Katsuyama Y, et al. **Dev Biol** 1999 Sep 15;213(2):257–68

Novel strategy yields candidate Gsh-1 homeobox gene targets using hypothalamus progenitor cell lines. Li H, et al. **Dev Biol** 1999 Jul 1;211(1):64–76

Paired-related homeobox genes cooperate in handplate and hindlimb zeugopod morphogenesis. Lu MF, et al. **Dev Biol** 1999 Jan 1;205(1):145–57

Activin-induced factors maintain goosecoid transcription through a paired homeodomain binding site. McKendry R, et al. **Dev Biol** 1998 Dec 1;204(1):172–86

Hoxa5 gene regulation: A gradient of binding activity to a brachial spinal cord element. Nowling T, et al. **Dev Biol** 1999 Apr 1;208(1):134–46

The planarian HOM/HOX homeobox genes (Plox) expressed along the anteroposterior axis. Orii H, et al. **Dev Biol** 1999 Jun 15;210(2):456–68

Normal reproductive and macrophage function in Pem homeobox gene-deficient mice. Pitman JL, et al. **Dev Biol** 1998 Oct 15;202(2):196–214

The even-skipped locus is contained in a 16-kb chromatin domain. Sackerson C, et al. **Dev Biol** 1999 Jul 1; 211(1):39–52

CnOtx, a member of the Otx gene family, has a role in cell movement in hydra. Smith KM, et al. **Dev Biol** 1999 Aug 15;212(2):392–404

Disruption of primary mesenchyme cell patterning by misregulated ectodermal expression of SpMsx in sea urchin embryos. Tan H, et al. **Dev Biol** 1998 Sep 15;201(2):230–46

Otx expression during lamprey embryogenesis provides insights into the evolution of the vertebrate head and jaw. Tomsa JM, et al. **Dev Biol** 1999 Mar 1;207(1):26–37

Regulation of the trunk-tail patterning in the ascidian embryo: a possible interaction of cascades between lithium/beta-catenin and localized maternal factor pem. Yoshida S, et al. **Dev Biol** 1998 Oct 15;202(2):264–79

Genetic analysis of a conserved sequence in the HoxD complex: regulatory redundancy or limitations of the transgenic approach? Beckers J, et al. **Dev Dyn** 1998 Sep; 213(1):1–11

Dlx-5 in limb initiation in the chick embryo. Ferrari D, et al. **Dev Dyn** 1999 Sep;216(1):10–5

RARbeta mediates the response of Hoxd4 and Hoxb4 to exogenous retinoic acid. Folberg A, et al. **Dev Dyn** 1999 Jun;215(2):96–107

Alx-4, a transcriptional activator whose expression is restricted to sites of epithelial-mesenchymal interactions. Hudson R, et al. **Dev Dyn** 1998 Oct;213(2):159–69

Multiple cis-acting regulatory regions are required for restricted spatio-temporal Hoxa5 gene expression. Larochelle C, et al. **Dev Dyn** 1999 Feb;214(2):127–40

Hox11-family genes XHox11 and XHox11L2 in xenopus: XHox11L2 expression is restricted to a subset of the primary sensory neurons. Patterson KD, et al. **Dev Dyn** 1999 Jan;214(1):34–43

Characterization of the Tribolium Deformed ortholog and its ability to directly regulate Deformed target genes in the rescue of a Drosophila Deformed null mutant. Brown S, et al. **Dev Genes Evol** 1999 Jul;209(7):389–98

Expression of MADS box genes ZMM8 and ZMM14 during inflorescence development of Zea mays discriminates between the upper and the lower floret of each spikelet. Cacharr n J, et al. **Dev Genes Evol** 1999 Jul;209(7):411–20

Organising activities of engrailed, hedgehog, wingless and decapentaplegic in the genital discs of Drosophila melanogaster. Emerald BS, et al. **Dev Genes Evol** 1998 Nov; 208(9):504–16

Evolution of homeobox genes: Q50 Paired-like genes founded the Paired class. Galliot B, et al. **Dev Genes Evol** 1999 Mar;209(3):186–97

A Caenorhabditis elegans homeobox gene expressed in the male tail, a link between pattern formation and sexual dimorphism? Kagoshima H, et al. **Dev Genes Evol** 1999 Jan;209(1):59–62

Hox C6 expression during development and regeneration of forelimbs in larval Notophthalmus viridescens. Khan PA, et al. **Dev Genes Evol** 1999 Jun;209(6):323–9

Comparison of the GAGA factor genes of Drosophila melanogaster and Drosophila virilis reveals high conservation of GAGA factor structure beyond the BTB/POZ and DNA-binding domains. Lintermann KG, et al. **Dev Genes Evol** 1998 Oct;208(8):447–56

The Xenopus bagpipe-related homeobox gene zampogna is expressed in the pharyngeal endoderm and the visceral musculature of the midgut. Newman CS, et al. **Dev Genes Evol** 1999 Feb;209(2):132–4

The embryonic expression pattern of labial, posterior homeotic complex genes and the teashirt homologue in an apterygote insect. Peterson MD, et al. **Dev Genes Evol** 1999 Feb;209(2):77–90

The expression of two engrailed-related genes in an apterygote insect and a phylogenetic analysis of insect engrailed-related genes. Peterson MD, et al. **Dev Genes Evol** 1998 Dec;208(10):547–57

Cloning and expression of the engrailed.a gene of the barnacle Sacculina carcini. Queinnec E, et al. **Dev Genes Evol** 1999 Mar;209(3):180–5

Of mites and zen: expression studies in a chelicerate arthropod confirm zen is a divergent Hox gene. Telford MJ, et al. **Dev Genes Evol** 1998 Dec;208(10):591–4

Distinct structural domains in the planarian brain defined by the expression of evolutionarily conserved homeobox genes. Umesono Y, et al. **Dev Genes Evol** 1999 Jan; 209(1):31–9

Sequence and developmental expression of amphioxus AmphiNk2-1: insights into the evolutionary origin of the vertebrate thyroid gland and forebrain. Venkatesh TV, et al. **Dev Genes Evol** 1999 Apr;209(4):254–9

Two Nkx-3-related genes are expressed in the adult and regenerating central nervous system of the urodele Pleurodeles waltl. Nicolas S, et al. **Dev Genet** 1999; 24(3–4):319–28

Cloning of zebrafish vsx1: expression of a paired-like homeobox gene during CNS development. Passini MA, et al. **Dev Genet** 1998;23(2):128–41

Analysis of murine HOXA-2 activity in Drosophila melanogaster. Percival-Smith A, et al. **Dev Genet** 1999; 24(3–4):336–44

Hbox1 and Hbox7 are involved in pattern formation in sea urchin embryos. Ishii M, et al. **Dev Growth Differ** 1999 Jun;41(3):241–52

Lim1 related homeobox gene (HpLim1) expressed in sea urchin embryos. Kawasaki T, et al. **Dev Growth Differ** 1999 Jun;41(3):273–82

Shh, Bmp-2 and Hoxd-13 gene expression in chick limb bud cells in culture. Kimura J, et al. **Dev Growth Differ** 1998 Aug;40(4):457–64

Mosaic analysis with oep mutant reveals a repressive interaction between floor-plate and non-floor-plate mutant cells in the zebrafish neural tube. Shinya M, et al. **Dev Growth Differ** 1999 Apr;41(2):135-42

Anterior organization of the Caenorhabditis elegans embryo by the labial-like Hox gene ceh-13. Brunschwig K, et al. **Development** 1999 Apr;126(7):1537-46

The Arabidopsis FILAMENTOUS FLOWER gene is required for flower formation. Chen Q, et al. **Development** 1999 Jun;126(12):2715-26

The Drosophila kismet gene is related to chromatin-remodeling factors and is required for both segmentation and segment identity. Daubresse G, et al. **Development** 1999 Mar;126(6):1175-87

Regulation of the spalt/spalt-related gene complex and its function during sensory organ development in the Drosophila thorax. de Celis JF, et al. **Development** 1999 Jun;126(12):2653-62

The beta-catenin homolog BAR-1 and LET-60 Ras coordinately regulate the Hox gene lin-39 during Caenorhabditis elegans vulval development. Eisenmann DM, et al. **Development** 1998 Sep;125(18):3667-80

The zebrafish bozozok locus encodes Dharma, a homeodomain protein essential for induction of gastrula organizer and dorsoanterior embryonic structures. Fekany K, et al. **Development** 1999 Apr;126(7):1427-38

Analysis of an even-skipped rescue transgene reveals both composite and discrete neuronal and early blastoderm enhancers, and multi-stripe positioning by gap gene repressor gradients. Fujioka M, et al. **Development** 1999 Jun;126(11):2527-38

Targeting gene expression to the head: the Drosophila orthodenticle gene is a direct target of the Bicoid morphogen. Gao Q, et al. **Development** 1998 Nov; 125(21):4185-93

Homologous association of the Bithorax-Complex during embryogenesis: consequences for transvection in Drosophila melanogaster. Gemkow MJ, et al. **Development** 1998 Nov;125(22):4541-52

Distinct signaling molecules control Hoxa-11 and Hoxa-13 expression in the muscle precursor and mesenchyme of the chick limb bud. Hashimoto K, et al. **Development** 1999 Jun; 126(12):2771-83

The Caenorhabditis elegans lim-6 LIM homeobox gene regulates neurite outgrowth and function of particular GABAergic neurons. Hobert O, et al. **Development** 1999 Apr;126(7):1547-62

The homeobox gene Msx1 is expressed in a subset of somites, and in muscle progenitor cells migrating into the forelimb. Houzelstein D, et al. **Development** 1999 Jun; 126(12):2689-701

Specification of distinct motor neuron identities by the singular activities of individual Hox genes. Jungbluth S, et al. **Development** 1999 Jun;126(12):2751-8

hedgehog and engrailed: pattern formation and polarity in the Drosophila abdomen. Lawrence PA, et al. **Development** 1999 Jun;126(11):2431-9

The hedgehog morphogen and gradients of cell affinity in the abdomen of Drosophila. Lawrence PA, et al. **Development** 1999 Jun;126(11):2441-9

Control of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. Lien CL, et al. **Development** 1999 Jan;126(1):75-84

A cap 'n' collar protein isoform contains a selective Hox repressor function. McGinnis N, et al. **Development** 1998 Nov;125(22):4553-64

Regulation of Hoxa2 in cranial neural crest cells involves members of the AP-2 family. Maconochie M, et al. **Development** 1999 Apr;126(7):1483-94

A short region of its homeodomain is necessary for engrailed nuclear export and secretion. Maizel A, et al. **Development** 1999 Jun;126(14):3183-90

A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al. **Development** 1999 Jan;126(1):37-49

Conserved and distinct roles of kreisler in regulation of the paralogous Hoxa3 and Hoxb3 genes. Manzanares M, et al. **Development** 1999 Feb;126(4):759-69

The centrosomin protein is required for centrosome assembly and function during cleavage in Drosophila. Megraw TL, et al. **Development** 1999 Jul;126(13):2829-39

Kinetic analysis of segmentation gene interactions in Drosophila embryos. Nasiadka A, et al. **Development** 1999 Apr;126(7):1515-26

Direct regulatory interaction of the eyeless protein with an eye-specific enhancer in the sine oculis gene during eye induction in Drosophila. Niimi T, et al. **Development** 1999 May;126(10):2253-60

Physical and genetic interactions between Alx4 and Cart1. Qu S, et al. **Development** 1999 Jan;126(2):359-69

Identification of upstream regulatory regions in the heart-expressed homeobox gene Nkx2-5. Reecy JM, et al. **Development** 1999 Feb;126(4):839-49

Dynamic changes in the functions of Odd-skipped during early Drosophila embryogenesis. Saulier-Le Drean B, et al. **Development** 1998 Dec;125(23):4851-61

A GATA-dependent nkx-2.5 regulatory element activates early cardiac gene expression in transgenic mice. Searcy RD, et al. **Development** 1998 Nov;125(22):4461-70

The Pristionchus HOX gene Ppa-lin-39 inhibits programmed cell death to specify the vulva equivalence group and is not required during vulval induction. Sommer RJ, et al. **Development** 1998 Oct;125(19):3865-73

The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons. Stanke M, et al. **Development** 1999 Sep;126(18):4087-94

The Drosophila homeobox genes zfh-1 and even-skipped are required for cardiac-specific differentiation of a numb-dependent lineage decision. Su MT, et al. **Development** 1999 Jun;126(14):3241-51

Bix1, a direct target of Xenopus T-box genes, causes formation of ventral mesoderm and endoderm. Tada M, et al. **Development** 1998 Oct;125(20):3997-4006

The role of Alx-4 in the establishment of anteroposterior polarity during vertebrate limb development [published erratum appears in Development 1998 Dec;125(23):preceding 4595] Takahashi M, et al. **Development** 1998 Nov;125(22):4417-25

Complex modular cis-acting elements regulate expression of the cardiac specifying homeobox gene Csx/Nkx2.5. Tanaka M, et al. **Development** 1999 Apr;126(7):1439-50

The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Tanaka M, et al. **Development** 1999 Mar;126(6):1269-80

Prx1 and Prx2 in skeletogenesis: roles in the craniofacial region, inner ear and limbs. ten Berge D, et al. **Development** 1998 Oct;125(19):3831-42

Gli3 is required for Emx gene expression during dorsal telencephalon development. Theil T, et al. **Development** 1999 Aug;126(16):3561-71

Fgf-8 determines rostral-caudal polarity in the first branchial arch. Tucker AS, et al. **Development** 1999 Jan;126(1):51-61

The trithorax group gene osa encodes an ARID-domain protein that genetically interacts with the brahma chromatin-remodeling factor to regulate transcription. Vázquez M, et al. **Development** 1999 Feb;126(4):733-42

Regulation of the Tribolium homologues of caudal and hunchback in Drosophila: evidence for maternal gradient systems in a short germ embryo. Wolff C, et al. **Development** 1998 Sep;125(18):3645-54

Proximodistal axis formation in the Drosophila leg: subdivision into proximal and distal domains by Homothorax and Distal-less. Wu J, et al. **Development** 1999 Jan;126(1):109-17

Characterization of the transvection mediating region of the abdominal-B locus in Drosophila. Zhou J, et al. **Development** 1999 Jun;126(14):3057-65

A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: indication for linkage with islet 1 locus on chromosome 5q. Clément K, et al. **Diabetes** 1999 Feb;48(2):398-402

In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Harmon JS, et al. **Diabetes** 1999 Oct;48(10):1995-2000

The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Sharma A, et al. **Diabetes** 1999 Mar;48(3):507-13

No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France. Dupont S, et al. **Diabetologia** 1999 Apr;42(4):480-4

Activity regulation of a Hox protein and a role for the homeodomain in inhibiting transcriptional activation. Li X, et al. **EMBO J** 1999 Jan 4;18(1):198-211

Sequence interval within the PEST motif of Bicoid is important for translational repression of caudal mRNA in the anterior region of the Drosophila embryo. Niessing D, et al. **EMBO J** 1999 Apr 1;18(7):1966-73

Loss-of-function mutations in the rice homeobox gene OSH15 affect the architecture of internodes resulting in dwarf plants. Sato Y, et al. **EMBO J** 1999 Feb 15; 18(4):992-1002

Structural organization and sequence of the homeotic gene Antennapedia of Drosophila melanogaster. Schneuwly S, et al. **EMBO J** 1986 Apr;5(4):733-9

Transcriptional repression due to high levels of Wingless signalling. Yu X, et al. **EMBO J** 1998 Dec 1;17(23):7021-32

Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of the human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and Gö 6976-insensitive pathway. Furukawa N, et al. **Endocr J** 1999 Feb; 46(1):43-58

Sequence analysis of thyroid transcription factor-1 gene reveals absence of mutations in patients with thyroid dysgenesis but presence of polymorphisms in the 5' flanking region and intron. Hishinuma A, et al. **Endocr J** 1998 Aug; 45(4):563-7

The bovine CYP17 promoter contains a transcriptional regulatory element cooperatively bound by tale homeodomain proteins. Bischof LJ, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):489-95

Pituitary homeobox 1 (Ptx1) is differentially expressed during pituitary development. Lanctôt C, et al. **Endocrinology** 1999 Mar;140(3):1416-22

The pancreatic homeodomain transcription factor IDX1/IPF1 is expressed in neural cells during brain development. Perez-Villamil B, et al. **Endocrinology** 1999 Aug;140(8):3857-60

The nuclear localization signal (NLS) of PDX-1 is part of the homeodomain and represents a novel type of NLS. Hessabi B, et al. **Eur J Biochem** 1999 Jul;263(1):170-7

Re-expression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphocytes. Giachino C, et al. **Eur J Immunol** 1998 Nov;28(11):3506-13

Human Prop-1: cloning, mapping, genomic structure. Mutations in familial combined pituitary hormone deficiency. Duquesnoy P, et al. **FEBS Lett** 1998 Oct 23; 437(3):216-20

Murine leukemia provirus-mediated activation of the Notch1 gene leads to induction of HES-1 in a mouse T lymphoma cell line, DL-3. Lee JS, et al. **FEBS Lett** 1999 Jul 23; 455(3):276-80

Evidence for an ancient chromosomal duplication in Arabidopsis thaliana by sequencing and analyzing a 400-kb contig at the APETALA2 locus on chromosome 4. Terryn N, et al. **FEBS Lett** 1999 Feb 26;445(2-3):237-45

A downstream splicing enhancer is essential for in vitro pre-mRNA splicing. Yue BG, et al. **FEBS Lett** 1999 May 14;451(1):10-4

Yeast tom1 mutant exhibits pleiotropic defects in nuclear division, maintenance of nuclear structure and nucleocytoplasmic transport at high temperatures. Utsugi T, et al. **Gene** 1999 Jul 8;234(2):285-95

Sequence of 10q24 locus surrounding the HOX11 oncogene reveals a new gene HUG1 expressed in a T-ALL cell line. Watt PM, et al. **Gene** 1999 Jun 24;234(1):169-76

Expression of the Vax family homeobox genes suggests multiple roles in eye development. Ohsaki K, et al. **Genes Cells** 1999 May;4(5):267-76

Identification of engrailed promoter elements essential for interactions with a stripe enhancer in Drosophila embryos. Orihara M, et al. **Genes Cells** 1999 Apr;4(4):205-18

Low frequency of rearrangements of the homeobox gene HOXA9/t(7;11) in adult acute myeloid leukemia. Kwong YL, et al. **Genes Chromosomes Cancer** 1999 May;25(1):70-4

Targeting genes for self-excision in the germ line. Bunting M, et al. **Genes Dev** 1999 Jun 15;13(12):1524-8

Formation and specification of ventral neuroblasts is controlled by vnd in Drosophila neurogenesis. Chu H, et al. **Genes Dev** 1998 Nov 15;12(22):3613-24

Six3 overexpression initiates the formation of ectopic retina. Loosli F, et al. **Genes Dev** 1999 Mar 15;13(6):649-54

Dorsoventral patterning in the Drosophila central nervous system: the vnd homeobox gene specifies ventral column identity. McDonald JA, et al. **Genes Dev** 1998 Nov 15; 12(22):3603-12

GAGA mediates the enhancer blocking activity of the eve promoter in the Drosophila embryo. Ohtsuki S, et al. **Genes Dev** 1998 Nov 1;12(21):3325-30

Alternative olfactory neuron fates are specified by the LIM homeobox gene lim-4. Sagasti A, et al. **Genes Dev** 1999 Jul 15;13(14):1794-806

Role of the Bicoid-related homeodomain factor Pitx1 in specifying hindlimb morphogenesis and pituitary development. Szeto DP, et al. **Genes Dev** 1999 Feb 15; 13(4):484-94

The bHLH gene Hes1 is essential for expansion of early T cell precursors. Tomita K, et al. **Genes Dev** 1999 May 1; 13(9):1203-10

A genetic screen of the Drosophila X chromosome for mutations that modify Deformed function. Florence B, et al. **Genetics** 1998 Dec;150(4):1497-511

Potential variance affecting homeotic Ultrabithorax and Antennapedia phenotypes in Drosophila melanogaster. Gibson G, et al. **Genetics** 1999 Mar;151(3):1081-91

Molecular population genetics of floral homeotic loci. Departures from the equilibrium-neutral model at the APETALA3 and PISTILLATA genes of Arabidopsis thaliana. Purugganan MD, et al. **Genetics** 1999 Feb; 151(2):839-48

Nipped-B, a Drosophila homologue of chromosomal adherins, participates in activation by remote enhancers in the cut and Ultrabithorax genes. Rollins RA, et al. **Genetics** 1999 Jun;152(2):577-93

Overexpression Beadex mutations and loss-of-function heldup-a mutations in Drosophila affect the 3' regulatory and coding components, respectively, of the Dlmo gene. Shoresh M, et al. **Genetics** 1998 Sep;150(1):283-99

Genomic cloning, structure, expression pattern, and chromosomal location of the human SIX3 gene. Granadino B, et al. **Genomics** 1999 Jan 1;55(1):100-5

Identification, chromosomal assignment, and expression analysis of the human homeodomain-containing gene Orthopedia (OTP). Lin X, et al. **Genomics** 1999 Aug 15; 60(1):96-104

PHTF, a novel atypical homeobox gene on chromosome 1p13, is evolutionarily conserved. Raich N, et al. **Genomics** 1999 Jul 1;59(1):108-9

Genomic structure and functional characterization of NBPhox (PMX2B), a homeodomain protein specific to catecholaminergic cells that is involved in second messenger-mediated transcriptional activation. Yokoyama M, et al. **Genomics** 1999 Jul 1;59(1):40-50

Cloning, characterization, and mapping of the mouse homeobox gene Hmx1. Yoshiura K, et al. **Genomics** 1998 May 15;50(1):61-8

Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements. Ding H, et al. **Hum Mol Genet** 1998 Oct;7(11):1681-94

Mutation in the RIEG1 gene in patients with iridogoniodysgenesis syndrome. Kulak SC, et al.

Hum Mol Genet 1998 Jul;7(7):1113-7

Promoter of mDMAHP/Six5: differential utilization of multiple transcription initiation sites and positive/negative regulatory elements. Murakami Y, et al. **Hum Mol Genet** 1998 Dec;7(13):2103-12

Goosecoid-like (Gscl), a candidate gene for velocardiofacial syndrome, is not essential for normal mouse development. Saint-Jore B, et al. **Hum Mol Genet** 1998 Nov;7(12):1841-9

Leber congenital amaurosis caused by a homozygous mutation (R90W) in the homeodomain of the retinal transcription factor CRX: direct evidence for the involvement of CRX in the development of photoreceptor function. Swaroop A, et al. **Hum Mol Genet** 1999 Feb; 8(2):299-305

Loss-of-function mutations in the LIM-homeodomain gene, LMX1B, in nail-patella syndrome [published erratum appears in Hum Mol Genet 1998 Aug;7(8):1333] Vollrath D, et al. **Hum Mol Genet** 1998 Jul;7(7):1091-8

MSX-1 gene expression and regulation in embryonic palatal tissue. Nugent P, et al. **In Vitro Cell Dev Biol Anim** 1998 Nov-Dec;34(10):831-5

Expression of two even-skipped genes evel and evx2 during zebrafish fin morphogenesis and their regulation by retinoic acid. Brulfert A, et al. **Int J Dev Biol** 1998 Nov; 42(8):1117-24

The 35UZ transposon of Drosophila melanogaster reveals differences in maintenance of transcriptional control between embryonic and larval stages. Docquier F, et al. **Int J Dev Biol** 1999 May;43(3):275-8

Differential expression of sea urchin Otx isoform (hpOtxE and HpOtxL) mRNAs during early development. Mitsunaga-Nakatsubo K, et al. **Int J Dev Biol** 1998 Jul; 42(5):645-51

Altered Hox expression and increased cell death distinguish Hypodactyly from Hoxa13 null mice. Post LC, et al. **Int J Dev Biol** 1999 Jul;43(4):287-94

A homeobox gene of the orthodenticle family is involved in antero-posterior patterning of regenerating planarians. Stornaiuolo A, et al. **Int J Dev Biol** 1998 Nov;42(8):1153-8

Hoxb-5 is expressed in gill arch 5 during pharyngeal arch development of flounder Paralichthys olivaceus embryos. Suzuki T, et al. **Int J Dev Biol** 1999 Jul;43(4):357-9

Identification of LMX1B gene point mutations in italian patients affected with Nail-Patella syndrome. Seri M, et al. **Int J Mol Med** 1999 Sep;4(3):285-90

Retinal degenerations with truncation mutations in the cone-rod homeobox (CRX) gene. Jacobson SG, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2417-26

An enhancer element for expression of the Ncx (Enx, Hox11L1) gene in neural crest-derived cells. Iitsuka Y, et al. **J Biol Chem** 1999 Aug 20;274(34):24401-7

c-myc intron element-binding proteins are required for 1, 25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4. Pan Q, et al. **J Biol Chem** 1999 Mar 26;274(13):8437-44

Regulation of the Dlx3 homeobox gene upon differentiation of mouse keratinocytes. Park GT, et al. **J Biol Chem** 1999 Sep 10;274(37):26599-608

GATA-6 activates transcription of thyroid transcription factor-1. Shaw-White JR, et al. **J Biol Chem** 1999 Jan 29; 274(5):2658-64

Cig30 and Pitx3 genes are arranged in a partially overlapping tail-to-tail array resulting in complementary transcripts. Tvrdik P, et al. **J Biol Chem** 1999 Sep 10;274(37):26387-92

Molecular cloning of a mutated HOXB7 cDNA encoding a truncated transactivating homeodomain-containing protein. Chariot A, et al. **J Cell Biochem** 1998 Oct 1; 71(1):46-54

Characterization of the human 36-kDa carboxyl terminal LIM domain protein (hCLIM1). Kotaka M, et al. **J Cell Biochem** 1999 Feb 1;72(2):279-85

"Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency. Deladoëy J, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1645-50

Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg-->Cys at codon 120 (R120C). Flück C, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3727-34

Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. Mendonca BB, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):942-5

Prop-1 gene expression in human pituitary tumors. Nakamura S, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2581-4

Characterization of Prophet of Pit-1 gene expression in normal pituitary and pituitary adenomas in humans. Nakamura Y, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1414-9

Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene. Rosenbloom AL, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):50-7

Evolution of the HOXB6 intergenic region: motif conservation at the lateral plate mesoderm (LPM) enhancer element. Deinard A, et al. **J Exp Zool** 1999 Aug 15; 285(2):170-6

Homeobox genes in the Australian lungfish, Neoceratodus forsteri. Longhurst TJ, et al. **J Exp Zool** 1999 Aug 15; 285(2):140-5

Hematopoietic progenitor cell abnormalities in Hoxc-8 null mutant mice. Shimamoto T, et al. **J Exp Zool** 1999 Feb 1;283(2):186-93

Genomic organization of the Hoxa4-Hoxa10 region from Morone saxatilis: implications for Hox gene evolution among vertebrates. Snell EA, et al. **J Exp Zool** 1999 Apr 15;285(1):41-9

Evolution of a HOXB6 intergenic region within the great apes and humans. Deinard A, et al. **J Hum Evol** 1999 Jun; 36(6):687-703

A mutation in the RIEG1 gene associated with Peters' anomaly. Doward W, et al. **J Med Genet** 1999 Feb; 36(2):152-5

TOM1p, a yeast hect-domain protein which mediates transcriptional regulation through the ADA/SAGA coactivator complexes. Saleh A, et al. **J Mol Biol** 1998 Oct 9;282(5):933-46

Regulation of a Purkinje cell-specific promoter by homeodomain proteins: repression by engrailed-2 vs. synergistic activation by Hoxa5 and Hoxb7. Sanlioglu S, et al. **J Neurobiol** 1998 Sep 15;36(4):559-71

Noradrenergic-specific transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2a-binding sites. Kim HS, et al. **J Neurosci** 1998 Oct 15;18(20):8247-60

An early phase of embryonic Dlx5 expression defines the rostral boundary of the neural plate. Yang L, et al. **J Neurosci** 1998 Oct 15;18(20):8322-30

Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma. Osborne J, et al. **J Soc Gynecol Investig** 1998 Sep-Oct;5(5):277-80

Hoxa-13 gene mutation results in abnormal seminal vesicle and prostate development. Podlasek CA, et al. **J Urol** 1999 May;161(5):1655-61

Modulation of homeobox B6 and B9 genes expression in human leukemia cell lines during myelomonocytic differentiation. Ohnishi K, et al. **Leuk Lymphoma** 1998 Nov; 31(5-6):599-608

Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice. Waurzyniak BJ, et al. **Leuk Lymphoma** 1998 Dec;32(1-2):77-87

Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells. Bijl JJ, et al. **Leukemia** 1998 Nov; 12(11):1724-32

Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Kawagoe H, et al. **Leukemia** 1999 May;13(5):687-98

Molecular characterization of a complex chromosomal translocation breakpoint t(10;14) including the HOX11 oncogene locus. Salvati PD, et al. **Leukemia** 1999 Jun; 13(6):975-9

The bicoid-related Pitx gene family in development. Gage PJ, et al. **Mamm Genome** 1999 Feb;10(2):197-200 (45 ref.)

Sequence and genomic organization of the mouse Lim1 gene. Li Y, et al. **Mamm Genome** 1999 May;10(5):444-6

Evolutionary conservation and tissue-specific processing of Hoxa 11 antisense transcripts. Potter SS, et al. **Mamm Genome** 1998 Oct;9(10):799-806

Analysis of Hoxa7/Hoxb7 mutants suggests periodicity in the generation of the different sets of vertebrae. Chen F, et al. **Mech Dev** 1998 Sep;77(1):49-57

Lbx2, a novel murine homeobox gene related to the Drosophila ladybird genes is expressed in the developing urogenital system, eye and brain. Chen F, et al. **Mech Dev** 1999 Jun;84(1-2):181-4

Expression of three Rx homeobox genes in embryonic and adult zebrafish. Chuang JC, et al. **Mech Dev** 1999 Jun; 84(1-2):195-8

cSix4, a member of the six gene family of transcription factors, is expressed during placode and somite development. Esteve P, et al. **Mech Dev** 1999 Jul; 85(1-2):161-5

Drosophila endoderm development requires a novel homeobox gene which is a target of Wingless and Dpp signalling. Fuss B, et al. **Mech Dev** 1998 Dec;79(1-2):83-97

Evidence that Hoxa expression domains are evolutionarily transposed in spinal ganglia, and are established by forward spreading in paraxial mesoderm. Gaunt SJ, et al. **Mech Dev** 1999 Apr;82(1-2):109-18

Identification and developmental expression of Ci-isl, a homologue of vertebrate islet genes, in the ascidian Ciona intestinalis. Giuliano P, et al. **Mech Dev** 1998 Nov; 78(1-2):199-202

Restricted expression of the homeobox gene prox 1 in developing zebrafish. Glasgow E, et al. **Mech Dev** 1998 Aug;76(1-2):175-8

Six6 (Optx2) is a novel murine Six3-related homeobox gene that demarcates the presumptive pituitary/hypothalamic axis and the ventral optic stalk. Jean D, et al. **Mech Dev** 1999 Jun;84(1-2):31-40

Six9 (Optx2), a new member of the six gene family of transcription factors, is expressed at early stages of vertebrate ocular and pituitary development. L pez-Rios J, et al. **Mech Dev** 1999 May;83(1-2):155-9

Pax 4 and 6 regulate gastrointestinal endocrine cell development. Larsson LI, et al. **Mech Dev** 1998 Dec; 79(1-2):153-9

Mab21, the mouse homolog of a C. elegans cell-fate specification gene, participates in cerebellar, midbrain and eye development. Mariani M, et al. **Mech Dev** 1998 Dec; 79(1-2):131-5

Characterization of platyhelminth POU domain genes: ubiquitous and specific anterior nerve cell expression of different epitopes of GtPOU-1. Muñoz-Mármol AM, et al. **Mech Dev** 1998 Aug;76(1-2):127-40

Expression of the homeobox gene GBX2 during chicken development. Niss K, et al. **Mech Dev** 1998 Aug; 76(1-2):151-5

Identification of chick rax/rx genes with overlapping patterns of expression during early eye and brain development. Ohuchi H, et al. **Mech Dev** 1999 Jul;85(1-2):193-5

Characterization of CMIX, a chicken homeobox gene related to the Xenopus gene mix.1. Peale FV Jr, et al. **Mech Dev** 1998 Jul;75(1-2):167-70

Transcriptional regulation of Xvent homeobox genes. Rastegar S, et al. **Mech Dev** 1999 Mar;81(1-2):139-49

Elimination of EVE protein by CALI in the short germ band insect Tribolium suggests a conserved pair-rule function for even skipped. Schröder R, et al. **Mech Dev** 1999 Feb; 80(2):191-5

Expression of Gbx-2 during early development of the chick embryo. Shamim H, et al. **Mech Dev** 1998 Aug; 76(1-2):157-9

CMIX, a paired-type homeobox gene expressed before and during formation of the avian primitive streak. Stein S, et al. **Mech Dev** 1998 Jul;75(1-2):163-5

Expression of the Nkx3.1 homobox gene during pre and postnatal development. Tanaka M, et al. **Mech Dev** 1999 Jul;85(1-2):179-82

Expression of the homebox gene Hex during early stages of chick embryo development. Yatskievych TA, et al. **Mech Dev** 1999 Jan;80(1):107-9

Phylogenetic relationships and evolution of the KNOTTED class of plant homeodomain proteins. Bharathan G, et al. **Mol Biol Evol** 1999 Apr;16(4):553-63

HUA1 and HUA2 are two members of the floral homeotic AGAMOUS pathway. Chen X, et al. **Mol Cell** 1999 Mar; 3(3):349-60

Generation of alternative Ultrabithorax isoforms and stepwise removal of a large intron by resplicing at exon-exon junctions. Hatton AR, et al. **Mol Cell** 1998 Dec;2(6):787-96

Allosteric regulation of even-skipped repression activity by phosphorylation. Li C, et al. **Mol Cell** 1999 Jan;3(1):77-86

Detection of RAG protein-V(D)J recombination signal interactions near the site of DNA cleavage by UV cross-linking. Eastman QM, et al. **Mol Cell Biol** 1999 May; 19(5):3788-97

Ajuba, a novel LIM protein, interacts with Grb2, augments mitogen-activated protein kinase activity in fibroblasts, and promotes meiotic maturation of Xenopus oocytes in a Grb2- and Ras-dependent manner. Goyal RK, et al. **Mol Cell Biol** 1999 Jun;19(6):4379-89

The T-cell oncogenic protein HOX11 activates Aldh1 expression in NIH 3T3 cells but represses its expression in mouse spleen development. Greene WK, et al. **Mol Cell Biol** 1998 Dec;18(12):7030-7

Trimeric association of Hox and TALE homeodomain proteins mediates Hoxb2 hindbrain enhancer activity. Jacobs Y, et al. **Mol Cell Biol** 1999 Jul;19(7):5134-42

Delta-1 activation of notch-1 signaling results in HES-1 transactivation. Jarriault S, et al. **Mol Cell Biol** 1998 Dec; 18(12):7423-31

CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Kasper LH, et al. **Mol Cell Biol** 1999 Jan;19(1):764-76

The notch pathway intermediate HES-1 silences CD4 gene expression. Kim HK, et al. **Mol Cell Biol** 1998 Dec; 18(12):7166-75

The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Lam PY, et al. **Mol Cell Biol** 1999 Jan;19(1):594-601

Trithorax and ASH1 interact directly and associate with the trithorax group-responsive bxd region of the Ultrabithorax promoter. Rozovskaia T, et al. **Mol Cell Biol** 1999 Sep; 19(9):6441-7

Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA. Sauter P, et al. **Mol Cell Biol** 1998 Dec;18(12):7397-409

DNA hairpin opening mediated by the RAG1 and RAG2 proteins. Shockett PE, et al. **Mol Cell Biol** 1999 Jun; 19(6):4159-66

RAG-2 promotes heptamer occupancy by RAG-1 in the assembly of a V(D)J initiation complex. Swanson PC, et al. **Mol Cell Biol** 1999 May;19(5):3674-83

Trithorax- and Polycomb-group response elements within an Ultrabithorax transcription maintenance unit consist of closely situated but separable sequences. Tillib S, et al. **Mol Cell Biol** 1999 Jul;19(7):5189-202

The PTX family of homeodomain transcription factors during pituitary developments. Drouin J, et al. **Mol Cell Endocrinol** 1998 May 25;140(1-2):31-6 (16 ref.)

Characterization of the porcine Lhx3/LIM-3/P-Lim LIM homeodomain transcription factor. Meier BC, et al. **Mol Cell Endocrinol** 1999 Jan 25;147(1-2):65-74

Combined pituitary hormone deficiency in an inbred Brazilian kindred associated with a mutation in the PROP-1 gene. Nogueira CR, et al. **Mol Genet Metab** 1999 May;67(1):58-61

Holoprosencephaly due to mutations in ZIC2, a homologue of Drosophila odd-paired. Brown SA, et al. **Nat Genet**

1998 Oct;20(2):180–3
Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9–deficient mice. Harrison KA, et al. **Nat Genet** 1999 Sep;23(1):71–5
Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9. Li H, et al. **Nat Genet** 1999 Sep; 23(1):67–70
Esx1 is an X–chromosome–imprinted regulator of placental development and fetal growth. Li Y, et al. **Nat Genet** 1998 Nov;20(3):309–11
Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Wallis DE, et al. **Nat Genet** 1999 Jun;22(2):196–8
Prox1 function is crucial for mouse lens–fibre elongation. Wigle JT, et al. **Nat Genet** 1999 Mar;21(3):318–22
Function of Rieger syndrome gene in left–right asymmetry and craniofacial development. Lu MF, et al. **Nature** 1999 Sep 16;401(6750):276–8
Caudal is the Hox gene that specifies the most posterior Drosophile segment. Moreno E, et al. **Nature** 1999 Aug 26;400(6747):873–7
The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Pattyn A, et al. **Nature** 1999 May 27;399(6734):366–70
A role of Ultrabithorax in morphological differences between Drosophila species. Stern DL. **Nature** 1998 Dec 3; 396(6710):463–6
Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity [see comments] Arber S, et al. **Neuron** 1999 Aug;23(4):659–74. Comment in: Neuron 1999 Aug;23(4):626–7.
Hoxa2 and Hoxb2 control dorsoventral patterns of neuronal development in the rostral hindbrain. Davenne M, et al. **Neuron** 1999 Apr;22(4):677–91
A case of mistaken identity [comment] Eisen JS. **Neuron** 1999 Aug;23(4):626–7. Comment on: Neuron 1999 Aug;23(4):659–74. Comment on: Neuron 1999 Aug;23(4):675–87.
Molecular cloning of the cone–rod homeobox gene (Crx) from the rat and its temporal expression pattern in the retina under a daily light–dark cycle. Sakamoto K, et al. **Neurosci Lett** 1999 Feb 12;261(1–2):101–4
A novel Drosophila paired–like homeobox gene related to Caenorhabditis elegans unc–4 is expressed in subsets of postmitotic neurons and epidermal cells. Tabuchi K, et al. **Neurosci Lett** 1998 Nov 20;257(1):49–52
Regulation of the LIM–type homeobox gene islet–1 during neuronal regeneration. Hol EM, et al. **Neuroscience** 1999; 88(3):917–25
The Homeodomain Resource: sequences, structures and genomic information. Banerjee–Basu S, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):336–7
Mutational analysis of the engrailed homeodomain recognition helix by phage display. Connolly JP, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):1182–9
Multiple negative elements contribute to repression of the HOX11 proto–oncogene. Brake RL, et al. **Oncogene** 1998 Oct 8;17(14):1787–95
CDX2 is mutated in a colorectal cancer with normal APC/beta–catenin signaling. da Costa LT, et al. **Oncogene** 1999 Sep 2;18(35):5010–4
EB–1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre–B ALL, which express oncoprotein E2a–Pbx1. Fu X, et al. **Oncogene** 1999 Sep 2;18(35):4920–9
Identification of the LMO4 gene encoding an interaction partner of the LIM–binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia. Grutz G, et al. **Oncogene** 1998 Nov 26; 17(21):2799–803
Downregulation of the colon tumour–suppressor homeobox gene Cdx–2 by oncogenic ras. Lorentz O, et al. **Oncogene** 1999 Jan 7;18(1):87–92
Sequence and location of SIX3, a homeobox gene expressed in the human eye [see comments] Leppert GS, et al. **Ophthalmic Genet** 1999 Mar;20(1):7–21. Comment in: Ophthalmic Genet 1999 Mar;20(1):1–6.
From Drosophila mutants to human disease [editorial; comment] Tomarev S. **Ophthalmic Genet** 1999 Mar; 20(1):1–6. Comment on: Ophthalmic Genet 1999 Mar;20(1):7–21.
Gnarley1 is a dominant mutation in the knox4 homeobox gene affecting cell shape and identity. Foster T, et al. **Plant Cell** 1999 Jul;11(7):1239–52
ANTHOCYANINLESS2, a homeobox gene affecting anthocyanin distribution and root development in Arabidopsis. Kubo H, et al. **Plant Cell** 1999 Jul; 11(7):1217–26
Interactions among APETALA1, LEAFY, and TERMINAL FLOWER1 specify meristem fate. Liljegren SJ, et al. **Plant Cell** 1999 Jun;11(6):1007–18
The FLF MADS box gene: a repressor of flowering in Arabidopsis regulated by vernalization and methylation. Sheldon CC, et al. **Plant Cell** 1999 Mar;11(3):445–58
A MADS box gene homologous to AG is expressed in seedlings as well as in flowers of ginseng. Kim YS, et al. **Plant Cell Physiol** 1998 Aug;39(8):836–45
Two dehydration–inducible transcripts from the resurrection plant Craterostigma plantagineum encode interacting homeodomain–leucine zipper proteins. Frank W, et al. **Plant J** 1998 Aug;15(3):413–21
Molecular characterisation of a novel plant homeobox gene expressed in the maturing xylem zone of Populus tremula x tremuloides. Hertzberg M, et al. **Plant J** 1998 Nov; 16(3):285–95
The expression of tobacco knotted1–type class 1 homeobox genes correspond to regions predicted by the cytohistological zonation model. Nishimura A, et al. **Plant J** 1999 May;18(4):337–47
Over–expression of a tobacco homeobox gene, NTH15, decreases the expression of a gibberellin biosynthetic gene encoding GA 20–oxidase. Tanaka–Ueguchi M, et al. **Plant J** 1998 Aug;15(3):391–400
A MADS box transcription factor of the AP1/AGL9 subfamily is also expressed in the seed coat of pea (Pisum sativum) during development. Buchner P, et al. **Plant Mol Biol** 1998 Dec;38(6):1253–5
Analysis of the C–terminal region of Arabidopsis thaliana APETALA1 as a transcription activation domain. Cho S, et al. **Plant Mol Biol** 1999 Jun;40(3):419–29
A new class of plant homeobox genes is expressed in specific regions of determinate symbiotic root nodules. Jørgensen JE, et al. **Plant Mol Biol** 1999 May;40(1):65–77
Identification of a rice APETALA3 homologue by yeast two–hybrid screening. Moon YH, et al. **Plant Mol Biol** 1999 May;40(1):167–77
Characterization of the KNOX class homeobox genes Oskn2 and Oskn3 identified in a collection of cDNA libraries covering the early stages of rice embryogenesis. Postma–Haarsma AD, et al. **Plant Mol Biol** 1999 Jan; 39(2):257–71
CaMADS1, a MADS box gene expressed in the carpel of hazelnut. Rigola D, et al. **Plant Mol Biol** 1998 Dec; 38(6):1147–60
Isolation and characterization of a rice homebox gene, OSH15. Sato Y, et al. **Plant Mol Biol** 1998 Dec; 38(6):983–98
Isolation and molecular characterization of a new vegetative MADS–box gene from Solanum tuberosum L. Carmona MJ, et al. **Planta** 1998 Dec;207(2):181–8
Homeotic genes and the arthropod head: expression patterns of the labial, proboscipedia, and Deformed genes in crustaceans and insects. Abzhanov A, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10224–9
A homeobox gene, vax2, controls the patterning of the eye dorsoventral axis. Barbieri AM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10729–34
Expression of a Hox gene, Cnox–2, and the division of labor in a colonial hydroid. Cartwright P, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2183–6
Detection of targeted GFP–Hox gene fusions during mouse embryogenesis. Godwin AR, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13042–7
rRNA–complementarity in the 5' untranslated region of mRNA specifying the Gtx homeodomain protein: evidence that base– pairing to 18S rRNA affects translational efficiency. Hu MC, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1339–44
Activity regulation of Hox proteins, a mechanism for altering functional specificity in development and evolution. Li X, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6802–7
Comparative studies on mammalian Hoxc8 early enhancer sequence reveal a baleen whale–specific deletion of a cis–acting element. Shashikant CS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15446–51
The anterior determinant bicoid of Drosophila is a derived Hox class 3 gene. Stauber M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3786–9
Mouse deformed epidermal autoregulatory factor 1 recruits a LIM domain factor, LMO–4, and CLIM coregulators. Sugihara TM, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15418–23
Homeotic transformation of rhombomere identity after localized Hoxb1 misexpression. Bell E, et al. **Science** 1999 Jun 25;284(5423):2168–71
Identification of a mating type–like locus in the asexual pathogenic yeast Candida albicans. Hull CM, et al. **Science** 1999 Aug 20;285(5431):1271–5
Molecular origin of species [comment] Nei M, et al. **Science** 1998 Nov 20;282(5393):1428–9. Comment on: Science 1998 Nov 20;282(5393):1501–4.
ROUGH SHEATH2: a Myb protein that represses knox homeobox genes in maize lateral organ primordia. Timmermans MC, et al. **Science** 1999 Apr 2; 284(5411):151–3
A rapidly evolving homeobox at the site of a hybrid sterility gene [see comments] Ting CT, et al. **Science** 1998 Nov 20;282(5393):1501–4. Comment in: Science 1998 Nov 20;282(5393):1428–9.
The maize rough sheath2 gene and leaf development programs in monocot and dicot plants. Tsiantis M, et al. **Science** 1999 Apr 2;284(5411):154–6
Transformation of tooth type induced by inhibition of BMP signaling. Tucker AS, et al. **Science** 1998 Nov 6; 282(5391):1136–8
Transcriptional activation of APETALA1 by LEAFY. Wagner D, et al. **Science** 1999 Jul 23;285(5427):582–4
Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5. Zhao Y, et al. **Science** 1999 May 14;284(5417):1155–8
Vertebrate tinman homologues and cardiac differentiation. Evans SM. **Semin Cell Dev Biol** 1999 Feb;10(1):73–83 (79 ref.)
Chromosomal mapping of a skeletal muscle specific LIM–only protein FHL3 to the distal end of the short arm of human chromosome 1. Lee SM, et al. **Somat Cell Mol Genet** 1998 May;24(3):197–202
Cystic malformation of the posterior cerebellar vermis in transgenic mice that ectopically express Engrailed–1, a homeodomain transcription factor. Rowitch DH, et al. **Teratology** 1999 Jul;60(1):22–8
Analysis of select folate pathway genes, PAX3, and human T in a Midwestern neural tube defect population. Trembath D, et al. **Teratology** 1999 May;59(5):331–41
[Molecular cloning, expression of rat Msx–1 and Msx–2 during early embryo genesis and roles for mandibular chondrogenesis] Ishiguro S. **Kokubyo Gakkai Zasshi** 1999 Mar;66(1):33–45 (Eng. Abstr.) **(Jpn)**
[Association of the genetic variation of (MSX1–7) and non syndromic cleft lip palate in Chilean subjects] Blanco R, et al. **Rev Med Chil** 1998 Jun;126(6):637–45 (Eng. Abstr.) **(Spa)**
[Genetic variation of MSX1 has a sexual dimorphism in non syndromic cleft palate in the Chilean population] Blanco R, et al. **Rev Med Chil** 1998 Jul;126(7):781–7 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

A tumor necrosis factor–induced model of human primary demyelinating diseases develops in immunodeficient mice. Kassiotis G, et al. **Eur J Immunol** 1999 Mar;29(3):912–7
Genetic control of experimental lyme arthritis in the absence of specific immunity. Brown CR, et al. **Infect Immun** 1999 Apr;67(4):1967–73
Immune surveillance against a solid tumor fails because of immunological ignorance. Ochsenbein AF, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2233–8

ISOLATION & PURIFICATION

The roles of the homeobox genes aristaless and Distal–less in patterning the legs and wings of Drosophila. Campbell G, et al. **Development** 1998 Nov;125(22):4483–93

METABOLISM

A range of clinical phenotypes associated with mutations in CRX, a photoreceptor transcription–factor gene. Sohocki MM, et al. **Am J Hum Genet** 1998 Nov;63(5):1307–15
Function and evolution of Otx proteins [published erratum appears in Biochem Biophys Res Commun 1999 Jul 5;260(2):575] Klein WH, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):229–33 (56 ref.)
Contributions to gene activation by multiple functions of Bicoid. Ma X, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):447–55
A monomer–dimer equilibrium modulates the interaction of the sunflower homeodomain leucine–zipper protein Hahb–4 with DNA. Palena CM, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):81–7
Sequence–specific DNA binding activity in the RAE28 protein, a mouse homologue of the Drosophila polyhomeotic protein. Nomura M, et al. **Biochem Mol Biol Int** 1998 Dec;46(5):905–12
The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter. Newberry EP, et al. **Biochemistry** 1999 Aug 17; 38(33):10678–90
Target genes of homeodomain proteins. Mannervik M. **Bioessays** 1999 Apr;21(4):267–70 (25 ref.)
The partial homeodomain of the transcription factor Pax–5 (BSAP) is an interaction motif for the retinoblastoma and TATA–binding proteins. Eberhard D, et al. **Cancer Res** 1999 Apr 1;59(7 Suppl):1716s–1724s; discussion 1724s–1725s
Engrailed and hedgehog make the range of Wingless asymmetric in Drosophila embryos. Sanson B, et al. **Cell** 1999 Jul 23;98(2):207–16
Specification of motor neuron identity by the MNR2 homeodomain protein. Tanabe Y, et al. **Cell** 1998 Oct 2; 95(1):67–80
Prox1 function is required for the development of the murine lymphatic system. Wigle JT, et al. **Cell** 1999 Sep 17; 98(6):769–78
The Drosophila semushi mutation blocks nuclear import of bicoid during embryogenesis. Epps JL, et al. **Curr Biol** 1998 Nov 19;8(23):1277–80
Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein. Joliot A, et al. **Curr Biol** 1998 Jul 16;8(15):856–63
Forced expression of the homeobox–containing gene Pem blocks differentiation of embryonic stem cells. Fan Y, et al. **Dev Biol** 1999 Jun 15;210(2):481–96
Inhibitory patterning of the anterior neural plate in Xenopus by homeodomain factors Dlx3 and Msx1. Feledy JA, et al. **Dev Biol** 1999 Aug 15;212(2):455–64
Requirement of SpOtx in cell fate decisions in the sea urchin embryo and possible role as a mediator of beta–catenin signaling. Li X, et al. **Dev Biol** 1999 Aug 15;212(2):425–39
A BMP–inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Miyama K, et al. **Dev Biol** 1999 Apr 1;208(1):123–33
Negative regulation of dorsoventral signaling by the homeotic gene Ultrabithorax during haltere development in Drosophila. Shashidhara LS, et al. **Dev Biol** 1999 Aug 15;212(2):491–502

Expression of chick Barx-1 and its differential regulation by FGF-8 and BMP signaling in the maxillary primordia. Barlow AJ, et al. **Dev Dyn** 1999 Apr;214(4):291-302

Role of Xrx1 in Xenopus eye and anterior brain development. Andreazzoli M, et al. **Development** 1999 Jun; 126(11):2451-60

The C. elegans homeodomain gene unc-42 regulates chemosensory and glutamate receptor expression. Baran R, et al. **Development** 1999 May;126(10):2241-51

A developmental pathway controlling outgrowth of the Xenopus tail bud. Beck CW, et al. **Development** 1999 Apr; 126(8):1611-20

The homeobox gene Pitx2: mediator of asymmetric left-right signaling in vertebrate heart and gut looping. Campione M, et al. **Development** 1999 Mar;126(6):1225-34

Transducing positional information to the Hox genes: critical interaction of cdx gene products with position-sensitive regulatory elements. Charité J, et al. **Development** 1998 Nov;125(22):4349-58

Regulation of touch receptor differentiation by the Caenorhabditis elegans mec-3 and unc-86 genes. Duggan A, et al. **Development** 1998 Oct;125(20):4107-19

Vertebrate tinman homologues XNkx2-3 and XNkx2-5 are required for heart formation in a functionally redundant manner. Fu Y, et al. **Development** 1998 Nov; 125(22):4439-49

Targeting gene expression to the head: the Drosophila orthodenticle gene is a direct target of the Bicoid morphogen. Gao Q, et al. **Development** 1998 Nov; 125(21):4185-93

Hedgehog is required for activation of engrailed during regeneration of fragmented Drosophila imaginal discs. Gibson MC, et al. **Development** 1999 Apr;126(8):1591-9

Mutual antagonism between signals secreted by adjacent wingless and engrailed cells leads to specification of complementary regions of the Drosophila parasegment. Gritzan U, et al. **Development** 1999 Sep;126(18):4107-15

Fgf8 and Gbx2 induction concomitant with Otx2 repression is correlated with midbrain-hindbrain fate of caudal prosencephalon. Hidalgo-Sánchez M, et al. **Development** 1999 Jun;126(14):3191-203

Goosecoid and mix.1 repress Brachyury expression and are required for head formation in Xenopus. Latinkic BV, et al. **Development** 1999 Apr;126(8):1769-79

Eve and ftz regulate a wide array of genes in blastoderm embryos: the selector homeoproteins directly or indirectly regulate most genes in Drosophila [published erratum appears in Development 1999 Feb;126(5):following table of contents] Liang Z, et al. **Development** 1998 Nov; 125(22):4471-82

A short region of its homeodomain is necessary for engrailed nuclear export and secretion. Maizel A, et al. **Development** 1999 Jun;126(14):3183-90

A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. Maloof JN, et al. **Development** 1999 Jan;126(1):37-49

Function and specificity of LIM domains in Drosophila nervous system and wing development. O'Keefe DD, et al. **Development** 1998 Oct;125(19):3915-23

Lhx2, a vertebrate homologue of apterous, regulates vertebrate limb outgrowth. Rodriguez-Esteban C, et al. **Development** 1998 Oct;125(20):3925-34

Sequential roles for Fgf4, En1 and Fgf8 in specification and regionalisation of the midbrain. Shamim H, et al. **Development** 1999 Feb;126(5):945-59

The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons. Stanke M, et al. **Development** 1999 Sep;126(18):4087-94

A comparison of in vivo and in vitro DNA-binding specificities suggests a new model for homeoprotein DNA binding in Drosophila embryos. Carr A, et al. **EMBO J** 1999 Mar 15;18(6):1598-608

The relative expression amounts of apterous and its co-factor dLdb/Chip are critical for dorso-ventral compartmentalization in the Drosophila wing. Fernández-Fúnez P, et al. **EMBO J** 1998 Dec 1; 17(23):6846-53

Co-operative DNA binding by GAGA transcription factor requires the conserved BTB/POZ domain and reorganizes promoter topology. Katsani KR, et al. **EMBO J** 1999 Feb 1;18(3):698-708

Activity regulation of a Hox protein and a role for the homeodomain in inhibiting transcriptional activation. Li X, et al. **EMBO J** 1999 Jan 4;18(1):198-211

Sequence interval within the PEST motif of Bicoid is important for translational repression of caudal mRNA in the anterior region of the Drosophila embryo. Niessing D, et al. **EMBO J** 1999 Apr 1;18(7):1966-73

Binding of trithorax and Polycomb proteins to the bithorax complex: dynamic changes during early Drosophila embryogenesis. Orlando V, et al. **EMBO J** 1998 Sep 1; 17(17):5141-50

Ptx1 regulates SF-1 activity by an interaction that mimics the role of the ligand-binding domain. Tremblay JJ, et al. **EMBO J** 1999 Jun 15;18(12):3431-41

The homeodomain transcription factors Islet 1 and HB9 are expressed in adult alpha and gamma motoneurons identified by selective retrograde tracing. Vult von Steyern F, et al. **Eur J Neurosci** 1999 Jun;11(6):2093-102

Localization of Six4/AREC3 in the developing mouse retina; implications in mammalian retinal development. Niiya A, et al. **Exp Eye Res** 1998 Dec;67(6):699-707

Pax6 and Cdx2/3 form a functional complex on the rat glucagon gene promoter G1-element. Andersen FG, et al. **FEBS Lett** 1999 Feb 26;445(2-3):306-10

Binding properties of the human homeodomain protein OTX2 to a DNA target sequence. Briata P, et al. **FEBS Lett** 1999 Feb 19;445(1):160-4

Control of the nuclear localization of Extradenticle by competing nuclear import and export signals. Abu-Shaar M, et al. **Genes Dev** 1999 Apr 15;13(8):935-45

Balancing import and export in development. Affolter M, et al. **Genes Dev** 1999 Apr 15;13(8):913-5 (27 ref.)

The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Berthelsen J, et al. **Genes Dev** 1999 Apr 15;13(8):946-53

Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements. Ding H, et al. **Hum Mol Genet** 1998 Oct;7(11):1681-94

Regulation of Prox 1 during lens regeneration. Del Rio-Tsonis K, et al. **Invest Ophthalmol Vis Sci** 1999 Aug; 40(9):2039-45

Recognition of multiple patterns of DNA sites by Drosophila homeodomain protein Bicoid. Yuan D, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):809-17

Transcriptional antagonism between Hmx1 and Nkx2.5 for a shared DNA-binding site. Amendt BA, et al. **J Biol Chem** 1999 Apr 23;274(17):11635-42

IkappaB-alpha enhances transactivation by the HOXB7 homeodomain-containing protein. Chariot A, et al. **J Biol Chem** 1999 Feb 26;274(9):5318-25

Intestinal expression of the calbindin-D9K gene in transgenic mice. Requirement for a Cdx2-binding site in a distal activator region. Colnot S, et al. **J Biol Chem** 1998 Nov 27;273(48):31939-46

The N-terminal POZ domain of GAGA mediates the formation of oligomers that bind DNA with high affinity and specificity. Espinás ML, et al. **J Biol Chem** 1999 Jun 4;274(23):16461-9

Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbx1-binding sites. Gemel J, et al. **J Biol Chem** 1999 Feb 26;274(9):6020-6

Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter. Goudet G, et al. **J Biol Chem** 1999 Feb 12;274(7):4067-73

Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein. Kaspar P, et al. **J Biol Chem** 1999 May 14;274(20):14422-8

Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. Kim YH, et al. **J Biol Chem** 1998 Oct 2;273(40):25875-9

The pipsqueak protein of Drosophila melanogaster binds to GAGA sequences through a novel DNA-binding domain. Lehmann M, et al. **J Biol Chem** 1998 Oct 23; 273(43):28504-9

CREB-binding [corrected] protein interacts with the homeodomain protein Cdx2 and enhances transcriptional activity [published erratum appears in J Biol Chem 1999 May 7;274(19):13728] Lorentz O, et al. **J Biol Chem** 1999 Mar 12;274(11):7196-9

Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells. Macfarlane WM, et al. **J Biol Chem** 1999 Jan 8;274(2):1011-6

RAG1 and RAG2 cooperate in specific binding to the recombination signal sequence in vitro. Mo X, et al. **J Biol Chem** 1999 Mar 12;274(11):7025-31

Hic-5, a paxillin homologue, binds to the protein-tyrosine phosphatase PEST (PTP-PEST) through its LIM 3 domain. Nishiya N, et al. **J Biol Chem** 1999 Apr 2; 274(14):9847-53

Calreticulin enhances the transcriptional activity of thyroid transcription factor-1 by binding to its homeodomain. Perrone L, et al. **J Biol Chem** 1999 Feb 19;274(8):4640-5

Pax-6 and Cdx-2/3 interact to activate glucagon gene expression on the G1 control element. Ritz-Laser B, et al. **J Biol Chem** 1999 Feb 12;274(7):4124-32

Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling. Shi X, et al. **J Biol Chem** 1999 May 7;274(19):13711-7

Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4. Shiojima I, et al. **J Biol Chem** 1999 Mar 19;274(12):8231-9

Identification of domains mediating transcriptional activation and cytoplasmic export in the caudal homeobox protein Cdx-3. Trinh KY, et al. **J Biol Chem** 1999 Feb 26; 274(9):6011-9

SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes. Verschueren K, et al. **J Biol Chem** 1999 Jul 16;274(29):20489-98

The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. Yamamoto H, et al. **J Bone Miner Res** 1999 Feb;14(2):240-7

Molecular cloning of a mutated HOXB7 cDNA encoding a truncated transactivating homeodomain-containing protein. Chariot A, et al. **J Cell Biochem** 1998 Oct 1; 71(1):46-54

POU family transcription factors in the nervous system. Latchman DS. **J Cell Physiol** 1999 May;179(2):126-33 (68 ref.)

Sex steroids mediate HOXA11 expression in the human peri-implantation endometrium. Taylor HS, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1129-35

Close spatial-temporal relationship between islet-1-expressing cells and growing primary afferent axons in the dorsal spinal cord of chick embryo. Shiga T, et al. **J Comp Neurol** 1999 Mar 15;405(3):388-93

Phylogenetically conserved CK-II phosphorylation site of the murine homeodomain protein Hoxb-6. Fienberg AA, et al. **J Exp Zool** 1999 Apr 15;285(1):76-84

The three-dimensional structure of the vnd/NK-2 homeodomain-DNA complex by NMR spectroscopy. Gruschus JM, et al. **J Mol Biol** 1999 Jun 11;289(3):529-45

The helix-loop-helix proteins dAP-4 and daughterless bind both in vitro and in vivo to SEBP3 sites required for transcriptional activation of the Drosophila gene Sgs-4. King-Jones K, et al. **J Mol Biol** 1999 Aug 6;291(1):71-82

TOM1p, a yeast hect-domain protein which mediates transcriptional regulation through the ADA/SAGA coactivator complexes. Saleh A, et al. **J Mol Biol** 1998 Oct 9;282(5):933-46

DNA distortion and multimerization: novel functions of the glutamine-rich domain of GAGA factor. Wilkins RC, et al. **J Mol Biol** 1999 Jan 15;285(2):515-25

Regulation of hippocampal neuronal differentiation by the basic helix-loop-helix transcription factors HES-1 and MASH-1. Castella P, et al. **J Neurosci Res** 1999 May 1; 56(3):229-40

Characterization of Lhx9, a novel LIM/homeobox gene expressed by the pioneer neurons in the mouse cerebral cortex. Bertuzzi S, et al. **Mech Dev** 1999 Mar;81(1-2):193-8

OTX2 homeodomain protein binds a DNA element necessary for interphotoreceptor retinoid binding protein gene expression. Bobola N, et al. **Mech Dev** 1999 Apr; 82(1-2):165-9

Lbx2, a novel murine homeobox gene related to the Drosophila ladybird genes is expressed in the developing urogenital system, eye and brain. Chen F, et al. **Mech Dev** 1999 Jun;84(1-2):181-4

Novel expression of the goosecoid transcription factor in the embryonic mouse heart. Conway SJ. **Mech Dev** 1999 Mar; 81(1-2):187-91

Expression of DLX5 during human embryonic craniofacial development. Davideau JL, et al. **Mech Dev** 1999 Mar; 81(1-2):183-6

Expression of the medaka (Oryzias latipes) Ol-Rx3 paired-like gene in two diencephalic derivatives, the eye and the hypothalamus. Desehet K, et al. **Mech Dev** 1999 May;83(1-2):179-82

The PBX-regulating protein PREP1 is present in different PBX-complexed forms in mouse. Ferretti E, et al. **Mech Dev** 1999 May;83(1-2):53-64

Comparative analysis of Otx2, Gbx2, Pax2, Fgf8 and Wnt1 gene expressions during the formation of the chick midbrain/hindbrain domain. Hidalgo-Sánchez M, et al. **Mech Dev** 1999 Mar;81(1-2):175-8

EMX2 protein in the developing mouse brain and olfactory area. Mallamaci A, et al. **Mech Dev** 1998 Oct;77(2):165-72

Neurons derived in vitro from ES cells express homeoproteins characteristic of motoneurons and interneurons. Renoncourt Y, et al. **Mech Dev** 1998 Dec; 79(1-2):185-97

Expression of the optx2 homeobox gene during mouse development. Toy J, et al. **Mech Dev** 1999 May; 83(1-2):183-6

A double interaction screen identifies positive and negative ftz gene regulators and ftz-interacting proteins. Yu Y, et al. **Mech Dev** 1999 May;83(1-2):95-105

Regulated nuclear entry of the C. elegans Pax-6 transcription factor. Zhang Y, et al. **Mech Dev** 1998 Nov;78(1-2):179-87

Asymmetric DDE (D35E)-like sequences in the RAG proteins: implications for V(D)J recombination and retroviral pathogenesis. Dreyfus DH, et al. **Med Hypotheses** 1999 Jun;52(6):545-9 (32 ref.)

Hairpin coding end opening is mediated by RAG1 and RAG2 proteins. Besmer E, et al. **Mol Cell** 1998 Dec;2(6):817-28

Regulation of LIM homeodomain activity in vivo: a tetramer of dLDB and apterous confers activity and capacity for regulation by dLMO. Milán M, et al. **Mol Cell** 1999 Aug; 4(2):267-73

A RAG1 and RAG2 tetramer complex is active in cleavage in V(D)J recombination. Bailin T, et al. **Mol Cell Biol** 1999 Jul;19(7):4664-71

Binding of Gal4p and bicoid to nucleosomal sites in yeast in the absence of replication. Balasubramanian B, et al. **Mol Cell Biol** 1999 Apr;19(4):2977-85

Residues in the Swi5 zinc finger protein that mediate cooperative DNA binding with the Pho2 homeodomain protein. Bhoite LT, et al. **Mol Cell Biol** 1998 Nov; 18(11):6436-46

Trimeric association of Hox and TALE homeodomain proteins mediates Hoxb2 hindbrain enhancer activity. Jacobs Y, et al. **Mol Cell Biol** 1999 Jul;19(7):5134-42

A conserved motif in goosecoid mediates groucho-dependent repression in Drosophila embryos. Jiménez G, et al. **Mol Cell Biol** 1999 Mar;19(3):2080-7

The yeast a1 and alpha2 homeodomain proteins do not contribute equally to heterodimeric DNA binding. Jin Y, et al. **Mol Cell Biol** 1999 Jan;19(1):585-93

Identification of the in vivo casein kinase II phosphorylation site within the homeodomain of the cardiac tisue-specifying homeobox gene product Csx/Nkx2.5. Kasahara H, et al.

Mol Cell Biol 1999 Jan;19(1):526–36

Homeoproteins CDP and SATB1 interact: potential for tissue-specific regulation. Liu J, et al. **Mol Cell Biol** 1999 Jul;19(7):4918–26

HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Shen WF, et al. **Mol Cell Biol** 1999 Apr; 19(4):3051–61

Roles of the "dispensable" portions of RAG-1 and RAG-2 in V(D)J recombination. Steen SB, et al. **Mol Cell Biol** 1999 Apr;19(4):3010–7

Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription. Tremblay JJ, et al. **Mol Cell Biol** 1999 Apr;19(4):2567–76

Cux/CDP homeoprotein is a component of NF-muNR and represses the immunoglobulin heavy chain intronic enhancer by antagonizing the bright transcription activator. Wang Z, et al. **Mol Cell Biol** 1999 Jan;19(1):284–95

The RAG-HMG1 complex enforces the 12/23 rule of V(D)J recombination specifically at the double-hairpin formation step. West RB, et al. **Mol Cell Biol** 1998 Nov; 18(11):6408–15

Characterization of a nuclear deformed epidermal autoregulatory factor-1 (DEAF-1)-related (NUDR) transcriptional regulator protein. Huggenvik JI, et al. **Mol Endocrinol** 1998 Oct;12(10):1619–39

Lasp-1, a novel type of actin-binding protein accumulating in cell membrane extensions. Schreiber V, et al. **Mol Med** 1998 Oct;4(10):675–87

prhJ and hrpG, two new components of the plant signal-dependent regulatory cascade controlled by PrhA in Ralstonia solanacearum. Brito B, et al. **Mol Microbiol** 1999 Jan;31(1):237–51

Structural basis of Hox specificity [news] Wilson DS, et al. **Nat Struct Biol** 1999 Apr;6(4):297–300

Helix 2 of the paired domain plays a key role in the regulation of DNA-binding by the Pax-3 homeodomain. Fortin AS, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4574–81

Specific local histone-DNA sequence contacts facilitate high-affinity, non-cooperative nucleosome binding of both adf-1 and GAGA factor. Gao J, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5394–401

The two homeodomains of the ZmHox2a gene from maize originated as an internal gene duplication and have evolved different target site specificities. Kirch T, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4714–20

Evolutionary conserved mechanism of transcriptional repression by even-skipped. McKay LM, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):3064–70

A dimer of the lymphoid protein RAG1 recognizes the recombination signal sequence and the complex stably incorporates the high mobility group protein HMG2. Rodgers KK, et al. **Nucleic Acids Res** 1999 Jul 15; 27(14):2938–46

Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells. Joh T, et al. **Oncogene** 1999 Jan 28;18(4):1125–30

Lung hypoplasia caused by nitrofen is mediated by down-regulation of thyroid transcription factor TTF-1. Losada A, et al. **Pediatr Surg Int** 1999;15(3–4):188–91

Determination of the motif responsible for interaction between the rice APETALA1/AGAMOUS-LIKE9 family proteins using a yeast two-hybrid system. Moon YH, et al. **Plant Physiol** 1999 Aug;120(4):1193–204

A homeobox gene, vax2, controls the patterning of the eye dorsoventral axis. Barbieri AM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10729–34

A binding site for homeodomain and Pax proteins is necessary for L1 cell adhesion molecule gene expression by Pax-6 and bone morphogenetic proteins. Meech R, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2420–5

Antiglucocorticoid activity of hepatocyte nuclear factor-6. Pierreux CE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8961–6

Bicoid functions without its TATA-binding protein-associated factor interaction domains. Schaeffer V, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4461–6

Expression of myogenin during embryogenesis is controlled by Six/sine oculis homeoproteins through a conserved MEF3 binding site. Spitz F, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14220–5

LIM protein interactions: Drosophila enters the stage. Dawid IB. **Trends Genet** 1998 Dec;14(12):480–2

PHARMACOLOGY

Adjuvant arthritis in the rat is associated with decreased binding of nuclear receptors to thyroid hormone responsive element in spleen extracts. Brtko J, et al. **Gen Physiol Biophys** 1998 Dec;17(4):341–7

PHYSIOLOGY

Gene expression in pancreatic adenocarcinoma. Frazier ML. **Ann N Y Acad Sci** 1999 Jun 30;880:1–4 (23 ref.)

DNA binding and transactivating properties of the paired and homeobox protein Pax4. Kalousová A, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):510–8

Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. Newberry EP, et al. **Biochemistry** 1998 Nov 17;37(46):16360–8

Activation of the iNOS gene promoter by Brn-3 POU family transcription factors is dependent upon the octamer motif in the promoter. Gay RD, et al. **Biochim Biophys Acta** 1998 Dec 22;1443(3):315–22

Thyroid-specific enhancer-binding protein/thyroid transcription factor 1 is not required for the initial specification of the thyroid and lung primordia. Kimura S, et al. **Biochimie** 1999 Apr;81(4):321–7

Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Crooks GM, et al. **Blood** 1999 Jul 15; 94(2):519–28

The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Gritsman K, et al. **Cell** 1999 Apr 2; 97(1):121–32

Role of WUSCHEL in regulating stem cell fate in the Arabidopsis shoot meristem. Mayer KF, et al. **Cell** 1998 Dec 11;95(6):805–15

LIM homeodomain factors Lhx3 and Lhx4 assign subtype identities for motor neurons. Sharma K, et al. **Cell** 1998 Dec 11;95(6):817–28

A Smad transcriptional corepressor. Wotton D, et al. **Cell** 1999 Apr 2;97(1):29–39

Hox genes: from master genes to micromanagers. Akam M. **Curr Biol** 1998 Sep 24;8(19):R676–8 (13 ref.)

Nodal signalling and the roles of the transcription factors SnR and Pitx2 in vertebrate left-right asymmetry. Patel K, et al. **Curr Biol** 1999 Jun 3;9(11):609–12

Ultrabithorax function in butterfly wings and the evolution of insect wing patterns. Weatherbee SD, et al. **Curr Biol** 1999 Feb 11;9(3):109–15 (32 ref.)

Hox proteins meet more partners. Mann RS, et al. **Curr Opin Genet Dev** 1998 Aug;8(4):423–9 (55 ref.)

RAG and RAG defects. Notarangelo LD, et al. **Curr Opin Immunol** 1999 Aug;11(4):435–42 (78 ref.)

Regulation of dorsal gene expression in Xenopus by the ventralizing homeodomain gene Vox. Melby AE, et al. **Dev Biol** 1999 Jul 15;211(2):293–305

Normal reproductive and macrophage function in Pem homeobox gene-deficient mice. Pitman JL, et al. **Dev Biol** 1998 Oct 15;202(2):196–214

A common mechanism for antenna-to-Leg transformation in Drosophila: suppression of homothorax transcription by four HOM-C genes. Yao LC, et al. **Dev Biol** 1999 Jul 15; 211(2):268–76

Interactions between Bmp-4 and Msx-1 act to restrict gene expression to odontogenic mesenchyme. Tucker AS, et al. **Dev Dyn** 1998 Aug;212(4):533–9

Msx1 is required for the induction of Patched by Sonic hedgehog in the mammalian tooth germ. Zhang Y, et al. **Dev Dyn** 1999 May;215(1):45–53

Tissue-specific requirements for a phosphorylation site in the Fushi tarazu homeodomain. Dong J, et al. **Dev Genes Evol** 1999 Jul;209(7):427–31

Apical ectodermal ridge induction by the transplantation of En-1-overexpressing ectoderm in chick limb bud. Tanaka M, et al. **Dev Growth Differ** 1998 Aug;40(4):423–9

Shoot apical meristem and cotyledon formation during Arabidopsis embryogenesis: interaction among the CUP-SHAPED COTYLEDON and SHOOT MERISTEMLESS genes. Aida M, et al. **Development** 1999 Apr;126(8):1563–70

FGFs and BMP4 induce both Msx1-independent and Msx1-dependent signaling pathways in early tooth development. Bei M, et al. **Development** 1998 Nov; 125(21):4325–33

The iroquois complex controls the somatotopy of Drosophila notum mechanosensory projections. Grillenzoni N, et al. **Development** 1998 Sep;125(18):3563–9

Hoxa1 and Krox-20 synergize to control the development of rhombomere 3. Helmbacher F, et al. **Development** 1998 Dec;125(23):4739–48

ladybird determines cell fate decisions during diversification of Drosophila somatic muscles. Jagla T, et al. **Development** 1998 Sep;125(18):3699–708

The Drosophila Pax gene eye gone is required for embryonic salivary duct development. Jones NA, et al. **Development** 1998 Nov;125(21):4163–74

Hindlimb patterning and mandible development require the Ptx1 gene. Lanctôt C, et al. **Development** 1999 May; 126(9):1805–10

prx-1 functions cooperatively with another paired-related homeobox gene, prx-2, to maintain cell fates within the craniofacial mesenchyme. Lu MF, et al. **Development** 1999 Feb;126(3):495–504

Targeted disruption of the homeobox transcription factor Nkx2-3 in mice results in postnatal lethality and abnormal development of small intestine and spleen. Pabst O, et al. **Development** 1999 May;126(10):2215–25

Sibling cell fate in the Drosophila adult external sense organ lineage is specified by prospero function, which is regulated by Numb and Notch. Reddy GV, et al. **Development** 1999 May;126(10):2083–92

Transcription factors Mash-1 and Prox-1 delineate early steps in differentiation of neural stem cells in the developing central nervous system. Torii Ma, et al. **Development** 1999 Feb;126(3):443–56

Interaction between Drosophila EGF receptor and vnd determines three dorsoventral domains of the neuroectoderm. Yagi Y, et al. **Development** 1998 Sep; 125(18):3625–33

Cooperative DNA-binding by Bicoid provides a mechanism for threshold-dependent gene activation in the Drosophila embryo. Burz DS, et al. **EMBO J** 1998 Oct 15; 17(20):5998–6009

Correlation of Pit-1 gene expression and Pit-1 content with proliferation and differentiation in human myeloid leukemic cells. Costoya JA, et al. **Exp Cell Res** 1998 Nov 25; 245(1):132–6

Roles for Nkx3.1 in prostate development and cancer. Bhatia-Gaur R, et al. **Genes Dev** 1999 Apr 15;13(8):966–77

The Iroquois homeodomain proteins are required to specify body wall identity in Drosophila. Diez del Corral R, et al. **Genes Dev** 1999 Jul 1;13(13):1754–61

Functional analysis of Gscl in the pathogenesis of the DiGeorge and velocardiofacial syndromes. Wakamiya M, et al. **Hum Mol Genet** 1998 Nov;7(12):1835–40

RAG reexpression and DNA recombination at T cell receptor loci in peripheral CD4+ T cells. McMahan CJ, et al. **Immunity** 1998 Nov;9(5):637–47

OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. Jacquemin P, et al. **J Biol Chem** 1999 Jan 29; 274(5):2665–71

Transcriptional repression of the cystic fibrosis transmembrane conductance regulator gene, mediated by CCAAT displacement protein/cut homolog, is associated with histone deacetylation. Li S, et al. **J Biol Chem** 1999 Mar 19;274(12):7803–15

Characterization of the murine A1 adenosine receptor promoter, potent regulation by GATA-4 and Nkx2.5. Rivkees SA, et al. **J Biol Chem** 1999 May 14; 274(20):14204–9

A gamete-specific, sex-limited homeodomain protein in Chlamydomonas. Kurvari V, et al. **J Cell Biol** 1998 Dec 28;143(7):1971–80

Abdominal-B expression in a spider suggests a general role for Abdominal-B in specifying the genital structure. Damen WG, et al. **J Exp Zool** 1999 Apr 15;285(1):85–91

The glutamine-rich domain of the Drosophila GAGA factor is necessary for amyloid fibre formation in vitro, but not for chromatin remodelling. Agianian B, et al. **J Mol Biol** 1999 Jan 15;285(2):527–44

Paired-like homeodomain proteins, Phox2a and Phox2b, are responsible for noradrenergic cell-specific transcription of the dopamine beta-hydroxylase gene. Yang C, et al. **J Neurochem** 1998 Nov;71(5):1813–26

Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells. Baader SL, et al. **J Neurosci** 1999 Jul 1;19(13):5370–9

Coordinated transcriptional regulation of the unc-25 glutamic acid decarboxylase and the unc-47 GABA vesicular transporter by the Caenorhabditis elegans UNC-30 homeodomain protein. Eastman C, et al. **J Neurosci** 1999 Aug 1;19(15):6225–34

A Meis family protein caudalizes neural cell fates in Xenopus. Salzberg A, et al. **Mech Dev** 1999 Jan;80(1):3–13

Chick Barx2b, a marker for myogenic cells also expressed in branchial arches and neural structures. Smith DM, et al. **Mech Dev** 1999 Feb;80(2):203–6

Vegetal cell fate specification and anterior neuroectoderm formation by Hroth, the ascidian homologue of orthodenticle/otx. Wada S, et al. **Mech Dev** 1999 Apr; 82(1–2):67–77

Ajuba, a novel LIM protein, interacts with Grb2, augments mitogen-activated protein kinase activity in fibroblasts, and promotes meiotic maturation of Xenopus oocytes in a Grb2- and Ras-dependent manner. Goyal RK, et al. **Mol Cell Biol** 1999 Jun;19(6):4379–89

Haploinsufficiency of MSX1: a mechanism for selective tooth agenesis. Hu G, et al. **Mol Cell Biol** 1998 Oct; 18(10):6044–51

The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells. Thorsteinsdottir U, et al. **Mol Cell Biol** 1999 Sep; 19(9):6355–66

Esx1 is an X-chromosome-imprinted regulator of placental development and fetal growth. Li Y, et al. **Nat Genet** 1998 Nov;20(3):309–11

Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling. Briscoe J, et al. **Nature** 1999 Apr 15;398(6728):622–7

Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis. Lin CR, et al. **Nature** 1999 Sep 16;401(6750):279–82

A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer. Millet S, et al. **Nature** 1999 Sep 9;401(6749):161–4

The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Pattyn A, et al. **Nature** 1999 May 27;399(6734):366–70

Hox proteins reach out round DNA [news; comment] Scott MP. **Nature** 1999 Feb 25;397(6721):649, 651. Comment on: Nature 1999 Feb 25;397(6721):714–9.

A LIM-homeodomain combinatorial code for motor-neuron pathway selection. Thor S, et al. **Nature** 1999 Jan 7; 397(6714):76–80

LIMitless combinations? Appel B. **Neuron** 1999 Jan;22(1):3–5 (11 ref.)

even-skipped determines the dorsal growth of motor axons in Drosophila. Landgraf M, et al. **Neuron** 1999 Jan; 22(1):43–52

Specification of neurotransmitter identity by Phox2 proteins in neural crest stem cells. Lo L, et al. **Neuron** 1999 Apr;

22(4):693–705
Engrailed negatively regulates the expression of cell adhesion molecules connectin and neuroglian in embryonic Drosophila nervous system. Siegler MV, et al. **Neuron** 1999 Feb;22(2):265–76
Transcriptional activation by the homeodomain protein distal-less 3. Feledy JA, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):764–70
CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Chariot A, et al. **Oncogene** 1999 Jul 8;18(27):4007–14
Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Juang JL, et al. **Oncogene** 1999 Sep 16;18(37):5138–47
HOX11 interacts with CTF1 and mediates hematopoietic precursor cell immortalization. Zhang N, et al. **Oncogene** 1999 Apr 1;18(13):2273–9
Leaf senescence is delayed in tobacco plants expressing the maize homeobox gene knotted1 under the control of a senescence-activated promoter. Ori N, et al. **Plant Cell** 1999 Jun;11(6):1073–80
A homeobox gene, vax2, controls the patterning of the eye dorsoventral axis. Barbieri AM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10729–34
Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. Beck F, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7318–23
The mouse bagpipe gene controls development of axial skeleton, skull, and spleen. Lettice LA, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9695–700
Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. McWhirter JR, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11464–9
Regulation of chamber-specific gene expression in the developing heart by Irx4. Bao ZZ, et al. **Science** 1999 Feb 19;283(5405):1161–4
Role of Pitx1 upstream of Tbx4 in specification of hindlimb identity [see comments] Logan M, et al. **Science** 1999 Mar 12;283(5408):1736–9. Comment in: Science 1999 Mar 12;283(5408):1615–6.
New findings reveal how legs take wing [news; comment] Vogel G. **Science** 1999 Mar 12;283(5408):1615–6. Comment on: Science 1999 Mar 12;283(5408):1736–9.
Vertebrate tinman homologues and cardiac differentiation. Evans SM. **Semin Cell Dev Biol** 1999 Feb;10(1):73–83 (79 ref.)
Intersecting signalling and transcriptional pathways in Drosophila heart specification. Frasch M. **Semin Cell Dev Biol** 1999 Feb;10(1):61–71 (45 ref.)
Cystic malformation of the posterior cerebellar vermis in transgenic mice that ectopically express Engrailed-1, a homeodomain transcription factor. Rowitch DH, et al. **Teratology** 1999 Jul;60(1):22–8

SECRETION

Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk. Garcés C, et al. **Differentiation** 1999 Jan;64(2):103–14

HOMEOPATHY

see related
PHARMACOPOEIAS, HOMEOPATHIC

Instrumental measurements of different homeopathic dilutions of potassium iodide in water. Jerman I, et al. **Acupunct Electrother Res** 1999;24(1):29–44
Readers react to Dr. Murray's remarks about homeopathy [letter; comment] Lange A. **Altern Ther Health Med** 1999 Jul;5(4):18–9; discussion 20, 22. Comment on: Altern Ther Health Med 1999 Jul;5(4):18–9; discussion 20, 22.
A double-blind, controlled clinical trial of homeopathy and an analysis of lunar phases and postoperative outcome [see comments] Smolle J, et al. **Arch Dermatol** 1998 Nov; 134(11):1368–70. Comment in: Arch Dermatol 1999 May;135(5):602.
Homeopathy re-revisited: is homeopathy compatible with biomedical observations? Eskinazi D. **Arch Intern Med** 1999 Sep 27;159(17):1981–7 (52 ref.)
5th Annual Symposium on Complementary Health Care; Exeter, UK, December 10–12th, 1998. Barnes J. **Br Homeopath J** 1999 Jul;88(3):151
Dual effects of a homeopathic mineral complex on carrageenan-induced oedema in rats. Bertani S, et al. **Br Homeopath J** 1999 Jul;88(3):101–5
Reporting and investigating adverse effects of homeopathy [editorial] Dantas F. **Br Homeopath J** 1999 Jul;88(3):99–100
How to prescribe Medorrhinum: the frequency of symptoms and signs in homeopathic patients. Mercaldo M. **Br Homeopath J** 1999 Apr;88(2):69–77
Homeopathy in HIV infection: a trial report of double-blind placebo controlled study. Rastogi DP, et al. **Br Homeopath J** 1999 Apr;88(2):49–57
Sicarius (six-eyed crab spider): a homeopathic treatment for Ebola haemorrhagic fever and disseminated intravascular coagulation? Richardson-Boedler C. **Br Homeopath J** 1999 Jan;88(1):24–7 (23 ref.)
Homeopathic effect on heart rate variability. Ruiz G, et al. **Br Homeopath J** 1999 Jul;88(3):106–11
Reduction of alcohol induced sleep time in albino mice by potentized Nux vomica prepared with 90% ethanol. Sukul A, et al. **Br Homeopath J** 1999 Apr;88(2):58–61
Similitude in modern pharmacology. Teixeira MZ. **Br Homeopath J** 1999 Jul;88(3):112–20 (126 ref.)
Use of homeopathy in the treatment of tinnitus. Simpson JJ, et al. **Br J Audiol** 1998 Aug;32(4):227–33
Integrating homoeopathy in health systems. Poitevin B. **Bull World Health Organ** 1999;77(2):160–6
Homeopathy in dermatology. Stibbe JR. **Clin Dermatol** 1999 Jan–Feb;17(1):65–8
Homeopathic Arnica 30x is ineffective for muscle soreness after long-distance running: a randomized, double-blind, placebo-controlled trial. Vickers AJ, et al. **Clin J Pain** 1998 Sep;14(3):227–31
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdoses. Datta S, et al. **Complement Ther Med** 1999 Jun;7(2):62–75
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing toxic effects produced by arsenic trioxide in mice: II. On alterations in body weight, tissue weight and total protein. Mitra K, et al. **Complement Ther Med** 1999 Mar;7(1):24–34
A homeopathic nosode for influenza-like syndromes. de Lange de Klerk E. **Forsch Komplementarmed** 1999 Feb; 6(1):31; discussion 31–2
And again: is homeopathy a placebo response? Leffers P, et al. **Forsch Komplementarmed** 1999 Feb;6(1):28; discussion 28–31 **(Eng, Ger)**
Rhythmical electrical events as indicators for biological actions of homeopathic remedies. Meyer DL. **Forsch Komplementarmed** 1999 Feb;6(1):37
A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis. Weiser M, et al. **Forsch Komplementarmed** 1999 Jun; 6(3):142–8
Can physics and physical chemistry explain the workings of homeopathy? A systemic memory view [letter; comment] Schwartz GE, et al. **J Altern Complement Med** 1998 Winter;4(4):366–7. Comment on: J Altern Complement Med 1998 Summer;4(2):132–5.
Impact of study quality on outcome in placebo-controlled trials of homeopathy. Linde K, et al. **J Clin Epidemiol** 1999 Jul;52(7):631–6
Homeopathic remedies in prenatal care. Brennan P. **J Nurse Midwifery** 1999 May–Jun;44(3):291–9 (20 ref.)
Homeopathy. A theoretical framework and clinical application. Castro M. **J Nurse Midwifery** 1999 May–Jun; 44(3):280–90 (24 ref.)
Hospital consultants' views on homoeopathy [letter; comment] Levene S. **J R Soc Med** 1999 Jun;92(6):325. Comment on: J R Soc Med 1999 Apr;92(4):215.
Hospital consultants' views on homoeopathy [letter] [see comments] Reilly D, et al. **J R Soc Med** 1999 Apr;92(4):215 . Comment in: J R Soc Med 1999 Jun;92(6):325.
Homeopathic medicine in the city of Oaxaca, Mexico: patients' perspectives and observations. Whiteford MB. **Med Anthropol Q** 1999 Mar;13(1):69–78
Homeopathic products. **Med Lett Drugs Ther** 1999 Feb 26; 41(1047):20–1
Serial killers from the homeopathic view [news] Spencer Jones J. **S Afr Med J** 1998 Dec;88(12):1540–1
Homoeopathy and clinical trials [letter; comment] Whitehead M. **Vet Rec** 1998 Aug 15;143(7):204. Comment on: Vet Rec 1998 Jul 11;143(2):56.
[Homeopathic "point of view" (letter; comment)] Morier-Genoud J. **Rev Med Suisse Romande** 1999 Apr; 119(4):353–4. Comment on: Rev Med Suisse Romande 1999 Jan;119(1):83–6. **(Fre)**
[Homeopathy: myth or reality?] Kahn MF. **Rev Prat** 1998 Mar 1;48(5):469–71 **(Fre)**
[The demonstration of the efficacy of homeopathic drugs] Strubelt O, et al. **Dtsch Med Wochenschr** 1999 Mar 5; 124(9):261–6 (91 ref.) **(Ger)**
[Guidelines for prevention and therapy in ecological animal farms as in the example of bovine mastitis] Spranger J. **DTW Dtsch Tierarztl Wochenschr** 1998 Aug;105(8):321–3 (Eng. Abstr.) **(Ger)**
[Biochemical efficacy of homeopathic and electronic preparations of D8 potassium cyanate] Dittmann J, et al. **Forsch Komplementarmed** 1999 Feb;6(1):15–8 (Eng. Abstr.) **(Ger)**
[Mainstream medicine versus complementary medicine (homeopathic) intervention: a critical methodology study of care in pregnancy] Hochstrasser B, et al. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:20–2 (Eng. Abstr.) **(Ger)**
[Quality of life of pregnant women in homeopathic or mainstream medical type of care and the course of the pregnancy] Hochstrasser B. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:23–5 (Eng. Abstr.) **(Ger)**
[Follow-up of retinoblastoma during homeopathic therapy] Käsmann-Kellner B, et al. **Klin Monatsbl Augenheilkd** 1999 Apr;214(4):aA12–6 **(Ger)**
[Is homeopathy more than a placebo?] Brockow T, et al. **Schweiz Rundsch Med Prax** 1998 Dec 3;87(49):1687–94 (31 ref.) (Eng. Abstr.) **(Ger)**
[Homeopathy--possibilities and limits] Halter K. **Schweiz Rundsch Med Prax** 1998 Aug 5;87(31–32):969–74 (0 ref.) **(Ger)**
[Homeopathy and other alternative therapies] Rossi G. **Recenti Prog Med** 1999 Mar;90(3):133–5 (20 ref.) **(Ita)**
[Are we really interested to find out if homeopathic therapy has any effect?] Baumgarten B, et al. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):394 **(Nor)**
[The basis for homeopathy as a therapeutic method] Greibrokk T, et al. **Tidsskr Nor Laegeforen** 1999 Feb 28; 119(6):849–51 (12 ref.) **(Nor)**
[Homeopathic therapy of chronic prostatitis in participants of the Chernobyl AES accident clean-up] Klimenko PM. **Klin Khir** 1998;(12):43–5 (Eng. Abstr.) **(Rus)**
[Homeopathy: principles, place and opportunities in current therapy] Krylov AA. **Klin Med (Mosk)** 1998;76(8):60–2 **(Rus)**
[Homeopathy or "viagra" (letter)] Cortada Villuendas LM. **Aten Primaria** 1998 Dec;22(10):668 **(Spa)**
[On homeopathy (letter)] Stenram A. **Lakartidningen** 1999 Mar 31;96(13):1555–6 **(Swe)**

ECONOMICS

Homeopathy and managed care: manageable or unmanageable [see comments] Ullman D. **J Altern Complement Med** 1999 Feb;5(1):65–73 (40 ref.). Comment in: J Altern Complement Med 1999 Feb;5(1):1–2.

EDUCATION

Homeopathy--the new orthodoxy [editorial] Leckridge B. **Br Homeopath J** 1999 Apr;88(2):47–8

HISTORY

Was Kent a Hahnemannian? Cassam A. **Br Homeopath J** 1999 Apr;88(2):78–83
20 years ago. The British Homoeopathic Journal, April 1979. Land ST. **Br Homeopath J** 1999 Apr;88(2):84–5
20 years ago: British Homeopathic Journal, July 1979. Land ST. **Br Homeopath J** 1999 Jul;88(3):142–4
20 years ago. The British Homoeopathic Journal, January 1979. Land ST. **Br Homeopath J** 1999 Jan;88(1):31–2
The early work of Dr. Edward Bach. Leary B. **Br Homeopath J** 1999 Jan;88(1):28–30
The relationship between homeopathy and the Dr Bach system of flower remedies: a critical appraisal. van Haselen RA. **Br Homeopath J** 1999 Jul;88(3):121–7
Adding women to the ranks, 1860–1890: a new view with a homeopathic lens. Kirschmann AT. **Bull Hist Med** 1999 Fall;73(3):429–46
The origins of classical homoeopathy? Campbell A. **Complement Ther Med** 1999 Jun;7(2):76–82 (22 ref.)
Charges of unethical conduct made by the Camden County Medical Society against Samuel D. Gross, M.D. and Joseph Pancoast, M.D. Sherk HH, et al. **Trans Stud Coll Physicians Phila** 1998 Dec;20:98–113
[The oldest "medicine". Wine and health--from Nippur to the Osterbro study] Hagen A. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4758–61 **(Nor)**

LEGISLATION & JURISPRUDENCE

Ayurvedic drug aggravating seizures: the legal implications [letter] Luiz N. **Indian Pediatr** 1998 Nov;35(11):1144–5

METHODS

Homeopathic remedies for jet lag [letter; comment] Welch J. **Aviat Space Environ Med** 1999 Feb;70(2):193. Comment on: Aviat Space Environ Med 1998 Aug;69(8):810.
The school nurse's role in homeopathic interventions. Selekman J, et al. **J Sch Health** 1998 Oct;68(8):342–5 (7 ref.)
[Homeopathy (see comments)] Bonard EC. **Rev Med Suisse Romande** 1999 Jan;119(1):83–6 (14 ref.). Comment in: Rev Med Suisse Romande 1999 Apr;119(4):353–4. **(Fre)**
[The use of antihomotoxic therapy in dentistry] Zorian EV, et al. **Stomatologiia (Mosk)** 1998;77(6):9–11 (Eng. Abstr.) **(Rus)**
[To know the other side of the coin (letter)] Ballester Sanz A, et al. **Aten Primaria** 1998 Oct 31;22(7):472–4 **(Spa)**

STANDARDS

Readers react to Dr Murray's remarks about homeopathy [letter; comment] Ullman D. **Altern Ther Health Med** 1999 Jul;5(4):18; discussion 20, 22. Comment on: Altern Ther Health Med 1999 Mar;5(2):76–84.
Efficacy of homeopathic arnica: a systematic review of placebo-controlled clinical trials. Ernst E, et al. **Arch Surg** 1998 Nov;133(11):1187–90 (23 ref.)
The quality control and stability testing of homeopathic preparations. Marotta M, et al. **Boll Chim Farm** 1998 Nov; 137(10):439–41
LM potencies: one of the hidden treasures of the sixth edition of the Organon. De Schepper L. **Br Homeopath J** 1999 Jul;88(3):128–34
Homeopathic terminology: a consensus quest. Guajardo G, et al. **Br Homeopath J** 1999 Jul;88(3):135–41
Community hospital homeopathy clinic: audit of the first 12 months activity. Neville-Smith R. **Br Homeopath J** 1999 Jan;88(1):20–3
Reproducibility of results with homeopathic remedies [letter]

Buckman R. **CMAJ** 1999 Apr 20;160(8):1128–9

Out of step with the Lancet homeopathy meta-analysis: more objections than objectivity? [see comments] Dean M. **J Altern Complement Med** 1998 Winter;4(4):389–98. Comment in: J Altern Complement Med 1998 Winter;4(4):355–7. Comment in: J Altern Complement Med 1999 Apr;5(2):119.

Randomized controlled trials of individualized homeopathy: a state-of-the-art review [see comments] Linde K, et al. **J Altern Complement Med** 1998 Winter;4(4):371–88 (50 ref.) . Comment in: J Altern Complement Med 1998 Winter;4(4):355–7.

Homeopathy and managed care: manageable or unmanageable [see comments] Ullman D. **J Altern Complement Med** 1999 Feb;5(1):65–73 (40 ref.). Comment in: J Altern Complement Med 1999 Feb;5(1):1–2.

Randomized double-blind placebo-controlled trial of homoeopathic 'proving' for Belladonna C30. Goodyear K, et al. **J R Soc Med** 1998 Nov;91(11):579–82

Review, critique, and guidelines for the use of herbs and homeopathy. Glisson J, et al. **Nurse Pract** 1999 Apr; 24(4):44–6, 53, 60 passim; quiz 68–9 (73 ref.)

[Homeopathy] Van Wassenhoven M. **Rev Med Brux** 1998 Sep;19(4):A277–82 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Patient characteristics and practice patterns of physicians using homeopathy. Jacobs J, et al. **Arch Fam Med** 1998 Nov–Dec;7(6):537–40

TRENDS

Homeopathy—the new orthodoxy [editorial] Leckridge B. **Br Homeopath J** 1999 Apr;88(2):47–8

[Homeopathy (see comments)] Bonard EC. **Rev Med Suisse Romande** 1999 Jan;119(1):83–6 (14 ref.). Comment in: Rev Med Suisse Romande 1999 Apr;119(4):353–4. **(Fre)**

HOMEOPROTEINS see **HOMEODOMAIN PROTEINS**

HOMEOSTASIS

see related
NEUROIMMUNOMODULATION

Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. Wójcik M, et al. **Acta Biochim Pol** 1999; 46(1):125–31

Inappropriately high plasma insulin levels in suspected perinatal asphyxia. Davis DJ, et al. **Acta Paediatr** 1999 Jan; 88(1):76–81

Energetics of alkaliphilic Bacillus species: physiology and molecules. Krulwich TA, et al. **Adv Microb Physiol** 1998; 40:401–38 (111 ref.)

Mechanisms of Na+–K+ pump regulation in cardiac myocytes during hyposmolar swelling. Bewick NL, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1091–9

[3H]taurine and D-[3H]aspartate release from astrocyte cultures are differently regulated by tyrosine kinases. Mongin AA, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1226–30

Acute regulation of Na/H exchanger NHE3 activity by protein kinase C: role of NHE3 phosphorylation. Wiederkehr MR, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1205–17

Iron homeostasis and the assessment of iron status. Sherwood RA, et al. **Ann Clin Biochem** 1998 Nov;35 (Pt 6):693–708 (133 ref.)

Regulation of glucose production by the liver. Nordlie RC, et al. **Annu Rev Nutr** 1999;19:379–406 (117 ref.)

Regulation of fatty acid oxidation in skeletal muscle. Rasmussen BB, et al. **Annu Rev Nutr** 1999;19:463–84 (85 ref.)

The development of extraocular muscle calcium homeostasis parallels visuomotor system maturation. Porter JD, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):678–83

Enzymes (isoenzyme system) as homeostatic mechanisms the isoenzyme (ADA2) of adenosine deaminase of human monocytes-macrophages as a regulator of the 2'deoxyadenosine. Gakis C, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):487–94

Antizyme modifications affecting polyamine homoeostasis. Mitchell JL, et al. **Biochem Soc Trans** 1998 Nov;26(4):591–5 (29 ref.)

pH and volume homeostasis in trypanosomatids: current views and perspectives. Vieira LL. **Biochim Biophys Acta** 1998 Aug 21;1376(2):221–41 (266 ref.)

Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Okar DA, et al. **Biofactors** 1999; 10(1):1–14 (109 ref.)

Intracellular Ca2+ homeostasis in rat round spermatids. Berrios J, et al. **Biol Cell** 1998 Sep;90(5):391–8

Action of androgens versus estrogens in male skeletal homeostasis. Vanderschueren D, et al. **Bone** 1998 Nov; 23(5):391–4 (40 ref.)

Chronic orthostatic intolerance: part of a spectrum of dysfunction in orthostatic cardiovascular homeostasis? [editorial] Narkiewicz K, et al. **Circulation** 1998 Nov 17; 98(20):2105–7

The consequences of traumatic brain injury on cerebral blood flow and autoregulation: a review. Golding EM, et al. **Clin Exp Hypertens** 1999 May;21(4):299–332 (152 ref.)

Iron homeostasis in relapsing steroid-sensitive nephrotic syndrome of childhood. Kemper MJ, et al. **Clin Nephrol** 1999 Jul;52(1):25–9

Glucose homeostasis standards for pancreas transplantation. Nankivell BJ, et al. **Clin Transplant** 1998 Oct;12(5):434–8

Calcium homeostasis and human evolution. Stini WA. **Coll Antropol** 1998 Dec;22(2):411–25

The stress response of critical illness. Epstein J, et al. **Crit Care Clin** 1999 Jan;15(1):17–33, v (56 ref.)

The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. He YW, et al. **Crit Rev Immunol** 1998; 18(6):503–24 (159 ref.)

Cholesterol homeostasis: a role for oxysterols. Accad M, et al. **Curr Biol** 1998 Aug 27;8(17):R601–4 (11 ref.)

Four cholesterol-sensing proteins. Lange Y, et al. **Curr Opin Struct Biol** 1998 Aug;8(4):435–9 (55 ref.)

Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Cherrington AD. **Diabetes** 1999 May; 48(5):1198–214 (57 ref.)

Role of the human kidney in glucose counterregulation. Meyer C, et al. **Diabetes** 1999 May;48(5):943–8

Correct homeostasis model assessment (HOMA) evaluation uses the computer program [letter; comment] Levy JC, et al. **Diabetes Care** 1998 Dec;21(12):2191–2. Comment on: Diabetes Care 1998 Apr;21(4):673–4.

Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Large V, et al. **Diabetes Metab** 1998 Nov;24(5):409–18 (91 ref.)

Leptin and its receptors: regulators of whole-body energy homeostasis. Houseknecht KL, et al. **Domest Anim Endocrinol** 1998 Nov;15(6):457–75 (166 ref.)

Impaired neutral sphingomyelinase activation and cutaneous barrier repair in FAN-deficient mice. Kreder D, et al. **EMBO J** 1999 May 4;18(9):2472–9

Cloning of mammalian Ire1 reveals diversity in the ER stress responses. Wang XZ, et al. **EMBO J** 1998 Oct 1; 17(19):5708–17

Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Kalra SP, et al. **Endocr Rev** 1999 Feb;20(1):68–100 (412 ref.)

Abnormal cell calcium homeostasis in type 2 diabetes mellitus: a new look on old disease. Levy J. **Endocrine** 1999 Feb;10(1):1–6 (99 ref.)

Parathyroid hormone-related protein in cardiovascular development and blood pressure regulation [editorial; comment] Massfelder T, et al. **Endocrinology** 1999 Apr; 140(4):1507–10 (27 ref.). Comment on: Endocrinology 1999 Apr;140(4):1815–25.

Effects of knockout of the protein kinase C beta gene on glucose transport and glucose homeostasis. Standaert ML, et al. **Endocrinology** 1999 Oct;140(10):4470–7

Cytoplasmic liberation of protein gene product 9.5 during the seasonal regulation of spermatogenesis in the monkey (Macaca fuscata). Tokunaga Y, et al. **Endocrinology** 1999 Apr;140(4):1875–83

Manganese homeostasis in the CNS. Aschner M. **Environ Res** 1999 Feb;80(2 Pt 1):105–9 (33 ref.)

Cysteine control over glutathione homeostasis in Chinese hamster fibroblasts overexpressing a gamma-glutamylcysteine synthetase activity. Vincent BR, et al. **Eur J Biochem** 1999 Jun;262(3):873–8

Regulation of dopamine-induced natriuresisby the dopamine-metabolizing enzyme catechol-O-methyltransferase. Odlind C, et al. **Exp Nephrol** 1999 Jul–Aug;7(4):314–22

Exercise-induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis. Hjeltnes N, et al. **FASEB J** 1998 Dec; 12(15):1701–12

Control of vascular smooth muscle cell growth in fowl. Shimada T, et al. **Gen Comp Endocrinol** 1998 Oct; 112(1):115–28

Noninvasive measurement of the Bayliss effect in retinal autoregulation. Blum M, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Apr; 237(4):296–300

Effects of fibrillar C-terminal fragment of cleaved alpha1-antitrypsin on cholesterol homeostasis in HepG2 cells. Janciauskiene S, et al. **Hepatology** 1999 Feb; 29(2):434–42

Calcium homeostasis during oral glucose load in healthy women. D'Erasmo E, et al. **Horm Metab Res** 1999 Apr; 31(4):271–3

Neurotransmitter transporters: target for endocrine regulation. Figlewicz DP, et al. **Horm Metab Res** 1999 May;31(5):335–9 (58 ref.)

Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Skinner JL, et al. **Hum Reprod** 1999 Mar;14(3):793–9

Structural autoregulation of terminal vascular beds: vascular adaptation and development of hypertension. Pries AR, et al. **Hypertension** 1999 Jan;33(1):153–61

The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Ernst B, et al. **Immunity** 1999 Aug;11(2):173–81

Is epinephrine-induced platelet aggregation autoregulated by its metabolic degradation products in vivo? Evangelou AM, et al. **In Vivo** 1998 May–Jun;12(3):321–5

Effect of rapid cooling and acidic pH on cellular homeostasis of Pectinatus frisingensis, a strictly anaerobic beer-spoilage bacterium. Chihib NE, et al. **Int J Food Microbiol** 1999 Jun 1;48(3):191–202

Rabbit spermatozoa: a model system for studying ATP homeostasis and motility. Minelli A, et al. **J Androl** 1999 Mar–Apr;20(2):259–66

Evaluation of nitrogen and organic matter balance in the feedlot as affected by level and source of dietary fiber. Bierman S, et al. **J Anim Sci** 1999 Jul;77(7):1645–53

Homeostasis in mice with genetically decreased angiotensinogen is primarily by an increased number of renin-producing cells. Kim HS, et al. **J Biol Chem** 1999 May 14;274(20):14210–7

The Golgi apparatus plays a significant role in the maintenance of Ca2+ homeostasis in the vps33Delta vacuolar biogenesis mutant of Saccharomyces cerevisiae. Miseta A, et al. **J Biol Chem** 1999 Feb 26;274(9):5939–47

Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. Postic C, et al. **J Biol Chem** 1999 Jan 1;274(1):305–15

Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells. Toth I, et al. **J Biol Chem** 1999 Feb 12;274(7):4467–73

Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. Trinh KY, et al. **J Biol Chem** 1998 Nov 20; 273(47):31615–20

Regulation of zinc homeostasis in yeast by binding of the ZAP1 transcriptional activator to zinc-responsive promoter elements. Zhao H, et al. **J Biol Chem** 1998 Oct 30;273(44):28713–20

The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. Zerwekh JE, et al. **J Bone Miner Res** 1998 Oct;13(10):1594–601

Differentiation of HL-60 promyelocytic leukemia cells is accompanied by a modification of magnesium homeostasis. Wolf FI, et al. **J Cell Biochem** 1998 Dec 1;71(3):441–8

Effects of calcium supplementation on calcium homeostasis and bone turnover in lactating women. Kalkwarf HJ, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):464–70

Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis. Santini F, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):493–8

The importance of pH in the regulation of ruminal acetate to propionate ratio and methane production in vitro [published erratum appears in J Dairy Sci 1999 Apr;82(4):830] Russell JB. **J Dairy Sci** 1998 Dec; 81(12):3222–30

Cellular control of renin secretion. Kurtz A, et al. **J Exp Biol** 1999 Feb;202 (Pt 3):219–25 (59 ref.)

Calcium homeostasis in crustacea: the evolving role of branchial, renal, digestive and hypodermal epithelia. Wheatly MG. **J Exp Zool** 1999 Jun 1;283(7):620–40 (134 ref.)

SCF-KIT pathway in human epidermal melanocyte homeostasis [letter] Longley BJ, et al. **J Invest Dermatol** 1999 Jul;113(1):139–40

Mammalian iron transport: an unexpected link between metal homeostasis and host defense. Fleming MD, et al. **J Lab Clin Med** 1998 Dec;132(6):464–8 (33 ref.)

Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. Begley JG, et al. **J Neurochem** 1999 Mar;72(3):1030–9

Upregulation of calcium homeostatic mechanisms in chronically depolarized rat myenteric neurons. Fickbohm DJ, et al. **J Neurophysiol** 1999 Jun;81(6):2683–95

Excessive Ca and P intake during early maturation in dogs alters Ca and P balance without long-term effects after dietary normalization. Schoenmakers I, et al. **J Nutr** 1999 May;129(5):1068–74

Possible role of plasma neurotensin on growth hormone regulation in neonates. Bozzola M, et al. **J Pediatr Endocrinol Metab** 1998 Sep–Oct;11(5):607–13

Plasma neurotensin levels in prepubertal children and adults: possible involvement in the regulation of growth hormone secretion. Bozzola M, et al. **J Pediatr Endocrinol Metab** 1998 Sep–Oct;11(5):615–21

The leptin era: new insight into the mechanisms of body weight homeostasis. Hoppin AG, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):250–64 (164 ref.)

Dietary deficiency of cystine and methionine in rats alters thiol homeostasis required for cyanide detoxification. Tor-Agbidye J, et al. **J Toxicol Environ Health** 1998 Dec 25;55(8):583–95

Chromium homeostasis in patients with type II (NIDDM) diabetes. Morris BW, et al. **J Trace Elem Med Biol** 1999 Jul;13(1–2):57–61

Chronic infusion of interleukin 1 induces hyperlactatemia and altered regulation of lactate metabolism in skeletal muscle. Vary TC, et al. **JPEN J Parenter Enteral Nutr** 1999 Jul–Aug;23(4):213–7

Lerner's homeostasis and blood pressure. Luna MB, et al. **Med Hypotheses** 1998 Aug;51(2):89–93

Evidence for functional ryanodine receptors in Schistosoma

mansoni and their putative role in the control of calcium homeostasis. Silva CL, et al. **Mem Inst Oswaldo Cruz** 1998; 93 Suppl 1:269–70

The contribution of glucose to neonatal glucose homeostasis in the lamb. Cowett RM, et al. **Metabolism** 1998 Oct; 47(10):1239–44

Antioxidative homeostasis: characterization by means of chemiluminescent technique. Popov I, et al. **Methods Enzymol** 1999;300:437–56

Glutathione homeostasis in response to exercise training and nutritional supplements. Sen CK. **Mol Cell Biochem** 1999 Jun;196(1–2):31–42 (99 ref.)

Control of food intake by fatty acid oxidation and ketogenesis. Scharrer E. **Nutrition** 1999 Sep;15(9):704–14 (144 ref.)

Endothelial factors and autoregulation during pressure changes in isolated newborn piglet cerebral arteries. Martinez-Orgado J, et al. **Pediatr Res** 1998 Aug; 44(2):161–7

A central role for thymic emigrants in peripheral T cell homeostasis. Berzins SP, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9787–91

Emergence of homeostasis and "noise imprinting" in an evolution model. Stern MD. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10746–51

The regulation of mineral absorption in the gastrointestinal tract. Powell JJ, et al. **Proc Nutr Soc** 1999 Feb;58(1):147–53 (41 ref.)

The effect of inactivity on dietary intake and energy homeostasis. Ritz P, et al. **Proc Nutr Soc** 1999 Feb; 58(1):115–22 (50 ref.)

Regulation of 5-lipoxygenase activity in mononuclear phagocytes: characterization of an endogenous cytosolic inhibitor. Coffey MJ, et al. **Prostaglandins Other Lipid Mediat** 1998 Jun;56(2–3):103–17

Serpins and regulation of cell death. Bird PI. **Results Probl Cell Differ** 1998;24:63–89 (130 ref.)

The IAP family of apoptotic regulators. Eiben LJ, et al. **Results Probl Cell Differ** 1998;24:91–104 (54 ref.)

Mechanisms that regulate the anticoagulant function of coagulation factor V. Thorelli E. **Scand J Clin Lab Invest Suppl** 1999;229:19–26 (35 ref.)

Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Ookhtens M, et al. **Semin Liver Dis** 1998; 18(4):313–29 (125 ref.)

Impact of brain death on hormonal homeostasis and hepatic microcirculation of transplant organ donors. Okamoto S, et al. **Transpl Int** 1998;11 Suppl 1:S404–7

Calcium homeostasis in dystrophic muscle. Ruegg UT, et al. **Trends Pharmacol Sci** 1999 Sep;20(9):351–2

[The central melanocortin system and its role in energy homeostasis] Cone RD. **Ann Endocrinol (Paris)** 1999 Mar; 60(1):3–9 (50 ref.) (Eng. Abstr.) **(Fre)**

[Renewal and stability] Leblond CP. **C R Seances Soc Biol Fil** 1998;192(5):843–6 **(Fre)**

[Regulation of phosphatemia and hypophosphatemia] Essig M, et al. **Rev Prat** 1998 Jun 1;48(11):1218–25 (13 ref.) (Eng. Abstr.) **(Fre)**

[Calciotropic hormones and integrated regulation of calcemia and calcium balance] Rizzoli R, et al. **Rev Prat** 1998 Jun 1;48(11):1178–84 (16 ref.) (Eng. Abstr.) **(Fre)**

[Homeostasis of antioxidant status in hemodialysis patients] Saionji K, et al. **Rinsho Byori** 1999 May;47(5):461–6 (Eng. Abstr.) **(Jpn)**

[Correction of several parameters of homeostasis in patients with ischemic heart disease by different methods of extracorporeal treatment of blood] Shapovalova NV, et al. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):29–32 (Eng. Abstr.) **(Rus)**

[Disorders of hormonal homeostasis in patients with kraurosis and leukoplakia vulvae] Vorob'eva LI, et al. **Lik Sprava** 1998 Aug;(6):82–3 (Eng. Abstr.) **(Rus)**

[Assessment of homeostasis by body's adaptative responses in patients with tuberculous pleurisy] Brazhenko NA, et al. **Probl Tuberk** 1998;(5):48–51 (Eng. Abstr.) **(Rus)**

[Homeostasis of small molecules originating from microbes and its role in microbial relations with the host] Beloborodova NV, et al. **Vestn Ross Akad Med Nauk** 1999; (7):25–31 (Eng. Abstr.) **(Rus)**

[Mechanisms of neuronal calcium homeostasis destabilization caused by hyperstimulation of glutamate receptors] Khodorov BI, et al. **Vestn Ross Akad Med Nauk** 1998; (8):41–6 (Eng. Abstr.) **(Rus)**

[Dopplerographic assessment of the autoregulation of the blood supply to the brain in neurosurgical pathology] Gaidar BV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Jul–Sep;(3):31–5; discussion 35–6 (Eng. Abstr.) **(Rus)**

[Glucose homeostasis against a background of respiratory distress in premature infants] Salabai ZV. **Lik Sprava** 1999 Mar;(2):110–2 (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Lin YJ, et al. **Acta Paediatr** 1998 Oct;87(10):1061–5

Acute effect of ethanol on lens cation homeostasis. Zeng J, et al. **Alcohol** 1998 Oct;16(3):189–93

Effect of progesterone on intracellular Ca2+ homeostasis in human myometrial smooth muscle cells. Fomin VP, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C379–85

Acute effect of EtOH on Mg2+ homeostasis in liver cells: evidence for the activation of an Na+/Mg2+ exchanger. Tessman PA, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1106–16

Dynamic cerebral autoregulation during sevoflurane anesthesia: a comparison with isoflurane. Summors AC, et al. **Anesth Analg** 1999 Feb;88(2):341–5

Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. Trenkwalder P. **Basic Res Cardiol** 1998;93 Suppl 2:140–4

Mammalian cell polyamine homeostasis is altered by the radioprotector WR1065. Mitchell JL, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):329–34

Protection against hydrogen peroxide cytotoxicity in rat-1 fibroblasts provided by the oncoprotein Bcl-2: maintenance of calcium homoeostasis is secondary to the effect of Bcl-2 on cellular glutathione. Rimpler MM, et al. **Biochem J** 1999 May 15;340 (Pt 1):291–7

Effects of low-molecular-weight aluminum complexes on brain tissue calcium homeostasis. Anghileri LJ, et al. **Biol Trace Elem Res** 1998 Sep;63(3):205–12

Acute effects of calcium sodium citrate supplementation of a test meal on mineral homeostasis, oxalate, and calcium oxalate crystallization in the urine of healthy humans--preliminary results in patients with idiopathic calcium urolithiasis. Herrmann U, et al. **Biomed Pharmacother** 1999 Jun;53(5–6):264–73

Sodium cyanate alters glutathione homeostasis in rodent brain: relationship to neurodegenerative diseases in protein-deficient malnourished populations in Africa. Tor-Agbidye J, et al. **Brain Res** 1999 Feb 27;820(1–2):12–9

Alteration of iron homeostasis following chronic exposure to manganese in rats. Zheng W, et al. **Brain Res** 1999 Jun 26;833(1):125–32

Evidence that hormesis represents an "overcompensation" response to a disruption in homeostasis. Calabreseci EJ. **Ecotoxicol Environ Saf** 1999 Feb;42(2):135–7

Differential effects of leptin in regulation of tissue glucose utilization in vivo. Wang JL, et al. **Endocrinology** 1999 May; 140(5):2117–24

Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group. Lindgren AC, et al. **Horm Res** 1999;51(4):157–61

Beneficial effect of serotonin 5-HT2-receptor antagonism on renal blood flow autoregulation in cyclosporin-treated rats. Verbeke M, et al. **J Am Soc Nephrol** 1999 Jan;10(1):28–34

Autoregulation of periodontal ligament cell phenotype and functions by transforming growth factor-beta1. Brady TA, et al. **J Dent Res** 1998 Oct;77(10):1779–90

Glutathione and glutathione ethyl ester supplementation of mice alter glutathione homeostasis during exercise. Leeuwenburgh C, et al. **J Nutr** 1998 Dec;128(12):2420–6

Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. Massimino SP, et al. **J Nutr** 1998 Oct;128(10):1786–93

Influence of ketanserin on experimental loss of renal blood flow autoregulation. Verbeke M, et al. **Kidney Int Suppl** 1998 Sep;67:S238–41 (25 ref.)

The effects of cannabinoids on the regulation of reproduction. Wenger T, et al. **Life Sci** 1999;65(6–7):695–701 (22 ref.)

Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats. Rajashree S, et al. **Mol Cell Biochem** 1999 Jul;197(1–2):203–8

Effects of ethanol on calcium homeostasis in the nervous system: implications for astrocytes. Catlin MC, et al. **Mol Neurobiol** 1999 Feb;19(1):1–24 (177 ref.)

Bombesin, calcium homeostasis and tumour growth. Meloni F, et al. **Monaldi Arch Chest Dis** 1998 Aug;53(4):405–9

Neurohumoral fluid regulation in chronic liver disease. Møller S, et al. **Scand J Clin Lab Invest** 1998 Aug; 58(5):361–72 (107 ref.)

Inhibitory action of oral thyrotropin-releasing hormone on the glucoregulatory response of the oral glucose tolerance test. Duntas LH, et al. **Thyroid** 1998 Oct;8(10):929–33

GENETICS

The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Tian H, et al. **Genes Dev** 1998 Nov 1;12(21):3320–4

Evidence for 3' untranslated region-dependent autoregulation of the Drosophila gene encoding the neuronal nuclear RNA-binding protein ELAV. Samson ML. **Genetics** 1998 Oct;150(2):723–33

Transcriptional organization of the czc heavy-metal homeostasis determinant from Alcaligenes eutrophus. Grosse C, et al. **J Bacteriol** 1999 Apr;181(8):2385–93

Genetic determinants of blood pressure regulation. Ambler SK, et al. **J Cardiovasc Nurs** 1999 Jul;13(4):59–77; quiz 127–8 (67 ref.)

Thyroid transcription factor 1 is calcium modulated and coordinately regulates genes involved in calcium homeostasis in C cells. Suzuki K, et al. **Mol Cell Biol** 1998 Dec;18(12):7410–22

TorC apocytochrome negatively autoregulates the trimethylamine N-oxide (TMAO) reductase operon in Escherichia coli. Ansaldi M, et al. **Mol Microbiol** 1999 Jul; 33(2):284–95

Brain mechanisms of mammalian fluid homeostasis: insights from use of immediate early gene mapping. Rowland NE. **Neurosci Biobehav Rev** 1998;23(1):49–63 (124 ref.)

Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Neel JV, et al. **Perspect Biol Med** 1998 Autumn;42(1):44–74 (167 ref.)

IMMUNOLOGY

IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. Soares MV, et al. **J Immunol** 1998 Dec 1;161(11):5909–17

Regulation of T cell homeostasis by heparan sulfate-bound IL-2. Wrenshall LE, et al. **J Immunol** 1999 Oct 1; 163(7):3793–800

Can high maternal melatonin concentrations be responsible for inducing fetal pathologies, and can melatonin participate in immunohormonal homeostasis by determining prohormone convertase activity?--Hypothesis and facts. Ciesla W. **Med Hypotheses** 1998 Oct;51(4):269–80 (100 ref.)

A new peak in the ALPS [news] Fischer A, et al. **Nat Med** 1999 Aug;5(8):876–7

CD27 and (TNFR) relatives in the immune system: their role in health and disease [editorial; comment] Loenen WA. **Semin Immunol** 1998 Dec;10(6):417–22. Comment on: Semin Immunol 1998 Dec;10(6):423–34.

[Immune homeostasis in the permanent inhabitants of mountain regions] Kitaev MI, et al. **Fiziol Cheloveka** 1998 Jul–Aug;24(4):136–8 **(Rus)**

PHYSIOLOGY

Indices for decreased cerebral blood flow control--a modelling study. Piechnik S, et al. **Acta Neurochir Suppl (Wien)** 1998;71:269–71

Relevance of calcium homeostasis in glial cell swelling from acidosis. Plesnila N, et al. **Acta Neurochir Suppl (Wien)** 1998;71:203–5

Failure of cerebral autoregulation in an experimental diffuse brain injury model. Prat R, et al. **Acta Neurochir Suppl (Wien)** 1998;71:123–6

Increase in transcranial Doppler pulsatility index does not indicate the lower limit of cerebral autoregulation. Richards HK, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:229–32

Evaluation of cerebrovascular CO2-reactivity and autoregulation in patients with post-traumatic diffuse brain swelling (diffuse injury III). Sahuquillo J, et al. **Acta Neurochir Suppl (Wien)** 1998;71:233–6

Hunger behaviour contributes to early nutritional homeostasis [letter] Hawdon JM, et al. **Acta Paediatr** 1999 Jun;88(6):691–2

Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR, et al. **Afr J Med Med Sci** 1996 Sep;25(3):243–9

Model for the regulation of energy balance and adiposity by the central nervous system. Schwartz MW, et al. **Am J Clin Nutr** 1999 Apr;69(4):584–96 (180 ref.)

Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Berthold H, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F417–24

Counterregulatory hormones oscillate during steady-state hypoglycemia. Genter P, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):E821–9

Cortical NOS inhibition raises the lower limit of cerebral blood flow-arterial pressure autoregulation. Jones SC, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1253–62

Tonic and phasic influences of nitric oxide on renal blood flow autoregulation in conscious dogs. Just A, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F442–9

Sleep after arousal from hibernation is not homeostatically regulated. Larkin JE, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R522–9

Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Levin BE, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1223–31 (114 ref.)

Endogenous thermoregulatory rhythms of squirrel monkeys in thermoneutrality and cold. Robinson EL, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1397–407

Impaired autoregulation of renal blood flow in the fawn-hooded rat. Van Dokkum RP, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R189–96

Reliability of the transient hyperemic response test in detecting changes in cerebral autoregulation induced by the graded variations in end-tidal carbon dioxide. Mahajan RP, et al. **Anesth Analg** 1998 Oct;87(4):843–9

Autoregulation of human inner ear blood flow during middle ear surgery with propofol or isoflurane anesthesia during controlled hypotension. Preckel MP, et al. **Anesth Analg** 1998 Nov;87(5):1002–8

Nonlinear analysis of renal autoregulation in rats using principal dynamic modes. Marmarelis VZ, et al. **Ann Biomed Eng** 1999 Jan–Feb;27(1):23–31

Adrenomeduilin and the control of fluid and electrolyte homeostasis. Samson WK. **Annu Rev Physiol** 1999; 61:363–89 (139 ref.)

Calcium homeostasis in early hamster preimplantation embryos. Lane M, et al. **Biol Reprod** 1998 Oct;59(4):1000–7

Factors affecting assessment of cerebral autoregulation using the transient hyperaemic response test. Cavill G, et al. **Br J Anaesth** 1998 Sep;81(3):317–21

Haemostatic and fibrinolytic responses to bone marrow

transplantation. Brown SA, et al. **Br J Haematol** 1999 Mar; 104(3):468–74

Regulation of epidermal homeostasis through P2Y2 receptors. Dixon CJ, et al. **Br J Pharmacol** 1999 Aug; 127(7):1680–6

Blood–brain barrier mechanisms involved in brain calcium and potassium homeostasis. Keep RF, et al. **Brain Res** 1999 Jan 9;815(2):200–5

Impairment of myocardial calcium homeostasis by antibodies against the adenine nucleotide translocator. Schulze K, et al. **Cell Calcium** 1999 May;25(5):361–70

Transient and steady-state effects of shear stress on endothelial cell adherens junctions. Noria S, et al. **Circ Res** 1999 Sep 17;85(6):504–14

Starvation, cessation of growth and bacterial aging. Nyström T. **Curr Opin Microbiol** 1999 Apr;2(2):214–9 (39 ref.)

High vagal tone is associated with more efficient regulation of homeostasis in low-risk human fetuses. Groome LJ, et al. **Dev Psychobiol** 1999 Jul;35(1):25–34

Metal ion transporters and homeostasis. Nelson N. **EMBO J** 1999 Aug 16;18(16):4361–71 (106 ref.)

Heart rate deflection compared to 4 mmol x l(-1) lactate threshold during incremental exercise and to lactate during steady-state exercise on an arm–cranking ergometer in paraplegic athletes. Schmid A, et al. **Eur J Appl Physiol** 1998 Jul;78(2):177–82

Parathyroid hormone is not a key hormone in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in rats [see comments] Wang W, et al. **Eur J Clin Invest** 1999 Apr;29(4):309–20. Comment in: Eur J Clin Invest 1999 Apr;29(4):274–7.

De novo lipogenesis in humans: metabolic and regulatory aspects. Hellerstein MK. **Eur J Clin Nutr** 1999 Apr;53 Suppl 1:S53–65 (83 ref.)

Swelling activated chloride channels in cultured bovine corneal endothelial cells. Srinivas SP, et al. **Exp Eye Res** 1999 Feb;68(2):165–77

Homeostasis, thymic hormones and aging. Goya RG, et al. **Gerontology** 1999 May–Jun;45(3):174–8 (65 ref.)

Autocellular coupling by gap junctions in cultured astrocytes: a new view on cellular autoregulation during process formation. Wolff JR, et al. **Glia** 1998 Sep;24(1):121–40

Homeostatic control of angiogenesis: A newly identified function of the liver? Clément B, et al. **Hepatology** 1999 Mar;29(3):621–3 (27 ref.)

IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Lodolce JP, et al. **Immunity** 1998 Nov;9(5):669–76

Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Ranger AM, et al. **Immunity** 1998 Nov;9(5):627–35

P2 purinoceptor saturation by adenosine triphosphate impairs renal autoregulation in dogs. Majid DS, et al. **J Am Soc Nephrol** 1999 Mar;10(3):492–8

Deterioration of cerebral autoregulation during orthostatic stress: insights from the frequency domain. Zhang R, et al. **J Appl Physiol** 1998 Sep;85(3):1113–22

Effects of impaired Ca2+ homeostasis on contraction in postinfarction myocytes. Zhang XQ, et al. **J Appl Physiol** 1999 Mar;86(3):943–50

Maintenance of homeostasis in coagulation during cardiopulmonary bypass. Spiess BD. **J Cardiothorac Vasc Anesth** 1999 Aug;13(4 Suppl 1):2–5; discussion 36–7

Genetic determinants of blood pressure regulation. Ambler SK, et al. **J Cardiovasc Nurs** 1999 Jul;13(4):59–77; quiz 127–8 (67 ref.)

Ovine chorionic somatomammotrophin (oCS) production by isolated cotyledon cells from sheep in early and mid gestation: auto-regulation by recombinant oCS. Soares MC, et al. **J Endocrinol** 1999 May;161(2):289–98

Orthostasis as a test for cerebral autoregulation in normal persons and patients with carotid artery disease. Stoll M, et al. **J Neuroimaging** 1999 Apr;9(2):113–7

Intracellular sodium and calcium homeostasis during hypoxia in dopamine neurons of rat substantia nigra pars compacta. Guatteo E, et al. **J Neurophysiol** 1998 Nov;80(5):2237–43

Autoregulatory sequences are revealed by complex stability screening of the mouse brn-3.0 locus. Trieu M, et al. **J Neurosci** 1999 Aug 1;19(15):6549–58

A delicate balance: homeostatic control of copper uptake and distribution. Peña MM, et al. **J Nutr** 1999 Jul; 129(7):1251–60 (94 ref.)

Ageing and the circadian and homeostatic regulation of human sleep during forced desynchrony of rest, melatonin and temperature rhythms. Dijk DJ, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):611–27

Na+-Ca2+ exchange and its implications for calcium homeostasis in primary cultured rat brain microvascular endothelial cells. Dömötör E, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):147–55

Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. Duchen MR. **J Physiol (Lond)** 1999 Apr 1;516 (Pt 1):1–17 (108 ref.)

Interaction between L-arginine: no system and cyclooxygenase metabolic products of arachidonic acid in coronary autoregulation. Jakovljević VL, et al. **J Physiol Pharmacol** 1999 Mar;50(1):63–74

Autoregulation of cerebral blood flow [letter; comment] Rennie JM. **Lancet** 1998 Dec 19–26;352(9145):2023. Comment on: Lancet 1998 Oct 31;352(9138):1406.

Lithium homeostasis in Xenopus oocytes: implications for the study of signal transduction. Gomez JR, et al. **Life Sci** 1998;63(19):1715–24

Subtleties in control by metabolic channelling and enzyme organization. Kholodenko BN, et al. **Mol Cell Biochem** 1998 Jul;184(1-2):311–20

Autoregulation of lactose uptake through the LacY permease by enzyme IIAGlc of the PTS in Escherichia coli K-12. Hogema BM, et al. **Mol Microbiol** 1999 Mar;31(6):1825–33

Neurobiology. A homeostatic switch [news; comment] Miles R. **Nature** 1999 Jan 21;397(6716):215–6. Comment on: Nature 1999 Jan 21;397(6716):251–5.

Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Hölscher C. **Neurobiol Dis** 1998 Sep;5(3):129–41 (139 ref.)

Upsetting the balance: VGF and the regulation of body weight [comment] Altshuler D, et al. **Neuron** 1999 Jul; 23(3):415–7 (9 ref.). Comment on: Neuron 1999 Jul;23(3):537–48.

Calcium homeostasis and ultrastructural studies in a patient with limb girdle muscular dystrophy type 2C. Hassoni AA, et al. **Neuropathol Appl Neurobiol** 1999 Jun;25(3):244–53

Evidence for homeostatic adjustments of rat somatosensory cortical neurons to changes in extracellular acetylcholine concentrations produced by iontophoretic administration of acetylcholine and by systemic diisopropylfluorophosphate treatment. Testylier G, et al. **Neuroscience** 1999;91(3):843–70

Loss of tolerance to amphetamine-induced hypophagia in rats: homeostatic readjustment vs. instrumental learning. Hughes KM, et al. **Pharmacol Biochem Behav** 1999 Sep; 64(1):177–82

A microstructural analysis of the control of water and isotonic saline ingestion by postingestional stimulation. Davis JD, et al. **Physiol Behav** 1999 May;66(3):543–8

Lipectomy, body weight, and body weight set point in rats. Michel C, et al. **Physiol Behav** 1999 May;66(3):473–9

Age-related changes in grooming behavior and motor activity in female rats. Scimonelli T, et al. **Physiol Behav** 1999 May;66(3):481–4

Signaling mechanisms underlying the vascular myogenic response. Davis MJ, et al. **Physiol Rev** 1999 Apr; 79(2):387–423 (402 ref.)

Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Reed JA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):321–32 (56 ref.)

Novel neurotransmitters for sleep and energy homeostasis. Sutcliffe JG, et al. **Results Probl Cell Differ** 1999;26:239–55 (30 ref.)

Epidermal enzymes: their role in homeostasis and their relationships with dermatoses. Redoules D, et al. **Skin Pharmacol Appl Skin Physiol** 1998;11(4–5):183–92 (69 ref.)

Circadian and homeostatic influences on sleep in the squirrel monkey: sleep after sleep deprivation. Klerman EB, et al. **Sleep** 1999 Feb 1;22(1):45–59

Grading of cerebral dynamic autoregulation from spontaneous fluctuations in arterial blood pressure. Panerai RB, et al. **Stroke** 1998 Nov;29(11):2341–6

Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. Anderson DR. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S5–9 (27 ref.)

Physiology of perfusion as it relates to the optic nerve head. Orgül S, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S17–26 (144 ref.)

Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Turrigiano GG. **Trends Neurosci** 1999 May;22(5):221–7 (58 ref.)

[Changes in homeostasis during surgical liver resection] Collin F, et al. **Ann Fr Anesth Reanim** 1999 Aug;18(7):711–8 (Eng. Abstr.) **(Fre)**

[An autoregulatory system of growth hormone secretion] Minami S. **Nippon Ika Daigaku Zasshi** 1998 Oct; 65(5):409–12 (14 ref.) **(Jpn)**

[Guanylin family: new intestinal peptides regulating salt and water homeostasis] Date Y, et al. **Nippon Rinsho** 1998 Sep; 56(9):2427–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Matured society in 21st century on the basis of the bio–defense] Nomoto K. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):22–8 **(Jpn)**

[Microcirculation in the brain: viewpoint of autoregulation] Ono N. **Nippon Yakurigaku Zasshi** 1999 Apr;113(4):203–10 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Stabilization of intracellular calcium investigated by electrophysiology] Kato K, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1561–6 (18 ref.) **(Jpn)**

[Mechanisms of homeostasis establishment during prolonged microgravity] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1998;32(6):20–6 (35 ref.) (Eng. Abstr.) **(Rus)**

[Paraventriculovagal path of carbohydrate homeostasis regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124–8 (35 ref.) **(Rus)**

[Extrapineal melatonin: its place and role in the neuroendocrine regulation of homeostasis] Kvetnoĭ IM, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):364–70 (60 ref.) **(Rus)**

[Carbon dioxide--a natural regulator of free radical homeostasis at various steps of evolution] Kogan AKh, et al. **Dokl Akad Nauk** 1998 Oct;362(5):705–8 **(Rus)**

[Brain proteinase activity and the mobilization of endogenous proteolytic inhibitors as factors in the development of the functional state of the body] Gurin VN, et al. **Fiziol Cheloveka** 1999 Jan–Feb;25(1):71–7 (36 ref.) **(Rus)**

[Autoinduced myocardial tolerance to ischemia: the role of stress proteins in the mechanisms of its occurrence] Shevchenko IuL, et al. **Fiziol Cheloveka** 1999 Jan–Feb; 25(1):134–9 (49 ref.) **(Rus)**

[The method of integral estimation of a functional status of the hemostatic system] Lobenko AA, et al. **Klin Khir** 1998; (7):30–2 (Eng. Abstr.) **(Rus)**

[Homeostasis parameters as indicators of human health] Malov IuS. **Klin Med (Mosk)** 1999;77(3):56–60 (25 ref.) **(Rus)**

[Positional regulators of bone tissue--a basis for the autoregulatory mechanism of the development and reproduction of osteoporosis] Avrunin AS, et al. **Morfologiia** 1998;114(4):7–12 (49 ref.) (Eng. Abstr.) **(Rus)**

[The interactions of functional systems at the homeostatic level in normal children and adolescents and in a radioecologically unfavorable environment] Glazachev OS, et al. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):73–92 (81 ref.) (Eng. Abstr.) **(Rus)**

[The role of the oxygen-binding properties of the blood in maintaining pro-oxidant-antioxidant equilibrium in the body] Zinchuk VV, et al. **Usp Fiziol Nauk** 1999 Jul–Sep; 30(3):38–48 (84 ref.) (Eng. Abstr.) **(Rus)**

[Use of academician P.K.Anokhin's creative heritage for analysis of mechanisms responsible for homeostasis formation under microgravity] Grigor'ev AI, et al. **Vestn Ross Akad Med Nauk** 1999;(6):11–5 (21 ref.) (Eng. Abstr.) **(Rus)**

[Recent advances in the knowledge of energy homeostasis (editorial; comment)] Bueno M. **An Esp Pediatr** 1998 Dec; 49(6):558–60 (18 ref.). Comment on: An Esp Pediatr 1997 Jan;46(1):1–2. **(Spa)**

RADIATION EFFECTS

[The interactions of functional systems at the homeostatic level in normal children and adolescents and in a radioecologically unfavorable environment] Glazachev OS, et al. **Usp Fiziol Nauk** 1999 Jul–Sep;30(3):73–92 (81 ref.) (Eng. Abstr.) **(Rus)**

HOMEOTIC GENES see **GENES, HOMEOBOX**

HOMES FOR THE AGED

see related

HOUSING FOR THE ELDERLY

Goal attainment scaling as a measure of clinically important change in nursing–home patients. Gordon JE, et al. **Age Ageing** 1999 May;28(3):275–81

Small bowel bacterial overgrowth in subjects living in residential care homes. Lewis SJ, et al. **Age Ageing** 1999 Mar;28(2):181–5

Inappropriate acute admissions from nursing homes [letter] Snape J, et al. **Age Ageing** 1999 Mar;28(2):239–40

A survey of hypnotic use in geriatric institutions in Sogn og Fjordane, Norway. Schjøtt J, et al. **Aging (Milano)** 1999 Feb;11(1):50–5

Medication use in residential care facilities for the elderly. Williams BR, et al. **Ann Pharmacother** 1999 Feb; 33(2):149–55

Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. van Dijk KN, et al. **Br J Clin Pharmacol** 1998 Sep;46(3):255–61

Consequences of MRSA carriage in nursing home residents. Niclaes L, et al. **Epidemiol Infect** 1999 Apr;122(2):235–9

Association between institutionalization and carriage of multiresistant bacteria in the elderly at the time of admission to a general hospital. Eveillard M, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):133–6

Seroprevalence of Helicobacter pylori and length of stay in a nursing home. Regev A, et al. **Helicobacter** 1999 Jun; 4(2):89–93

Institutional abuse of older people [editorial] [see comments] Bennett GC. **Hosp Med** 1999 Jun;60(6):396–7. Comment in: Hosp Med 1999 Jun;60(6):456.

Management of Urinary tract infections in the nursing home elderly: a proposed algorithmic approach. Beier MT. **Int J Antimicrob Agents** 1999 May;11(3–4):275–84

Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly. Marchand R, et al. **Int J Epidemiol** 1999 Jun; 28(3):563–70

Bacteriological investigation of an outbreak of Clostridium perfringens food poisoning caused by Japanese food without animal protein. Miwa N, et al. **Int J Food Microbiol** 1999 Aug 1;49(1–2):103–6

The relationship between staff burnout/distress and interactions with residents in two residential homes for older people. Jenkins H, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):466–72

Do health and use of services differ in residents of sheltered accommodation? A pilot study. Walker M, et al. **Int J Geriatr Psychiatry** 1998 Sep;13(9):617–24

Staff views on the Resident Assessment Instrument,

RAI/MDS, in nursing homes, and the use of the Cognitive Performance Scale, CPS, in different levels of care in Stockholm, Sweden. Hansebo G, et al. **J Adv Nurs** 1998 Sep;28(3):642–53

Review of nursing documentation in nursing home wards – changes after intervention for individualized care. Hansebo G, et al. **J Adv Nurs** 1999 Jun;29(6):1462–73

Transition in care: family carers' experience of nursing home placement. Kellett UM. **J Adv Nurs** 1999 Jun;29(6):1474–81

Health characteristics of elderly personal care home residents. Quinn ME, et al. **J Adv Nurs** 1999 Aug; 30(2):410–7

Discharging older people from hospital to care homes: implications for nursing. Reed J, et al. **J Adv Nurs** 1999 Apr;29(4):819–25

Motivation to perform activities of daily living in the institutionalized older adult: can a leopard change its spots? Resnick B. **J Adv Nurs** 1999 Apr;29(4):792–9

ADA responds to nursing home initiative; task force is developing nutrition care recommendations for HCFA [news] **J Am Diet Assoc** 1998 Oct;98(10):1106

Serving meals of reduced portion size did not improve appetite among elderly in a personal-care section of a long-term-care community. Cluskey M, et al. **J Am Diet Assoc** 1999 Jun;99(6):733–5

Seroprevalence of viral hepatitis in an older nursing home population. Chien NT, et al. **J Am Geriatr Soc** 1999 Sep; 47(9):1110–3

Two nursing home outbreaks of respiratory infection with Legionella sainthelensi. Loeb M, et al. **J Am Geriatr Soc** 1999 May;47(5):547–52

An evaluation of a family visit education program. McCallion P, et al. **J Am Geriatr Soc** 1999 Feb;47(2):203–14

Medication challenges in the assisted living facility. Crutchfield DB. **J Am Pharm Assoc (Wash)** 1999 Mar–Apr; 39(2):222–5; quiz 293–4 (5 ref.)

Predictors of mortality in nursing home residents. Cohen-Mansfield J, et al. **J Clin Epidemiol** 1999 Apr; 52(4):273–80

Public information and private search: evaluating the Patient Self-Determination Act. Bradley EH, et al. **J Health Polit Policy Law** 1999 Apr;24(2):239–73

Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. Bird J, et al. **J Hosp Infect** 1998 Nov;40(3):243–7

The carer's perspective: results of a survey of attitudes to dental care in 250 residential homes in Manchester. Hoad-Reddick G, et al. **J Oral Rehabil** 1993 Nov; 20(6):571–6

Can we create a therapeutic relationship with nursing home residents in the later stages of Alzheimer's disease? Williams CL, et al. **J Psychosoc Nurs Ment Health Serv** 1999 Mar; 37(3):28–35

Behavioural management in nursing and residential homes: a randomised controlled trial. Proctor R, et al. **Lancet** 1999 Jul 3;354(9172):26–9

Oral health of elderly occupants in residential homes [letter] Simons D, et al. **Lancet** 1999 May 22;353(9166):1761

A qualitative investigation into the receptivity to hip protective underwear among staff and residents of residential institutions. Butler M, et al. **N Z Med J** 1998 Oct 9;111(1075):383–5

Psychological adjustment variables as predictors of mortality among nursing home residents. O'Connor BP, et al. **Psychol Aging** 1998 Sep;13(3):368–74

Helpfulness of information sources in the selection of a nursing home. Lawrence FC, et al. **Psychol Rep** 1998 Dec; 83(3 Pt 2):1217–8

Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. Cooper JW. **South Med J** 1999 May;92(5):485–90

Ethics in long-term care. Are the principles different? Kuczewski MG. **Theor Med Bioeth** 1999 Jan;20(1):15–29

Pain assessment and management in the long-term care setting. Weissman DE, et al. **Theor Med Bioeth** 1999 Jan; 20(1):31–43 (53 ref.)

[The morbidity of osteoporosis and it's associated factors in a home for the aged in Guangzhou City] Chen S, et al. **Wei Sheng Yen Chiu** 1997 May;26(3):204–7 (Eng. Abstr.) **(Chi)**

[Venous thromboembolic diseases in the aged. Survey of patients living in long-term care facilities (letter)] Barrellier MT, et al. **Presse Med** 1999 Feb 13;28(6):282 **(Fre)**

[Prescribing neuroleptics to senile dementia patients. On outcome in old age homes after inpatient psychiatric treatment] Wilhelm-Gössling C. **Nervenarzt** 1998 Nov; 69(11):999–1006 (Eng. Abstr.) **(Ger)**

[Community integrated living with reliable care in the service home: the status of young handicapped patients in a model project "House at Weinberg" in Stuttgart] Gerngross-Haas G. **Rehabilitation (Stuttg)** 1999 May;38(2):100–6 (Eng. Abstr.) **(Ger)**

[Alimentary intake of selected pollutants and nitrate--results of a duplicate study in Bavarian homes for youth and seniors] Arnold R, et al. **Z Ernahrungswiss** 1998 Dec; 37(4):328–35 (Eng. Abstr.) **(Ger)**

[Nutritional content in the daily diet from selected nursing homes for the aged in State of Hessen Second Report--minerals] Stelz A, et al. **Z Ernahrungswiss** 1998 Sep;37(3):269–78 (Eng. Abstr.) **(Ger)**

[Profile of social work in inpatient elder care] Steiner B. **Z Gerontol Geriatr** 1998 Oct;31(5):343–7 (Eng. Abstr.) **(Ger)**

[The health and welfare system for elderly in France] Sauvaget C, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul; 45(7):664–74 (Eng. Abstr.) **(Jpn)**

[Nutritional status of institutionalized elderly. Valencia, State of Carabobo, Venezuela] Peña E, et al. **Arch Latinoam Nutr** 1998 Jun;48(2):104–11 (Eng. Abstr.) **(Spa)**

[Epidemic outbreak in a home for the aged caused probably by Bacillus cereus] Peña González P, et al. **Aten Primaria** 1998 Dec;22(10):649–54 (Eng. Abstr.) **(Spa)**

[What hygienic criteria should apply to community care? The risk of infection is increasing when more and more seriously ill patients are treated outside hospital] Tammelin A, et al. **Lakartidningen** 1998 Nov 18;95(47):5338–40 (Eng. Abstr.) **(Swe)**

CLASSIFICATION

[Consideration of mental symptoms and physical disabilities in deciding upon placement in a residential home versus a nursing home] Dijkstra GJ, et al. **Tijdschr Gerontol Geriatr** 1999 Jun;30(3):114–20 (Eng. Abstr.) **(Dut)**

ECONOMICS

Assisted living in Delaware. Callahan P, et al. **Del Med J** 1998 Oct;70(10):429–30

Assisted living [editorial] DeCherney GS. **Del Med J** 1998 Oct;70(10):431–2

HISTORY

[The development of dual specialization: the clinical geriatrician and the nursing home practitioner, 1945–1990] Robben PB, et al. **Tijdschr Gerontol Geriatr** 1999 Apr; 30(2):55–63 (Eng. Abstr.) **(Dut)**

[Institutional care for frail elderly from Weimar to Bonn (1924–1961)] Irmak KH. **Z Gerontol Geriatr** 1998 Dec; 31(6):438–47 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

The impact of OBRA '87 on psychiatric services in nursing homes. Joint testimony of the American Psychiatric Association and the American Association for Geriatric Psychiatry. Colenda CC, et al. **Am J Geriatr Psychiatry** 1999 Winter;7(1):12–7

A patient-centered approach to advance medical planning in the nursing home. Gillick M, et al. **J Am Geriatr Soc** 1999 Feb;47(2):227–30

MANPOWER

[The assessment of exposure to the risk of the manual lifting of patients and the results of a clinical study in the rest homes of the Mantua area] Beruffi M, et al. **Med Lav** 1999 Mar–Apr;90(2):291–307 (Eng. Abstr.) **(Ita)**

[The assessment of exposure to the risk of the manual lifting of patients. The results of a clinical study in a geriatric institute of Milan] Monti M, et al. **Med Lav** 1999 Mar–Apr; 90(2):308–16 (Eng. Abstr.) **(Ita)**

[Initial data on shoulder pathology in workers exposed to the risk of lifting patients in different rest homes in Trento Province] Uber D, et al. **Med Lav** 1999 Mar–Apr; 90(2):342–50 (Eng. Abstr.) **(Ita)**

ORGANIZATION & ADMINISTRATION

Long stay care and the NHS: discontinuities between policy and practice [see comments] Turrell AR, et al. **BMJ** 1998 Oct 3;317(7163):942–4 (21 ref.). Comment in: BMJ 1999 Mar 6;318(7184):668.

RN participation in organizational decision making and improvements in resident outcomes. Anderson RA, et al. **Health Care Manage Rev** 1999 Winter;24(1):7–16

A stimulation-retreat special care unit for elders with dementing illness. Lawton MP, et al. **Int Psychogeriatr** 1998 Dec;10(4):379–95

Maintenance of mobility in residents of an Alzheimer special care facility. Saxton J, et al. **Int Psychogeriatr** 1998 Jun; 10(2):213–24

Problem of a senior citizen [letter] Pai AM. **J Indian Med Assoc** 1998 May;96(5):165

[Waiting lists for psychogeriatric nursing home admissions: insight into the problematic waiting times] Meiland FJ, et al. **Tijdschr Gerontol Geriatr** 1998 Dec;29(6):285–91 (Eng. Abstr.) **(Dut)**

STANDARDS

Making a positive difference in the lives of nursing home residents with Alzheimer disease: the lifestyle approach. Simard J. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13 Suppl 1:S67–72

Pressure ulcer development in the VA: characteristics of nursing homes providing best care. Berlowitz DR, et al. **Am J Med Qual** 1999 Jan–Feb;14(1):39–44

Stakeholders' opinions regarding important measures of nursing home quality for consumers. Harrington C, et al. **Am J Med Qual** 1999 May–Jun;14(3):124–32

Care of the nursing-home resident with diabetes. Funnell MM. **Clin Geriatr Med** 1999 May;15(2):413–22 (42 ref.)

"Mine own countree": quality of care in nursing homes [editorial; comment] [see comments] Chouinard J. **CMAJ** 1999 May 18;160(10):1463–4. Comment on: CMAJ 1999 May 18;160(10):1441–5. Comment in: CMAJ 1999 Jul 27;161(2):127.

Quality control in nursing homes [letter; comment] Hirdes JP. **CMAJ** 1999 Jul 27;161(2):127. Comment on: CMAJ 1999 May 18;160(10):1463–4.

Reducing inappropriate restraint use in Colorado's long-term care facilities. Palmer L, et al. **Jt Comm J Qual Improv** 1999 Feb;25(2):78–94

[The "Duisgurg model" of intensified control of nursing homes and homes for the aged by the Duisberg public health services in cooperation with the Duisburg social welfare offices] Martin U, et al. **Gesundheitswesen** 1999 Jul; 61(7):337–9 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Targeting and quality of nursing home care. A five-nation study. Carpenter GI, et al. **Aging (Milano)** 1999 Apr; 11(2):83–9

Outdoor wandering parks for persons with dementia: a survey of characteristics and use. Cohen-Mansfield J, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13(2):109–17

Medication use in nursing homes for elderly people. Furniss L, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):433–9 (61 ref.)

An overview of behaviour difficulties found in long-term elderly care settings. Jackson GA, et al. **Int J Geriatr Psychiatry** 1999 Jun;14(6):426–30

Family caregiving in dementia: prediction of caregiver burden 12 months after relocation to group-living care. Elmståhl S, et al. **Int Psychogeriatr** 1998 Jun;10(2):127–46

The educational preparation of staff in nursing homes: relationship with resident autonomy. Davies S, et al. **J Adv Nurs** 1999 Jan;29(1):208–17

Psychological adjustment variables as predictors of mortality among nursing home residents. O'Connor BP, et al. **Psychol Aging** 1998 Sep;13(3):368–74

[New residents of residential care homes for the elderly. The problems of elders with mental disorders] Depla MF, et al. **Tijdschr Gerontol Geriatr** 1999 Jun;30(3):121–8 (Eng. Abstr.) **(Dut)**

[Prevalence and treatment of depressive syndromes in homes for the aged. Survey of a rural catchment area] Mönking HS, et al. **Psychiatr Prax** 1998 Jul;25(4):183–5 (Eng. Abstr.) **(Ger)**

[Incontinence, dementia and multiple morbidity--predictive factors for nursing care requirement and nursing home admission] Welz-Barth A, et al. **Wien Med Wochenschr** 1998;148(13):305–8 (Eng. Abstr.) **(Ger)**

[Chronic medical prescriptions for geriatric patients living in an old age home (letter)] Vivar Gómez C, et al. **Aten Primaria** 1999 Jun 30;24(2):115–7 **(Spa)**

TRENDS

Rapid growth of rehabilitation services in traditional community-based nursing homes. Murray PK, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):372–8

Development of nursing home infection control [editorial] Smith PW. **Infect Control Hosp Epidemiol** 1999 May; 20(5):303–5

[Future organizational structures for old age homes and nursing homes] Grün O. **Z Gerontol Geriatr** 1998 Dec; 31(6):398–406 (Eng. Abstr.) **(Ger)**

UTILIZATION

Where are the missing elders? The decline in nursing home use, 1985 and 1995. Bishop CE. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):146–55

Effects of the Medicare Alzheimer's Disease Demonstration on nursing home entry [see comments] Miller R, et al. **Health Serv Res** 1999 Aug;34(3):691–714. Comment in: Health Serv Res 1999 Aug;34(3):641.

[Nursing home admission for the elderly and chances for avoiding admission. Results of a representative study of facilities for inpatient nursing care] Klein T. **Z Gerontol Geriatr** 1998 Dec;31(6):407–16 (Eng. Abstr.) **(Ger)**

[Study of the elderly in long form care facilities and home services] Kobayashi M. **Nippon Koshu Eisei Zasshi** 1999 Mar;46(3):199–203 **(Jpn)**

HOMESICKNESS see **LONELINESS**

HOMICIDE

Homicidal poisoning by paraquat [letter; comment] Book RG. **Am J Forensic Med Pathol** 1998 Sep;19(3):294–5. Comment on: Am J Forensic Med Pathol 1997 Mar;18(1):33–9.

Intracranial insertion of a nasogastric tube in a case of homicidal head trauma. Gianelli Castiglione A, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):329–34 (34 ref.)

Entrance, exit, and reentrance of one shot with a shotgun. Gulmann C, et al. **Am J Forensic Med Pathol** 1999 Mar; 20(1):13–6

Use of liquid nitrogen to remove duct tape from a homicide victim. Stephens BG, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):154–7

Concealed homicidal strangulation by burning. Suárez-Peñaranda JM, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):141–4

What happened in Laramie. Klein DS. **Ann Intern Med** 1999 Feb 2;130(3):235–6
Unnatural sudden infant death [letter] Barson AJ. **Arch Dis Child** 1999 Jul;81(1):96
Unnatural sudden infant death [letter] Davis JA. **Arch Dis Child** 1999 Jul;81(1):96
Unnatural sudden infant death. Meadow R. **Arch Dis Child** 1999 Jan;80(1):7–14
Unnatural sudden infant death [letter] Spencer NJ. **Arch Dis Child** 1999 Jul;81(1):96
Port Arthur disaster. Wilkinson S. **Aust N Z J Surg** 1999 Aug;69(8):569–70
Doctors cleared of manslaughter [news] Dyer C. **BMJ** 1999 Jan 16;318(7177):148
Critical notice: why killing is not always worse--and is sometimes better--than letting die. Kuhse H. **Camb Q Healthc Ethics** 1998 Fall;7(4):371–4 (9 ref.)
Multivariate analysis ('forensiometrics')--a new tool in forensic medicine. Differentiation between firearm-related homicides and suicides. Karlsson T. **Forensic Sci Int** 1999 Apr 26;101(2):131–40
The Capitol shooting. No reflex legislation, no long-term solution. Silberner J. **Hastings Cent Rep** 1998 Nov–Dec; 28(6):5
School shootings. Damage control. Hudson T. **Hosp Health Netw** 1998 Sep 20;72(18):48
Attempted homicide by electrocution. Pfeiffer H, et al. **Int J Legal Med** 1998;111(6):331–3
Putting into words, putting to rest and putting aside the ancestors. How an analysand who was heir to the Armenian genocide of 1915 worked through mourning. Altounian J. **Int J Psychoanal** 1999 Jun;80 (Pt 3):439–48
Murder, minors, selective serotonin reuptake inhibitors, and the involuntary intoxication defense. Myers WC, et al. **J Am Acad Psychiatry Law** 1998;26(3):487–96
A practical approach to suspicious death in infancy--a personal view. Green MA. **J Clin Pathol** 1998 Aug; 51(8):561–3
Recovery of human skeletal elements from a recent UK murder inquiry: preservational signatures. Cox M, et al. **J Forensic Sci** 1999 Sep;44(5):945–50
Assassination in the United States: an operational study of recent assassins, attackers, and near-lethal approachers. Fein RA, et al. **J Forensic Sci** 1999 Mar;44(2):321–33
The contribution of forensic geology and other trace evidence analysis to the investigation of the killing of Italian Prime Minister Aldo Moro. Lombardi G. **J Forensic Sci** 1999 May;44(3):634–42
Murder masquerading as suicide: postmortem assessment of suicide risk factors at the time of death. Simon RI. **J Forensic Sci** 1998 Nov;43(6):1119–23
Homicide or accident off the coast of Florida: trauma analysis of mutilated human remains. Stubblefield PR. **J Forensic Sci** 1999 Jul;44(4):716–9
Cloning, killing, and identity. McMahan J. **J Med Ethics** 1999 Apr;25(2):77–86
Widespread horror over killing of AIDS activist in South Africa [news] Baleta A. **Lancet** 1999 Jan 9;353(9147):130
Homicide by paraquat poisoning. Daisley H, et al. **Med Sci Law** 1999 Jul;39(3):266–9
Do blacks believe that HIV/AIDS is a government conspiracy against them? Klonoff EA, et al. **Prev Med** 1999 May;28(5):451–7
Partner homicide-suicide involving female homicide victims: a population-based study in North Carolina, 1988–1992. Morton E, et al. **Violence Vict** 1998 Summer;13(2):91–106
Assassins [editorial] Ward SD. **W V Med J** 1998 Nov–Dec; 94(6):311
[Analyses of expert's testimonies about 22 mental patients occurred in trip] Wang Z. **Fa I Hsueh Tsa Chih** 1997; 13(3):145–6 inside back cover (Eng. Abstr.) **(Chi)**
[Evidence of DNA from epithelial cells of the hand of the suspect found on the tool of the crime] Förster R, et al. **Arch Kriminol** 1999 Jan–Feb;203(1–2):45–53 (Eng. Abstr.) **(Ger)**
[A case of identification of two persons from heavily burned teeth by age estimation] Tsuchimochi T, et al. **Nippon Hoigaku Zasshi** 1998 Dec;52(6):360–6 (Eng. Abstr.) **(Jpn)**
[Among murderers and Nobel Prize winners in Chicago] Christiansen E. **Tidsskr Nor Laegeforen** 1999 Mar 20; 119(8):1164 **(Nor)**
[Without shame, no moral. How physicians could commit murder] Riksen KI. **Tidsskr Nor Laegeforen** 1999 Mar 20; 119(8):1096–9 (22 ref.) (Eng. Abstr.) **(Nor)**

HISTORY

The death of King Charles XII--the forensic verdict. Nordling CO. **Forensic Sci Int** 1998 Sep 28;96(2–3):75–89
Religious mania and criminal nonculpability. Religious and psychiatric reactions to a case of manslaughter in The Netherlands (1900). Belzen JA. **Int J Law Psychiatry** 1998 Fall;21(4):433–45
Hysteria, hypnosis, and moral sense in French 19th-century forensic psychiatry. The Eyraud-Bompard case. Plas R. **Int J Law Psychiatry** 1998 Fall;21(4):397–407
The murder of Yitzhak Rabin [letter; comment] Moldavsky D. **Isr J Psychiatry Relat Sci** 1998;35(4):322–4. Comment on: Isr J Psychiatry Relat Sci 1998;35(2):136–9.
Dr. John Frederick May and the identification of John Wilkes Booth's body. Spiegel AD. **J Community Health** 1998 Oct; 23(5):383–405
The bag nobody claimed. Bloomfield J. **Med Sci Law** 1998 Oct;38(4):335–40
Pollen analysis reveals murder season [letter] Szibor R, et al. **Nature** 1998 Oct 1;395(6701):449–50
Amok--from the writings of Sir Frank Swettenham. Kua EH, et al. **Singapore Med J** 1999 Apr;40(4):327–8
[The murder at Gruerlkken--a centenary] Forsmo S, et al. **Tidsskr Nor Laegeforen** 1998 Dec 10;118(30):4678–82 (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Independent inquiries into homicide [editorial] Buchanan A. **BMJ** 1999 Apr 24;318(7191):1089–90
GP on trial for murder [news] Dyer C. **BMJ** 1999 Apr 24; 318(7191):1095
When doctors might kill their patients. Concept of intent is being defined inconsistently by courts [letter] Morris CR. **BMJ** 1999 Sep 4;319(7210):639–40
Marital conflict by proxy after father kills mother: the family therapist as an expert witness in court. Kaplan T. **Fam Process** 1998 Winter;37(4):479–94
Capital versus noncapital murderers. Frierson RL, et al. **J Am Acad Psychiatry Law** 1998;26(3):403–10
Reply: Staring down "the dark emptiness of legal jargon" [letter; comment] Haycock J, et al. **J Am Acad Psychiatry Law** 1999;27(1):171–8. Comment on: J Am Acad Psychiatry Law 1997;25(2):161–71.
Offender and offense characteristics of a nonrandom sample of mass murderers. Hempel AG, et al. **J Am Acad Psychiatry Law** 1999;27(2):213–25
Sexual burglaries and sexual homicide: clinical, forensic, and investigative considerations. Schlesinger LB, et al. **J Am Acad Psychiatry Law** 1999;27(2):227–38
The effects of motive information and crime unusualness on jurors' judgments in insanity cases. Pickel KL. **Law Hum Behav** 1998 Oct;22(5):571–84
The case of R. v. Sheila Bowler. Glass A, et al. **Med Sci Law** 1999 Jul;39(3):188–97
HIV strain analysis debuts in murder trial [news] Vogel G. **Science** 1998 Oct 30;282(5390):851,853
[Simulated suicide by hanging after homicidal strangulation] Mallach HJ, et al. **Arch Kriminol** 1998 Jul–Aug; 202(1–2):17–28 (Eng. Abstr.) **(Ger)**
[Homicide by gunshot. An evaluation of 50 homicides with reference to gunshot wound site] Rammelsberg JO, et al. **Arch Kriminol** 1999 Mar–Apr;203(3–4):65–72 (Eng. Abstr.) **(Ger)**
[Death caused by "attack dog" bites. A contribution to current discussion] Reuhl J, et al. **Arch Kriminol** 1998 Nov–Dec; 202(5–6):140–51 (Eng. Abstr.) **(Ger)**
[Self-inflicted stab wound for simulating self-defense?] Schnabel A, et al. **Arch Kriminol** 1999 May–Jun; 203(5–6):147–51 (Eng. Abstr.) **(Ger)**
[Forensic aspects of spatially and temporally related multiple corpses] Thomsen H, et al. **Arch Kriminol** 1999 May–Jun; 203(5–6):152–8 (Eng. Abstr.) **(Ger)**
[Intention to kill--the deciding criterion between allowed and prohibited assisted euthanasia] Rilinger L. **Wien Med Wochenschr** 1998;148(18):421–3 (Eng. Abstr.) **(Ger)**
[Withholding medical care as a physical injury--manslaughter and withdrawal of treatment] Ulsenheimer K. **Z Arztl Fortbild Qualitatssich** 1998 Oct; 92(8–9):548–54 (Eng. Abstr.) **(Ger)**
[Assisted suicide between release and life-long imprisonment] Sonnen BR. **Z Gerontol Geriatr** 1998 Aug;31(4):290–3 **(Ger)**

PREVENTION & CONTROL

Differentiating stranger murders: profiling offender characteristics from behavioral styles. Salfati CG, et al. **Behav Sci Law** 1999;17(3):391–406
Duck and take cover. Strasburger VC. **Clin Pediatr (Phila)** 1999 Jan;38(1):41–3
Gun control as a public health issue [editorial] DeCherney GS. **Del Med J** 1999 May;71(5):229–33
Extending Brady background checks opposed [news] Cole T. **JAMA** 1998 Dec 23–30;280(24):2065
Adolescent homicide. No quick fixes [editorial] McCafferty C. **Minn Med** 1998 Nov;81(11):25–6

PSYCHOLOGY

Suicide by cop. Hutson HR, et al. **Ann Emerg Med** 1998 Dec;32(6):665–9
Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Raine A, et al. **Behav Sci Law** 1998 Summer;16(3):319–32
Differentiating stranger murders: profiling offender characteristics from behavioral styles. Salfati CG, et al. **Behav Sci Law** 1999;17(3):391–406
Paternal filicide: a study of 10 men. Marleau JD, et al. **Can J Psychiatry** 1999 Feb;44(1):57–63
An adolescent vampire cult in rural America: clinical issues and case study. Miller TW, et al. **Child Psychiatry Hum Dev** 1999 Spring;29(3):209–19
Letter across the pacific. Berman L. **Crisis** 1999;20(2):51–3
Tentative injuries to exposed skin in a homicide case. Herbst J, et al. **Forensic Sci Int** 1999 Jun 28;102(2–3):193–6
Homicidal sex offenders: psychological, phallometric, and diagnostic features. Firestone P, et al. **J Am Acad Psychiatry Law** 1998;26(4):537–52
Serial murder of six victims by an African-American male. Leach G, et al. **J Forensic Sci** 1999 Sep;44(5):1073–8
Erotomania, triangulation, and homicide. Meloy JR. **J Forensic Sci** 1999 Mar;44(2):421–4
Dementia as a risk factor for homicide. Rayel MG, et al. **J Forensic Sci** 1999 May;44(3):565–7
Adolescent sexual matricide following repetitive mother-son incest. Schlesinger LB. **J Forensic Sci** 1999 Jul;44(4):746–9
Reflections on the denial of the Armenian Genocide. Boyajian LZ, et al. **Psychoanal Rev** 1998 Aug;85(4):505–16
Recollections of aged Armenian survivors of the Ottoman Turkish genocide: resilience through endurance, coping, and life accomplishments. Kalayjian A, et al. **Psychoanal Rev** 1998 Aug;85(4):489–504
Serial killers from the homeopathic view [news] Spencer Jones J. **S Afr Med J** 1998 Dec;88(12):1540–1
[Murderous impulses in two patients with chronic hepatitis C treated with interferon alpha (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):105–6 **(Fre)**
[Sexual homicide--a data collection from psychiatric records] Briken P, et al. **Fortschr Neurol Psychiatr** 1999 May;67(5):189–99 (Eng. Abstr.) **(Ger)**
[Homicide and hebephrenia-like syndrome in metachromatic leukodystrophy (published erratum appears in Nervenarzt 1999 Jul;70(7):619)] Rentrop M, et al. **Nervenarzt** 1999 Mar; 70(3):276–80 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Reliability of statistics on violent death and suicide in the former USSR, 1970–1990. Wasserman D, et al. **Acta Psychiatr Scand Suppl** 1998;394:34–41
University students' perceptions of tobacco, cocaine, and homicide fatalities. Giacopassi D, et al. **Am J Drug Alcohol Abuse** 1999 Feb;25(1):163–72
A decade of pediatric homicide: a retrospective study at the Medical University of South Carolina. Collins KA, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):169–72
Murder-suicide in central Virginia: a descriptive epidemiologic study and empiric validation of the Hanzlick-Koponen typology. Hannah SG, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):275–83
News media coverage and the epidemiology of homicide. Sorenson SB, et al. **Am J Public Health** 1998 Oct; 88(10):1510–4
Income inequality and homicide rates in Rio de Janeiro, Brazil. Szwarcwald CL, et al. **Am J Public Health** 1999 Jun;89(6):845–50
Suicide by cop. Hutson HR, et al. **Ann Emerg Med** 1998 Dec;32(6):665–9
The epidemiology of adolescent homicide in North Carolina from 1990 to 1995. Coyne-Beasley T, et al. **Arch Pediatr Adolesc Med** 1999 Apr;153(4):349–56
Mortality associated with use of weapons in armed conflicts, wartime atrocities, and civilian mass shootings: literature review. Coupland RM, et al. **BMJ** 1999 Aug 14; 319(7207):407–10 (36 ref.)
Suicide and homicide by people with mental illness [editorial; comment] Geddes J. **BMJ** 1999 May 8;318(7193):1225–6. Comment on: BMJ 1999 May 8;318(7193):1235–9. Comment on: BMJ 1999 May 8;318(7193):1240–4.
Mental disorder and clinical care in people convicted of homicide: national clinical survey [see comments] Shaw J, et al. **BMJ** 1999 May 8;318(7193):1240–4. Comment in: BMJ 1999 May 8;318(7193):1225–6.
Homicides by people with mental illness: myth and reality. Taylor PJ, et al. **Br J Psychiatry** 1999 Jan;174:9–14 (33 ref.)
Social factors and mortality from NASH in Canada. Leenaars AA, et al. **Crisis** 1998;19(2):73–7
Demographic and substance use factors related to violent and accidental injuries: results from an emergency room study. Macdonald S, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1–2):53–61
Multivariate analysis ('forensiometrics')--a new tool in forensic medicine. Findings on the victim of sharp-force homicide can predict the inter-relationship with the perpetrator. Karlsson T. **Forensic Sci Int** 1999 Apr 12; 101(1):33–41
A comparison of fatal with non-fatal knife injuries in Edinburgh. Webb E, et al. **Forensic Sci Int** 1999 Jan 25; 99(3):179–87
Maternal filicide: a cross-national comparison. McKee GR, et al. **J Clin Psychol** 1998 Aug;54(5):679–87
Child homicide in Oklahoma: a continuing public health problem. Cannon TC, et al. **J Okla State Med Assoc** 1998 Nov;91(8):449–51
Violence in a violent society. Terris M. **J Public Health Policy** 1998;19(3):289–302
Alcohol availability and homicide in New Orleans: conceptual considerations for small area analysis of the effect of alcohol outlet density. Scribner R, et al. **J Stud Alcohol** 1999 May;60(3):310–6
The relationship between socioeconomic factors and gang violence in the City of Los Angeles. Kyriacou DN, et al. **J Trauma** 1999 Feb;46(2):334–9
Firearm-related homicides among teenagers and young adults [letter; comment] Bosch X. **JAMA** 1999 Jan 27; 281(4):324. Comment on: JAMA 1998 Aug 5;280(5):423–7.
Firearm-related homicides among teenagers and young adults [letter; comment] Christoffel KK. **JAMA** 1999 Jan 27;281(4):323–4. Comment on: JAMA 1998 Aug

HOMICIDE

5;280(5):423-7.
Ebbing epidemic: youth homicide rate at a 14-year low [news] Cole TB. **JAMA** 1999 Jan 6;281(1):25-6
Lockerbie and Dunblane: disasters and dilemmas. Busuttil A. **Med Leg J** 1998;66 (Pt 4):126-40
Suicide and homicide in Caribbean nations. Lester D. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1350
The use of long guns for murder. Lester D. **Percept Mot Skills** 1998 Aug;87(1):162
Variation of suicide and homicide rates by longitude and latitude. Lester D, et al. **Percept Mot Skills** 1998 Aug; 87(1):186
The sex ratio, suicide, and homicide in nations of the world. Lester D. **Percept Mot Skills** 1998 Aug;87(1):50
Might stopping smoking reduce injury death risks? A meta-analysis of randomized, controlled trials. Leistikow BN, et al. **Prev Med** 1999 Mar;28(3):255-9
Involvement of alcohol in murder suicides. Cantor C, et al. **Psychol Rep** 1998 Aug;83(1):261-2
Correlates of primary and secondary murder. Lester D. **Psychol Rep** 1998 Aug;83(1):98
Subjective well-being, suicide, and homicide. Lester D. **Psychol Rep** 1998 Aug;83(1):234
Suicide and homicide rates in American states classified as introverted and neurotic. Lester D. **Psychol Rep** 1998 Oct; 83(2):686
Tobacco consumption and national rates of personal violence (suicide and homicide) [letter] Lester D. **Scand J Soc Med** 1998 Dec;26(4):299
Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957-95. Hakko H, et al. **Soc Sci Med** 1998 Dec;47(11):1695-8
Pattern of homicides in Nigeria--the Ile-Ife experience. Nwosu SO, et al. **West Afr J Med** 1998 Oct-Dec; 17(4):236-8

TRENDS

Homicides in war and peace in Croatia. Požgain I, et al. **J Forensic Sci** 1998 Nov;43(6):1124-6
Trends in intentional injury deaths in children and teenagers (1980-1995). Roberts I, et al. **J Public Health Med** 1998 Dec;20(4):463-6
Is there a regional subculture of firearm violence in Canada? Lester D, et al. **Med Sci Law** 1998 Oct;38(4):317-20
Pattern of homicides in Nigeria--the Ile-Ife experience. Nwosu SO, et al. **West Afr J Med** 1998 Oct-Dec; 17(4):236-8

HOMING BEHAVIOR

Sex-specific usage patterns of sleeping sites in grey mouse lemurs (Microcebus murinus) in northwestern Madagascar. Radespiel U, et al. **Am J Primatol** 1998;46(1):77-84
Sleeping sites, sleeping places, and presleep behavior of gibbons (Hylobates lar). Reichard U. **Am J Primatol** 1998; 46(1):35-62
Population subdivision among desert bighorn sheep (Ovis canadensis) ewes revealed by mitochondrial DNA analysis. Boyce WM, et al. **Mol Ecol** 1999 Jan;8(1):99-106
Spatial asynchrony and periodic travelling waves in cyclic populations of field voles. Lambin X, et al. **Proc R Soc Lond B Biol Sci** 1998 Aug 22;265(1405):1491-6

PHYSIOLOGY

Behavioral and mechanistic bases of long-term habituation in the crab Chasmagnathus. Tomsic D, et al. **Adv Exp Med Biol** 1998;446:17-35 (55 ref.)
Hippocampectomized rats are capable of homing by path integration. Alyan S, et al. **Behav Neurosci** 1999 Feb; 113(1):19-31
Sensory bases of navigation. Gould JL. **Curr Biol** 1998 Oct 8;8(20):R731-8 (56 ref.)
The homing pigeon hippocampus and the development of landmark navigation. Strasser R, et al. **Dev Psychobiol** 1998 Dec;33(4):305-15
Mushroom bodies of the cockroach: their participation in place memory. Mizunami M, et al. **J Comp Neurol** 1998 Dec 28;402(4):520-37
The role of orientation flights on homing performance in honeybees. Capaldi EA, et al. **J Exp Biol** 1999 Jun;202 (Pt 12):1655-66
Homing in pigeons: the role of the hippocampal formation in the representation of landmarks used for navigation. Gagliardo A, et al. **J Neurosci** 1999 Jan 1;19(1):311-5

HOMING RECEPTORS, T-CELL see **RECEPTORS, LYMPHOCYTE HOMING**

HOMINIDAE

Morphological and taxonomic affinities of the Olduvai ulna (OH 36). Aiello LC, et al. **Am J Phys Anthropol** 1999 May; 109(1):89-110
Effect of taphonomic processes on dental microwear. King T, et al. **Am J Phys Anthropol** 1999 Mar;108(3):359-73
Towards a theory of modern human origins: geography, demography, and diversity in recent human evolution. Lahr MM, et al. **Am J Phys Anthropol** 1998;Suppl 27:137-76 (98 ref.)
Growth changes in measurements of upper facial positioning. May R, et al. **Am J Phys Anthropol** 1999 Mar;108(3):269-80
A structural difference between the cell surfaces of humans and the great apes. Muchmore EA, et al. **Am J Phys Anthropol** 1998 Oct;107(2):187-98
Environmental hypotheses of hominin evolution. Potts R. **Am J Phys Anthropol** 1998;Suppl 27:93-136 (204 ref.)
On the taxonomic affinities of the Dmanisi mandible (Georgia). Rosas A, et al. **Am J Phys Anthropol** 1998 Oct; 107(2):145-62
Rare temporal bone pathology of the Singa calvaria from Sudan. Spoor F, et al. **Am J Phys Anthropol** 1998 Sep; 107(1):41-50
The brain and communication are basic for clinical human sciences. Gardner R Jr. **Br J Med Psychol** 1998 Dec;71 (Pt 4):493-508
Caesarean section: an evolving procedure? [see comments] Steer P. **Br J Obstet Gynaecol** 1998 Oct;105(10):1052-5. Comment in: Br J Obstet Gynaecol 1999 Mar;106(3):286-7.
5000-year-old myelin: uniquely intact in molecular configuration and fine structure [letter] Hess MW, et al. **Curr Biol** 1998 Jul 16;8(15):R512-3
Observations on ca. 175-year old human remains from Antarctica (Cape Shirreff, Livingston Island, South Shetlands). Torres D. **Int J Circumpolar Health** 1999 Apr; 58(2):72-83
A technique for establishing the identity of 'isolated' fossil hominin limb bones. Wood B, et al. **J Anat** 1998 Jul;193 (Pt 1):61-72
Resolution regarding the transport of hominid fossils beyond the country of origin. International Association for the Study of Human Paleontology. **J Hum Evol** 1999 Apr; 36(4):459
The TD6 (Aurora Stratum) hominid site. Final remarks and new questions. Bermúdez de Castro JM, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):695-700
The TD6 level lithic industry from Gran Dolina, Atapuerca (Burgos, Spain): production and use. Carbonell E, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):653-93
The Pleistocene site of Gran Dolina, Sierra de Atapuerca, Spain: a history of the archaeological investigations. Carbonell E, et al. **J Hum Evol** 1999 Sep-Oct; 37(3-4):313-24
Biochronological implications of the Arvicolidae (Rodentia, Mammalia) from the Lower Pleistocene hominid-bearing level of Trinchera Dolina 6 (TD6, Atapuerca, Spain). Cuenca-Bescós G, et al. **J Hum Evol** 1999 Sep-Oct; 37(3-4):353-73
Conference Report: phylogeny of Eurasian Neogene hominoid primates [news] de Bonis L, et al. **J Hum Evol** 1999 May;36(5):571-3
Zooarchaeology and taphonomy of Aurora Stratum (Gran Dolina, Sierra de Atapuerca, Spain). Diez JC, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):623-52
Earliest humans in Europe: the age of TD6 Gran Dolina, Atapuerca, Spain. Falguères C, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):343-52
Human cannibalism in the Early Pleistocene of Europe (Gran Dolina, Sierra de Atapuerca, Burgos, Spain). Fernández-Jalvo Y, et al. **J Hum Evol** 1999 Sep-Oct; 37(3-4):591-622
Cut marks on small mammals at Olduvai Gorge Bed-I [news] Fernández-Jalvo Y, et al. **J Hum Evol** 1999 May; 36(5):587-9
Evolutionary trends of stature in upper Paleolithic and Mesolithic Europe. Formicola V, et al. **J Hum Evol** 1999 Mar;36(3):319-33
Gibraltar and the Neanderthals 1848-1998 [news] Gamble C. **J Hum Evol** 1999 Feb;36(2):239-43
Carnivores from the Early Pleistocene hominid-bearing Trinchera Dolina 6 (Sierra de Atapuerca, Spain). García N, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):415-30
Additional human fossils from Klasies River Mouth South Africa. Grine FE, et al. **J Hum Evol** 1998 Jul;35(1):95-107
Grandmothering and the evolution of homo erectus. O'connell JF, et al. **J Hum Evol** 1999 May;36(5):461-85
Neanderthal skeleton from Tabun: U-series data by gamma-ray spectrometry. Schwarcz HP, et al. **J Hum Evol** 1998 Dec;35(6):635-45
The paleoenvironment of Sivapithecus parvada. Scott RS, et al. **J Hum Evol** 1999 Mar;36(3):245-74
Concerning the three stage model of carcass processing at FLK Zinjanthropus: a reply to Capaldo [news; comment] Selvaggio MM. **J Hum Evol** 1998 Sep;35(3):319-26. Comment on: J Hum Evol 1997 Nov;33(5):555-97.
The cost of bent-knee, bent-hip bipedal gait. A reply to Crompton et al. [news] Stern JT Jr. **J Hum Evol** 1999 May; 36(5):567-70
Australia's oldest human remains: age of the Lake Mungo 3 skeleton. Thorne A, et al. **J Hum Evol** 1999 Jun; 36(6):591-612
Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. Crawford MA, et al. **Lipids** 1999;34 Suppl:S39-47 (51 ref.)
A complete human pelvis from the Middle Pleistocene of Spain. Arsuaga JL, et al. **Nature** 1999 May 20; 399(6733):255-8
Palaeontology. The face of Cinderella [news] Gee H. **Nature** 1998 Dec 10;396(6711):521
The fate of the Neanderthals [news] Mellars P. **Nature** 1998 Oct 8;395(6702):539-40
Early hominid stone tool production and technical skill 2.34 Myr ago in West Turkana, Kenya [see comments] Roche H, et al. **Nature** 1999 May 6;399(6731):57-60. Comment in: Nature 1999 May 6;399(6731):24-5.
Palaeoanthropology. Stone legacy of skilled hands [news; comment] Steele J. **Nature** 1999 May 6;399(6731):24-5. Comment on: Nature 1999 May 6;399(6731):57-60.
The early Upper Paleolithic human skeleton from the Abrigo do Lagar Velho (Portugal) and modern human emergence in Iberia. Duarte C, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7604-9
Hominids and hybrids: the place of Neanderthals in human evolution. Tattersall I, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7117-9
Highly visible, curiously intangible. Clark GA. **Science** 1999 Mar 26;283(5410):2029,2031-2
A new human ancestor? [news; comment] Culotta E. **Science** 1999 Apr 23;284(5414):572-3. Comment on: Science 1999 Apr 23;284(5414):625-9. Comment on: Science 1999 Apr 23;284(5414):629-35.
Neanderthals were cannibals, bone show [news; comment] Culotta E. **Science** 1999 Oct 1;286(5437):18-9. Comment on: Science 1999 Oct 1;286(5437):128-31.
Neanderthal cannibalism at Moula-Guercy, Ardèche, France [see comments] Defleur A, et al. **Science** 1999 Oct 1; 286(5437):128-31. Comment in: Science 1999 Oct 1;286(5437):18-9.
Environment and behavior of 2.5-million-year-old Bouri hominids [see comments] de Heinzelin J, et al. **Science** 1999 Apr 23;284(5414):625-9. Comment in: Science 1999 Apr 23;284(5414):572-3.
Evolving smarts [letter; comment] Duke JA. **Science** 1999 Apr 23;284(5414):589. Comment on: Science 1999 Mar 26;283(5410):2004-5.
No last word on language origins [news] [see comments] Holden C. **Science** 1998 Nov 20;282(5393):1455-8. Comment in: Science 1998 Dec 11;282(5396):1991. Comment in: Science 1999 Jan 8;283(5399):175.
Chimp cultural diversity [letter; comment] Jablonski NG, et al. **Science** 1999 Aug 6;285(5429):836-7. Comment on: Science 1999 Jun 25;284(5423):2070-3.
Genetic study shakes up out of Africa theory [news] Pennisi E. **Science** 1999 Mar 19;283(5409):1828
Did cooked tubers spur the evolution of big brains? [news] [see comments] Pennisi E. **Science** 1999 Mar 26; 283(5410):2004-5. Comment in: Science 1999 Apr 23;284(5414):589. Comment in: Science 1999 Apr 30;284(5415):741.
Fire use [letter; comment] Rowlett RM. **Science** 1999 Apr 30;284(5415):741. Comment on: Science 1999 Mar 26;283(5410):2004-5.
Isotopic evidence for the diet of an early hominid, Australopithecus africanus [see comments] Sponheimer M, et al. **Science** 1999 Jan 15;283(5400):368-70. Comment in: Science 1999 Jan 15;283(5400):303.
Did early African hominids eat meat? [news; comment] Vogel G. **Science** 1999 Jan 15;283(5400):303. Comment on: Science 1999 Jan 15;283(5400):368-70.
New date for the dawn of dream time [news] Zimmer C. **Science** 1999 May 21;284(5418):1243,1245-6

ANATOMY & HISTOLOGY

The posterior border of the sphenoid greater wing and its phylogenetic usefulness in human evolution. Braga J, et al. **Am J Phys Anthropol** 1998 Dec;107(4):387-97
Dental anthropology of central-southern, Iron Age Italy: the evidence of metric versus nonmetric traits. Coppa A, et al. **Am J Phys Anthropol** 1998 Dec;107(4):371-86
Sexual dimorphism in the face of Australopithecus africanus. Lockwood CA. **Am J Phys Anthropol** 1999 Jan; 108(1):97-127
Cross-sectional morphology of the SK 82 and 97 proximal femora. Ruff CB, et al. **Am J Phys Anthropol** 1999 Aug; 109(4):509-21
Comparative review of the human bony labyrinth. Spoor F, et al. **Am J Phys Anthropol** 1998;Suppl 27:211-51 (128 ref.)
New evidence from Le Moustier 1: computer-assisted reconstruction and morphometry of the skull. Ponce de León MS, et al. **Anat Rec** 1999 Apr 1;254(4):474-89
Morphology, paleoanthropology, and Neanderthals. Tattersall I, et al. **Anat Rec** 1998 Aug;253(4):113-7 (20 ref.)
Early man, late journalists. Harris RF. **Curr Biol** 1999 Jun 3;9(11):R388
Mosaic evolution in the origin of the Hominoidea. Rae TC. **Folia Primatol (Basel)** 1999;70(3):125-35
Neandertal knees and ankles: a comment on Miller and Gross [letter; comment] [corrected and republished letter originally printed in J Biomech 1999 Feb;32(2):163-4] Trinkaus E. **J Biomech** 1999 Jul;32(7):751-4. Comment on: J Biomech 1998 Apr;31(4):355-61.
Neandertal knees and ankles: a comment on Miller and Gross [comment] [corrected and republished in J Biomech 1999 Jul;32(7):751-4] Trinkaus E. **J Biomech** 1999 Feb; 32(2):163-4. Comment on: J Biomech 1998 Apr;31(4):355-61.
The mandibular canal of a Neanderthal: the La Chapelle-aux-Saints man anatomical-radiological study. Goudot P. **J Craniomaxillofac Surg** 1999 Apr;27(2):134-9
Artificial cranial deformation and fossil Australians revisited. Antón SC, et al. **J Hum Evol** 1999 Feb;36(2):195-209
The human cranial remains from Gran Dolina Lower Pleistocene site (Sierra de Atapuerca, Spain). Arsuaga JL, et al. **J Hum Evol** 1999 Sep-Oct;37(3-4):431-57
Axial and appendicular skeleton of Homo antecessor. Carretero JM, et al. **J Hum Evol** 1999 Sep-Oct;

37(3–4):459–99
Observations on stria morphology in the lateral enamel of Pongo, Hylobates and Proconsul teeth. Dean MC, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):401–10
Brachial and crural indices of European late Upper Paleolithic and Mesolithic humans. Holliday TW. **J Hum Evol** 1999 May;36(5):549–66
Canine sexing and species number in the Paşalar large hominid sample [news] Kelley J, et al. **J Hum Evol** 1999 Mar;36(3):335–41
Biomechanics of masticatory force production [news] Kieser J. **J Hum Evol** 1999 May;36(5):575–9
Dental microwear of Griphopithecus alpani. King T, et al. **J Hum Evol** 1999 Jan;36(1):3–31
Recognizing species diversity among large-bodied hominoids: a simulation test using missing data finite mixture analysis. Kramer A, et al. **J Hum Evol** 1999 Apr; 36(4):409–21
The first Paranthropus from the Malawi Rift [news] Kullmer O, et al. **J Hum Evol** 1999 Jul;37(1):121–7
Patterns of sexual dimorphism in the hominoid distal humerus. Lague MR, et al. **J Hum Evol** 1999 Apr; 36(4):379–99
Hand and foot remains from the Gran Dolina Early Pleistocene site (Sierra de Atapuerca, Spain). Lorenzo C, et al. **J Hum Evol** 1999 Sep–Oct;37(3–4):501–22
Hip bone trabecular architecture shows uniquely distinctive locomotor behaviour in South African australopithecines. Macchiarelli R, et al. **J Hum Evol** 1999 Feb;36(2):211–32
Body proportions of Australopithecus afarensis and A. africanus and the origin of the genus Homo. McHenry HM, et al. **J Hum Evol** 1998 Jul;35(1):1–22
The premaxilla in Neandertal and early modern children: ontogeny and morphology. Maureille B, et al. **J Hum Evol** 1999 Aug;37(2):137–52
First record of hominid teeth from the Plio–Pleistocene site of Gondolin, South Africa. Menter CG, et al. **J Hum Evol** 1999 Aug;37(2):299–307
Modern human origins as seen from the peripheries [news] Neves WA, et al. **J Hum Evol** 1999 Jul;37(1):129–33
Lumbar anomalies in the Shanidar 3 Neandertal. Ogilvie MD, et al. **J Hum Evol** 1998 Dec;35(6):597–610
Can enamel microstructure be used to establish the presence of different species of Plio–Pleistocene hominids from Omo, Ethiopia? Ramirez Rozzi F. **J Hum Evol** 1998 Oct–Nov; 35(4–5):543–76
The ATD6–5 mandibular specimen from Gran Dolina (Atapuerca, Spain). Morphological study and phylogenetic implications. Rosas A, et al. **J Hum Evol** 1999 Sep–Oct; 37(3–4):567–90
Enamel thickness and the topography of the enamel–dentine junction in South African Plio–Pleistocene hominids with special reference to the Carabelli trait. Schwartz GT, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):523–42
Variations in molar enamel thickness among primates. Shellis RP, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):507–22
Hand function and tool behavior in early hominids. Susman RL. **J Hum Evol** 1998 Jul;35(1):23–46 (69 ref.)
AL 288–1—Lucy or Lucifer: gender confusion in the Pliocene. Tague RG, et al. **J Hum Evol** 1998 Jul;35(1):75–94
A new reconstruction of the Le Moustier 1 skull and investigation of internal structures using 3-D-muCT data. Thompson JL, et al. **J Hum Evol** 1998 Dec;35(6):647–65
Discovery of Homo sp. tooth associated with a mammalian cave fauna of Late Middle Pleistocene age, northern Thailand. Tougard C, et al. **J Hum Evol** 1998 Jul; 35(1):47–54
Diaphyseal cross-sectional geometry of the Boxgrove 1 Middle Pleistocene human tibia. Trinkaus E, et al. **J Hum Evol** 1999 Jul;37(1):1–25
South Turkwel: a new pliocene hominid site in Kenya. Ward CV, et al. **J Hum Evol** 1999 Jan;36(1):69–95
Hypoglossal canal size and hominid speech. DeGusta D, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1800–4
Neandertal nasal structures and upper respiratory tract "specialization". Franciscus RG. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1805–9
Evidence of hominid-like precision grip capability in the hand of the Miocene ape Oreopithecus. Moyà-Solà S, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):313–7
Anthropologists probe bones, stones and molecules [news] Culotta E. **Science** 1999 May 14;284(5417):1109,1111
A new look into Neandertals' noses [news] Holden C. **Science** 1999 Jul 2;285(5424):31,33
Hominid brain volume [letter; comment] Hollway RL. **Science** 1999 Jan 1;283(5398):34–5. Comment on: Science 1998 Jun 12;280(5370):1714. Comment on: Science 1998 Jun 12;280(5370):1730–1.
Silver-tongued Neandertals? [letter; comment] Lieberman P. **Science** 1999 Jan 8;283(5399):175. Comment on: Science 1998 Nov 20;282(5393):1455–8. Comment on: Science 1998 Dec 11;282(5396):1991.
The robust australopithecine face: a morphogenetic perspective [see comments] McCollum MA. **Science** 1999 Apr 9;284(5412):301–5. Comment in: Science 1999 Apr 9;284(5412):230–1.
Forming the robust australopithecine face [news; comment] Morell V. **Science** 1999 Apr 9;284(5412):230–1. Comment on: Science 1999 Apr 9;284(5412):301–5.
Patterns of faciodental sexual dimorphism in Hispanopithecus. Cameron DW. **Z Morphol Anthropol** 1998;82(1):47–58
Body height, body mass and surface area of the Neanderthals. Helmuth H. **Z Morphol Anthropol** 1998;82(1):1–12

CLASSIFICATION

The genomic record of Humankind's evolutionary roots. Goodman M. **Am J Hum Genet** 1999 Jan;64(1):31–9 (36 ref.)
Human evolution: sex-specific contributions to genome variation. Disotell TR. **Curr Biol** 1999 Jan 14;9(1):R29–31
The human cranial remains from Gran Dolina Lower Pleistocene site (Sierra de Atapuerca, Spain). Arsuaga JL, et al. **J Hum Evol** 1999 Sep–Oct;37(3–4):431–57
Dental remains from Atapuerca–TD6 (Gran Dolina site, Burgos, Spain). Bermúdez de Castro JM, et al. **J Hum Evol** 1999 Sep–Oct;37(3–4):523–66
Axial and appendicular skeleton of Homo antecessor. Carretero JM, et al. **J Hum Evol** 1999 Sep–Oct; 37(3–4):459–99
Hominoid phylogeny: inferences from a sub-terminal minisatellite analyzed by repeat expansion detection (RED) [news] Deinard AS, et al. **J Hum Evol** 1998 Sep;35(3):313–7
Radiators are cool: a response to Braga & Boesch's published paper and reply [news] Falk D, et al. **J Hum Evol** 1998 Sep;35(3):307–12
A simulation test of hominoid species number at Lufeng, China: implications for the use of the coefficient of variation in paleotaxonomy. Kelley J, et al. **J Hum Evol** 1998 Dec;35(6):577–96
Canine sexing and species number in the Paşalar large hominid sample [news] Kelley J, et al. **J Hum Evol** 1999 Mar;36(3):335–41
Is "Homo rudolfensis" a valid species? [news] Kennedy GE. **J Hum Evol** 1999 Jan;36(1):119–21
A large male hominin cranium from Sterkfontein, South Africa, and the status of Australopithecus africanus. Lockwood CA, et al. **J Hum Evol** 1999 Jun;36(6):637–85
Enamel structure and development and its application in hominid evolution and taxonomy. Ramirez Rozzi F. **J Hum Evol** 1998 Oct–Nov;35(4–5):327–30
Can enamel microstructure be used to establish the presence of different species of Plio–Pleistocene hominids from Omo, Ethiopia? Ramirez Rozzi F. **J Hum Evol** 1998 Oct–Nov; 35(4–5):543–76
'Homo rudolfensis' Alexeev, 1986–fact or phantom? [news] Wood B. **J Hum Evol** 1999 Jan;36(1):115–8
Early hominid biogeography. Strait DS, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9196–200
Australopithecus garhi: a new species of early hominid from Ethiopia [see comments] [published erratum appears in Science 1999 Jun 4;284(5420):1623] Asfaw B, et al. **Science** 1999 Apr 23;284(5414):629–35. Comment in: Science 1999 Apr 23;284(5414):572–3.
Cladistics and early hominid phylogeny [letter] Strait DS. **Science** 1999 Aug 20;285(5431):1210–1
Equatorius: a new hominoid genus from the Middle Miocene of Kenya [see comments] Ward S, et al. **Science** 1999 Aug 27;285(5432):1382–6. Comment in: Science 1999 Aug 27;285(5432):1335, 1337.
The systematics of Homo [letter; comment] Wolpoff MH. **Science** 1999 Jun 11;284(5421):1774–5. Comment on: Science 1999 Apr 2;284(5411):65–71.
The human genus. Wood B, et al. **Science** 1999 Apr 2; 284(5411):65–71 (50 ref.)
Paleoanthropology. Kenyan skeleton shakes ape family tree [news; comment] Zimmer C. **Science** 1999 Aug 27; 285(5432):1335, 1337. Comment on: Science 1999 Aug 27;285(5432):1382–6.

GENETICS

On the probability of Neanderthal ancestry [letter] Nordborg M. **Am J Hum Genet** 1998 Oct;63(4):1237–40
Genetic evidence for larger African population size during recent human evolution. Relethford JH, et al. **Am J Phys Anthropol** 1999 Mar;108(3):251–60
Human is a unique species among primates in terms of telomere length. Kakuo S, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):308–14
MIC genes in non-human primates. Pellet P, et al. **Eur J Immunogenet** 1999 Apr–Jun;26(2–3):239–41
Retroviruses, ascorbate, and mutations, in the evolution of Homo sapiens. Challem JJ, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):130–2 (25 ref.)
A view of modern human origins from Y chromosome microsatellite variation. Seielstad M, et al. **Genome Res** 1999 Jun;9(6):558–67
Evolution of a HOXB6 intergenic region within the great apes and humans. Deinard A, et al. **J Hum Evol** 1999 Jun; 36(6):687–703
Enamel structure and development and its application in hominid evolution and taxonomy. Ramirez Rozzi F. **J Hum Evol** 1998 Oct–Nov;35(4–5):327–30
Enamel thickness and the topography of the enamel–dentine junction in South African Plio–Pleistocene hominids with special reference to the Carabelli trait. Schwartz GT, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):523–42
Chips for chimps [news; comment] Clark AG. **Nat Genet** 1999 Jun;22(2):119–20. Comment on: Nat Genet 1999 Jun;22(2):164–7.
Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays [see comments] Hacia JG, et al. **Nat Genet** 1999 Jun;22(2):164–7. Comment in: Nat Genet 1999 Jun;22(2):119–20.
High genomic deleterious mutation rates in hominids [see comments] Eyre-Walker A, et al. **Nature** 1999 Jan 28; 397(6717):344–7. Comment in: Nature 1999 Jan 28;397(6717):293–4.
A modern human pattern of dental development in lower pleistocene hominids from Atapuerca–TD6 (Spain). Bermúdez de Castro JM, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):4210–3
Mitochondrial sequences show diverse evolutionary histories of African hominoids. Gagneux P, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):5077–82
Distribution of haplotypes from a chromosome 21 region distinguishes multiple prehistoric human migrations. Jin L, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3796–800
DNA sequence of the mitochondrial hypervariable region II from the neandertal type specimen. Krings M, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5581–5
Early hominid biogeography. Strait DS, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9196–200
Appendix: imprinted genes and regions in mouse and human. Beechey CV. **Results Probl Cell Differ** 1999;25:303–23 (97 ref.)
Neandertals: not so fast [letter; comment] [see comments] Wolpoff MH. **Science** 1998 Dec 11;282(5396):1991. Comment on: Science 1997 Jul 11;277(5323):176–88. Comment on: Science 1998 Nov 20;282(5393):1455–8. Comment in: Science 1999 Jan 8;283(5399):175.

GROWTH & DEVELOPMENT

Short adolescence in early hominids: infantile and adolescent growth of the human femur. Tardieu C. **Am J Phys Anthropol** 1998 Oct;107(2):163–78
Fetal growth. Steer P. **Br J Obstet Gynaecol** 1998 Nov; 105(11):1133–5
Radiographic and histological methodologies in estimating the chronology of crown development in modern humans and great apes: a review, with some applications for studies on juvenile hominids. Beynon AD, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):351–70 (57 ref.)
A comparative study of cross striation spacings in cuspal enamel and of four methods of estimating the time taken to grow molar cuspal enamel in Pan, Pongo and Homo. Dean MC. **J Hum Evol** 1998 Oct–Nov;35(4–5):449–62
Growth tracks in dental enamel. Risnes S. **J Hum Evol** 1998 Oct–Nov;35(4–5):331–50

METABOLISM

The Ice Man's diet as reflected by the stable nitrogen and carbon isotopic composition of his hair. Macko SA, et al. **FASEB J** 1999 Mar;13(3):559–62

PHYSIOLOGY

Evolution of the cerebellum in primates: differences in relative volume among monkeys, apes and humans. Rilling JK, et al. **Brain Behav Evol** 1998;52(6):308–14
Neandertal knees and ankles: a comment on Miller and Gross [comment] [corrected and republished in J Biomech 1999 Jul;32(7):751–4] Trinkaus E. **J Biomech** 1999 Feb; 32(2):163–4. Comment on: J Biomech 1998 Apr;31(4):355–61.
The mechanical effectiveness of erect and "bent-hip, bent-knee" bipedal walking in Australopithecus afarensis. Crompton RH, et al. **J Hum Evol** 1998 Jul;35(1):55–74
Uranium-series dating of the Tabun Neanderthal: a cautionary note [news] Millard AR, et al. **J Hum Evol** 1999 May;36(5):581–5
Hand function and tool behavior in early hominids. Susman RL. **J Hum Evol** 1998 Jul;35(1):23–46 (69 ref.)
Hypoglossal canal size and hominid speech. DeGusta D, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1800–4
A new look into Neandertals' noses [news] Holden C. **Science** 1999 Jul 2;285(5424):31,33

PSYCHOLOGY

Shadows on a changing landscape: comparing nesting patterns of hominids and chimpanzees since their last common ancestor. Sept J. **Am J Primatol** 1998;46(1):85–101
Aurignacian lithic economy and early modern human mobility: new perspectives from classic sites in the Vézère valley of France. Blades BS. **J Hum Evol** 1999 Jul; 37(1):91–120
Middle Palaeolithic burial is not a dead issue: the view from Qafzeh, Saint-Césaire, Kebara, Amud, and Dederiyeh. Gargett RH. **J Hum Evol** 1999 Jul;37(1):27–90

HOMINIDS see **HOMINIDAE**

HOMO SAPIENS see **HOMINIDAE**

HOMOARGININE

METABOLISM

Trypsin inhibitors and endogenous amino acids [letter; comment] Leterme P, et al. **J Nutr** 1998 Dec; 128(12):2526–7. Comment on: J Nutr 1998 Mar;128(3):598–605.

HOMOCYSTEINE

N-dansyl-S-nitrosohomocysteine a fluorescent probe for intracellular thiols and S-nitrosothiols. Ramachandran N, et al. **Biochim Biophys Acta** 1999 Feb 10;1430(1):149-54

ADMINISTRATION & DOSAGE

Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures. D'Emilia DM, et al. **Neurosci Lett** 1999 Apr 16; 265(2):103-6

ANALOGS & DERIVATIVES

Respiratory responses to chemical stimulation of the parabrachial nuclear complex in the rabbit. Mutolo D, et al. **Brain Res** 1998 Oct 5;807(1-2):182-6

Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: antioxidant implications. Ferguson E, et al. **Free Radic Biol Med** 1999 Apr;26(7-8):968-77

Reactivity of homocysteine-thiolactone and alpha-methylhomocysteine-thiolactone with e-(aq) and OH-radical: a pulse radiolysis study. Getoff N, et al. **Life Sci** 1998;63(16):1469-84

Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures. D'Emilia DM, et al. **Neurosci Lett** 1999 Apr 16; 265(2):103-6

S-nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons. Kim WK. **Neurosci Lett** 1999 Apr 16;265(2):99-102

In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Parsons RB, et al. **Neurotoxicology** 1998 Aug-Oct; 19(4-5):599-603

ANALYSIS

Determination of homocysteine and its related compounds by solid-phase microextraction-gas chromatography-mass spectrometry. Myung SW, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 30;727(1-2):1-8

BLOOD

Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Ali A, et al. **Am J Cardiol** 1998 Dec 15;82(12):1543-5, A8

Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Lobo A, et al. **Am J Cardiol** 1999 Mar 15;83(6):821-5

Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women. Brönstrup A, et al. **Am J Clin Nutr** 1998 Nov;68(5):1104-10

Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Brouwer IA, et al. **Am J Clin Nutr** 1999 Jan;69(1):99-104

Plasma homocysteine concentration in a Belgian school-age population. De Laet C, et al. **Am J Clin Nutr** 1999 May; 69(5):968-72

Effects of folic acid on homocysteine in persons classified by methylenetetrahydrofolate reductase genotype [letter; comment] Duell PB, et al. **Am J Clin Nutr** 1999 Jun; 69(6):1287-9. Comment on: Am J Clin Nutr 1998 May;67(5):858-66.

Higher total homocysteine concentrations and lower folate concentrations in premenopausal black women than in premenopausal white women. Gerhard GT, et al. **Am J Clin Nutr** 1999 Aug;70(2):252-60

Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Jacques PF, et al. **Am J Clin Nutr** 1999 Mar;69(3):482-9

Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Stolzenberg-Solomon RZ, et al. **Am J Clin Nutr** 1999 Mar;69(3):467-75

Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Kalmijn S, et al. **Am J Epidemiol** 1999 Aug 1;150(3):283-9

Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. van der Dijs FP, et al. **Am J Hematol** 1998 Nov;59(3):192-8

Measurement and use of total plasma homocysteine. American Society of Human Genetics/American College of Medical Genetics Test and Transfer Committee Working Group. **Am J Hum Genet** 1998 Nov;63(5):1541-3

Plasma homocysteine and folate are related to arterial blood pressure in type 2 diabetes mellitus. Fiorina P, et al. **Am J Hypertens** 1998 Sep;11(9):1100-7

Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Sharabi Y, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):766-71

Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Beto JA, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S172-83 (47 ref.)

Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Lee HA, et al. **Am J Kidney Dis** 1999 Aug;34(2):259-63

Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Hong SY, et al. **Am J Nephrol** 1998; 18(5):367-72

Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Spence JD, et al. **Am J Nephrol** 1999;19(3):405-10

Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Powers RW, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1605-11

Changes in homocysteine levels during normal pregnancy. Walker MC, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):660-4

Total plasma homocysteine as part of the routine aminogram by ion-exchange chromatography. Briddon A. **Amino Acids** 1998;15(3):235-9

Homocysteine associated hypercoagulability and disseminated thrombosis--a case report. Stern JM, et al. **Angiology** 1998 Sep;49(9):765-9

Stabilizing blood with 3-deazaadenosine interferes in the Abbott FPIA assay for plasma homocyst(e)ine. Dawling S. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):669-70

Stabilization of blood homocysteine by 3-deazaadenosine [see comments] al-Khafaji F, et al. **Ann Clin Biochem** 1998 Nov; 35 (Pt 6):780-2. Comment in: Ann Clin Biochem 1999 Jul;36(Pt 4):533.

Biological variability and reference intervals for total plasma homocysteine. Rossi E, et al. **Ann Clin Biochem** 1999 Jan; 36 (Pt 1):56-61

Abbott IMx homocysteine assay: significant interference by 3-deazaadenosine [letter; comment] Woltersdorf WW, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):533. Comment on: Ann Clin Biochem 1998 Nov;35(Pt 6):780-2.

Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. The Ears II Group. European Atherosclerosis Research Study. De Stefano V, et al. **Ann Hum Genet** 1998 Nov;62 (Pt 6):481-90

Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Bostom AG, et al. **Ann Intern Med** 1999 Sep 7;131(5):352-5

Ocular venous occlusion and hyperhomocysteinemia [letter] Ducloux D, et al. **Ann Intern Med** 1999 Oct 5;131(7):548-9

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence [see comments] Eikelboom JW, et al. **Ann Intern Med** 1999 Sep 7;131(5):363-75 (95 ref.). Comment in: Ann Intern Med 1999 Sep 7;131(5):387-8.

Homocysteine in health and disease [editorial; comment] Graham I. **Ann Intern Med** 1999 Sep 7;131(5):387-8. Comment on: Ann Intern Med 1999 Sep 7;131(5):321-30. Comment on: Ann Intern Med 1999 Sep 7;131(5):331-9. Comment on: Ann Intern Med 1999 Sep 7;131(5):363-75.

Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Hussein WI, et al. **Ann Intern Med** 1999 Sep 7;131(5):348-51

Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem [see comments] Kark JD, et al. **Ann Intern Med** 1999 Sep 7;131(5):321-30. Comment in: Ann Intern Med 1999 Sep 7;131(5):387-8.

Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations [see comments] Selhub J, et al. **Ann Intern Med** 1999 Sep 7; 131(5):331-9. Comment in: Ann Intern Med 1999 Sep 7;131(5):387-8.

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Haagsma CJ, et al. **Ann Rheum Dis** 1999 Feb;58(2):79-84

Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Bostom AG, et al. **Arch Intern Med** 1999 May 24;159(10):1077-80

Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Bots ML, et al. **Arch Intern Med** 1999 Jan 11;159(1):38-44

Emerging noninvasive biochemical measures: potential explanation for ethnic differences in cardiovascular risk [letter] Enas EA, et al. **Arch Intern Med** 1999 Aug 9-23; 159(15):1812-3

Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease [see comments] Clarke R, et al. **Arch Neurol** 1998 Nov;55(11):1449-55. Comment in: Arch Neurol 1998 Nov;55(11):1407-8.

Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Bostom AG, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2241-4

Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. de Jong SC, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1316-24

Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Demuth K, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec; 18(12):1838-43

Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Smilde TJ, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec;18(12):1958-63

Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Stehouwer CD, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec;18(12):1895-901

Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Ungvari Z, et al. **Arterioscler Thromb Vasc Biol** 1999 Aug; 19(8):1899-904

Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. House AA, et al. **ASAIO J** 1999 Jan-Feb;45(1):94-7

Homocysteine and coronary artery disease [letter] Cheng TO. **Atherosclerosis** 1999 Aug;145(2):419

Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. Motti C, et al. **Atherosclerosis** 1998 Aug; 139(2):377-83

Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease. Tsakiris DA, et al. **Atherosclerosis** 1999 Jan;142(1):193-200

Homocysteine and ischaemic heart disease in the Caerphilly cohort. Ubbink JB, et al. **Atherosclerosis** 1998 Oct; 140(2):349-56

The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Verhoeff BJ, et al. **Atherosclerosis** 1998 Nov;141(1):161-6

Plasma homocysteine concentrations of preterm infants. Hongsprabhas P, et al. **Biol Neonate** 1999 Aug;76(2):65-71

Determination of homocysteine in plasma by liquid chromatography with fluorescence detection. Gautier FC, et al. **Biomed Chromatogr** 1999 May;13(3):239-43

Plasma total homocysteine measurement by ion-paired reversed-phase HPLC with electrochemical detection. Martin SC, et al. **Biomed Chromatogr** 1999 Feb;13(1):81-2

Is the oral methionine loading test insensitive to the remethylation pathway of homocysteine? [letter; comment] Cattaneo M, et al. **Blood** 1999 Feb 1;93(3):1118-20. Comment on: Blood 1998 Jun 1;91(11):4158-63.

Mild hyperhomocysteinemia and MTHFR C677T do not increase the risk for venous thrombosis in a Spanish population [letter] Vargas M, et al. **Blood Coagul Fibrinolysis** 1998 Sep;9(6):555-6

Nutritional hyperhomocysteinaemia [editorial] Mohan IV, et al. **BMJ** 1999 Jun 12;318(7198):1569-70

Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Kato I, et al. **Br J Cancer** 1999 Apr;79(11-12):1917-22

Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over [see comments] Bates CJ, et al. **Br J Nutr** 1999 Mar; 81(3):191-201. Comment in: Br J Nutr 1999 Mar;81(3):175-6.

Homocyst(e)ine, vitamins and genetic interactions in vascular disease. Malinow MR. **Can J Cardiol** 1999 Apr;15 Suppl B:31B-34B

Homocysteine and risk for atherothrombotic events. Puddu P. **Cardiologia** 1999 Jul;44(7):627-31 (40 ref.)

Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Chambers JC, et al. **Circulation** 1999 Mar 9;99(9):1156-60

Homocysteine, B vitamins, and atherosclerosis [letter; comment] Cheng TO. **Circulation** 1999 Jan 26;99(3):459-60 . Comment on: Circulation 1998 Jul 21;98(3):204-10.

Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: the Bogalusa Heart Study. Greenlund KJ, et al. **Circulation** 1999 Apr 27;99(16):2144-9

Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Malinow MR, et al. **Circulation** 1999 Jan 5-12;99(1):178-82

Hyperhomocysteinemia: a risk factor for ischemic stroke in children. van Beynum IM, et al. **Circulation** 1999 Apr 27; 99(16):2070-2

Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Hernanz A, et al. **Clin Biochem** 1999 Feb;32(1):65-70

Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Geisler J, et al. **Clin Cancer Res** 1998 Sep;4(9):2125-8

Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Anker GB, et al. **Clin Chem** 1999 Feb;45(2):252-6

Evaluation of the measurement of lysate homocysteine in patients with symptomatic arterial disease and in healthy volunteers. Brandl R, et al. **Clin Chem** 1999 May; 45(5):699-702

Plasma homocysteine determined by capillary electrophoresis with laser-induced fluorescence detection. Caussé E, et al. **Clin Chem** 1999 Mar;45(3):412-4

Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients [see comments] Cole DE, et al. **Clin Chem** 1998 Nov; 44(11):2307–12. Comment in:; Clin Chem 1998 Nov;44(11):2238–9.

The plasma homocysteine/creatinine ratio can be used to study the implication of (C677T) MTHFR genetic variants in homocysteine homeostasis [letter] Cuer M, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1312

Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women. de Valk-de Roo GW, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1200–5

Interlaboratory variability for total homocysteine analysis in plasma [letter] Eliason SC, et al. **Clin Chem** 1999 Feb; 45(2):315–6

Acquired hyperhomocysteinemia in heart transplant recipients [editorial; comment] Jacobsen DW. **Clin Chem** 1998 Nov;44(11):2238–9. Comment on: Clin Chem 1998 Nov;44(11):2307–12.

Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. Leino A. **Clin Chem** 1999 Apr;45(4):569–71

Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Magera MJ, et al. **Clin Chem** 1999 Sep;45(9):1517–22

Measurement of plasma total homocysteine by HPLC with coulometric detection. Martin SC, et al. **Clin Chem** 1999 Jan;45(1):150–2

External quality assessment of methylmalonic acid and total homocysteine. Møller J, et al. **Clin Chem** 1999 Sep; 45(9):1536–42

Method comparison for total plasma homocysteine between the Abbott IMx analyzer and an HPLC assay with internal standardization. Pfeiffer CM, et al. **Clin Chem** 1999 Jan; 45(1):152–3

Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Pfeiffer CM, et al. **Clin Chem** 1999 Feb;45(2):290–2

Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Pfeiffer CM, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1261–8

Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Rasmussen K, et al. **Clin Chem** 1999 Oct;45(10):1850–5

Day-to-day, postprandial, and orthostatic variation of total plasma homocysteine. Thirup P, et al. **Clin Chem** 1999 Aug; 45(8 Pt 1):1280–3

Comparison of three different plasma homocysteine assays with gas chromatography-mass spectrometry. Ubbink JB, et al. **Clin Chem** 1999 May;45(5):670–5

The diagnostic value of serum homocysteine concentration as a risk factor for coronary artery disease. Dierkes J, et al. **Clin Chem Lab Med** 1998 Jun;36(7):453–7

Homocysteine: cholesterol of the 90s? Langman LJ, et al. **Clin Chim Acta** 1999 Aug;286(1–2):63–80 (111 ref.)

Homocysteine and B-group vitamins in renal transplant patients. Woodside JV, et al. **Clin Chim Acta** 1999 Apr; 282(1–2):157–66

Serum total homocysteine concentration does not predict outcome in renal transplant recipients. Dimény E, et al. **Clin Transplant** 1998 Dec;12(6):563–8

Abbott introduces new test for cardiac diagnostic: first automated test to measure levels of homocysteine in blood [news] **Compr Ther** 1999 Jan;25(1):58–9

High plasma homocysteine: a risk factor for vascular disease in the elderly. Moustapha A, et al. **Coron Artery Dis** 1998; 9(11):725–30 (36 ref.)

Homocysteine. Langman LJ, et al. **Crit Rev Clin Lab Sci** 1999 Aug;36(4):365–406 (243 ref.)

Lipoprotein(a), homocysteine, and remnantlike particles: emerging risk factors. Seman LJ, et al. **Curr Opin Cardiol** 1999 Mar;14(2):186–91 (84 ref.)

Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Refsum H, et al. **Curr Opin Lipidol** 1998 Dec;9(6):533–9 (89 ref.)

Identification of cognitive impairment in the elderly: homocysteine is an early marker. Lehmann M, et al. **Dement Geriatr Cogn Disord** 1999 Jan–Feb;10(1):12–20

Plasma homocysteine concentrations in patients with type 1 diabetes. Cronin CC, et al. **Diabetes Care** 1998 Nov; 21(11):1843–7

Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men [letter] Nagai Y, et al. **Diabetes Care** 1999 Jun;22(6):1004

Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Okada E, et al. **Diabetes Care** 1999 Mar;22(3):484–90

Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Smulders YM, et al. **Diabetes Care** 1999 Jan;22(1):125–32

Is plasma homocysteine related to albumin excretion rate in patients with diabetes mellitus? [letter; comment] Smulders YM, et al. **Diabetologia** 1999 Mar;42(3):382–3. Comment on: Diabetologia 1998 Jun;41(6):684–93.

Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Press RD, et al. **Diagn Mol Pathol** 1999 Mar; 8(1):54–8

Determining sulfur-containing amino acids by capillary electrophoresis: a fast novel method for total homocyst(e)ine human plasma. Vecchione G, et al. **Electrophoresis** 1999 Mar;20(3):569–74

Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Schwaninger M, et al. **Epilepsia** 1999 Mar;40(3):345–50

Homocysteine, vitamins and sex [editorial; comment] Hockly E, et al. **Eur Heart J** 1999 Sep;20(17):1222–3. Comment on: Eur Heart J 1999 Sep;20(17):1234–44.

Homocysteine, vitamin status and risk of vascular disease; effects of gender and menopausal status. European COMAC Group [see comments] Verhoef P, et al. **Eur Heart J** 1999 Sep;20(17):1234–44. Comment in: Eur Heart J 1999 Sep;20(17):1222–3.

Oral folate enhances endothelial function in hyperhomocysteinaemic subjects [see comments] Bellamy MF, et al. **Eur J Clin Invest** 1999 Aug;29(8):659–62. Comment in: Eur J Clin Invest 1999 Aug;29(8):657–8.

Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Brude IR, et al. **Eur J Clin Invest** 1999 Feb;29(2):100–8

Maternal plasma homocysteine, placenta status and docosahexaenoic acid concentration in erythrocyte phospholipids of the newborn. Böhles H, et al. **Eur J Pediatr** 1999 Mar;158(3):243–6

Elevated plasma levels of homocysteine in Parkinson's disease. Kuhn W, et al. **Eur Neurol** 1998 Nov;40(4):225–7

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Mijatovic V, et al. **Fertil Steril** 1998 Dec; 70(6):1085–9

Acute megaloblastic anemia: homocysteine levels are useful for diagnosis and follow-up [letter] Carrasco M, et al. **Haematologica** 1999 Aug;84(8):767–8

Plasma homocysteine levels in patients with coronary heart disease. Chacko KA. **Indian Heart J** 1998 May–Jun; 50(3):295–9

Atherogenic diet alters folate enzymes in mice: implications of folate deficient homocysteinemia. Kulkarni MV, et al. **Indian J Biochem Biophys** 1998 Oct;35(5):303–7

Homocysteine screening of a female Hispanic population. Wu AH, et al. **Int J Mol Med** 1999 Sep;4(3):295–7

Homocysteinemia and livedoid vasculitis. Gibson GE, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):279–81

Homocysteine and cardiovascular disease. Abby SL, et al. **J Am Board Fam Pract** 1998 Sep–Oct;11(5):391–8 (43 ref.)

Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. Siri PW, et al. **J Am Coll Nutr** 1998 Oct;17(5):435–41

Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. Bostom AG, et al. **J Am Soc Nephrol** 1999 Jan;10(1):164–6

Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. Shemin D, et al. **J Am Soc Nephrol** 1999 May;10(5):1095–9

Monitoring of homocysteine and related compounds in blood by MEKC. Giorgieri S, et al. **J Capillary Electrophor** 1997 Nov–Dec;4(6):257–60

Homocysteine and cardiovascular disease. Overview. Clarke R. **J Cardiovasc Risk** 1998 Aug;5(4):213–5

Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. Clarke R, et al. **J Cardiovasc Risk** 1998 Aug;5(4):249–55

Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. Danesh J, et al. **J Cardiovasc Risk** 1998 Aug;5(4):229–32

Pathogenesis of vascular disease in hyperhomocysteinaemia. Domagala TB, et al. **J Cardiovasc Risk** 1998 Aug; 5(4):239–47 (100 ref.)

Homocysteine levels and coronary heart disease in Syria. Joubran R, et al. **J Cardiovasc Risk** 1998 Aug;5(4):257–61

Homocysteine and vascular disease: nature or nurture? Meleady RA, et al. **J Cardiovasc Risk** 1998 Aug;5(4):233–7 (62 ref.)

High-performance liquid chromatographic determination of total plasma homocysteine with or without internal standards. Accinni R, et al. **J Chromatogr A** 1998 Dec 18; 828(1–2):397–400

Automated high-performance liquid chromatographic method for the determination of homocysteine in plasma samples. Carducci C, et al. **J Chromatogr A** 1999 Jun 18; 846(1–2):93–100

Quantitation of homocysteine in human plasma by capillary electrophoresis and laser-induced fluorescence detection. Caussé E, et al. **J Chromatogr A** 1998 Aug 21; 817(1–2):181–5

Determination of plasma and serum homocysteine by high-performance liquid chromatography with fluorescence detection. Minniti G, et al. **J Chromatogr A** 1998 Dec 18;828(1–2):401–5

Total homocysteine levels in plasma: high-performance liquid chromatographic determination with electrochemical detection and glassy carbon electrode. D'Eramo JL, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11;720(1–2):205–10

Gas chromatographic-mass spectrometric determination of total homocysteine in human plasma by stable isotope dilution: method and clinical applications. Ducros V, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11; 729(1–2):333–9

High-performance liquid chromatographic method for measuring total plasma homocysteine levels. Fermo I, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 20; 719(1–2):31–6

Occurrence of hyperhomocysteinemia 1 year after gastroplasty for severe obesity. Borson-Chazot F, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):541–5

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. Cook RC, et al. **J Heart Lung Transplant** 1999 May;18(5):420–4

Homocysteine, hypertension and stroke. Perry IJ. **J Hum Hypertens** 1999 May;13(5):289–93 (42 ref.)

Fasting, postprandial, and post-methionine-load homocysteinaemia and methylenetetrahydrofolate reductase polymorphism in vascular disease. Candito M, et al. **J Inherit Metab Dis** 1999 Jun;22(5):588–92

Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease? Thuillier L, et al. **J Inherit Metab Dis** 1998 Dec;21(8):812–22

Association between hyperhomocysteinaemia and hypertension in Sri Lankans. Mendis S, et al. **J Int Med Res** 1999 Jan–Feb;27(1):38–44

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Aarsand AK, et al. **J Intern Med** 1998 Aug;244(2):169–74

Elevated serum levels of methylmalonic acid and homocysteine in elderly people. A population-based intervention study. Björkegren K, et al. **J Intern Med** 1999 Sep;246(3):317–24

Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. de Jong SC, et al. **J Intern Med** 1999 Jul;246(1):87–96

Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. van Guldener C, et al. **J Intern Med** 1999 Feb;245(2):175–83

Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. Lee YK, et al. **J Korean Med Sci** 1999 Apr; 14(2):193–8

Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. Lalouschek W, et al. **J Lab Clin Med** 1999 Jun; 133(6):575–82

Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. Blacher J, et al. **J Nephrol** 1999 Jul–Aug;12(4):248–55

Hyperhomocysteinaemia in Parkinson's disease [letter] Kuhn W, et al. **J Neurol** 1998 Dec;245(12):811–2

Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. Brouwer IA, et al. **J Nutr** 1999 Jun; 129(6):1135–9

A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. Friedman G, et al. **J Nutr** 1999 Sep;129(9):1656–61

Ability of endogenous folate from soy protein isolate to maintain plasma homocysteine and hepatic DNA methylation during methyl group depletion in rats. Le Leu RK, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Jun; 44(3):457–64

Plasma homocysteine levels and folate status in children with sickle cell anemia [see comments] Rodriguez-Cortes HM, et al. **J Pediatr Hematol Oncol** 1999 May–Jun;21(3):219–23 . Comment in: J Pediatr Hematol Oncol 1999 May–Jun;21(3):176–8.

Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. Fijnheer R, et al. **J Rheumatol** 1998 Sep;25(9):1737–42

Total plasma homocysteine in patients with gout [letter] Istok R, et al. **J Rheumatol** 1999 Sep;26(9):2068–9

Effect of acute exercise on plasma homocysteine. Wright M, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):262–5

Effect of methionine supplementation on endothelial function, plasma homocysteine, and lipid peroxidation. McAuley DF, et al. **J Toxicol Clin Toxicol** 1999; 37(4):435–40

Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. Taylor LM Jr, et al. **J Vasc Surg** 1999 Jan;29(1):8–19; discussion 19–21

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. Nappo F, et al. **JAMA** 1999 Jun 9;281(22):2113–8

Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. Osganian SK, et al. **JAMA** 1999 Apr 7;281(13):1189–96

Homocysteine and risk of cardiovascular disease among postmenopausal women. Ridker PM, et al. **JAMA** 1999 May 19;281(19):1817–21

Serum total homocysteine concentration before and after

renal transplantation. Arnadottir M, et al. **Kidney Int** 1998 Oct;54(4):1380–4

Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. Födinger M, et al. **Kidney Int** 1999 Mar;55(3):1072–80

Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Manns BJ, et al. **Kidney Int** 1999 Jan;55(1):315–20

Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Stehouwer CD, et al. **Kidney Int** 1999 Jan; 55(1):308–14

Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Vychytil A, et al. **Kidney Int** 1999 May;55(5):2054–61

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Wollesen F, et al. **Kidney Int** 1999 Mar;55(3):1028–35

Lipid-lowering drugs and homocysteine [letter] [see comments] de Lorgeril M, et al. **Lancet** 1999 Jan 16; 353(9148):209–10. Comment in: Lancet 1999 Jun 5;353(9168):1974–5.

Serum homocysteine increases after therapy with fenofibrate or bezafibrate [letter] Dierkes J, et al. **Lancet** 1999 Jul 17; 354(9174):219–20

Homocysteine and vascular disease. Hankey GJ, et al. **Lancet** 1999 Jul 31;354(9176):407–13 (66 ref.)

Plasma homocysteine and all-cause mortality in diabetes [letter] Kark JD, et al. **Lancet** 1999 Jun 5;353(9168):1936–7

Lipid-lowering drugs and homocysteine [letter; comment] Landray MJ, et al. **Lancet** 1999 Jun 5;353(9168):1974–5. Comment on: Lancet 1999 Jan 16;353(9148):209–10.

Nigral endothelial dysfunction, homocysteine, and Parkinson's disease [letter] Müller T, et al. **Lancet** 1999 Jul 10;354(9173):126–7

Homocysteine and folate in healthy east London Bangladeshis [letter] Obeid OA, et al. **Lancet** 1998 Dec 5;352(9143):1829–30

Trimethoprim and fasting plasma homocysteine [letter] [published erratum appears in Lancet 1999 Feb 27;353(9154):758] Smulders YM, et al. **Lancet** 1998 Dec 5;352(9143):1827–8

Plasma homocysteine levels increase in women during psychological stress. Stoney CM. **Life Sci** 1999; 64(25):2359–65

Plasma homocysteine levels in indigenous Australians. Shaw JT, et al. **Med J Aust** 1999 Jan 4;170(1):19–22

Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Dierkes J, et al. **Metabolism** 1999 May;48(5):631–5

Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Stabler SP, et al. **Metabolism** 1999 Sep;48(9):1096–101

Plasma homocysteine levels related to interactions between folate status and methylenetetrahydrofolate reductase: a study in 52 healthy subjects. Zittoun J, et al. **Metabolism** 1998 Nov;47(11):1413–8

Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. Perna AF, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):95–9 (24 ref.)

Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine beta-synthase gene, and pyridoxal-5'-phosphate concentration. Tsai MY, et al. **Mol Genet Metab** 1999 Aug;67(4):352–6

The effect of folic acid fortification on plasma folate and total homocysteine concentrations. Jacques PF, et al. **N Engl J Med** 1999 May 13;340(19):1449–54

Folic acid fortification [letter] Oakley GP Jr. **N Engl J Med** 1999 Sep 16;341(12):922–3; discussion 924

Effect of pyridoxine or riboflavin supplementation on plasma homocysteine levels in women with oral lesions. Lakshmi AV, et al. **Natl Med J India** 1998 Jul-Aug;11(4):171–2

Influence of haemodialysis on plasma total homocysteine concentration. Arnadottir M, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):142–6

The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Brulez HF, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):154–9

Prevalence, determinants, and clinical significance of hyperhomocyst(e)inaemia in renal-transplant recipients. Ducloux D, et al. **Nephrol Dial Transplant** 1998 Nov; 13(11):2890–3

Dialysis adequacy and homocyst(e)ine concentrations in peritoneal dialysis patients. Ducloux D, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):728–31

Hyperhomocyst(e)inaemia in children with chronic renal failure. Lilien M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):366–8

Homocyst(e)ine and vascular access complications in haemodialysis patients: insights into a complex metabolic relationship. Sirrs S, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):738–43

The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Samuelsson O, et al. **Nephron** 1999; 82(4):306–11

Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. van den Berg M, et al. **Neth J Med** 1999 Jul;55(1):29–38

Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Virgos C, et al. **Neuroreport** 1999 Jul 13; 10(10):2035–8

Homocysteine and Alzheimer's disease. Miller JW. **Nutr Rev** 1999 Apr;57(4):126–9 (15 ref.)

Current international literature citation-nutrition. Grimble GK. **Nutrition** 1999 Jul-Aug;15(7-8):646–7

Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Laivuori H, et al. **Obstet Gynecol** 1999 Apr;93(4):489–93

Plasma homocyst(e)ine concentrations in eclamptic and preeclamptic African women postpartum. Rajkovic A, et al. **Obstet Gynecol** 1999 Sep;94(3):355–60

Cerebral vascular complication and hyperhomocysteinemia in a cystinotic uremic child. Merouani A, et al. **Pediatr Nephrol** 1999 Jan;13(1):73–6

Plasma total homocysteine response to oral doses of folic acid and pyridoxine hydrochloride (vitamin B6) in healthy individuals. Oral doses of vitamin B6 reduce concentrations of serum folate. Mansoor MA, et al. **Scand J Clin Lab Invest** 1999 Apr;59(2):139–46

Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988–1994. Giles WH, et al. **Stroke** 1998 Dec;29(12):2473–7

Homocyst(e)ine and risk of cerebral infarction in a biracial population : the stroke prevention in young women study. Kittner SJ, et al. **Stroke** 1999 Aug;30(8):1554–60

Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Spence JD, et al. **Stroke** 1999 May;30(5):969–73

Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Yoo JH, et al. **Stroke** 1998 Dec; 29(12):2478–83

The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Balasa VV, et al. **Thromb Haemost** 1999 May;81(5):739–44

Hyperhomocysteinemia and venous thrombosis: a meta-analysis. den Heijer M, et al. **Thromb Haemost** 1998 Dec;80(6):874–7

Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia. Grundt H, et al. **Thromb Haemost** 1999 Apr;81(4):561–5

Short-term reproducibility of total homocysteine determinations in stable renal transplant recipients. Beaulieu AJ, et al. **Transplant Proc** 1999 Aug;31(5):2121–3

Hyperhomocysteinemia and other coronary risk factors in 20-year renal transplant recipients (level 5A) with and without coronary heart disease. Braun WE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1280–2

Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients. Bostom AG, et al. **Transplantation** 1999 Jul 27;68(2):257–61

Pathological changes in cobalt-supplemented and non-supplemented twin lambs in relation to blood concentrations of methylmalonic acid and homocysteine. Vellema P, et al. **Vet Q** 1999 Jun;21(3):93–8

[A correlation study on homocysteine metabolism in pregnant women and neural tube defects in urban and rural areas] Zhan S, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jul;31(4):221–4 (Eng. Abstr.) **(Chi)**

[Plasma homocysteine levels in patients with indications for cardiac revascularization] Rath D, et al. **Vnitr Lek** 1998 May;44(5):255–8 (Eng. Abstr.) **(Cze)**

[The recommended daily amount of folic acid is insufficient for optimum homocysteine levels (letter)] Brouwer IA, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1473 **(Dut)**

[A young patient with chronic recurrent leg ulcers; hyperhomocysteinemia and heterozygote for factor V Leiden] Kolbach DN, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2706–7 **(Dut)**

[The recommended daily intake of folic acid is insufficient for optimum homocysteine level (letter)] Willems HPJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1473–4 **(Dut)**

[Blood levels of homocysteine by high pressure liquid chromatography and comparison with two other techniques] Ceppa F, et al. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):474–80 (Eng. Abstr.) **(Fre)**

[Homocysteine: a cardiovascular risk factor?] Suter PM, et al. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):259–72 (72 ref.) (Eng. Abstr.) **(Ger)**

[Plasma homocysteine concentration in healthy middle-aged men and its presumed association with cardiovascular mortality] Bogye G, et al. **Orv Hetil** 1999 Jul 11; 140(28):1573–7 (Eng. Abstr.) **(Hun)**

[Action of pravastatin treatment on blood levels of homocysteine] Blardi P, et al. **Minerva Cardioangiol** 1998 Sep;46(9):315–6 **(Ita)**

[Plasma levels of homocysteine and peripheral obliterating arteriopathies. An epidemiologic study of hospitalized patients] Laghi Pasini F, et al. **Minerva Cardioangiol** 1998 Sep;46(9):312 **(Ita)**

[Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery] Iwama Y, et al. **J Cardiol** 1998 Dec;32(6):357–62 (Eng. Abstr.) **(Jpn)**

[Homocysteine as a nonlipid factor in the pathogenesis of atherosclerosis] Magott M. **Postepy Hig Med Dosw** 1998; 52(3):259–67 (50 ref.) (Eng. Abstr.) **(Pol)**

[Hyperhomocysteinemia and vaso-occlusive diseases] Bydlowski SP, et al. **Arq Bras Cardiol** 1998 Jul;71(1):69–76 (90 ref.) **(Por)**

[The effect of sex and menopause on basal blood levels of homocysteine and after methionine loading] Reis RP, et al. **Rev Port Cardiol** 1999 Feb;18(2):155–9 (Eng. Abstr.) **(Por)**

[Homocysteine--a routine biochemical parameter in cardiovascular diseases?] Gábor D, et al. **Vnitr Lek** 1999 Jan;45(1):40–5 (Eng. Abstr.) **(Slo)**

[Relation between cytokines (TNF-alpha, IL-1 and 6) and homocysteine in android obesity and the phenomenon of insulin resistance syndromes] Hrnčiar J, et al. **Vnitr Lek** 1999 Jan;45(1):11–6 (Eng. Abstr.) **(Slo)**

[Serum homocysteine levels in healthy Chilean adults] Bunout D, et al. **Rev Med Chil** 1998 Aug;126(8):905–10 (Eng. Abstr.) **(Spa)**

[Homocysteine in blood. Deficiency marker and risk marker (letter)] Björkegren K. **Lakartidningen** 1999 Feb 24; 96(8):867–8 **(Swe)**

[Homocysteine as a deficiency marker. Attitudes and values (letter)] Lökk J. **Lakartidningen** 1999 May 12;96(19):2331 **(Swe)**

[Spin and pour off! Homocysteine is non-perishable when handled correctly! (letter; comment)] Norberg B. **Lakartidningen** 1999 Jan 6;96(1–2):14. Comment on: Lakartidningen 1998 Sep 2;95(36):3802–4. Comment on: Lakartidningen 1998 Nov 4;95(45):4965–6. **(Swe)**

CEREBROSPINAL FLUID

One-methyl group metabolism in non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid homocysteine levels. Van Hove JL, et al. **J Inherit Metab Dis** 1998 Dec;21(8):799–811

CHEMISTRY

Electrochemical reactivity of homocysteine at mercury electrodes as compared with cysteine. Heyrovský M, et al. **Bioelectrochem Bioenerg** 1999 Feb;48(1):43–51

DRUG EFFECTS

Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Jacobs RL, et al. **Diabetes** 1998 Dec;47(12):1967–70

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Aarsand AK, et al. **J Intern Med** 1998 Aug;244(2):169–74

Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. Morrow LE, et al. **South Med J** 1999 Sep;92(9):866–70

GENETICS

The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease [see comments] Gardemann A, et al. **Eur Heart J** 1999 Apr;20(8):584–92. Comment in: Eur Heart J 1999 Apr;20(8):552–3.

Association of the 677C-->T mutation on the methylenetetrahydrofolate reductase gene in Turkish patients with neural tube defects. Boduroğlu K, et al. **J Child Neurol** 1999 Mar;14(3):159–61

Factor V Leiden, mild hyperhomocyst(e)inemia and Buerger's disease [letter] Mercié P, et al. **Microvasc Res** 1998 May;55(3):271–2

[Homocysteine as a nonlipid factor in the pathogenesis of atherosclerosis] Magott M. **Postepy Hig Med Dosw** 1998; 52(3):259–67 (50 ref.) (Eng. Abstr.) **(Pol)**

HISTORY

Kilmer McCully: pioneer of the homocysteine theory [news] Larkin M. **Lancet** 1998 Oct 24;352(9137):1364

METABOLISM

Homocysteine and chronic renal failure. Hannedouche TP, et al. **Adv Nephrol Necker Hosp** 1998;28:287–310 (64 ref.)

Folate and homocysteine metabolism and gene polymorphisms in the etiology of Down syndrome [editorial; comment] Rosenblatt DS. **Am J Clin Nutr** 1999 Oct;70(4):429–30. Comment on: Am J Clin Nutr 1999 Oct;70(4):495–501.

Homocysteine metabolism. Selhub J. **Annu Rev Nutr** 1999; 19:217–46 (150 ref.)

Effect of spermidine on the activation of homocysteine. Leirvaag B, et al. **Biochem Soc Trans** 1998 Nov;26(4):S374

Folate and homocysteine metabolism in copper-deficient rats. Tamura T, et al. **Biochim Biophys Acta** 1999 May 24; 1427(3):351–6

Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Gisslinger H, et al. **Br J Haematol** 1998 May;105(2):551–5

Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Jacobs RL, et al. **Diabetes** 1998 Dec;47(12):1967–70

Homocysteine: an emerging age-related cardiovascular risk

factor [published erratum appears in Geriatrics 1999 Jul;54(7):17] Moustapha A, et al. **Geriatrics** 1999 Apr; 54(4):41, 44–6, 49–51 (30 ref.)

Homocysteine--a pathophysiological cornerstone in obstetrical and gynaecological disorders? Obwegeser R, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):64–72 (131 ref.)

Lowering of homocysteine concentrations in elderly men and women. Brönstrup A, et al. **Int J Vitam Nutr Res** 1999 May;69(3):187–93

Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. House JD, et al. **Kidney Int** 1998 Nov;54(5):1601–7

Homocysteine and methionine metabolism in ESRD: A stable isotope study. van Guldener C, et al. **Kidney Int** 1999 Sep; 56(3):1064–71

Homocysteine in cerebral macroangiography and microangiopathy [letter] Fassbender K, et al. **Lancet** 1999 May 8;353(9164):1586–7

Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase genotype in rural South African blacks with a history of pregnancy complicated by neural tube defects. Ubbink JB, et al. **Metabolism** 1999 Feb; 48(2):269–74

The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine-lowering effect of hormone replacement therapy. Brown CA, et al. **Mol Genet Metab** 1999 May;67(1):43–8

Folate-homocysteine interrelations: potential new markers of folate status. Lucock MD, et al. **Mol Genet Metab** 1999 May;67(1):23–35

High expression, purification, and properties of recombinant homocysteine alpha, gamma-lyase. Han Q, et al. **Protein Expr Purif** 1998 Nov;14(2):267–74

Vitamin supplementation during weight reduction--favourable effect on homocysteine metabolism. Henning BF, et al. **Res Exp Med (Berl)** 1998 Jul; 198(1):37–42

Homocyst(e)ine, atherosclerosis, and thrombosis. Alpert MA. **South Med J** 1999 Sep;92(9):858–65 (70 ref.)

Homocysteine and hypomethylation. A novel link to vascular disease. Lee ME, et al. **Trends Cardiovasc Med** 1999 Jan–Feb;9(1-2):49–54 (52 ref.)

[Molecular genetics of the remethylation of homocysteine] Chango A, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb; 57(1):37–42 (44 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Dialysis kinetics of homocysteine and reactive oxygen species. Biasioli S, et al. **ASAIO J** 1998 Sep–Oct; 44(5):M423–32

PHARMACOLOGY

Superoxide-dependent cerebrovascular effects of homocysteine. Zhang F, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1704–11

Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Bescond A, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):498–503

ERK2 activation by homocysteine in vascular smooth muscle cells. Brown JC, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):669–76

Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Outinen PA, et al. **Blood** 1999 Aug 1;94(3):959–67

Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Emsley AM, et al. **Br J Pharmacol** 1999 Feb; 126(4):1034–40

Blockade of nitric oxide-induced relaxation of rabbit aorta by cysteine and homocysteine. Li J, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):11–20

Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo. Dudman NP, et al. **Circ Res** 1999 Mar 5;84(4):409–16

Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Ikeda U, et al. **Circulation** 1999 Mar 9;99(9):1230–5

Identification of defensins in human lymphocyte nuclei. Blomqvist M, et al. **Eur J Biochem** 1999 Jul;263(2):312–8

Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Demuth K, et al. **Eur J Biochem** 1999 Jul;263(2):367–76

Electrophysiological effects of homocysteine in isolated rat right ventricular papillary muscles and left atria. Pacher P, et al. **Gen Pharmacol** 1999 Apr;32(4):439–43

Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage. Austin RC, et al. **J Biol Chem** 1998 Nov 13; 273(46):30808–17

Modulation of annexin II by homocysteine: implications for atherothrombosis. Hajjar KA, et al. **J Investig Med** 1998 Oct;46(8):364–9 (87 ref.)

Nonradioactive differential display cloning of genes induced by homocysteine in vascular endothelial cells. Kokame K, et al. **Methods** 1998 Dec;16(4):434–43

PHYSIOLOGY

B vitamins and homocysteine in cardiovascular disease and aging. Wilcken DE, et al. **Ann N Y Acad Sci** 1998 Nov 20;854:361–70 (29 ref.)

Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix. Tyagi SC. **Clin Exp Hypertens** 1999 Apr;21(3):181–98 (52 ref.)

Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. Scott JM, et al. **J Cardiovasc Risk** 1998 Aug;5(4):223–7 (6 ref.)

Homocysteine and cardiovascular disease [editorial; comment] Winder AF. **J Clin Pathol** 1998 Oct;51(10):713 . Comment on: J Clin Pathol 1998 Mar;51(3):183–8.

[What role does homocysteine play in vascular diseases?] Ecker-Schlipf B. **Med Monatsschr Pharm** 1999 Jan; 22(1):19–23 (3 ref.) **(Ger)**

POISONING

S-nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons. Kim WK. **Neurosci Lett** 1999 Apr 16;265(2):99–102

SECRETION

Higher export rate of homocysteine in a human endothelial cell line than in other human cell lines. Hultberg B, et al. **Biochim Biophys Acta** 1998 Nov 19;1448(1):61–9

TOXICITY

N-methyl-D-aspartate receptor agonists modulate homocysteine-induced developmental abnormalities. Rosenquist TH, et al. **FASEB J** 1999 Sep;13(12):1523–31

Analysis of gene expression in homocysteine-injured vascular endothelial cells: demonstration of GRP78/BiP expression, cloning and characterization of a novel reducing agent-tunicamycin regulated gene. Miyata T, et al. **Semin Thromb Hemost** 1998;24(3):285–91

URINE

Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Magera MJ, et al. **Clin Chem** 1999 Sep;45(9):1517–22

HOMOCYSTINE

BLOOD

Stabilizing blood with 3-deazaadenosine interferes in the Abbott FPIA assay for plasma homocyst(e)ine. Dawling S. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):669–70

Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. Gemmati D, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1761–7

Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. Lee YK, et al. **J Korean Med Sci** 1999 Apr; 14(2):193–8

Hyperhomocyst(e)inaemia in children with chronic renal failure. Lilien M, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):366–8

Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the Third National Health and Nutrition Examination Survey, 1988–1994. Giles WH, et al. **Stroke** 1998 Dec;29(12):2473–7

METABOLISM

Homocyst(e)ine, atherosclerosis, and thrombosis. Alpert MA. **South Med J** 1999 Sep;92(9):858–65 (70 ref.)

[Genetic polymorphisms of methylenetetrahydrofolate reductase and methionine synthase: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population] Morita H, et al. **J Cardiol** 1999 Feb;33(2):106–7 **(Jpn)**

PHYSIOLOGY

Homocyst(e)ine and heart disease: pathophysiology of extracellular matrix. Tyagi SC. **Clin Exp Hypertens** 1999 Apr;21(3):181–98 (52 ref.)

URINE see HOMOCYSTINURIA

HOMOCYSTINURIA

BLOOD

Decreased circulating plasma lipids in patients with homocystinuria. Moat SJ, et al. **J Inherit Metab Dis** 1999 May;22(3):243–6

COMPLICATIONS

Superior sagittal sinus thrombosis with homocystinuria and deficiency of antithrombin III and factor VII: case report. Kang HS, et al. **Acta Neurochir (Wien)** 1998;140(2):196–8

The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Kluijtmans LA, et al. **Am J Hum Genet** 1999 Jul;65(1):59–67

Ophthalmic abnormalities in homocystinuria: the value of screening. Taylor RH, et al. **Eye** 1998;12 (Pt 3a):427–30

Minor facial anomalies in combined methylmalonic aciduria and homocystinuria due to a defect in cobalamin metabolism. Cerone R, et al. **J Inherit Metab Dis** 1999 May; 22(3):247–50

Multifocal bursitis in a patient with homozygous homocystinuria. Haedecke C, et al. **J Inherit Metab Dis** 1999 Apr;22(2):185–6

Homocystinuria: a cause of hypercoagulability that may be unrecognized. Lobo CA, et al. **J Vasc Interv Radiol** 1998 Nov-Dec;9(6):971–5

Management of ophthalmic complications of homocystinuria. Harrison DA, et al. **Ophthalmology** 1998 Oct; 105(10):1886–90

[Homocysteine and cardiovascular risk] Lutteri L, et al. **Rev Med Liege** 1999 Jun;54(6):541–7 (36 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Ophthalmic abnormalities in homocystinuria: the value of screening. Taylor RH, et al. **Eye** 1998;12 (Pt 3a):427–30

Reliability of biochemical parameters used in prenatal diagnosis of combined methylmalonic aciduria and homocystinuria. Merinero B, et al. **Prenat Diagn** 1998 Sep; 18(9):947–52

DRUG THERAPY

Acute life-threatening event with rhabdomyolysis after starting on high-dose pyridoxine therapy in an infant with homocystinuria. Shoji Y, et al. **J Inherit Metab Dis** 1998 Jun;21(4):439–40

ENZYMOLOGY

Homocystinuria (methylenetetrahydrofolate reductase deficiency) and mutation of factor V gene. Goyette P, et al. **J Inherit Metab Dis** 1998 Aug;21(6):690–1

EPIDEMIOLOGY

Prevalence of congenital homocystinuria in Denmark [letter] Gaustadnes M, et al. **N Engl J Med** 1999 May 13; 340(19):1513

GENETICS

The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Kluijtmans LA, et al. **Am J Hum Genet** 1999 Jul;65(1):59–67

Functionally null mutations in patients with the cblG-variant form of methionine synthase deficiency. Wilson A, et al. **Am J Hum Genet** 1998 Aug;63(2):409–14

Evidence of carotid artery wall hypertrophy in homozygous homocystinuria. Megnien JL, et al. **Circulation** 1998 Nov 24;98(21):2276–81

Mutational analysis of the cystathionine beta-synthase gene: a splicing mutation, two missense mutations and an insertion in patients with homocystinuria. Mutations in brief no. 120. Online. Gordon RB, et al. **Hum Mutat** 1998; 11(4):332

Cystathionine beta-synthase mutations in homocystinuria. Kraus JP, et al. **Hum Mutat** 1999;13(5):362–75 (48 ref.)

Four novel mutations at the cystathionine beta-synthase locus causing homocystinuria. Coudé M, et al. **J Inherit Metab Dis** 1998 Dec;21(8):823–8

Homocystinuria (methylenetetrahydrofolate reductase deficiency) and mutation of factor V gene. Goyette P, et al. **J Inherit Metab Dis** 1998 Aug;21(6):690–1

Characterization of mutations in the cystathionine beta-synthase gene in Irish patients with homocystinuria. Gallagher PM, et al. **Mol Genet Metab** 1998 Dec; 65(4):298–302

PATHOLOGY

Evidence of carotid artery wall hypertrophy in homozygous homocystinuria. Megnien JL, et al. **Circulation** 1998 Nov 24;98(21):2276–81

Fatal haemorrhagic infarct in an infant with homocystinuria. Cardo E, et al. **Dev Med Child Neurol** 1999 Feb;41(2):132–5

PHYSIOPATHOLOGY

Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. Yap S, et al. **J Inherit Metab Dis** 1998 Oct;21(7):738–47

THERAPY

Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years' experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. Yap S, et al. **J Inherit Metab Dis** 1998 Oct;21(7):738–47

HOMO-GAMMA LINOLENIC ACID see 8,11,14-EICOSATRIENOIC ACID

HOMOGENTISIC ACID

HOMOGENTISIC ACID

URINE

'Pseudohypouricosuria' in alcaptonuria: homogentisic acid interference in the measurement of urinary uric acid with the uricase-peroxidase reaction. Moriwaki Y, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):501-3

A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. Suzuki Y, et al. **J Hum Genet** 1999; 44(2):79-84

HOMOGRAFT see **TRANSPLANTATION, HOMOLOGOUS**

HOMOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

HOMOGRAFT, ISOGENEIC see **TRANSPLANTATION, ISOGENEIC**

HOMOGRAFT, SYNGENEIC see **TRANSPLANTATION, ISOGENEIC**

HOMOLOGOUS RESTRICTION FACTOR 20 see **ANTIGENS, CD59**

HOMOLOGOUS SEQUENCES see **SEQUENCE HOMOLOGY**

HOMOLOGOUS SEQUENCES, AMINO ACID see **SEQUENCE HOMOLOGY, AMINO ACID**

HOMOLOGOUS SEQUENCES, NUCLEIC ACID see **SEQUENCE HOMOLOGY, NUCLEIC ACID**

HOMOLOGOUS WASTING DISEASE see **GRAFT VS HOST DISEASE**

HOMOPROTOCATECHUIC ACID see **3,4-DIHYDROXYPHENYLACETIC ACID**

HOMOSERINE

ANALOGS & DERIVATIVES

Quorum sensing and the cell-cell communication dependent regulation of gene expression in pathogenic and non-pathogenic bacteria. Hardman AM, et al. **Antonie Van Leeuwenhoek** 1998 Nov;74(4):199-210 (100 ref.)

Production of acylated homoserine lactones by psychrotrophic members of the Enterobacteriaceae isolated from foods. Gram L, et al. **Appl Environ Microbiol** 1999 Aug;65(8):3458-63

'Subinhibitory' erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Sofer D, et al. **Chemotherapy** 1999 Sep-Oct; 45(5):335-41

Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis. Hoang TT, et al. **J Bacteriol** 1999 Sep; 181(17):5489-97

Cell density-dependent starvation survival of Rhizobium leguminosarum bv. phaseoli: identification of the role of an N-acyl homoserine lactone in adaptation to stationary-phase survival. Thorne SH, et al. **J Bacteriol** 1999 Feb;181(3):981-90

Analogs of the autoinducer 3-oxooctanoyl-homoserine lactone strongly inhibit activity of the TraR protein of Agrobacterium tumefaciens. Zhu J, et al. **J Bacteriol** 1998 Oct;180(20):5398-405

Characterization of the Erwinia chrysanthemi expI-expR locus directing the synthesis of two N-acyl-homoserine lactone signal molecules. Nasser W, et al. **Mol Microbiol** 1998 Sep;29(6):1391-405

Regulation of autoinducer production in Salmonella typhimurium. Surette MG, et al. **Mol Microbiol** 1999 Jan; 31(2):585-95

Autoinducer binding by the quorum-sensing regulator TraR increases affinity for target promoters in vitro and decreases TraR turnover rates in whole cells. Zhu J, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4832-7

A new family of amino-acid-efflux proteins. Aleshin VV, et al. **Trends Biochem Sci** 1999 Apr;24(4):133-5

Command, control and communication in bacterial pathogenesis. Winans SC. **Trends Microbiol** 1998 Oct; 6(10):382-3

CLASSIFICATION

A new family of amino-acid-efflux proteins. Aleshin VV, et al. **Trends Biochem Sci** 1999 Apr;24(4):133-5

HOMOSERINE DEAMINASE see **CYSTATHIONINE GAMMA-LYASE**

HOMOSERINE DEHYDRATASE see **CYSTATHIONINE GAMMA-LYASE**

HOMOSERINE DEHYDROGENASE

CHEMISTRY

Crystallization and preliminary X-ray diffraction studies of homoserine dehydrogenase from Saccharomyces cerevisiae. DeLaBarre B, et al. **Acta Crystallogr D Biol Crystallogr** 1998 May 1;54 (Pt 3):413-5

Sequence analysis of functional regions of homoserine dehydrogenase genes from L-lysine and L-threonine-producing mutants of Brevibacterium lactofermentum. Sugimoto M, et al. **Biosci Biotechnol Biochem** 1997 Oct;61(10):1760-2

HOMOSEXUALITY

Incidence of HIV infection in homosexual men attending a sexually transmitted disease clinic in London measured by a novel unlinked anonymous method [letter] Miller E, et al. **AIDS** 1999 Jan 14;13(1):143-4

Prevalence of unprotected sex among men with AIDS in Los Angeles County, California 1995-1997. Simon PA, et al. **AIDS** 1999 May 28;13(8):987-90

Out on campus: sexual orientation and academic climate in a university context. Waldo CR. **Am J Community Psychol** 1998 Oct;26(5):745-74

Re: "Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992-1995" [letter; comment] Brody S, et al. **Am J Epidemiol** 1999 Aug 15;150(4):429-30. Comment on: Am J Epidemiol 1999 Jan 1;149(1):75-84.

Helping our hidden youth. Ryan C, et al. **Am J Nurs** 1998 Dec;98(12):37-41

Clinicians set a dangerous precedent when they begin using a word like "queer" [letter; comment] Craig JN. **Am J Orthopsychiatry** 1999 Apr;69(2):267-9. Comment on: Am J Orthopsychiatry 1998 Jul;68(3):447-54.

Recreating mother: the consolidation of 'heterosexual' gender identification in the young son of homosexual men [letter; comment] Eisold BK. **Am J Orthopsychiatry** 1998 Oct; 68(4):653-6. Comment on: Am J Orthopsychiatry 1998 Jul;68(3):433-42; discussion 443-6.

Utilization of psychotherapy by lesbians, gay men, and bisexuals: findings from a nationwide survey. Jones MA, et al. **Am J Orthopsychiatry** 1999 Apr;69(2):209-19

Learning medicine through the closet door. Curtis JR. **Ann Intern Med** 1999 Sep 21;131(6):470-1

Birth order and sibling sex ratio in homosexual versus heterosexual males and females. Blanchard R. **Annu Rev Sex Res** 1997;8:27-67 (110 ref.)

Bible is disapproving of homosexual activity but not homosexual orientation [letter] Wayte C. **BMJ** 1999 Jul 10;319(7202):123-4

Entitlement to cloning. Murphy TF. **Camb Q Healthc Ethics** 1999 Summer;8(3):364-8

Outbreak of hepatitis A in Rotterdam associated with visits to 'darkrooms' in gay bars. Reintjes R, et al. **Commun Dis Public Health** 1999 Jan;2(1):43-6

Lack of evidence for increased risk of hepatitis A infection in homosexual men. Corona R, et al. **Epidemiol Infect** 1999 Aug;123(1):89-93

Spontaneous otoacoustic emissions in heterosexuals, homosexuals, and bisexuals. McFadden D, et al. **J Acoust Soc Am** 1999 Apr;105(4):2403-13

Adolescent health care experience of gay, lesbian, and bisexual young adults. Allen LB, et al. **J Adolesc Health** 1998 Oct;23(4):212-20

Pediatricians' approach to the health care of lesbian, gay, and bisexual youth. East JA, et al. **J Adolesc Health** 1998 Oct;23(4):191-3

Controversy over relevancy of LGVMA continues [letter; comment] Dubielzig RR, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):616. Comment on: J Am Vet Med Assoc 1999 Jan 1;214(1):25-6.

Controversy over relevancy of LGVMA continues [letter; comment] Koltveit AJ. **J Am Vet Med Assoc** 1999 Mar 1;214(5):614. Comment on: J Am Vet Med Assoc 1999 Jan 1;214(1):25-6.

Controversy over relevancy of LGVMA continues [letter; comment] Nagell RL. **J Am Vet Med Assoc** 1999 Mar 1; 214(5):614-5. Comment on: J Am Vet Med Assoc 1999 Jan 1;214(1):25-6.

Relevancy of LGVMA questioned [letter] [see comments] Parker JS. **J Am Vet Med Assoc** 1999 Jan 1;214(1):25-6. Comment in: J Am Vet Med Assoc 1999 Mar 1;214(5):614. Comment in: J Am Vet Med Assoc 1999 Mar 1;214(5):614-5. Comment in: J Am Vet Med Assoc 1999 Mar 1;214(5):615. Comment in: J Am Vet Med Assoc 1999 Mar 1;214(5):615-6. Comment in: J Am Vet Med Assoc 1999 Mar 1;214(5):616.

Controversy over relevancy of LGVMA continues [letter; comment] Tansey G. **J Am Vet Med Assoc** 1999 Mar 1; 214(5):615. Comment on: J Am Vet Med Assoc 1999 Jan 1;214(1):25-6.

Controversy over relevancy of LGVMA continues [letter; comment] Walker HL. **J Am Vet Med Assoc** 1999 Mar 1;214(5):615-6. Comment on: J Am Vet Med Assoc 1999 Jan 1;214(1):25-6.

An experiential attitude change: social work students and homosexuality. Ben-Ari AT. **J Homosex** 1998;36(2):59-71

Multicultural queer: Australian narratives. Foreword. Dong TB. **J Homosex** 1999;36(3-4):xxiii-xxvi

Attitudes of military personnel toward homosexuals. Estrada AX, et al. **J Homosex** 1999;37(4):83-97

Love versus abuse: crossgenerational sexual relations of minors: a gay rights issue? Graupner H. **J Homosex** 1999; 37(4):23-56

Twenty years of the Journal of Homosexuality: a bibliometric examination of the first 24 volumes, 1974-1993. Joyce S, et al. **J Homosex** 1999;37(1):3-24

Medical student homophobia. Klamen DL, et al. **J Homosex** 1999;37(1):53-63

The psychometric properties of the Homonegativity Scale. Morrison TG, et al. **J Homosex** 1999;37(4):111-26

Gay, lesbian, and bisexual youth and young adults: social support in their own words. Nesmith AA, et al. **J Homosex** 1999;37(1):95-108

Unfixed in a fixated world: identity, sexuality, race and culture. Offord B, et al. **J Homosex** 1999;36(3-4):207-20

Accepting the gay person: rental accommodation in the community. Page S. **J Homosex** 1998;36(2):31-9

Diary entries from the "teachers' professional development playground": multiculturalism meets multisexualities in Australian education. Pallotta-Chiarolli M. **J Homosex** 1999;36(3-4):183-205

Gay male, lesbian and bisexual health-related research funded by the National Institutes of Health between 1974 and 1992. Silvestre AJ. **J Homosex** 1999;37(1):81-94

Heteronegativism? The attitudes of gay men and lesbians toward heterosexuals. White SM, et al. **J Homosex** 1999; 37(1):65-79

Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. Smith NA, et al. **J Infect Dis** 1999 Sep;180(3):600-6

HIV risk differences between African-American and white men who have sex with men. Heckman TG, et al. **J Natl Med Assoc** 1999 Feb;91(2):92-100

Domestic partnership benefits at medical universities. O'Hanlan KA. **JAMA** 1999 Oct 6;282(13):1289, 1292

Uneasy partners: the lesbian and gay health care community and the AMA. Schneider JS, et al. **JAMA** 1999 Oct 6; 282(13):1287-8

The North Carolina Medical Journal finds itself in the vanguard of progressive medical journalism or, the deputy editor finds his fifteen minutes of fame. Halperin EC. **N C Med J** 1999 May-Jun;60(3):138-9

Factors associated with hepatitis B vaccination among men having sexual relations with men in Montreal, Quebec, Canada. Omega Study Group. Dufour A, et al. **Sex Transm Dis** 1999 Jul;26(6):317-24

Exploring violence and abuse in gay male relationships. Cruz JM, et al. **Violence Vict** 1998 Summer;13(2):159-73

[Factors associated with survival in Kaposi's sarcoma in patients infected with the human immunodeficiency virus. Clinical Epidemiological Group for AIDS in Aquitaine] Cazorla C, et al. **Rev Epidemiol Sante Publique** 1999 Apr; 47(2):109-17 (Eng. Abstr.) **(Fre)**

[The homosexual, born or made?] Gonzalo LM. **Rev Med Univ Navarra** 1997 Oct-Dec;41(4):258-60 **(Spa)**

GENETICS

Homosexuality and the human genome project: private and public choices. Gabard DL. **J Homosex** 1999;37(1):25-51 (85 ref.)

HISTORY

Psychoanalysis and the model of homosexuality as psychopathology: a historical overview. Friedman RC, et al. **Am J Psychoanal** 1998 Sep;58(3):249-70

Glandular politics. Experimental biology, clinical medicine, and homosexual emancipation in fin-de-siècle central Europe. Sengoopta C. **Isis** 1998 Sep;89(3):445-73

Return of the past: the policy of the SED and the laws against homosexuality in Eastern Germany between 1946 and 1968. Sozialistische Einheitspartei Deutschlands. Grau G. **J Homosex** 1999;37(4):1-21

Political opportunism and the harassment of homosexuals in Florida, 1952-1965. Sullivan G. **J Homosex** 1999; 37(4):57-81

PSYCHOLOGY

Adolescent homosexuality. Stronski Huwiler SM, et al. **Adv Pediatr** 1998;45:107-44 (156 ref.)

Sexual orientation and family development: introduction. Litzenberger BW, et al. **Am J Orthopsychiatry** 1998 Jul; 68(3):344-51

Understanding the unprotected sexual behaviors of gay, lesbian, and bisexual youths: an empirical test of the cognitive-environmental model. Rosario M, et al. **Health Psychol** 1999 May;18(3):272-80

Homosexuality. Berman E. **Int J Psychoanal** 1998 Aug;79 (Pt 4):806-10

Gender differences in health and risk behaviors among bisexual and homosexual adolescents. Saewyc EM, et al. **J Adolesc Health** 1998 Sep;23(3):181-8

Homophobia: an evolutionary analysis of the concept as applied to nursing. Richmond JP, et al. **J Adv Nurs** 1998 Aug;28(2):362-9 (95 ref.)

'Coming out' as a life transition: homosexual identity formation and its implications for health care practice. Taylor B. **J Adv Nurs** 1999 Aug;30(2):520-5 (52 ref.)

Thinking about students who do not identify as gay, lesbian, or bisexual, but.... Green BC. **J Am Coll Health** 1998 Sep; 47(2):89–91

A new analytic dyad: homosexual analyst, heterosexual patient. Phillips SH. **J Am Psychoanal Assoc** 1998; 46(4):1195–219

Helping families with homosexual children: a model for counseling. Coenen ME. **J Homosex** 1998;36(2):73–85

The homoerotic behavior that never evolved. Muscarella F. **J Homosex** 1999;37(3):1–18 (46 ref.)

Gender-related factors influencing perceptions of homosexuality. Wong FY, et al. **J Homosex** 1999; 37(3):19–31

From lynching to gay bashing: the elusive connection between economic conditions and hate crime. Green DP, et al. **J Pers Soc Psychol** 1998 Jul;75(1):82–92

Religiosity is associated with affective and immune status in symptomatic HIV-infected gay men. Woods TE, et al. **J Psychosom Res** 1999 Feb;46(2):165–76

Sexual orientation and youth suicide. Remafedi G. **JAMA** 1999 Oct 6;282(13):1291–2

Homosexual parents: why appeals cases approximate the "gold standard" for science—a reply to Duncan. Cameron P, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):793–802

Homosexual parents and questions of character: a response to Cameron and Cameron. Duncan DF. **Psychol Rep** 1999 Jun;84(3 Pt 1):791–2

STATISTICS & NUMERICAL DATA

Sexual orientation, sexual behaviors, and pregnancy among American Indian adolescents. Saewyc EM, et al. **J Adolesc Health** 1998 Oct;23(4):238–47

HOMOSEXUALITY, EGO-DYSTONIC see **HOMOSEXUALITY**

HOMOSEXUALITY, FEMALE

College students' perceptual stigmatization of the children of lesbian mothers. King BR, et al. **Am J Orthopsychiatry** 1999 Apr;69(2):220–7

Lesbian divorce. Morton SB. **Am J Orthopsychiatry** 1998 Jul;68(3):410–9; discussion 420–3

ABC of sexual health: homosexual men and women. Bell R. **BMJ** 1999 Feb 13;318(7181):452–5 (0 ref.)

Bacterial vaginosis in lesbians: evidence for lack of sexual transmission. McCaffrey M, et al. **Int J STD AIDS** 1999 May;10(5):305–8

Extent of relational stigmatization of lesbians and their children by heterosexual college students. King BR, et al. **J Homosex** 1999;37(2):65–81 (62 ref.)

Genital human papillomavirus infection in women who have sex with women. Marrazzo JM, et al. **J Infect Dis** 1998 Dec;178(6):1604–9

Screening calcaneal ultrasound and risk factors for osteoporosis among lesbians and heterosexual women. Patton CL, et al. **J Womens Health** 1998 Sep;7(7):909–15

Health problems of lesbian women. Saunders JM. **Nurs Clin North Am** 1999 Jun;34(2):381–91 (38 ref.)

Optimal gynecologic and obstetric care for lesbians. Carroll NM. **Obstet Gynecol** 1999 Apr;93(4):611–3

ETHNOLOGY

Interface: reflections of an ethnic toygirl. Yue A. **J Homosex** 1999;36(3–4):113–34

HISTORY

The "we of me": Carson McCullers as lesbian novelist. Whitt J. **J Homosex** 1999;37(1):127–39

PSYCHOLOGY

The birds, the bees ... and the sperm banks: how lesbian mothers talk with their children about sex and reproduction. Mitchell V. **Am J Orthopsychiatry** 1998 Jul; 68(3):400–9

Lesbian parenthood: a review of the literature. Parks CA. **Am J Orthopsychiatry** 1998 Jul;68(3):376–89 (69 ref.)

Families of the lesbian baby boom: children's contact with grandparents and other adults. Patterson CJ, et al. **Am J Orthopsychiatry** 1998 Jul;68(3):390–9

The social construction of love and sexuality in a women's prison. Maeve MK. **ANS Adv Nurs Sci** 1999 Mar; 21(3):46–65

Relationship history and relationship attitudes in gay males and lesbians: attachment style and gender differences. Ridge SR, et al. **Aust N Z J Psychiatry** 1998 Dec; 32(6):848–59

Violence in lesbian and gay relationships: theory, prevalence, and correlational factors. Burke LK, et al. **Clin Psychol Rev** 1999 Aug;19(5):487–512 (72 ref.)

Development of sexual orientation among adolescent and young adult women. Diamond LM. **Dev Psychol** 1998 Sep; 34(5):1085–95

Psychoanalytic and biological perspectives on lesbian patients: why developmental themes are more important in psychotherapy. Vaughan SC. **Harv Rev Psychiatry** 1998 Sep–Oct;6(3):160–4

Lesbians, bisexual women, and body image: an investigation of gender roles and social group affiliation. Ludwig MR, et al. **Int J Eat Disord** 1999 Jan;25(1):89–97

Stigmatization, self-esteem, and coping among the adolescent children of lesbian mothers. Gershon TD, et al. **J Adolesc Health** 1999 Jun;24(6):437–45

Gay, lesbian, and bisexual youth risks for emotional, physical, and social problems: results from a community-based survey. Lock J, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar; 38(3):297–304

Female homosexuality: classical psychoanalytic theory reconsidered [see comments] Downey JI, et al. **J Am Psychoanal Assoc** 1998;46(2):471–506 (100 ref.). Comment in: J Am Psychoanal Assoc 1998 ;46(2):361–3.

Looking out, looking in: anti-semitism and racism in lesbian communities. Burstin HE. **J Homosex** 1999;36(3–4):143–57

Sister outsider, or "just another thing I am": intersections of cultural and sexual identities in Australia. Duruz A. **J Homosex** 1999;36(3–4):169–82

Masculinity scores as an artifact of feminist attitude: evidence from a study of lesbians and college women. Finlay B, et al. **J Homosex** 1999;37(4):139–47

Queerer than queer: reflections of a Kike dyke. Goldflam A. **J Homosex** 1999;36(3–4):135–42

A love letter from NADIA (non-anglo dykes in Australia). Kizinska R. **J Homosex** 1999;36(3–4):159–68

Recent improvement in mental health services to lesbian and gay clients. Liddle BJ. **J Homosex** 1999;37(4):127–37

This powerful opening of the heart: how ritual affirms lesbian identity. Manodori C. **J Homosex** 1998;36(2):41–58

Gay and lesbian tourists at a Southern U.S.A. beach event. Philipp SF. **J Homosex** 1999;37(3):69–86

Identity in political context: lesbian/gay representation in the public sphere. Smith RR, et al. **J Homosex** 1999;37(2):25–45 (86 ref.)

Introduction: ethnic minorities and the lesbian and gay community. Sullivan G, et al. **J Homosex** 1999;36(3–4):1–28

Coming out to parents: perceptions of family relations, perceived resources, and identity expression as predictors of identity disclosure for gay and lesbian adolescents. Waldner LK, et al. **J Homosex** 1999;37(2):83–100

Interface: reflections of an ethnic toygirl. Yue A. **J Homosex** 1999;36(3–4):113–34

Lesbian erotic role identification: behavioral, morphological, and hormonal correlates. Singh D, et al. **J Pers Soc Psychol** 1999 Jun;76(6):1035–49

Lesbian sexuality/female sexuality: searching for sexual subjectivity. Burch B. **Psychoanal Rev** 1998 Jun; 85(3):349–72 (42 ref.)

Gender portrayals in telephone books for gay community versus Pacific-Bell Yellow Pages. Waugh IM, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):751

The use of alcohol by lesbians: a review and research agenda. Abbott LJ. **Subst Use Misuse** 1998 Nov;33(13):2647–63

Health related behaviors and cancer screening of lesbians: results from the Boston Lesbian Health Project. Roberts SJ, et al. **Women Health** 1999;28(4):1–12 (32 ref.)

STATISTICS & NUMERICAL DATA

The nature and predictors of substance use among lesbians. Heffernan K. **Addict Behav** 1998 Jul–Aug;23(4):517–28

Survey of drug and alcohol use by lesbian women in New Zealand. Welch S, et al. **Addict Behav** 1998 Jul–Aug; 23(4):543–8

The relation of birth order to sexual orientation in men and women. Blanchard R, et al. **J Biosoc Sci** 1998 Oct; 30(4):511–9

Harassment of lesbians as medical students and physicians. Brogan DJ, et al. **JAMA** 1999 Oct 6;282(13):1290, 1292

HOMOSEXUALITY, MALE

Sexual risk behaviour among gay men in a relationship. Elford J, et al. **AIDS** 1999 Jul 30;13(11):1407–11

HIV serostatus of sexual partners of HIV-positive and HIV-negative homosexual men in Sydney [letter] Grulich AE, et al. **AIDS** 1998 Dec 24;12(18):2508

HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32 [letter] Heiken H, et al. **AIDS** 1999 Mar 11;13(4):529–30

Self-reported sexual behaviour and HIV risk taking among men who have sex with men in Fortaleza, Brazil. Kerr-Pontes LR, et al. **AIDS** 1999 Apr 16;13(6):709–17

Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). Tabet SR, et al. **AIDS** 1998 Oct 22;12(15):2041–8

Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. Xiao L, et al. **AIDS** 1998 Sep 10;12(13):F137–43

Factors associated with gay men's sexual behaviours and risk on holiday. Clift SM, et al. **AIDS Care** 1999 Jun; 11(3):281–95

Parallel accounts? Discrepancies between self-report (diary) and recall (questionnaire) measures of the same sexual behaviour. Coxon AP. **AIDS Care** 1999 Apr;11(2):221–34

HIV serostatus disclosure among gay and bisexual men in four American cities: general patterns and relation to sexual practices. Wolitski RJ, et al. **AIDS Care** 1998 Oct; 10(5):599–610

Psychosocial correlates of unprotected anal sex in a cohort of gay men attending an HIV-negative support group. Dilley JW, et al. **AIDS Educ Prev** 1998 Aug;10(4):317–26

Asymptomatic amebic colitis in a homosexual man. Yoshikawa I, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2306–8

Recreating mother: the consolidation of "heterosexual" gender identification in the young son of homosexual men [see comments] Eisold BK. **Am J Orthopsychiatry** 1998 Jul;68(3):433–42; discussion 443–6. Comment in: Am J Orthopsychiatry 1998 Oct;68(4):653–6.

Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Kalichman SC. **Am J Prev Med** 1998 Aug; 15(2):120–7

Birth order and sibling sex ratio in homosexual and heterosexual non-white men. Bogaert AF. **Arch Sex Behav** 1998 Oct;27(5):467–73

The relation between sexual orientation and penile size. Bogaert AF, et al. **Arch Sex Behav** 1999 Jun;28(3):213–21

ABC of sexual health: homosexual men and women. Bell R. **BMJ** 1999 Feb 13;318(7181):452–5 (0 ref.)

Sexual health of homosexual men and women. Universal vaccination against hepatitis A cannot be firmly recommended for homosexual men [letter] Brook G. **BMJ** 1999 Aug 28;319(7209):575

HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Bell JE, et al. **Brain** 1998 Nov;121 (Pt 11):2043–52

The perception of discrimination in the HIV policy among Czech gay men. Procházka I, et al. **Cent Eur J Public Health** 1998 Aug;6(3):192–4

Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. Woody GE, et al. **Drug Alcohol Depend** 1999 Feb 1;53(3):197–205

Determinants of antibodies to Cryptosporidium infection among gay and bisexual men with HIV infection. Caputo C, et al. **Epidemiol Infect** 1999 Apr;122(2):291–7

Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. Lyles CM, et al. **Eur J Epidemiol** 1999 Feb;15(2):99–108

Reaching homosexual men for HIV surveillance through a gay magazine. Wiessing LG, et al. **Eur J Epidemiol** 1999 May;15(5):429–37

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Colin JF, et al. **Hepatology** 1999 Apr;29(4):1306–10

Injector-inmates and anal sex with another man in prison [letter] Gore SM, et al. **Int J STD AIDS** 1998 Dec;9(12):781

'Face up to the truth': helping gay men in Vietnam protect themselves from AIDS. Wilson D, et al. **Int J STD AIDS** 1999 Jan;10(1):63–6

Incident HIV infection in a high-risk, homosexual, male cohort in Rio de Janeiro, Brazil. Harrison LH, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):408–12

An HIV community perspective on AIDS malignancy basic and clinical research. Marco M. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S84–6

Effect of receptive oral sex and smoking on the incidence of hairy leukoplakia in HIV-positive gay men. Shiboski CH, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1; 21(3):236–42

Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. Hays RB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):164–71

Effect of race on insurance coverage and health service use for HIV-infected gay men. Kass N, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):85–92

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. Maas JJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):254–9

Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. Scheer S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):172–8

Correlates of condom failure in a sexually active cohort of men who have sex with men. Stone E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):495–501

Geographic differences in noninjection and injection substance use among HIV-seropositive men who have sex with men: western United States versus other regions. Supplement to HIV/AIDS Surveillance Study Group. Sullivan PS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Nov 1;19(3):266–73

Group sex in gay men: its meaning and HIV prevention implications [letter; comment] Simmons P. **J Assoc Nurses AIDS Care** 1998 Sep–Oct;9(5):90–1. Comment on: J Assoc Nurses AIDS Care 1998 May–Jun;9(3):59–71.

On the prevalence of homosexuality and bisexuality, in a random community survey of 750 men aged 18 to 27. Bagley C, et al. **J Homosex** 1998;36(2):1–18

Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. Keet IP, et al. **J Infect Dis** 1999 Aug;180(2):299–309

Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with

men: site and frequency of shedding. Krone MR, et al. **J Infect Dis** 1998 Oct;178(4):978–82
Infrequent detection of TT virus infection in intravenous drug users, prostitutes, and homosexual men. MacDonald DM, et al. **J Infect Dis** 1999 Mar;179(3):686–9
Attitude change in response to information that male homosexuality has a biological basis. Oldham JD, et al. **J Sex Marital Ther** 1999 Apr–Jun;25(2):121–4
Spinal cord pathology and viral burden in homosexuals and drug users with AIDS. Shepherd EJ, et al. **Neuropathol Appl Neurobiol** 1999 Feb;25(1):2–10
Health problems of gay and bisexual men. Ungvarski PJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):313–31 (86 ref.)
Photo was "right on" [letter; comment] Krawetz DW. **Public Health Rep** 1999 Jan–Feb;114(1):6. Comment on: Public Health Rep 1998 Jul–Aug;113(4):296–7.
Clinical features of Chlamydia trachomatis rectal infection by serovar among homosexually active men. Boisvert JF, et al. **Sex Transm Dis** 1999 Aug;26(7):392–8
Of vice and men: reflections on drug abuse and male prostitution [letter; comment] [see comments] Potterat JJ, et al. **Sex Transm Dis** 1999 Feb;26(2):93–4. Comment on: Sex Transm Dis 1998 Aug;25(7):353–60. Comment in: Sex Transm Dis 1999 Feb;26(2):95.
The hustler's choice [letter; comment] Rietmeijer CA. **Sex Transm Dis** 1999 Feb;26(2):95. Comment on: Sex Transm Dis 1999 Feb;26(2):93–4.
A study of anal intraepithelial neoplasia in HIV positive homosexual men. Lacey HB, et al. **Sex Transm Infect** 1999 Jun;75(3):172–7
[The spread of AIDS among homosexuals in the Commonwealth of Independent States and Baltic countries] Mekkelsen H. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb;(1):11–3 (Eng. Abstr.) **(Rus)**

ETHNOLOGY

China doll - the experience of being a gay Chinese Australian. Ayres T. **J Homosex** 1999;36(3–4):87–97
The cinematic representation of Asian homosexuality in The Wedding Banquet. Chua LY. **J Homosex** 1999; 36(3–4):99–112
Using chopsticks to eat steak. Chuang K. **J Homosex** 1999; 36(3–4):29–41
"Asian" men on the scene: challenges to "gay communities". Ridge D, et al. **J Homosex** 1999;36(3–4):43–68
A social psychological perspective on HIV/AIDS and gay or homosexually active Asian men. Sanitioso R. **J Homosex** 1999;36(3–4):69–85

GENETICS

A family history study of male sexual orientation using three independent samples. Bailey JM, et al. **Behav Genet** 1999 Mar;29(2):79–86
Male homosexuality: absence of linkage to microsatellite markers at Xq28 [see comments] Rice G, et al. **Science** 1999 Apr 23;284(5414):665–7. Comment in: Science 1999 Apr 23;284(5414):571.
Discovery of 'gay gene' questioned [news; comment] Wickelgren I. **Science** 1999 Apr 23;284(5414):571. Comment on: Science 1999 Apr 23;284(5414):665–7.

PSYCHOLOGY

Subjective HIV attribution theories, coping and psychological functioning among homosexual men with HIV. Clement U, et al. **AIDS Care** 1998 Jun;10(3):355–63
Nature and consequences of stressful life events in homosexual HIV-positive men: a review. Nott KH, et al. **AIDS Care** 1999 Apr;11(2):235–43
Experiences of 100 men who have sex with men using the Reality condom for anal sex. Gibson S, et al. **AIDS Educ Prev** 1999 Feb;11(1):65–71
Hope and resilience in suicide ideation and behavior of gay and bisexual men following notification of HIV infection. Siegel K, et al. **AIDS Educ Prev** 1999 Feb;11(1):53–64
Clinical interpretation of "'My Secret Life': the emergence of one gay man's authentic identity" [comment] Crepeau EB. **Am J Occup Ther** 1998 Jul–Aug;52(7):570–2 (20 ref.) . Comment on: Am J Occup Ther 1998 Jul–Aug;52(7):563–9.
"My secret life": the emergence of one gay man's authentic identity [see comments] Walsh AL, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):563–9 (41 ref.). Comment in: Am J Occup Ther 1998 Jul–Aug;52(7):570–2.
Cross-gendered identifications and homosexual boyhood: toward a more complex theory of gender [see comments] Corbett K. **Am J Orthopsychiatry** 1998 Jul;68(3):352–60. Comment in: Am J Orthopsychiatry 1998 Oct;68(4):653.
Heterosexually married homosexual men: clinical and developmental issues. Isay RA. **Am J Orthopsychiatry** 1998 Jul;68(3):424–32
Origins of homophobia in males. Psychosexual vulnerabilities and defense development. Lock J, et al. **Am J Psychother** 1998 Fall;52(4):425–36
A randomized controlled clinical trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and -seronegative homosexual men [published erratum appears in Arch Gen Psychiatry 1999 Aug;56(8):693] Goodkin K, et al. **Arch Gen Psychiatry** 1999 Jan;56(1):52–9
Birth order in homosexual versus heterosexual sex offenders against children, pubescents, and adults. Blanchard R, et al. **Arch Sex Behav** 1998 Dec;27(6):595–603
Relationship history and relationship attitudes in gay males and lesbians: attachment style and gender differences. Ridge SR, et al. **Aust N Z J Psychiatry** 1998 Dec; 32(6):848–59
Violence in lesbian and gay relationships: theory, prevalence, and correlational factors. Burke LK, et al. **Clin Psychol Rev** 1999 Aug;19(5):487–512 (72 ref.)
Male homosexual behaviour accompanied by ejaculation in a free-ranging troop of Japanese macaques (Macaca fuscata). Takenoshita Y. **Folia Primatol (Basel)** 1998; 69(6):364–7
Longitudinal study of relapse from AIDS-preventive behavior among homosexual men. Graham RP, et al. **Health Educ Behav** 1998 Oct;25(5):625–39
Reinforcement value of unsafe sex as a predictor of condom use and continued HIV/AIDS risk behavior among gay and bisexual men. Kelly JA, et al. **Health Psychol** 1998 Jul;17(4):328–35
HIV sexual risk behavior following bereavement in gay men. Mayne TJ, et al. **Health Psychol** 1998 Sep;17(5):403–11
Avoidance as a predictor of the biological course of HIV infection over a 7-year period in gay men. Mulder CL, et al. **Health Psychol** 1999 Mar;18(2):107–13
Negative HIV-specific expectancies and AIDS-related bereavement as predictors of symptom onset in asymptomatic HIV-positive gay men. Reed GM, et al. **Health Psychol** 1999 Jul;18(4):354–63
Gay, lesbian, and bisexual youth risks for emotional, physical, and social problems: results from a community-based survey. Lock J, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar; 38(3):297–304
Epigenesis and sexual orientation: a report of five bisexual males. Bemporad JR. **J Am Acad Psychoanal** 1999 Summer; 27(2):221–37
Men's love for men: contrasting classical American film with The Crying Game. Hirsch I. **J Am Acad Psychoanal** 1999 Spring;27(1):151–66
The expressed needs of a group of HIV-infected gay men subsequent to hospital care. Cederfjäll C, et al. **J Assoc Nurses AIDS Care** 1999 Mar–Apr;10(2):66–74
The relation of closed birth intervals to the sex of the preceding child and the sexual orientation of the succeeding child. Blanchard R, et al. **J Biosoc Sci** 1997 Jan;29(1):111–8
Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. Bower JE, et al. **J Consult Clin Psychol** 1998 Dec;66(6):979–86
Shame and internalized homophobia in gay men. Allen DJ, et al. **J Homosex** 1999;37(3):33–43
China doll - the experience of being a gay Chinese Australian. Ayres T. **J Homosex** 1999;36(3–4):87–97
Exploring the links between interpersonal trust and the reasons underlying gay and bisexual males' disclosure of their sexual orientation to their mothers. Boon SD, et al. **J Homosex** 1999;37(3):45–68
The cinematic representation of Asian homosexuality in The Wedding Banquet. Chua LY. **J Homosex** 1999; 36(3–4):99–112
Using chopsticks to eat steak. Chuang K. **J Homosex** 1999; 36(3–4):29–41
Status passages: the experience of HIV-positive gay men. Lewis J. **J Homosex** 1999;37(3):87–115
Recent improvement in mental health services to lesbian and gay clients. Liddle BJ. **J Homosex** 1999;37(4):127–37
Gay and lesbian tourists at a Southern U.S.A. beach event. Philipp SF. **J Homosex** 1999;37(3):69–86
"Asian" men on the scene: challenges to "gay communities". Ridge D, et al. **J Homosex** 1999;36(3–4):43–68
A social psychological perspective on HIV/AIDS and gay or homosexually active Asian men. Sanitioso R. **J Homosex** 1999;36(3–4):69–85
Identity in political context: lesbian/gay representation in the public sphere. Smith RR, et al. **J Homosex** 1999;37(2):25–45 (86 ref.)
Introduction: ethnic minorities and the lesbian and gay community. Sullivan G, et al. **J Homosex** 1999;36(3–4):1–28
Coming out to parents: perceptions of family relations, perceived resources, and identity expression as predictors of identity disclosure for gay and lesbian adolescents. Waldner LK, et al. **J Homosex** 1999;37(2):83–100
The politics of counter-rejection: gay christians and the church. Yip AK. **J Homosex** 1999;37(2):47–63 (52 ref.)
Anodyspareunia, the unacknowledged sexual dysfunction: a validation study of painful receptive anal intercourse and its psychosexual concomitants in homosexual men. Rosser BR, et al. **J Sex Marital Ther** 1998 Oct–Dec;24(4):281–92
Covert discrimination against gay men by U.S. college students. Aberson CL, et al. **J Soc Psychol** 1999 Jun; 139(3):323–34
Cognitive-behavioral group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. Lee MR, et al. **Psychiatr Serv** 1999 Jul; 50(7):948–52
Gender in homosexual boys: some developmental and clinical considerations. Isay RA. **Psychiatry** 1999 Summer; 62(2):187–94
Gender portrayals in telephone books for gay community versus Pacific-Bell Yellow Pages. Waugh IM, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):751
Pain and depression in HIV illness. Evans S, et al. **Psychosomatics** 1998 Nov–Dec;39(6):528–35
Combined effects of HIV-infection status and psychosocial vulnerability on mental health in homosexual men. Dickey WC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Jan; 34(1):4–11
[Role of intimacy in the relationships of young men of homosexual orientation] Thériault J. **Contracept Fertil Sex** 1998 Oct;26(10):736–43 **(Fre)**

STATISTICS & NUMERICAL DATA

Cultures of sexual adventurism as markers of HIV seroconversion: a case control study in a cohort of Sydney gay men. Kippax S, et al. **AIDS Care** 1998 Dec;10(6):677–88
Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Vittinghoff E, et al. **Am J Epidemiol** 1999 Aug 1;150(3):306–11
Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996–98. Van de Ven P, et al. **Aust N Z J Public Health** 1998 Dec;22(7):814–8
Active surveillance of sexual behaviour among homosexual men in London. Nardone A, et al. **Commun Dis Public Health** 1998 Sep;1(3):197–201
AIDS and HIV infection in the United Kingdom: monthly report. HIV infection acquired through sex between men. **Commun Dis Rep CDR Wkly** 1999 Mar 26;9(13):121–2
Sexually transmitted diseases quarterly report: sexually transmitted diseases in England and Wales acquired through sexual intercourse between men [published erratum appears in Commun Dis Rep CDR Wkly 1999 Jun 4;9(23):204] **Commun Dis Rep CDR Wkly** 1999 Apr 30; 9(18):156–7
Alcohol and drug use patterns have declined between generations of younger gay–bisexual men in San Francisco. Crosby GM, et al. **Drug Alcohol Depend** 1998 Nov 1; 52(3):177–82
Awareness and utilization of the hepatitis B vaccine among young men in the Ann Arbor area who have sex with men. Neighbors K, et al. **J Am Coll Health** 1999 Jan;47(4):173–8
The relation of birth order to sexual orientation in men and women. Blanchard R, et al. **J Biosoc Sci** 1998 Oct; 30(4):511–9
Sampling gay men: Random Digit Dialing versus sources in the Gay Community. Meyer IH, et al. **J Homosex** 1999; 37(4):99–110
Developing surveillance for HIV transmission and risk behaviours among high-risk groups in a central London health district. Nardone A, et al. **J Public Health Med** 1999 Jun;21(2):208–14
Substance use disorders and the risk of HIV infection in gay men. Ryan CM, et al. **J Stud Alcohol** 1999 Jan;60(1):70–7
From the Centers for Disease Control and Prevention. Increases in unsafe sex and rectal gonorrhea among men who have sex with men--San Francisco, California, 1994–1997. **JAMA** 1999 Feb 24;281(8):696–7
Increases in unsafe sex and rectal gonorrhea among men who have sex with men--San Francisco, California, 1994–1997. **MMWR Morb Mortal Wkly Rep** 1999 Jan 29;48(3):45–8
Does homosexual activity shorten life? Cameron P, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):847–66
HIV infection among homosexual/bisexual males attending genitourinary clinics in Scotland. Goldberg D, et al. **Sex Transm Infect** 1998 Jun;74(3):185–8
Outbreak of hepatitis A in homosexual men in Riverside [letter] Newell A, et al. **Sex Transm Infect** 1998 Aug; 74(4):304–5

4-HOMOSULFANILAMIDE see **MAFENIDE**

HOMOVANILLIC ACID

BLOOD

Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. Posener JA, et al. **Biol Psychiatry** 1999 Jan 15;45(2):222–8
Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period. Sharma RP, et al. **Biol Psychiatry** 1998 Sep 15;44(6):488–92
Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Ferreira C, et al. **Lupus** 1998;7(6):392–7
Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls. Sumiyoshi T, et al. **Neuropsychopharmacology** 1999 Apr;20(4):365–9
Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine. Hatzimanolis J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1077–85
The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. van Berckel BN, et al. **Psychopharmacology (Berl)** 1998 Jun;137(3):271–81

CEREBROSPINAL FLUID

Low CSF concentration of a dopamine metabolite in tobacco smokers. Geracioti TD Jr, et al. **Am J Psychiatry** 1999 Jan;156(1):130–2
Changes in cerebrospinal fluid monoamine metabolites, tryptophan, and gamma-aminobutyric acid during the 1st year of life in normal infants. comparison with victims of sudden infant death syndrome. Cann-Moisan C, et al.

Biol Neonate 1999 Mar;75(3):152–9
Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. Geracioti TD Jr, et al. **Biol Psychiatry** 1998 Aug 1;44(3):228–33
Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Hibbeln JR, et al. **Biol Psychiatry** 1998 Aug 15;44(4):235–42
A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Hibbeln JR, et al. **Biol Psychiatry** 1998 Aug 15;44(4):243–9
Cerebrospinal fluid monoaminergic metabolites differ in wild anubis and hybrid (Anubis hamadryas) baboons: possible relationships to life history and behavior. Kaplan JR, et al. **Neuropsychopharmacology** 1999 Jun;20(6):517–24
Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration. Kanemaru K, et al. **Neurosci Lett** 1998 Apr 3;245(2):121–2
Pathogenetic role of monoamine metabolism in complex febrile seizures. Nishimura K, et al. **Pediatr Neurol** 1999 Aug;21(2):553–6
CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Wieselgren IM, et al. **Psychiatry Res** 1998 Nov 16; 81(2):101–10

METABOLISM

Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Court JA, et al. **Neuroscience** 1998 Nov; 87(1):63–78

URINE

Urinary homovanillic acid (HVA) and vanillymandelic acid (VMA) in workers exposed to manganese dust. Ai LB, et al. **Biol Trace Elem Res** 1998 Summer;64(1–3):89–99
Renal dopaminergic system in nephrotic syndrome and after remission. Pestana M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2559–62

HOMOZYGOTE

A case associated with Walker Warburg syndrome phenotype and homozygous pericentric inversion 9: coincidental finding or aetiological factor? Baltaci V, et al. **Acta Paediatr** 1999 May;88(5):579–83
Dietary oleic and palmitic acids and postprandial factor VII in middle-aged men heterozygous and homozygous for factor VII R353Q polymorphism. Sanders TA, et al. **Am J Clin Nutr** 1999 Feb;69(2):220–5
Homozygosity mapping of the Achromatopsia locus in the Pingelapese. Winick JD, et al. **Am J Hum Genet** 1999 Jun; 64(6):1679–85
Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus [see comments] Caridi G, et al. **Am J Kidney Dis** 1998 Dec;32(6):1059–62 (12 ref.). Comment in: Am J Kidney Dis 1998 Dec;32(6):1084–5.
Prenatal ultrasonographic prediction of homozygous type 1 alpha-thalassemia at 12 to 13 weeks of gestation. Lam YH, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):148–50
Hibernomas are characterized by homozygous deletions in the multiple endocrine neoplasia type I region. Metaphase fluorescence in situ hybridization reveals complex rearrangements not detected by conventional cytogenetics. Gisselsson D, et al. **Am J Pathol** 1999 Jul;155(1):61–6
Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Mamotte CD, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E553–7
Lack of vasopressin-independent upregulation of AQP-2 gene expression in homozygous Brattleboro rats. Saito T, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):R427–33
Optimization of genome search strategies for homozygosity mapping: influence of marker spacing on power and threshold criteria for identification of candidate regions. Génin E, et al. **Ann Hum Genet** 1998 Sep;62 (Pt 5):419–29
Increased risk for fetal loss in carriers of the factor V Leiden mutation. Meinardi JR, et al. **Ann Intern Med** 1999 May 4;130(9):736–9
Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Blumen SC, et al. **Ann Neurol** 1999 Jul;46(1):115–8
Is disomic homozygosity at the APECED locus the cause of increased autoimmunity in Down's syndrome? Shield JP, et al. **Arch Dis Child** 1999 Aug;81(2):147–50
Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Bertolini S, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb; 19(2):408–18
Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Ehrenforth S, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):276–80
Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis. Kalafatis M, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb; 19(2):336–42
The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Kitagawa K, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):146–51
Cloning and characterization of a novel Rab-family gene, Rab36, within the region at 22q11.2 that is homozygously deleted in malignant rhabdoid tumors. Mori T, et al. **Biochem Biophys Res Commun** 1999 Jan 27;254(3):594–600
Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3'-untranslated region of the prothrombin gene. Wulf GM, et al. **Blood Coagul Fibrinolysis** 1999 Mar;10(2):107–10
Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Ngan HY, et al. **Br J Cancer** 1999 Aug;80(11):1828–9
Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Castaman G, et al. **Br J Haematol** 1999 Jul;106(1):232–6
Homozygosity mapping and linkage analysis demonstrate that autosomal recessive congenital hereditary endothelial dystrophy (CHED) and autosomal dominant CHED are genetically distinct. Callaghan M, et al. **Br J Ophthalmol** 1999 Jan;83(1):115–9
Shared epitope homozygosity' is strongly associated with rheumatoid arthritis in Turkey. Istanbul Rheumatology Study Group. Saruhan-Direskeneli G. **Br J Rheumatol** 1998 Oct;37(10):1126–8
Evidence of carotid artery wall hypertrophy in homozygous homocystinuria. Megnien JL, et al. **Circulation** 1998 Nov 24;98(21):2276–81
Genetic analyses in homozygous and heterozygous variants of lactate dehydrogenase-B (H) subunit--LD-B Matsumoto I and II (LD-B W323R). Okumura N, et al. **Clin Chim Acta** 1999 Sep;287(1-2):163–71
Homozygosity for two mild glucocerebrosidase mutations of probable Iberian origin [letter] Amaral O, et al. **Clin Genet** 1999 Jul;56(1):100–2
Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Arruda VR, et al. **Clin Genet** 1998 Sep;54(3):210–4
Homozygosity for a novel DTDST mutation in a child with a 'broad bone-platyspondylic' variant of diastrophic dysplasia. Mégarbané A, et al. **Clin Genet** 1999 Jul; 56(1):71–6
How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? [letter; comment] Xie HG. **Clin Pharmacol Ther** 1998 Nov;64(5):575. Comment on: Clin Pharmacol Ther 1998 Mar;63(4):422–7.
Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis. Stefanutti C, et al. **Clin Ter** 1998 May-Jun;149(3):231–3 (20 ref.)
Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Kjaergaard S, et al. **Eur J Hum Genet** 1998 Jul-Aug;6(4):331–6
Homozygous alpha-thalassaemia and hypospadias--common aetiology or incidental association? Long-term survival of Hb Bart's hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Dame C, et al. **Eur J Pediatr** 1999 Mar;158(3):217–20
Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. Montine TJ, et al. **Exp Neurol** 1999 Jul; 158(1):234–41
Antenatal diagnosis of homozygous alpha thalassemia. A case report. Doridot V, et al. **Fetal Diagn Ther** 1999 Mar-Apr; 14(2):122–4
High-density screen of human tumor cell lines for homozygous deletions of loci on chromosome arm 8p. Levy A, et al. **Genes Chromosomes Cancer** 1999 Jan;24(1):42–7
Identification of a homozygous deletion at 8p12-21 in a human prostate cancer xenograft. Van Alewijk DC, et al. **Genes Chromosomes Cancer** 1999 Feb;24(2):119–26
Stage-specific apoptosis, developmental delay, and embryonic lethality in mice homozygous for a targeted disruption in the murine Bloom's syndrome gene. Chester N, et al. **Genes Dev** 1998 Nov 1;12(21):3382–93
Computing probabilities of homozygosity by descent. Schäffer AA. **Genet Epidemiol** 1999;16(2):135–49
Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Watson JE, et al. **Genome Res** 1999 Mar; 9(3):226–33
Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous beta-thalassemia. Galanello R, et al. **Haematologica** 1999 Feb;84(2):103–5
Development of a subdural vein thrombosis following aggressive factor VII replacement for postnatal intracranial haemorrhage in a homozygous factor VII-deficient infant. Worth LL, et al. **Haemophilia** 1998 Sep;4(5):757–61
Effects of a hair cell transcription factor, Brn-3.1, gene deletion on homozygous and heterozygous mouse cochleas in adulthood and aging. Keithley EM, et al. **Hear Res** 1999 Aug;134(1-2):71–6
Homozygous deletion of arginine-173 in the CYP11B2 gene in a girl with congenital hypoaldosteronism. Corticosterone methyloxidase deficiency type II. Peter M, et al. **Horm Res** 1998;50(4):222–5
A novel point mutation in an acceptor splice site of intron 32 (IVS32 A-12-->G) but no exon 3 mutations in the glycogen debranching enzyme gene in a homozygous patient with glycogen storage disease type IIIb [letter; comment] Chen YT. **Hum Genet** 1999 Jan;104(1):111–2. Comment on: Hum Genet 1998 Jan;102(1):1–5.
Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Ida H, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):120–6
Identification of a D579G homozygote cystic fibrosis patient with pancreatic sufficiency and minor lung involvement. Mutations in brief no. 221. Online. Picci L, et al. **Hum Mutat** 1999;13(2):173
Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. Bi L, et al. **J Biol Chem** 1999 Apr 16;274(16):10963–8
Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation. Christensen E, et al. **J Inherit Metab Dis** 1998 Jun;21(3):272–5
Large heterozygous deletion masquerading as homozygous missense mutation: a pitfall in diagnostic mutation analysis. Zschocke J, et al. **J Inherit Metab Dis** 1999 Aug; 22(6):687–92
Infected ovarian cyst in a homozygous beta-thalassemic patient. Sukcharoen N, et al. **J Med Assoc Thai** 1999 May; 82(5):511–4
Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis. Chabás A, et al. **J Med Genet** 1998 Sep;35(9):775–7
Homozygosity in Huntington's disease [letter] Dürr A, et al. **J Med Genet** 1999 Feb;36(2):172–3
Homozygosity mapping to the USH2A locus in two isolated populations. Fagerheim T, et al. **J Med Genet** 1999 Feb; 36(2):144–7
Myophosphorylase deficiency associated with a defect in complex I of the mitochondrial respiratory chain. Rubio JC, et al. **J Neurol Sci** 1998 Dec 11;161(2):110–3
A Japanese family with spinocerebellar ataxia type 6 which includes three individuals homozygous for an expanded CAG repeat in the SCA6/CACNL1A4 gene. Takiyama Y, et al. **J Neurol Sci** 1998 Jun 30;158(2):141–7
Postsplenectomy course in homozygous sickle cell disease. Wright JG, et al. **J Pediatr** 1999 Mar;134(3):304–9
Female pseudohermaphroditism associated with a novel homozygous G-to-A (V370-to-M) substitution in the P-450 aromatase gene. Ludwig M, et al. **J Pediatr Endocrinol Metab** 1998 Sep-Oct;11(5):657–64
An improved polymerase chain reaction (PCR) protocol for unambigous detection of growth hormone gene deletions. Mone CM, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug; 11(4):563–8
Homozygous factor V Leiden mutation in a child with Budd-Chiari syndrome. Gürakan F, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):516–7
Pregnancy and lactation in homozygous beta-thalassemia major. Surbek DV, et al. **J Perinat Med** 1998;26(3):240–3
Trace metal excretion in patients with homozygous hypercholesterolaemia. Jackson GE, et al. **J Trace Elem Med Biol** 1999 Jul;13(1-2):62–7
Radiological analysis of children with cystic fibrosis who are homozygous for cystic fibrosis transmembrane conductance regulator mutation S549R (T-->G). Frossard PM, et al. **J Trop Pediatr** 1999 Jun;45(3):158–60
One Lewis rat with homozygous defect of the serine proteinase inhibitor 2 (Spi-2) gene and two Lewis rats with heterozygous Spi-2 gene defect. Nakatsuji T. **Keio J Med** 1998 Sep;47(3):150–6
Homozygous arginine-72 in wild type p53 and risk of cervical cancer [letter] Hayes VM, et al. **Lancet** 1998 Nov 28; 352(9142):1756
Effect of ploidy and homozygosity on transgene expression in primary tobacco transformants and their androgenetic progenies. Beaujean A, et al. **Mol Gen Genet** 1998 Nov; 260(4):362–71
A patient with Ehlers-Danlos syndrome type VI is homozygous for a premature termination codon in exon 14 of the lysyl hydroxylase 1 gene. Walker LC, et al. **Mol Genet Metab** 1999 May;67(1):75–82
Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Duaux E, et al. **Mol Psychiatry** 1998 Jul;3(4):333–6
Spontaneous functional correction of homozygous fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Waisfisz Q, et al. **Nat Genet** 1999 Aug; 22(4):379–83
Simultaneous Cre catalyzed recombination of two alleles to restore neomycin sensitivity and facilitate homozygous mutations. Milstone DS, et al. **Nucleic Acids Res** 1999 Aug 1;27(15):e10
In utero exchange transfusion in homozygous alpha-thalassaemia: a case report. Fung TY, et al. **Prenat Diagn** 1998 Aug;18(8):838–41
Chromosomal in-vitro radiosensitivity of lymphocytes in radiotherapy patients and AT-homozygotes. Dunst J, et al. **Strahlenther Onkol** 1998 Oct;174(10):510–6

HONEY

Oral cavity onlay grafting using foam impregnated with honey:--a case report. Fasika OM, et al.

HONEY

Afr J Med Med Sci 1996 Sep;25(3):297
Osmotic effect of honey on growth and viability of Helicobacter pylori. Osato MS, et al. **Dig Dis Sci** 1999 Mar; 44(3):462–4
Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following caesarean sections and hysterectomies. Al-Waili NS, et al. **Eur J Med Res** 1999 Mar 26;4(3):126–30
Effects of honey consumption on enamel microhardness in normal versus xerostomic patients. Sela MO, et al. **J Oral Rehabil** 1998 Aug;25(8):630–4
Antibacterial activity of honey against strains of Staphylococcus aureus from infected wounds. Cooper RA, et al. **J R Soc Med** 1999 Jun;92(6):283–5
Honey, fructose absorption, and the laxative effect [editorial] Ladas SD, et al. **Nutrition** 1999 Jul–Aug;15(7–8):591–2 (18 ref.)
Prevention of ethanol-induced gastric lesions in rats by natural honey and glucose-fructose-sucrose-maltose mixture. Gharzouli K, et al. **Pharmacol Res** 1999 Feb; 39(2):151–6

ADVERSE EFFECTS

Allergic reactions to honey and royal jelly and their relationship with sensitization to compositae. Lombardi C, et al. **Allergol Immunopathol (Madr)** 1998 Nov–Dec; 26(6):288–90
Occupational asthma caused by honey. Johnson A, et al. **Allergy** 1999 Feb;54(2):189–90
Fifteen cases of atropine poisoning after honey ingestion. Ramirez M, et al. **Vet Hum Toxicol** 1999 Feb;41(1):19–20
[Infant botulism--rare, but dangerous. Preventive measures: infants must not be given honey!] **Med Monatsschr Pharm** 1999 May;22(5):152–3 **(Ger)**

ANALYSIS

Determination of acrinathrin residues in honey and beeswax. Türi MS, et al. **Acta Vet Hung** 1999;47(2):173–9
Immunochemical screening for antimicrobial drug residues in commercial honey. Heering W, et al. **Analyst** 1998 Dec; 123(12):2759–62
A test to detect cane-sugar-honey. Vit P. **Arch Latinoam Nutr** 1998 Mar;48(1):62–4
Chernobyl-derived radiocesium in heather honey and its dependence on deposition patterns. Fisk S, et al. **Health Phys** 1999 Oct;77(4):431–5
Solid-phase microextraction applied to the analysis of pesticide residues in honey using gas chromatography with electron-capture detection. Jiménez JJ, et al. **J Chromatogr A** 1998 Dec 31;829(1–2):269–77
Gas chromatography with electron-capture and nitrogen-phosphorus detection in the analysis of pesticides in honey after elution from a Florisil column. Influence of the honey matrix on the quantitative results. Jiménez JJ, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):381–7
Disposition of mirosamicin in honeybee hives. Nakajima C, et al. **J Vet Pharmacol Ther** 1998 Aug;21(4):269–73

MICROBIOLOGY

Study of the presence of the spores of Clostridium botulinum in honey in Brazil. Schocken-Iturrino RP, et al. **FEMS Immunol Med Microbiol** 1999 Jul;24(3):379–82
[Diagnosis of Clostridium botulinum intoxication] Mölle G, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Feb;106(2):73 **(Ger)**

HOODED SKUNKS see **SKUNKS**

HOOF AND CLAW

Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):119–24
Digital perfusion, evaluated scintigraphically, and hoof wall growth in horses with chronic laminitis treated with egg bar-heart bar shoeing and coronary grooving. Ritmeester AM, et al. **Equine Vet J Suppl** 1998 Sep;(26):111–8
Deep digital flexor tenotomy as a treatment for chronic laminitis in horses: 35 cases (1988–1997) [published erratum appears in J Am Vet Med Assoc 1999 Apr 15;214(8):1217] Eastman TG, et al. **J Am Vet Med Assoc** 1999 Feb 15; 214(4):517–9
Comparison of topical application of oxytetracycline and four nonantibiotic solutions for treatment of papillomatous digital dermatitis in dairy cows. Hernandez J, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):688–90
A case of bacterial endophthalmitis following perforating injury caused by a cat claw. Doi M, et al. **Ophthalmic Surg Lasers** 1999 Apr;30(4):315–6
Immediate and persistent complete heart block following a horse kick. Benitez RM, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):816–8
Serological evidence of spirochaetal infections associated with digital dermatitis in dairy cattle. Demirkan I, et al. **Vet J** 1999 Jan;157(1):69–77
Clinical study of toe ulcer and necrosis of the apex of the distal phalanx in 53 cattle. Kofler J. **Vet J** 1999 Mar; 157(2):139–47
Regular claw trimming for the control of lameness--good or bad? [editorial] Vermunt JJ. **Vet J** 1999 Mar; 157(2):109–10

ABNORMALITIES

Evidence against altered forms of MAG in the dysmyelinated mouse mutant claw paw. Niemann S, et al. **Mamm Genome** 1998 Nov;9(11):903–4 (17 ref.)

ANATOMY & HISTOLOGY

Hoof size, shape, and balance as possible risk factors for catastrophic musculoskeletal injury of Thoroughbred racehorses. Kane AJ, et al. **Am J Vet Res** 1998 Dec; 59(12):1545–52
Tubule density of the stratum medium of horse hoof. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):4–9
Pattern and process in the evolution of primate nails and claws. Hamrick MW. **J Hum Evol** 1999 Aug;37(2):293–7
Nails and claws in primate evolution. Soligo C, et al. **J Hum Evol** 1999 Jan;36(1):97–114
In-shoe foot force sensor to assess hoof balance determined by radiographic method in ponies trotting on a treadmill. Caudron I, et al. **Vet Q** 1998 Oct;20(4):131–5

BLOOD SUPPLY

Palmar digital vessel relaxation in healthy horses and in horses given carbohydrate. Schneider DA, et al. **Am J Vet Res** 1999 Feb;60(2):233–9
Equine laminitis: its development coincides with increased sublamellar blood flow. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):125–32
Scanning electron microscopic study of the vascular supply of the equine hoof. Nasu T, et al. **J Vet Med Sci** 1998 Jul;60(7):855–8
Microvasculature of the bovine claw demonstrated by improved micro-corrosion-casting technique. Hirschberg RM, et al. **Microsc Res Tech** 1999 May 1;45(3):184–97
Near infrared spectroscopy of the normal bovine claw. Pringle J, et al. **Vet J** 1998 Sep;156(2):155–8

CHEMISTRY

Cytokeratins of the equine hoof wall, chestnut and skin: bio- and immunohisto-chemistry. Wattle O. **Equine Vet J Suppl** 1998 Sep;(26):66–80

CYTOLOGY

Culture and characterization of equine terminal arch endothelial cells and hoof keratinocytes. Wunn D, et al. **Am J Vet Res** 1999 Jan;60(1):128–32
How structures in bovine hoof epidermis are influenced by nutritional factors. Mülling CK, et al. **Anat Histol Embryol** 1999 May;28(2):103–8
Effect of endocrine and paracrine factors on protein synthesis and cell proliferation in bovine hoof tissue culture. Hendry KA, et al. **J Dairy Res** 1999 Feb;66(1):23–33

EMBRYOLOGY

Fetal development of the white line (Zona alba) of the equine hoof. Bragulla H, et al. **Equine Vet J Suppl** 1998 Sep; (26):22–6

GROWTH & DEVELOPMENT

Effect of supplementary dietary biotin on hoof growth and hoof growth rate in ponies: a controlled trial. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):51–7
Effect of a supplementary dietary evening primrose oil mixture on hoof growth, hoof growth rate and hoof lipid fractions in horses: a controlled and blinded trial. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):58–65

INJURIES

Effect of hoof trimming on the occurrence of distal phalangeal palmar process fractures in foals. Kaneps AJ, et al. **Equine Vet J Suppl** 1998 Sep;(26):36–45
Detection of a radiographically occult fracture of the lateral palmar process of the distal phalanx in a horse using computed tomography. Martens P, et al. **Vet Radiol Ultrasound** 1999 Jul–Aug;40(4):346–9
Persistence of foot blocks used in the treatment of lame cows. Blowey R, et al. **Vet Rec** 1999 Jun 5;144(23):642–3
Foot lesions in finishing pigs and their associations with the type of floor. Mouttotou N, et al. **Vet Rec** 1999 Jun 5; 144(23):629–32

METABOLISM

A permeability barrier in the dorsal wall of the equine hoof capsule. Kempson SA, et al. **Equine Vet J Suppl** 1998 Sep; (26):15–21
Decreased glucose metabolism causes separation of hoof lamellae in vitro: a trigger for laminitis? Pass MA, et al. **Equine Vet J Suppl** 1998 Sep;(26):133–8
Effect of endocrine and paracrine factors on protein synthesis and cell proliferation in bovine hoof tissue culture. Hendry KA, et al. **J Dairy Res** 1999 Feb;66(1):23–33

MICROBIOLOGY

Onychomycosis in white line disease in horses: pathology, mycology and clinical features. Kuwano A, et al. **Equine Vet J Suppl** 1998 Sep;(26):27–35

PATHOLOGY

Chronic selenium toxicosis in growing-finishing pigs in southwestern Québec [see comments] Hélie P, et al. **Can Vet J** 1998 Sep;39(9):591–2. Comment in: Can Vet J 1998 Dec;39(12):742.
Onychomycosis in white line disease in horses: pathology, mycology and clinical features. Kuwano A, et al. **Equine Vet J Suppl** 1998 Sep;(26):27–35
Equine laminitis basement membrane pathology: loss of type IV collagen, type VII collagen and laminin immunostaining. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):139–44
Subclinical laminitis in dairy cows: use of severity of hoof lesions to rank and evaluate herds. Smilie RH, et al. **Vet Rec** 1999 Jan 2;144(1):17–21

PHYSIOLOGY

How structures in bovine hoof epidermis are influenced by nutritional factors. Mülling CK, et al. **Anat Histol Embryol** 1999 May;28(2):103–8
The effect of foot imbalance on point of force application in the horse. Wilson AM, et al. **Equine Vet J** 1998 Nov; 30(6):540–5
Exploring the possible functions of equine hoof wall tubules. Kasapi MA, et al. **Equine Vet J Suppl** 1998 Sep;(26):10–4
In vitro attenuation of impact shock in equine digits. Lanovaz JL, et al. **Equine Vet J Suppl** 1998 Sep;(26):96–102
Effects of season and diet on tensile strength and mineral content of the equine hoof wall. Ley WB, et al. **Equine Vet J Suppl** 1998 Sep;(26):46–50
Finite element analysis of static loading in donkey hoof wall. Newlyn HA, et al. **Equine Vet J Suppl** 1998 Sep;(26):103–10
Effect of rider and riding style on deformation of the front hoof wall in warmblood horses. Summerley HL, et al. **Equine Vet J Suppl** 1998 Sep;(26):81–5
Variation in surface strain on the equine hoof wall at the midstep with shoeing, gait, substrate, direction of travel, and hoof shape. Thomason JJ. **Equine Vet J Suppl** 1998 Sep;(26):86–95
Micromechanics of the equine hoof wall: optimizing crack control and material stiffness through modulation of the properties of keratin. Kasapi MA, et al. **J Exp Biol** 1999 Feb;202 (Pt 4):377–91
Control of claw movements in cats. Perfiliev S, et al. **Neurosci Res** 1998 Aug;31(4):337–42
Role of claws and pads in taking and holding food in cats. Pettersson LG, et al. **Neurosci Res** 1998 Aug;31(4):343–6
[Development of hoof cartilage with special considerations of its ossification] Bragulla H. **DTW Dtsch Tierarztl Wochenschr** 1999 Mar;106(3):87–93 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Radiologic findings in bovine laminitis] Gantke S, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Sep; 26(5):239–46 (Eng. Abstr.) **(Ger)**

SURGERY

Declawing cats--ludicrous [letter] Stokes R. **Aust Vet J** 1999 Apr;77(4):269
Effect of hoof trimming on the occurrence of distal phalangeal palmar process fractures in foals. Kaneps AJ, et al. **Equine Vet J Suppl** 1998 Sep;(26):36–45
Comments on tenectomy and onychectomy in cats [letter; comment] Branch C. **J Am Vet Med Assoc** 1998 Oct 1; 213(7):954–5. Comment on: J Am Vet Med Assoc 1998 Aug 1;213(3):370–3.
Comments on tenectomy and onychectomy in cats [letter; comment] Knudson D. **J Am Vet Med Assoc** 1998 Oct 1;213(7):954; discussion 954–5. Comment on: J Am Vet Med Assoc 1998 Aug 1;213(3):370–3.
Foot trimming by lay people [letter; comment] Richardson SP. **Vet Rec** 1999 Jan 23;144(4):104. Comment on: Vet Rec 1999 Jan 9;144(2):55–6.

ULTRASONOGRAPHY

Ultrasonographic imaging and thickness measurement of the sole horn and the underlying soft tissue layer in bovine claws [see comments] Kofler J, et al. **Vet J** 1999 May; 157(3):322–31. Comment in: Vet J 1999 May;157(3):218–9.

HOOKS, SURGICAL see **SURGICAL INSTRUMENTS**

HOOKWORM INFECTIONS

Case studies in international medicine. Kitchen LW. **Am Fam Physician** 1999 Jun;59(11):3040–4 (06 ref.)

BLOOD

The contribution of hookworm and other parasitic infections to haemoglobin and iron status among children and adults in western Kenya. Olsen A, et al. **Trans R Soc Trop Med Hyg** 1998 Nov–Dec;92(6):643–9

COMPLICATIONS

Evidence for an association between hookworm infection and cognitive function in Indonesian school children. Sakti H, et al. **Trop Med Int Health** 1999 May;4(5):322–34

DIAGNOSIS

Diagnosis of Oesophagostomum bifurcum and hookworm infection in humans: day-to-day and within-specimen variation of larval counts. Pit DS, et al. **Parasitology** 1999 Mar;118 (Pt 3):283-8

Hookworm disease misdiagnosed as intestinal lymphoma [letter] Singh S. **Scand J Infect Dis** 1999;31(2):217

Independent evaluation of the Nigrosin-Eosin modification of the Kato-Katz technique. Ramsan M, et al. **Trop Med Int Health** 1999 Jan;4(1):46-9

DRUG THERAPY

Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. Reynoldson JA, et al. **Acta Trop** 1998 Aug 15; 71(1):27-44

A controlled evaluation of two school-based anthelminthic chemotherapy regimens on intensity of intestinal helminth infections. Albonico M, et al. **Int J Epidemiol** 1999 Jun; 28(3):591-6

Effect of mebendazole therapy during pregnancy on birth outcome. de Silva NR, et al. **Lancet** 1999 Apr 3; 353(9159):1145-9

EPIDEMIOLOGY

Comparative prevalences of some common intestinal helminth infections in different altitudinal regions in Ethiopia. Jemaneh L. **Ethiop Med J** 1998 Jan;36(1):1-8

Epidemiology of human intestinal nematode infections in Wujiang and Pizhou counties, Jiangsu Province, China. Fenghua S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):605-10

Helminthic infections of urban and rural schoolchildren in Penang Island, Malaysia: implications for control. Rahman WA. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):596-8

Eosinophilia, anemia and parasitism in a rural region of northwest Thailand. Triteeraprapab S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):584-90

The use of morbidity questionnaires to identify communities with high prevalences of schistosome or geohelminth infections in Tanzania. Booth M, et al. **Trans R Soc Trop Med Hyg** 1998 Sep-Oct;92(5):484-90

The population biology and epidemiology of schistosome and geohelminth infections among schoolchildren in Tanzania. Booth M, et al. **Trans R Soc Trop Med Hyg** 1998 Sep-Oct; 92(5):491-5

The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast. Brooker S, et al. **Trans R Soc Trop Med Hyg** 1999 May-Jun;93(3):240-6

The proportion of helminth infections in a community in western Kenya which would be treated by mass chemotherapy of schoolchildren. Olsen A. **Trans R Soc Trop Med Hyg** 1998 Mar-Apr;92(2):144-8

Prevalence of hookworm infections amongst itinerant pupil Islamic scholars (Almajirai) in Zaria, northern Nigeria [letter] [see comments] Awofeso N, et al. **Trop Doct** 1998 Oct;28(4):246-7. Comment in: Trop Doct 1999 Jul;29(3):183-4.

PARASITOLOGY

Ancylostoma secreted protein 1 (ASP-1) homologues in human hookworms. Bin Z, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):143-9

VETERINARY

Hookworms (Uncinaria sp.) in Juan Fernandez fur seal pups (Arctocephalus philippii) from Alejandro Selkirk Island, Chile. Sepúlveda MS. **J Parasitol** 1998 Dec;84(6):1305-7

HOOKWORM, NEW WORLD see **NECATOR AMERICANUS**

HOOKWORM, OLD WORLD see **ANCYLOSTOMA**

HOOKWORMS see **ANCYLOSTOMATOIDEA**

HOPLOPLEURA see **ANOPLURA**

HORDEOLUM

[Blepharitis, hordeolum, abscess in the lids] Kitagawa K. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):329-32 (8 ref.) **(Jpn)**

DIAGNOSIS

Hordeola and chalazia. Lederman C, et al. **Pediatr Rev** 1999 Aug;20(8):283-4

THERAPY

Hordeola and chalazia. Lederman C, et al. **Pediatr Rev** 1999 Aug;20(8):283-4

HORDEUM see **BARLEY**

HOREHOUND see **LAMIACEAE**

HORIZONTAL TRANSMISSION see **DISEASE TRANSMISSION, HORIZONTAL**

HORMONAL ANTINEOPLASTIC AGENTS see **ANTINEOPLASTIC AGENTS, HORMONAL**

HORMONE ANALOGS see **HORMONES, SYNTHETIC**

HORMONE ANTAGONISTS

Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers. Mulders TM, et al. **Contraception** 1998 Jul;58(1):39-44

Prolactin receptor antagonists. Kuo CB, et al. **Endocrine** 1998 Oct;9(2):121-31 (84 ref.)

Mifepristone in combination with methotrexate for the medical treatment of tubal pregnancy: a randomized, controlled trial. Gazvani MR, et al. **Hum Reprod** 1998 Jul; 13(7):1987-90

ADMINISTRATION & DOSAGE

Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Rolf C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):63-9

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. **Hum Reprod** 1998 Nov;13(11):3023-31

Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Felberbaum RE, et al. **Hum Reprod** 1998 Jun; 13(6):1660-8

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Kol S, et al. **Hum Reprod** 1999 Sep;14(9):2242-4

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Olivennes F, et al. **Hum Reprod** 1998 Sep; 13(9):2411-4

A chronic, low-dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys. Zelinski-Wooten MB, et al. **Hum Reprod** 1998 Aug; 13(8):2132-8

Intrapreoptic microinjection of GHRH or its antagonist alters sleep in rats. Zhang J, et al. **J Neurosci** 1999 Mar 15; 19(6):2187-94

Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Alvarez-Nemegyei J, et al. **Lupus** 1998;7(6):414-9

ADVERSE EFFECTS

Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. Loewe C, et al. **Am J Forensic Med Pathol** 1998 Sep;19(3):258-60 (9 ref.)

Can somatostatin be administered in association with morphine in advanced cancer patients with pain? [letter] Ripamonti C, et al. **Ann Oncol** 1998 Aug;9(8):921-3

[Postpartum myocardial infarction induced by Parlodel] Pop C, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91(9):1171-4 (Eng. Abstr.) **(Fre)**

[Bromocriptine for the suppression of lactation and severe hypotension (letter)] Palop Larrea V, et al. **Aten Primaria** 1999 Apr 30;23(7):447-8 **(Spa)**

BLOOD

The development of a sensitive and specific enzyme immunoassay for FK480, a novel cholecystokinin type-A receptor antagonist, in human plasma. Nozaki K, et al. **J Pharm Biomed Anal** 1998 Sep;17(8):1381-92

CHEMICAL SYNTHESIS

A rational design strategy for protein hormone superagonists. Grossmann M, et al. **Nat Biotechnol** 1998 Sep;16(9):871-5

CHEMISTRY

Importance of the test medium for the release kinetics of a somatostatin analogue from poly(D,L-lactide-co-glycolide) microspheres. Blanco-Prieto MJ, et al. **Int J Pharm** 1999 Jul 20; 184(2):243-50

Function and molecular basis of action of vasopressin 4-8 and its analogues in rat brain. Du YC, et al. **Prog Brain Res** 1998;119:163-75 (68 ref.)

DIAGNOSTIC USE

Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Bernà L, et al. **Eur J Nucl Med** 1998 Nov;25(11):1482-8

METABOLISM

Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors. Mouillac B, et al. **Adv Exp Med Biol** 1998;449:359-61

Regulation of hypothalamic somatostatin and growth hormone releasing hormone mRNA levels by inhibin. Carro E, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1-2):191-4

Function and molecular basis of action of vasopressin 4-8 and its analogues in rat brain. Du YC, et al. **Prog Brain Res** 1998;119:163-75 (68 ref.)

Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. Andersen ME, et al. **Toxicol Sci** 1999 Mar;48(1):38-50 (50 ref.)

PHARMACOKINETICS

Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Duijkers IJ, et al. **Hum Reprod** 1998 Sep; 13(9):2392-8

Measurement of the novel decapeptide cetrorelix in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. Niwa M, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11; 729(1-2):245-53

Atosiban, an oxytocin receptor blocking agent: pharmacokinetics and inhibition of milk ejection in dairy cows. Wellnitz O, et al. **J Dairy Res** 1999 Feb;66(1):1-8

PHARMACOLOGY

Effect of an oxytocin antagonist on prostaglandin F2 alpha secretion and the course of luteolysis in sows. Kotwica G, et al. **Acta Vet Hung** 1999;47(2):249-62

Molecular pharmacology of human vasopressin receptors. Thibonnier M, et al. **Adv Exp Med Biol** 1998;449:251-76

Role of oxytocin in the initiation of term and preterm labor in rats: changes in oxytocin receptor density and plasma oxytocin concentration and the effect of an oxytocin antagonist, L-366,509. Kobayashi M, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):621-7

CCK-A receptor antagonists have selective effects on nutrient-induced food intake suppression in rats. Trigazis L, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R323-30

Duodenal loading with glucose induces fos expression in rat brain: selective blockade by devazepide. Wang L, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R667-74

The opposite effects of cysteamine on the acquisition of two different tasks in mice are associated with bidirectional testing-induced changes in hippocampal adenylyl cyclase activity. Guillou JL, et al. **Behav Neurosci** 1998 Aug; 112(4):900-8

Involvement of stress in the sleep rebound mechanism induced by sleep deprivation in the rat: use of alpha-helical CRH (9-41). González MM, et al. **Behav Pharmacol** 1998 Dec;9(8):655-62

Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Payen L, et al. **Biochem Biophys Res Commun** 1999 May 19; 258(3):513-8

Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. Gianotti L, et al. **Biol Psychiatry** 1999 Feb 1;45(3):334-9

Synthesis, biological activity, and conformational studies of insect allatostatin neuropeptide analogues incorporating turn-promoting moieties. Nachman RJ, et al. **Bioorg Med Chem** 1998 Aug;6(8):1379-88

Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists. Sinha J, et al. **Bioorg Med Chem** 1999 Jun;7(6):1127-30

Differential effects of somatostatin and angiopeptin on cell proliferation. Alderton F, et al. **Br J Pharmacol** 1998 May; 124(2):323-30

Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed. Heinemann A, et al. **Br J Pharmacol** 1998 Nov;125(6):1120-7

Sympathectomy-induced immune changes are not abrogated by the glucocorticoid receptor blocker RU-486. Kruszewska B, et al. **Brain Behav Immun** 1998 Sep; 12(3):181-200

Somatostatin enhances neurite outgrowth in PC12 cells. Traina G, et al. **Brain Res Dev Brain Res** 1998 Dec 7; 111(2):223-30

Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Darro F, et al. **Breast Cancer Res Treat** 1998 Sep;51(1):39-55

Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. El Etreby MF, et al. **Breast Cancer Res Treat** 1998 Sep;51(2):149-68

Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide). Kakar SS. **Cancer Res** 1998 Oct 15; 58(20):4558-60

Involvement of a putative G-protein-coupled receptor and a branching pathway in argipressin (4-8) signal transduction in rat hippocampus. Qiao LY, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):15-20

Screening for antiproliferative actions of mifepristone. Differential endometrial responses of primates versus rats.

Burleigh DW, et al. **Contraception** 1998 Jul;58(1):45–50

A progesterone antagonist cannot prevent fetal survival if the uterine horn is incised. Tamada H, et al. **Endocr J** 1998 Dec;45(6):785–9

Stimulation of spermatogonial differentiation in juvenile spermatogonial depletion (jsd) mutant mice by gonadotropin-releasing hormone antagonist treatment. Matsumiya K, et al. **Endocrinology** 1999 Oct;140(10):4912–5

The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Wagner BL, et al. **Endocrinology** 1999 Mar;140(3):1449–58

Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Jungwirth et al., Eur J Cancer 1997, 33(7), 1141–1148 [letter; comment] Limonta P, et al. **Eur J Cancer** 1998 Jun; 34(7):1134–6. Comment on: Eur J Cancer 1997 Jun;33(7):1141–8.

Contraceptive use of antiprogestin. Bygdeman M, et al. **Eur J Contracept Reprod Health Care** 1999 Jun;4(2):103–7 (24 ref.)

Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function. Varga G, et al. **Eur J Pharmacol** 1999 Feb 19; 367(2–3):315–23

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Mayinger B, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):157–65 (90 ref.)

Value of ovarian stromal blood flow velocity measurement after pituitary suppression in the prediction of ovarian responsiveness and outcome of in vitro fertilization treatment. Engmann L, et al. **Fertil Steril** 1999 Jan; 71(1):22–9

Induction of apoptosis in cells of GH3 line by bromocryptine. Waśko R, et al. **Folia Histochem Cytobiol** 1999;37(2):123–4

Onapristone suppresses prolactin production in explant cultures of leiomyoma. Austin DJ, et al. **Gynecol Obstet Invest** 1999;47(4):268–71

Disparate actions of mifepristone (RU 486) on glands and stroma in the primate endometrium. Greb RR, et al. **Hum Reprod** 1999 Jan;14(1):198–206

Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida. Morales P, et al. **Hum Reprod** 1999 Aug;14(8):2069–74

Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Chwalisz K, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):570–83

Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Spitz IM, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):584–93 (71 ref.)

Central somatostatin diminished inhibitory action of central CGRP on pancreatic basal secretion in conscious rats. Miyasaka K, et al. **J Auton Nerv Syst** 1998 Nov 10; 73(2–3):143–8

Vasopressin dilates the rat carotid artery by stimulating V1 receptors. Rutschmann B, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):637–41

Titrating luteinizing hormone replacement to sustain the structure and function of the corpus luteum after gonadotropin-releasing hormone antagonist treatment in rhesus monkeys. Duffy DM, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):342–9

Follicle-stimulating hormone-inhibin B interactions during the follicular phase of the primate menstrual cycle revealed by gonadotropin-releasing hormone antagonist and antiestrogen treatment. Fraser HM, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1365–9

Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. Swerdloff RS, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3527–33

Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. Welt CK, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2163–9

The cycle duration of the seminiferous epithelium remains unaltered during GnRH antagonist-induced testicular involution in rats and monkeys. Aslam H, et al. **J Endocrinol** 1999 May;161(2):281–8

The antiprogestin RU486 dissociates LH and FSH secretion in male rats: evidence for direct action at the pituitary level. Sánchez-Criado JE, et al. **J Endocrinol** 1999 Feb; 160(2):197–203

Exogenous cysteamine increases basal pancreatic exocrine secretion in the rat. Lee HS, et al. **J Korean Med Sci** 1999 Feb;14(1):52–6

A nitric oxide/cyclic GMP-dependent protein kinase pathway alters transmitter release and inhibition by somatostatin at a site downstream of calcium entry. Gray DB, et al. **J Neurochem** 1999 May;72(5):1981–90

The progesterone blockade of the luteinizing hormone surge is overcome by RU486. Skinner DC, et al. **J Neuroendocrinol** 1999 Aug;11(8):637–41

The effects of progesterone on oxytocin mRNA levels in the paraventricular nucleus of the female rat can be altered by the administration of diazepam or RU486. Thomas A, et al. **J Neuroendocrinol** 1999 Feb;11(2):137–44

Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity. Tallent MK, et al. **J Neurophysiol** 1999 Apr;81(4):1626–35

Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. Shaham Y, et al. **J Neurosci** 1997 Apr 1;17(7):2605–14

Glucocorticoids mediate the enhanced expression of intestinal type II arginase and arginino succinate lyase in postweaning pigs. Flynn NE, et al. **J Nutr** 1999 Apr;129(4):799–803

Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo. Critchley HO, et al. **J Reprod Fertil** 1999 Mar; 115(2):389–95

Comparison of the in vivo activity of different oxytocin antagonists in the pregnant baboon. Fejgin MD, et al. **J Soc Gynecol Investig** 1998 Sep–Oct;5(5):251–4

Corticotropin-inhibiting peptide enhances aldosterone secretion by dispersed rat zona glomerulosa cells. Malendowicz LK, et al. **J Steroid Biochem Mol Biol** 1998 Oct;67(2):149–52

Quantity of partial agonist activity for antiglucocorticoids complexed with mutant glucocorticoid receptors is constant in two different transactivation assays but not predictable from steroid structure. Sarlis NJ, et al. **J Steroid Biochem Mol Biol** 1999 Feb;68(3–4):89–102

Corticotropin-releasing factor-induced suppression of gastric emptying in the rat is blocked by cyclo(7-aminoheptanoyl-phe-D-TRP-LYS-THR[BZL], an in vivo somatostatin antagonist. Smedh U, et al. **Neurosci Lett** 1999 Jan 22;260(1):41–4

Effect of FK480, a CCK-A receptor antagonist, on spontaneously developed chronic pancreatitis in WBN/Kob rats. Ito H, et al. **Pancreas** 1998 Oct; 17(3):295–300

Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini. Tashiro M, et al. **Pancreas** 1999 Mar;18(2):156–64

Growth inhibitory effects of somatostatin on human leukemia cell lines mediated by somatostatin receptor subtype 1. Ishihara S, et al. **Peptides** 1999;20(3):313–8

LHRH antagonists. Haviv F, et al. **Pharm Biotechnol** 1998; 11:131–49 (56 ref.)

Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Csernus VJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3098–103

An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Montano MM, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6947–52

ICV administration of CRF blocker (CRF9-41 delta helical) reduces morphine withdrawal in rats. Brugger S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Jul; 22(5):775–85

Somatostatin and octreotide modulate the function of Kupffer cells in liver cirrhosis. Chao TC, et al. **Regul Pept** 1999 Feb 5;79(2–3):117–24

CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis. Håkanson R, et al. **Regul Pept** 1999 Mar 17;80(1–2):1–12 (117 ref.)

Corticotropin releasing hormone antagonist does not prevent adrenalectomy-induced apoptosis in the dentate gyrus of the rat hippocampus. Gerth A, et al. **Stress** 1998 Jul; 2(3):159–69

Effects of dienogest (a synthetic steroid) on coagulation, fibrinolysis, and platelet aggregation in female monkeys. Katsuki Y, et al. **Toxicol Lett** 1998 Sep 1;98(1–2):105–13

Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones. Beinborn M, et al. **Yale J Biol Med** 1998 May-Aug;71(3–4):337–46

[The influence of bromocriptine treatment on prolactin secretion in infertile women with suspicion of luteal phase insufficiency] Krzemiński A, et al. **Ginekol Pol** 1998 Dec; 69(12):1141–5 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women. Akerlund M, et al. **Adv Exp Med Biol** 1998;449:467–72

Progress in the development of oxytocin antagonists for use in preterm labor. Williams PD, et al. **Adv Exp Med Biol** 1998;449:473–9

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Hradec J, et al. **Am J Cardiol** 1999 May 15;83(10):1506–9, A8

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, et al. **Ann Oncol** 1999;10 Suppl 2:S31–8 (63 ref.)

Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. El Etreby MF, et al. **Breast Cancer Res Treat** 1998 May; 49(2):109–17

Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. Lin K, et al. **Clin Nucl Med** 1999 Jan;24(1):24–8

The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies. Badawy SZ, et al. **Early Pregnancy** 1997 Dec; 3(4):306–11

Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Saeki N, et al. **Endocr J** 1998 Aug;45(4):529–37

Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Robertson JF, et al. **Eur J Cancer** 1999 Feb;35(2):214–8

Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. El Rassi Z, et al. **Eur J Surg Oncol** 1998 Dec;24(6):562–7 (56 ref.)

Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Mayinger B, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):157–65 (90 ref.)

The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Fahy U, et al. **Hum Reprod** 1999 Feb; 14(2):285–7

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Rongières-Bertrand C, et al. **Hum Reprod** 1999 Mar;14(3):683–8

Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. Comaru-Schally AM, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):3826–31

Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban. Bossmar T. **J Perinat Med** 1998;26(6):458–65 (67 ref.)

Inhibition of endometrial cancer cell lines by mifepristone (RU 486). Schneider CC, et al. **J Soc Gynecol Investig** 1998 Nov-Dec;5(6):334–8

Growth-hormone and prolactin excess. Colao A, et al. **Lancet** 1998 Oct 31;352(9138):1455–61 (70 ref.)

Should prolactin be reconsidered as a therapeutic target in human breast cancer? Goffin V, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):79–87 (71 ref.)

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Pályi I, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2361–6

Plasmapheresis combined with somatostatin is a successful treatment of porphyrias. Medenica R, et al. **Ther Apher** 1997 May;1(2):159–64

[The influence of bromocriptine treatment on prolactin secretion in infertile women with suspicion of luteal phase insufficiency] Krzemiński A, et al. **Ginekol Pol** 1998 Dec; 69(12):1141–5 (Eng. Abstr.) **(Pol)**

TOXICITY

Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. Andersen ME, et al. **Toxicol Sci** 1999 Mar;48(1):38–50 (50 ref.)

HORMONE-DEPENDENT NEOPLASMS see **NEOPLASMS, HORMONE-DEPENDENT**

HORMONE REPLACEMENT THERAPY

Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Raudaskoski T, et al. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):540–5

Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy [see comments] Van Loan MD, et al. **AIDS** 1999 Feb 4; 13(2):241–8. Comment in: AIDS 1999 Feb 4;13(2):279–80.

Use and cost of breast imaging for postmenopausal women undergoing hormone replacement therapy. Harvey JA. **AJR Am J Roentgenol** 1999 Jun;172(6):1615–9

Cardioprotective effects of postmenopausal hormone treatment. Espeland MA. **Am J Cardiol** 1998 Nov 19; 82(10A):37S–39S (13 ref.)

Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels. Marcucci R, et al. **Am J Clin Pathol** 1999 Jun;111(6):769–72

Ambulatory--not office--blood pressures decline during hormone replacement therapy in healthy postmenopausal women. van Ittersum FJ, et al. **Am J Hypertens** 1998 Oct; 11(10):1147–52

Lipid metabolism, physical activity, and postmenopausal hormone therapy. Wenger NK. **Am J Kidney Dis** 1998 Nov; 32(5 Suppl 3):S80–8 (28 ref.)

Androgen cotherapy in menopause: evolving benefits and challenges. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar; 180(3 Pt 2):308–11 (42 ref.)

Vasomotor flushes in menopausal women. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):312–6 (26 ref.)

Patient profile 3: decreased libido and bone mineral density in a naturally menopausal woman. Burnett RG. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):334–6

Progestational effects of combinations of gestodene on the postmenopausal endometrium during hormone replacement therapy. Byrjalsen I, et al. **Am J Obstet Gynecol** 1999 Mar; 180(3 Pt 1):539–49

Role of androgens in surgical menopause. Gelfand MM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):325–7 (10 ref.)

Psychosexual effects of menopause: role of androgens. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):319–24

(29 ref.)
Improving adherence to hormone replacement therapy with effective patient-physician communication. Sarrel PM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):337–40 (15 ref.)
Androgens and bone: clinical implications for menopausal women. Shoupe D. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):329–33 (19 ref.)
Patient profile 1: unresolved vasomotor symptoms with conventional hormone replacement therapy. Studdard JD. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):317–8
A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Warren MP, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):42–8
Prevalence of and factors associated with hormone replacement therapy counseling: results from the 1994 National Health Interview Survey. Zhang P, et al. **Am J Public Health** 1999 Oct;89(10):1575–7
Prescribing hormone replacement therapy for menopausal symptoms. McNagny SE. **Ann Intern Med** 1999 Oct 19; 131(8):605–16 (181 ref.)
Effects of sex steroids on proliferation in normal mammary tissue. Söderqvist G. **Ann Med** 1998 Dec;30(6):511–24 (104 ref.)
Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Mustafa IA, et al. **Ann Surg** 1998 Nov; 228(5):638–51 (115 ref.)
Testosterone replacement therapy. Velázquez E, et al. **Arch Androl** 1998 Sep–Oct;41(2):79–90 (96 ref.)
A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Schlatterer K, et al. **Arch Sex Behav** 1998 Oct; 27(5):475–92 (34 ref.)
Hormone replacement therapy. Indications, benefits and risk. Davis S. **Aust Fam Physician** 1999 May;28(5):437–45 (37 ref.)
An audit of oestrogen implant hormone replacement therapy. Templeman C, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):455–60
Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Casaburi R. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):407–18 (89 ref.)
How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Chrisoulidou A, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):261–79 (52 ref.)
The rationale for physiological testosterone replacement in women. Davis SR, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):391–405 (60 ref.)
Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Ghigo E, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):341–58 (100 ref.)
Growth hormone deficiency and cardiovascular risk. Hew FL, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):199–216 (74 ref.)
Androgen replacement in children with constitutional delay of puberty: the case for aggressive therapy. Houchin LD, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):427–40 (65 ref.)
Acquired growth hormone resistance in adults. Jenkins RC, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul; 12(2):315–29 (73 ref.)
Growth hormone therapy and fracture risk in the growth hormone-deficient adult. Johannsson G, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):233–50 (107 ref.)
Recombinant human growth hormone as potential therapy for osteoporosis. Marcus R. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):251–60 (43 ref.)
Is there a case for DHEA replacement? Nippoldt TB, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):507–20 (87 ref.)
Potential adverse effects of long-term testosterone therapy. Rolf C, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct; 12(3):521–34 (66 ref.)
Growth hormone: a new therapy for heart failure? Saccà L. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):217–31 (83 ref.)
Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Swerdloff RS, et al. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):501–6 (32 ref.)
Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Tenover JS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):419–25 (39 ref.)
Ageing and growth hormone status. Toogood AA, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):281–96 (81 ref.)
Hormonal therapy after stem cell transplantation and risk of veno-occlusive disease [letter; comment] Sica S, et al. **Blood** 1999 May 1;93(9):3154. Comment on: Blood 1998 Dec 15;92(12):4568–72.
"Wrong" women taking HRT [news] Kenyon G. **BMJ** 1999 Jun 19;318(7199):1645
Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. Welton AJ, et al. **BMJ** 1999 Apr 24; 318(7191):1114–7
Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study. Dennison EM, et al. **Br J Rheumatol** 1998 Nov;37(11):1198–202
Androgen replacement for women. Basson R. **Can Fam Physician** 1999 Sep;45:2100–7
Hormone replacement therapy. Does it actually help with heart disease? Evans MF, et al. **Can Fam Physician** 1999 Apr;45:921–3
Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Feigelson HS, et al. **Cancer Res** 1999 Aug 15;59(16):3908–10
Promoting informed decision making: hormone replacement therapy. Bastian L, et al. **Cancer Treat Res** 1998;97:129–47 (98 ref.)
Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Blacher J, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):409–14
Migraine, female hormones, and stroke. Bousser MG. **Cephalalgia** 1999 Mar;19(2):75–9 (46 ref.)
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Cushman M, et al. **Circulation** 1999 Aug 17;100(7):717–22
Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Koh KK, et al. **Circulation** 1999 Jan 26;99(3):354–60
Hormone replacement therapy and increased plasma concentration of C-reactive protein. Ridker PM, et al. **Circulation** 1999 Aug 17;100(7):713–6
Prospective randomized study of the effect of "add-back" hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. Yim SF, et al. **Circulation** 1998 Oct 20;98(16):1631–5
The effects of testosterone on osteoporosis in men. Francis RM. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):411–4 (43 ref.)
Hormonal replacement therapy and gynecological cancer. Onnis A, et al. **Clin Exp Obstet Gynecol** 1999;26(1):5–8
Hormone replacement therapy: cardiovascular benefits for aging women. Sites CK. **Coron Artery Dis** 1998; 9(12):789–93 (44 ref.)
Bone markers in clinical practice. Souberbielle JC, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):312–9 (59 ref.)
Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy. Paggi A, et al. **Endocr Res** 1999 May;25(2):229–38
Male hormone replacement therapy including "andropause". Tenover JL. **Endocrinol Metab Clin North Am** 1998 Dec; 27(4):969–87, x (86 ref.)
Effects of castration and androgen replacement on erectile function in a rabbit model. Traish AM, et al. **Endocrinology** 1999 Apr;140(4):1861–8
Colorectal cancer and hormone replacement therapy: an unexpected finding [see comments] Franceschi S, et al. **Eur J Cancer Prev** 1998 Dec;7(6):427–38 (45 ref.). Comment in: Eur J Cancer Prev 1998 Dec;7(6):425–6.
Female sex hormones and colorectal cancer [editorial; comment] Hill MJ. **Eur J Cancer Prev** 1998 Dec;7(6):425–6 . Comment on: Eur J Cancer Prev 1998 Dec;7(6):427–38.
Regression of cardiac abnormalities after replacement therapy in Addison's disease. Fallo F, et al. **Eur J Endocrinol** 1999 May;140(5):425–8
Apo E phenotype and changes in serum lipids in adult patients during growth hormone replacement. Leese GP, et al. **Eur J Endocrinol** 1999 Feb;140(2):174–9
A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Ursic-Vrscaj M, et al. **Eur J Surg Oncol** 1999 Apr;25(2):146–51
Influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility and low back symptoms in a healthy early postmenopausal female population: a 2-year randomized controlled trial. Kyllönen ES, et al. **Eur Spine J** 1998;7(5):381–6
Aging, Alzheimer's disease, and estrogen therapy. Giacobini E. **Exp Gerontol** 1998 Nov–Dec;33(7–8):865–9 (14 ref.)
Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Cano A, et al. **Fertil Steril** 1999 Feb;71(2):261–7
Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and color flow doppler: study in different phases of sequential therapy. Exacoustòs C, et al. **Fertil Steril** 1999 Mar; 71(3):536–43
Does intravenous albumin prevent severe ovarian hyperstimulation syndrome? [letter; comment] Gulekli B. **Fertil Steril** 1999 Feb;71(2):387–8. Comment on: Fertil Steril 1997 Nov;68(5):851–4.
Induction of bone formation in rat osteoprogenitor cell culture by sera of climacteric women before and after hormone replacement therapy. Rojansky N, et al. **Fertil Steril** 1999 Jul;72(1):71–6
The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Suvanto-Luukkonen E, et al. **Fertil Steril** 1999 Jul; 72(1):161–3
HRT and cardiovascular risk factors? [letter; comment] Taskin O. **Fertil Steril** 1999 Feb;71(2):388. Comment on: Fertil Steril 1998 Feb;69(2):267–73.
Growth hormone binding protein correlates strongly with leptin and percentage body fat in GH-deficient adults, is increased by GH replacement but does not predict IGF-I response. Florkowski CM, et al. **Growth Horm IGF Res** 1999 Feb;9(1):35–40
Comparison of the effects of conjugated estrogen treatment on blood lipid and lipoprotein levels when initiated in the first or fifth postmenopausal year. Aygen EM, et al. **Gynecol Endocrinol** 1999 Apr;13(2):118–22
Color Doppler and hormone replacement therapy: the role of thromboxane and plasma viscosity. Battaglia C, et al. **Gynecol Endocrinol** 1999 Jun;13(3):183–8
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Mijatovic V, et al. **Gynecol Endocrinol** 1999 Apr; 13(2):130–44 (129 ref.)
L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. Pines A, et al. **Gynecol Endocrinol** 1999 Jun;13(3):196–201
Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. Lippert TH, et al. **Horm Metab Res** 1998 Sep;30(9):598–600
Endometrial responses to hormone replacement therapy: histological features compared with those of late luteal phase endometrium. Habiba MA, et al. **Hum Reprod** 1998 Jun;13(6):1674–82
Effects of progestogens on thrombosis and atherosclerosis [see comments] Badimon L, et al. **Hum Reprod Update** 1999 May-Jun;5(3):191–9 (110 ref.). Comment in: Hum Reprod Update 1999 May-Jun;5(3):189–90.
Progestins and coronary heart disease [comment] Cano A. **Hum Reprod Update** 1999 May-Jun;5(3):189–90 (11 ref.). Comment on: Hum Reprod Update 1999 May-Jun;5(3):191–9. Comment on: Hum Reprod Update 1999 May-Jun;5(3):200–4. Comment on: Hum Reprod Update 1999 May-Jun;5(3):205–9.
The differential effects of oestrogens and progestins on vascular tone [see comments] Sarrel PM. **Hum Reprod Update** 1999 May-Jun;5(3):205–9 (52 ref.). Comment in: Hum Reprod Update 1999 May-Jun;5(3):189–90.
Discussion on early clinical drug development in the target population with respect to the field of reproductive endocrinology. Klipping C, et al. **Int J Clin Pharmacol Ther** 1998 Nov;36(11):591–3
Interactions of familial and hormonal risk factors for large bowel cancer in women. Newcomb PA, et al. **Int J Epidemiol** 1999 Aug;28(4):603–8
Managing the climacteric. Rozenberg S, et al. **Int J Fertil Womens Med** 1999 Jan–Feb;44(1):12–8 (32 ref.)
Replacement therapy in postmenopausal women and breast cancer risk. Chiechi LM, et al. **Int J Gynaecol Obstet** 1999 Jan;64(1):79–80
Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Egarter C, et al. **Int J Gynaecol Obstet** 1999 Mar;64(3):281–6
Biochemical markers of bone turnover during hormone replacement therapy. Masahashi T, et al. **Int J Gynaecol Obstet** 1999 Feb;64(2):163–6
Extending the treatment boundaries: Zoladex and add-back. Schlaff WD. **Int J Gynaecol Obstet** 1999 Feb;64 Suppl 1:S25–31 (10 ref.)
The hormone replacement therapy self-efficacy scale. Ali NS. **J Adv Nurs** 1998 Nov;28(5):1115–9
Additive effects of simvastatin and hormone replacement therapy in hypercholesterolemic postmenopausal women [letter; comment] Fak AS, et al. **J Am Coll Cardiol** 1999 Jul;34(1):311–2. Comment on: J Am Coll Cardiol 1998 Nov;32(5):1244–50.
The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease [see comments] Sbarouni E, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1244–50. Comment in: J Am Coll Cardiol 1999 Jul;34(1):311–2.
Hormone replacement therapy and ischaemic heart disease among postmenopausal women. Kardos A, et al. **J Cardiovasc Risk** 1999 Apr;6(2):105–12 (91 ref.)
Which androgen replacement therapy for women? Buckler HM, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3920–4
Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study. Christ ER, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):307–16
Androgen replacement in women: a commentary. Davis S. **J Clin Endocrinol Metab** 1999 Jun;84(6):1886–91 (48 ref.)
Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Drake WM, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3913–9
Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. Ferretti E, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):924–9
Dehydroepiandrosterone replacement in aging humans.

Flynn MA, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1527–33

Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. Janssen YJ, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):279–84

Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study [see comments] Ranke MB, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1174–83. Comment in: J Clin Endocrinol Metab 1999 Apr;84(4):1172–3.

A mathematical model for predicting growth response to growth hormone replacement therapy—a useful clinical tool or an intellectual exercise? [editorial; comment] Rosenbloom AL. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1172–3. Comment on: J Clin Endocrinol Metab 1999 Apr;84(4):1174–83.

Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. Serri O, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):58–63

Growth hormone replacement therapy in the elderly with hypothalamic–pituitary disease: a dose–finding study. Toogood AA, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):131–6

Trading one "dangerous dogma" for another? Thyroid hormone treatment of the "euthyroid sick syndrome" [letter; comment] Wartofsky L, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1759–60. Comment on: J Clin Endocrinol Metab 1999 Jan;84(1):151–64.

Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. Weintraub M, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2532–6

Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. Chlebowski RT, et al. **J Clin Oncol** 1999 Jan;17(1):130–42

Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. Fleishaker JC, et al. **J Clin Pharmacol** 1999 Mar;39(3):260–7

Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. Reichenbach JR, et al. **J Comput Assist Tomogr** 1999 May–Jun;23(3):407–13

Insulin sensitivity in growth hormone (GH)–deficient adults and effect of GH replacement therapy. Alford FP, et al. **J Endocrinol Invest** 1999;22(5 Suppl):28–32

Dynamics of lipoprotein metabolism in adult growth hormone deficiency. Christ ER, et al. **J Endocrinol Invest** 1999;22(5 Suppl):16–21 (23 ref.)

The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH–deficient patients. Deijen JB, et al. **J Endocrinol Invest** 1999;22(5 Suppl):127–36 (54 ref.)

Determinants of circulating insulin–like growth factor–I. Hall K, et al. **J Endocrinol Invest** 1999;22(5 Suppl):48–57 (58 ref.)

Gender difference in growth hormone response in adults. Johansson AG. **J Endocrinol Invest** 1999;22(5 Suppl):58–60 (22 ref.)

Long–term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults. Johnston DG, et al. **J Endocrinol Invest** 1999;22(5 Suppl):37–40 (19 ref.)

Two hot topics in the field of GH therapy: quality of life in hypopituitary adults, and clinical implications of the somatopause. Report from an interactive discussion. Jørgensen JO. **J Endocrinol Invest** 1999;22(5 Suppl):150–6 (26 ref.)

Is the somatopause an indication for growth hormone replacement? Savine R, et al. **J Endocrinol Invest** 1999;22(5 Suppl):142–9 (49 ref.)

The somatopause is no indication for growth hormone therapy. von Werder K. **J Endocrinol Invest** 1999;22(5 Suppl):137–41 (20 ref.)

Dehydroepiandrosterone replacement in elderly individuals: still waiting for the proof of beneficial effects on mood or memory [letter; comment] Wolf OT, et al. **J Endocrinol Invest** 1999 Apr;22(4):316. Comment on: J Endocrinol Invest 1998 Sep;21(8):544.

Co–administration of an ACE–inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. Koch B, et al. **J Hum Hypertens** 1999 May;13(5):337–42

Hormone replacement for disabilities and diseases of aging. Dwivedi RN. **J Indian Med Assoc** 1998 May;96(5):139–40 (6 ref.)

Enhancement of post–ischemic myocardial function by chronic 17 beta –estradiol treatment: role of alterations in glucose metabolism. Fraser H, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1539–49

The effect of sex hormone replacement therapy on behavior problems and moods in adolescents with delayed puberty. Susman EJ, et al. **J Pediatr** 1998 Oct;133(4):521–5

Hormonal replacement therapy with HCG and HU–FSH in thalassaemic patients affected by hypogonadotropic hypogonadism. Cisternino M, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:885–90

Experience with low–dose replacement therapy in the initial management of severe pediatric acquired primary hypothyroidism. Slyper AH, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug;11(4):543–7

Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. Morgan TM, et al. **J Pharm Sci** 1998 Oct;87(10):1226–8

Hormone replacement therapy and cardioprotection in the elderly [see comments] Pines A, et al. **J R Soc Med** 1998 Sep;91(9):475–8 (33 ref.). Comment in: J R Soc Med 1998 Nov;91(11):611.

Effects of estrogens, progestins, and androgens on coronary vasomotion and atherosclerosis. Clarkson TB. **J Reprod Med** 1998 Aug;43(8 Suppl):741–5 (34 ref.)

Estrogen and estrogen–androgen replacement in postmenopausal women dissatisfied with estrogen–only therapy. Sexual behavior and neuroendocrine responses. Sarrel P, et al. **J Reprod Med** 1998 Oct;43(10):847–56

Broadened spectrum of menopausal symptom relief. Sarrel PM. **J Reprod Med** 1998 Aug;43(8 Suppl):734–40 (29 ref.)

Plasma androgens in women. Vermeulen A. **J Reprod Med** 1998 Aug;43(8 Suppl):725–33 (61 ref.)

The therapeutic use of androgens in women. Davis SR. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):177–84 (66 ref.)

Progestins in the menopause. Sitruk–Ware R. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):185–93 (61 ref.)

Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health. Curtis MG. **J Womens Health** 1999 Apr;8(3):321–33 (151 ref.)

Office of Research on Women's Health Seminar Series—Part I. Finding the answers on hormone replacement therapy. Meisler JG. **J Womens Health** 1999 Jan–Feb;8(1):51–7

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Banks E, et al. **JAMA** 1999 Mar 3;281(9):794; discussion 796–7. Comment on: JAMA 1998 Aug 19;280(7):605–13.

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Heckbert SR, et al. **JAMA** 1999 Mar 3;281(9):795–6; discussion 796–7. Comment on: JAMA 1998 Aug 19;280(7):605–13. Comment on: JAMA 1998 Aug 19;280(7):650–2.

Primary prevention of postmenopausal osteoporosis. Levinson W, et al. **JAMA** 1998 Dec 2;280(21):1821–2

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Ong PJ, et al. **JAMA** 1999 Mar 3;281(9):794–5; discussion 796–7. Comment on: JAMA 1998 Aug 19;280(7):605–13.

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Pan CX, et al. **JAMA** 1999 Mar 3;281(9):794; discussion 796–7. Comment on: JAMA 1998 Aug 19;280(7):605–13.

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Sullivan JL. **JAMA** 1999 Mar 3;281(9):795; discussion 796–7. Comment on: JAMA 1998 Aug 19;280(7):605–13. Comment on: JAMA 1998 Aug 19;280(7):650–2.

Hormone replacement therapy for secondary prevention of coronary heart disease [letter; comment] Vandenbroucke JP. **JAMA** 1999 Mar 3;281(9):796; discussion 797. Comment on: JAMA 1998 Aug 19;280(7):605–13. Comment on: JAMA 1998 Aug 19;280(7):650–2.

Hormone replacement therapy. Clinical Synthesis Panel on HRT [published erratum appears in Lancet 1999 Sep 4;354(9181):870] **Lancet** 1999 Jul 10;354(9173):152–5

Screening mammography for women starting hormone replacement therapy [letter] Achuthan R, et al. **Lancet** 1999 May 29;353(9167):1855

Attenuation of heart–rate variability in postmenopausal women on progestin–containing hormone replacement therapy [letter] [see comments] Christ M, et al. **Lancet** 1999 Jun 5;353(9168):1939–40. Comment in: Lancet 1999 Jul 17;354(9174):256.

Could institutional clinical trials exist in Europe? EUTERP Pilot Study Group. European Trial of Estrogen/progestin Replacement treatment in Post–menopause [see comments] Cornu C, et al. **Lancet** 1999 Jan 2;353(9146):63–4. Comment in: Lancet 1999 Mar 13;353(9156):929–30. Comment in: Lancet 1999 Mar 13;353(9156):930.

Specific binding and effects of dehydroepiandrosterone sulfate (DHEA–S) on skeletal muscle cells: possible implication for DHEA–S replacement therapy in patients with myotonic dystrophy. Tsuji K, et al. **Life Sci** 1999; 65(1):17–26

Hormone replacement therapy and urinary prostaglandins in postmenopausal women. Akgül C, et al. **Maturitas** 1998 Sep 20;30(1):79–83

Tibolone: a review. Albertazzi P, et al. **Maturitas** 1998 Nov 16;30(3):295–305 (57 ref.)

Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). Alwers R, et al. **Maturitas** 1999 May 31;32(1):41–50

Hormone replacement therapy in women treated for gynaecological malignancy. Burger CW, et al. **Maturitas** 1999 Jun 21;32(2):69–76 (34 ref.)

Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. de Aloysio D, et al. **Maturitas** 1998 Jun 17; 29(3):261–4

Menopause and the central nervous system: intervention options. Genazzani AR, et al. **Maturitas** 1999 Jan 4; 31(2):103–10 (88 ref.)

Hormone replacement therapy in postmenopausal women: carotid intima–media thickness and 3–D volumetric plaque quantification. Griewing B, et al. **Maturitas** 1999 May 31; 32(1):33–40

Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women. Gruber DM, et al. **Maturitas** 1998 Jun 17; 29(3):253–9

HRT and Vit D in prevention of non–vertebral fractures in postmenopausal women; a 5 year randomized trial. Komulainen MH, et al. **Maturitas** 1998 Nov 30;31(1):45–54

The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Mosekilde L, et al. **Maturitas** 1999 Mar 15; 31(3):207–19

Climacteric skin ageing of the face—a prospective longitudinal comparative trial on the effect of oral hormone replacement therapy. Piérard–Franchimont C, et al. **Maturitas** 1999 Jun 21;32(2):87–93

The effects of postmenopausal hormone replacement therapy on sympathetic skin response. Sahiner T, et al. **Maturitas** 1998 Sep 20;30(1):85–8

The effect of hormone replacement therapy on carotid arteries: measurement with a high frequency ultrasound system. Sator MO, et al. **Maturitas** 1998 Sep 20;30(1):63–8

Post–menopausal women and osteoporosis: available choices for maintenance of skeletal health. Termine JD, et al. **Maturitas** 1998 Nov 16;30(3):241–5 (42 ref.)

"Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women" by S.A.A. Beresford, N.S. Weiss, L.F. Voigt, B. McKnight. Published in: Lancet 1997; 349: 458–61. Wren BG, et al. **Maturitas** 1998 Sep 20;30(1):89–93

Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997 [letter] Peverill RE, et al. **Med J Aust** 1999 Sep 6;171(5):275

Impotence, androgens and prostate cancer [letter] Sandeman TF. **Med J Aust** 1998 Oct 5;169(7):400

Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Mulder JE. **Med Pediatr Oncol** 1999 Jul;33(1):46–52 (59 ref.)

Perceived barriers and recommendations concerning hormone replacement therapy counseling among primary care providers. Anderson LA, et al. **Menopause** 1999 Summer;6(2):161–6

Postmenopausal estrogen therapy and selected (less–often–considered) disease outcomes. Barrett–Connor E. **Menopause** 1999 Spring;6(1):14–20 (68 ref.)

Utilizing routine sonohysterography to detect intrauterine pathology before initiating hormone replacement therapy. Cohen MA, et al. **Menopause** 1999 Spring;6(1):68–70

Increased serum levels of growth hormone and insulin–like growth factor–I associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Fonseca E, et al. **Menopause** 1999 Spring;6(1):56–60

Hormone replacement therapy in perimenopause: effect of a low dose oral contraceptive preparation on bone quantitative ultrasound characteristics. Gambacciani M, et al. **Menopause** 1999 Spring;6(1):43–8

Gender difference in the response of growth hormone (GH)–deficient adults to GH therapy. Hayes FJ, et al. **Metabolism** 1999 Mar;48(3):308–13

Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women. Weintraub M, et al. **Metabolism** 1999 Sep;48(9):1193–6

The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine–lowering effect of hormone replacement therapy. Brown CA, et al. **Mol Genet Metab** 1999 May;67(1):43–8

Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow. Cacciatore B, et al. **Obstet Gynecol** 1998 Oct; 92(4 Pt 1):563–8

Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. van de Weijer PH, et al. **Obstet Gynecol** 1999 Apr;93(4):551–7

Estrogen may reduce colorectal cancer risk in postmenopausal women [news] **Oncology (Huntingt)** 1999 Jan;13(1):138

Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 1: Defining the problem. Proceedings of a conference held at the Boar's Head Inn Charlottesville, Virginia. September 21–23, 1997. **Oncology (Huntingt)** 1999 Jan;13(1):109–15, 119–20, 123–4 passim

Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: Hormone replacement therapy and breast cancer. **Oncology (Huntingt)** 1999 Feb; 13(2):245–8, 251–4, 257 passim

Why different forms of testosterone? Whitaker MD. **Postgrad Med** 1999 Jun;105(7):23

How long should a woman take HRT? Hart R, et al. **Practitioner** 1998 Feb;242(1583):114–6, 119

Serum leptin concentrations in response to acute exercise in postmenopausal women with and without hormone replacement therapy. Kraemer RR, et al. **Proc Soc Exp Biol Med** 1999 Jul;221(3):171–7

1998 Curt P. Richter Award. The effect of hormone

replacement therapy on cognitive function in elderly women. Hogervorst E, et al. **Psychoneuroendocrinology** 1999 Jan;24(1):43–68

Estrogen/hormone replacement therapy and the etiology of breast cancer. Pritchard KI. **Recent Results Cancer Res** 1998;152:22–31 (29 ref.)

Women's health. Lautenbach GL, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):539–65 (111 ref.)

Restriction as a method for reducing bias in the estimation of direct effects. Joffe MM, et al. **Stat Med** 1998 Oct 15; 17(19):2233–49

Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause--influence of hormone replacement therapy. Estellés A, et al. **Thromb Haemost** 1999 Jan; 81(1):104–10

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Curran MJ, et al. **Urology** 1999 Feb;53(2):423–4

Predictors of quality of life in women: hormone therapy self-efficacy and health-promoting behaviors. Ali NS. **Women Health** 1999;29(2):69–79

Effects of an intensive diet and exercise program on lipids in postmenopausal women. Barnard RJ, et al. **Womens Health Issues** 1999 May-Jun;9(3):155–61

[A central nerve conduction study in hypothyroidism: before and after thyroxine replacement] Lai CL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Dec; 14(12):743–50 (Eng. Abstr.) **(Chi)**

[Hormone replacement for pregnancy in functionally agonadal women after transfer of thawed embryos in the in vitro fertilization program--problems of placental incompetence] Mardešić T, et al. **Ceska Gynekol** 1998 Oct; 63(5):402–5 (Eng. Abstr.) **(Cze)**

[Estrogen and breast cancer (letter; comment)] Marckmann A. **Ugeskr Laeger** 1999 Mar 1;161(9):1287–8. Comment on: Ugeskr Laeger 1998 Nov 23;160(48):6954–7. **(Dan)**

[Post-menopausal hormone substitution and ischemic heart disease] Sørensen MB, et al. **Ugeskr Laeger** 1999 Feb 1; 161(5):607–8 **(Dan)**

[Hormone replacement therapy: practical recommendations] Gaspard U, et al. **Rev Med Liege** 1999 May;54(5):481–8 (3 ref.) (Eng. Abstr.) **(Fre)**

[Postmenopausal osteoporosis in women] Reginster JY, et al. **Rev Med Liege** 1999 Apr;54(4):335–40 (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy and breast cancer] Dobashi K. **Gan To Kagaku Ryoho** 1999 Jun;26(7):871–6 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of thyroid hormone replacement therapy on nocturnal apnea in elderly patients with hypothyroidism] Teramoto S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul; 36(7):590–4 (Eng. Abstr.) **(Jpn)**

[The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men] Rabijewski M, et al. **Pol Arch Med Wewn** 1998 Sep; 100(3):212–21 (Eng. Abstr.) **(Pol)**

[Hormonal therapy (HRT) in menopause] Ciszek-Doniec V. **Przegl Lek** 1999;56(4):308–12 (29 ref.) (Eng. Abstr.) **(Pol)**

[Replacement hormonal therapy: effects on ECG parameters in postmenopausal women] Zatikian EP, et al. **Ter Arkh** 1998;70(10):33–7 (Eng. Abstr.) **(Rus)**

[Bone mineral density in patients on long-term therapy with levothyroxine] Koršić M, et al. **Lijec Vjesn** 1998 May; 120(5):103–5 (Eng. Abstr.) **(Scr)**

[Difficult decisions on estrogen treatment of women with coronary diseases (letter)] al-Khalili F. **Lakartidningen** 1999 May 5;96(18):2196 **(Swe)**

[Gestagens have become of great clinical value. Disadvantages are irregular bleeding and bad temper] Landgren BM. **Lakartidningen** 1999 Mar 31;96(13):1578–81 (27 ref.) **(Swe)**

[Osteoporosis is prevented by physical activity, calcium and hormone supplementation] Piehl-Aulin K, et al. **Lakartidningen** 1999 Jan 20;96(3):210–4 (103 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Drug-related Churg-Strauss syndrome? Somogyi A, et al. **Adverse Drug React Toxicol Rev** 1998 Jun-Sep; 17(2-3):63–74 (41 ref.)

Low fibrinogen level: A predisposing factor for venous thromboembolic events with hormone replacement therapy. Whiteman MK, et al. **Am J Hematol** 1999 Aug; 61(4):271–3

Postmenopausal hormone therapy increases risk of deep vein thrombosis and pulmonary embolism [letter; comment] Ambrus JL. **Am J Med** 1999 Jul;107(1):104. Comment on: Am J Med 1998 Jul;105(1):41–3.

The effect of thyroid hormone on skeletal integrity. Greenspan SL, et al. **Ann Intern Med** 1999 May 4; 130(9):750–8 (81 ref.)

Hormone replacement therapy and risk of epithelial ovarian cancer. Purdie DM, et al. **Br J Cancer** 1999 Oct; 81(3):559–63

The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group. Connelly PW, et al. **Can J Cardiol** 1999 Apr; 15(4):419–27

A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. La Vecchia C, et al. **Cancer Causes Control** 1999 Apr;10(2):157–66

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Persson I, et al. **Cancer Causes Control** 1999 Aug;10(4):253–60

Contact allergy to a testosterone patch. Buckley DA, et al. **Contact Dermatitis** 1998 Aug;39(2):91–2

Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. MacKie RM. **Curr Opin Oncol** 1999 Mar;11(2):129–31 (15 ref.)

Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Oger E, et al. **Drugs Aging** 1999 Jan;14(1):55–61 (38 ref.)

The adverse effects of hormone replacement therapy. Tavani A, et al. **Drugs Aging** 1999 May;14(5):347–57 (99 ref.)

Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Rohan TE, et al. **Eur J Cancer Prev** 1999 Apr;8(2):123–30

Transsexualism and osteoporosis. Schlatterer K, et al. **Exp Clin Endocrinol Diabetes** 1998;106(4):365–8

Hormone replacement therapy: reassessing the risks and benefits. Shoupe D. **Hosp Pract (Off Ed)** 1999 Aug 15; 34(8):97–103, 107–8, 113–4

The effects of hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women. Taskin O, et al. **Hum Reprod** 1998 Sep;13(9):2399–401

Effects of progestins on cardiovascular diseases: the haemostatic system [see comments] Winkler UH. **Hum Reprod Update** 1999 May-Jun;5(3):200–4 (51 ref.). Comment in: Hum Reprod Update 1999 May-Jun;5(3):189–90.

Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Magnusson C, et al. **Int J Cancer** 1999 May 5;81(3):339–44

Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Negri E, et al. **Int J Cancer** 1999 Mar 15;80(6):848–51

Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Kennedy MM, et al. **Int J Gynecol Pathol** 1999 Apr;18(2):130–7

Hormone replacement therapy and breast cancer: revisiting the issues. DeGregorio MW, et al. **J Am Pharm Assoc (Wash)** 1998 Nov-Dec;38(6):738–44; quiz 744–6 (51 ref.)

Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. Borson-Chazot F, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1329–33

Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. Waddell TK, et al. **J Hypertens** 1999 Mar;17(3):413–8

Is there an association between hormone replacement therapy and breast cancer? Creasman WT. **J Womens Health** 1998 Dec;7(10):1231–46 (72 ref.)

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484] **Lancet** 1997 Oct 11;350(9084):1047–59. Comment in: Lancet 1997 Oct 11;350(9084):1042–3. Comment in: Lancet 1997 Nov 29;350(9091):1627–8. Comment in: ACP J Club 1998 May-Jun;128(3):72.

Time to act to avoid drug-safety scares [editorial; comment] **Lancet** 1997 Oct 11;350(9084):1041. Comment on: Lancet 1997 Oct 11;350(9084):1043–4.

Hormone replacement therapy in postmenopausal women and cardiovascular risk [letter; comment] Channer KS, et al. **Lancet** 1999 May 1;353(9163):1528. Comment on: Lancet 1998 Dec 19-26;352(9145):1965–9. Comment on: Lancet 1999 Feb 20;353(9153):674–5.

Hormone replacement therapy and heart-rate variability [letter; comment] Hayward CS, et al. **Lancet** 1999 Jul 17; 354(9174):256. Comment on: Lancet 1999 Jun 5;(9168):1939–40.

ICRF: from mayhem to meltdown. Imperial Cancer Research Fund [see comments] Horton R. **Lancet** 1997 Oct 11; 350(9084):1043–4. Comment in: Lancet 1997 Oct 11;350(9084):1041. Comment in: Lancet 1997 Nov 29;350(9091):1626; discussion 1627. Comment in: Lancet 1997 Nov 29;350(9091):1626–7. Comment in: Lancet 1997 Nov 29;350(9091):1627.

Breast cancer and hormone replacement therapy [comment] LaCroix AZ, et al. **Lancet** 1997 Oct 11;350(9084):1042–3 . Comment on: Lancet 1997 Oct 11;350(9084):1047–59.

Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Björn I, et al. **Maturitas** 1999 Jun 21;32(2):77–86

Endometrial cancer after combined hormone replacement therapy. Gruber DM, et al. **Maturitas** 1999 Mar 15; 31(3):237–40

Women's expectations and acceptance of cyclic induced HRT bleeds. van de Weijer PH, et al. **Maturitas** 1998 Nov 16;30(3):257–63

Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause. Salmon RJ, et al. **Oncol Rep** 1999 May-Jun;6(3):699–703

Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Waselenko JK, et al. **Semin Thromb Hemost** 1998;24 Suppl 1:33–9 (48 ref.)

Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial. Scarabin PY, et al. **Thromb Haemost** 1999 May;81(5):673–5

Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. van Baal WM, et al. **Thromb Haemost** 1999 Jun; 81(6):925–8

[Addisonian crisis provoked by levothyroxine substitution therapy] Dawson L, et al. **Ned Tijdschr Geneeskd** 1998 Aug 8;142(32):1826–9 (Eng. Abstr.) **(Dut)**

[Breast cancer and hormone replacement therapy] Küng F, et al. **Schweiz Med Wochenschr** 1999 Apr 17;129(15):590–4 (32 ref.) (Eng. Abstr.) **(Ger)**

[Hormonal aspects of nipple cancer] Niwińska A. **Ginekol Pol** 1997 Nov;68(11):558–62 (Eng. Abstr.) **(Pol)**

CONTRAINDICATIONS

Menopause: when hormone replacement therapy is not an option. Part II. Waldman TN. **J Womens Health** 1998 Aug; 7(6):673–83 (41 ref.)

[Hormone replacement therapy (HRT) in peri- and postmenopause. Is it also allowed after treatment of breast carcinoma?] Graf H, et al. **Zentralbl Chir** 1998;123 Suppl 5:151–5 (Eng. Abstr.) **(Ger)**

ECONOMICS

The impact of hormone replacement therapy on quality of life and willingness to pay [letter; comment] Morris EP. **Br J Obstet Gynaecol** 1999 Jun;106(6):614. Comment on: Br J Obstet Gynaecol 1997 Oct;104(10):1191–5.

METHODS

Transvaginal ultrasonography and endometrial histology in peri- and postmenopausal women on hormone replacement therapy. Lindgren R, et al. **Br J Obstet Gynaecol** 1999 May; 106(5):421–6

Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma [letter] Deshpande H, et al. **Cancer J Sci Am** 1999 Jan-Feb;5(1):52–3

Unexpected pregnancy during hormone-replacement therapy in a woman with elevated follicle-stimulating hormone levels and amenorrhea. Laml T, et al. **Gynecol Endocrinol** 1999 Apr;13(2):89–92

A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Archer DF, et al. **Menopause** 1999 Fall;6(3):201–8

Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials. Gitlin N, et al. **Menopause** 1999 Fall;6(3):216–24

Effect of raloxifene on the endometrium: will this be the ultimate key to its utilization? [editorial; comment] Goldstein SR. **Menopause** 1999 Fall;6(3):183–5 (17 ref.). Comment on: Menopause 1999 Fall;6(3):188–95.

Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study [see comments] Keefe DL, et al. **Menopause** 1999 Fall;6(3):196–200. Comment in: Menopause 1999 Fall;6(3):186–7.

Hormone replacement therapy for African American women: missed opportunities for effective intervention. Nicholson WK, et al. **Menopause** 1999 Summer;6(2):147–55 (105 ref.)

Blood flow in the internal carotid and middle cerebral arteries: effects of continuous oral conjugated equine estrogens administration with monthly progestogen supplementation on postmenopausal women. Penotti M, et al. **Menopause** 1999 Fall;6(3):225–9

Sleep apnea in menopause [editorial; comment] Regestein QR. **Menopause** 1999 Fall;6(3):186–7. Comment on: Menopause 1999 Fall;6(3):196–200.

[Hormone replacement therapy in the prevention of osteoporosis. Evolution of therapeutic methods] Trémollières F, et al. **Presse Med** 1999 Jun 19; 28(22):1188–94 (53 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Medical uncertainty and practice variation get personal: what should I do about hormone replacement therapy? [editorial; comment] Daley J. **Ann Intern Med** 1999 Apr 6; 130(7):602–4. Comment on: Ann Intern Med 1999 Apr 6;130(7):545–53.

Medical and psychological aspects of hormone replacement therapy in postmenopausal women: points of view from a cardiologist and a psychotherapist [editorial] Cohn PF, et al. **Clin Cardiol** 1998 Dec;21(12):875–7

Towards understanding women's decisions to cease HRT. Bond M, et al. **J Adv Nurs** 1999 Apr;29(4):852–8

Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Wolf OT, et al. **Psychoneuroendocrinology** 1998 Aug;23(6):617–29

HORMONE REPLACEMENT THERAPY

STANDARDS

[Consensus 'diagnosis of short stature in children.' National Organization for Quality Assurance in Hospitals] de Muinck Keizer-Schrama SM. **Ned Tijdschr Geneeskd** 1998 Nov 14;142(46):2519-25 (8 ref.) (Eng. Abstr.) **(Dut)**

[Is there a need for treatment in subclinical hypo- and hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369-73 (15 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Are long-term hormone replacement therapy users different from short-term and never users? Buist DS, et al. **Am J Epidemiol** 1999 Feb 1;149(3):275-81

Hormone replacement therapy, inflammation, and hemostasis in elderly women. Cushman M, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):893-9

Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhône programme. Séradour B, et al. **J Med Screen** 1999;6(2):99-102

Symptom responses of midlife Filipina Americans [see comments] Berg JA, et al. **Menopause** 1999 Summer; 6(2):115-21. Comment in: Menopause 1999 Summer;6(2):90-1.

Helping women achieve long-term continuance of estrogen replacement therapy (ERT) and hormone replacement therapy (HRT) [letter] Keenan NL, et al. **Menopause** 1999 Summer;6(2):179-80 (6 ref.)

Provider attitudes and self-reported behaviors related to hormone replacement therapy. Rolnick SJ, et al. **Menopause** 1999 Fall;6(3):257-63

TRENDS

Hormone replacement therapy: the perspectives for the 21st century. Genazzani AR, et al. **Maturitas** 1999 May 31; 32(1):11-7 (73 ref.)

Trends in the prescription of psychotropic drugs and hormone substitutes in Austria. Sator MO, et al. **Wien Klin Wochenschr** 1999 May 21;111(10):402-5

UTILIZATION

Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Grodstein F, et al. **Am J Med** 1999 May;106(5):574-82

Use of hormone replacement therapy by postmenopausal women in the United States [see comments] Keating NL, et al. **Ann Intern Med** 1999 Apr 6;130(7):545-53. Comment in: Ann Intern Med 1999 Apr 6;130(7):602-4.

Ethnic differences in use of hormone replacement therapy: community based survey. Harris TJ, et al. **BMJ** 1999 Sep 4;319(7210):610-1

Is there sufficient evidence for encouraging widespread use of HRT to prevent disease? [letter; comment] Lakhani MK. **Br J Gen Pract** 1998 Aug;48(433):1525. Comment on: Br J Gen Pract 1998 Feb;48(427):951-2.

Hormone replacement therapy: a survey of Ontario physicians' prescribing practices. Elinson L, et al. **CMAJ** 1999 Sep 21;161(6):695-8

Recent patterns of hormone replacement therapy use in a large managed care organization. Whitlock EP, et al. **J Womens Health** 1998 Oct;7(8):1017-26

Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997. MacLennan AH, et al. **Med J Aust** 1999 Jun 7; 170(11):524-7

Hormone replacement therapy awareness in a biracial cohort of women aged 50-54 years. MacDougall LA, et al. **Menopause** 1999 Fall;6(3):251-6

Why menopausal women do not want to take hormone replacement therapy. Rabin DS, et al. **Menopause** 1999 Spring;6(1):61-7

Racial differences in hormone replacement therapy prescriptions. Marsh JV, et al. **Obstet Gynecol** 1999 Jun; 93(6):999-1003

HORMONE REPLACEMENT THERAPY, POST-MENOPAUSAL see **ESTROGEN REPLACEMENT THERAPY**

HORMONES

see related
HORMONE ANTAGONISTS
RECEPTORS, CELL SURFACE

Hormones, autacoids, neurotransmitters and growth factors. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):105-33

Hormone abuse in sport. Russell-Jones DL. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:63-5 (14 ref.)

Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Gerhard I, et al. **Hum Reprod Update** 1998 May-Jun;4(3):301-9 (56 ref.)

Topological transition of the parametric expression site of tumor suppressor inactivation as a marker evidence of environmental hormone-oriented cancer risk increase. Kodama M, et al. **Int J Mol Med** 1999 Aug;4(2):153-61

Vitamins and Hormones, cumulative subject index, volumes 30-54. **Vitam Horm** 1999;56:1-157

[Hereditary risks of breast cancer. Interaction of genetic factors and hormonal factors] Plu-Bureau G, et al. **Ann Endocrinol (Paris)** 1998;59(6):465-9 (13 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Novel approaches for oral delivery of macromolecules. Fasano A. **J Pharm Sci** 1998 Nov;87(11):1351-6 (53 ref.)

ADVERSE EFFECTS

Possible implication of environmental hormones in the recent risk increase of cancers of the skin and the liver, but not of the female breast worldwide. Kodama M, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):789-98

AGONISTS

New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Nishikawa J, et al. **Toxicol Appl Pharmacol** 1999 Jan 1;154(1):76-83

ANALOGS & DERIVATIVES see HORMONES, SYNTHETIC

ANALYSIS

Proceedings of the 3rd International Symposium on Hormone and Veterinary Drug Residue Analysis. Bruges, Belgium, 2-5 June 1998. **Analyst** 1998 Dec;123(12):149N, 2401-915

New database on hormone and veterinary drug residue determination in animal products. Van Eeckhout NJ, et al. **Analyst** 1998 Dec;123(12):2423-7

Expression and localisation of stanniocalcin 1 in rat bladder, kidney and ovary. Worthington RA, et al. **Electrophoresis** 1999 Jul;20(10):2071-6

International Symposium on Hormone Disrupters [news] **Jpn J Clin Oncol** 1998 Oct;28(10):649

ANTAGONISTS & INHIBITORS see HORMONE ANTAGONISTS

BIOSYNTHESIS

Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Miller WL. **Clin Perinatol** 1998 Dec;25(4):799-817, v (104 ref.)

Regulation of p75kip2 and steroidogenic enzyme mRNA during adrenal regeneration. Fraticelli AI, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):975-6

Developmental expression of the peripheral-type benzodiazepine receptor and the advent of steroidogenesis in rat adrenal glands. Zilz A, et al. **Endocrinology** 1999 Feb;140(2):859-64

An update on the mechanism of action of the Steroidogenic Acute Regulatory (StAR) protein. Stocco DM. **Exp Clin Endocrinol Diabetes** 1999;107(4):229-35 (53 ref.)

Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. Baudin E, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):69-75

Paracrine regulation of human placenta: control of hormonogenesis. Petraglia F, et al. **J Reprod Immunol** 1998 Aug;39(1-2):221-33 (46 ref.)

Molecular medicine of steroid hormone biosynthesis. Biason-Lauber A. **Mol Aspects Med** 1998 Jun; 19(3):155-220 (160 ref.)

The significance of dietary boron, with particular reference to athletes. Naghii MR. **Nutr Health** 1999;13(1):31-7 (15 ref.)

Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Mensah-Nyagan AG, et al. **Pharmacol Rev** 1999 Mar;51(1):63-81 (298 ref.)

[Steroidogenesis in epithelial cells of rat epididymis] Wiszniewska B. **Ann Acad Med Stetin** 1998;Suppl 40:1-66 (263 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Vasopressor hormone response following mesenteric traction during major abdominal surgery. Brinkmann A, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):948-56

Lack of association of anabolic hormone status and muscle strength with regional and whole body bone mineral density in healthy men aged 60-79 years. Taaffe DR, et al. **Aging (Milano)** 1999 Feb;11(1):4-11

Effect of alcohol consumption on adult and aged bone: composition, morphology, and hormone levels of a rat animal model. Sampson HW, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1746-53

Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Adler GK, et al. **Am J Med** 1999 May; 106(5):534-43

Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. Kraus MD, et al. **Am J Med** 1999 Aug; 107(2):169-76 (31 ref.)

Reproductive hormones and aminoterminal propeptide of type III procollagen in serum as early markers of pelvic pain during late pregnancy. Kristiansson P, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):128-34

Bone and hormonal changes induced by skeletal unloading in the mature male rat. Dehority W, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E62-9

Counterregulatory hormones oscillate during steady-state hypoglycemia. Genter P, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):E821-9

Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia. Paramore DS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E872-81

Effect of fentanyl on morphine levels in the brain in rats receiving intracerebroventricular injection of TNF-alpha. Shirouzu Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E635-40

Sex differences and similarities of hormonal alterations in patients with anorexia nervosa. Tomova A, et al. **Andrologia** 1999 May;31(3):143-7

Endocrine and testicular changes in a short-day seasonally breeding bird, the emu (Dromaius novachollandiae), in southwestern Australia. Malecki IA, et al. **Anim Reprod Sci** 1998 Oct;53(1-4):143-55

Effects of post-ovulatory food deprivation on oviductal sperm concentration, embryo development and hormonal profiles in the pig. Mburu JN, et al. **Anim Reprod Sci** 1998 Sep 11;52(3):221-34

Hormonal factors in the development of differences in strength between boys and girls during adolescence: a longitudinal study. Round JM, et al. **Ann Hum Biol** 1999 Jan-Feb;26(1):49-62

Endocrine function in Lambert-Eaton myasthenic syndrome [letter] Maddison P, et al. **Ann Neurol** 1999 Mar;45(3):414-5

Endocrine status and LBNP-induced hormone changes during a 438-day spaceflight: a case study. Hinghofer-Szalkay HG, et al. **Aviat Space Environ Med** 1999 Jan;70(1):1-5

Behavioural and hormonal differences between two Lewis rat lines. Stöhr T, et al. **Behav Brain Res** 1999 Jun; 101(2):163-72

Performance and physiological variables in broiler chicken lines differing in susceptibility to the ascites syndrome: 2. Effect of ambient temperature on partial efficiencies of protein and fat retention and plasma hormone concentrations. Buys N, et al. **Br Poult Sci** 1999 Mar; 40(1):140-4

Decreased spermatogenic and androgenic testicular functions in adult rats submitted to immobilization-induced stress from prepuberty. Almeida SA, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1443-8

Response to surgical stress in elderly patients and Alzheimer's disease. Kudoh A, et al. **Can J Anaesth** 1999 Mar; 46(3):247-52

Acute and chronic hormonal responses to resistance training designed to promote muscle hypertrophy. McCall GE, et al. **Can J Appl Physiol** 1999 Feb;24(1):96-107

Cellular responses to moderate and heavy exercise. Nehlsen-Cannarella SL. **Can J Physiol Pharmacol** 1998 May;76(5):485-9 (58 ref.)

Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Anand I, et al. **Cardiovasc Drugs Ther** 1998 Jul;12(3):291-9

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Baruch L, et al. **Circulation** 1999 May 25;99(20):2658-64

The systemic stress response to thermal injury in children. Sedowofia K, et al. **Clin Endocrinol (Oxf)** 1998 Sep; 49(3):335-41

Hormones, sex ratios and juvenile rheumatoid arthritis [letter] James WH. **Clin Exp Rheumatol** 1999 May-Jun;17(3):392-3

Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Levy CJ, et al. **Diabetes Care** 1998 Aug;21(8):1330-8

Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Matyka KA, et al. **Diabetes Care** 1999 Jul;22(7):1144-50

The effects of equine somatotropin (eST) on follicular development and circulating plasma hormone profiles in cyclic mares treated during different stages of the estrous cycle. Cochran RA, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):57-67

Autonomic and hormonal ictal changes in gelastic seizures from hypothalamic hamartomas. Cerullo A, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 107(5):317-22

Effect of chronic thyroxine treatment on pregnancy in rats: effects on oestrogen, progesterone, prolactin and GH receptors in uterus, liver and mammary gland. Rosato RR, et al. **Endocr Res** 1998 May;24(2):269-84

The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Kiilavuori K, et al. **Eur Heart J** 1999 Mar;20(6):456-64

Hormonal responses to physical training in high-level peripubertal male gymnasts. Daly RM, et al. **Eur J Appl Physiol** 1998 Dec;79(1):74-81

Effect of carbohydrate ingestion and hormonal responses on ratings of perceived exertion during prolonged cycling and running. Utter AC, et al. **Eur J Appl Physiol** 1999 Jul; 80(2):92-9

A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects. Ahokoski O, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):27-34

Endocrine patterns during aging in the common tern (Sterna

hirundo). Nisbet IC, et al. **Gen Comp Endocrinol** 1999 May; 114(2):279–86

Premature ovarian failure. Falsetti L, et al. **Gynecol Endocrinol** 1999 Jun;13(3):189–95

Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Nola M, et al. **Gynecol Oncol** 1999 Mar;72(3):331–6

Evaluation of hypothalamic–pituitary–adrenocortical hormones and inflammatory cytokines in patients with persistent vegetative state. Munno I, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):519–29

Dose–dependence of bacterial lipopolysaccharide (LPS) effects on peak response and time course of the immune–endocrine host response in humans. Vedder H, et al. **Inflamm Res** 1999 Feb;48(2):67–74

Do early–life events permanently alter behavioral and hormonal responses to stressors? Anisman H, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):149–64 (104 ref.)

Hormonal profile of infertile Makkans. Khan ZA, et al. **Int Urol Nephrol** 1998;30(4):499–505

Systemic hormonal, electrolyte, and substrate changes after non–thermal limb injury in children. Rainer TH, et al. **J Accid Emerg Med** 1999 Mar;16(2):104–7

Hormonal responses to consecutive days of heavy–resistance exercise with or without nutritional supplementation. Kraemer WJ, et al. **J Appl Physiol** 1998 Oct;85(4):1544–55

Effects of heavy–resistance training on hormonal response patterns in younger vs. older men. Kraemer WJ, et al. **J Appl Physiol** 1999 Sep;87(3):982–92

Hormonal and metabolic responses to maintained hyperglycemia during prolonged exercise. MacLaren DP, et al. **J Appl Physiol** 1999 Jul;87(1):124–31

Soy isoflavones exert modest hormonal effects in premenopausal women. Duncan AM, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):192–7

Counterregulatory response to hypoglycemia differs according to the insulin delivery route, but does not affect glucose production in normal humans. Lewis GF, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1037–46

Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. Mendonca BB, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):942–5

Endocrine and metabolic evaluation of human immunodeficiency virus–infected patients with evidence of protease inhibitor–associated lipodystrophy. Yanovski JA, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1925–31

Luteolysis during two stages of the estrous cycle: subsequent endocrine profiles associated with radiotelemetrically detected estrus in heifers. Stevenson JS, et al. **J Dairy Sci** 1998 Nov;81(11):2897–903

Hormonal milieu in the maintenance of melasma in fertile women. Hassan I, et al. **J Dermatol** 1998 Aug;25(8):510–2

Three–month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine–metabolic parameters in abdominal obesity. Oleandri SE, et al. **J Endocrinol Invest** 1999 Feb; 22(2):134–40

Hypertriglyceridaemia in mild hypertension: impact on cardiovascular and hormonal reactivity under different stress tests. Scheuch K, et al. **J Hum Hypertens** 1999 Aug; 13(8):533–9

Identical hemodynamic and hormonal responses to 14–day infusions of renin or angiotensin II in conscious rats. Hu L, et al. **J Hypertens** 1998 Sep;16(9):1285–98

Differential effects of antihypertensive drugs on neurohormonal activation: insights from a population–based sample. Schunkert H, et al. **J Intern Med** 1998 Aug;244(2):109–19

Biochemical and hormonal variables in black and white women matched for age and weight [see comments] Aloia JF, et al. **J Lab Clin Med** 1998 Nov;132(5):383–9. Comment in: J Lab Clin Med 1998 Nov;132(5):358–9.

Adrenoceptors mediating the cardiovascular and metabolic effects of alpha–methylnoradrenaline in humans. Schäfers RF, et al. **J Pharmacol Exp Ther** 1999 May;289(2):918–25

Temporal relationships between hormonal and hemodynamic changes in early human pregnancy [published erratum appears in Kidney Int 1999 Mar;55(3):1185] Chapman AB, et al. **Kidney Int** 1998 Dec;54(6):2056–63

Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: a pilot study [see comments] O'Sullivan DA, et al. **Mayo Clin Proc** 1998 Nov;73(11):1035–45. Comment in: Mayo Clin Proc 1998 Nov;73(11):1123–4.

Clinical and hormonal response to general anaesthesia in patients affected by different degrees of mental retardation. Cavaliere F, et al. **Minerva Anestesiol** 1999 Jul–Aug; 65(7–8):499–505

Hormonal profile of patients with Leydig cell tumors: a urologic cause of gynecomastia. Xciarra A, et al. **Minerva Urol Nefrol** 1998 Dec;50(4):225–31 (108 ref.)

Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features [see comments] Anisman H, et al. **Mol Psychiatry** 1999 Mar;4(2):182–8. Comment in: Mol Psychiatry 1999 Mar;4(2):109–11.

Changes in the hormonal concentrations of pregnant rats and their fetuses following multiple exposures to a stressor during the third trimester. Williams MT, et al. **Neurotoxicol Teratol** 1999 Jul–Aug;21(4):403–14

Endocrine changes in postmenopausal women after high–dose danazol therapy. Rigano A, et al. **Panminerva Med** 1999 Jun;41(2):139–42

Stress and self–injurious behavior; hormonal and serotonergic parameters in mentally retarded subjects. Verhoeven WM, et al. **Pharmacopsychiatry** 1999 Jan;32(1):13–20

Endocrine and psychophysiological aspects of human adaptation to the extreme. Farrace S, et al. **Physiol Behav** 1999 Jun;66(4):613–20

Seasonality of meal patterns and hormonal correlates in red deer. Rhind SM, et al. **Physiol Behav** 1998 Nov 15; 65(2):295–302

Hormonal aspects of postpartum depression. Abou–Saleh MT, et al. **Psychoneuroendocrinology** 1998 Jul;23(5):465–75

Late feedback effects of hypothalamic–pituitary–adrenal axis hormones in healthy subjects. Posener JA, et al. **Psychoneuroendocrinology** 1998 May;23(4):371–83

Effects of 17 beta–estradiol on serum hormone concentrations and estrous cycle in female Crl:CD BR rats: effects on parental and first generation rats. Biegel LB, et al. **Toxicol Sci** 1998 Aug;44(2):143–54

Effects of dietary 17 beta–estradiol exposure on serum hormone concentrations and testicular parameters in male Crl:CD BR rats. Cook JC, et al. **Toxicol Sci** 1998 Aug; 44(2):155–68

Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic–releasing hormones. Riedel W, et al. **Z Rheumatol** 1998;57 Suppl 2:81–7

Biochemical and hormonal changes associated with experimental infection of chicks with infectious bursal disease virus. al–Afaleq AI. **Zentralbl Veterinarmed [B]** 1998 Nov;45(9):513–7

[Dynamic changes in the reactivity of the hormonal system regulation with the impact by LBNP sessions in long–term space mission] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1998;32(3):18–23 (Eng. Abstr.) **(Rus)**

[The correction of the immunohormonal disorders in patients with hyperplastic processes in the endometrium] Bespoiasnaia VV. **Lik Sprava** 1999 Apr–May;(3):82–5 (Eng. Abstr.) **(Rus)**

[The hormone level of the blood from the aorta and the coronary sinus in patients with ischemic heart disease under conditions of preoperative stress] Bobrov VA, et al. **Lik Sprava** 1998 Jun;(4):59–63 (Eng. Abstr.) **(Rus)**

[Disorders of hormonal homeostasis in patients with kraurosis and leukoplakia vulvae] Vorob'eva LI, et al. **Lik Sprava** 1998 Aug;(6):82–3 (Eng. Abstr.) **(Rus)**

[The role of an imbalance of sex and calcium–regulating hormones in osteoarthrosis deformans in women] Makarova NI, et al. **Ter Arkh** 1999;71(5):54–6 (Eng. Abstr.) **(Rus)**

[The correction of the hormonal response during the treatment of the dumping syndrome with potable mineral waters] Vladimirov VI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar–Apr; (2):11–4 (Eng. Abstr.) **(Rus)**

[An influence of preop chemotherapy on the hormonal status of the patient with stomach cancer] Vinnyk IuO. **Klin Khir** 1998;(5):22–3 (Eng. Abstr.) **(Ukr)**

[The effect of combined therapy with a salt solution of Poltava bischofite on the clinical status, adaptive hormone level and blood rheology in patients with ischemic heart disease and chronic inflammatory diseases of the liver and gallbladder] Trybrat TA. **Lik Sprava** 1999 Mar;(2):120–3 (Eng. Abstr.) **(Ukr)**

CHEMISTRY

pH–dependent secondary conformation of the peptide hormone leptin in different buffer solutions. Au LC, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1999 Mar; 27(2):119–34

Assignment of disulfide linkages in chum salmon stanniocalcin. Hulova I, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):295–9

Effect of chain length on absorption of biologically active peptides from the gastrointestinal tract. Roberts PR, et al. **Digestion** 1999 Jul–Aug;60(4):332–7

Neurologically active plant compounds and peptide hormones: a chirality connection. Fraternali F, et al. **FEBS Lett** 1999 Apr 9;448(2–3):217–20

An elusive role for glycosylation in the structure and function of reproductive hormones. Willey KP. **Hum Reprod Update** 1999 Jul–Aug;5(4):330–55 (154 ref.)

GENETICS

Molecular cloning of a second human stanniocalcin homologue (STC2). Ishibashi K, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):252–8

XXIII European Symposium on Hormones and Cell Regulation: cell proliferation cascades and protooncogenes. St. Odile near Strasbourg, France, September 25–28, 1998. Bartek J. **Biochim Biophys Acta** 1999 May 31; 1423(3):R69–73

Comparative analysis of mammalian stanniocalcin genes. Varghese R, et al. **Endocrinology** 1998 Nov;139(11):4714–25

Evidence for stanniocalcin gene expression in mammalian bone. Yoshiko Y, et al. **Endocrinology** 1999 Apr; 140(4):1869–74

Identification of INSL5, a new member of the insulin superfamily. Conklin D, et al. **Genomics** 1999 Aug 15; 60(1):50–6

Whole organism physiology and ethnic differences in bone [editorial; comment] Heaney RP. **J Lab Clin Med** 1998 Nov;132(5):358–9 (8 ref.). Comment on: J Lab Clin Med 1998 Nov;132(5):383–9.

Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Chang AC, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):95–9

Molecular cloning and characterization of stanniocalcin–related protein. DiMattia GE, et al. **Mol Cell Endocrinol** 1998 Nov 25;146(1–2):137–40

In situ hybridization analysis of stanniocalcin mRNA expressing cells in the mouse kidney. Yoshiko Y, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):37–40

Genes and hormones may not be identified with "information" [news] Sibatani A. **Riv Biol** 1998;91(3):561–4

IMMUNOLOGY

Preparation of a monoclonal antibody specific for human stanniocalcin. Koide Y, et al. **Biol Pharm Bull** 1998 Dec; 21(12):1352–5

Environmental modulation of the immune system via the endocrine system. Davis SL. **Domest Anim Endocrinol** 1998 Sep;15(5):283–9 (39 ref.)

METABOLISM

Obstructive nephropathy in the pig. Aspects of renal hemodynamics and hormonal changes during acute unilateral ureteral obstruction. Frøkiaer J. **APMIS Suppl** 1998;82:7–48 (259 ref.)

Effect of calf isolation on follicular wave dynamics, gonadotropin and metabolic hormone changes, and interval to first ovulation in beef cows fed either of two energy levels postpartum. Stagg K, et al. **Biol Reprod** 1998 Oct; 59(4):777–83

Role of nitric oxide in maternal hemodynamics and hormonal changes in pregnant rats. Salas SP. **Biol Res** 1998; 31(3):243–50 (37 ref.)

Integrative aspects of a human model of endotoxemia. Ottaway CA, et al. **Can J Physiol Pharmacol** 1998 May; 76(5):473–8

Exercise–induced hyperthermia and hormonal responses to exercise. Radomski MW, et al. **Can J Physiol Pharmacol** 1998 May;76(5):547–52 (29 ref.)

A personal history of the early development of the concept and methods of measurement of the metabolic clearance rate particularly of steroid hormones. Tait JF, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S101–18 (79 ref.)

An algorithm for detecting features of the hormone profiles of the human menstrual cycle. Krieg EF Jr, et al. **Comput Biol Med** 1999 Jul;29(4):229–42

Expression of nuclear hormone receptors in Escherichia coli. Mossakowska DE. **Curr Opin Biotechnol** 1998 Oct; 9(5):502–5 (29 ref.)

Amino acids and proteins—new definitions and requirements, hormonal interactions, methodological advances and pitfalls [editorial] Fürst P, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):5–8 (17 ref.)

Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Dannies PS. **Endocr Rev** 1999 Feb;20(1):3–21 (200 ref.)

Review: Ageing and hormones. Roshan S, et al. **Eur J Clin Invest** 1999 Mar;29(3):210–3 (26 ref.)

Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. de Wied D. **Eur J Pharmacol** 1999 Jun 30;375(1–3):1–11 (85 ref.)

Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Untergasser G, et al. **Exp Gerontol** 1999 Apr;34(2):275–87

Aneuploidy in human granulosa lutein cells obtained from gonadotrophin–stimulated follicles and its relation to intrafollicular hormone concentrations. Grunwald K, et al. **Hum Reprod** 1998 Oct;13(10):2679–87

Specific, high affinity relaxin–like factor receptors. Büllesbach EE, et al. **J Biol Chem** 1999 Aug 6; 274(32):22354–8

An additional region of coactivator GRIP1 required for interaction with the hormone–binding domains of a subset of nuclear receptors. Hong H, et al. **J Biol Chem** 1999 Feb 5;274(6):3496–502

Energy and water metabolism, body composition, and hormonal changes induced by 42 days of enforced inactivity and simulated weightlessness. Blanc S, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4289–97

The differential effect of food intake and beta–adrenergic stimulation on adipose–derived hormones and cytokines in man. Orban Z, et al. **J Clin Endocrinol Metab** 1999 Jun; 84(6):2126–33

Effects of energy balance of hormones, ovarian activity, and recovered oocytes in lactating Holstein cows using transvaginal follicular aspiration. Kendrick KW, et al. **J Dairy Sci** 1999 Aug;82(8):1731–41

Hormonal regulation of apolipoprotein AI. Hargrove GM, et al. **J Mol Endocrinol** 1999 Apr;22(2):103–11 (93 ref.)

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Ciampelli M, et al. **Metabolism** 1999 Feb;48(2):167–72

The GnRH promoter: target of transcription factors, hormones, and signaling pathways. Nelson SB, et al.

Mol Cell Endocrinol 1998 May 25;140(1-2):151-5 (22 ref.)
Oxidation of gonadotrophin (PMSG) by oxygen free radicals alters its structure and hormonal activity. Ortega-Camarillo C, et al. **Mol Reprod Dev** 1999 Mar;52(3):264-8
Chronic stress in dogs subjected to social and spatial restriction. II. Hormonal and immunological responses. Beerda B, et al. **Physiol Behav** 1999 Apr;66(2):243-54
Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. Andersen ME, et al. **Toxicol Sci** 1999 Mar;48(1):38-50 (50 ref.)
Hormonal regulation of microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney. Chen GF, et al. **Xenobiotica** 1999 May;29(5):437-51
[Hormones and auto-paracrine tumor growth regulators in osteogenic sarcoma] Kushlinskii NE. **Vestn Ross Akad Med Nauk** 1998;(12):54-8 (32 ref.) (Eng. Abstr.) **(Rus)**
[Reduced plasma volume and changes in vasoactive hormones in underweight pregnant women] Salas SP, et al. **Rev Med Chil** 1998 May;126(5):504-10 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Effect of chain length on absorption of biologically active peptides from the gastrointestinal tract. Roberts PR, et al. **Digestion** 1999 Jul-Aug;60(4):332-7

PHARMACOLOGY

Ethanol dissociates hormone-stimulated cAMP production from inhibition of TNF-alpha production in rat Kupffer cells. Aldred A, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G98-G106
Second messenger production in avian medullary nephron segments in response to peptide hormones. Goldstein DL, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R847-54
Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung. Wagle S, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L381-90
Identification of a new cytochrome P450 family, CYP45, from the lobster, Homarus americanus, and expression following hormone and xenobiotic exposures. Snyder MJ. **Arch Biochem Biophys** 1998 Oct 15;358(2):271-6
Hormonal control of rat fetal pancreas development. Morisset J, et al. **Biol Neonate** 1999 May;75(5):327-36
Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones. Birch MA, et al. **Bone** 1999 Jun; 24(6):571-8
Modulatory effect of hormones on insulin secretion in vitro in the toad. Flores LE, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):77-81
Convergent effects of growth factors, hormones, and fibronectin are necessary for the enterocyte differentiation of a colon adenocarcinoma cell line (HT29-D4). Rognoni JB, et al. **Differentiation** 1998 Sep;63(5):305-17
Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Douziech N, et al. **Endocrine** 1998 Oct;9(2):171-83
Studies of the hormonal regulation of type 2 5'-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcription-polymerase chain reaction. Kim SW, et al. **Endocrinology** 1998 Dec;139(12):4895-905
Hormonal regulation of epidermal growth factor receptor content and signaling in bovine mammary tissue. Sheffield LG. **Endocrinology** 1998 Nov;139(11):4568-75
Effects of cyclosporin A, FK506 and steroid hormones on hair growth. Tsuji Y, et al. **Exp Dermatol** 1999 Aug; 8(4):366-7
Hormonal effects on amino acids and related compounds in plasma, amniotic fluid, and allantoic fluid of the chicken embryo. Hohlweg A, et al. **Gen Comp Endocrinol** 1999 Jun; 114(3):378-86
Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions. de Groen PC, et al. **In Vitro Cell Dev Biol Anim** 1998 Oct;34(9):704-10
Hormonal factors from the mammalian pineal gland interfere with cell development in Hydra. Müller WA, et al. **Int J Dev Biol** 1998 Sep;42(6):821-4
Low-molecular-weight hormonal factors that affect head formation in Hydra. Müller WA, et al. **Int J Dev Biol** 1998 Sep;42(6):825-8
Hormone-evoked elementary Ca2+ signals are not stereotypic, but reflect activation of different size channel clusters and variable recruitment of channels within a cluster. Thomas D, et al. **J Biol Chem** 1998 Oct 16; 273(42):27130-6
Effect of endocrine and paracrine factors on protein synthesis and cell proliferation in bovine hoof tissue culture. Hendry KA, et al. **J Dairy Res** 1999 Feb;66(1):23-33
The effect of neuropeptides/hormones on Langerhans cells. Torii H, et al. **J Dermatol Sci** 1998 May;20(1):21-8 (47 ref.)
Heart medications: indications and interactions in stress testing. Duncan BH, et al. **J Nucl Cardiol** 1999 May-Jun; 6(3):357-61 (26 ref.)
Characterization and hormonal modulation of immunoreactive thiamin carrier protein in immature rat Sertoli cells in culture. Subramanian S, et al. **J Steroid Biochem Mol Biol** 1999 Jan;68(1-2):23-30
Hormone-stimulated Ca2+ reabsorption in rabbit kidney cortical collecting system is cAMP-independent and involves a phorbol ester-insensitive PKC isotype. Hoenderop JG, et al. **Kidney Int** 1999 Jan;55(1):225-33
Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia. Cowett RM, et al. **Metabolism** 1999 May;48(5):568-74
Impact of acute epinephrine removal on hepatic glucose metabolism during stress hormone infusion. McGuinness OP, et al. **Metabolism** 1999 Jul;48(7):910-4
Hormonal influences on tryptophan binding to rat hepatic nuclei. Sidransky H, et al. **Metabolism** 1999 Feb; 48(2):144-52
Hormonal modulation of phagocytosis and intracellular growth of Mycobacterium avium ss. paratuberculosis In bovine peripheral blood monocytes. Feola RP, et al. **Microb Pathog** 1999 Jan;26(1):1-11
The effect of hormones on the expression of five isoforms of UDP-glucuronosyltransferase in primary cultures of rat hepatocytes. Li YQ, et al. **Pharm Res** 1999 Feb;16(2):191-7
Phenobarbital induction of CYP2B1/2 in primary hepatocytes: endocrine regulation and evidence for a single pathway for multiple inducers. Ganem LG, et al. **Toxicol Appl Pharmacol** 1999 Feb 15;155(1):32-42
[Intracellular calcium channels, hormone receptors and intercellular calcium waves] Tordjmann T, et al. **C R Seances Soc Biol Fil** 1998;192(1):149-57 (Eng. Abstr.) **(Fre)**
[Hormonal substances used as ergogenic agents] Laudo Pardos C, et al. **Med Clin (Barc)** 1999 Jan 23;112(2):67-73 (75 ref.) **(Spa)**

PHYSIOLOGY

Flavonoids as hormones. A perspective from an analysis of molecular fossils. Baker ME. **Adv Exp Med Biol** 1998; 439:249-67 (89 ref.)
Structural basis for cytokine hormone-receptor recognition and receptor activation. Kossiakoff AA, et al. **Adv Protein Chem** 1998;52:67-108 (99 ref.)
Recent advances in noninvasive techniques to monitor hormone-behavior interactions. Whitten PL, et al. **Am J Phys Anthropol** 1998;Suppl 27:1-23 (137 ref.)
Hormonal regulation of leptin expression in broiler chickens. Ashwell CM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R226-32
Endocrinology of the ovarian cycle and pregnancy in the Asian (Elephas maximus) and African (Loxodonta africana) elephant. Hodges JK. **Anim Reprod Sci** 1998 Oct; 53(1-4):3-18 (49 ref.)
Hormonal pertubations in fibromyalgia syndrome. Neeck G, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:325-38; discussion 339 (74 ref.)
Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Wilder RL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:14-31 (152 ref.)
The relationship between hormones and human parturition. Chaim W, et al. **Arch Gynecol Obstet** 1998;262(1-2):43-51 (46 ref.)
Physiology and pathophysiology of baroreceptor function and neuro-hormonal abnormalities in heart failure. Kirchheim HR, et al. **Basic Res Cardiol** 1998;93 Suppl 1:1-22 (192 ref.)
A novel 17beta-hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Lanisnik Rizner T, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):425-31
Nutrient and hormonal regulation of pyruvate kinase gene expression. Yamada K, et al. **Biochem J** 1999 Jan 1;337 (Pt 1):1-11 (120 ref.)
Hormones as life regulators in the current molecular endocrinology. Pankov YA. **Biochemistry (Mosc)** 1998 Dec;63(12):1361-73 (125 ref.)
IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Martal JL, et al. **Biochimie** 1998 Aug-Sep;80(8-9):755-77 (236 ref.)
Risk factors for breast cancer in nulliparous women. Fioretti F, et al. **Br J Cancer** 1999 Apr;79(11-12):1923-8
Is there a hormonal basis to hysterectomy-related depression? Khastgir G, et al. **Br J Obstet Gynaecol** 1999 Jul; 106(7):620-2
Behavioural and hormonal effects of restraint stress and formalin test in male and female rats. Aloisi AM, et al. **Brain Res Bull** 1998 Sep 1;47(1):57-62
The neuroendocrine stress response and modern intensive care: the concept revisited. Van den Berghe GH. **Burns** 1999 Feb;25(1):7-16 (98 ref.)
Raging hormones: closing the loop from bench to bedside. The 22nd Arnold O. Beckman Conference in Clinical Chemistry. San Antonio, Texas, USA. February 21-22, 1999. Proceedings. **Clin Chem** 1999 Aug;45(8 Pt 2):1321-90
Hormonal control of calcium homeostasis. Mundy GR, et al. **Clin Chem** 1999 Aug;45(8 Pt 2):1347-52 (72 ref.)
Interaction of circulating hormones with the brain: the roles of the subfornical organ and the organum vasculosum of the lamina terminalis. McKinley MJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S61-7 (47 ref.)
Building transcriptional regulatory complexes: signals and surfaces. Yamamoto KR, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:587-98 (70 ref.)
Anabolic hormones in critically ill patients. Ferrando AA. **Curr Opin Clin Nutr Metab Care** 1999 Mar;2(2):171-5 (23 ref.)
Alzheimer's disease in 22 twin pairs--13-year follow-up: hormonal, infectious and traumatic factors. Nee LE, et al. **Dement Geriatr Cogn Disord** 1999 Mar-Apr;10(2):148-51
Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Response to Kitzmiller et al [comment] [published erratum appears in Diabetes Care 1999 Jul;22(7):1229] Jovanovic L. **Diabetes Care** 1999 May; 22(5):846-8. Comment on: Diabetes Care 1999 May;22(5):874-6.
Perimenopause: the complex endocrinology of the menopausal transition. Prior JC. **Endocr Rev** 1998 Aug; 19(4):397-428 (199 ref.)
The relaxin-like factor is a hormone. Büllesbach EE, et al. **Endocrine** 1999 Apr;10(2):167-9
Hormonal induction of mouse selenocysteine transfer ribonucleic acid (tRNA) gene transcription-activating factor and its functional importance in the selenocysteine tRNA gene transcription in mouse mammary gland. Adachi K, et al. **Endocrinology** 1999 Feb;140(2):618-23
A winged-helix family member is involved in a steroid hormone-triggered regulatory circuit. Dean DM, et al. **Endocrinology** 1998 Dec;139(12):4967-75
Has the elusive "natriuretic factor" been discovered, and if so, is it a hormone? Wechter WJ, et al. **Exp Nephrol** 1998 Nov-Dec;6(6):488-90 (12 ref.)
Albumin's role in steroid hormone action and the origins of vertebrates: is albumin an essential protein? Baker ME. **FEBS Lett** 1998 Nov 13;439(1-2):9-12
Environmental toxicants and female reproduction [see comments] Sharara FI, et al. **Fertil Steril** 1998 Oct; 70(4):613-22 (100 ref.). Comment in: Fertil Steril 1999 Apr;71(4):775-6.
Neurotransmitter transporters: target for endocrine regulation. Figlewicz DP, et al. **Horm Metab Res** 1999 May;31(5):335-9 (58 ref.)
Multiple hormone resistance in short children born with intrauterine growth retardation? Chatelain PG, et al. **Horm Res** 1998;49 Suppl 2:20-2 (26 ref.)
Cell-to-cell communication in the ovarian follicle: developmental and hormonal regulation of the expression of connexin43. Granot I, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:85-97 (46 ref.)
An elusive role for glycosylation in the structure and function of reproductive hormones. Willey KP. **Hum Reprod Update** 1999 Jul-Aug;5(4):330-55 (154 ref.)
Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Oparil S. **Hypertension** 1999 Jan;33(1 Pt 2):170-6 (56 ref.)
Hormonal regulation of MUC1 expression. Seregni E, et al. **Int J Biol Markers** 1999 Jan-Mar;14(1):29-35 (69 ref.)
Hormone-related, muscle-specific changes in protein metabolism and fiber type profile after faba bean intake. Frühbeck G, et al. **J Appl Physiol** 1999 Mar;86(3):852-9
Physiological variability of fluid-regulation hormones in young women. Stachenfeld NS, et al. **J Appl Physiol** 1999 Mar;86(3):1092-6
Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells. Sasaki CY, et al. **J Cell Physiol** 1999 Oct;181(1):1-13
Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome. Cannon JG, et al. **J Clin Immunol** 1998 Jul;18(4):291-8
3alpha,5alpha-THP in the midbrain ventral tegmental area of rats and hamsters is increased in exogenous hormonal states associated with estrous cyclicity and sexual receptivity. Frye CA, et al. **J Endocrinol Invest** 1999 Jun; 22(6):455-64
Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. Crestani M, et al. **J Lipid Res** 1998 Nov; 39(11):2192-200
Analysis of tissue- and hormone-specific regulation of the human prolactin-inducible protein/gross cystic disease fluid protein-15 gene in transgenic mice. Myal Y, et al. **J Mol Endocrinol** 1998 Oct;21(2):217-23
Hormonal regulation of the mRNA encoding the ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in neonatal primary cultures of cortical astrocytes and meningeal fibroblasts. Cullingford TE, et al. **J Neurochem** 1998 Nov;71(5):1804-12
Hormonal regulation of glutamate receptor gene expression in the anteroventral periventricular nucleus of the hypothalamus. Gu G, et al. **J Neurosci** 1999 Apr 15; 19(8):3213-22
Calcium-regulating hormones, bone mineral content, breaking load and trabecular remodeling are altered in growing pigs fed calcium-deficient diets. Eklou-Kalonji E, et al. **J Nutr** 1999 Jan;129(1):188-93
Postnatal ontogeny and hormonal regulation of sulfotransferase SULT1B1 in male and female rats. Dunn RT 2nd, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):319-24
The chromogranins and the counter-regulatory hormones: do they make homeostatic sense? Koeslag JH, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):643-9

Hormonally active agents throughout the environment [news] Marwick C. **JAMA** 1999 Aug 25;282(8):722
Nitration modifying function of proteins, hormones and neurotransmitters. Nakaki T, et al. **Jpn J Pharmacol** 1999 Feb;79(2):125–9 (53 ref.)
Hormone regulation of chondrocyte differentiation and endochondral bone formation. Stevens DA, et al. **Mol Cell Endocrinol** 1999 May 25;151(1–2):195–204 (71 ref.)
Developmental and hormonal regulation of murine scavenger receptor, class B, type 1. Cao G, et al. **Mol Endocrinol** 1999 Sep;13(9):1460–73
Regulation of ion channel expression in neural cells by hormones and growth factors. Chew LJ, et al. **Mol Neurobiol** 1998 Dec;18(3):175–225 (374 ref.)
Coding of time-varying hormonal signals in intracellular calcium spike trains. Prank K, et al. **Pac Symp Biocomput** 1998;:633–44
Behavioral effects of dopamine agonists and antagonists: influence of estrous cycle, ovariectomy, and estrogen replacement in rats. Díaz-Véliz G, et al. **Pharmacol Biochem Behav** 1999 Jan;62(1):21–9
Membrane-initiated steroid actions and the proteins that mediate them. Watson CS, et al. **Proc Soc Exp Biol Med** 1999 Jan;220(1):9–19 (176 ref.)
Hormonal control of cardiac ion channels and transporters. Shimoni Y. **Prog Biophys Mol Biol** 1999;72(1):67–108 (409 ref.)
Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Badawi AF, et al. **Prostaglandins Other Lipid Mediat** 1998 Jun;56(2–3):167–81
Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? Murad F. **Recent Prog Horm Res** 1998;53:43–59; discussion 59–60 (47 ref.)
Macrophage migration inhibitory factor: cytokine, hormone, or enzyme? Swope MD, et al. **Rev Physiol Biochem Pharmacol** 1999;139:1–32 (94 ref.)
Overview of the First International Meeting on Rapid Responses to Steroid Hormones. Norman AW, et al. **Steroids** 1999 Jan-Feb;64(1–2):3–4
Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Palange P. **Thorax** 1998 Nov; 53(11):989–91 (41 ref.)
[Calcitonin and stanniocalcin. Particular aspects of the endocrine regulation of phospho-calcium metabolism in mammals and fish] Barlet JP, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):281–90 (130 ref.) (Eng. Abstr.) **(Fre)**
[The pathology of receptors: a concept which revives endocrinology] Despert F. **Arch Pediatr** 1999;6 Suppl 2:494s–495s **(Fre)**
[Hormones and sexuality in the young and aging woman] Buvat-Herbaut M. **Contracept Fertil Sex** 1999 Jan; 27(1):17–22 (57 ref.) **(Fre)**
[Hormones and voice or does Orpheus have an age?] Marco-Dutoit ML. **Rev Med Suisse Romande** 1999 Apr; 119(4):335–9 (21 ref.) **(Fre)**
[Hormones and headaches. Epidemiology, physiopathology and drug therapy] Evers S, et al. **Med Monatsschr Pharm** 1998 Oct;21(10):294–303 (77 ref.) **(Ger)**
[The mechanisms of Na+, K(+)-ATPase in renal tubular epithelium] Beltowski J. **Postepy Biochem** 1998; 44(4):282–91 (159 ref.) **(Pol)**
[Regulation of expression of adrenergic receptors by steroid hormones] Dygalo NN, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1115–20 (30 ref.) (Eng. Abstr.) **(Rus)**
[Hormonal regulation of the Ca+ transport in blood and vascular cells] Tkachuk VA. **Ross Fiziol Zh Im I M Sechenova** 1998 Oct;84(10):1006–18 (90 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Involvement of hormonal circadian secretion in the growth of HIV-infected children. Rondanelli M, et al. **AIDS** 1998 Oct 1;12(14):1845–50
Joint recovery of pulsatile and basal hormone secretion by stochastic nonlinear random-effects analysis. Keenan DM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1939–49
Ovarian hormone secretory response to gonadotropins and nitric oxide following chronic nitric oxide deficiency in the rat. Dunnam RC, et al. **Biol Reprod** 1999 Apr; 60(4):959–63
Heme oxygenase and carbon monoxide: regulatory roles in islet hormone release: a biochemical, immunohistochemical, and confocal microscopic study. Henningsson R, et al. **Diabetes** 1999 Jan;48(1):66–76
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Hasegawa I, et al. **Fertil Steril** 1999 Feb;71(2):323–7
Forebrain pathways mediating stress-induced hormone secretion. Van de Kar LD, et al. **Front Neuroendocrinol** 1999 Jan;20(1):1–48 (380 ref.)
Aspects of secretion and actions of amylin: interplay between amylin and other hormones. Schmitz O, et al. **J Endocrinol Invest** 1999;22(5 Suppl):33–6 (32 ref.)
Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Kurbel S, et al. **Med Hypotheses** 1999 Apr;52(4):329–33 (52 ref.)
Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Murphy LL, et al. **Neurobiol Dis** 1998 Dec;5(6 Pt B):432–46 (126 ref.)
Regulation of gene expression in the endocrine heart. Durocher D, et al. **Recent Prog Horm Res** 1998;53:7–23; discussion 22–3 (79 ref.)
Longissimus dorsi muscle diameter, backfat thickness, body condition scores and skinfold values related to metabolic and endocrine traits in lactating dairy cows fed crystalline fat or free fatty acids. Bruckmaier RM, et al. **Zentralbl Veterinarmed A** 1998 Sep;45(6–7):397–410
[Peroxisomes and peroxisome proliferators. Specific environmental poisons and therapeutic agents affecting lipid metabolism and hormone release] Hammer TA, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3603–8 (66 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

Can we use steroid hormones to immunomodulate rheumatic diseases? Rheumatoid arthritis as an example. Bijlsma JW. **Ann N Y Acad Sci** 1999 Jun 22;876:366–76; discussion 376–7 (33 ref.)
The influence of L-triiodothyronine, L-thyroxine, estradiol-17beta, the luteinizing-hormone-releasing hormone, the epidermal growth factor and gastrin on cell proliferation in organ cultures of 35 benign and 13 malignant human thyroid tumors. Nagy N, et al. **J Cancer Res Clin Oncol** 1999;125(6):361–8
Metal mesh stents for ureteral obstruction caused by hormone-resistant carcinoma of prostate. Ahmed M, et al. **J Endourol** 1999 Apr;13(3):221–4
Complementary and alternative medicines for Alzheimer's disease. Ott BR, et al. **J Geriatr Psychiatry Neurol** 1998 Winter;11(4):163–73 (117 ref.)
ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Elgamal AA, et al. **Prostate** 1998 Dec 1;37(4):261–9 (29 ref.)
[Therapeutic update 1997-1998] Scheen AJ. **Rev Med Liege** 1998 Sep;53(9):518–23 (19 ref.) (Eng. Abstr.) **(Fre)**
[Acne vulgaris: local and systemic treatment] Kwiecień A, et al. **Pol Merkuriusz Lek** 1999 May;6(35):291–3 (29 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat. Burtea C, et al. **MAGMA** 1998 Dec;7(3):184–98
Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds. Andersen ME, et al. **Toxicol Sci** 1999 Mar;48(1):38–50 (50 ref.)

URINE

Preimplantation urinary hormone profiles and the probability of conception in healthy women. Baird DD, et al. **Fertil Steril** 1999 Jan;71(1):40–9

HORMONES, ECTOPIC

see related
NEOPLASTIC ENDOCRINE-LIKE SYNDROMES

BIOSYNTHESIS

Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, et al. **Blood** 1998 Nov 1;92(9):3388–93

IMMUNOLOGY

Human chorionic gonadotropin as a target for cancer vaccines. Triozzi PL, et al. **Oncol Rep** 1999 Jan-Feb; 6(1):7–17 (98 ref.)

METABOLISM

Esophageal small cell carcinoma with ectopic production of parathyroid hormone-related protein (PTHrp), secretin, and granulocyte colony-stimulating factor (G-CSF). Nagashima R, et al. **Dig Dis Sci** 1999 Jul;44(7):1312–6

SECRETION

Intact PTH-producing hepatocellular carcinoma treated by transcatheter arterial embolization. Koyama Y, et al. **Abdom Imaging** 1999 Mar-Apr;24(2):144–6
Establishment of a new cell line, OKT1, from small cell carcinoma secreting ectopic ACTH of the uterine cervix. Ohtake H, et al. **Gynecol Oncol** 1998 Nov;71(2):177–84
Is there an ectopic secretion of monomeric calcitonin in the human being? Engelbach M, et al. **Langenbecks Arch Surg** 1998 Dec;383(6):456–9
[Gammagraphy of somatostatin receptors in an ACTH secreting thymic carcinoid] Banzo J, et al. **Rev Esp Med Nucl** 1999;18(2):99–103 (Eng. Abstr.) **(Spa)**

TOXICITY

[Testicular descent and environmental hormones] Shono T, et al. **Fukuoka Igaku Zasshi** 1999 Jun;90(6):273–8 (18 ref.) **(Jpn)**

HORMONES, INVERTEBRATE see **INVERTEBRATE HORMONES**

HORMONES, SYNTHETIC

Somatostatin and octreotide: physiological background and pharmacological application. Beglinger C, et al. **Digestion** 1999;60 Suppl 2:2–8 (24 ref.)

ADMINISTRATION & DOSAGE

Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy volunteers. Schiedermaier P, et al. **Digestion** 1999 Mar-Apr; 60(2):132–40
Hormone delivery: small synthetic molecular mimics. Lopez-Liuchi JV. **Eur J Endocrinol** 1998 Nov;139(5):481–3
Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome. van der Meer M, et al. **Hum Reprod** 1998 Jun; 13(6):1465–9

ADVERSE EFFECTS

Hormones and cardiovascular diseases: oral contraceptives and hormonal replacement therapy: differential effects on coronary heart disease, deep venous thrombosis and stroke. The ESHRE Capri Workshop Group. **Hum Reprod** 1998 Aug;13(8):2325–33 (104 ref.)

CONTRAINDICATIONS

[Influence of adjuvant hormonal therapy on the whole female organism: benefit versus potential injury] Denison U, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(2):96–100 (13 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSTIC USE

Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Gerding MN, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):373–9
In-111 octreotide lung uptake in hypersensitive pneumonitis caused by fungal infection. Slavin JD Jr, et al. **Clin Nucl Med** 1998 Dec;23(12):847–8
Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. Klutmann S, et al. **J Nucl Med** 1998 Nov;39(11):1913–7
Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49–53 (15 ref.)
Intraoperative detection of lung cancer by octreotide labeled to Indium-111. Pastore V, et al. **Semin Surg Oncol** 1998 Dec;15(4):220–2

PHARMACOKINETICS

Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. Jenkins SA, et al. **HPB Surg** 1998;11(1):13–21
Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR. Comets E, et al. **J Controlled Release** 1999 May 20; 59(2):197–205
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Johansen PB, et al. **Xenobiotica** 1998 Nov; 28(11):1083–92

PHARMACOLOGY

Comparison of buserelin and nafarelin in IVF cycles and in subsequent frozen-thawed embryo transfer cycles. Simberg N, et al. **Acta Obstet Gynecol Scand** 1998 Sep; 77(8):854–9
Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Lekakis J, et al. **Am J Cardiol** 1998 Dec 15;82(12):1555–7, A8
Inhibition of L-type calcium channels by octreotide in isolated human neuroendocrine tumor cells of the gut. Glassmeier G, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):511–5
Parathyroid hormone (PTH)-(1–34), [Nle(8,18),Tyr34]PTH-(3–34) amide, PTH-(1–31) amide, and PTH-related peptide-(1–34) stimulate phosphatidylcholine hydrolysis in UMR-106 osteoblastic cells: comparison with effects of phorbol 12,13-dibutyrate. Singh AT, et al. **Endocrinology** 1999 Jan;140(1):131–7
Ipamorelin, the first selective growth hormone secretagogue. Raun K, et al. **Eur J Endocrinol** 1998 Nov;139(5):552–61
Gonadotrophin-releasing hormone agonist stimulates milt fluidity and plasma concentrations of 17,20beta-dihydroxylated and 5beta-reduced, 3alpha-hydroxylated C21 steroids in male plaice

(Pleuronectes platessa). Vermeirssen EL, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):163–77

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Johansen PB, et al. **Growth Horm IGF Res** 1999 Apr;9(2):106–13

Effects of chronic octreotide treatment on renal changes during cirrhosis in rats. Jonassen TE, et al. **Hepatology** 1999 May;29(5):1387–95

Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin-releasing hormone. Sakamoto S, et al. **In Vivo** 1998 May–Jun;12(3):333–7

Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. Conley LK, et al. **J Endocrinol** 1998 Sep; 158(3):367–75

Several environmental oestrogens are also anti-androgens. Sohoni P, et al. **J Endocrinol** 1998 Sep;158(3):327–39

Acute in vivo effect of octreotide acetate, a somatostatin analogue on the cellular function of gastric mucosa in the rat. Motegi M, et al. **J Gastroenterol Hepatol** 1998 Feb; 13(2):220–4

Somatostatin analogue predisposes enterocytes to apoptosis. Thompson JS. **J Gastrointest Surg** 1998 Mar–Apr; 2(2):167–73

Various actions of oestrogens on the vascular system. Stevenson JC. **Maturitas** 1998 Sep 20;30(1):5–9 (40 ref.)

The effect of octreotide on peritoneal alterations induced by high concentration of glucose. Günal AI, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):532–4

Somatostatin and octreotide modulate the function of Kupffer cells in liver cirrhosis. Chao TC, et al. **Regul Pept** 1999 Feb 5;79(2–3):117–24

THERAPEUTIC USE

Suppression of GH secretion in pituitary gigantism by continuous subcutaneous octreotide infusion in a pubertal boy. Näntö-Salonen K, et al. **Acta Paediatr** 1999 Jan; 88(1):29–33

Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Lekakis J, et al. **Am Heart J** 1998 Nov;136(5):905–12

Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis. Lin HC, et al. **Am J Gastroenterol** 1999 Apr;94(4):1012–7

Octreotide and ectopic Cushing's syndrome—a commentary [comment] James RA. **Clin Endocrinol (Oxf)** 1998 Oct; 49(4):419–20. Comment on: Clin Endocrinol (Oxf) 1998 Oct;49(4):541–6.

Octreotide. Outlook. Beglinger C. **Digestion** 1999;60 Suppl 2:57

A decade of octreotide [editorial] Büchler MW, et al. **Digestion** 1999;60 Suppl 2:1

Role of octreotide and somatostatin in the treatment of intestinal fistulae. Dorta G. **Digestion** 1999;60 Suppl 2:53–6 (23 ref.)

Octreotide in the treatment of refractory diarrhea. Fried M. **Digestion** 1999;60 Suppl 2:42–6 (38 ref.)

Continuous intravenous octreotide treatment for acute experimental pancreatitis. Greenberg R, et al. **Digestion** 1999 Mar–Apr;60(2):125–31

Somatostatin or octreotide in acute variceal bleeding. Hadengue A. **Digestion** 1999;60 Suppl 2:31–41 (60 ref.)

The role of octreotide and somatostatin in acute and chronic pancreatitis. Uhl W, et al. **Digestion** 1999;60 Suppl 2:23–31 (95 ref.)

Long-term results of GH therapy in GH-deficient children treated before 1 year of age. Huet F, et al. **Eur J Endocrinol** 1999 Jan;140(1):29–34

Changes in body composition and leptin levels during growth hormone (GH) treatment in short children with various GH secretory capacities. Matsuoka H, et al. **Eur J Endocrinol** 1999 Jan;140(1):35–42

Octreotide suppresses the incretin glucagon-like peptide (7–36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. Plöckinger U, et al. **Eur J Endocrinol** 1999 Jun; 140(6):538–44

Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. Van den Berghe G, et al. **Eur J Endocrinol** 1999 Jan;140(1):17–22

Pre or post-operative medical treatment with nafarelin in stage III–IV endometriosis: a French multicenter study [see comments] Audebert A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):145–8 . Comment in: Eur J Obstet Gynecol Reprod Biol 1998 Aug;79(2):143–4.

Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome. Morris RS, et al. **Fertil Steril** 1999 Mar;71(3):452–6

Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Surrey ES. **Fertil Steril** 1999 Mar;71(3):420–4 (17 ref.)

Effects of octreotide on propylotiouracil-induced goiter in rats: a quantitative evaluation. Pawlikowski M, et al. **Histol Histopathol** 1998 Jul;13(3):679–82

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. Dada T, et al. **Hum Reprod** 1999 Feb;14(2):288–93

Hormonal and volumetric long term control of a growth hormone-releasing hormone-producing carcinoid tumor. Van den Bruel A, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3162–9

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients [letter] Kaffy F, et al. **J Hepatol** 1999 Jan;30(1):174

Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly. Hernandez I, et al. **J Neurosurg** 1999 Apr;90(4):647–50

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist [see comments] Lustig RH, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):162–8. Comment in: J Pediatr 1999 Aug;135(2 Pt 1):142–4.

New GH secretagogues and potential usefulness in thalassemia. Karydis I, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:857–62 (60 ref.)

Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma. Chan NN, et al. **Postgrad Med J** 1999 Feb;75(880):96–7

Octapeptide somatostatin-analogue therapy of Cushing's syndrome [editorial] De Herder WW, et al. **Postgrad Med J** 1999 Feb;75(880):65–6

Carcinoid-associated ectopic ACTH syndrome with variable response to octreotide. Gill GV, et al. **Postgrad Med J** 1999 Feb;75(880):98–100

[A case of mediastinal pancreatic pseudocysts successfully treated with somatostatin analogue] Ishibashi K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Feb;96(2):176–80 **(Jpn)**

[Octreotide and a serotonin-secreting glomus tumor] García Galán F, et al. **Rev Esp Anestesiol Reanim** 1999 May; 46(5):219–22 (Eng. Abstr.) **(Spa)**

TOXICITY

US panel split on endocrine disruptors... [news] Macilwain C. **Nature** 1998 Oct 29;395(6705):828

URINE

Renal tubular transport and metabolism of carboxyamidated and glycine-extended gastrins in pigs. palnaes Hansen C, et al. **Acta Physiol Scand** 1998 Sep;164(1):29–38

HORN FLY see **MUSCIDAE**

HORNER'S SYNDROME

CHEMICALLY INDUCED

Horner's syndrome due to epidural analgesia [letter] Fan K, et al. **Can J Anaesth** 1998 Dec;45(12):1219

Just another explanation for: 'Horner's syndrome following low-dose epidural infusion for labour' presented by H. G. W. Paw [letter; comment] Schregel W, et al. **Eur J Anaesthesiol** 1998 Sep;15(5):617–8. Comment on: Eur J Anaesthesiol 1998 Jan;15(1):110–1.

[A possibility of central diffusion during stellate ganglion blockade: "the sheath of the spinal rachidian nerve"] Soriano C, et al. **Rev Esp Anestesiol Reanim** 1999 Mar; 46(3):123–5 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Neurotrophic corneal endothelial failure complicating acute Horner syndrome. Zamir E, et al. **Ophthalmology** 1999 Sep; 106(9):1692–6

Unilateral facial ulceration and Horner's syndrome. Loftus AM, et al. **Postgrad Med J** 1999 Feb;75(880):107–9

[Diagnostic quiz: facial ulceration and Horner syndrome] Füessl HS. **MMW Fortschr Med** 1999 Jun 3;141(22):51–2 **(Ger)**

[Chronic Cryptococcal meningitis with CSF oligoclonal IgG band in a patient with Claude syndrome] Kawanishi R, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):314–8 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Ophthalmologic manifestations of internal carotid artery dissection. Biousse V, et al. **Am J Ophthalmol** 1998 Oct; 126(4):565–77

Bilateral Horner's syndrome: detection and occurrence. Smith SA, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan; 66(1):48–51

[Painful Claude Bernard Horner syndrome: apropos of a painless carotid artery dissection] Ameline-Audelan V. **J Fr Ophtalmol** 1998 Oct;21(8):591–5 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Pharmacological reversal of ptosis in a patient with acquired Horner's syndrome and heterochromia [letter] Parsa CF, et al. **Br J Ophthalmol** 1998 Sep;82(9):1095

ETIOLOGY

Recurrent Horner's syndrome and epidural analgesia in labour [letter] Morgan-Hughes N, et al. **Anaesthesia** 1998 Aug;53(8):827

Horner's syndrome in infancy [letter; comment] Cates CA, et al. **Br J Ophthalmol** 1998 Sep;82(9):1097. Comment on: Br J Ophthalmol 1998 Jan;82(1):51–4.

Tuberculosis and Horner's syndrome [letter] Norhaya MR, et al. **Int J Tuberc Lung Dis** 1998 Dec;2(12):1049

Clinical diorama. Myers KJ. **J Am Optom Assoc** 1998 Sep; 69(9):606–7

Traumatic Horner syndrome without anhidrosis. Oono S, et al. **J Neuroophthalmol** 1999 Jun;19(2):148–51

Horner's syndrome [letter; comment] Lewis SL. **N Engl J Med** 1999 Jul 1;341(1):57. Comment on: N Engl J Med 1999 Jan 28;340(4):285.

Transient Horner's syndrome after lumbar epidural anesthesia. Biousse V, et al. **Neurology** 1998 Nov; 51(5):1473–5 (10 ref.)

Internal carotid artery thrombosis and Horner's syndrome as complications of parapharyngeal abscess. Koivunen P, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):160–2

[Horner's syndrome following lumbar epidural anaesthesia—subdural block?] Brudny P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):510–2 (Eng. Abstr.) **(Ger)**

[Horner's syndrome in a patient with diffuse malignant pleural mesothelioma] Minami T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Apr;37(4):287–90 (Eng. Abstr.) **(Jpn)**

[The role of the sympathetic system in ocular pathology] Cernea P, et al. **Oftalmologia** 1998;44(3):5–12 (15 ref.) (Eng. Abstr.) **(Rum)**

[Villaret syndrome. Manifestation of carotid dissection (letter)] Lleó A, et al. **Neurologia** 1999 Jan;14(1):47 **(Spa)**

[Horner syndrome during labor (letter)] Zarcos A, et al. **Rev Esp Anestesiol Reanim** 1999 Mar;46(3):130 **(Spa)**

PHYSIOPATHOLOGY

Painful Horner syndrome due to arteritis of the internal carotid artery. Bollen AE, et al. **Neurology** 1998 Nov; 51(5):1471–2

VETERINARY

Arteriovenous malformation of the cervical spinal cord in a dog. Hayashida E, et al. **J Comp Pathol** 1999 Jul; 121(1):71–6

Horner's syndrome in a puppy. Boydell IP. **J Small Anim Pract** 1998 Sep;39(9):448–9

HORNETS see **WASPS**

HORNS

[The testing of bulls for the polledness gene] Vinnichuk DT. **Tsitol Genet** 1998 Apr–May;32(3):81–3 (Eng. Abstr.) **(Rus)**

[The effect of a preparation from the horns of the saiga antelope on the goal-directed drinking behavior of rats] Tolpygo SM, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov–Dec; 48(6):1104–6 (Eng. Abstr.) **(Rus)**

INJURIES

Eye injuries caused by cow horns. Goldblum D, et al. **Retina** 1999;19(4):314–7

SURGERY

Behavioural, endocrine and cardiac responses in young calves undergoing dehorning without and with use of sedation and analgesia. Grondahl-Nielsen C, et al. **Vet J** 1999 Jul; 158(1):14–20

Mutilations: a necessary evil? [editorial] Kent JE. **Vet J** 1999 Jul;158(1):1–3

HORSE DISEASES

Presumed clostridial and aerobic bacterial infections of the cornea in two horses. Rebhun WC, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1519–22, 1496

Pulmonary aspergillosis in horses: 29 cases (1974–1997). Sweeney CR, et al. **J Am Vet Med Assoc** 1999 Mar 15; 214(6):808–11

International Congress, anniversary meeting. 20 years Swiss Equine Veterinary Association. Luzern, 11–13 December 1998. Abstracts. **Schweiz Arch Tierheilkd** 1998; 140(11):445–80 **(Eng, Ger)**

Abdominal neoplasia (excluding urogenital tract). East LM, et al. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):475–93, v–vi (68 ref.)

Equine sarcoids. Goodrich L, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):607–23, vii (86 ref.)

Dermatologic tumors (excluding sarcoids). Johnson PJ. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):625–58, viii (218 ref.)

Neoplasia of the female reproductive tract. McCue PM. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):505–15 (63 ref.)

Tumors of the central nervous system. Paradis MR. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):543–61, vii (52 ref.)

Tumors of the eye and ocular adnexal tissues. Rebhun WC. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):579–606, vii (78 ref.)

Lymphoproliferative and myeloproliferative disorders. Savage CJ. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):563–78, vii (52 ref.)

Neoplasia of the respiratory tract. Scarratt WK, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):451–73, v (123 ref.)

Musculoskeletal system neoplasia. Schooley EK, et al. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):535–42, vi (27 ref.)

Urinary tract neoplasia. Traub-Dargatz JL. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):495–504, vi (35 ref.)

[Equine protozoal myeloencephalitis (EPM) in the Netherlands?] Boersema JH. **Tijdschr Diergeneeskd** 1999 May 1;124(9):288–9 **(Dut)**

[HYPP: hyperkalemic periodic paralysis in the horse] Sloet van Oldruitenborgh-Oosterbaan MM. **Tijdschr Diergeneeskd** 1999 Mar 15;124(6):176–81 (37 ref.) (Eng. Abstr.) **(Dut)**

[Use of a fast test to detect rotavirus in feces] Otto P, et al. **Berl Munch Tierarztl Wochenschr** 1997 Oct; 110(10):397–400 (Eng. Abstr.) **(Ger)**

BLOOD

Changes in plasma protein concentrations in ponies with experimentally induced alimentary laminitis. Fagliari JJ, et al. **Am J Vet Res** 1998 Oct;59(10):1234–7

Effect of hypothyroidism on blood lipid concentrations in horses. Frank N, et al. **Am J Vet Res** 1999 Jun;60(6):730–3

Plasma myeloperoxidase level and polymorphonuclear leukocyte activation in horses suffering from large intestinal obstruction requiring surgery: preliminary results. Grulke S, et al. **Can J Vet Res** 1999 Apr;63(2):142–7

A non-competitive chemiluminescence enzyme immunoassay for the equine acute phase protein serum amyloid A (SAA) — a clinically useful inflammatory marker in the horse. Hultén C, et al. **Vet Immunol Immunopathol** 1999 May; 68(2–4):267–81

CHEMICALLY INDUCED

Renal medullary rim sign in 2 adult quarter horses. Ramirez S, et al. **Can Vet J** 1998 Oct;39(10):647–9

Presumed moxidectin toxicosis in three foals. Johnson PJ, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):678–80

Equine granulomatous enteritis linked with aluminum? [letter; comment] Collery P, et al. **Vet Hum Toxicol** 1999 Feb; 41(1):49–50. Comment on: Vet Hum Toxicol 1998 Oct;40(5):297–305.

A cluster of equine granulomatous enteritis cases: the link with aluminium [see comments] Fogarty U, et al. **Vet Hum Toxicol** 1998 Oct;40(5):297–305. Comment in: Vet Hum Toxicol 1999 Feb;41(1):49–50.

Toxicity of methomyl following intravenous administration in the horse. Krieger RI, et al. **Vet Hum Toxicol** 1998 Oct; 40(5):267–9

Propylene glycol toxicosis in a mare. McClanahan S, et al. **Vet Hum Toxicol** 1998 Oct;40(5):294–6

CLASSIFICATION

Postcastration eventration in 18 horses: the prognostic indicators for long-term survival (1985–1995). Thomas HL, et al. **Can Vet J** 1998 Dec;39(12):764–8

DIAGNOSIS

Diagnosis and prevention of equine infectious diseases: present status, potential, and challenges for the future. Desmettre P. **Adv Vet Med** 1999;41:359–77 (129 ref.)

Measurement of synovial fluid and serum concentrations of the 846 epitope of chondroitin sulfate and of carboxy propeptides of type II procollagen for diagnosis of osteochondral fragmentation in horses. Frisbie DD, et al. **Am J Vet Res** 1999 Mar;60(3):306–9

Evaluation of mild lameness in horses trotting on a treadmill by clinicians and interns or residents and correlation of their assessments with kinematic gait analysis. Keegan KG, et al. **Am J Vet Res** 1998 Nov;59(11):1370–7

Serologic testing of horses for granulocytic ehrlichiosis, using indirect fluorescent antibody staining and immunoblot analysis. Magnarelli LA, et al. **Am J Vet Res** 1999 May; 60(5):631–5

Vets gain significant backing in Victorian court decision [news] **Aust Vet J** 1999 Feb;77(2):130

Primary hypoparathyroidism in two horses. Hudson NP, et al. **Aust Vet J** 1999 Aug;77(8):504–8

Coprological methods for the diagnosis of Anoplocephala perfoliata infection of the horse. Williamson RM, et al. **Aust Vet J** 1998 Sep;76(9):618–21

Equine osteology: a self-assessment. Farrow CS. **Can Vet J** 1998 Jul;39(7):445–6

Comparing equine motor neuron disease (EMND) with equine grass sickness (EGS) [editorial; comment] Divers TJ. **Equine Vet J** 1999 Mar;31(2):90–1. Comment on: Equine Vet J 1999 Mar;31(2):99–110.

Lawsonia intracellularis proliferative enteropathy in a weanling foal [see comments] Frank N, et al. **Equine Vet J** 1998 Nov;30(6):549–52. Comment in: Equine Vet J 1998 Nov;30(6):452–3.

Thoracoscopy in the horse: diagnostic and therapeutic indications in 28 cases. Vachon AM, et al. **Equine Vet J** 1998 Nov;30(6):467–75

Computer-assisted gait analysis in equine orthopaedic practice: the case for inverse dynamic analysis [editorial; comment] van den Bogert AJ. **Equine Vet J** 1998 Sep; 30(5):362–3. Comment on: Equine Vet J 1998 Sep;30(5):384–9.

Reliability of using results of abdominal fluid analysis to determine treatment and predict lesion type and outcome for horses with colic: 218 cases (1991–1994). Freden GO, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):1012–5

Parietal hernia of the small intestine into the epiploic foramen of a horse. Hammock PD, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1354–6, 1334–5

Laparoscopic diagnosis of subcapsular splenic hematoma in a horse. Mehl ML, et al. **J Am Vet Med Assoc** 1998 Oct 15;213(8):1171–3, 1133

Effects of blood contamination of cerebrospinal fluid on western blot analysis for detection of antibodies against Sarcocystis neurona and on albumin quotient and immunoglobulin G index in horses. Miller MM, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):67–71

Evaluation of peritoneal fluid pH, glucose concentration, and lactate dehydrogenase activity for detection of septic peritonitis in horses. Van Hoogmoed L, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1032–6

Detection of Cryptosporidium parvum in horses: thresholds of acid-fast stain, immunofluorescence assay, and flow cytometry. Cole DJ, et al. **J Clin Microbiol** 1999 Feb; 37(2):457–60

Hyperthyroidism associated with a thyroid adenocarcinoma in a 21-year-old gelding. Ramirez S, et al. **J Vet Intern Med** 1998 Nov-Dec;12(6):475–7

Survey of the large animal diplomates of the American College of Veterinary Internal Medicine regarding percutaneous lung biopsy in the horse. Savage CJ, et al. **J Vet Intern Med** 1998 Nov-Dec;12(6):456–64

Diagnosis and sero-epizootiology of equine herpesvirus type 1 and type 4 infections in Japan using a type-specific ELISA. Yasunaga S, et al. **J Vet Med Sci** 1998 Oct; 60(10):1133–7

Neoplasia of the male reproductive tract. Brinsko SP. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):517–33 (71 ref.)

Thermographic diagnostics in equine back pain. Graf von Schweinitz D. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):161–77, viii (54 ref.)

Back problems. Historical perspective and clinical indications. Jeffcott LB. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):1–12, v (17 ref.)

Physical examination of horses with back pain. Martin BB Jr, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):61–70, vi (7 ref.)

Equine nasal and paranasal tumours [editorial; comment] Baker GJ. **Vet J** 1999 May;157(3):220–1. Comment on: Vet J 1999 May;157(3):279–94.

A PCR based method for the identification of equine influenza virus from clinical samples. Oxburgh L, et al. **Vet Microbiol** 1999 Jun 30;67(3):161–74

Molecular detection of Babesia equi and Babesia caballi in horse blood by PCR amplification of part of the 16S rRNA gene. Bashiruddin JB, et al. **Vet Parasitol** 1999 Jul; 84(1–2):75–83

Mucosal larval recovery techniques of cyathostomes: can they be standardized? Eysker M, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):137–44; discussion 145–9, 215–25

Neospora caninum-associated equine protozoal myeloencephalitis. Hamir AN, et al. **Vet Parasitol** 1998 Nov 27;79(4):269–74

Enzyme-linked immunosorbent assay (ELISA) for detection of anti-Trypanosoma evansi equine antibodies. Reyna-Bello A, et al. **Vet Parasitol** 1998 Dec 31; 80(2):149–57

A sensitive polymerase chain reaction based assay for the detection of Setaria digitata: the causative organism of cerebrospinal nematodiasis in goats, sheep and horses. Wijesundera WS, et al. **Vet Parasitol** 1999 Mar 1; 81(3):225–33

Detection of Trichinella infection in slaughter horses by ELISA and western blot analysis. Yepez-Mulia L, et al. **Vet Parasitol** 1999 Feb 1;81(1):57–68

Electromyography in the horse in veterinary medicine and in veterinary research--a review. van Wessum R, et al. **Vet Q** 1999 Jan;21(1):3–7 (36 ref.)

Cytological and microbiological results from equine guttural pouch lavages obtained percutaneously: correlation with histopathological findings. Chiesa OA, et al. **Vet Rec** 1999 May 29;144(22):618–21

Urine analysis in equine grass sickness [letter] Kerr M. **Vet Rec** 1999 Jul 31;145(5):147–8

Urine analysis in equine grass sickness [letter] Marrs J, et al. **Vet Rec** 1999 Jun 26;144(26):734–5

Comparison of radiography, scintigraphy and ultrasonography in the diagnosis of a case of temporomandibular joint arthropathy in a horse. Weller R, et al. **Vet Rec** 1999 Apr 3;144(14):377–9

Endoscopy of the calcaneal bursa in horses. Ingle-Fehr JE, et al. **Vet Surg** 1998 Nov-Dec;27(6):561–7

[Meconium obstipation in the foal] Boerma S. **Tijdschr Diergeneeskd** 1998 Nov 15;123(22):671–2 **(Dut)**

[Botulism--a forgotten disease?] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1999 Apr;112(4):139–45 (Eng. Abstr.) **(Ger)**

[Demonstration of intraocular leptospira in 4 horses suffering from equine recurrent uveitis (ERU)] Brem S, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec; 111(11–12):415–7 (Eng. Abstr.) **(Ger)**

[Detection of equine arteritis virus (EAV) in stallions--a contribution to the improvement of EAV diagnosis] Starick E. **Berl Munch Tierarztl Wochenschr** 1999 Jan;112(1):10–3 (Eng. Abstr.) **(Ger)**

[Case report. Increase in volume of the uterine horn in a foal] Kallenbach T. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Apr; 27(2):72–3, 128–30 **(Ger)**

[Case report. Urinary incontinence in a newborn foal] Wehrend A, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):8, 52–3 **(Ger)**

[Diagnostic validity of thermography of lameness in horses] Weil M, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov; 26(6):346–54 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Effects of orally administered enteric-coated omeprazole on gastric acid secretion in horses. Andrews FM, et al. **Am J Vet Res** 1999 Aug;60(8):929–31

Aerosolized albuterol sulfate used as a bronchodilator in horses with recurrent airway obstruction. Derksen FJ, et al. **Am J Vet Res** 1999 Jun;60(6):689–93

Effects of 6alpha-methylprednisolone acetate on an equine osteochondral fragment exercise model. Frisbie DD, et al. **Am J Vet Res** 1998 Dec;59(12):1619–28

Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. MacKay RJ, et al. **Am J Vet Res** 1999 Jan;60(1):68–75

Population pharmacokinetics of gentamicin in horses. Martin-Jiménez T, et al. **Am J Vet Res** 1998 Dec; 59(12):1589–98

Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Rees WA, et al. **Am J Vet Res** 1999 Jul;60(7):888–94

Anti-inflammatory effects of topically applied dimethyl sulfoxide gel on endotoxin-induced synovitis in horses. Smith G, et al. **Am J Vet Res** 1998 Sep;59(9):1149–52

Arterially perfused eye model of uveitis. Shiels IA, et al. **Aust Vet J** 1999 Feb;77(2):100–4

Investigations on the ability of clenbuterol hydrochloride to reduce clinical signs and inflammation associated with equine influenza A infection. Kästner SB, et al. **Equine Vet J** 1999 Mar;31(2):160–8

Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease. Marr KA, et al. **J Vet Pharmacol Ther** 1998 Jun; 21(3):241–6

Intralesional and topical chemotherapy and immunotherapy. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):659–71, viii (35 ref.)

Propylene glycol toxicosis in a mare. McClanahan S, et al. **Vet Hum Toxicol** 1998 Oct;40(5):294–6

A comparison of in vitro tests and a faecal egg count reduction test in detecting anthelmintic resistance in horse strongyles. Craven J, et al. **Vet Parasitol** 1999 Aug 16; 85(1):49–59

Pathogenicity of cyathostome infection. Love S, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):113–21; discussion 121–2, 215–25 (44 ref.)

Efficacy of praziquantel (0.25 mg kg(-1)) on the cecal tapeworm (Anoplocephala perfoliata) in horses. Lyons ET, et al. **Vet Parasitol** 1998 Aug 31;78(4):287–9

Pharmacology of anthelmintic resistance in cyathostomes: will it occur with the avermectin/milbemycins? Sangster NC. **Vet Parasitol** 1999 Aug 31;85(2–3):189–201; discussion 201–4, 215–25

Parasite diversity and anthelmintic resistance in two herds of horses. Young KE, et al. **Vet Parasitol** 1999 Aug 31; 85(2–3):205–14; discussion 215–25

Concerns about medicines availability highlighted at BEVA congress [news] **Vet Rec** 1998 Sep 26;143(13):346–7

Efficacy of a 2 per cent moxidectin gel against gastrointestinal parasites of ponies. Bauer C, et al. **Vet Rec** 1998 Nov 14; 143(20):558–61

Activity of moxidectin against bots and lungworm in equids. Coles GC, et al. **Vet Rec** 1998 Aug 8;143(6):169–70

Pilot study to investigate the efficacy of a 1 per cent selenium sulphide shampoo in the treatment of equine chorioptic mange. Curtis CF. **Vet Rec** 1999 Jun 12;144(24):674–5

Inhibition of antigen-induced cutaneous responses of ponies with insect hypersensitivity by the histamine-1 receptor antagonist chlorpheniramine. Foster AP, et al. **Vet Rec** 1998 Aug 15;143(7):189–93

Availability of equine medicines [letter] Mantell JA. **Vet Rec** 1998 Dec 5;143(23):643

Persistence of the efficacy of a moxidectin gel on the establishment of cyathostominae in horses. Vercruysse J, et al. **Vet Rec** 1998 Sep 12;143(11):307–9

Use of phenytoin to treat digitalis-induced cardiac arrhythmias in a miniature Shetland pony. Wijnberg ID, et al. **Vet Rec** 1999 Mar 6;144(10):259–61

Biodegradable drug delivery systems for gentamicin release

and treatment of synovial membrane infection. Cook VL, et al. **Vet Surg** 1999 Jul–Aug;28(4):233–41

Successful treatment of an equine preputial fibrosarcoma using 5-fluorouracil/evaluation of the treatment using quantitative PCNA and Ki67 (MIB 1) immunostaining. (case report). Roels S, et al. **Zentralbl Veterinarmed A** 1998 Dec;45(10):591–8

[Risks in treating sport horses (letter)] Breukink HJ. **Tijdschr Diergeneeskd** 1999 Mar 15;124(6):191 **(Dut)**

[New drugs for horses and agriculturally useful animals and changes in the pharmaceutical market since 1996] Kluge K, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov;26(6):301–6 (11 ref.) **(Ger)**

EMBRYOLOGY

The Dorothy Russell Havemeyer Foundation Third International Workshop on Equine Perinatology: comparative aspects. Proceedings [see comments] **Equine Vet J** 1998 Nov;30(6):455–66. Comment in: Equine Vet J 1998 Nov;30(6):454.

ENZYMOLOGY

Matrix metalloproteinase activity in equine synovial fluid: influence of age, osteoarthritis, and osteochondrosis. Brama PA, et al. **Ann Rheum Dis** 1998 Nov;57(11):697–9

Batimastat (BB–94) inhibits matrix metalloproteinases of equine laminitis. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):119–24

The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. Clegg PD, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):406–13

Equine neutrophil myeloperoxidase in plasma: design of a radio–immunoassay and first results in septic pathologies. Deby–Dupont G, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):257–71

Immunolocalization of cathepsin B in equine dyschondroplastic articular cartilage. Hernández–Vidal G, et al. **Vet J** 1998 Nov;156(3):193–201

EPIDEMIOLOGY

Hoof size, shape, and balance as possible risk factors for catastrophic musculoskeletal injury of Thoroughbred racehorses. Kane AJ, et al. **Am J Vet Res** 1998 Dec; 59(12):1545–52

Epizootic of equine influenza in 1969 in Poland. Kita J. **Arch Vet Pol** 1993;33(3–4):139–45

Borna disease virus infection in racing horses with behavioral and movement disorders. Berg AL, et al. **Arch Virol** 1999; 144(3):547–59

Epidemiology of equine herpesvirus abortion: searching for clues to the future [comment] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):675–6 (12 ref.). Comment on: Aust Vet J 1998 Oct;76(10):677–82.

Seroprevalence of equine herpesvirus 1 in thoroughbred foals before and after weaning [see comments] Gilkerson JR, et al. **Aust Vet J** 1998 Oct;76(10):677–82. Comment in: Aust Vet J 1998 Oct;76(10):675–6.

Prevalence of and risk factors for fecal shedding of Cryptosporidium parvum oocysts in horses. Cole DJ, et al. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1296–302

Prevalence of Clostridium perfringens enterotoxin and Clostridium difficile toxin A in feces of horses with diarrhea and colic. Donaldson MT, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):358–61

Evaluation of enterolithiasis in equids: 900 cases (1973–1996). Hassel DM, et al. **J Am Vet Med Assoc** 1999 Jan 15; 214(2):233–7

Isolation of Salmonella organisms from the mesenteric lymph nodes of horses at necropsy. House JK, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):507–10

Risk factors for nosocomial Salmonella infection among hospitalized horses. House JK, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1511–6

Public veterinary medicine: public health. Serologic evaluation of vesicular stomatitis virus exposure in horses and cattle in 1996. Mumford EL, et al. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1265–9

The seroprevalence of equine trypanosomosis in the pantanal. Dávila AM, et al. **Mem Inst Oswaldo Cruz** 1999 Mar–Apr; 94(2):199–202

Prevalence of Surra among camels and horses in Jordan. Abo–Shehada MN, et al. **Prev Vet Med** 1999 Feb 15; 38(4):289–93

The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Guthrie AJ, et al. **Rev Sci Tech** 1999 Apr;18(1):179–85 (6 ref.)

Gasterophilus intestinalis infections in horses in Belgium. Agneessens J, et al. **Vet Parasitol** 1998 Jun 15; 77(2–3):199–204

Prevalence of antibodies to Sarcocystis neurona, Toxoplasma gondii and Neospora caninum in horses from Argentina. Dubey JP, et al. **Vet Parasitol** 1999 Sep 15;86(1):59–62

Recent advances in Neospora and neosporosis. Dubey JP. **Vet Parasitol** 1999 Aug 1;84(3–4):349–67 (169 ref.)

Seroepidemiologic studies on Babesia equi and Babesia caballi infections in Brazil. Heuchert CM, et al. **Vet Parasitol** 1999 Aug 16;85(1):1–11

Historical perspective of cyathostomes: prevalence, treatment and control programs. Lyons ET, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):97–111; discussion 111–2, 215–25 (121 ref.)

Ragwort poisoning in horses [letter] McDowell DM. **Vet Rec** 1999 Jul 31;145(5):148

Subconjunctival haemorrhages in neonatal thoroughbred foals. Munroe G. **Vet Rec** 1999 Mar 13;144(11):279–82

Estimation of the prevalence of severe combined immunodeficiency disease in UK Arab horses as determined by a DNA–based test. Swinburne J, et al. **Vet Rec** 1999 Jul 3;145(1):22–3

[Prevalence of infections caused by Salmonella spp. in cattle and horses at the Veterinary Teaching Hospital of the Faculty of Veterinary Medicine of the University of Montreal] Ravary B, et al. **Can Vet J** 1998 Sep;39(9):566–72 (Eng. Abstr.) **(Fre)**

[Phenotypic characterization of equine Dermatophilus congolensis field isolates] Krüger B, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):374–8 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Suspected blue canary grass (Phalaris coerulescens) poisoning of horses. Colegate SM, et al. **Aust Vet J** 1999 Aug; 77(8):537–8

Acute renal failure from leptospirosis in a foal. Frazer ML. **Aust Vet J** 1999 Aug;77(8):499–500

Persistent right aortic arch in a yearling horse. Butt TD, et al. **Can Vet J** 1998 Nov;39(11):714–5

Post traumatic keratouveitis in horses. Moore CP, et al. **Equine Vet J** 1998 Sep;30(5):366–72

Decreased glucose metabolism causes separation of hoof lamellae in vitro: a trigger for laminitis? Pass MA, et al. **Equine Vet J Suppl** 1998 Sep;(26):133–8

Equine laminitis: its development coincides with increased sublamellar blood flow. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):125–32

Dietary and other management factors associated with colic in horses. Cohen ND, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):53–60

Ovarian disorders causing colic in neonatal foals [letter; comment] Fischer AT Jr. **J Am Vet Med Assoc** 1999 Feb 1;214(3):329–30. Comment on: J Am Vet Med Assoc 1998 Nov 15;213(10):1454–6.

Chyloperitoneum and abdominal adhesions in a miniature horse. May KA, et al. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):676–8

Theriogenology question of the month. Toxicosis associated with fescue grass infected with the endophyte Neotyphodium coenophialum (formerly Acremonium coenophialum). Mirza MH, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1405–6

Incarceration of the small colon through a rent in the gastrosplenic ligament in a pony. Rhoads WS, et al. **J Am Vet Med Assoc** 1999 Jan 15;214(2):226–8, 205

Ovarian torsion as a cause of colic in a neonatal foal [see comments] Valk N, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1454–6. Comment in: J Am Vet Med Assoc 1999 Feb 1;214(3):329–30.

Paraneoplastic syndromes. Ogilvie GK. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):439–49, v (38 ref.)

Studies on growth cartilage in the horse and their application to aetiopathogenesis of dyschondroplasia (osteochondrosis) [see comments] Jeffcott LB, et al. **Vet J** 1998 Nov; 156(3):177–92 (124 ref.). Comment in: Vet J 1998 Nov;156(3):167–8.

Equine developmental osteochondral lesions: the role of biomechanics [editorial; comment] Whitton RC. **Vet J** 1998 Nov;156(3):167–8 (8 ref.). Comment on: Vet J 1998 Nov;156(3):177–92.

False acacia poisoning in horses [letter] Hopper DW. **Vet Rec** 1999 Jul 24;145(4):115

The effect of a surgically created shunt between the corpus cavernosum penis and corpus spongiosum penis of stallions on erectile and ejaculatory function. Schumacher J, et al. **Vet Surg** 1999 Jan–Feb;28(1):21–4

[Botulism in horses] Venner M. **DTW Dtsch Tierarztl Wochenschr** 1999 Feb;106(2):73 **(Ger)**

GENETICS

Heritability of recurrent exertional rhabdomyolysis in Thoroughbred racehorses. MacLeay JM, et al. **Am J Vet Res** 1999 Feb;60(2):250–6

Phenytoin alters transcript levels of hormone-sensitive lipase in muscle from horses with hyperkalemic periodic paralysis. Yudkowsky ML, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):264–70

Hyperkalaemic periodic paralysis in homozygous and heterozygous horses: a co-dominant genetic condition. Naylor JM, et al. **Equine Vet J** 1999 Mar;31(2):153–9

Equine SCID: mechanistic analysis and comparison with murine SCID. Leber R, et al. **Vet Immunol Immunopathol** 1998 Sep 16;65(1):1–9

HISTORY

"A horse! a horse! my kingdom for a horse!" Versions of Greek horse medicine in medieval Italy. Fischer KD. **Medizinhist J** 1999;34(2):123–38

IMMUNOLOGY

The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379–87 (11 ref.)

Vaccination against Strongylus vulgaris in ponies: comparison of the humoral and cytokine responses of vaccinates and nonvaccinates. Swiderski CE, et al. **Adv Vet Med** 1999;41:389–404

In vitro allergen–induced degranulation of pulmonary mast cells from horses with recurrent airway obstruction (heaves). Hare JE, et al. **Am J Vet Res** 1999 Jul;60(7):841–7

Interaction of transforming growth factor–beta–1 with alpha–2–macroglobulin from normal and inflamed equine joints. Coté N, et al. **Can J Vet Res** 1998 Oct;62(4):279–86

Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Tobin DJ, et al. **Exp Dermatol** 1998 Oct;7(5):289–97

Development and evaluation of various enzyme–linked immunosorbent assays for the detection of Clostridium perfringens beta anti–toxins. Krt B. **FEMS Immunol Med Microbiol** 1999 Jul;24(3):293–7

Modulation of cytokine response of pneumonic foals by virulent Rhodococcus equi. Giguère S, et al. **Infect Immun** 1999 Oct;67(10):5041–7

Immunopathology of pineal glands from horses with uveitis. Kalsow CM, et al. **Invest Ophthalmol Vis Sci** 1999 Jun; 40(7):1611–5

Peripheral blood lymphocyte subpopulations and immunoglobulin concentrations in healthy foals and foals with Rhodococcus equi pneumonia. Flaminio MJ, et al. **J Vet Intern Med** 1999 May–Jun;13(3):206–12

Enzyme–linked immunosorbent assay for serological survey of equine arteritis virus in racehorses. Kondo T, et al. **J Vet Med Sci** 1998 Sep;60(9):1043–5

Understanding uveitis through the eyes of a horse: relevance of models of ocular inflammation to human disease [editorial] Dick AD. **Ocul Immunol Inflamm** 1998 Dec; 6(4):211–4 (19 ref.)

Retinal immunopathology in horses with uveitis. Kalsow CM, et al. **Ocul Immunol Inflamm** 1998 Dec;6(4):239–51

Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Lunn DP, et al. **Vaccine** 1999 May 4;17(18):2245–58

The role of neutrophil chemotactic cytokines in the pathogenesis of equine chronic obstructive pulmonary disease (COPD). Franchini M, et al. **Vet Immunol Immunopathol** 1998 Nov 6;66(1):53–65

Studies on pulmonary and systemic Aspergillus fumigatus–specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD). Schmallenbach KH, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):245–56

Equine herpesvirus type 1 infects dendritic cells in vitro: stimulation of T lymphocyte proliferation and cytotoxicity by infected dendritic cells. Siedek EM, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):17–32

Influence of age and plasma treatment on neutrophil phagocytosis and CD18 expression in foals. Gröndahl G, et al. **Vet Microbiol** 1999 Mar 12;65(3):241–54

Immunity in equine cyathostome infections. Klei TR, et al. **Vet Parasitol** 1999 Aug 31;85(2–3):123–33; discussion 133–6, 215–25 (30 ref.)

Immunohistochemical studies in equine recurrent uveitis (ERU). Romeike A, et al. **Vet Pathol** 1998 Nov; 35(6):515–26

Phenotypic analysis of bronchoalveolar lavage fluid lymphocytes in horses with chronic pulmonary disease. Kleiber C, et al. **Zentralbl Veterinarmed A** 1999 Apr; 46(3):177–84

[Chronic urticaria in sports horses] Francqueville M, et al. **Allerg Immunol (Paris)** 1999 Jun;31(6):212–3 (Eng. Abstr.) **(Fre)**

[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation] Neubauer A, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep;112(9):351–4 (Eng. Abstr.) **(Ger)**

METABOLISM

Plasma and urine nitric oxide concentrations in horses given below a low dose of endotoxin. Bueno AC, et al. **Am J Vet Res** 1999 Aug;60(8):969–76

Glucose uptake in horses with polysaccharide storage myopathy. De La Corte FD, et al. **Am J Vet Res** 1999 Apr;60(4):458–62

Local hemodynamics, permeability, and oxygen metabolism during acute inflammation of innervated or denervated isolated equine joints. Hardy J, et al. **Am J Vet Res** 1998 Oct;59(10):1307–16

Purification of two equine pepsinogens by use of high–performance liquid chromatography. Sayegh AI, et al. **Am J Vet Res** 1999 Jan;60(1):114–8

Effects of hypercapnia on endocrine and metabolic responses to anaesthesia in ponies. Taylor PM. **Res Vet Sci** 1998 Jul–Aug;65(1):41–6

MICROBIOLOGY

Experimental infection of lambs with an equine granulocytic Ehrlichia species resembling the agent that causes human granulocytic ehrlichiosis (HGE). Stuen S, et al. **Acta Vet Scand** 1998;39(4):491–7

Diversity of isolates of Rhodococcus equi from Australian thoroughbred horse farms. Morton AC, et al. **Antonie Van Leeuwenhoek** 1998 Jul–Oct;74(1–3):21–5

An unusual paracaecal abscess associated with Fusobacterium necrophorum in a horse. Trevillian CJ, et al. **Aust Vet J** 1998 Oct;76(10):659–62

Equine abortions in eastern Ontario due to leptospirosis. Shapiro JL, et al. **Can Vet J** 1999 May;40(5):350–1

Clostridium difficile associated with acute colitis in mares when their foals are treated with erythromycin and rifampicin for Rhodococcus equi pneumonia [see comments] Båverud V, et al. **Equine Vet J** 1998 Nov; 30(6):482–8. Comment in: Equine Vet J 1998 Nov;30(6):450–1.

Identification of equine proliferative enteropathy [editorial; comment] Smith DG. **Equine Vet J** 1998 Nov;30(6):452–3 . Comment on: Equine Vet J 1998 Nov;30(6):549–52.

Onychomycosis in white line disease in horses: pathology, mycology and clinical features. Kuwano A, et al. **Equine Vet J Suppl** 1998 Sep;(26):27–35

Molecular characterization of equine isolates of Streptococcus pneumoniae: natural disruption of genes encoding the virulence factors pneumolysin and autolysin. Whatmore AM, et al. **Infect Immun** 1999 Jun;67(6):2776–82

Enterotoxigenic Clostridium perfringens type A necrotic enteritis in a foal. Bueschel D, et al. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1305–7, 1280

Thoracic and abdominal blastomycosis in a horse. Toribio RE, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1357–60, 1335

Association of Clostridium difficile with enterocolitis and lactose intolerance in a foal. Weese JS, et al. **J Am Vet Med Assoc** 1999 Jan 15;214(2):229–32, 205

Prevalence of beta2-toxigenic Clostridium perfringens in horses with intestinal disorders. Herholz C, et al. **J Clin Microbiol** 1999 Feb;37(2):358–61

Digital arterial thrombosis in a septicemic foal. Forrest LJ, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):382–5

The prevalence of Aeromonas species in feces of horses with diarrhea. Hathcock TL, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):357–60

Epidemiologic features of equine Leptospira interrogans of human significance. Barwick RS, et al. **Prev Vet Med** 1998 Aug 7;36(2):153–65

Pulsed-field gel electrophoresis and distribution of the genes zag and fnz in isolates of Streptococcus equi. Lindmark H, et al. **Res Vet Sci** 1999 Apr;66(2):93–9

Preliminary characterisation of extracellular serine proteases of Dermatophilus congolensis isolates from cattle, sheep and horses. Ambrose NC, et al. **Vet Microbiol** 1998 Aug 15;62(4):321–35

In vivo pathogenicity and resistance to phagocytosis of Streptococcus equi strains with different levels of capsule expression. Anzai T, et al. **Vet Microbiol** 1999 Jul 1; 67(4):277–86

Biochemical fingerprinting and ribotyping of isolates of Actinobacillus equuli from healthy and diseased horses. Sternberg S, et al. **Vet Microbiol** 1999 Mar 31;66(1):53–65

Use of a PCR assay for Taylorella equigenitalis applied to samples from the United Kingdom. Chanter N, et al. **Vet Rec** 1998 Aug 22;143(8):225–7

Sudden death of two horses associated with pulmonary aspergillosis. Johnson PJ, et al. **Vet Rec** 1999 Jul 3; 145(1):16–20

Experimental infection of four horses with Ehrlichia phagocytophila. Pusterla N, et al. **Vet Rec** 1998 Sep 12; 143(11):303–5

Serum antibody in equine neonatal septicaemia due to Actinobacillus equuli. Rycroft AN, et al. **Vet Rec** 1998 Aug 29;143(9):254–5

Actinobacillus and Pasteurella species isolated from horses with lower airway disease. Ward CL, et al. **Vet Rec** 1998 Sep 5;143(10):277–9

[Phenotypic characterization of equine Dermatophilus congolensis field isolates] Krüger B, et al. **Berl Munch Tierarztl Wochenschr** 1998 Oct;111(10):374–8 (Eng. Abstr.) **(Ger)**

MORTALITY

Characteristics and risk factors for failure of horses with acute diarrhea to survive: 122 cases (1990–1996). Cohen ND, et al. **J Am Vet Med Assoc** 1999 Feb 1;214(3):382–90

Influence of fecal shedding of Salmonella organisms on mortality in hospitalized horses. Mainar-Jaime RC, et al. **J Am Vet Med Assoc** 1998 Oct 15;213(8):1162–6

Mortality supposedly due to intoxication by pyrrolizidine alkaloids from Heliotropium indicum in a horse population in Costa Rica: a case report. van Weeren PR, et al. **Vet Q** 1999 Apr;21(2):59–62

PARASITOLOGY

Ultrastructural aspects of feeding and secretion–excretion by the equine parasite Strongylus vulgaris. Mobarak MS, et al. **J Helminthol** 1999 Jun;73(2):147–55

Are Sarcocystis neurona and Sarcocystis falcatula synonymous? A horse infection challenge. Cutler TJ, et al. **J Parasitol** 1999 Apr;85(2):301–5

Description of a new Neospora species (Protozoa: Apicomplexa: Sarcocystidae). Marsh AE, et al. **J Parasitol** 1998 Oct;84(5):983–91

Multiple DNA markers differentiate Sarcocystis neurona and Sarcocystis falcatula. Tanhauser SM, et al. **J Parasitol** 1999 Apr;85(2):221–8

Serodiagnosis of equine piroplasmosis, dourine, and glanders using an arrayed immunoblotting method. Katz JB, et al. **J Vet Diagn Invest** 1999 May;11(3):292–4

Amebic meningoencephalitis caused by Balamuthia mandrillaris (leptomyxid ameba) in a horse. Kinde H, et al. **J Vet Diagn Invest** 1998 Oct;10(4):378–81

Pathogenesis of Babesia caballi infection in experimental horses. Hanafusa Y, et al. **J Vet Med Sci** 1998 Oct; 60(10):1127–32

Halicephalobus gingivalis (Stefanski, 1954) from a fatal infection in a horse in Ontario, Canada with comments on the validity of H. deletrix and a review of the genus. Anderson RC, et al. **Parasite** 1998 Sep;5(3):255–61

Transglutaminase activity in equine strongyles and its potential role in growth and development. Rao UR, et al. **Parasite** 1999 Jun;6(2):131–9

Species-specific amplification by PCR of ribosomal DNA from some equine strongyles. Hung GC, et al. **Parasitology** 1999 Jul;119 (Pt 1):69–80

Development of Sarcocystis falcatula in cell cultures demonstrates that it is different from Sarcocystis neurona. Lindsay DS, et al. **Parasitology** 1999 Mar;118 (Pt 3):227–33

Proceedings of a conference on equine cyathostomes. Athens, Georgia, USA. 7–8 November 1998. **Vet Parasitol** 1999 Aug 31;85(2–3):95–225

Trypanosoma evansi and T. equiperdum: distribution, biology, treatment and phylogenetic relationship (a review). Brun R, et al. **Vet Parasitol** 1998 Oct;79(2):95–107 (59 ref.)

Inter-relationship between Gasterophilus larvae and the horse's gastric and duodenal wall with special reference to penetration. Cogley TP, et al. **Vet Parasitol** 1999 Sep 30;86(2):127–42

Comparative efficacy evaluation of moxidectin gel and ivermectin paste against internal parasites of equines in Brazil. Costa AJ, et al. **Vet Parasitol** 1998 Dec 15; 80(1):29–36

Recovery of Oxyuris equi eggs from hemomelasma ilei lesions on ileal serosa of a Thoroughbred yearling filly. Tolliver SC, et al. **Vet Parasitol** 1999 Jan 28;80(4):353–7

PATHOLOGY

Idiopathic peripheral neuropathy in the horse with knuckling: muscle and nerve lesions in additional cases. Furuoka H, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):431–7

Morphometric analysis of endometrial periglandular fibrosis in mares. Evans TJ, et al. **Am J Vet Res** 1998 Oct; 59(10):1209–14

Pathologic changes in the lumbosacral vertebrae and pelvis in Thoroughbred racehorses. Haussler KK, et al. **Am J Vet Res** 1999 Feb;60(2):143–53

Culture and characterization of equine terminal arch endothelial cells and hoof keratinocytes. Wunn D, et al. **Am J Vet Res** 1999 Jan;60(1):128–32

Calcified cartilage morphometry and its relation to subchondral bone remodeling in equine arthrosis. Norrdin RW, et al. **Bone** 1999 Feb;24(2):109–14

Paranasal sinus cyst as a cause of stridor in a standardbred colt. Gilroy BJ, et al. **Can Vet J** 1999 Jan;40(1):49–51

Cytology of 100 samples of abdominal fluid from 100 horses with abdominal disease. Garma-Aviña A. **Equine Vet J** 1998 Sep;30(5):435–44

Subchondral bone changes and cartilage damage [editorial; comment] Radin EL. **Equine Vet J** 1999 Mar;31(2):94–5. Comment on: Equine Vet J 1999 Mar;31(2):111–5.

Ocular manifestations of equine motor neuron disease [see comments] Riis RC, et al. **Equine Vet J** 1999 Mar; 31(2):99–110. Comment in: Equine Vet J 1999 Mar;31(2):90–1.

Onychomycosis in white line disease in horses: pathology, mycology and clinical features. Kuwano A, et al. **Equine Vet J Suppl** 1998 Sep;(26):27–35

Equine laminitis basement membrane pathology: loss of type IV collagen, type VII collagen and laminin immunostaining. Pollitt CC, et al. **Equine Vet J Suppl** 1998 Sep;(26):139–44

Incidence and morphology of endometrial angiopathies in mares in relationship to age and parity. Grüninger B, et al. **J Comp Pathol** 1998 Oct;119(3):293–309

Malignant rhabdoid tumour in the orbit of a horse. Hong CB, et al. **J Comp Pathol** 1999 Aug;121(2):197–201

Oral metastasis of renal cell carcinoma in a horse. Rhind SM, et al. **J Comp Pathol** 1999 Jan;120(1):97–103

Dissecting aortic aneurysm in a horse. Shirai W, et al. **J Comp Pathol** 1999 Apr;120(3):307–11

Bilateral testicular leiomyosarcoma in a stallion. Allison N, et al. **J Vet Diagn Invest** 1999 Mar;11(2):179–82

Odontogenic myxoma of the mandible in a filly. Chandra AM, et al. **J Vet Diagn Invest** 1999 May;11(3):274–7

Clinical, serologic, and histopathologic characterization of experimental Borna disease in ponies. Katz JB, et al. **J Vet Diagn Invest** 1998 Oct;10(4):338–43

Abdominal spindle cell sarcoma of probable myofibroblastic origin in a horse. Newman SJ, et al. **J Vet Diagn Invest** 1999 May;11(3):278–82

Primary erythrocytosis in a 2-year-old Arabian gelding. McFarlane D, et al. **J Vet Intern Med** 1998 Sep–Oct; 12(5):384–8

Frontal septation of the bladder in a mare. Sponseller BA, et al. **J Vet Intern Med** 1998 Jul–Aug;12(4):313–5

Peripheral nerve lesions in a case of equine motor neuron disease. Furuoka H, et al. **J Vet Med Sci** 1999 May; 61(5):557–60

Retinal immunopathology in horses with uveitis. Kalsow CM, et al. **Ocul Immunol Inflamm** 1998 Dec;6(4):239–51

Osseous spinal pathology. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):103–12, vii (53 ref.)

Spinal muscle pathology. Valberg SJ. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):87–96, vi–vii (15 ref.)

Equine nasal and paranasal sinus tumours. Part 1: review of the literature and tumour classification. Head KW, et al. **Vet J** 1999 May;157(3):261–78 (100 ref.)

Histopathological findings in the medial palmar and dorsomedial intercarpal ligaments of the equine midcarpal joint [see comments] Whitton RC, et al. **Vet J** 1999 Jan; 157(1):23–9. Comment in: Vet J 1999 Jan;157(1):1–3.

Intestinal lesions in a horse associated with eastern equine encephalomyelitis virus infection. Poonacha KB, et al. **Vet Pathol** 1998 Nov;35(6):535–8

Amylopectinosis in fetal and neonatal Quarter Horses. Render JA, et al. **Vet Pathol** 1999 Mar;36(2):157–60

Necrotizing mycotic vasculitis with cerebral infarction caused by Aspergillus niger in a horse with acute typholocolitis. Tunev SS, et al. **Vet Pathol** 1999 Jul; 36(4):347–51

Ossifying fibroma/osteoma in the proximal tibia of a mature gelding. Collins JA. **Vet Rec** 1998 Sep 26;143(13):367–8

Prediction of long-term outcome following grass sickness (equine dysautonomia). Doxey DL, et al. **Vet Rec** 1999 Apr 3;144(14):386–7

Fibrous epulides in a horse [letter] King M, et al. **Vet Rec** 1999 Jul 10;145(2):56

Acquired flexural deformity of the metacarpophalangeal joint in five horses associated with tendonous damage in the palmar metacarpus. McDiarmid A. **Vet Rec** 1999 Apr 24; 144(17):475–8

Clinicopathological features of equine primary hepatic disease: a review of 50 cases. McGorum BC, et al. **Vet Rec** 1999 Jul 31;145(5):134–9

Vestibular disease in two horses: a case of mycotic otitis media and a case of temporohyoid osteoarthropathy. Newton SA, et al. **Vet Rec** 1999 Jul 31;145(5):142–4

Mammary carcinoma in three mares. Prendergast M, et al. **Vet Rec** 1999 Jun 26;144(26):731–2

False acacia poisoning in horses [letter] Thursby-Pelham RH. **Vet Rec** 1999 Jul 31;145(5):148

Pathological alterations caused by Anoplocephala perfoliata infection in the ileocaecal junction of equids. Rodriguez-Bertos A, et al. **Zentralbl Veterinarmed A** 1999 Jul;46(5):261–9

[A Shetland pony with a squamous cell carcinoma of the stomach] Geelen SN, et al. **Tijdschr Diergeneeskd** 1999 Apr 15;124(8):248–50 (Eng. Abstr.) **(Dut)**

PHYSIOPATHOLOGY

Idiopathic peripheral neuropathy in the horse with knuckling: muscle and nerve lesions in additional cases. Furuoka H, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):431–7

Relationship between hind limb lameness and radiographic signs of bone spavin in Icelandic horses in Sweden. Axelsson M, et al. **Acta Vet Scand** 1998;39(3):349–57

Modulation of ACh release from airway cholinergic nerves in horses with recurrent airway obstruction. Zhang XY, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L769–75

Techniques for evaluation of right ventricular relaxation rate in horses and effects of inhalant anesthetics with and without intravenous administration of calcium gluconate. Grubb TL, et al. **Am J Vet Res** 1999 Jul;60(7):872–9

In vitro contractile responses and contracture testing of skeletal muscle from Quarter Horses with exertional rhabdomyolysis. Lentz LR, et al. **Am J Vet Res** 1999 Jun; 60(6):684–8

Abnormal regulation of muscle contraction in horses with recurrent exertional rhabdomyolysis. Lentz LR, et al. **Am J Vet Res** 1999 Aug;60(8):992–9

Myeloperoxidase activity of the large intestine in an equine model of acute colitis. McConnico RS, et al. **Am J Vet Res** 1999 Jul;60(7):807–13

Comparison of forced oscillation with the conventional method for histamine bronchoprovocation testing in horses. Mazan MR, et al. **Am J Vet Res** 1999 Feb;60(2):174–80

Palmar digital vessel relaxation in healthy horses and in horses given carbohydrate. Schneider DA, et al. **Am J Vet Res** 1999 Feb;60(2):233–9

Instability-induced osteoarthritis in the metacarpophalangeal joint of horses. Simmons EJ, et al. **Am J Vet Res** 1999 Jan;60(1):7–13

Effects of buprenorphine on cardiovascular and pulmonary function in clinically normal horses and horses with chronic obstructive pulmonary disease. Szöke MO, et al. **Am J Vet Res** 1998 Oct;59(10):1287–91

Hemodynamic effects of thyroidectomy in sedentary horses. Vischer CM, et al. **Am J Vet Res** 1999 Jan;60(1):14–21

Alveolar clearance in horses with chronic obstructive pulmonary disease. Votion DM, et al. **Am J Vet Res** 1999 Apr;60(4):495–500

Transient alteration in intestinal permeability to technetium Tc99m diethylenetriaminopentaacetate during the prodromal stages of alimentary laminitis in ponies. Weiss DJ, et al. **Am J Vet Res** 1998 Nov;59(11):1431–4

Disease-specific changes in equine ground reaction force data documented by use of principal component analysis. Williams GE, et al. **Am J Vet Res** 1999 May;60(5):549–55

Phylogenetic characterization of a highly attenuated strain of equine arteritis virus from the semen of a persistently infected standardbred stallion. Patton JF, et al. **Arch Virol** 1999;144(4):817–27

Clinical assessment of gas exchange in mature horses. Davis MS, et al. **Equine Vet J** 1998 Sep;30(5):396–400

Effect of moderate exercise on the severity of clinical signs associated with influenza virus infection in horses. Gross DK, et al. **Equine Vet J** 1998 Nov;30(6):489–97

The continuity of life: from the fetus to old age [editorial; comment] Rossdale PD. **Equine Vet J** 1998 Nov;30(6):454 . Comment on: Equine Vet J 1998 Nov;30(6):455–66.

Intra-articular pressure, elastance and range of motion in healthy and injured racehorse metacarpophalangeal joints [published erratum appears in Equine Vet J 1999 Mar;31(2):120] Strand E, et al. **Equine Vet J** 1998 Nov; 30(6):520–7

Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Tobin DJ, et al. **Exp Dermatol** 1998 Oct;7(5):289–97

Lawsonia intracellularis-like organism infection in a miniature foal. Brees DJ, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):511–4, 483

Speed dependency of motion pattern consistency. Peham C, et al. **J Biomech** 1998 Sep;31(9):769–72

The neurology and enterology of equine grass sickness: a review of basic mechanisms [see comments] Cottrell DF, et al. **Neurogastroenterol Motil** 1999 Apr;11(2):79–92 (134 ref.). Comment in: Neurogastroenterol Motil 1999 Apr;11(2):i–ii.

Variations in systemic and pulmonary endothelin-1 in horses with recurrent airway obstruction (heaves). Benamou AE, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):231–5

Equine nasal and paranasal sinus tumours: part 2: a contribution of 28 case reports [see comments] Dixon PM, et al. **Vet J** 1999 May;157(3):279–94. Comment in: Vet J 1999 May;157(3):220–1.

Determinants of the maximal change in pleural pressure during tidal breathing in COPD-affected horses. Robinson NE, et al. **Vet J** 1999 Mar;157(2):160–5

Responses of guinea-pig lung parenchymal strips to tracheobronchial lavage fluid from horses affected with summer pasture-associated obstructive pulmonary disease. Venugopalan CS, et al. **Vet Res Commun** 1998 Nov; 22(7):493–503

Measurement of serum and synovial fluid keratan sulphate and antibody to collagen type II in equine osteoarthritis. Okumura M, et al. **Zentralbl Veterinarmed A** 1998 Oct; 45(8):513–6

[Diagnosis, therapy and endocrinologic parameters of persistent follicles in mares in comparison with preovulatory follicles] Kaiser B, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 May; 27(3):180–6 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Diagnosis and prevention of equine infectious diseases: present status, potential, and challenges for the future. Desmettre P. **Adv Vet Med** 1999;41:359–77 (129 ref.)

Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates. Turell MJ, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):1041–4

Effects of extrathoracic airway obstruction on intrathoracic pressure and pulmonary artery pressure in exercising horses. Hackett RP, et al. **Am J Vet Res** 1999 Apr; 60(4):485–94

Effect of timing and route of administration of furosemide on pulmonary hemorrhage and pulmonary arterial pressure in exercising thoroughbred racehorses. Lester G, et al. **Am J Vet Res** 1999 Jan;60(1):22–8

Equine piroplasmosis: the temporary importation of seropositive horses into Australia. Martin R. **Aust Vet J** 1999 May;77(5):308–9

Nosocomial infections: listening to human experience may help the horse [editorial; comment] Sage R. **Equine Vet J** 1998 Nov;30(6):450–1. Comment on: Equine Vet J 1998 Nov;30(6):482–8.

Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. Morley PS, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):61–6

Questions validity of equine vaccine field studies [letter] Piontkowski MD. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):620–1

Occlusion of the internal carotid artery by means of microcoils for preventing epistaxis caused by guttural pouch mycosis in horses. Matsuda Y, et al. **J Vet Med Sci** 1999 Mar;61(3):221–5

Review of furosemide in horse racing: its effects and regulation. Soma LR, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):228–40 (103 ref.)

Control of equine piroplasmosis in Brazil. Kerber CE, et al. **Onderstepoort J Vet Res** 1999 Jun;66(2):123–7

Tack and saddle fit. Harman J. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):247–61, ix (5 ref.)

Protective effects of equine herpesvirus-1 (EHV-1) glycoprotein B in a murine model of EHV-1-induced abortion. Kukreja A, et al. **Vet Microbiol** 1998 Aug 15; 62(4):303–11

Considerations for the control of equine cyathostomes in arid areas. Craig TM. **Vet Parasitol** 1999 Aug 31;85(2-3):181–6; discussion 186–8, 215–25

Alternative approaches to control of cyathostomes: an African perspective. Krecek RC, et al. **Vet Parasitol** 1999 Aug 31;85(2-3):151–60; discussion 160–2, 215–25

Current concerns about control programs in temperate climates. Reinemeyer CR. **Vet Parasitol** 1999 Aug 31; 85(2-3):163–9; discussion 169–72, 215–25

Strategic control of gastrointestinal nematode and lungworm infections with eprinomectin at turnout and eight weeks later. Epe C, et al. **Vet Rec** 1999 Apr 3;144(14):380–2

Control of equine viral arteritis [letter; comment] Parker J. **Vet Rec** 1999 Feb 13;144(7):186. Comment on: Vet Rec 1998 Dec 19–26;143(25):699.

Failure of psyllium mucilloid to hasten evaluation of sand from the equine large intestine. Hammock PD, et al. **Vet Surg** 1998 Nov-Dec;27(6):547–54

Equine arteritis virus derived from an infectious cDNA clone is attenuated and genetically stable in infected stallions. Balasuriya UB, et al. **Virology** 1999 Jul 20;260(1):201–8

[Veterinary recommendations for the handling of equine virus arteritis (EVA) in practical breeding care] Klug E, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):61–6 (38 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Prevalence and risk factors of bone spavin in Icelandic horses in Sweden: a radiographic field study. Eksell P, et al. **Acta Vet Scand** 1998;39(3):339–48

What is your diagnosis? A large, elongated mineral opacity extending proximal from the navicular bone. Blaik MA, et al. **J Am Vet Med Assoc** 1999 Feb 15;214(4):481–2

What is your diagnosis? Osteochondritis dissecans (OCD). Charlton A, et al. **J Am Vet Med Assoc** 1999 Jul 15; 215(2):191–2

What is your diagnosis? Extensive alveolar pattern in the caudodorsal and caudoventral aspects of the right and left lungs. Costa LR, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):623–4

What is your diagnosis? Small intestinal obstruction as a result of incarceration in a diaphragmatic hernia. Ethell MT, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):321–2

What is your diagnosis? Mass in the left nasal passage with evidence of mineralization. Lopez MJ, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1005–6

Back problems. Radiology and scintigraphy. Weaver MP, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):113–29, vii–viii (20 ref.)

Magnetic resonance (MR) imaging studies on horses [letter] Kneissl S, et al. **Vet Radiol Ultrasound** 1999 Mar-Apr; 40(2):208–9

The accuracy of the dorsoproximal-dorsodistal projection in assessing third carpal bone sclerosis in standardbred trotters. Uhlhorn H, et al. **Vet Radiol Ultrasound** 1998 Sep-Oct;39(5):412–7

Computed tomography of cholesterinic granulomas in the choroid plexus of horses. Vink-Nooteboom M, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec;39(6):512–6

[Radiologic examination of the spine in "back problems" of the standing horse] Ranner W, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Apr; 27(2):122–7 (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Pulmonary distribution of aerosolized technetium Tc 99m pentetate after administration of a single dose of aerosolized albuterol sulfate in horses with recurrent airway obstruction [published erratum appears in Am J Vet Res 1999 Jul;60(7):847] Rush BR, et al. **Am J Vet Res** 1999 Jun;60(6):764–9

Occult osseous metastasis of a colonic adenocarcinoma visualized with technetium tc 99m hydroxymethylene diphosphate scintigraphy in a horse. East LM, et al. **J Am Vet Med Assoc** 1998 Oct 15;213(8):1167–70, 1132–3

Back problems. Radiology and scintigraphy. Weaver MP, et al. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):113–29, vii–viii (20 ref.)

Abnormal bone scan findings of the equine ischial tuberosity and third trochanter. Geissbühler U, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec;39(6):572–7

Analysis of scintigraphical lung images before and after treatment of horses suffering from chronic pulmonary disease [published erratum appears in Vet Rec 1999 Apr 3;144(14):387] Votion D, et al. **Vet Rec** 1999 Feb 27; 144(9):232–6

RADIOTHERAPY

Radiation therapy in the horse. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec;14(3):673–88, viii (16 ref.)

SURGERY

Equine castration: review of anatomy, approaches, techniques and complications in normal, cryptorchid and monorchid horses. Searle D, et al. **Aust Vet J** 1999 Jul;77(7):428–34 (25 ref.)

Partial phallectomy to treat priapism in a horse. Van Harreveld PD, et al. **Aust Vet J** 1999 Mar;77(3):167–9

Urethrorectal fistula in a horse. Cruz AM, et al. **Can Vet J** 1999 Feb;40(2):122–4

Septic osteitis of the distal phalanx: findings and surgical treatment in 18 cases. Cauvin ER, et al. **Equine Vet J** 1998 Nov;30(6):512–9

Viability of an inguinal testis after laparoscopic cauterization and transection of its blood supply. Bergeron JA, et al. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1303–4, 1280

Surgical repair of a diaphragmatic hernia in a racehorse. Dabareiner RM, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1517–8, 1496

Deep digital flexor tenotomy as a treatment for chronic laminitis in horses: 35 cases (1988–1997) [published erratum appears in J Am Vet Med Assoc 1999 Apr 15;214(8):1217] Eastman TG, et al. **J Am Vet Med Assoc** 1999 Feb 15; 214(4):517–9

Cecocolic and cecocecal intussusception in horses: 30 cases (1976–1996). Martin BB Jr, et al. **J Am Vet Med Assoc** 1999 Jan 1;214(1):80–4

Neodymium:yttrium-aluminum-garnet laser-assisted excision of progressive ethmoid hematomas in horses: 20 cases (1986–1996). Rothaug PG, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1037–41

Inflammatory bowel disease in horses: 11 cases (1988–1998). Scott EA, et al. **J Am Vet Med Assoc** 1999 May 15; 214(10):1527–30

Anesthesia case of the month. Laryngeal stridor in a horse caused by an epiglottic cyst. Wilson DV, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):629–31

Ablation of the nephrosplenic space for treatment of recurring left dorsal displacement of the large colon in a racehorse. Zekas LJ, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1361–3, 1335

Postanaesthetic recumbency in a Belgian filly with polysaccharide storage myopathy. Bloom BA, et al. **Vet Rec** 1999 Jan 16;144(3):73–5

Biodegradable drug delivery systems for gentamicin release and treatment of synovial membrane infection. Cook VL, et al. **Vet Surg** 1999 Jul-Aug;28(4):233–41

Surgical reduction of ileal impactions in the horse: 28 cases. Hanson RR, et al. **Vet Surg** 1998 Nov-Dec;27(6):555–60

An in vitro biomechanical comparison of an interlocking nail system and dynamic compression plate fixation of osteotomized equine third metacarpal bones. Lopez MJ, et al. **Vet Surg** 1999 Sep-Oct;28(5):333–40

Standing surgical repair of cystorrhexis in two mares. Rodgerson DH, et al. **Vet Surg** 1999 Mar-Apr;28(2):113–6

Desmotomy of the accessory ligament of the superficial digital flexor tendon in the horse with use of a tenoscopic approach to the carpal sheath. Southwood LL, et al. **Vet Surg** 1999 Mar-Apr;28(2):99–105

[The prevention of pneumovagina and the effect of the Caslick operation on fertility: a retrospective study] van Ittersum AR, et al. **Tijdschr Diergeneeskd** 1999 May 1; 124(9):281–3 (Eng. Abstr.) **(Dut)**

[Transendoscopic laser surgery of exercise-induced dorsal displacement of the soft palate in horses] Ohnesorge B, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Sep; 26(5):287–93 (Eng. Abstr.) **(Ger)**

THERAPY

Ballistic shock wave lithotripsy in an 18-year-old thoroughbred gelding. Koenig J, et al. **Can Vet J** 1999 Mar; 40(3):185–6

Osteochondritis dessicans and subchondral cystic lesions in draft horses: a retrospective study. Riley CB, et al. **Can Vet J** 1998 Oct;39(10):627–33

Digital perfusion, evaluated scintigraphically, and hoof wall growth in horses with chronic laminitis treated with egg bar-heart bar shoeing and coronary grooving. Ritmeester AM, et al. **Equine Vet J Suppl** 1998 Sep;(26):111–8

Comparison of medical and surgical treatment for impaction of the small colon in horses: 84 cases (1986–1996). Rhoads WS, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1042–7

Endoscopic treatment of suspected infectious intertubercular bursitis in a horse. Tudor RA, et al. **J Am Vet Med Assoc** 1998 Dec 1;213(11):1584–5, 1570

Hemothorax in 2 horses. Perkins G, et al. **J Vet Intern Med** 1999 Jul-Aug;13(4):375–8

Factors influencing recovery from and duration of lameness in Michigan (USA) horses. Ross WA, et al. **Prev Vet Med** 1999 May 31;40(2):127–38

Physical therapy for the equine back. Bromiley MW. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):223–46 (57 ref.)

Back problems. Chiropractic evaluation and management. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):195–209 (43 ref.)

Medical management of back pain. Marks D. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):179–94, viii (27 ref.)

Acupuncture as a treatment modality for back problems. Ridgway K. **Vet Clin North Am Equine Pract** 1999 Apr; 15(1):211–21 (12 ref.)

Equine back rehabilitation. Ridgway K, et al. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):263–80, x (23 ref.)

Intralesional and topical chemotherapy and immunotherapy. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):659–71, viii (35 ref.)

Complications of balloon catheterization associated with aberrant cerebral arterial anatomy in a horse with guttural pouch mycosis. Bacon Miller C, et al. **Vet Surg** 1998 Sep-Oct;27(5):450–3

TRANSMISSION

Evaluation of temporal and spatial clustering of horses with Corynebacterium pseudotuberculosis infection. Doherr MG, et al. **Am J Vet Res** 1999 Mar;60(3):284–91

Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats. Williamson MM, et al. **Aust Vet J** 1998 Dec;76(12):813–8

Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV). McCormack JG, et al. **J Infect** 1999 Jan;38(1):22–3

Seasonal transmission of equine cyathostomes in warm climates. Courtney CH. **Vet Parasitol** 1999 Aug 31; 85(2–3):173–7; discussion 177–80, 215–25

Equine viral arteritis risk from imported semen [letter] [see comments] Pycock JF. **Vet Rec** 1998 Dec 19–26;143(25):699 Comment in: Vet Rec 1999 Feb 13;144(7):186.

ULTRASONOGRAPHY

Ultrasonographic confirmation of a space-occupying lesion in the brain of a horse: choroid plexus papilloma. Pirie RS, et al. **Equine Vet J** 1998 Sep;30(5):445–8

Ultrasonographic evaluation of back lesions. Denoix JM. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):131–59 (29 ref.)

Spinal ligament pathology. Gillis C. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):97–101 (20 ref.)

Ultrasound as an aid for diagnosis of ovarian abscesses in two mares. Ramirez S, et al. **Vet Radiol Ultrasound** 1999 Mar–Apr;40(2):165–8

Chronic renal failure associated with nephrolithiasis, ureterolithiasis, and renal dysplasia in a 2-year-old quarter horse gelding. Wooldridge AA, et al. **Vet Radiol Ultrasound** 1999 Jul–Aug;40(4):361–4

VIROLOGY

Rapid and sensitive detection of equine arteritis virus in semen and tissue samples by reverse transcription-polymerase chain reaction, dot blot hybridisation and nested polymerase chain reaction. Starick E. **Acta Virol** 1998 Nov;42(5):333–9

Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. Oberste MS, et al. **Am J Trop Med Hyg** 1999 Apr; 60(4):630–4

Detection of equine arteritis virus in semen by reverse transcriptase polymerase chain reaction-ELISA. Ramina A, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jul; 22(3):187–97

Serologic and molecular characterization of an abortigenic strain of equine arteritis virus isolated from infective frozen semen and an aborted equine fetus. Balasuriya UB, et al. **J Am Vet Med Assoc** 1998 Dec 1;213(11):1586–9, 1570

Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis. Balasuriya UB, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1949–58

Latency-associated transcripts of equine herpesvirus type 4 in trigeminal ganglia of naturally infected horses. Borchers K, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):2165–71

Genetic divergence with emergence of novel phenotypic variants of equine arteritis virus during persistent infection of stallions. Hedges JF, et al. **J Virol** 1999 May; 73(5):3672–81

Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5' noncoding region and glycoproteins. Spotts DR, et al. **J Virol** 1998 Dec;72(12):10286–91

Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor. Wang E, et al. **J Virol** 1999 May;73(5):4266–71

Screening of horse polyclonal antibodies with a random peptide library displayed on phage: identification of ligands used as antigens in an ELISA test to detect the presence of antibodies to equine arteritis virus. Iniguez P, et al. **J Virol Methods** 1998 Aug;73(2):175–83

Getah virus infection of Indian horses. Brown CM, et al. **Trop Anim Health Prod** 1998 Aug;30(4):241–52

Equine viral arteritis in a gelding in the UK [letter] Pleydell E, et al. **Vet Rec** 1999 Jul 10;145(2):54

Possible case of EHV-4 ataxia in warmblood mare [letter] Verheyen K, et al. **Vet Rec** 1998 Oct 17;143(16):456

Bovine papillomaviral gene expression in equine sarcoid tumours. Nasir L, et al. **Virus Res** 1999 Jun;61(2):171–5

[Cowpox viruses in Germany: an analysis of 5 cases in 1998] Pfeffer M, et al. **Berl Munch Tierarztl Wochenschr** 1999 Sep;112(9):334–8 (Eng. Abstr.) **(Ger)**

HORSERADISH PEROXIDASE

Ferrocene-conjugated m-phenylenediamine conducting polymer-incorporated peroxidase biosensors. Mulchandani A, et al. **Anal Biochem** 1999 Feb 1;267(1):141–7

In situ identification of cyanobacteria with horseradish peroxidase-labeled, rRNA-targeted oligonucleotide probes. Schönhuber W, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1259–67

Interaction of steroid--peroxidase conjugates with cellulose immunosorbents in aqueous and micellar media. Eryomin AN, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1148–59

Marking nitrocellulose membranes by peroxidase spotting. Eberini I, et al. **Electrophoresis** 1999 Mar;20(3):491–2

Fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification for sensitive DNA and mRNA detection. van de Corput MP, et al. **Histochem Cell Biol** 1998 Oct;110(4):431–7

Different effects of exogenous horseradish peroxidase on luminol-amplified chemiluminescence induced by soluble and particulate stimuli in human neutrophils. Kopprasch S, et al. **J Biolumin Chemilumin** 1998 Sep–Oct;13(5):267–71

Visualization of axonally transported horseradish peroxidase using enhanced immunocytochemical detection: a direct comparison with the tetramethylbenzidine method. Romero MI, et al. **J Histochem Cytochem** 1999 Feb; 47(2):265–72

Sensitive mRNA detection by fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification. van de Corput MP, et al. **J Histochem Cytochem** 1998 Nov; 46(11):1249–59

Analysis of the endocytic system by using horseradish peroxidase. Stoorvogel W. **Trends Cell Biol** 1998 Dec; 8(12):503–5

ADMINISTRATION & DOSAGE

Ocular drug targeting by liposomes and their corneal interactions. Velpandian T, et al. **J Microencapsul** 1999 Mar–Apr;16(2):243–50

ANTAGONISTS & INHIBITORS

Solution 1H NMR investigation of the heme cavity and substrate binding site in cyanide-inhibited horseradish peroxidase. de Ropp JS, et al. **Biochemistry** 1999 Jan 19; 38(3):1077–86

Inhibition of peroxidase, trypsin, and alpha-chymotrypsin by platinum (II) and platinum (IV) complexes. Muginova SV, et al. **Biochemistry (Mosc)** 1999 Apr;64(4):399–404

Effect of antioxidants (digoxin, quercetin, and ascorbic acid) on catalytic properties of horseradish peroxidase. Rogozhin VV, et al. **Biochemistry (Mosc)** 1998 Jun;63(6):657–61

Suicide inactivation of peroxidase by H2O2: kinetic equations for peroxidatic oxidation reaction of guaiacol and determination of the kinetic parameters. Moosavi Movahedi AA, et al. **Ital J Biochem** 1999 Mar;48(1):9–17

CHEMISTRY

Solution 1H NMR investigation of the heme cavity and substrate binding site in cyanide-inhibited horseradish peroxidase. de Ropp JS, et al. **Biochemistry** 1999 Jan 19; 38(3):1077–86

The distal cavity structure of carbonyl horseradish peroxidase as probed by the resonance Raman spectra of His 42 Leu and Arg 38 Leu mutants. Feis A, et al. **Biochemistry** 1998 Sep 29;37(39):13575–81

Hydrogen peroxide production from reactive liposomes encapsulating enzymes. Kaszuba M, et al. **Biochim Biophys Acta** 1999 Jul 15;1419(2):221–8

Photo-modulation of horseradish peroxidase activity via covalent attachment of carboxylated-spiropyran dyes. Weston DG, et al. **Biochim Biophys Acta** 1999 Aug 5; 1428(2–3):463–7

Apohorseradish peroxidase unfolding and refolding: intrinsic tryptophan fluorescence studies. Lasagna M, et al. **Biophys J** 1999 Jan;76(1 Pt 1):443–50

Hydrazide-functionalized poly(2-hydroxyethyl methacrylate) microspheres for immobilization of horseradish peroxidase. Horák D, et al. **Biotechnol Prog** 1999 Mar–Apr;15(2):208–15

Anterograde transport of horseradish-peroxidase conjugated isolectin B4 from Griffonia simplicifolia I in spinal primary sensory neurons of the rat. Wang HF, et al. **Brain Res** 1998 Nov 16;811(1–2):34–9

Heterogeneity of glycans at each N-glycosylation site of horseradish peroxidase. Gray JS, et al. **Carbohydr Res** 1998 Sep;311(1–2):61–9

The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives. Mazerska Z, et al. **Chem Biol Interact** 1998 Aug 14;115(1):1–22

Structural changes of horseradish peroxidase in presence of low concentrations of urea. Haque E, et al. **Eur J Biochem** 1999 Jan;259(1–2):269–74

Kinetic approach to the interaction of sodium n-dodecyl sulphate with heme enzymes. Gębicka L. **Int J Biol Macromol** 1999 Jan;24(1):69–74

Rapid alcohol determination in plasma and urine by column liquid chromatography with biosensor detection. Lidén H, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):1111–28

Retrograde and transganglionic transport of horseradish peroxidase-conjugated cholera toxin B subunit, wheatgerm agglutinin and isolectin B4 from Griffonia simplicifolia I in primary afferent neurons innervating the rat urinary bladder. Wang HF, et al. **Neuroscience** 1998 Nov; 87(1):275–88

[Mechanism of combined oxidation of ascorbic acid and hydroquinone in the presence of horseradish peroxidase] Rogozhin VV, et al. **Bioorg Khim** 1999 May;25(5):377–82 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Application of biotinylated tyramine to amplify reactions with horseradish peroxidase labelling. Surowiak P, et al. **Folia Histochem Cytobiol** 1999;37(2):57–8

GENETICS

Luminol activity of horseradish peroxidase mutants mimicking a proposed binding site for luminol in Arthromyces ramosus peroxidase. Tanaka M, et al. **Biochemistry** 1999 Aug 10;38(32):10463–73

Functional expression of horseradish peroxidase in E. coli by directed evolution. Lin Z, et al. **Biotechnol Prog** 1999 May–Jun;15(3):467–71

IMMUNOLOGY

Enhanced antigen transport across rat tracheal epithelium induced by sensitization and mast cell activation. Yang PC, et al. **J Immunol** 1999 Sep 1;163(5):2769–76

Development of a bispecific monoclonal antibody as a universal immunoprobe for detecting biotinylated macromolecules. Cao Y, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):85–91

METABOLISM

A bifunctional luminogenic substrate for two luminescent enzymes: firefly luciferase and horseradish peroxidase. Sudhaharan T, et al. **Anal Biochem** 1999 Jul 1;271(2):159–67

Reactions of N-N and N-O compounds with horseradish peroxidase and peroxidases from Mycobacterium tuberculosis. Brimnes J, et al. **APMIS** 1999 Jun; 107(6):555–65

Tryptophanless recombinant horseradish peroxidase: stability and catalytic properties. Gazaryan IG, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):297–301

Kinetic evidence for the formation of a Michaelis-Menten-like complex between horseradish peroxidase compound II and di-(N-acetyl-L-tyrosine). Wang W, et al. **Biochem J** 1999 May 15;340 (Pt 1):329–36

Mechanism of horseradish peroxidase catalyzed epinephrine oxidation: obligatory role of endogenous O2- and H2O2. Adak S, et al. **Biochemistry** 1998 Dec 1;37(48):16922–33

Luminol activity of horseradish peroxidase mutants mimicking a proposed binding site for luminol in Arthromyces ramosus peroxidase. Tanaka M, et al. **Biochemistry** 1999 Aug 10;38(32):10463–73

Taurocholate-induced inhibition of hepatic lysosomal degradation of horseradish peroxidase. Larocca MC, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2–3):341–7

Oxidation of 4-tert-butylcatechol and dopamine by hydrogen peroxide catalysed by horseradish peroxidase. García-Moreno M, et al. **Biol Chem** 1999 Jun;380(6):689–94

Immobilization of horseradish peroxidase in cross-linked phyllosilicates: conditions and characterizations. Shen S, et al. **Biotechnol Appl Biochem** 1999 Apr;29 (Pt 2):185–9

A simple, two-color fluorescence detection method for membrane blotting analysis using alkaline phosphatase and horseradish peroxidase. Kondoh Y, et al. **DNA Res** 1998 Jun 30;5(3):217–20

Hydroxyl-radical production in physiological reactions. A novel function of peroxidase. Chen SX, et al. **Eur J Biochem** 1999 Mar;260(3):726–35

Thiol-dependent degradation of protoporphyrin IX by plant peroxidases. Dayan FE, et al. **FEBS Lett** 1999 Feb 12; 444(2–3):227–30

DNA and 2'-deoxyguanosine damage in the horseradish-peroxidase-catalyzed autoxidation of aldehydes: the search for the oxidizing species. Adam W, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):566–79

Oxidative modification of human low-density lipoprotein by horseradish peroxidase in the absence of hydrogen peroxide. Natella F, et al. **Free Radic Res** 1998 Nov; 29(5):427–34

Peroxidase-mediated oxidation, a possible pathway for activation of the fungal nephrotoxin orellanine and related compounds. ESR and spin-trapping studies. Oubrahim H, et al. **Free Radic Res** 1998 May;28(5):497–505

Oxidation of phenols by horseradish peroxidase and lactoperoxidase compound II--kinetic considerations. Zahida MS, et al. **Indian J Biochem Biophys** 1998 Dec; 35(6):353–7

Discrete analysis of serum uric acid with immobilized uricase and peroxidase. Bhargava AK, et al. **J Biochem Biophys Methods** 1999 May 13;39(3):125–36

Electron paramagnetic resonance detection of free tyrosyl radical generated by myeloperoxidase, lactoperoxidase, and horseradish peroxidase. McCormick ML, et al. **J Biol Chem** 1998 Nov 27;273(48):32030–7

Oxidative 4-dechlorination of 2,4,6-trichlorophenol catalyzed by horseradish peroxidase. Ferrari RP, et al. **J Biol Inorg Chem** 1999 Apr;4(2):232–7

Limited uptake of foreign materials by resident macrophages in murine ovarian tissues. Itoh M, et al. **J Reprod Immunol** 1999 May;43(1):55–66

Striking activation of oxidative enzymes suspended in nonaqueous media. Dai L, et al. **Proc Natl Acad Sci U S A** 1999 Aug 17;96(17):9475–8

Hydrogen atom abstraction of 3,5-disubstituted analogues of paracetamol by horseradish peroxidase and cytochrome P450. Bessems JG, et al. **Xenobiotica** 1998 Sep;28(9):855–75

[Oxidative destruction of estradiol after treatment with

hydrogen peroxide catalyzed by horseradish peroxidase and methemoglobin] Petrenko IuM, et al. **Biofizika** 1999 Mar-Apr;44(2):236-43 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Stress stimulates transepithelial macromolecular uptake in rat jejunum. Kiliaan AJ, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1037-44

Adverse effects on rabbit anterior cruciate ligament after knee immobilization: changes in permeability of horseradish peroxidase. Kanda T, et al. **Arch Orthop Trauma Surg** 1998; 117(6-7):307-11

Scatter factor/hepatocyte growth factor gene transfer increases rat blood-glioma barrier permeability. Book AA, et al. **Brain Res** 1999 Jul 3;833(2):173-80

PHARMACOLOGY

Antioxidant effects of superoxide dismutase and horseradish peroxidase on lipid peroxidation. Gao SJ, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:284-7

Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Folkes LK, et al. **Biochem Pharmacol** 1999 Feb 15;57(4):375-82

PHYSIOLOGY

Peroxidase-catalyzed in vitro formation of polychlorinated dibenzo-p-dioxins and dibenzofurans from chlorophenols. Wittsiepe J, et al. **Toxicol Lett** 1999 Jun 1;106(2-3):191-200

HORSES

consider also terms at EQUINE

Equine cardiodilatin/ atrial natriuretic peptide. Primary structure and immunohistochemical localization in auricular cardiocytes. Richter R, et al. **Acta Anat (Basel)** 1998;162(4):185-93

Aerobic bacterial flora of semen and stallion reproductive tract and its relation to fertility under field conditions. Malmgren L, et al. **Acta Vet Scand** 1998;39(2):173-82

Effects of bovine serum albumin on function of cryopreserved stallion spermatozoa during medium culture and uterine tube epithelial cell coculture. Ellington JE, et al. **Am J Vet Res** 1999 Mar;60(3):363-7

Purification and biochemical characterization of equine pulmonary surfactant protein D. Hobo S, et al. **Am J Vet Res** 1999 Mar;60(3):368-72

Different approaches to the identification of a cortisol isomer compound in horse urine. Popot MA, et al. **Analyst** 1998 Dec;123(12):2649-52

Glutathione-independent prostaglandin D2 synthase in ram and stallion epididymal fluids: origin and regulation. Fouchécourt S, et al. **Biol Reprod** 1999 Mar;60(3):558-66

Scrotal heat stress induces altered sperm chromatin structure associated with a decrease in protamine disulfide bonding in the stallion [published erratum appears in Biol Reprod 1999 May;60(5):1271] Love CC, et al. **Biol Reprod** 1999 Mar;60(3):615-20

CD26 and adenosine deaminase interaction: its role in the fusion between horse membrane vesicles and spermatozoa. Minelli A, et al. **Biol Reprod** 1999 Sep;61(3):802-8

Rider injury rates and emergency medical services at equestrian events. Paix BR. **Br J Sports Med** 1999 Feb; 33(1):46-8

Synthesis of the equine estrogen metabolites 2-hydroxyequilin and 2-hydroxyequilenin. Zhang F, et al. **Chem Res Toxicol** 1999 Feb;12(2):200-3

Rabies prophylaxis following the feeding of a rabid pony. Feder HM, et al. **Clin Pediatr (Phila)** 1998 Aug; 37(8):477-81 (38 ref.)

Proud of Premarin [letter] Baumgartner AR. **CMAJ** 1999 Jun 29;160(13):1821

Effect of an equine-movement therapy program on gait, energy expenditure, and motor function in children with spastic cerebral palsy: a pilot study. McGibbon NH, et al. **Dev Med Child Neurol** 1998 Nov;40(11):754-62

Horse bite injury. Vidal S, et al. **Eur J Dermatol** 1998 Sep; 8(6):437-8

Equestrian injuries in the paediatric age group: a two centre study. Campbell-Hewson GL, et al. **Eur J Emerg Med** 1999 Mar;6(1):37-40

Prevalence of severe welfare problems in horses that arrive at slaughter plants. Grandin T, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1531-3

Radiation exposure to personnel during examination of limbs of horses with a portable hand-held fluoroscopic unit. Thomas HL, et al. **J Am Vet Med Assoc** 1999 Aug 1; 215(3):372-9

The development of microcracking and failure in bone depends on the loading mode to which it is adapted. Reilly GC, et al. **J Exp Biol** 1999 Mar;202 (Pt 5):543-52

Review of furosemide in horse racing: its effects and regulation. Soma LR, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):228-40 (103 ref.)

"A horse! a horse! my kingdom for a horse!" Versions of Greek horse medicine in medieval Italy. Fischer KD. **Medizinhist J** 1999;34(2):123-38

Safe handling of large animals. Grandin T. **Occup Med** 1999 Apr-Jun;14(2):195-212 (55 ref.)

Immediate and persistent complete heart block following a horse kick. Benitez RM, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):816-8

International Congress, anniversary meeting. 20 years Swiss Equine Veterinary Association. Luzern, 11-13 December 1998. Abstracts. **Schweiz Arch Tierheilkd** 1998; 140(11):445-80 **(Eng, Ger)**

Equine granulomatous enteritis linked with aluminum? [letter; comment] Collery P, et al. **Vet Hum Toxicol** 1999 Feb; 41(1):49-50. Comment on: Vet Hum Toxicol 1998 Oct;40(5):297-305.

A comparison of the bioequivalence of 0.5% fenbendazole top dress pellets or 10% fenbendazole oral suspension against a spectrum of equine parasites. Hutchens DE, et al. **Vet Parasitol** 1999 Jun 1;83(1):79-85

In-shoe foot force sensor to assess hoof balance determined by radiographic method in ponies trotting on a treadmill. Caudron I, et al. **Vet Q** 1998 Oct;20(4):131-5

Equine glanders in Turkey. Arun S, et al. **Vet Rec** 1999 Mar 6;144(10):255-8

Accuracy of different methods of estimating the weight of horses. Ellis JM, et al. **Vet Rec** 1998 Sep 19;143(12):335-6

Chemical destruction of horses [letter] Knottenbelt DC. **Vet Rec** 1999 Jul 10;145(2):54-5

Chemical destruction of horses [letter] Mantell JA. **Vet Rec** 1999 Jul 3;145(1):27

[Riding injuries] Houshian S, et al. **Ugeskr Laeger** 1998 Nov 23;160(48):6976-9 (Eng. Abstr.) **(Dan)**

[The bringing of the latest technology to the evolution of horse shoeing, from its origin to our time] Chuit P. **Schweiz Arch Tierheilkd** 1999;141(1):3-9 **(Fre)**

[Use of tempered, particle-reinforced aluminum horse shoes in sport horses under field conditions] Brandstetter J, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Feb;106(2):55-60 (Eng. Abstr.) **(Ger)**

[Branding of horses (letter; comment)] Meyer H. **DTW Dtsch Tierarztl Wochenschr** 1998 Sep;105(9):361. Comment on: DTW Dtsch Tierarztl Wochenschr 1998 Mar;105(3):112-3. **(Ger)**

[Equipment and aids in trotting races] Müller C. **DTW Dtsch Tierarztl Wochenschr** 1999 Apr;106(4):176-9 (Eng. Abstr.) **(Ger)**

[Equipment, methods of constraint and other aids in horse racing] Pick M. **DTW Dtsch Tierarztl Wochenschr** 1999 Apr;106(4):179-82 (Eng. Abstr.) **(Ger)**

[Traumatology and sports injuries in equestrian acrobatics in the adolescent] Horstmann T, et al. **Sportverletz Sportschaden** 1998 Jun;12(2):66-70 (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Persistent right aortic arch in a yearling horse. Butt TD, et al. **Can Vet J** 1998 Nov;39(11):714-5

What is your diagnosis and therapeutic plan? Congenital atresia of the left nasolacrimal duct. Grahn BH, et al. **Can Vet J** 1999 Jan;40(1):71-2

Incomplete ossification of the tarsal bones in foals: 22 cases (1988-1996). Dutton DM, et al. **J Am Vet Med Assoc** 1998 Dec 1;213(11):1590-4

A congenital malformation of the maxilla of a horse. Tudor RA, et al. **Vet Radiol Ultrasound** 1999 Jul-Aug;40(4):353-6

Chronic renal failure associated with nephrolithiasis, ureterolithiasis, and renal dysplasia in a 2-year-old quarter horse gelding. Wooldridge AA, et al. **Vet Radiol Ultrasound** 1999 Jul-Aug;40(4):361-4

Persistent vitelline vein in a foal. De Bosschere H, et al. **Vet Rec** 1999 Jul 17;145(3):75-7

Persistent frenulum of the epiglottis in four foals. Yarbrough TB, et al. **Vet Surg** 1999 Jul-Aug;28(4):287-91

ANATOMY & HISTOLOGY

Innervation of the equine mature and immature proximal sesamoid bone by calcitonin gene-related peptide and substance P-containing nerves. Cornelissen BP, et al. **Am J Vet Res** 1998 Nov;59(11):1378-85

Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Fortier LA, et al. **Am J Vet Res** 1998 Sep;59(9):1182-7

Hoof size, shape, and balance as possible risk factors for catastrophic musculoskeletal injury of Thoroughbred racehorses. Kane AJ, et al. **Am J Vet Res** 1998 Dec; 59(12):1545-52

Morphological character of the shoulder and leg skeleton in Przewalski's horse (Equus przewalskii). Sasaki M, et al. **Anat Anz** 1999 Jul;181(4):403-7

Possible significance of cells within intraluminal collagen masses in equine oviducts. Lantz KC, et al. **Anat Rec** 1998 Dec;252(4):568-79

Magnetic resonance imaging and ultrasonography of the lumbricale muscles in the horse. Bindeus T, et al. **Aust Vet J** 1999 Feb;77(2):82-4

Three dimensional structure of the distal condyles of the third metacarpal bone of the horse. Boyde A, et al. **Equine Vet J** 1999 Mar;31(2):122-9

Structural variation of the distal condyles of the third metacarpal and third metatarsal bones in the horse. Riggs CM, et al. **Equine Vet J** 1999 Mar;31(2):130-9

Tubule density of the stratum medium of horse hoof. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):4-9

Cytokeratins of the equine hoof wall, chestnut and skin: bio- and immunohisto-chemistry. Wattle O. **Equine Vet J Suppl** 1998 Sep;(26):66-80

Endoscopy of the intertubercular bursa in horses. Adams MN, et al. **J Am Vet Med Assoc** 1999 Jan 15;214(2):221-5, 205

Results of bone scintigraphy in horses used for show jumping, hunting, or eventing: 141 cases (1988-1994). Ehrlich PJ, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1460-7

Morphometric study of the equine navicular bone: variations with breeds and types of horse and influence of exercise. Gabriel A, et al. **J Anat** 1998 Nov;193 (Pt 4):535-49

Distribution of fast myosin heavy chain-based muscle fibres in the gluteus medius of untrained horses: mismatch between antigenic and ATPase determinants. Linnane L, et al. **J Anat** 1999 Apr;194 (Pt 3):363-72

Occurrence of prostasome-like membrane vesicles in equine seminal plasma. Minelli A, et al. **J Reprod Fertil** 1998 Nov; 114(2):237-43

Scanning electron microscopic study of the vascular supply of the equine hoof. Nasu T, et al. **J Vet Med Sci** 1998 Jul;60(7):855-8

An immunohistochemical study of interstitial cells of Cajal (ICC) in the equine gastrointestinal tract. Hudson NP, et al. **Res Vet Sci** 1999 Jun;66(3):265-71

Back problems. Neuroanatomy and neurological examination. Blythe LL, et al. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):71-85, vi (10 ref.)

Anatomy of the thoracolumbar vertebral region. Haussler KK. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):13-26, v (34 ref.)

Evaluation of magnetic resonance imaging techniques in the equine digit. Kleiter M, et al. **Vet Radiol Ultrasound** 1999 Jan-Feb;40(1):15-22

Identification of an ossicle associated with the palmar aspect of the carpus in the horse. Martens P. **Vet Radiol Ultrasound** 1999 Jul-Aug;40(4):342-5

Ultrasonography of the equine shoulder: technique and normal appearance. Tnibar MA, et al. **Vet Radiol Ultrasound** 1999 Jan-Feb;40(1):44-57

Ultrasonographic evaluation of equine tendons: a quantitative in vitro study of the effects of amplifier gain level, transducer-tilt, and transducer-displacement. van Schie JT, et al. **Vet Radiol Ultrasound** 1999 Mar-Apr;40(2):151-60 (48 ref.)

A technique for magnetic resonance imaging of equine cadaver specimens. Widmer WR, et al. **Vet Radiol Ultrasound** 1999 Jan-Feb;40(1):10-4

Radiographic assessment of equine interphalangeal joints asymmetry: articular impact of phalangeal rotations (Part I). Caudron I, et al. **Zentralbl Veterinarmed A** 1998 Sep; 45(6-7):319-25

Radiographic assessment of equine interphalangeal joints asymmetry: articular impact of asymmetric bearings (Part II). Caudron I, et al. **Zentralbl Veterinarmed A** 1998 Sep; 45(6-7):327-35

[Radiologic description of the growth plates of the atlas and axis in foals] Maierl J, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Nov; 26(6):341-5 (Eng. Abstr.) **(Ger)**

BLOOD

Histamine-induced adherence and migration of equine eosinophils. Foster AP, et al. **Am J Vet Res** 1998 Sep; 59(9):1153-9

Comparison of microbiologic and high-performance liquid chromatography assays to determine plasma concentrations, pharmacokinetics, and bioavailability of erythromycin base in plasma of foals after intravenous or intragastric administration. Lakritz J, et al. **Am J Vet Res** 1999 Apr;60(4):414-9

Hematologic and serum biochemical variables and plasma corticotropin concentration in healthy aged horses. McFarlane D, et al. **Am J Vet Res** 1998 Oct;59(10):1247-51

Evaluation of automated methods of measuring hemoglobin and hematocrit in horses. Sorrell-Raschi LA, et al. **Am J Vet Res** 1998 Dec;59(12):1519-22

Shear-induced platelet activation and platelet-neutrophil aggregate formation by equine platelets. Weiss DJ, et al. **Am J Vet Res** 1998 Oct;59(10):1243-6

Haematological parameters of the Polish Primitive Horses. Krumrych W, et al. **Arch Vet Pol** 1993;33(3-4):205-16

Assay for endogenous heparin in plasma of livestock using a synthetic chromogenic substrate. Ledwożyw A, et al. **Arch Vet Pol** 1993;33(3-4):269-73

The estimation of factor VIII levels in horse, cattle, sheep and pig plasma by the use of synthetic chromogenic substrate. Ledwożyw A, et al. **Arch Vet Pol** 1993; 33(3-4):275-81

Effect of exercise training, selenium and vitamin E on some free radical scavengers in horses (Equus caballus). Avellini L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jun;123(2):147-54

Measurement of parathyroid hormone in horses. Estepa JC, et al. **Equine Vet J** 1998 Nov;30(6):476-81

Dextran-70 inhibits equine platelet aggregation induced by PAF but not by other agonists. Heath MF, et al. **Equine Vet J** 1998 Sep;30(5):408-11

Oxygen-dependent K+ influxes in Mg2+-clamped equine red blood cells. Campbell EH, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):431-7

Perioperative plasma cortisol concentration in the horse. Stegmann GF, et al. **J S Afr Vet Assoc** 1998 Dec; 69(4):137-42

The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. Dyke TM, et al.

J Vet Pharmacol Ther 1998 Aug;21(4):298–303

Pharmacokinetics of gentamicin in healthy adult horses during intravenous fluid administration. Jones SL, et al. **J Vet Pharmacol Ther** 1998 Jun;21(3):247–9

Evidence that commercial calf and horse sera can contain substantial amounts of trans-10,cis-12 conjugated linoleic acid. Park Y, et al. **Lipids** 1998 Aug;33(8):817–9

Ultrastructural characteristics of Babesia caballi in equine erythrocytes in vitro. Kawai S, et al. **Parasitol Res** 1999 Oct;85(10):794–9

A non-competitive chemiluminescence enzyme immunoassay for the equine acute phase protein serum amyloid A (SAA) -- a clinically useful inflammatory marker in the horse. Hultén C, et al. **Vet Immunol Immunopathol** 1999 May; 68(2–4):267–81

Biochemical markers of bone metabolism in draught and warmblood horses [see comments] Lepage OM, et al. **Vet J** 1998 Nov;156(3):169–75. Comment in: Vet J 1998 Nov;156(3):163–5.

Biochemical markers of bone metabolism in horses: potentials and limitations? [editorial; comment] Price JS. **Vet J** 1998 Nov;156(3):163–5 (16 ref.). Comment on: Vet J 1998 Nov;156(3):169–75.

The flow cytometric evaluation of phagocytosis by equine peripheral blood neutrophils and pulmonary alveolar macrophages [see comments] Raidal SL, et al. **Vet J** 1998 Sep;156(2):107–16. Comment in: Vet J 1998 Sep;156(2):79–80.

Effects of acepromazine on equine polymorphonuclear neutrophil activation: a chemiluminescence study. Serteyn D, et al. **Vet J** 1999 May;157(3):332–5

Accuracy and precision of the portable StatPal II and the laboratory-based NOVA stat profile 1 for measurement of pH, P(CO2), and P(O2) in equine blood. Klein LV, et al. **Vet Surg** 1999 Jan–Feb;28(1):67–76

[Evaluation of the portable blood analyser i-STAT] Tschudi PR. **Schweiz Arch Tierheilkd** 1998;140(12):507–12 (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Anatomo-radiographic study on the osteogenesis of carpal and tarsal bones in horse fetus. Soana S, et al. **Anat Histol Embryol** 1998 Oct;27(5):301–5

Fetal development of the white line (Zona alba) of the equine hoof. Bragulla H, et al. **Equine Vet J Suppl** 1998 Sep; (26):22–6

The effects of intrafetal ACTH administration on the outcome of pregnancy in the mare. Ousey JC, et al. **Reprod Fertil Dev** 1998;10(4):359–67

Preliminary observations in in vitro development of equine embryo after ICSI. Guignot F, et al. **Reprod Nutr Dev** 1998 Nov–Dec;38(6):653–63

GENETICS

The actin multigene family and livestock speciation using the polymerase chain reaction. Fairbrother KS, et al. **Anim Biotechnol** 1998;9(2):89–100

Equine dinucleotide repeat loci LEX064 through LEX070. Coogle L, et al. **Anim Genet** 1999 Feb;30(1):71–2

Twelve equine dinucleotide repeats at microsatellite loci UCDEQ304, UCDEQ380, UCDEQ387, UCDEQ411, UCDEQ439, UCDEQ440, UCDEQ455, UCDEQ457, UCDEQ464, UCDEQ465, UCDEQ482 and UCDEQ497. Eggleston-Stott ML, et al. **Anim Genet** 1999 Feb; 30(1):69–70

Fourteen new polymorphic equine microsatellites. George LA, et al. **Anim Genet** 1998 Dec;29(6):469–70

FISH mapping assignment of two horse BAC clones containing HMS41 and HTG3 microsatellites. Godard S, et al. **Anim Genet** 1999 Jun;30(3):233–4

Equine dinucleotide repeat loci COR001–COR020. Hopman TJ, et al. **Anim Genet** 1999 Jun;30(3):225–6

Genetic polymorphisms of equine microsatellite loci: TKY16, TKY19 and TKY21. Kakoi H, et al. **Anim Genet** 1999 Feb; 30(1):68–9

Phylogenetic relationships of Cheju horses to other horse breeds as determined by mtDNA D-loop sequence polymorphism. Kim KI, et al. **Anim Genet** 1999 Apr; 30(2):102–8

Physical mapping of ten equine dinucleotide repeat microsatellites. Lear TL, et al. **Anim Genet** 1999 Jun; 30(3):235

Five equine dinucleotide microsatellite loci HTG17, HTG20, HTG21, HTG28 and HTG31. Lindgren G, et al. **Anim Genet** 1999 Feb;30(1):70–1

Equine dinucleotide repeat loci COR021–COR040. Murphie AM, et al. **Anim Genet** 1999 Jun;30(3):235–7

Mitochondrial control region and 12S rRNA variation in Przewalski's horse (Equus przewalskii). Oakenfull EA, et al. **Anim Genet** 1998 Dec;29(6):456–9

Eight new equine dinucleotide repeat microsatellites at the NVHEQ26, NVHEQ29, NVHEQ31, NVHEQ40, NVHEQ43, NVHEQ90, NVHEQ98 and NVHEQ100 loci. Røed KH, et al. **Anim Genet** 1998 Dec;29(6):470

Equine dinucleotide repeat loci COR041–COR060. Ruth LS, et al. **Anim Genet** 1999 Aug;30(4):320–1

A synteny map of the horse genome comprised of 240 microsatellite and RAPD markers. Shiue YL, et al. **Anim Genet** 1999 Feb;30(1):1–9

Cloning and characterization of the equine F18 gene, which has a novel exon. Tozaki T, et al. **Anim Genet** 1998 Oct; 29(5):381–4

A polymorphic horse microsatellite locus: VHL150. van Haeringen WA, et al. **Anim Genet** 1998 Dec;29(6):464

Construction of chromosome-specific paints for meta- and submetacentric autosomes and the sex chromosomes in the horse and their use to detect homologous chromosomal segments in the donkey. Raudsepp T, et al. **Chromosome Res** 1999;7(2):103–14

Polymorphism of Old Kladruber horses, a surviving but endangered baroque breed. Horin P, et al. **Eur J Immunogenet** 1998 Oct;25(5):357–63

Major histocompatibility complex variation in the endangered Przewalski's horse. Hedrick PW, et al. **Genetics** 1999 Aug;152(4):1701–10

Odds on the FAST gene. Bailey E. **Genome Res** 1998 Jun; 8(6):569–71

A primary male autosomal linkage map of the horse genome. Lindgren G, et al. **Genome Res** 1998 Sep;8(9):951–66

Phylogenetic relationships within the genus Equus and the evolution of alpha and theta globin genes. Oakenfull EA, et al. **J Mol Evol** 1998 Dec;47(6):772–83

Genetic analysis of three South African horse breeds. Cothran EG, et al. **J S Afr Vet Assoc** 1998 Dec;69(4):120–5

Linear SRY transcript in equine testis. Hasegawa T, et al. **J Vet Med Sci** 1999 Jan;61(1):97–100

The cDNA sequences of equine antioxidative enzyme genes Cu/Zn-SOD and Mn-SOD, and these expressions in equine tissues. Ishida N, et al. **J Vet Med Sci** 1999 Mar; 61(3):291–4

Molecular cloning of cDNA for equine follistatin and its gene expression in the reproductive tissues of the mare. Sugawara Y, et al. **J Vet Med Sci** 1999 Mar;61(3):201–7

Comparative mapping of 18 equine type I genes assigned by somatic cell hybrid analysis. Caetano AR, et al. **Mamm Genome** 1999 Mar;10(3):271–6

Two SINE families associated with equine microsatellite loci. Gallagher PC, et al. **Mamm Genome** 1999 Feb;10(2):140–4

Close association between sequence polymorphism in the KIT gene and the roan coat color in horses. Marklund S, et al. **Mamm Genome** 1999 Mar;10(3):283–8

Comparison of horse chromosome 3 with donkey and human chromosomes by cross-species painting and heterologous FISH mapping. Raudsepp T, et al. **Mamm Genome** 1999 Mar;10(3):277–82

Factors controlling epidermal growth factor (EGF) gene expression in the endometrium of the mare. Gerstenberg C, et al. **Mol Reprod Dev** 1999 Jul;53(3):255–65

Identification and initial characterization of calcyclin and phospholipase A2 in equine conceptuses. Simpson KS, et al. **Mol Reprod Dev** 1999 Jun;53(2):179–87

Quantitation of equine cytokine mRNA expression by reverse transcription-competitive polymerase chain reaction. Giguère S, et al. **Vet Immunol Immunopathol** 1999 Jan 4; 67(1):1–15

[Differentiation of domestic horse and Przewalskiš horse using various DNA sequences] Glazko VI, et al. **Genetika** 1998 Jul;34(7):996–9 (Eng. Abstr.) **(Rus)**

[Associations between the coat color and the blood-group system D antigens in horses] Kniazev SP, et al. **Genetika** 1999 Apr;35(4):499–503 (Eng. Abstr.) **(Rus)**

[The intraspecific differentiation of Przhewalski's horse and the domestic horse by 5 molecular genetic markers] Glazko VI, et al. **Tsitol Genet** 1998 Apr-May;32(3):97–103 (Eng. Abstr.) **(Rus)**

[The components of the phenotypic dispersion of the basic typological traits and of work capacity in horses of the Ukrainian saddle breed] Kotsiubenko AA. **Tsitol Genet** 1998 Apr-May;32(3):93–6 (Eng. Abstr.) **(Rus)**

[The variability and heritability of the indices of speed and exterior characters in horses of the Orlov trotter breed] Maĭboroda SN. **Tsitol Genet** 1998 Mar-Apr;32(2):88–91 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Effect of a supplementary dietary evening primrose oil mixture on hoof growth, hoof growth rate and hoof lipid fractions in horses: a controlled and blinded trial. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):58–65

Effect of supplementary dietary biotin on hoof growth and hoof growth rate in ponies: a controlled trial. Reilly JD, et al. **Equine Vet J Suppl** 1998 Sep;(26):51–7

Studies on growth cartilage in the horse and their application to aetiopathogenesis of dyschondroplasia (osteochondrosis) [see comments] Jeffcott LB, et al. **Vet J** 1998 Nov; 156(3):177–92 (124 ref.). Comment in: Vet J 1998 Nov;156(3):167–8.

Equine developmental osteochondral lesions: the role of biomechanics [editorial; comment] Whitton RC. **Vet J** 1998 Nov;156(3):167–8 (8 ref.). Comment on: Vet J 1998 Nov;156(3):177–92.

IMMUNOLOGY

Crystallization and preliminary crystallographic analysis of the major horse allergen Equ c 1. Grégoire C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):880–2

Effect of exercise on the immune response of young and old horses. Horohov DW, et al. **Am J Vet Res** 1999 May; 60(5):643–7

Organization of the equine immunoglobulin heavy chain constant region genes; III. Alignment of c mu, c gamma, c epsilon and c alpha genes. Wagner B, et al. **Immunobiology** 1998 Jul;199(1):105–18

Epithelial lymphocyte and macrophage distribution in the adult and fetal equine lung. Banks EM, et al. **J Comp Pathol** 1999 Jan;120(1):1–13

A histological and immunohistochemical study of the humoral immune system of the lungs in young Thoroughbred horses. Blunden AS, et al. **J Comp Pathol** 1999 May;120(4):347–56

Antibody selection for immunohistochemical survey of equine tissue. Kalsow CM, et al. **J Comp Pathol** 1998 Nov; 119(4):467–72

Characterisation of equine T helper cells: demonstration of Th1- and Th2-like cells in long-term equine T-cell cultures. Aggarwal N, et al. **Res Vet Sci** 1999 Jun; 66(3):277–9

Development and evaluation of the neutralizing capacity of horse antivenom against the Brazilian spider Loxosceles intermedia. Braz A, et al. **Toxicon** 1999 Sep;37(9):1323–8

Neutralizing potency of horse antibothropic antivenom. Correlation between in vivo and in vitro methods. Maria WS, et al. **Toxicon** 1998 Oct;36(10):1433–9

Thermal stability studies of hyperimmune horse antivenoms. Rodrigues-Silva R, et al. **Toxicon** 1999 Jan;37(1):33–45

Streptococcus equi but not Streptococcus zooepidemicus produces potent mitogenic responses from equine peripheral blood mononuclear cells. Anzai T, et al. **Vet Immunol Immunopathol** 1999 Feb 22;67(3):235–46

Interactions between lipopolysaccharides and blood factors on the stimulation of equine polymorphonuclear neutrophils. Benbarek H, et al. **Vet Immunol Immunopathol** 1998 Aug 31;64(4):313–22

Human interleukin 10 suppresses production of inflammatory mediators by LPS-stimulated equine peritoneal macrophages. Hawkins DL, et al. **Vet Immunol Immunopathol** 1998 Nov 6;66(1):1–10

Organisation of the equine immunoglobulin constant heavy chain genes. II. Equine cgamma genes. Overesch G, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):273–87

Studies on pulmonary and systemic Aspergillus fumigatus-specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD). Schmallenbach KH, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):245–56

INJURIES

Effects of 6alpha-methylprednisolone acetate on an equine osteochondral fragment exercise model. Frisbie DD, et al. **Am J Vet Res** 1998 Dec;59(12):1619–28

Hoof size, shape, and balance as possible risk factors for catastrophic musculoskeletal injury of Thoroughbred racehorses. Kane AJ, et al. **Am J Vet Res** 1998 Dec; 59(12):1545–52

Effect of three types of half-limb casts on in vitro bone strain recorded from the third metacarpal bone and proximal phalanx in equine cadaver limbs. Schneider RK, et al. **Am J Vet Res** 1998 Sep;59(9):1188–93

Nonsurgical management of type II fractures of the distal phalanx in 48 standardbred horses. O'Sullivan CB, et al. **Aust Vet J** 1999 Aug;77(8):501–3

Flat, hurdle and steeple racing: risk factors for musculoskeletal injury. Bailey CJ, et al. **Equine Vet J** 1998 Nov;30(6):498–503

Stress fractures of the vertebral lamina and pelvis in Thoroughbred racehorses [see comments] Haussler KK, et al. **Equine Vet J** 1998 Sep;30(5):374–81. Comment in: Equine Vet J 1998 Sep;30(5):364–5.

Thoracic trauma in newborn foals [see comments] Jean D, et al. **Equine Vet J** 1999 Mar;31(2):149–52. Comment in: Equine Vet J 1999 Mar;31(2):92.

Multidisciplinary investigation of the aetiopathogenesis of parasagittal fractures of the third metacarpal and metatarsal bones of Thoroughbreds [editorial; comment] Pool RR. **Equine Vet J** 1999 Mar;31(2):96. Comment on: Equine Vet J 1999 Mar;31(2):116–20.

Pathology of the distal condyles of the third metacarpal and third metatarsal bones of the horse. Riggs CM, et al. **Equine Vet J** 1999 Mar;31(2):140–8

Aetiopathogenesis of parasagittal fractures of the distal condyles of the third metacarpal and third metatarsal bones--review of the literature [see comments] Riggs CM. **Equine Vet J** 1999 Mar;31(2):116–20 (14 ref.). Comment in: Equine Vet J 1999 Mar;31(2):96.

Birth trauma in newborn foals [editorial; comment] Rossdale PD. **Equine Vet J** 1999 Mar;31(2):92. Comment on: Equine Vet J 1999 Mar;31(2):149–52.

Bone scintigraphy in the diagnosis of sacroiliac injury in twelve horses [see comments] Tucker RL, et al. **Equine Vet J** 1998 Sep;30(5):390–5. Comment in: Equine Vet J 1998 Sep;30(5):364–5.

Effect of hoof trimming on the occurrence of distal phalangeal palmar process fractures in foals. Kaneps AJ, et al. **Equine Vet J Suppl** 1998 Sep;(26):36–45

Results of physical inspection before races and race-related characteristics and their association with musculoskeletal injuries in Thoroughbreds during races. Cohen ND, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):654–61

Frequency of musculoskeletal injuries and risk factors associated with injuries incurred in Quarter Horses during races. Cohen ND, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):662–9

What is your diagnosis? Bilateral pneumothorax. Cornelisse

CJ, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1323–4
Nonsurgical treatment of suprascapular nerve injury in horses: 8 cases (1988–1998). Dutton DM, et al. **J Am Vet Med Assoc** 1999 Jun 1;214(11):1657–9
Fractures of the rostral portion of the mandible and maxilla in horses: 89 cases (1979–1997). Henninger RW, et al. **J Am Vet Med Assoc** 1999 Jun 1;214(11):1648–52
Effects of furosemide on athletic performance and exercise-induced pulmonary hemorrhage in horses. Hinchcliff KW. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):630–5 (48 ref.)
Management of rupture of the gastrocnemius and superficial digital flexor muscles with a modified Thomas splint–cast combination in a horse. Lescun TB, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1457–9
What is your diagnosis? Disruption of the caudal portion of the reciprocal apparatus in a horse. Mattoon JS, et al. **J Am Vet Med Assoc** 1999 Mar 15;214(6):783–4
What is your diagnosis. Bone sequestrum of the proximoplantaralateral aspect of the tuber calcaneus. May KA, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):627–8
What is your diagnosis? Bilateral increased uptake of technetium Tc 99m medronate in the region of the tarsal joints. Orsini JA, et al. **J Am Vet Med Assoc** 1999 Jun 1;214(11):1621–2
Arthroscopic removal of abaxial fracture fragments of the proximal sesamoid bones in horses: 47 cases (1989–1997). Southwood LL, et al. **J Am Vet Med Assoc** 1998 Oct 1; 213(7):1016–21
Use of a temporary indwelling ureteral stent catheter in a mare with a traumatic ureteral tear. Voss ED, et al. **J Am Vet Med Assoc** 1999 May 15;214(10):1523–6, 1496
Apical fracture of the proximal sesamoid bone in standardbred horses: 43 cases (1990–1996). Woodie JB, et al. **J Am Vet Med Assoc** 1999 Jun 1;214(11):1653–6
Parotid duct laceration repair in two horses. Olivier A, et al. **J S Afr Vet Assoc** 1998 Sep;69(3):108–11
Detection of a radiographically occult fracture of the lateral palmar process of the distal phalanx in a horse using computed tomography. Martens P, et al. **Vet Radiol Ultrasound** 1999 Jul–Aug;40(4):346–9
Imaging basilar skull fractures in the horse: a review. Ramirez O 3rd, et al. **Vet Radiol Ultrasound** 1998 Sep–Oct; 39(5):391–5 (17 ref.)
Antibacterial properties of a silver chloride–coated nylon wound dressing. Adams AP, et al. **Vet Surg** 1999 Jul–Aug; 28(4):219–25
Use of electrocautery probes in arthroscopic removal of apical sesamoid fracture fragments in 18 Standardbred horses. Bouré L, et al. **Vet Surg** 1999 Jul–Aug;28(4):226–32
Repair of complete dorsal fracture of the proximal phalanx in two horses. Dechant JE, et al. **Vet Surg** 1998 Sep–Oct; 27(5):445–9
Arthroscopic subchondral bone plate microfracture technique augments healing of large chondral defects in the radial carpal bone and medial femoral condyle of horses. Frisbie DD, et al. **Vet Surg** 1999 Jul–Aug; 28(4):242–55
An in vitro biomechanical comparison of two fixation methods for transverse osteotomies of the medial proximal forelimb sesamoid bones in horses. Wilson DA, et al. **Vet Surg** 1999 Sep–Oct;28(5):355–67
[Possibilities for computer tomography of the equine head based on two cases with a fracture of the base of the skull] Gardelle O, et al. **Schweiz Arch Tierheilkd** 1999; 141(6):267–72 (Eng. Abstr.) **(Ger)**

METABOLISM

Influence of site and age on biochemical characteristics of the collagen network of equine articular cartilage. Brama PA, et al. **Am J Vet Res** 1999 Mar;60(3):341–5
Pharmacokinetics of multiple-dose administration of eltenac in horses. Dyke TM, et al. **Am J Vet Res** 1998 Nov; 59(11):1447–50
Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Hammond RA, et al. **Am J Vet Res** 1999 Apr;60(4):426–31
Establishment of a monoclonal antibody (1/14/16H9) for detection of equine keratan sulfate. Okumura M, et al. **Am J Vet Res** 1998 Oct;59(10):1203–8
Content and distribution of macro- and micro-elements in the body of pasture-fed young horses. Grace ND, et al. **Aust Vet J** 1999 Mar;77(3):172–6
Concentrations of macro- and micro-elements in the milk of pasture-fed thoroughbred mares. Grace ND, et al. **Aust Vet J** 1999 Mar;77(3):177–80
Identification of a new aspartic proteinase expressed by the outer chorionic cell layer of the equine placenta. Green JA, et al. **Biol Reprod** 1999 May;60(5):1069–77
Production of gelatinases and tissue inhibitors of matrix metalloproteinases by equine ovarian stromal cells In vitro. Song L, et al. **Biol Reprod** 1999 Jan;60(1):1–7
Immobilized horse liver alcohol dehydrogenase as an on-line high-performance liquid chromatographic enzyme reactor for stereoselective synthesis. Sotolongo V, et al. **Chirality** 1999;11(1):39–45
Oxytocin-neurophysin I mRNA abundance in equine uterine endometrium. Behrendt-Adam CY, et al. **Domest Anim Endocrinol** 1999 Apr;16(3):183–92
Equine TIMP-1 and TIMP-2: identification, activity and cellular sources. Clegg PD, et al. **Equine Vet J** 1998 Sep; 30(5):416–23
A permeability barrier in the dorsal wall of the equine hoof capsule. Kempson SA, et al. **Equine Vet J Suppl** 1998 Sep; (26):15–21
Pharmacokinetics of a high dose of gentamicin administered intravenously or intramuscularly to horses. Magdesian KG, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):1007–11
Drug disposition and dosage determination of once daily administration of gentamicin sulfate in horses after abdominal surgery. Tudor RA, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):503–6
Effects of recombinant equine somatotropin on wound healing, carbohydrate and lipid metabolism, and endogenous somatotropin responses to secretagogues in geldings. Smith LA, et al. **J Anim Sci** 1999 Jul; 77(7):1815–22
Equine type estrogens produced by a pregnant woman carrying a Smith–Lemli–Opitz syndrome fetus. Shackleton CH, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1157–9
Unique localization of protein gene product 9.5 in type B synoviocytes in the joints of the horse. Kitamura HP, et al. **J Histochem Cytochem** 1999 Mar;47(3):343–52
Effects of anabolic steroid (19-nortestosterone) on the secretion of testicular hormones in the stallion. Nagata S, et al. **J Reprod Fertil** 1999 Mar;115(2):373–9
Transferability of cephalothin to the alveolar cavity in thoroughbreds. Matsuda Y, et al. **J Vet Med Sci** 1999 Mar; 61(3):209–12
Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid – a comparison with ketoprofen. Armstrong S, et al. **J Vet Pharmacol Ther** 1999 Jun; 22(3):196–201
Repeated administration of trimethoprim/sulfadiazine in the horse--pharmacokinetics, plasma protein binding and influence on the intestinal microflora. Gustafsson A, et al. **J Vet Pharmacol Ther** 1999 Feb;22(1):20–6
Lack of local anaesthetic efficacy of fentanyl in the abaxial sesamoid block model. Harkins JD, et al. **J Vet Pharmacol Ther** 1999 Feb;22(1):52–5
Lidocaine in the horse: its pharmacological effects and their relationship to analytical findings. Harkins JD, et al. **J Vet Pharmacol Ther** 1998 Dec;21(6):462–76
Bupivacaine in the horse: relationship of local anaesthetic responses and urinary concentrations of 3-hydroxybupivacaine. Harkins JD, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):181–95
The effects of dobutamine and ephedrine on packed cell volume, total protein, heart rate, and blood pressure in anaesthetized horses. Hellyer PW, et al. **J Vet Pharmacol Ther** 1998 Dec;21(6):497–9
Cimetidine inhibits nitric oxide associated nitrate production in a soft-tissue inflammation model in the horse. Hunter RP, et al. **J Vet Pharmacol Ther** 1999 Apr;22(2):136–47
Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. Jaraiz V, et al. **J Vet Pharmacol Ther** 1999 Aug;22(4):247–54
A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. Lees P, et al. **J Vet Pharmacol Ther** 1999 Apr;22(2):96–106
Regional intravenous perfusion of the distal limb of horses with amikacin sulfate. Murphey ED, et al. **J Vet Pharmacol Ther** 1999 Feb;22(1):68–71
Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. Pérez R, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):174–80
Pharmacokinetics of cisapride in the horse. Steel CM, et al. **J Vet Pharmacol Ther** 1998 Dec;21(6):433–6
Endocrine and metabolic responses to plasma volume expansion during halothane anesthesia in ponies. Taylor PM. **J Vet Pharmacol Ther** 1998 Dec;21(6):485–90
Adrenocortical and metabolic responses to dobutamine infusion during halothane anaesthesia in ponies. Taylor PM. **J Vet Pharmacol Ther** 1998 Aug;21(4):282–7
Testing for therapeutic medications: analytical/pharmacological relationships and limitations' on the sensitivity of testing for certain agents. Tobin T, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):220–33 (29 ref.)
Equine placental cup cells show glycan expression distinct from that of both chorionic girdle progenitor cells and early allantochorionic trophoblast of the placenta. Jones CJ, et al. **Placenta** 1999 May;20(4):347–60
Pharmacokinetics of medetomidine in ponies and elaboration of a medetomidine infusion regime which provides a constant level of sedation. Bettschart-Wolfensberger R, et al. **Res Vet Sci** 1999 Aug;67(1):41–6
Improved hepatic and pancreatic localisation of the equine alpha-1-proteinase inhibitor family of serpins using an antigen enhancement technique and a monoclonal antibody. Dagleish MP, et al. **Res Vet Sci** 1998 Nov-Dec; 65(3):215–21
Breath hydrogen measurement in ponies: a preliminary study. Murphy D, et al. **Res Vet Sci** 1998 Jul–Aug;65(1):47–51
Hepatotoxicity associated with pyrrolizidine alkaloid (Crotalaria spp) ingestion in a horse on Easter Island. Arzt J, et al. **Vet Hum Toxicol** 1999 Apr;41(2):96–9
Molecular studies of matrix metalloproteinases and tissue inhibitors of metalloproteinases in equine joints. Clegg PD, et al. **Vet J** 1999 May;157(3):336–8
The effect of sedation on gastric emptying of a liquid marker in ponies. Doherty TJ, et al. **Vet Surg** 1999 Sep–Oct; 28(5):375–9
Studies on equine lipid metabolism. 1. A fluorometric method for the measurement of lipolytic activity in isolated adipocytes of rats and horses. Breidenbach A, et al. **Zentralbl Veterinarmed A** 1998 Dec;45(10):635–43
Studies on equine lipid metabolism. 2. Lipolytic activities of plasma and tissue lipases in large horses and ponies. Breidenbach A, et al. **Zentralbl Veterinarmed A** 1999 Feb; 46(1):39–48

MICROBIOLOGY

Identification of Ruminococcus flavefaciens as the predominant cellulolytic bacterial species of the equine cecum. Julliand V, et al. **Appl Environ Microbiol** 1999 Aug; 65(8):3738–41
Detection of a common genotype among strains of Taylorella equigenitalis isolated from thoroughbred horses in Japan between 1994 and 1996. Matsuda M, et al. **J Basic Microbiol** 1999;39(2):127–30
Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. Seguin JC, et al. **J Clin Microbiol** 1999 May; 37(5):1459–63
Preliminary characterisation of extracellular serine proteases of Dermatophilus congolensis isolates from cattle, sheep and horses. Ambrose NC, et al. **Vet Microbiol** 1998 Aug 15;62(4):321–35
Biochemical fingerprinting and ribotyping of isolates of Actinobacillus equuli from healthy and diseased horses. Sternberg S, et al. **Vet Microbiol** 1999 Mar 31;66(1):53–65

PARASITOLOGY

A multifocal outbreak of trichinellosis linked to horse meat imported from North America to France in 1993. Ancelle T, et al. **Am J Trop Med Hyg** 1998 Oct;59(4):615–9
Seasonal changes in abundance and gonotrophic age of host-seeking Tabanidae (Diptera) from a subarctic Labrador peatland. McElligott PE, et al. **J Med Entomol** 1998 Sep;35(5):763–70
Culicoides (Diptera: Ceratopogonidae) associated with horses at Mogoditshane, Gaborone, Botswana. Mushi EZ, et al. **Vet Res Commun** 1998 Jul;22(5):295–7

PHYSIOLOGY

Mediators of anaphylaxis but not activated neutrophils augment cholinergic responses of equine small airways. Olszewski MA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L522–9
Pre- and postjunctional effects of inflammatory mediators in horse airways. Olszewski MA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L327–33
Effects of exercise and EDTA administration on blood ionized calcium and parathyroid hormone in horses. Aguilera-Tejero E, et al. **Am J Vet Res** 1998 Dec; 59(12):1605–7
Hepatic blood flow in horses during the recuperative period from maximal exercise. Dyke TM, et al. **Am J Vet Res** 1998 Nov;59(11):1476–80
Intensity-dependent effects of acute submaximal exercise on the pharmacokinetics of bromsulphalein in horses. Dyke TM, et al. **Am J Vet Res** 1998 Nov;59(11):1481–7
Morphologic comparisons among equine endometrium categories I, II, and III, using light and transmission electron microscopy. Ferreira-Dias GM, et al. **Am J Vet Res** 1999 Jan;60(1):49–55
Comparison of sedative effects of romifidine following intravenous, intramuscular, and sublingual administration to horses. Freeman SL, et al. **Am J Vet Res** 1999 Aug; 60(8):954–9
Purification and biochemical characterization of pulmonary surfactant protein A of horses. Hobo S, et al. **Am J Vet Res** 1999 Feb;60(2):169–73
Airway responses to histamine aerosol in clinically normal foods. Hoffman AM, et al. **Am J Vet Res** 1999 Aug; 60(8):965–8
Histamine-induced gastric acid secretion in horses. Kitchen DL, et al. **Am J Vet Res** 1998 Oct;59(10):1303–6
Evaluation of washing with cold water to facilitate heat dissipation in horses exercised in hot, humid conditions. Kohn CW, et al. **Am J Vet Res** 1999 Mar;60(3):299–305
Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies. Lee YH, et al. **Am J Vet Res** 1998 Nov;59(11):1463–72
Adrenergic, cholinergic, and nonadrenergic-noncholinergic intrinsic innervation of the jejunum in horses. Malone ED, et al. **Am J Vet Res** 1999 Jul;60(7):898–904
Comparison of two techniques for total intravenous anesthesia in horses. Mama KR, et al. **Am J Vet Res** 1998 Oct;59(10):1292–8
Effects of buprenorphine on cardiovascular and pulmonary function in clinically normal horses and horses with chronic obstructive pulmonary disease. Szöke MO, et al. **Am J Vet Res** 1998 Oct;59(10):1287–91
Temporal changes in core body temperature in anesthetized adult horses [see comments] Tomasic M. **Am J Vet Res** 1999 May;60(5):556–62. Comment in: Am J Vet Res 1999 May;60(5):648–51.
Comparison of peripheral and core temperatures in anesthetized horses [comment] Tomasic M, et al. **Am J Vet Res** 1999 May;60(5):648–51. Comment on: Am J Vet Res 1999 May;60(5):556–62.

Normal variation in, and effect of 2% pilocarpine on, intraocular pressure and pupil size in female horses. van der Woerdt A, et al. **Am J Vet Res** 1998 Nov; 59(11):1459–62

In vitro effects of nonsteroidal anti-inflammatory agents and prostaglandins I2, E2, and F2alpha on contractility of taenia of the large colon of horses. Van Hoogmoed L, et al. **Am J Vet Res** 1999 Aug;60(8):1004–9

In vitro interactions of cryopreserved stallion spermatozoa and oviduct (uterine tube) epithelial cells or their secretory products. Ellington JE, et al. **Anim Reprod Sci** 1999 May 17;56(1):51–65

A longitudinal study of racing thoroughbreds: performance during the first years of racing. More SJ. **Aust Vet J** 1999 Feb;77(2):105–12

Progesterone-induced acrosome reaction in stallion spermatozoa is mediated by a plasma membrane progesterone receptor. Cheng FP, et al. **Biol Reprod** 1998 Oct;59(4):733–42

Equine chorionic gonadotropin regulates luteal steroidogenesis in pregnant mares. Daels PF, et al. **Biol Reprod** 1998 Nov;59(5):1062–8

Gonadotropin response to naloxone in the mare: effect of time of year and reproductive status. Davison LA, et al. **Biol Reprod** 1998 Nov;59(5):1195–9

Follicle deviation and intrafollicular and systemic estradiol concentrations in mares. Gastal EL, et al. **Biol Reprod** 1999 Jul;61(1):31–9

Experimental assumption of dominance by a smaller follicle and associated hormonal changes in mares. Gastal EL, et al. **Biol Reprod** 1999 Sep;61(3):724–30

Intrafollicular content of luteinizing hormone receptor, alpha-inhibin, and aromatase in relation to follicular growth, estrous cycle stage, and oocyte competence for in vitro maturation in the mare. Goudet G, et al. **Biol Reprod** 1999 May;60(5):1120–7

A plasma membrane-associated hyaluronidase is localized to the posterior acrosomal region of stallion sperm and is associated with spermatozoal function. Meyers SA, et al. **Biol Reprod** 1999 Aug;61(2):444–51

Inhibin secretion in the mare: localization of inhibin alpha, betaA, and betaB subunits in the ovary. Nagamine N, et al. **Biol Reprod** 1998 Dec;59(6):1392–8

Comparison of the effects of halothane, isoflurane and methoxyflurane on the electroencephalogram of the horse. Johnson CB, et al. **Br J Anaesth** 1998 Nov;81(5):748–53

Metoclopramide ameliorates the effects of endotoxin on gastric emptying of acetaminophen in horses. Doherty TJ, et al. **Can J Vet Res** 1999 Jan;63(1):37–40

Effects of intravenously administered glycopyrrolate in anesthetized horses. Dyson DH, et al. **Can Vet J** 1999 Jan; 40(1):29–32

Muscle-tendon stresses and elastic energy storage during locomotion in the horse. Biewener AA. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):73–87 (44 ref.)

Physical exercise, oxidative stress and muscle damage in racehorses. Chiaradia E, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Apr; 119(4):833–6

Optimization of the mammalian respiratory system: symmorphosis versus single species adaptation. Jones JH. **Comp Biochem Physiol B Biochem Mol Biol** 1998 May; 120(1):125–38 (58 ref.)

The effects of equine somatotropin (eST) on follicular development and circulating plasma hormone profiles in cyclic mares treated during different stages of the estrous cycle. Cochran RA, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):57–67

Dual regulation of promoter II- and promoter 1f-derived cytochrome P450 aromatase transcripts in equine granulosa cells during human chorionic gonadotropin-induced ovulation: a novel model for the study of aromatase promoter switching. Boerboom D, et al. **Endocrinology** 1999 Sep;140(9):4133–41

Human chorionic gonadotropin induces an inverse regulation of steroidogenic acute regulatory protein messenger ribonucleic acid in theca interna and granulosa cells of equine preovulatory follicles. Kerban A, et al. **Endocrinology** 1999 Feb;140(2):667–74

Macroscopic 'degeneration' of equine superficial digital flexor tendon is accompanied by a change in extracellular matrix composition. Birch HL, et al. **Equine Vet J** 1998 Nov;30(6):534–9

Maintenance of anaesthesia with sevoflurane and oxygen in mechanically-ventilated horses subjected to exploratory laparotomy treated with intra- and post operative anaesthetic adjuncts. Carroll GL, et al. **Equine Vet J** 1998 Sep;30(5):402–7

Net joint moments and powers in the equine forelimb during the stance phase of the trot [see comments] Clayton HM, et al. **Equine Vet J** 1998 Sep;30(5):384–9. Comment in: Equine Vet J 1998 Sep;30(5):362–3.

Clinical assessment of gas exchange in mature horses. Davis MS, et al. **Equine Vet J** 1998 Sep;30(5):396–400

The menace response and pupillary light reflex in neonatal foals. Enzerink E. **Equine Vet J** 1998 Nov;30(6):546–8

Galloping exercise induces regional changes in bone density within the third and radial carpal bones of Thoroughbred horses [see comments] Firth EC, et al. **Equine Vet J** 1999 Mar;31(2):111–5. Comment in: Equine Vet J 1999 Mar;31(2):94–5.

An objective method for evaluating the flexibility of the back of standing horses. Licka T, et al. **Equine Vet J** 1998 Sep; 30(5):412–5

Total and respirable airborne dust endotoxin concentrations in three equine management systems. McGorum BC, et al. **Equine Vet J** 1998 Sep;30(5):430–4

Angular kinematic patterns of limbs in elite and riding horses at trot. Morales JL, et al. **Equine Vet J** 1998 Nov; 30(6):528–33

Is it poor or loss of performance?: the science of explanation [editorial; comment] Pilsworth R, et al. **Equine Vet J** 1998 Sep;30(5):364–5. Comment on: Equine Vet J 1998 Sep;30(5):374–81. Comment on: Equine Vet J 1998 Sep;30(5):390–5.

Muscle characteristics and plasma lactate and ammonia response after racing in Standardbred trotters: relation to performance. Ronéus N, et al. **Equine Vet J** 1999 Mar; 31(2):170–3

Muscle anaerobic response to a maximal treadmill exercise test in Standardbred trotters. Schuback K, et al. **Equine Vet J** 1998 Nov;30(6):504–10

Intra-articular pressure, elastance and range of motion in healthy and injured racehorse metacarpophalangeal joints [published erratum appears in Equine Vet J 1999 Mar;31(2):120] Strand E, et al. **Equine Vet J** 1998 Nov; 30(6):520–7

The effect of foot imbalance on point of force application in the horse. Wilson AM, et al. **Equine Vet J** 1998 Nov; 30(6):540–5

Exploring the possible functions of equine hoof wall tubules. Kasapi MA, et al. **Equine Vet J Suppl** 1998 Sep;(26):10–4

In vitro attenuation of impact shock in equine digits. Lanovaz JL, et al. **Equine Vet J Suppl** 1998 Sep;(26):96–102

Effects of season and diet on tensile strength and mineral content of the equine hoof wall. Ley WB, et al. **Equine Vet J Suppl** 1998 Sep;(26):46–50

Effect of rider and riding style on deformation of the front hoof wall in warmblood horses. Summerley HL, et al. **Equine Vet J Suppl** 1998 Sep;(26):81–5

Variation in surface strain on the equine hoof wall at the midstep with shoeing, gait, substrate, direction of travel, and hoof shape. Thomason JJ. **Equine Vet J Suppl** 1998 Sep;(26):86–95

Pancreatic alpha cell function in the fetal foal during late gestation. Fowden AL, et al. **Exp Physiol** 1999 Jul; 84(4):697–705

Laryngeal movements during the respiratory cycle measured with an endoscopic imaging technique in the conscious horse at rest. Lafortuna CL, et al. **Exp Physiol** 1999 Jul; 84(4):739–46

Novel cathelicidins in horse leukocytes(1). Scocchi M, et al. **FEBS Lett** 1999 Sep 3;457(3):459–64

Effect of furosemide on performance of Thoroughbreds racing in the United States and Canada. Gross DK, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):670–5

Cytologic examination of specimens obtained by means of tracheal washes performed before and after high-speed treadmill exercise in horses with a history of poor performance. Martin BB Jr, et al. **J Am Vet Med Assoc** 1999 Mar 1;214(5):673–7

Diurnal variation and age differences in the biochemical markers of bone turnover in horses. Black A, et al. **J Anim Sci** 1999 Jan;77(1):75–83

The influence of betaine on untrained and trained horses exercising to fatigue. Warren LK, et al. **J Anim Sci** 1999 Mar;77(3):677–84

Sarcoplasmic reticulum responses to repeated sprints are affected by conditioning of horses. Wilson JA, et al. **J Anim Sci** 1998 Dec;76(12):3065–71

Exercise-training-induced alterations in hepatic function in mares. Dyke TM, et al. **J Appl Physiol** 1998 Oct; 85(4):1442–7

Effect of furosemide on pulmonary blood flow distribution in resting and exercising horses. Erickson HH, et al. **J Appl Physiol** 1999 Jun;86(6):2034–43

Effect of tryptophan and of glucose on exercise capacity of horses. Farris JW, et al. **J Appl Physiol** 1998 Sep; 85(3):807–16

Effects of feeding frequency and voluntary salt intake on fluid and electrolyte regulation in athletic horses. Jansson A, et al. **J Appl Physiol** 1999 May;86(5):1610–6

V(O2) recovery kinetics in the horse following moderate, heavy, and severe exercise. Langsetmo I, et al. **J Appl Physiol** 1999 Apr;86(4):1170–7

Blood-gas measurements adjusted for temperature at three sites during incremental exercise in the horse. Taylor LE, et al. **J Appl Physiol** 1998 Sep;85(3):1030–6

Micromechanics of the equine hoof wall: optimizing crack control and material stiffness through modulation of the properties of keratin. Kasapi MA, et al. **J Exp Biol** 1999 Feb;202 (Pt 4):377–91

Developments in equine nutrition: comparing the beginning and end of this century. Harris PA. **J Nutr** 1998 Dec;128(12 Suppl):2698S–2703S (29 ref.)

Dietary carbohydrates and fat influence milk composition and fatty acid profile of Mare's milk. Hoffman RM, et al. **J Nutr** 1998 Dec;128(12 Suppl):2708S–2711S

Exercise affects digestibility and rate of passage of all-forage and mixed diets in thoroughbred horses. Pagan JD, et al. **J Nutr** 1998 Dec;128(12 Suppl):2704S–2707S

Cell proliferation patterns in the equine endometrium throughout the non-pregnant reproductive cycle. Gerstenberg C, et al. **J Reprod Fertil** 1999 May; 116(1):167–75

Gonadotrophin profiles and dioestrous pulsatile release patterns in mares as determined by collection of jugular blood at 4 h intervals throughout an oestrous cycle. Irvine CH, et al. **J Reprod Fertil** 1998 Jul;113(2):315–22

Endometrial oxytocin receptor and uterine prostaglandin secretion in mares during the oestrous cycle and early pregnancy. Starbuck GR, et al. **J Reprod Fertil** 1998 Jul; 113(2):173–9

The effect of dietary protein on reproduction in the mare. V. Endocrine changes and conception during the early post partum period. van Niekerk FE, et al. **J S Afr Vet Assoc** 1998 Sep;69(3):81–8

The effect of dietary protein on reproduction in the mare. VII. Embryonic development, early embryonic death, foetal losses and their relationship with serum progestagen. van Niekerk FE, et al. **J S Afr Vet Assoc** 1998 Dec; 69(4):150–5

Cardiovascular and metabolic adaptations in horses competing in cross-country events. Muñoz A, et al. **J Vet Med Sci** 1999 Jan;61(1):13–20

The effect of motilin on the regulation mechanism of intestinal motility in conscious horses. Sasaki N, et al. **J Vet Med Sci** 1999 Feb;61(2):167–70

The application of electrocecography for evaluation of cecum motility in horses. Sasaki N, et al. **J Vet Med Sci** 1998 Nov;60(11):1221–6

The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. Clegg PD, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):406–13

Mepivacaine: its pharmacological effects and their relationship to analytical findings in the horse. Harkins JD, et al. **J Vet Pharmacol Ther** 1999 Apr;22(2):107–21

Characterization of the antinociceptive and sedative effect of amitraz in horses. Queiroz-Neto A, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):400–5

A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle. Törneke K, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):388–92

The neurology and enterology of equine grass sickness: a review of basic mechanisms [see comments] Cottrell DF, et al. **Neurogastroenterol Motil** 1999 Apr;11(2):79–92 (134 ref.). Comment in: Neurogastroenterol Motil 1999 Apr;11(2):i=ii.

Physiological and behavioral consequences associated with short-term prevention of crib-biting in horses. McGreevy P, et al. **Physiol Behav** 1998 Aug;65(1):15–23

A lectin binding analysis of glycosylation patterns during development of the equine placenta. Jones CJ, et al. **Placenta** 1999 Jan;20(1):45–57

Variations in systemic and pulmonary endothelin-1 in horses with recurrent airway obstruction (heaves). Benamou AE, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):231–5

Characterisation of the cardiovascular pharmacology of medetomidine in the horse and sheep. Bryant CE, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):149–54

The cardiopulmonary effects of clenbuterol when administered to dorsally recumbent halothane-anaesthetised ponies--failure to increase arterial oxygenation. Lee YH, et al. **Res Vet Sci** 1998 Nov-Dec; 65(3):227–32

Locomotor, cardiocirculatory and metabolic adaptations to training in Andalusian and Anglo-Arabian horses. Muñoz A, et al. **Res Vet Sci** 1999 Feb;66(1):25–31

Spinal biomechanics and functional anatomy. Denoix JM. **Vet Clin North Am Equine Pract** 1999 Apr;15(1):27–60 (32 ref.)

Methods, applications and limitations of gait analysis in horses. Barrey E. **Vet J** 1999 Jan;157(1):7–22 (120 ref.)

Gait analysis comes of age [editorial] Clayton HM. **Vet J** 1999 Jan;157(1):5–6 (7 ref.)

Field exercise testing for assessing fitness in French standardbred trotters. Couroucé A. **Vet J** 1999 Mar; 157(2):112–22 (50 ref.)

Near infrared spectroscopy in large animals: optical pathlength and influence of hair covering and epidermal pigmentation. Pringle J, et al. **Vet J** 1999 Jul;158(1):48–52

Flow cytometric determination of oxidative burst activity of equine peripheral blood and bronchoalveolar lavage-derived leucocytes [see comments] Raidal SL, et al. **Vet J** 1998 Sep;156(2):117–26. Comment in: Vet J 1998 Sep;156(2):79–80.

Cytological and bacteriological findings in guttural pouch lavages of clinically normal horses. Chiesa OA, et al. **Vet Rec** 1999 Mar 27;144(13):346–9

Effects on the intramuscular blood flow and cardiopulmonary function of anaesthetised ponies of changing from halothane to isoflurane maintenance and vice versa. Lee YH, et al. **Vet Rec** 1998 Dec 5;143(23):629–33

Effects of glucose infusion on the endocrine, metabolic and cardiorespiratory responses to halothane anaesthesia of ponies. Luna SP, et al. **Vet Rec** 1999 Jul 24;145(4):100–3

Dental wear in horses in relation to the microhardness of enamel and dentine. Muylle S, et al. **Vet Rec** 1999 May 15;144(20):558–61

Practical evaluation of the fertilising capacity of frozen-thawed horse semen. Newcombe JR. **Vet Rec** 1999 Jul 10;145(2):46–7

Kinematics of the equine back: a method to study the

thoracolumbar flexion–extension movements at the trot. Pourcelot P, et al. **Vet Res** 1998 Nov–Dec;29(6):519–25

The influence of speed and height at the withers on the kinematics of sound horses at the hand-led trot. Galisteo AM, et al. **Vet Res Commun** 1998 Sep;22(6):415–23

Effects of ketamine on the equine electroencephalogram during anesthesia with halothane in oxygen. Johnson CB, et al. **Vet Surg** 1999 Sep–Oct;28(5):380–5

Recovery from sevoflurane anesthesia in horses: comparison to isoflurane and effect of postmedication with xylazine. Matthews NS, et al. **Vet Surg** 1998 Sep–Oct;27(5):480–5

Local and global stereopsis in the horse. Timney B, et al. **Vision Res** 1999 May;39(10):1861–7

Morphology and amplitude values of the P and T waves in the electrocardiograms of Spanish-bred horses of different ages. Ayala I, et al. **Zentralbl Veterinarmed A** 1999 May;46(4):225–30

Comparative biokinematic study of young and adult Andalusian horses at the trot. Cano MR, et al. **Zentralbl Veterinarmed A** 1999 Mar;46(2):91–101

A comparison of the ultrastructure and metabolic response of the skeletal muscle of horses performing intense treadmill exercise at 20 and 35 degrees C. Gottlieb-Vedi M, et al. **Zentralbl Veterinarmed A** 1999 May;46(4):209–18

[Effect of common head gear on horses] Preuschoft H, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Apr; 106(4):169–75 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Prevalence and characteristics of foal rejection in Arabian mares. Juarbe-Díaz SV, et al. **Equine Vet J** 1998 Sep; 30(5):424–8

Factors affecting the harem formation process by young Misaki feral stallions. Khalil AM, et al. **J Vet Med Sci** 1999 Jun;61(6):667–71

SURGERY

Technique for the subcutaneous relocation of the common carotid artery in the horse. Tavernor WD. **Am J Vet Res** 1969 Oct;30(10):1881–4

Effect of feed rate and drill speed on temperatures in equine cortical bone. Toews AR, et al. **Am J Vet Res** 1999 Aug; 60(8):942–4

Equine castration: review of anatomy, approaches, techniques and complications in normal, cryptorchid and monorchid horses. Searle D, et al. **Aust Vet J** 1999 Jul;77(7):428–34 (25 ref.)

Gravel impaction in a 2-year-old Morgan gelding. Gilroy BJ, et al. **Can Vet J** 1998 Nov;39(11):706–8

Postcastration eventration in 18 horses: the prognostic indicators for long-term survival (1985–1995). Thomas HL, et al. **Can Vet J** 1998 Dec;39(12):764–8

Effect of hoof trimming on the occurrence of distal phalangeal palmar process fractures in foals. Kaneps AJ, et al. **Equine Vet J Suppl** 1998 Sep;(26):36–45

Laparoscopically assisted resection of umbilical structures in foals. Fischer AT Jr. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1813–6, 1791–2

Parotid duct laceration repair in two horses. Olivier A, et al. **J S Afr Vet Assoc** 1998 Sep;69(3):108–11

Perioperative plasma cortisol concentration in the horse. Stegmann GF, et al. **J S Afr Vet Assoc** 1998 Dec; 69(4):137–42

Antibacterial properties of a silver chloride-coated nylon wound dressing. Adams AP, et al. **Vet Surg** 1999 Jul–Aug; 28(4):219–25

Complete biceps brachii tenotomy to facilitate internal fixation of supraglenoid tubercle fractures in three horses. Bleyaert HF, et al. **Vet Surg** 1999 Jan–Feb;28(1):48–53

Use of electrocautery probes in arthroscopic removal of apical sesamoid fracture fragments in 18 Standardbred horses. Bouré L, et al. **Vet Surg** 1999 Jul–Aug;28(4):226–32

Evaluation of a technique to occlude the internal carotid artery of horses. Cheramie HS, et al. **Vet Surg** 1999 Mar–Apr;28(2):83–90

A comparison of the Synthes 4.5-mm cannulated screw and the Synthes 4.5-mm standard cortex screw systems in equine bone. Colgan SA, et al. **Vet Surg** 1998 Nov–Dec; 27(6):540–6

Arthroscopic subchondral bone plate microfracture technique augments healing of large chondral defects in the radial carpal bone and medial femoral condyle of horses. Frisbie DD, et al. **Vet Surg** 1999 Jul–Aug; 28(4):242–55

Bilateral laparoscopic ovariectomy in standing mares: 22 cases. Hanson CA, et al. **Vet Surg** 1999 Mar–Apr; 28(2):106–12

Detomidine-propofol anesthesia for abdominal surgery in horses. Matthews NS, et al. **Vet Surg** 1999 May–Jun; 28(3):196–201

The effect of a surgically created shunt between the corpus cavernosum penis and corpus spongiosum penis of stallions on erectile and ejaculatory function. Schumacher J, et al. **Vet Surg** 1999 Jan–Feb;28(1):21–4

Effect of ischemia and reperfusion on neutrophil accumulation in equine microvascular tissue flaps. Scott WM, et al. **Vet Surg** 1999 May–Jun;28(3):180–7

Desmotomy of the accessory ligament of the superficial digital flexor tendon in the horse with use of a tenoscopic approach to the carpal sheath. Southwood LL, et al. **Vet Surg** 1999 Mar–Apr;28(2):99–105

Persistent frenulum of the epiglottis in four foals. Yarbrough TB, et al. **Vet Surg** 1999 Jul–Aug;28(4):287–91

URINE

Nortestosterone: endogenous in urine of goats, sheep and mares? Sterk S, et al. **Analyst** 1998 Dec;123(12):2633–6

The urinary elimination profiles of diazepam and its metabolites, nordiazepam, temazepam, and oxazepam, in the equine after a 10-mg intramuscular dose. Marland A, et al. **J Anal Toxicol** 1999 Jan–Feb;23(1):29–34

Detection of thiazide-based diuretics in equine urine by liquid chromatography/mass spectrometry. Garbis SD, et al. **J AOAC Int** 1998 Sep–Oct;81(5):948–57

VIROLOGY

Phylogenetic characterization of a highly attenuated strain of equine arteritis virus from the semen of a persistently infected standardbred stallion. Patton JF, et al. **Arch Virol** 1999;144(4):817–27

Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV). McCormack JG, et al. **J Infect** 1999 Jan;38(1):22–3

HORSESHOE CRABS

see related
LIMULUS TEST

CHEMISTRY

Horseshoe crab hemocyte-derived antimicrobial polypeptides, tachystatins, with sequence similarity to spider neurotoxins. Osaki T, et al. **J Biol Chem** 1999 Sep 10;274(37):26172–8

C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP. Shrive AK, et al. **J Mol Biol** 1999 Jul 30; 290(5):997–1008

Phospholipid composition of the granular amebocyte from the horseshoe crab, Limulus polyphemus. MacPherson JC, et al. **Lipids** 1998 Sep;33(9):931–40

ENZYMOLOGY

The involvement of protein kinase C in the regulation of choline cotransport in Limulus. Ford BD, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jul; 123(3):255–61

GENETICS

Molecular cloning of a putative cyclic nucleotide-gated ion channel cDNA from Limulus polyphemus. Chen FH, et al. **J Neurochem** 1999 Feb;72(2):461–71

IMMUNOLOGY

Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. Armstrong PB, et al. **Dev Comp Immunol** 1999 Jun–Jul;23(4–5):375–90 (95 ref.)

Role of lectins in the innate immunity of horseshoe crab. Kawabata S, et al. **Dev Comp Immunol** 1999 Jun–Jul; 23(4–5):391–400 (28 ref.)

Tachylectin-2: crystal structure of a specific GlcNAc/GalNAc-binding lectin involved in the innate immunity host defense of the Japanese horseshoe crab Tachypleus tridentatus. Beisel HG, et al. **EMBO J** 1999 May 4;18(9):2313–22

Horseshoe crab acetyl group-recognizing lectins involved in innate immunity are structurally related to fibrinogen. Gokudan S, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10086–91

METABOLISM

Functional and structural diversities of C-reactive proteins present in horseshoe crab hemolymph plasma. Iwaki D, et al. **Eur J Biochem** 1999 Sep;264(2):314–26

Inhibition of the calcineurin-like protein phosphatase activity in Limulus ventral eye photoreceptor cells alters the characteristics of the spontaneous quantal bumps and the light-mediated inward currents, and enhances arrestin phosphorylation. Kass L, et al. **Vis Neurosci** 1998 Nov–Dec;15(6):1039–49

PHYSIOLOGY

Efferent modulation of physiological properties of the Limulus lateral eye. Ruta VJ, et al. **Biol Bull** 1998 Oct; 195(2):189–90

Adaptation-dependent differences in electroretinographic latency patterns in uniform and variegated horseshoe crabs. Kim B, et al. **Biol Signals Recept** 1998 Jul–Aug;7(4):227–34

Cell-based model of the Limulus lateral eye. Passaglia CL, et al. **J Neurophysiol** 1998 Oct;80(4):1800–15

Cellular distributions and functions of histamine, octopamine, and serotonin in the peripheral visual system, brain, and circumesophageal ring of the horseshoe crab Limulus polyphemus. Battelle BA, et al. **Microsc Res Tech** 1999 Jan 15–Feb 1;44(2–3):70–80

HOSPICE CARE

see related
RESPITE CARE

Hospice care [letter; comment] Malone M. **Am J Nurs** 1998 Dec;98(12):23. Comment on: Am J Nurs 1998 Aug;98(8):44–8; discussion 49.

Hospice patients' and nurses' perceptions of self-care deficits based on symptom experience. Rhodes VA, et al. **Cancer Nurs** 1998 Oct;21(5):312–9

Hospice in nursing homes: a facility-level analysis of the distribution of hospice beneficiaries. Petrisek AC, et al. **Gerontologist** 1999 Jun;39(3):279–90

A hidden client group? Communication impairment in hospice patients. Salt N, et al. **Int J Lang Commun Disord** 1998;33 Suppl:96–101

Facing the issue of dependence: some implications from the literature for the hospice and hospice nurses. Flanagan J, et al. **J Adv Nurs** 1999 Mar;29(3):592–9 (47 ref.)

Characterization of breakthrough pain by hospice patients and their caregivers. Fine PG, et al. **J Pain Symptom Manage** 1998 Sep;16(3):179–83

The Dorothy Ley Hospice Day Respite Program. Filman J, et al. **J Palliat Care** 1998 Autumn;14(3):94–7

Congruence between patients' and family caregivers' perceptions of symptom distress in patients with terminal cancer. Kristjanson LJ, et al. **J Palliat Care** 1998 Autumn; 14(3):24–32

The Caregiver Quality of Life Index-Cancer (CQOLC) Scale: revalidation in a home hospice setting. Weitzner MA, et al. **J Palliat Care** 1999 Summer;15(2):13–20

Hospice care in the United States: a conversation with Florence S. Wald [interview by M. J. Friedrich] Wald FS. **JAMA** 1999 May 12;281(18):1683–5

Medicine and palliative care [editorial] Maddocks I. **Med J Aust** 1999 Jul 19;171(2):63–4

The attitude of health care professionals toward the availability of hospice services for cancer patients and their carers in Saudi Arabia. Almuzaini AS, et al. **Palliat Med** 1998 Sep;12(5):365–73

Treasure Weekend: supporting bereaved siblings. Potts S, et al. **Palliat Med** 1999 Jan;13(1):51–6

A survey of nursing and medical staff views on the use of cardiopulmonary resuscitation in the hospice. Thorns AR, et al. **Palliat Med** 1999 May;13(3):225–32

Barriers to the physician decision to offer hospice as an option for terminal care. Weggel JM. **WMJ** 1999 May–Jun; 98(3):49–53

[Home care for terminally ill cancer patients in 1997] Ashino Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:669–74 (Eng. Abstr.) **(Jpn)**

[Three patients with terminal gastric cancer who achieved good QOL through home hospice care] Muto Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:665–8 (Eng. Abstr.) **(Jpn)**

[Current status of cancer pain control in home hospice care--assessment by family members] Okuyama H, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:605–9 (Eng. Abstr.) **(Jpn)**

[Pain management in home hospice care] Sakai T, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:539–43 (Eng. Abstr.) **(Jpn)**

[Death at home: home care for terminal cancer patients] Sakuyama T, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:675–8 (Eng. Abstr.) **(Jpn)**

[A consideration in the care of elderly patients receiving home hospice care: administration of parenteral nutrition at home] Tomita M, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:705–8 (Eng. Abstr.) **(Jpn)**

[Factors influencing grief due to bereavement among elderly widows and widowers] Terasaki A, et al. **Nippon Koshu Eisei Zasshi** 1998 Jun;45(6):512–25 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Commentary: reconciling hospice benefits and needs. Jennings B. **J Pain Symptom Manage** 1998 Oct;16(4):265–7

Case presentation: limited hospice benefits. Michalakes LG. **J Pain Symptom Manage** 1998 Oct;16(4):263

METHODS

Predictors of oncology and hospice nurses' spiritual care perspectives and practices. Taylor EJ, et al. **Appl Nurs Res** 1999 Feb;12(1):30–7

Sedation for uncontrolled symptoms in a South African hospice [see comments] Fainsinger RL, et al. **J Pain Symptom Manage** 1998 Sep;16(3):145–52. Comment in: J Pain Symptom Manage 1999 Jun;17(6):448–9.

A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. Hunt R, et al. **J Pain Symptom Manage** 1999 Aug;18(2):111–9

Cancer pain assessment and management recommendations by hospice nurses. University of Kentucky, Lexington, Kentucky. Sloan PA, et al. **J Pain Symptom Manage** 1999 Aug;18(2):103–10

Experts describe optimal symptom management for hospice patients [news] Friedrich MJ. **JAMA** 1999 Oct 6; 282(13):1213–4

ORGANIZATION & ADMINISTRATION

Bereavement care in general practice: a survey in South Thames Health Region. Harris T, et al. **Br J Gen Pract** 1998 Sep;48(434):1560–4

Resuscitation in hospice. Henderson S, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):20; discussion 20–2

Palliative care services in the community: what do family doctors want? Higginson I. **J Palliat Care** 1999 Summer; 15(2):21–5
Making Michigan a model in palliative care. Lammers SR. **Mich Med** 1998 Sep;98(9):18–22
[Out-patient hospice services--their importance for palliative care in Germany] Sabatowski R, et al. **Z Arztl Fortbild Qualitatssich** 1998 Aug;92(6):377–83 (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Autonomy, power, and control in palliative care. Scott PA. **Camb Q Healthc Ethics** 1999 Spring;8(2):139–47 (35 ref.)
Resuscitation in hospice. Henderson S, et al. **Hastings Cent Rep** 1998 Nov–Dec;28(6):20; discussion 20–2
A study of the perceptions of hospice day care patients: my phenomenological methodology. Hopkinson JB. **Int J Nurs Stud** 1999 Jun;36(3):203–7
The place of metaphor and language in exploring nurses' emotional work. Froggatt K. **J Adv Nurs** 1998 Aug; 28(2):332–8
Length of cancer patients' stay at a hospice: does it affect psychological adjustment to the loss of the spouse? Gilbar O. **J Palliat Care** 1998 Winter;14(4):16–20
The relationship between patients' concerns and psychological distress in a hospice setting. Heaven CM, et al. **Psychooncology** 1998 Nov–Dec;7(6):502–7
[Terminal care of the cancer patient at home--patient and family spending the last moments together] Sekiya Y, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:684–8 (Eng. Abstr.) **(Jpn)**

STANDARDS

Competence: the basis of pain management. White L. **J Nurs Care Qual** 1999 Apr;13(4):86–8
The hospice alternative. Promoting dignity at the end of life. Sasso HS. **Mich Med** 1998 Nov;97(11):20–1
Relationships between symptom relief, quality of life, and satisfaction with hospice care. Tierney RM, et al. **Palliat Med** 1998 Sep;12(5):333–44

STATISTICS & NUMERICAL DATA

Health benefits for the terminally ill: reality and perception. Gabel JR, et al. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):120–7

TRENDS

Hospice and palliative care as a new social movement: a case illustration from South Australia. Elsey B. **J Palliat Care** 1998 Winter;14(4):38–46 (21 ref.)

UTILIZATION

Differences in physician access patterns to hospice care. Stillman MJ, et al. **J Pain Symptom Manage** 1999 Mar; 17(3):157–63
Why didn't our doctor tell us about hospice sooner? Martin EW. **Med Health R I** 1999 Feb;82(2):74–5

HOSPICE PROGRAMS see **HOSPICE CARE**

HOSPICES

The role of the family physician in hospice care [letter; comment] Wright JB. **Am Fam Physician** 1998 Oct 15; 58(6):1305–6. Comment on: Am Fam Physician 1998 Mar 1;57(5):935, 939–40.
Assessment of GP management of symptoms of dying patients in an Australian community hospice by chart audit. Mitchell G. **Fam Pract** 1998 Oct;15(5):420–5
How patients spend their time in a hospice and in an oncological unit. Rasmussen BH, et al. **J Adv Nurs** 1998 Oct;28(4):818–28
How Hospice Atlanta, Inc. came into its own. Booth AS Jr. **J Med Assoc Ga** 1999 Feb;88(1):13–5
Initial demographic, symptom, and medication profiles in patients admitted to continuing palliative care units. Jenkins CA, et al. **J Pain Symptom Manage** 1998 Sep;16(3):163–70
Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. Ng K, et al. **J Pain Symptom Manage** 1998 Nov;16(5):307–16
Palliative medicine: is it really specialist territory? [letter; comment] [see comments] Backhouse TW. **J R Soc Med** 1999 Jan;92(1):53. Comment on: J R Soc Med 1998 Nov;91(11):568–72. Comment in: J R Soc Med 1999 May;92(5):269.
Toward physician-assisted living. Improving end-of-life care. Brusstar G. **Mich Med** 1999 Feb;98(2):24–32
Quality of life in hospice patients. A pilot study. Bretscher M, et al. **Psychosomatics** 1999 Jul–Aug;40(4):309–13
[Philanthropic volunteer service for the public good: hospice volunteers in the United States of America] Coury JM. **Lijec Vjesn** 1999 Apr–May;121(4–5):162–4 **(Scr)**

ECONOMICS

The development of funding policies for hospices: is casemix-based funding an option? Carter H, et al. **N Z Med J** 1999 Jun 25;112(1090):236–9

HISTORY

Caring for cancer. Saunders C. **J R Soc Med** 1998 Aug; 91(8):439–41
The development for the Japanese Society for Palliative Medicine. Ishitani K. **Support Care Cancer** 1999 Mar; 7(2):62–3

ORGANIZATION & ADMINISTRATION

The hospice is dead. Avellanet C, et al. **J Nurs Adm** 1999 Mar;29(3):4–7, 20
Hospice Uganda: 1993–1998. Merriman A. **J Palliat Care** 1999 Spring;15(1):50–2
[PHOLY: A pilot study of drug utilization in civil hospices in Lyon – methodology and difficulties] Dubois V, et al. **Therapie** 1998 Mar–Apr;53(2):151–5 (Eng. Abstr.) **(Fre)**
[PHOLY: a pilot study of drug utilization in civil hospitals in Lyon. Results] Rachet F, et al. **Therapie** 1998 Mar–Apr; 53(2):157–64 (Eng. Abstr.) **(Fre)**

STANDARDS

End-of-life care and family practice [editorial] Reichel W. **Am Fam Physician** 1999 Mar 15;59(6):1388, 1395–6, 1399
Who needs palliativé care? [editorial; comment] [see comments] Higginson IJ. **J R Soc Med** 1998 Nov; 91(11):563–4. Comment on: J R Soc Med 1998 Nov;91(11):568–72. Comment in: J R Soc Med 1999 Feb;92(2):101.

STATISTICS & NUMERICAL DATA

A descriptive study of the demography, symptomology, management and outcome of the first 300 patients admitted to an independent hospice in Singapore. Low JA, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):824–9
High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Bercovitch M, et al. **Cancer** 1999 Sep 1; 86(5):871–7

UTILIZATION

Who dies at home? Determinants of site of death for community-based long-term care patients. Fried TR, et al. **J Am Geriatr Soc** 1999 Jan;47(1):25–9
Influence of patient preferences and local health system characteristics on the place of death. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Risks and Outcomes of Treatment [see comments] Pritchard RS, et al. **J Am Geriatr Soc** 1998 Oct;46(10):1242–50. Comment in: J Am Geriatr Soc 1998 Oct;46(10):1320–1.
Where do cancer patients die? Ten-year trends in the place of death of cancer patients in England. Higginson IJ, et al. **Palliat Med** 1998 Sep;12(5):353–63

HOSPITAL-ADDICTION SYNDROME see **MUNCHAUSEN SYNDROME**

HOSPITAL ADMINISTRATION

see related
PROFESSIONAL STAFF COMMITTEES

Hospital policies and their influence on newborn body weight. Mikiel-Kostyra K, et al. **Acta Paediatr** 1999 Jan; 88(1):72–5
Reporting fraud (letter) Passey J. **Am J Nurs** 1999 Jun; 99(6):14
Transfusion medicine's role in hospital performance improvement. An administrator's view. Krempel G, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):486–91 (4 ref.)
Time's running out as physicians await Y2K fallout. Elash A. **CMAJ** 1998 Sep 22;159(6):697–9
Manitoba hires spiritual care coordinator to promote nonmedical side of healing. Sibbald B. **CMAJ** 1999 May 18;160(10):1494
Physician involvement in management and governance: the moderating effects of staff structure and composition. Succi MJ, et al. **Health Care Manage Rev** 1999 Winter;24(1):33–44
Fun runs & faux pas. Lumsdon K. **Hosp Health Netw** 1999 Feb;73(2):94
What to tell families about drug errors [news] Mehn J, et al. **Hosp Health Netw** 1999 Feb;73(2):30
The unlearning curve. Learning is only half the process of achieving organizational change. Solovy A. **Hosp Health Netw** 1999 Jan;73(1):30
Revised UK guidelines for the control of methicillin-resistant Staphylococcus aureus in hospitals. Chadwick PR. **Int J Antimicrob Agents** 1999 Feb;11(2):89–91
Down-board thinking: what are our next moves? [letter; comment] DeMicco FJ, et al. **J Am Diet Assoc** 1999 Mar; 99(3):285–6. Comment on: J Am Diet Assoc 1998 Aug;98(8):860–2.
The influence of governmental policy on community health partnerships and community care networks: an analysis of three cases. Gamm LD, et al. **J Health Polit Policy Law** 1998 Oct;23(5):771–94
Demystifying the influence of hospital characteristics on inpatient mortality rates. van Servellen G, et al. **J Nurs Adm** 1999 Apr;29(4):39–47
Hospital participation in community partnerships to improve health. Boex JR, et al. **Jt Comm J Qual Improv** 1998 Oct; 24(10):541–8
Organ donor index: a benchmark for comparing hospital organ donor rates [see comments] Holt AW, et al. **Med J Aust** 1999 May 17;170(10):479–81. Comment in: Med J Aust 1999 May 17;170(10):463–4.
Why good hospitals get bad computing. Bleich HL. **Medinfo** 1998;9 Pt 2:969–72
Hospital management decision support: a balanced scorecard approach. Gordon D, et al. **Medinfo** 1998;9 Pt 1:453–6
A conceptual representation of clinical and managerial guidelines: the ATREUS workflow model. Grifoni P, et al. **Medinfo** 1998;9 Pt 2:940–4
The Stent report, one year on. Christchurch Hospital's Medical Specialists Association. Foate J, et al. **N Z Med J** 1999 Jul 23;112(1092):278–9
Management of health and safety in the organization of worktime at the local level. Jeppesen HJ, et al. **Scand J Work Environ Health** 1998;24 Suppl 3:81–7
From the bedside to the boardroom. Gabow PA. **Semin Nephrol** 1999 Mar;19(2):109–14
How a Tennessee hospital got ready for Y2K. Williams B. **Tenn Med** 1999 May;92(5):170
Forget fair play. Townend DW. **Tex Med** 1999 Jan; 95(1):42–3, 45
The transfusion medicine consultant and hospital transfusion committee. Popovsky MA. **Vox Sang** 1998;74 Suppl 2:391–3 (6 ref.)
[The administration of a clinical department] Vandenbroucke JP. **Ned Tijdschr Geneeskd** 1998 Dec 19;142(51):2803–5 (Eng. Abstr.) **(Dut)**
[Medical progress is as rapid and important in its management as that in its contents (editorial; comment)] Guérot C. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):707–8. Comment on: Arch Mal Coeur Vaiss 1998 Jun;91(6):709–14. **(Fre)**
[Cataract surgery and hospital practice] Chaine G. **J Fr Ophtalmol** 1999 Jun–Jul;22(6):709–10 **(Fre)**
[Promoting health in health care organizations and hospitals? A survey of the French community in Belgium] Deccache A, et al. **Promot Educ** 1999 Mar;6(1):31–5, 25 (Eng. Abstr.) **(Fre)**
[Controlling in clinical management] Bähr K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Feb; 34(2):90–3 (Eng. Abstr.) **(Ger)**
[Tuberculosis infection control practice in hospitals from the viewpoint of occupational health] Suzuki K, et al. **Kekkaku** 1999 Apr;74(4):413–20 (Eng. Abstr.) **(Jpn)**
[Insufficient knowledge about Karl Evang (letter)] Harvei S. **Tidsskr Nor Laegeforen** 1999 Apr 30;119(11):1650 **(Nor)**
[Hospital without patients? (letter; comment)] Opsahl R. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1507–8. Comment on: Tidsskr Nor Laegeforen 1999 Mar 10;119(7):918. **(Nor)**

ECONOMICS

Commentary: excess capacity, a commentary on markets, regulation, and values [comment] Friedman B. **Health Serv Res** 1999 Feb;33(6):1669–82 (31 ref.). Comment on: Health Serv Res 1999 Feb;33(6):1651–68.
Excess capacity: markets regulation, and values [see comments] Madden CW. **Health Serv Res** 1999 Feb; 33(6):1651–68 (31 ref.). Comment in: Health Serv Res 1999 Feb;33(6):1669–82.
Identifying efficiently and economically operated hospitals: the prospects and pitfalls of applying frontier regression techniques. Chirikos TN. **J Health Polit Policy Law** 1998 Dec;23(6):879–904 (16 ref.)
Use of administrative personnel in hospitals: a three nation comparison. Koeck CM, et al. **Wien Klin Wochenschr** 1998 Nov 27;110(22):789–95

METHODS

[Serious leadership! (see comments)] Mikkelsen B. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):918. Comment in: Tidsskr Nor Laegeforen 1999 Apr 20;119(10):1507–8. **(Nor)**

STANDARDS

Accounting for variation in hospital outcomes: a cross-national study. Sochalski J, et al. **Health Aff (Millwood)** 1999 May–Jun;18(3):256–9
Organizational tactics for the successful assimilation of medical practice guidelines. Sonnad SS. **Health Care Manage Rev** 1998 Summer;23(3):30–7 (15 ref.)
Managing the quality effort in a health care setting: an application. Yasin MM, et al. **Health Care Manage Rev** 1999 Winter;24(1):45–56
The eyes have it. Bilchik GS. **Hosp Health Netw** 1999 Apr; 73(4):62–6
The spies who.... Downey C. **Hosp Health Netw** 1999 Jul; 73(7):46–50, 52
Customer service. Worthier waits. Hudson T. **Hosp Health Netw** 1998 Dec 5–20;72(23–24):64
Reporting comparative results from hospital patient surveys. Rogers G, et al. **Int J Qual Health Care** 1999 Jun; 11(3):251–9
Review of magnet hospital research: findings and implications for professional nursing practice. Scott JG, et al. **J Nurs Adm** 1999 Jan;29(1):9–19
TQM implementation strategies in hospitals: an empirical perspective. Bringelson LS, et al. **J Soc Health Syst** 1998; 5(4):50–62

HOSPITAL ADMINISTRATION

Lessons in cooperation: an update on improving the quality of hospital care. Kabcenell A. **Jt Comm J Qual Improv** 1998 Oct;24(10):591–3

[Comprehensive quality management in hospitals--experience and recommendations] Schubert HJ. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):135–9 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Measuring hospital cost efficiency with panel data models. Linna M. **Health Econ** 1998 Aug;7(5):415–27

Outsourcing loses its 'MO'. Our annual survey points to a plateau for most contract services. Sunseri R. **Hosp Health Netw** 1998 Nov 20;72(22):36, 38, 40

Further evidence that hospital production is inefficient. Chirikos TN. **Inquiry** 1998–99 Winter;35(4):408–16

Impact of information systems on acute care hospitals: results from a survey in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):379–87

Information systems' approaches and designs and facility information: survey of acute care hospitals in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):389–96

Decision-making with and without information technology in acute care hospitals: survey in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):397–404

Estimating hospital inefficiency: does case mix matter? Rosko MD, et al. **J Med Syst** 1999 Feb;23(1):57–71

TRENDS

Hospitalists offer prospect for increased efficiencies [news] Thompson CA. **Am J Health Syst Pharm** 1999 Apr 1; 56(7):596–8

Marketing nets out. Spending--and expecting--more than ever, hospitals and systems take their message to the Web. Hudson T. **Hosp Health Netw** 1999 May;73(5):34, 36, 38

Hospital management in the 21st century. Maxwell RJ. **Ulster Med J** 1998 Jun;67 Suppl 1:95–6

[Hospital comparison--status quo and prospects] Betzler M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:938–43 **(Ger)**

[Success factors in hospital administration] Heberer M. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:926–37 **(Ger)**

[Trend of health policy and hospital laboratory service--view from hospital management] Takahashi T. **Rinsho Byori** 1999 Apr;47(4):313–7 (Eng. Abstr.) **(Jpn)**

[Future health care legislation, hospital management, and clinical tests] Takahashi T. **Rinsho Byori** 1999 Feb;Suppl 109:9–15 **(Jpn)**

HOSPITAL ADMINISTRATORS

Techno no-nos. Think you've mastered those gadgets around you? Think again. Lumsdon K. **Hosp Health Netw** 1999 Jan;73(1):92

[Suitability as head physician requires more than medical education (letter)] Norman C, et al. **Lakartidningen** 1999 Feb 17;96(7):717–8 **(Swe)**

ORGANIZATION & ADMINISTRATION

Effects of implementing patient-centered care models on nurse and non-nurse managers. Redman RW, et al. **J Nurs Adm** 1998 Nov;28(11):46–53

PSYCHOLOGY

Head games. Hiring trends. Greene J. **Hosp Health Netw** 1999 Jun;73(6):52–4, 56, 2

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of general hospital center directors. Reflections on the experiment undertaken at Clamecy] Faulconnier B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:232–6 **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center directors] Leclercq B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:229–31 (11 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Diversity. Still now Rainbow Coalition [news] Santoro J. **Hosp Health Netw** 1999 May;73(5):14, 16

How should our public hospitals respond to increasing ethical challenges? Bryson J. **N Z Med J** 1999 Feb 26; 112(1082):47–9

HOSPITAL ADMISSION TESTS see **DIAGNOSTIC TESTS, ROUTINE**

HOSPITAL ANCILLARY SERVICES see **ANCILLARY SERVICES, HOSPITAL**

HOSPITAL ANESTHESIA DEPARTMENT see **ANESTHESIA DEPARTMENT, HOSPITAL**

HOSPITAL ANESTHESIA-RESUSCITATION DEPARTMENT see **ANESTHESIA DEPARTMENT, HOSPITAL**

HOSPITAL-BASED HOME CARE see **HOME CARE SERVICES, HOSPITAL-BASED**

HOSPITAL BED CAPACITY

see related
BED OCCUPANCY

System failure? The problems of reductions in long-stay beds in the UK. Shepherd G. **Epidemiol Psichiatr Soc** 1998 May-Aug;7(2):127–34

Managing a bed crisis. Egan N. **J Accid Emerg Med** 1999 Mar;16(2):145–6

Did Wellington have too many acute psychiatric beds in 1996? MacDonald J, et al. **N Z Med J** 1999 Jul 23; 112(1092):275–6

[The number of beds needed for patients with infectious diseases that require hospitalization by law] Nakamura Y, et al. **Nippon Koshu Eisei Zasshi** 1998 Dec;45(12):1137–41 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Commentary: excess capacity, a commentary on markets, regulation, and values [comment] Friedman B. **Health Serv Res** 1999 Feb;33(6):1669–82 (31 ref.). Comment on: Health Serv Res 1999 Feb;33(6):1651–68.

Excess capacity: markets regulation, and values [see comments] Madden CW. **Health Serv Res** 1999 Feb; 33(6):1651–68 (31 ref.). Comment in: Health Serv Res 1999 Feb;33(6):1669–82.

STATISTICS & NUMERICAL DATA

[The status of neurologic intensive care in Germany. Current data] Harms L, et al. **Nervenarzt** 1998 Dec;69(12):1123–33 (Eng. Abstr.) **(Ger)**

[Contribution of psychiatric departments to restructuring inpatient management: the Saxony-Anhalt example] Böcker FM. **Psychiatr Prax** 1998 Jul;25(4):179–82 (Eng. Abstr.) **(Ger)**

[Identification of acute geriatric patients in the city of Hamburg ("direct data collection")] Willkomm M, et al. **Z Gerontol Geriatr** 1998 Aug;31(4):271–6 (Eng. Abstr.) **(Ger)**

[Evaluating the influence of hospital size on respiratory health care efficiency in Andalusia] Galán González-Serna JM, et al. **Arch Bronconeumol** 1999 May;35(5):202–7 (Eng. Abstr.) **(Spa)**

HOSPITAL BED CAPACITY, 300 TO 499

[Hillel Yaffe Medical Center] **Harefuah** 1998 Oct; 135(7–8):324 **(Heb)**

HOSPITAL CARDIOLOGY SERVICE see **CARDIOLOGY SERVICE, HOSPITAL**

HOSPITAL CENTRAL SUPPLIES see **CENTRAL SUPPLY, HOSPITAL**

HOSPITAL CENTRAL SUPPLY see **CENTRAL SUPPLY, HOSPITAL**

HOSPITAL CHAPLAINCY SERVICE see **CHAPLAINCY SERVICE, HOSPITAL**

HOSPITAL CHARGES

Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. Neylan JF, et al. **Am J Kidney Dis** 1998 Nov; 32(5):770–7

Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Carmeli Y, et al. **Arch Intern Med** 1999 May 24;159(10):1127–32

Arthroscopic or open Bankart procedures: what are the costs? Barber FA, et al. **Arthroscopy** 1998 Oct;14(7):671–4

Pre-transplant identification of risk factors that adversely affect length of stay and charges for renal transplantation. Johnson CP, et al. **Clin Transplant** 1999 Apr;13(2):168–75

The effect of user charges and socio-demographic environment on paediatric trauma hospitalisation in Helsinki in 1989–1994. Ahlamaa-Tuompo J. **Eur J Epidemiol** 1999 Feb;15(2):133–9

A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. Gold MR, et al. **J Interv Card Electrophysiol** 1998 Dec; 2(4):345–9

Charge and length of hospital stay analysis of radical retropubic prostatectomy and transperineal prostate brachytherapy. Wagner TT 3rd, et al. **J Urol** 1999 Apr; 161(4):1216–8

Public disclosure of performance information in Pennsylvania: impact on hospital charges and the views of hospital executives. Maxwell CI. **Jt Comm J Qual Improv** 1998 Sep;24(9):491–502

A comparison of the cost effectiveness of one-stage versus two-stage bilateral total hip replacement. Lorenze M, et al. **Orthopedics** 1998 Dec;21(12):1249–52

Sedation of pediatric patients for minor laceration repair: effect on length of emergency department stay and patient charges. Lawrence LM, et al. **Pediatr Emerg Care** 1998 Dec;14(6):393–5

Pricing strategy for aesthetic surgery: economic analysis of a resident clinic's change in fees. Krieger LM, et al. **Plast Reconstr Surg** 1999 Feb;103(2):695–700

Average charges for hip replacement surgeries: United States, 1997. Mushinski M. **Stat Bull Metrop Insur Co** 1999 Apr-Jun;80(2):32–40

[Appendectomy with respect to flat fee and special rate charges. Cost analysis of open and laparoscopic operation] Zaage J, et al. **Zentralbl Chir** 1998;123 Suppl 4:104–7 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Medical fees for A- and B-cases for hospital services] **Chirurg** 1998 Oct;69(10):suppl 306–7 **(Ger)**

[The duty of fee reduction according to Article 6 a GOA (Gebührenordnung für Arzte) and expenses reimbursement in the furnishing of inpatient services by established physicians. The judgement of the Federal High Court of 14 January 1998] Rieger HJ. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1497–8 **(Ger)**

STANDARDS

Does pediatric orthopedic subspecialization affect hospital utilization and charges? Smith JT, et al. **J Pediatr Orthop** 1999 Jul-Aug;19(4):553–5

STATISTICS & NUMERICAL DATA

Prospective, randomized trial of template-assisted versus undirected written recording of physician records in the emergency department. Marill KA, et al. **Ann Emerg Med** 1999 May;33(5):500–9

The influence of chronic disease on resource utilization in common acute pediatric conditions. Financial concerns for children's hospitals. Silber JH, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):169–79

A multicenter investigation of age-related differences in lengths of stay, hospitalization charges, and outcomes for a matched tetraplegia sample. Cifu DX, et al. **Arch Phys Med Rehabil** 1999 Jul;80(7):733–40

Stroke rehabilitation: clinical predictors of resource utilization. Harvey RL, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1349–55

The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. Wurtz R, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):382–7

Laparoscopic splenectomy: reduction of hospital charges. Schlinkert RT, et al. **J Gastrointest Surg** 1998 May-Jun; 2(3):278–82

Hospital charges for terminal care of cancer patients dying before age 65. Polednak AP, et al. **J Health Care Finance** 1998 Fall;25(1):26–34

Skeletal traction versus external fixation for pediatric femoral shaft fractures: a comparison of hospital costs and charges. Nork SE, et al. **J Orthop Trauma** 1998 Nov-Dec; 12(8):563–8

A comparative study of the costliness of Manitoba hospitals. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS101–22

Direct medical charges associated with myocardial infarction in patients with and without diabetes. Smith TL, et al. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS4–11

The effect of price information on test-ordering behavior and patient outcomes in a pediatric emergency department. Hampers LC, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):877–82

Charges for childhood asthma by hospital characteristics. Meurer JR, et al. **Pediatrics** 1998 Dec;102(6):E70

Impact of user charges and socio-economic environment on visits to paediatric trauma unit in Finland. Ahlamaa-Tuompo J, et al. **Scand J Soc Med** 1998 Dec; 26(4):265–9

Average charges for cholecystectomies in the United States, 1996. Mushinski M. **Stat Bull Metrop Insur Co** 1998 Oct-Dec;79(4):16–25

TRENDS

Market power and hospital pricing: are nonprofits different? Melnick G, et al. **Health Aff (Millwood)** 1999 May-Jun; 18(3):167–73

HOSPITAL CHIEF EXECUTIVE OFFICERS see **CHIEF EXECUTIVE OFFICERS, HOSPITAL**

HOSPITAL CLOSURE see **HEALTH FACILITY CLOSURE**

HOSPITAL CLOSURES see **HEALTH FACILITY CLOSURE**

HOSPITAL COMMUNICATION SYSTEMS

The benefits of hospital-wide picture archiving and communication systems: a survey of clinical users of radiology services. Bryan S, et al. **Br J Radiol** 1999 May; 72(857):469–78

Communication regarding adverse drug reactions between secondary and primary care: a postal questionnaire survey of general practitioners. Green CF, et al. **J Clin Pharm Ther** 1999 Apr;24(2):133–9

Humanizing voice mail in healthcare. Hoban L. **J Nurs Adm** 1999 Feb;29(2):50–6

Hypnosis using a communication device to increase magnetic resonance imaging tolerance with a claustrophobic patient. Simon EP. **Mil Med** 1999 Jan;164(1):71–2

Hospital pager systems may cause interference with pacemaker telemetry. Duru F, et al. **Pacing Clin Electrophysiol** 1998 Nov;21(11 Pt 2):2353–9

Mobile workers in healthcare and their information needs: are 2-way pagers the answer? Eisenstadt SA, et al. **Proc AMIA Symp** 1998;:135–9

Optimal use of communication channels in clinical event monitoring. Hogan WR, et al. **Proc AMIA Symp** 1998; :617–21

Development of a clinical event monitor for use with the Veterans Affairs Computerized Patient Record System and other data sources. Payne TH, et al. **Proc AMIA Symp** 1998;:145–9

Preferences of interns and residents for E-mail, paging, or traditional methods for the delivery of different types of clinical information. Wagner MM, et al. **Proc AMIA Symp** 1998;:140–4

Clinical event management using push technology--implementation and evaluation at two health care centers. Warner HR Jr, et al. **Proc AMIA Symp** 1998; :106–10

[Experience of telemedicine and information network system at Hokkaido University Hospital] Sakurai T, et al. **Hokkaido Igaku Zasshi** 1999 Jul;74(4):267–72 **(Jpn)**

ORGANIZATION & ADMINISTRATION

Bereavement care in general practice: a survey in South Thames Health Region. Harris T, et al. **Br J Gen Pract** 1998 Sep;48(434):1560–4

TRENDS

[Virtual workshop for hospital management] von Eiff W, et al. **Zentralbl Gynakol** 1998;120(11):563–8 (Eng. Abstr.) **(Ger)**

HOSPITAL COSTS

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective. Cohen DJ. **Am Heart J** 1999 May; 137(5):S133–7

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Mark DB, et al. **Am Heart J** 1999 May; 137(5):S123–5

Cost and outcomes analysis of abciximab use in a community teaching hospital. Abernathy GB, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S35–7

Cost analysis of remifentanil and fentanyl for neurosurgical anesthesia. Hogue S, et al. **Am J Health Syst Pharm** 1999 Mar 15;56(6):551–4

Risk factors for patient hospitalization. Saltsman CL, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):450–3

Clinical features and costs of care for hospitalized adults with primary Epstein-Barr virus infection. Borer A, et al. **Am J Med** 1999 Aug;107(2):144–8

A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Regueiro CR, et al. **Am J Med** 1998 Nov; 105(5):366–72

Prospective randomized clinical trial of laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy. Falcone T, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):955–62

Percutaneous endoscopic gastrostomy reduces total hospital costs in head-injured patients. Harbrecht BG, et al. **Am J Surg** 1998 Oct;176(4):311–4

The development of a method for comparative costing of individual intensive care units. The Intensive Care Working Group on Costing. Edbrooke D, et al. **Anaesthesia** 1999 Feb;54(2):110–20

Evaluation of proposed casemix criteria as a basis for costing patients in the adult general intensive care unit. Stevens VG, et al. **Anaesthesia** 1998 Oct;53(10):944–50

Symptomatic sialoadenitis and sialolithiasis in the English population, an estimate of the cost of hospital treatment. Escudier MP, et al. **Br Dent J** 1999 May 8;186(9):463–6

The hospital costs of treating lung cancer in the United Kingdom. Wolstenholme JL, et al. **Br J Cancer** 1999 Apr; 80(1–2):215–8

Improving cost and outcome of coronary surgery. Weintraub WS, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II23–8

Comparison of long-term care in an acute care institution and in a long-term care institution. Friedman R, et al. **CMAJ** 1998 Nov 3;159(9):1107–13

Results of a collaborative quality improvement program on outcomes and costs in a tertiary critical care unit [see comments] Clemmer TP, et al. **Crit Care Med** 1999 Sep; 27(9):1768–74. Comment in: Crit Care Med 1999 Sep;27(9):2034–5.

The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Edbrooke DL, et al. **Crit Care Med** 1999 Sep;27(9):1760–7

Quality, cost, and outcome of intensive care in a public hospital in Bombay, India [see comments] Parikh CR, et al. **Crit Care Med** 1999 Sep;27(9):1754–9. Comment in: Crit Care Med 1999 Sep;27(9):2032–3.

Evaluating outcome: medical and economic [editorial; comment] Stahl WM. **Crit Care Med** 1999 Jan;27(1):15. Comment on: Crit Care Med 1999 Jan;27(1):95–7.

Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer. Bonnema J, et al. **Eur J Cancer** 1998 Dec;34(13):2015–20

Good news about difficult decisions: the Canadian approach to hospital cost control. Roos NP, et al. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):239–46

Bundled Medicare payment for acute and postacute care. Welch WP. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):69–81

Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck R, et al. **Health Serv Res** 1998 Dec;33(5 Pt 1):1237–61

Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Abramson MA, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):408–11

A review of methods of drug cost management in hospitals. Pacey S, et al. **J Clin Pharm Ther** 1998 Jun;23(3):171–7 (73 ref.)

A multidisciplinary approach to hospital-based drug cost containment. Pacey S, et al. **J Clin Pharm Ther** 1998 Jun; 23(3):203–11

Who is managing your care? [editorial] Sabatier KH. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):11

An evidenced-based clinical pathway for acute appendicitis decreases hospital duration and cost. Warner BW, et al. **J Pediatr Surg** 1998 Sep;33(9):1371–5

Clinically significant gastroesophageal reflux in the at-risk premature neonate: relation to cognitive scores, days in the NICU, and total hospital charges. Ferlauto JJ, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):455–9

A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S27–37 (79 ref.)

Adverse events in health care: setting priorities based on economic evaluation. Rigby K, et al. **J Qual Clin Pract** 1999 Mar;19(1):7–12

Impact of a dedicated trauma service on the quality and cost of care provided to injured patients at an urban teaching hospital. Cohen MM, et al. **J Trauma** 1999 Jun;46(6):1114–9

The value of quality-adjusted life years: commentary on Séguin et al [comment] Esposito TJ. **J Trauma** 1999 Sep; 47(3 Suppl):S104–5. Comment on: J Trauma 1999 Sep;47(3 Suppl):S99–103.

Cost reduction and outcome improvement in the intensive care unit. Marx WH, et al. **J Trauma** 1999 Apr;46(4):625–9; discussion 629–30

A cost analysis: general endotracheal versus regional versus monitored anesthesia care. Brooks DM, et al. **Mil Med** 1999 Apr;164(4):303–5

Measuring the cost of neonatal and perinatal care. Rogowski J. **Pediatrics** 1999 Jan;103(1 Suppl E):329–35

Efficiency of hospital cholera treatment in Ecuador. Creamer G, et al. **Rev Panam Salud Publica** 1999 Feb;5(2):77–87

Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Benoit RM, et al. **Urology** 1998 Nov;52(5):820–4

[Implantable defibrillators. Good cost-effectiveness or supplementary expense to our hospitals?] Lévy S, et al. **Arch Mal Coeur Vaiss** 1999 Mar;92(3):289–91 **(Fre)**

[Direct cost of antibiotic therapy prescribed for nosocomial bacteremia. Prospective study during 6 months at a CHU (University Hospital Center)] Daumal F, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):470–5 (Eng. Abstr.) **(Fre)**

[Analysis of hospital activity costs: the case of the S. Pertini Hospital of Rome] Marinaro Manduca A, et al. **Ann Ig** 1998 May–Jun;10(3):201–17 (Eng. Abstr.) **(Ita)**

[The hemodynamics laboratory without cine film. A comparison between the production costs of 35-mm film and the recordable compact disk (see comments)] Danzi GB, et al. **G Ital Cardiol** 1998 Aug;28(8):887–92 (Eng. Abstr.). Comment in: G Ital Cardiol 1998 Nov;28(11):1324–5; discussion 1326–7. Comment in: G Ital Cardiol 1998 Nov;28(11):1325; discussion 1326–7. **(Ita)**

[The use of prosthetic meshes in the surgical treatment of inguinal hernia: the costs and profits for the local health screening unit] Leardi S, et al. **Minerva Chir** 1998 Jun; 53(6):581–5 (Eng. Abstr.) **(Ita)**

CLASSIFICATION

Commentary: "efficiency and civility in maternity care" or "how much jello can a mother eat?" Reinhardt UE. **Med Care Res Rev** 1999 Mar;56(1):47–54

DRG cost weights--getting it right. Phelan PD, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S36–8

LEGISLATION & JURISPRUDENCE

Performance of the '100 top hospitals': what does the report card report? Chen J, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):53–68

STATISTICS & NUMERICAL DATA

The economics of preventing revisions in total hip replacement. Persson U, et al. **Acta Orthop Scand** 1999 Apr; 70(2):163–9

Inpatient treatment of comorbid psychiatric and substance abuse disorders: comparison of public sector and privately insured populations. Leslie DL, et al. **Adm Policy Ment Health** 1999 Mar;26(4):253–68

Correlates of in-hospital cost among patients undergoing abdominal aortic aneurysm repair. Benzaquen BS, et al. **Am Heart J** 1998 Oct;136(4 Pt 1):696–702

Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison [see comments] Cooper CJ, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):430–6. Comment in: Am Heart J 1999 Sep;138(3 Pt 1):392–3.

Maternal minimum-stay legislation: cost and policy implications. Raube K, et al. **Am J Public Health** 1999 Jun; 89(6):922–3

A new economic benchmark for surgical treatment of appendicitis. Firilas AM, et al. **Am Surg** 1999 Aug; 65(8):769–73

Economics and anaesthesia. Rowe WL. **Anaesthesia** 1998 Aug;53(8):782–8 (52 ref.)

Paying a premium: how patient complexity affects costs and profit margins. Taheri PA, et al. **Ann Surg** 1999 Jun; 229(6):807–11; discussion 811–4

Cost analysis for total hip arthroplasty by measurement of time and material expenditure. Pingsmann A, et al. **Arch Orthop Trauma Surg** 1998;117(8):421–4

Transfusion medicine's role in hospital performance improvement. An administrator's view. Krempel G, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):486–91 (4 ref.)

Cost-effectiveness of laparoscopy in children. Luks FI, et al. **Arch Pediatr Adolesc Med** 1999 Sep;153(9):965–8

Impact of an aggressive stenting strategy on initial and one-year follow-up costs in patients undergoing coronary angioplasty. Farshid A, et al. **Aust N Z J Med** 1999 Apr; 29(2):243–8

Cost consequences of implementation of an early obstetrical discharge programme in a military teaching hospital. Calhoun BC, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb; 39(1):35–40

Influence of superstition on the date of hospital discharge and medical cost in Japan: retrospective and descriptive study. Hira K, et al. **BMJ** 1998 Dec 19–26;317(7174):1680–3

How should we evaluate new anti-infectives for respiratory tract infections? Paladino JA. **Can Respir J** 1999 Jan–Feb; 6 Suppl A:31A–4A

Direct costs of coronary artery bypass grafting in patients aged 65 years or more and those under age 65 [see comments] Naglie G, et al. **CMAJ** 1999 Mar 23; 160(6):805–11. Comment in: CMAJ 1999 Mar 23;160(6):823–5. Comment in: CMAJ 1999 Aug 24;161(4):365.

Cost analysis of laparoscopic cholecystectomy in children. Ure BM, et al. **Eur J Pediatr Surg** 1999 Feb;9(1):8–12

Cost-minimisation analysis of laparoscopic and open appendicectomy. Kald A, et al. **Eur J Surg** 1999 Jun; 165(6):579–82

Prenatal care, birth outcomes and newborn hospitalization costs: patterns among Hispanics in New Jersey. Reichman NE, et al. **Fam Plann Perspect** 1998 Jul–Aug;30(4):182–7, 200

Income levels of bad-debt and free-care patients in Massachusetts hospitals. Weissman JS, et al. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):156–66

Practice patterns, case mix, Medicare payment policy, and dialysis facility costs [see comments] Hirth RA, et al. **Health Serv Res** 1999 Feb;33(6):1567–92. Comment in: Health Serv Res 1999 Feb;33(6):1563–6.

Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. Bennett SJ, et al. **Heart Lung** 1999 Mar–Apr;28(2):102–9

Costs. Sick pay [news] **Hosp Health Netw** 1998 Dec 5–20; 72(23–24):14

Four costliest outpatient procedures. **Hosp Health Netw** 1998 Sep 20;72(18):32–3, 3

The costs of healthcare worker respiratory protection and fit-testing programs [see comments] Kellerman SE, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):629–34. Comment in: Infect Control Hosp Epidemiol 1998 Sep;19(9):626–8.

The relation between TISS and real paediatric ICU costs: a case study with generalizable methodology [see comments] de Keizer NF, et al. **Intensive Care Med** 1998 Oct;24(10):1062–9. Comment in: Intensive Care Med 1998 Oct;24(10):995–6.

Relationship between TISS and ICU cost [see comments] Dickie H, et al. **Intensive Care Med** 1998 Oct; 24(10):1009–17. Comment in: Intensive Care Med 1998 Oct;24(10):995–6.

Relationship between TISS and costs in intensive care [editorial; comment] Edbrooke D, et al. **Intensive Care Med** 1998 Oct;24(10):995–6 (13 ref.). Comment on: Intensive Care Med 1998 Oct;24(10):1009–17. Comment on: Intensive Care Med 1998 Oct;24(10):1062–9.

Trauma services: a profit center? Taheri PA, et al. **J Am Coll Surg** 1999 Apr;188(4):349–54

HOSPITAL COSTS

Opportunities for control of hospital costs for total joint arthroplasty after initial cost containment. Healy WL, et al. **J Arthroplasty** 1998 Aug;13(5):504–7

The timing of do–not–resuscitate orders and hospital costs. De Jonge KE, et al. **J Gen Intern Med** 1999 Mar; 14(3):190–2

Economic impact of feeding a phenylalanine–restricted diet to adults with previously untreated phenylketonuria. Brown MC, et al. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):30–7

Skeletal traction versus external fixation for pediatric femoral shaft fractures: a comparison of hospital costs and charges. Nork SE, et al. **J Orthop Trauma** 1998 Nov–Dec; 12(8):563–8

Economic and resource utilization analysis of outpatient management of fever and neutropenia in low–risk pediatric patients with cancer. Mullen CA, et al. **J Pediatr Hematol Oncol** 1999 May–Jun;21(3):212–8

Examining the "cost" of substance abuse in pregnancy: patient outcomes and resource utilization. Stichler JF, et al. **J Perinatol** 1998 Sep–Oct;18(5):384–8

Laparoscopic supracervical hysterectomy vs. abdominal hysterectomy in a community hospital. A cost comparison. Simon NV, et al. **J Reprod Med** 1999 Apr;44(4):339–45

Cost analysis of hospital material management systems. Egbelu PJ, et al. **J Soc Health Syst** 1998;5(4):1–10

Financial aspects of providing trauma care at the extremes of life. Sartorelli KH, et al. **J Trauma** 1999 Mar;46(3):483–7

An economic evaluation of trauma care in a Canadian lead trauma hospital [see comments] Séguin J, et al. **J Trauma** 1999 Sep;47(3 Suppl):S99–103. Comment in: J Trauma 1999 Sep;47(3 Suppl):S104–5.

Outcome and cost of trauma among the elderly: a real–life model of a single–payer reimbursement system. Young JS, et al. **J Trauma** 1998 Oct;45(4):800–4

Supracervical and total abdominal hysterectomy trends in New York State: 1990–1996. Sills ES, et al. **J Urban Health** 1998 Dec;75(4):903–10

Fixed vs variable costs of hospital care [letter] Propp DA. **JAMA** 1999 Aug 18;282(7):630

Distribution of variable vs fixed costs of hospital care. Roberts RR, et al. **JAMA** 1999 Feb 17;281(7):644–9

Fixed vs variable costs of hospital care [letter] Rosenstein AH. **JAMA** 1999 Aug 18;282(7):630

More or less?: Methods to compare VA and non–VA health care costs. Hendricks AM, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS54–62 (29 ref.)

A comparative study of the costliness of Manitoba hospitals. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS101–22

The unintended and unexpected impact of downsizing: costly hospitals become more costly. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS123–34

Drive–through delivery: where are the "savings"? Tai–Seale M, et al. **Med Care Res Rev** 1999 Mar;56(1):30–46

Transferred patients--more complex and more costly? Butt WW, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S42–3

Casemix funding for acute hospital inpatient services in Australia. Duckett SJ. **Med J Aust** 1998 Oct 19;169 Suppl:S17–21

The true cost of treating children. Hanson RM, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S39–41

Comparison of the hospital cost of primary and revision total hip arthroplasty after cost containment. Iorio R, et al. **Orthopedics** 1999 Feb;22(2):185–9

Comparison of the hospital cost of primary and revision total knee arthroplasty after cost containment. Iorio R, et al. **Orthopedics** 1999 Feb;22(2):195–9

Management paradigms for posterior epistaxis: A comparison of costs and complications. Monte ED, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):103–6

Benchmarking pathology services: implementing a longitudinal study. Gordon M, et al. **Pathology** 1999 May; 31(2):133–41

Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Diringer MN, et al. **Stroke** 1999 Apr;30(4):724–8

Direct costs of transient ischemic attacks: a hospital–based study of resource use during the first year after transient ischemic attacks in Denmark. Porsdal V, et al. **Stroke** 1998 Nov;29(11):2321–4

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Dranitsaris G, et al. **Support Care Cancer** 1999 Jul;7(4):271–9

The influence of clinical variables on hospital costs after orthotopic liver transplantation. Whiting JF, et al. **Surgery** 1999 Feb;125(2):217–22

[Laparoscopy versus the Shouldice intervention in the treatment of unilateral inguinal hernia: can the operative surcosts be minimized?] Perniceni T, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1061–4 (Eng. Abstr.) **(Fre)**

[Evaluation of direct hospital and extra–hospital cost of operative hysteroscopy and vaginal hysterectomy] Cravello L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul; 28(4):335–42 (Eng. Abstr.) **(Fre)**

["Routine laboratory screen". Cost saving in the hospital laboratory (see comments)] Heimpel H. **Internist (Berl)** 1998 Nov;39(11):1189–91. Comment in: Internist (Berl) 1998 Nov;39(11):1189–91. **(Ger)**

[Controlling in a surgical university clinic exemplified by bilateral thyroid gland resection] Mann B, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:850–3 (Eng. Abstr.) **(Ger)**

[Estimation for bugeting and evaluation of surgical procedures within the scope of comparative hospital administration. Value of LKA, PPR and DRG systems] Pinnau R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:864–9 (Eng. Abstr.) **(Ger)**

TRENDS

New trends in high–technology health care support services. Blumberg DF. **Biomed Instrum Technol** 1998 Nov–Dec; 32(6):592–604

Participation as a complicating mechanism: the effect of clinical professional and middle manager participation on hospital performance. Ashmos DP, et al. **Health Care Manage Rev** 1998 Fall;23(4):7–20

Price competition and hospital cost growth in the United States (1989–1994). Bamezai A, et al. **Health Econ** 1999 May;8(3):233–43

Changing cost of English HIV service provision 1996–1997. NPMS Steering Group. National Prospective Monitoring System. **Int J STD AIDS** 1999 Jun;10(6):357–62

Hospital management in the 21st century. Maxwell RJ. **Ulster Med J** 1998 Jun;67 Suppl 1:95–6

HOSPITAL DENTAL SERVICE see **DENTAL SERVICE, HOSPITAL**

HOSPITAL DEPARTMENTS

The role of departments of ophthalmology in the changing health care environment: resist or lead the change? [editorial] Clarkson JG. **Am J Ophthalmol** 1998 Nov; 126(5):713–6 (2 ref.)

Randomized controlled trial of physician–directed versus respiratory therapy consult service–directed respiratory care to adult non–ICU inpatients. Stoller JK, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1068–75

Impact and inequity of inpatient waiting times for advanced cardiovascular services in community hospitals across the greater Toronto area. Singh N, et al. **Can J Cardiol** 1999 Jul;15(7):777–82

The impact of department sub–division on hospital performance. Huang LY, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):171–80

The Neuropsychology Department at Hawaii State Hospital. Fujii DE. **Hawaii Med J** 1998 Sep;57(9):624, 636

An audit of diagnostic coding in genitourinary medicine clinics. Trent Region Genitourinary Medicine Audit Group [see comments] Carlin EM, et al. **Int J STD AIDS** 1999 Aug;10(8):554–6. Comment in: Int J STD AIDS 1999 Aug;10(8):493–4.

A clinical trial of a chest–pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators [see comments] Farkouh ME, et al. **N Engl J Med** 1998 Dec 24; 339(26):1882–8. Comment in: N Engl J Med 1998 Dec 24;339(26):1930–2. Comment in: N Engl J Med 1999 May 20;340(20):1596; discussion 1597. Comment in: N Engl J Med 1999 May 20;340(20):1596–7.

Chest–pain observation units [letter; comment] Getchell WS, et al. **N Engl J Med** 1999 May 20;340(20):1596–7. Comment on: N Engl J Med 1998 Dec 24;339(26):1882–8.

Chest–pain observation units [letter; comment] McFalls EO. **N Engl J Med** 1999 May 20;340(20):1596; discussion 1597 . Comment on: N Engl J Med 1998 Dec 24;339(26):1882–8.

The chest–pain unit--ready for prime time? [editorial; comment] Newby LK, et al. **N Engl J Med** 1998 Dec 24; 339(26):1930–2. Comment on: N Engl J Med 1998 Dec 24;339(26):1882–8.

[Computerized prescriptions in the hospital geriatric service. Improvement of the precision quality of medical computers] Medjahed S, et al. **Presse Med** 1998 May 2–9; 27(17):808–9 **(Fre)**

[Separate hospital department for patients with gastrointestinal hemorrhage (comment)] Rakonczai E. **Orv Hetil** 1998 Nov 15;139(46):2811. Comment on: Orv Hetil 1998 Sep 6;139(36):2121–6. **(Hun)**

[Preventive health care in hospitals] Ellingsen I, et al. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1162–3 **(Nor)**

[General practitioners in hospital] Werner EL. **Tidsskr Nor Laegeforen** 1998 Nov 30;118(29):4534–6 (Eng. Abstr.) **(Nor)**

[Inappropriate admissions to the Department of Internal Medicine evaluated by the AEP (Appropriateness Evaluation Protocol) (letter)] Ferrero Benéitez OL, et al. **An Med Interna** 1998 Dec;15(12):674–5 **(Spa)**

[Mortality in an Internal Medicine Department in a third–level hospital (letter; comment)] García Ordóñez MA, et al. **An Med Interna** 1999 Apr;16(4):212–3. Comment on: An Med Interna 1998 Apr;15(4):197–201. **(Spa)**

[Stays occasioned by patients hospitalized in internal medicine services] Obón Azuara B, et al. **An Med Interna** 1999 Feb;16(2):76–82 (Eng. Abstr.) **(Spa)**

[Study of consultation in an Internal Medicine Department] Díaz Peromingo JA, et al. **Rev Clin Esp** 1999 Feb; 199(2):66–72 (Eng. Abstr.) **(Spa)**

ECONOMICS

Some factors influencing the cost of a hospital based proton therapy centre. Cohilis P, et al. **Strahlenther Onkol** 1999 Jun;175 Suppl 2:102–4

[Activity and costs of diagnosis–related groups (DRG) of neurological services at the Virgen de las Nieves Hospital of Granada] Ortega–Moreno A, et al. **Rev Neurol** 1998 Sep; 27(157):453–8 (Eng. Abstr.) **(Spa)**

HISTORY

[Otolaryngologic hospital wards and out–patient clinics in Warsaw in the second part of the XIX–th and the beginning part of the XX–th century] Kierzek A. **Otolaryngol Pol** 1999;53(3):355–8 (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

[Quality assurance (editorial; comment)] Schmelzer A. **HNO** 1998 Oct;46(10):840–1. Comment on: HNO 1998 Oct;46(10):864–9. **(Ger)**

[Indicators for quality evaluation of inpatient patient care in an ENT clinic (see comments)] Streppel M, et al. **HNO** 1998 Oct;46(10):864–9 (15 ref.) (Eng. Abstr.). Comment in: HNO 1998 Oct;46(10):840–1. **(Ger)**

ORGANIZATION & ADMINISTRATION

Effective cost–reduction strategies in the management of regulated medical waste. Garcia R. **Am J Infect Control** 1999 Apr;27(2):165–75

Three rules for successfully merging clinical engineering departments. Piepenbrink J. **Biomed Instrum Technol** 1998 Sep–Oct;32(5):527–9

The new interventional centre--a multidisciplinary R&D clinic for interventional radiology and minimal access surgery. Laerum F, et al. **Comput Methods Programs Biomed** 1998 Aug–Sep; 57(1–2):29–34

The rise, heyday, and incipient decline of specialization: hospitals in Denmark, 1930–1990. Vallgårda S. **Int J Health Serv** 1999;29(2):431–57 (34 ref.)

Defining geriatric medicine in the managed care era [letter; comment] Sahadevan S, et al. **J Am Geriatr Soc** 1999 Apr; 47(4):494–5. Comment on: J Am Geriatr Soc 1997 Sep;45(9):1123–7.

Analysis and impact of infectious disease consultations in a general hospital. Schlesinger Y, et al. **J Hosp Infect** 1998 Sep;40(1):39–46

Pre–admission clinic in an orthopaedic department: evaluation over a 6–month period [letter; comment] Burdett–Smith P. **J R Coll Surg Edinb** 1998 Dec;43(6):428 . Comment on: J R Coll Surg Edinb 1998 Jun;43(3):178–81.

Recommended guidelines for optimal design of a plastic surgery service during mass casualty events. Cohen M, et al. **J Trauma** 1998 Nov;45(5):960–8

A model for merging vascular surgery and interventional radiology: clinical and economical implications. Ouriel K, et al. **J Vasc Surg** 1998 Dec;28(6):1006–10; discussion 1011–3

The Columbia medical informatics story: from clinical system to major department. Cimino JJ. **MD Comput** 1999 Mar–Apr;16(2):31–4

What prevents Japan from establishing a clinical service of sleep medicine: experience gained at a local hospital. Oka Y, et al. **Psychiatry Clin Neurosci** 1999 Apr;53(2):263–5

[Departments of internal medicine--there is a need to develop clinical working routines and organization (editorial)] Gjørup T. **Ugeskr Laeger** 1998 Oct 5; 160(41):5917 **(Dan)**

[Quality assurance of department administration] Lichtenberg SM, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):983–6 (10 ref.) **(Nor)**

[The organization of a digestive endoscopy unit] Bordas JM. **Gastroenterol Hepatol** 1999 Feb;22(2):93–9 **(Spa)**

[Starting up a low–cost postoperative acute pain ward (letter)] Chabás E, et al. **Rev Esp Anestesiol Reanim** 1998 Nov;45(9):401–2 **(Spa)**

[Hospital organization of cardiopulmonary resuscitation (see comments)] Gómez–Arnau J, et al. **Rev Esp Anestesiol Reanim** 1999 May;46(5):205–14 (63 ref.) (Eng. Abstr.). Comment in: Rev Esp Anestesiol Reanim 1999 May;46(5):183–5. **(Spa)**

STANDARDS

Basking in the glory [editorial] Gould JS. **Am J Orthop** 1999 Jan;28(1):12

[Leadership of hospital departments and professional conflicts. Quality strategy is the solution!] Helsingen N. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3319 **(Nor)**

[Sensitive quality indicators stimulate improvement of care] Britton M, et al. **Lakartidningen** 1999 Jan 20;96(3):217–20 (Eng. Abstr.) **(Swe)**

TRENDS

Trends in small hospital medical services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2107–12

HOSPITAL DESIGN AND CONSTRUCTION

Planning and design of a surgical intensive care unit in a

new regional hospital. Koay CK, et al. **Ann Acad Med Singapore** 1998 May;27(3):448–52
Hospital construction materials: poor shielding capacity with respect to signals transmitted by mobile telephones. Hanada E, et al. **Biomed Instrum Technol** 1998 Sep–Oct; 32(5):489–96
Interiors. Doctored design [news] Garber K. **Hosp Health Netw** 1999 Feb;73(2):26
Construction. Built to bend [news] Greene J. **Hosp Health Netw** 1999 Jun;73(6):20, 22
Minor miracles? Lumsdon K. **Hosp Health Netw** 1999 Jul; 73(7):68
Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Cornet M, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):508–13
Critical-care-unit bedside design and furnishing: impact on nosocomial infections. Harvey MA. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):597–601
New picture archiving and communications system plus new facility equals critical path planning challenge. Brye PE, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):130–3
Nosocomial aspergillosis during building work--a multidisciplinary approach [letter] Fitzpatrick F, et al. **J Hosp Infect** 1999 Jun;42(2):170–1
Painting collections in hospitals: humanity in medicine. James AE Jr. **J R Soc Health** 1998 Aug;118(4):227–30
[Requirements for patient rooms from the public health viewpoint. Guidelines for renovation and construction] Pitten FA, et al. **Dtsch Med Wochenschr** 1999 Jan 29; 124(4):94–7 **(Ger)**
[A project for the organization and planning of a diagnostic ultrasonography area at a radiology department] Cioffi V, et al. **Radiol Med (Torino)** 1998 Oct;96(4):360–8 (Eng. Abstr.) **(Ita)**

ECONOMICS

The private finance initiative: PFI in the NHS--is there an economic case? Gaffney D, et al. **BMJ** 1999 Jul 10; 319(7202):116–9

HISTORY

Operating theatre design. Essex-Lopresti M. **Lancet** 1999 Mar 20;353(9157):1007–10
[When women were allowed to make decisions Ersta hospital was equipped with light, air and pleasing interior decorations] Wendt B. **Lakartidningen** 1999 Jan 27; 96(4):316–7 **(Swe)**

LEGISLATION & JURISPRUDENCE

Seismic activity. Badly braced for the big one. Vanchieri C. **Hosp Health Netw** 1998 Oct 20;72(20):42

STANDARDS

Hospital projects whose designers and builders know how to get along. The VISTA Awards. **Hosp Health Netw** 1999 Mar;73(3):52–6, 2

HOSPITAL DISTRIBUTION SYSTEMS

Are new meal distribution systems worth the effort for improving patient satisfaction with foodservice? Lambert LG, et al. **J Am Diet Assoc** 1999 Sep;99(9):1112–4

ECONOMICS

Cost analysis of hospital material management systems. Egbelu PJ, et al. **J Soc Health Syst** 1998;5(4):1–10

ORGANIZATION & ADMINISTRATION

Hospital supply channel management. Frazier D. **J Soc Health Syst** 1998;5(4):63–8 (0 ref.)

HOSPITAL DIVERSIFICATION see **HOSPITAL RESTRUCTURING**

HOSPITAL DRUG DISTRIBUTION SYSTEMS see **MEDICATION SYSTEMS, HOSPITAL**

HOSPITAL ECONOMICS see **ECONOMICS, HOSPITAL**

HOSPITAL EMERGENCY SERVICE see **EMERGENCY SERVICE, HOSPITAL**

HOSPITAL ENGINEERING see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL EQUIPMENT AND SUPPLIES see **EQUIPMENT AND SUPPLIES, HOSPITAL**

HOSPITAL FINANCIAL MANAGEMENT see **FINANCIAL MANAGEMENT, HOSPITAL**

HOSPITAL FINANCIAL MANAGEMENTS see **FINANCIAL MANAGEMENT, HOSPITAL**

HOSPITAL FOOD SERVICE see **FOOD SERVICE, HOSPITAL**

HOSPITAL GROUNDSKEEPING see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL GROUP PURCHASING see **GROUP PURCHASING**

HOSPITAL HEMODIALYSIS UNITS see **HEMODIALYSIS UNITS, HOSPITAL**

HOSPITAL HOUSEKEEPING see **HOUSEKEEPING, HOSPITAL**

HOSPITAL INCIDENT REPORTING see **RISK MANAGEMENT**

HOSPITAL INFECTIONS see **CROSS INFECTION**

HOSPITAL INFORMATION SYSTEMS

Implementation of a computerized cardiovascular information system in a private hospital setting [see comments] Taylor GS, et al. **Am Heart J** 1998 Nov; 136(5):792–803. Comment in: Am Heart J 1998 Nov;136(5):751–2.
Clinical cardiovascular databases: ready for prime time? [editorial; comment] Weintraub WS. **Am Heart J** 1998 Nov; 136(5):751–2. Comment on: Am Heart J 1998 Nov;136(5):792–803.
Using hospital databases. Minarik PA, et al. **Am J Nurs** 1999 Feb;99(2):54
Governmental databases, hospital information systems, and clinical outcomes: big brother or big help? [editorial; comment] Fleisher LA, et al. **Anesth Analg** 1999 Oct; 89(4):811–3. Comment on: Anesth Analg 1999 Oct;89(4):814–22.
Long-term pharmaceutical cost reduction using a data management system. McNitt JD, et al. **Anesth Analg** 1998 Oct;87(4):837–42
A framework for building cooperative software agents in medical applications. Lanzola G, et al. **Artif Intell Med** 1999 Jul;16(3):223–49
Modeling and implementing a database on drugs into a hospital intranet. François M, et al. **Comput Biol Med** 1998 Sep;28(5):553–65
HIS/RIS contribution to image diagnosis and maximization of efficacy of PACS when coupled with HIS/RIS. Inamura K, et al. **Comput Methods Programs Biomed** 1998 Aug–Sep; 57(1–2):41–9
Implementation of multi-vendor DICOM standard image transfer in hospital wide ATM network. Kimura M, et al. **Comput Methods Programs Biomed** 1998 Aug–Sep; 57(1–2):85–9
Development and evaluation of PC-based HIS-RIS-modality-PACS coupling: the results of evaluation of initial stage with personal computer application. Kondoh H, et al. **Comput Methods Programs Biomed** 1998 Aug–Sep; 57(1–2):63–8
A hospital-wide PACS: 7 year experience and new development. Terae S, et al. **Comput Methods Programs Biomed** 1998 Aug–Sep; 57(1–2):5–12
Implementation of NANDA nursing diagnoses online. North American Nursing Diagnosis Association. Brooks BA, et al. **Comput Nurs** 1998 Nov–Dec;16(6):320–6
As good as it gets? Going online with a clinical information system. Sleutel M, et al. **Comput Nurs** 1999 Jul–Aug; 17(4):181–5
Integrating HIS-RIS-PACS: the Freiburg experience. Kotter E, et al. **Eur Radiol** 1998;8(9):1707–18 (47 ref.)
Hewlett-Packard Viridia Telemetry System can disable Viridia Information Center central station. **Health Devices** 1998 Sep–Oct;27(9–10):365–7
Evolution of an integrated HIS in The Netherlands. Bakker AR, et al. **Int J Med Inf** 1999 Jun;54(3):209–24
Using information systems to measure and improve quality. Bates DW, et al. **Int J Med Inf** 1999 Feb–Mar; 53(2–3):115–24
Happy birthday DIOGENE: a hospital information system born 20 years ago. Borst F, et al. **Int J Med Inf** 1999 Jun; 54(3):157–67
Computer based nursing documentation means to achieve the goal [see comments] Bürkle T, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):71–80. Comment in: ACP J Club 1999 May–Jun;130(3):61.
The HELP hospital information system: update 1998. Gardner RM, et al. **Int J Med Inf** 1999 Jun;54(3):169–82
Installing an appropriate information security policy. Gaunt N. **Int J Med Inf** 1998 Mar;49(1):131–4
A secure model for communication of health care information by sub-division of information and multiplication of communication paths. Ishida Y, et al. **Int J Med Inf** 1998 Mar;49(1):75–80
Adoption of security and confidentiality features in an operational community health information network: the Comox Valley experience--case example. Moehr JR, et al. **Int J Med Inf** 1998 Mar;49(1):81–7
Availability of software services for a hospital information system. Sakamoto N. **Int J Med Inf** 1998 Mar;49(1):89–96
The CCC system in two teaching hospitals: a progress report. Slack WV, et al. **Int J Med Inf** 1999 Jun;54(3):183–96
A Japanese approach to establish an electronic patient record system in an intelligent hospital. Takeda H, et al. **Int J Med Inf** 1998 Mar;49(1):45–51
The Brigham integrated computing system (BICS): advanced clinical systems in an academic hospital environment. Teich JM, et al. **Int J Med Inf** 1999 Jun;54(3):197–208
How can usability measurement affect the re-engineering process of clinical software procedures? Terazzi A, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):229–34
Component-based development for supporting workflows in hospitals. Toussaint PJ, et al. **Int J Med Inf** 1998 Oct–Dec; 52(1–3):53–60
Development of the electronic health record in Japan. Yoshihara H. **Int J Med Inf** 1998 Mar;49(1):53–8
The determination of relevant goals and criteria used to select an automated patient care information system: a Delphi approach. Chocholik JK, et al. **J Am Med Inform Assoc** 1999 May–Jun;6(3):219–33
Clinical information systems--what is the bottom line? [editorial; comment] Geissbuhler A. **J Am Med Inform Assoc** 1998 Nov–Dec;5(6):585–6. Comment on: J Am Med Inform Assoc 1998 Nov–Dec;5(6):546–53. Comment on: J Am Med Inform Assoc 1998 Nov–Dec;5(6):554–62.
Great earthquakes and medical information systems, with special reference to telecommunications. Miyamoto M, et al. **J Am Med Inform Assoc** 1999 May–Jun;6(3):252–8
Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial [see comments] Shojania KG, et al. **J Am Med Inform Assoc** 1998 Nov–Dec;5(6):554–62. Comment in: J Am Med Inform Assoc 1998 Nov–Dec;5(6):585–6.
Use of a common computerized program for echocardiogram archiving and reporting over a regional territory: feasibility and clinical and research impact during a 5-year experience. Badano LP, et al. **J Am Soc Echocardiogr** 1999 Aug;12(8):669–78
Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. Librero J, et al. **J Clin Epidemiol** 1999 Mar;52(3):171–9
A literature review on communication between picture archiving and communication systems and radiology information systems and/or hospital information systems. Creighton C. **J Digit Imaging** 1999 Aug;12(3):138–43
The Conquest Hospital picture archiving and communications system development, 1992 to 1999. Foord K, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):211–3
Sophisticated hospital information system/radiology information system/picture archiving and communications system (PACS) integration in a large-scale traumatology PACS. Peer S, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):99–102
Bridging the gap: linking a legacy hospital information system with a filmless radiology picture archiving and communications system within a nonhomogeneous environment. Rubin RK, et al. **J Digit Imaging** 1999 May; 12(2 Suppl 1):96–8
Smart cards: a specific application in the hospital. Güler I, et al. **J Med Syst** 1998 Dec;22(6):405–19
The computer based patient record: a strategic issue in process innovation. Sicotte C, et al. **J Med Syst** 1998 Dec; 22(6):431–43
Patient Dependency Knowledge-Based Systems. Soliman F. **J Med Syst** 1998 Oct;22(5):357–70
Improving computer skills to support hospital restructuring. Miller E, et al. **J Nurs Care Qual** 1999 Jun;13(5):44–56
A classification for incidents and accidents in the health-care system. Runciman WB, et al. **J Qual Clin Pract** 1998 Sep; 18(3):199–211
A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital [see comments] [published erratum appears in JAMA 1999 Feb 3;281(5):420] Raschke RA, et al. **JAMA** 1998 Oct 21;280(15):1317–20. Comment in: JAMA 1998 Oct 21;280(15):1360–1.
Finding and applying evidence during clinical rounds: the "evidence cart" [see comments] Sackett DL, et al. **JAMA** 1998 Oct 21;280(15):1336–8. Comment in: JAMA 1998 Oct 21;280(15):1363. Comment in: JAMA 1999 Apr 7;281(13):1171–2.
Information technology at the National Cancer Center. Information Committee of the National Cancer Center [editorial] **Jpn J Clin Oncol** 1998 Sep;28(9):527–30
Vision of an 'automated' hospital information system. Balkányi L, et al. **Medinfo** 1998;9 Pt 2:945–8
Measuring and improving quality using information systems. Bates DW, et al. **Medinfo** 1998;9 Pt 2:814–8
Happy birthday DIOGENE: a hospital information system born 20 years ago. Borst F, et al. **Medinfo** 1998;9 Pt 2:922–6
The future of knowledge-based components in the electronic health record. Broverman CA, et al. **Medinfo** 1998;9 Pt 1:457–61
Toward clinical end-user computing: programmable order protocols for efficient human computer interaction. Cho H, et al. **Medinfo** 1998;9 Pt 2:900–3
Implementation of a database on drugs into a university hospital Intranet. François M, et al. **Medinfo** 1998;9 Pt 1:156–60
Professional and organizational impact of using patient care information systems. Hebert M. **Medinfo** 1998;9 Pt 2:849–53
Privacy and efficiency in patients focused health care processes. Morger O, et al. **Medinfo** 1998;9 Pt 2:1143–7
The Electronic Wardeni management of the data security access in a heterogeneous university hospital environment in Belgium. Piret C, et al. **Medinfo** 1998;9 Pt 2:949–51
A practical object-oriented approach to a development of

a next generation hospital information system. Sakamoto N. **Medinfo** 1998;9 Pt 2:957–61

An object–modeling method for hospital information systems. Seto K, et al. **Medinfo** 1998;9 Pt 2:981–5

The Erlangen university hospital communication hub--proprietary and standardised communication. Wentz B, et al. **Medinfo** 1998;9 Pt 2:995–8

Stepwise evaluation of information systems in an university hospital. Bürkle T, et al. **Methods Inf Med** 1999 Mar; 38(1):9–15

ArchiMed: a medical information and retrieval system. Dorda W, et al. **Methods Inf Med** 1999 Mar;38(1):16–24

Distinction between planned and unplanned readmissions following discharge from a Department of Internal Medicine. Kossovsky MP, et al. **Methods Inf Med** 1999 Jun;38(2):140–3

Toward hospitals without paper. Lerner E. **N J Med** 1999 Jan;96(1):53–5

Towards interoperability of information sources within a hospital Intranet. Aymard S, et al. **Proc AMIA Symp** 1998; :638–42

Implementation of an on–line Emergency Unit nursing system. Bourie PQ, et al. **Proc AMIA Symp** 1998;:330–3

Architecture for a Web–based clinical information system that keeps the design open and the access closed. Cimino JJ, et al. **Proc AMIA Symp** 1998;:121–5

Modifiable templates facilitate customization of physician order entry. Franklin MJ, et al. **Proc AMIA Symp** 1998; :315–9

Renewing information infrastructure at Hospital das Clinicas. Moura L, et al. **Proc AMIA Symp** 1998;:200–4

Potential for meeting clinician information requirements in an intensive care unit (ICU) via the web. Randolph AG, et al. **Proc AMIA Symp** 1998;:96–100

Knowledge–based visualization of time–oriented clinical data. Shahar Y, et al. **Proc AMIA Symp** 1998;:155–9

Linking multiple heterogeneous data sources to practice guidelines. van Wingerde FJ, et al. **Proc AMIA Symp** 1998; :391–5

Clinical event management using push technology--implementation and evaluation at two health care centers. Warner HR Jr, et al. **Proc AMIA Symp** 1998; :106–10

P–CAPE: a high–level tool for entering and processing clinical practice guidelines. Partners Computerized Algorithm and Editor. Zielstorff RD, et al. **Proc AMIA Symp** 1998;:478–82

How a Tennessee hospital got ready for Y2K. Williams B. **Tenn Med** 1999 May;92(5):170

An analysis of errors in blood component transfusion records with regard to quality improvement of data acquisition and to the performance of lookback and traceback procedures. Zimmermann R, et al. **Transfusion** 1999 Apr;39(4):351–6

[Centralized information system of data on anesthesia] Bourgain JL, et al. **Ann Fr Anesth Reanim** 1997;16(7):fi23–4 **(Fre)**

[Interventional radiology and the medical applications of information systems: what consequences for the radiology department?] Vergnenègre A, et al. **J Radiol** 1999 Jun; 80(6):565–8 (Eng. Abstr.) **(Fre)**

[Experiences fo three year's routine operation of an anesthesia information management system (AIMS) at a university clinic in Giessin] Benson M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):17–23 (Eng. Abstr.) **(Ger)**

[Online infection recording within the scope of total quality management] Ehlebracht M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:847–9 (Eng. Abstr.) **(Ger)**

[Use of geographic information systems (GIS) in strategic planning of surgical capacity within a hospital organization] Meyer–Pannwitt U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:870–6 (Eng. Abstr.) **(Ger)**

[Uniform access to clinical data in a distributed system. The radiology example] Adelhard K, et al. **Radiologe** 1999 Apr; 39(4):298–303 (Eng. Abstr.) **(Ger)**

[Aspects of electronic patient records in radiology] Adelhard K, et al. **Radiologe** 1999 Apr;39(4):310–5 (Eng. Abstr.) **(Ger)**

[Modelling of radiological services in the context of a hospital information system: does the DICOM standard meet the requirements?] König H, et al. **Radiologe** 1998 Oct; 38(10):872–82 (Eng. Abstr.) **(Ger)**

[Modern network technologies for data communication in the hospital] Pelikan E, et al. **Radiologe** 1999 Apr; 39(4):292–7 (Eng. Abstr.) **(Ger)**

[Wish and reality in installation of a clinic–wide system for image and documentation access] Rau WS, et al. **Radiologe** 1999 Apr;39(4):304–9 (Eng. Abstr.) **(Ger)**

[Contribution of databases to regional and supra–regional quality improvement in rheumatologic treatment and patient management. Professional Society of Regional Cooperative Rheumatic Disease Centers] Zink A. **Z Rheumatol** 1998 Dec;57(6):442–5 (Eng. Abstr.) **(Ger)**

[Steps towards a hospital information system: illustrated by the example of the medical setting of the Westphalian Wilhelms University of Münster] Prokosch HU. **Zentralbl Gynakol** 1999;121(3):166–73 (Eng. Abstr.) **(Ger)**

[Experience with the use of computer technology in a military hospital] Kliuzhev VM, et al. **Voen Med Zh** 1999 Jun;320(6):7–9 **(Rus)**

[The potentials and prospects for the use of computer systems for the surveillance of hospital bacterial infections] Men'shikov DD, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):104–7 (47 ref.) **(Rus)**

[The limitations on the minimum basic data set as an information system for the hospital services of a university center (letter)] Salvador Oliván JA, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):198 **(Spa)**

CLASSIFICATION

[The impact of the data collection method on the medico–economic classification of admissions for myocardial infarction at the public hospitals in Lyon (see comments)] Rabilloud M, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):709–14 (Eng. Abstr.). Comment in: Arch Mal Coeur Vaiss 1998 Jun;91(6):707–8. **(Fre)**

ECONOMICS

[Substantiation of the choice of technical means in reduction of implementation costs of the project "Full automation of a central municipal hospital"] Nikitin IuD, et al. **Med Tekh** 1998 Nov–Dec;(6):32–5 (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

[Medical picture archiving and communication systems (PACS). Recommendations of the Committee of Computer Services of the German Research Society on compliance with recommendations of the university building code promotion law] **Radiologe** 1999 Apr;39(4):257–9 **(Ger)**

ORGANIZATION & ADMINISTRATION

Database model for patients admitted to a chest pain center. Abbott BG, et al. **Am J Emerg Med** 1999 Jan;17(1):55–8

EMERGEncy ID NET: an emergency department–based emerging infections sentinel network. The EMERGEncy ID NET Study Group. Talan DA, et al. **Ann Emerg Med** 1998 Dec;32(6):703–11

The challenges of a care information system reflecting holistic nursing care. Büssing A, et al. **Comput Nurs** 1998 Nov–Dec;16(6):311–7; quiz 318–9

Recent developments of care information systems in Germany. Büssing A, et al. **Comput Nurs** 1998 Nov–Dec; 16(6):307–10

Implementation and evaluation of workflow based on hospital information system/radiology information system/picture archiving and communications system. Osada M, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):103–5

Nursing practice models: implications for information system design. Brennan PF, et al. **J Nurs Adm** 1998 Oct; 28(10):26–31

The Columbia medical informatics story: from clinical system to major department. Cimino JJ. **MD Comput** 1999 Mar–Apr;16(2):31–4

Why good hospitals get bad computing. Bleich HL. **Medinfo** 1998;9 Pt 2:969–72

On the way to a Web based hospital information system: concepts for the use of a medical data dictionary to present context sensitive information in an intranet environment. Bürkle T, et al. **Medinfo** 1998;9 Pt 2:917–21

OOMM--Object–Oriented Matrix Modelling: an instrument for the integration of the Brasilia Regional Health Information System. Cammarota M, et al. **Medinfo** 1998; 9 Pt 2:965–8

Experimental assessment of the feasibility of integrating an endoscopic imaging system into an existing hospital information system. Chen TS, et al. **Medinfo** 1998;9 Pt 2:1095–9

Three–tiered integration of PACS and HIS toward next generation total hospital information system. Kim JH, et al. **Medinfo** 1998;9 Pt 2:1086–90

Migrating towards a client server architecture: a successful application in a 2,200–bed general hospital. Lee JS, et al. **Medinfo** 1998;9 Pt 2:927–30

The need for a thoughtful deployment strategy: evaluating clinicians' perceptions of critical deployment issues. Meyer KE, et al. **Medinfo** 1998;9 Pt 2:854–8

On stepwise integrating an electronic patient record based on digital–optical archiving and multi–purpose health professional workstations: experiences at the Heidelberg University Hospital. Reinhard O, et al. **Medinfo** 1998;9 Pt 1:89–92

Towards semantic integration within an existing medical information system. Staccini P, et al. **Medinfo** 1998;9 Pt 2:935–9

Transforming a hospital through growing, not building, an electronic patient record system. Atkinson CJ, et al. **Methods Inf Med** 1998 Sep;37(3):285–93

Economic evaluation of voice recognition for the clinicians' desktop at the Naval Hospital Roosevelt Roads. Threet E, et al. **Mil Med** 1999 Feb;164(2):119–26

Perinatal information systems for quality improvement: visions for today. Slagle TA. **Pediatrics** 1999 Jan;103(1 Suppl E):266–77 (64 ref.)

What is an electronic patient record? Gordon D, et al. **Proc AMIA Symp** 1998;:240–4

A graphical user interaction model for integrating complex clinical applications: a pilot study. Sittig DF, et al. **Proc AMIA Symp** 1998;:708–12

Clinical information systems for integrated healthcare networks. Teich JM. **Proc AMIA Symp** 1998;:19–28 (27 ref.)

A software architecture to support a large–scale, multi–tier clinical information system. Yungton JA, et al. **Proc AMIA Symp** 1998;:210–4

A radiology department intranet: development and applications. Willing SJ, et al. **Radiographics** 1999 Jan–Feb; 19(1):169–82

Intranet technology in Scottish NHS Trusts. Wilson SM, et al. **Scott Med J** 1999 Feb;44(1):14–5

[Patient management systems: towards a new era? (editorial)] Hoeft A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Oct; 33(10):635–6 **(Ger)**

STANDARDS

An analysis of concordance among hospital databases and physician records. Holt G, et al. **Ann Surg Oncol** 1998 Sep; 5(6):553–6

Computerized surveillance of adverse drug reactions in hospital: implementation. Levy M, et al. **Eur J Clin Pharmacol** 1999 Jan;54(11):887–92

MERIT–9: a patient information exchange guideline using MML, HL7 and DICOM. Kimura M, et al. **Int J Med Inf** 1998 Jul;51(1):59–68

Geriatric syndromes as outcome measures of hospital care: can administrative data be used? Berlowitz DR, et al. **J Am Geriatr Soc** 1999 Jun;47(6):692–6

Shopping in the healthcare information systems market--a search for well–camouflaged land mines. Grams RR. **J Med Syst** 1998 Oct;22(5):315–23

Assessing physician's expectations and attitudes toward hospital information systems. The IMASIS experience. Martin–Baranera M, et al. **MD Comput** 1999 Jan–Feb; 16(1):73–6

A hospital information system based on Common Object Request Broker Architecture (CORBA) for exchanging distributed medical objects--an approach to future environment of sharing healthcare information. Ohe K. **Medinfo** 1998;9 Pt 2:962–4

STATISTICS & NUMERICAL DATA

Health care's 100 most wired [published erratum appears in Hosp Health Netw 1999 Mar;73(3):12] Solovy A, et al. **Hosp Health Netw** 1999 Feb;73(2):43–51, 2

Assessing the availability of casemix information in hospital database systems in Rio de Janeiro, Brazil. Martins M, et al. **Int J Qual Health Care** 1998 Apr;10(2):125–33

Impact of information systems on acute care hospitals: results from a survey in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):379–87

Information systems' approaches and designs and facility information: survey of acute care hospitals in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):389–96

Internet usage and potential impact for acute care hospitals: survey in the United States. Hatcher M. **J Med Syst** 1998 Dec;22(6):371–8

[Statistics and evaluation of a graphic SQL user interface in an anesthesia information management system (AIMS)] Benson M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):24–32 (Eng. Abstr.) **(Ger)**

TRENDS

Beyond Y2K: status of key health care information systems projects. **Biomed Instrum Technol** 1999 May–Jun;33(3):205

No hospital is an island when it comes to Y2K bug. Silversides A. **CMAJ** 1999 Jan 26;160(2):246–7

Issues facing system vendors as we approach the 21st century and expected roles--implementing a hospital information system providing greater patient satisfaction. Asonuma M. **Medinfo** 1998;9 Pt 1:23–7

From legacy systems towards modern health information systems. Bercic B, et al. **Medinfo** 1998;9 Pt 2:931–4

From legacy systems via client/server to web browser technology in hospital informatics in Finland. Korpela M. **Medinfo** 1998;9 Pt 1:222–6

Data dictionaries at Giessen University Hospital: past--present--future. Bürkle T, et al. **Proc AMIA Symp** 1998;:875–9

UTILIZATION

Information technology in accident and emergency departments. Birkinshaw R, et al. **Eur J Emerg Med** 1998 Jun;5(2):245–8

Costs and benefits of connecting community physicians to a hospital WAN. Kouroubali A, et al. **Proc AMIA Symp** 1998;:205–9

HOSPITAL INSURANCE PROGRAM, MEDICARE see **MEDICARE PART A**

HOSPITAL INVENTORIES see **INVENTORIES, HOSPITAL**

HOSPITAL LABORATORIES see **LABORATORIES, HOSPITAL**

HOSPITAL LAUNDRY SERVICE see **LAUNDRY SERVICE, HOSPITAL**

HOSPITAL LIBRARIES see **LIBRARIES, HOSPITAL**

HOSPITAL LICENSURE see **LICENSURE, HOSPITAL**

HOSPITAL MAINTENANCE see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL MATERIALS MANAGEMENT see **MATERIALS MANAGEMENT, HOSPITAL**

HOSPITAL MEDICAL RECORDS DEPARTMENT see **MEDICAL RECORDS DEPARTMENT, HOSPITAL**

HOSPITAL MEDICAL STAFF see **MEDICAL STAFF, HOSPITAL**

HOSPITAL MEDICATION SYSTEM see **MEDICATION SYSTEMS, HOSPITAL**

HOSPITAL MEDICATION SYSTEMS see **MEDICATION SYSTEMS, HOSPITAL**

HOSPITAL MERGER see **HEALTH FACILITY MERGER**

HOSPITAL MORTALITY

No resuscitation orders and withdrawal of therapy in French paediatric intensive care units. Groupe Francophone de Réanimation et d'Urgences Pédiatriques [see comments] Martinot A, et al. **Acta Paediatr** 1998 Jul;87(7):769–73. Comment in: Acta Paediatr 1998 Jul;87(7):721–2.

Risk factors for maternal mortality: a case–control study in Dakar hospitals (Senegal). Garenne M, et al. **Afr J Reprod Health** 1997 Mar;1(1):14–24

Intensive care for very elderly patients: outcome and risk factors for in–hospital mortality. Van Den Noortgate N, et al. **Age Ageing** 1999 May;28(3):253–6

Mortality associated with an influenza outbreak on a dementia care unit. Brandeis GH, et al. **Alzheimer Dis Assoc Disord** 1998 Sep;12(3):140–5

Cause of in–hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group [see comments] Malenka DJ, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):632–8. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):582–4.

Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in–hospital outcomes. The Northern New England Cardiovascular Disease Study Group [see comments] Wennberg DE, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):639–45. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):585–7.

Reappraisal of the Norris score and the prognostic value of left ventricular ejection fraction measurement for in–hospital mortality after acute myocardial infarction. Christiansen JP, et al. **Am J Cardiol** 1999 Feb 15; 83(4):589–91, A8

Acquired organ system derangements and hospital mortality: are all organ systems created equally? Kollef MH, et al. **Am J Crit Care** 1999 May;8(3):180–8

Complications of emergency intubation with and without paralysis. Li J, et al. **Am J Emerg Med** 1999 Mar; 17(2):141–3

Morbidity and mortality of hospitalized patients after the 1995 Hanshin–Awaji earthquake. Tanaka H, et al. **Am J Emerg Med** 1999 Mar;17(2):186–91

Predicting hospital mortality in cirrhotic patients: comparison of Child–Pugh and Acute Physiology, Age and Chronic Health Evaluation (APACHE III) scoring systems. Butt AK, et al. **Am J Gastroenterol** 1998 Dec;93(12):2469–75

An audit of deaths occurring in hospital after discharge from the intensive care unit. Lawrence A, et al. **Anaesth Intensive Care** 1999 Apr;27(2):185–9

Validation of Tu's cardiac surgical risk prediction index in a Western Australian population. Leonard RC, et al. **Anaesth Intensive Care** 1999 Apr;27(2):182–4

Lead time bias and standardised mortality ratios in intensive care patients [letter; comment] Nielsen MS, et al. **Anaesthesia** 1999 Apr;54(4):399. Comment on: Anaesthesia 1998 Nov;53(11):1045–53.

The effect of lead time bias on severity of illness scoring, mortality prediction and standardised mortality ratio in intensive care--a pilot study [see comments] Tunnell RD, et al. **Anaesthesia** 1998 Nov;53(11):1045–53. Comment in: Anaesthesia 1999 Apr;54(4):399.

Risk factors for predicting mortality in a paediatric intensive care unit. Tan GH, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):813–8

Do advanced cardiac life support drugs increase resuscitation rates from in–hospital cardiac arrest? The OTAC Study Group. van Walraven C, et al. **Ann Emerg Med** 1998 Nov; 32(5):544–53

Bundle–branch block and in–hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Go AS, et al. **Ann Intern Med** 1998 Nov 1;129(9):690–7

Oregon's low in–hospital death rates: what determines where people die and satisfaction with decisions on place of death? Tolle SW, et al. **Ann Intern Med** 1999 Apr 20;130(8):681–5

Mortality after elective abdominal aortic aneurysm repair: not where ... but how many and by whom [see comments] Galland RB, et al. **Ann R Coll Surg Engl** 1998 Sep; 80(5):339–40. Comment in: Ann R Coll Surg Engl 1999 Jan;81(1):72. Comment in: Ann R Coll Surg Engl 1999 Mar;81(2):141–2.

Safety of pancreatic surgery in a small DGH. Millson CE, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):51–3

Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Fan ST, et al. **Ann Surg** 1999 Mar; 229(3):322–30

Using database information in your clinical practice. Dziuban SW Jr. **Ann Thorac Surg** 1999 Aug;68(2):350–2; discussion 374–6

Innovative uses of a cardiothoracic database. Nugent WC. **Ann Thorac Surg** 1999 Aug;68(2):359–61; discussion 374–6

Closing the loop: optimizing physicians' operational and strategic behavior. Sergeant PT, et al. **Ann Thorac Surg** 1999 Aug;68(2):362–6; discussion 374–6

Mortality of the institutionalized old–old hospitalized with congestive heart failure. Wang R, et al. **Arch Intern Med** 1998 Dec 7–21;158(22):2464–8

Quality of care before admission to intensive care. Deaths on the wards might be prevented [letter] Goldhill DR, et al. **BMJ** 1999 Jan 16;318(7177):195

Explaining differences in English hospital death rates using routinely collected data. Jarman B, et al. **BMJ** 1999 Jun 5;318(7197):1515–20

Hospital–based study of severe malaria and associated deaths in Myanmar. Ejov MN, et al. **Bull World Health Organ** 1999;77(4):310–4

Predictors of mortality in children hospitalized with dysentery in Harare, Zimbabwe. Nathoo KJ, et al. **Cent Afr J Med** 1998 Nov;44(11):272–6

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Kollef MH, et al. **Chest** 1999 Feb;115(2):462–74

Determinants of hospital mortality after coronary artery bypass grafting. Michalopoulos A, et al. **Chest** 1999 Jun; 115(6):1598–603

Comparison of outcome from intensive care admission after adjustment for case mix by the APACHE III prognostic system [see comments] Pappachan JV, et al. **Chest** 1999 Mar;115(3):802–10. Comment in: Chest 1999 Mar;115(3):614–6.

Community–wide assessment of intensive care outcomes using a physiologically based prognostic measure: implications for critical care delivery from Cleveland Health Quality Choice [see comments] Sirio CA, et al. **Chest** 1999 Mar;115(3):793–801. Comment in: Chest 1999 Mar;115(3):613–4.

Assessing quality of care using in–hospital mortality: does it yield informed choices? [editorial; comment] Sivak ED, et al. **Chest** 1999 Mar;115(3):613–4. Comment on: Chest 1999 Mar;115(3):793–801.

Critical care outcomes in the United Kingdom: sobering wake–up call or stability of the lamppost? [editorial; comment] Wood KE, et al. **Chest** 1999 Mar;115(3):614–6 . Comment on: Chest 1999 Mar;115(3):802–10.

Factors affecting the mortality of sick newborns admitted to intensive care units. Yau KI, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 Mar–Apr;40(2):75–82

The Pediatric Risk of Mortality (PRISM) Score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Castello FV, et al. **Crit Care Med** 1999 May;27(5):985–8

Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. García–Garmendia JL, et al. **Crit Care Med** 1999 Sep; 27(9):1794–9

Evaluation of an interdisciplinary data set for national intensive care unit assessment [see comments] Metnitz PG, et al. **Crit Care Med** 1999 Aug;27(8):1486–91. Comment in: Crit Care Med 1999 Aug;27(8):1659–61.

The relationship of pre mortem diagnoses and post mortem findings in a surgical intensive care unit [see comments] Mort TC, et al. **Crit Care Med** 1999 Feb;27(2):299–303. Comment in: Crit Care Med 1999 Feb;27(2):235–6.

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis–related problems" of the European Society of Intensive Care Medicine [see comments] Vincent JL, et al. **Crit Care Med** 1998 Nov;26(11):1793–800. Comment in: Crit Care Med 1998 Nov;26(11):1767–8.

Bacterial meningitis in a rural Kenyan hospital. Hõnnas A, et al. **East Afr Med J** 1998 Jul;75(7):396–401

The meaning of early mortality after CABG. Osswald BR, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):401–7

Decreased health care quality associated with emergency department overcrowding. Miró O, et al. **Eur J Emerg Med** 1999 Jun;6(2):105–7

Gastrostomy placement and mortality among hospitalized Medicare beneficiaries. Kobayashi K, et al. **Gastrointest Endosc** 1999 Jun;49(6):810–1 (8 ref.)

Hospital mortality of acute myocardial infarction in the thrombolytic era. Mahon NG, et al. **Heart** 1999 May; 81(5):478–82

Impact of nosocomial infections on outcome: myths and evidence [editorial; comment] Rello J. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):392–4 (15 ref.). Comment on: Infect Control Hosp Epidemiol 1999 Jun;20(6):396–401.

Mortality as an outcome in hospital–acquired pneumonia. Rello J, et al. **Infect Control Hosp Epidemiol** 1998 Oct; 19(10):795–7 (24 ref.)

A survey of hospital morbidity, mortality and quality of life following coronary artery bypass surgery in a UK Indo–Asian population. Goldsmith IR, et al. **Int J Clin Pract** 1999 Jan–Feb;53(1):9–14

Mortality in geriatric psychiatric inpatients. Hwang JP, et al. **Int J Psychiatry Med** 1998;28(3):327–31

Laboratory values improve predictions of hospital mortality [see comments] Pine M, et al. **Int J Qual Health Care** 1998 Dec;10(6):491–501. Comment in: Int J Qual Health Care 1998 Dec;10(6):463–5.

Proxy–perceived prior health status and hospital outcome among the critically ill: is there any relationship? Diaz–Prieto A, et al. **Intensive Care Med** 1998 Jul; 24(7):691–8

Decision support issues using a physiology based score. Marcin JP, et al. **Intensive Care Med** 1998 Dec; 24(12):1299–304

Prognostic performance and customization of the SAPS II: results of a multicenter Austrian study. Simplified Acute Physiology Score [see comments] Metnitz PG, et al. **Intensive Care Med** 1999 Feb;25(2):192–7. Comment in: Intensive Care Med 1999 Feb;25(2):140–2.

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. Garratt KN, et al. **J Am Coll Cardiol** 1999 Jan;33(1):119–24

Validation of risk adjustment models for in–hospital percutaneous transluminal coronary angioplasty mortality on an independent data set. Moscucci M, et al. **J Am Coll Cardiol** 1999 Sep;34(3):692–7

Management and outcome of acute myocardial infarction in older patients in the thrombolytic era. Mahon NG, et al. **J Am Geriatr Soc** 1999 Mar;47(3):291–4

Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989–1993 [see comments] Collins AJ, et al. **J Am Soc Nephrol** 1998 Nov;9(11):2108–17. Comment in: J Am Soc Nephrol 1998 Nov;9(11):2153–6.

Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days. Librero J, et al. **J Clin Epidemiol** 1999 Mar;52(3):171–9

Is hospital care involved in inequalities in coronary heart disease mortality? Results from the French WHO–MONICA Project in men aged 30–64. Lang T, et al. **J Epidemiol Community Health** 1998 Oct;52(10):665–71

Nosocomial infection, indices of intrinsic infection risk, and in–hospital mortality in general surgery. Delgado–Rodriguez M, et al. **J Hosp Infect** 1999 Mar; 41(3):203–11

Demystifying the influence of hospital characteristics on inpatient mortality rates. van Servellen G, et al. **J Nurs Adm** 1999 Apr;29(4):39–47

Computer generated discharge summaries and their use as a case mix sensitive audit engine. A tale of two cities. Ball A, et al. **J R Coll Physicians Lond** 1999 May–Jun; 33(3):260–3

Risk–adjusted in–hospital death rates for peer hospitals in rural and urban regions. Glenn LL, et al. **J Rural Health** 1999 Winter;15(1):94–107

Volume–outcome relationships in cardiovascular operations: New York State, 1990–1995. Sollano JA, et al. **J Thorac Cardiovasc Surg** 1999 Mar;117(3):419–28; discussion 428–30

Impact of hospital volume on operative mortality for major cancer surgery [see comments] Begg CB, et al. **JAMA** 1998 Nov 25;280(20):1747–51. Comment in: JAMA 1998 Nov 25;280(20):1783–4. Comment in: JAMA 1999 Apr 21;281(15):1374; discussion 1375. Comment in: JAMA 1999 Apr 21;281(15):1374–5 discussion 1375. Comment in: JAMA 1999 Apr 21;281(15):1375.

Hospital volume and patient outcomes in major cancer surgery: a catalyst for quality assessment and concentration of cancer services [editorial; comment] Hillner BE, et al. **JAMA** 1998 Nov 25;280(20):1783–4. Comment on: JAMA 1998 Nov 25;280(20):1747–51.

Influence of hospital volume on mortality following major cancer surgery [letter; comment] Hughes CM. **JAMA** 1999 Apr 21;281(15):1375. Comment on: JAMA 1998 Nov 25;280(20):1747–51.

Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery [see comments] Pronovost PJ, et al. **JAMA** 1999 Apr 14;281(14):1310–7. Comment in: JAMA 1999 Apr 14;281(14):1330–1.

Reorganizing the delivery of intensive care may improve patient outcomes [editorial; comment] Randolph AG. **JAMA** 1999 Apr 14;281(14):1330–1. Comment on: JAMA 1999 Apr 14;281(14):1310–7.

Influence of hospital volume on mortality following major cancer surgery [letter; comment] Schwarz RE, et al. **JAMA** 1999 Apr 21;281(15):1374; discussion 1375. Comment on: JAMA 1998 Nov 25;280(20):1747–51.

Influence of hospital volume on mortality following major cancer surgery [letter; comment] Simunovic M, et al. **JAMA** 1999 Apr 21;281(15):1374–5; discussion 1375. Comment on: JAMA 1998 Nov 25;280(20):1747–51.

Propofol–infusion syndrome in children [see comments] Hatch DJ. **Lancet** 1999 Apr 3;353(9159):1117–8 (12 ref.). Comment in: Lancet 1999 Jun 12;353(9169):2074–5.

HOSPITAL MORTALITY

The effect of staff nursing on length of stay and mortality. Czaplinski C, et al. **Med Care** 1998 Dec;36(12):1626–38

Patient preferences for location of care: implications for regionalization. Finlayson SR, et al. **Med Care** 1999 Feb; 37(2):204–9

The relationship of gender and in-hospital death: increased risk of death in men. Gordon HS, et al. **Med Care** 1999 Mar;37(3):318–24

A new casemix adjustment index for hospital mortality among patients with congestive heart failure. Polanczyk CA, et al. **Med Care** 1998 Oct;36(10):1489–99

Accuracy of risk-adjusted mortality rate as a measure of hospital quality of care. Thomas JW, et al. **Med Care** 1999 Jan;37(1):83–92

Research evidence on the validity of risk-adjusted mortality rate as a measure of hospital quality of care [published erratum appears in Med Care Res Rev 1999 Mar;56(1):118] Thomas JW, et al. **Med Care Res Rev** 1998 Dec; 55(4):371–404 (67 ref.)

Professional misconduct: the Bristol case [see comments] Bolsin SN. **Med J Aust** 1998 Oct 5;169(7):369–72. Comment in: Med J Aust 1998 Oct 5;169(7):351–2. Comment in: Med J Aust 1998 Oct 5;169(7):352–3.

The downside of whistleblowing [editorial; comment] Lennane KJ, et al. **Med J Aust** 1998 Oct 5;169(7):351–2. Comment on: Med J Aust 1998 Oct 5;169(7):369–72.

The Bristol case, the medical profession and trust [editorial; comment] Van Der Weyden MB. **Med J Aust** 1998 Oct 5;169(7):352–3. Comment on: Med J Aust 1998 Oct 5;169(7):369–72.

Suicide among psychiatric in-patients with schizophrenia in an Australian mental hospital. Shah A, et al. **Med Sci Law** 1999 Jul;39(3):251–9

The Stent report, one year on. Christchurch Hospital's Medical Specialists Association. Foate J, et al. **N Z Med J** 1999 Jul 23;112(1092):278–9

Intensive perioperative dialysis can improve the hospital mortality of haemodialysis patients undergoing cardiac surgery [letter] Okada H, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2713–4

Prognostication and certainty in the pediatric intensive care unit. Marcin JP, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):868–73

Health care professional staffing, hospital characteristics, and hospital mortality rates [see comments] Bond CA, et al. **Pharmacotherapy** 1999 Feb;19(2):130–8. Comment in: Pharmacotherapy 1999 May;19(5):555.

Experience with invasive Candida infections. Girishkumar H, et al. **Postgrad Med J** 1999 Mar;75(881):151–3

Treatment limiting decisions in a neurosurgical unit. Fitzpatrick MO, et al. **Scott Med J** 1999 Apr;44(2):47–8

R2: a useful measure of model performance when predicting a dichotomous outcome. Ash A, et al. **Stat Med** 1999 Feb 28;18(4):375–84

Predicting in-hospital mortality of patients receiving cardiopulmonary resuscitation: unit-weighted MultiODA for binary data. Yarnold PR, et al. **Stat Med** 1998 Oct 30; 17(20):2405–14

Relationship between provider volume and mortality for carotid endarterectomies in New York state. Hannan EL, et al. **Stroke** 1998 Nov;29(11):2292–7

Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Birkmeyer JD, et al. **Surgery** 1999 Mar;125(3):250–6

[Deaths at the neonatal department. Withholding or interruption of life-support treatment] Bjerager MO, et al. **Ugeskr Laeger** 1999 Mar 29;161(13):1916–9 (Eng. Abstr.) **(Dan)**

[Frequency and causes of maternal mortality in a hospital environment in Ouagadougou, Burkina Faso (letter)] Lankoande J, et al. **Med Trop (Mars)** 1998;58(3):309 **(Fre)**

[Effect of the mortality and morbidity conference on clinical success and clinical atmosphere] Rothmund M, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:655–60 (Eng. Abstr.) **(Ger)**

[Negative report--how does it affect us? (letter)] Gabrielsen AM. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1803 **(Nor)**

[Variation in hospital mortality should be seriously considered] Gulbrandsen P. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1418 **(Nor)**

[Electronic databases and studies on hospital mortality (letter)] Lofthus CM, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2079–80 **(Nor)**

[Improved treatment of myocardial infarction--how has the hospital mortality developed?] Reikvam A. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1078–9 **(Nor)**

[Acute stroke--who dies in a stroke unit?] Slørdahl SA, et al. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1419–22 (Eng. Abstr.) **(Nor)**

[Difference of hospital mortality of acute myocardial infarction between men and women treated with primary angioplasty] Passos LC, et al. **Arq Bras Cardiol** 1998 Oct; 71(4):587–90 (Eng. Abstr.) **(Por)**

[Mortality descriptors in HIV inpatients] Thuler LC, et al. **Rev Saude Publica** 1998 Dec;32(6):572–8 (Eng. Abstr.) **(Por)**

[Do chronic diseases prevent intra-hospital mortality? Paradoxes and biases in information about hospital morbidity] Librero J, et al. **Gac Sanit** 1998 Sep–Oct; 12(5):199–206 (Eng. Abstr.) **(Spa)**

[The unequal clinical profile, quality of life and hospital mortality in patients undergoing aortocoronary bypass in the public and private centers of Catalonia. The CIRCORCA Study] Permanyer Miralda G, et al. **Rev Esp Cardiol** 1998 Oct;51(10):806–15 (Eng. Abstr.) **(Spa)**

[Hospital mortality in ischemia: influence of two vascular risk factors] López-González FJ, et al. **Rev Neurol** 1998 Sep;27(157):473–7 (Eng. Abstr.) **(Spa)**

[Deaths at an emergency hospital. Circumstances around the cases as described by physicians and relatives] Sanner M, et al. **Lakartidningen** 1998 Oct 14;95(42):4596–600, 4602 (Eng. Abstr.) **(Swe)**

TRENDS

Falling hospital mortality for acute myocardial infarction in Quebec hospitals. Brophy J. **Can J Cardiol** 1998 Nov; 14(11):1358–62

Practice variations, chance and quality of care [editorial; comment] Brophy JM, et al. **CMAJ** 1998 Oct 20; 159(8):949–52. Comment on: CMAJ 1998 Oct 20;159(8):926–30.

Coronary artery bypass grafting in Canada: hospital mortality rates, 1992–1995 [see comments] Ghali WA, et al. **CMAJ** 1998 Oct 20;159(8):926–30. Comment in: CMAJ 1998 Oct 20;159(8):949–52.

Reduced mortality from septic shock--lessons for the future [editorial; comment] Cohen NH. **Crit Care Med** 1998 Dec; 26(12):1956–8 (25 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2078–86.

Has the mortality of septic shock changed with time [see comments] Friedman G, et al. **Crit Care Med** 1998 Dec; 26(12):2078–86 (144 ref.). Comment in: Crit Care Med 1998 Dec;26(12):1956–8.

Differences in pediatric ICU mortality risk over time [see comments] Tilford JM, et al. **Crit Care Med** 1998 Oct; 26(10):1737–43. Comment in: Crit Care Med 1998 Oct;26(10):1635–6.

Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study [see comments] Soufir L, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):396–401. Comment in: Infect Control Hosp Epidemiol 1999 Jun;20(6):392–4.

A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective [see comments] Goldberg RJ, et al. **J Am Coll Cardiol** 1999 May;33(6):1533–9. Comment in: J Am Coll Cardiol 1999 May;33(6):1540–2.

Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994–1996. Northern New England Cardiovascular Disease Study Group. O'Connor GT, et al. **J Am Coll Cardiol** 1999 Sep; 34(3):681–91

We have journeyed far [editorial; comment] Piña IL. **J Am Coll Cardiol** 1999 May;33(6):1540–2. Comment on: J Am Coll Cardiol 1999 May;33(6):1533–9.

Hospital mortality from acute myocardial infarction has been modestly reduced after introduction of thrombolytics and aspirin: results from a new analytical approach. European Secondary Prevention Study Group. Reikvam A, et al. **J Clin Epidemiol** 1999 Jul;52(7):609–13

Changing mortality and causes of death in infants 23–27 weeks' gestational age. Doyle LW, et al. **J Paediatr Child Health** 1999 Jun;35(3):255–9

Unexpected deaths and referrals to intensive care of patients on general wards. Are some cases potentially avoidable? McGloin H, et al. **J R Coll Physicians Lond** 1999 May–Jun; 33(3):255–9

Increased risk of death in patients with do-not-resuscitate orders [see comments] Shepardson LB, et al. **Med Care** 1999 Aug;37(8):727–37. Comment in: Med Care 1999 Aug;37(8):719. Comment in: Med Care 1999 Aug;37(8):722–6.

Temporal trends in cardiogenic shock complicating acute myocardial infarction. Goldberg RJ, et al. **N Engl J Med** 1999 Apr 15;340(15):1162–8

The German experience with primary angioplasty. Vogt A, et al. **Semin Interv Cardiol** 1999 Mar;4(1):43–6

[Morbidity and mortality in pediatric intensive care at the Brazzaville University Hospital Center after 5 months of war, October 1997–April 1998 (letter)] Mbika-Cardorelle A, et al. **Arch Pediatr** 1998 Nov;5(11):1289–91 **(Fre)**

[Systematic internal quality control in surgery 1993 to 1997] Junginger T, et al. **Z Arztl Fortbild Qualitatssich** 1998 Dec; 92(10):705–14 (Eng. Abstr.) **(Ger)**

[Admissions and mortality in a HIV unit before and after protease inhibitors (letter)] Soriano V, et al. **Rev Clin Esp** 1998 Oct;198(10):715 **(Spa)**

HOSPITAL NUCLEAR MEDICINE DEPARTMENT see **NUCLEAR MEDICINE DEPARTMENT, HOSPITAL**

HOSPITAL NURSERIES see **NURSERIES, HOSPITAL**

HOSPITAL NURSING SERVICE see **NURSING SERVICE, HOSPITAL**

HOSPITAL NURSING STAFF see **NURSING STAFF, HOSPITAL**

HOSPITAL OBSTETRICS AND GYNECOLOGY DEPARTMENT see **OBSTETRICS AND GYNECOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL ORGANIZATION AND ADMINISTRATION see **HOSPITAL ADMINISTRATION**

HOSPITAL OUTPATIENT CLINICS see **OUTPATIENT CLINICS, HOSPITAL**

HOSPITAL PATHOLOGY DEPARTMENT see **PATHOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL-PATIENT RELATIONS

Design of appointment systems for preanesthesia evaluation clinics to minimize patient waiting times: a review of computer simulation and patient survey studies. Dexter F. **Anesth Analg** 1999 Oct;89(4):925–31 (30 ref.)

Courtesy counts. Bucks start here [news] Lentz R. **Hosp Health Netw** 1999 May;73(5):20, 22

Do you hear what I hear? Lumsdon K. **Hosp Health Netw** 1999 Apr;73(4):84

Questions before I go. Lumsdon K. **Hosp Health Netw** 1999 Sep;73(9):84

Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center. Galt KA. **Pharmacotherapy** 1998 Sep–Oct; 18(5):1103–11

HOSPITAL PERSONNEL see **PERSONNEL, HOSPITAL**

HOSPITAL PERSONNEL ADMINISTRATION see **PERSONNEL ADMINISTRATION, HOSPITAL**

HOSPITAL PHARMACY SERVICE see **PHARMACY SERVICE, HOSPITAL**

HOSPITAL PHYSICAL THERAPY DEPARTMENT see **PHYSICAL THERAPY DEPARTMENT, HOSPITAL**

HOSPITAL-PHYSICIAN JOINT VENTURES

Anatomy of a joint venture: Dana Farber/Partners Cancer Care. Chabner BA. **Trans Am Clin Climatol Assoc** 1999; 110:168–79; discussion 179–80

ECONOMICS

Ambulatory surgery center joint ventures involving tax-exempt entities. Becker S, et al. **J Health Care Finance** 1999 Summer;25(4):47–58 (3 ref.)

LEGISLATION & JURISPRUDENCE

Marshfield Clinic, physician networks, and the exercise of monopoly power. Greenberg W. **Health Serv Res** 1998 Dec;33(5 Pt 2):1461–76

When ties to doctors look too close [news] Demuro P, et al. **Hosp Health Netw** 1999 Apr;73(4):28

ORGANIZATION & ADMINISTRATION

The integration of primary care sports medicine into an academic emergency medicine practice: academic and revenue enhancement. Veenema KR. **Acad Emerg Med** 1999 Aug;6(8):828–32

Assessing the value of hospitalists to academic health centers: Brigham and Women's Hospital and Harvard Medical School. Brown MD, et al. **Am J Med** 1999 Feb;106(2):134–7

Physician-hospital integration strategies: impact on physician involvement in hospital governance. Kocher C, et al. **Health Care Manage Rev** 1998 Summer;23(3):38–47

MSO development: progress versus pitfalls. Nauert RC, et al. **J Health Care Finance** 1999 Spring;25(3):37–43

Design and development of a computer-based clinical referral system for use within a physician hospital organization. Sittig DF, et al. **Medinfo** 1998;9 Pt 1:98–102

Physician integration options. You're not cats, they're not ranchers. Cawley KJ, et al. **Mich Med** 1998 Dec; 97(12):10–1, 36

TRENDS

Managed care and processes to integrate physicians/hospitals. Burns LR, et al. **Health Care Manage Rev** 1998 Fall;23(4):70–80

HOSPITAL-PHYSICIAN RELATIONS

How well do GPs and hospital consultants work together? A survey of the professional relationship. Marshall MN. **Fam Pract** 1999 Feb;16(1):33–8

Physician-hospital integration strategies: impact on physician involvement in hospital governance. Kocher C, et al. **Health Care Manage Rev** 1998 Summer;23(3):38–47

Physician involvement in management and governance: the moderating effects of staff structure and composition. Succi MJ, et al. **Health Care Manage Rev** 1999 Winter;24(1):33–44

Asthma: communication between hospital and general practitioners. Marks MK, et al. **J Paediatr Child Health** 1999 Jun;35(3):251–4

The quality of communication between hospitals and general

practitioners: an assessment. Bolton P, et al. **J Qual Clin Pract** 1998 Dec;18(4):241–7

Comparison of the views of junior doctors, consultants and managers on work and training. Dilworth JP, et al. **J R Coll Physicians Lond** 1998 Jul–Aug;32(4):344–50

Physician and clinical integration among rural hospitals. Alexander JA, et al. **J Rural Health** 1998 Fall;14(4):312–26

The effects of managed care on physician and clinical integration in hospitals. Morrisey MA, et al. **Med Care** 1999 Apr;37(4):350–61

The hospital doctor in legislation and medical deontology: tension between profession and institution. Schutyser K. **Med Law** 1998;17(4):519–44 (57 ref.)

Physician integration options. You're not cats, they're not ranchers. Cawley KJ, et al. **Mich Med** 1998 Dec; 97(12):10–1, 36

South Florida survey on the relationship between academic medical centers and community physicians. Baumann LS, et al. **South Med J** 1999 Jul;92(7):673–6

[Revocation of operating privileges is against the law! Bavarian Administrative Court decides in favor of the assistant medical director] Dobler S. **Unfallchirurg** 1999 Apr;102(4):319 **(Ger)**

[Physician harassment (editorial)] Agrest A. **Medicina (B Aires)** 1998;58(6):763–4 **(Spa)**

HOSPITAL PLANNING

Should CEO grow, then go? [news] Phelps D, et al. **Hosp Health Netw** 1999 Jul;73(7):24

Upstarts. Send in the clown [news] Santoro J. **Hosp Health Netw** 1999 Apr;73(4):14

Implementation of a subregional trauma system. Frascone RJ, et al. **Minn Med** 1999 Jun;82(6):49–52

[Use of geographic information systems (GIS) in strategic planning of surgical capacity within a hospital organization] Meyer-Pannwitt U, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:870–6 (Eng. Abstr.) **(Ger)**

[Contribution of databases to regional and supra-regional quality improvement in rheumatologic treatment and patient management. Professional Society of Regional Cooperative Rheumatic Disease Centers] Zink A. **Z Rheumatol** 1998 Dec;57(6):442–5 (Eng. Abstr.) **(Ger)**

[Insufficient knowledge about Karl Evang (letter)] Harvei S. **Tidsskr Nor Laegeforen** 1999 Apr 30;119(11):1650 **(Nor)**

ECONOMICS

Estimating the indirect effect of hospitals via complementary health care firms. Greene BB Jr. **J Health Care Finance** 1998 Winter;25(2):67–74

[Hospital planning] Schmidt KJ, et al. **Unfallchirurg** 1998 Jul; 101(7):574–9 **(Ger)**

METHODS

The economic consequences of reorganizing hospital services in Bishkek, Kyrgyzstan. Street A, et al. **Health Econ** 1999 Feb;8(1):53–64

ORGANIZATION & ADMINISTRATION

Preparing hospitals for toxicological mass casualties events [see comments] Tur-Kaspa I, et al. **Crit Care Med** 1999 May;27(5):1004–8. Comment in: Crit Care Med 1999 May;27(5):873–4.

Deep & Wide. Health care boards look beyond their communities for new trustees. Bilchik GS. **Hosp Health Netw** 1999 Sep;73(9):52–6

Recommended guidelines for optimal design of a plastic surgery service during mass casualty events. Cohen M, et al. **J Trauma** 1998 Nov;45(5):960–8

An assessment of the potential for repatriating care from urban to rural Manitoba. Black C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS167–86

The geographical assignment of cancer units: patient accessibility as an optimal allocation problem. Smallman-Raynor MR, et al. **Public Health** 1998 Nov; 112(6):379–83

TRENDS

[Hospital planning—an overview of the '90's. What are the effects on smaller hospitals?] Koselowski G, et al. **Chirurg** 1998 Nov;69(11):suppl 338–47 **(Ger)**

HOSPITAL PSYCHIATRIC DEPARTMENT see **PSYCHIATRIC DEPARTMENT, HOSPITAL**

HOSPITAL PURCHASING see **PURCHASING, HOSPITAL**

HOSPITAL PURCHASINGS see **PURCHASING, HOSPITAL**

HOSPITAL RADIOLOGY DEPARTMENT see **RADIOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL READMISSION see **PATIENT READMISSION**

HOSPITAL RECORDS

see related

FORMS AND RECORDS CONTROL

Preformatted admission charts for poisoning admissions facilitate clinical assessment and research. Buckley NA, et al. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):476–82

Evaluation of linked cancer registry and hospital records of breast cancer. McGeechan K, et al. **Aust N Z J Public Health** 1998 Dec;22(7):765–70

Integration and communication for the continuity of cardiac care (I4C). van Bemmel JH, et al. **J Electrocardiol** 1998; 31 Suppl:60–8 (18 ref.)

Automatic coding of diagnostic reports. de Bruijn LM, et al. **Methods Inf Med** 1998 Sep;37(3):260–5

The hospital record of the injured child and the need for external cause-of-injury codes.American Academy of Pediatrics. Committee on Injury and Poison Prevention, 1998–1999. Katcher ML, et al. **Pediatrics** 1999 Feb; 103(2):524–6

[Evaluation of aa tracking system for labile blood products in the Midi-Pyrenes region] Verret C, et al. **Transfus Clin Biol** 1998 Aug;5(4):275–82 (Eng. Abstr.) **(Fre)**

[Delivery of hospital discharge reports to health insurance and medical insurance medical services] Rieger HJ. **Dtsch Med Wochenschr** 1999 Apr 1;124(13):403–4 **(Ger)**

[Conceptual aspects in development and implementation of basic psychiatric documentation] Cording C. **Psychiatr Prax** 1998 Jul;25(4):175–8 (Eng. Abstr.) **(Ger)**

[Sense and nonsense in basic documentation (editorial) (published erratum appears in Psychiatr Prax 1998 Sep;25(5):XV)] Cording C. **Psychiatr Prax** 1998 Jul; 25(4):161–2 **(Ger)**

[Quality control of medical documentation of in-patients at the St. Stephen Municipal Hospital in Budapest] Keller L, et al. **Orv Hetil** 1999 Mar 14;140(11):593–6 (Eng. Abstr.) **(Hun)**

[Use of a system of presenting and processing medical records at the therapeutic-prophylactic facilities of primary care] Batyshev VV, et al. **Med Tekh** 1998 Jul–Aug;(4):37–41 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

[The impact of the data collection method on the medico-economic classification of admissions for myocardial infarction at the public hospitals in Lyon (see comments)] Rabilloud M, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):709–14 (Eng. Abstr.). Comment in: Arch Mal Coeur Vaiss 1998 Jun;91(6):707–8. **(Fre)**

LEGISLATION & JURISPRUDENCE

[Compliance with regulations for medical records in 15 Aquitaine public health facilities. Aquitaine DIM Physician's Group] Michel P, et al. **Presse Med** 1998 Nov 28;27(37):1884–9 (Eng. Abstr.) **(Fre)**

STANDARDS

An analysis of concordance among hospital databases and physician records. Holt G, et al. **Ann Surg Oncol** 1998 Sep; 5(6):553–6

Figures about firearms—what are the facts? [editorial] Wigton A. **S Afr Med J** 1999 Apr;89(4):396

[Continuous improvement in anesthesiological quality documentation] Junger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Nov; 33(11):715–21 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Pulmonary tuberculosis: data of general somatic hospital] Shul'ga IA, et al. **Probl Tuberk** 1998;(6):4–7 (45 ref.) (Eng. Abstr.) **(Rus)**

HOSPITAL RECOVERY ROOM see **RECOVERY ROOM**

HOSPITAL RECOVERY ROOMS see **RECOVERY ROOM**

HOSPITAL REFERRAL see **REFERRAL AND CONSULTATION**

HOSPITAL RENOVATION see **HOSPITAL DESIGN AND CONSTRUCTION**

HOSPITAL RENOVATIONS see **HOSPITAL DESIGN AND CONSTRUCTION**

HOSPITAL REORGANIZATION see **HOSPITAL RESTRUCTURING**

HOSPITAL RESPIRATORY THERAPY DEPARTMENT see **RESPIRATORY THERAPY DEPARTMENT, HOSPITAL**

HOSPITAL RESTRUCTURING

Learning from a merger opportunity. Francoeur DE. **Biomed Instrum Technol** 1999 Jan–Feb;33(1):45–9

Improved trauma care after reorganisation: a retrospective analysis. Alberts KA, et al. **Eur J Surg** 1999 May; 165(5):426–30

Safeguarding care gains: a grounded theory study of organizational change. Ardern P. **J Adv Nurs** 1999 Jun; 29(6):1370–6

Measuring and evaluating hospital restructuring efforts: 18-month follow-up and extension to critical care, Part 2. Bryan YE, et al. **J Nurs Adm** 1998 Oct;28(10):13–9

Longitudinal evaluation of professional nursing practice redesign [see comments] Krugman M, et al. **J Nurs Adm** 1999 May;29(5):10–20. Comment in: J Nurs Adm 1999 May;29(5):4.

Assessing the impact of reengineering on nursing [see comments] Pillar B, et al. **J Nurs Adm** 1999 May; 29(5):57–64. Comment in: J Nurs Adm 1999 May;29(5):4.

Who cares for junior medical officers? Brown MA, et al. **Med J Aust** 1998 Nov 2;169(9):475–7

Re-engineering the elective surgical service of a tertiary hospital: a historical controlled trial [letter; comment] Hall JC. **Med J Aust** 1999 Feb 1;170(3):141. Comment on: Med J Aust 1998 Sep 7;169(5):239. Comment on: Med J Aust 1998 Sep 7;169(5):247–51.

Transforming a hospital through growing, not building, an electronic patient record system. Atkinson CJ, et al. **Methods Inf Med** 1998 Sep;37(3):285–93

Did Wellington have too many acute psychiatric beds in 1996? MacDonald J, et al. **N Z Med J** 1999 Jul 23; 112(1092):275–6

Complaints against nurses: a reflection of 'the new managerialism' and consumerism in health care? Beardwood B, et al. **Soc Sci Med** 1999 Feb;48(3):363–74 (57 ref.)

[The relationship between intensive care medicine and pneumology in Switzerland. The situation in 1998] Chevrolet JC, et al. **Rev Mal Respir** 1999 Jun;16(3):317–24 (Eng. Abstr.) **(Fre)**

ECONOMICS

The economic consequences of reorganizing hospital services in Bishkek, Kyrgyzstan. Street A, et al. **Health Econ** 1999 Feb;8(1):53–64

Practicing restraint. **Hosp Health Netw** 1999 Jul;73(7):43, 2

Buy vs. bye. Hudson T. **Hosp Health Netw** 1999 Jul; 73(7):42–4, 2

Hospitals' vertical integration into skilled nursing: a rational approach to controlling transaction costs. Lehrman S, et al. **Inquiry** 1998 Fall;35(3):303–14

Those conversion blues. Forgione DA. **J Health Care Finance** 1999 Summer;25(4):38–46 (17 ref.)

The unintended and unexpected impact of downsizing: costly hospitals become more costly. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS123–34

Improving cost-effectiveness in a substance abuse treatment program. Francis E, et al. **Psychiatr Serv** 1999 May; 50(5):633–5

HISTORY

[Social change in the hospital during the 19th century. The example of the Munich General Hospital] Spree R. **Medizinhist J** 1998;33(3–4):245–91 **(Ger)**

LEGISLATION & JURISPRUDENCE

The REIT stuff. Do real estate investment trusts have what it takes to bridge hospital compliance gaps? Haugh R. **Hosp Health Netw** 1998 Nov 5;72(21):36–9, 3

MANPOWER

The impact of re-engineering and other cost reduction strategies on the staff of a large teaching hospital: a longitudinal study. Woodward CA, et al. **Med Care** 1999 Jun;37(6):556–69

METHODS

Fulcrum for the future: the creation of a values-driven culture. Taft S, et al. **Health Care Manage Rev** 1999 Winter; 24(1):17–32

ORGANIZATION & ADMINISTRATION

The implementation of business process reengineering in American and Canadian hospitals. Ho SJ, et al. **Health Care Manage Rev** 1999 Spring;24(2):19–31

In times of transition: an organizational change from a family systems perspective. Speice J, et al. **Health Care Manage Rev** 1999 Winter;24(1):73–80

Transformation of an academic medical center: lessons learned from restructuring and downsizing. Woodard B, et al. **Health Care Manage Rev** 1999 Winter;24(1):81–94

Financial and organizational determinants of hospital diversification into subacute care. Wheeler JR, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):61–81

The tactical made practical. **Hosp Health Netw** 1998 Nov 5;72(21):40–1, 3

Improving computer skills to support hospital restructuring. Miller E, et al. **J Nurs Care Qual** 1999 Jun;13(5):44–56

Reengineering health care materials management. Connor LR. **J Soc Health Syst** 1998;5(4):74–89

Monitoring the impact of hospital downsizing on access to care and quality of care. Brownell MD, et al. **Med Care** 1999 Jun;37(6 Suppl):JS135–50

Hospital conversions from for-profit to nonprofit status: the other side of the story [letter] Lee B.

Med Care Res Rev 1999 Jun;56(2):220–2
Academic medical centers: a prescription for success in an era of managed care and capitation. Huntsinger CR Jr, et al. **Mil Med** 1999 Aug;164(8):585–9 (11 ref.)
Hospital restructuring and the changing nature of the physical therapist's role. Lopopolo RB. **Phys Ther** 1999 Feb;79(2):171–85
Reorganizing departments of psychiatry, hospitals, and medical centers for the 21st century. Schreter RK. **Psychiatr Serv** 1998 Nov;49(11):1429–33 (51 ref.)

STANDARDS

The impact of mental health service integration on systemic function: a staff perspective. Le Bas J, et al. **Aust N Z J Psychiatry** 1998 Oct;32(5):666–72
Reengineering: deja vu all over again. Arndt M, et al. **Health Care Manage Rev** 1998 Summer;23(3):58–66 (65 ref.)
Roads to recovery. Meyer H. **Hosp Health Netw** 1998 Sep 20;72(18):24–6, 28–30, 3

TRENDS

Uncompensated care and hospital conversions in Florida. Needleman J, et al. **Health Aff (Millwood)** 1999 Jul–Aug; 18(4):125–33
Academic health centers in turbulent times: strategies for survival. Topping S, et al. **Health Care Manage Rev** 1999 Spring;24(2):7–18 (52 ref.)
[Contribution of psychiatric departments to restructuring inpatient management: the Saxony-Anhalt example] Böcker FM. **Psychiatr Prax** 1998 Jul;25(4):179–82 (Eng. Abstr.) **(Ger)**
[Quality management in rheumatologic rehabilitation at a time of structural change] Ehlebracht-König I. **Z Rheumatol** 1998 Dec;57(6):420–3 (Eng. Abstr.) **(Ger)**
[Breast carcinoma in routine surgery. Challenges and reality] Kurz W. **Zentralbl Chir** 1998;123 Suppl 5:94–5 (Eng. Abstr.) **(Ger)**

HOSPITAL SERVICES, CENTRALIZED see **CENTRALIZED HOSPITAL SERVICES**

HOSPITAL SHARED SERVICES

ORGANIZATION & ADMINISTRATION

The accent's on access. Public and private hospitals join hands to improve health care for poorer Chicagoans. Novarro L. **Hosp Health Netw** 1998 Oct 5;72(19):20
[The Vosges-Meuse mobile MRI unit] Bernard C, et al. **J Radiol** 1999 Jul;80(7):745–6 (Eng. Abstr.) **(Fre)**

HOSPITAL SIZE see **HEALTH FACILITY SIZE**

HOSPITAL SOCIAL WORK DEPARTMENT see **SOCIAL WORK DEPARTMENT, HOSPITAL**

HOSPITAL SURGERY DEPARTMENT see **SURGERY DEPARTMENT, HOSPITAL**

HOSPITAL UNITS

Stroke units: more trials needed. Stone S. **Age Ageing** 1999 Mar;28(2):95–7
Lessons learned from a community hospital chest pain center. Stomel R, et al. **Am J Cardiol** 1999 Apr 1;83(7):1033–7
Trace nitrous oxide levels in the postanesthesia care unit. McGregor DG, et al. **Anesth Analg** 1999 Aug;89(2):472–5
Emergency department observation unit funding [letter] Ross MA, et al. **Ann Emerg Med** 1999 Aug;34(2):293–4
Psychiatric illness in women: a review of the function of a specialist mother-baby unit. Milgrom J, et al. **Aust N Z J Psychiatry** 1998 Oct;32(5):680–6
Early discharge after surgery for breast cancer. Hotel wards are good option for patients [letter; comment] Spigelman AD. **BMJ** 1999 May 1;318(7192):1210; discussion 1211. Comment on: BMJ 1998 Nov 7;317(7168):1264–5. Comment on: BMJ 1998 Nov 7;317(7168):1275–9.
Reducing the length of stay after kidney transplantation--the intensive outpatient unit. Shapiro R, et al. **Clin Transplant** 1998 Oct;12(5):482–5
Hospital wards spreading vancomycin-resistant enterococci to intensive care units: returning coals to Newcastle [editorial; comment] Farr BM. **Crit Care Med** 1998 Dec; 26(12):1942–3 (14 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2001–4.
Differing epidemiology of Clostridium difficile-associated diarrhea between an oncology ward and a general medicine ward [letter] Rojas S, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):14–5
A care package for managing female sexual assault in genitourinary medicine. Harrison JM, et al. **Int J STD AIDS** 1999 May;10(5):283–9
From stroke unit care to stroke care unit. Sulter G, et al. **J Neurol Sci** 1999 Jan 1;162(1):1–5 (34 ref.)
Implementing pediatric diversionary programs on adult units. Stamoulis SC. **J Nurs Adm** 1999 Sep;29(9):3
Symptoms and attitudes of 100 consecutive patients admitted to an acute hospice/palliative care unit. Ng K, et al. **J Pain Symptom Manage** 1998 Nov;16(5):307–16
Treatment in a combined acute and rehabilitation stroke unit: which aspects are most important? Indredavik B, et al. **Stroke** 1999 May;30(5):917–23
Treatment and rehabilitation on a stroke unit improves 5-year survival. A community-based study. Jørgensen HS, et al. **Stroke** 1999 May;30(5):930–3
The process of rehabilitation and discharge planning in stroke: a controlled comparison between stroke units. Patel M, et al. **Stroke** 1998 Dec;29(12):2484–7
[An observation department for children with acute disease] Daneman KL. **Ugeskr Laeger** 1999 Feb 8;161(6):776–9 **(Dan)**
[A survey of forensic psychiatric resources. Trends in the flow of patients to a new unit of forensic psychiatry, Sygehus Fyn, December 31, 1985 to December 31, 1995] Hansen PE, et al. **Ugeskr Laeger** 1999 Mar 22; 161(12):1766–9 (Eng. Abstr.) **(Dan)**
[Why hospitalize stroke patients in a specialized unit? (editorial)] Jaillard A, et al. **Presse Med** 1999 Jan 30; 28(4):179–80 (Eng. Abstr.) **(Fre)**
[7 reasons for hospitalizing stroke patients in special treatment units (editorial)] Leys D. **Presse Med** 1999 Jan 30; 28(4):181–3 (Eng. Abstr.) **(Fre)**
[Industrial hygiene and toxicology at the hospital department of occupational medicine] Apostoli P. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):163–5 (Eng. Abstr.) **(Ita)**
[Competent occupational physicians: privileges from the UOOML] Cassina T. **G Ital Med Lav Ergon** 1998 Jul–Sep; 20(3):182–4 (Eng. Abstr.) **(Ita)**
[Diagnosis and consultation at the Hospital Unit of Occupational Medicine (UOOML)] Catenacci G. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):185–7 (Eng. Abstr.) **(Ita)**
[DGR and therapeutic approaches in an angiology unit] Urbano O, et al. **Minerva Cardioangiol** 1998 Oct; 46(10):403–4 **(Ita)**
[Acute stroke--who dies in a stroke unit?] Slørdahl SA, et al. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1419–22 (Eng. Abstr.) **(Nor)**
[Care of aged and chronic patients in a short-stay medical unit] Marti Cipriano JM, et al. **An Med Interna** 1999 Aug; 16(8):398–406 (Eng. Abstr.) **(Spa)**

ECONOMICS

Obstetric postanesthesia care unit stays: reevaluation of discharge criteria after regional anesthesia. Cohen SE, et al. **Anesthesiology** 1998 Dec;89(6):1559–65
Emergency department observation unit: can it be funded through reduced inpatient admission? Sinclair D, et al. **Ann Emerg Med** 1998 Dec;32(6):670–5
Cost-effectiveness of intermediate intensive care units for mechanically-ventilated patients. Pierson DJ. **Monaldi Arch Chest Dis** 1998 Jun;53(3):360–4
An analysis of the costs of ischemic stroke in an Italian stroke unit. Mamoli A, et al. **Neurology** 1999 Jul 13;53(1):112–6

MANPOWER

Improving staffing with a resource management plan. Kirkby MP, et al. **J Nurs Adm** 1998 Nov;28(11):25–9
SDM95--reducing aggregate care team costs through optimal patient placement. Ledersnaider DL, et al. **J Nurs Adm** 1998 Oct;28(10):48–54
FOCUS on preparation for RSV season. Kempker-Russell MK. **MCN Am J Matern Child Nurs** 1999 Sep-Oct; 24(5):226–9

ORGANIZATION & ADMINISTRATION

Combined use of portable CT and fluoroscopy in the angiography suite. Dowd MT, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):497–8
Nuns to run first heroin injecting room [news] Zinn C. **BMJ** 1999 Aug 14;319(7207):400
Early pregnancy assessment units. Shillito J, et al. **Br J Hosp Med** 1998 Nov 19–Dec 9;58(10):505–9
The Speech and Language Therapy Research Unit at Frenchay Hospital, Bristol. Cotton S. **Int J Lang Commun Disord** 1998;33 Suppl:6–9
Rapid treatment status: a square peg in a round hole. Dunkle J, et al. **J Nurs Adm** 1999 Jul–Aug;29(7–8):38–42
Performance of first-line management functions on productivity of hospital unit personnel. Fox RT, et al. **J Nurs Adm** 1999 Sep;29(9):12–8
Informatics and process improvement. The clinical design unit. Merryman T, et al. **J Nurs Adm** 1999 Jun;29(6):55–61
The workings of a renal unit. Hedger NA. **J R Nav Med Serv** 1998;84(1):20–3
Health promotion in a hospital ward; reality or asking the impossible? Coakley AL. **J R Soc Health** 1998 Aug; 118(4):217–20 (25 ref.)
Personal decontamination after exposure to stimulated liquid phase contaminants: functional assessment of a new unit. Törngren S, et al. **J Toxicol Clin Toxicol** 1998;36(6):567–73
Otolaryngology care unit: a safe and cost-reducing way to deliver quality care. Strauss M, et al. **Laryngoscope** 1999 Sep;109(9):1428–32
FOCUS on preparation for RSV season. Kempker-Russell MK. **MCN Am J Matern Child Nurs** 1999 Sep-Oct; 24(5):226–9
The impact of a geriatrics evaluation and management unit compared to standard care in a community teaching hospital. Stewart M, et al. **Md Med J** 1999 Mar-Apr; 48(2):62–7
Organization and outcomes of inpatient AIDS care. Aiken LH, et al. **Med Care** 1999 Aug;37(8):760–72
The effect of staff nursing on length of stay and mortality. Czaplinski C, et al. **Med Care** 1998 Dec;36(12):1626–38
Evaluation of a bed utilization system in a surgical nursing section. Rivers FM, et al. **Mil Med** 1998 Dec; 163(12):839–43
Observation units: the role of an outpatient extended treatment site in pediatric care. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1998 Dec;14(6):444–7
Post procedural interventional cardiology patients on the progressive care unit. Miller DL. **Prog Cardiovasc Nurs** 1999 Winter;14(1):14–7, 36
The geographical assignment of cancer units: patient accessibility as an optimal allocation problem. Smallman-Raynor MR, et al. **Public Health** 1998 Nov; 112(6):379–83
Palliative care in the University Hospital Lausanne: from consultations to an integrated regional program. Mazzocato C, et al. **Support Care Cancer** 1999 Jul;7(4):221–3 (3 ref.)
[How is the management of postoperative pain in organized in surgical wards?] Bouaziz H. **Ann Fr Anesth Reanim** 1998; 17(6):494–501 (42 ref.) (Eng. Abstr.) **(Fre)**
[Management of postoperative pain in surgical units] Delbos A. **Ann Fr Anesth Reanim** 1998;17(6):649–62 (17 ref.) (Eng. Abstr.) **(Fre)**
[Pediatric activity in a rural hospital in Tokombéré (Cameroon). Description and qualitative approach during a one year period] Buffin A, et al. **Arch Pediatr** 1998 Oct; 5(10):1072–81 (Eng. Abstr.) **(Fre)**
[Taking charge in a general hospital: from liaison psychiatry to medical-psychiatric units] Archinard M. **Rev Med Interne** 1998;19 Suppl 3:347S–349S **(Fre)**

STANDARDS

Impacting quality: assessment of a hospital-based geriatric acute care unit. Barrick C, et al. **Am J Med Qual** 1999 May-Jun;14(3):133–7
Telling the story of quality: the use of storyboards in nursing units. Hetherington LT. **J Nurs Adm** 1999 Jan;29(1):3, 25
Identifying medical center units with disproportionate shares of patient complaints. Pichert JW, et al. **Jt Comm J Qual Improv** 1999 Jun;25(6):288–99
Auditing outcomes from a medicine for the elderly service. Ramage L. **Scott Med J** 1997 Oct;42(5):156–7
Stroke units in their natural habitat: can results of randomized trials be reproduced in routine clinical practice? Riks-Stroke Collaboration. Stegmayr B, et al. **Stroke** 1999 Apr;30(4):709–14
[Setting up a quality assurance system for the management of blood glucose monitoring in hospital units] Prévosto JM, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):606–11 **(Fre)**
[Care of spinal injuries in New Zealand. International recognition of devoted work in research and development] Friden J. **Lakartidningen** 1999 Sep 1;96(35):3680–2 **(Swe)**
[Stroke unit care saves lives. The Swedish national quality assessment registry of stroke care is the first of its kind in the world] Stegmayr B, et al. **Lakartidningen** 1999 Jun 2;96(22):2719–24, 2726 (Eng. Abstr.) **(Swe)**

STATISTICS & NUMERICAL DATA

Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System. **Am J Infect Control** 1999 Jun;27(3):279–84
Adverse drug events in hospitalized patients. A comparison of doctors, nurses and patients as sources of reports. van den Bemt PM, et al. **Eur J Clin Pharmacol** 1999 Apr; 55(2):155–8
An overview of behaviour difficulties found in long-term elderly care settings. Jackson GA, et al. **Int J Geriatr Psychiatry** 1999 Jun;14(6):426–30
Prevalence and patterns of physical restraint use in the acute care setting. Minnick AF, et al. **J Nurs Adm** 1998 Nov; 28(11):19–24
Utilization analysis of an observation unit for children with asthma. Gouin S, et al. **Pediatr Emerg Care** 1999 Apr; 15(2):79–83
[A model of occupational, environmental and community medicine. History and evolution of the Hospital Unit of Occupational Medicine (UOOML) in Lombardia] Cirla AM, et al. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):172–81 (Eng. Abstr.) **(Ita)**
[Network of the occupational medicine hospital unit (UOOML) in Lombardia: an example of network] Occhipinti E, et al. **G Ital Med Lav Ergon** 1998 Jul–Sep; 20(3):166–71 (Eng. Abstr.) **(Ita)**
[Hospital detoxification unit: 4-year experience. Environmental factors] Gutiérrez del Rio C, et al. **An Med Interna** 1998 Nov;15(11):584–7 (Eng. Abstr.) **(Spa)**

TRENDS

HIV/AIDS units: is there still a need? [editorial] Morrison C. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):16–8
Census trends in AIDS specialty units. Napper RL Jr. **J Assoc Nurses AIDS Care** 1998 Nov-Dec;9(6):42–6
Forensic psychiatric service in Israel: ten years experience in an in-patient hospital unit. Kimhi R, et al. **Med Law**

1998;17(3):393-9
[An adolescent treatment unit: development and resistance (editorial)] Gautry P, et al. **Arch Pediatr** 1998 Aug; 5(8):839-43 **(Fre)**

UTILIZATION

The impact of minor perioperative anesthesia-related incidents, events, and complications on postanesthesia care unit utilization. Bothner U, et al. **Anesth Analg** 1999 Aug; 89(2):506-13
Unscheduled return visits within 72 hours to an assessment unit. Lal MK, et al. **Arch Dis Child** 1999 May;80(5):455-8
Basic characteristics of hospital stroke services in Eastern Hungary. Mihálka L, et al. **Eur J Epidemiol** 1999 May; 15(5):461-6
Are short-stay admissions to an acute general medical unit appropriate? Wellington Hospital experience. Burgess CD. **N Z Med J** 1998 Aug 28;111(1072):314-5

HOSPITAL UROLOGY DEPARTMENT see **UROLOGY DEPARTMENT, HOSPITAL**

HOSPITALISTS

"Financial transfers": standard of care? [letter] Gipe B. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):565-6
A Canadian perspective on the American hospitalist movement. Redelmeier DA. **Arch Intern Med** 1999 Aug 9-23;159(15):1665-8
The hospitalist movement: ten issues to consider. Wachter RM. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):95-8, 104-6, 111
Hospitalists and 'officists' preparing for the future of general internal medicine [see comments] Bryant DC. **J Gen Intern Med** 1999 Mar;14(3):182-5. Comment in: J Gen Intern Med 1999 Mar;14(3):205-6.
Specialization by practice location [editorial; comment] Fihn SD. **J Gen Intern Med** 1999 Mar;14(3):205-6. Comment on: J Gen Intern Med 1999 Mar;14(3):182-6.
Communication problems for patients hospitalized with chest pain [see comments] Simon SR, et al. **J Gen Intern Med** 1998 Dec;13(12):836-8. Comment in: J Gen Intern Med 1998 Dec;13(12):852-3.
Hospitalists and officists [letter] Smith LG. **J Gen Intern Med** 1999 Aug;14(8):518
Economic effects of community versus hospital-based faculty pneumonia care [see comments] Stein MD, et al. **J Gen Intern Med** 1998 Nov;13(11):774-7. Comment in: J Gen Intern Med 1998 Nov;13(11):783-5.
The hospitalist movement and the future of academic general internal medicine [editorial; comment] Wachter RM, et al. **J Gen Intern Med** 1998 Nov;13(11):783-5. Comment on: J Gen Intern Med 1998 Nov;13(11):774-7.
Old debate, new direction [editorial; comment] Wolpaw DR, et al. **J Gen Intern Med** 1998 Dec;13(12):852-3. Comment on: J Gen Intern Med 1998 Dec;13(12):836-8.
Hospitalism in the USA. Maviglia SM, et al. **Lancet** 1999 Jun 5;353(9168):1902
The changing role of acute-care hospitals [letter] Denaro CP, et al. **Med J Aust** 1999 Aug 16;171(4):224
Whither continuity of care? [letter] Freer SD. **N Engl J Med** 1999 Sep 9;341(11):850; discussion 851-2
Whither continuity of care? Manian FA. **N Engl J Med** 1999 Apr 29;340(17):1362-3
Whither continuity of care? [letter] Marshall MJ. **N Engl J Med** 1999 Sep 9;341(11):851; discussion 851-2
Whither continuity of care? [letter] Morris W. **N Engl J Med** 1999 Sep 9;341(11):850-1; discussion 851-2
Whither continuity of care? [letter] Rakatansky H. **N Engl J Med** 1999 Sep 9;341(11):851-2
The hospitalist movement and its implications for the care of hospitalized children [see comments] Bellet PS, et al. **Pediatrics** 1999 Feb;103(2):473-7. Comment in: Pediatrics 1999 Feb;103(2):497.
A hospitalist movement? Where to? [comment] Roberts KB, et al. **Pediatrics** 1999 Feb;103(2):497. Comment on: Pediatrics 1999 Feb;103(2):473-7.
The real impact of hospitalists [editorial] Morris W, et al. **Postgrad Med** 1999 Sep;106(3):21-2, 25

ECONOMICS

The hospitalist movement [letter] Hofmann CE. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
An employer's perspective on hospitalists as a source of improved health care value. Milstein A. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):360-3

EDUCATION

The hospitalist movement [letter] Flansbaum B, et al. **Ann Intern Med** 1999 Oct 5;131(7):544-5
Hospitalism debate [letter; comment] Epperson WJ. **J Fam Pract** 1998 Dec;47(6):420; discussion 421. Comment on: J Fam Pract 1998 Jun;46(6):465-8.
Hospitalism debate [letter; comment] Granat P. **J Fam Pract** 1998 Dec;47(6):420-1. Comment on: J Fam Pract 1998 Jun;46(6):465-8.

ORGANIZATION & ADMINISTRATION

The family physician as a hospitalist [letter] Guyn J, et al. **Am Fam Physician** 1999 Aug;60(2):402, 404
Assessing the value of hospitalists to academic health centers: Brigham and Women's Hospital and Harvard Medical School. Brown MD, et al. **Am J Med** 1999 Feb;106(2):134-7
Implications of the hospitalist movement for academic departments of medicine: lessons from the UCSF experience. Wachter RM, et al. **Am J Med** 1999 Feb; 106(2):127-33
The hospitalist movement [letter] Flansbaum B, et al. **Ann Intern Med** 1999 Oct 5;131(7):544-5
The Park Nicollet experience in establishing a hospitalist system. Freese RB. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):350-4
The impact of hospitalists on medical education and the academic health system. Goldman L. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):364-7
The hospitalist movement [letter] Rastegar DA. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
The hospitalist movement [letter] Starr LA. **Ann Intern Med** 1999 Oct 5;131(7):543-4; discussion 545
An introduction to the hospitalist model. Wachter RM. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):338-42
The hospitalist movement [letter] Wald H. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
The hospitalist: the new addition to the inpatient management team. Noyes BJ, et al. **J Nurs Adm** 1999 Feb;29(2):21-4
Just don't make me. Moran T. **Tex Med** 1999 Jul;95(7):32-6

STANDARDS

Hospitalists: cost and quality of care [letter; comment] Bellin E. **Ann Intern Med** 1999 Mar 2;130(5):450-1. Comment on: Ann Intern Med 1998 Aug 1;129(3):197-203.
The hospitalist movement [letter] Hofmann CE. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
The hospitalist movement [letter] Rastegar DA. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
The hospitalist movement [letter] Starr LA. **Ann Intern Med** 1999 Oct 5;131(7):543-4; discussion 545
The hospitalist movement [letter] Wald H. **Ann Intern Med** 1999 Oct 5;131(7):544; discussion 545
Hospitalists: cost and quality of care [letter; comment] Warren J. **Ann Intern Med** 1999 Mar 2;130(5):450-1. Comment on: Ann Intern Med 1998 Aug 1;129(3):197-203.
A new doctor in the house: ethical issues in hospitalist systems. Pantilat SZ, et al. **JAMA** 1999 Jul 14;282(2):171-4

STATISTICS & NUMERICAL DATA

The potential size of the hospitalist workforce in the United States. Lurie JD, et al. **Am J Med** 1999 Apr;106(4):441-5
Implementation of a hospitalist system in a large health maintenance organization: the Kaiser Permanente experience. Craig DE, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):355-9
Hospitalists and the practice of inpatient medicine: results of a survey of the National Association of Inpatient Physicians. Lindenauer PK, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):343-9

TRENDS

The hospitalist movement in the United States: what does it mean for internists? [editorial] Goldmann DR. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):326-7
The hospitalist: a new medical specialty? Kelley MA. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):373-5
The hospitalist: new boon for internal medicine or retreat from primary care? Schroeder SA, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):382-7
Evaluating the impact of hospitalists. Showstack J, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):376-81
The hospitalist model: perspectives of the patient, the Internist, and internal medicine. Sox HC. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):368-72
The emerging role of hospitalists--will family physicians continue to practice hospital medicine? McConaghy JR. **J Am Board Fam Pract** 1998 Jul-Aug;11(4):324-6
Hospital practice. Mansfield AO. **J R Soc Med** 1998;91 Suppl 36:14-7

HOSPITALIZATION

see related
CHILD, HOSPITALIZED
INSTITUTIONALIZATION
LENGTH OF STAY
PATIENT DISCHARGE

Identification of intra-abdominal injuries in children hospitalized following blunt torso trauma. Holmes JF, et al. **Acad Emerg Med** 1999 Aug;6(8):799-806
Patient satisfaction with an emergency department asthma observation unit. Rydman RJ, et al. **Acad Emerg Med** 1999 Mar;6(3):178-83
Severe sepsis in the emergency department and its association with a complicated clinical course. Smith SW, et al. **Acad Emerg Med** 1998 Dec;5(12):1169-76
An evaluation of the general effect of the New Zealand graduated driver licensing system on motorcycle traffic crash hospitalisations. Reeder AI, et al. **Accid Anal Prev** 1999 Nov;31(6):651-61
Does preoperative night pulse oximetry provide a reliable baseline? Rasmussen LS, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):34-6
Risk factors for violence among long-stay psychiatric patients: national study. Rabinowitz J, et al. **Acta Psychiatr Scand** 1999 May;99(5):341-7
One-year outcome of an integrative inpatient treatment for dual diagnosis patients. Moggi F, et al. **Addict Behav** 1999 Jul-Aug;24(4):589-92
Hospital admission and opinions of cardiopulmonary resuscitation [letter; comment] Bowker L, et al. **Age Ageing** 1998 Jul;27(4):545-6. Comment on: Age Ageing 1997 Nov;26(6):429-34.
Effect of immobilization on vitamin D status and bone mass in chronically hospitalized disabled stroke patients. Sato Y, et al. **Age Ageing** 1999 May;28(3):265-9
Pneumonia: projected age-related needs for hospital services in Finland [letter] Timo K, et al. **Age Ageing** 1999 Jan; 28(1):83-4
Changes in nutritional status during the hospital stay: a predictor of long-term survival. Antonelli Incalzi R, et al. **Aging (Milano)** 1998 Dec;10(6):490-6
Decreased needs for hospital care and antibiotics in children with advanced HIV-1 disease after protease inhibitor-containing combination therapy [letter] Canani RB, et al. **AIDS** 1999 May 28;13(8):1005-6
Associations of clinical parameters with health-related quality of life in hospitalized persons with HIV disease. Globe DR, et al. **AIDS Care** 1999 Feb;11(1):71-86
Benefits of massage therapy for hospitalized patients: a descriptive and qualitative evaluation. Smith MC, et al. **Altern Ther Health Med** 1999 Jul;5(4):64-71
Historical overview of inpatient care of mental patients who are deaf. Vernon M, et al. **Am Ann Deaf** 1999 Mar; 144(1):51-61
Comparison of medical care and survival of hospitalized patients with acute myocardial infarction in Poland and the United States. Rosamond W, et al. **Am J Cardiol** 1999 Apr 15;83(8):1180-5
Re: "Hormone replacement therapy and risk of hospitalization for venous thromboembolism: a population-based study in southern Europe" [letter; comment] Oger E, et al. **Am J Epidemiol** 1999 Feb 1;149(3):292-3. Comment on: Am J Epidemiol 1998 Feb 15;147(4):387-90.
Hospitalization in peritoneal dialysis patients. Fried L, et al. **Am J Kidney Dis** 1999 May;33(5):927-33
A prognostic rule for elderly patients admitted with community-acquired pneumonia. Conte HA, et al. **Am J Med** 1999 Jan;106(1):20-8
The effect of hospital experience on mortality among patients hospitalized with acquired immunodeficiency syndrome in California. Cunningham WE, et al. **Am J Med** 1999 Aug; 107(2):137-43
Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Inouye SK, et al. **Am J Med** 1999 May;106(5):565-73 (103 ref.)
Delivered dialysis dose is suboptimal in hospitalized patients. Obialo CI, et al. **Am J Nephrol** 1998;18(6):525-30
Uniform Data System for Medical Rehabilitation: report of first admissions for 1997. Fiedler RC, et al. **Am J Phys Med Rehabil** 1998 Sep-Oct;77(5):444-50
Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Cassidy F, et al. **Am J Psychiatry** 1999 Sep;156(9):1417-20
Childhood trauma and perceived parental dysfunction in the etiology of dissociative symptoms in psychiatric inpatients. Draijer N, et al. **Am J Psychiatry** 1999 Mar;156(3):379-85
Patients' revisions of their beliefs about the need for hospitalization [see comments] Gardner W, et al. **Am J Psychiatry** 1999 Sep;156(9):1385-91. Comment in: Am J Psychiatry 1998 Sep;156(9):1307-10.
Psychological and behavioral functioning in adolescent psychiatric inpatients who report histories of childhood abuse [see comments] Grilo CM, et al. **Am J Psychiatry** 1999 Apr;156(4):538-43. Comment in: Am J Psychiatry 1999 Apr;156(4):501-3.
Concurrent and predictive validity of the personality disorder diagnosis in adolescent inpatients. Levy KN, et al. **Am J Psychiatry** 1999 Oct;156(10):1522-8
Evaluation of bipolar disorder in inpatients with prelingual deafness. Shapira NA, et al. **Am J Psychiatry** 1999 Aug; 156(8):1267-9
Association of depressive symptoms during abstinence with the subjective high produced by cocaine. Uslaner J, et al. **Am J Psychiatry** 1999 Sep;156(9):1444-6
Evaluating and treating violent adolescents in the managed care era [clinical conference] Villani S, et al. **Am J Psychiatry** 1999 Mar;156(3):458-64
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Kessler R, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):158-64
Severity of illness models for respiratory syncytial virus-associated hospitalization. Moler FW, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1234-40
African children with malaria in an area of intense Plasmodium falciparum transmission: features on admission to the hospital and risk factors for death. Schellenberg D, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):431-8
Same admission colon resection with primary anastomosis for acute diverticulitis. Maggard MA, et al. **Am Surg** 1999 Oct;65(10):927-30
What is the paradigm: hospital or home health care for pressure ulcers? O'Brien SP, et al. **Am Surg** 1999 Apr; 65(4):303-6

Same hospitalization resection for acute diverticulitis. Wasvary H, et al. **Am Surg** 1999 Jul;65(7):632–5; discussion 636

The profile of hospitalised patients with Parkinson's disease. Tan LC, et al. **Ann Acad Med Singapore** 1998 Nov; 27(6):808–12

Review of investigation and management of severe hyponatraemia in a hospital population [see comments] Crook MA, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):158–62. Comment in: Ann Clin Biochem 1999 Jul;36(Pt 4):531–2.

Clinical correlates of response to valproate in geriatric inpatients. Niedermier JA, et al. **Ann Clin Psychiatry** 1998 Dec;10(4):165–8

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Robertson WO. **Ann Emerg Med** 1999 Jan;33(1):130–1. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.

Emergency department observation unit funding [letter] Ross MA, et al. **Ann Emerg Med** 1999 Aug;34(2):293–4

Depressive symptoms and 3-year mortality in older hospitalized medical patients. Covinsky KE, et al. **Ann Intern Med** 1999 Apr 6;130(7):563–9

Delayed hospital arrival for acute stroke [letter; comment] Lacy CR, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):328 . Comment on: Ann Intern Med 1998 Aug 1;129(3):190–6.

Delays in the suspicion and treatment of tuberculosis among hospitalized patients. Rao VK, et al. **Ann Intern Med** 1999 Mar 2;130(5):404–11

Laparoscopic cholecystectomy: day-care versus clinical observation. Keulemans Y, et al. **Ann Surg** 1998 Dec; 228(6):734–40

Who should care for hospitalized patients with severe skin disease? [letter; comment] [see comments] Kerdel FA, et al. **Arch Dermatol** 1998 Sep;134(9):1159, 1161–2. Comment on: Arch Dermatol 1998 Mar;134(3):358–60. Comment in: Arch Dermatol 1999 Aug;135(8):991.

Perception of need for emergency admission to hospital [letter; comment] Goodyear H, et al. **Arch Dis Child** 1999 Apr;80(4):398. Comment on: Arch Dis Child 1998 Sep;79(3):213–8.

Older persons' opinions about life-sustaining procedures in the face of dementia. Gjerdingen DK, et al. **Arch Fam Med** 1999 Sep-Oct;8(5):421–5

Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Goldhaber SZ, et al. **Arch Intern Med** 1998 Nov 23;158(21):2325–8

Risk factors for hospitalization in people with diabetes. Moss SE, et al. **Arch Intern Med** 1999 Sep 27;159(17):2053–7

Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. White DJ, et al. **Arch Intern Med** 1998 Oct 26;158(19):2149–54

Acute hospitalization and discharge outcome of neurologically intact trauma patients sustaining thoracolumbar vertebral fractures managed conservatively with thoracolumbosacral orthoses and physical therapy. Melchiorre PJ. **Arch Phys Med Rehabil** 1999 Feb; 80(2):221–4

The use of critical pathways in caring for schizophrenic patients in a mental hospital. Chan SW, et al. **Arch Psychiatr Nurs** 1999 Jun;13(3):145–53

Hospital experience and mortality in patients with systemic lupus erythematosus. Ward MM. **Arthritis Rheum** 1999 May;42(5):891–8

Optimising care of the hospitalised elderly. A literature review and suggestions for future research. Scott I. **Aust N Z J Med** 1999 Apr;29(2):254–64 (76 ref.)

Six-month outcome following a relapse of schizophrenia. Bergen J, et al. **Aust N Z J Psychiatry** 1998 Dec; 32(6):815–22

Suboptimal ward care of critically ill patients. Suboptimal care should have been defined [letter; comment] Gorard D. **BMJ** 1999 Jan 2;318(7175):51. Comment on: BMJ 1998 Jun 20;316(7148):1853–8.

A randomised trial of hospital versus home administered enemas for flexible sigmoidoscopy. Lund JN, et al. **BMJ** 1998 Oct 31;317(7167):1201

Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study. Maxwell K, et al. **BMJ** 1999 Jun 12;318(7198):1585–90

Suboptimal ward care of critically ill patients. Assessment of quality of care was flawed [letter; comment] Walshe K. **BMJ** 1999 Jan 2;318(7175):51. Comment on: BMJ 1998 Jun 20;316(7148):1853–8.

Final consensus statement of the Royal College of Physicians of Edinburgh Consensus Conference on atrial fibrillation in hospital and general practice, 3–4 September 1998. **Br J Haematol** 1999 Jan;104(1):195–6 (0 ref.)

Satisfaction with in-patient psychiatric services. Relationship to patient and treatment factors. Greenwood N, et al. **Br J Psychiatry** 1999 Feb;174:159–63

Influence of volume of work on the outcome of treatment for patients with colorectal cancer. Parry JM, et al. **Br J Surg** 1999 Apr;86(4):475–81

Unanticipated admission after ambulatory surgery--a prospective study. Fortier J, et al. **Can J Anaesth** 1998 Jul; 45(7):612–9

N-CPAP in the prevention of recurrent intubations and hospitalizations in a patient with refractory congestive heart failure. Parmar MS, et al. **Can J Cardiol** 1998 Nov; 14(11):1405–8 (22 ref.)

The frequency, aetiology and outcome of severe hyponatraemia in adult hospitalised patients. Erasmus RT, et al. **Cent Afr J Med** 1998 Jun;44(6):154–8

Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Suhr B, et al. **Cephalalgia** 1999 Jan;19(1):44–9

Effect of continuously nebulized ipratropium bromide plus albuterol on emergency department length of stay and hospital admission rates in patients with acute bronchospasm. A randomized, controlled trial [see comments] Weber EJ, et al. **Chest** 1999 Apr;115(4):937–44 . Comment in: Chest 1999 Apr;115(4):911–2.

Hospital readmission after cardiac surgery. Does "fast track" cardiac surgery result in cost saving or cost shifting? Lahey SJ, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II35–40

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Malmberg K, et al. **Circulation** 1999 May 25;99(20):2626–32

Clinical characteristics of ruptured chordae tendinae in hospitalized patients: primary tear versus infective endocarditis [letter; comment] Cheng TO. **Clin Cardiol** 1999 Feb;22(2):158. Comment on: Clin Cardiol 1998 Nov;21(11):813–6.

The independent effects of left ventricular ejection fraction on short-term outcomes and resource utilization following hospitalization for heart failure. Harjai KJ, et al. **Clin Cardiol** 1999 Mar;22(3):184–90

Transitional care: hospital to home. Hall WJ, et al. **Clin Geriatr Med** 1998 Nov;14(4):799–812 (45 ref.)

Delirium in hospitalized older patients. Inouye SK. **Clin Geriatr Med** 1998 Nov;14(4):745–64 (81 ref.)

Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program--Active (IMPACT). Halperin SA, et al. **Clin Infect Dis** 1999 Jun;28(6):1238–43

Predictors and outcome of admission for invasive Streptococcus pneumoniae infections at a Canadian children's hospital. Laupland KB, et al. **Clin Infect Dis** 1998 Sep;27(3):597–602

Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group. Vuori E, et al. **Clin Infect Dis** 1998 Sep;27(3):566–72

Oral methadone for the treatment of severe pain in hospitalized children: a report of five cases [see comments] Shir Y, et al. **Clin J Pain** 1998 Dec;14(4):350–3. Comment in: Clin J Pain 1998 Dec;14(4):277–9.

At which body mass index and degree of weight loss should hospitalized elderly patients be considered at nutritional risk? Beck AM, et al. **Clin Nutr** 1998 Oct;17(5):195–8 (34 ref.)

Effect of providing fortified meals and between-meal snacks on energy and protein intake of hospital patients. Gall MJ, et al. **Clin Nutr** 1998 Dec;17(6):259–64

Survey to establish the current status of artificial nutritional support in Europe. Jonkers C, et al. **Clin Nutr** 1999 Jun; 18(3):179–88

Nutritional status at submission for dietetic services and screening for malnutrition at admission to hospital [see comments] Thorsdóttir I, et al. **Clin Nutr** 1999 Feb; 18(1):15–21. Comment in: Clin Nutr 1999 Feb;18(1):3–4.

Psychosocial impact of high-risk pregnancy: hospital and home care. Heaman M. **Clin Obstet Gynecol** 1998 Sep; 41(3):626–39 (52 ref.)

Pre-transplant identification of risk factors that adversely affect length of stay and charges for renal transplantation. Johnson CP, et al. **Clin Transplant** 1999 Apr;13(2):168–75

The use and abuse of restraints [letter; comment] Sedran RJ, et al. **CMAJ** 1998 Nov 17;159(10):1239–40. Comment on: CMAJ 1998 Jun 16;158(12):1603–7.

The involvement of families in Indian psychiatry. Nunley M. **Cult Med Psychiatry** 1998 Sep;22(3):317–53

Symptomatic gastroesophageal reflux in acutely hospitalized patients. Newton M, et al. **Dig Dis Sci** 1999 Jan;44(1):140–8

Rehabilitation in the home versus the hospital: the importance of context. von Koch L, et al. **Disabil Rehabil** 1998 Oct; 20(10):367–72

Predictors of discharges against medical advice from a short-term hospital detoxification unit. Armenian SH, et al. **Drug Alcohol Depend** 1999 Aug 2;56(1):1–8

Hospitalizations after the Persian Gulf War [letter; comment] Leisure KM, et al. **Emerg Infect Dis** 1998 Oct-Dec; 4(4):707–9. Comment on: Emerg Infect Dis 1998 Apr-Jun;4(2):211–9.

Value of inpatient diagnostic CCTV-EEG monitoring in the elderly. Drury I, et al. **Epilepsia** 1999 Aug;40(8):1100–2

Three-year follow-up of child psychiatric inpatient treatment. Sourander A, et al. **Eur Child Adolesc Psychiatry** 1998 Sep;7(3):153–62

The coronary care unit: a 35-year perspective [editorial; comment] Alpert JS. **Eur Heart J** 1999 Jun;20(11):784–5 . Comment on: Eur Heart J 1999 Jun;20(11):813–8. Comment on: Eur Heart J 1999 Jun;20(11):819–25.

Ruling out acute myocardial infarction early with two serial creatine kinase-MBmass determinations [see comments] de Winter RJ, et al. **Eur Heart J** 1999 Jul;20(13):967–72. Comment in: Eur Heart J 1999 Jul;20(13):925–7.

Can negative results for protein markers of myocardial damage justify discharge of acute chest pain patients after a few hours in hospital? [editorial; comment] Noble MI. **Eur Heart J** 1999 Jul;20(13):925–7. Comment on: Eur Heart J 1999 Jul;20(13):967–72.

Validation of a self-administered form for recording food intake in hospital patients. Førli L, et al. **Eur J Clin Nutr** 1998 Dec;52(12):929–33

Protein-calorie malnutrition does not predict subtle vitamin K depletion in hospitalized patients. Jatoi A, et al. **Eur J Clin Nutr** 1998 Dec;52(12):934–7

Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy [see comments] Menniti-Ippolito F, et al. **Eur J Clin Pharmacol** 1998 Jul; 54(5):393–7. Comment in: Eur J Clin Pharmacol 1999 Mar;55(1):81, 83.

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Soriano V, et al. **Eur J Epidemiol** 1999 Jan;15(1):1–4

Caring for hospital patients is invaluable experience [letter; comment] Zervanos NJ. **Fam Med** 1998 Nov-Dec; 30(10):694. Comment on: Fam Med 1998 Jul-Aug;30(7):517–8.

Hospital-treated psychiatric disorders in adults with a single-parent and two-parent family background: a 28-year follow-up of the 1966 Northern Finland Birth Cohort. Mäkikyrö T, et al. **Fam Process** 1998 Fall;37(3):335–44

Safety and feasibility of coronary stenting during rescue PTCA: in-hospital outcome. Repetto S, et al. **G Ital Cardiol** 1999 Jun;29(6):630–6

The meaning of hospital care, as narrated by elderly patients with chronic heart failure. Ekman I, et al. **Heart Lung** 1999 May-Jun;28(3):203–9

Crucial decision points in hospital care. Steen P. **Hosp Pract (Off Ed)** 1999 Jan 15;34(1):107–8, 111

Prevalence of rotavirus diarrhoea among hospitalized children in Pune, India. Kelkar SD, et al. **Indian J Med Res** 1999 Apr;109:131–5

Hospital-resource utilization and tuberculosis [editorial; comment] Brennan PJ. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):744–6. Comment on: Infect Control Hosp Epidemiol 1998 Oct;19(10):747–53.

Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. Torgerson JS, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23(2):190–7

An exploration of psychiatric nurses' and patients' opinions regarding in-patient care for suicidal patients. McLaughlin C. **J Adv Nurs** 1999 May;29(5):1042–51

Deconstructing the language of psychiatric hospitalization. Mohr WK. **J Adv Nurs** 1999 May;29(5):1052–9

The meaning of suicidal psychiatric in-patients' experiences of being cared for by mental health nurses. Talseth AG, et al. **J Adv Nurs** 1999 May;29(5):1034–41

Is diagnosis relevant in the hospitalization of potentially dangerous children and adolescents? Gutterman EM. **J Am Acad Child Adolesc Psychiatry** 1998 Oct; 37(10):1030–7; discussion 1038–40

Fatty acid nutriture in hospitalized elderly women. Schmuck A, et al. **J Am Coll Nutr** 1998 Oct;17(5):448–53

Protein-energy undernutrition and the risk of mortality within six years of hospital discharge. Sullivan DH, et al. **J Am Coll Nutr** 1998 Dec;17(6):571–8

Nutrition education needs an appropriate setting [letter; comment] Antzis LE. **J Am Diet Assoc** 1999 Jul;99(7):793 Comment on: J Am Diet Assoc 1998 Dec;98(12):1400; discussion 1402.

The relationship between clinical assessments of nutritional status and adverse outcomes in older hospitalized medical patients. Covinsky KE, et al. **J Am Geriatr Soc** 1999 May; 47(5):532–8

Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. Parker SE, et al. **J Antimicrob Chemother** 1998 Sep;42(3):373–80

Dose-response characteristics of nebulized albuterol in the treatment of acutely ill, hospitalized asthmatics. Ciccolella DE, et al. **J Asthma** 1999 Sep;36(6):539–46

Extremely high levels of alkaline phosphatase in hospitalized patients. Maldonado O, et al. **J Clin Gastroenterol** 1998 Dec;27(4):342–5

Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn JA, et al. **J Clin Psychiatry** 1998 Dec; 59(12):657–63

IgM antibodies in hospitalized children with febrile illness during an inter-epidemic period of measles, in Somalia. Nur YA, et al. **J Clin Virol** 1999 Jan;12(1):21–5

Preventing delirium in hospitalized older patients. Epling J, et al. **J Fam Pract** 1999 Jun;48(6):417–8

Survival after in-hospital cardiopulmonary resuscitation. A meta-analysis. Ebell MH, et al. **J Gen Intern Med** 1998 Dec;13(12):805–16

Older persons' preferences for site of treatment in acute illness. Fried TR, et al. **J Gen Intern Med** 1998 Aug; 13(8):522–7

Risk factors for falls in hospitalized older medical patients. Chu LW, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jan; 54(1):M38–43

Use of an ambulation assistive device predicts functional decline associated with hospitalization. Mahoney JE, et al. **J Gerontol A Biol Sci Med Sci** 1999 Feb;54(2):M83–8

Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous

pharmacologic circulatory support. Gronda EG, et al. **J Heart Lung Transplant** 1999 Jul;18(7):654–63

Thiamin and riboflavin status of medical inpatients. Songchitsomboon S, et al. **J Med Assoc Thai** 1998 Dec; 81(12):931–7

Comorbid mood disorders as modifiers of treatment response among inpatients with borderline personality disorder. Goodman G, et al. **J Nerv Ment Dis** 1998 Oct; 186(10):616–22

Perceived abuse and neglect as risk factors for suicidal behavior in adolescent inpatients. Lipschitz DS, et al. **J Nerv Ment Dis** 1999 Jan;187(1):32–9

Posttraumatic stress disorder symptoms related to psychosis and acute involuntary hospitalization in schizophrenic and delusional patients. Meyer H, et al. **J Nerv Ment Dis** 1999 Jun;187(6):343–52

Suicide in patients hospitalized for schizophrenia: 1913–1940. Stephens JH, et al. **J Nerv Ment Dis** 1999 Jan;187(1):10–4

High quality, cost-effective care for adolescents with pelvic inflammatory disease. Rich M. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):193–4

When to treat adolescents with pelvic inflammatory disease as outpatients. Shrier LA. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):191–2

Childhood antisocial behaviors as predictors of psychotic symptoms and DSM-III-R borderline criteria among inpatients with borderline personality disorder. Goodman G, et al. **J Personal Disord** 1999 Spring;13(1):35–46

Depression and social functioning in general hospital in-patients. Arolt V, et al. **J Psychosom Res** 1998 Aug; 45(2):117–26

The effectiveness of hospital at home compared with in-patient hospital care: a systematic review. Shepperd S, et al. **J Public Health Med** 1998 Sep;20(3):344–50 (20 ref.)

Malnutrition in hospitals: a report on the Professorial Inaugural Lecture, delivered by Professor Susan Holmes presented at Canterbury Christ Church College, June 17th 1998. Brandon H. **J R Soc Health** 1998 Aug;118(4):245

Ambulatory cervical ripening in term pregnancy. Upadhyaya NB, et al. **J Reprod Med** 1999 Apr;44(4):363–6

Does refrigeration of urine alter culture results in hospitalized patients with neurogenic bladders? Horton JA 3rd, et al. **J Spinal Cord Med** 1998 Oct;21(4):342–7

Correlates of protracted homelessness in a sample of dually diagnosed psychiatric inpatients. Leal D, et al. **J Subst Abuse Treat** 1999 Mar;16(2):143–7

Predictive versus measured energy expenditure using limits-of-agreement analysis in hospitalized, obese patients. Glynn CC, et al. **JPEN J Parenter Enteral Nutr** 1999 May-Jun;23(3):147–54

Paramedic direct admission of heart-attack patients to a coronary-care unit [letter] [see comments] Sandler DA. **Lancet** 1998 Oct 10;352(9135):1198. Comment in: Lancet 1998 Dec 19–26;352(9145):2017–8; discussion 2018–9. Comment in: Lancet 1998 Dec 19–26;352(9145):2018–9.

The dark at the bottom of the stairs: performance and participation of hospitalized older people. Latimer J. **Med Anthropol Q** 1999 Jun;13(2):186–213

Carepartner experiences with hospital care. vom Eigen KA, et al. **Med Care** 1999 Jan;37(1):33–8

Insurance and inpatient utilization for HIV: better answers, still further questions [editorial; comment] Wu AW. **Med Care** 1999 Apr;37(4):325–8. Comment on: Med Care 1999 Mar;37(3):220–7.

Recognising clinical instability in hospital patients before cardiac arrest or unplanned admission to intensive care. A pilot study in a tertiary-care hospital [see comments] Buist MD, et al. **Med J Aust** 1999 Jul 5;171(1):22–5. Comment in: Med J Aust 1999 Jul 5;171(1):8–9.

Hospital in the home: a randomised controlled trial [see comments] Caplan GA, et al. **Med J Aust** 1999 Feb 15; 170(4):156–60. Comment in: Med J Aust 1999 Feb 15;170(4):148–9. Comment in: ACP J Club 1999 Jul-Aug;131(1):7.

A multicomponent intervention to prevent delirium in hospitalized older patients [see comments] Inouye SK, et al. **N Engl J Med** 1999 Mar 4;340(9):669–76. Comment in: N Engl J Med 1999 Mar 4;340(9):720–1. Comment in: N Engl J Med 1999 Jul 29;341(5):369; discussion 370. Comment in: N Engl J Med 1999 Jul 29;341(5):369–70; discussion 370. Comment in: N Engl J Med 1999 Jul 29;341(5):370.

Delirium in hospitalized older patients [letter; comment] Leff B. **N Engl J Med** 1999 Jul 29;341(5):369; discussion 370. Comment on: N Engl J Med 1999 Mar 4;340(9):669–76.

Geriatrics, prevention, and the remodeling of Medicare [editorial; comment] [see comments] Rowe JW. **N Engl J Med** 1999 Mar 4;340(9):720–1. Comment on: N Engl J Med 1999 Mar 4;340(9):669–76. Comment in: N Engl J Med 1999 Jul 29;341(5):369–70; discussion 370.

Management of stroke in Auckland Hospital in 1996. Charleston AJ, et al. **N Z Med J** 1999 Mar 12; 112(1083):71–4

The elderly dialysis patient: management of the hospital stay. Röhrich B, et al. **Nephrol Dial Transplant** 1998;13 Suppl 7:69–72

A patient-centered model of acute care for elders. Kresevic DM, et al. **Nurs Clin North Am** 1998 Sep;33(3):515–27 (6 ref.)

Adult emergency visits for chronic cardiorespiratory disease: does dyspnea matter? Parshall MB. **Nurs Res** 1999 Mar-Apr;48(2):62–70

An evaluation of resting energy expenditure in hospitalized, severely underweight patients. Ahmad A, et al. **Nutrition** 1999 May;15(5):384–8

Patient education: reaching the Hispanic community. Surath Y, et al. **Oncol Nurs Forum** 1999 Jun;26(5):834

Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost. Oster G. **Oncology (Huntingt)** 1999 Jul;13(7 Suppl 3):41

Severe pneumonia. When and why to hospitalize. Kohler RB. **Postgrad Med** 1999 Apr;105(4):117–24 (19 ref.)

Smokers hospitalized in an urban, public hospital: addiction, stages of change, and self-efficacy. Vernon JD, et al. **Prev Med** 1999 May;28(5):488–95

Suicidal inpatients' perceptions of therapeutic and nontherapeutic aspects of constant observation. Cardell R, et al. **Psychiatr Serv** 1999 Aug;50(8):1066–70

Word-association patterns of mental hospital patients. Klionsky EJ, et al. **Psychol Rep** 1998 Dec;83(3 Pt 2):1419–24

Use of the SF-36 to identify community dwelling rural elderly at risk for hospitalization. Benjamin-Coleman R, et al. **Public Health Nurs** 1999 Jun;16(3):223–7

Hospitalization for lung disease in early childhood and asthma symptoms in young adulthood. Svanes C, et al. **Respir Med** 1998 Aug;92(8):1003–9

Increased use of inhaled corticosteroids and reduced hospitalizations in adult asthmatics: 11 years' experience in a Japanese hospital. Ishihara K, et al. **Respirology** 1998 Sep;3(3):193–7

Plasma N-terminal atrial natriuretic peptide predicts hospitalization in patients with heart failure. Dickstein K, et al. **Scand Cardiovasc J** 1998;32(6):361–4

Emotional reactivity and debilitating beliefs during hospitalization predict future adjustment to first myocardial infarction in men. Melamed S, et al. **Scand J Rehabil Med** 1999 Mar;31(1):23–30

Postoperative complications and unanticipated hospital admissions. Westman HR. **Semin Pediatr Surg** 1999 Feb; 8(1):23–9

A pilot study evaluating the effectiveness of individual inpatient cognitive-behavioural therapy in early psychosis. Haddock G, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 May;34(5):254–8

Use of hospital services, religious attendance, and religious affiliation. Koenig HG, et al. **South Med J** 1998 Oct; 91(10):925–32

First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma [see comments] Blais L, et al. **Thorax** 1998 Dec;53(12):1025–9 . Comment in: Thorax 1998 Dec;53(12):1005–6.

[Assessment of the need for and length of hospitalization at the internal medicine department] Hroboň P, et al. **Vnitr Lek** 1998 Sep;44(9):541–6 (Eng. Abstr.) **(Cze)**

[Proceedings of the 1st International Meeting on Hospital Toxicology. Liege, 22–23 October 1998] **Acta Clin Belg Suppl** 1999;1:1–100 **(Fre)**

[Assessment of sub-clinical thyroid disfunction in aged hospitalized patients in Limousin] Teissier MP, et al. **Ann Endocrinol (Paris)** 1999 Mar;60(1):23–32 (Eng. Abstr.) **(Fre)**

[Quality of the care of the pediatric patient admitted to the emergency room] Bodart E, et al. **Arch Pediatr** 1998 Dec; 5(12):1334–7 (Eng. Abstr.) **(Fre)**

[Depression and somatic diseases. On one retrospective study of 210 patients with major depression hospitalized in a psychiatric hospital] Bigot T, et al. **Encephale** 1999 Jan-Feb;25(1):3–10 (Eng. Abstr.) **(Fre)**

[Surgical management of non-palpable breast lesions in ambulatory care] Guihard P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul;28(4):330–4 (Eng. Abstr.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of a regional hospitalization agency director] Péricard B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:220–3 **(Fre)**

[Optimizing antibiotic therapy in a hospital setting] Guérin JM. **Presse Med** 1999 Jan 9;28(1):20–8 (57 ref.) (Eng. Abstr.) **(Fre)**

[Iatrogenic nosocomial drug-induced conditions: where is the risk? (editorial)] Schmitt E. **Presse Med** 1999 May 15; 28(18):970–2 **(Fre)**

[Management of community-acquired lower respiratory infections. Management in the hospital] Chidiac C. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S11–2 **(Fre)**

[Thinking about death inside a hospital institution] Leclerc P. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S200–1 **(Fre)**

[Hospitalization of alcoholics is of primary importance. Interview] Tretter F. **Fortschr Med** 1999 Mar 10; 117(7):30–1 **(Ger)**

[Patient satisfaction-subjective quality assessment by patients and success factor for clinics] Olandt H, et al. **Gesundheitswesen** 1998 Dec;60(12):721–8 (Eng. Abstr.) **(Ger)**

[Quality control of medical documentation of in-patients at the St. Stephen Municipal Hospital in Budapest] Keller L, et al. **Orv Hetil** 1999 Mar 14;140(11):593–6 (Eng. Abstr.) **(Hun)**

[Preoperative bowel cleansing: outpatient versus inpatient preparation] Tocchi A, et al. **G Chir** 1998 Nov-Dec; 19(11-12):463–5 (Eng. Abstr.) **(Ita)**

[The management of syncope in the hospital: the OESIL Study (Osservatorio Epidemiologico della Sincope nel Lazio)] Ammirati F, et al. **G Ital Cardiol** 1999 May; 29(5):533–9 (Eng. Abstr.) **(Ita)**

[OTTO: the Intra-Hospital Organization of and Time to the Treatment of Acute Myocardial Infarct. A regional multicenter observational study. ANMCO Regionale Piemonte e Valle d'Aosta] Ferrero V, et al. **G Ital Cardiol** 1999 Jun;29(6):714–8 **(Ita)**

[The use of HIV-1 protease inhibitors. Their effects on AIDS-correlated outpatient and hospitalization activities. A catchment area study] Resta F, et al. **Recenti Prog Med** 1998 Dec;89(12):623–4 (Eng. Abstr.) **(Ita)**

[Risk factors for sudden death during hospitalization] Tsukamoto H, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):825–9 (Eng. Abstr.) **(Jpn)**

[Risk factors for persistent diarrhea in hospitalized children] Pinto EA, et al. **Arq Gastroenterol** 1998 Apr-Jun; 35(2):126–31 (Eng. Abstr.) **(Por)**

[The prevalence of viral hepatitis markers in patients hospitalized in infectious disease wards with a diagnosis of acute viral hepatitis] Bălan A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec; 43(4):247–53 (Eng. Abstr.) **(Rum)**

[The hospitalization of elderly mental patients in relation to the different forms of dispensary observation] Ognev AE, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999; 99(7):49–51 (Eng. Abstr.) **(Rus)**

[Reduction in the number of hospitalizations for asthma. Quality assurance program for the management of asthma crises in a district hospital] Díaz Vázquez C, et al. **An Esp Pediatr** 1998 Nov;49(5):456–60 (Eng. Abstr.) **(Spa)**

[Is it necessary to hospitalize so many children for so many days? Unnecessary pediatric hospitalization] Oterino de la Fuente D, et al. **An Esp Pediatr** 1999 Apr;50(4):373–8 (Eng. Abstr.) **(Spa)**

[Impact of HIV infection in hospital environment] Martínez Avilés P, et al. **An Med Interna** 1998 Dec;15(12):633–7 (Eng. Abstr.) **(Spa)**

[Stays occasioned by patients hospitalized in internal medicine services] Obón Azuara B, et al. **An Med Interna** 1999 Feb;16(2):76–82 (Eng. Abstr.) **(Spa)**

[The effect of human immunodeficiency virus infection on the consumption of hospital resources. A correlation with the degree of immunodeficiency] Rovira Daudí E, et al. **An Med Interna** 1999 Jan;16(1):8–14 (Eng. Abstr.) **(Spa)**

[Community-acquired pneumonia referred for hospital management. Its epidemiology and the diagnostic and therapeutic approaches] Carretero Gracia JA, et al. **Arch Bronconeumol** 1999 Jan;35(1):27–32 (Eng. Abstr.) **(Spa)**

[Avoidable pediatric hospitalization in the Community of Valencia and Catalonia] Casanova Matutano C, et al. **Gac Sanit** 1998 Jul-Aug;12(4):160–8 (Eng. Abstr.) **(Spa)**

[Hospitalization versus ambulatory treatment of patients with upper digestive tract hemorrhage not connected to portal hypertension (comment)] Benages A, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):420–1. Comment on: Gastroenterol Hepatol 1998 Apr;21(4):194–5. **(Spa)**

[The epidemiological surveillance of human immunodeficiency virus (HIV) infection in a hospital population of Catalonia. Collaborators in the VIHHOSP project] Blanch C, et al. **Med Clin (Barc)** 1998 Dec 5; 111(19):731–5 (Eng. Abstr.) **(Spa)**

[The night hospital: another alternative to traditional hospitalization (letter)] del Castllo Rueda A. **Med Clin (Barc)** 1999 Feb 6;112(4):159 **(Spa)**

[Effects of environmental factors on the number of emergency admissions to the Hospital Complex Juan Canalejo in La Coruña: creation of a prediction model] Lage Ferrón MB, et al. **Rev Esp Salud Publica** 1999 Jan-Feb;73(1):45–60 (Eng. Abstr.) **(Spa)**

[Mortality risk factors in patients over 65 years of age hospitalized in a São Paulo, Brasil university hospital] Martins SJ, et al. **Rev Panam Salud Publica** 1999 Jun; 5(6):386–91 (Eng. Abstr.) **(Spa)**

ECONOMICS

Medications used for paediatric HIV infection in the USA, 1991-1992. Hsia DC. **AIDS Care** 1998 Dec;10(6):761–70

Study quantifies impact of resistant Pseudomonas on outcomes [news] Kepple SR. **Am J Health Syst Pharm** 1999 Jul 15;56(14):1392

Geographic variation in expenditures for Workers' Compensation hospitalized claims. Miller TR, et al. **Am J Ind Med** 1999 Feb;35(2):103–11

A comparison of generalist and pulmonologist care for patients hospitalized with severe chronic obstructive pulmonary disease: resource intensity, hospital costs, and survival. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Regueiro CR, et al. **Am J Med** 1998 Nov; 105(5):366–72

Service utilization and cost of community care for discharged state hospital patients: a 3-year follow-up study. Rothbard AB, et al. **Am J Psychiatry** 1999 Jun;156(6):920–7

Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935–7

Clinical and financial impact of intravenous erythromycin therapy in hospitalized patients. Classen DC, et al.

Ann Pharmacother 1999 Jun;33(6):669–73

Managed care and end-of-life decisions: learning to live ungagged [see comments] Kuczewski MG, et al. **Arch Intern Med** 1998 Dec 7–21;158(22):2424–8. Comment in: Arch Intern Med 1998 Dec 7–21;158(22):2419–22.

Home-based versus hospital-based care for serious mental illness. Controlled cost-effectiveness study over four years. Knapp M, et al. **Br J Psychiatry** 1998 Jun;172:506–12

Estimation of costs due to hospitalization for first-ever stroke patients in northern Taiwan. Chiu L, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 May;62(5):261–7

Admission to hospitals with on-site cardiac catheterization facilities :impact on long-term costs and outcomes. Krumholz HM, et al. **Circulation** 1998 Nov 10; 98(19):2010–6

Hospitalization costs associated with leiomyoma. Zhao SZ, et al. **Clin Ther** 1999 Mar;21(3):563–75

Comparison of long-term care in an acute care institution and in a long-term care institution. Friedman R, et al. **CMAJ** 1998 Nov 3;159(9):1107–13

The health and cost effects of substituting home care for inpatient acute care: a review of the evidence [see comments] Soderstrom L, et al. **CMAJ** 1999 Apr 20; 160(8):1151–5 (36 ref.). Comment in: CMAJ 1999 Aug 24;161(4):365–6.

The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Lyman GH, et al. **Eur J Cancer** 1998 Nov;34(12):1857–64

The effect of user charges and socio-demographic environment on paediatric trauma hospitalisation in Helsinki in 1989–1994. Ahlamaa-Tuompo J. **Eur J Epidemiol** 1999 Feb;15(2):133–9

Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. Bennett SJ, et al. **Heart Lung** 1999 Mar–Apr;28(2):102–9

Economic effects of community versus hospital-based faculty pneumonia care [see comments] Stein MD, et al. **J Gen Intern Med** 1998 Nov;13(11):774–7. Comment in: J Gen Intern Med 1998 Nov;13(11):783–5.

Detection and treatment of psychiatric illness in a general medical ward: a modified cost-benefit analysis [see comments] Gater RA, et al. **J Psychosom Res** 1998 Nov; 45(5):437–48. Comment in: J Psychosom Res 1998 Nov;45(5):433–6.

The lesson of Icarus [letter; comment] Levenson JL. **J Psychosom Res** 1998 Nov;45(5):433–6. Comment on: J Psychosom Res 1998 Nov;45(5):437–48.

Direct medical charges associated with myocardial infarction in patients with and without diabetes. Smith TL, et al. **Med Care** 1999 Apr;37(4 Suppl Lilly):AS4–11

The casemix system of hospital funding can further disadvantage Aboriginal children. Ruben AR, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S6–10

The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants [see comments] Muennig P, et al. **N Engl J Med** 1999 Mar 11;340(10):773–9. Comment in: N Engl J Med 1999 Jul 29;341(5):377; discussion 378. Comment in: N Engl J Med 1999 Jul 29;341(5):377–8.

Replacing abdominally implanted defibrillators: effect of procedure setting on cost. Vorperian VR, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):698–705

Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT). Law B, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):7–14

Hospitalized low-risk community-acquired pneumonia: outcome and potential for cost-savings. Hoe LK, et al. **Respirology** 1999 Sep;4(3):307–9

'Unfettered' hospitalisation in private sector no longer possible [news] Permain D. **S Afr Med J** 1998 Aug; 88(8):932, 934

Demographic and socio-economic determinants of community and hospital services costs for people with HIV/AIDS in London. Kupek E, et al. **Soc Sci Med** 1999 May;48(10):1433–40

Decreasing costs of stroke hospitalization in Toronto [letter] Tran C, et al. **Stroke** 1999 Jan;30(1):185–6

[Family expenses caused by pediatric hospitalization in Niamey (Niger)] Barennes H, et al. **Sante** 1998 Nov–Dec; 8(6):405–10 (Eng. Abstr.) **(Fre)**

[What is the cost of inappropriate admission of pneumonia patients?] González-Moraleja J, et al. **Arch Bronconeumol** 1999 Jul–Aug;35(7):312–6 (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Medicolegal errors in the ED related to the involuntary confinement of psychiatric patients. Reeves RR, et al. **Am J Emerg Med** 1998 Nov;16(7):631–3

A clinical study of competency in child psychiatric inpatients. Billick SB, et al. **J Am Acad Psychiatry Law** 1998; 26(4):587–94

Sexual predators. Zonana HV, et al. **Psychiatr Clin North Am** 1999 Mar;22(1):109–27, vii (68 ref.)

Sexual predators and the abuse of psychiatry [editorial; comment] Maier GJ. **Psychiatr Serv** 1999 Mar;50(3):295. Comment on: Psychiatr Serv 1999 Mar;50(3):349–61.

[Psychiatric hospitalizations after the June 27 1990 Law in a French department] Gisselmann A, et al. **Encephale** 1998 Nov-Dec;24(6):517–21 (Eng. Abstr.) **(Fre)**

[Hospitalization in the prison milieu. Postpenal consultations] Niveau G. **Rev Med Suisse Romande** 1999 Aug; 119(8):666–9 **(Fre)**

[Third party hospitalization request and mandatory placement, guardianship, trusteeship, legal protection] Garré JB, et al. **Rev Prat** 1998 Jan 15;48(2):187–91 **(Fre)**

[The number of beds needed for patients with infectious diseases that require hospitalization by law] Nakamura Y, et al. **Nippon Koshu Eisei Zasshi** 1998 Dec;45(12):1137–41 (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

Retrospective review of emergency department patients with non-variceal upper gastrointestinal hemorrhage for potential outpatient management. Tham KY, et al. **Acad Emerg Med** 1999 Mar;6(3):196–201

Burden of human rotavirus-associated hospitalizations in three geographic regions of Hungary. Szücs G, et al. **Acta Paediatr Suppl** 1999 Jan;88(426):61–5

Impact of rotavirus disease in Spain: an estimate of hospital admissions due to rotavirus. Visser LE, et al. **Acta Paediatr Suppl** 1999 Jan;88(426):72–6

Increasing rates of hospital admission for men with major mental illnesses: data from Scottish mental health units, 1980–1995. Cavanagh JT, et al. **Acta Psychiatr Scand** 1999 May;99(5):353–9

The Nordic Comparative Study on Sectorized Psychiatry--length of in-patient stay. Oiesvold T, et al. **Acta Psychiatr Scand** 1999 Sep;100(3):220–8

A risk-adjusted measure of hospitalization rates for evaluating community mental health program performance. Banks SM, et al. **Adm Policy Ment Health** 1999 Mar; 26(4):269–79

The use of general practitioner elderly beds in community hospitals [letter] Rhodes KM, et al. **Age Ageing** 1998 Nov; 27(6):753

The impact of highly active antiretroviral therapy on HIV-related hospitalizations in 17 county hospitals in Catalonia, Spain. Catalonian County Hospitals HIV Infection Study Group [letter] Altés J, et al. **AIDS** 1999 Jul 30;13(11):1418–9

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. Paul S, et al. **AIDS** 1999 Feb 25;13(3):415–8

Prevalence of HIV infection among hospital patients in north west Tanzania. Kwesigabo G, et al. **AIDS Care** 1999 Feb; 11(1):87–93

Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Alexander M, et al. **Am Heart J** 1999 May;137(5):919–27

Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients. Ofili EO, et al. **Am J Cardiol** 1999 May 1;83(9):1350–5

Impact of home health care on health care costs and hospitalization frequency in patients with heart failure. Wilson JR, et al. **Am J Cardiol** 1999 Feb 15;83(4):615–7, A10

Morbidity and mortality of hospitalized patients after the 1995 Hanshin-Awaji earthquake. Tanaka H, et al. **Am J Emerg Med** 1999 Mar;17(2):186–91

The postwar hospitalization experience of Gulf War Veterans possibly exposed to chemical munitions destruction at Khamisiyah, Iraq. Gray GC, et al. **Am J Epidemiol** 1999 Sep 1;150(5):532–40

Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Kajdasz DK, et al. **Am J Epidemiol** 1999 Aug 1; 150(3):271–8

Recurrence in affective disorder: analyses with frailty models. Kessing LV, et al. **Am J Epidemiol** 1999 Mar 1; 149(5):404–11

A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease [see comments] Almqvist EW, et al. **Am J Hum Genet** 1999 May;64(5):1293–304. Comment in: Am J Hum Genet 1999 May;64(5):1289–92.

IX. Hospitalization in ESRD. **Am J Kidney Dis** 1999 Aug; 34(2 Suppl 1):S114–23

Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. Neylan JF, et al. **Am J Kidney Dis** 1998 Nov; 32(5):770–7

Hospitalization for motor vehicle injuries among American Indians and Alaska Natives in Washington. Sullivan M, et al. **Am J Prev Med** 1999 Jul;17(1):38–42

The importance of continuity of care in the likelihood of future hospitalization: is site of care equivalent to a primary clinician? Mainous AG 3rd, et al. **Am J Public Health** 1998 Oct;88(10):1539–41

Hospital volume and survival of breast cancer patients in Connecticut [letter] Polednak AP. **Am J Public Health** 1999 Jun;89(6):946–7

Driving through: postpartum care during World War II. Temkin E. **Am J Public Health** 1999 Apr;89(4):587–95

Outpatient laparoscopic cholecystectomy: what predicts the need for admission? Simpson JP, et al. **Am Surg** 1999 Jun; 65(6):525–8; discussion 529

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Nichol KL, et al. **Ann Intern Med** 1999 Mar 2;130(5):397–403

Complications of varicella in a defined central European population. Jaeggi A, et al. **Arch Dis Child** 1998 Dec; 79(6):472–7

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Rosenheck R, et al. **Arch Gen Psychiatry** 1999 Jun;56(6):565–72

Benefits of influenza vaccination for bedridden patients [letter] Fukushima T, et al. **Arch Intern Med** 1999 Jun 14; 159(11):1258

Acute care hospital utilization by patients with visual impairment. Morse AR, et al. **Arch Ophthalmol** 1999 Jul; 117(7):943–9

Congenital airway abnormalities in patients requiring hospitalization. Altman KW, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):525–8

How commonly are children hospitalized for asthma eligible for care in alternative settings? McConnochie KM, et al. **Arch Pediatr Adolesc Med** 1999 Jan;153(1):49–55

Impact of respiratory syncytial virus immune globulin in 1996–1997: a local controlled comparison. Redding GJ, et al. **Arch Pediatr Adolesc Med** 1999 May;153(5):503–7

Utilization of healthcare resources for asthma in Singapore: demographic features and trends. Chew FT, et al. **Asian Pac J Allergy Immunol** 1998 Jun–Sep;16(2–3):57–68

Length of stay, leave and re-offending by patients from a Queensland security patients hospital. Green B, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):839–47

Delirium in hospital: does it increase length of stay? Stevens LE, et al. **Aust N Z J Psychiatry** 1998 Dec;32(6):805–8

Hospital use for potentially preventable conditions in aboriginal and Torres Strait Islander and other Australian populations. Stamp KM, et al. **Aust N Z J Public Health** 1998 Oct;22(6):673–8

Socio-economic, migrant and geographic differentials in coronary heart disease occurrence in New South Wales. Taylor R, et al. **Aust N Z J Public Health** 1999 Feb; 23(1):20–6

Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. Chandna SM, et al. **BMJ** 1999 Jan 23; 318(7178):217–23

Measuring quality of care with routine data: avoiding confusion between performance indicators and health outcomes [see comments] Giuffrida A, et al. **BMJ** 1999 Jul 10;319(7202):94–8. Comment in: BMJ 1999 Jul 10;319(7202):67–8.

What do hospital admission rates say about primary care? [editorial; comment] Jankowski R. **BMJ** 1999 Jul 10; 319(7202):67–8. Comment on: BMJ 1999 Jul 10;319(7202):94–8. Comment on: BMJ 1999 Jul 10;319(7202):98–103.

Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study. Melville M, et al. **BMJ** 1999 Jul 24;319(7204):230–1

Admissions for depression have not increased among men in Republic of Ireland [letter; comment] Walsh D. **BMJ** 1998 Oct 24;317(7166):1158. Comment on: BMJ 1998 May 16;316(7143):1496–7.

Hospital outcome measures following assertive community treatment in Edmonton, Alberta. Tibbo P, et al. **Can J Psychiatry** 1999 Apr;44(3):276–9

Hospital utilization of Saskatchewan people with fetal alcohol syndrome. Loney EA, et al. **Can J Public Health** 1998 Sep–Oct;89(5):333–6

Morbidity and mortality related to human immunodeficiency virus in Canadian men and women, 1987–94. Weber AE, et al. **Can J Public Health** 1999 Mar–Apr;90(2):127–32

Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior. Major S, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):450–61

Rates of adverse events among hospital admissions and day surgeries in Ontario from 1992 to 1997 [letter] Hunter D, et al. **CMAJ** 1999 Jun 1;160(11):1585–6

Rethinking the numbers on adverse drug reactions [letter; comment] Lexchin J. **CMAJ** 1999 May 18;160(10):1432. Comment on: CMAJ 1999 Feb 9;160(3):350–1.

Do diabetes clinic attendees stay out of hospital? A matched case-control study. Goyder EC, et al. **Diabet Med** 1999 Aug;16(8):687–91

Contra-indications to metformin therapy are largely disregarded. Holstein A, et al. **Diabet Med** 1999 Aug; 16(8):692–6

Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. Frost F, et al. **Emerg Infect Dis** 1998 Oct–Dec;4(4):619–25 (13 ref.)

Carbon monoxide and hospital admissions for congestive heart failure: evidence of an increased effect at low temperatures. Morris RD, et al. **Environ Health Perspect** 1998 Oct;106(10):649–53

Mortality and hospitalizations of 24-year-old members of the low-birthweight cohort in northern Finland. Xu B, et al. **Epidemiology** 1998 Nov;9(6):662–5

Suspected adverse drug events requiring emergency department visits or hospital admissions. Raschetti R, et al. **Eur J Clin Pharmacol** 1999 Feb;54(12):959–63

Basic characteristics of hospital stroke services in Eastern Hungary. Mihálka L, et al. **Eur J Epidemiol** 1999 May; 15(5):461–6

Seasonal variations in hospital treatment periods and deaths among adult asthmatics. Harju T, et al. **Eur Respir J** 1998 Dec;12(6):1362–5

Referral rates and waiting lists: some empirical evidence. Goddard JA, et al. **Health Econ** 1998 Sep;7(6):545–9

Current and future hospitalization after heart attack. Johansen H, et al. **Health Rep** 1998 Autumn;10(2):21–8 (Eng); 23–31 (Fre) **(Eng, Fre)**

Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations? Cromwell DM, et al. **Health Serv Res** 1999 Feb;33(6):1593–610

Incidence and duration of hospitalizations among persons with AIDS: an event history approach. Crystal S, et al. **Health Serv Res** 1999 Feb;33(6):1611–38

Hospitalizations for back and neck problems: a comparison between the Province of Ontario and Washington State. Taylor VM, et al. **Health Serv Res** 1998 Oct;33(4 Pt 1):929–45

Cost effective management programme for heart failure reduces hospitalisation [see comments] Cline CM, et al. **Heart** 1998 Nov;80(5):442–6. Comment in: Heart 1998 Nov;80(5):430–1. Comment in: ACP J Club 1999 May–Jun;130(3):81.

Spinal cord stimulation significantly decreases the need for acute hospital admission for chest pain in patients with refractory angina pectoris. Murray S, et al. **Heart** 1999 Jul; 82(1):89–92

Benchmarking guide '99. Solovy A. **Hosp Health Netw** 1999 Jan;73(1):49–54, 56, 58 passim

The prevalence of leg ulcers in hospitals. Barclay KM, et al. **Hosp Med** 1998 Nov;59(11):850

Resurgence of malaria in Calcutta in 1995: a hospital based study. Basu K, et al. **Indian J Public Health** 1998 Apr–Jun; 42(2):50–2

Impact of hospitalization on patients and their families. Subramanian T. **Indian J Public Health** 1998 Jan–Mar; 42(1):15–6

Unintentional poisoning hospitalisations among young children in Victoria. Hoy JL, et al. **Inj Prev** 1999 Mar; 5(1):31–5

Injury hospitalizations among American Indian youth in Washington. Johnson SJ, et al. **Inj Prev** 1999 Jun; 5(2):119–23

The course of childhood bronchiectasis: a case report and considerations of hospital use. Säynäjäkangas O, et al. **Int J Circumpolar Health** 1998 Oct;57(4):276–9

RSV-associated hospitalizations in Alaska Native infants. Singleton R, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:255–9

Drug-induced admissions to medical wards at Jordan University Hospital. Gharaibeh M, et al. **Int J Clin Pharmacol Ther** 1998 Sep;36(9):478–82

Dementia in the hospitalized elderly--a study of 100 consecutive cases in Singapore. Sahadevan S, et al. **Int J Geriatr Psychiatry** 1999 Apr;14(4):266–71

Variations in diagnostic and therapeutic intensity between home and conventional hospitalization. Oterino-de-la-Fuente D, et al. **Int J Qual Health Care** 1998 Aug;10(4):331–8

Hospitalization for mental illness in adolescents: risk groups and impact on the health care system. Chabra A, et al. **J Adolesc Health** 1999 May;24(5):349–56

Suicide attempts among formerly hospitalized adolescents: a prospective naturalistic study of risk during the first 5 years after discharge. Goldston DB, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jun;38(6):660–71

The changing status of inpatient dermatology at American academic dermatology programs. Kirsner RS, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):755–7

Who dies at home? Determinants of site of death for community-based long-term care patients. Fried TR, et al. **J Am Geriatr Soc** 1999 Jan;47(1):25–9

Use of physician and acute care services by persons with and without Alzheimer's disease: a population-based comparison. Leibson C, et al. **J Am Geriatr Soc** 1999 Jul; 47(7):864–9

Patterns of use of common major procedures in medical care of older adults. Levinsky NG, et al. **J Am Geriatr Soc** 1999 May;47(5):553–8

Gender differences in the sequelae of hospitalization for acute myocardial infarction among older adults. Wolinsky FD, et al. **J Am Geriatr Soc** 1999 Feb;47(2):151–8

Hematocrit levels and hospitalization risks in hemodialysis patients. Xia H, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1309–16

A comparison of asthma-related healthcare use between African-Americans and Caucasians belonging to a health maintenance organization (HMO). Blixen CE, et al. **J Asthma** 1999;36(2):195–204

Socioeconomic factors and asthma hospitalization rates in New York City. Claudio L, et al. **J Asthma** 1999 Jun; 36(4):343–50

Asthma hospitalization rates and socioeconomic status in New York State (1987–1993). Lin S, et al. **J Asthma** 1999 May;36(3):239–51

Association of dialyzer reuse with hospitalization and survival rates among U.S. hemodialysis patients: do comorbidities matter? Feldman HI, et al. **J Clin Epidemiol** 1999 Mar;52(3):209–17

Misclassification and under-reporting of acute myocardial infarction by elderly persons: implications for community-based observational studies and clinical trials. O'Donnell CJ, et al. **J Clin Epidemiol** 1999 Aug; 52(8):745–51

Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. Rawson NS, et al. **J Clin Epidemiol** 1998 Dec;51(12):1343–55

Distribution of Kala-azar cases treated in Delhi. Bora D, et al. **J Commun Dis** 1998 Mar;30(1):68–70

Nebulized ipratropium for children with acute asthma. Hachey D, et al. **J Fam Pract** 1999 Jan;48(1):12–3

Hospitalization and mortality rates for nursing home-acquired pneumonia. Thompson RS, et al. **J Fam Pract** 1999 Apr;48(4):291–3

Hospitalization and Alzheimer's disease: results from a community-based study. Albert SM, et al. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):M267–71

The risk of hospitalization for acute myocardial infarction among older adults. Wolinsky FD, et al. **J Gerontol A Biol Sci Med Sci** 1999 May;54(5):M254–61

Relationship between ambulatory care accessibility and hospitalization for persons with advanced HIV disease. Laine C, et al. **J Health Care Poor Underserved** 1999 Aug; 10(3):313–27

The psychological impact of psychiatric admission: some preliminary findings. Morrison AP, et al. **J Nerv Ment Dis** 1999 Apr;187(4):250–3

Hospitalization for pneumonia in children in Auckland, New Zealand. Grant CC, et al. **J Paediatr Child Health** 1998 Aug;34(4):355–9

Respiratory morbidity of hospitalized children with Trisomy 21. Hilton JM, et al. **J Paediatr Child Health** 1999 Aug; 35(4):383–6

Frequency, timing, and diagnoses of antenatal hospitalizations in women with high-risk pregnancies. Brooten D, et al. **J Perinatol** 1998 Sep–Oct;18(5):372–6

Prediction of hospitalizations by schizophrenia patients' assessment of treatment: an expanded study. Priebe S, et al. **J Psychiatr Res** 1999 Mar–Apr;33(2):113–9

Hospital use by an ageing cohort: an investigation into the association between biological, behavioural and social risk markers and subsequent hospital utilization. Hanlon P, et al. **J Public Health Med** 1998 Dec;20(4):467–76

Impact of infection on mortality and hospitalization in the North East of England. Wilson D, et al. **J Public Health Med** 1998 Dec;20(4):386–95

Diabetes and pregnancy. Preconception care, pregnancy outcomes, resource utilization and costs. Herman WH, et al. **J Reprod Med** 1999 Jan;44(1):33–8

Population-based analysis of 10,766 hospitalizations for mandibular fractures in California, 1991 to 1993. Azevedo AB, et al. **J Trauma** 1998 Dec;45(6):1084–7

Reasons for hospitalization due to abortion and pregnancy termination. de Souza AI, et al. **J Trop Pediatr** 1999 Feb; 45(1):31–6

From the Centers for Disease Control and Prevention. Firearm-associated deaths and hospitalizations--California, 1995–1996. **JAMA** 1999 Aug 18;282(7):627–8

Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group [see comments] Showstack J, et al. **JAMA** 1999 Apr 21;281(15):1381–6. Comment in: JAMA 1999 Apr 21;281(15):1431–2.

Protein-energy undernutrition among elderly hospitalized patients: a prospective study. Sullivan DH, et al. **JAMA** 1999 Jun 2;281(21):2013–9

Trends in hospitalization associated with traumatic brain injury [see comments] Thurman D, et al. **JAMA** 1999 Sep 8;282(10):954–7. Comment in: JAMA 1999 Sep 8;282(10):989–91.

Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Ikizler TA, et al. **Kidney Int** 1999 May; 55(5):1945–51

Facility characteristics associated with hospitalization of nursing home residents: results of a national study. Intrator O, et al. **Med Care** 1999 Mar;37(3):228–37

Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial. Lorig KR, et al. **Med Care** 1999 Jan;37(1):5–14

Effects of utilization management on patterns of hospital care among privately insured adult patients. Wickizer TM, et al. **Med Care** 1998 Nov;36(11):1545–54

Antenatal hospitalisations in New South Wales, 1995–96. Adelson PL, et al. **Med J Aust** 1999 Mar 1;170(5):211–5

Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993–1996 [letter; comment] Holmes WR. **Med J Aust** 1999 Feb 15; 170(4):189–90. Comment on: Med J Aust 1998 Sep 7;169(5):252–6.

Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Baum SE, et al. **Mil Med** 1999 Sep;164(9):609–12

Hospitalization of British troops during Operation Joint Endeavor (Bosnia). Croft AM, et al. **Mil Med** 1999 Jul; 164(7):460–5

Firearm-associated deaths and hospitalizations--California, 1995–1996. **MMWR Morb Mortal Wkly Rep** 1999 Jun 18; 48(23):485–8

Hospitalization for hip fractures among North Carolina's Medicare population. Schenck AP, et al. **N C Med J** 1999 May–Jun;60(3):149–51

The association between hospital volume and survival after acute myocardial infarction in elderly patients [see comments] Thiemann DR, et al. **N Engl J Med** 1999 May 27;340(21):1640–8. Comment in: N Engl J Med 1999 May 27;340(21):1677–9.

Alternate child care, history of hospitalization, and preschool child behavior. Youngblut JM, et al. **Nurs Res** 1999 Jan–Feb;48(1):29–34

What is the risk associated with being a qualified military parachutist? Bricknell MC, et al. **Occup Med (Lond)** 1999 Apr;49(3):139–45

Ward Six Psychiatric Unit at the Port Moresby General Hospital: a historical review and admission statistics from 1980 to 1989. Johnson FY. **P N G Med J** 1997 Jun; 40(2):79–88

Utilization analysis of an observation unit for children with asthma. Gouin S, et al. **Pediatr Emerg Care** 1999 Apr; 15(2):79–83

Clinical utility of polymerase chain reaction testing for enteroviral meningitis. Hamilton MS, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):533–7

Resource utilization associated with initial hospital stays complicated by early onset group B streptococcal disease. Platt R, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):529–33

Follow-up experience in pediatric liver transplantation in an academic, non-transplant-based gastroenterology group. Kessler B, et al. **Pediatr Transplant** 1999 Feb; 3(1):45–8

The safety of acetaminophen and ibuprofen among children younger than two years old. Lesko SM, et al. **Pediatrics** 1999 Oct;104(4):e39

Socioeconomic variation in asthma hospitalization: excess utilization or greater need? McConnochie KM, et al. **Pediatrics** 1999 Jun;103(6):e75

Perinatal risk factors for infant hospitalization with viral gastroenteritis. Newman RD, et al. **Pediatrics** 1999 Jan; 103(1):E3

Increase in admission threshold explains stable asthma hospitalization rates. Russo MJ, et al. **Pediatrics** 1999 Sep; 104(3 Pt 1):454–62

Smoking during pregnancy and hospitalization of the child. Wisborg K, et al. **Pediatrics** 1999 Oct;104(4):e46

Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Hamilton RA, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):1112–20

Involuntary first admission of patients with schizophrenia as a predictor of future admissions. Fennig S, et al. **Psychiatr Serv** 1999 Aug;50(8):1049–52

Counting the uninsured using state-level hospitalization data. Turner C, et al. **Public Health Rep** 1999 Mar–Apr; 114(2):149–56

Inpatient management of chronic obstructive pulmonary disease. Stoller JK, et al. **Respir Care Clin N Am** 1998 Sep; 4(3):425–38 (25 ref.)

Schizophrenia and seasonality of admissions: the northern Finland 1966 birth cohort study [letter] Räsänen P, et al. **Schizophr Res** 1999 Jan 11;35(2):183–5

An audit of admissions of patients with epilepsy to a district general hospital. Irving P, et al. **Seizure** 1999 May; 8(3):166–9

Suicide following an inpatient hospitalization for a suicide attempt: a Canadian follow-up study. Holley HL, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Nov; 33(11):543–51

The Bwamanda hospital insurance scheme: effective for whom? A study of its impact on hospital utilization patterns. Criel B, et al. **Soc Sci Med** 1999 Apr;48(7):897–911

Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. Cooper JW. **South Med J** 1999 May;92(5):485–90

Cumulative incidence of lumbar disc diseases leading to hospitalization up to the age of 28 years. Zitting P, et al. **Spine** 1998 Nov 1;23(21):2337–43; discussion 2343–4

Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment. Fugelstad A, et al. **Subst Use Misuse** 1998 Dec;33(14):2803–17

The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status. Stenbacka M, et al. **Subst Use Misuse** 1998 Dec; 33(14):2819–34

Relationship between hospital volume and late survival after pancreaticoduodenectomy. Birkmeyer JD, et al. **Surgery** 1999 Aug;126(2):178–83

Air pollution, pollens, and daily admissions for asthma in London 1987–92. Anderson HR, et al. **Thorax** 1998 Oct; 53(10):842–8

National hospital discharge survey: annual summary, 1996. Graves EJ, et al. **Vital Health Stat 13** 1999 Jan;(140):i–iv, 1–46

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Graves EJ, et al. **Vital Health Stat 13** 1998 Sep;(138):i–iii, 1–151 (16 ref.)

Ambulatory and inpatient procedures in the United States, 1996. Owings MF, et al. **Vital Health Stat 13** 1998 Nov; (139):1–119

[Alcohol-related admissions to a psychiatric departments] Jacobsen CW. **Ugeskr Laeger** 1999 Feb 1;161(5):602–5 (Eng. Abstr.) **(Dan)**

[Extrapulmonary tuberculosis in children in Abidjan (letter)]

Niangué-Beugré NM, et al. **Arch Pediatr** 1999 Mar; 6(3):341-2 **(Fre)**

[Precarious situation of obstetric practice in Gabon] Roudière JL. **Sante** 1998 Sep-Oct;8(5):325-9 (Eng. Abstr.) **(Fre)**

[Tuberculosis in children at the Tokoin University Medical Center of Lome, Togo. 202 cases in the pediatric service (1980-1990)] Agbére AR, et al. **Tunis Med** 1999 Mar; 77(3):149-53 **(Fre)**

[Hospital morbidity in the elderly in the Monastir health region (Tunisia)] Ben Salem K, et al. **Tunis Med** 1999 Apr; 77(4):209-14 (Eng. Abstr.) **(Fre)**

[Differences in average hospital stay in German inpatient institutions analysed on a regional basis before and after re-unification] Lebok U, et al. **Gesundheitswesen** 1999 Jun; 61(6):280-6 (Eng. Abstr.) **(Ger)**

[Impact of influenza A virus infection as a cause of pediatric hospitalization and use of rapid antigen test of influenza A virus] Mitamura K, et al. **Kansenshogaku Zasshi** 1998 Sep;72(9):883-9 (Eng. Abstr.) **(Jpn)**

[Substance abuse among patients in a department of general medicine] Iversen PO, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4348-52 (Eng. Abstr.) **(Nor)**

[Clinico-statistical analysis of chronic cardiac failure] Tereshchenko SN, et al. **Ter Arkh** 1999;71(1):42-6 (Eng. Abstr.) **(Rus)**

[Evaluating the influence of hospital size on respiratory health care efficiency in Andalusia] Galán González-Serna JM, et al. **Arch Bronconeumol** 1999 May;35(5):202-7 (Eng. Abstr.) **(Spa)**

[Hospital admission in ambulatory surgery: quality control system (editorial; comment)] Bassons Herbera J. **Med Clin (Barc)** 1999 Mar 20;112(10):377-8. Comment on: Med Clin (Barc) 1999 Mar 20;112(10):361-4. **(Spa)**

[Functional deterioration secondary to hospitalization for an acute disease in the elderly. An analysis of its incidence and the associated risk factors] Gutiérrez Rodríguez J, et al. **Rev Clin Esp** 1999 Jul;199(7):418-23 (Eng. Abstr.) **(Spa)**

[Admissions and mortality in a HIV unit before and after protease inhibitors (letter)] Soriano V, et al. **Rev Clin Esp** 1998 Oct;198(10):715 **(Spa)**

TRENDS

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. Mocroft A, et al. **AIDS** 1999 Jul 9; 13(10):1255-61

Costs and outcomes of hip fracture and stroke, 1984 to 1994. Sloan FA, et al. **Am J Public Health** 1999 Jun;89(6):935-7

Functional decline associated with hospitalization for acute illness. Sager MA, et al. **Clin Geriatr Med** 1998 Nov; 14(4):669-79

Trends in hospitalizations associated with gastroenteritis among adults in the United States, 1979-1995. Mounts AW, et al. **Epidemiol Infect** 1999 Aug;123(1):1-8

Opposing time trends of peptic ulcer and reflux disease. el-Serag HB, et al. **Gut** 1998 Sep;43(3):327-33

Hospital admission with childhood asthma--recent trends [letter] Loh NR, et al. **Ir Med J** 1998 Dec;91(6):215

Hospitalisation of the elderly during the last year of life: an application of record linkage in Western Australia 1985-1994. Brameld KJ, et al. **J Epidemiol Community Health** 1998 Nov;52(11):740-4

Changes in inpatient mental health utilization and costs in a privately insured population, 1993 to 1995 [see comments] Leslie DL, et al. **Med Care** 1999 May;37(5):457-68. Comment in: Med Care 1999 May;37(5):434-5.

Trends in hospitalization and mortality from rotavirus disease in New Zealand infants. Ardern-Holmes SL, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):614-9

Trends in diarrhea-associated hospitalizations among American Indian and Alaska native children, 1980-1995. Holman RC, et al. **Pediatrics** 1999 Jan;103(1):E11

Smoking trends in the United States between 1969 and 1995 based on patients hospitalized with non-smoking-related diseases. Zang EA, et al. **Prev Med** 1998 Nov-Dec; 27(6):854-61

Influence of patient's dressing on spontaneous physical activity and length of hospital stay in surgical patients. Despond O, et al. **Soz Praventivmed** 1999;44(1):8-13

Acute medical bed usage by nursing home residents. Beringer TR, et al. **Ulster Med J** 1999 May;68(1):27-9

[Differences in average hospital stay in German inpatient institutions analysed on a regional basis before and after re-unification] Lebok U, et al. **Gesundheitswesen** 1999 Jun; 61(6):280-6 (Eng. Abstr.) **(Ger)**

[Recent changes in emergency room visits and hospitalization for asthma in childhood] Benito Fernández J, et al. **An Esp Pediatr** 1998 Dec;49(6):577-81 (Eng. Abstr.) **(Spa)**

HOSPITALIZATION INSURANCE see **INSURANCE, HOSPITALIZATION**

HOSPITALIZATION, PARTIAL see **DAY CARE**

HOSPITALIZED CHILD see **CHILD, HOSPITALIZED**

HOSPITALS

see related
ECONOMICS, HOSPITAL

EQUIPMENT AND SUPPLIES, HOSPITAL
HOSPITAL ADMINISTRATION

Designing a comprehensive hospital-wide patient education program. Duffy MM. **Adv Ren Replace Ther** 1999 Jul; 6(3):289-93

Evaluating the protective value of hospital gowns... [letter; comment] Belkin NL. **Am J Infect Control** 1999 Apr; 27(2):178-9. Comment on: Am J Infect Control 1998 Apr;26(2):85-93.

Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95-7 (03 ref.)

Control of methicillin-resistant Staphylococcus aureus in the hospital setting. Herwaldt LA. **Am J Med** 1999 May 3; 106(5A):11S-18S; discussion 48S-52S (52 ref.)

Workplace violence. Carroll V. **Am J Nurs** 1999 Mar;99(3):60

BOMB! Making a difference during a hospital emergency. Wilkinson RM. **Am J Nurs** 1998 Oct;98(10):68-9

Setting goals for reductions in Canadian cesarean delivery rates: benchmarking medical practice patterns. Richman VV. **Am J Obstet Gynecol** 1999 Sep;181(3):635-7

Antibiotic resistance in Acinetobacter spp. isolated from sewers receiving waste effluent from a hospital and a pharmaceutical plant. Guardabassi L, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3499-502

Antibiotic susceptibility in the surgical intensive care unit compared with the hospital-wide antibiogram. Kaufman D, et al. **Arch Surg** 1998 Oct;133(10):1041-5

In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates. Ling TK, et al. **Chemotherapy** 1999 Jan-Feb;45(1):22-7

Boarder babies and placement in foster care. Maza PL. **Clin Perinatol** 1999 Mar;26(1):201-11, ix

Avoiding malpractice in private practice and the hospital setting. Martello J, et al. **Clin Plast Surg** 1999 Jan; 26(1):29-35

Survival after rectal cancer: differences between hospital catchment areas. A nationwide study in Sweden. Blomqvist P, et al. **Gut** 1999 Jul;45(1):39-44

Resistance in hospitals: implications for empiric choice of therapy. Masterton R. **Int J Clin Pract Suppl** 1998 Jun; 95:9-13

Disinfection of hospital waste sludge using hypochlorite and chlorine dioxide. Tsai CT, et al. **J Appl Microbiol** 1999 May;86(5):827-33

Evaluation of efficacy of Dettol-H in hospital use. Kapoor H, et al. **J Commun Dis** 1998 Sep;30(3):167-70

Interhospital network system using the worldwide web and the common gateway interface. Oka A, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):205-7

Anaerobic infections in an Indian tertiary care hospital with special reference to bacteroidaceae [letter] Chaudhry R, et al. **J Infect** 1999 Jan;38(1):54-5

Tax exempt hospitals' condition improves with new physician recruitment guidelines. Seiffert JC. **J Ky Med Assoc** 1999 Jan;97(1):23-6

Hospital peer review and clinical privileges actions: to report or not report [editorial; comment] Brennan TA. **JAMA** 1999 Jul 28;282(4):381-2. Comment on: JAMA 1999 Jul 28;282(4):349-55.

Public protests after rape in Pakistani hospital [news] Ahmad K. **Lancet** 1999 Aug 21;354(9179):659

Effects of NATO's bombing in the Balkans [letter] Podmore W. **Lancet** 1999 Jun 26;353(9171):2249

Recognising and preventing serious in-hospital events [editorial; comment] Hillman KM. **Med J Aust** 1999 Jul 5;171(1):8-9. Comment on: Med J Aust 1999 Jul 5;171(1):22-5.

Audit of quality of hospital haemodialysis in Scotland. The Scottish Renal Registry [letter; comment] Junor BJ. **Nephrol Dial Transplant** 1998 Sep;13(9):2426-7. Comment on: Nephrol Dial Transplant 1997 Jan;12(1):29-32.

Hospitals and primary health care [letter] Komta YB. **World Health Forum** 1998;19(3):299-300

[Virus resistance in a hospital environment: overview of the virucide activity of disinfectants used in liquid form] Soule H, et al. **Ann Biol Clin (Paris)** 1998 Nov-Dec;56(6):693-703 (49 ref.) (Eng. Abstr.) **(Fre)**

[The medicosurgical field hospital: first African unit in a humanitarian situation] Breda Y, et al. **Med Trop (Mars)** 1998;58(4):323-7 **(Fre)**

[A survey regarding the problem of cigarette smoke pollution in a hospital environment] Castello D, et al. **Minerva Pediatr** 1999 Apr;51(4):93-9 (Eng. Abstr.) **(Ita)**

[Adolescents and health services: the hospital] Perletti L, et al. **Minerva Pediatr** 1998 Jun;50(6):221-6 **(Ita)**

[Towards a pain-free hospital. A project and a campaign for the improvement of health care] Visentin M. **Recenti Prog Med** 1999 Jun;90(6):321-4 (Eng. Abstr.) **(Ita)**

[Susceptibility of Pseudomonas aeruginosa isolated from hospital infections to antibiotics] Gniadkowski M, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):346-50 (Eng. Abstr.) **(Pol)**

[Nontuberculous mycobacteria in the hospital environment] Toma F. **Bacteriol Virusol Parazitol Epidemiol** 1998 Oct-Dec;43(4):229-35 (Eng. Abstr.) **(Rum)**

[Cooperation. Relationship between district and referred medical center services] Sesma Sánchez P, et al. **An Med Interna** 1998 Aug;15(8):449-50 (Eng. Abstr.) **(Spa)**

[Biomedical research in Spain (I). An evaluation of the Fondo de Investigacion Sanitaria (FIS) through research projects financed in the 1988-1995 period in health-care institutions (hospitals)] Espinosa de los Monteros J, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):182-97 **(Spa)**

[Teaching in a non-teaching health center] Gérvas J, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):218-21 **(Spa)**

[Violence in the hospital (letter)] Reyes Núñez M, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):78-9 **(Spa)**

[The basis of the terms "therapeutic-prophylactic and medical institutions"] Deĭkun MP. **Lik Sprava** 1999 Apr-May; (3):165-8 **(Ukr)**

CLASSIFICATION

Hospital peer review and the National Practitioner Data Bank: clinical privileges action reports [see comments] Baldwin LM, et al. **JAMA** 1999 Jul 28;282(4):349-55. Comment in: JAMA 1999 Jul 28;282(4):381-2.

Differences of case-mix according to the type of hospital: methodological aspects and results. Constant E, et al. **Medinfo** 1998;9 Pt 2:874-8

Comparing hospitals [letter; comment] Hartz A, et al. **N Engl J Med** 1999 Jun 24;340(25):2006-7; discussion 2007 . Comment on: N Engl J Med 1999 Jan 28;340(4):286-92.

ECONOMICS see ECONOMICS, HOSPITAL

HISTORY

Thomas Hodgkin and the museum at Guy's Hospital. Daws JJ. **Cancer Treat Rev** 1999 Jun;25(3):145-9

Medicine in Macon--a history. Johnson MI Jr. **J Med Assoc Ga** 1999 Apr;88(2):25-31

NHS at 50. The hospital surveys, 1942-44. National Health Service. Godber G. **Lancet** 1998 Jul 4;352(9121):49-50

[Place of the works of Aziza Othmana in the history of medicine in Tunisia] Essaddam H. **Tunis Med** 1998 Oct; 76(10):290-2 (Eng. Abstr.) **(Fre)**

[The Internal Medicine Clinic I UJ in the prose mirror of Emila Zegadłowicza] Gajda Z. **Przegl Lek** 1998; 55(10):558-60 (Eng. Abstr.) **(Pol)**

[Hospitals in Europe and Yugoslavia through the centuries] Topalović R. **Med Pregl** 1998 Nov-Dec;51(11-12):559-61 (Eng. Abstr.) **(Scr)**

[The hospital scene in Puebla during the viceroyalty] Fajardo-Ortiz G. **Gac Med Mex** 1999 Jul-Aug; 135(4):427-31 **(Spa)**

[Constant improvement in Sodertalje Lazarett--the oldest hospital in the county of Stockholm] Fränne M. **Lakartidningen** 1999 Sep 8;96(36):3811 **(Swe)**

INSTRUMENTATION see EQUIPMENT AND SUPPLIES, HOSPITAL

LEGISLATION & JURISPRUDENCE see LEGISLATION, HOSPITAL

MANPOWER

Who coordinates infection control programs in Australia? Murphy CL, et al. **Am J Infect Control** 1999 Jun; 27(3):291-5

Still attractive after all these years? Magnet hospitals in a changing health care environment. Buchan J. **J Adv Nurs** 1999 Jul;30(1):100-8

[Sensible management structure in the hospital. Reply to the article of Prof. Rückert regarding the view of the medical directors] Quirini W. **Chirurg** 1999 Jul;70(7):suppl 185-6 **(Ger)**

ORGANIZATION & ADMINISTRATION see HOSPITAL ADMINISTRATION

STANDARDS

Accidental out-of-hospital births in Finland: incidence and geographical distribution 1963-1995. Viisainen K, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):372-8

Robinson-Patman Act and the own-use exemption in health systems. Welch CW. **Am J Health Syst Pharm** 1999 May 15;56(10):990-4

Utilization and monitoring of aminoglycosides in oncology patients at a Hong Kong government hospital [letter] Chang S, et al. **Ann Pharmacother** 1999 May;33(5):646-9

Going beyond information management: using the Comprehensive Accreditation Manual for Hospitals to promote knowledge-based information services. Schardt CM. **Bull Med Libr Assoc** 1998 Oct;86(4):504-7

Trends in compliance with the guidelines for preventing the transmission of Mycobacterium tuberculosis among New Jersey hospitals, 1989 to 1996. Manangan LP, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):337-40

Hospital accreditation as a means of achieving international quality standards in health [editorial] Arce HE. **Int J Qual Health Care** 1998 Dec;10(6):469-72

A comparative analysis of surveyors from six hospital accreditation programmes and a consideration of the related management issues. Bohigas L, et al. **Int J Qual Health Care** 1998 Feb;10(1):7-13

Does the Complications Screening Program flag cases with process of care problems? Using explicit criteria to judge processes. Iezzoni LI, et al. **Int J Qual Health Care** 1999 Apr;11(2):107-18

Revised guidelines for the control of methicillin-resistant

Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association [see comments] [published erratum appears in J Hosp Infect 1999 May;42(1):83] **J Hosp Infect** 1998 Aug; 39(4):253–90. Comment in: J Hosp Infect 1999 Jan;41(1):72–4. Comment in: J Hosp Infect 1999 May;42(1):71–2.

Survey of hospitals and healthcare provider organizations--requirements for physician continuing medical education credits in Louisiana. LSMS Committee on Medical Education. **J La State Med Soc** 1999 Apr; 151(4):151–3

Best nursing practices and best hospitals. Pinkerton S. **J Prof Nurs** 1999 Jul–Aug;15(4):207

Patient perceived quality-of-care in hospital in the context of clinical pathways: development of an approach. Chou SC, et al. **J Qual Clin Pract** 1999 Jun;19(2):89–93

Results and possible productiveness of comparative study with overseas hospitals [letter] Yamamoto J. **Jpn J Clin Oncol** 1998 Oct;28(10):648

Improving the care of patients with community-acquired pneumonia: a multihospital collaborative QI project. Metersky ML, et al. **Jt Comm J Qual Improv** 1999 Apr; 25(4):182–90

Screening inpatient quality using post-discharge events. Iezzoni LI, et al. **Med Care** 1999 Apr;37(4):384–98

Grading the graders: how hospitals in California and New York perceive and interpret their report cards. Romano PS, et al. **Med Care** 1999 Mar;37(3):295–305

Hospital readmissions and quality of care. Weissman JS, et al. **Med Care** 1999 May;37(5):490–501

Research evidence on the validity of risk-adjusted mortality rate as a measure of hospital quality of care [published erratum appears in Med Care Res Rev 1999 Mar;56(1):118] Thomas JW, et al. **Med Care Res Rev** 1998 Dec; 55(4):371–404 (67 ref.)

From the ground up: the evolution of a hospital in the Third World. Bliss MJ. **Med Health R I** 1999 Apr;82(4):137–9

Measuring and improving quality using information systems. Bates DW, et al. **Medinfo** 1998;9 Pt 2:814–8

Do "America's Best Hospitals" perform better for acute myocardial infarction? [see comments] Chen J, et al. **N Engl J Med** 1999 Jan 28;340(4):286–92. Comment in: N Engl J Med 1999 Jan 28;340(4):309–10. Comment in: N Engl J Med 1999 Jun 24;340(25):2006–7; discussion 2007.

Hospitals, heal yourselves [editorial; comment] [see comments] Kassirer JP. **N Engl J Med** 1999 Jan 28; 340(4):309–10. Comment on: N Engl J Med 1999 Jan 28;340(4):286–92. Comment on: N Engl J Med 1999 Jun 28;340(4):293–9. Comment in: N Engl J Med 1999 Jun 24;340(25):2007.

Comparing hospitals [letter; comment] Lane WL, et al. **N Engl J Med** 1999 Jun 24;340(25):2007. Comment on: N Engl J Med 1999 Jan 28;340(4):309–10.

Implementation of a quality system in a therapeutic drug monitoring laboratory. Gaillard-France S, et al. **Therapie** 1999 May–Jun;54(3):315–20

[Towards an accreditation system for the Dutch hospitals (see comments)] van Gennip EM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):89–93 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 3;143(14):764–5. **(Dut)**

[Towards an accreditation system for the Dutch hospitals (letter; comment)] Van Wermeskerken RK. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):764–5. Comment on: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):89–93. **(Dut)**

[Setting up a quality assurance system for the management of blood glucose monitoring in hospital units] Prévosto JM, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):606–11 **(Fre)**

[Risk management as a means of quality assurance in the hospital] Bergmann KO, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jan;93(1):57–62 (Eng. Abstr.) **(Ger)**

[Hospital hygiene--an essential aspect of quality assurance. Results of a survey in the hospitals of the German state of Saxony] Görisch G, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):293–301 (Eng. Abstr.) **(Ger)**

[Quality control in Austrian hospitals--results of evaluation] Mechtler R. **Z Arztl Fortbild Qualitatssich** 1998 Aug; 92(6):433–6 (Eng. Abstr.) **(Ger)**

[Medicine and industry learning from each other] Mašić I, et al. **Med Arh** 1998;52(4):239–40 (Eng. Abstr.) **(Scr)**

[Assessment of patients' expectations before admission to a tertiary-care center] Lledó R, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):211–5 (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Compliance with OSHA's respiratory protection standard in hospitals. Krishnan U, et al. **Am Ind Hyg Assoc J** 1999 Mar–Apr;60(2):228–36

Hospital evacuations due to hazardous materials incidents. Burgess JL. **Am J Emerg Med** 1999 Jan;17(1):50–2

Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Harmon JW, et al. **Ann Surg** 1999 Sep;230(3):404–11; discussion 411–3

Variation in hospital rates of intraaortic balloon pump use in coronary artery bypass operations. Ghali WA, et al. **Ann Thorac Surg** 1999 Feb;67(2):441–5

Unwinding Ariadne's thread: some methodological and interpretative considerations on international hospital admission comparisons, with special reference to cancer. Lionis C, et al. **Anticancer Res** 1999 Mar–Apr; 19(2B):1411–8

The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Glasgow RE, et al. **Arch Surg** 1999 Jan;134(1):30–5

Adverse reporting on adverse reactions [editorial] [see comments] Bains N, et al. **CMAJ** 1999 Feb 9;160(3):350–1 . Comment in: CMAJ 1999 May 18;160(10):1432.

Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system [see comments] Simunovic M, et al. **CMAJ** 1999 Mar 9;160(5):643–8. Comment in: CMAJ 1999 Mar 9;160(5):671–3.

More procedures, better quality of care? Is there a case for regionalization of pancreatic resection for neoplasm? [editorial; comment] [see comments] Wexler MJ. **CMAJ** 1999 Mar 9;160(5):671–3. Comment on: CMAJ 1999 Mar 9;160(5):643–8. Comment in: CMAJ 1999 Jun 29;160(13):1820.

Improving the care of patients with community-acquired pneumonia: a multihospital collaborative QI project. Metersky ML, et al. **Conn Med** 1999 Jul;63(7):425–31

The Danish National Hospital Register. A valuable source of data for modern health sciences. Andersen TF, et al. **Dan Med Bull** 1999 Jun;46(3):263–8

Health care's 100 most wired [published erratum appears in Hosp Health Netw 1999 Mar;73(3):12] Solovy A, et al. **Hosp Health Netw** 1999 Feb;73(2):43–51, 2

A survey of hospital management practices for vulvar melanoma. Creasman WT, et al. **J Am Coll Surg** 1999 Jun; 188(6):670–5

An analysis of falls in the hospital: can we do without bedrails? [see comments] Hanger HC, et al. **J Am Geriatr Soc** 1999 May;47(5):529–31. Comment in: J Am Geriatr Soc 1999 May;47(5):627–8.

Solar retinopathy in a hospital-based primary care clinic. Stokkermans TJ, et al. **J Am Optom Assoc** 1998 Oct; 69(10):625–36 (75 ref.)

Should hepatic resections be performed at high-volume referral centers? Choti MA, et al. **J Gastrointest Surg** 1998 Jan–Feb;2(1):11–20

A hospital's annual rate of esophagectomy influences the operative mortality rate [see comments] Patti MG, et al. **J Gastrointest Surg** 1998 Mar–Apr;2(2):186–92. Comment in: J Gastrointest Surg 1998 Sep–Oct;2(5):492.

National prevalence survey on hospital infections in Norway. Scheel O, et al. **J Hosp Infect** 1999 Apr;41(4):331–5

Adverse drug reactions in hospitalized patients [letter; comment] Bush T. **JAMA** 1998 Nov 25;280(20):1742; discussion 1743–4. Comment on: JAMA 1995 Jul 5;274(1):29–34. Comment on: JAMA 1998 Apr 15;279(15):1200–5.

Adverse drug reactions in hospitalized patients [letter; comment] Fremont-Smith K. **JAMA** 1998 Nov 25; 280(20):1741; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5.

Adverse drug reactions in hospitalized patients [letter; comment] Hanzlick R, et al. **JAMA** 1998 Nov 25; 280(20):1742; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Adverse drug reactions in hospitalized patients [letter; comment] Hui KK. **JAMA** 1998 Nov 25;280(20):1742–3; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Adverse drug reactions in hospitalized patients [letter; comment] Kravitz GR. **JAMA** 1998 Nov 25;280(20):1741; discussion 1743–4. Comment on: JAMA 1995 Jul 5;274(1):29–34. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Physician order entry in U.S. hospitals. Ash JS, et al. **Proc AMIA Symp** 1998;:235–9

Identification of incident stroke in Norway: hospital discharge data compared with a population-based stroke register. Ellekjaer H, et al. **Stroke** 1999 Jan;30(1):56–60

[Secondary infection with methacillin resistant Staphylococcus aureus in Dutch hospitals (July 1997–June 1996)] Esveld MI, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23;143(4):205–8 (Eng. Abstr.) **(Dut)**

[Scarcity of physicians and hospitals--planning for the needs of yesterday (letter)] Claussen B. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):568–9 **(Nor)**

TRENDS

Research and the acute-care hospital of the future [editorial; comment] Braithwaite J, et al. **Med J Aust** 1999 Apr 5; 170(7):292–3 (11 ref.). Comment on: Med J Aust 1999 Apr 5;170(7):325–8.

[The role of non-invasive positive pressure ventilation in lung volume reduction surgery of pulmonary emphysema--a survey of German hospitals] Wiebel M, et al. **Med Klin** 1999 Apr;94(1 Spec No):81–5 (Eng. Abstr.) **(Ger)**

[A day in the hospital of the future (editorial)] Trilla A. **Enferm Infecc Microbiol Clin** 1999 Apr;17(4):159–61 **(Spa)**

UTILIZATION

The hospitalist debate [letter; comment] Andreini S. **Am Fam Physician** 1999 Mar 15;59(6):1406. Comment on: Am Fam Physician 1998 Aug;58(2):336, 339. Comment on: Am Fam Physician 1998 Aug;58(2):339, 342.

The hospitalist debate [letter; comment] Murkin SA. **Am Fam Physician** 1999 Mar 15;59(6):1406, 1411–2. Comment on: Am Fam Physician 1998 Aug;58(2):339, 342.

The impact of smoking, alcohol consumption, and physical activity on use of hospital services. Haapanen-Niemi N, et al. **Am J Public Health** 1999 May;89(5):691–8

Role of hospitals in NHS must not be undervalued [letter; comment] [see comments] Majeed A. **BMJ** 1998 Dec 12; 317(7173):1653. Comment on: BMJ 1998 Jun 6;316(7146):1687–8. Comment in: BMJ 1999 May 22;318(7195):1420–1.

Associations of smoking with hospital-based care and quality of life in patients with obstructive airway disease. Sippel JM, et al. **Chest** 1999 Mar;115(3):691–6

Rationing of hospital services in the Australian health system. Kovač M. **Croat Med J** 1998 Sep;39(3):339–45

Choice of hospital: comments on 'global budgets and excess demand for hospital care' [letter; comment] Kalant N. **Health Econ** 1998 Sep;7(6):557–9. Comment on: Health Econ 1997 Mar–Apr;6(2):187–96.

A European version of the Appropriateness Evaluation Protocol. Goals and presentation. The BIOMED I Group on Appropriateness of Hospital Use. Lang T, et al. **Int J Technol Assess Health Care** 1999 Winter;15(1):185–97

Relationship between preventive health services and use of inpatient and outpatient care by residents aged 40 or older in 44 municipalities in Osaka Prefecture, Japan. Nakanishi N, et al. **J Epidemiol** 1998 Dec;8(5):264–71

Health literacy and the risk of hospital admission [see comments] Baker DW, et al. **J Gen Intern Med** 1998 Dec; 13(12):791–8. Comment in: J Gen Intern Med 1998 Dec;13(12):850–1.

Assessing the extent to which hospitals are used for acute care purposes. DeCoster C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS151–66

Variation in inpatient resource use in the treatment of HIV: do the privately insured receive more care? [see comments] Joyce GF, et al. **Med Care** 1999 Mar;37(3):220–7. Comment in: Med Care 1999 Apr;37(4):325–8.

Do market-level hospital and physician resources affect small area variation in hospital use? Alexander JA, et al. **Med Care Res Rev** 1999 Mar;56(1):94–117

The Aboriginal and Torres Strait Islander casemix study. Fisher DA, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S11–6

Introducing ICD-10-AM in Australian hospitals. Roberts RF, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S32–5

The relation between volume and outcome in health care [editorial; comment] Hannan EL. **N Engl J Med** 1999 May 27;340(21):1677–9. Comment on: N Engl J Med 1999 May 27;340(21):1640–8.

The relation between volume and outcome in health care [letter] Sheikh K. **N Engl J Med** 1999 Sep 30;341(14):1085–6

The association between hospital volume and survival after acute myocardial infarction in elderly patients [see comments] Thiemann DR, et al. **N Engl J Med** 1999 May 27;340(21):1640–8. Comment in: N Engl J Med 1999 May 27;340(21):1677–9.

A cohort study of resource use by medicaid children with asthma. Nash DR, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):310–2

Acute medical bed usage by nursing home residents. Beringer TR, et al. **Ulster Med J** 1999 May;68(1):27–9

Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996. Graves EJ, et al. **Vital Health Stat 13** 1998 Sep;(138):i–iii, 1–151 (16 ref.)

National hospital discharge survey: annual summary, 1996. Graves EJ, et al. **Vital Health Stat 13** 1999 Jan;(140):i–iv, 1–46

[Risk factors, diseases and health care acceptance in perinatology: a predictive model of hospital use] Combier E, et al. **Rev Epidemiol Sante Publique** 1999 Jun; 47(3):249–61 (Eng. Abstr.) **(Fre)**

[Request of health services by foreign patients in a roman hospital: a six year survey (1990–1995)] Arista AA, et al. **Ann Ig** 1998 May–Jun;10(3):181–8 (Eng. Abstr.) **(Ita)**

HOSPITALS, AIR FORCE see **HOSPITALS, MILITARY**

HOSPITALS, ANIMAL

Anesthetic gas exposure in veterinary clinics. Korczynski RE. **Appl Occup Environ Hyg** 1999 Jun;14(6):384–90

[Occupational exposure to inhalation anesthetics at the work-place of veterinary surgery] Hoerauf K, et al. **Zentralbl Hyg Umweltmed** 1998 Dec;201(4–5):405–12 (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Zoning--how veterinarians are affected. Hannah HW. **J Am Vet Med Assoc** 1998 Oct 1;213(7):964

STATISTICS & NUMERICAL DATA

A survey of radiology reporting practices in veterinary teaching hospitals. Adams WM. **Vet Radiol Ultrasound** 1998 Sep–Oct;39(5):482–6

[Prevalence of infections caused by Salmonella spp. in cattle

HOSPITALS, ANIMAL

and horses at the Veterinary Teaching Hospital of the Faculty of Veterinary Medicine of the University of Montreal] Ravary B, et al. **Can Vet J** 1998 Sep;39(9):566–72 (Eng. Abstr.) **(Fre)**

HOSPITALS, ARMY see **HOSPITALS, MILITARY**

HOSPITALS, CANCER see **CANCER CARE FACILITIES**

HOSPITALS, CHRONIC DISEASE

ECONOMICS

Economic impact of feeding a phenylalanine-restricted diet to adults with previously untreated phenylketonuria. Brown MC, et al. **J Intellect Disabil Res** 1999 Feb;43 (Pt 1):30–7

HOSPITALS, CITY see **HOSPITALS, URBAN**

HOSPITALS, CITY, NON-PUBLIC-OWNED see **HOSPITALS, URBAN**

HOSPITALS, CITY, PUBLIC-OWNED see **HOSPITALS, MUNICIPAL**

HOSPITALS, COMMUNITY

Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction. Oude Ophuis TJ, et al. **Am Heart J** 1999 May; 137(5):846–53

Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. Blanchette HA, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1551–9

Bloodless surgery: establishment of a program for the special medical needs of the Jehovah's witness community--the gynecologic surgery experience at a community hospital. deCastro RM. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1491–8

Effects of obstetrician characteristics on cesarean delivery rates. A community hospital experience. Poma PA. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1364–72

Outcomes and resource utilization for patients with prolonged critical illness managed by university-based or community-based subspecialists. Bach PB, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1410–5

Validation in a community hospital setting of a clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Tobin K, et al. **Arch Intern Med** 1999 Feb 22;159(4):353–7

Evaluation and implementation of the gel test for indirect antiglobulin testing in a community hospital laboratory. Cate JC 4th, et al. **Arch Pathol Lab Med** 1999 Aug; 123(8):693–7

Surgical residencies and community teaching hospitals [letter; comment] Becker JM, et al. **Arch Surg** 1998 Nov; 133(11):1255. Comment on: Arch Surg 1998 Oct;133(10):1039–40.

The value of surgical residencies to community teaching hospitals [see comments] McMillen MA. **Arch Surg** 1998 Oct;133(10):1039–40. Comment in: Arch Surg 1998 Nov;133(11):1255. Comment in: Arch Surg 1999 Apr;134(4):445–7. Comment in: Arch Surg 1999 May;134(5):575.

Acceptability of early discharge, hospital at home schemes. Care in community hospitals is another alternative [letter; comment] Seamark DA, et al. **BMJ** 1998 Dec 12; 317(7173):1652–3. Comment on: BMJ 1998 Jun 13;316(7147):1786–91. Comment on: BMJ 1998 Jun 13;316(7147):1796–801.

Impact and inequity of inpatient waiting times for advanced cardiovascular services in community hospitals across the greater Toronto area. Singh N, et al. **Can J Cardiol** 1999 Jul;15(7):777–82

Incidence of transient acantholytic dermatosis (Grover's disease) in a hospital setting. French LE, et al. **Dermatology** 1999;198(4):410–1

The use of systemic antibiotics in seven community hospitals in Northern Israel. Raz R, et al. **J Infect** 1998 Nov; 37(3):224–8

Bringing community involvement into a Cretan primary/hospital care center: an evaluation of population habits and attitudes toward health care. Chatziarsenis M, et al. **J Med Syst** 1999 Apr;23(2):123–31

Unenhanced CT in the evaluation of the acute abdomen: the community hospital experience. Malone AJ. **Semin Ultrasound CT MR** 1999 Apr;20(2):68–76 (18 ref.)

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians in neighborhood maternities. Experience of Ambert maternity (Puy-de-Dome) and Mauriac maternity (Cantal)] Souteyrand P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:121–6 **(Fre)**

[Problems with employment of a staff anesthesiologist in a local hospital] Sekiguchi M, et al. **Masui** 1999 Jun; 48(6):678–81 (Eng. Abstr.) **(Jpn)**

[Treatment of childhood acute lymphoblastic leukemia in a community hospital of the state of Veracruz] Verduzco-Rodriguez L, et al. **Rev Invest Clin** 1998 Nov-Dec;50(6):477–81 (Eng. Abstr.) **(Spa)**

[Quarantine and plasmapheresis in a community hospital (letter; comment)] Domingo JM, et al. **Sangre (Barc)** 1998 Oct;43(5):461–2. Comment on: Sangre (Barc) 1998 Jun;43(3):261–2. **(Spa)**

ECONOMICS

Does pediatric orthopedic subspecialization affect hospital utilization and charges? Smith JT, et al. **J Pediatr Orthop** 1999 Jul-Aug;19(4):553–5

Laparoscopic supracervical hysterectomy vs. abdominal hysterectomy in a community hospital. A cost comparison. Simon NV, et al. **J Reprod Med** 1999 Apr;44(4):339–45

A comparative study of the costliness of Manitoba hospitals. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS101–22

Charges for childhood asthma by hospital characteristics. Meurer JR, et al. **Pediatrics** 1998 Dec;102(6):E70

[The use of prosthetic meshes in the surgical treatment of inguinal hernia: the costs and profits for the local health screening unit] Leardi S, et al. **Minerva Chir** 1998 Jun; 53(6):581–5 (Eng. Abstr.) **(Ita)**

HISTORY

Kenney Memorial Hospital. White RM. **J Natl Med Assoc** 1999 May;91(5):282–8

[The St. John Hospital is 100 years old] Krakovits G. **Orv Hetil** 1999 May 2;140(18):1004–7 **(Hun)**

[The community hospital and the poorhouse of Buda in the 16th century] Sági E. **Orv Hetil** 1999 May 30; 140(22):1255–9 **(Hun)**

MANPOWER

Recruitment barriers in rural community hospitals: a comparison of nursing and nonnursing factors. Stratton TD, et al. **Appl Nurs Res** 1998 Nov;11(4):183–9

ORGANIZATION & ADMINISTRATION

Improved continuity of care in a community teaching hospital model. Mittal V, et al. **Arch Surg** 1999 May; 134(5):555–8

Disaster planning. Fire escape. Gibson L. **Hosp Health Netw** 1998 Oct 20;72(20):36–8

Backups and beyond. Nothing boosts disaster planning like a second hospital. Solovy A. **Hosp Health Netw** 1999 Apr; 73(4):34

A blueprint for linking academic oncology and the community. Linggood R, et al. **J Health Polit Policy Law** 1998 Dec;23(6):973–94

Professional and organizational impact of using patient care information systems. Hebert M. **Medinfo** 1998;9 Pt 2:849–53

Discharge planning in a community hospital--a multidisciplinary approach. Tan C, et al. **Singapore Med J** 1998 Oct;39(10):461–4

Special care for newborns at a community hospital: a 5-year experience. Borulkar PD, et al. **Trop Doct** 1998 Oct; 28(4):201–3

[The medical Foundation of Mar del Plata and the private community hospital] Paz RA. **Medicina (B Aires)** 1998; 58(2):221–7 **(Spa)**

STANDARDS

Community hospital homeopathy clinic: audit of the first 12 months activity. Neville-Smith R. **Br Homeopath J** 1999 Jan;88(1):20–3

Cardiology or primary care for heart failure in the community setting: process of care and clinical outcomes. Philbin EF, et al. **Chest** 1999 Aug;116(2):346–54

1999 Nova Award winners. Speer TL. **Hosp Health Netw** 1999 Jan;73(1):40–4, 46

Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Jochimsen EM, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):106–9

Managing quality in hospital practice [see comments] Weinberg NS, et al. **Int J Qual Health Care** 1998 Aug; 10(4):295–302. Comment in: Int J Qual Health Care 1998 Aug;10(4):289–90.

Predicting patient satisfaction: a study of two emergency departments. Yarnold PR, et al. **J Behav Med** 1998 Dec; 21(6):545–63

Comparison of outpatient laparoscopic cholecystectomy in a private nonteaching hospital versus a private teaching community hospital. Smith M 2nd, et al. **J Soc Laparoendosc Surg** 1997 Jan-Mar;1(1):51–3

The five-year evolution of a malnutrition treatment program in a community hospital. Brugler L, et al. **Jt Comm J Qual Improv** 1999 Apr;25(4):191–206

STATISTICS & NUMERICAL DATA

The effect of hospital-type and operating volume on the survival of hip replacements. A review of 39,505 primary total hip replacements reported to the Norwegian Arthroplasty Register, 1988–1996. Espehaug B, et al. **Acta Orthop Scand** 1999 Feb;70(1):12–8

The use of general practitioner elderly beds in community hospitals [letter] Rhodes KM, et al. **Age Ageing** 1998 Nov; 27(6):753

Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification. Siebert JD, et al. **Am J Clin Pathol** 1999 Mar;111(3):379–86

Hospital pulse ... April 1998. **Hosp Health Netw** 1998 Oct 20;72(20):40

Hospital pulse ... March 1998. **Hosp Health Netw** 1998 Oct 5;72(19):46

Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Birkmeyer JD, et al. **Surgery** 1999 Mar;125(3):250–6

TRENDS

ASHP national survey of pharmacy practice in acute care settings: prescribing and transcribing--1998. American Society of Health-System Pharmacists. Ringold DJ, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):142–57

Trends in small hospital medical services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2107–12

Trends in small hospital obstetric services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2117–24

UTILIZATION

Shifts in case mix and locus of mental health care for Washington State adults with severe mental illness. Semke J. **Adm Policy Ment Health** 1999 Jan;26(3):191–205

Community hospitals...and district general hospitals [letter] George J. **Age Ageing** 1999 Mar;28(2):240

Community hospitals...and district general hospitals [letter] Knox J. **Age Ageing** 1999 Mar;28(2):240

Endoscopic practice for upper gastrointestinal hemorrhage: differences between major teaching and community-based hospitals. Cooper GS, et al. **Gastrointest Endosc** 1998 Oct; 48(4):348–53

Preventable causative factors leading to hospital admission with decompensated heart failure [see comments] Michalsen A, et al. **Heart** 1998 Nov;80(5):437–41. Comment in: Heart 1998 Nov;80(5):426–7. Comment in: Heart 1998 Nov;80(5):430–1.

HOSPITALS, CONVALESCENT

[Tuberculosis in a social health care center: epidemiologic study and prevention activities] Serrate G, et al. **Enferm Infecc Microbiol Clin** 1999 Mar;17(3):130–4 (Eng. Abstr.) **(Spa)**

HISTORY

The Throne Hospital: a short history. Beringer TR. **Ulster Med J** 1998 Nov;67(2):115–6

The Throne Hospital and early plastic surgery in Northern Ireland. Colville J. **Ulster Med J** 1998 Nov;67(2):117–20

HOSPITALS, COUNTY

HISTORY

Historical perspectives on health: personal reflections on work in a provincial hospital laboratory, 1942–1948. Dickerson JW. **J R Soc Health** 1999 Mar;119(1):56–8

ORGANIZATION & ADMINISTRATION

Comebacks. Talent route [news] Serb C. **Hosp Health Netw** 1999 Jan;73(1):24, 26

STANDARDS

Satisfaction with care among patients with diabetes in two public health care systems [see comments] Piette JD. **Med Care** 1999 Jun;37(6):538–46. Comment in: Med Care 1999 Jun;37(6):527–8.

[Closure of pediatric clinics resulted in worsened care in county hospitals] Bergqvist G, et al. **Lakartidningen** 1999 Mar 3;96(9):1024–5 **(Swe)**

STATISTICS & NUMERICAL DATA

Outcome of 1000 consecutive clinic- and hospital-based cataract surgeries in a Danish county. Wegener M, et al. **J Cataract Refract Surg** 1998 Aug;24(8):1152–60

UTILIZATION

Primary care use by specialty clinic patients at a county hospital [letter] Fenton JJ, et al. **J Health Care Poor Underserved** 1998 Feb;9(1):5–13

HOSPITALS, DISTRICT

Establishing a laboratory for surveillance of invasive bacterial infections in a tertiary care government hospital in a rural province in the Philippines. Herva E, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):1035–40

Diagnostic cardiac catheterisation in a hospital without on-site cardiac surgery. Papaconstantinou HD, et al. **Heart** 1999 May;81(5):465–9

[Theoretical substantiation and results of licensing and accreditation technology in a region] Diul'din VA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov-Dec;(6):37–40 (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

[The regional explantation team: an important contribution to organ procurement for transplantation in the Netherlands] van Goor H, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26;142(52):2843-6 (Eng. Abstr.) **(Dut)**

STANDARDS

Rectal cancer surgery in a district general hospital: controlled follow-up study. Schütz G, et al. **World J Surg** 1999 May; 23(5):509-13

STATISTICS & NUMERICAL DATA

The effect of hospital-type and operating volume on the survival of hip replacements. A review of 39,505 primary total hip replacements reported to the Norwegian Arthroplasty Register, 1988-1996. Espehaug B, et al. **Acta Orthop Scand** 1999 Feb;70(1):12-8

Safety of pancreatic surgery in a small DGH. Millson CE, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):51-3

UTILIZATION

A comparison of hospital and critical-care activity. Ridley SA, et al. **Anaesthesia** 1999 Jun;54(6):521-8

The Bwamanda hospital insurance scheme: effective for whom? A study of its impact on hospital utilization patterns. Criel B, et al. **Soc Sci Med** 1999 Apr;48(7):897-911

HOSPITALS, FEDERAL

ORGANIZATION & ADMINISTRATION

Control issues. Tribal turnabout [news] Garber K. **Hosp Health Netw** 1999 Apr;73(4):16, 18

HOSPITALS, GENERAL

Leak of abortion information creates turmoil at Foothills [news] Cairney R. **CMAJ** 1999 Aug 24;161(4):424-5

Diagnostic cardiac catheterisation in a hospital without on-site cardiac surgery. Papaconstantinou HD, et al. **Heart** 1999 May;81(5):465-9

Chlamydia in a district general hospital: an audit of treatment and contact tracing [see comments] White C, et al. **Int J STD AIDS** 1999 Jan;10(1):57-9. Comment in: Int J STD AIDS 1999 Jul;10(7):492.

Awareness about tuberculosis among nurses working in a tuberculosis hospital and in a general hospital in Delhi, India. Singla N, et al. **Int J Tuberc Lung Dis** 1998 Dec; 2(12):1005-10

Use of anxiolytics and hypnotics in gynecological, surgical and medical departments of general hospitals. Wancata J, et al. **Pharmacopsychiatry** 1998 Sep;31(5):178-86

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of obstetricians of general hospital centers] Dauptain G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:110-6 (13 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of general hospital center directors. Reflections on the experiment undertaken at Clamecy] Faulconnier B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:232-6 **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of central general hospital pediatricians] Zaoui C. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:162-4 (21 ref.) **(Fre)**

[Hillel Yaffe Medical Center] **Harefuah** 1998 Oct; 135(7-8):324 **(Heb)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 3. Current status of tuberculosis patient care in university hospitals and general hospitals in Japan] Kurane S, et al. **Kekkaku** 1999 Feb;74(2):139-43 (Eng. Abstr.) **(Jpn)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 1. Diagnosis and treatment of mycobacterial diseases in a community general hospital] Matsumura T, et al. **Kekkaku** 1999 Feb; 74(2):129-31 (Eng. Abstr.) **(Jpn)**

[Problems with employment of a staff anesthesiologist in a local hospital] Sekiguchi M, et al. **Masui** 1999 Jun; 48(6):678-81 (Eng. Abstr.) **(Jpn)**

[Provision of pediatric cardiology care in Macau. Initial experience of the central hospital of Conde de S. Januario] Paixão A, et al. **Acta Med Port** 1998 Jul;11(7):649-53 (Eng. Abstr.) **(Por)**

ECONOMICS

[Risk of survival of general hospitals is increasing (letter)] Boll G. **Chirurg** 1998 Nov;69(11):suppl 351 **(Ger)**

[Means for the economic utilization of the beds in a treatment hospital under market terms] Nazar PS, et al. **Lik Sprava** 1998 Dec;(8):158-60 **(Ukr)**

HISTORY

The rise, heyday, and incipient decline of specialization: hospitals in Denmark, 1930-1990. Vallgårda S. **Int J Health Serv** 1999;29(2):431-57 (34 ref.)

Emory's General Hospital 43. Mullen R. **J Med Assoc Ga** 1999 Apr;88(2):50-3

The rebirth of Vienna's old General Hospital. de Bousingen DD. **Lancet** 1998 Oct 3;352(9134):1157

Physical medicine and rehabilitation at the Mount Sinai medical center during the 20th century. Ragnarsson KT. **Mt Sinai J Med** 1999 May;66(3):139-44

Hospitals in Cape Town during the Anglo-Boer War. de Villiers JC. **S Afr Med J** 1999 Jan;89(1):75-82

[The history of the Saint-Jacques de Besançon Hospital] Maurat JP, et al. **Rev Prat** 1999 Feb 1;49(3):241-4 **(Fre)**

[Social change in the hospital during the 19th century. The example of the Munich General Hospital] Spree R. **Medizinhist J** 1998;33(3-4):245-91 **(Ger)**

ORGANIZATION & ADMINISTRATION

The new look acute general hospital. Wilkins D. **Ann R Coll Surg Engl** 1998 May;80(3 Suppl):109-11

The rise, heyday, and incipient decline of specialization: hospitals in Denmark, 1930-1990. Vallgårda S. **Int J Health Serv** 1999;29(2):431-57 (34 ref.)

Analysis and impact of infectious disease consultations in a general hospital. Schlesinger Y, et al. **J Hosp Infect** 1998 Sep;40(1):39-46

Other people's practices: a world close to home. Cheng AC. **Med J Aust** 1999 Apr 5;170(7):323-4

Power, control and resistance in the timing of health and care. Fox NJ. **Soc Sci Med** 1999 May;48(10):1307-19

From general hospital to Baby-Friendly hospital [letter] Satpathy R, et al. **World Health Forum** 1998;19(4):433-4

[Taking charge in a general hospital: from liaison psychiatry to medical-psychiatric units] Archinard M. **Rev Med Interne** 1998;19 Suppl 3:347S-349S **(Fre)**

[The evaluation by performance indicators of the impact of organizational changes on the activities of a hospital presidium of Lombardy] Pagano A, et al. **Ann Ig** 1998 Jul-Aug;10(4):255-65 **(Ita)**

[The experience of managing the risk due to the manual lifting of patients in the hospital reality of Local Health Screening Unit Enterprise 18, the Veneto region] Torri P, et al. **Med Lav** 1999 Mar-Apr;90(2):362-80 (Eng. Abstr.) **(Ita)**

[The effect of a rational and consensual protocol for the use of ceftriaxone in a general hospital] Gómez Vargas J, et al. **Rev Esp Quimioter** 1998 Dec;11(4):327-32 (Eng. Abstr.) **(Spa)**

STANDARDS

The difficulties encountered in completing an audit cycle in a district general hospital. Ong CC, et al. **Int J Clin Pract** 1998 Jul-Aug;52(5):298-9

Rectal cancer surgery in a district general hospital: controlled follow-up study. Schütz G, et al. **World J Surg** 1999 May; 23(5):509-13

[Evaluation of low molecular weight heparin prescription at the Centre Hospitalier Intercommunal de Créteil] Callaert S, et al. **Therapie** 1998 Nov-Dec;53(6):587-90 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Safety of pancreatic surgery in a small DGH. Millson CE, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):51-3

Head injuries at a Provincial General Hospital in Kenya. Muyembe VM, et al. **East Afr Med J** 1999 Apr;76(4):200-5

Risk-sharing integration efforts in the hospital sector. Jantzen R, et al. **Health Care Manage Rev** 1999 Spring;24(2):83-92

Prevalence of nosocomial infections in general hospitals in Belo Horizonte. Rezende EM, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):872-6

Ward Six Psychiatric Unit at the Port Moresby General Hospital: a historical review and admission statistics from 1980 to 1989. Johnson FY. **P N G Med J** 1997 Jun; 40(2):79-88

Is the general practitioner hospital a potential "patient trap"? A panel study of emergency cases transferred to higher level hospitals. Aaraas I, et al. **Scand J Prim Health Care** 1998 Jun;16(2):76-80

[Emergency computed tomography in a general hospital center] Flais S, et al. **J Radiol** 1999 May;80(5):441-6 (Eng. Abstr.) **(Fre)**

[Pulmonary tuberculosis: data of general somatic hospital] Shul'ga IA, et al. **Probl Tuberk** 1998;(6):4-7 (45 ref.) (Eng. Abstr.) **(Rus)**

UTILIZATION

Community hospitals...and district general hospitals [letter] George J. **Age Ageing** 1999 Mar;28(2):240

Community hospitals...and district general hospitals [letter] Knox J. **Age Ageing** 1999 Mar;28(2):240

A comparison of hospital and critical-care activity. Ridley SA, et al. **Anaesthesia** 1999 Jun;54(6):521-8

Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV-related resources between HIV-infected women and men. Davidson AJ, et al. **Med Care** 1998 Dec;36(12):1676-84

Use of Massachusetts hospitals by Rhode Island residents. Buechner JS. **Med Health R I** 1999 Aug;82(8):300-1

HOSPITALS, GROUP PRACTICE

HISTORY

Dr John S. Lundy and the 75th anniversary of anesthesiology at Mayo. Nelson CW. **Mayo Clin Proc** 1999 Jul;74(7):650

First Mayo Clinic Hospital opens. Nelson CW. **Mayo Clin Proc** 1999 Feb;74(2):112

ORGANIZATION & ADMINISTRATION

The Park Nicollet experience in establishing a hospitalist system. Freese RB. **Ann Intern Med** 1999 Feb 16;130(4 Pt 2):350-4

The Mayo Vascular Center experience. Hallett JW, et al. **Cardiovasc Surg** 1998 Aug;6(4):333-6

The socialization of newly hired medical staff into a large health system. Bender C, et al. **Health Care Manage Rev** 1999 Winter;24(1):95-108

Profiles of the Endocrine Clinic: the Mayo Clinic. Brennan MD, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3427-34

HOSPITALS, MATERNITY

Clocks in delivery wards may not be sufficiently accurate to validate birth of "millennium babies" [letter] Round J, et al. **BMJ** 1999 Jul 24;319(7204):260

Investigation of a nosocomial outbreak due to Serratia marcescens in a maternity hospital. Berthelot P, et al. **Infect Control Hosp Epidemiol** 1999 Apr;20(4):233-6

[Medical responsibility of midwives in public and private maternity units. Results of a survey of 11 French regions] Blondel B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Nov; 27(7):692-701 (Eng. Abstr.) **(Fre)**

[Readmission in a Maternity Hospital for early mother-child relationship disorders] Poizat A. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):632-4 (Eng. Abstr.) **(Fre)**

[Testing for HIV infection in pregnant women at the obstetric centers in Italy] D'Ubaldo C, et al. **Minerva Ginecol** 1999 Jan-Feb;51(1-2):7-14 (Eng. Abstr.) **(Ita)**

[Length of stay in maternity wards (letter; comment)] Myr R. **Tidsskr Nor Laegeforen** 1999 Jun 20;119(16):2391-2. Comment on: Ned Tijdschr Geneeskd 1999 May 20;119(13):1893-6. **(Nor)**

[Trends in cesarean section procedures in three locations of the Mexican Social Security Institute Medical Services during the period 1981-1995] Martin Corral-Chávez C, et al. **Ginecol Obstet Mex** 1999 Jan;67:9-12 (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

[State of the locations of obstetric and neonatal structures in France] Ruffié A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:37-51 **(Fre)**

STANDARDS

[Comparative evaluation of maternity hospitals in Auvergne: from planning to contracting] Gerbaud L, et al. **Cah Sociol Demogr Med** 1998 Oct-Dec;38(4):297-323 (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Identifying problems with data collection at a local level: survey of NHS maternity units in England. Kenney N, et al. **BMJ** 1999 Sep 4;319(7210):619-22

HOSPITALS, METROPOLITAN see **HOSPITALS, URBAN**

HOSPITALS, MILITARY

Redefining the practice of military pharmacy. Normark JW, et al. **Am J Health Syst Pharm** 1999 Mar 15;56(6):568-71

Use of a focussed teen prenatal clinic at a military teaching hospital: model for improved outcomes of unmarried mothers. Perez R, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):280-3

Closure of Royal Hospital Haslar is necessary [letter] Baird JA. **BMJ** 1999 Jul 10;319(7202):122-3

Outpatient waiting times: indicators of hospital performance? Croft AM, et al. **J R Army Med Corps** 1998 Oct; 144(3):131-7

Surgical interventions at field hospitals during the Iran and Iraq War (1980-1987). Heidarpour A, et al. **Mil Med** 1999 Feb;164(2):136-7

Patients, diagnoses, and procedures in a military internal medicine clinic: comparison with civilian practices. Jackson JL, et al. **Mil Med** 1999 Mar;164(3):194-7

Disease prevention while deployed [letter] Kortepeter MG, et al. **Mil Med** 1999 Aug;164(8):viii, 561

Improving maternal and newborn nursing services in a military medical center. Padderatz AY. **Mil Med** 1999 Jul; 164(7):466-70

One year's trauma mortality experience at Brooke Army Medical Center: is aeromedical transportation of trauma patients necessary? Phillips RT, et al. **Mil Med** 1999 May; 164(5):361-5

Development of a pediatric critical care transport team: experience at a military medical center. Wheeler DS, et

HOSPITALS, MILITARY

al. **Mil Med** 1999 Mar;164(3):188–93

[The Danish International Brigade field hospital] Lauritzen JB, et al. **Ugeskr Laeger** 1999 Apr 26;161(17):2552 **(Dan)**

[Oxygen in the field hospitals: current experience in the military health service] Rouvier B, et al. **Bull Acad Natl Med** 1998;182(6):1209–18 (Eng. Abstr.) **(Fre)**

[Assaf Harofeh Medical Center] **Harefuah** 1998 Aug; 135(3–4):153 **(Heb)**

[Experience in preparing injection solutions in the pharmacy of a military hospital] Chirkov AI, et al. **Voen Med Zh** 1999 May;320(5):73–4 **(Rus)**

[Experience with the use of computer technology in a military hospital] Kliuzhev VM, et al. **Voen Med Zh** 1999 Jun;320(6):7–9 **(Rus)**

[Assessing the sanitary status of military hospital pharmacies by the degree of surface chemical contamination] Zholus BI, et al. **Voen Med Zh** 1999 Jul;320(7):66–9 **(Rus)**

[The role of day care hospitals in psychosocial rehabilitation of patients with psychiatric war injuries] Samardžić R, et al. **Vojnosanit Pregl** 1998 Jul–Aug;55(4):385–90 (Eng. Abstr.) **(Scc)**

HISTORY

Base or general hospitals during the Civil War. Rutkow IM. **Arch Surg** 1999 Sep;134(9):1021

Another look at Civil War medical care: Atlanta's Confederate hospitals. Davis S. **J Med Assoc Ga** 1999 Apr; 88(2):9–23

Scutari revisited [letter] Whelan TR. **J R Army Med Corps** 1999 Feb;145(1):43–4

Hospitals in Cape Town during the Anglo-Boer War. de Villiers JC. **S Afr Med J** 1999 Jan;89(1):75–82

[Otolaryngological department of the Polish Military Hospital in Zeithain] Gerwel T, et al. **Otolaryngol Pol** 1999; 53(2):227–9 **(Pol)**

[The 80th anniversary of the P. V. Mandryka Central Military Clinical Hospital] **Voen Med Zh** 1999 Apr; 320(4):4–7 **(Rus)**

[The history of the instructional work at the P. V. Mandryka Central Military Clinical Hospital] Nininchenko VI. **Voen Med Zh** 1999 Apr;320(4):85–90 **(Rus)**

[The 45th anniversary of Totskoe Military Hospital] Prokof'ev OI, et al. **Voen Med Zh** 1999 Mar;320(3):80–1 **(Rus)**

[The first operation under anesthesia in Russia in a brigade hospital] Shabunin AV. **Voen Med Zh** 1999 Jul;320(7):77–8 **(Rus)**

[The development of gynecological care at the P. V. Mandryka Central Military Clinical Hospital] Zagvozdkin SS. **Voen Med Zh** 1999 Apr;320(4):95–7 **(Rus)**

[120 years' of the Military Hospital in Niš (editorial)] Kostić C. **Vojnosanit Pregl** 1998 Sep–Oct;55(5 Suppl):3–10 **(Scc)**

ORGANIZATION & ADMINISTRATION

Overhaul of military pharmacy system recommended [news] **Am J Health Syst Pharm** 1998 Aug 15;55(16):1656, 1658

Clinical services assessment and reengineering: lessons learned. Lyche DK, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):127–9

Use of host nation facilities as medical force multipliers at the Operation Joint Guard intermediate staging base, March to October 1997. Berger M, et al. **Mil Med** 1999 Jul;164(7):457–9

Academic medical centers: a prescription for success in an era of managed care and capitation. Huntsinger CR Jr, et al. **Mil Med** 1999 Aug;164(8):585–9 (11 ref.)

[Experience in organizing the scientific work in a military district hospital] Chuiko VI, et al. **Voen Med Zh** 1998 Dec; 319(12):8–11 **(Rus)**

STANDARDS

Core formulary issued for military treatment facilities [news] **Am J Health Syst Pharm** 1998 Aug 15;55(16):1658, 1660

STATISTICS & NUMERICAL DATA

[The need for the hospital treatment of surgical patients] Bobil BV, et al. **Voen Med Zh** 1998 Sep;319(9):12–6 **(Rus)**

HOSPITALS, MUNICIPAL

Pulmonary sarcoidosis: comparison of patients at a university and a municipal hospital [see comments] Yeager H Jr, et al. **J Natl Med Assoc** 1999 Jun;91(6):322–7. Comment in: J Natl Med Assoc 1999 Jun;91(6):327–8.

Are sociodemographic factors important in sarcoidosis? [comment] Young RC Jr. **J Natl Med Assoc** 1999 Jun; 91(6):327–8. Comment on: J Natl Med Assoc 1999 Jun;91(6):322–7.

ECONOMICS

[Substantiation of the choice of technical means in reduction of implementation costs of the project "Full automation of a central municipal hospital"] Nikitin IuD, et al. **Med Tekh** 1998 Nov–Dec;(6):32–5 (Eng. Abstr.) **(Rus)**

HISTORY

[Fernand-Widal hospital. Origins and avatars] Bismuth C, et al. **Rev Prat** 1999 Jan 1;49(1):8–10 **(Fre)**

[Communication from the Szent István Municipal Hospital. Data on the surgical management of scarified pyloric stenosis (historical article)] Herczel M. **Orv Hetil** 1999 Jul 25;140(30):1699–702 **(Hun)**

[The old municipal hospital in Pest] Sági E. **Orv Hetil** 1998 Oct 18;139(42):2519–21 **(Hun)**

[Decline ot the old municipal hospital in Pest and the preliminaries for the establishment of the Rókus Hospital] Sági E. **Orv Hetil** 1998 Nov 15;139(46):2785–7 **(Hun)**

[One hundred years since setting up Bakhrushin hospital's prosectorium--Moscow City Center for Pathology Studies at A.A. Ostroumov Clinical Hospital No. 33 (editorial)] Zaĭrat'iants OV. **Arkh Patol** 1999 Mar–Apr;61(2):3–9 (Eng. Abstr.) **(Rus)**

STANDARDS

Impact of surgeon's technique on outcome after treatment of rectal carcinoma. Hermanek P. **Dis Colon Rectum** 1999 May;42(5):559–62

Towards safer blood transfusion practice. Hodgkinson B, et al. **J Qual Clin Pract** 1999 Mar;19(1):63–7

UTILIZATION

Medical-resource use for suspected tuberculosis in a New York City hospital [see comments] Griffiths RI, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):747–53. Comment in: Infect Control Hosp Epidemiol 1998 Oct;19(10):744–6.

Ambulatory health care use by patients in a public hospital emergency department. Rask KJ, et al. **J Gen Intern Med** 1998 Sep;13(9):614–20

Whither the almshouse? Overutilization and the role of the emergency department. Malone RE. **J Health Polit Policy Law** 1998 Oct;23(5):795–832

HOSPITALS, NAVY see **HOSPITALS, MILITARY**

HOSPITALS, PEDIATRIC

Pediatric hospitals' and physician strategies for the 21st century. Thompson JW, et al. **Clin Pediatr (Phila)** 1999 May;38(5):259–63

The National Meningococcal Reference Laboratory [editorial] Cafferkey M. **Ir Med J** 1998 Dec;91(6):196–7

A profile of attenders at the A&E Department of the Children's Hospital, Temple Street, Dublin. Mallon B, et al. **Ir Med J** 1997 Nov;90(7):266–7

Mission focused. How Egleston Children's Health Care System and Scottish Rite Children's Medical Center work to provide charity care for children. Webster B. **J Med Assoc Ga** 1999 Feb;88(1):39–41

Chemistry test ordering patterns after elimination of predefined multitest chemistry panels in a children's hospital. Pysher TJ, et al. **Pediatr Dev Pathol** 1999 Sep–Oct; 2(5):446–53

Pediatric oncology and hematology in Birmingham, England. Mann JR, et al. **Pediatr Hematol Oncol** 1999 Jan–Feb; 16(1):3–7

21st century health care for children in Afghanistan? Sogan D, et al. **Pediatrics** 1998 Nov;102(5):1193–8

[Closure of pediatric clinics resulted in worsened care in county hospitals] Bergqvist G, et al. **Lakartidningen** 1999 Mar 3;96(9):1024–5 **(Swe)**

ECONOMICS

A new economic benchmark for surgical treatment of appendicitis. Firilas AM, et al. **Am Surg** 1999 Aug; 65(8):769–73

A cost-saving algorithm for children hospitalized for status asthmaticus. McDowell KM, et al. **Arch Pediatr Adolesc Med** 1998 Oct;152(10):977–84

Skeletal traction versus external fixation for pediatric femoral shaft fractures: a comparison of hospital costs and charges. Nork SE, et al. **J Orthop Trauma** 1998 Nov–Dec; 12(8):563–8

Does pediatric orthopedic subspecialization affect hospital utilization and charges? Smith JT, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):553–5

The true cost of treating children. Hanson RM, et al. **Med J Aust** 1998 Oct 19;169 Suppl:S39–41

[Surveillance and the costs related to the prescription of antimicrobials in a pediatric hospital] Navarrete-Navarro S, et al. **Gac Med Mex** 1999 Jul–Aug;135(4):383–9 (Eng. Abstr.) **(Spa)**

HISTORY

Case study of institution-building by nurse Bertha Wright and colleagues. Nichols DJ, et al. **Image J Nurs Sch** 1998; 30(4):385–9

Ladd's vision. Clatworthy HW Jr. **J Pediatr Surg** 1999 May; 34(5 Suppl 1):32–7

The Mason Brown Lecture. Scots and paediatric surgery. Young DG. **J R Coll Surg Edinb** 1999 Aug;44(4):211–5

Charles Dickens' work to help establish Great Ormond Street Hospital, London. Markel H. **Lancet** 1999 Aug 21; 354(9179):673–5

The Throne Hospital: a short history. Beringer TR. **Ulster Med J** 1998 Nov;67(2):115–6

The Throne Hospital and early plastic surgery in Northern Ireland. Colville J. **Ulster Med J** 1998 Nov;67(2):117–20

['Pediatric and teaching hospital' in the early 18th century? Facilities for patient care in the Francke institutions] Helm J. **Medizinhist J** 1998;33(2):107–41 **(Ger)**

LEGISLATION & JURISPRUDENCE

Recent changes in residency requirements for pediatrics: who agrees? Ector WL, et al. **Clin Pediatr (Phila)** 1998 Oct; 37(10):625–30

Controversial HSC clinical trials report made public. Hospital for Sick Children [news; comment] Birmingham K. **Nat Med** 1999 Jan;5(1):7. Comment on: Nat Med 1999 Jan;5(1):2.

HSC clinical trials controversy continues. Hospital for Sick Children [letter; comment] [see comments] Buchwald M, et al. **Nat Med** 1999 Jan;5(1):2–3. Comment on: Nat Med 1998 Oct;4(10):1089. Comment on: Nat Med 1998 Oct;4(10):1095. Comment in: Nat Med 1999 Jan;5(1):7.

ORGANIZATION & ADMINISTRATION

Computerized pediatric telephone triage and advice programs at children's hospitals: operating and financial characteristics. Melzer SM, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):858–63

Fulcrum for the future: the creation of a values-driven culture. Taft S, et al. **Health Care Manage Rev** 1999 Winter; 24(1):17–32

Waterfalls and geysers: the development of diversity awareness at Children's Hospital. Ratliff SS. **J Nurs Care Qual** 1999 Feb;13(3):36–46

Young people with spina bifida: transfer from paediatric to adult health care. Sawyer SM, et al. **J Paediatr Child Health** 1998 Oct;34(5):414–7

Participant satisfaction and comfort with multidisciplinary pediatric telemedicine consultations. Dick PT, et al. **J Pediatr Surg** 1999 Jan;34(1):137–41; discussion 141–2

Is asthma documentation improved by computer-facilitated data entry? Kabir A, et al. **J Qual Clin Pract** 1998 Sep; 18(3):187–93

STANDARDS

APIC and CDC survey of Mycobacterium tuberculosis isolation and control practices in hospitals caring for children. Part 1: Patient and family isolation policies and procedures. Association for Professionals in Infection and Epidemiology, Inc. Kellerman SE, et al. **Am J Infect Control** 1998 Oct;26(5):478–82

APIC and CDC survey of Mycobacterium tuberculosis isolation and control practices in hospitals caring for children. Part 2: Environmental and administrative controls. Association for Professionals in Infection control and Epidemiology, Inc. Kellerman SE, et al. **Am J Infect Control** 1998 Oct;26(5):483–7

Using the measure of processes of care with parents of children hospitalized for head injury. Swaine BR, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):323–9

Parental leave and pediatric residents [letter; comment] Bradford BJ. **Arch Pediatr Adolesc Med** 1999 Apr; 153(4):429–30. Comment on: Arch Pediatr Adolesc Med 1998 Jul;152(7):629–33.

Conditional Length of Stay. Silber JH, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):349–63

European and Irish paediatric services [letter; comment] McCarthy E. **Ir Med J** 1999 Apr;92(3):311. Comment on: Ir Med J 1999 Jan–Feb;92(1):224, 226.

Quality of paediatric IDDM care in Germany: a multicentre analysis. German Paediatric Diabetology Group. Hecker W, et al. **J Pediatr Endocrinol Metab** 1999 Jan–Feb; 12(1):31–8

Medication errors in a pediatric emergency department. Selbst SM, et al. **Pediatr Emerg Care** 1999 Feb;15(1):1–4

Costs associated with tuberculosis control programs at hospitals caring for children. Kellerman S, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):604–8

[Follow up of pediatric care is a good resource of knowledge that can be even better] Sjögren LH, et al. **Lakartidningen** 1999 Mar 10;96(10):1201–5 (10 ref.) **(Swe)**

STATISTICS & NUMERICAL DATA

Use of urokinase in pediatric hematology/oncology patients. Kellerman S, et al. **Am J Infect Control** 1998 Oct; 26(5):502–6

Paediatric burns in Iceland. Hospital admissions 1982–1995, a populations based study. Elisdóttir R, et al. **Burns** 1999 Mar;25(2):149–51

Screening for congenital heart malformation in child health centres. Juttmann RE, et al. **Int J Epidemiol** 1998 Dec; 27(6):989–94

Suspected infection in children with cancer. Jones PD, et al. **J Qual Clin Pract** 1998 Dec;18(4):275–84

[Determinants of the use of pediatric consultations: study of child morbidity and maternal variables] Soriano Faura J, et al. **Aten Primaria** 1999 Feb 28;23(3):132–6 (Eng. Abstr.) **(Spa)**

UTILIZATION

Injury surveillance in an accident and emergency department:

a year in the life of CHIRPP. Morrison A, et al. **Arch Dis Child** 1999 Jun;80(6):533–6

Congenital airway abnormalities in patients requiring hospitalization. Altman KW, et al. **Arch Otolaryngol Head Neck Surg** 1999 May;125(5):525–8

A prospective study of the length of stay of 150 children following tonsillectomy and/or adenoidectomy. Drake-Lee A, et al. **Clin Otolaryngol** 1998 Dec;23(6):491–5

Pediatric surgical workload during the past decade: impact on clinical activity and hospital finance at a children's hospital. Adzick NS, et al. **J Pediatr Surg** 1999 Jan; 34(1):133–6

The blizzard of 1996: a pediatric emergency department [see comments] Attia MW. **Prehosp Emerg Care** 1998 Oct–Dec; 2(4):285–8. Comment in: Prehosp Emerg Care 1998 Oct–Dec;2(4):334–5.

HOSPITALS, PRIVATE

Need for vision rehabilitation in India. Survey of a private eye hospital. Herse P, et al. **Acta Ophthalmol Scand** 1998 Oct;76(5):606–9

Cesarean deliveries for medicaid patients: a comparison in public and private hospitals in Los Angeles county. Gregory KD, et al. **Am J Obstet Gynecol** 1999 May; 180(5):1177–84

Patient satisfaction in Turkey: differences between public and private hospitals. Tengilimoglu D, et al. **J Community Health** 1999 Feb;24(1):73–91

Antenatal care in developing countries. Belizán JM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:1–3

[Pain management of private hospital in home care] Hashimoto Y. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:545–8 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Cost reduction with successful implementation of an antibiotic prophylaxis program in a private hospital in Ribeirão Preto, Brazil. Fonseca SN, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):77–9

More or less?: Methods to compare VA and non-VA health care costs. Hendricks AM, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS54–62 (29 ref.)

Casemix perspectives for clinicians in the private sector. Maxwell CN. **Med J Aust** 1998 Oct 19;169 Suppl:S48–50

The life and times of medi-clinic [interview] Hertzog E, et al. **S Afr Med J** 1999 Mar;89(3):244–5

ORGANIZATION & ADMINISTRATION

The accent's on access. Public and private hospitals join hands to improve health care for poorer Chicagoans. Novarro L. **Hosp Health Netw** 1998 Oct 5;72(19):20

Health care markets in Australia: ownership of the private hospital sector. White K, et al. **Int J Health Serv** 1998; 28(3):487–510

Limited private practice—to be or not to be? [letter] Adno J. **S Afr Med J** 1999 Jan;89(1):10

[Systems of hospital (public and private) and ambulatory care. Structures and principles of rating] Bertrand D. **Rev Prat** 1998 Jun 15;48(12):1345–1 **(Fre)**

[The private hospital system before and after the 24 April 1996 regulations] Mesatfa N. **Sante Publique** 1999 Mar; 11(1):49–55 (Eng. Abstr.) **(Fre)**

[The organization of the health enterprise] Passerino C. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):192 **(Ita)**

[The probable changes in the structure of the network of state and private dental clinics] Leont'ev VK. **Stomatologiia (Mosk)** 1999;78(3):54–7 **(Rus)**

[The medical Foundation of Mar del Plata and the private community hospital] Paz RA. **Medicina (B Aires)** 1998; 58(2):221–7 **(Spa)**

STATISTICS & NUMERICAL DATA

Risk-sharing integration efforts in the hospital sector. Jantzen R, et al. **Health Care Manage Rev** 1999 Spring;24(2):83–92

Outcome of 1000 consecutive clinic- and hospital-based cataract surgeries in a Danish county. Wegener M, et al. **J Cataract Refract Surg** 1998 Aug;24(8):1152–60

UTILIZATION

Racial/ethnic disparities in admissions to public and private psychiatric inpatient settings: the effect of managed care. Crawford K, et al. **Adm Policy Ment Health** 1998 Nov; 26(2):101–9

Household health care facility utilization in the Philippines. Russo G, et al. **Asia Pac J Public Health** 1996–97;9:6–12

Dual use of VA and non-VA primary care [see comments] Borowsky SJ, et al. **J Gen Intern Med** 1999 May; 14(5):274–80. Comment in: J Gen Intern Med 1999 May;14(5):318–9.

Does the VA provide "primary" primary care? [editorial; comment] Petersen LA, et al. **J Gen Intern Med** 1999 May; 14(5):318–9 (17 ref.). Comment on: J Gen Intern Med 1999 May;14(5):274–80.

Increasing use of Medicare services by veterans with acute myocardial infarction [see comments] Wright SM, et al. **Med Care** 1999 Jun;37(6):529–37. Comment in: Med Care 1999 Jun;37(6):527–8.

HOSPITALS, PRIVATE, FOR-PROFIT see **HOSPITALS, PROPRIETARY**

HOSPITALS, PRIVATE, INVESTOR-OWNED see **HOSPITALS, PROPRIETARY**

HOSPITALS, PRIVATE, NOT-FOR-PROFIT see **HOSPITALS, VOLUNTARY**

HOSPITALS, PROPRIETARY

ECONOMICS

Nonprofit hospital conversions and community benefits: new evidence from three states. Young GJ, et al. **Health Aff (Millwood)** 1999 Sep–Oct;18(5):146–55

Columbia watch. Tamer ... not timid [news] Blecher MB. **Hosp Health Netw** 1999 Jan;73(1):16, 18

The association between for-profit hospital ownership and increased Medicare spending [see comments] Silverman EM, et al. **N Engl J Med** 1999 Aug 5;341(6):420–6. Comment in: N Engl J Med 1999 Aug 5;341(6):444–6.

When money is the mission—the high costs of investor-owned care [editorial; comment] Woolhandler S, et al. **N Engl J Med** 1999 Aug 5;341(6):444–6. Comment on: N Engl J Med 1999 Aug 5;341(6):420–6.

LEGISLATION & JURISPRUDENCE

Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131–82 (0 ref.)

Nonprofit to for-profit hospital transactions: all roads lead to the attorney general's office. Moore BE. **J Health Care Finance** 1999 Spring;25(3):29–36

ORGANIZATION & ADMINISTRATION

Evaluating the sale of a nonprofit health system to a for-profit hospital management company: the Legacy Experience. King JG, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):103–21

Analysis of the rationale for, and consequences of, nonprofit and for-profit ownership conversions. Mark TL. **Health Serv Res** 1999 Apr;34(1 Pt 1):83–101

Comparing change readiness, quality improvement, and cost management among Veterans Administration, for-profit, and nonprofit hospitals. West TD. **J Health Care Finance** 1998 Fall;25(1):46–58

Hospital conversions from for-profit to nonprofit status: the other side of the story [letter] Lee B. **Med Care Res Rev** 1999 Jun;56(2):220–2

Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J. **Public Health Rep** 1999 Mar–Apr;114(2):108–19 (41 ref.)

TRENDS

Uncompensated care and hospital conversions in Florida. Needleman J, et al. **Health Aff (Millwood)** 1999 Jul–Aug; 18(4):125–33

HOSPITALS, PSYCHIATRIC

Ambient sound levels in a state psychiatric hospital. Holmberg SK, et al. **Arch Psychiatr Nurs** 1999 Jun; 13(3):117–26

High security facilities must not be closed until viable alternatives are in place [letter] Sayal K, et al. **BMJ** 1999 Jul 3;319(7201):59

Physician satisfaction with review boards: the provincial psychiatric hospital perspective. Persad E, et al. **Can J Psychiatry** 1998 Nov;43(9):905–9

Efficacy of crisis intervention. Reisch T, et al. **Crisis** 1999; 20(2):78–85

Amoebiasis among institutionalized psychiatric patients in Taiwan. Cheng HS, et al. **Epidemiol Infect** 1999 Apr; 122(2):317–22

The Qualyop Project. 1: Monitoring the dismantlement of Italian public psychiatric hospitals. Characteristics of patients scheduled for discharge. D'Avanzo B, et al. **Int J Soc Psychiatry** 1999 Summer;45(2):79–92

The psychological impact of psychiatric admission: some preliminary findings. Morrison AP, et al. **J Nerv Ment Dis** 1999 Apr;187(4):250–3

Crowding and violent behavior: the influence of patient density on violent and self-harming behaviour at a medium secure unit. Hardie TJ. **Med Sci Law** 1999 Apr;39(2):161–6

Suicide among psychiatric in-patients with schizophrenia in an Australian mental hospital. Shah A, et al. **Med Sci Law** 1999 Jul;39(3):251–9

Mobile crisis: moving emergency psychiatry out of the hospital setting. Alexander C, et al. **New Dir Ment Health Serv** 1999 Summer;(82):93–9

Comparison of outcomes of acute care in short-term residential treatment and psychiatric hospital settings. Hawthorne WB, et al. **Psychiatr Serv** 1999 Mar;50(3):401–6

Adverse effects of poor behavior management of an inpatient's difficult behaviors. Hilton NZ, et al. **Psychiatr Serv** 1999 Jul;50(7):964–6

The computerized lab alert system for patient management in clinical care. Modai I, et al. **Psychiatr Serv** 1999 Jul; 50(7):869–70, 885

Psychiatric hospital care among children and adolescents in Finland: a nationwide register study. Sourander A, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Feb;34(2):105–10

The first five years: a review of the collaboration between DHHR and the WVU School of Medicine. Withersty DJ, et al. **W V Med J** 1999 Mar–Apr;95(2):62–3

ECONOMICS

Shrinking costs of inpatient mental health care [editorial; comment] Burnam A, et al. **Med Care** 1999 May; 37(5):434–5. Comment on: Med Care 1999 May;37(5):457–68.

[How significant is the comparison for length of stay in psychiatric hospitals based on diagnosis and age?] Richter D. **Gesundheitswesen** 1999 May;61(5):227–33 (Eng. Abstr.) **(Ger)**

HISTORY

St. Patrick's hospital. Clare AW. **Am J Psychiatry** 1998 Nov; 155(11):1599

A tale of two centuries: voices of the past and present. Mohr WK. **Arch Psychiatr Nurs** 1998 Dec;12(6):301–10

R. D. Laing in Scotland: facts and fictions of the 'Rumpus Room' and interpersonal psychiatry. Andrews J. **Clio Med** 1998;49:121–50

Enemies within: postwar Bethlem and the Maudsley Hospital. Waddington K. **Clio Med** 1998;49:185–202

The asylum, the workhouse, and the voice of the insane poor in 19th-century England. Bartlett P. **Int J Law Psychiatry** 1998 Fall;21(4):421–32

Psychiatry in the Palestine Authority: legal, ethical and forensic issues. Murad IJ. **Isr J Psychiatry Relat Sci** 1999; 36(1):65–71; discussion 71–4

High ideals versus harsh reality. A historical analysis of mental health nursing in Dutch asylums, 1890–1920. Boschma G. **Nurs Hist Rev** 1999;7:127–51

Asylum nursing and institutional service. A case study of the south of England, 1861–1881. Wright D. **Nurs Hist Rev** 1999;7:153–69

Whither Singapore psychiatry? How the mental hospital survived the Japanese occupation and the post-war years (Part I). Ng BY. **Singapore Med J** 1999 Apr;40(4):325–6

[Supplementary remarks (letter)] Kohl F. **Nervenarzt** 1997 Nov;68(11):928–9 **(Ger)**

[Outstanding neuropsychiatric scientific activities of physicians at the Lipótmezö mental institution from the institute's foundation to the 1950's] Kárpáti M. **Orv Hetil** 1999 Mar 21;140(12):661–6 (64 ref.) **(Hun)**

[Order and comfort in Konradsberg—the first modern psychiatric hospital in Sweden] Lidberg L. **Lakartidningen** 1999 May 5;96(18):2216–7 **(Swe)**

LEGISLATION & JURISPRUDENCE

The psychiatric "supermax"?: long-term, high-security psychiatric services. Mason T. **Int J Law Psychiatry** 1999 Mar–Apr;22(2):155–66

Seclusion and restraint: Congress reacts to reports of abuse. Appelbaum PS. **Psychiatr Serv** 1999 Jul;50(7):881–2, 885

MANPOWER

Psychiatric staffing [letter] Barglow P, et al. **Psychiatr Serv** 1999 Jan;50(1):113–4

Psychiatric staffing [letter] Dinakar HS, et al. **Psychiatr Serv** 1999 Jan;50(1):113; discussion 114

ORGANIZATION & ADMINISTRATION

Ashworth report confirms problems with special hospitals [news] [see comments] Warden J. **BMJ** 1999 Jan 23; 318(7178):211. Comment in: BMJ 1999 Jan 23;318(7178):206–7.

How managed care organizations develop selective contracting networks for psychiatric inpatient care: a Massachusetts case study. Fisher WH, et al. **Inquiry** 1998–99 Winter;35(4):417–31

The horrors of Ashworth: misdiagnosis [letter; comment] Johnson B. **Lancet** 1999 Mar 13;353(9156):931. Comment on: Lancet 1999 Jan 23;353(9149):251.

'A scandalous and corrupt hospital'—reflections on the Fallon report. Prins H. **Med Sci Law** 1999 Jul;39(3):209–13

Psychotropic drug prescription in a psychiatric university hospital. Voirol P, et al. **Pharmacopsychiatry** 1999 Jan; 32(1):29–37

STANDARDS

Comparison of patient satisfaction with community-based vs. hospital psychiatric services. Henderson C, et al. **Acta Psychiatr Scand** 1999 Mar;99(3):188–95

Novel antipsychotics and patient care in state hospitals. Buckley PF. **Ann Pharmacother** 1998 Sep;32(9):906–14 (72 ref.)

Gold Award: Confronting mood disorders through clinical care, research, and education. McMaster Regional Mood Disorders Program, Hamilton Psychiatric Hospital, Hamilton, Ontario. **Psychiatr Serv** 1998 Oct;49(10):1341–3

Improving pharmacotherapy in a psychiatric hospital. Moebius RE, et al. **Psychiatr Serv** 1999 Mar;50(3):335–8

[An analysis of public psychiatric hospital activities] Koike K, et al. **Seishin Shinkeigaku Zasshi** 1999;101(3):277–92 **(Jpn)**

HOSPITALS, PSYCHIATRIC

STATISTICS & NUMERICAL DATA

Service utilization and cost of community care for discharged state hospital patients: a 3-year follow-up study. Rothbard AB, et al. **Am J Psychiatry** 1999 Jun;156(6):920-7

Lunar cycles and violent behaviour. Owen C, et al. **Aust N Z J Psychiatry** 1998 Aug;32(4):496-9

Observation levels in acute psychiatric admissions. Langenbach M, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(1):28-33

Selected characteristics of absconders and non-absconders from mental hospitals: a comparison. Andoh B. **Int J Soc Psychiatry** 1999 Summer;45(2):117-24

Morbidity of homebound versus inpatient elderly psychiatric patients [see comments] Pasternak R, et al. **Int Psychogeriatr** 1998 Jun;10(2):117-25. Comment in: Int Psychogeriatr 1999 Mar;11(1):105-6.

Homelessness and psychiatric admission rates through the criminal justice system [letter] James DV, et al. **Lancet** 1999 Apr 3;353(9159):1158

Characteristics of nonresponders to a patient satisfaction survey at discharge from psychiatric hospitals. Ito H, et al. **Psychiatr Serv** 1999 Mar;50(3):410-2

The management of epilepsy in a hospital for people with a learning disability. Carvill S, et al. **Seizure** 1999 May; 8(3):175-80

A clinical study of 100 new admissions to an adolescent psychiatric inpatient unit in Singapore. Fung DS, et al. **Singapore Med J** 1999 Feb;40(2):91-5

Frequently hospitalised psychiatric patients: a study of predictive factors. Korkeila JA, et al. **Soc Psychiatry Psychiatr Epidemiol** 1998 Nov; 33(11):528-34

A transition rate model for first admissions to psychiatric institutions. Oldehinkel AJ. **Stat Med** 1999 May 15; 18(9):1111-8

[Seroprevalence of hepatitis B and C viruses in a psychiatric institution] Eveillard M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):543-8 (Eng. Abstr.) **(Fre)**

[Suicide in the psychiatric clinic: weekend leave as risk factor. A qualitative analysis] Hoffmann-Richter U, et al. **Psychiatr Prax** 1999 Jan;26(1):32-6 (Eng. Abstr.) **(Ger)**

TRENDS

Practice of seclusion: a five-year retrospective review in north Cheshire. Salib E, et al. **Med Sci Law** 1998 Oct; 38(4):321-7

[Historical and current construction principles for psychiatric clinics (letter; comment)] Boroffka A. **Nervenarzt** 1997 Nov;68(11):927, 929. Comment on: Nervenarzt 1997 Mar;68(3):184-95. **(Ger)**

[Internal structure of inpatient psychiatric hospital care 22 years after the psychiatry inquest] Gebhardt RP, et al. **Nervenarzt** 1998 Sep;69(9):791-8 (Eng. Abstr.) **(Ger)**

[Back to the 70's (editorial)] Bauer M. **Psychiatr Prax** 1998 Nov;25(6):267-8 **(Ger)**

[Should severely disturbed patients be concentrated or distributed overseveral psychiatric wards? Effects of internal sectorisation, partial ward opening and sex integration policy on ward atmosphere] Gebhardt RP, et al. **Psychiatr Prax** 1999 Mar;26(2):61-6 **(Ger)**

UTILIZATION

Immigration, moving house and psychiatric admissions. Johansson LM, et al. **Acta Psychiatr Scand** 1998 Aug; 98(2):105-11

Regional differences in the use of psychiatric hospital beds in Finland: a national case-register study. Korkeila JA, et al. **Acta Psychiatr Scand** 1998 Sep;98(3):193-9

The Nordic Comparative Study on Sectorized Psychiatry: patients who use only psychiatric in-patient care in comprehensive community-based services--a 1-year follow-up study. Saarento O, et al. **Acta Psychiatr Scand** 1998 Aug;98(2):98-104

Racial/ethnic disparities in admissions to public and private psychiatric inpatient settings: the effect of managed care. Crawford K, et al. **Adm Policy Ment Health** 1998 Nov; 26(2):101-9

Systematic review of the effectiveness of planned short hospital stays for mental health care. Johnstone P, et al. **BMJ** 1999 May 22;318(7195):1387-90 (27 ref.)

Do aftercare services reduce inpatient psychiatric readmissions? Foster EM. **Health Serv Res** 1999 Aug; 34(3):715-36

Assertive community treatment for people with severe mental illness: the effect on hospital use and costs. Salkever D, et al. **Health Serv Res** 1999 Jun;34(2):577-601

The new long stay in an inner city service: a tale of two cohorts. Holloway F, et al. **Int J Soc Psychiatry** 1999 Summer;45(2):93-103

Psychiatric hospital service utilization of children and adolescents in state custody. Leon SC, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar;38(3):305-10

Classifying psychiatric inpatients: seeking better measures. Durbin J, et al. **Med Care** 1999 Apr;37(4):415-23

Inpatient psychiatric treatment of elderly Medicare beneficiaries. Ettner SL, et al. **Psychiatr Serv** 1998 Sep; 49(9):1173-9

A comparative study of clinical events as triggers for psychiatric readmission of multiple recidivists. Frazier RS, et al. **Psychiatr Serv** 1998 Nov;49(11):1423-5

The influence of social deprivation as measured by the CNI on psychiatric admissions. Malmström M, et al. **Scand J Public Health** 1999 Sep;27(3):189-95

[Basic documentation: inpatient management in a region by a psychiatric hospital and a psychiatric department. Results of a joint evaluation] Kipp J, et al. **Nervenarzt** 1998 Sep; 69(9):782-90 (Eng. Abstr.) **(Ger)**

HOSPITALS, PUBLIC

Cesarean deliveries for medicaid patients: a comparison in public and private hospitals in Los Angeles county. Gregory KD, et al. **Am J Obstet Gynecol** 1999 May; 180(5):1177-84

Health care technology in public health institutions in Kenya. Ogembo-Kachieng'a M. **East Afr Med J** 1998 Nov; 75(11):632-6 (20 ref.)

Methicillin-resistant Staphylococcus aureus in French hospitals: A 2-month survey in 43 hospitals, 1995. The Hôpital Propre II Study Group. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):478-86

Patient satisfaction in Turkey: differences between public and private hospitals. Tengilimoglu D, et al. **J Community Health** 1999 Feb;24(1):73-91

Intervention to increase mammography utilization in a public hospital [letter; comment] de Souza RM, et al. **J Gen Intern Med** 1998 Nov;13(11):786. Comment on: J Gen Intern Med 1998 Apr;13(4):230-3.

Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. Preston RA, et al. **J Hum Hypertens** 1999 Apr;13(4):249-55

The clinical characteristics of pulmonary alveolar proteinosis: experience at Seoul National University Hospital, and review of the literature. Kim G, et al. **J Korean Med Sci** 1999 Apr;14(2):159-64 (21 ref.)

Neurosurgery in Greece [letter; comment] Garfield J. **J Neurosurg** 1998 Dec;89(6):1074. Comment on: J Neurosurg 1998 Apr;88(4):782-5.

Antenatal care in developing countries. Belizán JM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12 Suppl 2:1-3

[Outpatient gynecologic surgery in public hospitals] Fernandez H. **Ann Chir** 1999;53(5):363-6 **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of public hospital anesthetists] Palot M. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:182-5 (8 ref.) **(Fre)**

[Ambulatory surgery in French public hospitals. Present and future. "Public hospitals" group of the French Association of Ambulatory Surgery] L'Huillier MC, et al. **Presse Med** 1998 Feb 28;27(8):347-50 (Eng. Abstr.) **(Fre)**

[Palliative and continuous care in a public hospital. Experience at C.H.U. Brugmann] Markstein C, et al. **Rev Med Brux** 1999 Apr;20(2):A107-12 **(Fre)**

[A study visit to three hospitals in Cairns, Australia] Amaha K. **Masui** 1999 Jun;48(6):665-9 **(Jpn)**

ECONOMICS

The private finance initiative: planning the "new" NHS: downsizing for the 21st century. Pollock AM, et al. **BMJ** 1999 Jul 17;319(7203):179-84

Quality, cost, and outcome of intensive care in a public hospital in Bombay, India [see comments] Parikh CR, et al. **Crit Care Med** 1999 Sep;27(9):1754-9. Comment in: Crit Care Med 1999 Sep;27(9):2032-3.

Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Trap R, et al. **Endoscopy** 1999 Feb;31(2):125-30

Internal markets and health care efficiency: a multiple-output stochastic frontier analysis. Gerdtham UG, et al. **Health Econ** 1999 Mar;8(2):151-64

The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. Wurtz R, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):382-7

Suitability of casemix classification for output funding of blood services in Victoria. Victorian Blood Users Group [see comments] Whyte GS, et al. **Med J Aust** 1998 Oct 19;169(8):415-8. Comment in: Med J Aust 1998 Oct 19;169(8):407-8.

The development of funding policies for hospices: is casemix-based funding an option? Carter H, et al. **N Z Med J** 1999 Jun 25;112(1090):236-9

Risk adjustment and hospital cost-based resource allocation, with an application to El Salvador. Fiedler JL, et al. **Soc Sci Med** 1999 Jan;48(2):197-212

[The libraries of the public hospitals in Spain. An economic analysis. The Research Group on Libraries] Sánchez Gómez C, et al. **Gac Sanit** 1999 Mar-Apr;13(2):141-9 (Eng. Abstr.) **(Spa)**

HISTORY

From factory row to the Grosvenor Road. Clarke RS. **Ulster Med J** 1998 Jun;67 Suppl 1:8-11

The 'connexion' between the Royal and Queen's 1849-1949. Alliance or special relationship? Froggatt P. **Ulster Med J** 1998 Jun;67 Suppl 1:108-23

[Oral medicine at the Public Assistance Hospital in Paris] Laufer J. **Rev Stomatol Chir Maxillofac** 1999 Apr; 100(1):45-53 **(Fre)**

LEGISLATION & JURISPRUDENCE

[Compliance with regulations for medical records in 15 Aquitaine public health facilities. Aquitaine DIM Physician's Group] Michel P, et al. **Presse Med** 1998 Nov 28;27(37):1884-9 (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

The accent's on access. Public and private hospitals join hands to improve health care for poorer Chicagoans. Novarro L. **Hosp Health Netw** 1998 Oct 5;72(19):20

The lack of integration of clinical audit and the maintenance of medical dominance within British hospital trusts. McErlain-Burns TL, et al. **J Eval Clin Pract** 1999 Aug; 5(3):323-33 (36 ref.)

The Medicare Critical Access Hospital program: the first year. Reif SS, et al. **J Rural Health** 1999 Winter;15(1):61-6

The changing role of acute-care hospitals [see comments] Hillman K. **Med J Aust** 1999 Apr 5;170(7):325-8 (23 ref.) . Comment in: Med J Aust 1999 Apr 5;170(7):292-3.

Linking measures of health gain to explicit priority setting by an area health service in Australia. Cromwell DA, et al. **Soc Sci Med** 1998 Dec;47(12):2067-74

Use of hammocks in a rural hospital [letter] Campos-Navarro R. **World Health Forum** 1998;19(4):431-3

[The impact of the data collection method on the medico-economic classification of admissions for myocardial infarction at the public hospitals in Lyon (see comments)] Rabilloud M, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):709-14 (Eng. Abstr.). Comment in: Arch Mal Coeur Vaiss 1998 Jun;91(6):707-8. **(Fre)**

[Systems of hospital (public and private) and ambulatory care. Structures and principles of rating] Bertrand D. **Rev Prat** 1998 Jun 15;48(12):1345-1 **(Fre)**

[The organization of the health enterprise] Passerino C. **G Ital Med Lav Ergon** 1997 Oct-Dec;19(4):192 **(Ita)**

STANDARDS

A survey of the implementation of health service guidelines on arrangements for infection control in health trusts in the West Midlands. Hawker JI. **Commun Dis Public Health** 1999 Jan;2(1):54-8

Quality, cost, and outcome of intensive care in a public hospital in Bombay, India [see comments] Parikh CR, et al. **Crit Care Med** 1999 Sep;27(9):1754-9. Comment in: Crit Care Med 1999 Sep;27(9):2032-3.

Attitudes of pharmacists and physicians to antibiotic policies in hospitals. Adu A, et al. **J Clin Pharm Ther** 1999 Jun; 24(3):181-9

A case from a government hospital venipuncture clinic (what was the problem? Who was responsible?). Wiwanitkit V. **J Med Assoc Thai** 1999 May;82(5):528-30

Maintaining good medical practice. Clinical governance and self regulation for physicians. A report of the Royal College of Physicians. **J R Coll Physicians Lond** 1999 May-Jun; 33(3):241-5 (6 ref.)

The extraction of quality-of-care clinical indicators from State health department administrative databases. Majoor JW, et al. **Med J Aust** 1999 May 3;170(9):420-4

How should our public hospitals respond to increasing ethical challenges? Bryson J. **N Z Med J** 1999 Feb 26; 112(1082):47-9

[An analysis of public psychiatric hospital activities] Koike K, et al. **Seishin Shinkeigaku Zasshi** 1999;101(3):277-92 **(Jpn)**

STATISTICS & NUMERICAL DATA

Explaining differences in English hospital death rates using routinely collected data. Jarman B, et al. **BMJ** 1999 Jun 5;318(7197):1515-20

A survey of percutaneous/mucocutaneous injury reporting in a public teaching hospital [published erratum appears in J Hosp Infect 1999 May;42(1):83] Haiduven DJ, et al. **J Hosp Infect** 1999 Feb;41(2):151-4

[Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance] Imbs JL, et al. **Therapie** 1999 Jan-Feb;54(1):21-7 (Eng. Abstr.) **(Fre)**

[Evaluating the influence of hospital size on respiratory health care efficiency in Andalusia] Galán González-Serna JM, et al. **Arch Bronconeumol** 1999 May;35(5):202-7 (Eng. Abstr.) **(Spa)**

TRENDS

The changing role of acute-care hospitals [letter] Denaro CP, et al. **Med J Aust** 1999 Aug 16;171(4):224

The changing role of acute-care hospitals [letter] Kelly WJ. **Med J Aust** 1999 Aug 16;171(4):223-4

UTILIZATION

Racial/ethnic disparities in admissions to public and private psychiatric inpatient settings: the effect of managed care. Crawford K, et al. **Adm Policy Ment Health** 1998 Nov; 26(2):101-9

Household health care facility utilization in the Philippines. Russo G, et al. **Asia Pac J Public Health** 1996-97;9:6-12

Public hospital utilisation during the 1997 Arafura Games [letter] O'Grady KA, et al. **Aust N Z J Public Health** 1999

Apr;23(2):218–9
Factors associated with inappropriate hospitalization days in internal medicine wards in Israel: a cross-national survey. Merom D, et al. **Int J Qual Health Care** 1998 Apr; 10(2):155–62
The cost of tuberculosis: utilization and estimated charges for the diagnosis and treatment of tuberculosis in a public health system. Wurtz R, et al. **Int J Tuberc Lung Dis** 1999 May;3(5):382–7
Private patients in NHS hospitals: comparison of two sources of information. Williams BT, et al. **J Public Health Med** 1999 Mar;21(1):70–3
Queuing for coronary angiography during severe supply–demand mismatch in a US public hospital: analysis of a waiting list registry [see comments] Rosanio S, et al. **JAMA** 1999 Jul 14;282(2):145–52. Comment in: JAMA 1999 Jul 14;282(2):184–5.
Lack of a regular source of care among children using a public hospital emergency department. Jones DS, et al. **Pediatr Emerg Care** 1999 Feb;15(1):13–6

HOSPITALS, RELIGIOUS

HISTORY

Beaver kidneys at your bedside. Oldest hospital in Canada has seen it all. Blair L. **Can Fam Physician** 1999 Apr; 45:881–4, 888–92 **(Eng, Fre)**
[Fernand-Widal hospital. Origins and avatars] Bismuth C, et al. **Rev Prat** 1999 Jan 1;49(1):8–10 **(Fre)**
[The history of the Saint-Jacques de Besançon Hospital] Maurat JP, et al. **Rev Prat** 1999 Feb 1;49(3):241–4 **(Fre)**
[Between "Christian Women's Service" and professional cancer care. On the development of institutional patient care exemplified by the Kaiserwerth Deaconess Institution] Paul N. **Medizinhist J** 1998;33(2):143–60 **(Ger)**
[The Spanish hospital of Tunisia (Work of the Castilian Order of the Trinitarians) 1720–1818] Zitouna MM, et al. **Tunis Med** 1998 Oct;76(10):336–7 (Eng. Abstr.) **(Spa)**
[When women were allowed to make decisions Ersta hospital was equipped with light, air and pleasing interior decorations] Wendt B. **Lakartidningen** 1999 Jan 27; 96(4):316–7 **(Swe)**

ORGANIZATION & ADMINISTRATION

An education-service partnership: analysis of the development of a satellite baccalaureate nursing programme. Sullinger H, et al. **J Adv Nurs** 1998 Dec; 28(6):1334–8

STANDARDS

Performance improvement integration: a whole systems approach. Page CK. **J Nurs Care Qual** 1999 Feb; 13(3):59–70

STATISTICS & NUMERICAL DATA

How does Catholic hospital sponsorship affect services provided? White KR, et al. **Inquiry** 1998–99 Winter; 35(4):398–407

HOSPITALS, RURAL

Poison center data accuracy: a comparison of rural hospital chart data with the TESS database. Toxic Exposure Surveillance System. Hoyt BT, et al. **Acad Emerg Med** 1999 Aug;6(8):851–5
Establishing a laboratory for surveillance of invasive bacterial infections in a tertiary care government hospital in a rural province in the Philippines. Herva E, et al. **Am J Trop Med Hyg** 1999 Jun;60(6):1035–40
Differences in management of heart attack patients between metropolitan and regional hospitals in the Hunter Region of Australia. Lim LL, et al. **Aust N Z J Public Health** 1999 Feb;23(1):61–6
Australia's breast surgery workload is changing: comparison of a metropolitan and a rural hospital. Spillane AJ, et al. **Aust N Z J Surg** 1999 Mar;69(3):178–82
Barriers to rural physician use of a digital health sciences library. D'Alessandro DM, et al. **Bull Med Libr Assoc** 1998 Oct;86(4):583–93
A performance comparison of communication links between rural hospitals and a digital health sciences library. D'Alessandro MP, et al. **Bull Med Libr Assoc** 1998 Oct; 86(4):564–8
The Healthnet project: extending online information resources to end users in rural hospitals. Holtum E, et al. **Bull Med Libr Assoc** 1998 Oct;86(4):569–75
Advanced trauma life support (ATLS) courses: should training be refocused towards rural physicians? Ben-Abraham R, et al. **Eur J Emerg Med** 1999 Jun; 6(2):111–4
Fragile future: a rural hospital weighs its options. Bybee B, et al. **Hosp Health Netw** 1999 May;73(5):20
The significance of telemedicine in a rural emergency department. Stamford P, et al. **IEEE Eng Med Biol Mag** 1999 Jul–Aug;18(4):45–52
Study of the outcome of patients transferred to a level I hospital after stabilization at an outlying hospital in a rural setting. Rogers FB, et al. **J Trauma** 1999 Feb;46(2):328–33
The procedural skills of rural hospital doctors. Reid SJ, et al. **S Afr Med J** 1999 Jul;89(7):769–74
Closing rural hospitals in Saskatchewan: on the road to wellness? James AM. **Soc Sci Med** 1999 Oct;49(8):1021–34
Quality of care for Medicare patients hospitalized with heart failure in rural Georgia. Baker DW, et al. **South Med J** 1999 Aug;92(8):782–9
Medicare rural hospital flexibility program. Jolley B. **Tenn Med** 1999 Sep;92(9):345–6
Neonatal care during a residents' strike. Daga SR, et al. **Trop Doct** 1999 Apr;29(2):73–5

ECONOMICS

The effects of group size and group economic factors on collaboration: a study of the financial performance of rural hospitals in consortia. Chan B, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):9–31
Collective clout. Share the health. Castrey M. **Hosp Health Netw** 1998 Nov 20;72(22):43–4
Rural health. Solo act. Castrey M. **Hosp Health Netw** 1998 Nov 5;72(21):50
A stormy season for rurals. Greene J. **Hosp Health Netw** 1998 Nov 20;72(22):28, 30
Networks and the fiscal performance of rural hospitals in Oklahoma: are they associated? Broyles RW, et al. **J Rural Health** 1998 Fall;14(4):327–37
Hospital mergers and closures: survival of rural hospitals. Sinay UT. **J Rural Health** 1998 Fall;14(4):357–65

HISTORY

The early history of tuberculosis in central East Africa: insights fron. the clinical records of the first twenty years of Mengo Hospital and review of relevant literature. Daniel TM. **Int J Tuberc Lung Dis** 1998 Oct;2(10):784–90 (28 ref.)
The Throne Hospital: a short history. Beringer TR. **Ulster Med J** 1998 Nov;67(2):115–6
The Throne Hospital and early plastic surgery in Northern Ireland. Colville J. **Ulster Med J** 1998 Nov;67(2):117–20

MANPOWER

Recruitment barriers in rural community hospitals: a comparison of nursing and nonnursing factors. Stratton TD, et al. **Appl Nurs Res** 1998 Nov;11(4):183–9
An evaluation of the nurse practitioner role in a major rural emergency department. Chang E, et al. **J Adv Nurs** 1999 Jul;30(1):260–8

ORGANIZATION & ADMINISTRATION

Pharmacy and therapeutics committee 'virtual' meetings [letter] Devenport C. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1132
Airborne surgical outreach services in eastern Africa [see comments] Wachira J, et al. **East Afr Med J** 1998 Oct; 75(10):563–6. Comment in: East Afr Med J 1998 Oct;75(10):561–2.
Enhancing the family medicine curriculum in deliveries and emergency medicine as a way of developing a rural teaching site. Rodney WM, et al. **Fam Med** 1998 Nov–Dec; 30(10):712–9
Are rural hospitals "strategic"? Trinh HQ. **Health Care Manage Rev** 1999 Summer;24(3):42–54
The adoption of provider-based rural health clinics by rural hospitals: a study of market and institutional forces. Krein SL. **Health Serv Res** 1999 Apr;34(1 Pt 1):33–60
Rural hospital mergers, antitrust policy, and the Ukiah case. Blackstone EA, et al. **J Health Polit Policy Law** 1998 Dec; 23(6):949–71
Nurse case managers in rural hospitals. Anderson-Loftin W. **J Nurs Adm** 1999 Feb;29(2):42–9
Physician and clinical integration among rural hospitals. Alexander JA, et al. **J Rural Health** 1998 Fall;14(4):312–26
Missouri Advantage. Casey M, et al. **J Rural Health** 1998 Summer;14(3):257–67
The Medicare Critical Access Hospital program: the first year. Reif SS, et al. **J Rural Health** 1999 Winter;15(1):61–6
Rural hospitals in New Zealand. Janes R. **N Z Med J** 1999 Aug 13;112(1093):297–9
Use of hammocks in a rural hospital [letter] Campos-Navarro R. **World Health Forum** 1998;19(4):431–3
[Pediatric activity in a rural hospital in Tokombéré (Cameroon). Description and qualitative approach during a one year period] Buffin A, et al. **Arch Pediatr** 1998 Oct; 5(10):1072–81 (Eng. Abstr.) **(Fre)**

STANDARDS

The application of the Task Force report in rural and frontier settings. Moss AH. **J Clin Ethics** 1999 Spring;10(1):42–8 (11 ref.)
Risk-adjusted in-hospital death rates for peer hospitals in rural and urban regions. Glenn LL, et al. **J Rural Health** 1999 Winter;15(1):94–107
The fake patient: a research experiment in a Ghanaian hospital. Van der Geest S, et al. **Soc Sci Med** 1998 Nov; 47(9):1373–81

STATISTICS & NUMERICAL DATA

Admission trends in a rural South African hospital during the early years of the HIV epidemic. Floyd K, et al. **JAMA** 1999 Sep 15;282(11):1087–91

TRENDS

Rural hospital service trends [editorial] Hutten-Czapski P. **Can Fam Physician** 1998 Oct;44:2041–3, 2050–2 **(Eng, Fre)**
Trends in small hospital medical services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2107–12
Trends in small hospital obstetric services in Ontario. Rourke JT. **Can Fam Physician** 1998 Oct;44:2117–24

UTILIZATION

Trauma on rural roads: the role of a peripheral hospital. Street JT, et al. **Injury** 1999 Jun;30(5):337–40
Patterns of surgical practice in a small rural hospital. Sariego J. **J Am Coll Surg** 1999 Jul;189(1):8–10
An assessment of the potential for repatriating care from urban to rural Manitoba. Black C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS167–86
The Bwamanda hospital insurance scheme: effective for whom? A study of its impact on hospital utilization patterns. Criel B, et al. **Soc Sci Med** 1999 Apr;48(7):897–911

HOSPITALS, SPECIAL

High security facilities must not be closed until viable alternatives are in place [letter] Sayal K, et al. **BMJ** 1999 Jul 3;319(7201):59
The St John Ophthalmic Hospital: a medical ambassador in Jerusalem [letter] O'Shea JG. **Eye** 1999 Apr;13 (Pt 2):270–2
Awareness about tuberculosis among nurses working in a tuberculosis hospital and in a general hospital in Delhi, India. Singla N, et al. **Int J Tuberc Lung Dis** 1998 Dec; 2(12):1005–10
A breast clinic in a department of obstetrics and gynecology. Hindle WH, et al. **Obstet Gynecol** 1999 Jun;93(6):1044–8
Evaluation of the effectiveness of vaccination against diphtheria among medical staff of the chair and the Jagiellonian University Hospital of Infectious Diseases in Cracow, Poland. Some epidemiological observations. Borysiewicz J, et al. **Zentralbl Bakteriol** 1999 Apr; 289(2):227–33
[Infection hospitals--a continuous need?] Pedersen BK. **Ugeskr Laeger** 1999 Mar 29;161(13):1937 **(Dan)**
[The COPD patient in the field of tension between family physician, pneumonologist and hospital for lung diseases: who does what?-- a discussion paper] Steinkamp G. **Pneumologie** 1999 Jul;53(7):M31–2 **(Ger)**
[Backache from exertion in health personnel of the Istituti Ortopedici Rizzoli in Bologna. A case-control study of the injury phenomenon in the 10-year period of 1987–1996] Rossi A, et al. **Epidemiol Prev** 1999 Apr–Jun;23(2):98–104 (Eng. Abstr.) **(Ita)**

ECONOMICS

[Impact of hospital infection on medical expenditures in a continuing care and rehabilitation service at a geriatric hospital] Le Gonidec P, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):398–402 (Eng. Abstr.) **(Fre)**

HISTORY

The New York Eye and Ear Infirmary at 175 years. A historical review of the department of otolaryngology. Mattucci KF. **Bull N Y Acad Med** 1995 Winter;72(2):518–37
Francesco Rizzoli's dream (1809–1880). Campanacci M. **Chir Organi Mov** 1998 Oct-Dec;83(4):317–21 **(Eng, Ita)**
[From Lazaretto to the Rabta Hospital] Zitouna MM, et al. **Tunis Med** 1998 Oct;76(10):311–3 (Eng. Abstr.) **(Fre)**
[Early orthopedics in Munich around 1860] Halter U. **Z Orthop Ihre Grenzgeb** 1999 May–Jun;137(3):284–7 (Eng. Abstr.) **(Ger)**
[The 75th anniversary of the Physiotherapeutic Clinical Hospital (news)] Filatov VI. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Jul–Aug;(4):54 **(Rus)**
[The first specialty hospitals in Latin America] Quijano-Pitman F. **Gac Med Mex** 1998 May–Jun; 134(3):351–2 **(Spa)**
[Leprosy in the Bible--incorrect translation!] Gejrot T. **Lakartidningen** 1999 Mar 24;96(12):1463 **(Swe)**

LEGISLATION & JURISPRUDENCE

[Do the responsible persons believe that problems disappear when a special hospital will be closed? (letter)] Kåreland H. **Lakartidningen** 1999 Mar 3;96(9):997 **(Swe)**

METHODS

[Mental evaluation of new cases of pulmonary tuberculosis in different treatment settings] Makieva VG, et al. **Probl Tuberk** 1999;(4):7–10 (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Ashworth report confirms problems with special hospitals [news] [see comments] Warden J. **BMJ** 1999 Jan 23; 318(7178):211. Comment in: BMJ 1999 Jan 23;318(7178):206–7.
The changing role of acute-care hospitals [see comments] Hillman K. **Med J Aust** 1999 Apr 5;170(7):325–8 (23 ref.) . Comment in: Med J Aust 1999 Apr 5;170(7):292–3.

HOSPITALS, SPECIAL

STANDARDS

The horrors of Ashworth [editorial] [see comments] **Lancet** 1999 Jan 23;353(9149):251. Comment in: Lancet 1999 Mar 13;353(9156):931.

STATISTICS & NUMERICAL DATA

Medical activities and states of preparedness of donor hospitals. Hasegawa T, et al. **Transplant Proc** 1999 Aug; 31(5):1948–9

[New principles of clinical and X-ray examination of children and adolescents registered in special antituberculous hospitals] Aksenova VA, et al. **Probl Tuberk** 1999;(1):16–20 (Eng. Abstr.) **(Rus)**

[Results of polyresistant tuberculosis treatment: data of the Santarishkes Republican tuberculous hospital] Mishkinis K, et al. **Probl Tuberk** 1999;(1):30–1 (Eng. Abstr.) **(Rus)**

TRENDS

WHO meeting on the future role of leprosy training and/or research institutions, Addis Ababa, February 25–26, 1998. **Indian J Lepr** 1998 Oct–Dec;70(4):441–53

UTILIZATION

[Intrauterine and postnatal transfer of high risk newborn infants. Swiss Society of Neonatology] Bucher HU, et al. **Schweiz Med Wochenschr** 1998 Oct 24;128(43):1646–53 (Eng. Abstr.) **(Ger)**

VETERINARY see HOSPITALS, ANIMAL

HOSPITALS, STATE

Ambient sound levels in a state psychiatric hospital. Holmberg SK, et al. **Arch Psychiatr Nurs** 1999 Jun; 13(3):117–26

ORGANIZATION & ADMINISTRATION

Limited private practice--to be or not to be? [letter] Adno J. **S Afr Med J** 1999 Jan;89(1):10

[The probable changes in the structure of the network of state and private dental clinics] Leont'ev VK. **Stomatologiia (Mosk)** 1999;78(3):54–7 **(Rus)**

STANDARDS

Novel antipsychotics and patient care in state hospitals. Buckley PF. **Ann Pharmacother** 1998 Sep;32(9):906–14 (72 ref.)

STATISTICS & NUMERICAL DATA

Service utilization and cost of community care for discharged state hospital patients: a 3-year follow-up study. Rothbard AB, et al. **Am J Psychiatry** 1999 Jun;156(6):920–7

Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions. Chengappa KN, et al. **J Clin Psychiatry** 1999 Jun;60(6):373–8

UTILIZATION

Shifts in case mix and locus of mental health care for Washington State adults with severe mental illness. Semke J. **Adm Policy Ment Health** 1999 Jan;26(3):191–205

HOSPITALS, TEACHING

Trends in quality of anesthesia care associated with changing staffing patterns, productivity, and concurrency of case supervision in a teaching hospital. Posner KL, et al. **Anesthesiology** 1999 Sep;91(3):839–47

Surgical residencies and community teaching hospitals [letter; comment] Becker JM, et al. **Arch Surg** 1998 Nov; 133(11):1255. Comment on: Arch Surg 1998 Oct;133(10):1039–40.

The value of surgical residencies to community teaching hospitals [see comments] McMillen MA. **Arch Surg** 1998 Oct;133(10):1039–40. Comment in: Arch Surg 1998 Nov;133(11):1255. Comment in: Arch Surg 1999 Apr;134(4):445–7. Comment in: Arch Surg 1999 May;134(5):575.

The value of physician assistants to surgical education in teaching hospitals [comment] McMillen MA, et al. **Arch Surg** 1999 Apr;134(4):445–7. Comment on: Arch Surg 1998 Oct;133(10):1039–40.

Use of a focussed teen prenatal clinic at a military teaching hospital: model for improved outcomes of unmarried mothers. Perez R, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):280–3

Evidence-based medicine training for residents and students at a teaching hospital: the library's role in turning evidence into action. Earl MF, et al. **Bull Med Libr Assoc** 1999 Apr; 87(2):211–4

Facilities and resources for diabetes care at regional health facilities in southern Ghana. Amoah AG, et al. **Diabetes Res Clin Pract** 1998 Nov;42(2):123–30

Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985–1996. Crowe M, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):377–84

Risk factors for hospital-acquired urinary tract infection in a large English teaching hospital: a case-control study. Nguyen-Van-Tam SE, et al. **Infection** 1999 May–Jun; 27(3):192–7

The CCC system in two teaching hospitals: a progress report. Slack WV, et al. **Int J Med Inf** 1999 Jun;54(3):183–96

The Brigham integrated computing system (BICS): advanced clinical systems in an academic hospital environment. Teich JM, et al. **Int J Med Inf** 1999 Jun;54(3):197–208

Should hospital diets meet the dietary guidelines for healthy persons? [letter; comment] Miller MA, et al. **J Am Diet Assoc** 1998 Dec;98(12):1401; discussion 1402. Comment on: J Am Diet Assoc 1998 Jun;98(6):639–41.

Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. Sevinç F, et al. **J Antimicrob Chemother** 1999 Apr;43(4):601–6

Use of indapamide in hospital and community clinics and its effect on plasma potassium in Chinese patients. Chang S, et al. **J Clin Pharm Ther** 1998 Aug;23(4):295–302

Periodic syphilis profile in a New Delhi hospital. Rathore AS, et al. **J Commun Dis** 1998 Sep;30(3):153–7

Medicare GME reimbursement for hospital dental residency training: overview and reporting of survey results. Rutkauskas JS, et al. **J Dent Educ** 1998 Nov;62(11):929–33

Establishing radiologic image transmission via a transmission control protocol/Internet protocol network between two teaching hospitals in Houston. Shepherd B. **J Digit Imaging** 1999 May;12(2 Suppl 1):88–90

Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. Preston RA, et al. **J Hum Hypertens** 1999 Apr;13(4):249–55

Med schools and teaching hospitals tackle "Y2K" problem [news] D'Auria J. **J Investig Med** 1999 Mar;47(3):91–3

Prescribing practices: an overview of three teaching hospitals in Pakistan. Najmi MH, et al. **JPMA J Pak Med Assoc** 1998 Mar;48(3):73–7

Inquiry into clinical trial scandal at Canadian research hospital [news] [see comments] Bonetta L. **Nat Med** 1998 Oct;4(10):1095. Comment in: Nat Med 1998 Oct;4(10):1089. Comment in: Nat Med 1999 Jan;5(1):2–3.

The impact of managed care on the academic missions of medical schools and teaching hospitals. Wilson DE. **P R Health Sci J** 1998 Jun;17(2):127–34

Pediatric oncology at the National Institute of Pediatrics in Mexico City. Rivera-Luna R. **Pediatr Hematol Oncol** 1999 Mar–Apr;16(2):95–9

Characteristics of patients adhering to a hospital's no-smoking policy. Emmons KM, et al. **Prev Med** 1998 Nov–Dec;27(6):846–53

Maslow in the classroom and the clinic. DeMarco ML, et al. **Radiol Technol** 1998 Sep–Oct;70(1):91–4

[Teaching resources of a hospital Gynecology–Obstetrics service. Review of the literature and practical applications] Levêque J, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May;28(2):171–8 (Eng. Abstr.) **(Fre)**

[University duties at Sentralsykehuset in Akershus (letter) (see comments)] Røttingen JA. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):862. Comment in: Tidsskr Nor Laegeforen 1999 Apr 10;119(9):1340–1. Comment in: Tidsskr Nor Laegeforen 1999 Apr 20;119(10):1511–2. **(Nor)**

[Theoretical substantiation and results of licensing and accreditation technology in a region] Diul'din VA, et al. **Probl Sotsialnoi Gig Istor Med** 1998 Nov–Dec;(6):37–40 (Eng. Abstr.) **(Rus)**

ECONOMICS

Under new Medicare regulations, can we still educate for uncertainty? Paller MS, et al. **Acad Med** 1998 Oct; 73(10):1033–5

Valuing the work performed by anesthesiology residents [letter; comment] Gerancher JC. **Anesth Analg** 1999 Apr; 88(4):964–5. Comment on: Anesth Analg 1998 Aug;87(2):242–4. Comment on: Anesth Analg 1998 Aug;87(2):245–54.

Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Carmeli Y, et al. **Arch Intern Med** 1999 May 24;159(10):1127–32

Who says teaching hospitals are thriving? [letter] Cohen JJ. **Health Aff (Millwood)** 1999 Jul–Aug;18(4):199–202

Drug utilization in a hospital general medical outpatient clinic with particular reference to antihypertensive and antidiabetic drugs. Yuen YH, et al. **J Clin Pharm Ther** 1998 Aug;23(4):287–94

AAMC analyzes 1997 Balanced Budget Act. Association of American Medical Colleges [news] Marwick C. **JAMA** 1999 May 19;281(19):1781–2

Distribution of variable vs fixed costs of hospital care. Roberts RR, et al. **JAMA** 1999 Feb 17;281(7):644–9

Teaching and research in a casemix funding environment. Phillips PA. **Med J Aust** 1998 Oct 19;169 Suppl:S53–5

Managed care and medical education. Kuttner R. **N Engl J Med** 1999 Sep 30;341(14):1092–6

Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries [see comments] Taylor DH Jr, et al. **N Engl J Med** 1999 Jan 28;340(4):293–9 . Comment in: N Engl J Med 1999 Jan 28;340(4):309–10.

Is research suffering at academic health centers? [news] Ault A. **Nat Med** 1999 May;5(5):472

Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Beech R, et al. **Stroke** 1999 Apr;30(4):729–35

[Impact of hospital infection on medical expenditures in a continuing care and rehabilitation service at a geriatric hospital] Le Gonidec P, et al. **Pathol Biol (Paris)** 1998 Jun; 46(6):398–402 (Eng. Abstr.) **(Fre)**

HISTORY

A suitable memorial to Henry Grady. Moran M. **J Med Assoc Ga** 1999 Apr;88(2):45–9

Medicine in Columbus, Georgia during a time of great change, 1940–1950. Pike B. **J Med Assoc Ga** 1999 Apr; 88(2):62–8

The 'connexion' between the Royal and Queen's 1849–1949. Alliance or special relationship? Froggatt P. **Ulster Med J** 1998 Jun;67 Suppl 1:108–23

['Pediatric and teaching hospital' in the early 18th century? Facilities for patient care in the Francke institutions] Helm J. **Medizinhist J** 1998;33(2):107–41 **(Ger)**

[The 60th anniversary of the Department of Hospital Operative Dentistry and Maxillofacial Surgery of the Moscow Medical Stomatological Institute] Rud'ko VF. **Stomatologiia (Mosk)** 1998;77(4):65 **(Rus)**

[The history of the instructional work at the P. V. Mandryka Central Military Clinical Hospital] Nininchenko VI. **Voen Med Zh** 1999 Apr;320(4):85–90 **(Rus)**

LEGISLATION & JURISPRUDENCE

Clinical integration and new options for academic medical institutions in network development. Taylor PL. **Acad Med** 1999 Mar;74(3):213–20

Institutional liability for needlestick injury [letter] Tereskerz PM, et al. **Infect Control Hosp Epidemiol** 1998 Oct; 19(10):737

An analysis of drug abuse policies in teaching hospitals. Montoya ID, et al. **J Behav Health Serv Res** 1999 Feb; 26(1):28–38

ORGANIZATION & ADMINISTRATION

Graduate medical education at Chubu Hospital, Okinawa, Japan. Hefelfinger DC. **Acad Med** 1998 Dec;73(12):1274–6

Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Mannebach MA, et al. **Am J Health Syst Pharm** 1999 Apr 1;56(7):622–8

Hand hygiene in hospitals [letter] Mortimer PP. **Ann Intern Med** 1999 Oct 5;131(7):546

The vascular center at Brigham and Women's Hospital. Whittemore A, et al. **Cardiovasc Surg** 1998 Aug;6(4):327–32

Full time professor and Hon. professor. Joglekar SV. **Indian J Med Sci** 1998 Aug;52(8):357–61

Leadership at Mbarara [letter; comment] Craven J. **Lancet** 1998 Dec 19–26;352(9145):2026. Comment on: Lancet 1998 Jul 11;352(9122):141–2.

The impact of re-engineering and other cost reduction strategies on the staff of a large teaching hospital: a longitudinal study. Woodward CA, et al. **Med Care** 1999 Jun;37(6):556–69

Privatisation of teaching hospitals. Brooks PM. **Med J Aust** 1999 Apr 5;170(7):321–2 (17 ref.)

Winning the battle but losing the war: methicillin-resistant Staphylococcus aureus (MRSA) infection at a teaching hospital. Farrington M, et al. **QJM** 1998 Aug;91(8):539–48

STANDARDS

An audit of standards and quality in a teaching hospital colposcopy clinic. Teale G, et al. **Br J Obstet Gynaecol** 1999 Jan;106(1):83–6

Quality of care for two common illnesses in teaching and nonteaching hospitals. Ayanian JZ, et al. **Health Aff (Millwood)** 1998 Nov–Dec;17(6):194–205

Reliability of a hospital utilization review method in Turkey. Kaya S, et al. **Int J Qual Health Care** 1998 Feb;10(1):53–8

The contribution of multiple data sources to a clinical audit of lymphoma in a teaching hospital. Paltiel O, et al. **Int J Qual Health Care** 1998 Aug;10(4):303–9

Internal quality assurance activities of a surgical pathology department in an Australian teaching hospital. Zardawi IM, et al. **J Clin Pathol** 1998 Sep;51(9):695–9

Accuracy of the recording of operative events by the Scottish Morbidity Record 1 (SMR1) for a teaching hospital vascular unit. Raza Z, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):96–8

Prospective study of high dependency care requirements and provision. Turner M, et al. **J R Coll Surg Edinb** 1999 Feb; 44(1):19–23

Comparison of outpatient laparoscopic cholecystectomy in a private nonteaching hospital versus a private teaching community hospital. Smith M 2nd, et al. **J Soc Laparoendosc Surg** 1997 Jan–Mar;1(1):51–3

Time-frame for investigations into quality of clinical care [editorial] **Lancet** 1999 Sep 18;354(9183):963

Prestige of training programs and experience of bypass surgeons as factors in adjusted patient mortality rates. Hartz AJ, et al. **Med Care** 1999 Jan;37(1):93–103

Hospitals, heal yourselves [editorial; comment] [see comments] Kassirer JP. **N Engl J Med** 1999 Jan 28; 340(4):309–10. Comment on: N Engl J Med 1999 Jan 28;340(4):286–92. Comment on: N Engl J Med 1999 Jan 28;340(4):293–9. Comment in: N Engl J Med 1999 Jun 24;340(25):2007.

Comparing hospitals [letter; comment] Lane WL, et al. **N Engl J Med** 1999 Jun 24;340(25):2007. Comment on: N Engl J Med 1999 Jan 28;340(4):309–10.

[Productivity of teaching hospitals in the state of São Paulo,Brazil] Zucchi P, et al. **Rev Panam Salud Publica** 1998 Nov;4(5):311–6 (Eng. Abstr.) **(Por)**

[What is happening with teaching accreditation and reaccreditation for our primary care centers and tutors? (editorial)] Martín Zurro A. **Aten Primaria** 1999 Mar 31; 23(5):257–9 **(Spa)**

STATISTICS & NUMERICAL DATA

Prescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil. Heineck I, et al. **Am J Infect Control** 1999 Jun; 27(3):296–300

Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior. Major S, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):450–61

Incidence of post operative wound infection and their antibiogram in a teaching and referral hospital. Murthy R, et al. **Indian J Med Sci** 1998 Dec;52(12):553–5

Pseudo-epidemic in an acute-care teaching hospital [letter; comment] Zafar AB. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):739–40. Comment on: Infect Control Hosp Epidemiol 1998 May;19(5):345–7.

Experience in running a Diarrhoeal Training cum Treatment Unit (DTTU) in a state teaching hospital in Calcutta. Sengupta B, et al. **J Indian Med Assoc** 1998 Apr; 96(4):104–5, 108

TRENDS

Medical schools and teaching hospitals--serving the needs of America's communities. Cohen JJ. **Acad Med** 1998 Nov; 73(11):1177

Trends in exodontia under general anaesthesia at a dental teaching hospital. Grant SM, et al. **Br Dent J** 1998 Oct 10;185(7):347–52

Maternal mortality in Ramathibodi Hospital: a 28-year comparative study. Roungspragarn R, et al. **J Med Assoc Thai** 1999 Apr;82(4):357–62

UTILIZATION

Endoscopic practice for upper gastrointestinal hemorrhage: differences between major teaching and community-based hospitals. Cooper GS, et al. **Gastrointest Endosc** 1998 Oct; 48(4):348–53

Influence of patient preferences and local health system characteristics on the place of death. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Risks and Outcomes of Treatment [see comments] Pritchard RS, et al. **J Am Geriatr Soc** 1998 Oct;46(10):1242–50. Comment in: J Am Geriatr Soc 1998 Oct;46(10):1320–1.

HOSPITALS, UNIVERSITY

A review of radiation protection facilities at the University College Hospital, Ibadan, Nigeria. Adeniran SA. **Afr J Med Med Sci** 1996 Sep;25(3):269–71

Acupuncture in a university hospital: implications for an inpatient consulting service. Nasir L. **Arch Fam Med** 1998 Nov-Dec;7(6):593–6

Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Schmitz FJ, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jun; 18(6):414–21

Construction. Built to bend [news] Greene J. **Hosp Health Netw** 1999 Jun;73(6):20, 22

Methicillin-resistant Staphylococcus aureus in French hospitals: A 2-month survey in 43 hospitals, 1995. The Hôpital Propre II Study Group. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):478–86

Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. Pittet D, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):37–42

Resistance problems in two university hospitals in Denmark. Jensen TG, et al. **Int J Antimicrob Agents** 1999 Jun; 12(1):71–3

In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study. Soussy CJ, et al. **J Antimicrob Chemother** 1999 Jun;43 Suppl C:43–50

Lifestyle modification program in management of patients with coronary artery disease: the clinical experience in a tertiary care hospital. Rutledge JC, et al. **J Cardiopulm Rehabil** 1999 Jul-Aug;19(4):226–34

Cefepime--assessment of its need at a tertiary care center. Harbarth S, et al. **J Clin Pharm Ther** 1998 Feb;23(1):11–7

The clinical characteristics of pulmonary alveolar proteinosis: experience at Seoul National University Hospital, and review of the literature. Kim G, et al. **J Korean Med Sci** 1999 Apr;14(2):159–64 (21 ref.)

Pulmonary sarcoidosis: comparison of patients at a university and a municipal hospital [see comments] Yeager H Jr, et al. **J Natl Med Assoc** 1999 Jun;91(6):322–7. Comment in: J Natl Med Assoc 1999 Jun;91(6):327–8.

Are sociodemographic factors important in sarcoidosis? [comment] Young RC Jr. **J Natl Med Assoc** 1999 Jun; 91(6):327–8. Comment on: J Natl Med Assoc 1999 Jun;91(6):322–7.

A first evaluation of a pedagogical network for medical students at the University Hospital of Rennes. Fresnel A, et al. **Med Inform (Lond)** 1998 Jul-Sep;23(3):253–64

University medical information network--past, present, and future. Kiuchi T, et al. **Medinfo** 1998;9 Pt 1:420–4

Surgical and endovascular treatment of unruptured cerebral aneurysms at university hospitals. Johnston SC, et al. **Neurology** 1999 Jun 10;52(9):1799–805

Differences in prostate size between patients from University and Veterans Affairs Medical Center populations. Nixon RG, et al. **Prostate** 1999 Feb 1;38(2):144–50

Detection of fowl mites inside two hospital rooms. Nagakura K, et al. **Tokai J Exp Clin Med** 1998 Oct;23(4):173–6

Evaluation of the effectiveness of vaccination against diphtheria among medical staff of the chair and the Jagiellonian University Hospital of Infectious Diseases in Cracow, Poland. Some epidemiological observations. Borysiewicz J, et al. **Zentralbl Bakteriol** 1999 Apr; 289(2):227–33

[Ambulatory anesthesia practice in a University Hospital Center: what is done; what could be done. Ambulatory Anesthesia Study Group] Esposito J, et al. **Ann Fr Anesth Reanim** 1997;16(7):866–72 (Eng. Abstr.) **(Fre)**

[Use of a medium and long chain triglyceride mixture for parenteral nutrition in a university hospital: results of an internal audit] Desport JC, et al. **Gastroenterol Clin Biol** 1998 Apr;22(4):419–24 (Eng. Abstr.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center directors] Leclercq B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:229–31 (11 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center obstetricians] Lévy G. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:104–9 (9 ref.) **(Fre)**

[Perinatal care: advantages and disadvantages of network functioning. Analysis and point-of-view of university hospital center pediatricians] Rozé JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:153–61 (61 ref.) **(Fre)**

[Current practices in obstetrical analgesia in German university clinics. Results of a 1996 survey. Part 2] Wulf H, et al. **Anaesthesist** 1998 Sep;47(9):757–64 (Eng. Abstr.) **(Ger)**

[Our university clinics need research--so does our specialty! (editorial)] Haller U, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):117–8 (Eng. Abstr.) **(Ger)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 2. The problems of management of the patients diagnosed pulmonary tuberculosis after admission to the respiratory ward of university hospital having no an isolation ward for the tuberculous patients] Hiraoka H, et al. **Kekkaku** 1999 Feb; 74(2):133–7 (Eng. Abstr.) **(Jpn)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 4. Actual status of the management of tuberculosis patients in a university hospital without isolation wards for infectious diseases] Kako K, et al. **Kekkaku** 1999 Feb;74(2):145–50 (Eng. Abstr.) **(Jpn)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 5. The management of the patients excreting tubercle bacilli in a university hospital without isolation ward for tuberculosis] Kato H, et al. **Kekkaku** 1999 Feb;74(2):151–6 (Eng. Abstr.) **(Jpn)**

[Management of mycobacteriosis in general hospital without isolation ward for tuberculosis patients. 3. Current status of tuberculosis patient care in university hospitals and general hospitals in Japan] Kurane S, et al. **Kekkaku** 1999 Feb;74(2):139–43 (Eng. Abstr.) **(Jpn)**

[Clinical experience at Uppsala University] Igarashi M. **Masui** 1998 Dec;47(12):1495–9 (Eng. Abstr.) **(Jpn)**

[Reconstruct university hospitals as educational institutions] Brodal P, et al. **Tidsskr Nor Laegeforen** 1999 Apr 20; 119(10):1496–7 **(Nor)**

[A university clinic in Lørenskog? (letter; comment)] Lekven J. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1340–1. Comment on: Tidsskr Nor Laegeforen 1999 Feb 28;119(6):862. **(Nor)**

[University duties at Sentralsykehuset in Akershus (letter) (see comments)] Røttingen JA. **Tidsskr Nor Laegeforen** 1999 Feb 28;119(6):862. Comment in: Tidsskr Nor Laegeforen 1999 Apr 10;119(9):1340–1. Comment in: Tidsskr Nor Laegeforen 1999 Apr 20;119(10):1511–2. **(Nor)**

[University function at the central hospital in Akershus (letter)] Smeland E. **Tidsskr Nor Laegeforen** 1999 Apr 30; 119(11):1647 **(Nor)**

[Physician training, university hospitals, and the Unified Health System in Brazil] Campos GW. **Cad Saude Publica** 1999 Jan-Mar;15(1):187–93 (Eng. Abstr.) **(Por)**

[Role of I.M.Sechenov Moscow Medical Academy clinics in development of higher medical education] Makolkin VI. **Klin Med (Mosk)** 1998;76(10):68–70 (0 ref.) **(Rus)**

ECONOMICS

Influence of superstition on the date of hospital discharge and medical cost in Japan: retrospective and descriptive study. Hira K, et al. **BMJ** 1998 Dec 19-26;317(7174):1680–3

Economic consequences of hospital infections in a 1,000-bed university hospital in Norway. Andersen BM. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):805–7

Financial burden of trauma care on a university hospital in a developing country. Kaya E, et al. **J Trauma** 1999 Sep; 47(3):572–5

Direct costs of transient ischemic attacks: a hospital-based study of resource use during the first year after transient ischemic attacks in Denmark. Porsdal V, et al. **Stroke** 1998 Nov;29(11):2321–4

How competitive forces mold strategy in academic surgery [see comments] Souba WW. **Surgery** 1999 Jun; 125(6):616–29. Comment in: Surgery 1999 Jun;125(6):632–4.

The influence of clinical variables on hospital costs after orthotopic liver transplantation. Whiting JF, et al. **Surgery** 1999 Feb;125(2):217–22

[Direct cost of antibiotic therapy prescribed for nosocomial bacteremia. Prospective study during 6 months at a CHU (University Hospital Center)] Daumal F, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):470–5 (Eng. Abstr.) **(Fre)**

[Activity and costs of diagnosis-related groups (DRG) of neurological services at the Virgen de las Nieves Hospital of Granada] Ortega-Moreno A, et al. **Rev Neurol** 1998 Sep; 27(157):453–8 (Eng. Abstr.) **(Spa)**

HISTORY

Flexner and the whole-time system: the second Flexner report and the whole-time system in American academic surgery [editorial] Fischer JE. **Am J Surg** 1999 Jul; 178(1):2–13

The history of neurological surgery at Northwestern University [see comments] Engelhard HH, et al. **Neurosurgery** 1998 Oct;43(4):914–25. Comment in: Neurosurgery 1999 Apr;44(4):920–1.

The history of neurological surgery at Northwestern University [letter; comment] Engelhard HH. **Neurosurgery** 1999 Apr;44(4):920–1. Comment on: Neurosurgery 1998 Oct;43(4):914–25.

Neurosurgery at the State University of New York at Buffalo. Grand W, et al. **Neurosurgery** 1999 Jan;44(1):179–85

[The discourse of Robert Debré. I. The hospital] Chabot JM. **Rev Prat** 1998 Sep 15;48(14):1573–4 **(Fre)**

[History of the Rostock University Gynecology Clinic 1887–1997: what remains?] Schwarz R. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):151–7 (Eng. Abstr.) **(Ger)**

[History of the University Clinic of Dermatology and Venereology in Graz. A review of 125 years (1873–1998)] Kopera D, et al. **Hautarzt** 1998 Oct;49(10):791–4 **(Ger)**

[Diagnosis of allergic diseases. Contribution of the Zurich Allergy Unit 1948–1998] Bircher AJ. **Schweiz Rundsch Med Prax** 1998 Sep 30;87(40):1277–84 (Eng. Abstr.) **(Ger)**

[O.D.Krylov--the first professor of therapeutic clinic of Empire Nikoli University] Nushtaev IA. **Klin Med (Mosk)** 1999;77(3):65–7 **(Rus)**

[30th anniversary of the Urology Clinic at the Dérer University Hospital in Bratislava--Kramáre (1968–1998)] Zvara V. **Bratisl Lek Listy** 1999 Feb;100(2):99–117 (Eng. Abstr.) **(Slo)**

MANPOWER

Hospital explores winning balance in perioperative education. Onstott AT. **AORN J** 1998 Sep;68(3):395–9

ORGANIZATION & ADMINISTRATION

The integration of primary care sports medicine into an academic emergency medicine practice: academic and revenue enhancement. Veenema KR. **Acad Emerg Med** 1999 Aug;6(8):828–32

The patient as partner. Johns Hopkins pins the success of its inner-city programs on involving community leaders. Babwin D. **Hosp Health Netw** 1998 Nov 5;72(21):24

Shorter turn-around-time and improved patient care in peripheral blood progenitor cell collection procedures. Ratcliffe N, et al. **J Clin Apheresis** 1999;14(1):35–41

Establishing a research coordinator network: the birth of an idea. Ecklund DJ. **J Nurs Adm** 1999 Jan;29(1):20–5

Merger of top Californian medical schools turns sour [news] Dalton R. **Nature** 1999 Jul 22;400(6742):300

Psychotropic drug prescription in a psychiatric university hospital. Voirol P, et al. **Pharmacopsychiatry** 1999 Jan; 32(1):29–37

Hospital professionalization of the organ procurement process maximizes the retrieval potential. López-Navidad A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1039

[Drug management at the level of the Psychiatry Department of the Fann University Hospital Center: problem and perspectives] Toure K, et al. **Dakar Med** 1997;42(2):99–102 (Eng. Abstr.) **(Fre)**

[Evaluation of the actual traceability of labile blood products using medical records] Ingrand P, et al. **Transfus Clin Biol** 1998 Dec;5(6):397–407 (Eng. Abstr.) **(Fre)**

[Steps towards a hospital information system: illustrated by the example of the medical setting of the Westphalian Wilhelms University of Münster] Prokosch HU. **Zentralbl Gynakol** 1999;121(3):166–73 (Eng. Abstr.) **(Ger)**

HOSPITALS, UNIVERSITY

STANDARDS

Performance of the AutoPap primary screening system at Jefferson University Hospital. Bibbo M, et al. **Acta Cytol** 1999 Jan-Feb;43(1):27-9

Comparing medical centers treating hip fractures in the elderly: the importance of multi-outcome measurements. Mozes B, et al. **Am J Med Qual** 1999 May-Jun;14(3):117-23

Impact of surgeon's technique on outcome after treatment of rectal carcinoma. Hermanek P. **Dis Colon Rectum** 1999 May;42(5):559-62

Vancomycin use in a hospital with vancomycin restriction. Roghmann MC, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):60-3

Predicting patient satisfaction: a study of two emergency departments. Yarnold PR, et al. **J Behav Med** 1998 Dec; 21(6):545-63

[Research on university hospitals for feasibility of implementing specialty board certification] Segawa Y, et al. **Seishin Shinkeigaku Zasshi** 1998;100(8):558-68 **(Jpn)**

STATISTICS & NUMERICAL DATA

The effect of hospital-type and operating volume on the survival of hip replacements. A review of 39,505 primary total hip replacements reported to the Norwegian Arthroplasty Register, 1988-1996. Espehaug B, et al. **Acta Orthop Scand** 1999 Feb;70(1):12-8

Referral patterns to a University-based cardiac rehabilitation program. Bittner V, et al. **Am J Cardiol** 1999 Jan 15; 83(2):252-5, A5

Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification. Siebert JD, et al. **Am J Clin Pathol** 1999 Mar;111(3):379-86

Frequent ED users: patterns of use over time. Kne T, et al. **Am J Emerg Med** 1998 Nov;16(7):648-52

Prevention and control of epidemic keratoconjunctivitis in a teaching eye institute. Gottsch JD, et al. **Ophthalmic Epidemiol** 1999 Mar;6(1):29-39

Antibiotic use in 3 European university hospitals. Kiivet RA, et al. **Scand J Infect Dis** 1998;30(3):277-80

A survey of blood utilization in children and adolescents in a German university hospital. Zimmermann R, et al. **Transfus Med** 1998 Sep;8(3):185-94

[Imported dengue: study of 44 cases observed from 1994 to 1997 in 9 university hospital centers. Infectio-Sud-France group] Badiaga S, et al. **Pathol Biol (Paris)** 1999 May; 47(5):539-42 (Eng. Abstr.) **(Fre)**

[Prospective study on admissions for iatrogenic adverse effects in the emergency service of hospital university center in Poitiers] Perault MC, et al. **Therapie** 1999 Jan-Feb;54(1):183-5 (Eng. Abstr.) **(Fre)**

[Identification of emergencies for asthma and chronic obstructive pulmonary disease in the emergency rooms of a hospital. A reliability study] Merelles Tormo A, et al. **Gac Sanit** 1999 Jan-Feb;13(1):30-7 (22 ref.) (Eng. Abstr.) **(Spa)**

[Record of neurological emergencies at a tertiary care hospital] Figuerola A, et al. **Rev Neurol** 1998 Nov; 27(159):750-4 (Eng. Abstr.) **(Spa)**

TRENDS

Clinical trial potential of academic centers in India. Bhandari M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1104-5

UTILIZATION

An analysis of frequent users of emergency care at an urban university hospital. Lucas RH, et al. **Ann Emerg Med** 1998 Nov;32(5):563-8

Cost effective management programme for heart failure reduces hospitalisation [see comments] Cline CM, et al. **Heart** 1998 Nov;80(5):442-6. Comment in: Heart 1998 Nov;80(5):430-1. Comment in: ACP J Club 1999 May-Jun;130(3):81.

Hospital length of stay in the United States and Japan: a case study of myocardial infarction patients. Muramatsu N, et al. **Int J Health Serv** 1999;29(1):189-209

Improved health care resource utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. Martin RC, et al. **Seizure** 1998 Oct; 7(5):385-90

Use of hospital services, religious attendance, and religious affiliation. Koenig HG, et al. **South Med J** 1998 Oct; 91(10):925-32

HOSPITALS, URBAN

Differences in management of heart attack patients between metropolitan and regional hospitals in the Hunter Region of Australia. Lim LL, et al. **Aust N Z J Public Health** 1999 Feb;23(1):61-6

Communication between hospitals and isolated aboriginal community health clinics. Mackenzie G, et al. **Aust N Z J Public Health** 1999 Apr;23(2):204-6

Australia's breast surgery workload is changing: comparison of a metropolitan and a rural hospital. Spillane AJ, et al. **Aust N Z J Surg** 1999 Mar;69(3):178-82

Epidemiology of Streptococcus pneumoniae infections at the Edinburgh City Hospital: 1980-95. Kalima P, et al. **Epidemiol Infect** 1999 Apr;122(2):251-7

Advanced trauma life support (ATLS) courses: should training be refocused towards rural physicians? Ben-Abraham R, et al. **Eur J Emerg Med** 1999 Jun; 6(2):111-4

ECONOMICS

The economic impact of Staphylococcus aureus infection in New York City hospitals. Rubin RJ, et al. **Emerg Infect Dis** 1999 Jan-Feb;5(1):9-17

Distribution of variable vs fixed costs of hospital care. Roberts RR, et al. **JAMA** 1999 Feb 17;281(7):644-9

HISTORY

[For the 40th anniversary of the union of The 1st and The 2nd Moscow City Hospitals. Research schools of L.I. Sverzhevski'i, B.S. Preobrazhenski'i, V.T. Pal'chun] Grinchuk VI. **Vestn Otorinolaringol** 1999;(3):5-18 **(Rus)**

ORGANIZATION & ADMINISTRATION

Breast-feeding initiation in New York City, 1979 to 1996. Rosenberg KD, et al. **Am J Public Health** 1998 Dec; 88(12):1850-2

Trends in hospital efficiency among metropolitan markets. Wang BB, et al. **J Med Syst** 1999 Apr;23(2):83-97

Implementing outcome facilitation teams in an integrated system. Schifalacqua M. **J Nurs Care Qual** 1999 Feb; 13(3):71-4

An assessment of the potential for repatriating care from urban to rural Manitoba. Black C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS167-86

The effects of managed care on physician and clinical integration in hospitals. Morrisey MA, et al. **Med Care** 1999 Apr;37(4):350-61

STANDARDS

Impact of clinical pathways for total hip replacement: a community-based analysis. Card SJ, et al. **J Nurs Care Qual** 1998 Dec;13(2):67-76

Risk-adjusted in-hospital death rates for peer hospitals in rural and urban regions. Glenn LL, et al. **J Rural Health** 1999 Winter;15(1):94-107

STATISTICS & NUMERICAL DATA

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. Mocroft A, et al. **AIDS** 1999 Jul 9; 13(10):1255-61

Frequent ED users: patterns of use over time. Kne T, et al. **Am J Emerg Med** 1998 Nov;16(7):648-52

Consultations at central hospitals: reasons and outcome of referrals from urban clinics in Bulawayo, Zimbabwe. Tshimanga M, et al. **Cent Afr J Med** 1998 May;44(5):121-5

Management and outcome of tuberculosis in two St Louis hospitals, 1988 to 1994. L'Ecuyer PB, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):836-41

Dementia in the hospitalized elderly--a study of 100 consecutive cases in Singapore. Sahadevan S, et al. **Int J Geriatr Psychiatry** 1999 Apr;14(4):266-71

Decreased prevalence of retinopathy of prematurity in an inner-city hospital. Lim J, et al. **Ophthalmic Surg Lasers** 1999 Jan;30(1):12-6

Improving the appropriateness of carotid endarterectomy: results of a prospective city-wide study. Wong JH, et al. **Stroke** 1999 Jan;30(1):12-5

[Management of foreign tourists' diseases at the American Hospital in Neuilly] Beth B, et al. **Bull Soc Pathol Exot** 1998;91(5 Pt 1-2):464-6 (Eng. Abstr.) **(Fre)**

UTILIZATION

History of domestic violence among male patients presenting to an urban emergency department. Mechem CC, et al. **Acad Emerg Med** 1999 Aug;6(8):786-91

Analysis of cocaine chronotoxicology in an urban ED. Erickson TB, et al. **Am J Emerg Med** 1998 Oct;16(6):568-71

Elderly use of the ED in an Asian metropolis. Hu SC, et al. **Am J Emerg Med** 1999 Jan;17(1):95-9

Hospital length of stay in the United States and Japan: a case study of myocardial infarction patients. Muramatsu N, et al. **Int J Health Serv** 1999;29(1):189-209

A multihospital effort to reduce inpatient lengths of stay for pneumonia. Murphy M, et al. **J Nurs Care Qual** 1999 Jun; 13(5):11-23

HOSPITALS, VETERANS

Critical limits (alert values) for physician notification: universal or medical center specific limits? Lum G. **Ann Clin Lab Sci** 1998 Sep-Oct;28(5):261-71

Breast cancer practice patterns at VA hospitals: implications for future research. Hynes DM, et al. **Cancer Treat Res** 1998;97:149-58 (28 ref.)

Mortality one-year postdischarge from a Veterans Affairs geriatric evaluation and management unit: assessing mortality risks. Williams AR, et al. **J Am Geriatr Soc** 1999 Jul;47(7):860-3

Carotid surgery in octogenarians in Veterans Affairs medical centers. Kazmers A, et al. **J Surg Res** 1999 Jan;81(1):87-90

Patterns of morbidity and resource consumption associated with laparoscopic cholecystectomy in a VA medical center. Molloy M, et al. **J Surg Res** 1999 Jan;81(1):15-20

A six-year epidemiologic review of pneumonia in Department of Veterans Affairs facilities. Roselle GA, et al. **Mil Med** 1999 Apr;164(4):293-7

Ethical failures block Los Angeles research [news] Dalton R. **Nature** 1999 Apr 8;398(6727):448

Differences in prostate size between patients from University and Veterans Affairs Medical Center populations. Nixon RG, et al. **Prostate** 1999 Feb 1;38(2):144-50

Research shutdown roils Los Angeles VA [news] Cohen J. **Science** 1999 Apr 2;284(5411):18-9,21

ECONOMICS

Cost implications of regionalizing open heart surgery units. Menke TJ, et al. **Inquiry** 1999 Spring;36(1):57-67

Use of the Decision Support System for VA cost-effectiveness research. Barnett PG, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS63-70

Review of methods to determine VA health care costs. Barnett PG. **Med Care** 1999 Apr;37(4 Suppl Va):AS9-17 (40 ref.)

Cost as a study outcome: sensitivity of study conclusions to the method of estimating cost. Chapko MK, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS37-44

More or less?: Methods to compare VA and non-VA health care costs. Hendricks AM, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS54-62 (29 ref.)

Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. Hynes D, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS27-36

Determining costs in VA: research design problems and solutions illustrated with case studies. Menke TJ, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS18-26

Cost analysis in the Department of Veterans Affairs: consensus and future directions. Swindle R, et al. **Med Care** 1999 Apr;37(4 Suppl Va):AS3-8 (13 ref.)

Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs Medical Center. Galt KA. **Pharmacotherapy** 1998 Sep-Oct; 18(5):1103-11

HISTORY

Kenney Memorial Hospital. White RM. **J Natl Med Assoc** 1999 May;91(5):282-8

MANPOWER

Psychiatric staffing [letter] Barglow P, et al. **Psychiatr Serv** 1999 Jan;50(1):113-4

Psychiatric staffing [letter] Dinakar HS, et al. **Psychiatr Serv** 1999 Jan;50(1):113; discussion 114

ORGANIZATION & ADMINISTRATION

Efficient operation of a high-volume anticoagulation clinic. Foss MT, et al. **Am J Health Syst Pharm** 1999 Mar 1; 56(5):443-9

Preventive practicum training in healthcare organizations. The Meharry model. Levine RS, et al. **Am J Prev Med** 1999 Jul;17(1):91-6

Improving access to disability benefits among homeless persons with mental illness: an agency-specific approach to services integration. Rosenheck R, et al. **Am J Public Health** 1999 Apr;89(4):524-8

How far down the managed care road? A comparison of primary care outpatient services in a Veterans Affairs medical center and a capitated multispecialty group practice. Peabody JW, et al. **Arch Intern Med** 1998 Nov 23;158(21):2291-9

Comparing change readiness, quality improvement, and cost management among Veterans Administration, for-profit, and nonprofit hospitals. West TD. **J Health Care Finance** 1998 Fall;25(1):46-58

Decision-making activity and influence of nurse executives in top management teams. Banaszak-Holl J, et al. **J Nurs Adm** 1999 Apr;29(4):18-24

Improving cost-effectiveness in a substance abuse treatment program. Francis E, et al. **Psychiatr Serv** 1999 May; 50(5):633-5

STANDARDS

Core formulary issued for military treatment facilities [news] **Am J Health Syst Pharm** 1998 Aug 15;55(16):1658, 1660

The "new VA": a national laboratory for health care quality management. Kizer KW. **Am J Med Qual** 1999 Jan-Feb; 14(1):3-20 (108 ref.)

Implementing quality improvement in hospitals: the role of leadership and culture. Parker VA, et al. **Am J Med Qual** 1999 Jan-Feb;14(1):64-9

Patients' desires and expectations for medical care: a challenge to improving patient satisfaction. Zemencuk JK, et al. **Am J Med Qual** 1999 Jan-Feb;14(1):21-7

Relation of surgical volume to outcome in eight common operations: results from the VA National Surgical Quality Improvement Program. Khuri SF, et al. **Ann Surg** 1999 Sep;230(3):414-29; discussion 429-32

The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Khuri SF, et al. **Ann Surg** 1998 Oct;228(4):491-507

The hospital multistay rate as an indicator of quality of care.

Wray NP, et al. **Health Serv Res** 1999 Aug;34(3):777–90
Geriatric syndromes as outcome measures of hospital care: can administrative data be used? Berlowitz DR, et al. **J Am Geriatr Soc** 1999 Jun;47(6):692–6
An empirical assessment of the validity of explicit and implicit process-of-care criteria for quality assessment. Ashton CM, et al. **Med Care** 1999 Aug;37(8):798–808
The association of quality of care and occurrence of in-hospital, treatment-related complications. Geraci JM, et al. **Med Care** 1999 Feb;37(2):140–8
Satisfaction with care among patients with diabetes in two public health care systems [see comments] Piette JD. **Med Care** 1999 Jun;37(6):538–46. Comment in: Med Care 1999 Jun;37(6):527–8.
Patient satisfaction with Department of Veterans Affairs health care: do women differ from men? Kressin NR, et al. **Mil Med** 1999 Apr;164(4):283–8
Mental illness as a predictor of satisfaction with inpatient care at Veterans Affairs hospitals. Hoff RA, et al. **Psychiatr Serv** 1999 May;50(5):680–5

STATISTICS & NUMERICAL DATA

The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution. Tokars JI, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):171–5
Racial variation in the use of laparoscopic cholecystectomy in the Department of Veterans Affairs medical system. Arozullah AM, et al. **J Am Coll Surg** 1999 Jun; 188(6):604–22
Oral/pharyngeal, laryngeal, and lung cancer discharge trends in Department of Veterans Affairs hospitals. Fedele DJ, et al. **J Public Health Dent** 1998 Fall;58(4):309–12
Repeated assaults by patients in VA hospital and clinic settings. Blow FC, et al. **Psychiatr Serv** 1999 Mar; 50(3):390–4
A survey of assaultive behavior in Veterans Health Administration facilities. Lehmann LS, et al. **Psychiatr Serv** 1999 Mar;50(3):384–9
Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Voris JC, et al. **Psychiatr Serv** 1999 Feb;50(2):163–4, 168

UTILIZATION

Variations in the use of cardiac procedures in the Veterans Health Administration [see comments] Mirvis DM, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):706–13. Comment in: Am Heart J 1999 Apr;137(4 Pt 1):588–9.
Rates of health services utilization and survival in patients with heart failure in the Department of Veterans Affairs medical care system. Ashton CM, et al. **Am J Med Qual** 1999 Jan–Feb;14(1):55–63
Substance abuse as a predictor of VA medical care utilization among Vietnam veterans. Virgo KS, et al. **J Behav Health Serv Res** 1999 May;26(2):126–39
Dual use of VA and non-VA primary care [see comments] Borowsky SJ, et al. **J Gen Intern Med** 1999 May; 14(5):274–80. Comment in: J Gen Intern Med 1999 May;14(5):318–9.
Does the VA provide "primary" primary care? [editorial; comment] Petersen LA, et al. **J Gen Intern Med** 1999 May; 14(5):318–9 (17 ref.). Comment on: J Gen Intern Med 1999 May;14(5):274–80.
The use of VA and non-VA mental health services by female veterans. Hoff RA, et al. **Med Care** 1998 Nov; 36(11):1524–33
Interpreting risk-adjusted length of stay patterns for VA hospitals. Thomas JW, et al. **Med Care** 1998 Dec; 36(12):1660–75
Increasing use of Medicare services by veterans with acute myocardial infarction [see comments] Wright SM, et al. **Med Care** 1999 Jun;37(6):529–37. Comment in: Med Care 1999 Jun;37(6):527–8.
The focus on women veterans who use Veterans Administration health care: the Veterans Administration Women's Health Project. Skinner KM, et al. **Mil Med** 1998 Nov;163(11):761–6
Geographic variations in utilization rates in Veterans Affairs hospitals and clinics [see comments] Ashton CM, et al. **N Engl J Med** 1999 Jan 7;340(1):32–9. Comment in: N Engl J Med 1999 Jan 7;340(1):52–3.
Understanding geographic variations in health care delivery [editorial; comment] Wennberg JE. **N Engl J Med** 1999 Jan 7;340(1):52–3. Comment on: N Engl J Med 1999 Jan 7;340(1):32–9.
The receipt of prevention services by veterans using VA versus non-VA facilities. Rabiner DJ, et al. **Prev Med** 1998 Sep–Oct;27(5 Pt 1):690–6

HOSPITALS, VETERINARY see **HOSPITALS, ANIMAL**

HOSPITALS, VOLUNTARY

ECONOMICS

Market power and hospital pricing: are nonprofits different? Melnick G, et al. **Health Aff (Millwood)** 1999 May–Jun; 18(3):167–73
Mission statement rationales and organizational alignment in the not-for-profit health care sector. Bart CK, et al. **Health Care Manage Rev** 1998 Fall;23(4):54–69
Social workers and the tradition of charity in the changing health care system. Kelly JM. **Health Soc Work** 1998 Aug; 23(3):236–40
Stewardship: the distinguishing characteristic of not-for-profit health care [editorial] Maynard GF 3rd, et al. **Health Soc Work** 1998 Nov;23(4):243–8
Conflicts of interest during a financial crisis [news] Rines B, et al. **Hosp Health Netw** 1999 Jan;73(1):24
Those conversion blues. Forgione DA. **J Health Care Finance** 1999 Summer;25(4):38–46 (17 ref.)
How much profit can a not-for-profit hospital make? A defense of the property tax exemption. Merz CM, et al. **J Health Care Finance** 1999 Summer;25(4):59–66
Public disclosure of performance information in Pennsylvania: impact on hospital charges and the views of hospital executives. Maxwell CI. **Jt Comm J Qual Improv** 1998 Sep;24(9):491–502

HISTORY

The infirmary of the Glasgow Town's Hospital, 1733–1800: a case for voluntarism? Macdonald FA. **Bull Hist Med** 1999 Spring;73(1):64–105

LEGISLATION & JURISPRUDENCE

Should government intervene to protect nonprofits? Bloche MG. **Health Aff (Millwood)** 1998 Sep–Oct;17(5):7–25 (43 ref.)
Nonprofit conversion: theory, evidence, and state policy options. Marsteller JA, et al. **Health Serv Res** 1998 Dec; 33(5 Pt 2):1495–535 (90 ref.)
Form 990. Disclosure as PR [news] Menduno M. **Hosp Health Netw** 1999 Sep;73(9):14
Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131–82 (0 ref.)
Nonprofit to for-profit hospital transactions: all roads lead to the attorney general's office. Moore BE. **J Health Care Finance** 1999 Spring;25(3):29–36

ORGANIZATION & ADMINISTRATION

Positioning for partnerships. Assessing public health agency readiness. Nelson JC, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):103–17
Mission statement content and hospital performance in the Canadian not-for-profit health care sector. Bart CK, et al. **Health Care Manage Rev** 1999 Summer;24(3):18–29
Evaluating the sale of a nonprofit health system to a for-profit hospital management company: the Legacy Experience. King JG, et al. **Health Serv Res** 1999 Apr;34(1 Pt 1):103–21
Analysis of the rationale for, and consequences of, nonprofit and for-profit ownership conversions. Mark TL. **Health Serv Res** 1999 Apr;34(1 Pt 1):83–101
Do managerial efficiency and social responsibility drive long-term financial performance of not-for-profit hospitals before acquisition? Phillips JF. **J Health Care Finance** 1999 Summer;25(4):67–76
Comparing change readiness, quality improvement, and cost management among Veterans Administration, for-profit, and nonprofit hospitals. West TD. **J Health Care Finance** 1998 Fall;25(1):46–58
Heart failure management. Warner PM, et al. **J Nurs Adm** 1999 Jul–Aug;29(7–8):28–37
The Medicare Critical Access Hospital program: the first year. Reif SS, et al. **J Rural Health** 1999 Winter;15(1):61–6
From the board room to the community room: a health improvement collaboration that's working. Community Health Improvement Partners. **Jt Comm J Qual Improv** 1998 Oct;24(10):549–65
Hospital conversions from for-profit to nonprofit status: the other side of the story [letter] Lee B. **Med Care Res Rev** 1999 Jun;56(2):220–2
Nonprofit to for-profit conversions by hospitals, health insurers, and health plans. Needleman J. **Public Health Rep** 1999 Mar–Apr;114(2):108–19 (41 ref.)

STANDARDS

Public disclosure of performance information in Pennsylvania: impact on hospital charges and the views of hospital executives. Maxwell CI. **Jt Comm J Qual Improv** 1998 Sep;24(9):491–502
[A proposed methodology for an attempt at evaluating the research activities included in a hospital structure] Borgo A. **G Ital Med Lav Ergon** 1997 Oct–Dec;19(4):193–7 **(Ita)**

HOST-PARASITE RELATIONS

Association between cytosolic low molecular weight phosphotyrosine-phosphatase and malaria—a possible mechanism. Bottini E. **Am J Phys Anthropol** 1999 Feb; 108(2):241–4
The use of confocal laser scanning microscopy to analyze the process of parasitic protozoon-host cell interaction. de-Souza W, et al. **Braz J Med Biol Res** 1998 Nov; 31(11):1459–70 (49 ref.)
Host-microbe interactions: fungi/viruses/parasites [editorial] Cormack B, et al. **Curr Opin Microbiol** 1999 Aug;2(4):343–7
Web alert. Host-microbe interactions: fungi/viruses/parasites. Waterman SR. **Curr Opin Microbiol** 1999 Aug;2(4):341–2
Web alert. Host-microbe interactions: fungi/viruses/parasites. Waterman SR. **Curr Opin Microbiol** 1998 Aug;1(4):375–6
Maintenance of a Pseudomonas fluorescens plasmid in heterologous hosts: metabolic burden as a more reliable variable to predict plasmid instability. Chandrasekaran S, et al. **Indian J Exp Biol** 1998 Jul;36(7):693–8
Apical organelles and host-cell invasion by Apicomplexa. Dubremetz JF, et al. **Int J Parasitol** 1998 Jul;28(7):1007–13 (40 ref.)
Parasite diversity/host age and size relationship in three coral-reef fishes from French Polynesia. Lo CM, et al. **Int J Parasitol** 1998 Nov;28(11):1695–708
Most of the species on Earth are parasites. Windsor DA. **Int J Parasitol** 1998 Dec;28(12):1939–41
Wild rabbit host and some parasites show trophic-level relationships for delta 13C and delta 15N: a first report. Boag B, et al. **Isotopes Environ Health Stud** 1998; 34(1–2):81–5
The evolution of diapause in a coupled host-parasitoid system. Ringel MS, et al. **J Theor Biol** 1998 Sep 21; 194(2):195–204
Infection kinetics and developmental biology of Cryptosporidium muris (strain MCR) in Korean native kids and Corriedale lambs. Rhee JK, et al. **Korean J Parasitol** 1998 Sep;36(3):171–81
Interrelationship between ectoparasites and wild rodents from Tijucas do Sul, state of Paraná, Brazil. Barros-Battesti DM, et al. **Mem Inst Oswaldo Cruz** 1998 Nov-Dec; 93(6):719–25
Batflies parasitic on some phyllostomid bats in southeastern Brazil: parasitism rates and host-parasite relationships. Komeno CA, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr; 94(2):151–6
Ecology of host parasite relationships in the Baltic Sea. Zander CD. **Naturwissenschaften** 1998 Sep;85(9):426–36 (38 ref.)
Longer-term population dynamics of Gyrodactylus bullatarudis and G. turnbulli (Monogenea) on adult guppies (Poecilia reticulata) in 50-l experimental arenas. Richards GR, et al. **Parasitol Res** 1998 Sep;84(9):753–6
Host choice by larval parasites: a study of Biomphalaria glabrata snails and Schistosoma mansoni miracidia related to host size. Théron A, et al. **Parasitol Res** 1998 Sep; 84(9):727–32
Interactions between intestinal tapeworms and their hosts: present knowledge and problems. Andreassen J. **Parassitologia** 1997 Dec;39(4):259–67 (104 ref.)
Parasitism, host immune function, and sexual selection. Møller AP, et al. **Q Rev Biol** 1999 Mar;74(1):3–20
Experimental evolution of parasites. Ebert D. **Science** 1998 Nov 20;282(5393):1432–5 (78 ref.)
Host exclusion and coexistence in apparent and direct competition: An application of bifurcation theory. Greenman JV, et al. **Theor Popul Biol** 1999 Aug;56(1):48–64
[Effect of the intensity of host parasitemia on the vectorial competence of Glossina morsitans Westwood, 1850 (Mall) infected by Trypanosoma (Nannonmonas) congolense IL 1180] Kazadi JM, et al. **Parasite** 1999 Mar;6(1):57–62 (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Impact of repeated large scale ivermectin treatments on the transmission of Loa loa. Chippaux JP, et al. **Trans R Soc Trop Med Hyg** 1998 Jul–Aug;92(4):454–8

GENETICS

Genetic evidence suggests that Psoroptes isolates of different phenotypes, hosts and geographic origins are conspecific. Zahler M, et al. **Int J Parasitol** 1998 Nov;28(11):1713–9
The tegument of Schistosoma mansoni: genes, antigens and the host-parasite relationship. Xavier EM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:85–6
Population dynamics under parasitic sex ratio distortion. Hatcher MJ, et al. **Theor Popul Biol** 1999 Aug;56(1):11–28
Dispersal-induced instabilities in host-parasitoid metapopulations. Rohani P, et al. **Theor Popul Biol** 1999 Feb;55(1):23–36

IMMUNOLOGY

Effects of infestation by Rhipicephalus sanguineus on lymphocyte blastogenic responses to mitogens in dogs. Inokuma H, et al. **J Vet Med Sci** 1998 Sep;60(9):1013–6
The tegument of Schistosoma mansoni: genes, antigens and the host-parasite relationship. Xavier EM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:85–6
Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). da Silva J, et al. **Mol Biol Evol** 1998 Oct; 15(10):1259–68
Immunization of rabbits with Amblyomma hebraeum nymphal homogenates and implications for the host amplification system. Tembo SD. **Onderstepoort J Vet Res** 1998 Jun;65(2):97–103
New malaria vaccine shows promise [news] Josefson D. **West J Med** 1999 May;170(5):304

HOST-PARASITE RELATIONS

PHYSIOLOGY

Molecular mechanisms of cytoadherence in malaria. Ho M, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1231-42 (101 ref.)

A DNA-based demonstration of a three-host life-cycle for the Bivesiculidae (Platyhelminthes: Digenea) Cribb TH, et al. **Int J Parasitol** 1998 Nov;28(11):1791-5

Aggregated parasite distributions on hosts in a homogeneous environment: examining the Poisson null model. Leung B. **Int J Parasitol** 1998 Nov;28(11):1709-12

HOST VS GRAFT REACTION

IMMUNOLOGY

The promise of xenografting. Hanaway MJ, et al. **Adv Ren Replace Ther** 1998 Oct;5(4):299-308 (55 ref.)

Minor transplantation antigens: mouse models for human host-versus-graft, graft-versus-host and graft-versus-leukemia reactions. Simpson E. **Arch Immunol Ther Exp (Warsz)** 1998;46(6):331-9 (60 ref.)

Survival of cryopreserved fetal substantia nigra implanted into the rat brain in the two forms and estimation of the host brain reaction against graft. Kosno-Kruszewska E. **Folia Neuropathol** 1999;37(1):1-9

Host H-2 haplotype modulates the induction of host-versus-graft disease after the induction of neonatal tolerance to H-2 alloantigens. Ramos A, et al. **Int J Mol Med** 1998 Feb;1(2):431-7

HOSTAGES see **PRISONERS**

HOSTILITY

Relation between myocardial infarction, depression, hostility, and death. Kaufmann MW, et al. **Am Heart J** 1999 Sep; 138(3 Pt 1):549-54

Hostility, social support, and coronary heart disease in the National Heart, Lung, and Blood Institute Family Heart Study. Knox SS, et al. **Am J Cardiol** 1998 Nov 15; 82(10):1192-6

Anger inhibition, cardiovascular recovery, and vagal function: a model of the link between hostility and cardiovascular disease. Brosschot JF, et al. **Ann Behav Med** 1998 Fall;20(4):326-32

Measures of hostility as predictors of facial affect during social interaction: evidence for construct validity. Brummett BH, et al. **Ann Behav Med** 1998 Summer; 20(3):168-73

The relation of hostility to lipids and lipoproteins in women: evidence for the role of antagonistic hostility. Suarez EC, et al. **Ann Behav Med** 1998 Spring;20(2):59-63

Doctors badmouthing each other. Does it affect medical students' career choices? [see comments] Kamien BA, et al. **Aust Fam Physician** 1999 Jun;28(6):576-9. Comment in: Aust Fam Physician 1999 Jun;28(6):581.

Badmouthing between disciplines [comment] Peach HG. **Aust Fam Physician** 1999 Jun;28(6):581. Comment on: Aust Fam Physician 1999 Jun;28(6):576-9.

Aggression Questionnaire hostility scale predicts anger in response to mistreatment. Felsten G, et al. **Behav Res Ther** 1999 Jan;37(1):87-97

Communicating with patients. Hostility can be a barrier to effective communication [letter; comment] Taylor RE. **BMJ** 1999 Jan 2;318(7175):60. Comment on: BMJ 1998 Jun 20;316(7148):1890-1.

Development and testing of a new hostility scale. Arthur HM, et al. **Can J Cardiol** 1999 May;15(5):539-44 (30 ref.)

The role of maternal hostility and family environment upon cardiovascular functioning among youth two years later: socioeconomic and ethnic differences. Wright LB, et al. **Ethn Dis** 1998 Autumn;8(3):367-76

Temporal linkages between wives' pursuit and husbands' withdrawal during marital conflict. Turgeon L, et al. **Fam Process** 1998 Fall;37(3):323-34

The short-term effects of a hostility-reduction intervention on male coronary heart disease patients. Gidron Y, et al. **Health Psychol** 1999 Jul;18(4):416-20

Modeling relationships among socioeconomic status, hostility, cardiovascular reactivity, and left ventricular mass in African American and White children. Gump BB, et al. **Health Psychol** 1999 Mar;18(2):140-50

Effects of hostility on ambulatory blood pressure and mood during daily living in healthy adults [published erratum appears in Health Psychol 1999 May;18(3):228] Räikkönen K, et al. **Health Psychol** 1999 Jan;18(1):44-53

Facial expression and the affective component of cynical hostility in male coronary heart disease patients. Rosenberg EL, et al. **Health Psychol** 1998 Jul;17(4):376-80

Agency, communion, and cardiovascular reactivity during marital interaction. Smith TW, et al. **Health Psychol** 1998 Nov;17(6):537-45

Hostility, dieting, and nutrition attitudes in overweight and weight-cycling men and women. Carmody TP, et al. **Int J Eat Disord** 1999 Jul;26(1):37-42

Exposure to violence, depression, and hostility in a sample of inner city high school youth. Moses A. **J Adolesc** 1999 Feb;22(1):21-32

Reasoning about scientific evidence: effects of juror gender and evidence quality on juror decisions in a hostile work environment case. Kovera MB, et al. **J Appl Psychol** 1999 Jun;84(3):362-75

Sibling interactions, self-regulation, and cynical hostility in adult male twins. Smith TW, et al. **J Behav Med** 1998 Aug; 21(4):337-49

Differences in anger, hostility, and interpersonal aggressiveness in Type A and Type B adolescents. Farber EW, et al. **J Clin Psychol** 1998 Nov;54(7):945-52

Increased serum mitogenic activity for arterial smooth muscle cells associated with relaxation and low educational level in human subjects with high but not low hostility traits: implications for atherogenesis. Gutstein WH, et al. **J Psychosom Res** 1999 Jan;46(1):51-61

Anger, hostility, and visceral adipose tissue in healthy postmenopausal women. Räikkönen K, et al. **Metabolism** 1999 Sep;48(9):1146-51

Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Handelsman L, et al. **Psychiatry Res** 1998 Jul 27; 80(1):1-12

Response of hostile individuals to stressful changes in their working lives: test of a psychosocial vulnerability model. Kivimäki M, et al. **Psychol Med** 1998 Jul;28(4):903-13

Social support and hostility as predictors of depressive symptoms in cardiac patients one month after hospitalization: a prospective study. Brummett BH, et al. **Psychosom Med** 1998 Nov-Dec;60(6):707-13

Hostility is associated with increased platelet activation in coronary heart disease. Markovitz JH. **Psychosom Med** 1998 Sep-Oct;60(5):586-91

Are hostility and anxiety associated with carotid atherosclerosis in healthy postmenopausal women? Matthews KA, et al. **Psychosom Med** 1998 Sep-Oct; 60(5):633-8

Hostility and coping capacity as risk factors of elder mistreatment. Comijs HC, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Jan;34(1):48-52

HOT FLASHES

Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. Utian WH, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):71-9

CHEMICALLY INDUCED

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Quella SK, et al. **J Urol** 1999 Jul;162(1):98-102 (15 ref.)

DIAGNOSIS

Feasibility and psychometrics of an ambulatory hot flash monitoring device. Carpenter JS, et al. **Menopause** 1999 Fall;6(3):209-15

DRUG THERAPY

Patient profile 1: unresolved vasomotor symptoms with conventional hormone replacement therapy. Studdard JD. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):317-8

Prescribing hormone replacement therapy for menopausal symptoms. McNagny SE. **Ann Intern Med** 1999 Oct 19; 131(8):605-16 (181 ref.)

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Quella SK, et al. **J Urol** 1999 Jul;162(1):98-102 (15 ref.)

The effect of estrogens and antiestrogens in a rat model for hot flush. Merchenthaler I, et al. **Maturitas** 1998 Nov 16; 30(3):307-16

The relationship between stress-coping and vasomotor symptoms in postmenopausal women. Nedstrand E, et al. **Maturitas** 1998 Nov 30;31(1):29-34

Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Simon J, et al. **Menopause** 1999 Summer;6(2):138-46

Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. Sartor O, et al. **South Med J** 1999 Apr;92(4):415-6

ETHNOLOGY

Racial differences in menopause information and the experience of hot flashes. Grisso JA, et al. **J Gen Intern Med** 1999 Feb;14(2):98-103

ETIOLOGY

Light-therapy-induced hot flushes in a patient with seasonal affective disorder [letter] Sher L, et al. **J Psychiatry Neurosci** 1999 May;24(3):249-50

Male menopause after unilateral inguinal herniorrhaphy. Vanderpump MP. **J R Soc Med** 1998 Oct;91(10):536-7

Predictors of menopausal hot flashes. Staropoli CA, et al. **J Womens Health** 1998 Nov;7(9):1149-55

[Hot flashes resistant to hormone replacement in menopausal women: panic disorder?] van der Feltz-Cornelis CM. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):281-4 (Eng. Abstr.) **(Dut)**

METABOLISM

Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy. Hammar M, et al. **Maturitas** 1999 Jan 4;31(2):117-22

PHYSIOPATHOLOGY

Vasomotor flushes in menopausal women. Bachmann GA. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):312-6 (26 ref.)

Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Freedman RR, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):66-70

Menopausal-like hot flashes reported in women of reproductive age. Hahn PM, et al. **Fertil Steril** 1998 Nov; 70(5):913-8

Effect of estrogen replacement therapy on cardiac function in postmenopausal women with and without flushes. Beljic T, et al. **Gynecol Endocrinol** 1999 Apr;13(2):104-12

Definitions of hot flashes in breast cancer survivors. Finck G, et al. **J Pain Symptom Manage** 1998 Nov;16(5):327-33

Habitual physical activity and menopausal symptoms: a case-control study. Sternfeld B, et al. **J Womens Health** 1999 Jan-Feb;8(1):115-23

PREVENTION & CONTROL

Dietary soy supplementation and phytoestrogen levels. Albertazzi P, et al. **Obstet Gynecol** 1999 Aug;94(2):229-31

Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Leonetti HB, et al. **Obstet Gynecol** 1999 Aug;94(2):225-8

PSYCHOLOGY

Some relationships between perceived control and women's reported coping strategies for menopausal hot flushes. Reynolds F. **Maturitas** 1999 May 31;32(1):25-32

THERAPY

[Hot flashes resistant to hormone replacement in menopausal women: panic disorder?] van der Feltz-Cornelis CM. **Ned Tijdschr Geneeskd** 1999 Feb 6;143(6):281-4 (Eng. Abstr.) **(Dut)**

URINE

Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Wyon Y, et al. **Maturitas** 1998 Nov 16;30(3):289-94

HOTLINES

Calls to teen line: representative concerns of adolescents. Boehm KE, et al. **Adolescence** 1998 Winter;33(132):797-803

Characteristics of calls to Israeli hotlines during the Gulf War. Gilat I, et al. **Am J Community Psychol** 1998 Oct; 26(5):697-704

Effect of visual cues, vital signs, and protocols on triage: a prospective randomized crossover trial. Salk ED, et al. **Ann Emerg Med** 1998 Dec;32(6):655-64

NHS direct: evaluate, integrate, or bust [editorial; comment] Pencheon D. **BMJ** 1998 Oct 17;317(7165):1026-7. Comment on: BMJ 1998 Oct 17;317(7165):1054-9.

No, it's not just listening. Greenbury S. **Crisis** 1999;20(2):56-8

Patient acceptance and use of an emergency telephone hotline service in pediatric diabetes care [letter] Kapellen TM, et al. **Diabetes Care** 1998 Aug;21(8):1365

Could the community social alarm system serve also as a primary health care service? Premik M, et al. **Med Arh** 1998;52(3):153-5

Telephone triage as a strategy to ensure 24-hour access to medical care after the closure of supporting medical activity. Flynn DM. **Mil Med** 1998 Oct;163(10):702-6

Emergency medical services dispatcher identification of stroke and transient ischemic attack. Porteous GH, et al. **Prehosp Emerg Care** 1999 Jul-Sep;3(3):211-6

A tuberculosis hotline in Tyler: a Texas resource for primary health care providers for the control of infectious diseases. Robison VA, et al. **Tex Med** 1998 Oct;94(10):48-52

ECONOMICS

Increased funding bolsters FARAD; hotline to return [news] Nolen S. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1742

ORGANIZATION & ADMINISTRATION

Reaching out to the suicidal in Thailand. Tan-Atichat L. **Crisis** 1998;19(2):56-7, 59

Call 1-888-NOT-2-LATE: promoting emergency contraception in the United States. Trussell J, et al. **J Am Med Womens Assoc** 1998;53(5 Suppl 2):247-50

Telephone counselling in psychiatry. Perera I, et al. **Singapore Med J** 1998 Nov;39(11):488-90

[Emergencies by telephone] Carrel J, et al. **Rev Med Suisse Romande** 1999 Apr;119(4):341-4 **(Fre)**

STANDARDS

Use of the DSM at hotlines. Seeley MF. **Crisis** 1998; 19(4):152-3, 176

UTILIZATION

Celebrity's death from cancer resulted in increased calls to

CancerBACUP [letter] Boudioni M, et al. **BMJ** 1998 Oct 10;317(7164):1016

Concerns and dilemmas of Hispanic AIDS information seekers: Spanish-speaking callers to the CDC National AIDS hotline. Scott SA, et al. **Health Educ Behav** 1998 Aug;25(4):501–16

Telephone helplines for people with dementia [letter] Gilliard J, et al. **Int J Geriatr Psychiatry** 1998 Oct;13(10):734–5

An analysis of calls to a Vietnam veterans' telephone counselling service. Bryant RA. **J Trauma Stress** 1998 Jul; 11(3):589–96

[Organization of telephone counseling for psychosocial emergencies. An evaluation after 12 months] Grabe HJ, et al. **Psychiatr Prax** 1999 Jan;26(1):29–31 (Eng. Abstr.) **(Ger)**

HOUSE CALLS

Conducting research with urban elders: issues of recruitment, data collection, and home visits. Wrobel AJ, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13 Suppl 1:S34–8

Home telemedicine: merging the old and new ways [editorial] Jerant AF. **Am Fam Physician** 1999 Sep 15;60(4):1096, 1098

Triage of house call requests [letter; comment] Gallagher M, et al. **Br J Gen Pract** 1998 Sep;48(434):1613–4. Comment on: Br J Gen Pract 1998 Jun;48(431):1303–6.

Practice tips. What should I have in my little black bag? Pereles L. **Can Fam Physician** 1999 Apr;45:907

The effectiveness of predischarge home assessment visits: a systematic review. Patterson CJ, et al. **Clin Rehabil** 1999 Apr;13(2):101–4 (14 ref.)

A medical student's home visit. Curi MB. **Conn Med** 1999 Aug;63(8):489–90

House calls in Lebanon: reflections on personal experience. Sarru E, et al. **Fam Pract** 1998 Dec;15(6):571–5

Home visiting: Recent program evaluations. Selected bibliography. **Future Child** 1999 Spring–Summer;9(1):Inside back cover

The Home Instruction Program for Preschool Youngsters (HIPPY). Baker AJ, et al. **Future Child** 1999 Spring–Summer;9(1):116–33, 192–4

Healthy Families America: using research to enhance practice. Daro DA, et al. **Future Child** 1999 Spring–Summer;9(1):152–78

Evaluation of Hawaii's Healthy Start Program. Duggan AK, et al. **Future Child** 1999 Spring–Summer;9(1):66–90; discussion 177–8

Understanding evaluations of home visitation programs. Gomby DS. **Future Child** 1999 Spring–Summer;9(1):27–43

Home visiting: recent program evaluations—analysis and recommendations. Gomby DS, et al. **Future Child** 1999 Spring–Summer;9(1):4–26, 195–223 (19 ref.)

Using home visits for multiple purposes: the Comprehensive Child Development Program. St Pierre RG, et al. **Future Child** 1999 Spring–Summer;9(1):134–51

The Parents as Teachers program: results from two demonstrations. Wagner MM, et al. **Future Child** 1999 Spring–Summer;9(1):91–115, 179–89

The family physician and house calls. A survey of Colorado family physicians. Ingram CJ, et al. **J Fam Pract** 1999 Jan; 48(1):62–5

A postpartum home follow-up project by student nurses using marker model standards. Brodsky PL. **J Nurs Educ** 1998 Nov;37(8):373–5

Determinants of home health visit length: results of a multisite prospective study. Payne SM, et al. **Med Care** 1998 Oct; 36(10):1500–14

STATISTICS & NUMERICAL DATA

A report on home visiting practices conducted in remote districts of Nepal in an NGO-run tuberculosis control programme. White AJ, et al. **Int J Tuberc Lung Dis** 1999 Jun;3(6):534–6

A survey of home visits at peritoneal dialysis centers in the United States. Bernardini J, et al. **Perit Dial Int** 1998 Sep–Oct;18(5):528–31

TRENDS

Consultant home visits: Orrell and Katona—Journal (vol. 13, 355–357) [letter; comment] Jolley DJ. **Int J Geriatr Psychiatry** 1999 May;14(5):401. Comment on: Int J Geriatr Psychiatry 1998 Jun;13(6):355–7.

A changing world—the need and value of home visits [letter] van Praagh P. **N Z Med J** 1999 Aug 13;112(1093):302

HOUSE STAFF see **INTERNSHIP AND RESIDENCY**

HOUSEDUST see **DUST**

HOUSEFLIES

Flotation method for extracting insects from poultry manure samples. Tobin PC, et al. **J Med Entomol** 1999 Jan; 36(1):121–3

Susceptibility of Musca domestica L. (Diptera: Muscidae) from various breeding sites to commonly used insecticides. Nazni WA, et al. **J Vector Ecol** 1999 Jun;24(1):54–60

Effects of contrast on attraction of the housefly, Musca domestica, to visual targets. Howard JJ, et al. **Med Vet Entomol** 1998 Jul;12(3):322–4

[The biological activity of Ricinus communis on the housefly (Musca domestica)] Alvarez Montes de Oca DM, et al. **Rev Cubana Med Trop** 1996;48(3):192–4 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Isolation, characterization and biological activity of a diuretic myokinin neuropeptide from the housefly, Musca domestica. Holman GM, et al. **Peptides** 1999;20(1):1–10

ENZYMOLOGY

Effect of gamma irradiation on proteases activities in Musca domestica. Ahmed S, et al. **Biochem Soc Trans** 1998 Nov; 26(4):S355

Effects of organophosphate pesticides on protease activities in M. domestica and man. Ahmed S, et al. **Biochem Soc Trans** 1998 Nov;26(4):S356

Effect of DDT exposure on protease activities in Musca domestica. Ahmed S, et al. **Biochem Soc Trans** 1998 Nov; 26(4):S357

A novel endogenous inhibitor of phenoloxidase from Musca domestica has a cystine motif commonly found in snail and spider toxins. Daquinag AC, et al. **Biochemistry** 1999 Feb 16;38(7):2179–88

Mechanism of cytochrome P450 reductase from the house fly: evidence for an FMN semiquinone as electron donor. Murataliev MB, et al. **FEBS Lett** 1999 Jun 18; 453(1–2):201–4

Kinetic mechanism of cytochrome P450 reductase from the house fly (Musca domestica). Murataliev MB, et al. **Insect Biochem Mol Biol** 1999 Mar;29(3):233–42

Mechanism of an insect glutathione S-transferase: kinetic analysis supporting a rapid equilibrium random sequential mechanism with housefly I1 isoform. Nay B, et al. **Insect Biochem Mol Biol** 1999 Jan;29(1):71–9

GENETICS

Distribution of heterochromatin on the mitotic chromosomes of Musca domestica L. in relation to the activity of male-determining factors. Hediger M, et al. **Chromosoma** 1998 Sep;107(4):267–71

House-fly cytochrome P450 CYP6D1: 5' flanking sequences and comparison of alleles. Scott JG, et al. **Gene** 1999 Jan 21;226(2):347–53

The female-determining gene F of the housefly, Musca domestica, acts maternally to regulate its own zygotic activity. Dübendorfer A, et al. **Genetics** 1998 Sep; 150(1):221–6

The male-determining activity on the Y chromosome of the housefly (Musca domestica L.) consists of separable elements. Hediger M, et al. **Genetics** 1998 Oct;150(2):651–61

Mutations in the house fly Vssc1 sodium channel gene associated with super-kdr resistance abolish the pyrethroid sensitivity of Vssc1/tipE sodium channels expressed in Xenopus oocytes. Lee SH, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):185–94

[Preparation of transgenic house flies Musca domestica] Erist LK, et al. **Dokl Akad Nauk** 1999 Jul;367(3):430–2 **(Rus)**

GROWTH & DEVELOPMENT

Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Yan LJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12896–901

METABOLISM

Toxicity and tissue distribution of 2,2',4,4'- and 3,3',4,4'-tetrachlorobiphenyls in houseflies. Saghir SA, et al. **Ecotoxicol Environ Saf** 1999 Feb;42(2):177–84

MICROBIOLOGY

Detection of Escherichia coli O157:H7 from Musca domestica (Diptera: Muscidae) at a cattle farm in Japan. Iwasa M, et al. **J Med Entomol** 1999 Jan;36(1):108–12

PARASITOLOGY

House flies (Musca domestica) as transport hosts of Cryptosporidium parvum. Graczyk TK, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):500–4

PHYSIOLOGY

Comparison of proteolytic enzyme activities in adults of insecticide resistant and susceptible strains of the housefly M. domestica L. Ahmed S, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):629–39

Neurotransmitters alter the numbers of synapses and organelles in photoreceptor terminals in the lamina of the housefly, Musca domestica. Pyza E, et al. **J Comp Physiol [A]** 1998 Dec;183(6):719–27

Neurotransmitter regulation of circadian structural changes in the fly's visual system. Meinertzhagen IA, et al. **Microsc Res Tech** 1999 Apr 15;45(2):96–105 (75 ref.)

Survival of olfactory memory through metamorphosis in the fly Musca domestica. Ray S. **Neurosci Lett** 1999 Jan 4; 259(1):37–40

HOUSEHOLD ARTICLES

Vacuum cleaners and airborne dog allergen. Green R, et al. **Allergy** 1999 Apr;54(4):403–5

Effect of two different types of vacuum cleaners on airborne Fel d 1 levels. Rønborg SM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):307–10

Reduction of faecal coliform, coliform and heterotrophic plate count bacteria in the household kitchen and bathroom by disinfection with hypochlorite cleaners. Rusin P, et al. **J Appl Microbiol** 1998 Nov;85(5):819–28

Ceiling fan injuries: the Townsville experience [see comments] Potts JR. **Med J Aust** 1999 Feb 1;170(3):119–20 . Comment in: Med J Aust 1999 Jul 5;171(1):54–5.

Concentrations and decay rates of ozone in indoor air in dependence on building and surface materials. Moriske HJ, et al. **Toxicol Lett** 1998 Aug;96–97:319–23

STANDARDS

Controlling the ergonomic hazards of wiring tasks for household appliances. National Institute for Occupational Safety and Health. **Appl Occup Environ Hyg** 1999 May; 14(5):289–91

HOUSEHOLD EQUIPMENT see **HOUSEHOLD ARTICLES**

HOUSEHOLD PRODUCTS

Boron exposure from consumer products. Richold M. **Biol Trace Elem Res** 1998 Winter;66(1–3):121–9 (13 ref.)

Testing of household products and materials for emission of toluene diisocyanate. Kelly TJ, et al. **Indoor Air** 1999 Jun;9(2):117–24

Neonatal tetanus—Montana, 1998. **MMWR Morb Mortal Wkly Rep** 1998 Nov 6;47(43):928–30

[Silicosis and scouring powder] Vincent M. **Rev Mal Respir** 1999 Jun;16(3):404–6 **(Fre)**

ADVERSE EFFECTS

Prolonged formation of methemoglobin following nitroethane ingestion. Shepherd G, et al. **J Toxicol Clin Toxicol** 1998;36(6):613–6

Severe lung injury after exposure to chloramine gas from household cleaners [letter] Tanen DA, et al. **N Engl J Med** 1999 Sep 9;341(11):848–9

POISONING

Urban legend on Internet a headache for poison center, Procter & Gamble [news] Nolen S. **J Am Vet Med Assoc** 1999 May 1;214(9):1304, 1312

Household poisoning exposure among children of Mexican-born mothers: an ethnographic study. Mull DS, et al. **West J Med** 1999 Jul;171(1):16–9

TOXICITY

[Experimental research on the effect of the components in household chemical preparations on the body] Sidorin GI, et al. **Med Tr Prom Ekol** 1998;(11):9–12 (Eng. Abstr.) **(Rus)**

HOUSEHOLD SUPPLIES see **HOUSEHOLD PRODUCTS**

HOUSEKEEPING

Physiological and perceptual responses during household activities performed by healthy women. Andrew M, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):556–62

Gender, household labor, and psychological distress: the impact of the amount and division of housework. Bird CE. **J Health Soc Behav** 1999 Mar;40(1):32–45

The long-term home-making functioning of women with schizophrenia [letter] Srinivasan TN, et al. **Schizophr Res** 1999 Jan 4;35(1):97–8

Labor status of 137 patients with liver transplantation. Loinaz C, et al. **Transplant Proc** 1999 Sep;31(6):2470–1

Effect of sun-drying and chemical disinfection on contaminated cleaning cloth. Ofielu LO. **West Afr J Med** 1998 Oct–Dec;17(4):239–42

[Comments on the work of H.M. Ockenfels, U. Seeman, M. Goos "Contact dermatitis in housewives." Hautarzt (1998) 49:280–290 (comment)] Roth E. **Hautarzt** 1998 Dec; 49(12):936–7. Comment on: Hautarzt 1998 Apr;49(4):280–90. **(Ger)**

[Gender differences in the influence of housework on health (see comments)] Artazcoz L, et al. **Gac Sanit** 1999 May–Jun; 13(3):201–7 (Eng. Abstr.). Comment in: Gac Sanit 1999 May–Jun;13(3):173–6. **(Spa)**

METHODS

Effect of two different types of vacuum cleaners on airborne Fel d 1 levels. Rønborg SM, et al. **Ann Allergy Asthma Immunol** 1999 Mar;82(3):307–10

Nasal patency and lavage biomarkers in relation to settled dust and cleaning routines in schools. Wålinder R, et al. **Scand J Work Environ Health** 1999 Apr;25(2):137–43

STANDARDS

An evaluation of worker lead exposures and cleaning effectiveness during removal of deteriorated lead-based paint. Sussell A, et al. **Appl Occup Environ Hyg** 1999 Mar; 14(3):177–85

HOUSEKEEPING, HOSPITAL

'Light' and 'heavy' work in the housekeeping service of a hospital. Messing K, et al. **Appl Ergon** 1998 Dec;29(6):451–9

Active tuberculosis in a deployed field hospital. Emmons EE, et al. **Mil Med** 1999 Apr;164(4):289–92

Disease prevention while deployed [letter] Kortepeter MG, et al. **Mil Med** 1999 Aug;164(8):viii, 561

HISTORY

Asylum nursing and institutional service. A case study of the south of England, 1861–1881. Wright D. **Nurs Hist Rev** 1999;7:153–69

METHODS

Routine disinfection of patients' environmental surfaces. Myth or reality? Dharan S, et al. **J Hosp Infect** 1999 Jun; 42(2):113–7

STANDARDS

Hospital environmental cleaning standards [letter; comment] Wilcox MH, et al. **J Hosp Infect** 1999 Jun;42(2):168. Comment on: J Hosp Infect 1999 Jan;41(1):72–4.

HOUSING

A housing support programme for the mentally ill: need profile and satisfaction among users. Middelboe T, et al. **Acta Psychiatr Scand** 1998 Oct;98(4):321–7

Monitoring house reinfestation by vectors of Chagas disease: a comparative trial of detection methods during a four-year follow-up. Gürtler RE, et al. **Acta Trop** 1999 Mar 15; 72(2):213–34

Mites in Jakarta homes. Baratawidjaja IR, et al. **Allergy** 1998 Dec;53(12):1226–7

Distribution and abundance of dust mites within homes. Colloff MJ. **Allergy** 1998;53(48 Suppl):24–7 (14 ref.)

A pilot study of the effect of mechanical ventilation and heat exchange on house-dust mites and Der p 1 in New Zealand homes. Crane J, et al. **Allergy** 1998 Aug;53(8):755–62

Reflections on the control of mites and mite allergens. de Boer R. **Allergy** 1998;53(48 Suppl):41–6 (72 ref.)

Mite-allergen levels in Norwegian homes. Gaarder PI. **Allergy** 1998;53(48 Suppl):58–9 (13 ref.)

Life cycle and reproduction of house-dust mites: environmental factors influencing mite populations. Hart BJ. **Allergy** 1998;53(48 Suppl):13–7 (48 ref.)

Epidemiology of house-dust mites. Korsgaard J. **Allergy** 1998;53(48 Suppl):36–40 (21 ref.)

House-dust mites and asthma. A review on house-dust mites as a domestic risk factor for mite asthma. Korsgaard J. **Allergy** 1998;53(48 Suppl):77–83 (32 ref.)

Mite sensitization in the Scandinavian countries and factors influencing exposure levels. Munir AK. **Allergy** 1998;53(48 Suppl):64–70 (56 ref.)

Mite fauna in the home and sensitivity to house-dust and storage mites. Warner A, et al. **Allergy** 1999 Jul; 54(7):681–90

Radon and lung cancer: a cost-effectiveness analysis. Ford ES, et al. **Am J Public Health** 1999 Mar;89(3):351–7

Building momentum: an ethnographic study of inner-city redevelopment. Fullilove MT, et al. **Am J Public Health** 1999 Jun;89(6):840–4

Interior surface materials in the home and the development of bronchial obstruction in young children in Oslo, Norway. Jaakkola JJ, et al. **Am J Public Health** 1999 Feb; 89(2):188–92

Hemolysis, toxicity, and randomly amplified polymorphic DNA analysis of Stachybotrys chartarum strains. Vesper SJ, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3175–81

Estimation of organ dose equivalents from residents of radiation-contaminated buildings with Rando phantom measurements. Lee JS, et al. **Appl Radiat Isot** 1999 May; 50(5):867–73

Toxic chemicals found in thousands of hotel rooms: are hotel guests facing dangerous health hazards from imported minibars? [letter] Lloyd F. **Arch Environ Health** 1999 May-Jun;54(3):220–1

Residential magnetic field measurements in France: comparison of indoor and outdoor measurements. Clinard F, et al. **Bioelectromagnetics** 1999;20(5):319–26

Comparison of residential power-frequency magnetic fields away from appliances in different countries. Swanson J, et al. **Bioelectromagnetics** 1999;20(4):244–54

Potential problems for tenants. Donnelly PD. **BMJ** 1999 Aug 7;319(7206):373

Pesticides in homes in Western Australia. Dingle P, et al. **Bull Environ Contam Toxicol** 1999 Mar;62(3):309–14

Chronic residential crowding and children's well-being: an ecological perspective. Evans GW, et al. **Child Dev** 1998 Dec;69(6):1514–23

Home dampness and respiratory health status in european children [see comments] Andriessen JW, et al. **Clin Exp Allergy** 1998 Oct;28(10):1191–200. Comment in: Clin Exp Allergy 1998 Oct;28(10):1178–81.

Environmental allergens and childhood asthma. Boner AL, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:76–81 (67 ref.)

Indoor environmental factors and respiratory illness [editorial; comment] Custovic A, et al. **Clin Exp Allergy** 1998 Oct;28(10):1178–81. Comment on: Clin Exp Allergy 1998 Oct;28(10):1191–200.

Mechanical ventilation protects one-storey single-dwelling houses against increased air humidity, domestic mite allergens and indoor pollutants in a cold climatic region. Emenius G, et al. **Clin Exp Allergy** 1998 Nov; 28(11):1389–96

Creature comforts--living with mites and moulds [editorial; comment] Harrison PT. **Clin Exp Allergy** 1999 Feb; 29(2):148–9 (12 ref.). Comment on: Clin Exp Allergy 1999 Feb;29(2):186–92.

Indoor survey of moulds and prevalence of mould atopy in Israel [see comments] Katz Y, et al. **Clin Exp Allergy** 1999 Feb;29(2):186–92. Comment in: Clin Exp Allergy 1999 Feb;29(2):148–9.

Indoor factors associated with concentrations of house dust mite allergen, Der p 1, in a random sample of houses in Norwich, UK. Luczynska C, et al. **Clin Exp Allergy** 1998 Oct;28(10):1201–9

Ventilation in homes and bronchial obstruction in young children. Oie L, et al. **Epidemiology** 1999 May;10(3):294–9

Neighborhood deterioration, religious coping, and changes in health during late life. Krause N. **Gerontologist** 1998 Dec; 38(6):653–64

Response to the Goldsmith commentary [letter; comment] Cohen BL. **Health Phys** 1999 May;76(5):568–9. Comment on: Health Phys 1999 May;76(5):553–7.

Dependence of indoor radon concentration on the year of house construction. Fujimoto K, et al. **Health Phys** 1999 Oct;77(4):410–9

The residential radon-lung cancer association in U.S. counties: a commentary [comment] [see comments] Goldsmith JR. **Health Phys** 1999 May;76(5):553–7. Comment on: Health Phys 1991 May;60(5):631–42. Comment on: Health Phys 1995 Feb;68(2):157–74. Comment in: Health Phys 1999 May;76(5):568–9.

Study of 222Rn concentrations in some dwellings of Rajasthan. Singh AK, et al. **Health Phys** 1999 Mar; 76(3):306–10

Radon mitigation survey among New York State residents living in high radon homes. Wang Y, et al. **Health Phys** 1999 Oct;77(4):403–9

Leprosy among hotel workers [letter] Dinni SV. **Indian J Lepr** 1998 Oct-Dec;70(4):412

A reliable and valid home visit report for studies of asthma in young adults. Dharmage S, et al. **Indoor Air** 1999 Sep; 9(3):188–92

Measurements of biological contaminants and particulate matter inside a dwelling in Japan. Nakai S, et al. **Indoor Air** 1999 Mar;9(1):41–6

Assessing quality of life among adults with mental retardation living in various settings. Schwartz C, et al. **Int J Rehabil Res** 1999 Jun;22(2):123–30

Fungal extracellular polysaccharides in house dust as a marker for exposure to fungi: relations with culturable fungi, reported home dampness, and respiratory symptoms. Douwes J, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):494–500

Results of the National Cooperative Inner-City Asthma Study (NCICAS) environmental intervention to reduce cockroach allergen exposure in inner-city homes. Gergen PJ, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):501–6

Home dampness and molds as determinants of respiratory symptoms and asthma in pre-school children. Jaakkola JJ, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:129–42

Vertical and horizontal variability of volatile organic compounds in homes in Eastern Germany. Schneider P, et al. **J Expo Anal Environ Epidemiol** 1999 Jul-Aug; 9(4):282–92

Exposure to air pollution from transitional household fuels in a South African population. Terblanche AP, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:15–22

At risk on the cusp of old age: living arrangements and functional status among black, white and Hispanic adults. Waite LJ, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 May;54(3):S136–44

Accepting the gay person: rental accommodation in the community. Page S. **J Homosex** 1998;36(2):31–9

Mycotoxins and building-related illness [letter; comment] Page E, et al. **J Occup Environ Med** 1998 Sep;40(9):761–4 . Comment on: J Occup Environ Med 1998 Mar;40(3):241–9.

Laying out and viewing the body at home--a forgotten tradition? Weber M, et al. **J Palliat Care** 1998 Winter; 14(4):34–7

Healthy housing--advice for students. Snaith C. **J Public Health Med** 1998 Dec;20(4):434–40

Cryptococcus neoformans isolated from human dwellings in Rio de Janeiro, Brazil: an analysis of the domestic environment of AIDS patients with and without cryptococcosis. Passoni LF, et al. **Med Mycol** 1998 Oct; 36(5):305–11

Radon testing in households with a residential smoker--United States, 1993–1994. **MMWR Morb Mortal Wkly Rep** 1999 Aug 13;48(31):683–6

Preventing construction injuries. **Occup Health Saf** 1999 Apr; 68(4):70–2

Homelessness and mental illness: a story of failure [editorial] Drake RE, et al. **Psychiatr Serv** 1999 May;50(5):589

Seasonal deposition of housedusts onto household surfaces. Edwards RD, et al. **Sci Total Environ** 1998 Dec 11; 224(1-3):69–80

A study of fibrous aerosols in the home environment in Sosnowiec, Poland. Pastuszka JS, et al. **Sci Total Environ** 1999 May 7;229(1-2):131–6

Accommodation for patients and carers during relocation for treatment for leukaemia: a descriptive profile. McGrath P. **Support Care Cancer** 1999 Jan;7(1):6–10

Respiratory symptoms and home environment in children: a national survey [published erratum appears in Thorax 1999 Apr;54(4):376] Burr ML, et al. **Thorax** 1999 Jan; 54(1):27–32

Effect of dampness at home in childhood on bronchial hyperreactivity in adolescence. Nicolai T, et al. **Thorax** 1998 Dec;53(12):1035–40

Anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: vertical distribution of cases in apartment blocks. Hewitt S, et al. **Trans R Soc Trop Med Hyg** 1998 May-Jun;92(3):273–4

Comparative investigations of airborne culturable microorganisms in selected waste treatment facilities and in neighbouring residential areas. Reinthaler FF, et al. **Zentralbl Hyg Umweltmed** 1999 Jun;202(1):1–17

[Smoke alarms and domestic fire death rates in children (letter)] Lévêque B. **Arch Pediatr** 1999 Jun;6(6):688 **(Fre)**

[Housing and health] Fiedler K. **Gesundheitswesen** 1998 Nov; 60(11):656–60 (5 ref.) (Eng. Abstr.) **(Ger)**

[Housing conditions and allergic sensitization in children] Heinrich J, et al. **Zentralbl Hyg Umweltmed** 1998 Sep; 201(3):211–28 (Eng. Abstr.) **(Ger)**

[Sedimentation method for measuring dispersion of fibers from asbestos cement roofs] Chiappino G, et al. **Med Lav** 1999 May-Jun;90(3):519–26 (Eng. Abstr.) **(Ita)**

[Change of housing environment and withdrawal of corticosteroid as treatments of atopic dermatitis] Fukaya M. **Arerugi** 1999 May;48(5):520–5 (Eng. Abstr.) **(Jpn)**

[Occurrence and evaluation of a law frequency noise in residential buildings] Koszarny Z, et al. **Rocz Panstw Zakl Hig** 1998;49(3):347–63 (Eng. Abstr.) **(Pol)**

[Volatile organic compounds in the air of the premises of residential and public buildings] Malysheva AG. **Gig Sanit** 1999 Jan-Feb;(1):43–6 **(Rus)**

STANDARDS

Architectural acoustics in residences for adults with mental retardation and its relation to perceived homelikeness. Egli M, et al. **Am J Ment Retard** 1999 Jan;104(1):53–66

Radon action level for high-rise buildings. Leung JK, et al. **Health Phys** 1999 May;76(5):537–43

Radiation hazard of coal-slags as building material in Tatabánya town (Hungary). Somlai J, et al. **Health Phys** 1998 Dec;75(6):648–51

Use of 222Rn-resistant techniques in new home construction. Watson JE Jr, et al. **Health Phys** 1999 Jan;76(1):62–5

Mismatches between the home environment and physical capabilities among community-living older persons [see comments] Gill TM, et al. **J Am Geriatr Soc** 1999 Jan; 47(1):88–92. Comment in: J Am Geriatr Soc 1999 Jan;47(1):111–2.

The importance of including the home environment in assessment of frail older persons [editorial; comment] Rubenstein LZ. **J Am Geriatr Soc** 1999 Jan;47(1):111–2. Comment on: J Am Geriatr Soc 1999 Jan;47(1):88–92.

Housing and environmental factors and their effects on the health of children in the slums of Karachi, Pakistan. D'Souza RM. **J Biosoc Sci** 1997 Jul;29(3):271–81

Housing placement and subsequent days homeless among formerly homeless adults with mental illness. Goldfinger SM, et al. **Psychiatr Serv** 1999 May;50(5):674–9

Security and safe havens: health issues among women in mobile homes. Manderson L, et al. **Women Health** 1998; 28(1):83–96

[Habitat of the allergic child: theory and practice] Héraud MC. **Arch Pediatr** 1999;6 Suppl 1:94S–97S (Eng. Abstr.) **(Fre)**

[Quality of life and well-being in a housing project in Berlin--experiences gained in cooperation between a community health promotion office and a university-based public health project] Gottwald S, et al. **Gesundheitswesen** 1999 May;61(5):234–40 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

A population-based study of environmental hazards in the homes of older persons. Gill TM, et al. **Am J Public Health** 1999 Apr;89(4):553–6

How low can it go? Declining black-white segregation in a multiethnic context. Krivo LJ, et al. **Demography** 1999 Feb;36(1):93–109

Do housing tenure and car access predict health because they are simply markers of income or self esteem? A Scottish study. Macintyre S, et al. **J Epidemiol Community Health** 1998 Oct;52(10):657–64

From the Centers for Disease Control and Prevention. Deaths resulting from residential fires and the prevalence of smoke alarms--United States, 1991–1995. **JAMA** 1998 Oct 28;280(16):1395

Tourism and hotel revenues before and after passage of smoke-free restaurant ordinances. Glantz SA, et al. **JAMA** 1999 May 26;281(20):1911–8

Residential smoke alarms and fire escape plans [published erratum appears in Public Health Rep 1998

Nov-Dec;113(6):507] Harvey PA, et al.
Public Health Rep 1998 Sep-Oct;113(5):459-64

TRENDS

How low can it go? Declining black-white segregation in a multiethnic context. Krivo LJ, et al. **Demography** 1999 Feb;36(1):93-109

The healthy home of the future comes to Japan [news] Watts J. **Lancet** 1999 May 8;353(9164):1597

HOUSING, ANIMAL

Health of laying hens in an aviary system over five batches of birds. Abrahamsson P, et al. **Acta Vet Scand** 1998; 39(3):367-79

Airborne microflora in Quebec dairy farms: lack of effect of bacterial hay preservatives. Duchaine C, et al.
Am Ind Hyg Assoc J 1999 Jan-Feb;60(1):89-95

Airway responses in naive subjects to exposure in poultry houses: comparison between cage rearing system and alternative rearing system for laying hens. Larsson BM, et al. **Am J Ind Med** 1999 Feb;35(2):142-9

Social housing and pregnancy outcome in captive pigtailed macaques. Ha JC, et al. **Am J Primatol** 1999;47(2):153-63

Perception of novel changes in a familiar environment by socially-housed rhesus monkeys. Platt DM, et al.
Am J Primatol 1999;47(2):117-31

Sensitivity, specificity, and predictive values of three Salmonella rapid detection kits using fresh and frozen poultry environmental samples versus those of standard plating. Peplow MO, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1055-60

Evaluation of Salmonella serotype distributions from commercial broiler hatcheries and grower houses. Byrd JA, et al. **Avian Dis** 1999 Jan-Mar;43(1):39-47

Crop impaction resulting from feather ball formation in caged layers. Morishita TY, et al. **Avian Dis** 1999 Jan-Mar; 43(1):160-3

Movement of flocks of laying hens in and out of the hen house in four free range systems. Bubier NE, et al.
Br Poult Sci 1998 Dec;39 Suppl:S5-6

Laying hens in large flocks in a perchery system: influence of stocking density on location, use of resources and behaviour. Carmichael NL, et al. **Br Poult Sci** 1999 May; 40(2):165-76

Effect of rearing factors on the prevalence of floor eggs, cloacal cannibalism and feather pecking in commercial flocks of loose housed laying hens. Gunnarsson S, et al.
Br Poult Sci 1999 Mar;40(1):12-8

Reflective properties of domestic fowl (Gallus g. domesticus), the fabric of their housing and the characteristics of the light environment in environmentally controlled poultry houses. Prescott NB, et al. **Br Poult Sci** 1999 May; 40(2):185-93

Ability of laying hens to jump between perches: individual variation and the effects of perch separation and motivation on behaviour. Scott GB, et al. **Br Poult Sci** 1999 May; 40(2):177-84

Egg shell colour is affected by laying cage design. Walker AW, et al. **Br Poult Sci** 1998 Dec;39(5):696-9

Effect of early-stage thermal conditioning and food restriction on performance and thermotolerance of male broiler chickens. Yahav S, et al. **Br Poult Sci** 1999 Mar; 40(1):120-6

Restriction of environmental space attenuates locomotor activity and hippocampal acetylcholine release in male rats. Mitsushima D, et al. **Brain Res** 1998 Sep 14;805(1-2):207-12

Interactions between environmental temperature and porcine growth hormone (pGH) treatment in neonatal pigs. Carroll JA, et al. **Domest Anim Endocrinol** 1999 Feb;16(2):103-13

Effects of low feed intake and hot environment on plasma profiles of glucose, nonesterified fatty acids, insulin, glucagon, and IGF-I in lactating sows. de Bragança MM, et al. **Domest Anim Endocrinol** 1999 Feb;16(2):89-101

An immunoconcentration-PCR assay to detect Salmonella in the environment of poultry houses. Soumet C, et al.
Int J Food Microbiol 1999 Jun 1;48(3):221-4

Nutrient management procedures to enhance environmental conditions: an introduction. Adeola O. **J Anim Sci** 1999 Feb;77(2):427-9 (11 ref.)

Effect of pen size on behavioral, endocrine, and immune responses of water buffalo (Bubalus bubalis) calves. Grasso F, et al. **J Anim Sci** 1999 Aug;77(8):2039-46

Effects of feeder type, space allowance, and mixing on the growth performance and feed intake pattern of growing pigs. Hyun Y, et al. **J Anim Sci** 1998 Nov;76(11):2771-8

Intensive indoor versus outdoor swine production systems: genotype and supplemental iron effects on blood hemoglobin and selected immune measures in young pigs. Kleinbeck SN, et al. **J Anim Sci** 1999 Sep;77(9):2384-90

The effect of the Hurnik-Morris (HM) system on sow reproduction, attrition, and longevity. Morris JR, et al.
J Anim Sci 1998 Nov;76(11):2759-62

Artificial pigs in space: using artificial intelligence and artificial life techniques to design animal housing. Stricklin WR, et al. **J Anim Sci** 1998 Oct;76(10):2609-13 (18 ref.)

Effects of individual housing design and size on behavior and stress indicators of special-fed Holstein veal calves. Wilson LL, et al. **J Anim Sci** 1999 Jun;77(6):1341-7

Dust-borne bacteria in animal sheds, schools and children's day care centres. Andersson AM, et al.
J Appl Microbiol 1999 Apr;86(4):622-34

Bacterial counts associated with sawdust and recycled manure bedding treated with commercial conditioners. Hogan JS, et al. **J Dairy Sci** 1999 Aug;82(8):1690-5

Effects of laparotomy, cage type, gestation period and spaceflight on abdominal muscles of pregnant rodents. Fejtek M, et al. **J Exp Zool** 1999 Aug 1;284(3):252-64

Effects of water dilution, housing, and food on rat urine collected from the metabolism cage. Lee KM, et al.
Lab Anim Sci 1998 Oct;48(5):520-5

Transmission of Helicobacter hepaticus infection to sentinel mice by contaminated bedding. Livingston RS, et al.
Lab Anim Sci 1998 Jun;48(3):291-3

Identification by a multiplex PCR-based assay of Salmonella typhimurium and Salmonella enteritidis strains from environmental swabs of poultry houses. Soumet C, et al.
Lett Appl Microbiol 1999 Jul;29(1):1-6

Evaluation of a multiplex PCR assay for simultaneous identification of Salmonella sp., Salmonella enteritidis and Salmonella typhimurium from environmental swabs of poultry houses. Soumet C, et al. **Lett Appl Microbiol** 1999 Feb;28(2):113-7

Animal facility design. Rahija R. **Occup Med** 1999 Apr-Jun; 14(2):407-22 (36 ref.)

Illness and injury in animal confinement workers. Von Essen S, et al. **Occup Med** 1999 Apr-Jun;14(2):337-50 (69 ref.)

Behavioral effects of perches on group-housed adult female Japanese monkeys. Nakamichi M, et al.
Percept Mot Skills 1998 Oct;87(2):707-14

Modification of laying hen cages to improve behavior. Appleby MC. **Poult Sci** 1998 Dec;77(12):1828-32 (38 ref.)

Equipment design for breeding flocks. Brake J. **Poult Sci** 1998 Dec;77(12):1833-41 (96 ref.)

Effects on commercial broiler chicks of constant exposure to ultraviolet light from insect traps. Hogsette JA, et al.
Poult Sci 1999 Mar;78(3):324-6

The effect of light regimen, floor space, and energy and protein levels during the growing period on body weight and early egg size. Keshavarz K. **Poult Sci** 1998 Sep; 77(9):1266-79

Growth performance, carcass characteristics, and the incidence of ascites in broilers in response to feed restriction and litter oiling. McGovern RH, et al. **Poult Sci** 1999 Apr; 78(4):522-8

Effect of housing birds in cages or an aviary system on bone characteristics. Newman S, et al. **Poult Sci** 1998 Oct; 77(10):1492-6

Ahemeral lighting of turkey breeder hens. 3. Temporary application and early age at lighting. Siopes TD, et al.
Poult Sci 1999 Mar;78(3):387-91

Health and production in improved cage designs. Tauson R. **Poult Sci** 1998 Dec;77(12):1820-7 (53 ref.)

Prevalence and risk factors associated with adventitious bursitis in live growing and finishing pigs in south-west England. Mouttotou N, et al. **Prev Vet Med** 1999 Mar 12; 39(1):39-52

The prevalence and risk factors associated with forelimb skin abrasions and sole bruising in preweaning piglets. Mouttotou N, et al. **Prev Vet Med** 1999 Apr 27;39(4):231-45

Housing familiar male wildtype rats together reduces the long-term adverse behavioural and physiological effects of social defeat. Ruis MA, et al.
Psychoneuroendocrinology 1999 Apr;24(3):285-300

Energy balance and ovulation: small cages versus natural habitats. Bronson FH. **Reprod Fertil Dev** 1998;10(2):127-37 (77 ref.)

Testing the genetics of behavior in mice [letter] Pohorecky LA. **Science** 1999 Sep 24;285(5436):2067-8; discussion 2069-70

Restraint and housing of ratites. Raines AM.
Vet Clin North Am Food Anim Pract 1998 Nov; 14(3):387-99, v (1 ref.)

Effects of simulated lairage conditions on the physiology and behaviour of pigs. Geverink NA, et al. **Vet Rec** 1998 Aug 29;143(9):241-4

Assessment of the injuries sustained by pregnant sows housed in groups using electronic feeders. Hodgkiss NJ, et al.
Vet Rec 1998 Nov 28;143(22):604-7

[Pathologic-anatomic investigations in laying hens in various housing systems] Keutgen H, et al.
DTW Dtsch Tierarztl Wochenschr 1999 Apr;106(4):127-33 (Eng. Abstr.) **(Ger)**

[Housing of dogs and cats in animal shelters] Rusch T.
DTW Dtsch Tierarztl Wochenschr 1999 Apr;106(4):166-9 (Eng. Abstr.) **(Ger)**

[Emissions and immisions of bio-aerosols from a duck fattening unit] Seedorf J, et al.
Zentralbl Hyg Umweltmed 1998 Dec;201(4-5):387-403 (Eng. Abstr.) **(Ger)**

ECONOMICS

An economic analysis of a modified, enriched cage egg production system. Walker AW, et al. **Br Poult Sci** 1998 Dec;39 Suppl:S14-5

STANDARDS

Investigations on airborne microorganisms in animal stables. 2. Report: further characterization of airborne Clostridium perfringens. Draz A, et al.
Berl Munch Tierarztl Wochenschr 1999 Apr;112(4):124-6

A laboratory cage for foster nursing newborn mice. Marques-de-Araújo S, et al. **Braz J Med Biol Res** 1999 Mar;32(3):319-21

Welfare of animals in quarantine [letter] [see comments] Bessant C. **Vet Rec** 1999 May 1;144(18):512. Comment in: Vet Rec 1999 May 15;144(20):568.

Calf welfare legislation [letter] Laven RA. **Vet Rec** 1998 Aug 8;143(6):175

Measurement of the residual contamination of post-weaning facilities for pigs and related risk factors. Madec F, et al.
Zentralbl Veterinarmed [B] 1999 Feb;46(1):37-45

[Fungal flora in chicken stalls and its etiopathogenic importance for humans and animals] Vissiennon T.
Berl Munch Tierarztl Wochenschr 1999 Mar;112(3):104-7 (Eng. Abstr.) **(Ger)**

[Voluntary testing procedures of farm animal housing equipment according to the Animal Welfare Act of 1998] Hesse D, et al. **DTW Dtsch Tierarztl Wochenschr** 1999 Apr; 106(4):138-41 (Eng. Abstr.) **(Ger)**

[Domestic animal welfare--practice oriented solutions] Petermann S. **DTW Dtsch Tierarztl Wochenschr** 1999 Apr; 106(4):160-3 (Eng. Abstr.) **(Ger)**

[Laying hen maintenance in the future--the Proposal of the Commission for a Council Directive setting minimum standards for the protection of laying hens under various rearing systems] Schwabenbauer K.
DTW Dtsch Tierarztl Wochenschr 1999 Apr;106(4):157-60 (Eng. Abstr.) **(Ger)**

HOUSING FOR THE ELDERLY

see related
HOMES FOR THE AGED

Patterns and predictors of formal and informal care among elderly persons living in board and care homes. Hopp FP.
Gerontologist 1999 Apr;39(2):167-76

Organizational determinants of resident satisfaction with assisted living. Sikorska E. **Gerontologist** 1999 Aug; 39(4):450-6

Going home: community reentry of light care nursing facility residents age 65 and over. Chapin R, et al.
J Health Care Finance 1998 Winter;25(2):35-48

ECONOMICS

Potential cost savings in residential care for Alzheimer's disease patients. Leon J, et al. **Gerontologist** 1999 Aug; 39(4):440-9

LEGISLATION & JURISPRUDENCE

Older Americans Act: implications for nursing. Wallace DC, et al. **Nurs Outlook** 1999 Jul-Aug;47(4):181-5 (21 ref.)

STANDARDS

The autonomy of elderly patients [letter; comment] Alibhai SM. **CMAJ** 1999 Jan 12;160(1):23, 25. Comment on: CMAJ 1998 Jul 28;159(2):143-8. Comment on: CMAJ 1998 Jul 28;159(2):151-2.

Quality of care in unlicensed homes for the aged in the eastern townships of Quebec [see comments] Bravo G, et al.
CMAJ 1999 May 18;160(10):1441-5. Comment in: CMAJ 1999 May 18;160(10):1463-4.

Assisted living. Big brother [news] **Hosp Health Netw** 1998 Oct 20;72(20):16

HOWELL-JOLLY BODIES see **ERYTHROCYTE INCLUSIONS**

HPLC see **CHROMATOGRAPHY, HIGH PRESSURE LIQUID**

4-HPR see **FENRETINIDE**

HPRT see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

HPTH (1-34) see **TERIPARATIDE**

HPV DNA PROBES see **DNA PROBES, HPV**

HRF20 see **ANTIGENS, CD59**

HSAN see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSAN TYPE I see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSAN TYPE II see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSAN TYPE III see **DYSAUTONOMIA, FAMILIAL**

HSAN TYPE IV see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSAN TYPE V see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSN TYPE I see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSN TYPE II see **NEUROPATHIES, HEREDITARY SENSORY AND AUTONOMIC**

HSP10 FAMILY

HSP10 FAMILY see **CHAPERONIN 10**

HSP60 FAMILY see **CHAPERONIN 60**

HSP70 FAMILY see **HEAT-SHOCK PROTEINS 70**

HSP90 FAMILY see **HEAT-SHOCK PROTEINS 90**

HSPG see **HEPARAN SULFATE PROTEOGLYCAN**

HSV-1 see **HERPESVIRUS 1, HUMAN**

HSV-1 PROTEIN VP16 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

5-HT see **SEROTONIN**

5-HT AGONISTS see **SEROTONIN AGONISTS**

5-HT ANTAGONISTS see **SEROTONIN ANTAGONISTS**

5-HT RECEPTORS see **RECEPTORS, SEROTONIN**

5-HT UPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

HT29 CELLS

CYTOLOGY

Follicle-like structures formed by intestinal cell lines derived from the HT29-D4 adenocarcinoma cell line: morphological and functional characterization. Mirrione A, et al. **Biol Cell** 1999 Mar;91(2):143-55

DRUG EFFECTS

Effects of pituitary adenylate cyclase activating polypeptide-27 (PACAP) and vasoactive intestinal polypeptide (VIP) on chloride in HT29 cells studied by X-ray microanalysis. Zhang W, et al. **Acta Physiol Scand** 1999 Jan;165(1):95-101

Photo-oxidative killing of human colonic cancer cells using indocyanine green and infrared light. Bäumler W, et al. **Br J Cancer** 1999 May;80(3-4):360-3

Decreased phospholipase A2 activity in butyrate differentiated HT29 cells. Madesh M, et al. **Indian J Biochem Biophys** 1998 Dec;35(6):372-6

Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. Martinsson T. **J Pharmacol Exp Ther** 1999 Feb;288(2):660-4

ENZYMOLOGY

Decreased phospholipase A2 activity in butyrate differentiated HT29 cells. Madesh M, et al. **Indian J Biochem Biophys** 1998 Dec;35(6):372-6

METABOLISM

A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells. Szegedi Z, et al. **Endocrine** 1999 Feb; 10(1):25-34

Subcellular localization of meta-tetra (hydroxyphenyl) chlorin in human tumor cells subjected to photodynamic treatment. Melnikova VO, et al. **J Photochem Photobiol B** 1999 Apr;49(2-3):96-103

MICROBIOLOGY

The isoflavone genistein inhibits internalization of enteric bacteria by cultured Caco-2 and HT-29 enterocytes. Wells CL, et al. **J Nutr** 1999 Mar;129(3):634-40

PATHOLOGY

Nitric oxide prevents anoxia-induced apoptosis in colonic HT29 cells. Madesh M, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):240-8

Retinoic acid receptor alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells. Nicke B, et al. **Biochem Biophys Res Commun** 1999 Aug 11; 261(3):572-7

Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Carles G, et al. **Br J Cancer** 1999 Jun;80(8):1162-8

Inhibition of selenite-induced cytotoxicity and apoptosis in human colonic carcinoma (HT-29) cells by copper. Davis RL, et al. **Nutr Cancer** 1998;32(3):181-9

ULTRASTRUCTURE

Follicle-like structures formed by intestinal cell lines derived from the HT29-D4 adenocarcinoma cell line: morphological and functional characterization. Mirrione A, et al. **Biol Cell** 1999 Mar;91(2):143-55

HTLV ANTIBODIES see **HTLV-BLV ANTIBODIES**

HTLV ANTIGENS see **HTLV-BLV ANTIGENS**

HTLV-BLV ANTIBODIES

Establishment of monoclonal antibody, gp21-34, against HTLV-II envelope protein (p20E). Miyagawa E, et al. **Hybridoma** 1998 Aug;17(4):347-54

ANALYSIS

Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1? Calleja E, et al. **Am J Hematol** 1999 Jun;61(2):94-7

BLOOD

Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Andersson S, et al. **Transfusion** 1999 Aug;39(8):845-51

IMMUNOLOGY

Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides. Londos-Gagliardi D, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):909-20

The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes. Hadlock KG, et al. **J Virol** 1999 Feb;73(2):1205-12

HTLV-BLV ANTIGENS

IMMUNOLOGY

Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides. Londos-Gagliardi D, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):909-20

HTLV-BLV INFECTIONS

Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Slattery JP, et al. **Genome Res** 1999 Jun;9(6):525-40 (113 ref.)

9th International Conference on Human Retrovirology HTLV and Related Viruses. Kagoshima, Japan, April 5-9, 1999. Abstracts.. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):A1-88

COMPLICATIONS

Coinfection of macaques with simian immunodeficiency virus and simian T cell leukemia virus type I: effects on virus burdens and disease progression. Fultz PN, et al. **J Infect Dis** 1999 Mar;179(3):600-11

HTLV-I associated primary CNS T-cell lymphoma [published erratum appears in J Neurol Sci 1999 Jan 15;162(2):210] Marshall AG, et al. **J Neurol Sci** 1998 Jun 30;158(2):226-31

EPIDEMIOLOGY

Sexual practices and prevalence of HIV, HTLV-I/II, and Treponema pallidum among clandestine female sex workers in Lima, Peru. Trujillo L, et al. **Sex Transm Dis** 1999 Feb; 26(2):115-8

[Prevalence of HIV, HTLV, and hepatitis B and C viruses in blood donors in France, 1992-1996] Pillonel J, et al. **Transfus Clin Biol** 1998 Oct;5(5):305-12 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Coinfection of macaques with simian immunodeficiency virus and simian T cell leukemia virus type I: effects on virus burdens and disease progression. Fultz PN, et al. **J Infect Dis** 1999 Mar;179(3):600-11

PREVENTION & CONTROL

HTLV testing in blood transfusion. Couroucé AM, et al. **Vox Sang** 1998;74 Suppl 2:165-9 (25 ref.)

[Anti-HB-core antibodies as a surrogate marker in blood donors (letter)] Blejer JL, et al. **Sangre (Barc)** 1999 Jun; 44(3):240-1 **(Spa)**

VETERINARY

Phylogenetic analysis of simian T lymphotropic virus type I from Kenyan olive baboons (Papio anubis), lowland Sykes monkeys (Cercopithecus mitis), and vervet monkeys (Cercopithecus aethiops pygerythrus). van Rensburg E, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):781-4

Simian T-lymphotropic virus type I infection among wild-caught Indonesian pig-tailed macaques (Macaca nemestrina). Richards AL, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):542-5

T-cell lymphoma in a savanna monkey (Cercopithecus aethiops) probably related to simian T-cell leukemia virus infection. Sato Y, et al. **J Vet Med Sci** 1999 Jan;61(1):49-52

Simian T-cell lymphotropic virus type 1 from Mandrillus sphinx as a simian counterpart of human T-cell lymphotropic virus type 1 subtype D. Mahieux R, et al. **J Virol** 1998 Dec;72(12):10316-22

Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Hislop AD, et al. **Nat Med** 1998 Oct; 4(10):1193-6

Evolutionary inferences of novel simian T lymphotropic virus type 1 from wild-caught chacma (Papio ursinus) and olive baboons (Papio anubis). Mahieux R, et al. **Virology** 1998 Nov 10;251(1):71-84

VIROLOGY

Application of an in situ PCR hybridization method to detection of human T-lymphotropic virus type I-infected cells in the lung. Qiu Y, et al. **Acta Med Okayama** 1999 Feb;53(1):1-4

Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis: double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Matsuoka E, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):340-6

Mammary epithelial cells support and transfer productive human T-cell lymphotropic virus infections. LeVasseur RJ, et al. **J Hum Virol** 1998 Mar-Apr;1(3):214-23

HTLV-BLV VIRUSES

9th International Conference on Human Retrovirology HTLV and Related Viruses. Kagoshima, Japan, April 5-9, 1999. Abstracts.. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):A1-88

HTLV INFECTIONS see **HTLV-BLV INFECTIONS**

HTLV VIRUSES see **HTLV-BLV VIRUSES**

HTLV-I

Human T-cell lymphotropic virus type I infection and ocular manifestations in São Paulo, Brazil. Yamamoto JH, et al. **Arch Ophthalmol** 1999 Apr;117(4):513-7

Extracellular human T cell leukemia virus type I tax protein stimulates the proliferation of human synovial cells. Aono H, et al. **Arthritis Rheum** 1998 Nov;41(11):1995-2003

Expression of metalloproteinase-2 (gelatinase A) in labial salivary glands of patients with Sjögren's syndrome with HTLV-I infection. Tominaga M, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):463-6

Role of HTLV-1 co-infection in the AIDS epidemic in the Caribbean: a cause for concern. Daisley H, et al. **Int J STD AIDS** 1999 Jul;10(7):487-9

Human T cell leukemia virus type-I and rheumatoid arthritis. Hasunuma T, et al. **Int Rev Immunol** 1998;17(5-6):291-307 (48 ref.)

Human T-cell lymphotropic virus type I and systemic lupus erythematosus [editorial; comment] Ijichi S, et al. **Intern Med** 1999 Jun;38(6):459-60 (24 ref.). Comment on: Intern Med 1999 Jun;38(6):512-5.

Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I-infected T-cells. Cereseto A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1575-81

HTLV-I associated primary CNS T-cell lymphoma [published erratum appears in J Neurol Sci 1999 Jan 15;162(2):210] Marshall AG, et al. **J Neurol Sci** 1998 Jun 30;158(2):226-31

Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. Calabresi PA, et al. **J Neurovirol** 1999 Feb;5(1):102-8

Human T-lymphotropic virus type I infection. Manns A, et al. **Lancet** 1999 Jun 5;353(9168):1951-8 (82 ref.)

Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Zhang Q, et al. **Leuk Res** 1999 Apr; 23(4):373-84

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) pathogenesis hypothesis. A shift of homologous peptides pairs, central nervous system (CNS)/HTLF-1, HTLV-1/thymus, thymus/CNS, in a thymus-like CNS environment, underlies the pathogenesis of HAM/TSP. Plumelle Y. **Med Hypotheses** 1999 Jun; 52(6):595-604 (99 ref.)

HLA class I and class II of the Nivkhi, an indigenous population carrying HTLV-I in Sakhalin, Far Eastern Russia. Lou H, et al. **Tissue Antigens** 1998 Nov;52(5):444-51

Human T-lymphotropic virus type I among blood donors from Guadeloupe: donation, demographic, and biologic characteristics. Rouet F, et al. **Transfusion** 1999 Jun; 39(6):639-44

The simian origins of the pathogenic human T-cell lymphotropic virus type I. Vandamme AM, et al. **Trends Microbiol** 1998 Dec;6(12):477-83 (54 ref.)

Association between HTLV-1 Tax and I kappa B alpha is dependent on the I kappa B alpha phosphorylation state. Petropoulos L, et al. **Virology** 1998 Dec 5;252(1):189-99

CHEMISTRY

Solution structure of the capsid protein from the human T-cell leukemia virus type-I. Khorasanizadeh S, et al. **J Mol Biol** 1999 Aug 13;291(2):491-505

Detection of human T-lymphotropic virus type I p40tax

protein in cerebrospinal fluid cells from patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. Moritoyo T, et al. **J Neurovirol** 1999 Jun;5(3):241-8

Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Kobe B, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4319-24

CLASSIFICATION

Community-based molecular epidemiology of HTLV type I in Taiwan and Kinmen: implication of the origin of the cosmopolitan subtype in northeast Asia. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):229-37

Subtyping of human T cell lymphotropic virus type I from tropical spastic paraparesis/HTLV-associated myelopathy patients in Mozambique. Engelbrecht S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):71-2

Identification and phylogenetic characterization of a human T-cell leukaemia virus type I isolate from a native inhabitant (Rapa Nui) of Easter Island. Ohkura S, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1995-2001

DRUG EFFECTS

Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection. Nyland SB, et al. **DNA Cell Biol** 1999 Apr;18(4):285-91

ENZYMOLOGY

Substrates and inhibitors of human T-cell leukemia virus type I protease. Ding YS, et al. **Biochemistry** 1998 Dec 15; 37(50):17514-8

Characterization of human T-cell leukemia virus type I integrase expressed in Escherichia coli. Müller B, et al. **Eur J Biochem** 1999 Jan;259(1-2):79-87

Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. Louis JM, et al. **J Biol Chem** 1999 Mar 5; 274(10):6660-6

GENETICS

Sequence of the env gene of some KwaZulu-Natal, South African strains of HTLV type I. Bhigjee AI, et al. **AIDS Res Hum Retroviruses** 1999 Sep 1;15(13):1229-33

Community-based molecular epidemiology of HTLV type I in Taiwan and Kinmen: implication of the origin of the cosmopolitan subtype in northeast Asia. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):229-37

The HTLV type I sequence from an asymptomatic German blood donor is related to sequences from South America. Duwe S, et al. **AIDS Res Hum Retroviruses** 1998 Dec 20; 14(18):1645-7

Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas. Ellerbrok H, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1199-203

Subtyping of human T cell lymphotropic virus type I from tropical spastic paraparesis/HTLV-associated myelopathy patients in Mozambique. Engelbrecht S, et al. **AIDS Res Hum Retroviruses** 1999 Jan 1;15(1):71-2

Sequences downstream of the RNA initiation site of the HTLV type I long terminal repeat are sufficient for trans-activation by human cytomegalovirus immediate-early proteins. Kim JM, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):545-50

Phylogenetic relatedness of HTLV type I from Bellona, a Polynesian outlier within the Solomon Islands, to HTLV type I from Japan and far Eastern Asia. Ohkura S, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20;15(11):1041-5

Induction of lymphocytic inflammatory changes in lung interstitium by human T lymphotropic virus type I. Kawakami K, et al. **Am J Respir Crit Care Med** 1999 Sep; 160(3):995-1000

Experimental HTLV-I infection and associated myelopathy. Costa CM, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):494-7

Human T-cell lymphotrophic virus type-I tax gene induces secretion of human macrophage inflammatory protein-1alpha. Sharma V, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):429-32

Random integration of HTLV-1 provirus: increasing chromosomal instability. Ohshima K, et al. **Cancer Lett** 1998 Oct 23;132(1-2):203-12

Localization of HTLV-1 and HIV-1 proviral sequences in chromosomes of persistently infected cells. Glukhova LA, et al. **Chromosome Res** 1999;7(3):177-83

Human T-cell lymphotropic virus type 1 tax among American blood donors. Zucker-Franklin D, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):831-5

Involvement of autoimmunity against type II collagen in the development of arthritis in mice transgenic for the human T cell leukemia virus type I tax gene. Kotani M, et al. **Eur J Immunol** 1999 Jan;29(1):54-64

NF-kappaB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Arima N, et al. **Exp Hematol** 1999 Jul;27(7):1168-75

Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Slattery JP, et al. **Genome Res** 1999 Jun;9(6):525-40 (113 ref.)

A rapid method for determination of the relative copy number of HTLV-I proviral genome in HTLV-I carriers and adult T-cell leukemia patients by polymerase chain reaction. Hori T, et al. **Haematologia (Budap)** 1999; 29(4):265-76

Comparison of HTLV-I basal transcription and expression of CREB/ATF-1/CREM family members in peripheral blood mononuclear cells and Jurkat T cells. Newbound GC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):1-10

The coactivator CBP stimulates human T-cell lymphotrophic virus type I Tax transactivation in vitro. Kashanchi F, et al. **J Biol Chem** 1998 Dec 18; 273(51):34646-52

An extended alpha-helix and specific amino acid residues opposite the DNA-binding surface of the cAMP response element binding protein basic domain are important for human T cell lymphotropic retrovirus type I Tax binding. Tang Y, et al. **J Biol Chem** 1998 Oct 16;273(42):27339-46

Early assembly step of a retroviral envelope glycoprotein: analysis using a dominant negative assay. Rosenberg AR, et al. **J Cell Biol** 1999 Apr 5;145(1):57-68

Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] [corrected] in Latin America [published erratum appears in J Gen Virol 1999 Apr;80(Pt 4):1087] Van Dooren S, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2695-708

The human T cell leukemia virus type I-tax gene is responsible for the development of both inflammatory polyarthropathy resembling rheumatoid arthritis and noninflammatory ankylotic arthropathy in transgenic mice. Habu K, et al. **J Immunol** 1999 Mar 1;162(5):2956-63

The development of autoimmune inflammatory arthropathy in mice transgenic for the human T cell leukemia virus type-I env-pX region is not dependent on H-2 haplotypes and modified by the expression levels of Fas antigen. Iwakura Y, et al. **J Immunol** 1998 Dec 15;161(12):6592-8

Nucleotide sequence analysis of human T-cell lymphotropic virus type I pX and LTR regions from patients with sicca syndrome. Beby-Defaux A, et al. **J Med Virol** 1999 Oct; 59(2):245-55

The tax protein-DNA interaction is essential for HTLV-I transactivation in vitro. Lenzmeier BA, et al. **J Mol Biol** 1999 Aug 27;291(4):731-44

Taxing the cellular capacity for repair: human T-cell leukemia virus type 1, DNA damage, and adult T-cell leukemia [editorial; comment] Kibler KV, et al. **J Natl Cancer Inst** 1999 Jun 2;91(11):903-4. Comment on: J Natl Cancer Inst 1999 Jun 2;91(11):933-42.

Defective DNA repair in cells with human T-cell leukemia/bovine leukemia viruses: role of tax gene [see comments] Philpott SM, et al. **J Natl Cancer Inst** 1999 Jun 2;91(11):933-42. Comment in: J Natl Cancer Inst 1999 Jun 2;91(11):903-4.

Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. Nagai M, et al. **J Neurovirol** 1998 Dec;4(6):586-93

Tumours derived from HTLV-I tax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. Hall AP, et al. **J Pathol** 1998 Oct; 186(2):209-14

Interaction of Gli2 with CREB protein on DNA elements in the long terminal repeat of human T-cell leukemia virus type 1 is responsible for transcriptional activation by tax protein. Dan S, et al. **J Virol** 1999 Apr;73(4):3258-63

Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type I Tax mutants expressed in a functional molecular clone. Robek MD, et al. **J Virol** 1999 Jun;73(6):4856-65

A lysine-to-arginine change found in natural alleles of the human T-cell lymphotropic/leukemia virus type I p12(I) protein greatly influences its stability. Trovato R, et al. **J Virol** 1999 Aug;73(8):6460-7

Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. Tosswill JH, et al. **J Virol Methods** 1998 Nov;75(1):21-6

A novel single cell PCR assay: detection of human T lymphotropic virus type I DNA in lymphocytes of patients with adult T cell leukemia. Miyagi T, et al. **Leukemia** 1998 Oct;12(10):1645-50

Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. Harhaj EW, et al. **Oncogene** 1999 Feb 11; 18(6):1341-9

Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans-dominant HTLV-1 rex mutants. Heger P, et al. **Oncogene** 1999 Jul 15;18(28):4080-90

Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells. Sun SC, et al. **Oncogene** 1999 Feb 18;18(7):1401-9

Binding of the human T-cell leukemia virus Tax protein to the coactivator CBP interferes with CBP-mediated transcriptional control. Van Orden K, et al. **Oncogene** 1999 Jun 24;18(25):3766-72

Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Bangham CR, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):691-700 (76 ref.)

Gene regulation mediated by interaction between HTLV-1 promoter elements and transcription factors Tax and CREB. Goren I, et al. **Virology** 1999 Apr 10;256(2):303-12

Host range of human T-cell leukemia virus type I analyzed by a cell fusion-dependent reporter gene activation assay. Okuma K, et al. **Virology** 1999 Feb 15;254(2):235-44

Defective and wild-type human T-cell leukemia virus type I proviruses: characterization of gene products and trans-interactions between proviruses. Shuh M, et al. **Virology** 1999 Sep 30;262(2):442-51

Sp1 is involved in a protein kinase C-independent activation of human T cell leukemia virus type I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate. Torgeman A, et al. **Virology** 1999 Feb 15;254(2):279-87

Molecular epidemiology of human T-cell leukemia virus type I (HTLV-1) Brazil: the predominant HTLV-1s in South America differ from HTLV-1s of Japan and Africa, as well as those of Japanese immigrants and their relatives in Brazil. Yamashita M, et al. **Virology** 1999 Aug 15;261(1):59-69

GROWTH & DEVELOPMENT

Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Ishitsuka K, et al. **Br J Haematol** 1998 Dec; 103(3):721-8

Human Th1 and Th2 T-cell clones are equally susceptible to infection and immortalization by human T-lymphotropic virus type I. Macchi B, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2469-74

IMMUNOLOGY

Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides. Londos-Gagliardi D, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):909-20

Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-I? Calleja E, et al. **Am J Hematol** 1999 Jun;61(2):94-7

Human T-cell lymphotropic virus type I tax among American blood donors. Zucker-Franklin D, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):831-5

The dynamics of HTLV-I and the CTL response. Wodarz D, et al. **Immunol Today** 1999 May;20(5):220-7 (28 ref.)

HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. Bartholomew C, et al. **J Hum Virol** 1998 May-Jun;1(4):302-5

Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. Azimi N, et al. **J Immunol** 1999 Oct 1; 163(7):4064-72

Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. Bieganowska K, et al. **J Immunol** 1999 Feb 1; 162(3):1765-71

Human complement component C1q inhibits the infectivity of cell-free HTLV-I. Ikeda F, et al. **J Immunol** 1998 Nov 15;161(10):5712-9

Monocyte-driven activation-induced apoptotic cell death of human T-lymphotropic virus type I-infected T cells. Wakamatsu S, et al. **J Immunol** 1999 Oct 1;163(7):3914-9

The humoral immune response to human T-cell lymphotropic virus type I envelope glycoprotein gp46 is directed primarily against conformational epitopes. Hadlock KG, et al. **J Virol** 1999 Feb;73(2):1205-12

Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type I-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding. Hildreth JE. **J Virol** 1998 Dec;72(12):9544-52

Hepatocyte growth inhibitory factor derived from HTLV-I(+) T-cell line is identical to IL-6. Kawai Y, et al. **Leuk Res** 1999 May;23(5):489-97

Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Bangham CR, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Apr 29; 354(1384):691-700 (76 ref.)

HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Jeffery KJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3848-53

Identification of membrane antigens important for adsorption of human T-cell leukaemia virus type I. Fu DX, et al. **Res Virol** 1998 Nov-Dec;149(6):383-92

Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Andersson S, et al. **Transfusion** 1999 Aug;39(8):845-51

Relationship between anti-Tax antibody responses and cocultivatable virus in HTLV-I-infected rabbits. Lydy SL, et al. **Virology** 1998 Oct 10;250(1):60-6

ISOLATION & PURIFICATION

Application of an in situ PCR hybridization method to detection of human T-lymphotropic virus type I-infected cells in the lung. Qiu Y, et al. **Acta Med Okayama** 1999 Feb;53(1):1-4

A rat model of human T lymphocyte virus type I (HTLV-I) infection: in situ detection of HTLV-I provirus DNA in microglia/macrophages in affected spinal cords of rats with HTLV-I-induced chronic progressive myeloneuropathy. Kasai T, et al. **Acta Neuropathol (Berl)** 1999 Feb; 97(2):107–12

Perivascular T cells are infected with HTLV-I in the spinal cord lesions with HTLV-I-associated myelopathy/tropical spastic paraparesis: double staining of immunohistochemistry and polymerase chain reaction in situ hybridization. Matsuoka E, et al. **Acta Neuropathol (Berl)** 1998 Oct;96(4):340–6

Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas. Ellerbrok H, et al. **AIDS Res Hum Retroviruses** 1998 Sep 1;14(13):1199–203

Clonal expansion of gammadelta-T lymphocytes in an HTLV-I carrier, associated with chronic neutropenia and rheumatoid arthritis. Horiuchi T, et al. **Ann Hematol** 1999 Feb;78(2):101–4

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Lehky TJ, et al. **Ann Neurol** 1998 Dec;44(6):942–7

Accumulation of human T lymphotropic virus type I-infected T cells in the salivary glands of patients with human T lymphotropic virus type I-associated Sjögren's syndrome. Ohyama Y, et al. **Arthritis Rheum** 1998 Nov; 41(11):1972–8

Prognostic significance of quantitative viral markers in adult T-cell leukemia/lymphoma [letter] Manns A, et al. **Blood** 1999 Jul 1;94(1):372–3

HTLV-I-associated myelopathy following allogeneic bone marrow transplantation. Emmanouilides CE, et al. **Bone Marrow Transplant** 1999 Jul;24(2):205–6

Defective human T-lymphotrophic virus type I provirus in T-cell prolymphocytic leukaemia. Kojima K, et al. **Br J Haematol** 1999 May;105(2):376–81

Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II (HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results. Carneiro-Proietti AB, et al. **Haemophilia** 1998 Jan; 4(1):47–50

Geographical clustering of human T-cell lymphotropic virus type I in Guadeloupe, an endemic Caribbean area. Rouet F, et al. **Int J Cancer** 1999 May 5;81(3):330–4

Human T-cell lymphotropic virus type I infects eccrine sweat gland epithelia. Setoyama M, et al. **Int J Cancer** 1999 Mar 1;80(5):652–5

Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Ureta-Vidal A, et al. **Int J Cancer** 1999 Sep 9;82(6):832–6

Adult T-cell leukemia/lymphoma in northeastern Brazil: a clinical, histopathologic, and molecular study. Barbosa HS, et al. **J Acquir Immune Defic Syndr** 1999 May 1;21(1):65–71

Evaluation of the INNO-LIA HTLV I/II assay for confirmation of human T-cell leukemia virus-reactive sera in blood bank donations. Sabino EC, et al. **J Clin Microbiol** 1999 May;37(5):1324–8

Crusted scabies in association with human T-cell lymphotropic virus I [clinical conference] Bergman JN, et al. **J Cutan Med Surg** 1999 Jan;3(3):148–52

Search for human T-lymphotropic virus type I carriers among northeastern Chinese. Geng L, et al. **J Dermatol Sci** 1998 Sep;18(1):30–4

HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. Soldan SS, et al. **J Infect Dis** 1999 Sep;180(3):685–94

Human T cell leukemia virus type I expression in salivary glands of infected patients. Tangy F, et al. **J Infect Dis** 1999 Feb;179(2):497–502

Quantification of human T-cell lymphotropic virus type I proviral load by quantitative competitive polymerase chain reaction. Albrecht B, et al. **J Virol Methods** 1998 Nov; 75(2):123–40

HTLV-I infection among relatives of patients with adult T-cell leukemia/lymphoma in Brazil: analysis of infection transmission. Borducchi DM, et al. **Leuk Lymphoma** 1998 Oct;31(3-4):411–6

A novel single cell PCR assay: detection of human T lymphotropic virus type I DNA in lymphocytes of patients with adult T cell leukemia. Miyagi T, et al. **Leukemia** 1998 Oct;12(10):1645–50

Hypopigmented mycosis fungoides associated with human T cell lymphotropic virus type I tax in a pediatric patient. Zucker-Franklin D, et al. **Pediatrics** 1999 May;103(5 Pt 1):1039–45

Multiplex detection of four pathogenic retroviruses using molecular beacons. Vet JA, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6394–9

Low copy numbers of human T-cell lymphotropic virus type I (HTLV-I) tax-like DNA detected in the salivary gland of seronegative patients with Sjögren's syndrome in an HTLV-I endemic area. Mizokami A, et al. **Scand J Rheumatol** 1998;27(6):435–40

Two types of HTLV-1 particles are released from MT-2 cells. Morozov VA, et al. **Virology** 1999 Mar 15; 255(2):279–84

METABOLISM

HTLV type I Tax activation of the CXCR4 promoter by association with nuclear respiratory factor 1. Moriuchi M, et al. **AIDS Res Hum Retroviruses** 1999 Jun 10;15(9):821–7

Analysis of Tax-expressing cell lines generated from HTLV-I tax-transgenic mice: correlation between c-myc overexpression and neoplastic potential. Saggioro D, et al. **Exp Cell Res** 1999 Mar 15;247(2):525–33

Analysis of potential phosphorylation sites in human T cell leukemia virus type 1 Tax. Krause Boehm A, et al. **J Biomed Sci** 1999 May-Jun;6(3):206–12

The effect of the cellular stress response on human T-lymphotropic virus type I envelope protein expression. Andrews JM, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2905–8

The tax protein-DNA interaction is essential for HTLV-I transactivation in vitro. Lenzmeier BA, et al. **J Mol Biol** 1999 Aug 27;291(4):731–44

Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. Berlioz-Torrent C, et al. **J Virol** 1999 Feb;73(2):1350–61

The human T-cell leukemia virus type 1 oncoprotein Tax inhibits the transcriptional activity of c-Myb through competition for the CREB binding protein. Colgin MA, et al. **J Virol** 1998 Nov;72(11):9396–9

Multimer formation is not essential for nuclear export of human T-cell leukemia virus type 1 Rex trans-activator protein. Heger P, et al. **J Virol** 1998 Nov;72(11):8659–68

Human T-cell leukemia virus type 1 tax protein abrogates interleukin-2 dependence in a mouse T-cell line. Iwanaga Y, et al. **J Virol** 1999 Feb;73(2):1271–7

Disruption of nucleotide excision repair by the human T-cell leukemia virus type 1 Tax protein. Kao SY, et al. **J Virol** 1999 May;73(5):4299–304

Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Mesnard JM, et al. **Virology** 1999 May 10;257(2):277–84 (101 ref.)

Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV-1 through two distinct mechanisms. Suzuki T, et al. **Virology** 1999 Jul 5; 259(2):384–91

PATHOGENICITY

Induction of lymphocytic inflammatory changes in lung interstitium by human T lymphotropic virus type I. Kawakami K, et al. **Am J Respir Crit Care Med** 1999 Sep; 160(3):995–1000

Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. Furusyo N, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):85–91

Heat shock cognate protein 70 is a cell fusion-enhancing factor but not an entry factor for human T-cell lymphotropic virus type I. Fang D, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):357–63

Involvement of autoimmunity against type II collagen in the development of arthritis in mice transgenic for the human T cell leukemia virus type I tax gene. Kotani M, et al. **Eur J Immunol** 1999 Jan;29(1):54–64

Mammary epithelial cells support and transfer productive human T-cell lymphotropic virus infections. LeVasseur RJ, et al. **J Hum Virol** 1998 Mar-Apr;1(3):214–23

Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. Mulloy JC, et al. **J Virol** 1998 Nov;72(11):8852–60

Genomic organization of human B-ATF, a target for regulation by EBV and HTLV-1. Meyer NP, et al. **Mamm Genome** 1998 Oct;9(10):849–52

Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells. Cereseto A, et al. **Oncogene** 1999 Apr 15;18(15):2441–50

PHYSIOLOGY

Identification of a novel bovine serum protein which is involved in human T-cell leukemia virus type I (HTLV-I)-induced syncytium formation. Okuma K, et al. **Arch Virol** 1999;144(1):1–18

Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. Ekholm D, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):935–50

Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Bazarbachi A, et al. **Blood** 1999 Jan 1;93(1):278–83

High rate of chromosomal abnormalities in HTLV-I-infected T-cell colonies derived from prodromal phase of adult T-cell leukemia: a study of IL-2-stimulated colony formation in methylcellulose. Fujimoto T, et al. **Cancer Genet Cytogenet** 1999 Feb;109(1):1–13

Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy. Mor-Vaknin N, et al. **Cell Biol Int** 1998;22(2):95–103

Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J. **Clin Infect Dis** 1998 Nov;27(5):1309–10

Regulation of NF-kappaB by the HTLV-1 Tax protein. Li XH, et al. **Gene Expr** 1999;7(4–6):233–45 (124 ref.)

Anti-apoptotic strategies of lymphotropic viruses. Meinl E, et al. **Immunol Today** 1998 Oct;19(10):474–9 (55 ref.)

CD2 signalling induces phosphorylation of CREB in primary lymphocytes. Guyot DJ, et al. **Immunology** 1998 Dec; 95(4):544–52

Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Etoh K, et al. **Int J Cancer** 1999 Jun 11; 81(6):859–64

DNA binding properties of the nucleocapsid protein from human T-cell leukemia virus type-I. Chechelnitsky G, et al. **Int J Oncol** 1998 Oct;13(4):749–55

Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis. Van Orden K, et al. **J Biol Chem** 1999 Sep 10;274(37):26321–8

Human T-cell leukaemia/lymphoma virus type I syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin beta2 or beta7. Daenke S, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1429–36

Transformation of guinea pig leukocytes by coinfection with human T-cell lymphotropic virus types I and II. Murakami K, et al. **J Hum Virol** 1998 Jan-Feb;1(2):101–6

Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. Bogerd HP, et al. **J Virol** 1998 Nov;72(11):8627–35

Establishment of a seronegative human T-cell leukemia virus type I (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax. Koya Y, et al. **J Virol** 1999 Aug; 73(8):6436–43

Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission. Le Blanc I, et al. **J Virol** 1999 Mar; 73(3):1860–7

Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells. Ohashi T, et al. **J Virol** 1999 Jul;73(7):6031–40

A lysine-to-arginine change found in natural alleles of the human T-cell lymphotropic/leukemia virus type 1 p12(I) protein greatly influences its stability. Trovato R, et al. **J Virol** 1999 Aug;73(8):6460–7

Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. Tsukahara T, et al. **J Virol** 1999 Oct;73(10):7981–7

Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines. Weil R, et al. **J Virol** 1999 May;73(5):3709–17

Human T-cell leukemia virus type I can infect a wide variety of cells in mice. Feng R, et al. **Jpn J Cancer Res** 1999 Jan;90(1):48–54

Detection of inducible nitric oxide synthase (iNOS) mRNA by RT-PCR in ATL patients and HTLV-I infected cell lines: clinical features and apoptosis by NOS inhibitor. Sonoki T, et al. **Leukemia** 1999 May;13(5):713–8

Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Höllsberg P. **Microbiol Mol Biol Rev** 1999 Jun;63(2):308–33 (325 ref.)

Mitochondrial targeting of the p13II protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I). Ciminale V, et al. **Oncogene** 1999 Aug 5;18(31):4505–14

Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. Suzuki T, et al. **Oncogene** 1999 Jul 15;18(28):4137–43

Trans-activator Tax of human T-cell leukemia virus type 1 enhances mutation frequency of the cellular genome. Miyake H, et al. **Virology** 1999 Jan 20;253(2):155–61

HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. Smith D, et al. **Virology** 1999 May 10; 257(2):314–21

[HTLV-I and HTLV-II virus] Maniez-Montreuil M. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):563–70 (13 ref.) (Eng. Abstr.) **(Fre)**

HTLV-I ANTIBODIES

ANALYSIS

Failure to detect anti-HTLV-1 antibody in a patient with adult T-cell leukaemia/lymphoma [letter] Luo SS, et al. **Br J Haematol** 1998 Dec;103(4):1207–8

Ethnic cluster of HTLV-I infection in Israel among the Mashhadi Jewish population. Miller M, et al. **J Med Virol** 1998 Nov;56(3):269–74

[Clinical investigation of 15 patients with pulmonary cryptococcosis--clinical comparison of HTLV-I carriers and non-carriers] Matsuyama W, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Feb;37(2):108–14 (Eng. Abstr.) **(Jpn)**

BLOOD

Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Gotuzzo E, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):146–9

Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Medeot S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):623–9

Human T-cell lymphotropic virus type 1 tax among American blood donors. Zucker-Franklin D, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):831–5

Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Ureta-Vidal A, et al. **Int J Cancer** 1999 Sep 9;82(6):832–6

HTLV-I/II antibodies among three different Indian groups from Paraguay [letter] de Cabral MB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):548–9

Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. Telzak EE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):513–8

HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. Bartholomew C, et al. **J Hum Virol** 1998 May-Jun;1(4):302–5

Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Arisawa K, et al. **Jpn J Cancer Res** 1998 Aug; 89(8):797–805

Detection of HTLV-I antibodies and DNA in blood sample of a patient with myelopathy in Nigeria. Olaleye OD, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jan-Feb;40(1):55–7

Relationship between anti-Tax antibody responses and cocultivatable virus in HTLV-I-infected rabbits. Lydy SL, et al. **Virology** 1998 Oct 10;250(1):60–6

Prevalence of antibodies to HTLV-I/II in blood donors and risk populations in South China [letter] Cao F, et al. **Vox Sang** 1998;75(2):154

Antibodies to human T-cell lymphotropic virus type I (HTLV-I) by particle agglutination (PA) test in Korean blood donors. Kim JM, et al. **Yonsei Med J** 1999 Apr; 40(2):173–7

HTLV-I ANTIGENS

BLOOD

Comparison of four HTLV-I and HTLV-I + II ELISAs. Vrielink H, et al. **Vox Sang** 1999;76(3):187–91

HTLV-I-ASSOCIATED MYELOPATHY see **PARAPARESIS, TROPICAL SPASTIC**

HTLV-I-ASSOCIATED T-CELL LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HTLV-I INFECTIONS

Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Slattery JP, et al. **Genome Res** 1999 Jun;9(6):525–40 (113 ref.)

Human T-lymphotropic virus type I infection. Manns A, et al. **Lancet** 1999 Jun 5;353(9168):1951–8 (82 ref.)

BLOOD

A rapid method for determination of the relative copy number of HTLV-I proviral genome in HTLV-I carriers and adult T-cell leukemia patients by polymerase chain reaction. Hori T, et al. **Haematologia (Budap)** 1999; 29(4):265–76

Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Etoh K, et al. **Int J Cancer** 1999 Jun 11; 81(6):859–64

COMPLICATIONS

Clonal expansion of gammadelta-T lymphocytes in an HTLV-I carrier, associated with chronic neutropenia and rheumatoid arthritis. Horiuchi T, et al. **Ann Hematol** 1999 Feb;78(2):101–4

HTLV-I associated Sjögren's syndrome is aetiologically distinct from anti-centromere antibodies positive Sjögren's syndrome. Hida A, et al. **Ann Rheum Dis** 1999 May; 58(5):320–2

Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Murphy EL, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1485–91

Human T-cell lymphotropic virus type 1-associated neurologic disorder without spastic paraparesis [letter; comment] Ito H, et al. **Arch Neurol** 1999 Sep;56(9):1167. Comment on: Arch Neurol 1997 Jul;54(7):896–900.

Experimental HTLV-I infection and associated myelopathy. Costa CM, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):494–7

Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Analo HI, et al. **Cent Afr J Med** 1998 May; 44(5):130–4

Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and -seropositive SS patients. Nakamura H, et al. **Clin Exp Immunol** 1998 Oct; 114(1):106–12

Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J. **Clin Infect Dis** 1998 Nov;27(5):1309–10

Duodenal obstruction caused by Strongyloides stercoralis enteritis in an HTLV-1-infected host. Friedenberg F, et al. **Dig Dis Sci** 1999 Jun;44(6):1184–8 (17 ref.)

Primary gastric T-cell lymphoma accompanied by HTLV-I, HBV and H. pylori infection. Itatsu T, et al. **Dig Dis Sci** 1999 Sep;44(9):1823–36 (67 ref.)

Human T cell leukemia virus type-I and rheumatoid arthritis. Hasunuma T, et al. **Int Rev Immunol** 1998;17(5–6):291–307 (48 ref.)

Low prevalence of HTLV-I/II infection among HIV-1-infected injecting drug users in Russia [letter] Bobkova MR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):354

Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies). Agapé P, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 1;20(4):394–402

Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. Neva FA, et al. **J Infect Dis** 1998 Dec;178(6):1856–9

Gray-white, spherical deposition on retinal vessel associated with acute retinal necrosis and diabetic retinopathy in HTLV-I carriers. Nakao K, et al. **Jpn J Ophthalmol** 1998 Nov-Dec;42(6):490–4

Relationship between the human T-lymphotropic virus type 1 infection and clinical manifestations of tegumentary leishmaniasis in the Colombian Pacific Coast. Lenis AM, et al. **Mem Inst Oswaldo Cruz** 1999 Jan-Feb;94(1):19–20

Episcleritis associated with pigmentary retinal degeneration in an HTLV-I carrier. Nomura E, et al. **Tokai J Exp Clin Med** 1998 Oct;23(4):183–5

Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Tanabe K, et al. **Transplant Proc** 1998 Nov;30(7):3168–70

[A case of encephalomyeloneuritis and HTLV-I infection] Tateyama M, et al. **No To Shinkei** 1999 Aug;51(8):723–8 (Eng. Abstr.) **(Jpn)**

[A case of HTLV-I associated polyradiculoneuropathy and cerebral white matter lesions with smouldering type adult T cell leukemia] Hori T, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):645–8 (Eng. Abstr.) **(Jpn)**

[A case of limbic encephalitis associated with breast cancer developed in an HTLV-1 carrier] Kikuchi A, et al. **Rinsho Shinkeigaku** 1999 May;39(5):555–9 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Rheumatologic manifestations of HIV-1 and HTLV-1 infections. Vassilopoulos D, et al. **Cleve Clin J Med** 1998 Sep;65(8):436–41 (33 ref.)

[HTLV-I and HTLV-II virus] Maniez-Montreuil M. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):563–70 (13 ref.) (Eng. Abstr.) **(Fre)**

[Anguilluliasis associated with HTLV-I infection (letter)] Bonnet C, et al. **Presse Med** 1999 Apr 17;28(15):788 **(Fre)**

[Strongyloidiasis and HTLV-I infection (letter; comment)] Calderón E, et al. **Med Clin (Barc)** 1999 Feb 27;112(7):279 . Comment on: Med Clin (Barc) 1997 Nov 1;109(15):609. **(Spa)**

DRUG THERAPY

Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Ishitsuka K, et al. **Br J Haematol** 1998 Dec; 103(3):721–8

Multi-clonal expansion of unique human T-lymphotropic virus type-I-infected T cells with high growth potential in response to interleukin-2 in prodromal phase of adult T cell leukemia. Hata T, et al. **Leukemia** 1999 Feb; 13(2):215–21

EPIDEMIOLOGY

Human T-cell leukaemia/lymphoma virus type I infection in West African patients with clinical AIDS [letter] Kanmogné G, et al. **AIDS** 1998 Nov 12;12(16):2239

HTLV-I infection in Spain. HTLV Spanish Study Group [letter] Machuca A, et al. **AIDS** 1998 Oct 1;12(14):1927–8

Community-based molecular epidemiology of HTLV type I in Taiwan and Kinmen: implication of the origin of the cosmopolitan subtype in northeast Asia. Chen YM, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):229–37

Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Gotuzzo E, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):146–9

Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Medeot S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):623–9

Human T-cell lymphotropic virus type 1 infection and ocular manifestations in São Paulo, Brazil. Yamamoto JH, et al. **Arch Ophthalmol** 1999 Apr;117(4):513–7

Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Hisada M, et al. **Blood** 1998 Nov 15;92(10):3557–61

Seroprevalence study of HTLV-1 and HIV infection in blood donors and patients with lymphoid malignancies in Lagos, Nigeria. Analo HI, et al. **Cent Afr J Med** 1998 May; 44(5):130–4

Human T-cell lymphotropic virus type 1 tax among American blood donors. Zucker-Franklin D, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):831–5

Role of HTLV-1 co-infection in the AIDS epidemic in the Caribbean: a cause for concern. Daisley H, et al. **Int J STD AIDS** 1999 Jul;10(7):487–9

HTLV-I and HTLV-II coexist among the Embera and Inga Amerindians of Colombia [letter] Arango C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):102–3

HIV-1, HTLV-I, and HTLV-II in a semiurban population in East Gabon [letter] Bertherat E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):430–2

High prevalence of HTLV-I infection in Argentinian blood donors: a new HTLV-I-endemic area? [letter] Biglione M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):101–2

HTLV-I/II antibodies among three different Indian groups from Paraguay [letter] de Cabral MB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):548–9

HTLV-I in Northeast Brazil: differences for male and female injecting drug users. Dourado I, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):426–9

Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. Telzak EE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):513–8

Search for human T-lymphotropic virus type I carriers among northeastern Chinese. Geng L, et al. **J Dermatol Sci** 1998 Sep;18(1):30–4

HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy/tropical spastic paraparesis. Bartholomew C, et al. **J Hum Virol** 1998 May-Jun;1(4):302–5

Human T lymphotropic virus type I (HTLV-I) infection in neurological patients in Salvador, Bahia, Brazil. Gomes I, et al. **J Neurol Sci** 1999 May 1;165(1):84–9

Human T-cell lymphotropic virus types I and II infections in mother-child pairs in Nigeria. Olaleye DO, et al. **J Trop Pediatr** 1999 Apr;45(2):66–70

Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Dourado I, et al. **Mem Inst Oswaldo Cruz** 1999 Jan-Feb;94(1):13–8

Low prevalence of human T-cell lymphotropic virus type I infection among volunteer blood donors in Taiwan [letter] Chang CS, et al. **Transfusion** 1998 Nov-Dec; 38(11-12):1118–9

Molecular epidemiology of human T-cell leukemia virus type I (HTLV-1) Brazil: the predominant HTLV-Is in South America differ from HTLV-Is of Japan and Africa, as well as those of Japanese immigrants and their relatives in Brazil. Yamashita M, et al. **Virology** 1999 Aug 15;261(1):59–69

Prevalence of antibodies to HTLV-I/II in blood donors and risk populations in South China [letter] Cao F, et al. **Vox Sang** 1998;75(2):154

[Prevalence of HTLV-I/II infection in various population groups in Gran Canaria (letter)] Evora Santana O, et al. **Med Clin (Barc)** 1999 Feb 20;112(6):237 **(Spa)**

ETHNOLOGY

Ethnic cluster of HTLV-I infection in Israel among the Mashhadi Jewish population. Miller M, et al. **J Med Virol** 1998 Nov;56(3):269–74

ETIOLOGY

Persistent infection with human T lymphotropic virus type 1 after allogeneic bone marrow transplantation from a seronegative donor [letter] Kanda Y, et al. **Bone Marrow Transplant** 1999 Aug;24(3):349

GENETICS

Polymorphism of the 5'-flanking region of the tumor necrosis factor (TNF)-alpha gene and susceptibility to human T-cell lymphotropic virus type I (HTLV-I) uveitis. Seki N, et al. **J Infect Dis** 1999 Sep;180(3):880–3

IMMUNOLOGY

Accumulation of human T lymphotropic virus type I-infected T cells in the salivary glands of patients with human T lymphotropic virus type I-associated Sjögren's syndrome. Ohyama Y, et al. **Arthritis Rheum** 1998 Nov;

41(11):1972–8
Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV-I carriers in Japan. Hisada M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 1;19(4):421–5
Clonal expansion within CD4+ and CD8+ T cell subsets in human T lymphotropic virus type I–infected individuals. Eiraku N, et al. **J Immunol** 1998 Dec 15;161(12):6674–80
Human complement component C1q inhibits the infectivity of cell-free HTLV-I. Ikeda F, et al. **J Immunol** 1998 Nov 15;161(10):5712–9
Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. Neva FA, et al. **J Infect Dis** 1998 Dec;178(6):1856–9
The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes. Hadlock KG, et al. **J Virol** 1999 Feb;73(2):1205–12
Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Arisawa K, et al. **Jpn J Cancer Res** 1998 Aug; 89(8):797–805
Human T-cell leukemia virus type I can infect a wide variety of cells in mice. Feng R, et al. **Jpn J Cancer Res** 1999 Jan;90(1):48–54
In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers [published erratum appears in Leukemia 1999 Jul;13(7):1108] Tricarico M, et al.
Leukemia 1999 Feb;13(2):222–9
HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Jeffery KJ, et al.
Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3848–53
[Pathogenetic significance of HTLV-I infection and immune surveillance in HAM] Fujihara K. **Rinsho Shinkeigaku** 1999 Jan;39(1):21–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia. Zhang Q, et al. **Leuk Res** 1999 Apr; 23(4):373–84

MORTALITY

Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Arisawa K, et al. **Jpn J Cancer Res** 1998 Aug; 89(8):797–805

PATHOLOGY

Extracellular human T cell leukemia virus type I tax protein stimulates the proliferation of human synovial cells. Aono H, et al. **Arthritis Rheum** 1998 Nov;41(11):1995–2003
Low prevalence of flower cells in U.S.A. blood donors infected with human T-lymphotrophic virus types I and II. Sacher RA, et al. **Br J Haematol** 1999 Jun;105(3):758–63
Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I–infected T-cells. Cereseto A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1575–81

PHYSIOPATHOLOGY

Role of interleukin-8 and transforming growth factor-beta1 in enhancement of human cytomegalovirus replication by human T cell leukemia-lymphoma virus type I in macrophages coinfected with both viruses. Szabó J, et al.
J Interferon Cytokine Res 1999 Feb;19(2):209–17
Quantitative assessment of subclinical spasticity in human T-cell lymphotropic virus type I infection. Zunt JR, et al. **Neurology** 1999 Jul 22;53(2):386–90

PREVENTION & CONTROL

[Blood-borne viral infection in hemodialysis units: special reference to hepatitis B virus, hepatitis C virus and human T-lymphotropic virus type I] Washio M.
Nippon Koshu Eisei Zasshi 1998 Oct;45(10):960–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Psychological distress in blood donors notified of HTLV-I/II infection. Retrovirus Epidemiology Donor Study. Guiltinan AM, et al. **Transfusion** 1998 Nov-Dec; 38(11–12):1056–62

THERAPY

Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells. Ohashi T, et al. **J Virol** 1999 Jul;73(7):6031–40

TRANSMISSION

High prevalence of HTLV-I infection among the family members of a patient with adult T-cell leukemia/lymphoma from northeastern Japan. Shimizu K. **Am J Hematol** 1999 May;61(1):78–81
HTLV-I-associated myelopathy following allogeneic bone marrow transplantation. Emmanouilides CE, et al.
Bone Marrow Transplant 1999 Jul;24(2):205–6
Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Ureta-Vidal A, et al. **Int J Cancer** 1999 Sep 9;82(6):832–6
HTLV-I in Northeast Brazil: differences for male and female injecting drug users. Dourado I, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 1;19(4):426–9
Transmission of HTLV-I to rats via peripheral blood mononuclear cells and serum from a patient with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with amyotrophic lateral sclerosis (ALS)-like features. Miller M, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Apr 1;20(4):403–7
Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. Wiktor SZ, et al. **J Hum Virol** 1997 Nov-Dec;1(1):37–44
No evidence of vertical transmission of HTLV-I and HTLV-II in children at high risk for HIV-1 infection from São Paulo, Brazil. Caterino-de-Araujo A, et al.
J Trop Pediatr 1999 Feb;45(1):42–7
HTLV-I infection among relatives of patients with adult T-cell leukemia/lymphoma in Brazil: analysis of infection transmission. Borducchi DM, et al. **Leuk Lymphoma** 1998 Oct;31(3–4):411–6
Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Dourado I, et al. **Mem Inst Oswaldo Cruz** 1999 Jan-Feb;94(1):13–8
Apoptosis in placentas from human T-lymphotropic virus type I–seropositive pregnant women: a possible defense mechanism against transmission from mother to fetus. Fujino T, et al. **Obstet Gynecol** 1999 Aug;94(2):279–83
Vertical transmission of HTLV-I/II: a review. Bittencourt AL. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug; 40(4):245–51 (68 ref.)
Human T-lymphotropic virus type I among blood donors from Guadeloupe: donation, demographic, and biologic characteristics. Rouet F, et al. **Transfusion** 1999 Jun; 39(6):639–44
[Laboratory diagnosis of viral infections. 9. Viral infections related to blood transfusion and organ transplantation] Miyamoto A, et al. **Rinsho Byori** 1998 Nov;Suppl 108:111–5 (6 ref.) **(Jpn)**
[HTLV examination of Norwegian blood donors] Samdal HH, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):206–8 (Eng. Abstr.) **(Nor)**

VIROLOGY

Sequence of the env gene of some KwaZulu-Natal, South African strains of HTLV type I. Bhigjee AI, et al.
AIDS Res Hum Retroviruses 1999 Sep 1;15(13):1229–33
Sequence analysis of the first HTLV-I infection in Germany without relations to endemic areas. Ellerbrok H, et al.
AIDS Res Hum Retroviruses 1998 Sep 1;14(13):1199–203
Is human T-cell lymphotropic virus type I more clever than human immunodeficiency virus type 1? Casseb J.
Clin Infect Dis 1998 Nov;27(5):1309–10
Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] [corrected] in Latin America [published erratum appears in J Gen Virol 1999 Apr;80(Pt 4):1087] Van Dooren S, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2695–708
Human T cell leukemia virus type I expression in salivary glands of infected patients. Tangy F, et al. **J Infect Dis** 1999 Feb;179(2):497–502
Nucleotide sequence analysis of human T-cell lymphotropic virus type I pX and LTR regions from patients with sicca syndrome. Beby-Defaux A, et al. **J Med Virol** 1999 Oct; 59(2):245–55
Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax. Koya Y, et al. **J Virol** 1999 Aug; 73(8):6436–43
Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. Tosswill JH, et al.
J Virol Methods 1998 Nov;75(1):21–6
Molecular epidemiology of human T-cell leukemia virus type I (HTLV-1) Brazil: the predominant HTLV-Is in South America differ from HTLV-Is of Japan and Africa, as well as those of Japanese immigrants and their relatives in Brazil. Yamashita M, et al. **Virology** 1999 Aug 15;261(1):59–69

HTLV-I POST-TRANSCRIPTIONAL REGULATOR PROTEIN see **GENE PRODUCTS, REX**

HTLV-I REX GENES see **GENES, PX**

HTLV-I REX PROTEIN see **GENE PRODUCTS, REX**

HTLV-I TAX GENES see **GENES, PX**

HTLV-I TAX PROTEIN see **GENE PRODUCTS, TAX**

HTLV-I TRANS-ACTIVATOR PROTEIN see **GENE PRODUCTS, TAX**

HTLV-II

Molecular evidence for transmission of human T-lymphotropic virus type II infection by a human bite. Bolton WV, et al. **J Clin Microbiol** 1999 Jan;37(1):238–40
[Analysis of HTLV-II particle formation by recombinant baculovirus system] Takahashi R.
Hokkaido Igaku Zasshi 1998 Sep;73(5):451–61 (Eng. Abstr.) **(Jpn)**

GENETICS

Seroepidemiological and molecular studies of human T cell lymphotropic virus type II, subtype b, in isolated groups of Mataco and Toba Indians of northern Argentina. Biglione M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):407–17
The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy. Salemi M, et al. **Gene** 1999 Jun 24;234(1):11–21 (92 ref.)
Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Slattery JP, et al.
Genome Res 1999 Jun;9(6):525–40 (113 ref.)
Early assembly step of a retroviral envelope glycoprotein: analysis using a dominant negative assay. Rosenberg AR, et al. **J Cell Biol** 1999 Apr 5;145(1):57–68
The complete genomic sequence of an HTLV-II isolate from a Guahibo Indian from Venezuela. Dube S, et al.
Virology 1999 Jan 20;253(2):181–92

IMMUNOLOGY

Establishment of monoclonal antibody, gp21-34, against HTLV-II envelope protein (p20E). Miyagawa E, et al.
Hybridoma 1998 Aug;17(4):347–54
Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Andersson S, et al. **Transfusion** 1999 Aug;39(8):845–51

ISOLATION & PURIFICATION

Presence of human immunodeficiency virus (HIV) and T-lymphotropic virus type I and II (HTLV-I/II) in a haemophiliac population in Belo Horizonte, Brazil, and correlation with additional serological results. Carneiro-Proietti AB, et al. **Haemophilia** 1998 Jan; 4(1):47–50
Evaluation of the INNO-LIA HTLV I/II assay for confirmation of human T-cell leukemia virus-reactive sera in blood bank donations. Sabino EC, et al.
J Clin Microbiol 1999 May;37(5):1324–8
HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. Soldan SS, et al. **J Infect Dis** 1999 Sep;180(3):685–94
Multiplex detection of four pathogenic retroviruses using molecular beacons. Vet JA, et al.
Proc Natl Acad Sci U S A 1999 May 25;96(11):6394–9

PATHOGENICITY

Mammary epithelial cells support and transfer productive human T-cell lymphotropic virus infections. LeVasseur RJ, et al. **J Hum Virol** 1998 Mar-Apr;1(3):214–23

PHYSIOLOGY

Transformation of guinea pig leukocytes by coinfection with human T-cell lymphotropic virus types I and II. Murakami K, et al. **J Hum Virol** 1998 Jan-Feb;1(2):101–6
Human T-cell leukemia virus type 2 Rex protein increases stability and promotes nuclear to cytoplasmic transport of gag/pol and env RNAs. Kusuhara K, et al. **J Virol** 1999 Oct;73(10):8112–9
Analysis of human lymphotropic T-cell virus type II-like particle production by recombinant baculovirus-infected insect cells. Takahashi RH, et al. **Virology** 1999 Apr 10; 256(2):371–80
[HTLV-I and HTLV-II virus] Maniez-Montreuil M.
Ann Biol Clin (Paris) 1998 Sep-Oct;56(5):563–70 (13 ref.) (Eng. Abstr.) **(Fre)**

HTLV-II ANTIBODIES

BLOOD

Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Medeot S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):623–9
HTLV-I/II antibodies among three different Indian groups from Paraguay [letter] de Cabral MB, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 15;19(5):548–9
Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. Telzak EE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):513–8
Prevalence of antibodies to HTLV-I/II in blood donors and

risk populations in South China [letter] Cao F, et al. **Vox Sang** 1998;75(2):154

HTLV-II ANTIGENS

BLOOD

Comparison of four HTLV-I and HTLV-I + II ELISAs. Vrielink H, et al. **Vox Sang** 1999;76(3):187–91

HTLV-II-ASSOCIATED T-CELL LEUKEMIA see **LEUKEMIA, T-CELL, HTLV-II-ASSOCIATED**

HTLV-II-HCL see **LEUKEMIA, T-CELL, HTLV-II-ASSOCIATED**

HTLV-II INFECTIONS

Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Slattery JP, et al. **Genome Res** 1999 Jun;9(6):525–40 (113 ref.)

COMPLICATIONS

High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. Egan JF, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):699–705

Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Murphy EL, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1485–91

Low prevalence of HTLV-I/II infection among HIV-1-infected injecting drug users in Russia [letter] Bobkova MR, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):354

DIAGNOSIS

[HTLV-I and HTLV-II virus] Maniez-Montreuil M. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):563–70 (13 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Seroepidemiological and molecular studies of human T cell lymphotropic virus type II, subtype b, in isolated groups of Mataco and Toba Indians of northern Argentina. Biglione M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):407–17

High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. Egan JF, et al. **AIDS Res Hum Retroviruses** 1999 May 20;15(8):699–705

Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Medeot S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):623–9

Human T-cell leukemia/lymphoma virus type II infection in Spain. HTLV Spanish Study Group. Soriano V, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jan;18(1):75–7

Is there a focus of HTLV-II infections in the Horn of Africa? [letter] Andersson S, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):353–4

HTLV-I and HTLV-II coexist among the Embera and Inga Amerindians of Colombia [letter] Arango C, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Jan 1;20(1):102–3

HIV-1, HTLV-I, and HTLV-II in a semiurban population in East Gabon [letter] Bertherat E, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 1;19(4):430–2

HTLV-I/II antibodies among three different Indian groups from Paraguay [letter] de Cabral MB, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):548–9

Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study. Telzak EE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):513–8

Risk factors for human T cell lymphotropic virus type II infection among the Guaymi Indians of Panama. Maloney EM, et al. **J Infect Dis** 1999 Sep;180(3):876–9

Human T-cell lymphotropic virus types I and II infections in mother-child pairs in Nigeria. Olaleye DO, et al. **J Trop Pediatr** 1999 Apr;45(2):66–70

Prevalence of antibodies to HTLV-I/II in blood donors and risk populations in South China [letter] Cao F, et al. **Vox Sang** 1998;75(2):154

[Prevalence of HTLV-I/II infection in various population groups in Gran Canaria (letter)] Evora Santana O, et al. **Med Clin (Barc)** 1999 Feb 20;112(6):237 **(Spa)**

ETHNOLOGY

HTLV-II risk factors in Native Americans in Florida. Lowis GW, et al. **Neuroepidemiology** 1999;18(1):37–47

PATHOLOGY

Low prevalence of flower cells in U.S.A. blood donors infected with human T-lymphotrophic virus types I and II. Sacher RA, et al. **Br J Haematol** 1999 Jun;105(3):758–63

PSYCHOLOGY

Psychological distress in blood donors notified of HTLV-I/II infection. Retrovirus Epidemiology Donor Study. Guiltinan AM, et al. **Transfusion** 1998 Nov-Dec; 38(11-12):1056–62

TRANSMISSION

Molecular evidence for transmission of human T-lymphotropic virus type II infection by a human bite. Bolton WV, et al. **J Clin Microbiol** 1999 Jan;37(1):238–40

No evidence of vertical transmission of HTLV-I and HTLV-II in children at high risk for HIV-1 infection from São Paulo, Brazil. Caterino-de-Araujo A, et al. **J Trop Pediatr** 1999 Feb;45(1):42–7

Vertical transmission of HTLV-I/II: a review. Bittencourt AL. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug; 40(4):245–51 (68 ref.)

[HTLV examination of Norwegian blood donors] Samdal HH, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):206–8 (Eng. Abstr.) **(Nor)**

VIROLOGY

HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. Soldan SS, et al. **J Infect Dis** 1999 Sep;180(3):685–94

HTLV-II POST-TRANSCRIPTIONAL REGULATOR PROTEIN see **GENE PRODUCTS, REX**

HTLV-II REX GENES see **GENES, PX**

HTLV-II REX PROTEIN see **GENE PRODUCTS, REX**

HTLV-II TAX GENES see **GENES, PX**

HTLV-II TAX PROTEIN see **GENE PRODUCTS, TAX**

HTLV-II TRANS-ACTIVATOR PROTEIN see **GENE PRODUCTS, TAX**

HTLV-III see **HIV**

HTLV-III ANTIBODIES see **HIV ANTIBODIES**

HTLV-III ANTIGENS see **HIV ANTIGENS**

HTLV-III GP41 see **HIV ENVELOPE PROTEIN GP41**

HTLV-III GP120 see **HIV ENVELOPE PROTEIN GP120**

HTLV-III GP160 see **HIV ENVELOPE PROTEIN GP160**

HTLV-III INFECTIONS see **HIV INFECTIONS**

HTLV-III-LAV ANTIBODIES see **HIV ANTIBODIES**

HTLV-III-LAV ANTIGENS see **HIV ANTIGENS**

HTLV-III-LAV INFECTIONS see **HIV INFECTIONS**

HTLV-III PROTEASE see **HIV PROTEASE**

HTLV-III RECEPTORS see **RECEPTORS, HIV**

HTLV-III SEROCONVERSION see **HIV SEROPOSITIVITY**

HTLV-III SERODIAGNOSIS see **AIDS SERODIAGNOSIS**

HTLV-III SEROLOGY see **AIDS SERODIAGNOSIS**

HTLV-III SERONEGATIVITY see **HIV SERONEGATIVITY**

HTLV-III SEROPOSITIVITY see **HIV SEROPOSITIVITY**

HTLV-IV see **HIV-2**

5-HTP see **5-HYDROXYTRYPTOPHAN**

HUMAN ACTIVITIES

Consequences of retirement activities for distress and the sense of personal control. Ross CE, et al. **J Health Soc Behav** 1998 Dec;39(4):317–34

Global climate change. Alley RB, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9987–8

[Consciousness as the highest integrative function of brain] Chailakhian LM. **Vestn Ross Akad Med Nauk** 1999;(6):35–8 (8 ref.) (Eng. Abstr.) **(Rus)**

[Role of proteinase inhibitors in the process that provide coupling between body's functional systems] Gurin VN, et al. **Vestn Ross Akad Med Nauk** 1999;(6):25–9 (25 ref.) (Eng. Abstr.) **(Rus)**

[Theory of functional systems and integrative physiology] Sudakov KV. **Vestn Ross Akad Med Nauk** 1999;(6):5–10 (40 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Norms for 439 action events: familiarity, emotionality, motor activity, and memorability. Molander B, et al. **Scand J Psychol** 1998 Dec;39(4):275–300

HUMAN BODY

The electric field induced in the human body when exposed to electromagnetic fields at 1–30 MHz on shipboard. King RW. **IEEE Trans Biomed Eng** 1999 Jun;46(6):747–51

Intellectual evaluations of adolescents via human figure drawings: an empirical comparison of two methods. Abell SC, et al. **J Clin Psychol** 1998 Oct;54(6):811–5

Evolutionary-derived anatomical characteristics and universal attractiveness. Magro AM. **Percept Mot Skills** 1999 Feb;88(1):147–66

[Who will shape the female body? Culture, surgery and conflict] Sundby J. **Tidsskr Nor Laegeforen** 1998 Nov 10; 118(27):4194 **(Nor)**

HUMAN CHORIONIC GONADOTROPIN, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

HUMAN CHORIONIC GONADOTROPIN, BETA SUBUNIT see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

HUMAN CHORIONIC GONADOTROPIN RECEPTORS see **RECEPTORS, LH**

HUMAN CLASS II ANTIGENS see **HLA-D ANTIGENS**

HUMAN CLONING see **CLONING, ORGANISM**

HUMAN DEVELOPMENT

Human potential phases in the second half of life [editorial] Cohen GD. **Am J Geriatr Psychiatry** 1999 Winter;7(1):1–7

A commentary on Newman's theory of health as expanding consciousness. Yamashita M, et al. **ANS Adv Nurs Sci** 1998 Sep;21(1):65–75 (39 ref.)

Developmental task achievement and learned resourcefulness in healthy older adults. Zauszniewski JA, et al. **Arch Psychiatr Nurs** 1999 Feb;13(1):41–7

Knowledge enrichment and conceptual change in folkbiology: evidence from Williams syndrome. Johnson SC, et al. **Cognit Psychol** 1998 Nov;37(2):156–200

Relationship of body size and body mass to blood pressure: sex-specific and developmental influences. Gerber LM, et al. **Hum Biol** 1999 Aug;71(4):505–28 (113 ref.)

Coping in young women: theoretical retroduction. Gramling LF, et al. **J Adv Nurs** 1998 Nov;28(5):1082–91

Developmental differences in the ability to inhibit the initial misinterpretation of garden path passages. Lorsbach TC, et al. **J Exp Child Psychol** 1998 Dec;71(3):275–96

Reducing risks and building developmental assets: essential actions for promoting adolescent health. Scales PC. **J Sch Health** 1999 Mar;69(3):113–9 (16 ref.)

Culture and biology in emotional development. Fischer KW, et al. **New Dir Child Dev** 1998 Fall;(81):21–43 (62 ref.)

The primacy of primary control is a human universal: a reply to Gould's (1999) critique of the life-span theory of control. Heckhausen J, et al. **Psychol Rev** 1999 Jul;106(3):605–9 (36 ref.)

Some implications of chaos theory for the genetic analysis of human development and variation [see comments] Eaves LJ, et al. **Twin Res** 1999 Mar;2(1):43–8. Comment in: Twin Res 1999 Mar;2(1):49–52.

Additional aspects of third source variation for the genetic analysis of human development and behaviour: a commentary on Eaves et al [comment] Molenaar PC, et al. **Twin Res** 1999 Mar;2(1):49–52. Comment on: Twin Res 1999 Mar;2(1):43–8.

Programming for adolescent health and development. Report of a WHO/UNFPA/UNICEF Study Group on Programming for Adolescent Health. **World Health Organ Tech Rep Ser** 1999;886:i–vi, 1–260

[Human development and child neurology (interview)] Maekawa K. **No To Hattatsu** 1999 Jan;31(1):3–13 **(Jpn)**

[Special "Dr. Ignacio Chávez" lecture. Health and human development] Soberón G. **Gac Med Mex** 1999 Mar-Apr; 135(2):217–30 **(Spa)**

HUMAN ENDOGENOUS RETROVIRUSES see **ENDOGENOUS RETROVIRUSES**

HUMAN ENGINEERING

see related
PSYCHOLOGY, INDUSTRIAL

Importance of human factors engineering in error-and-medicine education [letter; comment] Gosbee J. **Acad Med** 1999 Jul;74(7):748–9. Comment on: Acad Med 1999 Jan;74(1):19–22.

Adverse work and environmental conditions predict occupational injuries. The Israeli Cardiovascular Occupational Risk Factors Determination in Israel (CORDIS) Study. Melamed S, et al. **Am J Epidemiol** 1999 Jul 1;150(1):18–26

Effects of a participatory ergonomics team among hospital orderlies. Evanoff BA, et al. **Am J Ind Med** 1999 Apr;

35(4):358–65
Effect of four computer keyboards in computer users with upper extremity musculoskeletal disorders. Tittiranonda P, et al. **Am J Ind Med** 1999 Jun;35(6):647–61
Ergonomic evaluation of laparoscopic bowel suturing. Joice P, et al. **Am J Surg** 1998 Oct;176(4):373–8
Prevalence of back discomfort and estimates of back load in two manufacturing facilities. Liu WC, et al. **Ann Occup Hyg** 1998 Nov;42(8):549–56
Work content and satisfaction before and after a reorganisation of data entry work. Aborg C, et al. **Appl Ergon** 1998 Dec;29(6):473–80
Anthropometric variability, equipment usability and musculoskeletal pain in a group of nurses in the Western Cape. Botha WE, et al. **Appl Ergon** 1998 Dec;29(6):481–90
An ergonomic approach to public squatting-type toilet design. Cai D, et al. **Appl Ergon** 1998 Apr;29(2):147–53
Task design, psycho-social work climate and upper extremity pain disorders--effects of an organisational redesign on manual repetitive assembly jobs. Christmansson M, et al. **Appl Ergon** 1999 Oct;30(5):463–72
Measurement of postural stability before and after immersion in a virtual environment. Cobb SV. **Appl Ergon** 1999 Feb; 30(1):47–57
Influence of mouse position on muscular activity in the neck, shoulder and arm in computer users. Cook CJ, et al. **Appl Ergon** 1998 Dec;29(6):439–43
Self-administered preventive programme for sedentary workers: reducing musculoskeletal symptoms or increasing awareness? Coury HJ. **Appl Ergon** 1998 Dec;29(6):415–21
Subjective assessment of fork-lift truck seats under laboratory conditions. Donati P, et al. **Appl Ergon** 1999 Aug; 30(4):295–309
Factors affecting minimum push and pull forces of manual carts. Al-Eisawi KW, et al. **Appl Ergon** 1999 Jun; 30(3):235–45
Musculoskeletal symptoms due to technical preconditions in long cycle time work in an automobile assembly plant: a study of prevalence and relation to psychosocial factors and physical exposure. Engström T, et al. **Appl Ergon** 1999 Oct;30(5):443–53
Effects of arm suspension in simulated assembly line work: muscular activity and posture angles. Feng Y, et al. **Appl Ergon** 1999 Jun;30(3):247–53
The role of 'know-how' in maintenance activities and reliability in a high-risk process control plant. Garrigou A, et al. **Appl Ergon** 1998 Apr;29(2):127–31
Interface pressure and the prediction of car seat discomfort. Gyi DE, et al. **Appl Ergon** 1999 Apr;30(2):99–107
Theory and practice for the implementation of 'in-house', continuous improvement participatory ergonomic programs. Haims MC, et al. **Appl Ergon** 1998 Dec; 29(6):461–72
Ergonomics considerations in the design and use of single disc floor cleaning machines. Haslam RA, et al. **Appl Ergon** 1999 Oct;30(5):391–9
On using psychophysical techniques to achieve urgency mapping in auditory warnings. Hellier E, et al. **Appl Ergon** 1999 Apr;30(2):167–71
Industrial inspection performance depends on both viewing distance and oculomotor characteristics. Jebaraj D, et al. **Appl Ergon** 1999 Jun;30(3):223–8
The ability of non-ergonomists in the health care setting to make manual handling risk assessments and implement changes. Jones JA, et al. **Appl Ergon** 1999 Apr;30(2):159–66
Coach design for the Korean high-speed train: a systematic approach to passenger seat design and layout. Jung ES, et al. **Appl Ergon** 1998 Dec;29(6):507–19
VRUSE--a computerised diagnostic tool: for usability evaluation of virtual/synthetic environment systems. Kalawsky RS. **Appl Ergon** 1999 Feb;30(1):11–25
A process for the development, specification and evaluation of VDU work tables. Karlqvist L. **Appl Ergon** 1998 Dec; 29(6):423–32
Static three-dimensional modelling of prolonged seated posture. Kayis B, et al. **Appl Ergon** 1999 Jun;30(3):255–62
Measurement of forces applied to handgrips and pedals for a sample population of Mexican males. Lara-Lopez A, et al. **Appl Ergon** 1999 Apr;30(2):173–6
Lumbosacral loads in bedmaking. Milburn PD, et al. **Appl Ergon** 1999 Jun;30(3):263–73
Physical ergonomics of virtual environment use. Nichols S. **Appl Ergon** 1999 Feb;30(1):79–90
Guidelines for force-travel combinations of push button switches for older populations. Rahman MM, et al. **Appl Ergon** 1998 Apr;29(2):93–100
Full-body interface pressure testing as a method for performance evaluation of clinical support surfaces. Shelton F, et al. **Appl Ergon** 1998 Dec;29(6):491–7
Motion sickness and proprioceptive aftereffects following virtual environment exposure. Stanney KM, et al. **Appl Ergon** 1999 Feb;30(1):27–38
Virtual environments applications and applied ergonomics. Wilson JR. **Appl Ergon** 1999 Feb;30(1):3–9 (39 ref.)
Ergonomic criteria in large-scale engineering design--I. Management by documentation only? Formal organization vs. designers' perceptions. Wulff IA, et al. **Appl Ergon** 1999 Jun;30(3):191–205
Ergonomic criteria in large-scale engineering design--II. Evaluating and applying requirements in the real world of design. Wulff IA, et al. **Appl Ergon** 1999 Jun;30(3):207–21
National Academy of Sciences Workshop and Report on the Science of Ergonomics. Schneider S. **Appl Occup Environ Hyg** 1999 Feb;14(2):75–7
Surgery and ergonomics. Berguer R. **Arch Surg** 1999 Sep; 134(9):1011–6
Using a screen filter positively influences the physical well-being of VDU operators. Hladký A, et al. **Cent Eur J Public Health** 1998 Aug;6(3):249–53
Application of ergonomics principles of burdening of the worker in the process of clothes cutting. Mijović B, et al. **Coll Antropol** 1998 Dec;22 Suppl:229–40
Contribution to the ergonomic investigations in textile industry. Skoko M. **Coll Antropol** 1998 Dec;22 Suppl:223–7
Ergonomically effective grommet [letter] Parlette EC, et al. **Dermatol Surg** 1999 Jan;25(1):74–5
Work-related problems in metal handling tasks in Bangladesh: obstacles to the development of safety and health measures. Ahasan MR, et al. **Ergonomics** 1999 Feb; 42(2):385–96
An ergonomics investigation into human thermal comfort using an automobile seat heated with encapsulated carbonized fabric (ECF). Brooks JE, et al. **Ergonomics** 1999 May;42(5):661–73
Benefit of heat acclimation is limited by the evaporative potential when wearing chemical protective clothing. Chang SK, et al. **Ergonomics** 1999 Aug;49(8):1038–50
Children's behaviour and the design of school furniture. Knight G, et al. **Ergonomics** 1999 May;42(5):747–60
Assessment of human muscle strength for engineering purposes: a review of the basics. Kroemer KH. **Ergonomics** 1999 Jan;42(1):74–93
Seated work postures for manual, visual and combined tasks. Li G, et al. **Ergonomics** 1999 Aug;49(8):1060–86
A biomechanical evaluation of lifting speed using work- and moment-related measures. Lin CJ, et al. **Ergonomics** 1999 Aug;49(8):1051–9
A comprehensive analysis of low-back disorder risk and spinal loading during the transferring and repositioning of patients using different techniques. Marras WS, et al. **Ergonomics** 1999 Jul;42(7):904–26
Chainsaw size for delimbing. Parker R, et al. **Ergonomics** 1999 Jul;42(7):897–903
Effects of pacing when using material handling manipulators. Nussbaum MA, et al. **Hum Factors** 1999 Jun;41(2):214–25
Designing an interface to optimize reading with small display windows. Rahman T, et al. **Hum Factors** 1999 Mar; 41(1):106–17
Ergonomic strategies for improving working conditions in some developing countries in Asia. Kawakami T, et al. **Ind Health** 1999 Apr;37(2):187–98 (33 ref.)
The effects of an ergonomic-educational course. Postural load, perceived physical exertion, and biomechanical errors in nursing. Engels JA, et al. **Int Arch Occup Environ Health** 1998 Jul;71(5):336–42
Collaborative field research and training in occupational health and ergonomics. Kogi K. **Int J Occup Environ Health** 1998 Jul-Sep;4(3):189–95 (24 ref.)
Shoulder disorders related to work organization and other occupational factors among supermarket cashiers. Niedhammer I, et al. **Int J Occup Environ Health** 1998 Jul-Sep;4(3):168–78
Ergonomic exposure assessment: an application of the PATH systematic observation method to retail workers. Postures, Activities, Tools and Handling. Pan CS, et al. **Int J Occup Environ Health** 1999 Apr-Jun;5(2):79–87
Mismatch of classroom furniture and student body dimensions: empirical findings and health implications [see comments] Parcells C, et al. **J Adolesc Health** 1999 Apr; 24(4):265–73 (29 ref.). Comment in: J Adolesc Health 1999 Apr;24(4):229.
A behavior-based inverse kinematics algorithm to predict arm prehension postures for computer-aided ergonomic evaluation. Wang X. **J Biomech** 1999 May;32(5):453–60
Applying human factors to the design of medical equipment: patient-controlled analgesia. Lin L, et al. **J Clin Monit Comput** 1998 May;14(4):253–63
Retention of supportive properties by eggcrate and foam wheelchair cushions. Shaw CG. **J Rehabil Res Dev** 1998 Oct;35(4):396–404
Video display terminals: safe use guidelines. Pealer LN, et al. **J Sch Health** 1998 Sep;68(7):307–8
Report from SFIMAR. Informatics, ergonomics, and team work [news] Gage JS. **MD Comput** 1999 Jul-Aug;16(4):13
Improving the human-computer interface: a human factors engineering approach. Salvemini AV. **MD Comput** 1998 Sep-Oct;15(5):311–5 (37 ref.)
Evaluation must include vision [letter; comment] Anshel J. **Occup Health Saf** 1999 Feb;68(2):8. Comment on: Occup Health Saf 1998 Aug;67(8):106–8.
The unbridled joy of a good chair. Johnson LF. **Occup Health Saf** 1999 Jan;68(1):80–1
Establishing an ergonomics program [see comments] Wynn M. **Occup Health Saf** 1998 Aug;67(8):106–8. Comment in: Occup Health Saf 1999 Feb;68(2):8.
A low-cost, effective approach to office ergonomics. Bettendorf RF. **Occup Med** 1999 Jan-Mar;14(1):125–34, iv
Effects of an ergonomic training program on workers with video display units. Brisson C, et al. **Scand J Work Environ Health** 1999 Jun;25(3):255–63
Instruments for minimally invasive surgery: principles of ergonomic handles. Matern U, et al. **Surg Endosc** 1999 Feb; 13(2):174–82
[An ergonomic study of the work sites of female tellers in a state savings bank] Kamenova Z, et al. **Probl Khig** 1997; 22:3–10 (Eng. Abstr.) **(Bul)**
[Ergonomic aspects in the prevention of occupational cumulative trauma disorders of the locomotor system] Swat K. **Med Pr** 1998;49(6):589–602 (37 ref.) (Eng. Abstr.) **(Pol)**
[Ergo-ophthalmologic problems of electronic display devices] Francisc F, et al. **Oftalmologia** 1998;45(4):4–9 (7 ref.) (Eng. Abstr.) **(Rum)**
[A hygienic and ergonomic assessment of the work sites of operators at computer video terminals] Sautkin VS, et al. **Lik Sprava** 1998 Oct-Nov;(7):163–6 (Eng. Abstr.) **(Rus)**
[Methodologic approaches to solving problems concerning development and improvement of means protecting against detrimental ecological factors] Turzin PS, et al. **Med Tr Prom Ekol** 1999;(1):13–6 (Eng. Abstr.) **(Rus)**

HISTORY

Ergonomic design in ancient Greece. Marmaras N, et al. **Appl Ergon** 1999 Aug;30(4):361–8

INSTRUMENTATION

A quantitative model for designing keyboard layout. Shieh KK, et al. **Percept Mot Skills** 1999 Feb;88(1):113–25

METHODS

Applying the BeSafe method to product safety evaluation. Benedyk R, et al. **Appl Ergon** 1998 Feb;29(1):5–13 (16 ref.)
Mattress evaluation--assessment of contact pressure, comfort and discomfort. Buckle P, et al. **Appl Ergon** 1998 Feb; 29(1):35–9
Ergonomics in consumer product evaluation: an evolving process. Butters LM, et al. **Appl Ergon** 1998 Feb;29(1):55–8
Seat pressure measurement technologies: considerations for their evaluation. Gyi DE, et al. **Appl Ergon** 1998 Apr; 29(2):85–91
Usage centred research for everyday product design. Kanis H. **Appl Ergon** 1998 Feb;29(1):75–82 (21 ref.)
Testing usability with 3D paper prototypes--Case Halton system. Säde S, et al. **Appl Ergon** 1998 Feb;29(1):67–73
Is utility in the mind of the beholder? A study of ergonomics methods. Stanton N, et al. **Appl Ergon** 1998 Feb;29(1):41–54
Designing for consumers [editorial] Stanton NA, et al. **Appl Ergon** 1998 Feb;29(1):1–3
Heart rate variability; an index for monitoring and analyzing human autonomic activities. Kobayashi H, et al. **Appl Human Sci** 1999 Mar;18(2):53–9 (49 ref.)
Current techniques for assessing physical exposure to work-related musculoskeletal risks, with emphasis on posture-based methods. Li G, et al. **Ergonomics** 1999 May; 42(5):674–95 (147 ref.)
The Penn State Safety Floor: Part I--Design parameters associated with walking deflections. Casalena JA, et al. **J Biomech Eng** 1998 Aug;120(4):518–26
The Penn State Safety Floor: Part II--Reduction of fall-related peak impact forces on the femur. Casalena JA, et al. **J Biomech Eng** 1998 Aug;120(4):527–32
The 45 degree tilt: improvement in surgical ergonomics. Wallace RB 3rd. **J Cataract Refract Surg** 1999 Feb; 25(2):174–6

PSYCHOLOGY

Human factors for pleasure in product use. Jordan PW. **Appl Ergon** 1998 Feb;29(1):25–33
Is utility in the mind of the beholder? A study of ergonomics methods. Stanton N, et al. **Appl Ergon** 1998 Feb;29(1):41–54

STANDARDS

Human factors for pleasure in product use. Jordan PW. **Appl Ergon** 1998 Feb;29(1):25–33
Controlling the ergonomic hazards of wiring tasks for household appliances. National Institute for Occupational Safety and Health. **Appl Occup Environ Hyg** 1999 May; 14(5):289–91
The ergonomic use of hand tools: guidelines for the practitioner. National Institute for Occupational Safety and Health. Dababneh A, et al. **Appl Occup Environ Hyg** 1999 Apr;14(4):208–15
The OSHA poultry initiative. Motley K, et al. **Appl Occup Environ Hyg** 1999 Jul;14(7):436–9
New draft OSHA ergonomics rule. Schneider SP. **Appl Occup Environ Hyg** 1999 Jul;14(7):413–26
International standards on mental work-load--the ISO 10,075 series. Nachreiner F. **Ind Health** 1999 Apr; 37(2):125–33 (14 ref.)
Misfits and mishaps: the need for ergonomics standards in schools [editorial; comment] Litt IF. **J Adolesc Health** 1999 Apr;24(4):229. Comment on: J Adolesc Health 1999 Jan;24(1):1. Comment on: J Adolesc Health 1999 Apr;24(4):265–73.
[The use of the new ergonomic index Ergocapacity in the hygienic evaluation and certification of manual instruments] Butkovskaia ZM, et al. **Med Tr Prom Ekol** 1998;(11):12–5 (Eng. Abstr.) **(Rus)**

HUMAN EXPERIMENTATION

Protecting the rights and welfare of human research subjects. Ellis GB. **Acad Med** 1999 Sep;74(9):1008–9

Alzheimer's Disease International and International Working Group for Harmonization of Dementia Drug Guidelines for research involving human subjects with dementia [see comments] Brodaty H, et al. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13(2):71-9. Comment in: Alzheimer Dis Assoc Disord 1999 Apr-Jun;13(2):63-5.

Ethical issues in Alzheimer disease research. Fry ST. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13 Suppl 1:S54-8

Gaining and sustaining minority participation in longitudinal research projects. Gauthier MA, et al. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13 Suppl 1:S29-33

Conducting research with urban elders: issues of recruitment, data collection, and home visits. Wrobel AJ, et al. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13 Suppl 1:S34-8

When physicians are not physicians [letter; comment] Merrill JM. **Am J Med Sci** 1999 May;317(5):353. Comment on: Am J Med Sci 1999 Jan;317(1):1-4. Comment on: Am J Med Sci 1999 Jan;317(1):5-8.

Research on violence in developing countries: benefits and perils [editorial] Neugebauer R. **Am J Public Health** 1999 Oct;89(10):1473-4

NIH orders Duke Medical Center to stop studies [news] **Ann Oncol** 1999 Jul;10(7):739

Ethics, the prison system, and dermatology [letter] Krivo J. **Arch Dermatol** 1999 Apr;135(4):469

Medical ethics relating to clinical investigations using human subjects [editorial] Webster SB. **Arch Dermatol** 1999 Apr; 135(4):457-8

The National Bioethics Advisory Commission report: the response of the psychiatric research community is critical to restoring public trust [comment] Charney DS. **Arch Gen Psychiatry** 1999 Aug;56(8):699-700. Comment on: Arch Gen Psychiatry 1999 Aug;56(8):688-93.

Almost persuaded: reactions to Oldham et al [comment] Childress JF, et al. **Arch Gen Psychiatry** 1999 Aug; 56(8):697-8. Comment on: Arch Gen Psychiatry 1999 Aug;56(8):688-93.

Protecting vulnerable research subjects without unduly constraining neuropsychiatric research [comment] Miller FG, et al. **Arch Gen Psychiatry** 1999 Aug;56(8):701-2; discussion 703-4. Comment on: Arch Gen Psychiatry 1999 Aug;56(8):688-93.

Protection of persons with mental disorders from research risk: a response to the report of the National Bioethics Advisory Commission [see comments] Oldham JM, et al. **Arch Gen Psychiatry** 1999 Aug;56(8):688-93. Comment in: Arch Gen Psychiatry 1999 Aug;56(8):697-8. Comment in: Arch Gen Psychiatry 1999 Aug;56(8):699-700. Comment in: Arch Gen Psychiatry 1999 Aug;56(8):701-2; discussion 703-4.

Australian army infected troops and internees in second world war [news] Kenyon G. **BMJ** 1999 May 8; 318(7193):1233

Adjudicating ethics in research [letter; comment] Crelinsten G. **CMAJ** 1999 Jun 1;160(11):1552, 1554. Comment on: CMAJ 1999 Feb 9;160(3):386-8.

Adjudicating ethics in research [letter; comment] Frei JV. **CMAJ** 1999 Jun 1;160(11):1554. Comment on: CMAJ 1999 Feb 9;160(3):386-8.

Ethical considerations in the use of human tissues in research. Sobel ME, et al. **Cytometry** 1999 Aug 15;38(4):192-3

Vaccines, human experimentation, and ethics in evolutionary perspective. Hilleman MR. **Dev Biol Stand** 1998;95:13-7

Time for new rules on human subjects research? Dresser R. **Hastings Cent Rep** 1998 Nov-Dec;28(6):23-4 (32 ref.)

A world of research subjects. Emanuel EJ. **Hastings Cent Rep** 1998 Nov-Dec;28(6):25

Science in the service of healing. Grady C. **Hastings Cent Rep** 1998 Nov-Dec;28(6):34-8 (19 ref.)

Remodelling IRBs. Silberner J. **Hastings Cent Rep** 1998 Jul-Aug;28(4):5

Ethical issues in the design and conduct of randomised controlled trials. Edwards SJ, et al. **Health Technol Assess** 1998 Dec;2(15):i-vi, 1-132 (620 ref.)

When others decide: reasons for allowing patients with Alzheimer's disease to participate in nontherapeutic research. Lynöe N, et al. **Int Psychogeriatr** 1998 Dec; 10(4):435-6

Executive summary of cloning human beings: report and recommendations of the National Bioethics Advisory Commission. **Issues Law Med** 1998 Fall;14(2):217-22

Informed consent for research on human subjects with dementia. AGS Ethics Committee. American Geriatrics Society. **J Am Geriatr Soc** 1998 Oct;46(10):1308-10

"Ethical problems in psychiatric research" [letter; comment] Carpenter WT. **J Behav Health Serv Res** 1998 Nov; 25(4):465-6; discussion 468-9. Comment on: J Ment Health Adm 1997 Spring;24(2):227-50.

"Ethical problems in psychiatric research" [letter; comment] Davis KL. **J Behav Health Serv Res** 1998 Nov;25(4):467; discussion 468-9. Comment on: J Ment Health Adm 1997 Spring;24(2):227-50.

Institutional Review Board issues related to special populations. Ferraro FR, et al. **J Gen Psychol** 1998 Apr; 125(2):156-64

Human experimentation with Neisseria gonorrhoeae: progress and goals. Cohen MS, et al. **J Infect Dis** 1999 Mar;179 Suppl 2:S375-9 (30 ref.)

Should Zelen pre-randomised consent designs be used in some neonatal trials? [see comments] Allmark P. **J Med Ethics** 1999 Aug;25(4):325-9. Comment in: J Med Ethics 1999 Aug;25(4):291-2.

Can the written information to research subjects be improved?--an empirical study [see comments] Bjørn E, et al. **J Med Ethics** 1999 Jun;25(3):263-7. Comment in: J Med Ethics 1999 Jun;25(3):219-20.

Research into emergency treatments--could the offer of 'advance directives' help? [editorial; comment] Gillon R. **J Med Ethics** 1999 Aug;25(4):291-2. Comment on: J Med Ethics 1999 Aug;25(4):325-9.

Ethics panel urges new research regulations [news] **J Psychosoc Nurs Ment Health Serv** 1999 Feb;37(2):9-10

Research based on archived information and samples. Recommendations from the Royal College of Physicians Committee on Ethical Issues in Medicine. **J R Coll Physicians Lond** 1999 May-Jun;33(3):264-6 (15 ref.)

Naturalistic follow-up of drinking behavior following participation in an alcohol administration study. Sinha R, et al. **J Subst Abuse Treat** 1999 Jul-Sep;17(1-2):159-62

Primary care research and protection for human subjects [letter; comment] Beasley JW. **JAMA** 1999 May 12; 281(18):1697-8. Comment on: JAMA 1998 Dec 9;280(22):1951-8.

Protecting subjects of clinical research [news] Marwick C. **JAMA** 1999 Aug 11;282(6):516-7

Updating protections for human subjects involved in research. Project on Informed Consent, Human Research Ethics Group [see comments] Moreno J, et al. **JAMA** 1998 Dec 9;280(22):1951-8. Comment in: JAMA 1999 May 12;281(18):1697-8.

From the Food and Drug Administration. Nightingale SL. **JAMA** 1999 Feb 3;281(5):408

Declaration of Helsinki--nothing to declare? [editorial] [see comments] **Lancet** 1999 Apr 17;353(9161):1285. Comment in: Lancet 1999 May 29;353(9167):1888. Comment in: Lancet 1999 Jul 24;354(9175):343.

The National Institutes of Health flexes its muscle--but why now? [news] Ault A. **Lancet** 1999 Jun 19;353(9170):2138

When institutional review boards fail the system [news] Greenberg DS. **Lancet** 1999 May 22;353(9166):1773

Hidden data and abuse in research come to light in the USA [news] Greenberg DS. **Lancet** 1997 Oct 11;350(9084):1083

Proposed revisions to the Declaration of Helsinki--will they weaken the ethical principles underlying human research? Brennan TA. **N Engl J Med** 1999 Aug 12;341(7):527-31

Ethical and human-rights issues in research on mental disorders that may affect decision-making capacity. Capron AM. **N Engl J Med** 1999 May 6;340(18):1430-4

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Carome MA. **N Engl J Med** 1999 Aug 5;341(6):448-9; discussion 450. Comment on: N Engl J Med 1999 Mar 11;340(10):804-7.

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Grodin MA. **N Engl J Med** 1999 Aug 5;341(6):449; discussion 450. Comment on: N Engl J Med 1999 Mar 11;340(10):804-7.

The need to revise the Declaration of Helsinki. Levine RJ. **N Engl J Med** 1999 Aug 12;341(7):531-4

Are research ethics bad for our mental health? Michels R. **N Engl J Med** 1999 May 6;340(18):1427-30

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Tenery RM Jr. **N Engl J Med** 1999 Aug 5;341(6):450. Comment on: N Engl J Med 1999 Mar 11;340(10):804-7.

Is informed consent always necessary for randomized, controlled trials? [see comments] Truog RD, et al. **N Engl J Med** 1999 Mar 11;340(10):804-7. Comment in: N Engl J Med 1999 Aug 5;341(6):448-9; discussion 450. Comment in: N Engl J Med 1999 Aug 5;341(6):449; discussion 450. Comment in: N Engl J Med 1999 Aug 5;341(6):449-50; discussion 450.

Genetic determinism and the overprotection of human subjects [letter] Wilcox AJ, et al. **Nat Genet** 1999 Apr; 21(4):362

Organizing a public debate: ethical guidelines on biomedical research in humans [news] Pandya SK. **Natl Med J India** 1998 Nov-Dec;11(6):294-6

A suitable case for treatment [editorial] **Nature** 1999 May 20;399(6733):183

Proposed restrictions relaxed on research on mentally disabled [news] Macilwain C. **Nature** 1998 Oct 22; 395(6704):731

NIH ethics office clamps down on Duke...as basic scientists feel the pinch in LA [news] Wadman M. **Nature** 1999 May 20;399(6733):190

Higher status for 'research risks' office? [news] Wadman M. **Nature** 1999 Feb 18;397(6720):550

Methodological issues of human experimental research with hallucinogens. Gouzoulis-Mayfrank E, et al. **Pharmacopsychiatry** 1998 Jul;31 Suppl 2:114-8 (20 ref.)

Tuskegee as metaphor [letter] Caplan AL, et al. **Science** 1999 Jul 2;285(5424):48-9; discussion 49-50

Tuskegee as a metaphor [letter] Corbie-Smith G. **Science** 1999 Jul 2;285(5424):47; discussion 49-50

Uses and abuses of Tuskegee. Fairchild AL, et al. **Science** 1999 May 7;284(5416):919-21

Genomics research and human subjects [editorial] [published erratum appears in Science 1998 Dec 4;282(5395):1827] [see comments] Greely HT. **Science** 1998 Oct 23;282(5389):625. Comment in: Science 1998 Dec 11;282(5396):1993.

University of Illinois. Chancellor quits after research shutdown [news] Holden C. **Science** 1999 Sep 24; 285(5436):2047

EPA ponders pesticide tests in humans [news] Kaiser J. **Science** 1999 Jan 1;283(5398):18-9

Tuskegee as a metaphor [letter] Lurie P, et al. **Science** 1999 Jul 2;285(5424):47-8; discussion 49-50

Panel pulls back report after NIH critique [news] Marshall E. **Science** 1998 Oct 30;282(5390):857,859

Policy forum: human genetics. Ethical considerations in leaping from bench to bedside [comment] Sugarman J. **Science** 1999 Sep 24;285(5436):2071-2. Comment on: Science 1999 Sep 24;285(5436):2084-8.

The role of social work in HIV/AIDS clinical trials. Williams JK, et al. **Soc Work Health Care** 1999;29(1):35-56 (19 ref.)

Sex biases in subject selection: a survey of articles published in American medical journals. Resnik DB. **Theor Med Bioeth** 1999 Jun;20(3):245-60

Patients for sale: the seamy side of clinical trials. Shuchman M. **West J Med** 1999 Aug;171(2):130-1

[Patient information concerning trials (editorial)] Andersen D. **Ugeskr Laeger** 1999 May 3;161(18):2650 **(Dan)**

[Medical treatment and research on humans: ethical fundamentals of physicians' concerns] Nagel E. **Chirurg** 1999 Apr;70(4):suppl 90-4 **(Ger)**

[Clinical research on human subjects. (2) Preclinical] Labs R, et al. **Dtsch Med Wochenschr** 1999 May 7;124(18):A15-7 **(Ger)**

[Clinical research on human beings (1)] Labs R, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):A17-20 **(Ger)**

[The acceptability of experimentation on the efficacy of an anti-HIV vaccine among Italian drug addicts] Nicolosi A. **Ann Ig** 1999 Jan-Feb;11(1):27-34 (Eng. Abstr.) **(Ita)**

ECONOMICS

What's the price of a research subject? Approaches to payment for research participation. Dickert N, et al. **N Engl J Med** 1999 Jul 15;341(3):198-203

HISTORY

The continuing legacy of the Tuskegee Syphilis Study: considerations for clinical investigation [see comments] Corbie-Smith G. **Am J Med Sci** 1999 Jan;317(1):5-8. Comment in: Am J Med Sci 1999 Jan;317(1):1-4. Comment in: Am J Med Sci 1999 May;317(5):353.

Tuskegee: from science to conspiracy to metaphor [editorial; comment] [see comments] Thomas SB, et al. **Am J Med Sci** 1999 Jan;317(1):1-4. Comment on: Am J Med Sci 1999 Jan;317(1):5-8. Comment in: Am J Med Sci 1999 May;317(5):353.

Ethical lapses in dermatologic "research". Hornblum AM. **Arch Dermatol** 1999 Apr;135(4):383-5

The Nuremberg doctors' trial in historical context. Marrus MR. **Bull Hist Med** 1999 Spring;73(1):106-23

Neurosciences in the Third Reich: from Ivory Tower to death camps [see comments] Shevell MI. **Can J Neurol Sci** 1999 May;26(2):132-8. Comment in: Can J Neurol Sci 1999 May;26(2):75-6.

The study of untreated syphilis in the negro male: regarding Brawley IJROBP 40:5-8; 1998 [letter; comment] White RM. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):940-1. Comment on: Int J Radiat Oncol Biol Phys 1998 Jan 1;40(1):5-8.

Human experiments in Nazi Germany: reflections on Ernst Klee's book "Auschwitz, die NS-Medizin und ihre Opfer" (1997) and film "Arzte ohne Gewissen" (1996). Weindling P. **Medizinhist J** 1998;33(2):161-78

Rethinking the Tuskegee Syphilis Study. Nurse Rivers, silence and the meaning of treatment. Reverby SM. **Nurs Hist Rev** 1999;7:3-28

History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Gouzoulis-Mayfrank E, et al. **Pharmacopsychiatry** 1998 Jul; 31 Suppl 2:63-8

Pernkopf's Atlas--a product of Nazi atrocities perpetrated in Austria during World War II [see comments] Querido D. **S Afr Med J** 1998 Aug;88(8):956-8. Comment in: S Afr Med J 1998 Dec;88(12):1534-5.

Tuskegee as a metaphor [letter] Bowman JE. **Science** 1999 Jul 2;285(5424):47; discussion 49-50

[Neurology in the "3rd Reich" and consequences] Peiffer J. **Nervenarzt** 1998 Aug;69(8):728-33 (Eng. Abstr.) **(Ger)**

["Auschwitz, NS-medicine and its victims" Comments by 3 human genetics scientists on the book by Ernst Klee] Fonatsch C, et al. **Wien Klin Wochenschr** 1998 Jul 31; 110(13-14):507-8 **(Ger)**

[Neuropathology in the Third Reich] Peiffer J. **Epidemiol Prev** 1998 Jul-Sep;22(3):184-90 **(Ita)**

[Without shame, no moral. How physicians could commit murder] Riksen KI. **Tidsskr Nor Laegeforen** 1999 Mar 20; 119(8):1096-9 (22 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Protecting the rights and welfare of human research subjects. Ellis GB. **Acad Med** 1999 Sep;74(9):1008-9

Protecting patients, preserving progress: ethics in mental health illness research. Hyman SE. **Acad Med** 1999 Mar; 74(3):258-9

Unity in diversity [news] Nicholson RH.

HUMAN EXPERIMENTATION

Hastings Cent Rep 1999 Jan-Feb;29(1):6
Regulating research on the terminally ill: a proposal for heightened safeguards. Addicott DC.
J Contemp Health Law Policy 1999 Spring;15(2):479-524 (225 ref.)
Far beyond informed consent. US research institutions keep close watch on OPRR's suspensions [interview] Russell-Einhorn M, et al. **J Investig Med** 1999 Jul; 47(6):259-66
Reply to Lebech or the ontological humility of the lawyer faced with philosophical consistency [comment] Byk JC. **J Med Ethics** 1998 Oct;24(5):348-9. Comment on: J Med Ethics 1998 Oct;24(5):345-7.
Comment on a proposed draft protocol for the European Convention on Biomedicine relating to research on the human embryo and fetus [comment] [see comments] Lebech MM. **J Med Ethics** 1998 Oct;24(5):345-7. Comment on: J Med Ethics 1997 Feb;23(1):32-7. Comment in: J Med Ethics 1998 Oct;24(5):348-9.
UK inquiry opened into human trials of biological and chemical weapons [news] Ashraf H. **Lancet** 1999 Aug 28; 354(9180):753
The protection of the person in medical research in Germany. Deutsch E. **Med Law** 1999;18(1):77-92
A higher standard for human research [editorial] **Nat Med** 1999 Jun;5(6):591
Indecision over human pesticide data [news] Dove A. **Nat Med** 1999 Sep;5(9):972
The International Conference on Harmonization Good Clinical Practice guideline. Dixon JR Jr. **Qual Assur** 1998 Apr-Jun;6(2):65-74
Panel tightens rules on mental disorders [news] Marshall E. **Science** 1998 Nov 27;282(5394):1617
Developing regulations for research involving adults who lack decision-making capacity. Fleischman AR. **Trans Am Clin Climatol Assoc** 1999;110:131-43; discussion 143-5
Media watch. Thier SL. **West J Med** 1999 Jul;171(1):53-4
[Emphasizing of ethical criteria for medical scientific reporting and the Declaration of Helsinki (editorial; comment)] **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):33-6 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Feb 27;143(9):494-5. **(Dut)**
[Supervision of medical scientific research with mentally competent subjects is impossible without reviewing (comment) (see comments)] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):8-10 (Eng. Abstr.) . Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):45-50. Comment in: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):700-1. **(Dut)**
[Informed well-considered consent ('informed consent'): an end or a means? (letter)] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1115-6 **(Dut)**
[Medical scientific research with humans: what the law does not foresee (letter; comment)] van Agt FM, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):700-1. Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):8-10. Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):45-50. **(Dut)**
[Medical scientific research with people: what the law does not regulate (see comments)] van Agt FM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):45-50 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):8-10. Comment in: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):700-1. **(Dut)**
[Ethics and rights in biomedical research: documents by the Council of Europe and UNESCO] Bompiani A. **Ann Ist Super Sanita** 1998;34(2):187-95 (Eng. Abstr.) **(Ita)**

HUMAN FIGURE see **HUMAN BODY**

HUMAN FOAMY VIRUS see **SPUMAVIRUS**

HUMAN FOREFOOT see **FOREFOOT, HUMAN**

HUMAN GENOME see **GENOME, HUMAN**

HUMAN GENOME PROJECT

Impact of the human genome project on the principles for classification and nomenclature of 5-HT receptors. Hoyer D, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:230-1
The Human Genome Project: applications in the diagnosis and treatment of neurologic disease. Evans GA. **Arch Neurol** 1998 Oct;55(10):1287-90
Comparative genomics: the key to understanding the Human Genome Project. Clark MS. **Bioessays** 1999 Feb; 21(2):121-30 (44 ref.)
Snapping up SNPs. Brown SM. **Biotechniques** 1999 Jun; 26(6):1090-2, 1093
Introduction to the post-Human Genome Project era, a target for interactions between polygenic and/or multiphenotypical components in cancer control in South America. Iscovich J. **Cad Saude Publica** 1998;14 Suppl 3:15-23 (28 ref.)
The Human Genome Project and the role of genetics in health care. van Ommen GJ. **Clin Chem Lab Med** 1998 Aug;36(8):515-7
The Human Genome Project: from mapping to sequencing. Weissenbach J. **Clin Chem Lab Med** 1998 Aug;36(8):511-4
Family physicians' perspectives on genetics and the human genome project. Fetters MD, et al. **Clin Genet** 1999 Jul; 56(1):28-34
We have some whole genome sequences. What now? [editorial] Mortimer P. **Commun Dis Public Health** 1999 Jun;2(2):83-4
Genome jumpers. Harris RF. **Curr Biol** 1998 Oct 22; 8(21):R742
The Environmental Genome Project: suggestions and concerns [letter] Loffredo CA, et al. **Environ Health Perspect** 1998 Aug;106(8):A368; discussion A368-9
Regional inference with averaged P values increases the power to detect linkage. Goldin LR, et al. **Genet Epidemiol** 1999;17(3):157-64
Toward a complete human genome sequence. **Genome Res** 1998 Nov;8(11):1097-108
Assessing the quality of the DNA sequence from the Human Genome Project. Felsenfeld A, et al. **Genome Res** 1999 Jan;9(1):1-4 (9 ref.)
The human genome project aims for 2003. Goodman L. **Genome Res** 1998 Oct;8(10):997-9
Random shotgun fire [editorial] Goodman L. **Genome Res** 1998 Jun;8(6):567-8
The involvement of genome researchers in high school science education. Munn M, et al. **Genome Res** 1999 Jul; 9(7):597-607 (23 ref.)
WebWise: guide to the joint genome institute web site. Pruitt KD. **Genome Res** 1998 Sep;8(9):864-9 (1 ref.)
Webwise: guide to the institute for genomic research web site. Pruitt KD. **Genome Res** 1998 Oct;8(10):1000-4
Genomics and hypertension: concepts, potentials, and opportunities. Pratt RE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):238-47 (73 ref.)
Genetics in gastrointestinal disease: how much can we learn from molecular analysis? [editorial] Schreiber S, et al. **Int J Colorectal Dis** 1999 Feb;14(1):10-2
Geneticizing disability: the Human Genome Project and the commodification of self. Fitzgerald J. **Issues Law Med** 1998 Fall;14(2):147-63
Phosphoglycerate kinase 1 (PGK1) maps to Xq1.2 in the porcine genome. Rohrer GA. **J Anim Sci** 1999 Feb; 77(2):497-8
Homosexuality and the human genome project: private and public choices. Gabard DL. **J Homosex** 1999;37(1):25-51 (85 ref.)
Indigenous peoples and the morality of the Human Genome Diversity Project. Dodson M, et al. **J Med Ethics** 1999 Apr;25(2):204-8
Discussing HUGO: the German debate on the ethical implications of the Human Genome Project. Boshammer S, et al. **J Med Philos** 1998 Jun;23(3):324-33
What ever happened to ...?: A 10-year retrospective [news] Nelson NJ. **J Natl Cancer Inst** 1999 Jan 20;91(2):114-7
Genetics in the context of medical practice. Karanjawala ZE, et al. **JAMA** 1998 Nov 4;280(17):1533-4
Divining and altering the future: implications from the Human Genome Project [editorial] Lin JH. **JAMA** 1998 Nov 4;280(17):1532
Geneticists discuss ethics of human genome project [news] Bosch X. **Lancet** 1998 Oct 31;352(9138):1448
J Craig Venter: sequencing genomes his way [news] Larkin M. **Lancet** 1999 Jun 26;353(9171):2218
The human genome project and the future of diagnostics, treatment, and prevention. van Ommen GJ, et al. **Lancet** 1999 Jul;354 Suppl 1:SI5-10 (49 ref.)
The Human Genome Project: promise versus reality. Ayala FJ. **Law Hum Genome Rev** 1998 Jul-Dec;(9):23-34
Securing public access to genomic information: the race is on [news] Brooksbank C. **Mol Med Today** 1999 Jun; 5(6):235-6
Genes and environment: informing future public health decisions [news] Brooksbank C. **Mol Med Today** 1999 Jun; 5(6):236
Data disclosure in the human genome project [letter; comment] Dunham I. **Mol Med Today** 1998 Aug;4(8):335-6 . Comment on: Mol Med Today 1998 Apr;4(4):148-50.
Shattuck lecture--medical and societal consequences of the Human Genome Project. Collins FS. **N Engl J Med** 1999 Jul 1;341(1):28-37
Genome II: the next frontier [news] Brower V. **Nat Biotechnol** 1998 Nov;16(11):1004
A second Human Genome Project? [editorial; comment] Long R. **Nat Biotechnol** 1998 Sep;16(9):793. Comment on: Nat Biotechnol 1998 Sep;16(9):825-9.
Five stages of the Human Genome Project [published erratum appears in Nat Biotechnol 1999 Apr;17(4):314] Strohman RC. **Nat Biotechnol** 1999 Feb;17(2):112
The Human Genome Project after a decade: policy issues. Burris J, et al. **Nat Genet** 1998 Dec;20(4):333-5
Genome sequencers square off down under [news] Rouse R. **Nat Med** 1999 May;5(5):471
Gene estimate rises as US and UK discuss freedom of access [news] Dickson D. **Nature** 1999 Sep 23;401(6751):311
Energy department revises terms of Venter deal after complaints [news] Macilwain C. **Nature** 1999 Jan 14; 397(6715):93
Britain sought to speed-up sequencing efforts [news] Masood E. **Nature** 1999 Mar 18;398(6724):177
Japan to launch ambitious genome project [news] Saegusa A. **Nature** 1999 Jul 1;400(6739):6
Human Genome Project aims to finish 'working draft' next year [news] Wadman M. **Nature** 1999 Mar 18;398(6724):177
Virgil database for rich links (1999 update). Achard F, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):113-4
Implications of the human genome project for understanding gene-environment interactions. Velázquez A, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S39-41; discussion S41-2 (18 ref.)
The new biology enters the generalist pediatrician's office: lessons from the Human Genome Project. McCabe ER. **Pediatr Rev** 1999 Sep;20(9):314-9
Genetic sampling: big brother or big science? [news] **Public Health Rep** 1998 Jan-Feb;113(1):7
New goals for the U.S. Human Genome Project: 1998-2003. Collins FS, et al. **Science** 1998 Oct 23;282(5389):682-9
A high-stakes gamble on genome sequencing [news] Marshall E. **Science** 1999 Jun 18;284(5422):1906-9
Human Genome Project. Sequencers endorse plan for a draft in 1 year [news] Marshall E. **Science** 1999 May 28; 284(5419):1439,1441
Team wrapping up sequence of first human chromosome [news] Normile D, et al. **Science** 1999 Sep 24; 285(5436):2038-9
Academic sequencers challenge Celera in a sprint to the finish [news] Pennisi E. **Science** 1999 Mar 19;283(5409):1822-3
The human genome project: a dream becoming a reality. Haddad FF, et al. **Surgery** 1999 Jun;125(6):575-80
Human genome mapping and sequencing: perspectives for toxicology. Weissenbach J. **Toxicol Lett** 1998 Dec 28; 102-103:1-4
Coordination of human genome sequencing via a consensus framework map. Bentley DR, et al. **Trends Genet** 1998 Oct; 14(10):381-4
[The human genome project initiative in China] Qiang BQ, et al. **C R Seances Soc Biol Fil** 1998;192(5):925-8 **(Fre)**
[The Human Genome Project and its consequences for surgery] Schackert HK, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:90-2 (Eng. Abstr.) **(Ger)**
[Highlights and trends German Genome Product 1999 anniversity in Ulm: from the sick-bed to workbench or "from bench to bedside"] Schober O. **Nuklearmedizin** 1999; 38(5):51-60 **(Ger)**
[Genetic type of progressive hearing loss] Martini A. **Acta Otorhinolaryngol Ital** 1998 Aug;18(4 Suppl 59):21-7 (97 ref.) (Eng. Abstr.) **(Ita)**
[Trends in genome informatics] Takagi T. **Nippon Rinsho** 1998 Nov;56(11):2963-72 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Recent advances in the gene chip and its role in the post-genome era] Uchida K. **Seikagaku** 1999 Feb; 71(2):119-24 (14 ref.) **(Jpn)**
[The Declaration of the World Medical Association (WMA) on the Human Genome Project (Marbella, Spain, 1992)] **Chirurgia (Bucur)** 1998 May-Jun;93(3):201-2 **(Rum)**
[A harvest time for genomic research] Landegren U. **Lakartidningen** 1999 Aug 11;96(32-33):3426-8 (Eng. Abstr.) **(Swe)**

ECONOMICS

Biotechnology's long-term promise. Feldbaum CB. **Nat Biotechnol** 1999 Feb;17 Suppl:BE11
Britain loses out on genome market [news] Birmingham K. **Nat Med** 1999 Oct;5(10):1097
Human genome project. Commercial firms win U.S. sequencing funds [news] Marshall E. **Science** 1999 Jul 16; 285(5426):310

LEGISLATION & JURISPRUDENCE

An analysis of genetic discrimination legislation proposed by the 105th congress. Colby JA. **Am J Law Med** 1998; 24(4):443-80 (0 ref.)
Protecting genetic privacy by permitting employer access only to job-related employee medical information: analysis of a unique Minnesota law. Rothstein MA, et al. **Am J Law Med** 1998;24(4):399-416 (0 ref.)
Ethical and legal issues in the procurement, storage and use of DNA. McQueen MJ. **Clin Chem Lab Med** 1998 Aug; 36(8):545-9 (12 ref.)

ORGANIZATION & ADMINISTRATION

The Sanger Centre. **Curr Biol** 1998 Jul 16;8(15):R510
Mapping and sequencing of the human genome. Ruddle FH. **Jpn J Cancer Res** 1998 Dec;89(12):inside front cover

HUMAN GROWTH HORMONE see **SOMATROPIN**

HUMAN IDENTIFICATION see **FORENSIC ANTHROPOLOGY**

HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED NEPHROPATHY see **AIDS-ASSOCIATED NEPHROPATHY**

HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT see **HIV LONG TERMINAL REPEAT**

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 see **HIV-1**

HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 see **HIV-2**

HUMAN IMMUNODEFICIENCY VIRUSES see **HIV**

HUMAN LEUKOCYTE ANTIGEN DNA PROBES see **DNA PROBES, HLA**

HUMAN LEUKOCYTE ANTIGENS see **HLA ANTIGENS**

HUMAN B-LYMPHOTROPIC VIRUS see **HERPESVIRUS 6, HUMAN**

HUMAN T LYMPHOTROPIC VIRUS-ASSOCIATED LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HUMAN T-LYMPHOTROPIC VIRUS II see **HTLV-II**

HUMAN T-LYMPHOTROPIC VIRUS II ANTIBODIES see **HTLV-II ANTIBODIES**

HUMAN T-LYMPHOTROPIC VIRUS II ANTIGENS see **HTLV-II ANTIGENS**

HUMAN T-LYMPHOTROPIC VIRUS TYPE III see **HIV**

HUMAN T-LYMPHOTROPIC VIRUS TYPE IV see **HIV-2**

HUMAN PAPILLOMA VIRUS DNA PROBES see **DNA PROBES, HPV**

HUMAN PARATHYROID HORMONE (1-34) see **TERIPARATIDE**

HUMAN PARVOVIRUS B19 see **PARVOVIRUS B19, HUMAN**

HUMAN-PET BONDING see **BONDING, HUMAN-PET**

HUMAN PLATELET ANTIGENS see **ANTIGENS, HUMAN PLATELET**

HUMAN RESOURCES DEVELOPMENT see **STAFF DEVELOPMENT**

HUMAN RIGHTS

see related
CIVIL RIGHTS
WOMEN'S RIGHTS

Of wars and human rights [editorial] Mason DJ. **Am J Nurs** 1999 Jun;99(6):7

Welfare reform as a human rights issue [editorial; comment] Albisa C. **Am J Public Health** 1999 Oct;89(10):1476–8. Comment on: Am J Public Health 1999 Oct;89(10):1514–27.

Sanctions and the struggle for health in South Africa. Coovadia HM. **Am J Public Health** 1999 Oct;89(10):1505–8

Pathologies of power: rethinking health and human rights. Farmer P. **Am J Public Health** 1999 Oct;89(10):1486–96

The impact of economic sanctions on health and human rights in Haiti, 1991–1994 [see comments] Gibbons E, et al. **Am J Public Health** 1999 Oct;89(10):1499–504. Comment in: Am J Public Health 1999 Oct;89(10):1509–13.

Economic sanctions as human rights violations: reconciling political and public health imperatives [comment] Marks SP. **Am J Public Health** 1999 Oct;89(10):1509–13 (60 ref.) . Comment on: Am J Public Health 1999 Oct;89(10):1499–504.

Research on violence in developing countries: benefits and perils [editorial] Neugebauer R. **Am J Public Health** 1999 Oct;89(10):1473–4

Public health and complex emergencies: new issues, new conditions. Waldman R, et al. **Am J Public Health** 1999 Oct;89(10):1483–5

Rights and ethics in transplantation: perspectives. Aluwihare AP, et al. **Ann Transplant** 1998;3(3):38–41

Xenotransplantation. Ethics and rights: an interaction. Aluwihare AP. **Ann Transplant** 1998;3(3):59–61

Sharia punishment, treatment, and speaking out. **BMJ** 1999 Aug 14;319(7207):445–7 (3 ref.)

Health care is not a human right [letter] Barlow P. **BMJ** 1999 Jul 31;319(7205):321

New challenges for humanitarian protection. Bruderlein C, et al. **BMJ** 1999 Aug 14;319(7207):430–5 (31 ref.)

US doctors file lawsuit against antiabortionists [news] Charatan F. **BMJ** 1999 Jan 23;318(7178):214

Eugenics and human rights. Kevles DJ. **BMJ** 1999 Aug 14; 319(7207):435–8 (4 ref.)

Hungary passes non-smokers' rights bill [news] Kovac C. **BMJ** 1999 May 29;318(7196):1438

Medicine and international humanitarian law. Law provides norms that must guide doctors in war and peace [editorial] Leaning J. **BMJ** 1999 Aug 14;319(7207):393–4

"Health care is a human right" is a meaningless and devastating manifesto [letter] Loefler IJ. **BMJ** 1999 Jun 26;318(7200):1766

Psychiatric aspects of the Truth and Reconciliation Commission in South Africa [editorial] Stein DJ. **Br J Psychiatry** 1998 Dec;173:455–7

The health impact of economic sanctions. Garfield R, et al. **Bull N Y Acad Med** 1995 Winter;72(2):454–69

Children's rights, parents' prerogatives, and society's obligations. Westman JC. **Child Psychiatry Hum Dev** 1999 Summer;29(4):315–28

Challenge of Goodness II: new humanitarian technology, developed in croatia and bosnia and Herzegovina in 1991–1995, and applied and evaluated in Kosovo 1999. Lang S. **Croat Med J** 1999 Sep;40(3):438–45

Building peace from scratch: some theoretical and technological aspects. Terselic V. **Croat Med J** 1999 Sep; 40(3):446–9

Human rights and abortion laws. Cook RJ, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):81–7 (50 ref.)

Tuberculosis control and directly observed therapy from the public health/human rights perspective. Hurtig AK, et al. **Int J Tuberc Lung Dis** 1999 Jul;3(7):553–60 (62 ref.)

Case problem: balancing risk of foodborne illness with patient rights and quality of life. Theis M. **J Am Diet Assoc** 1999 Sep;99(9):1132–3

Health and human rights of adolescent girls in Afghanistan. Heisler M, et al. **J Am Med Womens Assoc** 1999 Summer; 54(3):155–7

Teaching medical students on the ethical dimensions of human rights: meeting the challenge in South Africa. London L, et al. **J Med Ethics** 1998 Aug;24(4):257–62

Persons and their copies. McCarthy D. **J Med Ethics** 1999 Apr;25(2):98–104

Cloning, killing, and identity. McMahan J. **J Med Ethics** 1999 Apr;25(2):77–86

Equality and selection for existence [see comments] Persson I. **J Med Ethics** 1999 Apr;25(2):130–6. Comment in: J Med Ethics 1999 Apr;25(2):172–5.

Should we clone human beings? Cloning as a source of tissue for transplantation [see comments] Savulescu J. **J Med Ethics** 1999 Apr;25(2):87–95. Comment in: J Med Ethics 1999 Apr;25(2):96–7.

UNESCO: universal declaration on the human genome and human rights. **J Med Philos** 1998 Jun;23(3):334–41

A map to a new treasure island: the human genome and the concept of common heritage. Byk C. **J Med Philos** 1998 Jun;23(3):234–46

Teaching human rights in the medical curriculum [letter] Ahmadi R. **JAMA** 1999 Sep 15;282(11):1034–5

Health and human rights in the medical school curriculum [letter; comment] Cobey JC. **JAMA** 1999 Jan 27; 281(4):324–5. Comment on: JAMA 1998 Aug 5;280(5):462–4, 469–70.

What can we do about violence? [editorial] Cole TB, et al. **JAMA** 1999 Aug 4;282(5):481–3

Virginity examinations in Turkey: role of forensic physicians in controlling female sexuality. Frank MW, et al. **JAMA** 1999 Aug 4;282(5):485–90

War and health: from Solferino to Kosovo--the evolving role of physicians [editorial; comment] Iacopino V, et al. **JAMA** 1999 Aug 4;282(5):479–81. Comment on: JAMA 1999 Aug 4;282(5):433–9. Comment on: JAMA 1999 Aug 4;282(5):455–62.

Amnesty International condemns US human-rights violations [news] Chelala C. **Lancet** 1998 Oct 17;352(9136):1294

Human rights in the USA: land of the free? Freer R. **Lancet** 1998 Dec 5;352(9143):1853–4

Labour rights are human rights. Holtz TH. **Lancet** 1999 Mar 13;353(9156):923

Human rights and epidemiology [letter; comment] Loff B, et al. **Lancet** 1998 Oct 3;352(9134):1153. Comment on: Lancet 1998 Sep 5;352(9130):810–3.

Learning a culture of respect for human rights [comment] Loff B, et al. **Lancet** 1998 Dec 5;352(9143):1800. Comment on: Lancet 1998 Dec 5;352(9143):1852–3.

Torture continues in Turkey: findings of new report. Salinsky M. **Lancet** 1998 Dec 5;352(9143):1854

Health and human rights of the East Timorese. Silove D. **Lancet** 1999 Jun 12;353(9169):2067

What are human rights? [letter] Staples VJ. **Lancet** 1999 May 8;353(9164):1626

Health care in Burma [letter; comment] Wakai S. **Lancet** 1998 Oct 10;352(9135):1230. Comment on: Lancet 1998 Aug 15;352(9127):556.

Japan: prisoners wait for rights. Welsh J. **Lancet** 1999 Mar 13;353(9156):922

Health and human rights. An international minefield. Welsh J, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV14 (5 ref.)

Truth and reconciliation...and justice [see comments] Welsh J. **Lancet** 1998 Dec 5;352(9143):1852–3. Comment in: Lancet 1998 Dec 5;352(9143):1800.

Medical aid and human rights in Kosovo. Woodall J. **Lancet** 1998 Oct 31;352(9138):1467

UNESCO's Universal Declaration on the Human Genome and Human Rights, 11 November 1997. Lenoir N. **Law Hum Genome Rev** 1998 Jul-Dec;(9):119–41

Recent medical evidence for torture and human rights abuse in Sierra Leone: a report for the Medical Foundation for the Care of Victims of Torture. Lawson M. **Med Confl Surviv** 1999 Jul-Sep;15(3):255–70

Health a human right? [letter; comment] Prociv P. **Med J Aust** 1999 Jul 5;171(1):56. Comment on: Med J Aust 1999 Apr 5;170(7):295–6.

HIV/AIDS and human rights in prison. The Costa Rican experience. Valerio Monge CJ. **Med Law** 1998; 17(2):197–210

Human rights and health--the Universal Declaration of Human Rights at 50. Annas GJ. **N Engl J Med** 1998 Dec 10;339(24):1778–81

Human genome declaration looks set for United Nations approval [news] Butler D. **Nature** 1998 Nov 26; 396(6709):297

Health as a fundamental right for all children. Newman-Williams M. **Promot Educ** 1998 Sep-Dec; 5(3-4):9–10, 91, 119 **(Eng, Fre, Spa)**

The difficult road to truth and reconciliation--the health sector takes its first steps. Health and Human Rights Project Support Group. de Gruchy J, et al. **S Afr Med J** 1998 Aug;88(8):975–9

Health and human rights into the new millennium. Jones JS. **S Afr Med J** 1999 Jan;89(1):25–6

Rural health and human rights--summary of a submission to the Truth and Reconciliation Commission Health Sector Hearings, 17 June 1997 [see comments] Reid S, et al. **S Afr Med J** 1998 Aug;88(8):980–2. Comment in: S Afr Med J 1998 Dec;88(12):1533.

Declaration of rights and statement of needs of twins and higher order multiples [news] Malmstrom P, et al. **Twin Res** 1998 May;1(1):52–5

[Firing the editor of JAMA (letter)] Rosdahl N. **Ugeskr Laeger** 1999 Mar 1;161(9):1285–6 **(Dan)**

[Apropos of: Public health: ethics and human rights (comment)] Lazarus A. **Sante Publique** 1998 Sep; 10(3):251–5. Comment on: Sante Publique 1998 Sep;10(3):239–50. **(Fre)**

[Public health: ethics and human rights (see comments)] Mann J. **Sante Publique** 1998 Sep;10(3):239–50. Comment in: Sante Publique 1998 Sep;10(3):251–5. **(Fre)**

[AIDS in the world: above all a problem of human rights and equality] Martin J. **Sante Publique** 1998 Sep; 10(3):349–51 **(Fre)**

[Courage--the mother of all virtues] Fugelli P. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1143–5 (Eng. Abstr.) **(Nor)**

[Justice--the most demanding of virtues] Gulbrandsen P. **Tidsskr Nor Laegeforen** 1999 Mar 20;119(8):1149–53 (29 ref.) (Eng. Abstr.) **(Nor)**

[The firing of JAMA's editor is a shame for the American Medical Society] Nylenna M. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):351 **(Nor)**

[Physicians and human rights] Stoltenberg C. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):10 **(Nor)**

[Human rights and genetics: the fundamental principles of the Universal Declaration on the Human Genome and Human Rights] Bergel SD. **Law Hum Genome Rev** 1998 Jul-Dec;(9):37–57 (Eng. Abstr.) **(Spa)**

[Compliance with human rights: primary indicator of public health (editorial)] Jiménez García-Pascual R. **Rev Esp Salud Publica** 1998 Nov-Dec;72(6):477–80 **(Spa)**

["Torture has become an epidemic": Turkish physicians organize to help their countrymen] Bakkalci M. **Lakartidningen** 1999 Feb 10;96(6):633–5 **(Swe)**

EDUCATION

Teaching on gender-related issues; a survey of psychiatry faculty and residents. Des Rosiers P, et al. **Med Educ** 1998 Sep;32(5):522–6

Health science faculties--how committed are they to building a culture of human rights in health? [letter] Baldwin-Ragaven L, et al. **S Afr Med J** 1998 Aug; 88(8):923–4

HISTORY

Medical journals and human rights. Kandela P. **Lancet** 1998; :SII7–11

[Equality and brotherhood--values worth preserving in the health services] Westin S. **Tidsskr Nor Laegeforen** 1999 Apr 20;119(10):1474–9 (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Do the dead have interests? Policy issues for research after life. Nelkin D, et al. **Am J Law Med** 1998;24(2-3):261–91 (288 ref.)

Can sanctions be sanctioned? Sidel VW. **Am J Public Health** 1999 Oct;89(10):1497–8

Patient choice and the maternal-fetal relationship. Number 214, April 1999 (replaces number 55, October 1987). Committee on Ethics. **Int J Gynaecol Obstet** 1999 May; 65(2):213–5

The United States and the universality of human rights. Chomsky N. **Int J Health Serv** 1999;29(3):623–6

UN condemns Taliban's continued human rights abuse in Afghanistan [news] Ahmad K. **Lancet** 1999 Aug 28; 354(9180):752

UK Government's immigration proposals disregard human rights. Gill PS, et al. **Lancet** 1998 Oct 31;352(9138):1468

Palestinian health care under siege. Pourgourides C. **Lancet** 1999 Jul 31;354(9176):420–1

Sri Lanka: torture continues. Welsh J. **Lancet** 1999 Jul 31; 354(9176):420

Irrationality: psychological, ethical and legal aspects. Dimitrov A. **Med Law** 1999;18(1):55–60

Towards a universal definition of the right to health? Hendriks A, et al. **Med Law** 1998;17(3):319–32

To clone or not to clone--whither the law? Lupton ML. **Med Law** 1999;18(1):107–23

To what extent can the law control human cloning? Wood PG. **Med Sci Law** 1999 Jan;39(1):5–10

Protection and advocacy system standing--to vindicate the rights of persons with disabilities. Gross GP.

HUMAN RIGHTS

Ment Phys Disabil Law Rep 1998 Sep-Oct;22(5):674-82
Embargoes that harm health. The case for physician leadership. Miles S. **Minn Med** 1999 Jul;82(7):51-2
Human rights in the United States. Illusions and realities. Parker D, et al. **Minn Med** 1999 Jul;82(7):42-4
Child survival. A fundamental human right. Pham H, et al. **Minn Med** 1999 Jul;82(7):20-6
Physicians and the ethic of human rights. Rubenstein LS. **Minn Med** 1999 Jul;82(7):46-8
Human rights of psychiatrically disturbed persons in the tropical Pacific. Wilson LG. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S252-5
[Human dignity ... is vulnerable! (editorial; comment)] Feuser G. **Wien Klin Wochenschr** 1997 Dec 12;109(23):907-9. Comment on: Wien Klin Wochenschr 1997 Dec 12;109(23):925-31. **(Ger)**
[Ethics and rights in biomedical research: documents by the Council of Europe and UNESCO] Bompiani A. **Ann Ist Super Sanita** 1998;34(2):187-95 (Eng. Abstr.) **(Ita)**
[Science, law, freedom, customs] Dulawa J. **Przegl Lek** 1999; 56(3):248-50 **(Pol)**
[An additional protocol to the Convention for the Protection of Human Rights and Human Dignity with regard to the Application of Biology and Medicine on the prohibition of the cloning of human beings, 6 November 1997] **Law Hum Genome Rev** 1998 Jul-Dec;(9):251-3 **(Spa)**

STANDARDS

Understanding sexual and reproductive violence: an overview. Barzelatto J. **Int J Gynaecol Obstet** 1998 Dec; 63 Suppl 1:S13-8 (10 ref.)
[A suffering person's rights in the light of John Paul II's teaching] Kubik KK. **Przegl Lek** 1999;56(3):253-60 (Eng. Abstr.) **(Pol)**

TRENDS

Learning human-rights lessons from physics [editorial] **Lancet** 1998 Oct 31;352(9138):1401

HUMAN SPUMAVIRUS see **SPUMAVIRUS**

HUMAN T-CELL LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUSES see **HTLV-BLV VIRUSES**

HUMAN T-CELL LEUKEMIA VIRUS ANTIBODIES see **HTLV-BLV ANTIBODIES**

HUMAN T-CELL LEUKEMIA VIRUS ANTIGENS see **HTLV-BLV ANTIGENS**

HUMAN T-CELL LEUKEMIA VIRUS I see **HTLV-I**

HUMAN T-CELL LEUKEMIA VIRUS I ANTIBODIES see **HTLV-I ANTIBODIES**

HUMAN T-CELL LEUKEMIA VIRUS I ANTIGENS see **HTLV-I ANTIGENS**

HUMAN T-CELL LEUKEMIA VIRUS II see **HTLV-II**

HUMAN T-CELL LEUKEMIA VIRUS II ANTIBODIES see **HTLV-II ANTIBODIES**

HUMAN T-CELL LEUKEMIA VIRUS II ANTIGENS see **HTLV-II ANTIGENS**

HUMAN T-CELL LEUKEMIA VIRUS TYPE I REX PROTEIN see **GENE PRODUCTS, REX**

HUMAN T-CELL LEUKEMIA VIRUS TYPE I TAX PROTEIN see **GENE PRODUCTS, TAX**

HUMAN T-CELL LEUKEMIA VIRUSES see **HTLV-BLV VIRUSES**

HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III see **HIV**

HUMAN TIMP-3 see **TISSUE INHIBITOR OF-METALLOPROTEINASE-3**

HUMANISM

Scholarship, humanism, and the young physician. Fishbein RH. **Acad Med** 1999 Jun;74(6):646-51
The habit of humanism: a framework for making humanistic care a reflexive clinical skill. Miller SZ, et al. **Acad Med** 1999 Jul;74(7):800-3
On a practitioner's "being" as the true healing agent. Devroede G. **Adv Mind Body Med** 1999 Spring;15(2):134-6
Response to special section: cloning: technology, policy, and ethics (CQ vol 7, no 2). Humanness, personhood, and a lamb named Dolly [comment] Koch T, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):241-5. Comment on: Camb Q Healthc Ethics 1998 Spring;7(2):145-9. Comment on: Camb Q Healthc Ethics 1998 Spring;7(2):163-7.
A little lady called Pandora: an exploration of philosophical traditions of humanism and existentialism in nursing ill children. Holyoake DD. **Child Care Health Dev** 1998 Jul; 24(4):325-36 (51 ref.)
Clinical teachers as humanistic caregivers and educators: perceptions of senior clerks and second-year residents [see comments] Beaudoin C, et al. **CMAJ** 1998 Oct 6; 159(7):765-9. Comment in: CMAJ 1998 Oct 6;159(7):787-8. Comment in: CMAJ 1999 Feb 23;160(4):480. Comment in: CMAJ 1999 Apr 6;160(7):983; discussion 984. Comment in: CMAJ 1999 Apr 6;160(7):984.
Physician as humanist: still an educational challenge [editorial; comment] [see comments] Neufeld VR. **CMAJ** 1998 Oct 6;159(7):787-8. Comment on: CMAJ 1998 Oct 6;159(7):765-9. Comment in: CMAJ 1999 Feb 23;160(4):479-80. Comment in: CMAJ 1999 Feb 23;160(4):480.
Death: merely biological? [letter] Lizza JP. **Hastings Cent Rep** 1999 Jan-Feb;29(1):4; discussion 5
Humanizing voice mail in healthcare. Hoban L. **J Nurs Adm** 1999 Feb;29(2):50-6
"You are a number, not a human being": Israeli breast cancer patients' experiences with the medical establishment. Sered S, et al. **Med Anthropol Q** 1999 Jun;13(2):223-52 (36 ref.)
A powerful paradigm made stronger. Sperry RW. **Neuropsychologia** 1998 Oct;36(10):1063-8
Sperry's concept of mind as an emergent property of brain function and its implications for the future of humankind. Voneida TJ. **Neuropsychologia** 1998 Oct;36(10):1077-82
Lessons in humanity from corporate America and Patch Adams. [editorial] Setness PA. **Postgrad Med** 1999 Apr; 105(4):23-6
Prescriptions: autonomy, humanism and the purpose of health technology. Krakauer EL. **Theor Med Bioeth** 1998 Dec; 19(6):525-45 (27 ref.)
[Humanism and development] Mottini G. **Med Trop (Mars)** 1998;58(3):218-20 **(Fre)**
[Medicine and humanism: clinical ethics and the community dimension of geriatrics] Forest MI, et al. **Rev Med Suisse Romande** 1998 Dec;118(12):1013-7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Humanity and science] Frühwald W. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:909-15 **(Ger)**
[Humanity in medicine] Horn J. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:916-20 **(Ger)**
[The humanization of health care--the psychological aspects of nurses in cardiac surgery] Carvalho C. **Rev Port Cardiol** 1999 Jul-Aug;18(7-8):763-6 (Eng. Abstr.) **(Por)**
[Physician writers versus medical writers (a humanistic facet of medicine)] Cruz y Hermida J. **An R Acad Nac Med (Madr)** 1998;115(4):887-99; discussion 899-903 **(Spa)**

HISTORY

The humanistic legacy of Doctor Ignacio Chávez. de Micheli A. **Arch Inst Cardiol Mex** 1998 Jul-Aug;68(4):346-9
Gabriele Zerbi's De cautelis medicorum and the tradition of medical prudence. Linden DE. **Bull Hist Med** 1999 Spring;73(1):19-37
[Social welfare in the XIXth century] Bouchet H. **Rev Prat** 1998 Nov 15;48(18):1981-3 **(Fre)**
[On the tracks of humane medicine. Comments on Goethe's 250th birthday] Engelhardt K. **Dtsch Med Wochenschr** 1999 Aug 27;124(34-35):1015-7 **(Ger)**
[At last a humanistic medicine?] Figueroa G. **Rev Med Chil** 1999 Jan;127(1):94-100 (Eng. Abstr.) **(Spa)**

HUMANITARIANISM see **ALTRUISM**

HUMANITIES

Fragmented ethics and "bridge bioethics". Potter VR. **Hastings Cent Rep** 1999 Jan-Feb;29(1):38-40 (17 ref.)
Bioethics and humanities: what makes us one field? Kopelman LM. **J Med Philos** 1998 Aug;23(4):356-68
Health informatics and the humanities. Hultengren E. **Medinfo** 1998;9 Pt 2:1180-3
[Humanity in medicine] Horn J. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:916-20 **(Ger)**

EDUCATION

Teaching history of medicine in the perspective of "medical humanities". von Engelhardt D. **Croat Med J** 1999 Mar; 40(1):1-7
Nursing faculty teaching in the general education sequence: the value of liberal arts as a component of professional nursing practice. Anthony ML, et al. **J Nurs Educ** 1998 Oct;37(7):321-3

HUMERAL FRACTURES

T-condylar fractures of the distal humerus in children and adolescents. Re PR, et al. **J Pediatr Orthop** 1999 May-Jun; 19(3):313-8
[Fracture of the lower humerus in children] Willemen L, et al. **Rev Prat** 1998 Jan 15;48(2):205-8 **(Fre)**

CLASSIFICATION

E. Amory Codman, surgeon of the 1990s [letter] Mallon WJ. **J Shoulder Elbow Surg** 1999 Mar-Apr;8(2):204

COMPLICATIONS

Severance of the radial nerve complicating transverse fracture of the mid-shaft of the humerus. Takami H, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):109-11
Interruption of the radial nerve at proximal level: reconstruction following anterior transposition. Acciarri N, et al. **Chir Organi Mov** 1998 Oct-Dec;83(4):435-40 **(Eng, Ita)**
Neurological complications in children with supracondylar fractures of the humerus. The RM, et al. **Eur J Surg** 1999 Mar;165(3):180-2
Supracondylar fracture of the humerus with ipsilateral fracture of the scaphoid in a child. Nashi M, et al. **J Accid Emerg Med** 1998 Nov;15(6):431
Nonunion of a pediatric lateral condyle fracture without ulnar nerve palsy: sixty-year follow-up. Morgan SJ, et al. **J Orthop Trauma** 1999 Aug;13(6):456-8
Pediatric elbow dislocation associated with a milch type I lateral condyle fracture of the humerus. Rovinsky D, et al. **J Orthop Trauma** 1999 Aug;13(6):458-60
The clinical relevance of posttraumatic avascular necrosis of the humeral head. Gerber C, et al. **J Shoulder Elbow Surg** 1998 Nov-Dec;7(6):586-90
Median nerve palsy after humeral shaft fracture: case report. Apergis E, et al. **J Trauma** 1998 Oct;45(4):825-6
Hypercalcemia. Barnett ML. **Semin Oncol Nurs** 1999 Aug; 15(3):190-201 (53 ref.)

DIAGNOSIS

Assessment of stability in children's minimally displaced lateral humeral condyle fracture by magnetic resonance imaging. Kamegaya M, et al. **J Pediatr Orthop** 1999 Sep-Oct;19(5):570-2

EPIDEMIOLOGY

Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Hagino H, et al. **Bone** 1999 Mar;24(3):265-70

ETIOLOGY

Nontraumatic seizure-associated bilateral fractures of the head of the humerus [letter] Heckmann JG, et al. **Intensive Care Med** 1999 May;25(5):548-9
Relationship between ligamentous laxity and the site of upper extremity fractures in children: extension supracondylar fracture versus distal forearm fracture. Nork SE, et al. **J Pediatr Orthop B** 1999 Apr;8(2):90-2
Periprosthetic humeral fractures: mechanisms of fracture and treatment options. Campbell JT, et al. **J Shoulder Elbow Surg** 1998 Jul-Aug;7(4):406-13
Humeral shaft fracture after a total elbow arthroplasty. Hanyu T, et al. **J Shoulder Elbow Surg** 1998 Sep-Oct; 7(5):541-4
Periprosthetic fractures about the elbow. O'Driscoll SW, et al. **Orthop Clin North Am** 1999 Apr;30(2):319-25 (18 ref.)
Throwing-induced humeral shaft fracture in skeletally immature adolescents. Hennigan SP, et al. **Orthopedics** 1999 Jun;22(6):621-2
Humeral fracture following shoulder arthroplasty. Kligman M, et al. **Orthopedics** 1999 May;22(5):511-3
Fallen fragment sign [letter; comment] Hoeffel C, et al. **Radiology** 1998 Dec;209(3):884-5. Comment on: Radiology 1998 Apr;207(1):261-2.

HISTORY

A case of fracture of the Os Humeri, in which the broken ends of the bone not uniting in the usual manner, a cure was effected by means of a seton. 1803 [classical article] Physick PS. **Clin Orthop** 1998 Oct;(355 Suppl):S4-6

PATHOLOGY

Arm pain in a 24-year-old woman [clinical conference] Shin KH, et al. **Clin Orthop** 1999 Apr;(361):245-9, 261-3
The Baumann angle in supracondylar fractures of the distal humerus in children. Mohammad S, et al. **J Pediatr Orthop** 1999 Jan-Feb;19(1):65-9

PHYSIOPATHOLOGY

The functional outcome of operative treatment of ununited fractures of the humeral diaphysis in older patients. Ring D, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):177-90

PREVENTION & CONTROL

Biomechanical analysis of prophylactic fixation for middle third humeral impending pathologic fractures. Damron TA, et al. **Clin Orthop** 1999 Jun;(363):240-8

RADIOGRAPHY

Radiographic evaluation of Baumann angle in Chinese children and its clinical relevance. Dai L. **J Pediatr Orthop B** 1999 Jul;8(3):197-9
Chronic displaced medial epicondyle fracture. McCance SE,

et al. **Orthopedics** 1998 Aug;21(8):904–6

SURGERY

Complications using the Seidel intramedullary humeral nail: outcome in 31 patients. Svend-Hansen H, et al. **Acta Orthop Belg** 1998 Sep;64(3):291–5

Intramedullary nailing of humeral shaft fractures. A retrospective study of 126 cases. Flinkkilä T, et al. **Acta Orthop Scand** 1999 Apr;70(2):133–6

Closed reduction and percutaneous pinning of supracondylar fractures in children [letter] Ritter RJ. **Am J Orthop** 1999 Jan;28(1):52, 55

Surgical results of open reduction and plating of humeral shaft fractures. Hee HT, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):772–5

Pathological fractures of the humeral shaft. Flinkkilä T, et al. **Ann Chir Gynaecol** 1998;87(4):321–4

Staple augmentation to treat a humeral nonunion after failed Seidel locked nailing. Wu CC, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):42–4 (10 ref.)

Flexible intramedullary "classical" nailing in childhood: use in fractures of the femur and humerus. Spina N, et al. **Chir Organi Mov** 1998 Jul–Sep;83(3):277–83 **(Eng, Ita)**

Acute closed humeral shaft fractures treated with dynamic compression plate. Chen CM, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Oct; 61(10):584–8

Salvage of contaminated fractures of the distal humerus with thin wire external fixation. Ring D, et al. **Clin Orthop** 1999 Feb;(359):203–8

Olecranon screw traction for displaced supracondylar fractures of the humerus in children. Badhe NP, et al. **Injury** 1998 Jul;29(6):457–60

A method of treatment of non-union of humeral shaft fractures following treatment by locked intramedullary nail: a report of three cases. Emmerson KP, et al. **Injury** 1998 Sep;29(7):550–2

An aid to distal locking of the Russell–Taylor humeral nail. Harrington P, et al. **Injury** 1998 Nov;29(9):732–3

Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal. Ochsner PE, et al. **Injury** 1998;29 Suppl 2:B1–10

Type four fracture of the medial epicondyle: a true indication for surgical intervention. Pimpalnerkar AL, et al. **Injury** 1998 Dec;29(10):751–6

Fractures of the capitellum--a comparison of two fixation methods. Poynton AR, et al. **Injury** 1998 Jun;29(5):341–3

Use of an elastic intramedullary nail in difficult humeral fractures. Williams PR, et al. **Injury** 1998 Nov;29(9):661–70

Evaluation of the stability of pin configuration in K-wire fixation of displaced supracondylar fractures in children. Onwuanyi ON, et al. **Int Surg** 1998 Jul–Sep;83(3):271–4

The functional outcome of operative treatment of ununited fractures of the humeral diaphysis in older patients. Ring D, et al. **J Bone Joint Surg Am** 1999 Feb;81(2):177–90

One-stage open cancellous bone grafting of infected fracture and nonunion. Lei H, et al. **J Orthop Sci** 1998;3(6):318–23

The Monteggia lesion and ipsilateral supracondylar humerus and distal radius fractures. Arazi M, et al. **J Orthop Trauma** 1999 Jan;13(1):60–3

Biomechanical comparison of bending and torsional properties in retrograde intramedullary nailing of humeral shaft fractures. Blum J, et al. **J Orthop Trauma** 1999 Jun–Jul;13(5):344–50

Complications of intramedullary nailing for fractures of the humeral shaft: a review. Farragos AF, et al. **J Orthop Trauma** 1999 May;13(4):258–67 (45 ref.)

The spiral compression plate for proximal humeral shaft nonunion: a case report and description of a new technique. Gill DR, et al. **J Orthop Trauma** 1999 Feb;13(2):141–4

Early versus delayed reduction and pinning of type III displaced supracondylar fractures of the humerus in children: a comparative study. Iyengar SR, et al. **J Orthop Trauma** 1999 Jan;13(1):51–5

Schuhli augmentation of plate and screw fixation for humeral shaft fractures: a laboratory study. Simon JA, et al. **J Orthop Trauma** 1999 Mar–Apr;13(3):196–9

Use of a hybrid external fixator for a severely comminuted juxta-articular fracture of the distal humerus. Skaggs DL, et al. **J Orthop Trauma** 1998 Aug;12(6):439–42

Ulnar nerve palsies after percutaneous cross-pinning of supracondylar fractures in children's elbows [letter; comment] Blanco JS. **J Pediatr Orthop** 1998 Nov–Dec; 18(6):824. Comment on: J Pediatr Orthop 1998 Jan–Feb;18(1):43–5.

The Baumann angle in supracondylar fractures of the distal humerus in children. Mohammad S, et al. **J Pediatr Orthop** 1999 Jan–Feb;19(1):65–9

Ulnar nerve injury after K-wire fixation of supracondylar humerus fractures in children. Rasool MN. **J Pediatr Orthop** 1998 Sep–Oct;18(5):686–90

Supracondylar fractures: posterolateral type with brachialis muscle penetration and neurovascular injury. Rasool MN, et al. **J Pediatr Orthop** 1999 Jul–Aug;19(4):518–22

Anterior approach versus posterior approach to surgical treatment of children's supracondylar fractures: comparative study of thirty cases in each series. Gennari JM, et al. **J Pediatr Orthop B** 1998 Oct;7(4):307–13

Periprosthetic humeral fractures: mechanisms of fracture and treatment options. Campbell JT, et al. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):406–13

Ununited humeral diaphyses. Jupiter JB, et al. **J Shoulder Elbow Surg** 1998 Nov–Dec;7(6):644–53 (84 ref.)

Complex fractures of the distal humerus and their complications. Ring D, et al. **J Shoulder Elbow Surg** 1999 Jan–Feb;8(1):85–97 (122 ref.)

Treatment of closed humeral shaft fractures with intramedullary elastic nails. Zatti G, et al. **J Trauma** 1998 Dec;45(6):1046–50

Periprosthetic fractures of the humerus and scapula: management and prevention. Cameron B, et al. **Orthop Clin North Am** 1999 Apr;30(2):305–18 (28 ref.)

[Repair of massive bone defect with free vascularized fibular graft] Huang C, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):88–9 (Eng. Abstr.) **(Chi)**

[Systemic enzyme therapy in the treatment of supracondylar fractures of the humerus in children] Gál P, et al. **Rozhl Chir** 1998 Dec;77(12):574–6 (Eng. Abstr.) **(Cze)**

[Reconstruction of a complex defect of the upper third of the humerus by pedicle transplant of the lateral edge of the scapula. A case report] Benmansour BM, et al. **Ann Chir Plast Esthet** 1999 Apr;44(2):199–203 (Eng. Abstr.) **(Fre)**

[Internal screwed plate for recent fractures of the humeral diaphysis in adults] Dayez J. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):238–44 (Eng. Abstr.) **(Fre)**

[Intramedullary pinning for humeral diaphysis fractures. A minimal risk osteosynthesis. 82 cases] De la Caffinière JY, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 May; 85(2):125–35 (Eng. Abstr.) **(Fre)**

[Treatment of fresh humeral diaphysis fractures by Seidel intramedullary locked nailing. A study of 23 initial cases after 2.5 years with rotator cuff evaluation] Gaullier O, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jul; 85(4):349–61 (Eng. Abstr.) **(Fre)**

[Antegrade or retrograde intramedullary nailing in diaphyseal or sub-capital humeral fractures in the adult] Togninalli D, et al. **Swiss Surg** 1998;(4):193–7 (Eng. Abstr.) **(Fre)**

[Compartment syndrome and Volkmann contracture--can they be prevented in supracondylar humerus fracture?] Krenzien J, et al. **Chirurg** 1998 Nov;69(11):1252–6 (Eng. Abstr.) **(Ger)**

[Retrograde intramedullary nailing of humeral fractures with new implants. Analysis of 120 consecutive cases] Loitz D, et al. **Unfallchirurg** 1998 Jul;101(7):543–50 (Eng. Abstr.) **(Ger)**

[Prolonged transitory paralysis after pneumatic tourniquet use on the upper arm] Savvidis E, et al. **Unfallchirurg** 1999 Feb;102(2):141–4 (Eng. Abstr.) **(Ger)**

THERAPY

Non-operative treatment versus tension-band osteosynthesis in three- and four-part proximal humeral fractures. A retrospective study of 34 fractures from two different trauma centers. Ilchmann T, et al. **Int Orthop** 1998; 22(5):316–20

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Support for uncomplicated shaft of humerus fractures. Herren K. **J Accid Emerg Med** 1999 Mar;16(2):141

Functional fracture bracing. Sarmiento A, et al. **J Am Acad Orthop Surg** 1999 Jan;7(1):66–75 (37 ref.)

Posterior shoulder dislocation associated with fracture of the humeral anatomic neck: treatment guidelines and long-term outcome. Ogawa K, et al. **J Trauma** 1999 Feb;46(2):318–23

Immediate application of fracture braces in humeral shaft fractures. Rangger C, et al. **J Trauma** 1999 Apr;46(4):732–5

Fractures of the elbow. Kuntz DG Jr, et al. **Orthop Clin North Am** 1999 Jan;30(1):37–61 (89 ref.)

Humeral fracture following shoulder arthroplasty. Kligman M, et al. **Orthopedics** 1999 May;22(5):511–3

[Difficulties in the management of supracondylar fractures of the humerus in children living in Central African Republic] Gaudeuille A, et al. **Med Trop (Mars)** 1998; 58(3):273–6 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Hill-Sachs lesion in recurrent shoulder dislocation: sonographic detection. Cičak N, et al. **J Ultrasound Med** 1998 Sep;17(9):557–60

VETERINARY

Type 1-2 hybrid external fixator with tied-in intramedullary pin for treating comminuted distal humeral fractures in a dog and a cat. Beck JA, et al. **Aust Vet J** 1999 Jan; 77(1):18–20

Interlocking nail treatment of diaphyseal long-bone fractures in dogs. Dueland RT, et al. **J Am Vet Med Assoc** 1999 Jan 1;214(1):59–66

Comminuted supracondylar humeral fractures repaired with a modified type I external skeletal fixator construct. Guerin SR, et al. **J Small Anim Pract** 1998 Nov;39(11):525–32

Fluoroscopically guided closed reduction and internal fixation of fractures of the lateral portion of the humeral condyle: prospective clinical study of the technique and results in ten dogs. Cook JL, et al. **Vet Surg** 1999 Sep–Oct; 28(5):315–21

HUMERAL FRACTURES, PROXIMAL see **SHOULDER FRACTURES**

HUMERUS

Cranio-facial and humeral melorrheostosis. Tueche SG, et al. **Acta Chir Belg** 1999 Feb;99(1):47–50

Cystic changes of the humeral head on MR imaging. Relation to age and cuff-tears. Sano A, et al. **Acta Orthop Scand** 1998 Aug;69(4):397–400

Contralateral intrathoracic migration of humeral head fracture dislocation. Abbott GF, et al. **AJR Am J Roentgenol** 1999 May;172(5):1403–4

A novel surgical procedure for osteonecrosis of the humeral head: reposition of the joint surface and bone engraftment. Nakagawa Y, et al. **Arthroscopy** 1999 May;15(4):433–8

Congenital Ewing's sarcoma of the humerus. Hsieh HY, et al. **Br J Radiol** 1998 Dec;71(852):1313–6

Haemophilus aphrophilus osteomyelitis after dental prophylaxis. A case report. Dewire P, et al. **Clin Orthop** 1999 Jun;(363):196–202

Long-term results of limb salvage with the Fabroni custom made endoprosthesis. Fabroni RH, et al. **Clin Orthop** 1999 Jan;(358):41–52

Osteonecrosis of the humeral head treated by core decompression. LaPorte DM, et al. **Clin Orthop** 1998 Oct; (355):254–60

Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Lindner NJ, et al. **Clin Orthop** 1999 Jan;(358):83–9

Bone pain after lymphadenitis. Bartonella henselae granulomatous osteitis. Maggiore G, et al. **Eur J Pediatr** 1999 Feb;158(2):165–6

Evanescent exostosis. A new case. Revilla Y, et al. **Eur J Radiol** 1999 Mar;29(3):270–2 (11 ref.)

Osteonecrosis of the humeral head. Loebenberg MI, et al. **Instr Course Lect** 1999;48:349–57 (34 ref.)

What is your diagnosis? Bone cyst causing acute lameness in a dog. Brady MA, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):957–8

Mycobacterium bovis osteomyelitis as a complication of Bacille Calmette-Guérin (BCG) vaccination: rapid diagnosis with use of DNA sequencing analysis: a case report. Lin CJ, et al. **J Bone Joint Surg Am** 1999 Sep; 81(9):1305–11

Geometric analysis of commonly used prosthetic systems for proximal humeral replacement. Pearl ML, et al. **J Bone Joint Surg Am** 1999 May;81(5):660–71

The clinical relevance of posttraumatic avascular necrosis of the humeral head. Gerber C, et al. **J Shoulder Elbow Surg** 1998 Nov–Dec;7(6):586–90

Isolated CNS involvement in Ewing sarcoma. Mendes WL, et al. **Med Pediatr Oncol** 1999 Jun;32(6):469–70

Isolated granulocytic sarcoma of the humerus. Woodard WL 3rd, et al. **Orthopedics** 1999 Aug;22(8):773–5

A simple bone cyst containing secretory cells in its lining membrane in a patient with polyostotic fibrous dysplasia. Kitoh H, et al. **Pediatr Radiol** 1999 Jun;29(6):481–3

Osteogenic sarcoma with skeletal muscle metastases. Peh WC, et al. **Skeletal Radiol** 1999 May;28(5):298–304

Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Kuntz CA, et al. **Vet Surg** 1998 Sep–Oct;27(5):417–22

[Role of arthroscopy in shoulder osteonecrosis] Baillon JM, et al. **Acta Orthop Belg** 1999;65 Suppl 1:104 **(Fre)**

[Grammont prosthesis in humeral head osteonecrosis. Indications--results] Baulot E, et al. **Acta Orthop Belg** 1999; 65 Suppl 1:109–15 **(Fre)**

[Incidence of humeral head osteonecrosis after fracture of the superior end of the humerus] Zygas P. **Acta Orthop Belg** 1999;65 Suppl 1:99–103 (19 ref.) **(Fre)**

[Aneurysmal diaphyseal bone cyst. Etio-pathogenic hypothesis and review of the literature. A case report] Essadki B, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):297–301 (21 ref.) (Eng. Abstr.) **(Fre)**

[Primary bone tumors and "tumor-like lesions" of the shoulder. Their histopathology and imaging] Link TM, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):507–13 (25 ref.) (Eng. Abstr.) **(Ger)**

[Nonmetastatic accumulations in bone radionuclide scans in a patient with breast neoplasm] Muñoz A, et al. **Rev Esp Med Nucl** 1998;17(5):365–7 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Musculoskeletal manifestations of the Antley-Bixler syndrome. Rumball KM, et al. **J Pediatr Orthop B** 1999 Apr;8(2):139–43 (17 ref.)

Deltoid contracture: a radiographic survey of bone and joint abnormalities. Ogawa K, et al. **J Shoulder Elbow Surg** 1999 Jan–Feb;8(1):22–5

ANATOMY & HISTOLOGY

The scapulohumeral line revisited. Harding WG 3rd. **Am J Orthop** 1999 May;28(5):313–5

Sexual dimorphism in the humerus: a comparative analysis of Chinese, Japanese and Thais. Işcan MY, et al. **Forensic Sci Int** 1998 Nov 30;98(1–2):17–29

Handedness identification from intertubercular sulcus of the humerus by discriminant function analysis. Selvaraj KG, et al. **Forensic Sci Int** 1998 Nov 30;98(1–2):101–8

A visual method of determining the sex of skeletal remains using the distal humerus. Rogers TL. **J Forensic Sci** 1999 Jan;44(1):57–60

HUMERUS

Patterns of sexual dimorphism in the hominoid distal humerus. Lague MR, et al. **J Hum Evol** 1999 Apr; 36(4):379–99

Comparison of humeral head retroversion with the humeral axis/biceps groove relationship: a study in live subjects and cadavers. Doyle AJ, et al. **J Shoulder Elbow Surg** 1998 Sep–Oct;7(5):453–7

Variations in the retroversion of the humeral head. Edelson G. **J Shoulder Elbow Surg** 1999 Mar–Apr;8(2):142–5

Evaluation of articular cartilage thickness of the humeral head and the glenoid fossa by MR arthrography: anatomic correlation in cadavers. Yeh LR, et al. **Skeletal Radiol** 1998 Sep;27(9):500–4

Intertubercular sulcus of the humerus: biometry and morphology of 100 dry bones. Ueberham K, et al. **Surg Radiol Anat** 1998;20(5):351–4

[Preferential direction of collagen fibrils in the sub-chondral bone bone and the hip and shoulder joint] Vogt S, et al. **Anat Anz** 1999 Mar;181(2):181–9 (Eng. Abstr.) **(Ger)**

[Investigating methods for age estimation (1). Height of the apex of the medullary cavity of the humerus] Terazawa K, et al. **Nippon Hoigaku Zasshi** 1998 Aug;52(4):261–4 (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

An aneurysm involving the axillary artery and its branch vessels in a major league baseball pitcher. A case report and review of the literature. Schneider K, et al. **Am J Sports Med** 1999 May–Jun;27(3):370–5 (23 ref.)

EMBRYOLOGY

New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age. Bahado-Singh RO, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1627–31

INJURIES

Posterior capsular avulsion in a college football player. Weinberg J, et al. **Am J Sports Med** 1999 Mar–Apr; 27(2):235–7

Tossed on the horn of humerus: a legal case report. Finnbogason T, et al. **Eur Radiol** 1998;8(8):1495–6

Anterior interosseous nerve compression after supracondylar fracture of the humerus: a metaanalysis. Joist A, et al. **J Neurosurg** 1999 Jun;90(6):1053–6

Posterior dislocation of the humeral head in association with obstetric paralysis. Torode I, et al. **J Pediatr Orthop** 1998 Sep–Oct;18(5):611–5

Toxic shock syndrome after a closed comminuted fracture surgery at the distal end of the humerus. Kato N, et al. **J Shoulder Elbow Surg** 1999 Mar–Apr;8(2):165–9

Chronic avulsive injury of the deltoid insertion in adolescents: imaging findings in three cases. Donnelly LF, et al. **Radiology** 1999 Apr;211(1):233–6

[Ultrasonographic diagnosis of an epiphyseal detachment of the upper end of the humerus due to birth injury] Schmit P, et al. **J Radiol** 1999 May;80(5):466–8 (Eng. Abstr.) **(Fre)**

[Comparison of the efficacy of intraarticular and intraarterial injections of two betamethasone preparations in patients with osteoarthritis or epicondilytis] Oksenberg D, et al. **Rev Med Chil** 1998 Jun;126(6):623–8 (Eng. Abstr.) **(Spa)**

METABOLISM

Rate of aspartic acid racemization in bone. Ohtani S. **Am J Forensic Med Pathol** 1998 Sep;19(3):284–7

PATHOLOGY

Primary glenohumeral osteoarthritis: clinical and radiographic classification. The Aequalis Group. Walch G, et al. **Acta Orthop Belg** 1998;64 Suppl 2:46–52

Evaluation of humeral head erosions in rheumatoid arthritis: a comparison of ultrasonography, magnetic resonance imaging, computed tomography and plain radiography. Alasaarela E, et al. **Br J Rheumatol** 1998 Nov;37(11):1152–6

Heat-induced segmental necrosis after reaming of one humeral and two tibial fractures with a narrow medullary canal. Ochsner PE, et al. **Injury** 1998;29 Suppl 2:B1–10

Periosteal osteoblastoma of the distal humerus. Kawaguchi K, et al. **J Orthop Sci** 1998;3(6):341–5

Growth arrest resulting from unicameral bone cyst [letter; comment] Crawford AH. **J Pediatr Orthop** 1998 Nov–Dec; 18(6):824–5. Comment on: J Pediatr Orthop 1998 Mar–Apr;18(2):198–201.

PHYSIOLOGY

Histomorphometric, physical, and mechanical effects of spaceflight and insulin-like growth factor-I on rat long bones. Bateman TA, et al. **Bone** 1998 Dec;23(6):527–35

Results from demineralized bone creep tests suggest that collagen is responsible for the creep behavior of bone. Bowman SM, et al. **J Biomech Eng** 1999 Apr;121(2):253–8

RADIOGRAPHY

Greater tuberosity changes as revealed by radiography: lack of clinical usefulness in patients with rotator cuff disease. Huang LF, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1381–8

Deltoid contracture: a radiographic survey of bone and joint abnormalities. Ogawa K, et al. **J Shoulder Elbow Surg** 1999 Jan–Feb;8(1):22–5

Separation of the proximal humeral epiphysis. Aroojis A, et al. **Postgrad Med J** 1998 Dec;74(878):752–5

[Lytic epiphyseal-metaphyseal lesion] Lamer S, et al. **Presse Med** 1998 Jun 27;27(23):1197–8 **(Fre)**

[Osseous site of systemic cryptococcosis in an immunocompetent patient] Goncalves J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Sep; 84(5):451–5 (Eng. Abstr.) **(Fre)**

[Apropos of: "Non-traumatic circumscript myositis ossificans" (letter; comment)] Hoeffel JC, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Sep;84(5):458 . Comment on: Rev Chir Orthop Reparatrice Appar Mot 1998 Feb;84(1):79–83. **(Fre)**

RADIONUCLIDE IMAGING

Symmetric avascular necrosis of the shoulders and hips in sickle cell disease. Sinha P, et al. **Clin Nucl Med** 1999 Jun; 24(6):445

SURGERY

Disseminated intravascular coagulation in a patient undergoing removal of humeral head for pain relief. Terasako K. **Anaesth Intensive Care** 1999 Jun;27(3):287–8

Impingement syndrome following total shoulder arthroplasty and humeral hemiarthroplasty: treatment with arthroscopic acromioplasty. Freedman KB, et al. **Arthroscopy** 1998 Oct; 14(7):665–70

Olecranon screw traction for displaced supracondylar fractures of the humerus in children. Badhe NP, et al. **Injury** 1998 Jul;29(6):457–60

Primary replacement of the humeral head in iatrogenically displaced fracture-dislocations of the shoulder: a report about six cases. Demirhan M, et al. **Injury** 1998 Sep; 29(7):525–8

Humeral hemiarthroplasty of the elbow joint in young patients with rheumatoid arthritis: a report on 7 arthroplasties. Swoboda B, et al. **J Arthroplasty** 1999 Aug; 14(5):553–9

Complications and functional outcomes of reconstruction with an osteoarticular allograft after intra-articular resection of the proximal aspect of the humerus. Getty PJ, et al. **J Bone Joint Surg Am** 1999 Aug;81(8):1138–46

Late treatment of brachial plexus palsy secondary to birth injuries: rotational osteotomy of the proximal part of the humerus. Kirkos JM, et al. **J Bone Joint Surg Am** 1998 Oct;80(10):1477–83

Geographic variations in the rates of operative procedures involving the shoulder, including total shoulder replacement, humeral head replacement, and rotator cuff repair. Vitale MG, et al. **J Bone Joint Surg Am** 1999 Jun; 81(6):763–72

Combined Sever's release of the shoulder and osteotomy of the humerus for Erb's palsy. Al-Zahrani S. **J Hand Surg [Br]** 1997 Oct;22(5):591–3

Dome osteotomy with T-plate fixation for cubitus varus deformity in an adult patient. Myint S, et al. **J R Coll Surg Edinb** 1998 Oct;43(5):353–4

Effect of humeral head component size on hemiarthroplasty translations and rotations. Blevins FT, et al. **J Shoulder Elbow Surg** 1998 Nov–Dec;7(6):591–8

Toxic shock syndrome after a closed comminuted fracture surgery at the distal end of the humerus. Kato N, et al. **J Shoulder Elbow Surg** 1999 Mar–Apr;8(2):165–9

Extensile approach to the anterolateral surface of the humerus and the radial nerve. Mekhail AO, et al. **J Shoulder Elbow Surg** 1999 Mar–Apr;8(2):112–8

Fixation of humeral prostheses and axial micromotion. Peppers TA, et al. **J Shoulder Elbow Surg** 1998 Jul–Aug; 7(4):414–8

[Application of artificial humeral head in the treatment of tumor of upper end of humerus] Zhang Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 May;11(3):139–41 (Eng. Abstr.) **(Chi)**

[Clinical and radiologic outcome of humeral implants in shoulder arthroplasty] Maynou C, et al. **Acta Orthop Belg** 1999 Mar;65(1):57–64 (Eng. Abstr.) **(Fre)**

[Results of shoulder hemiarthroplasty in patients with acute and old fractures of the proximal humerus] Göbel F, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb;137(1):25–30 (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

Support of the anterior column with allografts in tuberculosis of the spine. Govender S, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):106–9

ULTRASONOGRAPHY

Ultrasonographic examination of the glenoid labrum of healthy volunteers. Schydlowsky P, et al. **Eur J Ultrasound** 1998 Nov;8(2):85–9

Hill-Sachs lesion in recurrent shoulder dislocation: sonographic detection. Čičak N, et al. **J Ultrasound Med** 1998 Sep;17(9):557–60

Humerospinous distance measurements: accuracy and usefulness for predicting shoulder dystocia in delivery at term. Klaij FA, et al. **Ultrasound Obstet Gynecol** 1998 Aug; 12(2):115–9

HUMIC ACIDS

ANALYSIS

Chemical analysis of water of the Anticolana Valley: isolation of humic compounds. Calace N, et al. **Nephron** 1999;81 Suppl 1:93–7

CHEMISTRY

The application of ultracentrifugation methods to ion-induced association of humic substances. Bryan ND, et al. **Biochem Soc Trans** 1998 Nov;26(4):762–5

The effect of humic acids on the water solubility and water-organic carbon partitioning of fluorene and its NSO-heteroanalogues: carbazole, dibenzofuran, and dibenzothiophene. Lassen P, et al. **Chemosphere** 1999 Jun; 38(13):2959–68

Humic acid capillary zone electrophoresis adsorption on capillary walls, separation in metal ion supplemented buffer and the fingerprints. Fetsch D, et al. **Electrophoresis** 1998 Oct;19(14):2465–73

Quantification of phenylurea herbicides and their free and humic acid-associated metabolites in natural waters. Di Corcia A, et al. **J Chromatogr A** 1999 Aug 13;852(2):465–74

ISOLATION & PURIFICATION

Humic acid capillary zone electrophoresis adsorption on capillary walls, separation in metal ion supplemented buffer and the fingerprints. Fetsch D, et al. **Electrophoresis** 1998 Oct;19(14):2465–73

Separation and characterization of humic acids and metal humates by electrophoretic methods. Keuth U, et al. **Electrophoresis** 1998 Jun;19(7):1091–6

METABOLISM

Purification and characterization of laccase from Chaetomium thermophilium and its role in humification. Chefetz B, et al. **Appl Environ Microbiol** 1998 Sep; 64(9):3175–9

Biodeterioration of cardboard-based liquid containers collected for fibre reuse. Koivula N, et al. **Chemosphere** 1999 Apr;38(8):1873–87

Degradation of humic acids by manganese peroxidase from the white-rot fungus Clitocybula dusenii. Ziegenhagen D, et al. **J Basic Microbiol** 1998;38(4):289–99

PHARMACOLOGY

Development and disappearance of tolerance to induction of interferon and tumor necrosis factor response in athletes treated with natural immunostimulant. Inglot AD, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(4):237–44

Influence of an aquatic humic acid on the bioconcentration of selected compounds in Daphnia magna. Schramm KW, et al. **Ecotoxicol Environ Saf** 1998 Sep;41(1):73–6

Effect of natural dissolved humic material on bioavailability and acute toxicity of fenpropathrin to the grass carp, Ctenopharyngodon idellus. Wu WZ, et al. **Ecotoxicol Environ Saf** 1999 Mar;42(3):203–6

Peroxisome proliferation, adipocyte determination and differentiation of C3H10T1/2 fibroblast cells induced by humic acid: induction of PPAR in diverse cells. Lee Y, et al. **J Cell Physiol** 1999 May;179(2):218–25

Buthionine sulfoximine prevents the reduction of the genotoxic activity of maleic hydrazide by soil humic substances in Vicia faba seedlings. De Marco A, et al. **Mutat Res** 1999 Jan 13;438(2):89–95

The influence of humic substances on the absorption and distribution of cadmium in mice. Lind Y, et al. **Pharmacol Toxicol** 1999 Jun;84(6):267–73

[The antimutagenic effect of gumizol in cultures of blood T-lymphocytes exposed to cyclophosphane] Sevost'ianova NV. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Jul–Aug; (4):46–7 **(Rus)**

TOXICITY

Bioassays for risk assessment of coal conversion products. Schacht S, et al. **Appl Microbiol Biotechnol** 1999 Jul; 52(1):127–30

Oxidative injury induced by synthetic humic acid polymer and monomer in cultured rabbit articular chondrocytes. Liang HJ, et al. **Life Sci** 1999;65(11):1163–73

[Studies on mutagenicity of humic acid samples collected from arsenosis-affected areas in China] Yu X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Mar;32(2):70–2 (Eng. Abstr.) **(Chi)**

HUMIDITY

Temperature and relative humidity affect the selection of shelters by Triatoma infestans, vector of Chagas disease. Lorenzo MG, et al. **Acta Trop** 1999 Apr 30;72(3):241–9

The effect of dry heat on mite, cat, and dog allergens. Cain G, et al. **Allergy** 1998 Dec;53(12):1213–5

Life cycle and reproduction of house-dust mites: environmental factors influencing mite populations. Hart BJ. **Allergy** 1998;53(48 Suppl):13–7 (48 ref.)

Improving indoor air quality through the use of continual multipoint monitoring of carbon dioxide and dew point. Bearg DW. **Am Ind Hyg Assoc J** 1998 Sep;59(9):636–41

Prevention of visual field defect after macular hole surgery

by passing air used for fluid-air exchange through water. Ohji M, et al. **Am J Ophthalmol** 1999 Jan;127(1):62-6
The heat moisture exchange device (HME) in neonatal ventilation. Wilmshurst JM, et al. **Am J Perinatol** 1999; 16(1):13-6
Hyperventilation with dry air increases airway surface fluid osmolality in canine peripheral airways. Freed AN, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1101-7
Effects of truss mattress upon sleep and bed climate. Okamoto K, et al. **Appl Human Sci** 1998 Nov;17(6):233-7
In vitro study of the failure of skin surface after influence of hydration and preconditioning. Nicolopoulos CS, et al. **Arch Dermatol Res** 1998 Nov;290(11):638-40
Effect of humidity on posterior lens opacification during fluid-air exchange. Harlan JB Jr, et al. **Arch Ophthalmol** 1999 Jun;117(6):802-4
Wet bulb globe temperature (WBGT)--to what extent is GT essential? Moran DS, et al. **Aviat Space Environ Med** 1999 May;70(5):480-4
Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure. Massie CA, et al. **Chest** 1999 Aug;116(2):403-8
Bedside evaluation of efficient airway humidification during mechanical ventilation of the critically ill. Ricard JD, et al. **Chest** 1999 Jun;115(6):1646-52
Comparing two heat and moisture exchangers, one hydrophobic and one hygroscopic, on humidifying efficacy and the rate of nosocomial pneumonia. Thomachot L, et al. **Chest** 1998 Nov;114(5):1383-9
Direct measurements of temperature and humidity in dust mite microhabitats. Cunningham MJ. **Clin Exp Allergy** 1998 Sep;28(9):1104-12
Do the components of heat and moisture exchanger filters affect their humidifying efficacy and the incidence of nosocomial pneumonia? Thomachot L, et al. **Crit Care Med** 1999 May;27(5):923-8
Thermal and mechanical characterization of cellulose acetate phthalate films for pharmaceutical tablet coating: effect of humidity during measurements. Karlsson A, et al. **Drug Dev Ind Pharm** 1998 Sep;24(9):827-34
Physicochemical stability of crystalline sugars and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers. Naini V, et al. **Drug Dev Ind Pharm** 1998 Oct;24(10):895-909
Multiple-layer compression-coated tablets: formulation and humidity studies of novel chewable amoxicillin/clavulanate tablet formulations. Wardrop J, et al. **Drug Dev Ind Pharm** 1998 Aug;24(8):729-36
User experience network. Overheating connector in Fisher & Paykel MR700 series humidifier. **Health Devices** 1999 Sep;28(9):374-5
Dry condition affects desquamation of stratum corneum in vivo. Sato J, et al. **J Dermatol Sci** 1998 Dec;18(3):163-9
Low humidity stimulates epidermal DNA synthesis and amplifies the hyperproliferative response to barrier disruption: implication for seasonal exacerbations of inflammatory dermatoses. Denda M, et al. **J Invest Dermatol** 1998 Nov;111(5):873-8
Development of Rhodnius prolixus (Hemiptera: Reduviidae) under constant and cyclic conditions of temperature and humidity. Luz C, et al. **Mem Inst Oswaldo Cruz** 1999 May-Jun;94(3):403-9
How dry are dried samples? Water adsorption measured by STM. Freund J, et al. **Microsc Res Tech** 1999 Mar 1; 44(5):327-38
The assessment proposal for long-term and short-term tolerable hygrothermal microclimatic conditions. Jirák Z, et al. **Physiol Res** 1997;46(4):307-17
Studies on the influence of temperature, relative humidity and microenvironment on the natural fermentation of African oil bean seeds to 'Ugba'. Isu NR, et al. **Plant Foods Hum Nutr** 1998;52(4):337-51
The effect of temperature and humidity on dengue virus propagation in Aedes aegypti mosquitos. Thu HM, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):280-4
Effect of high versus low ambient humidity on the severity of obstructive sleep apnoea. Jokic R, et al. **Thorax** 1999 Aug;54(8):711-3
Effect of dampness at home in childhood on bronchial hyperreactivity in adolescence. Nicolai T, et al. **Thorax** 1998 Dec;53(12):1035-40
[Study of skin temperature, microclimate and comfort of clothing of old females at rest--ambient temperature x humidity: 30 degrees C. R.H.80%, 30 degrees C. R.H.45%, 20 degrees C. R.H.45%] Nakazato Y, et al. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):477-88 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Clothing evaporative heat resistance--proposal for improved representation in standards and models [see comments] Havenith G, et al. **Ann Occup Hyg** 1999 Jul;43(5):339-46 (17 ref.). Comment in: Ann Occup Hyg 1999 Jul;43(5):347-52.
The effects of wind and human movement on the heat and vapour transfer properties of clothing [comment] Parsons KC, et al. **Ann Occup Hyg** 1999 Jul;43(5):347-52. Comment on: Ann Occup Hyg 1999 Jul;43(5):329-38. Comment on: Ann Occup Hyg 1999 Jul;43(5):339-46.
Dampness and airway inflammation and systemic symptoms in office building workers. Wan GH, et al. **Arch Environ Health** 1999 Jan-Feb;54(1):58-63
Home dampness and respiratory health status in european children [see comments] Andriessen JW, et al. **Clin Exp Allergy** 1998 Oct;28(10):1191-200. Comment in: Clin Exp Allergy 1998 Oct;28(10):1178-81.
Advantages of a smaller bodymass in humans when distance-running in warm, humid conditions. Dennis SC, et al. **Eur J Appl Physiol** 1999 Feb;79(3):280-4
Home dampness and molds as determinants of respiratory symptoms and asthma in pre-school children. Jaakkola JJ, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:129-42

PREVENTION & CONTROL

Attempting to control mite allergens with mechanical ventilation and dehumidification in British houses. Niven R, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):756-62

HUMOR see **WIT AND HUMOR**

HUMPBACK DOLPHINS see **DOLPHINS**

HUMPBACK WHALE see **WHALES**

HUNGER

The effectiveness of a short form of the Household Food Security Scale. Blumberg SJ, et al. **Am J Public Health** 1999 Aug;89(8):1231-4
A figurative measure of subjective hunger sensations. Friedman MI, et al. **Appetite** 1999 Jun;32(3):395-404
Changes in food attitudes as a function of hunger. Lozano DI, et al. **Appetite** 1999 Apr;32(2):207-18
Moratorium on GM food would perpetuate world hunger [news] Woodman R. **BMJ** 1999 Jun 5;318(7197):1506
Household food insecurity and hunger among families using food banks. Tarasuk VS, et al. **Can J Public Health** 1999 Mar-Apr;90(2):109-13
Hunger sensation in Graves' disease before and after pharmacological therapy. Cugini P, et al. **Clin Ter** 1999 Mar-Apr;150(2):115-9
Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Jones KL, et al. **Diabetes Care** 1999 Feb;22(2):339-44
The effect of covertly manipulating the energy density of mixed diets on ad libitum food intake in 'pseudo free-living' humans. Stubbs RJ, et al. **Int J Obes Relat Metab Disord** 1998 Oct;22(10):980-7
Hunger and satiety: deceptively simple words for the complex mechanisms that tell us when to eat and when to stop [news] **J Am Diet Assoc** 1998 Oct;98(10):1111
Measuring food insecurity and hunger in the United States: development of a national benchmark measure and prevalence estimates. Carlson SJ, et al. **J Nutr** 1999 Feb; 129(2S Suppl):510S-516S (45 ref.)
Validation of measures of food insecurity and hunger. Frongillo EA Jr. **J Nutr** 1999 Feb;129(2S Suppl):506S-509S (21 ref.)
Nutrition and health outcomes associated with food insecurity and hunger. Olson CM. **J Nutr** 1999 Feb;129(2S Suppl):521S-524S (14 ref.)
Symposium: Advances in Measuring Food Insecurity and Hunger in the U.S. Introduction. Olson CM. **J Nutr** 1999 Feb;129(2S Suppl):504S-505S (4 ref.)
Economic determinants and dietary consequences of food insecurity in the United States. Rose D. **J Nutr** 1999 Feb; 129(2S Suppl):517S-520S (11 ref.)
How hunger keeps the population down [letter] [see comments] Bondi H. **Nature** 1999 Feb 25;397(6721):644. Comment in: Nature 1999 Apr 15;398(6728):556.
Women's strategies to alleviate nutritional stress in a rural African society. Bentley GR, et al. **Soc Sci Med** 1999 Jan; 48(2):149-62
Good breakfast for good learning. Janowski J. **WMJ** 1998 Sep;97(8):33-6
[Hunger and mental illness] Rebello LMV. **Cad Saude Publica** 1998 Jul-Sep;14(3):643-6 (Eng. Abstr.) **(Por)**

DRUG EFFECTS

Role of GLP-1 in meal-taking. Hellström PM, et al. **Appetite** 1999 Apr;32(2):276
Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients [see comments] Shimizu H, et al. **Diabetes Care** 1998 Sep;21(9):1470-4. Comment in: Diabetes Care 1999 Jul;22(7):1227-8.

PHYSIOLOGY

Hunger behaviour contributes to early nutritional homeostasis [letter] Hawdon JM, et al. **Acta Paediatr** 1999 Jun;88(6):691-2
Chocolate craving and hunger state: implications for the acquisition and expression of appetite and food choice. Gibson EL, et al. **Appetite** 1999 Apr;32(2):219-40
Influence of hunger on the expression of discriminative appetite by the rat (first published in French in 1960) [classical article] Le Magnen J. **Appetite** 1999 Aug; 33(1):52-4
Olfactory alliesthesia in human neonates: prandial state and stimulus familiarity modulate facial and autonomic responses to milk odors. Soussignan R, et al. **Dev Psychobiol** 1999 Jul;35(1):3-14
Interrelationship between circulating leptin concentrations, hunger, and energy intake in healthy subjects receiving tube feeding. Stratton RJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov-Dec;22(6):335-9
The ontogeny of salt hunger in the rat. Leshem M. **Neurosci Biobehav Rev** 1999 May;23(5):649-59 (86 ref.)
Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion. Greenough A, et al. **Physiol Behav** 1998 Nov 15;65(2):303-10
Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography. Tataranni PA, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4569-74
[A coherence analysis of the electrical activity of the rabbit brain during the creation of a "polarization" hunger dominant] Liubimova IuV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):600-6 (Eng. Abstr.) **(Rus)**
[The thermal activity of the rabbit brain in motivational states of hunger or thirst] Malikova AK, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Jul-Aug; 48(4):623-9 (Eng. Abstr.) **(Rus)**

HUNTER CORRECTIVE FACTOR see **IDURONATE SULFATASE**

HUNTER'S SYNDROME see **MUCOPOLYSACCHARIDOSIS II**

HUNTINGTON CHOREA see **HUNTINGTON'S DISEASE**

HUNTINGTON'S DISEASE

Atypical rigid form of Huntington's disease: a case with peripheral amyotrophy and congenital defects of a lower limb. Kanzato N, et al. **Intern Med** 1998 Nov;37(11):978-81
Reversible Huntington's disease? [letter] [see comments] Bonelli R, et al. **Lancet** 1998 Nov 7;352(9139):1520-1. Comment in: Lancet 1999 Jan 16;353(9148):240-1.
A fly's eye view of Huntington's disease [news] Mitchell A. **Nature** 1998 Oct 29;395(6705):841
[Huntington's disease--clinical characteristics and physiopathology] Kanazawa I. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1647-57 (20 ref.) **(Jpn)**
[Huntington disease] Kanazawa I. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):86-8 (7 ref.) **(Jpn)**
[Benign hereditary chorea] Sato H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):95-7 (11 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Montine TJ, et al. **Neurology** 1999 Mar 23;52(5):1104-5

COMPLICATIONS

A non-typical neuropsychological case presentation of Huntington's disease. Gontkovsky ST, et al. **Brain Inj** 1999 Jun;13(6):457-62
Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Sørensen SA, et al. **Cancer** 1999 Oct 1;86(7):1342-6
A patient with Huntington's disease presenting with laryngeal chorea. Mochizuki H, et al. **Eur Neurol** 1999;41(2):119-20
Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398-403 (70 ref.)
Huntington's disease and alcohol abuse. Mattoo SK, et al. **Neurol India** 1999 Mar;47(1):68-70

DIAGNOSIS

The causes of sporadic and 'senile' chorea. Warren JD, et al. **Aust N Z J Med** 1998 Aug;28(4):429-31
Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Wilkinson FL, et al. **Brain Res Mol Brain Res** 1999 May 21;69(1):10-20
Movement disorder in a 56-year-old woman. Franco-Bronson K, et al. **Cleve Clin J Med** 1998 Oct; 65(9):491-5
The evaluation of the 'stages of change' model for use in counselling client's undergoing predictive testing for Huntington's disease. Houlihan GD. **J Adv Nurs** 1999 May; 29(5):1137-43 (38 ref.)
Consistency of handwriting movements in dementia of the Alzheimer's type: a comparison with Huntington's and Parkinson's diseases. Slavin MJ, et al. **J Int Neuropsychol Soc** 1999 Jan;5(1):20-5
Neuroacanthocytosis masquerading as Huntington's disease: CT/MRI findings. Kutcher JS, et al. **J Neuroimaging** 1999 Jul;9(3):187-9
Differences in duration of Huntington's disease based on age at onset. Foroud T, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):52-6
Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's

diseases. A report of the ANPA Committee on Research. American Neuropsychiatric Association. Lauterbach EC, et al. **J Neuropsychiatry Clin Neurosci** 1998 Summer; 10(3):249–66 (256 ref.)

Presymptomatic testing for Huntington's disease: the role of genetic counseling. Walsh A. **Med Health R I** 1999 May; 82(5):168–70 (12 ref.)

A 32-year-old man with progressive spasticity and parkinsonism [clinical conference] Frucht S, et al. **Mov Disord** 1999 Mar;14(2):350–7

Unified Huntington's disease rating scale: a follow up. Siesling S, et al. **Mov Disord** 1998 Nov;13(6):915–9

Non-disclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas. Braude PR, et al. **Prenat Diagn** 1998 Dec;18(13):1422–6 (17 ref.)

Experience in prenatal testing for Huntington's disease in The Netherlands: procedures, results and guidelines (1987–1997). Maat-Kievit A, et al. **Prenat Diagn** 1999 May; 19(5):450–7

Preimplantation diagnosis for Huntington's disease (HD): clinical application and analysis of the HD expansion in affected embryos. Sermon K, et al. **Prenat Diagn** 1998 Dec; 18(13):1427–36

Utilisation of predictive, prenatal and diagnostic testing for Huntington's disease in Johannesburg. Kromberg JG, et al. **S Afr Med J** 1999 Jul;89(7):774–8

[Psychosocial consequences of presymptomatic genetic testing. A retrospective study of testing for Huntington disease] Jakobsen LB, et al. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1913–6 (Eng. Abstr.) **(Nor)**

[Huntington chorea in a boy aged 14 years] Marszal E, et al. **Neurol Neurochir Pol** 1998 Jul–Sep;32(4):923–31 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Reggio R, et al. **Brain Res** 1999 Jun 12;831(1–2):315–8

The IGF-1 amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Alexi T, et al. **Exp Neurol** 1999 Sep; 159(1):84–97

Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Kordower JH, et al. **Exp Neurol** 1999 Sep;159(1):4–20 (73 ref.)

Effectiveness of risperidone in Huntington chorea patients [letter] Dallocchio C, et al. **J Clin Psychopharmacol** 1999 Feb;19(1):101–3

Antiglutamate therapies in Huntington's disease. Kieburtz K. **J Neural Transm Suppl** 1999;55:97–102 (32 ref.)

The use of olanzapine for movement disorder in Huntington's disease: a first case report [letter] Dipple HC. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):123–4

Levodopa responsive parkinsonism in an adult with Huntington's disease. Racette BA, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):577–9

Riluzole therapy in Huntington's disease (HD). Rosas HD, et al. **Mov Disord** 1999 Mar;14(2):326–30

Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Centonze D, et al. **Neuropharmacology** 1998 Aug;37(8):1063–70

Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Hughes PE, et al. **Neuroscience** 1999;92(1):197–209

ENZYMOLOGY

Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Cooper AJ, et al. **Dev Neurosci** 1998;20(4–5):462–8

Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease. Yu P, et al. **Mamm Genome** 1999 Sep;10(9):845–52

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease [see comments] Ona VO, et al. **Nature** 1999 May 20;399(6733):263–7. Comment in: Nature 1999 May 20;399(6733):204–5, 207.

EPIDEMIOLOGY

[Population genetic study of Huntington's disease--prevalence and founder's effect in the San-in area, western Japan] Adachi Y, et al. **Nippon Rinsho** 1999 Apr; 57(4):900–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETHNOLOGY

Analysis of CAG repeat expansion in Huntington's disease gene (IT 15) in a Hungarian population. Jakab K, et al. **Eur Neurol** 1999;41(2):107–10

ETIOLOGY

Recent advances on the pathogenesis of Huntington's disease. Petersén A, et al. **Exp Neurol** 1999 May;157(1):1–18 (168 ref.)

In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hackam AS, et al. **Hum Mol Genet** 1999 Jan;8(1):25–33

In vitro and in vivo models for Huntington disease: lessons for the polyglutamine expansion disorders. Hayden MR. **Pathol Biol (Paris)** 1998 Nov;46(9):695–6 **(Eng, Fre)**

GENETICS

The genetic analysis of Turkish patients with Huntington's disease. Ataç FB, et al. **Acta Neurol Scand** 1999 Sep; 100(3):195–8

Two novel single-base-pair substitutions adjacent to the CAG repeat in the huntington disease gene (IT15): implications for diagnostic testing [letter] Margolis RL, et al. **Am J Hum Genet** 1999 Jan;64(1):323–6

A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. Xiang F, et al. **Am J Hum Genet** 1998 Nov;63(5):1431–8

Genetics session: the human genome. Prognostications and predispositions. Wexler N. **Ann N Y Acad Sci** 1999 Jun 30;882:22–31; discussion 56–65

Does CAG repeat number predict the rate of pathological changes in Huntington's disease? [letter; comment] Rosenblatt A, et al. **Ann Neurol** 1998 Oct;44(4):708–9. Comment on: Ann Neurol 1997 May;41(5):689–92.

Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Yen L, et al. **Ann Neurol** 1999 Sep; 46(3):366–73

Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Kirkwood SC, et al. **Arch Neurol** 1999 May;56(5):563–8

Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Swerdlow RH, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):701–4

Isolation and characterization of the rat huntingtin promoter. Holzmann C, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):227–34

Polyglutamine expansion and Huntington's disease. Bates GP, et al. **Biochem Soc Trans** 1998 Aug;26(3):471–5 (38 ref.)

Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Harris GJ, et al. **Brain** 1999 Sep;122 (Pt 9):1667–78

Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's disease transgenic mice. Manley K, et al. **Brain Res** 1999 Jul 17;835(1):74–9

Usefulness of molecular testing in Huntington's disease. Wang V, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Sep; 62(9):586–90

Juvenile Huntington's disease: report of one case. Sue WC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep–Oct;39(5):342–5

Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. Bruland O, et al. **Clin Genet** 1999 Mar;55(3):198–202

Distribution of CAG repeats in normal and Huntington's disease patients in Israel [letter] Gazit E, et al. **Clin Genet** 1998 Sep;54(3):250–1

To be or not to be an aggregate. Nasir J. **Clin Genet** 1999 Jan;55(1):9–10 (2 ref.)

Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Hurlbert MS, et al. **Diabetes** 1999 Mar;48(3):649–51

The primary structure and genomic organization of five novel transcripts located close to the Huntington's disease gene on human chromosome 4p16.3. Hadano S, et al. **DNA Res** 1998 Jun 30;5(3):177–86

A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease. Losekoot M, et al. **Eur J Hum Genet** 1999 Feb–Mar;7(2):217–22

Analysis of CAG repeat expansion in Huntington's disease gene (IT 15) in a Hungarian population. Jakab K, et al. **Eur Neurol** 1999;41(2):107–10

Characterization of the Huntington's disease (HD) gene homologue in the zebrafish Danio rerio. Karlovich CA, et al. **Gene** 1998 Sep 14;217(1–2):117–25

Characterization of the mouse Src homology 3 domain gene Sh3d2c on Chr 7 demonstrates coexpression with huntingtin in the brain and identifies the processed pseudogene Sh3d2c-ps1 on Chr 2. Zechner U, et al. **Genomics** 1998 Dec 15;54(3):505–10

Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism [published erratum appears in Hum Mol Genet 1999 Apr;8(4):717] Leeflang EP, et al. **Hum Mol Genet** 1999 Feb;8(2):173–83

Formation of polyglutamine inclusions in non-CNS tissue. Sathasivam K, et al. **Hum Mol Genet** 1999 May;8(5):813–22

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May;8(5):943] Schilling G, et al. **Hum Mol Genet** 1999 Mar;8(3):397–407

A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Shelbourne PF, et al. **Hum Mol Genet** 1999 May;8(5):763–74

Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Usdin MT, et al. **Hum Mol Genet** 1999 May;8(5):839–46

Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Wheeler VC, et al. **Hum Mol Genet** 1999 Jan;8(1):115–22

A novel PCR-based approach for the detection of the Huntington disease associated trinucleotide repeat expansion. Panagopoulos I, et al. **Hum Mutat** 1999; 13(3):232–6

Adults seeking presymptomatic gene testing for Huntington disease. Williams JK, et al. **Image J Nurs Sch** 1999; 31(2):109–14

Analysis of the CAG repeat number in a patient with Huntington's disease. Kono Y, et al. **Intern Med** 1999 May; 38(5):407–11

Huntington disease: clinical, genetic, and social aspects. Nance MA. **J Geriatr Psychiatry Neurol** 1998 Summer; 11(2):61–70 (65 ref.)

Cloning, expression analysis, and chromosomal localization of HIP1R, an isolog of huntingtin interacting protein (HIP1). Seki N, et al. **J Hum Genet** 1998;43(4):268–71

Homozygosity in Huntington's disease [letter] Dürr A, et al. **J Med Genet** 1999 Feb;36(2):172–3

Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. Kehoe P, et al. **J Med Genet** 1999 Feb;36(2):108–11

Life without huntingtin: normal differentiation into functional neurons. Metzler M, et al. **J Neurochem** 1999 Mar; 72(3):1009–18

Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Reynolds GP, et al. **J Neurochem** 1999 Apr;72(4):1773–6

Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. Carter RJ, et al. **J Neurosci** 1999 Apr 15;19(8):3248–57

Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease. Yu P, et al. **Mamm Genome** 1999 Sep;10(9):845–52

Presymptomatic testing for Huntington's disease: the role of genetic counseling. Walsh A. **Med Health R I** 1999 May; 82(5):168–70 (12 ref.)

SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Sittler A, et al. **Mol Cell** 1998 Oct;2(4):427–36

Huntington's disease confirmed by genetic testing in five African families. Silber E, et al. **Mov Disord** 1998 Jul; 13(4):726–30

Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Reddy PH, et al. **Nat Genet** 1998 Oct;20(2):198–202

Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Sawa A, et al. **Nat Med** 1999 Oct; 5(10):1194–8

Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease. Canals JM, et al. **Neurobiol Dis** 1998 Nov;5(5):357–64

Larger CAG expansions in skeletal muscle compared with lymphocytes in Kennedy disease but not in Huntington disease. Ansved T, et al. **Neurology** 1998 Nov;51(5):1442–4

Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Nance MA, et al. **Neurology** 1999 Jan 15;52(2):392–4

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Hodgson JG, et al. **Neuron** 1999 May;23(1):181–92

Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Butterworth NJ, et al. **Neuroscience** 1998 Nov;87(1):49–53

Are there multiple pathways in the pathogenesis of Huntington's disease? Aronin N, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):995–1003 (61 ref.)

CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Frontali M, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1089–94 (38 ref.)

Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Hackam AS, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1047–55 (45 ref.)

Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. Harper PS. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):957–61

Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Lunkes A, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1013–9 (38 ref.)

Evidence for a recruitment and sequestration mechanism in Huntington's disease. Preisinger E, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1029–34

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Reddy PH, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1035–45

Polyglutamine pathogenesis. Ross CA, et al.

Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1005–11 (82 ref.)

Transgenic models of Huntington's disease. Sathasivam K, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):963–9 (36 ref.)

Non-disclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas. Braude PR, et al. **Prenat Diagn** 1998 Dec;18(13):1422–6 (17 ref.)

Preimplantation diagnosis for Huntington's disease (HD): clinical application and analysis of the HD expansion in affected embryos. Sermon K, et al. **Prenat Diagn** 1998 Dec; 18(13):1427–36

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid–induced striatal excitotoxicity. Hansson O, et al.
Proc Natl Acad Sci U S A 1999 Jul 20;96(15):8727–32

Course of distress experienced by persons at risk for an autosomal dominant inheritable disorder participating in a predictive testing program: an explorative study. Rotterdam/Leiden Genetics Workgroup. Dudok deWit AC, et al. **Psychosom Med** 1998 Sep–Oct;60(5):543–9

Nota bene: triplet repeat diseases. Innocent inclusions. Kelner KL. **Science** 1998 Oct 23;282(5389):643

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Huang CC, et al. **Somat Cell Mol Genet** 1998 Jul; 24(4):217–33

Recent advances in understanding the pathogenesis of Huntington's disease. Reddy PH, et al. **Trends Neurosci** 1999 Jun;22(6):248–55 (70 ref.)

[Transcriptional regulation of Huntington disease gene] Nagao Y, et al. **Nippon Rinsho** 1999 Apr;57(4):912–6 (8 ref.) (Eng. Abstr.) **(Jpn)**

[The function of Huntington disease gene product (huntingtin) and the pathomechanism of Huntington disease] Nukina N. **Nippon Rinsho** 1999 Apr;57(4):905–11 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Huntington's disease: clinical and molecular genetics] Warita H, et al. **Nippon Rinsho** 1999 Apr;57(4):896–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea] Vojvodić N, et al. **Srp Arh Celok Lek** 1998 Mar–Apr; 126(3–4):77–82 (Eng. Abstr.) **(Scc)**

[Huntington chorea: clniical and molecular analysis in Asturian patients] Hernando I, et al. **Neurologia** 1999 Jan; 14(1):11–5 (Eng. Abstr.) **(Spa)**

[Clinical and genetic implications of dynamic mutations in neuropediatric practice] Benitez J. **Rev Neurol** 1999 Jan 1–15;28(1):60–3 (8 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. Harper PS.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):957–61

IMMUNOLOGY

Activated immune system in patients with Huntington's disease. Leblhuber F, et al. **Clin Chem Lab Med** 1998 Oct; 36(10):747–50

METABOLISM

Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Tabrizi SJ, et al. **Ann Neurol** 1999 Jan; 45(1):25–32

Increased basal ganglia iron levels in Huntington disease. Bartzokis G, et al. **Arch Neurol** 1999 May;56(5):569–74

Polyglutamine expansion and Huntington's disease. Bates GP, et al. **Biochem Soc Trans** 1998 Aug;26(3):471–5 (38 ref.)

Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Sørensen SA, et al. **Cancer** 1999 Oct 1;86(7):1342–6

Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Goodchild RE, et al.
Eur J Neurosci 1999 Feb;11(2):449–56

Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Calabresi P, et al. **Exp Neurol** 1999 Jul;158(1):97–108

Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Sieradzan KA, et al. **Exp Neurol** 1999 Mar;156(1):92–9

In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hackam AS, et al. **Hum Mol Genet** 1999 Jan;8(1):25–33

Modeling protein homopolymeric repeats: possible polyglutamine structural motifs for Huntington's disease. Lathrop RH, et al. **Ismb** 1998;6:105–14

Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Reynolds GP, et al.
J Neurochem 1999 Apr;72(4):1773–6

Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. Fusco FR, et al.
J Neurosci 1999 Feb 15;19(4):1189–202

Molecular aspects of Huntington's disease. Walling HW, et al. **J Neurosci Res** 1998 Nov 1;54(3):301–8 (88 ref.)

PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease [published erratum appears in Neuroscience 1999;88(3):993] Utal AK, et al. **Neuroscience** 1998 Oct;86(4):1055–63

From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Davies SW, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):981–9

The localization and interactions of huntingtin. Jones AL.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1021–7 (65 ref.)

Evidence for a recruitment and sequestration mechanism in Huntington's disease. Preisinger E, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1029–34

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Karpuj MV, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7388–93

NURSING

Adults seeking presymptomatic gene testing for Huntington disease. Williams JK, et al. **Image J Nurs Sch** 1999; 31(2):109–14

PATHOLOGY

Does CAG repeat number predict the rate of pathological changes in Huntington's disease? [letter; comment] Rosenblatt A, et al. **Ann Neurol** 1998 Oct;44(4):708–9. Comment on: Ann Neurol 1997 May;41(5):689–92.

Full length huntingtin is not detected in intranuclear inclusions in Huntington's disease brain. Thomas P, et al.
Biochem Soc Trans 1998 Aug;26(3):S243

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia [see comments] Schapira AH.
Biochim Biophys Acta 1999 Feb 9;1410(2):159–70 (112 ref.) . Comment in: Biochim Biophys Acta 1999 Feb 9;1410(2):99–102.

Oxidative stress in Huntington's disease. Browne SE, et al.
Brain Pathol 1999 Jan;9(1):147–63 (105 ref.)

Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. O'Kusky JR, et al. **Brain Res** 1999 Feb 13;818(2):468–79

Glyceraldehyde 3-phosphate dehydrogenase abnormality in metabolically stressed Huntington disease fibroblasts. Cooper AJ, et al. **Dev Neurosci** 1998;20(4–5):462–8

Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Calabresi P, et al. **Exp Neurol** 1999 Jul;158(1):97–108

Striatal grafts in a rat model of Huntington's disease: time course comparison of MRI and histology. Guzman R, et al. **Exp Neurol** 1999 Mar;156(1):180–90

Regional specificity of brain atrophy in Huntington's disease. Halliday GM, et al. **Exp Neurol** 1998 Dec;154(2):663–72

Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Li H, et al. **Hum Mol Genet** 1999 Jul;8(7):1227–36

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May;8(5):943] Schilling G, et al. **Hum Mol Genet** 1999 Mar;8(3):397–407

Alzheimer-type lesions in Huntington's disease. Jellinger KA. **J Neural Transm** 1998;105(8–9):787–99

Huntington's disease and other choreas. Quinn N, et al.
J Neurol 1998 Nov;245(11):709–16 (76 ref.)

Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. Maat-Schieman ML, et al. **J Neuropathol Exp Neurol** 1999 Feb;58(2):129–37

Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. Sapp E, et al. **J Neuropathol Exp Neurol** 1999 Feb; 58(2):165–73

Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. Fusco FR, et al.
J Neurosci 1999 Feb 15;19(4):1189–202

Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. Gutekunst CA, et al.
J Neurosci 1999 Apr 1;19(7):2522–34

Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Hughes PE, et al. **Neuroscience** 1999;92(1):197–209

Are there multiple pathways in the pathogenesis of Huntington's disease? Aronin N, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):995–1003 (61 ref.)

Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Cha JH, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):981–9 (53 ref.)

Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain. Dorsman JC, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1061–7

Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Hackam AS, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1047–55 (45 ref.)

The localization and interactions of huntingtin. Jones AL.
Philos Trans R Soc Lond B Biol Sci 1999 Jun 29; 354(1386):1021–7 (65 ref.)

Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Scherzinger E, et al.
Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4604–9

Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease [corrected and republished in Psychiatry Res 1999 Feb 22;90(1):67–75] Dierks T, et al. **Psychiatry Res** 1998 Nov 9;84(1):27–35

PHYSIOPATHOLOGY

A non-familial Huntington's disease patient with grumose degeneration in the dentate nucleus. Ishikawa A, et al.
Acta Neurol Scand 1999 May;99(5):322–6

Analysis of gait abnormalities in Huntington disease. Reynolds NC Jr, et al. **Arch Phys Med Rehabil** 1999 Jan; 80(1):59–65

Motor learning by imagery is differentially affected in Parkinson's and Huntington's diseases. Yágüez L, et al.
Behav Brain Res 1999 Jul;102(1–2):115–27

Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)15O-PET. Boecker H, et al.
Brain 1999 Sep;122 (Pt 9):1651–65

Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Harris GJ, et al. **Brain** 1999 Sep;122 (Pt 9):1667–78

Is there a "subcortical" profile of attentional dysfunction? A comparison of patients with Huntington's and Parkinson's diseases on a global-local focused attention task. Roman MJ, et al. **J Clin Exp Neuropsychol** 1998 Dec;20(6):873–84

Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases. Hebb MO, et al. **J Comp Neurol** 1999 Jul 19;410(1):99–114

Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Bogdanov MB, et al.
J Neurochem 1998 Dec;71(6):2642–4

Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. Reynolds DS, et al. **J Neurosci** 1998 Dec 1; 18(23):10116–27

Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Georgiou N, et al. **Mov Disord** 1999 Mar;14(2):320–5

Neurophysiological abnormalities in the Westphal variant of Huntington's disease. Töpper R, et al. **Mov Disord** 1998 Nov;13(6):920–8

Cerebral blood flow velocity decreases during cognitive stimulation in Huntington's disease. Deckel AW, et al.
Neurology 1998 Dec;51(6):1576–83

Kinematic analysis of the reach to grasp movement in Parkinson's and Huntington's disease subjects. Bonfiglioli C, et al. **Neuropsychologia** 1998 Nov;36(11):1203–8

Transgenic models of Huntington's disease. Sathasivam K, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):963–9 (36 ref.)

Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Shear DA, et al.
Prog Neuropsychopharmacol Biol Psychiatry 1998 Oct; 22(7):1217–40

PSYCHOLOGY

Use of risperidone in psychosis associated with Huntington's disease [letter] Madhusoodanan S, et al.
Am J Geriatr Psychiatry 1998 Fall;6(4):347–9

A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease [see comments] Almqvist EW, et al. **Am J Hum Genet** 1999 May;64(5):1293–304. Comment in: Am J Hum Genet 1999 May;64(5):1289–92.

Outrageous fortune: the risk of suicide in genetic testing for Huntington disease [editorial; comment] Bird TD.
Am J Hum Genet 1999 May;64(5):1289–92. Comment on: Am J Hum Genet 1999 May;64(5):1293–304.

Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. Madhusoodanan S, et al. **Ann Clin Psychiatry** 1998 Sep;10(3):117–20

Striking changes in anxiety in Huntington's disease transgenic mice. File SE, et al. **Brain Res** 1998 Sep 14;805(1–2):234–40

Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature. Leroi I, et al.
Can J Psychiatry 1998 Nov;43(9):933–40 (65 ref.)

Predictive testing for Huntington's disease: I. Predictors of uptake in South Wales. Binedell J, et al. **Clin Genet** 1998 Dec;54(6):477–88

Predictive testing for Huntington's disease: II. Qualitative findings from a study of uptake in South Wales. Binedell

HUNTINGTON'S DISEASE

J, et al. **Clin Genet** 1998 Dec;54(6):489–96

The evaluation of the 'stages of change' model for use in counselling client's undergoing predictive testing for Huntington's disease. Houlihan GD. **J Adv Nurs** 1999 May; 29(5):1137–43 (38 ref.)

A test of odor fluency in patients with Alzheimer's and Huntington's disease. Bacon Moore AS, et al. **J Clin Exp Neuropsychol** 1999 Jun;21(3):341–51

The subcortical dementia of Huntington's disease. Zakzanis KK. **J Clin Exp Neuropsychol** 1998 Aug;20(4):565–78

Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. DudokdeWit AC, et al. **J Med Genet** 1998 Sep;35(9):745–54

Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls [see comments] Jensen P, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct; 65(4):467–71. Comment in: J Neurol Neurosurg Psychiatry 1998 Oct;65(4):435.

Crime in Huntington's disease [editorial; comment] Ring HA. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):435. Comment on: J Neurol Neurosurg Psychiatry 1998 Oct;65(4):467–71.

Micrographia in Huntington's disease [letter] Iwasaki Y, et al. **J Neurol Sci** 1999 Jan 1;162(1):106–7

The education of a brain transplant [comment] Marshall JF. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9976–8 (29 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10524–9.

Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Shear DA, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1217–40

RADIONUCLIDE IMAGING

Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. Boecker H, et al. **Brain** 1999 Sep;122 (Pt 9):1651–65

Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Andrews TC, et al. **Mol Med Today** 1998 Dec;4(12):532–9 (58 ref.)

Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease [corrected and republished article originally printed in Psychiatry Res 1998 Nov 9;84(1):27–35] Dierks T, et al. **Psychiatry Res** 1999 Feb 22;90(1):67–75

SURGERY

Neural transplantation of hNT neurons for Huntington's disease. Hurlbert MS, et al. **Cell Transplant** 1999 Jan–Feb; 8(1):143–51

Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1. Kaemmerer WF, et al. **Exp Neurol** 1999 Aug;158(2):301–11

Cerebral implantation in movement disorders: state of the art [editorial] Lindvall O. **Mov Disord** 1999 Mar;14(2):201–5 (48 ref.)

Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Nakao N, et al. **Neuroscience** 1999 Jan;88(2):469–77

THERAPY

Advances in Huntington's disease: implications for experimental therapeutics. Feigin A. **Curr Opin Neurol** 1998 Aug;11(4):357–62 (61 ref.)

Striatal transplantation in a transgenic mouse model of Huntington's disease. Dunnett SB, et al. **Exp Neurol** 1998 Nov;154(1):31–40

Reversible Huntington's disease--lesion to the globus pallidus? [letter; comment] Altschuler EL. **Lancet** 1999 Jan 16;353(9148):240–1. Comment on: Lancet 1998 Nov 7;352(9139):1520–1.

In vivo magnetic resonance spectroscopy of human fetal neural transplants. Ross BD, et al. **NMR Biomed** 1999 Jun; 12(4):221–36

The education of a brain transplant [comment] Marshall JF. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):9976–8 (29 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10524–9.

Prospectives for cell and gene therapy in Huntington's disease. Bachoud-Lévi AC, et al. **Prog Brain Res** 1998; 117:511–24 (117 ref.)

HURLER-SCHEIE SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

HURLER'S SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

HURRICANES see **NATURAL DISASTERS**

HURST DISEASE see **LEUKOENCEPHALITIS, ACUTE HEMORRHAGIC**

HUSBANDS see **SPOUSES**

HUTCHINSON-GILFORD SYNDROME see **PROGERIA**

HUTCHINSON'S MELANOTIC FRECKLE

CLASSIFICATION

Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Flotte TJ, et al. **Hum Pathol** 1999 May; 30(5):533–6

PATHOLOGY

Extrafacial lentigo maligna melanoma: analysis of 71 cases and comparison with lentigo maligna melanoma of the head and neck. Cox NH, et al. **Br J Dermatol** 1998 Sep; 139(3):439–43

Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Rocamora V, et al. **Cutis** 1999 Jul;64(1):53–6 (33 ref.)

Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Flotte TJ, et al. **Hum Pathol** 1999 May; 30(5):533–6

Amelanotic lentigo maligna and amelanotic lentigo maligna melanoma: a report of three cases mimicking intraepidermal squamous carcinoma. Allan SJ, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):78–81

Amelanotic lentigo maligna [letter] Sanz de Galdeano C, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):83–5

SURGERY

Lentigo maligna melanoma and excisional biopsy techniques [letter; comment] Meffert JJ, et al. **Am Fam Physician** 1999 Mar 1;59(5):1108, 1113, 1116. Comment on: Am Fam Physician 1998 Sep 15;58(4):873–84, 887–8.

Surgical treatment of lentigo maligna and lentigo maligna melanoma. Hill DC, et al. **Australas J Dermatol** 1999 Feb; 40(1):25–30 (16 ref.)

Q-switched neodymium:yttrium-aluminum-garnet laser treatment of lentigo maligna. Orten SS, et al. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):296–302

HUTCHINSON'S TEETH see **SYPHILIS, CONGENITAL**

HY ANTIGEN see **H-Y ANTIGEN**

HYAENIDAE see **CARNIVORA**

HYALIN

Hyalinizing clear cell carcinoma of the oral cavity and of the parotid gland. Rinaldo A, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Jan–Feb; 61(1):48–51

[Asteroid hyalosis--development and disappearance of asteroid bodies of the vitreous body] Pau H. **Klin Monatsbl Augenheilkd** 1999 May;214(5):aA20–3 **(Ger)**

[Juvenile hyaline fibromatosis] Adamicová K, et al. **Bratisl Lek Listy** 1998 Nov;99(11):587–96 (Eng. Abstr.) **(Slo)**

CHEMISTRY

The structures of alpha 2u-globulin and its complex with a hyaline droplet inducer. Chaudhuri BN, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):753–62

METABOLISM

Astrocytic hyaline inclusions contain advanced glycation endproducts in familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation: immunohistochemical and immunoelectron microscopical analyses. Kato S, et al. **Acta Neuropathol (Berl)** 1999 Mar; 97(3):260–6

Advanced glycation endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Shibata N, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):240–6

Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Stumptner C, et al. **Am J Pathol** 1999 Jun; 154(6):1701–10

Glassy hyaline globules in granular cell carcinoma, chromophobe cell carcinoma, and oncocytoma of the kidney. Hes O, et al. **Ann Diagn Pathol** 1998 Feb;2(1):12–8

Fine-needle aspiration biopsy cytology of hyalinizing trabecular adenomas of the thyroid. Akin MR, et al. **Diagn Cytopathol** 1999 Feb;20(2):90–4

Juvenile hyaline fibromatosis: a case report. Nunziata Rega A, et al. **J Pediatr Orthop B** 1998 Jul;7(3):235–8

A rat model of acute respiratory distress syndrome (ARDS): Part 1. Time dependency of histological and pathological changes. Germann PG, et al. **J Pharmacol Toxicol Methods** 1998 Aug;40(2):101–7

Ultrastructure of peritubular tissue in association with tubular hyalinization in human testis. Haider SG, et al. **Tissue Cell** 1999 Feb;31(1):90–8

Lysozyme-containing renal tubular hyaline droplets in F344 rats bearing a rat fibrosarcoma-derived transplantable tumor. Yamate J, et al. **Toxicol Pathol** 1998 Sep–Oct; 26(5):699–703

[Microstructure of subcutaneous lesions in juvenile hyaline fibromatosis] Adamicová K, et al. **Cesk Patol** 1998 Jul; 34(3):99–104 (Eng. Abstr.) **(Slo)**

[Hyalinizing trabecular adenoma of the thyroid] Hardisson Hernáez D, et al. **Acta Otorrinolaringol Esp** 1999 Apr; 50(3):243–6 (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

[Hyalin substance--is it irreparable...? (editorial)] Kohn D, et al. **Orthopade** 1999 Jan;28(1):3 **(Ger)**

ULTRASTRUCTURE

Micro-imaging of articular cartilage: T2, proton density, and the magic angle effect. Goodwin DW, et al. **Acad Radiol** 1998 Nov;5(11):790–8

HYALIN SUBSTANCE see **HYALIN**

HYALINE MEMBRANE DISEASE

BLOOD

Haemodynamic effects of altering arterial oxygen saturation in preterm infants with respiratory failure. Skinner JR, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F81–7

DRUG THERAPY

Seizures after inadvertent umbilical venous infusion of synthetic surfactant (Exosurf): cause or coincidence? [letter] Frey B, et al. **Eur J Pediatr** 1999 Jul;158(7):610

Improved outcome of extremely premature infants in the 1990s. Paranka MS, et al. **Mil Med** 1999 Aug;164(8):568–71

Tracheal aspirate surface tension in babies with hyaline membrane disease: effects of synthetic surfactant replacement. McMillan DD, et al. **Pediatr Pulmonol** 1998 Sep;26(3):173–82

PHYSIOPATHOLOGY

Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Ivy DD, et al. **Pediatr Res** 1998 Aug; 44(2):175–80

PREVENTION & CONTROL

Increased survival in low birth weight neonates given prophylactic surfactant. Brown DR, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):431–5

RADIOGRAPHY

New-born infants with severe hyaline membrane disease: radiological evaluation during high frequency oscillatory versus conventional ventilation. Helbich TH, et al. **Eur J Radiol** 1998 Oct;28(3):243–9

Radiological analysis of hyaline membrane disease after exogenous surfactant treatment. Slama M, et al. **Pediatr Radiol** 1999 Jan;29(1):56–60

THERAPY

Surfactant treatment may accelerate epithelial cell regeneration in hyaline membrane disease of the newborn. Gonda TA, et al. **Am J Perinatol** 1998;15(9):539–44

Randomised controlled trial of low dose fentanyl infusion in preterm infants with hyaline membrane disease. Lago P, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov; 79(3):F194–7

New-born infants with severe hyaline membrane disease: radiological evaluation during high frequency oscillatory versus conventional ventilation. Helbich TH, et al. **Eur J Radiol** 1998 Oct;28(3):243–9

Continuous tracheal gas insufflation enables a volume reduction strategy in hyaline membrane disease: technical aspects and clinical results. Dassieu G, et al. **Intensive Care Med** 1998 Oct;24(10):1076–82

Endotracheal continuous positive airway pressure after rescue surfactant therapy. Mandy GT, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):444–8

Airway rescue and drug delivery in an 800 g neonate with the laryngeal mask airway [letter] Brimacombe J, et al. **Paediatr Anaesth** 1999;9(2):178

[The effect of surfactant therapy on the oxygen treatment of premature infants with HMD] Iarúkova N. **Akush Ginekol (Sofiia)** 1998;37(1):3–5 (Eng. Abstr.) **(Bul)**

[For or against the early use of nasal continuous positive pressure and exogenous surfactant in hyaline membrane disease. Physiopathologic arguments] Storme L, et al. **Arch Pediatr** 1999 May;6(5):549–55 (60 ref.) (Eng. Abstr.) **(Fre)**

HYALINOSIS, SEGMENTAL see **GLOMERULOSCLEROSIS, FOCAL**

HYALURONAN-BINDING PROTEIN see **ANTIGENS, CD44**

HYALURONAN RECEPTORS see **ANTIGENS, CD44**

HYALURONIC ACID

Semisynthetic resorbable materials from hyaluronan

esterification. Campoccia D, et al. **Biomaterials** 1998 Dec; 19(23):2101–27 (174 ref.)

Hyaluronate–alginate gel as a novel biomaterial: mechanical properties and formation mechanism. Oerther S, et al. **Biotechnol Bioeng** 1999 Apr 20;63(2):206–15

Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Duranti F, et al. **Dermatol Surg** 1998 Dec;24(12):1317–25

In vitro release kinetics of gentamycin from a sodium hyaluronate gel delivery system suitable for the treatment of peripheral vestibular disease. Kelly RM, et al. **Drug Dev Ind Pharm** 1999 Jan;25(1):15–20

Diclofenac/hyaluronic acid. Peters DC, et al. **Drugs Aging** 1999 Apr;14(4):313–9; discussion 320–1 (26 ref.)

Hyaluronan and proteoglycans in ovarian follicles. Salustri A, et al. **Hum Reprod Update** 1999 Jul–Aug;5(4):293–301 (79 ref.)

Chondrocyte aggregation and reorganization into three–dimensional scaffolds. Brun P, et al. **J Biomed Mater Res** 1999 Sep 5;46(3):337–46

New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. Bulpitt P, et al. **J Biomed Mater Res** 1999 Nov;47(2):152–69

Polypeptide resurfacing method improves fibroblast's adhesion to hyaluronan strands. Hu M, et al. **J Biomed Mater Res** 1999 Oct;47(1):79–84

Comparison of the effects of viscoelastic agents on clinical properties of the Unfolder lens injection system. Myers TD, et al. **J Cataract Refract Surg** 1999 Jul;25(7):953–8

Reticulated hyaluronic acid implant in nonperforating trabecular surgery [see comments] Sourdille P, et al. **J Cataract Refract Surg** 1999 Mar;25(3):332–9. Comment in: J Cataract Refract Surg 1999 Mar;25(3):298–300.

Hyaluronic acid (with fibronectin) as a bioimplant for the vocal fold mucosa. Chan RW, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1142–9

Capsular hyaluronic acid of group A streptococci hampers their invasion into human pharyngeal epithelial cells. Kawabata S, et al. **Microb Pathog** 1999 Aug;27(2):71–80

Prevention of adhesion formation with use of sodium hyaluronate–based bioresorbable membrane in a rat model of ventral hernia repair with polypropylene mesh––a randomized, controlled study. Hooker GD, et al. **Surgery** 1999 Feb;125(2):211–6

[Clinical uses of medical hyaluronic acid] Gu Q, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):124–6 (26 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Reliability of the drop test for the lacrimal drainage function. Sahlin S, et al. **Acta Ophthalmol Scand** 1999 Aug; 77(4):381–5

Intra–articular hyaluronan treatment for osteoarthritis. George E. **Ann Rheum Dis** 1998 Nov;57(11):637–40

Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Duranti F, et al. **Dermatol Surg** 1998 Dec;24(12):1317–25

Clinical evaluation of 0.5% ferric hyaluronate adhesion prevention gel for the reduction of adhesions following peritoneal cavity surgery: open–label pilot study. Thornton MH, et al. **Hum Reprod** 1998 Jun;13(6):1480–5

Disc position and morphology in patients with nonreducing disc displacement treated by injection of sodium hyaluronate. Sato S, et al. **Int J Oral Maxillofac Surg** 1999 Aug;28(4):253–7

Intraarticular injection of sodium hyaluronate plus steroid versus steroid in adhesive capsulitis of the shoulder. Rovetta G, et al. **Int J Tissue React** 1998;20(4):125–30

Dispersive–cohesive viscoelastic soft shell technique. Arshinoff SA. **J Cataract Refract Surg** 1999 Feb; 25(2):167–73

Variation in the diffusion and release of ribonuclease through and from esterified hyaluronic acid membranes: effect of changes in matrix characteristics. Simon LD, et al. **J Controlled Release** 1999 Aug 27;61(1–2):159–64

Novel formulation of fibroblast growth factor–2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. Radomsky ML, et al. **J Orthop Res** 1999 Jul; 17(4):607–14

Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group [see comments] [published erratum appears in J Rheumatol 1999 May;26(5):1216] Altman RD, et al. **J Rheumatol** 1998 Nov; 25(11):2203–12. Comment in: J Rheumatol 1998 Nov;25(11):2056–8.

Intraperitoneal addition of hyaluronan improves peritoneal dialysis efficiency. Wang T, et al. **Perit Dial Int** 1999;19 Suppl 2:S106–11

[Non–perforating surgery of the trabeculum with reticulated hyaluronic acid implant: why, how, what results?] Sourdille P, et al. **J Fr Ophtalmol** 1999 Aug–Sep;22(7):794–7 **(Fre)**

[Corneal endothelial protection in phacoemulsification of high risk eyes with cornea guttata. Intra–individual comparison of 2 visco–elastic substances of different viscosity and molecular size] Schmidl B, et al. **Ophthalmologe** 1999 Jun;96(6):382–6 (Eng. Abstr.) **(Ger)**

[Effectiveness of intra–articular application of hyaluronic acid on early forms of femoropatellar arthrosis––an experimental study in dogs] Wenz W, et al. **Z Orthop Ihre Grenzgeb** 1998 Jul–Aug;136(4):298–303 (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Disla E, et al. **Arthritis Rheum** 1999 Jun;42(6):1302–3

Pyrophosphate arthritis after intraarticular injection of hyaluronan: comment on the article by Luzar and Altawil [letter; comment] Maillefert JF, et al. **Arthritis Rheum** 1999 Mar;42(3):594. Comment on: Arthritis Rheum 1998 May;41(5):939–40.

Post–operative myopic shift due to trapped intracapsular Healon [letter] Reck AC, et al. **Eye** 1998;12 (Pt 5):900–1

Suspected ciliary block associated with Viscoat use. Berger RR, et al. **J Cataract Refract Surg** 1999 Apr;25(4):594–6

ANALOGS & DERIVATIVES

Hyaluronic acid treatment (viscosupplementation) for OA of the knee. Cohen MD. **Bull Rheum Dis** 1998 Nov; 47(7):4–7 (15 ref.)

Hyaluronate derivatives in drug delivery. Vercruysse KP, et al. **Crit Rev Ther Drug Carrier Syst** 1998;15(5):513–55 (142 ref.)

Cartilage tissue engineering with novel nonwoven structured biomaterial based on hyaluronic acid benzyl ester. Aigner J, et al. **J Biomed Mater Res** 1998 Nov;42(2):172–81

Effects of interleukin–1 receptor antagonist in a slow–release hylan vehicle on rat type II collagen arthritis. Bendele A, et al. **Pharm Res** 1998 Oct;15(10):1557–61

Viscosupplementation: a new concept in the treatment of sacroiliac joint syndrome: a preliminary report of four cases. Srejic U, et al. **Reg Anesth Pain Med** 1999 Jan–Feb; 24(1):84–8

ANALYSIS

Histochemical study of hyaluronate in alcoholic liver disease. Urashima S, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4 Suppl):56S–60S

Quantification of hyaluronan and chondroitin/dermatan sulfates in the tissue sections on glass slides. Koshiishi I, et al. **Anal Biochem** 1999 Feb 1;267(1):222–6

Enzymatic method for the simultaneous determination of hyaluronan and chondroitin sulfates using high–performance liquid chromatography. Koshiishi I, et al. **Anal Biochem** 1998 Dec 1;265(1):49–54

Capillary electrophoresis of N–acetylneuraminic acid polymers and hyaluronic acid: correlation between migration order reversal and biological functions. Kakehi K, et al. **Anal Chem** 1999 Apr 15;71(8):1592–6

Separation and quantification by ion–association capillary zone electrophoresis of unsaturated disaccharide units of chondroitin sulfates and oligosaccharides derived from hyaluronan. Payan E, et al. **Anal Chem** 1998 Nov 15; 70(22):4780–6

Salivary and serum hyaluronic acid concentrations in patients with Sjögren's syndrome. Tishler M, et al. **Ann Rheum Dis** 1998 Aug;57(8):506–8

Histochemical localization of hyaluronan and versican in the rat molar dental pulp. Shibata S, et al. **Arch Oral Biol** 1999 Apr;44(4):373–6

Differences in the migration capacity of primary human colon carcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). Kubens BS, et al. **Cancer Lett** 1998 Sep 11;131(1):55–64

Localization of hyaluronan in pseudocapsule from total hip arthroplasty. Namba RS, et al. **Clin Orthop** 1999 Jun; (363):158–62

Distribution of hyaluronan and dermatan/chondroitin sulfate proteoglycans in human aortic dissection. Gutierrez PS, et al. **Connect Tissue Res** 1998;37(3–4):151–61

High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Söderblom T, et al. **Eur Respir J** 1999 Mar; 13(3):519–22

Hyaluronan and CD44 in the human cornea and limbal conjunctiva [letter] Lerner LE, et al. **Exp Eye Res** 1998 Oct;67(4):481–4

Histochemical localization of hyaluronic acid in vitreous during embryonic development. Bremer FM, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2466–9

Use of hyaluronic acid binding protein for detection of hyaluronan in ligature–induced periodontitis tissue. Shibutani T, et al. **J Periodontal Res** 1998 Jul;33(5):265–73

Lung hyaluronan and water content in preterm and term rabbit pups exposed to oxygen or air. Johnsson H, et al. **Pediatr Res** 1998 Nov;44(5):716–22

An increase in hyaluronan by lung fibroblasts: a biomarker for intensity and activity of interstitial pulmonary fibrosis? Zhao HW, et al. **Respirology** 1999 Jun;4(2):131–8

Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Hirvikoski P, et al. **Virchows Arch** 1999 Jan;434(1):37–44

[Determination of hyaluronic acid in the nucleus pulposis in acute and chronic degenerative intervertebral disk changes] Zöllner J, et al. **Z Orthop Ihre Grenzgeb** 1999 May–Jun;137(3):211–3 (Eng. Abstr.) **(Ger)**

[Hyaluronic acid concentrations in cell membranes are inversely proportional to histological grade and ploidy in infiltrating ductal carcinoma of the breast (letter)] Ruibal A, et al. **Rev Esp Med Nucl** 1998;17(4):310–1 **(Spa)**

BIOSYNTHESIS

CD44, bFGF and hyaluronan in human pancreatic cancer cell lines. Ringel J, et al. **Ann N Y Acad Sci** 1999 Jun 30; 880:238–42

Hyaluronan production in human rheumatoid fibroblastic synovial lining cells is increased by interleukin 1 beta but inhibited by transforming growth factor beta 1. Kawakami M, et al. **Ann Rheum Dis** 1998 Oct;57(10):602–5

Stimulation of hyaluronan synthesis by tumor necrosis factor–alpha is mediated by the p50/p65 NF–kappa B complex in MRC–5 myofibroblasts. Ohkawa T, et al. **Biochim Biophys Acta** 1999 Jan 11;1448(3):416–24

Oocytectomy does not influence synthesis of hyaluronic acid by pig cumulus cells: retention of hyaluronic acid after insulin–like growth factor–I treatment in serum–free medium. Nagyová E, et al. **Biol Reprod** 1999 Sep; 61(3):569–74

Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage–independent growth and tumorigenicity. Kosaki R, et al. **Cancer Res** 1999 Mar 1;59(5):1141–5

Cellular response and reactive hyaluronan production in UV–exposed rabbit corneas. Podskochy A, et al. **Cornea** 1998 Nov;17(6):640–5

HMC–1 mast cells activate human orbital fibroblasts in coculture: evidence for up–regulation of prostaglandin E2 and hyaluronan synthesis. Smith TJ, et al. **Endocrinology** 1999 Aug;140(8):3518–25

A two–component regulatory system, CsrR–CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Heath A, et al. **Infect Immun** 1999 Oct;67(10):5298–305

Characterization of a two–component system in Streptococcus pyogenes which is involved in regulation of hyaluronic acid production. Bernish B, et al. **J Biol Chem** 1999 Feb 19;274(8):4786–93

Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase–2 expression. Insights into potential pathogenic mechanisms of thyroid–associated ophthalmopathy. Cao HJ, et al. **J Biol Chem** 1998 Nov 6;273(45):29615–25

Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44–dependent pathway in vivo. Estess P, et al. **J Exp Med** 1999 Jul 5;190(1):9–19

Effects of diabetes and insulin treatment of diabetic rats on hyaluronan and hyaluronectin production in injured aorta. Chajara A, et al. **J Vasc Res** 1999 May–Jun;36(3):209–21

Regulation of proteoglycan and hyaluronan synthesis by elevated level of intracellular cyclic adenosine monophosphate in peritubular cells from immature rat testis. Thiébot B, et al. **Mol Cell Biochem** 1998 Oct; 187(1–2):99–112

Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Levin JC, et al. **Mol Microbiol** 1998 Oct; 30(1):209–19

Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Yamagata K, et al. **Perit Dial Int** 1999 Mar–Apr;19(2):131–7

Production and elimination of hyaluronan in rheumatoid arthritis patients: estimation with a loading test. Torsteinsdottir I, et al. **Semin Arthritis Rheum** 1999 Feb; 28(4):268–79

N–Methyl–L–serine stimulates hyaluronan production in human skin fibroblasts. Sakai S, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Sep–Oct; 12(5):276–83

Hyaluronan synthesis in virus PBCV–1–infected chlorella–like green algae. Graves MV, et al. **Virology** 1999 Apr 25;257(1):15–23

BLOOD

Hyperhyalurononanemia in alcoholic hepatitis is associated with increased levels of circulating soluble intercellular adhesion molecule–1. Hill DB, et al. **Alcohol Clin Exp Res** 1998 Sep; 22(6):1324–7

Increased serum concentration of hyaluronate in dermatomyositis patients. Kubo M, et al. **Arch Dermatol Res** 1998 Oct;290(10):579–81

Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Manicourt DH, et al. **Arthritis Rheum** 1999 Jun;42(6):1159–67

Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Dahl IM, et al. **Blood** 1999 Jun 15;93(12):4144–8

Dermatomyositis with elevated serum hyaluronate. Kubo M, et al. **Clin Exp Dermatol** 1999 Jul;24(4):275–8

Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. Rössler A, et al. **Eur J Appl Physiol** 1998 Nov;78(6):573–7

Serum hyaluronan as a predictor of hepatic regeneration after hepatectomy in humans. Ogata T, et al. **Eur J Clin Invest** 1999 Sep;29(9):780–5

Does laparoscopic cholecystectomy influence peri–sinusoidal

cell activity? Bendet N, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1603-6
Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. Ninomiya T, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):68-74
Effects of eating on plasma hyaluronan in patients with cirrhosis: its mechanism and influence on clinical interpretation. Wong CS, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1218-24
Elevated levels of hyaluronic acid in the sera of women with fibromyalgia [letter] Barkhuizen A, et al. **J Rheumatol** 1999 Sep;26(9):2063-4
The SHAP-HA complex in sera from patients with rheumatoid arthritis and osteoarthritis. Kida D, et al. **J Rheumatol** 1999 Jun;26(6):1230-8
Serum hyaluronic acid in Down's syndrome. Hutchin T, et al. **Mech Ageing Dev** 1998 Dec 1;106(1-2):155-60
Serum hyaluronic acid levels during pregnancy and labor. Kobayashi H, et al. **Obstet Gynecol** 1999 Apr;93(4):480-4
[Clinical study on relationship between liver-blood stasis and liver fibrosis] Tang ZM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb; 17(2):81-3 (Eng. Abstr.) **(Chi)**
[Adult T-cell leukemia with elevated serum hyaluronic acid levels paralleling disease activity] Sanada I, et al. **Rinsho Ketsueki** 1999 Jan;40(1):51-4 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation. Moriyama K, et al. **J Controlled Release** 1999 May 1;59(1):77-86

CHEMISTRY

New approaches to the investigation of hyaluronan networks. Hardingham T, et al. **Biochem Soc Trans** 1999 Feb; 27(2):124-7 (23 ref.)
The conformations of hyaluronan in aqueous solution: comparison of theory and experiment. Sheehan J, et al. **Biochem Soc Trans** 1999 Feb;27(2):121-4
Hyaluronate-alginate combination for the preparation of new biomaterials: investigation of the behaviour in aqueous solutions. Oerther S, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):185-94
Hydroxyapatite-collagen-hyaluronic acid composite. Bakos D, et al. **Biomaterials** 1999 Jan;20(2):191-5
An osteoconductive collagen/hyaluronate matrix for bone regeneration. Liu LS, et al. **Biomaterials** 1999 Jun; 20(12):1097-108
Degradation of hyaluronic acid, poly- and monosaccharides, and model compounds by hypochlorite: evidence for radical intermediates and fragmentation. Hawkins CL, et al. **Free Radic Biol Med** 1998 Jun;24(9):1396-410
Dynamic exchange between stabilized conformations predicted for hyaluronan tetrasaccharides: comparison of molecular dynamics simulations with available NMR data. Almond A, et al. **Glycobiology** 1998 Oct;8(10):973-80
Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. Knoflach A, et al. **J Am Soc Nephrol** 1999 May; 10(5):1059-66
Measurements of zeta potentials of particulate biomaterials in protein-rich hyaluronan solution with changes in pH and protein constituents. Kitano T, et al. **J Biomed Mater Res** 1998 Dec 5;42(3):453-7
Quantitative method to determine the cohesion of viscoelastic agents by dynamic aspiration. Poyer JF, et al. **J Cataract Refract Surg** 1998 Aug;24(8):1130-5
Molecular weight determination of hyaluronic acid by gel filtration chromatography coupled to matrix-assisted laser desorption ionization mass spectrometry. Yeung B, et al. **J Chromatogr A** 1999 Aug 13;852(2):573-81
Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. Prestwich GD, et al. **J Controlled Release** 1998 Apr 30;53(1-3):93-103
Deducing polymeric structure from aqueous molecular dynamics simulations of oligosaccharides: predictions from simulations of hyaluronan tetrasaccharides compared with hydrodynamic and X-ray fibre diffraction data. Almond A, et al. **J Mol Biol** 1998 Dec 18;284(5):1425-37
Characterization of the effect of high molecular weight hyaluronan on trans-synovial flow in rabbit knees. Coleman PJ, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):265-82
Hyaluronan forms specific stable tertiary structures in aqueous solution: a 13C NMR study. Scott JE, et al. **Proc Natl Acad Sci U S A** 1999 Apr 27;96(9):4850-5

DEFICIENCY

Primary open-angle glaucoma may be a hyaluronic acid deficiency disease: potential for glucosamine in prevention and therapy. McCarty MF. **Med Hypotheses** 1998 Dec; 51(6):483-4 (13 ref.)

ECONOMICS

[Cost-effectiveness of conservative therapy of knee joint osteoarthritis (see comments)] Allhoff P, et al. **Z Orthop Ihre Grenzgeb** 1998 Jul-Aug;136(4):288-92 (Eng. Abstr.). Comment in: Z Orthop Ihre Grenzgeb 1998 Jul-Aug;136(4):287. **(Ger)**

IMMUNOLOGY

Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. Moore AR, et al. **Int J Immunopharmacol** 1999 Mar;21(3):195-203
Activation and interaction of CD44 and hyaluronan in immunological systems. Siegelman MH, et al. **J Leukoc Biol** 1999 Aug;66(2):315-21 (49 ref.)

METABOLISM

Renomedullary interstitial cells regulate hyaluronan turnover depending on growth media osmolality suggesting a role in renal water handling. Hansell P, et al. **Acta Physiol Scand** 1999 Jan;165(1):115-6
Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD. Lai KN, et al. **Am J Kidney Dis** 1999 Feb;33(2):318-24
Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Evanko SP, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):1004-13
The structure and regulation of hyaluronan-binding proteins. Day AJ. **Biochem Soc Trans** 1999 Feb;27(2):115-21 (44 ref.)
New approaches to the investigation of hyaluronan networks. Hardingham T, et al. **Biochem Soc Trans** 1999 Feb; 27(2):124-7 (23 ref.)
The chondrocyte pericellular matrix: a model for hyaluronan-mediated cell-matrix interactions. Knudson CB, et al. **Biochem Soc Trans** 1999 Feb;27(2):142-7 (50 ref.)
Hyaluronic acid-receptor binding demonstrated by synthetic adhesive proteoglycan peptide constructs and by cell receptors on the marine sponge Microciona prolifera. Kuhns WJ, et al. **Biol Bull** 1998 Oct;195(2):216-8
Inter-alpha-inhibitor binding to hyaluronan in the cumulus extracellular matrix is required for optimal ovulation and development of mouse oocytes. Hess KA, et al. **Biol Reprod** 1999 Aug;61(2):436-43
Hyaluronan, hydration and flow conductivity of rat dermis. Bert J, et al. **Biorheology** 1998 May-Jun;35(3):211-9
Hyaluronan expression in gastric cancer cells is associated with local and nodal spread and reduced survival rate. Setälä LP, et al. **Br J Cancer** 1999 Mar;79(7-8):1133-8
Regulation of CD44-hyaluronan interactions in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid B cells by PMA and interleukin-4. Kryworuchko M, et al. **Cell Immunol** 1999 May 25; 194(1):54-66
TNFalpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Levesque MC, et al. **Cell Immunol** 1999 May 1; 193(2):209-18
Identification of two regions in the cytoplasmic domain of CD44 through which PMA, calcium, and foskolin differentially regulate the binding of CD44 to hyaluronic acid. Liu D, et al. **Cell Immunol** 1998 Dec 15;190(2):132-40
Immunolocalization of hyaluronic acid and inter-alpha-trypsin inhibitor in mice. Kobayashi H, et al. **Cell Tissue Res** 1999 Jun;296(3):587-97
CD44 expression and hyaluronic acid binding of malignant glioma cells. Knüpfer MM, et al. **Clin Exp Metastasis** 1999 Feb;17(1):71-6
Release of hyaluronan and laminin into pancreatic secretions. Löhr M, et al. **Digestion** 1999 Jan-Feb;60(1):48-55
Mechanism of adrenomedullin-stimulated hyaluronic acid release in rat mesangial cells. Parameswaran N, et al. **Eur J Pharmacol** 1999 Apr 16;370(3):313-8
Interferon-gamma inhibits CD44-hyaluronan interactions in normal human B lymphocytes. Kryworuchko M, et al. **Exp Cell Res** 1999 Jul 10;250(1):241-52
Rapid hyaluronan uptake is associated with enhanced motility: implications for an intracellular mode of action. Collis L, et al. **FEBS Lett** 1998 Dec 4;440(3):444-9
Hyaluronan in human and rat muscle spindles. Pedrosa-Domellöf F, et al. **Histochem Cell Biol** 1998 Aug; 110(2):179-82
CD3-mediated T cell activation is inhibited by anti-CD44 monoclonal antibodies directed to the hyaluronan-binding region. Sugiyama K, et al. **Immunol Invest** 1999 Mar-May; 28(2-3):185-200
Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Victor R, et al. **Int J Cancer** 1999 Jul 2;82(1):77-83
Hyaluronidases in tissue invasion. Csóka TB, et al. **Invasion Metastasis** 1997;17(6):297-311 (106 ref.)
SPACR, a novel interphotoreceptor matrix glycoprotein in human retina that interacts with hyaluronan. Acharya S, et al. **J Biol Chem** 1998 Nov 20;273(47):31599-606
Hyaluronan bound to CD44 on keratinocytes is displaced by hyaluronan decasaccharides and not hexasaccharides. Tammi R, et al. **J Biol Chem** 1998 Oct 30;273(44):28878-88
Immunolocalization of hyaluronan and CD44 in quiescent and proliferating human lens epithelial cells. Saika S, et al. **J Cataract Refract Surg** 1998 Sep;24(9):1266-70
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Banerji S, et al. **J Cell Biol** 1999 Feb 22;144(4):789-801
Intracellular localization of hyaluronan in proliferating cells. Evanko SP, et al. **J Histochem Cytochem** 1999 Oct; 47(10):1331-42
Cutting edge: an inducible sialidase regulates the hyaluronic acid binding ability of CD44-bearing human monocytes. Katoh S, et al. **J Immunol** 1999 May 1;162(9):5058-61
Hyaluronic acid-based polymers as cell carriers for tissue-engineered repair of bone and cartilage. Solchaga LA, et al. **J Orthop Res** 1999 Mar;17(2):205-13
Possible role of the 34-kilodalton hyaluronic acid-binding protein in visceral Leishmaniasis. Rao CM, et al. **J Parasitol** 1999 Aug;85(4):682-7
The SHAP-HA complex in sera from patients with rheumatoid arthritis and osteoarthritis. Kida D, et al. **J Rheumatol** 1999 Jun;26(6):1230-8
Intravitreal gas injection diminishes hyaluronic acid. Lincoff H, et al. **Klin Monatsbl Augenheilkd** 1999 Feb;214(2):100-2
Changes of tissue fluid hyaluronan (hyaluronic acid) in peripheral lymphedema. Liu NF, et al. **Lymphology** 1998 Dec;31(4):173-9
Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia coli. Banerji S, et al. **Protein Expr Purif** 1998 Dec; 14(3):371-81
[Changes of extracellular matrix components in bronchoalveolar lavage fluid in patients with idiopathic pulmonary fibrosis] Zhao H, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):457-60 (Eng. Abstr.) **(Chi)**
[Hyaluronan aggregating proteoglycans] Bobiński R, et al. **Postepy Biochem** 1998;44(3):245-51 (75 ref.) **(Pol)**
[Isolation and purification of a membrane hyaluronate-binding protein from embryonic human brain] Tkach VL, et al. **Ukr Biokhim Zh** 1998 Sep-Oct; 70(5):69-74 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Studies on the kinetics, metabolism and re-utilisation after intra-articular administration of hyaluronan to rabbits. Komatsu S, et al. **Arzneimittelforschung** 1999 May; 49(5):427-33
Uptake of hyaluronan in hepatic metastases after blocking of liver endothelial cell receptors. Mahteme H, et al. **Glycoconj J** 1998 Sep;15(9):935-9
Production and elimination of hyaluronan in rheumatoid arthritis patients: estimation with a loading test. Torsteinsdottir I, et al. **Semin Arthritis Rheum** 1999 Feb; 28(4):268-79

PHARMACOLOGY

The efficacy of hyaluronic acid foam as a middle ear packing agent in experimental tympanoplasty. Krupala JL, et al. **Am J Otol** 1998 Sep;19(5):546-50
Effects of hyaluronic acid on meniscal injury in rabbits. Suzuki Y, et al. **Arch Orthop Trauma Surg** 1998; 117(6-7):303-6
Production of prostanoids via increased cyclo-oxygenase-2 expression in human amnion cells in response to low molecular weight hyaluronic acid fragment. Kobayashi H, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):369-76
Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes: biological properties. Denuziere A, et al. **Biomaterials** 1998 Jul;19(14):1275-85
The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Till KJ, et al. **Cancer Res** 1999 Sep 1;59(17):4419-26
Impact of various glycosaminoglycans upon cAMP-dependent protein kinase. Dittmann J, et al. **Cell Biochem Funct** 1999 Mar;17(1):21-8
The effect of hyaluronan on mouse intramembranous osteogenesis in vitro. Pilloni A, et al. **Cell Tissue Res** 1998 Nov;294(2):323-33
Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury. Horton MR, et al. **Chest** 1999 Jul;116(1 Suppl):17S
Changes in the expression of c-myc, RB and tyrosine-phosphorylated proteins during proliferation of NIH 3T3 cells induced by hyaluronic acid. Moon SO, et al. **Exp Mol Med** 1998 Mar 31;30(1):29-33
A comparison of the effect of hyaluronic acid versus gentamicin on corneal epithelial healing. Stiebel-Kalish H, et al. **Eye** 1998;12 (Pt 5):829-33
High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. Neumann A, et al. **FEBS Lett** 1999 Jun 25;453(3):283-7
A novel method of endoscopic mucosal resection using sodium hyaluronate. Yamamoto H, et al. **Gastrointest Endosc** 1999 Aug;50(2):251-6
Effect of interleukin-3, interleukin 5 and hyaluronic acid on cultured eosinophils derived from human umbilical cord blood mononuclear cells. Ohashi H, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):44-50
Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. Coradini D, et al. **Int J Cancer** 1999 May 5;81(3):411-6
Hyaluronan activates mitogen-activated protein kinase via Ras-signaling pathway. Serbulea M, et al. **Int J Oncol** 1999 Apr;14(4):733-8
Hyaluronan induces monocyte chemoattractant protein-1

expression in renal tubular epithelial cells. Beck-Schimmer B, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2283-90

Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. Knoflach A, et al. **J Am Soc Nephrol** 1999 May; 10(5):1059-66

Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. Horton MR, et al. **J Biol Chem** 1998 Dec 25; 273(52):35088-94

Hyaluronic acid stimulates human fibroblast proliferation within a collagen matrix. Greco RM, et al. **J Cell Physiol** 1998 Dec;177(3):465-73

Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. Kawasaki K, et al. **J Cell Physiol** 1999 May; 179(2):142-8

Induction and regulation of macrophage metalloelastase by hyaluronan fragments in mouse macrophages. Horton MR, et al. **J Immunol** 1999 Apr 1;162(7):4171-6

Effects of hyaluronan on periosteal grafts for large full-thickness defects in rabbit articular cartilage. Katsumi A, et al. **J Orthop Sci** 1999;4(2):127-34

Bacteriostatic effects of hyaluronic acid. Pirnazar P, et al. **J Periodontol** 1999 Apr;70(4):370-4

Characterization of the effect of high molecular weight hyaluronan on trans-synovial flow in rabbit knees. Coleman PJ, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):265-82

Histomorphometric and biochemical effect of various hyaluronans on early osteoarthritis. Shimizu C, et al. **J Rheumatol** 1998 Sep;25(9):1813-9

Effect of hyaluronic acid on migration, proliferation and alpha-smooth muscle actin expression by cultured rat and human fibroblasts. Andreutti D, et al. **J Submicrosc Cytol Pathol** 1999 Apr;31(2):173-7

Hyaluronan decreases peritoneal fluid absorption: effect of molecular weight and concentration of hyaluronan. Wang T, et al. **Kidney Int** 1999 Feb;55(2):667-73

Hyaluronic acid enhances peripheral nerve regeneration in vivo. Wang KK, et al. **Microsurgery** 1998;18(4):270-5

Urinary trypsin inhibitor down-regulates hyaluronic acid fragment-induced prostanoid release in cultured human amnion cells by inhibiting cyclo-oxygenase-2 expression. Kobayashi H, et al. **Mol Hum Reprod** 1999 Jul;5(7):662-7

Regulation of hyaluronan-stimulated VCAM-1 expression in murine renal tubular epithelial cells. Schawalder A, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2130-6

The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta(IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Takahashi K, et al. **Osteoarthritis Cartilage** 1999 Mar;7(2):182-90

Hyaluronic acid suppresses the reduction of alpha2(VI) collagen gene expression caused by interleukin-1beta in cultured rabbit articular chondrocytes. Goto H, et al. **Tohoku J Exp Med** 1999 Jan;187(1):1-13

Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Knoflach A, et al. **Transplantation** 1999 Mar 27; 67(6):909-14

Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Iocono JA, et al. **Wound Repair Regen** 1998 Sep-Oct;6(5):442-8

Hyaluronic acid enhances induction of the acrosome reaction of human sperm through interaction with the PH-20 protein. Sabeur K, et al. **Zygote** 1998 May;6(2):103-11

PHYSIOLOGY

Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Henry CB, et al. **Am J Physiol** 1999 Aug; 277(2 Pt 2):H508-14

Hyaluronic acid and chemoattractant substance from follicular fluid: in vitro effect of human sperm migration. Sliwa L. **Arch Androl** 1999 Jul-Aug;43(1):73-6

Receptor for hyaluronan-mediated motility (RHAMM), a hyaladherin that regulates cell responses to growth factors. Cheung WF, et al. **Biochem Soc Trans** 1999 Feb; 27(2):135-42 (38 ref.)

Hyaluronan in joint cavitation. Ward AC, et al. **Biochem Soc Trans** 1999 Feb;27(2):128-35 (48 ref.)

Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Khaldoyanidi S, et al. **Blood** 1999 Aug 1;94(3):940-9

Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Pilarski LM, et al. **Blood** 1999 May 1; 93(9):2918-27

Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Itano N, et al. **Cancer Res** 1999 May 15;59(10):2499-504

Hyaluronan and proteoglycans in ovarian follicles. Salustri A, et al. **Hum Reprod Update** 1999 Jul-Aug;5(4):293-301 (79 ref.)

Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. Hayen W, et al. **J Cell Sci** 1999 Jul;112 (Pt 13):2241-51

During human thymic development, beta 1 integrins regulate adhesion, motility, and the outcome of RHAMM/hyaluronan engagement. Gares SL, et al. **J Leukoc Biol** 1998 Dec;64(6):781-90

The hyaluronic acid receptor is induced by stretch injury of rat bladder in vivo and influences smooth muscle cell contraction in vitro. Bägli DJ, et al. **J Urol** 1999 Sep;162(3 Pt 1):832-40

The role of low molecular weight hyaluronic acid contained in Wharton's jelly in necrotizing funisitis. Kanayama N, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):510-4

Functions of hyaluronan in wound repair. Chen WY, et al. **Wound Repair Regen** 1999 Mar-Apr;7(2):79-89 (105 ref.)

[Role of hyaluronic acid in the arterial response to angioplasty] Chajara A, et al. **Pathol Biol (Paris)** 1998 Sep; 46(7):561-70 (55 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Quantitative alterations of hyaluronan and dermatan sulfate in the hairless mouse dorsal skin exposed to chronic UV irradiation. Koshiishi I, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):327-33

THERAPEUTIC USE

Cross-linked hyaluronan (Hylan B gel): a new injectable remedy for treatment of vocal fold insufficiency--an animal study. Hallén L, et al. **Acta Otolaryngol (Stockh)** 1999 Jan; 119(1):107-11

Prevention of intra-abdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model. Reijnen MM, et al. **Arch Surg** 1999 Sep;134(9):997-1001

Hyaluronic acid treatment (viscosupplementation) for OA of the knee. Cohen MD. **Bull Rheum Dis** 1998 Nov; 47(7):4-7 (15 ref.)

Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Menzel EJ, et al. **Cancer Lett** 1998 Sep 11;131(1):3-11 (56 ref.)

Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Frizziero L, et al. **Clin Exp Rheumatol** 1998 Jul-Aug; 16(4):441-9

Effects of hyaluronic acid on cartilage degradation. Uebelhart D, et al. **Curr Opin Rheumatol** 1999 Sep; 11(5):427-35 (52 ref.)

Dehydroepiandrosterone sulphate promotes hyaluronic acid-induced cervical ripening in rabbits. Belayet HM, et al. **Hum Reprod** 1999 May;14(5):1361-7

Adhesion preventive effect of hyaluronic acid after intraperitoneal surgery in mice. Sawada T, et al. **Hum Reprod** 1999 Jun;14(6):1470-2

Biochemical effect of intra-articular injections of high molecular weight hyaluronate in rheumatoid arthritis patients. Matsuno H, et al. **Inflamm Res** 1999 Mar; 48(3):154-9

Inclusive references [letter; comment] Kremer I. **J Cataract Refract Surg** 1999 Feb;25(2):160. Comment on: J Cataract Refract Surg 1997 Dec;23(10):1449-53. Comment on: J Cataract Refract Surg 1998 Jun;24(6):827-33.

The effect of a new tear substitute containing glycerol and hyaluronate on keratoconjunctivitis sicca. Solomon A, et al. **J Ocul Pharmacol Ther** 1998 Dec;14(6):497-504

Viscosupplementation for osteoarthritis: current status, unresolved issues, and future directions [editorial; comment] Marshall KW. **J Rheumatol** 1998 Nov; 25(11):2056-8 (14 ref.). Comment on: J Rheumatol 1998 Nov;25(11):2203-12.

New horizons in the treatment of osteoarthritis of the knee. LaPrade RF, et al. **JAMA** 1999 Mar 10;281(10):876-8

Use of hyaluronic acid and cultured autologous keratinocytes and fibroblasts in extensive burns [letter] Harris PA, et al. **Lancet** 1999 Jan 2;353(9146):35-6

Hyaluronic acid treatment for osteoarthritis of the knee. Leslie M. **Nurse Pract** 1999 Jul;24(7):38, 41-8 (32 ref.)

Use of viscoelastics post-trabeculectomy: a survey of members of the American Glaucoma Society. Salvo EC Jr, et al. **Ophthalmic Surg Lasers** 1999 Apr;30(4):271-5

Healing large tympanic membrane perforations using hyaluronic acid, basic fibroblast growth factor, and epidermal growth factor. Chauvin K, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):43-7

Hyaluronate, tetrachlorodecaoxide, and galactolipid prevent adhesions after implantation of Gore-Tex and dura mater into the abdominal wall in rats. Schier F, et al. **Pediatr Surg Int** 1999;15(3-4):255-9

The lubricating ability of biomembrane models with dipalmitoyl phosphatidylcholine and gamma-globulin. Higaki H, et al. **Proc Inst Mech Eng [H]** 1998;212(5):337-46

Viscosupplementation therapy with intra-articular hyaluronic acid. Fact or fantasy? Simon LS. **Rheum Dis Clin North Am** 1999 May;25(2):345-57 (20 ref.)

Hyaluronic acid in the treatment of osteoarthritis of the knee. Huskisson EC, et al. **Rheumatology (Oxford)** 1999 Jul; 38(7):602-7

[The use of viscoelastic compounds in cataract surgery] Stefan C, et al. **Oftalmologia** 1998;44(3):32-5 (17 ref.) (Eng. Abstr.) **(Rum)**

ULTRASTRUCTURE

Tapping mode atomic force microscopy of hyaluronan: extended and intramolecularly interacting chains. Cowman MK, et al. **Biophys J** 1998 Oct;75(4):2030-7

Hyaluronic acid by atomic force microscopy. Jacoboni I, et al. **J Struct Biol** 1999 Jun 1;126(1):52-8

URINE

A competitive enzyme-linked immunosorbent assay-like method for the measurement of urinary hyaluronan. Maeda H, et al. **Biosci Biotechnol Biochem** 1999 May;63(5):892-5

HYALURONIDASE see **HYALURONOGLUCOSAMINIDASE**

HYALURONOGLUCOSAMINIDASE

Cluster of diplopia cases after periocular anesthesia without hyaluronidase. Brown SM, et al. **J Cataract Refract Surg** 1999 Sep;25(9):1245-9

ADMINISTRATION & DOSAGE

Sub-Tenon's block: the effect of hyaluronidase on speed of onset and block quality. Guise P, et al. **Anaesth Intensive Care** 1999 Apr;27(2):179-81

Adjuvant therapy with hyaluronidase prior to excision of dermatofibrosarcoma protuberans. Menon P, et al. **Dermatol Surg** 1999 Mar;25(3):205-9

Pulsatile ocular blood flow and intraocular pressure during retrobulbar injection of lignocaine: influence of additives. Hulbert MF, et al. **J Glaucoma** 1998 Dec;7(6):413-6

[Lymphotherapy of early postoperative period in intraocular cataract correction] Bocharov VE, et al. **Vestn Oftalmol** 1999 Jan-Feb;115(1):22-4 (Eng. Abstr.) **(Rus)**

ANALYSIS

Examination of synovial fluid and serum hyaluronidase activity as a joint marker in rheumatoid arthritis and osteoarthritis patients (by zymography). Nagaya H, et al. **Ann Rheum Dis** 1999 Mar;58(3):186-8

ANTAGONISTS & INHIBITORS

[Inhibitory effects of natural medicines on the enzymes related to the skin] Sawabe Y, et al. **Yakugaku Zasshi** 1998 Sep;118(9):423-9 (Eng. Abstr.) **(Jpn)**

[Surveillance of phytotherapeutic drugs in the state of Minas Gerais. Quality assessment of commercial samples of chamomile] Brandão MGL, et al. **Cad Saude Publica** 1998 Jul-Sep;14(3):613-6 (Eng. Abstr.) **(Por)**

BLOOD

Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers. Muckenschnabel I, et al. **Cancer Lett** 1998 Sep 11;131(1):13-20

CHEMISTRY

Enzymatic reconstruction of a hybrid glycosaminoglycan containing 6-sulfated, 4-sulfated, and unsulfated N-acetylgalactosamine. Takagaki K, et al. **Biochem Biophys Res Commun** 1999 May 19;258(3):741-4

CLASSIFICATION

Hyaluronidases in tissue invasion. Csóka TB, et al. **Invasion Metastasis** 1997;17(6):297-311 (106 ref.)

GENETICS

Structural organization and chromosomal localization of Hyal2, a gene encoding a lysosomal hyaluronidase. Strobl B, et al. **Genomics** 1998 Oct 15;53(2):214-9

Novel immunogenic antigen homologous to hyaluronidase in meningioma. Heckel D, et al. **Hum Mol Genet** 1998 Nov; 7(12):1859-72

Expression profile of hyaluronidase mRNA transcripts in the kidney and in renal cells. Sun L, et al. **Kidney Blood Press Res** 1998;21(6):413-8

Expression pattern of a novel hyaluronidase during Xenopus embryogenesis. Hyde CE, et al. **Mech Dev** 1999 Apr; 82(1-2):213-7

Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Triggs-Raine B, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6296-300

Cloning and characterization of the cDNA encoding the PH20 protein in the European red fox Vulpes vulpes. ten Have J, et al. **Reprod Fertil Dev** 1998;10(2):165-72

ISOLATION & PURIFICATION

Expression and activity of articular cartilage hyaluronidases. Flannery CR, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):824-9

Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Lokeshwar VB, et al. **Cancer Res** 1999 Sep 1;59(17):4464-70

METABOLISM

Activation and inhibition of human cancer cell hyaluronidase by proteins. Maingonnat C, et al. **Anal Biochem** 1999 Mar 1;268(1):30-4

A plasma membrane-associated hyaluronidase is localized to the posterior acrosomal region of stallion sperm and is associated with spermatozoal function. Meyers SA, et al. **Biol Reprod** 1999 Aug;61(2):444-51

HYALURONOGLUCOSAMINIDASE

Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Victor R, et al. **Int J Cancer** 1999 Jul 2;82(1):77–83

Hyaluronidases in tissue invasion. Csóka TB, et al. **Invasion Metastasis** 1997;17(6):297–311 (106 ref.)

Changes in hyaluronidase, acrosin, and N-acetylhexosaminidase activities of dog sperm after incubation. Kawakami E, et al. **J Vet Med Sci** 1999 Feb; 61(2):183–4

Biochemical maturation of Spam1 (PH-20) during epididymal transit of mouse sperm involves modifications of N-linked oligosaccharides. Deng X, et al. **Mol Reprod Dev** 1999 Feb;52(2):196–206

PH-20 but not acrosin is involved in sperm penetration of the macaque zona pellucida. Yudin AI, et al. **Mol Reprod Dev** 1999 Jul;53(3):350–62

Association of hyaluronidase and breast adenocarcinoma invasiveness. Madan AK, et al. **Oncol Rep** 1999 May–Jun; 6(3):607–9

Activity of hyaluronidase in placental tissues from cows with and without retained fetal membranes. Kankofer M, et al. **Zentralbl Veterinarmed A** 1998 Sep;45(6–7):337–41

PHARMACOLOGY

Use of a plant enzyme preparation (Coronase) instead of hyaluronidase for cumulus cell removal before intracytoplasmic sperm injection. Parinaud J, et al. **Hum Reprod** 1998 Jul;13(7):1933–5

Effects of hyaluronan lyase, hyaluronidase, and chondroitin ABC lyase on mammalian vitreous gel. Bishop PN, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2173–8

Hyaluronidase treatment and preimplantation development of mouse embryos. Tachibe T, et al. **Lab Anim Sci** 1998 Jun;48(3):298–9

Effect of hyaluronidase on albumin diffusion in lung interstitium. Qiu XL, et al. **Lung** 1999;177(5):273–88

Effect of concentration and hyaluronidase on albumin diffusion across rabbit mesentery. Parameswaran S, et al. **Microcirculation** 1999 Jun;6(2):117–26

Repeated additions of hyaluronan alters granulation tissue deposition in sponge implants in mice. Iocono JA, et al. **Wound Repair Regen** 1998 Sep–Oct;6(5):442–8

[Effect of hyaluronidase on porcine pancreatic elastase-induced lung injury] Murakami H, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):577–84 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Chang NS. **Int J Mol Med** 1998 Dec;2(6):653–9 (53 ref.)

SECRETION

Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells. Lokeshwar VB, et al. **Cancer Lett** 1998 Sep 11;131(1):21–7

THERAPEUTIC USE

The impact of extracellular matrix on chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy [editorial] Baumgartner G. **Cancer Lett** 1998 Sep 11; 131(1):1–2

The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Baumgartner G, et al. **Cancer Lett** 1998 Sep 11;131(1):85–99

Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Brekken C, et al. **Cancer Lett** 1998 Sep 11;131(1):65–70

p53 overexpression and downregulation of inter-alpha-inhibitor are associated with hyaluronidase enhancement of TNF cytotoxicity in L929 fibroblasts. Chang NS, et al. **Cancer Lett** 1998 Sep 11;131(1):45–54

Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase. Haselsberger K, et al. **Cancer Lett** 1998 Sep 11; 131(1):109–11

Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Menzel EJ, et al. **Cancer Lett** 1998 Sep 11;131(1):3–11 (56 ref.)

Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Pillwein K, et al. **Cancer Lett** 1998 Sep 11;131(1):101–8

Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. St. Croix B, et al. **Cancer Lett** 1998 Sep 11;131(1):35–44 (48 ref.)

Pretreatment with intralesional hyaluronidase prior to excision of dermatofibrosarcoma protuberans. Smith K, et al. **Cancer Lett** 1998 Sep 11;131(1):117–26

Percutaneous epidural neuroplasty: prospective evaluation of 0.9% NaCl versus 10% NaCl with or without hyaluronidase [see comments] Heavner JE, et al. **Reg Anesth Pain Med** 1999 May–Jun;24(3):202–7. Comment in: Reg Anesth Pain Med 1999 May–Jun;24(3):198–201.

Hyaluronidase ameliorates rejection-induced edema. Johnsson C, et al. **Transpl Int** 1999;12(4):235–43

HYBRID CELLS

Point and interval estimates of marker location in radiation hybrid mapping. Stringham HM, et al. **Am J Hum Genet** 1999 Aug;65(2):545–53

Chromosome engineering: generation of mono- and dicentric isochromosomes in a somatic cell hybrid system. Higgins AW, et al. **Chromosoma** 1999 Aug;108(4):256–65

RNA polymerase I transcription in a Brassica interspecific hybrid and its progenitors: Tests of transcription factor involvement in nucleolar dominance. Frieman M, et al. **Genetics** 1999 May;152(1):451–60

Karyotype analysis of interspecific rat/mouse somatic cell hybrids by reverse chromosome painting. Helou K, et al. **Hereditas** 1998;129(1):91–4

Comparative mapping of 18 equine type I genes assigned by somatic cell hybrid analysis. Caetano AR, et al. **Mamm Genome** 1999 Mar;10(3):271–6

Construction and optimization of a dog whole-genome radiation hybrid panel. Vignaux F, et al. **Mamm Genome** 1999 Sep;10(9):888–94

Zebrafish/mouse somatic cell hybrids for the characterization of the zebrafish genome. Ekker M, et al. **Methods Cell Biol** 1999;60:303–21 (26 ref.)

Construction and characterization of zebrafish whole genome radiation hybrids. Kwok C, et al. **Methods Cell Biol** 1999; 60:287–302 (12 ref.)

Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: developing the first mouse model of mitochondrial DNA disease. Marchington DR, et al. **Nat Med** 1999 Aug;5(8):957–60

Identification of fragments of human transcripts froma defined chromosomal region: representational difference analysis of somatic cell hybrids. Groot PC, et al. **Nucleic Acids Res** 1998 Oct 1;26(19):4476–81

The radiation hybrid database. Rodriguez-Tomé P, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):115–8

Gene targeting and somatic cell genetics--a rebirth or a coming of age? Sedivy JM, et al. **Trends Genet** 1999 Mar; 15(3):88–90 (24 ref.)

CHEMISTRY

Modified giemsa-11 staining protocol for chromosomes of human and hybrid cells. Stein CK. **Somat Cell Mol Genet** 1998 May;24(3):191–5

CYTOLOGY

Expression and localization of hepatocyte domain-specific plasma membrane proteins in hepatoma x fibroblast hybrids and in hepatoma dedifferentiated variants. Bender V, et al. **J Cell Sci** 1998 Nov;111 (Pt 22):3437–50

Claim of human-cow embryo greeted with skepticism [news] Marshall E. **Science** 1998 Nov 20;282(5393):1390–1

Plasticity of cell fate: insights from heterokaryons. Blau HM, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):267–72 (57 ref.)

Use of somatic cell fusion to reprogram globin genes. Broyles RH. **Semin Cell Dev Biol** 1999 Jun;10(3):259–65 (35 ref.)

DRUG EFFECTS

Activities of enzymes of acetyl-CoA and acetylcholine metabolism in SN56 hybrid cholinergic cell line differentiated by dibutyryl cyclic AMP and all-trans retinoic acid. Jankowska A, et al. **Folia Neuropathol** 1997; 35(4):247–9

Mutation in mammalian cells in vitro and in vivo as indicators of exposure to carcinogens. van Zeeland AA, et al. **IARC Sci Publ** 1999;(146):355–65 (48 ref.)

Inhibition of ATP-induced cAMP formation by 5'-p-fluorosulfonylbenzoyladenosine in NG108-15 cells. Ohkubo S, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Aug; 358(2):153–9

METABOLISM

Radiation hybrid mapping of the two highly homologous human-variant pMCHL genes by PCR-SSCP. Miller CL, et al. **Genome Res** 1998 Jul;8(7):737–40

Parallel radiation hybrid mapping: a powerful tool for high-resolution genomic comparison. Yang YP, et al. **Genome Res** 1998 Jul;8(7):731–6

Long-range chromatin reorganization of the human serpin gene cluster at 14q32.1 accompanies gene activation and extinction in microcell hybrids. Rollini P, et al. **Genomics** 1999 Feb 15;56(1):22–30

Characterization of the phosphoinositide-linked dopamine receptor in a mouse hippocampal-neuroblastoma hybrid cell line. Jin LQ, et al. **J Neurochem** 1998 Nov; 71(5):1935–43

Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids. Isfort RJ, et al. **Mol Carcinog** 1999 May; 25(1):30–41

Melanoma x macrophage fusion hybrids acquire increased melanogenesis and metastatic potential: altered N-glycosylation as an underlying mechanism. Sodi SA, et al. **Pigment Cell Res** 1998 Oct;11(5):299–309

Plasticity of cell fate: insights from heterokaryons. Blau HM, et al. **Semin Cell Dev Biol** 1999 Jun;10(3):267–72 (57 ref.)

Reprogramming a somatic nucleus by trans-modification activity in germ cells. Surani MA. **Semin Cell Dev Biol** 1999 Jun;10(3):273–7 (16 ref.)

Mouse-human somatic cell hybrids: loss of mouse and human chromosomes. Wang X, et al. **Somat Cell Mol Genet** 1998 May;24(3):165–71

PATHOLOGY

Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. Mendonca MS, et al. **Cancer Res** 1999 Aug 15;59(16):3972–9

PHYSIOLOGY

Assignment1 of the CD59 gene to pig chromosome band 2p17-->p14 with somatic cell hybrids. Garrido JJ, et al. **Cytogenet Cell Genet** 1998;83(1–2):86–7

Transcription factor effects on chromosome constitution of cell hybrids. Hines MD, et al. **Cytogenet Cell Genet** 1998; 83(1–2):64–72

Human DXYS156 of pentanucleotide repeat (TAAAA)n: chromosomal localization by somatic hybrid mapping and sequencing analysis. Kim HS, et al. **Cytogenet Cell Genet** 1998;83(1–2):54–5

The structural and functional polarity of the hepatic human/rat hybrid WIF-B is a stable and dominant trait. Bender V, et al. **Hepatology** 1999 Oct;30(4):1002–10

Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Perrem K, et al. **Oncogene** 1999 Jun 3;18(22):3383–90

RADIATION EFFECTS

Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells. Mendonca MS, et al. **Cancer Res** 1999 Aug 15;59(16):3972–9

Evidence for a role of delayed death and genomic instability in radiation-induced neoplastic transformation of human hybrid cells. Mendonca MS, et al. **Int J Radiat Biol** 1998 Dec;74(6):755–64 (84 ref.)

Isolation and radiation hybrid mapping of a highly polymorphic CA repeat sequence at the human nuclear factor kappa-beta subunit 1 (NFKB1) locus. Ota N, et al. **J Hum Genet** 1999;44(2):129–30

A high-resolution radiation hybrid map of the proximal region of rat chromosome 4. al-Majali KM, et al. **Mamm Genome** 1999 May;10(5):471–6

[Statistical methods of radiation hybrid mapping: analysis of a small number of genes] Svishcheva GR, et al. **Genetika** 1999 Mar;35(2):392–9 (Eng. Abstr.) **(Rus)**

[Statistical methods of radiation hybrid mapping: selective models] Svishcheva GR. **Genetika** 1999 Jan;35(1):95–100 (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Swerdlow RH, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):701–4

Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss. Jox A, et al. **Cancer Res** 1998 Nov 1;58(21):4930–9

HYBRID VIGOR

Preweaning growth traits for Senepol, Hereford, and reciprocal crossbred calves and feedlot performance and carcass characteristics of steers. Chase CC Jr, et al. **J Anim Sci** 1998 Dec;76(12):2967–75

Heterosis and developmental stability of body and organ weights at hatch for parental line broiler breeders and specific crosses among them. Yang A, et al. **Poult Sci** 1999 Jul;78(7):942–8

GENETICS

An approach for predicting heterosis based on an additive, dominance and additive x additive model with environment interaction. Xu ZC, et al. **Heredity** 1999 May;82 (Pt 5):510–7

HYBRIDIZATION

Crosses between diabetic BB/OK and wild rats confirm that a third gene is essential for diabetes development. Klöting I, et al. **Acta Diabetol** 1998 Jul;35(2):109–11

In vitro promastigote fitness of putative Leishmania (Viannia) braziliensis/Leishmania (Viannia) peruviana hybrids. Torrico MC, et al. **Acta Trop** 1999 Jan 15;72(1):99–110

Meiosis of wheat x lymegrass hybrids. Anamthawat-Jónsson K, et al. **Chromosome Res** 1998 Aug;6(5):339–43

Introgression through rare hybridization: A genetic study of a hybrid zone between red and sika deer (genus Cervus) in Argyll, Scotland. Goodman SJ, et al. **Genetics** 1999 May; 152(1):355–71

Hybridization between wapiti (Cervus elephus manitobensis) and sika deer (Cervus nippon): a comparison of two artificial insemination techniques. Willard ST, et al. **J Zoo Wildl Med** 1998 Sep;29(3):295–9

Possible hybridization of Brazilian planorbid snails and its importance in population dynamics. Mello-Silva CC, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:227–32

Interspecific hybridization increases transposition rates of Osvaldo. Labrador M, et al. **Mol Biol Evol** 1999 Jul; 16(7):931–7
Genetic evidence for a recent origin by hybridization of red wolves. Reich DE, et al. **Mol Ecol** 1999 Jan;8(1):139–44
Why quasi-persons are not patentable [letter] Lebovitz RM. **Nature** 1999 Aug 12;400(6745):610
Experimental evidence of hybrid breakdown between genetically distinct populations of Echinostoma caproni. Trouvé S, et al. **Parasitology** 1998 Aug;117 (Pt 2):133–5
Hybridizing Old and New World camelids: Camelus dromedarius x Lama guanicoe. Skidmore JA, et al. **Proc R Soc Lond B Biol Sci** 1999 Apr 7;266(1420):649–56
[Inheritance of quantitative traits in hybrid pedigrees: mixed models] Aksenovich TI. **Genetika** 1999 Apr;35(4):530–9 (Eng. Abstr.) **(Rus)**
[Genetic control of isolating mechanisms in the genus Drosophila] Mitrofanov VG, et al. **Genetika** 1998 Sep; 34(9):1189–99 (Eng. Abstr.) **(Rus)**
[Alkaline phosphatase in Drosophila melanogaster strains differing in male mating activity and their F1 hybrids] Sukhanova MZh, et al. **Genetika** 1998 Sep;34(9):1239–42 (Eng. Abstr.) **(Rus)**

GENETICS

Does hybrid lethality depend on sex or genotype? [letter] Orr HA. **Genetics** 1999 Aug;152(4):1767–9
Hybrid zones and the genetic architecture of a barrier to gene flow between two sunflower species. Rieseberg LH, et al. **Genetics** 1999 Jun;152(2):713–27
Assisted suicide of a selfish gene. Thomson MS, et al. **J Hered** 1999 Jan–Feb;90(1):191–4
Nuclear ribosomal DNA (nrDNA) concerted evolution in natural and artificial hybrids of Armeria (Plumbaginaceae). Fuertes Aguilar J, et al. **Mol Ecol** 1999 Aug;8(8):1341–6
Amplified fragment length polymorphism (AFLP) reveals introgression in weedy Onopordum thistles: hybridization and invasion. O'Hanlon PC, et al. **Mol Ecol** 1999 Aug; 8(8):1239–46
Origin of a new Phytophthora pathogen through interspecific hybridization. Brasier CM, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5878–83
Spontaneous heterosis in larval life-history traits of hemiclonal frog hybrids. Hotz H, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2171–6
Tandem constructs: preventing the rise of superweeds. Gressel J. **Trends Biotechnol** 1999 Sep;17(9):361–6 (62 ref.)

HYBRIDIZATION IN SITU see **IN SITU HYBRIDIZATION**

HYBRIDIZATION IN SITU, FLUORESCENCE see **IN SITU HYBRIDIZATION, FLUORESCENCE**

HYBRIDOMA GROWTH FACTOR see **INTERLEUKIN-6**

HYBRIDOMAS

see related
ANTIBODIES, MONOCLONAL

Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Zhu Y, et al. **Hum Antibodies** 1999;9(1):1–7
Characterization of Schistosoma mansoni specific human T-T hybrids. Contigli C, et al. **Hybridoma** 1998 Oct; 17(5):421–9
Characteristic immunolocalization of Ku protein as nuclear matrix. Yu E, et al. **Hybridoma** 1998 Oct;17(5):413–20
[Establishment of hybridoma technique and study on fusion conditions of hybridoma cells] Pan S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):179–82 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Construction and characterization of a quadruplex DNA selective single-chain autoantibody from a viable motheaten mouse hybridoma with homology to telomeric DNA binding proteins. Brown JC, et al. **Biochemistry** 1998 Nov 17;37(46):16338–48
Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Krenn V, et al. **Clin Exp Immunol** 1999 Jan;115(1):168–75
Improving the expression of chimeric antibodies following homologous recombination in hybridoma cells. Mocikat R. **J Immunol Methods** 1999 May 27;225(1–2):185–9
Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T cell receptor in mouse hybridoma cells. Vollmer J, et al. **J Invest Dermatol** 1999 Aug;113(2):175–81

CYTOLOGY

IgG and hybridoma partitioning in aqueous two-phase systems containing a dye-ligand. Zijlstra GM, et al. **Bioseparation** 1998;7(2):117–26
Transition probability cell cycle model with product formation. Cain SJ, et al. **Biotechnol Bioeng** 1998 May 20; 58(4):387–99
Growth factor and bcl-2 mediated survival during abortive proliferation of hybridoma cell line. Chung JD, et al. **Biotechnol Bioeng** 1998 Jan 20;57(2):164–71
Predictive control of hollow-fiber bioreactors for the production of monoclonal antibodies. Dowd JE, et al. **Biotechnol Bioeng** 1999 May 20;63(4):484–92
Metabolic flux analysis of hybridoma continuous culture steady state multiplicity. Follstad BD, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):675–83
Dynamic reoptimization of a fed-batch fermentor. Iyer MS, et al. **Biotechnol Bioeng** 1999 Apr 5;63(1):10–21
Application of hypoosmolar medium to fed-batch culture of hybridoma cells for improvement of culture longevity. Ryu JS, et al. **Biotechnol Bioeng** 1999 Jan 5;62(1):120–3
In hybridoma cultures, deprivation of any single amino acid leads to apoptotic death, which is suppressed by the expression of the bcl-2 gene. Simpson NH, et al. **Biotechnol Bioeng** 1998 Jul 5;59(1):90–8
Multi-rate nonlinear state and parameter estimation in a bioreactor. Tatiraju S, et al. **Biotechnol Bioeng** 1999 Apr 5;63(1):22–32
Determinants and rate laws of growth and death of hybridoma cells in continuous culture. Zeng AP, et al. **Biotechnol Bioeng** 1998 Mar 20;57(6):642–54
Intracellular pH monitoring as a tool for the study of hybridoma cell behavior in batch and continuous bioreactor cultures. Cherlet M, et al. **Biotechnol Prog** 1998 Jul-Aug; 14(4):626–38
The production of monoclonal antibody in growth-arrested hybridomas cultivated in suspension and immobilized modes. Seifert DB, et al. **Biotechnol Prog** 1999 Jul-Aug; 15(4):655–66
Analysis of changes during subclone development and ageing of human antibody-producing heterohybridoma cells by northern blot and flow cytometry. Borth N, et al. **J Biotechnol** 1999 Jan 8;67(1):57–66
Dielectric spectroscopy in the cultivation of suspended and immobilized hybridoma cells. Noll T, et al. **J Biotechnol** 1998 Aug 27;63(3):187–98
Hybridoma cell growth and anti-neuroblastoma monoclonal antibody production in spinner flasks using a protein-free medium with microcarriers. Voigt A, et al. **J Biotechnol** 1999 Feb 19;68(2–3):213–26
Production of rat monoclonal antibodies specific for mouse integrins. Delcommenne M, et al. **Methods Mol Biol** 1999; 129:19–34

DRUG EFFECTS

Activity of glutamate dehydrogenase is increased in ammonia-stressed hybridoma cells. Bonarius HP, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):447–53
[Resistance of a hybridoma to the plant toxin viscumin does not depend on antibody affinity] Maliuchenko NV, et al. **Dokl Akad Nauk** 1999 Jul;367(1):126–9 **(Rus)**

ENZYMOLOGY

Activity of glutamate dehydrogenase is increased in ammonia-stressed hybridoma cells. Bonarius HP, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):447–53

IMMUNOLOGY

Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Lengweiler S, et al. **Biochem Biophys Res Commun** 1999 Aug 19; 262(1):167–73
IgG and hybridoma partitioning in aqueous two-phase systems containing a dye-ligand. Zijlstra GM, et al. **Bioseparation** 1998;7(2):117–26
Selective PCR amplification of functional immunoglobulin light chain from hybridoma containing the aberrant MOPC 21-derived V kappa by PNA-mediated PCR clamping. Cochet O, et al. **Biotechniques** 1999 May;26(5):818–20, 822
Rapid hybridoma screening method for the identification of monoclonal antibodies to low-abundance cytoplasmic proteins. O'Reilly LA, et al. **Biotechniques** 1998 Nov; 25(5):824–30
Monoclonal antibody to rat CD63 detects different molecular forms in rat tissue. Kennel SJ, et al. **Hybridoma** 1998 Dec; 17(6):509–15
A new method to generate quadromas by electrofusion and FACS sorting. Kreutz FT, et al. **Hybridoma** 1998 Jun; 17(3):267–73
A comparison of three methods for production of human hybridomas secreting autoantibodies. Niedbala WG, et al. **Hybridoma** 1998 Jun;17(3):299–304
Long-term production of human monoclonal antibodies by five human-mouse heterohybridomas in a serum-free medium. Yoshinari K, et al. **Hybridoma** 1998 Oct; 17(5):479–85
TCR diversity in gammadeltaTCR+ hybridomas derived from mice given portal vein donor-specific pre-immunization and skin allografts. Sun Y, et al. **Immunol Lett** 1998 Dec;64(2–3):85–95
Feasibility studies of large scale production of human anti-tetanus toxoid monoclonal antibodies. Martial-Gros A, et al. **J Biotechnol** 1999 Jan 22;67(2–3):205–16
Hybridoma cell growth and anti-neuroblastoma monoclonal antibody production in spinner flasks using a protein-free medium with microcarriers. Voigt A, et al. **J Biotechnol** 1999 Feb 19;68(2–3):213–26
T cell receptor (TCR) antagonism without a negative signal: evidence from T cell hybridomas expressing two independent TCRs. Stotz SH, et al. **J Exp Med** 1999 Jan 18;189(2):253–64
Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. Annenkov AE, et al. **J Immunol** 1998 Dec 15;161(12):6604–13
Anti-human red cell monoclonal antibodies produced by macaque-mouse heterohybridomas: their reactivity with human and nonhuman primate erythrocytes. Blancher A, et al. **J Med Primatol** 1999 Jun;28(3):118–28
Screening for weak monoclonal antibodies in hybridoma technology. Leickt L, et al. **J Mol Recognit** 1998 Winter; 11(1–6):114–6
In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Introduction. de Geus B, et al. **Res Immunol** 1998 Jul-Aug;149(6):533–4
Monoclonal antibody production: problems and solutions. Falkenberg FW. **Res Immunol** 1998 Jul-Aug;149(6):542–7 (11 ref.)
Production of monoclonal antibodies in the miniPERM bioreactor: comparison with other hybridoma culture methods. Falkenberg FW. **Res Immunol** 1998 Jul-Aug; 149(6):560–70
In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Discussion. Hendriksen CF, et al. **Res Immunol** 1998 Jul-Aug; 149(6):611–20
Hollow fibre bioreactors: an alternative to murine ascites for small scale (<1 gram) monoclonal antibody production. Lipman NS, et al. **Res Immunol** 1998 Jul-Aug;149(6):571–6
Evaluation of small to moderate scale in vitro monoclonal antibody production via the use of the i-MAb gas-permeable bag system. Lipski LA, et al. **Res Immunol** 1998 Jul-Aug;149(6):547–52
Membrane-based cell culture technologies: a scientifically and economically satisfactory alternative to malignant ascites production for monoclonal antibodies. Marx U. **Res Immunol** 1998 Jul-Aug;149(6):557–9
Considerations for in vitro monoclonal antibody production. Peterson NC. **Res Immunol** 1998 Jul-Aug;149(6):553–7
The use of oxygen carriers for increasing the production of monoclonal antibodies from hollow fibre bioreactors. Shi Y, et al. **Res Immunol** 1998 Jul-Aug;149(6):576–87

METABOLISM

Isolation of a low-molecular-weight growth inhibitory factor from hybridoma cell cultures. Røe O, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):138–42
Metabolite-balancing techniques vs. 13C tracer experiments to determine metabolic fluxes in hybridoma cells. Bonarius HP, et al. **Biotechnol Bioeng** 1998 Apr 20–May 5; 58(2–3):258–62
Metabolic flux analysis of hybridoma continuous culture steady state multiplicity. Follstad BD, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):675–83
Effect of extracellular glutamine concentration on primary and secondary metabolism of a murine hybridoma: an in vivo 13C nuclear magnetic resonance study. Mancuso A, et al. **Biotechnol Bioeng** 1998 Jan 20;57(2):172–86
Elevated glutamate dehydrogenase flux in glucose-deprived hybridoma and myeloma cells: evidence from 1H/15N NMR. Martinelle K, et al. **Biotechnol Bioeng** 1998 Nov 20;60(4):508–17
Capture of human monoclonal antibodies from cell culture supernatant by ion exchange media exhibiting high charge density. Necina R, et al. **Biotechnol Bioeng** 1998 Dec 20; 60(6):689–98
Development and validation of a methodology for intracellular pH measurements of hybridoma cells under bioreactor culture conditions. Cherlet M, et al. **Biotechnol Prog** 1999 Jul-Aug;15(4):630–9
Intracellular pH monitoring as a tool for the study of hybridoma cell behavior in batch and continuous bioreactor cultures. Cherlet M, et al. **Biotechnol Prog** 1998 Jul-Aug; 14(4):626–38
The production of monoclonal antibody in growth-arrested hybridomas cultivated in suspension and immobilized modes. Seifert DB, et al. **Biotechnol Prog** 1999 Jul-Aug; 15(4):655–66
Experimental and theoretical considerations on oxygen supply for animal cell growth in fixed-bed reactors. Fassnacht D, et al. **J Biotechnol** 1999 Jul 2;72(3):169–84
Detection of the changing substrate requirements of cultured animal cells by stoichiometric growth equations validated by enthalpy balances. Guan YH, et al. **J Biotechnol** 1999 Apr 15;69(2–3):95–114
Alternative splicing and hypermutation of a nonproductively rearranged TCR alpha-chain in a T cell hybridoma. Marshall B, et al. **J Immunol** 1999 Jan 15;162(2):871–7
Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma. White J, et al. **J Immunol** 1999 Mar 1;162(5):2671–6
Continuous antibody production by phytohemagglutinin-L-aggregated hybridoma cells. Takamatsu H, et al. **J Immunol Methods** 1999 Mar 4; 223(2):165–70

PHYSIOLOGY

In hybridoma cultures, deprivation of any single amino acid leads to apoptotic death, which is suppressed by the

HYBRIDOMAS

expression of the bcl-2 gene. Simpson NH, et al. **Biotechnol Bioeng** 1998 Jul 5;59(1):90–8

Bcl-2 over-expression reduces growth rate and prolongs G1 phase in continuous chemostat cultures of hybridoma cells. Simpson NH, et al. **Biotechnol Bioeng** 1999 Jul 20; 64(2):174–86

Characterization of a mutant T-cell hybridoma line with defects in the TCR-mediated apoptotic pathway. Morgan G, et al. **Cell Death Differ** 1999 Jan;6(1):36–47

Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium. Kawahara H, et al. **Hum Antibodies** 1999;9(2):83–7

New human fusion partners, ICLU-B, -T, -E for making human hybridomas derived from various immunological cells. Kawahara H, et al. **Hum Antibodies** 1999;9(2):89–94

TRANSPLANTATION

Local delivery of cytokines by retrovirally transduced antigen-specific TCR+ hybridoma cells in experimental autoimmune encephalomyelitis. Dal Canto RA, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):83–91

VIROLOGY

Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Adamson SR. **Dev Biol Stand** 1998;93:89–96 (18 ref.)

HYDANTOINS

ADVERSE EFFECTS

Irritant contact dermatitis due to 1-bromo-3-chloro-5,5-dimethylhydantoin in a hydrotherapy pool. Risk assessments: the need for continuous evidence-based assessments. Loughney E, et al. **Occup Med (Lond)** 1998 Oct;48(7):461–3

Contact dermatitis due to BCDMH in a hydrotherapy pool [letter] Penny PT. **Occup Med (Lond)** 1999 May;49(4):265–7

CHEMICAL SYNTHESIS

Inhibitors of glycogen phosphorylase b: synthesis, biochemical screening, and molecular modeling studies of novel analogues of hydantocidin. Agasimundin YS, et al. **Bioorg Med Chem** 1998 Jul;6(7):911–23

Combinatorial chemistry of hydantoins. Boeijen A, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2375–80

Synthesis of hydantoins via N,N'-ureas derived from polymer-bound amino acids. Bauser M, et al. **Mol Divers** 1998;3(4):257–60

CHEMISTRY

Synthesis of CpFe(CO)(L) complexes of hydantoin anions (Cp = eta5-C5H5, L = CO, PPh3), and the use of the 5,5-diphenylhydantoin anion complexes as tracers in the nonisotopic immunoassay CMIA of this antiepileptic drug. Vessières A, et al. **Bioconjug Chem** 1999 May-Jun; 10(3):379–85

Combinatorial chemistry of hydantoins. Boeijen A, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2375–80

METABOLISM

The solid phase synthesis of a series of tri-substituted hydantoin ligands for the somatostatin SST5 receptor. Sciciński JJ, et al. **Bioorg Med Chem Lett** 1998 Dec 15; 8(24):3609–14

Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. Brown ML, et al. **J Med Chem** 1999 May 6;42(9):1537–45

TOXICITY

Evaluation of neutralized chemical agent identification sets (CAIS) for skin injury with an overview of the vesicant potential of agent degradation products. Olajos EJ, et al. **J Appl Toxicol** 1998 Nov-Dec;18(6):409–20

HYDATID CYST see **ECHINOCOCCOSIS**

HYDATID CYST, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

HYDATID CYST, PULMONARY see **ECHINOCOCCOSIS, PULMONARY**

HYDATIDIFORM MOLE

Androgenetic complete mole coexistent with a twin live fetus. Matsui H, et al. **Gynecol Oncol** 1999 Aug;74(2):217–21

Delivery of a severely anaemic fetus after partial molar pregnancy: clinical and ultrasonographic findings. Hsieh CC, et al. **Hum Reprod** 1999 Apr;14(4):1122–6

Delayed-interval delivery in a quadruplet pregnancy after intrauterine death of a partial molar pregnancy and preterm delivery. A case report. Marinoff DN, et al. **J Reprod Med** 1998 Dec;43(12):1051–4

BLOOD

Gonadotropin-releasing hormone-induced elevation of serum hCG in choriocarcinoma: a case report. Furuhashi M, et al. **Endocr J** 1998 Aug;45(4):585–90

Serum and tissue vascular endothelial growth factor levels in hydatidiform mole. Nomura S, et al. **Life Sci** 1998; 63(20):1793–805

CHEMISTRY

Immunolocalization and quantitation of transforming growth factor alpha in hydatidiform mole. Molykutty J, et al. **Tumori** 1999 May-Jun;85(3):183–7

COMPLICATIONS

Molar pregnancy presenting with hyperemesis gravidarum. Glick MM, et al. **J Am Osteopath Assoc** 1999 Mar; 99(3):162–4

Molar pregnancy--associated ectopic decidua: report of a case and review of the literature. Kularbkaew C, et al. **J Med Assoc Thai** 1998 Nov;81(11):918–22 (45 ref.)

[Hyperthyroidism and acute renal failure in partial bladder mole] Rönisch G, et al. **Zentralbl Gynakol** 1999; 121(2):88–91 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Photo quiz. Vaginal bleeding at 16 weeks. Viera AJ, et al. **Am Fam Physician** 1999 Feb 1;59(3):649–51

Term twin pregnancy with hydatidiform mole and a normal fetus. Abbi M, et al. **Arch Gynecol Obstet** 1999; 262(3-4):189–91

Screening of persistent trophoblastic disease with various serum markers. Mungan T, et al. **Eur J Gynaecol Oncol** 1998;19(5):495–7

The contribution of maternal serum markers in the early prenatal diagnosis of molar pregnancies. Jauniaux E, et al. **Hum Reprod** 1999 Mar;14(3):842–6

The diagnosis and prognosis of molar pregnancy: the experience of the National Referral Centre in London. Paradinas FJ. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S57–64

DNA flow cytometric quantification and DNA polymorphism analysis in the case of a complete mole with a coexisting fetus. Hirose M, et al. **J Assist Reprod Genet** 1999 May;16(5):263–7

Molecular genetic testing from paraffin-embedded tissue distinguishes nonmolar hydropic abortion from hydatidiform mole. Bell KA, et al. **Mol Diagn** 1999 Mar; 4(1):11–9

Hydatidiform moles associated with multiple gestations after assisted reproduction: diagnosis by analysis of DNA fingerprint. Shozu M, et al. **Mol Hum Reprod** 1998 Sep; 4(9):877–80

In routine diagnostic practice, how many sections should we examine from cases of products of conception? [letter] Heatley MK. **Pathology** 1998 Nov;30(4):425–6

Partial moles: from postnatal to prenatal diagnosis. Jauniaux E. **Placenta** 1999 Jul-Aug;20(5-6):379–88 (60 ref.)

[Brown vaginal discharge in early pregnancy, hyperemesis. Intact hydatidiform mole] Keel JB, et al. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31-32):1283–4 **(Ger)**

[Partial hydatidiform mmole at the 17th week of pregnancy] Calleri LF, et al. **Minerva Ginecol** 1999 Jan-Feb; 51(1-2):43–8 (Eng. Abstr.) **(Ita)**

[Diagnosis of partial hydatidiform mole using molecular genetics] Repiská V, et al. **Ceska Gynekol** 1998 Jun; 63(3):189–92 (Eng. Abstr.) **(Slo)**

ENZYMOLOGY

Telomerase activity in complete hydatidiform mole. Bae SN, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):328–33

Expression of telomerase subunits and localization of telomerase activation in hydatidiform mole. Nishi H, et al. **Placenta** 1999 May;20(4):317–23

EPIDEMIOLOGY

Molar pregnancy and risk for cancer in women and their male partners. Olsen JH, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):630–4

Lack of association of gestational trophoblastic diseases (GTD) with syphilis and AIDS. Swapna E, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):277–9

Epidemiology of molar pregnancies in Northern Ireland. Giwa-Osagie MO, et al. **Int J Gynaecol Obstet** 1999 Aug; 66(2):175–7

Hydatidiform mole in Okinawa islands and mainland Japan. Sakumoto K, et al. **Int J Gynaecol Obstet** 1999 Mar; 64(3):309–10

The pattern of benign gestational trophoblastic disease in Karachi. Talati NJ. **JPMA J Pak Med Assoc** 1998 Oct; 48(10):296–300

Hydatidiform mole in Kandang Kerbau Hospital--a 5-year review. Chong CY, et al. **Singapore Med J** 1999 Apr; 40(4):265–70

[Gestational trophoblastic tumors: epidemiology and prognosis in Dakar University teaching hospital] Cissé CT, et al. **Contracept Fertil Sex** 1999 Jan;27(1):65–72 (Eng. Abstr.) **(Fre)**

GENETICS

Trizygotic pregnancy consisting of two fetuses and a complete hydatidiform mole with dispermic androgenesis. Higashino M, et al. **Am J Med Genet** 1999 Jan 1;82(1):67–9

DNA ploidy determination of early molar pregnancies by image analysis: comparison to histologic classification. Gschwendtner A, et al. **Arch Pathol Lab Med** 1998 Nov; 122(11):1000–4

p53 expression in human gestational trophoblastic tumors. Li F, et al. **Chin Med J (Engl)** 1998 Apr;111(4):379–80

Biological characterization of hydatidiform mole by flow cytometry. Cristofori A, et al. **Eur J Histochem** 1997;41 Suppl 2:125–6

A familial case of recurrent hydatidiform molar pregnancies with biparental genomic contribution. Helwani MN, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):112–5

Genetic mapping of a maternal locus responsible for familial hydatidiform moles. Moglabey YB, et al. **Hum Mol Genet** 1999 Apr;8(4):667–71

Involvement of IGF2 and H19 imprinting in choriocarcinoma development. Wake N, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S1–8 (21 ref.)

Hydatidiform moles associated with multiple gestations after assisted reproduction: diagnosis by analysis of DNA fingerprint. Shozu M, et al. **Mol Hum Reprod** 1998 Sep; 4(9):877–80

[Detection of p53 gene mutations in human gestational trophoblastic neoplasia by polymerase chain reaction-single strand conformational polymorphism techniques] Wu Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):338–40 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Molar and nonmolar placentas [letter] Schammel DP, et al. **Am J Clin Pathol** 1999 Oct;112(4):578

Cellular immune response levels in gestational trophoblastic tumor patients after hydatidiform mole. Sutoto MT. **Int J Gynaecol Obstet** 1999 Jun;65(3):273–9

METABOLISM

Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG. Birken S, et al. **Endocrine** 1999 Apr;10(2):137–44

Detection of the alpha-subunit of inhibin in trophoblastic neoplasia. Pelkey TJ, et al. **Hum Pathol** 1999 Jan; 30(1):26–31

Biology of human trophoblast. Mochizuki M, et al. **Int J Gynaecol Obstet** 1998 Apr;60 Suppl 1:S21–8

PATHOLOGY

Proliferative activity in placentas with hydropic change and hydatidiform mole as detected by Ki-67 and proliferating cell nuclear antigen immunostaining. Ostrzega N, et al. **Am J Clin Pathol** 1998 Dec;110(6):776–81

Telomerase activity in complete hydatidiform mole. Sukcharoen N, et al. **J Reprod Med** 1999 May;44(5):465–70

Metastatic lung choriocarcinoma resected nine years after hydatidiform mole. Suzuki T, et al. **Scand Cardiovasc J** 1999;33(3):180–2

SURGERY

Ampullary tubal hydatidiform mole treated with linear salpingotomy. A case report. Newcomer JR. **J Reprod Med** 1998 Oct;43(10):913–5

ULTRASONOGRAPHY

Color Doppler ultrasonography in the earlier differentiation of benign molehydatidiforms from malignant gestational trophoblastic disease. Gungor T, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):860–2

The diagnosis of molar pregnancy by sonography and gross morphology. Lindholm H, et al. **Acta Obstet Gynecol Scand** 1999 Jan;78(1):6–9

Coexistent surviving neonate twin and complete hydatidiform mole. Winter TC 3rd, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):451–3

Sonographic appearance of early complete molar pregnancies. Lazarus E, et al. **J Ultrasound Med** 1999 Sep; 18(9):589–94; quiz 595–6

[Intact pregnancy with concomitant hydatidiform mole of a coexisting placenta] Bonatz G, et al. **Z Geburtshilfe Neonatol** 1998 Sep;202(5):212–3 (Eng. Abstr.) **(Ger)**

[Hydatidiform mole. A case of hydrothorax, expression of a non-neoplastic complication] Mancino P, et al. **Minerva Ginecol** 1999 Mar;51(3):103–5 (Eng. Abstr.) **(Ita)**

HYDATIDIFORM MOLE, INVASIVE

DIAGNOSIS

Malignant trophoblastic disease following a twin pregnancy consisting of a complete hydatiform mole and a normal fetus and placenta. A case report. Vandeginste S, et al. **Eur J Gynaecol Oncol** 1999;20(2):105–7

DRUG THERAPY

Forty-five year's experience of the treatment of choriocarcinoma and invasive mole. Song HZ, et al.

Int J Gynaecol Obstet 1998 Apr;60 Suppl 1:S77-83

HYDATIDOSIS see **ECHINOCOCCOSIS**

HYDATIDOSIS, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

HYDATIDOSIS, PULMONARY see **ECHINOCOCCOSIS, PULMONARY**

HYDRA

Dangers in the ocean: the traveler and marine envenomation. I. jellyfish. Fenner PJ. **J Travel Med** 1998 Sep;5(3):135-41 (18 ref.)

[Maintenance of laboratory strain of Hydra magnipapillata] Fujisawa T. **Tanpakushitsu Kakusan Koso** 1999 Apr; 44(5):699-701 (4 ref.) **(Jpn)**

CHEMISTRY

Purification, crystallization and initial X-ray analysis of the C1 subunit of the astaxanthin protein, V600, of the chondrophore Velella velella. Chayen NE, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):266-8

CYTOLOGY

Alteration of fibronectin affinity during differentiation modulates the in vitro migration velocities of Hydra nematocytes. Stidwill RP, et al. **Cell Motil Cytoskeleton** 1998;41(1):68-73

DRUG EFFECTS

Low-molecular-weight hormonal factors that affect head formation in Hydra. Müller WA, et al. **Int J Dev Biol** 1998 Sep;42(6):825-8

Hormonal factors from the mammalian pineal gland interfere with cell development in Hydra. Müller WA, et al. **Int J Dev Biol** 1998 Sep;42(6):821-4

Utilization of electrochemically generated ozone in the degradation and detoxication of benzo[a]pyrene. Ottinger SE, et al. **J Toxicol Environ Health** 1999 Aug 27; 57(8):565-83

Kelletinin A, from the marine mollusc Buccinulum corneum, promotes differentiation in Hydra vulgaris. De Petrocellis L, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan; 103(1):17-28

EMBRYOLOGY

Calcium fluxes in hydrozoan embryos depend, in part, on exocytosis and fluid phase endocytosis. Ridgway EB, et al. **Cell Calcium** 1999 Mar;25(3):179-89

HyBra1, a Brachyury homologue, acts during head formation in Hydra. Technau U, et al. **Development** 1999 Feb; 126(5):999-1010

GENETICS

Expression and developmental regulation of the Hydra-RFamide and Hydra-LWamide preprohormone genes in Hydra: evidence for transient phases of head formation. Mitgutsch C, et al. **Dev Biol** 1999 Mar 1; 207(1):189-203

CnOtx, a member of the Otx gene family, has a role in cell movement in hydra. Smith KM, et al. **Dev Biol** 1999 Aug 15;212(2):392-404

Phospholipase C cDNAs from sponge and hydra: antiquity of genes involved in the inositol phospholipid signaling pathway. Koyanagi M, et al. **FEBS Lett** 1998 Nov 13; 439(1-2):66-70

The structure and expression of a preprohormone of a neuropeptide, Hym-176 in Hydra magnipapillata. Yum S, et al. **FEBS Lett** 1998 Nov 13;439(1-2):31-4

Characterization of the Hydra lamin and its gene: A molecular phylogeny of metazoan lamins. Erber A, et al. **J Mol Evol** 1999 Aug;49(2):260-71

Extensive gene duplication in the early evolution of animals before the parazoan-eumetazoan split demonstrated by G proteins and protein tyrosine kinases from sponge and hydra. Suga H, et al. **J Mol Evol** 1999 Jun;48(6):646-53

Expression of a Hox gene, Cnox-2, and the division of labor in a colonial hydroid. Cartwright P, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2183-6

Head-specific gene expression in Hydra: complexity of DNA- protein interactions at the promoter of ks1 is inversely correlated to the head activation potential. Endl I, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1445-50

GROWTH & DEVELOPMENT

Interactions between the foot and the head patterning systems in Hydra vulgaris. Forman BJ, et al. **Dev Biol** 1999 Jun 15;210(2):351-66

The novel signal peptides, pedibin and Hym-346, lower positional value thereby enhancing foot formation in hydra. Grens A, et al. **Development** 1999 Feb;126(3):517-24

Colony integration and the expression of the Hox gene, Cnox-2, in Hydractinia symbiolongicarpus (Cnidaria: Hydrozoa). Cartwright P, et al. **J Exp Zool** 1999 Apr 15; 285(1):57-62

Head-specific gene expression in Hydra: complexity of DNA- protein interactions at the promoter of ks1 is inversely correlated to the head activation potential. Endl I, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1445-50

PHYSIOLOGY

Interactions between the foot and bud patterning systems in Hydra vulgaris. Schiliro DM, et al. **Dev Biol** 1999 May 15;209(2):399-408

A head-activator binding protein is present in hydra in a soluble and a membrane-anchored form. Hampe W, et al. **Development** 1999 Sep;126(18):4077-86

Potential of two hydra species as standard toxicity test animals. Pollino CA, et al. **Ecotoxicol Environ Saf** 1999 Jul;43(3):309-16

Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. De Petrocellis L, et al. **Neuroscience** 1999; 92(1):377-87

HYDRALAZINE

ADVERSE EFFECTS

Hydralazine-induced lupus and vocal fold paralysis. Hari CK, et al. **J Laryngol Otol** 1998 Sep;112(9):875-7 (31 ref.)

ANALYSIS

Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Allen LV Jr, et al. **Am J Health Syst Pharm** 1998 Sep 15;55(18):1915-20

PHARMACOLOGY

Changes in DNA supercoiling in fibroblasts cultured in the presence of hydralazine. Węglarz L, et al. **Biochimie** 1998 Jul;80(7):627-30

Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy. Nordsmark M, et al. **Br J Cancer Suppl** 1996 Jul;27:S232-5

Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. Nguyen T, et al. **Circulation** 1998 Nov 10;98(19):2074-80

Hydralazine prevents endothelial dysfunction, but not the increase in superoxide production in nitric oxide-deficient hypertension [published erratum appears in Eur J Pharmacol 1999 Feb 19;367(2-3):437] Bauersachs J, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):77-81

Thermoradiotherapy with hydralazine: the effect of preirradiation of the tumor bed on blood flow and growth delay of Ehrlich carcinoma. Kozin SV, et al. **Radiat Res** 1999 Jan;151(1):79-84

THERAPEUTIC USE

Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Matsumoto K, et al. **Hypertension** 1999 Aug;34(2):279-84

Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate. Adigun AQ, et al. **Int J Cardiol** 1998 Nov 30;67(1):81-6

Oral nifedipine therapy in the management of severe preeclampsia. Kwawukume EY, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):265-9

Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. Nguyen T, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):884-95

HYDRALLAZIN see **HYDRALAZINE**

HYDRAMNIOS see **POLYHYDRAMNIOS**

HYDRANENCEPHALY

DIAGNOSIS

Brain functions of an infant with hydranencephaly revealed by auditory evoked potentials. Yuge T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):91-5

ETIOLOGY

Congenital hydranencephalic-hydrocephalic syndrome associated with mitochondrial dysfunction. Castro-Gago M, et al. **J Child Neurol** 1999 Feb;14(2):131-5

The association between maternal smoking and fetal hydranencephaly. To WW, et al. **J Obstet Gynaecol Res** 1999 Feb;25(1):39-42

ULTRASONOGRAPHY

Diagnosis please. Case 7: Hydranencephaly. Kurtz AB, et al. **Radiology** 1999 Feb;210(2):419-22

VETERINARY

Hydranencephaly and cerebellar hypoplasia in two kittens attributed to intrauterine parvovirus infection. Sharp NJ, et al. **J Comp Pathol** 1999 Jul;121(1):39-53

HYDRANGIN see **UMBELLIFERONES**

HYDRARTHROSIS

RADIOGRAPHY

More on detection of ankle effusions [letter; comment] Hall FM. **AJR Am J Roentgenol** 1998 Nov;171(5):1428. Comment on: AJR Am J Roentgenol 1998 May;170(5):1231-8.

HYDRASES see **HYDRO-LYASES**

HYDRATED ALUMINA see **ALUMINUM HYDROXIDE**

HYDRAZINES

Development of a chemiluminescent urease activity assay for Helicobacter pylori infection diagnosis in gastric mucosa biopsies. Roda A, et al. **Anal Biochem** 1998 Nov 1;264(1):47-52

A cross-sectional observation of the health effects of hydrazine hydrate and differences of its metabolism by NAT2 polymorphism. Nomiyama T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S33-6

The nitric oxide donor, diethylamine NONOate, enhances preservation of the donor rat heart. Du ZY, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1113-20

ADVERSE EFFECTS

Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, France, 17-24 February 1998. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 1:1-315

CHEMICAL SYNTHESIS

New NO donors with antithrombotic and vasodilating activities, Part 24. Hydrazine derivatives. Rehse K, et al. **Arch Pharm (Weinheim)** 1998 Oct;331(10):308-12

Peptide inhibitors of N-succinyl diaminopimelic acid aminotransferase (DAP-AT): a novel class of antimicrobial compounds. Cox RJ, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):945-50

Synthesis and antimicrobial activity of N-[(alpha-methyl)benzylidene]-(3-substituted-1,2,4-triazol-5-yl-thio) acetohydrazides. Ersan S, et al. **Farmaco** 1998 Dec 30;53(12):773-6

Design and synthesis of hydrazinopeptides and their evaluation as human leukocyte elastase inhibitors. Guy L, et al. **J Med Chem** 1998 Nov 19;41(24):4833-43

Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. Shyam K, et al. **J Med Chem** 1999 Mar 11;42(5):941-6

CHEMISTRY

Preparative purification of a high-mannose type N-glycan from soy bean agglutinin by hydrazinolysis and tyrosinamide derivatization. Evers DL, et al. **Anal Biochem** 1998 Dec 15;265(2):313-6

Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Decristoforo C, et al. **Bioconjug Chem** 1999 May-Jun;10(3):431-8

N2-amination of guanine to 2-hydrazinohypoxanthine, a novel in vivo nucleic acid modification produced by the hepatocarcinogen 2-nitropropane. Sodum RS, et al. **Chem Res Toxicol** 1998 Dec;11(12):1453-9

Structure of NG-061, a novel potentiator of nerve growth factor (NGF) isolated from Penicillium minioluteum F-4627. Bhandari R, et al. **J Antibiot (Tokyo)** 1999 Mar; 52(3):231-4

Domain-structured N1,N2-derivatized hydrazines as inhibitors of ribonucleoside diphosphate reductase: redox-cycling considerations. Sarel S, et al. **J Med Chem** 1999 Jan 28;42(2):242-8

Behaviour of dehydroalanine derivatives under hydrazinolysis conditions. Possible relevance to glycoprotein hydrazinolysis. Suzen S, et al. **J Pept Sci** 1999 Jun;5(6):283-6

N-(4-nitro-2,1,3-benzoxadiazoyl-7-yl)-N-methyl-2-aminoacetohydrazide (NBD-CO-Hz) as a precolumn fluorescent derivatization reagent for carboxylic acids in high-performance liquid chromatography. Santa T, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1065-70

A micro-Raman spectroscopic study of hydrazine-treated human dental calculus. Tsuda H, et al. **Scanning Microsc** 1996;10(4):1015-23; discussion 1023-4

METABOLISM

Hydrazide synthesis: novel substrate specificity of amidase. Kobayashi M, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):415-8

PHARMACOKINETICS

Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Ono M, et al. **Bioconjug Chem** 1999 May-Jun;10(3):386-94

HYDRAZINES

PHARMACOLOGY

Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. Kati WM, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):363–75

Effect of hydrazine upon vitamin B12–dependent methionine synthase activity and the sulphur amino acid pathway in isolated rat hepatocytes. Kenyon SH, et al. **Biochem Pharmacol** 1999 Jun 1;57(11):1311–9

Hydralazine–induced vasodilation involves opening of high conductance Ca2+–activated K+ channels. Bang L, et al. **Eur J Pharmacol** 1998 Nov 13;361(1):43–9

In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries. Homer K, et al. **Eur J Pharmacol** 1998 Aug 28;356(1):49–57

Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries. Salom JB, et al. **Gen Pharmacol** 1999 Jan;32(1):75–9

Tannic acid and thiocarbohydrazide as structural reinforcement agents in the preparation of rabbit knee articular cartilage for the scanning electron microscope. Levanon D, et al. **Histochem J** 1999 Jan;31(1):71–3

Basis for selective action of a synthetic molting hormone agonist, RH–5992 on lepidopteran insects. Sundaram M, et al. **Insect Biochem Mol Biol** 1998 Sep;28(9):693–704

A novel fungal metabolite NG–061 enhances and mimics neurotrophic effect of nerve growth factor (NGF) on neurite outgrowth in PC12 cells. Ito M, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):224–30

The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation. Sandirasegarane L, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):799–808

Continuing: Biology of cachexia [letter] Gold J. **J Natl Cancer Inst** 1999 Jun 16;91(12):1077; discussion 1077–8

Ecdysone agonist inducible transcription in transgenic tobacco plants. Martinez A, et al. **Plant J** 1999 Jul; 19(1):97–106

[Effects of SOD and NO donor on disturbances of the cardiac rhythm caused by reperfusion in rats] Kostiuk VA, et al. **Biull Eksp Biol Med** 1999 Feb;127(2):137–40 **(Rus)**

[Membranotropic effect of 2-(chloroethoxy)-para–N-dimethylaminophenylphosphinylacetic acid hydrazide (Kapakh)] Semina IG, et al. **Biull Eksp Biol Med** 1998 Aug; 126(8):175–7 **(Rus)**

[Combined inhibition of monoamine oxidase] Nikol'skaia EB, et al. **Dokl Akad Nauk** 1999 Apr;365(6):829–31 **(Rus)**

[Neuroprotective effect of kapakh, representative of new nootropic class non–anticholinesterase organophosphoric compounds] Semina II, et al. **Vestn Ross Akad Med Nauk** 1999;(3):32–6 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Continuing: Biology of cachexia [letter; comment] Bozzetti F. **J Natl Cancer Inst** 1999 Jun 16;91(12):1077; discussion 1077–8. Comment on: J Natl Cancer Inst 1997 Dec 3;89(23):1763–73. Comment on: J Natl Cancer Inst 1998 Apr 15;90(8):628.

Evaluation of AL–05712 and AL–05741 as thioltransferase mimics for the prevention and recovery of pre–cataractous changes in lens. Dickerson JE Jr, et al. **J Ocul Pharmacol Ther** 1998 Oct;14(5):437–45

HYDRAZONES

CHEMICAL SYNTHESIS

Bis–cationic heteroaromatics as macrofilaricides: synthesis of bis–amidine and bis–guanylhydrazone derivatives of substituted imidazo[1,2–a]pyridines. Sundberg RJ, et al. **J Med Chem** 1998 Oct 22;41(22):4317–28

CHEMISTRY

Crystallographic evidence for the electronic distribution in (2,4–cyclopentadien–1–yl–idenehydrazono) triphenylphosphorane. Minutolo F, et al. **Acta Crystallogr C** 1999 Jun 15;55 (Pt 6):1016–9

Binding of carbohydrates to solid supports Part 3: Reaction of sugar hydrazones with polystyrene substituted with aromatic aldehydes. Tweeddale HJ, et al. **Glycoconj J** 1998 Sep;15(9):847–54

Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. Prestwich GD, et al. **J Controlled Release** 1998 Apr 30;53(1–3):93–103

Antimicrobial and mutagenic activity of some carbono– and thiocarbonohydrazone ligands and their copper(II), iron(II) and zinc(II) complexes. Bacchi A, et al. **J Inorg Biochem** 1999 Jun 15;75(2):123–33

Complexes of salicylaldehyde acylhydrazones: cytotoxicity, QSAR and crystal structure of the sterically hindered t–butyl dimer. Koh LL, et al. **J Inorg Biochem** 1998 Dec; 72(3–4):155–62

Synthesis of lipopeptides using hydrazone chemical ligation. Melnyk O, et al. **J Pept Res** 1998 Sep;52(3):180–4

PHARMACOKINETICS

The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium–sensitizing drug levosimendan. Antila S, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):446–9

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Sundberg S, et al. **Int J Clin Pharmacol Ther** 1998 Dec;36(12):629–35

PHARMACOLOGY

Investigations on the mechanism of action of the novel antitumor agents 2–benzothiazolyl, 2–benzoxazolyl, and 2–benzimidazolyl hydrazones derived from 2–acetylpyridine. Hall IH, et al. **Arch Pharm (Weinheim)** 1999 Apr;332(4):115–23

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Hasenfuss G, et al. **Circulation** 1998 Nov 17; 98(20):2141–7

Calcium sensitization as new principle of inotropic therapy in end–stage heart failure? Zimmermann N, et al. **Eur J Cardiothorac Surg** 1998 Jul;14(1):70–5

Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Sundberg S, et al. **Int J Clin Pharmacol Ther** 1998 Dec;36(12):629–35

Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo–controlled trial. Nijhawan N, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):219–28

Antimicrobial and mutagenic activity of some carbono– and thiocarbonohydrazone ligands and their copper(II), iron(II) and zinc(II) complexes. Bacchi A, et al. **J Inorg Biochem** 1999 Jun 15;75(2):123–33

Complexes of salicylaldehyde acylhydrazones: cytotoxicity, QSAR and crystal structure of the sterically hindered t–butyl dimer. Koh LL, et al. **J Inorg Biochem** 1998 Dec; 72(3–4):155–62

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin–loaded right–ventricular papillary muscles and indo–1–loaded single ventricular cardiomyocytes of the rabbit. Sato S, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1115–28

Anti–inflammatory profile of N–phenylpyrazole arylhydrazone derivatives in rats. Barja–Fidalgo C, et al. **J Pharm Pharmacol** 1999 Jun;51(6):703–7

Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. Bowman P, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):316–25

Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff–perfused guinea pig heart. Du Toit EF, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):505–14

Differential inhibitory effect of OK–1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Kruszewski M, et al. **Mutat Res** 1998 Oct 21;409(1):31–6

Fetuin (alpha2–HS–glycoprotein) opsonizes cationic macrophagedeactivating molecules. Wang H, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14429–34

CNI–1493 attenuates hemodynamic and pro–inflammatory responses to LPS. Molina PE, et al. **Shock** 1998 Nov; 10(5):329–34

The physiologic consequences of macrophage pacification during severe acute pancreatitis. Yang J, et al. **Shock** 1998 Sep;10(3):169–75

THERAPEUTIC USE

Anti–inflammatory effects of a new tumour necrosis factor–alpha (TNF–alpha) inhibitor (CNI–1493) in collagen–induced arthritis (CIA) in rats. kerlund K, et al. **Clin Exp Immunol** 1999 Jan;115(1):32–41

HYDRO–LYASES

[Nitrile hydratase and cobalt] Kobayashi M, et al. **Tanpakushitsu Kakusan Koso** 1999 Jan;44(1):42–50 (45 ref.) **(Jpn)**

ANALYSIS

Immunohistochemical localisation of pterin–4alpha–carbinolamine dehydratase in rat peripheral organs. Résibois A, et al. **Histochem Cell Biol** 1999 May; 111(5):381–90

A novel peroxisomal enzyme, D–3–hydroxyacyl–CoA dehydratase/D–3–hydroxyacyl–CoA dehydrogenase bifunctional protein: its expression in the developing human brain. Itoh M, et al. **Microsc Res Tech** 1999 Jun 15; 45(6):383–8

ANTAGONISTS & INHIBITORS

Structure–based design of potent inhibitors of scytalone dehydratase: displacement of a water molecule from the active site. Chen JM, et al. **Biochemistry** 1998 Dec 22; 37(51):17735–44

Design of scytalone dehydratase inhibitors as rice blast fungicides: derivatives of norephedrine. Basarab GS, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1613–8

Design of scytalone dehydratase inhibitors as rice blast fungicides: (N–phenoxypropyl)–carboxamides. Jordan DB, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1607–12

Design and synthesis of beta–carboxamido phosphonates as potent inhibitors of imidazole glycerol phosphate dehydratase. Schweitzer BA, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2053–8

High–resolution structures of scytalone dehydratase–inhibitor complexes crystallized at physiological pH. Wawrzak Z, et al. **Proteins** 1999 Jun 1;35(4):425–39

BIOSYNTHESIS

Molecular characterisation of a novel thermophilic nitrile hydratase. Cramp RA, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):249–60

Cloning and characterization of a mammalian pseudouridine synthase. Chen J, et al. **RNA** 1999 Mar;5(3):409–19

BLOOD

Sensitive analysis of serum 3alpha, 7alpha, 12alpha,24–tetrahydroxy– 5beta–cholestan–26–oic acid diastereomers using gas chromatography–mass spectrometry and its application in peroxisomal D–bifunctional protein deficiency. Vreken P, et al. **J Lipid Res** 1998 Dec;39(12):2452–8

CHEMISTRY

Crystallization and characterization of a fragment of pseudouridine synthase RluC from Escherichia coli. Corollo D, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):302–4

The folding and assembly of the dodecameric type II dehydroquinases. Price NC, et al. **Biochem J** 1999 Feb 15; 338 (Pt 1):195–202

Catalytic mechanism of scytalone dehydratase: site–directed mutagenisis, kinetic isotope effects, and alternate substrates. Basarab GS, et al. **Biochemistry** 1999 May 11; 38(19):6012–24

Crystal structure of 3–amino–5–hydroxybenzoic acid (AHBA) synthase. Eads JC, et al. **Biochemistry** 1999 Aug 3;38(31):9840–9

Evolution of enzymatic activities in the enolase superfamily: crystal structure of (D)–glucarate dehydratase from Pseudomonas putida. Gulick AM, et al. **Biochemistry** 1998 Oct 13;37(41):14358–68

Identification and characterization of kinetically competent carbinolamine and alpha–iminoglutarate complexes in the glutamate dehydrogenase–catalyzed oxidation of L–glutamate using a multiwavelength transient state approach. Maniscalco SJ, et al. **Biochemistry** 1998 Oct 13; 37(41):14585–90

Tertiary and quaternary structures of photoreactive Fe–type nitrile hydratase from Rhodococcus sp. N–771: roles of hydration water molecules in stabilizing the structures and the structural origin of the substrate specificity of the enzyme. Nakasako M, et al. **Biochemistry** 1999 Aug 3; 38(31):9887–98

Evolution of enzymatic activities in the enolase superfamily: partitioning of reactive intermediates by (D)–glucarate dehydratase from Pseudomonas putida. Palmer DR, et al. **Biochemistry** 1998 Oct 13;37(41):14350–7

RNA:pseudouridine synthetase Pus1 from Saccharomyces cerevisiae: oligomerization property and stoichiometry of the complex with yeast tRNA(Phe). Arluison V, et al. **Biochimie** 1999 Jul;81(7):751–6

Acetylene hydratase of Pelobacter acetylenicus. Molecular and spectroscopic properties of the tungsten iron–sulfur enzyme. Meckenstock RU, et al. **Eur J Biochem** 1999 Aug; 264(1):176–82

Biochemistry and biotechnology of mesophilic and thermophilic nitrile metabolizing enzymes. Cowan D, et al. **Extremophiles** 1998 Aug;2(3):207–16 (70 ref.)

Structural and enzymatic characterization of human recombinant GDP–D–mannose–4,6–dehydratase. Bisso A, et al. **FEBS Lett** 1999 Aug 13;456(3):370–4

A structural comparison of molybdenum cofactor–containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503–21 (73 ref.)

The two types of 3–dehydroquinase have distinct structures but catalyze the same overall reaction. Gourley DG, et al. **Nat Struct Biol** 1999 Jun;6(6):521–5

Rational design of a scytalone dehydratase–like enzyme using a structurally homologous protein scaffold. Nixon AE, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3568–71

DEFICIENCY

Prenatal diagnosis of peroxisomal D–3–hydroxyacyl–CoA dehydratase/D–3–hydroxyacyl–CoA dehydrogenase bifunctional protein deficiency. Suzuki Y, et al. **J Hum Genet** 1999;44(3):143–7

Variable clinical presentation in three patients with 3–methylglutaconyl–coenzyme A hydratase deficiency. Gibson KM, et al. **J Inherit Metab Dis** 1998 Aug; 21(6):631–8

GENETICS

Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. van Grunsven EG, et al. **Am J Hum Genet** 1999 Jan; 64(1):99–107

Molecular characterization of the Drosophila melanogaster gene encoding the pterin 4alpha–carbinolamine

dehydratase. Seong C, et al. **Biochim Biophys Acta** 1998 Oct 14;1388(1):273–8

Characterization of the chicken and rat DCoH gene domains using an improved ligation-mediated PCR method. Bossow S, et al. **Biol Chem** 1998 Nov;379(11):1359–65

Characterization of expression of the gene for human pterin carbinolamine dehydratase/dimerization cofactor of HNF1. Lei XD, et al. **DNA Cell Biol** 1999 Mar;18(3):243–52

Heterologous expression in the Archaea: transcription from Pyrococcus furiosus gdh and mlrA promoters in Haloferax volcanii. Schreier HJ, et al. **Extremophiles** 1999 Jan; 3(1):11–9

Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes. Daniel R, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):553–66 (61 ref.)

Mutations in the pterin-4alpha-carbinolamine dehydratase (PCBD) gene cause a benign form of hyperphenylalaninemia. Thöny B, et al. **Hum Genet** 1998 Aug;103(2):162–7

rfb mutations in Vibrio cholerae do not affect surface production of toxin-coregulated pili but still inhibit intestinal colonization. Chiang SL, et al. **Infect Immun** 1999 Feb;67(2):976–80

Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C. Mao Y, et al. **J Bacteriol** 1999 Apr;181(7):2199–208

Identification and expression of the genes encoding a reactivating factor for adenosylcobalamin-dependent glycerol dehydratase. Tobimatsu T, et al. **J Bacteriol** 1999 Jul;181(13):4110–3

Analysis of the Corynebacterium glutamicum dapA promoter. Vasicová P, et al. **J Bacteriol** 1999 Oct; 181(19):6188–91

Functional expression of nitrile hydratase in Escherichia coli: requirement of a nitrile hydratase activator and post-translational modification of a ligand cysteine. Nojiri M, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):696–704

Expression of Saccharomyces cerevisiae MATa and MAT alpha enhances the HO endonuclease-stimulation of chromosomal rearrangements directed by his3 recombinational substrates. Fasullo M, et al. **Mutat Res** 1999 Jan 26;433(1):33–44

A 42 bp fragment of the pmas1' promoter containing an ocs-like element confers a developmental, wound- and chemically inducible expression pattern. Guevara-García A, et al. **Plant Mol Biol** 1998 Nov;38(5):743–53

The Arabidopsis thaliana dhdps gene encoding dihydrodipicolinate synthase, key enzyme of lysine biosynthesis, is expressed in a cell-specific manner. Vauterin M, et al. **Plant Mol Biol** 1999 Mar;39(4):695–708

Cloning and sequence analysis of the Pichia pastoris TRP1, IPP1 and HIS3 genes. Cosano I, et al. **Yeast** 1998 Jun 30; 14(9):861–7

IMMUNOLOGY

Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Ward SJ, et al. **Infect Immun** 1999 May; 67(5):2145–52

ISOLATION & PURIFICATION

Crystallization and characterization of a fragment of pseudouridine synthase RluC from Escherichia coli. Corollo D, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):302–4

Nitrile hydratase involved in aldoxime metabolism from Rhodococcus sp. strain YH3-3 purification and characterization. Kato Y, et al. **Eur J Biochem** 1999 Aug; 263(3):662–70

METABOLISM

Biotransformation of nitriles by rhodococci. Bunch AW. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):89–97 (40 ref.)

4-hydroxycinnamoyl-CoA hydratase/lyase (HCHL)--An enzyme of phenylpropanoid chain cleavage from Pseudomonas. Mitra A, et al. **Arch Biochem Biophys** 1999 May 1;365(1):10–6

Detection of a nitric oxide synthase possibly involved in the regulation of the Rhodococcus sp R312 nitrile hydratase. Sari MA, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):364–8

The folding and assembly of the dodecameric type II dehydroquinases. Price NC, et al. **Biochem J** 1999 Feb 15; 338 (Pt 1):195–202

Enzymes that exploit imines--one way or the other. Abell C. **Biochem Soc Trans** 1998 Aug;26(3):310–5 (15 ref.)

Catalytic mechanism of scytalone dehydratase: site-directed mutagenisis, kinetic isotope effects, and alternate substrates. Basarab GS, et al. **Biochemistry** 1999 May 11; 38(19):6012–24

Pterin-4a-carbinolamine dehydratase from Pseudomonas aeruginosa: characterization, catalytic mechanism and comparison to the human enzyme. Köster S, et al. **Biol Chem** 1998 Dec;379(12):1427–32

Nitrile hydratase involved in aldoxime metabolism from Rhodococcus sp. strain YH3-3 purification and characterization. Kato Y, et al. **Eur J Biochem** 1999 Aug; 263(3):662–70

Biosynthesis of the 3-acetyl and 13(1)-oxo groups of bacteriochlorophyll a in the facultative aerobic bacterium, Rhodovulum sulfidophilum--the presence of both oxygenase and hydratase pathways for isocyclic ring formation. Porra RJ, et al. **Eur J Biochem** 1998 Oct 1; 257(1):185–91

Biochemistry and biotechnology of mesophilic and thermophilic nitrile metabolizing enzymes. Cowan D, et al. **Extremophiles** 1998 Aug;2(3):207–16 (70 ref.)

A novel thermostable nitrile hydratase. Pereira RA, et al. **Extremophiles** 1998 Aug;2(3):347–57

Structural and enzymatic characterization of human recombinant GDP-D-mannose-4,6-dehydratase. Bisso A, et al. **FEBS Lett** 1999 Aug 13;456(3):370–4

Metabolism of L(-)-carnitine by Enterobacteriaceae under aerobic conditions. Elssner T, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):295–301

Biochemistry of coenzyme B12-dependent glycerol and diol dehydratases and organization of the encoding genes. Daniel R, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):553–66 (61 ref.)

Characterization of biosynthetic enzymes for ectoine as a compatible solute in a moderately halophilic eubacterium, Halomonas elongata. Ono H, et al. **J Bacteriol** 1999 Jan; 181(1):91–9

PhhB, a Pseudomonas aeruginosa homolog of mammalian pterin 4a-carbinolamine dehydratase/DCoH, does not regulate expression of phenylalanine hydroxylase at the transcriptional level. Song J, et al. **J Bacteriol** 1999 May; 181(9):2789–96

Identification and expression of the genes encoding a reactivating factor for adenosylcobalamin-dependent glycerol dehydratase. Tobimatsu T, et al. **J Bacteriol** 1999 Jul;181(13):4110–3

Functional expression of nitrile hydratase in Escherichia coli: requirement of a nitrile hydratase activator and post-translational modification of a ligand cysteine. Nojiri M, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):696–704

Substrate specificity and kinetic mechanism of the insect sulfotransferase, retinol dehydratase. Vakiani E, et al. **J Biol Chem** 1998 Dec 25;273(52):35381–7

Decreased availability of GDP-L-fucose in a patient with LAD II with normal GDP-D-mannose dehydratase and FX protein activities. Körner C, et al. **J Leukoc Biol** 1999 Jul;66(1):95–8

Pseudouridine synthetase Pus1 of Saccharomyces cerevisiae: kinetic characterisation, tRNA structural requirement and real-time analysis of its complex with tRNA. Arluison V, et al. **J Mol Biol** 1999 Jun 11;289(3):491–502

Pseudouridine mapping in the Saccharomyces cerevisiae spliceosomal U small nuclear RNAs (snRNAs) reveals that pseudouridine synthase pus1p exhibits a dual substrate specificity for U2 snRNA and tRNA. Massenet S, et al. **Mol Cell Biol** 1999 Mar;19(3):2142–54

The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction. Gourley DG, et al. **Nat Struct Biol** 1999 Jun;6(6):521–5

Dehydration of 3-hydroxyacyl-CoA in brain very-long-chain fatty acid synthesis. Knoll A, et al. **Neurochem Int** 1999 Apr;34(4):255–67

Rational design of a scytalone dehydratase-like enzyme using a structurally homologous protein scaffold. Nixon AE, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3568–71

PHYSIOLOGY

An enzyme controlled by light: the molecular mechanism of photoreactivity in nitrile hydratase. Endo I, et al. **Trends Biotechnol** 1999 Jun;17(6):244–8

HYDROA VACCINIFORME

Hydroa vacciniforme persistent in a 60-year-old man. Pietro UD, et al. **Eur J Dermatol** 1999 Jun;9(4):311–2

COMPLICATIONS

Hydroa vacciniforme with ocular involvement. Wisuthsarewong W, et al. **J Med Assoc Thai** 1998 Oct; 81(10):807–11

DIAGNOSIS

Atypical hydroa vacciniforme in childhood: from a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy [letter; comment] Iwatsuki K, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):283–4. Comment on: J Am Acad Dermatol 1998 Apr;38(4):574–9.

HYDROCARBONS

A laboratory rig for studying aspects of worker exposure to bitumen fumes. Brandt HC, et al. **Am Ind Hyg Assoc J** 1999 Mar-Apr;60(2):182–90

NK1-receptor activation prevents hydrocarbon-induced lung injury in mice. Robledo RF, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L229–38

Comparative study of hydrocarbon, fluorocarbon, and aromatic bonded RP-HPLC stationary phases by linear solvation energy relationships. Reta M, et al. **Anal Chem** 1999 Aug 15;71(16):3484–96

ADVERSE EFFECTS

Factory performance evaluations of engineering controls for asphalt paving equipment. Mead KR, et al. **Appl Occup Environ Hyg** 1999 Aug;14(8):565–73

The first international conference on the environmental health and safety of jet fuel. Zeiger E, et al. **Environ Health Perspect** 1998 Nov;106(11):763–4

Exposure to asphalt or bitumen fume and renal disease [letter; comment] Douglas D, et al. **Occup Environ Med** 1998 Sep; 55(9):645–6. Comment on: Occup Environ Med 1997 Oct;54(10):766.

Building-related illness and employee lost time following application of hot asphalt roof: a call for prevention. Lynch RM, et al. **Toxicol Ind Health** 1998 Nov-Dec;14(6):857–68

Investigation of some immunological functions in a group of asphalt workers exposed to polycyclic aromatic hydrocarbons. Karakaya A, et al. **Toxicology** 1999 Jul 1; 135(1):43–7

[Pneumatocele after hydrocarbon aspiration] Leuchter D, et al. **Klin Padiatr** 1998 Nov-Dec;210(6):422–4 (Eng. Abstr.) **(Ger)**

[Justifying the approaches to occupational regulation of water-mixable lubricant coolants] Rozhkovskaia GP, et al. **Med Tr Prom Ekol** 1999;(4):28–31 (Eng. Abstr.) **(Rus)**

ANALYSIS

Air pollution. Fox DL. **Anal Chem** 1999 Jun 15; 71(12):109R–119R (333 ref.)

Quantification and interpretation of total petroleum hydrocarbons in sediment samples by a GC/MS method and comparison with EPA 418.1 and a rapid field method. Xie G, et al. **Anal Chem** 1999 May 1;71(9):1899–904

Measurements of mineral oil mist, hydrocarbon vapor, and noise in engine rooms of ships. Svendsen K, et al. **Appl Occup Environ Hyg** 1999 Mar;14(3):186–91

Evaluation of sink effects on VOCs from a latex paint. Chang JC, et al. **J Air Waste Manag Assoc** 1998 Oct;48(10):953–8

Characterization of emissions of volatile organic compounds from interior alkyd paint. Fortmann R, et al. **J Air Waste Manag Assoc** 1998 Oct;48(10):931–40

Indoor air quality impacts of ventilation ducts: ozone removal and emissions of volatile organic compounds. Morrison GC, et al. **J Air Waste Manag Assoc** 1998 Oct;48(10):941–52

Distribution of n-alkanes, polynuclear aromatic hydrocarbons and nitrated polynuclear aromatic hydrocarbons between the fine and coarse fractions of inhalable atmospheric particulates. Cecinato A, et al. **J Chromatogr A** 1999 Jun 18;846(1-2):255–64

Chemical characterization and screening of hydrocarbon pollution in industrial soils by headspace solid-phase microextraction. Havenga WJ, et al. **J Chromatogr A** 1999 Jul 2;848(1-2):279–95

Cuticular hydrocarbon composition analysis for taxonomic differentiation of phlebotomine sandfly species (Diptera: Psychodidae) in Kenya. Mahamat H, et al. **J Med Entomol** 1998 Sep;35(5):778–81

Clinical use of photoionization gas chromatography for detection of lipid peroxidation. Mohler ER 3rd, et al. **Methods Enzymol** 1999;300:456–62

Exposure to polycyclic aromatic hydrocarbons and genotoxic effects on nonsmoking Swedish road pavement workers. Järvholm B, et al. **Scand J Work Environ Health** 1999 Apr; 25(2):131–6

Natural and anthropogenic inputs of hydrocarbons to the Strait of Georgia. Yunker MB, et al. **Sci Total Environ** 1999 Jan 26;225(3):181–209

A new look at the jovian planets. Bézard B, et al. **Science** 1999 Feb 5;283(5403):800–1

Archean molecular fossils and the early rise of eukaryotes [see comments] Brocks JJ, et al. **Science** 1999 Aug 13; 285(5430):1033–6. Comment in: Science 1999 Aug 13;285(5430):1025–7.

A new molecular window on early life [see comments] Knoll AH. **Science** 1999 Aug 13;285(5430):1025–6. Comment in: Science 1999 Aug 13;285(5430):1033–6.

[Volatile organic compounds in the air of the premises of residential and public buildings] Malysheva AG. **Gig Sanit** 1999 Jan-Feb;(1):43–6 **(Rus)**

CHEMICAL SYNTHESIS

Abiotic formation of hydrocarbons and oxygenated compounds during thermal decomposition of iron oxalate. McCollom TM, et al. **Orig Life Evol Biosph** 1999 Mar; 29(2):167–86

CHEMISTRY

Hydrocarbon chain packing and the effect of ethanol on the thermotropic phase behavior of mixed-chain phosphatidylglycerols. Durvasula RV, et al. **Biochim Biophys Acta** 1999 Feb 4;1417(1):101–10

Modeling the chemistry of complex petroleum mixtures. Quann RJ. **Environ Health Perspect** 1998 Dec;106 Suppl 6:1441–8

Hydrocarbon rulers in UDP-N-acetylglucosamine acyltransferases [published erratum appears in J Biol Chem 1999 Jan 29;274(5):3252] Wyckoff TJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32369–72

Theory of hydrophobic interactions. Scheraga HA. **J Biomol Struct Dyn** 1998 Oct;16(2):447–60

METABOLISM

Aerobic degradation of a hydrocarbon mixture in natural

uncontaminated potting soil by indigenous microorganisms at 20 degrees C and 6 degrees C. Eriksson M, et al. **Appl Microbiol Biotechnol** 1999 Apr;51(4):532–5

Effects of nitrogen limitation on biofilm formation in a hydrocarbon-degrading trickle-bed filter. Holubar P, et al. **Appl Microbiol Biotechnol** 1999 Apr;51(4):536–40

Bioavailability of hydrocarbons during microbial remediation of a sandy soil. Löser C, et al. **Appl Microbiol Biotechnol** 1999 Jan;51(1):105–11

Biodegradation of gasoline: kinetics, mass balance and fate of individual hydrocarbons. Solano-Serena F, et al. **J Appl Microbiol** 1999 Jun;86(6):1008–16

Cracking anaerobic bacteria [news] Parkes J. **Nature** 1999 Sep 16;401(6750):217–8

Characterization of antarctic hydrocarbon-degrading bacteria capable of producing bioemulsifiers. Yakimov MM, et al. **New Microbiol** 1999 Jul;22(3):249–56

Effect of high irradiance and iron on volatile odour compounds in the cyanobacterium Microcystis aeruginosa. Walsh K, et al. **Phytochemistry** 1998 Nov;49(5):1227–39

Comparison of the fuel oil biodegradation potential of hydrocarbon-assimilating microorganisms isolated from a temperate agricultural soil. Chaineau CH, et al. **Sci Total Environ** 1999 Mar 9;227(2–3):237–47

PHARMACOKINETICS

Toxicokinetics of 1,2,4-trimethylbenzene in humans exposed to vapours of white spirit: comparison with exposure to 1,2,4-trimethylbenzene alone. Järnberg J, et al. **Arch Toxicol** 1998 Jul-Aug;72(8):483–91

Parasitism, feeding rate, and hydrocarbon uptake of pink shrimp Pandalus borealis fed a crude oil contaminated diet. Moles A. **Bull Environ Contam Toxicol** 1999 Mar; 62(3):259–65

Comparison of internal dose measures of solvents in breath, blood and urine and genotoxic changes in aircraft maintenance personnel. Lemasters GK, et al. **Drug Chem Toxicol** 1999 Feb;22(1):181–200

PHARMACOLOGY

Induction of cell death by hydrophobic hydrocarbons. Kelly TA, et al. **Biotechniques** 1999 May;26(5):864–8

Effects of hydrocarbon enrichment on trichloroethylene biodegradation and microbial populations in finished compost. Sukesan S, et al. **J Appl Microbiol** 1998 Oct; 85(4):635–42

The effect of in vitro exposure to white spirit on [Ca2+i] in synaptosomes from rats exposed prenatally to white spirit. Edelfors S, et al. **Pharmacol Toxicol** 1999 May; 84(5):197–200

[Determination of the mutagenic activity of cyclohexane extract of atmospheric air dust and polycyclic aromatic hydrocarbons on various strains of Drosophila melanogaster] Krogulski A, et al. **Rocz Panstw Zakl Hig** 1998;49(3):279–83 (Eng. Abstr.) **(Pol)**

POISONING

Soft tissue injection of hydrocarbons: a case report and review of the literature. Shusterman EM, et al. **J Emerg Med** 1999 Jan-Feb;17(1):63–5 (25 ref.)

Shining the light on lamp oil [letter] Martins L, et al. **Pediatrics** 1999 May;103(5 Pt 1):1080

Abnormal liver function tests following inadvertent inhalation of volatile hydrocarbons. Pyatt JR, et al. **Postgrad Med J** 1998 Dec;74(878):747–8

TOXICITY

Toxicokinetics of 1,2,4-trimethylbenzene in humans exposed to vapours of white spirit: comparison with exposure to 1,2,4-trimethylbenzene alone. Järnberg J, et al. **Arch Toxicol** 1998 Jul-Aug;72(8):483–91

Comparison of internal dose measures of solvents in breath, blood and urine and genotoxic changes in aircraft maintenance personnel. Lemasters GK, et al. **Drug Chem Toxicol** 1999 Feb;22(1):181–200

A comprehensive evaluation of the carcinogenic potential of middle distillate fuels. Nessel CS. **Drug Chem Toxicol** 1999 Feb;22(1):165–80 (24 ref.)

Development of toxicity criteria for petroleum hydrocarbon fractions in the Petroleum Hydrocarbon Criteria Working Group approach for risk-based management of total petroleum hydrocarbons in soil. Twerdok LE. **Drug Chem Toxicol** 1999 Feb;22(1):275–91 (31 ref.)

Development of an on-line coupling of liquid-liquid extraction, normal-phase liquid chromatography and high-resolution gas ,chromatography producing an analytical marker for the prediction of mutagenicity and carcinogenicity of bitumen and bitumen fumes. Blomberg J, et al. **J Chromatogr A** 1999 Jul 23;849(2):483–94

Repeated exposure of rats to JP-4 vapor induces changes in neurobehavioral capacity and 5-HT/5-HIAA levels. Nordholm AF, et al. **J Toxicol Environ Health** 1999 Apr 9;56(7):471–99

Cytogenetic biomonitoring of workers exposed to bitumen fumes. Burgaz S, et al. **Mutat Res** 1998 Nov 9; 419(1-3):123–30

Enhancement of DNA damage and involvement of reactive oxygen species after exposure to bitumen with UVA irradiation. Hong YC, et al. **Mutat Res** 1999 May 3; 426(1):63–9

Induction of micronuclei in V79 cells by fractions of roofing asphalt fume condensate. Qian H, et al. **Mutat Res** 1999 May 17;441(2):163–70

Effects of short-term hydrocarbon inhalation on rat tracheal mucosa. Koptagel E, et al. **Okajimas Folia Anat Jpn** 1998 Aug;75(2-3):71–86

Exposure to hydrocarbons and renal disease: an experimental animal model. Mutti A, et al. **Ren Fail** 1999 May-Jul; 21(3–4):369–85

Induction of DNA adducts in vivo in rat lung cells by fume condensates of roofing asphalt. Qian HW, et al. **Teratog Carcinog Mutagen** 1998;18(3):131–40

Modulation of bronchial epithelial cell barrier function by in vitro jet propulsion fuel 8 exposure. Robledo RF, et al. **Toxicol Sci** 1999 Sep;51(1):119–25

HYDROCARBONS, ALICYCLIC

METABOLISM

Degradation of alicyclic molecules by Rhodococcus ruber CD4. Schumacher JD, et al. **Appl Microbiol Biotechnol** 1999 Jul;52(1):85–90

TOXICITY

Inhalation toxicity of cyclododecatriene in rats. Bamberger JR, et al. **Drug Chem Toxicol** 1999 Aug;22(3):435–54

HYDROCARBONS, AROMATIC

Changes in the peripheral blood of workers with occupational exposure to aromatic hydrocarbons. Hristeva-Mirtcheva V. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S81–3

An assessment of the exposure of technicians working in a chemical laboratory for aromatic hydrocarbons at Neftochim, Burgas. Panev T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S60–3

Health survey of former workers in a Norwegian coke plant: Part. 1. Estimation of historical exposures. Romundstad PR, et al. **Occup Environ Med** 1998 Sep;55(9):616–21

Influence of genetic polymorphisms of biotransformation enzymes on gene mutations, strand breaks of deoxyribonucleic acid, and micronuclei in mononuclear blood cells and urinary 8-hydroxydeoxyguanosine in potroom workers exposed to polyaromatic hydrocarbons. Carstensen U, et al. **Scand J Work Environ Health** 1999 Aug;25(4):351–60

ADVERSE EFFECTS

Aromatic hydrocarbons as reproductive hazards for women in a control laboratory of petrochemical plant. Vergieva T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S70–4

Nitroaromatic munition compounds: environmental effects and screening values. Talmage SS, et al. **Rev Environ Contam Toxicol** 1999;161:1–156 (278 ref.)

[Deviations in the hematological indices of women exposed to aromatic hydrocarbons] Khristeva-Mircheva V, et al. **Probl Khig** 1997;22:86–91 (Eng. Abstr.) **(Bul)**

ANALYSIS

Aromatic and polycyclic hydrocarbons in air and their urinary metabolites in coke plant workers. Bieniek G. **Am J Ind Med** 1998 Nov;34(5):445–54

Exposure to PAH and fluoride in aluminum reduction plants in Norway: historical estimation of exposure using process parameters and industrial hygiene measurements. Romundstad P, et al. **Am J Ind Med** 1999 Feb;35(2):164–74

Selective determination of aromatic sulfonates in landfill leachates and groundwater using microbore liquid chromatography coupled with mass spectrometry. Suter MJ, et al. **Anal Chem** 1999 Feb 15;71(4):897–904

Rapid determination of polycyclic aromatic hydrocarbons in tea infusion samples by high-performance liquid chromatography and fluorimetric detection based on solid-phase extraction. Kayali-Sayadi MN, et al. **Analyst** 1998 Oct;123(10):2145–8

PCDD/F, PCB and PAH content of Brazilian compost. Grossi G, et al. **Chemosphere** 1998 Oct-Nov; 37(9–12):2153–60

PCDD/F- and PAH-emission from house heating systems. Launhardt T, et al. **Chemosphere** 1998 Oct-Nov; 37(9–12):2013–20

Surface contamination with PASH, PAH and PCDD/F after fire accidents in private residences. Wobst M, et al. **Chemosphere** 1999 Mar;38(7):1685–91

Validity of biomarkers in environmental health studies: the case of PAHs and benzene. Dor F, et al. **Crit Rev Toxicol** 1999 Mar;29(2):129–68 (128 ref.)

Changes in PAH levels during production of rapeseed oil. Cejpek K, et al. **Food Addit Contam** 1998 Jul;15(5):563–74

Headspace solid-phase microextraction for the determination of volatile and semi-volatile pollutants in water and air. Llompart M, et al. **J Chromatogr A** 1998 Oct 16; 824(1):53–61

Analysis of aromatic sulfonates in water by solid-phase extraction and capillary electrophoresis. Loos R, et al. **J Chromatogr A** 1998 Oct 2;822(2):291–303

Determination of hydroxyaromatic compounds in water by solid-phase microextraction coupled to high-performance liquid chromatography. Wu YC, et al. **J Chromatogr A** 1999 Mar 12;835(1–2):127–35

Use of sensitized luminescence of lanthanides in analysis of drugs. Beltyukova SV, et al. **J Pharm Biomed Anal** 1998 Oct;18(1–2):261–6

Polycyclic aromatic hydrocarbons in the diet. Phillips DH. **Mutat Res** 1999 Jul 15;443(1–2):139–47 (52 ref.)

Biomarkers of dose and susceptibility in cyclists exposed to monoaromatic hydrocarbons. Bergamaschi E, et al. **Toxicol Lett** 1999 Sep 5;108(2–3):241–7

CHEMISTRY

Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. Knize MG, et al. **Adv Exp Med Biol** 1999;459:179–93 (60 ref.)

On the use of ultraviolet resonance Raman intensities to elaborate molecular force fields: application to nucleic acid bases and aromatic amino acid residues models. Lagant P, et al. **Biospectroscopy** 1998;4(6):379–93

Anaerobic formation and degradation of toxic aromatic compounds in agricultural and communal sewage deposits. Hofmann K, et al. **Chemosphere** 1999 May;38(11):2561–8

Molecular motion and orientation distributions in melt-processed, fully aromatic liquid crystalline polyesters from 1H NMR. Gentzler M, et al. **Solid State Nucl Magn Reson** 1998 Sep;12(2–3):97–112

METABOLISM

Contrasting effects of a nonionic surfactant on the biotransformation of polycyclic aromatic hydrocarbons to cis-dihydrodiols by soil bacteria. Allen CC, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1335–9

Enhancement of solubilization and biodegradation of polyaromatic hydrocarbons by the bioemulsifier alasan. Barkay T, et al. **Appl Environ Microbiol** 1999 Jun; 65(6):2697–702

Isolation and characterization of a Mycobacterium species capable of degrading three- and four-ring aromatic and aliphatic hydrocarbons. Churchill SA, et al. **Appl Environ Microbiol** 1999 Feb;65(2):549–52

Biodegradation of aromatic compounds and TCE by a filamentous bacteria-dominated consortium. Bielefeldt AR, et al. **Biodegradation** 1999 Feb;10(1):1–13

Biofilter performance and characterization of a biocatalyst degrading alkylbenzene gases. Veiga MC, et al. **Biodegradation** 1999 Jun;10(3):169–76

Cross-induction of pyrene and phenanthrene in a Mycobacterium sp. isolated from polycyclic aromatic hydrocarbon contaminated river sediments. Molina M, et al. **Can J Microbiol** 1999 Jun;45(6):520–9

Utilization of low molecular weight aromatic compounds by heterobasidiomycetous yeasts: taxonomic implications. Sampaio JP. **Can J Microbiol** 1999 Jun;45(6):491–512

Degradation of phenolic and chloroaromatic compounds by Coprinus spp. Guiraud P, et al. **Chemosphere** 1999 May; 38(12):2775–89

Estimating the ozone formation potential of volatile aromatic compounds in vehicle tunnels. Hsieh CC, et al. **Chemosphere** 1999 Oct;39(9):1433–44

Aromatic ring cleavage of a non-phenolic beta-O-4 lignin model dimer by laccase of Trametes versicolor in the presence of 1-hydroxybenzotriazole. Kawai S, et al. **FEBS Lett** 1999 Mar 12;446(2-3):355–8

Fate of phenanthrene, pyrene and benzo[a]pyrene during biodegradation of crude oil added to two soils. Smith MJ, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):445–52

Clostridium methoxybenzovorans sp. nov., a new aromatic o-demethylating homoacetogen from an olive mill wastewater treatment digester. Mechichi T, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1201–9

Taxonomic characterization of denitrifying bacteria that degrade aromatic compounds and description of Azoarcus toluvorans sp. nov. and Azoarcus toluclasticus sp. nov. Song B, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1129–40

The phn genes of Burkholderia sp. strain RP007 constitute a divergent gene cluster for polycyclic aromatic hydrocarbon catabolism. Laurie AD, et al. **J Bacteriol** 1999 Jan;181(2):531–40

Biodegradation of benzene, toluene, ethylbenzene, and o-xylene by a coculture of Pseudomonas putida and Pseudomonas fluorescens immobilized in a fibrous-bed bioreactor. Shim H, et al. **J Biotechnol** 1999 Jan 22; 67(2-3):99–112

Bacterial sulfate production by biodesulfurization of aromatic hydrocarbons, determined by ion chromatography. Soto LM, et al. **J Chromatogr A** 1998 Oct 16;824(1):45–52

Aromatic hydroxylation. Salicylic acid as a probe for measuring hydroxyl radical production. Ghiselli A. **Methods Mol Biol** 1998;108:89–100

[Protective effects of agar during immobilization of strains capable to degrade aromatic compounds] Fedorov AIu, et al. **Prikl Biokhim Mikrobiol** 1999 Mar-Apr;35(2):165–72 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Toxicokinetics of an environmentally relevant mixture of dioxin-like PHAHs with or without a non-dioxin-like PCB in a semi-chronic exposure study in female Sprague Dawley rats. van der Plas SA, et al. **Chemosphere** 1998

Oct-Nov;37(9-12):1941-55
Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat. Lipniak-Gawlik M. **J Toxicol Environ Health** 1998 Dec 11;55(7):503-16
Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). DeJongh J, et al. **Toxicol Sci** 1998 Sep;45(1):26-32

PHARMACOLOGY

Effect of organic solvents on the yield of solvent-tolerant Pseudomonas putida S12. Isken S, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2631-5
Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Piscaglia F, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):157-65
Study of erythrocytes, hemoglobin levels, and menstrual cycle characteristics of women exposed to aromatic hydrocarbons. Georgieva T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S16-8

TOXICITY

Bioassays for risk assessment of coal conversion products. Schacht S, et al. **Appl Microbiol Biotechnol** 1999 Jul; 52(1):127-30
Sensitivity of the mysid Mysidopsis bahia to a weathered oils. Barron MG, et al. **Bull Environ Contam Toxicol** 1999 Mar;62(3):266-71
Toxicity evaluation of organic sediment extracts resolved by size exclusion chromatography using rainbow trout hepatocytes. Gagné F, et al. **Chemosphere** 1999 Oct; 39(9):1545-70
Multi-bioassay approach for assessing the potency of complex mixtures of polycyclic aromatic hydrocarbons. Mayura K, et al. **Chemosphere** 1999 Apr;38(8):1721-32
Toxicity of creosote water-soluble fractions generated from contaminated sediments to the bay mysid. Padma TV, et al. **Ecotoxicol Environ Saf** 1999 Feb;42(2):171-6
Development of a new genotoxicity test system with Salmonella typhimurium OY1001/1A2 expressing human CYP1A2 and NADPH-P450 reductase. Aryal P, et al. **Mutat Res** 1999 Jun 25;442(2):113-20
Evaluation of Escherichia coli DJ4309 expressing human P450 1A2 in mutagenicity testing of complex food mixtures. Constable A, et al. **Mutat Res** 1999 Jun 25;442(2):79-87
The alkaline single cell gel electrophoresis assay with mouse multiple organs: results with 30 aromatic amines evaluated by the IARC and U.S. NTP. Sasaki YF, et al. **Mutat Res** 1999 Mar 15;440(1):1-18
Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). DeJongh J, et al. **Toxicol Sci** 1998 Sep;45(1):26-32

HYDROCARBONS, BROMINATED

ADVERSE EFFECTS

Occupational health survey on workers exposed to 2-bromopropane at low concentrations. Ichihara G, et al. **Am J Ind Med** 1999 May;35(5):523-31
Health effects associated with sulfuryl fluoride and methyl bromide exposure among structural fumigation workers. Calvert GM, et al. **Am J Public Health** 1998 Dec; 88(12):1774-80
The occupational exposure level (OEL) for 2-bromopropane: the first OEL established by Korea. Yu IJ, et al. **Appl Occup Environ Hyg** 1999 Jun;14(6):356-8 (15 ref.)
Genotoxicity in workers exposed to methyl bromide. Calvert GM, et al. **Mutat Res** 1998 Sep 11;417(2-3):115-28
Hematopoietic and reproductive toxicity of 2-bromopropane, a recently introduced substitute for chlorofluorocarbons. Kim Y, et al. **Toxicol Lett** 1999 Sep 5;108(2-3):309-13

ANALYSIS

Health hazard evaluation of methyl bromide soil fumigations. Lenhart SW, et al. **Appl Occup Environ Hyg** 1999 Jul; 14(7):407-12
Exposure to methyl bromide during greenhouse fumigation on Crete, Greece. de Vreede JA, et al. **Arch Environ Contam Toxicol** 1998 Oct;35(3):539-47
Methyl bromide and bromide ion in soil after experimental greenhouse fumigation. Dimitriou A, et al. **Bull Environ Contam Toxicol** 1998 Dec;61(6):695-701
Enhancement of electron-capture detection of methyl bromide in air by iodination. Hughes RA, et al. **J Chromatogr A** 1999 Aug 13;852(2):535-43
An isotopic approach for understanding the CH(3)Br budget of the atmosphere. McCauley SE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10006-9

BLOOD

Flame retardant exposure: polybrominated diphenyl ethers in blood from Swedish workers. Sjödin A, et al. **Environ Health Perspect** 1999 Aug;107(8):643-8
Predicting vehicle effects on the dermal absorption of halogenated methanes using physiologically based modeling. Jepson GW, et al. **Toxicol Sci** 1999 Apr; 48(2):180-8

CHEMICAL SYNTHESIS

Convenient gas phase bromination of [11C]methane and production of [11C]methyl triflate. Mock BH, et al. **Nucl Med Biol** 1999 May;26(4):467-71

CHEMISTRY

Structural analysis and quantitative evaluation of the modifications produced in human hemoglobin by methyl bromide using mass spectrometry and Edman degradation. Mamone G, et al. **Rapid Commun Mass Spectrom** 1998; 12(22):1783-92

ISOLATION & PURIFICATION

New brominated and halogen-less derivatives and structure-activity relationship of azaphilones inhibiting gp120-CD4 binding. Matsuzaki K, et al. **J Antibiot (Tokyo)** 1998 Nov;51(11):1004-11

METABOLISM

Stability and DNA alkylation rates of the simplest functional analogues of CC-1065, para-hydroxy and para-amino phenethyl bromides. Shalders RL, et al. **Chem Biol Interact** 1999 Jan 1;117(1):83-94
Photometric determination of human serum bromide levels--a convenient biomonitoring parameter for methyl bromide exposure. Müller M, et al. **Toxicol Lett** 1999 Jun 30;107(1-3):155-9

PHARMACOKINETICS

Increased bioactivation of dihaloalkanes in rat liver due to induction of class theta glutathione S-transferase T1-1. Sherratt PJ, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):619-30
Comparative toxicokinetics of chlorinated and brominated haloacetates in F344 rats. Schultz IR, et al. **Toxicol Appl Pharmacol** 1999 Jul 15;158(2):103-14
Influence of oral administration of a quaternary mixture of trihalomethanes on their blood kinetics in the rat. Luciene da Silva M, et al. **Toxicol Lett** 1999 May 20;106(1):49-57

PHARMACOLOGY

The effects of 2-bromopropane on viability and testosterone production ability of rat Leydig cells in primary culture. Wu XD, et al. **Biomed Environ Sci** 1999 Mar;12(1):43-9
Structural basis for the inhibition of firefly luciferase by a general anesthetic. Franks NP, et al. **Biophys J** 1998 Nov; 75(5):2205-11
Methyl bromide causes DNA methylation in rats and mice but fails to induce somatic mutations in lambda lacZ transgenic mice. Pletsa V, et al. **Cancer Lett** 1999 Jan 8; 135(1):21-7
New brominated and halogen-less derivatives and structure-activity relationship of azaphilones inhibiting gp120-CD4 binding. Matsuzaki K, et al. **J Antibiot (Tokyo)** 1998 Nov;51(11):1004-11

TOXICITY

Methyl bromide. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:721-35 (64 ref.)
Reinnervation of the rat olfactory bulb after methyl bromide-induced lesion: timing and extent of reinnervation. Schwob JE, et al. **J Comp Neurol** 1999 Sep 27;412(3):439-57
Effects of 2-bromopropane on spermatogenesis in the Sprague-Dawley rat. Son HY, et al. **Reprod Toxicol** 1999 May-Jun;13(3):179-87
2-Bromopropane causes ovarian dysfunction by damaging primordial follicles and their oocytes in female rats. Yu X, et al. **Toxicol Appl Pharmacol** 1999 Sep 15;159(3):185-93
Histopathological evidence that spermatogonia are the target cells of 2-bromopropane. Omura M, et al. **Toxicol Lett** 1999 Jan 11;104(1-2):19-26
Effect of inhalation exposure to 2-bromopropane on the nervous system in rats. Yu X, et al. **Toxicology** 1999 Jul 15;135(2-3):87-93

HYDROCARBONS, CHLORINATED

Chlorinated Dioxins and Related Compounds 1996. Proceedings of the 16th International Symposium. Amsterdam, The Netherlands, 12-16 August 1996. **Chemosphere** 1998 Oct-Nov;37(9-12):1627-2561
Spheres of influence: no POPS. Persistent organic pollutants. Schmidt CW. **Environ Health Perspect** 1999 Jan; 107(1):A24-5
Surrogate burns in deactivation furnace system. Shah JK. **J Hazard Mater** 1999 May 14;66(3):279-90

ADVERSE EFFECTS

Gender differences in risk of renal cell carcinoma and occupational exposures to chlorinated aliphatic hydrocarbons. Dosemeci M, et al. **Am J Ind Med** 1999 Jul;36(1):54-9
Most unwanted. Fisher BE. **Environ Health Perspect** 1999 Jan;107(1):A18-23
Relationships between environmental organochlorine contaminant residues, plasma corticosterone concentrations, and intermediary metabolic enzyme activities in Great Lakes herring gull embryos. Lorenzen A, et al. **Environ Health Perspect** 1999 Mar;107(3):179-86
Chest wall pain and possible rhabdomyolysis after chloropicrin exposure. A case series. Prudhomme JC, et al. **J Occup Environ Med** 1999 Jan;41(1):17-22
Breast cancer and organochlorines: a marker for susceptibility? Musgrave MA, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):1-4 (22 ref.)

ANALYSIS

Organochlorine compounds and xenoestrogens in human endometrium. Schäfer WR, et al. **Adv Exp Med Biol** 1998; 444:5-8
Health hazard evaluation of methyl bromide soil fumigations. Lenhart SW, et al. **Appl Occup Environ Hyg** 1999 Jul; 14(7):407-12
Chlorinated hydrocarbons in coastal lagoons of the pacific coast of Nicaragua. Carvalho FP, et al. **Arch Environ Contam Toxicol** 1999 Feb;36(2):132-9
Organochlorine contamination in bald eagle eggs and nestlings from the Canadian Great Lakes. Donaldson GM, et al. **Arch Environ Contam Toxicol** 1999 Jan;36(1):70-80
Residues of organochlorines in sediments and tilapia collected from inland water systems of Hong Kong. Zhou HY, et al. **Arch Environ Contam Toxicol** 1999 May;36(4):424-31
Organochlorine compounds in pelicans (Pelecanus crispus and Pelecanus onocrotalus) nesting at Lake Mikri Prespa, north western Greece. Crivelli AJ, et al. **Bull Environ Contam Toxicol** 1999 Apr;62(4):383-9
Polychlorinated naphthalenes in sediments from the Venice and Orbetello lagoons, Italy. Eljarrat E, et al. **Chemosphere** 1999 Apr;38(8):1901-12
Levels of chlordane compounds in fish muscle, -meal, -oil and -feed. Karl H, et al. **Chemosphere** 1998 Jun; 36(13):2819-32
Chlorinated hydrocarbon contaminants in Hong Kong surficial sediments. Richardson BJ, et al. **Chemosphere** 1999 Sep;39(6):913-23
Combined microwave-assisted extraction and gel permeation chromatography for the determination of chlorinated hydrocarbons in seal blubber and cod livers. Vetter W, et al. **Chemosphere** 1998 Oct-Nov;37(9-12):2439-49
Volatile and semivolatile organo-halogen trace analysis in surface water by direct aqueous injection GC-ECD. Wolska L, et al. **Chemosphere** 1998 Dec;37(13):2645-51
Evidence for organochlorine contamination in tissues of salmonids in Lake Tahoe. Datta S, et al. **Ecotoxicol Environ Saf** 1999 Jan;42(1):94-101
Organochlorines in breast milk from two cities in Ukraine [see comments] Gladen BC, et al. **Environ Health Perspect** 1999 Jun;107(6):459-62. Comment in: Environ Health Perspect 1999 Jun;107(6):429-30.
Quantitative structure-retention relationships of polychlorinated naphthalenes in gas chromatography. Olivero J, et al. **J Chromatogr A** 1999 Jul 23;849(2):621-7
Residues of organochlorine pesticides in fruits, vegetables and tubers from Nigerian markets. Adeyeye A, et al. **Sci Total Environ** 1999 Jul 1;231(2-3):227-33
Time trend of organochlorine pesticide residues in human adipose tissue in Veracruz, Mexico: 1988-1997 survey. Waliszewski SM, et al. **Sci Total Environ** 1998 Oct 8; 221(2-3):201-4
[Identification and quantitative determination of chlorinated++ solvents after solid phase microextraction. Applications in hospital toxicology] Humbert L, et al. **Acta Clin Belg Suppl** 1999;1:89-93 (Eng. Abstr.) **(Fre)**

BLOOD

Chlorinated hydrocarbons in women with repeated miscarriages. Gerhard I, et al. **Environ Health Perspect** 1998 Oct;106(10):675-81
Chlorinated hydrocarbons in infertile women. Gerhard I, et al. **Environ Res** 1999 May;80(4):299-310
Organochlorine in the serum of inhabitants living near an electrochemical factory. Sala M, et al. **Occup Environ Med** 1999 Mar;56(3):152-8
Factors affecting organochlorine contaminant concentrations in milk and blood of northern fur seal (Callorhinus ursinus) dams and pups from St. George Island, Alaska. Beckmen KB, et al. **Sci Total Environ** 1999 Jul 1;231(2-3):183-200

CHEMISTRY

Applicability of competitive and noncompetitive kinetics to the reductive dechlorination of chlorinated ethenes. Garant H, et al. **Biotechnol Bioeng** 1998 Mar 20;57(6):751-5
Discrimination of structural isomers of chlorinated phenols in waters using gas chromatography-mass spectrometry in the negative chemical ionization mode. Crespin MA, et al. **J Chromatogr A** 1999 Jan 8;830(1):165-74

IMMUNOLOGY

Generation of antibodies to Di- and trichloroacetylated proteins and immunochemical detection of protein adducts in rats treated with perchloroethene. Pähler A, et al. **Chem Res Toxicol** 1998 Sep;11(9):995-1004

METABOLISM

Crystallization and preliminary crystallographic analysis of the hydroxyquinol 1,2-dioxygenase from Nocardioides simplex 3E: a novel dioxygenase involved in the biodegradation of polychlorinated aromatic compounds. Benvenuti M, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Apr;55 (Pt 4):901-3

HYDROCARBONS, CHLORINATED

Reductive dechlorination of chlorinated ethenes and 1, 2-dichloroethane by "Dehalococcoides ethenogenes" 195. Maymó-Gatell X, et al. **Appl Environ Microbiol** 1999 Jul; 65(7):3108–13

Anaerobic dechlorination of perchloroethene in an extractive membrane bioreactor. Pampel LW, et al. **Appl Microbiol Biotechnol** 1998 Sep;50(3):303–8

Sex-related levels of selenium, heavy metals, and organochlorine compounds in American white pelicans (Pelecanus erythrorhyncos). Donaldson GM, et al. **Arch Environ Contam Toxicol** 1999 Jul;37(1):110–4

Organochlorines in stranded pilot whales (Globicephala melaena) from the coast of Massachusetts. Tilbury KL, et al. **Arch Environ Contam Toxicol** 1999 Jul;37(1):125–34

Cometabolism of chlorinated solvents and binary chlorinated solvent mixtures using M. trichosporium OB3b PP358. Aziz CE, et al. **Biotechnol Bioeng** 1999 Oct 5;65(1):100–7

Glutathione conjugation of perchloroethene in subcellular fractions from rodent and human liver and kidney. Dekant W, et al. **Chem Biol Interact** 1998 Nov 6;116(1–2):31–43

Generation of antibodies to Di- and trichloroacetylated proteins and immunochemical detection of protein adducts in rats treated with perchloroethene. Pähler A, et al. **Chem Res Toxicol** 1998 Sep;11(9):995–1004

Degradation of phenolic and chloroaromatic compounds by Coprinus spp. Guiraud P, et al. **Chemosphere** 1999 May; 38(12):2775–89

Methanotrophs, Methylosinus trichosporium OB3b, sMMO, and their application to bioremediation. Sullivan JP, et al. **Crit Rev Microbiol** 1998;24(4):335–73 (165 ref.)

Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Cheek AO, et al. **Environ Health Perspect** 1999 Apr; 107(4):273–8

The interaction of chlorinated alicyclic insecticides with brain GABA(A) receptors in channel catfish (Ictalurus punctatus). Carr RL, et al. **J Toxicol Environ Health** 1999 Apr 23;56(8):543–53

Factors affecting organochlorine contaminant concentrations in milk and blood of northern fur seal (Callorhinus ursinus) dams and pups from St. George Island, Alaska. Beckmen KB, et al. **Sci Total Environ** 1999 Jul 1;231(2–3):183–200

Dose-dependent protein adduct formation in kidney, liver, and blood of rats and in human blood after perchloroethene inhalation. Pähler A, et al. **Toxicol Sci** 1999 Mar;48(1):5–13

PHARMACOKINETICS

Contamination levels and specific accumulation of persistent organochlorines in Caspian seal (Phoca caspica) from the Caspian sea, Russia. Watanabe M, et al. **Arch Environ Contam Toxicol** 1999 Oct;37(3):396–407

QSAR for polychlorinated organic compounds (PCOCs). 1. Prediction of partition properties for PCOCs using quantum chemical parameters. Dai J, et al. **Bull Environ Contam Toxicol** 1999 May;62(5):530–8

Glutathione activation of chloropicrin in the Salmonella mutagenicity test. Schneider M, et al. **Mutat Res** 1999 Feb 19;439(2):233–8

Comparative toxicokinetics of chlorinated and brominated haloacetates in F344 rats. Schultz IR, et al. **Toxicol Appl Pharmacol** 1999 Jul 15;158(2):103–14

Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). DeJongh J, et al. **Toxicol Sci** 1998 Sep;45(1):26–32

PHARMACOLOGY

Induction and enhancement of stress proteins in a trichloroethylene-degrading methanotrophic bacterium, Methylocystis sp. M. Uchiyama H, et al. **FEMS Microbiol Lett** 1999 Jan 1;170(1):125–30

POISONING

[Identification and quantitative determination of chlorinated + + solvents after solid phase microextraction. Applications in hospital toxicology] Humbert L, et al. **Acta Clin Belg Suppl** 1999;1:89–93 (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass. Rosoff JD, et al. **J Cardiothorac Vasc Anesth** 1998 Aug; 12(4):397–401

TOXICITY

Effect of an acaricide on the reproduction and survival of Daphnia magna. Villarroel MJ, et al. **Bull Environ Contam Toxicol** 1999 Aug;63(2):167–73

Effects of organochlorine xenobiotics on human spermatozoa. Silvestroni L, et al. **Chemosphere** 1999 Oct;39(8):1249–52

Reproductive and morphological condition of wild mink (Mustela vison) and river otters (Lutra canadensis) in relation to chlorinated hydrocarbon contamination. Harding LE, et al. **Environ Health Perspect** 1999 Feb; 107(2):141–7

1,1,2,2-Tetrachloroethane. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:817–27 (39 ref.)

Correlation between the activation of Neu tyrosine kinase and promotion of foci formation induced by selected organochlorine compounds in the MCF-7 model system. Hatakeyama M, et al. **J Biochem Mol Toxicol** 1999; 13(6):296–302

The interaction of chlorinated alicyclic insecticides with brain GABA(A) receptors in channel catfish (Ictalurus punctatus). Carr RL, et al. **J Toxicol Environ Health** 1999 Apr 23;56(8):543–53

Role of kinetics in acute lethality of nonreactive volatile organic compounds (VOCs). DeJongh J, et al. **Toxicol Sci** 1998 Sep;45(1):26–32

HYDROCARBONS, CYCLIC

see related
CYCLOPARAFFINS
POLYCYCLIC HYDROCARBONS

ANALYSIS

Validity of biomarkers in environmental health studies: the case of PAHs and benzene. Dor F, et al. **Crit Rev Toxicol** 1999 Mar;29(2):129–68 (128 ref.)

CHEMISTRY

Determination of Kow values for a series of aryl glucuronides. Kuehl DW, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):109–16

PHARMACOKINETICS

Effect of polycyclic aromatic hydrocarbons on the elimination kinetics of pyrene and the urinary excretion profile of 1-hydroxypyrene in the rat. Lipniak-Gawlik M. **J Toxicol Environ Health** 1998 Dec 11;55(7):503–16

HYDROCARBONS, FLUORINATED

see related
FLUOROCARBON POLYMERS

Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Tiwari D, et al. **Drug Dev Ind Pharm** 1998 Apr; 24(4):345–52

Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Leach CL, et al. **Eur Respir J** 1998 Dec;12(6):1346–53

Chlorofluorocarbon- and hydrofluoroalkalane-cromolyn sodium for asthma: the issue of equivalence trials [letter; comment] Avila PC. **J Allergy Clin Immunol** 1998 Sep; 102(3):529–30. Comment on: J Allergy Clin Immunol 1998 Jan;101(1 Pt 1):7–13.

Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. Bronsky E, et al. **J Asthma** 1999;36(1):107–14

Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Davies RJ, et al. **Respir Med** 1998 Jun;92 Suppl A:23–31

Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 micrograms day-1 delivered as an extrafine aerosol in adults with moderate asthma. Matthys H, et al. **Respir Med** 1998 Jun;92 Suppl A:17–22

Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Milanowski J, et al. **Respir Med** 1999 Apr; 93(4):245–51

Inhaled beclomethasone dipropionate symposium [letter] Newman SP, et al. **Respir Med** 1999 May;93(5):366–9

[O44—a solvent for silicone oil adhesions on intraocular lenses] Hoerauf H, et al. **Klin Monatsbl Augenheilkd** 1999 Feb;214(2):71–6 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers. Goldberg ME, et al. **Anesth Analg** 1999 Feb; 88(2):437–45

Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ramsdell JW, et al. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):593–9

Extra fine hydrofluoroalkane-134A beclomethasone aerosols: selecting an optimal inhaled steroid for an individual patient [letter] Dean NL. **Chest** 1999 Sep;116(3):841–2

Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma [see comments] Gross G, et al. **Chest** 1999 Feb;115(2):343–51. Comment in: Chest 1999 Feb;115(2):316–8.

Safety of long-term treatment with HFA albuterol. Ramsdell JW, et al. **Chest** 1999 Apr;115(4):945–51

Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages [editorial; comment] Tashkin DP. **Chest** 1999 Feb;115(2):316–8. Comment on: Chest 1999 Feb;115(2):343–51.

Formulation of a protein with propellant HFA 134a for aerosol delivery. Williams RO 3rd, et al. **Eur J Pharm Sci** 1999 Jan;7(2):137–44

A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Gabrio BJ, et al. **Int J Pharm** 1999 Sep 10; 186(1):3–12

Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy. Quinn EA, et al. **Int J Pharm** 1999 Sep 10;186(1):31–41

Drug-surfactant-propellant interactions in HFA-formulations. Vervaet C, et al. **Int J Pharm** 1999 Sep 10;186(1):13–30 (84 ref.)

ADVERSE EFFECTS

Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines [see comments] Ayres JG, et al. **BMJ** 1998 Oct 3; 317(7163):926–30. Comment in: BMJ 1999 Mar 20;318(7186):810; discussion 810–11. Comment in: BMJ 1999 Mar 20;318(7186):810–1.

New delivery systems and propellants. Dolovich M. **Can Respir J** 1999 May–Jun;6(3):290–5 (20 ref.)

Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. Harrison LI, et al. **J Pharm Pharmacol** 1999 Mar; 51(3):263–9

Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients. Ayres JG, et al. **Respir Med** 1999 Jan;93(1):27–32

Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Thompson PJ, et al. **Respir Med** 1998 Jun;92 Suppl A:33–9

ANALYSIS

Compound A concentration is decreased by cooling anaesthetic circuit during low-flow sevoflurane anaesthesia. Osawa M, et al. **Can J Anaesth** 1998 Dec; 45(12):1215–8

CHEMISTRY

The elimination of sodium and potassium hydroxides from desiccated soda lime diminishes degradation of desflurane to carbon monoxide and sevoflurane to compound A but does not compromise carbon dioxide absorption. Neumann MA, et al. **Anesth Analg** 1999 Sep;89(3):768–73

Stabilization of integral membrane proteins in aqueous solution using fluorinated surfactants. Chabaud E, et al. **Biochimie** 1998 May–Jun;80(5–6):515–30

Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution. Krafft MP, et al. **Biochimie** 1998 May–Jun;80(5–6):489–514 (154 ref.)

Metered-dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a. Steckel H, et al. **Eur J Pharm Biopharm** 1998 Jul;46(1):77–83

Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. Upham BL, et al. **Int J Cancer** 1998 Nov 9;78(4):491–5

Elimination of difluorocarbene from the molecular ions of alpha, alpha,alpha-trifluorocresols with a fluorine atom migration in an ion trap mass spectrometer. Tajima S, et al. **Rapid Commun Mass Spectrom** 1999;13(14):1458–61

DIAGNOSTIC USE

19F-MRI of perfluorononane as a novel contrast modality for gastrointestinal imaging. Schwarz R, et al. **Magn Reson Med** 1999 Jan;41(1):80–6

METABOLISM

19F NMR study on the biodegradation of fluorophenols by various Rhodococcus species. Bondar VS, et al. **Biodegradation** 1998;9(6):475–86

Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5. Matthews J, et al. **Br J Cancer Suppl** 1996 Jul;27:S200–3

PHARMACOKINETICS

Fate and toxicity of 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A)-derived mercapturates in male, Fischer 344 rats. Uttamsingh V, et al. **Anesthesiology** 1998 Nov; 89(5):1174–83

Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia. Bergeron M, et al. **Neuroscience** 1999;89(4):1357–66

PHARMACOLOGY

Activation of nuclear factor-kappaB by lipopolysaccharide in mononuclear leukocytes is prevented by inhibitors of cytosolic phospholipase A2. Burgermeister E, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):373–86

Mitochondrial stress protein recognition of inactivated dehydrogenases during mammalian cell death. Bruschi SA, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13413–8

THERAPEUTIC USE

Highly fluorinated amphiphiles and colloidal systems, and their applications in the biomedical field. A contribution. Krafft MP, et al. **Biochimie** 1998 May-Jun;80(5-6):489-514 (154 ref.)

A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass. Rosoff JD, et al. **J Cardiothorac Vasc Anesth** 1998 Aug; 12(4):397-401

TOXICITY

Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association [letter; comment] Njoku DB, et al. **Anesthesiology** 1999 Mar; 90(3):921-2. Comment on: Anesthesiology 1998 Jun;88(6):1624-33.

Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats. Njoku DB, et al. **Anesthesiology** 1999 Feb;90(2):458-69

Biodegradation and ecotoxicity of HFCs and HCFCs. Berends AG, et al. **Arch Environ Contam Toxicol** 1999 Feb; 36(2):146-51

Analytical toxicology of fluorinated inhalation anaesthetics. Pihlainen K, et al. **Forensic Sci Int** 1998 Nov 9; 97(2-3):117-33 (84 ref.)

Structure-pulmonary toxicity/retention relationships of inhaled fluorocyclobutenes. Maidment MP, et al. **J Appl Toxicol** 1999 Mar-Apr;19(2):113-23

[Compound A: toxicology and clinical relevance] Kharasch ED. **Anaesthesist** 1998 Nov;47 Suppl 1:S7-10 (34 ref.) (Eng. Abstr.) **(Ger)**

HYDROCARBONS, HALOGENATED

ADVERSE EFFECTS

Workshop report. Health risks of drinking water chlorination by-products: report of an expert working group. Mills CJ, et al. **Chronic Dis Can** 1998;19(3):91-102 (52 ref.)

Exposure to trihalomethanes and adverse pregnancy outcomes [see comments] Gallagher MD, et al. **Epidemiology** 1998 Sep;9(5):484-9. Comment in: Epidemiology 1998 Sep;9(5):479-81.

ANALYSIS

Determination of halogenated hydrocarbons by helium microwave plasma torch time-of-flight mass spectrometry coupled to gas chromatography. Pack BW, et al. **Anal Chem** 1998 Sep 15;70(18):3957-63

Volatile halocarbons in a drinking water supply system: forecasting contamination values and estimating health risk. Crosta GF, et al. **Chemosphere** 1998 Dec;37(14-15):2873-84

Exposure estimates to disinfection by-products of chlorinated drinking water. Weisel CP, et al. **Environ Health Perspect** 1999 Feb;107(2):103-10

Selected polyhalogenated hydrocarbons in breast milk. Bencko V, et al. **Toxicol Lett** 1998 Aug;96-97:341-5

BLOOD

Simulated blood levels of CF3I in personnel exposed during its release from an F-15 jet engine nacelle and during intentional inhalation. Vinegar A, et al. **Am Ind Hyg Assoc J** 1999 May-Jun;60(3):403-8

Predicting vehicle effects on the dermal absorption of halogenated methanes using physiologically based modeling. Jepson GW, et al. **Toxicol Sci** 1999 Apr; 48(2):180-8

CHEMISTRY

Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodo-Pt(IV)-ethylenediamines. Kratochwil NA, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):279-85 (30 ref.)

Synthesis and characterization of bay region halohydrins derived from Benzo[a]pyrene diol epoxide and their role as intermediates in halide-catalyzed cis adduct formation. Song Q, et al. **Chem Res Toxicol** 1998 Sep;11(9):1057-66

Ultrafast electron diffraction and direct observation of transient structures in a chemical reaction. Cao J, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):338-42

Evaluation of forcefields for molecular mechanics/dynamics calculations involving halogenated anesthetics. Trudell JR, et al. **Toxicol Lett** 1998 Nov 23;100-101:413-9

METABOLISM

Pseudomonas sp. strain 273, an aerobic alpha, omega-dichloroalkaneDegrading bacterium. Wischnak C, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3507-11

Bacterial dehalogenation. Fetzner S. **Appl Microbiol Biotechnol** 1998 Dec;50(6):633-57 (183 ref.)

Organic halogen removal from chlorinated humic ground water and lake water by nitrifying fluidized-bed biomass characterised by electron microscopy and molecular methods. Kostyál E, et al. **Appl Microbiol Biotechnol** 1998 Nov;50(5):612-22

Dehalogenases applied to industrial-scale biocatalysis. Swanson PE. **Curr Opin Biotechnol** 1999 Aug;10(4):365-9 (38 ref.)

PHARMACOKINETICS

Estimation of absorption of trihalomethanes and carbon tetrachloride in low-level exposure by inhalation pharmacokinetic analysis in rats. Yoshida T, et al. **Arch Environ Contam Toxicol** 1999 Apr;36(3):347-54

Toxicokinetics of an environmentally relevant mixture of dioxin-like PHAHs with or without a non-dioxin-like PCB in a semi-chronic exposure study in female Sprague Dawley rats. van der Plas SA, et al. **Chemosphere** 1998 Oct-Nov;37(9-12):1941-55

Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. Dekant W, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):174-81 (93 ref.)

Influence of oral administration of a quaternary mixture of trihalomethanes on their blood kinetics in the rat. Luciene da Silva M, et al. **Toxicol Lett** 1999 May 20;106(1):49-57

PHARMACOLOGY

In vitro inhibition of thyroid hormone sulfation by hydroxylated metabolites of halogenated aromatic hydrocarbons. Schuur AG, et al. **Chem Res Toxicol** 1998 Sep;11(9):1075-81

Effect of 2,6-diisopropylphenol and halogenated anesthetics on tetraphenylphosphonium uptake by rat brain synaptosomes: determination of membrane potential. Marian M, et al. **Neurochem Res** 1999 Jul;24(7):875-81

TOXICITY

The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals. Denison MS, et al. **Bull Environ Contam Toxicol** 1998 Nov; 61(5):557-68 (45 ref.)

Quantitative structure-toxicity relationships for halogenated substituted-benzenes to Vibrio fischeri, using atom-based semi-empirical molecular-orbital descriptors. Warne MA, et al. **Chemosphere** 1999 Jun;38(14):3357-82

Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. Dekant W, et al. **J Cancer Res Clin Oncol** 1999;125(3-4):174-81 (93 ref.)

Evaluation of the potential immunotoxicity of bromodichloromethane in rats and mice. French AS, et al. **J Toxicol Environ Health** 1999 Mar 12;56(5):297-310

Evaluation of 10 aliphatic halogenated hydrocarbons in the mouse bone marrow micronucleus test. Crebelli R, et al. **Mutagenesis** 1999 Mar;14(2):207-15

URINE

Determination of volatile organohalogen compounds in human urine. Polkowska Z, et al. **Appl Occup Environ Hyg** 1999 Apr;14(4):240-5

HYDROCARBONS, IODINATED

ADVERSE EFFECTS

Irritant contact dermatitis caused by methyl iodide [letter] Knudsen HE, et al. **Am J Contact Dermat** 1999 Jun; 10(2):98-9

HYDROCARBONS, POLYCYCLIC see **POLYCYCLIC HYDROCARBONS**

HYDROCELE

[An abdomino-scrotal hydrocele] Geryk B, et al. **Rozhl Chir** 1999 Apr;78(4):180-2 (Eng. Abstr.) **(Cze)**

DIAGNOSIS

Early diagnosis and management of neonatal abdominoscrotal hydroceles. Cooper CS, et al. **Urol Int** 1999;62(1):61-3

[Tubular ectasia of the rete testis as cystic space-occupying lesion of the testis--magnetic resonance tomography aspects in 5 cases] Hüppe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):594-7 **(Ger)**

[Phimosis, hydrocele and varicocele. 3 frequent pathologies in the male child and adolescent] Pereira NM. **Acta Med Port** 1999 Jan-Mar;12(1-3):137-43 (25 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Talc sclerotherapy for hydroceles. Yilmaz U, et al. **Br J Urol** 1998 Sep;82(3):440-1

EPIDEMIOLOGY

Risk of contralateral hydrocele or hernia after unilateral hydrocele repair in children. Lym L, et al. **J Urol** 1999 Sep;162(3 Pt 2):1169-70; discussion 1171

The relationship between infection and disease in Wuchereria bancrofti infection in Ghana. Gyapong JO. **Trans R Soc Trop Med Hyg** 1998 Jul-Aug;92(4):390-2

ETIOLOGY

Migration of the abdominal catheter of a ventriculoperitoneal shunt into the scrotum--case report. Ozveren MF, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):313-5

PATHOLOGY

Calcified hydrocele in a young man. Lau MW, et al. **BJU Int** 1999 May;83(7):877

Pseudomalignancy in a hydrocele fluid. Stephen MR, et al. **Cytopathology** 1999 Aug;10(4):283-7

Inguinal hernia revisited through comparative evaluation of peritoneum, processus vaginalis, and sacs obtained from children with hernia, hydrocele, and undescended testis. Tanyel FC, et al. **J Pediatr Surg** 1999 Apr;34(4):552-5

[Spontaneous rupture of hydrocele: an unusual complication] Cuervo Pinna C, et al. **Actas Urol Esp** 1998 Jul-Aug; 22(7):610-2 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Does incision of the tunica vaginalis during the Palomo procedure prevent postoperative hydrocele? [letter; comment] Halwagy H. **Br J Urol** 1998 Sep;82(3):462. Comment on: Br J Urol 1998 Apr;81(4):612-3.

RADIOGRAPHY

Computed tomographic features of hydrocele 'en bisac' with hydronephrosis. Dick EA, et al. **BJU Int** 1999 Jul; 84(1):185-6

SURGERY

Risk of contralateral hydrocele or hernia after unilateral hydrocele repair in children. Lym L, et al. **J Urol** 1999 Sep;162(3 Pt 2):1169-70; discussion 1171

Remedying an intriguing complication of laparoscopic appendectomy [letter; comment] Ng WT, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):405-6. Comment on: Surg Laparosc Endosc 1997 Jun;7(3):262.

Scrotal (Bianchi) approach to patent processus vaginalis in children. Koyle MA, et al. **Tech Urol** 1999 Jun;5(2):95-9

Experience with window formation technique for hydrocele. Singh RK, et al. **Trop Doct** 1999 Jul;29(3):163-4

[Anesthesia in a patient with Rosai-Dorfman disease (letter)] Ortiz JR, et al. **Rev Esp Anestesiol Reanim** 1998 Dec; 45(10):443-4 **(Spa)**

THERAPY

Treatment of 40 cases of hydroceles with massage at qichong (St 30). Wang R. **J Tradit Chin Med** 1998 Sep;18(3):218-9

HYDROCEPHALUS

A new experimental model of obstructive hydrocephalus in the rat: the micro-balloon technique. Kim DS, et al. **Childs Nerv Syst** 1999 May;15(5):250-5

Evaluation of shunt function in hydrocephalic patients with the radionuclide 99mTc-pertechnetate. May CH, et al. **Childs Nerv Syst** 1999 May;15(5):239-44; discussion 245

Proceedings of the Genoa Meeting of the Society for Research into Hydrocephalus and Spina Bifida, 1998. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:1-76

Joubert's syndrome and prenatal hydrocephalus. Anderson JS, et al. **Pediatr Neurol** 1999 May;20(5):403-5

Concerning the article by Colak A et al. Pediatr Neurosurg 1997;27:208-210. Follow-up of children with shunted hydrocephalus [letter; comment] James HE. **Pediatr Neurosurg** 1998 Jun;28(6):327. Comment on: Pediatr Neurosurg 1997 Oct;27(4):208-10.

CEREBROSPINAL FLUID

First clinical results with a telemetric shunt-integrated ICP-sensor. Richard KE, et al. **Neurol Res** 1999 Jan; 21(1):117-20

Endoscopic third ventriculocisternostomy: MR assessment of patency with 2-D cine phase-contrast versus T2-weighted fast spin echo technique. Fischbein NJ, et al. **Pediatr Neurosurg** 1998 Feb;28(2):70-8

[Study of free radical oxidation of lipids in cerebrospinal fluid of hydrocephalic children] Aref'eva IA, et al. **Vopr Med Khim** 1998 Jul-Aug;44(4):388-92 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Kaolin-induced hydrocephalus in the hamster: temporal sequence of changes in intracranial pressure, ventriculomegaly and whole-brain specific gravity. Azzi GM, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):245-50

COMPLICATIONS

The relationship between ventricular size and visual function in children with hydrocephalus. Odebode TO, et al. **Afr J Med Med Sci** 1998 Sep-Dec;27(3-4):213-8

The origin of hypsarrhythmia and tonic spasms in West syndrome: evidence from a case of porencephaly and hydrocephalus with focal hypsarrhythmia. Haginoya K, et al. **Brain Dev** 1999 Mar;21(2):129-31

Development of a middle fossa arachnoid cyst. A theory on its pathogenesis. Martinez-Lage JF, et al. **Childs Nerv Syst** 1999 Mar;15(2-3):94-7

Evidence of cognitive visual problems in children with hydrocephalus: a structured clinical history-taking strategy [see comments] Houliston MJ, et al. **Dev Med Child Neurol** 1999 May;41(5):298-306. Comment in: Dev Med Child Neurol 1999 May;41(5):291.

Prenatally detected mild/moderate cerebral

ventriculomegaly: associated anomalies and outcome. Northern Congenital Abnormality Survey Steering Group. Robson S, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:70–1

Haemophilus aphrophilus meningitis complicated by hydrocephalus in an immunocompetent adult. Adeyemi-Doro FA, et al. **Infection** 1998 Nov–Dec; 26(6):405–7

A blinding headache and two black eyes. Lawn ND, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug;67(2):246–7

Epilepsy in children with shunted hydrocephalus. Bourgeois M, et al. **J Neurosurg** 1999 Feb;90(2):274–81

Chronic hydrocephalus and suprasellar arachnoid cyst presenting with rhinorrhea. Maiuri F, et al. **Minim Invasive Neurosurg** 1999 Jun;42(2):83–5

Memory functions in children with early hydrocephalus. Scott MA, et al. **Neuropsychology** 1998 Oct;12(4):578–89

Low-pressure shunt 'malfunction' following lumbar puncture in children with shunted obstructive hydrocephalus. Dias MS, et al. **Pediatr Neurosurg** 1999 Mar;30(3):146–50

Intramedullary lipoma of dorsocervicothoracic spinal cord with intracranial extension and hydrocephalus. Kogler A, et al. **Pediatr Neurosurg** 1998 May;28(5):257–60

Gastroesophageal reflux in infants with hydrocephalus before and after ventriculo-peritoneal shunt operation. Shteyer E, et al. **Pediatr Neurosurg** 1998 Sep;29(3):138–41

Avoiding complicated shunt systems by open fenestration of symptomatic fourth ventricular cysts associated with hydrocephalus. Villavicencio AT, et al. **Pediatr Neurosurg** 1998 Dec;29(6):314–9

Ventriculoperitoneal shunt obstruction presenting as apnea and bradycardia. Weiner D, et al. **Pediatr Neurosurg** 1998 Jul;29(1):52

Orbital hydrocephalus: a proven cause for optic atrophy. Towbin R, et al. **Pediatr Radiol** 1998 Dec;28(12):995–7

[Primary amenorrhea in patient with persistent communicating hydrocephalus] Slopien R, et al. **Ginekol Pol** 1999 May;70(5):389–91 (Eng. Abstr.) **(Pol)**

[Neural endoscopy in hydrocephalus treatment in a case of tuberous sclerosis] Pyrich M, et al. **Neurol Neurochir Pol** 1999 Jan–Feb;33(1):227–34 (Eng. Abstr.) **(Pol)**

[Isolated fourth ventricle: report of 2 cases] Da Silva JA, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):621–8 (Eng. Abstr.) **(Por)**

[The excessive drainage syndrome as a complication in the surgical treatment of hydrocephalus in children] Lubnin AIu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar;(1):31–5 (82 ref.) (Eng. Abstr.) **(Rus)**

[Craniocerebral trauma in children operated on earlier for hydrocephalus] Orlov IuA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1998 Jul–Sep;(3):36–8 (Eng. Abstr.) **(Rus)**

[The excessive cerebrospinal fluid drainage syndrome as a complication of the surgical treatment of hydrocephalus] Shkarubo AN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Apr–Jun; (2):37–9; discussion 40 (14 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Cine MR CSF flow study in hydrocephalus: what are the valuable parameters? Kim MH, et al. **Acta Neurochir Suppl (Wien)** 1998;71:343–6

Non-invasive measurement of intracranial pressure in neonates and infants: experience with the Rotterdam teletransducer. Wayenberg JL. **Acta Neurochir Suppl (Wien)** 1998;71:70–3

Factors affecting the outcome of foetal hydrocephaly. Jamjoom AB, et al. **Acta Neurochir (Wien)** 1998; 140(11):1121–5

Kabuki make-up syndrome and report of a case with hydrocephalus. Kasuya H, et al. **Childs Nerv Syst** 1998 Jun; 14(6):230–5 (45 ref.)

A clinical survey of hydrocephalus and current treatment for hydrocephalus in Japan: analysis by nationwide questionnaire. Miyake H, et al. **Childs Nerv Syst** 1999 Aug; 15(8):363–8

Spontaneous recovery of an aqueductal stenosis. Kehler U, et al. **Clin Neurol Neurosurg** 1998 Sep;100(3):231–3

Fetal hydrocephalus secondary to intraventricular hemorrhage diagnosed by ultrasonography and in utero fast magnetic resonance imaging. A case report. Hashimoto I, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):248–53

In vivo 1H MR spectroscopic imaging and diffusion weighted MRI in experimental hydrocephalus. Braun KP, et al. **Magn Reson Med** 1998 Dec;40(6):832–9

Hydrocephalus in children: neurosurgical and neuroimaging concerns. Boaz JC, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):73–91 (53 ref.)

Constructive interference in steady-state 3D Fourier-transform MRI in the management of hydrocephalus and third ventriculostomy. Laitt RD, et al. **Neuroradiology** 1999 Feb;41(2):117–23

Image of the month: Joubert syndrome. Mittler MA, et al. **Pediatr Neurosurg** 1999 Apr;30(4):218

Prenatal diagnosis in a family with severe type I plasminogen deficiency, ligneous conjunctivitis and congenital hydrocephalus. Schuster V, et al. **Prenat Diagn** 1999 May; 19(5):483–7

Posthemorrhagic hydrocephalus and brain injury in the preterm infant: dilemmas in diagnosis and management. du Plessis AJ. **Semin Pediatr Neurol** 1998 Sep;5(3):161–79 (286 ref.)

[The usefulness of lumbar infusion test in the evaluation of the intracranial volume pressure compensation in hydrocephalus before and after shunt insertion] Czepko R, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1461–72 (Eng. Abstr.) **(Pol)**

[Neural endoscopy in hydrocephalus treatment in a case of tuberous sclerosis] Pyrich M, et al. **Neurol Neurochir Pol** 1999 Jan–Feb;33(1):227–34 (Eng. Abstr.) **(Pol)**

[Contemporary concepts of the problem of hydrocephaly] Orlov IuA. **Klin Khir** 1998;(6):38–40 (15 ref.) **(Rus)**

[Idiopathic external hydrocephalus in childhood (letter)] Calleja-López S, et al. **Rev Neurol** 1999 Jan 16–31; 28(2):212–4 **(Spa)**

DRUG THERAPY

Intraventricular administration of human recombinant plasminogen activator for posthemorrhagic hydrocephalus of the newborn [letter] Nowak S, et al. **Acta Paediatr** 1999 Mar;88(3):348–9

Fibrinolytic agents in the management of posthemorrhagic hydrocephalus in preterm infants: the evidence. Haines SJ, et al. **Childs Nerv Syst** 1999 May;15(5):226–34 (19 ref.)

Acetazolamide in posthaemorrhagic ventricular dilatation [letter; comment] Raupp P. **Lancet** 1998 Nov 7; 352(9139):1548–9. Comment on: Lancet 1998 Aug 8;352(9126):433–40.

EMBRYOLOGY

Hydrocephalus chronology in the fetus: pathophysiology of aqueductal stenosis and morphological findings in animal models. Reply to the letter from Dr. H. C. Jones [letter; comment] Oi S. **Childs Nerv Syst** 1998 Nov;14(11):614–6. Comment on: Childs Nerv Syst 1997 Oct;13(10):503–4.

[Measurement of velocity waveforms in the median cerebral artery in cases of ventriculomegaly in mature fetuses] Dienes J, et al. **Orv Hetil** 1998 Oct 25;139(43):2577–9 (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Outcome and clinical course of prenatally diagnosed cerebral ventriculomegaly. Arora A, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:63–4

Neural tube defects and congenital hydrocephalus in the Sultanate of Oman. Rajab A, et al. **J Trop Pediatr** 1998 Oct;44(5):300–3

[Occurrence of congenital hydrocephalus in the Czech Republic 1961–1995] Sipek A, et al. **Ceska Gynekol** 1998 Jun;63(3):207–10 (Eng. Abstr.) **(Cze)**

ETIOLOGY

Low rate of shunt revision in tumoural obstructive hydrocephalus. Jamjoom AB, et al. **Acta Neurochir (Wien)** 1998;140(6):595–7

Intraventricular administration of human recombinant plasminogen activator for posthemorrhagic hydrocephalus of the newborn [letter] Nowak S, et al. **Acta Paediatr** 1999 Mar;88(3):348–9

Tuberculous meningitis with hydrocephalus. Contribution of PCR assay of CSF before VP shunting. Arimoto A, et al. **Childs Nerv Syst** 1998 Nov;14(11):623–6

Fetal hydrocephalus secondary to intraventricular hemorrhage diagnosed by ultrasonography and in utero fast magnetic resonance imaging. A case report. Hashimoto I, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):248–53

Congenital hydranencephalic–hydrocephalic syndrome associated with mitochondrial dysfunction. Castro-Gago M, et al. **J Child Neurol** 1999 Feb;14(2):131–5

Post-traumatic hydrocephalus: experience in 17 consecutive cases. Phuenpathom N, et al. **J Med Assoc Thai** 1999 Jan; 82(1):46–53

Systemic sarcoidosis: a case with a focal hydrocephalus and elevated lysozyme and angiotensin-converting enzyme in the cerebrospinal fluid [letter] Nakamura A, et al. **J Neurol** 1999 Apr;246(4):320–2

Acute hydrocephalus following lateral C1–2 puncture. Case illustration. Lin J, et al. **J Neurosurg** 1999 Apr;90(4 Suppl):277

Expanding lacunae causing triventricular hydrocephalus. Report of two cases. Mascalchi M, et al. **J Neurosurg** 1999 Oct;91(4):669–74

Endosaccular aneurysm occlusion with Guglielmi detachable coils for obstructive hydrocephalus caused by a large basilar tip aneurysm. Case report. Watanabe A, et al. **J Neurosurg** 1999 Oct;91(4):675–8

Acute hydrocephalus and chronic hydrocephalus with the need of postoperative shunting after aneurysmal subarachnoid hemorrhage. Lin CL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Mar; 15(3):137–45

Prolactinoma manifesting with symptomatic hydrocephalus. Zikel OM, et al. **Mayo Clin Proc** 1999 May;74(5):475–7

Transient hydrocephalus as a presenting sign associated with adrenoleukodystrophy. Wong M, et al. **Neurology** 1999 Jan 15;52(2):424–5

Transient hemifacial spasm associated with subarachnoid brainstem cysticercosis: a case report. Revuelta Gutierrez R, et al. **Neurosurg Rev** 1998;21(2–3):167–70

Communicating hydrocephalus secondary to diffuse meningeal spread of Wegener's granulomatosis: case report and literature review. Scarrow AM, et al. **Neurosurgery** 1998 Dec;43(6):1470–3

Hemocephalus and not hydrocephalus as a predictor of poor outcome from supratentorial intracerebral hemorrhage [letter] Stehbens WE. **Stroke** 1998 Dec;29(12):2668

Cystic malformation of the posterior cerebellar vermis in transgenic mice that ectopically express Engrailed-1, a homeodomain transcription factor. Rowitch DH, et al. **Teratology** 1999 Jul;60(1):22–8

[Hydrocephalus and rebleeding in subarachnoid hemorrhage] Marini G. **Minerva Anestesiol** 1998 May;64(5):239–41 (0 ref.) (Eng. Abstr.) **(Ita)**

[Germinal matrix hemorrhage and hydrocephalus in premature infants] Dehara M, et al. **No To Shinkei** 1999 Jul;51(7):627–31 (Eng. Abstr.) **(Jpn)**

GENETICS

Congenital hydrocephalus internus and aqueduct stenosis: aetiology and implications for genetic counselling. Haverkamp F, et al. **Eur J Pediatr** 1999 Jun;158(6):474–8

Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Socci DJ, et al. **Exp Neurol** 1999 Jan; 155(1):109–17

Ontogeny of recurrent hydrocephalus: presentation in three fetuses in one consanguineous family. Brady TB, et al. **Fetal Diagn Ther** 1999 Jul–Aug;14(4):198–200

Pleiotropic skeletal and ocular phenotypes of the mouse mutation congenital hydrocephalus (ch/Mf1) arise from a winged helix/forkhead transcriptionfactor gene. Hong HK, et al. **Hum Mol Genet** 1999 Apr;8(4):625–37

Hydrocephalus and spastic paraplegia result from a donor splice site mutation (2872 + 1G to A) in the L1CAM gene in a Venezuelan pedigree. Claes S, et al. **Hum Mutat** 1998; Suppl 1:S240–1

Identification of novel L1CAM mutations using fluorescence-assisted mismatch analysis. Saugier-Veber P, et al. **Hum Mutat** 1998;12(4):259–66

The site of a missense mutation in the extracellular Ig or FN domains of L1CAM influences infant mortality and the severity of X linked hydrocephalus. Michaelis RC, et al. **J Med Genet** 1998 Nov;35(11):901–4

METABOLISM

Altered formation and bulk absorption of cerebrospinal fluid in FGF-2-induced hydrocephalus. Johanson CE, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R263–71

Expression of cholecystokinin and somatostatin in the cortex of hydrocephalic and normal HTx rats. Liniger P, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:65–6

Progressive changes in cortical water and electrolyte content at three stages of rat infantile hydrocephalus and the effect of shunt treatment. Jones HC, et al. **Exp Neurol** 1998 Nov; 154(1):126–36

Cerebral metabolism in experimental hydrocephalus: an in vivo 1H and 31P magnetic resonance spectroscopy study. Braun KP, et al. **J Neurosurg** 1999 Oct;91(4):660–8

Monoamine neurotransmitters and their metabolites in the mature rabbit brain following induction of hydrocephalus. Del Bigio MR, et al. **Neurochem Res** 1998 Nov; 23(11):1379–86

Growth-associated protein-43 is increased in cerebrum of immature rats following induction of hydrocephalus. Zhang YW, et al. **Neuroscience** 1998 Oct;86(3):847–54

MICROBIOLOGY

Acute obstructive hydrocephalus complicating bacterial meningitis. Neuroimaging has limitations [letter; comment] Abernethy L. **BMJ** 1999 Jan 9;318(7176):124. Comment on: BMJ 1998 Jun 20;316(7148):1887–9.

Acute obstructive hydrocephalus complicating bacterial meningitis. Hydrocephalus was probably non-obstructive [letter; comment] Cooke RS, et al. **BMJ** 1999 Jan 9; 318(7176):124. Comment on: BMJ 1998 Jun 20;316(7148):1887–9.

Acute obstructive hydrocephalus complicating bacterial meningitis. In meningitis, one antibiotic is better than two [letter; comment] Settle C, et al. **BMJ** 1999 Jan 9; 318(7176):123. Comment on: BMJ 1998 Jun 20;316(7148):1887–9.

NURSING

External ventriculostomy: a practical application for the acute care nurse. Pope W. **J Neurosci Nurs** 1998 Jun; 30(3):185–90 (11 ref.)

PARASITOLOGY

Endoscopic removal of a third ventricular cysticercal cyst. Cudlip SA, et al. **Br J Neurosurg** 1998 Oct;12(5):452–4

PATHOLOGY

The relationship between ventricular size and visual function in children with hydrocephalus. Odebode TO, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):213–8

The ependyma in chronic hydrocephalus. Kiefer M, et al. **Childs Nerv Syst** 1998 Jun;14(6):263–70

Siblings with a syndrome of hydrocephalus with patent aqueduct, growth retardation and associated anomalies.

Slee J, et al. **Clin Dysmorphol** 1999 Jan;8(1):11–4
The pachygyria–polymicrogyria spectrum of cortical dysplasia in X-linked hydrocephalus. Graf WD, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:10–4
The microglial response in experimental infantile hydrocephalus. McAllister JP 2nd, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:62
Differential ventricular expansion in hydrocephalus. McAllister JP 2nd, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:39–42
Cell death in the brain of the HTx rat. Miyan JA, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:43–8
Cell death, axonal damage, and cell birth in the immature rat brain following induction of hydrocephalus. Del Bigio MR, et al. **Exp Neurol** 1998 Nov;154(1):157–69
Magnetization transfer measurements in normal-appearing cerebral white matter in patients with chronic obstructive hydrocephalus. Hähnel S, et al. **J Comput Assist Tomogr** 1999 Jul–Aug;23(4):516–20
Developmental neuropathology and impact of perinatal brain damage. III: gray matter lesions of the neocortex. Marin-Padilla M. **J Neuropathol Exp Neurol** 1999 May; 58(5):407–29
Human arachnoid villi response to subarachnoid hemorrhage: possible relationship to chronic hydrocephalus. Massicotte EM, et al. **J Neurosurg** 1999 Jul;91(1):80–4
Ventricular volume following third ventriculostomy. Schwartz TH, et al. **J Neurosurg** 1999 Jul;91(1):20–5
Ultramicroscopic structures of the leptomeninx of mice with communicating hydrocephalus induced by human recombinant transforming growth factor-beta 1. Nitta J, et al. **Neurol Med Chir (Tokyo)** 1998 Dec;38(12):819–24; discussion 824–5
The microglial response to progressive hydrocephalus in a model of inherited aqueductal stenosis. Mangano FT, et al. **Neurol Res** 1998 Dec;20(8):697–704
Frontal and occipital horn ratio: A linear estimate of ventricular size for multiple imaging modalities in pediatric hydrocephalus. O'Hayon BB, et al. **Pediatr Neurosurg** 1998 Nov;29(5):245–9

PHYSIOPATHOLOGY

The possible role of CSF hydrodynamic parameters following in management of SAH patients. Heinsoo M, et al. **Acta Neurochir Suppl (Wien)** 1998;71:13–5
Hydrocephalus chronology in the fetus: pathophysiology of aqueductal stenosis and morphological findings in animal models. Reply to the letter from Dr. H. C. Jones [letter; comment] Oi S. **Childs Nerv Syst** 1998 Nov;14(11):614–6 . Comment on: Childs Nerv Syst 1997 Oct;13(10):503–4.
The relation between CSF pressure and ventricular dilatation in hydrocephalic HTx rats. Jones HC, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:55–8
Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Socci DJ, et al. **Exp Neurol** 1999 Jan; 155(1):109–17
A positron emission tomography study of cerebrovascular reserve before and after shunt surgery in patients with idiopathic chronic hydrocephalus. Klinge PM, et al. **J Neurosurg** 1999 Oct;91(4):605–9
Computer modelling of the cerebrospinal fluid flow dynamics of aqueduct stenosis. Jacobson EE, et al. **Med Biol Eng Comput** 1999 Jan;37(1):59–63
Effects of brain ventricular shape on periventricular biomechanics: a finite-element analysis. Peña A, et al. **Neurosurgery** 1999 Jul;45(1):107–16; discussion 116–8
Low-pressure shunt 'malfunction' following lumbar puncture in children with shunted obstructive hydrocephalus. Dias MS, et al. **Pediatr Neurosurg** 1999 Mar;30(3):146–50
Intraventricular pressure dynamics in patients with ventriculopleural shunts: a telemetric study. Munshi I, et al. **Pediatr Neurosurg** 1998 Feb;28(2):67–9
[A peculiar mechanism of hydrocephalus: the "water-hammering" effect] Marinescu M, et al. **Neurochirurgie** 1998 Apr;44(2):117–20 (Eng. Abstr.) **(Fre)**
[Structural-functional interrelations in patients with an epileptic syndrome in posttraumatic hydrocephalus] Borisenko VV. **Lik Sprava** 1998 Jun;(4):77–9 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Serial lumbar tapping to prevent posthaemorrhagic hydrocephalus after intracranial haemorrhage in preterm infants. Müller W, et al. **Wien Klin Wochenschr** 1998 Oct 2;110(18):631–4

PSYCHOLOGY

Mother and teacher reports of behaviour and perceived self-competence of children with hydrocephalus. Williams J, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:5–9
Neuropsychologic and adaptive functioning in adolescents and young adults shunted for congenital hydrocephalus. Hommet C, et al. **J Child Neurol** 1999 Mar;14(3):144–50 (48 ref.)

RADIONUCLIDE IMAGING

PET and CBF studies of chronic hydrocephalus: a contribution to surgical indication and prognosis. Klinge P, et al. **J Neuroimaging** 1998 Oct;8(4):205–9

SURGERY

Hydrodynamic properties of hydrocephalus shunts. Czosnyka Z, et al. **Acta Neurochir Suppl (Wien)** 1998;71:334–9
Cerebral blood flow in chronic hydrocephalus--a parameter indicating shunt failure--new aspects. Klinge-Xhemajli P, et al. **Acta Neurochir Suppl (Wien)** 1998;71:347–9
Clinical significance of ventricular size in shunted-hydrocephalic children. Sakamoto H, et al. **Acta Neurochir Suppl (Wien)** 1998;71:357–9
Dual-switch valve: clinical performance of a new hydrocephalus valve. Trost HA, et al. **Acta Neurochir Suppl (Wien)** 1998;71:360–3
CSF dynamics in a patient with a programmable shunt. Tsuji O, et al. **Acta Neurochir Suppl (Wien)** 1998;71:364–7
A comparison between ventriculo-peritoneal and ventriculo-atrial cerebrospinal fluid shunts in relation to rate of revision and durability. Borgbjerg BM, et al. **Acta Neurochir (Wien)** 1998;140(5):459–64; discussion 465
Transseptal illumination in endoscopic fenestration of septum pellucidum in the new-born. Hennig R, et al. **Acta Neurochir (Wien)** 1998;140(9):989–90
Low rate of shunt revision in tumoural obstructive hydrocephalus. Jamjoom AB, et al. **Acta Neurochir (Wien)** 1998;140(6):595–7
Cerebral blood flow velocity and vasomotor reactivity before and after shunting surgery in patients with normal pressure hydrocephalus. Lee EJ, et al. **Acta Neurochir (Wien)** 1998; 140(6):599–604; discussion 604–5
Four-year experience with the routine use of the programmable Hakim valve in the management of children with hydrocephalus. Rohde V, et al. **Acta Neurochir (Wien)** 1998;140(11):1127–34
Adult patients with "asymptomatic" and "compensated" hydrocephalus benefit from surgery. Larsson A, et al. **Acta Neurol Scand** 1999 Feb;99(2):81–90
Omental transfer to the brain: an experimental study in hydrocephalic rabbits. Morwood DT, et al. **Ann Plast Surg** 1999 Feb;42(2):174–9
Epidural hematoma after ventriculoperitoneal shunt surgery. Report of two cases. Pereira CU, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3B):629–32
Failure to follow patients with hydrocephalus shunts can lead to death. Buxton N, et al. **Br J Neurosurg** 1998 Oct; 12(5):399–401
Total migration of a ventriculo-peritoneal shunt into the ventricles. Gupta PK, et al. **Br J Neurosurg** 1999 Feb; 13(1):73–4
The combined use of image-guided frameless stereotaxy and neuroendoscopy for the surgical management of occlusive hydrocephalus and intracranial cysts. Rohde V, et al. **Br J Neurosurg** 1998 Dec;12(6):531–8
Tuberculous meningitis with hydrocephalus. Contribution of PCR assay of CSF before VP shunting. Arimoto A, et al. **Childs Nerv Syst** 1998 Nov;14(11):623–6
Indications for shunt insertion or III ventriculostomy in hydrocephalic children, guided by lumbar and intraventricular infusion tests. Bech RA, et al. **Childs Nerv Syst** 1999 May;15(5):213–7; discussion 218
Neuroendoscopy in the premature population. Buxton N, et al. **Childs Nerv Syst** 1998 Nov;14(11):649–52
Hydrocephalus and epileptic seizures. Keene DL, et al. **Childs Nerv Syst** 1999 Apr;15(4):158–62
Multiple shunt failures: an analysis of relevant factors [see comments] Lazareff JA, et al. **Childs Nerv Syst** 1998 Jun; 14(6):271–5. Comment in: Childs Nerv Syst 1999 Mar;15(2–3):79.
A clinical survey of hydrocephalus and current treatment for hydrocephalus in Japan: analysis by nationwide questionnaire. Miyake H, et al. **Childs Nerv Syst** 1999 Aug; 15(8):363–8
Neuroendoscopic surgery for specific forms of hydrocephalus. Oi S, et al. **Childs Nerv Syst** 1999 Jan; 15(1):56–68
Adjustable antisiphon shunt. Sood S, et al. **Childs Nerv Syst** 1999 May;15(5):246–9
Multiple shunt failures: an analysis of relevant features [letter; comment] Tuli S, et al. **Childs Nerv Syst** 1999 Mar; 15(2–3):79. Comment on: Childs Nerv Syst 1998 Jun;14(6):271–5.
Pneumocephalus after shunting for hydrocephalus. Villarejo F, et al. **Childs Nerv Syst** 1998 Jul;14(7):333–7 (25 ref.)
Control of intraoperative bleeding with hydrostatic pressure during endoscopic surgery. Wang KC, et al. **Childs Nerv Syst** 1998 Jun;14(6):280–4
Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Park MK, et al. **Clin Infect Dis** 1999 Mar;28(3):629–33
Epilepsy in shunt-treated hydrocephalus. Klepper J, et al. **Dev Med Child Neurol** 1998 Nov;40(11):731–6
Overnight shunt pressure monitoring in children. Baxter PS, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:49–51
Clinical, gross morphological and neurochemical follow-up in normal, hydrocephalic and hydrocephalic-shunted rats. Kaiser GL, et al. **Eur J Pediatr Surg** 1998 Oct;8(5):258–61
Laparoscopy-assisted abdominal shunt revisions in children with hydrocephalus. Rolle U, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:60
Quantitative assessment of intracranial pressure by the tympanic membrane displacement audiometric technique in children with shunted hydrocephalus. Samuel M, et al. **Eur J Pediatr Surg** 1998 Aug;8(4):200–7
Pitfalls in shunting of hydrocephalus--clinical reality and improvement by the hydrostatic dual-switch valve. Sprung C, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:26–30
Ventriculoperitoneal shunt placement with video-laparoscopic guidance. Reimer R, et al. **J Am Coll Surg** 1998 Dec;187(6):637–9
Abdominal cerebrospinal fluid pseudocyst in a severely handicapped patient with hydrocephalus. Horikawa M, et al. **J Child Neurol** 1999 May;14(5):329–31
Effects of transient and persistent cerebrospinal fluid drainage on sleep disordered breathing in patients with idiopathic adult hydrocephalus syndrome. Kristensen B, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):497–501
Epilepsy in children with shunted hydrocephalus. Bourgeois M, et al. **J Neurosurg** 1999 Feb;90(2):274–81
Sylvian aqueduct syndrome and global rostral midbrain dysfunction associated with shunt malfunction [see comments] Cinalli G, et al. **J Neurosurg** 1999 Feb; 90(2):227–36. Comment in: J Neurosurg 1999 Feb;90(2):373. Comment in: J Neurosurg 1999 Jul;91(1):169–70.
Failure of third ventriculostomy in the treatment of aqueductal stenosis in children. Cinalli G, et al. **J Neurosurg** 1999 Mar;90(3):448–54
A positron emission tomography study of cerebrovascular reserve before and after shunt surgery in patients with idiopathic chronic hydrocephalus. Klinge PM, et al. **J Neurosurg** 1999 Oct;91(4):605–9
Persistent bilateral hearing loss after shunt placement for hydrocephalus. Case report. Stoeckli SJ, et al. **J Neurosurg** 1999 Apr;90(4):773–5
Experience with a programmable valve shunt system. Yamashita N, et al. **J Neurosurg** 1999 Jul;91(1):26–31
How to perforate safely a resistant floor of the 3rd ventricle? Technical note. Kehler U, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):198–9
Neuroendoscopic third ventriculostomy in the management of fourth ventricular outlet obstruction. Mohanty A, et al. **Minim Invasive Neurosurg** 1999 Mar;42(1):18–21
Experience with an ultrasonic aspirator in neuroendoscopy. Oka K, et al. **Minim Invasive Neurosurg** 1999 Mar; 42(1):32–4
Variations in the site and size of third ventriculocisternostomy. Zohdi A, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):194–7
Migration of the abdominal catheter of a ventriculoperitoneal shunt into the scrotum--case report. Ozveren MF, et al. **Neurol Med Chir (Tokyo)** 1999 Apr;39(4):313–5
Ultrastructure of obstructive tissue in malfunctioning ventricular catheters without infection. Takahashi Y, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):399–404; discussion 403–4
Reduction cranioplasty for macrocephaly. Two case reports. Takahashi Y, et al. **Neurol Med Chir (Tokyo)** 1999 Jun; 39(6):459–62
Subtemporal decompression: the treatment of noncompliant ventricle syndrome. Buxton N, et al. **Neurosurgery** 1999 Mar;44(3):513–8; discussion 518–9
The role of endoscopic third ventriculostomy in the management of shunt malfunction. Cinalli G, et al. **Neurosurgery** 1998 Dec;43(6):1323–7; discussion 1327–9 (34 ref.)
Determining the best cerebrospinal fluid shunt valve design: the pediatric valve design trial [letter; comment] Drake JM, et al. **Neurosurgery** 1998 Nov;43(5):1259–60. Comment on: Neurosurgery 1998 Apr;42(4):949–51.
Randomized trial of cerebrospinal fluid shunt valve design in pediatric hydrocephalus. Drake JM, et al. **Neurosurgery** 1998 Aug;43(2):294–303; discussion 303–5
Chronic shunt-dependent hydrocephalus after early surgical and early endovascular treatment of ruptured intracranial aneurysms. Gruber A, et al. **Neurosurgery** 1999 Mar; 44(3):503–9; discussion 509–12
Endoscopic third ventriculostomy: outcome analysis of 100 consecutive procedures. Hopf NJ, et al. **Neurosurgery** 1999 Apr;44(4):795–804; discussion 804–6
Treatment of subdural effusion with hydrocephalus after ruptured intracranial aneurysm clipping. Kawaguchi T, et al. **Neurosurgery** 1998 Nov;43(5):1033–9
Basilar artery perforation as a complication of endoscopic third ventriculostomy. Abtin K, et al. **Pediatr Neurosurg** 1998 Jan;28(1):35–41
Chemical meningitis from bile reflux in a lumbar-gallbladder shunt. Barami K, et al. **Pediatr Neurosurg** 1998 Dec; 29(6):328–30
Percutaneous placement of ventriculoatrial shunts in the pediatric population. Britz GW, et al. **Pediatr Neurosurg** 1998 Sep;29(3):161–3
Neuroendoscopic third ventriculostomy in patients less than 1 year old. Buxton N, et al. **Pediatr Neurosurg** 1998 Aug; 29(2):73–6
Endoscopic third ventriculocisternostomy: MR assessment of patency with 2-D cine phase-contrast versus T2-weighted fast spin echo technique. Fischbein NJ, et al. **Pediatr Neurosurg** 1998 Feb;28(2):70–8
Shunt revision by coagulation with retention of the ventricular catheter. Hudgins RJ, et al. **Pediatr Neurosurg** 1998 Aug;29(2):57–9
An assessment of observer bias in the shunt design trial. Kestle J, et al. **Pediatr Neurosurg** 1999 Feb;30(2):57–61
Intraventricular pressure dynamics in patients with ventriculopleural shunts: a telemetric study. Munshi I, et

al. **Pediatr Neurosurg** 1998 Feb;28(2):67–9

Gastroesophageal reflux in infants with hydrocephalus before and after ventriculo-peritoneal shunt operation. Shteyer E, et al. **Pediatr Neurosurg** 1998 Sep;29(3):138–41

Third ventriculostomy versus cerebrospinal fluid shunt as a first procedure in pediatric hydrocephalus. Tuli S, et al. **Pediatr Neurosurg** 1999 Jan;30(1):11–5

A simple and safe technique for endoscopic third ventriculocisternostomy. Wellons JC 3rd, et al. **Pediatr Neurosurg** 1999 Apr;30(4):219–23

The use of laparoscopy in the diagnosis and treatment of ventriculo-peritoneal shunt in children [letter] Vrsansky. **Pediatr Surg Int** 1999;15(3–4):300

Posthemorrhagic hydrocephalus and brain injury in the preterm infant: dilemmas in diagnosis and management. du Plessis AJ. **Semin Pediatr Neurol** 1998 Sep;5(3):161–79 (286 ref.)

Revision of ventriculo-peritoneal shunt under laparoscopic guidance in patients with hydrocephalus. Kusano T, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):474–6

Endoscopic surgery for monoventricular hydrocephalus. Gangemi M, et al. **Surg Neurol** 1999 Sep;52(3):246–50; discussion 250–1

A rare cause of right atrial mass: thrombus formation and infection complicating a ventriculoatrial shunt for hydrocephalus. Yavuzgil O, et al. **Surg Neurol** 1999 Jul; 52(1):54–60; discussion 60–1

[Ventriculo-peritoneal shunts for thirty-two patients with traumatic hydrocephalus] Xie J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):431–3 (Eng. Abstr.) **(Chi)**

[What are the indications for neurosurgery in the early stage of head injury?] **Ann Fr Anesth Reanim** 1999 Jan; 18(1):58–71 (31 ref.) **(Fre)**

[Anesthetic management of a child with hydrocephaly or with a ventricular shunt] Bissonnette B. **Ann Fr Anesth Reanim** 1997;16(8):f122–4 **(Fre)**

[Clinical experience with the Sp[hy adjustable valve in the treatment of adult hydrocephalus. A series of 147 cases] Bret P, et al. **Neurochirurgie** 1999 May;45(2):98–108; discussion 108–9 (Eng. Abstr.) **(Fre)**

[Follow-up of children with early neonatal surgery of fetal hydrocephalus] Wada K, et al. **No To Shinkei** 1999 Mar; 51(3):215–20 (Eng. Abstr.) **(Jpn)**

[The usefulness of lumbar infusion test in the evaluation of the intracranial volume pressure compensation in hydrocephalus before and after shunt insertion] Czepko R, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1461–72 (Eng. Abstr.) **(Pol)**

[Surgical treatment of hydrocephalus: comments on the use of valves inserted into the burr hole (letter)] Jurkiewicz J. **Neurol Neurochir Pol** 1999 Jan–Feb;33(1):245–7 **(Pol)**

[The central nervous system and the lymphatic system. Lymphatic drainage of the cerebrospinal fluid] Kiwic G, et al. **Neurol Neurochir Pol** 1998 May–Jun;32(3):633–41 (20 ref.) (Eng. Abstr.) **(Pol)**

[IQ in hydrocephalus and myelomeningocele. Implications of surgical treatment] Fobe JL, et al. **Arq Neuropsiquiatr** 1999 Mar;57(1):44–50 (Eng. Abstr.) **(Por)**

[The excessive drainage syndrome as a complication in the surgical treatment of hydrocephalus in children] Lubnin AIu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar;(1):31–5 (82 ref.) (Eng. Abstr.) **(Rus)**

[Shunting operations in the hypertensive hydrocephalic syndrome in children with developmental defects of the central nervous system] Sufianov AA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):7–11 (Eng. Abstr.) **(Rus)**

[Endoscopic ventriculocisternostomy of the third cerebral ventricle] Paladino J, et al. **Lijec Vjesn** 1999 Jun; 121(6):181–5 (Eng. Abstr.) **(Scr)**

[Rapid breakthrough for endoscopy in neurosurgery] Kourtopoulos H, et al. **Lakartidningen** 1999 Feb 3; 96(5):466–8 **(Swe)**

THERAPY

Endoscopic third ventriculostomy. Sripairojkul B, et al. **J Med Assoc Thai** 1999 Jan;82(1):20–6

Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Libenson MH, et al. **Pediatr Neurol** 1999 Mar;20(3):185–91

Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device. Hudgins RJ, et al. **Pediatr Neurosurg** 1998 Dec;29(6):309–13

ULTRASONOGRAPHY

Transcranial Doppler-determined pulsatility index in the evaluation of endoscopic third ventriculostomy (preliminary data). Vajda Z, et al. **Acta Neurochir (Wien)** 1999;141(3):247–50

Sonographic ventriculography: a new potential use for sonographic contrast agents in neonatal hydrocephalus. Taylor GA, et al. **AJNR Am J Neuroradiol** 1998 Nov–Dec; 19(10):1931–4

Outcome and clinical course of prenatally diagnosed cerebral ventriculomegaly. Arora A, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:63–4

Outcome of prenatally detected mild/moderate cerebral ventriculomegaly. Rankin J, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:72

Prenatally detected mild/moderate cerebral ventriculomegaly: associated anomalies and outcome. Northern Congenital Abnormality Survey Steering Group. Robson S, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:70–1

Transcranial Doppler ultrasonography to evaluate need for cerebrospinal fluid drainage in hydrocephalic children. Westra SJ, et al. **J Ultrasound Med** 1998 Sep;17(9):561–9

Hydrolethalus syndrome in a non-Finnish family: confirmation of the entity and early prenatal diagnosis. de Ravel TJ, et al. **Prenat Diagn** 1999 Mar;19(3):279–81

Outcome of fetuses with isolated borderline unilateral ventriculomegaly diagnosed at mid-gestation. Lipitz S, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):23–6

VETERINARY

Magnetic resonance imaging of a medullary dermoid cyst with secondary hydrocephalus in a dog. Targett MP, et al. **Vet Radiol Ultrasound** 1999 Jan–Feb;40(1):23–6

VIROLOGY

Experimental mumps virus-induced hydrocephalus: viral neurotropism and neuronal maturity. Takano T, et al. **Neuroreport** 1999 Aug 2;10(11):2215–21

HYDROCEPHALUS, NORMAL PRESSURE

CEREBROSPINAL FLUID

Sinusoidal intrathecal infusion for assessment of CSF dynamics in kaolin-induced hydrocephalus. Brinker T, et al. **Acta Neurochir (Wien)** 1998;140(10):1069–75

COMPLICATIONS

Syndrome of inappropriate secretion of antidiuretic hormone associated with idiopathic normal pressure hydrocephalus. Yoshino M, et al. **Intern Med** 1999 Mar;38(3):290–2

Dutch Normal-Pressure Hydrocephalus Study: the role of cerebrovascular disease. Boon AJ, et al. **J Neurosurg** 1999 Feb;90(2):221–6

Reversible dementia in idiopathic normal pressure hydrocephalus. A case report. Bekkelund SI, et al. **Scand J Prim Health Care** 1999 Mar;17(1):22–4

DIAGNOSIS

Quantitative analysis of CSF flow dynamics using MRI in normal pressure hydrocephalus. Mase M, et al. **Acta Neurochir Suppl (Wien)** 1998;71:350–3

Magnetic resonance imaging, unstable intracranial pressure and clinical outcome in patients with normal pressure hydrocephalus. Qureshi AI, et al. **Acta Neurochir Suppl (Wien)** 1998;71:354–6

Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus. Williams MA, et al. **Acta Neurochir Suppl (Wien)** 1998;71:328–30

Differential diagnosis of NPH and brain atrophy assessed by measurement of intracranial and ventricular CSF volume with 3D FASE MRI. Yoshihara M, et al. **Acta Neurochir Suppl (Wien)** 1998;71:371–4

Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus. Holodny AI, et al. **J Neurosurg** 1998 Nov;89(5):742–7

[Secondary normal pressure hydrocephalus. A complication of chronic neuroborreliosis] Druschky K, et al. **Nervenarzt** 1999 Jun;70(6):556–9 (Eng. Abstr.) **(Ger)**

[Neuropsychology of normal pressure hydrocephalus] Merten T. **Nervenarzt** 1999 Jun;70(6):496–503 (30 ref.) (Eng. Abstr.) **(Ger)**

[Clinically suspected normal-pressure hydrocephalus diagnosis--current status of diagnosis and therapy] Zeilinger FS, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep; 92(7):495–501 (16 ref.) (Eng. Abstr.) **(Ger)**

[Normal pressure hydrocephalus--evaluation of investigation procedures] Tallaksen CM, et al. **Tidsskr Nor Laegeforen** 1999 May 10;119(12):1744–9 (Eng. Abstr.) **(Nor)**

[Current diagnostic methods in normotensive hydrocephalus] Czepko R, et al. **Przegl Lek** 1998;55(9):480–4 (45 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Normal pressure hydrocephalus in a patient with systemic lupus erythematosus: a case report. You HY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1998 Sep;61(9):551–5

[Secondary normal pressure hydrocephalus. A complication of chronic neuroborreliosis] Druschky K, et al. **Nervenarzt** 1999 Jun;70(6):556–9 (Eng. Abstr.) **(Ger)**

[A case of late adult-onset dentatorubral-pallidoluysian atrophy (DRPLA) successfully treated with V-P shunt operation] Fujita N, et al. **Rinsho Shinkeigaku** 1998 Jun; 38(6):516–9 (Eng. Abstr.) **(Jpn)**

PATHOLOGY

CSF spaces in idiopathic normal pressure hydrocephalus: morphology and volumetry [see comments] Kitagaki H, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1277–84. Comment in: AJNR Am J Neuroradiol 1998 Aug;19(7):1285–6.

PHYSIOPATHOLOGY

Clinical perspective in normal pressure hydrocephalus [letter] Mori E, et al. **AJNR Am J Neuroradiol** 1999 Jun–Jul; 20(6):1187–9

Continuous lumbar cerebrospinal fluid pressure monitoring in idiopathic normal-pressure hydrocephalus: predictive value in the selection for shunt surgery [letter] Pisani R, et al. **Clin Neurol Neurosurg** 1998 Jun;100(2):160–2

Cerebral blood flow in patients with normal pressure hydrocephalus. Chang CC, et al. **Nucl Med Commun** 1999 Feb;20(2):167–9

RADIONUCLIDE IMAGING

Cerebral blood flow in patients with normal pressure hydrocephalus. Chang CC, et al. **Nucl Med Commun** 1999 Feb;20(2):167–9

SURGERY

Does CSF outflow resistance predict the response to shunting in patients with normal pressure hydrocephalus? Boon AJ, et al. **Acta Neurochir Suppl (Wien)** 1998;71:331–3

Cine phase-contrast MR imaging in normal pressure hydrocephalus patients: relation to surgical outcome. Egeler-Peerdeman SM, et al. **Acta Neurochir Suppl (Wien)** 1998;71:340–2

Evaluation of shunt function in patients who are never better, or better than worse after shunt surgery for NPH. Williams MA, et al. **Acta Neurochir Suppl (Wien)** 1998;71:368–70

Pitfalls in shunting of hydrocephalus--clinical reality and improvement by the hydrostatic dual-switch valve. Sprung C, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:26–30

Laparoscopic transabdominal lumboperitoneal shunt. Huie F, et al. **Surg Endosc** 1999 Feb;13(2):161–3

[A case of late adult-onset dentatorubral-pallidoluysian atrophy (DRPLA) successfully treated with V-P shunt operation] Fujita N, et al. **Rinsho Shinkeigaku** 1998 Jun; 38(6):516–9 (Eng. Abstr.) **(Jpn)**

THERAPY

MR prediction of shunt response in NPH: CSF morphology versus physiology [comment] Bradley WG Jr. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1285–6. Comment on: AJNR Am J Neuroradiol 1998 Aug;19(7):1277–84.

HYDROCHLORIC ACID

see related

GASTRIC ACID

Effectiveness of acidic oxidative potential water in preventing bacterial infection in islet transplantation. Miyamoto M, et al. **Cell Transplant** 1999 Jul–Aug; 8(4):405–11

Effect of temperature on the intrinsic viscosity and conformation of chitosans in dilute HCl solution. Chen RH, et al. **Int J Biol Macromol** 1998 Aug;23(2):135–41

[Protective effects of teprenone and gefarnate against taurocholate/hydrochloric acid-induced acute gastric mucosal lesions in rats] Katoh Y, et al. **Nippon Yakurigaku Zasshi** 1998 Nov;112(5):323–31 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Involvement of PACAP in acid-induced HCO3- response in rat duodenums. Takeuchi K, et al. **Pharmacol Res** 1998 Dec;38(6):475–80

Squamous cell carcinoma arising from a hydrochloric acid burn [letter] Kargi E, et al. **Plast Reconstr Surg** 1999 Jun; 103(7):2086

ANALYSIS

[Potentiometric methods for determining boron, hydrogen cyanide and hydrogen chloride compounds and their use in controlling the quality of manufacturing and natural environments] Markova OL, et al. **Med Tr Prom Ekol** 1998; (11):24–6 (Eng. Abstr.) **(Rus)**

CHEMISTRY

The use of SIMS, XPS and in situ AFM to probe the acid catalysed hydrolysis of poly(orthoesters). Leadley SR, et al. **Biomaterials** 1998 Aug;19(15):1353–60

Prevention of small black spots on sugar-coated tablets containing aluminum acetylsalicylic acid. Tomida Y, et al. **Drug Dev Ind Pharm** 1999 Apr;25(4):445–52

The magnitude of changes in guanidine-HCl unfolding m-values in the protein, iso-1-cytochrome c, depends upon the substructure containing the mutation. Hammack B, et al. **Protein Sci** 1998 Aug;7(8):1789–95

PHARMACOLOGY

The effect of cisapride on duodenal acid exposure in the proximal duodenum in healthy subjects. Verhagen MA, et al. **Aliment Pharmacol Ther** 1999 May;13(5):621–30

Synergistic effect of hydrochloric acid and bile acids on the pars esophageal mucosa of the porcine stomach. Lang J, et al. **Am J Vet Res** 1998 Sep;59(9):1170–6

Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients [see comments] Samsom M, et al. **Gastroenterology** 1999 Mar;116(3):515–20. Comment in: Gastroenterology 1999

Mar;116(3):761–3.
Larynx vs. esophagus as reflexogenic sites for acid-induced bronchoconstriction in dogs. Ishikawa T, et al. **J Appl Physiol** 1999 Apr;86(4):1226–30
Gastric cytoprotection is secondary to increased mucosal fluid secretion: a study of six cytoprotective agents in the rat. Morris GP, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S53–63
Isolation and characterization of acid- and bile-tolerant isolates from strains of Lactobacillus acidophilus. Chou LS, et al. **J Dairy Sci** 1999 Jan;82(1):23–31
Heterogeneity of phenotypic and genotypic traits including organic-acid resistance in Escherichia coli O157 isolates. Horii T, et al. **Microbiol Immunol** 1998;42(12):871–4
Thromboxane mimics the pulmonary but not systemic vascular responses to bolus HCl injections in broiler chickens. Wideman RF Jr, et al. **Poult Sci** 1999 May; 78(5):714–21
Hydrochloric acid treatment for rapid recovery of Shiga toxin-producing Escherichia coli O26, O111 and O157 from faeces, food and environmental samples. Fukushima H, et al. **Zentralbl Bakteriol** 1999 Jul;289(3):285–99

POISONING

Delayed sequelae of hydrochloric acid ingestion. Wilasrusmee C, et al. **J Med Assoc Thai** 1999 Jun; 82(6):628–31
Swallowing of hydrochloric acid: study of 25 cases. Muñoz Muñoz E, et al. **Rev Esp Enferm Dig** 1998 Oct;90(10):701–7 **(Eng, Spa)**

THERAPEUTIC USE

Use of hydrochloric acid as a source of anions for prevention of milk fever. Goff JP, et al. **J Dairy Sci** 1998 Nov; 81(11):2874–80

TOXICITY

Experimental esophagitis induced by acid and pepsin in rabbits mimicking human reflux esophagitis. Lanas A, et al. **Gastroenterology** 1999 Jan;116(1):97–107

HYDROCHLORIC ACID, GASTRIC see **GASTRIC ACID**

HYDROCHLOROTHIAZIDE

ADMINISTRATION & DOSAGE

Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction. Uderman HD, et al. **Ann Pharmacother** 1999 May;33(5):525–30
Effects of losartan on hypertension and left ventricular mass: a long-term study [see comments] Tedesco MA, et al. **J Hum Hypertens** 1998 Aug;12(8):505–10. Comment in: J Hum Hypertens 1998 Aug;12(8):493–5.

ADVERSE EFFECTS

Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Ruml LA, et al. **Am J Kidney Dis** 1999 Jul;34(1):107–13
Emergency! Hyponatremia. De Jong MJ. **Am J Nurs** 1998 Dec;98(12):36
Hydrochlorothiazide-induced pulmonary edema and associated immunologic changes. Bernal C, et al. **Ann Pharmacother** 1999 Feb;33(2):172–4
Comment: hydrochlorothiazide-induced pulmonary edema and associated immunologic changes [letter] Chittivelu S. **Ann Pharmacother** 1999 Sep;33(9):1010–1
Severe hyponatraemia in an amiloride/hydrochlorothiazide-treated patient [see comments] van Assen S, et al. **Neth J Med** 1999 Mar; 54(3):108–13. Comment in: Neth J Med 1999 Mar;54(3):101–4.

PHARMACOKINETICS

Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction. Uderman HD, et al. **Ann Pharmacother** 1999 May;33(5):525–30
Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination. Weir SJ, et al. **Biopharm Drug Dispos** 1998 Sep;19(6):365–71
Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs. Reppas C, et al. **Eur J Pharm Sci** 1998 Apr;6(2):131–9
[Studies of lymphocyte membrane transport of sodium in patients with essential hypertension] Negrusz-Kawecka M. **Pol Merkuriusz Lek** 1999 Mar;6(33):125–7 (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Valsartan/hydrochlorothiazide. Langtry HD, et al. **Drugs** 1999 May;57(5):751–5; discussion 756–8 (9 ref.)
Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide. Pickkers P, et al. **Hypertension** 1999 Apr;33(4):1043–8
Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Charpiot P, et al. **Matrix Biol** 1998 Dec;17(8–9):559–74

THERAPEUTIC USE

Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide. Salako BL, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):73–5
Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. Radevski IV, et al. **Am J Cardiol** 1999 Jul 1;84(1):70–5
Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Kochar M, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):797–805
Study of supplemental oral l-arginine in hypertensives treated with enalapril + hydrochlorothiazide [letter] Pezza V, et al. **Am J Hypertens** 1998 Oct;11(10):1267–70
Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Adams JS, et al. **Ann Intern Med** 1999 Apr 20;130(8):658–60
Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Kirchlechner V, et al. **Arch Dis Child** 1999 Jun;80(6):548–52
Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group. Klein G. **Blood Press** 1998 Nov; 7(5–6):308–12
Isradipine in prediabetic hypertensive subjects. Byington RP, et al. **Diabetes Care** 1998 Dec;21(12):2103–10
Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats. Giummelly P, et al. **Hypertension** 1999 Aug;34(2):207–11
Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Muiesan ML, et al. **Hypertension** 1999 Jan;33(1 Pt 2):575–80
Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Pickkers P, et al. **Hypertension** 1998 Dec;32(6):1071–6
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Breithaupt-Grögler K, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):425–31
The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. Rosenstock J, et al. **J Clin Pharm Ther** 1998 Dec;23(6):433–40
Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. Benz JR, et al. **J Hum Hypertens** 1998 Dec; 12(12):861–6
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. Conlin PR, et al. **J Hum Hypertens** 1998 Oct; 12(10):693–9
Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. Nielsen S, et al. **J Hypertens** 1998 Oct;16(10):1539–44
Successful long-term treatment of congenital nephrogenic diabetes insipidus in a dog. Takemura N. **J Small Anim Pract** 1998 Dec;39(12):592–4
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Buter H, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1682–5
[Calcium antagonist vs diuretics. Doppler velocimetric monitoring of the carotid flow in patients with essential hypertension] Bellisi M, et al. **Minerva Cardioangiol** 1998 Jan–Feb;46(1–2):9–14 (Eng. Abstr.) **(Ita)**
[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension] Luna RL, et al. **Arq Bras Cardiol** 1998 Oct; 71(4):601–8 (Eng. Abstr.) **(Por)**
[Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study] Santello JL, et al. **Arq Bras Cardiol** 1998 Nov;71(5):713–6 (Eng. Abstr.) **(Por)**
[The additional efficacy of the nifedipine-diuretic combination depends on the potency of the drug administered first and not the sequence of administration. A double blind study in salt-sensitive black hypertensives] Damasceno A, et al. **Rev Port Cardiol** 1999 Jan;18(1):9–19 (Eng. Abstr.) **(Por)**

URINE

Simple method for determination of hydrochlorothiazide in human urine by high performance liquid chromatography utilizing narrowbore chromatography. Farthing D, et al. **J Pharm Biomed Anal** 1998 Sep;17(8):1455–9

HYDROCODEINONEBITARTRATE see **HYDROCODONE**

HYDROCODONE

Comparison of oral ketorolac and hydrocodone for pain relief after anterior cruciate ligament reconstruction. Barber FA, et al. **Arthroscopy** 1998 Sep;14(6):605–12

ADVERSE EFFECTS

Hiccup and apparent myoclonus after hydrocodone: review of the opiate-related hiccup and myoclonus literature. Lauterbach EC. **Clin Neuropharmacol** 1999 Mar–Apr; 22(2):87–92 (61 ref.)

ANALOGS & DERIVATIVES

Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity. McLaughlin JP, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):304–11

PHARMACOLOGY

Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Lelas S, et al. **Drug Alcohol Depend** 1999 May 3; 54(3):239–49
Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity. McLaughlin JP, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):304–11

THERAPEUTIC USE

Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain. Wideman GL, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):66–76
Tramadol or hydrocodone-acetaminophen for acute musculoskeletal pain? Marshall RC. **J Fam Pract** 1998 Nov; 47(5):330–1

HYDROCON see **HYDROCODONE**

18-HYDROCORTICOSTERONE see **18-HYDROXYCORTICOSTERONE**

HYDROCORTISONE

ADMINISTRATION & DOSAGE

Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Macefield VG, et al. **Blood Press** 1998 Jul;7(4):215–22
Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density [letter] Peacey SR, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):815–7
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study [see comments] Briegel J, et al. **Crit Care Med** 1999 Apr;27(4):723–32. Comment in: Crit Care Med 1999 Apr;27(4):672–4.
Effects of pulsed or continuous infusion of cortisol on immune function in sheep. Rhind SM, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):1–9
High doses of hydrocortisone improved tracheal autograft revascularization [see comments] Jadczuk E. **Eur J Cardiothorac Surg** 1998 Dec;14(6):615–20. Comment in: Eur J Cardiothorac Surg 1998 Dec;14(6):621–3.
Oral or intravenous steroids in acute severe asthma. Smith M. **J Accid Emerg Med** 1999 Jul;16(4):281–2
Levels of leptin during hydrocortisone infusions that mimic normal and reversed diurnal cortisol levels in subjects with adrenal insufficiency. Purnell JQ, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3125–8
An investigation into the need for supplementary steroids in organ transplant patients undergoing gingival surgery. A double-blind, split-mouth, cross-over study. Thomason JM, et al. **J Clin Periodontol** 1999 Sep;26(9):577–82
Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. Kang WH, et al. **J Dermatol** 1998 Sep;25(9):587–96
Low-dose hydrocortisone for chronic fatigue syndrome [letter; comment] Baschetti R. **JAMA** 1999 May 26; 281(20):1887; discussion 1888–9. Comment on: JAMA 1998 Sep 23–30;280(12):1061–6.
Low-dose hydrocortisone for chronic fatigue syndrome [letter; comment] Friedman TC, et al. **JAMA** 1999 May 26;281(20):1888–9. Comment on: JAMA 1998 Sep 23–30;280(12):1061–6.
Low-dose hydrocortisone for chronic fatigue syndrome [letter; comment] Teitelbaum JE, et al. **JAMA** 1999 May 26;281(20):1887–8; discussion 1888–9. Comment on: JAMA 1998 Sep 23–30;280(12):1061–6.
Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial [see comments] Cleare AJ, et al. **Lancet** 1999 Feb 6;353(9151):455–8. Comment in: Lancet 1999 Feb 6;353(9151):424–5. Comment in: Lancet 1999 May 8;353(9164):1618; discussion 1619–20. Comment in: Lancet 1999 May 8;353(9164):1618–9; discussion 1619–20. Comment in: Lancet 1999 May 8;353(9164):1619–20.
Equine antirabies serum treatment during an epizootic outbreak in the city of Ribeirão Preto, Brazil [letter] Wilde H. **Trans R Soc Trop Med Hyg** 1999 Jan–Feb;93(1):106; discussion 106–7
[The effects of high-dose steroid therapy on sudden deafness] Ochi K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Nov; 101(11):1311–5 (Eng. Abstr.) **(Jpn)**

HYDROCORTISONE

ADVERSE EFFECTS

Skin tests of steroid allergy. Asakawa H, et al. **Allergy** 1999 Jun;54(6):645–6

Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose–response study in humans. Lupien SJ, et al. **Behav Neurosci** 1999 Jun;113(3):420–30

Allergic contact dermatitis from dibucaine in Proctosedyl ointment without cross-sensitivity. Lee AY. **Contact Dermatitis** 1998 Nov;39(5):261

Complications of lumbar puncture with injection of hydrosoluble material. Hoeffel C, et al. **J Spinal Disord** 1999 Apr;12(2):168–71

[Total hip replacement in patients with steroid-induced femoral head necrosis] Dong W, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 May;11(3):161–3 (Eng. Abstr.) **(Chi)**

ANALOGS & DERIVATIVES

Hydrocortisone sodium succinate suppressed production of interleukin-10 by human peripheral blood mononuclear cells: clinical significance. Kohka H, et al. **Acta Med Okayama** 1999 Feb;53(1):55–9

The benefit of patch testing with a corticosteroid at a low concentration. Isaksson M, et al. **Am J Contact Dermat** 1999 Mar;10(1):31–3

Plasma cortisol concentrations in normal dogs given hydrocortisone sodium succinate. Church DB, et al. **Aust Vet J** 1999 May;77(5):316–7

Comparison of urinary 6beta-hydroxycortisol/cortisol ratio between neonates and their mothers. Nakamura H, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):31–4

Safe relief of rest pain that eases with activity in achillodynia by intrabursal or peritendinous steroid injection: the rupture rate was not increased by these steroid injections. Read MT. **Br J Sports Med** 1999 Apr;33(2):134–5

A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Lucas RA, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):639–43

Modified water containing hydrophilic ointment with suspended hydrocortisone-21-acetate--the influence of the microstructure of the cream on the in vitro drug release and in vitro percutaneous penetration. Müller-Goymann CC, et al. **Eur J Pharm Biopharm** 1999 Mar;47(2):139–43

Effect of short-term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Scheurlen C, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1539–45

The in vitro evaluation of polyethylene glycol esters of hydrocortisone 21-succinate as ocular prodrugs. Foroutan SM, et al. **Int J Pharm** 1999 May 10;182(1):79–92

Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Clark AF, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):2158–62

Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol. Koup JR, et al. **J Clin Pharmacol** 1998 Sep;38(9):815–8

Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women. Lin Y, et al. **J Clin Pharmacol** 1999 Jun;39(6):578–82

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. Tran JQ, et al. **J Clin Pharmacol** 1999 May; 39(5):487–94

Regulation of 18-oxocortisol and 18-hydroxycortisol by the renin-angiotensin system and ACTH in man. Yamakita N, et al. **J Steroid Biochem Mol Biol** 1993 Sep;46(3):395–9

Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Burstein AH, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1271–6

In vitro effect of ketone bodies, glucocorticosteroids and bovine pregnancy-associated glycoprotein on cultures of bone marrow progenitor cells of cows and calves. Hoeben D, et al. **Vet Immunol Immunopathol** 1999 May; 68(2-4):229–40

[The Locoid treatment of dermatoses in middle-aged and elderly persons] Tarasenko GN, et al. **Voen Med Zh** 1999 Jul;320(7):44–5 **(Rus)**

ANALYSIS

Minor physical anomalies, dermatoglyphic asymmetries, and cortisol levels in adolescents with schizotypal personality disorder. Weinstein DD, et al. **Am J Psychiatry** 1999 Apr; 156(4):617–23

A longitudinal study of work load and variations in psychological well-being, cortisol, smoking, and alcohol consumption. Steptoe A, et al. **Ann Behav Med** 1998 Spring; 20(2):84–91

Concentration of cortisol in the synovial fluid of patients with untreated rheumatoid arthritis. Relation to in vitro IL-8 production by synovial mononuclear cells. Perotti LA, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:255–8

Salivary cortisol responses in prepubertal boys: the effects of parental substance abuse and association with drug use behavior during adolescence. Moss HB, et al. **Biol Psychiatry** 1999 May 15;45(10):1293–9

Assessing salivary cortisol in studies of child development. Schwartz EB, et al. **Child Dev** 1998 Dec;69(6):1503–13

Social behavior correlates of cortisol activity in child care: gender differences and time-of-day effects. Tout K, et al. **Child Dev** 1998 Oct;69(5):1247–62

Reproducibility of the low dose dexamethasone suppression test: comparison between direct plasma and salivary cortisol assays. Reynolds RM, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):307–10

Hormonal and behavioral homeostasis in boys at risk for substance abuse. Dawes MA, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1-2):165–76

Effects of amount of training on the saliva concentrations of cortisol, dehydroepiandrosterone and on the dehydroepiandrosterone: cortisol concentration ratio in women over 16 weeks of training. Filaire E, et al. **Eur J Appl Physiol** 1998 Oct;78(5):466–71

Effects of video-relayed social support on hemodynamic reactivity and salivary cortisol during laboratory-based behavioral challenge. Thorsteinsson EB, et al. **Health Psychol** 1998 Sep;17(5):436–44

Presence of immunoreactive corticotropin-releasing hormone and cortisol molecules in invertebrate haemocytes and lower and higher vertebrate thymus. Ottaviani E, et al. **Histochem J** 1998 Feb;30(2):61–7

Testosterone, cortisol, and mood in a sports team competition. Gonzalez-Bono E, et al. **Horm Behav** 1999 Feb;35(1):55–62

Assessment of the follicular cortisol:cortisone ratio. Yding Andersen C, et al. **Hum Reprod** 1999 Jun;14(6):1562–8

The effect of stress on salivary cortisol in panic disorder patients. Stones A, et al. **J Affect Disord** 1999 Jan-Mar; 52(1-3):197–201

The effect of shot biopsy on behavior, salivary cortisol, and heart rate in slaughter pigs. Geverink NA, et al. **J Anim Sci** 1999 Jul;77(7):1614–9

Presence of cortisol in gingival crevicular fluid. A pilot study. Axtelius B, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):929–32

Differential effects of harassment on cardiovascular and salivary cortisol stress reactivity and recovery in women and men. Earle TL, et al. **J Psychosom Res** 1999 Feb; 46(2):125–41

Chronic burnout, somatic arousal and elevated salivary cortisol levels. Melamed S, et al. **J Psychosom Res** 1999 Jun;46(6):591–8

Technique for continuous monitoring of salivary cortisol concentration in pigs. Schönreiter S, et al. **Lab Anim Sci** 1999 Aug;49(4):429–32

A pilot investigation into the neuroendocrine correlates of personality in the workplace. Senior C, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):794

No evidence for a close relationship between personality traits and circadian cortisol rhythm or a single cortisol stress response. Schommer NC, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):840–2

The relationship between salivary cortisol concentrations in frozen versus mailed samples. Clements AD, et al. **Psychoneuroendocrinology** 1998 Aug;23(6):613–6

Increased salivary cortisol reliably induced by a protein-rich midday meal. Gibson EL, et al. **Psychosom Med** 1999 Mar-Apr;61(2):214–24

Burnout, perceived stress, and cortisol responses to awakening. Pruessner JC, et al. **Psychosom Med** 1999 Mar-Apr;61(2):197–204

Blunted cortisol response to a psychosocial stressor in schizophrenia. Jansen LM, et al. **Schizophr Res** 1998 Sep 7;33(1-2):87–94

[Salivary cortisol as a stress parameter in piglets] Schönreiter S, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 May;27(3):175–9 (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Treatment with growth hormone suppresses cortisol production in man. Vierhapper H, et al. **Metabolism** 1998 Nov;47(11):1376–8

[Ketoconazole in the control of arterial hypertension in Cushing's syndrome] Calvo Romero JM, et al. **Rev Clin Esp** 1999 Jan;199(1):25–7 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Effects of interferons on cortisol production in bovine adrenal fasciculata cells stimulated by adrenocorticotropin. Tachikawa E, et al. **J Pharm Pharmacol** 1999 Apr; 51(4):465–73

Is there a defect in cortisol production in rheumatoid arthritis? Harbuz MS, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):298–302 (60 ref.)

Cortisol production rate measurement by stable isotope dilution using gas chromatography-negative ion chemical ionization mass spectrometry. Brandon DD, et al. **Steroids** 1999 Jun;64(6):372–8

Effects of in vitro exposures to cadmium, mercury, zinc, and 1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane on steroidogenesis by dispersed interrenal cells of rainbow trout (Oncorhynchus mykiss). Leblond VS, et al. **Toxicol Appl Pharmacol** 1999 May 15; 157(1):16–22

BLOOD

Adrenal dysfunction in hemodynamically unstable patients in the emergency department. Rivers EP, et al. **Acad Emerg Med** 1999 Jun;6(6):626–30

Transcatheter adrenal arterial embolization of cortisol-producing tumors. Two cases of Cushing's syndrome. Ueno K, et al. **Acta Radiol** 1999 Jan;40(1):100–3

Effects of differently composed feeds and physical stress on plasma gastrin concentration in horses. Sandin A, et al. **Acta Vet Scand** 1998;39(2):265–72

Adrenocortical responses and family history of alcoholism. Wand GS, et al. **Alcohol Clin Exp Res** 1999 Jul; 23(7):1185–90

Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Straub RH, et al. **Am J Gastroenterol** 1998 Nov;93(11):2197–202

Maturation of cortisol responses to adrenocorticotropic hormone in twin fetal sheep in vivo. Block WA Jr, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):498–502

Adenosine modulates corticotropin and cortisol release during hypoxia in fetal sheep. Chau A, et al. **Am J Obstet Gynecol** 1999 May;180(5):1272–7

An increase in fetal plasma cortisol but not dehydroepiandrosterone sulfate is followed by the onset of preterm labor in patients with preterm premature rupture of the membranes. Yoon BH, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1107–14

Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis. Carlson GL, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):E658–62

Effects of estrogen and estrous cycle on glucocorticoid and catecholamine responses to stress in sheep. Komesaroff PA, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E671–8

Environmental enrichment of brown capuchins (Cebus apella): behavioral and plasma and fecal cortisol measures of effectiveness. Boinski S, et al. **Am J Primatol** 1999; 48(1):49–68

Rearing condition and plasma cortisol in rhesus monkey infants. Shannon C, et al. **Am J Primatol** 1998;46(4):311–21

Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Zobel AW, et al. **Am J Psychiatry** 1999 Jun;156(6):949–51

Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Derom E, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):157–61

Changes in cortisol concentration in response to stress and postoperative pain in client-owned cats and correlation with objective clinical variables. Smith JD, et al. **Am J Vet Res** 1999 Apr;60(4):432–6

Evaluation of 2-deoxy-D-glucose for induction of a stress response in pigs. Stabel TJ. **Am J Vet Res** 1999 Jun; 60(6):708–13

The effect of environment on plasma cortisol and beta-endorphin in the parturient pig and the involvement of endogenous opioids. Jarvis S, et al. **Anim Reprod Sci** 1998 Aug 21;52(2):139–51

Plasma beta-endorphin around parturition and its relationship to cortisol level and resumption of pituitary and ovarian functions in dairy cows. Osawa T, et al. **Anim Reprod Sci** 1998 Jun 30;52(1):27–38

Cognitive-behavioral intervention effects on mood and cortisol during exercise training. Perna FM, et al. **Ann Behav Med** 1998 Spring;20(2):92–8

Effects of emergency ambulance transportation on heart rate, blood pressure, corticotropin, and cortisol [letter] Witzel K. **Ann Emerg Med** 1999 May;33(5):598–9

Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Krishnan-Sarin S, et al. **Arch Gen Psychiatry** 1999 Jul;56(7):663–8

Effects of high-dose inhaled corticosteroids on plasma cortisol concentrations in healthy adults. Brus R. **Arch Intern Med** 1999 Sep 13;159(16):1903–8

Plasma cortisol concentrations in normal dogs given hydrocortisone sodium succinate. Church DB, et al. **Aust Vet J** 1999 May;77(5):316–7

Ketoconazole attenuates the cortisol response but not the subjective effects of smoked cocaine in humans. Ward AS, et al. **Behav Pharmacol** 1998 Nov;9(7):577–86

Plasma melatonin and cortisol in patients with obsessive-compulsive disorder: relationship with axillary temperature, physical activity, and clinical symptoms. Millet B, et al. **Biol Psychiatry** 1998 Nov 1;44(9):874–81

Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Mück-Seler D, et al. **Biol Psychiatry** 1999 Jun 1;45(11):1433–9

Dual relation between leptin and cortisol in humans is disturbed in Alzheimer's disease [letter; comment] Olsson T, et al. **Biol Psychiatry** 1998 Sep 1;44(5):374–6. Comment on: Biol Psychiatry 1996 Mar 1;39(5):311–8.

Sustained but not repeated acute elevation of cortisol impaired the luteinizing hormone surge, estrus, and ovulation in gilts. Turner AI, et al. **Biol Reprod** 1999 Sep; 61(3):614–20

Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy. Jenkins PJ, et al. **Br J Cancer** 1999 Aug;80(11):1815–9

Similar response of adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis [letter] Eijsbouts A, et al. **Br J Rheumatol** 1998 Oct;37(10):1138–9

Effect of endogenous cortisol levels on natural killer cell activity in healthy humans. Bodner G, et al. **Brain Behav Immun** 1998 Dec;12(4):285–96

Spinal cord noradrenergic dynamics in diabetic and

hypercortisolaemic states. Bitar MS, et al. **Brain Res** 1999 May 29;830(1):1-9

Hypercortisolemia and post-ECT confusion [letter] Kiraly SJ, et al. **Can J Psychiatry** 1999 Feb;44(1):92-3

Profound postanesthetic hypoglycemia attributable to glucocorticoid deficiency in 2 dogs. Lane IF, et al. **Can Vet J** 1999 Jul;40(7):497-500

Pediatric reference ranges for creatine kinase, CKMB, Troponin I, iron, and cortisol. Soldin SJ, et al. **Clin Biochem** 1999 Feb;32(1):77-80

A reference system for cortisol. Thienpont LM. **Clin Biochem** 1998 Aug;31(6):483-8

Biological day-to-day variation and reference change limits of serum cortisol and aldosterone in healthy young men on unrestricted diets. Ahokoski O, et al. **Clin Chem** 1999 Jul;45(7):1097-9

The use of free cortisol index for laboratory assessment of pituitary-adrenal function. Bonte HA, et al. **Clin Chem Lab Med** 1999 Feb;37(2):127-32

Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders [see comments] Clark PM, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):287-92. Comment in: Clin Endocrinol (Oxf) 1998 Sep;49(3):283.

Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. Dullaart RP, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):465-71

Circadian variation of plasma cortisol in prepubertal children with normal stature, short stature and growth hormone deficiency. Hermida RC, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):473-9

Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome. Katayama M, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):311-6

Correlation between cortisol and insulin-like growth factor-binding proteins (IGFBPs) under physiological conditions in children. Martinelli Jr CE, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):767-74

Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST). Orme SM, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):773-8

Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Tsagarakis S, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):165-71

Hormonal responses to endurance training and overtraining in female athletes. Uusitalo AL, et al. **Clin J Sport Med** 1998 Jul;8(3):178-86

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Angst MS, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):499-510

Twenty-four-hour cortisol response to multiple daily exercise sessions of moderate and high intensity. Hackney AC, et al. **Clin Physiol** 1999 Mar;19(2):178-82

Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Wilson AM, et al. **Clin Sci (Colch)** 1998 Oct;95(4):513-7

Rank dependent seasonal levels of IGF-1, cortisol and reproductive hormones in male pudu (Pudu puda). Bartoš L, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jun;120(2):373-8

Seasonal levels of metabolic hormones and substrates in male and female reindeer (Rangifer tarandus). Bubenik GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):307-15

Reduced plasma cortisol binding to albumin in ocular hypertension and primary open-angle glaucoma. McCarty GR, et al. **Curr Eye Res** 1999 Jun;18(6):467-76

Dampening of the cortisol response to handling at 3 months in human infants and its relation to sleep, circadian cortisol activity, and behavioral distress. Larson MC, et al. **Dev Psychobiol** 1998 Dec;33(4):327-37

Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus [see comments] Björntorp P, et al. **Diabet Med** 1999 May;16(5):373-83. Comment in: Diabet Med 1999 May;16(5):355-7.

Depressive symptomatology and cocaine-induced pituitary-adrenal axis activation in individuals with cocaine dependence. Elman I, et al. **Drug Alcohol Depend** 1999 Aug 2;56(1):39-45

A case of congenital hypopituitarism: difficulty in the diagnosis of ACTH deficiency due to high serum cortisol levels from a hypothyroid state. Nanao K, et al. **Endocr J** 1999 Feb;46(1):183-6

Free running circadian rhythms of melatonin, luteinizing hormone, and cortisol in Syrian hamsters bearing the circadian tau mutation. Lucas RJ, et al. **Endocrinology** 1999 Feb;140(2):758-64

Seizure-refractory period after a single stimulation and inhibition of seizures after repetitive stimulation in the gerbil: effects on blood cortisol levels. Revilla V, et al. **Epilepsia** 1999 Jan;40(1):1-4

Affective disorder subtyped by psychomotor symptoms, monoamine oxidase, melatonin and cortisol: identification of patients with latent bipolar disorder. Wahlund B, et al. **Eur Arch Psychiatry Clin Neurosci** 1998;248(5):215-24

Hydroxyurea influences adrenocortical function in humans [letter] Navarra P, et al. **Eur J Clin Pharmacol** 1998 Aug; 54(6):491-2

The influence of the mode of emergency ambulance transportation on the emergency patient's outcome. Witzel K, et al. **Eur J Emerg Med** 1999 Jun;6(2):115-8

Variations in glucocorticoid levels within the physiological range affect plasma leptin levels. Elimam A, et al. **Eur J Endocrinol** 1998 Dec;139(6):615-20

Comparisons of urinary versus serum cortisol in older persons. Kelly KS, et al. **Exp Aging Res** 1999 Apr-Jun; 25(2):161-7

Correlates of long-term hypocortisolism after transsphenoidal microsurgery for Cushing's disease. Flitsch J, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):183-9

Acute reserpine treatment alters the catecholamine, glucocorticoid and opioid response to walking exercise in sheep. Pierzchala-Koziec K, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):85-8

Effects of fetal endotoxin administration on plasma prostaglandin f(2alpha) and cortisol levels in late-gestation fetal goats. Kijima K, et al. **Fetal Diagn Ther** 1999 Jul-Aug; 14(4):240-3

The effect of photoperiod on diel rhythms in serum melatonin, cortisol, glucose, and electrolytes in the common dentex, Dentex dentex. Pavlidis M, et al. **Gen Comp Endocrinol** 1999 Feb;113(2):240-50

Lipid reactivity to stress: II. Biological and behavioral influences. Stoney CM, et al. **Health Psychol** 1999 May; 18(3):251-61

Relationships between dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels and everyday memory in Alzheimer's disease patients compared to healthy controls. Carlson LE, et al. **Horm Behav** 1999 Jun; 35(3):254-63

Dissociation of ACTH, beta-endorphin and cortisol in graded sepsis. Legakis I, et al. **Horm Metab Res** 1998 Sep; 30(9):570-4

Increased cortisol levels in human umbilical cord blood inhibit interferon alpha production of neonates. Reissland P, et al. **Immunobiology** 1999 Jun;200(2):227-33

Temporal relationships between leukocytes, IL-5 and IL-8 in guinea pig lungs, plasma cortisol and airway function after antigen challenge. Danahay H, et al. **Inflamm Res** 1999 Jan;48(1):41-7

Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Mormont MC, et al. **Int J Cancer** 1998 Nov 9;78(4):421-4

Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Meibohm B, et al. **Int J Clin Pharmacol Ther** 1999 Aug; 37(8):367-76

ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Pasquali R, et al. **Int J Obes Relat Metab Disord** 1999 Apr; 23(4):419-24

A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls. Ramasubbu R, et al. **J Affect Disord** 1999 Jan-Mar;52(1-3):121-33

Corticotropin-releasing hormone and cortisol: longitudinal associations with depression and antisocial behavior in pregnant adolescents. Susman EJ, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Apr;38(4):460-7

Effect of pen size on behavioral, endocrine, and immune responses of water buffalo (Bubalus bubalis) calves. Grasso F, et al. **J Anim Sci** 1999 Aug;77(8):2039-46

Effects of repeated jugular puncture on plasma cortisol concentrations in loose-housed dairy cows. Hopster H, et al. **J Anim Sci** 1999 Mar;77(3):708-14

The effect of age and teat order on alpha1-acid glycoprotein, neutrophil-to-lymphocyte ratio, cortisol, and average daily gain in commercial growing pigs. Stull CL, et al. **J Anim Sci** 1999 Jan;77(1):70-4

Adrenocorticotropic hormone and cortisol in calves after corticotropin-releasing hormone. Veissier I, et al. **J Anim Sci** 1999 Aug;77(8):2047-53

Relative eosinophilia (Thorn test) as a bioassay to judge the clinical relevance of cortisol values during severe stress [letter] Beishuizen A, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3400

Cortisol, androstenedione (A4), dehydroepiandrosterone sulphate (DHEAS) and 17 hydroxyprogesterone (17OHP) responses to low doses of (1-24)ACTH [published erratum appears in J Clin Endocrinol Metab 1999 Aug;84(8):2972] Bridges NA, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3750-3

Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. Dennison E, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3058-63

Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. Drake WM, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3542-4

A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. Kalmijn S, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3487-92

Temperature-dependent cortisol distribution among the blood compartments in man. Lentjes EG, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):682-7

Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. Plat L, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3082-92

Levels of leptin during hydrocortisone infusions that mimic normal and reversed diurnal cortisol levels in subjects with adrenal insufficiency. Purnell JQ, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3125-8

Elevated plasma cortisol reduces permeability of mammary tight junctions in the lactating bovine mammary epithelium. Stelwagen K, et al. **J Endocrinol** 1998 Oct;159(1):173-8

Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. Görges R, et al. **J Endocrinol Invest** 1999 Apr;22(4):241-9

The estimation of endogenous tumor necrosis factor alpha and cortisol levels in serum in advanced neoplasm. Baranowski M, et al. **J Exp Clin Cancer Res** 1999 Jun; 18(2):241-5

CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. Tornatore KM, et al. **J Med** 1998;29(3-4):159-83

Prolactin response to the severity of surgical insult. Peter S, et al. **J Natl Med Assoc** 1999 May;91(5):262-4

Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication. Takebayashi M, et al. **J Neural Transm** 1998;105(4-5):537-42

The hormonal response to stress is not modified by the dramatic decrease in prolactin plasma concentration during surgery for microprolactinoma. Guieu R, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):502-7

Pretreatment of young pigs with vitamin E attenuates the elevation in plasma interleukin-6 and cortisol caused by a challenge dose of lipopolysaccharide. Webel DM, et al. **J Nutr** 1998 Oct;128(10):1657-60

Diurnal variation of plasma cortisol levels in infancy. Mantagos S, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):549-53

Life events and social support as moderators of individual differences in cardiovascular and cortisol reactivity. Roy MP, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1273-81

The role of granulocyte-macrophage-colony stimulating factor, cortisol, and melatonin in the regulation of the circadian rhythms of peripheral blood cells in healthy volunteers and patients with breast cancer. Akbulut H, et al. **J Pineal Res** 1999 Jan;26(1):1-8

Perioperative plasma cortisol concentration in the horse. Stegmann GF, et al. **J S Afr Vet Assoc** 1998 Dec; 69(4):137-42

Reversal of diurnal cortisol rhythm and suppression of plasma testosterone in obstetric residents on call [see comments] Chatterton RT Jr, et al. **J Soc Gynecol Investig** 1999 Jan-Feb;6(1):50-4. Comment in: J Soc Gynecol Investig 1999 Jan-Feb;6(1):2.

A time-resolved fluoroimmunoassay for cortisol in unextracted bovine plasma or serum with optimized procedures to eliminate steroid binding protein interference and to minimize non-specific streptavidin-europium binding. Erkens JH, et al. **J Steroid Biochem Mol Biol** 1998 Oct;67(2):153-61

Effects of peripheral blood polymorphonuclear leukocyte function and blood components in Japanese black steers administered ACTH in a cold environment. Ishizaki H, et al. **J Vet Med Sci** 1999 May;61(5):487-92

Adrenocortical and metabolic responses to dobutamine infusion during halothane anaesthesia in ponies. Taylor PM. **J Vet Pharmacol Ther** 1998 Aug;21(4):282-7

Effects of single and multiple injections of ketamine hydrochloride on serum hormone concentrations in male cynomolgus monkeys. Malaivijitnond S, et al. **Lab Anim Sci** 1998 Jun;48(3):270-4

What test for hypothalamic-pituitary-adrenocortical insufficiency? Streeten DH. **Lancet** 1999 Jul 17; 354(9174):179-80

The cortisol response to awakening in relation to different challenge tests and a 12-hour cortisol rhythm. Schmidt-Reinwald A, et al. **Life Sci** 1999;64(18):1653-60

The hypothalamic-pituitary response in SLE. Regulation of prolactin, growth hormone and cortisol release. Rovenský J, et al. **Lupus** 1998;7(6):409-13

Evaluation of biological stress markers in police officers. Piercecchi-Marti MD, et al. **Med Law** 1999;18(1):125-44

The hormonal response to a d-fenfluramine challenge in trained and sedentary men. Strachan AT, et al. **Med Sci Sports Exerc** 1999 Apr;31(4):547-53

Plasma cortisol responses after intramuscular corticotropin 1-24 in healthy men. Longui CA, et al. **Metabolism** 1998 Nov;47(11):1419-22

Recurrent hypoglycemia does not impair the cortisol response to adrenocorticotropin infusion in healthy humans. Welt CK, et al. **Metabolism** 1998 Oct; 47(10):1252-7

Cortisol levels during human aging predict hippocampal atrophy and memory deficits [see comments] [published erratum appears in Nat Neurosci 1998 Aug;1(4):329] Lupien SJ, et al. **Nat Neurosci** 1998 May;1(1):69-73. Comment in: Nat Neurosci 1998 May;1(1):3-4.

Paper chromatography prior to cortisol RIA allows for accurate use of the dexamethasone suppression test in chronic renal failure. Van Herle AJ, et al. **Nephron** 1998

Sep;80(1):79–84

Adrenocorticotropin-related modulation of the human EEG and individual variability. Sannita WG, et al. **Neurosci Lett** 1999 Mar 12;262(3):147–50

Correlation between increased cortisol:DHEA ratio and malnutrition in HIV-positive men. Christeff N, et al. **Nutrition** 1999 Jul–Aug;15(7–8):534–9

Timing of peak serum cortisol values in preterm infants in low-dose and the standard ACTH tests. Karlsson R, et al. **Pediatr Res** 1999 Mar;45(3):367–9

Time-course studies on plasma glucose, insulin, and cortisol in sea bass (Dicentrarchus labrax) held under different photoperiodic regimes. Cerdá-Reverter JM, et al. **Physiol Behav** 1998 Jun 1;64(3):245–50

Scent-marking and cortisol response in the small-eared bushbaby (Otolemur garnettii). Watson SL, et al. **Physiol Behav** 1999 Jun;66(4):695–9

Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report. Fukuda M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Jul; 22(5):909–15

Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Sinha SS, et al. **Psychiatry Res** 1999 May 31;86(2):93–8

Influence of psychological stress on immune-inflammatory variables in normal humans. Part II. Altered serum concentrations of natural anti-inflammatory agents and soluble membrane antigens of monocytes and T lymphocytes. Song C, et al. **Psychiatry Res** 1999 Mar 22; 85(3):293–303

The effect of depressive symptomatology on plasma cortisol responses to acute bicycle exercise among post-menopausal women. van der Pompe G, et al. **Psychiatry Res** 1999 Jan 18;85(1):113–7

Cognitive-behavioral stress management buffers decreases in dehydroepiandrosterone sulfate (DHEA-S) and increases in the cortisol/DHEA-S ratio and reduces mood disturbance and perceived stress among HIV-seropositive men. Cruess DG, et al. **Psychoneuroendocrinology** 1999 Jul; 24(5):537–49

Cortisol levels of young children in full-day childcare centers: relations with age and temperament. Dettling AC, et al. **Psychoneuroendocrinology** 1999 Jul;24(5):519–36

Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population. Gispen-de Wied CC, et al. **Psychoneuroendocrinology** 1998 Apr;23(3):295–306

Do panic disorder and posttraumatic stress disorder share a common psychoneuroendocrinology? Kellner M, et al. **Psychoneuroendocrinology** 1999 Jul;24(5):485–504 (160 ref.)

Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Laakmann G, et al. **Psychoneuroendocrinology** 1999 Oct;24(7):769–84

Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resemble aspects of hypercortisolism in humans. Lyons DM, et al. **Psychoneuroendocrinology** 1999 Feb;24(2):131–42

High-dose naloxone (1.0 mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone. Martin-Del-Campo AF, et al. **Psychoneuroendocrinology** 1998 May;23(4):413–24

Sleep and endocrine changes after intranasal administration of growth hormone-releasing hormone in young and aged humans. Perras B, et al. **Psychoneuroendocrinology** 1999 Oct;24(7):743–57

Effects of competition and its outcome on serum testosterone, cortisol and prolactin. Suay F, et al. **Psychoneuroendocrinology** 1999 Jul;24(5):551–66

Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Sargent PA, et al. **Psychopharmacology (Berl)** 1998 Nov; 140(1):120–2

The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. van Berckel BN, et al. **Psychopharmacology (Berl)** 1998 Jun;137(3):271–81

Childhood attachment and loss experiences affect adult cardiovascular and cortisol function. Luecken LJ. **Psychosom Med** 1998 Nov-Dec;60(6):765–72

Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Schweiger U, et al. **Psychosom Med** 1999 May-Jun;61(3):292–6

The potential roles of cytokines, IL-5 and IL-8, and plasma cortisol in the anti-inflammatory actions of phosphodiesterase inhibitors in sensitized guinea-pig airways. Danahay H, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5–6):277–85

Changes in plasma cortisol concentrations in bitches in response to different combinations of halothane and butorphanol, with or without ovariohysterectomy. Fox SM, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):125–33

Studies of endotoxin-dependent fever in pre-pubertal pigs following acute activation of the pituitary-adrenocortical axis: towards a new hypothesis of fever regulation. Parrott RF, et al. **Res Vet Sci** 1999 Apr;66(2):85–91

Corticosteroid treatment of asthma: now at the crossroads [letter; comment] Hallett C. **Respir Med** 1999 Apr; 93(4):292–4 (26 ref.). Comment on: Respir Med 1999 Feb;93(2):141–6.

Fenfluramine and idiopathic pain: a serotonergic study in non-psychiatric patients with functional gastrointestinal disorder. Tanum L, et al. **Scand J Gastroenterol** 1998 Jul; 33(7):684–90

Hypothalamo-pituitary-adrenal axis and growth hormone axis in patients with rheumatoid arthritis. Demir H, et al. **Scand J Rheumatol** 1999;28(1):41–6

Serum cortisol levels in patients with uncomplicated and cerebral malaria. Shwe T, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):46–9

Effects of major depression, aging and gender upon calculated diurnal free plasma cortisol concentrations: a re-evaluation study. Deuschle M, et al. **Stress** 1998 Dec; 2(4):281–7

Ultrastructural and hormonal changes in the contralateral adrenal gland in unilateral adrenal gland ischemia: an experimental study in rats. Cakmak M, et al. **Surg Today** 1998;28(9):907–14

Heat-shock protein 72/73 and impaired wound healing in diabetic and hypercortisolemic states. Bitar MS, et al. **Surgery** 1999 Jun;125(6):594–601

The effect of short duration transportation on serum cortisol response in alpacas (Llama pacos). Anderson DE, et al. **Vet J** 1999 Mar;157(2):189–91

Effects of haemolysis, lipaemia and bilirubinaemia on an enzyme-linked immunosorbent assay for cortisol and free thyroxine in serum samples from dogs. Lucena R, et al. **Vet J** 1998 Sep;156(2):127–31

Effects of preslaughter handling on the behaviour, blood biochemistry and carcases of farmed red deer. Grigor PN, et al. **Vet Rec** 1999 Feb 27;144(9):223–7

[Changes in serum cortisone levels in patients with non-insulin-dependent diabetes mellitus] Shi Q, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):inside back cover **(Chi)**

[Familial cortisol resistance and mutations of the glucocorticoid receptor gene] Iida S, et al. **Nippon Rinsho** 1998 Jul;56(7):1887–91 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Hyperkalemic periodic muscle paralysis in primary adrenocortical insufficiency. A case report] Przedlacki J, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):330–1 (Eng. Abstr.) **(Pol)**

[The effect of the patient's hormonal status on the outcome of an operation for stomach cancer] Vinnik IuA, et al. **Klin Khir** 1998;(11):31–3 (Eng. Abstr.) **(Rus)**

[Quantitative characteristics of radiation sickness clinical manifestations in large-sized laboratory animals exposed to extra-lethal radiation doses. The endocrine system reactions in dogs and monkeys] Korotkevich AO. **Radiats Biol Radioecol** 1998 Jul–Aug;38(4):522–34 (Eng. Abstr.) **(Rus)**

[Levels of biologically active substances in the blood of patients resistant and nonresistant to antihypertensive therapy] Tabak'ian EA, et al. **Ter Arkh** 1999;71(3):62–7 (Eng. Abstr.) **(Rus)**

[Analyzing correlation between neurophysiological parameters and level of stress hormone cortisol in aging] Ponomareva NV, et al. **Vestn Ross Akad Med Nauk** 1999; (3):46–9 (Eng. Abstr.) **(Rus)**

[Dependence of the outcome of cerebral ischemia on the types of neurohypophysis reactions and dynamics of the level of hormones of hypophysis-dependent endocrine glands] Dolgov AM, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(10):45–7 **(Rus)**

[Relation between levels of leptin, insulin and cortisol in persons with the 5H (X) syndrome] Hrnčiar J, et al. **Vnitr Lek** 1998 Feb;44(2):68–75 (Eng. Abstr.) **(Slo)**

[Inducing high-specificity anti-cortisol antibodies for use in RIA (radioimmunoassay)] Merino Ruiz MC, et al. **Ginecol Obstet Mex** 1999 Aug;67:390–6 (Eng. Abstr.) **(Spa)**

[Partial remission of hypercortisolism in Cushing disease after pituitary apoplexy. A case report] Araya V, et al. **Rev Med Chil** 1998 Dec;126(12):1497–501 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Cavalli R, et al. **Int J Pharm** 1999 May 10;182(1):59–69

DEFICIENCY

The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Wichers M, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):759–65

Cortisol deficiency may account for elevated apoptotic cell population in patients with chronic fatigue syndrome [letter; comment] [see comments] Baschetti R. **J Intern Med** 1999 Apr;245(4):409–10. Comment on: J Intern Med 1997 Dec;242(6):465–78. Comment in: J Intern Med 1999 Apr;245(4):410–2.

[Glucocorticoid deficiency of the adrenal cortex in chronic liver diseases] Astaf'eva OV, et al. **Ter Arkh** 1999; 71(2):52–4 (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Gass RJ, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9–10):741–7

Levels of leptin during hydrocortisone infusions that mimic normal and reversed diurnal cortisol levels in subjects with adrenal insufficiency. Purnell JQ, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3125–8

Differential effects of hydrocortisone and dexamethasone on cortisol suppression in a child psychiatric population. Gispen-de Wied CC, et al. **Psychoneuroendocrinology** 1998 Apr;23(3):295–306

IMMUNOLOGY

Interaction of steroid--peroxidase conjugates with cellulose immunosorbents in aqueous and micellar media. Eryomin AN, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1148–59

Cortisol induces apoptosis in activated B cells, not in other lymphoid cells of the common carp, Cyprinus carpio L.. Weyts FA, et al. **Dev Comp Immunol** 1998 Sep–Dec; 22(5–6):551–62

The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Newell-Price J, et al. **Endocr Rev** 1998 Oct;19(5):647–72 (286 ref.)

Improving the affinity and the fine specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display. Chames P, et al. **J Immunol** 1998 Nov 15; 161(10):5421–9

Is there a defect in cortisol production in rheumatoid arthritis? Harbuz MS, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):298–302 (60 ref.)

METABOLISM

A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone. Edsbäcker S, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):219–24

Regulation of the action of hydrocortisone in airway epithelial cells by 11beta-hydroxysteroid dehydrogenase. Feinstein MB, et al. **Am J Respir Cell Mol Biol** 1999 Sep; 21(3):403–8

Endogenous cortisol and lung damage in a predominantly smoking population. Clark KD, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):755–9

Cortisol in fetal fluids and the fetal adrenal at parturition in the tammar wallaby (Macropus eugenii). Ingram JN, et al. **Biol Reprod** 1999 Mar;60(3):651–5

Adjustment of the human melatonin and cortisol rhythms to shortening of the natural summer photoperiod. Vondrasová-Jelínková D, et al. **Brain Res** 1999 Jan 16; 816(1):249–53

Corticosteroid-binding globulin and free cortisol in the early postoperative period after cardiac surgery. Vogeser M, et al. **Clin Biochem** 1999 Apr;32(3):213–6

An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Katz JR, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):63–8

Growth hormone and cortisol metabolism. Monson JP. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):281–2

Glucocorticoids and insulin resistance: old hormones, new targets. Andrews RC, et al. **Clin Sci (Colch)** 1999 May; 96(5):513–23 (102 ref.)

Cortisol inhibits apoptosis in carp neutrophilic granulocytes. Weyts FA, et al. **Dev Comp Immunol** 1998 Sep–Dec; 22(5–6):563–72

Effects of metyrapone on hepatic cortisone-cortisol conversion in the rat. Thomson LM, et al. **Endocr Res** 1998 Aug-Nov;24(3–4):607–11

Pituitary-adrenal reactivity in a child psychiatric population: salivary cortisol response to stressors. Jansen LM, et al. **Eur Neuropsychopharmacol** 1999 Jan;9(1–2):67–75

Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Malo JL, et al. **Eur Respir J** 1999 May; 13(5):993–8

Seasonal and social correlates of fecal testosterone and cortisol levels in wild male muriquis (Brachyteles arachnoides). Strier KB, et al. **Horm Behav** 1999 Apr; 35(2):125–34

Saliva cortisol, testosterone and T/C ratio variations during a wrestling competition and during the post-competitive recovery period. Passelergue P, et al. **Int J Sports Med** 1999 Feb;20(2):109–13

Psychological correlates of salivary cortisol secretion among unemployed men and women. Grossi G, et al. **Integr Physiol Behav Sci** 1998 Jul–Sep;33(3):249–63

Hypothermic, ACTH, and cortisol responses to ipsapirone in patients with mania and healthy controls. Yatham LN, et al. **J Affect Disord** 1999 Aug;54(3):295–301

Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. Castro M, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):878–82

Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. Finken MJ, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3316–21

Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. Mulatero P, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3996–4001

Light affects morning salivary cortisol in humans. Scheer FA, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3395–8

Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central

adiposity. Stewart PM, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1022–7

Characterization of 11beta–hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. Bland R, et al. **J Endocrinol** 1999 Jun;161(3):455–64

Effects of growth hormone–releasing peptide–6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. Frieboes RM, et al. **J Neuroendocrinol** 1999 Jun;11(6):473–8

Cortisol concentrations in early porcine embryos. Klemcke HG, et al. **Life Sci** 1999;64(15):1307–12

Peculiarities of axonal transport of steroid hormones (hydrocortisone, testosterone) in spinal root fibres of adult and old rats. Frolkis VV, et al. **Neuroscience** 1999; 92(4):1399–404

The cortisol–cortisone shuttle in children born with intrauterine growth retardation. Houang M, et al. **Pediatr Res** 1999 Aug;46(2):189–93

Interconversion of cortisol and cortisone by 11beta–hydroxysteroid dehydrogenases type 1 and 2 in the perfused human placenta. Sun K, et al. **Placenta** 1999 Jan; 20(1):13–9

Ipsapirone neuroendocrine challenge: relationship to aggression as measured in the human laboratory. Moeller FG, et al. **Psychiatry Res** 1998 Oct 19;81(1):31–8

Stressors and mood measured on a momentary basis are associated with salivary cortisol secretion. Smyth J, et al. **Psychoneuroendocrinology** 1998 May;23(4):353–70

Baseline salivary cortisol levels and preconscious selective attention for threat. A pilot study. van Honk J, et al. **Psychoneuroendocrinology** 1998 Oct;23(7):741–7

Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reactions. Rook GA, et al. **Trop Med Int Health** 1999 Jul;4(7):493–8 (45 ref.)

[Studies on biological monitoring of adrenocortical function in workers exposed to carbon disulfide] Yang X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May; 32(3):147–9 (Eng. Abstr.) **(Chi)**

[11 beta–hydroxysteroid–dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism] Kerstens MN, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):509–14 (47 ref.) (Eng. Abstr.) **(Dut)**

PHARMACOKINETICS

Influence of drug lipophilicity on terpenes as transdermal penetration enhancers. Godwin DA, et al. **Drug Dev Ind Pharm** 1999 Aug;25(8):905–15

Neither dapsone hydroxylation nor cortisol 6beta–hydroxylation detects the inhibition of CYP3A4 by HIV–1 protease inhibitors. Gass RJ, et al. **Eur J Clin Pharmacol** 1998 Nov–Dec;54(9–10):741–7

Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Lottenberg SA, et al. **Int J Clin Pharmacol Ther** 1998 Sep;36(9):501–5

Use of 1–methyl–pyrrolidone as a solubilizing agent for determining the uptake of poorly soluble drugs. Uch AS, et al. **Pharm Res** 1999 Jun;16(6):968–71

PHARMACOLOGY

Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol–induced renal vasodilatation in sheep. de Matteo R, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1125–31

Evaluation of the role of endotoxin and cortisol on modulation of CD18 adhesion receptors in cows with mastitis caused by Escherichia coli. Roets E, et al. **Am J Vet Res** 1999 May;60(5):534–40

Combinations of antiviral and anti–inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model. Awan AR, et al. **Antivir Chem Chemother** 1998 Jan;9(1):19–24

Decreased memory performance in healthy humans induced by stress–level cortisol treatment. Newcomer JW, et al. **Arch Gen Psychiatry** 1999 Jun;56(6):527–33

Dose–dependent cortisol–induced increases in plasma leptin concentration in healthy humans. Newcomer JW, et al. **Arch Gen Psychiatry** 1998 Nov;55(11):995–1000

Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions. Bray PJ, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1180–9

Suppression of apoptotic cell death progressed in vitro with incubation of the chorion laeve tissues of human fetal membrane by glucocorticoid. Ohyama K, et al. **Biol Pharm Bull** 1998 Oct;21(10):1024–9

Hypothalamic–pituitary–adrenal axis effects on plasma homovanillic acid in man. Posener JA, et al. **Biol Psychiatry** 1999 Jan 15;45(2):222–8

Effect of stress–like concentrations of cortisol on estradiol–dependent expression of gonadotropin–releasing hormone receptor in orchidectomized sheep. Adams TE, et al. **Biol Reprod** 1999 Jan;60(1):164–8

Effect of stress–like concentrations of cortisol on gonadotroph function in orchidectomized sheep. Daley CA, et al. **Biol Reprod** 1999 Jan;60(1):158–63

Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in their response to corticosterone, cortisol, and cortisone. Bellows CG, et al. **Bone** 1998 Aug; 23(2):119–25

Administration of glucocorticoids markedly increases the numbers of granulocytes and extrathymic T cells in the bone marrow. Maruyama S, et al. **Cell Immunol** 1999 May 25;194(1):28–35

The effect of short–term cortisol changes on growth hormone responses to the pyridostigmine–growth–hormone–releasing–hormone test in healthy adults and patients with suspected growth hormone deficiency. Andersen M, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):241–9

Cortisol and hypertension. Kelly JJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S51–6 (51 ref.)

Influence of cortisol on insulin– and insulin–like growth factor 1 (IGF–1)–induced steroid production and on IGF–1 receptors in cultured bovine granulosa cells and thecal cells. Spicer LJ, et al. **Endocrine** 1998 Oct;9(2):153–61

Cortisol selectively stimulates pituitary gonadotropin beta–subunit in a primitive teleost, Anguilla anguilla. Huang YS, et al. **Endocrinology** 1999 Mar;140(3):1228–35

Cortisol enhances the expression of mac25/insulin–like growth factor–binding protein–related protein–1 in cultured osteoblasts. Pereira RC, et al. **Endocrinology** 1999 Jan;140(1):228–32

Zymogen granule alterations in caerulein–induced pancreatitis developed during continuous hydrocortisone administration. Garcia–Montero AC, et al. **Eur J Clin Invest** 1999 Jun;29(6):496–503

Hydrocortisone inhibits granulocyte–macrophage colony–stimulating factor production from normal human peripheral blood mononuclear cells and CD3+ T cells. Chikkappa G, et al. **Exp Hematol** 1998 Dec;26(13):1240–6

Increased expression of the Na(+)/Ca(2+) exchanger in the rat heart after immobilization stress is not induced by cortisol. Zacikova L, et al. **FEBS Lett** 1999 Sep 3; 457(3):423–8

Cortisol levels and control of inflammatory responses to toxic shock syndrome toxin–1 (TSST–1): the prevalence of night–time deaths in sudden infant death syndrome (SIDS). Gordon AE, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):199–206

Effects of insulin–like growth factor–I and cortisol on Na+, K+–ATPase expression in osmoregulatory tissues of brown trout (Salmo trutta). Seidelin M, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):331–42

T3–hydrocortisone synergism on adult–type erythroblast proliferation and T3–mediated apoptosis of larval–type erythroblasts during erythropoietic conversion in Xenopus laevis. Nishikawa A, et al. **Histochem Cell Biol** 1999 Apr; 111(4):325–34

Hormonal regulation of malate–aspartate shuttle enzymes during postnatal development of mice. Dey S, et al. **Indian J Biochem Biophys** 1998 Aug;35(4):224–8

Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS. Patel R, et al. **Inflamm Res** 1999 Jun;48(6):337–43

Glucocorticoid hormone suppression of human neutrophil–mediated tumor cell cytostasis. Yazawa H, et al. **Int J Cancer** 1999 Mar 31;81(1):74–80

Mechanism–based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Meibohm B, et al. **Int J Clin Pharmacol Ther** 1999 Aug; 37(8):367–76

Glutamine synthetase expression and activity are regulated by 3,5,3'–triodo–L–thyronine and hydrocortisone in rat oligodendrocyte cultures. Baas D, et al. **Int J Dev Neurosci** 1998 Aug;16(5):333–40

The effects of upper respiratory infection on T–cell proliferation and steroid sensitivity of asthmatics. Vianna EO, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):592–7

Increased IkappaB expression and diminished nuclear NF–kappaB in human mononuclear cells following hydrocortisone injection. Aljada A, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3386–9

Increase in plasma interleukin–10 following hydrocortisone injection. Dandona P, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1141–4

Characteristics of transport systems of L–alanine in mouse mammary gland and their regulation by lactogenic hormones: evidence for two broad spectrum systems. Sharma R, et al. **J Dairy Res** 1999 Aug;66(3):385–98

Progesterone inhibits glucocorticoid–dependent aromatase induction in human adipose fibroblasts. Schmidt M, et al. **J Endocrinol** 1998 Sep;158(3):401–7

Osteoprotegerin mRNA is expressed in primary human osteoblast–like cells: down–regulation by glucocorticoids. Vidal NO, et al. **J Endocrinol** 1998 Oct;159(1):191–5

Enterochromaffin cells in the stomach of the rat after prolonged administration of cortisol and both cortisol and salmon calcitonin. Orlicz–Szczęsna G, et al. **J Endocrinol Invest** 1999 May;22(5):323–6

16–Epiestriol, a novel anti–inflammatory nonglycogenic steroid, does not inhibit IFN–gamma production by murine splenocytes. Miller E, et al. **J Interferon Cytokine Res** 1998 Nov;18(11):921–5

Modulation of adhesion and chemotaxis of human neutrophils by cortisol, transforming growth factor–beta and antiinflammatory drugs. Zak–Nejmark T, et al. **J Investig Allergol Clin Immunol** 1998 Nov–Dec; 8(6):346–52

Corticosteroids inhibit the production of inflammatory mediators in immature monocyte–derived DC and induce the development of tolerogenic DC3. de Jong EC, et al. **J Leukoc Biol** 1999 Aug;66(2):201–4

Suppression of the nicotinic acetylcholine response in rat superior cervical ganglionic neurons by steroids. Uki M, et al. **J Neurochem** 1999 Feb;72(2):808–14

Glucocorticoids decrease phenylethanolamine N–methyltransferase mRNA expression in the immature foetal sheep adrenal. Adams MB, et al. **J Neuroendocrinol** 1999 Jul;11(7):569–75

Effect of chronic high–dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. Leverenz JB, et al. **J Neurosci** 1999 Mar 15;19(6):2356–61

Stimulus–secretion coupling in porcine adrenal chromaffin cells: acute effects of glucocorticoids. Wagner PG, et al. **J Neurosci Res** 1999 Sep 1;57(5):643–50

Glucocorticoid modulation of Ca2+ homeostasis in human B lymphoblasts. Gardner JP, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):385–96

Regulation of histidase gene expression by glucagon, hydrocortisone and protein–free/high carbohydrate diet in the rat. Alemán G, et al. **Life Sci** 1998;63(18):1663–72

Hormonal modulation of branchial Na+–K+–ATPase subunit mRNA in a marine teleost Sparus sarba. Deane EE, et al. **Life Sci** 1999;64(20):1819–29

Rapid and opposite effects of cortisol and estradiol on human erythrocyte Na+,K+–ATPase activity: relationship to steroid intercalation into the cell membrane. Golden GA, et al. **Life Sci** 1999;65(12):1247–55

Cortisol's purpose. Weber C. **Med Hypotheses** 1998 Oct; 51(4):289–91 (23 ref.)

Does hydrocortisone modify the in vitro susceptibility of Aspergillus fumigatus to itraconazole and amphotericin B? Ramondenc I, et al. **Med Mycol** 1998 Apr;36(2):69–73

Repeated in vivo hydrocortisone treatment promotes a dual modulation of cytokeratin expression by mouse thymic epithelial cells. Cirne–Lima EO, et al. **Neuroimmunomodulation** 1998 Nov–Dec;5(6):328–31

Dose response of adrenocorticotropin and cortisol to the CCK–B agonist pentagastrin. Abelson JL, et al. **Neuropsychopharmacology** 1999 Oct;21(4):485–94

Perinatal myocardial DNA and protein changes in the lamb: effect of cortisol in the fetus. Rudolph AM, et al. **Pediatr Res** 1999 Aug;46(2):141–6

Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal antiinflammatory agents. Little RJ, et al. **Pharm Res** 1999 Jun;16(6):961–7

The effects of chronic plasma cortisol elevation on the feeding behaviour, growth, competitive ability, and swimming performance of juvenile rainbow trout. Gregory TR, et al. **Physiol Biochem Zool** 1999 May–Jun; 72(3):286–95

Effects of cortisol on ion regulation in developing tilapia (Oreochromis mossambicus) larvae on seawater adaptation. Lin GR, et al. **Physiol Biochem Zool** 1999 Jul–Aug; 72(4):397–404

5–Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. Porter RJ, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):243–50

The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Young AH, et al. **Psychopharmacology (Berl)** 1999 Aug;145(3):260–6

Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Hudnall SD, et al. **Transplantation** 1999 Mar 15;67(5):648–52

[Effect of high density lipoproteins and hydrocortisone on apolipoprotein E production in Kupffer cells] Panin LE, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):43–5 **(Rus)**

[Brain cerebrosides and sulfocerebrosides after treatment with hydrocortisone] Chaeva LS, et al. **Vopr Med Khim** 1998 Sep–Oct;44(5):459–63 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Cortisol facilitates induction of sexual behavior in the female musk shrew (Suncus murinus). Schiml PA, et al. **Behav Neurosci** 1999 Feb;113(1):166–75

Identification of potential sites of cortisol actions on the reproductive axis in rainbow trout. Teitsma C, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):243–9 (33 ref.)

Negative emotionality and cortisol during adolescent pregnancy and its effects on infant health and autonomic nervous system reactivity. Ponirakis A, et al. **Dev Psychobiol** 1998 Sep;33(2):163–74

Neuroendocrine activity and memory–related impairments in posttraumatic stress disorder. Golier J, et al. **Dev Psychopathol** 1998 Fall;10(4):857–69 (63 ref.)

The regulation of prolactin receptor messenger ribonucleic acid levels in the sheep liver before birth: relative roles of the fetal hypothalamus, cortisol, and the external photoperiod. Phillips ID, et al. **Endocrinology** 1999 May; 140(5):1966–71

Activation of the adult mode of ovine growth hormone receptor gene expression by cortisol during late fetal development. Li J, et al. **FASEB J** 1999 Mar;13(3):545–52

Influence of thyroxine and hydrocortisone in vivo on porcine preadipocyte recruitment, development and expression of C/EBP binding proteins in fetal stromal vascular (S–V) cell cultures. Hausman GJ, et al. **Growth Dev Aging** 1998 Autumn;62(3):107–18

The impact of a new emotional self–management program on stress, emotions, heart rate variability, DHEA and

cortisol. McCraty R, et al. **Integr Physiol Behav Sci** 1998 Apr-Jun;33(2):151-70

The interaction of hydrocortisone and thyroxine during fetal adipose tissue differentiation: CCAAT enhancing binding protein expression and capillary cytodifferentiation. Hausman GJ. **J Anim Sci** 1999 Aug;77(8):2088-97

The effects of endogenous opioids and cortisol on thyrotropin and prolactin secretion in patients with Addison's disease. Hangaard J, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1595-601

Dual regulation of insulin-like growth factor binding protein-1 levels by insulin and cortisol during fasting [see comments] Katz LE, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4426-30. Comment in: J Clin Endocrinol Metab 1999 Jun;84(6):2259-61.

Role of endogenous cortisol in basal liquid clearance from distal air spaces in adult guinea-pigs. Norlin A, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:261-72

Cortisol as a mineralocorticoid in human disease. Stewart PM. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):403-8 (51 ref.)

Reduced cortisol potentiates the exercise-induced increase in corticotropin to a greater extent in trained compared with untrained men. Del Corral P, et al. **Metabolism** 1999 Mar;48(3):390-4

Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Rainey WE. **Mol Cell Endocrinol** 1999 May 25;151(1-2):151-60 (79 ref.)

Stress, splicing, cortisol, and the aging hippocampus [news] Collier DA. **Mol Psychiatry** 1998 Jul;3(4):298

RADIATION EFFECTS

Endocrine and reproductive health status of men who had experienced short-term radiation exposure at Chernobyl. Goncharov NP, et al. **Int J Androl** 1998 Oct;21(5):271-6

SECRETION

Effect of alternate-day prednisolone administration on hypophyseal-adrenocortical activity in dogs. Brockus CW, et al. **Am J Vet Res** 1999 Jun;60(6):698-702

Absence of seasonal variation in the phase of the endogenous circadian rhythm in humans. Van Dongen HP, et al. **Chronobiol Int** 1998 Nov;15(6):623-32

Using 'off the shelf', computer programs to mine additional insights from published data: diurnal variation in potency of ACTH stimulation of cortisol secretion revealed. Gonzalez-Heydrich J, et al. **Comput Methods Programs Biomed** 1999 Mar;58(3):227-38

Dopaminergic stimulation of cortisol secretion from bovine zfr cells occurs through nonspecific stimulation of adrenergic beta-receptors. Bird IM, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):769-72

Basal catecholamine and cortisol secretion in primary chromaffin cell cultures before and after purification and retroviral transfection. Uhlmann K, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):753-7

Native urotensins influence cortisol secretion and plasma cortisol concentration in the euryhaline flounder, platichthys flesus. Kelsall CJ, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):210-9

Longitudinal evaluation of salivary cortisol levels in full-term and preterm neonates. Bettendorf M, et al. **Horm Res** 1998; 50(6):303-8

Circadian plasma leptin levels in patients with anorexia nervosa: relation to insulin and cortisol. Herpertz S, et al. **Horm Res** 1998;50(4):197-204

Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Fraser R, et al. **Hypertension** 1999 Jun;33(6):1364-8

Social separation in infant Cebus apella: patterns of behavioral and cortisol response. Byrne G, et al. **Int J Dev Neurosci** 1999 Jun;17(3):265-74

The relationship between salivary secretory immunoglobulin A and cortisol: neuroendocrine response to awakening and the diurnal cycle. Hucklebridge F, et al. **Int J Psychophysiol** 1998 Dec;31(1):69-76

Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. Arvat E, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4207-11

The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. Arvat E, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2611-5

Cortisol secretion is related to electroencephalographic alertness in human subjects during daytime wakefulness. Chapotot F, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4263-8

Neuroendocrine processes underlying ultradian sleep regulation in man. Gronfier C, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2686-90

Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. Torlontano M, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2381-5

A high-sensitivity test in the assessment of adrenocortical insufficiency: 10 microg vs 250 microg cosyntropin dose assessment of adrenocortical insufficiency. González-González JG, et al. **J Endocrinol** 1998 Nov; 159(2):275-80

Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease. Arvat E, et al. **J Endocrinol Invest** 1999 Jan; 22(1):23-8

Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. Jiang HK, et al. **J Formos Med Assoc** 1998 Dec;97(12):830-7

Salivary cortisol in women with and without perimenstrual mood changes. Odber J, et al. **J Psychosom Res** 1998 Dec; 45(6):557-68

The inhibitor of phospholipase-A2, AACOCF3, stimulates steroid secretion by dispersed human and rat adrenocortical cells. Andreis PG, et al. **Life Sci** 1999;64(15):1287-94

The awakening cortisol response and blood glucose levels. Hucklebridge FH, et al. **Life Sci** 1999;64(11):931-7

Stress-induced cortisol, mood, and fat distribution in men. Epel EE, et al. **Obes Res** 1999 Jan;7(1):9-15

Antenatal glucocorticoids modulate the amplitude of pulsatile cortisol secretion in premature neonates. Arnold JD, et al. **Pediatr Res** 1998 Dec;44(6):876-81

Rapid transcranial magnetic stimulation and normalization of the dexamethasone suppression test. Pridmore S. **Psychiatry Clin Neurosci** 1999 Feb;53(1):33-7

Cortisol fluctuates with increases and decreases in negative affect. Buchanan TW, et al. **Psychoneuroendocrinology** 1999 Feb;24(2):227-41

[Effect of somatostatin-octreotide on secretion of adrenocorticotropin, cortisol and neuro-hypophyseal hormones in acromegaly] Julesz J, et al. **Orv Hetil** 1998 Dec 20;139(51):3071-4 (Eng. Abstr.) **(Hun)**

[The effect of the photoperiod on steroid hormone secretion, on seasonal reproductive rhythms and on fertility in female silver foxes] Osadchuk LV. **Izv Akad Nauk Ser Biol** 1999 Mar-Apr;(2):191-200 (Eng. Abstr.) **(Rus)**

STANDARDS

A reference system for cortisol. Thienpont LM. **Clin Biochem** 1998 Aug;31(6):483-8

THERAPEUTIC USE

Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. De Palma GD, et al. **Am J Gastroenterol** 1999 Apr;94(4):982-5

Pre-treatment of transplant bone marrow cells with hydrocortisone and cyclosporin A alleviates graft-versus-host reaction in a murine allogeneic host-donor combination. Grcević D, et al. **Bone Marrow Transplant** 1999 Jun;23(11):1145-52

Adrenal failure in the critically ill [letter; comment] Knighton JD, et al. **Br J Anaesth** 1999 Jan;82(1):152-3. Comment on: Br J Anaesth 1998 Sep;81(3):308-10. Comment on: Br J Anaesth 1998 Sep;81(3):468-70.

Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma [letter] Deshpande H, et al. **Cancer J Sci Am** 1999 Jan-Feb;5(1):52-3

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Ellerhorst JA, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2371-6

The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Wichers M, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):759-65

Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Chun A, et al. **Inflamm Bowel Dis** 1998 Aug;4(3):177-81

Treatment of cutaneous sarcoidosis using phonophoresis. Gogstetter DS, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):767-9

Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome [letter] Baschetti R. **J Clin Endocrinol Metab** 1999 Jun;84(6):2263-4

Hydrocortisone and chronic fatigue syndrome [letter; comment] Baschetti R. **Lancet** 1999 May 8;353(9164):1618; discussion 1619-20. Comment on: Lancet 1999 Feb 6;353(9151):455-8.

Hydrocortisone and chronic fatigue syndrome [letter; comment] Dessein PH, et al. **Lancet** 1999 May 8; 353(9164):1618; discussion 1619-20. Comment on: Lancet 1999 Feb 6;353(9151):455-8.

Chronic fatigue syndrome and functional hypoadrenia--fighting vainly the old ennui [see comments] Jeffcoate WJ. **Lancet** 1999 Feb 6;353(9151):424-5. Comment in: Lancet 1999 Feb 6;353(9151):445-8. Comment in: Lancet 1999 May 8;353(9164):1619-20.

Hydrocortisone and chronic fatigue syndrome [letter; comment] Rea T, et al. **Lancet** 1999 May 8; 353(9164):1618-9; discussion 1619-20. Comment on: Lancet 1999 Feb 6;353(9151):455-8.

Hydrocortisone and chronic fatigue syndrome [letter; comment] Shepherd C. **Lancet** 1999 May 8; 353(9164):1619-20. Comment on: Lancet 1999 Feb 6;353(9151):424-5. Comment on: Lancet 1999 Feb 6;353(9151):455-8.

Effect of topical tretinoin under occlusion on atypical naevi. Stam-Posthuma JJ, et al. **Melanoma Res** 1998 Dec; 8(6):539-48

Lichen planus pemphigoides in a 9-year-old child: Successful treatment with topical corticosteroids [letter] Hofmann-Wellenhof R, et al. **Pediatr Dermatol** 1999 Jan-Feb;16(1):70-1

[Hydrocortisone in catecholamine regulated circulatory insufficiency] Briegel J. **Anaesthesist** 1999 Apr;48(4):263-5 **(Ger)**

TOXICITY

RT-PCR quantification of AHR, ARNT, GR, and CYP1A1 mRNA in craniofacial tissues of embryonic mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone. Abbott BD, et al. **Toxicol Sci** 1999 Jan; 47(1):76-85

URINE

Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Maes M, et al. **Acta Psychiatr Scand** 1998 Oct;98(4):328-35

Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder [published erratum appears in Am J Psychiatry 1999 Jun;156(6):986] Baker DG, et al. **Am J Psychiatry** 1999 Apr;156(4):585-8

Different approaches to the identification of a cortisol isomer compound in horse urine. Popot MA, et al. **Analyst** 1998 Dec;123(12):2649-52

A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems [see comments] De Bellis MD, et al. **Biol Psychiatry** 1999 May 15;45(10):1259-70 (67 ref.). Comment in: Biol Psychiatry 1999 May 15;45(10):1235-6.

Comparison of urinary 6beta-hydroxycortisol/cortisol ratio between neonates and their mothers. Nakamura H, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):31-4

Urinary free cortisol is not affected by short-term water diuresis [letter] Fenske M. **Clin Chem** 1999 Feb;45(2):316-7

Improved specificity of a new direct assay for urinary cortisol: application in corticoid treated patients. Sapin R, et al. **Clin Chem Lab Med** 1998 Nov;36(11):855-8

Correlation between urinary cortisol and 6-sulphatoxymelatonin rhythms in field studies of blind subjects. Skene DJ, et al. **Clin Endocrinol (Oxf)** 1999 Jun; 50(6):715-9

Undetectable urinary free cortisol concentrations in a case of Cushing's disease. Issa BG, et al. **Eur J Endocrinol** 1999 Feb;140(2):148-51

Comparisons of urinary versus serum cortisol in older persons. Kelly KS, et al. **Exp Aging Res** 1999 Apr-Jun; 25(2):161-7

Quantification of cortisol inactivation in cirrhosis of the liver. Vogeser M, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(5):410-4

The relation between cortisol excretion and fractures in healthy older people: results from the MacArthur studies-Mac. Greendale GA, et al. **J Am Geriatr Soc** 1999 Jul;47(7):799-803

Development of a urinary free cortisol assay using solid-phase extraction-capillary electrophoresis. Rao LV, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 25; 730(1):123-8

The midnight to morning urinary cortisol increment is an accurate, noninvasive method for assessment of the hypothalamic-pituitary-adrenal axis. Kong WM, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3093-8

Lack of specificity of urinary free cortisol determinations: why does it continue? [letter; comment] Pearson Murphy BE. **J Clin Endocrinol Metab** 1999 Jun;84(6):2258-9. Comment on: J Clin Endocrinol Metab 1998 May;83(5):1806-9.

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. Tran JQ, et al. **J Clin Pharmacol** 1999 May; 39(5):487-94

Abdominal obesity increases overnight cortisol excretion. Duclos M, et al. **J Endocrinol Invest** 1999 Jun;22(6):465-71

Diagnosis of Cushing's syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. Görges R, et al. **J Endocrinol Invest** 1999 Apr;22(4):241-9

Urinary free cortisol (UFC) values in newborns under stress. Zadik Z, et al. **J Pediatr Endocrinol Metab** 1999 Jul-Aug; 12(4):543-7

Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. Harrison LI, et al. **J Pharm Pharmacol** 1999 Mar; 51(3):263-9

Age-related levels of urinary free cortisol in the tree shrew. Van Kampen M, et al. **Neurobiol Aging** 1998 Jul-Aug; 19(4):363-6

Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Burstein AH, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1271-6

Evidence from urinary cortisol that maternal behavior is related to stress in gorillas. Bahr NI, et al. **Physiol Behav** 1998 Jun 15;64(4):429-37

Ambulatory blood pressure, heart rate, and neuroendocrine responses in women nurses during work and off work days.

Goldstein IB, et al. **Psychosom Med** 1999 May-Jun; 61(3):387-96

HYDROCORTISONE, TOPICAL

ADMINISTRATION & DOSAGE

Modified water containing hydrophilic ointment with suspended hydrocortisone-21-acetate--the influence of the microstructure of the cream on the in vitro drug release and in vitro percutaneous penetration. Müller-Goymann CC, et al. **Eur J Pharm Biopharm** 1999 Mar;47(2):139-43

ADVERSE EFFECTS

Patch tests with corticosteroids in Poland. Rudzki E, et al. **Contact Dermatitis** 1998 Nov;39(5):269

THERAPEUTIC USE

[The Locoid treatment of dermatoses in middle-aged and elderly persons] Tarasenko GN, et al. **Voen Med Zh** 1999 Jul;320(7):44-5 **(Rus)**

HYDROCYANIC ACID see **HYDROGEN CYANIDE**

HYDROELECTRIC POWER PLANTS see **POWER PLANTS**

HYDROFLUORIC ACID

Deglycosylation by gaseous hydrogen fluoride of mucus glycoproteins immobilized on nylon membranes and in microtiter wells. Axelsson MA, et al. **Glycoconj J** 1998 Aug;15(8):749-55

PHARMACOLOGY

Increased CD3 positive cells in bronchoalveolar lavage fluid after hydrogen fluoride inhalation. Lund K, et al. **Scand J Work Environ Health** 1999 Aug;25(4):326-34

POISONING

Ingestion of low-concentration hydrofluoric acid: an insidious and potentially fatal poisoning. Kao WF, et al. **Ann Emerg Med** 1999 Jul;34(1):35-41

TOXICITY

Short-term exposures of rats to airborne hydrogen fluoride. Dalbey W, et al. **J Toxicol Environ Health** 1998 Oct 23; 55(4):241-75

HYDROGEL

Basic fibroblast growth factor impregnated hydrogel microspheres for embolization of cerebral arteriovenous malformations. Nishi S, et al. **ASAIO J** 1998 Sep-Oct; 44(5):M405-10

Hydrogel contact lens dehydration and oxygen transmissibility. Efron N, et al. **CLAO J** 1999 Jul; 25(3):148-51

Omafilcon A (Proclear) soft contact lenses in a dry eye population. Lemp MA, et al. **CLAO J** 1999 Jan;25(1):40-7

Advaseal for acute aortic dissection: experimental study [letter] Tanaka K, et al. **Eur J Cardiothorac Surg** 1999 Jan; 15(1):114-5

Lysozyme sorption in hydrogel contact lenses. Garrett Q, et al. **Invest Ophthalmol Vis Sci** 1999 Apr;40(5):897-903

Effect of expandable full-size intraocular lenses on lens centration and capsule opacification in rabbits. Assia EI, et al. **J Cataract Refract Surg** 1999 Mar;25(3):347-56

Enhanced loading and activity retention of bioactive proteins in hydrogel delivery systems. Gehrke SH, et al. **J Controlled Release** 1998 Oct 30;55(1):21-33

Treatment of congenital anophthalmos with self-inflating polymer expanders: a new method. Wiese KG, et al. **J Craniomaxillofac Surg** 1999 Apr;27(2):72-6

Influences of hydrogel contact lens care solutions on corneal epithelial wound healing. Lin CP, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Oct; 14(10):639-43

Folding angle critical with hydrogel lens [letter] Dada T, et al. **Ophthalmic Surg Lasers** 1999 Mar;30(3):244

ADMINISTRATION & DOSAGE

Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. Pugach JL, et al. **J Urol** 1999 Sep;162(3 Pt 1):883-7

ADVERSE EFFECTS

Long-term complications of silicone and hydrogel explants in retinal reattachment surgery. Roldán-Pallarés M, et al. **Arch Ophthalmol** 1999 Feb;117(2):197-201

Effect of lens wear on corneal stroma: preliminary findings. Jalbert I, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug; 27(3-4):211-3

ANALOGS & DERIVATIVES see HYDROGELS

CHEMICAL SYNTHESIS

Synthesis and characterization of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. Chiu HC, et al. **J Biomater Sci Polym Ed** 1999; 10(5):591-608

CHEMISTRY

Silicone rubber/hydrogel composite ophthalmic inserts: preparation and preliminary in vitro/in vivo evaluation. Chetoni P, et al. **Eur J Pharm Biopharm** 1998 Jul; 46(1):125-32

Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. Akiyoshi K, et al. **J Controlled Release** 1998 Aug 14;54(3):313-20

PHARMACOKINETICS

Transdermal absorption of L-dopa from hydrogel in rats. Sudo J, et al. **Eur J Pharm Sci** 1998 Dec;7(1):67-71

TOXICITY

In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Draye JP, et al. **Biomaterials** 1998 Sep;19(18):1677-87

HYDROGELS

Chitosan hydrogel as a base for transdermal delivery of berberine and its evaluation in rat skin. Tsai CJ, et al. **Biol Pharm Bull** 1999 Apr;22(4):397-401

The importance of physicochemical swelling in cartilage illustrated with a model hydrogel system. Broom ND, et al. **Biomaterials** 1998 Jul;19(13):1179-88

Characterization of transient platelet contacts on a polyvinyl alcohol hydrogel by video microscopy. Godo MN, et al. **Biomaterials** 1999 Jun;20(12):1117-26

Fabrication of porous gelatin scaffolds for tissue engineering. Kang HW, et al. **Biomaterials** 1999 Jul;20(14):1339-44

Temperature modulated protein release from pH/temperature-sensitive hydrogels. Park TG. **Biomaterials** 1999 Mar;20(6):517-21

Alginate hydrogels as synthetic extracellular matrix materials. Rowley JA, et al. **Biomaterials** 1999 Jan;20(1):45-53

Cell viability and inflammatory response in hydrogel sponges implanted in the rabbit cornea. Vijayasekaran S, et al. **Biomaterials** 1998 Dec;19(24):2255-67

Smart hydrogels for bioseparation. Kim JJ, et al. **Bioseparation** 1998-99;7(4-5):177-84 (66 ref.)

Water-absorbent polymer as a carrier for a discrete deposit of antisense oligodeoxynucleotides in the central nervous system. Bannai M, et al. **Brain Res Brain Res Protoc** 1998 Sep;3(1):83-7

Implantation of collagen IV/poly(2-hydroxyethyl methacrylate) hydrogels containing Schwann cells into the lesioned rat optic tract. Plant GW, et al. **Cell Transplant** 1998 Jul-Aug;7(4):381-91

Possibilities of conveying a cationic drug in Carbomer hydrogels. Realdon N, et al. **Drug Dev Ind Pharm** 1998 Apr;24(4):337-43

Determination of doping methyltestosterone by capillary electrophoresis immunological analysis with thermally reversible hydrogel and laser-induced fluorescence. Zhang XX, et al. **Electrophoresis** 1999 Jul;20(10):1998-2002

The use of poloxamer hydrogels for the assessment of biofilm susceptibility towards biocide treatments. Gilbert P, et al. **J Appl Microbiol** 1998 Dec;85(6):985-90

Performance evaluation of disinfectant formulations using poloxamer-hydrogel biofilm-constructs. Wirtanen G, et al. **J Appl Microbiol** 1998 Dec;85(6):965-71

Investigation into the biphasic properties of a hydrogel for use in a cushion form replacement joint. Goldsmith AA, et al. **J Biomech Eng** 1998 Jun;120(3):362-9

Entropic trapping of macromolecules by mesoscopic periodic voids in a polymer hydrogel. Liu L, et al. **Nature** 1999 Jan 14;397(6715):141-4

Adverse events with extended wear of disposable hydrogels: results for the first 13 months of lens wear. Sankaridurg PR, et al. **Ophthalmology** 1999 Sep;106(9):1671-80

Polysaccharide film-coating process for freely swellable hydrogels. Coppi G, et al. **Pharm Dev Technol** 1998 Aug; 3(3):347-53

ADMINISTRATION & DOSAGE

A liposomal hydrogel for the prevention of bacterial adhesion to catheters. DiTizio V, et al. **Biomaterials** 1998 Oct; 19(20):1877-84

A new amorphous hydrocolloid for the treatment of pressure sores: a randomised controlled study. Matzen S, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):13-5

ADVERSE EFFECTS

Adverse reactions due to Aquavene [letter; comment] Mermel L. **J Biomed Mater Res** 1998 Nov;42(2):339-40. Comment on: J Biomed Mater Res 1998 Mar 15;39(4):642-9.

Experimental encircling scleral buckle with silicone and hydrogel: histopathologic and comparative study of 26 rabbit eyes. D'Hermies F, et al. **Retina** 1999;19(2):148-57

CHEMICAL SYNTHESIS

Novel hydrophilic cyclic monomers in hydrogel synthesis. Jarvie AW, et al. **Biomaterials** 1998 Nov;19(21):1957-61

Preparation and characterization of poly(propylene fumarate-co-ethylene glycol) hydrogels. Suggs LJ, et al. **J Biomater Sci Polym Ed** 1998;9(7):653-66

Synthesis and characterization of dextran-maleic acid based hydrogel. Kim SH, et al. **J Biomed Mater Res** 1999 Aug; 46(2):160-70

Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release. Lu S, et al. **J Controlled Release** 1999 Feb 22;57(3):291-300

Reductive amination using poly(ethylene glycol) acetaldehyde hydrate generated in situ: applications to chitosan and lysozyme. Bentley MD, et al. **J Pharm Sci** 1998 Nov;87(11):1446-9

Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Wang C, et al. **Nature** 1999 Feb 4;397(6718):417-20

Polymer chemistry. Designer jell-o. Peters R, et al. **Science** 1999 Mar 19;283(5409):1872

CHEMISTRY

A fluorescence-based glucose biosensor using concanavalin A and dextran encapsulated in a poly(ethylene glycol) hydrogel. Russell RJ, et al. **Anal Chem** 1999 Aug 1; 71(15):3126-32

New biodegradable hydrogels based on a photocrosslinkable modified polyaspartamide: synthesis and characterization. Giammona G, et al. **Biochim Biophys Acta** 1999 Jun 28; 1428(1):29-38

Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: thermal stabilization with refolding of carbonic anhydrase B. Akiyoshi K, et al. **Bioconjug Chem** 1999 May-Jun;10(3):321-4

Novel pH-sensitive hydrogels with adjustable swelling kinetics. Akala EO, et al. **Biomaterials** 1998 Jun; 19(11-12):1037-47

Light-induced tailoring of PEG-hydrogel properties. Andreopoulos FM, et al. **Biomaterials** 1998 Aug; 19(15):1343-52

A potentiostatic study of oxygen transmissibility and permeability through hydrogel membranes. Compañ V, et al. **Biomaterials** 1998 Dec;19(23):2139-45

Effect of charged groups on the adsorption and penetration of proteins onto and into carboxymethylated poly(HEMA) hydrogels. Garrett Q, et al. **Biomaterials** 1998 Dec; 19(23):2175-86

Irreversible adsorption of human serum albumin to hydrogel contact lenses: a study using electron spin resonance spectroscopy. Garrett Q, et al. **Biomaterials** 1999 Jul; 20(14):1345-56

In vitro sorption and desorption of basic fibroblast growth factor from biodegradable hydrogels. Tabata Y, et al. **Biomaterials** 1998 Oct;19(19):1781-9

The development of artificial articular cartilage--PVA-hydrogel. Gu ZQ, et al. **Biomed Mater Eng** 1998;8(2):75-81

Dielectric properties of alginate beads and bound water relaxation studied by electrorotation. Esch M, et al. **Biopolymers** 1999 Sep;50(3):227-37

The effect of structural changes on swelling kinetics of polybasic/hydrophobic pH-sensitive hydrogels. Falamarzian M, et al. **Drug Dev Ind Pharm** 1998 Jul; 24(7):667-9

Development of a "continuous-flow adhesion cell" for the assessment of hydrogel adhesion. Le Ray AM, et al. **Drug Dev Ind Pharm** 1999 Aug;25(8):897-904

Topical oleo-hydrogel preparation of ketoprofen with enhanced skin permeability. Rhee GJ, et al. **Drug Dev Ind Pharm** 1999 Jun;25(6):717-26

Drug diffusion and binding in ionizable interpenetrating networks from poly(vinyl alcohol) and poly(acrylic acid). Peppas NA, et al. **Eur J Pharm Biopharm** 1998 Jul; 46(1):15-29

Innovative ambulatory drug delivery system using an electrolytic hydrogel infusion pump. Kim HC, et al. **IEEE Trans Biomed Eng** 1999 Jun;46(6):663-9

A study on hydroxyapatite formation on/in the hydroxyl groups-bearing nonionic hydrogels. Taguchi T, et al. **J Biomater Sci Polym Ed** 1999;10(1):19-32

Apatite formation on/in hydrogel matrices using an alternate soaking process: II. Effect of swelling ratios of poly(vinyl alcohol) hydrogel matrices on apatite formation. Taguchi T, et al. **J Biomater Sci Polym Ed** 1999;10(3):331-9

The modulation of cellular responses to poly(2-hydroxyethyl methacrylate) hydrogel surfaces: phosphorylation decreases macrophage collagenase production in vitro. Ziegelaar BW, et al. **J Biomater Sci Polym Ed** 1998; 9(8):849-62

Dual-stimuli-responsive drug release from interpenetrating polymer network-structured hydrogels of gelatin and dextran. Kurisawa M, et al. **J Controlled Release** 1998 Jul 31;54(2):191-200

Equilibrium swelling of poly(methacrylic acid-g-ethylene glycol) hydrogels. Effect of swelling medium and synthesis conditions. Mathur AM, et al. **J Controlled Release** 1998 Jul 31;54(2):177-84

How interactions between drugs and agarose-carrageenan hydrogels influence the simultaneous transport of drugs. Sjöberg H, et al. **J Controlled Release** 1999 Jun 2; 59(3):391-400

Growth factor release from amylopectin hydrogel based on copper coordination. Tabata Y, et al. **J Controlled Release** 1998 Dec 4;56(1-3):135-48

HYDROGELS

Poly(acrylamide-co-monoethyl itaconate) hydrogels as devices for cytarabine release in rats. Gomez C, et al. **J Pharm Pharmacol** 1998 Jul;50(7):703-12

Inulin hydrogels as carriers for colonic drug targeting. Rheological characterization of the hydrogel formation and the hydrogel network. Vervoort L, et al. **J Pharm Sci** 1999 Feb;88(2):209-14

Novel degradable poly(ethylene glycol) hydrogels for controlled release of protein. Zhao X, et al. **J Pharm Sci** 1998 Nov;87(11):1450-8

A reversibly antigen-responsive hydrogel. Miyata T, et al. **Nature** 1999 Jun 24;399(6738):766-9

Partition and diffusion of sodium and chloride ions in soft charged foam: the effect of external salt concentration and mechanical deformation. Lanir Y, et al. **Tissue Eng** 1998 Winter;4(4):365-78

METABOLISM

Biodegradation of ornithine-containing polylysine hydrogels. Ohkawa K, et al. **Biomaterials** 1998 Oct;19(20):1855-60

In vitro and in vivo erosion of two different hydrophilic gel matrix tablets. Abrahamsson B, et al. **Eur J Pharm Biopharm** 1998 Jul;46(1):69-75

PHARMACOKINETICS

Growth factor release from amylopectin hydrogel based on copper coordination. Tabata Y, et al. **J Controlled Release** 1998 Dec 4;56(1-3):135-48

THERAPEUTIC USE

Sealing effect of rapidly curable gelatin-poly (L-glutamic acid) hydrogel glue on lung air leak. Otani Y, et al. **Ann Thorac Surg** 1999 Apr;67(4):922-6

Heterogeneous PHPMA hydrogels for tissue repair and axonal regeneration in the injured spinal cord. Woerly S, et al. **J Biomater Sci Polym Ed** 1998;9(7):681-711

[The application of endoscopic methods in the treatment of vesico-ureteral reflux in children with the use of polyacrylamide hydrogel "Interfall"] Barukhovich VIa, et al. **Klin Khir** 1999;(3):53-4 **(Rus)**

TOXICITY

In vitro cytotoxicity and in vivo biocompatibility of poly(propylene fumarate-co-ethylene glycol) hydrogels. Suggs LJ, et al. **J Biomed Mater Res** 1999 Jul;46(1):22-32

HYDROGEN

Multiple isotope effects as a probe of proton and hydride transfer in the 6-phosphogluconate dehydrogenase reaction. Hwang CC, et al. **Biochemistry** 1998 Nov 10; 37(45):15698-702

Thermal denaturation of Escherichia coli thioredoxin studied by hydrogen/deuterium exchange and electrospray ionization mass spectrometry: monitoring a two-state protein unfolding transition. Maier CS, et al. **Biochemistry** 1999 Jan 19;38(3):1136-43

Extracellular H+ stimulates the expression of c-fos/c-jun mRNA through Ca2+/calmodulin in PC12 cells. Shimokawa N, et al. **Cell Signal** 1998 Jul;10(7):499-503

Hydrogen tunneling in biology. Kohen A, et al. **Chem Biol** 1999 Jul;6(7):R191-8 (43 ref.)

Virtual atom representation of hydrogen bonds in minimal off-lattice models of alpha helices: effect on stability, cooperativity and kinetics. Klimov DK, et al. **Fold Des** 1998;3(6):481-96

Hydrogen exchange in ribonuclease A and ribonuclease S: evidence for residual structure in the unfolded state under native conditions. Neira JL, et al. **J Mol Biol** 1999 Jan 15;285(2):627-43

Experimental hydrogen kerma factors for incident neutron energies from 25 to 75 MeV. Corcalciuc V, et al. **Phys Med Biol** 1999 Mar;44(3):719-26

Interiors of giant planets inside and outside the solar system. Guillot T. **Science** 1999 Oct 1;286(5437):72-7 (58 ref.)

Far-ultraviolet imaging spectroscopy of Io's atmosphere with HST/STIS. Roesler FL, et al. **Science** 1999 Jan 15; 283(5400):353-7

ANALYSIS

Reproducibility of breath hydrogen concentration measurements in dogs after change of diet. Bissett SA, et al. **Am J Vet Res** 1998 Dec;59(12):1523-5

Use of the breath hydrogen test to assess the effect of age on orocecal transit time and carbohydrate assimilation in cats. Papasouliotis K, et al. **Am J Vet Res** 1998 Oct; 59(10):1299-302

Use of breath hydrogen testing to detect experimentally induced disaccharide malabsorption in healthy adult dogs. Spohr A, et al. **Am J Vet Res** 1999 Jul;60(7):836-40

On-line technique for measuring stable oxygen and hydrogen isotopes from microliter quantities of water. Socki RA, et al. **Anal Chem** 1999 Jun 1;71(11):2250-3

Using a cutoff of <10 ppm for breath hydrogen testing: a review of five years' experience. Karcher RE, et al. **Ann Clin Lab Sci** 1999 Jan-Mar;29(1):1-8

Bowel function in runners after ingestion of sweeteners. D'Alessandro A, et al. **Clin Ter** 1999 Jan-Feb;150(1):29-32

Assessment of a breath collection technique and portable breath hydrogen monitor for use in cats and dogs. German AJ, et al. **Res Vet Sci** 1998 Sep-Oct;65(2):173-5

Breath hydrogen measurement in ponies: a preliminary study. Murphy D, et al. **Res Vet Sci** 1998 Jul-Aug;65(1):47-51

A new look at the jovian planets. Bézard B, et al. **Science** 1999 Feb 5;283(5403):800-1

[Determination of food oral-colon transit time with breath hydrogen test] Yin W, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):306-8 (Eng. Abstr.) **(Chi)**

[Lactose intolerance in children. An analysis of hydrogen gas in exhaled air simplifies and improves diagnosis] Särnblad S, et al. **Lakartidningen** 1999 Mar 10;96(10):1180-3 (12 ref.) **(Swe)**

BLOOD

Evaluation of absolute cerebral blood flow by laser-Doppler scanning-- comparison with hydrogen clearance. Uranishi R, et al. **J Vasc Res** 1999 Mar-Apr;36(2):100-5

CHEMISTRY

Liberation of hydrogen sulfide during the catalytic action of Desulfovibrio hydrogenase under the atmosphere of hydrogen. Higuchi Y, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):295-9

Catalytic electron transport in Chromatium vinosum [NiFe]-hydrogenase: application of voltammetry in detecting redox-active centers and establishing that hydrogen oxidation is very fast even at potentials close to the reversible H+/H2 value. Pershad HR, et al. **Biochemistry** 1999 Jul 13;38(28):8992-9

Effects of structure on alpha C-H bond enthalpies of amino acid residues: relevance to H transfers in enzyme mechanisms and in protein oxidation. Rauk A, et al. **Biochemistry** 1999 Jul 13;38(28):9089-96

Studies on the heme and H2-uptake reaction from Azotobacter vinelandii bacterial ferritin. Huang HQ, et al. **Bioelectrochem Bioenerg** 1999 Feb;48(1):87-93

Changes in water structure induced by a hydrophobic solute probed by simulation of the water hydrogen bond angle and radial distribution functions. Madan B, et al. **Biophys Chem** 1999 Apr 5;78(1-2):33-41

C-H activation. Holland HL. **Curr Opin Chem Biol** 1999 Feb; 3(1):22-7 (35 ref.)

Pre-steady-state kinetics of the reactions of [NiFe]-hydrogenase from Chromatium vinosum with H2 and CO. Happe RP, et al. **Eur J Biochem** 1999 Feb; 259(3):602-8

Stopped-flow kinetics of hydride transfer between nucleotides by recombinant domains of proton-translocating transhydrogenase. Venning JD, et al. **Eur J Biochem** 1998 Oct 1;257(1):202-9

Hydration of gas-phase ions formed by electrospray ionization. Rodriguez-Cruz SE, et al. **J Am Soc Mass Spectrom** 1999 Oct;10(10):958-68

Asymmetric adiabatic pulses for NH selection. Hwang TL, et al. **J Magn Reson** 1999 May;138(1):173-7

Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. Word JM, et al. **J Mol Biol** 1999 Jan 29;285(4):1711-33

Structural mobility of the human prion protein probed by backbone hydrogen exchange. Hosszu LL, et al. **Nat Struct Biol** 1999 Aug;6(8):740-3

Enzyme dynamics and hydrogen tunnelling in a thermophilic alcohol dehydrogenase [see comments] Kohen A, et al. **Nature** 1999 Jun 3;399(6735):496-9. Comment in: Nature 1999 Jun 3;399(6735):417-8.

Hydroxyl radical-induced hydrogen/deuterium exchange in amino acid carbon-hydrogen bonds. Goshe MB, et al. **Radiat Res** 1999 Jan;151(1):50-8

1H-13C-27Al triple resonance transfer of populations in double resonance experiments for the detection of 13C-27Al dipolar interactions. van Wüllen L. **Solid State Nucl Magn Reson** 1998 Nov;13(1-2):123-7

Removal of the bridging ligand atom at the Ni-Fe active site of [NiFe] hydrogenase upon reduction with H2, as revealed by X-ray structure analysis at 1.4 A resolution. Higuchi Y, et al. **Structure Fold Des** 1999 May;7(5):549-56

Native-state HX [letter; comment] Englander SW. **Trends Biochem Sci** 1998 Oct;23(10):378; discussion 379-81 . Comment on: Trends Biochem Sci 1997 Aug;22(8):284-7.

The slow-exchange core and protein folding [letter; comment] Woodward C, et al. **Trends Biochem Sci** 1998 Oct;23(10):379-81. Comment on: Trends Biochem Sci 1997 Aug;22(8):284-7.

Hydrogen atom abstraction of 3,5-disubstituted analogues of paracetamol by horseradish peroxidase and cytochrome P450. Bessems JG, et al. **Xenobiotica** 1998 Sep;28(9):855-75

DIAGNOSTIC USE

Influence of the substrate on the reproducibility of the hydrogen breath test to measure the orocecal transit time. Casellas F, et al. **Digestion** 1998 Nov-Dec;59(6):696-702

A comparison of 1H8- and 2H8-toluene toxicokinetics in men. Pierce CH, et al. **Xenobiotica** 1999 Jan;29(1):93-108

METABOLISM

Hydration of C-H groups in natural dithymidine nucleotide and its methylphosphonate analogues. Kulińska K, et al. **Acta Biochim Pol** 1998;45(4):977-85

Subunit interactions coupling H+ transport and ATP synthesis in F1F0 ATP synthase. Fillingame RH, et al. **Acta Physiol Scand Suppl** 1998 Aug;643:163-8 (28 ref.)

Regulation of intracellular pH and blood flow in rat duodenal epithelium in vivo. Akiba Y, et al. **Am J Physiol** 1999 Jan; 276(1 Pt 1):G293-302

Incubation of OKP cells in low-K+ media increases NHE3 activity after early decrease in intracellular pH. Amemiya M, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):C711-6

Osmotic shock: modulation of contractile function, pHi, and ischemic damage in perfused guinea pig heart. Befroy DE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1236-44

Regulation of intracellular pH in proximal tubules of avian long-looped mammalian-type nephrons. Brokl OH, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1526-35

Basolateral regulation of pHi in isolated snake renal proximal tubules in presence and absence of bicarbonate. Dantzler WH, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1673-81

Nitric oxide inhibits sodium/hydrogen exchange activity in the thick ascending limb. Garvin JL, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):F377-82

Regulation of intracellular pH gradients by identified Na/H exchanger isoforms and a short-chain fatty acid. Gonda T, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G259-70

Effects of hypoxia on energy state and pH in resting pulmonary and femoral arterial smooth muscles. Leach RM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):L1051-60

pH-dependent modulation of the cloned renal K+ channel, ROMK. McNicholas CM, et al. **Am J Physiol** 1998 Dec; 275(6 Pt 2):F972-81

pHi and pHo at different depths in perfused myocardium measured by confocal fluorescence microscopy. Muller-Borer BJ, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H1937-47

Effects of pH changes on systems ASC and B in rabbit ileum. Munck BG, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G173-84

Differential depression of myocardial function and metabolism by lactate and H+. Samaja M, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H3-8

Characterization of two subsurface H2-utilizing bacteria, Desulfomicrobium hypogeium sp. nov. and Acetobacterium psammolithicum sp. nov., and their ecological roles. Krumholz LR, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2300-6

The purified and reconstituted ornithine/citrulline carrier from rat liver mitochondria catalyses a second transport mode: ornithine+/H+ exchange. Indiveri C, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):705-11

Presence of a vacuolar H+-pyrophosphatase in promastigotes of Leishmania donovani and its localization to a different compartment from the vacuolar H+-ATPase. Rodrigues CO, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):759-66

MgATP-independent hydrogen evolution catalysed by nitrogenase: an explanation for the missing electron(s) in the MgADP-AlF4 transition-state complex. Yousafzai FK, et al. **Biochem J** 1999 May 1;339 (Pt 3):511-5

H(2) photoproduction by batch culture of Anabaena variabilis ATCC 29413 and its mutant PK84 in a photobioreactor. Tsygankov AA, et al. **Biotechnol Bioeng** 1999 Sep 20;64(6):709-15

Intraesophageal pH monitoring during acid infusion in patients with systemic sclerosis. Carola F, et al. **Dig Dis Sci** 1999 Aug;44(8):1716-20

Food but not a chemically defined diet interferes with maintenance of intragastric pH at a predefined level using continuous pH-stat-adjusted intravenous infusion of ranitidine in healthy volunteers. Thomson AB, et al. **Dig Dis Sci** 1999 Sep;44(9):1858-64

The pH response of rat cutaneous nociceptors correlates with extracellular [Na+] and is increased under amiloride. Steen KH, et al. **Eur J Neurosci** 1999 Aug;11(8):2783-92

Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Vincent AM, et al. **Exp Neurol** 1999 Jan;155(1):79-94

Role of the ionic environment and internal pH on sperm activity. Hamamah S, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:20-30 (62 ref.)

Hydrogenophilus thermoluteolus gen. nov., sp. nov., a thermophilic, facultatively chemolithoautotrophic, hydrogen-oxidizing bacterium. Hayashi NR, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:783-6

Identification and characterization of hupT, a gene involved in negative regulation of hydrogen oxidation in Bradyrhizobium japonicum. Van Soom C, et al. **J Bacteriol** 1999 Aug;181(16):5085-9

Role of histidines identified by mutagenesis in the NADPH oxidase-associated H+ channel. Henderson LM. **J Biol Chem** 1998 Dec 11;273(50):33216-23

A K319N/E325Q double mutant of the lactose permease cotransports H+ with lactose. Implications for a proposed mechanism of H+/lactose symport. Johnson JL, et al. **J Biol Chem** 1999 Feb 12;274(7):4074-81

Carbon monoxide and cyanide as intrinsic ligands to iron in the active site of [NiFe]-hydrogenases. NiFe(CN)2CO, Biology's way to activate H2. Pierik AJ, et al. **J Biol Chem** 1999 Feb 5;274(6):3331-7

Pulsatile influxes of H+, K+ and Ca2+ lag growth pulses of Lilium longiflorum pollen tubes. Messerli MA, et al. **J Cell Sci** 1999 May;112 (Pt 10):1497-509

Protein carboxyl methylation controls intracellular pH in

human platelets. Otsuka K, et al. **J Hypertens** 1998 Sep; 16(9):1261–6

pH, cholesterol sulfate, and fatty acids affect the stratum corneum lipid organization. Bouwstra JA, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(2):69–74

Determination of the pH gradient across the stratum corneum. Turner NG, et al. **J Investig Dermatol Symp Proc** 1998 Aug;3(2):110–3

Defining protein ensembles with native-state NH exchange: kinetics of interconversion and cooperative units from combined NMR and MS analysis. Arrington CB, et al. **J Mol Biol** 1999 Jan 22;285(3):1265–75

Hydrogen exchange kinetics of proteins in denaturants: a generalized two-process model. Qian H, et al. **J Mol Biol** 1999 Feb 19;286(2):607–16

Intracellular pH buffering shapes activity-dependent Ca2+ dynamics in dendrites of CA1 interneurons. Tombaugh GC. **J Neurophysiol** 1998 Oct;80(4):1702–12

Hydrogen production in dogs adapts to addition of lactulose and to a meat and rice diet. Pouteau E, et al. **J Nutr** 1998 Dec;128(12 Suppl):2666S–2668S

Sources of breath hydrogen in infants [letter; comment] Shulman RJ. **J Pediatr** 1999 May;134(5):659–61. Comment on: J Pediatr 1998 Jul;133(1):95–8.

The glow of the colonic pH microclimate kindled by short-chain fatty acids, chloride and bicarbonate [editorial; comment] Chu S, et al. **J Physiol (Lond)** 1999 Jun 1;517 (Pt 2):315 (6 ref.). Comment on: J Physiol (Lond) 1999 Jun 1;517 (Pt 2):507–19.

Maintenance and regulation of the pH microclimate at the luminal surface of the distal colon of guinea-pig [see comments] Genz AK, et al. **J Physiol (Lond)** 1999 Jun 1; 517 (Pt 2):507–19. Comment in: J Physiol (Lond) 1999 Jun 1;517 (Pt 2):315.

Regulation of intracellular pH during H+-coupled oligopeptide absorption in enterocytes from guinea-pig ileum. Hayashi H, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):573–86

Psychrotrophic clostridia mediated gas and botulinal toxin production in vacuum-packed chilled meat. Moorhead SM, et al. **Lett Appl Microbiol** 1999 Feb;28(2):108–12

Do forestomach epithelia exhibit a Mg2+/2H(+)-exchanger? Leonhard-Marek S. **Magnes Res** 1999 Jun;12(2):99–108 (89 ref.)

Regulation of intracellular pH and proton-potassium exchange in fermenting Escherichia coli grown anaerobically in alkaline medium. Trchounian A, et al. **Membr Cell Biol** 1998;12(1):67–78

A hydrogenosome with pyruvate formate-lyase: anaerobic chytrid fungi use an alternative route for pyruvate catabolism. Akhmanova A, et al. **Mol Microbiol** 1999 Jun; 32(5):1103–14

Identification of histidine residues in Wolinella succinogenes hydrogenase that are essential for menaquinone reduction by H2. Gross R, et al. **Mol Microbiol** 1998 Nov; 30(3):639–46

A hydrogenosome with a genome [letter] [see comments] Akhmanova A, et al. **Nature** 1998 Dec 10;396(6711):527–8 . Comment in: Nature 1998 Dec 10;396(6711):517–9.

A hydrogen-producing mitochondrion [news; comment] Embley TM, et al. **Nature** 1998 Dec 10;396(6711):517–9. Comment on: Nature 1998 Dec 10;396(6711):527–8.

Expression of truncated utrophin improves pH recovery in exercising muscles of dystrophic mdx mice: a 31P NMR study. Goudemant JF, et al. **Neuromuscul Disord** 1998 Aug; 8(6):371–9

The pH dependence of late sodium current in large sensory neurons. Baker MD, et al. **Neuroscience** 1999;92(3):1119–30

A novel multicomponent regulatory system mediates H2 sensing in Alcaligenes eutrophus. Lenz O, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12474–9

Conformational dynamics of cytochrome c: correlation to hydrogen exchange. Garcia AE, et al. **Proteins** 1999 Aug 1;36(2):175–91

Non-invasive detection of low-intestinal lactase activity in children by use of a combined 13CO2/H2 breath test. Koetse HA, et al. **Scand J Gastroenterol** 1999 Jan; 34(1):35–40

Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Yang CY, et al. **Scand J Gastroenterol** 1998 Aug; 33(8):867–71

Biological hydrogen production: not so elementary [comment] [see comments] Adams MW, et al. **Science** 1998 Dec 4;282(5395):1842–3. Comment on: Science 1998 Dec 4;282(5395):1853–8. Comment in: Science 1999 Mar 19;283(5409):1851.

Free electrons? [letter; comment] Williams JM. **Science** 1999 Mar 19;283(5409):1851. Comment on: Science 1998 Dec 4;282(5395):1842–3.

Measurement of cerebral blood flow in rats and mice by hydrogen clearance during hyperbaric oxygen exposure. Demchenko IT, et al. **Undersea Hyperb Med** 1998 Fall; 25(3):147–52

[Effect of temperature on H+-K+ exchange in Escherichia coli bacteria during their anaerobic growth] Vardanian V, et al. **Biofizika** 1998 Nov-Dec;43(6):1026–9 (Eng. Abstr.) **(Rus)**

[The possible H+-dependent functional connection between cell membrane and mitochondria in smooth muscle cells] Kosterin SA. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):152–60 (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Usefulness of the hydrogen--deuterium exchange method in the study of drug metabolism using liquid chromatography-tandem mass spectrometry. Ohashi N, et al. **J Pharm Biomed Anal** 1998 Nov;18(3):325–34

Ion transport processes of crustacean epithelial cells. Ahearn GA, et al. **Physiol Biochem Zool** 1999 Jan-Feb;72(1):1–18 (101 ref.)

PHARMACOLOGY

Relationship between T-wave amplitude and oxygen pulse in guinea pigs in hyperbaric helium and hydrogen. Kayar SR, et al. **J Appl Physiol** 1998 Sep;85(3):798–806

Pharmacological properties of the CO2/H+-sensitive area in the ventral medullary surface assessed by the effects of chemical stimulation on respiration. Kanazawa M, et al. **J Auton Nerv Syst** 1998 Aug 6;72(1):24–33

Blockade of HERG channels expressed in Xenopus oocytes by external H+. Jo SH, et al. **Pflugers Arch** 1999 Jun; 438(1):23–9

PHYSIOLOGY

Intracellular H+ regulates the alpha-subunit of ENaC, the epithelial Na+ channel. Chalfant ML, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):C477–86

Experimental determination of hydrogen bandwidth for the ion parametric resonance model. Blackman CF, et al. **Bioelectromagnetics** 1999;20(1):5–12

HYDROGEN BONDING

Hydrogen bonding in quinolinium-4-carboxylate trihydrate. Dobson AJ, et al. **Acta Crystallogr C** 1999 Jul 15;55 (Pt 7):1192–5

Hydrogen bonding and C-H...O interactions in 2,2'-dihydroxy-5,5'-dimethoxybiphenyl-3,3'-dicarbaldehyde. Gerkin RE. **Acta Crystallogr C** 1999 Jul 15;55 (Pt 7):1176–9

Structural evidence for the aromatic-(i+1) amine hydrogen bond in peptides: L-tyr-L-tyr-L-Leu monohydrate. Steiner T. **Acta Crystallogr D Biol Crystallogr** 1998 Jul 1;54 (Pt 4):584–8

The low barrier hydrogen bond in enzymatic catalysis. Cleland WW, et al. **J Biol Chem** 1998 Oct 2; 273(40):25529–32 (49 ref.)

Two-H-bonded and one-H-bonded structure alternations in collagen. Milchevsky JV, et al. **J Biomol Struct Dyn** 1999 Feb;16(4):977–88

Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. Klebe G, et al. **J Comput Aided Mol Des** 1999 Jan;13(1):1–10

Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. van de Waterbeemd H, et al. **J Drug Target** 1998;6(2):151–65 (58 ref.)

The name is bond--H bond [news] Martin TW, et al. **Nat Struct Biol** 1999 May;6(5):403–6

Hydrogen bonds between short polar side chains and peptide backbone: prevalence in proteins and effects on helix-forming propensities. Vijayakumar M, et al. **Proteins** 1999 Mar 1;34(4):497–507

HYDROGEN CARBONATES see **BICARBONATES**

HYDROGEN CHLORIDE see **HYDROCHLORIC ACID**

HYDROGEN CYANIDE

ANALYSIS

Chemistry in cometary comae. Irvine WM, et al. **Faraday Discuss** 1998;(109):475–92

Low cyanide exposure from consumption of cassava in Dar es Salaam, Tanzania. Mlingi N, et al. **Nat Toxins** 1998; 6(2):67–72

[Potentiometric methods for determining boron, hydrogen cyanide and hydrogen chloride compounds and their use in controlling the quality of manufacturing and natural environments] Markova OL, et al. **Med Tr Prom Ekol** 1998; (11):24–6 (Eng. Abstr.) **(Rus)**

POISONING

Acute cyanide toxicity caused by apricot kernel ingestion. Suchard JR, et al. **Ann Emerg Med** 1998 Dec;32(6):742–4

TOXICITY

Cyanide exposure affects the production and excretion of ammonia by the mudskipper Boleophthalmus boddaerti. Chew SF, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Oct;120(3):441–8

HYDROGEN FLUORIDE see **HYDROFLUORIC ACID**

HYDROGEN-ION CONCENTRATION

see related

BUFFERS

Skeletal muscle Na+/H+ exchange in rats: pH dependency and the effect of training. Juel C. **Acta Physiol Scand** 1998 Oct;164(2):135–40

Energetics of alkaliphilic Bacillus species: physiology and molecules. Krulwich TA, et al. **Adv Microb Physiol** 1998; 40:401–38 (111 ref.)

Effects of extracellular pH on restitution and proliferation of rabbit oesophageal epithelial cells. Jimenez P, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):545–52

Activation of H+-ATPase by hypotonicity: a novel regulatory mechanism for H+ secretion in IMCD cells. Amlal H, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F487–501

Intracellular acidosis differentially regulates KV channels in coronary and pulmonary vascular muscle. Berger MG, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1351–9

Intracellular pH regulation in bombesin-stimulated secretion in isolated bile duct units from rat liver. Cho WK, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1028–36

Loading pyranine via purinergic receptors or hypotonic stress for measurement of cytosolic pH by imaging. Gan BS, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1158–66

Changes in intracellular Na+ and pH in rat heart during ischemia: role of Na+/H+ exchanger. Park CO, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1581–90

Role of intracellular Ca2+ and pH in positive inotropic response of cardiomyocytes to diacylglycerol. Pi Y, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1473–81

Cytosolic pH regulates GCl through control of phosphorylation states of CFTR. Reddy MM, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1040–7

Intracellular pH regulation in neurons from chemosensitive and nonchemosensitive areas of the medulla. Ritucci NA, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1152–63

Identification of the pH sensor and activation by chemical modification of the ClC-2G Cl- channel. Stroffekova K, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C1113–23

Cross bridge-dependent activation of contraction in cardiac myofibrils at low pH. Swartz DR, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1460–7

Effect of gastrin on antroduodenal motility: role of intraluminal acidity. Verkijk M, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1209–16

A method for the determination of the pH optima of proteases using unexposed photographic film. Buckwold VE, et al. **Anal Biochem** 1999 Feb 15;267(2):420–1

Correcting for artifacts in complex aqueous solutions when using the pH-sensitive dye 2',7'-bis-(2-carboxyethyl)-5-(and -6)carboxyfluorescein. Cardullo RA, et al. **Anal Biochem** 1999 Feb 15;267(2):351–6

Mercury contamination during pH measurement and its effect on creatine kinase activity. Ellis KJ. **Anal Biochem** 1978 Nov;91(1):224–9

Lifetime-based pH sensors: indicators for acidic environments. Lin HJ, et al. **Anal Biochem** 1999 Apr 10; 269(1):162–7

Acid-sensitive enteric pathogens are protected from killing under extremely acidic conditions of pH 2.5 when they are inoculated onto certain solid food sources. Waterman SR, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3882–6

Acidic stimulation induces a negative regulatory factor that affects alternative exon selection in vitro in human ATP synthase gamma-subunit pre-mRNA. Hayakawa M, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):603–8

Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Sierra EE, et al. **Biochem Pharmacol** 1998 May 1;55(9):1505–12

Resolution of the paradox of red cell shape changes in low and high pH. Gedde MM, et al. **Biochim Biophys Acta** 1999 Mar 4;1417(2):246–53

Reactivity of trypsin in reverse micelles: pH-effects on the W0 versus enzyme activity profiles. Fadnavis NW, et al. **Biochimie** 1998 Dec;80(12):1025–30

The motility of human spermatozoa as influenced by prostasomes at various pH levels. Arienti G, et al. **Biol Cell** 1999 Jan;91(1):51–4

Mitochondrial nitric oxide synthase regulates mitochondrial matrix pH. Ghafourifar P, et al. **Biol Chem** 1999 Jul-Aug; 380(7-8):1025–8

Influence of cytoplasmic pH on the aggregation and Ca2+ mobilization in rabbit platelets. Hashizume T, et al. **Biol Pharm Bull** 1999 Jul;22(7):663–6

A preliminary study of the effect of glass-ionomer and related dental cements on the pH of lactic acid storage solutions. Nicholson JW, et al. **Biomaterials** 1999 Jan;20(2):155–8

Tropomyosin modulates pH dependence of isometric tension. Fujita H, et al. **Biophys J** 1999 Sep;77(3):1540–6

Swelling studies on the cornea and sclera: the effects of pH and ionic strength. Huang Y, et al. **Biophys J** 1999 Sep; 77(3):1655–65

The effect of temperature and solution pH on the nucleation of tetragonal lysozyme crystals. Judge RA, et al. **Biophys J** 1999 Sep;77(3):1585–93

Interactions of pulmonary surfactant protein A with phospholipid monolayers change with pH. Ruano ML, et al. **Biophys J** 1999 Sep;77(3):1469–76

Development and validation of a methodology for intracellular pH measurements of hybridoma cells under bioreactor culture conditions. Cherlet M, et al. **Biotechnol Prog** 1999 Jul-Aug;15(4):630–9

The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Gerweck LE, et al. **Br J Cancer** 1999 Feb;

79(5-6):838-42
Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). Kuin A, et al. **Br J Cancer** 1999 Feb;79(5-6):793-801
Acidic environment causes apoptosis by increasing caspase activity. Park HJ, et al. **Br J Cancer** 1999 Aug; 80(12):1892-7
Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer. Jordan RE, et al. **Br J Pharmacol** 1998 Oct;125(4):761-6
Fading and rebound of P2X2 currents at millimolar ATP concentrations caused by low pH. Stoop R, et al. **Br J Pharmacol** 1998 Sep;125(2):235-7
Effects of muscle pH and chilling on development of PSE-like turkey breast meat. Wynveen EJ, et al. **Br Poult Sci** 1999 May;40(2):253-6
Mechanism of action and the substrate-dependent pH maximum shift of the alpha-amylase of Bacillus coagulans. Keating L, et al. **Carbohydr Res** 1998 Jul;309(4):311-8
pHi regulatory ion transporters: an update on structure, regulation and cell function. Pucéat M. **Cell Mol Life Sci** 1999 Aug 15;55(10):1216-29 (159 ref.)
Sodium, PMA and calcium play an important role on intracellular pH modulation in rat mast cells. Alfonso A, et al. **Cell Physiol Biochem** 1998;8(6):314-27
Stretch-induced alkalinization of feline papillary muscle: an autocrine-paracrine system. Cingolani HE, et al. **Circ Res** 1998 Oct 19;83(8):775-80
Determination of pH in human erythrocytes. Sources of systematic error. Büttner D, et al. **Clin Chem Lab Med** 1998 Oct;36(10):757-61
Effect of extracellular pH on contractile responses of the guinea-pig vas deferens. Nakanishi H, et al. **Clin Exp Pharmacol Physiol** 1999 Jan;26(1):35-8
The effect of pH on biological activity of plant cytotoxin cauloside C. Aminin DL, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jan; 122(1):45-51
Virtual instrumentation for pH measurements in biological systems. Rigobello MP, et al. **Comput Methods Programs Biomed** 1999 Jul;60(1):55-64
Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives. Mason RP. **Curr Med Chem** 1999 Jun;6(6):481-99 (175 ref.)
Intraluminal pH of the human gastrointestinal tract. Fallingborg J. **Dan Med Bull** 1999 Jun;46(3):183-96 (183 ref.)
Intracellular pH regulation by HCO3-/Cl- exchange is activated during early mouse zygote development. Phillips KP, et al. **Dev Biol** 1999 Apr 15;208(2):392-405
Changes in gastric intramucosal pH following mesenteric traction in patients undergoing pancreas surgery. Brinkmann A, et al. **Dig Surg** 1999;16(2):117-24
Capillary zone electrophoresis with optimized temperature control for studying thermal denaturation of proteins at various pH. Rochu D, et al. **Electrophoresis** 1999 Jun; 20(7):1586-94
Enzyme level of enterococcal F1Fo-ATPase is regulated by pH at the step of assembly [published erratum appears in Eur J Biochem 1999 Apr;261(2):591] Arikado E, et al. **Eur J Biochem** 1999 Jan;259(1-2):262-8
Direct measurement of cytosolic calcium and pH in living Chlamydomonas reinhardtii cells. Braun FJ, et al. **Eur J Cell Biol** 1999 Mar;78(3):199-208
Modulation of calcium signalling by intracellular pH in exocrine acinar cells. Speake T, et al. **Eur J Morphol** 1998 Aug;36 Suppl:165-9
Acid oro-pharyngeal secretions can predict gastro-oesophageal reflux in preterm infants. James ME, et al. **Eur J Pediatr** 1999 May;158(5):371-4
Surface acidity of solid pharmaceutical excipients III. Excipients for solid dosage forms. Scheef CA, et al. **Eur J Pharm Biopharm** 1998 Sep;46(2):209-13
The in vitro enhancement of rat myofibroblast contractility by alterations to the pH of the physiological solution. Pipelzadeh MH, et al. **Eur J Pharmacol** 1998 Sep 18; 357(2-3):257-9
Enterococcus hirae vacuolar ATPase is expressed in response to pH as well as sodium. Ikegami M, et al. **FEBS Lett** 1999 Jul 2;454(1-2):67-70
Design of a pH-dependent cellulose-binding domain. Linder M, et al. **FEBS Lett** 1999 Mar 19;447(1):13-6
Identification and linkage mapping of the phsA gene of Aspergillus nidulans, where mutation affects growth and pigmentation of colonies in a temperature- and pH-dependent way. Cuadros SC, et al. **FEMS Microbiol Lett** 1999 Feb 15;171(2):103-6
Involvement of Nha1 antiporter in regulation of intracellular pH in Saccharomyces cerevisiae. Sychrová H, et al. **FEMS Microbiol Lett** 1999 Feb 15;171(2):167-72
Vaginal fluid pH as a screening test for vaginitis. Thinkhamrop J, et al. **Int J Gynaecol Obstet** 1999 Aug; 66(2):143-8
Intracellular alkalinisation in Vero cells parasitised by Trypanosoma cruzi. Rodriguez-Cabezas N, et al. **Int J Parasitol** 1998 Dec;28(12):1841-51
alpha-Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): influence of pH, concentration and various cyclodextrins. Fredholt K, et al. **Int J Pharm** 1999 Feb 15;178(2):223-9
Glucose-induced acid tolerance appearing at neutral pH in log-phase Escherichia coli and its reversal by cyclic AMP. Rowbury RJ, et al. **J Appl Microbiol** 1998 Sep;85(3):615-20
Modeling the effects of proteins on pH in plasma. Watson PD. **J Appl Physiol** 1999 Apr;86(4):1421-7
Mechanism of citrate metabolism in Lactococcus lactis: resistance against lactate toxicity at low pH. Magni C, et al. **J Bacteriol** 1999 Mar;181(5):1451-7
Effect of salt concentration and pH on the hydrophobicity parameters of surfactants studied by TLC and spectral mapping technique. Cserháti T, et al. **J Biochem Biophys Methods** 1999 Jan 13;38(1):1-15
Diverse roles of single membrane organelles: factors establishing the acid lumenal pH. Futai M, et al. **J Biochem (Tokyo)** 1998 Aug;124(2):259-67 (109 ref.)
Essential requirement of cytosolic phospholipase A(2) for activation of the H(+) channel in phagocyte-like cells. Lowenthal A, et al. **J Biol Chem** 1999 Jul 30; 274(31):21603-8
Carboxypeptidase E, a peripheral membrane protein implicated in the targeting of hormones to secretory granules, co-aggregates with granule content proteins at acidic pH. Rindler MJ. **J Biol Chem** 1998 Nov 20; 273(47):31180-5
Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. Weisburg JH, et al. **J Biol Chem** 1999 Apr 16; 274(16):10877-88
Transport of water and glycerol in aquaporin 3 is gated by H(+). Zeuthen T, et al. **J Biol Chem** 1999 Jul 30; 274(31):21631-6
Improved low pH bicelle system for orienting macromolecules over a wide temperature range. Cavagnero S, et al. **J Biomol NMR** 1999 Apr;13(4):387-91
Bicelle-based liquid crystals for NMR-measurement of dipolar couplings at acidic and basic pH values. Ottiger M, et al. **J Biomol NMR** 1999 Feb;13(2):187-91
Intracellular pH regulation of CA1 neurons in Na(+)/H(+) isoform 1 mutant mice. Yao H, et al. **J Clin Invest** 1999 Sep;104(5):637-45
Effectiveness of salt, pH, and diacetyl as inhibitors for Escherichia coli O157:H7 in dairy foods stored at refrigeration temperatures. Guraya R, et al. **J Food Prot** 1998 Sep;61(9):1098-102
The pH gradient over the stratum corneum differs in X-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"? Ohman H, et al. **J Invest Dermatol** 1998 Oct;111(4):674-7
Effect of pH, temperature and surface contact on the elaboration of fimbriae and flagella by Salmonella serotype Enteritidis. Walker SL, et al. **J Med Microbiol** 1999 Mar; 48(3):253-61
Role of apical H-K exchange and basolateral K channel in the regulation of intracellular pH in rat distal colon crypt cells. Ikuma M, et al. **J Membr Biol** 1998 Dec 1; 166(3):205-12
pH-modulation of chloride channels from the sarcoplasmic reticulum of skeletal muscle. Kourie JI. **J Membr Biol** 1999 Jan 1;167(1):73-83
pH-sensitive gating kinetics of the maxi-K channel in the tonoplast of Cchara australis. Lühring H. **J Membr Biol** 1999 Mar 1;168(1):47-61
Comparison of amphibian and human ClC-5: similarity of functional properties and inhibition by external pH. Mo L, et al. **J Membr Biol** 1999 Apr 1;168(3):253-64
The ectodomain of HA2 of influenza virus promotes rapid pH dependent membrane fusion. Epand RF, et al. **J Mol Biol** 1999 Feb 19;286(2):489-503
DNA cleavage by the EcoRV restriction endonuclease: pH dependence and proton transfers in catalysis. Stanford NP, et al. **J Mol Biol** 1999 Apr 23;288(1):105-16
In vivo microdialysis of 2-deoxyglucose 6-phosphate into brain: a novel method for the measurement of interstitial pH using 31P-NMR. Kintner DB, et al. **J Neurochem** 1999 Jan;72(1):405-12
Acidosis potentiates oxidative neuronal death by multiple mechanisms. Ying W, et al. **J Neurochem** 1999 Oct; 73(4):1549-56
The pH-sensitive dye acridine orange as a tool to monitor exocytosis/endocytosis in synaptosomes. Zoccarato F, et al. **J Neurochem** 1999 Feb;72(2):625-33
Modulation of N-type Ca2+ channels by intracellular pH in chick sensory neurons. Kiss L, et al. **J Neurophysiol** 1999 Apr;81(4):1839-47
Endogenous pH shifts facilitate spreading depression by effect on NMDA receptors. Tong CK, et al. **J Neurophysiol** 1999 Apr;81(4):1988-91
H+ permeation and pH regulation at a mammalian serotonin transporter. Cao Y, et al. **J Neurosci** 1997 Apr 1; 17(7):2257-66
The vomiting infant [letter; comment] Rosh JR, et al. **J Pediatr** 1999 May;134(5):662-3; discussion 662-3. Comment on: J Pediatr 1998 Aug;133(2):306-7.
Helix-enhancing propensity of fluoro and alkyl alcohols: influence of pH, temperature and cosolvent concentration on the helical conformation of peptides. Kumaran S, et al. **J Pept Res** 1999 Mar;53(3):284-93
Solid-phase total synthesis of polymyxin B1. Sharma SK, et al. **J Pept Res** 1999 May;53(5):501-6
pH modulation of Ca2+ responses and a Ca2+-dependent K+ channel in cultured rat hippocampal neurones. Church J, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):119-32
Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat. Andersson SE, et al. **J Rheumatol** 1999 Sep; 26(9):2018-24
pH dependence of junctional conductance. Dunina-Barkovskaya AYa. **Membr Cell Biol** 1998; 11(6):793-801
Regulation of intracellular pH and proton-potassium exchange in fermenting Escherichia coli grown anaerobically in alkaline medium. Trchounian A, et al. **Membr Cell Biol** 1998;12(1):67-78
Molecular characterization of the pH-inducible and growth phase-dependent promoter P170 of Lactococcus lactis. Madsen SM, et al. **Mol Microbiol** 1999 Apr;32(1):75-87
Differential sensitivity of voltage-gated potassium channels Kv1.5 and Kv1.2 to acidic pH and molecular identification of pH sensor. Steidl JV, et al. **Mol Pharmacol** 1999 May; 55(5):812-20
pH influences fluoride coordination number of the AlFx phosphoryl transfer transition state analog. Schlichting I, et al. **Nat Struct Biol** 1999 Aug;6(8):721-3
H+-sensitivity of cultured neurons from the dorsomedial and ventrolateral medulla of neonate rats. Sugama S, et al. **Neurosci Lett** 1998 Aug 7;252(1):29-32
Effects of pH changes on calcium-mediated potentials in rat hippocampal neurons in vitro. Church J. **Neuroscience** 1999 Mar;89(3):731-42
Anoxia-evoked intracellular pH and Ca2+ concentration changes in cultured postnatal rat hippocampal neurons. Diarra A, et al. **Neuroscience** 1999;93(3):1003-16
Correlation of laryngeal and pharyngeal carcinomas and 24-hour pH monitoring of the esophagus and pharynx [retracted by Chen MY, Ott DJ, Koufman JA. In: Otolaryngol Head Neck Surg 1999 Jul;121(1):168] Chen MY, et al. **Otolaryngol Head Neck Surg** 1998 Nov; 119(5):460-2
Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil. Merino V, et al. **Pharm Res** 1999 May;16(5):758-61
The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis. Reymond F, et al. **Pharm Res** 1999 May; 16(5):616-24
pH-sensitive imaging by low-frequency EPR: a model study for biological applications. Sotgiu A, et al. **Phys Med Biol** 1998 Jul;43(7):1921-30
Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Altan N, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4432-7
Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation. Tien M, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7809-14
Volatile buffers can override the "pH memory" of subtilisin catalysis in organic media. Zacharis E, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1201-5
Ceruloplasmin releases pH-induced inhibition of cell proliferation stimulated by growth factors. Alcaín FJ, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):287-93
Effects of extracellular pH upon the insulinotropic action of alpha-D-glucose pentaacetate. Ayvaz G, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan;103(1):83-90
Determination of the effect of pH and foetal haemoglobin fraction on haemoglobin oxygen saturation readings by the OSM3 hemoximeter. Mackay AR, et al. **Scand J Clin Lab Invest** 1999 May;59(3):233-7
Comparative study of intramucosal pH in histologic damage from small bowel ischemia-reperfusion injury. Iwanami K, et al. **Transplant Proc** 1998 Nov;30(7):3467-8
[24 hour pH monitoring of the hypopharymx] Schlottmann A, et al. **HNO** 1999 Feb;47(2):112-6 (Eng. Abstr.) **(Ger)**
[Measuring apparatus for pH (discussion)] Horiba M, et al. **Tanpakushitsu Kakusan Koso** 1998 Aug;43(10):1389-94 **(Jpn)**
[Effect of pH on cea gene expression in cells irradiated with UV-light and unirradiated Escherichia coli cells] Smirnova GV, et al. **Genetika** 1998 Nov;34(11):1480-3 (Eng. Abstr.) **(Rus)**
[Why is the esophageal pH-metry required? Comparison with the recommendations of the American Association of Gastroenterology for its correct use] Carmona-Sánchez R, et al. **Rev Gastroenterol Mex** 1998 Apr-Jun;63(2):93-6 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

N,N-Dimethylformamide modulates acid extrusion from murine hepatoma cells. Twiner MJ, et al. **Toxicol Appl Pharmacol** 1998 Dec;153(2):143-51

HYDROGEN IONS see **PROTONS**

HYDROGEN PEROXIDE

Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine. Kimura I, et al. **Arzneimittelforschung** 1998 Oct;48(10):1007-11
Effect of hydrogen peroxide disinfection during incubation of chicken eggs on microbial levels and productivity.

Sander JE, et al. **Avian Dis** 1999 Apr-Jun;43(2):227-33

Hydrogen peroxide improves the efficiency of a peripheral blood PCR assay for diagnosis of human brucellosis. Queipo-Ortuño MI, et al. **Biotechniques** 1999 Aug; 27(2):248-50, 252

Method of melanin bleaching in MIB1-Ki67 immunostaining of pigmented lesions: A quantitative evaluation in malignant melanomas. Li LX, et al. **Histochem J** 1999 Apr; 31(4):237-40

The presterilization microbial load on used medical devices and the effectiveness of hydrogen peroxide gas plasma against Bacillus subtilis spores [see comments] Penna TC, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):465-72 Comment in: Infect Control Hosp Epidemiol 1999 Jul;20(7):463-5.

Characterization of a peroxide-resistant mutant of the anaerobic Bacterium bacteroides fragilis. Rocha ER, et al. **J Bacteriol** 1998 Nov;180(22):5906-12

What do we measure with luminol-, lucigenin- and penicillin-amplified chemiluminescence? 1. Investigations with hydrogen peroxide and sodium hypochlorite. Rost M, et al. **J Biolumin Chemilumin** 1998 Nov-Dec; 13(6):355-63

Inactivation of Listeria monocytogenes/Pseudomonas biofilms by peracid sanitizers. Fatemi P, et al. **J Food Prot** 1999 Jul;62(7):761-5

Inactivation of duck hepatitis B virus by a hydrogen peroxide gas plasma sterilization system: laboratory and 'in use' testing. Vickery K, et al. **J Hosp Infect** 1999 Apr; 41(4):317-22

Peroxide-modified titanium dioxide: a chemical analog of putative Martian soil oxidants. Quinn RC, et al. **Orig Life Evol Biosph** 1999 Jan;29(1):59-72 (27 ref.)

[Baeyer-Villiger reaction of benzaldehydes possessing oxygen functions with SeO2-H2O2] Nishioka H, et al. **Yakugaku Zasshi** 1999 Jul;119(7):519-28 (Eng. Abstr.) **(Jpn)**

[Effect of shikonin and alkannin on hydroxyl radical generation system concerned with iron ion] Sekine T, et al. **Yakugaku Zasshi** 1998 Dec;118(12):609-15 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Gas embolism caused by erroneous intraventricular administration of hydrogen peroxide solution] Lubnin AIu, et al. **Anesteziol Reanimatol** 1998 Nov-Dec;(6):76-7 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Gas embolism produced by hydrogen peroxide abscess irrigation in an infant. Schwab C, et al. **Anaesth Intensive Care** 1999 Aug;27(4):418-20

Intradermal irritation of dental bleaching agents in rats. Gonçalves CE, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep;19(5):422-4

Patch test reactions and occupational dermatoses caused by hydrogen peroxide. Kanerva L, et al. **Contact Dermatitis** 1998 Sep;39(3):146

Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, France, 17-24 February 1998. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 1:1-315

Crepitus following a dog bite. Gill P, et al. **Injury** 1998 Sep; 29(7):543-5

Hydrogen peroxide is not carcinogenic [news] **J Am Dent Assoc** 1999 May;130(5):632

Growth suppression and branchitis in trout exposed to hydrogen peroxide. Speare DJ, et al. **J Comp Pathol** 1999 May;120(4):391-402

Data linking hydrogen peroxide and cancerous lesions is withdrawn [news] **N Y State Dent J** 1999 Mar;65(3):37

[Severe air embolism after surgical irrigation with hydrogen peroxide] Donati S, et al. **Presse Med** 1999 Jan 30; 28(4):173-5 (Eng. Abstr.) **(Fre)**

[Fatal gas embolism during corrective surgery for scoliosis using the posterior approach] López LM, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul;46(6):267-70 (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES see PEROXIDES

ANALYSIS

Measurement of hydrogen peroxide in biological samples containing high levels of ascorbic acid. Bleau G, et al. **Anal Biochem** 1998 Oct 1;263(1):13-7

Sol-gel thin-film immobilized soybean peroxidase biosensor for the amperometric determination of hydrogen peroxide in acid medium. Wang B, et al. **Anal Chem** 1999 May 15; 71(10):1935-9

The influence of liposome-encapsulated prostaglandin E1 on hydrogen peroxide concentrations in the exhaled breath of patients with the acute respiratory distress syndrome. Heard SO, et al. **Anesth Analg** 1999 Aug;89(2):353-7

Hydrogen peroxide production from reactive liposomes encapsulating enzymes. Kaszuba M, et al. **Biochim Biophys Acta** 1999 Jul 15;1419(2):221-8

Role of peroxide in AC electrical field exposure effects on friend murine erythroleukemia cells during dielectrophoretic manipulations. Wang X, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):53-68

Improved operational stability of biosensors based on enzyme-polyelectrolyte complex adsorbed into a porous carbon electrode. Gavalas VG, et al. **Biosens Bioelectron** 1998 Nov 15;13(11):1205-11

Measurement of the extracellular H2O2 in the brain by microdialysis. Lei B, et al. **Brain Res Brain Res Protoc** 1998 Sep;3(1):33-6

Hydrogen peroxide in exhaled air of healthy children: reference values. Jöbsis Q, et al. **Eur Respir J** 1998 Aug; 12(2):483-5

Hydrogen peroxide determination in pharmaceutical formulations and cosmetics using a new catalase biosensor. Campanella L, et al. **J Pharm Biomed Anal** 1998 Oct; 18(1-2):105-16

Microscopic analysis of enzyme activity, mitochondrial distribution and hydrogen peroxide in two-cell rat embryos. Matsumoto H, et al. **J Reprod Fertil** 1998 Jul; 113(2):231-8

Principal component analysis of measured quantities during degradation of hydroperoxides in oxidized vegetable oils. Héberger K, et al. **Lipids** 1999 Jan;34(1):83-92

Analysis of novel hydroperoxides and other metabolites of oleic, linoleic, and linolenic acids by liquid chromatography-mass spectrometry with ion trap MSn. Oliw EH, et al. **Lipids** 1998 Sep;33(9):843-52

In vivo measurement of hydrogen peroxide by microelectrode. Yokoyama H. **Methods Enzymol** 1999; 300:275-84

Histochemical method for localization of hydrogen peroxide and oxygen radicals in the intact neonatal brain. Hamby-Mason RL, et al. **Methods Find Exp Clin Pharmacol** 1998 Nov;20(9):743-8

Hydrogen peroxide on the surface of Europa. Carlson RW, et al. **Science** 1999 Mar 26;283(5410):2062-4

A spectrophotometric method for the determination of hydroperoxides in liposomes. Cimato A, et al. **Spectrochim Acta A Mol Biomol Spectrosc** 1998 Oct; 54A(12):2001-8

[A sensitive method for quantitative analysis of hydrogen peroxide and oxidase substrates in biological samples] Honchar MV. **Ukr Biokhim Zh** 1998 Sep-Oct;70(5):157-63 (Eng. Abstr.) **(Ukr)**

ANTAGONISTS & INHIBITORS

Protection by L-2-oxothiazolidine-4-carboxylic acid of hydrogen peroxide-induced CD3zeta and CD16zeta chain down-regulation in human peripheral blood lymphocytes and lymphokine-activated killer cells. Corsi MM, et al. **Biochem Pharmacol** 1998 Sep 1;56(5):657-62

Protective effect of ebselen against hydrogen peroxide-induced cytotoxicity and DNA damage in HepG2 cells. Yang CF, et al. **Biochem Pharmacol** 1999 Feb 1;57(3):273-9

Inhibitors of the activity of poly (ADP-ribose) synthetase reduce the cell death caused by hydrogen peroxide in human cardiac myoblasts. Bowes J, et al. **Br J Pharmacol** 1998 Aug;124(8):1760-6

Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. Abrahamse SL, et al. **Carcinogenesis** 1999 Apr; 20(4):629-34

Structure-activity relationships of quercetin in antagonizing hydrogen peroxide-induced calcium dysregulation in PC12 cells. Wang H, et al. **Free Radic Biol Med** 1999 Sep; 27(5-6):683-94

Characterization of LY231617 protection against hydrogen peroxide toxicity. Fuson KS, et al. **J Neurochem** 1999 Mar; 72(3):1154-60

Radical scavenging compound J 811 inhibits hydrogen peroxide-induced death of cerebellar granule cells. Götz ME, et al. **J Neurosci Res** 1999 May 15;56(4):420-6

The pineal secretory product melatonin reduces hydrogen peroxide-induced DNA damage in U-937 cells. Romero MP, et al. **J Pineal Res** 1999 May;26(4):227-35

Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage. De Salvia R, et al. **Mutagenesis** 1999 Jan;14(1):107-12

BLOOD

Determination of glutathione peroxidase activity and its contribution to hydrogen peroxide removal in erythrocytes. Wakimoto M, et al. **Acta Med Okayama** 1998 Oct; 52(5):233-7

Impaired production of nitric oxide, superoxide, and hydrogen peroxide in glucose 6-phosphate-dehydrogenase-deficient granulocytes. Tsai KJ, et al. **FEBS Lett** 1998 Oct 9;436(3):411-4

Characterization of reactive oxygen species induced effects on human spermatozoa movement and energy metabolism. Armstrong JS, et al. **Free Radic Biol Med** 1999 Apr; 26(7-8):869-80

Exercise-induced increase in hydrogen peroxide plasma levels is diminished by endurance training after myocardial infarction. Deskur E, et al. **Int J Cardiol** 1998 Dec 31; 67(3):219-24

Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. Södergren E, et al. **J Biochem Biophys Methods** 1998 Nov 18;37(3):137-46

Accumulation and metabolism of low density lipoprotein-derived cholesteryl linoleate hydroperoxide and hydroxide by macrophages. Kritharides L, et al. **J Lipid Res** 1998 Dec;39(12):2394-405

Cytomegalovirus mononucleosis with decreased H2O2 production of neutrophil in an immunocompetent adult. Watanabe H, et al. **Kansenshogaku Zasshi** 1998 Sep; 72(9):939-44

CHEMISTRY

Glove resistance to permeation by a 7.5% hydrogen peroxide sterilizing and disinfecting solution. Monticello MV, et al. **Am J Infect Control** 1999 Aug;27(4):364-6

Enhanced degradation of polyvinyl alcohol by Pycnoporus cinnabarinus after pretreatment with Fenton's reagent. Larking DM, et al. **Appl Environ Microbiol** 1999 Apr; 65(4):1798-800

Two moles of O2 consumption and one mole of H2O2 formation during cholesterol peroxidation with cholesterol oxidase from Pseudomonas sp. strain ST-200. Doukyu N, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):621-7

Crosslinking of DNA and proteins induced by protein hydroperoxides. Gebicki S, et al. **Biochem J** 1999 Mar 15; 338 (Pt 3):629-36

Reactions of cross-linked ferric haemoglobins with hydrogen peroxide. Dunne J, et al. **Biochem Soc Trans** 1998 Nov; 26(4):S320

8-Nitro-2'-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxide-nitrite system of activated human phagocytes. Byun J, et al. **Biochemistry** 1999 Feb 23;38(8):2590-600

Direct evidence for a tyrosine radical in the reaction of cytochrome c oxidase with hydrogen peroxide. MacMillan F, et al. **Biochemistry** 1999 Jul 20;38(29):9179-84

Resolution of electrogenic steps coupled to conversion of cytochrome c oxidase from the peroxy to the ferryl-oxo state. Siletsky S, et al. **Biochemistry** 1999 Apr 13; 38(15):4853-61

Interaction of peroxynitrite and hydrogen peroxide with dinitrosyl iron complexes containing thiol ligands in vitro. Lobysheva II, et al. **Biochemistry (Mosc)** 1999 Feb; 64(2):153-8

Reactions of prostaglandin endoperoxide synthase with hydroperoxide and reducing substrates under single turnover conditions. Koshkin V, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):47-52

Improvement of the performance of H2O2 oxidation at low working potential by incorporating TTF-TCNQ into a platinum wire electrode for glucose determination. Li QS, et al. **Biosens Bioelectron** 1999 Mar 15;14(3):327-34

Use of ozone and hydrogen peroxide to remove alachlor from surface water. Beltrán F, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):9-14

Oxidation of 2-chlorophenol wastewater by hydrogen peroxide in the presence of basic oxygen furnace slag. Li Y, et al. **Bull Environ Contam Toxicol** 1999 Mar; 62(3):336-43

Conversion of pentahalogenated phenols by microperoxidase-8/H2O2 to benzoquinone-type products. Osman AM, et al. **Chem Res Toxicol** 1998 Nov; 11(11):1319-25

Oxidative degradation of p-toluenesulfonic acid using hydrogen peroxide. Stöffler B, et al. **Chemosphere** 1999 Feb; 38(5):1035-47

Formation of the paramagnetic complex [Cr(OH)5O2]5- in the reaction between chromium(VI) oxide, and hydrogen peroxide or superoxide anion radicals studied by EPR spectroscopy. Lagercrantz C. **Free Radic Biol Med** 1999 May;26(9-10):1134-7

Effects of cysteamine and cystamine on the sonochemical accumulation of hydrogen peroxide--implications for their mechanisms of action in ultrasound-exposed cells. Misik V, et al. **Free Radic Biol Med** 1999 Apr;26(7-8):961-7

Reactions of sperm whale myoglobin with hydrogen peroxide. Effects of distal pocket mutations on the formation and stability of the ferryl intermediate. Alayash AI, et al. **J Biol Chem** 1999 Jan 22;274(4):2029-37

Reaction of peroxynitrite with reduced nicotinamide nucleotides, the formation of hydrogen peroxide. Kirsch M, et al. **J Biol Chem** 1999 Aug 27;274(35):24664-70

Estimation of .OH radical reaction rate constants for phenol and chlorinated phenols using UV/H2O2 photo-oxidation. De AK, et al. **J Hazard Mater** 1999 Jan 1;64(1):91-104

Determination of degradation products from the calcium-channel blocker isradipine. Bartlett MG, et al. **J Pharm Biomed Anal** 1998 Nov;18(3):335-45

Imaging of hydroperoxides in a rat glomerulus stimulated by puromycin aminonucleoside. Aoyagi K, et al. **Kidney Int Suppl** 1999 Jul;71:S153-5

DIAGNOSTIC USE

Endoscopic hydrogen peroxide spray may facilitate localization of the bleeding site in acute upper gastrointestinal bleeding. Wu DC, et al. **Endoscopy** 1999 Mar;31(3):237-41

Clinical usefulness of 3% hydrogen peroxide in acute upper GI bleeding: a pilot study. Kalloo AN, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):518-21

METABOLISM

Immunotargeting of glucose oxidase: intracellular production

of H(2)O(2) and endothelial oxidative stress. Gow AJ, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L271–81

Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Horváth I, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1042–6

Production of hydrogen peroxide in cancerous tissue by intravenous administration of sodium 5,6–benzylidene–L–ascorbate. Asano K, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):229–36

Optimization of simultaneous chemical and biological mineralization of perchloroethylene. Büyüksönmez F, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2784–8

Hydrogen peroxide in expired air condensate correlates positively with early steps of peripheral neutrophil activation in asthmatic patients. Antczak A, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):119–26

Restoration of culturability of starvation–stressed and low–temperature–stressed Escherichia coli O157 cells by using H2O2–degrading compounds. Mizunoe Y, et al. **Arch Microbiol** 1999 Jul;172(1):63–7

Ultracytochemical localization of hydrogen peroxide production by dental plaque bacteria. Oyarzún A, et al. **Arch Oral Biol** 1998 Nov;43(11):907–10

Oxidation of alpha1–proteinase inhibitor by the myeloperoxidase–hydrogen peroxidase system promotes binding to immunoglobulin A. Scott LJ, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):562–7

Formation of phospholipid hydroperoxides and its inhibition by alpha–tocopherol in rat brain synaptosomes induced by peroxynitrite. Shi H, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):651–6

Lipid peroxidation induced by the Cu,Zn–superoxide dismutase and hydrogen peroxide system. Kwon OB, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):645–53

Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL–60 cells. Ikeda K, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1361–5

Mechanism of horseradish peroxidase catalyzed epinephrine oxidation: obligatory role of endogenous O2– and H2O2. Adak S, et al. **Biochemistry** 1998 Dec 1;37(48):16922–33

The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Huang X, et al. **Biochemistry** 1999 Jun 15;38(24):7609–16

Evaluation of relative contributions of two enzymes supposed to metabolise hydrogen peroxide in Paracoccus denitrificans. Koutn M, et al. **Biochim Biophys Acta** 1999 Jan 27;1410(1):71–6

Biochemical characterization of a Ca2+/NAD(P)H–dependent H2O2 generator in human thyroid tissue. Leseney AM, et al. **Biochimie** 1999 Apr; 81(4):373–80

Oxidation of 4–tert–butylcatechol and dopamine by hydrogen peroxide catalysed by horseradish peroxidase. García–Moreno M, et al. **Biol Chem** 1999 Jun;380(6):689–94

Generation of reactive oxygen species by raphidophycean phytoplankton. Oda T, et al. **Biosci Biotechnol Biochem** 1997 Oct;61(10):1658–62

Susceptibility to hydrogen peroxide and catalase activity of root nodule bacteria. Ohwada T, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):457–62

Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide–dependent pathway. Jing Y, et al. **Blood** 1999 Sep 15;94(6):2102–11

Decreased ability of cells overexpressing MYC proteins to reduce peroxide and hydroperoxides. Tuttle S, et al. **Br J Cancer Suppl** 1996 Jul;27:S140–44

Involvement of NO, H2O2 and TNF–alpha in the reduced antitumor activity of murine peritoneal macrophages by aflatoxin B1. Moon EY, et al. **Cancer Lett** 1999 Mar 1; 136(2):167–76

Polyclonal antibodies to adenine N1–oxide: characterization and use for the measurement of DNA damage. Signorini N, et al. **Chem Res Toxicol** 1998 Oct;11(10):1169–75

Selection of vaginal H2O2–generating Lactobacillus species for probiotic use. Ocaña VS, et al. **Curr Microbiol** 1999 May;38(5):279–84

Single–cell measurement of superoxide anion and hydrogen peroxide production by human neutrophils with digital imaging fluorescence microscopy. Szucs S, et al. **Cytometry** 1998 Sep 1;33(1):19–31

A sensitive fluorometric assay for determining hydrogen peroxide–mediated sublethal and lethal endothelial cell injury. Oral HB, et al. **Endothelium** 1998;6(2):143–51

Hydrogen peroxide mediates doxorubicin–induced transglutaminase 2 expression in PC–14 human lung cancer cell line. Han JA, et al. **Exp Mol Med** 1999 Jun 30; 31(2):83–8

Redox signaling: hydrogen peroxide as intracellular messenger. Rhee SG. **Exp Mol Med** 1999 Jun 30;31(2):53–9 (60 ref.)

Hydrogen peroxide produced during gamma–glutamyl transpeptidase activity is involved in prevention of apoptosis and maintainance of proliferation in U937 cells. del Bello B, et al. **FASEB J** 1999 Jan;13(1):69–79

Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming. Schmid E, et al. **FASEB J** 1999 Sep;13(12):1491–500

Hydrogen peroxide generation by higher plant mitochondria oxidizing complex I or complex II substrates. Braidot E, et al. **FEBS Lett** 1999 May 28;451(3):347–50

An early salicylic acid–, pathogen– and elicitor–inducible tobacco glucosyltransferase: role in compartmentalization of phenolics and H2O2 metabolism. Chong J, et al. **FEBS Lett** 1999 Sep 17;458(2):204–8

Physiological production of singlet molecular oxygen in the myeloperoxidase–H2O2–chloride system. Kiryu C, et al. **FEBS Lett** 1999 Jan 25;443(2):154–8

Copper–induced LDL peroxidation: interrelated dependencies of the kinetics on the concentrations of copper, hydroperoxides and tocopherol. Pinchuk I, et al. **FEBS Lett** 1999 May 7;450(3):186–90

Arachidonic acid induces the activation of the stress–activated protein kinase, membrane ruffling and H2O2 production via a small GTPase Rac1. Shin EA, et al. **FEBS Lett** 1999 Jun 11;452(3):355–9

Generation of hydrogen peroxide precedes loss of mitochondrial membrane potential during DNA alkylation–induced apoptosis. Tada–Oikawa S, et al. **FEBS Lett** 1999 Jan 8;442(1):65–9

Major differences in oxysterol formation in human low density lipoproteins (LDLs) oxidized by •OH/O2•– free radicals or by copper. Zarev S, et al. **FEBS Lett** 1999 May 21;451(2):103–8

Growth inhibition of Staphylococcus aureus by H2O2–producing Lactobacillus paracasei subsp. paracasei isolated from the human vagina. Ocaña VS, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):87–92

Lipoxygenase/H2O2–catalyzed oxidation of dihdroxyindoles: synthesis of melanin pigments and study of their antioxidant properties. Blarzino C, et al. **Free Radic Biol Med** 1999 Feb;26(3–4):446–53

Vitamin E regulates mitochondrial hydrogen peroxide generation. Chow CK, et al. **Free Radic Biol Med** 1999 Sep;27(5–6):580–7

Redox modulation of cell surface protein thiols in U937 lymphoma cells: the role of gamma–glutamyl transpeptidase–dependent H2O2 production and S–thiolation. Dominici S, et al. **Free Radic Biol Med** 1999 Sep;27(5–6):623–35

Role of xanthine oxidase in hydrogen peroxide production. Lacy F, et al. **Free Radic Biol Med** 1998 Oct;25(6):720–7

Scavenging of hydrogen peroxide and inhibition of ultraviolet light–induced oxidative DNA damage by aqueous extracts from green and black teas. Wei H, et al. **Free Radic Biol Med** 1999 Jun;26(11–12):1427–35

In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long–term administration of a neuroleptic. Yokoyama H, et al. **Free Radic Biol Med** 1998 Apr;24(6):1056–60

Determinants of intestinal detoxication of lipid hydroperoxides. Aw TY. **Free Radic Res** 1998 Jun; 28(6):637–46 (52 ref.)

Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide–C/EBPbeta–dependent mechanism in rat hepatic stellate cells. García–Trevijano ER, et al. **Hepatology** 1999 Mar;29(3):960–70

Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein–2 in the regenerating mice [correction of rat] liver. Lee FY, et al. **Hepatology** 1999 Mar;29(3):677–87

Enhanced potential for oxidative stress in hyperinsulinemic rats: imbalance between hepatic peroxisomal hydrogen peroxide production and decomposition due to hyperinsulinemia. Xu L, et al. **Horm Metab Res** 1999 Apr; 31(4):278–82

Potentiation of hydrogen peroxide, nitric oxide, and cytokine production in RAW 264.7 macrophage cells exposed to human and commercial isolates of Bifidobacterium. Park SY, et al. **Int J Food Microbiol** 1999 Feb 18;46(3):231–41

NO–dependent regulation of lectin– and menadione–induced H2O2 production by cells from pleural effusions of lung cancer patients and by immune cells. Timoshenko AV, et al. **Int J Oncol** 1999 Apr;14(4):793–8

Peroxide–supported in–vitro cytochrome P450 activities in Haemonchus contortus. Kotze AC. **Int J Parasitol** 1999 Mar;29(3):389–96

Role for the oxyS gene in regulation of intracellular hydrogen peroxide in Escherichia coli. González–Flecha B, et al. **J Bacteriol** 1999 Jun;181(12):3833–6

Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase–1 and –2. Chen W, et al. **J Biol Chem** 1999 Jul 16;274(29):20301–6

An electron spin resonance spin–trapping investigation of the free radicals formed by the reaction of mitochondrial cytochrome c oxidase with H2O2. Chen YR, et al. **J Biol Chem** 1999 Feb 5;274(6):3308–14

Role of heme in intracellular trafficking of thyroperoxidase and involvement of H2O2 generated at the apical surface of thyroid cells in autocatalytic covalent heme binding. Fayadat L, et al. **J Biol Chem** 1999 Apr 9;274(15):10533–8

Reactions of hydrogen peroxide with familial amyotrophic lateral sclerosis mutant human copper–zinc superoxide dismutases studied by pulse radiolysis. Goto JJ, et al. **J Biol Chem** 1998 Nov 13;273(46):30104–9

Effects of the location of distal histidine in the reaction of myoglobin with hydrogen peroxide. Matsui T, et al. **J Biol Chem** 1999 Jan 29;274(5):2838–44

The identification of primary sites of superoxide and hydrogen peroxide formation in the aerobic respiratory chain and sulfite reductase complex of Escherichia coli. Messner KR, et al. **J Biol Chem** 1999 Apr 9; 274(15):10119–28

Requirement of caspase–3(–like) protease–mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. Simizu S, et al. **J Biol Chem** 1998 Oct 9;273(41):26900–7

Formation of S–nitrosothiols via direct nucleophilic nitrosation of thiols by peroxynitrite with elimination of hydrogen peroxide. van der Vliet A, et al. **J Biol Chem** 1998 Nov 13;273(46):30255–62

Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP–1–mediated induction of matrix–degrading metalloprotease–1. Wenk J, et al. **J Biol Chem** 1999 Sep 3;274(36):25869–76

Identification of and hydrogen peroxide production by fecal and vaginal lactobacilli isolated from Japanese women and newborn infants. Song YL, et al. **J Clin Microbiol** 1999 Sep;37(9):3062–4

Highly specific detection of H2O2–dependent luminol chemiluminescence in stimulated human leukocytes using polyvinyl films. Moriguchi K, et al. **J Electron Microsc (Tokyo)** 1999;48(2):177–9

Complementary roles for scavenger receptor A and CD36 of human monocyte–derived macrophages in adhesion to surfaces coated with oxidized low–density lipoproteins and in secretion of H2O2. Maxeiner H, et al. **J Exp Med** 1998 Dec 21;188(12):2257–65

Oxidation of dichlorvos with hydrogen peroxide using ferrous ion as catalyst. Lu MC, et al. **J Hazard Mater** 1999 Mar 19;65(3):277–88

Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils. Sterner–Kock A, et al. **J Leukoc Biol** 1999 Jun;65(6):834–40

Increase in external glutamate and NMDA receptor activation contribute to H2O2–induced neuronal apoptosis. Mailly F, et al. **J Neurochem** 1999 Sep;73(3):1181–8

Hydrogen peroxide production in immune–reactive Drosophila melanogaster. Nappi AJ, et al. **J Parasitol** 1998 Dec;84(6):1150–7

Neonatal oxidative liver metabolism: effects of hydrogen peroxide, a putative mediator of septic damage. Romeo C, et al. **J Pediatr Surg** 1999 Jul;34(7):1107–11

Premature induction of aging in sublethally H2O2–treated young MRC5 fibroblasts correlates with increased glutathione peroxidase levels and resistance to DNA breakage. Caldini R, et al. **Mech Ageing Dev** 1998 Sep 15; 105(1–2):137–50

Lysophosphatidic acid increases intracellular H2O2 by phospholipase D and RhoA in rat–2 fibroblasts. Shin I, et al. **Mol Cells** 1999 Jun 30;9(3):292–9

Pyruvate prevents peroxide–induced injury of in vitro preimplantation bovine embryos. Morales H, et al. **Mol Reprod Dev** 1999 Feb;52(2):149–57

Cigarette smoking does not increase hydrogen peroxide levels in expired breath condensate of patients with stable COPD. Nowak D, et al. **Monaldi Arch Chest Dis** 1998 Jun; 53(3):268–73

Synergistic lethal effect between hydrogen peroxide and neocuproine (2,9–dimethyl 1,10–phenanthroline) in Escherichia coli. Almeida CE, et al. **Mutat Res** 1999 Jan 26;433(1):59–66

Laboratory evolution of peroxide–mediated cytochrome P450 hydroxylation [see comments] Joo H, et al. **Nature** 1999 Jun 17;399(6737):670–3. Comment in: Nature 1999 Jun 17;399(6737):636–7.

Enzymes. Picking a winner [news; comment] Sheldon R. **Nature** 1999 Jun 17;399(6737):636–7. Comment on: Nature 1999 Jun 17;399(6737):670–3.

Restriction of peroxidase–mediated antibody reactivity to single neurons by local hydrogen peroxide production. Shayan H, et al. **Neuroscience** 1999 Mar;89(1):279–90

Nitric oxide, superoxide, and hydrogen peroxide production in brain mitochondria after haloperidol treatment. Arnaiz SL, et al. **Nitric Oxide** 1999 Jun;3(3):235–43

Plant tannins as inhibitors of hydroperoxide production and tumor promotion induced by ultraviolet B radiation in mouse skin in vivo. Gali–Muhtasib HU, et al. **Oncol Rep** 1999 Jul–Aug;6(4):847–53

Regulation by biotic and abiotic stress of a wheat germin gene encoding oxalate oxidase, a H2O2–producing enzyme. Berna A, et al. **Plant Mol Biol** 1999 Feb;39(3):539–49

Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Mazzio EA, et al. **Planta Med** 1998 Oct;64(7):603–6

Activation of flavin–containing oxidases underlies light–induced production of H2O2 in mammalian cells. Hockberger PE, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6255–60

Hydrogen peroxide is generated systemically in plant leaves by wounding and systemin via the octadecanoid pathway. Orozco–Cardenas M, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6553–7

Nitration of gamma–tocopherol and oxidation of alpha–tocopherol by copper–zinc superoxide dismutase/H2O2/NO2–: role of nitrogen dioxide free radical. Singh RJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12912–7

Increased content of thiobarbituric acid–reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Nowak D, et al. **Respir Med** 1999 Jun;93(6):389–96

Effects of modulators of the production and degradation of

hydrogen peroxide on erythropoietin synthesis. Canbolat O, et al. **Respir Physiol** 1998 Nov;114(2):175–83

Systemic signaling and acclimation in response to excess excitation energy in Arabidopsis [see comments] Karpinski S, et al. **Science** 1999 Apr 23;284(5414):654–7. Comment in: Science 1999 Apr 23;284(5414):599–601.

Receptor and non-receptor mediated formation of superoxide anion and hydrogen peroxide in neutrophils of intensive care patients. Manhart N, et al. **Wien Klin Wochenschr** 1998 Nov 27;110(22):796–801

[Soluble proteins from Staphylococcus aureus can change expression of CD11b and CD62L, but not H2O2 production by human blood granulocytes] Onogawa T, et al. **Kansenshogaku Zasshi** 1999 Apr;73(4):328–35 (Eng. Abstr.) **(Jpn)**

[Generation of hydrogen peroxide during reduction of 2,4,6-trinitrotoluene and its related compounds] Kiria-Sakai M, et al. **Sangyo Eiseigaku Zasshi** 1999 Jan; 41(1):11–2 **(Jpn)**

[Oxidative destruction of estradiol after treatment with hydrogen peroxide catalyzed by horseradish peroxidase and methemoglobin] Petrenko IuM, et al. **Biofizika** 1999 Mar–Apr;44(2):236–43 (Eng. Abstr.) **(Rus)**

[Peroxide-dependent oxidation of substrates of polysynthetic flavocytochrome 2B4] Shumiantseva VV, et al. **Vopr Med Khim** 1998 Jul–Aug;44(4):369–75 (Eng. Abstr.) **(Rus)**

[Hydrogen peroxide in the aqueous humor: 1992–1997] Garcia-Castiñeiras S. **P R Health Sci J** 1998 Dec; 17(4):335–43 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. Dringen R, et al. **J Neurochem** 1999 Jun;72(6):2523–30

PHARMACOLOGY

Hydrogen peroxide effects in Escherichia coli cells. Asad NR, et al. **Acta Biochim Pol** 1998;45(3):677–90

Effects of hydrogen peroxide on the guinea-pig tracheobronchial mucosa in vivo. Greiff L, et al. **Acta Physiol Scand** 1999 Apr;165(4):415–20

Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity. Barlow RS, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1283–9

Hydrogen peroxide inhibits cAMP-induced Cl- secretion across colonic epithelial cells. DuVall MD, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):C1313–22

Influence of glutathione peroxidase on coronary artery responses to alterations in PO2 and H2O2. Mohazzab-H KM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H235–41

Sensitivity of canine intrinsic cardiac neurons to H2O2 and hydroxyl radical. Thompson GW, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1434–40

Hydrogen peroxide stimulates tyrosine phosphorylation of focal adhesion kinase in vascular endothelial cells. Vepa S, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):L150–8

EGF-Receptor phosphorylation and signaling are targeted by H2O2 redox stress. Goldkorn T, et al. **Am J Respir Cell Mol Biol** 1998 Nov;19(5):786–98

Hydrogen peroxide enhances shedding of type I soluble tumor necrosis factor receptor from pulmonary epithelial cells. Hino T, et al. **Am J Respir Cell Mol Biol** 1999 Jan; 20(1):122–8

Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. Janssen-Heininger YM, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):942–52

Protective effects of heme oxygenase-1 against oxidant-induced injury in the cultured human tracheal epithelium. Yamada N, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):428–35

Endonuclease activity and hydrogen peroxide-induced cytotoxicity in human glioblastoma and glioma cell lines. Iida M, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):1235–40

A mechanism of resistance to hydrogen peroxide in Vibrio rumoiensis S-1. Ichise N, et al. **Appl Environ Microbiol** 1999 Jan;65(1):73–9

Mechanism of stimulation of glucose transport by H2O2: role of phospholipase C. Prasad RK, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):113–22

Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide. DiPietrantonio AM, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):477–82

Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against oxidative stress. Fiander H, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):591–5

EPR detection of protein-derived radicals in the reaction of H(2)O(2) with Fe bound in mitochondrial F(1)ATPase. Polizio F, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):281–5

Hydrogen peroxide-induced DNA damage is independent of nuclear calcium but dependent on redox-active ions. Jornot L, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):85–94

Protection against hydrogen peroxide cytotoxicity in rat-1 fibroblasts provided by the oncoprotein Bcl-2: maintenance of calcium homoeostasis is secondary to the effect of Bcl-2 on cellular glutathione. Rimpler MM, et al. **Biochem J** 1999 May 15;340 (Pt 1):291–7

The activation of protein kinase B by H2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Shaw M, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):241–6

Ascorbic acid-dependent cytoprotection of ovarian cells by leukocyte and nonleukocyte peroxidases. Kolodecik TR, et al. **Biochem Pharmacol** 1998 May 1;55(9):1497–503

The anti-proliferative and cell death-inducing effect of H2O2 on squamous cell carcinoma cells. Ulukaya E, et al. **Biochem Soc Trans** 1998 Nov;26(4):S347

Hydrogen peroxide inhibits the growth of cyanobacteria. Samuilov VD, et al. **Biochemistry (Mosc)** 1999 Jan; 64(1):47–53

Influence of different types of effectors on the kinetic parameters of suicide inactivation of catalase by hydrogen peroxide. Ghadermarzi M, et al. **Biochim Biophys Acta** 1999 Apr 12;1431(1):30–6

Superoxide dismutase and hydrogen peroxide cause rapid nitric oxide breakdown, peroxynitrite production and subsequent cell death. McBride AG, et al. **Biochim Biophys Acta** 1999 Aug 30;1454(3):275–88

Transcriptional activation of the alternative oxidase gene of the fungus Magnaporthe grisea by a respiratory-inhibiting fungicide and hydrogen peroxide. Yukioka H, et al. **Biochim Biophys Acta** 1998 Nov 8;1442(2-3):161–9

Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved. Rodríguez-Martínez MA, et al. **Br J Pharmacol** 1998 Nov;125(6):1329–35

Pharmacological enhancement of cutaneous flap survival with topical dimethyl sulphoxide and hydrogen peroxide. Raposio E, et al. **Br J Plast Surg** 1998 Oct;51(7):551–4

Endothelium-dependent relaxation to hydrogen peroxide in canine basilar artery: a potential new cerebral dilator mechanism. Yang ZW, et al. **Brain Res Bull** 1998 Oct; 47(3):257–63

Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Uberti D, et al. **Brain Res Mol Brain Res** 1999 Mar 5;65(2):167–75

The role of catalase in hydrogen peroxide resistance in fission yeast Schizosaccharomyces pombe. Mutoh N, et al. **Can J Microbiol** 1999 Feb;45(2):125–9

Apurinic endonuclease (Ref-1) is induced in mammalian cells by oxidative stress and involved in clastogenic adaptation. Grösch S, et al. **Cancer Res** 1998 Oct 1;58(19):4410–6

Hydrogen peroxide induced impairment of post-ischemic ventricular function is prevented by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). Myers ML, et al. **Cardiovasc Res** 1998 Nov;40(2):290–6

Phosphorylation is not essential for protection of L929 cells by Hsp25 against H2O2-mediated disruption actin cytoskeleton, a protection which appears related to the redox change mediated by Hsp25. Préville X, et al. **Cell Stress Chaperones** 1998 Sep;3(3):177–87

Hydrogen peroxide, potassium currents, and membrane potential in human endothelial cells. Bychkov R, et al. **Circulation** 1999 Apr 6;99(13):1719–25

Stimulation of active sodium-potassium transport by hydrogen peroxide in cultured rabbit nonpigmented ciliary epithelium. Chin S, et al. **Curr Eye Res** 1999 Apr; 18(4):254–60

Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Lean ME, et al. **Diabetes** 1999 Jan;48(1):176–81

Susceptibility of differentiated thyrocytes in primary culture to undergo apoptosis after exposure to hydrogen peroxide: relation with the level of expression of apoptosis regulatory proteins, Bcl-2 and Bax. Riou C, et al. **Endocrinology** 1999 May;140(5):1990–7

Hydrogen peroxide induces oxidative DNA damage in rat type II pulmonary epithelial cells. Meehan WJ, et al. **Environ Mol Mutagen** 1999;33(4):273–8

Endothelium-independent and -dependent vasoactivity of 6-nitronorepinephrine. Nakaki T, et al. **Eur J Pharmacol** 1998 Sep 18;357(2-3):193–7

Both D-cis- and L-cis-diltiazem attenuate hydrogen peroxide-induced derangements in rat hearts. Xiao CY, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):387–98

Hydrogen peroxide suppresses U937 cell death by two different mechanisms depending on its concentration. Lee BR, et al. **Exp Cell Res** 1999 May 1;248(2):430–8

Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells. Ballinger SW, et al. **Exp Eye Res** 1999 Jun;68(6):765–72

Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. Räisänen SR, et al. **FASEB J** 1999 Mar;13(3):513–22

Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. Clément MV, et al. **FEBS Lett** 1998 Nov 27;440(1-2):13–8

Cyclosporin A inhibits H2O2-induced apoptosis of human fibroblasts. Sugano N, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):274–6

The extensin multigene family responds differentially to superoxide or hydrogen peroxide in tomato cell cultures. Wisniewski JP, et al. **FEBS Lett** 1999 Mar 26; 447(2-3):264–8

Beta-carotene enhances hydrogen peroxide-induced DNA damage in human hepatocellular HepG2 cells. Woods JA, et al. **FEBS Lett** 1999 Apr 23;449(2-3):255–8

Probing cellular protein targets of H2O2 with fluorescein-conjugated iodoacetamide and antibodies to fluorescein. Wu Y, et al. **FEBS Lett** 1998 Nov 27; 440(1-2):111–5

Effects of hydrogen peroxide on growth and selected properties of Porphyromonas gingivalis. Leke N, et al. **FEMS Microbiol Lett** 1999 May 15;174(2):347–53

Identification of the catalase gene promoter region involved in superinduction in Schizosaccharomyces pombe caused by cycloheximide and hydrogen peroxide. Nakagawa CW, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):373–8

Inactivation of the plasma membrane ATPase of Schizosaccharomyces pombe by hydrogen peroxide and by the Fenton reagent (Fe2+/H2O2): nonradical vs. radical-induced oxidation. Sigler K, et al. **Folia Microbiol (Praha)** 1998;43(4):361–7

Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Chua CC, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):891–7

Severe energy impairment consequent to inactivation of mitochondrial ATP synthase as an early event in cell death: a mechanism for the selective sensitivity to H2O2 of differentiating erythroleukemia cells. Comelli M, et al. **Free Radic Biol Med** 1998 Apr;24(6):924–32

Oxidative insult specifically decreases levels of a mitochondrial transcript. Elliott RM, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):646–55

A new look at a time-worn system: oxidation of CuZn-SOD by H2O2. Jewett SL, et al. **Free Radic Biol Med** 1999 Apr; 26(7-8):905–18

Impairment of the mitochondrial electron chain transport prevents NF-kappa B activation by hydrogen peroxide. Josse C, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):104–12

Heme and apoprotein modification of cytochrome P450 2B4 during its oxidative inactivation in monooxygenase reconstituted system. Karuzina II, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):620–32

Role of cadherin internalization in hydrogen peroxide-mediated endothelial permeability. Kevil CG, et al. **Free Radic Biol Med** 1998 Apr;24(6):1015–22

Cyclooxygenase dependent release of heme from microsomal hemeproteins correlates with induction of heme oxygenase 1 transcription in human fibroblasts. Kvam E, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):511–7

Mechanisms involved in the contraction of endothelial cells by hydrogen peroxide. López-Ongil S, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):501–10

Glucose oxidase-produced H2O2 induces Ca2+-dependent DNA damage in human peripheral blood lymphocytes. Panayiotidis M, et al. **Free Radic Biol Med** 1999 Mar; 26(5-6):548–56

Reactive oxygen species activate human peripheral blood dendritic cells. Rutault K, et al. **Free Radic Biol Med** 1999 Jan;26(1-2):232–8

Hydrogen peroxide induces endothelial cell atypia and cytoskeleton depolymerization. Valen G, et al. **Free Radic Biol Med** 1999 Jun;26(11-12):1480–8

Hydrogen peroxide-induced apoptosis in HL-60 cells requires caspase-3 activation. Matsura T, et al. **Free Radic Res** 1999 Jan;30(1):73–83

Oxidative modification of human low-density lipoprotein by horseradish peroxidase in the absence of hydrogen peroxide. Natella F, et al. **Free Radic Res** 1998 Nov; 29(5):427–34

Pyruvate prevents hydrogen peroxide-induced apoptosis. Ramakrishnan N, et al. **Free Radic Res** 1998 Oct; 29(4):283–95

Preconditioning with hydrogen peroxide (H2O2) or ischemia in H2O2-induced cardiac dysfunction. Valen G, et al. **Free Radic Res** 1998 Sep;29(3):235–45

Role of intracellular calcium in peroxide-induced potentiation of norepinephrine release from bovine isolated irides. Opere CA, et al. **Gen Pharmacol** 1998 Nov; 31(5):793–8

Another disinfectant for enterococci [letter; comment] Neely AN, et al. **Infect Control Hosp Epidemiol** 1999 Jun; 20(6):388–9. Comment on: Infect Control Hosp Epidemiol 1997 May;18(5):345–7.

Effect of hydrogen peroxide on the metabolism of articular chondrocytes. Asada S, et al. **Inflamm Res** 1999 Jul; 48(7):399–403

Intracellular mechanisms of nitric oxide plus hydrogen peroxide-mediated neutrophil adherence to cultured human endothelial cells. Okayama N, et al. **Inflamm Res** 1998 Nov;47(11):428–33

Oxidative stress induces differential gene expression in a human lens epithelial cell line. Carper DA, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):400–6

Suicide inactivation of peroxidase by H2O2: kinetic equations for peroxidatic oxidation reaction of guaiacol and determination of the kinetic parameters. Moosavi Movahedi AA, et al. **Ital J Biochem** 1999 Mar;48(1):9–17

Safety and efficacy of hydrogen peroxide plasma sterilization for repeated use of electrophysiology catheters. Bathina MN, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1384–8

Response surface methodology, an approach to predict the effects of a lactoperoxidase system, Nisin, alone or in combination, on Listeria monocytogenes in skim milk. Boussouel N, et al. **J Appl Microbiol** 1999 Apr;86(4):642–52

The use of poloxamer hydrogels for the assessment of biofilm susceptibility towards biocide treatments. Gilbert P, et al.

J Appl Microbiol 1998 Dec;85(6):985–90

Benzene-induced uncoupling of naphthalene dioxygenase activity and enzyme inactivation by production of hydrogen peroxide. Lee K. **J Bacteriol** 1999 May; 181(9):2719–25

Bacterioferritin A modulates catalase A (KatA) activity and resistance to hydrogen peroxide in Pseudomonas aeruginosa. Ma JF, et al. **J Bacteriol** 1999 Jun; 181(12):3730–42

Comparison of the apoptotic pathways induced by L-amino acid oxidase and hydrogen peroxide. Suhr SM, et al. **J Biochem (Tokyo)** 1999 Feb;125(2):305–9

Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage. Austin RC, et al. **J Biol Chem** 1998 Nov 13; 273(46):30808–17

Human cytoplasmic aconitase (Iron regulatory protein 1) is converted into its [3Fe-4S] form by hydrogen peroxide in vitro but is not activated for iron-responsive element binding. Brazzolotto X, et al. **J Biol Chem** 1999 Jul 30; 274(31):21625–30

Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-kappaB DNA binding. Carballo M, et al. **J Biol Chem** 1999 Jan 1;274(1):93–100

The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2. Caselli A, et al. **J Biol Chem** 1998 Dec 4;273(49):32554–60

Insulin signaling is inhibited by micromolar concentrations of H(2)O(2). Evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. Hansen LL, et al. **J Biol Chem** 1999 Aug 27;274(35):25078–84

Thiolation of the gammaB-crystallins in intact bovine lens exposed to hydrogen peroxide. Hanson SR, et al. **J Biol Chem** 1999 Feb 19;274(8):4735–42

Hydrogen peroxide induces intracellular calcium overload by activation of a non-selective cation channel in an insulin-secreting cell line. Herson PS, et al. **J Biol Chem** 1999 Jan 8;274(2):833–41

H2O2 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-1 and NF-kappaB to the interleukin-8 promoter in endothelial and epithelial cells. Lakshminarayanan V, et al. **J Biol Chem** 1998 Dec 4;273(49):32670–8

Involvement of tyrosine phosphorylation and protein kinase C in the activation of phospholipase D by H2O2 in Swiss 3T3 fibroblasts. Min DS, et al. **J Biol Chem** 1998 Nov 6; 273(45):29986–94

FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. Sonoda Y, et al. **J Biol Chem** 1999 Apr 9;274(15):10566–70

The activation of the rat copper/zinc superoxide dismutase gene by hydrogen peroxide through the hydrogen peroxide-responsive element and by paraquat and heat shock through the same heat shock element. Yoo HY, et al. **J Biol Chem** 1999 Aug 20;274(34):23887–92

Enzymatic removal of phenols from aqueous solutions by Coprinus cinereus peroxidase and hydrogen peroxide. Kauffmann C, et al. **J Biotechnol** 1999 Jul 30;73(1):71–4

Expression of HSP27 results in increased sensitivity to tumor necrosis factor, etoposide, and H2O2 in an oxidative stress-resistant cell line. Mairesse N, et al. **J Cell Physiol** 1998 Dec;177(4):606–17

H2O2 acts on cellular membranes to generate ceramide signaling and initiate apoptosis in tracheobronchial epithelial cells. Goldkorn T, et al. **J Cell Sci** 1998 Nov; 111 (Pt 21):3209–20

Efficacy of oxonia active against selected spore formers. Blakistone B, et al. **J Food Prot** 1999 Mar;62(3):262–7

Irreversible inactivation of purple acid phosphatase by hydrogen peroxide and ascorbate. Beck JL, et al. **J Inorg Biochem** 1999 Apr;73(4):245–52

UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. Peus D, et al. **J Invest Dermatol** 1999 May;112(5):751–6

H2O2 induces DNA repair in mononuclear cells: evidence for association with cytosolic Ca2+ fluxes. Korzets A, et al. **J Lab Clin Med** 1999 Apr;133(4):362–9

Nitric oxide-induced potentiation of the killing of Burkholderia cepacia by reactive oxygen species: implications for cystic fibrosis. Smith AW, et al. **J Med Microbiol** 1999 May;48(5):419–23

Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. Bhat NR, et al. **J Neurochem** 1999 Jan;72(1):112–9

Depolarization of in situ mitochondria due to hydrogen peroxide-induced oxidative stress in nerve terminals: inhibition of alpha-ketoglutarate dehydrogenase. Chinopoulos C, et al. **J Neurochem** 1999 Jul;73(1):220–8

Protective properties of tin- and manganese-centered porphyrins against hydrogen peroxide-mediated injury in rat astroglial cells. Dwyer BE, et al. **J Neurochem** 1998 Dec;71(6):2497–504

Possible involvement of mitogen-activated protein kinase in phospholipase D activation induced by H2O2, but not by carbachol, in rat pheochromocytoma PC12 cells. Ito Y, et al. **J Neurochem** 1998 Dec;71(6):2278–85

Changes in membrane and synaptic properties of thalamocortical circuitry caused by hydrogen peroxide. Frantseva MV, et al. **J Neurophysiol** 1998 Sep; 80(3):1317–26

Oxidative stress oppositely modulates protein tyrosine phosphorylation stimulated by muscarinic G protein-coupled and epidermal growth factor receptors. Jope RS, et al. **J Neurosci Res** 1999 Feb 1;55(3):329–40

H2O2-induced apoptotic death in serum-deprived cultures of oligodendroglia origin is linked to cell differentiation. Kameshwar-Rao AS, et al. **J Neurosci Res** 1999 Jun 1; 56(5):447–56

Delayed oligodendrocyte degeneration induced by brief exposure to hydrogen peroxide. Laszkiewicz I, et al. **J Neurosci Res** 1999 Feb 1;55(3):303–10

Antibacterial synergistic effect of chlorhexidine and hydrogen peroxide against Streptococcus sobrinus, Streptococcus faecalis and Staphylococcus aureus. Steinberg D, et al. **J Oral Rehabil** 1999 Feb;26(2):151–6

Interference of H2O2 with stimulus-secretion coupling in mouse pancreatic beta-cells. Krippeit-Drews P, et al. **J Physiol (Lond)** 1999 Jan 15;514 (Pt 2):471–81

Effects of glutathione depletion on oxidant-induced endothelial cell injury. Gilmont RR, et al. **J Surg Res** 1998 Nov;80(1):62–8

Hydrogen peroxide-induced apoptosis and necrosis in human lung fibroblasts: protective roles of glutathione. Teramoto S, et al. **Jpn J Pharmacol** 1999 Jan;79(1):33–40

Hydrogen peroxide activates ion currents in rat mesangial cells. Gloy J, et al. **Kidney Int** 1999 Jul;56(1):181–9

H2O2 induces apoptosis in bovine tracheal epithelial cells in vitro. Nakajima Y, et al. **Life Sci** 1999;64(26):2489–96

Stimulation of in vitro angiogenesis by hydrogen peroxide and the relation with ETS-1 in endothelial cells. Yasuda M, et al. **Life Sci** 1999;64(4):249–58

Activation of mitogen-activated protein kinase and cytosolic phospholipase A2 by hydrogen peroxide in fibroblasts. van Rossum GS, et al. **Lipids** 1999;34 Suppl:S65

Further studies of the effects of diamide and hydrogen peroxide on calcium signaling in the human platelet. Hedin HL, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun; 21(5):321–5

Peroxide-inducible catalase in Aeromonas salmonicida subsp. salmonicida protects against exogenous hydrogen peroxide and killing by activated rainbow trout, Oncorhynchus mykiss L., macrophages. Barnes AC, et al. **Microb Pathog** 1999 Mar;26(3):149–58

Expression of the Oenococcus oeni trxA gene is induced by hydrogen peroxide and heat shock. Jobin MP, et al. **Microbiology** 1999 May;145 (Pt 5):1245–51

Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Mathee K, et al. **Microbiology** 1999 Jun;145 (Pt 6):1349–57

Intracellular mechanisms of hydrogen peroxide-mediated neutrophil adherence to cultured human endothelial cells. Okayama N, et al. **Microvasc Res** 1999 Mar;57(2):63–74

Role of H2O2 in changing beta-adrenoceptor and adenylyl cyclase in ischemia-reperfused hearts. Persad S, et al. **Mol Cell Biochem** 1998 Sep;186(1-2):99–106

Induction of ascorbate peroxidase by ethylene and hydrogen peroxide during growth of cultured soybean cells. Lee SC, et al. **Mol Cells** 1999 Apr 30;9(2):166–71

Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage. De Salvia R, et al. **Mutagenesis** 1999 Jan;14(1):107–12

The nature and origin of DNA single-strand breaks determined with the comet assay. Horváthová E, et al. **Mutat Res** 1998 Dec 14;409(3):163–71

Hydrogen peroxide induces necrosis, apoptosis, oncosis and apoptotic oncosis of mouse terminal proximal straight tubule cells. Takeda M, et al. **Nephron** 1999 Feb;81(2):234–8

The effect of hydrogen peroxide upon beta-adrenoceptor density and function in C6 rat glioma cells. Bergström D, et al. **Neurochem Int** 1999 Jan;34(1):63–70

Protective effect of neurotrophic factors, neuropoietic cytokines and dibutyryl cyclic AMP on hydrogen peroxide-induced cytotoxicity on PC12 cells: a possible link with the state of differentiation. Charon I, et al. **Neurochem Int** 1998 Dec;33(6):503–11

Comparison of the effects of hydrogen peroxide, 4-hydroxy-2-nonenal and beta-amyloid (25-35) upon calcium signalling. Fowler CJ, et al. **Neurochem Int** 1998 Aug;33(2):161–72

Bifemelane hydrochloride protects against cytotoxicity of hydrogen peroxide on cultured rat neuroblastoma cell line. Miyazaki I, et al. **Neurochem Res** 1999 Jul;24(7):857–60

Prejunctional alpha2-adrenoceptors and peroxide-induced potentiation of norepinephrine release from the bovine iris. Opere CA, et al. **Neurochem Res** 1998 Aug;23(8):1093–8

An acquired sensitivity to H2O2-induced apoptosis during neuronal differentiation of NT2/D1 cells. Wang S, et al. **Neuroreport** 1998 Oct 5;9(14):3207–11

Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappaB. Dumont A, et al. **Oncogene** 1999 Jan 21;18(3):747–57

Resistance of common environmental spores of the genus Bacillus to vapor hydrogen peroxide. Kokubo M, et al. **PDA J Pharm Sci Technol** 1998 Sep-Oct;52(5):228–31

Cell-cycle-dependent changes in membrane potential of L-929 cells caused by the effect of hydrogen peroxide. Gamaley IA, et al. **Pflugers Arch** 1999 Jun;438(1):113–5

Repair of (6-4) photoproducts in cultured goldfish cells at confluence or treated with H2O2. Uchida N, et al. **Photochem Photobiol** 1998 Nov;68(5):725–8

Regulation of the OxyR transcription factor by hydrogen peroxide and the cellular thiol-disulfide status. Aslund F, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6161–5

Poly-ADP ribose polymerase activates nuclear proteasome to degrade oxidatively damaged histones. Ullrich O, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6223–8

Molecular mechanism of the sensing of the hydrogen peroxide stress response in Escherichia coli. Dawes IW. **Redox Rep** 1997 Oct-Dec;3(5-6):255–6

N-demethylation of phenothiazines by lipoxygenase from soybean and human term placenta in the presence of hydrogen peroxide. Rajadhyaksha AV, et al. **Teratog Carcinog Mutagen** 1999;19(3):211–22

[Adaptive response of CHL to hydrogen peroxide induced oxidative stress and the mechanism] Xue L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):285–8 (Eng. Abstr.) **(Chi)**

[Synthesis, antimicrobial effects and adverse effects of new structures of urea, hydrogen peroxide and tensides] Jülich WD, et al. **Pharmazie** 1999 Mar;54(3):171–8 (Eng. Abstr.) **(Ger)**

[Role of ryanodine receptors in hydrogen peroxide-induced DNA fragmentation and thymidine incorporation in cultured rat astrocytes] Tanaka K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:108P–112P (Eng. Abstr.) **(Jpn)**

[Hydrogen peroxide modulates intracellular levels of thiols and potassium in Escherichia coli cells] Smirnova GV, et al. **Mikrobiologiia** 1998 Sep-Oct;67(5):594–600 (Eng. Abstr.) **(Rus)**

[The development of a technology for producing a new disinfecting agent with a universal spectrum of antimicrobial action] Buianov VV, et al. **Vestn Ross Akad Med Nauk** 1999;(8):54–7 (Eng. Abstr.) **(Rus)**

POISONING

Metallothionein-overexpressing neonatal mouse cardiomyocytes are resistant to H2O2 toxicity. Wang GW, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H167–75

Differential sensitivity of cultured tanycytes and astrocytes to hydrogen peroxide toxicity. Prieto M, et al. **Exp Neurol** 1999 Jan;155(1):118–27

[Acute, oral poisoning with hydrogen peroxide (concentrated peracetic acid) with neurologic sequelae] Wiernikowski A, et al. **Przegl Lek** 1999;56(6):463–4 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

The inhibitory effect of combining chlorhexidine and hydrogen peroxide on 3-day plaque accumulation. Dona BL, et al. **J Clin Periodontol** 1998 Nov;25(11 Pt 1):879–83

An atomic force microscopy study on the effect of bleaching agents on enamel surface. Hegedüs C, et al. **J Dent** 1999 Sep;27(7):509–15

Current understanding of the role of microscopic monitoring, baking soda, and hydrogen peroxide in the treatment of periodontal disease. Committee on Research, Science and Therapy. The American Academy of Periodontology [see comments] **J Periodontol** 1998 Aug;69(8):951–4. Comment in: J Periodontol 1999 Apr;70(4):455–6.

TOXICITY

Involvement of the oxygen storage protein myoglobin in muscle damage under oxidative stress. Kamin-Belsky N, et al. **Adv Exp Med Biol** 1998;454:219–23

Keratinocyte growth factor promotes alveolar epithelial cell DNA repair after H2O2 exposure. Wu KI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L780–7

Role of hydrogen peroxide in cytotoxicity induction by ascorbates and other redox compounds. Iwasaka K, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4333–7

Enhancement of cytotoxicity of hydrogen peroxide by hyperthermia in chinese hamster ovary cells: role of antioxidant defenses. Lord-Fontaine S, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):283–95

Melatonin attenuates hydrogen peroxide toxicity in MCF7 cells only at pharmacological concentrations. Baldwin WS, et al. **Biochem Biophys Res Commun** 1998 Sep 29; 250(3):602–5

Glutathione and catalase provide overlapping defenses for protection against hydrogen peroxide in the yeast Saccharomyces cerevisiae. Grant CM, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):893–8

7,8-Dihydroneopterin-induced apoptosis in Jurkat T lymphocytes: a comparison with anti-Fas- and hydrogen peroxide-mediated cell death. Wirleitner B, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1181–7

Application and modulation of a permanent hydrogen peroxide-induced oxidative stress to cultured astroglial cells. Hirrlinger J, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):223–9

Tumor promotion by hydrogen peroxide in rat liver epithelial cells. Huang RP, et al. **Carcinogenesis** 1999 Mar; 20(3):485–92

Acute exposure to hair bleach causes airway hyperresponsiveness in a rabbit model. Mensing T, et al. **Eur Respir J** 1998 Dec;12(6):1371–4

Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells.
Richter-Landsberg C, et al. **Exp Cell Res** 1998 Oct 10; 244(1):218-29

Ca2+-dependent cytotoxicity of H2O2 in L929 cells: the role of H2O2-induced Na+-influx. Jussofie A, et al. **Free Radic Biol Med** 1998 Oct;25(6):712-9

Association of redox-active iron bound to high molecular weight structures in nuclei with inhibition of cell growth by H2O2. Li H, et al. **Free Radic Biol Med** 1999 Jan; 26(1-2):49-60

Calcium vs. iron-mediated processes in hydrogen peroxide toxicity to L929 cells: effects of glucose. Lomonosova EE, et al. **Free Radic Biol Med** 1998 Sep;25(4-5):493-503

H2O2 mediates O2 toxicity in cultured fetal rat distal lung epithelial cells. Luo X, et al. **Free Radic Biol Med** 1999 Jun;26(11-12):1357-68

Quercetin inhibits hydrogen peroxide-induced oxidation of the rat lens. Sanderson J, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):639-45

Zinc protects against oxidative damage in cultured human retinal pigment epithelial cells. Tate DJ Jr, et al. **Free Radic Biol Med** 1999 Mar;26(5-6):704-13

Protection by alpha-tocopherol but not ascorbic acid from hydrogen peroxide induced cell death in normal human breast epithelial cells in culture. Dabrosin C, et al. **Free Radic Res** 1998 Sep;29(3):227-34

Hydrogen peroxide-induced apoptosis mediated by p53 protein in glial cells. Kitamura Y, et al. **Glia** 1999 Jan 15; 25(2):154-64

Fanconi's anemia cells are relatively resistant to H2O2-induced damage. Notaro R, et al. **Haematologica** 1998 Oct;83(10):868-74

Hydrogen peroxide.
IARC Monogr Eval Carcinog Risks Hum 1999;71 Pt 2:671-89 (94 ref.)

Cytotoxicity and site-specific DNA damage induced by nitroxyl anion (NO(-)) in the presence of hydrogen peroxide. Implications for various pathophysiological conditions. Chazotte-Aubert L, et al. **J Biol Chem** 1999 Jul 23;274(30):20909-15

Acidosis potentiates oxidative neuronal death by multiple mechanisms. Ying W, et al. **J Neurochem** 1999 Oct; 73(4):1549-56

Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. Goins WF, et al. **J Virol** 1999 Jan; 73(1):519-32

Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Gassen M, et al. **Mov Disord** 1998 Jul;13(4):661-7

Hydrogen peroxide and coffee induce G:C-->T:A transversions in the lacI gene of catalase-defective Escherichia coli. Ruiz-Laguna J, et al. **Mutagenesis** 1999 Jan;14(1):95-102

Ultrasensitive detection of hydrogen peroxide-mediated DNA damage after alkaline single cell gel electrophoresis using occultation microscopy and TUNEL labeling. Kindzelskii AL, et al. **Mutat Res** 1999 May 3;426(1):11-22

Protective effects of nicergoline against hydrogen peroxide toxicity in rat neuronal cell line. Iwata E, et al. **Neurosci Lett** 1998 Jul 17;251(1):49-52

Effect of nitric oxide on hydrogen peroxide-induced damage in isolated rabbit gastric glands. Kim H, et al. **Pharmacology** 1998 Dec;57(6):323-30

Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Doré S, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2445-50

Starvation-induced autophagocytosis paradoxically decreases the susceptibility to oxidative stress of the extremely oxidative stress-sensitive NIT insulinoma cells. Olejnicka BT, et al. **Redox Rep** 1997 Oct-Dec;3(5-6):311-8

Methyl methanesulfonate and hydrogen peroxide differentially regulate p53 accumulation in hepatoblastoma cells. Jiang MC, et al. **Toxicol Lett** 1999 Jun 1; 106(2-3):201-8

The sensitivity to DNA single strand breakage in mitochondria, but not in nuclei, of Chinese hamster V79 and variant cells correlates with their cellular sensitivity to hydrogen peroxide. Kaneko M, et al. **Toxicol Lett** 1998 Sep 30;99(1):15-22

Does H2O2-mediated oxidative stress reproduce mitochondrial cold preservation/reoxygenation injury in endothelial cells? Stadlmann S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):993

URINE

Hydrogen peroxide in human urine: implications for antioxidant defense and redox regulation. Long LH, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):605-9

Relation between natriuresis and urinary excretion of hydrogen peroxide. Kuge N, et al. **Free Radic Res** 1999 Feb;30(2):119-23

HYDROGEN, POTASSIUM, ADENOSINETRIPHOSPHATASE see **H(+)-K(+)-EXCHANGING ATPASE**

HYDROGEN, POTASSIUM ATPASE see **H(+)-K(+)-EXCHANGING ATPASE**

HYDROGEN SULFIDE

ADVERSE EFFECTS

Respiratory protection on offshore drilling rigs. Mattorano DA, et al. **Appl Occup Environ Hyg** 1999 Mar;14(3):141-8

Neuropsychological effects of occupational exposures to carbon disulfide and hydrogen sulfide. De Fruyt F, et al. **Int J Occup Environ Health** 1998 Jul-Sep;4(3):139-46

Long-term effects on the olfactory system of exposure to hydrogen sulphide. Hirsch AR, et al. **Occup Environ Med** 1999 Apr;56(4):284-7

[Neurologic side effects of chemicals used in industry] Igisu H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):628-32 (16 ref.) **(Jpn)**

[Experimental studies of the effects of polysulfide of natural gas and condensate on the reproductive function] Fateeva TA, et al. **Gig Sanit** 1998 Sep-Oct;(5):5-7 (Eng. Abstr.) **(Rus)**

ANALYSIS

Association of excess sulfur intake and an increase in hydrogen sulfide concentrations in the ruminal gas cap of recently weaned beef calves with polioencephalomalacia. Loneragan GH, et al. **J Am Vet Med Assoc** 1998 Dec 1; 213(11):1599-604, 1571

CHEMISTRY

Liberation of hydrogen sulfide during the catalytic action of Desulfovibrio hydrogenase under the atmosphere of hydrogen. Higuchi Y, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):295-9

METABOLISM

Re: Levine et al. Fecal hydrogen sulfide production in ulcerative colitis [letter; comment] Florin T, et al. **Am J Gastroenterol** 1998 Dec;93(12):2638. Comment on: Am J Gastroenterol 1998 Jan;93(1):83-7.

Orientation of the heme vinyl groups in the hydrogen sulfide-binding hemoglobin I from Lucina pectinata. Silfa E, et al. **Biospectroscopy** 1998;4(5):311-26

Thiosulfate elimination and permeability in a sulfide-adapted marine invertebrate. Julian D, et al. **Physiol Biochem Zool** 1999 Jul-Aug;72(4):416-25

[The identification of species in the family Enterobacteriaceae that form hydrogen sulfide] Pokhil SI, et al. **Mikrobiol Z** 1998 Jul-Aug;60(4):3-14 (Eng. Abstr.) **(Rus)**

POISONING

Bronchial injury and pulmonary edema caused by hydrogen sulfide poisoning [letter] Tanaka S, et al. **Am J Emerg Med** 1999 Jul;17(4):427-9

Hydrogen sulfide poisoning: clarification of some controversial issues. Milby TH, et al. **Am J Ind Med** 1999 Feb;35(2):192-5 (34 ref.)

Persistent cognitive and motor deficits following acute hydrogen sulphide poisoning. Schneider JS, et al. **Occup Med (Lond)** 1998 May;48(4):255-60

[Analysis of 25 episodes of acute occupational poisoning accidents and studies on its preventive strategy] Wang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):235-7 (Eng. Abstr.) **(Chi)**

HYDROGENASE

BIOSYNTHESIS

Heterologous biosynthesis and characterization of the [2Fe-2S]-containing N-terminal domain of Clostridium pasteurianum hydrogenase. Atta M, et al. **Biochemistry** 1998 Nov 10;37(45):15974-80

CHEMISTRY

Photodegradation of organic waste coupling hydrogenase and titanium dioxide. Mura GM, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:267-75

Liberation of hydrogen sulfide during the catalytic action of Desulfovibrio hydrogenase under the atmosphere of hydrogen. Higuchi Y, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):295-9

Structural bases for the catalytic mechanism of [NiFe] hydrogenases. Garcin E, et al. **Biochem Soc Trans** 1998 Aug;26(3):396-401 (22 ref.)

Structural similarities between the N-terminal domain of Clostridium pasteurianum hydrogenase and plant-type ferredoxins. Kümmerle R, et al. **Biochemistry** 1999 Feb 9; 38(6):1938-43

Catalytic electron transport in Chromatium vinosum [NiFe]-hydrogenase: application of voltammetry in detecting redox-active centers and establishing that hydrogen oxidation is very fast even at potentials close to the reversible H+/H2 value. Pershad HR, et al. **Biochemistry** 1999 Jul 13;38(28):8992-9

Pre-steady-state kinetics of the reactions of [NiFe]-hydrogenase from Chromatium vinosum with H2 and CO. Happe RP, et al. **Eur J Biochem** 1999 Feb; 259(3):602-8

Fusion of two subunits does not impair the function of a [NiFeSe]-hydrogenase in the archaeon Methanococcus voltae. Pfeiffer M, et al. **Eur J Biochem** 1998 Sep 1; 256(2):447-52

A low-spin iron with CN and CO as intrinsic ligands forms the core of the active site in [Fe]-hydrogenases. Pierik AJ, et al. **Eur J Biochem** 1998 Dec 1;258(2):572-8

Methanobacterium thermoautotrophicum encodes two multisubunit membrane-bound [NiFe] hydrogenases. Transcription of the operons and sequence analysis of the deduced proteins. Tersteegen A, et al. **Eur J Biochem** 1999 Sep;264(3):930-43

Characterization of the active site of a hydrogen sensor from Alcaligenes eutrophus. Pierik AJ, et al. **FEBS Lett** 1998 Nov 6;438(3):231-5

On the prosthetic groups of the NiFe sulfhydrogenase from Pyrococcus furiosus: topology, structure, and temperature-dependent redox chemistry. Silva PJ, et al. **J Biol Inorg Chem** 1999 Jun;4(3):284-91

Crystal structure of the hydrogenase maturating endopeptidase HYBD from Escherichia coli. Fritsche E, et al. **J Mol Biol** 1999 May 21;288(5):989-98

Identification of histidine residues in Wolinella succinogenes hydrogenase that are essential for menaquinone reduction by H2. Gross R, et al. **Mol Microbiol** 1998 Nov; 30(3):639-46

Hydrogenase sophistication [news] Cammack R. **Nature** 1999 Jan 21;397(6716):214-5

Biological hydrogen production: not so elementary [comment] [see comments] Adams MW, et al. **Science** 1998 Dec 4;282(5395):1842-3. Comment on: Science 1998 Dec 4;282(5395):1853-8. Comment in: Science 1999 Mar 19;283(5409):1851.

X-ray crystal structure of the Fe-only hydrogenase (CpI) from Clostridium pasteurianum to 1.8 angstrom resolution [published errata appear in Science 1999 Jan 1;283(5398):35 and 1999 Mar 26;283(5410):2102] Peters JW, et al. **Science** 1998 Dec 4;282(5395):1853-8

The crystal structure of a reduced [NiFeSe] hydrogenase provides an image of the activated catalytic center. Garcin E, et al. **Structure Fold Des** 1999 May;7(5):557-66

Removal of the bridging ligand atom at the Ni-Fe active site of [NiFe] hydrogenase upon reduction with H2, as revealed by X-ray structure analysis at 1.4 A resolution. Higuchi Y, et al. **Structure Fold Des** 1999 May;7(5):549-56

Desulfovibrio desulfuricans iron hydrogenase: the structure shows unusual coordination to an active site Fe binuclear center. Nicolet Y, et al. **Structure Fold Des** 1999 Jan 15; 7(1):13-23

GENETICS

hoxX (hypX) is a functional member of the Alcaligenes eutrophus hyp gene cluster. Buhrke T, et al. **Arch Microbiol** 1998 Nov;170(6):460-3

The vhuU gene encoding a small subunit of a selenium-containing [NiFe]-hydrogenase in Methanococcus voltae appears to be essential for the cell. Pfeiffer M, et al. **Arch Microbiol** 1998 Nov;170(6):418-26

Duplication of hyp genes involved in maturation of [NiFe] hydrogenases in Alcaligenes eutrophus H16. Wolf I, et al. **Arch Microbiol** 1998 Nov;170(6):451-9

Methanobacterium thermoautotrophicum encodes two multisubunit membrane-bound [NiFe] hydrogenases. Transcription of the operons and sequence analysis of the deduced proteins. Tersteegen A, et al. **Eur J Biochem** 1999 Sep;264(3):930-43

Rhizobium leguminosarum bv. viciae hypA gene is specifically expressed in pea (Pisum sativum) bacteroids and required for hydrogenase activity and processing. Hernando Y, et al. **FEMS Microbiol Lett** 1998 Dec 15; 169(2):295-302

Transcriptional regulation of genes encoding the selenium-free [NiFe]-hydrogenases in the archaeon Methanococcus voltae involves positive and negative control elements. Noll I, et al. **Genetics** 1999 Aug; 152(4):1335-41

Cyclic AMP receptor protein and TyrR are required for acid pH and anaerobic induction of hyaB and aniC in Salmonella typhimurium. Park KR, et al. **J Bacteriol** 1999 Jan; 181(2):689-94

Positive transcriptional feedback controls hydrogenase expression in Alcaligenes eutrophus H16. Schwartz E, et al. **J Bacteriol** 1999 Sep;181(18):5684-92

Identification and characterization of hupT, a gene involved in negative regulation of hydrogen oxidation in Bradyrhizobium japonicum. Van Soom C, et al. **J Bacteriol** 1999 Aug;181(16):5085-9

ISOLATION & PURIFICATION

Purification and characterization of hydrogenase from the marine green alga, Chlorococcum littorale. Ueno Y, et al. **FEBS Lett** 1999 Jan 25;443(2):144-8

METABOLISM

Electrochemical study of reversible hydrogenase reaction of Desulfovibrio vulgaris cells with methyl viologen as an electron carrier. Tatsumi H, et al. **Anal Chem** 1999 May 1;71(9):1753-9

Structural bases for the catalytic mechanism of [NiFe] hydrogenases. Garcin E, et al. **Biochem Soc Trans** 1998 Aug;26(3):396-401 (22 ref.)

The hyperthermophilic bacterium, Thermotoga maritima, contains an unusually complex iron-hydrogenase: amino

acid sequence analyses versus biochemical characterization. Verhagen MF, et al. **Biochim Biophys Acta** 1999 Aug 4; 1412(3):212–29

Stability and sulfur–reduction activity in non–aqueous phase liquids of the hydrogenase from the hyperthermophile Pyrococcus furiosus. Kim C, et al. **Biotechnol Bioeng** 1999 Oct 5;65(1):108–13

Characterization of the active site of a hydrogen sensor from Alcaligenes eutrophus. Pierik AJ, et al. **FEBS Lett** 1998 Nov 6;438(3):231–5

Redox control of hydrogenase activity in the green alga Scenedesmus obliquus by thioredoxin and other thiols. Wünschiers R, et al. **FEBS Lett** 1999 Jul 16;455(1–2):162–4

First evidence for the presence of a hydrogenase in the sulfur–reducing bacterium Desulfuromonas acetoxidans. Brugna M, et al. **J Bacteriol** 1999 Sep;181(17):5505–8

Carboxy–terminal processing of the large subunit of [Fe] hydrogenase from Desulfovibrio desulfuricans ATCC 7757. Hatchikian EC, et al. **J Bacteriol** 1999 May;181(9):2947–52

Carbon monoxide and cyanide as intrinsic ligands to iron in the active site of [NiFe]–hydrogenases. NiFe(CN)2CO, Biology's way to activate H2. Pierik AJ, et al. **J Biol Chem** 1999 Feb 5;274(6):3331–7

Co–translocation of a periplasmic enzyme complex by a hitchhiker mechanism through the bacterial tat pathway. Rodrigue A, et al. **J Biol Chem** 1999 May 7;274(19):13223–8

On the prosthetic groups of the NiFe sulfhydrogenase from Pyrococcus furiosus: topology, structure, and temperature–dependent redox chemistry. Silva PJ, et al. **J Biol Inorg Chem** 1999 Jun;4(3):284–91

Kinetics and interaction studies between cytochrome c3 and Fe–only hydrogenase from Desulfovibrio vulgaris Hildenborough. Brugna M, et al. **Proteins** 1998 Dec 1; 33(4):590–600

Biological hydrogen production: not so elementary [comment] [see comments] Adams MW, et al. **Science** 1998 Dec 4;282(5395):1842–3. Comment on: Science 1998 Dec 4;282(5395):1853–8. Comment in: Science 1999 Mar 19;283(5409):1851.

HYDROGENOMONAS see **PSEUDOMONAS**

HYDROLASES

Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. McGraw WT, et al. **Infect Immun** 1999 Jul;67(7):3248–56

ADMINISTRATION & DOSAGE

Orally administered proteases in aesthetic surgery. Dusková M, et al. **Aesthetic Plast Surg** 1999 Jan–Feb;23(1):41–4

[Systemic enzyme therapy in the treatment of supracondylar fractures of the humerus in children] Gál P, et al. **Rozhl Chir** 1998 Dec;77(12):574–6 (Eng. Abstr.) **(Cze)**

ANALYSIS

Caveat: mycoplasma arginine deiminase masquerading as nitric oxide synthase in cell cultures. Choi JW, et al. **Biochim Biophys Acta** 1998 Sep 16;1404(3):314–20

Analytical titration curves of glycosyl hydrolase Cel45 by combined isoelectric focusing–electrophoresis. Attanasio F, et al. **Electrophoresis** 1999 Jun;20(7):1403–11

Two different types of dehalogenases, LinA and LinB, involved in gamma–hexachlorocyclohexane degradation in Sphingomonas paucimobilis UT26 are localized in the periplasmic space without molecular processing. Nagata Y, et al. **J Bacteriol** 1999 Sep;181(17):5409–13

Proton–nuclear magnetic resonance analyses of the substrate specificity of a beta–ketolase from Pseudomonas putida, acetopyruvate hydrolase. Pokorny D, et al. **J Bacteriol** 1999 Aug;181(16):5051–9

Galactosyltransferase, pyrophosphatase and phosphatase activities in luminal plasma of the cauda epididymidis and in the rete testis fluid of some mammals. Tang Y. **J Reprod Fertil** 1998 Nov;114(2):277–85

ANTAGONISTS & INHIBITORS

Haloalkane dehalogenases: steady–state kinetics and halide inhibition. Schindler JF, et al. **Biochemistry** 1999 May 4; 38(18):5772–8

A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Pritzker LB, et al. **Biochim Biophys Acta** 1998 Oct 14; 1388(1):154–60

S–aryl cysteine S,S–dioxides as inhibitors of mammalian kynureninase. Drysdale MJ, et al. **Bioorg Med Chem Lett** 1998 Jan 20;8(2):133–8

3–deazaadenosine, a S–adenosylhomocysteine hydrolase inhibitor, has dual effects on NF–kappaB regulation. Inhibition of NF–kappaB transcriptional activity and promotion of IkappaBalpha degradation. Jeong SY, et al. **J Biol Chem** 1999 Jul 2;274(27):18981–8

The mechanism of inactivation of S–adenosylhomocysteine hydrolase by fluorinated analogs of 5'–methylthioadenosine. Muzard M, et al. **J Enzyme Inhib** 1998 Sep;13(6):443–56

Antiviral drug therapy of filovirus infections: S–adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. Huggins J, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S240–7

A new series of mechanism–based inhibitors of S–adenosyl–L–homocysteine hydrolase from beef liver. Vandenplas C, et al. **Nucleosides Nucleotides** 1999 Apr–May;18(4–5):569–70

BIOSYNTHESIS

Turning on and turning off the arginine deiminase system in oral streptococci. Curran TM, et al. **Can J Microbiol** 1998 Nov;44(11):1078–85

CHEMISTRY

Haloalkane dehalogenase from Xanthobacter autotrophicus GJ10 refined at 1.15 A resolution. Ridder IS, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jul;55 (Pt 7):1273–90

Crystallization and preliminary X–ray diffraction analysis of haloalkane dehalogenase LinB from Sphingomonas paucimobilis UT26. Smatanová I, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1231–3

Crystal structure of S–adenosylhomocysteine hydrolase from rat liver. Hu Y, et al. **Biochemistry** 1999 Jun 29; 38(26):8323–33

Kinetic analysis and X–ray structure of haloalkane dehalogenase with a modified halide–binding site. Krooshof GH, et al. **Biochemistry** 1998 Oct 27;37(43):15013–23

Crystallographic and kinetic evidence of a collision complex formed during halide import in haloalkane dehalogenase. Pikkemaat MG, et al. **Biochemistry** 1999 Sep 14; 38(37):12052–61

Haloalkane dehalogenases: steady–state kinetics and halide inhibition. Schindler JF, et al. **Biochemistry** 1999 May 4; 38(18):5772–8

Microbial dehalogenases: enzymes recruited to convert xenobiotic substrates. Copley SD. **Curr Opin Chem Biol** 1998 Oct;2(5):613–7 (39 ref.)

6–Hydroxycyclohex–1–ene–1–carbonyl–CoA dehydrogenase and 6–oxocyclohex–1–ene–1–carbonyl–CoA hydrolase, enzymes of the benzoyl–CoA pathway of anaerobic aromatic metabolism in the denitrifying bacterium Thauera aromatica. Laempe D, et al. **Eur J Biochem** 1999 Jul; 263(2):420–9

Functional analysis of the Escherichia coli genome for members of the alpha/beta hydrolase family. Zhang L, et al. **Fold Des** 1998;3(6):535–48

Sulphamidase. Anson DS, et al. **Int J Biochem Cell Biol** 1999 Mar–Apr;31(3–4):363–7 (15 ref.)

Structure and function analysis of Pseudomonas plant cell wall hydrolases. Hazlewood GP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:211–41 (81 ref.)

The 1.8 A crystal structure of the ycaC gene product from Escherichia coli reveals an octameric hydrolase of unknown specificity. Colovos C, et al. **Structure** 1998 Oct 15;6(10):1329–37

Of barn owls and bankers: a lush variety of alpha/beta hydrolases. Heikinheimo P, et al. **Structure Fold Des** 1999 Jun 15;7(6):R141–6 (27 ref.)

DRUG EFFECTS

Alterations in rat erythrocyte membrane due to hexachlorocyclohexane (technical) exposure. Bhalla P, et al. **Hum Exp Toxicol** 1998 Nov;17(11):638–42

GENETICS

Genetically modified ruminal bacteria protect sheep from fluoroacetate poisoning. Gregg K, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3496–8

Characterization of the meta–cleavage compound hydrolase gene involved in degradation of the lignin–related biphenyl structure by Sphingomonas paucimobilis SYK–6. Peng X, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2789–93

Modulating electron density in the bound product, 4–hydroxybenzoyl–CoA, by mutations in 4–chlorobenzoyl–CoA dehalogenase near the 4–hydroxy group. Dong J, et al. **Biochemistry** 1999 Mar 30; 38(13):4198–206

Product catalyzes the deamidation of D145N dehalogenase to produce the wild–type enzyme. Xiang H, et al. **Biochemistry** 1999 Mar 30;38(13):4207–13

Purification, cDNA cloning and expression of human NG,NG–dimethylarginine dimethylaminohydrolase. Kimoto M, et al. **Eur J Biochem** 1998 Dec 1;258(2):863–8

Molecular cloning of cDNAs of mouse peptidylarginine deiminase type I, type III and type IV, and the expression pattern of type I in mouse. Rus'd AA, et al. **Eur J Biochem** 1999 Feb;259(3):660–9

Functional analysis of the Escherichia coli genome for members of the alpha/beta hydrolase family. Zhang L, et al. **Fold Des** 1998;3(6):535–48

Identification and characterization of kraken, a gene encoding a putative hydrolytic enzyme in Drosophila melanogaster. Edwin Chan HY, et al. **Gene** 1998 Nov 19;222(2):195–201

Mutation 1091delC is highly prevalent in Spanish Sanfilippo syndrome type A patients. Montfort M, et al. **Hum Mutat** 1998;12(4):274–9

Investigation of two evolutionarily unrelated halocarboxylic acid dehalogenase gene families. Hill KE, et al. **J Bacteriol** 1999 Apr;181(8):2535–47

The arcABDC gene cluster, encoding the arginine deiminase pathway of Bacillus licheniformis, and its activation by the arginine repressor argR. Maghnouj A, et al. **J Bacteriol** 1998 Dec;180(24):6468–75

Degradation of 1,2–dibromoethane by Mycobacterium sp. strain GP1. Poelarends GJ, et al. **J Bacteriol** 1999 Apr; 181(7):2050–8

Cloning and characterization of a cryptic haloacid dehalogenase from Burkholderia cepacia MBA4. Tsang JS, et al. **J Bacteriol** 1999 Oct;181(19):6003–9

Genes encoding three new members of the leukocyte antigen 6 superfamily and a novel member of Ig superfamily, together with genes encoding the regulatory nuclear chloride ion channel protein (hRNCC) and an N omega–N omega–dimethylarginine dimethylaminohydrolase homologue, are found in a 30–kb segment of the MHC class III region. Ribas G, et al. **J Immunol** 1999 Jul 1; 163(1):278–87

Identification of a common mutation (R245H) in Sanfilippo A patients from The Netherlands. Weber B, et al. **J Inherit Metab Dis** 1998 Jun;21(4):416–22

Cloning and sequencing of the fcbB gene encoding 4–chlorobenzoate–coenzyme A dehalogenase from Pseudomonas sp. DJ–12. Chae JC, et al. **Mol Cells** 1999 Apr 30;9(2):225–9

The developmental expression and activity of peptidylarginine deiminase in the mouse. Pritzker LB, et al. **Neurosci Lett** 1999 May 14;266(3):161–4

ISOLATION & PURIFICATION

6–Hydroxycyclohex–1–ene–1–carbonyl–CoA dehydrogenase and 6–oxocyclohex–1–ene–1–carbonyl–CoA hydrolase, enzymes of the benzoyl–CoA pathway of anaerobic aromatic metabolism in the denitrifying bacterium Thauera aromatica. Laempe D, et al. **Eur J Biochem** 1999 Jul; 263(2):420–9

Isolation of poly(beta–L–malic acid)–degrading bacteria and purification and characterization of the PMA hydrolase from Comamonas acidovorans strain 7789. Gödde C, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):365–72

METABOLISM

A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM1025. Bozdogan B, et al. **Antimicrob Agents Chemother** 1999 Apr;43(4):925–9

Characterization of the meta–cleavage compound hydrolase gene involved in degradation of the lignin–related biphenyl structure by Sphingomonas paucimobilis SYK–6. Peng X, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2789–93

Characterisation of a starch–hydrolysing enzyme of Aspergillus niger. Suresh C, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):673–5

Unsaturated glucuronyl hydrolase of Bacillus sp. GL1: novel enzyme prerequisite for metabolism of unsaturated oligosaccharides produced by polysaccharide lyases. Hashimoto W, et al. **Arch Biochem Biophys** 1999 Aug 15; 368(2):367–74

Alterations in kidney enzyme pattern in acute hypervitaminosis A. Alarcón OM, et al. **Arch Latinoam Nutr** 1998 Jun;48(2):129–33

Identification of the Mg2+–binding site in the P–type ATPase and phosphatase members of the HAD (haloacid dehalogenase) superfamily by structural similarity to the response regulator protein CheY. Ridder IS, et al. **Biochem J** 1999 Apr 15;339 (Pt 2):223–6

Effects of ions on adenosine binding and enzyme activity of purified S–adenosylhomocysteine hydrolase from bovine kidney. Kloor D, et al. **Biochem Pharmacol** 1998 Dec 1; 56(11):1493–6

Modulating electron density in the bound product, 4–hydroxybenzoyl–CoA, by mutations in 4–chlorobenzoyl–CoA dehalogenase near the 4–hydroxy group. Dong J, et al. **Biochemistry** 1999 Mar 30; 38(13):4198–206

Kinetic analysis and X–ray structure of haloalkane dehalogenase with a modified halide–binding site. Krooshof GH, et al. **Biochemistry** 1998 Oct 27;37(43):15013–23

Crystallographic and kinetic evidence of a collision complex formed during halide import in haloalkane dehalogenase. Pikkemaat MG, et al. **Biochemistry** 1999 Sep 14; 38(37):12052–61

Product catalyzes the deamidation of D145N dehalogenase to produce the wild–type enzyme. Xiang H, et al. **Biochemistry** 1999 Mar 30;38(13):4207–13

Identification and characterization of alkenyl hydrolase (lysoplasmalogenase) in microsomes and identification of a plasmalogen–active phospholipase A2 in cytosol of small intestinal epithelium. Jurkowitz MS, et al. **Biochim Biophys Acta** 1999 Feb 25;1437(2):142–56

Alteration of the substrate range of haloalkane dehalogenase by site–directed mutagenesis. Holloway P, et al. **Biotechnol Bioeng** 1998 Aug 20;59(4):520–3

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Ito A, et al. **Circulation** 1999 Jun 22;99(24):3092–5

Dehalogenases applied to industrial–scale biocatalysis. Swanson PE. **Curr Opin Biotechnol** 1999 Aug;10(4):365–9 (38 ref.)

Hydrolase and transferase activities of the beta–1,3–exoglucanase of Candida albicans. Stubbs HJ, et al. **Eur J Biochem** 1999 Aug;263(3):889–95

Dimethylarginine dimethylaminohydrolase (DDAH) as a

nerve-injury-associated molecule: mRNA localization in the rat brain and its coincident up-regulation with neuronal NO synthase (nNOS) in axotomized motoneurons. Nakagomi S, et al. **Eur J Neurosci** 1999 Jun;11(6):2160-6
Dynamic aspects of protein deimination in developing mouse epidermis. Akiyama K, et al. **Exp Dermatol** 1999 Jun; 8(3):177-86
Hair follicle peptidylarginine deiminase. Rogers G, et al. **Exp Dermatol** 1999 Aug;8(4):362-3 (10 ref.)
Identification of the catalytic triad in the haloalkane dehalogenase from Sphingomonas paucimobilis UT26. Hynková K, et al. **FEBS Lett** 1999 Mar 5;446(1):177-81
Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Smith MA, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):898-902
Effect of ethanol administration on activities of some lysosomal hydrolases in the mouse. Witek B, et al. **Gen Pharmacol** 1999 Jan;32(1):163-8
Arginine dihydrolase pathway in Lactobacillus plantarum from orange. Arena ME, et al. **Int J Food Microbiol** 1999 Mar 15;47(3):203-9
Proton-nuclear magnetic resonance analyses of the substrate specificity of a beta-ketolase from Pseudomonas putida, acetopyruvate hydrolase. Pokorny D, et al. **J Bacteriol** 1999 Aug;181(16):5051-9
Reaction mechanism of fluoroacetate dehalogenase from Moraxella sp. B. Liu JQ, et al. **J Biol Chem** 1998 Nov 20;273(47):30897-902
DL-2-Haloacid dehalogenase from Pseudomonas sp. 113 is a new class of dehalogenase catalyzing hydrolytic dehalogenation not involving enzyme-substrate ester intermediate. Nardi-Dei V, et al. **J Biol Chem** 1999 Jul 23;274(30):20977-81
S-adenosyl-L-homocysteine hydrolase regulates aldosterone-induced Na+ transport. Stockand JD, et al. **J Biol Chem** 1999 Feb 5;274(6):3842-50
Collateral occurrence of deimination of keratins with differentiation of an immortalized newborn rat keratinocyte cell line cultured at air-liquid interface. Ohsawa T, et al. **J Dermatol Sci** 1999 Jan;19(1):68-73
Deimination of 70-kD nuclear protein during epidermal apoptotic events in vitro. Mizoguchi M, et al. **J Histochem Cytochem** 1998 Nov;46(11):1303-9
Stability of chitosan and poly-L-lysine membranes coating DNA-alginate beads when exposed to hydrolytic enzymes. Quong D, et al. **J Microencapsul** 1999 Jan-Feb;16(1):73-82
A study of the enzymatic profile of soil isolates of Nocardia asteroides. Khan ZU, et al. **Mycopathologia** 1998-99; 143(3):151-4
Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis. De Keyser J, et al. **Neurosci Lett** 1999 Jan 22;260(1):74-6
Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for patched. Fuse N, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):10992-9
Structure and function analysis of Pseudomonas plant cell wall hydrolases. Hazlewood GP, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:211-41 (81 ref.)
Computational site-directed mutagenesis of haloalkane dehalogenase in position 172. Damborský J, et al. **Protein Eng** 1998 Oct;11(10):901-7
Thermodynamic analysis of halide binding to haloalkane dehalogenase suggests the occurrence of large conformational changes. Krooshof GH, et al. **Protein Sci** 1999 Feb;8(2):355-60
A spheroplast rate assay for determination of cell wall integrity in yeast. Ovalle R, et al. **Yeast** 1998 Sep 30; 14(13):1159-66
Effect of heavy metal salts on the activity of rat liver and kidney catalase and lysosomal hydrolases. Popova MP, et al. **Zentralbl Veterinarmed A** 1998 Sep;45(6-7):343-51
[Human drug metabolizing enzymes. II. Conjugation enzymes] Vereczkey L, et al. **Acta Pharm Hung** 1998 Sep; 68(5):284-8 (21 ref.) (Eng. Abstr.) **(Hun)**
[Properties of soluble and membrane intestinal hydrolases in Macaca rhesus monkeys] Gordova LA, et al. **Zh Evol Biokhim Fiziol** 1998 May-Jun;34(3):338-45 **(Rus)**

PHARMACOLOGY

Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Gong H, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):10-4

PHYSIOLOGY

Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Boger DL, et al. **Curr Pharm Des** 1998 Aug; 4(4):303-14 (81 ref.)

THERAPEUTIC USE

[The use of enzymes in treating patients with malignant lymphoma with a large tumor mass] Gubareva AA. **Lik Sprava** 1998 Aug;(6):141-3 (Eng. Abstr.) **(Rus)**
[Wobenzym in the combined pathogenetic therapy of chronic urethrogenic prostatitis] Martynenko AV. **Lik Sprava** 1998 Aug;(6):118-20 (Eng. Abstr.) **(Rus)**
[The pathogenetic basis for and clinical use of systemic enzyme therapy in traumatology and orthopedics] Neverov VA, et al. **Vestn Khir Im I I Grek** 1999;158(1):41-4 (Eng. Abstr.) **(Rus)**

HYDROMORPHON see **HYDROMORPHONE**

HYDROMORPHONE

ADMINISTRATION & DOSAGE

A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. Sharar SR, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):516-21
Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. Miller MG, et al. **J Pain Symptom Manage** 1999 Jul;18(1):9-16
Comparison of subcutaneous hydromorphone with intramuscular meperidine for immediate postoperative analgesia. Chan WH, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jul; 15(7):419-27

ADVERSE EFFECTS

Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. Katcher J, et al. **J Pain Symptom Manage** 1999 Jan;17(1):70-2

ANALOGS & DERIVATIVES

[Production of morphinone as a metabolite of morphine and its physiological role] Toki S, et al. **Yakugaku Zasshi** 1999 Apr;119(4):249-67 (63 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Johnson CE, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):164-9

PHARMACOLOGY

Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose. Preston KL, et al. **Behav Pharmacol** 1998 Nov;9(7):533-43
Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Lelas S, et al. **Drug Alcohol Depend** 1999 May 3; 54(3):239-49
Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure. Jones HE, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1350-61
Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. Walker DJ, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1454-64

THERAPEUTIC USE

The relationship between the visual analog pain intensity and pain relief scale changes during analgesic drug studies in chronic pain patients. Angst MS, et al. **Anesthesiology** 1999 Jul;91(1):34-41
Comparison of epidural morphine, hydromorphone and fentanyl for postoperative pain control in children undergoing orthopaedic surgery. Goodarzi M. **Paediatr Anaesth** 1999;9(5):419-22

HYDRONEPHROSIS

Abnormal urinary acidification in infants with hydronephrosis. Chandar J, et al. **Pediatr Nephrol** 1999 May;13(4):315-8

BLOOD

[Hyperammonemia in hydronephrosis (letter; comment)] Dejong CH, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30; 143(5):274. Comment on: Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2414-5. **(Dut)**

CHEMICALLY INDUCED

Cyclophosphamide-associated uroepithelial toxicity [letter] Aviles RJ, et al. **Ann Intern Med** 1999 Oct 5;131(7):549
[Hydronephrosis caused by indinavir (letter)] Reus S, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):47-8 **(Spa)**

COMPLICATIONS

Blepharophimosis, hypoplastic radius, hypoplastic left heart, telecanthus, hydronephrosis, fused metacarpals, and "prehensile" halluces: a new syndrome? Day-Salvatore D, et al. **Am J Med Genet** 1998 Dec 4;80(4):309-13
Isolated iliac artery aneurysms with associated hydronephrosis. O'Driscoll D, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):197-9
A multicenter outcomes analysis of patients with neonatal reflux presenting with prenatal hydronephrosis. Herndon CD, et al. **J Urol** 1999 Sep;162(3 Pt 2):1203-8
Vesicoureteral reflux in infants with prenatal hydronephrosis confirmed at birth: racial differences. Horowitz M, et al. **J Urol** 1999 Jan;161(1):248-50
Idiopathic retroperitoneal fibrosis with bilateral lower ureteric obstruction--a case report with literature review. Koh JS, et al. **Singapore Med J** 1998 Sep;39(9):416-7 (15 ref.)
[Hyperammonemia in hydronephrosis (see comments)] van Daele PL, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31; 142(44):2414-5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jan 30;143(5):274. **(Dut)**
[Anesthetic management of a child with Lenz dysplasia associated with panhypopituitarism] Oobayashi C, et al. **Masui** 1998 Sep;47(9):1118-21 (Eng. Abstr.) **(Jpn)**
[Bilateral hydronephrosis with papillary polypoid cystitis] Valero Puerta JA, et al. **Arch Esp Urol** 1999 May; 52(4):396-8 (Eng. Abstr.) **(Spa)**

CONGENITAL

Crossed fused renal ectopia with hydronephrosis. Taweel W, et al. **Aust N Z J Surg** 1998 Nov;68(11):808-9
Features of primary vesicoureteric reflux detected by investigation of foetal hydronephrosis. Oliveira EA, et al. **Int Urol Nephrol** 1998;30(5):535-41
Supranormal renographic differential renal function in congenital hydronephrosis: fact, not artifact. Capolicchio G, et al. **J Urol** 1999 Apr;161(4):1290-4
Antibiotic prophylaxis for infants with congenital hydronephrosis. Caldamone A. **Pediatr Infect Dis J** 1999 Apr;18(4):398-9

DIAGNOSIS

MR pyelography and conventional MR imaging in urinary tract obstruction. Catalano C, et al. **Acta Radiol** 1999 Mar; 40(2):198-202
Effect of routine screening for Down's syndrome on the significance of isolated fetal hydronephrosis. Thompson MO, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):860-4
Features of primary vesicoureteric reflux detected by investigation of foetal hydronephrosis. Oliveira EA, et al. **Int Urol Nephrol** 1998;30(5):535-41
Retroperitoneal abscess presenting with a buttock swelling and anaemia. Spedding RL, et al. **J Accid Emerg Med** 1999 Jul;16(4):302-3
Prenatal diagnosis of hydronephrosis: impact on renal function and its recovery after pyeloplasty. Capolicchio G, et al. **J Urol** 1999 Sep;162(3 Pt 2):1029-32
Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. Furness PD 3rd,, et al. **J Urol** 1999 Sep;162(3 Pt 2):1033-6
Giant hydronephrosis--a diagnostic dilemma. Mountney J, et al. **Urol Int** 1998;61(2):121-3
[The prenatal diagnosis of hydronephrosis, when and why to operate?] González R, et al. **Arch Esp Urol** 1998 Jul-Aug;51(6):575-9 (18 ref.) (Eng. Abstr.) **(Spa)**
[The prenatal diagnosis of hydronephrosis: when and why NOT to operate?] Koff SA. **Arch Esp Urol** 1998 Jul-Aug; 51(6):569-74 (18 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Prevalence of hydronephrosis in patients with genital prolapse. Gemer O, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):11-3

ETIOLOGY

Unilateral hydronephrosis and recurrent endometrial stromal sarcoma with review of the literature. Janssen van Doorn K, et al. **Acta Clin Belg** 1999 Jun;54(3):165-8
Reversible bilateral hydronephrosis without obstruction in hepatitis B-associated polyarteritis nodosa. Casserly LF, et al. **Am J Kidney Dis** 1999 Sep;34(3):e11 (29 ref.)
Rapid oral hydration results in hydronephrosis as demonstrated by bedside ultrasound. Morse JW, et al. **Ann Emerg Med** 1999 Aug;34(2):134-40
Ureteropelvic urinary extravasation due to iliac artery aneurysm. Obrand DI, et al. **Ann Vasc Surg** 1998 Sep; 12(5):468-70
Sonographic diagnosis of hydronephrosis in patients with spinal cord injury: influence of bladder fullness. Bih LI, et al. **Arch Phys Med Rehabil** 1998 Dec;79(12):1557-9
Horseshoe kidney with hydronephrosis secondary to ureteric stenosis: construction of a ureter from the renal pelvis. Al-Shamsi A, et al. **BJU Int** 1999 Jan;83(1):146-7
Renal adenomatosis and unilateral hydronephrosis. Spence GM, et al. **BJU Int** 1999 Aug;84(3):380-1
Hydronephrosis: a rare late complication of barium enema. Harries SR, et al. **Clin Radiol** 1998 Mar;54(3):187-8
A case of hydronephrosis caused by arteriosclerotic compression of the renal pelvis. Yoshida H, et al. **Int J Urol** 1998 Nov;5(6):606-9
Ureteral compromise after laparoscopic Burch colpopexy. Ferland RD, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):217-9
Prune belly syndrome with penile and urethral agenesis: report of a case. Kuga T, et al. **J Pediatr Surg** 1998 Dec; 33(12):1825-8
Hydronephrosis as a prognostic indicator in bladder cancer patients [see comments] Haleblian GE, et al. **J Urol** 1998 Dec;160(6 Pt 1):2011-4. Comment in: J Urol 1999 Sep;162(3 Pt 1):808.
Re: Hydronephrosis as a prognostic indicator in bladder cancer patients [letter; comment] Leibovitch I. **J Urol** 1999 Sep;162(3 Pt 1):808. Comment on: J Urol 1998 Dec;160(6 Pt 1):2011-4.
Ureteric tunnel incision in the fetal pig: a model for non-obstructive prenatal vesicoureteric reflux. Dewan PA,

et al. **Pediatr Surg Int** 1999 Jul;15(5–6):350–2
Systemic multifocal fibrosclerosis. Johal SS, et al. **Postgrad Med J** 1998 Oct;74(876):608–9
A variation and ureterovascular hydronephrosis [comment] Aydinlioğlu A, et al. **Scand J Urol Nephrol** 1999 Apr; 33(2):119–20. Comment on: Scand J Urol Nephrol 1998 Apr;32(2):150–2.
The role of macrophages and reactive oxygen species in experimental hydronephrosis. Ricardo SD, et al. **Semin Nephrol** 1998 Nov;18(6):612–21 (80 ref.)
Case no. 4. Chronic left flank pain. Ureteral fibroepithelial polyp causing gross hydronephrosis and hydroureter. Toh KL, et al. **Tech Urol** 1999 Mar;5(1):59–60
Prenatal bladder outlet obstruction secondary to ureterocele. Austin PF, et al. **Urology** 1998 Dec;52(6):1132–5
Hydronephrosis: unrecognized complication following restorative proctocolectomy with ileal pouch–anal anastomosis. Boddie DE, et al. **World J Surg** 1999 Feb; 23(2):194–6
[Hyperammonemia in hydronephrosis (letter; comment)] Dejong CH, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30; 143(5):274. Comment on: Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2414–5. **(Dut)**
[Pelvic lipomatosis: cause of extrinsic ureteral obstruction. Report of a case] Pérez García FJ, et al. **Actas Urol Esp** 1998 Oct;22(9):798–803 (Eng. Abstr.) **(Spa)**
[Secondary amyloidosis: urologic involvement (letter)] García Vivar ML, et al. **An Med Interna** 1998 Nov; 15(11):619–20 **(Spa)**

METABOLISM

Ureter obliteration transiently depresses erythropoietin production. Nečas E, et al. **Eur J Clin Invest** 1998 Nov; 28(11):918–23
Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Diamond JR, et al. **Kidney Int** 1998 Nov;54(5):1501–9
Urinary excretion of tubular proteins and the technetium–99m dimercaptosuccinic acid (DMSA) absolute renal uptake in partial ureteral obstruction in rats: a functional evaluation of hydronephrotic kidneys. Everaert K, et al. **Urol Res** 1999 Apr;27(2):127–33

PARASITOLOGY

Long–term suppression of adult bladder morbidity and severe hydronephrosis following selective population chemotherapy for Schistosoma haematobium. Subramanian AK, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):476–81

PATHOLOGY

Cyclophosphamide–associated uroepithelial toxicity [letter] Aviles RJ, et al. **Ann Intern Med** 1999 Oct 5;131(7):549
Two brothers with varying combinations of severe developmental delay, epilepsy, microcephaly, tetralogy of Fallot and hydronephrosis. Ryan A, et al. **Clin Dysmorphol** 1999 Jan;8(1):15–8
Biophysical signals underlying myogenic responses in rat interlobular artery. Takenaka T, et al. **Hypertension** 1998 Dec;32(6):1060–5
Hydronephrosis in pregnancy: simultaneous depiction of fetal and maternal hydronephrosis by magnetic resonance urography. Fradin JM, et al. **Urology** 1999 Apr;53(4):825–7

PHYSIOPATHOLOGY

Effects of aortic ligation on the renin angiotensin system in hydronephrotic mice. Zhang DY, et al. **Blood Press** 1999; 8(2):122–7
Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. Ozawa Y, et al. **J Cardiovasc Pharmacol** 1999 Feb; 33(2):243–7
Effects of BQ–123 on systemic and renal hemodynamic responses to endothelin–1 in the rat split hydronephrotic kidney. Cavarape A, et al. **J Hypertens** 1998 Oct; 16(10):1449–58
Does early detection of ureteropelvic junction obstruction improve surgical outcome in terms of renal function? Chertin B, et al. **J Urol** 1999 Sep;162(3 Pt 2):1037–40
[In vivo visualization of renal microcirculation using hydronephrotic rat kidney] Miura K, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112(4):251–6 (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Computed tomographic features of hydrocele 'en bisac' with hydronephrosis. Dick EA, et al. **BJU Int** 1999 Jul; 84(1):185–6
The value of three–dimensional helical computed tomographic angiography in the diagnosis of pelvi–ureteric junction obstruction caused by crossing vessels. Ou TW, et al. **BJU Int** 1999 May;83(7):853–6
Hydronephrosis in pregnancy: simultaneous depiction of fetal and maternal hydronephrosis by magnetic resonance urography. Fradin JM, et al. **Urology** 1999 Apr;53(4):825–7

RADIONUCLIDE IMAGING

Urine leaks in renal transplant patients. Diagnostic usefulness of sonography and renography. Gottlieb RH, et al. **Clin Imaging** 1999 Jan–Feb;23(1):35–9
Iodine–131 MIBG uptake in hydronephrosis due to compression by a large adrenal mass. Akaki S, et al. **Clin Nucl Med** 1999 Mar;24(3):192–3
The value of renal scintigraphy during controlled diuresis [letter] Gordon I. **Eur J Nucl Med** 1999 Aug;26(8):938–9
The value of renal scintigraphy during controlled diuresis in children with hydronephrosis. Steiner D, et al. **Eur J Nucl Med** 1999 Jan;26(1):18–21
Supranormal renographic differential renal function in congenital hydronephrosis: fact, not artifact. Capolicchio G, et al. **J Urol** 1999 Apr;161(4):1290–4
Renal function before and after pyeloplasty: does it improve? McAleer IM, et al. **J Urol** 1999 Sep;162(3 Pt 2):1041–4

SURGERY

Ureterovascular hydronephrosis in children: is pyeloplasty always necessary? Pesce C, et al. **Eur Urol** 1999;36(1):71–4
Follow–up of children after fetal treatment for obstructive uropathy. Shimada K, et al. **Int J Urol** 1998 Jul;5(4):312–6
Endoscopic retrograde stenting for allograft hydronephrosis. Sigman DB, et al. **J Endourol** 1999 Feb;13(1):21–5
Prenatal diagnosis of hydronephrosis: impact on renal function and its recovery after pyeloplasty. Capolicchio G, et al. **J Urol** 1999 Sep;162(3 Pt 2):1029–32
Does early detection of ureteropelvic junction obstruction improve surgical outcome in terms of renal function? Chertin B, et al. **J Urol** 1999 Sep;162(3 Pt 2):1037–40
Transperitoneal and retroperitoneal laparoscopic nephrectomy for giant hydronephrosis. Hemal AK, et al. **J Urol** 1999 Jul;162(1):35–9
Renal function before and after pyeloplasty: does it improve? McAleer IM, et al. **J Urol** 1999 Sep;162(3 Pt 2):1041–4
Modified technique for dilatation of difficult nephrostomy tracts. Morsy A, et al. **Tech Urol** 1998 Sep;4(3):148–51
[Surgical treatment of hydronephrosis] Scheinar J, et al. **Rozhl Chir** 1998 Nov;77(11):512–6 (Eng. Abstr.) **(Cze)**
[Methods of surgical treatment of advanced hydronephrosis in children] Utikalová A. **Rozhl Chir** 1998 Nov; 77(11):517–22 (Eng. Abstr.) **(Cze)**
[Drainage by echo–guided nephrostomy in hydronephrosis secondary to a pyelo–ureteral junction in a single kidney syndrome in a pregnant woman. Apropos of a case] Chelli H, et al. **J Urol (Paris)** 1996;102(5–6):240–2 (Eng. Abstr.) **(Fre)**
[Long–term surgical treatment results for hydronephrosis in children] Fryczkowski M, et al. **Wiad Lek** 1998;51 Suppl 3:54–9 (Eng. Abstr.) **(Pol)**
[Use of intestinal plasty in ureterohydronephrosis] Karpenko VS. **Klin Khir** 1998;(12):34–40 (Eng. Abstr.) **(Rus)**
[The prenatal diagnosis of hydronephrosis, when and why to operate?] González R, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):575–9 (18 ref.) (Eng. Abstr.) **(Spa)**
[The prenatal diagnosis of hydronephrosis: when and why NOT to operate?] Koff SA. **Arch Esp Urol** 1998 Jul–Aug; 51(6):569–74 (18 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Apparent unilateral ureteropelvic junction obstruction in the newborn: expectations for resolution. Takla NV, et al. **J Urol** 1998 Dec;160(6 Pt 1):2175–8
The relevance of urethral resistance in children with myelodysplasia: its impact on upper urinary tract deterioration and the outcome of conservative management [see comments] Tanaka H, et al. **J Urol** 1999 Mar; 161(3):929–32. Comment in: J Urol 1999 Mar;161(3):933.

ULTRASONOGRAPHY

Renal diuretic duplex Doppler sonography in childhood hydronephrosis. Akata D, et al. **Acta Radiol** 1999 Mar; 40(2):203–6
Long–term suppression of adult bladder morbidity and severe hydronephrosis following selective population chemotherapy for Schistosoma haematobium. Subramanian AK, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):476–81
Rapid oral hydration results in hydronephrosis as demonstrated by bedside ultrasound. Morse JW, et al. **Ann Emerg Med** 1999 Aug;34(2):134–40
Sonographic diagnosis of hydronephrosis in patients with spinal cord injury: influence of bladder fullness. Bih LI, et al. **Arch Phys Med Rehabil** 1998 Dec;79(12):1557–9
Urine leaks in renal transplant patients. Diagnostic usefulness of sonography and renography. Gottlieb RH, et al. **Clin Imaging** 1999 Jan–Feb;23(1):35–9
Should renal ultrasonography be done routinely in children with first urinary tract infection? Alon US, et al. **Clin Pediatr (Phila)** 1999 Jan;38(1):21–5
Utility of ultrasound of the upper urinary tract in elderly men with indicators of obstructive symptoms or abnormal flow: how often can silent hydronephrosis be detected in general practice? van der Waart TH, et al. **Fam Pract** 1998 Dec;15(6):534–6
Utility of the resistance index ratio in differentiating obstructive from nonobstructive hydronephrosis in children. Lim GY, et al. **J Clin Ultrasound** 1999 May; 27(4):187–93
Ultrasonography by emergency physicians in patients with suspected ureteral colic. Rosen CL, et al. **J Emerg Med** 1998 Nov–Dec;16(6):865–70
Resistive indices in the evaluation of infants with obstructive and nonobstructive pyelocaliectasis. Vade A, et al. **J Ultrasound Med** 1999 May;18(5):357–61
A multicenter outcomes analysis of patients with neonatal reflux presenting with prenatal hydronephrosis. Herndon CD, et al. **J Urol** 1999 Sep;162(3 Pt 2):1203–8
Vesicoureteral reflux in infants with prenatal hydronephrosis confirmed at birth: racial differences. Horowitz M, et al. **J Urol** 1999 Jan;161(1):248–50
Complications of voiding cystourethrography in the evaluation of infants with prenatally detected hydronephrosis. Vates TS, et al. **J Urol** 1999 Sep;162(3 Pt 2):1221–3
Does every patient with prenatal hydronephrosis need voiding cystourethrography? Yerkes EB, et al. **J Urol** 1999 Sep;162(3 Pt 2):1218–20
Case No. 4. Newborn with prenatal hydronephrosis: what further studies are necessary? Baskin LS. **Tech Urol** 1999 Jun;5(2):121, 122
Antenatal hydronephrosis: thresholds of renal pelvic diameter to predict insignificant postnatal pelviectasis. Siemens DR, et al. **Tech Urol** 1998 Dec;4(4):198–201
Gastroschisis associated with bladder evisceration complicated by hydronephrosis presenting antenatally. Ikhena SE, et al. **Ultrasound Obstet Gynecol** 1999 May; 13(5):370–2

URINE

Elevated bladder urine concentration of transforming growth factor–beta1 correlates with upper urinary tract obstruction in children. Furness PD 3rd,, et al. **J Urol** 1999 Sep;162(3 Pt 2):1033–6

VETERINARY

Bilateral hydroureter and hydronephrosis in a nine–year–old female German shepherd dog. Ruiz de Gopegui R, et al. **J Small Anim Pract** 1999 May;40(5):224–6
Obstructive uropathy and hydronephrosis in male KK–Ay mice: a report of cases. Ninomiya H, et al. **J Vet Med Sci** 1999 Jan;61(1):53–7
Hydronephrosis and ureteral duplication in a young alpaca. Cardwell JM, et al. **Vet Rec** 1999 Jul 24;145(4):104–7

HYDROPHOBIA see **RABIES**

HYDROPHTHALMOS

COMPLICATIONS

Cataract extraction and intraocular lens implantation in anterior megalophthalmos. Dua HS, et al. **J Cataract Refract Surg** 1999 May;25(5):716–9

SURGERY

Absence of malignant hyperthermia in an infant with Wolf–Hirschhorn syndrome undergoing anesthesia for ophthalmic surgery. Sammartino M, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jan–Feb;36(1):42–3

HYDROPNEUMOTHORAX

ETIOLOGY

Oesophageal hiatal hernia–induced hydropneumothorax. Fukuda T, et al. **J Gastroenterol Hepatol** 1998 Sep; 13(9):931–5
Idiopathic bronchiolitis obliterans with organizing pneumonia presenting with spontaneous hydropneumothorax and solitary pulmonary nodule. Yang DG, et al. **Respirology** 1999 Sep;4(3):267–70

MICROBIOLOGY

[Pulmonary abscess and hydropneumothorax secondary to nocardiosis (letter)] Fullana Monllor J, et al. **Arch Bronconeumol** 1999 Jul–Aug;35(7):360–1 **(Spa)**

HYDROPONICS

METHODS

A simple hydroponic culture method for the development of a highly viable root system in Arabidopsis thaliana. Toda T, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):210–2

HYDROPS see **EDEMA**

HYDROPS FETALIS

BLOOD

Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. Forestier F, et al. **Br J Haematol** 1999 Mar;104(4):925–7
Hematopoietic cytokine levels and in vitro colony formation assay in fetal anemia. Yamada H, et al. **Semin Thromb Hemost** 1998;24(5):485–90

CHEMICALLY INDUCED

Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. Mas C, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):106–7

COMPLICATIONS

Fetal tachydysrhythmia associated with nonimmune hydrops. Ahel V, et al. **Acta Med Croatica** 1999;53(1):41–3

Successful treatment of refractory supraventricular tachycardia by repeat intravascular injection of amiodarone in a fetus with hydrops. Mangione R, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):105–7

Intrauterine anemia due to parvovirus B19: successful treatment with intravenous immunoglobulins [letter] Rugolotto S, et al. **Haematologica** 1999 Jul;84(7):668–9

Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome. de Koning TJ, et al. **J Inherit Metab Dis** 1998 Aug;21(6):681–2

Radiofrequency catheter ablation in a haemodynamically compromised premature neonate with hydrops fetalis. Osborn DA, et al. **J Paediatr Child Health** 1999 Aug; 35(4):406–8

Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Lambert-Messerlian GM, et al. **Prenat Diagn** 1998 Oct;18(10):1061–7

DIAGNOSIS

Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization. Musiani M, et al. **J Clin Microbiol** 1999 Jul;37(7):2326–9

Investigation of nonimmune hydrops fetalis: multidisciplinary studies are necessary for diagnosis--review of 94 cases. Lallemand AV, et al. **Pediatr Dev Pathol** 1999 Sep–Oct; 2(5):432–9

[Parvovirus B19 infection in pregnancy: a cause of non-immune hydrops fetalis (see comments)] van Gessel PH, et al. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):3–7 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 6;143(10):541; discussion 542. **(Dut)**

[Analysis of cardiotocographic recordings preceding intrauterine death of fetus with non-immunological hydrops] Błaszczak G, et al. **Ginekol Pol** 1998 Aug; 69(8):660–3 (Eng. Abstr.) **(Pol)**

[Nonimmunological fetal hydrops and the oligohydramnios deformation sequence as a manifestation of the twin-twin transfusion syndrome] González de Dios J, et al. **An Esp Pediatr** 1998 Dec;49(6):627–30 (22 ref.) **(Spa)**

DRUG THERAPY

Two cases of atrial flutter with fetal hydrops: successful fetal drug therapy. Won HS, et al. **J Korean Med Sci** 1998 Dec; 13(6):676–9

Successful prenatal digoxin therapy for Ebstein's anomaly with hydrops fetalis. A case report. Hsieh YY, et al. **J Reprod Med** 1998 Aug;43(8):710–2

Resolution of fetal tachycardia and hydrops by a single adenosine administration. Hubinont C, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):718

ENZYMOLOGY

Beta-glucuronidase deficiency as cause of recurrent hydrops fetalis: the first early prenatal diagnosis by chorionic villus sampling. Van Eyndhoven HW, et al. **Prenat Diagn** 1998 Sep;18(9):959–62

ETIOLOGY

Hydrops foetalis caused by hepatic haemangioma. Albano G, et al. **Acta Paediatr** 1998 Dec;87(12):1307–9

Refractory congenital ascites as a manifestation of neonatal sialidosis: clinical, biochemical and morphological studies in a newborn Syrian male infant. Sergi C, et al. **Am J Perinatol** 1999;16(3):133–41

The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. Yaegashi N, et al. **J Infect** 1998 Jul;37(1):28–35

Familial perinatal hemochromatosis: a disease that causes recurrent non-immune hydrops. Kassem E, et al. **J Perinat Med** 1999;27(2):122–7

Rapid development of hydrops fetalis in the donor twin following death of the recipient twin in twin–twin transfusion syndrome. Ries M, et al. **J Perinat Med** 1999; 27(1):68–73

Intrauterine growth acceleration in the case of a severe form of mucopolysaccharidosis type VII. Tokieda K, et al. **J Perinat Med** 1998;26(3):235–9 (12 ref.)

Resolution of human parvovirus B19-induced nonimmune hydrops after intrauterine transfusion. Odibo AO, et al. **J Ultrasound Med** 1998 Sep;17(9):547–50

Fluid abnormalities occur in the chronically cannulated mid-gestation but not late gestation ovine fetus. Dodic M, et al. **Pediatr Res** 1998 Dec;44(6):894–9

Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Kessel I, et al. **Pediatrics** 1999 Jan;103(1):E9

[Parvovirus-B19 infection in pregnancy: a cause of nonimmune hydrops fetalis (letter; comment)] Knol A. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):541; discussion 542. Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):3–7. **(Dut)**

[Maternal hepatitis B infection as the cause of nonimmunologic hydrops fetalis] Schröter B, et al. **Z Geburtshilfe Neonatol** 1999 Jan–Feb;203(1):36–8 (Eng. Abstr.) **(Ger)**

[Hydrops fetalis correlated with voluminous chorioangioma of the placenta] Berzioli M, et al. **Pediatr Med Chir** 1999 Jan–Feb;21(1):37–8 (Eng. Abstr.) **(Ita)**

GENETICS

Mapping of a new SGBS locus to chromosome Xp22 in a family with a severe form of Simpson-Golabi-Behmel syndrome. Brzustowicz LM, et al. **Am J Hum Genet** 1999 Sep;65(3):779–83

A genetic syndrome associating dehydrated hereditary stomatocytosis, pseudohyperkalaemia and perinatal oedema. Grootenboer S, et al. **Br J Haematol** 1998 Nov; 103(2):383–6

Hereditary dehydrated and overhydrated stomatocytosis: recent advances. Delaunay J, et al. **Curr Opin Hematol** 1999 Mar;6(2):110–4 (33 ref.)

Homozygous alpha-thalassaemia and hypospadias--common aetiology or incidental association? Long-term survival of Hb Bart's hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Dame C, et al. **Eur J Pediatr** 1999 Mar;158(3):217–20

Cervical ribs: useful marker of monosomy X in fetal hydrops. Keeling JW, et al. **Pediatr Dev Pathol** 1999 Mar–Apr; 2(2):119–23

Prenatal diagnosis of de novo distal 5q duplication associated with hygroma colli, fetal oedema and complex cardiopathy. Witters I, et al. **Prenat Diagn** 1998 Dec;18(12):1304–7

IMMUNOLOGY

Ontogeny of the fetal immune system: study on pregnancies with Rh-isoimmunization and nonimmune fetal hydrops. Noia G, et al. **Clin Immunol** 1999 Jan;90(1):115–8

[Analysis of cardiotocographic recordings preceding intrauterine death of fetus with non-immunological hydrops] Błaszczak G, et al. **Ginekol Pol** 1998 Aug; 69(8):660–3 (Eng. Abstr.) **(Pol)**

MORTALITY

Nonimmune hydrops fetalis: fetal and neonatal outcome during 1983–1992. Wafelman LS, et al. **Biol Neonate** 1999; 75(2):73–81

PATHOLOGY

Early-onset fetal hydrops and muscle degeneration in siblings due to a novel variant of type IV glycogenosis. Cox PM, et al. **Am J Med Genet** 1999 Sep 10;86(2):187–93

Glycogen storage disease type IV presenting as hydrops fetalis. Alegria A, et al. **J Inherit Metab Dis** 1999 May; 22(3):330–2

Feto-placentary pathology in human parvovirus B19 infection. Garcia AG, et al. **Rev Inst Med Trop Sao Paulo** 1998 May–Jun;40(3):145–50

PHYSIOPATHOLOGY

Fluid abnormalities occur in the chronically cannulated mid-gestation but not late gestation ovine fetus. Dodic M, et al. **Pediatr Res** 1998 Dec;44(6):894–9

THERAPY

Long-term outcome of 51 liveborn neonates with non-immune hydrops fetalis. Nakayama H, et al. **Acta Paediatr** 1999 Jan;88(1):24–8

Is homozygous alpha-thalassaemia a lethal condition in the 1990s? Ng PC, et al. **Acta Paediatr** 1998 Nov;87(11):1197–9

Thoracoamniotic shunting for treatment of fetal bilateral hydrothorax with hydrops. Chao AS, et al. **J Formos Med Assoc** 1998 Sep;97(9):646–8

Resolution of human parvovirus B19-induced nonimmune hydrops after intrauterine transfusion. Odibo AO, et al. **J Ultrasound Med** 1998 Sep;17(9):547–50

Diagnosis and management of non-immune hydrops fetalis [letter; comment] Ettore G, et al. **Prenat Diagn** 1998 Nov; 18(11):1213. Comment on: Prenat Diagn 1997 Dec;17(13):1261–8.

Direct intrauterine fetal therapy in a case of bronchopulmonary sequestration associated with non-immune hydrops fetalis. Anandakumar C, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):263–5

ULTRASONOGRAPHY

Congenital rapidly fatal form of nemaline myopathy with fetal hydrops and arthrogryposis. A case report and review. Vardon D, et al. **Fetal Diagn Ther** 1998 Jul–Aug; 13(4):244–9

A case of large placental chorioangioma with non-immunological hydrops fetalis. Makino Y, et al. **J Perinat Med** 1999;27(2):128–31

Spontaneous resolution of nonimmune hydrops in a fetus with a cystic adenomatoid malformation. Higby K, et al. **J Perinatol** 1998 Jul–Aug;18(4):308–10

Diagnosis and management of non-immune hydrops fetalis [letter; comment] Ettore G, et al. **Prenat Diagn** 1998 Nov; 18(11):1213. Comment on: Prenat Diagn 1997 Dec;17(13):1261–8.

[Congenital generalized dropsy and intrapericardial fetal teratoma. Report of a case of prenatal diagnosis] Lindner V, et al. **Ann Pathol** 1999 Apr;19(2):131–4 (Eng. Abstr.) **(Fre)**

VIROLOGY

Survival of a preterm neonate with late onset hydrops fetalis due to parvovirus B19 infection. McNamara PJ, et al. **Acta Paediatr** 1998 Oct;87(10):1088–9

Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Rodis JF, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):985–8

Parvovirus B19 in fetal hydrops [letter; comment] Rogers BB, et al. **Hum Pathol** 1999 Feb;30(2):247. Comment on: Hum Pathol 1998 Jul;29(7):696–701.

Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization. Musiani M, et al. **J Clin Microbiol** 1999 Jul;37(7):2326–9

Severe nonimmune hydrops fetalis and congenital corneal opacification secondary to human parvovirus B19 infection. A case report. Plachouras N, et al. **J Reprod Med** 1999 Apr;44(4):377–80

HYDROQUINONES

ADMINISTRATION & DOSAGE

A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans retinoic acid aqueous gel. Yoshimura K, et al. **Aesthetic Plast Surg** 1999 Jul–Aug; 23(4):285–91

Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. Kang WH, et al. **J Dermatol** 1998 Sep;25(9):587–96

ADVERSE EFFECTS

Contact hypersensitivity to monobenzyl ether of hydroquinone used to treat vitiligo. Lyon CC, et al. **Contact Dermatitis** 1998 Sep;39(3):132–3

ANALYSIS

Determination of hydroquinone in air by high performance liquid chromatography. Scobbie E, et al. **Ann Occup Hyg** 1999 Feb;43(2):131–41

Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. Vree TB, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22; 721(2):217–28

Quantitative determination of butylated hydroxyanisole, butylated hydroxytoluene, and tert-butyl hydroquinone in oils, foods, and biological fluids by high-performance liquid chromatography with fluorometric detection. Yankah VV, et al. **Lipids** 1998 Nov;33(11):1139–45

CHEMICAL SYNTHESIS

Synthesis and antibacterial activities of 4-hydroxy-o-phenylphenol and 3,6-diallyl-4-hydroxy-o-phenylphenol against a cariogenic bacterium Streptococcus mutans OMZ 176. Bae KH, et al. **Arch Pharm Res** 1991 Mar;14(1):41–3

CHEMISTRY

Hydroquinone as a buffer additive for suppression of bubbles formed by electrochemical oxidation of the CE buffer at the outlet electrode in capillary electrophoresis/electrospray ionization-mass spectrometry. Moini M, et al. **Anal Chem** 1999 Apr 15;71(8):1658–61

Hydroquinone-based derivatization reagents for the quantitation of amines using electrochemical detection. Rose MJ, et al. **Anal Chem** 1999 Jun 1;71(11):2221–30

Complexation of 1,2,4-benzenetriol with inorganic and ferritin-released iron in vitro. Ahmad S, et al. **Biochem Biophys Res Commun** 1999 May 27;259(1):169–71

pH-dependent spectroscopic changes associated with the hydroquinone of FMN in flavodoxins. Yalloway GN, et al. **Biochemistry** 1999 Mar 23;38(12):3753–62

HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone), an anti-lipid-peroxidative compound: its chemical and biochemical characterizations. Hino T, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):47–60

Immunochemical detection of quinol--thioether-derived protein adducts. Kleiner HE, et al. **Chem Res Toxicol** 1998 Nov;11(11):1283–90

Immunochemical analysis of quinol-thioether-derived covalent protein adducts in rodent species sensitive and resistant to quinol-thioether-mediated nephrotoxicity. Kleiner HE, et al. **Chem Res Toxicol** 1998 Nov; 11(11):1291–300

Different kinetics of hydroquinone depletion in various medicinal plant tissue cultures producing arbutin. Jahodář L, et al. **Pharmazie** 1999 Mar;54(3):234–5

[Mechanism of combined oxidation of ascorbic acid and hydroquinone in the presence of horseradish peroxidase] Rogozhin VV, et al. **Bioorg Khim** 1999 May;25(5):377–82 (Eng. Abstr.) **(Rus)**

METABOLISM

A two-component tetrachlorohydroquinone reductive dehalogenase system from the lignin-degrading basidiomycete Phanerochaete chrysosporium. Reddy GV, et al. **Biochem Biophys Res Commun** 1999 Apr 21;

257(3):901-5
Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Bornheim LM, et al. **Chem Res Toxicol** 1998 Oct; 11(10):1209-16
Biodegradative mechanism of the brown rot basidiomycete Gloeophyllum trabeum: evidence for an extracellular hydroquinone-driven fenton reaction. Kerem Z, et al. **FEBS Lett** 1999 Mar 5;446(1):49-54
Inhibition of 2,3-dimethyl-1,4-naphthohydroquinone auto-oxidation by copper and by superoxide dismutase. Munday R. **Free Radic Biol Med** 1999 Jun;26(11-12):1475-9
A functional 4-hydroxysalicylate/hydroxyquinol degradative pathway gene cluster is linked to the initial dibenzo-p-dioxin pathway genes in Sphingomonas sp. strain RW1. Armengaud J, et al. **J Bacteriol** 1999 Jun; 181(11):3452-61
Pathways for proton release during ubihydroquinone oxidation by the bc(1) complex. Crofts AR, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10021-6

PHARMACOKINETICS

Prodrug for bioreductive activation-independent delivery of menahydroquinone-4: human liver enzymatic activation and its action in warfarin-poisoned human liver. Takata J, et al. **Biol Pharm Bull** 1999 Feb;22(2):172-8
Bioavailability and metabolism of hydroquinone after intratracheal instillation in male rats. Deisinger PJ, et al. **Drug Metab Dispos** 1999 Apr;27(4):442-8
Distribution and excretion of radiolabelled tert-butylhydroquinone in Fischer 344 rats. Ikeda GJ, et al. **Food Chem Toxicol** 1998 Nov;36(11):907-14

PHARMACOLOGY

Inhibition of prostaglandin-H-synthase by o-phenylphenol and its metabolites. Freyberger A, et al. **Arch Toxicol** 1998 Oct;72(10):637-44
Inducible expression of the gamma-glutamylcysteine synthetase light subunit by t-butylhydroquinone in HepG2 cells is not dependent on an antioxidant-responsive element. Galloway DC, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):535-9
Coordinated induction of the c-jun gene with genes encoding quinone oxidoreductases in response to xenobiotics and antioxidants. Radjendirane V, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):597-603
HTHQ (1-O-hexyl-2,3,5-trimethylhydroquinone), an anti-lipid-peroxidative compound: its chemical and biochemical characterizations. Hino T, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):47-60
A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Winski SL, et al. **Clin Cancer Res** 1998 Dec;4(12):3083-8
Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Münzel PA, et al. **Drug Metab Dispos** 1999 May; 27(5):569-73
2,5-Di-t-butyl-1,4-benzohydroquinone induces endothelium-dependent relaxation of rat thoracic aorta. Fusi F, et al. **Eur J Pharmacol** 1999 Feb 5;366(2-3):181-7
Mechanism of rise and decay of 2,5-di-tert-butylhydroquinone-induced Ca2+ signals in Madin Darby canine kidney cells. Jan CR, et al. **Eur J Pharmacol** 1999 Jan 15;365(1):111-7
Free radical formation and erythrocyte membrane alterations during MetHb formation induced by the BHA metabolite, tert-butylhydroquinone. Stolze K, et al. **Free Radic Res** 1999 Apr;30(4):295-303
Enhancement of myeloid cell growth by benzene metabolites via the production of active oxygen species. Wiemels J, et al. **Free Radic Res** 1999 Feb;30(2):93-103
Modulation of normal human eosinophil chemotaxis in vitro by herbimycin A, erbstatin and pervanadate. El-Shazly A, et al. **Int Arch Allergy Immunol** 1998 Sep;117 Suppl 1:10-3
Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: A possible mechanism of carcinogenesis. Kuo ML, et al. **Mol Pharmacol** 1999 May;55(5):894-901
Antibacterial and cytotoxic natural and synthesized hydroquinones from sponge Ircinia spinosula. Mihopoulos N, et al. **Z Naturforsch [C]** 1999 May-Jun;54(5-6):417-23

THERAPEUTIC USE

Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Kakita LS, et al. **Clin Ther** 1998 Sep-Oct;20(5):960-70
Efficacy of hydroquinone in the treatment of cutaneous hyperpigmentation in hairless descendants of Mexican hairless dogs (Xoloitzcuintli). Kimura T, et al. **Lab Anim Sci** 1998 Oct;48(5):469-75

TOXICITY

Tumor-promoting activities of hydroquinone and 1,1-dimethylhydrazine after initiation of newborn mice with 1-methyl-1-nitrosourea. Tamura T, et al. **Cancer Lett** 1999 Aug 23;143(1):71-80
Quinol-glutathione conjugate-induced mutation spectra in the supF gene replicated in human AD293 cells and bacterial MBL50 cells. Jeong JK, et al. **Cancer Res** 1999 Aug 1;59(15):3641-5
Immunochemical analysis of quinol-thioether-derived covalent protein adducts in rodent species sensitive and resistant to quinol-thioether-mediated nephrotoxicity. Kleiner HE, et al. **Chem Res Toxicol** 1998 Nov; 11(11):1291-300
The toxicology of hydroquinone--relevance to occupational and environmental exposure. DeCaprio AP. **Crit Rev Toxicol** 1999 May;29(3):283-330 (414 ref.)
Depigmentation with tert-butyl hydroquinone using black guinea pigs. Patrick E, et al. **Food Chem Toxicol** 1999 Feb-Mar;37(2-3):169-75
Hydroquinone. **IARC Monogr Eval Carcinog Risks Hum** 1999;71 Pt 2:691-719 (130 ref.)
DNA damage by hydroquinone in human white blood cells: analysis by alkaline single-cell gel electrophoresis. Andreoli C, et al. **Mutat Res** 1999 Jan 2;438(1):37-45
Identification of hydroxyhydroquinone in coffee as a generator of reactive oxygen species that break DNA single strands. Hiramoto K, et al. **Mutat Res** 1998 Nov 9; 419(1-3):43-51

HYDROSTATIC PRESSURE

In vivo effects of hydrostatic pressure on interstitium of abdominal wall muscle. Zakaria ER, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H517-29
Monounsaturated but not polyunsaturated fatty acids are required for growth of the deep-sea bacterium Photobacterium profundum SS9 at high pressure and low temperature. Allen EE, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1710-20
Variation in resistance of natural isolates of Escherichia coli O157 to high hydrostatic pressure, mild heat, and other stresses. Benito A, et al. **Appl Environ Microbiol** 1999 Apr; 65(4):1564-9
Response of pathogenic Vibrio species to high hydrostatic pressure. Berlin DL, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2776-80
Does pressure antagonize anesthesia? Opposite effects on specific and nonspecific inhibitors of firefly luciferase. Ueda I, et al. **Biophys J** 1999 Jan;76(1 Pt 1):483-8
Does pressure antagonize anesthesia? High-pressure stopped-flow study of firefly luciferase and anatomy of initial flash. Ueda I, et al. **Biophys J** 1999 Jan;76(1 Pt 1):478-82
The transduction of very small hydrostatic pressures. Macdonald AG, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jan; 122(1):13-36 (153 ref.)
Barophiles: deep-sea microorganisms adapted to an extreme environment. Horikoshi K. **Curr Opin Microbiol** 1998 Jun; 1(3):291-5 (30 ref.)
An improved technique for studying pleural fluid pressure and composition in rabbits. Del Fabbro M. **Exp Physiol** 1998 Jul;83(4):435-48
Analysis of intracellular pH in the yeast Saccharomyces cerevisiae under elevated hydrostatic pressure: a study in baro- (piezo-) physiology. Abe F, et al. **Extremophiles** 1998 Aug;2(3):223-8 (35 ref.)
Effect of high hydrostatic pressure on the porin OmpC from Escherichia coli. Macdonald AG, et al. **FEMS Microbiol Lett** 1999 Apr 15;173(2):327-34
Exposure of human peripheral blood mononuclear cells (PBMC) to hydrostatic pressure increases their proliferative response to phytohemagglutinin A (PHA) and anti-CD3 antibody. Eisenthal A, et al. **Immunol Invest** 1999 Jan; 28(1):55-65
Thermococcus barophilus sp. nov., a new barophilic and hyperthermophilic archaeon isolated under high hydrostatic pressure from a deep-sea hydrothermal vent. Marteinsson VT, et al. **Int J Syst Bacteriol** 1999 Apr;49 Pt 2:351-9
Hydraulic pressure stimulates adenosine 3',5'-cyclic monophosphate accumulation in endothelial cells from Schlemm's canal. Stamer WD, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):1983-8
Protective effect of calcium on inactivation of Escherichia coli by high hydrostatic pressure. Hauben KJ, et al. **J Appl Microbiol** 1998 Oct;85(4):678-84
Yeast cell mortality related to a high-pressure shift: occurrence of cell membrane permeabilization. Perrier-Cornet JM, et al. **J Appl Microbiol** 1999 Jul; 87(1):1-7
RecD function is required for high-pressure growth of a deep-sea bacterium. Bidle KA, et al. **J Bacteriol** 1999 Apr; 181(8):2330-7
Sensitivity of Staphylococcus aureus and Lactobacillus helveticus in ovine milk subjected to high hydrostatic pressure. Gervilla R, et al. **J Dairy Sci** 1999 Jun; 82(6):1099-107
Application of high hydrostatic pressure to eliminate Listeria monocytogenes from fresh pork sausage. Murano EA, et al. **J Food Prot** 1999 May;62(5):480-3
High-pressure destruction kinetics of Listeria monocytogenes on pork. Mussa DM, et al. **J Food Prot** 1999 Jan;62(1):40-5
Oscillatory high hydrostatic pressure inactivation of Zygosaccharomyces bailii. Palou E, et al. **J Food Prot** 1998 Sep;61(9):1213-5
High hydrostatic pressure come-up time and yeast viability. Palou E, et al. **J Food Prot** 1998 Dec;61(12):1657-60
High pressure response of fruit jams contaminated with Listeria monocytogenes. Préstamo G, et al. **Lett Appl Microbiol** 1999 Apr;28(4):313-6
Surface pressure-dependent cross-modulation of sphingomyelinase and phospholipase A2 in monolayers. Fanani ML, et al. **Lipids** 1998 Nov;33(11):1079-87
The effects of hydrostatic pressure on ribosome conformation in Escherichia coli: and in vivo study using differential scanning calorimetry. Niven GW, et al. **Microbiology** 1999 Feb;145 (Pt 2):419-25
Outer hair cells isolated from the organ of corti exposed to increased hydrostatic pressure. Conradi P, et al. **ORL J Otorhinolaryngol Relat Spec** 1999 Mar-Apr; 61(2):57-62
High hydrostatic pressure inactivation of Salmonella typhimurium: effects of pressure, duration, pH and temperature studied by analysis of variance. Ritz M, et al. **Vet Res** 1998 Nov-Dec;29(6):547-56
[Action of hydrostatic pressure on proteins: emergence of high pressure biotechnology, potential pharmaceutical and medical applications] Masson P. **Ann Pharm Fr** 1999 Jan; 57(1):49-55 (47 ref.) (Eng. Abstr.) **(Fre)**

HYDROTHERAPY

The efficacy of complementary medical treatments, as used by spas: a review of the evidence. Tabacchi MH. **Altern Ther Health Med** 1998 Nov;Suppl:1-5 (120 ref.)
Effects of hydrotherapy on pressure ulcer healing. Burke DT, et al. **Am J Phys Med Rehabil** 1998 Sep-Oct;77(5):394-8
Nonselective debridement and antimicrobial cleansing of a venting ductal breast carcinoma. Nash MS, et al. **Arch Phys Med Rehabil** 1999 Jan;80(1):118-21
Central cooling effects in patients with hypercholesterolaemia. De Lorenzo F, et al. **Clin Sci (Colch)** 1998 Aug;95(2):213-7
Aquatic therapy in the rehabilitation of athletic injuries. Prins J, et al. **Clin Sports Med** 1999 Apr;18(2):447-61, ix (41 ref.)
Quantitative evaluation of the stretch reflex before and after hydro kinesy therapy in patients affected by spastic paresis. Pagliaro P, et al. **J Electromyogr Kinesiol** 1999 Apr; 9(2):141-8
Hot-tub therapy for type 2 diabetes mellitus [letter] Hooper PL. **N Engl J Med** 1999 Sep 16;341(12):924-5
Improvement in ejection fraction by hydrotherapy as rehabilitation in patients with chronic pulmonary emphysema. Kurabayashi H, et al. **Physiother Res Int** 1998; 3(4):284-91
The energy cost of level walking before and after hydro-kinesi therapy in patients with spastic paresis. Zamparo P, et al. **Scand J Med Sci Sports** 1998 Aug; 8(4):222-8
[Occurrence of free-living amoebae and Legionella in whirlpool bathes] Kuroki T, et al. **Kansenshogaku Zasshi** 1998 Oct;72(10):1056-63 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Comparison of responses of men to immersion in circulating water at 40.0 and 41.5 degrees C. Allison TG, et al. **Aviat Space Environ Med** 1998 Sep;69(9):845-50
Legionnaires' disease--outbreak in The Netherlands. **Commun Dis Rep CDR Wkly** 1999 Apr 2;9(14):123
Irritant contact dermatitis due to 1-bromo-3-chloro-5,5-dimethylhydantoin in a hydrotherapy pool. Risk assessments: the need for continuous evidence-based assessments. Loughney E, et al. **Occup Med (Lond)** 1998 Oct;48(7):461-3
[Supplementary history and occupational dermatologic evaluation of medical bath workers, masseurs, and physical therapists] Wessbecher R, et al. **Hautarzt** 1998 Dec; 49(12):912-9 (64 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Current state of the research on hydrotherapy in France. Boulangé M. **Forsch Komplementarmed** 1999 Feb;6(1):47-8

HYDROTHORAX

Primary fetal hydrothorax: A literature review and proposed antenatal clinical strategy. Aubard Y, et al. **Fetal Diagn Ther** 1998 Nov-Dec;13(6):325-33 (67 ref.)

CHEMICALLY INDUCED

Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Siegall CB, et al. **Clin Cancer Res** 1997 Mar;3(3):339-45

DIAGNOSIS

Hepatic hydrothorax: pathogenesis, diagnosis, and management. Lazaridis KN, et al. **Am J Med** 1999 Sep; 107(3):262-7 (39 ref.)
Pseudo-Meigs' syndrome caused by paraovarian fibroma. Giannacopoulos K, et al. **Eur J Gynaecol Oncol** 1998; 19(4):389-90

Not a red herring. Speich R, et al. **Respiration** 1998; 65(5):401–2

[Hydatidiform mole. A case of hydrothorax, expression of a non-neoplastic complication] Mancino P, et al. **Minerva Ginecol** 1999 Mar;51(3):103–5 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Pleurodesis treatment with tetracycline in peritoneal dialysis-complicated hydrothorax [letter] Bakkaloglu SA, et al. **Pediatr Nephrol** 1999 Sep;13(7):637–8

ETIOLOGY

Detection of diaphragmatic defect as the cause of severe hepatic hydrothorax with magnetic resonance imaging. Zenda T, et al. **Am J Gastroenterol** 1998 Nov;93(11):2288–9

Massive ascites and bilateral hydrothorax complicating severe pre-eclampsia. Ashmore J, et al. **Ceylon Med J** 1998 Dec; 43(4):235–7

Hepatic hydrothorax in the absence of ascites. Kakizaki S, et al. **Liver** 1998 Jun;18(3):216–20

Hydrothorax in continuous ambulatory peritoneal dialysis: therapeutic implications of Tc-99m MAA peritoneal scintigraphy. Huang JJ, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):992–7

Pleurodesis treatment with tetracycline in peritoneal dialysis-complicated hydrothorax [letter] Bakkaloglu SA, et al. **Pediatr Nephrol** 1999 Sep;13(7):637–8

[Hydrothorax caused by intravasal triple-lumen subclavian catheter] Laugesen H. **Ugeskr Laeger** 1999 Jan 25; 161(4):439–40 (Eng. Abstr.) **(Dan)**

[Hepatic hydrothorax without ascites: presentation of a case and review of the literature] Golpe Gómez R, et al. **An Med Interna** 1998 Oct;15(10):541–3 (Eng. Abstr.) **(Spa)**

[Late hydrothorax due to central venous catheterization (letter)] Rubiato Aragón R, et al. **Arch Bronconeumol** 1999 Mar;35(3):143–4 **(Spa)**

PHYSIOPATHOLOGY

Hepatic hydrothorax in the absence of ascites. Kakizaki S, et al. **Liver** 1998 Jun;18(3):216–20

PREVENTION & CONTROL

Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Siegall CB, et al. **Clin Cancer Res** 1997 Mar;3(3):339–45

RADIOGRAPHY

Ovarian hyperstimulation syndrome manifests only as hydrothorax. Papanicolaou N, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):941–3

SURGERY

Thoracoscopic surgery and pleurodesis for pleuroperitoneal communication in patients on continuous ambulatory peritoneal dialysis. Okada H, et al. **Am J Kidney Dis** 1999 Jul;34(1):170–2

Refractory hepatic hydrothorax treated with transjugular intrahepatic portosystemic shunt [see comments] Degawa M, et al. **J Gastroenterol** 1999 Feb;34(1):128–31. Comment in: J Gastroenterol 1999 Feb;34(1):154–6.

Further experiments are necessary to determine whether transjugular intrahepatic portosystemic shunt is the definitive treatment for refractory hepatic hydrothorax [editorial; comment] Mitamura K. **J Gastroenterol** 1999 Feb;34(1):154–6 (18 ref.). Comment on: J Gastroenterol 1999 Feb;34(1):128–31.

A successful surgical repair of the hepatic hydrothorax using pneumoperitoneum: report of a case. Yaguchi T, et al. **Surg Today** 1999;29(8):795–8

[Treatment of refractory hydrothorax with intrahepatic portosystemic shunt in the course of primary biliary cirrhosis (letter)] Bechade D, et al. **Gastroenterol Clin Biol** 1998 Aug-Sep;22(8-9):743–5 **(Fre)**

[Treatment by porto-systemic intrahepatic shunt for refractory hydrothorax during cirrhosis] Péron JM, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):414–5 **(Fre)**

THERAPY

Hepatic hydrothorax: pathogenesis, diagnosis, and management. Lazaridis KN, et al. **Am J Med** 1999 Sep; 107(3):262–7 (39 ref.)

Thoracoamniotic shunting for treatment of fetal bilateral hydrothorax with hydrops. Chao AS, et al. **J Formos Med Assoc** 1998 Sep;97(9):646–8

Hydrothorax complicating continuous ambulatory peritoneal dialysis: successful management with talc pleurodesis under thoracoscopy. Kanaan N, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1590–2

Hydrothorax in peritoneal dialysis. Effective treatment with pleurodesis [letter] Moreno A, et al. **Perit Dial Int** 1998 Nov-Dec;18(6):657–8

[Hepatic hydrothorax. Recommendations for a rational therapy] Rössle M, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1485–9 (39 ref.) **(Ger)**

ULTRASONOGRAPHY

Primary fetal hydrothorax with lymphangiectasia, pulmonary situs inversus and abnormal tracheo-bronchial tree [letter] Selby DM, et al. **Prenat Diagn** 1999 Mar;19(3):288–9

HYDROXAMIC ACIDS

ADMINISTRATION & DOSAGE

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Primrose JN, et al. **Br J Cancer** 1999 Feb;79(3–4):509–14

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Tierney GM, et al. **Eur J Cancer** 1999 Apr;35(4):563–8

CHEMICAL SYNTHESIS

Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides. Xu LC, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):9–17

Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Hanessian S, et al. **Bioorg Med Chem Lett** 1999 Jun 21;9(12):1691–6

Synthesis and evaluation of a new inhibitor of phosphoglucose isomerases: the enediolate analogue 5-phospho-D-arabinohydroxamate. Hardré R, et al. **Bioorg Med Chem Lett** 1998 Dec 1;8(23):3435–8

Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase. Jeng AY, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):897–902

Syntheses and kinetic evaluation of hydroxamate-based peptide inhibitors of glyoxalase I. Ly HD, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):705–10

Synthesis and ESR study of new dihydroxamic acid siderophores S as scavengers of hydroxyl radicals. Nguyen MV, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):227–32

The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement. Pratt LM, et al. **Bioorg Med Chem Lett** 1998 Jun 2;8(11):1359–64

The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. Steinman DH, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2087–92

Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates. Bergeron RJ, et al. **J Med Chem** 1999 Jul 29;42(15):2881–6

Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template. Groneberg RD, et al. **J Med Chem** 1999 Feb 25;42(4):541–4

Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. Pikul S, et al. **J Med Chem** 1999 Jan 14;42(1):87–94

Effects of benzohydroxamic acids on L1210 lymphoid leukemia cell nucleic acid metabolism. Hall IH, et al. **Pharmazie** 1998 Nov;53(11):794–9

CHEMISTRY

Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Li YC, et al. **Biochemistry** 1998 Oct 6;37(40):14048–56

NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound. Moy FJ, et al. **Biochemistry** 1999 Jun 1;38(22):7085–96

Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci. Safavy A, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):18–23

Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production. Cherney RJ, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1279–84

Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases. Jacobson IC, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):837–42

Effects of the host cavity size and the preparation method on the physicochemical properties of ibuproxam-cyclodextrin systems. Mura P, et al. **Drug Dev Ind Pharm** 1999 Mar;25(3):279–87

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. II. Physico-chemical properties and structure elucidation. Iijima M, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):25–8

Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase. Toba S, et al. **J Med Chem** 1999 Apr 8;42(7):1225–34

The crystal structure of Escherichia coli class II fructose-1, 6-bisphosphate aldolase in complex with phosphoglycolohydroxamate reveals details of mechanism and specificity. Hall DR, et al. **J Mol Biol** 1999 Mar 26; 287(2):383–94

Compatibility study between ibuproxam and pharmaceutical excipients using differential scanning calorimetry, hot-stage microscopy and scanning electron microscopy. Mura P, et al. **J Pharm Biomed Anal** 1998 Oct;18(1-2):151–63

Synthesis, chemistry, and applications of nitroxyl ion releasers sodium trioxodinitrate or Angeli's salt and Piloty's acid. Hughes MN, et al. **Methods Enzymol** 1999;301:279–87

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Finnin MS, et al. **Nature** 1999 Sep 9;401(6749):188–93

METABOLISM

Iron removal from monoferric human serum transferrins by 1, 2-dimethyl-3-hydroxypyridin-4-one, 1-hydroxypyridin-2-one and acetohydroxamic acid. Li Y, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):89–102

L-Glutamic acid gamma-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo. Goldwaser I, et al. **J Biol Chem** 1999 Sep 10; 274(37):26617–24

The aerobactin iron transport system genes in Shigella flexneri are present within a pathogenicity island. Vokes SA, et al. **Mol Microbiol** 1999 Jul;33(1):63–73

PHARMACOLOGY

Inhibition of gelatinase A by oleic acid. Emonard H, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:647–9

Attenuation of oxidant-induced lung injury by the synthetic matrix metalloproteinase inhibitor BB-3103. Foda HD, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:650–3

MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model. Loftus IM, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:547–50

Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro. Choudhuri SK, et al. **Anticancer Drugs** 1998 Oct;9(9):825–32

A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies. Li L, et al. **Anticancer Res** 1999 Jan-Feb; 19(1A):51–60

Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Inokoshi J, et al. **Biochem Biophys Res Commun** 1999 Mar 16;256(2):372–6

The amyloid precursor protein (APP) and the angiotensin converting enzyme (ACE) secretase are inhibited by hydroxamic acid-based inhibitors. Parvathy S, et al. **Biochem Soc Trans** 1998 Aug;26(3):S242

Identification of active substances from Streptomyces culture fluids using p53-independent expression of p21/WAF1/Cip1 gene and their mode of action. Egawa K, et al. **Biol Pharm Bull** 1998 Sep;21(9):899–904

Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing. Bailey S, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):23–8

Selective inhibition of low affinity IgE receptor (CD23) processing. Bailey S, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):29–34

Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis. Chen MH, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):313–8

N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Connolly PJ, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):979–84

Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Curtin ML, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1443–8

Inhibition stereochemistry of hydroxamate inhibitors for thermolysin. Jin Y, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3515–8

Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. Sheppard GS, et al. **Bioorg Med Chem Lett** 1998 Nov 17;8(22):3251–6

Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. Ishiguro K, et al. **Blood** 1998 Dec 1;92(11):4383–93

Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Qiu L, et al. **Br J Cancer** 1999 Jun;80(8):1252–8

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Watson SA, et al. **Br J Cancer** 1999 Sep;81(1):19–23

Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Porter KE, et al. **Br J Surg** 1998 Oct;85(10):1373–7

Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Treharne GD, et al. **Br J Surg** 1999 Aug;86(8):1053–8

Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Joshi B, et al. **Cancer Res** 1999 Sep 1;59(17):4343–55

Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Sowa Y, et al. **Cancer Res** 1999 Sep 1; 59(17):4266–70

Sequence specificity of DNA cleavage by bisnetropsin-linked hydroxamic acid-metal complexes: highly specific cleavage by ferrous complexes. Hashimoto S, et al. **Chem Pharm Bull (Tokyo)** 1998 Dec;46(12):1941–3

phd1+, a histone deacetylase gene of Schizosaccharomyces pombe, is required for the meiotic cell cycle and resistance to trichostatin A. Kim YB, et al. **FEBS Lett** 1998 Oct 2; 436(2):193–6

Hydroxamate derivatives of substrate-analogous peptides

containing aminomalonic acid are potent inhibitors of matrix metalloproteinases. Krumme D, et al. **FEBS Lett** 1998 Oct 2;436(2):209–12

A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction. Scott KA, et al. **FEBS Lett** 1998 Dec 11;441(1):137–40

A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Niki T, et al. **Hepatology** 1999 Mar; 29(3):858–67

Helicobacter pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Zullo A, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):405–9

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454–19. I. Taxonomy, fermentation, isolation and biological activity. Iijima M, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):20–4

Repression of dioxin signal transduction in fibroblasts. Identification Of a putative repressor associated with Arnt. Gradin K, et al. **J Biol Chem** 1999 May 7;274(19):13511–8

Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents. Webb Y, et al. **J Biol Chem** 1999 May 14;274(20):14280–7

Trichostatin A up-regulates human papillomavirus type 11 upstream regulatory region-E6 promoter activity in undifferentiated primary human keratinocytes. Zhao W, et al. **J Virol** 1999 Jun;73(6):5026–33

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Cameron EE, et al. **Nat Genet** 1999 Jan;21(1):103–7

Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Kim YB, et al. **Oncogene** 1999 Apr 15;18(15):2461–70

[Discovery of cell cycle inhibitors and their application to molecular biology] Yoshida M. **Jpn J Antibiot** 1999 Feb; 52(2):172–3 **(Jpn)**

[Antitumor effect of a matrix metalloproteinase inhibitor, TA-2516 (Marimastat), on a nude mouse model of intraperitoneal seeding of stomach cancer] Kimata D, et al. **Nippon Geka Gakkai Zasshi** 1999 May;100(5):363 **(Jpn)**

[The effect of linoleyl hydroxamic acid on lipid peroxidation processes and on the enzymatic activity of the antioxidant system in rats under hypoxia] Kukoba TV, et al. **Fiziol Zh** 1998;44(5–6):43–8 (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Rosemurgy A, et al. **Am J Clin Oncol** 1999 Jun;22(3):247–52

A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies. Li L, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):61–9

A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. Hattori K, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1283–9

A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation. Hattori K, et al. **Br J Haematol** 1999 Apr; 105(1):303–12

Marimastat (BB2516): current status of development. Steward WP. **Cancer Chemother Pharmacol** 1999;43 Suppl:S56–60 (18 ref.)

Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Lozonschi L, et al. **Cancer Res** 1999 Mar 15;59(6):1252–8

Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). Moore G, et al. **J Vasc Surg** 1999 Mar;29(3):522–32

BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Tang DG, et al. **Pathol Oncol Res** 1998;4(3):179–90

[Effects of modifications of lipoproteins by water soluble forms of lineoleic-hydroxamic acid on biochemical markers of development of atherosclerosis] Chobot'ko HM. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):64–8 (Eng. Abstr.) **(Ukr)**

TOXICITY

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Tonn JC, et al. **Int J Cancer** 1999 Mar 1;80(5):764–72

[A study on cell malignant transformation caused by dihydroxyglyoxime] Shen J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Nov; 31(6):346–8 (Eng. Abstr.) **(Chi)**

HYDROXIDES

Diesel exhaust and lung cancer mortality in potash mining. Säverin R, et al. **Am J Ind Med** 1999 Oct;36(4):415–22

Rapid determination of cholesterol in milk and milk products by direct saponification and capillary gas chromatography. Fletouris DJ, et al. **J Dairy Sci** 1998 Nov;81(11):2833–40

Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide. Leibl H, et al. **Vaccine** 1999 Mar 5;17(9–10):1017–23

ADMINISTRATION & DOSAGE

Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Hergesell O, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):863–7

ADVERSE EFFECTS

Chemical burn from alkaline batteries--a case report. Winek CL, et al. **Forensic Sci Int** 1999 Mar 15;100(1–2):101–4

CHEMISTRY

The elimination of sodium and potassium hydroxides from desiccated soda lime diminishes degradation of desflurane to carbon monoxide and sevoflurane to compound A but does not compromise carbon dioxide absorption. Neumann MA, et al. **Anesth Analg** 1999 Sep;89(3):768–73

Hydroxide rather than histidine is coordinated to the heme in five-coordinate ferric Scapharca inaequivalvis hemoglobin. Das TK, et al. **J Biol Chem** 1999 Jan 29; 274(5):2916–9

PHARMACOLOGY

Lipid peroxidation, antioxidant enzymes and glutathione levels in human erythrocytes exposed to colloidal iron hydroxide in vitro. Ferreira AL, et al. **Braz J Med Biol Res** 1999 Jun;32(6):689–94

THERAPEUTIC USE

Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Romiti R, et al. **Pediatr Dermatol** 1999 May-Jun;16(3):228–31

TOXICITY

Synergistic induction of hydroxyl radical-induced DNA single-strand breaks by chromium(VI) compound and cigarette smoke solution. Liu X, et al. **Mutat Res** 1999 Mar 15;440(1):109–17

HYDROXOCOBALAMIN

ADMINISTRATION & DOSAGE

Syncope following intramuscular injection of hydroxocobalamin in a paraplegic patient: indication for oral administration of cyanocobalamin in spinal cord injury patients. Vaidyanathan S, et al. **Spinal Cord** 1999 Feb; 37(2):147–9

ADVERSE EFFECTS

Anaphylactoid reaction to hydroxycobalamin with tolerance of cyanocobalamin [letter] Vidal C, et al. **Postgrad Med J** 1998 Nov;74(877):702

Syncope following intramuscular injection of hydroxocobalamin in a paraplegic patient: indication for oral administration of cyanocobalamin in spinal cord injury patients. Vaidyanathan S, et al. **Spinal Cord** 1999 Feb; 37(2):147–9

PHARMACOLOGY

Effects of hydroxocobalamin and carboxy-PTIO on nitrergic transmission in porcine anococcygeus and retractor penis muscles. Li CG, et al. **Br J Pharmacol** 1999 May; 127(1):172–6

THERAPEUTIC USE

Pernicious anemia (PA) subsequent to insulin-dependent diabetes mellitus and idiopathic thrombocytopenic purpura, and effects of oral cobalamin on PA [letter] Kondo H, et al. **Am J Hematol** 1999 Sep;62(1):61–2

Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin. Enns GM, et al. **J Inherit Metab Dis** 1999 Jun;22(5):599–607

HYDROXY ACIDS

ISOLATION & PURIFICATION

Relationship between hydroxy fatty acids and prostaglandin E2 in gingival tissue. Nichols F, et al. **Infect Immun** 1998 Dec;66(12):5805–11

METABOLISM

Biocatalyst engineering by assembly of fatty acid transport and oxidation activities for In vivo application of cytochrome P-450BM-3 monooxygenase. Schneider S, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3784–90

Oxylipin formation in fungi: biotransformation of arachidonic acid to 3-hydroxy-5,8-tetradecadienoic acid by Mucor genevensis. Pohl CH, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):703–6

Synthesis of 2-hydroxy acid from 2-amino acid by Clostridium butyricum. Khelifa N, et al. **Bioorg Med Chem Lett** 1998 Dec 1;8(23):3429–34

Re-evaluation of the primary structure of Ralstonia eutropha phasin and implications for polyhydroxyalkanoic acid granule binding. Hanley SZ, et al. **FEBS Lett** 1999 Mar 19;447(1):99–105

Polyhydroxyalkanoates, biopolyesters from renewable resources: physiological and engineering aspects. Braunegg G, et al. **J Biotechnol** 1998 Oct 27;65(2–3):127–61 (240 ref.)

PHARMACOLOGY

Enhancement of hydroxyl radical generation in the Fenton reaction by alpha-hydroxy acid. Ali MA, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):137–45

Pharmacologic preconditioning with monophosphoryl lipid A is abolished by 5-hydroxydecanoate, a specific inhibitor of the K(ATP) channel. Janin Y, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):337–42

Suppression of reperfusion arrhythmias by preconditioning is inhibited by an ATP-sensitive potassium channel blocker, 5-hydroxydecanoate, but not by protein kinase C blockers in the rat. Kita H, et al. **J Cardiovasc Pharmacol** 1998 Nov; 32(5):791–7

Pharmacological and histochemical distinctions between molecularly defined sarcolemmal KATP channels and native cardiac mitochondrial KATP channels. Hu H, et al. **Mol Pharmacol** 1999 Jun;55(6):1000–5

THERAPEUTIC USE

[Fruit acid facial scrubs. Dermatological and esthetic correction with alpha-hydroxy acids (AHA)] Fratila A, et al. **Hautarzt** 1999 Jun;50(6):448–60 (41 ref.) **(Ger)**

URINE

Adsorption of small hydroxy acids on glass: a pitfall in quantitative urinary organic acid analysis by GC-MS. van Landeghem AA, et al. **J Inherit Metab Dis** 1999 May; 22(3):293–6

HYDROXYACETANILIDE see **ACETAMINOPHEN**

HYDROXYACETYLAMINOFLUORENE

METABOLISM

Pseudoenzymatic reduction of N-hydroxy-2-acetylaminofluorene to 2-acetylaminofluorene mediated by cytochrome P450. Kitamura S, et al. **Carcinogenesis** 1999 Feb;20(2):347–50

Molecular cloning, expression, and characterization of novel human SULT1C sulfotransferases that catalyze the sulfonation of N-hydroxy-2-acetylaminofluorene. Sakakibara Y, et al. **J Biol Chem** 1998 Dec 18; 273(51):33929–35

3-HYDROXYACYL COA DEHYDROGENASES

BLOOD

Sensitive analysis of serum 3alpha, 7alpha, 12alpha,24-tetrahydroxy- 5beta-cholestan-26-oic acid diastereomers using gas chromatography-mass spectrometry and its application in peroxisomal D-bifunctional protein deficiency. Vreken P, et al. **J Lipid Res** 1998 Dec;39(12):2452–8

Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. van Grunsven EG, et al. **Am J Hum Genet** 1999 Jan; 64(1):99–107

3-HYDROXYACYL COA DEHYDROGENASES

ANALYSIS

A novel peroxisomal enzyme, D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein: its expression in the developing human brain. Itoh M, et al. **Microsc Res Tech** 1999 Jun 15; 45(6):383–8

ANTAGONISTS & INHIBITORS

The mechanism of inhibition of beta-oxidation by aspirin metabolites in skin fibroblasts from Reye's syndrome patients and controls. Glasgow JF, et al. **Biochim Biophys Acta** 1999 May 31;1454(1):115–25

BIOSYNTHESIS

Cross-talk between orphan nuclear hormone receptor RZRalpha and peroxisome proliferator-activated receptor alpha in regulation of the peroxisomal hydratase-dehydrogenase gene. Winrow CJ, et al. **J Biol Chem** 1998 Nov 20;273(47):31442–8

Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. Suto K, et al. **J Cancer Res Clin Oncol** 1999; 125(2):83–8

CHEMISTRY

Biochemical characterization and crystal structure determination of human heart short chain L-3-hydroxyacyl-CoA dehydrogenase provide insights into catalytic mechanism. Barycki JJ, et al. **Biochemistry** 1999 May 4;38(18):5786-98

Interchange of catalytic activity within the 2-enoyl-coenzyme A hydratase/isomerase superfamily based on a common active site template. Xiang H, et al. **Biochemistry** 1999 Jun 15;38(24):7638-52

Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. He XY, et al. **J Biol Chem** 1999 May 21; 274(21):15014-9

Structural organization of the human short-chain L-3-hydroxyacyl-CoA dehydrogenase gene. Vredendaal PJ, et al. **Mamm Genome** 1998 Sep;9(9):763-8

DEFICIENCY

Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Tyni T, et al. **Acta Paediatr** 1999 Mar;88(3):237-45 (66 ref.)

Long-chain L 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency does not appear to be the primary cause of lipid myopathy in patients with Bannayan-Riley-Ruvalcaba syndrome (BRRS). Otto LR, et al. **Am J Med Genet** 1999 Mar 5;83(1):3-5

Clinical and biochemical features of fatty acid oxidation disorders. Rinaldo P, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):615-21 (48 ref.)

Prenatal diagnosis of peroxisomal D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency. Suzuki Y, et al. **J Hum Genet** 1999;44(3):143-7

Determination of total fatty acids in plasma: cis-5-tetradecenoic acid (C14:1 omega-9) in the diagnosis of long-chain fatty acid oxidation defects. Divry P, et al. **J Inherit Metab Dis** 1999 May;22(3):286-8

Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). A case report and survey. Gillingham M, et al. **J Inherit Metab Dis** 1999 Apr; 22(2):123-31

Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Harding CO, et al. **J Inherit Metab Dis** 1999 May;22(3):276-80

Fatty acid oxidation in fibroblasts from patients with defects in beta-oxidation and in the respiratory chain. Venizelos N, et al. **J Inherit Metab Dis** 1998 Jun;21(4):409-15

HELLP syndrome [letter; comment] Buist NR, et al. **JAMA** 1999 Feb 24;281(8):704-5. Comment on: JAMA 1998 Aug 12;280(6):559-62.

Long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency neuropathy: response to cod liver oil. Tein I, et al. **Neurology** 1999 Feb;52(3):640-3

Fatal hepatic short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: clinical, biochemical, and pathological studies on three subjects with this recently identified disorder of mitochondrial beta-oxidation. Bennett MJ, et al. **Pediatr Dev Pathol** 1999 Jul-Aug; 2(4):337-45

Diagnosis of mitochondrial trifunctional protein deficiency in a blood spot from the newborn screening card by tandem mass spectrometry and DNA analysis. Matern D, et al. **Pediatr Res** 1999 Jul;46(1):45-9

Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Strauss AW, et al. **Semin Perinatol** 1999 Apr;23(2):100-12 (55 ref.)

GENETICS

Cloning of an L-3-hydroxyacyl-CoA dehydrogenase that interacts with the GLUT4 C-terminus. Shi Y, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):323-32

Identity of heart and liver L-3-hydroxyacyl coenzyme A dehydrogenase. He XY, et al. **Biochim Biophys Acta** 1999 Feb 25;1437(2):119-23

Orphan nuclear hormone receptor RevErbalpha modulates expression from the promoter of the hydratase-dehydrogenase gene by inhibiting peroxisome proliferator-activated receptor alpha-dependent transactivation. Kassam A, et al. **J Biol Chem** 1999 Aug 6;274(32):22895-900

Absence of spontaneous peroxisome proliferation in enoyl-CoA Hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver. Further support for the role of fatty acyl CoA oxidase in PPARalpha ligand metabolism. Qi C, et al. **J Biol Chem** 1999 May 28; 274(22):15775-80

Structural organization of the human short-chain L-3-hydroxyacyl-CoA dehydrogenase gene. Vredendaal PJ, et al. **Mamm Genome** 1998 Sep;9(9):763-8

METABOLISM

Cloning of an L-3-hydroxyacyl-CoA dehydrogenase that interacts with the GLUT4 C-terminus. Shi Y, et al. **Arch Biochem Biophys** 1999 Mar 15;363(2):323-32

Peroxisomal Delta3-cis-Delta2-trans-enoyl-CoA isomerase encoded by ECI1 is required for growth of the yeast Saccharomyces cerevisiae on unsaturated fatty acids. Gurvitz A, et al. **J Biol Chem** 1998 Nov 20; 273(47):31366-74

Role of ERAB/L-3-hydroxyacyl-coenzyme A dehydrogenase type II activity in Abeta-induced cytotoxicity. Yan SD, et al. **J Biol Chem** 1999 Jan 22; 274(4):2145-56

Bifunctional protein deficiency: complementation within the same group suggesting differential enzyme defects and clues to the underlying basis. Van Grunsven EG, et al. **J Inherit Metab Dis** 1998 Jun;21(3):298-301

Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. de Launoit Y, et al. **J Mol Endocrinol** 1999 Jun;22(3):227-40 (110 ref.)

3-HYDROXYACYL COA HYDROLYASES see **ENOYL-COA HYDRATASE**

3-HYDROXYACYL DEHYDRATASES see **ENOYL-COA HYDRATASE**

S-HYDROXYALKYL GLUTATHIONE LYASE see **GLUTATHIONE TRANSFERASE**

4-HYDROXYAMINOQUINOLINE-1-OXIDE

CHEMISTRY

Enzymatic and nonenzymatic production of free radicals from the carcinogens 4-nitroquinoline N-oxide and 4-hydroxylaminoquinoline N-oxide. Fann YC, et al. **Chem Res Toxicol** 1999 May;12(5):450-8

4-HYDROXYAMINOQUINOLINE-N-OXIDE see **4-HYDROXYAMINOQUINOLINE-1-OXIDE**

P-HYDROXYAMPHETAMINE

THERAPEUTIC USE

The clinical efficacy of paremyd with and without dapiprazole in subjects with light and dark brown irides. Anicho UM, et al. **Optom Vis Sci** 1999 Feb;76(2):94-101

HYDROXYAMPICILLIN see **AMOXICILLIN**

HYDROXYANDROSTANES see **ANDROSTANOLS**

HYDROXYANDROSTENES see **ANDROSTENOLS**

HYDROXYANILINES see **AMINOPHENOLS**

3-HYDROXYANTHRANILIC ACID

ANALOGS & DERIVATIVES

Effects of the 3-hydroxyanthranilic acid analogue NCR-631 on anoxia-, IL-1 beta- and LPS-induced hippocampal pyramidal cell loss in vitro. Luthman J, et al. **Amino Acids** 1998;14(1-3):263-9

HYDROXYAPATITE see **DURAPATITE**

HYDROXYAPATITES

Radiation sterilization of a bifunctional cement formulation of hydroxilapatite-plaster-polymers. Sainz Vidal D, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:64-70

Hydroxyapatite coating versus cemented fixation of the tibial component in total knee arthroplasty: prospective randomized comparison of hydroxyapatite-coated and cemented tibial components with 5-year follow-up using radiostereometry. Nilsson KG, et al. **J Arthroplasty** 1999 Jan;14(1):9-20

The cement setting reaction in the CaHPO4-alpha-Ca3(PO4)2 system: an X-ray diffraction study. Fernández E, et al. **J Biomed Mater Res** 1998 Dec 5;42(3):403-6

Prostaglandin E1 and recombinant bone morphogenetic protein effect on strength of hydroxyapatite implants. Ono I, et al. **J Biomed Mater Res** 1999 Jun 15;45(4):337-44

The effect of hydroxyapatite coating on the bonding of bone to titanium implants in the femora of ovariectomised rats. Hara T, et al. **J Bone Joint Surg Br** 1999 Jul;81(4):705-9

Hydroxyapatite augmentation of the porous coating improves fixation of tibial components [letter; comment] Nelissen RG, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):368-9. Comment on: J Bone Joint Surg Br 1998 May;80(3):417-25.

The influence of crystallinity of the hydroxyapatite coating on the fixation of implants. Mechanical and histomorphometric results. Overgaard S, et al. **J Bone Joint Surg Br** 1999 Jul;81(4):725-31

Hydroxyapatite-coated femoral stems. Histology and histomorphometry around five components retrieved at post mortem. Tonino AJ, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):148-54

Augmentation of distal radius fracture fixation with coralline hydroxyapatite bone graft substitute. Wolfe SW, et al. **J Hand Surg [Am]** 1999 Jul;24(4):816-27

Correlation between hydroxyapatite osseointegration and Young's Modulus. Jallot E. **Med Eng Phys** 1998 Nov-Dec; 20(9):697-701

Treatment of the postenucleation socket syndrome with a new hydroxyapatite tricalcium phosphate ceramic implant. Adenis JP, et al. **Ophthal Plast Reconstr Surg** 1999 Jul; 15(4):277-83

A method of cranioplasty using coralline hydroxyapatite. Choi SH, et al. **Pediatr Neurosurg** 1998 Dec;29(6):324-7

Anterior interbody fusion of the cervical spine with coralline hydroxyapatite. Thalgott JS, et al. **Spine** 1999 Jul 1; 24(13):1295-9

[Ocular socket plasty with orbital implant of hydroxyapatite] He Q, et al. **Chung Hua Yen Ko Tsa Chih** 1997 May; 33(3):219-21 (Eng. Abstr.) **(Chi)**

[Processing of ceramiclike xenogeneic bone and experimental study of its bone formation from composite graft combined with bone marrow] Li Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):94-8 (Eng. Abstr.) **(Chi)**

[Clinical study of bioactive glass ceramics as orbital implants] Xu X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(5):440-2 (Eng. Abstr.) **(Chi)**

[Secondary reconstruction of anophthalmic orbits by intraorbital biomaterial implantation] Adenis JP, et al. **J Fr Ophtalmol** 1999 Mar;22(2):269-73 (Eng. Abstr.) **(Fre)**

[Long-term radiologic evolution of coral implanted in cancellous bone of the lower limb. Madreporic coral versus coral hydroxyapatite] de la Caffinière JY, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Oct; 84(6):501-7 (Eng. Abstr.) **(Fre)**

[Substance-technical and optical studies of test bodies of hydroxylapatite ceramics] Reichel A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:414-5 **(Ger)**

ADMINISTRATION & DOSAGE

Changes in articular synovial lining volume measured by magnetic resonance in a randomized, double-blind, controlled trial of intra-articular samarium-153 particulate hydroxyapatite for chronic knee synovitis. Clunie GP, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):113-7

CHEMISTRY

The influence of anionic chitin derivatives on calcium phosphate crystallization. Andrew CA, et al. **Biomaterials** 1998 Jul;19(14):1309-16

Physicochemical properties of calcium phosphate coatings produced by pulsed laser deposition at different water vapour pressures. Arias JL, et al. **Biomaterials** 1998 May; 19(10):883-8

Critical ageing of hydroxyapatite sol-gel solutions. Chai CS, et al. **Biomaterials** 1998 Dec;19(24):2291-6

Surface modification of nano-apatite by grafting organic polymer. Liu Q, et al. **Biomaterials** 1998 Jun; 19(11-12):1067-72

Hydroxyapatite-polyethylene composites for bone substitution: effects of ceramic particle size and morphology. Wang M, et al. **Biomaterials** 1998 Dec; 19(24):2357-66

Ultrastructural study of apatite precipitation in implanted calcium phosphate ceramic: influence of the implantation site. Rohanizadeh R, et al. **Calcif Tissue Int** 1999 May; 64(5):430-6

Structure-function relationships for coralline hydroxyapatite bone substitute. Haddock SM, et al. **J Biomed Mater Res** 1999 Oct;47(1):71-8

Hydrophobicity, surface tension, and zeta potential measurements of glass-reinforced hydroxyapatite composites. Lopes MA, et al. **J Biomed Mater Res** 1999 Jun 15;45(4):370-5

Polymethylmethacrylate-based bone cement modified with hydroxyapatite. Vallo CI, et al. **J Biomed Mater Res** 1999; 48(2):150-8

Preparation and properties of inhomogeneous hydroxyapatite ceramics. Zyman ZZ, et al. **J Biomed Mater Res** 1999 Aug; 46(2):135-40

La ions in precipitated hydroxyapatites. Mayer I, et al. **J Inorg Biochem** 1999 Apr;73(4):221-6

METABOLISM

Inorganic phase composition of remineralisation in porous CaP ceramics. Zyman Z, et al. **Biomaterials** 1998 Jul; 19(14):1269-73

A streptococcal adhesion system for salivary pellicle and platelets. Gong K, et al. **Infect Immun** 1998 Nov; 66(11):5388-92

PHARMACOLOGY

Hydroxyapatite coated with insulin-like growth factor I (IGF1) stimulates human osteoblast activity in vitro. Zambonin G, et al. **Acta Orthop Scand** 1999 Apr; 70(2):217-20

Structural and functional macrophages alterations by ceramics of different composition. Bosetti M, et al. **Biomaterials** 1999 Feb;20(4):363-70

Cell culture approach to biocompatibility evaluation of unconventionally prepared hydroxyapatite. Kundu PK, et al. **Med Biol Eng Comput** 1998 Sep;36(5):654-8

Use of a hydroxylapatite-based material and calcium sulfate as artificial floors to repair furcal perforations. Alhadainy

HYDROXYAPATITES

HA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998 Dec;86(6):723–9

THERAPEUTIC USE

Double blind glucocorticoid controlled trial of samarium–153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis. O'Duffy EK, et al.
Ann Rheum Dis 1999 Sep;58(9):554–8

Chromosomal analysis of peripheral lymphocytes of patients before and after radiation synovectomy with samarium–153 particulate hydroxyapatite. O'Duffy EK, et al.
Rheumatology (Oxford) 1999 Apr;38(4):316–20

Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite–tricalcium phosphate after laminectomy in the nonhuman primate. Boden SD, et al.
Spine 1999 Jun 15;24(12):1179–85

P-HYDROXYBENZOATE HYDROXYLASE see **4-HYDROXYBENZOATE-3-MONOOXYGENASE**

4-HYDROXYBENZOATE-3-MONOOXYGENASE

CHEMISTRY

Use of free energy relationships to probe the individual steps of hydroxylation of p–hydroxybenzoate hydroxylase: studies with a series of 8–substituted flavins. Ortiz–Maldonado M, et al. **Biochemistry** 1999 Jun 22; 38(25):8124–37

Substrate recognition by "password" in p–hydroxybenzoate hydroxylase. Palfey BA, et al. **Biochemistry** 1999 Jan 26; 38(4):1153–8

Switch of coenzyme specificity of p–hydroxybenzoate hydroxylase. Eppink MH, et al. **J Mol Biol** 1999 Sep 10; 292(1):87–96

METABOLISM

Mechanistic insights into p–hydroxybenzoate hydroxylase from studies of the mutant Ser212Ala. Moran GR, et al. **Biochemistry** 1999 May 11;38(19):6292–9

Substrate recognition by "password" in p–hydroxybenzoate hydroxylase. Palfey BA, et al. **Biochemistry** 1999 Jan 26; 38(4):1153–8

Phe161 and Arg166 variants of p–hydroxybenzoate hydroxylase. Implications for NADPH recognition and structural stability. Eppink MH, et al. **FEBS Lett** 1999 Jan 29;443(3):251–5

HYDROXYBENZOIC ACIDS

ADMINISTRATION & DOSAGE

Lifibrol enhances the low density lipoprotein apolipoprotein B–100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Winkler K, et al. **Atherosclerosis** 1999 May;144(1):167–75

Oral low–molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. Salartash K, et al. **J Vasc Surg** 1999 Sep;30(3):526–31

ADVERSE EFFECTS

Occupational contact allergy to nifuroxazide simulating prurigo nodularis. Kieć–Swierczyńska M, et al.
Contact Dermatitis 1998 Aug;39(2):93–4

ANALYSIS

LC/MS analysis of hydroxylation products of salicylate as an indicator of in vivo oxidative stress. Tabatabaei AR, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):1054–8

Simultaneous measurement of monoamines, their metabolites and 2,3– and 2,5–dihydroxybenzoates by high–performance liquid chromatography with electrochemical detection. Application to rat brain dialysates. Duine JM, et al.
J Chromatogr B Biomed Sci Appl 1998 Sep 25; 716(1–2):350–3

Assay of acetylsalicylic acid and three of its metabolites in human plasma and urine using non–aqueous capillary electrophoresis with reversed electroosmotic flow. Hansen SH, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):1155–60

CHEMICAL SYNTHESIS

Synthesis and anti–human immunodeficiency virus type 1 integrase activity of hydroxybenzoic and hydroxycinnamic acid flavon–3–yl esters. Desideri N, et al.
Antivir Chem Chemother 1998 Nov;9(6):497–509

CHEMISTRY

Iron–binding catechols oxidating lignin and chlorolignin. Parra C, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):399–402

Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP–dependent protein kinase. Narayana N, et al.
Biochemistry 1999 Feb 23;38(8):2367–76

Characteristics and occurrence of phenolic phytochemicals. King A, et al. **J Am Diet Assoc** 1999 Feb;99(2):213–8 (42 ref.)

Detection of siderophore production from several fungi and bacteria by a modification of chrome azurol S (CAS) agar plate assay. Milagres AM, et al. **J Microbiol Methods** 1999 Jul;37(1):1–6

Comparison of the properties of polymeric and C8 based materials for solid phase extraction. Martin P, et al.
J Pharm Biomed Anal 1998 Sep 1;17(6–7):1093–100

IMMUNOLOGY

An improved method for the production of antibodies to lipophilic carboxylic hapten using small amount of hapten–carrier conjugate. Pauillac S, et al.
J Immunol Methods 1998 Nov 1;220(1–2):105–14

METABOLISM

Stability and DNA alkylation rates of the simplest functional analogues of CC–1065, para–hydroxy and para–amino phenethyl bromides. Shalders RL, et al.
Chem Biol Interact 1999 Jan 1;117(1):83–94

The siderophore 2,3–dihydroxybenzoic acid is not required for virulence of Brucella abortus in BALB/c mice. Bellaire BH, et al. **Infect Immun** 1999 May;67(5):2615–8

Interaction of Bacillus subtilis Fur (ferric uptake repressor) with the dhb operator in vitro and in vivo. Bsat N, et al.
J Bacteriol 1999 Jul;181(14):4299–307

The physiological contribution of Acinetobacter PcaK, a transport system that acts upon protocatechuate, can be masked by the overlapping specificity of VanK. D'Argenio DA, et al. **J Bacteriol** 1999 Jun;181(11):3505–15

Genetic analysis of a chromosomal region containing vanA and vanB, genes required for conversion of either ferulate or vanillate to protocatechuate in Acinetobacter. Segura A, et al. **J Bacteriol** 1999 Jun;181(11):3494–504

PcaR–mediated activation and repression of pca genes from Pseudomonas putida are propagated by its binding to both the –35 and the –10 promoter elements. Guo Z, et al.
Mol Microbiol 1999 Apr;32(2):253–63

PHARMACOKINETICS

The chemistry and biological effects of flavonoids and phenolic acids. Croft KD. **Ann N Y Acad Sci** 1998 Nov 20;854:435–42 (41 ref.)

PHARMACOLOGY

Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. Curto EV, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):663–72

Antimycobacterial activity of lichen metabolites in vitro. Ingólfsdóttir K, et al. **Eur J Pharm Sci** 1998 Apr;6(2):141–4

Salicylate promotes myeloperoxidase–initiated LDL oxidation: antagonization by its metabolite gentisic acid. Hermann M, et al. **Free Radic Biol Med** 1999 May; 26(9–10):1253–60

Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. Vega GL, et al.
J Intern Med 1999 Jul;246(1):1–9

Lichen metabolites. 2. Antiproliferative and cytotoxic activity of gyrophoric, usnic, and diffractaic acid on human keratinocyte growth. Kumar KC, et al. **J Nat Prod** 1999 Jun;62(6):821–3

Anti–inflammatory activity in rats and mice of phenolic acids isolated from Scrophularia frutescens. Fernández MA, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1183–6

Differential and selective inhibition of protein kinase A and protein kinase C in intact cells by balanol congeners. Gustafsson AB, et al. **Mol Pharmacol** 1999 Aug; 56(2):377–82

Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily. Setyawan J, et al. **Mol Pharmacol** 1999 Aug;56(2):370–6

Inhibition of chemiluminescence in human PMNs by monocyclic phenolic acids and flavonoids. Limasset B, et al. **Planta Med** 1999 Feb;65(1):23–9

Kelletinin A, from the marine mollusc Buccinulum corneum, promotes differentiation in Hydra vulgaris. De Petrocellis L, et al. **Res Commun Mol Pathol Pharmacol** 1999 Jan; 103(1):17–28

THERAPEUTIC USE

Effects of protocatechuic acid, S–methylmethanethiosulfonate or 5–hydroxy–4–(2–phenyl–(E)ethenyl)–2(5H)–furanone (KYN–54) on 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone–induced pulmonary carcinogenesis in mice. Mori H, et al.
Cancer Lett 1999 Jan 29;135(2):123–7

Antihepatotoxic activity of p–methoxy benzoic acid from Capparis spinosa. Gadgoli C, et al. **J Ethnopharmacol** 1999 Aug;66(2):187–92

[Comparative study of the evolution of inflammatory colitis treated with an elemental diet, glutamine and 5–ASA. An experimental study in rats] Biondo–Simões M de L, et al.
Arq Gastroenterol 1998 Apr–Jun;35(2):116–25 (Eng. Abstr.) **(Por)**

TOXICITY

Oxidative injury induced by synthetic humic acid polymer and monomer in cultured rabbit articular chondrocytes. Liang HJ, et al. **Life Sci** 1999;65(11):1163–73

4-HYDROXYBENZOIC ACIDS see **PARABENS**

HYDROXYBRAZILIN see **HEMATOXYLIN**

3-HYDROXYBUTYRATE see **3-HYDROXYBUTYRIC ACID**

HYDROXYBUTYRATE DEHYDROGENASE

BLOOD

[Increased CK, LDH and alpha–HBDH without myoglobin or CK–MB increase] Wieland E. **Internist (Berl)** 1999 Jan; 40(1):105–8 **(Ger)**

GENETICS

Poly–3–hydroxybutyrate degradation in Rhizobium (Sinorhizobium) meliloti: isolation and characterization of a gene encoding 3–hydroxybutyrate dehydrogenase. Aneja P, et al. **J Bacteriol** 1999 Feb;181(3):849–57

METABOLISM

Poly–3–hydroxybutyrate degradation in Rhizobium (Sinorhizobium) meliloti: isolation and characterization of a gene encoding 3–hydroxybutyrate dehydrogenase. Aneja P, et al. **J Bacteriol** 1999 Feb;181(3):849–57

Neurochemical and electrophysiological evidence for the existence of a functional gamma–hydroxybutyrate system in NCB–20 neurons. Kemmel V, et al. **Neuroscience** 1998 Oct;86(3):989–1000

4-HYDROXYBUTYRATE SODIUM see **SODIUM OXYBATE**

HYDROXYBUTYRATES

A new resorbable wrap–around implant as an alternative nerve repair technique. Hazari A, et al.
J Hand Surg [Br] 1999 Jun;24(3):291–5

Neuronal survival using a resorbable synthetic conduit as an alternative to primary nerve repair. Ljungberg C, et al. **Microsurgery** 1999;19(6):259–64

[Roentgen contrasting of resorbable biomaterials PHB and PLA] Michalik I, et al. **Biomed Tech (Berl)** 1998;43 Suppl:426–7 **(Ger)**

[The hemostasis system as an indicator of hemocompatibility of implant materials] Zinner G, et al.
Biomed Tech (Berl) 1998;43 Suppl:432–3 **(Ger)**

ADMINISTRATION & DOSAGE

Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Qi Z, et al. **Scand J Immunol** 1998 Oct; 48(4):379–88

ADVERSE EFFECTS

A case of gamma–hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Addolorato G, et al.
Clin Neuropharmacol 1999 Jan–Feb;22(1):60–2

Gamma–hydroxybutyric acid: an endogenous neuromodulator with abuse potential? Bernasconi R, et al.
Trends Pharmacol Sci 1999 Apr;20(4):135–41

ANALYSIS

Poly–3–hydroxybutyrate in Legionella pneumophila, an energy source for survival in low–nutrient environments. James BW, et al. **Appl Environ Microbiol** 1999 Feb; 65(2):822–7

Quantification of bacterial polyhydroxyalkanoic acids by Nile red staining. Gorenflo V, et al.
Appl Microbiol Biotechnol 1999 Jun;51(6):765–72

Determination of polyhydroxyalkanoates in activated sludge by ion chromatographic and enzymatic methods. Hesselmann RP, et al. **J Microbiol Methods** 1999 Mar; 35(2):111–9

CHEMICAL SYNTHESIS

Chiral alcohol synthesis with microbial carbonyl reductases in a water–organic solvent two–phase system. Shimizu S, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:87–95

Cloning of the Alcaligenes latus polyhydroxyalkanoate biosynthesis genes and use of these genes for enhanced production of Poly(3–hydroxybutyrate) in Escherichia coli. Choi JI, et al. **Appl Environ Microbiol** 1998 Dec; 64(12):4897–903

Ring–opening polymerisation of beta–butyrolactone catalysed by distannoxane complexes: study of the mechanism. Hori Y, et al. **Int J Biol Macromol** 1999 Jun–Jul;25(1–3):237–45

Novel synthesis of functionalized poly(3–hydroxybutanoic acid) and its copolymers. Jedliński Z, et al.
Int J Biol Macromol 1999 Jun–Jul;25(1–3):247–53

CHEMISTRY

Crystallization behavior and thermal properties of melt-crystallized poly[(R)-3-hydroxybutyric acid-co-6-hydroxyhexanoic acid] films. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):177-83

Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):185-92 (52 ref.)

Structure and enzymatic degradation of poly(3-hydroxybutyrate) copolymer single crystals with an extracellular PHB depolymerase from Alcaligenes faecalis T1. Iwata T, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):169-76

Properties and biodegradability of ultra-high-molecular-weight poly[(R)-hydroxybutyrate] produced by a recombinant Escherichia coli. Kusaka S, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):87-94

Chemical composition distribution of bacterial copolyesters. Yoshie N, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):193-200 (54 ref.)

ISOLATION & PURIFICATION

Removal of endotoxin during purification of poly(3-hydroxybutyrate) from gram-negative bacteria. Lee SY, et al. **Appl Environ Microbiol** 1999 Jun;65(6):2762-4

Efficient and economical recovery of poly(3-hydroxybutyrate) from recombinant Escherichia coli by simple digestion with chemicals. Choi J, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):546-53

Aqueous release and purification of poly(beta-hydroxybutyrate) from Escherichia coli. Resch S, et al. **J Biotechnol** 1998 Oct 27;65(2-3):173-82

METABOLISM

Methylobacterium extorquens strain P14, a new methylotrophic bacteria producing poly-beta-hydroxybutyrate (PHB). Ostafin M, et al. **Acta Microbiol Pol** 1999;48(1):39-51

Genetic analysis of Comamonas acidovorans polyhydroxyalkanoate synthase and factors affecting the incorporation of 4-hydroxybutyrate monomer. Sudesh K, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3437-43

Efficient and economical recovery of poly(3-hydroxybutyrate) from recombinant Escherichia coli by simple digestion with chemicals. Choi J, et al. **Biotechnol Bioeng** 1999 Mar 5;62(5):546-53

Metabolic modeling of polyhydroxybutyrate biosynthesis. Leaf TA, et al. **Biotechnol Bioeng** 1998 Mar 5;57(5):557-70

High cell density culture of metabolically engineered Escherichia coli for the production of poly(3-hydroxybutyrate) in a defined medium. Wang F, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):325-8

Photosynthetic accumulation of poly-(hydroxybutyrate) by cyanobacteria--the metabolism and potential for CO2 recycling. Asada Y, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):37-42 (21 ref.)

Structure and enzymatic degradation of poly(3-hydroxybutyrate) copolymer single crystals with an extracellular PHB depolymerase from Alcaligenes faecalis T1. Iwata T, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):169-76

Production of two phase polyhydroxyalkanoic acid granules in Ralstonia eutropha. Kelley AS, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):61-7

Properties and biodegradability of ultra-high-molecular-weight poly[(R)-hydroxybutyrate] produced by a recombinant Escherichia coli. Kusaka S, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):87-94

Recent advances in polyhydroxyalkanoate production by bacterial fermentation: mini-review. Lee SY, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):31-6 (46 ref.)

Extracellular polymerization of 3-hydroxyalkanoate monomers with the polymerase of Alcaligenes eutrophus. Lenz RW, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):55-60

Chain termination in polyhydroxyalkanoate synthesis: involvement of exogenous hydroxy-compounds as chain transfer agents. Madden LA, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):43-53

Production of poly(3-hydroxybutyrate) and its copolymer poly(3-hydroxybutyrate-co-3-hydroxyvalerate) by Erwinia sp. USMI-20. Majid MI, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):95-104

Hydrolysis of native poly(hydroxybutyrate) granules (PHB), crystalline PHB, and artificial amorphous PHB granules by intracellular and extracellular depolymerases. Merrick JM, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):129-34

Chemical composition distribution of bacterial copolyesters. Yoshie N, et al. **Int J Biol Macromol** 1999 Jun-Jul; 25(1-3):193-200 (54 ref.)

Poly-3-hydroxybutyrate degradation in Rhizobium (Sinorhizobium) meliloti: isolation and characterization of a gene encoding 3-hydroxybutyrate dehydrogenase. Aneja P, et al. **J Bacteriol** 1999 Feb;181(3):849-57

Analyses of a polyhydroxyalkanoic acid granule-associated 16-kilodalton protein and its putative regulator in the pha locus of Paracoccus denitrificans. Maehara A, et al. **J Bacteriol** 1999 May;181(9):2914-21

Cloning and molecular analysis of the Poly(3-hydroxybutyrate) and Poly(3-hydroxybutyrate-co-3-hydroxyalkanoate) biosynthesis genes in Pseudomonas sp. strain 61-3. Matsusaki H, et al. **J Bacteriol** 1998 Dec;180(24):6459-67

Molecular cloning, sequencing and expression in Escherichia coli of the poly(3-hydroxyalkanoate) synthesis genes from Alcaligenes latus DSM1124. Genser KF, et al. **J Biotechnol** 1998 Oct 8;64(2-3):125-35

Dynamics and modeling on fermentative production of poly (beta-hydroxybutyric acid) from sugars via lactate by a mixed culture of Lactobacillus delbrueckii and Alcaligenes eutrophus. Katoh T, et al. **J Biotechnol** 1999 Jan 22; 67(2-3):113-34

Gating kinetics of E. coli poly-3-hydroxybutyrate/polyphosphate channels in planar bilayer membranes. Das S, et al. **J Membr Biol** 1999 Jul 15;170(2):135-45

Polyphosphate/poly-(R)-3-hydroxybutyrate) ion channels in cell membranes. Reusch RN. **Prog Mol Subcell Biol** 1999; 23:151-82 (101 ref.)

Polyhydroxybutyrate: plastic made and degraded by microorganisms. Hankermeyer CR, et al. **Rev Environ Contam Toxicol** 1999;159:1-24 (37 ref.)

PHARMACOKINETICS

Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers. Abe H, et al. **Int J Biol Macromol** 1999 Jun-Jul;25(1-3):185-92 (52 ref.)

[Effect of softening agents on biodegradation and biocompatibility of poly-beta-hydroxybutyric acid in vivo] Behrend D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:430-1 **(Ger)**

[Comparative studies of the degradation kinetics and effect on mechanical properties of polylactide and polyhydroxybutyric acid in vitro] Lootz D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:428-9 **(Ger)**

PHARMACOLOGY

Gamma-hydroxybutyric acid reducing effect on ethanol intake: evidence in favour of a substitution mechanism. Agabio R, et al. **Alcohol Alcohol** 1998 Sep-Oct;33(5):465-74

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Bruneau JM, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):299-303

Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide. Mirmohammadsadegh A, et al. **Biochem Pharmacol** 1998 May 1;55(9):1523-9

A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Hamilton LC, et al. **Br J Pharmacol** 1999 Aug;127(7):1589-96

Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Ferrara SD, et al. **Eur J Clin Pharmacol** 1999 Jan;54(11):821-7

Intravenous self-administration of gamma-hydroxybutyric acid in drug-naive mice. Martellotta MC, et al. **Eur Neuropsychopharmacol** 1998 Dec;8(4):293-6

Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Slauson SD, et al. **Immunol Lett** 1999 Apr 15;67(3):179-83

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. Manna SK, et al. **J Immunol** 1999 Feb 15;162(4):2095-102

[Gamma-hydroxybutyric acid or "liquid ecstasy": a poisoning to come? (editorial)] Dueñas Laita A. **Med Clin (Barc)** 1998 Oct 17;111(12):458-60 (36 ref.) **(Spa)**

POISONING

Toxic ingestion of gamma-hydroxybutyric acid. Viera AJ, et al. **South Med J** 1999 Apr;92(4):404-5

THERAPEUTIC USE

The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Poldrugo F, et al. **Alcohol Alcohol** 1999 Jan-Feb;34(1):15-24 (113 ref.)

Treatment of alcoholic fatty liver: is the metabolic effect of metadoxine the only reason for improved liver function? [letter; comment] Stefanini GF, et al. **J Hepatol** 1999 Apr; 30(4):739-40. Comment on: J Hepatol 1998 Jan;28(1):54-60.

Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide. Stosic-Grujicic S, et al. **Transplant Proc** 1998 Dec;30(8):4132-3

URINE

Two exon-skipping mutations as the molecular basis of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Chambliss KL, et al. **Am J Hum Genet** 1998 Aug;63(2):399-408

Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism. Hecht SS, et al. **Chem Res Toxicol** 1999 Feb;12(2):172-9

Stereoselective metabolism of nicotine and tobacco-specific N-nitrosamines to 4-hydroxy-4-(3-pyridyl)butanoic acid in rats. Trushin N, et al. **Chem Res Toxicol** 1999 Feb; 12(2):164-71

Rapid screening test for gamma-hydroxybutyric acid (GHB, Fantasy) in urine [letter] Badcock NR, et al. **Ther Drug Monit** 1999 Jun;21(3):376

3-HYDROXYBUTYRIC ACID

ANALOGS & DERIVATIVES

Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein. Poenaru S, et al. **J Med Chem** 1999 Jul 1; 42(13):2318-31

ANALYSIS

In vivo lactate and beta-hydroxybutyrate editing using a pure-phase refocusing pulse train. Shen J, et al. **Magn Reson Med** 1998 Nov;40(5):783-8

BLOOD

Serum beta-hydroxybutyrate measurement in patients with uncontrolled diabetes mellitus. Fulop M, et al. **Arch Intern Med** 1999 Feb 22;159(4):381-4

Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Boden G, et al. **Diabetes** 1999 Mar;48(3):577-83

The Diabetes in Early Pregnancy Study: beta-hydroxybutyrate levels in type 1 diabetic pregnancy compared with normal pregnancy. NICHD-Diabetes in Early Pregnancy Study Group (DIEP). National Institute of Child Health and Development. Jovanovic L, et al. **Diabetes Care** 1998 Nov;21(11):1978-84

Effect of diet on plasma triglycerides, cholesterol, beta-hydroxybutyrate and free fatty acids in cats. Dobenecker B, et al. **J Nutr** 1998 Dec;128(12 Suppl):2648S-2650S

A predominant increase of arterial beta-hydroxybutyrate concentration during partial hepatectomies in patients with impaired indocyanine green clearance test. Higashi S, et al. **J Surg Res** 1999 Feb;81(2):243-8

Relations between plasma acetate, 3-hydroxybutyrate, FFA, glucose levels and energy nutrition in lactating dairy cows. Sato H, et al. **J Vet Med Sci** 1999 May;61(5):447-51

Use of metabolic profiles in dairy cattle in tropical and subtropical countries on smallholder dairy farms. Whitaker DA, et al. **Prev Vet Med** 1999 Jan 27;38(2-3):119-31

Differences between blood and plasma concentrations of acetate, beta-hydroxybutyrate, glucose, ammonia and urea: implications for measurement of portal net fluxes in ewes. Nozière P, et al. **Reprod Nutr Dev** 1998 Sep-Oct; 38(5):509-18

Evaluation of beta-oxidation parameters and mitochondrial redox state as early markers of hepatic function in hepatic transplantation. Igea J, et al. **Transplant Proc** 1999 Sep; 31(6):2441-2

Beta-hydroxybutyrate levels in peripheral blood and ketone bodies supplemented in culture media affect the in vitro chemotaxis of bovine leukocytes. Suriyasathaporn W, et al. **Vet Immunol Immunopathol** 1999 May;68(2-4):177-86

[Changes in intraoperative blood glucose and ketone body concentrations during the repair of lipomyelomeningocele in children] Nonogaki M, et al. **Masui** 1998 Oct; 47(10):1226-8 (Eng. Abstr.) **(Jpn)**

CHEMICAL SYNTHESIS

Gene dosage effects on polyhydroxyalkanoates synthesis from n-alcohols in Paracoccus denitrificans. Maehara A, et al. **Biotechnol Bioeng** 1998 Oct 5;60(1):61-9

Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein. Poenaru S, et al. **J Med Chem** 1999 Jul 1; 42(13):2318-31

METABOLISM

Production of poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid) and poly(4-hydroxybutyric acid) without subsequent degradation by Hydrogenophaga pseudoflava. Choi MH, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1570-7

Accumulation of poly (3-hydroxybutyric acid) by some soil Streptomyces. Manna A, et al. **Curr Microbiol** 1999 Sep; 39(3):153-8

Intramuscular 3-hydroxybutyrate levels after 60 tetani/min contraction in diabetic and non-diabetic rats. Oshida Y, et al. **Endocr J** 1998 Jun;45(3):363-70

Effect of hypocalcaemia on glucose metabolism in hyperketonaemic piglets. Schlumbohm C, et al. **Exp Physiol** 1999 Jul;84(4):707-23

In vitro synthesis of poly(3-hydroxybutyric acid) by using an enzymatic coenzyme A recycling system. Jossek R, et al. **FEMS Microbiol Lett** 1998 Nov 15;168(2):319-24

Fatal hepatic short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: clinical, biochemical, and

pathological studies on three subjects with this recently identified disorder of mitochondrial beta-oxidation. Bennett MJ, et al. **Pediatr Dev Pathol** 1999 Jul-Aug; 2(4):337-45

PHARMACOLOGY

Pathways of beta-hydroxybutyrate contribution to metabolism of acetyl-CoA and acetylcholine in rat brain nerve terminals. Tomaszewicz M, et al. **Folia Neuropathol** 1997;35(4):244-6

Acetoacetate and beta-hydroxybutyrate differentially regulate endothelin-1 and vascular endothelial growth factor in mouse brain microvascular endothelial cells. Isales CM, et al. **J Diabetes Complications** 1999 Mar-Apr; 13(2):91-7

In vitro effect of ketone bodies, glucocorticosteroids and bovine pregnancy-associated glycoprotein on cultures of bone marrow progenitor cells of cows and calves. Hoeben D, et al. **Vet Immunol Immunopathol** 1999 May; 68(2-4):229-40

4-HYDROXYBUTYRIC ACID LACTONE see **4-BUTYROLACTONE**

HYDROXYCARBAMID see **HYDROXYUREA**

HYDROXYCHLOROBENZENES see **CHLOROPHENOLS**

HYDROXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

HYDROXYCHLOROQUINE

ADMINISTRATION & DOSAGE

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension [see comments] Furst DE, et al. **Arthritis Rheum** 1999 Feb;42(2):357-65. Comment in: Arthritis Rheum 1999 Jul;42(7):1556.

Dose-loading with hydroxychloroquine in rheumatoid arthritis: comment on the article by Furst et al [letter; comment] Handler RP. **Arthritis Rheum** 1999 Jul;42(7):1556. Comment on: Arthritis Rheum 1999 Feb;42(2):357-65.

Dose-loading with hydroxychloroquine is effective in early and active rheumatoid arthritis. Emery P. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):399-400

Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. Ferraccioli G, et al. **J Rheumatol** 1998 Oct;25(10):1874-9

ADVERSE EFFECTS

Hydroxychloroquine-induced pruritus [letter] Holme SA, et al. **Acta Derm Venereol** 1999 Jul;79(4):333

Hydroxychloroquine retinopathy. Maturi RK, et al. **Arch Ophthalmol** 1999 Sep;117(9):1262-3

Acral keratotic graft versus host disease simulating warts. Kossard S, et al. **Australas J Dermatol** 1999 Aug; 40(3):161-3

Screening for hydroxychloroquine retinopathy. Screening should be selective [letter; comment] May K, et al. **BMJ** 1998 Nov 14;317(7169):1388-9. Comment on: BMJ 1998 Mar 7;316(7133):716-7.

Ototoxicity due to hydroxychloroquine: report of two cases. Johansen PB, et al. **Clin Exp Rheumatol** 1998 Jul-Aug; 16(4):472-4

Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Fielder A, et al. **Eye** 1998;12 (Pt 6):907-9

An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine [editorial] [see comments] Easterbrook M. **J Rheumatol** 1999 Sep; 26(9):1866-8. Comment in: J Rheumatol 1999 Sep;26(9):1868.

Hydroxychloroquine myopathy. Richards AJ. **J Rheumatol** 1998 Aug;25(8):1642-3

Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. Shojania K, et al. **J Rheumatol** 1999 Jan;26(1):195-6

[Discoloration of hair under the effect of hyroxychloroquine (letter)] Lecocq P, et al. **Presse Med** 1999 Apr 10; 28(14):741 **(Fre)**

PHARMACOLOGY

The in vitro effect of hydroxychloroquine on skin morphology in psoriasis. Wolf R, et al. **Int J Dermatol** 1999 Feb;38(2):154-7

Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Emami J, et al. **Life Sci** 1999;64(5):325-35

THERAPEUTIC USE

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Tishler M, et al. **Ann Rheum Dis** 1999 Apr; 58(4):253-6

Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Raoult D, et al. **Arch Intern Med** 1999 Jan 25;159(2):167-73

The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. Furst DE. **Clin Exp Rheumatol** 1999 Jan-Feb; 17(1):39-40 (2 ref.)

Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. Adams JS, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):799-801

Methotrexate nodulosis. Jang KA, et al. **J Dermatol** 1999 Jul;26(7):460-4

A rheumatologist's verdict on the safety of chloroquine versus hydroxychloroquine. Liability in off-label prescribing [editorial] [see comments] Houpt JB. **J Rheumatol** 1999 Sep;26(9):1864-6 (16 ref.). Comment in: J Rheumatol 1999 Sep;26(9):1868.

Discontinuation of antimalarial drugs in systemic lupus erythematosus. Wang C, et al. **J Rheumatol** 1999 Apr; 26(4):808-15

25-HYDROXYCHOLECALCIFEROL see **CALCIFEDIOL**

25-HYDROXYCHOLECALCIFEROL 1-HYDROXYLASE

ANTAGONISTS & INHIBITORS

Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Ly LH, et al. **Endocrinology** 1999 May;140(5):2071-6

DEFICIENCY

Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Wang JT, et al. **Am J Hum Genet** 1998 Dec; 63(6):1694-702

GENETICS

Capacity of a low calcium diet to induce the renal vitamin D 1a-hydroxylase is decreased in adult rats. Armbrecht HJ, et al. **Biochem Biophys Res Commun** 1999 Feb 24; 255(3):731-4

The importance of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene in vitamin D-dependent rickets. Kato S, et al. **Curr Opin Nephrol Hypertens** 1998 Jul; 7(4):377-83 (61 ref.)

Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Bland R, et al. **Endocrinology** 1999 May;140(5):2027-34

Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Murayama A, et al. **Endocrinology** 1999 May;140(5):2224-31

Cloning of porcine 25-hydroxyvitamin D3 1alpha-hydroxylase and its regulation by cAMP in LLC-PK1 cells. Yoshida T, et al. **J Am Soc Nephrol** 1999 May;10(5):963-70

Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type II [see comments] Yoshida T, et al. **Kidney Int** 1998 Nov; 54(5):1437-43. Comment in: Kidney Int 1998 Nov;54(5):1762-4.

Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Shinki T, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8253-8

ISOLATION & PURIFICATION

Molecular cloning of (25-OH D)-1 alpha-hydroxylase: an approach to the understanding of vitamin D pseudo-deficiency. Glorieux FH, et al. **Recent Prog Horm Res** 1998;53:341-9; discussion 350

METABOLISM

Enzymatic properties of mouse 25-hydroxyvitamin D3 1 alpha-hydroxylase expressed in Escherichia coli. Sakaki T, et al. **Eur J Biochem** 1999 Feb;259(3):731-8

HYDROXYCHOLECALCIFEROLS

ADMINISTRATION & DOSAGE

Calcium balance during pulse alfacalcidol therapy for secondary hyperparathyroidism in CAPD patients treated with 1.0 and 1.25 mmol/L dialysate calcium. Chagnac A, et al. **Am J Kidney Dis** 1999 Jan;33(1):82-6

Effect of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Huraib S, et al. **Am J Kidney Dis** 1998 Dec;32(6):1036-40

ADVERSE EFFECTS

[Do alpha-calcidol or calcitriol modify kidney function?] Lange H. **Dtsch Med Wochenschr** 1999 Jul 16; 124(28-29):881-2 **(Ger)**

BLOOD

Hypovitaminosis D in a sunny country [letter] Fuleihan GE, et al. **N Engl J Med** 1999 Jun 10;340(23):1840-1

CHEMISTRY

Improved and efficient synthesis of 1alpha-hydroxy-[6-(2)H] and 1alpha-hydroxy-[6,19,19-(2)H]vitamin D3 derivatives. Iwasaki H, et al. **Steroids** 1999 Jun;64(6):396-403

METABOLISM

Human keratinocyte line HaCaT metabolizes 1alpha-hydroxyvitamin D3 and vitamin D3 to 1alpha,25-dihydroxyvitamin D3 (calcitriol). Lehmann B, et al. **J Dermatol Sci** 1998 Nov;18(2):118-27

PHARMACOKINETICS

Sustained osteoblast nuclear receptor binding of converted 1alpha, 25-dihydroxyvitamin D3 after administration of 3H-1alpha-hydroxyvitamin D3: a combined receptor autoradiography and radioassay time course study with comparison to 3H-1alpha, 25-dihydroxyvitamin D3. Koike N, et al. **Calcif Tissue Int** 1998 Nov;63(5):391-5

PHARMACOLOGY

Prevention of osteopenia induced with a gonadotropin-releasing hormone agonist in rats. Sakamoto S, et al. **Calcif Tissue Int** 1999 Aug;65(2):152-5

Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Brandi L, et al. **J Intern Med** 1998 Aug;244(2):121-31

THERAPEUTIC USE

Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3. Gorai I, et al. **Calcif Tissue Int** 1999 Jul;65(1):16-22

Regression of massive tumoral calcinosis of the ischium in a dialysis patient after treatment with reduced calcium dialysate and i.v. administration. Apostolou T, et al. **Clin Nephrol** 1998 Oct;50(4):247-51

Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Iseki K, et al. **Int J Cancer** 1999 May 31;81(5):730-3

Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutic effects of estrogen and alfacalcidol in women with osteoporosis. Zhan Z, et al. **J Bone Miner Metab** 1999;17(2):113-8

Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson's disease. Sato Y, et al. **J Neurol Neurosurg Psychiatry** 1999 Jan;66(1):64-8

Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Reginster JY, et al. **Osteoporos Int** 1999; 9(1):75-81

[Effects of calcitriol and alfacalcidol on an osteoporosis model in rats with hepatic failure] Yamanishi A, et al. **Nippon Yakurigaku Zasshi** 1999 Jan;113(1):55-65 (Eng. Abstr.) **(Jpn)**

[Influence of alphacalcidole on selected markers of the bone turnover in hemodialysed patients with secondary hyperparathyroidism] Nowak Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):288-91 (Eng. Abstr.) **(Pol)**

HYDROXYCHOLESTANES see **CHOLESTANOLS**

HYDROXYCHOLESTEROLS

BLOOD

Determination of 7alpha-hydroxycholesterol in dog plasma by high-performance liquid chromatography with fluorescence detection. Saisho Y, et al. **Anal Biochem** 1998 Dec 15;265(2):361-7

Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Ziedén B, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr; 19(4):967-71

Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. Björkhem I, et al. **J Lipid Res** 1998 Aug;39(8):1594-600

Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. Del Puppo M, et al. **J Lipid Res** 1998 Dec;39(12):2477-82

CHEMICAL SYNTHESIS

An improved synthesis of (20R,22R)-cholest-5-ene-3beta,20,22-triol, an intermediate in steroid hormone formation and an activator of nuclear orphan receptor LXR alpha. Ruan B, et al. **Steroids** 1999 Jun;64(6):385-95

CHEMISTRY

Anomalous enantioselectivity in the sharpless asymmetric dihydroxylation reaction of 24-nor-5beta-cholest-23-ene-3alpha,7alpha,12alpha-triol: synthesis of substrates for studies of cholesterol side-chain oxidation. Ertel NH, et al. **Lipids** 1999 Apr;34(4):395-405

ISOLATION & PURIFICATION

[Studies on the isolation, structure identification and biological function of two tumor cell suppressors of human fetal liver origin] Zhang QL, et al. **Sheng Li Hsueh Pao** 1997 Jun;49(3):327-32 (Eng. Abstr.) **(Chi)**

METABOLISM

Hepatic and extrahepatic dehydrogenation/isomerization of 5-cholestene-3 beta,7 alpha-diol: localization of 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase in pig tissues and subcellular fractions. Furster C. **Biochim Biophys Acta** 1999 Jan 4;1436(3):343-53

Distribution of exogenous 25-hydroxycholesterol in Hep G2 cells between two different pools. Kisseleva AF, et al. **FEBS Lett** 1999 Mar 5;446(1):163-8

Oxysterols in cap and core of human advanced atherosclerotic lesions. Garcia-Cruset S, et al. **Free Radic Res** 1999 May;30(5):341-50

Oxysterol regulation of steroidogenic acute regulatory protein gene expression. Structural specificity and transcriptional and posttranscriptional actions. Christenson LK, et al. **J Biol Chem** 1998 Nov 13;273(46):30729-35

Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. Björkhem I, et al. **J Lipid Res** 1998 Aug;39(8):1594-600

27-hydroxycholesterol: production rates in normal human subjects. Duane WC, et al. **J Lipid Res** 1999 Jul; 40(7):1194-9

[Elimination of cholesterol in human endothelial cells] Xiu R, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):676-9 (Eng. Abstr.) **(Chi)**

[Effects of hydroxysterols on expression of inflammatory cytokine genes and their level in macrophages tolerant to endotoxin] Dushkin MI, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):71-4 **(Rus)**

PHARMACOLOGY

Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro. Moog C, et al. **Antivir Chem Chemother** 1998 Nov;9(6):491-6

Characterization and comparison of the mode of cell death, apoptosis versus necrosis, induced by 7beta-hydroxycholesterol and 7-ketocholesterol in the cells of the vascular wall. Lizard G, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1190-200

Cholesterol regulates oxysterol binding protein (OSBP) phosphorylation and Golgi localization in Chinese hamster ovary cells: correlation with stimulation of sphingomyelin synthesis by 25-hydroxycholesterol. Storey MK, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):247-56

Apoptosis induced by oxysterol in CEM cells is associated with negative regulation of c-myc. Ayala-Torres S, et al. **Exp Cell Res** 1999 Jan 10;246(1):193-202

Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-, 7beta-hydroxycholesterol, or 7-ketocholesterol. Lemaire S, et al. **FEBS Lett** 1998 Dec 4;440(3):434-9

Chinese hamster ovary cells overexpressing the oxysterol binding protein (OSBP) display enhanced synthesis of sphingomyelin in response to 25-hydroxycholesterol. Lagace TA, et al. **J Lipid Res** 1999 Jan;40(1):109-16

Alpha-tocopherol inhibits oxidative stress induced by cholestanetriol and 25-hydroxycholesterol in porcine ovarian granulosa cells. McCluskey S, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):217-25

TOXICITY

The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Kölsch H, et al. **Brain Res** 1999 Feb 6;818(1):171-5

HYDROXYCINNAMIC ACIDS see **COUMARIC ACIDS**

HYDROXYCOBALAMIN see **HYDROXOCOBALAMIN**

HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

17-HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

HYDROXYCORTICOSTEROIDS

THERAPEUTIC USE

Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome [letter] Baschetti R. **J Clin Endocrinol Metab** 1999 Jun;84(6):2263-4

11-HYDROXYCORTICOSTEROIDS

BLOOD

[Modification of the effects of microwave irradiation on biochemical processes by using foreign protein] Podkovkin VG, et al. **Radiats Biol Radioecol** 1998 Nov-Dec; 38(6):916-9 (Eng. Abstr.) **(Rus)**

11-HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

11-HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

17-HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

18-HYDROXYCORTICOSTERONE

PHARMACOLOGY

Dose-dependence of the effects of corticosterone and the non-glucocorticoid, 18-hydroxycorticosterone, on the brush-border Na+/K+ exchanger. Igarreta P, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):601-5

4-HYDROXYCOUMARINS

CHEMISTRY

[Free radical scavenging activity of 4-hydroxycoumarin derivatives] Kirkiacharian S, et al. **Ann Pharm Fr** 1999 May; 57(3):251-4 (Eng. Abstr.) **(Fre)**

POISONING

Brodifacoum [letter; comment] Gallo J. **Anaesth Intensive Care** 1998 Dec;26(6):708-9. Comment on: Anaesth Intensive Care 1997 Dec;25(6):707-9.

Pericardial effusion and cardiac tamponade secondary to brodifacoum toxicosis in a dog. Petrus DJ, et al. **J Am Vet Med Assoc** 1999 Sep 1;215(5):647-8

Fatal brodifacoum rodenticide poisoning: autopsy and toxicologic findings. Palmer RB, et al. **J Forensic Sci** 1999 Jul;44(4):851-5

Brodifacoum toxicity and treatment in a white-winged wood duck (Cairina scutulata). James SB, et al. **J Zoo Wildl Med** 1998 Sep;29(3):324-7

Successful donation and transplantation of multiple organs after fatal poisoning with brodifacoum, a long-acting anticoagulant rodenticide: case report. Ornstein DL, et al. **Transplantation** 1999 Feb 15;67(3):475-8

URINE

Detection of 4-hydroxycoumarin anticoagulants and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. Maurer HH, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 4;714(2):181-95

7-HYDROXYCOUMARINS see **UMBELLIFERONES**

HYDROXYDIAZEPAM see **TEMAZEPAM**

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN

ADMINISTRATION & DOSAGE

8-OH-DPAT in the median raphe nucleus decreases while in the medial septal area it may increase anxiety in female rats. De Almeida RM, et al. **Neurosci Biobehav Rev** 1998; 23(2):259-64

ADVERSE EFFECTS

8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. Chu TC, et al. **Exp Eye Res** 1999 Aug;69(2):227-38

ANALOGS & DERIVATIVES

In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors. Ahlenius S, et al. **Eur Neuropsychopharmacol** 1999 Jan;9(1-2):15-9

Differential discrimination of G-protein coupling of serotonin(1A) receptors from bovine hippocampus by an agonist and an antagonist. Harikumar KG, et al. **FEBS Lett** 1999 Sep 3;457(3):389-92

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. Lahti AC, et al. **J Neural Transm** 1998;105(6-7):719-34

The effects of (+)-UH232 and (-)-DS121 on local cerebral glucose utilization in rats. Walker EL, et al. **J Neural Transm** 1999;106(1):59-74

ANTAGONISTS & INHIBITORS

Attenuation of the lordosis-inhibiting effects of 8-OH-DPAT by TFMPP and quipazine. Wolf A, et al. **Brain Res** 1998 Sep 7;804(2):206-11

METABOLISM

Modulation of agonist and antagonist interactions in serotonin 1A receptors by alcohols. Harikumar KG, et al. **FEBS Lett** 1998 Oct 30;438(1-2):96-100

PHARMACOLOGY

Interaction of CCK and 8-OH-DPAT in the satiation of alcohol intake. Kulkosky PJ, et al. **Alcohol** 1998 Nov; 16(4):305-9

The effects of 8-hydroxy-2-(di-n-propylamino)tetralin on the cholinergic contraction in guinea pig and human airways in vitro. Dupont LJ, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1479-86

The septum and the hippocampus differentially mediate anxiolytic effects of R(+)-8-OH-DPAT. Menard J, et al. **Behav Pharmacol** 1998 Mar;9(2):93-101

8-OH-DPAT-sensitive neurons in the nucleus raphe magnus modulate thermoregulatory output in rats. Berner NJ, et al. **Brain Res** 1999 Jun 12;831(1-2):155-64

Comparison of the effects of aging on 5-HT7 and 5-HT1A receptors in discrete regions of the circadian timing system in hamsters. Duncan MJ, et al. **Brain Res** 1999 May 22; 829(1-2):39-45

The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Gerber K, et al. **Brain Res** 1998 Oct 5; 807(1-2):243-5

Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but not a 5-HT1A, antagonist. Matuszewich L, et al. **Brain Res** 1999 Feb 27; 820(1-2):55-62

Effects of postmortem delay on serotonin and (+)8-OH-DPAT-mediated inhibition of adenylyl cyclase activity in rat and human brain tissues [published erratum appears in Brain Res 1999 Apr 24;826(1):155] Palego L, et al. **Brain Res** 1999 Jan 16;816(1):165-74

Attenuation of the lordosis-inhibiting effects of 8-OH-DPAT by TFMPP and quipazine. Wolf A, et al. **Brain Res** 1998 Sep 7;804(2):206-11

Metal ion and guanine nucleotide modulations of agonist interaction in G-protein-coupled serotonin1A receptors from bovine hippocampus. Harikumar KG, et al. **Cell Mol Neurobiol** 1998 Oct;18(5):535-53

The effects of 8-OH-DPAT and (+/-)-pindolol on isolation-induced ultrasonic vocalizations in 3-, 10-, and 14-day-old rats. Joyce MP, et al. **Dev Psychobiol** 1999 Mar; 34(2):109-17

Differential effects of (R)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on the monosynaptic spinal reflex in rats. Honda M, et al. **Eur J Pharmacol** 1999 Jun 4;373(2-3):171-9

Acute rise in corticosterone facilitates 5-HT(1A) receptor-mediated behavioural responses. Meijer OC, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):7-14

GR46611 potentiates 5-HT1A receptor-mediated locomotor activity in the guinea pig. O'Neill MF, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):85-92

Neuroprotection against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT. Oosterink BJ, et al. **Eur J Pharmacol** 1998 Oct 2;358(2):147-52

Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone. Protais P, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):179-87

Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. Zangrossi H Jr, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):267-70

Reduced efficacy of 8-OH-DPAT's inhibition of lordosis behavior by prior estrogen treatment. Trevino A, et al. **Horm Behav** 1999 Jun;35(3):215-23

Modulation of sympathetic nerve activity by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the rostroventrolateral medulla. Bago M, et al. **J Auton Nerv Syst** 1999 May 28;76(2-3):127-34

Roles of suprachiasmatic nuclei and intergeniculate leaflets in mediating the phase-shifting effects of a serotonergic agonist and their photic modulation during subjective day [published erratum appears in J Biol Rhythms 1998 Dec;13(6):539] Challet E, et al. **J Biol Rhythms** 1998 Oct; 13(5):410-21

Differential regulation of somatodendritic serotonin 5-HT1A receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(Di-n-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain. Casanovas JM, et al. **J Neurochem** 1999 Jan;72(1):262-72

Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. de Boer SF, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1125-33

Pindolol suppresses serotonergic neuronal activity and does

not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. Fornal CA, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):229-38

Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins. Raap DK, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):561-7

Full and partial 5-HT1A receptor agonists disrupt learning and performance in rats. Winsauer PJ, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):335-47

Effect of a long-term low tryptophan diet on the prolactin responses to the 5-HT1A and 5-HT2C agonists, 8-OH-DPAT and mCPP in the male rat. Franklin M, et al. **J Psychopharmacol** 1999;13(1):58-63

5-HT1A receptor agonist (8-OH-DPAT) and 5-HT2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task. Ruotsalainen S, et al. **J Psychopharmacol** 1998;12(2):177-85

Dimerization of 8-OH-DPAT increases activity at serotonin 5-HT1A receptors. Pauwels PJ, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Oct; 358(4):404-10

8-OH-DPAT in the median raphe nucleus decreases while in the medial septal area it may increase anxiety in female rats. De Almeida RM, et al. **Neurosci Biobehav Rev** 1998; 23(2):259-64

A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Filakovszky J, et al. **Neurosci Lett** 1999 Feb 12;261(1-2):89-92

In Syrian hamsters, 5-HT fibres within the suprachiasmatic nuclei are necessary for the expression of 8-OH-DPAT induced phase-advance of locomotor activity rhythm. Schuhler S, et al. **Neurosci Lett** 1998 Oct 30;256(1):33-6

Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Nakai K, et al. **Neurosci Res** 1998 May; 31(1):23-9

Production of serotonin syndrome by 8-OH DPAT in Cryptotis parva. Darmani NA, et al. **Physiol Behav** 1998 Nov 15;65(2):327-31

WAY-100635 reverses 8-OH-DPAT-induced performance impairment in the radial maze. Helsley S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1179-84

Blockade of the anxiolytic-like action of ipsapirone and buspirone, but not that of 8-OH-DPAT, by adrenalectomy in male rats. López-Rubalcava C, et al. **Psychoneuroendocrinology** 1999 May;24(4):409-22

6-HYDROXYDOPAMINE see **OXIDOPAMINE**

20-HYDROXYECDYSONE see **ECDYSTERONE**

12-S-HYDROXYEICOSATETRAENOIC ACID see **12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID**

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID

ANALYSIS

Hypoxia stimulates the synthesis of cytochrome P450-derived inflammatory eicosanoids in rabbit corneal epithelium. Vafeas C, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):903-10

ANTAGONISTS & INHIBITORS

10-alpha-Aminoacyl-9(10H)-anthracenones: inhibition of 12(S)-HETE biosynthesis and HaCaT cell growth. Müller K, et al. **Arch Pharm (Weinheim)** 1999 Jan;332(1):31-5

BIOSYNTHESIS

[Ability of the neoplastic tissue to biosynthesize 12- and 15-hydroxyeicosatetraenoic acids as criterion of metastasizing activity of human lung neoplasms] Kudriavtsev IA, et al. **Biull Eksp Biol Med** 1998 Sep; 126(9):338-41 **(Rus)**

METABOLISM

12(S)-HETE in cancer metastasis. Tang K, et al. **Adv Exp Med Biol** 1999;447:181-91 (84 ref.)

The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit. Herbertsson H, et al. **Arch Biochem Biophys** 1999 Jul 1;367(1):33-8

Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. Mancini JA, et al. **J Biol Chem** 1998 Dec 4;273(49):32842-7

Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: involvement of a cytochrome P-4504B1 isoform. Mastyugin V, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1611-9

PHARMACOLOGY

12-Hydroxyeicosatetraenoic acid upregulates P-selectin-induced tissue factor activity on monocytes. Pellegrini G, et al. **FEBS Lett** 1998 Dec 28;441(3):463-6

12-hydroxy-5Z, 8Z, 10E, 14Z, eicosatetraenoic acid (12-HETE) stimulates cAMP production in normal human fibroblasts. Ueki S, et al. **J Cell Physiol** 1999 Jan;178(1):63-8

The priming effect of 12(S)-hydroxyeicosatetraenoic acid on lymphocyte phospholipase D involves specific binding sites. Zakaroff-Girard A, et al. **Life Sci** 1999;64(23):2135-48

PHYSIOLOGY

Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation. Katoh A, et al. **Circulation** 1998 Dec 22-29;98(25):2891-8

HYDROXYEICOSATETRAENOIC ACIDS

BIOSYNTHESIS

Airway synthesis of 20-hydroxyeicosatetraenoic acid: metabolism by cyclooxygenase to a bronchodilator. Jacobs ER, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L280-8

Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Wang MH, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F246-53

Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. Chiang N, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):779-90

Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Spokas EG, et al. **Methods Mol Biol** 1999;120:213-47 (145 ref.)

[Ability of the neoplastic tissue to biosynthesize 12- and 15-hydroxyeicosatetraenoic acids as criterion of metastasizing activity of human lung neoplasms] Kudriavtsev IA, et al. **Biull Eksp Biol Med** 1998 Sep; 126(9):338-41 **(Rus)**

BLOOD

A method for the measurement of plasma hydroxyeicosatetraenoic acid levels. Chavis C, et al. **Anal Biochem** 1999 Jun 15;271(1):105-8

Electrospray mass spectrometric analysis of 5-hydroperoxy and 5-hydroxyeicosatetraenoic acids generated by lipid peroxidation of red blood cell ghost phospholipids. Hall LM, et al. **J Am Soc Mass Spectrom** 1998 May;9(5):527-32

Albumin modifies the metabolism of hydroxyeicosatetraenoic acids via 12-lipoxygenase in human platelets. Dadaian M, et al. **J Lipid Res** 1999 May;40(5):940-7

Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Clish CB, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8247-52

CHEMISTRY

Lipoxin A4: a new class of ligand for the Ah receptor. Schaldach CM, et al. **Biochemistry** 1999 Jun 8; 38(23):7594-600

Novel membrane target proteins for lipoxygenase-derived mono(S)hydroxy fatty acids. Kang LT, et al. **Biochim Biophys Acta** 1999 Jun 10;1438(3):388-98

IMMUNOLOGY

Modulation of LTB4 receptor in T-lymphocytes by lipoxin A4 (LXA4) and its role in delayed-type hypersensitivity. Lin KT, et al. **Adv Exp Med Biol** 1999;447:151-63

Aspirin-triggered 15-epi-lipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways. Serhan CN, et al. **Adv Exp Med Biol** 1999;447:133-49 (46 ref.)

ISOLATION & PURIFICATION

Separation of hydroxyeicosatetraenoic acids and leukotrienes originating from kidney tissue by C-18 reverse-phase high-pressure liquid chromatography. Sharma M, et al. **Methods Mol Biol** 1999;120:45-54

METABOLISM

Effect of 15-HETE on the 5-lipoxygenase pathway in neutrophils. Genuine inhibitor or alternative substrate? Schewe T, et al. **Adv Exp Med Biol** 1999;447:95-105 (25 ref.)

Interleukin-4 enhances 15-lipoxygenase activity and incorporation of 15(S)-HETE into cellular phospholipids in cultured pulmonary epithelial cells. Profita M, et al. **Am J Respir Cell Mol Biol** 1999 Jan;20(1):61-8

Lipoxin A4: a new class of ligand for the Ah receptor. Schaldach CM, et al. **Biochemistry** 1999 Jun 8; 38(23):7594-600

Lipoxygenase inhibition in prostate cancer. Myers CE, et al. **Eur Urol** 1999;35(5-6):395-8 (3 ref.)

Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4. Levy BD, et al. **FASEB J** 1999 May;13(8):903-11

IL-4 and IgE-anti-IgE modulation of 15(S)-hydroxyeicosatetraenoic acid release by mononuclear phagocytes. Profita M, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):159-64

Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. Mancini JA, et al. **J Biol Chem** 1998 Dec 4;273(49):32842-7

The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis. Mallat Z, et al. **J Clin Invest** 1999 Feb; 103(3):421-7

Defective oxidation of hydroxyeicosatetraenoic acids in the liver of patients with Zellweger syndrome. Mayatepek E, et al. **J Inherit Metab Dis** 1998 Jun;21(3):295-7

[Lipoxygenase activity and 15-hete content of rat spleen lymphocytes after exposure to ionizing radiation] Matyshevskaia OP, et al. **Ukr Biokhim Zh** 1998 Sep-Oct; 70(5):91-6 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Regulation of human airway mucins by acrolein and inflammatory mediators. Borchers MT, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L549-55

LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. Gewirtz AT, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C988-94

Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Oltman CL, et al. **Circ Res** 1998 Nov 2;83(9):932-9

Nitric oxide-20-hydroxyeicosatetraenoic acid interaction in the regulation of K+ channel activity and vascular tone in renal arterioles. Sun CW, et al. **Circ Res** 1998 Nov 30; 83(11):1069-79

Lipoxin and aspirin-triggered 15-epi-lipoxin cellular interactions anti-inflammatory lipid mediators. Serhan CN, et al. **Clin Chem Lab Med** 1999 Mar;37(3):299-309 (55 ref.)

12-Hydroxyeicosatetraenoic acid directly potentiates angiotensin II-induced vascular contraction. Takai S, et al. **Eur J Pharmacol** 1998 Oct 2;358(2):161-4

Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Sun CW, et al. **Hypertension** 1999 Jan;33(1 Pt 2):414-8

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. Hachicha M, et al. **J Exp Med** 1999 Jun 21;189(12):1923-30

20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Muthalif MM, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12701-6

PHYSIOLOGY

20-HETE and the kidney: resolution of old problems and new beginnings. McGiff JC, et al. **Am J Physiol** 1999 Sep; 277(3 Pt 2):R607-23 (118 ref.)

Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Ito O, et al. **Hypertension** 1999 Jan;33(1 Pt 2):419-23

Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. Chiang N, et al. **J Clin Invest** 1999 Aug; 104(3):309-16

[The physiological role of P450-derived arachidonic acid metabolites] Imaoka S, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):23-31 (45 ref.) (Eng. Abstr.) **(Jpn)**

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO) PROSTA-5,13-DIENOIC ACID

ANTAGONISTS & INHIBITORS

Prostanoids and related compounds. VII. Synthesis and inhibitory activity of 1-isoindolinone derivatives possessing inhibitory activity against thromboxane A2 analog (U-46619)-induced vasoconstriction. Kato Y, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr;47(4):529-35

PHARMACOLOGY

Hemodynamic and renal effects of U-46619, a TXA2/PGH2 analog, in late-pregnant rats. Kriston T, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R831-7

Superoxide and endothelium-dependent constriction to flow in porcine small pulmonary arteries. Liu Q, et al. **Br J Pharmacol** 1998 May;124(2):331-6

Vagal blockade does not prevent adrenocorticotropin, cortisol, and cardiopulmonary responses to thromboxane A2. Cudd TA. **Can J Physiol Pharmacol** 1998 Dec; 76(12):1087-94

U46619-mediated vasoconstriction of the fetal placental vasculature in vitro in normal and hypertensive pregnancies. Read MA, et al. **J Hypertens** 1999 Mar; 17(3):389-96

Pharmacological antagonism of Anchietia salutaris extracts on the contraction induced by prostaglandin D2 and U46619 in guinea-pig lung parenchymal strips. Gambero A, et al. **J Pharm Pharmacol** 1998 Nov;50(11):1287-92

25-HYDROXYERGOCALCIFEROL see **25-HYDROXYVITAMIN D 2**

HYDROXYESTRONES

BIOSYNTHESIS

Translesional synthesis on DNA templates containing an estrogen quinone-derived adduct: N2-(2-hydroxyestron-6-yl)-2'-deoxyguanosine and N6-(2-hydroxyestron-6-yl)-2'-deoxyadenosine. Terashima I, et al. **Biochemistry** 1998 Sep 29; 37(39):13807-15

CHEMISTRY

Effect of metal ions on the stable adduct formation of 16alpha-hydroxyestrone with a primary amine via the Heyns rearrangement. Miyairi S, et al. **Steroids** 1999 Apr; 64(4):252-8

Enzymic and chemical O-methylation of a 4-hydroxyestrone N-acetylcysteine conjugate. Suzuki E, et al. **Steroids** 1998 Dec;63(12):672-7

METABOLISM

Effect of metal ions on the stable adduct formation of 16alpha-hydroxyestrone with a primary amine via the Heyns rearrangement. Miyairi S, et al. **Steroids** 1999 Apr; 64(4):252-8

PHARMACOLOGY

[The effects of E2 and it's metabolites on the proliferation of rat anterior pituitary cells in vitro] Di A, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Dec; 19(6):424-9 (Eng. Abstr.) **(Chi)**

URINE

Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Meilahn EN, et al. **Br J Cancer** 1998 Nov;78(9):1250-5

Re: "A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer" [letter; comment] Bradlow HL, et al. **Environ Health Perspect** 1998 Mar;106(3):A126-7 . Comment on: Environ Health Perspect 1997 Apr;105 Suppl 3:601-5.

Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. Ursin G, et al. **J Natl Cancer Inst** 1999 Jun 16;91(12):1067-72

The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Westerlind KC, et al. **Steroids** 1999 Mar; 64(3):233-43

HYDROXYETHYL STARCH see **HETASTARCH**

N-2-HYDROXYETHYLPIPERAZINE-N'-2'-ETHANESULFONIC ACID see **HEPES**

HYDROXYETHYLRUTOSIDE

ANALOGS & DERIVATIVES

Effects of Venoruton on early postradiation damage in the lungs of rats. Staroslawska E, et al. **Rocz Akad Med Bialymst** 1998;43:95-109

[Prospective double-blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer] Grötz KA, et al. **Strahlenther Onkol** 1999 Aug;175(8):397-403; discussion 404 (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Effect of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Roland IH, et al. **Cardiovasc Drugs Ther** 1998 Sep; 12(4):375-81

Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. van Acker SA, et al. **Clin Cancer Res** 1997 Oct;3(10):1747-54

THERAPEUTIC USE

Intravenous hydroxyethylrutosides combined with long-term oral anticoagulation in atherosclerotic nonreconstructable critical leg ischemia: a retrospective study. Lund F, et al. **Angiology** 1999 Jun;50(6):433-45

The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study. Pronk LC, et al. **Cancer Chemother Pharmacol** 1999;43(2):173-7

[Effectiveness and safety of hydroxyethyl-rutosides in the local treatment of symptoms of venous insufficiency during air travel] Gouny AM, et al. **J Mal Vasc** 1999 Jun; 24(3):214-20 (Eng. Abstr.) **(Fre)**

HYDROXYETHYLSULFONIC ACID see **ISETHIONIC ACID**

HYDROXYFLUORENYLACETAMIDE see **HYDROXYACETYLAMINOFLUORENE**

HYDROXYIMINO COMPOUNDS see **OXIMES**

HYDROXYINDOLE O-METHYLTRANSFERASE see **ACETYLSEROTONIN N-METHYLTRANSFERASE**

HYDROXYINDOLEACETIC ACID

ANALYSIS

Functional chemical neuroanatomy of serotonergic neurons and their targets: antibody production and immunohistochemistry (IHC) for 5-HT, its precursor (5-HTP) and metabolite (5-HIAA), biosynthetic enzyme (TPH), transporter (SERT), and three receptors (5-HT2A, 5-ht5a, 5-HT7). Brownfield MS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:232-3

The dopamine D2 receptor antagonist sulpiride causes long-lasting serotonin release. Nakazato T, et al. **Eur J Pharmacol** 1998 Dec 11;363(1):29-34

Red light suppresses N-acetylserotonin but does not elevate 5-HT and 5-HIAA of the rat pineal glands at night. Chen LW, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Feb;15(2):113-8

BLOOD

Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. Williams WA, et al. **J Neurochem** 1999 Apr;72(4):1641-7

Plasma levels of 5-HT and 5-HIAA increased after intestinal ischemia/reperfusion in rats. Teramoto Y, et al. **Jpn J Physiol** 1998 Oct;48(5):333-9

Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Schwarz MJ, et al. **Neurosci Lett** 1999 Jan 15;259(3):196-8

Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine. Hatzimanolis J, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1077-85

CEREBROSPINAL FLUID

Changes in cerebrospinal fluid monoamine metabolites, tryptophan, and gamma-aminobutyric acid during the 1st year of life in normal infants. comparison with victims of sudden infant death syndrome. Cann-Moisan C, et al. **Biol Neonate** 1999 Mar;75(3):152-9

Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid. Geracioti TD Jr, et al. **Biol Psychiatry** 1998 Aug 1;44(3):228-33

Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Hibbeln JR, et al. **Biol Psychiatry** 1998 Aug 15;44(4):235-42

A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Hibbeln JR, et al. **Biol Psychiatry** 1998 Aug 15;44(4):243-9

Salivary prolactin as a marker for central serotonin turnover. Lindell SG, et al. **Biol Psychiatry** 1999 Aug 15;46(4):568-72

Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Little JT, et al. **Biol Psychiatry** 1999 Feb 1;45(3):285-9

CSF 5-HIAA correlates with neuroticism in depressed patients. Roy A. **J Affect Disord** 1999 Jan-Mar; 52(1-3):247-9

Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. Williams WA, et al. **J Neurochem** 1999 Apr;72(4):1641-7

A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease. Liu H, et al. **Neurobiol Dis** 1999 Feb;6(1):35-42

Cerebrospinal fluid monoaminergic metabolites differ in wild anubis and hybrid (Anubis hamadryas) baboons: possible relationships to life history and behavior. Kaplan JR, et al. **Neuropsychopharmacology** 1999 Jun;20(6):517-24

Brain serotonin synthesis rates in rhesus monkeys determined by [11C]alpha-methyl-L-tryptophan and positron emission tomography compared to CSF 5-hydroxyindole-3-acetic acid concentrations [see comments] Shoaf SE, et al. **Neuropsychopharmacology** 1998 Nov;19(5):345-53. Comment in: Neuropsychopharmacology 1999 Jul;21(1):153-7.

Pathogenetic role of monoamine metabolism in complex febrile seizures. Nishimura K, et al. **Pediatr Neurol** 1999 Aug;21(2):553-6

CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Wieselgren IM, et al. **Psychiatry Res** 1998 Nov 16; 81(2):101-10

METABOLISM

Altered daily rhythms of brain and pituitary indolamines and neuropeptides in long-term hypoxic rats. Poncet L, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R66-75

Nitric oxide modulates the release of serotonin in the rat hypothalamus. Kaehler ST, et al. **Brain Res** 1999 Jul 24; 835(2):346-9

Anoxic and hypoxic immature rat model for measurement of monoamine using in vivo microdialysis. Nakajima W, et al. **Brain Res Brain Res Protoc** 1999 Jan;3(3):252-6

The effects of oestrogen and progesterone on serotonin and its metabolite in the lateral septum, medial preoptic area and ventromedial hypothalamic nucleus of female rats. Lu H, et al. **J Neuroendocrinol** 1998 Dec;10(12):919-26

Effects of local MAO inhibition in the locus coeruleus on extracellular serotonin and 5-HIAA during exposure to sensory and cardiovascular stimuli. Kaehler ST, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):187-93

Effects of L-tryptophan on indoleamines and catecholamines in discrete brain regions of wild type and Lurcher mutant mice. Reader TA, et al. **Neurochem Res** 1999 Sep; 24(9):1125-34

Effects of carotid sinus nerve transection on changes in neuropeptide Y and indolamines induced by long-term hypoxia in rats. Poncet L, et al. **Pflugers Arch** 1998 Dec; 437(1):130-8

Effects of antihistamines on fenfluramine-induced depletion of indoles in the brain of rats. Yeh SY. **Synapse** 1999 Jun 15;32(4):301-11

URINE

The urinary ratio of 5-hydroxytryptophol to 5-hydroxyindole-3-acetic acid in surgical patients with chronic alcohol misuse. Spies CD, et al. **Alcohol** 1999 Jan; 17(1):19-27

Comparison of urinary 5-hydroxytryptophol, breath ethanol, and self-report for detection of recent alcohol use during outpatient treatment: a study on methadone patients. Helander A, et al. **Drug Alcohol Depend** 1999 Aug 2; 56(1):33-8

Fluorescence derivatizing procedure for 5-hydroxytryptamine and 5-hydroxyindoleacetic acid using 1,2-diphenylethylenediamine reagent and their sensitive liquid chromatographic determination. Kai M, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1-2):25-31

Carcinoid tumors [letter; comment] Kema IP, et al. **N Engl J Med** 1999 Aug 5;341(6):453-4; discussion 454-5 . Comment on: N Engl J Med 1999 Mar 18;340(11):858-68.

HYDROXYL RADICAL

Effect of lu-duo-wei on scavenging superoxide and hydroxyl radicals in vitro. Fang YZ, et al. **Am J Chin Med** 1998; 26(2):153-8

Protein L-dopa as an index of hydroxyl radical attack on protein tyrosine. Cohen G, et al. **Anal Biochem** 1998 Oct 15;263(2):232-9

Hydroxyl radical-induced cross-linking of thymine and lysine: identification of the primary structure and mechanism. Morimoto S, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):865-70

Hydroxyl radical generation after the third hour following ischemia contributes to brain damage. Takamatsu H, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):165-9

LC/MS analysis of hydroxylation products of salicylate as an indicator of in vivo oxidative stress. Tabatabaei AR, et al. **Free Radic Biol Med** 1999 Apr;26(7-8):1054-8

Bleomycin versus OH-radical-induced malonaldehydic-product formation in DNA. Rashid R, et al. **Int J Radiat Biol** 1999 Jan;75(1):101-9

The hydroxyl radical in lens nuclear cataractogenesis. Fu S, et al. **J Biol Chem** 1998 Oct 30;273(44):28603-9

Mapping the ribosomal RNA neighborhood of protein L11 by directed hydroxyl radical probing. Holmberg L, et al. **J Mol Biol** 1999 Jun 4;289(2):223-33

Generation of hydroxyl radical by photolysis of mercaptopyridine N-oxides: application to redox chemistry of purines. Vieira AJ, et al. **Methods Enzymol** 1999; 300:194-201

Alkaline phosphatase and type I collagen gene expressions were reduced by hydroxyl radical-treated fibronectin substratum. Hosoya S, et al. **Mol Genet Metab** 1998 Sep; 65(1):31-4

Oxidation of gonadotrophin (PMSG) by oxygen free radicals alters its structure and hormonal activity. Ortega-Camarillo C, et al. **Mol Reprod Dev** 1999 Mar;52(3):264-8

Hydroxyl radicals and DNA base damage. Cadet J, et al. **Mutat Res** 1999 Mar 8;424(1-2):9-21 (111 ref.)

Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs. Maga G, et al. **Nucleic Acids Res** 1999 Feb 15;27(4):972-8

Metallothionein isoforms provide neuroprotection against 6-hydroxydopamine-generated hydroxyl radicals and superoxide anions. Ebadi M, et al. **Proc West Pharmacol Soc** 1998;41:155-8

[Scavenging effects of sodium selenite on hydroxyl radicals] Cao Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(3):275-6 **(Chi)**

ADVERSE EFFECTS

SOS-dependent A-->G transitions induced by hydroxyl radical generating system hypoxanthine/xanthine oxidase/Fe3+/EDTA are accompanied by the increase of Fapy-adenine content in M13 mp18 phage DNA. Grąziewicz MA, et al. **Mutat Res** 1999 May 14;434(1):41-52

HYDROXYL RADICAL

AGONISTS

Increased vulnerability of neurones and glial cells to low concentrations of methylmercury in a prooxidant situation. Sorg O, et al. **Acta Neuropathol (Berl)** 1998 Dec;96(6):621–7

ANALYSIS

Superoxide anion and hydroxyl radical scavenging activities of vegetable extracts measured using electron spin resonance. Kaneyuki T, et al. **Biochem Mol Biol Int** 1999 Jun;47(6):979–89

EPR characterization of free radical intermediates formed during ultrasound exposure of cell culture media. M...k V, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):936–43

Hydroxyl radical formation in chondrocytes and cartilage as detected by electron paramagnetic resonance spectroscopy using spin trapping reagents. Tiku ML, et al. **Free Radic Res** 1998 Sep;29(3):177–87

Estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection. Acworth IN, et al. **Methods Enzymol** 1999;300:297–313

Measurement of hydroxyl radical by salicylate in striatum of intact brain. Hiramatsu M, et al. **Methods Enzymol** 1999; 300:252–5

Trace determination of hydroxyl radical using fluorescence detection. Li B, et al. **Methods Enzymol** 1999;300:202–16

Hydroxyl and 1-hydroxyethyl free radical detection using spin traps followed by derivatization and gas chromatography–mass spectrometry. Castro GD, et al. **Redox Rep** 1997 Oct–Dec;3(5–6):343–7

CHEMISTRY

ESR and HPLC-EC analysis of the interaction of hydroxyl radical with DMSO: rapid reduction and quantification of POBN and PBN nitroxides. Stoyanovsky DA, et al. **Anal Chem** 1999 Feb 1;71(3):715–21

The hydroxyl free radical reactions of ascorbyl palmitate as measured in various in vitro models. Perricone N, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):661–5

Directed hydroxyl radical probing of 16S ribosomal RNA in 70S ribosomes from internal positions of the RNA. Newcomb LF, et al. **Biochemistry** 1999 Jan 19;38(3):945–51

The hydroxyl of threonine 13 of the bovine 70-kDa heat shock cognate protein is essential for transducing the ATP-induced conformational change. Sousa MC, et al. **Biochemistry** 1998 Nov 3;37(44):15392–9

EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on •OH formation by the Fenton reaction. Hermes-Lima M, et al. **Biochim Biophys Acta** 1999 Feb 2;1426(3):475–82

Urocanic acid isomers are good hydroxyl radical scavengers: a comparative study with structural analogues and with uric acid. Kammeyer A, et al. **Biochim Biophys Acta** 1999 Jun 28;1428(1):117–20

Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols. Nappi AJ, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):159–67

Electron spin resonance studies on photosensitized formation of hydroxyl radical by C-phycocyanin from Spirulina platensis. Zhang S, et al. **Biochim Biophys Acta** 1999 Jan 4;1426(1):205–11

Binding affinity of Cu(II)–VP-16 (etoposide) complex and its analogues to DNA and hydroxyl radical generation during DNA strand breaks. Tawa R, et al. **Bioorg Med Chem** 1998 Jul;6(7):1003–8

Synthesis and ESR study of new dihydroxamic acid siderophores S as scavengers of hydroxyl radicals. Nguyen MV, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):227–32

Synthesis of alpha-aryl N-adamant-1-yl nitrones and using them for spin trapping of hydroxyl radicals. Sár CP, et al. **Bioorg Med Chem Lett** 1998 Feb 17;8(4):379–84

Quinolinic acid, alpha-picolinic acid, fusaric acid, and 2,6-pyridinedicarboxylic acid enhance the Fenton reaction in phosphate buffer. Iwahashi H, et al. **Chem Biol Interact** 1999 Apr 15;118(3):201–15

Effect of •NO on the decomposition of peroxynitrite: reaction of N2O3 with ONOO-. Goldstein S, et al. **Chem Res Toxicol** 1999 Feb;12(2):132–6

OH radical reactivity of pesticides adsorbed on aerosol materials: first results of experiments with filter samples. Palm WU, et al. **Ecotoxicol Environ Saf** 1998 Sep; 41(1):36–43

The relative importance of HO• and ONOO- in mediating the toxicity of O•- [letter; comment] Liochev SI, et al. **Free Radic Biol Med** 1999 Mar;26(5–6):777–8. Comment on: Free Radic Biol Med 1998 Sep;25(4–5):385–91.

Induction of DNA strand breakage and base oxidation by nitroxyl anion through hydroxyl radical production. Ohshima H, et al. **Free Radic Biol Med** 1999 May; 26(9–10):1305–13

Estimation of .OH radical reaction rate constants for phenol and chlorinated phenols using UV/H2O2 photo-oxidation. De AK, et al. **J Hazard Mater** 1999 Jan 1;64(1):91–104

Ferrous iron-induced luminol chemiluminescence: a method for hydroxyl radical study. Yildiz G, et al. **J Pharmacol Toxicol Methods** 1998 Apr;39(3):179–84

Hydroxyl radical-induced hydrogen/deuterium exchange in amino acid carbon-hydrogen bonds. Goshe MB, et al. **Radiat Res** 1999 Jan;151(1):50–8

Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Regoli F, et al. **Toxicol Appl Pharmacol** 1999 Apr 15;156(2):96–105

IMMUNOLOGY

Reactive oxygen species modified polyguanylic acid: immunogenicity and implications for systemic autoimmunity. Garg DK, et al. **J Autoimmun** 1998 Aug; 11(4):371–8

METABOLISM

Effect of hemorrhagic hypotension on hydroxyl radicals in cat brain. Song D, et al. **Adv Exp Med Biol** 1998;454:173–80

Estrogen diminishes postischemic hydroxyl radical production. McHugh NA, et al. **Am J Physiol** 1998 Jun; 274(6 Pt 2): H1950–4

Sensitivity of canine intrinsic cardiac neurons to H2O2 and hydroxyl radical. Thompson GW, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1434–40

Uptake of bromosulfophthalein via SO2-4/OH- exchange increases the K+ conductance of rat hepatocytes. Wehner F, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1380–90

Evidence that the reactions of cadmium in the presence of metallothionein can produce hydroxyl radicals. O'Brien P, et al. **Arch Toxicol** 1998 Nov;72(11):690–700

Acceleration of adhesion of cancer cells and neutrophils to endothelial cells in the absence of de novo protein synthesis: possible implication for involvement of hydroxyl radicals. Suzuki K, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):214–7

A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Tan DX, et al. **Biochem Biophys Res Commun** 1998 Dec 30; 253(3):614–20

Enhancement of hydroxyl radical generation in the Fenton reaction by alpha-hydroxy acid. Ali MA, et al. **Biochem Mol Biol Int** 1998 Sep;46(1):137–45

Involvement of hydrogen peroxide and hydroxyl radical in chemically induced apoptosis of HL-60 cells. Ikeda K, et al. **Biochem Pharmacol** 1999 Jun 15;57(12):1361–5

Hydroxyl radical formation via iron-mediated Fenton chemistry is inhibited by methylated catechols. Nappi AJ, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):159–67

Generation of reactive oxygen species by raphidophycean phytoplankton. Oda T, et al. **Biosci Biotechnol Biochem** 1997 Oct;61(10):1658–62

Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. Dajas-Bailador FA, et al. **Brain Res** 1998 Nov 30; 813(1):18–25

A microdialysis study investigating the mechanisms of hydroxyl radical formation in rat striatum exposed to glutamate. Lancelot E, et al. **Brain Res** 1998 Nov 2; 809(2):294–6

Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum. Obata T. **Brain Res** 1999 May 15; 828(1–2):68–73

Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Opacka-Juffry J, et al. **Brain Res** 1998 Nov 9;810(1–2):27–33

Removal of hydroxyl radical facilitates Ca2+-dependent [3H]GABA release by peroxynitrite. Higo A, et al. **Brain Res Mol Brain Res** 1998 Nov 12;62(1):96–100

Hydroxyl radical formation during inhalation anesthesia in the reperfused working rat heart. Nakamura T, et al. **Can J Anaesth** 1999 May;46(5 Pt 1):470–5

Effects of catechins on superoxide and hydroxyl radical. Kashima M. **Chem Pharm Bull (Tokyo)** 1999 Feb; 47(2):279–83

Melatonin decreases production of hydroxyl radical during cerebral ischemia-reperfusion. Li XJ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):394–6

Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Praticó D, et al. **Circulation** 1999 Jun 22;99(24):3118–24

Hydroxyl-radical production in physiological reactions. A novel function of peroxidase. Chen SX, et al. **Eur J Biochem** 1999 Mar;260(3):726–35

Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Ferger B, et al. **Eur J Pharmacol** 1998 Nov 6;360(2–3):155–63

Protective effect of imidaprilat, a new angiotensin-converting enzyme inhibitor against 1-methyl-4-phenylpyridinium ion-induced •OH generation in rat striatum. Obata T. **Eur J Pharmacol** 1999 Jul 28;378(1):39–45

Cataract formation through the polyol pathway is associated with free radical production. Kubo E, et al. **Exp Eye Res** 1999 Apr;68(4):457–64

Diffusion distances of known iron complexes in model systems. Li H, et al. **Free Radic Biol Med** 1999 Jan; 26(1–2):61–72

Differences in the reactivity of phthalic hydrazide and luminol with hydroxyl radicals. Schiller J, et al. **Free Radic Res** 1999 Jan;30(1):45–57

Hydroxyl radical formation in chondrocytes and cartilage as detected by electron paramagnetic resonance spectroscopy using spin trapping reagents. Tiku ML, et al. **Free Radic Res** 1998 Sep;29(3):177–87

Studies by electron paramagnetic resonance of the importance of iron in the hydroxyl scavenging properties of ascorbic acid in plasma: effects of iron chelators. Benderitter M, et al. **Fundam Clin Pharmacol** 1998; 12(5):510–6

Excimer laser-induced hydroxyl radical formation and keratocyte death in vitro. Shimmura S, et al. **Invest Ophthalmol Vis Sci** 1999 May;40(6):1245–9

Neuronal nitric oxide synthase inhibition reduces MPP+-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. Rose S, et al. **J Neural Transm** 1999;106(5–6):477–86

Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. Ferger B, et al. **J Neurochem** 1999 Sep;73(3):1329–32

Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. Shankaran M, et al. **J Neurochem** 1999 Jun; 72(6):2516–22

Reducing hemoglobin oxygen affinity does not increase hydroxyl radicals after acute subdural hematoma in the rat. Doppenberg EM, et al. **J Neurotrauma** 1999 Feb; 16(2):123–33

The effects of methamphetamine on the production of free radicals and oxidative stress. Yamamoto BK, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):107–14

Protective effect of histidine on iron (II)-induced hydroxyl radical generation in rat hearts. Obata T, et al. **J Physiol Paris** 1999 May-Jun;93(3):213–8

Iron-mediated cardiotoxicity develops independently of extracellular hydroxyl radicals in isolated rat hearts. Watts JA, et al. **J Toxicol Clin Toxicol** 1999;37(1):19–28

Protective effect of histidine on hydroxyl radical generation induced by potassium-depolarization in rat myocardium. Obata T, et al. **Jpn J Pharmacol** 1999 Jul;80(3):217–22

Reactivity of homocysteine-thiolactone and alpha-methylhomocysteine-thiolactone with e-(aq) and OH-radical: a pulse radiolysis study. Getoff N, et al. **Life Sci** 1998;63(16):1469–84

Effects of endurance physical training on hydroxyl radical generation in rat tissues. Itoh H, et al. **Life Sci** 1998; 63(21):1921–9

The mechanism of "Fenton-like" reactions and their importance for biological systems. A biologist's view. Liochev SI. **Met Ions Biol Syst** 1999;36:1–39 (169 ref.)

Detection of chromatin-associated hydroxyl radicals generated by DNA-bound metal compounds and antitumor antibiotics. Makrigiorgos GM. **Met Ions Biol Syst** 1999; 36:521–45 (75 ref.)

Products of creatinine with hydroxyl radical as a useful marker of oxidative stress in vivo. Aoyagi K, et al. **Methods Mol Biol** 1998;108:157–64

Aromatic hydroxylation. Salicylic acid as a probe for measuring hydroxyl radical production. Ghiselli A. **Methods Mol Biol** 1998;108:89–100

The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-kappaB. Shi X, et al. **Mol Cell Biochem** 1999 Apr;194(1–2):63–70

Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Zhong Z, et al. **Mol Pharmacol** 1999 Sep;56(3):455–63

Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Ferger B, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Sep; 358(3):351–9

1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline increases extracellular serotonin and stimulates hydroxyl radical production in rats. Gerlach M, et al. **Neurosci Lett** 1998 Nov 20;257(1):17–20

Manganese scavenges superoxide and hydroxyl radicals: an in vitro study in rats. Hussain S, et al. **Neurosci Lett** 1999 Feb 12;261(1–2):21–4

Site-directed hydroxyl radical probing of 30S ribosomal subunits by using Fe(II) tethered to an interruption in the 16S rRNA chain. Samaha RR, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):366–70

Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. Liu R, et al. **Radiat Res** 1999 Feb; 151(2):133–41

Increased formation of interstitial hydroxyl radical following myocardial ischemia: possible relationship to endogenous opioid peptides. Yang CS, et al. **Redox Rep** 1997 Oct–Dec; 3(5–6):295–301

[Oxidative stress and hypercholesterolemia: increase of radical hydroxyl in patients with hypercholesterolemia] Natoli S, et al. **Cardiologia** 1999 Feb;44(2):187–90 (Eng. Abstr.) **(Ita)**

[Effect of shikonin and alkannin on hydroxyl radical generation system concerned with iron ion] Sekine T, et al. **Yakugaku Zasshi** 1998 Dec;118(12):609–15 (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Indole-3-propionate: a potent hydroxyl radical scavenger in rat brain. Poeggeler B, et al. **Brain Res** 1999 Jan 9; 815(2):382–8

PHARMACOLOGY

Protein cleavage by transition metal complexes bearing amino acid substituents. Buranaprapuk A, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1–2):309–16

Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Flesch M, et al. **Circulation** 1999 Jul 27;100(4):346-53

Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Janssen PM, et al. **Eur J Pharmacol** 1999 Feb 5;366(2-3):223-32

The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against •OH-mediated strand breaks. Hermes-Lima M, et al. **Free Radic Biol Med** 1998 Nov 15;25(8):875-80

Hydroxyl radical scavengers inhibit TNF-alpha production in mononuclear cells but not in polymorphonuclear leukocytes. Vulcano M, et al. **Int J Immunopharmacol** 1998 Dec;20(12):709-22

Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation. Kim KC, et al. **Int J Mol Med** 1999 Sep;4(3):273-7

Effects of hydroxyl radicals on KATP channels in guinea-pig ventricular myocytes. Tokube K, et al. **Pflugers Arch** 1998 Dec;437(1):155-7

TOXICITY

Protection of DNA in HL-60 cells from damage generated by hydroxyl radicals produced by reaction of H2O2 with cell iron by zinc-metallothionein. Elgohary WG, et al. **Chem Biol Interact** 1998 Sep 4;115(2):85-107

HYDROXYLAMINE

Enzymatic and chemical cleavage methods. Taylor GR. **Electrophoresis** 1999 Jun;20(6):1125-30 (32 ref.)

ANALOGS & DERIVATIVES see HYDROXYLAMINES

ANALYSIS

Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring the metabolic hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. Peng SX, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 5;724(1):181-7

METABOLISM

Hydroxylamine oxidation and subsequent nitrous oxide production by the heterotrophic ammonia oxidizer Alcaligenes faecalis. Otte S, et al. **Appl Microbiol Biotechnol** 1999 Feb;51(2):255-61

Effect of long-term ammonia starvation on the oxidation of ammonia and hydroxylamine by Nitrosomonas europaea. Wilhelm R, et al. **J Biochem (Tokyo)** 1998 Oct;124(4):811-5

Peroxygenase metabolism of N-acetylbenzidine by prostaglandin H synthase. Formation of an N-hydroxylamine. Zenser TV, et al. **J Biol Chem** 1999 May 21;274(21):14850-6

PHARMACOLOGY

Hydroxylamine blocks pre- but not postsynaptic adenosine A(1) receptor-mediated actions in rat hippocampus. Fowler JC, et al. **Brain Res** 1999 Aug 7;837(1-2):309-13

Hydroxylamine blocks adenosine A1 receptor-mediated inhibition of synaptic transmission in rat hippocampus. Fowler JC, et al. **Brain Res** 1999 Jan 9;815(2):414-8

[Effect of hydroxylamine hydrochloride on the bacterium Shigella dysenteriae 1 and antigens isolated from them] Zakharova NE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec;(6):82-3 **(Rus)**

HYDROXYLAMINES

METABOLISM

E2P phosphoforms of Na,K-ATPase. I. Comparison of phosphointermediates formed from ATP and Pi by their reactivity toward hydroxylamine and vanadate. Fedosova NU, et al. **Biochemistry** 1998 Sep 29;37(39):13634-42

Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. Dikalov SI, et al. **J Biol Chem** 1999 Apr 2;274(14):9392-9

Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions. Reilly TP, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):951-9

PHARMACOLOGY

Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivative. Okamoto M, et al. **Antivir Chem Chemother** 1999 Mar;10(2):71-7

New NO donors with antithrombotic and vasodilating activities, part 25. Hydroxylamine derivatives. Rehse K, et al. **Arch Pharm (Weinheim)** 1998 Nov;331(11):365-7

Probing the "active site" of diamine oxidase: structure-activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium. High A, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):490-501

TOXICITY

Two mechanisms for toxic effects of hydroxylamines in human erythrocytes: involvement of free radicals and risk of potentiation. Evelo CT, et al. **Blood Cells Mol Dis** 1998 Sep;24(3):280-95

Only the glutathione dependent antioxidant enzymes are inhibited by haematotoxic hydroxylamines. Spooren AA, et al. **Hum Exp Toxicol** 1998 Oct;17(10):554-9

HYDROXYLAPATITE see DURAPATITE

HYDROXYLASES

ANALYSIS

A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Schwaneberg U, et al. **Anal Biochem** 1999 May 1;269(2):359-66

Development of a carbon dioxide-capture assay in microtiter plate for aspartyl-beta-hydroxylase. Zhang JH, et al. **Anal Biochem** 1999 Jul 1;271(2):137-42

Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Sumida A, et al. **Biochem Biophys Res Commun** 1999 Aug 27;262(2):499-503

Monoclonal antibodies to 2,4-dichlorophenol hydroxylase as probes for the 2,4-D-degradative phenotype. Farhana L, et al. **Can J Microbiol** 1998 Oct;44(10):920-8

ANTAGONISTS & INHIBITORS

10-Undecynoic acid, an inhibitor of cytochrome P450 4A1, inhibits ethanolamine-specific phospholipid base exchange reaction in rat liver microsomes. Lenart J, et al. **Acta Biochim Pol** 1999;46(1):203-10

Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Sagar M, et al. **Aliment Pharmacol Ther** 1999 Apr;13(4):453-8

The effect of oxygen on propofol-induced inhibition of microsomal cytochrome P450 3A4. Miller E, et al. **Anaesthesia** 1999 Apr;54(4):320-2

Inactivation of toluene 2-monooxygenase in Burkholderia cepacia G4 by alkynes. Yeager CM, et al. **Appl Environ Microbiol** 1999 Feb;65(2):632-9

Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. He K, et al. **Biochemistry** 1998 Dec 15;37(50):17448-57

4-Phenyl-4-oxo-butanoic acid derivatives inhibitors of kynurenine 3-hydroxylase. Giordani A, et al. **Bioorg Med Chem Lett** 1998 Oct 20;8(20):2907-12

The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl. Palkama VJ, et al. **Br J Anaesth** 1998 Oct;81(4):598-600

Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Tateishi T, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):454-7

Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450. Reilly PE, et al. **Chem Biol Interact** 1999 Mar 1;118(1):39-49

The interaction of diltiazem with lovastatin and pravastatin. Azie NE, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):369-77

6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Edwards DJ, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):237-44

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Furuta T, et al. **Clin Pharmacol Ther** 1999 May;65(5):552-61

Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Hamaoka N, et al. **Clin Pharmacol Ther** 1999 Aug;66(2):110-7

Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Ko JW, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):606-14

Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Baune B, et al. **Drug Metab Dispos** 1999 May;27(5):565-8

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Gibbs MA, et al. **Drug Metab Dispos** 1999 Feb;27(2):180-7

Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Yamazaki H, et al. **Drug Metab Dispos** 1998 Nov;26(11):1053-7

Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions. Bonnabry P, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):341-7

Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Gass RJ, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):741-7

Absence of interaction between erythromycin and a single dose of clozapine. Hägg S, et al. **Eur J Clin Pharmacol** 1999 May;55(3):221-6

Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Rasmussen BB, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):735-40

Pyrrolo[3,2-c]quinoline derivatives: a new class of kynurenine-3-hydroxylase inhibitors. Heidempergher F, et al. **Farmaco** 1999 Mar 31;54(3):152-60

The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Antila S, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):446-9

Three- and four-dimensional quantitative structure activity relationship anaiyses of cytochrome P-450 3A4 inhibitors. Ekins S, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):429-38

In vivo inhibition of peptidylglycine-alpha-hydroxylating monooxygenase by 4-phenyl-3-butenoic acid. Mueller GP, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1331-6

Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. Stevens JC, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):594-602

Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Iwai N, et al. **Lung Cancer** 1999 Mar;23(3):209-22

Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Isohanni MH, et al. **Pharmacol Toxicol** 1999 Mar;84(3):143-6

Captopril inhibits peptidylglycine- alpha-hydroxylating monooxygenase: implications for therapeutic effects. Mueller SA, et al. **Pharmacology** 1999 May;58(5):270-80

Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Furukori H, et al. **Psychopharmacology (Berl)** 1999 Jul;145(2):189-92

BIOSYNTHESIS

The induction of cytochrome P450 isoform, CYP4A1, by clofibrate coincides with activation of ethanolamine-specific phospholipid base exchange reaction in rat liver microsomes. Lenart J, et al. **Acta Biochim Pol** 1998;45(1):119-26

Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Enriquez A, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):300-6

Amperometric phenol biosensor based on a thermostable phenol hydroxylase. Metzger J, et al. **Biosens Bioelectron** 1998 Nov 1;13(10):1077-82

Synthesis of alkane hydroxylase of Pseudomonas oleovorans increases the iron requirement of alk+ bacterial strains. Staijen IE, et al. **Biotechnol Bioeng** 1998 Jan 20;57(2):228-37

The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Reichel C, et al. **Br J Clin Pharmacol** 1998 Dec;46(6):535-9

Induction of lauric acid hydroxylase activity in catfish and bluegill by peroxisome proliferating agents. Haasch ML, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Nov;121(1-3):297-303

A molluscan peptide alpha-amidating enzyme precursor that generates five distinct enzymes. Spijker S, et al. **FASEB J** 1999 Apr;13(6):735-48

Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. Kroetz DL, et al. **J Biol Chem** 1998 Nov 20;273(47):31581-9

Induction of integral membrane PAM expression in AtT-20 cells alters the storage and trafficking of POMC and PC1. Ciccotosto GD, et al. **J Cell Biol** 1999 Feb 8;144(3):459-71

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. Tran JQ, et al. **J Clin Pharmacol** 1999 May;39(5):487-94

Differential regulation of peptide alpha-amidation by dexamethasone and disulfiram. Driscoll WJ, et al. **Mol Pharmacol** 1999 Jun;55(6):1067-76

Feedback regulation of GA5 expression and metabolic engineering of gibberellin levels in Arabidopsis. Xu YL, et al. **Plant Cell** 1999 May;11(5):927-36

An Atropa belladonna hyoscyamine 6beta-hydroxylase gene is differentially expressed in the root pericycle and anthers. Suzuki K, et al. **Plant Mol Biol** 1999 May;40(1):141-52

BLOOD

Fatty acid omega- and (omega-1)-hydroxylation in experimental alcoholic liver disease: relationship to different dietary fatty acids. Amet Y, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1493-500

Effects of chronic pulmonary overcirculation on pulmonary vasomotor tone. Parviz M, et al. **Ann Thorac Surg** 1999 Feb;67(2):522-7

[Low serum dopamine -- beta-hydroxylase activity in patients with panic disorder] Landowski J, et al. **Psychiatr Pol** 1998 Nov-Dec;32(6):781-8 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Crystallization and preliminary X-ray diffraction analysis of cytochrome P450sca-2 from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase. Ito S,

et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1209–11

Unique properties of purified, Escherichia coli–expressed constitutive cytochrome P4504A5. Hosny G, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):199–206

P450BM–3: absolute configuration of the primary metabolites of palmitic acid. Truan G, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):192–8

Kinetic isotope effects of peptidylglycine alpha–hydroxylating mono–oxygenase reaction. Takahashi K, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):131–7

Mechanistic probes of flavocytochrome P–450 BM3. Noble MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):S213

Characterization of the macrolide P–450 hydroxylase from Streptomyces venezuelae which converts narbomycin to picromycin. Betlach MC, et al. **Biochemistry** 1998 Oct 20; 37(42):14937–42

Peroxodiferric intermediate of stearoyl–acyl carrier protein delta 9 desaturase: oxidase reactivity during single turnover and implications for the mechanism of desaturation. Broadwater JA, et al. **Biochemistry** 1998 Oct 20; 37(42):14664–71

Dynamics of protein–bound water in the heme domain of P450BM3 studied by high–pressure spectroscopy: comparison with P450cam and P450 2B4. Davydov DR, et al. **Biochemistry** 1999 Jan 12;38(2):751–61

Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Helvig C, et al. **Biochemistry** 1998 Sep 8;37(36):12546–58

Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P–450 BM3. Noble MA, et al. **Biochemistry** 1998 Nov 10;37(45):15799–807

A new assay method of gamma–glutamyltransferase with 4–aminobenzoate hydroxylase from Agaricus bisporus as a coupling enzyme. Mizutani Y, et al. **Clin Chim Acta** 1999 Sep;287(1–2):83–97

Mutual conversion of fatty–acid substrate specificity by a single amino–acid exchange at position 527 in P–450Cm2 and P–450Alk3A. Zimmer T, et al. **Eur J Biochem** 1998 Sep 1;256(2):398–403

A structural comparison of molybdenum cofactor–containing enzymes. Kisker C, et al. **FEMS Microbiol Rev** 1998 Dec; 22(5):503–21 (73 ref.)

The role of CMP–N–acetylneuraminic acid hydroxylase in determining the level of N–glycolylneuraminic acid in porcine tissues. Malykh YN, et al. **Glycoconj J** 1998 Sep; 15(9):885–93

Chemical modification of 3–HBA–6–hydroxylase by phenylglyoxal: kinetic and physicochemical studies on the modified enzyme. Sumathi S, et al. **Indian J Biochem Biophys** 1998 Oct;35(5):266–72

Molecular dynamics simulations of P450 BM3–-examination of substrate–induced conformational change. Chang YT, et al. **J Biomol Struct Dyn** 1999 Jun;16(6):1189–203

Three–dimensional–quantitative structure activity relationship analysis of cytochrome P–450 3A4 substrates. Ekins S, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):424–33

NIH shift in flavin–dependent monooxygenation: mechanistic studies with 2–aminobenzoyl–CoA monooxygenase/reductase. Hartmann S, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7831–6

Structure of a cytochrome P450–redox partner electron–transfer complex. Sevrioukova IF, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1863–8

Homology modeling and substrate binding study of human CYP4A11 enzyme. Chang YT, et al. **Proteins** 1999 Feb 15;34(3):403–15

Warfarin resistance is associated with a protein component of the vitamin K 2,3–epoxide reductase enzyme complex in rat liver. Cain D, et al. **Thromb Haemost** 1998 Jul; 80(1):128–33

Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Lewis DF, et al. **Toxicology** 1999 Mar 1;133(1):1–33

Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate–bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Lewis DF, et al. **Xenobiotica** 1999 Apr;29(4):361–93

DRUG EFFECTS

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Kivistö KT, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):648–54

Mechanism–based inactivation of cytochrome P–450–3A4 by mifepristone (RU486). He K, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):791–7

Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. Lamberg TS, et al. **Pharmacol Toxicol** 1999 Apr;84(4):165–9

A reporter gene assay to assess the molecular mechanisms of xenobiotic–dependent induction of the human CYP3A4 gene in vitro. Ogg MS, et al. **Xenobiotica** 1999 Mar; 29(3):269–79

GENETICS

A continuous spectrophotometric assay for P450 BM–3, a fatty acid hydroxylating enzyme, and its mutant F87A. Schwaneberg U, et al. **Anal Biochem** 1999 May 1; 269(2):359–66

CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Kortunay S, et al. **Ann Rheum Dis** 1999 Mar;58(3):182–5

Genes specific for the biosynthesis of clavam metabolites antipodal to clavulanic acid are clustered with the gene for clavaminate synthase 1 in Streptomyces clavuligerus. Mosher RH, et al. **Antimicrob Agents Chemother** 1999 May; 43(5):1215–24

Molecular detection, isolation, and physiological characterization of functionally dominant phenol–degrading bacteria in activated sludge. Watanabe K, et al. **Appl Environ Microbiol** 1998 Nov;64(11):4396–402

Utilization of phenoxyacetic acid, by strains using either the ortho or meta cleavage of catechol during phenol degradation, after conjugal transfer of tfdA, the gene encoding a 2,4–dichlorophenoxyacetic acid/2–oxoglutarate dioxygenase. Radnoti de Lipthay J, et al. **Appl Microbiol Biotechnol** 1999 Feb;51(2):207–14

Regiospecific cytochrome P450 limonene hydroxylases from mint (Mentha) species: cDNA isolation, characterization, and functional expression of (–)–4S–limonene–3–hydroxylase and (–)–4S–limonene–6–hydroxylase. Lupien S, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):181–92

Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6betaB) and characterization of the recombinant protein. Nagata K, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):242–53

Hepatocyte nuclear factor 4–mediated activation of rat CYP3A1 gene and its modes of modulation by apolipoprotein A1 regulatory protein I and v–ErbA–related protein 3. Ogino M, et al. **Arch Biochem Biophys** 1999 Feb 1;362(1):32–7

CYP81E1, a cytochrome P450 cDNA of licorice (Glycyrrhiza echinata L.), encodes isoflavone 2'–hydroxylase. Akashi T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):67–70

Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. Bylund J, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):169–74

The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR–RFLP. Kitagawa K, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):146–51

Cloning and functional characterization of CYP94A2, a medium chain fatty acid hydroxylase from Vicia sativa. Le Bouquin R, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):156–62

CYP2A6 gene deletion reduces susceptibility to lung cancer. Miyamoto M, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):658–60

Cloning of CYP4F7, a kidney–specific P450 in the sea bass Dicentrarchus labrax. Sabourault C, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):155–61

Expression of cytochrome P450RA1 (CYP26) in human fetal hepatic and cephalic tissues. Trofimova–Griffin ME, et al. **Biochem Biophys Res Commun** 1998 Nov 18;252(2):487–91

Carnitine biosynthesis: identification of the cDNA encoding human gamma–butyrobetaine hydroxylase. Vaz FM, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):506–10

Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'–upstream regulatory region. Westlind A, et al. **Biochem Biophys Res Commun** 1999 May 27;259(1):201–5

Analysis of RNA–protein interactions of mouse liver cytochrome P4502A5 mRNA. Tilloy–Ellul A, et al. **Biochem J** 1999 May 1;339 (Pt 3):695–703

Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Helvig C, et al. **Biochemistry** 1998 Sep 8;37(36):12546–58

Studies with lysine N6–hydroxylase. Effect of a mutation in the assumed FAD binding site on coenzyme affinities and on lysine hydroxylating activity. Stehr M, et al. **Biol Chem** 1999 Jan;380(1):47–54

A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Itoh K, et al. **Biol Pharm Bull** 1999 Jan;22(1):77–9

Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population [published erratum appears in Br J Clin Pharmacol 1999 May;47(5):603] Hoskins JM, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):499–504

Phenol degradation by an enterobacterium: a Klebsiella strain carries a TOL–like plasmid and a gene encoding a novel phenol hydroxylase. Heesche–Wagner K, et al. **Can J Microbiol** 1999 Feb;45(2):162–71

Gene sequences of the pcpB gene of pentachlorophenol–degrading Sphingomonas chlorophenolica found in nondegrading bacteria. Saboo VM, et al. **Can J Microbiol** 1998 Jul;44(7):667–75

Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. Crawford EL, et al. **Carcinogenesis** 1998 Oct; 19(10):1867–71

Expression of cytochrome P450 2A3 in rat esophagus: relevance to N–nitrosobenzylmethylamine. Gopalakrishnan R, et al. **Carcinogenesis** 1999 May;20(5):885–91

Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Aynacioglu AS, et al. **Clin Pharmacol Ther** 1999 Aug; 66(2):185–92

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Furuta T, et al. **Clin Pharmacol Ther** 1999 May;65(5):552–61

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Herrlin K, et al. **Clin Pharmacol Ther** 1998 Oct; 64(4):391–401

Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Ko JW, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):606–14

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E–3174 [clinical conference] McCrea JB, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):348–52

Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Nowak MP, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):378–83

Phenotypic–genotypic analysis of CYP2C19 in the Jewish Israeli population. Sviri S, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):275–82

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug–metabolizing enzyme in an ethnic or racial population? [letter; comment] Xie HG. **Clin Pharmacol Ther** 1998 Nov;64(5):575. Comment on: Clin Pharmacol Ther 1998 Mar;63(4):422–7.

Expression and molecular cloning of human liver leukotriene B4 omega–hydroxylase (CYP4F2) gene. Kikuta Y, et al. **DNA Cell Biol** 1999 Sep;18(9):723–30

Purification, characterization and gene cloning of 6–hydroxynicotinate 3–monooxygenase from Pseudomonas fluorescens TN5. Nakano H, et al. **Eur J Biochem** 1999 Feb;260(1):120–6

Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity. Bathum L, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):427–30

Variability of coumarin 7– and 3–hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Hadidi H, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):437–41

Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Wanwimolruk S, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):431–5

CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Yamada H, et al. **Eur J Clin Pharmacol** 1998 Aug;54(6):479–81

CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Zhou Q, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):43–7

Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C–oxidase. Oscarson M, et al. **FEBS Lett** 1998 Nov 6;438(3):201–5

Characterisation and PCR–based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. Oscarson M, et al. **FEBS Lett** 1999 Apr 1; 448(1):105–10

The role of the Sphingomonas species UG30 pentachlorophenol–4–monooxygenase in p–nitrophenol degradation. Leung KT, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):247–53

Structure and expression of three src2 homologues and a novel subfamily of flavoprotein monooxygenase genes revealed by the analysis of a 25kb fragment from Arabidopsis thaliana chromosome IV. Aubourg S, et al. **Gene** 1999 Apr 16;230(2):197–205

Multiple p450alk (cytochrome P450 alkane hydroxylase) genes from the halotolerant yeast Debaryomyces hansenii. Yadav JS, et al. **Gene** 1999 Jan 21;226(2):139–46

Role of ornibactin biosynthesis in the virulence of Burkholderia cepacia: characterization of pvdA, the gene encoding L–ornithine N(5)–oxygenase. Sokol PA, et al. **Infect Immun** 1999 Sep;67(9):4443–55

Transcriptional activation of CYP2C, MxA and Fas in sudden infant death syndrome. Beurton F, et al. **Int J Mol Med** 1999 Jan;3(1):33–9

NahW, a novel, inducible salicylate hydroxylase involved in mineralization of naphthalene by Pseudomonas stutzeri AN10. Bosch R, et al. **J Bacteriol** 1999 Apr;181(8):2315–22

Molecular analysis of a novel methanesulfonic acid monooxygenase from the methylotroph Methylosulfonomonas methylovora. de Marco P, et al. **J Bacteriol** 1999 Apr;181(7):2244–51

Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P–450 hydroxylase gene. Lomovskaya N, et al. **J Bacteriol** 1999 Jan; 181(1):305–18

Expression of alkane hydroxylase from Acinetobacter sp. Strain ADP1 is induced by a broad range of n–alkanes and requires the transcriptional activator AlkR. Ratajczak A, et al. **J Bacteriol** 1998 Nov;180(22):5822–7

The PalkBFGHJKL promoter is under carbon catabolite repression control in Pseudomonas oleovorans but not in Escherichia coli alk+ recombinants. Staijen IE, et al. **J Bacteriol** 1999 Mar;181(5):1610–6

Null mutation in IRE1 gene inhibits overproduction of microsomal cytochrome P450Alk1 (CYP 52A3) and proliferation of the endoplasmic reticulum in Saccharomyces cerevisiae. Takewaka T, et al. **J Biochem (Tokyo)** 1999 Mar;125(3):507–14

Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. Christmas P, et al. **J Biol Chem** 1999 Jul 23;274(30):21191-9

Alternative splicing of sur2 Exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel. Chutkow WA, et al. **J Biol Chem** 1999 May 7; 274(19):13656-65

Induction of integral membrane PAM expression in AtT-20 cells alters the storage and trafficking of POMC and PC1. Ciccotosto GD, et al. **J Cell Biol** 1999 Feb 8;144(3):459-71

Molecular basis of Refsum disease: identification of new mutations in the phytanoyl-CoA hydroxylase cDNA. Jansen GA, et al. **J Inherit Metab Dis** 1998 Jun;21(3):288-91

Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [letter] Ando Y, et al. **J Natl Cancer Inst** 1999 Sep 15;91(18):1587-90

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Ibeanu GC, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):635-40

A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. Nunoya KI, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):437-42

Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. Stevens JC, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):594-602

Pharmacogenetics of CYP2C subfamily in a Japanese population. Ieiri I, et al. **J Toxicol Sci** 1998 Jul;23 Suppl 2:129-31 (12 ref.)

Expression of cytochrome P450 3A4 in foveolar epithelium with intestinal metaplasia of the human stomach. Yokose T, et al. **Jpn J Cancer Res** 1998 Oct;89(10):1028-32

CYP2A6 polymorphism, nicotine, and environmental nitrosamines [letter; comment] Idle JR. **Lancet** 1999 Jun 12;353(9169):2073. Comment on: Lancet 1999 Mar 13;353(9156):898-9.

Genetic variation of CYP2A6, smoking, and risk of cancer [letter; comment] London SJ, et al. **Lancet** 1999 Mar 13; 353(9156):898-9. Comment on: Lancet 1999 Jun 12;353(9169):2073.

CYP2E1 and CYP3A1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. Nguyen TD, et al. **Life Sci** 1999; 65(11):1103-13

Adaptation of Comamonas testosteroni TA441 to utilize phenol: organization and regulation of the genes involved in phenol degradation. Arai H, et al. **Microbiology** 1998 Oct;144 (Pt 10):2895-903

A novel positive regulatory element that enhances hamster CYP2A8 gene expression mediated by xenobiotic responsive element. Kurose K, et al. **Mol Pharmacol** 1999 Feb;55(2):279-87

Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Chen GF, et al. **Pharmacogenetics** 1999 Jun;9(3):327-32

Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction. Griese EU, et al. **Pharmacogenetics** 1999 Jun;9(3):389-91

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Ibeanu GC, et al. **Pharmacogenetics** 1998 Apr; 8(2):129-35

Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Kaneko A, et al. **Pharmacogenetics** 1999 Jun;9(3):317-26

Ribozymes targeted to stearoyl-ACP delta9 desaturase mRNA produce heritable increases of stearic acid in transgenic maize leaves. Merlo AO, et al. **Plant Cell** 1998 Oct;10(10):1603-22

Phytochrome regulation and differential expression of gibberellin 3beta-hydroxylase genes in germinating Arabidopsis seeds. Yamaguchi S, et al. **Plant Cell** 1998 Dec; 10(12):2115-26

Modification of gibberellin production and plant development in Arabidopsis by sense and antisense expression of gibberellin 20-oxidase genes. Coles JP, et al. **Plant J** 1999 Mar;17(5):547-56

Flavonoid hydroxylase from Catharanthus roseus: cDNA, heterologous expression, enzyme properties and cell-type specific expression in plants. Kaltenbach M, et al. **Plant J** 1999 Jul;19(2):183-93

Gibberellin 2-oxidation and the SLN gene of Pisum sativum. Lester DR, et al. **Plant J** 1999 Jul;19(1):65-73

Over-expression of a tobacco homeobox gene, NTH15, decreases the expression of a gibberellin biosynthetic gene encoding GA 20-oxidase. Tanaka-Ueguchi M, et al. **Plant J** 1998 Aug;15(3):391-400

The presence of CYP79 homologues in glucosinolate-producing plants shows evolutionary conservation of the enzymes in the conversion of amino acid to aldoxime in the biosynthesis of cyanogenic glucosides and glucosinolates. Bak S, et al. **Plant Mol Biol** 1998 Nov;38(5):725-34

Feedback control and diurnal regulation of gibberellin 20-oxidase transcript levels in potato. Carrera E, et al. **Plant Physiol** 1999 Feb;119(2):765-74

Overexpression of 20-oxidase confers a gibberellin-overproduction phenotype in Arabidopsis. Huang S, et al. **Plant Physiol** 1998 Nov;118(3):773-81

Regulation and functional expression of cinnamate 4-hydroxylase from parsley. Koopmann E, et al. **Plant Physiol** 1999 Jan;119(1):49-56

Regulation of ferulate-5-hydroxylase expression in Arabidopsis in the context of sinapate ester biosynthesis. Ruegger M, et al. **Plant Physiol** 1999 Jan;119(1):101-10

Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein. Chambraud B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2104-9

Association of CYP3A4 genotype with treatment-related leukemia. Felix CA, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13176-81

A cytochrome P450 terpenoid hydroxylase linked to the suppression of insect juvenile hormone synthesis. Sutherland TD, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12884-9

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Sagar M, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1034-8

A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Ogg MS, et al. **Xenobiotica** 1999 Mar; 29(3):269-79

[Genetic polymorphism of the CYP2C subfamily] Chiba K. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):15-21 (47 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese] Yokoi T, et al. **Nippon Yakurigaku Zasshi** 1998 Jul; 112(1):5-14 (45 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Epitope mapping of monoclonal antibodies against 4-aminobenzoate hydroxylase from Agaricus bisporus. Tsuji H, et al. **Biochim Biophys Acta** 1998 Nov 27; 1425(3):628-31

Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. Wang RW, et al. **Drug Metab Dispos** 1999 Feb; 27(2):167-72

ISOLATION & PURIFICATION

Unique properties of purified, Escherichia coli-expressed constitutive cytochrome P4504A5. Hosny G, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):199-206

METABOLISM

Regulation of P-450 4A activity in the glomerulus of the rat. Ito O, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1749-57

Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Nguyen X, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1691-700

Novel double bond-transferring hydroxylation reaction involved in microbial metabolism of eugenol. Furukawa H, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:81-6

Cytochrome P-450 3A4: regulation and role in drug metabolism. Guengerich FP. **Annu Rev Pharmacol Toxicol** 1999;39:1-17 (108 ref.)

Biocatalyst engineering by assembly of fatty acid transport and oxidation activities for In vivo application of cytochrome P-450BM-3 monooxygenase. Schneider S, et al. **Appl Environ Microbiol** 1998 Oct;64(10):3784-90

Role of human CYP4F2 in hepatic catabolism of the proinflammatory agent leukotriene B4. Jin R, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):89-98

Substrate specificity of the cytochrome P450 enzymes CYP79A1 and CYP71E1 involved in the biosynthesis of the cyanogenic glucoside dhurrin in Sorghum bicolor (L.) Moench. Kahn RA, et al. **Arch Biochem Biophys** 1999 Mar 1;363(1):9-18

Regiospecific cytochrome P450 limonene hydroxylases from mint (Mentha) species: cDNA isolation, characterization, and functional expression of (-)-4S-limonene-3-hydroxylase and (-)-4S-limonene-6-hydroxylase. Lupien S, et al. **Arch Biochem Biophys** 1999 Aug 1;368(1):181-92

P450BM-3: absolute configuration of the primary metabolites of palmitic acid. Truan G, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):192-8

Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Voice MW, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):116-24

Investigations on the role of cytochrome b5 and divalent cations in the maximal nifedipine oxidase activity of human liver. Müller-Enoch D. **Arzneimittelforschung** 1999 May; 49(5):470-5

Cloning and functional characterization of CYP94A2, a medium chain fatty acid hydroxylase from Vicia sativa. Le Bouquin R, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):156-62

Kinetic and inhibition studies on substrate channelling in the bifunctional enzyme catalysing C-terminal amidation. Moore AB, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):33-40

Roles of key active-site residues in flavocytochrome P450 BM3. Noble MA, et al. **Biochem J** 1999 Apr 15;339 (Pt 2):371-9

Production in vitro by the cytochrome P450 CYP94A1 of major C18 cutin monomers and potential messengers in plant-pathogen interactions: enantioselectivity studies. Pinot F, et al. **Biochem J** 1999 Aug 15;342 (Pt 1):27-32

Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Shou M, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):845-53

Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Yasumori T, et al. **Biochem Pharmacol** 1999 Jun 1;57(11):1297-303

Flavocytochrome P-450 BM3: a paradigm for the analysis of electron transfer and its control in the P-450s. Munro AW, et al. **Biochem Soc Trans** 1999 Feb;27(2):190-6 (40 ref.)

The interaction of eukaryotic cytochrome b5 with flavocytochrome P-450 BM3 from Bacillus megaterium. Munro AW, et al. **Biochem Soc Trans** 1998 Aug;26(3):S212

Mechanistic probes of flavocytochrome P-450 BM3. Noble MA, et al. **Biochem Soc Trans** 1998 Aug;26(3):S213

Characterization of active and inactive forms of the phenol hydroxylase stimulatory protein DmpM. Cadieux E, et al. **Biochemistry** 1999 Aug 17;38(33):10714-22

Role of hydrophobic partitioning in substrate selectivity and turnover of the ricinus communis stearoyl acyl carrier protein delta(9) desaturase. Haas JA, et al. **Biochemistry** 1999 Sep 28;38(39):12833-40

Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Jung F, et al. **Biochemistry** 1998 Nov 17;37(46):16270-9

N-acylglycine amidation: implications for the biosynthesis of fatty acid primary amides. Wilcox BJ, et al. **Biochemistry** 1999 Mar 16;38(11):3235-45

6alpha-hydroxylation of taurochenodeoxycholic acid and lithocholic acid by CYP3A4 in human liver microsomes. Araya Z, et al. **Biochim Biophys Acta** 1999 Apr 19; 1438(1):47-54

Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5beta-cholestane-3alpha,7alpha,12alpha-triol in human liver microsomes. Furster C, et al. **Biochim Biophys Acta** 1999 Jan 29;1437(1):46-52

The five cysteine residues located in the active site region of bovine aspartyl (asparaginyl) beta-hydroxylase are not essential for catalysis. McGinnis K, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):454-6

Studies with lysine N6-hydroxylase. Effect of a mutation in the assumed FAD binding site on coenzyme affinities and on lysine hydroxylating activity. Stehr M, et al. **Biol Chem** 1999 Jan;380(1):47-54

Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Kimura M, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):115-9

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. May-Manke A, et al. **Cancer Chemother Pharmacol** 1999;44(4):327-34

Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Murphy SE, et al. **Chem Res Toxicol** 1999 Jul;12(7):639-45

Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Shen S, et al. **Chem Res Toxicol** 1999 Feb;12(2):214-22

Inhibitory effects of quinidine and quinine on liver microsome oxidation enzymes in man and rat. Tu ZG, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):541-4

No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity. Xie HG, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):216-8

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Arlander E, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):484-91

In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Krecic-Shepard ME, et al. **Clin Pharmacol Ther** 1999 Jul; 66(1):40-50

Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Schwarz UI, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):283-90

Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system. Ozminkowski RJ, et al. **Clin Ther** 1998 Jul-Aug;20(4):780-96

Cytidine monophosphate-N-acetylneuraminate hydroxylase in the starfish Asterias rubens and other echinoderms. Gollub M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jul; 120(3):605-15

Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Björkhem I, et al. **Curr Opin Lipidol** 1999 Apr;10(2):161-5 (20 ref.)

Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Becquemont L, et al. **Drug Metab Dispos** 1999 Sep;27(9):1068-73

Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen

(droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Dehal SS, et al. **Drug Metab Dispos** 1999 Jun;27(6):681-8

Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Dupont I, et al. **Drug Metab Dispos** 1999 Mar;27(3):322-6

Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Granvil CP, et al. **Drug Metab Dispos** 1999 Apr;27(4):533-41

The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Mankowski DC. **Drug Metab Dispos** 1999 Sep;27(9):1024-8

Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Yamazaki H, et al. **Drug Metab Dispos** 1999 Sep;27(9):999-1004

The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Mamiya K, et al. **Epilepsia** 1998 Dec;39(12):1317-23

Hydroxylation reaction catalyzed by the Burkholderia cepacia AC1100 bacterial strain. Involvement of the chlorophenol-4-monooxygenase. Martin G, et al. **Eur J Biochem** 1999 Apr;261(2):533-9

Purification, characterization and gene cloning of 6-hydroxynicotinate 3-monooxygenase from Pseudomonas fluorescens TN5. Nakano H, et al. **Eur J Biochem** 1999 Feb;260(1):120-6

Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Hadidi H, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):437-41

A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Lucas RA, et al. **Eur J Clin Pharmacol** 1998 Oct;54(8):639-43

Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). Sandwall P, et al. **Eur J Clin Pharmacol** 1999 Jun;55(4):279-83

CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Tamminga WJ, et al. **Eur J Clin Pharmacol** 1999 May;55(3):177-84

Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Wanwimolruk S, et al. **Eur J Clin Pharmacol** 1998 Jul;54(5):431-5

The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. van Agtmael MA, et al. **Eur J Drug Metab Pharmacokinet** 1998 Jul-Sep;23(3):429-36

Novel mechanism of aliphatic hydroxylation in enzymatic and biomimetic systems: problems of the reaction dynamics. Karasevich EI, et al. **Exp Toxicol Pathol** 1999 Jul; 51(4-5):335-41 (18 ref.)

The zeaxanthin biosynthesis enzyme beta-carotene hydroxylase is involved in myxoxanthophyll synthesis in Synechocystis sp. PCC 6803. Lagarde D, et al. **FEBS Lett** 1999 Jul 9;454(3):247-51

The role of the Sphingomonas species UG30 pentachlorophenol-4-monooxygenase in p-nitrophenol degradation. Leung KT, et al. **FEMS Microbiol Lett** 1999 Apr 1;173(1):247-53

Mechanistic aspects of molybdenum-containing enzymes. Hille R, et al. **FEMS Microbiol Rev** 1998 Dec;22(5):489-501 (40 ref.)

Peptidylglycine alpha-amidating mono-oxygenase: neuropeptide amidation as a target for drug design. Bolkenius FN, et al. **Gen Pharmacol** 1998 Nov;31(5):655-9 (60 ref.)

H1 antihistamines, cytochrome P450 and multidrug resistance: is there a link? Rihoux JP, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S71-2 (8 ref.)

Cloning and characterization of a sulfonate/alpha-ketoglutarate dioxygenase from Saccharomyces cerevisiae. Hogan DA, et al. **J Bacteriol** 1999 Sep;181(18):5876-9

Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene. Lomovskaya N, et al. **J Bacteriol** 1999 Jan; 181(1):305-18

The PalkBFGHJKL promoter is under carbon catabolite repression control in Pseudomonas oleovorans but not in Escherichia coli alk+ recombinants. Staijen IE, et al. **J Bacteriol** 1999 Mar;181(5):1610-6

P-CIP1, a novel protein that interacts with the cytosolic domain of peptidylglycine alpha-amidating monooxygenase, is associated with endosomes. Chen L, et al. **J Biol Chem** 1998 Dec 11;273(50):33524-32

Phosphorylation of cytosolic domain Ser(937) affects both biosynthetic and endocytic trafficking of peptidylglycine alpha-amidating monooxygenase. Steveson TC, et al. **J Biol Chem** 1999 Jul 23;274(30):21128-38

Peroxygenase metabolism of N-acetylbenzidine by prostaglandin H synthase. Formation of an N-hydroxylamine. Zenser TV, et al. **J Biol Chem** 1999 May 21;274(21):14850-6

Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. Kharasch ED, et al. **J Clin Pharmacol** 1999 Jul;39(7):664-9

Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. Venkatakrishnan K, et al. **J Clin Pharmacol** 1999 Jun; 39(6):567-77

Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Yasui N, et al. **J Clin Psychopharmacol** 1999 Apr;19(2):149-54

Immunocytochemical mapping of the amidating enzyme PAM in the developing and adult mouse lung. Guembe L, et al. **J Histochem Cytochem** 1999 May;47(5):623-36

In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice. Guéraud F, et al. **J Lipid Res** 1999 Jan;40(1):152-9

Differences in the ways sympathetic neurons and endocrine cells process, store, and secrete exogenous neuropeptides and peptide-processing enzymes. Marx R, et al. **J Neurosci** 1999 Oct 1;19(19):8300-11

Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. Ekins S, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):424-33

Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). He K, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):791-7

Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. Ludwig E, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):1-8

In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. Nielsen TL, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):31-7

Biotransformation of coumarin by rodent and human cytochromes P-450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. Zhuo X, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):463-71

Expression of cytochrome P450 3A4 in foveolar epithelium with intestinal metaplasia of the human stomach. Yokose T, et al. **Jpn J Cancer Res** 1998 Oct;89(10):1028-32

Phytanic acid alpha-hydroxylation by bacterial cytochrome P450. Matsunaga I, et al. **Lipids** 1998 Dec;33(12):1213-6

The hxB gene, necessary for the post-translational activation of purine hydroxylases in Aspergillus nidulans, is independently controlled by the purine utilization and the nicotinate utilization transcriptional activating systems. Amrani L, et al. **Mol Microbiol** 1999 Feb;31(4):1065-73

Induced expression of CYP2A5 in inflamed trematode-infested mouse liver. Montero R, et al. **Mutagenesis** 1999 Mar;14(2):217-20

Enzymatic formation of C-terminal amides. Kulathila R, et al. **Nat Prod Rep** 1999 Apr;16(2):145-54 (102 ref.)

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Fang J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Feb; 359(2):147-51

Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Chiarugi A, et al. **Neuropharmacology** 1999 Aug;38(8):1225-33

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach. Ito K, et al. **Pharm Res** 1999 Feb;16(2):225-31

In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pan LP, et al. **Pharmacogenetics** 1998 Oct;8(5):383-9

An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Sai Y, et al. **Pharmacogenetics** 1999 Apr;9(2):229-37

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Shou M, et al. **Pharmacogenetics** 1998 Oct;8(5):391-401

Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Burstein AH, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1271-6

Novel characteristics and regulation of a divergent cinnamate 4-hydroxylase (CYP73A15) from French bean: engineering expression in yeast. Nedelkina S, et al. **Plant Mol Biol** 1999 Apr;39(6):1079-90

Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein. Chambraud B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2104-9

A cytochrome b5 is required for full activity of flavonoid 3', 5'-hydroxylase, a cytochrome P450 involved in the formation of blue flower colors. de Vetten N, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):778-83

NIH shift in flavin-dependent monooxygenation: mechanistic studies with 2-aminobenzoyl-CoA monooxygenase/reductase. Hartmann S, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7831-6

New routes for lignin biosynthesis defined by biochemical characterization of recombinant ferulate 5-hydroxylase, a multifunctional cytochrome P450-dependent monooxygenase. Humphreys JM, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10045-50

Coniferyl aldehyde 5-hydroxylation and methylation direct syringyl lignin biosynthesis in angiosperms. Osakabe K, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):8955-60

Structure of a cytochrome P450-redox partner electron-transfer complex. Sevrioukova IF, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1863-8

Expression of a soybean cytochrome P450 monooxygenase cDNA in yeast and tobacco enhances the metabolism of phenylurea herbicides. Siminszky B, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1750-5

A cytochrome P450 terpenoid hydroxylase linked to the suppression of insect juvenile hormone synthesis. Sutherland TD, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12884-9

Molecular cloning and functional expression of gibberellin 2- oxidases, multifunctional enzymes involved in gibberellin deactivation. Thomas SG, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4698-703

Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. von Moltke LL, et al. **Psychopharmacology (Berl)** 1999 Jul; 145(1):113-22

Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids. Broun P, et al. **Science** 1998 Nov 13;282(5392):1315-7

Cofactor- and substrate-binding domains in flavin-dependent N-hydroxylating enzymes [letter; comment] Dick S, et al. **Trends Biochem Sci** 1998 Nov;23(11):414-5. Comment on: Trends Biochem Sci 1998 Feb;23(2):56-7.

PHYSIOLOGY

Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Salmela KS, et al. **Alcohol Clin Exp Res** 1998 Dec; 22(9):2125-32

Cytochrome P-450 omega-hydroxylase senses O2 in hamster muscle, but not cheek pouch epithelium, microcirculation. Lombard JH, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H503-8

Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Wang MH, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F246-53

Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Yamazaki H, et al. **Arch Toxicol** 1999 Mar;73(2):65-70

Macrolide biosynthesis: a single cytochrome P450, PicK, is responsible for the hydroxylations that generate methymycin, neomethymycin, and picromycin in Streptomyces venezuelae. Graziani EI, et al. **Bioorg Med Chem Lett** 1998 Nov 17;8(22):3117-20

Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Foster DJ, et al. **Br J Clin Pharmacol** 1999 Apr; 47(4):403-12

Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Imig JD, et al. **Br J Pharmacol** 1999 Jul; 127(6):1399-405

Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Tang W, et al. **Chem Res Toxicol** 1999 Feb;12(2):192-9

Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. Khoo SM, et al. **J Pharm Sci** 1998 Dec; 87(12):1538-41

Intracellular nucleotide-mediated gating of SUR/Kir6.0 complex potassium channels expressed in a mammalian cell line and its modification by pinacidil. Satoh E, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):663-74

HYDROXYLYSINE

ANALOGS & DERIVATIVES

Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Al-Dehaimi AW, et al. **Clin Chem** 1999 May;45(5):676-81

Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility. Lo Cascio V, et al. **J Bone Miner Res** 1999 Aug; 14(8):1420-4

Development of an immunoassay for urinary galactosylhydroxylysine. Leigh SD, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):169-78

ANALYSIS

Recombinant human type II collagens with low and high levels of hydroxylysine and its glycosylated forms show marked differences in fibrillogenesis in vitro. Notbohm H, et al. **J Biol Chem** 1999 Mar 26;274(13):8988-92

Assay for 5-hydroxylysine and L-lysine in human and rat urine and in bone by gas chromatography. Euli D, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 19;724(2):373-9

CHEMISTRY

3-Hydroxylysine, a potential marker for studying radical-induced protein oxidation. Morin B, et al. **Chem Res Toxicol** 1998 Nov;11(11):1265-73

HYDROXYMERCURIBENZOATES

PHARMACOLOGY

Intrathecal administration of p-hydroxymercuribenzoate or phosphoramidon/bestatin-combined induces antinociceptive effects through different opioid mechanisms. Tan-No K, et al. **Neuropeptides** 1998 Oct; 32(5):411-5

HYDROXYMETHACRYLATE GEL see **POLYHYDROXYETHYL METHACRYLATE**

HYDROXYMETHOLONE see **OXYMETHOLONE**

HYDROXYMETHOXYPHENYLGLYCOL see **METHOXYHYDROXYPHENYLGLYCOL**

HYDROXYMETHYL AND FORMYL TRANSFERASES

ANTAGONISTS & INHIBITORS

Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines. Faessel HM, et al. **Biochem Pharmacol** 1999 Mar 1;57(5):567-77

A multisubstrate adduct inhibitor of AICAR transformylase. Wall M, et al. **J Med Chem** 1999 Sep 9;42(18):3421-4

CHEMISTRY

Crystallization and preliminary X-ray analysis of Escherichia coli methionyl-tRNAMet(f) formyltransferase complexed with formyl-methionyl-tRNAMet(f). Schmitt E, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):332-4

Crystallization and preliminary X-ray crystallographic analysis of deoxycytidylate hydroxymethylase from bacteriophage T4. Sohn SH, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):1061-3

X-ray crystal structure of glycinamide ribonucleotide synthetase from Escherichia coli. Wang W, et al. **Biochemistry** 1998 Nov 10;37(45):15647-62

Crystal structure of methionyl-tRNAfMet transformylase complexed with the initiator formyl-methionyl-tRNAfMet. Schmitt E, et al. **EMBO J** 1998 Dec 1;17(23):6819-26

Crystal structure of deoxycytidylate hydroxymethylase from bacteriophage T4, a component of the deoxyribonucleoside triphosphate-synthesizing complex. Song HK, et al. **EMBO J** 1999 Mar 1;18(5):1104-13

The amino-terminal region of the Escherichia coli T-protein of the glycine cleavage system is essential for proper association with H-protein. Okamura-Ikeda K, et al. **Eur J Biochem** 1999 Sep;264(2):446-53

Identification of the folate binding sites on the Escherichia coli T-protein of the glycine cleavage system. Okamura-Ikeda K, et al. **J Biol Chem** 1999 Jun 18; 274(25):17471-7

Combinatorial protein engineering by incremental truncation. Ostermeier M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3562-7

Induced fit of a peptide loop of methionyl-tRNA formyltransferase triggered by the initiator tRNA substrate. Ramesh V, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):875-80

GENETICS

Catalytic mechanism of Escherichia coli glycinamide ribonucleotide transformylase probed by site-directed mutagenesis and pH-dependent studies. Shim JH, et al. **Biochemistry** 1999 Aug 3;38(31):10024-31

Cloning and complete nucleotide sequence of Acinetobacter radioresistens CMC-1 AglyA gene encoding serine hydroxymethyltransferase. Hong MC, et al. **FEMS Microbiol Lett** 1999 Jan 15;170(2):413-8

Expression and characterization of bovine mitochondrial methionyl-tRNA transformylase. Takeuchi N, et al. **J Biochem (Tokyo)** 1998 Dec 1;124(6):1069-71

Roles for GcvA-binding sites 3 and 2 and the Lrp-binding region in gcvT::lacZ expression in Escherichia coli. Stauffer LT, et al. **Microbiology** 1998 Oct;144 (Pt 10):2865-72

The Aspergillus nidulans panB gene encodes ketopantoate hydroxymethyltransferase, required for biosynthesis of pantothenate and Coenzyme A. Kurtov D, et al. **Mol Gen Genet** 1999 Aug;262(1):115-20

Molecular cloning and sequence analysis of the Schizosaccharomyces pombe ade10+ gene. Liedtke C, et al. **Yeast** 1998 Oct;14(14):1307-10

ISOLATION & PURIFICATION

Crystallization and preliminary X-ray analysis of Escherichia coli methionyl-tRNAMet(f) formyltransferase complexed with formyl-methionyl-tRNAMet(f). Schmitt E, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):332-4

METABOLISM

Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Baggott JE, et al. **Arch Dermatol** 1999 Jul;135(7):813-7

Mapping the active site of the Haemophilus influenzae methionyl-tRNA formyltransferase: residues important for catalysis and tRNA binding. Newton DT, et al. **Biochem J** 1999 Apr 1;339 (Pt 1):63-9

Catalytic mechanism of Escherichia coli glycinamide ribonucleotide transformylase probed by site-directed mutagenesis and pH-dependent studies. Shim JH, et al. **Biochemistry** 1999 Aug 3;38(31):10024-31

Lyotropic-salt-induced changes in monomer/dimer/tetramer association equilibrium of formyltransferase from the hyperthermophilic Methanopyrus kandleri in relation to the activity and thermostability of the enzyme. Shima S, et al. **Eur J Biochem** 1998 Nov 15;258(1):85-92

Expression and characterization of bovine mitochondrial methionyl-tRNA transformylase. Takeuchi N, et al. **J Biochem (Tokyo)** 1998 Dec 1;124(6):1069-71

Formylation is not essential for initiation of protein synthesis in all eubacteria. Newton DT, et al. **J Biol Chem** 1999 Aug 6;274(32):22143-6

Combinatorial protein engineering by incremental truncation. Ostermeier M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3562-7

Induced fit of a peptide loop of methionyl-tRNA formyltransferase triggered by the initiator tRNA substrate. Ramesh V, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):875-80

PHYSIOLOGY

Functional interaction of an arginine conserved in the sixteen amino acid insertion module of Escherichia coli methionyl-tRNA formyltransferase with determinants for formylation in the initiator tRNA. Ramesh V, et al. **Biochemistry** 1998 Nov 10;37(45):15925-32

HYDROXYMETHYLBILANE SYNTHASE

see related
PORPHYRIA

CHEMISTRY

Determination of the structure of seleno-methionine-labelled hydroxymethylbilane synthase in its active form by multi-wavelength anomalous dispersion. Hädener A, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Mar;55 (Pt 3):631-43

Dipyrromethane cofactor assembly in porphobilinogen deaminase. McNeill LA, et al. **Biochem Soc Trans** 1998 Aug;26(3):S286

Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle. Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326-36 (43 ref.)

DEFICIENCY

The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria. Tishler PV. **Life Sci** 1999;65(2):207-14

GENETICS

Rat porphobilinogen deaminase gene: a pseudogene-free internal standard for laser-assisted cell picking. Fink L, et al. **Biotechniques** 1999 Mar;26(3):510-6

Exon 1 donor splice site mutations in the porphobilinogen deaminase gene in the non-erythroid variant form of acute intermittent porphyria. Puy H, et al. **Hum Genet** 1998 Nov; 103(5):570-5

Comparison of complementary and genomic DNA sequencing for the detection of mutations in the HMBS gene in British patients with acute intermittent porphyria: identification of 25 novel mutations. Whatley SD, et al. **Hum Genet** 1999 Jun;104(6):505-10

Acute intermittent porphyria: characterization of two novel mutations in the porphobilinogen deaminase gene, one amino acid deletion (453-455delAGC) and one splicing aceptor site mutation (IVS8-1G>T). De Siervi A, et al. **Hum Mutat (Online)** 1999 Oct;14(4):355

Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA. Hilf R, et al. **Photochem Photobiol** 1999 Sep;70(3):334-40

METABOLISM

Structure and mechanism of enzymes involved in the assembly of the tetrapyrrole macrocycle. Shoolingin-Jordan PM. **Biochem Soc Trans** 1998 Aug; 26(3):326-36 (43 ref.)

Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA. Hilf R, et al. **Photochem Photobiol** 1999 Sep;70(3):334-40

Acute intermittent porphyria: mutation analysis and identification of gene carriers in a German kindred by PCR-DGGE analysis. Petrides PE. **Skin Pharmacol Appl Skin Physiol** 1998 Nov-Dec; 11(6):374-80 (24 ref.)

PHYSIOLOGY

Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. Lindberg RL, et al. **J Clin Invest** 1999 Apr; 103(8):1127-34

3-HYDROXY-3-METHYLGLUTARIC ACID see **MEGLUTOL**

HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS

see related
HYDROXYMETHYLGLUTARYL COA REDUCTASES

Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme A reductase-inhibitor therapy. Strauss WE, et al. **Clin Ther** 1999 Feb;21(2):422-9

[Statins: a new group of anti-inflammatory agents?] Hansen PR, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4421-2 **(Dan)**

[Atorvastatin . A new generation of hypolipemic agents?] Azanza JR, et al. **Rev Med Univ Navarra** 1998 Jan-Mar; 42(1):51-5 (35 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Crouse JR 3rd, et al. **Am J Cardiol** 1999 May 15; 83(10):1476-7, A7

Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Kayikçioğlu M, et al. **Am J Cardiol** 1999 Apr 1;83(7):1135-7, A9

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Riegger G, et al. **Atherosclerosis** 1999 May; 144(1):263-70

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Rothe G, et al. **Atherosclerosis** 1999 May;144(1):251-61

Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Schaefer JR, et al. **Atherosclerosis** 1999 May; 144(1):177-84

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Ballantyne CM, et al. **Circulation** 1999 Feb 16;99(6):736-43

Efficacy of three statins at lower maintenance doses. Carr-Lopez S, et al. **Clin Ther** 1999 Feb;21(2):331-9

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Nazzaro P, et al. **Hypertension** 1999 Feb;33(2):719-25

Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Nakamura N, et al. **Int J Clin Lab Res** 1999;29(1):22-5

Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. Nakamura N, et al. **Int J Clin Lab Res** 1998;28(3):192-5

Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism. Wittke R. **Sports Med** 1999 May;27(5):329-35

ADVERSE EFFECTS

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Gruer PJ, et al. **Am J Cardiol** 1999 Oct 1; 84(7):811-5

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy [see comments] Pogson GW, et al. **Am J Cardiol** 1999 Apr 1; 83(7):1146. Comment in: Am J Cardiol 1999 Aug 15;84(4):497.

Acute cholestatic hepatitis associated with pravastatin. Hartleb M, et al. **Am J Gastroenterol** 1999 May; 94(5):1388-90

Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves [letter] Jiménez-Alonso J, et al. **Arch Intern Med** 1999 Aug 9-23;159(15):1811-2

Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Apr;143(2):459-60

Case of the month: February 1999--54 year old man with severe muscle weakness. Hill MD, et al. **Brain Pathol** 1999 Jul;9(3):607-8

HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS

Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Liebhaber MI, et al. **Chest** 1999 Mar;115(3):886-9

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Thibault A, et al. **Clin Cancer Res** 1996 Mar;2(3):483-91

Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. Landesman KA, et al. **Conn Med** 1999 Aug;63(8):455-7

Cheilitis due to treatment with simvastatin. Mehregan DR, et al. **Cutis** 1998 Oct;62(4):197-8

Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers. Mazzu A, et al. **J Clin Pharmacol** 1998 Aug;38(8):715-9

Atorvastatin-induced severe thrombocytopenia [letter] González-Ponte ML, et al. **Lancet** 1998 Oct 17; 352(9136):1284

Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. Rudski L, et al. **Medicine (Baltimore)** 1998 Nov; 77(6):378-83 (18 ref.)

Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury. Dietz BL, et al. **Pharmacotherapy** 1999 Feb;19(2):232-5

Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Ehrenberg BL, et al. **Sleep** 1999 Feb 1;22(1):117-21

[Gynecomastia due to pravastatin (letter; comment)] Aerts J, et al. **Presse Med** 1999 Apr 17;28(15):787. Comment on: Presse Med 1994 Sep;23(28):1304-10. **(Fre)**

[Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase] Fuentes I, et al. **Med Clin (Barc)** 1998 Nov 28;111(18):700 **(Spa)**

BLOOD

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Lilja JJ, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):477-83

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Lilja JJ, et al. **Clin Pharmacol Ther** 1999 Aug;66(2):118-27

Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Kojima J, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 5; 724(1):173-80

CHEMICAL SYNTHESIS

Synthesis and biological testings as inhibitors of HMGCoA reductase of the seco-acid of tuckolide and its C-7 epimer. Colle S, et al. **Bioorg Med Chem** 1999 Jun;7(6):1049-57

ECONOMICS

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective. Jackson JD. **Am Heart J** 1999 May;137(5):S105-10

Cost-effectiveness of statins. Huse DM, et al. **Am J Cardiol** 1998 Dec 1;82(11):1357-63

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Grover SA, et al. **Arch Intern Med** 1999 Mar 22;159(6):593-600

Maximizing the cost-effectiveness of lipid-lowering therapy. Jacobson TA, et al. **Arch Intern Med** 1998 Oct 12; 158(18):1977-89 (101 ref.)

Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. Bottorff MB, et al. **Clin Ther** 1999 Jan;21(1):218-35

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE, et al. **Clin Ther** 1999 Mar;21(3):536-62

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Pickin DM, et al. **Heart** 1999 Sep; 82(3):325-32

[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study] Szucs TD, et al. **Herz** 1998 Aug;23(5):319-29 (Eng. Abstr.) **(Ger)**

METABOLISM

Crystallization and preliminary X-ray diffraction analysis of cytochrome P450sca-2 from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase. Ito S, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1209-11

Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Kojima J, et al. **Biol Pharm Bull** 1999 Feb;22(2):142-50

Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. Lindahl A, et al. **J Pharm Pharmacol** 1998 Jul;50(7):737-44

Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. Jacobsen W, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):131-9

In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Ubeaud G, et al. **Life Sci** 1999; 65(13):1403-12

PHARMACOKINETICS

Dual hepatic metabolism of cerivastatin--clarifications [letter; comment] Guyton JR, et al. **Am J Cardiol** 1999 Aug 15;84(4):497. Comment on: Am J Cardiol 1999 Apr 1;83(7):1146.

Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. Ohtawa M, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):383-9

The interaction of diltiazem with lovastatin and pravastatin. Azie NE, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):369-77

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Mück W, et al. **Clin Pharmacol Ther** 1999 Mar; 65(3):251-61

Metabolism and excretion of atorvastatin in rats and dogs. Black AE, et al. **Drug Metab Dispos** 1999 Aug;27(8):916-23

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Fischer V, et al. **Drug Metab Dispos** 1999 Mar;27(3):410-6

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Mück W. **Drugs** 1998;56 Suppl 1:15-23; discussion 33 (49 ref.)

Effect of itraconazole on cerivastatin pharmacokinetics. Kantola T, et al. **Eur J Clin Pharmacol** 1999 Jan; 54(11):851-5

Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. Becquemont L, et al. **Fundam Clin Pharmacol** 1999;13(2):232-6

Lack of drug-drug interaction between cerivastatin and nifedipine. Sachse R, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):409-13

Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers. Mazzu A, et al. **J Clin Pharmacol** 1998 Aug;38(8):715-9

Erythromycin coadministration increases plasma atorvastatin concentrations. Siedlik PH, et al. **J Clin Pharmacol** 1999 May;39(5):501-4

Surface activity and concentration dependent intestinal permeability in the rat. Lindahl A, et al. **Pharm Res** 1999 Jan;16(1):97-102

Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Tokui T, et al. **Pharm Res** 1999 Jun;16(6):904-8

PHARMACOLOGY

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Stein E, et al. **Am J Cardiol** 1999 May 15;83(10):1433-6

Distinct drug-interaction profiles for statins [letter] Bottorf MB. **Am J Health Syst Pharm** 1999 May 15;56(10):1019-20

Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Jiang J, et al. **Am J Hypertens** 1998 Oct; 11(10):1222-31

Lovastatin preserves renal function in experimental diabetes. Inman SR, et al. **Am J Med Sci** 1999 Apr;317(4):215-21

In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity. Johnson DW, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):F467-75

Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. Schobel HP, et al. **Angiology** 1998 Sep; 49(9):743-8

Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Alfon J, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1812-7

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Bellosta S, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov;18(11):1671-8

The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Burnett JR, et al. **Arterioscler Thromb Vasc Biol** 1998 Dec; 18(12):1906-14

Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages. Hrboticky N, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1267-75

Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Miyake Y, et al. **Arzneimittelforschung** 1999 Apr;49(4):324-9

Metabolic modes of action of the statins in the hyperlipoproteinemias. Aguilar-Salinas CA, et al. **Atherosclerosis** 1998 Dec;141(2):203-7 (48 ref.)

Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Alfon J, et al. **Atherosclerosis** 1999 Aug;145(2):325-31

Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition. Llorente-Cortés V, et al. **Atherosclerosis** 1999 Jun;144(2):335-42

NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Ooyen C, et al. **Atherosclerosis** 1999 Jul;145(1):87-95

HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. Sugiyama S. **Biochem Mol Biol Int** 1998 Dec;46(5):923-31

Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Conde K, et al. **Biochem Pharmacol** 1999 Oct 1;58(7):1209-19

The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Draude G, et al. **Biochem Pharmacol** 1999 Feb 15;57(4):383-6

Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Suzumura K, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):697-703

Interactions between HMG-CoA reductase inhibition and UVB irradiation on proliferation and apoptosis in SM1 smooth muscle cells. Unlu S, et al. **Biochem Soc Trans** 1998 Nov;26(4):S322

Role of isoprenylation in the inhibitory action of lovastatin on proliferation of SV40 immortalized human saphenous vein smooth muscle cells. Unlu S, et al. **Biochem Soc Trans** 1998 Nov;26(4):S324

Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Bassa BV, et al. **Biochim Biophys Acta** 1999 Mar 8;1449(2):137-49

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Dimitroulakos J, et al. **Blood** 1999 Feb 15; 93(4):1308-18

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Prueksaritanont T, et al. **Br J Clin Pharmacol** 1999 Mar;47(3):291-8

Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. Harsch M, et al. **Br J Pharmacol** 1998 May;124(2):277-82

Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Shiomi M, et al. **Br J Pharmacol** 1999 Feb;126(4):961-8

Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. Girgert R, et al. **Cancer Lett** 1999 Apr 1;137(2):167-72

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Ridker PM, et al. **Circulation** 1999 Jul 20;100(3):230-5

Calcium channel blocker-simvastatin interaction [letter; comment] Tobert JA, et al. **Clin Pharmacol Ther** 1999 May; 65(5):583-5. Comment on: Clin Pharmacol Ther 1998 Aug;64(2):177-82.

Statins and the kidney. Wheeler DC. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):579-84 (58 ref.)

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Fischer V, et al. **Drug Metab Dispos** 1999 Mar;27(3):410-6

Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Jacobsen W, et al. **Drug Metab Dispos** 1999 Feb;27(2):173-9

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Mück W. **Drugs** 1998;56 Suppl 1:15-23; discussion 33 (49 ref.)

Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Kimura T, et al. **Eur J Endocrinol** 1999 Jan;140(1):94-103

Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro. Kreuzer J, et al. **Eur J Med Res** 1999 Apr 27;4(4):135-43

Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Oi S, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):139-48

Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Yamamoto A, et al. **Eur J Pharmacol** 1998 Nov 13;361(1):143-9

Role of tyrosine phosphorylation of phospholipase C gamma1 in the signaling pathway of HMG-CoA reductase

inhibitor-induced cell death of L6 myoblasts. Mutoh T, et al. **FEBS Lett** 1999 Mar 5;446(1):91-4

Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. Mutoh T, et al. **FEBS Lett** 1999 Feb 5;444(1):85-9

HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway. Nakagawa H, et al. **FEBS Lett** 1998 Nov 6; 438(3):289-92

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. Schoonjans K, et al. **FEBS Lett** 1999 Jun 11;452(3):160-4

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Hooiveld GJ, et al. **Gastroenterology** 1999 Sep;117(3):678-87

The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Kallien G, et al. **Hepatology** 1999 Jul;30(1):14-20

Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia [letter] Saito M, et al. **Int J Hematol** 1999 Jun;69(4):274-6

Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Müller C, et al. **Int J Mol Med** 1999 Jan;3(1):63-8

Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. Essig M, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1377-88

Lovastatin inhibits mesangial cell proliferation via p27Kip1. Terada Y, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2235-43

Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. Yoshimura A, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2027-39

Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro. Sato I, et al. **J Atheroscler Thromb** 1998;4(3):102-6

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). Laufs U, et al. **J Biol Chem** 1999 Jul 30; 274(31):21926-31

Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. Tesfamariam B, et al. **J Cardiovasc Pharmacol** 1999 Jul; 34(1):95-101

Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. Stern RH, et al. **J Clin Pharmacol** 1998 Aug;38(8):753-7

Effects of simvastatin on fasting and postprandial triglyceride-rich lipoproteins in patients with type I diabetes mellitus. Noutsou M, et al. **J Diabetes Complications** 1999 Mar-Apr;13(2):98-104

Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. Mazume H, et al. **J Hepatol** 1999 May; 30(5):904-10

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Wilcox LJ, et al. **J Lipid Res** 1999 Jun;40(6):1078-89

Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. Michikawa M, et al. **J Neurochem** 1999 Jun;72(6):2278-85

Select 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors vary in their ability to reduce egg yolk cholesterol levels in laying hens through alteration of hepatic cholesterol biosynthesis and plasma VLDL composition. Elkin RG, et al. **J Nutr** 1999 May; 129(5):1010-9

Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin. Hatanaka T, et al. **J Pharmacokinet Biopharm** 1998 Jun;26(3):329-47

Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. Choi JW, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):572-9

Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Guijarro C, et al. **Kidney Int Suppl** 1999 Jul; 71:S88-91

Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Nishimura M, et al. **Kidney Int Suppl** 1999 Jul;71:S97-100

Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Nogaki F, et al. **Kidney Int Suppl** 1999 Jul;71:S198-201

Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Oda H, et al. **Kidney Int Suppl** 1999 Jul;71:S202-5

Effect of lipid-lowering strategies on tubular cell biology. Vrtovsnik F, et al. **Kidney Int Suppl** 1999 Jul;71:S92-6 (27 ref.)

Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Yokota T, et al. **Kidney Int Suppl** 1999 Jul;71:S178-81

Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Yoshimura A, et al. **Kidney Int Suppl** 1999 Jul;71:S84-7 (7 ref.)

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Moghadasian MH. **Life Sci** 1999;65(13):1329-37 (59 ref.)

Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver. Carrella M, et al. **Metabolism** 1999 May; 48(5):618-26

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects. Ntanios FY, et al. **Metabolism** 1999 Jan;48(1):68-73

HMG-CoA reductase inhibitors and apoptosis [letter] Senatore M, et al. **Nephron** 1999;81(4):439-40

Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Ghosh PM, et al. **Oncogene** 1999 Jul 15;18(28):4120-30

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Christians U, et al. **Pharmacol Ther** 1998 Oct;80(1):1-34 (317 ref.)

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Park HJ, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11525-30

Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Komukai M, et al. **Scand J Clin Lab Invest** 1999 May;59(3):159-66

Neuroprotective properties of statins in cerebral ischemia and stroke. Vaughan CJ, et al. **Stroke** 1999 Sep;30(9):1969-73 (40 ref.)

[Renewed proof: inhibition of cholesterol biosynthesis by dried extract of artichoke leaves] **Forsch Komplementarmed** 1999 Jun;6(3):168-9 **(Ger)**

[HMG-CoA reductase antagonists in review] Manns D. **Pharm Unserer Zeit** 1999 May;28(3):147-52 (5 ref.) **(Ger)**

[Pharmacology of HMG CoA reductase inhibitors (statins)] Kostner GM. **Wien Med Wochenschr** 1999;149(5-6):120-4 (13 ref.) (Eng. Abstr.) **(Ger)**

[Simvastatin and ischemia-reperfusion damage: its effects on apoptotic myocyte death and on the endothelial expression of nitric-oxide synthetase in an experimental model of the isolated rat heart] Di Napoli P, et al. **Cardiologia** 1999 Jan; 44(1):69-74 (Eng. Abstr.) **(Ita)**

[Action of pravastatin treatment on blood levels of homocysteine] Blardi P, et al. **Minerva Cardioangiol** 1998 Sep;46(9):315-6 **(Ita)**

[Antioxidative effects of fluvastatin, and its major metabolites] Nakashima A, et al. **Yakugaku Zasshi** 1999 Jan;119(1):93-9 (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Murdock DK, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):151-5

Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia. Strauss WE, et al. **Am Heart J** 1999 Mar;137(3):458-62

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis? [letter; comment] Banks T. **Am J Cardiol** 1999 Mar 1; 83(5):818. Comment on: Am J Cardiol 1998 Aug 1;82(3):311-6.

Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Egan DA, et al. **Am J Cardiol** 1999 Feb 15;83(4):569-75

State-of-the-art update and review: clinical trials of lipid-lowering agents. Kwiterovich PO Jr. **Am J Cardiol** 1998 Dec 17;82(12A):3U-17U; discussion 39U-41U (82 ref.)

Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Mölgaard J, et al. **Am J Cardiol** 1999 Apr 1;83(7):1043-8

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Stein E, et al. **Am J Cardiol** 1999 May 15;83(10):1433-6

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Larner J, et al. **Am J Clin Oncol** 1998 Dec;21(6):579-83

Successful use of an HMG-CoA reductase inhibitor as adjunctive therapy in the management of refractory bile leak complicating laparoscopic cholecystectomy. Rabine J, et al. **Am J Gastroenterol** 1998 Dec;93(12):2602-3

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Malinowski JM. **Am J Health Syst Pharm** 1998 Nov 1;55(21):2253-67; quiz 2302-3 (90 ref.)

Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Gotto AM Jr. **Am J Med** 1999 Aug 23;107(2A):36S-39S

Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Matzkies FK, et al. **Am J Nephrol** 1999;19(4):492-4

Present status of HMG reductase inhibitors in treatment of dyslipidemia. Kalmansohn RB, et al. **Angiology** 1998 Oct; 49(10):801-5 (23 ref.)

Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment. Lin JC, et al. **Ann Pharmacother** 1999 Feb;33(2):163-6

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Grover SA, et al. **Arch Intern Med** 1999 Mar 22;159(6):593-600

Clinical outcomes in statin treatment trials: a meta-analysis. Ross SD, et al. **Arch Intern Med** 1999 Aug 9-23; 159(15):1793-802

Effects of lovastatin therapy on susceptibility of LDL to oxidation during alpha-tocopherol supplementation. Palomäki A, et al. **Arterioscler Thromb Vasc Biol** 1999 Jun; 19(6):1541-8

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. Bischoff H, et al. **Atherosclerosis** 1998 Sep;139 Suppl 1:S7-13 (22 ref.)

Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Contacos C, et al. **Atherosclerosis** 1998 Nov;141(1):87-98

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Heath KE, et al. **Atherosclerosis** 1999 Mar;143(1):41-54

Atorvastatin in the management of an index patient with complete hepatic lipase deficiency [letter] Hegele RA, et al. **Atherosclerosis** 1999 Mar;143(1):219-22

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Shiomi M, et al. **Atherosclerosis** 1999 Feb; 142(2):345-53

Atorvastatin and fibrinogen--a small subgroup shows extreme response [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Aug;145(2):415-7

Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety. Stein E. **Atherosclerosis** 1998 Sep;139 Suppl 1:S15-22 (25 ref.)

Communicating risk reductions. One example is not enough [letter; comment] [published erratum appears in BMJ 1999 Apr 17;318(7190):1040] Galton DJ, et al. **BMJ** 1999 Feb 27;318(7183):602-3; discussion 603-4. Comment on: BMJ 1998 Jun 27;316(7149):1956-8.

Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Gotto AM Jr, et al. **Circulation** 1999 Mar 2; 99(8):E1-7

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Lefer AM, et al. **Circulation** 1999 Jul 13;100(2):178-84

Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS) [letter] Lim PO, et al. **Circulation** 1999 Aug 10;100(6):686

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Iliadis EA, et al. **Clin Cardiol** 1999 Jan;22(1):25-8

Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Matar P, et al. **Clin Exp Metastasis** 1999 Feb;17(1):19-25

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE, et al. **Clin Ther** 1999 Mar;21(3):536-62

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Lye M, et al. **Coron Artery Dis** 1998;9(9):583-90

Therapy and clinical trials [editorial] Bachorik PS. **Curr Opin Lipidol** 1998 Oct;9(5):515-7

Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients. Miossec P, et al. **Diabet Med** 1999 May; 16(5):424-30

Fluvastatin: a review of its use in lipid disorders. Langtry HD, et al. **Drugs** 1999 Apr;57(4):583-606 (107 ref.)

Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Stein EA. **Drugs** 1998;56 Suppl 1:25-31; discussion 33

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. **Eur Heart J** 1999 May;20(10):725-41

A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Serruys PW, et al. **Eur Heart J** 1999 Jan;20(1):58-69

Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid

synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Naoumova RP, et al. **Eur J Clin Invest** 1999 May;29(5):404-12

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. Bustos C, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2057-64

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile [see comments] Dangas G, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1294-304. Comment in: J Am Coll Cardiol 1999 Apr;33(5):1305-7.

Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. Flaker GC, et al. **J Am Coll Cardiol** 1999 Jul;34(1):106-12

The anti-thrombotic effects of statins [editorial; comment] Kearney D, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1305-7 (23 ref.). Comment on: J Am Coll Cardiol 1999 Apr;33(5):1286-93. Comment on: J Am Coll Cardiol 1999 Apr;33(5):1294-304.

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia [see comments] Szczeklik A, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1286-93. Comment in: J Am Coll Cardiol 1999 Apr;33(5):1305-7.

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Bairaktari ET, et al. **J Cardiovasc Risk** 1999 Apr;6(2):113-6

Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. Bruckert E, et al. **J Clin Epidemiol** 1999 Jun;52(6):589-94

Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. Hunninghake D, et al. **J Fam Pract** 1998 Nov; 47(5):349-56

Treating average cholesterol levels in patients with coronary heart disease. Lindbloom EJ. **J Fam Pract** 1999 Feb; 48(2):94-5

Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. Alvarez de Sotomayor M, et al. **J Hypertens** 1999 Jun;17(6):769-76

Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. Bak AA, et al. **J Intern Med** 1998 Nov;244(5):371-8

Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Geiss HC, et al. **J Intern Med** 1999 Jan; 245(1):47-55

Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Hoogerbrugge N. **J Intern Med** 1998 Aug;244(2):143-7

Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study [letter; comment] Kandzari DE, et al. **JAMA** 1999 Feb 3;281(5):415; discussion 417-9. Comment on: JAMA 1998 May 27;279(20):1643-50.

Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study [letter; comment] McDiarmid TD, et al. **JAMA** 1999 Feb 3;281(5):416; discussion 417-9. Comment on: JAMA 1998 May 27;279(20):1615-22.

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial [see comments] Stein EA, et al. **JAMA** 1999 Jan 13;281(2):137-44. Comment in: JAMA 1999 Jan 13;281(2):180-1.

Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Katznelson S. **Kidney Int Suppl** 1999 Jul;71:S117-21 (35 ref.)

Effect of simvastatin on the lipid profile of hemodialysis patients. Nishikawa O, et al. **Kidney Int Suppl** 1999 Jul; 71:S219-21

Recent advances in statins and the kidney. Oda H, et al. **Kidney Int Suppl** 1999 Jul;71:S2-5 (46 ref.)

Clinical trials in stroke [letter; comment] Kendall MJ, et al. **Lancet** 1999 Jan 9;353(9147):151. Comment on: Lancet 1998 Oct;352 Suppl 3:SIII28-30.

Inhibition of proinflammatory cytokine production by pravastatin [letter] Rosenson RS, et al. **Lancet** 1999 Mar 20;353(9157):983-4

Effect of statins on C-reactive protein in patients with coronary artery disease [letter] [see comments] Strandberg TE, et al. **Lancet** 1999 Jan 9;353(9147):118-9. Comment in: Lancet 1999 Apr 10;353(9160):1274. Comment in: Lancet 1999 Apr 10;353(9160):1274-5.

Pravastatin and coronary heart disease [letter; comment] Bloom JM. **N Engl J Med** 1999 Apr 8;340(14):1116-7. Comment on: N Engl J Med 1998 Aug 20;339(8):489-97.

Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography [see comments] Callister TQ, et al. **N Engl J Med** 1998 Dec 31;339(27):1972-8. Comment in: N Engl J Med 1998 Dec 31;339(27):2014-5. Comment in: N Engl J Med 1998 Dec 31;339(27):2018-20.

Pravastatin and coronary heart disease [letter; comment] Meyer FP. **N Engl J Med** 1999 Apr 8;340(14):1115-6; discussion 1116-7. Comment on: N Engl J Med 1998 Nov 5;339(19):1349-57.

Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. Stuyt PM, et al. **Neth J Med** 1998 Nov;53(5):228-33

No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin [letter] Singhal MK, et al. **Perit Dial Int** 1999 Jan-Feb;19(1):89-91

The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice. Khong TK, et al. **Postgrad Med J** 1998 Oct;74(876):600-1

Aggressive lipid therapy in the statin era. Farmer JA. **Prog Cardiovasc Dis** 1998 Sep-Oct;41(2):71-94 (67 ref.)

Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Rubenfire M, et al. **Prog Cardiovasc Dis** 1998 Sep-Oct; 41(2):95-116 (145 ref.)

Coronary risk factor management for the prevention and treatment of graft vessel disease in heart transplant patients. Jaeger BR, et al. **Ther Apher** 1999 Aug;3(3):214-8

Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors. Katznelson S. **Transplant Proc** 1999 May;31(3B Suppl):22S-24S (15 ref.)

Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Rodriguez JA, et al. **Transplant Proc** 1999 Sep;31(6):2522-3

[Recent knowledge about the effect of HMG-CoA reductase inhibitors (letter; comment)] Jirak P. **Dtsch Med Wochenschr** 1998 Oct 16;123(42):1261. Comment on: Dtsch Med Wochenschr 1997 Oct 10;122(41):1255-9. **(Ger)**

[Therapy with CSE inhibitors--more than lipid lowering?] Weizel A. **Herz** 1999 Feb;24(1):42-50 (60 ref.) (Eng. Abstr.) **(Ger)**

[HMG-CoA reductase inhibitors] Thiery J, et al. **Internist (Berl)** 1998 Aug;39(8):866-7 **(Ger)**

[Various HMG-CoA reductase inhibitors] Thiery J, et al. **Internist (Berl)** 1999 Jan;40(1):113-4 **(Ger)**

[Comparison of cholesterol synthesizing enzymes (CSE) inhibitors] Ecker-Schlipf B. **Med Monatsschr Pharm** 1999 Jun;22(6):184-6 **(Ger)**

[HMG-CoA reductase inhibitor and risk of stroke] Endres M, et al. **Nervenarzt** 1998 Aug;69(8):717-21 (42 ref.) (Eng. Abstr.) **(Ger)**

[Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared] Kostner KM, et al. **Wien Klin Wochenschr** 1998 Oct 2;110(18):625-30 (21 ref.) (Eng. Abstr.) **(Ger)**

[Statins in diabetic hyperlipidemia] Kirchmair R, et al. **Wien Med Wochenschr** 1999;149(5-6):139-43 (26 ref.) (Eng. Abstr.) **(Ger)**

[HMA CoA reductase inhibitors (editorial)] Kostner GM. **Wien Med Wochenschr** 1999;149(5-6):109-10 **(Ger)**

[Aggressive therapy and combination therapy in severe hyperlipidemia] Kostner KM. **Wien Med Wochenschr** 1999; 149(5-6):146-8 (20 ref.) (Eng. Abstr.) **(Ger)**

[Statins in primary prevention of coronary heart disease] Paulweber B. **Wien Med Wochenschr** 1999;149(5-6):129-38 (38 ref.) (Eng. Abstr.) **(Ger)**

[Statins in secondary prevention of coronary heart disease] Sandhofer F. **Wien Med Wochenschr** 1999;149(5-6):125-8 (8 ref.) (Eng. Abstr.) **(Ger)**

[Statins--attaining goal values--with reference to recent studies] Toplak H, et al. **Wien Med Wochenschr** 1999; 149(5-6):144-5 (Eng. Abstr.) **(Ger)**

[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia] Liguori E, et al. **Minerva Cardioangiol** 1998 Sep;46(9):317-8 **(Ita)**

[Anti-atherogenic drugs] Kanaki T, et al. **Nippon Rinsho** 1998 Oct;56(10):2635-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease] Kaiser SE, et al. **Arq Bras Cardiol** 1998 Aug; 71(2):153-62 (75 ref.) **(Por)**

[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease] da Silva PM. **Rev Port Cardiol** 1999 Jan;18(1):65-76 (66 ref.) (Eng. Abstr.) **(Por)**

[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia] Tvorogova MG, et al. **Ter Arkh** 1998;70(12):8-13 (Eng. Abstr.) **(Rus)**

[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke] Marta-Moreno J, et al. **Rev Neurol** 1998 Nov; 27(159):827-30 (28 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Pierno S, et al. **Eur J Pharmacol** 1999 Jan 1;364(1):43-8

28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats [published erratum appears in J Toxicol Sci 1999 Feb;24(1):77] Akiba T, et al. **J Toxicol Sci** 1998 Nov;23 Suppl 5:701-11

Six-month repeated oral toxicity study of NK-104 in rats [published erratum appears in J Toxicol Sci 1999 Feb;24(1):77] Akiba T, et al. **J Toxicol Sci** 1998 Nov;23 Suppl 5:713-20

Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. Diaz-Zagoya JC, et al. **Life Sci** 1999;65(9):947-56

Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Nakahara K, et al. **Toxicol Appl Pharmacol** 1998 Sep;152(1):99-106

Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Walsh KM, et al. **Toxicol Pathol** 1999 Jul-Aug;27(4):395-401

HYDROXYMETHYLGLUTARYL COA REDUCTASES

see related
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS

ADMINISTRATION & DOSAGE

Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Alfon J, et al. **Thromb Haemost** 1999 May;81(5):822-7

ANTAGONISTS & INHIBITORS see HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS

BIOSYNTHESIS

Comparison of the effects of gemfibrozil and clofibric acid on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes. Hashimoto F, et al. **Biol Pharm Bull** 1998 Nov; 21(11):1142-7

BLOOD

Effect of dietary cholesterol on low density lipoprotein-receptor, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotein receptor-related protein mRNA expression in healthy humans. Boucher P, et al. **Lipids** 1998 Dec;33(12):1177-86

CHEMISTRY

Aminoethylcysteine can replace the function of the essential active site lysine of Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl coenzyme A reductase. Bochar DA, et al. **Biochemistry** 1999 Jul 13;38(28):8879-83

Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Bochar DA, et al. **Mol Genet Metab** 1999 Feb;66(2):122-7

Substrate-induced closure of the flap domain in the ternary complex structures provides insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl-CoA reductase. Tabernero L, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7167-71

GENETICS

HMG CoA reductase and LDL receptor genes are regulated differently by 15-ketosterols in Hep G2 cells. Kisseleva AF, et al. **Biochem Biophys Res Commun** 1999 Jun 16; 259(3):688-94

Juvenile hormone regulation of HMG-R gene expression in the bark beetle Ips paraconfusus (Coleoptera: Scolytidae): implications for male aggregation pheromone biosynthesis. Tittiger C, et al. **Cell Mol Life Sci** 1999 Jan;55(1):121-7

Effects of dietary alpha- or gamma-linolenic acid on levels and fatty acid compositions of serum and hepatic lipids, and activity and mRNA abundance of 3-hydroxy-3-methylglutaryl CoA reductase in rats. Ihara-Watanabe M, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Feb; 122(2):213-20

Structural analysis of a hmg-coA-reductase pseudogene: insights into evolutionary processes affecting the hmgr gene family in allotetraploid cotton (Gossypium hirsutum L.). Loguercio LL, et al. **Curr Genet** 1998 Oct;34(4):241-9

Mapping and molecular characterization of five HMG1-related DNA sequences. Rogalla P, et al. **Cytogenet Cell Genet** 1998;83(1-2):124-9

Integrity and distribution of HMG CoA reductase mRNA in lens: relationship to cessation of membrane formation [letter] Zhu XL, et al. **Exp Eye Res** 1999 Mar;68(3):371-3

Structure of genes encoding chromosomal HMG1 proteins from maize. Krech AB, et al. **Gene** 1999 Jun 24; 234(1):45-50

Purification, characterization, and cloning of a eubacterial 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme involved in biosynthesis of terpenoids. Takahashi S, et al. **J Bacteriol** 1999 Feb;181(4):1256-63

Splice donor site mutations in the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene cause a deficiency of the endoplasmic reticulum 3-hydroxy-3-methylglutaryl coenzyme A reductase protein in UT2 cells. Engfelt WH, et al. **J Lipid Res** 1998 Nov;39(11):2182-91

The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region. Di Croce L, et al. **Mol Endocrinol** 1999 Aug;13(8):1225-36

Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Bochar DA, et al. **Mol Genet Metab** 1999 Feb;66(2):122-7

Developmental biology. Attractive genetics [news; comment] Howard K. **Nature** 1998 Dec 3;396(6710):406-7. Comment on: Nature 1998 Dec 3;396(6710):466-9.

Hmg-coA reductase gene family in cotton (Gossypium hirsutum L.): unique structural features and differential expression of hmg2 potentially associated with synthesis of specific isoprenoids in developing embryos. Loguercio LL, et al. **Plant Cell Physiol** 1999 Jul;40(7):750-61

METABOLISM

Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Caruso MG, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):451-4

Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells. Asslan R, et al. **Biochem Biophys Res Commun** 1999 Jul 14;260(3):699-706

Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Conde K, et al. **Biochem Pharmacol** 1999 Oct 1;58(7):1209-19

The level of 7-dehydrocholesterol in plasma reflects the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the human liver. Axelson M, et al. **Biochim Biophys Acta** 1998 Nov 2;1394(2-3):153-7

Inhibition of farnesylation blocks growth but not differentiation in FRTL-5 thyroid cells. Bifulco M, et al. **Biochimie** 1999 Apr;81(4):287-90

Synthesis and biological testings as inhibitors of HMGCoA reductase of the seco-acid of tuckolide and its C-7 epimer. Colle S, et al. **Bioorg Med Chem** 1999 Jun;7(6):1049-57

Sterol synthesis. Synthesis of 3 beta-hydroxy-25,26,26,26,27,27,27-heptafluorocholest-5-en-7-one and its effects on HMG-CoA reductase activity in Chinese hamster ovary cells, on ACAT activity in rat jejunal microsomes, and serum cholesterol levels in rats. Carroll JN, et al. **Chem Phys Lipids** 1998 Aug;94(2):209-25

Effects of dietary alpha- or gamma-linolenic acid on levels and fatty acid compositions of serum and hepatic lipids, and activity and mRNA abundance of 3-hydroxy-3-methylglutaryl CoA reductase in rats. Ihara-Watanabe M, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Feb;122(2):213-20

3-Hydroxy-3-methylglutaryl coenzyme a reductase activity in liver of athymic mice with or without an implanted human carcinoma. Polo M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Apr;122(4):433-7

Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. Cheng HH, et al. **J Biol Chem** 1999 Jun 11;274(24):17171-8

Treatment of mammalian cells with the endoplasmic reticulum-proliferator compactin strongly induces recombinant and endogenous xenobiotic metabolizing enzymes and 3-hydroxy-3-methylglutaryl-CoA reductase in vitro. McLaughlin L, et al. **J Cell Sci** 1999 Feb;112 (Pt 4):515-23

HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. Petras SF, et al. **J Lipid Res** 1999 Jan;40(1):24-38

Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. Wilcox LJ, et al. **J Lipid Res** 1999 Jun;40(6):1078-89

Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. Bok SH, et al. **J Nutr** 1999 Jun;129(6):1182-5

Effects of n-3 and n-6 polyunsaturated fatty acids on 3-hydroxy-3-methylglutaryl-CoA reductase in liver and mammary glands of low density lipoprotein-receptor knockout mice. El-Sohemy A, et al. **Lipids** 1999;34 Suppl:S135

Sequence determinants for regulated degradation of yeast 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein [published erratum appears in Mol Biol Cell 1999 Mar;10(3):preceding table of contents] Gardner R, et al. **Mol Biol Cell** 1998 Sep;9(9):2611-26

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Rao S, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7797-802

In vivo and in vitro studies on the regulatory link between 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rat liver. Boll M, et al. **Z Naturforsch [C]** 1999 May-Jun;54(5-6):371-82

PHYSIOLOGY

HMG-CoA reductase guides migrating primordial germ cells [see comments] Van Doren M, et al. **Nature** 1998 Dec 3; 396(6710):466-9. Comment in: Nature 1998 Dec 3;396(6710):406-7.

THERAPEUTIC USE

Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Christenson JT. **Eur J Cardiothorac Surg** 1999 Apr;15(4):394-9; discussion 399-400

[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia] Prat H, et al. **Rev Med Chil** 1999 Mar;127(3):286-94 (Eng. Abstr.) **(Spa)**

HYDROXYMETHYLGLUTARYL-COA SYNTHASE

ANTAGONISTS & INHIBITORS

Synthesis and inhibitory action on HMG-CoA synthase of racemic and optically active oxetan-2-ones (beta-lactones). Romo D, et al. **Bioorg Med Chem** 1998 Aug;6(8):1255-72

DEFICIENCY

Clinical and biochemical features of fatty acid oxidation disorders. Rinaldo P, et al. **Curr Opin Pediatr** 1998 Dec; 10(6):615-21 (48 ref.)

Hepatic mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme a synthase deficiency. Morris AA, et al. **Pediatr Res** 1998 Sep; 44(3):392-6

GENETICS

Isolation of pig mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene promoter: characterization of a peroxisome proliferator-responsive element. Ortiz JA, et al. **Biochem J** 1999 Jan 15;337 (Pt 2):329-35

A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. Meertens LM, et al. **EMBO J** 1998 Dec 1;17(23):6972-8

A critical role for cAMP response element-binding protein (CREB) as a Co-activator in sterol-regulated transcription of 3-hydroxy-3-methylglutaryl coenzyme A synthase promoter. Dooley KA, et al. **J Biol Chem** 1999 Feb 26; 274(9):5285-91

Atypical expression of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in subcutaneous adipose tissue of male rats. Thumelin S, et al. **J Lipid Res** 1999 Jun;40(6):1071-7

Hormonal regulation of the mRNA encoding the ketogenic enzyme mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase in neonatal primary cultures of cortical astrocytes and meningeal fibroblasts. Cullingford TE, et al. **J Neurochem** 1998 Nov;71(5):1804-12

METABOLISM

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Hegardt FG. **Biochem J** 1999 Mar 15;338 (Pt 3):569-82 (165 ref.)

A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. Meertens LM, et al. **EMBO J** 1998 Dec 1;17(23):6972-8

Mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase and carnitine palmitoyltransferase II are potential control sites of hepatic ketogenesis under conditions of peroxisome proliferation. Berge RK, et al. **Lipids** 1999;34 Suppl:S163

HYDROXYMYCIN see **PAROMOMYCIN**

HYDROXYNAPHTHALENES see **NAPHTHOLS**

M-HYDROXYNOREPHEDRINE see **METARAMINOL**

HYDROXYPHENYLISOPROPYLAMINE see **P-HYDROXYAMPHETAMINE**

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE

ANTAGONISTS & INHIBITORS

Design and synthesis of 3-fluoro-2-oxo-3-phenylpropionic acid derivatives as potent inhibitors of 4-hydroxyphenylpyruvate dioxygenase from pig liver. Ling TS, et al. **Bioorg Med Chem** 1999 Jul;7(7):1459-65

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by sethoxydim, a potent inhibitor of acetyl-coenzyme A carboxylase. Lin S, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):551-4

Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. Grompe M, et al. **J Inherit Metab Dis** 1998 Aug;21(5):518-31

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). Holme E, et al. **J Inherit Metab Dis** 1998 Aug;21(5):507-17 (23 ref.)

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. Lock EA, et al. **J Inherit Metab Dis** 1998 Aug; 21(5):498-506 (30 ref.)

NTBC as palliative treatment in chronic tyrosinaemia type I. Ros J, et al. **J Inherit Metab Dis** 1999 Jun;22(5):665-6

[Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I] Barkaoui E, et al. **Arch Pediatr** 1999 May;6(5):540-4 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Crystal structure of Pseudomonas fluorescens 4-hydroxyphenylpyruvate dioxygenase: an enzyme involved in the tyrosine degradation pathway. Serre L, et al. **Structure Fold Des** 1999 Aug 15;7(8):977-88

METABOLISM

Characterization and subcellular compartmentation of recombinant 4-hydroxyphenylpyruvate dioxygenase from Arabidopsis in transgenic tobacco. Garcia I, et al. **Plant Physiol** 1999 Apr;119(4):1507-16

P-HYDROXYPHENYLPYRUVATE HYDROXYLASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

P-HYDROXYPHENYLPYRUVATE OXIDASE see **4-HYDROXYPHENYLPYRUVATE DIOXYGENASE**

HYDROXYPREGNENOLONE

ANALOGS & DERIVATIVES

Mechanism of 17 alpha-hydroxylase/17,20-lyase--an initial geometric perspective for the lyase of the C(17)-C(20) bond of C21 steroids. Ahmed S, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1023-8

BLOOD

Age relationships and sex differences in serum levels of pregnenolone and 17-hydroxypregnenolone in healthy subjects. Hill M, et al. **Clin Chem Lab Med** 1999 Apr; 37(4):439-47

Elimination of cross-reactivity by addition of an excess of cross-reactant for radioimmunoassay of 17alpha-hydroxypregnenolone. Hill M, et al. **Steroids** 1999 May;64(5):341-55

CHEMISTRY

Mechanism of 17 alpha-hydroxylase/17,20-lyase--an initial geometric perspective for the lyase of the C(17)-C(20) bond of C21 steroids. Ahmed S, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1023-8

METABOLISM

Modulation of adrenal cell functions by cadmium salts. 4. Ca(2+)-dependent sites affected by CdCl2 during basal and ACTH-stimulated steroid synthesis. Mathias SA, et al. **Cell Biol Toxicol** 1998 Jun;14(3):225-36

17-HYDROXYPROGESTERONE

ANALYSIS

Development of a highly sensitive nonisotopic immunoassay for the determination of salivary 17-hydroxyprogesterone: reference ranges throughout childhood and adolescence. Dressendorfer RA, et al. **Pediatr Res** 1998 Nov;44(5):650-5

BLOOD

Relationship of ovarian stromal volume and serum 17-hydroxyprogesterone concentrations in patients with PCOS [letter] Keleştimur F, et al. **Hum Reprod** 1999 Aug; 14(8):2177

Cortisol, androstenedione (A4), dehydroepiandrosterone sulphate (DHEAS) and 17 hydroxyprogesterone (17OHP) responses to low doses of (1-24)ACTH [published erratum appears in J Clin Endocrinol Metab 1999 Aug;84(8):2972] Bridges NA, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3750-3

Increased plasma 17-hydroxyprogesterone response to ACTH in patients with nonhyperfunctioning adrenal adenomas is not due to a deficiency in 21-hydroxylase activity [letter] Tóth M, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3756-7

Home monitoring of 17 hydroxyprogesterone levels in congenitx127drenal hyperplasia with filter paper blood samples [see comments] Bode HH, et al. **J Pediatr** 1999 Feb;134(2):185-9. Comment in: J Pediatr 1999 Feb;134(2):140-2.

Home monitoring of 17 hydroxyprogesterone levels: "throw away the urine jug, mom, the filter paper just arrived" [editorial; comment] Schwartz RP. **J Pediatr** 1999 Feb; 134(2):140-2. Comment on: J Pediatr 1999 Feb;134(2):185-9.

21-HYDROXYPROGESTERONE see **DESOXYCORTICOSTERONE**

HYDROXYPROGESTERONES

HYDROXYPROGESTERONES

ADMINISTRATION & DOSAGE

[Injectable progesterone in hormone replacement therapy in menopause] Patacchiola F, et al. **Clin Ter** 1998 Nov-Dec; 149(6):425-7 (Eng. Abstr.) **(Ita)**

BLOOD

Gonadotrophin-releasing hormone agonist stimulates milt fluidity and plasma concentrations of 17,20beta-dihydroxylated and 5beta-reduced, 3alpha-hydroxylated C21 steroids in male plaice (Pleuronectes platessa). Vermeirssen EL, et al. **Gen Comp Endocrinol** 1998 Nov;112(2):163-77

Effects of testosterone on gonadotropins, testes, and plasma 17alpha,20beta-dihydroxy-4-pregnene-3-one levels in postbreeding mature Atlantic salmon, Salmo salar, male parr. Antonopoulou E, et al. **J Exp Zool** 1999 Sep 1; 284(4):425-36

METABOLISM

Synthesis of 17,20alpha/beta-dihydroxy-4-pregnen-3-one and 5beta-pregnanes in spermatozoa of primary and 17alpha-methyltestosterone-induced secondary male grouper (Epinephelus coioides). Lee ST, et al. **Gen Comp Endocrinol** 1998 Oct;112(1):1-9

The glucocorticoid properties of the synthetic steroid pregna-1,4-diene-11beta-ol-3,20-dione (deltaHOP) are not entirely correlated with the steroid binding to the glucocorticoid receptor. Vicent GP, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1-2):207-19

HYDROXYPROLINE

Molecular characterization of two light-induced, gamete-specific genes from Chlamydomonas reinhardtii that encode hydroxyproline-rich proteins. Rodriguez H, et al. **Mol Gen Genet** 1999 Mar;261(2):267-74

ANALOGS & DERIVATIVES

Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Parnham MJ. **Biochem Pharmacol** 1999 Jul 15;58(2):209-15 (61 ref.)

Oxaceprol is as effective as diclofenac in the therapy of osteoarthritis of the knee and hip. Bauer HW, et al. **Clin Rheumatol** 1999;18(1):4-9

Chiral separation of alpha-amino acids by ligand-exchange capillary electrophoresis using N-(2-hydroxy-octyl)-L-4-hydroxyproline as a selector. Végvári A, et al. **Electrophoresis** 1998 Sep;19(12):2109-12

ANALYSIS

Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline. Toyoki Y, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2261-4

[Enthalpic denaturation of collagen satisfies the general relation of the change in Delta H(d) from Delta C(p) for proteins at zero hydroxyproline level] Burdzhanadze TV. **Biofizika** 1999 May-Jun;44(3):565-7 (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Evidence for 4-hydroxyproline in viral proteins. Characterization of a viral prolyl 4-hydroxylase and its peptide substrates. Eriksson M, et al. **J Biol Chem** 1999 Aug 6;274(32):22131-4

BLOOD

[Evaluating clinical significance of tumor necrosis factor-alpha and hydroxyproline in blood of patients with active pulmonary tuberculosis] Peng Y, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Oct; 20(5):305-6 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Substituted 4-hydroxyproline di- and tri-peptides as cytotoxic agents. Hall IH, et al. **Amino Acids** 1999; 16(1):79-89

Synthesis and evaluation of hydroxyproline-derived isoprenyltransferase inhibitors. O'Connell CE, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2095-100

A thermodynamic analysis of the contribution of hydroxyproline to the structural stability of the collagen triple helix. Burjanadze TV, et al. **Connect Tissue Res** 1997; 36(4):347-65 (92 ref.)

Chiral separation of alpha-amino acids by ligand-exchange capillary electrophoresis using N-(2-hydroxy-octyl)-L-4-hydroxyproline as a selector. Végvári A, et al. **Electrophoresis** 1998 Sep;19(12):2109-12

Hydroxyproline interference during the gas chromatographic analysis of D/L aspartic acid in human dentine. Waite ER, et al. **Int J Legal Med** 1999;112(2):124-31

URINE

4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride as a fluorescent labeling reagent for determination of amino acids in high-performance liquid chromatography and its application for determination of urinary free hydroxyproline. Tsuruta Y, et al. **Anal Biochem** 1998 Dec 1;265(1):15-21

Age-related changes in body composition, hydroxyproline, and creatinine excretion in normal women. Worsfold M, et al. **Calcif Tissue Int** 1999 Jan;64(1):40-4

Highly sensitive determination of N-terminal prolyl dipeptides, proline and hydroxyproline in urine by high-performance liquid chromatography using a new fluorescent labelling reagent, 4-(5,6-dimethoxy-2-phthalimidinyl)-2-methoxyphenylsulfonyl chloride. Inoue H, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 19; 724(2):221-30

Involvement of the skull base and vault in chronic idiopathic hyperphosphatasia. Mazzanti L, et al. **Pediatr Radiol** 1999 Jan;29(1):16-8

[Determination of bone markers in dairy cows with parturient paresis] Liesegang A, et al. **Schweiz Arch Tierheilkd** 1998; 140(10):405-11 (Eng. Abstr.) **(Ger)**

HYDROXYPROSTAGLANDIN DEHYDROGENASES

ANTAGONISTS & INHIBITORS

Inhibition of 15-hydroxyprostaglandin dehydrogenase activity in rabbit gastric antral mucosa by panaxynol isolated from oriental medicines. Fujimoto Y, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1075-8

BIOSYNTHESIS

In vitro modulation of the expression of 15-hydroxy-prostaglandin dehydrogenase by trophoblast differentiation. Lennon C, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):690-5

GENETICS

Down-regulation of oxytocin-induced cyclooxygenase-2 and prostaglandin F synthase expression by interferon-tau in bovine endometrial cells. Xiao CW, et al. **Biol Reprod** 1999 Mar;60(3):656-63

cDNA cloning, expression, and mutagenesis study of liver-type prostaglandin F synthase. Suzuki T, et al. **J Biol Chem** 1999 Jan 1;274(1):241-8

METABOLISM

Threonine 188 is critical for interaction with NAD+ in human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. Zhou H, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):414-7

Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. Matsuura K, et al. **J Biochem (Tokyo)** 1998 Nov; 124(5):940-6

15-Hydroxyprostaglandin dehydrogenase: Cinderella meets Prince Serendip [editorial; comment] Funder JW. **J Clin Endocrinol Metab** 1999 Feb;84(2):393-4. Comment on: J Clin Endocrinol Metab 1999 Feb;84(2):395-400.

Local modulation by 11beta-hydroxysteroid dehydrogenase of glucocorticoid effects on the activity of 15-hydroxyprostaglandin dehydrogenase in human chorion and placental trophoblast cells [see comments] Patel FA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):395-400. Comment in: J Clin Endocrinol Metab 1999 Feb;84(2):393-4.

Steroid regulation of prostaglandin dehydrogenase activity and expression in human term placenta and chorio-decidua in relation to labor. Patel FA, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):291-9

Hormonal and cellular brain mechanisms regulating the amplexus of male and female water frog (Rana esculenta). Gobbetti A, et al. **J Neuroendocrinol** 1999 Aug;11(8):589-96

Prostaglandin dehydrogenase and the initiation of labor. Challis JR, et al. **J Perinat Med** 1999;27(1):26-34 (34 ref.)

Prostaglandin E2 9-keto reductase from bovine term placenta. Kankofer M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul; 61(1):29-32

8-HYDROXYQUINOLINE see **OXYQUINOLINE**

HYDROXYQUINOLINES

Study of nitrophenols preconcentration using quinolin-8-ol immobilized on controlled-pore glass in the presence of iron(III). Chromatographic determination of dinoseb in lemon juice. Fernández-Salinero G, et al. **J Chromatogr A** 1999 Apr 16;839(1-2):227-32

CHEMICAL SYNTHESIS

Synthesis of 5,8-dimethoxy-3-hydroxy-4-quinolone, a reported inhibitor of HIV RT, and evidence the original proposed structure was incorrect. Zembower DE, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):543-6

An improved synthesis of [11C]L-703,717 as a radioligand for the glycine site of the NMDA receptor. Haradahira T, et al. **Nucl Med Biol** 1999 Feb;26(2):245-7

CHEMISTRY

A high-sensitive spectrofluorimetric method for the determination of micromolar concentrations of iron(III) in bovine liver with 4-hydroxyquinoline. Ragos GC, et al. **Farmaco** 1998 Aug-Sep;53(8-9):611-6

IMMUNOLOGY

The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids. Pekarski O, et al. **Autoimmunity** 1998;28(4):235-41

Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes. Karussis D, et al. **Immunol Lett** 1999 Apr 15;67(3):203-8

ISOLATION & PURIFICATION

Isolation and characterization of the fungal metabolite 3-O-methylviridicatin as an inhibitor of tumour necrosis factor alpha-induced human immunodeficiency virus replication. Heguy A, et al. **Antivir Chem Chemother** 1998 Mar;9(2):149-55

METABOLISM

Stopped-flow studies of the binding of 2-n-heptyl-4-hydroxyquinoline-N-oxide to fumarate reductase of Escherichia coli. Zhao Z, et al. **Eur J Biochem** 1999 Feb;260(1):50-6

Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor. Deyrup MD, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):168-77

PHARMACOLOGY

Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Tian WZ, et al. **Acta Neurol Scand** 1998 Aug;98(2):94-101

Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Zhu J, et al. **Clin Exp Immunol** 1999 Jan; 115(1):56-63

Linomide induces apoptotic death of cortical CD4/CD8 double positive thymocytes and thymic atrophy by a corticosteroid-independent pathway. Arbel I, et al. **Clin Immunol** 1999 Jan;90(1):108-14

Reduction in basic fibroblast growth factor mediated angiogenesis in vivo by linomide. Nagler A, et al. **Connect Tissue Res** 1998;37(1-2):61-8

Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Karpati T, et al. **Immunol Lett** 1998 Oct;63(3):141-5

Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes. Karussis D, et al. **Immunol Lett** 1999 Apr 15;67(3):203-8

Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents [see comments] Joseph IB, et al. **J Natl Cancer Inst** 1998 Nov 4;90(21):1648-53. Comment in: J Natl Cancer Inst 1998 Nov 4;90(21):1583-4. Comment in: J Natl Cancer Inst 1999 May 5;91(9):804-6.

Tumor-associated macrophages as targets for cancer therapy [editorial; comment] [see comments] Wahl LM, et al. **J Natl Cancer Inst** 1998 Nov 4;90(21):1583-4. Comment on: J Natl Cancer Inst 1998 Nov 4;90(21):1648-53. Comment in: J Natl Cancer Inst 1999 May 5;91(9):804-6.

A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Shen AY, et al. **Life Sci** 1999;64(9):813-25

THERAPEUTIC USE

Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Coutant R, et al. **Diabetologia** 1998 Sep;41(9):1040-6

Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis. Hutchings P, et al. **Immunology** 1999 Mar;96(3):340-7

Re: Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents [letter; comment] Dabrowska A, et al. **J Natl Cancer Inst** 1999 May 5; 91(9):804-6. Comment on: J Natl Cancer Inst 1998 Nov 4;90(21):1583-4. Comment on: J Natl Cancer Inst 1998 Nov 4;90(21):1648-53.

Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. Zhu J, et al. **J Neurol Sci** 1998 Oct 8;160(2):113-20

HYDROXYSTEROID DEHYDROGENASES

11 beta-Hydroxysteroid dehydrogenase. Stewart PM, et al. **Vitam Horm** 1999;57:249-324 (388 ref.)

ANALYSIS

11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Robson AC, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):1-10

Expression of the 11beta-hydroxysteroid dehydrogenase types 1 and 2 proteins in human and baboon placental syncytiotrophoblast. Pepe GJ, et al. **Placenta** 1999 Sep;

20(7):575–82

ANTAGONISTS & INHIBITORS

Inhibition of skin 11beta-hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids. Hennebold JD, et al. **Arch Dermatol Res** 1998 Aug;290(8):413–9

Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells. Hardy DB, et al. **Biol Reprod** 1999 Jul;61(1):40–5

Inhibition of renal 11beta-hydroxysteroid dehydrogenase in vivo by carbenoxolone in the rat and its relationship to sodium excretion. Sewell KJ, et al. **Clin Sci (Colch)** 1998 Oct;95(4):435–43

Structure and mechanism of action and inhibition of steroid dehydrogenase enzymes involved in hypertension. Duax WL, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):521–9

Selective inhibition of human type 1 11beta-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. Hult M, et al. **FEBS Lett** 1998 Dec 11;441(1):25–8

Inhibition of 11beta-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis. Ackermann D, et al. **Hepatology** 1999 Sep;30(3):623–9

BIOSYNTHESIS

Tissue- and temporal-specific regulation of 11beta-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo. Jamieson PM, et al. **J Steroid Biochem Mol Biol** 1999 Mar;68(5–6):245–50

CHEMISTRY

Regulatory factors and motifs in SDR enzymes. Oppermann U, et al. **Adv Exp Med Biol** 1999;463:365–71

Bioinformatics in studies of SDR and MDR enzymes. Persson B, et al. **Adv Exp Med Biol** 1999;463:373–7

Serines at the active site of 11 beta-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Obeyesekere VR, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):469–73

DEFICIENCY

'The fat lady sings', but what is she telling us? [comment] Stewart PM. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):9–10. Comment on: Clin Endocrinol (Oxf) 1998 Jul;49(1):13–20.

Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity. Nordenström A, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1210–3

[11 beta-hydroxysteroid-dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism] Kerstens MN, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):509–14 (47 ref.) (Eng. Abstr.) **(Dut)**

DRUG EFFECTS

Regulation of 11beta-hydroxysteroid dehydrogenase type 2 by diuretics and the renin-angiotensin-aldosterone axis. Ricketts ML, et al. **Clin Sci (Colch)** 1999 Jun;96(6):669–75

GENETICS

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Li A, et al. **Am J Hum Genet** 1998 Aug;63(2):370–9

Improved ligation-mediated polymerase chain reaction of GC-rich transcriptional control regions. Nawrocki A, et al. **Anal Biochem** 1999 Aug 1;272(2):280–2

Expression of human kidney 11beta-hydroxysteroid dehydrogenase (11-HSD2) in bacteria. Nunez BS, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):652–6

Cloning of the 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-2 gene in the baboon: effects of estradiol on promoter activity of 11beta-HSD-1 and -2 in placental JEG-3 cells. Pepe GJ, et al. **Biochim Biophys Acta** 1999 Jan 18;1444(1):101–10

Expression of 11beta-hydroxysteroid dehydrogenase, glucocorticoid receptor, and mineralocorticoid receptor genes in rat ovary. Tetsuka M, et al. **Biol Reprod** 1999 Feb;60(2):330–5

Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells. Tremblay J, et al. **Biol Reprod** 1999 Mar;60(3):541–5

Human endometrial decidual cell-associated 11 beta-hydroxysteroid dehydrogenase expression: its potential role in implantation. Arcuri F, et al. **Early Pregnancy** 1997 Dec;3(4):259–64

11beta-hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. Mazzocchi G, et al. **FASEB J** 1998 Nov;12(14):1533–9

Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess. Morineau G, et al. **Hypertension** 1999 Sep;34(3):435–41

Coexpression of mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenase 2 in human gastric mucosa. Kato K, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2568–73

The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. Rogoff D, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4391–3

Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. Kotelevtsev Y, et al. **J Clin Invest** 1999 Mar;103(5):683–9

Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. Brand E, et al. **J Hypertens** 1998 Nov;16(11):1627–33

Regulation of the genes for 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidney of the Dahl rat. Franco-Saenz R, et al. **J Hypertens** 1999 Aug; 17(8):1089–93

11Beta-hydroxysteroid dehydrogenase expression in first trimester human trophoblasts. Arcuri F, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):13–20

Expression of oestrogen receptor isoforms in relation to enzymes of oestrogen synthesis in rat ovary. Tetsuka M, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):29–35

Effects of sustained hypoxaemia with 72 hours recovery on 11beta-hydroxysteroid dehydrogenase types 1 and 2 gene expression in near-term fetal sheep. Asano H, et al. **Reprod Fertil Dev** 1997;9(8):755–61

METABOLISM

Immunohistochemical study of steroidogenic enzymes in the ovary and placenta during pregnancy in the dog. Nishiyama T, et al. **Anat Histol Embryol** 1999 May;28(2):125–9

11 beta-hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms. Takahashi K, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3381–8

Serines at the active site of 11 beta-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Obeyesekere VR, et al. **Biochem Biophys Res Commun** 1998 Sep 18;250(2):469–73

Dual effects of anti-inflammatory 2-arylpropionic acid derivatives on a major isoform of human liver 3alpha-hydroxysteroid dehydrogenase. Yamamoto T, et al. **Biol Pharm Bull** 1998 Nov;21(11):1148–53

11beta-hydroxysteroid dehydrogenase type 2 is the predominant isozyme in the guinea pig placenta: decreases in messenger ribonucleic acid and activity at term. Sampath-Kumar R, et al. **Biol Reprod** 1998 Dec; 59(6):1378–84

NAD- and NADP-dependent 11 beta-hydroxysteroid dehydrogenase isoforms in guinea pig kidney with gossypol inhibition. Wang MS, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):481–5

Inhibition of 11 beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by some bioflavonoids and triterpenoids. Zhang YD, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):240–4

An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Katz JR, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):63–8

Growth hormone replacement inhibits renal and hepatic 11 beta-hydroxysteroid dehydrogenases in ACTH-deficient patients. Walker BR, et al. **Clin Endocrinol (Oxf)** 1998 Aug; 49(2):257–63

Sexual dimorphism in 11 beta hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects [see comments] Weaver JU, et al. **Clin Endocrinol (Oxf)** 1998 Jul; 49(1):13–20. Comment in: Clin Endocrinol (Oxf) 1998 Jul;49(1):9–10.

Hepatic microsomal enzyme activity in the koala and tammar wallaby: high 17beta-hydroxysteroid oxidoreductase activity in koala liver microsomes. Stupans I, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 May;123(1):67–73

11 beta-Hydroxysteroid dehydrogenase enzyme activity in granulosa cells derived from ovarian follicles of in vitro fertilization patients. O'Shaughnessy A, et al. **Early Pregnancy** 1997 Sep;3(3):183–9

Expression of 11betaHSD-2 in human adrenal cortical carcinoma and adenoma. Coulter CL, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):875–6

Regulation of 11beta-hydroxysteroid dehydrogenase type II in rat adrenocortical cells. Lecybyl R, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):643–7

Novel effects of deoxycorticosterone on testicular 11beta-hydroxysteroid dehydrogenase activity and plasma testosterone levels in normal and adrenalectomized rats. Nwe KH, et al. **Exp Clin Endocrinol Diabetes** 1999; 107(5):288–94

Maternal hypertension and progeny blood pressure: role of aldosterone and 11beta-HSD. Gomez-Sanchez EP, et al. **Hypertension** 1999 Jun;33(6):1369–73

Renal 11beta-hydroxysteroid dehydrogenase in genetically salt-sensitive hypertensive rats. Takeda Y, et al. **Hypertension** 1998 Dec;32(6):1077–82

11 beta HSD and the mechanism of gossypol-induced hypokalemia [letter; comment] Michael AE. **Int J Androl** 1998 Oct;21(5):313. Comment on: Int J Androl 1998 Feb;21(1):2–7. Comment on: Int J Androl 1998 Feb;21(1):8–12.

11Beta-hydroxysteroid dehydrogenase, mineralocorticoid receptor, and thiazide-sensitive Na-Cl cotransporter expression by distal tubules [published erratum appears in J Am Soc Nephrol 1998 Nov;9(11):2179] Bostanjoglo M, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1347–58

Inhibition of IMCD 11 beta-hydroxysteroid dehydrogenase type 2 by low pH and acute acid loading. Nolan PJ, et al. **J Am Soc Nephrol** 1997 Apr;8(4):530–4

Roles of the Ser146, Tyr159, and Lys163 residues in the catalytic action of 7alpha-hydroxysteroid dehydrogenase from Escherichia coli. Tanabe T, et al. **J Biochem (Tokyo)** 1998 Sep;124(3):634–41

Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11beta-hydroxysteroid dehydrogenase and the 50-kDa esterase. Mziaut H, et al. **J Biol Chem** 1999 May 14;274(20):14122–9

Expression of type 2 11beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. Condon J, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4490–7

Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. Finken MJ, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3316–21

11Beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in human fetal development. Hirasawa G, et al. **J Clin Endocrinol Metab** 1999 Apr; 84(4):1453–8

Local modulation by 11beta-hydroxysteroid dehydrogenase of glucocorticoid effects on the activity of 15-hydroxyprostaglandin dehydrogenase in human chorion and placental trophoblast cells [see comments] Patel FA, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):395–400. Comment in: J Clin Endocrinol Metab 1999 Feb;84(2):393–4.

11Beta-hydroxysteroid dehydrogenase type 2 in human lung: possible regulator of mineralocorticoid action. Suzuki T, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4022–5

Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. Vogt B, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):811–4

Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. Bland R, et al. **J Endocrinol** 1999 Jun;161(3):455–64

Interactions between oestradiol and glucocorticoid regulatory effects on liver-specific glucocorticoid-inducible genes: possible evidence for a role of hepatic 11beta-hydroxysteroid dehydrogenase type 1. Jamieson PM, et al. **J Endocrinol** 1999 Jan;160(1):103–9

11beta-hydroxysteroid dehydrogenase is a predominant reductase in intact rat Leydig cells. Leckie CM, et al. **J Endocrinol** 1998 Nov;159(2):233–8

Activation of 11 beta-hydroxysteroid dehydrogenase by dehydroepiandrosterone sulphate as an anti-hypertensive agent in spontaneously hypertensive rats. Homma M, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1139–45

The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. Krozowski Z, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):391–401 (71 ref.)

Expression of 11beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer. Parks LL, et al. **J Steroid Biochem Mol Biol** 1998 Nov;67(4):341–6

Activity of renal 11betahydroxysteroid dehydrogenase 2 (11betaHSD2) in stressed animals. Igarreta P, et al. **Life Sci** 1999;64(24):2285–90

11Beta-hydroxysteroid dehydrogenase expression in first trimester human trophoblasts. Arcuri F, et al. **Mol Cell Endocrinol** 1998 Jun 25;141(1–2):13–20

The cortisol-cortisone shuttle in children born with intrauterine growth retardation. Houang M, et al. **Pediatr Res** 1999 Aug;46(2):189–93

Interconversion of cortisol and cortisone by 11beta-hydroxysteroid dehydrogenases type 1 and 2 in the perfused human placenta. Sun K, et al. **Placenta** 1999 Jan; 20(1):13–9

Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies. McCalla CO, et al. **Steroids** 1998 Oct;63(10):511–5

[11 beta-hydroxysteroid-dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism] Kerstens MN, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):509–14 (47 ref.) (Eng. Abstr.) **(Dut)**

[11 beta-hydroxysteroid dehydrogenases: key enzymes in the action of mineralocorticoids and glucocorticoids] Diederich S, et al. **Dtsch Med Wochenschr** 1999 Jan 22; 124(3):51–5 (43 ref.) **(Ger)**

PHARMACOLOGY

Regulation of the action of hydrocortisone in airway epithelial cells by 11beta-hydroxysteroid dehydrogenase. Feinstein MB, et al. **Am J Respir Cell Mol Biol** 1999 Sep; 21(3):403–8

PHYSIOLOGY

The protective role of 11 beta-hydroxysteroid dehydrogenase/carbonyl reductase against tobacco-smoke related lung cancer. Maser E. **Adv Exp Med Biol** 1999; 463:379–87

Mechanism of adrenal insufficiency following trauma and severe hemorrhage: role of hepatic 11beta-hydroxysteroid dehydrogenase. Wang P, et al. **Arch Surg** 1999 Apr; 134(4):394–401

Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and

local steroid action. Burton PJ, et al. **Biol Reprod** 1999 Feb;60(2):234–40 (98 ref.)

Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Bujalska IJ, et al. **Endocrinology** 1999 Jul;140(7):3188–96

11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hatakeyama H, et al. **Hypertension** 1999 May;33(5):1179–84

The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects. Krozowski Z. **Mol Cell Endocrinol** 1999 May 25;151(1–2):121–7 (70 ref.)

Expression of 11 beta-hydroxysteroid dehydrogenase in early pregnancy: implications in human trophoblast-endometrial interactions. Arcuri F, et al. **Semin Reprod Endocrinol** 1999; 17(1):53–61 (63 ref.)

URINE

11Beta-HSD and 17beta-HSD as biological markers of depression: sex differences and correlation with symptom severity. Raven PW, et al. **Endocr Res** 1998 Aug–Nov; 24(3–4):659–62

3-HYDROXYSTEROID DEHYDROGENASES

ANALYSIS

Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. El-Alfy M, et al. **Endocrinology** 1999 Mar;140(3):1481–91

ANTAGONISTS & INHIBITORS

Gentamicin induced inhibition of steroidogenic enzymes in rat testis. Ghosh S, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):247–50

BIOSYNTHESIS

Regulation of 3beta-hydroxysteroid dehydrogenase in gonadotropin-induced steroidogenic desensitization of Leydig cells. Tang PZ, et al. **Endocrinology** 1998 Nov; 139(11):4496–505

Expression of 3beta-hydroxysteroid dehydrogenase type I and type VI isoforms in the mouse testis during development. Baker PJ, et al. **Eur J Biochem** 1999 Mar; 260(3):911–7

BLOOD

Biochemical variants of Smith-Lemli-Opitz syndrome. Neklason DW, et al. **Am J Med Genet** 1999 Aug 27; 85(5):517–23

CHEMISTRY

Conversion of mammalian 3alpha-hydroxysteroid dehydrogenase to 20alpha-hydroxysteroid dehydrogenase using loop chimeras: changing specificity from androgens to progestins. Ma H, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11161–6

DEFICIENCY

Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Moran C, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):596–600

An inborn error of bile acid synthesis (3beta-hydroxy-delta5-C27-steroid dehydrogenase deficiency) presenting as malabsorption leading to rickets. Akobeng AK, et al. **Arch Dis Child** 1999 May;80(5):463–5

GENETICS

Cloning and sequencing of a new Comamonas testosteroni gene encoding 3 alpha-hydroxysteroid dehydrogenase/carbonyl reductase. Möbus E, et al. **Adv Exp Med Biol** 1999;463:395–402

Age- and region-specific expressions of the messenger RNAs encoding for steroidogenic enzymes p450scc, P450c17 and 3beta-HSD in the postnatal rat brain. Kohchi C, et al. **Brain Res** 1998 Aug 10;801(1–2):233–8

Expression and activity of 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase in different regions of the avian brain. Ukena K, et al. **Brain Res** 1999 Feb 13;818(2):536–42

Cloning of zebrafish cDNA for 3beta-hydroxysteroid dehydrogenase and P450scc. Lai WW, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):927–31

Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. Matsuura K, et al. **J Biochem (Tokyo)** 1998 Nov; 124(5):940–6

Molecular cloning and characterization of hemolymph 3-dehydroecdysone 3beta-reductase from the cotton leafworm, Spodoptera littoralis. A new member of the third superfamily of oxidoreductases. Chen JH, et al. **J Biol Chem** 1999 Apr 9;274(15):10551–6

Molecular cloning, overexpression, and characterization of steroid-inducible 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni. A novel member of the short-chain dehydrogenase/reductase superfamily. Möbus E, et al. **J Biol Chem** 1998 Nov 20;273(47):30888–96

Steroidogenic acute regulatory protein (StAR) transcripts constitutively expressed in the adult rat central nervous system: colocalization of StAR, cytochrome P-450SCC (CYP XIA1), and 3beta-hydroxysteroid dehydrogenase in the rat brain. Furukawa A, et al. **J Neurochem** 1998 Dec; 71(6):2231–8

The gene mutated in bare patches and striated mice encodes a novel 3beta-hydroxysteroid dehydrogenase. Liu XY, et al. **Nat Genet** 1999 Jun;22(2):182–7

Decrease in the expression of the 3beta-hydroxysteroid dehydrogenase gene in human adrenal tissue during prepuberty and early puberty: implications for the mechanism of adrenarche. Dardis A, et al. **Pediatr Res** 1999 Mar;45(3):384–8

[Genetic control of the activity of microsomal enzymes of steroidogenesis in Leydig cells of inbred strains of mice] Osadchuk AV, et al. **Genetika** 1998 Sep;34(9):1277–85 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Human leukocyte antigen-DQB1* genotypes encoding aspartate at position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure. Arif S, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1056–60

METABOLISM

Structure-function relationships of 3 beta-hydroxysteroid dehydrogenases involved in bile acid metabolism. Filling C, et al. **Adv Exp Med Biol** 1999;463:389–94

Ultracytochemistry of 3beta-hydroxysteroid dehydrogenase in Leydig cell precursors and vascular endothelial cells of the postnatal rat testis. Haider SG, et al. **Anat Embryol (Berl)** 1998 Aug;198(2):101–10

Purification and properties of 3 alpha-hydroxysteroid dehydrogenase and 3-keto-5 beta-steroid-delta 4-dehydrogenase. Gao X, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:383–92

The arginine 276 anchor for NADP(H) dictates fluorescence kinetic transients in 3 alpha-hydroxysteroid dehydrogenase, a representative aldo-keto reductase. Ratnam K, et al. **Biochemistry** 1999 Jun 15;38(24):7856–64

Hepatic and extrahepatic dehydrogenation/isomerization of 5-cholestene-3 beta,7 alpha-diol: localization of 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase in pig tissues and subcellular fractions. Furster C. **Biochim Biophys Acta** 1999 Jan 4;1436(3):343–53

Opposing changes in 3alpha-hydroxysteroid dehydrogenase oxidative and reductive activities in rat leydig cells during pubertal development. Ge RS, et al. **Biol Reprod** 1999 Apr; 60(4):855–60

Expression of 3beta-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro. Gunasegaram R, et al. **Breast Cancer Res Treat** 1998 Jul;50(2):117–23

Battle of the kinases: integration of adrenal responses to cAMP, DG and Ca2+ at the level of steroidogenic cytochromes P450 and 3betaHSD expression in H295R cells. Bird IM, et al. **Endocr Res** 1998 Aug–Nov; 24(3–4):345–54

Ontogeny of 3beta-hydroxysteroid dehydrogenase expression in the rat adrenal gland as studied by immunohistochemistry. Pignatelli D, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):613–4

Ontogeny of 3beta-hydroxysteroid dehydrogenase expression in the rat adrenal gland as studied by immunohistochemistry. Pignatelli D, et al. **Endocr Res** 1999 Feb;25(1):21–7

Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. Gingras S, et al. **Endocrinology** 1999 Oct;140(10):4573–84

Metabolism of dihydrotestosterone in human liver: importance of 3alpha- and 3beta-hydroxysteroid dehydrogenase. Pirog EC, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3217–21

Localization of immunoreactive testosterone and 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase in cynomolgus monkey (Macaca fascicularis) testes during postnatal development. Liang JH, et al. **J Med Primatol** 1999 Apr;28(2):62–6

Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3alpha-hydroxysteroid dehydrogenase. Penning TM. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):211–25 (59 ref.)

Regulation of steroidogenesis in jc-410, a stable cell line of porcine granulosa origin. Rodway MR, et al. **Mol Cell Endocrinol** 1999 Feb 25;148(1–2):87–94

Steroidogenic enzyme expression in human corpora lutea in the presence and absence of exogenous human chorionic gonadotrophin (HCG). Duncan WC, et al. **Mol Hum Reprod** 1999 Apr;5(4):291–8

[Role of 3 beta hydroxysteroid dehydrogenase (3 beta HSD) in human adrenal androgen synthesis] Dardis A, et al. **Medicina (B Aires)** 1999;59(1):79–82 (Eng. Abstr.) **(Spa)**

URINE

[Urinary excretion of steroid hormone and 3 beta-hydroxysteroid dehydrogenase activity in normal young adult women] Takeyasu M, et al. **Rinsho Byori** 1999 Jan;47(1):70–5 (Eng. Abstr.) **(Jpn)**

17-HYDROXYSTEROID DEHYDROGENASES

ANALYSIS

Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. El-Alfy M, et al. **Endocrinology** 1999 Mar;140(3):1481–91

ANTAGONISTS & INHIBITORS

Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Tremblay MR, et al. **Bioorg Med Chem** 1999 Jun;7(6):1013–23

Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Le Bail JC, et al. **Cancer Lett** 1998 Nov 13;133(1):101–6

Gentamicin induced inhibition of steroidogenic enzymes in rat testis. Ghosh S, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):247–50

Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Chetrite GS, et al. **J Steroid Biochem Mol Biol** 1999 Jan;68(1–2):51–6

BIOSYNTHESIS

Human estrogenic 17beta-hydroxysteroid dehydrogenase: predominance of estrone reduction and its induction by NADPH. Jin JZ, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):489–93

CHEMISTRY

3D-structure of human estrogenic 17beta-HSD1: binding with various steroids. Lin SX, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):425–9 (16 ref.)

Two non-reactive ternary complexes of estrogenic 17beta-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis. Qiu W, et al. **J Steroid Biochem Mol Biol** 1999 Mar;68(5–6):239–44

DEFICIENCY

Natural potent androgens: lessons from human genetic models. Zhu YS, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):83–113 (170 ref.)

Adrenarche results from development of a 3beta-hydroxysteroid dehydrogenase-deficient adrenal reticularis. Gell JS, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3695–701

17Beta-hydroxysteroid dehydrogenase 3 deficiency in women. Mendonca BB, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):802–4

GENETICS

A novel 17beta-hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Lanisnik Rizner T, et al. **Biochem J** 1999 Feb 1;337 (Pt 3):425–31

Assignment of HSD17B5 encoding type 5 17 beta-hydroxysteroid dehydrogenase to human chromosome bands 10p15-->p14 and mouse chromosome 13 region A2 by in situ hybridization: identification of a new syntenic relationship. Rheault P, et al. **Cytogenet Cell Genet** 1999;84(3–4):241–2

Cloning and expression of a novel tissue specific 17beta-hydroxysteroid dehydrogenase. Li KX, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):663–7

Identification of essential subelements in the hHSD17B1 enhancer: difference in function of the enhancer and that of the hHSD17BP1 analog is due to -480C and -486G. Leivonen S, et al. **Endocrinology** 1999 Aug;140(8):3478–87

Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Puranen TJ, et al. **Endocrinology** 1999 Jul;140(7):3334–41

The rat 17beta-hydroxysteroid dehydrogenase type III: molecular cloning and gonadotropin regulation. Tsai-Morris CH, et al. **Endocrinology** 1999 Aug; 140(8):3534–42

The cDNA cloning and transient expression of an ovary-specific 17beta-hydroxysteroid dehydrogenase of chickens. Wajima Y, et al. **Gene** 1999 Jun 11;233(1–2):75–82

Expression of 17beta-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe. Stoffel-Wagner B, et al. **J Endocrinol** 1999 Jan;160(1):119–26

Characterization of the HSD17B4 gene: D-specific multifunctional protein 2/17beta-hydroxysteroid dehydrogenase IV. Möller G, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun;69(1–6):441–6

Structure of the gene for the human 17beta-hydroxysteroid dehydrogenase type IV. Leenders F, et al. **Mamm Genome** 1998 Dec;9(12):1036-41

Abnormal regulation of the Ke 6 gene, a new 17beta-hydroxysteroid dehydrogenase in the cpk mouse kidney. Ramirez S, et al. **Mol Cell Endocrinol** 1998 Aug 25;143(1-2):9-22

[Genetic control of the activity of microsomal enzymes of steroidogenesis in Leydig cells of inbred strains of mice] Osadchuk AV, et al. **Genetika** 1998 Sep;34(9):1277-85 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase. He XY, et al. **J Biol Chem** 1999 May 21; 274(21):15014-9

METABOLISM

Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Chetrite GS, et al. **Anticancer Res** 1999 Jan-Feb; 19(1A):261-7

Androgen metabolism in sebaceous glands from subjects with and without acne [see comments] Thiboutot D, et al. **Arch Dermatol** 1999 Sep;135(9):1041-5. Comment in: Arch Dermatol 1999 Sep;135(9):1101-2.

Cloning and expression of a novel tissue specific 17beta-hydroxysteroid dehydrogenase. Li KX, et al. **Endocr Res** 1998 Aug-Nov;24(3-4):663-7

Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Dufort I, et al. **Endocrinology** 1999 Feb;140(2):568-74

Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Puranen TJ, et al. **Endocrinology** 1999 Jul;140(7):3334-41

Expression and activity of 3beta-hydroxysteroid dehydrogenase/delta5-delta4-isomerase in the rat Purkinje neuron during neonatal life. Ukena K, et al. **Endocrinology** 1999 Feb;140(2):805-13

17Beta-hydroxysteroid dehydrogenases in human bone cells. Dong Y, et al. **J Bone Miner Res** 1998 Oct;13(10):1539-46

Peroxisome targeting of porcine 17beta-hydroxysteroid dehydrogenase type IV/D-specific multifunctional protein 2 is mediated by its C-terminal tripeptide AKI. Möller G, et al. **J Cell Biochem** 1999 Apr 1;73(1):70-8

Loss of estrogen inactivation in colonic cancer. English MA, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2080-5

17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas. Green VL, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1340-5

17Beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development. Takeyama J, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3710-5

Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. Zeitoun K, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4474-80

Minoxidil increases 17 beta-hydroxysteroid dehydrogenase and 5 alpha-reductase activity of cultured human dermal papilla cells from balding scalp. Sato T, et al. **J Dermatol Sci** 1999 Feb;19(2):123-5

Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. Pelletier G, et al. **J Histochem Cytochem** 1999 Jun;47(6):731-8

Unique multifunctional HSD17B4 gene product: 17beta-hydroxysteroid dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A dehydrogenase/hydratase involved in Zellweger syndrome. de Launoit Y, et al. **J Mol Endocrinol** 1999 Jun;22(3):227-40 (110 ref.)

17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. Peltoketo H, et al. **J Mol Endocrinol** 1999 Aug; 23(1):1-11 (89 ref.)

Characterization of 17beta-hydroxysteroid dehydrogenase activity in brain tissue: testosterone formation in the human temporal lobe. Steckelbroeck S, et al. **J Neuroendocrinol** 1999 Jun;11(6):457-64

Two 17beta-hydroxysteroid dehydrogenases (17HSDs) of estradiol biosynthesis: 17HSD type 1 and type 7. Peltoketo H, et al. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1-6):431-9 (46 ref.)

Regulation of estrogen action: role of 17 beta-hydroxysteroid dehydrogenases. Peltoketo H, et al. **Vitam Horm** 1999; 55:353-98 (202 ref.)

PHYSIOLOGY

Estrone potentiates myeloid cell differentiation: a role for 17 beta-hydroxysteroid dehydrogenase in modulating hemopoiesis. Mountford JC, et al. **Exp Hematol** 1999 Mar; 27(3):451-60

URINE

11Beta-HSD and 17beta-HSD as biological markers of depression: sex differences and correlation with symptom severity. Raven PW, et al. **Endocr Res** 1998 Aug-Nov; 24(3-4):659-62

20-HYDROXYSTEROID DEHYDROGENASES

CHEMISTRY

Conversion of mammalian 3alpha-hydroxysteroid dehydrogenase to 20alpha-hydroxysteroid dehydrogenase using loop chimeras: changing specificity from androgens to progestins. Ma H, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11161-6

GENETICS

Mutation of tyrosine-194 and lysine-198 in the catalytic site of pig 3alpha/beta,20beta-hydroxysteroid dehydrogenase. Nakajin S, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):553-7

METABOLISM

Characterization of homogeneous recombinant rat ovarian 20alpha-hydroxysteroid dehydrogenase: fluorescent properties and inhibition profile. Ma H, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):853-9

HYDROXYSTEROIDS

see related
HYDROXYCORTICOSTEROIDS

METABOLISM

Transformation of 3-hydroxy-steroids by Fusarium moniliforme 7alpha-hydroxylase. Cotillon AC, et al. **J Steroid Biochem Mol Biol** 1999 Mar;68(5-6):229-37

HYDROXYTETRACYCLINE see **OXYTETRACYCLINE**

HYDROXYTHIAMINE see **OXYTHIAMINE**

5-HYDROXYTRYPTAMINE see **SEROTONIN**

5-HYDROXYTRYPTAMINE AGONISTS see **SEROTONIN AGONISTS**

5-HYDROXYTRYPTAMINE ANTAGONISTS see **SEROTONIN ANTAGONISTS**

5-HYDROXYTRYPTAMINE RECEPTORS see **RECEPTORS, SEROTONIN**

5-HYDROXYTRYPTAMINE UPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

5-HYDROXYTRYPTOPHAN

ANALYSIS

Functional chemical neuroanatomy of serotonergic neurons and their targets: antibody production and immunohistochemistry (IHC) for 5-HT, its precursor (5-HTP) and metabolite (5-HIAA), biosynthetic enzyme (TPH), transporter (SERT), and three receptors (5-HT2A, 5-ht5a, 5-HT7). Brownfield MS, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:232-3

CHEMISTRY

Regulatory properties of recombinant tropomyosins containing 5-hydroxytryptophan: Ca2+-binding to troponin results in a conformational change in a region of tropomyosin outside the troponin binding site. Farah CS, et al. **Biochemistry** 1999 Aug 10;38(32):10543-51

PHARMACOLOGY

Evidence for the putative 5-HT7 receptor mediating direct relaxation to 5-hydroxytryptamine in canine cerebral blood vessels. Terrón JA. **Ann N Y Acad Sci** 1998 Dec 15;861:283

Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. Artaiz I, et al. **Behav Pharmacol** 1998 Mar;9(2):103-12

Responsiveness of tuberoinfundibular dopaminergic neurons to 5-hydroxytryptophan: effects of aging. MohanKumar PS, et al. **Endocrine** 1998 Aug;9(1):33-7

Adrenocorticotropic hormone secretion in rats induced by stimulation with serotonergic compounds. hsj@mfi.ku.dk. Jørgensen H, et al. **J Neuroendocrinol** 1999 Apr; 11(4):283-90

Elevation of melatonin in chicken retina by 5-hydroxytryptophan: differential light/dark responses. Thomas KB, et al. **Neuroreport** 1998 Dec 21;9(18):4041-4

D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype. Sallinen J, et al. **Neuroscience** 1998 Oct;86(3):959-65

Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Sargent PA, et al. **Psychopharmacology (Berl)** 1998 Nov; 140(1):120-2

THERAPEUTIC USE

L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency. Lado-Abeal J, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):203-7

HYDROXYTRYPTOPHOL

URINE

The urinary ratio of 5-hydroxytryptophol to 5-hydroxyindole-3-acetic acid in surgical patients with chronic alcohol misuse. Spies CD, et al. **Alcohol** 1999 Jan; 17(1):19-27

Urinary excretion of methanol and 5-hydroxytryptophol as biochemical markers of recent drinking in the hangover state. Bendtsen P, et al. **Alcohol Alcohol** 1998 Jul-Aug; 33(4):431-8

Comparison of urinary 5-hydroxytryptophol, breath ethanol, and self-report for detection of recent alcohol use during outpatient treatment: a study on methadone patients. Helander A, et al. **Drug Alcohol Depend** 1999 Aug 2; 56(1):33-8

HYDROXYTYRAMINE see **DOPAMINE**

HYDROXYUREA

Hydroxyurea: new insights on an old drug. Navarra P, et al. **Crit Rev Oncol Hematol** 1999 Feb;29(3):249-55 (59 ref.)

How safe is hydroxyurea in the treatment of polycythemia vera? [editorial] **Haematologica** 1999 Aug;84(8):673-4

ADMINISTRATION & DOSAGE

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR, et al. **Blood** 1999 Sep 1;94(5):1550-4

Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Philip PA, et al. **Clin Cancer Res** 1996 Feb; 2(2):303-10

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Beitler JJ, et al. **Invest New Drugs** 1998;16(2):161-9

Antiretroviral treatment [letter; comment] Boelaert JR, et al. **Lancet** 1998 Oct 10;352(9135):1224-5. Comment on: Lancet 1998 Jun 20;351(9119):1825.

ADVERSE EFFECTS

Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Diav-Citrin O, et al. **Am J Hematol** 1999 Feb;60(2):148-50 (21 ref.)

Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia. Quintás-Cardama A, et al. **Ann Hematol** 1999 Apr;78(4):187-8

Leg ulcers and hydroxyurea: forty-one cases. Sirieix ME, et al. **Arch Dermatol** 1999 Jul;135(7):818-20

Hydroxyurea-induced fever and hepatitis. Westerman DA, et al. **Aust N Z J Med** 1998 Oct;28(5):657-9

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR, et al. **Blood** 1999 Sep 1;94(5):1550-4

Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor [letter] Stagno F, et al. **Blood** 1999 Aug 15;94(4):1479-80

Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostagladin E1 and pentoxifylline [letter] Kido M, et al. **Br J Dermatol** 1998 Dec;139(6):1124-6

Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer [letter] Suehiro M, et al. **Br J Dermatol** 1998 Oct;139(4):748-9

Hydroxyurea-induced fever in cervical carcinoma: case report and review of the literature. Cheung AY, et al. **Cancer Invest** 1999;17(4):245-8 (7 ref.)

Hydroxyurea-induced skin disease mimicking the baboon syndrome [letter] Chowdhury MM, et al. **Clin Exp Dermatol** 1999 Jul;24(4):336-7

Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Weissman SB, et al. **Clin Infect Dis** 1999 Jul;29(1):223-4

Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. De Simone C, et al. **Eur J Dermatol** 1998 Mar;8(2):114-5

Hydroxyurea as a cause of drug fever in essential thrombocythaemia [letter] Lannemyr O, et al. **Eur J Haematol** 1999 May;62(5):354-5

Acute myeloid leukemia occurring in a patient with polycythemia vera in treatment with hydroxyurea [letter] Cacciola E, et al. **Haematologica** 1999 Aug;84(8):755-6

Nail changes after chemotherapy. Las Heras G, et al. **Haematologica** 1998 Aug;83(8):748

Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. Hernández-Martín A, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):333–4

Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. Kato N, et al. **J Dermatol** 1999 Jan;26(1):56–62 (35 ref.)

Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? Vélez A, et al. **J Eur Acad Dermatol Venereol** 1999 May;12(3):243–4

Multiple skin cancers associated with hydroxyurea therapy. Best PJ, et al. **Mayo Clin Proc** 1998 Oct;73(10):961–3

Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia [letter] Ruiz-Argüelles GJ, et al. **Mayo Clin Proc** 1998 Nov; 73(11):1125

Tumor lysis syndrome. Ezzone SA. **Semin Oncol Nurs** 1999 Aug;15(3):202–8 (15 ref.)

[Hyperalgesic malleolar ulcer: recovery on the withdrawal of hydroxyurea (letter)] Liebschutz S, et al. **Rev Med Interne** 1998 May;19(5):360–1 **(Fre)**

[Symmetrical foot ulcer in chronic myeloid leukemia treated with hydroxyurea (Litalir)] Reichenberger F. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1370–2 **(Ger)**

[Myositis caused by hydroxyurea in a patient with chronic myelogenous leukemia] Ikeda K, et al. **Rinsho Ketsueki** 1998 Sep;39(9):676–9 (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. Frieri M, et al. **Ann Allergy Asthma Immunol** 1998 Oct;81(4):331–6

In vivo correlation of neutrophil receptor expression, ischemia-reperfusion injury, and selective 5-lipoxygenase inhibition in guinea pigs. Dolan R, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec; 124(12):1377–80

N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Connolly PJ, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):979–84

Antileukotrienes and asthma: alternative or adjunct to inhaled steroids? Kavuru MS, et al. **Cleve Clin J Med** 1998 Nov-Dec;65(10):519–26 (25 ref.)

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety. Dubé LM, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer;17(1-2):213–21 (36 ref.)

Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Machinist JM, et al. **Drug Metab Dispos** 1998 Oct;26(10):970–6

Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. Wong SL, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):715–9

Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease. Marr KA, et al. **J Vet Pharmacol Ther** 1998 Jun; 21(3):241–6

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Drazen JM, et al. **Nat Genet** 1999 Jun;22(2):168–70

The effects of multiple dosing with zileuton on antigen-induced responses in sheep. Scuri M, et al. **Pulm Pharmacol Ther** 1998;11(4):277–80

Leukotriene antagonism in asthma and rhinitis. Lane SJ. **Respir Med** 1998 Jun;92(6):795–809 (150 ref.)

CHEMISTRY

The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Kim-Shapiro DB, et al. **Biochim Biophys Acta** 1999 Aug 5;1428(2-3):381–7

METABOLISM

Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Glover RE, et al. **Mol Pharmacol** 1999 Jun;55(6):1006–10

PHARMACOKINETICS

Hydroxyurea influences adrenocortical function in humans [letter] Navarra P, et al. **Eur J Clin Pharmacol** 1998 Aug; 54(6):491–2

PHARMACOLOGY

Hydroxyurea treatment enhances metastatic cell adhesiveness: a possible chemotherapy-induced increase in metastatic potential? Smith TA. **Anticancer Drugs** 1999 Apr;10(4):429–30

Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Palmer S, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2046–50

Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. Wadler S, et al. **Biochem Pharmacol** 1998 May 1;55(9):1353–60

Screening of five specific cell cycle inhibitors using a T cell lymphoma cell line synchrony/release assay. Yerly-Motta V, et al. **Biotech Histochem** 1999 May;74(3):119–28

Uptake of glucose analogues by colonic tumour cells during growth and after treatment with hydroxyurea. Smith TA, et al. **Cancer Lett** 1999 Jul 1;141(1-2):85–91

Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Wong SJ, et al. **Clin Cancer Res** 1999 Feb; 5(2):439–43

Differential effects of hydroxyurea upon deoxyribonucleoside triphosphate pools, analyzed with vaccinia virus ribonucleotide reductase. Hendricks SP, et al. **J Biol Chem** 1998 Nov 6;273(45):29519–23

Differential sensitivity of double minute chromosomes to hydroxyurea treatment in cultured methotrexate-resistant mouse cells. Nevaldine BH, et al. **Mutat Res** 1999 Aug; 406(2-4):55–62

Characterization by pulse-field electrophoresis of a new region of DNA amplification containing the M2 subunit of ribonucleotide reductase in hydroxyurea-resistant Leishmania. Lye LF, et al. **Parasitol Res** 1999 Mar; 85(3):188–93

Hydroxyurea to inhibit human immunodeficiency virus-1 replication. Romanelli F, et al. **Pharmacotherapy** 1999 Feb; 19(2):196–204 (39 ref.)

Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea in mice. Platzek T, et al. **Teratog Carcinog Mutagen** 1999;19(3):223–32

THERAPEUTIC USE

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine [editorial] De Boer RJ, et al. **AIDS** 1998 Sep 10;12(13):1567–70 (49 ref.)

Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). Lori F, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):619–24

Successful hydroxyurea treatment of a patient with SD hemoglobinopathy [letter] Udden MM, et al. **Am J Hematol** 1999 Jan;60(1):84–5

Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Ballas SK, et al. **Br J Haematol** 1999 May;105(2):491–6

Hydroxyurea treatment in thalassaemia [letter] Konstantopoulos K, et al. **Br J Haematol** 1998 Nov; 103(2):587

Use of hydroxyurea in psoriasis. Smith CH. **Clin Exp Dermatol** 1999 Jan;24(1):2–6 (33 ref.)

Long-term hydroxyurea treatment in young sickle cell patients. Maier-Redelsperger M, et al. **Curr Opin Hematol** 1999 Mar;6(2):115–20 (50 ref.)

Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection [letter] Grunke M, et al. **J Acquir Immune Defic Syndr** 1999 Aug 15;21(5):424–6

Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine [letter] Luzzati R, et al. **J Antimicrob Chemother** 1998 Oct;42(4):565–6

Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea. Schultz JC. **J Clin Lab Anal** 1999;13(2):82–9

Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. Yerly S, et al. **J Infect Dis** 1999 Sep;180(3):850–3

Amsterdam Duration of Antiretroviral Medication (ADAM) study [letter; comment] Torres RA, et al. **Lancet** 1998 Oct 3;352(9134):1149. Comment on: Lancet 1998 Jul 18;352(9123):185–90.

Treatment of high-risk cervical cancer [letter] Piver MS. **N Engl J Med** 1999 Aug 26;341(9):696–7

Sickle cell patients find a brand New World. Noonan SS. **N J Med** 1999 Aug;96(8):23–5

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A, et al. **Pediatr Hematol Oncol** 1999 May-Jun;16(3):221–32

[Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin] de Montalembert M. **Pathol Biol (Paris)** 1999 Jan;47(1):55–8 (17 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Early development of mushroom bodies in the brain of the honeybee Apis mellifera as revealed by BrdU incorporation and ablation experiments. Malun D. **Learn Mem** 1998 May-Jun;5(1-2):90–101

Involvement of germ cell apoptosis in the induction of testicular toxicity following hydroxyurea treatment. Shin JH, et al. **Toxicol Appl Pharmacol** 1999 Mar 1;155(2):139–49

25-HYDROXYVITAMIN D 2

BLOOD

Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay. Outila TA, et al. **Am J Clin Nutr** 1999 Jan; 69(1):95–8

Ineffective vitamin D synthesis in cats is reversed by an inhibitor of 7-dehydrocholestrol-delta7-reductase. Morris JG. **J Nutr** 1999 Apr;129(4):903–8

Plasma 25-hydroxyvitamin D in growing kittens is related to dietary intake of cholecalciferol. Morris JG, et al. **J Nutr** 1999 Apr;129(4):909–12

DEFICIENCY

High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Bettica P, et al. **Osteoporos Int** 1999;9(3):226–9

25-HYDROXYVITAMIN D 3 see **CALCIFEDIOL**

25-HYDROXYVITAMIN D(3) 1 ALPHA-HYDROXYLASE see **25-HYDROXYCHOLECALCIFEROL 1-HYDROXYLASE**

HYDROXYVITAMINS D see **HYDROXYCHOLECALCIFEROLS**

HYDROXYZINE

Is chloral hydrate/hydroxyzine a good option for paediatric dental outpatient sedation? Avalos-Arenas V, et al. **Curr Med Res Opin** 1998;14(4):219–26

ADMINISTRATION & DOSAGE

The effect of metoclopramide and hydroxyzine in sedation of infants undergoing dental treatment. Ram D, et al. **ASDC J Dent Child** 1999 Jan-Feb;66(1):49–52, 13

ADVERSE EFFECTS

[Benzodiazepine withdrawal presenting as pseudo-surgical abdominal pain] Loeb P, et al. **Ann Fr Anesth Reanim** 1997; 16(5):521–2 (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Hydroxyzine inhibits neurogenic bladder mast cell activation. Minogiannis P, et al. **Int J Immunopharmacol** 1998 Oct; 20(10):553–63

THERAPEUTIC USE

Recent clinical trials of hydroxyzine in generalized anxiety disorder. Ferreri M, et al. **Acta Psychiatr Scand Suppl** 1998; 393:102–8 (52 ref.)

The effects of nitrous oxide on pediatric dental patients sedated with chloral hydrate and hydroxyzine. Wilson S, et al. **Pediatr Dent** 1998 Jul-Aug;20(4):253–8

A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Lader M, et al. **Psychopharmacology (Berl)** 1998 Oct;139(4):402–6

[Therapy of cardio-neurotic diseases in general practice: clinical experience with atarax] Smulevich AB, et al. **Klin Med (Mosk)** 1999;77(1):43–6 (Eng. Abstr.) **(Rus)**

HYDROZOA see **HYDRA**

HYENAS see **CARNIVORA**

HYGIENE

Hygienic mycology in Hungary. Novák EK, et al. **Acta Microbiol Immunol Hung** 1999;46(2-3):219–24

The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Wold AE. **Allergy** 1998;53(46 Suppl):20–5 (73 ref.)

Relationship of blood lead levels to personal hygiene habits in lead battery workers: Taiwan, 1991-1997. Chuang HY, et al. **Am J Ind Med** 1999 Jun;35(6):595–603

48th Annual meeting of the American Society of Tropical Medicine and Hygiene. Washington DC, USA. November 28-December 2, 1999. Abstracts. **Am J Trop Med Hyg** 1999 Sep;61(3 Suppl):149–530

Poor anaesthetist hygienic practices – a problem across all grades of anaesthetist [letter] McNamara JT, et al. **Anaesthesia** 1999 Jul;54(7):718–9

Hygienic practices of consultant anaesthetists: a survey in the north-west region of the UK [see comments] el Mikatti N, et al. **Anaesthesia** 1999 Jan;54(1):13–8. Comment in: Anaesthesia 1999 Jul;54(7):718–9.

The need for a home hygiene policy and guidelines on home hygiene. Beumer R, et al. **Ann Ig** 1999 Jan-Feb;11(1):11–26

The street food culture of Guatemala City: a case study from a downtown, urban park. Freese E, et al. **Arch Latinoam Nutr** 1998 Jun;48(2):95–103

Hygiene aspects of drinking water ultrafiltration. Sefcová H. **Cent Eur J Public Health** 1998 Nov;6(4):314–6

Effectiveness of a training program in reducing infections in toddlers attending day care centers [see comments] Carabin H, et al. **Epidemiology** 1999 May;10(3):219–27. Comment in: Epidemiology 1999 May;10(3):209–10.

Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study [see comments] Duggan AE, et al. **Gut** 1998 Oct;43(4):494–8. Comment in: Gut 1998 Oct;43(4):451.

Appendicectomy and childhood hygiene: different sides of the same coin? [comment] Ekbom A. **Gut** 1998 Oct;

43(4):451. Comment on: Gut 1998 Oct;43(4):494–8.
Hygiene behaviour in rural Nicaragua in relation to diarrhoea. Gorter AC, et al. **Int J Epidemiol** 1998 Dec; 27(6):1090–100
Towards integrated hygiene and food safety management systems: the Hygieneomic approach. Armstrong GD. **Int J Food Microbiol** 1999 Sep 15;50(1–2):19–24 (0 ref.)
Circumcision and hygiene in geriatric patients [letter] Frank R. **J Am Geriatr Soc** 1999 Sep;47(9):1155
Atopy, hygiene, and anthroposophic lifestyle. San Marino Study Group [letter] Matricardi PM, et al. **Lancet** 1999 Jul 31;354(9176):430
Increase in Campylobacter gastroenteritis coinciding with Melbourne gas restrictions [letter] Hemphill CM, et al. **Med J Aust** 1999 Mar 1;170(5):236
Characteristics of women who use perineal powders. Rosenblatt KA, et al. **Obstet Gynecol** 1998 Nov;92(5):753–6
Ethnicity, Sleep Hygiene Knowledge, and Sleep Hygiene Practices. Hicks RA, et al. **Percept Mot Skills** 1999 Jun; 88(3 Pt 2):1095–6
An informal look at use of bakery department tongs and tissues. Trinkaus J. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):801–2
Hygienic practices and acute respiratory illness in family and group day care homes. St Sauver J, et al. **Public Health** 1998 Nov–Dec;113(6):544–51
Hygienic practices and acute respiratory illness in family and group day care homes. St. Sauver J, et al. **Public Health Rep** 1998 Nov–Dec;113(6):544–51
The hygiene hypothesis in the development of atopy and asthma—still a matter of controversy? Hertzen LC. **QJM** 1998 Nov;91(11):767–71 (45 ref.)
Bacterial vaginosis, ethnicity, and the use of genital cleaning agents: a case control study. Rajamanoharan S, et al. **Sex Transm Dis** 1999 Aug;26(7):404–9
[Hand-hygiene and sickness among small children attending day care centers. An intervention study] Ladegaard MB, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4396–400 (Eng. Abstr.) **(Dan)**
[Hygienic preventive measure in nurseries] Régnier F, et al. **Arch Pediatr** 1999;6 Suppl 3:636s–638s **(Fre)**
[Information and education interventions on hygiene levels of a population in which trachoma exists in a hyperendemic and serious form] Chraibi-Hasseini K, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1997;74:45–55 (Eng. Abstr.) **(Fre)**
[The presence of the mother during induction of anesthesia—from the standpoint of hygiene] Geiss HK. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Sep; 33(9):598–9 **(Ger)**
[Hygiene in ENT. What is necessary, what is possible?] Geiss HK, et al. **HNO** 1998 Jul;46(7):695–8 **(Ger)**
[Focal aspects of prevention of infection and hygienic quality management in otorhinolaryngology with special reference to surgical interventions] Kramer A. **Laryngorhinootologie** 1999 May;78(5):263–8 (Eng. Abstr.) **(Ger)**
[How important are attitudes towards washroom hygiene and spitting in schools? A telephone survey of school attendants in the Baselstadt canton, April 1998] Stürchler MS, et al. **Schweiz Rundsch Med Prax** 1999 Apr 22;88(17):747–54 (Eng. Abstr.) **(Ger)**
[The end of handwashing: to the next millennium with hygienic disinfection of hands] Widmer AF. **Schweiz Rundsch Med Prax** 1999 Apr 22;88(17):761–3 (6 ref.) **(Ger)**
[Hospital hygiene—an essential aspect of quality assurance. Results of a survey in the hospitals of the German state of Saxony] Görisch G, et al. **Z Arztl Fortbild Qualitatssich** 1999 Jun;93(4):293–301 (Eng. Abstr.) **(Ger)**
[The Annali di Igiene has obtained accreditation from the Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (news)] **Ann Ig** 1999 Jan–Feb;11(1):1 **(Ita)**
[The 69th annual meeting of the Japanese Society for Hygiene. Chiba, Japan. March 24–27, 1999. Abstracts] **Nippon Eiseigaku Zasshi** 1999 Apr;54(1):1–445 **(Jpn)**
[Construction and its characteristic on the concept of a 'health culture'] Takizawa T. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):398–406 (42 ref.) (Eng. Abstr.) **(Jpn)**
[Hygiene and problems of the exploitation of mineral resources] Korabel'nikov IV. **Gig Sanit** 1998 Sep–Oct; (5):78–80 **(Rus)**
[Role of socio-hygienic science in reforming national public health] Shchepin OP, et al. **Vestn Ross Akad Med Nauk** 1999;(7):54–9 (7 ref.) **(Rus)**
[Hygienic-sanitary conditions in school lunch rooms in the municipality of Oviedo] Arias Diaz C, et al. **Rev Esp Salud Publica** 1998 Nov–Dec;72(6):571–81 (Eng. Abstr.) **(Spa)**

EDUCATION

Help with HACCP. Worsfold D. **J R Soc Health** 1998 Oct; 118(5):295–9
[Teaching hygiene and public health with student facilitators an attempt to enhance student participation] Yano E, et al. **Nippon Koshu Eisei Zasshi** 1999 Aug;46(8):644–9 (Eng. Abstr.) **(Jpn)**
[The use of a rating system to control student knowledge in the teaching of hygiene] Kuchma VR, et al. **Gig Sanit** 1999 Jan–Feb;(1):76–9 **(Rus)**
[Hygienic and ecological training of pediatricians] Kuchma VR. **Gig Sanit** 1999 Jul–Aug;(4):30–3 (Eng. Abstr.) **(Rus)**
[The hygiene education and training of the population: the problems and the means for implementation] Stroev EA, et al. **Gig Sanit** 1999 Jan–Feb;(1):65–6 **(Rus)**

HISTORY

[Public hygiene, microbiology and water management] Lesne J. **Bull Soc Pathol Exot** 1998;91(5 Pt 1–2):438–44 (Eng. Abstr.) **(Fre)**
[Dr. Johann Peter Frank (1745–1821) and the Johann Peter Frank Society of Rodalben] Matheis H, et al. **Gesundheitswesen** 1999 Mar;61(3):151–4 **(Ger)**
[The Chemnitz Pathologic-Hygienic Institute and its leader from 1898 to 1998] Künzel W. **Pathologe** 1999 May; 20(3):200–3 (Eng. Abstr.) **(Ger)**
[Hygiene and public health in Italy. From an imposed solution to informed consent] Cosmacini G. **Ann Ig** 1998 Sep–Dec;10(5–6):293–6 (Eng. Abstr.) **(Ita)**
[German science and the Italian university: perception of foreign models in the institutionalization of Hygiene disciplines in Italy (1885–1900)] D'Orazio U. **Medizinhist J** 1998;33(3–4):293–321 **(Ita)**
[Educated assistants, genius laboratory assistants and quiet volunteers — first women employed at the National Institute of Hygiene in 1919–1925] Gromulska M. **Rocz Panstw Zakl Hig** 1998;49(4):401–8 **(Pol)**
[80-th anniversary of the National Institute of Hygiene (editorial)] Jellaszewicz J. **Rocz Panstw Zakl Hig** 1998; 49(4):393–400 **(Pol)**
[Noteworthy and anniversary dates of the history of hygiene and sanitation in 1998] Mirskii MB. **Gig Sanit** 1998 Sep–Oct; (5):71–3 **(Rus)**
[Significant and anniversary dates of the history of hygiene and sanitation in 1999] Mirskii MB. **Gig Sanit** 1999 Jul–Aug; (4):74–6 **(Rus)**
[History of the development of public hygiene in Russia] Nushtaev IA. **Gig Sanit** 1999 Jul–Aug;(4):76–8 **(Rus)**
[Medical care and environmental hygiene in Mexico City from the 16th through the 18th centuries (letter)] Rodríguez ME, et al. **Gac Med Mex** 1999 Jul–Aug;135(4):455 **(Spa)**
[Medical care and environmental hygiene in Mexico City from the 16th through the 18th century (see comments)] Rodríguez ME, et al. **Gac Med Mex** 1999 Mar–Apr; 135(2):189–98 (Eng. Abstr.). Comment in: Gac Med Mex 1999 May–Jun;135(3):361. **(Spa)**

LEGISLATION & JURISPRUDENCE

Catalonia regulates body artists' work [news] Bosch X. **Lancet** 1998 Oct 31;352(9138):1454
[Requirements of mandatory accident insurance for hospitals, which participate in inpatient treatment of occupational accident patients: position of the National Reference Center for Hospital Hygiene] Hauer T, et al. **Chirurg** 1998 Sep; 69(9):924–7; discussion 928–9 (Eng. Abstr.) **(Ger)**
[Alteration of rendering and meat hygiene legislation in the course of the BSE/TSE crisis. Validity of decisive legal provisions (1)] Fertig H. **DTW Dtsch Tierarztl Wochenschr** 1998 Dec;105(12):475–81 (Eng. Abstr.) **(Ger)**

STANDARDS

Knowledge and practices of preventing diarrhoea in malnourished children. McLennan JD. **J Diarrhoeal Dis Res** 1998 Dec;16(4):235–40
Environmental and personal hygiene practices: risk factors for diarrhoea among children of Nigerian market women. Oyemade A, et al. **J Diarrhoeal Dis Res** 1998 Dec; 16(4):241–7
Occupational hygiene science and its application in occupational health policy, at home and abroad. Vincent JH. **Occup Med (Lond)** 1999 Jan;49(1):27–35 (22 ref.)
Proposals to strengthen enforcement of meat hygiene rules [news] **Vet Rec** 1998 Dec 12;143(24):647–8
[Disinfection and sterilization of reusable devices] Darbord JC. **Rev Prat** 1998 Sep 15;48(14):1552–7 (Eng. Abstr.) **(Fre)**
[Condensation water drainage of cooling systems in cold storage rooms—a problem of hygiene] Lubbe R. **Gesundheitswesen** 1999 Jul;61(7):360–4 (Eng. Abstr.) **(Ger)**
[Ethic aspects of conducting physiological-hygienic and psychological studies on human subjects as applied to the activities in extreme environments] Genin AM, et al. **Aviakosm Ekolog Med** 1998;32(6):50–5 (4 ref.) (Eng. Abstr.) **(Rus)**
[The use of the new ergonomic index Ergocapacity in the hygienic evaluation and certification of manual instruments] Butkovskaia ZM, et al. **Med Tr Prom Ekol** 1998;(11):12–5 (Eng. Abstr.) **(Rus)**

HYGROMA see **LYMPHANGIOMA, CYSTIC**

HYGROMA, CYSTIC see **LYMPHANGIOMA, CYSTIC**

HYGROMYCIN B

PHARMACOLOGY

Transformation of the phytopathogen Mycosphaerella graminicola to carbendazim and hygromycin B resistance. Payne AC, et al. **Curr Genet** 1998 Aug;34(2):100–4
Genetic transformation of germinated conidia of the thermophilic fungus Humicola grisea var. thermoidea to hygromycin B resistance. Dantas-Barbosa C, et al. **FEMS Microbiol Lett** 1998 Dec 1;169(1):185–90

HYLOBATES

ANATOMY & HISTOLOGY

Observations on stria morphology in the lateral enamel of Pongo, Hylobates and Proconsul teeth. Dean MC, et al. **J Hum Evol** 1998 Oct–Nov;35(4–5):401–10

GENETICS

Cross-species colour segmenting: a novel tool in human karyotype analysis. Müller S, et al. **Cytometry** 1998 Dec 1;33(4):445–52
Evolution of the gibbon subgenera inferred from cytochrome b DNA sequence data. Hall LM, et al. **Mol Phylogenet Evol** 1998 Dec;10(3):281–6

GROWTH & DEVELOPMENT

Development of the female great call in Hylobates gabriellae: A case study. Merker B, et al. **Folia Primatol (Basel)** 1999 Mar–Apr;70(2):97–106
Histological reconstruction of dental development and age at death in a juvenile gibbon (Hylobates lar). Dirks W. **J Hum Evol** 1998 Oct–Nov;35(4–5):411–25

PSYCHOLOGY

Sleeping sites, sleeping places, and presleep behavior of gibbons (Hylobates lar). Reichard U. **Am J Primatol** 1998; 46(1):35–62
Observations on food sharing in wild lar gibbons (Hylobates lar). Nettelbeck AR. **Folia Primatol (Basel)** 1998; 69(6):386–91
Encounters between lar gibbons (Hylobates lar) and binturongs (Arctictis binturong). Nettelbeck AR. **Folia Primatol (Basel)** 1998;69(6):392–6

HYLOBATIDAE

GENETICS

MIC genes in non-human primates. Pellet P, et al. **Eur J Immunogenet** 1999 Apr–Jun;26(2–3):239–41

HYMECROMONE

ANALOGS & DERIVATIVES

Structural studies on the binding of 4-methylumbelliferone glycosides of chitin to rainbow trout lysozyme. Vollan VB, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):60–6
Fluorogenic substrates based on fluorinated umbelliferones for continuous assays of phosphatases and beta-galactosidases. Gee KR, et al. **Anal Biochem** 1999 Aug 15;273(1):41–8
Use of Mfu-galactoside enzymatic activity as ecotoxicological endpoint on rainbow trout red blood cells. Pablos MV, et al. **Bull Environ Contam Toxicol** 1998 Dec; 61(6):786–92
False-positive fluorescence by pink salmon tissue and staphylococci in a rapid test for Escherichia coli. Himelbloom BH, et al. **J Food Prot** 1998 Sep;61(9):1119–23

HYMEN

ABNORMALITIES

A girl with constipation and acute urinary retention. Kitapçi F, et al. **Eur J Pediatr** 1999 Apr;158(4):337–8
Imperforate hymen with hydrocolpos. Krishna A, et al. **Indian Pediatr** 1998 Oct;35(10):1028
An unusual case of urinary retention due to imperforate hymen. Hall DJ. **J Accid Emerg Med** 1999 May;16(3):232–3
Imperforate hymen and ruptured hematosalpinx: a case report with a review of the literature. Bakos O, et al. **J Adolesc Health** 1999 Mar;24(3):226–8 (25 ref.)
Fetal ascites associated with an imperforate hymen: sonographic observation. Jacquemyn Y, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):67–9
[Imperforate hymen. A simple, but overlooked diagnosis] Johansen JK, et al. **Ugeskr Laeger** 1998 Oct 5; 160(41):5948–9 (Eng. Abstr.) **(Dan)**

ANATOMY & HISTOLOGY

Appearance of the hymen in adolescents is not well documented [letter; comment] Curtis E, et al. **BMJ** 1999 Feb 27;318(7183):605. Comment on: BMJ 1998 Aug 8;317(7155):414.
Circumferential hymen elasticity. A marker of physiologic maturity. Pokorny SF, et al. **J Reprod Med** 1998 Nov; 43(11):943–8

INJURIES

Genital findings in prepubertal girls evaluated for sexual

HYMEN

abuse. A different perspective on hymenal measurements. Pugno PA. **Arch Fam Med** 1999 Sep-Oct;8(5):403-6

Accidental hymenal injury mimicking sexual trauma. Boos SC. **Pediatrics** 1999 Jun;103(6 Pt 1):1287-90

PATHOLOGY

What is an 'intact' hymen? A critique of the literature. Goodyear-Smith FA, et al. **Med Sci Law** 1998 Oct; 38(4):289-300 (60 ref.)

HYMENOLEPIASIS

DIAGNOSIS

[Hymenolepis nana. 45-year-old refugee from the Kosovo region with epigastric pain and detection of Hymenolepis nana and Blastocystis hominis in the stool] Camli C, et al. **Schweiz Rundsch Med Prax** 1999 May 6;88(19):877-9 **(Ger)**

DRUG THERAPY

Hymenolepis diminuta: praziquantel removal of adult tapeworms is followed by apoptotic down-regulation of mucosal mastocytosis. Starke WA, et al. **Exp Parasitol** 1999 Jul;92(3):171-81

[The technology for manufacturing antiparasitic preparations. 9. The new preparation tizanox and an evaluation of its anti-Hymenolepis activity] Mikhailitsyn FS, et al. **Med Parazitol (Mosk)** 1999 Jan-Mar;(1):49-51 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Epidemiological study on Hymenolepis nana infection in Ciego de Avila Province, Cuba] Suárez Hernández M, et al. **Bol Chil Parasitol** 1998 Jan-Jun;53(1-2):31-4 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Suppressive activity of the chloroform extract of Tripterygium wilfordii Hook f on effector T cell activation during Hymenolepis nana infection in mice. Asano K, et al. **Am J Chin Med** 1998;26(2):181-9

Mucosal mast cell responses and release of mast cell protease-I in infections of mice with Hymenolepis diminuta and H. microstoma: modulation by cyclosporin A. McLauchlan PE, et al. **Parasite Immunol** 1999 Mar; 21(3):151-61

METABOLISM

The spatial and temporal concentrations of choline in the lumen contents of the small intestine of uninfected and Hymenolepis diminuta infected rats. Webb RA, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):705-11

PARASITOLOGY

Hymenolepis diminuta infestation in a child. Verghese SL, et al. **J Commun Dis** 1998 Sep;30(3):201-3

VETERINARY

Immunology and biochemistry of Hymenolepis diminuta. Andreassen J, et al. **Adv Parasitol** 1999;42:223-75 (250 ref.)

HYMENOLEPIS

ENZYMOLOGY

Hymenolepis diminuta: catalysis of transmembrane proton translocation by mitochondrial NADPH-->NAD transhydrogenase. Mercer NA, et al. **Exp Parasitol** 1999 Jan;91(1):52-8

Metabolic transition in the development of Hymenolepis diminuta (Cestoda). Fioravanti CF, et al. **Parasitol Res** 1998 Oct;84(10):777-82

GROWTH & DEVELOPMENT

Metabolic transition in the development of Hymenolepis diminuta (Cestoda). Fioravanti CF, et al. **Parasitol Res** 1998 Oct;84(10):777-82

IMMUNOLOGY

Immunology and biochemistry of Hymenolepis diminuta. Andreassen J, et al. **Adv Parasitol** 1999;42:223-75 (250 ref.)

Suppressive activity of the chloroform extract of Tripterygium wilfordii Hook f on effector T cell activation during Hymenolepis nana infection in mice. Asano K, et al. **Am J Chin Med** 1998;26(2):181-9

Eosinophil chemotactic factors from cysticercoids of Hymenolepis nana. Niwa A, et al. **J Helminthol** 1998 Sep; 72(3):273-5

Mucosal mast cell responses and release of mast cell protease-I in infections of mice with Hymenolepis diminuta and H. microstoma: modulation by cyclosporin A. McLauchlan PE, et al. **Parasite Immunol** 1999 Mar; 21(3):151-61

[Endo- and ectoparasites as factors influencing variability of the humoral immunity response in a natural population of red vole (Clethrionomys rutilus)] Dobrotvorskiĭ AK, et al. **Parazitologiia** 1998 Jul-Aug;32(4):289-99 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

The spatial and temporal concentrations of choline in the lumen contents of the small intestine of uninfected and Hymenolepis diminuta infected rats. Webb RA, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):705-11

Hymenolepis diminuta infestation in a child. Verghese SL, et al. **J Commun Dis** 1998 Sep;30(3):201-3

[Epidemiological study on Hymenolepis nana infection in Ciego de Avila Province, Cuba] Suárez Hernández M, et al. **Bol Chil Parasitol** 1998 Jan-Jun;53(1-2):31-4 (Eng. Abstr.) **(Spa)**

METABOLISM

Immunology and biochemistry of Hymenolepis diminuta. Andreassen J, et al. **Adv Parasitol** 1999;42:223-75 (250 ref.)

Hymenolepis diminuta: glucose and glycogen gradients in the adult tapeworm. Pappas PW, et al. **Exp Parasitol** 1999 Apr;91(4):315-26

PHYSIOLOGY

Evidence that the factor used by the tapeworm, Hymenolepis diminuta, to direct the foraging of its intermediate host, Tribolium confusum, is a volatile attractant. Evans WS, et al. **J Parasitol** 1998 Dec;84(6):1098-101

Beetle-to-beetle transmission and dispersal of Hymenolepis diminuta (Cestoda) eggs via the feces of Tenebrio molitor. Pappas PW, et al. **J Parasitol** 1999 Apr;85(2):384-5

HYMENOPTERA

[The results of research on the prevalence of allergy to Hymenoptera venom in Southwestern Poland] Nittner-Marszalska M, et al. **Pol Arch Med Wewn** 1998 Sep;100(3):245-51 (Eng. Abstr.) **(Pol)**

[Toxic reaction induced by Hymenoptera stings] Nittner-Marszalska M, et al. **Pol Arch Med Wewn** 1998 Sep;100(3):252-6 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Isolation of p-hydroxycinnamaldehyde as an antibacterial substance from the saw fly, Acantholyda parki S. Leem JY, et al. **FEBS Lett** 1999 Jan 8;442(1):53-6

CLASSIFICATION

The chromosomes of Diprion pini and D. similis (Hymenoptera: Diprionidae): implications for karyotype evolution. Rousselet J, et al. **Heredity** 1998 Nov;81 (Pt 5):573-8

GENETICS

The chromosomes of Diprion pini and D. similis (Hymenoptera: Diprionidae): implications for karyotype evolution. Rousselet J, et al. **Heredity** 1998 Nov;81 (Pt 5):573-8

Cross-order transfer of Wolbachia from Muscidifurax uniraptor (Hymenoptera: Pteromalidae) to Drosophila simulans (Diptera: Drosophilidae). Van Meer MM, et al. **Heredity** 1999 Feb;82 (Pt 2):163-9

Satellite DNA transcription in Diadromus pulchellus (Hymenoptera). Renault S, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):103-11

Evolutionary dynamics of a mitochondrial rearrangement "hot spot" in the Hymenoptera. Dowton M, et al. **Mol Biol Evol** 1999 Feb;16(2):298-309

Hierarchical analysis of variation in the mitochondrial 16S rRNA gene among Hymenoptera. Whitfield JB, et al. **Mol Biol Evol** 1998 Dec;15(12):1728-43

Relationships among the cyclostome braconid (Hymenoptera: Braconidae) subfamilies inferred from a mitochondrial tRNA gene rearrangement. Dowton M. **Mol Phylogenet Evol** 1999 Mar;11(2):283-7

Phylogenetic relationships among the microgastroid wasps (Hymenoptera: braconidae): combined analysis of 16S and 28S rDNA genes and morphological data. Dowton M, et al. **Mol Phylogenet Evol** 1998 Dec;10(3):354-66

Molecular phylogeny of the Ceratosolen species pollinating Ficus of the subgenus Sycomorus sensu stricto: biogeographical history and origins of the species-specificity breakdown cases. Kerdelhue C, et al. **Mol Phylogenet Evol** 1999 Apr;11(3):401-14

A phylogeny of aphid parasitoids (Hymenoptera: Braconidae: Aphidiinae) inferred from mitochondrial NADH 1 dehydrogenase gene sequence. Smith PT, et al. **Mol Phylogenet Evol** 1999 Mar;11(2):236-45

IMMUNOLOGY

An antibody diagnostic for hymenopteran parasitism is specific for a homologue of elongation factor-1 alpha. Stuart MK. **Arch Insect Biochem Physiol** 1998;39(1):1-8

[Allergy to hymenoptera venoms in children] Rancé F, et al. **Arch Pediatr** 1999;6 Suppl 1:55S-60S (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Mimicry profiles are affected by human-induced habitat changes. Azmeh S, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 7;265(1412):2285-90

Vectors, routes and maps: new discoveries about navigation in insects. Giurfa M, et al. **Trends Neurosci** 1999 Jun; 22(6):237-42 (44 ref.)

ULTRASTRUCTURE

Organization and possible functions of microtubule cytoskeleton in hymenopteran nurse cells. Biliński SM, et al. **Cell Motil Cytoskeleton** 1999;43(3):213-20

VIROLOGY

Presence of polydnavirus transcripts in an egg-larval parasitoid and its lepidopterous host. Johner A, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1847-54

HYMENOSTOMATIDA

GENETICS

The gene for an abundant parasite coat protein predicts tandemly repetitive metal binding domains. Clark TG, et al. **Gene** 1999 Mar 18;229(1-2):91-100

HYOID BONE

ABNORMALITIES

Eagle's syndrome: a review. Rechtweg JS, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):316-21

Fusion of the thyrohyoid interval in a patient with a thyroglossal duct cyst. Urben SL, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):757-9

ANATOMY & HISTOLOGY

Changes in airway and hyoid position in response to mandibular protrusion in subjects with obstructive sleep apnoea (OSA). Battagel JM, et al. **Eur J Orthod** 1999 Aug; 21(4):363-76 (46 ref.)

Silver-tongued Neandertals? [letter; comment] Lieberman P. **Science** 1999 Jan 8;283(5399):175. Comment on: Science 1998 Nov 20;282(5393):1455-8. Comment on: Science 1998 Dec 11;282(5396):1991.

An anomalous digastric muscle with three accessory bellies and one fibrous band. Sarikcioglu L, et al. **Surg Radiol Anat** 1998;20(6):453-4

DRUG EFFECTS

Hyoid bone syndrome and its treatment with nonsteroidal anti-inflammatory drugs. Nir D, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):296-300

GROWTH & DEVELOPMENT

Age and sex-related variation in hyoid bone morphology. Miller KW, et al. **J Forensic Sci** 1998 Nov;43(6):1138-43

INJURIES

Traumatic fracture of the hyoid bone: three case presentations of cardiorespiratory compromise secondary to missed diagnosis. Kaufman HJ, et al. **Am Surg** 1999 Sep; 65(9):877-80 (10 ref.)

[Healed fractures of the larynx and lingual bone in forensic autopsy] Maxeiner H. **Arch Kriminol** 1999 May-Jun; 203(5-6):175-83 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Mesenchymal chondrosarcoma of the hyoid bone: a case report. Joo M, et al. **J Korean Med Sci** 1998 Dec; 13(6):696-700

Chondroma of the hyoid bone: a case report. Nakagawa Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):333-6

Is there a potential role for hyoid bone compression in pathogenesis of carotid artery stenosis? Abdelaziz OS, et al. **Surg Neurol** 1999 Jun;51(6):650-3

RADIOGRAPHY

Symptomatic presentation of an enlarged, ossified triticeal cartilage. Alsarraf R, et al. **Am J Otolaryngol** 1998 Sep-Oct; 19(5):339-41

[Stylohyoid syndrome in childhood] Riaño Galán I, et al. **An Esp Pediatr** 1999 May;50(5):507-8 **(Spa)**

SURGERY

Eagle's syndrome: a review. Rechtweg JS, et al. **Am J Otolaryngol** 1998 Sep-Oct;19(5):316-21

Transverse infrahyoid approach to bilateral glottic tumors. Reino AJ, et al. **Ann Otol Rhinol Laryngol** 1999 Jan; 108(1):24-30

Modified subtotal laryngectomy with cricohyoidoepiglottopexy--long term results in 81 patients. Crampette L, et al. **Head Neck** 1999 Mar;21(2):95-103

Tongue base reduction with hyoepiglottoplasty: a treatment for severe obstructive sleep apnea. Chabolle F, et al. **Laryngoscope** 1999 Aug;109(8):1273-80

[Tongue base reduction with hyoid-epiglottoplasty. A surgical alternative in severe sleep apnea syndromes]

Chabolle F, et al. **Ann Otolaryngol Chir Cervicofac** 1998 Dec;115(6):322–31 (Eng. Abstr.) **(Fre)**
[The hyoid bone in reconstructive laryngeal and cervical surgery] Croce A, et al. **Ann Ital Chir** 1999 Mar–Apr; 70(2):239–45 (Eng. Abstr.) **(Ita)**

HYOSCINBUTYLBROMIDE see **BUTYLSCOPOLAMMONIUM BROMIDE**

HYOSCINE see **SCOPOLAMINE**

HYOSCYAMINE see **ATROPINE**

HYPERACTIVITY, MOTOR see **HYPERKINESIS**

HYPERALDOSTERONISM

Primary aldosteronism. Ganguly A. **N Engl J Med** 1998 Dec 17;339(25):1828–34 (64 ref.)
Hyper- and hypoaldosteronism. Torpy DJ, et al. **Vitam Horm** 1999;57:177–216 (122 ref.)
[Primary hyperaldosteronism. Update on a topic of physiopathology and clinical features] Lima T, et al. **Minerva Med** 1998 Nov–Dec;89(11–12):411–8 (37 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

[Generalized edema] Peghini PE, et al. **Schweiz Rundsch Med Prax** 1998 Dec 10;87(50):1766–8 **(Ger)**

COMPLICATIONS

A rare combination consisting of primary hyperaldosteronism and glucagonoma. Abe H, et al. **Am J Gastroenterol** 1999 May;94(5):1397–401 (31 ref.)
Cardiovascular complications in patients with primary aldosteronism. Nishimura M, et al. **Am J Kidney Dis** 1999 Feb;33(2):261–6
Coronary artery aneurysms, aortic dissection, and hypertension secondary to primary aldosteronism: a rare triad. A case report. Safi AM, et al. **Angiology** 1999 Jun; 50(6):503–8
Ventricular fibrillation: an extreme presentation of primary hyperaldosteronism. Abdo A, et al. **Can J Cardiol** 1999 Mar;15(3):347–8
Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism [letter] Hasegawa J, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):599–600
Latent tetany associated with the hypokalaemia of Conn's syndrome. Davies JS, et al. **Int J Clin Pract** 1998 Jul–Aug; 52(5):347–8
A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism. Shimada T, et al. **Intern Med** 1999 Aug; 38(8):655–9
Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: the Cross-sectional Primary Aldosteronism and Heart Italian Multicenter Study. Napoli C, et al. **J Investig Med** 1999 May;47(5):212–21
A case of aldosterone-producing adenoma with severe postoperative hyperkalemia. Taniguchi R, et al. **Tohoku J Exp Med** 1998 Nov;186(3):215–23
Bilateral adrenal cortical adenomas in primary hyperaldosteronism. Engel JD, et al. **Urology** 1998 Oct; 52(4):711–4
[Acute intermittent porphyria associated with hyperaldosteronism and inappropriate antidiuretic hormone secretion syndrome] Frère T, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep;22(8–9):727–31 (Eng. Abstr.) **(Fre)**
[Mixed corticomedullary tumor] Delèvaux I, et al. **Presse Med** 1998 Sep 5;27(25):1272–4 (Eng. Abstr.) **(Fre)**
[Rhabdomyolysis secondary to Conn's syndrome (letter)] Abellán Martínez J, et al. **Rev Clin Esp** 1998 Aug; 198(8):557–8 **(Spa)**
[Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements] Fardella CE, et al. **Rev Med Chil** 1999 May;127(5):604–10 (41 ref.) (Eng. Abstr.) **(Spa)**
[Mineralocorticoid hypertension. A new form of secondary hypertension? (editorial)] Román O. **Rev Med Chil** 1999 May;127(5):511–3 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Primary aldosteronism: A common and curable form of hypertension. Young WF Jr. **Cardiol Rev** 1999 Jul–Aug; 7(4):207–14 (40 ref.)
Conn's syndrome: no longer a needle in a haystack?[comment] Fraser R, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):709–10. Comment on: Clin Endocrinol (Oxf) 1998 Dec;49(6):713–23.
Screening for primary aldosteronism with a logistic multivariate discriminant analysis [see comments] Rossi GP, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):713–23. Comment in: Clin Endocrinol (Oxf) 1998 Dec;49(6):709–10.
Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. MacConnachie AA, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4328–31
Primary aldosteronism in general practice [letter; comment] Chan NN, et al. **Lancet** 1999 Mar 20;353(9157):1013; discussion 1014. Comment on: Lancet 1999 Jan 2;353(9146):40.
Primary aldosteronism in general practice [letter] Wilson P. **Lancet** 1999 Mar 20;353(9157):1013–4
Approach to a patient with suspected primary aldosteronism. Loh KC. **Singapore Med J** 1999 May;40(5):371–4
An easy diagnostic approach to primary aldosteronism. Zavagli G, et al. **Steroids** 1999 Apr;64(4):296–300
Diagnosis and treatment of primary aldosteronism. Blumenfeld JD, et al. **World J Urol** 1999 Feb;17(1):15–21 (29 ref.)
[Diagnosis and management of Conn's syndrome] Vallotton MB. **Rev Med Suisse Romande** 1999 Jun;119(6):445–8 **(Fre)**
[Idiopathic primary hyperaldosteronism: significance of functional diagnosis] Bianda T, et al. **Schweiz Med Wochenschr** 1998 Aug 29;128(35):1277–83 (11 ref.) (Eng. Abstr.) **(Ger)**
[Arterial hypertension with concomitant hypokalemia] Nordmann A. **Schweiz Rundsch Med Prax** 1998 Nov 4; 87(45):1517–8 **(Ger)**
[Progress in diagnosis of secondary hypertension] Saito I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):236–40 (5 ref.) **(Jpn)**
[Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients] Kreze A Jr, et al. **Vnitr Lek** 1999 Jan;45(1):17–21 (Eng. Abstr.) **(Slo)**
[The Conn syndrome. The clinical and surgical aspects of 18 cases of adrenal adenoma] Lorenzo Romero JG, et al. **Actas Urol Esp** 1999 Jan;23(1):14–21 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. MacConnachie AA, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4328–31
[Diagnosis and management of Conn's syndrome] Vallotton MB. **Rev Med Suisse Romande** 1999 Jun;119(6):445–8 **(Fre)**

EPIDEMIOLOGY

Potentially high prevalence of primary aldosteronism in a primary-care population [letter] [see comments] Lim PO, et al. **Lancet** 1999 Jan 2;353(9146):40. Comment in: Lancet 1999 Mar 20;353(9157):1013; discussion 1014.

ETIOLOGY

Primary aldosteronism with aldosterone-producing adrenal adenoma in a pregnant woman. Fujiyama S, et al. **Intern Med** 1999 Jan;38(1):36–9
Hormonal characteristics of primary aldosteronism due to unilateral adrenal hyperplasia. Otsuka F, et al. **J Endocrinol Invest** 1998 Sep;21(8):531–6
Primary aldosteronism due to aldosterone producing adenoma without hypertension. Suzuki Y, et al. **J Urol** 1999 Apr;161(4):1272
[Conn adenoma manifesting as reversible tetraparesis and rhabdomyolysis] Mourad JJ, et al. **Rev Med Interne** 1998 Mar;19(3):203–5 (Eng. Abstr.) **(Fre)**

GENETICS

Aldosterone synthase gene in patients suffering from hyperaldosteronism. Hampf M, et al. **Endocr Res** 1998 Aug–Nov;24(3–4):877–80
Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. Takeda Y, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1633–7
Mineralocorticoid hypertension. Stewart PM. **Lancet** 1999 Apr 17;353(9161):1341–7 (65 ref.)
Adrenal angiotensin II type 1 and type 2 receptors in Cushing's and Conn's syndromes. Kitamura Y, et al. **Mol Cell Endocrinol** 1998 Sep 25;144(1–2):37–45
[Single gene forms of hypertension. Glucocorticoid suppressible aldosteronism, Liddle syndrome et al.] Rettig R. **Fortschr Med** 1998 Aug 20;116(22–23):38 **(Ger)**

PATHOLOGY

[Hyperplastic changes and aldosterone content in the adrenal cortex in essential hypertension and primary aldosteronism] Sokolova RI, et al. **Arkh Patol** 1999 May–Jun;61(3):11–4 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Decreased blood pressure variability at rest in patients with primary aldosteronism. Munakata M, et al. **Am J Hypertens** 1998 Jul;11(7):828–38
Establishment of an adrenocortical carcinoma xenograft with normotensive hyperaldosteronism in vivo. Yamazaki H, et al. **APMIS** 1998 Nov;106(11):1056–60
Impaired baroreflex function and arterial compliance in primary aldosteronism. Veglio F, et al. **J Hum Hypertens** 1999 Jan;13(1):29–36
Left ventricular systolic function in primary aldosteronism and hypertension. Rossi GP, et al. **J Hypertens** 1998 Dec; 16(12 Pt 2):2075–7
Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy. Uzu T, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1745–8

RADIOGRAPHY

Soft-tissue images. Adrenocortical adenocarcinoma presenting as Conn's syndrome. Schmidt N. **Can J Surg** 1999 Apr;42(2):86–7

SURGERY

Anaesthesia for Conn's syndrome. Winship SM, et al. **Anaesthesia** 1999 Jun;54(6):569–74
Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Shen WT, et al. **Arch Surg** 1999 Jun;134(6):628–31; discussion 631–2
Conn syndrome: 14 year's experience from two European centres. Puccini M, et al. **Eur J Surg** 1998 Nov; 164(11):811–7
Laparoscopic adrenalectomy for primary aldosteronism: clinical experience in 12 patients. Sirén J, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):9–13
Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Proye CA, et al. **Surgery** 1998 Dec; 124(6):1128–33
Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. Rutherford JC, et al. **World J Surg** 1998 Dec;22(12):1243–5

THERAPY

Primary aldosteronism: A common and curable form of hypertension. Young WF Jr. **Cardiol Rev** 1999 Jul–Aug; 7(4):207–14 (40 ref.)
Diagnosis and treatment of primary aldosteronism. Blumenfeld JD, et al. **World J Urol** 1999 Feb;17(1):15–21 (29 ref.)

HYPERALGESIA

CHEMICALLY INDUCED

Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Sjøgren P, et al. **Acta Anaesthesiol Scand** 1998 Oct;42(9):1070–5
Controlling myoclonus after high-dosage morphine infusions. Ferris DJ. **Am J Health Syst Pharm** 1999 May 15; 56(10):1009–10
Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Osborne MG, et al. **Br J Pharmacol** 1999 Apr;126(8):1840–6
Differential effect of painful heterotopic stimulation on capsaicin-induced pain and allodynia. Witting N, et al. **Brain Res** 1998 Aug 10;801(1–2):206–10
Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Mollay C, et al. **Eur J Pharmacol** 1999 Jun 18;374(2):189–96
Midazolam-induced hyperalgesia in rats: modulation via GABA(A) receptors at supraspinal level. Tatsuo MA, et al. **Eur J Pharmacol** 1999 Apr 1;370(1):9–15
Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanalgesic mechanisms triggered by the stress of an intracerebroventricular injection. Suaudeau C, et al. **Fundam Clin Pharmacol** 1998; 12(4):420–5
Intraspinal and behavioral consequences of nerve growth factor-induced nociceptive sprouting and nerve growth factor-induced hyperalgesia compared in adult rats. Pertens E, et al. **J Comp Neurol** 1999 Jul 19;410(1):73–89
Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. Khasar SG, et al. **J Neurophysiol** 1999 Mar; 81(3):1104–12
Flare and hyperalgesia after intradermal capsaicin injection in human skin. Serra J, et al. **J Neurophysiol** 1998 Dec; 80(6):2801–10
Force of limb withdrawals elicited by graded noxious heat compared with other behavioral measures of carrageenan-induced hyperalgesia and allodynia. Tabo E, et al. **J Neurosci Methods** 1998 Jun 1;81(1–2):139–49
Effect of colchicine on nerve growth factor-induced leukocyte accumulation and thermal hyperalgesia in the rat. Schuligoi R. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Aug;358(2):264–9
Brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study. Baron R, et al. **Neurology** 1999 Aug 11;53(3):548–57
N-methyl D-aspartate induced mechanical allodynia is blocked by nitric oxide synthase and cyclooxygenase-2 inhibitors. Dolan S, et al. **Neuroreport** 1999 Feb 25; 10(3):449–52
COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Yamamoto T, et al. **Neuroreport** 1998 Dec 1;9(17):3869–73
Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75. Bergmann I, et al. **Neurosci Lett** 1998 Oct 16;255(2):87–90
Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Morris V, et al. **Neurosci Lett** 1998 Jul 10; 250(3):205–7
Intrathecal substance P-induced thermal hyperalgesia and

spinal release of prostaglandin E2 and amino acids. Hua XY, et al. **Neuroscience** 1999 Mar;89(2):525–34

Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Laulin JP, et al. **Neuroscience** 1999 Mar;89(3):631–6

Experimental human muscle pain and muscular hyperalgesia induced by combinations of serotonin and bradykinin. Babenko V, et al. **Pain** 1999 Jul;82(1):1–8

Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils. Bennett G, et al. **Pain** 1998 Sep;77(3):315–22

Development of mustard oil–induced hyperalgesia in rats. Jiang MC, et al. **Pain** 1998 Sep;77(3):305–13

Lipopolysaccharide-induced hyperalgesia of intracranial capsaicin sensitive afferents in conscious rats. Kemper RH, et al. **Pain** 1998 Dec;78(3):181–90

Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat. Khandwala H, et al. **Pain** 1998 Jul;77(1):87–95

The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Li J, et al. **Pain** 1999 May;81(1–2):25–33

Treatment with either high or low frequency TENS reduces the secondary hyperalgesia observed after injection of kaolin and carrageenan into the knee joint. Sluka KA, et al. **Pain** 1998 Jul;77(1):97–102

Involvement of excitatory amino acid receptors and nitric oxide in the rostral ventromedial medulla in modulating secondary hyperalgesia produced by mustard oil. Urban MO, et al. **Pain** 1999 May;81(1–2):45–55

Test type influences the expression of lithium chloride–induced hyperalgesia. McNally GP, et al. **Pharmacol Biochem Behav** 1998 Dec;61(4):385–94

Differential effects of intrathecally and intracerebroventricularly administered nitric oxide donors on noxious mechanical and thermal stimulation. Machelska H, et al. **Pol J Pharmacol** 1998 Nov–Dec;50(6):407–15

[Hyperalgesic malleolar ulcer: recovery on the withdrawal of hydroxyurea (letter)] Liebschutz S, et al. **Rev Med Interne** 1998 May;19(5):360–1 **(Fre)**

DIAGNOSIS

Visceral algesia in irritable bowel syndrome, fibromyalgia, and sphincter of oddi dysfunction, type III. Chun A, et al. **Dig Dis Sci** 1999 Mar;44(3):631–6

Nonsystemic vasculitic neuropathy presenting with truncal segmental sensory disturbance and hyperhidrosis [letter] Tsunemi T, et al. **Muscle Nerve** 1999 May;22(5):646–7

DRUG THERAPY

Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Koppert W, et al. **Anesth Analg** 1999 Jan;88(1):117–22

Adenosine reduces secondary hyperalgesia in two human models of cutaneous inflammatory pain. Sjölund KF, et al. **Anesth Analg** 1999 Mar;88(3):605–10

Low-dose lidocaine suppresses experimentally induced hyperalgesia in humans. Koppert W, et al. **Anesthesiology** 1998 Dec;89(6):1345–53

Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide–induced hyperalgesia in rats. Masue T, et al. **Anesthesiology** 1999 Jul;91(1):198–206

The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Mikkelsen S, et al. **Anesthesiology** 1999 Jun;90(6):1539–45

Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. Nozaki-Taguchi N, et al. **Anesthesiology** 1999 Jan; 90(1):225–34

AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans [see comments] Sang CN, et al. **Anesthesiology** 1998 Nov;89(5):1060–7. Comment in: Anesthesiology 1998 Nov;89(5):1049–51.

Differential effects of intrathecally administered morphine and its interaction with cholecystokinin-B antagonist on thermal hyperalgesia following two models of experimental mononeuropathy in the rat. Yamamoto T, et al. **Anesthesiology** 1999 May;90(5):1382–91

Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Osborne MG, et al. **Br J Pharmacol** 1999 Apr;126(8):1840–6

Effect of post-injury NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain. Hudspith MJ, et al. **Brain Res** 1999 Mar 20;822(1–2):220–7

Effect of pre-emptive NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain. Munglani R, et al. **Brain Res** 1999 Mar 20;822(1–2):210–9

Effect of subcutaneous administration of calcium channel blockers on nerve injury–induced hyperalgesia. White DM, et al. **Brain Res** 1998 Aug 10;801(1–2):50–8

Modulation of formalin-evoked hyperalgesia by intrathecal N-type Ca channel and protein kinase C inhibitor in the rat. Nakanishi O, et al. **Cell Mol Neurobiol** 1999 Apr; 19(2):191–7

Intrathecal galanin alleviates allodynia-like behaviour in rats after partial peripheral nerve injury. Hao JX, et al. **Eur J Neurosci** 1999 Feb;11(2):427–32

Effects of endothelin-1 on capsaicin-induced nociception in mice. Piovezan AP, et al. **Eur J Pharmacol** 1998 Jun 12; 351(1):15–22

Effects of yohimbine on naloxone-induced antinociception in a rat model of inflammatory hyperalgesia. Tsuruoka M, et al. **Eur J Pharmacol** 1998 May 8;348(2–3):161–5

Supraspinal hyperalgesia and spinal analgesia by [Phe1psi(CH2–NH)Gly2]nociceptin-(1–13)-NH2 in rat. Wang YQ, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):R1–3

Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. DeHaven-Hudkins DL, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):494–502

Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. Lu Y, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):214–9

Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. Quartaroli M, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):158–69

The novel analgesic compound OT-7100 (5-n-butyl-7-(3,4,5-trimethoxybenzoylamino) pyrazolo[1,5-a]pyrimid ine) attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Yasuda T, et al. **Jpn J Pharmacol** 1999 Jan;79(1):65–73

Antinociception produced by systemic, spinal and supraspinal administration of amiloride in mice. Ferreira J, et al. **Life Sci** 1999;65(10):1059–66

Effects of neurotropin on hyperalgesia and allodynia in mononeuropathic rats. Saleh MR, et al. **Life Sci** 1998; 63(21):1931–8

Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Boyce S, et al. **Neuropharmacology** 1999 May;38(5):611–23

Zinc alleviates thermal hyperalgesia due to partial nerve injury. Liu T, et al. **Neuroreport** 1999 May 14;10(7):1619–23

Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats. Nakagawa T, et al. **Neurosci Lett** 1999 Apr 9;265(1):64–6

Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea-pig. Campbell EA, et al. **Neuroscience** 1998 Dec; 87(3):527–32

The kainate receptor antagonist 2S,4R-4-methylglutamate attenuates mechanical allodynia and thermal hyperalgesia in a rat model of nerve injury. Sutton JL, et al. **Neuroscience** 1999;91(1):283–92

Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Bickel A, et al. **Pain** 1998 Jun; 76(3):317–25

The kappa opioid agonist GR89,696 blocks hyperalgesia and allodynia in rat models of peripheral neuritis and neuropathy. Eliav E, et al. **Pain** 1999 Feb;79(2–3):255–64

Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Field MJ, et al. **Pain** 1999 Mar; 80(1–2):383–9

Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Hao JX, et al. **Pain** 1998 Jun;76(3):385–93

Mechanical hyperalgesia after spinal nerve ligation in rat is not reversed by intraplantar or systemic administration of adrenergic antagonists. Ringkamp M, et al. **Pain** 1999 Feb; 79(2–3):135–41

The glutamate synapse: a target in the pharmacological management of hyperalgesic pain states. Urban MO, et al. **Prog Brain Res** 1998;116:407–20 (81 ref.)

ENZYMOLOGY

Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Ohsawa M, et al. **Eur J Pharmacol** 1999 May 21;372(3):221–8

Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Maes M, et al. **Psychol Med** 1998 Jul; 28(4):957–65

ETIOLOGY

Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Koppert W, et al. **Anesth Analg** 1999 Jan;88(1):117–22

Adenosine reduces secondary hyperalgesia in two human models of cutaneous inflammatory pain. Sjölund KF, et al. **Anesth Analg** 1999 Mar;88(3):605–10

Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. Sluka KA. **J Pharmacol Exp Ther** 1998 Oct; 287(1):232–7

Pain related behaviour during vincristine-induced neuropathy in rats. Authier N, et al. **Neuroreport** 1999 Apr 6;10(5):965–8

Zinc alleviates thermal hyperalgesia due to partial nerve injury. Liu T, et al. **Neuroreport** 1999 Feb 25;10(3):645–9

A new human experimental pain model: the heat/capsaicin sensitization model. Petersen KL, et al. **Neuroreport** 1999 May 14;10(7):1511–6

Transgenic mice over-expressing substance P exhibit allodynia and hyperalgesia which are reversed by substance P and N-methyl-D-aspartate receptor antagonists. McLeod AL, et al. **Neuroscience** 1999 Mar;89(3):891–9

Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Fox A, et al. **Pain** 1999 Jun;81(3):307–16

Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Khalil Z, et al. **Pain** 1999 Jan;79(1):31–7

Spinal nerve lesion–induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Ramer MS, et al. **Pain** 1998 Nov;78(2):115–21

Hyperalgesia due to nerve damage: role of nerve growth factor. Theodosiou M, et al. **Pain** 1999 Jun;81(3):245–55

Central hyperalgesic effects of noxious stimulation associated with the use of tourniquets [editorial; comment] Abram SE. **Reg Anesth Pain Med** 1999 Mar–Apr;24(2):99–101. Comment on: Reg Anesth Pain Med 1999 Mar–Apr;24(2):102–9.

GENETICS

Hyperalgesia in mice lacking the Kv1.1 potassium channel gene. Clark JD, et al. **Neurosci Lett** 1998 Jul 24; 251(2):121–4

IMMUNOLOGY

Involvement of capsaicin sensitive primary afferents in thymulin-induced hyperalgesia. Saadé NE, et al. **J Neuroimmunol** 1998 Nov 2;91(1–2):171–9

Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils. Bennett G, et al. **Pain** 1998 Sep;77(3):315–22

METABOLISM

Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Calo G, et al. **Br J Pharmacol** 1998 Sep;125(2):373–8

Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. Cunha FQ, et al. **Br J Pharmacol** 1999 Jun; 127(3):671–8

Nerve growth factor inducer, 4-methyl catechol, potentiates central sensitization associated with acceleration of spinal glutamate release after mustard oil paw injection in rats. Ishikawa T, et al. **Cell Mol Neurobiol** 1999 Oct;19(5):587–96

A neuronal nitric oxide synthase inhibitor 7-nitroindazole reduces the 5-HT1A receptor against 8-OH-DPAT–elicited hyperphagia in rats. Sugimoto Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):1–5

Influence of trimebutine on inflammation- and stress-induced hyperalgesia to rectal distension in rats. Lacheze C, et al. **J Pharm Pharmacol** 1998 Aug;50(8):921–8

PATHOLOGY

Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. Cunha FQ, et al. **Br J Pharmacol** 1999 Jun; 127(3):671–8

PHYSIOPATHOLOGY

Tourniquet constriction exacerbates hyperalgesia-related pain induced by intradermal capsaicin injection. Byas-Smith MG, et al. **Anesthesiology** 1999 Sep; 91(3):617–25

Primary and secondary hyperalgesia in a rat model for human postoperative pain. Zahn PK, et al. **Anesthesiology** 1999 Mar;90(3):863–72

Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats. Jett MF, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:369–71

Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats. Courteix C, et al. **Br J Pharmacol** 1999 Jul; 127(6):1454–62

Bradykinin B1 and B2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia. Poole S, et al. **Br J Pharmacol** 1999 Feb;126(3):649–56

In vivo pathway of thermal hyperalgesia by intrathecal administration of alpha,beta-methylene ATP in mouse spinal cord: involvement of the glutamate–NMDA receptor system. Tsuda M, et al. **Br J Pharmacol** 1999 May; 127(2):449–56

Priming enhances endotoxin-induced thermal hyperalgesia and mechanical allodynia in rats. Cahill CM, et al. **Brain Res** 1998 Oct 12;808(1):13–22

Aging and neuropathic pain. Novak JC, et al. **Brain Res** 1999 Jul 3;833(2):308–10

Role of intracellular calcium in thermal allodynia and hyperalgesia in diabetic mice. Ohsawa M, et al. **Brain Res** 1999 Jul 3;833(2):278–81

Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Strangman NM, et al. **Brain Res** 1998 Dec 7;813(2):323–8

Peripheral contributions to visceral hyperalgesia. Gebhart GF. **Can J Gastroenterol** 1999 Mar;13 Suppl A:37A–41A (16 ref.)

A neuronal nitric oxide synthase inhibitor 7-nitroindazole reduces the 5-HT1A receptor against

8-OH-DPAT-elicited hyperphagia in rats. Sugimoto Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):1-5

A role for spinal nitric oxide in mediating visceral hyperalgesia in the rat. Coutinho SV, et al. **Gastroenterology** 1999 Jun;116(6):1399-408

Sphincter of Oddi dysfunction type III: another manifestation of visceral hyperalgesia? [editorial; comment] Kellow JE. **Gastroenterology** 1999 Apr;116(4):996-1000. Comment on: Gastroenterology 1999 Apr;116(4):900-5.

Enhancement of thermal hyperalgesia by alpha-adrenoceptors in capsaicin-treated skin. Drummond PD. **J Auton Nerv Syst** 1998 Apr 30;69(2-3):96-102

Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. Lin Q, et al. **J Neurophysiol** 1999 Mar;81(3):1075-85

Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. Yamamura H, et al. **J Neurophysiol** 1999 Feb;81(2):479-93

Role of protein kinase A in the maintenance of inflammatory pain. Aley KO, et al. **J Neurosci** 1999 Mar 15;19(6):2181-6

Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. Kerr BJ, et al. **J Neurosci** 1999 Jun 15; 19(12):5138-48

Effect of sympathetic activity on capsaicin-evoked pain, hyperalgesia, and vasodilatation [see comments] Baron R, et al. **Neurology** 1999 Mar 23;52(5):923-32. Comment in: Neurology 1999 Mar 23;52(5):905-7.

The role of systemic, spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Ferreira J, et al. **Neuropharmacology** 1999 Jun;38(6):835-42

N-methyl D-aspartate induced mechanical allodynia is blocked by nitric oxide synthase and cyclooxygenase-2 inhibitors. Dolan S, et al. **Neuroreport** 1999 Feb 25; 10(3):449-52

Zinc alleviates thermal hyperalgesia due to partial nerve injury. Liu T, et al. **Neuroreport** 1999 Feb 25;10(3):645-9

Sensory threshold changes without initial pain or alterations in cutaneous blood flow, in the area of secondary hyperalgesia caused by topical application of capsaicin in humans. Andrews K, et al. **Neurosci Lett** 1999 Apr 30; 266(1):45-8

Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Morris V, et al. **Neurosci Lett** 1998 Jul 10; 250(3):205-7

A novel model of primary and secondary hyperalgesia after mild thermal injury in the rat. Nozaki-Taguchi N, et al. **Neurosci Lett** 1998 Sep 18;254(1):25-8

Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide TX14(A). Otero DA, et al. **Neurosci Lett** 1999 Jul 23;270(1):29-32

Genetic differences in the antinociceptive effect of morphine and its potentiation by dextromethorphan in rats. Plesan A, et al. **Neurosci Lett** 1999 Mar 19;263(1):53-6

Lowering barometric pressure aggravates mechanical allodynia and hyperalgesia in a rat model of neuropathic pain. Sato J, et al. **Neurosci Lett** 1999 Apr 30;266(1):21-4

Brief electrical stimulation of c-fibers in rats produces thermal hyperalgesia lasting weeks. Vatine JJ, et al. **Neurosci Lett** 1998 May 1;246(3):125-8

The sodium channel auxiliary subunits beta1 and beta2 are differentially expressed in the spinal cord of neuropathic rats. Blackburn-Munro G, et al. **Neuroscience** 1999 Apr; 90(1):153-64

A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance. Kwak JY, et al. **Neuroscience** 1998 Sep;86(2):619-26

Descending modulation of opioid-containing nociceptive neurons in rats with peripheral inflammation and hyperalgesia. MacArthur L, et al. **Neuroscience** 1999 Jan; 88(2):499-506

Descending facilitatory influences from the rostral medial medulla mediate secondary, but not primary hyperalgesia in the rat. Urban MO, et al. **Neuroscience** 1999 May; 90(2):349-52

Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia. Coutinho SV, et al. **Pain** 1998 Oct;78(1):59-69

Transient inhibition of responses to thermal stimuli of spinal sensory tract neurons in monkeys during sensitization by intradermal capsaicin. Dougherty PM, et al. **Pain** 1998 Aug; 77(2):129-36

Intrathecal administration of the mGluR compound, (S)-4CPG, attenuates hyperalgesia and allodynia associated with sciatic nerve constriction injury in rats. Fisher K, et al. **Pain** 1998 Jul;77(1):59-66

Windup leads to characteristics of central sensitization. Li J, et al. **Pain** 1999 Jan;79(1):75-82

Spinal neurokinin3 receptors mediate thermal but not mechanical hyperalgesia via nitric oxide. Linden DR, et al. **Pain** 1999 Mar;80(1-2):309-17

Spinal neurokin3 receptors facilitate the nociceptive flexor reflex via a pathway involving nitric oxide. Linden DR, et al. **Pain** 1999 Mar;80(1-2):301-8

Morphine, the NMDA receptor antagonist MK801 and the tachykinin NK1 receptor antagonist RP67580 attenuate the development of inflammation-induced progressive tactile hypersensitivity. Ma QP, et al. **Pain** 1998 Jul;77(1):49-57

Secondary hyperalgesia to heat stimuli after burn injury in man. Pedersen JL, et al. **Pain** 1998 Jun;76(3):377-84

Mechanical hyperalgesia after spinal nerve ligation in rat is not reversed by intraplantar or systemic administration of adrenergic antagonists. Ringkamp M, et al. **Pain** 1999 Feb; 79(2-3):135-41

Lumbar sympathectomy failed to reverse mechanical allodynia- and hyperalgesia-like behavior in rats with L5 spinal nerve injury. Ringkamp M, et al. **Pain** 1999 Feb; 79(2-3):143-53

Patterns of hyperalgesia in complex regional pain syndrome. Sieweke N, et al. **Pain** 1999 Mar;80(1-2):171-7

5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. Tokunaga A, et al. **Pain** 1998 Jun;76(3):349-55

Involvement of excitatory amino acid receptors and nitric oxide in the rostral ventromedial medulla in modulating secondary hyperalgesia produced by mustard oil. Urban MO, et al. **Pain** 1999 May;81(1-2):45-55

Wallerian degeneration and hyperalgesia after peripheral nerve injury are glutathione-dependent. Wagner R, et al. **Pain** 1998 Aug;77(2):173-9

Nucleus reticularis gigantocellularis and nucleus raphe magnus in the brain stem exert opposite effects on behavioral hyperalgesia and spinal Fos protein expression after peripheral inflammation [published erratum appears in Pain 1999 May;81(1-2):215-9] Wei F, et al. **Pain** 1999 Mar;80(1-2):127-41

Hyperalgesia with reduced laser evoked potentials in neuropathic pain. Wu Q, et al. **Pain** 1999 Mar; 80(1-2):209-14

Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645-9 (69 ref.)

Neurotrophins and hyperalgesia. Shu XQ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7693-6 (40 ref.)

Supraspinal contributions to hyperalgesia. Urban MO, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7687-92 (53 ref.)

The glutamate synapse: a target in the pharmacological management of hyperalgesic pain states. Urban MO, et al. **Prog Brain Res** 1998;116:407-20 (81 ref.)

Hyperalgesia or hypervigilance? An evoked potential approach to the study of fibromyalgia syndrome. Lorenz J. **Z Rheumatol** 1998;57 Suppl 2:19-22

PREVENTION & CONTROL

Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Yosipovitch G, et al. **Acta Derm Venereol** 1999 Mar;79(2):118-21

Influence of preemptive treatment with MK-801, an N-methyl-D-aspartate receptor antagonist, on development of neuropathic symptoms induced by spinal nerve ligation in the rat. Wei H, et al. **Anesthesiology** 1999 Jul;91(1):313-6

Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Cunha FQ, et al. **Br J Pharmacol** 1999 Jan; 126(1):45-50

Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Jones DL, et al. **Brain Res** 1998 Nov 9;810(1-2):93-9

Effect of intrathecal agmatine on inflammation-induced thermal hyperalgesia in rats. Horváth G, et al. **Eur J Pharmacol** 1999 Mar 5;368(2-3):197-204

d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. Davis AM, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1048-53

Differential contribution of R and S isomers in ketoprofen anti-inflammatory activity: role of cytokine modulation. Ghezzi P, et al. **J Pharmacol Exp Ther** 1998 Dec; 287(3):969-74

Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNF-alpha nerve injection. Wagner R, et al. **Neuroreport** 1998 Aug 24;9(12):2827-31

Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Ceseña RM, et al. **Neurosci Lett** 1999 Mar 5;262(2):101-4

Nitroprusside inhibits thermal hyperalgesia induced by noradrenaline in capsaicin-treated skin. Drummond PD. **Pain** 1999 Mar;80(1-2):405-12

Dorsal column lesion prevents mechanical hyperalgesia and allodynia in osteotomy model. Houghton AK, et al. **Pain** 1999 Jul;82(1):73-80

Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat. Khandwala H, et al. **Pain** 1998 Jul;77(1):87-95

The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Li J, et al. **Pain** 1999 May;81(1-2):25-33

PSYCHOLOGY

Neurokinin-1 receptors are involved in behavioral responses to high-intensity heat stimuli and capsaicin-induced hyperalgesia in mice. Mansikka H, et al. **Anesthesiology** 1999 Jun;90(6):1643-9

Anxiety and pain: epinephrine-induced hyperalgesia and attentional influences. Janssen SA, et al. **Pain** 1998 Jun; 76(3):309-16

THERAPY

Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide TX14(A). Otero DA, et al. **Neurosci Lett** 1999 Jul 23;270(1):29-32

Treatment with either high or low frequency TENS reduces the secondary hyperalgesia observed after injection of kaolin and carrageenan into the knee joint. Sluka KA, et al. **Pain** 1998 Jul;77(1):97-102

Hyperalgesia due to nerve damage: role of nerve growth factor. Theodosiou M, et al. **Pain** 1999 Jun;81(3):245-55

HYPERALIMENTATION, PARENTERAL see **PARENTERAL NUTRITION, TOTAL**

HYPERANDROGENISM

see related
HIRSUTISM
VIRILISM

Hyperandrogenic anovulation (the polycystic ovary syndrome)--back to the ovary? Ben-Shlomo I, et al. **Hum Reprod Update** 1998 May-Jun;4(3):296-300 (39 ref.)

Polycystic ovary syndrome: clinical perspectives and management. Futterweit W. **Obstet Gynecol Surv** 1999 Jun; 54(6):403-13 (91 ref.)

BLOOD

The relationship of serum androgens and ovulatory status to blood pressure in reproductive-age women. Ayala C, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):772-7

Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Vainionpää LK, et al. **Ann Neurol** 1999 Apr;45(4):444-50

Insulin action during variable hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women. Dumesic DA, et al. **Fertil Steril** 1999 Sep;72(3):458-66

Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism. Escobar-Morreale HF, et al. **Fertil Steril** 1998 Dec;70(6):1090-100

Transient hyperandrogenemia and its relation to ovulation. Martins JM, et al. **Fertil Steril** 1998 Oct;70(4):664-70

Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Morán C, et al. **Fertil Steril** 1999 Apr; 71(4):671-4

Serum leptin levels in young females with insulin-dependent diabetes and the relationship to hyperandrogenicity and microalbuminuria. Rudberg S, et al. **Horm Res** 1998; 50(6):297-302

The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche. Vuguin P, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2037-42

CHEMICALLY INDUCED

Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Vainionpää LK, et al. **Ann Neurol** 1999 Apr;45(4):444-50

[Iatrogenic androgenization] Mangold R, et al. **Zentralbl Gynakol** 1998;120(10):515-7 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Morán C, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):596-600

Polycystic ovary syndrome and hyperandrogenism as a risk factor for cardiovascular disease. Martikainen H, et al. **Int J Circumpolar Health** 1998 Jul;57(2-3):133-7 (14 ref.)

Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome. Carmina E, et al. **J Endocrinol Invest** 1998 Oct;21(9):580-8 (56 ref.)

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558-66 (88 ref.)

Clearance of acanthosis nigricans associated with the HAIR-AN syndrome after partial pancreatectomy: an 11-year follow-up. Pfeifer SL, et al. **Postgrad Med J** 1999 Jul;75(885):421-2

[Hyperandrogenism and fertility] Deneux C, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):311-8 (26 ref.) **(Fre)**

DIAGNOSIS

Virilizing ovarian tumor of cell tumor type not otherwise specified: a case report. Faraj G, et al. **Gynecol Endocrinol** 1998 Oct;12(5):347-52

[Acne in the male resistant to isotretinoin and responsibility of androgens: 9 cases, therapeutic implications (see comments)] Chaspoux C, et al. **Ann Dermatol Venereol** 1999 Jan;126(1):17-9 (Eng. Abstr.). Comment in: Ann Dermatol Venereol 1999 Jan;126(1):9-10. **(Fre)**

[What indications for assessing acne in the man? (editorial; comment)] Jamin C. **Ann Dermatol Venereol** 1999 Jan; 126(1):9-10. Comment on: Ann Dermatol Venereol 1999 Jan;126(1):17-9. **(Fre)**

HYPERANDROGENISM

[Molecular background of hyperandrogenism of ovarian origin] Katulski K, et al. **Ginekol Pol** 1999 May; 70(5):315–22 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1510–2

[Hyperandrogenism: clinical aspects, investigation and treatment] Beckers A, et al. **Rev Med Liege** 1999 Apr; 54(4):274–82 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Syndromes of hyperandrogenism in women. Davis S. **Aust Fam Physician** 1999 May;28(5):447–51 (5 ref.)

Hilus cell tumour of the ovary in a virilized, premenopausal woman. Case report and review of hyperandrogenism of ovarian origin. Moore A, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):75–8 (16 ref.)

Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Carmina E, et al. **Fertil Steril** 1999 Feb;71(2):319–22

Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. Ibañez L, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3558–62

Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal. Morán C, et al. **J Endocrinol Invest** 1998 Nov; 21(10):707–20 (94 ref.)

[Managing hyperandrogenism] Faure M, et al. **Ann Dermatol Venereol** 1998 Aug;125(8):533–40 (66 ref.) **(Fre)**

[Hyperandrogenism: clinical aspects, investigation and treatment] Beckers A, et al. **Rev Med Liege** 1999 Apr; 54(4):274–82 (Eng. Abstr.) **(Fre)**

GENETICS

Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status. Dolžan V, et al. **Eur J Endocrinol** 1999 Aug; 141(2):132–9

Heritability and the risk of developing androgen excess. Kashar-Miller M, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):261–8 (25 ref.)

Glucocorticoid resistance in premature pubarche and adolescent hyperandrogenism. Witchel SF, et al. **Mol Genet Metab** 1999 Feb;66(2):137–41

Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Legro RS, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14956–60

[Molecular background of hyperandrogenism of ovarian origin] Katulski K, et al. **Ginekol Pol** 1999 May; 70(5):315–22 (Eng. Abstr.) **(Pol)**

METABOLISM

The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM. Andersson B, et al. **Acta Obstet Gynecol Scand** 1999 Mar;78(3):260–1

Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism. Cagnacci A, et al. **Hum Reprod** 1999 Apr;14(4):893–7

PHYSIOPATHOLOGY

Naltrexone effects on insulin sensitivity and insulin secretion in hyperandrogenic women. Sir-Petermann T, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):389–94

SURGERY

Comparison of ovarian electrocautery and oral contraceptives in the treatment of hyperandrogenism in women with polycystic ovary syndrome. Gjønnaess H. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):530–3

THERAPY

How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. Apter D. **J Endocrinol Invest** 1998 Oct; 21(9):613–7 (30 ref.)

HYPERBARIC OXYGENATION

Hyperbaric oxygenation of mechanically ventilated patients poisoned with carbon monoxide [letter] Rivers EP. **Acad Emerg Med** 1998 Dec;5(12):1231–2

Hyperbaric oxygen. Some unanswered questions despite clinical usefulness. Whelan HT, et al. **Adv Exp Med Biol** 1998;454:441–5 (0 ref.)

HOT MI pilot study. Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction [letter; comment] Laden G. **Am Heart J** 1998 Oct;136(4 Pt 1):749. Comment on: Am Heart J 1997 Sep;134(3):544–50.

Hyperbaric oxygen therapy for perineal Crohn's disease. Noyer CM, et al. **Am J Gastroenterol** 1999 Feb;94(2):318–21 (27 ref.)

Hemodilution, cerebral O2 delivery, and cerebral blood flow: a study using hyperbaric oxygenation. Tomiyama Y, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1190–6

Hyperbaric oxygen therapy in sports [letter; comment] Strauss MB. **Am J Sports Med** 1999 Mar–Apr;27(2):265–6 . Comment on: Am J Sports Med 1998 Jul–Aug;26(4):489–90.

The effects of hyperbaric oxygen on normal and ischemic colon anastomoses. Hamzaoğlu I, et al. **Am J Surg** 1998 Nov;176(5):458–61

Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah's witness. McLoughlin PL, et al. **Anaesthesia** 1999 Sep;54(9):891–5

The synergistic effect of sympathectomy and hyperbaric oxygen exposure on transcutaneous PO2 in healthy volunteers. Thomas PS, et al. **Anesth Analg** 1999 Jan; 88(1):67–71

Management of clostridial gas gangrene and the role of hyperbaric oxygen. Korhonen K, et al. **Ann Chir Gynaecol** 1999;88(2):139–42

Effect of hyperbaric oxygen on survival of the composite ear graft in rats. Zhang F, et al. **Ann Plast Surg** 1998 Nov; 41(5):530–4

Hyperbaric oxygenation, plasma exchange, and hemodialysis for treatment of acute liver failure in a 3-year-old child. Ponikvar R, et al. **Artif Organs** 1998 Nov;22(11):952–7

Outcome after treatment of neurological decompression illness is predicted by a published clinical scoring system. Pitkin AD, et al. **Aviat Space Environ Med** 1999 May; 70(5):517–21

Hyperbaric oxygen therapy. Combination with radiotherapy in cancer is of proved benefit but rarely used [letter; comment] Coles C, et al. **BMJ** 1999 Apr 17; 318(7190):1076–7; discussion 1077–8. Comment on: BMJ 1998 Oct 24;317(7166):1140–3.

Hyperbaric oxygen therapy [see comments] Leach RM, et al. **BMJ** 1998 Oct 24;317(7166):1140–3 (0 ref.). Comment in: BMJ 1999 Apr 17;318(7190):1076–7; discussion 1077–8. Comment in: BMJ 1999 Apr 17;318(7190):1077–8.

Hyperbaric oxygen in the treatment of refractory haemorrhagic cystitis. Hughes AJ, et al. **Bone Marrow Transplant** 1998 Sep;22(6):585–6

Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Kohshi K, et al. **Br J Cancer** 1999 Apr; 80(1–2):236–41

Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Saunders M, et al. **Br J Cancer Suppl** 1996 Jul;27:S271–8 (48 ref.)

Hyperbaric oxygen increases plasma exudation in rat trachea: involvement of nitric oxide. Bernareggi M, et al. **Br J Pharmacol** 1999 Feb;126(3):794–800

Adaptive protection against the induction of oxidative DNA damage after hyperbaric oxygen treatment. Rothfuss A, et al. **Carcinogenesis** 1998 Nov;19(11):1913–7

Hyperbaric oxygen and thrombolysis in myocardial infarction: the 'HOT MI' randomized multicenter study. Stavitsky Y, et al. **Cardiology** 1998 Oct;90(2):131–6

Hyperbaric oxygen therapy in deep sternal wound infection after heart transplantation. Petzold T, et al. **Chest** 1999 May;115(5):1455–8

Hyperbaric oxygen corrects sacral plexopathy due to osteoradionecrosis appearing 15 years after pelvic irradiation. Videtic GM, et al. **Clin Oncol (R Coll Radiol)** 1999;11(3):198–9

The effect of hyperbaric oxygen on medial collateral ligament healing in a rat model. Horn PC, et al. **Clin Orthop** 1999 Mar;(360):238–42

Hyperbaric oxygen in systemic inflammation ... HBO is not just a movie channel anymore [editorial; comment] Slotman GJ. **Crit Care Med** 1998 Dec;26(12):1932–3 (28 ref.). Comment on: Crit Care Med 1998 Dec;26(12):1972–6.

Hyperbaric oxygen therapy in childhood carbon monoxide poisoning. Liebelt EL. **Curr Opin Pediatr** 1999 Jun; 11(3):259–64 (30 ref.)

Cardiovascular effects of hyperbaric oxygen with and without addition of carbon dioxide. Bergo GW, et al. **Eur J Appl Physiol** 1999 Sep;80(4):264–75

Effects of a standard hyperbaric oxygen treatment protocol on pulmonary function. Thorsen E, et al. **Eur Respir J** 1998 Dec;12(6):1442–5

Effects of hyperbaric oxygen treatment on neutrophil activation and pulmonary sequestration in intestinal ischemia-reperfusion in rats. Tjärnström J, et al. **Eur Surg Res** 1999;31(2):147–54

Effects of hyperbaric and hyperoxic conditions on the disposition of drugs: theoretical considerations and a review of the literature. Rump AF, et al. **Gen Pharmacol** 1999 Jan;32(1):127–33 (45 ref.)

Hyperbaric oxygen: a novel modality to ameliorate experimental colitis. Rachmilewitz D, et al. **Gut** 1998 Oct; 43(4):512–8

Hyperbaric oxygenation as adjuvant therapy to surgery of emphysematous cholecystitis. Kraljevic D, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):775–7

Early post-operative hyperbaric oxygen therapy modifies neutrophile activation. Ueno S, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1798–9

Blood lactate changes in men during graded workloads at normal atmospheric pressure (100 kPa) and under simulated caisson conditions (400 kPa). Neubauer B, et al. **Int Arch Occup Environ Health** 1999 May;72(3):178–81

Histomorphometric evaluation of the effect of hyperbaric oxygen treatment on healing around hydroxyapatite implants in irradiated rat bone. Chen X, et al. **Int J Oral Maxillofac Implants** 1999 Jan–Feb;14(1):61–8

Carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. Haffty BG, et al. **Int J Radiat Oncol Biol Phys** 1999 Aug 1;45(1):13–20

Carbon monoxide poisoning: an update. Turner M, et al. **J Accid Emerg Med** 1999 Mar;16(2):92–6 (35 ref.)

Effects of prolonged oxygen exposure at 1.5, 2.0, or 2.5 ATA on pulmonary function in men (predictive studies V). Clark JM, et al. **J Appl Physiol** 1999 Jan;86(1):243–59

Osseointegrated implants in irradiated bone: a case-controlled study using adjunctive hyperbaric oxygen therapy. Granström G, et al. **J Oral Maxillofac Surg** 1999 May;57(5):493–9

Hyperbaric oxygen therapy for intestinal obstruction in children: an exceptional experience in a compromised child. Ohno Y, et al. **J Pediatr Surg** 1998 Oct;33(10):1543–5

Effect of hyperbaric oxygen therapy as a monitoring technique for digital replantation survival. Kiyoshige Y. **J Reconstr Microsurg** 1999 Jul;15(5):327–30

Hyperbaric oxygen therapy for massive arterial air embolism during cardiac operations. Ziser A, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):818–21

The use of hyperbaric oxygen in urology. Capelli-Schellpfeffer M, et al. **J Urol** 1999 Sep;162(3 Pt 1):647–54 (75 ref.)

Hyperbaric oxygen therapy for pediatric hemorrhagic cystitis. Furness PD 3rd, et al. **J Urol** 1999 May; 161(5):1596–7

Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis. Mathews R, et al. **J Urol** 1999 Feb; 161(2):435–7

Effect of hyperbaric oxygen on ophthalmic artery blood velocity in patients with diabetic neuropathy. Okamoto N, et al. **Jpn J Ophthalmol** 1998 Sep–Oct;42(5):406–10

Is oxygen an antibiotic? [letter; comment] Schechter R. **Lancet** 1998 Nov 7;352(9139):1552–3. Comment on: Lancet 1998 Sep 5;352(9130):782.

Hyperbaric oxygen for toxic megacolon [letter; comment] Welfare MR, et al. **Lancet** 1999 Jan 2;353(9146):70–1. Comment on: Lancet 1998 Sep 5;352(9130):782.

Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. Mazariegos GV, et al. **Liver Transpl Surg** 1999 Sep;5(5):429–36

A role for oxygen-induced osmosis in hyperbaric oxygen therapy. Hills BA. **Med Hypotheses** 1999 Mar;52(3):259–63 (31 ref.)

Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Was the neuropsychological testing appropriate? [letter; comment] Denson LA, et al. **Med J Aust** 1999 Jun 7;170(11):563; discussion 564–5. Comment on: Med J Aust 1999 Mar 1;170(5):203–10.

Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Some evidence at last [letter; comment] Kamill PG. **Med J Aust** 1999 Jun 7;170(11):563–4; discussion 564–5. Comment on: Med J Aust 1999 Mar 1;170(5):203–10.

Hyperbaric oxygen for carbon monoxide poisoning [editorial; comment] Moon RE, et al. **Med J Aust** 1999 Mar 1; 170(5):197–9. Comment on: Med J Aust 1999 Mar 1;170(5):203–10.

Carbon monoxide poisoning [letter; comment] Weaver LK, et al. **N Engl J Med** 1999 Apr 22;340(16):1290; discussion 1292. Comment on: N Engl J Med 1998 Nov 26;339(22):1603–8.

Effects of dimethylthiourea, melatonin, and hyperbaric oxygen therapy on the survival of reimplanted rabbit auricular composite grafts. Lim AA, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):231–7

Thermal myringotomy for eustachian tube dysfunction in hyperbaric oxygen therapy. Potocki SE, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):185–9

Hyperbaric oxygen therapy in the pediatric patient: the experience of the Israel Naval Medical Institute. Waisman D, et al. **Pediatrics** 1998 Nov;102(5):E53

In vivo and in vitro hyperbaric studies in mice suggest novel sites of action for ethanol. Davies DL, et al. **Psychopharmacology (Berl)** 1999 Feb;141(4):339–50

Hyperbaric oxygen in the treatment of life-threatening soft-tissue infections. Clark LA, et al. **Respir Care Clin N Am** 1999 Jun;5(2):203–19 (101 ref.)

Appendix: education and information resources in hyperbaric medicine. Clarke D, et al. **Respir Care Clin N Am** 1999 Jun;5(2):297–317

Treatment of decompression illness and latrogenic gas embolism. Moon RE, et al. **Respir Care Clin N Am** 1999 Mar;5(1):93–135 (184 ref.)

Hyperbaric oxygen therapy: from the nineteenth to the twenty-first century. Moon RE, et al. **Respir Care Clin N Am** 1999 Mar;5(1):1–5

Operational use and patient monitoring in a multiplace hyperbaric chamber. Moon RE, et al. **Respir Care Clin N Am** 1999 Mar;5(1):21–49 (59 ref.)

Diagnosis and treatment of carbon monoxide poisoning. Piantadosi CA. **Respir Care Clin N Am** 1999 Jun; 5(2):183–202 (95 ref.)

Assessment of tissue oxygenation. Robertson PW, et al. **Respir Care Clin N Am** 1999 Jun;5(2):221–63 (192 ref.)

Medical field management of the injured diver. Van Meter K. **Respir Care Clin N Am** 1999 Mar;5(1):137–77, vi

Hyperbaric oxygen therapy for children with cerebral palsy [letter; comment] Cronje F. **S Afr Med J** 1999 Apr; 89(4):359–60; discussion 361. Comment on: S Afr Med J 1998 Nov;88(11):1362–3.

Hyperbaric oxygen therapy for children with cerebral palsy [letter; comment] van Bever Donker SC. **S Afr Med J** 1999 Apr;89(4):360–1. Comment on: S Afr Med J 1998 Nov;88(11):1362–3.

Hyperbaric oxygen therapy for children with cerebral palsy [letter] [see comments] Venter A, et al. **S Afr Med J** 1998 Nov;88(11):1362–3. Comment in: S Afr Med J 1999 Apr;89(4):359–60; discussion 361. Comment in: S Afr Med J 1999 Apr;89(4):360–1.

Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Leber KA, et al. **Stereotact Funct Neurosurg** 1998 Oct;70 Suppl 1:229–36

Management of postoperative radiation injury of the urinary bladder by hyperbaric oxygen (HBO). Peusch–Dreyer D, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:99–100

The treatment of late radiation effects with hyperbaric oxygenation (HBO). Plafki C, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:66–8 (30 ref.)

Undersea and Hyperbaric Medical Society annual meeting, June 26–29, 1999 and the VI High Pressure Biology meeting, June 30, 1999. Boston, Massachusetts, USA. Abstracts. **Undersea Hyperb Med** 1999;26 Suppl:1–85

Underwater and Hyperbaric Medicine, abstracts from the literature. **Undersea Hyperb Med** 1999 Fall;26(3):185–211

Underwater and Hyperbaric Medicine, abstracts from the literature. **Undersea Hyperb Med** 1999 Summer; 26(2):123–35

Oxidative stress during a 3.5-hour exposure to 120 kPa(a) PO2 in human divers. Bearden SE, et al. **Undersea Hyperb Med** 1999 Fall;26(3):159–64

Hyperbaric oxygen as a signal transducer: upregulation of platelet derived growth factor–beta receptor in the presence of HBO2 and PDGF. Bonomo SR, et al. **Undersea Hyperb Med** 1998 Winter;25(4):211–6

Immune function in hyperbaric environments, diving, and decompression. Brenner I, et al. **Undersea Hyperb Med** 1999 Spring;26(1):27–39 (115 ref.)

Hyperbaric oxygen treatment for symptomatic breast edema after radiation therapy. Carl UM, et al. **Undersea Hyperb Med** 1998 Winter;25(4):233–4

Measurement of cerebral blood flow in rats and mice by hydrogen clearance during hyperbaric oxygen exposure. Demchenko IT, et al. **Undersea Hyperb Med** 1998 Fall; 25(3):147–52

Platelet aggregation and release function in hyperbaric oxygenation. Ersöz G, et al. **Undersea Hyperb Med** 1998 Winter;25(4):229–32

Cytokine response after acute hyperbaric exposure in the rat. Ersson A, et al. **Undersea Hyperb Med** 1998 Winter; 25(4):217–21

Effect of hyperbaric oxygenation treatment on lengthened callus. Kitakoji T, et al. **Undersea Hyperb Med** 1999 Fall; 26(3):165–8

Effect of hyperbaric conditions on plasma stress hormone levels and endothelin-1. Lund V, et al. **Undersea Hyperb Med** 1999 Summer;26(2):87–92

Effect of hyperbaric oxygen therapy in experimental subcutaneous and pulmonary infections due to Pseudomonas aeruginosa. Luongo C, et al. **Undersea Hyperb Med** 1999 Spring;26(1):21–5

Therapy with hyperbaric oxygen and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats. Mendel V, et al. **Undersea Hyperb Med** 1999 Fall; 26(3):169–74

Quantification of the dermal vascular response to hyperbaric oxygen with laser–Doppler flowmetry. Ratzenhofer–Komenda B, et al. **Undersea Hyperb Med** 1998 Winter;25(4):223–7

Physiologic and biochemical monitoring during hyperbaric oxygenation: a review. Rogatsky GG, et al. **Undersea Hyperb Med** 1999 Summer;26(2):111–22 (193 ref.)

Lack of effect of 24 atm abs environment on face immersion bradycardia in human subjects [letter] Shiraki K, et al. **Undersea Hyperb Med** 1998 Fall;25(3):189–90

Effect of caffeine consumption on tissue oxygen levels during hyperbaric oxygen treatment. Stephens M, et al. **Undersea Hyperb Med** 1999 Summer;26(2):93–7

Enhanced aggregability of human red blood cells by diving. Taylor WF, et al. **Undersea Hyperb Med** 1998 Fall; 25(3):167–70

Detection of viable myocardium: comparison of dobutamine echocardiography and echocardiography after hyperbaric oxygenation. Veselka J, et al. **Undersea Hyperb Med** 1999 Spring;26(1):9–13

Exercise after acute hyperbaric oxygenation: is there an ergogenic effect? Webster AL, et al. **Undersea Hyperb Med** 1998 Fall;25(3):153–9

Calciphylaxis: a favorable outcome with hyperbaric oxygen. Dean SM, et al. **Vasc Med** 1998;3(2):115–20

[Effects of hyperbaric oxygen on the skin graft survival] Jiang P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):91–3 (23 ref.) **(Chi)**

[Wound healing and hyperbaric oxygen. Experimental study of the angiogenesis phase in the rat] Méchine A, et al. **Ann Chir** 1999;53(4):307–13 (Eng. Abstr.) **(Fre)**

[Perineal anaerobic necrotizing cellulite after preoperative radiotherapy for rectal cancer (letter)] Lederman E, et al. **Gastroenterol Clin Biol** 1998 Mar;22(3):360–1 **(Fre)**

[The role of hyperbaric oxygen therapy in radiation-induced digestive disorders. 36 cases] Gouëllo JP, et al. **Presse Med** 1999 Jun 5;28(20):1053–7 (Eng. Abstr.) **(Fre)**

[Carbon monoxide intoxication. Physiopathology, etiology, diagnosis, treatment] Bocquet J, et al. **Rev Prat** 1998 Oct 15;48(16):1817–20 **(Fre)**

[Hyperbaric oxygenation therapy in wound healing disorders?] Trefzer D, et al. **Fortschr Med** 1999 Mar 30; 117(9):15–6 **(Ger)**

[Hyperbaric oxygen therapy (HBO) after acute focal cerebral ischemia] Berrouschot J, et al. **Nervenarzt** 1998 Dec; 69(12):1037–44 (82 ref.) (Eng. Abstr.) **(Ger)**

[Hyperbaric oxygen therapy in a patient with bilateral Legg–Calvé–Perthes disease] Sparacia G, et al. **Radiol Med (Torino)** 1998 Dec;96(6):621–3 **(Ita)**

[Current topics on hyperbaric oxygenation therapy—application of hyperbaric oxygenation to multiple organ failure] Arikawa K. **Masui** 1998 Dec;47 Suppl:S46–51 (19 ref.) **(Jpn)**

[Hyperbaric oxygenation therapy in idiopathic sudden sensory neural hearing loss] Shiraishi T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Dec;101(12):1380–4 (Eng. Abstr.) **(Jpn)**

[Role of hyperbaric oxygenation in mechanisms correcting the immunological reactivity in endotoxic shock and serum sickness] D'iachkova SIa, et al. **Anesteziol Reanimatol** 1999 Jan–Feb;(1):56–8 (Eng. Abstr.) **(Rus)**

[Hyperbaric oxygenation as a method of intensive therapy in acute exogenous poisoning] Ermolov AS, et al. **Anesteziol Reanimatol** 1998 Nov–Dec;(6):16–9 (Eng. Abstr.) **(Rus)**

[Role of hyperbaric oxygenation in the treatment of posthypoxic encephalopathy of toxic etiology] Ermolov AS, et al. **Anesteziol Reanimatol** 1998 Nov–Dec;(6):20–5 (Eng. Abstr.) **(Rus)**

[Changes in the oxidant–antioxidant system activity in patients with hepatic failure treated with hyperbaric oxygenation and actoprotectors] Lakhin RE, et al. **Anesteziol Reanimatol** 1999 Mar–Apr;(2):55–8 (Eng. Abstr.) **(Rus)**

[Oxygen regimen during various intensive care methods in severe exotoxic shock] Shapovalova NV, et al. **Anesteziol Reanimatol** 1998 Nov–Dec;(6):26–8 (Eng. Abstr.) **(Rus)**

[The dynamics of the autonomic indices in participants in the cleanup of the aftermath of the accident at the Chernobyl Atomic Electric Power Station at the stages of therapeutic hyperoxia] Vorob'ev KP, et al. **Lik Sprava** 1998 Dec;(8):33–6 (Eng. Abstr.) **(Rus)**

[Changes in autonomic regulation in patients with multiple sclerosis during hyperbaric oxygenation] Vorob'eva KP, et al. **Lik Sprava** 1998 Oct–Nov;(7):85–8 (Eng. Abstr.) **(Rus)**

[The effect of hyperbaric oxygenation on the antioxidant status of Xenopus laevis after its preliminary adaptation to oxygen] Gus'kov EP, et al. **Ontogenez** 1999 Mar–Apr; 30(2):91–6 (Eng. Abstr.) **(Rus)**

[The effect of hyperbaric oxygenation on the urea content of the saliva in acute and chronic soft-tissue inflammation in the maxillofacial area] Volozhin AI, et al. **Patol Fiziol Eksp Ter** 1998 Oct–Dec;(4):20–2 (Eng. Abstr.) **(Rus)**

[Clinical manifestation, diagnosis and treatment of rare forms of acute drug poisoning (lecture)] Luzhnikov EA, et al. **Ter Arkh** 1998;70(10):65–8 **(Rus)**

[Effect of hyperbaric oxygenation of lipid peroxidation and the antioxidant system in liver of white rats with acute sodium nitrate poisoning] Glebova LIu. **Ukr Biokhim Zh** 1998 May–Jun;70(3):91–5 (Eng. Abstr.) **(Rus)**

[Effects of hyperbaric oxygenation on oxidative phosphorylation in post-nephrotomy tissues sutured with different surgical threads (an experimental study)] Kostenko VA. **Urol Nefrol (Mosk)** 1998 Nov–Dec;(6):7–8 (Eng. Abstr.) **(Rus)**

[The role of hyperbaric medicine in the treatment of cerebral and myocardial ischemic disease] Krgović M, et al. **Vojnosanit Pregl** 1998 Sep–Oct;55(5):523–8 (40 ref.) **(Scc)**

[Hyperbaric oxygenation and neurological recovery in children with organic brain damage] Córdoba–Cabeza T, et al. **Rev Neurol** 1998 Oct;27(158):571–4 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Fibroblast response to rapid decompression and hyperbaric oxygenation. Piepmeier EH, et al. **Aviat Space Environ Med** 1999 Jun;70(6):589–93

Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. Rump AF, et al. **Aviat Space Environ Med** 1999 Aug;70(8):769–72

Hyperbaric chamber–related decompression illness in a patient with asymptomatic pulmonary sarcoidosis. Tetzlaff K, et al. **Aviat Space Environ Med** 1999 Jun;70(6):594–7

Hyperbaric oxygen therapy. Complication rates are much lower than author suggest [letter; comment] Trytko BE, et al. **BMJ** 1999 Apr 17;318(7190):1077–8. Comment on: BMJ 1998 Oct 24;317(7166):1140–3.

Hyperbaric oxygen therapy elicits acute arthritis attack and exacerbation of infection in a patient with infected tophaceous gout and vascular insufficiency [letter] Kung YY, et al. **Clin Exp Rheumatol** 1998 Nov–Dec;16(6):764

Rapid progression of squamous cell carcinoma of the cervix after hyperbaric oxygenation. Wang PH, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):89–91

Hyperbaric oxygen in vivo accelerates the loss of cytoskeletal proteins and MIP26 in guinea pig lens nucleus. Padgaonkar VA, et al. **Exp Eye Res** 1999 Apr;68(4):493–504

Attenuation of brain hyperbaric oxygen toxicity by fasting is not related to ketosis. Chavko M, et al. **Undersea Hyperb Med** 1999 Summer;26(2):99–103

ECONOMICS

Lessons from a life in surgery. I. Do you want the high figure or the low? Thompson JC. **Surgery** 1999 Mar;125(3):345–6

HISTORY

Hyperbaric oxygenation. 1965 [classical article] Rendell–Baker L, et al. **Int Anesthesiol Clin** 1999 Winter; 37(1):137–67

INSTRUMENTATION

Operational use and patient care in the monoplace hyperbaric chamber. Weaver LK. **Respir Care Clin N Am** 1999 Mar; 5(1):51–92 (73 ref.)

[Oxygen treatment methods—a critical analysis of established and controversial procedures (II)] Lutz J. **Versicherungsmedizin** 1998 Oct 1;50(5):190–4 (24 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Three cases of spinal decompression sickness treated by U.S. Navy Treatment Table 7. Ito M, et al. **Aviat Space Environ Med** 1999 Feb;70(2):141–5

Effects of hyperbaric oxygen exposure on a zymosan–induced shock model [see comments] Luongo C, et al. **Crit Care Med** 1998 Dec;26(12):1972–6. Comment in: Crit Care Med 1998 Dec;26(12):1932–3.

Evaluation of ozonated oxygen in an experimental animal model of osteomyelitis as a further treatment option for skull–base osteomyelitis. Steinhart H, et al. **Eur Arch Otorhinolaryngol** 1999;256(3):153–7

Carbon monoxide poisoning treated with hyperbaric oxygen: metabolic acidosis as a predictor of treatment requirements. Turner M, et al. **J Accid Emerg Med** 1999 Mar;16(2):96–8

Analgesic effect of hyperbaric oxygen for pain caused by cancer treatment. Krahn MJ, et al. **J Palliat Care** 1999 Summer;15(2):53–5

Hyperbaric oxygen treatment: a brief overview of a controversial topic. Sheridan RL, et al. **J Trauma** 1999 Aug; 47(2):426–35 (125 ref.)

Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Unfortunate methodological flaws [letter; comment] Gorman DF. **Med J Aust** 1999 Jun 7;170(11):563; discussion 564–5. Comment on: Med J Aust 1999 Mar 1;170(5):203–10.

Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial [see comments] Scheinkestel CD, et al. **Med J Aust** 1999 Mar 1;170(5):203–10 (52 ref.). Comment in: Med J Aust 1999 Mar 1;170(5):197–9. Comment in: Med J Aust 1999 Jun 7;170(11):563; discussion 564–5. Comment in: Med J Aust 1999 Jun 7;170(11):563–4; discussion 564–5. Comment in: Med J Aust 1999 Jun 7;170(11):564–5. Comment in: ACP J Club 1999 Jul–Aug;131(1):11.

Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Was the best treatment protocol used? [letter; comment] Unsworth IP. **Med J Aust** 1999 Jun 7;170(11):564–5. Comment on: Med J Aust 1999 Mar 1;170(5):203–10.

Long–term effect of hyperbaric oxygenation treatment on chronic distressing tinnitus. Tan J, et al. **Scand Audiol** 1999; 28(2):91–6

Limb–threatening necrotizing alternariosis salvaged by adjunctive hyperbaric oxygen therapy. Lee SS, et al. **Scand J Infect Dis** 1998;30(2):194–6

Treatment of radiation proctitis with hyperbaric oxygen: what is the optimal number of HBO treatments? Carl UM, et al. **Strahlenther Onkol** 1998 Sep;174(9):482–3 (11 ref.)

Effect of hyperbaric oxygen on human skin cells in culture and in human dermal and skin equivalents. Dimitrijevich SD, et al. **Wound Repair Regen** 1999 Jan–Feb;7(1):53–64

[The dosage of hyperbaric oxygen therapy in patients with sudden hearing loss] Lu X, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Sep; 11(9):399–401 (Eng. Abstr.) **(Chi)**

[Hyperbaric oxygen in vertebro–basilar ischemia (letter; comment)] Martínez–Arencibia RL, et al. **Rev Neurol** 1998 Sep;27(157):521. Comment on: Rev Neurol 1998 Jan;26(149):106–13. **(Spa)**

[Hyperbaric oxygenation: a promising treatment for Binswanger's disease (editorial; comment)] Román GC. **Rev Neurol** 1999 Apr 1–15;28(7):707 (15 ref.). Comment on: Rev Neurol 1999 Apr 1–15;28(7):655–60. **(Spa)**

[Hyperbaric oxygenation in subcortical frontal syndrome due to small artery disorders with leukoaraiosis (see comments)] Vila JF, et al. **Rev Neurol** 1999 Apr 1–15;28(7):655–60 (Eng. Abstr.). Comment in: Rev Neurol 1999 Apr 1–15;28(7):707.

HYPERBARIC OXYGENATION

(Spa)
[The efficacy of complex treatment of an acute calculous pyelonephritis] Iantsalovs'kyi OI, et al. **Klin Khir** 1998; (6):52–3 (Ukr)

PSYCHOLOGY

Personality patterns of anxiety during occupational deep dives with long-term confinement in hyperbaric chamber. Abraini JH, et al. **J Clin Psychol** 1998 Oct;54(6):825–30

UTILIZATION

Osteoradionecrosis and hyperbaric oxygen [letter; comment] Schwartz HC. **Br J Oral Maxillofac Surg** 1999 Apr; 37(2):150–1. Comment on: Br J Oral Maxillofac Surg 1996 Oct;34(5):424–7.
Customers lining up for high-cost hyperbaric therapy. Kent H. **CMAJ** 1999 Apr 6;160(7):1043
Oral implant rehabilitation in irradiated patients without adjunctive hyperbaric oxygen. Andersson G, et al. **Int J Oral Maxillofac Implants** 1998 Sep–Oct;13(5):647–54
British Hyperbaric Association carbon monoxide database, 1993–96. Hamilton-Farrell MR. **J Accid Emerg Med** 1999 Mar;16(2):98–103

HYPERBETALIPOPROTEINEMIA see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERBILIRUBINEMIA

BLOOD

Genetic basis of fasting hyperbilirubinemia [letter; comment] Ishihara T, et al. **Gastroenterology** 1999 May;116(5):1272. Comment on: Gastroenterology 1997 Nov;113(5):1707–13.

CHEMICALLY INDUCED

An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Brown MC. **Chemotherapy** 1999 Sep–Oct;45(5):392–5 (6 ref.)
Itraconazole and HIV protease inhibitors: an important interaction [letter] MacKenzie-Wood AR, et al. **Med J Aust** 1999 Jan 4;170(1):46–7
Alteration in bilirubin excretion in individuals chronically exposed to arsenic in Mexico. Hernández-Zavala A, et al. **Toxicol Lett** 1998 Oct 15;99(2):79–84

CLASSIFICATION

[Benign hyperbilirubinemias] Vaev IV, et al. **Klin Med (Mosk)** 1999;77(6):9–14 (42 ref.) (Rus)

COMPLICATIONS

Late neurological sequelae of non-hemolytic hyperbilirubinemia of healthy term neonates. Grimmer I, et al. **Acta Paediatr** 1999 Jun;88(6):661–3
Glucose-6-phosphate dehydrogenase deficiency: why girls are affected? [letter; comment] Goyal R. **Indian Pediatr** 1998 Jul;35(7):688–9. Comment on: Indian Pediatr 1998 Jan;35(1):52–5.
Bilirubin pigmentation of human teeth caused by hyperbilirubinemia. Watanabe K, et al. **J Oral Pathol Med** 1999 Mar;28(3):128–30
Hyperbilirubinemia associated with a cystic abdominal mass in a 6-week-old girl: case report. Schleef J, et al. **Pediatr Surg Int** 1998 Dec;14(3):224–6
Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase- deficient newborns [letter] Kaplan M, et al. **Pediatrics** 1999 Feb;103(2):536–7
[An emergent coronary artery bypass grafting to total occlusion of all three coronary arteries in a patient with severe hyperbilirubinemia] Kaneda K, et al. **Kyobu Geka** 1998 Nov;51(12):1013–6 (Eng. Abstr.) (Jpn)

CONGENITAL see HYPERBILIRUBINEMIA, HEREDITARY

DIAGNOSIS

Transcutaneous measurement of hyperbilirubinaemia: comparison of the Minolta jaundice meter and the Ingram icterometer. Bilgen H, et al. **Ann Trop Paediatr** 1998 Dec; 18(4):325–8
Dubin-Johnson syndrome as a cause of neonatal jaundice: the importance of coproporphyrins investigation. Haimi-Cohen Y, et al. **Clin Pediatr (Phila)** 1998 Aug; 37(8):511–3
Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns [see comments] Bhutani VK, et al. **Pediatrics** 1999 Jan;103(1):6–14. Comment in: Pediatrics 1999 Feb;103(2):493–5.
Predicting hyperbilirubinemia in newborns: the importance of timing [comment] Maisels MJ, et al. **Pediatrics** 1999 Feb; 103(2):493–5. Comment on: Pediatrics 1999 Jan;103(1):6–14.
[Hyperbilirubinemia in full-term newborns. Predictive factors] Carbonell Estrany X, et al. **An Esp Pediatr** 1999 Apr;50(4):389–92 (Eng. Abstr.) (Spa)

DRUG THERAPY

Continuous administration of prostaglandin E1 for hyperbilirubinemia after extended right hepatic lobectomy [letter] Yamaguchi M, et al. **Can J Surg** 1999 Apr; 42(2):149–50
Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Martinez JC, et al. **Pediatrics** 1999 Jan; 103(1):1–5

ENZYMOLOGY

Beta-glucuronidase and hyperbilirubinemia in breast-Fed babies. La Torre A, et al. **Biol Neonate** 1999;75(2):82–4
Genetic basis of fasting hyperbilirubinemia [letter; comment] Ishihara T, et al. **Gastroenterology** 1999 May;116(5):1272. Comment on: Gastroenterology 1997 Nov;113(5):1707–13.
Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Maruo Y, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1224–7

EPIDEMIOLOGY

Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. Kaplan M, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):68–74

ETIOLOGY

Appearance of severe jaundice after radiometabolical treatment of thyrotoxicosis. Babini G, et al. **J Endocrinol Invest** 1999 Mar;22(3):209–11
Increased urinary excretion of bilirubin metabolites in association with hyperbilirubinemia after esophagectomy. Tsujinaka T, et al. **Surg Today** 1998;28(11):1119–23

GENETICS

Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Akaba K, et al. **Biochem Mol Biol Int** 1998 Sep; 46(1):21–6
Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Biondi ML, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):897–8
Co-inherited Gilbert's syndrome: a factor determining hyperbilirubinemia in homozygous beta-thalassemia. Galanello R, et al. **Haematologica** 1999 Feb;84(2):103–5
Intermittent jaundice in patients with acute leukaemia: a common mutation of the bilirubin uridine-diphosphate glucuronosyltransferase gene among Asians. Kimura T, et al. **J Inherit Metab Dis** 1999 Aug;22(6):747–53
Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. Kaplan M, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):68–74
Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Maruo Y, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1224–7

METABOLISM

Reduced folate derivatives are endogenous substrates for cMOAT in rats. Kusuhara H, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G789–96
Altered biliary bilirubin profile in patients with persistent hyperbilirubinaemia after hepatic resection: analysis of bile bilirubin subfractions by high-performance liquid chromatography [see comments] Ishiyama S, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):709–14. Comment in: J Gastroenterol Hepatol 1998 Jul;13(7):673–4.

PREVENTION & CONTROL

Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase- deficient newborns [letter] Kaplan M, et al. **Pediatrics** 1999 Feb;103(2):536–7

RADIONUCLIDE IMAGING

Evaluation of 99mTc-mercaptoacetyltriglycine-biocytin as a new hepatobiliary imaging agent in mice coinjected with bilirubin. Kim M, et al. **Nucl Med Biol** 1999 Jan;26(1):43–9

SURGERY

Improvement of the effect of hepatocyte isograft in the Gunn rat by cotransplantation of islets of Langerhans. Genin B, et al. **J Pediatr Surg** 1999 Feb;34(2):321–4

THERAPY

Nutrition and jaundice: hold the bottle, keep the breast [letter; comment] Hertz GS. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):1002–3. Comment on: Arch Pediatr Adolesc Med 1999 Feb;153(2):184–8.
Three different hepatocyte transplantation techniques for enzyme deficiency disease and acute hepatic failure. te Velde AA, et al. **Artif Organs** 1992 Oct;16(5):522–6
Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion. Mertens PR, et al. **Blood Purif** 1998;16(6):341–8
Linking multiple heterogeneous data sources to practice guidelines. van Wingerde FJ, et al. **Proc AMIA Symp** 1998; :391–5
Postoperative management following massive hepatectomy in a patient with Dubin-Johnson syndrome: report of a case. Ueno S, et al. **Surg Today** 1998;28(12):1274–8
Bilirubin adsorbent column for plasma perfusion. Takenaka Y. **Ther Apher** 1998 May;2(2):129–33 (25 ref.)
[Plasma separation and bilirubin adsorption therapy in excessive hyperbilirubinemia after liver transplantation] Ott R, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1563–5 (Eng. Abstr.) (Ger)

VETERINARY

Effects of haemolysis, lipaemia and bilirubinaemia on an enzyme-linked immunosorbent assay for cortisol and free thyroxine in serum samples from dogs. Lucena R, et al. **Vet J** 1998 Sep;156(2):127–31

HYPERBILIRUBINEMIA, HEREDITARY

The hereditary hyperbilirubinaemias. Nowicki MJ, et al. **Baillieres Clin Gastroenterol** 1998 Jun;12(2):355–67 (47 ref.)

DIAGNOSIS

Clinical quiz. Dubin-Johnson syndrome or Rotor syndrome. Teh CP, et al. **Pediatr Nephrol** 1999 Sep;13(7):627–8

GENETICS

Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. Monaghan G, et al. **J Pediatr** 1999 Apr;134(4):441–6

METABOLISM

Decreased pancreatic exocrine function in the mutant Eisai hyperbilirubinemic rat (EHBR). Inagaki T, et al. **Pancreas** 1999 Mar;18(2):172–9

HYPERBILIRUBINEMIA, NEONATAL see **JAUNDICE, NEONATAL**

HYPERCALCEMIA

A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Larsson P, et al. **Clin Exp Immunol** 1998 Nov;114(2):277–83
Hypercalcemia of the newborn: etiology, evaluation, and management. Rodd C, et al. **Pediatr Nephrol** 1999 Aug; 13(6):542–7 (35 ref.)
[Hypercalcemia: etiology, diagnosis, treatment] Essig M, et al. **Rev Prat** 1998 Sep 15;48(14):1581–5 (0 ref.) (Fre)
[Clinical features of hypercalcemia] Nagata N. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1921–7 (24 ref.) (Jpn)

BLOOD

Comparison of two immunoradiometric assays for parathyroid hormone-related protein in the evaluation of cancer patients with and without hypercalcemia. de Miguel F, et al. **Clin Chim Acta** 1998 Oct;277(2):171–80
Parathyroid hormone related protein and carcinoma of the penis: paraneoplastic hypercalcemia. Dorfinger K, et al. **J Urol** 1999 May;161(5):1570
Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. Vlasveld LT, et al. **Neth J Med** 1999 Jan;54(1):21–6

CHEMICALLY INDUCED

Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol [letter] Georgiou S, et al. **Acta Derm Venereol** 1999 Jan;79(1):86
Transient foscarnet-induced hypercalcaemia [letter] Barba R, et al. **AIDS** 1998 Oct 1;12(14):1930–1
Retinoid-induced hypercalcemia in a patient with kaposi sarcoma associated with acquired immunodeficiency syndrome. Aboulafia DM, et al. **Am J Clin Oncol** 1998 Oct;21(5):513–7
Life-threatening tamoxifen-induced hypercalcaemia. Mulvenna PM, et al. **Clin Oncol (R Coll Radiol)** 1999; 11(3):193–5
Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology. Lee KW, et al. **Conn Med** 1999 Jul;63(7):399–403 (24 ref.)
Ganciclovir-associated hypercalcemia in a renal transplant patient. Georgiev OP, et al. **Int J Artif Organs** 1998 Nov; 21(11):702–4
Lithium, hypercalcemia, and arrhythmia [letter] Wolf ME, et al. **J Clin Psychopharmacol** 1998 Oct;18(5):420–3
Effect of lithium maintenance therapy on thyroid and parathyroid function. Kusalic M, et al. **J Psychiatry Neurosci** 1999 May;24(3):227–33
The irritable patient [see comments] Argilés A, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2481–3. Comment in: Nephrol Dial Transplant 1998 Oct;13(10):2483–4.
Iatrogenic hypercalcaemia, hypokalaemia and metabolic alkalosis in a lady with vena cava thrombosis--beware of overzealous diuretic treatment. Böhmig GA, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):782–4
Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol. Boots JM, et al. **Neth J Med** 1999 Jan;54(1):16–20
[Severe hypercalcemia in a patient treated with fluconazole and rifampicin (letter)] Bani-Sadr F, et al. **Presse Med** 1998 May 16;27(18):860 (Fre)

[Idiopathic calcium lithiasis. Diuresis treatment] Pruna A, et al. **Presse Med** 1998 Feb 7;27(5):225–9 (33 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Humoral hypercalcemia associated with a uterine fibroid [letter] Ravakhah K, et al. **Ann Intern Med** 1999 Apr 20; 130(8):702

Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor. Hotta M, et al. **Endocr J** 1998 Dec;45(6):773–8

Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes inspidus and hyperthyroidism. Wada S, et al. **Intern Med** 1999 Jun; 38(6):486–90

A dose-finding study of zoledronate in hypercalcemic cancer patients. Body JJ, et al. **J Bone Miner Res** 1999 Sep; 14(9):1557–61

Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma. Kato N, et al. **J Dermatol** 1999 Jun;26(6):352–8

Parathyroid hormone related protein and carcinoma of the penis: paraneoplastic hypercalcemia. Dorfinger K, et al. **J Urol** 1999 May;161(5):1570

Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. Kakizaki S, et al. **Jpn J Clin Oncol** 1998 Sep;28(9):563–6 (18 ref.)

Hypercalcaemic acute renal failure--a complication of granuloma annulare elastolyticum. Ehehalt R, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2125–7

Hypercalcaemia and paracoccidioidomycosis. Silva LC, et al. **Trans R Soc Trop Med Hyg** 1998 Mar–Apr;92(2):187

[Idiopathic calcium lithiasis. Practical guide for dietary measures prescriptions (published erratum appears in Presse Med 1998 Mar 7;27(9):415)] Achard JM, et al. **Presse Med** 1998 Feb 7;27(5):230–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic calcium lithiasis. Dietary correction of metabolic risk factors. Physiopathological bases] Bataille P, et al. **Presse Med** 1998 Feb 7;27(5):218–24 (63 ref.) (Eng. Abstr.) **(Fre)**

[Hypercalcemia associated with hyperleukocytosis, a new paraneoplastic syndrome] Peyrade F, et al. **Presse Med** 1998 Apr 11;27(14):658–60 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Elderly man presenting with asymptomatic hypercalcemia [clinical conference] Nuckols DA, et al. **Am J Otolaryngol** 1998 Sep–Oct;19(5):311–5

Electrocardiographic abnormalities in combined hypercalcaemia and hypokalaemia--case report. Chia BL, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):567–9 (6 ref.)

Hypercalcemic cardiomyopathy associated with primary hyperparathyroidism mimicking primary obstructive hypertrophic cardiomyopathy. Demers C, et al. **Can J Cardiol** 1998 Nov;14(11):1397–400 (19 ref.)

A 48-year-old woman with peripheral neuropathy, hypercalcemia, and pulmonary infiltrates. Donnelly TJ, et al. **Chest** 1998 Oct;114(4):1205–9

Severe hyperparathyroidism with hypercalcemia associated with chronic renal failure at pre-dialysis stage. Takasaki I, et al. **Endocr J** 1999 Feb;46(1):167–71

Renal cell carcinoma with hypercalcemia complicating a pregnancy: case report and review of the literature. Usta IM, et al. **Eur J Gynaecol Oncol** 1998;19(6):584–7 (27 ref.)

Symptomatic hypercalcemia in the first months of life: calcium-regulating hormones and treatment. Ghirri P, et al. **J Endocrinol Invest** 1999 May;22(5):349–53

Hypercalcaemia in sarcoidosis. Young C, et al. **Lancet** 1999 Jan 30;353(9150):374

Primary multifocal lymphoma of bone presenting as hypercalcemic crisis: report of a rare manifestation of extranodal lymphoma. Evron E, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):197–200

[Somnolence and vomiting in a patient after parathyroid gland carcinoma surgery] Geier A, et al. **Internist (Berl)** 1999 Mar;40(3):311–5 **(Ger)**

[Chronic dermatosis and hypercalcemia] Truniger B. **Schweiz Med Wochenschr** 1998 Oct 3;128(40):1519 **(Ger)**

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Urologe A** 1999 May;38(3):285–95 (6 ref.) **(Ger)**

DIET THERAPY

[Idiopathic calcium lithiasis. Dietary correction of metabolic risk factors. Physiopathological bases] Bataille P, et al. **Presse Med** 1998 Feb 7;27(5):218–24 (63 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The use of etidronate in therapy-resistant hypercalcemia. Oğuz A, et al. **Acta Oncol** 1999;38(1):125–7

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Akatsu T, et al. **Bone** 1998 Dec;23(6):495–8

Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer. El Abdaimi K, et al. **Cancer Res** 1999 Jul 15;59(14):3325–8

Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Sims EC, et al. **Clin Oncol (R Coll Radiol)** 1998;10(6):407–9

Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy [letter] De Schepper J, et al. **Eur J Pediatr** 1999 Sep;158(9):765–6

Comparison of pharmacokinetics of clodronate after single and repeated doses. Ylitalo P, et al. **Int J Clin Pharmacol Ther** 1999 Jun;37(6):294–300

A dose-finding study of zoledronate in hypercalcemic cancer patients. Body JJ, et al. **J Bone Miner Res** 1999 Sep; 14(9):1557–61

Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia. Endo K, et al. **J Bone Miner Res** 1998 Sep;13(9):1378–83

Inability of short-term, low-dose hydroxychloroquine to resolve vitamin D-mediated hypercalcemia in patients with B-cell lymphoma. Adams JS, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):799–801

Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn [see comments] Rice AM, et al. **J Pediatr** 1999 Mar;134(3):349–51 (18 ref.). Comment in: J Pediatr 1999 Mar;134(3):264–7.

The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication. Lee DC, et al. **J Toxicol Clin Toxicol** 1998;36(7):719–21

Efficacy of bisphosphonate for hypercalcemia in patients with adult T-cell leukemia [letter] Sadamori N, et al. **Leuk Res** 1999 Feb;23(2):199–200

The use of pamidronate in three children with renal disease. Sellers E, et al. **Pediatr Nephrol** 1998 Nov;12(9):778–81

Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Attard TM, et al. **Pediatr Transplant** 1998 May;2(2):157–9

[Idiopathic calcium lithiasis. Practical guide for dietary measures prescriptions (published erratum appears in Presse Med 1998 Mar 7;27(9):415)] Achard JM, et al. **Presse Med** 1998 Feb 7;27(5):230–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Bisphosphonates. A neu therapy principle in calcium and bone metabolism disorders] Raue F. **Internist (Berl)** 1999 Apr;40(4):448–55 (61 ref.) **(Ger)**

[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate] Koshida H, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):833–6 (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Familial hypocalciuric hypercalcaemia in Australia [comment] Gutteridge DH, et al. **Calcif Tissue Int** 1999 May;64(5):456 (3 ref.). Comment on: Calcif Tissue Int 1997 Jul;61(1):36–8.

Prevalence of hypercalcaemia in normal and in hospital populations. Frølich A. **Dan Med Bull** 1998 Sep;45(4):436–9 (39 ref.)

Hypercalcaemia in patients with newly diagnosed tuberculosis in Malaysia. Liam CK, et al. **Int J Tuberc Lung Dis** 1998 Oct;2(10):818–23

Hypercalcemia in patients with esophageal cancer. Geddes LG Jr, et al. **J Exp Clin Cancer Res** 1999 Mar;18(1):61–2

ETIOLOGY

Significance of parathyroid hormone-related protein as a factor stimulating bone resorption and causing hypercalcemia in myeloma. Tsujimura H, et al. **Am J Hematol** 1998 Oct;59(2):168–70

Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Barhoum M, et al. **Am J Med Sci** 1999 Sep;318(3):203–5

Immunohistochemical detection of parathyroid hormone-related protein in a cutaneous squamous cell carcinoma causing humoral hypercalcemia of malignancy. Crespo M, et al. **Arch Pathol Lab Med** 1999 Aug; 123(8):725–30

Case study in hypercalcaemia. Phillips PJ, et al. **Aust Fam Physician** 1999 Apr;28(4):377–8

Hypercalcaemia caused by Pneumocystis carinii pneumonia while in leukaemic remission [letter] Mills AK, et al. **Aust N Z J Med** 1999 Feb;29(1):102–3

Calcitriol mediated hypercalcaemia in a T cell rich B cell lymphoma [letter] Moore JJ, et al. **Aust N Z J Med** 1998 Aug;28(4):479–80

Asymptomatic hypercalcemia [letter; comment] Sarshar M. **Cleve Clin J Med** 1998 Oct;65(9):500. Comment on: Cleve Clin J Med 1998 May;65(5):237–40.

Asymptomatic hypercalcemia in subcutaneous fat necrosis. Lum CK, et al. **Clin Pediatr (Phila)** 1999 Sep;38(9):547–50

Recurrent clear cell carcinoma of the ovary changing into producing parathyroid hormone-related protein (PTH-rP) with hypercalcemia. Koshiyama M, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):227–9

Hypercalcemia in malignant paraganglioma due to parathyroid hormone-related protein. Loh K, et al. **Horm Res** 1998;50(4):217–21

Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Yeung SC, et al. **Horm Res** 1998; 49(6):288–91

Manifestations of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. Chu CW, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):807–10

Lytic skull lesions and symptomatic hypercalcaemia in bone marrow sarcoidosis [letter] Slart RM, et al. **J Intern Med** 1999 Jul;246(1):117–20

Power Doppler imaging findings in multilocular giant parathyroid adenoma which caused hypercalcaemic crisis. Wang Q, et al. **J Laryngol Otol** 1998 Aug;112(8):796–9

Hypercalcemia associated with squamous cell carcinoma of the renal pelvis. Cadeddu JA, et al. **J Urol** 1998 Nov; 160(5):1798 (3 ref.)

Brief report: Medulloblastoma with widespread skeletal metastases presenting with hypercalcemia. Akyüz C, et al. **Med Pediatr Oncol** 1999 Aug;33(2):126–8

Ovarian small cell carcinoma of the hypercalcemic type in a 14 month old: the youngest reported case. Florell SR, et al. **Med Pediatr Oncol** 1999 Apr;32(4):304–7

Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein. Kageshita T, et al. **Melanoma Res** 1999 Feb;9(1):69–73

Hypercalcemia and hyperparathyroidism after renal transplantation [letter] Apaydin S, et al. **Nephron** 1999; 81(3):364–5

Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia. Vlasveld LT, et al. **Neth J Med** 1999 Jan;54(1):21–6

Lessons from an unusual case: malignancy associated hypercalcemia, pancreatitis and respiratory failure due to ARDS. Wymenga AN, et al. **Neth J Med** 1999 Jan; 54(1):27–30

Metastatic pulmonary calcification with ossification in a child with acute lymphoblastic leukemia. Cohen MC, et al. **Pediatr Pulmonol** 1999 Feb;27(2):134–7

Small-cell carcinoma of the ovary of the hypercalcemic type in an 8-year-old girl. Schleef J, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):431–4

Low prevalence of hypercalcemia in Korean dialysis patients: possible role of dietary phosphate intake. Park MS, et al. **Perit Dial Int** 1999 May–Jun;19(3):270–3

Dysphagia and hypercalcaemia. Balcombe NR. **Postgrad Med J** 1999 Jun;75(884):373–4

Hypercalcaemia and abdominal pain. Scott-Coombes D, et al. **Postgrad Med J** 1998 Jun;74(872):377–8

Bone marrow examinations as final clue to diagnosis of hypercalcemia: report of two cases. Lam KK, et al. **Ren Fail** 1999 Jan;21(1):101–5

Hypercalcemia and multiple pulmonary nodules. Zurkirchen M, et al. **Respiration** 1998;65(4):331–2

Parathyroid cyst: an uncommon cause of a palpable neck mass and hypercalcemia. Pinney SP, et al. **West J Med** 1999 Feb;170(2):118–20

[Esophageal epidermoid carcinoma manifesting as a humoral, malignant hypercalcemia in a patient with cirrhosis (letter)] Viguier J, et al. **Gastroenterol Clin Biol** 1998 Nov; 22(11):972–4 **(Fre)**

[A recalcitrant hypercalcemia] Jégo A, et al. **Rev Med Interne** 1998;19 Suppl 2:299s–300s **(Fre)**

[Extraparathyroid hypercalcemia] Rizzoli R, et al. **Rev Prat** 1998 Jun 1;48(11):1197–200 (Eng. Abstr.) **(Fre)**

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Internist (Berl)** 1998 Aug;39(8):825–30 (6 ref.) **(Ger)**

[Sarcoidosis with hypercalcemia, urolithiasis, renal insufficiency, and heart failure] Nagayama M, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):571–6 (Eng. Abstr.) **(Jpn)**

[Hypercalcemia caused by tumors] Tomašević Z, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):206–15 (60 ref.) **(Scc)**

GENETICS

Localization of familial benign hypercalcemia, Oklahoma variant (FBHOk), to chromosome 19q13. Lloyd SE, et al. **Am J Hum Genet** 1999 Jan;64(1):189–95

Effect of the viable-yellow (A(vy)) agouti allele on skin tumorigenesis and humoral hypercalcemia in v-Ha-ras transgenic TGxAC mice. Hansen LA, et al. **Carcinogenesis** 1998 Oct;19(10):1837–45

An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor. Chikatsu N, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):537–43

Extracellular "calcistat" in health and disease [comment] Pearce S. **Lancet** 1999 Jan 9;353(9147):83–4. Comment on: Lancet 1999 Jan 9;353(9147):112–5.

METABOLISM

Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. Earm JH, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2181–93

Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Brandi L, et al. **J Intern Med** 1998 Aug;244(2):121–31

Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein. Kageshita T, et al. **Melanoma Res** 1999 Feb;9(1):69–73

Dependence of humoral hypercalcemia of malignancy on parathyroid hormone-related protein expression in the

HYPERCALCEMIA

canine anal sac apocrine gland adenocarcinoma (CAC-8) nude mouse model. Gröne A, et al. **Vet Pathol** 1998 Sep; 35(5):344–51

NURSING

Hypercalcemia. Barnett ML. **Semin Oncol Nurs** 1999 Aug; 15(3):190–201 (53 ref.)

PHYSIOPATHOLOGY

Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Neunteufl T, et al. **Cardiovasc Res** 1998 Nov;40(2):396–401

PREVENTION & CONTROL

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. Morony S, et al. **J Bone Miner Res** 1999 Sep;14(9):1478–85

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. Body JJ, et al. **J Clin Oncol** 1998 Dec;16(12):3890–9 (68 ref.)

RADIONUCLIDE IMAGING

Technetium-99m-methylene disphosphonate (MDP) bone scan hypercalcemia. Basoglu T, et al. **J Nucl Med** 1998 Dec;39(12):2034, 5A

REHABILITATION

Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Massagli TL, et al. **Arch Phys Med Rehabil** 1999 Sep;80(9):998–1000

THERAPY

Symptomatic hypercalcemia in the first months of life: calcium-regulating hormones and treatment. Ghirri P, et al. **J Endocrinol Invest** 1999 May;22(5):349–53

Control of hypercalcaemia of parathyroid carcinoma by immunisation [see comments] Bradwell AR, et al. **Lancet** 1999 Jan 30;353(9150):370–3. Comment in: Lancet 1999 Jan 30;353(9150):340. Comment in: Lancet 1999 Apr 3;353(9159):1188–9.

Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Kebebew E, et al. **Surg Oncol Clin N Am** 1998 Oct;7(4):721–48 (89 ref.)

URINE

Raised urinary pyridinium cross-links in humoral hypercalcaemia of malignancy. Toori KU, et al. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):107–8

VETERINARY

Rumen motility during induced hyper- and hypocalcaemia. Jørgensen RJ, et al. **Acta Vet Scand** 1998;39(3):331–8

Hypercalcemia and parathyroid hormone-related protein in a dog with undifferentiated nasal carcinoma. Anderson GM, et al. **Can Vet J** 1999 May;40(5):341–2

Hypercalcemia and calcium oxalate urolithiasis in cats: a report of five cases. McClain HM, et al. **J Am Anim Hosp Assoc** 1999 Jul-Aug;35(4):297–301

VIROLOGY

Hypercalcemia as an early sign of lymphoma in a patient with acquired immunodeficiency syndrome (AIDS). Al-Tawfiq JA, et al. **South Med J** 1999 Sep;92(9):924–6

HYPERCAPNIA

Use of permissive hypercapnia in the ventilation of infants with respiratory syncytial virus infection. Tibby SM, et al. **Eur J Pediatr** 1999 Jan;158(1):42–5

Permissive hypercapnia in ARDS. Mancebo J. **Intensive Care Med** 1998 Dec;24(12):1339–40

[Effects of permissive hypercapnia on cardiopulmonary function in acute lung injury model] Huang J, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Apr; 20(2):76–9 (Eng. Abstr.) **(Chi)**

[Functional homology in response of human cardiorespiratory system to effects of hypoxia and hypercapnia under different environmental conditions] Elfimov AI, et al. **Med Tr Prom Ekol** 1999;(1):28–36 (Eng. Abstr.) **(Rus)**

BLOOD

Permissive hypercapnia during thoracic anaesthesia. Morisaki H, et al. **Acta Anaesthesiol Scand** 1999 Sep;43(8):845–9

Acute hypercapnia increases the oxygen-carrying capacity of the blood in ventilated dogs. Torbati D, et al. **Crit Care Med** 1998 Nov;26(11):1863–7

[Acute hypercapnia increases the permeability of blood/cerebrospinal fluid barrier for gentamicin in rabbits under general anesthesia] Pakulski C, et al. **Neurol Neurochir Pol** 1998 Jul-Sep;32(4):781–92 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis. Bradley S, et al. **Chest** 1999 Sep;116(3):647–54

Deep breathing and awake apnoea in a patient who had recurrent hypoxaemia and hypercapnia without sleep apnoea. Chin K, et al. **Eur Respir J** 1998 Sep;12(3):739–41

Prolonged severe hypercapnia complicating near fatal asthma in a 35-year-old woman [see comments] Adnet F, et al. **Intensive Care Med** 1998 Dec;24(12):1335–8. Comment in: Intensive Care Med 1999 Apr;25(4):425.

DIAGNOSIS

Transcutaneous PCO2 monitoring in the evaluation of hyperventilation of patients with recurrent nerve paralysis. Miyazaki H, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S47–50

[Sensitivity of the respiratory center to carbon dioxide during prolonged exposure of humans to gas environment with unchanging level of hypercapnia] Bragin LKh, et al. **Aviakosm Ekolog Med** 1999;33(2):19–21 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effect of chronic furosemide administration on acid-base balance in patients with chronic hypercapnic respiratory failure. Urano T, et al. **Tokai J Exp Clin Med** 1998 Oct; 23(4):193–7

ETIOLOGY

Fear of hypercapnia is leading to inadequate oxygen treatment [letter] Lavery GG. **BMJ** 1999 Mar 27; 318(7187):872

A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Forman D, et al. **Chest** 1999 Mar;115(3):899–901

Late onset of subcutaneous emphysema and hypercarbia following laparoscopic cholecystectomy. Santana A, et al. **Chest** 1999 May;115(5):1468–71

Tidal volume, PaCO2, and lung injury [editorial; comment] Gregory GA, et al. **Crit Care Med** 1998 Oct;26(10):1632–3 (16 ref.). Comment on: Crit Care Med 1998 Oct;26(10):1690–7.

Distinctive features and long-term survival of reversible and chronic hypercapnic patients with COPD. Saryal S, et al. **Monaldi Arch Chest Dis** 1999 Jun;54(3):212–6

Non-invasive ventilation in hypercapnic respiratory failure secondary to sclerodermic chest wall restriction. Nageh TT, et al. **Respir Med** 1998 Sep;92(9):1170–2

[Mechanical ventilation therapy with permissive hypercapnia on ARDS] Xu L, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Apr; 20(2):72–5 (Eng. Abstr.) **(Chi)**

[Cardiorespiratory effects of laparoscopic surgery] Bazin JE. **Presse Med** 1998 Mar 7;27(9):388–93 (60 ref.) (Eng. Abstr.) **(Fre)**

[Review on the use of CO2 in laparoscopy surgery] Van Glabeke E, et al. **Prog Urol** 1998 Sep;8(4):586–9 (34 ref.) (Eng. Abstr.) **(Fre)**

[Excess caloric intake induced severe hypercapnia in a patient with Duchenne muscular dystrophy on noninvansive positive pressure ventilation] Matsumura T, et al. **Rinsho Shinkeigaku** 1998 Sep;38(9):822–5 (Eng. Abstr.) **(Jpn)**

METABOLISM

Nitric oxide and prostaglandin pathways interact in the regulation of hypercapnic cerebral vasodilatation. Heinert G, et al. **Acta Physiol Scand** 1999 Jul;166(3):183–93

Effect of prior O2 breathing on hypoxic hypercapnic ventilatory responses in humans. Masuda A, et al. **Adv Exp Med Biol** 1998;450:1–6

CO(2)-induced expression of c-fos in the nucleus of the solitary tract and the area postrema of developing swine. Sica AL, et al. **Brain Res** 1999 Aug 7;837(1–2):106–16

Influence of hypoxia and hypoxia/hypercapnia upon brain and blood peroxidative and glutathione status in normal weight and growth-restricted newborn piglets. Barth A, et al. **Exp Toxicol Pathol** 1998 Sep;50(4–6):402–10

Intraretinal oxygen distribution in the rat with graded systemic hyperoxia and hypercapnia. Yu DY, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):2082–7

Copper exposure impairs intra- and extracellular acid–base regulation during hypercapnia in the fresh water rainbow trout (Oncorhynchus mykiss). Wang T, et al. **J Comp Physiol [B]** 1998 Dec;168(8):591–9

Regulation of ventilation before and after sleep in patients with obstructive sleep apnoea. Fuse K, et al. **Respirology** 1999 Jun;4(2):125–30

Analysis of CO2 vasomotor reactivity and vessel diameter changes by simultaneous venous and arterial Doppler recordings. Valdueza JM, et al. **Stroke** 1999 Jan;30(1):81–6

[The influence of acute hypercapnia on the permeability of the blood–brain barrier for gentamycin under conditions of general anesthesia in rabbits] Pakulski C. **Ann Acad Med Stetin** 1998;44:285–96 (Eng. Abstr.) **(Pol)**

PATHOLOGY

In vitro responses of neurons in the periaqueductal gray to hypoxia and hypercapnia. Kramer JM, et al. **Brain Res** 1999 Jul 24;835(2):197–203

PHYSIOPATHOLOGY

Cerebrovascular reactivity in carotid artery occlusion: possible implications for surgical management of selected groups of patients. Silvestrini M, et al. **Acta Neurol Scand** 1999 Mar;99(3):187–91

Nitric oxide and prostaglandin pathways interact in the regulation of hypercapnic cerebral vasodilatation. Heinert G, et al. **Acta Physiol Scand** 1999 Jul;166(3):183–93

Phase relations between rhythmical forearm movements and breathing under normacapnic and hypercapnic conditions. Ebert D, et al. **Adv Exp Med Biol** 1998;450:101–10

The influence of hypercapnic hyperpnea on the interaction between breathing and finger tracking movements in humans. Rassler B, et al. **Adv Exp Med Biol** 1998;450:213–8

Chronic hypercapnia resets CO2 sensitivity of avian intrapulmonary chemoreceptors. Bebout DE, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R317–22

Nitric oxide differentially attenuates microvessel response to hypoxia and hypercapnia in injured lungs. Naoki K, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R181–9

Possible obligatory functions of cyclic nucleotides in hypercapnia-induced cerebral vasodilation in adult rats. Wang Q, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H480–7

NO and prostanoids: age dependence of hypercapniaand histamine-induced dilations of pig pial arterioles. Willis AP, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H299–307

Expiratory phase tracheal gas insufflation and pressure control in sheep with permissive hypercapnia. Imanaka H, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):49–54

Relationship between resting hypercapnia and physiologic parameters before and after lung volume reduction surgery in severe chronic obstructive pulmonary disease. Shade D Jr, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1405–11

Hypercapnic acidosis may attenuate acute lung injury by inhibition of endogenous xanthine oxidase. Shibata K, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1578–84

The divergent ventilatory and heart rate response to moderate hypercapnia in infants with apnoea of infancy. Katz-Salamon M, et al. **Arch Dis Child** 1998 Sep; 79(3):231–6

Cardiorenal effects of behavioral inhibition of breathing. Anderson DE. **Biol Psychol** 1998 Sep;49(1–2):151–63 (42 ref.)

Involvement of barium-sensitive K+ channels in endothelium-dependent vasodilation produced by hypercapnia in rat mesenteric vascular beds. Okazaki K, et al. **Br J Pharmacol** 1998 Sep;125(1):168–74

Calcium-dependent and ATP-sensitive potassium channels and the 'permissive' function of cyclic GMP in hypercapnia-induced pial arteriolar relaxation. Wang Q, et al. **Brain Res** 1998 May 18;793(1–2):187–96

Regional distribution of cerebral blood volume and cerebral blood flow in newborn piglets--effect of hypoxia/hypercapnia. Bauer R, et al. **Brain Res Dev Brain Res** 1999 Jan 11;112(1):89–98

Anemia, hypoxia and hypercapnia thresholds. Lessons from physiological limits in critically ill patients. Kavanagh BP. **Can J Anaesth** 1999 May;46(5 Pt 2):R145–55 (35 ref.) **(Eng, Fre)**

Ventilatory and metabolic effects of hypercapnia in conscious rats: AVP V1 receptor block. Walker JK, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):361–6

A pharmacologic study on CO2 responsiveness of intracranial pressure in rats with chronic hypercapnia. Kondo T, et al. **Chest** 1999 May;115(5):1402–6

Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Narkiewicz K, et al. **Circulation** 1999 Jul 20;100(3):262–7

Near infrared spectroscopy-measured changes in cerebral blood volume and cytochrome aa3 in newborn lambs exposed to hypoxia and hypercapnia, and ischemia: a comparison with changes in brain perfusion and O2 metabolism. Shadid M, et al. **Early Hum Dev** 1999 Jun; 55(2):169–82

The effects of intermittent exposure to hypoxia during endurance exercise training on the ventilatory responses to hypoxia and hypercapnia in humans. Katayama K, et al. **Eur J Appl Physiol** 1998 Aug;78(3):189–94

Phase-dependence of breathing and finger tracking movements during normocapnia and hypercapnia. Rassler B, et al. **Eur J Appl Physiol** 1999 Sep;80(4):324–32

Chronic hypercapnia should not exclude patients from lung volume reduction surgery. Wisser W, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):107–12

Near infrared spectroscopy and transcranial Doppler in monohemispheric stroke. Vernieri F, et al. **Eur Neurol** 1999; 41(3):159–62

Mouth occlusion pressure, CO2 response and hypercapnia in severe chronic obstructive pulmonary disease. Montes de Oca M, et al. **Eur Respir J** 1998 Sep;12(3):666–71

Acute effects of hypoxaemia, hyperoxaemia and hypercapnia on renal blood flow in normal and renal transplant subjects. Sharkey RA, et al. **Eur Respir J** 1998 Sep;12(3):653–7

Spike generation from dorsal roots and cutaneous afferents by hypoxia or hypercapnia in the rat in vivo. Pethö G, et al. **Exp Physiol** 1999 Jan;84(1):1–15

Prolonged severe hypercapnia complicating near fatal asthma [letter; comment] Jardin F. **Intensive Care Med** 1999 Apr; 25(4):425. Comment on: Intensive Care Med 1998 Dec;24(12):1335–8.

Regional differences in retinal vascular reactivity. Chung HS, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2448–53
Changes in respiratory timing induced by hypercapnia in maturing rats. Abu-Shaweesh JM, et al. **J Appl Physiol** 1999 Aug;87(2):484–90
Effect of nitric oxide synthase inhibition on hypercapnia-induced hypothermia and hyperventilation. Barros RC, et al. **J Appl Physiol** 1998 Sep;85(3):967–72
Dopamine, sensory discharge, and stimulus interaction with CO2 and O2 in cat carotid body. Buerk DG, et al. **J Appl Physiol** 1998 Nov;85(5):1719–26
Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. Greenberg HE, et al. **J Appl Physiol** 1999 Jan;86(1):298–305
Respiratory changes associated with rapid eye movements in normo- and hypercapnia during sleep. Schäfer T, et al. **J Appl Physiol** 1998 Dec;85(6):2213–9
Inhibition of dopamine release with simultaneous chemosensory excitation by hypercapnia with and without [Ca2+]0 in the cat carotid body. Rozanov C, et al. **J Auton Nerv Syst** 1998 Apr 30;69(2–3):184–9
The area postrema of newborn swine is activated by hypercapnia: relevance to sudden infant death syndrome? Ruggiero DA, et al. **J Auton Nerv Syst** 1999 May 28; 76(2–3):167–75
Moderate hypothermia reduces hypotensive, but not hypercapnic vasodilation of pial arterioles in rats. Irikura K, et al. **J Cereb Blood Flow Metab** 1998 Dec;18(12):1294–7
Hypercapnic cerebral blood flow in spontaneously hypertensive rats. Heinert G, et al. **J Hypertens** 1998 Oct; 16(10):1491–8
Multimodality monitoring during passive tilt and Valsalva maneuver under hypercapnia. Hetzel A, et al. **J Neuroimaging** 1999 Apr;9(2):108–12
Ventilatory responses to hypercapnia and hypoxia after 6 h passive hyperventilation in humans. Ren X, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):885–94
Role of the respiratory control system in the pathophysiology of hypercapnia. Gardner WN. **Monaldi Arch Chest Dis** 1998 Jun;53(3):281–6 (71 ref.)
Cerebral blood-flow responses to induced hypotension and to CO2 inhalation in patients with major cerebral artery occlusive disease: a positron-emission tomography study. Nishimura S, et al. **Neuroradiology** 1999 Feb;41(2):73–9
Effects of experimental hypercapnia on hippocampal long-term potentiation in anesthetized rats. Itoh Y, et al. **Neurosci Lett** 1999 Feb 5;260(3):201–3
Hypoxia- and hypercapnia-induced DC potential shifts in rat at the scalp and the skull are opposite in polarity to those at the cerebral cortex. Lehmenkühler A, et al. **Neurosci Lett** 1999 Jul 30;270(2):67–70
Changes in laryngeal muscle activities during hypercapnia in the cat [letter; comment] Kuna ST. **Otolaryngol Head Neck Surg** 1999 Mar;120(3):449. Comment on: Otolaryngol Head Neck Surg 1998 Apr;118(4):537–44.
Ventilatory, cardiovascular and metabolic responses to hypoxia and hypercapnia in the armadillo. Boggs DF, et al. **Respir Physiol** 1998 Aug;113(2):101–9
The effects of restraint on ventilatory responses to hypercapnia and hypoxia in adult mice. Dauger S, et al. **Respir Physiol** 1998 May;112(2):215–25
Determinants of the hypercapnic and hypoxic response in normal man. van Klaveren RJ, et al. **Respir Physiol** 1998 Aug;113(2):157–65
Regulation of ventilation before and after sleep in patients with obstructive sleep apnoea. Fuse K, et al. **Respirology** 1999 Jun;4(2):125–30
Regulation of intracranial pressure in the rat with chronic moderate hypercapnia. Kumagai M, et al. **Tokai J Exp Clin Med** 1998 Nov;23(5):221–3
[The effect of a repeated stay in a hypercapnic environment on the properties of the respiratory system] Pogodin MA, et al. **Fiziol Cheloveka** 1998 Nov–Dec;24(6):72–5 **(Rus)**
[Normal ventilatory response to hypoxia and hypercapnia at an altitude of 2240 meters] Vázquez-García JC, et al. **Rev Invest Clin** 1998 Jul–Aug;50(4):323–9 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Intravascular membrane oxygenator and carbon dioxide removal devices: a review of performance and improvements. Zwischenberger JB, et al. **ASAIO J** 1999 Jan–Feb;45(1):41–6 (24 ref.)

PSYCHOLOGY

Phase-dependence of breathing and finger tracking movements during normocapnia and hypercapnia. Rassler B, et al. **Eur J Appl Physiol** 1999 Sep;80(4):324–32

SURGERY

Improvements in lung function, exercise, and quality of life in hypercapnic COPD patients after lung volume reduction surgery. O'Brien GM, et al. **Chest** 1999 Jan;115(1):75–84

THERAPY

Expiratory washout versus optimization of mechanical ventilation during permissive hypercapnia in patients with severe acute respiratory distress syndrome. Richecoeur J, et al. **Am J Respir Crit Care Med** 1999 Jul;160(1):77–85
Arteriovenous extracorporeal carbon dioxide removal: a mathematical model and experimental evaluation. Conrad SA, et al. **ASAIO J** 1998 Jul–Aug;44(4):267–77
Non-invasive home ventilation in patients over 75 years of age: tolerance, compliance, and impact on quality of life. Janssens JP, et al. **Respir Med** 1998 Dec;92(12):1311–20
Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Simonds AK, et al. **Thorax** 1998 Nov;53(11):949–52

ULTRASONOGRAPHY

Analysis of CO2 vasomotor reactivity and vessel diameter changes by simultaneous venous and arterial Doppler recordings. Valdueza JM, et al. **Stroke** 1999 Jan;30(1):81–6

VETERINARY

Effects of hypercapnia on endocrine and metabolic responses to anaesthesia in ponies. Taylor PM. **Res Vet Sci** 1998 Jul–Aug;65(1):41–6

HYPERCHOLESTEREMIA see **HYPERCHOLESTEROLEMIA**

HYPERCHOLESTEROLEMIA

BLOOD

Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk. Handelman GJ, et al. **Am J Clin Nutr** 1999 Aug;70(2):247–51
A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Mensink RP, et al. **Am J Clin Nutr** 1999 Feb;69(2):213–9
Low-density lipoproteins supply phospholipid-bound arachidonic acid for platelet eicosanoid production. Dobner P, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E777–84
Lymphocyte T subset counts in children with hypercholesterolemia receiving dietary therapy. Moreno LA, et al. **Ann Nutr Metab** 1998;42(5):261–5
Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. Davidson MH, et al. **Arch Intern Med** 1999 Jun 28; 159(12):1331–8
Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Grundy SM, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1670–8 (64 ref.)
Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. Contacos C, et al. **Atherosclerosis** 1998 Nov;141(1):87–98
Influence of hypercholesterolemia and endothelin-3 pre-treatment on the effects of shear forces on platelet aggregation and cyclic GMP content. Gagnet C, et al. **Atherosclerosis** 1999 Mar;143(1):91–7
Diminished susceptibility to in vitro oxidation of low-density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content. Leonhardt W, et al. **Atherosclerosis** 1999 May;144(1):103–7
Increased metabolism of peroxynitrite-modified [125I] beta-VLDL by monocytes from hypercholesterolemic rabbits. da Silva EL, et al. **Biochem Mol Biol Int** 1998 Oct; 46(2):343–53
Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents. Svegliati Baroni S, et al. **Biofactors** 1999;9(2–4):325–30
Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Gottsäter A, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):133–40
Communicating risk reductions. One example is not enough [letter; comment] [published erratum appears in BMJ 1999 Apr 17;318(7190):1040] Galton DJ, et al. **BMJ** 1999 Feb 27;318(7183):602–3; discussion 603–4. Comment on: **BMJ** 1998 Jun 27;316(7149):1956–8.
Comparison of the effects of fish oil and olive oil on blood lipids and aortic atherosclerosis in Watanabe heritable hyperlipidaemic rabbits. Mortensen A, et al. **Br J Nutr** 1998 Dec;80(6):565–73
Elevated blood cholesterol and the prevention of heart disease [editorial; comment] MacLean DR, et al. **Can J Cardiol** 1999 Apr;15(4):407–8. Comment on: Can J Cardiol 1999 Apr;15(4):434–44. Comment on: Can J Cardiol 1999 Apr;15(4):445–51.
Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated for elevated blood cholesterol. Canadian Heart Health Surveys Research Group [see comments] MacLean DR, et al. **Can J Cardiol** 1999 Apr;15(4):445–51. Comment in: Can J Cardiol 1999 Apr;15(4):407–8.
Significance of soluble P-selectin, von Willebrand factor, and other adhesion molecules in hypercholesterolemia and peripheral artery disease [letter; comment] Blann AD, et al. **Circulation** 1999 May 11;99(18):2478–9. Comment on: Circulation 1998 Mar 17;97(10):953–7.
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Böger RH, et al. **Circulation** 1998 Nov 3;98(18):1842–7
Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine. Corseaux D, et al. **Circulation** 1998 Oct 27;98(17):1776–82
Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia. Lindbohm N, et al. **Clin Chim Acta** 1999 Jul;285(1–2):69–84
Hemorheological changes in children with polygenic hypercholesterolemia. Vaya A, et al. **Clin Hemorheol Microcirc** 1998 Nov;19(3):259–62
Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet. Nagao K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jul; 120(3):579–86
Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients. Miossec P, et al. **Diabet Med** 1999 May; 16(5):424–30
Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients. Harada N, et al. **Diabetes Res Clin Pract** 1999 Feb; 43(2):111–20
Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia. Sörös P, et al. **Hepatology** 1998 Nov;28(5):1199–205
Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia [letter] Saito M, et al. **Int J Hematol** 1999 Jun;69(4):274–6
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia [see comments] Szczeklik A, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1286–93. Comment in: J Am Coll Cardiol 1999 Apr;33(5):1305–7.
Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. Houterman S, et al. **J Intern Med** 1999 Jul;246(1):25–33
Serum sterols during stanol ester feeding in a mildly hypercholesterolemic population. Gylling H, et al. **J Lipid Res** 1999 Apr;40(4):593–600
Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. Han KH, et al. **J Lipid Res** 1999 Jun;40(6):1053–63
Impact of a cholesterol enriched diet on maternal and fetal plasma lipids and fetal deposition in pregnant rabbits. Montoudis A, et al. **Life Sci** 1999;64(26):2439–50
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients. Ferlito S, et al. **Minerva Cardioangiol** 1999 Apr;47(4):91–4 **(Eng, Ita)**
Does a high level of HDL-C cholesterol undo the bad effects of a high LDL-C cholesterol? Perris AL, et al. **N C Med J** 1999 Jul–Aug;60(4):217–21
Effect of a phytosterol mixture diet on the plasma level of fatty acids in hypercholesterolaemic rats (PHHC). Ambrošová Z, et al. **Pharmazie** 1999 Apr;54(4):312–3
Influence of bezafibrate on total antioxidant activity of serum and deformability of blood cells in hypercholesterolaemic patients. Grodzińska L, et al. **Pol J Pharmacol** 1998 Jul–Oct;50(4–5):361–4
Serum cholesterol trends among members of the Finnish parliament. Nikkari ST, et al. **Prev Med** 1999 Mar; 28(3):260–3
Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase. Bergeron N, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15647–52
Decreased blood oxygen diffusion in hypercholesterolemia. Menchaca HJ, et al. **Surgery** 1998 Oct;124(4):692–8
Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits [editorial] Yamamoto T, et al. **Ther Apher** 1998 Feb; 2(1):25–30 (42 ref.)
Possible mechanisms through which dietary pectin influences fibrin network architecture in hypercholesterolaemic subjects. Veldman FJ, et al. **Thromb Res** 1999 Mar 15; 93(6):253–64
Changes in serum lipid and (APO) lipoprotein levels in renal transplant recipients. Ishii T, et al. **Transplant Proc** 1998 Nov;30(7):3021–2
Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Kirk G, et al. **Vasc Med** 1999;4(1):23–6
[Dyslipidemia: prevention of cardiovascular risk (interview)] Farnier M. **Presse Med** 1999 Apr 24;28(16):849–51 **(Fre)**
[Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):17–21 (16 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Charco R, et al. **Liver Transpl Surg** 1999 May;5(3):204–8

HYPERCHOLESTEROLEMIA

COMPLICATIONS

Usefulness in predicting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress tests. Giral P, et al. **Am J Cardiol** 1999 Jul 1;84(1):14–7

Assessment by transesophageal echography of atherosclerosis of the descending thoracic aorta in patients with hypercholesterolemia. Tomochika Y, et al. **Am J Cardiol** 1999 Mar 1;83(5):703–9

Risk reduction in relation to cholesterol reduction [letter] Boot K. **Am J Med** 1999 Sep;107(3):294–5

Combined hyperlipidemia as a risk factor for premature atherosclerotic disease. East C. **Am J Med** 1999 Aug 23; 107(2A):46S–47S (17 ref.)

Young adults with hypercholesterolemia. Kwiterovich PO Jr. **Am J Med** 1999 Aug 23;107(2A):40S–42S (17 ref.)

Reperfusion-induced changes in capillary perfusion and filtration: effects of hypercholesterolemia. Harris NR. **Am J Physiol** 1999 Aug;277(2 Pt 2):H669–75

Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves [letter] Jiménez-Alonso J, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1811–2

Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits. Chen YL, et al. **Atherosclerosis** 1999 Mar;143(1):115–23

Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate. Wilson TA, et al. **Atherosclerosis** 1998 Sep;140(1):147–53

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial [see comments] Dupuis J, et al. **Circulation** 1999 Jun 29;99(25):3227–33. Comment in: Circulation 1999 Jun 29;99(25):3215–7.

Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Yokoyama I, et al. **Circulation** 1999 Jul 13;100(2):117–22

Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Más R, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):439–47

Coronary heart disease risk factors among blood donors in northwest Ethiopia. Gebre-Yohannes A, et al. **East Afr Med J** 1998 Sep;75(9):495–500

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Nazzaro P, et al. **Hypertension** 1999 Feb;33(2):719–25

Job strain and arterial blood pressure, serum cholesterol, and smoking as risk factors for coronary heart disease in Japan. Kawakami N, et al. **Int Arch Occup Environ Health** 1998 Sep;71(6):429–32

Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. Le Tourneau T, et al. **J Am Coll Cardiol** 1999 Mar;33(3):876–82

Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. Hayakawa H, et al. **J Hypertens** 1999 May;17(5):611–9

Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. Houterman S, et al. **J Intern Med** 1999 Jul;246(1):25–33

Lifetime risk of developing coronary heart disease [letter; comment] Ulrich S, et al. **Lancet** 1999 Mar 13;353(9156):925 . Comment on: Lancet 1999 Jan 9;353(9147):89–92.

Coronary risk assessment methods and cholesterol lowering [letter] Wight J. **Lancet** 1999 Mar 27;353(9158):1096–7

Atherosclerosis--an inflammatory disease [letter; comment] Williams KJ, et al. **N Engl J Med** 1999 Jun 17;340(24):1928; discussion 1929. Comment on: N Engl J Med 1999 Jan 14;340(2):115–26.

Cholesterol-lowering and vascular reactivity in relation to coronary heart disease. de Divitiis M, et al. **Nutr Metab Cardiovasc Dis** 1999 Jun;9(3):133–42 (104 ref.)

Anterior ischemic optic neuropathy: trouble waiting to happen [editorial; comment] Feldon SE. **Ophthalmology** 1999 Apr;106(4):651–2 (19 ref.). Comment on: Ophthalmology 1999 Apr;106(4):739–42.

Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy [see comments] Salomon O, et al. **Ophthalmology** 1999 Apr;106(4):739–42. Comment in: Ophthalmology 1999 Apr;106(4):651–2.

Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253–62 (34 ref.)

Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Caligiuri G, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6920–4

Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA? Kanemitsu S, et al. **Ther Apher** 1998 Feb;2(1):65–70

[Heart and brain: are the risk factors the same? Are the results of primary and secondary trials comparable?] Castaigne A, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:59–63 (Eng. Abstr.) **(Fre)**

[Dyslipidemia: a predisposing or etiologic factor in atherosclerosis] Emmerich J. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:13–9 (36 ref.) (Eng. Abstr.) **(Fre)**

[Cholesterolemia and pathology: update] Schlienger JL, et al. **Rev Med Interne** 1998 Mar;19(3):180–4 (42 ref.) (Eng. Abstr.) **(Fre)**

[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):2–3 (Eng. Abstr.) **(Fre)**

[Hypercholesterolemia in diabetes in Dakar. Sociodemographic and etiological factors and therapeutic bases] Sidibe el-H, et al. **Sante** 1998 Jul–Aug;8(4):311–3 (Eng. Abstr.) **(Fre)**

[A hypothesis prevails: cholesterol and coronary heart disease (editorial)] Battegay E. **Schweiz Rundsch Med Prax** 1998 Oct 21;87(43):1425–7 **(Ger)**

[Major nutrition-related risk factors of ischemic heart disease: dyslipoproteinemia, obesity, hypertension, glucose intolerance] Pados G. **Orv Hetil** 1999 Jul 11; 140(28):1563–72 (50 ref.) (Eng. Abstr.) **(Hun)**

[Interleukin-8 (IL-8) and lipid disorders in chronic renal graft rejection] Boratyńska M, et al. **Przegl Lek** 1998; 55(12):645–9 (Eng. Abstr.) **(Pol)**

[Cholesterol and atherosclerosis] Alekseeva RI. **Vopr Pitan** 1998;(3):44–5 **(Rus)**

DIAGNOSIS

Relation between low-density lipoprotein cholesterol and thoracic aortic atherosclerosis. Tribouilloy CM, et al. **Am J Cardiol** 1999 Sep 1;84(5):603–5, A9

Psychosocial factors in nutrition education for hypercholesterolemic children. McHale SM, et al. **Ann Behav Med** 1998 Summer;20(3):233–40

Measuring serum total cholesterol: do vascular surgeons know what they are doing? Wijesinghe LD, et al. **Ann R Coll Surg Engl** 1999 Jan;81(1):32–6

Serum cholesterol is elevated in patients with Achilles tendon ruptures. Mathiak G, et al. **Arch Orthop Trauma Surg** 1999; 119(5–6):280–4

Flow cytometric assessment of LDL receptor activity in peripheral blood mononuclear cells compared to gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia. Raungaard B, et al. **Cytometry** 1999 May 1;36(1):52–9

Genes, hypercholesterolaemia and carotid atherosclerosis [comment] Pintó X. **Eur J Clin Invest** 1998 Dec; 28(12):980–2. Comment on: Eur J Clin Invest 1998 Dec;28(12):971–9.

Feasibility of a national cholesterol guideline in daily practice. A randomized controlled trial in 20 general practices. van der Weijden T, et al. **Int J Qual Health Care** 1999 Apr;11(2):131–7

Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. Grover SA, et al. **J Clin Epidemiol** 1999 Jan;52(1):49–55

Coronary risk assessment methods and cholesterol lowering [letter] Tang JL, et al. **Lancet** 1999 Mar 27; 353(9158):1095–6; discussion 1096–7

How much screening in the elderly? Wong JG. **Postgrad Med** 1999 Feb;105(2):27–8

Detection and measurement of hypercholesterolaemia in South Africans attending general practitioners in private practice--the cholesterol monitor. Steyn K, et al. **S Afr Med J** 1998 Dec;88(12):1569–74

DIET THERAPY

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients: why is someone still using the phase I diet for patients at risk for atherosclerosis? [letter; comment] Banks T. **Am J Cardiol** 1999 Mar 1; 83(5):818. Comment on: Am J Cardiol 1998 Aug 1;82(3):311–6.

Revisiting the effectiveness of the National Cholesterol Education Program's Step I and Step II diets: cholesterol-lowering diets in a pharmaceutically driven world [editorial; comment] Denke MA. **Am J Clin Nutr** 1999 Apr;69(4):581–2. Comment on: Am J Clin Nutr 1999 Apr;69(4):632–46.

Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Hallikainen MA, et al. **Am J Clin Nutr** 1999 Mar;69(3):403–10

Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement [see comments] Heber D, et al. **Am J Clin Nutr** 1999 Feb;69(2):231–6. Comment in: Am J Clin Nutr 1999 Jul;70(1):106–8.

Plasma lipid changes after supplementation with beta-glucan fiber from yeast. Nicolosi R, et al. **Am J Clin Nutr** 1999 Aug;70(2):208–12

Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men. Wong WW, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1385S–1389S

Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis [see comments] Yu-Poth S, et al. **Am J Clin Nutr** 1999 Apr; 69(4):632–46. Comment in: Am J Clin Nutr 1999 Apr;69(4):581–2.

Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Knopp RH, et al. **Am J Prev Med** 1999 Jul;17(1):18–23

Lymphocyte T subset counts in children with hypercholesterolemia receiving dietary therapy. Moreno LA, et al. **Ann Nutr Metab** 1998;42(5):261–5

Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. Davidson MH, et al. **Arch Intern Med** 1999 Jun 28; 159(12):1331–8

Retinol, vitamin D, carotenes and alpha-tocopherol in serum of a moderately hypercholesterolemic population consuming sitostanol ester margarine. Gylling H, et al. **Atherosclerosis** 1999 Aug;145(2):279–85

Protective effect of dietary tomato against endothelial dysfunction in hypercholesterolemic mice. Suganuma H, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):78–82

Cholesterol lowering diets and coronary heart disease. Farmed and wild fish may have different effects [letter; comment] Bhopal R. **BMJ** 1999 Apr 3;318(7188):945. Comment on: BMJ 1998 Oct 31;317(7167):1253.

Cholesterol lowering diets and coronary heart disease. Diet alone substantially reduces cholesterol in hypercholesterolaemia [letter; comment] Evans DW. **BMJ** 1999 Apr 3;318(7188):945. Comment on: BMJ 1998 Oct 31;317(7167):1253.

Therapy and clinical trials [editorial] Cramb R. **Curr Opin Lipidol** 1998 Aug;9(4):381–3

Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. Butowski PF, et al. **Eur Heart J** 1998 Sep; 19(9):1328–33

Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Bertolami MC, et al. **Eur J Clin Nutr** 1999 Feb;53(2):97–101

Solid monounsaturated diet lowers LDL unsaturation trait and oxidisability in hypercholesterolemic (type IIb) patients. Baroni SS, et al. **Free Radic Res** 1999 Apr; 30(4):275–85

Effect of pistachio nuts on serum lipid levels in patients with moderate hypercholesterolemia. Edwards K, et al. **J Am Coll Nutr** 1999 Jun;18(3):229–32

Cookies enriched with psyllium or oat bran lower plasma LDL cholesterol in normal and hypercholesterolemic men from Northern Mexico. Romero AL, et al. **J Am Coll Nutr** 1998 Dec;17(6):601–8

Dietary advice to reduce fat intake is more successful when it does not restrict habitual eating patterns. King S, et al. **J Am Diet Assoc** 1999 Jun;99(6):685–9

What to consider when conducting a cost-effectiveness analysis in a clinical setting. Naglak M, et al. **J Am Diet Assoc** 1998 Oct;98(10):1149–54

Responsiveness to a self-administered diet history questionnaire in a work-site dietary intervention trial for mildly hypercholesterolemic Japanese subjects: correlation between change in dietary habits and serum cholesterol levels. Sasaki S, et al. **J Cardiol** 1999 Jun;33(6):327–38

Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. Bak AA, et al. **J Intern Med** 1998 Nov;244(5):371–8

Under-reporting of dietary intake by smoking and non-smoking subjects counselled for hypercholesterolaemia. Tonstad S, et al. **J Intern Med** 1999 Apr;245(4):337–44

Weight loss due to energy restriction suppresses cholesterol biosynthesis in overweight, mildly hypercholesterolemic men. Di Buono M, et al. **J Nutr** 1999 Aug;129(8):1545–8

Combined effect of vegetable protein (soy) and soluble fiber added to a standard cholesterol-lowering diet. Jenkins DJ, et al. **Metabolism** 1999 Jun;48(6):809–16

Effects of diet and exercise on cholesterol levels [letter; comment] Elkin PL, et al. **N Engl J Med** 1998 Nov 19; 339(21):1552; discussion 1553. Comment on: N Engl J Med 1998 Jul 2;339(1):12–20.

The potential role of soluble fibre in the treatment of hypercholesterolaemia. Coats AJ. **Postgrad Med J** 1998 Jul; 74(873):391–4 (27 ref.)

DRUG THERAPY

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs. Schwartz JS. **Am Heart J** 1999 May;137(5):S97–104

Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia. Strauss WE, et al. **Am Heart J** 1999 Mar;137(3):458–62

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Capuzzi DM, et al. **Am J Cardiol** 1998 Dec 17;82(12A):74U–81U; discussion 85U–86U

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Dangas G, et al. **Am J Cardiol** 1999 Sep 15;84(6):639–43

Secondary prevention practices after acute myocardial infarction in a large city hospital. Elasy TA, et al. **Am J Cardiol** 1998 Oct 15;82(8):987–9

Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Goldberg AC. **Am J Cardiol** 1998 Dec 17;82(12A):35U–38U; discussion 39U–41U

State-of-the-art update and review: clinical trials of lipid-lowering agents. Kwiterovich PO Jr. **Am J Cardiol** 1998 Dec 17;82(12A):3U–17U; discussion 39U–41U (82 ref.)

Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Mölgaard J, et al. **Am J Cardiol** 1999 Apr 1;83(7):1043–8

Preventing coronary artery disease in the West of Scotland: implications for primary prevention. Shepherd J. **Am J Cardiol** 1998 Nov 26;82(10B):57T–59T

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Spósito AC, et al. **Am J Cardiol** 1999 May 15; 83(10):1497–9, A8

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Stein E, et al. **Am J Cardiol** 1999 May 15;83(10):1433–6

Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP). Ito MK, et al. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1107–13

Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Moisan J, et al. **Am J Health Syst Pharm** 1999 Jul 15; 56(14):1437–41

Effect of 17beta-estradiol in hypercholesterolemic rabbits with severe endothelial dysfunction. Nascimento CA, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1788–94

Dietary intervention for cholesterol reduction in public clinic patients. Hyman DJ, et al. **Am J Prev Med** 1998 Aug; 15(2):139–45

Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. Schobel HP, et al. **Angiology** 1998 Sep; 49(9):743–8

Drug treatment of hypercholesterolaemia. Tay JC, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):794–9

Gemfibrozil to prevent myocardial infarction [letter] Rembold CM. **Ann Intern Med** 1998 Nov 1;129(9):750

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS, et al. **Ann Pharmacother** 1998 Oct;32(10):1030–43 (99 ref.)

Forecasting patient outcomes in the management of hyperlipidemia. Brier KL, et al. **Arch Intern Med** 1999 Mar 22;159(6):569–75

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Davidson MH, et al. **Arch Intern Med** 1999 Sep 13;159(16):1893–900

Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves [letter] Jiménez-Alonso J, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1811–2

Lipid levels and estrogen replacement therapy in postmenopausal women [letter] Ness J, et al. **Arch Intern Med** 1999 May 10;159(9):1013–4

Clinical outcomes in statin treatment trials: a meta-analysis. Ross SD, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1793–802

Cholesterol and lipoprotein metabolism in aging: reversal of hypercholesterolemia by growth hormone treatment in old rats. Parini P, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):832–9

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Rothe G, et al. **Atherosclerosis** 1999 May;144(1):251–61

Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Winkler K, et al. **Atherosclerosis** 1999 May;144(1):167–75

Biochemical basis for a cholesterol-lowering activity of 2-[2"-(1",3"-dioxolane)]-2-methyl-4-(2'-oxo-1'-pyrrolidinyl)-6- nitro-2H-1-benzopyran (SKP-450), a novel antihypertensive agent. Lee EY, et al. **Biochem Pharmacol** 1999 Mar 1;57(5):579–82

Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis in hypercholesterolemic rats. Adan Y, et al. **Biosci Biotechnol Biochem** 1999 Jan; 63(1):111–9

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Gottsäter A, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):133–40

From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. Fairhurst K, et al. **BMJ** 1998 Oct 24;317(7166):1130–4

Communicating risk reductions. Modifying risk is different to treating illness [letter] Steel N. **BMJ** 1999 Feb 27; 318(7183):603–4

Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Soma MR, et al. **Br J Pharmacol** 1998 Dec; 125(7):1471–6

Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin. Leiter LA, et al. **Can J Cardiol** 1999 May;15(5):545–55 (38 ref.)

Controversies in primary prevention among hyperlipidemic patients. McPherson R. **Can J Cardiol** 1999 Apr;15 Suppl B:16B–19B

Treatment challenges in hypercholesterolemia. Pauciullo P, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):325–37 (116 ref.)

Hypercholesterolemia, abnormal coronary vasomotion, and calcium antagonists [letter; comment] David DS. **Circulation** 1999 Apr 13;99(14):1922. Comment on: Circulation 1998 Apr 14;97(14):1348–54.

Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Gotto AM Jr, et al. **Circulation** 1999 Mar 2; 99(8):E1–7

Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Guethlin M, et al. **Circulation** 1999 Feb 2;99(4):475–81

Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Koh KK, et al. **Circulation** 1999 Jan 26;99(3):354–60

Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS) [letter] Lim PO, et al. **Circulation** 1999 Aug 10;100(6):686

Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Prasad K. **Circulation** 1999 Mar 16; 99(10):1355–62

Cholesterol lowering. Should it continue to be the last thing we do? [editorial; comment] Waters D. **Circulation** 1999 Jun 29;99(25):3215–7. Comment on: Circulation 1999 Jun 29;99(25):3227–33.

Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Yokoyama I, et al. **Circulation** 1999 Jul 13;100(2):117–22

Should hypercholesterolemia be treated in patients older than 65? Messinger-Rapport B. **Cleve Clin J Med** 1999 Jul-Aug; 66(7):393–4

Lipid lowering therapy in women at risk of coronary disease [letter] Davis SR, et al. **Clin Endocrinol (Oxf)** 1999 Mar; 50(3):405–6

Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Mas R, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):439–47

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE, et al. **Clin Ther** 1999 Mar;21(3):536–62

Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet. Nagao K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Jul; 120(3):579–86

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Lye M, et al. **Coron Artery Dis** 1998;9(9):583–90

Therapy and clinical trials [editorial] Cramb R. **Curr Opin Lipidol** 1998 Aug;9(4):381–3

Therapy and clinical trials [editorial] Ogunko A, et al. **Curr Opin Lipidol** 1998 Dec;9(6):617–8

Therapy and clinical trials [editorial] von Bergmann K, et al. **Curr Opin Lipidol** 1998 Dec;9(6):519–20

Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia [letter] Sheu WH, et al. **Diabetes Care** 1999 Jul;22(7):1224–5

Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients. Harada N, et al. **Diabetes Res Clin Pract** 1999 Feb; 43(2):111–20

Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. Butowski PF, et al. **Eur Heart J** 1998 Sep; 19(9):1328–33

The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Korhonen T, et al. **Eur J Clin Pharmacol** 1999 Feb;54(12):903–10

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. Lanzarotto F, et al. **Gut** 1999 Apr;44(4):552–6

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Nazzaro P, et al. **Hypertension** 1999 Feb;33(2):719–25

The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography. Saia F, et al. **Int J Cardiol** 1998 Dec 31;67(3):247–9

The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study. **J Am Coll Cardiol** 1999 Mar 15;33(4):909–15

Additive effects of simvastatin and hormone replacement therapy in hypercholesterolemic postmenopausal women [letter; comment] Fak AS, et al. **J Am Coll Cardiol** 1999 Jul;34(1):311–2. Comment on: J Am Coll Cardiol 1998 Nov;32(5):1244–50.

The anti-thrombotic effects of statins [editorial; comment] Kearney D, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1305–7 (23 ref.). Comment on: J Am Coll Cardiol 1999 Apr;33(5):1286–93. Comment on: J Am Coll Cardiol 1999 Apr;33(5):1294–304.

Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. Kugiyama K, et al. **J Am Coll Cardiol** 1999 May;33(6):1512–8

Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. Pfeffer MA, et al. **J Am Coll Cardiol** 1999 Jan;33(1):125–30

The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease [see comments] Sbarouni E, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1244–50. Comment in: J Am Coll Cardiol 1999 Jul;34(1):311–2.

Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. Fogari R, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):534–9

Ispaghula husk in the treatment of hypercholesterolaemia: a double-blind controlled study. MacMahon M, et al. **J Cardiovasc Risk** 1998 Jun;5(3):167–72

Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. Bruckert E, et al. **J Clin Epidemiol** 1999 Jun;52(6):589–94

Does cholesterol lowering prevent stroke? Henry RY, et al. **J Clin Pharm Ther** 1998 Oct;23(5):337–44 (30 ref.)

Non-lipid properties of statins. Kendall MJ, et al. **J Clin Pharm Ther** 1999 Feb;24(1):3–5

Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. Schwed A, et al. **J Clin Pharmacol** 1999 Apr;39(4):402–9

Reduction of plasma cholesterol by Curcuma comosa extract in hypercholesterolaemic hamsters. Piyachaturawat P, et al. **J Ethnopharmacol** 1999 Aug;66(2):199–204

Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. Bak AA, et al. **J Intern Med** 1998 Nov;244(5):371–8

Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis. Geiss HC, et al. **J Intern Med** 1999 Jan; 245(1):47–55

Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. Vega GL, et al. **J Intern Med** 1999 Jul;246(1):1–9

Effects of dietary inulin on serum lipids. Davidson MH, et al. **J Nutr** 1999 Jul;129(7 Suppl):1474S–7S (13 ref.)

Management of ischaemic heart disease in primary care: towards better practice. STaRNet. South Thames Region Network. Thiru K, et al. **J Public Health Med** 1999 Jun; 21(2):179–84

Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Martínez-Castelao A, et al. **Kidney Int Suppl** 1999 Jul; 71:S231–4

Effect of probucol on hypercholesterolemia in renal transplant patients. Okubo M, et al. **Kidney Int Suppl** 1999 Jul;71:S229–30

Indications for cholesterol-lowering medication: comparison of risk-assessment methods [see comments] [published erratum appears in Lancet 1999 Jul 10;354(9173):166] Durrington PN, et al. **Lancet** 1999 Jan 23;353(9149):278–81 . Comment in: Lancet 1999 Jan 23;353(9149):254–5. Comment in: Lancet 1999 mar 27;353(9158):1095; discussion 1096– 7.

Gambling with cardiovascular risk: picking the winners and the losers [comment] Grover S. **Lancet** 1999 Jan 23; 353(9149):254–5. Comment on: Lancet 1999 Jan 23;353(9149):278–81.

Clinical trials in stroke [letter; comment] Kendall MJ, et al. **Lancet** 1999 Jan 9;353(9147):151. Comment on: Lancet 1998 Oct;352 Suppl 3:SIII28–30.

Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin [letter] Nakad A, et al. **Lancet** 1999 May 22;353(9166):1763–4

Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Murakami S, et al. **Life Sci** 1999;64(1):83–91

Lipoprotein response to a National Cholesterol Education Program step II diet with and without energy restriction. Flynn MM, et al. **Metabolism** 1999 Jul;48(7):822–6

Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients. Baldassarre D, et al. **Nutr Metab Cardiovasc Dis** 1999 Jun;9(3):108–17

Study of the hypolipidemic properties of pectin, garlic and ginseng in hypercholesterolemic rabbits. Ismail MF, et al. **Pharmacol Res** 1999 Feb;39(2):157–66

The outcome of very low dosages of simvastatin in patients with hypercholesterolemia. Rindone JP. **Pharmacotherapy** 1999 Apr;19(4):399–403

Salvadora persica L.: hypolipidemic activity on experimental hypercholesterolemia in rat. Galati EM, et al. **Phytomedicine** 1999 Jul;6(3):181–5

Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention? Grundy SM. **Postgrad Med** 1998 Nov; 104(5):117–20, 123–4, 129 (21 ref.)

Heart disease in older patients. Pascual J. **Practitioner** 1998 Aug;242(1589):577, 580–2, 584, passim (10 ref.)
Aggressive lipid therapy in the statin era. Farmer JA. **Prog Cardiovasc Dis** 1998 Sep–Oct;41(2):71–94 (67 ref.)
Secondary prevention and treatment of hypercholesterolemia in women. Drown DJ. **Prog Cardiovasc Nurs** 1998 Summer; 13(3):42–3
Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. Foss OP, et al. **Scand J Prim Health Care** 1999 Jun;17(2):122–7
Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Ehrenberg BL, et al. **Sleep** 1999 Feb 1;22(1):117–21
Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation. Alvarez ML, et al. **Transplant Proc** 1999 Sep;31(6):2328–9
Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Gómez G, et al. **Transplant Proc** 1999 Sep; 31(6):2326–7
Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients. Nakamura H, et al. **Transplant Proc** 1998 Nov;30(7):3047–8
Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Kirk G, et al. **Vasc Med** 1999;4(1):23–6
[Heart magnyl or statins? (letter)] Astrup P, et al. **Ugeskr Laeger** 1998 Dec 14;160(51):7455 **(Dan)**
[Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO (see comments) (published erratum appears in Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2232)] Simoons ML, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19;142(38):2096–101 (12 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2075–7. Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2078–82. Comment in: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2083–6. **(Dut)**
[Practice guidelines to physicians and their economic aspects; merits and drawbacks (see comments)] Stehouwer CD. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):776–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Apr 17;143(16):874–5. **(Dut)**
[Consideration of the risk of decision to treat hypercholesterolemia] Bruckert E. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):105–8 **(Fre)**
[Therapeutic management of hypercholesterolemia] Mégnien JL, et al. **Presse Med** 1998 Dec 12;27(39):2056–61 (Eng. Abstr.) **(Fre)**
[Is it necessary to institute primary preventive treatment in women with hypercholesterolemia?] Paquot N. **Rev Med Liege** 1999 Apr;54(4):240–3 (Eng. Abstr.) **(Fre)**
[Treatment of combined hyperlipidemia: fibrate and/or statin?] Scheen AJ. **Rev Med Liege** 1999 Jul;54(7):583–7 (Eng. Abstr.) **(Fre)**
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):2–3 (Eng. Abstr.) **(Fre)**
[Lipid lowering: myth or therapeutic necessity?] **Dtsch Med Wochenschr** 1998 Oct 2;123(40 Suppl):2–8 **(Ger)**
[Plaque stabilization and endothelial protection by cholesterol synthesis inhibitors] Müller-Wieland D, et al. **Herz** 1999 May;24(3):254–7 (23 ref.) **(Ger)**
[Therapy with CSE inhibitors—more than lipid lowering?] Weizel A. **Herz** 1999 Feb;24(1):42–50 (60 ref.) (Eng. Abstr.) **(Ger)**
[Current lipid reducers. Cholesterol lowering alone is not enough] **Internist (Berl)** 1999 Aug;40(8 Suppl Cholesteri):1–4 **(Ger)**
[Important differences in metabolism of CSE inhibitors] Feuring M, et al. **Internist (Berl)** 1999 Feb;40(2):235–6 **(Ger)**
[Cholesterol synthesis inhibitors. Clinical studies on lowering coronary risk and plaque stabilization] Müller-Wieland D, et al. **Internist (Berl)** 1998 Sep;39(9):934–42 (42 ref.) **(Ger)**
[Are there differences in various statins?] Otto C, et al. **Internist (Berl)** 1998 Sep;39(9):987–93 (42 ref.) **(Ger)**
[Comparison of cholesterol synthesizing enzymes (CSE) inhibitors] Ecker-Schlipf B. **Med Monatsschr Pharm** 1999 Jun;22(6):184–6 **(Ger)**
[Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared] Kostner KM, et al. **Wien Klin Wochenschr** 1998 Oct 2;110(18):625–30 (21 ref.) (Eng. Abstr.) **(Ger)**
[HMA CoA reductase inhibitors (editorial)] Kostner GM. **Wien Med Wochenschr** 1999;149(5–6):109–10 **(Ger)**
[Aggressive therapy and combination therapy in severe hyperlipidemia] Kostner KM. **Wien Med Wochenschr** 1999; 149(5–6):146–8 (20 ref.) (Eng. Abstr.) **(Ger)**
[Statins in primary prevention of coronary heart disease] Paulweber B. **Wien Med Wochenschr** 1999;149(5–6):129–38 (38 ref.) (Eng. Abstr.) **(Ger)**
[Statins in secondary prevention of coronary heart disease] Sandhofer F. **Wien Med Wochenschr** 1999;149(5–6):125–8 (8 ref.) (Eng. Abstr.) **(Ger)**
[Statins—attaining goal values—with reference to recent studies] Toplak H, et al. **Wien Med Wochenschr** 1999; 149(5–6):144–5 (Eng. Abstr.) **(Ger)**
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering] **Z Kardiol** 1999 Mar;88(3 Suppl):1–4 **(Ger)**
[Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia] Baller D, et al. **Z Kardiol** 1998;87 Suppl 2:136–44 (Eng. Abstr.) **(Ger)**
[Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS] Rensing UF, et al. **Z Kardiol** 1999 Apr;88(4):270–82 (Eng. Abstr.) **(Ger)**
[Action of pravastatin treatment on blood levels of homocysteine] Blardi P, et al. **Minerva Cardioangiol** 1998 Sep;46(9):315–6 **(Ita)**
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia] Liguori E, et al. **Minerva Cardioangiol** 1998 Sep;46(9):317–8 **(Ita)**
[Effect of one-year treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia] Adamska-Dyniewska H, et al. **Pol Arch Med Wewn** 1998 May;99(5):366–72 (Eng. Abstr.) **(Pol)**
[Pharmacological treatment of lipid disorders according to present clinical studies] Bańcarz A, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):162–6 (46 ref.) (Eng. Abstr.) **(Pol)**
[Effect of eggplant on plasma lipid levels, lipidic peroxidation and the reversion of endothelial dysfunction in experimental hypercholesterolemia (letter)] Caramelli B, et al. **Arq Bras Cardiol** 1998 Jul;71(1):89 **(Por)**
[Effect of eggplant on plasma lipid levels, lipidic peroxidation and the reversion of endothelial dysfunction in experimental hypercholesterolemia (letter)] Jorge PA. **Arq Bras Cardiol** 1998 Jul;71(1):90–1 **(Por)**
[Necessity of hypolipemic treatment in patients with coronary disease (letter)] Fernández-Miranda C, et al. **Med Clin (Barc)** 1999 Mar 27;112(11):438 **(Spa)**
[All mortality by cause of death. The challenge of coronary prevention] Fernández-Cruz A. **Rev Esp Cardiol** 1998;51 Suppl 6:23–9 (24 ref.) (Eng. Abstr.) **(Spa)**
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke] Marta-Moreno J, et al. **Rev Neurol** 1998 Nov; 27(159):827–30 (28 ref.) (Eng. Abstr.) **(Spa)**
[The structural organization of the aortic endothelium in hypercholesterolemia and the effect of L-arginine] Tkachenko MM, et al. **Fiziol Zh** 1998;44(5–6):59–64 (Eng. Abstr.) **(Ukr)**

ECONOMICS

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Hilleman DE, et al. **Clin Ther** 1999 Mar;21(3):536–62
Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. van der Weijden T, et al. **J Epidemiol Community Health** 1998 Sep; 52(9):586–94 (114 ref.)
[Basic principles of cost–benefit analysis in long-term treatment of risk factors] Szucs TD, et al. **Schweiz Med Wochenschr** 1998 Dec 5;128(49):1958–64 (31 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Warnholtz A, et al. **Circulation** 1999 Apr 20;99(15):2027–33
Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. Schwarz M, et al. **J Lipid Res** 1998 Sep;39(9):1833–43

EPIDEMIOLOGY

Coronary heart disease risk factors among blood donors in northwest Ethiopia. Gebre-Yohannes A, et al. **East Afr Med J** 1998 Sep;75(9):495–500
Positive and negative life changes and LDL cholesterol. Helminen A, et al. **J Biosoc Sci** 1999 Apr;31(2):269–77
Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. Bruckert E, et al. **J Clin Epidemiol** 1999 Jun;52(6):589–94
Serum cholesterol trends among members of the Finnish parliament. Nikkari ST, et al. **Prev Med** 1999 Mar; 28(3):260–3
Screening for hypercholesterolaemia in patients with other risk factors for coronary heart disease. Lee GH, et al. **Singapore Med J** 1999 Jun;40(6):397–401
[Misleading cholesterol statistics (letter)] Ravnskov U. **Lakartidningen** 1999 Apr 21;96(16):1947, 1949 **(Swe)**

ETIOLOGY

Serum cholesterol is elevated in patients with Achilles tendon ruptures. Mathiak G, et al. **Arch Orthop Trauma Surg** 1999; 119(5–6):280–4
Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Merat S, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1223–30
Helicobacter pylori-associated protein-losing hypertrophic gastropathy with hypercholesterolemia. Kapsoritakis AN, et al. **Dig Dis Sci** 1999 Sep;44(9):1843–7
Alterations in carbohydrate and lipid metabolism induced by a diet rich in coconut oil and cholesterol in a rat model. Zulet MA, et al. **J Am Coll Nutr** 1999 Feb;18(1):36–42
Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. Grover SA, et al. **J Clin Epidemiol** 1999 Jan;52(1):49–55
Manifestations of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. Chu CW, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):807–10
[Extreme hypercholesterolemia with xanthomatous eruptions caused by HIV-associated pericholangitis] van Leusen R. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2232 **(Dut)**
[The role of a systemic inflammatory process in the atherogenic modification of lipoproteins and the development of hypercholesterolemia] Bratus' VV, et al. **Fiziol Zh** 1999;45(1–2):40–9 (Eng. Abstr.) **(Ukr)**

GENETICS

Genetic differences in cholesterol absorption in 129/Sv and C57BL/6 mice: effect on cholesterol responsiveness. Jolley CD, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1117–24
Statistically robust approaches for sib–pair linkage analysis. Wang J, et al. **Ann Hum Genet** 1998 Jul;62 (Pt 4):349–59
Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Zuliani G, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):802–9
Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice. Trieu VN, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):377–81
Genetics and molecular biology [editorial] Talmud PJ, et al. **Curr Opin Lipidol** 1999 Apr;10(2):181–3
Genes, hypercholesterolaemia and carotid atherosclerosis [comment] Pintó X. **Eur J Clin Invest** 1998 Dec; 28(12):980–2. Comment on: Eur J Clin Invest 1998 Dec;28(12):971–9.
A novel point mutation in a splice acceptor site of intron 1 of the human low density lipoprotein receptor gene which causes severe hypercholesterolemia: an unexpected absence of exon skipping. Mutations in brief no. 139. Online. Maruyama T, et al. **Hum Mutat** 1998;11(6):480–1
Regional cholesterol synthesis in the intestinal mucosa of the genetically hypercholesterolaemic RICO rat: kinetic study following whole-body gamma-irradiation. Lutton C, et al. **Int J Radiat Biol** 1999 Feb;75(2):175–81
Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels [see comments] Barth JA, et al. **J Lab Clin Med** 1999 Mar;133(3):237–44. Comment in: J Lab Clin Med 1999 Mar;133(3):216–7.
Identification of a novel Arg-->Cys mutation in the LDL receptor that contributes to spontaneous hypercholesterolemia in pigs. Grunwald KA, et al. **J Lipid Res** 1999 Mar;40(3):475–85
Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. Haddad L, et al. **J Lipid Res** 1999 Jun;40(6):1113–22
Trace metal excretion in patients with homozygous hypercholesterolaemia. Jackson GE, et al. **J Trace Elem Med Biol** 1999 Jul;13(1–2):62–7
[The "second atherogenic phenotype" or the role of insulin resistance in vascular risk] Ziegler O, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:33–9 (58 ref.) (Eng. Abstr.) **(Fre)**
[The RICO rat (genetically hypercholesteremic): a good model for testing a food substance or a drug specific for a key enzyme of cholesterol metabolism] Lutton C. **Reprod Nutr Dev** 1999 Jul–Aug;39(4):481–95 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Zhou X, et al. **Scand J Immunol** 1999 Jul;50(1):25–30

METABOLISM

Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. Anderson JW, et al. **Am J Clin Nutr** 1999 Oct;70(4):466–73
Effect of 17beta-estradiol in hypercholesterolemic rabbits with severe endothelial dysfunction. Nascimento CA, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1788–94
The effect of hypercholesterolemia on the rabbit transarterial wall oxygen gradient. Santilli SM, et al. **Ann Vasc Surg** 1998 Sep;12(5):418–23
Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Wasan KM, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3146–52

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Davidson MH, et al. **Arch Intern Med** 1999 Sep 13;159(16):1893–900

Hypercholesterolemia enhances oxidant production in mesenteric venules exposed to Ischemia/Reperfusion. Kurose I, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct; 18(10):1583–8

Cholesterol oxidation products induce vascular foam cell lesion formation in hypercholesterolemic New Zealand white rabbits. Rong JX, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2179–88

Charge heterogeneity of LDL in asymptomatic hypercholesterolemic men is related to lipid parameters and variations in the ApoB and CIII genes. Védie B, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov;18(11):1780–9

Protective effect of L-arginine on hypercholesterolemia-enhanced renal ischemic injury. Campos SB, et al. **Atherosclerosis** 1999 Apr;143(2):327–34

Oxidizability of low density lipoprotein and total antioxidative capacity of plasma are differently altered during induction and regression of hypercholesterolemia in rabbits. Schneider W, et al. **Atherosclerosis** 1999 May; 144(1):69–72

Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice. Trieu VN, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):377–81

Effects of insulin deficiency on lipoproteins and their hepatic receptors in Rico rats. Milliat F, et al. **C R Acad Sci III** 1998 Dec;321(12):999–1006

Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Kakoki M, et al. **Circulation** 1999 Mar 9;99(9):1242–8

Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. Tangphao O, et al. **Clin Sci (Colch)** 1999 Feb;96(2):199–207

The diurnal rhythms of cholesterol metabolism and plasma clearance of model chylomicrons: comparison of normal and genetically hypercholesterolemic rats (RICO). Mortimer BC, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Aug; 120(4):671–80

Genetics and molecular biology [editorial] Talmud PJ, et al. **Curr Opin Lipidol** 1999 Apr;10(2):181–3

Increased tissue endothelin-1-like immunoreactivity in the internal mammary artery of patients with diabetes or hypercholesterolemia modulates the graft flow in the peri-operative period. Göbel H, et al. **Eur J Cardiothorac Surg** 1998 Oct;14(4):367–72

Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Hendriks HF, et al. **Eur J Clin Nutr** 1999 Apr; 53(4):319–27

Regional cholesterol synthesis in the intestinal mucosa of the genetically hypercholesterolaemic RICO rat: kinetic study following whole-body gamma-irradiation. Lutton C, et al. **Int J Radiat Biol** 1999 Feb;75(2):175–81

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. Feron O, et al. **J Clin Invest** 1999 Mar; 103(6):897–905

Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. Vega GL, et al. **J Intern Med** 1999 Jul;246(1):1–9

Altered signal pathway in granulocytes from patients with hypercholesterolemia. Paragh G, et al. **J Lipid Res** 1999 Sep;40(9):1728–33

Antioxidative effects of docosahexaenoic acid in the cerebrum versus cerebellum and brainstem of aged hypercholesterolemic rats. Hossain MS, et al. **J Neurochem** 1999 Mar;72(3):1133–8

Varying dietary fat type of reduced-fat diets has little effect on the susceptibility of LDL to oxidative modification in moderately hypercholesterolemic subjects. Schwab US, et al. **J Nutr** 1998 Oct;128(10):1703–9

Differential efficacy of vasodilators in hypercholesterolaemic rabbits. Rozsa Z, et al. **J Pharm Pharmacol** 1998 Sep; 50(9):1035–44

Effects of LY295427, a low-density lipoprotein (LDL) receptor up-regulator, on LDL receptor gene transcription and cholesterol metabolism in normal and hypercholesterolemic hamsters. Bensch WR, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):85–92

Oral adsorbent ameliorates renal TGF-beta 1 expression in hypercholesterolemic rats. Aoyama I, et al. **Kidney Int Suppl** 1999 Jul;71:S193–7

Role of glomerular epithelial cell-derived heat shock protein 47 in experimental lipid nephropathy. Razzaque MS, et al. **Kidney Int Suppl** 1999 Jul;71:S256–9

Effects of long-term feeding of marine oils with different positional distribution of eicosapentaenoic and docosahexaenoic acids on lipid metabolism, eicosanoid production, and platelet aggregation in hypercholesterolemic rats. Ikeda I, et al. **Lipids** 1998 Sep; 33(9):897–904

Combined effect of vegetable protein (soy) and soluble fiber added to a standard cholesterol-lowering diet. Jenkins DJ, et al. **Metabolism** 1999 Jun;48(6):809–16

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects. Ntanios FY, et al. **Metabolism** 1999 Jan;48(1):68–73

The effect of dried tomato, grape and apple pomace on the cholesterol metabolism and antioxidative enzymatic system in rats with hypercholesterolemia. Bobek P, et al. **Nahrung** 1998 Oct;42(5):317–20

Influence of docosahexaenoic acid on cerebral lipid peroxide level in aged rats with and without hypercholesterolemia. Hossain MS, et al. **Neurosci Lett** 1998 Mar 20;244(3):157–60

The role of vitamin E on the anti-atherosclerotic effect of fish oil in diet-induced hypercholesterolemic rabbits. Chen MF, et al. **Prostaglandins Other Lipid Mediat** 1999 May; 57(2–3):99–111

[Effects of aerobic exercise on regulation of activities of hepatic low density lipoprotein receptor in hypercholesterolemic rats] Yan Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):18–20 (Eng. Abstr.) **(Chi)**

[Oxidative stress and hypercholesterolemia: increase of radical hydroxyl in patients with hypercholesterolemia] Natoli S, et al. **Cardiologia** 1999 Feb;44(2):187–90 (Eng. Abstr.) **(Ita)**

[Interleukin-8 (IL-8) and lipid disorders in chronic renal graft rejection] Boratyńska M, et al. **Przegl Lek** 1998; 55(12):645–9 (Eng. Abstr.) **(Pol)**

[The cholesterol-lowering effect of black beans (Phaseolus vulgaris, L.) without hulls in hypercholesterolemic rats] Rosa CO, et al. **Arch Latinoam Nutr** 1998 Dec; 48(4):299–305 (Eng. Abstr.) **(Por)**

[The cholesterol-lowering effect of black, carioquinha and red beans (Phaseolus vulgaris, L.) in hypercholesterolemic rats] Rosa CO, et al. **Arch Latinoam Nutr** 1998 Dec; 48(4):306–10 (Eng. Abstr.) **(Por)**

MORTALITY

Cholesterol and long-term mortality after acute myocardial infarction in elderly patients. Bo M, et al. **Age Ageing** 1999 May;28(3):313–5

Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Rywik SL, et al. **Am J Cardiol** 1999 Sep 1;84(5):540–8

NURSING

A cholesterol intervention program for public health nurses in the rural southeast: description of the intervention, study design, and baseline results. Keyserling TC, et al. **Public Health Nurs** 1999 Jun;16(3):156–67

PATHOLOGY

Early morphology of accelerated vein graft atheroma in experimental vein grafts. Davies MG, et al. **Ann Vasc Surg** 1999 Jul;13(4):378–85

Cholesterol oxidation products induce vascular foam cell lesion formation in hypercholesterolemic New Zealand white rabbits. Rong JX, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2179–88

Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. Donetti E, et al. **Atherosclerosis** 1998 Nov; 141(1):45–51

Coronary artery apoptosis in experimental hypercholesterolemia. Hasdai D, et al. **Atherosclerosis** 1999 Feb;142(2):317–25

Experimental hypercholesterolemia induces ultrastructural changes in the internal elastic lamina of porcine coronary arteries. Kwon HM, et al. **Atherosclerosis** 1998 Aug; 139(2):283–9

Oxidizability of low density lipoprotein and total antioxidative capacity of plasma are differently altered during induction and regression of hypercholesterolemia in rabbits. Schneider W, et al. **Atherosclerosis** 1999 May; 144(1):69–72

Ultrastructural studies of the liver during experimental hypercholesterolaemia. Fortak A, et al. **Folia Histochem Cytobiol** 1999;37(2):107–8

Ultrastructural changes of the internal elastic lamina in experimental hypercholesterolemic porcine coronary arteries. Kwon HM, et al. **J Korean Med Sci** 1998 Dec; 13(6):603–11

Estrogen replacement therapy with its physiological dose does not eliminate the aggravating effect of ovariectomy on glomerular injury in hypercholesterolemic female Imai rats. Sakemi T, et al. **Nephron** 1998 Nov;80(3):324–30

Ultrastructural changes of the external elastic lamina in experimental hypercholesterolemic porcine coronary arteries. Kwon HM, et al. **Yonsei Med J** 1999 Jun; 40(3):273–82

[Changes in Bruch's membrane in experimental hypercholesteremia in rats] Tokura T, et al. **Nippon Ganka Gakkai Zasshi** 1999 Feb;103(2):85–91 (Eng. Abstr.) **(Jpn)**

[Clasmatosis and hepatocyte proliferation during initial stage experimental hypercholesterolemia in rabbits] Nagornev VA, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):467–71 **(Rus)**

[The effect of L-arginine on the ultrastructure of atrial cardiomyocytes in experimental hypercholesterolemia] Stechenko LO, et al. **Fiziol Zh** 1999;45(1–2):72–9 (Eng. Abstr.) **(Ukr)**

[The structural organization of the aortic endothelium in hypercholesterolemia and the effect of L-arginine] Tkachenko MM, et al. **Fiziol Zh** 1998;44(5–6):59–64 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Retrobulbar and peripheral capillary blood flow in hypercholesterolemic subjects. Senn B, et al. **Am J Ophthalmol** 1999 Sep;128(3):310–6

Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia. Cooper A, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1482–8

Reperfusion-induced changes in capillary perfusion and filtration: effects of hypercholesterolemia. Harris NR. **Am J Physiol** 1999 Aug;277(2 Pt 2):H669–75

Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training. Niebauer J, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1346–54

Cholesterol, but not cigarette smoke, decreases rabbit carotid artery relaxation. Johnson D, et al. **Ann Vasc Surg** 1999 Sep;13(5):480–3

Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Böger RH, et al. **Atherosclerosis** 1998 Nov;141(1):31–43

Lovastatin maintains nitric oxide--but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Brandes RP, et al. **Atherosclerosis** 1999 Jan;142(1):97–104

Impaired adaptive vascular growth in hypercholesterolemic rabbit. Bucay M, et al. **Atherosclerosis** 1998 Aug; 139(2):243–51

Improvement in the endothelium-dependent relaxation in hypercholesterolemic rabbits treated with vitamin E. Ribeiro Jorge PA, et al. **Atherosclerosis** 1998 Oct; 140(2):333–9

A critical analysis of the role of cholesterol in atherogenesis. Sloop GD. **Atherosclerosis** 1999 Feb;142(2):265–8 (33 ref.)

Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Skatchkov MP, et al. **Biochem Biophys Res Commun** 1999 Jan 19;254(2):319–24

Protective effect of dietary tomato against endothelial dysfunction in hypercholesterolemic mice. Suganuma H, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):78–82

Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Best PJ, et al. **Circulation** 1999 Apr 6;99(13):1747–52

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Böger RH, et al. **Circulation** 1998 Nov 3;98(18):1842–7

Hypercholesterolemia, abnormal coronary vasomotion, and calcium antagonists [letter; comment] David DS. **Circulation** 1999 Apr 13;99(14):1922. Comment on: Circulation 1998 Apr 14;97(14):1348–54.

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial [see comments] Dupuis J, et al. **Circulation** 1999 Jun 29;99(25):3227–33. Comment in: Circulation 1999 Jun 29;99(25):3215–7.

Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Napoli C, et al. **Circulation** 1999 Apr 20;99(15):2003–10

Cholesterol lowering. Should it continue to be the last thing we do? [editorial; comment] Waters D. **Circulation** 1999 Jun 29;99(25):3215–7. Comment on: Circulation 1999 Jun 29;99(25):3227–33.

Central cooling effects in patients with hypercholesterolaemia. De Lorenzo F, et al. **Clin Sci (Colch)** 1998 Aug;95(2):213–7

Beneficial effect of vitamin E administration on nitric oxide function in subjects with hypercholesterolaemia. Green D, et al. **Clin Sci (Colch)** 1998 Sep;95(3):361–7

Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia [letter] Sheu WH, et al. **Diabetes Care** 1999 Jul;22(7):1224–5

Improvement of nitrergic relaxation by farnesol of the sphincter of Oddi from hypercholesterolaemic rabbits. Szilvassy Z, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):75–8

Effects of hypercholesterolaemia on Leydig and Sertoli cell secretory function and the overall sperm fertilizing capacity in the rabbit. Yamamoto Y, et al. **Hum Reprod** 1999 Jun; 14(6):1516–21

Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypercholesterolemia. Hasdai D, et al. **Hypertension** 1999 Jul;34(1):89–95

The role of nitric oxide in bradykinin-induced dilation of coronary resistance vessels in patients with hypercholesterolemia. Kato M, et al. **Intern Med** 1999 May; 38(5):394–400

Impairment of the nitric oxide-mediated vasodilator response to mental stress in hypertensive but not in hypercholesterolemic patients. Cardillo C, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1207–13

Effect of vitamin E on endothelial vasodilator function in

patients with hypercholesterolemia, chronic smoking or both. Heitzer T, et al. **J Am Coll Cardiol** 1999 Feb; 33(2):499–505

Involvement of endothelial nitric oxide synthase in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbit. Seo KK, et al. **J Androl** 1999 Mar–Apr;20(2):298–306

Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. Tsao PS, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S48–53 (62 ref.)

Pressor hyperreactivity to mental and hand–grip stresses in patients with hypercholesterolemia. Minami M, et al. **J Hypertens** 1999 Feb;17(2):185–92

Diabetes attenuates the alterations in both venous endothelial and smooth muscle cell function induced by prolonged hypercholesterolemia in an experimental model. Davies MG, et al. **J Invest Surg** 1999 Mar–Apr;12(2):107–14

Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats. Kodama N, et al. **Kidney Int Suppl** 1999 Jul;71:S174–7

Stiffness of the aortic wall in hypercholesterolemic children. Iannuzzi A, et al. **Metabolism** 1999 Jan;48(1):55–9

Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Caligiuri G, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6920–4

Cholesterol, cholesterol lowering, and endothelial function. Vogel RA, et al. **Prog Cardiovasc Dis** 1998 Sep–Oct; 41(2):117–36 (270 ref.)

Adenovirus-mediated gene transfer is augmented in basilar and carotid arteries of heritable hyperlipidemic rabbits. Lund DD, et al. **Stroke** 1999 Jan;30(1):120–5

Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit. Rossoni G, et al. **Thromb Res** 1999 Jun 1;94(5):327–38

PREVENTION & CONTROL

Young adults with hypercholesterolemia. Kwiterovich PO Jr. **Am J Med** 1999 Aug 23;107(2A):40S–42S (17 ref.)

The effect of percutaneous oestradiol on atheroma formation in ovariectomized cholesterol-fed rabbits. Haines CJ, et al. **Atherosclerosis** 1999 Apr;143(2):369–75

Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria [letter; comment] Ramsay LE, et al. **BMJ** 1999 Apr 24; 318(7191):1140–1. Comment on: BMJ 1998 Oct 24;317(7166):1125–30.

Direct vascular antiatherogenic effects of oleic acid: a clue to the cardioprotective effects of the Mediterranean diet. Massaro M, et al. **Cardiologia** 1999 Jun;44(6):507–13 (42 ref.)

CAD-prevention--a perspective [editorial] Maisch B, et al. **Herz** 1999 Feb;24(1):1–2

Feasibility of a national cholesterol guideline in daily practice. A randomized controlled trial in 20 general practices. van der Weijden T, et al. **Int J Qual Health Care** 1999 Apr;11(2):131–7

The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. Goldman L, et al. **J Am Coll Cardiol** 1999 Sep;34(3):768–76

Selective opportunistic screening for hypercholesterolemia in primary care practice. Hutchison B, et al. **J Clin Epidemiol** 1998 Oct;51(10):817–25

Treating average cholesterol levels in patients with coronary heart disease. Lindbloom EJ. **J Fam Pract** 1999 Feb; 48(2):94–5

JAMA patient page: cholesterol. **JAMA** 1999 Jan 13; 281(2):206

The National Cholesterol Education Program: progress and prospects. Cleeman JI, et al. **JAMA** 1998 Dec 23–30; 280(24):2099–104

Are there good and bad carbohydrates for HDL cholesterol? [comment] Katan MB. **Lancet** 1999 Mar 27; 353(9158):1029–30. Comment on: Lancet 1999 Mar 27;353(9158):1045–8.

Seven weeks feeding of magnesium and fluoride modifies plasma lipids of hypercholesterolaemic rats in late growth phase. Luoma H, et al. **Magnes Res** 1998 Dec;11(4):271–82

Current controversies in screening: cholesterol, breast cancer, and prostate cancer. Sox HC. **Mt Sinai J Med** 1999 Mar; 66(2):91–101

Preventive pediatric cardiology. Tobacco, cholesterol, obesity, and physical activity. Gidding SS. **Pediatr Clin North Am** 1999 Apr;46(2):253–62 (34 ref.)

The effect of physician office visits on CHD risk factor modification as part of a worksite cholesterol screening program. Wang JS, et al. **Prev Med** 1999 Mar;28(3):221–8

[Guidelines and costs (comment)] Casparie AF, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19;142(38):2075–7 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2096–101. **(Dut)**

[The decision to treat based on epidemiological methodology: the paradigm of hypercholesterolemia] Kornitzer M. **Rev Med Brux** 1999 Jun;20(3):135–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[Hypercholesterolemia-related cardiovascular risk: a continuum from a notion of normality, intervention threshold and therapeutic objectives] Scheen AJ. **Rev Med Liege** 1999 Jan;54(1):17–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Secondary prevention of ischemic heart disease after coronary revascularization] Delacrétaz E, et al. **Schweiz Rundsch Med Prax** 1998 Nov 4;87(45):1497–503 (Eng. Abstr.) **(Fre)**

[Dietary cholesterol as a conditioner of ingestion of other nutrients and various blood parameters in young women] Ortega RM, et al. **Nutr Hosp** 1998 Sep–Oct;13(5):221–7 (55 ref.) (Eng. Abstr.) **(Spa)**

[Attitude change of Spanish cardiologist with respect to hypolipidemic treatment in secondary prevention. The role of outside hospital care] Plaza Pérez I, et al. **Rev Esp Cardiol** 1998;51 Suppl 6:54–62 (Eng. Abstr.) **(Spa)**

[The new debate on cholesterol: is the lowest level the best?] Olsson AG. **Lakartidningen** 1999 Feb 10;96(6):648–52 (16 ref.) **(Swe)**

PSYCHOLOGY

Psychosocial factors in nutrition education for hypercholesterolemic children. McHale SM, et al. **Ann Behav Med** 1998 Summer;20(3):233–40

REHABILITATION

[Ambulatory heart groups after inpatient cardiologic rehabilitation] Keck M, et al. **Rehabilitation (Stuttg)** 1999 May;38(2):79–87 (Eng. Abstr.) **(Ger)**

SURGERY

Role of the surgeon in managing hypercholesterolemia. Buchwald H. **Surgery** 1999 May;125(5):465–7 (13 ref.)

THERAPY

Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis. Katerndahl DA, et al. **Am J Epidemiol** 1999 Mar 1;149(5):429–41

Determinants of cholesterol screening and treatment patterns. Insights for decision-makers [published erratum appears in Am J Prev Med 1998 Nov;15(4):433] Davis SK, et al. **Am J Prev Med** 1998 Oct;15(3):178–86

Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Grundy SM, et al. **Arch Intern Med** 1999 Aug 9–23;159(15):1670–8 (64 ref.)

Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Park JW, et al. **Atherosclerosis** 1998 Aug;139(2):401–9

Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated for elevated blood cholesterol. Canadian Heart Health Surveys Research Group [see comments] MacLean DR, et al. **Can J Cardiol** 1999 Apr;15(4):445–51. Comment in: Can J Cardiol 1999 Apr;15(4):407–8.

Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Coleman KR, et al. **Circ Res** 1999 Jun 11;84(11):1268–76

Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines [letter; comment] Danias PG, et al. **Circulation** 1999 Jun 29; 99(25):3325–6. Comment on: Circulation 1998 Sep 1;98(9):851–5.

Therapy and clinical trials [editorial] Evans PM. **Curr Opin Lipidol** 1999 Apr;10(2):195–7

Safety and effectiveness of long-term LDL-apheresis in patients at high risk. Thiery J, et al. **Curr Opin Lipidol** 1998 Dec;9(6):521–6 (45 ref.)

The role of cholesterol management in coronary disease risk reduction in elderly patients. Grundy SM. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):655–75, x (85 ref.)

Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. Anderson JW, et al. **J Am Coll Nutr** 1999 Feb;18(1):43–50

Evidence for hypocholesterolemic effect of Lactobacillus reuteri in hypercholesterolemic mice. Taranto MP, et al. **J Dairy Sci** 1998 Sep;81(9):2336–40

A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. Davidson MH, et al. **J Nutr** 1998 Nov; 128(11):1927–32

The effects of nutritional supplements on the treatment of depression, diabetes, and hypercholesterolemia in the renal patient. Duncan MG. **J Ren Nutr** 1999 Apr;9(2):58–62 (16 ref.)

Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Allison TG, et al. **Mayo Clin Proc** 1999 May; 74(5):466–73

Effects of diet and exercise on cholesterol levels [letter; comment] Lichtenstein AH. **N Engl J Med** 1998 Nov 19; 339(21):1552–3. Comment on: N Engl J Med 1998 Jul 2;339(1):12–20.

Detection and measurement of hypercholesterolaemia in South Africans attending general practitioners in private practice--the cholesterol monitor. Steyn K, et al. **S Afr Med J** 1998 Dec;88(12):1569–74

Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Bosch T, et al. **Ther Apher** 1999 Aug;3(3):209–13

Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Koga N. **Ther Apher** 1999 May;3(2):155–60 (26 ref.)

LDL-Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Koll RA. **Ther Apher** 1998 May;2(2):142–6

Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis. Schettler V, et al. **Ther Apher** 1999 Aug;3(3):219–26 (67 ref.)

Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits [editorial] Yamamoto T, et al. **Ther Apher** 1998 Feb; 2(1):25–30 (42 ref.)

[LDL-apheresis therapy, methods and indications] Assogba U, et al. **Presse Med** 1999 May 15;28(18):985–91 (60 ref.) (Eng. Abstr.) **(Fre)**

[Lipoprotein plasmapheresis] Busnach G. **Cardiologia** 1998 Sep;43(9):971–4 **(Ita)**

ULTRASONOGRAPHY

Brachial artery ultrasound: a noninvasive tool in the assessment of triglyceride-rich lipoproteins. Vogel RA. **Clin Cardiol** 1999 Jun;22(6 Suppl):II34–9 (19 ref.)

URINE

Trace metal excretion in patients with homozygous hypercholesterolaemia. Jackson GE, et al. **J Trace Elem Med Biol** 1999 Jul;13(1–2):62–7

Hypercholesterolemia and glomerular diseases in urinary screening of school children. Asami T, et al. **Pediatr Nephrol** 1999 Feb;13(2):125–8

HYPERCHOLESTEROLEMIA, ESSENTIAL see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERCHOLESTEROLEMIA, FAMILIAL

An update on familial hypercholesterolaemia. Ose L. **Ann Med** 1999 Apr;31 Suppl 1:13–8 (19 ref.)

Integrin mediated adhesion of mononuclear cells from patients with familial hypercholesterolemia. de Bont N, et al. **Eur J Clin Invest** 1999 Sep;29(9):749–57

BLOOD

Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Raal FJ, et al. **Am J Cardiol** 1999 May 1;83(9):1330–3

Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Lagrost L, et al. **Atherosclerosis** 1999 Apr; 143(2):415–25

LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Rovers C, et al. **Atherosclerosis** 1998 Nov;141(1):99–105

The cholesterol/phospholipid ratio of the erythrocyte membrane in children with familial hypercholesterolemia. Its relationship with plasma lipids and red blood cell aggregability. Martinez M, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(4):259–63

Thrombomodulin levels in asymptomatic familial hypercholesterolemia. Vayá A, et al. **Clin Hemorheol Microcirc** 1999;20(2):91–6

Plasma thrombomodulin is not increased in familial hypercholesterolemic children with rheological alterations. Vayá A, et al. **Clin Hemorheol Microcirc** 1998 Oct; 19(2):133–8

Erythrocyte deformability in young familial hypercholesterolemics. Vayá A, et al. **Clin Hemorheol Microcirc** 1998 Sep;19(1):43–8

Pattern of red blood cells and platelets cholesterol and fatty acids in homozygous familial hypercholesterolemic patients treated with LDL-apheresis. Stefanutti C, et al. **Clin Ter** 1998 May–Jun;149(3):231–3 (20 ref.)

A novel low-density lipoprotein apheresis device for removal of atherogenic lipoproteins from whole blood [comment] Derfler K, et al. **Eur J Clin Invest** 1998 Dec;28(12):1003–5 . Comment on: Eur J Clin Invest 1998 Dec;28(12):994–1002.

Concentrations of the atherogenic Lp(a) are elevated in FH. Lingenhel A, et al. **Eur J Hum Genet** 1998 Jan;6(1):50–60

Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Hennermann JB, et al. **Eur J Pediatr** 1998 Nov;157(11):912–8

Correction of erythrocyte shape abnormalities in familial hypercholesterolemia after LDL-apheresis: does it influence cerebral hemodynamics? Iannuzzi A, et al. **Heart Vessels** 1997;12(5):234–40

Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. Cabezas MC, et al. **J Intern Med** 1998 Oct;244(4):299–307

Lipoprotein (a) metabolism estimated by nonsteady-state kinetics. Parhofer KG, et al. **Lipids** 1999 Apr;34(4):325–35

Impact of different low-density lipoprotein (LDL) receptor mutations on the ability of LDL to support lymphocyte

proliferation. Martínez-Botas J, et al. **Metabolism** 1999 Jul; 48(7):834–9

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Wetterau JR, et al. **Science** 1998 Oct 23;282(5389):751–4

The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone. Kitano Y, et al. **Ther Apher** 1997 May;1(2):187–90

[The plasma antioxidant status and trace elements in patients with familial hypercholesterolemia treated with LDL-apheresis] Delattre J, et al. **Ann Pharm Fr** 1998; 56(1):18–25 (Eng. Abstr.) **(Fre)**

[Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy] Madej A, et al. **Pol Arch Med Wewn** 1998 Apr;99(4):308–13 (Eng. Abstr.) **(Pol)**

[Colony forming megakaryocyte units in the peripheral blood of patients with hyperlipoproteinemia] Popkova VM, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):221–4 **(Rus)**

[Familial hypercholesterolemia and plasma Lp(a) levels: 2 cardiovascular risk factors] Real JT, et al. **An Med Interna** 1999 Feb;16(2):69–72 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Assessment by transesophageal echography of atherosclerosis of the descending thoracic aorta in patients with hypercholesterolemia. Tomochika Y, et al. **Am J Cardiol** 1999 Mar 1;83(5):703–9

Role of family history and family testing in cardiovascular risk assessment. Lauer RM. **Am J Med** 1999 Aug 23; 107(2A):14S–15S (26 ref.)

Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment. Koga N, et al. **Artif Organs** 1992 Apr;16(2):171–6

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Shiomi M, et al. **Atherosclerosis** 1999 Feb; 142(2):345–53

LDL-apheresis improves microalbuminuria in patients with severe familial heterozygous hypercholesterolemia [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Mar;143(1):223–4

Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia. Winder AF, et al. **Clin Genet** 1998 Dec;54(6):497–502

Xanthomas of the Achilles tendon: report of a bilateral case and review of the literature. Carranza-Bencano A, et al. **Foot Ankle Int** 1999 May;20(5):314–6 (21 ref.)

Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Rallidis L, et al. **Heart** 1998 Dec;80(6):583–90

Case study: analysis of an acute anterior-lateral myocardial infarction in a 16-year-old patient with familial hypercholesterolemia. McCauley KM, et al. **J Cardiovasc Nurs** 1999 Apr;13(3):114–8

Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. Raal FJ, et al. **J Intern Med** 1999 Jul;246(1):75–80

Surgical excision of the tendon xanthoma in familial hypercholesterolemia--a case report. Lin GT. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jul; 15(7):441–6

[Biological and clinical safety of nomegestrol acetate administered alone then associated in inverse sequence with transdermal 17 beta estradiol, in women at risk of dyslipoproteinemia type IIa] Zartarian M, et al. **Ann Endocrinol (Paris)** 1998 Dec;59(5):411–6 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Alberto FL, et al. **Braz J Med Biol Res** 1999 Jun;32(6):739–45

Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Kotze MJ, et al. **Clin Genet** 1998 Jul;54(1):74–8

Improved detection of familial hypercholesterolemia by determining low density lipoprotein receptor expression in mitogen-induced proliferating lymphocytes. Chan PC, et al. **J Lipid Res** 1998 Nov;39(11):2261–70

Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia [letter] Kontula K, et al. **Lancet** 1999 Jul 3;354(9172):46–7

Increased plasma, serum and urinary 8-epi-prostaglandin F2 alpha in heterozygous hypercholesterolemia. Oguogho A, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):113–8

DIET THERAPY

Effect of dietary fish supplementation on lipoprotein levels in patients with hyperlipoproteinemia. Sučić M, et al. **Coll Antropol** 1998 Jun;22(1):77–83

[Comparative study on the effect of antiatherosclerotic diet enriched with polyunsaturated omega-3 fatty acids of plant and animal origin on the level of natural antibodies against catecholamines in patients with cardiovascular diseases] Pogozheva AV, et al. **Vopr Pitan** 1998;(4):32–5 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Pitsavos CE, et al. **Am J Cardiol** 1998 Dec 15;82(12):1484–8

Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Sánchez-Quesada JL, et al. **Am J Cardiol** 1999 Sep 15; 84(6):655–9

More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia [letter] Bertolotto A, et al. **Atherosclerosis** 1999 Apr;143(2):455–7

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Heath KE, et al. **Atherosclerosis** 1999 Mar;143(1):41–54

Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Inazu A, et al. **Atherosclerosis** 1999 Aug; 145(2):405–13

Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Lagrost L, et al. **Atherosclerosis** 1999 Apr; 143(2):415–25

Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Apr;143(2):459–60

Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits. Harsch M, et al. **Br J Pharmacol** 1998 May;124(2):277–82

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans [see comments] Eriksson M, et al. **Circulation** 1999 Aug 10;100(6):594–8. Comment in: Circulation 1999 Aug 10;100(6):576–8.

Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Verhaar MC, et al. **Circulation** 1999 Jul 27;100(4):335–8

Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Hennermann JB, et al. **Eur J Pediatr** 1998 Nov;157(11):912–8

Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Arruzazabala ML, et al. **Int J Tissue React** 1998;20(4):119–24

Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures. Fukuzawa S, et al. **Intern Med** 1999 Apr;38(4):330–5

Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Hoogerbrugge N. **J Intern Med** 1998 Aug;244(2):143–7

When should patients with heterozygous familial hypercholesterolemia be treated? [editorial; comment] Rifkind BM, et al. **JAMA** 1999 Jan 13;281(2):180–1. Comment on: JAMA 1999 Jan 13;281(2):137–44.

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial [see comments] Stein EA, et al. **JAMA** 1999 Jan 13;281(2):137–44. Comment in: JAMA 1999 Jan 13;281(2):180–1.

Statins and C-reactive protein [letter; comment] Kluft C, et al. **Lancet** 1999 Apr 10;353(9160):1274. Comment on: Lancet 1999 Jan 9;353(9147):118–9.

Tamoxifen and hypertriglyceridemia [letter] [see comments] Jonkers GH. **Neth J Med** 1999 Aug;55(2):84–5. Comment in: Neth J Med 1999 Aug;55(2):47–9.

Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. Stuyt PM, et al. **Neth J Med** 1998 Nov;53(5):228–33

Efficacy of statin therapy: possible effect of phenytoin. Murphy MJ, et al. **Postgrad Med J** 1999 Jun;75(884):359–60

The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone. Kitano Y, et al. **Ther Apher** 1997 May;1(2):187–90

[Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy] Madej A, et al. **Pol Arch Med Wewn** 1998 Apr;99(4):308–13 (Eng. Abstr.) **(Pol)**

[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia] Prat H, et al. **Rev Med Chil** 1999 Mar;127(3):286–94 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Molecular epidemiology of familial hypercholesterolaemia. Defesche JC, et al. **Lancet** 1998 Nov 21;352(9141):1643–4

[Tracing of patients with familial hypercholesterolemia in the Netherlands] Umans-Eckenhausen MA, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1157–61 (Eng. Abstr.) **(Dut)**

ETIOLOGY

A 13-year-old girl with hyperlipoproteinaemia type IIb and low plasma protein levels. Stozicky F, et al. **Eur J Pediatr** 1999 May;158(5):427–8

GENETICS

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Kawaguchi A, et al. **Am Heart J** 1999 Mar;137(3):410–8

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1–p32. Varret M, et al. **Am J Hum Genet** 1999 May;64(5):1378–87

Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Bertolini S, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb; 19(2):408–18

Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Mak YT, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct;18(10):1600–5

Unusual inheritance of severe primary hypercholesterolemia. Calandra S, et al. **Atherosclerosis** 1999 Jun;144(2):464–6

P1A1/A2 polymorphism of platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial hypercholesterolemia. Cenarro A, et al. **Atherosclerosis** 1999 Mar;143(1):99–104

Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1–p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Couture P, et al. **Atherosclerosis** 1999 Mar;143(1):145–51

The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Heath KE, et al. **Atherosclerosis** 1999 Mar;143(1):41–54

Medped FH: a paradigm for other common monogenic diseases in South Africa. Kotze MJ, et al. **Atherosclerosis** 1999 Jun;144(2):467–8

MedPed in Vienna. Widhalm K, et al. **Atherosclerosis** 1999 Jun;144(2):469–70

The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Alberto FL, et al. **Braz J Med Biol Res** 1999 Jun;32(6):739–45

Long-distance PCR-based screening for large rearrangements of the LDL receptor gene in Korean patients with familial hypercholesterolemia. Kim SH, et al. **Clin Chem** 1999 Sep;45(9):1424–30

Three novel small deletion mutations of the LDL receptor gene in Korean patients with familial hypercholesterolemia. Chae JJ, et al. **Clin Genet** 1999 May;55(5):325–31

Rapid detection of polymorphisms in exons 10, 11 and 12 of the low density lipoprotein receptor gene (LDLR) and their use in a clinical genetic diagnostic setting [letter] Heath KE, et al. **Clin Genet** 1999 Mar;55(3):212–4

Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Kotze MJ, et al. **Clin Genet** 1998 Jul;54(1):74–8

Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. Loubser O, et al. **Clin Genet** 1999 May; 55(5):340–5

Mutation screening of the LDLR gene and ApoB gene in patients with a phenotype of familial hypercholesterolemia and normal values in a functional LDL receptor/apolipoprotein B assay. Nissen H, et al. **Clin Genet** 1998 Jul;54(1):79–82

Evaluation of a clinically applicable mutation screening technique for genetic diagnosis of familial hypercholesterolemia and familial defective apolipoprotein B. Nissen H, et al. **Clin Genet** 1998 Jun;53(6):433–9

Genetic investigation of patients with hypercholesterolemia type IIa [letter] Szalai C, et al. **Clin Genet** 1999 Jan; 55(1):67–8

Genotype/phenotype correlations in familial hypercholesterolaemia. Nicholls P, et al. **Curr Opin Lipidol** 1998 Aug;9(4):313–7 (39 ref.)

Mutations in the low-density lipoprotein receptor gene in Swedish familial hypercholesterolaemia patients: clinical expression and treatment response. Ekström U, et al. **Eur J Clin Invest** 1998 Sep;28(9):740–7

New type of the internalization-defective low-density lipoprotein receptor owing to two-nucleotide deletion (2199delCA or 2201delCA) in Japanese patients with familial hypercholesterolaemia. Tashiro J, et al. **Eur J Clin Invest** 1998 Sep;28(9):712–9

Concentrations of the atherogenic Lp(a) are elevated in FH. Lingenhel A, et al. **Eur J Hum Genet** 1998 Jan;6(1):50–60

Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. Mutations in brief no. 135. Online. Cenarro A, et al. **Hum Mutat** 1998;11(5):413

Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Couture P, et al. **Hum Mutat** 1998;Suppl 1:S226–31

Mutation analysis in 46 German families with familial hypercholesterolemia: identification of 8 new mutations.

Mutations in brief no. 226. Online. Ebhardt M, et al. **Hum Mutat** 1999;13(3):257

Identification of recurrent and novel mutations in the LDL receptor gene in Japanese familial hypercholesterolemia. Mutation in brief no. 248. Online. Hattori H, et al. **Hum Mutat** 1999;14(1):87

Identification of three new mutations of the low density lipoprotein receptor gene in Dutch familial hypercholesterolemic patients. Lombardi P, et al. **Hum Mutat** 1998;Suppl 1:S172–4

Possible common mutations in the low density lipoprotein receptor gene in Chinese. Mak YT, et al. **Hum Mutat** 1998; Suppl 1:S310–3

Prevalence of Lithuanian mutation among St. Petersburg Jews with familial hypercholesterolemia. Mandelshtam M, et al. **Hum Mutat** 1998;12(4):255–8

Rapid screening of the LDL receptor point mutation FH–Genoa/Palermo. Mutation in brief no. 238. Online. Marino G, et al. **Hum Mutat** 1999;13(5):412

Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. Thiart R, et al. **Hum Mutat** 1998; Suppl 1:S232–3

Heterozygous familial hypercholesterolemia: a new point-mutation (1372del2) in the LDL-receptor gene which causes severe hypercholesterolemia. Widhalm K, et al. **Hum Mutat (Online)** 1999 Oct;14(4):357

Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. Norman D, et al. **J Clin Invest** 1999 Sep;104(5):619–28

Five familial hypercholesterolemic kindreds in Japan with novel mutations of the LDL receptor gene. Hirayama T, et al. **J Hum Genet** 1998;43(4):250–4

Familial hypercholesterolemia kindred in Utah with novel C54S mutations of the LDL receptor gene. Emi M, et al. **Jpn Heart J** 1998 Nov;39(6):785–9

Molecular genetic diagnosis of a family with hypercholesterolemia by a mismatched PCR-RFLP method for genotyping single base substitution of the LDL receptor gene. Yamaki E, et al. **Jpn Heart J** 1998 Sep; 39(5):681–6

Molecular epidemiology of familial hypercholesterolaemia. Defesche JC, et al. **Lancet** 1998 Nov 21;352(9141):1643–4

Impact of different low-density lipoprotein (LDL) receptor mutations on the ability of LDL to support lymphocyte proliferation. Martinez-Botas J, et al. **Metabolism** 1999 Jul; 48(7):834–9

Two novel low-density lipoprotein receptor gene mutations (E397X and 347delGCC) in St. Petersburg familial hypercholesterolemia. Kh C, et al. **Mol Genet Metab** 1998 Dec;65(4):311–4

Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease [letter; comment] Gaffney D, et al. **N Engl J Med** 1998 Nov 26;339(22):1640–1; discussion 1641–2. Comment on: N Engl J Med 1998 May 28;338(22):1577–84.

Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease [letter; comment] Schaefer JR, et al. **N Engl J Med** 1998 Nov 26;339(22):1641–2. Comment on: N Engl J Med 1998 May 28;338(22):1577–84.

Increased plasma, serum and urinary 8-epi-prostaglandin F2 alpha in heterozygous hypercholesterolemia. Oguogho A, et al. **Wien Klin Wochenschr** 1999 Feb 12;111(3):113–8

[The sequence analysis of the 3'end of intron 15 from human LDL receptor gene and its application in the study of gene diagnosis for familial hypercholesterolaemia] Zhou TH, et al. **I Chuan Hsueh Pao** 1999;26(1):1–7 (Eng. Abstr.) **(Chi)**

[Direct detection of mutations in the LDL receptor gene in patients with familial hypercholesterolemia] Freiberger T, et al. **Cas Lek Cesk** 1998 Dec 14;137(24):750–2 (Eng. Abstr.) **(Cze)**

[Attitude of patients toward detection of hereditary disease. Heterozygote familial hypercholesterolemia] Andersen LK, et al. **Ugeskr Laeger** 1998 Oct 12;160(42):6075–81 (Eng. Abstr.) **(Dan)**

[Tracing of patients with familial hypercholesterolemia in the Netherlands] Umans-Eckenhausen MA, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1157–61 (Eng. Abstr.) **(Dut)**

[Evaluation of a newly discovered LDL receptor mutation (exon 10, GAC>AAC, D271N, "FH Graz-1") in familial hypercholesterolemia-- a familystudy] de Campo A, et al. **Acta Med Austriaca** 1999;26(1):20–5 (Eng. Abstr.) **(Ger)**

[Primary hypercholesterolemia: mechanisms of its development in man] Chernyshov VA. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):24–32 (54 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Increased formation of distinct F2 isoprostanes in hypercholesterolemia [see comments] Reilly MP, et al. **Circulation** 1998 Dec 22-29;98(25):2822–8. Comment in: Circulation 1998 Dec 22-29;98(25):2785–7.

Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. Frénais R, et al. **J Lipid Res** 1999 Aug;40(8):1506–11

Regulation of classic and alternative bile acid synthesis in hypercholesterolemic rabbits: effects of cholesterol feeding and bile acid depletion. Xu G, et al. **J Lipid Res** 1998 Aug; 39(8):1608–15

MORTALITY

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. **Atherosclerosis** 1999 Jan;142(1):105–12

PATHOLOGY

Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects [see comments] Tonstad S, et al. **Eur J Clin Invest** 1998 Dec;28(12):971–9. Comment in: Eur J Clin Invest 1998 Dec;28(12):980–2.

Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Rallidis L, et al. **Heart** 1998 Dec;80(6):583–90

Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Aliev G, et al. **Histol Histopathol** 1998 Jul;13(3):797–817 (199 ref.)

Inhibitory effects of Dai-saiko-to (Da-Chai-Hu-Tang) on the progression of atherosclerotic lesions in Kurosawa and Kusanagi-hypercholesterolemic rabbits [published erratum appears in J Ethnopharmacol 1999 Apr;65(1):79] Iizuka A, et al. **J Ethnopharmacol** 1998 Dec;63(3):209–18

RADIOGRAPHY

Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Gidding SS, et al. **Circulation** 1998 Dec 8;98(23):2580–3

SURGERY

Arterial revascularization. 18-year experience with coronary artery bypass grafting in familial hypercholesterolemia. Kawasuji M, et al. **Jpn J Thorac Cardiovasc Surg** 1999 Jul; 47(7):330–4

THERAPY

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Mabuchi H, et al. **Am J Cardiol** 1998 Dec 15;82(12):1489–95

Garlic extract therapy in children with hypercholesterolemia. McCrindle BW, et al. **Arch Pediatr Adolesc Med** 1998 Nov; 152(11):1089–94

Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Nishimura S, et al. **Atherosclerosis** 1999 Jun;144(2):409–17

Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Stefanutti C, et al. **Drugs Exp Clin Res** 1999;25(1):23–8

Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Hennermann JB, et al. **Eur J Pediatr** 1998 Nov;157(11):912–8

Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase--ganciclovir treatment. Pakkanen TM, et al. **Gene Ther** 1999 Jan; 6(1):34–41

A novel soluble chimera for the treatment of familial hypercholesterolemia [comment] Paillard F. **Hum Gene Ther** 1999 May 1;10(7):1093–4. Comment on: Hum Gene Ther 1999 May 1;10(7):1219–28.

Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia [see comments] Parise F, et al. **Hum Gene Ther** 1999 May 1; 10(7):1219–28. Comment in: Hum Gene Ther 1999 May 1;10(7):1043–4.

Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. Koga N, et al. **J Intern Med** 1999 Jul;246(1):35–43

Images in clinical medicine. Homozygous familial hypercholesterolemia. Genest J Jr, et al. **N Engl J Med** 1999 Aug 12;341(7):490

The effect of selective low-density lipoprotein apheresis on plasma lipoperoxides and antioxidant vitamins in familial hypercholesterolemic patients. Baricchi R, et al. **Ther Apher** 1998 Aug;2(3):218–23

Clinical application and effectiveness of low-density lipoprotein apheresis in the treatment of coronary artery disease. Daida H, et al. **Ther Apher** 1997 Aug;1(3):253–4

The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. Koga N. **Ther Apher** 1997 Aug; 1(3):260–70 (33 ref.)

Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns. Koga N. **Ther Apher** 1999 May;3(2):155–60 (26 ref.)

Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Richter WO, et al. **Ther Apher** 1999 Aug;3(3):203–8

The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia [editorial] Thompson GR, et al. **Ther Apher** 1997 Feb;1(1):13–6 (18 ref.)

[The plasma antioxidant status and trace elements in patients with familial hypercholesterolemia treated with LDL-apheresis] Delattre J, et al. **Ann Pharm Fr** 1998; 56(1):18–25 (Eng. Abstr.) **(Fre)**

[The treatment of familial hypercholesterolemia and of the dyslipidemias responsible for cardiovascular disease] Sampietro T, et al. **G Ital Cardiol** 1999 Feb;29(2):171–3 **(Ita)**

HYPERCHYLOMICRONEMIA, FAMILIAL see **LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL**

HYPERCOAGULABILITY see **THROMBOPHILIA**

HYPERCORTICISM see **ADRENAL GLAND HYPERFUNCTION**

HYPEREMESIS GRAVIDARUM

Hyperemesis gravidarum. Goodwin TM. **Clin Obstet Gynecol** 1998 Sep;41(3):597–605 (24 ref.)

BLOOD

Immunologic and biochemical factors in hyperemesis gravidarum with or without hyperthyroxinemia. Leylek OA, et al. **Gynecol Obstet Invest** 1999;47(4):229–34

COMPLICATIONS

Wernicke's encephalopathy induced by hyperemesis gravidarum. Gárdián G, et al. **Acta Neurol Scand** 1999 Mar; 99(3):196–8

Rhabdomyolysis secondary to hyperemesis gravidarum. Fukada Y, et al. **Acta Obstet Gynecol Scand** 1999 Jan; 78(1):71

Thyroid function in hyperemesis gravidarum [letter; comment] Chan NN. **Lancet** 1999 Jun 26;353(9171):2243. Comment on: Lancet 1999 May 8;353(9164):1584.

Management of hyperemesis in pregnant women [letter; comment] Child TJ. **Lancet** 1999 Jan 23;353(9149):325. Comment on: Lancet 1998 Nov 14;352(9140):1594.

Management of hyperemesis in pregnant women [letter; comment] Dickson MJ. **Lancet** 1999 Jan 23;353(9149):325 . Comment on: Lancet 1998 Nov 14;352(9140):1594.

Pregnant, vomiting, and coma [see comments] Hillbom M, et al. **Lancet** 1999 May 8;353(9164):1584. Comment in: Lancet 1999 Jun 26;353(8171):2243.

Pregnant, vomiting, and going blind [see comments] Tesfaye S, et al. **Lancet** 1998 Nov 14;352(9140):1594. Comment in: Lancet 1999 Jan 23;353(9149):325.

Coagulopathy secondary to vitamin K deficiency in hyperemesis gravidarum. Robinson JN, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):673–5

[Central pontine myelinolysis induced by hyperemesis gravidarum] Tonelli J, et al. **Medicina (B Aires)** 1999; 59(2):176–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Pregnant, vomiting, and coma [see comments] Hillbom M, et al. **Lancet** 1999 May 8;353(9164):1584. Comment in: Lancet 1999 Jun 26;353(8171):2243.

DRUG THERAPY

The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. Safari HR, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):921–4

Rapid marked response of severe hyperemesis gravidarum to oral erythromycin. El Younis CM, et al. **Am J Perinatol** 1998;15(9):533–4

EPIDEMIOLOGY

Saturated fat intake and the risk of severe hyperemesis gravidarum. Signorello LB, et al. **Epidemiology** 1998 Nov; 9(6):636–40

Symptomatic gastro-oesophageal reflux in pregnancy: a prospective study among Singaporean women. Ho KY, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1020–6

ETIOLOGY

Molar pregnancy presenting with hyperemesis gravidarum. Glick MM, et al. **J Am Osteopath Assoc** 1999 Mar; 99(3):162–4

[Brown vaginal discharge in early pregnancy, hyperemesis. Intact hydatidiform mole] Keel JB, et al. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31–32):1283–4 **(Ger)**

IMMUNOLOGY

Immunologic and biochemical factors in hyperemesis gravidarum with or without hyperthyroxinemia. Leylek OA, et al. **Gynecol Obstet Invest** 1999;47(4):229–34

METABOLISM

Acidic isoforms of chorionic gonadotrophin in European and Samoan women are associated with hyperemesis gravidarum and may be thyrotrophic. Jordan V, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):619–27

MICROBIOLOGY

Helicobacter pylori infection and persistent hyperemesis gravidarum. Jacoby EB, et al. **Am J Perinatol** 1999; 16(2):85–8

PHYSIOPATHOLOGY

Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy. Maes BD, et al.
Aliment Pharmacol Ther 1999 Feb;13(2):237–43

Hyperemesis gravidarum is not associated with hypofunction of the pituitary-adrenal axis [letter] la Marca A, et al.
Am J Obstet Gynecol 1998 Nov;179(5):1381–2

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM.
Thyroid 1999 Jul;9(7):653–7 (42 ref.)

THERAPY

Hypnosis in the treatment of hyperemesis gravidarum [letter] Simon EP. **Am Fam Physician** 1999 Jul;60(1):56, 61

Total parenteral nutrition (TPN) and steroid usage in the management of hyperemesis gravidarum. Subramaniam R, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):339–41

Enteral nutrition by percutaneous endoscopic gastrojejunostomy in severe hyperemesis gravidarum: a report of two cases. Serrano P, et al. **Clin Nutr** 1998 Jun; 17(3):135–9

HYPEREMIA

Reliability of the transient hyperemic response test in detecting changes in cerebral autoregulation induced by the graded variations in end-tidal carbon dioxide. Mahajan RP, et al. **Anesth Analg** 1998 Oct;87(4):843–9

CHEMICALLY INDUCED

The effects of sevoflurane and nitrous oxide on middle cerebral artery blood flow velocity and transient hyperemic response. Bedforth NM, et al. **Anesth Analg** 1999 Jul; 89(1):170–4

The effects of nitrous oxide and oxygen on transient hyperemic response in human volunteers. Girling KJ, et al. **Anesth Analg** 1999 Jul;89(1):175–80

Mechanism of acid-induced mesenteric hyperemia in rats. Seno K, et al. **Life Sci** 1998;63(18):1653–62

The effect of the base on the kinetics of action of the capsaicinoid nonivamide: evaluation with a hyperemic test. Stücker M, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Sep–Oct;12(5):289–98

Gas-body-based contrast agent enhances vascular bioeffects of 1.09 MHz ultrasound on mouse intestine. Miller DL, et al. **Ultrasound Med Biol** 1998 Oct;24(8):1201–8

DIAGNOSIS

Bilateral acute suppurative otitis media: the stage of hyperemia. Pulec JL, et al. **Ear Nose Throat J** 1999 Mar; 78(3):142

The association between laser Doppler reactive hyperaemia curves and the distribution of peripheral arterial disease. Ray SA, et al. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):245–8

Hyperperfusion syndrome following carotid endarterectomy: evaluation using diffusion-weighted magnetic resonance imaging--case report. Shinno K, et al.
Neurol Med Chir (Tokyo) 1998 Sep;38(9):557–61

Hyperperfusion syndrome after extracranial-intracranial bypass in a patient with moyamoya disease--case report. Uno M, et al. **Neurol Med Chir (Tokyo)** 1998 Jul;38(7):420–4

DRUG THERAPY

Suppression of hyperemia after brain ischemia by L-threo-3,4-dihydroxyphenylserine. Yamagami S, et al.
Neuroreport 1998 Sep 14;9(13):2939–43

ETIOLOGY

Neurogenic origin of articular hyperemia in early degenerative joint disease. McDougall JJ, et al.
Am J Physiol 1999 Mar;276(3 Pt 2):R745–52

Coronary reactive hyperaemia after two periods of coronary occlusion in the anaesthetized goat. Ariaudo S, et al.
Boll Soc Ital Biol Sper 1997 Nov–Dec;73(11–12):165–73

Vasodilation contributes to the rapid hyperemia with rhythmic contractions in humans. Shoemaker JK, et al.
Can J Physiol Pharmacol 1998 Apr;76(4):418–27

Ischaemic preconditioning changes the pattern of coronary reactive hyperaemia in the goat: role of adenosine and nitric oxide. Gattullo D, et al. **Cardiovasc Res** 1999 Apr; 42(1):57–64

Images in cardiovascular medicine. Reactive hyperemia after release of coronary spasm. Sugihara H, et al.
Circulation 1999 Feb 2;99(4):589–90

Role of enteral nutrition-induced splanchnic hyperemia in ameliorating splanchnic ischemia [editorial] Eleftheriadis E. **Nutrition** 1999 Mar;15(3):247–8 (13 ref.)

[Reactive hyperemia in hypertension] Doloman LB.
Fiziol Zh 1999;45(1-2):80–6 (Eng. Abstr.) **(Ukr)**

PATHOLOGY

Effects of antiaggregant and antiinflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs. Andrieu S, et al.
J Cardiovasc Pharmacol 1999 Feb;33(2):264–72

PHYSIOPATHOLOGY

Inhibition of phospholipase A2 attenuates functional hyperemia in the hamster cremaster muscle. Nuttle LC, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1289–94

Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Reuter U, et al.
Am J Physiol 1998 Jun;274(6 Pt 2): H1979–87

Impaired response of the forearm resistance but not conductance vessels to reactive hyperemia in hypertrophic cardiomyopathy. Dimitrow PP, et al. **Angiology** 1999 Apr; 50(4):267–72

Ischemic and pressure-induced hyperemia: a comparison. Rendell MS, et al. **Arch Phys Med Rehabil** 1998 Nov; 79(11):1451–5

Factors affecting assessment of cerebral autoregulation using the transient hyperaemic response test. Cavill G, et al.
Br J Anaesth 1998 Sep;81(3):317–21

Prostaglandin inhibition causes an increase in reactive hyperaemia after ischaemic exercise in human forearm. Naylor HL, et al. **Clin Physiol** 1999 May;19(3):211–20

Intravascular source of adenosine during forearm ischemia in humans: implications for reactive hyperemia. Costa F, et al. **Hypertension** 1999 Jun;33(6):1453–7

Bone hyperemia precedes disuse-induced intracortical bone resorption. Gross TS, et al. **J Appl Physiol** 1999 Jan; 86(1):230–5

Upright posture blunts postprandial splanchnic hyperemia in patients with cirrhosis and portal hypertension [see comments] Iwao T, et al. **J Gastroenterol** 1999 Jun; 34(3):359–65. Comment in: J Gastroenterol 1999 Jun;34(3):428–30.

Blood digestion-induced splanchnic hyperemia and portal blood flow in portal hypertensive rats and the role of octreotide. Kotzampassi K, et al. **J Gastroenterol** 1998 Oct; 33(5):678–83

Trigeminal and carotid body inputs controlling vascular resistance in muscle during post-contraction hyperaemia in cats. de Burgh Daly M, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):543–54

The effects of ischemic preconditioning on resting coronary flow and reactive hyperemia: involvement of A1 adenosine receptors. Pagliaro P, et al. **Life Sci** 1999;64(12):1071–8

Mechanism of acid-induced mesenteric hyperemia in rats. Seno K, et al. **Life Sci** 1998;63(18):1653–62

An electrical model of biological tissues undergoing hyperaemia. Olmi R, et al. **Phys Med Biol** 1998 Nov; 43(11):3405–18

RADIONUCLIDE IMAGING

Discrepancies in brain perfusion SPECT findings between Tc-99m HMPAO and Tc-99m ECD: evaluation using dynamic SPECT in patients with hyperemia. Miyazawa N, et al. **Clin Nucl Med** 1998 Oct;23(10):686–90

ULTRASONOGRAPHY

Long-term haemodynamic effects of octreotide on postprandial splanchnic hyperemia in humans: a placebo-controlled echo-doppler study. Ludwig D, et al.
Aliment Pharmacol Ther 1999 Aug;13(8):1119–29

Transcranial Doppler monitoring during carotid endarterectomy helps to identify patients at risk of postoperative hyperperfusion. Dalman JE, et al.
Eur J Vasc Endovasc Surg 1999 Sep;18(3):222–7

HYPEREOSINOPHILIC SYNDROME

Differentiation of a human eosinophilic leukemic cell line, EoL-1: characterization by the expression of cytokine receptors, adhesion molecules, CD95 and eosinophilic cationic protein (ECP). Wong CK, et al. **Immunol Lett** 1999 Jun 1;68(2-3):317–23

[The eosinophil: doctor Jekyll or mister Hyde? (editorial)] Bletry O. **Med Trop (Mars)** 1998;58(4 Suppl):423–5 (30 ref.) **(Fre)**

[Eosinophilic gastroenteritis: an example of gastrointestinal toxicity of eosinophils] Carre D, et al.
Med Trop (Mars) 1998;58(4 Suppl):485–8 (Eng. Abstr.) **(Fre)**

[Disseminated eosinophilic collagen disease] Ishiyama T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):123–5 (7 ref.) **(Jpn)**

[Idiopathic hypereosinophilic syndrome] Koike M, et al.
Ryoikibetsu Shokogun Shirizu 1998;(21 Pt 2):119–22 (16 ref.) **(Jpn)**

[Eosinophilic leukemia] Moriyama Y.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):149–52 (15 ref.) **(Jpn)**

BLOOD

Bcl-2 expression by eosinophils in a patient with hypereosinophilia. Plötz SG, et al.
J Allergy Clin Immunol 1998 Dec;102(6 Pt 1):1037–40

Study of release of eosinophil cationic proteins (ECP and EPX) in the hypereosinophilic syndrome (HES) and other hypereosinophilic conditions. Bobbio-Pallavicini E, et al.
Panminerva Med 1998 Sep;40(3):186–90

[Methods and criteria for studying polynuclear eosinophil activation] Coussinier-Paris P. **Med Trop (Mars)** 1998;58(4 Suppl):503–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Value of laboratory findings in the diagnosis of hypereosinophilia] Magnaval JF. **Med Trop (Mars)** 1998; 58(4 Suppl):493–8 (63 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Hypereosinophilic syndrome: progression of peripheral neuropathy despite controlled eosinophil levels. Cengiz B, et al. **Acta Neurol Belg** 1999 Jun;99(2):133–7

Systemic lupus erythematosus, eosinophilia and Löffler's endocarditis. An unusual association. Thomeer M, et al.
Eur Respir J 1999 Apr;13(4):930–3 (21 ref.)

Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. Johnston AM, et al. **J R Soc Med** 1998 Sep;91(9):492–3

Hypereosinophilic syndrome in a trisomy 21 fetus. Kusanagi Y, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):701–2 (8 ref.)

Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Schulman H, et al. **Pediatr Radiol** 1999 Aug;29(8):595–7

Destructive joint lesions and bursitis in idiopathic hypereosinophilic syndrome [letter] Anders HJ, et al.
Rheumatology (Oxford) 1999 Feb;38(2):185–6

[Eosinophilia and renal pathology] Giudicelli CP, et al.
Med Trop (Mars) 1998;58(4 Suppl):477–81 (64 ref.) (Eng. Abstr.) **(Fre)**

[Idiopathic hypereosinophilia syndrome and specific hepatitis. A case report (letter)] Lamarque P, et al.
Rev Med Interne 1998 Mar;19(3):209–10 **(Fre)**

[Hypereosinophilic syndrome complicated by myelofibrosis] Okabe S, et al. **Rinsho Ketsueki** 1999 May;40(5):420–2 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

MRI findings of muscle involvement in idiopathic hypereosinophilic syndrome. Hundt W, et al.
Eur Radiol 1999;9(3):525–8

Löeffler endomyocarditis: a clinical presentation as right ventricular tumor. De Cock C, et al.
J Heart Valve Dis 1998 Nov;7(6):668–71

Hypereosinophilic syndrome or chronic eosinophilic leukemia? [letter; comment] Bolaños-Meade J, et al.
Mayo Clin Proc 1999 Jul;74(7):742. Comment on: Mayo Clin Proc 1998 Dec;73(12):1177–84.

[Incidental discovery of asymptomatic Loeffler fibroplastic endocarditis. Report of a case] Pop C, et al.
Ann Cardiol Angeiol (Paris) 1998 Dec;47(10):728–31 (Eng. Abstr.) **(Fre)**

[Hypereosinophilia: what is important to the clinician?] Bertrand E. **Med Trop (Mars)** 1998;58(4 Suppl):512 **(Fre)**

[Acute eosinophilic myocarditis: a diagnostic and therapeutic emergency] Fourcade L, et al. **Med Trop (Mars)** 1998;58(4 Suppl):465–70 (Eng. Abstr.) **(Fre)**

[Diagnostic approach to hypereosinophilia] Granel B, et al.
Med Trop (Mars) 1998;58(4 Suppl):489–92 (Eng. Abstr.) **(Fre)**

[Value of laboratory findings in the diagnosis of hypereosinophilia] Magnaval JF. **Med Trop (Mars)** 1998; 58(4 Suppl):493–8 (63 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent subacute encephalopathy in the framework of idiopathic hypereosinophilic syndrome] Balestra B, et al.
Dtsch Med Wochenschr 1999 Mar 19;124(11):321–4 (Eng. Abstr.) **(Ger)**

[Recurring vertigo and syncope in a patient with eosinophilia] Wendtner CM, et al. **Internist (Berl)** 1999 Mar;40(3):305–10 **(Ger)**

[Comment on the contribution: A. Hagendorff et al., Löffler fibroplastic endocarditis in the thrombotic stage in isolated right ventricular tissue eosinophilia (letter; comment)] Schwab J, et al. **Z Kardiol** 1998 Aug;87(8):644. Comment on: Z Kardiol 1998 Apr;87(4):293–9. **(Ger)**

DRUG THERAPY

Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ceretelli S, et al.
Ann Hematol 1998 Oct;77(4):161–4

AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Luciano L, et al. **Haematologica** 1999 Jul;84(7):651–3

ENZYMOLOGY

Cytosolic phospholipase A2, increased and activated in the eosinophils of patients with hypereosinophilic syndrome in vivo, is involved in the augmented release of leukotriene C4. Urasaki T, et al. **Inflamm Res** 1999 Jan;48(1):36–40

ETIOLOGY

[Diagnostic approach to hypereosinophilia] Granel B, et al.
Med Trop (Mars) 1998;58(4 Suppl):489–92 (Eng. Abstr.) **(Fre)**

GENETICS

Clonality of isolated eosinophils in the hypereosinophilic syndrome. Chang HW, et al. **Blood** 1999 Mar 1;93(5):1651–7

Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by

fluorescence in situ hybridization. Forrest DL, et al. **Cancer Genet Cytogenet** 1998 Nov;107(1):65–8

Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Oliver JW, et al. **Cancer Genet Cytogenet** 1998 Dec;107(2):111–7 (49 ref.)

The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Ma SK, et al. **Hum Pathol** 1999 Jul; 30(7):864–8

[Genetic control of hypereosinophilias] Granel B, et al. **Med Trop (Mars)** 1998;58(4 Suppl):508–11 (16 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Idiopathic hypereosinophilic syndrome associated with elevated plasma levels of interleukin-10 and soluble interleukin-2 receptor [letter] Kanbe N, et al. **Br J Dermatol** 1998 Nov;139(5):916–8

Eosinophilia--idiopathic or not? [editorial; comment] Bain BJ. **N Engl J Med** 1999 Oct 7;341(15):1141–3. Comment on: N Engl J Med 1999 Oct 7;341(15):1112–20.

Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia [see comments] Simon HU, et al. **N Engl J Med** 1999 Oct 7;341(15):1112–20. Comment in: N Engl J Med 1999 Oct 7;341(15):1141–3.

[Methods and criteria for studying polynuclear eosinophil activation] Coussinier-Paris P. **Med Trop (Mars)** 1998;58(4 Suppl):503–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[The heart and the eosinophil] Touze JE, et al. **Med Trop (Mars)** 1998;58(4 Suppl):459–64 (33 ref.) (Eng. Abstr.) **(Fre)**

[Hypereosinophilic syndrome associated with antineutrophil cytoplasmic antibody] Yoshimura N, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jul;37(7):554–9 (Eng. Abstr.) **(Jpn)**

METABOLISM

The interleukin-5 messenger RNA expression in a patient with idiopathic hypereosinophilic syndrome. Ho KK, et al. **Clin Exp Allergy** 1998 Jul;28(7):889–92

PARASITOLOGY

Löeffler endomyocarditis: a clinical presentation as right ventricular tumor. De Cock C, et al. **J Heart Valve Dis** 1998 Nov;7(6):668–71

[Diagnostic and treatment of hypereosinophilia upon return from the tropics: 102 patients] Molinier S, et al. **Med Trop (Mars)** 1998;58(4 Suppl):499–502 (Eng. Abstr.) **(Fre)**

PATHOLOGY

New human fusion partners, ICLU-B, -T, -E for making human hybridomas derived from various immunological cells. Kawahara H, et al. **Hum Antibodies** 1999;9(2):89–94

Solar urticaria as the presenting sign of hypereosinophilic syndrome [letter] Aragone MG, et al. **Int J Dermatol** 1999 Mar;38(3):234

[The hypereosinophilic variant of Ph'-positive chronic myeloleukemia] Khoroshko ND, et al. **Ter Arkh** 1998; 70(7):29–37 (30 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Chockalingam A, et al. **Bone Marrow Transplant** 1999 May;23(10):1093–4

The eosinophil, a Trojan Horse? [editorial] Koenderman L, et al. **Neth J Med** 1999 May;54(5):181–3

THERAPY

Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Chockalingam A, et al. **Bone Marrow Transplant** 1999 May;23(10):1093–4

Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Basara N, et al. **Leuk Lymphoma** 1998 Dec;32(1–2):189–93

[Hypereosinophilia: what is important to the clinician?] Bertrand E. **Med Trop (Mars)** 1998;58(4 Suppl):512 **(Fre)**

[Acute eosinophilic myocarditis: a diagnostic and therapeutic emergency] Fourcade L, et al. **Med Trop (Mars)** 1998;58(4 Suppl):465–70 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Hepatic involvement in hypereosinophilia: sonographic findings. Nam KJ, et al. **J Ultrasound Med** 1999 Jul; 18(7):475–9

VETERINARY

Hypereosinophilic syndrome with Hodgkin's-like lymphoma in a ferret. Blomme EA, et al. **J Comp Pathol** 1999 Feb; 120(2):211–7

HYPERESTHESIA

Creativity, hyperesthesia, and mental illness [letter; comment] Gordon AG. **Can J Psychiatry** 1999 Feb;44(1):91. Comment on: Can J Psychiatry 1998 Mar;43(2):166–72.

CHEMICALLY INDUCED

Involvement of primary afferent C-fibres in touch-evoked pain (allodynia) induced by prostaglandin E2. Minami T, et al. **Eur J Neurosci** 1999 Jun;11(6):1849–56

Painful hyperaesthesia caused by protease inhibitors? [letter] Colebunders R, et al. **Infection** 1998 Jul-Aug;26(4):250–1

COMPLICATIONS

Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. Pagano R. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):79–83

DRUG THERAPY

Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. Pagano R. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):79–83

Carbamazepine in the treatment of Lyme disease-induced hyperacusis. Nields JA, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter;11(1):97–9

ETIOLOGY

Patient and injury characteristics in the development of cold sensitivity of the hand: a prospective cohort study. Craigen M, et al. **J Hand Surg [Am]** 1999 Jan;24(1):8–15

PHYSIOPATHOLOGY

Involvement of primary afferent C-fibres in touch-evoked pain (allodynia) induced by prostaglandin E2. Minami T, et al. **Eur J Neurosci** 1999 Jun;11(6):1849–56

Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Murphy PG, et al. **Eur J Neurosci** 1999 Jul;11(7):2243–53

Receptor subtype mediating the adrenergic sensitivity of pain behavior and ectopic discharges in neuropathic Lewis rats. Lee DH, et al. **J Neurophysiol** 1999 May;81(5):2226–33

Generalized vibrotactile allodynia in a patient with temporomandibular disorder. Fillingim RB, et al. **Pain** 1998 Oct;78(1):75–8

Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Moriwaki K, et al. **Pain** 1999 May;81(1–2):1–6 (43 ref.)

HYPERGAMMAGLOBULINEMIA

[X-linked hyper IgM syndrome] Kimura N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):460–3 (22 ref.) **(Jpn)**

[Polyclonal hypergammaglobulinemia] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):534–6 (7 ref.) **(Jpn)**

[Benign IgM gammopathy] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):537–9 (8 ref.) **(Jpn)**

[Biclonal gammopathy] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):540–2 (9 ref.) **(Jpn)**

[Immunodeficiency with hyper-IgM] Sugai S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):210–2 (9 ref.) **(Jpn)**

[Lambda light chain deposition disease without renal involvement (letter)] Armengou A, et al. **Med Clin (Barc)** 1998 Sep 26;111(9):358–9 **(Spa)**

BLOOD

Hyperglobulinemia with an increased anion gap. Kirschbaum B. **Am J Med Sci** 1998 Dec;316(6):393–7

Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E. Miller RL, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):503–11

COMPLICATIONS

Immunoblastic lymphadenopathy-like T cell lymphoma evolving into a massive plasma cell proliferation with biclonal paraproteinemia. Higuchi T, et al. **Acta Haematol** 1998 Dec;100(3):151–5

Monozygotic twin brothers with primary immunodeficiency presenting with metastatic adenocarcinoma of unknown primary. Wood LA, et al. **Acta Oncol** 1998;37(7–8):771–2

A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. Witzens M, et al. **Ann Hematol** 1998 Nov;77(5):231–4

Central retinal vein occlusion in a patient with IgG lambda monoclonal gammopathy. Enzenauer RW, et al. **Arch Ophthalmol** 1999 Jan;117(1):134–5

Solitary crystal-storing histiocytosis of the tongue in a patient with rheumatoid arthritis and polyclonal hypergammaglobulinemia. Bosman C, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):920–4

Necrotizing toxoplasmic encephalitis in a child with the X-linked hyper-IgM syndrome. Tsuge I, et al. **Eur J Pediatr** 1998 Sep;157(9):735–7

Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. Leiva LE, et al. **J Clin Immunol** 1998 Jul;18(4):283–90

Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. Cunningham CK, et al. **J Pediatr** 1999 May;134(5):584–8

Crescentic glomerulonephritis in hyper IgD syndrome. Tsimaratos M, et al. **Pediatr Nephrol** 1999 Feb;13(2):132–4

[Pseudo-periodic disease with hyperimmunoglobulinemia D: a never-ending story with probable prenatal onset] Grouteau E, et al. **Arch Pediatr** 1998 Mar;5(3):280–4 (Eng. Abstr.) **(Fre)**

[Tracheobronchial aspergillosis in a patient with Buckley's syndrome (letter)] Barel R, et al. **Presse Med** 1998 Oct 3;27(29):1477 **(Fre)**

[Necrobiotic xanthogranulomatosis: a cutaneous manifestation of a monoclonal IgM gammopathy] Sève P, et al. **Rev Med Interne** 1998 May;19(5):338–40 (Eng. Abstr.) **(Fre)**

[Interstitial pneumonia, pulmonary thrombotic microangiopathy, and hyperimmunoglobulinemia associated with Basedow's disease] Tojima H, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Apr;37(4):311–6 (Eng. Abstr.) **(Jpn)**

[Plasma cell leukemia (IgA-lambda type) with polyclonal hypergammaglobulinemia] Hyodo T, et al. **Rinsho Ketsueki** 1998 Sep;39(9):680–5 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

A man with a swollen leg and abnormal globulins. Parnassa DT, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):15–6, 22

[Fever that came from the North] Oziol E, et al. **Rev Med Interne** 1999;20 Suppl 2:236s–238s **(Fre)**

ETIOLOGY

Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):212–6

GENETICS

An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome). Webster EA, et al. **Arthritis Rheum** 1999 Jun;42(6):1291–6

The 78C --> T (T254M) XHIM mutation: lack of a tight phenotype-genotype relationship [letter] de Vries E, et al. **Blood** 1999 Aug 15;94(4):1488–90

Hereditary fevers. Grateau G, et al. **Curr Opin Rheumatol** 1999 Jan;11(1):75–8 (31 ref.)

CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization. de Saint Basile G, et al. **Eur J Immunol** 1999 Jan;29(1):367–73

CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand. Seyama K, et al. **J Biol Chem** 1999 Apr 16;274(16):11310–20

Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome. Atkinson TP, et al. **J Clin Immunol** 1998 Nov;18(6):430–9

Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. Cunningham CK, et al. **J Pediatr** 1999 May;134(5):584–8

Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group [see comments] Drenth JP, et al. **Nat Genet** 1999 Jun;22(2):178–81. Comment in: Nat Genet 1999 Jun;22(2):121–2.

Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome [see comments] Houten SM, et al. **Nat Genet** 1999 Jun;22(2):175–7. Comment in: Nat Genet 1999 Jun;22(2):121–2.

You give me fever [news; comment] Valle D. **Nat Genet** 1999 Jun;22(2):121–2. Comment on: Nat Genet 1999 Jun;22(2):175–7. Comment on: Nat Genet 1999 Jun;22(2):178–81.

The X-linked hyperimmunoglobulin M syndrome. Fuleihan RL. **Semin Hematol** 1998 Oct;35(4):321–31 (96 ref.)

IMMUNOLOGY

Placental antibody transfer: influence of maternal HIV infection and placental malaria. de Moraes-Pinto MI, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov; 79(3):F202–5

CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization. de Saint Basile G, et al. **Eur J Immunol** 1999 Jan;29(1):367–73

CD40–CD154 interaction in experimental and human disease (review). Biancone L, et al. **Int J Mol Med** 1999 Apr; 3(4):343–53 (112 ref.)

Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. Jain A, et al. **J Clin Invest** 1999 Apr;103(8):1151–8

Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. Lacroix-Desmazes S, et al. **J Immunol** 1999 May 1;162(9):5601–8

IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. Matsumoto M, et al. **J Immunol** 1999 Jan 15;162(2):1056–63

CD40–CD40 ligand interaction is central to cell-mediated

immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. Subauste CS, et al. **J Immunol** 1999 Jun 1;162(11):6690–700

[Low concentration monoclonal IgM and demyelinating peripheral neuropathy] Dehan C, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr;57(2):221–3 **(Fre)**

PHYSIOPATHOLOGY

Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Müller F, et al. **Blood** 1998 Nov 15;92(10):3721–9

THERAPY

Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM. Bordigoni P, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1111–4

Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. Kato T, et al. **Bone Marrow Transplant** 1999 May;23(10):1081–3

Immunological reconstitution by allogeneic bone marrow transplantation in a child with the X-linked hyper-IgM syndrome. Kawai S, et al. **Eur J Pediatr** 1999 May; 158(5):394–7

Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer. Hong NM, et al. **J Autoimmun** 1998 Aug;11(4):301–7

VETERINARY

Systemic plasmacytosis and polyclonal gammopathy in a dog. Gookin JL, et al. **J Vet Intern Med** 1998 Nov–Dec; 12(6):471–4

HYPERGLYCEMIA

Hyperglycemia and intensive glycemic control in diabetic patients with chronic renal disease. Manske CL. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S157–71 (132 ref.)

Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Fujita Y, et al. **Diabetologia** 1998 Dec;41(12):1459–66

Hyperglycemia regulates the glucose-transport system of clonal choriocarcinoma cells in vitro. A potential molecular mechanism contributing to the adjunct effect of glucose in tumor therapy. Hahn T, et al. **Int J Cancer** 1998 Oct 29;78(3):353–60

Increased serum neuron specific enolase concentrations in patients with hyperglycemic cortical ischemic stroke. Sulter G, et al. **Neurosci Lett** 1998 Aug 28;253(1):71–3

BLOOD

Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Lehto S, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr; 19(4):1014–9

Haemorheological consequences of hyperglycaemic spike in healthy volunteers and insulin-dependent diabetics. Khodabandehlou T, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):105–14

Autoregulation of glucose production in health and disease. Tappy L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):161–4 (34 ref.)

Reduction of activity, but no decrease in concentration, of erythrocyte Cu,Zn-superoxide dismutase by hyperglycaemia in diabetic patients. Kotake M, et al. **Diabet Med** 1998 Aug;15(8):668–71

Glucose production, utilization, and cycling in response to moderate exercise in obese subjects with type 2 diabetes and mild hyperglycemia. Giacca A, et al. **Diabetes** 1998 Nov;47(11):1763–70

Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Rao AK, et al. **Diabetes** 1999 May;48(5):1156–61

Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Shaw JE, et al. **Diabetologia** 1999 Sep; 42(9):1050–4

Hormonal and metabolic responses to maintained hyperglycemia during prolonged exercise. MacLaren DP, et al. **J Appl Physiol** 1999 Jul;87(1):124–31

Hyperglycemia in vitro attenuates insulin-stimulated chemokinesis in normal human neutrophils. Role of protein kinase C activation. Oldenborg PA, et al. **J Leukoc Biol** 1999 May;65(5):635–40

Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. Erenmemisoglu A, et al. **J Pharm Pharmacol** 1999 Jun;51(6):741–3

[Which HbA1c to look at?] Marre M. **Journ Annu Diabetol Hotel Dieu** 1998;:249–56 (26 ref.) **(Fre)**

CHEMICALLY INDUCED

Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):89–94

Hyperglycemia and olanzapine [letter] Ober SK, et al. **Am J Psychiatry** 1999 Jun;156(6):970

The hyperglycemia induced by angiotensin II in rats is mediated by AT1 receptors. Machado LJ, et al. **Braz J Med Biol Res** 1998 Oct;31(10):1349–52

High-dose vitamin C supplementation increases plasma glucose [letter] Branch DR. **Diabetes Care** 1999 Jul; 22(7):1218–9

p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Yamada J, et al. **Eur J Pharmacol** 1998 Oct 23;359(2–3):185–90

Hyperglycemia associated with olanzapine [letter] Fertig MK, et al. **J Clin Psychiatry** 1998 Dec;59(12):687–9

Hyperglycemic effect of a neurotoxic fraction (F3) from Naja haje venom: role of hypothalamo-pituitary adrenal axis (HPA). el-Fiky MA. **J Nat Toxins** 1999 Jun;8(2):203–12

Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic suprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Chun S, et al. **Neurosci Lett** 1998 Dec 4;257(3):135–8

A review of protease inhibitor-induced hyperglycemia. Kaufman MB, et al. **Pharmacotherapy** 1999 Jan;19(1):114–7 (17 ref.)

Fetal development in alloxan-treated rats [see comments] Palomar-Morales M, et al. **Reprod Toxicol** 1998 Nov–Dec; 12(6):659–65. Comment in: Reprod Toxicol 1999 Mar–Apr;13(2):153.

Drug selection and the management of corticosteroid-related diabetes mellitus. Hoogwerf B, et al. **Rheum Dis Clin North Am** 1999 Aug;25(3):489–505 (69 ref.)

COMPLICATIONS

Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations. Lin B, et al. **Acta Neuropathol (Berl)** 1998 Dec; 96(6):610–20

A "touch of sugar" can be fatal [editorial; comment] Clark CM Jr, et al. **Am Heart J** 1998 Nov;136(5):762–4. Comment on: Am Heart J 1998 Nov;136(5):919–27.

Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled. Sadoff L. **Am J Clin Oncol** 1998 Dec;21(6):605–7

Hyperglycemia-induced vasculopathy in the murine vitelline vasculature: correlation with PECAM-1/CD31 tyrosine phosphorylation state. Pinter E, et al. **Am J Pathol** 1999 May;154(5):1367–79

Screening for ketonemia in patients with diabetes. Schwab TM, et al. **Ann Emerg Med** 1999 Sep;34(3):342–6

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction [editorial; comment] Mogensen CE. **BMJ** 1998 Sep 12; 317(7160):693–4. Comment on: BMJ 1998 Mar 14;316(7134):823–8. Comment on: BMJ 1998 Sep 12;317(7160):703–13. Comment on: BMJ 1998 Sep 12;317(7160):713–20. Comment on: BMJ 1998 Sep 12;317(7160):720–6.

Hyperglycemia-exaggerated ischemic brain damage following 30 min of middle cerebral artery occlusion is not due to capillary obstruction. Li PA, et al. **Brain Res** 1998 Aug 31;804(1):36–44

Insulin resistance. Leiter L. **Can J Cardiol** 1999 Apr;15 Suppl B:20B–22B

Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Kong MF, et al. **Clin Geriatr Med** 1999 May;15(2):321–38 (98 ref.)

Perioperative hyperglycemia, infection or risk? Khaodhiar L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Jan; 2(1):79–82 (22 ref.)

Episodic hyperglycaemia in pregnant women with well-controlled Type 1 diabetes mellitus: a major potential factor underlying macrosomia [see comments] Kyne-Grzebalski D, et al. **Diabet Med** 1999 Aug; 16(8):702–6. Comment in: Diabet Med 1999 Aug;16(8):621–2.

Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. Muggeo M. **Diabet Med** 1998;15 Suppl 4:S60–2

Hyperglycemia and cardiovascular disease in type 2 diabetes. Laakso M. **Diabetes** 1999 May;48(5):937–42 (50 ref.)

Hyperglycemia-induced embryonic dysmorphogenesis correlates with genomic DNA mutation frequency in vitro and in vivo. Lee AT, et al. **Diabetes** 1999 Feb;48(2):371–6

Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Daimon M, et al. **Diabetes Care** 1998 Sep;21(9):1525–8

Epidemiological studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Haffner SM. **Diabetes Care** 1999 Apr; 22 Suppl 3:C54–6 (27 ref.)

Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Response to Kitzmiller et al [comment] [published erratum appears in Diabetes Care 1999 Jul;22(7):1229] Jovanovic L. **Diabetes Care** 1999 May; 22(5):846–8. Comment on: Diabetes Care 1999 May;22(5):874–6.

Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Niskanen L, et al. **Diabetes Care** 1998 Nov;21(11):1861–9

Chorea in hyperglycemia [letter; comment] Piccolo I, et al. **Diabetes Care** 1998 Oct;21(10):1777. Comment on: Diabetes Care 1997 Jul;20(7):1209–10.

Toxicity of hyperglycaemia in type 2 diabetes. Yki-Järvinen H. **Diabetes Metab Rev** 1998 Sep;14 Suppl 1:S45–50 (38 ref.)

Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Baron AD. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S51–5 (8 ref.)

Asymptomatic hyperglycaemia and early atherosclerotic changes. Kawamori R. **Diabetes Res Clin Pract** 1998 Jul; 40 Suppl:S35–42

Postprandial hyperglycaemic state: importance and consequences. Lebovitz HE. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S27–8 (37 ref.)

The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Haffner SM. **Endocr Rev** 1998 Oct;19(5):583–92 (109 ref.)

Hyperglycemia and the pathogenesis of atherosclerosis: lessons from murine models. Vischer UM. **Eur J Endocrinol** 1999 Jan;140(1):1–3 (12 ref.)

Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Kunt T, et al. **Exp Clin Endocrinol Diabetes** 1999; 107(4):252–6

Hyperglycemia and focal brain ischemia. Gisselsson L, et al. **J Cereb Blood Flow Metab** 1999 Mar;19(3):288–97

Pyloric stenosis in a boy with non-ketotic hyperglycinaemia. al-Essa M, et al. **J Inherit Metab Dis** 1999 Feb;22(1):81–2

Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Zheng F, et al. **Kidney Int** 1998 Dec;54(6):1999–2007

Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia. Sparks JD, et al. **Metabolism** 1998 Nov; 47(11):1315–24

Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways [see comments] Moley KH, et al. **Nat Med** 1998 Dec; 4(12):1421–4. Comment in: Nat Med 1999 Feb;5(2):126–7.

Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus. Swidan SZ, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):961–72 (86 ref.)

Hyperglycemia found not to be teratogenic [letter; comment] Kalter H. **Reprod Toxicol** 1999 Mar–Apr;13(2):153. Comment on: Reprod Toxicol 1998 Nov–Dec;12(6):659–65.

A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Waziri R, et al. **Schizophr Res** 1999 Jun 22;37(3):205–15

Insulin receptor antibodies and insulin resistance. Magsino CH Jr, et al. **South Med J** 1999 Jul;92(7):717–9

DHF with complication of acute pancreatitis related hyperglycemia: a case report. Jusuf H, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):367–9

Effects of hyperglycemia on small cerebral infarctions in awake rabbits. Roos MW. **Ups J Med Sci** 1999; 104(2):145–61

[The hyperglycemic dehydration syndrome (letter; comment)] Hafkamp GJ. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2262–3. Comment on: Ned Tijdschr Geneeskd 1998 Jul 11;142(28):1585–8. **(Dut)**

[The hyperglycemic dehydration syndrome (letter; comment)] Lips J. **Ned Tijdschr Geneeskd** 1998 Oct 10; 142(41):2263. Comment on: Ned Tijdschr Geneeskd 1998 Jul 11;142(28):1585–8. **(Dut)**

[The hyperglycemic dehydration syndrome (letter; comment)] Ter Braak GI. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2262. Comment on: Ned Tijdschr Geneeskd 1998 Jul 11;142(28):1585–8. **(Dut)**

[A case of chorea-ballism with bilateral lesion of the corpus striatum and hyperglycemia] Sato A, et al. **Nippon Naika Gakkai Zasshi** 1998 Dec 10;87(12):2502–3 **(Jpn)**

[Prognostic significance of transient hyperglycemia in acute phase of ischemic stroke] Słowik A, et al. **Neurol Neurochir Pol** 1998 Mar–Apr;32(2):317–29 (Eng. Abstr.) **(Pol)**

[Diarrhea associated with enteral feeding: hyperglycemia and other factors] Monteiro JP, et al. **Arq Gastroenterol** 1998 Jan–Mar;35(1):40–4 (Eng. Abstr.) **(Por)**

[Striatal petechial hemorrhage and non-ketone hyperglycemia as the cause of hemichorea in a patient with unknown diabetes mellitus (letter)] Carrasco Sánchez FJ, et al. **Neurologia** 1998 Oct;13(8):406–7 **(Spa)**

DIAGNOSIS

Plasma lipids, phospholipid fatty acids and indices of glycaemia in 10-year-old children born as small-for-gestational-age or preterm infants [see comments] Decsi T, et al. **Acta Paediatr** 1999 May; 88(5):500–4. Comment in: Acta Paediatr 1999 May;88(5):483–4.

[New neurometabolic disorders: indicative clinical signs] Garcia-Silva MT. **Rev Neurol** 1999 Jan 1–15;28(1):4–11 (33 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Anti-hyperglycemic activity of moxonidine: metabolic and

molecular effects in obese spontaneously hypertensive rats. Friedman JE, et al. **Blood Press** 1998;Suppl 3:32–9
Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study [news] Laakso M. **Circulation** 1999 Feb 2;99(4):461–2
Intravenous insulin infusion therapies for postoperative coronary artery bypass graft patients. DeCherney GS, et al. **Del Med J** 1998 Sep;70(9):399–404
Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia [letter] Bardini G, et al. **Diabet Med** 1998 Aug;15(8):706
Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Rassam AG, et al. **Diabetes Care** 1999 Jan; 22(1):133–6
Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Baron AD. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S51–5 (8 ref.)
Drug therapy of postprandial hyperglycaemia. Mooradian AD, et al. **Drugs** 1999 Jan;57(1):19–29 (95 ref.)
Different effects of octreotide by continuous night infusion at increasing rate or by evening injections at different times on morning hyperglycemia and growth hormone levels in insulin-dependent diabetic patients. Lunetta M, et al. **J Endocrinol Invest** 1998 Jul–Aug;21(7):454–8
Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. Fuloria M, et al. **Pediatrics** 1998 Dec;102(6):1401–6
Glucose and insulin therapy in acute stroke: why delay further? Scott JF, et al. **QJM** 1998 Jul;91(7):511–5
Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Scott JF, et al. **Stroke** 1999 Apr;30(4):793–9
[Continuous insulin perfusion in preterm infants with weight less than 1,500 grams who receive parenteral nutrition (letter)] Tejera Ramirez C, et al. **An Esp Pediatr** 1998 Aug; 49(2):213–5 **(Spa)**

ENZYMOLOGY

Hyperglycemia inhibits insulin activation of Akt/protein kinase B but not phosphatidylinositol 3-kinase in rat skeletal muscle. Kurowski TG, et al. **Diabetes** 1999 Mar; 48(3):658–63

EPIDEMIOLOGY

Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Tomura S, et al. **Am J Nephrol** 1999;19(1):13–20
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Barrett-Connor E, et al. **Diabetes Care** 1998 Aug;21(8):1236–9
Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke [letter] Scott JF, et al. **Lancet** 1999 Jan 30;353(9150):376–7

ETIOLOGY

The potato's placement in the dietary pyramid [letter; comment] Forbes GB. **Am J Clin Nutr** 1999 Mar; 69(3):572–3. Comment on: Am J Clin Nutr 1998 Aug;68(2):218–9.
Prognostic implications of hyperglycaemia in paediatric head injury. Chiaretti A, et al. **Childs Nerv Syst** 1998 Sep; 14(9):455–9
Synergistic effect of counterregulatory hormones during insulin-induced hypoglycemia in rats: participation of lipolysis and gluconeogenesis to hyperglycemia. Souza HM, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep; 17(5):455–9
Glucotoxicity: potential mechanisms. Mooradian AD, et al. **Clin Geriatr Med** 1999 May;15(2):255 (59 ref.)
Hepatic glucose cycling does not contribute to the development of hyperglycemia in Zucker diabetic fatty rats. Henly DC, et al. **Diabetes** 1999 Feb;48(2):342–6
Hyperglycaemia in a patient with congenital hemihypertrophy. Chan NN, et al. **Postgrad Med J** 1998 Oct;74(876):625–6
Stress hyperglycemia in minimally invasive surgery. Engin A, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):435–7

GENETICS

Hyperglycemia increases vascular adrenomedullin expression. Hayashi M, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):453–6
Regulation of gene expression by alternative polyadenylation and mRNA instability in hyperglycaemic mesangial cells. Abdel Wahab N, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):405–11
Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Mahalingam B, et al. **Diabetes** 1999 Sep;48(9):1698–705
The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus. Shaw JT, et al. **Diabetologia** 1999 Jan; 42(1):24–7
Identification of possible quantitative trait loci responsible for hyperglycaemia after 70% pancreatectomy using a spontaneously diabetogenic rat. Ogino T, et al. **Genet Res** 1999 Feb;73(1):29–36

METABOLISM

Oxygen consumption and ATPase activity in the corneal epithelium of rabbits with alloxan induced hyperglycemia. Herse P, et al. **Acta Ophthalmol Scand** 1998 Oct; 76(5):528–32
The effect of hyperglycaemia on regional cerebral glucose oxidation in humans studied with [1-11C]-D-glucose. Blomqvist G, et al. **Acta Physiol Scand** 1998 Aug; 163(4):403–15
Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR, et al. **Afr J Med Med Sci** 1996 Sep;25(3):243–9
Effect of hyperglycemia-hyperinsulinemia on whole body and regional fatty acid metabolism. Sidossis LS, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E427–34
Preischemic blood glucose supply to the brain modulates HSP(72) synthesis and neuronal damage in gerbils. Garnier P, et al. **Brain Res** 1999 Jul 31;836(1–2):245–55
Cerebral metabolic profile, selective neuron loss, and survival of acute and chronic hyperglycemic rats following cardiac arrest and resuscitation. Hoxworth JM, et al. **Brain Res** 1999 Mar 13;821(2):467–79
Effect of hyperglycemia on extracellular levels of amino acids and free fatty acids in the ischemic/reperfused rat cerebral cortex. Phillis JW, et al. **Brain Res** 1999 Aug 7; 837(1–2):177–83
Effect of high-carbohydrate versus high-monounsaturated fatty acid diet on metabolic control in diabetes and hyperglycemic patients. Wright J. **Clin Nutr** 1998 Sep;17 Suppl 2:35–45 (105 ref.)
Identification and characterization of a hyperglycemic hormone from freshwater giant prawn, Macrobrachium rosenbergii. Lin CY, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Dec; 121(4):315–21
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Ihara Y, et al. **Diabetes** 1999 Apr;48(4):927–32
Opposite effects of acute hypoglycemia and acute hyperglycemia on glucose transport and glucose transporters in perfused rat skeletal muscle. Mathoo JM, et al. **Diabetes** 1999 Jun;48(6):1281–8
Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Friedman EA. **Diabetes Care** 1999 Mar;22 Suppl 2:B65–71 (62 ref.)
Changes in glucose transport and protein kinase Cbeta(2) in rat skeletal muscle induced by hyperglycaemia. Kawano Y, et al. **Diabetologia** 1999 Sep;42(9):1071–9
Hyperglycaemia reduces gastrin-stimulated gastric acid secretion in humans. Lam WF, et al. **Eur J Clin Invest** 1998 Oct;28(10):826–30
Effects of the non-selective 5-HT receptor agonist, 5-carboxamidotryptamine, on plasma glucose levels in rats. Yamada J, et al. **Eur J Pharmacol** 1998 Oct 16;359(1):81–6
Hypothermia ameliorates ischemic brain damage and suppresses the release of extracellular amino acids in both normo- and hyperglycemic subjects. Li PA, et al. **Exp Neurol** 1999 Jul;158(1):242–53
Blood-brain barrier glutamine transport during normoglycemic and hyperglycemic focal cerebral ischemia. Kawai N, et al. **J Cereb Blood Flow Metab** 1999 Jan; 19(1):79–86
Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. Simpson IA, et al. **J Neurochem** 1999 Jan;72(1):238–47
Hyperglycemia inhibits liver fatty acid oxidation and increases triacylglycerol secretion in humans. Sidossis S, et al. **Lipids** 1999;34 Suppl:S95
2-Chloroadenosine reverses hyperglycemia-induced inhibition of phosphoinositide synthesis in cultured human retinal pigment epithelial cells and prevents reduced nerve conduction velocity in diabetic rats. Kato K, et al. **Metabolism** 1999 Jul;48(7):827–33
Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Song Y, et al. **Mol Biol Cell** 1999 May; 10(5):1609–19
Glycosaminoglycan prevents hyperglycemia-induced renal TGF-beta 1 gene expression. Gambaro G, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:20–1
Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic suprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats. Chun S, et al. **Neurosci Lett** 1998 Dec 4;257(3):135–8
An investigation into the biochemical basis of the observed hyperglycaemia in rats treated with ethanol root extract of plumbago zeylanica. Olagunju JA, et al. **Phytother Res** 1999 Jun;13(4):346–8
[Effects of stimulation and damage of afferent nerves on the glucose and free fatty acid levels in the rat blood under various glycemic conditions] Spiridonov VK, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Dec;84(12):1333–8 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes. Rosenkranz AC, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):519–21
Ultrastructural examination of corneal epithelium of spontaneously obese, hyperglycemic rats. Saika S, et al. **Curr Eye Res** 1998 Nov;17(11):1049–57
Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. Jonas JC, et al. **J Biol Chem** 1999 May 14;274(20):14112–21
Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Song Y, et al. **Mol Biol Cell** 1999 May; 10(5):1609–19

PHYSIOPATHOLOGY

Hyperglycemia induces progressive changes in the cerebral microvasculature and blood-brain barrier transport during focal cerebral ischemia. Kawai N, et al. **Acta Neurochir Suppl (Wien)** 1998;71:219–21
Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR, et al. **Afr J Med Med Sci** 1996 Sep;25(3):243–9
Influence of age, hyperglycemia, leptin, and NPY on islet blood flow in obese-hyperglycemic mice. Carlsson PO, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E594–601
Effects of duodenal distension on antropyloroduodenal pressures and perception are modified by hyperglycemia. Lingenfelser T, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G711–8
Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Sidossis LS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E798–805
Calculating the anion gap for patients with acidosis and hyperglycemia [letter] Tomer Y. **Ann Intern Med** 1998 Nov 1;129(9):753
Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Masuda H, et al. **Br J Pharmacol** 1999 Jan;126(1):211–8
Effect of bilateral lesions of the suprachiasmatic nucleus on hyperglycemia caused by 2-deoxy-D-glucose and vasoactive intestinal peptide in rats. Chun SJ, et al. **Brain Res** 1998 Nov 2;809(2):165–74
The postprandial state and risk of cardiovascular disease. Lefebvre PJ, et al. **Diabet Med** 1998;15 Suppl 4:S63–8 (52 ref.)
Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Donath MY, et al. **Diabetes** 1999 Apr;48(4):738–44
Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice. Sreenan SK, et al. **Diabetes** 1998 Dec;47(12):1881–8
Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Yerneni KK, et al. **Diabetes** 1999 Apr;48(4):855–64
The burden of chronic hyperglycemia. Clark CM Jr. **Diabetes Care** 1998 Dec;21 Suppl 3:C32–4
Insulin resistance and hyperglycemic associated risk factors: session summary. Després JP. **Diabetes Care** 1999 Apr;22 Suppl 3:C38–40 (24 ref.)
Is glucose a continuous risk factor for cardiovascular mortality? [editorial; comment] Gerstein HC. **Diabetes Care** 1999 May;22(5):659–60 (20 ref.). Comment on: Diabetes Care 1999 May;22(5):696–9.
Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Jones KL, et al. **Diabetes Care** 1999 Feb;22(2):339–44
Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. King GL, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C31–7 (41 ref.)
Glycemic control and CAD risk: a heretical thought [letter] Orchard TJ. **Diabetes Care** 1999 Jul;22(7):1220
Postprandial hyperglycaemic state: importance and consequences. Lebovitz HE. **Diabetes Res Clin Pract** 1998 Jul;40 Suppl:S27–8 (37 ref.)
Evidence for direct action of alloxan to induce insulin resistance at the cellular level. Ader M, et al. **Diabetologia** 1998 Nov;41(11):1327–36
Effect of acute hyperglycemia on jejunal compliance and peristaltic reflex in healthy humans. Soffer EE, et al. **Dig Dis Sci** 1999 Jan;44(1):50–5
Hyperglycemia reduces pancreaticobiliary secretion in response to modified sham feeding in humans. Lam WF, et al. **Digestion** 1999 Mar–Apr;60(2):141–6
Peripheral nerve conduction in healthy subjects during short-term hyperglycemia. Halonen JP, et al. **Electromyogr Clin Neurophysiol** 1998 Sep;38(6):355–8
The United Kingdom Prospective Diabetes Study--everything you needed to know about diabetes but were afraid to ask? [editorial] Yudkin JS. **Eur Heart J** 1999 Jun;20(11):781–3
The effect of hyperglycaemia on cerebral potentials evoked by rapid rectal distension in healthy humans. Russo A, et al. **Eur J Clin Invest** 1999 Jun;29(6):512–8
Acute hyperglycaemia causes severe disturbances of mesenteric microcirculation in an in vivo rat model. Schäffler A, et al. **Eur J Clin Invest** 1998 Nov;28(11):886–93
Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Marre M, et al. **Hypertension** 1999 Mar;33(3):775–80
Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. Kawano H, et al. **J Am Coll Cardiol** 1999 Jul;34(1):146–54

Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. Miller JA. **J Am Soc Nephrol** 1999 Aug;10(8):1778–85

Hyperglycemia suppresses the sympatho-adrenal response to hypoxia, but not to handling stress. Benthem L, et al. **J Auton Nerv Syst** 1998 Nov 10;73(2–3):149–55

Role of alpha2-adrenoceptors on the hyperglycaemic and insulin secretory effects derived from alpha1- and beta-adrenoceptor stimulation in the rabbit. Garcia-Barrado MJ, et al. **J Auton Pharmacol** 1998 Oct; 18(5):287–95

Hyperglycemia without hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. Hoffman RP, et al. **J Diabetes Complications** 1999 Jan-Feb;13(1):17–22

Impaired microvascular responses to acute hyperglycemia in type I diabetic rats. Renaudin C, et al. **J Diabetes Complications** 1999 Jan-Feb;13(1):39–44

Acute hyperglycaemia in the forearm induces vasodilation that is not modified by hyperinsulinaemia. van Veen S, et al. **J Hum Hypertens** 1999 Apr;13(4):263–8

Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia [see comments] Akbari CM, et al. **J Vasc Surg** 1998 Oct;28(4):687–94. Comment in: J Vasc Surg 1999 May;29(5):942–3.

Regarding "Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia" [letter; comment] Title L. **J Vasc Surg** 1999 May;29(5):942–3. Comment on: J Vasc Surg 1998 Oct;28(4):687–94.

Effect of acute hyperglycemia on basal, secretin and secretin + cholecystokinin stimulated exocrine pancreatic secretion in humans. Lam WF, et al. **Life Sci** 1999;64(8):617–26

Thermogenic effect of slight hyperglycemia during a lipid infusion. Rigalleau V, et al. **Metabolism** 1999 Mar; 48(3):278–84

Effects of streptozotocin-induced hyperglycemia on brain damage following transient ischemia. Li C, et al. **Neurobiol Dis** 1998 Aug;5(2):117–28

Influence of hyperglycemia on the satiating effect of CCK in humans. Lam WF, et al. **Physiol Behav** 1998 Dec 1; 65(3):505–11

Circulating leptin did not associate with the development of the hyperglycemia accompanied by insulin insensitivity in spontaneous noninsulin dependent diabetes mellitus model Otsuka-Long-Evans-Tokushima-Fatty rats. Iida M, et al. **Regul Pept** 1998 Oct 16;77(1–3):141–6

Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Petrakis IE, et al. **Scand J Gastroenterol** 1999 Apr;34(4):396–403

Spreading depression-induced gene expression is regulated by plasma glucose. Koistinaho J, et al. **Stroke** 1999 Jan; 30(1):114–9

PREVENTION & CONTROL

Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Liang Y, et al. **Biochim Biophys Acta** 1998 Oct 21;1405(1–3):1–13

Blood glucose control in pregnancy [editorial; comment] Amiel SA. **Diabet Med** 1999 Aug;16(8):621–2. Comment on: Diabet Med 1999 Aug;16(8):702–6.

UKPDS: a message of hope and a need for change. United Kingdom Prospective Diabetes Study [editorial] Watkins PJ. **Diabet Med** 1998 Nov;15(11):895–6

In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Harmon JS, et al. **Diabetes** 1999 Oct;48(10):1995–2000

Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice. Tonra JR, et al. **Diabetes** 1999 Mar;48(3):588–94

Four years after the diabetes control and complications trial report: nonimplementation in high-risk patients [letter] Dahl AA, et al. **Diabetes Care** 1998 Aug;21(8):1367–9

Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Kentrup H, et al. **Eur J Pediatr** 1999 Jun;158(6):455–9

Implications of the diabetes control and complications trial. American Diabetes Association. **J Fla Med Assoc** 1998 Aug;85(2):22–4

Targeted glycemic control in type 2 diabetes. Skyler JS. **J Fla Med Assoc** 1998 Aug;85(2):7–15

Periodontal treatment and its effects on glycemic control: a review of the evidence. Taylor GW. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Mar;87(3):311–6 (58 ref.)

[The 'Diabetes mellitus type 2' guideline (first revision) of the Dutch College of General Practitioners: response from internal medicine] Erkelens DW. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1686–8 (Eng. Abstr.) **(Dut)**

[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications (see comments)] Wolffenbuttel BH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1197–201 (20 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1188–91. **(Dut)**

[Evaluation of factors related with glycemia control in type-2 diabetes mellitus] Fernández Herráez E, et al. **Aten Primaria** 1999 Jun 15;24(1):39–43 (Eng. Abstr.) **(Spa)**

SURGERY

Reversal of hyperglycemia in streptozotocin diabetic mice by xenotransplantation of microencapsulated rat islets. Tatarkiewicz K, et al. **Ann Transplant** 1997;2(2):20–3

Reversal of hyperglycemia in mice after subcutaneous transplantation of macroencapsulated islets. Tatarkiewicz K, et al. **Transplantation** 1999 Mar 15;67(5):665–71

THERAPY

Adenovirus-mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice. Short DK, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E748–56

Rationale for specialized nutrition support for hyperglycemic patients. Schrezenmeir J. **Clin Nutr** 1998 Sep;17 Suppl 2:26–34 (148 ref.)

How do the results of the diabetes control and complications trial relate to the practice of pediatrics: who should have intensive management? Fenton CL, et al. **Pediatr Ann** 1999 Sep;28(9):600–4

URINE

Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus. Pelikánová T, et al. **J Diabetes Complications** 1998 Sep-Oct;12(5):264–72

VETERINARY

Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. Elliott DA, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1794–8

Fasting hyperglycaemia with oral glucose tolerance in acute Trypanosoma congolense infection of rats. Igbokwe IO, et al. **Vet Parasitol** 1999 Feb 25;81(2):167–71

HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA

BLOOD

Increased urinary atrial natriuretic peptide-like immunoreactivity excretion but decreased plasma atrial natriuretic peptide concentration in patients with hyperosmolar-hyperglycemic nonketotic syndrome. Shin SJ, et al. **Diabetes Care** 1999 Jul;22(7):1181–5

ETIOLOGY

Hyperosmolar coma [letter; comment] MacGregor DA, et al. **Lancet** 1999 Apr 3;353(9159):1189. Comment on: Lancet 1995 Aug 12;346(8972):413–7.

[The hyperglycemic dehydration syndrome (see comments)] Melief PH, et al. **Ned Tijdschr Geneeskd** 1998 Jul 11; 142(28):1585–8 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 10;142(41):2262. Comment in: Ned Tijdschr Geneeskd 1998 Oct 10;142(41):2262–3. Comment in: Ned Tijdschr Geneeskd 1998 Oct 10;142(41):2263. **(Dut)**

PHYSIOPATHOLOGY

Exaggerated vasopressin secretion and attenuated osmoregulated thirst in human survivors of hyperosmolar coma. McKenna K, et al. **Diabetologia** 1999 May; 42(5):534–8

THERAPY

Severe non-ketotic hyperosmolar coma--intensive care management. Gupta S, et al. **Eur J Anaesthesiol** 1998 Sep; 15(5):603–6

URINE

Increased urinary atrial natriuretic peptide-like immunoreactivity excretion but decreased plasma atrial natriuretic peptide concentration in patients with hyperosmolar-hyperglycemic nonketotic syndrome. Shin SJ, et al. **Diabetes Care** 1999 Jul;22(7):1181–5

HYPERGLYCEMIC MICE see MICE, OBESE

HYPERGRAVITY

Effects of hypergravity environment on the parathyroid gland of the norepinephrine-treated golden hamster: a stereological study. Shoumura S, et al. **Acta Anat (Basel)** 1992;145(4):349–53

Morphometry of fish inner ear otoliths after development at 3g hypergravity. Anken RH, et al. **Acta Otolaryngol (Stockh)** 1998 Jul;118(4):534–9

Premature ventricular contractions during +Gz with and without pressure breathing and extended coverage anti-G suit. Bolldin UI, et al. **Aviat Space Environ Med** 1999 Mar; 70(3 Pt 1):209–12

Gravitational changes affect tibial growth plates according to Hert's curve. Montufar-Solis D, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 1):245–9

Response to thyrotropin of normal thyroid follicular cell strain FRTL5 in hypergravity. Meli A, et al. **Biochimie** 1999 Apr;81(4):281–5

Stimulative effect of high-level hypergravity on differentiated functions of osteoblast-like cells. Kawashima K, et al. **Cell Struct Funct** 1998 Aug;23(4):221–9

A mild stress, hypergravity exposure, postpones behavioral aging in Drosophila melanogaster. Le Bourg E, et al. **Exp Gerontol** 1999 Apr;34(2):157–72

Changes in lower limb volume in humans during parabolic flight. Bailliart O, et al. **J Appl Physiol** 1998 Dec; 85(6):2100–5

Dispersion of 0.5- to 2-micron aerosol in microG and hypergravity as a probe of convective inhomogeneity in the lung. Darquenne C, et al. **J Appl Physiol** 1999 Apr; 86(4):1402–9

Deposition and dispersion of 1-micrometer aerosol boluses in the human lung: effect of micro- and hypergravity. Darquenne C, et al. **J Appl Physiol** 1998 Oct;85(4):1252–9

Effects of pre- and perinatal exposure to hypergravity on muscular structure development in rat. Martrette JM, et al. **J Muscle Res Cell Motil** 1998 Aug;19(6):689–94

Behaviour of adult hamsters subjected to hypergravity. Sondag HN, et al. **J Vestib Res** 1999;9(1):13–8

Resistance to stress as a function of age in Drosophila melanogaster living in hypergravity. Minois N, et al. **Mech Ageing Dev** 1999 Jun 1;109(1):53–64

HSP70 induction may explain the long-lasting resistance to heat of Drosophila melanogaster having lived in hypergravity. Minois N, et al. **Mech Ageing Dev** 1999 Jun 1;109(1):65–77

Hypergravity increases the molecular mass of xyloglucans by decreasing xyloglucan-degrading activity in azuki bean epicotyls. Soga K, et al. **Plant Cell Physiol** 1999 Jun; 40(6):581–5

The gravity field of Mars: results from Mars Global Surveyor. Smith DE, et al. **Science** 1999 Oct 1; 286(5437):94–7

[Human tolerance of +Gx loads in anti-G suits during deorbiting of the "Soiuz" space vehicles] Kotovskaia AR, et al. **Aviakosm Ekolog Med** 1998;32(6):30–6 (Eng. Abstr.) **(Rus)**

[Repeated hypergravity: morphologic investigations of pituitary, thyroid, blood and bone marrow in rats] Krasnov IB, et al. **Aviakosm Ekolog Med** 1998;32(5):31–40 (Eng. Abstr.) **(Rus)**

[The use of microfluorimetric analysis for the studies of the influence of changed gravity on isolated lymphocytes in the spleen of the mouse] Turovetskiĭ VB, et al. **Aviakosm Ekolog Med** 1999;33(2):12–5 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Echocardiographic evaluation of female centrifuge subjects for chronic changes in cardiac function. Albery WB. **Aviat Space Environ Med** 1999 Jun;70(6):561–4

Female exposure to high G: echocardiographic evaluation for chronic changes in cardiac function. Albery WB, et al. **Aviat Space Environ Med** 1998 Sep;69(9):857–61

Female exposure to high G: performance of simulated flight after 24 hours of sleep deprivation. Chelette TL, et al. **Aviat Space Environ Med** 1998 Sep;69(9):862–8

Degradation of visual pursuit during sustained +3 Gz acceleration. Cheung B, et al. **Aviat Space Environ Med** 1999 May;70(5):451–8

Female exposure to high G: chronic adaptations of cardiovascular functions. Convertino VA, et al. **Aviat Space Environ Med** 1998 Sep;69(9):875–82

EMG activity of three rat hindlimb muscles during microgravity and hypergravity phase of parabolic flight. Leterme D, et al. **Aviat Space Environ Med** 1998 Nov; 69(11):1065–70

Gender and effect of impact acceleration on neck motion. Morris CE, et al. **Aviat Space Environ Med** 1999 Sep; 70(9):851–6

Patterns of physical conditioning in Royal Australian Air Force F/A-18 pilots and the implications for +Gz tolerance. Newman DG, et al. **Aviat Space Environ Med** 1999 Aug;70(8):739–44

Female exposure to high G: effects of simulated combat sorties on cerebral and arterial O2 saturation. Tripp LD, et al. **Aviat Space Environ Med** 1998 Sep;69(9):869–74

Visual symptoms and G-LOC in the operational environment and during centrifuge training of Turkish jet pilots. Yilmaz U, et al. **Aviat Space Environ Med** 1999 Jul;70(7):709–12

Cognitive performance and physiological changes in females at high G while protected with COMBAT EDGE and ATAGS. Zhang L. **Aviat Space Environ Med** 1999 Sep; 70(9):857–62

Chronic exposure to hypergravity affects thyrotropin-releasing hormone levels in rat brainstem and cerebellum. Daunton NG, et al. **Biol Signals Recept** 1998 Nov-Dec;7(6):337–44

A review of the effects of microgravity and of hypergravity on aging and longevity. Le Bourg E. **Exp Gerontol** 1999 Jun;34(3):319–36 (50 ref.)

Neck training and +Gz-related neck pain: a preliminary study. Hämäläinen O, et al. **Mil Med** 1998 Oct; 163(10):707–8

Hyper- and hypogravity alter posture in rats compensated on Earth for a vestibular asymmetry. Etard O, et al. **Neuroreport** 1999 Mar 17;10(4):669–73

HYPERHIDROSIS

[Who shall be treated for excessive sweating and how?] Mørk C. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):178 **(Nor)**

COMPLICATIONS

Episodic spontaneous hyperhidrosis hypothermia in human immunodeficiency virus-positive patients. Okechukwu CN, et al. **Clin Infect Dis** 1999 Jul;29(1):210

Symmetrical lividity of the soles. Shelley WB, et al. **Cutis** 1999 Sep;64(3):175-6

Acute varicella zoster with postherpetic hyperhidrosis as the initial presentation of HIV infection. Chopra KF, et al. **J Am Acad Dermatol** 1999 Jul;41(1):119-21

Unilateral hyperhidrosis, callosities, and nail dystrophy in a boy with tethered spinal cord syndrome [letter] Wollina U, et al. **Pediatr Dermatol** 1998 Nov-Dec;15(6):486-7

[Gerstmann-Sträussler-Scheinker syndrome with a Pro102Leu mutation in the prion protein gene and atypical MRI findings, hyperthermia, tachycardia, and hyperhidrosis] Imaiso Y, et al. **Rinsho Shinkeigaku** 1998 Oct-Nov;38(10-11):920-5 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Nonsystemic vasculitic neuropathy presenting with truncal segmental sensory disturbance and hyperhidrosis [letter] Tsunemi T, et al. **Muscle Nerve** 1999 May;22(5):646-7

DRUG THERAPY

Follow-up of patients with axillary hyperhidrosis after botulinum toxin injection [letter; comment] Heckmann M, et al. **Arch Dermatol** 1998 Oct;134(10):1298-9. Comment on: Arch Dermatol 1998 Mar;134(3):301-4.

The use of topical glycopyrrolate in the treatment of hyperhidrosis. Seukeran DC, et al. **Clin Exp Dermatol** 1998 Sep;23(5):204-5

Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. Benohanian A, et al. **Int J Dermatol** 1998 Sep;37(9):701-3

Influence of an antiperspirant on foot blister incidence during cross-country hiking [letter] Benohanian A, et al. **J Am Acad Dermatol** 1999 Oct;41(4):655-6

Botulinum toxin in the treatment of palmar hyperhidrosis [letter; comment] Holmes S, et al. **J Am Acad Dermatol** 1998 Dec;39(6):1040-1. Comment on: J Am Acad Dermatol 1998 Feb;38(2 Pt 1):227-9.

Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Bergmann I, et al. **Muscle Nerve** 1998 Dec;21(12):1790-3

[Treatment of hyperhidrosis by botulinum toxin] Beaulieu P. **Ann Dermatol Venereol** 1999 May;126(5):469-73 **(Fre)**

ETIOLOGY

Segmental hyperhidrosis as a manifestation of spinal and paraspinal disease. Schulz V, et al. **Can J Neurol Sci** 1998 Nov;25(4):325-7

Unilateral segmental hyperhidrosis associated with pulmonary adenocarcinoma. Slabbynck H, et al. **Chest** 1998 Oct;114(4):1215-7

Cutaneous metastases from a chondroblastoma initially presenting as unilateral palmar hyperhidrosis. Seline PC, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):325-7

Focal (segmental) dyshidrosis in syringomyelia. Sudo K, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):106-8

Fever, weight loss, and night sweats: infection or malignancy? [clinical conference] Winter AJ, et al. **Sex Transm Infect** 1998 Dec;74(6):439-44

[Hyperhidrosis] Brehler R. **Internist (Berl)** 1999 Mar; 40(3):316 **(Ger)**

MICROBIOLOGY

Dermacase. Pitted keratolysis. Enta T. **Can Fam Physician** 1998 Nov;44:2387, 2396

PHYSIOPATHOLOGY

Hyperhidrosis and sympathetic skin response in chronic alcoholic patients. Tugnoli V, et al. **Clin Auton Res** 1999 Feb;9(1):17-22

Changes in hemodynamics of the carotid and middle cerebral arteries before and after endoscopic sympathectomy in patients with palmar hyperhidrosis: preliminary results. Jeng JS, et al. **J Neurosurg** 1999 Mar;90(3):463-7

Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Bergmann I, et al. **Muscle Nerve** 1998 Dec;21(12):1790-3

Vasomotor and sudomotor function in the hand after thoracoscopic transection of the sympathetic chain: implications for choice of therapeutic strategy. Rex L, et al. **Muscle Nerve** 1998 Nov;21(11):1486-92

SURGERY

A comparative study of the surgical treatment of axillary osmidrosis by instrument, manual, and combined subcutaneous shaving procedures. Park DH, et al. **Ann Plast Surg** 1998 Nov;41(5):488-97

Results of thoracoscopic sympathectomy for 96 cases of palmar hyperhidrosis. Tan V, et al. **Ann Thorac Cardiovasc Surg** 1998 Oct;4(5):244-6

Outpatient thoracoscopic limited sympathectomy for hyperhidrosis palmaris. Hsia JY, et al. **Ann Thorac Surg** 1999 Jan;67(1):258-9

Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis: intermediate term results. Erak S, et al. **Aust N Z J Surg** 1999 Jan;69(1):60-4

Early experience with day-case transthoracic endoscopic sympathectomy [letter; comment] Cameron A. **Br J Surg** 1999 Jan;86(1):139. Comment on: Br J Surg 1998 Sep;85(9):1266.

Intermediate-term results of endoscopic transaxillary T2 sympathectomy for primary palmar hyperhidrosis [see comments] Chiou TS, et al. **Br J Surg** 1999 Jan;86(1):45-7 . Comment in: Br J Surg 1999 Jul;86(7):969-70.

Intermediate-term results of endoscopic transaxillary T2 sympathectomy for primary palmar hyperhidrosis [letter; comment] Hashmonai M, et al. **Br J Surg** 1999 Jul; 86(7):969-70. Comment on: Br J Surg 1999 Jan;86(1):45-7.

Resympathectomy for palmar and axillary hyperhidrosis. Hsu CP, et al. **Br J Surg** 1998 Nov;85(11):1504-5

Non-dependent axillary artery compression during needlescopic thoracic sympathectomy [letter] Liu EH, et al. **Can J Anaesth** 1999 May;46(5 Pt 1):515

The results of thoracoscopic sympathetic trunk transection for palmar hyperhidrosis and sympathetic ganglionectomy for axillary hyperhidrosis. Fox AD, et al. **Eur J Vasc Endovasc Surg** 1999 Apr;17(4):343-6

Transthoracic endoscopic sympathectomy for palmar hyperhidrosis in children and adolescents: analysis of 350 cases. Lin TS. **J Laparoendosc Adv Surg Tech A** 1999 Aug; 9(4):331-4

Changes in hemodynamics of the carotid and middle cerebral arteries before and after endoscopic sympathectomy in patients with palmar hyperhidrosis: preliminary results. Jeng JS, et al. **J Neurosurg** 1999 Mar;90(3):463-7

Vasomotor and sudomotor function in the hand after thoracoscopic transection of the sympathetic chain: implications for choice of therapeutic strategy. Rex L, et al. **Muscle Nerve** 1998 Nov;21(11):1486-92

Thoracoscopic T2-T3 sympathicolysis for essential hyperhidrosis in childhood: effects on pulmonary function. Noppen M, et al. **Pediatr Pulmonol** 1998 Oct;26(4):262-4

Treatment of axillary bromhidrosis with superficial liposuction [letter] Park DH. **Plast Reconstr Surg** 1999 Oct; 104(5):1580-1

Endoscopic transthoracic dorsal sympathectomy for the treatment of upper extremity hyperhidrosis: a new minimally invasive approach. Raposio E, et al. **Plast Reconstr Surg** 1998 Oct;102(5):1629-32

Video-endoscopic and mini-endoscopic sympathectomy for hyperhidrosis. Pillay PK, et al. **Stereotact Funct Neurosurg** 1997;69(1-4 Pt 2):274-7

Thoracoscopic sympathectomy for hyperhidrosis: is there a learning curve? Kopelman D, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):370-5

Resympathectomy for sympathetic regeneration. Singh B, et al. **Surg Laparosc Endosc** 1998 Aug;8(4):257-60

The long-term results of upper dorsal sympathetic ganglionectomy and endoscopic thoracic sympathectomy for palmar hyperhidrosis. Lin CL, et al. **Surg Today** 1999; 29(3):209-13

[Video-assisted thoracosopic sympathectomy: spectrum of indications and our own results (1995-1997)] Ghisletta N, et al. **Schweiz Med Wochenschr** 1999 Jul 3;129(26):985-92 (Eng. Abstr.) **(Ger)**

[Dorsal sympathectomy for palmar hyperhidrosis by the thin thoracoscope] Sugiyama S, et al. **Kyobu Geka** 1998 Dec; 51(13):1087-9 (Eng. Abstr.) **(Jpn)**

[Craniofacial hyperhidrosis: a treatment with sympathectomy through videothoracoscopy (letter; comment)] Callejas MA, et al. **Med Clin (Barc)** 1998 Oct 17;111(12):479. Comment on: Med Clin (Barc) 1998 Feb 28;110(7):279. **(Spa)**

[Anesthesia in a case of bilateral sympathectomy using thoracoscopy (letter)] Alonso Chico A, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul;46(6):271-2 **(Spa)**

[Complications are frequent after surgery for excessive hand sweating. Patient should be informed about the risks] Claes G, et al. **Lakartidningen** 1999 Feb 24;96(8):930-2 **(Swe)**

[Need for more careful alternative to sympathectomy. Complications following surgery for palmar sweating are more common than previously thought] Meyerson B. **Lakartidningen** 1999 Mar 3;96(9):980-1 **(Swe)**

THERAPY

Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application [letter] Naumann M, et al. **Br J Dermatol** 1998 Dec;139(6):1123-4

Treatment of hyperhidrosis. Stolman LP. **Dermatol Clin** 1998 Oct;16(4):863-9 (32 ref.)

Hyperhidrosis treated by botulinum A exotoxin. Odderson IR. **Dermatol Surg** 1998 Nov;24(11):1237-41 (26 ref.)

[Skin (cancer), hair and sweat] Dummer R. **Schweiz Med Wochenschr** 1999 Jan 12;129(1-2):46-8 **(Ger)**

[Palmoplantar hyperhidrosis: a therapeutic approach using iontophoresis] Lucchi M, et al. **Minerva Cardioangiol** 1998 Oct;46(10):397-8 **(Ita)**

HYPERHIDROSIS, GUSTATORY see **SWEATING, GUSTATORY**

HYPERHOMOCYSTEINEMIA

see related
HOMOCYSTINURIA

Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status. Green R, et al. **Semin Hematol** 1999 Jan;36(1):47-64 (127 ref.)

BLOOD

Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Ali A, et al. **Am J Cardiol** 1998 Dec 15;82(12):1543-5, A8

Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. de Jong SC, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1316-24

Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Voutilainen S, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1263-6

Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. Bostom AG, et al. **Atherosclerosis** 1999 Jul;145(1):221-4

Hyperhomocyst(e)inemia--determining factors and treatment. Genest J Jr. **Can J Cardiol** 1999 Apr;15 Suppl B:35B-38B

Association between hyperhomocysteinaemia and hypertension in Sri Lankans. Mendis S, et al. **J Int Med Res** 1999 Jan-Feb;27(1):38-44

Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Vychytil A, et al. **Kidney Int** 1999 May;55(5):2054-61

Plasma homocysteine levels in indigenous Australians. Shaw JT, et al. **Med J Aust** 1999 Jan 4;170(1):19-22

CHEMICALLY INDUCED

Serum homocysteine increases after therapy with fenofibrate or bezafibrate [letter] Dierkes J, et al. **Lancet** 1999 Jul 17; 354(9174):219-20

COMPLICATIONS

Mild to moderate hyperhomocysteinaemia in cardiovascular disease. De Vriese AS, et al. **Acta Cardiol** 1998;53(6):337-44 (82 ref.)

The implications of hyperhomocysteinemia in a patient with type 1 diabetes. van Leeuwen-Wintjens HR, et al. **Acta Clin Belg** 1998 Oct;53(5):349-52

Coronary artery disease and homocysteine: a case study. Shinnick MA, et al. **Am J Crit Care** 1999 May;8(3):193-6

Hyperhomocysteinemia, aortic thrombus, and peripheral arterial emboli--a case report. Sindhav JB, et al. **Angiology** 1999 Jul;50(7):599-603

Ocular venous occlusion and hyperhomocysteinemia [letter] Cruysberg JR. **Ann Intern Med** 1999 Oct 19;131(8):632-3

Ocular venous occlusion and hyperhomocysteinemia [letter] de Bruijne EL, et al. **Ann Intern Med** 1999 Jan 5;130(1):78

Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Hussein WI, et al. **Ann Intern Med** 1999 Sep 7;131(5):348-51

Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Ray JG. **Arch Intern Med** 1998 Oct 26;158(19):2101-6

Hyperhomocysteinemia: a new risk factor for Alzheimer disease? [editorial; comment] Diaz-Arrastia R. **Arch Neurol** 1998 Nov;55(11):1407-8. Comment on: Arch Neurol 1998 Nov;55(11):1449-55.

Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Herrmann W, et al. **Atherosclerosis** 1999 May;144(1):91-101

Hyperhomocysteinaemia and upper extremity deep venous thrombosis: a case report. Cable GG. **Aviat Space Environ Med** 1999 Jul;70(7):701-4

The placenta in maternal hyperhomocysteinaemia. Khong TY, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):273-8

Homocysteine. Is it a modifiable risk factor for patients with coronary artery disease? Por CP, et al. **Can Fam Physician** 1998 Nov;44:2409-11

Homocysteine and arterial occlusive disease: a concise review. Andreotti F, et al. **Cardiologia** 1999 Apr; 44(4):341-5 (22 ref.)

Homocysteine and arteriosclerosis: subclinical and clinical disease associations [editorial; comment] Bostom AG, et al. **Circulation** 1999 May 11;99(18):2361-3. Comment on: Circulation 1999 May 11;99(18):2383-8.

Inherited protein C deficiency, protein S deficiency and hyperhomocysteinaemia in a patient with hereditary spherocytosis. Taylor CP, et al. **Clin Lab Haematol** 1999 Jun;21(3):211-4

Homocysteine as a novel risk factor for atherosclerosis. Guthikonda S, et al. **Curr Opin Cardiol** 1999 Jul; 14(4):283-91 (95 ref.)

Mechanisms of thrombosis in hyperhomocysteinemia. Lentz SR. **Curr Opin Hematol** 1998 Sep;5(5):343-9 (79 ref.)

Evaluation of hyperhomocysteinaemia in children with stroke. Cardo E, et al. **Europ J Paediatr Neurol** 1999; 3(3):113-7

Homocysteine: an emerging age-related cardiovascular risk factor [published erratum appears in Geriatrics 1999 Jul;54(7):17] Moustapha A, et al. **Geriatrics** 1999 Apr; 54(4):41, 44–6, 49–51 (30 ref.)
Moderate hyperhomocysteinemia is a highly prevalent defect in Spanish patients with venous thromboembolic disease [letter] González Y, et al. **Haematologica** 1998 Dec; 83(12):1126–7
Hyperhomocysteinemia in chronic renal disease. Bostom AG, et al. **J Am Soc Nephrol** 1999 Apr;10(4):891–900 (94 ref.)
Pathogenesis of vascular disease in hyperhomocysteinaemia. Domagala TB, et al. **J Cardiovasc Risk** 1998 Aug; 5(4):239–47 (100 ref.)
Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. de Jong SC, et al. **J Intern Med** 1999 Jul;246(1):87–96
Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. Perna AF, et al. **J Nephrol** 1999 Jul–Aug;12(4):230–40 (121 ref.)
Hyperhomocysteinemia presenting as chronic inferior vena caval thrombosis in an adolescent. Gemery J, et al. **J Vasc Interv Radiol** 1999 May;10(5):565–8
Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. Taylor LM Jr, et al. **J Vasc Surg** 1999 Jan;29(1):8–19; discussion 19–21
Homocysteine in cerebral macroangiopathy and microangiopathy [letter] Ducloux D, et al. **Lancet** 1999 Sep 18;354(9183):1029–30
Venous thrombosis and hyperhomocysteinaemia. Eikelboom JW, et al. **Med J Aust** 1998 Sep 21;169(6):313–5
Improvement of coronary artery disease in a patient with hyperhomocysteinemia: report of a case. Rothkopf MM, et al. **Nutrition** 1998 Sep;14(9):687–90
Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Ray JG, et al. **Placenta** 1999 Sep;20(7):519–29
Hyperhomocysteinemia and venous thrombosis. Bos GM, et al. **Semin Thromb Hemost** 1998;24(4):387–91 (29 ref.)
Hyperhomocysteinemia and atherothrombotic disease. de Jong SC, et al. **Semin Thromb Hemost** 1998;24(4):381–5 (32 ref.)
Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Kristensen B, et al. **Stroke** 1999 May; 30(5):974–80
The elevated risk for venous thrombosis in persons with hyperhomocysteinemia is not reflected by the endogenous thrombin potential [letter] Bos GM, et al. **Thromb Haemost** 1999 Mar;81(3):467–8
High prevalence of hyperchromocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Cattaneo M, et al. **Thromb Haemost** 1998 Oct;80(4):542–5
Hyperhomocysteinemia, atherosclerosis and thrombosis. Cattaneo M. **Thromb Haemost** 1999 Feb;81(2):165–76 (156 ref.)
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Eichinger S, et al. **Thromb Haemost** 1998 Oct;80(4):566–9
Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans. Yoo JH, et al. **Thromb Res** 1999 Apr 1;94(1):45–52
[Obstetric problems followed by stroke] Lubbers MF, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):705–8 (Eng. Abstr.) **(Dut)**
[Hyperhomocysteinemia as a risk factor for venous thrombosis] Willems HP, et al. **Ned Tijdschr Geneeskd** 1999 Mar 13;143(11):552–6 (36 ref.) (Eng. Abstr.) **(Dut)**
[Homocysteine, 5,10-methylenetetrahydrofolate reductase and deep venous thrombosis. Survey of 120 patients in internal medicine] Quéré I, et al. **Rev Med Interne** 1998 Jan;19(1):29–33 (Eng. Abstr.) **(Fre)**
[Homocysteine and cardiovascular risk] Lutteri L, et al. **Rev Med Liege** 1999 Jun;54(6):541–7 (36 ref.) (Eng. Abstr.) **(Fre)**
[Hyperhomocysteinemia: development of deep vein thrombosis in another location during heparin anticoagulation therapy] Tsuda H, et al. **Rinsho Ketsueki** 1999 May;40(5):396–401 (Eng. Abstr.) **(Jpn)**
[Homocysteinemia and vascular disease--a new risk factor is born] Reis RP, et al. **Rev Port Cardiol** 1999 May; 18(5):507–14 (62 ref.) (Eng. Abstr.) **(Por)**
[Moderate hyperhomocysteinemia and atherothrombosis] Falcón CR. **Medicina (B Aires)** 1998;58(5 Pt 1):511–4 (17 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Recommended approaches for the laboratory measurement of homocysteine in the diagnosis and monitoring of patients with hyperhomocysteinaemia. Moat SJ, et al. **Ann Clin Biochem** 1999 May;36 (Pt 3):372–9
Venous thrombosis and hyperhomocysteinaemia. Eikelboom JW, et al. **Med J Aust** 1998 Sep 21;169(6):313–5
Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. van den Berg M, et al. **Neth J Med** 1999 Jul;55(1):29–38
[Obstetric problems followed by stroke] Lubbers MF, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):705–8 (Eng. Abstr.) **(Dut)**

DIET THERAPY

Improvement of coronary artery disease in a patient with hyperhomocysteinemia: report of a case. Rothkopf MM, et al. **Nutrition** 1998 Sep;14(9):687–90

DRUG THERAPY

Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. van der Griend R, et al. **Atherosclerosis** 1999 Mar;143(1):177–83
Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Dierkes J, et al. **Clin Nephrol** 1999 Feb;51(2):108–15
Homocysteine: an emerging age-related cardiovascular risk factor [published erratum appears in Geriatrics 1999 Jul;54(7):17] Moustapha A, et al. **Geriatrics** 1999 Apr; 54(4):41, 44–6, 49–51 (30 ref.)
Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. de Jong SC, et al. **J Intern Med** 1999 Jul;246(1):87–96
Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. van Guldener C, et al. **J Intern Med** 1999 Feb;245(2):175–83
Treatment of hyperhomocysteinemia in children on dialysis by folic acid. Schröder CH, et al. **Pediatr Nephrol** 1999 Sep;13(7):583–5

ENZYMOLOGY

The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia [see comments] Guenther BD, et al. **Nat Struct Biol** 1999 Apr;6(4):359–65 . Comment in: Nat Struct Biol 1999 Apr;6(4):293–4.

EPIDEMIOLOGY

Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) [see comments] McQuillan BM, et al. **Circulation** 1999 May 11; 99(18):2383–8. Comment in: Circulation 1999 May 11;99(18):2361–3.
Hyperhomocysteinemia: a risk factor for ischemic stroke in children. van Beynum IM, et al. **Circulation** 1999 Apr 27; 99(16):2070–2
Homocysteine and cardiovascular disease. Overview. Clarke R. **J Cardiovasc Risk** 1998 Aug;5(4):213–5
Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. Danesh J, et al. **J Cardiovasc Risk** 1998 Aug;5(4):229–32
Homocysteine levels and coronary heart disease in Syria. Joubran R, et al. **J Cardiovasc Risk** 1998 Aug;5(4):257–61
Homocysteine and vascular disease: nature or nurture? Meleady RA, et al. **J Cardiovasc Risk** 1998 Aug;5(4):233–7 (62 ref.)
Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. Wilcken DE. **J Cardiovasc Risk** 1998 Aug;5(4):217–21 (31 ref.)
Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Moustapha A, et al. **Kidney Int** 1999 Apr;55(4):1470–5

ETHNOLOGY

Homocysteine and folate in healthy east London Bangladeshis [letter] Obeid OA, et al. **Lancet** 1998 Dec 5;352(9143):1829–30

ETIOLOGY

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. Cook RC, et al. **J Heart Lung Transplant** 1999 May;18(5):420–4
How folate fights disease [editorial; comment] **Nat Struct Biol** 1999 Apr;6(4):293–4. Comment on: Nat Struct Biol 1999 Apr;6(4):307. Comment on: Nat Struct Biol 1999 Apr;6(4):359–65.
[Molecular genetics of the remethylation of homocysteine] Chango A, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb; 57(1):37–42 (44 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Tsai MY, et al. **Atherosclerosis** 1999 Mar;143(1):163–70
Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. De Stefano V, et al. **Br J Haematol** 1999 Aug;106(2):564–8
Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Brattström L, et al. **Circulation** 1998 Dec 8;98(23):2520–6
Hyperhomocysteinaemia, genetics and cardiovascular disease risk [editorial; comment] Gudnason V, et al. **Eur Heart J** 1999 Apr;20(8):552–3 (7 ref.). Comment on: Eur Heart J 1999 Apr;20(8):584–92.
Plasma homocysteine levels in indigenous Australians. Shaw JT, et al. **Med J Aust** 1999 Jan 4;170(1):19–22
A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Yoo JH, et al. **Metabolism** 1999 Aug;48(8):1047–51
[Diagnostic significance of mild hyperhomocysteinemia in a population of children with parents or grandparents who have peripheral or coronary artery disease] Hyánek J, et al. **Cas Lek Cesk** 1999 May 24;138(11):333–6 (Eng. Abstr.) **(Cze)**
[A hyperhomocysteinemia study in a population with a familial factor for acute myocardial infarct and sudden cardiac death at a young age] Bollani G, et al. **Cardiologia** 1999 Jan;44(1):75–81 (Eng. Abstr.) **(Ita)**

PATHOLOGY

Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. Southern FN, et al. **J Vasc Surg** 1998 Nov;28(5):909–18
Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Charpiot P, et al. **Matrix Biol** 1998 Dec;17(8–9):559–74

PHYSIOPATHOLOGY

Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Powers RW, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1605–11
Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Herrmann W, et al. **Atherosclerosis** 1999 May;144(1):91–101
Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Bellamy MF, et al. **Circulation** 1998 Nov 3;98(18):1848–52
Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Chambers JC, et al. **Circulation** 1999 Mar 9;99(9):1156–60
Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Kanani PM, et al. **Circulation** 1999 Sep 14;100(11):1161–8
Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Usui M, et al. **Clin Sci (Colch)** 1999 Mar;96(3):235–9
Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. Lee YK, et al. **J Korean Med Sci** 1999 Apr; 14(2):193–8
Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. van den Berg M, et al. **Neth J Med** 1999 Jul;55(1):29–38
Hyperhomocysteinaemia and endothelial dysfunction in peripheral arterial disease [letter] Mercié P, et al. **Thromb Res** 1999 Jan 15;93(2):97–9

PREVENTION & CONTROL

Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Spence JD, et al. **Am J Nephrol** 1999;19(3):405–10
Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. House AA, et al. **ASAIO J** 1999 Jan–Feb;45(1):94–7
Homocysteine. Is it a modifiable risk factor for patients with coronary artery disease? Por CP, et al. **Can Fam Physician** 1998 Nov;44:2409–11
Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. Clarke R, et al. **J Cardiovasc Risk** 1998 Aug;5(4):249–55
[The recommended daily intake of folic acid is insufficient for optimum homocysteine level (letter)] Willems HPJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 20;142(25):1473–4 **(Dut)**

THERAPY

Effects of folate supplementation in hyperhomocysteinemic pigs. Ambrosi P, et al. **J Am Coll Cardiol** 1999 Jul; 34(1):274–9

HYPERICACEAE see **THEALES**

HYPERICUM PERFORATUM see **THEALES**

HYPERIMMUNOGLOBULIN E-RECURRENT INFECTION SYNDROME see **JOB'S SYNDROME**

HYPERINSULINEMIA

see related
HYPERINSULINISM
Fasting hyperinsulinemia and increased waist-to-hip ratios

in non-wasting individuals with AIDS. Shikuma CM, et al. **AIDS** 1999 Jul 30;13(11):1359–65

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558–66 (88 ref.)

BLOOD

Insulinemia and pancreatic alpha2-adrenoceptors in salt-sensitive (SBH) and salt-resistant (SBN) Sabra rats: effect of high salt diet. Ilhami N, et al. **Am J Hypertens** 1998 Jul;11(7):790–5

Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Hsieh PS, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E930–7

Plasma insulin levels and incidence of hypertension in African Americans and whites. He J, et al. **Arch Intern Med** 1999 Mar 8;159(5):498–503

Reduced serum dehydroepiandrosterone levels in diabetic patients with hyperinsulinaemia. Yamaguchi Y, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):377–83

Elevation of plasma leptin concentrations in obese hyperinsulinaemic hypothyroidism before and after treatment. Kautzky-Willer A, et al. **Eur J Clin Invest** 1999 May;29(5):395–403

Hyperinsulinaemic hypoglycaemia associated with persistent hyperammonaemia. Kitaura J, et al. **Eur J Pediatr** 1999 May;158(5):410–3

Erythrocyte deformability is related to fasting insulin and declines during euglycaemic hyperinsulinaemia in hypertensive patients [letter] Linde T, et al. **J Hum Hypertens** 1999 Apr;13(4):285–6

Studies in hypertriglyceridaemia. VI: Serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. Asplund-Carlson A, et al. **J Intern Med** 1999 Mar; 245(3):247–52

Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. Koopmans SJ, et al. **Metabolism** 1999 Mar;48(3):330–7

[Trends in the measurement of body heights: correlation with lipoparticle LpA1 and insulinemia in the obese (letter)] Lecerf JM, et al. **Presse Med** 1998 Oct 31;27(33):1680–1 **(Fre)**

[The values of selected lipid parameters and atrial pressure in persons with hyperinsulinemia and normal glucose tolerance] Klin MJ, et al. **Pol Merkuriusz Lek** 1998 Jun; 4(24):312–4 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Protease inhibitor-associated hyperinsulinaemia [letter] Martínez E, et al. **AIDS** 1998 Oct 22;12(15):2077–9

COMPLICATIONS

Hypokalemic periodic paralysis associated with hypophosphatemia in a patient with hyperinsulinemia. Ogawa T, et al. **Am J Med Sci** 1999 Jul;318(1):69–72

Malformations of hypothalamic nuclei in hyperinsulinemic offspring of rats with gestational diabetes. Plagemann A, et al. **Dev Neurosci** 1999;21(1):58–67

Autonomic neuropathy in Type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Gottsäter A, et al. **Diabet Med** 1999 Jan;16(1):49–54

Clustering of cardiovascular risk factors in hyperinsulinemia in Japanese without diabetes. Adachi H, et al. **Diabetes Res Clin Pract** 1998 Jun;40(3):181–90

Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Moore MA, et al. **Eur J Cancer Prev** 1998 Apr;7(2):89–107 (243 ref.)

Treatment of hyperinsulinaemic hypoglycaemia with nifedipine. Eichmann D, et al. **Eur J Pediatr** 1999 Mar; 158(3):204–6

Hyperinsulinaemic hypoglycaemia associated with persistent hyperammonaemia. Kitaura J, et al. **Eur J Pediatr** 1999 May;158(5):410–3

Upper body obesity and hyperinsulinemia are associated with anovulation. Morán C, et al. **Gynecol Obstet Invest** 1999; 47(1):1–5

Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. Ibáñez L, et al. **J Endocrinol Invest** 1998 Oct; 21(9):558–66 (88 ref.)

The haemodynamic response to hyperinsulinaemia in hypertensive subjects. Lind L, et al. **J Hum Hypertens** 1999 Jan;13(1):41–5

Studies in hypertriglyceridaemia. VI: Serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. Asplund-Carlson A, et al. **J Intern Med** 1999 Mar; 245(3):247–52

Obesity worsens cardiovascular risk profiles independently of hyperinsulinaemia. Bonora E, et al. **J Intern Med** 1997 Jun;241(6):463–70

Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. Raal FJ, et al. **J Intern Med** 1999 Jul;246(1):75–80

Foregut dysmotility complicating persistent hyperinsulinaemic hypoglycaemia of infancy. Cade A, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):355–8

Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia. Cowett RM, et al. **Metabolism** 1999 May;48(5):568–74

Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia. Sparks JD, et al. **Metabolism** 1998 Nov; 47(11):1315–24

Temporal association between obesity and hyperinsulinemia in children, adolescents, and young adults: the Bogalusa Heart Study. Srinivasan SR, et al. **Metabolism** 1999 Jul; 48(7):928–34

Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Zavaroni I, et al. **Metabolism** 1999 Aug;48(8):989–94

The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes [editorial] Sobel BE. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):313–8

Nesidioblastosis with hyperinsulinemic hypoglycemia in adults: report of two cases. Eriguchi N, et al. **Surg Today** 1999;29(4):361–3

[Tophaceous gout in plurimetabolic syndrome] Iannello S, et al. **Minerva Med** 1998 Nov-Dec;89(11-12):419–37 (168 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

Histochemical, clinical, and in vitro beta cell responses in a neonate with persistent hyperinsulinaemic hypoglycaemia of infancy. Panesar NS, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F141–4

DIAGNOSIS

Screening for type II diabetes candidates [letter; comment] Simon K, et al. **Am J Med** 1999 Apr;106(4):489–91. Comment on: Am J Med 1997 Aug;103(2):152–62.

DIET THERAPY

Insulin unexpectedly increases the glucose 6-phosphate Ka of skeletal muscle glycogen synthase in calorie-restricted monkeys. Ortmeyer HK, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):309–23

DRUG THERAPY

Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Goyal RK. **Clin Exp Hypertens** 1999 Jan-Feb;21(1–2):167–79 (44 ref.)

Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Ehrmann DA. **Endocrinol Metab Clin North Am** 1999 Jun;28(2):423–38, viii (55 ref.)

Treatment of hyperinsulinaemic hypoglycaemia with nifedipine. Eichmann D, et al. **Eur J Pediatr** 1999 Mar; 158(3):204–6

Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Paoletti AM, et al. **Fertil Steril** 1999 Sep;72(3):448–53

Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? Ehrmann DA. **J Endocrinol Invest** 1998 Oct;21(9):632–5 (36 ref.)

BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Pill J, et al. **Metabolism** 1999 Jan;48(1):34–40

EPIDEMIOLOGY

Hyperinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: a community-based study. Chien KL, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):838–46

ETHNOLOGY

Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Goksel DL, et al. **Hum Genet** 1998 Sep;103(3):280–5

ETIOLOGY

Chronic hypertension leads to hyperinsulinemia in Sprague-Dawley rats treated with nitric oxide synthase inhibitor. Erlich Y, et al. **Am J Hypertens** 1998 Sep; 11(9):1129–33

Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Merat S, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1223–30

Physical activity and metabolic cardiovascular syndrome [comment] Tremblay A. **Br J Nutr** 1998 Sep;80(3):215–6 . Comment on: Br J Nutr 1998 Sep;80(3):235–41.

Insulinoma with hyperproinsulinemia during hypoglycemia and loss of expression of vacuolar-type H(+)-ATPase (V-ATPase) in the tumor tissue. Hiura A, et al. **Int J Pancreatol** 1999 Feb;25(1):11–6

Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose. de Lonlay P, et al. **J Pediatr** 1999 Sep;135(3):379–83

[Persistent hyperinsulinemic hypoglycemia in the newborn and infants] de Lonlay-Debeney P, et al. **Arch Pediatr** 1998 Dec;5(12):1347–52 (30 ref.) (Eng. Abstr.) **(Fre)**

[Arterial hypertension and disorders of hydrocarbon metabolism] González Maqueda I, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:3–14 (Eng. Abstr.) **(Spa)**

GENETICS

Effect of insulin on farnesyltransferase gene transcription and mRNA stability. Goalstone ML, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):243–7

Hyperinsulinemia and dyslipidemia in non-obese, normotensive offspring of hypertensive parents in northern India. Misra A, et al. **Blood Press** 1998 Nov;7(5–6):286–90

Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Lei HH, et al. **Diabetes** 1999 Sep;48(9):1868–72

A new mouse model of spontaneous diabetes derived from ddY strain. Suzuki W, et al. **Exp Anim** 1999 Jul;48(3):181–9

Women relatives of Hispanic patients with type 2 diabetes are more prone to exhibit metabolic disturbances. Florez H, et al. **Invest Clin** 1999 Jun;40(2):127–42

IMMUNOLOGY

Induction of hypothermia, hypoglycemia and hyperinsulinemia after acute leptin immunoneutralization in overnight fasted mice. Martínez-Ansó E, et al. **Int J Mol Med** 1998 Dec;2(6):681–3

METABOLISM

Insulin secretion and hepatic insulin clearance as determinants of hyperinsulinaemia in normotolerant grossly obese adolescents. Cerutti F, et al. **Acta Paediatr** 1998 Oct; 87(10):1045–50

Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. Meyer C, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):F915–21

Effect of hyperglycemia-hyperinsulinemia on whole body and regional fatty acid metabolism. Sidossis LS, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E427–34

Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Russell RR 3rd, et al. **Circulation** 1998 Nov 17; 98(20):2180–6

Enhanced potential for oxidative stress in hyperinsulinemic rats: imbalance between hepatic peroxisomal hydrogen peroxide production and decomposition due to hyperinsulinemia. Xu L, et al. **Horm Metab Res** 1999 Apr; 31(4):278–82

Vasodilator response to systemic but not to local hyperinsulinemia in the human forearm. Cardillo C, et al. **Hypertension** 1998 Oct;32(4):740–5

Relationships of PPARgamma and PPARgamma2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. Hotta K, et al. **Int J Obes Relat Metab Disord** 1998 Oct;22(10):1000–10

Role of hyperinsulinemia on hepatic insulin receptor concentration and autophosphorylation in the presence of high growth hormone levels in transgenic mice overexpressing growth hormone gene. Dominici FP, et al. **J Endocrinol** 1998 Oct;159(1):15–25

Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. Fang TC, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1767–74

Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. Hautanen A, et al. **J Intern Med** 1997 Jun;241(6):451–61

Clinical features of neonates with hyperinsulinism [letter] Hawdon JM, et al. **N Engl J Med** 1999 Aug 26;341(9):701–2

Interleukin-1beta-induced nitric oxide synthesis in aortic rings from normal and hyperinsulinaemic rats: effect of physical exercise. Kähönen M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):63–8

The influence of hyperinsulinaemia on calcium-phosphate metabolism in renal failure. Nowicki M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2566–71

PATHOLOGY

Malformations of hypothalamic nuclei in hyperinsulinemic offspring of rats with gestational diabetes. Plagemann A, et al. **Dev Neurosci** 1999;21(1):58–67

PHYSIOPATHOLOGY

The effect of euglucaemic hyperinsulinaemia on forearm blood flow and glucose uptake in the human forearm. Fugmann A, et al. **Acta Diabetol** 1998 Dec;35(4):203–6

Failure of acute hyperinsulinemia to alter blood pressure is not due to baroreceptor feedback. Richey JM, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):405–13

Effects of hyperinsulinemia on the regulation of regional blood flow and blood pressure in anesthetized dogs:

hemodynamic role of nitric oxide. Villa E, et al. **Am J Hypertens** 1998 Oct;11(10):1232–8

Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Van De Borne P, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R178–83

Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Laitinen T, et al. **Diabetes** 1999 Jun;48(6):1295–9

Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Suga A, et al. **Diabetes** 1999 Oct;48(10):2034–8

Insulin-like growth factor binding protein-1 as a predictor of glucose-stimulated hyperinsulinemia in prepubertal obese children. Saitoh H, et al. **Eur J Endocrinol** 1999 Mar; 140(3):231–4

Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi-quantitative coronary angiography. Tsuchihashi K, et al. **Intern Med** 1999 Sep;38(9):691–7

Postexercise responses of muscle sympathetic nerve activity and blood flow to hyperinsulinemia in humans. Forjaz CL, et al. **J Appl Physiol** 1999 Aug;87(2):824–9

Sympathetic hyperactivity in Wistar rats with insulin-resistance. Chang CJ, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2–3):116–9

Impaired vagal reflex activity in insulin-resistant rats. Miller AW, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):698–702

Relationship between hyperinsulinemia and ambulatory blood pressure monitoring of lean and overweight male hypertensives. Feldstein CA, et al. **J Cardiovasc Risk** 1998 Feb;5(1):25–30

Supraphysiological hyperinsulinemia acutely increases hypothalamic-pituitary-adrenal secretory activity in humans. Fruehwald-Schultes B, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3041–6

The haemodynamic response to hyperinsulinaemia in hypertensive subjects. Lind L, et al. **J Hum Hypertens** 1999 Jan;13(1):41–5

Acute hyperglycaemia in the forearm induces vasodilation that is not modified by hyperinsulinaemia. van Veen S, et al. **J Hum Hypertens** 1999 Apr;13(4):263–8

Effects of hyperinsulinemia on vascular blood flows in experimental obesity. Villa E, et al. **J Steroid Biochem Mol Biol** 1999 Apr–Jun;69(1–6):273–9

Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin-1 levels in men with essential hypertension and normotensive controls. Surdacki A, et al. **Metabolism** 1999 Jul;48(7):887–91

PREVENTION & CONTROL

Sympathectomy prevents fructose-induced hyperinsulinemia and hypertension. Verma S, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):R1–4

Long-term alpha1-adrenergic blockade attenuates diet-induced dyslipidemia and hyperinsulinemia in the rat. Fajardo N, et al. **J Cardiovasc Pharmacol** 1998 Dec; 32(6):913–9

Elimination of hyperinsulinemia after pancreas transplantation in rats. Nakai I, et al. **Transplant Proc** 1999 Aug;31(5):2010–1

SURGERY

Pancreatic exocrine and endocrine function after pancreatectomy for persistent hyperinsulinaemic hypoglycaemia of infancy. Cade A, et al. **Arch Dis Child** 1998 Nov;79(5):435–9

Partial or near total pancreatectomy for persistent neonatal hyperinsulinaemic hypoglycaemia: the pathologist's role [letter; comment] Cox P. **Histopathology** 1999 Jan;34(1):78 . Comment on: Histopathology 1998 Jan;32(1):15–9.

THERAPY

Long-term follow up of persistent hyperinsulinaemic hypoglycaemia of infancy. Cresto JC, et al. **Arch Dis Child** 1998 Nov;79(5):440–4

Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Seufert J, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):674–9

URINE

Effect of hyperinsulinaemia on renal function and nitrate/nitrite excretion in healthy subjects. Komers R, et al. **Clin Exp Pharmacol Physiol** 1999 Apr;26(4):336–41

VETERINARY

Clenbuterol-induced insulin resistance in calves measured by hyperinsulinemic, euglycemic clamp technique. Sternbauer K, et al. **Acta Vet Scand** 1998;39(2):281–9

Monkey leptin receptor mRNA: sequence, tissue distribution, and mRNA expression in the adipose tissue of normal, hyperinsulinemic, and type 2 diabetic rhesus monkeys. Hotta K, et al. **Obes Res** 1998 Sep;6(5):353–60

HYPERINSULINISM

see related
HYPERINSULINEMIA

Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Kekäläinen P, et al. **Diabetes Care** 1999 Jan;22(1):86–92

Assessing insulin sensitivity in the cat: evaluation of the hyperinsulinemic euglycemic clamp and the minimal model analysis. Petrus DJ, et al. **Res Vet Sci** 1998 Sep–Oct; 65(2):179–81

[Persistent hyperinsulinemic hypoglycemia in the newborn and infants] de Lonlay-Debeney P, et al. **Arch Pediatr** 1998 Dec;5(12):1347–52 (30 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Low levels of sex hormone-binding globulin and hyperproinsulinemia as markers of increased pancreatic beta-cell demand in men. Reis AF, et al. **Braz J Med Biol Res** 1998 Dec;31(12):1545–51

Serum soluble adhesion molecule concentrations are not regulated by acute hyperinsulinaemia in healthy men [letter] Nagai Y, et al. **Diabet Med** 1999 Jul;16(7):618

Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men [letter] Nagai Y, et al. **Diabetes Care** 1999 Jun;22(6):1004

Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism. Villa P, et al. **Fertil Steril** 1999 Jan;71(1):115–21

CHEMICALLY INDUCED

Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. Hostens K, et al. **J Clin Invest** 1999 Jul;104(1):67–72

COMPLICATIONS

Nesidioblastosis, myelodysplastic syndrome and nodular diabetic glomerulosclerosis in an elderly nondiabetic woman: an autopsy report. Yeh SP, et al. **Diabet Med** 1999 May;16(5):437–41

A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Otonkoski T, et al. **Diabetes** 1999 Feb;48(2):408–15

Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Ibáñez L, et al. **Diabetologia** 1998 Sep;41(9):1057–63

The metabolic parameters of obese children and the role of hyperinsulinism on weight loss [letter] Alikasifoglu A, et al. **Eur J Pediatr** 1999 Mar;158(3):269–70

Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: possible role of hyperinsulinemia. Nagamani M, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1685–9

Hyperinsulinism plus hyperammonemia [letter; comment] Parini R, et al. **J Pediatr** 1998 Dec;133(6):800–1. Comment on: J Pediatr 1997 Apr;130(4):661–4.

[Occurrence of diabetes, hyperinsulinism and other risk factors for atherosclerosis in patients with pernicious anemia] Kessler P, et al. **Vnitr Lek** 1998 Apr;44(4):222–6 (Eng. Abstr.) **(Cze)**

CONGENITAL

Neonatal hyperinsulinism. Schwitzgebel VM, et al. **Clin Perinatol** 1998 Dec;25(4):1015–38, viii (78 ref.)

Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Meissner T, et al. **Hum Mutat** 1999; 13(5):351–61 (80 ref.)

Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. Lovvorn HN 3rd, et al. **J Pediatr Surg** 1999 May;34(5):786–92; discussion 792–3

Clinical features of 52 neonates with hyperinsulinism [see comments] de Lonlay-Debeney P, et al. **N Engl J Med** 1999 Apr 15;340(15):1169–75. Comment in: N Engl J Med 1999 Apr 15;340(15):1200–1.

DIAGNOSIS

Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. Service FJ, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1582–9

Hyperinsulinism and hyperammonaemia. al-Shamsan L, et al. **J Inherit Metab Dis** 1998 Aug;21(6):671–3

DRUG THERAPY

Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Touati G, et al. **Eur J Pediatr** 1998 Aug; 157(8):628–33

[Preliminary clinical results with fructose-1,6-diphosphate in patients with hyperinsulinism] Avogaro P, et al. **Minerva Anestesiol** 1981 Jul;47(7):375–8 **(Ita)**

ENZYMOLOGY

Hyperinsulinism-hyperammonemia syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics. Yorifuji T, et al. **Hum Genet** 1999 Jun; 104(6):476–9

EPIDEMIOLOGY

Fetal growth and hyperinsulinaemia in adult life. Martyn CN, et al. **Diabet Med** 1998 Aug;15(8):688–94

Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Baan CA, et al. **Diabetes Care** 1999 Feb;22(2):213–9

ETHNOLOGY

Hyperinsulinism and sex hormones in young adult African Americans. Falkner B, et al. **Metabolism** 1999 Jan; 48(1):107–12

ETIOLOGY

Neuroglycopenic and other symptoms in patients with insulinomas. Dizon AM, et al. **Am J Med** 1999 Mar; 106(3):307–10

Persistent hyperinsulinemic hypoglycemia of infancy. Desai MP, et al. **Indian Pediatr** 1998 Apr;35(4):317–28

Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. Ibáñez L, et al. **J Clin Endocrinol Metab** 1998 Oct; 83(10):3558–62

[Transitory hyperinsulinism with hypoglycemia in asphyxia neonatorum (letter; comment)] Sann L. **Arch Pediatr** 1999 Feb;6(2):228. Comment on: Arch Pediatr 1997 Dec;4(12):1213–6. **(Fre)**

GENETICS

Loss of imprinted genes and paternal SUR1 mutations lead to hyperinsulinism in focal adenomatous hyperplasia. Fournet JC, et al. **Ann Endocrinol (Paris)** 1998;59(6):485–91

Hyperinsulinism: molecular aetiology of focal disease. Ryan F, et al. **Arch Dis Child** 1998 Nov;79(5):445–7

Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Glaser B, et al. **Diabetes** 1999 Aug;48(8):1652–7

A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Otonkoski T, et al. **Diabetes** 1999 Feb;48(2):408–15

Tumour necrosis factor beta alleles and hyperinsulinaemia in coronary artery disease. Braun J, et al. **Eur J Clin Invest** 1998 Jul;28(7):538–42

Hyperinsulinism-hyperammonemia syndrome caused by mutant glutamate dehydrogenase accompanied by novel enzyme kinetics. Yorifuji T, et al. **Hum Genet** 1999 Jun; 104(6):476–9

Genetic heterogeneity in familial hyperinsulinism [published erratum appears in Hum Mol Genet 1998 Sep;7(9):1527] Nestorowicz A, et al. **Hum Mol Genet** 1998 Jul; 7(7):1119–28

Intragenic single nucleotide polymorphism haplotype analysis of SUR1 mutations in familial hyperinsulinism. Glaser B, et al. **Hum Mutat** 1999;14(1):23–9

Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Meissner T, et al. **Hum Mutat** 1999; 13(5):351–61 (80 ref.)

Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor. Katz LE, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3117–24

Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. Verkarre V, et al. **J Clin Invest** 1998 Oct 1; 102(7):1286–91

Differences between African American and white girls in the insulin-like growth factor-I and the binding proteins: importance of insulin resistance and hyperinsulinemia [editorial; comment] Caprio S. **J Pediatr** 1999 Sep; 135(3):270–1 (13 ref.). Comment on: J Pediatr 1999 Sep;135(3):296–300.

Clinical and molecular heterogeneity of familial hyperinsulinism [letter; comment] Glaser B, et al. **J Pediatr** 1998 Dec;133(6):801–2. Comment on: J Pediatr 1998 Jan;132(1):9–14.

The causes of neonatal hypoglycemia [editorial; comment] Stanley CA, et al. **N Engl J Med** 1999 Apr 15; 340(15):1200–1. Comment on: N Engl J Med 1999 Apr 15;340(15):1169–75.

Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Kushi A, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15659–64

METABOLISM

Acute hyperinsulinemia fails to change GLUT-4 content in crude membranes from goat skeletal muscles and adipose tissue. Balage M, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):425–30

Increased amounts of farnesylated p21Ras in tissues of hyperinsulinaemic animals. Goalstone ML, et al. **Diabetologia** 1999 Mar;42(3):310–6

Impact of hyperinsulinemia on myosin heavy chain gene regulation. Houmard JA, et al. **J Appl Physiol** 1999 Jun; 86(6):1828–32

HYPERINSULINISM

PATHOLOGY

Morphological alterations of hypothalamic nuclei due to intrahypothalamic hyperinsulinism in newborn rats. Plagemann A, et al. **Int J Dev Neurosci** 1999 Feb; 17(1):37–44

Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. Juan CC, et al. **Metabolism** 1999 Apr;48(4):465–71

PHYSIOPATHOLOGY

Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Kong MF, et al. **Diabetologia** 1999 Mar;42(3):365–72

Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus–infected women. Hadigan C, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1932–7

Hepatic amino– to urea–N clearance and forearm amino–N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. Grøfte T, et al. **J Hepatol** 1999 May;30(5):819–25

[Hypoglycemia due to cibenzoline: role of hyperinsulinism (letter)] Yazbeck R, et al. **Presse Med** 1999 May 22–29; 28(19):1017–8 **(Fre)**

SURGERY

Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. Lovvorn HN 3rd, et al. **J Pediatr Surg** 1999 May;34(5):786–92; discussion 792–3

THERAPY

[Personal experience with the treatment of organic hyperinsulinism] Skrha J, et al. **Vnitr Lek** 1998 Apr; 44(4):217–21 (Eng. Abstr.) **(Cze)**

HYPERKALEMIA

Hyperkalemia probably reverses the antiarrhythmic effects of amiodarone: a case report. Akiyama J, et al. **Jpn Circ J** 1999 Apr;63(4):323–5

Potassium and anaesthesia. Reddy VG. **Singapore Med J** 1998 Nov;39(11):511–6 (56 ref.)

[Hyperkalemia] Chevet D. **Rev Prat** 1998 Feb 15;48(4):451–6 **(Fre)**

BLOOD

Renin–aldosterone in elderly patients with hyperkalaemia under anaesthesia. Kudoh A, et al. **Eur J Anaesthesiol** 1999 Apr;16(4):231–5

CHEMICALLY INDUCED

Acute hyperkalemia associated with intravenous epsilon–aminocaproic acid therapy. Perazella MA, et al. **Am J Kidney Dis** 1999 Apr;33(4):782–5

Trimethoprim–sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Alappan R, et al. **Am J Nephrol** 1999;19(3):389–94

An unexpected hyperkalemic response to succinylcholine during electroconvulsive therapy for catatonic schizophrenia. Cooper RC, et al. **Anesthesiology** 1999 Aug; 91(2):574–5

Succinylcholine hyperkalemia after burns [letter] Gronert GA. **Anesthesiology** 1999 Jul;91(1):320–2

Hyperkalemia risks in hemodialysed patients consuming fluoride–rich water. Nicolay A, et al. **Clin Chim Acta** 1999 Mar;281(1–2):29–36

Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Sheehan MT, et al. **Clin Nephrol** 1998 Sep;50(3):188–93 (39 ref.)

Trimethoprim–induced hyperkalemia: An analysis of reported cases. Marinella MA. **Gerontology** 1999 Jul–Aug; 45(4):209–12 (21 ref.)

Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study. Verma A, et al. **J Clin Neurophysiol** 1999 Jan;16(1):46–50

Secondary hyperkalaemic paralysis [letter; comment] Gledhill RF. **J Neurol Neurosurg Psychiatry** 1998 Oct; 65(4):614. Comment on: J Neurol Neurosurg Psychiatry 1998 Feb;64(2):249–52.

The aging kidney [clinical conference] Rodríguez–Puyol D. **Kidney Int** 1998 Dec;54(6):2247–65

Hyperkalaemic muscle paresis—side–effect of prostaglandin inhibition in a haemodialysis patient. Nielsen EH. **Nephrol Dial Transplant** 1999 Feb;14(2):480–2

Life–threatening hyperkalaemia during a haemodialysis session: an avoidable risk [see comments] Romagnoni M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2480–1. Comment in: Nephrol Dial Transplant 1998 Oct;13(10):2483–4.

Iatrogenic hyperkalaemia—points to consider in diagnosis and management. Siamopoulos KC, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2402–6

[Hyperkalemia after trimethoprim or pentamidine. Until now, a little noticed side effect of antimicrobial therapeutic measures in AIDS patients] Gabriëls G, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1351–5 (25 ref.) **(Ger)**

COMPLICATIONS

Hyperkalemic periodic paralysis M1592V mutation modifies activation in human skeletal muscle Na+ channel. Rojas CV, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):C259–66

Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: possible culprits for postcountershock arrhythmias? Niemann JT, et al. **Ann Emerg Med** 1999 Jul;34(1):1–7

Hyperkalaemic paralysis—a bizarre presentation of renal failure. Cumberbatch GL, et al. **J Accid Emerg Med** 1999 May;16(3):230–2

Succinylcholine induced hyperkalemia and cardiac arrest death related to an EEG study. Verma A, et al. **J Clin Neurophysiol** 1999 Jan;16(1):46–50

Long–term myocardial preservation: effects of hyperkalemia, sodium channel, and Na/K/2Cl cotransport inhibition on extracellular potassium accumulation during hypothermic storage. Snabaitis AK, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):123–34

Hyperkalemia in patients infected with the human immunodeficiency virus: involvement of a systemic mechanism. Caramelo C, et al. **Kidney Int** 1999 Jul; 56(1):198–205

Hyperkalaemic muscle paresis—side–effect of prostaglandin inhibition in a haemodialysis patient. Nielsen EH. **Nephrol Dial Transplant** 1999 Feb;14(2):480–2

Marked bradycardia associated with profound hyperkalemia in patients with end–stage renal disease [letter] Abe R, et al. **Nephron** 1998 Nov;80(3):355–6

Fibromyalgia in hyperkalemic periodic paralysis. Götze FR, et al. **Scand J Rheumatol** 1998;27(5):383–4

[Hyperkalemic periodic muscle paralysis in primary adrenocortical insufficiency. A case report] Przedlacki J, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):330–1 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

H+–ATPase in hyperkalemic distal renal tubular acidosis. Danesh FR, et al. **Am J Kidney Dis** 1998 Dec;32(6):1091–5; discussion 1095–7

ECG abnormalities in a comatose diabetic woman. Hancock EW. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):37–8

Hyperkalemic renal tubular acidosis. Shah SM, et al. **Indian Pediatr** 1998 Dec;35(12):1224–7

Enhanced exercise–induced hyperkalemia in patients with syndrome X. Bøtker HE, et al. **J Am Coll Cardiol** 1999 Mar 15;33(4):1056–61

Iatrogenic hyperkalaemia—points to consider in diagnosis and management. Siamopoulos KC, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2402–6

Creatinine, electrolytes and urea—do I hear much groaning? Swanepoel CR. **S Afr Med J** 1999 Mar;89(3):251–4

Abnormal electrocardiographic patterns in renal failure. Ventricular tachycardia. Quek SC, et al. **Singapore Med J** 1999 Jan;40(1):57–8

[The Gordon syndrome: the first reported case in Spain (letter)] García Morillo S, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):198–9 (8 ref.) **(Spa)**

DRUG THERAPY

Albuterol for the treatment of hyperkalemia. Wong SL, et al. **Ann Pharmacother** 1999 Jan;33(1):103–6 (15 ref.)

Salbutamol metered–dose inhaler with spacer for hyperkalemia: how fast? How safe? Mandelberg A, et al. **Chest** 1999 Mar;115(3):617–22

ENZYMOLOGY

Regulation of Na/K–ATPase gene expression by thyroid hormone and hyperkalemia in the heart. Yalcin Y, et al. **Thyroid** 1999 Jan;9(1):53–9

ETIOLOGY

Hyperkalemic metabolic acidosis. DuBose TD Jr. **Am J Kidney Dis** 1999 May;33(5):XLV–XLVIII

A case of pseudohyperkalacmia and thrombocytosis. Seah TG, et al. **Ann Acad Med Singapore** 1998 May;27(3):442–3

Is the potassium really elevated? Phillips PJ, et al. **Aust Fam Physician** 1998 Dec;27(12):1129–30

ECG abnormalities in a comatose diabetic woman. Hancock EW. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):37–8

Exercise–induced hyperkalemia and concentration of Na,K–pumps in skeletal muscle in mitral stenosis: effect of balloon mitral valvotomy. Barlow CW, et al. **J Heart Valve Dis** 1999 Jul;8(4):430–9

Hyperkalemia due to a potassium–based water softener [letter] Graves JW. **N Engl J Med** 1998 Dec 10; 339(24):1790–1

Extreme hyperkalemia in Munchausen–by–proxy syndrome [letter] Magen D, et al. **N Engl J Med** 1999 Apr 22; 340(16):1293–4

A case of aldosterone–producing adenoma with severe postoperative hyperkalemia. Taniguchi R, et al. **Tohoku J Exp Med** 1998 Nov;186(3):215–23

[Disorders of potassium balance] Gross P, et al. **Internist (Berl)** 1998 Aug;39(8):810–4 (11 ref.) **(Ger)**

[Hyperkalemia after irradiated blood transfusion] Fukuoka Y, et al. **Masui** 1999 Feb;48(2):192–4 (Eng. Abstr.) **(Jpn)**

[Unexpected hyperkalemia during general anesthesia in three patients undergoing hepatic, cholangioler or pancreatic surgery] Yagi E, et al. **Masui** 1999 Feb;48(2):189–91 (Eng. Abstr.) **(Jpn)**

GENETICS

Phenytoin alters transcript levels of hormone–sensitive lipase in muscle from horses with hyperkalemic periodic paralysis. Yudkowsky ML, et al. **Arch Biochem Biophys** 1998 Oct 15;358(2):264–70

Familial pseudohyperkalemia maps to the same locus as dehydrated hereditary stomatocytosis (hereditary xerocytosis). Iolascon A, et al. **Blood** 1999 May 1; 93(9):3120–3

A variant of hereditary stomatocytosis with marked pseudohyperkalaemia. Coles SE, et al. **Br J Haematol** 1999 Feb;104(2):275–83

A genetic syndrome associating dehydrated hereditary stomatocytosis, pseudohyperkalaemia and perinatal oedema. Grootenboer S, et al. **Br J Haematol** 1998 Nov; 103(2):383–6

Activation and inactivation of the voltage–gated sodium channel: role of segment S5 revealed by a novel hyperkalaemic periodic paralysis mutation. Bendahhou S, et al. **J Neurosci** 1999 Jun 15;19(12):4762–71

Disruption of the beta subunit of the epithelial Na+ channel in mice: hyperkalemia and neonatal death associated with a pseudohypoaldosteronism phenotype. McDonald FJ, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1727–31

METABOLISM

Recurrent calcium stones in Gordon's syndrome. Stratton JD, et al. **Br J Urol** 1998 Dec;82(6):925

Protection of cardiomyocytes by pinacidil during metabolic inhibition and hyperkalemia. Tang T, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):179–87

PHYSIOPATHOLOGY

Quantitative characterization of epicardial wave fronts during regional ischemia and elevated extracellular potassium ion concentration. Punske BB, et al. **Ann Biomed Eng** 1998 Nov–Dec;26(6):1010–21

Hyperkalemia enhances the effect of adenosine on IK,ADO in rabbit isolated AV nodal myocytes and on AV nodal conduction in guinea pig isolated heart. Martynyuk AE, et al. **Circulation** 1999 Jan 19;99(2):312–8

Hyperkalemia: a potential silent killer. Weiner ID, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1535–43 (107 ref.)

Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases. Martinez–Vea A, et al. **J Electrocardiol** 1999 Jan;32(1):45–9

Loss of atrial capture during DDD pacing: what is the mechanism? Barold SS. **Pacing Clin Electrophysiol** 1998 Oct;21(10):1988–9

Intraoperative QRS–interval changes caused by hyperkalaemia in an infant with Arima syndrome. Koizuka S, et al. **Paediatr Anaesth** 1998;8(5):425–8

Does hypothermia or hyperkalemia influence the preconditioning response? Takeshima S, et al. **Scand Cardiovasc J** 1999;33(2):79–87

PREVENTION & CONTROL

A new treatment forInterdialytic hyperkalemia – the use of fosinopril sodium. Mousa D, et al. **Am J Nephrol** 1999; 19(3):395–9

Life–threatening reperfusion injury in skeletal muscle: a simple technique to control critical hyperkalemia. Utoh J, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):651–4

THERAPY

Serendipitous prophylactic pacemaker treatment for hyperkalemia [letter] Stabroth C, et al. **Am J Med** 1999 Jan;106(1):123–4

Approach to hyperkalemic end–stage renal disease patients in the emergency department. Perazella MA. **Conn Med** 1999 Mar;63(3):131–6 (34 ref.)

VETERINARY

Hyperkalaemic periodic paralysis in homozygous and heterozygous horses: a co–dominant genetic condition. Naylor JM, et al. **Equine Vet J** 1999 Mar;31(2):153–9

[HYPP: hyperkalemic periodic paralysis in the horse] Sloet van Oldruitenborgh–Oosterbaan MM. **Tijdschr Diergeneeskd** 1999 Mar 15;124(6):176–81 (37 ref.) (Eng. Abstr.) **(Dut)**

HYPERKERATOSIS, EPIDERMOLYTIC

DIAGNOSIS

Prenatal diagnosis for keratin mutations to exclude transmission of epidermolytic hyperkeratosis. Rothnagel JA, et al. **Prenat Diagn** 1998 Aug;18(8):826–30

GENETICS

Cyclic ichthyosis with epidermolytic hyperkeratosis: A phenotype conferred by mutations in the 2B domain of keratin K1. Sybert VP, et al. **Am J Hum Genet** 1999 Mar; 64(3):732–8

Dominant traits may give rise to paired patches of either

excessive or absent involvement [letter; comment] Happle R, et al. **Am J Med Genet** 1999 May 21;84(2):176–7. Comment on: Am J Med Genet 1996 Dec 11;66(2):241–2.
An asparagine to threonine substitution in the 1A domain of keratin 1: a novel mutation that causes epidermolytic hyperkeratosis. Arin MJ, et al. **Exp Dermatol** 1999 Apr; 8(2):124–7
Arginine in the beginning of the 1A rod domain of the keratin 10 gene is the hot spot for the mutation in epidermolytic hyperkeratosis. Yang JM, et al. **J Dermatol Sci** 1999 Feb; 19(2):126–33 (35 ref.)
A novel substitution in keratin 10 in epidermolytic hyperkeratosis. Arin MJ, et al. **J Invest Dermatol** 1999 Apr; 112(4):506–8
An atypical form of bullous congenital ichthyosiform erythroderma is caused by a mutation in the L12 linker region of keratin 1. Kremer H, et al. **J Invest Dermatol** 1998 Dec;111(6):1224–6
A novel helix termination mutation in keratin 10 in annular epidermolytic ichthyosis, a variant of bullous congenital ichthyosiform erythroderma. Suga Y, et al. **J Invest Dermatol** 1998 Dec;111(6):1220–3
A novel glutamic acid to aspartic acid mutation near the end of the 2B rod domain in the keratin 1 chain in epidermolytic hyperkeratosis. Yang JM, et al. **J Invest Dermatol** 1999 Mar;112(3):376–9
Prenatal diagnosis for keratin mutations to exclude transmission of epidermolytic hyperkeratosis. Rothnagel JA, et al. **Prenat Diagn** 1998 Aug;18(8):826–30

PATHOLOGY

Normal ultrastructure, but altered stratum corneum lipid and protein composition in a mouse model for epidermolytic hyperkeratosis. Reichelt J, et al. **J Invest Dermatol** 1999 Sep;113(3):329–34

HYPERKERATOSIS PALMARIS ET PLANTARIS see **KERATODERMA, PALMOPLANTAR**

HYPERKINESIS

CHEMICALLY INDUCED

Neonatal alcohol exposure produces hyperactivity in high-alcohol-sensitive but not in low-alcohol-sensitive rats. Thomas JD, et al. **Alcohol** 1998 Oct;16(3):237–42
Inhibitory effects of ginseng total saponin on nicotine-induced hyperactivity, reverse tolerance and dopamine receptor supersensitivity. Kim HS, et al. **Behav Brain Res** 1999 Aug;103(1):55–61
Chronic ethanol administration alters activity in ventral tegmental area neurons after cessation of withdrawal hyperexcitability. Bailey CP, et al. **Brain Res** 1998 Aug 24;803(1–2):144–52
Cyclosporine A-induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Borlongan CV, et al. **Cell Transplant** 1999 Jan–Feb;8(1):153–9
The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. Carlsson ML, et al. **J Neural Transm** 1999;106(2):123–9
Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Hagell P, et al. **Mov Disord** 1999 May;14(3):448–55
Deficit in selective and divided attention associated with cholinergic basal forebrain immunotoxic lesion produced by 192-saporin; motoric/sensory deficit associated with Purkinje cell immunotoxic lesion produced by OX7-saporin. Waite JJ, et al. **Neurobiol Learn Mem** 1999 May;71(3):325–52

DIAGNOSIS

DSM-IV and ICD-10: a comparison of the correlates of ADHD and hyperkinetic disorder. Tripp G, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Feb;38(2):156–64
Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398–403 (70 ref.)
Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Hagell P, et al. **Mov Disord** 1999 May;14(3):448–55

DRUG THERAPY

The full expression of locomotor and motor hyperactivities induced by pressure requires both striatal dopaminergic and N-methyl-D-aspartate receptor activities in the rat. Darbin O, et al. **Neurosci Lett** 1999 Jun 4;267(3):149–52
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity [see comments] Gainetdinov RR, et al. **Science** 1999 Jan 15; 283(5400):397–401. Comment in: Science 1999 Jan 15;283(5400):306.
How stimulant drugs may calm hyperactivity [news; comment] Marx J. **Science** 1999 Jan 15;283(5400):306. Comment on: Science 1999 Jan 15;283(5400):397–401.

ETIOLOGY

Cyclosporine A-induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Borlongan CV, et al. **Cell Transplant** 1999 Jan–Feb;8(1):153–9
Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Krauss JK, et al. **Mov Disord** 1999 May;14(3):497–501

METABOLISM

Effects of growth rate and cell density on nerve growth factor secretion in cultures of vascular and bladder smooth muscle cells from hypertensive and hyperactive rats. Clemow DB, et al. **Cell Tissue Res** 1998 Dec;294(3):431–8
Reaction time performance following unilateral striatal dopamine depletion and lesions of the subthalamic nucleus in the rat. Phillips JM, et al. **Eur J Neurosci** 1999 Mar; 11(3):1003–10
Peptide N- and P/Q-type Ca2+ blockers inhibit stimulant-induced hyperactivity in mice. Ogura H, et al. **Peptides** 1998;19(6):1017–22

PHYSIOPATHOLOGY

Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398–403 (70 ref.)

PREVENTION & CONTROL

Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats. Niittykoski M, et al. **Behav Pharmacol** 1997 Oct;8(5):465–70
Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. McCreary AC, et al. **Neuropsychopharmacology** 1999 Jun;20(6):556–64

PSYCHOLOGY

Cognitive functioning moderates the relation between hyperactivity and drinking habits. Span SA, et al. **Alcohol Clin Exp Res** 1999 Feb;23(2):224–9
Effect of dopamine blockers on cerebral ischemia-induced hyperactivity in gerbils. Araki H, et al. **Physiol Behav** 1999 Apr;66(2):263–8

HYPERKINETIC HEART SYNDROME see **NEUROCIRCULATORY ASTHENIA**

HYPERKINETIC SYNDROME see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

HYPERLIPEMIA see **HYPERLIPIDEMIA**

HYPERLIPEMIA, MIXED see **HYPERLIPOPROTEINEMIA TYPE V**

HYPERLIPIDEMIA

see related

ANTILIPEMIC AGENTS

Hyperlipidemia in patients with chronic renal disease. Kasiske BL. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S142–56 (117 ref.)
Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). Ockene IS, et al. **Arch Intern Med** 1999 Apr 12;159(7):725–31
Evaluation and management of lipid disorders. Rekhraj S, et al. **Curr Opin Cardiol** 1999 Jul;14(4):298–302 (16 ref.)
[Hyperlipidemia in elderly] Iguchi A. **Nippon Ronen Igakkai Zasshi** 1999 Jan;36(1):29–34 (44 ref.) **(Jpn)**
[Friedreich's type of ataxia with hypoalbuminemia and hyperlipidemia (FHH)] Yuasa T. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):215–7 (8 ref.) **(Jpn)**

BLOOD

Influence of the acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in normoglycemic and normolipidemic rats. Horák J, et al. **Acta Physiol Hung** 1997–98;85(4):347–51
Effects of acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in hyperlipidemic albino rats. Horák J, et al. **Acta Physiol Hung** 1997–98; 85(4):353–8
Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Papadakis JA, et al. **Am J Hypertens** 1999 Jul;12(7):673–81
Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis. Yang C, et al. **Am J Nephrol** 1998; 18(5):384–90
Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Desrumaux C, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):266–75
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Geppert A, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct;18(10):1634–42
Raised levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the plasma of patients with ischaemic heart disease and hyperlipidaemia [letter; comment] Blann AD, et al. **Atherosclerosis** 1998 Nov; 141(1):177–8. Comment on: Atherosclerosis 1997 May;131(1):43–8.
Fat loading experiments with the vitamins A and E suggest that in postprandial lipemia transfer/diffusion of chylomicron lipids to VLDL contributes to beta-VLDL formation. Demacker PN, et al. **Atherosclerosis** 1998 Dec; 141 Suppl 1:S109–13
Atorvastatin and fibrinogen--a small subgroup shows extreme response [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Aug;145(2):415–7
Evidence of modified lipoprotein in the plasma of Watanabe heritable hyperlipidemic rabbits by anion-exchange high-performance liquid chromatographic assay. Yamaguchi Y, et al. **Atherosclerosis** 1998 Aug; 139(2):323–31
Chromium levels in patients with internal diseases. Zima T, et al. **Biochem Mol Biol Int** 1998 Oct;46(2):365–74
Cholesterol synthesis is increased in mixed hyperlipidaemia. Naoumova RP, et al. **Biochim Biophys Acta** 1998 Nov 2; 1394(2–3):146–52
Plasma ubiquinol-10 as a marker for disease: is the assay worthwhile? Kontush A, et al. **Biofactors** 1999;9(2–4):225–9
Acceleration of development of diabetic cataract by hyperlipidemia and low high-density lipoprotein in rats. Tsutsumi K, et al. **Biol Pharm Bull** 1999 Jan;22(1):37–41
Endogenous inhibitors of nitric oxide synthesis and lipid peroxidation in hyperlipidemic rabbits. Xiong Y, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Mar;17(2):149–52
Pitfalls of direct HDL-cholesterol measurements in mouse models of hyperlipidemia and atherosclerosis. Escolà-Gil JC, et al. **Clin Chem** 1999 Sep;45(9):1567–9
Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia. Lindbohm N, et al. **Clin Chim Acta** 1999 Jul;285(1–2):69–84
Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Yoshinari M, et al. **Diabetes Res Clin Pract** 1998 Dec;42(3):149–54
Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. Wasan KM, et al. **J Pharm Sci** 1999 Feb;88(2):185–90
Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Nakao T, et al. **Kidney Int Suppl** 1999 Jul;71:S206–9
Analysis of ubiquinone and tocopherol levels in normal and hyperlipidemic human plasma. Zhang Y, et al. **Lipids** 1998 Aug;33(8):811–5
Small low-density lipoproteins and vascular cell adhesion molecule-1 are increased in association with hyperlipidemia in preeclampsia. Hubel CA, et al. **Metabolism** 1998 Oct; 47(10):1281–8
Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. Koopmans SJ, et al. **Metabolism** 1999 Mar;48(3):330–7
Redox dynamics of alpha-tocopherol in erythrocyte membranes of elderly patients with asymptomatic primary hyperlipidemia. Yanagawa K, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr;21(3):195–201
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients. Ferlito S, et al. **Minerva Cardioangiol** 1999 Apr;47(4):91–4 **(Eng, Ita)**
Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. Hickman TB, et al. **Prev Med** 1998 Nov–Dec; 27(6):879–90
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Alfon J, et al. **Thromb Haemost** 1999 May;81(5):822–7
Effect of dietary supplementation with evening primrose oil on vascular thrombogenesis in hyperlipemic rabbits. Villalobos MA, et al. **Thromb Haemost** 1998 Oct; 80(4):696–701
Contribution of acute-phase proteins and cardiovascular risk factors to erythrocyte aggregation in normolipidemic and hyperlipidemic individuals. Weng X, et al. **Thromb Haemost** 1998 Dec;80(6):903–8
[Influence of gypenoside on serum lipoprotein and atherosclerosis in hyperlipidaemia animals] Qi G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Sep;21(9):562–4 inside back cover (Eng. Abstr.) **(Chi)**
[Lp(a) and the cardiovascular risk in dyslipidemia subjects] Arsenio L, et al. **Acta Biomed Ateneo Parmense** 1998; 69(3–4):97–103 (Eng. Abstr.) **(Ita)**
[Increased body mass index increase and insulin resistance parameters in dyslipidemia. Risk and positive correlation in essential obesity] Alberto G, et al. **Minerva Endocrinol** 1998 Sep;23(3):65–9 (Eng. Abstr.) **(Ita)**
[Diabetes and dyslipidemia (editorial)] Fatati G. **Recenti Prog Med** 1999 Jan;90(1):21–4 (28 ref.) **(Ita)**

CHEMICALLY INDUCED

Atorvastatin for protease inhibitor-related hyperlipidaemia [letter] Murillas J, et al. **AIDS** 1999 Jul 30;13(11):1424–5

HYPERLIPIDEMIA

Hyperlipidemia associated with protease inhibitor therapy. Echevarria KL, et al. **Ann Pharmacother** 1999 Jul-Aug; 33(7-8):859-63

Hyperlipidemia of diuretic therapy. Ames R. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:23-7 (27 ref.)

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection [letter] Churchill DR, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):518-9

The salubrious effects of ascorbic acid on cyclophosphamide instigated lipid abnormalities in fibrosarcoma bearing rats. Vasavi H, et al. **Cancer Biochem Biophys** 1998 Jun; 16(1-2):71-83

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Périard D, et al. **Circulation** 1999 Aug 17; 100(7):700-5

Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use. Colls BM, et al. **Clin Oncol (R Coll Radiol)** 1998;10(4):270-1

Propofol toxicity in critically ill pediatric patients: show us the proof [editorial; comment] Susla GM. **Crit Care Med** 1998 Dec;26(12):1959-60 (15 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2087-92.

Hyperlipidaemia in cisplatin-induced nephrotic rats. Abdel-Gayoum AA, et al. **Hum Exp Toxicol** 1999 Jul; 18(7):454-9

Hyperlipidemia under treatment with proteinase inhibitors. Segerer S, et al. **Infection** 1999 Mar-Apr;27(2):77-81

The importance of obesity and hyperlipidaemia in patients with renal transplants. Locsey L, et al. **Int Urol Nephrol** 1998;30(6):767-75

Intervention for hyperlipidemia associated with protease inhibitors. Melroe NH, et al. **J Assoc Nurses AIDS Care** 1999 Jul-Aug;10(4):55-69

Lipid abnormalities associated with protease inhibitors. Melroe NH, et al. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):22-30

ApoE genotype and protease-inhibitor-associated hyperlipidaemia [letter; comment] Behrens G, et al. **Lancet** 1999 Jul 3;354(9172):76. Comment on: Lancet 1999 May 15;353(9165):1678.

Lipid lowering therapy in patients with HIV infection [letter; comment] McBride M, et al. **Lancet** 1998 Nov 28; 352(9142):1782-3. Comment on: Lancet 1998 Sep 26;352(9133):1031-2.

Antioxidant potential of evening primrose oil administration in hyperlipemic rabbits. De La Cruz JP, et al. **Life Sci** 1999;65(5):543-55

Effect of in utero exposure of Toddy (coconut palm wine) on liver function and lipid metabolism in rat fetuses. Lal JJ, et al. **Plant Foods Hum Nutr** 1998;52(3):209-19

[Protease inhibitor-associated hypertriglyceridemia and diabetes mellitus in HIV-infected patients (letter)] Knobel H, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):599 **(Spa)**

[Serum lipids. lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or phenytoin] Pita-Calandre E, et al. **Rev Neurol** 1998 Nov; 27(159):785-9 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Comparison of LDL-cholesterol results calculated by using apolipoproteins A1, B or HDL-cholesterol for classification of non-chylomicron dyslipidemias] Szmidt-Adjid V, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):345-50 **(Fre)**

COMPLICATIONS

Diffuse papular eruption. Berger MS, et al. **Am Fam Physician** 1998 Oct 15;58(6):1463-4

Cardiovascular risk profiling in blacks: don't forget the lipids [editorial] Kountz DS, et al. **Am Fam Physician** 1998 Nov 1;58(7):1541-2 (9 ref.)

Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). Esselstyn CB Jr. **Am J Cardiol** 1999 Aug 1;84(3):339-41, A8

Diabetes, hyperlipidemia, and coronary artery disease. Haffner SM. **Am J Cardiol** 1999 May 13;83(9B):17F-21F (22 ref.)

Diabetic dyslipidemia. Kreisberg RA. **Am J Cardiol** 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U (33 ref.)

Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Brunzell JD, et al. **Am J Med** 1999 Aug 23;107(2A):16S-18S (25 ref.)

Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives [editorial; comment] Gotto AM Jr. **Arch Intern Med** 1999 May 24;159(10):1038-40. Comment on: Arch Intern Med 1999 May 24;159(10):1049-57.

New perspectives on the management of low levels of high-density lipoprotein cholesterol [see comments] Harper CR, et al. **Arch Intern Med** 1999 May 24;159(10):1049-57 (64 ref.). Comment in: Arch Intern Med 1999 May 24;159(10):1038-40.

Effect of dietary fish oil on tumor-induced hyperlipidemia and tumor growth in rats implanted with a methylcholanthrene-induced sarcoma. Radcliffe J, et al. **Biochem Mol Biol Int** 1999 Feb;47(2):293-9

Pseudouveitis as a manifestation of hyperlipidaemia [letter] Thanh HX, et al. **Br J Ophthalmol** 1998 Oct;82(10):1215-6

Insulin resistance. Leiter L. **Can J Cardiol** 1999 Apr;15 Suppl B:20B-22B

Lipids and stroke: neglect of a useful preventive measure? Papadakis JA, et al. **Cardiovasc Res** 1998 Nov;40(2):265-71 (77 ref.)

Lipids and vascular disease: what we do and do not know. Sniderman AD, et al. **Clin Chim Acta** 1999 Aug; 286(1-2):7-22 (65 ref.)

Xanthoma disseminatum: a case with hepatic involvement, diabetes insipidus and type IIb hyperlipidaemia. Woollons A, et al. **Clin Exp Dermatol** 1998 Nov;23(6):277-80

Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Peschke B, et al. **Clin Nephrol** 1999 May; 51(5):290-5

Hyperlipidaemia and cardiovascular disease. **Curr Opin Lipidol** 1998 Aug;9(4):345-60

Hyperlipidaemia and cardiovascular disease [editorial] Dominiczak MH. **Curr Opin Lipidol** 1998 Dec;9(6):609-11

Hyperlipidaemia and cardiovascular disease. Khan N, et al. **Curr Opin Lipidol** 1999 Aug;10(4):371-3

Hyperlipidaemia and cardiovascular disease [editorial] Kuller L. **Curr Opin Lipidol** 1998 Aug;9(4):375-7

Dyslipidemia of central obesity and insulin resistance. Brunzell JD, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C10-3 (69 ref.)

An atherogenic midband lipoprotein: a risk factor for coronary artery disease in diabetes mellitus with hyperlipidemia. Kawano M, et al. **Diabetes Res Clin Pract** 1998 Jul;41(1):45-8

Paediatric and hereditary aspects of chronic pancreatitis. Dodge JA. **Digestion** 1998;59 Suppl 4:49-59 (87 ref.)

Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin: aggravation of this phenomenon in heritable hyperlipidemia. Alexiou K, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1773-8

Association between hyperlipidemia and microalbuminuria in essential hypertension. Campese VM, et al. **Kidney Int Suppl** 1999 Jul;71:S10-3 (33 ref.)

Hyperlipidemia and diabetes mellitus. O'Brien T, et al. **Mayo Clin Proc** 1998 Oct;73(10):969-76 (87 ref.)

Significance of the atherosclerogenic index and body fat in children as markers for future, potential coronary heart disease. Washino K, et al. **Pediatr Int** 1999 Jun;41(3):260-5

No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure. Hillebrand GF, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1391-2

[Management of atherogenic hyperlipidemia] Turpin G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Nov;47(9):627-32 (Eng. Abstr.) **(Fre)**

[Cardiovascular risk and dyslipidemias] Vergès B. **Ann Endocrinol (Paris)** 1998 Nov;59(4):335-43 (45 ref.) (Eng. Abstr.) **(Fre)**

[Lipotoxicity and glycemic regulation] Avignon A, et al. **Diabetes Metab** 1999 Sep;25(3):275-82 **(Fre)**

[Dyslipidemia: prevention of cardiovascular risk (interview)] Farnier M. **Presse Med** 1999 Apr 24;28(16):849-51 **(Fre)**

[Major nutrition-related risk factors of ischemic heart disease: dyslipoproteinemia, obesity, hypertension, glucose intolerance] Pados G. **Orv Hetil** 1999 Jul 11; 140(28):1563-72 (50 ref.) (Eng. Abstr.) **(Hun)**

[Tophaceous gout in plurimetabolic syndrome] Iannello S, et al. **Minerva Med** 1998 Nov-Dec;89(11-12):419-37 (168 ref.) (Eng. Abstr.) **(Ita)**

[Lipid metabolism and atherosclerosis risk in renal diseases in pediatric age] Ferrara P, et al. **Minerva Pediatr** 1998 Dec;50(12):513-8 (35 ref.) (Eng. Abstr.) **(Ita)**

[Lipid distress syndrome in surgery] Savel'ev VS, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):604-11 (24 ref.) **(Rus)**

[Association of the metabolic syndrome components in patients with arterial hypertension and their relationship with dyslipidemia] Oganov RG, et al. **Ter Arkh** 1998; 70(12):19-23 (Eng. Abstr.) **(Rus)**

[Hypertension and dyslipidemia] de Lombera Romero F, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:24-35 (118 ref.) (Eng. Abstr.) **(Spa)**

[Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia] Vázquez-Chávez C, et al. **Rev Invest Clin** 1998 Nov-Dec; 50(6):491-6 (Eng. Abstr.) **(Spa)**

[Time for more active lipid-lowering treatment of patients with diabetes. Negative effect of hyperlipidemia on beta-cells is a neglected field] Sjöholm A. **Lakartidningen** 1998 Dec 9;95(50):5750-2 (38 ref.) (Eng. Abstr.) **(Swe)**

DIAGNOSIS

Diffuse papular eruption. Berger MS, et al. **Am Fam Physician** 1998 Oct 15;58(6):1463-4

Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Parhofer KG, et al. **Atherosclerosis** 1999 May;144(1):159-66

Hyperlipidemia and neuropathy. David WS, et al. **Electromyogr Clin Neurophysiol** 1999 Jun;39(4):227-30

Gestational hyperlipidemic pancreatitis without non-gestational hyperlipidemia. Fujita N, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2018-9

Detecting and correcting hyperlipidemia. Hall RR. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):83-90, 95-9; discussion 99-100, 102

Management of hyperlipidaemia in general practice. Qidwai W. **JPMA J Pak Med Assoc** 1998 Sep;48(9):285-7 (14 ref.)

Significance of the atherosclerogenic index and body fat in children as markers for future, potential coronary heart disease. Washino K, et al. **Pediatr Int** 1999 Jun;41(3):260-5

[Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment] Zambrana Garcia JL, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):303-7 (96 ref.) **(Spa)**

DIET THERAPY

Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Jenkins DJ, et al. **Am J Clin Nutr** 1999 Mar;69(3):395-402

Therapy and clinical trials [editorial] Cramb R. **Curr Opin Lipidol** 1998 Aug;9(4):381-3

Effect of wheat bran on serum lipids: influence of particle size and wheat protein. Jenkins DJ, et al. **J Am Coll Nutr** 1999 Apr;18(2):159-65

The Plate Model: a visual method of teaching meal planning. DAIS Project Group. Diabetes Atherosclerosis Intervention Study. Camelon KM, et al. **J Am Diet Assoc** 1998 Oct;98(10):1155-8

Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: a randomized clinical trial. Haynes RB, et al. **J Am Diet Assoc** 1999 Sep;99(9):1077-83

A dietitian-delivered group nutrition program leads to reductions in dietary fat, serum cholesterol, and body weight: the Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). Hebert JR, et al. **J Am Diet Assoc** 1999 May;99(5):544-52

The influence of experimental hyperlipidemia on the time course of contractility during simulated ischaemia and reperfusion and responsiveness to phenylephrine of rat heart papillary muscle. Kocić I, et al. **J Physiol Pharmacol** 1998 Sep;49(3):353-65

The effect of palmitic acid on lipoprotein cholesterol levels and endogenous cholesterol synthesis in hyperlipidemic subjects. Clandinin MT, et al. **Lipids** 1999;34 Suppl:S121-4

Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Canadian Collaborative Cardiac Assessment Group. Lalonde L, et al. **Med Decis Making** 1999 Apr-Jun; 19(2):149-56

Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention. Jacobson MS, et al. **Prev Med** 1998 Nov-Dec;27(6):775-80

[Dietary therapy for thrombotic diseases of artery and vein] Ishikawa T. **Nippon Rinsho** 1999 Jul;57(7):1602-8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of marine pectin in complex with mineral water on blood antioxidant system in experimental hyperlipidemia] Ivanova IL, et al. **Vopr Pitan** 1998;(4):36-8 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Atorvastatin for protease inhibitor-related hyperlipidaemia [letter] Murillas J, et al. **AIDS** 1999 Jul 30;13(11):1424-5

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Murdock DK, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):151-5

Treatment of hyperlipidemia with combined niacin-statin regimens. Guyton JR, et al. **Am J Cardiol** 1998 Dec 17; 82(12A):82U-84U; discussion 85-86U (29 ref.)

Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Knopp RH. **Am J Cardiol** 1998 Dec 17; 82(12A):24U-28U; discussion 39U-41U (13 ref.)

A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Morgan JM, et al. **Am J Cardiol** 1998 Dec 17; 82(12A):29U-34U; discussion 39U-41U

Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Pedersen TR. **Am J Cardiol** 1998 Nov 26;82(10B):53T-56T

Frequency of lipid-lowering therapy after a coronary event in Helsinki, Finland. Strandberg TE, et al. **Am J Cardiol** 1999 Jul 1;84(1):95, A8

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Sueta CA, et al. **Am J Cardiol** 1999 May 1; 83(9):1303-7

Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men. Jones PJ, et al. **Am J Clin Nutr** 1999 Jun;69(6):1144-50

Effect of fenofibrate on serum uric acid levels [letter] Liamis G, et al. **Am J Kidney Dis** 1999 Sep;34(3):594

Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Capone D, et al. **Am J Nephrol** 1999;19(3):411-5

Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Matzkies FK, et al. **Am J Nephrol** 1999;19(4):492-4

Present status of HMG reductase inhibitors in treatment of dyslipidemia. Kalmansohn RB, et al. **Angiology** 1998 Oct; 49(10):801-5 (23 ref.)

Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Beghin L, et al. **Ann Clin Biochem** 1999 Jul; 36 (Pt 4):523-5

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS,

et al. **Ann Pharmacother** 1998 Oct;32(10):1030–43 (99 ref.)
Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. Durrington PN. **Atherosclerosis** 1998 Sep;139 Suppl 1:S1–5 (25 ref.)
Atorvastatin in the management of an index patient with complete hepatic lipase deficiency [letter] Hegele RA, et al. **Atherosclerosis** 1999 Mar;143(1):219–22
Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice. Jong MC, et al. **Atherosclerosis** 1998 Dec; 141 Suppl 1:S77–80
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Krause BR, et al. **Atherosclerosis** 1998 Sep;140(1):15–24 (108 ref.)
Best practice--ongoing polemics. Paoletti R, et al. **Atherosclerosis** 1999 May;143 Suppl 1:S3–6 (19 ref.)
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Riegger G, et al. **Atherosclerosis** 1999 May; 144(1):263–70
Atorvastatin and fibrinogen--a small subgroup shows extreme response [letter] Sinzinger H, et al. **Atherosclerosis** 1999 Aug;145(2):415–7
Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety. Stein E. **Atherosclerosis** 1998 Sep;139 Suppl 1:S15–22 (25 ref.)
Management of hyperlipidemia: whom and when to treat and new statin options. Stein EA. **Atherosclerosis** 1998 Sep; 139 Suppl 1:ix
Antihyperlipidemic action of Ogi-Keishi-Gomotsu-To-Ka-Kojin against cyclophosphamide-induced hyperlipidemia in rabbits. Inoue M, et al. **Biol Pharm Bull** 1999 May;22(5):486–90
Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients. Kario K, et al. **Blood Coagul Fibrinolysis** 1999 Jul;10(5):269–76
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Hansson L. **Blood Press** 1998;Suppl 3:20–2 (19 ref.)
Controversies in primary prevention among hyperlipidemic patients. McPherson R. **Can J Cardiol** 1999 Apr;15 Suppl B:16B–19B
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Iliadis EA, et al. **Clin Cardiol** 1999 Jan;22(1):25–8
Lisinopril improves arterial function in hyperlipidaemia. Lee AF, et al. **Clin Sci (Colch)** 1999 May;96(5):441–8
Therapy and clinical trials [editorial] Cramb R. **Curr Opin Lipidol** 1998 Aug;9(4):381–3
Intensive lipid-lowering strategy in patients with diabetes mellitus. Kanters SD, et al. **Diabet Med** 1999 Jun; 16(6):500–8
Micronized fenofibrate in the management of dyslipidemia [letter] Steiner G. **Diabetes Care** 1998 Nov;21(11):2039–40
Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Yoshinari M, et al. **Diabetes Res Clin Pract** 1998 Dec;42(3):149–54
Fluvastatin: a review of its use in lipid disorders. Langtry HD, et al. **Drugs** 1999 Apr;57(4):583–606 (107 ref.)
Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Stein EA. **Drugs** 1998;56 Suppl 1:25–31; discussion 33
Pharmacological treatment for hyperlipidaemia--the best preventive measure? [editorial; comment] Rosengren A, et al. **Eur Heart J** 1999 Feb;20(4):245–6 (7 ref.). Comment on: Eur Heart J 1999 Feb;20(4):263–8.
Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Gebara OC, et al. **Heart** 1998 Sep; 80(3):235–9
Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks FM, et al. **Herz** 1999 Feb; 24(1):51–6 (16 ref.)
Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Tada K, et al. **Horm Res** 1998;49(6):295–7
Treatment of hyperlipidaemia as a risk factor for coronary heart disease: the role of fibrates. Linssen R. **Hosp Med** 1999 Apr;60(4):298–301
Detecting and correcting hyperlipidemia. Hall RR. **Hosp Pract (Off Ed)** 1998 Nov 15;33(11):83–90, 95–9; discussion 99–100, 102
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Papadakis JA, et al. **Int J Cardiol** 1999 Jun 1;69(3):237–44
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. Nakamura N, et al. **Int J Clin Lab Res** 1998;28(3):192–5
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Nakamura N, et al. **Int J Clin Lab Res** 1999;29(1):22–5
The role of lipid lowering in transplantation. Wierzbicki AS. **Int J Clin Pract** 1999 Jan-Feb;53(1):54–9 (78 ref.)
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile [see comments] Dangas G, et al. **J Am Coll Cardiol** 1999 Apr; 33(5):1294–304. Comment in: J Am Coll Cardiol 1999 Apr;33(5):1305–7.
Interim report from project ImPACT: hyperlipidemia. Bluml BM, et al. **J Am Pharm Assoc (Wash)** 1998 Sep-Oct; 38(5):529–34
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. de Lorgeril M, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):473–8
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Bairaktari ET, et al. **J Cardiovasc Risk** 1999 Apr;6(2):113–6
Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. Gholami K, et al. **J Clin Pharm Ther** 1998 Jun;23(3):213–21
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia. Ko GT, et al. **J Clin Pharmacol** 1998 Oct;38(10):912–7
Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia. Zambrana JL, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1213–9
The effect of probucol on oxidized cholesterol disposition in hyperlipidaemic patients. Inouye M, et al. **J Int Med Res** 1998 Oct-Nov;26(5):233–8
Lipid disorders in NIDDM: implications for treatment. Taskinen MR, et al. **J Intern Med** 1998 Nov;244(5):361–70 (49 ref.)
Effects of inulin on lipid parameters in humans. Williams CM. **J Nutr** 1999 Jul;129(7 Suppl):1471S–3S (14 ref.)
Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation. Ferraris JR, et al. **J Pediatr** 1998 Oct;133(4):533–6
Lowering cholesterol in old age. Oliver MF. **J R Coll Physicians Lond** 1999 May-Jun;33(3):252–3 (15 ref.)
Statins and C-reactive protein [letter; comment] Kluft C, et al. **Lancet** 1999 Apr 10;353(9160):1274. Comment on: Lancet 1999 Jan 9;353(9147):118–9.
Effect of statins on C-reactive protein in patients with coronary artery disease [letter] [see comments] Strandberg TE, et al. **Lancet** 1999 Jan 9;353(9147):118–9. Comment in: Lancet 1999 Apr 10;353(9160):1274. Comment in: Lancet 1999 Apr 10;353(9160):1274–5.
Lipid lowering therapy in patients with HIV infection [letter; comment] Wierzbicki AS, et al. **Lancet** 1998 Nov 28; 352(9142):1782. Comment on: Lancet 1998 Sep 26;352(9133):1031–2.
Should smoking be an indication for lipid-lowering therapy? [letter] Forge B. **Med J Aust** 1999 Jul 19;171(2):112
Should smoking be an indication for lipid-lowering therapy? [letter] Peeters A, et al. **Med J Aust** 1999 Mar 1;170(5):240
Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Zhang Y, et al. **Metabolism** 1999 Aug;48(8):1033–40
Drug treatment of lipid disorders. Knopp RH. **N Engl J Med** 1999 Aug 12;341(7):498–511 (138 ref.)
Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. Querfeld U, et al. **Pediatr Nephrol** 1999 Jan;13(1):7–12
Should hyperlipidemia in children with the nephrotic syndrome be treated? Querfeld U. **Pediatr Nephrol** 1999 Jan;13(1):77–84 (83 ref.)
Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. ISPD guidelines/recommendations. International Society for Peritoneal Dialysis. Fried L, et al. **Perit Dial Int** 1999 Jan-Feb;19(1):7–16
No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin [letter] Singhal MK, et al. **Perit Dial Int** 1999 Jan-Feb;19(1):89–91
Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs? Weissgarten J, et al. **Perit Dial Int** 1999 Mar-Apr;19(2):180–2
Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug. Hoffman A, et al. **Pharm Res** 1999 Jul;16(7):1093–7
Lipid-lowering drugs in the management of hyperlipidaemia. Bhatnagar D. **Pharmacol Ther** 1998 Sep;79(3):205–30 (182 ref.)
When to treat raised lipids. Jolleys J. **Practitioner** 1999 Jun; 243(1599):510–3, 515–6 (0 ref.)
Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Belalcazar LM, et al. **Prog Cardiovasc Dis** 1998 Sep-Oct;41(2):151–74 (186 ref.)
[Tactics of hypolipidemic therapy after myocardial revascularization] Chlumský J, et al. **Vnitr Lek** 1998 Mar; 44(3):142–4 (Eng. Abstr.) **(Cze)**
[Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels] Bonneux L, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):772–5 (Eng. Abstr.) **(Dut)**
[Dyslipoproteinemia of diabetes: fibrates or statins?] Moulin P. **Diabetes Metab** 1999 Sep;25(3):270–4 (21 ref.) **(Fre)**
[Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?] Luc G. **Presse Med** 1998 Apr 18;27(15):720–2 (Eng. Abstr.) **(Fre)**
[New developments in the treatment of diabetes and hyperlipidemias] Ducobu J. **Rev Med Brux** 1998 Sep; 19(4):A379–85 (17 ref.) (Eng. Abstr.) **(Fre)**
[Lipid lowering: myth or therapeutic necessity?] **Dtsch Med Wochenschr** 1998 Oct 2;123(40 Suppl):2–8 **(Ger)**
[Current lipid reducers. Cholesterol lowering alone is not enough] **Internist (Berl)** 1999 Aug;40(8 Suppl Cholesteri):1–4 **(Ger)**
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?] **Internist (Berl)** 1999 Mar;40(3 Suppl Gibt Es):1–4 **(Ger)**
[Statins in diabetic hyperlipidemia] Kirchmair R, et al. **Wien Med Wochenschr** 1999;149(5–6):139–43 (26 ref.) (Eng. Abstr.) **(Ger)**
[Hypolipemic therapy in peripheral arterial diseases: reasons of its clinical use] Balbarini A, et al. **Cardiologia** 1999 Feb; 44(2):137–45 (65 ref.) **(Ita)**
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia] Liguori E, et al. **Minerva Cardioangiol** 1998 Sep;46(9):317–8 **(Ita)**
[Anti-hyperlipidemic drug] Nakaya N. **Nippon Rinsho** 1999 Jul;57(7):1570–6 (19 ref.) (Eng. Abstr.) **(Jpn)**
[The immunomodulating and antioxidants actions of plant preparations and abisib in disordered lipid metabolism] Uteshev BS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct; 61(5):30–3 (Eng. Abstr.) **(Rus)**
[Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy] Robles NR, et al. **An Med Interna** 1998 Nov;15(11):572–5 (Eng. Abstr.) **(Spa)**
[Noncompliance with programmed appointments in dyslipidemia patients in pharmacologic treatment] Piñeiro Chousa F, et al. **Aten Primaria** 1999 Jun 15;24(1):19–25 (Eng. Abstr.) **(Spa)**
[Dyslipemia in the elderly (letter)] Garrido Sanjuán JA. **Med Clin (Barc)** 1999 May 29;112(19):757 **(Spa)**
[Relationship between medical treatment compliance and the degree of control in patients with high blood pressure, non-insulin dependent diabetes mellitus and dyslipidemia] Piñeiro F, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):565–7 (Eng. Abstr.) **(Spa)**

ECONOMICS

[Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels] Bonneux L, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):772–5 (Eng. Abstr.) **(Dut)**

ENZYMOLOGY

Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Watanabe H, et al. **Atherosclerosis** 1999 Jul;145(1):45–50
A novel frameshift mutation in exon 6 (the site of Asn 291) of the lipoprotein lipase gene in type I hyperlipidemia. Kobayashi J, et al. **Clin Chim Acta** 1999 Jul;285(1-2):173–82
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Paragh G, et al. **Nephron** 1998 Oct;80(2):166–70

EPIDEMIOLOGY

Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia. Pontiroli AE, et al. **Acta Diabetol** 1998 Oct;35(3):130–6
The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group. Connelly PW, et al. **Can J Cardiol** 1999 Apr; 15(4):419–27
Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Oxford Regional Prospective Study of Childhood Diabetes. Abraha A, et al. **Diabet Med** 1999 Jul;16(7):598–604
Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study [comment] Yarbrough DE, et al. **Diabetes Care** 1998 Oct;21(10):1652–8. Comment on: Diabetes Care 1998 Jan;21(1):157–9. Comment on: Diabetes Care 1998 Jan;21(1):179–82.
Cardiovascular risk factors in the young [letter; comment] Rumboldt Z, et al. **Eur Heart J** 1998 Sep;19(9):1410. Comment on: Eur Heart J 1998 Mar;19(3):395–401.
Regional disparities in cardiovascular risk factors in France: a five-year analysis of the GAZEL cohort. Tran PD, et al. **Eur J Epidemiol** 1998 Sep;14(6):535–43
Supplement. Obesity, hypertension, insulin resistance and lipid disorders: cross-sectional and longitudinal studies in Japanese adolescents and middle-aged men. Hirose H, et al. **Intern Med** 1999 Feb;38(2):198–200 (17 ref.)
Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. Little J, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1931–9

Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physician's Health Study. Ariyo A, et al. **J Cardiovasc Risk** 1998 Aug;5(4):273–8

Smoking, diabetes and hyperlipidaemia. Mikhailidis DP, et al. **J R Soc Health** 1998 Apr;118(2):91–3 (35 ref.)

Distributions and trends of serum lipid levels among United States children and adolescents ages 4–19 years: data from the Third National Health and Nutrition Examination Survey. Hickman TB, et al. **Prev Med** 1998 Nov–Dec; 27(6):879–90

[The prevalence of hypertension, diabetes mellitus and hyperlipemia among 1369 subjects for physical examination in Changsha] Duan Y, et al.
Hunan I Ko Ta Hsueh Hsueh Pao 1997;22(5):407–10 (Eng. Abstr.) **(Chi)**

[Prevalence of hyperlipidemia in children adn adolescents in the Province of Cáceres] Prieto Albino L, et al.
Rev Esp Salud Publica 1998 Jul–Aug;72(4):343–55 (54 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Hyperlipidaemia in Chinese populations. Tomlinson B, et al. **Hosp Med** 1998 Jul;59(7):549–52 (19 ref.)

ETIOLOGY

Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Lichtman AH, et al.
Arterioscler Thromb Vasc Biol 1999 Aug;19(8):1938–44

Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Fernández-Real JM, et al. **Diabetes** 1999 May; 48(5):1108–12

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Vigouroux C, et al.
Diabetes Metab 1999 Sep;25(3):225–32

Diabetic dyslipidaemia. Betteridge DJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:12–6 (30 ref.)

Optimal management of hypertensive patients with LVH and dyslipidaemia. Plouin PF. **Int J Clin Pract Suppl** 1998 Nov; 98:9–12

Dietary fructose but not starch is responsible for hyperlipidemia associated with copper deficiency in rats: effect of high-fat diet. Fields M, et al. **J Am Coll Nutr** 1999 Feb;18(1):83–7

Alcohol and lipids. Baraona E, et al. **Recent Dev Alcohol** 1998;14:97–134 (339 ref.)

[Age and changes in dietary habits affect hyperlipoproteinemia after kidney transplantation] Teplan V, et al. **Cas Lek Cesk** 1999 Feb 22;138(4):111–5 (Eng. Abstr.) **(Cze)**

[Hyperlipidemia after kidney transplantation and its control by individualized therapy: evaluation of the first years' trial] Teplan V, et al. **Vnitr Lek** 1998 Feb;44(2):98–103 (Eng. Abstr.) **(Cze)**

[Causes and risks of hyperlipidemia during dialysis and after renal transplantation] Verzola A, et al.
Recenti Prog Med 1998 Nov;89(11):590–7 (51 ref.) (Eng. Abstr.) **(Ita)**

[Dyslipidemia in diabetes mellitus: statins treatment raises survival of patients] Shestakova MV. **Ter Arkh** 1999; 71(1):67–9 **(Rus)**

[Dyslipidemias and autoimmune diseases] Alekberova ZS, et al. **Vestn Ross Akad Med Nauk** 1998;(12):43–5 (14 ref.) (Eng. Abstr.) **(Rus)**

[Hyperlipoproteinemia in patients after heart transplantation] Goncalvesová E, et al. **Bratisl Lek Listy** 1998 Dec; 99(12):640–3 (Eng. Abstr.) **(Slo)**

GENETICS

Evidence of modified lipoprotein in the plasma of Watanabe heritable hyperlipidemic rabbits by anion-exchange high-performance liquid chromatographic assay.
Yamaguchi Y, et al. **Atherosclerosis** 1998 Aug; 139(2):323–31

Apolipoprotein A-I of hyperlipidemia atherosclerosis prone (LAP) quail: cDNA sequence and tissue expression. Iwasaki H, et al. **Biosci Biotechnol Biochem** 1999 Jan; 63(1):29–34

Hyperinsulinemia and dyslipidemia in non-obese, normotensive offspring of hypertensive parents in northern India. Misra A, et al. **Blood Press** 1998 Nov;7(5–6):286–90

Molecular diagnostics for cardiovascular disease. Pang CP. **Clin Chem Lab Med** 1998 Aug;36(8):605–14 (94 ref.)

Identification of compound heterozygous mutations (G188E/W382X) of lipoprotein lipase gene in a Japanese infant with hyperchylomicronemia: the G188E mutation was newly identified in Japanese. Takagi A, et al.
Clin Chim Acta 1999 Jul;285(1–2):143–54

Hepatic lipase deficiency. Connelly PW, et al.
Crit Rev Clin Lab Sci 1998 Dec;35(6):547–72 (62 ref.)

Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Wägner AM, et al. **Diabetes Care** 1999 May;22(5):812–7

The relative risks of hyperglycaemia, obesity and dyslipidaemia in the relatives of patients with Type II diabetes mellitus. Shaw JT, et al. **Diabetologia** 1999 Jan; 42(1):24–7

Effects of intragenic variability at 3 polymorphic sites of the apolipoprotein B gene on serum lipids and lipoproteins in a multiethnic Asian population. Choong ML, et al.
Hum Biol 1999 Jun;71(3):381–97

Dyslipidemias associated with heterozygous lipoprotein lipase mutations in the French–Canadian population. Julien P, et al. **Hum Mutat** 1998;Suppl 1:S148–53

Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. Costet P, et al.
J Biol Chem 1998 Nov 6;273(45):29577–85

First-degree kinship with young coronary artery disease patients markedly increases lipid-level disorders in asymptomatic hypertensives. Giannini SD, et al.
J Cardiovasc Risk 1998 Jun;5(3):141–5

Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. Horton JD, et al. **J Clin Invest** 1999 Apr;103(7):1067–76

Spontaneously hyperlipidemic (SHL) mice: Japanese wild mice with apolipoprotein E deficiency. Matsushima Y, et al. **Mamm Genome** 1999 Apr;10(4):352–7

Apolipoprotein E polymorphism in indigenous Australians: allelic frequencies and relationship with dyslipidaemia. Shaw JT, et al. **Med J Aust** 1999 Feb 15;170(4):161–4

Congenic strains for genetic analysis of hypertension and dyslipidemia in the spontaneously hypertensive rat. Pravenec M, et al. **Transplant Proc** 1999 May;31(3):1555–6

METABOLISM

Insulin resistance and lipid metabolism. Howard BV.
Am J Cardiol 1999 Jul 8;84(1A):28J–32J (25 ref.)

Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice. Jong MC, et al. **Atherosclerosis** 1998 Dec; 141 Suppl 1:S77–80

Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits. Lauridsen ST, et al.
Atherosclerosis 1999 Jan;142(1):169–78

Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Parhofer KG, et al. **Atherosclerosis** 1999 May;144(1):159–66

Hyperlipidaemia and cardiovascular disease [editorial] Le NA. **Curr Opin Lipidol** 1999 Apr;10(2):187–9

Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. O'Doherty RM, et al. **Diabetes** 1999 Oct; 48(10):2022–7

Diabetic dyslipidaemia. Betteridge DJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:12–6 (30 ref.)

Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits [see comments] Witting P, et al.
J Clin Invest 1999 Jul;104(2):213–20. Comment in: J Clin Invest 1999 Jul;104(2):135–6.

Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. Wójcicki J, et al.
J Clin Pharmacol 1999 Aug;39(8):826–33

Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. Hautanen A, et al. **J Intern Med** 1997 Jun;241(6):451–61

Lipid disorders in NIDDM: implications for treatment. Taskinen MR, et al. **J Intern Med** 1998 Nov;244(5):361–70 (49 ref.)

Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. Eliot LA, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):188–93

Protective role of melatonin and retinol palmitate in oxidative stress and hyperlipidemic nephropathy induced by adriamycin in rats. Montilla PL, et al. **J Pineal Res** 1998 Sep;25(2):86–93

The effect of palmitic acid on lipoprotein cholesterol levels and endogenous cholesterol synthesis in hyperlipidemic subjects. Clandinin MT, et al. **Lipids** 1999;34 Suppl:S121–4

Effects of dietary methionine and cystine on lipid metabolism in hepatoma-bearing rats with hyperlipidemia. Kawasaki M, et al. **Lipids** 1998 Sep;33(9):905–11

Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Eliot LA, et al. **Pharm Res** 1999 Feb; 16(2):309–13

[Causes and risks of hyperlipidemia during dialysis and after renal transplantation] Verzola A, et al.
Recenti Prog Med 1998 Nov;89(11):590–7 (51 ref.) (Eng. Abstr.) **(Ita)**

MORTALITY

Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Rywik SL, et al.
Am J Cardiol 1999 Sep 1;84(5):540–8

PATHOLOGY

Characterization of apoptotic macrophages in atheromatous tissue of humans and heritable hyperlipidemic rabbits. Kinscherf R, et al. **Atherosclerosis** 1999 May;144(1):33–9

[Increased body mass index increase and insulin resistance parameters in dyslipidemia. Risk and positive correlation in essential obesity] Alberto G, et al.
Minerva Endocrinol 1998 Sep;23(3):65–9 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Insulin resistance and lipid metabolism. Howard BV.
Am J Cardiol 1999 Jul 8;84(1A):28J–32J (25 ref.)

Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice. Lamping KG, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1023–9

Contrast sensitivity in obese dyslipidemic patients with insulin resistance. Dosso AA, et al. **Arch Ophthalmol** 1998 Oct; 116(10):1316–20

Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Watts GF, et al. **Atherosclerosis** 1998 Nov;141(1):17–30

Postprandial dyslipidaemia in a nutshell: food for thought. Watts GF, et al. **Aust N Z J Med** 1998 Dec;28(6):816–23 (62 ref.)

Restoration of nitric oxide function in human hyperlipidaemia, congestive heart failure and liver cirrhosis. Chin-Dusting JP, et al.
Clin Exp Pharmacol Physiol 1998 Sep;25(9):645–52 (101 ref.)

Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Liao D, et al. **Diabetes Care** 1998 Dec; 21(12):2116–22

Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Large V, et al. **Diabetes Metab** 1998 Nov;24(5):409–18 (91 ref.)

Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Vergès BL.
Diabetes Metab 1999 Jun;25 Suppl 3:32–40 (85 ref.)

Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers. Brude IR, et al.
Eur J Clin Invest 1999 Feb;29(2):100–8

Experimental hyperlipidemia prevents the protective effect of ischemic preconditioning on the contractility and responsiveness to phenylephrine of rat-isolated stunned papillary muscle. Kocić I, et al. **Gen Pharmacol** 1999 Sep; 33(3):213–9

Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Jandeleit-Dahm K, et al.
Kidney Int Suppl 1999 Jul;71:S31–6 (27 ref.)

Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats. Golda V, et al. **Physiol Res** 1997;46(6):439–42

Increased cerebral CO(2) reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Pfefferkorn TK, et al. **Stroke** 1999 Sep;30(9):1802–6

Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Stevenson FT, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):307–14 (94 ref.)

[Heart rate and lipids] Mounier-Véhier C, et al.
Ann Cardiol Angeiol (Paris) 1998 Jun;47(6):425–8 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Cardiovascular risk profiling in blacks: don't forget the lipids [editorial] Kountz DS, et al. **Am Fam Physician** 1998 Nov 1;58(7):1541–2 (9 ref.)

Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Liang Y, et al.
Biochim Biophys Acta 1998 Oct 21;1405(1–3):1–13

Cholesterol screening and management guidelines. Having several guidelines is confusing [letter; comment] Bulusu S. **BMJ** 1999 Apr 24;318(7191):1140. Comment on: BMJ 1998 Oct 24;317(7166):1125–30.

Effect of 14 weeks of resistance training on lipid profile and body fat percentage in premenopausal women. Prabhakaran B, et al. **Br J Sports Med** 1999 Jun;33(3):190–5

Hyperlipidaemia and cardiovascular disease [editorial] Sussekov AV. **Curr Opin Lipidol** 1998 Oct;9(5):507–10

Hyperlipidaemia: differences in management practices and attitudes in two regions in Europe--Sicily and the Stockholm area. Danielsson B, et al. **Eur J Epidemiol** 1998 Jul;14(5):477–82

Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. Vergès BL, et al. **J Cardiopulm Rehabil** 1998 Nov–Dec;18(6):408–15

Long-term alpha1-adrenergic blockade attenuates diet-induced dyslipidemia and hyperinsulinemia in the rat. Fajardo N, et al. **J Cardiovasc Pharmacol** 1998 Dec; 32(6):913–9

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO, et al.
J Heart Lung Transplant 1999 Apr;18(4):336–45

Antioxidant potential of evening primrose oil administration in hyperlipemic rabbits. De La Cruz JP, et al. **Life Sci** 1999;65(5):543–55

[Effect of tongxinluo capsule on experimental myocardial ischemia, arrhythmia and hyperlipidemia] Liu JX, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jul;

17(7):425–8 (Eng. Abstr.) **(Chi)**

[The 'Diabetes mellitus type 2' guideline (first revision) of the Dutch College of General Practitioners: response from internal medicine] Erkelens DW. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1686–8 (Eng. Abstr.) **(Dut)**

[Laboratory diagnosis in preventive cardiology] Soufi M, et al. **Herz** 1999 Feb;24(1):13–25 (47 ref.) (Eng. Abstr.) **(Ger)**

[Lipids and primary prevention of coronary disease] Idzior-Walus B. **Przegl Lek** 1998;55(2):77–84 (61 ref.) (Eng. Abstr.) **(Pol)**

[Prevention of dyslipidemia--the foremost challenge in the management of diabetes] Smith U, et al. **Lakartidningen** 1999 Jan 27;96(4):334–6 (20 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Canadian Collaborative Cardiac Assessment Group. Lalonde L, et al. **Med Decis Making** 1999 Apr–Jun; 19(2):149–56

THERAPY

Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). Esselstyn CB Jr. **Am J Cardiol** 1999 Aug 1;84(3):339–41, A8

Therapy for hyperlipidemia when it is the only risk factor--fact or fiction? Keller KB, et al. **Am J Crit Care** 1998 Sep;7(5):395–7

Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives [editorial; comment] Gotto AM Jr. **Arch Intern Med** 1999 May 24;159(10):1038–40. Comment on: Arch Intern Med 1999 May 24;159(10):1049–57.

New perspectives on the management of low levels of high-density lipoprotein cholesterol [see comments] Harper CR, et al. **Arch Intern Med** 1999 May 24;159(10):1049–57 (64 ref.). Comment in: Arch Intern Med 1999 May 24;159(10):1038–40.

Type 2 diabetes towards the new millennium--the relative importance of glycaemic versus lipid control. Florkowski CM, et al. **Aust N Z J Med** 1999 Apr;29(2):249–53 (35 ref.)

Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Jong MC, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):281–7

Randomized clinical trial comparing the effectiveness of two dietary interventions for patients with hyperlipidaemia. Mhurchú CN, et al. **Clin Sci (Colch)** 1998 Oct;95(4):479–87

Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease [published erratum appears in CMAJ 1999 Jul 13;161(1):21] Perreault S, et al. **CMAJ** 1999 May 18;160(10):1449–55

Hyperlipidaemia and cardiovascular disease [editorial] Le NA. **Curr Opin Lipidol** 1999 Apr;10(2):187–9

Comments on the position statements "Management of dyslipidemia in adults with diabetes" and "diabetic retinopathy" [letter] Davidson MB. **Diabetes Care** 1998 Aug;21(8):1378–9

Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Halbert JA, et al. **Eur J Clin Nutr** 1999 Jul;53(7):514–22

Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Mikhailidis DP, et al. **Int Angiol** 1998 Dec;17(4):225–33

Establishing a lipid management service in the pharmacy. Schoen MD. **J Am Pharm Assoc (Wash)** 1999 May–Jun; 39(3):408–10

Intervention for hyperlipidemia associated with protease inhibitors. Melroe NH, et al. **J Assoc Nurses AIDS Care** 1999 Jul–Aug;10(4):55–69

Hyperlipidemia management in patients with cardiovascular and cerebrovascular disease. **J Fla Med Assoc** 1998 Apr; 85(1):26–8

Somatic gene therapy for dyslipidemias. Belalcazar M, et al. **J Lab Clin Med** 1999 Sep;134(3):194–214 (191 ref.)

Management of hyperlipidaemia in general practice. Qidwai W. **JPMA J Pak Med Assoc** 1998 Sep;48(9):285–7 (14 ref.)

Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism. Wittke R. **Sports Med** 1999 May;27(5):329–35

LDL apheresis in clinical practice: long-term treatment of severe hyperlipidemia. Bambauer R, et al. **Ther Apher** 1997 Feb;1(1):49–54

Hyperlipidemia and renal disease: the use of animal models in understanding pathophysiology and approaches to treatment. Stevenson FT, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):307–14 (94 ref.)

[Hyperlipidemia after kidney transplantation and its control by individualized therapy: evaluation of the first years' trial] Teplan V, et al. **Vnitr Lek** 1998 Feb;44(2):98–103 (Eng. Abstr.) **(Cze)**

[Opposable medical references of the ANDEM concerning hyperlipidemia and its treatment] Luc G. **Rev Med Interne** 1999 Apr;20(4):341–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of familial hypercholesterolemia and of the dyslipidemias responsible for cardiovascular disease] Sampietro T, et al. **G Ital Cardiol** 1999 Feb;29(2):171–3 **(Ita)**

[Dyslipidemia in children and adolescents. Therapeutic bases] Forti N, et al. **Arq Bras Cardiol** 1998 Dec;71(6):807–10 (25 ref.) **(Por)**

URINE

The effect of probucol on oxidized cholesterol disposition in hyperlipidaemic patients. Inouye M, et al. **J Int Med Res** 1998 Oct–Nov;26(5):233–8

VETERINARY

Blue eye in a cat. Hardman C, et al. **Aust Vet J** 1998 Sep; 76(9):595, 602–3

Effects of haemolysis, lipaemia and bilirubinaemia on an enzyme-linked immunosorbent assay for cortisol and free thyroxine in serum samples from dogs. Lucena R, et al. **Vet J** 1998 Sep;156(2):127–31

HYPERLIPIDEMIA, FAMILIAL COMBINED

BLOOD

Diet, smoking, and blood lipids in patients with combined familial hyperlipidaemia. Králiková E, et al. **Cent Eur J Public Health** 1999 Feb;7(1):19–23

Serum leptin is elevated out of proportion to the body mass index in adolescent females with familial combined hyperlipidemia (FCH). Jacobson MS, et al. **Clin Pediatr (Phila)** 1999 Jan;38(1):49–53

Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension. Netea RT, et al. **Neth J Med** 1999 Jul;55(1):39–45

[Lipid composition of high density lipoproteins in familial hyperlipoproteinemias] Tvorogova MG, et al. **Vopr Med Khim** 1998 Sep–Oct;44(5):452–8 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension. Netea RT, et al. **Neth J Med** 1999 Jul;55(1):39–45

DRUG THERAPY

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Zambón D, et al. **Metabolism** 1999 Jan;48(1):47–54

[Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen] Urbánek R, et al. **Vnitr Lek** 1998 May;44(5):259–62 (Eng. Abstr.) **(Cze)**

[HMG-CoA reductase inhibitors] Thiery J, et al. **Internist (Berl)** 1998 Aug;39(8):866–7 **(Ger)**

[Various HMG-CoA reductase inhibitors] Thiery J, et al. **Internist (Berl)** 1999 Jan;40(1):113–4 **(Ger)**

GENETICS

Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Allayee H, et al. **Am J Hum Genet** 1998 Aug;63(2):577–85

A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Aouizerat BE, et al. **Am J Hum Genet** 1999 Aug; 65(2):397–412

A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Juo SH, et al. **Am J Hum Genet** 1998 Aug;63(2):586–94

Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Pajukanta P, et al. **Am J Hum Genet** 1999 May;64(5):1453–63

Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. Tahvanainen E, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov;18(11):1810–7

The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21.3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH). Schäffler A, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):416–25

Novel genes for familial combined hyperlipidemia. Aouizerat BE, et al. **Curr Opin Lipidol** 1999 Apr;10(2):113–22 (77 ref.)

Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul;19 Suppl H:H23–6 (13 ref.)

Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. Groenendijk M, et al. **J Lipid Res** 1999 Jun;40(6):1036–44

Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. Ribalta J, et al. **J Lipid Res** 1999 Mar;40(3):426–31

METABOLISM

Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Karjalainen L, et al. **Arterioscler Thromb Vasc Biol** 1998 Oct;18(10):1548–53

Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant (A-3826G) of the uncoupling protein 1 gene in familial combined hyperlipidemia. Pihlajamäki J, et al. **Metabolism** 1998 Nov;47(11):1397–402

PHYSIOPATHOLOGY

Coronary flow reserve in young men with familial combined hyperlipidemia. Pitkänen OP, et al. **Circulation** 1999 Apr 6;99(13):1678–84

THERAPY

[Negative aspects of the Western life style and possibilities of intervention in patients with familial combined hyperlipidemia] Králiková E, et al. **Cas Lek Cesk** 1999 Apr 19;138(8):239–44 (Eng. Abstr.) **(Cze)**

HYPERLIPIDEMIA, MULTIPLE LIPOPROTEIN-TYPE
see **HYPERLIPIDEMIA, FAMILIAL COMBINED**

HYPERLIPOPROTEINEMIA

Women, dyslipoproteinemia, and estrogens. LaRosa JC. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):627–39, x (65 ref.)

[Hyperlipoproteinemias. Epidemiology, etiology, physiopathology, diagnosis, treatment] Chadarevian R, et al. **Rev Prat** 1998 Jun 15;48(12):1353–9 (3 ref.) **(Fre)**

BLOOD

A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Mensink RP, et al. **Am J Clin Nutr** 1999 Feb;69(2):213–9

Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia. Otto C, et al. **Br J Clin Pharmacol** 1998 Nov;46(5):473–8

Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Zhang XJ, et al. **Eur J Clin Invest** 1998 Sep;28(9):730–9

Interrelationships between postprandial lipoprotein B:CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia. Saïdi Y, et al. **Metabolism** 1999 Jan;48(1):60–7

Apolipoprotein(a) and thrombosis: molecular and genetic bases of hyper-lipoprotein(a)-emia. Ichinose A, et al. **Semin Thromb Hemost** 1998;24(3):237–43

[Trends in the measurement of body heights: correlation with lipoparticle LpA1 and insulinemia in the obese (letter)] Lecerf JM, et al. **Presse Med** 1998 Oct 31;27(33):1680–1 **(Fre)**

[Chylomicronemia syndrome complicating type I hyperlipoproteinemia with concomitant insulin-dependent diabetes] Wojtukiewicz MZ, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):84–6 (Eng. Abstr.) **(Pol)**

[Hyperlipoproteinemias and proteinase inhibitor balance in patients with proliferative diabetic retinopathy with solid exudates in retina] Chesnokova NB, et al. **Vestn Oftalmol** 1999 Jan–Feb;115(1):14–6 (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

Drugs causing dyslipoproteinemia. Donahoo WT, et al. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):677–97 (165 ref.)

COMPLICATIONS

Lipoprotein(a) as a risk factor for coronary artery disease. Marcovina SM, et al. **Am J Cardiol** 1998 Dec 17; 82(12A):57U–66U; discussion 86U (104 ref.)

A case of Buerger's disease associated with high levels of lipoprotein(a). Biasi D, et al. **Clin Rheumatol** 1999; 18(1):59–60

Dyslipoproteinemia and diabetes. Garg A. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):613–25, ix-x (43 ref.)

Lipid and lipoprotein ratios as risk factors of atherosclerosis in patients with chronic renal insufficiency (CRI). Kimak E, et al. **Int Urol Nephrol** 1999;31(2):263–7

[Management of atherogenic hyperlipidemia] Turpin G, et al. **Ann Cardiol Angeiol (Paris)** 1998 Nov;47(9):627–32 (Eng. Abstr.) **(Fre)**

[Chylomicronemia syndrome complicating type I hyperlipoproteinemia with concomitant insulin-dependent diabetes] Wojtukiewicz MZ, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):84–6 (Eng. Abstr.) **(Pol)**

[Early and late (during 3 years) results of coronary bypass operation in patients with ischemic heart disease with moderate dyslipoproteinemia] Tepliakov AT, et al. **Ter Arkh** 1998;70(12):35–8 (Eng. Abstr.) **(Rus)**

[Specific features of cardiovascular diseases in patients with mono- and polygenic types of dyslipoproteinemia]

HYPERLIPOPROTEINEMIA

Ol'binskaia LI, et al. **Vestn Ross Akad Med Nauk** 1998; (10):56–60 (26 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Detection and evaluation of dyslipoproteinemia. Cleeman JI. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):597–611, ix (39 ref.)

Evaluation and management of dyslipoproteinemia in children. Franklin FA Jr, et al. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):641–54 (17 ref.)

[Frequency of newly detected hypothyroidism in lipid clinics] Szabó M, et al. **Vnitr Lek** 1998 Nov;44(11):642–5 (Eng. Abstr.) **(Cze)**

DRUG THERAPY

Dyslipoproteinemia in the elderly: to treat or not to treat? Hazzard WR. **Am J Med** 1999 Aug 23;107(2A):51S–53S (12 ref.)

Effect of L-carnitine on plasma lipoprotein fatty acids pattern in patients with primary hyperlipoproteinemia. Stefanutti C, et al. **Clin Ter** 1998 Mar–Apr;149(2):115–9

[Dyslipoproteinemia of diabetes: fibrates or statins?] Moulin P. **Diabetes Metab** 1999 Sep;25(3):270–4 (21 ref.) **(Fre)**

[Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency] Hottelart C, et al. **Nephrologie** 1999; 20(1):41–4 (Eng. Abstr.) **(Fre)**

[Lipanor treatment of atherogenic hyperlipoproteinemia] Susekov AV, et al. **Ter Arkh** 1998;70(9):57–61 (Eng. Abstr.) **(Rus)**

[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia] Tvorogova MG, et al. **Ter Arkh** 1998;70(12):8–13 (Eng. Abstr.) **(Rus)**

[A comparison of the hypolipidemic action of probucol at doses of 500 and 1000 mg/day in moderate hyperlipoproteinemia] Tvorogova MG, et al. **Ter Arkh** 1998;70(8):17–21 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Reiner E, et al. **Chem Biol Interact** 1999 May 14;119–120:405–11

Decreased neutrophil antioxidative enzyme activities and increased lipid peroxidation in hyperlipoproteinemic human subjects. Efe H, et al. **Clin Chim Acta** 1999 Jan; 279(1–2):155–65

[Changes in the proteinase-inhibitor system of rats with hyperlipoproteinemia during transcerebral exposures to a 100-Hz-frequency pulse current and to an ultrahigh-frequency field] Zubkova SM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 May-Jun; (3):11–4 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group [see comments] MacLean DR, et al. **Can J Cardiol** 1999 Apr; 15(4):434–44. Comment in: Can J Cardiol 1999 Apr;15(4):407–8.

GENETICS

Genes, variation of cholesterol and fat intake and serum lipids. Ordovas JM, et al. **Curr Opin Lipidol** 1999 Feb; 10(1):15–22 (33 ref.)

Genetics of lipoprotein disorders. Davignon J, et al. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):521–50 (244 ref.)

Genetic deficiency of acylation stimulating protein (ASP(C3ades-Arg)) does not cause hyperapobetalipoproteinemia in mice. Wetsel RA, et al. **J Biol Chem** 1999 Jul 2;274(27):19429–33

Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from southern Italy. Seripa D, et al. **J Inherit Metab Dis** 1999 Jun;22(5):670–1

Apolipoprotein(a) and thrombosis: molecular and genetic bases of hyper-lipoprotein(a)-emia. Ichinose A, et al. **Semin Thromb Hemost** 1998;24(3):237–43

Lipoprotein (a) immunapheresis in the treatment of familial lipoprotein (a) hyperlipoproteinemia in a patient with coronary heart disease. Straube R, et al. **Ther Apher** 1998 Aug;2(3):243–5

METABOLISM

Metabolic modes of action of the statins in the hyperlipoproteinemias. Aguilar-Salinas CA, et al. **Atherosclerosis** 1998 Dec;141(2):203–7 (48 ref.)

MORTALITY

Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Rywik SL, et al. **Am J Cardiol** 1999 Sep 1;84(5):540–8

THERAPY

Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation. Reiner E, et al. **Chem Biol Interact** 1999 May 14;119–120:405–11

Evaluation and management of dyslipoproteinemia in children. Franklin FA Jr, et al. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):641–54 (17 ref.)

HYPERLIPOPROTEINEMIA TYPE I see **LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL**

HYPERLIPOPROTEINEMIA TYPE II see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERLIPOPROTEINEMIA TYPE III

BLOOD

Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages. Whitman SC, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1238–49

beta-VLDL of patients with type III hyperlipoproteinemia interferes with homogeneous determination of HDL-cholesterol based on polyethylene glycol-modified enzymes. Lackner KJ, et al. **Clin Chem** 1998 Dec; 44(12):2546–8

Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. Marcoux C, et al. **J Lipid Res** 1999 Apr;40(4):636–47

CHEMICALLY INDUCED

Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors [letter] [see comments] Lister RK, et al. **Lancet** 1999 May 15;353(9165):1678. Comment in: Lancet 1999 Jul 3;354(9172):76.

DIAGNOSIS

[Type-III hyperlipoproteinemia in a girl with Wilson's disease] Bonet Serra B, et al. **An Esp Pediatr** 1999 Jan; 50(1):71–3 (12 ref.) **(Spa)**

DRUG THERAPY

Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia [see comments] Civeira F, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):156–62. Comment in: Am Heart J 1999 Jul;138(1 Pt 1):17–8.

Treatment of type III hyperlipoproteinemia [editorial; comment] Guyton JR. **Am Heart J** 1999 Jul;138(1 Pt 1):17–8. Comment on: Am Heart J 1999 Jul;138(1 Pt 1):156–62.

GENETICS

A novel apolipoprotein E2 variant, E2Toranomon (Q187E), identified in a type III hyperlipoproteinemia patient with coronary atherosclerosis [letter] Okubo M, et al. **Atherosclerosis** 1998 Sep;140(1):187–90

Simple precipitation-based method for the screening of type III hyperlipoproteinemia. Nauck M, et al. **Clin Chem** 1999 Jun;45(6 Pt 1):909–11

HYPERLIPOPROTEINEMIA TYPE IV

BLOOD

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Pownall HJ, et al. **Atherosclerosis** 1999 Apr; 143(2):285–97

Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. Marcoux C, et al. **J Lipid Res** 1999 Apr;40(4):636–47

DIET THERAPY

Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Pownall HJ, et al. **Atherosclerosis** 1999 Apr; 143(2):285–97

GENETICS

Metabolic basis for hypertriglyceridaemia in familial combined hyperlipidaemia. Erkelens DW. **Eur Heart J** 1998 Jul;19 Suppl H:H23–6 (13 ref.)

HYPERLIPOPROTEINEMIA TYPE V

DRUG THERAPY

Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Kayikçioğlu M, et al. **Am J Cardiol** 1999 Apr 1;83(7):1135–7, A9

HYPERMEDIA

A hypertext-based tutorial with links to the Web for teaching statistics and research methods. Koch C, et al. **Behav Res Methods Instrum Comput** 1999 Feb;31(1):7–13

Visualizing physiological concepts and research hypotheses: a hypermedia module of the drainage of the cerebrospinal fluid by lymphatics. Chorney KM. **J Biocommun** 1998; 25(3):25–32

Using commercially available off-the-shelf software and hardware to develop an intranet-based hypertext markup language teaching file. Wendt GJ. **J Digit Imaging** 1999 May;12(2 Suppl 1):122–3

Intuitive hypertext-based molecular identification of micro-organisms [letter] Harmsen D, et al. **Lancet** 1999 Jan 23;353(9149):291

Methodology for developing educational hypermedia systems. Bearman M, et al. **Medinfo** 1998;9 Pt 2:720–6

A hypermedia tool to support the interaction between radiologists and clinicians. DeSimone M, et al. **Medinfo** 1998;9 Pt 2:1301–5

A hypermedia-based medical records management system. Laforest F, et al. **Medinfo** 1998;9 Pt 1:50–4

Impact of the TOP-FORUM hypermedia system in a pediatric oncology care unit. Soula G, et al. **Medinfo** 1998; 9 Pt 2:809–13

Formalising and acquiring model-based hypertext in medicine: an integrative approach. Spreckelsen C, et al. **Methods Inf Med** 1998 Sep;37(3):239–46

Forging links in an electronic paper chain [letter; comment] Gerstein M. **Nature** 1999 Mar 4;398(6722):20. Comment on: Nature 1999 Jan 21;397(6716):195–200.

Hypertextual navigation operationalizing generic clinical practice guidelines for patient-specific therapeutic decisions. Bouaud J, et al. **Proc AMIA Symp** 1998;:488–92

Hospitexte: towards a document-based hypertextual electronic medical record. Charlet J, et al. **Proc AMIA Symp** 1998;:713–7

Delivering labeled teaching images over the Web. Lehmann HP, et al. **Proc AMIA Symp** 1998;:418–22

Developing search strategies for detecting high quality reviews in a hypertext test collection. Zacks MP, et al. **Proc AMIA Symp** 1998;:663–7

HYPERMENORRHEA see **MENORRHAGIA**

HYPERMETROPIA see **HYPEROPIA**

HYPERMOBILITY, JOINT see **JOINT INSTABILITY**

HYPERNATREMIA

BLOOD

Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Peskind ER, et al. **Biol Psychiatry** 1998 Nov 15;44(10):1007–16

CHEMICALLY INDUCED

Hypernatraemia and polyuria due to high-dose colchicine in a suicidal patient. Usalan C, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1556–7

Fatal ingestion of sodium hypochlorite bleach with associated hypernatremia and hyperchloremic metabolic acidosis. Ross MP, et al. **Vet Hum Toxicol** 1999 Apr;41(2):82–6 (34 ref.)

COMPLICATIONS

Hypernatremia with edema [letter; comment] Luft FC. **Arch Intern Med** 1999 Jul 12;159(13):1499. Comment on: Arch Intern Med 1999 Jan 11;159(1):93–8.

Radiological case of the month. Sagittal sinus thrombosis in hypernatremic dehydration. Hilliard TN, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1147; discussion 1148

Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Totsuka E, et al. **Liver Transpl Surg** 1999 Sep;5(5):421–8

Hypernatraemia and polyuria in a patient with acute myeloid leukaemia and allogeneic bone marrow transplant [see comments] [published erratum appears in Nephrol Dial Transplant 1999 May;14(5):1349] Dickenmann MJ, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2687–9. Comment in: Nephrol Dial Transplant 1999 May;14(5):1332–3.

Cerebral bleeding, infarcts, and presumed extrapontine myelinolysis in hypernatraemic dehydration. AlOrainy IA, et al. **Neuroradiology** 1999 Feb;41(2):144–6

Transient thalamic changes on MRI in a child with hypernatremia. Hartfield DS, et al. **Pediatr Neurol** 1999 Jan;20(1):60–2

DIAGNOSIS

Hypernatremia with edema [see comments] Kahn T. **Arch Intern Med** 1999 Jan 11;159(1):93–8. Comment in: Arch Intern Med 1999 Jul 12;159(13):1499.

Creatinine, electrolytes and urea--do I hear much groaning? Swanepoel CR. **S Afr Med J** 1999 Mar;89(3):251–4

DRUG THERAPY

Antidiuretic hormone infusion reduces taurine and NaCl-induced hypernatremia in the rat. McBroom MJ, et al. **Amino Acids** 1998;15(1-2):89-97

ECONOMICS

Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. Bennett SJ, et al. **Heart Lung** 1999 Mar-Apr;28(2):102-9

EPIDEMIOLOGY

Hypernatremia in the intensive care unit: an indicator of quality of care? [see comments] Polderman KH, et al. **Crit Care Med** 1999 Jun;27(6):1105-8. Comment in: Crit Care Med 1999 Jun;27(6):1041-2.

Frequency, aetiology and outcome of hypernatraemia in hospitalised patients in Umtata, Transkei, South Africa. Erasmus RT, et al. **East Afr Med J** 1999 Feb;76(2):85-8

The changing pattern of hypernatremia in hospitalized children. Moritz ML, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):435-9

ETIOLOGY

Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease. Cao L, et al. **Am J Med Sci** 1999 Jul;318(1):67-8

Fatal hypernatremia associated with the antegrade continence enema procedure. Schreiber CK, et al. **J Urol** 1999 Oct;162(4):1433; discussion 1433-4

The CNS symptoms of rotavirus infections under the age of two. Schumacher RF, et al. **Klin Padiatr** 1999 Mar-Apr; 211(2):61-4

Disturbances in plasma sodium in patients with war head injuries. Bačić A, et al. **Mil Med** 1999 Mar;164(3):214-7

Hypernatraemia and tonicity balance [letter; comment] Mallié JP. **Nephrol Dial Transplant** 1999 May;14(5):1332-3. Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2687-9.

[Hypertonic dehydration in "silent" malnutrition of breast-fed infants (see comments)] van der Heide PA, et al. **Ned Tijdschr Geneeskd** 1998 May 2;142(18):993-5 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Aug 1;142(31):1789. **(Dut)**

[Holoprosencephaly with neurogenic hypernatremia] Cuisset JM, et al. **Arch Pediatr** 1999 Jan;6(1):43-5 (7 ref.) (Eng. Abstr.) **(Fre)**

[Sodium and water balance for clinical routine practice] Luft FC. **Internist (Berl)** 1998 Aug;39(8):804-9 (9 ref.) **(Ger)**

[Disorders of sodium and water balance. Diagnosis and therapy.] Rüchardt A, et al. **Internist (Berl)** 1999 Aug; 40(8):W861-71 (9 ref.) **(Ger)**

[A case of severe hypernatremia complicated with rhabdomyolysis] Asahara H, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):301-4 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Diabetes insipidus and adipsic hypernatremia in a patient with a craniopharyngioma] Macias Batista A, et al. **An Med Interna** 1999 Feb;16(2):87-8 (9 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Acquired disorder of thirst perception with intact osmoregulation of vasopressin] Zünd S, et al. **Wien Klin Wochenschr** 1998 Aug 21;110(15):538-41 (Eng. Abstr.) **(Ger)**

THERAPY

Hypernatremia in the intensive care unit: instant quality--just add water [editorial; comment] Sterns RH. **Crit Care Med** 1999 Jun;27(6):1041-2. Comment on: Crit Care Med 1999 Jun;27(6):1105-8.

The management of extreme hypernatraemia secondary to salt poisoning in an infant. Paut O, et al. **Paediatr Anaesth** 1999;9(2):171-4

[Central pontine myelinolysis following correction of hypernatremia in an aged patient (letter)] Bour-Guichenez G, et al. **Presse Med** 1999 Jun 12;28(21):1112 **(Fre)**

VETERINARY

Adipsia and hypernatraemia in a dog with focal hypothalamic granulomatous meningoencephalitis. Mackay BM, et al. **Aust Vet J** 1999 Jan;77(1):14-7

Treatment of hypernatremia in an acidotic neonatal calf. Angelos SM, et al. **J Am Vet Med Assoc** 1999 May 1; 214(9):1364-7, 1335

VIROLOGY

A prospective clinical study of patients with hypernatraemic dehydration. Eke F, et al. **Afr J Med Med Sci** 1996 Sep; 25(3):209-12

Adipsic hypernatremia in two patients with AIDS and cytomegalovirus encephalitis. Keuneke C, et al. **Am J Kidney Dis** 1999 Feb;33(2):379-82

HYPERNEPHROMA see **CARCINOMA, RENAL CELL**

HYPEROODON see **WHALES**

HYPEROPIA

From a hyperope's point of view [editorial] Freeman PB. **J Am Optom Assoc** 1999 Apr;70(4):209-10

A clinical review of hyperopia in young children. The Hyperopic Infants' Study Group, THIS Group. Moore B, et al. **J Am Optom Assoc** 1999 Apr;70(4):215-24 (84 ref.)

COMPLICATIONS

Pregnancy-associated overcorrection following myopic excimer laser photorefractive keratectomy [letter] Starr MB. **Arch Ophthalmol** 1998 Nov;116(11):1551

A randomized comparison of prism adaptation and augmented surgery in the surgical management of esotropia associated with hypermetropia. Hwang JM, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jul-Aug; 36(4):196-200

Intracranial hypertension associated with acquired hyperopia and choroidal folds. Sharma M, et al. **Retina** 1999; 19(3):260-2

DIAGNOSIS

Screening for abnormal levels of hyperopia in children: a non-cycloplegic method with a hand held refractor. Cordonnier M, et al. **Br J Ophthalmol** 1998 Nov; 82(11):1260-4

EPIDEMIOLOGY

Refractive errors among young adults and university students in Norway. Kinge B, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):692-5

ETHNOLOGY

Refractive errors in a black adult population: the Barbados Eye Study. Wu SY, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2179-84

ETIOLOGY

Refractive changes after pediatric intraocular lens implantation [letter] Basti S, et al. **Am J Ophthalmol** 1999 Sep;128(3):394-5

Refractive changes after pediatric intraocular lens implantation [letter; comment] Ruben JB. **Am J Ophthalmol** 1999 Aug;128(2):260-1. Comment on: Am J Ophthalmol 1998 Dec;126(6):772-81.

Interface keratitis-induced stromal thinning: an early postoperative complication of laser in situ keratomileusis. Schneider DM, et al. **J Cataract Refract Surg** 1998 Sep; 24(9):1277-9

Interpseudophakos Elschnig pearls associated with late hyperopic shift: a complication of piggyback posterior chamber intraocular lens implantation. Shugar JK, et al. **J Cataract Refract Surg** 1999 Jun;25(6):863-7

Intraocular lens power calculation after decentered photorefractive keratectomy. Speicher L, et al. **J Cataract Refract Surg** 1999 Jan;25(1):140-3

Epithelial haze, punctate keratopathy, and induced hyperopia after photorefractive keratectomy for myopia. Price FW Jr, et al. **J Refract Surg** 1999 May-Jun;15(3):384-7

GENETICS

Autosomal dominant nanophthalmos (NNO1) with high hyperopia and angle-closure glaucoma maps to chromosome 11. Othman MI, et al. **Am J Hum Genet** 1998 Nov;63(5):1411-8

PATHOLOGY

Histology of rabbit corneas after 10-diopter photorefractive keratectomy for hyperopia. Dierick HG, et al. **J Refract Surg** 1999 Jul-Aug;15(4):459-68

PHYSIOPATHOLOGY

Refractive changes in the elderly. Bengtsson B, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):37-9

Refractive changes among Norwegian university students--a three-year longitudinal study. Kinge B, et al. **Acta Ophthalmol Scand** 1999 Jun;77(3):302-5

Emmetropization in the rhesus monkey (Macaca mulatta): birth to young adulthood. Bradley DV, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):214-29

SURGERY

Excimer laser treatment of hyperopia. Füst A, et al. **Acta Ophthalmol Scand** 1998 Dec;76(6):686-91

Lasso procedure to revise overcorrection with radial keratotomy. Miyashiro MJ, et al. **Am J Ophthalmol** 1998 Dec;126(6):825-7

Hyperopic automated lamellar keratoplasty [letter; comment] Kliger CH. **Arch Ophthalmol** 1999 Mar;117(3):416; discussion 417. Comment on: Arch Ophthalmol 1998 Apr;116(4):425-8.

Hyperopic automated lamellar keratoplasty [letter; comment] Pulaski JP. **Arch Ophthalmol** 1999 Mar;117(3):416-7. Comment on: Arch Ophthalmol 1998 Apr;116(4):425-8.

A cautionary tale of innovation in refractive surgery. Waring GO 3rd. **Arch Ophthalmol** 1999 Aug;117(8):1069-73 (57 ref.)

Corneal iron ring after hyperopic laser-assisted in situ keratomileusis. Ozdamar A, et al. **Cornea** 1999 Mar; 18(2):243-5

Consultation section. Refractive surgical problem. **J Cataract Refract Surg** 1999 Mar;25(3):307-11

Consultation section. Refractive surgical problem [see comments] **J Cataract Refract Surg** 1999 Jan;25(1):2-6. Comment in: J Cataract Refract Surg 1999 Jan;25(1):1.

Laser in situ keratomileusis for hyperopia [see comments] Argento CJ, et al. **J Cataract Refract Surg** 1998 Aug; 24(8):1050-8. Comment in: J Cataract Refract Surg 1998 Aug;24(8):1013-4. Comment in: J Cataract Refract Surg 1998 Nov;24(11):1419-20.

Results of laser in situ keratomileusis in hyperopic compound astigmatism. Barraquer C, et al. **J Cataract Refract Surg** 1999 Sep;25(9):1198-204

Corneal iron ring after hyperopic photorefractive keratectomy. Bilgihan K, et al. **J Cataract Refract Surg** 1999 May;25(5):685-7

Diode laser thermokeratoplasty: application strategy and dosimetry. Brinkmann R, et al. **J Cataract Refract Surg** 1998 Sep;24(9):1195-207

Excimer laser assisted in situ keratomileusis for hyperopia. Buzard KA, et al. **J Cataract Refract Surg** 1999 Feb; 25(2):197-204

Continuous-wave diode laser thermokeratoplasty: first clinical experience in blind human eyes. Geerling G, et al. **J Cataract Refract Surg** 1999 Jan;25(1):32-40

Evaluation of current techniques of corneal epithelial removal in hyperopic photorefractive keratectomy. Griffith M, et al. **J Cataract Refract Surg** 1998 Aug;24(8):1070-8

Noncontact thermokeratoplasty to correct hyperopia induced by laser in situ keratomileusis. Ismail MM, et al. **J Cataract Refract Surg** 1998 Sep;24(9):1191-4

Laser thermokeratoplasty after lamellar corneal cutting. Ismail MM, et al. **J Cataract Refract Surg** 1999 Feb; 25(2):212-5

Finding the perfect match [editorial; comment] Koch DD. **J Cataract Refract Surg** 1998 Aug;24(8):1013-4. Comment on: J Cataract Refract Surg 1998 Aug;24(8):1039-49. Comment on: J Cataract Refract Surg 1998 Aug;24(8):1050-8.

Excimer ablation design and elliptical transition zones [see comments] MacRae S. **J Cataract Refract Surg** 1999 Sep; 25(9):1191-7. Comment in: J Cataract Refract Surg 1999 Sep;25(9):1175.

Pseudo-Fleischer ring after hyperopic laser in situ keratomileusis. Probst LE, et al. **J Cataract Refract Surg** 1999 Jun;25(6):868-70

Comparing hyperopia treatments [letter; comment] Pulaski JP. **J Cataract Refract Surg** 1998 Nov;24(11):1419-20. Comment on: J Cataract Refract Surg 1998 Aug;24(8):1050-8.

Laser in situ keratomileusis for hyperopia and hyperopic astigmatism. Arbelaez MC, et al. **J Refract Surg** 1999 Jul-Aug;15(4):406-14

Centered vs. inferior off-center ablation to correct hyperopia and presbyopia. Bauerberg JM. **J Refract Surg** 1999 Jan-Feb;15(1):66-9

Photorefractive keratectomy for hyperopia using an erodible disc and axicon lens: 2-year results. Carones F, et al. **J Refract Surg** 1998 Sep-Oct;14(5):504-11

Histology of rabbit corneas after 10-diopter photorefractive keratectomy for hyperopia. Dierick HG, et al. **J Refract Surg** 1999 Jul-Aug;15(4):459-68

Treatment of hyperopia with contact Ho:YAG laser thermal keratoplasty. Eggink CA, et al. **J Refract Surg** 1999 Jan-Feb;15(1):16-22

Clear lens extraction with intraocular lens implantation for hyperopia. Kolahdouz-Isfahani AH, et al. **J Refract Surg** 1999 May-Jun;15(3):316-23

Posterior chamber collamer phakic intraocular lens for myopia and hyperopia. Pesando PM, et al. **J Refract Surg** 1999 Jul-Aug;15(4):415-23

Laser in situ keratomileusis for hyperopia after thermal keratoplasty. Portellinha W, et al. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):S218-20

Bacterial keratitis following laser in situ keratomileusis for hyperopia. al-Reefy M. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):216-7

Laser in situ keratomileusis for hyperopia. Rosa DS, et al. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):S212-5

Posterior chamber phakic intraocular lens for hyperopia. Sanders DR, et al. **J Refract Surg** 1999 May-Jun; 15(3):309-15

Photorefractive keratectomy to correct myopic or hyperopic astigmatism with a cross-cylinder ablation. Vinciguerra P, et al. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):S183-5

Algorithm to correct hyperopic astigmatism with the Nidek EC-5000 excimer laser. Vinciguerra P, et al. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):S186-7

Photorefractive keratectomy for hyperopia: long-term nonlinear and vector analysis of refractive outcome. Corones F, et al. **Ophthalmology** 1999 Oct;106(10):1976-82; discussion 1982-3

Piggybacking intraocular implants to correct pseudophakic refractive error. Gayton JL, et al. **Ophthalmology** 1999 Jan; 106(1):56-9

Laser thermal keratoplasty for PRK overcorrection [letter; comment] [published erratum appears in Ophthalmology 1999 Mar;106(3):443] Kliger CH. **Ophthalmology** 1998 Dec; 105(12):2165-7. Comment on: Ophthalmology 1998 May;105(5):926-31.

HYPEROPIA

Acute corneal necrosis after excimer laser keratectomy for hyperopia. Mietz H, et al. **Ophthalmology** 1999 Mar; 106(3):490–6

Very high-frequency ultrasound corneal analysis identifies anatomic correlates of optical complications of lamellar refractive surgery: anatomic diagnosis in lamellar surgery. Reinstein DZ, et al. **Ophthalmology** 1999 Mar;106(3):474–82

LASIK for hyperopia and hyperopic astigmatism--results of a pilot study. Knorz MC, et al. **Semin Ophthalmol** 1998 Jun;13(2):83–7

[Photorefractive keratectomy in hypermetropia] Sener AB, et al. **J Fr Ophtalmol** 1998 Jan;21(1):19–22 (Eng. Abstr.) **(Fre)**

[Diode laser thermokeratoplasty. Initial clinical experiences] Geerling G, et al. **Ophthalmologe** 1999 May;96(5):306–11 (Eng. Abstr.) **(Ger)**

[Thermal damage to the corneal endothelium in diode laser thermokeratoplasty] Koop N, et al. **Ophthalmologe** 1999 Jun;96(6):392–7 (Eng. Abstr.) **(Ger)**

[A confocal microscopic and histological study on rabbit corneas after photorefractive keratectomy for hyperopia] Hosoda Y, et al. **Nippon Ganka Gakkai Zasshi** 1999 Mar; 103(3):243–51 (Eng. Abstr.) **(Jpn)**

[Comparison of hyperopic photorefractive keratectomy and LASIK in correction of hypermetropia with excimer laser] Juhás T, et al. **Cesk Slov Oftalmol** 1999 Jan;55(1):14–20 (Eng. Abstr.) **(Slo)**

THERAPY

Contact zone of piggyback acrylic intraocular lenses [see comments] Findl O, et al. **J Cataract Refract Surg** 1999 Jun;25(6):860–2. Comment in: J Cataract Refract Surg 1999 Jun;25(6):729.

Face to face with IOLs [editorial; comment] Rosen ES. **J Cataract Refract Surg** 1999 Jun;25(6):729. Comment on: J Cataract Refract Surg 1999 Jun;25(6):860–2.

HYPEROSTOSIS

Skull bone mass deficit in prepubertal highly-trained gymnast girls. Courteix D, et al. **Int J Sports Med** 1999 Jul; 20(5):328–33

COMPLICATIONS

[Inflammatory spondylodiscitis as a unique radiological manifestation of the SAPHO syndrome] Cabay JE, et al. **J Radiol** 1998 Apr;79(4):337–40 (Eng. Abstr.) **(Fre)**

CONGENITAL

A case with Weaver syndrome operated for congenital cardiac defect. Sarigül A, et al. **Pediatr Cardiol** 1999 Sep-Oct;20(5):375–6

DIAGNOSIS

[Anterior hyperostosis of the cervical spine: diagnostic studies and surgical therapy] Motsch C, et al. **Laryngorhinootologie** 1999 Mar;78(3):150–4 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Parathyroid hormone [PTH(1–34)] and parathyroid hormone-related protein [PTHrP(1–34)] promote reversion of hypertrophic chondrocytes to a prehypertrophic proliferating phenotype and prevent terminal differentiation of osteoblast-like cells. Zerega B, et al. **J Bone Miner Res** 1999 Aug;14(8):1281–9

ETIOLOGY

Fluorosis--a rare complication of diabetes insipidus. Mehta MN, et al. **Indian Pediatr** 1998 May;35(5):463–7

PATHOLOGY

Stress-induced SAPHO syndrome. Orion E, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):43–6

Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion. Pieper DR, et al. **Neurosurgery** 1999 Apr;44(4):742–6; discussion 746–7

PHYSIOPATHOLOGY

Influence of retinyl acetate on osteochondral junction chondrocytes in C3H and balb mice. Takase T, et al. **J Rheumatol** 1999 Jan;26(1):156–65

RADIOGRAPHY

Sacroiliitis, hyperostosis sternoclavicularis, and psoriasis palmoplantaris in monozygotic twins. Hoffmann A, et al. **Arthritis Rheum** 1999 Mar;42(3):574–6

Childhood periosteal chondroma: femoral neck thickening and remote hyperostosis as clues to plain film diagnosis. Tillich M, et al. **Pediatr Radiol** 1998 Nov;28(11):899

SURGERY

[Anterior hyperostosis of the cervical spine: diagnostic studies and surgical therapy] Motsch C, et al. **Laryngorhinootologie** 1999 Mar;78(3):150–4 (Eng. Abstr.) **(Ger)**

HYPEROSTOSIS, CORTICAL, CONGENITAL

Sporadic congenital infantile cortical hyperostosis (Caffey's disease). Al-Tawil KI, et al. **Am J Perinatol** 1998; 15(11):629–33

Radiological and laboratory features of infantile cortical hyperostosis. A case report. Hatori M, et al. **Int Orthop** 1998;22(4):272–4

CLASSIFICATION

[Van Buchem disease. Maxillofacial changes, diagnostic classification and general principles of treatment] Scopelliti D, et al. **Minerva Stomatol** 1999 May;48(5):227–34 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Caffey-Silverman syndrome (infantile cortical hyperostosis) mimicking periorbital cellulitis. Rogosin A, et al. **J Pediatr Ophthalmol Strabismus** 1999 Jan-Feb;36(1):40–1

[Caffey disease (infantile cortical hyperostosis)] Benomar S, et al. **Arch Pediatr** 1998 Jan;5(1):31–4 (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiologic case study. Infantile cortical hyperostosis (Caffey's disease). Kocher MS, et al. **Orthopedics** 1999 Jul; 22(7):712, 707–8

HYPEROSTOSIS CORTICALIS GENERALISATA see **OSTEOCHONDRODYSPLASIAS**

HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL

COMPLICATIONS

Aspiration pneumonia secondary to giant cervical osteophyte formation (diffuse idiopathic skeletal hyperostosis or Forrestier's disease): a case report. Babores M, et al. **Chest** 1998 Nov;114(5):1481–2

Forestier disease and interscalene brachial plexus block [letter] Tortosa JA, et al. **Eur J Anaesthesiol** 1998 Nov; 15(6):805–6

An unusual case of stridor due to osteophytes of the cervical spine: (Forestier's disease). Papakostas K, et al. **J Laryngol Otol** 1999 Jan;113(1):65–7 (15 ref.)

Transpharyngeal approach for the treatment of dysphagia due to Forestier's disease. Uppal S, et al. **J Laryngol Otol** 1999 Apr;113(4):366–8

[Forestier's disease. Ear, nose and throat manifestations] Salazar C, et al. **Acta Otorrinolaringol Esp** 1999 May; 50(4):327–31 (Eng. Abstr.) **(Spa)**

[Forestier disease as unusual cause of dysphagia] Zsigmond P, et al. **Lakartidningen** 1999 Apr 21;96(16):1979–81 **(Swe)**

DRUG THERAPY

Calcitonin simultaneously regulates both periosteal hyperostosis and trabecular osteopenia in the spinal hyperostotic mouse (twy/twy) in vivo. Okawa A, et al. **Calcif Tissue Int** 1999 Mar;64(3):239–47

ETIOLOGY

[A case of motor and sensory polyneuropathy with retinitis pigmentosa and diffuse idiopathic skeletal hyperostosis] Osoegawa M, et al. **Rinsho Shinkeigaku** 1999 May; 39(5):542–5 (Eng. Abstr.) **(Jpn)**

METABOLISM

Retinoid and bone metabolic marker in ossification of the posterior longitudinal ligament. Kodama T, et al. **In Vivo** 1998 May-Jun;12(3):339–44

RADIOGRAPHY

Comprehensive radiographic evaluation of diffuse idiopathic skeletal hyperostosis: development and interrater reliability of a scoring system. Mata S, et al. **Semin Arthritis Rheum** 1998 Oct;28(2):88–96

[Forestier's disease. Ear, nose and throat manifestations] Salazar C, et al. **Acta Otorrinolaringol Esp** 1999 May; 50(4):327–31 (Eng. Abstr.) **(Spa)**

HYPEROSTOSIS FRONTALIS INTERNA

DIAGNOSIS

Unusually exuberant hyperostosis frontalis interna: MRI. Chaljub G, et al. **Neuroradiology** 1999 Jan;41(1):44–5

Renal osteodystrophy with leontiasis ossea deformity. Reidy JM, et al. **Otolaryngol Head Neck Surg** 1998 Nov; 119(5):525–7

PATHOLOGY

Hyperostosis frontalis interna: an anthropological perspective. Hershkovitz I, et al. **Am J Phys Anthropol** 1999 Jul;109(3):303–25 (36 ref.)

SURGERY

[Fibrous dysplasia: management of a severe case of pseudo-leontiasis ossea] Ruhin B, et al. **Rev Stomatol Chir Maxillofac** 1998 Dec;99(5-6):250–7 (Eng. Abstr.) **(Fre)**

HYPEROSTOSIS, STERNOCOSTOCLAVICULAR

Chronic recurrent multifocal osteomyelitis [letter] Mandell GA. **AJR Am J Roentgenol** 1999 Oct;173(4):1130–1

RADIOGRAPHY

Panclavicular ankylosis in pustulotic arthroosteitis. A case report. Tamai K, et al. **Clin Orthop** 1999 Feb;(359):146–50

[Spondarthritis hyperostotica pustulo-psoriatica: nosologic study with clinical and radiologic presentation in relation to the SAPHO syndrome] Schilling F, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Dec;169(6):576–84 (38 ref.) (Eng. Abstr.) **(Ger)**

HYPEROXALURIA

BLOOD

Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Hoppe B, et al. **Kidney Int** 1998 Sep;54(3):921–5

CHEMICALLY INDUCED

Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Auer BL, et al. **Eur J Clin Invest** 1998 Sep;28(9):695–700

COMPLICATIONS

Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Toblli JE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):225–31

[Iterative fractures in type I primary hyperoxaluria. Report of 2 cases] Levadoux M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Mar; 85(1):75–80 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Takei K, et al. **Urol Int** 1998;61(3):192–5

ETIOLOGY

Jejuno-ileal bypass, enteric hyperoxaluria, and oxalate nephrosis: a role for polarised light in the renal biopsy. Hicks K, et al. **J Clin Pathol** 1998 Sep;51(9):700–2

Abnormal arachidonic acid content of membrane phospholipids--the unifying hypothesis for the genesis of hypercalciuria and hyperoxaluria in idiopathic calcium nephrolithiasis. Baggio B, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):553–5

GENETICS

Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: glyoxylate aminotransferase gene. Pirulli D, et al. **Hum Genet** 1999 Jun;104(6):523–5

METABOLISM

Effect of gamma-glutamyl carboxylation of renal microsomes on calcium oxalate monohydrate crystal binding in hyperoxaluria. Angayarkanni N, et al. **Nephron** 1999; 81(3):342–6

Low calcium diet in hypercalciuric calcium nephrolithiasis: first do no harm. Hess B. **Scanning Microsc** 1996; 10(2):547–54; discussion 554–6 (62 ref.)

PATHOLOGY

Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Toblli JE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):225–31

PHYSIOPATHOLOGY

Role of glutathione on renal mitochondrial status in hyperoxaluria. Muthukumar A, et al. **Mol Cell Biochem** 1998 Aug;185(1-2):77–84

SURGERY

[Iterative fractures in type I primary hyperoxaluria. Report of 2 cases] Levadoux M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Mar; 85(1):75–80 (Eng. Abstr.) **(Fre)**

THERAPY

Steroid-responsive pleuropericarditis and livedo reticularis in an unusual case of adult-onset primary hyperoxaluria. Singh S, et al. **Am J Kidney Dis** 1999 Apr;33(4):e5 (36 ref.)

URINE

High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load

in humans. Hess B, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2241-7

HYPEROXALURIA, PRIMARY

BLOOD

Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Hoppe B, et al. **Kidney Int** 1999 Jul;56(1):268-74

COMPLICATIONS

Oxalate kinetics and reversal of the complications after orthotopic liver transplantation in a patient with primary hyperoxalosis type 1 awaiting renal transplantation. Bastani B, et al. **Am J Nephrol** 1999;19(1):64-9

Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Hoppe B, et al. **Kidney Int** 1999 Jul;56(1):268-74

Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301-3 (13 ref.)

Unusual heel pain in a patient with primary oxalosis treated by liver-kidney transplantation [letter] Javier RM, et al. **Rev Rhum Engl Ed** 1998 Jul-Sep;65(7-9):517-8

DIAGNOSIS

Late onset primary oxalosis type I: an uncommon presentation of a rare disease. Glück T, et al. **Eur J Gastroenterol Hepatol** 1998 Sep;10(9):809-12

Primary hyperoxaluria type 1 [clinical conference] Cochat P. **Kidney Int** 1999 Jun;55(6):2533-47 (64 ref.)

Diagnosis and management of primary hyperoxaluria type 1 in infancy [see comments] Parekh RS, et al. **Pediatr Transplant** 1997 Aug;1(1):48-54. Comment in: Pediatr Transplant 1997 Aug;1(1):4-7.

DRUG THERAPY

Transplantation strategies in type 1 primary hyperoxaluria: the issue of pyridoxine responsiveness [editorial] Marangella M. **Nephrol Dial Transplant** 1999 Feb; 14(2):301-3 (13 ref.)

[Results of treatment with oral citrate and pyridoxine in patients with primary hyperoxaluria type 1] Castelló Girona F, et al. **An Esp Pediatr** 1999 Apr;50(4):397-401 **(Spa)**

GENETICS

Gene symbol: AGXT. Disease: primary hyperoxaluria type I. Amoroso A, et al. **Hum Genet** 1999 May;104(5):441

PATHOLOGY

A case of late onset primary hyperoxaluria type I (PH-I) presented with black liver. Kazama-Saegusa S, et al. **Clin Nephrol** 1998 Sep;50(3):184-7 (14 ref.)

[Primary hyperoxaluria type 1 detected by liver biopsy] Nielsen EH, et al. **Ugeskr Laeger** 1999 Mar 15; 161(11):1601-2 (Eng. Abstr.) **(Dan)**

SURGERY

Primary hyperoxaluria 1: catch up growth and normalization of oxaluria 6 years after hepatorenal transplantation in a prepubertal boy. Walden U, et al. **Eur J Pediatr** 1999 Sep; 158(9):727-9

Transplantation for primary hyperoxaluria in the United States. Saborio P, et al. **Kidney Int** 1999 Sep;56(3):1094-100

Diagnosis and management of primary hyperoxaluria type 1 in infancy [see comments] Parekh RS, et al. **Pediatr Transplant** 1997 Aug;1(1):48-54. Comment in: Pediatr Transplant 1997 Aug;1(1):4-7.

Optimal management of renal failure in primary hyperoxaluria in infancy, and the use of combined kidney/liver transplantation [editorial; comment] Scheinman JI, et al. **Pediatr Transplant** 1997 Aug;1(1):4-7 Comment on: Pediatr Transplant 1997 Aug;1(1):48-54.

HYPEROXIA

Metabolic features of the adaptive effect of delta-sleep inducing peptide and piracetam under hyperoxic conditions. Lysenko AV, et al. **Biochemistry (Mosc)** 1999 Jun;64(6):652-7

Hyperoxia and glucocorticoid modify retinal vessel growth and interleukin-1 receptor antagonist in newborn rabbits. Lawas-Alejo PA, et al. **Pediatr Res** 1999 Mar;45(3):313-7

BLOOD

Effects of hyperoxia on oxygen uptake kinetics in cystic fibrosis patients as determined by pseudo-random binary sequence exercise. Kusenbach G, et al. **Eur J Appl Physiol** 1999 Jan;79(2):192-6

The effect of hyperoxaemia on erythropoietin secretion in anaemic patients. Tsangaris H, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):120-5

[Pre-analytic errors in the determination of arterial O(2)-partial pressure under hyperoxic conditions] Risch A, et al. **Anaesthesist** 1999 Aug;48(8):533-7 (Eng. Abstr.) **(Ger)**

[Comparative analysis of the serum albumin level by immunochemical, radioisotopic, and dye-sorption protein identification in rat tissues during hyperoxia] Sinichkin AA. **Zh Evol Biokhim Fiziol** 1999 Jan-Feb;35(1):33-5 **(Rus)**

[Hyperoxia effect on the serum albumin level in rat tissues. Results of the electrophoretic analysis] Sinichkin AA. **Zh Evol Biokhim Fiziol** 1999 Jan-Feb;35(1):54-6 **(Rus)**

CHEMICALLY INDUCED

Effects of intraalveolar oxygen concentration on alveolar fluid absorption and metabolism in isolated rat lungs. Suzuki S, et al. **Respir Physiol** 1999 May 3;115(3):325-32

COMPLICATIONS

Effects of lisofylline on hyperoxia-induced lung injury. George CL, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L776-85

Cyclosporin A protects lung function from hyperoxic damage. Matthew E, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L786-95

Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Watkins RH, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L858-67

Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. Saldias FJ, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):626-33

Influence of inhaled nitric oxide and hyperoxia on Na,K-ATPase expression and lung edema in newborn piglets. Youssef JA, et al. **Biol Neonate** 1999 Mar; 75(3):199-209

Isoproterenol improves ability of lung to clear edema in rats exposed to hyperoxia. Saldias FJ, et al. **J Appl Physiol** 1999 Jul;87(1):30-5

Hyperoxic myopia in a closed-circuit mixed-gas scuba diver. Butler FK Jr, et al. **Undersea Hyperb Med** 1999 Spring; 26(1):41-5

ENZYMOLOGY

Age-dependent ultrastructural alterations and biochemical response of rat skeletal muscle after hypoxic or hyperoxic treatments. Amicarelli F, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):105-14

Hypoxic and hyperoxic effect on blood phosphodiesterase activity in young and old rats. Spoto G, et al. **Life Sci** 1998;63(25):PL349-53

ETIOLOGY

The effect of hyperoxaemia on erythropoietin secretion in anaemic patients. Tsangaris H, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):120-5

GENETICS

ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Buckley S, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):L159-66

METABOLISM

Exposure to hyperoxia decreases the expression of vascular endothelial growth factor and its receptors in adult rat lungs. Klekamp JG, et al. **Am J Pathol** 1999 Mar; 154(3):823-31

KGF prevents hyperoxia-induced reduction of active ion transport in alveolar epithelial cells. Borok Z, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1352-60

Hyperoxia increases keratinocyte growth factor mRNA expression in neonatal rabbit lung. Charafeddine L, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):L105-13

Iron uptake promotes hyperoxic injury to alveolar macrophages. Wesselius LJ, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):100-6

Hyperventilation, hyperoxia, and cerebral oxygenation after traumatic brain injury [letter; comment] Savva D. **Anesth Analg** 1999 Jul;89(1):258. Comment on: Anesth Analg 1998 Oct;87(4):850-3.

Hyperoxia induces the neuronal differentiated phenotype of PC12 cells via a sustained activity of mitogen-activated protein kinase induced by Bcl-2. Katoh S, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):465-70

Role for NF-kappa B in mediating the effects of hyperoxia on IGF-binding protein 2 promoter activity in lung alveolar epithelial cells. Cazals V, et al. **Biochim Biophys Acta** 1999 Jan 11;1448(3):349-62

Combined effects of inhaled nitric oxide and hyperoxia on pulmonary vascular permeability and lung mechanics [see comments] Storme L, et al. **Crit Care Med** 1999 Jun; 27(6):1168-74. Comment in: Crit Care Med 1999 Jun;27(6):1059-60.

Effect of hyperoxia and hypoxia on subcutaneous tissue gases and pH. An experimental study in pigs. Mellström A, et al. **Eur Surg Res** 1999;31(4):333-9

Discordant pulmonary proinflammatory cytokine expression during acute hyperoxia in the newborn rabbit. D'Angio CT, et al. **Exp Lung Res** 1999 Jul-Aug;25(5):443-65

Chemokine mRNA alterations in newborn and adult mouse lung during acute hyperoxia. D'Angio CT, et al. **Exp Lung Res** 1998 Sep-Oct;24(5):685-702

Oxygen uptake kinetics of older humans are slowed with age but are unaffected by hyperoxia. Bell C, et al. **Exp Physiol** 1999 Jul;84(4):747-59

Interleukin-1 expression during hyperoxic lung injury in the mouse. Piedboeuf B, et al. **Free Radic Biol Med** 1998 Jun; 24(9):1446-54

Intraretinal oxygen distribution in the rat with graded systemic hyperoxia and hypercapnia. Yu DY, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):2082-7

Hyperoxia-induced changes in antioxidant capacity and the effect of dietary antioxidants. Cao G, et al. **J Appl Physiol** 1999 Jun;86(6):1817-22

Tracking oxygen effects on MR signal in blood and skeletal muscle during hyperoxia exposure. Noseworthy MD, et al. **J Magn Reson Imaging** 1999 Jun;9(6):814-20

Brain tissue oxygenation during hemorrhagic shock, resuscitation, and alterations in ventilation. Manley GT, et al. **J Trauma** 1999 Feb;46(2):261-7

Effects of hyperoxia on nitric oxide synthase expression, nitric oxide activity, and lung injury in rat pups. Potter CF, et al. **Pediatr Res** 1999 Jan;45(1):8-13

Effect of hyperoxia on human macrophage cytokine response. Desmarquest P, et al. **Respir Med** 1998 Jul; 92(7):951-60

PATHOLOGY

Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Barazzone C, et al. **Am J Pathol** 1999 May;154(5):1479-87

Carbon monoxide provides protection against hyperoxic lung injury. Otterbein LE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L688-94

Iron uptake promotes hyperoxic injury to alveolar macrophages. Wesselius LJ, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):100-6

Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. Yamada H, et al. **J Cell Physiol** 1999 May; 179(2):149-56

PHYSIOPATHOLOGY

Hypoxia and hyperoxia both transiently affect distribution of pulmonary perfusion but not ventilation in awake sheep. Melsom MN, et al. **Acta Physiol Scand** 1999 Jun; 166(2):151-8

Specific blood flow reducing effects of hyperoxaemia on high flow capillaries in the pig brain. Sjöberg F, et al. **Acta Physiol Scand** 1999 Jan;165(1):33-8

ERK activation protects against DNA damage and apoptosis in hyperoxic rat AEC2. Buckley S, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):L159-66

Accumulation of p21(Cip1/WAF1) during hyperoxic lung injury in mice. O'Reilly MA, et al. **Am J Respir Cell Mol Biol** 1998 Nov;19(5):777-85

Hyperoxaemia in extreme haemodilution. Habler O, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:79-82 (29 ref.)

Hyperoxia increases paradoxical sleep rhythm in the pontine cat. Arnulf I, et al. **Brain Res** 1998 Oct 5;807(1-2):160-6

Acute effects of hypoxaemia, hyperoxaemia and hypercapnia on renal blood flow in normal and renal transplant subjects. Sharkey RA, et al. **Eur Respir J** 1998 Sep;12(3):653-7

Mechanisms of hyperoxia-induced reductions in retinal blood flow in newborn pig. Zhu Y, et al. **Exp Eye Res** 1998 Sep; 67(3):357-69

Effect of normobaric hyperoxia on two indexes of synaptic function in Fisher 344 rats. Bickford PC, et al. **Free Radic Biol Med** 1999 Apr;26(7-8):817-24

Regional differences in retinal vascular reactivity. Chung HS, et al. **Invest Ophthalmol Vis Sci** 1999 Sep;40(10):2448-53

Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. Folz RJ, et al. **J Clin Invest** 1999 Apr;103(7):1055-66

Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. Otterbein LE, et al. **J Clin Invest** 1999 Apr; 103(7):1047-54

Heart rate responses to altered ambient oxygen in early (days 3-9) chick embryos in the intact egg. Akiyama R, et al. **J Comp Physiol [B]** 1999 Mar;169(2):85-92

Postexercise decrease in arterial blood pressure, total peripheral resistance and in circulatory responses to brief hyperoxia in subjects with mild essential hypertension. Izdebska E, et al. **J Hum Hypertens** 1998 Dec;12(12):855-60

Slow recovery of impaired phrenic responses to hypoxia following perinatal hyperoxia in rats. Ling L, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):599-603

Hyperoxia and local organ blood flow in the developing chick embryo. van Golde JM, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):243-8

The effects of hyperoxia on the biosynthesis of cyclooxygenase products and haemodynamic response to nitric oxide synthase inhibition with L-NAME in endotoxaemic pigs. Hellyer PW, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):348-57

Oxygen toxicity and tolerance. Capellier G, et al. **Minerva Anestesiol** 1999 Jun;65(6):388-92 (51 ref.)

Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits. Issa A, et al. **Pediatr Res** 1999 Feb;45(2):247-54

Influence of hypoxia and hyperoxia on the cardiovascular and lethal effects of ethanol. Strubelt O, et al. **Pharmacol Toxicol** 1999 Mar;84(3):101-6

Oxygen toxicity. Carraway MS, et al.

HYPEROXIA

Respir Care Clin N Am 1999 Jun;5(2):265–95 (158 ref.)

Physiology of hyperbaric hyperoxia. Piantadosi CA.
Respir Care Clin N Am 1999 Mar;5(1):7–19, v (46 ref.)

The effect of hyperoxia on embryonic and organ mass in the developing chick embryo. van Golde J, et al.
Respir Physiol 1998 Jul;113(1):75–82

Glutathione in the cellular defense of human lung cells exposed to hyperoxia and high pressure. Djurhuus R, et al. **Undersea Hyperb Med** 1999 Summer;26(2):75–85

[Blood carbon dioxide tension and its effect on the oxygen transport in the rat brain during normobaric hyperoxia] Sokolova IB, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May-Jun;84(5–6):536–40 (Eng. Abstr.) **(Rus)**

[Reactivity to hyperoxia in disorders of autonomic regulation] Vorobiov KP. **Fiziol Zh** 1999;45(3):98–102 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

Carbon monoxide provides protection against hyperoxic lung injury. Otterbein LE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L688–94

Alarm settings for the Marquette 8000 pulse oximeter to prevent hyperoxic and hypoxic episodes. Cust AE, et al. **J Paediatr Child Health** 1999 Apr;35(2):159–62

THERAPY

Oxygen toxicity. Carraway MS, et al.
Respir Care Clin N Am 1999 Jun;5(2):265–95 (158 ref.)

VETERINARY

Specific blood flow reducing effects of hyperoxaemia on high flow capillaries in the pig brain. Sjöberg F, et al.
Acta Physiol Scand 1999 Jan;165(1):33–8

HYPERPARATHYROIDISM

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
OSTEITIS FIBROSA CYSTICA

Primary hyperparathyroidism of postmenopausal women. Prospective population-based case-control analysis on prevalence, clinical findings and treatment. Minireview based on a doctoral thesis. Lundgren E.
Ups J Med Sci 1999;104(2):87–130 (338 ref.)

[Primary hyperparathyroidism] Paillard M. **Rev Prat** 1998 Jun 1;48(11):1191–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of the localization of diseased glands in primary hyperparathyroidism: comparison of gammagraphy with 99mTc-sestamibi, echography and computerized tomography (letter; comment)] Piñero Madrona A, et al. **Med Clin (Barc)** 1998 Oct 31;111(14):558–9. Comment on: Med Clin (Barc) 1998 Mar 7;110(8):285–9. **(Spa)**

BLOOD

Beta 2-microglobulin does not behave as a biological marker of bone remodeling in patients with primary hyperparathyroidism. Broulik PD, et al. **Clin Chim Acta** 1998 Nov;278(1):61–6

Maintenance of serum calcium by parathyroid hormone-related peptide during lactation in a hypoparathyroid patient. Mather KJ, et al.
J Clin Endocrinol Metab 1999 Feb;84(2):424–7

Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment [letter; comment] Barna I, et al. **J Intern Med** 1999 Mar; 245(3):311–3. Comment on: J Intern Med 1998 Sep;244(3):241–9.

CHEMICALLY INDUCED

Pathology and outcome of surgical treatment for lithium-associated hyperparathyroidism. Abdullah H, et al. **Br J Surg** 1999 Jan;86(1):91–3

Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. Mak TW, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3857–9

CLASSIFICATION

Sporadic primary hyperparathyroidism in young patients: a separate disease entity? Harman CR, et al. **Arch Surg** 1999 Jun;134(6):651–5; discussion 655–6

COMPLICATIONS

Primary hyperparathyroidism and osteoporosis. Mazzuoli GF, et al. **Aging (Milano)** 1998 Jun;10(3):225–31 (75 ref.)

Brown tumor of the palate in a patient with primary hyperparathyroidism. Scott SN, et al.
Ann Otol Rhinol Laryngol 1999 Jan;108(1):91–4

Rapid improvement of osteoporosis following parathyroidectomy in a premenopausal woman with acute primary hyperparathyroidism. Tritos NA, et al.
Arch Intern Med 1999 Jul 12;159(13):1495–8

Clinical dilemma: A parathyroid adenoma cannot be found during neck exploration of a patient with presumed primary hyperparathyroidism. How should this problem be tackled? Rothmund M. **Br J Surg** 1999 Jun;86(6):725–6

Advanced skeletal manifestations in primary hyperparathyroidism. Agarwal A, et al. **Can J Surg** 1998 Oct;41(5):342–3

Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Piovesan A, et al.
Clin Endocrinol (Oxf) 1999 Mar;50(3):321–8

Tc-99m sestamibi uptake in a patient with gynecomastia: a potential pitfall in the diagnosis of breast cancer. Gellett LR, et al. **Clin Nucl Med** 1999 Jun;24(6):466

Hypocalcemia due to spontaneous infarction of parathyroid adenoma and osteomalacia in a patient with primary hyperparathyroidism. Otsuka F, et al. **Endocr J** 1998 Oct; 45(5):617–23

Coincidence of hot thyroid nodules and primary hyperparathyroidism. Klemm T, et al.
Exp Clin Endocrinol Diabetes 1999;107(5):295–8 (25 ref.)

Low back pain years after thyroid surgery. Archer TP, et al. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):127–30

Complete recovery from intractable bulimia nervosa by the surgical cure of primary hyperparathyroidism. Ozawa Y, et al. **Int J Eat Disord** 1999 Jul;26(1):107–10

Primary hyperparathyroidism and acute pancreatitis during pregnancy. Report of a case and a review of the English and Japanese literature. Kondo Y, et al.
Int J Pancreatol 1998 Aug;24(1):43–7 (24 ref.)

Changes in renal hemodynamics and tubular function of surgically cured primary hyperparathyroid patients are probably due to chronic hypercalcemic nephropathy. Farias ML, et al. **J Bone Miner Res** 1998 Nov; 13(11):1679–86

Coexistence of primary hyperparathyroidism and thyroid disease. Regal M, et al. **J Endocrinol Invest** 1999 Mar; 22(3):191–7

Co-existence of osteogenesis imperfecta and hyperparathyroidism. Zimmermann-Belsing T, et al.
J Endocrinol Invest 1999 Jul-Aug;22(7):547–50

Primary hyperparathyroidism presenting with pathological fracture. Deshmukh RG, et al. **J R Coll Surg Edinb** 1998 Dec;43(6):424–7

'The vanished occiput'. Freyschmidt J.
Nephrol Dial Transplant 1999 Feb;14(2):499–500

An uncommon aetiology of perforated gastric ulcer. Ahmad M, et al. **Postgrad Med J** 1999 Feb;75(880):113–4

Hypercalcaemia and abdominal pain. Scott-Coombes D, et al. **Postgrad Med J** 1998 Jun;74(872):377–8

Tumor-related osteomalacia followed after treatment by hyperparathyroidism. Heylen A, et al.
Rev Rhum Engl Ed 1999 Jan;66(1):53–7

Hyperparathyroidism and chronic pancreatitis. Smith MD, et al. **S Afr J Surg** 1999 Feb;37(1):12–4

Sigmoid colon cancer associated with primary hyperparathyroidism: report of a case. Kawamura YJ, et al. **Surg Today** 1999;29(8):789–90

Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. Mollerup CL, et al. **World J Surg** 1999 Feb;23(2):173–5; discussion 176

[Fahr syndrome and hyperparathyroidism (letter)] Ceccaldi B, et al. **Presse Med** 1999 Apr 3;28(13):689 **(Fre)**

[Cardiopulmonary parameters in hyperthyroidism] Nieswandt J, et al. **Med Klin** 1999 Jan 15;94(1):9–14 (Eng. Abstr.) **(Ger)**

[Diagnostic quiz. Unusual cause of ulcus vnetriculi] Füessl HS. **MMW Fortschr Med** 1999 Jun 17;141(24):53–4 **(Ger)**

[Space occupying lesion in the basis of the skull] Schulz-Ertner D, et al. **Radiologe** 1999 Feb;39(2):161–3 **(Ger)**

[Primary hyperparathyroidism and acute pancreatitis. A rare clinical association] Boneschi M, et al. **Minerva Chir** 1999 Jun;54(6):451–4 (Eng. Abstr.) **(Ita)**

[Markers of bone formation and resorption in primary and secondary hyperparathyroidism] Kosowicz J, et al.
Pol Arch Med Wewn 1998 Apr;99(4):287–97 (Eng. Abstr.) **(Pol)**

CONGENITAL

Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Pearce S, et al.
Clin Endocrinol (Oxf) 1999 Jun;50(6):691–3

DIAGNOSIS

Intrinsic limitations to unilateral parathyroid exploration. Moore FD Jr, et al. **Ann Surg** 1999 Sep;230(3):382–8; discussion 388–91

Primary hyperparathyroidism in pregnancy--report of 3 cases. Hsieh YY, et al. **Arch Gynecol Obstet** 1998; 261(4):209–14

Lymphoma infiltrate or hyperparathyroidism? Comment on the clinical image by Drosos and Bai [letter; comment] Kilcoyne RF. **Arthritis Rheum** 1999 Jul;42(7):1559–60. Comment on: Arthritis Rheum 1998 Dec;41(12):2275.

Hypercalcemic cardiomyopathy associated with primary hyperparathyroidism mimicking primary obstructive hypertrophic cardiomyopathy. Demers C, et al.
Can J Cardiol 1998 Nov;14(11):1397–400 (19 ref.)

Severe hyperparathyroidism with hypercalcemia associated with chronic renal failure at pre-dialysis stage. Takasaki I, et al. **Endocr J** 1999 Feb;46(1):167–71

The elevated serum alkaline phosphatase--the chase that led to two endocrinopathies and one possible unifying diagnosis. Li-Fern H, et al. **Eur J Endocrinol** 1999 Feb; 140(2):143–7

Reoperative parathyroidectomy in the era of localization technology. Rotstein L, et al. **Head Neck** 1998 Sep; 20(6):535–9

Diffuse pulmonary calcinosis and multiple soft tissue calcification in renal failure patient with pathological femoral fracture. al-Homrany M, et al.
Indian J Chest Dis Allied Sci 1998 Jul-Sep;40(3):205–11 (35 ref.)

Multiple endocrine neoplasia type IIa: a case report. Seeherunvong T, et al. **J Med Assoc Thai** 1998 Oct; 81(10):789–93

Lessons to be learned: a case study approach. Primary hyperparathyroidism simulating an acute severe polyneuritis. Olukoga A. **J R Soc Health** 1998 Apr; 118(2):103–6

A patient of primary hyperparathyroidism with full-blown bone changes simulating malignancy. Chuang TC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):584–9

Clinical profile of 128 subjects operated for primary hyperparathyroidism. Haddock L, et al.
P R Health Sci J 1998 Dec;17(4):309–16

Managing primary hyperparathyroidism. Gallacher S.
Practitioner 1999 Feb;243(1595):126–30 (7 ref.)

The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. James C, et al. **Surg Oncol Clin N Am** 1999 Jan;8(1):145–69 (114 ref.)

Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Lundgren E, et al.
Surgery 1998 Dec;124(6):980–5; discussion 985–6

[Enhance the diagnostic level of primary hyperparathyroidism in China (editorial)] Xu S.
Chung Hua I Hsueh Tsa Chih 1997 Jun;77(6):405–6 **(Chi)**

[Peroperative parathyroid hormone assay: assurance of successful surgical treatment of primary hyperparathyroidism] Smit PC, et al.
Ned Tijdschr Geneeskd 1999 Apr 3;143(14):742–6 (Eng. Abstr.) **(Dut)**

[Hematuria revealing primary hyperparathyroidism in a child] Ichay L, et al. **Arch Pediatr** 1999 Feb;6(2):182–5 (Eng. Abstr.) **(Fre)**

[Coexistence of two different neuroendocrine tumors of the upper gastrointestinal tract and of the pancreas] Pfeiffer A. **Dtsch Med Wochenschr** 1999 Jun 4;124(22):712–3 **(Ger)**

[Coexistence of two different neuroendocrine tumors of the upper gastrointestinal tract and of the pancreas (comment)] Ritter MR, et al. **Dtsch Med Wochenschr** 1999 Jun 4; 124(22):712; discussion 713. Comment on: Dtsch Med Wochenschr 1998 Dec 4;123(49):1472–7. **(Ger)**

[Multiple brown tumors of the paranasal sinuses in tertiary hyperparathyroidism] Pöckler-Schöniger C, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999 Jul;171(1):72–5 (10 ref.) **(Ger)**

[Primary hyperparathyroidism] Lorz B, et al.
Schweiz Rundsch Med Prax 1999 Jan 28;88(5):192–4 **(Ger)**

[A diagnostic strategy in persistent hyperparathyroidism] Valvano L, et al. **Minerva Chir** 1998 Jun;53(6):465–70 (Eng. Abstr.) **(Ita)**

[Diagnostic difficulties in primary hyperparathyroidism: a case report] Suchecki G, et al.
Chir Narzadow Ruchu Ortop Pol 1999;64(1):81–3 (Eng. Abstr.) **(Pol)**

[Primary hyperparathyroidism diagnosed as a multicentric giant cell tumor of bone--case report] Filarska D, et al. **Przegl Lek** 1998;55(10):549–51 (Eng. Abstr.) **(Pol)**

[Role of preoperative localization studies in the surgical treatment of primary hyperparathyroidism (letter; comment)] Alvarez Ruiz S. **Med Clin (Barc)** 1998 Nov 21; 111(17):679. Comment on: Med Clin (Barc) 1998 Mar 7;110(8):285–9. **(Spa)**

[Fulminant acute pancreatitis caused by a large parathyroid adenoma. Hyperparathyroidism was diagnosed after 5 years] Meldahl I, et al. **Lakartidningen** 1999 May 26; 96(21):2603–6 **(Swe)**

DRUG THERAPY

Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Kakuta T, et al. **Am J Kidney Dis** 1999 Jun;33(6):1091–9

Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Goldenberg MM. **Clin Ther** 1999 Mar;21(3):432–41 (27 ref.)

Parathyroid hormone after adenectomy for primary hyperparathyroidism. A study of peptide hormone elimination kinetics in humans. Maier GW, et al.
J Clin Endocrinol Metab 1998 Nov;83(11):3852–6

Hyperphosphatemia: a serious limiting factor preventing the possible benefit from intravenous calcitriol therapy [letter] Arik N, et al. **Nephron** 1999;82(1):77–8

ECONOMICS

Re: Cost utility of routine imaging with Tc-99m-Sestamibi in primary hyperparathyroidism before initial surgery [letter; comment] Denham DW, et al. **Am Surg** 1999 Aug; 65(8):796–7. Comment on: Am Surg 1998 May;64(5):391–5; discussion 395–6.

Cost implications of different surgical management strategies

for primary hyperparathyroidism. Sosa JA, et al. **Surgery** 1998 Dec;124(6):1028–35; discussion 1035–6

ETIOLOGY

Hyperparathyroidism in congestive heart failure [letter; comment] Field MH. **Am J Med** 1999 Jul;107(1):102–3. Comment on: Am J Med 1997 Sep;103(3):197–207. Comment on: Am J Med 1998 May;104(5):508–9.

You're the flight surgeon. Parathyroid adenoma with primary hyperparathyroidism, recurrent renal calculi, and brown tumor. Funke BJ. **Aviat Space Environ Med** 1998 Oct; 69(10):1013–4

Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Miller MA, et al. **Bone** 1998 Sep;23(3):257–66

Ganglioneuromatous polyposis of the colon associated with adenocarcinoma and primary hyperparathyroidism. Macenlle R, et al. **Eur J Gastroenterol Hepatol** 1999 Apr; 11(4):447–50

Effects of age, gender and hyperparathyroidism on lean body mass in hemodialysis patients. Trovato GM, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar–Apr;2(2):89–95

Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis [letter; comment] Shaker JL, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):384–5. Comment on: J Clin Endocrinol Metab 1998 Jan;83(1):93–8.

Effect of dietary phosphate restriction on renal secondary hyperparathyroidism in the cat. Barber PJ, et al. **J Small Anim Pract** 1999 Feb;40(2):62–70

Molecular pathogenesis of secondary hyperparathyroidism in renal failure: basic and clinical aspects. Fukagawa M, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:61–2 (19 ref.)

Hyperphosphatemia: a serious limiting factor preventing the possible benefit from intravenous calcitriol therapy [letter] Arik N, et al. **Nephron** 1999;82(1):77–8

Bilateral hemothorax revealing mediastinal parathyroid adenoma. Santelmo N, et al. **Respiration** 1999;66(2):176–8

Hypercalcemia and multiple pulmonary nodules. Zurkirchen M, et al. **Respiration** 1998;65(4):331–2

Use of parathyroidectomy to treat hyperparathyroidism that persists after kidney transplantation. Morimoto Y, et al. **Transplant Proc** 1998 Nov;30(7):3049

[Diagnostic difficulties in primary hyperparathyroidism: a case report] Suchecki G, et al. **Chir Narzadow Ruchu Ortop Pol** 1999;64(1):81–3 (Eng. Abstr.) **(Pol)**

[Influence of alphacalcidole on selected markers of the bone turnover in hemodialysed patients with secondary hyperparathyroidism] Nowak Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):288–91 (Eng. Abstr.) **(Pol)**

[Four cases of parathyroid cancer] Chew-Wong A, et al. **Rev Invest Clin** 1998 May–Jun;50(3):239–44 (Eng. Abstr.) **(Spa)**

GENETICS

BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients. Tagliabue J, et al. **Am J Clin Pathol** 1999 Sep;112(3):366–70

Hyperparathyroidism-jaw tumor syndrome: the HRPT2 locus is within a 0.7-cM region on chromosome 1q. Hobbs MR, et al. **Am J Hum Genet** 1999 Feb;64(2):518–25

A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors [letter] Teh BT, et al. **Am J Hum Genet** 1998 Nov;63(5):1544–9

Novel V184E MEN1 germline mutation in a Japanese kindred with familial hyperparathyroidism. Fujimori M, et al. **Am J Med Genet** 1998 Nov 16;80(3):221–2

Lack of relationship between BsmI vitamin D receptor polymorphism and primary hyperparathyroidism in a Spanish female population. Menárguez J, et al. **Calcif Tissue Int** 1999 Sep;65(3):214–6

Parathyroid hormone gene polymorphisms in primary hyperparathyroidism. Kanzawa M, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):583–8

Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Wassif WS, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):191–6

Germline mutation of the multiple endocrine neoplasia type 1 (MEN1) gene in a family with primary hyperparathyroidism. Ohye H, et al. **Endocr J** 1998 Dec; 45(6):719–23

Familial isolated hyperparathyroidism caused by single adenoma: a distinct entity different from multiple endocrine neoplasia. Watanabe T, et al. **Endocr J** 1998 Oct; 45(5):637–46 (50 ref.)

Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguese kindred to chromosome 1q22–q31. Williamson C, et al. **J Bone Miner Res** 1999 Feb;14(2):230–9

The vitamin D receptor (VDR) start codon polymorphism in primary hyperparathyroidism and parathyroid VDR messenger ribonucleic acid levels. Correa P, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1690–4

Autosomal dominant hypoparathyroidism associated with short stature and premature osteoarthritis. Stock JL, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3036–40

Microsatellite instability and loss of heterozygosity in primary and secondary proliferative lesions of the parathyroid gland. Koshiishi N, et al. **Lab Invest** 1999 Sep;79(9):1051–8

Dominantly inherited isolated hyperparathyroidism: a syndromic association? Kozlowski K, et al. **Pediatr Radiol** 1999 Jan;29(1):10–5

Familial hyperparathyroidism: report of a case. Abe H, et al. **Surg Today** 1999;29(1):63–6

METABOLISM

Vitamin D and the parathyroid. Beckerman P, et al. **Am J Med Sci** 1999 Jun;317(6):363–9 (75 ref.)

Clinical assessment of collagen cross-linked N-telopeptides as a marker of bone metabolism in patients with primary hyperparathyroidism. Takami H, et al. **Biomed Pharmacother** 1999 Aug;53(7):329–33

Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Christiansen P, et al. **Bone** 1999 Aug; 25(2):237–44

Relationship between Ca-dependent change of serum PTH and extracellular Ca2+-sensing receptor expression in parathyroid adenoma. Kaneko C, et al. **Calcif Tissue Int** 1999 Mar;64(3):271–2

Is there a relationship between 99mTc-Sestamibi uptake and oxyphil cell content in hyperparathyroidism? [letter; comment] Staudenherz A, et al. **J Nucl Med** 1999 Aug; 40(8):1402–3. Comment on: J Nucl Med 1998 Aug;39(8):1441–4.

Expression of the alpha- and beta-subunits of human chorionic gonadotropin by subsets of parathyroid cells in states of hyperparathyroidism. Carlinfante G, et al. **J Pathol** 1998 Aug;185(4):389–93

Expression of stem cell factor by osteoblasts in normal and hyperparathyroid bone: relation to ectopic mast cell differentiation. Blair HC, et al. **Virchows Arch** 1999 Jul; 435(1):50–7

Immunohistochemical detection of human mtDNA polymerase gamma and of human mitochondrial transcription factor A in cytochrome-c-oxidase-deficient oxyphil cells of hyperfunctional parathyroids. Müller-Höcker J, et al. **Virchows Arch** 1998 Dec; 433(6):529–36

MORTALITY

Death risk factor analysis in primary hyperparathyroidism. Hedbäck G, et al. **Eur J Clin Invest** 1998 Dec;28(12):1011–8

Survival of patients operated on for primary hyperparathyroidism [letter; comment] Hedbäck G, et al. **Surgery** 1999 Feb;125(2):240–1. Comment on: Surgery 1997 Dec;122(6):1117–23.

PATHOLOGY

Effects of age, gender and hyperparathyroidism on lean body mass in hemodialysis patients. Trovato GM, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar–Apr;2(2):89–95

Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Martin LN, et al. **Histopathology** 1998 Jul;33(1):46–51

Heterogeneous gland size in sporadic multiple gland parathyroid hyperplasia. Berger AC, et al. **J Am Coll Surg** 1999 Apr;188(4):382–9

On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. Dempster DW, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1562–6

Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Kovacs KA, et al. **Medicine (Baltimore)** 1998 Nov;77(6):398–402 (26 ref.)

PHYSIOPATHOLOGY

Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure [letter; comment] Diez-Perez A, et al. **Am J Med** 1998 Oct;105(4):358–9. Comment on: Am J Med 1997 Sep;103(3):197–207.

Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Neunteufl T, et al. **Cardiovasc Res** 1998 Nov;40(2):396–401

Pseudohypohyperparathyroidism-pseudohypoparathyroidism type Ib [letter] Farfel Z. **J Bone Miner Res** 1999 Jun;14(6):1016

Organ calcification in renal hyperparathyroidism [letter; comment] Goldsmith D. **J R Soc Med** 1998 Nov;91(11):611 . Comment on: J R Soc Med 1998 Aug;91(8):430–1.

Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery. Bernini G, et al. **Metabolism** 1999 Mar;48(3):298–300

A pain in the arm. Kettritz R, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1593–4

PREVENTION & CONTROL

No effect of vitamin K1 supplementation on biochemical bone markers in haemodialysis patients [letter] Reichel H. **Nephrol Dial Transplant** 1999 Jan;14(1):249–50

RADIONUCLIDE IMAGING

Re: Cost utility of routine imaging with Tc-99m-Sestamibi in primary hyperparathyroidism before initial surgery [letter; comment] Denham DW, et al. **Am Surg** 1999 Aug; 65(8):796–7. Comment on: Am Surg 1998 May;64(5):391–5; discussion 395–6.

Quantitative comparison of technetium-99m tetrofosmin and thallium-201 images of the thyroid and abnormal parathyroid glands. Giordano A, et al. **Eur J Nucl Med** 1999 Aug;26(8):907–11

Preoperative localization procedures for initial surgery in primary hyperparathyroidism. Huang SH, et al. **J Formos Med Assoc** 1998 Oct;97(10):679–83

On the comparison of correlated proportions for clustered data. Obuchowski NA. **Stat Med** 1998 Jul 15; 17(13):1495–507

The efficacy of technetium-99m-MIBI scan and intraoperative methylene blue staining for the localization of abnormal parathyroid glands. Takei H, et al. **Surg Today** 1999;29(4):307–12

Minimally invasive radioguided parathyroidectomy in the reoperative neck. Norman J, et al. **Surgery** 1998 Dec; 124(6):1088–92; discussion 1092–3

SURGERY

Success of cervical exploration for patients with asymptomatic primary hyperparathyroidism. Coston SD, et al. **Am J Surg** 1999 Jan;177(1):69–74

99m-Technetium sestamibi localized solitary parathyroid adenoma as an indication for limited unilateral surgical exploration. Gupta VK, et al. **Am J Surg** 1998 Nov; 176(5):409–12

Hyperparathyroidism and pregnancy. Kort KC, et al. **Am J Surg** 1999 Jan;177(1):66–8 (27 ref.)

Ultrasound-guided unilateral neck exploration for sporadic primary hyperparathyroidism: is it worthwhile? Ammori BJ, et al. **Ann R Coll Surg Engl** 1998 Nov;80(6):433–7

Primary hyperparathyroidism: a surgical perspective. Wheeler MH. **Ann R Coll Surg Engl** 1998 Sep;80(5):305–12 (26 ref.)

Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay. Irvin GL 3rd, et al. **Ann Surg** 1999 Jun;229(6):874–8; discussion 878–9

Bilateral neck exploration under hypnosedation: a new standard of care in primary hyperparathyroidism? Meurisse M, et al. **Ann Surg** 1999 Mar;229(3):401–8

Intrinsic limitations to unilateral parathyroid exploration. Moore FD Jr, et al. **Ann Surg** 1999 Sep;230(3):382–8; discussion 388–91

Mediastinal parathyroid cysts revisited. Shields TW, et al. **Ann Thorac Surg** 1999 Feb;67(2):581–90 (75 ref.)

Rapid improvement of osteoporosis following parathyroidectomy in a premenopausal woman with acute primary hyperparathyroidism. Tritos NA, et al. **Arch Intern Med** 1999 Jul 12;159(13):1495–8

Effect of surgeon expertise on the outcome in primary hyperparathyroidism. Willeke F, et al. **Arch Surg** 1998 Oct; 133(10):1066–70; discussion 1071

Reoperative surgery for recurrent or persistent primary hyperparathyroidism: comment [letter; comment] Talbot ML, et al. **Aust N Z J Surg** 1999 May;69(5):395–6. Comment on: Aust N Z J Surg 1998 Feb;68(2):103–7.

Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Christiansen P, et al. **Bone** 1999 Aug; 25(2):237–44

Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Piovesan A, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):321–8

Inappropriate elevation of intact PTH in the presence of normocalcemia after successful surgery for primary hyperparathyroidism. Mimura Y, et al. **Endocr J** 1998 Oct; 45(5):609–16

Parathyroidectomy via bilateral cervical exploration: a retrospective review of 866 cases. Low RA, et al. **Head Neck** 1998 Oct;20(7):583–7

Reoperative parathyroidectomy in the era of localization technology. Rotstein L, et al. **Head Neck** 1998 Sep; 20(6):535–9

Complete recovery from intractable bulimia nervosa by the surgical cure of primary hyperparathyroidism. Ozawa Y, et al. **Int J Eat Disord** 1999 Jul;26(1):107–10

Changes in renal hemodynamics and tubular function of surgically cured primary hyperparathyroid patients are probably due to chronic hypercalcemic nephropathy. Farias ML, et al. **J Bone Miner Res** 1998 Nov; 13(11):1679–86

Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. Abdelhadi M, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3845–51

Therapeutic controversies in primary hyperparathyroidism. Silverberg SJ, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2275–85

Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment [letter; comment] Barna I, et al. **J Intern Med** 1999 Mar; 245(3):311–3. Comment on: J Intern Med 1998 Sep;244(3):241–9.

Minimally invasive videoscopic parathyroidectomy by lateral approach. Henry JF, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):298–301

Minimal-access parathyroid surgery using intraoperative parathyroid hormone assay. Sofferman RA, et al.

Laryngoscope 1998 Oct;108(10):1497–503

Renin–angiotensin–aldosterone system in primary hyperparathyroidism before and after surgery. Bernini G, et al. **Metabolism** 1999 Mar;48(3):298–300

Surgical correction of primary hyperparathyroidism improves quality of life. Burney RE, et al. **Surgery** 1998 Dec;124(6):987–91; discussion 991–2

Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Burney RE, et al. **Surgery** 1999 Jun;125(6):608–14

Survival of patients operated on for primary hyperparathyroidism [letter; comment] Hedbäck G, et al. **Surgery** 1999 Feb;125(2):240–1. Comment on: Surgery 1997 Dec;122(6):1117–23.

Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Hellman P, et al. **Surgery** 1998 Dec;124(6):993–9

Tertiary hyperparathyroidism after renal transplantation: surgical strategy. Kilgo MS, et al. **Surgery** 1998 Oct; 124(4):677–83; discussion 683–4

Subcutaneous parathyroid autografts [letter; comment] Kinnaert P, et al. **Surgery** 1999 Apr;125(4):462–3. Comment on: Surgery 1998 Jul;124(1):1–5.

Endoscopic parathyroidectomy: report of an initial experience. Miccoli P, et al. **Surgery** 1998 Dec; 124(6):1077–9; discussion 1079–80

Minimally invasive radioguided parathyroidectomy in the reoperative neck. Norman J, et al. **Surgery** 1998 Dec; 124(6):1088–92; discussion 1092–3

Cost implications of different surgical management strategies for primary hyperparathyroidism. Sosa JA, et al. **Surgery** 1998 Dec;124(6):1028–35; discussion 1035–6

[Personal experience with treatment of primary hyperparathyroidism] Vlasák V, et al. **Acta Medica (Hradec Kralove) Suppl** 1997;40(2):101–2 (Eng. Abstr.) **(Cze)**

[Peroperative parathyroid hormone assay: assurance of successful surgical treatment of primary hyperparathyroidism] Smit PC, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):742–6 (Eng. Abstr.) **(Dut)**

[Videocervicoscopy in surgery of primary hyperparathyroidism. Preliminary study of 19 patients] Cougard P, et al. **Ann Chir** 1998;52(9):885–9 (Eng. Abstr.) **(Fre)**

[Anesthesia and postoperative recovery for parathyroid gland surgery] Roland E. **Ann Chir** 1999;53(2):150–61 (48 ref.) (Eng. Abstr.) **(Fre)**

[End-stage renal failure following parathyroidectomy for advanced primary hyperparathyroidism] Laroche M, et al. **Rev Med Interne** 1998 Nov;19(11):787–91 (Eng. Abstr.) **(Fre)**

[Improvement of diabetes mellitus after excision of a parathyroid adenoma] Gerl H, et al. **Wien Klin Wochenschr** 1998 Dec 11;110(23):841–4 (Eng. Abstr.) **(Ger)**

[99mTc-MIBI-scintigraphy before parathyroid surgery?] Walgenbach S, et al. **Zentralbl Chir** 1999;124(3):214–9 (Eng. Abstr.) **(Ger)**

[Primary hyperparathyroidism. Critical analysis of a 20-year experience] Favia G, et al. **Ann Ital Chir** 1999 May–Jun; 70(3):399–403 (Eng. Abstr.) **(Ita)**

[Surgical treatment of parathyroid hyperplasia] Poletti EM, et al. **Minerva Chir** 1998 Dec;53(12):1009–13 (Eng. Abstr.) **(Ita)**

[Role of preoperative localization studies in the surgical treatment of primary hyperparathyroidism (letter; comment)] Alvarez Ruiz S. **Med Clin (Barc)** 1998 Nov 21; 111(17):679. Comment on: Med Clin (Barc) 1998 Mar 7;110(8):285–9. **(Spa)**

[A Scandinavian multicenter study will investigate the question: surgery or not in mild primary hyperparathyroidism?] Lundgren E, et al. **Lakartidningen** 1999 Mar 24;96(12):1479–80 (Eng. Abstr.) **(Swe)**

THERAPY

Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Harman CR, et al. **Surgery** 1998 Dec; 124(6):1011–9; discussion 1019–20

[One more time! Treatment of borderline primary hyperparathyroidism (letter)] Mollerup CL, et al. **Ugeskr Laeger** 1999 Mar 15;161(11):1621–2 **(Dan)**

[Treatment of primary hyperparathyroidism (letter; comment)] Sørensen HA, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):56–7. Comment on: Ugeskr Laeger 1997 Feb 24;159(9):1252–6. **(Dan)**

ULTRASONOGRAPHY

Ultrasound-guided unilateral neck exploration for sporadic primary hyperparathyroidism: is it worthwhile? Ammori BJ, et al. **Ann R Coll Surg Engl** 1998 Nov;80(6):433–7

Preoperative localization procedures for initial surgery in primary hyperparathyroidism. Huang SH, et al. **J Formos Med Assoc** 1998 Oct;97(10):679–83

Color-Doppler in the imaging work-up of primary hyperparathyroidism. Meola M, et al. **J Nephrol** 1999 Jul–Aug;12(4):270–4

VETERINARY

Percutaneous ultrasound-guided chemical parathyroid ablation for treatment of primary hyperparathyroidism in dogs. Long CD, et al. **J Am Vet Med Assoc** 1999 Jul 15; 215(2):217–21

Resolution of metastatic calcification in the paws of a cat with successful dietary management of renal hyperparathyroidism. Jackson HA, et al. **J Small Anim Pract** 1998 Oct;39(10):495–7

Rat hypoplastic kidney (hpk/hpk) induces renal anemia, hyperparathyroidism, and osteodystrophy at the end stage of renal failure. Suzuki H, et al. **J Vet Med Sci** 1998 Oct; 60(10):1051–8

HYPERPARATHYROIDISM, SECONDARY

Resolution of hyperparathyroidism associated with immunosuppressive therapy. Jassal SV, et al. **Clin Nephrol** 1998 Nov;50(5):326–9

BLOOD

Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic bone disease. Weinreich T, et al. **Clin Nephrol** 1999 Jan;51(1):27–33

Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. Schmitt CP, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1832–44

[Intraoperative blood sampling for parathyroid hormone measurement during total parathyroidectomy and autotransplantation in patients with renal hyperparathyroidism] Koeberle-Wuehrer R, et al. **Wien Klin Wochenschr** 1999 Mar 26;111(6):246–50 (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Secondary hyperparathyroidism exacerbation: a rare side-effect of interferon-alpha? Calvino J, et al. **Clin Nephrol** 1999 Apr;51(4):248–51 (23 ref.)

COMPLICATIONS

Update on renal osteodystrophy: pathogenesis and clinical management. Sakhaee K, et al. **Am J Med Sci** 1999 Apr; 317(4):251–60 (66 ref.)

Brown tumor in association with secondary hyperparathyroidism. A case report and review of the literature. Balon BP, et al. **Am J Nephrol** 1998;18(5):460–3

Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency. Bruce DG, et al. **J Am Geriatr Soc** 1999 Mar;47(3):354–9

Bone loss in celiac disease is related to secondary hyperparathyroidism. Selby PL, et al. **J Bone Miner Res** 1999 Apr;14(4):652–7

Calcification of the small bowel in renal hyperparathyroidism [see comments] Morris-Stiff GJ, et al. **J R Soc Med** 1998 Aug;91(8):430–1. Comment in: J R Soc Med 1998 Nov;91(11):611.

DIAGNOSIS

Unknown case. Dockery WD, et al. **Spine** 1999 Jan 15; 24(2):198–9

[A diagnostic strategy in persistent hyperparathyroidism] Valvano L, et al. **Minerva Chir** 1998 Jun;53(6):465–70 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Calcium balance during pulse alfacalcidol therapy for secondary hyperparathyroidism in CAPD patients treated with 1.0 and 1.25 mmol/L dialysate calcium. Chagnac A, et al. **Am J Kidney Dis** 1999 Jan;33(1):82–6

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Llach F, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S48–54

Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Martin KJ, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S61–6

Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Park CW, et al. **Am J Kidney Dis** 1999 Jan;33(1):73–81

Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Slatopolsky E, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S40–7

Medical management of secondary hyperparathyroidism in uremia. Drüeke TB. **Am J Med Sci** 1999 Jun;317(6):383–9 (51 ref.)

Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements. Teruel JL, et al. **Am J Nephrol** 1999;19(3):428–32

A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Chertow GM, et al. **Clin Nephrol** 1999 Jan;51(1):18–26

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. Martin KJ, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1427–32

The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure. Cardinal H, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3839–44

Clinical outcome of calcitriol therapy and patient education program on hyperparathyroidism. Poole R, et al. **J Ren Nutr** 1999 Apr;9(2):95–8

22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Monier-Faugere MC, et al. **Kidney Int** 1999 Mar; 55(3):821–32

Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Rodriguez M, et al. **Kidney Int** 1999 Jul;56(1):306–17

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Salusky IB, et al. **Kidney Int** 1998 Sep;54(3):907–14

Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Fletcher S, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3111–7

Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism [letter] Boran M, et al. **Nephron** 1998 Sep;80(1):119–20

Calcium and vitamin D are effective in preventing fractures in elderly people by reversing senile secondary hyperparathyroidism [editorial] Meunier PJ. **Osteoporos Int** 1998;8 Suppl 2:S1–2

Consequences of intermittent calcitriol therapy in pediatric patients with secondary hyperparathyroidism. Salusky IB, et al. **Perit Dial Int** 1999;19 Suppl 2:S441–4

EPIDEMIOLOGY

[Prevalence of secondary hyperparathyroidism in patients aged 80 and over] Jensen ON. **Ugeskr Laeger** 1999 Apr 19;161(16):2362–4 (Eng. Abstr.) **(Dan)**

ETIOLOGY

Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus. Bover J, et al. **Bone** 1999 Sep;25(3):279–85

Patients with analgetic nephropathy on chronic hemodialysis have a high incidence of severe secondary hyperparathyroidism. Pecovnik Balon B, et al. **Clin Nephrol** 1998 Dec;50(6):347–51

Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. Indridason OS, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3860–6

Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Ghazali A, et al. **Kidney Int** 1999 Jun; 55(6):2169–77

Persistent secondary hyperparathyroidism after renal transplantation. Messa P, et al. **Kidney Int** 1998 Nov; 54(5):1704–13

Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Rodriguez M, et al. **Kidney Int** 1999 Jul;56(1):306–17

The role of calcium-sensing receptor abnormality in the pathogenesis of secondary hyperparathyroidism. Akizawa T, et al. **Nephrol Dial Transplant** 1999;14 Suppl 1:66–7

Hypercalcemia and hyperparathyroidism after renal transplantation [letter] Apaydin S, et al. **Nephron** 1999; 81(3):364–5

Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. McKenna MJ, et al. **Osteoporos Int** 1998;8 Suppl 2:S3–6 (38 ref.)

Secondary hyperparathyroidism is an expected consequence of parathyroidectomy for primary hyperparathyroidism: a prospective study. Mandal AK, et al. **Surgery** 1998 Dec; 124(6):1021–6; discussion 1026–7

[Evaluation of clinical utility of 99mTc-MIBI scintigraphy in the localization of hyperfunctioning parathyroid lesions in patients with hyperparathyroidism—a report of multicenter phase III clinical trials] Kusakabe K, et al. **Kaku Igaku** 1998 Nov;35(9):887–99 (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic alterations in primary and secondary hyperparathyroidism. Shan L, et al. **Pathol Int** 1998 Aug; 48(8):569–74 (55 ref.)

METABOLISM

The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Slatopolsky E, et al. **Am J Med Sci** 1999 Jun;317(6):370–6 (40 ref.)

Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. Graham KA, et al. **J Am Soc Nephrol** 1997 Apr;8(4):627–31

Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L–1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. Brandi L, et al. **J Intern Med** 1998 Aug;244(2):121–31

Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Matsushita H, et al. **Kidney Int** 1999 Jan;55(1):130-8

PATHOLOGY

Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Matsushita H, et al. **Kidney Int** 1999 Jan;55(1):130-8

PHYSIOPATHOLOGY

Pathogenesis and treatment of secondary hyperparathyroidism in chronic renal disease [editorial] Cannella G, et al. **Int J Artif Organs** 1999 Jan;22(1):1-7

Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. Felsenfeld AJ, et al. **J Am Soc Nephrol** 1999 Apr;10(4):878-90 (57 ref.)

Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Sanchez CP, et al. **Kidney Int** 1998 Dec;54(6):1879-87

PREVENTION & CONTROL

Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism. Vlassopoulos D, et al. **Ren Fail** 1999 Mar;21(2):199-207

RADIONUCLIDE IMAGING

Double-phase Tc-99m sestamibi scintigraphy in a patient with uremia and secondary hyperparathyroidism: an aid for subtotal parathyroidectomy. Valli N, et al. **Clin Nucl Med** 1999 Mar;24(3):189-91

Quantitative comparison of technetium-99m tetrofosmin and thallium-201 images of the thyroid and abnormal parathyroid glands. Giordano A, et al. **Eur J Nucl Med** 1999 Aug;26(8):907-11

Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography. Neumann DR, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3867-71

SURGERY

Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Stracke S, et al. **Am J Kidney Dis** 1999 Feb;33(2):304-11

Surgical management of secondary hyperparathyroidism in uremia. Tominaga Y. **Am J Med Sci** 1999 Jun;317(6):390-7 (50 ref.)

Prospective evaluation of total parathyroidectomy and autotransplantation for the treatment of secondary hyperparathyroidism. Zaraca F, et al. **Arch Surg** 1999 Jan; 134(1):68-72

Prospective study of parathyroid graft function in patients with renal hyperparathyroidism after total parathyroidectomy and heterotopic autotransplantation by measurement of the intact parathyroid hormone concentrations in both antecubital veins. Walgenbach S, et al. **Eur J Surg** 1999 Apr;165(4):343-50

Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. Abdelhadi M, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3845-51

Advancing medical care: the role of nuclear medicine in radioguided surgery [news] Kotz D. **J Nucl Med** 1998 Oct; 39(10):13N-14N, 22N

Minimally invasive radioguided parathyroidectomy: an endocrine surgeon's perspective [news] Norman JG. **J Nucl Med** 1998 Oct;39(10):15N, 24N

Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism [see comments] Hindié E, et al. **Lancet** 1999 Jun 26; 353(9171):2200-4. Comment in: Lancet 1999 Jun 26;353(9171):2174-5.

Preoperative parathyroid scanning in secondary hyperparathyroidism [comment] Wheeler MH. **Lancet** 1999 Jun 26;353(9171):2174-5. Comment on: Lancet 1999 Jun 26;353(9171):2200-4.

Long-term follow-up after subtotal parathyroidectomy in patients with renal failure. Yu I, et al. **Laryngoscope** 1998 Dec;108(12):1824-8

Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Hampl H, et al. **Miner Electrolyte Metab** 1999 May-Jun;25(3):161-70

Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Fletcher S, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3111-7

Tumoral calcinosis regression after subtotal parathyroidectomy: a case presentation and review of the literature. Thakur A, et al. **Surgery** 1999 Jul;126(1):95-8 (10 ref.)

Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. Chou FF, et al. **World J Surg** 1999 May;23(5):452-6; discussion 456-7

THERAPY

Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Llach F, et al. **Am J Kidney Dis** 1998 Oct;32(2 Suppl 2):S3-12 (72 ref.)

Superior thyroid artery lesion after US-guided chemical parathyroidectomy: angiographic diagnosis and treatment by embolization. Perona F, et al. **Cardiovasc Intervent Radiol** 1999 May-Jun;22(3):249-50

Pathogenesis and treatment of secondary hyperparathyroidism in chronic renal disease [editorial] Cannella G, et al. **Int J Artif Organs** 1999 Jan;22(1):1-7

Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly. Chel VG, et al. **J Bone Miner Res** 1998 Aug;13(8):1238-42

[Therapy of secondary hyperparathyroidism] Stein G. **Dtsch Med Wochenschr** 1999 Feb 5;124(5):133-4 **(Ger)**

HYPERPHAGIA

see related

OBESITY

The metabolic syndrome: overeating, inactivity, poor compliance or 'dud' advice? Petrie JR, et al. **Diabet Med** 1998 Nov;15 Suppl 3:S29-31 (25 ref.)

Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? Holte J. **J Endocrinol Invest** 1998 Oct;21(9):589-601 (101 ref.)

Genetically determined obesity in Prader-Willi syndrome: the ethics and legality of treatment. Holland AJ, et al. **J Med Ethics** 1999 Jun;25(3):230-6

Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Williams CM, et al. **Psychopharmacology (Berl)** 1999 Apr;143(3):315-7

CHEMICALLY INDUCED

Mirtazepine causing hyperphagia [letter] Abed RT, et al. **Br J Psychiatry** 1999 Feb;174:181

Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Bergen HT, et al. **Endocrinology** 1998 Nov;139(11):4483-8

Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats. Leventhal L, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):538-44

Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Kask A, et al. **Neuroreport** 1999 Mar 17;10(4):707-11

Role of the ventromedial hypothalamus in prolactin-induced hyperphagia in ring doves. Buntin JD, et al. **Physiol Behav** 1999 Apr;66(2):255-61

Hyperphagia in pre-fed rats following oral delta9-THC. Williams CM, et al. **Physiol Behav** 1998 Nov 15;65(2):343-6

ETIOLOGY

Effects of palatability-induced hyperphagia and food restriction on mRNA levels of neuropeptide-Y in the arcuate nucleus. Kim EM, et al. **Brain Res** 1998 Sep 21; 806(1):117-21

Low plasma leptin levels contribute to diabetic hyperphagia in rats. Sindelar DK, et al. **Diabetes** 1999 Jun;48(6):1275-80

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene [see comments] Nonogaki K, et al. **Nat Med** 1998 Oct; 4(10):1152-6. Comment in: Nat Med 1998 Oct;4(10):1124-5.

Hyperphagia induced by hypoglycemia in rats is independent of leptin and hypothalamic neuropeptide Y (NPY). Dryden S, et al. **Peptides** 1998;19(9):1549-55

GENETICS

Ontogeny of hyperphagia in the Zucker (fa/fa) rat: role of neuropeptide Y. Kowalski TJ. **Appetite** 1999 Apr;32(2):275

Mahogany (mg) stimulates feeding and increases basal metabolic rate independent of its suppression of agouti. Dinulescu DM, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12707-12

METABOLISM

Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating. Inoue K, et al. **Biol Psychiatry** 1998 Dec 15;44(12):1329-36

Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Bergen HT, et al. **Endocrinology** 1998 Nov;139(11):4483-8

Role of the CNS melanocortin system in the response to overfeeding. Hagan MM, et al. **J Neurosci** 1999 Mar 15; 19(6):2362-7

Neuropeptide Y release in the paraventricular nucleus is decreased during transient hyperphagia induced by microinjection of colchicine into the ventromedial nucleus of rats. Jain MR, et al. **Neurosci Lett** 1998 Oct 30; 256(1):21-4

[The effect of overfeeding the young in early postnatal ontogeny on brown fatty tissue] Medvedev LN, et al. **Ontogenez** 1999 Jan-Feb;30(1):61-3 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Ontogeny of hyperphagia in the Zucker (fa/fa) rat. Kowalski TJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1106-9

Hypothalamic galanin is upregulated during hyperphagia. Kalra PS, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:432-4

Disruption of neural signaling within the hypothalamic ventromedial nucleus upregulates galanin gene expression in association with hyperphagia: an in situ hybridization analysis. Pu S, et al. **Brain Res Mol Brain Res** 1999 Jan 22;64(1):85-91

Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats. Alemzadeh R, et al. **Endocrinology** 1999 Jul; 140(7):3197-202

A rose is a rose is a rose--or is it? [editorial; comment] Zeitler P. **J Pediatr** 1999 Aug;135(2 Pt 1):142-4. Comment on: J Pediatr 1999 Aug;135(2 Pt 1):162-8.

Diazepam-induced hyperphagia in mice is sensitive to quinpirole. Rahminiwati M, et al. **J Vet Med Sci** 1999 Jul; 61(7):777-80

Role of nonexercise activity thermogenesis in resistance to fat gain in humans [see comments] Levine JA, et al. **Science** 1999 Jan 8;283(5399):212-4. Comment in: Science 1999 Jan 8;283(5399):184-5. Comment in: Science 1999 May 14;284(5417):1125-6.

Beyond sloth--physical activity and weight gain [comment] Ravussin E, et al. **Science** 1999 Jan 8;283(5399):184-5. Comment on: Science 1999 Jan 8;283(5399):212-4.

PSYCHOLOGY

Body image alterations in binge eating disorder [letter] Adami GF, et al. **Can J Psychiatry** 1998 Dec;43(10):1052-3

Feeding laboratory studies in patients with eating disorders: a review. Mitchell JE, et al. **Int J Eat Disord** 1998 Sep; 24(2):115-24 (21 ref.)

Natural history of hyperphagia and other eating changes in dementia. Keene J, et al. **Int J Geriatr Psychiatry** 1998 Oct;13(10):700-6

REHABILITATION

Case report: treatment of a woman with alcohol and binge eating problems. Dawe S, et al. **J Behav Ther Exp Psychiatry** 1998 Sep;29(3):249-60

THERAPY

Group cognitive-behavioral treatment of binge eating disorder: a comparison of therapist-led versus self-help formats. Peterson CB, et al. **Int J Eat Disord** 1998 Sep; 24(2):125-36

HYPERPIGMENTATION

Specification and migration of melanoblasts at the vagal level and in hyperpigmented Silkie chickens. Reedy MV, et al. **Dev Dyn** 1998 Dec;213(4):476-85

Cole-Engman syndrome associated with leukoplakia of the tongue: a case report. Tanaka A, et al. **J Oral Maxillofac Surg** 1999 Sep;57(9):1138-41

CHEMICALLY INDUCED

Screening patch tests for pigmented contact dermatitis in Israel. Trattner A, et al. **Contact Dermatitis** 1999 Mar; 40(3):155-7

Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. Hernández-Martín A, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):333-4

Imipramine-induced hyperpigmentation: four cases and a review of the literature. Ming ME, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):159-66 (20 ref.)

Vitamin A toxicity secondary to excessive intake of yellow-green vegetables, liver and laver. Nagai K, et al. **J Hepatol** 1999 Jul;31(1):142-8

[Hyperpigmentation induced by busulfan: a case with ultrastructure examination] Simonart T, et al. **Ann Dermatol Venereol** 1999 May;126(5):439-40 **(Fre)**

COMPLICATIONS

Solitary hyperpigmented island in a sea of elastosis (anelastosis). Ramos-Caro FA, et al. **Int J Dermatol** 1998 Sep;37(9):699-700

CONGENITAL

Triple-A syndrome. Shivananda, et al. **Indian Pediatr** 1998 Nov;35(11):1131-5

DIAGNOSIS

Hereditary ochronosis: hyperpigmented skin overlying cartilaginous structures. Garcia SF, et al. **Cutis** 1999 Jun; 63(6):337-8

An additional case of linear and whorled nevoid hypermelanosis associated with birth defects and mental retardation [letter] Romano C, et al. **Pediatr Dermatol** 1999 Jan-Feb;16(1):71-3

DRUG THERAPY

A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans retinoic acid aqueous gel. Yoshimura K, et al. **Aesthetic Plast Surg** 1999 Jul-Aug; 23(4):285-91

Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Ando

H, et al. **Arch Dermatol Res** 1998 Jul;290(7):375–81

Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Kakita LS, et al. **Clin Ther** 1998 Sep–Oct;20(5):960–70

Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Lowe NJ, et al. **Clin Ther** 1998 Sep–Oct;20(5):945–59

Effectiveness of topical adapalene in Dowling-Degos disease [letter] Altomare G, et al. **Dermatology** 1999;198(2):176–7

ETIOLOGY

Unusual hyperpigmentation developing in congenital reticular ichthyosiform erythroderma (ichthyosis variegata). Brusasco A, et al. **Br J Dermatol** 1998 Nov; 139(5):893–6

Solar-induced postinflammatory hyperpigmentation after laser hair removal. Hasan AT, et al. **Dermatol Surg** 1999 Feb;25(2):113–5

Reticulate postinflammatory hyperpigmentation with band-like mucin deposition. Noto G, et al. **Int J Dermatol** 1998 Nov;37(11):829–32

Extensive Mongolian spots associated with Hunter syndrome. Sapadin AN, et al. **J Am Acad Dermatol** 1998 Dec; 39(6):1013–5

Phytophotodermatitis: the other "lime" disease. Weber IC, et al. **J Emerg Med** 1999 Mar–Apr;17(2):235–7

Cobalamin deficiency presenting with cutaneous hyperpigmentation: a report of two siblings. Sabatino D, et al. **Pediatr Hematol Oncol** 1998 Sep–Oct;15(5):447–50

Skin commotion from repetitive devotion. Prayer callus. Mishriki YY. **Postgrad Med** 1999 Mar;105(3):153–4

[Medicine in images. A special "suntan" and bradycardia] Ameneiros Lago E, et al. **Rev Clin Esp** 1998 Oct; 198(10):707–8 **(Spa)**

GENETICS

Hereditary perioral pigmented follicular atrophoderma associated with milia and epidermoid cysts. Inoue Y, et al. **Br J Dermatol** 1998 Oct;139(4):713–8 (27 ref.)

Skin pigmentary anomalies and mosaicism for an acentric marker chromosome originating from 3q. Portnoï MF, et al. **J Med Genet** 1999 Mar;36(3):246–50

PATHOLOGY

Nevoid hyperkeratosis of the areola in men: response to cryotherapy [letter] Mitxelena J, et al. **Dermatology** 1999; 199(1):73–4

Progressive cribriform and zosteriform hyperpigmentation: the late-onset feature of linear and whorled nevoid hypermelanosis associated with congenital neurological, skeletal and cutaneous anomalies [letter] Schepis C, et al. **Dermatology** 1999;199(1):72–3

Diabetic pigmented spots on the extrapretibial region: immunohistochemical study of type IV collagen in dermal vessel wall. Chishiki M, et al. **Eur J Dermatol** 1998 Dec; 8(8):560–2

Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. Kim YC, et al. **J Am Acad Dermatol** 1999 Mar;40(3):462–7

Sporadic reticulate acropigmentation of Kitamura on pale skin [letter] Albes B, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):71–2

[Hyperpigmented spots on the lips, oral mucosa, fingers and nails] Paricio Rubio JF, et al. **Rev Clin Esp** 1998 Nov; 198(11):769–70 (13 ref.) **(Spa)**

PREVENTION & CONTROL

Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. West TB, et al. **Dermatol Surg** 1999 Jan;25(1):15–7

SURGERY

Laugier-Hunziker syndrome: case report and treatment with the Q-switched Nd-Yag laser. Ferreira MJ, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):171–3

The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Patel BC. **Semin Ophthalmol** 1998 Sep;13(3):158–70 (7 ref.)

HYPERPIPECOLIC ACIDEMIA see **PEROXISOMAL DISORDERS**

HYPERPLASIA

see related

PRECANCEROUS CONDITIONS

Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Xie W, et al. **Oncogene** 1999 Jun 17;18(24):3593–607

CHEMICALLY INDUCED

Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Heinemann LA, et al. **Eur J Contracept Reprod Health Care** 1998 Dec; 3(4):194–200

The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51

COMPLICATIONS

[Diarrhea associated with enteral feeding: hyperglycemia and other factors] Monteiro JP, et al. **Arq Gastroenterol** 1998 Jan-Mar;35(1):40–4 (Eng. Abstr.) **(Por)**

DRUG THERAPY

CD10/neutral endopeptidase inhibition augments pulmonary neuroendocrine cell hyperplasia in hamsters treated with diethylnitrosamine and hyperoxia. Willett CG, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):13–20

ETIOLOGY

Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Giovannini M, et al. **Genes Dev** 1999 Apr 15;13(8):978–86

GENETICS

Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. Sunday ME, et al. **Oncogene** 1999 Jul 29;18(30):4336–47

IMMUNOLOGY

[Hyperplasia and endocrine neoplasms associated with gastritis] Monges G. **Ann Pathol** 1998;18(5 Suppl):104–6 **(Fre)**

PATHOLOGY

Micronodular pneumocyte hyperplasia: the versatile type 2 pneumocyte all dressed up in yet another brand new suit! Myers JL. **Adv Anat Pathol** 1999 Jan;6(1):49–55 (38 ref.)

Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. Fukukura Y, et al. **J Hepatol** 1998 Sep;29(3):470–5

Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Vasef MA, et al. **Mod Pathol** 1999 Apr;12(4):412–6

Pleomorphic adenoma of the minor salivary gland with pseudoepitheliomatous hyperplasia of the overlying oral mucosa: report of two cases. Takeda Y, et al. **Pathol Int** 1998 May;48(5):389–95

The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51

Clinical aspects of ECL-cell abnormalities. Hirschowitz BI. **Yale J Biol Med** 1998 May–Aug;71(3–4):303–10 (65 ref.)

[Adrenal medullary hyperplasia: a rare etiology of arterial hypertension--report of a case] Boissy C, et al. **Ann Pathol** 1999 Mar;19(1):38–41 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Strecker EP, et al. **Cardiovasc Intervent Radiol** 1998 Nov-Dec;21(6):487–96

HYPERPLASIA, FOCAL EPITHELIAL see **FOCAL EPITHELIAL HYPERPLASIA**

HYPERPLASIA, GIANT LYMPH NODE see **GIANT LYMPH NODE HYPERPLASIA**

HYPERPLASIA, REACTIVE LYMPHOID see **PSEUDOLYMPHOMA**

HYPERPOTASSEMIA see **HYPERKALEMIA**

HYPERPREBETALIPOPROTEINEMIA see **HYPERLIPOPROTEINEMIA TYPE IV**

HYPERPROLACTINEMIA

Hyperprolactinemia. Biller BM. **Int J Fertil Womens Med** 1999 Mar–Apr;44(2):74–7 (13 ref.)

[Prolactin--a hormone with many effects] Werner S, et al. **Lakartidningen** 1999 Mar 10;96(10):1171–4 (37 ref.) **(Swe)**

BLOOD

Prolactin and colorectal cancer: is there a connection? Baert D, et al. **Acta Gastroenterol Belg** 1998 Oct-Dec;61(4):407–9

Polyethylene glycol precipitation as a screening method for macroprolactinemia [letter; comment] Fahie-Wilson MN. **Clin Chem** 1999 Mar;45(3):436–7. Comment on: Clin Chem 1998 Aug;44(8 Pt 1):1758–9.

Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Shaarawy M, et al. **Clin Chem Lab Med** 1999 Apr;37(4):433–8

The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Fahy U, et al. **Hum Reprod** 1999 Feb; 14(2):285–7

Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. Touraine P, et al. **J Endocrinol Invest** 1998 Dec;21(11):732–6

Hyperprolactinemia in males with systemic lupus erythematosus. Mok CC, et al. **J Rheumatol** 1998 Dec; 25(12):2357–63

Effects of hyperprolactinemia on calcitonin secretion in male rats. Lu CC, et al. **Metabolism** 1999 Feb;48(2):221–6

Establishment of reference values for endocrine tests. II: Hyperprolactinemia. Le Moli R, et al. **Neth J Med** 1999 Aug;55(2):71–5

Neurohypophysial hormone secretion in hyperprolactinaemic women. Laczi F, et al. **Neuropeptides** 1998 Oct;32(5):435–7

CHEMICALLY INDUCED

Hyperprolactinemia and male sexual dysfunction [letter] Dickson RA, et al. **J Clin Psychiatry** 1999 Feb;60(2):125

Neuroleptic-induced hyperprolactinemia. Dickson RA, et al. **Schizophr Res** 1999 Mar 1;35 Suppl:S75–86 (81 ref.)

Prolactin and antipsychotic medications: mechanism of action. Petty RG. **Schizophr Res** 1999 Mar 1;35 Suppl:S67–73 (21 ref.)

[Hyperprolactinemia induced by indoramin (letter)] Pradalier A, et al. **Therapie** 1998 Sep–Oct;53(5):500–2 **(Fre)**

COMPLICATIONS

Re: Prolactin and systemic lupus erythematosus [letter; comment] Leaños-Miranda A, et al. **Br J Rheumatol** 1998 Sep;37(9):1029–30. Comment on: Br J Rheumatol 1997 Sep;36(9):986–9.

Hyperprolactinemia: an inductor of neoplastic changes in endometrium? A report of two cases. Dexeus S, et al. **Gynecol Endocrinol** 1998 Aug;12(4):273–5

The prevalence of hyperprolactinemia in patients with primary Sjögren's syndrome. Haga HJ, et al. **J Rheumatol** 1999 Jun;26(6):1291–5

Unilateral gestational macromastia--an unusual presentation of a rare disorder. Zargar AH, et al. **Postgrad Med J** 1999 Feb;75(880):101–3

[Erectile dysfunction secondary to hyperprolactinemia. Apropos of 13 cases] Abram F, et al. **Prog Urol** 1998 Sep; 8(4):537–41 (Eng. Abstr.) **(Fre)**

[The method of treatment of functional evident hyperprolactinemia in sterile women] Dudkiewicz J, et al. **Ginekol Pol** 1998 Dec;69(12):1171–4 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. Cavaco B, et al. **J Endocrinol Invest** 1999 Mar;22(3):203–8

Misleading hyperprolactinaemia in pregnancy. Heaney AP, et al. **Lancet** 1999 Feb 27;353(9154):720

[Diagnostic inquiry into hyperprolactinemic pathologies] Jaquet P, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):330–3 **(Fre)**

[Hyperprolactinemia: I. Etiopathogenesis, clinical features] Nowakowski G, et al. **Przegl Lek** 1998;55(7–8):393–6 (37 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Two-year treatment with oral contraceptives in hyperprolactinemic patients. Testa G, et al. **Contraception** 1998 Aug;58(2):69–73

New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline. Moro M, et al. **Eur J Pharmacol** 1999 Feb 26;368(1):57–66

Vaginal bromocriptine administration in patients with hyperprolactinemia. Carranza-Lira S, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):77–8

Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Verhelst J, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2518–22

Hyperprolactinaemia and pituitary adenomas in adolescence. Dissanecvate P, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):531–41 (60 ref.)

Advances in TCM treatment of hyperprolactinemia. Lei J, et al. **J Tradit Chin Med** 1998 Sep;18(3):230–4 (11 ref.)

Growth-hormone and prolactin excess. Colao A, et al. **Lancet** 1998 Oct 31;352(9138):1455–61 (70 ref.)

Complete regression of a major hyperprolactinaemia after renal transplantation. Bry-Gauillard H, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):466–8

[The method of treatment of functional evident hyperprolactinemia in sterile women] Dudkiewicz J, et al. **Ginekol Pol** 1998 Dec;69(12):1171–4 (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

The prevalence of hyperprolactinemia in patients with primary Sjögren's syndrome. Haga HJ, et al. **J Rheumatol** 1999 Jun;26(6):1291–5

ETIOLOGY

Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report. Albuquerque FC, et al. **J Neurosurg** 1998 Dec;89(6):1043–6

Complete regression of a major hyperprolactinaemia after renal transplantation. Bry-Gauillard H, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):466–8

Establishment of reference values for endocrine tests. II: Hyperprolactinemia. Le Moli R, et al. **Neth J Med** 1999 Aug;55(2):71–5

[Diagnostic inquiry into hyperprolactinemic pathologies] Jaquet P, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):330–3 **(Fre)**

IMMUNOLOGY

Hyperprolactinemia, uveitis, and systemic lupus erythematosus: clinical-immunological correlation. Scali JJ, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:378-82

Immunoglobulin levels and autoantibody titers in women with hyperprolactinaemia [letter] Alves J, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):515-6

Immunological aspects of human growth hormone and prolactin. Hattori N, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):371-5 (11 ref.)

Anti-endothelial cell antibodies in the sera of hyperprolactinemic women. Krause I, et al. **Lupus** 1998; 7(6):377-82

Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Leaños A, et al. **Lupus** 1998;7(6):398-403

PATHOLOGY

Alterations in the mitochondria of rat spermatozoa after experimental hyperprolactinemia. Laszczyńska M, et al. **Folia Histochem Cytobiol** 1999;37(2):87-8

PHYSIOPATHOLOGY

Hyperprolactinemia, uveitis, and systemic lupus erythematosus: clinical-immunological correlation. Scali JJ, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:378-82

ULTRASONOGRAPHY

[An increased prevalence of thyroid echographic and autoimmune changes in hyperprolactinemic women on therapy with dopaminergic drugs] Giusti M, et al. **Recenti Prog Med** 1999 Mar;90(3):147-51 (Eng. Abstr.) **(Ita)**

HYPERPYREXIA, MALIGNANT see **MALIGNANT HYPERTHERMIA**

HYPERREFLEXIA see **REFLEX, ABNORMAL**

HYPERSALIVATION see **SIALORRHEA**

HYPERSENSITIVITY

see related
ANTI-ALLERGIC AGENTS
DESENSITIZATION, IMMUNOLOGIC
MULTIPLE CHEMICAL SENSITIVITY

3rd Symposium on Specific Allergy '99. Copenhagen, Denmark, April 15-17, 1999. Abstracts. **Allergy** 1999;54 Suppl 54:5-10

Joint meeting of Paediatric Assembly, European Respiratory Society and European Society of Pediatric Allergy and Clinical Immunology. Berlin, Germany, May 26-29, 1999. Abstracts. **Allergy** 1999;54 Suppl 51:1-48

XX Nordic Congress of Allergology. Oslo, Norway, May 13-16, 1999. Proceedings and abstracts. **Allergy** 1999;54 Suppl 50:5-51

The Annual meeting of the European Academy of Allergology and Clinical Immunology. EAACI '98. Birmingham, United Kingdom, June 21-26, 1998. Abstracts [published erratum appears in Allergy 1998 Jun;53(6):629] **Allergy** 1998;53(43 Suppl):5-236

The word "pollens" and related species [letter] Frenz DA. **Ann Allergy Asthma Immunol** 1999 Jan;82(1):66

Enzymatically active papain preferentially induces an allergic response in mice. Chambers L, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):837-40

An Internet linkage and mutation database for the complex phenotype asthma. Wjst M, et al. **Bioinformatics** 1998; 14(9):827-8

The Cheshire cat's grin--is cat allergy here to stay? [editorial; comment] Bateman BJ, et al. **Clin Exp Allergy** 1999 Jun; 29(6):725-8 (30 ref.). Comment on: Clin Exp Allergy 1999 Jun;29(6):759-61. Comment on: Clin Exp Allergy 1999 Jun;29(6):762-5.

Atopic allergy and other hypersensitivities. Autoimmunity. Web alert. Greaves DR. **Curr Opin Immunol** 1998 Dec; 10(6):603

Proceedings of the International Symposium on The Atopy Syndrome in the 3rd Millennium. Zurich, Switzerland, October 2-3, 1998. **Curr Probl Dermatol** 1999;28:IX-XII, 1-211

The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies. Kraft D, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):171-6

American Academy of Allergy, Asthma and Immunology, (AAAAI) 55th annual meeting. Orlando, Florida, USA. February 26-March 3, 1999. Abstracts. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 2):S1-328

Learning, immunology and allergic responses. Slavkin HC. **J Am Dent Assoc** 1999 Jun;130(6):863-7

Best articles relevant to pediatric allergy and immunology. Selected by members of the section on allergy and immunology of the American Academy of Pediatrics from articles appearing in the medical literature between December 1, 1997 and November 30, 1998. **Pediatrics** 1999 Aug;104(2 Pt 2):357-404

[Cross reaction allergies: what importance to the clinician?] Kaeser P, et al. **Rev Med Suisse Romande** 1999 Jan; 119(1):43-8 (13 ref.) **(Fre)**

[11th spring meeting of the Japanese Society of Allergology. Osaka, Japan. May 13-15, 1999. Abstracts] **Arerugi** 1999 Mar;48(2-3):95-405 **(Jpn)**

[49th general meeting of the Japanese Society of Allergology. Hiroshima, Japan. October 18-20, 1999. Abstracts] **Arerugi** 1999 Sep;48(8-9):755-1137 **(Jpn)**

[48th general meeting of the Japanese Society of Allergology. Kobe, Japan. December 1-3, 1998. Abstracts] **Arerugi** 1998 Oct;47(9-10):811-1148 **(Jpn)**

[Annual change of the pet in allergic patients home for ten years] Maeda Y, et al. **Arerugi** 1999 Jan;48(1):27-32 (Eng. Abstr.) **(Jpn)**

[Human ecological viewpoint of allergic diseases] Torii S. **Arerugi** 1998 Nov;47(11):1151-5 (25 ref.) **(Jpn)**

[Molecular biology and genetics in the field of otorhinolaryngology--molecular biology of allergy] Masuyama K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Dec;101(12):1442-5 (3 ref.) **(Jpn)**

[Alimentary allergies] Santos Vicente J. **Gastroenterol Hepatol** 1998 Aug-Sep;21(7):361-9 (115 ref.) **(Spa)**

BLOOD

Effect of lactoferrin on the phagocytic activity of polymorphonuclear leucocytes isolated from blood of patients with autoimmune diseases and Staphylococcus aureus allergy. Manev V, et al. **Adv Exp Med Biol** 1998; 443:321-30

Blood eosinophils from asymptomatic allergics have a reduced capacity to produce oxygen-free radicals. Woschnagg C, et al. **Allergy** 1998 Dec;53(12):1162-71

Soluble CD23 in allergic diseases. Rogala B, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(4):251-5

Antioxidant enzymatic activities in human blood cells after an allergic reaction to pollen or house dust mite. Matés JM, et al. **Blood Cells Mol Dis** 1999 Apr;25(2):103-9

Reduced interferon gamma production by antigen-stimulated cord blood mononuclear cells is a risk factor of allergic disorders--6-year follow-up study [see comments] Kondo N, et al. **Clin Exp Allergy** 1998 Nov;28(11):1340-4. Comment in: Clin Exp Allergy 1998 Nov;28(11):1313-6.

Soluble cytokine receptor CD30 in atopic disorders: a case-control study. Latza U, et al. **Clin Exp Allergy** 1999 Jan;29(1):97-104

Chemical nature of antioxidant complement activators in allergenic extracts. Berrens L, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):328-9

Does IgE bind to and activate eosinophils from patients with allergy? Kita H, et al. **J Immunol** 1999 Jun 1; 162(11):6901-11

Effect of disodium cromoglycate treatment on peripheral blood mononuclear cell adhesion to cultured endothelium in allergic asthmatics. Horváthová M, et al. **Physiol Res** 1998;47(6):445-51

CHEMICALLY INDUCED see DRUG HYPERSENSITIVITY

CLASSIFICATION

Basic concepts relating to the field of allergology [letter] Dubois AE, et al. **Allergy** 1999 Jul;54(7):760-2

Allergy--atopy--hypersensitivity--a matter of definition [editorial; comment] [see comments] Lilja G, et al. **Allergy** 1998 Nov;53(11):1011-2. Comment on: Allergy 1998 Nov;53(11):1074-7. Comment in: Allergy 1999 Jun;54(6):640-2.

[Immunological bases and classification of allergy] Bongrand P. **Arch Pediatr** 1999;6 Suppl 1:20S-28S (24 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

The prevalence of allergy in Kawasaki disease. Matsubara T, et al. **Allergy** 1998 Aug;53(8):815-6

Recurrent respiratory tract infections during the first 3 years of life and atopy at school age. Nystad W, et al. **Allergy** 1998 Dec;53(12):1189-94

Pseudoallergy or nonallergic hypersensitivity [letter] Zuberbier T. **Allergy** 1999 Apr;54(4):397-8

Anti-CD86 (B7.2) treatment abolishes allergic airway hyperresponsiveness in mice. Haczku A, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1638-43

Comprehensive management of allergic fungal sinusitis. Marple BF, et al. **Am J Rhinol** 1998 Jul-Aug;12(4):263-8

Role of allergy in nasal polyps of Thai patients. Pumhirun P, et al. **Asian Pac J Allergy Immunol** 1999 Mar;17(1):13-5

Assessment of the indoor environment in respiratory allergy. Sarpong SB, et al. **Ear Nose Throat J** 1998 Dec; 77(12):960-4 (30 ref.)

Eosinophilic lung disease associated with Candida albicans allergy. Pacheco A, et al. **Eur Respir J** 1998 Aug; 12(2):502-4

Alternate occurrence of allergic disease and an unusual form of interstitial cystitis. Yamada T, et al. **Int J Urol** 1998 Jul;5(4):329-35; discussion 335-6

Asthma induced by allergy to Trichophyton rubrum. Elewski BE, et al. **J Eur Acad Dermatol Venereol** 1999 May; 12(3):250-3

Ozone effects on the immediate-phase response to allergen in the nasal airways of allergic asthmatic subjects. Michelson PH, et al. **Otolaryngol Head Neck Surg** 1999 Feb;120(2):225-32

Individual allergens as risk factors for bronchial responsiveness in young adults. Chinn S, et al. **Thorax** 1998 Aug;53(8):662-7

Infections in asthma and allergy [editorial] Lewis SA. **Thorax** 1998 Nov;53(11):911-2

Serum immunoglobulin and immunoglobulin G subclasses in children with allergic colitis. Ojuawo A, et al. **West Afr J Med** 1998 Jul-Sep;17(3):206-9

[DNA autosensitivity] Mase K. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):397-9 (6 ref.) **(Jpn)**

[Some clinical symptoms and allergens on asthma-prurigo syndrome] Rudzki E, et al. **Przegl Lek** 1998;55(5):239-41 (Eng. Abstr.) **(Pol)**

[Three-dimensional structure of myocardial filaments during cardiac insufficiency caused by toxic allergic myocarditis] Samsonidze TG, et al. **Biull Eksp Biol Med** 1999 Jan; 127(1):101-5 **(Rus)**

[Conformational changes in myocardial actin during cardiac insufficiency caused by toxic allergic myocarditis] Sukoian GV, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):395-9 **(Rus)**

[Dobutamine stress echocardiography in prediction of dilated cardiomyopathy in patients with allergic myocarditis] Sisakian AS. **Klin Med (Mosk)** 1999;77(7):31-3 (Eng. Abstr.) **(Rus)**

[Contact cheilitis (letter; comment)] López Sánchez AF, et al. **Aten Primaria** 1999 Feb 28;23(3):177-8. Comment on: Aten Primaria 1998 Jun 15;22(1):53-8. **(Spa)**

DIAGNOSIS

A case of human adjuvant disease after augmentation rhinoplasty. Shiba A, et al. **Aesthetic Plast Surg** 1999 May-Jun;23(3):175-8

Skin tests or in vitro tests? [editorial; comment] Muñoz-López F. **Allergol Immunopathol (Madr)** 1998 Sep-Oct;26(5):203-8. Comment on: Allergol Immunopathol (Madr) 1998 Sep-Oct;26(5):228-33. **(Eng, Spa)**

Allergy to human seminal fluid: a case of self-diagnosis. Prandini M, et al. **Allergy** 1999 May;54(5):530

What makes a child allergic? Analysis of risk factors for allergic sensitization in preschool children from East and West Germany. Schäfer T, et al. **Allergy Asthma Proc** 1999 Jan-Feb;20(1):23-7

Systemic reactions to allergy skin tests. Valyasevi MA, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):132-6

Is it allergy? Little C. **Aust Fam Physician** 1998 Aug; 27(8):673-7 (8 ref.)

Reference values of total serum IgE and their significance in the diagnosis of allergy among the young adult Kuwaiti population. Ezeamuzie CI, et al. **Clin Exp Allergy** 1999 Mar;29(3):375-81

How far can we simplify in vitro diagnostics for Fagales tree pollen allergy? A study with three whole pollen extracts and purified natural and recombinant allergens. Van Ree R, et al. **Clin Exp Allergy** 1999 Jun;29(6):848-55

Detection of allergen-induced basophil activation by expression of CD63 antigen using a tricolour flow cytometric method. Monneret G, et al. **Clin Exp Immunol** 1999 Mar;115(3):393-6

Allergy testing alert [editorial] Rubin W. **Ear Nose Throat J** 1999 Mar;78(3):140

Perspective of purified natural and recombinant allergens in diagnosis and treatment of inhalant allergies. van Ree R, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2-4):212-3

Lupin allergy in a child. Novembre E, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1214-6

Evaluation and treatment of allergic fungal sinusitis. I. Demographics and diagnosis. Schubert MS, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):387-94

Atopy and food allergy in varioliform gastritis [letter] Ustündağ Y, et al. **J Clin Gastroenterol** 1998 Oct; 27(3):275-6

Age of entry to day nursery and allergy in later childhood [see comments] Krämer U, et al. **Lancet** 1999 Feb 6; 353(9151):450-4. Comment in: Lancet 1999 Jun 5;353(9168):1969.

In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Halmerbauer G, et al. **Pediatr Allergy Immunol** 1999 Feb;10(1):53-7

The importance of diagnosis of allergy in early wheezing. Trindade JC. **Pediatr Allergy Immunol** 1998;9(11 Suppl):23-9 (50 ref.)

Markers of allergy & inflammation. Warner JO, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):53-7 (33 ref.)

A pediatrician's view. Why is allergy confusing? [editorial] Altemeier WA 3rd. **Pediatr Ann** 1998 Nov;27(11):707

Is it allergy? Issues, impacts, and interventions [editorial; comment] Meltzer EO. **Pediatr Ann** 1998 Nov;27(11):708 . Comment on: Pediatr Ann 1998 Nov;27(11):710-6. Comment on: Pediatr Ann 1998 Nov;27(11):719-24. Comment on: Pediatr Ann 1998 Nov;27(11):727-34. Comment on: Pediatr Ann 1998 Nov;27(11):736-9. Comment on: Pediatr Ann 1998 Nov;27(11):743-50. Comment on: Pediatr Ann 1998 Nov;27(11):752-8. Comment on: Pediatr Ann 1998 Nov;27(11):759-66.

Verification of self-reported asthma and allergy in subjects and their family members volunteering for gene mapping studies. Kauppi P, et al. **Respir Med** 1998 Nov;

92(11):1281–8
Nasal hyperreactivity. Gerth van Wijk RG, et al. **Rhinology** 1999 Jun;37(2):50–5 (49 ref.)
[Efficiency of mixed RASTs in serological screening of possibly allergic patients] van Toorenenbergen AW, et al. **Ned Tijdschr Geneeskd** 1998 Apr 11;142(15):855–9 (Eng. Abstr.) **(Dut)**
[Allergology: quo vadis?] Wüthrich B. **Schweiz Med Wochenschr** 1999 Jun 19;129(24):905–14 (84 ref.) (Eng. Abstr.) **(Ger)**
[The evaluation of the irritating and sensitizing effects of benzalkonium chloride (published erratum appears in Med Pr 1998;49(5):456)] Krysiak B, et al. **Med Pr** 1998; 49(4):371–9 (Eng. Abstr.) **(Pol)**
[Skin reactivity in subjects sensitive to different concentrations of nickel, chromium and cobalt] Piela Z, et al. **Med Pr** 1998;49(5):457–63 (Eng. Abstr.) **(Pol)**
[The role of bacteria in allergic and pseudoallergic reactions] Szymaniak L, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):37–40 (31 ref.) (Eng. Abstr.) **(Pol)**
[Insulin sensitivity in NIDDM patients with normo- and microalbuminuria] Trzepióra B, et al. **Wiad Lek** 1998; 51(9–10):435–40 (20 ref.) (Eng. Abstr.) **(Pol)**
[Sensitivity of the respiratory center to carbon dioxide during prolonged exposure of humans to gas environment with unchanging level of hypercapnia] Bragin LKh, et al. **Aviakosm Ekolog Med** 1999;33(2):19–21 (Eng. Abstr.) **(Rus)**
[Comparative study of the immune status of preschool children in different districts of Moscow] Petrova IV, et al. **Gig Sanit** 1998 Sep–Oct;(5):31–3 **(Rus)**
[The characteristics of the clinical manifestations and treatment of chronic obstructive bronchitis in patients with hepatobiliary system diseases and pseudoallergy] Provotorov VM, et al. **Klin Med (Mosk)** 1998;76(7):28–31 (Eng. Abstr.) **(Rus)**
[The allergic pathology problem in the Navy and the means for its resolution] Sharaevskiĭ GIu, et al. **Voen Med Zh** 1999 Mar;320(3):62–4, 96 (Eng. Abstr.) **(Rus)**
[Respiratory function and allergic reactions in paper recycling workers] Zuškin E, et al. **Arh Hig Rada Toksikol** 1998 Jun;49(2):165–77 (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Pharmacological modulation of the allergic response: different modes of action. Scadding G. **Allergy** 1999;54 Suppl 50:39–42 (13 ref.)
The in vivo and in vitro effects of rhG-CSF on allergic, haematological and biochemical variables. Kristensen KS, et al. **APMIS** 1998 Nov;106(11):1108–12
Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge. Diaz-Sanchez D, et al. **Clin Immunol** 1999 Mar;90(3):313–22
The treatment of bovine collagen allergy with cyclosporin. Baumann LS, et al. **Dermatol Surg** 1999 Mar;25(3):247–9
Chemokine receptors and their antagonists in allergic lung disease. Wells TN, et al. **Inflamm Res** 1999 Jul;48(7):353–62 (64 ref.)
IgE inhibition as a therapy for allergic disease. Jardieu PM, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):112–5 (12 ref.)
Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives. Pauli G, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):216–7
Clinical testing of recombinant allergens of the mold Alternaria alternata. Unger A, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):220–1
Perspective of purified natural and recombinant allergens in diagnosis and treatment of inhalant allergies. van Ree R, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):212–3
Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy. Vrtala S, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):218–9
The American College of Allergy, Asthma, and Immunology Registry for Allergic, Asthmatic Pregnant Patients (RAAPP). Lipkowitz MA. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 2):S364–72
Effects of Y-24180, a receptor antagonist to platelet-activating factor, on allergic cutaneous eosinophilia in mice. Yamaguchi S, et al. **Life Sci** 1999; 64(11):PL139–44
Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen. Ueno M, et al. **Pharmacology** 1998 Oct;57(4):206–14
[Corticosteroids] Hassoun S, et al. **Allerg Immunol (Paris)** 1999 Apr;31(4):109–11 (4 ref.) (Eng. Abstr.) **(Fre)**
[Corticoids and allergy] Delacourt C. **Arch Pediatr** 1999;6 Suppl 1:105S–107S (Eng. Abstr.) **(Fre)**
[Cetirizine] Groschner K, et al. **Dtsch Med Wochenschr** 1998 Dec 11;123(50):1523–4 (0 ref.) **(Ger)**
[Antihistaminics. II] Reider N, et al. **Hautarzt** 1998 Sep; 49(9):734–42; quiz 472 (0 ref.) **(Ger)**
[T-cells as immunomodulation targets: a new strategy in allergy therapy] Muller V.-D., et al. **Patol Fiziol Eksp Ter** 1999 Jan–Mar;(1):14–7 (25 ref.) **(Rus)**
[The efficacy of using enzymes in treating toxic-allergic reactions after cataract extraction with intraocular lens implantation] Narbut NP, et al. **Vestn Oftalmol** 1998 Sep–Oct;114(5):21–3 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics--comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Van Der Velden VH, et al. **Clin Exp Allergy** 1999 Jun;29(6):813–23

EPIDEMIOLOGY

Increased risk of allergy in children due to formaldehyde exposure in homes. Garrett MH, et al. **Allergy** 1999 Apr; 54(4):330–7
What makes a child allergic? Analysis of risk factors for allergic sensitization in preschool children from East and West Germany. Schäfer T, et al. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):23–7
Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Hospers JJ, et al. **Am J Epidemiol** 1999 Sep 1; 150(5):482–91
Differential latex allergy prevalence in anesthesiology subspecialties [letter] Greenberg RS, et al. **Anesthesiology** 1999 Apr;90(4):1238
Allergy prevalence and causal factors in the domestic environment: results of a random population survey in the United Kingdom. Brown CW, et al. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):240–4
Sensitivity to metals in 40 patients with failed hip endoprosthesis. Milavec-Puretić V, et al. **Arch Orthop Trauma Surg** 1998;117(6–7):383–6
Prevalence of allergic sensitization to regional inhalants among allergic patients in Jakarta, Indonesia. Baratawidjaja IR, et al. **Asian Pac J Allergy Immunol** 1999 Mar;17(1):9–12
Allergic diseases in preschool children in Taichung City. Wang WC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Sep–Oct;39(5):314–8
The International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Steering Committee. Asher MI, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:52–66; discussion 90–1
Prevalence of hay fever and allergic sensitization in farmer's children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air Pollution. Braun-Fahrländer C, et al. **Clin Exp Allergy** 1999 Jan; 29(1):28–34
Association between body mass index and allergy in teenage girls in Taiwan [see comments] Huang SL, et al. **Clin Exp Allergy** 1999 Mar;29(3):323–9. Comment in: Clin Exp Allergy 1999 Mar;29(3):291–3.
High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats [see comments] Ichikawa K, et al. **Clin Exp Allergy** 1999 Jun; 29(6):754–61. Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.
Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Novembre E, et al. **Clin Exp Allergy** 1998 Jul;28(7):834–8
The rising trends in asthma and allergic disease. von Mutius E. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:45–9; discussion 50–1 (41 ref.)
Respiratory diseases and allergies in two polluted areas in East Germany. Heinrich J, et al. **Environ Health Perspect** 1999 Jan;107(1):53–62
Trends in allergies among children in a region of former East Germany between 1992–1993 and 1995–1996. Heinrich J, et al. **Eur J Med Res** 1999 Mar 26;4(3):107–13
Allergography of Salomvar, Hungary. preliminary results. Nekam K, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):242–4
Environmental risk factors for respiratory and skin atopy: results from epidemiological studies in former East and West Germany. Ring J, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):403–7
Expression of lymphocyte subpopulations, cytokine serum levels, and blood and urinary trace elements in asymptomatic atopic men exposed to an urban environment. Boscolo P, et al. **Int Arch Occup Environ Health** 1999 Jan;72(1):26–32
The prevalence of allergic disease and linoleic acid in the diet. Black PN. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):351–2
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. Williams H, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):125–38
The prevalence of allergic diseases and atopy in Ankara, Turkey: a two-step population-based epidemiological study. Celik G, et al. **J Asthma** 1999 May;36(3):281–90
Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. Korelitz BI, et al. **J Clin Gastroenterol** 1999 Jun;28(4):341–4
Association of allergy with Tourette's syndrome. Ho CS, et al. **J Formos Med Assoc** 1999 Jul;98(7):492–5
Sensitization to cockroach allergens in a sample from the urban population living in Naples (southern Italy). Liccardi G, et al. **J Investig Allergol Clin Immunol** 1998 Jul–Aug; 8(4):245–8
International Study of Asthma and Allergies in Childhood (ISAAC) written questionnaire: validation of the asthma component among Brazilian children. Solé D, et al. **J Investig Allergol Clin Immunol** 1998 Nov–Dec; 8(6):376–82
Intake of trans fatty acids and prevalence of childhood asthma and allergies in Europe. ISAAC Steering Committee [letter] Weiland SK, et al. **Lancet** 1999 Jun 12; 353(9169):2040–1
Age of entry to nursery and allergies in later life [letter; comment] Xu B, et al. **Lancet** 1999 Jun 5;353(9168):1969 . Comment on: Lancet 1999 Feb 6;353(9151):450–4.
Specific childhood allergic diseases in southern Europe: synthesis and conclusions. César-Ramos JM. **Pediatr Pulmonol Suppl** 1999;18:172–4 (8 ref.)
Allergic diseases and pediatric allergology in Portugal. Trindade JC. **Pediatr Pulmonol Suppl** 1999;18:150–3 (15 ref.)
Allergy: etiology and epidemiology. Nimmagadda SR, et al. **Pediatr Rev** 1999 Apr;20(4):111–5; quiz 116 (10 ref.)
[House dust mite allergens and mite allergy in Copenhagen dwellings. A cross-sectional study (see comments)] Mosbech H, et al. **Ugeskr Laeger** 1999 Jan 25;161(4):419–23 (Eng. Abstr.). Comment in: Ugeskr Laeger 1998 Apr 20;160(17):2550–1. **(Dan)**
[A society on the move and allergy] Spertini F. **Rev Med Suisse Romande** 1999 Aug;119(8):613–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[ISAAC, the world-wide study of asthma and allergies in childhood] von Mutius E. **Pneumologie** 1999 Feb; 53(2):101–2 **(Ger)**
[Housing conditions and allergic sensitization in children] Heinrich J, et al. **Zentralbl Hyg Umweltmed** 1998 Sep; 201(3):211–28 (Eng. Abstr.) **(Ger)**
[Change in prevalence of allergic diseases in primary school children in Fukuoka City for the last fifteen years] Matsumoto I, et al. **Arerugi** 1999 Apr;48(4):435–42 (Eng. Abstr.) **(Jpn)**
[Analysis of air pollution and prevalence rate of allergic diseases among elementary school children in Kawaguchi and Hatogaya city] Oyama S, et al. **Arerugi** 1998 Nov; 47(11):1190–7 (Eng. Abstr.) **(Jpn)**
[A survey of allergic diseases among elementary school children in Saga Prefecture. The first report. Prevalence and past history] Kai K, et al. **Nippon Koshu Eisei Zasshi** 1998 Jul;45(7):625–33 (Eng. Abstr.) **(Jpn)**
[Dispersal of pollen and the variation in number of patients prescribed medicine for allergies in Otaru] Akino J, et al. **Yakugaku Zasshi** 1999 Mar;119(3):215–20 (Eng. Abstr.) **(Jpn)**
[The results of research on the prevalence of allergy to Hymenoptera venom in Southwestern Poland] Nittner-Marszalska M, et al. **Pol Arch Med Wewn** 1998 Sep;100(3):245–51 (Eng. Abstr.) **(Pol)**
[Occurrence of allergy in school-age children and their parents in relation to atmospheric air pollution. Prospective study in Cracow] Jędrychowski W, et al. **Przegl Lek** 1998; 55(9):437–41 (Eng. Abstr.) **(Pol)**
[Frequent allergies in Mexico Valley in children] Hernández Chávez LA, et al. **Rev Alerg Mex** 1999 Jan–Feb;46(1):23–5 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Unusual skin reaction to silicone content in breast implants. Marcusson JA, et al. **Acta Derm Venereol** 1999 Mar; 79(2):136–8
The house-dust mite: its biology and role in allergy. Proceedings of an international scientific workshop. Oslo, Norway, 4–7 September 1997. **Allergy** 1998;53(48 Suppl):1–135
Dietary assessment in five cases of allergic reactions due to gastroallergic anisakiasis. Alonso A, et al. **Allergy** 1999 May;54(5):517–20
Immediate and delayed hypersensitivity to ammonium persulfate. Borelli S, et al. **Allergy** 1999 Aug;54(8):893–4
Malaria as a possible evolutionary cause of allergy. Bottini N, et al. **Allergy** 1999 Feb;54(2):188–9
Increased risk of allergy in children due to formaldehyde exposure in homes. Garrett MH, et al. **Allergy** 1999 Apr; 54(4):330–7
Occupational allergy to the umbrella tree (Schefflera). Grob M, et al. **Allergy** 1998 Oct;53(10):1008–9
Occupational rhinitis caused by beech wood dust. Hernandez M, et al. **Allergy** 1999 Apr;54(4):405–6
The Th1/Th2 paradigm and allergic disorders. Romagnani S. **Allergy** 1998;53(46 Suppl):12–5 (33 ref.)
Genes, factor X, and allergens: what causes allergic diseases? Wjst M, et al. **Allergy** 1999 Jul;54(7):757–9
The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Wold AE. **Allergy** 1998;53(46 Suppl):20–5 (73 ref.)
Sensitization to green coffee beans and work-related allergic symptoms in coffee workers. Larese F, et al. **Am J Ind Med** 1998 Dec;34(6):623–7
Ovalbumin (OVA) and Mycobacterium tuberculosis bacilli cooperatively polarize anti-OVA T-helper (Th) cells toward a Th1-dominant phenotype and ameliorate murine tracheal eosinophilia. Sano K, et al. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1260–7
Allergy prevalence and causal factors in the domestic environment: results of a random population survey in the

United Kingdom. Brown CW, et al.
Ann Allergy Asthma Immunol 1999 Sep;83(3):240–4
Healthy gut microflora and allergy: factors influencing development of the microbiota. Kirjavainen PV, et al.
Ann Med 1999 Aug;31(4):288–92 (47 ref.)
Patient education. House dust mite allergy. Katelaris C.
Aust Fam Physician 1998 Aug;27(8):733
Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery. Geerts IS, et al. **Br J Pharmacol** 1999 Jul; 127(6):1327–36
Occupational allergies and asthma [see comments] Tarlo SM.
Can Fam Physician 1999 Jun;45:1516–22. Comment in: Can Fam Physician 1999 Jun;45 :1401–3, 1412–4.
Induction of allergic reactions in guinea pigs with purified house dust mite allergens. Yasue M, et al.
Cell Immunol 1999 Mar 15;192(2):185–93
Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Szebeni J, et al. **Circulation** 1999 May 4;99(17):2302–9
Effects of birch pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive patients. Asero R.
Clin Exp Allergy 1998 Nov;28(11):1368–73
Pillow talk: have we made the wrong beds for our patients to lie in? [editorial; comment] Fitzharris P, et al.
Clin Exp Allergy 1999 Apr;29(4):429–32. Comment on: Clin Exp Allergy 1999 Feb;29(2):144–7. Comment on: Clin Exp Allergy 1999 Feb;29(2):182–5. Comment on: Clin Exp Allergy 1999 Apr;29(4):457–60.
The relationship between anthropometric measurements at birth: asthma and atopy in childhood. Gregory A, et al.
Clin Exp Allergy 1999 Mar;29(3):330–3
Early life receipt of antibiotics and atopic disorder [editorial] Hopkin JM. **Clin Exp Allergy** 1999 Jun;29(6):733–4 (21 ref.)
Is diesel exhaust a cause for increasing allergies? [editorial; comment] Salvi SS, et al. **Clin Exp Allergy** 1999 Jan; 29(1):4–8 (44 ref.). Comment on: Clin Exp Allergy 1999 Jan;29(1):52–9.
The interaction between the dust mite antigen Der p 1 and cell-signalling molecules in amplifying allergic disease. Schulz O, et al. **Clin Exp Allergy** 1999 Apr;29(4):439–44 (72 ref.)
Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Tsuge I, et al. **Clin Exp Immunol** 1999 Mar;115(3):385–92
The effects of environmental and other chemicals on the human immune system: the emergence of immunotoxicology [editorial; comment] Burchiel SW.
Clin Immunol 1999 Mar;90(3):285–6. Comment on: Clin Immunol 1999 Mar;90(3):287–301.
The frequency of mercury intolerance in patients with chronic fatigue syndrome and healthy controls [letter] Marcusson JA. **Contact Dermatitis** 1999 Jul;41(1):60–1
Sensitization and development of allergic contact dermatitis caused by a single contact with an electrosurgical grounding plate containing acrylates. Borelli S, et al.
Dermatology 1998;197(4):381–2
Respiratory diseases and allergies in two polluted areas in East Germany. Heinrich J, et al.
Environ Health Perspect 1999 Jan;107(1):53–62
Risk factors for allergy. De Swert LF. **Eur J Pediatr** 1999 Feb;158(2):89–94 (81 ref.)
The association between pre- and postnatal tobacco smoke exposure and allergic sensitization during early childhood. Multicentre Allergy Study Group, Germany. Kulig M, et al. **Hum Exp Toxicol** 1999 Apr;18(4):241–4
An allergic reaction following intrauterine insemination. Al-Ramahi M, et al. **Hum Reprod** 1998 Dec;13(12):3368–70
Dapsone syndrome: hepatitis-B infection a risk factor for its development? [letter] Pavithran K, et al.
Int J Lepr Other Mycobact Dis 1999 Jun;67(2):171–2
The prevalence of asthma in schoolboys of travellers' families. Kearney PM, et al. **Ir Med J** 1998 Dec;91(6):203–6
Allergic lung responses are increased in prostaglandin H synthase-deficient mice. Gavett SH, et al. **J Clin Invest** 1999 Sep;104(6):721–32
Rhinosinusitis and atopy in patients infected with HIV. Garcia-Rodriguez JF, et al. **Laryngoscope** 1999 Jun; 109(6):939–44
Systemic effects of ingested nickel on the immune system of nickel sensitised women. Boscolo P, et al. **Life Sci** 1999; 64(17):1485–91
Prevalence of latex sensitivity among patients with chronic renal failure--a new risk group? [letter] Kalpaklioğlu AF, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1899–900
Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr-Jun;14(2):285–304 (130 ref.)
Allergy: etiology and epidemiology. Nimmagadda SR, et al.
Pediatr Rev 1999 Apr;20(4):111–5; quiz 116 (10 ref.)
Allergy and the environment: a meeting report. Mariéthoz E, et al. **Rev Environ Health** 1999 Apr-Jun;14(2):63–78 (72 ref.)
Mechanisms of allergy and chemical sensitivity. Meggs WJ.
Toxicol Ind Health 1999 Apr-Jun;15(3-4):331–8 (56 ref.)
The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications. Miller CS, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):370–85
Exacerbation of chemical sensitivity: a case study. Miller CS, et al. **Toxicol Ind Health** 1999 Apr-Jun;15(3-4):398–402
A rat model of neurobehavioral sensitization to toluene. Rogers WR, et al. **Toxicol Ind Health** 1999 Apr-Jun; 15(3-4):356–69
Allergy, asthma and the environment: an introduction. Kimber I. **Toxicol Lett** 1998 Dec 28;102-103:301–6
Development of a flow cytometry assay for the identification and differentiation of chemicals with the potential to elicit irritation, IgE-mediated, or T cell-mediated hypersensitivity responses. Manetz TS, et al. **Toxicol Sci** 1999 Apr;48(2):206–17
Allergic responses to the biopesticide Metarhizium anisopliae in Balb/c mice. Ward MD, et al. **Toxicol Sci** 1998 Oct; 45(2):195–203
Electrical hypersensitivity in humans--fact or fiction? Silny J. **Zentralbl Hyg Umweltmed** 1999 Aug;202(2-4):219–33 (37 ref.)
[Occupational sensitization to methylene diphenyl diisocyanate during the manufacture of polyurethane products] Nosko M, et al. **Probl Khig** 1997;22:10–6 (Eng. Abstr.) **(Bul)**
[Pet animals and allergy] Gyntelberg F. **Ugeskr Laeger** 1999 Jun 7;161(23):3467 **(Dan)**
[Pollution and allergy: a relationship that needs proof (editorial)] Charpin D. **Allerg Immunol (Paris)** 1998 Dec; 30(10):307–8 (0 ref.) **(Fre)**
[Multicenter study on sensitization to Alternaria mold] Vassal P. **Allerg Immunol (Paris)** 1999 Jun;31(6):187–91 (Eng. Abstr.) **(Fre)**
[Allergy to hymenoptera venoms in children] Rancé F, et al. **Arch Pediatr** 1999;6 Suppl 1:55S–60S (Eng. Abstr.) **(Fre)**
[Age of entrance to day care and allergies in childhood] Annesi-Maesano J. **Rev Epidemiol Sante Publique** 1999 Jun; 47(3):298–300 **(Fre)**
[The child, his mother and allergies] Hofer MF.
Rev Med Suisse Romande 1999 Aug;119(8):623–7 (12 ref.) (Eng. Abstr.) **(Fre)**
[Allergies: the difference from illness] Polla BS.
Rev Med Suisse Romande 1999 Aug;119(8):609–12 **(Fre)**
[A society on the move and allergy] Spertini F.
Rev Med Suisse Romande 1999 Aug;119(8):613–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[New allergens and pediatric allergology] Eng PA.
Schweiz Rundsch Med Prax 1998 Sep 30;87(40):1285–92 (38 ref.) (Eng. Abstr.) **(Ger)**
[Prospective study of the significance of contact sensitization caused by metal implants] Duchna HW, et al.
Zentralbl Chir 1998;123(11):1271–6 (Eng. Abstr.) **(Ger)**
[Insulin sensitivity in NIDDM patients with normo- and microalbuminuria] Trzepióra B, et al. **Wiad Lek** 1998; 51(9-10):435–40 (20 ref.) (Eng. Abstr.) **(Pol)**
[The role of biological factors in the formation of working conditions at agricultural enterprises] Tsapko VG, et al.
Med Tr Prom Ekol 1999;(4):15–9 (34 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The genetics of atopy. Rosenwasser LJ. **Allergy** 1998;53(46 Suppl):8–11 (20 ref.)
Genes, factor X, and allergens: what causes allergic diseases? Wjst M, et al. **Allergy** 1999 Jul;54(7):757–9
Asthma, wheezy bronchitis, and atopy across two generations. Christie GL, et al.
Am J Respir Crit Care Med 1999 Jan;159(1):125–9
Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Hobbs K, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1958–62
Differences of genetic effects for the development of allergic diseases in two cities of Japan. Agata H, et al.
Ann Allergy Asthma Immunol 1999 Jun;82(6):586–90
Genetics of allergy and asthma. Borish L.
Ann Allergy Asthma Immunol 1999 May;82(5):413–24; quiz 424–6 (97 ref.)
Mapping susceptibility genes for asthma and allergy. Bleecker ER. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:6–12; discussion 26–8 (63 ref.)
Association studies on beta2-adrenoceptor polymorphisms and enhanced IgE responsiveness in an atopic population. Deichmann KA, et al. **Clin Exp Allergy** 1999 Jun; 29(6):794–9
Genetics of allergy and bronchial hyperresponsiveness. Howard TD, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:86–9 (21 ref.)
Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Tanaka K, et al. **Clin Exp Allergy** 1999 Jun; 29(6):800–3
Genetics of complex human diseases: genome screening, association studies and fine mapping. Xu J, et al.
Clin Exp Allergy 1998 Nov;28 Suppl 5:1–5; discussion 26–8 (20 ref.)
Allergy, immunology, and related disorders [editorial] Fuleihan RL. **Curr Opin Pediatr** 1998 Dec;10(6):581–3 (11 ref.)
HLA-DPB1 alleles in house dust mite allergic patients. O'Brien RM, et al. **Eur J Immunogenet** 1999 Aug; 26(4):281–4
Cutting edge: effects of an allergy-associated mutation in the human IL-4R alpha (Q576R) on human IL-4-induced signal transduction. Wang HY, et al. **J Immunol** 1999 Apr 15;162(8):4385–9
Current status of the Asthma and Allergy Database. Immervoll T, et al. **Nucleic Acids Res** 1999 Jan 1; 27(1):213–4
Prevalence of specific allergic diseases in school children as related to parental atopy. Matsuoka S, et al. **Pediatr Int** 1999 Feb;41(1):46–51
Biophysical characterization of a designed TMV coat protein mutant, R46G, that elicits a moderate hypersensitivity response in Nicotiana sylvestris. Toedt JM, et al.
Protein Sci 1999 Feb;8(2):261–70
Verification of self-reported asthma and allergy in subjects and their family members volunteering for gene mapping studies. Kauppi P, et al. **Respir Med** 1998 Nov; 92(11):1281–8
A factor analysis of associations among self-reported immune related symptoms in a large twin sample. Duffy DL, et al. **Twin Res** 1998 Jun;1(2):71–7
[Atopy and interleukin-4 receptor] Izuhara K.
Rinsho Byori 1999 Jun;47(6):525–30 (7 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

[Diagnosis of allergic diseases. Contribution of the Zurich Allergy Unit 1948–1998] Bircher AJ.
Schweiz Rundsch Med Prax 1998 Sep 30;87(40):1277–84 (Eng. Abstr.) **(Ger)**
[Curious history of the eosinophil from the allergy perspective] Garcia-Procel E. **Gac Med Mex** 1998 Sep-Oct;134(5):583–6 **(Spa)**

IMMUNOLOGY

In vivo and in vitro studies on the residual allergenicity of partially hydrolysed infant formulae. Niggemann B, et al.
Acta Paediatr 1999 Apr;88(4):394–8
Immunotherapy and mast cell activation. Carlos AG, et al.
Allerg Immunol (Paris) 1998 Oct;30(8):257–8
Induction of allergy to new aeroallergens during specific immunotherapy (SIT) in grass pollen sensitive patients. Obtulowicz K, et al. **Allerg Immunol (Paris)** 1998 Oct; 30(8):250–4
30 Years with IgE. Proceedings of an international symposium on basic and clinical aspects of atopic allergy. Stockholm, Sweden, 1–2 September 1998. **Allergy** 1998; 53(45 Suppl):5–97
The role of shock organs in influencing the clinical expression of allergy [editorial] Bonini S, et al. **Allergy** 1999 Jan; 54(1):3–6
Dendritic cells in allergy. Novak N, et al. **Allergy** 1999 Aug; 54(8):792–803 (89 ref.)
The clinical expression of allergy in the skin. Ring J, et al.
Allergy 1999 Mar;54(3):192–7 (36 ref.)
Environmental priming influences allergen-specific nasal reactivity. Toth J, et al. **Allergy** 1998 Dec;53(12):1172–7
The role of allergen-specific T cells in the allergic immune response: relevance to allergy vaccination. van Neerven RJ. **Allergy** 1999 Jun;54(6):552–61 (134 ref.)
Bronchial allergen challenge in subjects with low levels of allergic sensitization to indoor allergens. Witteman AM, et al. **Allergy** 1999 Apr;54(4):366–74
Cytokines and allergic diseases: clinical aspects. Bellanti JA.
Allergy Asthma Proc 1998 Nov-Dec;19(6):337–41 (14 ref.)
Shifts in lung lymphocyte profiles correlate with the sequential development of acute allergic and chronic tolerant stages in a murine asthma model. Yiamouyiannis CA, et al. **Am J Pathol** 1999 Jun;154(6):1911–21
IFN-gamma potentiates the release of TNF-alpha and MIP-1alpha by alveolar macrophages during allergic reactions. Dery RE, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):407–12
Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Gudmundsson G, et al.
Am J Respir Cell Mol Biol 1998 Nov;19(5):812–8
Differential effects of endogenous and exogenous interferon-gamma on immunoglobulin E, cellular infiltration, and airway responsiveness in a murine model of allergic asthma. Hofstra CL, et al.
Am J Respir Cell Mol Biol 1998 Nov;19(5):826–35
Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation. Umland SP, et al.
Am J Respir Cell Mol Biol 1999 Mar;20(3):481–92
Minimal requirements for adequate labeling of allergy extracts and skin tests report forms. ACAAI Board of Regents. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):201
A summary of the atmospheric surveys published in the United States allergy literature, 1966–1996. Frenz DA, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):543–7
Allergen immunotherapy: a long-term perspective [editorial] Patterson R, et al. **Ann Allergy Asthma Immunol** 1999 Apr; 82(4):315–6
IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus. Morton S, et al. **Ann Rheum Dis** 1998 Nov;57(11):660–3
Brief neonatal exposure to cows' milk and atopy [letter; comment] Tamburlini G, et al. **Arch Dis Child** 1999 Feb; 80(2):208. Comment on: Arch Dis Child 1998 Aug;79(2):126–30.

Onset and persistence of the allergic inflammation: a molecular explanation? Spinozzi F.
Arch Immunol Ther Exp (Warsz) 1998;46(5):277–84 (44 ref.)
Allergy in the airway. Sutherland M, et al.
Aust Fam Physician 1998 Aug;27(8):681–5 (32 ref.)
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)–3 in mast cell–mediated type I hypersensitivity reactions. Malaviya R, et al.
Biochem Biophys Res Commun 1999 Apr 21;257(3):807–13
It's spring, and thoughts turn to...allergies. Metzger H.
Cell 1999 Apr 30;97(3):287–90 (20 ref.)
Histamine—a major role in allergy? Bachert C.
Clin Exp Allergy 1998 Dec;28 Suppl 6:15–9 (18 ref.)
Regulation of allergy and asthma by T-cell Vbeta family subsets [editorial; comment] Bakakos P, et al.
Clin Exp Allergy 1998 Dec;28(12):1449–53. Comment on: Clin Exp Allergy 1998 Dec;28(12):1571–80.
Grass pollen: trends and predictions [editorial] Burr ML.
Clin Exp Allergy 1999 Jun;29(6):735–8 (26 ref.)
Sensitization to cat without direct exposure to cats [see comments] Chan–Yeung M, et al. **Clin Exp Allergy** 1999 Jun;29(6):762–5. Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.
High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats [see comments] Ichikawa K, et al. **Clin Exp Allergy** 1999 Jun; 29(6):754–61. Comment in: Clin Exp Allergy 1999 Jun;29(6):725–8.
Which is the true regulator of TH2 cell development in allergic immune responses? [editorial; comment] Kirman J, et al. **Clin Exp Allergy** 1998 Aug;28(8):908–10 (35 ref.) . Comment on: Clin Exp Allergy 1998 Aug;28(8):950–5.
The anti–IgE/anti–FcepsilonRIalpha autoantibody network in allergic and autoimmune diseases. Marone G, et al.
Clin Exp Allergy 1999 Jan;29(1):17–27 (109 ref.)
Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model. Michils A, et al. **Clin Exp Allergy** 1999 Jun;29(6):832–9
Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Novembre E, et al. **Clin Exp Allergy** 1998 Jul;28(7):834–8
The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy. Schleimer RP, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:15–23 (93 ref.)
Asthma, atopy and Chlamydia pneumoniae antibodies in adults. Von Hertzen L, et al. **Clin Exp Allergy** 1999 Apr; 29(4):522–8
Maternal programming in asthma and allergy. Warner JA, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:35–8; discussion 50–1
Enzymatic activity of soluble phospholipase A2 does not affect the specific IgE, IgG4 and cytokine responses in bee sting allergy. Wymann D, et al. **Clin Exp Allergy** 1998 Jul;28(7):839–49
Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects. Jenks PJ, et al. **Clin Exp Dermatol** 1999 Mar;24(2):112–7
Contrasting roles for RANTES and macrophage inflammatory protein–1 alpha (MIP–1 alpha) in a murine model of allergic peritonitis. Das AM, et al.
Clin Exp Immunol 1999 Aug;117(2):223–9
Characterization of Epstein–Barr virus (EBV)–infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL–2–dependent NK–like cell line. Tsuge I, et al. **Clin Exp Immunol** 1999 Mar;115(3):385–92
Activation of the human RANTES gene promoter in a macrophage cell line by lipopolysaccharide is dependent on stress–activated protein kinases and the IkappaB kinase cascade: implications for exacerbation of allergic inflammation by environmental pollutants [see comments] Hiura TS, et al. **Clin Immunol** 1999 Mar;90(3):287–301. Comment in: Clin Immunol 1999 Mar;90(3):285–6.
Redirecting Th2 responses in allergy. Parronchi P, et al.
Curr Top Microbiol Immunol 1999;238:27–56 (193 ref.)
Immunoblot analysis of components of barley recognized by IgE antibodies in sera from pig farm workers. Chiung YM, et al. **Electrophoresis** 1998 Jun;19(8–9):1317–8
Cytokine antagonists and allergy. Grunewald SM, et al.
Eur Cytokine Netw 1998 Sep;9(3 Suppl):92–4 (16 ref.)
Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. Braun A, et al.
Eur J Immunol 1998 Oct;28(10):3240–51
Seasonal variations in T–lymphocyte response to grass pollen allergens from pollen–allergic patients and healthy controls. Jepsen KF, et al. **Exp Clin Immunogenet** 1998;15(3):144–53
B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. Ball T, et al. **FASEB J** 1999 Aug; 13(11):1277–90
10th International Congress of Mucosal Immunology. Amsterdam, The Netherlands, 27 June–1 July, 1999. Proceedings and abstracts. **Immunol Lett** 1999 Jun 15; 69(1):1–216
Modulation of eosinophilic chemotaxis with azelastine and budesonide in allergic patients. Ventura MT, et al.
Immunopharmacol Immunotoxicol 1998 Aug;20(3):383–98
Increase in histamine production by inflammatory exudate in the chronic phase of allergic inflammation in rats. Hirasawa N, et al. **Inflammation** 1998 Oct;22(5):471–82
Eosinophils in allergy and related diseases. Proceedings of a workshop. Tokyo, Japan, June 28, 1997.
Int Arch Allergy Immunol 1998 Sep;117 Suppl 1:1–82
IgE–mediated reactions to autoantigens in allergic diseases. Appenzeller U, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):193–6
A new paradigm of T cell allergy: requirement for the B–1 cell subset. Askenase PW, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):145–9
Regulation of FcepsilonARI synthesis in human eosinophils. Bjerke T, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):440–2
Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. Bonini S, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):159–62 (25 ref.)
Validation of family sampling for mite allergen (Der p 1) exposure. Carswell F, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):324–5
Recurrent vulvovaginal candidiasis – allergy or immune deficiency? Clancy R, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):349–50
Allergic respiratory responses to Der p 1 in mice. Clarke AH, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):287–8
Do allergens induce type–2 immune responses? Comoy E, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):399–402
Anti–inflammatory activity in human skin: it prevents edema formation in vitro. Dorsch W, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):236–9
Cytokines in breast milk from allergic and nonallergic mothers. Fageräs Böttcher M, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):319–20
Role of the Th2 cytokines in the development of allergen–induced airway inflammation and hyperresponsiveness. Hamelmann E, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):90–4
Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1. Hoyne GF, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):122–4
IgE inhibition as a therapy for allergic disease. Jardieu PM, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):112–5 (12 ref.)
Nonapeptides selected by phage display mimic the binding sites of monoclonal antibodies BIP1 and BIP4 on Bet v 1, the major birch pollen allergen. Jensen–Jarolim E, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):224–5
Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice. Kasai M, et al.
Int Arch Allergy Immunol 1998 Sep;117 Suppl 1:14–9
IgE–related peptide mimotopes. Basic structures for anti–allergy vaccine development. Kricek F, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):222–3
An in vitro model for the allergen–IgE–FcARI interaction. Laffer S, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):116–8
Implications of the grass group I allergens on the sensitization and provocation process. Petersen A, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):411–3
Environmental risk factors for respiratory and skin atopy: results from epidemiological studies in former East and West Germany. Ring J, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):403–7
Do Tr1 cells play a role in immunotherapy? Saloga J, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):210–1
Mimotope and anti–idiotypic vaccines to induce an anti–IgE response. Stadler BM, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):119–21
CD8 T–lymphocyte–mediated regulation of ovalbumin–specific murine IgE responses. Thomas MJ, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):289–91
Comparison of T–cell responses induced by major and less major allergens of the house dust mite. Thomas WR, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):214–5
Hypersensitivity of bronchial asthmatics to cockroach in Taiwan. comparative study between American and German cockroaches. Tsai JJ, et al. **Int Arch Allergy Immunol** 1998 Nov;117(3):180–6
Clinical testing of recombinant allergens of the mold Alternaria alternata. Unger A, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):220–1
Differential recognition of recombinant Phl p 5 isoallergens by Phl p 5–specific T cells. van Neerven R, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):125–8
Molecular basis of drug recognition by specific T–cell receptors. von Greyerz S, et al.
Int Arch Allergy Immunol 1999 Jul;119(3):173–80 (49 ref.)
Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type–I allergy. Wiedermann U, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):129–32
Relationship of indoor allergen exposure to skin test sensitivity in inner–city children with asthma. Eggleston PA, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):563–70
Exposure–response relationships for work–related sensitization in workers exposed to rat urinary allergens: results from a pooled study. Heederik D, et al.
J Allergy Clin Immunol 1999 Apr;103(4):678–84
Molecular modulation of allergic responses. Huang SK.
J Allergy Clin Immunol 1998 Dec;102(6 Pt 1):887–92 (64 ref.)
Molecular mechanisms of CD8+ T cell–mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. Kalish RS, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):192–9 (100 ref.)
Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. Nel AE, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):539–54 (115 ref.)
The value of acoustic rhinometry in assessing nasal responses to cat exposure. Phipatanakul W, et al.
J Allergy Clin Immunol 1998 Dec;102(6 Pt 1):896–901
Biologic activities of IL–1 and its role in human disease. Rosenwasser LJ. **J Allergy Clin Immunol** 1998 Sep; 102(3):344–50 (47 ref.)
Evaluation and treatment of allergic fungal sinusitis. I. Demographics and diagnosis. Schubert MS, et al.
J Allergy Clin Immunol 1998 Sep;102(3):387–94
Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL–12 production. Tang L, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):428–35
Gelatin–induced T–cell activation in children with nonanaphylactic–type reactions to vaccines containing gelatin. Taniguchi K, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):1028–32
GM–CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice. Stämpfli MR, et al. **J Clin Invest** 1998 Nov 1; 102(9):1704–14
Point–counterpoint: "Allergy" in atopic dermatitis [see comments] Beltrani VS. **J Cutan Med Surg** 1999 Apr; 3(4):198. Comment in: J Cutan Med Surg 1999 Apr;3(4):199–200.
Point–counterpoint: "Allergy in atopic dermatitis: more harm than good?" [comment] Weston WL. **J Cutan Med Surg** 1999 Apr;3(4):199–200. Comment on: J Cutan Med Surg 1999 Apr;3(4):198.
Fc epsilon RI on dendritic cells: a receptor, which links IgE mediated allergic reaction and T cell mediated cellular response. Shibaki A. **J Dermatol Sci** 1998 May;20(1):29–38 (90 ref.)
In vivo function of an interleukin 2 receptor beta chain (IL–2Rbeta)/IL–4Ralpha cytokine receptor chimera potentiates allergic airway disease. Youn J, et al.
J Exp Med 1998 Nov 16;188(10):1803–16
Specific V beta T cell subsets are associated with cat and birch pollen allergy in humans. Beyer K, et al.
J Immunol 1999 Jan 15;162(2):1186–91
Does IgE bind to and activate eosinophils from patients with allergy? Kita H, et al. **J Immunol** 1999 Jun 1; 162(11):6901–11
Patterns of immunoglobulin E sensitization to chironomids in exposed and unexposed subjects. Galindo PA, et al.
J Investig Allergol Clin Immunol 1999 Mar–Apr;9(2):117–22
Sensitization to cockroach allergens in a sample from the urban population living in Naples (southern Italy). Liccardi G, et al. **J Investig Allergol Clin Immunol** 1998 Jul–Aug; 8(4):245–8
The molecular and cell biology of allergy. Holgate ST, et al. **J Laryngol Otol** 1998 Dec;112(12):1126–37 (12 ref.)
Comparison of sensitization to crude and purified house dust mite allergens in inbred mice. Yasue M, et al.
Lab Anim Sci 1998 Aug;48(4):346–52
Expression of IgH chain genes in antibody response to ragweed and purified Amb a 1: evidence for differential regulation of isotype production. Allauzen S, et al.
Mol Immunol 1999 Jun;36(9):587–98
Cell–mediated allergy to a cerebral aneurysm clip: case report [letter] McFadden JT. **Neurosurgery** 1999 Jul;45(1):200–2
Allergy to house dust mite and snails: a model of cross–reaction between food and inhalant allergens with a clinical impact. Pajno GB, et al.
Pediatr Pulmonol Suppl 1999;18:163–4
Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415–20 (39 ref.)
Endothelin–1 expression during early response after antigen challenge in brown–norway rats. Sánchez–Cifuentes MV, et al. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):215–9
The immune response to dermatophytes. Woodfolk JA, et al. **Res Immunol** 1998 May–Jun;149(4–5):436–45; discussion 522–3 (65 ref.)
Increased frequencies of allergen–induced interleukin–13–producing cells in atopic individuals during the pollen season. Gabrielsson S, et al.
Scand J Immunol 1998 Oct;48(4):429–35
[Effects of cigarette smoke on allergic diseases] Wang L, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Mar; 31(2):78–80 (Eng. Abstr.) **(Chi)**
[Cytokines and allergic response] Guenounou M.
Ann Biol Clin (Paris) 1998 May–Jun;56(3):297–304 (29 ref.) (Eng. Abstr.) **(Fre)**
[Immunological bases and classification of allergy] Bongrand P. **Arch Pediatr** 1999;6 Suppl 1:20S–28S (24 ref.) (Eng. Abstr.) **(Fre)**
[IgE levels in cord blood in an area of the Veneto region] Tenderini ML, et al. **Minerva Pediatr** 1998 May; 50(5):157–61 (Eng. Abstr.) **(Ita)**
[Allergic inflammation and cytokine network] Iwamoto I.
Arerugi 1999 Jan;48(1):9–12 (7 ref.) **(Jpn)**

[Roles of eosinophils in allergic skin diseases] Satoh T. **Arerugi** 1999 May;48(5):496–9 (7 ref.) **(Jpn)**

[The role of chemokines such as RANTES in allergic disease] Chihara J. **Rinsho Byori** 1998 Aug;46(8):816–20 (21 ref.) (Eng. Abstr.) **(Jpn)**

[The role of basophils in the pathogenesis of allergic diseases] Grzywacz Z, et al. **Pneumonol Alergol Pol** 1998; 66(3–4):229–34 (30 ref.) **(Pol)**

[The role of bacteria in allergic and pseudoallergic reactions] Szymaniak L, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):37–40 (31 ref.) (Eng. Abstr.) **(Pol)**

[Allergy and lung function in school children] Jędrychowski W, et al. **Przegl Epidemiol** 1998;52(4):505–12 (Eng. Abstr.) **(Pol)**

[Changes in activation marker expression by lymphocytes in patients with infectious allergic myocarditis associated with disease progression] Poriadin GV, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):86–8 **(Rus)**

[Increased sensitivity to cockroaches of the species Blattella germanica in patients with allergic diseases] Gerbazieva VB, et al. **Patol Fiziol Eksp Ter** 1999 Jan–Mar;(1):11–4 (Eng. Abstr.) **(Rus)**

[Allergy: allergens, induction and IgE synthesis regulation] Gushchin IS. **Patol Fiziol Eksp Ter** 1999 Jan–Mar;(1):24–32 (17 ref.) **(Rus)**

[Proteins of the complement system in normergy and anergy on mycobacterial antigens] Kochubinskiĭ VV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov–Dec; (6):52–7 (Eng. Abstr.) **(Rus)**

[T lymphocytes in allergic inflammation] Tomić-Spirić V, et al. **Srp Arh Celok Lek** 1998 Jul–Aug;126(7–8):309–15 (42 ref.) (Eng. Abstr.) **(Scc)**

METABOLISM

Atopic disease and milk fatty acid composition [comment] Hamosh M. **Acta Paediatr** 1998 Jul;87(7):719–20. Comment on: Acta Paediatr 1998 Jul;87(7):729–36.

Fatty acid composition in colostrum and mature milk from non-atopic and atopic mothers during the first 6 months of lactation [see comments] Yu G, et al. **Acta Paediatr** 1998 Jul;87(7):729–36. Comment in: Acta Paediatr 1998 Jul;87(7):719–20.

Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1-mediated histamine release from human nasal mucosa. Fujikura T, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1331–5

Histamine synthesis, action and inactivation: is the balance disturbed in allergy? [editorial; comment] Clough GF, et al. **Clin Exp Allergy** 1999 Jan;29(1):9–11. Comment on: Clin Exp Allergy 1999 Jan;29(1):76–83.

Association studies on beta2-adrenoceptor polymorphisms and enhanced IgE responsiveness in an atopic population. Deichmann KA, et al. **Clin Exp Allergy** 1999 Jun; 29(6):794–9

STAT6: an intracellular target for the inhibition of allergic disease [editorial; comment] Foster PS. **Clin Exp Allergy** 1999 Jan;29(1):12–6 (38 ref.). Comment on: Clin Exp Allergy 1999 Jan;29(1):114–23.

Tumour necrosis factor alpha (TNFalpha) in tears of atopic patients after conjunctival allergen challenge. Vesaluoma M, et al. **Clin Exp Allergy** 1999 Apr;29(4):537–42

Hydrolysis of peripheral leucine enkephalin in allergic asthma. Fuso L, et al. **Clin Immunol** 1999 Mar;90(3):411–9

Relationship between acetylation polymorphism and risk of atopic diseases. Gawrońska-Szklarz B, et al. **Clin Pharmacol Ther** 1999 May;65(5):562–9

Allergy receptor pictured [news] **Environ Health Perspect** 1999 Jun;107(6):A294–6

Nerve growth factor: an important molecule in allergic inflammation and tissue remodelling. Bonini S, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):159–62 (25 ref.)

Molecular modulation of allergic responses. Huang SK. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):887–92 (64 ref.)

Chemokines and chemokine receptors in allergic diseases. Uguccioni M. **Pediatr Pulmonol Suppl** 1999;18:113–4 (10 ref.)

IgE binding patterns to German cockroach whole body extract in Korean atopic asthmatic children. Lee SY, et al. **Yonsei Med J** 1998 Oct;39(5):409–16

MICROBIOLOGY

The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Björkstén B, et al. **Clin Exp Allergy** 1999 Mar;29(3):342–6

NURSING

Allergy and nursing [editorial] Twarog FJ. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):209

PARASITOLOGY

Ascaris-specific IgE and allergic sensitization in a cohort of school children in the former East Germany. Dold S, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):414–20

Parasite infections and the risk of asthma and atopy [editorial] Lynch NR, et al. **Thorax** 1999 Aug;54(8):659–60

PATHOLOGY

Allergic esophagitis in children: a clinicopathological entity. Walsh SV, et al. **Am J Surg Pathol** 1999 Apr;23(4):390–6

The hypersensitive response. A programmed cell death associated with plant resistance. Pontier D, et al. **C R Acad Sci III** 1998 Sep;321(9):721–34 (174 ref.)

In vitro effects of Uriage spring water on the apoptosis of human eosinophils. Beauvais F, et al. **Fundam Clin Pharmacol** 1998;12(4):446–50

PHYSIOPATHOLOGY

Influence of the allergic response on the mucociliary system in the eustachian tube. Tanaka A, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:98–101

Asthma, wheezy bronchitis, and atopy across two generations. Christie GL, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):125–9

Influence of shift work and host factors on endotoxin-related acute peak flow changes. Zock JP, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):137–42

Reciprocal effects of age and clinical allergy: is there more to be learned? [editorial; comment] Bernstein IL. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):131–2. Comment on: Ann Allergy Asthma Immunol 1999 Feb;82(2):152–6.

Development of inflammatory hypersensitivity and augmentation of sodium channels in rat dorsal root ganglia. Gould HJ 3rd, et al. **Brain Res** 1999 Apr 10;824(2):296–9

Exhaled and nasal nitric oxide is increased in laboratory animal allergy. Adisesh LA, et al. **Clin Exp Allergy** 1998 Jul;28(7):876–80

The route of antigen delivery determines the airway and lung tissue mechanical responses in allergic rats. Hall GL, et al. **Clin Exp Allergy** 1999 Apr;29(4):562–8

The biological function of allergens: relevant for the induction of allergic diseases? Bufe A. **Int Arch Allergy Immunol** 1998 Dec;117(4):215–9 (47 ref.)

Receptors and cytokines involved in allergic TH2 cell responses. de Vries JE, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 2):S492–6 (31 ref.)

Apoptosis of eosinophils and lymphocytes in allergic inflammation. Ohta K, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):14–21 (57 ref.)

Adhesive explant culture of allergic nasal mucosa: effect of emedastine difumarate, an anti-allergic drug. Okubo K, et al. **Jpn J Pharmacol** 1999 Mar;79(3):351–7

Further evidence for allergic pathophysiology in allergic fungal sinusitis. Manning SC, et al. **Laryngoscope** 1998 Oct; 108(10):1485–96

Enhanced allergic responses to house dust mite by oral exposure to carbaryl in rats. Dong W, et al. **Toxicol Sci** 1998 Jul;44(1):63–9

[Role of superoxide generation and degradation system of mast cells in allergic inflammation] Akagi M, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:73P–77P (Eng. Abstr.) **(Jpn)**

[The functional activity of the minor salivary glands of the lips in allergic cheilitis] Obraztsov IuL, et al. **Stomatologiia (Mosk)** 1999;78(3):15–8 (Eng. Abstr.) **(Rus)**

[Physical properties of tracheobronchial contents in patients with bronchial asthma and patients with nonpulmonary allergy] Dobrykh VA, et al. **Ter Arkh** 1999;71(3):14–6 (Eng. Abstr.) **(Rus)**

[Cytokines in allergic inflammation] Bonači-Nikolić B, et al. **Srp Arh Celok Lek** 1999 Jan–Feb;127(1–2):48–53 (39 ref.) **(Scc)**

[The role of prostaglandins in allergic inflammation] Raśković S, et al. **Srp Arh Celok Lek** 1998 Sep–Oct; 126(9–10):388–93 (33 ref.) (Eng. Abstr.) **(Scc)**

[The role of endothelial cells in allergic inflammation reactions] Stefanović Lj, et al. **Srp Arh Celok Lek** 1998 Mar–Apr;126(3–4):138–44 (29 ref.) (Eng. Abstr.) **(Scc)**

[The role of eosinophilic leukocytes in allergic inflammation] Stošović R, et al. **Srp Arh Celok Lek** 1998 Mar–Apr; 126(3–4):130–7 (40 ref.) (Eng. Abstr.) **(Scc)**

PREVENTION & CONTROL

Prevention of allergies of infants: breast-feeding and special formulas. Influence on the response to immunization. Salvioli GP, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:21–7

Effects of maternal dietary avoidance during lactation on allergy in children at 10 years of age. Hattevig G, et al. **Acta Paediatr** 1999 Jan;88(1):7–12

The effect of air filtration on airborne dog allergen. Green R, et al. **Allergy** 1999 May;54(5):484–8

Strategic targets for primary prevention of allergic disease in childhood. Holt PG, et al. **Allergy** 1998;53(45 Suppl):72–6

Complete mattress encasing is not superior to partial encasing in the reduction of mite allergen. Vichyanond P, et al. **Allergy** 1999 Jul;54(7):736–41

What's in a name? Vaccine versus extracts [editorial; comment] Finegold I. **Ann Allergy Asthma Immunol** 1998 Nov;81(5 Pt 1):377. Comment on: Ann Allergy Asthma Immunol 1998 Nov;81(5 Pt 1):401–5.

Control of immune responses by gene immunization. Lee DJ, et al. **Ann Med** 1998 Oct;30(5):460–8 (73 ref.)

House dust mite control measures in the management of asthma: meta-analysis [see comments] Gøtzsche PC, et al. **BMJ** 1998 Oct 24;317(7166):1105–10; discussion 1110. Comment in: BMJ 1999 Mar 27;318(7187):870; dicussion 871. Comment in: BMJ 1999 Mar 27;318(7187):870–1. Comment in: BMJ 1999 Mar 27;318(7187):871.

Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model. El-Hashim AZ, et al. **Br J Pharmacol** 1999 Mar;126(6):1513–21

Evidence that cyclosporin A and dexamethasone inhibit allergic airway eosinophilic inflammation via suppression of interleukin-5 synthesis by T cells. Nakata A, et al. **Br J Pharmacol** 1998 Aug;124(7):1425–32

Proceedings of the 1st International Symposium on Allergy Management. Cannes, February 1998. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:1–61

Attenuation of house dust mite Dermatophagoides farinae-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. Yu CK, et al. **Clin Exp Allergy** 1999 Mar;29(3):414–22

Salviae radix root extract inhibits immunoglobulin E-mediated allergic reaction. Kim HM, et al. **Gen Pharmacol** 1999 May;32(5):603–8

H1- and H2-receptor antagonists prevent histamine release in allergic patients after the administration of midazolam-ketamine. A randomized controlled study. Kimura K, et al. **Inflamm Res** 1999 Mar;48(3):128–32

Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. Hodson T, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):581–5

Atopy, hygiene, and anthroposophic lifestyle. San Marino Study Group [letter] Matricardi PM, et al. **Lancet** 1999 Jul 31;354(9176):430

Occupational allergy to animals. Seward JP. **Occup Med** 1999 Apr–Jun;14(2):285–304 (130 ref.)

Allergy--a public health issue: when should governments act? [editorial] Warner JO. **Pediatr Allergy Immunol** 1999 Feb;10(1):1–2

[Prevention of allergic diseases] Le Sellin J. **Allerg Immunol (Paris)** 1999 May;31(5):145–7 (5 ref.) (Eng. Abstr.) **(Fre)**

[Habitat of the allergic child: theory and practice] Héraud MC. **Arch Pediatr** 1999;6 Suppl 1:94S–97S (Eng. Abstr.) **(Fre)**

[The child, his mother and allergies] Hofer MF. **Rev Med Suisse Romande** 1999 Aug;119(8):623–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Methods and applications in the control of hypersensitivity in exposed occupational populations] Previdi M, et al. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):131–7 (Eng. Abstr.) **(Ita)**

[Environmental control for allergic diseases--avoiding and killing effect on housedust-mite by eastern red cedar] Enomoto T, et al. **Arerugi** 1999 Jun;48(6):626–31 (Eng. Abstr.) **(Jpn)**

[A case received pre-exposure immunization against rabies by intradermal injection of rabies vaccine because of allergic reaction to the component of the vaccine] Takayama N, et al. **Kansenshogaku Zasshi** 1999 Jun; 73(6):600–1 (Eng. Abstr.) **(Jpn)**

[Prevention of allergic illness in the year 2000 (editorial)] Pérez Martín J. **Rev Alerg Mex** 1999 Jul–Aug;46(4):89–92 **(Spa)**

PSYCHOLOGY

The emotional needs of allergic and asthmatic patients and their families. Wallerstedt DB, et al. **Allergy Asthma Proc** 1998 Jul–Aug;19(4):189–91

Allergic and non-allergic students' perception of the same high school environment. Lundin L. **Indoor Air** 1999 Jun; 9(2):92–102

REHABILITATION

[The efficacy of treating patients with allergic diseases at a health resort with a gastroenterologic profile] Avdeeva EV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov–Dec;(6):29–30 (Eng. Abstr.) **(Rus)**

THERAPY

Grass pollen specific sublingual/swallow immunotherapy in children: open-controlled comparison among different treatment protocols. Di Rienzo V, et al. **Allergol Immunopathol (Madr)** 1999 May–Jun;27(3):145–51

Non-specific hyperreactivity before and after nasal specific immunotherapy. Filiaci F, et al. **Allergol Immunopathol (Madr)** 1999 Jan–Feb;27(1):24–8

Local immunotherapy. Malling HJ, et al. **Allergy** 1998 Oct; 53(10):933–44 (89 ref.)

Injection of anti-IgE antibodies will suppress IgE and allergic symptoms. Patalano F. **Allergy** 1999 Feb; 54(2):103–10 (43 ref.)

Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Spiegelberg HL, et al. **Allergy** 1998;53(45 Suppl):93–7

The future of allergy practice: an academician's perspective. Rich RR. **Allergy Asthma Proc** 1998 Sep–Oct;19(5):295–9 (11 ref.)

An allergy and asthma educational outreach program for school nurses and staff. Wu F, et al. **Allergy Asthma Proc** 1998 Sep–Oct;19(5):307–10

Allergen immunotherapy: a long-term perspective [editorial] Patterson R, et al. **Ann Allergy Asthma Immunol** 1999 Apr; 82(4):315–6

Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Valenta R, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):815–24 (103 ref.)

Systemic immune response to specific immunotherapy [editorial; comment] Ebner C. **Clin Exp Allergy** 1998 Jul; 28(7):781–3. Comment on: Clin Exp Allergy 1998 Jul;28(7):791–8.

Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Gehlhar K, et al. **Clin Exp Allergy** 1999 Apr;29(4):497–506

Activation of B-lymphocytes during pollen season. Effect of immunotherapy [see comments] Håkansson L, et al. **Clin Exp Allergy** 1998 Jul;28(7):791–8. Comment in: Clin Exp Allergy 1998 Jul;28(7):781–3.

The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy. Schleimer RP, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:15–23 (93 ref.)

Immunotherapy of allergy: anergy, deletion, and immune deviation. Rolland J, et al. **Curr Opin Immunol** 1998 Dec; 10(6):640–5 (53 ref.)

Allergy, immunology, and related disorders [editorial] Fuleihan RL. **Curr Opin Pediatr** 1998 Dec;10(6):581–3 (11 ref.)

Specific immunotherapy in children is safe and effective [letter] Cantani A, et al. **Eur Rev Med Pharmacol Sci** 1998 Jan–Feb;2(1):41–4

IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. Akdis CA, et al. **FASEB J** 1999 Apr; 13(6):603–9 (74 ref.)

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Bousquet J, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):558–62 (58 ref.)

Stinging insect hypersensitivity: a practice parameter. The Joint Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Portnoy JM, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):963–80

Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up. Schubert MS, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):395–402

Herbal interventions in asthma and allergy. Bielory L, et al. **J Asthma** 1999;36(1):1–65 (235 ref.)

Effect of immunotherapy on allergen-specific production of sulphidoleukotriene and histamine. Ferrer M, et al. **J Investig Allergol Clin Immunol** 1998 Sep–Oct;8(5):277–80

[Therapeutics of the future for allergy] Sibille G. **Allerg Immunol (Paris)** 1999 Apr;31(4):120–1 (4 ref.) (Eng. Abstr.) **(Fre)**

[Climate therapy for children with respiratory allergy] Juchet A, et al. **Rev Mal Respir** 1999 Apr;16(2):235–40 (Eng. Abstr.) **(Fre)**

[Specific immunotherapy--past--present--future] Kägi MK. **Schweiz Rundsch Med Prax** 1998 Sep 30;87(40):1330–4 (23 ref.) (Eng. Abstr.) **(Ger)**

[WHO position paper. "Allergen immunotherapy: therapeutic vaccines for allergic diseases"] **Arerugi** 1998 Jul; 47(7):698–704 **(Jpn)**

[Role of polyunsaturated fatty acids in diet therapy of children with allergic diseases] Gorelova ZhIu, et al. **Vopr Pitan** 1999;68(1):31–5 (Eng. Abstr.) **(Rus)**

[We are in the year 2000 (editorial)] Acosta Ortíz R. **Rev Alerg Mex** 1999 Jan–Feb;46(1):1 **(Spa)**

[Therapeutic vaccines in allergic diseases (editorial)] Pérez Martín J. **Rev Alerg Mex** 1999 Mar–Apr;46(2):36–7 **(Spa)**

[Immunotherapy outside the allergy clinic (editorial)] Pérez Martín J. **Rev Alerg Mex** 1998 Nov–Dec;45(6):141–2 **(Spa)**

[Incidence of adverse reactions to immunotherapy in allergic patients at Puebla University Hospital] Sosa Jiménez G, et al. **Rev Alerg Mex** 1998 Nov–Dec;45(6):147–9 (Eng. Abstr.) **(Spa)**

VETERINARY

Observations on the use of cyproheptadine hydrochloride as an antipruritic agent in allergic cats. Scott DW, et al. **Can Vet J** 1998 Oct;39(10):634–7

Parasite infection and Japanese cedar pollinosis in monkeys. Kobayashi C, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):93–100

Immunology of helminth infections, with special reference to immunopathology. Meeusen EN. **Vet Parasitol** 1999 Aug 1;84(3–4):259–73 (58 ref.)

Inhibition of antigen-induced cutaneous responses of ponies with insect hypersensitivity by the histamine-1 receptor antagonist chlorpheniramine. Foster AP, et al. **Vet Rec** 1998 Aug 15;143(7):189–93

HYPERSENSITIVITY ANGIITIS see **VASCULITIS, HYPERSENSITIVITY**

HYPERSENSITIVITY, ATOPIC see **HYPERSENSITIVITY, IMMEDIATE**

HYPERSENSITIVITY, CONTACT see **DERMATITIS, CONTACT**

HYPERSENSITIVITY, DELAYED

see related
CELL MIGRATION INHIBITION
ENCEPHALOMYELITIS, ACUTE DISSEMINATED

Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. McNeel DG, et al. **Blood** 1999 Apr 15;93(8):2653–9

Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Sassi A, et al. **Clin Exp Immunol** 1999 Apr;116(1):127–32

Hypersensitivity reaction over lesions of post-kala-azar dermal leishmaniasis mimicking type 1 reaction in leprosy [letter] Dhar S, et al. **Int J Lepr Other Mycobact Dis** 1999 Mar;67(1):66–7

Effect of UV exposure and beta-carotene supplementation on delayed-type hypersensitivity response in healthy older men. Herraiz LA, et al. **J Am Coll Nutr** 1998 Dec; 17(6):617–24

In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. Maas JJ, et al. **J Infect Dis** 1998 Oct;178(4):1024–9

The immune response to Haemophilus ducreyi resembles a delayed-type hypersensitivity reaction throughout experimental infection of human subjects. Palmer KL, et al. **J Infect Dis** 1998 Dec;178(6):1688–97

GABA(A) receptors mediate inhibition of T cell responses. Tian J, et al. **J Neuroimmunol** 1999 Apr 1;96(1):21–8

Effects of the lipopolysaccharide-protein complex and crude capsular antigens of Pasteurella multocida serotype A on antibody responses and delayed type hypersensitivity responses in the chicken. Maslog FS, et al. **J Vet Med Sci** 1999 May;61(5):565–7

CHEMICALLY INDUCED

The significance of previous contact dermatitis for elicitation of contact allergy to nickel. Hindsén M, et al. **Acta Derm Venereol** 1998 Sep;78(5):367–70

Combined immediate- and delayed-type hypersensitivity to metamizole. Bellegrandi S, et al. **Allergy** 1999 Jan; 54(1):88–90

Delayed-type hypersensitivity to subcutaneous enoxaparin. Méndez J, et al. **Allergy** 1998 Oct;53(10):999–1003

Serum dioxin and immunologic response in veterans of Operation Ranch Hand. Michalek JE, et al. **Am J Epidemiol** 1999 Jun 1;149(11):1038–46

Delayed hypersensitivity to diclofenac: a report on two cases. Romano A, et al. **Ann Allergy Asthma Immunol** 1998 Oct; 81(4):373–5

Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Olaison L, et al. **Arch Intern Med** 1999 Mar 22; 159(6):607–15

Late-type allergy to the X-ray contrast medium Solutrast (iopamidol). Gall H, et al. **Contact Dermatitis** 1999 May; 40(5):248–50

Inconsistent intracutaneous and patch test results in a patient allergic to mepivacaine and prilocaine. Kanerva L, et al. **Contact Dermatitis** 1998 Oct;39(4):197–9

Eyelid dermatitis caused by delayed-type hypersensitivity to natural rubber latex. Katoh N, et al. **Contact Dermatitis** 1999 Jun;40(6):336–7

Occupational chemical burns caused by bromine. Kim IH, et al. **Contact Dermatitis** 1999 Jul;41(1):43

Delayed-type allergy to technetium Tc 99m. Mooser G, et al. **Contact Dermatitis** 1998 Nov;39(5):269–70

A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. Romano A, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1186–90

Delayed hypersensitivity to enoxaparin. Cabañas R, et al. **J Investig Allergol Clin Immunol** 1998 Nov–Dec;8(6):383–4

Allergic responses to titanium [letter; comment] Matthew I, et al. **J Oral Maxillofac Surg** 1998 Dec;56(12):1466–7. Comment on: J Oral Maxillofac Surg 1998 Feb;56(2):184–8.

Re: Delayed hypersensitivity and systemic arthralgia following transurethral collagen injection for stress urinary incontinence [letter; comment] Elson ML. **J Urol** 1999 Feb; 161(2):610. Comment on: J Urol 1998 May;159(5):1507–9.

Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. John M, et al. **Med J Aust** 1998 Nov 2;169(9):473–4

COMPLICATIONS

Frequency of delayed-type hypersensitivity to contact allergens in psoriatic patients. Stinco G, et al. **Contact Dermatitis** 1999 Jun;40(6):323–4

Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum. Rea TH, et al. **Int J Lepr Other Mycobact Dis** 1998 Sep;66(3):316–27

DIAGNOSIS

Cutaneous allergic reaction to intramuscular vitamin K1. Wong DA, et al. **Australas J Dermatol** 1999 Aug; 40(3):147–52

Severe delayed adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs). Hernández Fernández de Rojas. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:47–51 (27 ref.)

Delayed hypersensitivity to aminopenicillins. Romano A. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:29–32

Delayed-type allergy to technetium Tc 99m. Mooser G, et al. **Contact Dermatitis** 1998 Nov;39(5):269–70

Trans vivo analysis of human delayed-type hypersensitivity reactivity. Carrodeguas L, et al. **Hum Immunol** 1999 Aug; 60(8):640–51

Monitoring cellular immune function in HIV infection by the delayed hypersensitivity skin test: alternative to the CD4 T-cell count? [editorial; comment] Shearer WT. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):26–8. Comment on: J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):93–8.

Immediate and delayed hypersensitivity to mite antigens in atopic dermatitis. Varela P, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):1–5

No relation of tuberculin reactivity with quantitative analysis of peripheral blood lymphocyte subsets in haemodialysis patients. Yildiz A, et al. **Respir Med** 1999 Feb;93(2):119–22

[Absence of changes in viral plasma of the human immunodeficiency virus after the application of the delayed cutaneous hypersensitivity test (letter)] Pachón J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):77 **(Spa)**

DRUG THERAPY

Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. Pallast EG, et al. **Am J Clin Nutr** 1999 Jun;69(6):1273–81

Comparison of immunopharmacological actions of 8 kinds of kampo-hozais clinically used in atopic dermatitis on delayed-type hypersensitivity in mice. Nose M, et al. **Biol Pharm Bull** 1999 Jan;22(1):48–54

Effects of intravenous omega-3 and omega-6 fat emulsion on cytokine production and delayed type hypersensitivity in burned rats receiving total parenteral nutrition. Hayashi N, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov–Dec; 22(6):363–7

Effects of fujibitol, a remedy for nasal symptoms of immediate and delayed type allergic reactions. Kakimoto M, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun; 21(5):353–6

[Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice] Sengoku T, et al. **Nippon Yakurigaku Zasshi** 1998 Sep; 112(3):221–32 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Restricted cyclooxygenase-2 expression in the central nervous system following acute and delayed-type hypersensitivity responses to bacillus Calmette-Guérin. Minghetti L, et al. **Neuroscience** 1999;92(4):1405–15

EPIDEMIOLOGY

Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. Kattan M. **J Pediatr** 1999 Aug;135(2 Pt 2):8–13 (38 ref.)

ETIOLOGY

Comparison of Q fever cellular and chloroform-methanol residue vaccines as skin test antigens in the sensitized guinea pig. Elliott JJ, et al. **Acta Virol** 1998 Jun;42(3):147–55

Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG. Harenberg J, et al. **Allergy** 1999 May;54(5):473–7

Severe delayed adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs). Hernández Fernández de Rojas. **Clin Exp Allergy** 1998 Sep;28 Suppl 4:47–51 (27 ref.)

Dynamics of wound healing after silicone device implantation. Shanklin DR, et al. **Exp Mol Pathol** 1999 Sep;67(1):26–39

Intraoral contact allergy: a literature review and case reports [see comments] De Rossi SS, et al. **J Am Dent Assoc** 1998 Oct;129(10):1435–41 (40 ref.). Comment in: J Am Dent Assoc 1999 Jan;130(1):24, 26.

Fibroin allergy. IgE mediated hypersensitivity to silk suture materials. Kurosaki S, et al. **Nippon Ika Daigaku Zasshi** 1999 Feb;66(1):41–4

Higher abnormal leukocyte and lymphocyte counts 20 years after exposure to severe stress: research and clinical implications. Boscarino JA, et al. **Psychosom Med** 1999 May–Jun;61(3):378–86

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Rosenthal KS, et al. **Vaccine** 1999 Feb 12; 17(6):535–42

[The development of delayed-type hypersensitivity in the progeny of female rats with a chronic liver lesion from the action of immobilization stress] Briukhin GV, et al. **Fiziol Zh** 1999;45(3):35–42 (Eng. Abstr.) **(Rus)**

[Absence of changes in viral plasma of the human immunodeficiency virus after the application of the delayed cutaneous hypersensitivity test (letter)] Pachón J, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):77 **(Spa)**

GENETICS

Quantitative analysis of T-cell receptor beta variable-gene

usage in cutaneous late-phase reactions: implications for T-lymphocyte recruitment in cutaneous inflammation. Lessin SR, et al. **Clin Diagn Lab Immunol** 1999 Jan; 6(1):85-8

A Th1 response is essential for induction of crescentic glomerulonephritis in mice. Schatzmann U, et al. **Kidney Blood Press Res** 1999;22(3):135-9

IMMUNOLOGY

Modulation of LTB4 receptor in T-lymphocytes by lipoxin A4 (LXA4) and its role in delayed-type hypersensitivity. Lin KT, et al. **Adv Exp Med Biol** 1999;447:151-63

Delayed-type hypersensitivity to a nonionic, radiopaque contrast medium. Courvoisier S, et al. **Allergy** 1998 Dec; 53(12):1221-4

Effect of dietary supplementation with black currant seed oil on the immune response of healthy elderly subjects. Wu D, et al. **Am J Clin Nutr** 1999 Oct;70(4):536-43

Serum dioxin and immunologic response in veterans of Operation Ranch Hand. Michalek JE, et al. **Am J Epidemiol** 1999 Jun 1;149(11):1038-46

Persistence and boosting of bacille Calmette-Guérin-induced delayed-type hypersensitivity. Hoft DF, et al. **Ann Intern Med** 1999 Jul 6;131(1):32-6

Socially inhibited individuals show heightened DTH response during intense social engagement. Cole SW, et al. **Brain Behav Immun** 1999 Jun;13(2):187-200

Lymphocyte recirculation, exercise, and immune responses. Hay JB, et al. **Can J Physiol Pharmacol** 1998 May; 76(5):490-6 (38 ref.)

Immune mechanisms of the occupational sensitization with methylen-dyphenyl diisocyanate (MDI). Nosko M, et al. **Cent Eur J Public Health** 1998 Aug;6(3):199-201

Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Waanders GA, et al. **Clin Cancer Res** 1997 May; 3(5):685-96

Quantitative analysis of T-cell receptor beta variable-gene usage in cutaneous late-phase reactions: implications for T-lymphocyte recruitment in cutaneous inflammation. Lessin SR, et al. **Clin Diagn Lab Immunol** 1999 Jan; 6(1):85-8

T lymphocytes are not the target for estradiol-mediated suppression of DTH in reconstituted female severe combined immunodeficient (SCID) mice. Taube M, et al. **Clin Exp Immunol** 1998 Nov;114(2):147-53

Dose-responses for UV-induced suppression of various immune responses. Kim T, et al. **Eur J Dermatol** 1998 Apr-May;8(3):195

Delayed-type hypersensitivity reactions to nominal protein antigens and to environmental allergens: similarities and differences. Tsicopoulos A, et al. **Eur J Dermatol** 1999 Jun; 9(4):261-8 (59 ref.)

Bystander suppression of occupational hapten sensitization in rats made tolerant to ovalbumin. Pullerits T, et al. **Eur Respir J** 1998 Oct;12(4):889-94

Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). D'Orazio TJ, et al. **Immunology** 1998 Sep;95(1):47-55

The role of urocanic acid in UVB-induced suppression of immunity to Trichinella spiralis infection in the rat. Garssen J, et al. **Immunology** 1999 Feb;96(2):298-306

Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection. Pais TF, et al. **Immunology** 1998 Sep;95(1):69-75

Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Blackstock R, et al. **Infect Immun** 1999 Jul;67(7):3601-9

Murine splenocytes induce severe gastritis and delayed-type hypersensitivity and suppress bacterial colonization in Helicobacter pylori-infected SCID mice. Eaton KA, et al. **Infect Immun** 1999 Sep;67(9):4594-602

Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. Moore AR, et al. **Int J Immunopharmacol** 1999 Mar;21(3):195-203

The effect of immunodeficiency on cutaneous delayed-type hypersensitivity testing in HIV-infected women without anergy: implications for tuberculin testing. HER Study Group. HIV Epidemiology Research. Klein RS, et al. **Int J Tuberc Lung Dis** 1999 Aug;3(8):681-8

T-cell-mediated immune responses in alloepithelial rejection after murine keratoepithelioplasty. Miyazaki D, et al. **Invest Ophthalmol Vis Sci** 1999 Oct;40(11):2590-7

Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). Anastos K, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):141-7

Stability of cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiology Research Study Group. Klein RS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Mar 1;20(3):238-44

Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. Kalish RS, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):192-9 (100 ref.)

Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group [see comments] Klein RS, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):93-8. Comment in: J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):26-8.

Trichophyton antigens associated with IgE antibodies and delayed type hypersensitivity. Sequence homology to two families of serine proteinases. Woodfolk JA, et al. **J Biol Chem** 1998 Nov 6;273(45):29489-96

Late recall urticaria. Karaayvaz M, et al. **J Investig Allergol Clin Immunol** 1998 Sep-Oct;8(5):309-11

Delayed reaction to cow's milk proteins: a case study. Vila Sexto L, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):249-52

Modulation of cellular annexin I in human leukocytes infiltrating DTH skin reactions. Perretti M, et al. **J Leukoc Biol** 1999 May;65(5):583-9

Immunologic mechanisms of virus-induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14-20 (41 ref.)

N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. Särnstrand B, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1174-84

Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Ampel NM. **Med Mycol** 1999 Aug;37(4):245-50

Cell-mediated allergy to a cerebral aneurysm clip: case report. Ross IB, et al. **Neurosurgery** 1998 Nov; 43(5):1209-11

Effects of several drugs on the liver injury induced by delayed-type hypersensitivity to picryl chloride by regulating suppressor or helper T cells. Cao J, et al. **Pharmacol Res** 1999 Feb;39(2):97-102

Cutaneous delayed-type hypersensitivity reactions in smokers with chronic bronchitis and recurrent exacerbations: comparison with asymptomatic smokers and never-smokers. Qvarfordt I, et al. **Respir Med** 1999 Jul; 93(7):491-7

The traffic of resting lymphocytes through delayed hypersensitivity and chronic inflammatory lesions: a dynamic equilibrium. Seabrook T, et al. **Semin Immunol** 1999 Apr;11(2):115-23 (41 ref.)

Delayed-type hypersensitivity reactions to Onchocerca volvulus antigens in exposed and non-exposed African individuals. Burchard GD, et al. **Trans R Soc Trop Med Hyg** 1999 Jan-Feb;93(1):103-5

Specific IgG to gelatin in children with systemic immediate- and nonimmediate-type reactions to measles, mumps and rubella vaccines. Miyazawa H, et al. **Vaccine** 1999 Apr 23; 17(17):2176-80

[Chronic urticaria caused by cow's milk allergy: immediate or delayed allergy? (apropos of a case)] Drouet M, et al. **Allerg Immunol (Paris)** 1999 Mar;31(3):79-81 (Eng. Abstr.) **(Fre)**

[Delayed-type hypersensitivity in insulin-dependent diabetes mellitus and effects of short-action insulins produced by different pharmaceutical firms] Zhuk EA, et al. **Ter Arkh** 1998;70(12):46-9 (Eng. Abstr.) **(Rus)**

METABOLISM

Biology of basophils and their role in allergic inflammation. Chugh L. **Indian J Chest Dis Allied Sci** 1998 Oct-Dec; 40(4):257-67 (56 ref.)

MICROBIOLOGY

Phlyctenular conjunctivitis. Banapurmath CR, et al. **Indian Pediatr** 1998 Jun;35(6):561

Delayed-type hypersensitivity to Mycobacterium leprae soluble antigens as a test for infection with the leprosy bacillus. Sterne JA, et al. **Int J Epidemiol** 1998 Aug; 27(4):713-21

An assessment of the role of Candida albicans antigen in atopic dermatitis. Morita E, et al. **J Dermatol** 1999 May; 26(5):282-7

PATHOLOGY

Repeated challenge with dinitrobenzene sulphonic acid in dinitrofluorobenzene-sensitized mice results in vascular hyperpermeability in the trachea: a role for tachykinins. van Houwelingen A, et al. **Br J Pharmacol** 1999 Aug; 127(7):1583-8

Localization and ultrastructure of pulmonary dendritic cells during delayed-type hypersensitivity reactions in mice. Nishida T, et al. **Cell Tissue Res** 1999 Sep;297(3):485-92

Phlyctenular conjunctivitis. Banapurmath CR, et al. **Indian Pediatr** 1998 Jun;35(6):561

The UV waveband dependencies in mice differ for the suppression of contact hypersensitivity, delayed-type hypersensitivity and cis-urocanic acid formation. El-Ghorr AA, et al. **J Invest Dermatol** 1999 May;112(5):757-62

PHYSIOPATHOLOGY

Inflammation, leukotrienes and the pathogenesis of the late asthmatic response [editorial; comment] Wenzel SE. **Clin Exp Allergy** 1999 Jan;29(1):1-3. Comment on: Clin Exp Allergy 1999 Jan;29(1):42-51.

Suppression of delayed and contact hypersensitivity responses in mice have different UV dose responses. Kim TH, et al. **Photochem Photobiol** 1998 Nov;68(5):738-44

PREVENTION & CONTROL

Immunosuppression induced by chronic ultraviolet irradiation in humans and its prevention by sunscreens. Moyal D. **Eur J Dermatol** 1998 Apr-May;8(3):209-11

An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production. Pullerits T, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):843-9

Cutaneous delayed-type hypersensitivity response is inhibited in transgenic mice with keratinocyte-specific CD44 expression defect [letter] Kaya G, et al. **J Invest Dermatol** 1999 Jul;113(1):137-8

Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress. Seiter S, et al. **J Invest Dermatol** 1999 Jul;113(1):11-21

Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation. Okamoto S, et al. **Ocul Immunol Inflamm** 1998 Mar;6(1):1-11

Persistent suppression of delayed-type hypersensitivity in adult F344 rats after perinatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Gehrs BC, et al. **Toxicology** 1999 May 3;134(1):79-88

PSYCHOLOGY

Socially inhibited individuals show heightened DTH response during intense social engagement. Cole SW, et al. **Brain Behav Immun** 1999 Jun;13(2):187-200

THERAPY

Delayed toxic reaction following massive bee envenomation. Kolecki P. **Ann Emerg Med** 1999 Jan;33(1):114-6

VETERINARY

Relation between pathologic findings and cellular immune responses in sheep with naturally acquired paratuberculosis. Pérez V, et al. **Am J Vet Res** 1999 Jan;60(1):123-7

Induction of the delayed footpad and wattle reaction to killed Staphylococcus aureus in chickens. Zhu XY, et al. **Poult Sci** 1999 Mar;78(3):346-52

The efficacy of the skin delayed-type hypersensitivity using a Brucellin prepared from a mucoid strain of Brucella abortus to detect brucellosis. Bercovich Z, et al. **Vet J** 1999 Jan;157(1):61-7

VIROLOGY

Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. Kattan M. **J Pediatr** 1999 Aug;135(2 Pt 2):8-13 (38 ref.)

Immunologic mechanisms of virus-induced wheezing and asthma. Welliver RC. **J Pediatr** 1999 Aug;135(2 Pt 2):14-20 (41 ref.)

HYPERSENSITIVITY, DRUG see **DRUG HYPERSENSITIVITY**

HYPERSENSITIVITY, ENVIRONMENTAL see **ENVIRONMENTAL ILLNESS**

HYPERSENSITIVITY, FOOD see **FOOD HYPERSENSITIVITY**

HYPERSENSITIVITY, IMMEDIATE

see related

LATEX ALLERGY

Relation between IgG antibodies to foods and IgE antibodies to milk, egg, cat, dog and/or mite in a cross-sectional study [see comments] Eysink PE, et al. **Clin Exp Allergy** 1999 May;29(5):604-10. Comment in: Clin Exp Allergy 1999 May;29(5):576-8.

What is atopy? Condition, disease or a syndrome? Wüthrich B. **Curr Probl Dermatol** 1999;28:1-8 (38 ref.)

Symptoms related to the sick building syndrome in a general population sample: associations with atopy, bronchial hyper-responsiveness and anxiety. Björnsson E, et al. **Int J Tuberc Lung Dis** 1998 Dec;2(12):1023-8

Atopy, anergic status, and cytokine expression in HIV-infected subjects. Empson M, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):833-42

BLOOD

Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. Crocker IC, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):797-804

IL-1 receptor-type expression in relation to atopy. Gupta K, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1100-7

Reduced expression of hemopoietic cytokine receptors on cord blood progenitor cells in neonates at risk for atopy. Upham JW, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):370-5

Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and nonatopic control subjects. Zeibecoglou K, et al. **J Allergy Clin Immunol** 1999

Jan;103(1 Pt 1):99-106
Identification of basophilic cells that express mast cell granule proteases in the peripheral blood of asthma, allergy, and drug-reactive patients. Li L, et al. **J Immunol** 1998 Nov 1;161(9):5079-86
Measurement of specific IgEs in the diagnosis of drug allergy. Anania A. **Panminerva Med** 1999 Jun;41(2):115-7
[The eosinophilic leukocyte as a key cell of inflammation in atopic bronchial asthma] Fassakhov RS. **Patol Fiziol Eksp Ter** 1999 Jan-Mar;(1):22-4 (14 ref.) **(Rus)**

CHEMICALLY INDUCED

Positive skin tests in late reactions to radiographic contrast media. Brockow K, et al. **Allerg Immunol (Paris)** 1999 Feb; 31(2):49-51
Combined immediate- and delayed-type hypersensitivity to metamizole. Bellegrandi S, et al. **Allergy** 1999 Jan; 54(1):88-90
Niacin reaction: common vitamin, uncommon ED diagnosis [letter] Morse JW, et al. **Am J Emerg Med** 1999 May; 17(3):320-1
The effects of different levels of air pollution on atopy and symptoms of allergic rhinitis. Keleş N, et al. **Am J Rhinol** 1999 May-Jun;13(3):185-90
Allergic reactions to lignocaine. Ball IA. **Br Dent J** 1999 Mar 13;186(5):224-6
Immediate skin and mucosal symptoms from pot plants and vegetables in gardeners and greenhouse workers. Paulsen E, et al. **Contact Dermatitis** 1998 Oct;39(4):166-70
Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Meyer FJ, et al. **Eur Respir J** 1998 Oct;12(4):996-7
Acute reaction to dipyridamole during myocardial scintigraphy [letter] Angelides S, et al. **N Engl J Med** 1999 Feb 4;340(5):394
Mechanisms of severe, immediate reactions to iodinated contrast material [see comments] Laroche D, et al. **Radiology** 1998 Oct;209(1):183-90. Comment in: Radiology 1998 Oct;209(1):35-6.
Guidelines on pulmonary embolism [letter; comment] Davies CW. **Thorax** 1998 Jul;53(7):625. Comment on: Thorax 1997 Oct;52 Suppl 4:S1-24.
[Two patients with chlorhexidine allergy--anaphylactic reactions and eczema] Thune P. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3295-6 (Eng. Abstr.) **(Nor)**

CLASSIFICATION

[Relation between the total plasma IgE concentration and the prevalence of the various RAST (radioallergosorbent) classes of allergy (see comments)] San Martin Ciges E, et al. **Allergol Immunopathol (Madr)** 1998 Sep-Oct; 26(5):228-33 (Eng. Abstr.). Comment in: Allergol Immunopathol (Madr) 1998 Sep-Oct;26(5):203-8. **(Spa)**

COMPLICATIONS

The presence of atopy does not determine the type of cellular infiltrate in nasal polyps. Park HS, et al. **Allergy Asthma Proc** 1998 Nov-Dec;19(6):373-7
Natural killer cell-derived large granular lymphocyte lymphoma of lung developed in a patient with hypersensitivity to mosquito bites and reactivated Epstein-Barr virus infection. Mizuki M, et al. **Am J Hematol** 1998 Dec;59(4):309-15
Immediate hypersensitivity in adults with IgG deficiency and recurrent respiratory infections. Popa V, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):567-73
Difference in airway reactivity in children with atopic vs nonatopic asthma. Mochizuki H, et al. **Chest** 1999 Sep; 116(3):619-24
Croup and recurrent croup: their association with asthma and allergy. An epidemiological study on 5-8-year-old children. Van Bever HP, et al. **Eur J Pediatr** 1999 Mar; 158(3):253-7
Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma. Silvestri M, et al. **Eur Respir J** 1999 Feb;13(2):321-6
Genetic association between atopy and behavioral symptoms in middle childhood. Wamboldt MZ, et al. **J Child Psychol Psychiatry** 1998 Oct;39(7):1007-16
The relation between scabies and hypersensitivity to antigens of house dust mites and storage mites. Moustafa EH, et al. **J Egypt Soc Parasitol** 1998 Dec;28(3):777-87
How much asthma is really attributable to atopy? Pearce N, et al. **Thorax** 1999 Mar;54(3):268-72 (49 ref.)
Update on the "Dutch hypothesis" for chronic respiratory disease. Vestbo J, et al. **Thorax** 1998 Aug;53 Suppl 2:S15-9 (45 ref.)
[The role of allergy in interstitial cystitis] Pelikan Z, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1289-92 (Eng. Abstr.) **(Dut)**
[Corneal ulcerative lesions in type-I immediate hypersensitivity] Giuri S. **Oftalmologia** 1998;44(3):20-6 (34 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Determination of total and specific IgE using UNICAP 100: comparative study with the CAP system. Cots P, et al. **Allergol Immunopathol (Madr)** 1998 Sep-Oct;26(5):223-7
Atopy patch testing--a diagnostic tool? de Bruin-Weller MS, et al. **Allergy** 1999 Aug;54(8):784-91 (59 ref.)
Prediction and prevention of atopic allergy. Kjellman NI. **Allergy** 1998;53(45 Suppl):67-71
Recombinant allergens: the future of the diagnosis and treatment of atopic allergy. Kraft D, et al. **Allergy** 1998; 53(45 Suppl):62-6
Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. Paganelli R, et al. **Allergy** 1998 Aug;53(8):763-8
Airways inflammation, atopy, and (1-->3)-beta-D-glucan exposures in two schools. Rylander R, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1685-7
Definitive diagnosis of nut allergy. Armstrong D, et al. **Arch Dis Child** 1999 Feb;80(2):175-7
The value of a single skin prick testing for specific IgE Dermatophagoides pteronyssinus to distinguish atopy from non-atopic asthmatic children in the tropics. Santoso H. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2-3):69-74
Protein contact dermatitis in food workers. Case report of a meat sorter and summary of seven other cases. Kumar A, et al. **Australas J Dermatol** 1999 Aug;40(3):138-40 (12 ref.)
Prevalence of muscle relaxant sensitivity in a general population: implications for a preoperative screening. Porri F, et al. **Clin Exp Allergy** 1999 Jan;29(1):72-5
Glove-related hand urticaria in the absence of Type I latex allergy. Armstrong DK, et al. **Contact Dermatitis** 1999 Jul; 41(1):42
Quantitative assessment of immediate cutaneous hypersensitivity in a model of genetic predisposition to atopy. Daser A, et al. **Int Arch Allergy Immunol** 1998 Dec; 117(4):239-43
Sensitization to Alternaria and Cladosporium in asthmatic patients and its in vitro diagnostic confirmation. Resano A, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec; 8(6):353-8
Immediate and delayed hypersensitivity to mite antigens in atopic dermatitis. Varela P, et al. **Pediatr Dermatol** 1999 Jan-Feb;16(1):1-5
[The role of allergy in interstitial cystitis] Pelikan Z, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19;143(25):1289-92 (Eng. Abstr.) **(Dut)**
[Search for a threshold to distinguish between locoregional and systemic reactions using the histamine liberation value and the LTC4 level] Collin N, et al. **Allerg Immunol (Paris)** 1999 Jan;31(1):7-10 (Eng. Abstr.) **(Fre)**
[Level of histamine in supernatants from the basophil activation test: applications to hymenoptera allergy and drug allergy--preliminary study] Tamim S, et al. **Allerg Immunol (Paris)** 1999 Feb;31(2):35-44 (Eng. Abstr.) **(Fre)**
[The monthly question. Is the systematic use of standard set of allergens lawful?] **Ann Dermatol Venereol** 1998 Apr; 125(4):298-300 **(Fre)**
[Methods for the diagnosis of atopy in asthma] Tabar Purroy AI, et al. **Arch Bronconeumol** 1999 May;35 Suppl 3:98-101 **(Spa)**

DRUG THERAPY

A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Grant JA, et al. **Allergy** 1999 Jul; 54(7):700-7
Ulcerative colitis following introduction of zafirlukast and corticosteroid withdrawal in severe atopic asthma [letter] Kroegel C, et al. **Eur Respir J** 1999 Jul;14(1):243
Effect of Rehmannia glutinosa on immediate type allergic reaction. Kim H, et al. **Int J Immunopharmacol** 1998 Apr-May;20(4-5):231-40
Inhibition of immediate type allergic reactions by the aqueous extract of Kum-Hwang-San. Kim H, et al. **Int J Immunopharmacol** 1998 Jun;20(6):285-94
Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. Swystun VA, et al. **J Allergy Clin Immunol** 1998 Sep; 102(3):363-7
Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. Mizushima Y, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):849-57
Effects of fujibitol, a remedy for nasal symptoms of immediate and delayed type allergic reactions. Kakimoto M, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun; 21(5):353-6
Inhibitory effect of mast cell-mediated immediate-type allergic reactions by Cichorium intybus. Kim HM, et al. **Pharmacol Res** 1999 Jul;40(1):61-5
Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. van Rensen EL, et al. **Thorax** 1999 May;54(5):403-8
[Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice] Sengoku T, et al. **Nippon Yakurigaku Zasshi** 1998 Sep; 112(3):221-32 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. Malaviya R, et al. **J Biol Chem** 1999 Sep 17;274(38):27028-38
Restricted cyclooxygenase-2 expression in the central nervous system following acute and delayed-type hypersensitivity responses to bacillus Calmette-Guerin. Minghetti L, et al. **Neuroscience** 1999;92(4):1405-15

EPIDEMIOLOGY

Atopy and enteroparasites. de Almeida MM, et al. **Allerg Immunol (Paris)** 1998 Nov;30(9):291-4
Immediate allergic and nonallergic reactions to Christmas and Easter cacti. Andersen F, et al. **Allergy** 1999 May; 54(5):511-6
Allergy to storage mites. Marcos Bravo C, et al. **Allergy** 1999 Jul;54(7):769-70
Allergic disease in teenagers in relation to urban or rural residence at various stages of childhood. Nilsson L, et al. **Allergy** 1999 Jul;54(7):716-21
Prevalence of occupational asthma among automobile and furniture painters in the center of Eskisehir (Turkey): the effects of atopy and smoking habits on occupational asthma. Ucgun I, et al. **Allergy** 1998 Nov;53(11):1096-100
Incidence of cockroach allergy in atopic Italian children. Peruzzi M, et al. **Ann Allergy Asthma Immunol** 1999 Aug; 83(2):167-71
Hay fever, eczema, and wheeze: a nationwide UK study (ISAAC, international study of asthma and allergies in childhood). Austin JB, et al. **Arch Dis Child** 1999 Sep; 81(3):225-30
Cross sectional study of the relation between sibling number and asthma, hay fever, and eczema. Ponsonby AL, et al. **Arch Dis Child** 1998 Oct;79(4):328-33
Allergy to complex salts of platinum in refinery workers: prospective evaluations of IgE and Phadiatop status. Calverley AE, et al. **Clin Exp Allergy** 1999 May; 29(5):703-11
Accumulation of atopic disorders within families: a sibling effect only in the offspring of atopic fathers [see comments] Mattes J, et al. **Clin Exp Allergy** 1998 Dec;28(12):1480-6 . Comment in: Clin Exp Allergy 1998 Dec;28(12):1454-6.
Atopic and non-atopic asthma. Frew AJ. **Curr Probl Dermatol** 1999;28:129-34 (28 ref.)
Perspectives of atopic eczema in the third millennium. Ring J. **Curr Probl Dermatol** 1999;28:194-204 (49 ref.)
Socioeconomic risk factors in the prevalence of asthma and other atopic diseases in children 6 to 7 years old in Valencia Spain. Suárez-Varela MM, et al. **Eur J Epidemiol** 1999 Jan;15(1):35-40
Domestic aeroallergen exposures among infants in an English town. Atkinson W, et al. **Eur Respir J** 1999 Mar;13(3):583-9
Lower prevalence of asthma and atopy in Turkish children living in Germany. Kabesch M, et al. **Eur Respir J** 1999 Mar;13(3):577-82
The prevalence of reported asthma is independent of exposure in house dust mite-sensitized children. Vervloet D, et al. **Eur Respir J** 1999 May;13(5):983-7
Atopy in children of families with an anthroposophic lifestyle [see comments] Alm JS, et al. **Lancet** 1999 May 1; 353(9163):1485-8. Comment in: Lancet 1999 May 1;353(9163):1457-8.
The prevalence of asthma symptoms, bronchial hyperresponsiveness and atopy in New Zealand adults. D'Souza W, et al. **N Z Med J** 1999 Jun 11; 112(1089):198-202
Atopic sensitization during the first year of life in relation to long chain polyunsaturated fatty acid levels in human milk. Duchén K, et al. **Pediatr Res** 1998 Oct;44(4):478-84
Prevalence of atopy, asthma symptoms and diagnosis, and the management of asthma: comparison of an affluent and a non-affluent country. Faniran AO, et al. **Thorax** 1999 Jul;54(7):606-10
Worldwide variations in the prevalence of atopic symptoms: what does it all mean? Warner JO. **Thorax** 1999 Aug;54 Suppl 2:S46-51 (46 ref.)
[European study of asthma. Prevalence of atopy in young adults of 5 areas in Spain. Spanish Group of European Asthma Study] Cortés X, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):573-7 (Eng. Abstr.) **(Spa)**
[Non-fatal reactions to iodinated contrast media: 29 years of experience] Guillén Toledo JG, et al. **Rev Alerg Mex** 1998 Jul-Aug;45(4):112-5 (Eng. Abstr.) **(Spa)**

ETIOLOGY

Multiple vaccination effects on atopy [letter] Taylor-Robinson AW. **Allergy** 1999 Apr;54(4):398-400
Tobacco allergy: demonstration of cross-reactivity with other members of Solanaceae family and mugwort pollen. Ortega N, et al. **Ann Allergy Asthma Immunol** 1999 Feb; 82(2):194-7
Infant feeding causes all cases of asthma, eczema, and hay fever. Or does it? [comment] David TJ. **Arch Dis Child** 1998 Aug;79(2):97-8. Comment on: Arch Dis Child 1998 Aug;79(2):126-30.
Randomised controlled trial of brief neonatal exposure to cows' milk on the development of atopy [see comments] de Jong MH, et al. **Arch Dis Child** 1998 Aug;79(2):126-30 . Comment in: Arch Dis Child 1998 Aug;79(2):97-8. Comment in: Arch Dis Child 1999 Feb;80(2):208.

Alcohol: intolerance syndromes, urticarial and anaphylactoid reactions. Sticherling M, et al. **Clin Dermatol** 1999 Jul–Aug; 17(4):417–22 (92 ref.)

Urticaria from beer: an immediate hypersensitivity reaction due to a 10-kDa protein derived from barley. Curioni A, et al. **Clin Exp Allergy** 1999 Mar;29(3):407–13

Immediate hypersensitivity to sesame in foods and cosmetics. Pecquet C, et al. **Contact Dermatitis** 1998 Dec;39(6):313

The atopic child and the environment. Businco L, et al. **Curr Probl Dermatol** 1999;28:161–72 (94 ref.)

Cockroach allergy and asthma in a 30-year-old man. O'Connor GT, et al. **Environ Health Perspect** 1999 Mar; 107(3):243–7

Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children [see comments] von Mutius E, et al. **Eur Respir J** 1999 Jul;14(1):4–11. Comment in: Eur Respir J 1999 Jul;14(1):2–3.

Atopic disorders: a default pathway in the absence of infection? Erb KJ. **Immunol Today** 1999 Jul;20(7):317–22 (54 ref.)

Is enhanced fetal growth a risk factor for the development of atopy or asthma? Beasley R, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):408–10

Childhood environment and adult atopy: results from the European Community Respiratory Health Survey. Svanes C, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):415–20

Association of atopic diseases with breast-feeding: food allergens, fatty acids, and evolution [editorial; comment] Goldman AS. **J Pediatr** 1999 Jan;134(1):5–7 (22 ref.). Comment on: J Pediatr 1999 Jan;134(1):27–32.

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years [see comments] Stein RT, et al. **Lancet** 1999 Aug 14;354(9178):541–5. Comment in: Lancet 1999 Aug 14;354(9178):527–8.

Lifestyle and atopy [comment] Strachan DP. **Lancet** 1999 May 1;353(9163):1457–8. Comment on: Lancet 1999 May 1;353(9163):1485–8.

Exposure-response relations of alpha-amylase sensitisation in British bakeries and flour mills. Nieuwenhuijsen MJ, et al. **Occup Environ Med** 1999 Mar;56(3):197–201

Is atopy and smoking important in the workplace? Niven RM, et al. **Occup Med (Lond)** 1999 Apr;49(3):197–200

The hygiene hypothesis in the development of atopy and asthma--still a matter of controversy? Hertzen LC. **QJM** 1998 Nov;91(11):767–71 (45 ref.)

Consistent effects of high socioeconomic status and low birth order, and the modifying effect of maternal smoking on the risk of allergic disease during childhood. Lewis SA, et al. **Respir Med** 1998 Oct;92(10):1237–44

Early childhood infection and atopic disorder. Farooqi IS, et al. **Thorax** 1998 Nov;53(11):927–32

[MMR-vaccination of children allergic to eggs] Christensen M, et al. **Ugeskr Laeger** 1999 Mar 1;161(9):1270–2 (Eng. Abstr.) **(Dan)**

[Allergy to stuffing material in bedding and its role in disease (letter)] Thestrup-Pedersen K. **Ugeskr Laeger** 1999 Apr 26;161(17):2550–2 **(Dan)**

[Hypersensitivity to Anisakis simplex: apropos of 36 cases] Mendizabal-Basagoiti L. **Allerg Immunol (Paris)** 1999 Jan; 31(1):15–7 (Eng. Abstr.) **(Fre)**

[Basophil activation test using flow cytometry in Hymenoptera venom allergy] Stevens S, et al. **Allerg Immunol (Paris)** 1999 Jan;31(1):11–4 (Eng. Abstr.) **(Fre)**

[Allergies and environment] Duchateau J. **Rev Med Brux** 1998 Sep;19(4):A355–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Diseases associated with organic dusts] Michel O. **Rev Med Brux** 1998 Sep;19(4):A358–62 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Lack of association between atopy and RsaI polymorphism within intron 2 of the Fc(epsilon)RI-beta gene in a Spanish population sample. Castro J, et al. **Allergy** 1998 Nov; 53(11):1083–6

Genetic aspects of atopic allergy. Cookson WO. **Allergy** 1998; 53(45 Suppl):9–14 (67 ref.)

Approaches toward the genetic analysis of complex traits: asthma and atopy. Marsh DG. **Allergy** 1999 Mar; 54(3):198–205 (37 ref.)

Linkage of house dust mite allergy with the HLA region. Torres-Galván MJ, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):198–203

Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. Gao PS, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):425–9

Accumulation of atopic disorders within families: a sibling effect only in the offspring of atopic fathers [see comments] Mattes J, et al. **Clin Exp Allergy** 1998 Dec;28(12):1480–6. Comment in: Clin Exp Allergy 1998 Dec;28(12):1454–6.

Promoter polymorphisms predisposing to the development of asthma and atopy. Rosenwasser LJ, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:13–5; discussion 26–8 (30 ref.)

The influence of birth order on the expression of atopy in families: a gene-environment interaction? [editorial; comment] von Mutius E. **Clin Exp Allergy** 1998 Dec; 28(12):1454–6. Comment on: Clin Exp Allergy 1998 Dec;28(12):1480–6.

Genetics of atopic diseases. Chatila TA. **Curr Opin Pediatr** 1998 Dec;10(6):584–7 (37 ref.)

Screening of the Fc epsilon RI-beta-gene in a Swiss population of asthmatic children: no association with E237G and identification of new sequence variations. Rohrbach M, et al. **Dis Markers** 1998 Nov;14(3):177–86

Analysis of two IL-4 promoter polymorphisms in a cohort of atopic and asthmatic subjects. Hook S, et al. **Exp Clin Immunogenet** 1999;16(1):33–5

Genetic variance components analysis for binary phenotypes using generalized linear mixed models (GLMMs) and Gibbs sampling. Burton PR, et al. **Genet Epidemiol** 1999; 17(2):118–40

The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction. Kruse S, et al. **Immunology** 1999 Mar;96(3):365–71

Quantitative assessment of immediate cutaneous hypersensitivity in a model of genetic predisposition to atopy. Daser A, et al. **Int Arch Allergy Immunol** 1998 Dec; 117(4):239–43

Two common polymorphisms in the coding part of the CD43 gene are not associated with atopy. Kruse S, et al. **Int Arch Allergy Immunol** 1998 Dec;117(4):244–7

Positional candidate gene approach and functional genomics strategy in atopy gene discovery. Nickel RG, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):282–4

Promoter polymorphism in the candidate genes, IL-4, IL-9, TGF-beta1, for atopy and asthma. Rosenwasser LJ. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):268–70

Candidate gene and mutational analysis in asthma and atopy. Wilkinson J, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):265–7

Dense mapping of chromosome 12q13.12–q23.3 and linkage to asthma and atopy. Barnes KC, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):485–91

Genetic influences of chromosomes 5q31–q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):449–53

Association of 3 gene polymorphisms with atopic diseases. Hollá L, et al. **J Allergy Clin Immunol** 1999 Apr; 103(4):702–8

A variant in the gene for GM-CSF, I117T, is associated with atopic asthma in a Swiss population of asthmatic children. Rohrbach M, et al. **J Allergy Clin Immunol** 1999 Jul; 104(1):247–8

Linkage and association studies of atopy and the chromosome 11q13 region. Deichmann KA, et al. **J Med Genet** 1999 May;36(5):379–82

Recent advances in the genetics of allergy and asthma. Anderson GG, et al. **Mol Med Today** 1999 Jun;5(6):264–73 (53 ref.)

Day care attendance in the first year of life and illnesses of the upper and lower respiratory tract in children with a familial history of atopy. Celedon JC, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):495–500

Is the increase in asthma prevalence occurring in children without a family history of atopy? Christie GL, et al. **Scott Med J** 1998 Dec;43(6):180–2

[Reagin sensitizations and date of birth. Differences in function according to family history] de Montis G. **Arch Pediatr** 1999 Mar;6(3):259–62 (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Do infections protect against atopic diseases? [comment] Bråbäck L. **Acta Paediatr** 1999 Jul;88(7):705–8 (27 ref.). Comment on: Acta Paediatr 1999 Jul;88(7):710–4.

Infections in early childhood and risk of atopic disease [see comments] Pekkanen J, et al. **Acta Paediatr** 1999 Jul; 88(7):710–4. Comment in: Acta Paediatr 1999 Jul;88(7):705–8.

Importance of indoor allergens in the induction of allergy and elicitation of allergic disease. Custovic A, et al. **Allergy** 1998;53(48 Suppl):115–20 (64 ref.)

In vitro effects of the pyrethroid S-bioallethrin on lymphocytes and basophils from atopic and nonatopic subjects. Diel F, et al. **Allergy** 1998 Nov;53(11):1052–9

Mite allergens. Collection, determination, expression of results, and risk levels for sensitization and symptom induction. Dreborg S. **Allergy** 1998;53(48 Suppl):88–91 (15 ref.)

Mite-allergen levels in Norwegian homes. Gaarder PI. **Allergy** 1998;53(48 Suppl):58–9 (13 ref.)

Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma. Menz G, et al. **Allergy** 1998;53(45 Suppl):15–21 (57 ref.)

Mite sensitization in the Scandinavian countries and factors influencing exposure levels. Munir AK. **Allergy** 1998;53(48 Suppl):64–70 (56 ref.)

Allergen-stimulated expression of CD154 (CD40 ligand) on CD3+ lymphocytes in atopic, but not in nonatopic individuals. Modulation by bacterial lipopolysaccharide. Nakstad B, et al. **Allergy** 1999 Jul;54(7):722–9

Skin-test responses to mycobacteria in atopy and asthma [letter] Rook GA, et al. **Allergy** 1999 Mar;54(3):285–6

Pizza, an unsuspected source of soybean allergen exposure. Senna GE, et al. **Allergy** 1998 Nov;53(11):1106–7

Allergy to bumblebee venom. II. IgE cross-reactivity between bumblebee and honeybee venom. Stapel SO, et al. **Allergy** 1998 Aug;53(8):769–77

House-dust mite hypersensitivity, eczema, and other nonpulmonary manifestations of allergy. Tupker RA, et al. **Allergy** 1998;53(48 Suppl):92–6 (33 ref.)

Clinical and immunologic aspects of storage mite allergy. van Hage-Hamsten M, et al. **Allergy** 1998;53(48 Suppl):49–53 (34 ref.)

Increases in eotaxin-positive cells in induced sputum from atopic asthmatic subjects after inhalational allergen challenge. Zeibecoglou K, et al. **Allergy** 1999 Jul; 54(7):730–5

Regulation of IgE synthesis: the molecular basis and implications for clinical modulation. Bacharier LB, et al. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):1–8 (58 ref.)

Effect of granulocyte macrophage-colony stimulating factor on Langerhans cells in normal and healthy atopic subjects. Smith CH, et al. **Br J Dermatol** 1998 Aug;139(2):239–46

Allergic eye disease mechanisms. McGill JI, et al. **Br J Ophthalmol** 1998 Oct;82(10):1203–14 (118 ref.)

Immune mechanisms of the occupational sensitization with methylen-dyphenyl diisocyanate (MDI). Nosko M, et al. **Cent Eur J Public Health** 1998 Aug;6(3):199–201

Early biomarkers of allergic disease in children [editorial; comment] Arshad SH, et al. **Clin Exp Allergy** 1999 May; 29(5):576–8. Comment on: Clin Exp Allergy 1999 May;29(5):604–10.

Circulating cat allergen and immune complexes in cat-allergic children. Casas R, et al. **Clin Exp Allergy** 1998 Oct;28(10):1258–63

Bee sting allergy in beekeepers. Eich-Wanger C, et al. **Clin Exp Allergy** 1998 Oct;28(10):1292–8

Is allergy increasing?--early life influences. Howarth PH. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:2–7 (35 ref.)

The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Kapsenberg ML, et al. **Clin Exp Allergy** 1999 Jun;29 Suppl 2:33–6 (23 ref.)

Cereal alpha-amylase inhibitors cause occupational sensitization in the wood industry. López-Rico R, et al. **Clin Exp Allergy** 1998 Oct;28(10):1286–91

Mapping of T-cell epitopes of Phl p 5: evidence for crossreacting and non-crossreacting T-cell epitopes within Phl p 5 isoallergens. Müller WD, et al. **Clin Exp Allergy** 1998 Dec;28(12):1538–48

Interleukin-5 and allergic inflammation [editorial; comment] O'Byrne PM, et al. **Clin Exp Allergy** 1999 May;29(5):573–5. Comment on: Clin Exp Allergy 1999 May;29(5):595–603.

Reciprocal age-related patterns of allergen-specific T-cell immunity in normal vs. atopic infants. Prescott SL, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:39–44; discussion 50–1

Atopic and vernal keratoconjunctivitis: a model for studying atopic disease. Bonini S, et al. **Curr Probl Dermatol** 1999; 28:88–94 (20 ref.)

Allergen exposure, atopy and smoking as determinants of allergy to rats in a cohort of laboratory employees. Cullinan P, et al. **Eur Respir J** 1999 May;13(5):1139–43

LFA-1 expression by blood eosinophils is increased in atopic asthmatic children and is involved in eosinophil locomotion. Lantero S, et al. **Eur Respir J** 1998 Nov; 12(5):1094–8

Allergen mimotopes in food enhance type I allergic reactions in mice. Jensen-Jarolim E, et al. **FASEB J** 1999 Sep; 13(12):1586–92

Identification of Cannabis pollens using an allergic patient's immunoglobulin E and purification and characterization of allergens in Cannabis pollens. Tanaka H, et al. **Forensic Sci Int** 1998 Nov 9;97(2–3):139–53

Ragweed allergy: correlation between skin reactivity and in vitro complement activation. Dervaderics M, et al. **Immunol Lett** 1998 Dec;64(2–3):119–23

Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Denburg JA. **Immunol Today** 1999 Mar;20(3):111–3

Soil exposure no protection against atopy [letter] Montgomery SM, et al. **Immunol Today** 1999 Jun; 20(6):289–90

Expression of the T-cell markers CD3, CD4 and CD8 in healthy and atopic children during the first 18 months of life. Aniansson Zdolsek H, et al. **Int Arch Allergy Immunol** 1999 May;119(1):6–12

Cat-specific IgA antibodies in breast milk from atopic and non-atopic mothers: detection of Fel d 1-IgG immune complexes in cord blood and sera. Casas R, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):317–8

Quantitative assessment of immediate cutaneous hypersensitivity in a model of genetic predisposition to atopy. Daser A, et al. **Int Arch Allergy Immunol** 1998 Dec; 117(4):239–43

Polyunsaturated fatty acids in breast milk in relation to atopy in the mother and her child. Duchén K, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):321–3

Immunological mechanisms operative in allergen-specific immunotherapy. Ebner C. **Int Arch Allergy Immunol** 1999 May;119(1):1–5 (62 ref.)

Matrix metalloproteinase-9 in myeloid cells: implications for allergic inflammation. Hayashi M, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):429–32

T-Cell function in atopic children. Jenmalm MC. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):395–8 (57 ref.)

Lack of systemic anaphylaxis and aeroallergen-induced airway plasma extravasation in allergic immunoglobulin-deficient mice. Korsgren M, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):67–73

Pertussis adjuvant prolongs intestinal hypersensitivity.

Kosecka U, et al. **Int Arch Allergy Immunol** 1999 Jul; 119(3):205–11

Effects of structure modifications on IgE binding properties of serum albumins. Restani P, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):113–9

Autoantibodies in Estonia and Sweden, populations with different responses to allergens. Uibo R, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):126–30

Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Wiedermann U, et al. **Int Immunol** 1999 Jul;11(7):1131–8

Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. Moore AR, et al. **Int J Immunopharmacol** 1999 Mar;21(3):195–203

Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo. Corne JM, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):727–31

Genetic influences of chromosomes 5q31–q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):449–53

CD80 (B7-1) and CD86 (B7-2) antigens on house dust mite-specific T cells in atopic disease function through T-T cell interactions. Nakada M, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):222–7

The relevance of TH1 and TH2 cells in immediate and nonimmediate reactions to gelatin-containing vaccine [see comments] Ohsaki M, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):276–81. Comment in: J Allergy Clin Immunol 1999 Feb;103(2 Pt 1):200–2.

Association between atopic sensitization and asthma and bronchial hyperresponsiveness in swedish adults: pets, and not mites, are the most important allergens. Plaschke P, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):58–65

Biologic activities of IL-1 and its role in human disease. Rosenwasser LJ. **J Allergy Clin Immunol** 1998 Sep; 102(3):344–50 (47 ref.)

Differential regulation of allergen-specific T(H2)- but not T(H1)-type responses by alveolar macrophages in atopic asthma. Tang C, et al. **J Allergy Clin Immunol** 1998 Sep; 102(3):368–75

Systemic allergic reaction to coconut (Cocos nucifera) in 2 subjects with hypersensitivity to tree nut and demonstration of cross-reactivity to legumin-like seed storage proteins: new coconut and walnut food allergens. Teuber SS, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1180–5

Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. Wiedermann U, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1202–10

Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. Brugnolo F, et al. **J Immunol** 1999 Jul 15; 163(2):1053–9

Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. Larché M, et al. **J Immunol** 1998 Dec 1;161(11):6375–82

IL-4 inhibits mouse mast cell Fc epsilonRI expression through a STAT6-dependent mechanism. Ryan JJ, et al. **J Immunol** 1998 Dec 15;161(12):6915–23

Bat feces as an indoor allergen. Alonso A, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec;8(6):365–9

Serum IgE levels during the first 6 years of life. Kulig M, et al. **J Pediatr** 1999 Apr;134(4):453–8

Allergy priming early in life [comment] [see comments] Björkstén B. **Lancet** 1999 Jan 16;353(9148):167–8. Comment on: Lancet 1999 Jan 16;353(9148):196–200. Comment in: Lancet 1999 Apr 3;353(9159):1187–8.

Development of allergen-specific T-cell memory in atopic and normal children [see comments] Prescott SL, et al. **Lancet** 1999 Jan 16;353(9148):196–200. Comment in: Lancet 1999 Jan 16;353(9148):167–8. Comment in: Lancet 1999 Apr 3;353(9159):1187–8.

Expression of IgH chain genes in antibody response to ragweed and purified Amb a 1: evidence for differential regulation of isotype production. Allauzen S, et al. **Mol Immunol** 1999 Jun;36(9):587–98

gammadelta T cells provide a breath of fresh air for asthma research [news; comment] Holt PG, et al. **Nat Med** 1999 Oct;5(10):1127–8. Comment on: Nat Med 1999 Oct;5(10):1150–6.

Development of the immune system in atopic children. Jenmalm MC, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):5–12 (93 ref.)

Magnoliae flos inhibits mast cell-dependent immediate-type allergic reactions. Kim HM, et al. **Pharmacol Res** 1999 Feb; 39(2):107–11

Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis. Helm BA, et al. **Technol Health Care** 1998 Sep;6(2–3):195–207

Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Nightingale JA, et al. **Thorax** 1998 Jul;53(7):563–71

Specific IgG to gelatin in children with systemic immediate- and nonimmediate-type reactions to measles, mumps and rubella vaccines. Miyazawa H, et al. **Vaccine** 1999 Apr 23; 17(17):2176–80

[Chronic urticaria caused by cow's milk allergy: immediate or delayed allergy? (apropos of a case)] Drouet M, et al. **Allerg Immunol (Paris)** 1999 Mar;31(3):79–81 (Eng. Abstr.) **(Fre)**

[Reagin sensitizations and date of birth. Differences in function according to family history] de Montis G. **Arch Pediatr** 1999 Mar;6(3):259–62 (Eng. Abstr.) **(Fre)**

[Role of eosinophilia in atopic pathology] Magnan A, et al. **Med Trop (Mars)** 1998;58(4 Suppl):444–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Expression of L-selectin on peripheral memory CD4+ T cells in atopic diseases] Yamashita H, et al. **Arerugi** 1998 Nov;47(11):1168–75 (Eng. Abstr.) **(Jpn)**

[DPB 1 *0501-associated opticomyelitis and atopic myelitis: novel disease entities] Kira J. **Rinsho Shinkeigaku** 1999 Jan; 39(1):19–20 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Round Table: Immunological urticaria mediated by IgE] Eseverri JL, et al. **Allergol Immunopathol (Madr)** 1999 Mar-Apr;27(2):104–11 (28 ref.) (Eng. Abstr.) **(Spa)**

[Interrelationship between asthma, atopy, IgE and bronchial hyperreactivity (editorial)] Roncoroni AJ. **Medicina (B Aires)** 1998;58(2):243–6 **(Spa)**

METABOLISM

Near infrared reflectance spectroscopy in the study of atopy. Part 3. Interactions between the skin and fomblins. Corti P, et al. **Analyst** 1998 Nov;123(11):2313–7

Biology of basophils and their role in allergic inflammation. Chugh L. **Indian J Chest Dis Allied Sci** 1998 Oct-Dec; 40(4):257–67 (56 ref.)

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients and the effect of diesel exhaust particles in vitro. Bayram H, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):771–82

Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. Fukagawa K, et al. **J Allergy Clin Immunol** 1999 Jun; 103(6):1220–1

Expression of the IL-4 receptor alpha-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects. Kotsimbos TC, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):859–66

Gene expression of the GATA-3 transcription factor is increased in atopic asthma. Nakamura Y, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):215–22

Inhaled IL-5 increases concentrations of soluble intracellular adhesion molecule-1 in sputum from atopic asthmatic subjects. Shi HZ, et al. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 1):463–7

Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. Mizushima Y, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):849–57

MICROBIOLOGY

Microbial stimulation as an aetiologic factor in atopic disease. Holt PG, et al. **Allergy** 1999;54 Suppl 49:12–6

Ophthalmic manifestations of allergic fungal sinusitis. Carter KD, et al. **Am J Ophthalmol** 1999 Feb;127(2):189–95

PATHOLOGY

Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Fartasch M, et al. **Arch Dermatol** 1999 Jul; 135(7):823–32

Differences in nasal cellular infiltrates between allergic children and age-matched controls. Vinke JG, et al. **Eur Respir J** 1999 Apr;13(4):797–803

CD80 (B7-1) and CD86 (B7-2) antigens on house dust mite-specific T cells in atopic disease function through T-T cell interactions. Nakada M, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):222–7

PHYSIOPATHOLOGY

Time course of the inflammatory response to histamine and allergen skin prick test in guinea-pigs. Evilevitch V, et al. **Acta Physiol Scand** 1999 Apr;165(4):409–13

Hemopoietic progenitors and cytokines in allergic inflammation. Denburg JA. **Allergy** 1998;53(45 Suppl):22–6 (53 ref.)

Peak expiration flow variations may reflect house-dust-mite exposure and patient reactivity. Hallas TE, et al. **Allergy** 1998;53(48 Suppl):101–3

Chemokines and the late-phase reaction. Kaplan AP, et al. **Allergy** 1998;53(45 Suppl):27–32 (15 ref.)

Allergy to mites: relation to lung function and airway hyperresponsiveness. van der Heide S, et al. **Allergy** 1998; 53(48 Suppl):104–7 (28 ref.)

Signal transduction via the interleukin-4 receptor and its correlation with atopy. Izuhara K, et al. **Int J Mol Med** 1999 Jan;3(1):3–10 (107 ref.)

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients and the effect of diesel exhaust particles in vitro. Bayram H, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):771–82

Skin reactivity to inhalant allergens, total serum IgE levels, and bronchial responsiveness to methacholine are increased in parents of nonatopic asthmatic children. Kim YK, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):311–6

Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. Hakonarson H, et al. **J Clin Invest** 1999 Apr;103(7):1077–87

Autocrine interaction between IL-5 and IL-1beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. Hakonarson H, et al. **J Clin Invest** 1999 Sep;104(5):657–67

Residual oil fly ash exposure enhances allergic sensitization to house dust mite. Lambert AL, et al. **Toxicol Appl Pharmacol** 1999 Aug 1;158(3):269–77

PREVENTION & CONTROL

Prediction and prevention of atopic allergy. Kjellman NI. **Allergy** 1998;53(45 Suppl):67–71

Does early exposure to cat or dog protect against later allergy development? Hesselmar B, et al. **Clin Exp Allergy** 1999 May;29(5):611–7

Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Jarman ER, et al. **Clin Exp Immunol** 1999 Feb;115(2):221–8

Primary and secondary prevention of atopic diseases in children. Vandenplas Y, et al. **Curr Probl Dermatol** 1999; 28:173–93 (138 ref.)

Evaluation of antiallergic activity (type I hypersensitivity) of Inula racemosa in rats. Srivastava S, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):235–41

Lavender oil inhibits immediate-type allergic reaction in mice and rats. Kim HM, et al. **J Pharm Pharmacol** 1999 Feb;51(2):221–6

Is allergy prevention realistic and beneficial? Kjellman NI, et al. **Pediatr Allergy Immunol** 1999;10(12 Suppl):11–7

[Allergies and environment] Duchateau J. **Rev Med Brux** 1998 Sep;19(4):A355–7 (12 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Psychological status and motivation for psychosocial intervention in patients with allergic disorders] Augustin M, et al. **Hautarzt** 1999 Jun;50(6):422–7 (Eng. Abstr.) **(Ger)**

THERAPY

The frequency of phospholipase A2 binding of basophilic granulocytes does not decrease during bee-venom-specific immunotherapy. Irsch J, et al. **Allergy** 1999 Jul;54(7):742–7

Recombinant allergens: the future of the diagnosis and treatment of atopic allergy. Kraft D, et al. **Allergy** 1998; 53(45 Suppl):62–6

Intravaginal desensitization to seminal fluid. Nusam D, et al. **Allergy** 1999 Jul;54(7):765

The role of immunoglobulin therapy in allergic diseases. Rabinovitch N, et al. **Allergy** 1999 Jul;54(7):662–8 (28 ref.)

Rush immunotherapy in a dog with severe ragweed and grass pollen allergy. Patterson R, et al. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):213–6

Cytokines and their receptors as therapeutic targets in asthma. Pauwels RA, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:1–5 (45 ref.)

Polarized TH1 responses by liposome-entrapped allergen and its potential in immunotherapy of allergic disorders. Sehra S, et al. **Clin Exp Allergy** 1998 Dec;28(12):1530–7

Immunological mechanisms operative in allergen-specific immunotherapy. Ebner C. **Int Arch Allergy Immunol** 1999 May;119(1):1–5 (62 ref.)

Gene therapy for peanut allergy [news; comment] Moffatt MF, et al. **Nat Med** 1999 Apr;5(4):380–1. Comment on: Nat Med 1999 Apr;5(4):387–91.

VETERINARY

Observations on the use of tetracycline and niacinamide as antipruritic agents in atopic dogs. Beningo KE, et al. **Can Vet J** 1999 Apr;40(4):268–70

Studies on the role of mucus and mucosal hypersensitivity reactions during rejection of Trichostrongylus colubriformis from the intestine of immune sheep using an experimental challenge model. Harrison GB, et al. **Int J Parasitol** 1999 Mar;29(3):459–68

Antihistamines in the management of allergic pruritus in dogs and cats. Scott DW, et al. **J Small Anim Pract** 1999 Aug; 40(8):359–64

Evaluation of a commercial ELISA test for the detection of allergen-specific IgE antibodies in atopic dogs. Ginel PJ, et al. **Zentralbl Veterinarmed [B]** 1998 Sep;45(7):421–5

HYPERSENSITIVITY, MILK see **MILK HYPERSENSITIVITY**

HYPERSENSITIVITY PNEUMONITIS see **ALVEOLITIS, EXTRINSIC ALLERGIC**

HYPERSENSITIVITY PNEUMONITIS, AVIAN see **BIRD FANCIER'S LUNG**

HYPERSENSITIVITY, RESPIRATORY see **RESPIRATORY HYPERSENSITIVITY**

HYPERSENSITIVITY, TUBERCULIN-TYPE see **HYPERSENSITIVITY, DELAYED**

HYPERSENSITIVITY, TYPE I see **HYPERSENSITIVITY, IMMEDIATE**

HYPERSENSITIVITY, TYPE III see **IMMUNE COMPLEX DISEASES**

HYPERSENSITIVITY, TYPE IV see **HYPERSENSITIVITY, DELAYED**

HYPERSENSITIVITY VASCULITIS see **VASCULITIS, HYPERSENSITIVITY**

HYPERSOMNIA

DIAGNOSIS

Idiopathic hypersomnia in an aircrew member. Withers BG, et al. **Aviat Space Environ Med** 1999 Aug;70(8):797–801 (19 ref.)

Psychometric evaluation of daytime sleepiness and nocturnal sleep onset scales in a representative community sample. Johnson EO, et al. **Biol Psychiatry** 1999 Mar 15; 45(6):764–70

The effects of sleep inertia on decision-making performance. Bruck D, et al. **J Sleep Res** 1999 Jun;8(2):95–103

A dose-response study of total sleep time and the ability to maintain wakefulness. Härmä M, et al. **J Sleep Res** 1998 Sep;7(3):167–74

Mokken scaling of the Epworth Sleepiness Scale items in patients with the sleep apnoea/hypopnoea syndrome [letter] Kingshott R, et al. **J Sleep Res** 1998 Dec;7(4):293–4

Two cases of HLA-DR2-negative hypersomnia manifesting sleep-onset rapid eye movement periods in the multiple sleep latency test. Yoshida Y, et al.
Psychiatry Clin Neurosci 1999 Apr;53(2):295–7

Narcolepsy and other causes of excessive daytime sleepiness. Gerhardstein R, et al. **Respir Care Clin N Am** 1999 Sep; 5(3):427–46, viii–ix (49 ref.)

Clinical and laboratory evaluations of excessive daytime sleepiness. Westbrook PR. **Respir Care Clin N Am** 1999 Sep;5(3):349–61, viii (20 ref.)

Empirical data is essential in understanding both sleepiness and MSLT [letter] Bonnet MH, et al. **Sleep** 1999 Mar 15; 22(2):143

Characteristics of apneas and hypopneas during sleep and relation to excessive daytime sleepiness. Chervin RD, et al. **Sleep** 1998 Dec 15;21(8):799–806

The detection of brief daytime sleep episodes. Rosenthal L, et al. **Sleep** 1999 Mar 15;22(2):211–4

[Hypersomnia] Masson C. **Presse Med** 1998 Nov 7; 27(34):1745–6 **(Fre)**

[Pathologic hypersomnia (variant of narcolepsy without sleep onset REM phases and cataplexy)] Keller T.
Schweiz Rundsch Med Prax 1998 Oct 7;87(41):1373–4 **(Ger)**

[Hypersomnia and thalamic and brain stem stroke: a study of seven patients] Blanco M, et al. **Neurologia** 1999 Jun–Jul; 14(6):307–14 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Excessive daytime somnolence in the adult population of Warsaw] Zieliński J, et al. **Pol Arch Med Wewn** 1998 May; 99(5):407–13 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Modeling hypersomnolence in sleep-disordered breathing. A novel approach using survival analysis. Punjabi NM, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1703–9

Hypersomnia following uvulopalatopharyngoplasty for snoring. Smith RP, et al. **Eur Respir J** 1999 Jul;14(1):239–41

[Hypersomnia. Investigational strategy for evaluating hypersomnia] Petiau C, et al. **Presse Med** 1998 Nov 7; 27(34):1758–62 (14 ref.) (Eng. Abstr.) **(Fre)**

[Cerebrovascular disorder with memory disturbance, drowsiness, and a lack of drive as major symptoms] Tagawa K. **Fukuoka Igaku Zasshi** 1998 Nov;89(11):303–11 (16 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Relation of sleepiness to respiratory disturbance index: the Sleep Heart Health Study. Gottlieb DJ, et al.
Am J Respir Crit Care Med 1999 Feb;159(2):502–7

Natural evolution of sleepiness. A 5-year follow-up study in a middle-aged population. Martikainen K, et al.
Eur J Neurol 1998 Jul;5(4):355–63

Pupillographic sleepiness testing in hypersomniacs and normals. Wilhelm H, et al.
Graefes Arch Clin Exp Ophthalmol 1998 Oct;236(10):725–9

[Sleep-arousal dissociation in a case of hypersomnia] Rodriguez-Gómez J. **Rev Neurol** 1998 Nov;27(159):841–3 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

[Continued driving habits of patients diagnosed with excessive daytime sleepiness (letter; comment)] Van Keimpema AR. **Ned Tijdschr Geneeskd** 1998 Nov 14; 142(46):2539. Comment on: Ned Tijdschr Geneeskd 1998 Sep 26;142(39):2146–50. **(Dut)**

THERAPY

Bright light treatment used for adaptation to night work and re-adaptation back to day life. A field study at an oil platform in the North Sea. Bjorvatn B, et al.
J Sleep Res 1999 Jun;8(2):105–12

HYPERSOMNIA, PERIODIC see **KLEINE-LEVIN SYNDROME**

HYPERSOMNIA WITH PERIODIC RESPIRATION see **SLEEP APNEA SYNDROMES**

HYPERSPLENISM

Case of hepatosplenic gammadelta T-cell lymphoma presenting with severe hypersplenism [letter] Dinçol G, et al. **Am J Hematol** 1999 Apr;60(4):313–4

DIAGNOSIS

Could serum haptoglobin concentration be used as a marker of hypersplenism in chronic liver disease? [letter] Ozatli D, et al. **Am J Gastroenterol** 1998 Dec;93(12):2641–2

[Secondary hypersplenism syndrome. Etiology of thrombo- and leukocytopenia in sarcoidosis?] Koehler U, et al.
Internist (Berl) 1998 Nov;39(11):1181–4 **(Ger)**

ETIOLOGY

Could serum haptoglobin concentration be used as a marker of hypersplenism in chronic liver disease? [letter] Ozatli D, et al. **Am J Gastroenterol** 1998 Dec;93(12):2641–2

Reversible hypersplenism after splenopexy for wandering spleen. Benoist S, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2430–1

Could spleen-size determine long-term thrombocytopenia following orthotopic liver transplant even after reversal of portal hypertension? [letter] D'Arienzo A, et al.
Ital J Gastroenterol Hepatol 1998 Aug;30(4):441–2

Distal splenorenal shunt with splenopancreatic disconnection for portal hypertension in biliary atresia. Hasegawa T, et al. **Pediatr Surg Int** 1999;15(2):92–6

PHYSIOPATHOLOGY

[Percutaneous intrahepatic portosystemic shunt: its effects on hypersplenism] Añón Rodriguez R, et al.
Gastroenterol Hepatol 1999 Jan;22(1):7–10 (Eng. Abstr.) **(Spa)**

SURGERY

A new technique for laparoscopic splenectomy with massively enlarged spleens. Hebra A, et al. **Am Surg** 1998 Dec;64(12):1161–4

Concomitant splenectomy for hypersplenic thrombocytopenia in hepatic resection for hepatocellular carcinoma. Lin MC, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):630–4

THERAPY

Partial splenic embolization in five children with hypersplenism: effects of reduced-volume embolization on efficacy and morbidity. Harned RK 2nd, et al.
Radiology 1998 Dec;209(3):803–6

[Therapeutic embolization of the spleen] Pervulov S, et al.
Vojnosanit Pregl 1998 Nov–Dec;55(6):657–63 (Eng. Abstr.) **(Scc)**

HYPERTELORISM

GENETICS

Teebi hypertelorism syndrome with tetralogy of Fallot. Nakagawa M, et al. **Am J Med Genet** 1998 Jun 5; 77(5):345–7

HYPERTENSINOGEN see **ANGIOTENSINOGEN**

HYPERTENSION

see related
ANTIHYPERTENSIVE AGENTS
VASCULAR RESISTANCE

Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Innes KE, et al.
Acta Obstet Gynecol Scand 1999 Apr;78(4):263–84 (359 ref.)

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Grundy SM. **Am J Cardiol** 1999 May 13; 83(9B):25F–29F (63 ref.)

Asymptomatic hypertension in the ED. Chiang WK, et al.
Am J Emerg Med 1998 Nov;16(7):701–4

American Society of Hypertension 14th scientific meeting. New York, New York, USA. May 20–22, 1999. Abstracts.
Am J Hypertens 1999 Apr;12(4 Pt 2):1A–239A

Should induced hypertension be beneficial after traumatic brain injury? [editorial; comment] [see comments] Bedell EA, et al. **Anesth Analg** 1998 Oct;87(4):751–3. Comment on: Anesth Analg 1998 Sep;87(3):574–8. Comment in: Anesth Analg 1999 Jun;88(6):1423–4.

Blood pressure set point. Taquini AC. **Biol Res** 1998; 31(3):131–4 (17 ref.)

The renin-angiotensin system in essential hypertension: associations with cardiovascular risk. Allikmets K, et al.
Blood Press 1999;8(2):70–8 (111 ref.)

The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects. Thijs L, et al. **Blood Press Monit** 1999 Apr;4(2):77–86

Rat models of hypertension, cardiac hypertrophy and failure. Doggrell SA, et al. **Cardiovasc Res** 1998 Jul;39(1):89–105 (194 ref.)

Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Pinto YM, et al. **Cardiovasc Res** 1998 Jul;39(1):77–88 (107 ref.)

Factors influencing the frequency of visits by hypertensive patients to primary care physicians in Winnipeg [comment] Roos NP, et al. **CMAJ** 1998 Oct 6;159(7):777–83. Comment on: CMAJ 1998 Oct 6;159(7):795–6.

Primary care visits and health policy [editorial; see comments] Starfield B. **CMAJ** 1998 Oct 6;159(7):795–6. Comment in: CMAJ 1998 Oct 6;159(7):777–83.

Bibliography. Current world literature. Hypertension.
Curr Opin Cardiol 1998 Sep;13(5):B177–203

Hypertension [editorial] Frohlich ED. **Curr Opin Cardiol** 1998 Sep;13(5):295–7

A review of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Schwartz GL, et al.
Curr Opin Cardiol 1999 Mar;14(2):161–8 (44 ref.)

Cyclosporin-induced hypertension: incidence, pathogenesis and management. Taler SJ, et al. **Drug Saf** 1999 May; 20(5):437–49 (70 ref.)

Epidemiological aspects and cost of managing hypertension in Saudi Arabian primary health care centres. al-Shahri M, et al. **East Mediterr Health J** 1998 Dec;4(3):493–501

Hypertension: setting new goals for lower readings. Butler RN, et al. **Geriatrics** 1999 Apr;54(4):20–1, 25–6, 29–30 passim

Blood pressure in the Caribbean. Halberstein RA.
Hum Biol 1999 Aug;71(4):659–84 (102 ref.)

Abstracts for the 21st Annual Meeting of the Japanese Society of Hypertension in Hiroshima, September 24–26, 1998. **Hypertens Res** 1998 Dec;21(4):297–321

53rd Annual fall conference of the Council for High Blood Pressure Research. Orlando, Florida, USA. September 13–16, 1999. Abstracts. **Hypertension** 1999 Aug; 34(2):327–70

Harry Goldblatt Award 1998. **Hypertension** 1999 Jan;33(1 Pt 2):603–4

Irvine Page-Alva Bradley Lifetime Achievement Award 1998. **Hypertension** 1999 Jan;33(1 Pt 2):600

Novartis Award for Hypertension Research 1998.
Hypertension 1999 Jan;33(1 Pt 2):601–2

Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1998. **Hypertension** 1999 Jan;33(1 Pt 2):598–9

Proceedings of the 52nd annual fall conference of the American Hearth Association Council for High Blood Pressure Research. Philadelphia, Pennsylvania, USA. September 15–18, 1998 [published erratum appears in Hypertension 1999 Apr;33(4):921] **Hypertension** 1999 Jan; 33(1 Pt 2):169–606

13th Scientific meeting of the Inter-American Society of Hypertension. Abstracts. **Hypertension** 1999 Apr; 33(4):1064–95

Annual progress report: our 20th anniversary celebration [editorial] Frohlich ED, et al. **Hypertension** 1999 Jan; 33(1):1–6

Story of the birth of the journal called Hypertension. Tobian L. **Hypertension** 1999 Jan;33(1):7

The relationship between perceptions of social support and adherence to dietary recommendations among African-American elders with hypertension. Schoenberg NE. **Int J Aging Hum Dev** 1998;47(4):279–97

Approach to polypharmacy [letter; comment] Solomon GL. **J Am Board Fam Pract** 1998 Jul–Aug;11(4):331–2. Comment on: J Am Board Fam Pract 1998 Mar–Apr;11(2):140–4. Comment on: J Am Board Fam Pract 1998 Mar–Apr;11(2):166–7.

Blood pressure behavior in the nursing home: implications for diagnosis and treatment of hypertension [see comments] Auseon A, et al. **J Am Geriatr Soc** 1999 Mar;47(3):285–90 . Comment in: J Am Geriatr Soc 1999 Mar;47(3):373–4.

Hypertension in the Elderly. Proceedings of a satellite symposium to the 8th meeting of the European Society of Hypertension. Krakow, Poland, 21 June 1997.
J Hum Hypertens 1998 Sep;12(9):573–655

Annual scientific meeting of the British Hypertension Society. 14–16 September 1998. Abstracts.
J Hum Hypertens 1998 Nov;12(11):777–96

White-coat hypertension: a selection bias? [letter; comment] Verdecchia P, et al. **J Hypertens** 1999 Jan;17(1):148–9. Comment on: J Hypertens 1998 Jul;16(7):977–84.

Correlation of coagulation abnormalities with clinical outcome in neonates of mothers with pregnancy induced hypertension. Agarwal K, et al. **J Indian Med Assoc** 1998 Jun;96(6):171–3

Granulocyte colony-stimulating factor in the cord blood of premature neonates born to mothers with pregnancy-induced hypertension. Tsao PN, et al.
J Pediatr 1999 Jul;135(1):56–9

Hypertension. Vallance P. **J R Coll Physicians Lond** 1999 Mar–Apr;33(2):119–23 (15 ref.)

A pressure to agree [editorial; comment] **Lancet** 1999 Sep 4;354(9181):787. Comment on: Lancet 1999 Sep 4;354(9181):791–2.

British guidelines on hypertension management issued [news] Bradbury J. **Lancet** 1999 Sep 4;354(9181):839

Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. Franklin SS. **Pathol Biol (Paris)** 1999 Jun;47(6):594–603 (56 ref.)

Childhood hypertension. An update on etiology, diagnosis, and treatment. Bartosh SM, et al. **Pediatr Clin North Am** 1999 Apr;46(2):235–52 (85 ref.)

Prolonged hypertension (> 10 years) is a significant risk factor in older cadaver donor renal transplants. Cho YW, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1283

[Progresses in the study of cardiovascular diseases in China, 1997] Huang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Dec;77(12):883–5 (0 ref.) **(Chi)**

[What is arterial hypertension? The balance of 50 years of research and rational therapy] Jerie P. **Cas Lek Cesk** 1998 Dec 14;137(24):739–42 (31 ref.) (Eng. Abstr.) **(Cze)**

[Anatomic and functional basis for the effect of systemic hypertension on focal cerebral ischemia] Smrčka M, et al. **Cesk Fysiol** 1999 May;48(2):77–9 (Eng. Abstr.) **(Cze)**

[Hypertension in general practice] Holm J, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4286–90 (Eng. Abstr.) **(Dan)**

[Tobacco, hypertension and kidney (editorial)] Muller S, et al. **Nephrologie** 1998;19(5):235–7 (27 ref.) **(Fre)**

[Pathophysiology and treatment of elderly hypertensive patients] Shimamoto K. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):821–4 (12 ref.) **(Jpn)**

[Clinical guidelines for hypertension] Hetlevik I, et al. **Tidsskr Nor Laegeforen** 1999 Aug 30;119(20):3037–41 **(Nor)**

[Consensus on hypertension?] Omvik P. **Tidsskr Nor Laegeforen** 1998 Oct 20;118(25):3979–81 (43 ref.) **(Nor)**

[Consensus on hypertension?] Widerøe TE, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):690–3 (30 ref.) **(Nor)**

[The sixth report of Joint national commission on prevention, detection, assessment and treatment of hypertension] Metelitsa VI, et al. **Klin Med (Mosk)** 1999;77(1):47–54 **(Rus)**

[Hypertension–essential hypertension: 75 years of studies and current views in publications of "Terapevticheskii Arkhiv" journal] Gogin EE. **Ter Arkh** 1998;70(9):24–9 **(Rus)**

[The effect of the blood serum cholesterol level on the late prognosis of stenocardia in men 40–59 years old without arterial hypertension] Prazdnov AS. **Ter Arkh** 1998; 70(8):11–4 (Eng. Abstr.) **(Rus)**

[Arterial hypertension in pregnancy] Ivanović-Krstić B, et al. **Srp Arh Celok Lek** 1999 May–Jun;127(5–6):178–82 (26 ref.) **(Scc)**

[Non-compliance with scheduled appointments in hypertensive patients: profile of the non-compliant patient] Pineiro Chousa F, et al. **Rev Clin Esp** 1998 Oct; 198(10):669–72 (Eng. Abstr.) **(Spa)**

[Arterial hypertension and pregnancy: diagnostic criteria and therapeutic approach] Palma Gámiz JL. **Rev Esp Cardiol** 1998;51 Suppl 4:50–8 (34 ref.) (Eng. Abstr.) **(Spa)**

[Evolution and prognosis of arterial hypertension in women] Velasco Rami JA. **Rev Esp Cardiol** 1998;51 Suppl 4:44–9 (29 ref.) (Eng. Abstr.) **(Spa)**

[Effects of an educational intervention on the quality of life of the hypertensive patient] Barrón-Rivera AJ, et al. **Salud Publica Mex** 1998 Nov–Dec;40(6):503–9 (Eng. Abstr.) **(Spa)**

BLOOD

Hyperprolactinemia in obese as well as in lean females of Koletsky rats: effect of long lasting terguride treatment. Golda V, et al. **Acta Medica (Hradec Kralove)** 1998; 41(4):159–62

Development of lipid and glycide abnormalities in genetically hypertensive obese Koletsky rats and in their lean siblings. Golda V, et al. **Acta Medica (Hradec Kralove)** 1998; 41(4):163–6

Plasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Zheng ZJ, et al. **Am J Epidemiol** 1999 Sep 1;150(5):492–500

Reduced bcl-2 concentrations in hypertensive patients after lisinopril or nifedipine administration. Buemi M, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):73–5

Lipids in hypertensive patients. Cobbe SM. **Am J Hypertens** 1998 Jul;11(7):887–9

Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test. Corica F, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):128–36

Can insulin action induce myocardial texture alterations in essential hypertension? Di Bello V, et al. **Am J Hypertens** 1999 Mar;12(3):283–90

Platelet aggregation in young men with contrasting predisposition to high blood pressure. Dockrell ME, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):115–9

The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Ergul S, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1381–5

Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Gasic S, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):217–22

Endothelin-1-like immunoreactivity in a new rodent model of spontaneous hypertension. Gulati A, et al. **Am J Hypertens** 1998 Jul;11(7):866–9

Insulinemia and pancreatic alpha2-adrenoceptors in salt-sensitive (SBH) and salt-resistant (SBN) Sabra rats: effect of high salt diet. Iihami N, et al. **Am J Hypertens** 1998 Jul;11(7):790–5

Increased erythrocyte aggregation in spontaneously hypertensive rats. Lominadze D, et al. **Am J Hypertens** 1998 Jul;11(7):784–9

Adrenocortical activity in the newborn spontaneously hypertensive rat. Malee MP, et al. **Am J Hypertens** 1999 May;12(5):511–8

Can we use erythrocytes for the study of the activity of the ubiquitous Na+/H+ exchanger (NHE-1) in essential hypertension? Orlov SN, et al. **Am J Hypertens** 1998 Jul; 11(7):774–83

Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Papadakis JA, et al. **Am J Hypertens** 1999 Jul;12(7):673–81

Ca2+ channels of the L-type in peripheral blood lymphocytes of essential hypertensives. Ricci A, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):40–6

Increased plasma levels of platelet-derived growth factor (PDGF-BB + PDGF-AB) in patients with never-treated mild essential hypertension. Rossi E, et al. **Am J Hypertens** 1998 Oct;11(10):1239–43

Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Sharabi Y, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):766–71

Na-K-ATPase inhibitor dissociated from hypertension-associated plasma protein. Weiler EW, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):364–73

Higher level of plasma nitric oxide in spontaneously hypertensive rats. Wu CC, et al. **Am J Hypertens** 1999 May;12(5):476–82

Effects of pregnancy-induced hypertension on the essential fatty acid statuses of Ecuadorian and Dutch women. Otto S, et al. **Am J Obstet Gynecol** 1999 May;180(5):1185–90

Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Silver HM, et al. **Am J Obstet Gynecol** 1999 May;180(5):1131–7

Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension. Kuwasako K, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):622–8

Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Peacock JM, et al. **Ann Epidemiol** 1999 Apr; 9(3):159–65

Plasma insulin levels and incidence of hypertension in African Americans and whites. He J, et al. **Arch Intern Med** 1999 Mar 8;159(5):498–503

Pathophysiological role of leptin in patients with chronic renal failure, in kidney transplant patients, in patients with essential hypertension, and in pregnant women with preeclampsia. Kokot F, et al. **Artif Organs** 1999 Jan; 23(1):70–4

Changes in plasma and urinary norepinephrine following transdermal clonidine in spontaneously hypertensive rats. Ishii R, et al. **Arzneimittelforschung** 1998 Aug;48(8):811–7

Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment. Bagdade JD, et al. **Atherosclerosis** 1998 Sep;140(1):167–72

The relationship between apolipoprotein E, dementia, and vascular illness. Marin DB, et al. **Atherosclerosis** 1998 Sep; 140(1):173–80

Platelet cytosolic calcium hyperresponsivity to serotonin in patients with hypertension and depressive symptoms. Delisi JS, et al. **Biol Psychiatry** 1999 Apr 15;45(8):1035–41

Changes of plasma L-arginine levels in spontaneously hypertensive rats under induced hypotension. Prados P, et al. **Biomed Chromatogr** 1999 Feb;13(1):27–32

Effects of hemodialysis on circulating adrenomedullin concentrations in patients with end-stage renal disease. Toepfer M, et al. **Blood Purif** 1998;16(5):269–74

Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. Connelly PW, et al. **Can J Cardiol** 1999 Apr;15(4):428–33

Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients. Papadopoulos CL, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):345–6

Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension. Dijkhorst-Oei LT, et al. **Cardiovasc Res** 1998 Nov;40(2):402–9

Left ventricular hypertrophy and parathyroid hormone: a causal connection? [letter; comment] Schlüter KD, et al. **Cardiovasc Res** 1998 Aug;39(2):523–4. Comment on: Cardiovasc Res 1998 Jan;37(1):34–41.

Gender differences in the oxygen transport system during maximal exercise in hypertensive subjects. Reybrouck T, et al. **Chest** 1999 Mar;115(3):788–92

Erythrocyte and plasma Ca2+, Mg2+ and cell membrane adenosine triphosphatase activity in patients with essential hypertension. Fu Y, et al. **Chin Med J (Engl)** 1998 Feb; 111(2):147–9

Smoking, obesity, and hypertension alter the dose-response curve and test sensitivity of carbohydrate-deficient transferrin as a marker of alcohol intake. Whitfield JB, et al. **Clin Chem** 1998 Dec;44(12):2480–9

Difficulties in detecting parathyroid hypertensive factor in the rat. Mangos GJ, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):936–8

Essential hypertension: leukocyte rheology and polymorphonuclear cytosolic Ca2+ content at baseline and after activation. Caimi G, et al. **Clin Hemorheol Microcirc** 1998 Dec;19(4):281–9

First International Conference on Microcirculation in Hypertension. Hypertension, hemorheology and oxygen transport, Bari, Italy, 1996. Hardeman MR, et al. **Clin Hemorheol Microcirc** 1998 Sep;19(1):49–81

A modified Casson equation to characterize blood rheology for hypertension. Shi YD, et al. **Clin Hemorheol Microcirc** 1998 Oct;19(2):115–27

G-protein-coupled receptor kinase expression in hypertension. Gros R, et al. **Clin Pharmacol Ther** 1999 May; 65(5):545–51

Hormonal response to orthostasis in elderly people with systemic systolic hypertension. Vardan S, et al. **Coron Artery Dis** 1998;9(9):597–601

Differential glucose tolerance in dipper and nondipper essential hypertension: the implications of circadian blood pressure regulation on glucose tolerance in hypertension. Chen JW, et al. **Diabetes Care** 1998 Oct;21(10):1743–8

Gestational hypertension plasma and human umbilical vein endothelial cells: an in vitro study. Cester N, et al. **Eur J Clin Invest** 1998 Dec;28(12):989–93

Pregnancy-induced hypertension: maternal and neonatal plasma lipid-soluble antioxidant levels and its relationship with fatty acid unsaturation. Oostenbrug GS, et al. **Eur J Clin Nutr** 1998 Oct;52(10):754–9

Maternal serum nitric oxide levels associated with biochemical and clinical parameters in hypertension in pregnancy. Bartha JL, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):201–7

Indices of carbohydrate and lipid metabolism in vasopressin-replete and -deficient New Zealand genetically hypertensive rats. Al-Barazanji KA, et al. **Horm Metab Res** 1998 Dec;30(12):717–20

Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Uçkaya G, et al. **Horm Metab Res** 1999 Jul;31(7):435–8

Plasma glutathione S-transferase Pi 1-1 measurements in the study of hemolysis in hypertensive disorders of pregnancy. Knapen MF, et al. **Hypertens Pregnancy** 1999;18(2):147–56

Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Kato J, et al. **Hypertens Res** 1999 Mar;22(1):61–5

Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Koshida H, et al. **Hypertens Res** 1998 Dec;21(4):279–82

Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Alderman MH, et al. **Hypertension** 1999 Jul;34(1):144–50

Preactivated peripheral blood monocytes in patients with essential hypertension. Dörffel Y, et al. **Hypertension** 1999 Jul;34(1):113–7

Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Ferri C, et al. **Hypertension** 1998 Nov;32(5):862–8

High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Fagot-Campagna A, et al. **Int J Epidemiol** 1998 Oct; 27(5):808–13

Effects of losartan, an angiotensin II receptor antagonist, on the fibrinolytic system in hypertensive patients [letter] Saito M, et al. **Int J Hematol** 1999 Jul;70(1):60–1

Effects of a novel calcium antagonist, benidipine hydrochloride, on platelet responsiveness to mental stress in patients with essential hypertension. Tomoda F, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):248–53

Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects. Dominguez LJ, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4402–7

Plasma insulin, plasminogen activator inhibitor, and ankle-brachial systolic blood pressure ratio in overweight hypertensive subjects. Achimastos A, et al. **J Hum Hypertens** 1999 May;13(5):329–35

Erythrocyte deformability is related to fasting insulin and declines during euglycaemic hyperinsulinaemia in hypertensive patients [letter] Linde T, et al. **J Hum Hypertens** 1999 Apr;13(4):285–6

Homocysteine, hypertension and stroke. Perry IJ. **J Hum Hypertens** 1999 May;13(5):289–93 (42 ref.)

Hypertriglyceridaemia in mild hypertension: impact on cardiovascular and hormonal reactivity under different stress tests. Scheuch K, et al. **J Hum Hypertens** 1999 Aug; 13(8):533–9

Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men [see comments] Agewall S, et al. **J Hypertens** 1998 Apr;16(4):537–41. Comment in: J Hypertens 1998 Oct;16(10):1555. Comment in: J Hypertens 1998 Oct;16(10):1557–9.

The erythrocyte Na,K,Cl cotransporter and its circulating

inhibitor in Dahl salt-sensitive rats. Alvarez-Guerra M, et al. **J Hypertens** 1998 Oct;16(10):1499-504

Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients [corrected and republished in J Hypertens 1998 Nov;16(11):1357-69] de Champlain J, et al. **J Hypertens** 1998 Sep;16(9):1357-69

Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive [see comments] Jullien V, et al. **J Hypertens** 1998 Jul; 16(7):1043-7. Comment in: J Hypertens 1998 Nov;16(11):1703-4.

Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study [see comments] Junker R, et al. **J Hypertens** 1998 Jul;16(7):917-23. Comment in: J Hypertens 1998 Jul;16(7):913-6.

Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. Koska J, et al. **J Hypertens** 1999 Apr; 17(4):529-35

Does hypertension confer a hypercoagulable state? [editorial; comment] Lip GY, et al. **J Hypertens** 1998 Jul;16(7):913-6 (39 ref.). Comment on: J Hypertens 1998 Jul;16(7):917-23.

Lack of relationship between left ventricular mass and serum cholesterol in hypertensives [letter; comment] Lip GY, et al. **J Hypertens** 1998 Nov;16(11):1703-4. Comment on: J Hypertens 1998 Jul;16(7):1043-7.

An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. Narkiewicz K, et al. **J Hypertens** 1999 Feb;17(2):245-9

Neutrophil arachidonic acid level and adhesive capability are increased in essential hypertension. Olivieri O, et al. **J Hypertens** 1998 May;16(5):585-92

Adrenomedullin and membrane fluidity of erythrocytes in mild essential hypertension. Tsuda K, et al. **J Hypertens** 1999 Feb;17(2):201-10

Association of arginine vasopressin and arterial blood pressure in a population-based sample. Zhang X, et al. **J Hypertens** 1999 Mar;17(3):319-24

Membrane microviscosity, blood pressure and cytosolic pH in Dahl rats: the influence of plasma lipids. Zicha J, et al. **J Hypertens** 1999 Jun;17(6):785-92

Noradrenaline spillover and microneurography measurements in patients with primary hypertension. Jennings GL. **J Hypertens Suppl** 1998 Aug;16(3):S35-8 (41 ref.)

Association between hyperhomocysteinaemia and hypertension in Sri Lankans. Mendis S, et al. **J Int Med Res** 1999 Jan-Feb;27(1):38-44

Parathyroid hormone and calcitriol in hypertension caused by dietary calcium deficiency in rats. López-Miranda V, et al. **J Vasc Res** 1998 Nov-Dec;35(6):397-404

Glucose metabolism and insulin sensitivity in Dahl hypertensive rats. Somova L, et al. **Methods Find Exp Clin Pharmacol** 1999 Jul-Aug; 21(6):421-5

Determination of serum cystatin C in patients with essential hypertension [letter] Seco ML, et al. **Nephron** 1999; 81(4):446-7

Effect of a hemodialysis session on plasma levels of endothelin-1 in hypertensive and normotensive subjects with end-stage renal failure. Surdacki A, et al. **Nephron** 1999 Jan;81(1):31-6

Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension. Netea RT, et al. **Neth J Med** 1999 Jul;55(1):39-45

Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Barron WM, et al. **Obstet Gynecol** 1999 Sep;94(3):364-70

C-type natriuretic peptide levels in women with gestational hypertension and preeclampsia. Stepan H, et al. **Obstet Gynecol** 1999 Feb;93(2):199-202

Changes of arterial arachidonic acid metabolites in hypertensive patients during haemodialysis. Keskil ZA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Jun; 58(6):395-7

Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with a history of preeclampsia. He S, et al. **Thromb Haemost** 1999 Apr; 81(4):538-42

[Effect of huoxue tablet on the rheology of erythrocyte in primary hypertension] Cheng WL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Dec; 17(12):718-20 (Eng. Abstr.) **(Chi)**

[Effect of theo-polyphenols on oxygen free radicals and hemorrheology in patients with essential hypertension] Ke YS, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr;17(4):221-3 (Eng. Abstr.) **(Chi)**

[Changes of the contents of insulin and vasoactive intestinal peptides in the patients with primary hypertension] Xu L, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb;13(1):93-4 **(Chi)**

[Influence of qi-gong on plasma TXB2 and 6-keto-PGF1 alpha in two TCM types of essential hypertension] Li W, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):497-9 (Eng. Abstr.) **(Chi)**

[The central mechanism of corticoids in the incidence of stress-induced hypertension] Zhu DN. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):324-6 (Eng. Abstr.) **(Chi)**

[Levels of lipid peroxidation products in blood serum and placental tissue of women with pregnancy induced hypertension] Lutnicki K, et al. **Ginekol Pol** 1998 Dec; 69(12):895-901 (Eng. Abstr.) **(Pol)**

[Monitoring oxypurines levels in women with pregnancy induced hypertension and in women with physiological pregnancy] Szczęśniak A, et al. **Ginekol Pol** 1997 Sep; 68(9):407-12 (Eng. Abstr.) **(Pol)**

[Plasma adrenomodullin concentration in patients wtih essential hypertension] Halawa B. **Pol Merkuriusz Lek** 1998 Sep;5(27):111-3 (Eng. Abstr.) **(Pol)**

[Increased blood viscosity syndrome in SHR rats: analysis of the model adequacy] Plotnikov MB, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):150-1 **(Rus)**

[Complex interpretation of aggregatograms for assessing the functional activity of platelets in patients with hypertension] Kochetov AG, et al. **Klin Lab Diagn** 1999 Apr;(4):43-5 **(Rus)**

[Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan] Koval' SN, et al. **Lik Sprava** 1999 Mar;(2):117-20 (Eng. Abstr.) **(Rus)**

[Relations between blood insulin concentration, renin-angiotensin-aldosterone system and clinical picture of hypertension] Didenko VA, et al. **Ter Arkh** 1999; 71(1):26-31 (Eng. Abstr.) **(Rus)**

[Levels of biologically active substances in the blood of patients resistant and nonresistant to antihypertensive therapy] Tabak'ian EA, et al. **Ter Arkh** 1999;71(3):62-7 (Eng. Abstr.) **(Rus)**

[Effect of coagulation and fibrinolytic changes on fetal growth in pregnant women with chronic hypertension] Kendić S. **Med Arh** 1998;52(2):85-8 (Eng. Abstr.) **(Scr)**

[The seasonal variation in the plasma fibrinogen concentrations in patients with essential arterial hypertension] Murciano Revert J, et al. **Aten Primaria** 1998 Sep 30;22(5):298-301 (Eng. Abstr.) **(Spa)**

[Calcium pump changes in patients with essential arterial hypertension] Sobrino J, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):441-5 (Eng. Abstr.) **(Spa)**

[The morphofunctional changes in the erythrocytes in cerebral vascular lesions in patients with hypertension and cerebral arteriosclerosis] Mardar HI, et al. **Lik Sprava** 1998 Dec;(8):7-10 (44 ref.) **(Ukr)**

[Change in the lipid status of the erythrocyte membrane in essential hypertension] Semykopna TV, et al. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):132-4 (Eng. Abstr.) **(Ukr)**

CHEMICALLY INDUCED

Hypertensive crisis from herbal treatment of impotence [letter] Ruck B, et al. **Am J Emerg Med** 1999 May; 17(3):317-8

Chronic hypertension leads to hyperinsulinemia in Sprague-Dawley rats treated with nitric oxide synthase inhibitor. Erlich Y, et al. **Am J Hypertens** 1998 Sep; 11(9):1129-33

Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. Yu M, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):845-8

Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis. Khurana V, et al. **Am J Med** 1999 Jan;106(1):118-9

What is the role of dietary sodium and potassium in hypertension and target organ injury? He J, et al. **Am J Med Sci** 1999 Mar;317(3):152-9 (50 ref.)

In vivo regulation of protein-serine kinases by insulin in skeletal muscle of fructose-hypertensive rats. Bhanot S, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E299-307

Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats. Giulumian AD, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1613-8

Effect of amiloride analogs on DOCA-salt-induced hypertension in rats. Keep RF, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2215-20

Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Oyekan AO, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R766-75

Salt-induced hypertension in Dahl salt-resistant and salt-sensitive rats with NOS II inhibition. Rudd MA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H732-9

Ouabain- and central sodium-induced hypertension depend on the ventral anteroventral third ventricle region. Veerasingham SJ, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H63-70

5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Watts SW, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H944-52

Lead and hypertension in a sample of middle-aged women. Korrick SA, et al. **Am J Public Health** 1999 Mar; 89(3):330-5

Are vasopressors beneficial after cranial trauma? [letter; comment] Talmor D, et al. **Anesth Analg** 1999 Jun; 88(6):1423-4. Comment on: Anesth Analg 1998 Oct;87(4):751-3.

An unexpected central hypertensive effect of the new imidazoline compound benazoline. Bruban V, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:102-5

Mercury intoxication presenting with hypertension and tachycardia. Wössmann W, et al. **Arch Dis Child** 1999 Jun; 80(6):556-7

Interaction between the irreversible MAOIs and certain foods [letter] Beavis D. **Aust Fam Physician** 1999 Jul;28(7):650, 652

Aldosterone directly induces Na, K-ATPase alpha 1-subunit mRNA in the renal cortex of rat. Seok JH, et al. **Biochem Mol Biol Int** 1999 Feb;47(2):251-4

Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans. Macefield VG, et al. **Blood Press** 1998 Jul;7(4):215-22

Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat. Sato J, et al. **Br J Pharmacol** 1998 Oct;125(3):469-76

Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia. Hosomi N, et al. **Brain Res** 1999 Jul 24;835(2):188-96

Hypertension during coprescription of mirtazapine and low-dose amitriptyline [letter] Zedkova L, et al. **Can J Psychiatry** 1998 Oct;43(8):858-9

The role of corticosteriods in the regulation of vascular tone. Ullian ME. **Cardiovasc Res** 1999 Jan;41(1):55-64 (115 ref.)

Cadmium induced hypertension. Puri VN. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):79-84

Hypertension development in Dahl S and R rats on high salt-low potassium diet: calcium, magnesium and sympathetic nervous system. Wu X, et al. **Clin Exp Hypertens** 1998 Oct;20(7):795-815

Cortisol and hypertension. Kelly JJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S51-6 (51 ref.)

Blood pressure in children exposed prenatally to cocaine. Needlman R, et al. **Clin Pediatr (Phila)** 1998 Nov; 37(11):659-64

Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Rush CR, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1-2):1-12

Kappa-opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension. Wright RC, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):57-61

Strain differences of hypertension induced by dietary NG-nitro-L-arginine in normotensive rats. Kawakami K, et al. **Exp Anim** 1999 Jul;48(3):171-80

Brain renin-angiotensin system and ouabain-induced sympathetic hyperactivity and hypertension in Wistar rats. Huang BS, et al. **Hypertension** 1999 Jul;34(1):107-12

Renal injury and salt-sensitive hypertension after exposure to catecholamines. Johnson RJ, et al. **Hypertension** 1999 Jul;34(1):151-9

Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Lombardi D, et al. **Hypertension** 1999 Apr;33(4):1013-9

Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Ni Z, et al. **Hypertension** 1998 Oct;32(4):724-9

Hypertension and arsenic exposure in Bangladesh. Rahman M, et al. **Hypertension** 1999 Jan;33(1):74-8

Mechanisms of FK 506-induced hypertension in the rat. Takeda Y, et al. **Hypertension** 1999 Jan;33(1):130-6

Alpha-adrenergic systems mediate chronic central AII hypertension in rats fed high sodium chloride diet from weaning. Camara AK, et al. **J Auton Nerv Syst** 1999 Apr 16;76(1):28-34

AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning. Camara AK, et al. **J Auton Nerv Syst** 1998 Aug 6;72(1):16-23

Blood pressure changes during short-term fluoxetine treatment. Amsterdam JD, et al. **J Clin Psychopharmacol** 1999 Feb;19(1):9-14

Blood lead and blood pressure: evidence from the Health Survey for England 1995. Bost L, et al. **J Hum Hypertens** 1999 Feb;13(2):123-8

Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension. Alam S, et al. **J Hypertens** 1999 Aug; 17(8):1195-202

Lacidipine reduces high blood pressure and the target organ damage induced by high fructose diet in rats. Cosenzi A, et al. **J Hypertens** 1999 Jul;17(7):965-71

Overexpression of vascular endothelin-1 and endothelin-A receptors in a fructose-induced hypertensive rat model. Juan CC, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1775-82

Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. Li M, et al. **J Hypertens** 1999 Mar;17(3):419-26

Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. Schrama YC, et al. **J Hypertens Suppl** 1998 Sep;16(4):S33-8 (89 ref.)

Different contributions of the endothelin ET(A) receptor to hypertension induced by acute or chronic inhibition of nitric oxide synthesis. Hashimoto N, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1051-8

Hypersensitivity myocarditis associated with ephedra use. Zaacks SM, et al. **J Toxicol Clin Toxicol** 1999;37(4):485-9

The salt dilemma: some answers, many questions. Nicholls MG, et al. **Med J Aust** 1999 Feb 15;170(4):178-80 (82 ref.)

Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. Juan CC, et al. **Metabolism** 1999 Apr;48(4):465-71

Pontefract cakes can be bad for you: refractory hypertension and liquorice excess. Dellow EL, et al.

Nephrol Dial Transplant 1999 Jan;14(1):218–20

Daytime hypertension, sleep apnea and metabolic alkalosis in a haemodialysis patient--the result of sodium bicarbonate abuse. Okada H, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):452–4

Hypertensive encephalopathy as a complication of hyperdynamic therapy for vasospasm: report of two cases. Amin-Hanjani S, et al. **Neurosurgery** 1999 May; 44(5):1113–6

Salt-sensitive hypertension: renal and cardiovascular implications. Campese VM. **Nutr Metab Cardiovasc Dis** 1999 Jun;9(3):143–56 (147 ref.)

Dietary sodium intake and mortality. Esslinger KA, et al. **Nutr Rev** 1998 Oct;56(10):311–3 (13 ref.)

Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies. Delini-Stula A, et al. **Pharmacopsychiatry** 1999 Mar;32(2):61–7

Nitric oxide in cyclosporine A-induced hypertension: endothelin receptors gene expression. Oriji GK. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul; 61(1):41–4

[Edema tendency, dyspnea and hypertension in the treatment with mirtazapine (Remeron)] Jensen JB. **Ugeskr Laeger** 1999 May 3;161(18):2699 **(Dan)**

[Hypertensive effects of qat] Mion G, et al. **Med Trop (Mars)** 1998;58(3):266–8 (Eng. Abstr.) **(Fre)**

[Erythropoietin and hypertension (editorial)] Azzadin A, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):295–7 (31 ref.) (Eng. Abstr.) **(Pol)**

[Arterial hypertension and alcoholism among workers in an oil refinery] Lima CT, et al. **Rev Panam Salud Publica** 1999 Sep;6(3):185–91 (Eng. Abstr.) **(Por)**

CLASSIFICATION

Relationship between Joint National Committee-VI classification of hypertension and ambulatory blood pressure in patients with hypertension diagnosed by casual blood pressure. Inden Y, et al. **Clin Cardiol** 1998 Nov; 21(11):801–6

Ambulatory blood pressure monitoring and the taxonomy of hypertension [editorial; comment] Floras JS. **J Hypertens** 1998 Dec;16(12 Pt 1):1719–20. Comment on: J Hypertens 1998 Dec;16(12 Pt 1):1735–43.

[Types of hypertension in pregnant women of Benin admitted to the National University Hospital of Cotonou] Attolou V, et al. **Sante** 1998 Sep-Oct;8(5):353–6 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

The combination of risk factors for sudden death in a resuscitated elderly patient with an exceptional cause of left ventricular hypertrophy. Tavernier R, et al. **Acta Cardiol** 1999 Feb;54(1):41–3

Microinfarction as a result of hypertension in a primate model of cerebrovascular disease. Kemper T, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):295–303

Left ventricular hypertrophy as a risk factor in hypertension. Balogun MO, et al. **Afr J Med Med Sci** 1996 Sep; 25(3):277–83 (67 ref.)

Venous hypertensive encephalopathy [comment] Deveikis JP. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1274–5. Comment on: AJNR Am J Neuroradiol 1998 Aug;19(7):1267–73.

Current hypertension control is just not good enough [editorial; comment] Dustan HP. **Am Fam Physician** 1998 Oct 15;58(6):1292, 1295–6. Comment on: Am Fam Physician 1998 Oct 15;58(6):1323–30.

Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Hall WD. **Am Heart J** 1999 Sep;138(3 Pt 2):225–30 (21 ref.)

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. He J, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):211–9 (34 ref.)

Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Kannel WB. **Am Heart J** 1999 Sep;138(3 Pt 2):205–10 (20 ref.)

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Celentano A, et al. **Am J Cardiol** 1999 Apr 15;83(8):1196–200

Aortic valve thickening associated with power training: is it pressure overload? [see comments] Dickerman RD, et al. **Am J Cardiol** 1998 Oct 15;82(8):996. Comment in: Am J Cardiol 1999 Apr 15;83(8):1300.

Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Estacio RO, et al. **Am J Cardiol** 1998 Nov 12; 82(9B):9R–14R

Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Gaziano JM, et al. **Am J Cardiol** 1999 Oct 1;84(7):768–73

Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Kohara K, et al. **Am J Cardiol** 1999 Feb 1; 83(3):367–70

Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Kostis JB, et al. **Am J Cardiol** 1998 Dec 15;82(12):1501–8

Prevalence and risk factors for abdominal aortic aneurysms in older adults with and without isolated systolic hypertension. Naydeck BL, et al. **Am J Cardiol** 1999 Mar 1;83(5):759–64

Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) [see comments] Sowers JR. **Am J Cardiol** 1998 Nov 12; 82(9B):15R–19R. Comment in: Am J Cardiol 1999 Mar 1;83(5):819–20.

Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris. Tenenbaum A, et al. **Am J Cardiol** 1999 Aug 1;84(3):294–8

Diabetes and hypertension in Mexican American families: relation to cardiovascular risk. Mitchell BD, et al. **Am J Epidemiol** 1999 Jun 1;149(11):1047–56

The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Bakris GL. **Am J Hypertens** 1998 Oct; 11(10):158S–162S (23 ref.)

Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Borghi C, et al. **Am J Hypertens** 1999 Jul;12(7):665–72

Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Buğra Z, et al. **Am J Hypertens** 1998 Oct;11(10):1164–70

The clinical significance of systolic hypertension. Cushman WC. **Am J Hypertens** 1998 Nov;11(11 Pt 2):182S–185S (10 ref.)

Chronic hypertension leads to hyperinsulinemia in Sprague-Dawley rats treated with nitric oxide synthase inhibitor. Erlich Y, et al. **Am J Hypertens** 1998 Sep; 11(9):1129–33

Cardiovascular abnormalities in never-treated hypertensives according to nondipper status. Ferrara AL, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1352–7

Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension. Jeng JR. **Am J Hypertens** 1999 May; 12(5):443–50

The prevalence and etiology of impotence in 101 male hypertensive outpatients. Jensen J, et al. **Am J Hypertens** 1999 Mar;12(3):271–5

Atenolol and fetal growth in pregnancies complicated by hypertension. Lydakis C, et al. **Am J Hypertens** 1999 Jun; 12(6):541–7

Disease management, pharmacoeconomics, and molecular biology: tools for prevention of hypertensive complications. Materson BJ. **Am J Hypertens** 1998 Aug;11(8 Pt 2):101S–102S; discussion 109S–111S

Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Meyrier A, et al. **Am J Hypertens** 1998 Sep;11(9):1087–92

Left ventricular contractile performance, ventriculoarterial coupling, and left ventricular efficiency in hypertensive patients with left ventricular hypertrophy. Nitenberg A, et al. **Am J Hypertens** 1998 Oct;11(10):1188–98

Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Okaishi K, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):778–83

Early atherosclerosis in human hypertension. Simon A, et al. **Am J Hypertens** 1998 Jul;11(7):882–3

Hypertension in the hemodialysis population? High time for answers [editorial; comment] [see comments] Salem M. **Am J Kidney Dis** 1999 Mar;33(3):592–4. Comment on: Am J Kidney Dis 1999 Mar;33(3):498–506. Comment on: Am J Kidney Dis 1999 Mar;33(3):507–17. Comment in: Am J Kidney Dis 1999 Aug;34(2):400.

Aortic dissection in young patients with chronic hypertension. Vogt BA, et al. **Am J Kidney Dis** 1999 Feb; 33(2):374–8

The role of hypertension, obesity, and diabetes in causing renal vascular disease. Crook ED. **Am J Med Sci** 1999 Mar;317(3):183–8 (36 ref.)

Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation. Koide M, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H350–8

Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Kaplan RC, et al. **Am J Public Health** 1999 Sep;89(9):1414–7

A study of the association between epistaxis and the severity of hypertension. Lubianca-Neto JF, et al. **Am J Rhinol** 1998 Jul-Aug;12(4):269–72

Multivessel spontaneous coronary artery dissection in a patient with severe systolic hypertension: a possible association. A case report. Greenblatt JM, et al. **Angiology** 1999 Jun;50(6):509–13

Anxiety and coronary heart disease: a synthesis of epidemiological, psychological, and experimental evidence. Kubzansky LD, et al. **Ann Behav Med** 1998 Spring; 20(2):47–58 (140 ref.)

Chronic hypertension in pregnancy. Haddad B, et al. **Ann Med** 1999 Aug;31(4):246–52 (47 ref.)

Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload. Dhalla NS, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:100–10

Mutual influences between paroxysmal hypertension and psychiatric disturbance [letter] Boylan LS. **Arch Intern Med** 1999 Sep 27;159(17):2091–2

Profile for estimating risk of heart failure. Kannel WB, et al. **Arch Intern Med** 1999 Jun 14;159(11):1197–204

Antihypertensive therapy in the elderly: evidence-based guidelines and reality [letter; comment] Messerli FH, et al. **Arch Intern Med** 1999 Jul 26;159(14):1621–2. Comment on: Arch Intern Med 1998 Nov 23;158(21):2377–85.

Antihypertensive agents in diabetic patients: great benefits, special risks [editorial; comment] Peters AL, et al. **Arch Intern Med** 1999 Mar 22;159(6):541–2. Comment on: Arch Intern Med 1999 Mar 22;159(6):551–8. Comment on: Arch Intern Med 1999 Mar 22;159(6):535–7.

Protective effects of delapril, indapamide and their combination on stroke occurrence and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Razzetti R, et al. **Arzneimittelforschung** 1998 Nov; 48(11):1083–7

Systemic hypertension as a risk factor for complications with an aortic mechanical valve. Natsuaki M, et al. **ASAIO J** 1998 Sep-Oct;44(5):M486–90

The health status and characteristics of hypertensives in Guam. Pinhey TK. **Asia Pac J Public Health** 1995; 8(3):177–80

Control and cardiovascular risk factors of hypertension. An assessment of a sample of patients. Steven ID, et al. **Aust Fam Physician** 1999 Jan;28(1):45–8

Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Müller-Wieland D, et al. **Basic Res Cardiol** 1998;93 Suppl 2:131–4 (16 ref.)

Antihypertensive therapy before, during, and after stroke. Mzimba ZS, et al. **Basic Res Cardiol** 1998;93 Suppl 2:59–62 (37 ref.)

Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. Trenkwalder P. **Basic Res Cardiol** 1998;93 Suppl 2:140–4

Isolated systolic hypertension: an important cardiovascular risk factor. Himmelmann A, et al. **Blood Press** 1998 Jul; 7(4):197–207 (36 ref.)

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy. British trial shows clear effects of treatment, especially blood pressure reduction [editorial; comment] Mogensen CE. **BMJ** 1998 Sep 12; 317(7160):693–4. Comment on: BMJ 1998 Mar 14;316(7134):823–8. Comment on: BMJ 1998 Sep 12;317(7160):703–13. Comment on: BMJ 1998 Sep 12;317(7160):713–20. Comment on: BMJ 1998 Sep 12;317(7160):720–6.

Dietary restriction reduces the prevalence of osteonecrosis of the caput femoris in spontaneously hypertensive rats. Tomita M, et al. **Calcif Tissue Int** 1999 Mar;64(3):259–62

Do calcium channel blockers increase the risk of myocardial infarction in hypertensive patients with diabetes mellitus? Park L, et al. **Can Fam Physician** 1998 Nov;44:2405–7

Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Julius S. **Cardiology** 1999;91 Suppl 1:8–13 (47 ref.)

Modulation of the pacemaker current If by beta-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats. Cerbai E, et al. **Cardiovasc Res** 1999 Apr;42(1):121–9

Heat stress-induced resistance to myocardial infarction in the isolated heart from transgenic [(mREN-2)27] hypertensive rats. Joyeux M, et al. **Cardiovasc Res** 1998 Oct;40(1):124–30

Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats. Zolk O, et al. **Cardiovasc Res** 1998 Jul;39(1):242–56 (144 ref.)

Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Bae H, et al. **Cerebrovasc Dis** 1999 Mar-Apr;9(2):102–8

Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin [see comments] Ding B, et al. **Circ Res** 1999 Apr 2;84(6):729–34 . Comment in: Circ Res 1999 Apr 2;84(6):741–3.

LOX-1, a possible clue to the missing link between hypertension and atherogenesis [comment] Kita T. **Circ Res** 1999 May 14;84(9):1113–5 (45 ref.). Comment on: Circ Res 1999 May 14;84(9):1043–9.

Dipyridamole stress echocardiography for risk stratification in hypertensive patients with chest pain. Cortigiani L, et al. **Circulation** 1998 Dec 22–29;98(25):2855–9

Impaired force-frequency relations in patients with hypertensive left ventricular hypertrophy. A possible physiological marker of the transition from physiological to pathological hypertrophy. Inagaki M, et al. **Circulation** 1999 Apr 13;99(14):1822–30

Ventricular pacing with premature excitation for treatment of hypertensive-cardiac hypertrophy with cavity-obliteration [see comments] Kass DA, et al. **Circulation** 1999 Aug 24;100(8):807–12. Comment in: Circulation 1999 Aug 24;100(8):786–8.

Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study [see comments] Khattar RS, et al. **Circulation** 1998 Nov 3;98(18):1892–7. Comment in: Circulation 1998 Nov 3;98(18):1834–6.

Relationship between left ventricular mass and

endothelium-dependent vasodilation in never-treated hypertensive patients. Perticone F, et al. **Circulation** 1999 Apr 20;99(15):1991-6

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension [see comments] Thürmann PA, et al. **Circulation** 1998 Nov 10;98(19):2037-42. Comment in: Circulation 1998 Nov 10;98(19):1987-9.

United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Nasr CE, et al. **Cleve Clin J Med** 1999 Apr;66(4):247-53

Aneurysms of the ascending aorta: diagnostic features and prognosis in patients with Marfan's syndrome versus hypertension. von Kodolitsch Y, et al. **Clin Cardiol** 1998 Nov;21(11):817-24

Comparative efficacies of a calcium antagonist and an alpha1 blocker in elderly hypertensive patients with stroke. Setoguchi M, et al. **Clin Exp Hypertens** 1998 Oct; 20(7):763-74

Pathogenesis of atherosclerosis in diabetes and hypertension. Shantaram V. **Clin Exp Hypertens** 1999 Jan-Feb; 21(1-2):69-77 (16 ref.)

Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease. Brahimi M, et al. **Clin Sci (Colch)** 1998 Sep;95(3):261-7

The impact of residual renal function on the adequacy of peritoneal dialysis. Lameire NH. **Contrib Nephrol** 1998; 124:76-93; discussion 93-102 (99 ref.)

Diabetic vascular disease and hypertension. Hamaty M, et al. **Curr Opin Cardiol** 1998 Sep;13(5):298-303 (63 ref.)

Microalbuminuria in essential hypertension. Mimran A, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):359-63 (44 ref.)

Parental hypertension and risk of diabetic nephropathy [letter; comment] Lindsay RS, et al. **Diabet Med** 1998 Sep; 15(9):798. Comment on: Diabet Med 1998 May;15(5):418-26.

Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Ferri C, et al. **Diabetes** 1999 Aug; 48(8):1623-30

Diabetic hypertensive patients. Is this a group in need of particular care and attention? Parving HH. **Diabetes Care** 1999 Mar;22 Suppl 2:B76-9 (27 ref.)

Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Bruno G, et al. **Diabetologia** 1999 Mar;42(3):297-301

Drug treatment of hypertension complicating diabetes mellitus. MacLeod MJ, et al. **Drugs** 1998 Aug;56(2):189-202 (97 ref.)

Perinatal outcome of babies born to black South African women with hypertension. Rankhethoa NM, et al. **East Afr Med J** 1998 Jul;75(7):388-91

Incidence and aetiology of heart failure; a population-based study [see comments] Cowie MR, et al. **Eur Heart J** 1999 Mar;20(6):421-8. Comment in: Eur Heart J 1999 Mar;20(6):398-9.

Long-term effects of balloon angioplasty on systemic hypertension in adolescent and adult patients with coarctation of the aorta. Fawzy ME, et al. **Eur Heart J** 1999 Jun;20(11):827-32

Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Buter H, et al. **Eur J Clin Pharmacol** 1999 Feb; 54(12):953-8

Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea. Heitmann J, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):691-6

The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. Salo TM, et al. **Eur J Clin Pharmacol** 1999 May;55(3):191-8

Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus. Pavlovic M, et al. **Eur J Pediatr** 1999 Jan;158(1):18-23

Cardioprotective effects of quinapril after myocardial infarction in hypertensive rats. Mori T, et al. **Eur J Pharmacol** 1998 May 8;348(2-3):229-34

Symptomatic BPH and hypertension: does comorbidity affect quality of life? Man in 't Veld AJ. **Eur Urol** 1998;34 Suppl 2:29-36; discussion 47

Reversible anterior ischaemic optic neuropathy in accelerated hypertension [letter] Gallagher MJ, et al. **Eye** 1998;12 (Pt 5):896-7

Microemboli are not a prerequisite in retinal artery occlusive diseases. Haase CG, et al. **Eye** 1998;12 (Pt 4):659-62

Hypertension, blood pressure variability, and target organ damage. Lantelme P, et al. **Fundam Clin Pharmacol** 1998; 12 Suppl 1:57s-63s (33 ref.)

Influence of cigarette smoking on the electrocardiographic diagnosis of left ventricular hypertrophy in arterial hypertension. Schillaci G, et al. **G Ital Cardiol** 1999 Jan; 29(1):34-8

The heart in arterial hypertension [editorial] Verdecchia P, et al. **G Ital Cardiol** 1999 Jul;29(7):769-80 (81 ref.)

The hypertensive elderly male with prostatism [clinical conference] Lowenthal DT, et al. **Geriatr Nephrol Urol** 1999;9(1):57-60

Framingham: the town with heart [editorial] Butler RN. **Geriatrics** 1999 Apr;54(4):3-4

Fetal compromise assessed by Doppler ultrasound of venous flow in pregnancy-induced hypertension. Ochi H, et al. **Gynecol Obstet Invest** 1999;47(4):235-8

Episodic chest pain in a young woman with hypertension. Hancock EW. **Hosp Pract (Off Ed)** 1999 May 15;34(5):23-4

Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Devereux RB, et al. **Hypertens Res** 1999 Mar;22(1):1-9 (85 ref.)

Influence of mild to moderate obesity on left ventricular stress filling pattern in hypertension. Seto S, et al. **Hypertens Res** 1998 Dec;21(4):245-50

Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension. Tomita S, et al. **Hypertens Res** 1998 Dec;21(4):259-66

Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Alderman MH, et al. **Hypertension** 1999 Jul;34(1):144-50

Diabetes and cardiovascular events in hypertensive patients. Alderman MH, et al. **Hypertension** 1999 May;33(5):1130-4

Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Blacher J, et al. **Hypertension** 1999 May;33(5):1111-7

Genetic and gender influences on sensitivity to focal cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Carswell HV, et al. **Hypertension** 1999 Feb;33(2):681-5

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Dahlöf B, et al. **Hypertension** 1998 Dec;32(6):989-97

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Nazzaro P, et al. **Hypertension** 1999 Feb;33(2):719-25

Myocardial osteopontin expression coincides with the development of heart failure. Singh K, et al. **Hypertension** 1999 Feb;33(2):663-70

Hypertension and hormone-related neoplasms in women. Soler M, et al. **Hypertension** 1999 Aug;34(2):320-5

Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Verdecchia P, et al. **Hypertension** 1998 Dec;32(6):983-8

Job strain and arterial blood pressure, serum cholesterol, and smoking as risk factors for coronary heart disease in Japan. Kawakami N, et al. **Int Arch Occup Environ Health** 1998 Sep;71(6):429-32

Oedema, Starling and pulse reverse osmosis: towards a possible biochemical marker for oedema. Prior FG, et al. **Int J Artif Organs** 1999 Mar;22(3):138-44

Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate. Adigun AQ, et al. **Int J Cardiol** 1998 Nov 30;67(1):81-6

Cardiovascular risk: which is the most important in blood pressure? Meinertz T. **Int J Clin Pract Suppl** 1998 Nov; 98:6-8 (7 ref.)

Optimal management of hypertensive patients with LVH and dyslipidaemia. Plouin PF. **Int J Clin Pract Suppl** 1998 Nov; 98:9-12

The development of cardiovascular disease in relation to anthropometric indices and hypertension in British adults. Cox BD, et al. **Int J Obes Relat Metab Disord** 1998 Oct; 22(10):966-73

Insulin resistance in obese hypertensive Asian Indian subjects. Marita AR, et al. **Int J Obes Relat Metab Disord** 1999 May;23(5):445-8

Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. Fragasso G, et al. **J Am Coll Cardiol** 1999 Aug;34(2):441-7

Heart murmurs, valvular regurgitation and electrical disturbances in copper-deficient genetically hypertensive, hypertrophic cardiomyopathic rats. Shiry LJ, et al. **J Am Coll Nutr** 1999 Feb;18(1):51-60

Epistaxis in the older hypertensive patient [letter] Pantanowitz L. **J Am Geriatr Soc** 1999 May;47(5):631

Hypertension and the development of heart failure. de Leeuw PW, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 1:S9-15 (59 ref.)

The kidney as part of the cardiovascular system. Ruilope LM. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S7-10; discussion S41-3 (50 ref.)

First-degree kinship with young coronary artery disease patients markedly increases lipid-level disorders in asymptomatic hypertensives. Giannini SD, et al. **J Cardiovasc Risk** 1998 Jun;5(3):141-5

Functional reduction and associated cellular rearrangement in SHRSP rat basilar arteries are affected by salt load and calcium antagonist treatment. Arribas SM, et al. **J Cereb Blood Flow Metab** 1999 May;19(5):517-27

Antihypertensive therapy in type 2 diabetes mellitus. Miser WF. **J Fam Pract** 1998 Dec;47(6):413-4

Tight blood pressure control in type 2 diabetes. Wroth T, et al. **J Fam Pract** 1998 Dec;47(6):412-3

Adrenal cancer with hypertension but low plasma renin and aldosterone. Cheng WY, et al. **J Formos Med Assoc** 1999 Jan;98(1):73-5

Can high blood pressure mask severe aortic stenosis? [editorial; comment] Chambers J. **J Heart Valve Dis** 1999 May;8(3):277-8. Comment on: J Heart Valve Dis 1999 May;8(3):279-83.

Hypertension in the elderly: attitudes of British patients and general practitioners. Cranney M, et al. **J Hum Hypertens** 1998 Aug;12(8):539-45

Progression of asymmetric pattern of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy accompanied by hypertension in the elderly. Dimitrow PP, et al. **J Hum Hypertens** 1998 Sep;12(9):631-2

Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. Fogari R, et al. **J Hum Hypertens** 1999 Jan;13(1):47-53

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? Gosse P, et al. **J Hum Hypertens** 1999 Aug;13(8):505-9

Target organ involvement in hypertensive patients in Eastern Sudan. Hussain AA, et al. **J Hum Hypertens** 1999 Jan; 13(1):9-12

Cerebellar infarction as a complication of malignant hypertension. Johnson K, et al. **J Hum Hypertens** 1998 Aug;12(8):569-70

Value of ambulatory intra-arterial blood pressure monitoring in the long-term prediction of left ventricular hypertrophy and carotid atherosclerosis in essential hypertension [see comments] Khattar RS, et al. **J Hum Hypertens** 1999 Feb; 13(2):111-6. Comment in: J Hum Hypertens 1999 Feb;13(2):81-3.

Gender specific differences in left ventricular adaptation to obesity and hypertension. Kuch B, et al. **J Hum Hypertens** 1998 Oct;12(10):685-91

Renal artery aneurysms and hypertension. Lebel M, et al. **J Hum Hypertens** 1998 Nov;12(11):765-6

Changes in cardiac diastolic dimensions precede hypertrophy in early stages of hypertension. Lemme C, et al. **J Hum Hypertens** 1998 Oct;12(10):679-83

The haemodynamic response to hyperinsulinaemia in hypertensive subjects. Lind L, et al. **J Hum Hypertens** 1999 Jan;13(1):41-5

Silent myocardial ischaemia in patients with essential arterial hypertension and non-insulin dependent diabetes mellitus. Lubaszewski W, et al. **J Hum Hypertens** 1999 May; 13(5):309-13

Blood pressure and other risk factors before the onset of myocardial infarction in hypertensive patients. Minami J, et al. **J Hum Hypertens** 1998 Oct;12(10):713-8

Hypertension and renal failure in Kumasi, Ghana. Plange-Rhule J, et al. **J Hum Hypertens** 1999 Jan; 13(1):37-40

Renal function in treated and untreated hypertension. Rahn KH. **J Hum Hypertens** 1998 Sep;12(9):599-601 (12 ref.)

The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. Spargias K, et al. **J Hum Hypertens** 1999 Aug;13(8):511-6

Prediction of cardiovascular damage in hypertensive patients: clinic or ambulatory blood pressures? [comment] Stanton AV. **J Hum Hypertens** 1999 Feb;13(2):81-3 (11 ref.). Comment on: J Hum Hypertens 1999 Feb;13(2):111-6.

Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. Antikainen R, et al. **J Hypertens** 1998 May; 16(5):577-83

Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Bigazzi R, et al. **J Hypertens** 1998 Sep;16(9):1325-33

A prospective study of hypertension and the incidence of kidney stones in men. Cappuccio FP, et al. **J Hypertens** 1999 Jul;17(7):1017-22

Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. Cohn JN. **J Hypertens** 1998 Dec;16(12 Pt 2):2117-24 (53 ref.)

Hypertensive men who exercise regularly have lower rate of cardiovascular mortality. Engström G, et al. **J Hypertens** 1999 Jun;17(6):737-42

Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. Gamble G, et al. **J Hypertens** 1998 Sep;16(9):1389-95

Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. Gerritsen TA, et al. **J Hypertens** 1998 May;16(5):689-96

Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. Grimm D, et al. **J Hypertens** 1998 Sep;16(9):1345-55

Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men [letter; comment] Lip GY, et al. **J Hypertens** 1998 Oct;16(10):1557-9. Comment on: J Hypertens 1998 Apr;16(4):537-41.

Type A behavior is associated with an increased risk of left ventricular hypertrophy in male patients with essential hypertension. Munakata M, et al. **J Hypertens** 1999 Jan; 17(1):115-20

Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. Nielsen S, et al. **J Hypertens** 1998 Oct;16(10):1539-44

Hypertension, antihypertensive drugs, and mortality from cancer among women. Peeters PH, et al. **J Hypertens** 1998

Jul;16(7):941–7
Hypertension and long-term cancer incidence and mortality among Swedish men. Rosengren A, et al. **J Hypertens** 1998 Jul;16(7):933–40
Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Rossi MA. **J Hypertens** 1998 Jul; 16(7):1031–41
Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. Watanabe K, et al. **J Hypertens** 1999 Aug;17(8):1153–60
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. Zanchetti A, et al. **J Hypertens** 1998 Jul;16(7):949–61
Does essential hypertension cause progressive renal disease? Fliser D, et al. **J Hypertens Suppl** 1998 Sep;16(4):S13–5 (41 ref.)
Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. He J, et al. **J Hypertens Suppl** 1999 Jun;17(2):S7–13
The importance of left ventricular hypertrophy in human hypertension. Kahan T. **J Hypertens Suppl** 1998 Sep; 16(7):S23–9 (40 ref.)
Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients. Leenen FH. **J Hypertens Suppl** 1998 Oct;16(5):S9–15 (33 ref.)
Cardiovascular risks of hypertension: lessons from observational studies. O'Donnell CJ, et al. **J Hypertens Suppl** 1998 Oct;16(6):S3–7 (21 ref.)
Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. Sadowski Z, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S55–62
Perceived symptoms amongst hypertensive patients in routine clinical practice– a population-based study. Kjellgren KI, et al. **J Intern Med** 1998 Oct;244(4):325–32
Pediatric sarcoidosis presenting with hypertensive encephalopathy. Jungthirapanich J, et al. **J Med Assoc Thai** 1998 Nov;81(11):911–7
Hypertension corner. Clinical significance of various blood pressure components [editorial] Birbari AE. **J Med Liban** 1998 Sep–Oct;46(5):243
Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc-fa cp rats. Sharkey LC, et al. **J Mol Cell Cardiol** 1999 Aug; 31(8):1527–37
Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. Tamura T, et al. **J Mol Cell Cardiol** 1998 Nov; 30(11):2175–81
Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. Malatino LS, et al. **J Nephrol** 1999 Jul–Aug;12(4):256–60
Vascular risk factors for perimesencephalic nonaneurysmal subarachnoid hemorrhage. Canhão P, et al. **J Neurol** 1999 Jun;246(6):492–6
Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. Leker RR, et al. **J Neurol Sci** 1999 Jan 15;162(2):114–9
Paraplegia after coronary bypass operations: relationship to severe hypertension and vascular disease. Thomas NJ, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):834–6
Relationship between brain atrophy estimated by a longitudinal computed tomography study and blood pressure control in patients with essential hypertension. Yamano S, et al. **Jpn Circ J** 1999 Feb;63(2):79–84
Relationship between microalbuminuria, left ventricular mass and function in essential hypertension. Wu SG, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):536–41
Essential arterial hypertension and stone disease. Borghi L, et al. **Kidney Int** 1999 Jun;55(6):2397–406
Association between hyperlipidemia and microalbuminuria in essential hypertension. Campese VM, et al. **Kidney Int Suppl** 1999 Jul;71:S10–3 (33 ref.)
Therapeutic implications and new perspectives for essential hypertension and renal damage. González-Albarrán O, et al. **Kidney Int Suppl** 1998 Dec;68:S46–50 (43 ref.)
Microalbuminuria in essential hypertension. Rodicio JL, et al. **Kidney Int Suppl** 1998 Dec;68:S51–4 (63 ref.)
Hypertension as cause of end-stage renal disease: lessons from international registries. Valderrábano F, et al. **Kidney Int Suppl** 1998 Dec;68:S60–6 (3 ref.)
The UK Prospective Diabetes Study [letter; comment] Fowler PB. **Lancet** 1998 Dec 12;352(9144):1933; discussion 1934. Comment on: Lancet 1998 Sep 12;352(9131):837–53. Comment on: Lancet 1998 Sep 12;352(9131):854–65.
Lifetime risk of developing coronary heart disease [letter; comment] Ulrich S, et al. **Lancet** 1999 Mar 13;353(9156):925 . Comment on: Lancet 1999 Jan 9;353(9147):89–92.
Is epistaxis evidence of end-organ damage in patients with hypertension? Lubianca Neto JF, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1111–5
Streptozotocin-induced diabetes enhances protective effects of enalapril on nitric oxide-deficient stroke in stroke-prone rats. Ahmad S, et al. **Life Sci** 1998;63(26):2353–63
Hypertensive cardiomyopathy relieved by pacing? [letter; comment] DeSilvey DL. **Mil Med** 1999 May;164(5):318. Comment on: Mil Med 1998 Dec;163(12):861–3.
Hypertensive left ventricular hypertrophy with left ventricular outflow tract obstructive physiology: a case of successful treatment with dual-chamber pacing [see comments] Wicks AB, et al. **Mil Med** 1998 Dec; 163(12):861–3. Comment in: Mil Med 1999 May;164(5):318.
Management of hypertension in renal disease. Marcantoni C, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):80–3 (14 ref.)
Hypertensive nephropathy – an increasing clinical problem. Rutkowski B, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):65–8
Left ventricular hypertrophy in hypertension [editorial; comment] Dunn FG, et al. **N Engl J Med** 1999 Apr 22; 340(16):1279–80. Comment on: N Engl J Med 1999 Apr 22;340(16):1221–7.
Images in clinical medicine. Heart in the heart. Schuler J, et al. **N Engl J Med** 1999 Sep 30;341(14):1045
Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Kennedy CR, et al. **Nat Med** 1999 Feb;5(2):217–20
Neurovascular decompression of the left ventrolateral medulla as a treatment of hypertension in a patient with renal artery stenosis [see comments] Anding K, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3253–7. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1398.
The clinical diagnosis of hypertensive nephrosclerosis--how reliable is it? [editorial] Caetano EP, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):288–90 (16 ref.)
Hypertension in haemodialysis patients: who cares? [editorial; comment] Dorhout Mees EJ. **Nephrol Dial Transplant** 1999 Jan;14(1):28–30. Comment on: Nephrol Dial Transplant 1999 Jan;14(1):125–8.
Proteinuria, hypertension and chronic renal failure in X-linked Kallmann's syndrome, a defined genetic cause of solitary functioning kidney. Duke V, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1998–2003
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Ecder T, et al. **Nephrol Dial Transplant** 1999 May;14(5):1113–6
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Holdaas H, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3096–102
Clinical diagnosis of hypertensive nephrosclerosis [letter] Kincaid-Smith P. **Nephrol Dial Transplant** 1999 Sep; 14(9):2255–6
Hypertensive encephalopathy and nephrotic syndrome: a possible link? Pearson ER, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1750–2
Hypertension in patients with cerebrovascular accident. To treat or not to treat? [editorial] Ringleb PA, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2179–81 (19 ref.)
Is renal failure caused by primary hypertension? Why does the controversy continue? [editorial; comment] Rostand SG. **Nephrol Dial Transplant** 1998 Dec;13(12):3007–10 (17 ref.). Comment on: Nephrol Dial Transplant 1998 Dec;13(12):3084–90.
Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Göteborg, Sweden [see comments] Siewert-Delle A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3084–90 . Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3007–10.
Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension. Netea RT, et al. **Neth J Med** 1999 Jul;55(1):39–45
The significance of hypothermic acid-base management induced before ischemia in a rat model of transient middle cerebral artery occlusion. Nagai S, et al. **Neurol Res** 1999 Mar;21(2):204–8
Hypertensive brainstem encephalopathy: three cases presenting with severe brainstem edema. Chang GY, et al. **Neurology** 1999 Aug 11;53(3):652–4
Microvascular decompression of the left lateral medulla oblongata for severe refractory neurogenic hypertension. Rafael H. **Neurosurgery** 1999 Mar;44(3):691–2
Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: a meta-analysis of observational studies. Ananth CV, et al. **Obstet Gynecol** 1999 Apr;93(4):622–8
Management of epistaxis complicated by a previously undiagnosed aortic coarctation. Pulli RS. **Otolaryngol Head Neck Surg** 1999 Apr;120(4):584–7
Effect of different AV delays on left ventricular diastolic function and ANF levels in DDD paced hypertensive patients during daily activity and exercise. Panou FK, et al. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 1):635–42
Arterial hypertension with normal urinalysis in Henoch-Schönlein disease: a further case [letter] Truttmann AC, et al. **Pediatr Nephrol** 1998 Aug;12(6):523
What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. Kochar MS, et al. **Postgrad Med** 1999 Aug;106(2):149–52, 155–7 (17 ref.)
Blurred vision and high blood pressure in a young woman. Flanagan DE, et al. **Postgrad Med J** 1998 Oct;74(876):614–5
Hypertension and the diabetic patient. Gadsby R. **Practitioner** 1998 Aug;242(1589):587–9 (9 ref.)
Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Klungel OH, et al. **Stroke** 1999 Jul;30(7):1312–8
"Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Wilcox I, et al. **Thorax** 1998 Oct; 53 Suppl 3:S25–8 (40 ref.)
Hypertension accelerates the pace of chronic graft dysfunction in the rat. Szabo A, et al. **Transpl Int** 1998; 11 Suppl 1:S10–4
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Lowe FC, et al. **Urology** 1999 Jul;54(1):81–5
Hypertension in the elderly with coexisting benign prostatic hyperplasia. Maruenda J, et al. **Urology** 1999 Mar;53(3 Suppl 3a):7–12; discussion 12–3, 41–2 (40 ref.)
Hypertensive heart failure: a report of 3 cases. Dosumu EA. **West Afr J Med** 1999 Apr–Jun;18(2):147–50
[Relationship between genotype of angiotensin converting enzyme gene and left ventricular hypertrophy in Chinese hypertensives] Shen D, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1998 Dec 10;15(6):364–6 (Eng. Abstr.) **(Chi)**
[Left ventricular hypertrophy remodeling in hypertension] Hu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun; 36(6):424–6 (19 ref.) **(Chi)**
[Relationship between urinary albumin excretion and blood vessel lesion in non-insulin-dependent diabetics] Long Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):259–61 (Eng. Abstr.) **(Chi)**
[Left ventricular hypertrophy and cardiovascular risk in hypertension] Amabile G. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):86–90 (52 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of the tolerance and effectiveness of Diltiazem LP 300 mg in hypertensive patients with chronic renal insufficiency] Bernadet-Monrozies P, et al. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):589–94 (Eng. Abstr.) **(Fre)**
[Hypertension and Takayasu disease. Report of 8 cases] Fadouach S, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):155–9 (Eng. Abstr.) **(Fre)**
[The absolute cardiovascular risk: a valid but incomplete concept] Silhol F, et al. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):91–3 **(Fre)**
[The contribution of genetics in the evaluation of cardiovascular risk] Amouyel P. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:13–8 (16 ref.) (Eng. Abstr.) **(Fre)**
[Heart and brain: are the risk factors the same? Are the results of primary and secondary trials comparable?] Castaigne A, et al. **Arch Mal Coeur Vaiss** 1998 Oct;91 Spec No 5:59–63 (Eng. Abstr.) **(Fre)**
[Evaluation of the cardiovascular risk in hypertensive patients: left ventricular hypertrophy] Gosse P, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:19–22 (18 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of heart failure] Logeart D, et al. **Arch Mal Coeur Vaiss** 1998 Nov;91(11):1333–41 (Eng. Abstr.) **(Fre)**
[Can we reduce the cardiovascular risk in hypertensive patients? (editorial)] Plouin PF. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:7–8; discussion 29–30 **(Fre)**
[Cardiovascular risk and the measurement of arterial pressure] Vaisse B, et al. **Arch Mal Coeur Vaiss** 1998 Sep; 91 Suppl:9–12 (22 ref.) (Eng. Abstr.) **(Fre)**
[Contribution of arterial hypertension to vascular risk in diabetic patients] Marre M, et al. **Diabetes Metab** 1999 Jun; 25 Suppl 3:27–31 (26 ref.) (Eng. Abstr.) **(Fre)**
[Isolated occlusion of a cilioretinal artery] Velasque L, et al. **J Fr Ophtalmol** 1999 Apr;22(3):388–93 (Eng. Abstr.) **(Fre)**
[Microalbuminuria and arterial hypertension] Hornych A, et al. **Presse Med** 1999 Mar 20;28(11):597–604 (65 ref.) (Eng. Abstr.) **(Fre)**
[Double-blind placebo-controlled European trial for systolic hypertension--and prevention of dementia] Tzourio C. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):191–2 **(Fre)**
[Aging and regression of cardiac hypertrophy in the hypertensive patient] Du Cailar G, et al. **Rev Med Interne** 1998 Dec;19(12):870–7 (Eng. Abstr.) **(Fre)**
[Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"] Scheen AJ. **Rev Med Liege** 1999 Mar;54(3):197–9 (Eng. Abstr.) **(Fre)**
[Blood pressure and Alzheimer's disease] Pasquier F, et al. **Rev Neurol (Paris)** 1998 Nov;154(11):743–51 (114 ref.) (Eng. Abstr.) **(Fre)**
[Impact of arterial hypertension on the heart] Herpin D. **Rev Prat** 1999 Mar 1;49(5):491–4 (Eng. Abstr.) **(Fre)**
[Impact of essential hypertension on the arteries] Laurent S, et al. **Rev Prat** 1999 Mar 1;49(5):495–502 (Eng. Abstr.) **(Fre)**
[Cardiovascular risk evaluation in three exposed populations] Mazigh C, et al. **Tunis Med** 1999 Jan;77(1):19–22 **(Fre)**
[Blood pressure regulation in stroke. Current aspects. 105th Congress of the German Society for Internal Medicine, Wiesbaden, 12 April 1999] **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6 Suppl):1–4 **(Ger)**
[A 51-year-old patient with arterial hypertension, respiratory insufficiency and polycythemia--an unusual cause of nocturnal sleep-associated breathing disorder] Krabbe C, et al. **Dtsch Med Wochenschr** 1999 Jun 11;124(23):721–6 (Eng. Abstr.) **(Ger)**

[Microangiopathy in hypertensive heart disease. Angina pectoris with negative coronary angiogram] Gleichmann U, et al. **Fortschr Med** 1999 Apr 20;117(11):37–8 **(Ger)**

[Perioperative management of patients with arterial hypertension] Filipovic M, et al. **Ther Umsch** 1999 Jan; 56(1):37–42 (25 ref.) (Eng. Abstr.) **(Ger)**

[Hypertension–induced organ damage] Lohmann FW. **Versicherungsmedizin** 1998 Oct 1;50(5):169–72 (Eng. Abstr.) **(Ger)**

[Major nutrition–related risk factors of ischemic heart disease: dyslipoproteinemia, obesity, hypertension, glucose intolerance] Pados G. **Orv Hetil** 1999 Jul 11; 140(28):1563–72 (50 ref.) (Eng. Abstr.) **(Hun)**

[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension] Mancia G, et al. **Ann Ital Med Int** 1997 Oct–Dec;12(4):217–22 (42 ref.) (Eng. Abstr.) **(Ita)**

[Role of hypertension in determining valvular diseases in patients with chronic uremia and dialytic treatment] Facchin L, et al. **Cardiologia** 1998 Dec;43(12):1361–6 (Eng. Abstr.) **(Ita)**

[Microalbuminuria, arterial hypertension and the cardiovascular risk] Pedrinelli R, et al. **Cardiologia** 1998 Oct;43(10):1037–43 (111 ref.) **(Ita)**

[Dipyridamole–echocardiography and thallium exercise myocardial scintigraphy in the diagnosis of obstructive coronary or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina] Astarita C, et al. **G Ital Cardiol** 1998 Sep;28(9):996–1004 (Eng. Abstr.) **(Ita)**

[Presence and severity of carotid atherosclerosis in asymptomatic hypertension patients with left ventricular hypertrophy] Guarini P, et al. **G Ital Cardiol** 1999 Aug; 29(8):910–4 (Eng. Abstr.) **(Ita)**

[Tophaceous gout in plurimetabolic syndrome] Iannello S, et al. **Minerva Med** 1998 Nov–Dec;89(11–12):419–37 (168 ref.) (Eng. Abstr.) **(Ita)**

[The concept of "preclinical arterial hypertension" – in light of non–invasive, ambulatory blood pressure monitoring] Cugini P, et al. **Recenti Prog Med** 1998 Nov;89(11):559–68 (Eng. Abstr.) **(Ita)**

[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report] Soeki T, et al. **J Cardiol** 1999 Jun;33(6):339–45 (Eng. Abstr.) **(Jpn)**

[Treatment of hypertension with complications] Abe I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):277–84 (5 ref.) **(Jpn)**

[hypertensive encephalopathy] Akutsu T, et al. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):845–50 (7 ref.) **(Jpn)**

[Etiology and therapy of kidney disease due to hypertension] Ito S. **Nippon Naika Gakkai Zasshi** 1998 Jul 10;87(7):1292–7 (4 ref.) **(Jpn)**

[Usefulness of aspiration surgery for elderly patients with hypertensive cerebellar hemorrhage] Takanashi Y, et al. **No To Shinkei** 1998 Aug;50(8):751–4 (Eng. Abstr.) **(Jpn)**

[A case of hypertensive intracerebral hemorrhage associated with ipsilateral internal carotid artery occlusion] Ueno M, et al. **No To Shinkei** 1999 May;51(5):444–6 (Eng. Abstr.) **(Jpn)**

[Hypertension and atherosclerosis] Jędrusik P, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):507–12 (54 ref.) **(Pol)**

[Pregnancy and delivery in a pregnant woman with polycystic kidneys complicated by hypertension] Cyrkowicz A. **Pol Merkuriusz Lek** 1998 Sep;5(27):149–50 (Eng. Abstr.) **(Pol)**

[Mean values of blood pressure and endothelin plasma concentration in patients with chronic renal failure] Kocur E, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):114–6 (Eng. Abstr.) **(Pol)**

[Circulatory system in obese patients] Przywara B, et al. **Wiad Lek** 1998;51(5–6):277–83 (21 ref.) (Eng. Abstr.) **(Pol)**

[Systemic arterial hypertension and psychiatric morbidity in the outpatient care setting of a tertiary hospital] Benseñor IM, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):406–11 (Eng. Abstr.) **(Por)**

[Ischemic cardiopathy in the hypertensive] da Silva JD. **Rev Port Cardiol** 1999 Apr;18(4):393–9 (54 ref.) (Eng. Abstr.) **(Por)**

[Hypertensive cardiopathy. From arterial hypertension to congestive heart failure] Nogueira JB. **Rev Port Cardiol** 1999 Jun;18(6):635–46 (41 ref.) (Eng. Abstr.) **(Por)**

[Myocardial hypertrophy and coronary insufficiency as a cause of arrhythmia in patients with hypertension] Israpilov MM, et al. **Ter Arkh** 1999;71(4):37–40 (Eng. Abstr.) **(Rus)**

[Association of the metabolic syndrome components in patients with arterial hypertension and their relationship with dyslipidemia] Oganov RG, et al. **Ter Arkh** 1998; 70(12):19–23 (Eng. Abstr.) **(Rus)**

[Hypertensive crises] Zadionchenko VS, et al. **Ter Arkh** 1998; 70(8):72–4 **(Rus)**

[Significance of left ventricular hypertrophy in hypertension] Ghanem WM, et al. **Vnitr Lek** 1998 Sep;44(9):513–7 (Eng. Abstr.) **(Slo)**

[The effects of arterial hypertension during pregnancy on birth weight, intrauterine growth retardation and neonatal evolution. A matched case–control study] Fernández Jonusas S, et al. **An Esp Pediatr** 1999 Jan;50(1):52–6 (Eng. Abstr.) **(Spa)**

[Arterial pressure and IDDM: what does ambulatory arterial pressure measurement provide? (editorial)] Lurbe E, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):294–6 (41 ref.) **(Spa)**

[Tobaccoism and albuminuria in hypertension and diabetes: is tobacco also harmful for the kidney? (editorial)] Martínez Ocaña JC, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):176–8 (61 ref.) **(Spa)**

[Hypertensive crisis and vesical mass (letter)] García Robles R. **Rev Clin Esp** 1998 Dec;198(12):852 **(Spa)**

[Postmenopausal arterial hypertension and cardiovascular risk] Artigao R. **Rev Esp Cardiol** 1998;51 Suppl 4:36–43 (37 ref.) (Eng. Abstr.) **(Spa)**

[Obesity and arterial hypertension] Casasnovas Lenguas JA, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:15–8 (9 ref.) (Eng. Abstr.) **(Spa)**

[Hypertension and dyslipidemia] de Lombera Romero F, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:24–35 (118 ref.) (Eng. Abstr.) **(Spa)**

[Accumulated probability of hypertension in diabetes and of diabetes in hypertension] Guerrero–Romero JF, et al. **Rev Invest Clin** 1998 Jul–Aug;50(4):281–5 (Eng. Abstr.) **(Spa)**

[Cerebral hemorrhage and angiopathy amyloid] Cartier L, et al. **Rev Med Chil** 1999 Mar;127(3):295–303 (Eng. Abstr.) **(Spa)**

[Reactive hyperemia in hypertension] Doloman LB. **Fiziol Zh** 1999;45(1–2):80–6 (Eng. Abstr.) **(Ukr)**

CONGENITAL

Unusual vascular dysplasia presenting as an intra–abdominal catastrophe. Menon P, et al. **Pediatr Surg Int** 1999 Jul; 15(5–6):440–1

DIAGNOSIS

Prognostic significance of exercise–induced systemic hypertension in healthy subjects. Allison TG, et al. **Am J Cardiol** 1999 Feb 1;83(3):371–5

Why ambulatory blood pressure monitoring? Punzi HA. **Am J Health Syst Pharm** 1998 Nov 15;55 Suppl 3:S12–6 (27 ref.)

White coat hypertension detected during screening of male adolescent athletes. Kouidi E, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):223–6

Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Pérez Fontán M, et al. **Am J Kidney Dis** 1999 Jan;33(1):21–8

The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Joffe GM, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):1032–7

Linking community–based blood pressure measurement to clinical care: a randomized controlled trial of outreach and tracking by community health workers. Krieger J, et al. **Am J Public Health** 1999 Jun;89(6):856–61

The long–term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10–year follow–up [see comments] Alli C, et al. **Arch Intern Med** 1999 Jun 14; 159(11):1205–12. Comment in: Arch Intern Med 1999 Jun 14;159(11):1165–6.

Which blood pressure measurement is more important in the elderly? [editorial; comment] Elliott WJ. **Arch Intern Med** 1999 Jun 14;159(11):1165–6. Comment on: Arch Intern Med 1999 Jun 14;159(11):1205–12.

Quiet resting is not necessary prior to routine antenatal blood pressure measurement. Duggan PM. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):19–20

Comparison of clinic, home self–measured, and work self–measured blood pressures. García–Vera MP, et al. **Behav Med** 1999 Spring;25(1):13–22

Hypertension and pain sensitivity: effects of gender and cardiovascular reactivity. Nykliček I, et al. **Biol Psychol** 1999 Jun;50(2):127–42

Measurements of blood pressure with various techniques in daily practice: uncertainty in diagnosing office hypertension with short–term in–hospital registration of blood pressure. Braun HJ, et al. **Blood Press Monit** 1999 Apr;4(2):59–64

Home blood pressure measurement: reproducibility and relationship with left ventricular mass. Kok RH, et al. **Blood Press Monit** 1999 Apr;4(2):65–9

A novel method of guideline development for the diagnosis and management of mild to moderate hypertension. Adams JL, et al. **Br J Gen Pract** 1999 Mar;49(440):175–9 (22 ref.)

Pressure for change: unresolved issues in blood pressure measurement. Aylett M. **Br J Gen Pract** 1999 Feb; 49(439):136–9

Echocardiography for primary care evaluation of hypertension. Nahas R, et al. **Can Fam Physician** 1998 Dec; 44:2702–6

Intermittent blood pressure control: potential consequences for outcome. Leenen FH. **Can J Cardiol** 1999 May;15 Suppl C:13C–18C

Pseudocoarctation of the aorta: complementary findings on plain film radiography, CT, DSA, and MRA. Taneja K, et al. **Cardiovasc Intervent Radiol** 1998 Sep–Oct; 21(5):439–41

Relationship between Joint National Committee–VI classification of hypertension and ambulatory blood pressure in patients with hypertension diagnosed by casual blood pressure. Inden Y, et al. **Clin Cardiol** 1998 Nov; 21(11):801–6

The diagnostic relevance of red cell rigidity. Banerjee R, et al. **Clin Hemorheol Microcirc** 1998 Sep;19(1):21–4

Broad–band spectral analysis of 24 h continuous finger blood pressure: comparison with intra–arterial recordings [see comments] Castiglioni P, et al. **Clin Sci (Colch)** 1999 Aug; 97(2):129–39. Comment in: Clin Sci (Colch) 1999 Aug;97(2):253–4.

Erythrocyte Na+/Li+ countertransport and Na+/K+–2Cl– co–transport measurement in essential hypertension: useful diagnostic tools or failure? A meta–analysis of 17 years of literature. Tepper T, et al. **Clin Sci (Colch)** 1998 Dec;95(6):649–57

Age–related changes in blood pressure twenty–four–hour pattern in normotensive subjects of two populations. Cugini P, et al. **Clin Ter** 1999 Jan–Feb;150(1):21–7

Accurate blood pressure measurement: why does it matter? [editorial] Campbell NR, et al. **CMAJ** 1999 Aug 10; 161(3):277–8

Persistent hypertension after removal of adrenal tumours. Sapienza P, et al. **Eur J Surg** 1999 Mar;165(3):187–92

Better by half: hypertension in the elderly and the 'rule of halves': a primary care audit of the clinical computer record as a springboard to improving care. Hooker RC, et al. **Fam Pract** 1999 Apr;16(2):123–8

Cardiovascular reactivity and central adiposity in older African Americans. Waldstein SR, et al. **Health Psychol** 1999 May;18(3):221–8

Detection, adherence and control of hypertension for the prevention of strokes: a systematic review. Ebrahim S. **Health Technol Assess** 1998;2(11):i–iv, 1–78 (260 ref.)

Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension. Tomita S, et al. **Hypertens Res** 1998 Dec;21(4):259–66

The paradigm has shifted, to systolic blood pressure [editorial; comment] Black HR. **Hypertension** 1999 Sep; 34(3):386–7. Comment on: Hypertension 1999 Sep;34(3):381–5.

Isolated systolic hypertension : prognostic information provided by pulse pressure. Domanski MJ, et al. **Hypertension** 1999 Sep;34(3):375–80

Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. Jula A, et al. **Hypertension** 1999 Aug;34(2):261–6

Differential impact of systolic and diastolic blood pressure level on JNC–VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [see comments] Lloyd–Jones DM, et al. **Hypertension** 1999 Sep;34(3):381–5. Comment in: Hypertension 1999 Sep;34(3):386–7.

Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Owens P, et al. **Hypertension** 1999 Aug;34(2):267–72

Correlation dimension estimation: can this nonlinear description contribute to the characterization of blood pressure control in rats? Almog Y, et al. **IEEE Trans Biomed Eng** 1999 May;46(5):535–47

Current issue in hypertension––ambulatory blood pressure monitoring [letter] Thakur S. **Indian J Med Sci** 1998 Aug; 52(8):366–7

Ambulatory blood pressure monitoring in pediatrics. Nangia S. **Indian Pediatr** 1998 Jun;35(6):577–9

Inferior vena cava diameter and the risk of pregnancy–induced hypertension and fetal compromise. Ryo E, et al. **Int J Gynaecol Obstet** 1999 May;65(2):143–8

Measuring blood pressure and treating hypertension in (frail) older people [editorial; comment] Cushman WC. **J Am Geriatr Soc** 1999 Mar;47(3):373–4 (19 ref.). Comment on: J Am Geriatr Soc 1999 Mar;47(3):285–90.

How many self–measured blood pressure readings are needed to estimate hypertensive patients' "true" blood pressure? García–Vera MP, et al. **J Behav Med** 1999 Feb;22(1):93–113

Clinical criteria for the use of a decision–making framework for the medically compromised patient: hypertension and diabetes mellitus. Lapointe HJ, et al. **J Can Dent Assoc** 1998 Nov;64(10):704–9

Microalbuminuria as a predictive factor for cardiovascular events. Luft FC, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S11–5; discussion S41–3

Association between health–related knowledge and the awareness of blood pressure readings. Japan Lifestyle Monitoring Study Group. Tanihara S, et al. **J Epidemiol** 1999 Aug;9(4):245–53

A systematic review of the use of computers in the management of hypertension. Montgomery AA, et al. **J Epidemiol Community Health** 1998 Aug;52(8):520–5

Antihypertensive drug treatment: a comparison of usual care with self blood pressure measurement. Bailey B, et al. **J Hum Hypertens** 1999 Feb;13(2):147–50

The role of the hypertension specialist [see comments] Beevers DG. **J Hum Hypertens** 1998 Oct;12(10):659–61 (16 ref.). Comment in: J Hum Hypertens 1999 Feb;13(2):151–2.

Reproducibility of salt sensitivity testing using a dietary approach in essential hypertension. Gerdts E, et al. **J Hum Hypertens** 1999 Jun;13(6):375–84

Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits. Kocemba J, et al. **J Hum Hypertens** 1998 Sep;12(9):621–6 (51 ref.)

Tracking and factors predicting rising in 'tracking quartile'

in blood pressure from childhood to adulthood: Odense Schoolchild Study. Lambrechtsen J, et al. **J Hum Hypertens** 1999 Jun;13(6):385–91

Twenty-four hour ambulatory blood pressure monitoring in young and elderly hypertensive subjects. Musialik D, et al. **J Hum Hypertens** 1998 Sep;12(9):641–2

Arm position is important for blood pressure measurement [see comments] Netea RT, et al. **J Hum Hypertens** 1999 Feb;13(2):105–9. Comment in: J Hum Hypertens 1999 Feb;13(2):85–6.

Hypertension is associated with a high risk of cancer. Xie L, et al. **J Hum Hypertens** 1999 May;13(5):295–301

Ambulatory blood pressure monitoring and the taxonomy of hypertension [editorial; comment] Floras JS. **J Hypertens** 1998 Dec;16(12 Pt 1):1719–20. Comment on: J Hypertens 1998 Dec;16(12 Pt 1):1735–43.

Clinic–daytime blood pressure difference and cardiovascular damage. Guida L, et al. **J Hypertens** 1999 Mar;17(3):331–7

Increased plasma dopamine in patients presenting with the pseudopheochromocytoma quandary: retrospective analysis of 10 years' experience. Kuchel O. **J Hypertens** 1998 Oct;16(10):1531–7

Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population–based observation in Ohasama, Japan. Ohkubo T, et al. **J Hypertens** 1998 Jul;16(7):971–5

White–coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study [see comments] Palatini P, et al. **J Hypertens** 1998 Jul;16(7):977–84. Comment in: J Hypertens 1999 Jan;17(1):148–9.

Sphygmomanometry induces different blood pressure changes in normotensive and untreated (borderline) hypertensive subjects [letter] Rollnik JD, et al. **J Hypertens** 1999 Feb;17(2):303–4

Hypertension corner. Clinical significance of various blood pressure components [editorial] Birbari AE. **J Med Liban** 1998 Sep–Oct;46(5):243

Hypertension corner. Wide pulse pressure: diagnostic, prognostic and therapeutic implications [editorial] Birbari AE. **J Med Liban** 1998 Nov–Dec;46(6):303–5 (22 ref.)

Differences in behavior profile between normotensive subjects and patients with white–coat and sustained hypertension. Coelho R, et al. **J Psychosom Res** 1999 Jan; 46(1):15–27

Sino–aortic denervation augments the increase in blood pressure seen during paradoxical sleep in the rat. Sei H, et al. **J Sleep Res** 1999 Mar;8(1):45–50

Osler maneuver to detect pseudohypertension [letter] Cheng TO. **JAMA** 1999 Sep 8;282(10):943

What is hypertension? [letter] Murray S, et al. **Lancet** 1999 Aug 14;354(9178):593–4

What is "hypertension"? O'Brien E, et al. **Lancet** 1999 May 8;353(9164):1541–3

What is hypertension? [letter] Pickering TG. **Lancet** 1999 Aug 14;354(9178):593; discussion 594

Ambulatory blood pressure monitoring and diagnostic errors in hypertension: a Bayesian approach. Mar J, et al. **Med Decis Making** 1998 Oct–Dec;18(4):429–35

Does the blood pressure need lowering? Johnson AG. **Med J Aust** 1999 Jun 21;170(12):609–15 (42 ref.)

Acute angulation of the left renal artery imitating renal artery stenosis in a patient with neurofibromatosis type 1. Vrentzos G, et al. **Nephrol Dial Transplant** 1999 Jul; 14(7):1767–70

Hypertension in the transplanted patient. Zeier M, et al. **Nephron** 1998 Nov;80(3):257–68 (86 ref.)

A two–stage screening test for pregnancy–induced hypertension and preeclampsia. Benedetto C, et al. **Obstet Gynecol** 1998 Dec;92(6):1005–11

Failure of platelet angiotensin II binding to predict pregnancy–induced hypertension. O'Brien PM, et al. **Obstet Gynecol** 1999 Feb;93(2):203–6

Ambulatory blood pressure monitoring in pregnancy. Walker SP, et al. **Obstet Gynecol Surv** 1998 Oct;53(10):636–44 (56 ref.)

Controlling isolated systolic hypertension. No time to be complacent. Pentz WH. **Postgrad Med** 1999 May 1; 105(5):95–6, 99–100, 105–6 passim (25 ref.)

Turning up the heat on hypertension. It's time to be more aggressive in finding and treating this silent killer. Sorrentino MJ. **Postgrad Med** 1999 May 1;105(5):82–4, 89–93 (19 ref.)

Ambulatory blood pressure monitoring and echocardiography––noninvasive techniques for evaluation of the hypertensive patient. Phillips RA, et al. **Prog Cardiovasc Dis** 1999 May–Jun;41(6):397–440 (401 ref.)

Effect of family responsibilities and job strain on ambulatory blood pressure among white–collar women. Brisson C, et al. **Psychosom Med** 1999 Mar–Apr;61(2):205–13

Blood pressure reactivity and marital distress in employed women. Carels RA, et al. **Psychosom Med** 1998 Sep–Oct; 60(5):639–43

White coat hypertension in a general practice. Prevalence, cardiovascular risk factors and clinical implications. Sandvik E, et al. **Scand J Prim Health Care** 1998 Dec; 16(4):222–6

The orthogonal and 12 lead ECG in adult negroes with systemic hypertension: comparison with age–matched control. Araoye MA, et al. **West Afr J Med** 1998 Jul–Sep; 17(3):157–64

[Incidental high blood pressure in family practice: due to hypertension and/or left ventricular hypertrophy in more than half of the patients] Boekhout I, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2404–8 (Eng. Abstr.) **(Dut)**

[Ambulatory blood pressure measurement] van der Steen MS, et al. **Ned Tijdschr Geneeskd** 1998 Jul 25;142(30):1704–9 (36 ref.) (Eng. Abstr.) **(Dut)**

[Cardiovascular risk and ambulatory blood pressure measurement of arterial pressure] Asmar R. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):75–80 (Eng. Abstr.) **(Fre)**

[Approach of Moroccan cardiologists to arterial hypertension] Bennis A, et al. **Ann Cardiol Angeiol (Paris)** 1998 Oct;47(8):555–62 (Eng. Abstr.) **(Fre)**

[Current aspects of arterial hypertension. Prognostic value of self–monitoring blood pressure measurements in aged hypertensive patients: a SHEAF study protocol] Genès N, et al. **Presse Med** 1999 Apr 24;28(16):870–4 (24 ref.) (Eng. Abstr.) **(Fre)**

[Apropos of the JNC VI (Joint National Committee) (interview) (comment)] Girerd X. **Presse Med** 1999 Apr 24;28(16):858–60. Comment on: Presse Med 1999 Apr 24;28(16):853–8. **(Fre)**

[Current development on hypertension] Jan F. **Presse Med** 1999 Apr 24;28(16):861 **(Fre)**

[Hypertensive syndrpomes in pregnancy] Jan F. **Presse Med** 1999 Apr 24;28(16):879 **(Fre)**

[Hypertensive syndromes in pregnancy. Physiopathology, definition and fetomaternal complications] Mounier–Vehier C, et al. **Presse Med** 1999 Apr 24;28(16):880–5 (Eng. Abstr.) **(Fre)**

[Hypertensive syndromes in pregnancy. Diagnosis and therapy] Mounier–Vehier C, et al. **Presse Med** 1999 Apr 24;28(16):886–91 (42 ref.) (Eng. Abstr.) **(Fre)**

[Sixth report of the Joint National Committee on the prevention, detection, evaluation and treatment of arterial hypertension (see comments)] Vallée JP. **Presse Med** 1999 Apr 24;28(16):853–8. Comment in: Presse Med 1999 Apr 24;28(16):858–60. **(Fre)**

[The measurement of arterial pressure and the diagnosis of hypertension] Mallion JM. **Rev Prat** 1999 Mar 1;49(5):483–8 (Eng. Abstr.) **(Fre)**

[The significance of 24–hour blood pressure monitoring in patients with diabetes mellitus] Schernthaner G, et al. **Dtsch Med Wochenschr** 1999 Apr 1;124(13):393–5 (19 ref.) **(Ger)**

[Will blood pressure measuring by the Riva–Rocci and Korotkoff method soon by substituted? Missing oscillometric appliances––technical data kept secret] Anlauf M. **Fortschr Med** 1999 Apr 10;117(10):21, 31 **(Ger)**

[Blood pressure self–monitoring supplements diagnosis and therapy. advantages over occasional monitoring] Eckert S. **Fortschr Med** 1999 Feb 20;117(5):39–40 **(Ger)**

[Errors in blood pressure measuring with modern automated machines. Effects of errors in non–invasive oscillometric blood pressure measuring] Forstner K. **Fortschr Med** 1999 Apr 10;117(10):22–5 (Eng. Abstr.) **(Ger)**

[Blood pressure behavior in standardized ergometry] Franz IW. **Fortschr Med** 1999 Feb 20;117(5):40–1 **(Ger)**

[Hypertension measurement––a critical review] Krönig B. **Fortschr Med** 1999 Jan 20;117(1–2):33–4 **(Ger)**

[Outstanding hypertension research] Rettig R. **Fortschr Med** 1999 Mar 20;117(8):45 **(Ger)**

[Practical conducting of blood pressure measuring. Important contributing factors and possibilities of errors] Tholl U. **Fortschr Med** 1999 Apr 10;117(10):26–8, 30–1 (Eng. Abstr.) **(Ger)**

[Arterial hypertension and heart diseases. Diagnostic–therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension] Agabiti–Rosei E, et al. **Cardiologia** 1999 Mar;44(3):299–312 (312 ref.) **(Ita)**

[Arterial hypertension and cardiac pathology. Diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO–SIC–SIIA. Assoziane Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell'Ipertensione Arteriosa] Agabiti–Rosei E, et al. **G Ital Cardiol** 1999 Mar;29(3):341–56 **(Ita)**

[Calcium antagonist vs diuretics. Doppler velocimetric monitoring of the carotid flow in patients with essential hypertension] Bellisi M, et al. **Minerva Cardioangiol** 1998 Jan–Feb;46(1–2):9–14 (Eng. Abstr.) **(Ita)**

[The concept of "preclinical arterial hypertension" – in light of non–invasive, ambulatory blood pressure monitoring] Cugini P, et al. **Recenti Prog Med** 1998 Nov;89(11):559–68 (Eng. Abstr.) **(Ita)**

[Methods for diagnosis of hypertension] Hiwada K. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):230–5 (7 ref.) **(Jpn)**

[Isolated office hypertension] Kuwajima I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):241–6 (14 ref.) **(Jpn)**

[White coat hypertension] Soma J, et al. **Tidsskr Nor Laegeforen** 1999 Feb 20;119(5):667–70 (55 ref.) (Eng. Abstr.) **(Nor)**

[The burden of blood pressure in the first half of pregnancy] Baszak E, et al. **Ginekol Pol** 1998 Dec;69(12):1213–7 (Eng. Abstr.) **(Pol)**

[The evaluation of concentration myeloperoxidase and interleukin–8 in blood serum of pregnant women with or without pregnancy induced hypertension] Heimrath J, et al. **Ginekol Pol** 1998 Sep;69(9):705–7 (Eng. Abstr.) **(Pol)**

[Macroscopic assessment of the placenta using a morphometric grid. Part II: other selected pathologies] Podciechowski L, et al. **Ginekol Pol** 1998 Dec;69(12):982–8 (Eng. Abstr.) **(Pol)**

[Clinical assessment of utility of computerized system for cardiotocographic analysis in patients with pregnancy–induced hypertension] Zych I, et al. **Ginekol Pol** 1998 Dec;69(12):1035–40 (Eng. Abstr.) **(Pol)**

[Mean values of blood pressure and endothelin plasma concentration in patients with chronic renal failure] Kocur E, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):114–6 (Eng. Abstr.) **(Pol)**

[Time of occurrence of paroxysmal atrial fibrillation in Holter monitoring in patients with coronary heart disease and in patients with hypertension] Negrusz–Kawecka M, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):309–11 (Eng. Abstr.) **(Pol)**

[Norms of arterial blood pressure for 24 hours based on biological activity] Skrobowski A, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):192–3 (Eng. Abstr.) **(Pol)**

[Examination of skin microcirculation with laser–Doppler flowmetry in patients with essential hypertension] Zygocki K, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):73–5 (Eng. Abstr.) **(Pol)**

[Clinical value of ambulatory monitoring of blood pressure] Peixoto AJ, et al. **Rev Assoc Med Bras** 1998 Oct–Dec; 44(4):325–30 (51 ref.) **(Por)**

[Arterial hypertension as a problem of medical certification of the flying personnel in civil aviation] Razsolov MA, et al. **Aviakosm Ekolog Med** 1999;33(2):50–5 (Eng. Abstr.) **(Rus)**

[Clinical course of surgery–related diseases with hormonally active tumors] Mal'tsev V, et al. **Klin Khir** 1999;(2):55 **(Rus)**

[Surgical treatment of symptomatic arterial hypertension] Nikonenko AS, et al. **Klin Khir** 1998;(7):12–4 (Eng. Abstr.) **(Rus)**

[Aspects of hypertensive heart in arterial hypertension and insulin–resistant syndrome] Didenko VA, et al. **Klin Med (Mosk)** 1999;77(6):28–33 (Eng. Abstr.) **(Rus)**

[Non–invasive instrumental diagnosis of central, peripheral and cerebral circulation in essential hypertension (editorial)] Gogin EE, et al. **Ter Arkh** 1999;71(4):5–10 (17 ref.) **(Rus)**

[Late ventricular potentials in left ventricular hypertrophy in patients with stage–II hypertension] Israpilov MM, et al. **Ter Arkh** 1999;71(2):64–6 (Eng. Abstr.) **(Rus)**

[Isolated systolic arterial hypertension in the elderly] Ivanović–Krstić B, et al. **Srp Arh Celok Lek** 1998 Mar–Apr; 126(3–4):125–9 (39 ref.) (Eng. Abstr.) **(Scc)**

[Analysis of arterial pressure variability among individuals with white coat hypertension and essential arterial hypertension using blood pressure ambulatory monitoring] Márquez Contreras E, et al. **Aten Primaria** 1998 Oct 15; 22(6):347–52 (Eng. Abstr.) **(Spa)**

[The introduction of quality control: the auditing of an arterial hypertension protocol (letter)] Sánchez Castro P, et al. **Aten Primaria** 1999 May 31;23(9):557–8 **(Spa)**

[The Gordon syndrome: the first reported case in Spain (letter)] García Morillo S, et al. **Med Clin (Barc)** 1999 Jul 10;113(5):198–9 (8 ref.) **(Spa)**

[An intrathoracic hypertension syndrome or spontaneous pneumomediastinum? (letter)] López Jiménez L. **Med Clin (Barc)** 1999 Jul 3;113(4):159 **(Spa)**

[Arterial pressure and IDDM: what does ambulatory arterial pressure measurement provide? (editorial)] Lurbe E, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):294–6 (41 ref.) **(Spa)**

[Unification of diagnosis criteria in epidemiologic studies on arterial hypertension (letter; comment)] Puras Tellaeche A. **Med Clin (Barc)** 1998 Nov 14;111(16):638–9. Comment on: Med Clin (Barc) 1998 Mar 14;110(9):328–33. **(Spa)**

[Circadian rhythms variability of arterial pressure: methodological aspects for the measurement] Redón J, et al. **Med Clin (Barc)** 1999 Mar 6;112(8):285–9 (Eng. Abstr.) **(Spa)**

[The contribution of molecular biology to genetic arterial hypertension (editorial)] Repetto HA. **Medicina (B Aires)** 1999;59(1):109–10 **(Spa)**

[Ambulatory blood pressure monitoring in the aged. The EPICARDIAN study. The EPICARDIAN Work Group] Suárez C, et al. **Rev Esp Cardiol** 1998 Dec;51(12):965–71 (Eng. Abstr.) **(Spa)**

[Idiopathic intracranial hypertension in childhood] Sierra–Rodriguez J, et al. **Rev Neurol** 1998 Sep; 27(157):434–7 (Eng. Abstr.) **(Spa)**

DIET THERAPY

The effects of high dietary calcium on salt–induced hypertension in rats. Adegunloye BJ, et al. **Afr J Med Med Sci** 1996 Sep;25(3):285–91

The "calcium antihypertension theory" [comment] [see comments] Cappuccio FP. **Am J Hypertens** 1999 Jan;12(1 Pt 1):93–5 (8 ref.). Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):84–92. Comment in: Am J Hypertens 1999 Jan;12(1 Pt 1):82–3.

The influence of dietary and nondietary calcium supplementation on blood pressure: an updated

metaanalysis of randomized controlled trials [see comments] Griffith LE, et al. **Am J Hypertens** 1999 Jan; 12(1 Pt 1):84–92. Comment in: Am J Hypertens 1999 Jan;12(1 Pt 1):82–3. Comment in: Am J Hypertens 1999 Jan;12(1 Pt 1):93–5.

Potassium intake and blood pressure [editorial] He FJ, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):849–51

Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Hunt SC, et al. **Am J Hypertens** 1999 May;12(5):460–6

Therapeutic implications of calcium intake in hypertension: more analyses, a little progress, and a different approach [comment] Resnick LM. **Am J Hypertens** 1999 Jan;12(1 Pt 1):82–3 (4 ref.). Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):84–92. Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):93–5. Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):96–8. Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):99–112.

The role of dietary calcium in hypertension: a hierarchical overview [see comments] Resnick LM. **Am J Hypertens** 1999 Jan;12(1 Pt 1):99–112 (93 ref.). Comment in: Am J Hypertens 1999 Jan;12(1 Pt 1):82–3.

A low-calorie unrestricted protein diet attenuates kidney damage in uninephrectomized spontaneously hypertensive rats. Reisin E, et al. **Am J Nephrol** 1999;19(3):433–40

To salt, or not to salt? [editorial] Kotchen TA. **Am J Physiol** 1999 May;276(5 Pt 2):H1807–10

Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Svetkey LP, et al. **Arch Intern Med** 1999 Feb 8;159(3):285–93

An exercise training combined with dietary program for patients with hypertension. Hoque MS, et al. **Bangladesh Med Res Counc Bull** 1998 Apr;24(1):14–9

Nonpharmacologic therapies that reduce blood pressure: a fresh perspective. Appel LJ. **Clin Cardiol** 1999 Jul;22(7 Suppl):III1–5 (41 ref.)

Dietary Approaches to Stop Hypertension (DASH) in clinical practice: a primary care experience. Kolasa KM. **Clin Cardiol** 1999 Jul;22(7 Suppl):III16–22 (15 ref.)

A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Sacks FM, et al. **Clin Cardiol** 1999 Jul;22(7 Suppl):III6–10

The nutritional aspects of hypertension. Simopoulos AP. **Compr Ther** 1999 Feb;25(2):95–100 (22 ref.)

Reduction in blood pressure with a sodium-reduced, potassium- and magnesium-enriched mineral salt in subjects with mild essential hypertension. Kawasaki T, et al. **Hypertens Res** 1998 Dec;21(4):235–43

Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Bao DQ, et al. **Hypertension** 1998 Oct;32(4):710–7

Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. He FJ, et al. **Hypertension** 1998 Nov;32(5):820–4

Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Moore TJ, et al. **Hypertension** 1999 Sep;34(3):472–7

Recruitment and baseline characteristics of participants in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. Appel LJ, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S69–75

Dietary Approaches to Stop Hypertension: a summary of study results. DASH Collaborative Research Group. Harsha DW, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S35–9

Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: a randomized clinical trial. Haynes RB, et al. **J Am Diet Assoc** 1999 Sep;99(9):1077–83

Pre-enrollment diets of Dietary Approaches to Stop Hypertension trial participants. DASH Collaborative Research Group. Karanja NM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S28–34

Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. Karanja NM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S19–27

The Linear Index Model for establishing nutrient goals in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. Lin PH, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S40–4

Comparison of 4 nutrient databases with chemical composition data from the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. McCullough ML, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S45–53

Using feeding studies to test the efficacy of dietary interventions: lessons from the Dietary Approaches to Stop Hypertension trial. Obarzanek E, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S9–11

Validation of diet composition for the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. Phillips KM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S60–8

The effects of dietary patterns on quality of life: a substudy of the Dietary Approaches to Stop Hypertension trial. Plaisted CS, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S84–9

The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. Svetkey LP, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S96–104

Menu design and selection for multicenter controlled feeding studies: process used in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. Swain JF, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S54–9

Dietary Approaches to Stop Hypertension: rationale, design, and methods. DASH Collaborative Research Group. Vogt TM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S12–8 (60 ref.)

Dietary adherence in the Dietary Approaches to Stop Hypertension trial. DASH Collaborative Research Group. Windhauser MM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S76–83

Translating the Dietary Approaches to Stop Hypertension diet from research to practice: dietary and behavior change techniques. DASH Collaborative Research Group. Windhauser MM, et al. **J Am Diet Assoc** 1999 Aug;99(8 Suppl):S90–5

Nutritional counselling in general practice: a cost effective analysis. Pritchard DA, et al. **J Epidemiol Community Health** 1999 May;53(5):311–6

The effect of sour tea (Hibiscus sabdariffa) on essential hypertension. Haji Faraji M, et al. **J Ethnopharmacol** 1999 Jun;65(3):231–6

Dietary fiber, psyllium, attenuates salt-accelerated hypertension in stroke-prone spontaneously hypertensive rats. Obata K, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1959–64

Dietary sucrose does not increase twenty-four-hour ambulatory blood pressure in patients with either essential hypertension or polycystic kidney disease [letter] Van der Schaaf MR, et al. **J Hypertens** 1999 Mar;17(3):453–4

Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Engler MM, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):32–8

A multiple comparison procedure for three- and four-armed controlled clinical trials. Proschan MA. **Stat Med** 1999 Apr 15;18(7):787–98

[The effect of reduced sodium intake on blood pressure, body weight, renin, aldosterone, catecholamines, cholesterol and triglycerides. A meta-analysis] Graudal NA, et al. **Ugeskr Laeger** 1999 Apr 26;161(17):2526–30 (Eng. Abstr.) **(Dan)**

[Non-drug treatment of hypertension--dietary salt and hypertension] Fujita T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1873–8 (9 ref.) **(Jpn)**

[Effect of diet enriched with marine omega-3 polyunsaturated fatty acids on microcirculation system in patients with cardiorespiratory pathology] Enikeeva NA, et al. **Vopr Pitan** 1998;(4):39–41 (Eng. Abstr.) **(Rus)**

[Comparative study on the effect of antiatherosclerotic diet enriched with polyunsaturated omega-3 fatty acids of plant and animal origin on the level of natural antibodies against catecholamines in patients with cardiovascular diseases] Pogozheva AV, et al. **Vopr Pitan** 1998;(4):32–5 (Eng. Abstr.) **(Rus)**

[Effects of antiatherosclerosis diet including soy protein on the dynamics of clinical, biochemical and immunologic indicators in patients with ischemic heart disease and hypertension] Pogozheva AV, et al. **Vopr Pitan** 1999; 68(4):27–31 (Eng. Abstr.) **(Rus)**

[Dynamics of the natural antibody level as affected by the biologically active food supplement "Vitol" in patients with hypertensive disease and obesity] Pogozheva AV, et al. **Vopr Pitan** 1999;68(1):36–41 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effects of spironolactone-altizide on left ventricular hypertrophy. Degre S, et al. **Acta Cardiol** 1998;53(5):261–7

Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Calò L, et al. **Acta Diabetol** 1998 Jul;35(2):96–100

Angiotensin-converting enzyme inhibitors in pregnancy: a new aspect of indication [letter; comment] Rigó J Jr, et al. **Acta Obstet Gynecol Scand** 1999 Feb;78(2):169. Comment on: Acta Obstet Gynecol Scand 1998 May;77(5):570–1.

Catecholamines in pericardial fluid of normotensive, spontaneously hypertensive and reserpine-treated rats. Klemola R, et al. **Acta Physiol Scand** 1999 Mar;165(3):293–7

Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide. Salako BL, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1–2):73–5

Amlodipine as monotherapy in hypertensive Africans: clinical efficacy and safety studies. Sowunmi A, et al. **Afr J Med Med Sci** 1996 Sep;25(3):213–6

Why patients with diabetes, hypertension and/or proteinuria are not on angiotensin converting enzyme inhibitors. Gordian ME, et al. **Alaska Med** 1998 Jul-Sep;40(3):51–4

Antihypertensive treatment and CHD in the elderly [letter] Fink KS, et al. **Am Fam Physician** 1999 Sep 15;60(4):1102, 1104, 1107

Angiotensin II receptor antagonists in the treatment of hypertension. Kaplan NM. **Am Fam Physician** 1999 Sep 15;60(4):1185–90 (16 ref.)

Angiotensin-II receptor antagonists: their place in therapy. Kirk JK. **Am Fam Physician** 1999 Jun;59(11):3140–8 (42 ref.)

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Brooks DP, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):246–51 (53 ref.)

Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas? Carruthers SG. **Am Heart J** 1999 Sep; 138(3 Pt 2):256–60 (27 ref.)

Integrated approaches to management of hypertension: promoting treatment acceptance. McInnes GT. **Am Heart J** 1999 Sep;138(3 Pt 2):252–5 (20 ref.)

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group. Neutel JM, et al. **Am Heart J** 1999 Jan;137(1):118–25

Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Sakata K, et al. **Am Heart J** 1999 Jun;137(6):1094–9

Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Shusterman NH. **Am Heart J** 1999 Sep; 138(3 Pt 2):238–45 (28 ref.)

Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Swales JD. **Am Heart J** 1999 Sep;138(3 Pt 2):231–7

Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Bell TP, et al. **Am J Cardiol** 1999 Jan 15;83(2):272–5, A6

How do angiotensin II receptor antagonists affect blood pressure? de Leeuw PW. **Am J Cardiol** 1999 Jul 22; 84(2A):5K–6K (30 ref.)

Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Estacio RO, et al. **Am J Cardiol** 1998 Nov 12; 82(9B):9R–14R

Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Kostis JB, et al. **Am J Cardiol** 1998 Dec 15;82(12):1501–8

The International Nifedipine GITS Study of Intervention as a Goal in Hypertension Treatment (INSIGHT) trial. Mancia G, et al. **Am J Cardiol** 1998 Nov 12; 82(9B):23R–28R

Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Meredith PA. **Am J Cardiol** 1999 Jul 22;84(2A):7K–12K (16 ref.)

The calcium antagonist controversy: a posthumous commentary. Messerli FH, et al. **Am J Cardiol** 1998 Nov 12;82(9B):35R–39R (33 ref.)

Safety and efficacy of angiotensin II receptor antagonists. Neutel JM. **Am J Cardiol** 1999 Jul 22;84(2A):13K–17K (13 ref.)

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Oparil S, et al. **Am J Cardiol** 1999 Aug 1; 84(3):289–93

The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies [letter; comment] Pahor M, et al. **Am J Cardiol** 1999 Mar 1; 83(5):819–20. Comment on: Am J Cardiol 1998 Nov 12;82(9B):15R–19R.

Overview of angiotensin II-receptor antagonists. Pitt B, et al. **Am J Cardiol** 1998 Nov 19;82(10A):47S–49S (12 ref.)

Calcium antagonists and the diabetic patient: a response to recent controversies. Poulter NR. **Am J Cardiol** 1998 Nov 12;82(9B):40R–41R (18 ref.)

Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. Radevski IV, et al. **Am J Cardiol** 1999 Jul 1;84(1):70–5

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Reif M, et al. **Am J Cardiol** 1998 Oct 15;82(8):961–5

Current status of calcium antagonists in Japan. Saruta T. **Am J Cardiol** 1998 Nov 12;82(9B):32R–34R (14 ref.)

Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) [see comments] Sowers JR. **Am J Cardiol** 1998 Nov 12; 82(9B):15R–19R. Comment in: Am J Cardiol 1999 Mar 1;83(5):819–20.

Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Staessen JA, et al. **Am J Cardiol** 1998 Nov 12;82(9B):20R–22R

Guidelines for assessing outcomes of antihypertensive treatment. Weber M. **Am J Cardiol** 1999 Jul 22; 84(2A):2K–4K (4 ref.)

Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Ylitalo A, et al. **Am J Cardiol** 1999 Mar 15; 83(6):885–9

Impact of hypertension and antihypertensive treatment on organ damage. Zanchetti A. **Am J Cardiol** 1999 Jul 22; 84(2A):18K–24K (26 ref.)

Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension. Han KH, et al. **Am J Chin Med** 1998;26(2):199–209

Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Shapiro JA, et al. **Am J Epidemiol** 1999 Mar 15;149(6):521–30

Optimizing delivery systems to tailor pharmacotherapy to

cardiovascular circadian events. Carter BL.
Am J Health Syst Pharm 1998 Nov 15;55 Suppl 3:S17-23 (26 ref.)

Intravenous clonidine for hypertensive emergencies. Cline JC, et al. **Am J Health Syst Pharm** 1999 Mar 15;56(6):572-4 (7 ref.)

Antihypertensive and vasodilator actions of antioxidants in spontaneously hypertensive rats. Akpaffiong MJ, et al.
Am J Hypertens 1998 Dec;11(12):1450-60

The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Bakris GL. **Am J Hypertens** 1998 Oct; 11(10):158S-162S (23 ref.)

Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril. Bauduceau B, et al. **Am J Hypertens** 1998 Sep; 11(9):1065-73

A chronotherapeutic approach to the management of high-risk patients with hypertension/ischemic heart disease: introduction. Black HR. **Am J Hypertens** 1999 Feb; 12(2 Pt 2):33S-34S (6 ref.)

Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Blumenfeld JD, et al. **Am J Hypertens** 1999 May;12(5):451-9

Different effects of antihypertensive agents on cardiac and vascular hypertrophy in the transgenic rat line TGR(mRen2)27. Brosnan MJ, et al. **Am J Hypertens** 1999 Jul;12(7):724-31

Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan [letter; comment] Bunt T. **Am J Hypertens** 1999 Jan;12(1 Pt 1):79-81. Comment on: Am J Hypertens 1998 Apr;11(4 Pt 1):445-53.

The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. Cook JR, et al. **Am J Hypertens** 1998 Dec;11(12):1433-41

The clinical significance of systolic hypertension. Cushman WC. **Am J Hypertens** 1998 Nov;11(11 Pt 2):182S-185S (10 ref.)

The Pandora Project: results of the pilot study. Degli Esposti E, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):790-6

Comparison of two strategies for intensifying antihypertensive treatment: low-dose combination (enalapril + felodipine ER) versus increased dose of monotherapy (enalapril). LEVEL (Lexxel vs Enalapril) Study Group. Elliott WJ, et al. **Am J Hypertens** 1999 Jul; 12(7):691-6

Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Fogari R, et al.
Am J Hypertens 1998 Oct;11(10):1244-7

Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months. Gerdts E, et al. **Am J Hypertens** 1998 Oct;11(10):1178-87

Clinical trials of single-drug therapy for the cardiac effects of hypertension. Gottdiener JS. **Am J Hypertens** 1999 Jan; 12(1 Pt 2):12S-18S (68 ref.)

Masoprocol lowers blood pressure in rats with fructose-induced hypertension. Gowri MS, et al.
Am J Hypertens 1999 Jul;12(7):744-6

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Hedner T, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):414-7

Effect of L-arginine infusion on systemic and renal hemodynamics in hypertensive patients. Higashi Y, et al.
Am J Hypertens 1999 Jan;12(1 Pt 1):8-15

A clinical trial to improve high blood pressure care in young urban black men: recruitment, follow-up, and outcomes. Hill MN, et al. **Am J Hypertens** 1999 Jun;12(6):548-54

Management of high casual blood pressure in a disaster situation: the 1995 Hanshin-Awaji earthquake [letter] Kario K. **Am J Hypertens** 1998 Sep;11(9):1138-9

Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension. Kawano Y, et al. **Am J Hypertens** 1998 Oct;11(10):1141-6

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Kochar M, et al.
Am J Hypertens 1999 Aug;12(8 Pt 1):797-805

Arterial structural changes with verapamil in spontaneously hypertensive rats. Koffi I, et al. **Am J Hypertens** 1999 Jul; 12(7):732-8

Renin system analysis defines the special value of combination antihypertensive therapy using an antirenin agent (CEI) with a long-acting calcium channel blocker (CCB). Laragh JH. **Am J Hypertens** 1998 Oct; 11(10):170S-174S (42 ref.)

A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Lender D, et al. **Am J Hypertens** 1999 Mar;12(3):298-303

Effects of antihypertensive single-drug therapy on heart rate. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Materson BJ, et al.
Am J Hypertens 1999 Jan;12(1 Pt 2):9S-11S

Prospective, double-blind, seemingly ignored clinical trials [editorial] Materson BJ. **Am J Hypertens** 1999 Jan;12(1 Pt 1):76-8 (14 ref.)

Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Mehta SS, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):333-40

Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Messerli FH.
Am J Hypertens 1999 Aug;12(8 Pt 2):86S-90S (321 ref.)

New directions in the management of hypertension and the cardiovascular risk. Introduction. Messerli FH.
Am J Hypertens 1999 Aug;12(8 Pt 2):63S-64S

Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Meyrier A, et al. **Am J Hypertens** 1998 Sep;11(9):1087-92

Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Neutel JM. **Am J Hypertens** 1999 Aug;12(8 Pt 2):73S-79S

Hypertension: where have we gone wrong and how can we fix it? Neutel JM, et al. **Am J Hypertens** 1998 Oct; 11(10):150S-157S (41 ref.)

Effect of alpha-tocopherol on lipid peroxidation and total antioxidant status in spontaneously hypertensive rats. Newaz MA, et al. **Am J Hypertens** 1998 Dec;11(12):1480-5

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Norton GR, et al. **Am J Hypertens** 1999 Jun;12(6):563-71

Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals. Olsen ME, et al.
Am J Hypertens 1999 Feb;12(2 Pt 1):209-16

Management of the hypertensive patient with coronary artery disease. Oparil S. **Am J Hypertens** 1999 Feb;12(2 Pt 2):56S-62S (49 ref.)

Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Oparil S, et al.
Am J Hypertens 1999 Jul;12(7):653-64 (31 ref.)

The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study. Oparil S.
Am J Hypertens 1998 Nov;11(11 Pt 2):192S-194S

Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Papadakis JA, et al.
Am J Hypertens 1999 Jul;12(7):673-81

Study of supplemental oral l-arginine in hypertensives treated with enalapril + hydrochlorothiazide [letter] Pezza V, et al. **Am J Hypertens** 1998 Oct;11(10):1267-70

Renoprotective effects of antihypertensive drugs. Preston RA. **Am J Hypertens** 1999 Jan;12(1 Pt 2):19S-32S (107 ref.)

Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Radevski I, et al. **Am J Hypertens** 1999 Feb; 12(2 Pt 1):194-203

Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Sheinfeld GR, et al. **Am J Hypertens** 1999 Aug; 12(8 Pt 2):80S-85S (39 ref.)

Pharmacologic treatment of hypertension in the Department of Veterans Affairs during 1995 and 1996. Siegel D, et al.
Am J Hypertens 1998 Nov;11(11 Pt 1):1271-8

Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Vaur L, et al.
Am J Hypertens 1999 Apr;12(4 Pt 1):374-80

The challenge of very mild hypertension: should treatment be sooner or later? [editorial] Weber MA, et al.
Am J Hypertens 1998 Dec;11(12):1495-6

Unsolved problems in treating hypertension: rationale for new approaches. Weber MA. **Am J Hypertens** 1998 Oct; 11(10):145S-149S

The rationale for combination versus single-entity therapy in hypertension. Weir MR. **Am J Hypertens** 1998 Oct; 11(10):163S-169S (30 ref.)

Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. White WB, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):806-14

Low dose bendrofluazide (1.25 mg) effectively lowers blood pressure over 24 h: results of a randomized, double-blind, placebo-controlled crossover study. Wiggam MI, et al.
Am J Hypertens 1999 May;12(5):528-31

Assessing patient wellness: new perspectives on quality of life and compliance. Williams GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):186S-191S (27 ref.)

Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Wynckel A, et al. **Am J Hypertens** 1998 Sep;11(9):1080-6

Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats. Yu M, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):845-8

Value of randomized clinical trials [letter; comment] Lewis EJ. **Am J Kidney Dis** 1998 Nov;32(5):907. Comment on: Am J Kidney Dis 1998 May;31(5):866-7.

Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients [see comments] Rahman M, et al. **Am J Kidney Dis** 1999 Mar;33(3):498-506 . Comment in: Am J Kidney Dis 1999 Mar;33(3):492-4.

Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Kohno M, et al.
Am J Med 1999 May;106(5):544-9

Blood pressure level and incidence of myocardial infarction among patients treated for hypertension. Kaplan RC, et al. **Am J Public Health** 1999 Sep;89(9):1414-7

Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327-30 (7 ref.)

Isosorbide aerosol: an option for the treatment of hypertensive crises. Rubio-Guerra AF, et al. **Angiology** 1999 Feb;50(2):137-42

Talking about treatment: the language of populations and the language of individuals [see comments] Steiner JF.
Ann Intern Med 1999 Apr 6;130(7):618-22. Comment in: Ann Intern Med 1999 Apr 6;130(7):604-6.

Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al.
Ann N Y Acad Sci 1999 Jun 21;881:420-9 (33 ref.)

ACE inhibitor switch in an indigent community clinic [letter] Knight MR, et al. **Ann Pharmacother** 1999 Jul-Aug; 33(7-8):872-3

Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. Yamreudeewong W, et al.
Ann Pharmacother 1999 Jan;33(1):7-10

Maternal hypertension and neurodevelopmental outcome in very preterm infants [see comments] Gray PH, et al.
Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F88-93 Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F158-9.

Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Anderson RB, et al. **Arch Intern Med** 1999 Apr 12;159(7):693-700

Calcium channel blockers and benign hypertension [letter] Gurm HS, et al. **Arch Intern Med** 1999 May 10;159(9):1011

Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. Hall WD, et al.
Arch Intern Med 1998 Oct 12;158(18):2029-34

Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments] Lakshman MR, et al. **Arch Intern Med** 1999 Mar 22; 159(6):551-8. Comment in: Arch Intern Med 1999 Mar 22;159(6):541-2.

Antihypertensive therapy in the elderly: evidence-based guidelines and reality [letter; comment] Messerli FH, et al. **Arch Intern Med** 1999 Jul 26;159(14):1621-2. Comment on: Arch Intern Med 1998 Nov 23;158(21):2377-85.

National recommendations for the pharmacological treatment of hypertension: should they be revised? [comment] Moser M. **Arch Intern Med** 1999 Jul 12;159(13):1403-6 (23 ref.) Comment on: Arch Intern Med 1997 Nov 24;157(21):2413-46.

Hyperlipidemia of diuretic therapy. Ames R.
Arch Mal Coeur Vaiss 1998 Sep;91 Suppl:23-7 (27 ref.)

Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Guo Z, et al.
Arch Neurol 1999 Aug;56(8):991-6

Persistent antihypertensive effect of oral nitrite supplied up to one year via the drinking water in spontaneously hypertensive rats. Haas M, et al. **Arzneimittelforschung** 1999 Apr;49(4):318-23

Clinical audit activity. Prescribing for common conditions--hypertension. Clearihan L.
Aust Fam Physician 1999 Jun;28(6):590; quiz 593-5

Outcomes from treatment. Clinical applications from recent trials. Howes LG. **Aust Fam Physician** 1999 Jul; 28(7):707-10

Compliance and the adverse event profile. Mant A.
Aust Fam Physician 1999 Jun;28(6):591

Clinical audit activity. Prescribing for common conditions--hypertension. Mant A. **Aust Fam Physician** 1999 Apr;28(4):361-2; quiz 363-4

Clinical audit activity. Prescribing for common conditions--hypertension. Mant A. **Aust Fam Physician** 1999 May;28(5):484-5, quiz 487

Nephroprotection by antihypertensive therapy. Jacobi J, et al. **Basic Res Cardiol** 1998;93 Suppl 2:109-19 (98 ref.)

Therapeutic advantages of AT1 blockers in hypertension. Kendall MJ. **Basic Res Cardiol** 1998;93 Suppl 2:47-50 (20 ref.)

Antihypertensive therapy before, during, and after stroke. Mzimba ZS, et al. **Basic Res Cardiol** 1998;93 Suppl 2:59-62 (37 ref.)

Clinical efficacy of a new AT1 blocker. Philipp T, et al.
Basic Res Cardiol 1998;93 Suppl 2:51-3 (20 ref.)

Hypertension and stroke--rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors. Schrader J, et al. **Basic Res Cardiol** 1998;93 Suppl 2:69-78 (61 ref.)

Effects of candesartan cilexetil on glucose homeostasis. Multicenter Study Group. Trenkwalder P.
Basic Res Cardiol 1998;93 Suppl 2:140-4

Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies. Brude IR, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):183-91

Preventive effects of Shichimotsu-koka-to on renal lesions in stroke-prone spontaneously hypertensive rats. Higuchi Y, et al. **Biol Pharm Bull** 1998 Sep;21(9):914-8

Reduction of cardiovascular structural changes by nifedipine

GITS in essential hypertensive patients. Agabiti-Rosei E, et al. **Blood Press** 1998 May;7(3):160-9
Candesartan cilexetil vs losartan [letter; comment] Bunt T. **Blood Press** 1998 Jul;7(4):251-2. Comment on: Blood Press 1998 Jan;7(1):53-9.
Changes in antihypertensive therapy--the role of adverse effects and compliance. Düsing R, et al. **Blood Press** 1998 Nov;7(5-6):313-5
Moxonidine: pharmacology, clinical pharmacology and clinical profile. Elliott HL. **Blood Press** 1998;Suppl 3:23-7 (20 ref.)
Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Hansson L. **Blood Press** 1998;Suppl 3:20-2 (19 ref.)
Combination therapy with felodipine and metoprolol compared with captopril and hydrochlorothiazide. German MC Study Group. Klein G. **Blood Press** 1998 Nov; 7(5-6):308-12
Insulin resistance and diabetes in the context of treatment of hypertension. Lithell HO. **Blood Press** 1998;Suppl 3:28-31 (28 ref.)
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Mann J, et al. **Blood Press** 1998 May; 7(3):176-83
No impaired cognitive function in treated patients with mild-moderate hypertension compared to normotensive controls. Nilsson P, et al. **Blood Press** 1998 Jul;7(4):209-13
Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Olsen H, et al. **Blood Press** 1999;8(2):94-101
Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. Reneland R, et al. **Blood Press** 1999; 8(1):16-22
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Sega R. **Blood Press** 1999;8(2):114-21
Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Trenkwalder P, et al. **Blood Press** 1998 May;7(3):170-5
Calcium antagonists and safety: the turning of the tide. Van Zwieten PA, et al. **Blood Press** 1999;8(1):5-8 (31 ref.)
Cardiovascular effects of dietary salts and isosorbide-5-mononitrate in spontaneously hypertensive rats. Vaskonen T, et al. **Blood Press** 1998 May;7(3):184-92
Relationship between the circulating and vascular renin-angiotensin system and the vasodilating effect of captopril in human hypertension. Virdis A, et al. **Blood Press** 1999;8(2):85-93
Clinical advantages of lipophilic dihydropyridines. Mancia G, et al. **Blood Press Suppl** 1998;2:23-6 (30 ref.)
Calcium channel blockers: is the jury still out? [letter; comment] Wright JM. **BMJ** 1998 Dec 5;317(7172):1591-2 Comment on: BMJ 1998 May 16;316(7143):1471-3.
Antihypertensive effect of amlodipine compared with nifedipine retard in patients with mild and moderate essential hypertension. Kalina Z, et al. **Boll Chim Farm** 1998 Jul-Aug;137(7):281-5
Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Cheung BM, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):179-87
Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Fogari R, et al. **Br J Clin Pharmacol** 1998 Nov; 46(5):467-71
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Pfister M, et al. **Br J Clin Pharmacol** 1999 Jun;47(6):645-51
Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Püchler K, et al. **Br J Clin Pharmacol** 1998 Oct; 46(4):363-7
Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor. Scholze J, et al. **Br J Clin Pharmacol** 1998 Aug; 46(2):169-72
Cost-effective monotherapy of concomitant benign prostatic hyperplasia and hypertension. Altwein JE. **Br J Hosp Med** 1998 Dec 10;58(11):592-4 (31 ref.)
Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol. Borges AC, et al. **Br J Pharmacol** 1999 Jun;127(3):772-8
The contribution of nitric oxide to cardiovascular status and responses to vasodilators in conscious, hypertensive, transgenic ((mRen-2)27) rats. Gardiner SM, et al. **Br J Pharmacol** 1998 May;124(2):299-306
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. Kirby RS. **Br J Urol** 1998 Sep;82(3):373-9
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients? Evans MF. **Can Fam Physician** 1998 Dec;44:2655-7
Do calcium channel blockers increase the risk of myocardial infarction in hypertensive patients with diabetes mellitus? Park L, et al. **Can Fam Physician** 1998 Nov;44:2405-7
Effects of antihypertensive therapies on the sympathetic nervous system. de Champlain J, et al. **Can J Cardiol** 1999 Mar;15 Suppl A:8A-14A (30 ref.)
What is apoptosis and what is its relevance to vascular biology? Hamet P. **Can J Cardiol** 1999 Apr;15 Suppl B:5B-7B
Hypertension in the elderly: a patient case study. Larochelle P. **Can J Cardiol** 1999 Mar;15 Suppl A:22A-24A (16 ref.)
Adherence to pharmacologic management of hypertension. Feldman R, et al. **Can J Public Health** 1998 Sep-Oct; 89(5):116-8
Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Brekken C, et al. **Cancer Lett** 1998 Sep 11;131(1):65-70
Treatment of hypertension in the elderly. Abate G, et al. **Cardiologia** 1999 May;44(5):427-32 (36 ref.)
Single-drug therapy and reduction of left ventricular mass in hypertension. Gottdiener JS. **Cardiologia** 1998 Nov; 43(11):1177-83 (68 ref.)
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Julius S. **Cardiology** 1999;91 Suppl 1:8-13 (47 ref.)
Clinical advantage of valsartan. McInnes GT. **Cardiology** 1999;91 Suppl 1:14-8 (34 ref.)
Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives. Fogari R, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):243-8
Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Mitsunami K, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):469-74
Personal viewpoint: new developments in the therapy of diabetic hypertensive disease. The ABCD study adds to strong evidence favoring the prime use of ACE inhibitors. Appropriate Blood Pressure Control in Diabetes. Opie LH. **Cardiovasc Drugs Ther** 1998 Jul;12(3):233-8 (42 ref.)
Endothelial function and antihypertensive treatment [editoria; comment] Chang PC. **Cardiovasc Res** 1999 Jan; 41(1):19-20. Comment on: Cardiovasc Res 1999 Jan;41(1):299-306.
Chronic blockade of endothelin ETA receptors improves flow dependent dilation in resistance arteries of hypertensive rats. Iglarz M, et al. **Cardiovasc Res** 1998 Sep; 39(3):657-64
Endothelin in hypertension: a role for receptor antagonists? Moreau P. **Cardiovasc Res** 1998 Sep;39(3):534-42 (81 ref.)
Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients [see comments] Perticone F, et al. **Cardiovasc Res** 1999 Jan;41(1):299-306. Comment in: Cardiovasc Res 1999 Jan;41(1):19-20.
Comparison of the effects of supplementation with whey mineral and potassium on arterial tone in experimental hypertension. Wu X, et al. **Cardiovasc Res** 1998 Nov; 40(2):364-74
A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension. Jhee SS, et al. **Cephalalgia** 1999 Mar; 19(2):95-9
Hypertension in a general medical clinic in the National Hospital of Sri Lanka [letter] Constantine GR, et al. **Ceylon Med J** 1998 Dec;43(4):250-1
Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension. Chern MS, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar;22(1):44-51
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension [letter; comment] Gottdiener JS. **Circulation** 1999 Aug 10;100(6):685-6. Comment on: Circulation 1998 Nov 10;98(19):2037-42.
Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study [news] Laakso M. **Circulation** 1999 Feb 2;99(4):461-2
Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system [editorial; comment] Pitt B. **Circulation** 1998 Nov 10;98(19):1987-9 (20 ref.). Comment on: Circulation 1998 Nov 10;98(19):2037-42.
Aggressive blood pressure lowering is safe, but benefit is still hard to prove. Vidt DG, et al. **Cleve Clin J Med** 1999 Feb;66(2):105-11
Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Andersson F, et al. **Clin Exp Hypertens** 1998 Nov;20(8):833-46
Antihypertensive drugs and the nervous system: ACE-inhibitors restore oscillatory potentials in hypertensives. Cosenzi A, et al. **Clin Exp Hypertens** 1999 Apr;21(3):223-31
Involvement of nitric oxide and potassium channels in the reduction of basal tone produced by blockade of thromboxane A2/prostaglandin H2 receptors in aortic rings of hypertensive rats. DelliPizzi A, et al. **Clin Exp Hypertens** 1998 Nov;20(8):903-16
Alterations in the vasoreactivity of hypertensive rat aortic rings: role of nitric oxide and superoxide radicals. Hegde LG, et al. **Clin Exp Hypertens** 1998 Nov;20(8):885-901
Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Keaton AK, et al. **Clin Exp Hypertens** 1998 Nov;20(8):847-66
Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Kosegawa I, et al. **Clin Exp Hypertens** 1998 Oct;20(7):751-61
Modification of cardiac subcellular remodeling due to pressure overload by captopril and losartan. Liu X, et al. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):145-56
The effects of short-term nifedipine treatment on responsiveness of aortic rings of cadmium-hypertensive rats. Ozdem SS, et al. **Clin Exp Hypertens** 1999 May; 21(4):423-40
Effect of experimental diabetes on the protection by angiotensin blockers on nitric oxide deficient stroke in stroke-prone spontaneously hypertensive rats. Raje R, et al. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):37-49
Depressor effect of kappa opioid agonist on hypertension induced by isolation in the rat. Shen S, et al. **Clin Exp Hypertens** 1999 Apr;21(3):275-97
New classes of antihypertensive drugs: therapeutic potentials. Singh NK, et al. **Clin Exp Hypertens** 1999 Jan-Feb; 21(1-2):137-43 (19 ref.)
Left ventricular mass regression with amlodipine in elderly hypertensives. Singh NK, et al. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):113-9
Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Webb RL, et al. **Clin Exp Hypertens** 1998 Oct;20(7):775-93
Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade. Xie Z, et al. **Clin Exp Hypertens** 1999 May;21(4):441-52
Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Ishimitsu T, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):500-4
Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat. Kost CK Jr, et al. **Clin Exp Pharmacol Physiol** 1999 May-Jun; 26(5-6):449-55
Kinetics of beneficial effect of pentoxifylline on persistent forms of arterial hypertension. Mchedlishvili G, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(4):285-90
Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension. Muravyov AV, et al. **Clin Hemorheol Microcirc** 1998 Jul;18(2-3):185-90
Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Hempel G, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):622-35
Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade. Leenen FH, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):522-35
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Wallis EJ, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):439-49
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan [letter; comment] Bunt T. **Clin Ther** 1999 Mar; 21(3):611-2. Comment on: Clin Ther 1998 May-Jun;20(3):398-409.
Amlodipine, felodipine, and isradipine in the treatment of Chinese patients with mild-to-moderate hypertension. Cheung BM, et al. **Clin Ther** 1998 Nov-Dec;20(6):1159-69
Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Gradman AH, et al. **Clin Ther** 1999 Mar;21(3):442-53
Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Paster RZ, et al. **Clin Ther** 1998 Sep-Oct;20(5):978-89
Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators. Zuschke CA, et al. **Clin Ther** 1999 Mar;21(3):464-74
Reversible impairment of renal function associated with enalapril in a diabetic patient. Albareda MM, et al. **CMAJ** 1998 Nov 17;159(10):1279-81
Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors [see comments] Bourgault C, et al. **CMAJ** 1999 Aug 10; 161(3):255-60. Comment in: CMAJ 1999 Aug 10;161(3):273-4.
Persistence with treatment for hypertension in actual practice [see comments] Caro JJ, et al. **CMAJ** 1999 Jan 12; 160(1):31-7. Comment in: CMAJ 1999 Jan 12;160(1):64-5.
Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data [see comments] Caro JJ, et al. **CMAJ** 1999 Jan 12; 160(1):41-6. Comment in: CMAJ 1999 Jan 12;160(1):64-5.
Searching for a link between calcium-channel blockers and cognitive function [editorial; comment] Dinsdale HB. **CMAJ** 1999 Sep 7;161(5):534-5. Comment on: CMAJ 1999 Sep 7;161(5):501-6.
The treatment of hypertension in Canada: are we making progress? [editorial; comment] McAlister FA. **CMAJ** 1999 Sep 21;161(6):713-4. Comment on: CMAJ 1999 Sep 21;161(6):699-704.
Compliance in hypertension: why don't patients take their pills? [editorial; comment] Myers MG. **CMAJ** 1999 Jan 12;160(1):64-5. Comment on: CMAJ 1999 Jan

12;160(1):31-7. Comment on: CMAJ 1999 Jan 12;160(1):41-6.
Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? Wright JM, et al. **CMAJ** 1999 Jul 13;161(1):25-32 (64 ref.)
Antihypertensive drug therapy and antioxidant enzyme mRNA levels in spontaneously hypertensive (SHR) rats. Ma L, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan; 122(1):119-26
Mass mailing and staff experience in a total recruitment program for a clinical trial: the SHEP experience. Systolic Hypertension in the Elderly Program. Cooperative Research Group. Cosgrove N, et al. **Control Clin Trials** 1999 Apr;20(2):133-48
Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. Wittes J, et al. **Control Clin Trials** 1999 Apr;20(2):121-32
Hypertension in the elderly: management issues. Gennari FJ, et al. **Coron Artery Dis** 1998;9(11):719-24 (35 ref.)
Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Argenziano L, et al. **Curr Med Res Opin** 1999;15(1):9-14
Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group. Diamond JA, et al. **Curr Med Res Opin** 1999;15(1):1-8
Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Gavras I, et al. **Curr Med Res Opin** 1999;15(1):15-24
Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? Hayduk K, et al. **Curr Med Res Opin** 1999;15(1):39-45
Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Levine B. **Curr Med Res Opin** 1999; 15(1):25-32
Bibliography. Current world literature. Pharmacology and therapeutics. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):609-34
Antioxidants for hypertension. Kitiyakara C, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):531-8 (61 ref.)
Angiotensin converting enzyme inhibitors: first line therapy in patients with diabetic hypertension? [editorial] Levy EM. **Curr Opin Nephrol Hypertens** 1999 May;8(3):333-4 (8 ref.)
Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Perico N, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):571-8 (62 ref.)
Recent advances in antihypertensive therapy. Quadri L, et al. **Curr Pharm Des** 1998 Dec;4(6):489-512 (194 ref.)
Small is beautiful - but too cheap [editorial; comment] Amiel SA. **Diabet Med** 1999 Jun;16(6):445. Comment on: Diabet Med 1999 Jun;16(6):482-7.
Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study [see comments] Hunter SJ, et al. **Diabet Med** 1999 Jun;16(6):482-7. Comment in: Diabet Med 1999 Jun;16(6):445.
Isradipine in prediabetic hypertensive subjects. Byington RP, et al. **Diabetes Care** 1998 Dec;21(12):2103-10
Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication [letter] Cooper JW. **Diabetes Care** 1998 Dec;21(12):2197-8
Calcium antagonists and cardiovascular risk in diabetes. A review of the evidence. Mason RP, et al. **Diabetes Care** 1999 Jul;22(7):1206-8 (17 ref.)
Diabetes and risk of adverse events with calcium antagonists [letter; comment] Parving HH, et al. **Diabetes Care** 1998 Oct;21(10):1779-80. Comment on: Diabetes Care 1998 Apr;21(4):597-603.
Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Takeda S, et al. **Diabetes Res Clin Pract** 1999 Jun; 44(3):197-205
Development of tablets for controlled joint release of nifedipine and atenolol. Iglesias R, et al. **Drug Dev Ind Pharm** 1998 Sep;24(9):835-40
Safety and tolerability of moxonidine in the treatment of hypertension. Schachter M, et al. **Drug Saf** 1998 Sep; 19(3):191-203 (43 ref.)
Urapidil. A reappraisal of its use in the management of hypertension. Dooley M, et al. **Drugs** 1998 Nov; 56(5):929-55 (52 ref.)
Valsartan/hydrochlorothiazide. Langtry HD, et al. **Drugs** 1999 May;57(5):751-5; discussion 756-8 (9 ref.)
Candesartan cilexetil. A review of its use in essential hypertension. McClellan KJ, et al. **Drugs** 1998 Nov; 56(5):847-69 (95 ref.)
Telmisartan. McClellan KJ, et al. **Drugs** 1998 Dec; 56(6):1039-44; discussion 1045-6 (22 ref.)
Nebivolol in the management of essential hypertension: a review [published erratum appears in Drugs 1999 Jun;57(6):870] McNeely W, et al. **Drugs** 1999 Apr; 57(4):633-51 (73 ref.)
Management of the hypertensive patient who smokes. Pardell H, et al. **Drugs** 1998 Aug;56(2):177-87 (106 ref.)
A perspective on the calcium antagonists in blacks (CAB) trial [editorial] Hall WD. **Ethn Dis** 1998 Autumn;8(3):296-8
The use of free and fixed drug combinations to improve hypertension control in our populations [editorial] Chalmers J. **Eur Heart J** 1999 Aug;20(15):1060-1
The place for beta-blockers in treating hypertension [editorial; comment] Kaplan NM. **Eur Heart J** 1999 Jan; 20(1):5-6 (9 ref.). Comment on: Eur Heart J 1999 Jan;20(1):11-24. Comment on: Eur Heart J 1999 Jan;20(1):25-30.
The calcium channel antagonist debate: recent developments. Lubsen J. **Eur Heart J** 1998 Aug;19 Suppl I:I3-7 (32 ref.)
Calcium antagonists, appropriate therapy for diabetic patients with hypertension? [editorial] Malmberg K, et al. **Eur Heart J** 1998 Sep;19(9):1269-72 (14 ref.)
Diuretics, beta-blockers, and gin and tonic [see comments] Messerli FH, et al. **Eur Heart J** 1999 Jan;20(1):25-30 (54 ref.). Comment in: Eur Heart J 1999 Jan;20(1):5-6.
Acute effects of angiotensin-converting enzyme inhibition on coronary vasomotion in hypertensive patients. Nitenberg A, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J45-51 (39 ref.)
Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use. Silvestry FE, et al. **Eur Heart J** 1998 Aug; 19 Suppl I:I8-14 (54 ref.)
Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension [see comments] Staessen JA, et al. **Eur Heart J** 1999 Jan; 20(1):11-24 (113 ref.). Comment in: Eur Heart J 1999 Jan;20(1):5-6.
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Willenheimer R, et al. **Eur Heart J** 1999 Jul;20(14):997-1008 (105 ref.)
Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause. Agabiti-Rosei E, et al. **Eur J Clin Pharmacol** 1999 May;55(3):185-9
Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Fridman K, et al. **Eur J Clin Pharmacol** 1998 Sep;54(7):497-501
Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea. Heitmann J, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):691-6
No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers. Mores N, et al. **Eur J Clin Pharmacol** 1999 Jun;55(4):251-4
The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. Salo TM, et al. **Eur J Clin Pharmacol** 1999 May;55(3):191-8
Drug treatment for hypertension in Finnish primary health care. Wallenius S, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec;54(9-10):793-9
Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis. Nakayama J, et al. **Eur J Dermatol** 1998 Dec;8(8):563-8
Oral clonidine to control hypertension after head injury. Kariya N, et al. **Eur J Emerg Med** 1999 Mar;6(1):77-9
Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. Al-Waili NS, et al. **Eur J Med Res** 1999 May 26;4(5):193-8
Amlodipine once-daily in systemic hypertension. Pfammatter JP, et al. **Eur J Pediatr** 1998 Aug;157(8):618-21
Losartan and enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rats. Kähönen M, et al. **Eur J Pharmacol** 1999 Mar 5; 368(2-3):213-22
Beta-adrenoceptor antagonist propranolol potentiates hypotensive action of natriuretic peptides. Yoshimoto T, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):61-6
Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats. Kristek F. **Exp Physiol** 1998 Sep;83(5):595-603
Treatment of moderate or severe arterial hypertension with losartan. Dimitrova A, et al. **Folia Med (Plovdiv)** 1998; 40(3B Suppl 3):43-5
Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Lahlou S, et al. **Fundam Clin Pharmacol** 1998;12(6):599-606
Control of hypertension in Italy: results of the "Study on Antihypertensive Treatment in General Practice (STAP)". Physicians Taking Part in STAP. Avanzini F, et al. **G Ital Cardiol** 1998 Jul;28(7):760-6
Protection against endothelial abnormalities by a novel calcium channel blocker, AE0047, in stroke-prone spontaneously hypertensive rats. Nishikawa M, et al. **Gen Pharmacol** 1999 Mar;32(3):299-305
Nifedipine effectively lowers salt-induced high blood pressure in diabetic rats. Orie NN, et al. **Gen Pharmacol** 1999 Apr;32(4):471-4
Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role? Bursztyn M, et al. **Geriatr Nephrol Urol** 1999;9(1):5-10
The efficacy of long-term captopril treatment on micro- and macroalbuminuria in hypertensive diabetics. Vörös P, et al. **Geriatr Nephrol Urol** 1998;8(2):65-8
Hypertension: how comorbid disease influences the choice of therapy. Part 4 of a roundtable discussion. Butler RN, et al. **Geriatrics** 1999 Aug;54(8):34, 39-44
Hypertension: drug therapy options for older patients. Butler RN, et al. **Geriatrics** 1999 Jul;54(7):27-8, 33-4, 37
Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Tamás P, et al. **Gynecol Obstet Invest** 1999;47(3):210-3
Potassium supplementation induces beneficial cardiovascular changes during rest and stress in salt sensitive individuals. West SG, et al. **Health Psychol** 1999 May;18(3):229-40
Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Heise T, et al. **Horm Metab Res** 1999 Jul;31(7):418-23
Irbesartan treatment in hypertension. Brown MJ. **Hosp Med** 1998 Oct;59(10):808-11 (14 ref.)
Benign prostatic hyperplasia and hypertension [letter] Papadakis JA, et al. **Hosp Med** 1998 Oct;59(10):825
Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction. Ayoub JC, et al. **Hypertens Res** 1999 Jul;22(2):155-9
Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Koshida H, et al. **Hypertens Res** 1998 Dec;21(4):279-82
Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients. Minami J, et al. **Hypertens Res** 1998 Sep; 21(3):215-9
Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Sato A, et al. **Hypertens Res** 1999 Mar;22(1):17-22
Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arterioles in rats. Chillon JM, et al. **Hypertension** 1999 Mar;33(3):856-61
Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Dessi-Fulgheri P, et al. **Hypertension** 1999 Feb;33(2):658-62
Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats. Giummelly P, et al. **Hypertension** 1999 Aug;34(2):207-11
ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hausberg M, et al. **Hypertension** 1999 Mar;33(3):862-8
Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Jia H, et al. **Hypertension** 1999 Jul;34(1):8-14
Irbesartan reduces QT dispersion in hypertensive individuals. Lim PO, et al. **Hypertension** 1999 Feb;33(2):713-8
Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Linz W, et al. **Hypertension** 1999 Aug;34(2):291-5
Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Nakamura Y, et al. **Hypertension** 1999 Aug;34(2):273-8
Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Nazzaro P, et al. **Hypertension** 1999 Feb;33(2):719-25
Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Sakata K, et al. **Hypertension** 1999 Jun; 33(6):1447-52
Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators. Staessen JA, et al. **Hypertension** 1999 Jun;33(6):1476-7
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Tikkanen T, et al. **Hypertension** 1998 Oct;32(4):778-85
Influence of baseline values. I: Effects on plasma total cholesterol and triglyceride levels during doxazosin treatment for hypertension. Ahaneku JE, et al. **Int J Clin Pharmacol Res** 1998;18(4):159-63
Influence of baseline values. II: Variations in plasma lipoprotein fractions during doxazosin treatment for hypertension. Ahaneku JE, et al. **Int J Clin Pharmacol Res** 1998;18(4):165-70
Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease. Pordy R, et al. **Int J Clin Pharmacol Res** 1998;18(3):105-8
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Breithaupt-Grögler K, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):425-31
Effects of benidipine hydrochloride on 24-hour blood pressure and blood pressure response to mental stress in elderly patients with essential hypertension. Muneta S, et al. **Int J Clin Pharmacol Ther** 1999 Mar;37(3):141-7
Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and serum urate in hypertensive patients. Swedish-Finnish Study Group. Thulin T, et al. **Int J Clin Pharmacol Ther** 1999 Jan;37(1):28-33
Blood pressure control and cardiovascular risk in patients

of Indo-Asian and African-Caribbean descent. Burden AC. **Int J Clin Pract** 1998 Sep;52(6):388-94

Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Schaefer RM, et al. **Int J Clin Pract** 1998 Sep;52(6):381-6

Improved blood pressure control by monitoring compliance with antihypertensive therapy. Waeber B, et al. **Int J Clin Pract** 1999 Jan-Feb;53(1):37-8

Nisoldipine coat-core and heart rate response during treatment of hypertension. Zannad F. **Int J Clin Pract** 1999 Jan-Feb;53(1):65-71

Definition of high blood pressure, epidemiology and goals of hypertension treatment. Dahlöf B. **Int J Clin Pract Suppl** 1998 Nov;98:3-5 (9 ref.)

Optimal management of hypertensive patients with type 2 diabetes and microalbuminuria. Mogensen CE. **Int J Clin Pract Suppl** 1998 Nov;98:13-20 (74 ref.)

Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension. Fawzy A, et al. **Int J Urol** 1999 Jul; 6(7):346-54

An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Ramsey SD, et al. **J Am Board Fam Pract** 1999 Mar-Apr;12(2):105-14

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Pepine CJ, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1228-37

Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. Warner JG Jr, et al. **J Am Coll Cardiol** 1999 May; 33(6):1567-72

Measuring blood pressure and treating hypertension in (frail) older people [editorial; comment] Cushman WC. **J Am Geriatr Soc** 1999 Mar;47(3):373-4 (19 ref.). Comment on: J Am Geriatr Soc 1999 Mar;47(3):285-90.

Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. Mendelson G, et al. **J Am Geriatr Soc** 1999 May;47(5):597-9

Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. Gourley GA, et al. **J Am Pharm Assoc (Wash)** 1998 Sep-Oct;38(5):586-97

Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. Solomon DK, et al. **J Am Pharm Assoc (Wash)** 1998 Sep-Oct; 38(5):574-85

Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. Brochu E, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1440-6

Comparative antihypertensive effects of angiotensin II receptor antagonists. Burnier M, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S278-82 (40 ref.)

Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments. Fortepiani LA, et al. **J Am Soc Nephrol** 1999 Jan;10(1):21-7

Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. Gross V, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1430-9

Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. Inscho EW, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S178-83

Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. Jordan J, et al. **J Am Soc Nephrol** 1999 Jan;10(1):35-42

Angiotensin receptor blockers: pharmacology and clinical significance. Mimran A, et al. **J Am Soc Nephrol** 1999 Apr; 10 Suppl 12:S273-7 (48 ref.)

Angiotensin blocking drugs and the heart beyond 2000. Morgan TO, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S243-7 (39 ref.)

Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats. Pollock DM, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S116-9

Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. Sorof JM, et al. **J Am Soc Nephrol** 1999 Jun; 10(6):1324-30

Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. Esler M, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2-3):210-9 (47 ref.)

Effects of clonidine on power spectral analysis of heart rate variability in mild essential hypertension. Lazzeri C, et al. **J Auton Nerv Syst** 1998 Dec 11;74(2-3):152-9

The diuretic indapamide increases bone mass and decreases bone resorption in spontaneously hypertensive rats supplemented with sodium. Lalande A, et al. **J Bone Miner Res** 1998 Sep;13(9):1444-50

A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. Arita M, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):186-92

Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. Fogari R, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):534-9

ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. Fogari R, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):616-20

Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. Gaudio C, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):760-8

Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. Mallion JM, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):673-8

Valsartan and the kidney: present and future. Mann JF. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S37-40; discussion S41-3 (19 ref.)

The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial. Martina B, et al. **J Cardiovasc Pharmacol** 1999 Apr; 33(4):647-51

Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. Nguyen T, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):884-95

Long-term morbidity and mortality trials with amlodipine. Oparil S. **J Cardiovasc Pharmacol** 1999;33 Suppl 2:S1-6 (25 ref.)

Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. Os I, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):791-7

New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. Pahor M, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 2:S18-23 (24 ref.)

Usefulness of transdermal clonidine in hypertensive patients undergoing minor surgical operations. Pini A, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):920-6

Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. Rizzoni D, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):798-806

Long-acting lacidipine versus short-acting nifedipine in the treatment of asymptomatic acute blood pressure increase. Sánchez M, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):479-84

Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. Schwieler JH, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):268-74

The place of ACE inhibition in the modern therapeutic era: beyond blood pressure control. Introduction. Waeber B. **J Cardiovasc Pharmacol** 1998;32 Suppl 2:v-vi

Patients' and physicians' assessment of risks associated with hypertension and benefits from treatment. Kjellgren KI, et al. **J Cardiovasc Risk** 1998 Jun;5(3):161-6

The effect of propofol and thiamylal on hypertensive responses to a rapid increase in isoflurane concentration. Nakayama M, et al. **J Clin Anesth** 1999 Feb;11(1):8-10

Population trends in antihypertensive drug use: results from the MONICA Augsburg Project 1984 to 1995. Gasse C, et al. **J Clin Epidemiol** 1999 Jul;52(7):695-703

The HOT Study. Hypertension Optimal Therapy. Kendall MJ, et al. **J Clin Pharm Ther** 1998 Apr;23(2):137-9

The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. Rosenstock J, et al. **J Clin Pharm Ther** 1998 Dec;23(6):433-40

The relevance of T-type calcium antagonists: a profile of mibefradil. Glasser SP. **J Clin Pharmacol** 1998 Aug; 38(8):659-69 (58 ref.)

Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. Smith DA, et al. **J Clin Pharmacol** 1998 Aug;38(8):685-93

The effect of ACE inhibitors on cardiovascular morbidity and mortality. Hachey D, et al. **J Fam Pract** 1999 Jun; 48(6):414-5

Antihypertensive therapy in type 2 diabetes mellitus. Miser WF. **J Fam Pract** 1998 Dec;47(6):413-4

Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension. Hung MJ, et al. **J Formos Med Assoc** 1999 Jun;98(6):403-9

Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. Bogden PE, et al. **J Gen Intern Med** 1998 Nov;13(11):740-5

PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee. **J Hum Hypertens** 1998 Sep; 12(9):627-9

Improved efficacy with maintained tolerability in the treatment of primary hypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril. Swedish Multicentre Group. Andersson OK. **J Hum Hypertens** 1999 Jan;13(1):55-60

The influence of different antihypertensive drugs on left ventricular hypertrophy in a population sample of elderly men [see comments] Andrén B, et al. **J Hum Hypertens** 1999 Aug;13(8):499-504. Comment in: J Hum Hypertens 1999 Aug;13(8):497-8.

Antihypertensive drug treatment: a comparison of usual care with self blood pressure measurement. Bailey B, et al. **J Hum Hypertens** 1999 Feb;13(2):147-50

JNC-VI: a view from the United Kingdom. Beevers DG, et al. **J Hum Hypertens** 1998 Sep;12(9):649-51 (16 ref.)

Beta-blockers for hypertension: time to call a halt. Beevers DG. **J Hum Hypertens** 1998 Dec;12(12):807-10 (24 ref.)

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. Benz JR, et al. **J Hum Hypertens** 1998 Dec; 12(12):861-6

Tailoring anti-hypertensive treatment in the elderly. Bonapace S, et al. **J Hum Hypertens** 1998 Sep;12(9):615-20 (18 ref.)

Bisoprolol in the treatment of hypertension in the elderly. Broncel M, et al. **J Hum Hypertens** 1998 Sep;12(9):643-4

Baroreflex sensitivity and the blood pressure response to beta-blockade. Chen X, et al. **J Hum Hypertens** 1999 Mar; 13(3):185-90

Valsartan and atenolol in patients with severe essential hypertension. Cifkova R, et al. **J Hum Hypertens** 1998 Aug; 12(8):563-7

Does the treatment of isolated systolic hypertension prevent dementia? Clarke CE. **J Hum Hypertens** 1999 Jun; 13(6):357-8; discussion 419-20 (11 ref.)

A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. Conlin PR, et al. **J Hum Hypertens** 1998 Oct; 12(10):693-9

Prevalence, awareness, treatment and control of arterial hypertension in an elderly population in Belgium [see comments] De Backer G, et al. **J Hum Hypertens** 1998 Oct;12(10):701-6. Comment in: J Hum Hypertens 1998 Oct;12(10):665-6.

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. Elliott WJ. **J Hum Hypertens** 1999 Jun;13(6):413-7

Traditional drug therapy of hypertension in transplant recipients. Elliott WJ. **J Hum Hypertens** 1998 Dec; 12(12):845-9 (44 ref.)

Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives [letter] Forette B. **J Hum Hypertens** 1999 Mar;13(3):211-3

Diabetes and hypertension: an era of clarity or confusion? Fox C. **J Hum Hypertens** 1999 Apr;13 Suppl 2:S9-17; discussion S25-8 (26 ref.)

Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators. Gasowski J, et al. **J Hum Hypertens** 1999 Feb;13(2):135-45

Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. Higashiura K, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S71-4

Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. Hilleman DE, et al. **J Hum Hypertens** 1999 Jul;13(7):477-83

Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. Holzgreve H, et al. **J Hum Hypertens** 1999 Jan;13(1):61-7

The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. Hughes D, et al. **J Hum Hypertens** 1998 Aug;12(8):533-7

Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension. Ibsen H. **J Hum Hypertens** 1998 Nov; 12(11):731-2

Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action. Inada Y, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S75-80 (34 ref.)

A randomised double-blind study comparing nifedipine GITS 20 mg and bendrofluazide 2.5 mg administered once daily in mild-to-moderate hypertension. Isles CG, et al. **J Hum Hypertens** 1999 Jan;13(1):69-73

Which elderly patients should be considered for anti-hypertensive treatment? An evidence-based approach. Jackson R. **J Hum Hypertens** 1998 Sep;12(9):607-13 (16 ref.)

Baroreflex sensitivity changes with calcium antagonist therapy in elderly subjects with isolated systolic hypertension. James MA, et al. **J Hum Hypertens** 1999 Feb;13(2):87-95

Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. Koch B, et al. **J Hum Hypertens** 1999 May;13(5):337-42

The 'Birmingham Hypertension Square' for the optimum choice of add-in drugs in the management of resistant hypertension [see comments] Lip GY, et al. **J Hum Hypertens** 1998 Nov;12(11):761-3. Comment in: J Hum Hypertens 1999 May;13(5):353-4.

Antihypertensive agents and left ventricular hypertrophy with 'usual' care in the population setting [comment] Lip GY. **J Hum Hypertens** 1999 Aug;13(8):497-8 (11 ref.). Comment on: J Hum Hypertens 1999 Aug;13(8):449-504.

Diuretic therapy for hypertension: a cancer risk? Lip GY, et al. **J Hum Hypertens** 1999 Jul;13(7):421-3 (23 ref.)

Beta-blockers in hypertension: to reappraise or to call a halt?

Lip GY. **J Hum Hypertens** 1998 Dec;12(12):799–801

Why beta-blockers are good for some patients with hypertension: a case study of a hypertensive patient with adrenergic paroxysmal atrial fibrillation [letter] Lip GY, et al. **J Hum Hypertens** 1998 Dec;12(12):867–8

The St George's Star' and 'Imploding Diamond' [letter; comment] MacGregor G. **J Hum Hypertens** 1999 May; 13(5):353–4. Comment on: J Hum Hypertens 1998 Nov;12(11):761–3.

Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. Millgård J, et al. **J Hum Hypertens** 1998 Aug; 12(8):511–6

Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation. Nold G, et al. **J Hum Hypertens** 1999 Mar; 13(3):173–7

Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan. Ogihara T, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S27–31; discussion S33–4 (42 ref.)

Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. Pool JL, et al. **J Hum Hypertens** 1999 Apr;13(4):275–81

Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. Preston RA, et al. **J Hum Hypertens** 1999 Apr;13(4):249–55

Intensive blood pressure/glucose control in type 2 diabetes: why is it so difficult to decrease coronary heart disease? Reaven GM. **J Hum Hypertens** 1999 Apr;13 Suppl 2:S19–23; discussion S25–8 (20 ref.)

Comparison between isosorbide dinitrate aerosol and nifedipine in the treatment of hypertensive emergencies. Rubio-Guerra AF, et al. **J Hum Hypertens** 1999 Jul; 13(7):473–6

Hypertension in black South Africans. Seedat YK. **J Hum Hypertens** 1999 Feb;13(2):96–103 (79 ref.)

Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. Sever PS. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S3–10; discussion S33–4

Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Singh RB, et al. **J Hum Hypertens** 1999 Mar;13(3):203–8

The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. Spargias K, et al. **J Hum Hypertens** 1999 Aug;13(8):511–6

Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. Starmans-Kool MJ, et al. **J Hum Hypertens** 1998 Aug;12(8):557–61

Hypertension in the elderly [comment] Stott DJ. **J Hum Hypertens** 1998 Oct;12(10):665–6. Comment on: J Hum Hypertens 1998 Oct;12(10):701–6.

Effects of losartan on hypertension and left ventricular mass: a long-term study [see comments] Tedesco MA, et al. **J Hum Hypertens** 1998 Aug;12(8):505–10. Comment in: J Hum Hypertens 1998 Aug;12(8):493–5.

Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. Vanmolkot FH, et al. **J Hum Hypertens** 1999 Aug; 13(8):559–63

The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. Villarosa IP, et al. **J Hum Hypertens** 1998 Sep;12(9):653–5 (20 ref.)

1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. **J Hypertens** 1999 Feb;17(2):151–83

Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats. Alvarez de Sotomayor M, et al. **J Hypertens** 1999 Jun;17(6):769–76

Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. Ambrosioni E, et al. **J Hypertens** 1998 Nov;16(11):1677–84

Effects of chronic long-term therapy with calcium antagonists on cytogenetic damage in humans. Andreassi MG, et al. **J Hypertens** 1999 Jun;17(6):843–6

Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. Birkenhäger WH, et al. **J Hypertens** 1999 Jul;17(7):873–81 (85 ref.)

Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Brown MJ, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2113–6

Hypertension optimal treatment (HOT) study: a brilliant concept, but a qualified success [see comments] Chalmers J. **J Hypertens** 1998 Oct;16(10):1403–5 (16 ref.). Comment in: J Hypertens 1998 Oct;16(10):1401–2.

Lacidipine reduces high blood pressure and the target organ damage induced by high fructose diet in rats. Cosenzi A, et al. **J Hypertens** 1999 Jul;17(7):965–71

Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. [corrected and republished with original paging, article originally printed in J Hypertens 1998 Sep;16(9):357–69] de Champlain J, et al. **J Hypertens** 1998 Nov; 16(11):1357–69

Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients [corrected and republished in J Hypertens 1998 Nov;16(11):1357–69] de Champlain J, et al. **J Hypertens** 1998 Sep;16(9):1357–69

Interaction between lifetime captopril treatment and NaCl-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. Fang Z, et al. **J Hypertens** 1999 Jul;17(7):983–91

Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). Galletti F, et al. **J Hypertens** 1999 Mar;17(3):439–45

Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. Gamble G, et al. **J Hypertens** 1998 Sep;16(9):1389–95

Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. Gerritsen TA, et al. **J Hypertens** 1998 May;16(5):689–96

Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. Gillies LK, et al. **J Hypertens** 1998 Apr; 16(4):477–86

A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. Girvin B, et al. **J Hypertens** 1998 Jul;16(7):1049–54

Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. Grassi G, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1789–96

Antihypertensive treatment and the prevention of dementia: further insights from the Syst-Eur trial [editorial] Hansson L. **J Hypertens** 1999 Mar;17(3):307–8 (8 ref.)

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. Hedner T, et al. **J Hypertens** 1999 Jan;17(1):129–36

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Karlberg BE, et al. **J Hypertens** 1999 Feb;17(2):293–302

Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. Kastarinen MJ, et al. **J Hypertens** 1998 Sep;16(9):1379–87

Calcium supplementation in patients with essential hypertension: assessment by office, home and ambulatory blood pressure. Kawano Y, et al. **J Hypertens** 1998 Nov; 16(11):1693–9

Is the use of placebo in antihypertensive drug studies ethical? [letter] Kisch ES. **J Hypertens** 1999 Jan;17(1):147

Undertreatment of hypertension in a population-based study in The Netherlands. Klungel OH, et al. **J Hypertens** 1998 Sep;16(9):1371–8

Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. Klungel OH, et al. **J Hypertens** 1998 Oct;16(10):1545–53

Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. Kyselovic J, et al. **J Hypertens** 1998 Oct;16(10):1515–22

Renal afferent arteriolar structure in the genetically hypertensive (GH) rat and the ability of losartan and enalapril to cause structural remodelling. Ledingham JM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1945–52

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. Liu L, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1823–9

Effects of antihypertensive therapy on factors mediating endothelium-dependent relaxation in rats treated chronically with L-NAME. Maeso R, et al. **J Hypertens** 1999 Feb;17(2):221–7

Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. Maeso R, et al. **J Hypertens** 1998 May; 16(5):665–72

Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. Marceau M, et al. **J Hypertens** 1998 May;16(5):673–9

Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. Naruse M, et al. **J Hypertens** 1999 Jan;17(1):53–60

Effect of the calcium channel blocker nitrendipine in normotensive and spontaneously hypertensive, diabetic rats on kidney morphology and urinary albumin excretion. Nielsen B, et al. **J Hypertens** 1999 Jul;17(7):973–81

Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators. Omboni S, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1831–8

L-arginine reverses severe nephrosclerosis in aged spontaneously hypertensive rats. Ono H, et al. **J Hypertens** 1999 Jan;17(1):121–8

Hypertension, antihypertensive drugs, and mortality from cancer among women. Peeters PH, et al. **J Hypertens** 1998 Jul;16(7):941–7

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Puig JG, et al. **J Hypertens** 1999 Jul;17(7):1033–9

Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. Rhéaume C, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2085–9

Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. Sharifi AM, et al. **J Hypertens** 1998 Apr;16(4):457–66

Influence of treated blood pressure on progression of silent cerebral infarction. Sugiyama T, et al. **J Hypertens** 1999 May;17(5):679–84

Nephroprotective effect of antihypertensive drugs in essential hypertension. Susic D, et al. **J Hypertens** 1998 May; 16(5):555–67 (182 ref.)

Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. Susic D, et al. **J Hypertens** 1999 Aug;17(8):1209–15

Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. Taddei S, et al. **J Hypertens** 1998 Apr;16(4):447–56

Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. Gastrointestinal Therapeutic System. Testa MA, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1839–47

Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Tsuchihashi T, et al. **J Hypertens** 1999 Jul;17(7):917–22

Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. Varo N, et al. **J Hypertens** 1999 Jan;17(1):107–14

Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. Waeber B, et al. **J Hypertens** 1999 Jul;17(7):1041–5

The ethics of using placebo in hypertension clinical trials [editorial] Weber MA. **J Hypertens** 1999 Jan;17(1):5–8 (15 ref.)

Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. Wiggam MI, et al. **J Hypertens** 1998 Nov;16(11):1651–7

The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Zanchetti A, et al. **J Hypertens** 1998 Nov; 16(11):1667–76

Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group. Zannad F, et al. **J Hypertens** 1999 Jan;17(1):137–46

Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. Zannad F, et al. **J Hypertens** 1999 Jul;17(7):1023–32

Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients. Beltman F, et al. **J Hypertens Suppl** 1998 Oct;16(6):S15–9

Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. Brooks DP, et al. **J Hypertens Suppl** 1999 Jun;17(2):S27–32 (63 ref.)

Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC Jr. **J Hypertens Suppl** 1999 Feb; 17(1):S37–43 (49 ref.)

Existing treatment strategies: does noncompliance make a difference? Caro JJ, et al. **J Hypertens Suppl** 1998 Sep; 16(7):S31–4 (17 ref.)

High blood pressure management: potential benefits of II agents. Esler M. **J Hypertens Suppl** 1998 Aug;16(3):S19–24 (47 ref.)

Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. Flack JM, et al. **J Hypertens Suppl** 1999 Feb;17(1):S19–24 (45 ref.)

The Hypertension Optimal Treatment study and the importance of lowering blood pressure. Hansson L. **J Hypertens Suppl** 1999 Feb;17(1):S9–13

Management of hypertension: the advent of a new angiotensin II receptor antagonist. Hedner T. **J Hypertens Suppl** 1999 Jun;17(2):S21–5 (28 ref.)

Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. Jennings G, et al. **J Hypertens Suppl** 1998 Oct;16(6):S29–34

A call to action for more aggressive treatment of hypertension. Lenfant C, et al. **J Hypertens Suppl** 1999 Feb;17(1):S3–7 (24 ref.)

The importance of systolic control: a new paradigm for effective blood pressure management. Introduction. McInnes G. **J Hypertens Suppl** 1999 Jun;17(2):S1

Clinical benefits of a consistent reduction in blood pressure. Mancia G, et al. **J Hypertens Suppl** 1998 Oct;16(6):S35–9 (15 ref.)

Can good surrogate end-points predict the prognosis of hypertensive patients? Mancia G, et al. **J Hypertens Suppl** 1998 Oct;16(5):S3–7 (38 ref.)

A rationale for treatment of endothelial dysfunction in hypertension. Ruschitzka F, et al. **J Hypertens Suppl** 1999 Feb;17(1):S25–35 (161 ref.)

Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood pressure Elevation: Regional and Global (EISBERG) project. Swales JD. **J Hypertens Suppl** 1999 Jun; 17(2):S15–9 (11 ref.)

Introduction: the role of calcium antagonists. van Zwieten PA. **J Hypertens Suppl** 1998 Oct;16(6):S1–2 (27 ref.)

A look through the new therapeutic window: irbesartan. Waeber B, et al. **J Hypertens Suppl** 1998 Sep;16(7):S11–6 (24 ref.)

Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension. Wang X, et al. **J Hypertens Suppl** 1998 Sep;16(4):S43–7

Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group. Ostman J, et al. **J Intern Med** 1998 Aug; 244(2):95–107

Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. Rantala AO, et al. **J Intern Med** 1999 Feb;245(2):163–74

Hypertension corner. Wide pulse pressure: diagnostic, prognostic and therapeutic implications [editorial] Birbari AE. **J Med Liban** 1998 Nov–Dec;46(6):303–5 (22 ref.)

Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. Prisant LM, et al. **J Natl Med Assoc** 1999 Jan;91(1):40–8

Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its major metabolites. Yeung PK, et al. **J Pharm Pharmacol** 1998 Nov; 50(11):1247–53

PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. Ferrari P, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1074–83

Renin profiling to predict response to antihypertensive therapy [letter; comment] Blaufox MD, et al. **JAMA** 1999 Mar 3;281(9):793–4. Comment on: JAMA 1998 Oct 7;280(13):1168–72.

Diuretics for hypertension [letter] Fisher J. **JAMA** 1999 Aug 11;282(6):523–4; discussion 525

Beta-blockers as first-line agents for hypertension in the elderly [letter; comment] Kendall MJ, et al. **JAMA** 1999 Jan 13;281(2):131–3. Comment on: JAMA 1998 Jun 17;279(23):1903–7.

Diuretics for hypertension [letter] Messerli FH, et al. **JAMA** 1999 Aug 11;282(6):523; discussion 525

Should beta-blockers be used to treat hypertension in elderly patients? [letter; comment] Shaughnessy AF, et al. **JAMA** 1999 Jun 2;281(21):1988–9. Comment on: JAMA 1999 Jan 13;281(2):114–6.

Diuretics for hypertension [letter] Simonovska S. **JAMA** 1999 Aug 11;282(6):524; discussion 525

Diuretics for hypertension [letter] Szekacs B, et al. **JAMA** 1999 Aug 11;282(6):524; discussion 525

Treatment of hypertension on the basis of home measurements: a case report. Kurata C, et al. **Jpn Circ J** 1998 Nov;62(11):858–9

Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. Tomita S, et al. **Jpn Heart J** 1999 Jan;40(1):55–63

Rearrangement of the ventricular capillary network in stroke-prone spontaneously hypertensive rats (SHRSP) following a late start of treatment with the angiotensin converting enzyme blocker temocapril. Xie Z, et al. **Jpn Heart J** 1998 Sep;39(5):699–706

Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat. Quest DW, et al. **Jpn J Pharmacol** 1998 Dec;78(4):479–86

Impact of hypertension guideline implementation on blood pressure control and drug use in primary care clinics. O'Connor PJ, et al. **Jt Comm J Qual Improv** 1999 Feb; 25(2):68–77

Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients. Wu SG, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Feb; 15(2):62–8

Urinary dopamine and renal handling of L-DOPA in fasted spontaneously hypertensive rats. Dantonello TM, et al. **Kidney Blood Press Res** 1998;21(6):438–44

Enalaprilat improves the impaired left ventricular pump function during exercise in hypertensives with coronary microangiopathy and with coronary artery disease. Franz I, et al. **Kidney Blood Press Res** 1998;21(6):452–8

Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the prague hypertensive rat. Heller J, et al. **Kidney Blood Press Res** 1998;21(6):445–51

Target blood pressure in the treatment of essential hypertension. Rahn KH, et al. **Kidney Blood Press Res** 1998;21(2–4):271–3 (10 ref.)

Supervised atenolol therapy in the management of hemodialysis hypertension. Agarwal R. **Kidney Int** 1999 Apr;55(4):1528–35

Calcium antagonists and renal disease [clinical conference] Epstein M. **Kidney Int** 1998 Nov;54(5):1771–84

Therapeutic implications and new perspectives for essential hypertension and renal damage. González-Albarrán O, et al. **Kidney Int Suppl** 1998 Dec;68:S46–50 (43 ref.)

Is uric acid really an independent cardiovascular risk factor? [letter; comment] Beevers DG, et al. **Lancet** 1998 Nov 7; 352(9139):1556. Comment on: Lancet 1998 Aug 29;352(9129):670–1.

CAPPP trial. Captopril Prevention Project [letter] Brown J, et al. **Lancet** 1999 May 22;353(9166):1795–6

Which drug for treatment of hypertension? [comment] Cutler J. **Lancet** 1999 Feb 20;353(9153):604–5. Comment on: Lancet 1999 Feb 20;353(9153):611–6.

Optimisation of antihypertensive treatment by crossover rotation of four major classes. Dickerson JE, et al. **Lancet** 1999 Jun 12;353(9169):2008–13

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial [see comments] Forette F, et al. **Lancet** 1998 Oct 24;352(9137):1347–51. Comment in: Lancet 1999 Jan 16;353(9148):235; discussion 236–7. Comment in: Lancet 1999 Jan 16;353(9148):235–6; discussion 236–7. Comment in: Lancet 1999 Jan 16;353(9148):236–7. Comment in: Lancet 1999 Apr 3;353(9159):1184. Comment in: ACP J Club 1999 May–Jun;130(3):57.

CAPPP trial. Captopril Prevention Project [letter] Gueyffier F, et al. **Lancet** 1999 May 22;353(9166):1795–6

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial [see comments] Hansson L, et al. **Lancet** 1999 Feb 20; 353(9153):611–6. Comment in: Lancet 1999 Feb 20;353(9153):604–5. Comment in: Lancet 1999 Jul 3;354(9172):73. Comment in: ACP J Club 1999 Jul–Aug;131(1):18.

Calcium antagonist and prevention of dementia in elderly people [letter; comment] Kario K, et al. **Lancet** 1999 Apr 3;353(9159):1184. Comment on: Lancet 1998 Oct 24;352(9137):1347–51. Comment on: Lancet 1999 Jan 16;353(9148):235–6; discussion 236–7.

Losartan and anaemia of end-stage renal disease [letter; comment] Lang SM, et al. **Lancet** 1998 Nov 21; 352(9141):1708. Comment on: Lancet 1998 Jul 25;352(9124):286.

Antihypertensive treatment [letter] Lesser GT. **Lancet** 1999 Sep 18;354(9183):1028; discussion 1028–9

Prevention of dementia: Syst-Eur trial [letter; comment] Leys D, et al. **Lancet** 1999 Jan 16;353(9148):236–7. Comment on: Lancet 1998 Oct 24;352(9137):1347–51.

CAPPP trial. Captopril Prevention Project [letter] Lim PO. **Lancet** 1999 May 22;353(9166):1793; discussion 1795–6

CAPPP trial. Captopril Prevention Project [letter] Messerli FH, et al. **Lancet** 1999 May 22;353(9166):1794–5; discussion 1795–6

Trends in prescribing calcium-channel blockers [letter; comment] Opie LH. **Lancet** 1998 Nov 21;352(9141):1708. Comment on: Lancet 1998 Sep 19;352(9132):943–8.

Prevention of dementia: Syst-Eur trial [letter; comment] Pahor M, et al. **Lancet** 1999 Jan 16;353(9148):235; discussion 236–7. Comment on: Lancet 1998 Oct 24;352(9137):1347–51.

Failure of randomisation by "sealed" envelope [letter; comment] Peto R. **Lancet** 1999 Jul 3;354(9172):73. Comment on: Lancet 1999 Feb 20;353(9153):611–6.

CAPPP trial. Captopril Prevention Project [letter] Scheen AJ. **Lancet** 1999 May 22;353(9166):1793–4; discussion 1795–6

ACE inhibitors and prevention of aspiration pneumonia in elderly hypertensives [letter; comment] Teramoto S, et al. **Lancet** 1999 Mar 6;353(9155):843. Comment on: Lancet 1998 Dec 12;352(9144):1937–8.

CAPPP trial. Captopril Prevention Project [letter] Wiggam MI, et al. **Lancet** 1999 May 22;353(9166):1794; discussion 1795–6

Prevention of dementia: Syst-Eur trial [letter; comment] [see comments] Zuccalà G, et al. **Lancet** 1999 Jan 16; 353(9148):235–6; discussion 236–7. Comment on: Lancet 1998 Oct 24;352(9137):1347–51. Comment in: Lancet 1999 Apr 3;353(9159):1184.

Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. Stimpel M, et al. **Maturitas** 1998 Sep 20;30(1):69–77

United Kingdom Prospective Diabetes Study: the end of the beginning? [editorial] Davis TM. **Med J Aust** 1998 Nov 16;169(10):511–2

Diuretics, beta-blockers and gin-and-tonic [letter; comment] Messerli FH. **Med J Aust** 1998 Sep 21;169(6):344. Comment on: Med J Aust 1998 Mar 2;168(5):232–5.

A new paradigm for funding cardiovascular-outcome research in general practice. The Second Australian National Blood Pressure Study. ANBP2 Management Committee [editorial] Reid CM, et al. **Med J Aust** 1998 Oct 5;169(7):349–50

Candesartan for hypertension. **Med Lett Drugs Ther** 1998 Nov 20;40(1040):109–10

Drugs for hypertension. **Med Lett Drugs Ther** 1999 Mar 12; 41(1048):23–8

Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. Mulvany MJ. **Metabolism** 1998 Dec;47(12 Suppl 1):20–3 (38 ref.)

Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Patel V, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):28–33

Capillary blood cell velocity in finger nailfold: effect of enalapril and mibefradil in patients with mild to moderate hypertension. Martina B, et al. **Microvasc Res** 1999 Mar; 57(2):94–9

Comparison of intravenous nifedipine and sodium nitroprusside for treatment of acute hypertension after cardiac surgery. Bertolissi M, et al. **Minerva Anestesiol** 1998 Jul–Aug;64(7–8):321–8

Inadequate management of blood pressure in a hypertensive population [see comments] Berlowitz DR, et al. **N Engl J Med** 1998 Dec 31;339(27):1957–63. Comment in: N Engl J Med 1999 May 20;340(20):1593; discussion 1594–5. Comment in: N Engl J Med 1999 May 20;340(20):1593–5.

Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure [see comments] Ligtenberg G, et al. **N Engl J Med** 1999 Apr 29; 340(17):1321–8. Comment in: N Engl J Med 1999 Apr 29;340(17):1360–1.

Inadequate management of blood pressure in a hypertensive population [letter; comment] Pinto-Sietsma SJ, et al. **N Engl J Med** 1999 May 20;340(20):1593–5. Comment on: N Engl J Med 1998 Dec 31;339(27):1957–63.

Calcium-channel blockade and hypertension [letter; comment] Salpeter S. **N Engl J Med** 1999 Jul 29; 341(5):372–3. Comment on: N Engl J Med 1999 Mar 4;340(9):677–84.

Inadequate management of blood pressure in a hypertensive population [letter; comment] Sechi LA, et al. **N Engl J Med** 1999 May 20;340(20):1593; discussion 1594–5 . Comment on: N Engl J Med 1998 Dec 31;339(27):1957–63.

Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators [see comments] Tuomilehto J, et al. **N Engl J Med** 1999 Mar 4;340(9):677–84. Comment in: N Engl J Med 1999 Jul 29;341(5):372–3.

Inadequate management of blood pressure in a hypertensive population [letter; comment] Ward HJ. **N Engl J Med** 1999 May 20;340(20):1593; discussion 1594–5. Comment on: N Engl J Med 1998 Dec 31;339(27):1957–63.

Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Ecder T, et al. **Nephrol Dial Transplant** 1999 May;14(5):1113–6

Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Holdaas H, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3096–102

Efficacy of antihypertensive therapy in decreasing renal and cardiovascular complications in diabetes mellitus. Nosadini R, et al. **Nephrol Dial Transplant** 1998;13 Suppl 8:44–8 (20 ref.)

Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension. Plum J, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:25–7

Hypertension in patients with cerebrovascular accident. To treat or not to treat? [editorial] Ringleb PA, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2179–81 (19 ref.)

A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function. Schulz E, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:27–8

Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Göteborg, Sweden [see comments] Siewert-Delle A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3084–90 . Comment in: Nephrol Dial Transplant 1998 Dec;13(12):3007–10.

Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Venkat-Raman G, et al. **Nephrol Dial Transplant** 1998 Oct; 13(10):2612–6

Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Rachmani R, et al. **Nephron** 1998 Oct;80(2):175–82

Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis axis in SHR and WKY rats. Durand M, et al. **Neuropharmacology** 1999 Jun;38(6):893–907

Effect of dopamine receptor anatagonists on the calcium-dependent central function that reduces blood pressure in spontaneously hypertensive rats. Sutoo D, et al. **Neurosci Lett** 1999 Jul 16;269(3):133–6

Adverse reactions to short-acting nifedipine in hypertensive crises [letter; comment] Spizzirri F, et al. **Pediatr Nephrol** 1999 May;13(4):366. Comment on: Pediatr Nephrol 1998 Apr;12(3):259.

Efficacy of amlodipine in pediatric patients with hypertension. Tallian KB, et al. **Pediatr Nephrol** 1999 May; 13(4):304–10

Influence of baseline values on lipids and lipoprotein changes during amlodipine treatment of hypertension. Ahaneku JE. **Pharmacol Res** 1998 Sep;38(3):179–82

Perioperative hypertension. Goldberg ME, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):911–4 (30 ref.)

Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension

or congestive heart failure? Nawarskas JJ, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):1041-52 (86 ref.)

Comparison of 24-hour ambulatory blood pressure data in hypertensive patients switched from nifedipine-GITS to nifedipine-CC. Wurdeman RL, et al. **Pharmacotherapy** 1999 Jan;19(1):94-100

The effect of multiple doses of "Biolactin" (prolactin) on the systolic blood pressure in rats with spontaneous arterial hypertension. Ryszka F, et al. **Pharmazie** 1998 Dec; 53(12):886

Antihypertensives. Daniels V, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):319-35, viii (104 ref.)

Heart disease in older patients. Pascual J. **Practitioner** 1998 Aug;242(1589):577, 580-2, 584, passim (10 ref.)

Special considerations in the therapy of diabetic hypertension. Guzmán CB, et al. **Prog Cardiovasc Dis** 1999 May-Jun;41(6):461-70 (75 ref.)

Compliance of patients with arterial hypertension to therapeutic recommendations. Więcek A. **Przegl Lek** 1998; 55 Suppl 1:65-6 (8 ref.) **(Eng, Pol)**

Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril. Steigerwalt RD Jr, et al. **Retina** 1998;18(6):539-45

Evaluation and treatment of hypertension. Chou CM. **Rheum Dis Clin North Am** 1999 Aug;25(3):521-37 (69 ref.)

Hypertension management of medical aid patients attending private practices. Edwards PR, et al. **S Afr Med J** 1999 Feb;89(2):160-4

Response of serum total renin to ramipril and metoprolol in hypertensive patients. Matinlauri IH, et al. **Scand J Clin Lab Invest** 1998 Dec;58(8):655-60

Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention. Foss OP, et al. **Scand J Prim Health Care** 1999 Jun;17(2):122-7

Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. Shohat J, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):57-62

Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. Morrow LE, et al. **South Med J** 1999 Sep;92(9):866-70

Simultaneous mucosal and small bowel angioedema due to captopril. Smoger SH, et al. **South Med J** 1998 Nov; 91(11):1060-3

Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials. Boutitie F, et al. **Stat Med** 1998 Dec 30;17(24):2883-903

Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension. Fagerberg B, et al. **Stroke** 1999 Feb;30(2):299-305

Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Klungel OH, et al. **Stroke** 1999 Jul;30(7):1312-8

Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Topouchian J, et al. **Stroke** 1999 May;30(5):1056-64

Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function--a pilot study. Gosse P, et al. **Therapie** 1999 Mar-Apr;54(2):217-22

Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Prisco D, et al. **Thromb Res** 1998 Aug 1;91(3):105-12

Effects of treatment with nilvadipine on cerebral ischemia in rats. Kawamura S, et al. **Tohoku J Exp Med** 1998 Aug; 185(4):239-46

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. Lowe FC, et al. **Urology** 1999 Jul;54(1):81-5

Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Tewari A, et al. **Urology** 1999 Mar;53(3 Suppl 3a):14-20; discussion 41-2 (88 ref.)

[Effects of plendil on serum oxygen free radicals and insulin resistance in patients with essential hypertension] Zhu X, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):30-2 (Eng. Abstr.) **(Chi)**

[Prevention and treatment of stroke after hypertension for ten years in Hunan Province] Sun M, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):312-4 (Eng. Abstr.) **(Chi)**

[Prevention and treatment of hypertension and coronary heart disease--therapeutic drug control] Huang X, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Sep; 17(9):515-8 **(Chi)**

[Mechanisms of yiqi tongluo pill on oxygen free radicals, nitric oxide and fibrinolysis in coronary heart diseases and hypertension patients] Shen JG, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jul; 17(7):410-3 (Eng. Abstr.) **(Chi)**

[Clinical study on combined treatment of shuizhi tuyuan powder and nifedipine in treating hypertension patients complicated with left ventricular hypertrophy] Wei AY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov;16(11):652-4 (Eng. Abstr.) **(Chi)**

[Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil] Li G, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):419-21, 424 (Eng. Abstr.) **(Chi)**

[Effects of lacidipine on serum oxygen free radicals and fasting levels of insulin in patients with essential hypertension] Liu S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):53-5, 58 (Eng. Abstr.) **(Chi)**

[The changes of intraerythrocyte calcium metabolism and their responses to nifedipine in patients with essential hypertension] Lu G, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(1):66-8 (Eng. Abstr.) **(Chi)**

[Effects of perindopril on hypertension, serum angiotensin-I-converting enzyme activity and urine level of N-acetyl-beta-D-glucosaminidase] Wang Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):233-6 (Eng. Abstr.) **(Chi)**

[Control of hypertension in the Czech part of the Pardubice-Augsburg Study] Matějka J, et al. **Vnitr Lek** 1998 Nov;44(11):633-6 (Eng. Abstr.) **(Cze)**

[Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study] Spinar J, et al. **Vnitr Lek** 1998 Jun;44(6):332-5 (Eng. Abstr.) **(Cze)**

[Changes in pharmacotherapy of hypertension 1989-1996 in patients with diabetes mellitus] Vlha R, et al. **Vnitr Lek** 1998 Apr;44(4):212-6 (Eng. Abstr.) **(Cze)**

[The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil] Widimský J, et al. **Vnitr Lek** 1998 Jun;44(6):326-31 (Eng. Abstr.) **(Cze)**

[Antihypertensive treatment of the elderly. Does it help?] Nielsen WB, et al. **Ugeskr Laeger** 1998 Oct 19; 160(43):6195-7 **(Dan)**

[Hypertension in the Negro patient] Timmers GJ, et al. **Ned Tijdschr Geneeskd** 1999 Jan 30;143(5):229-34 (37 ref.) (Eng. Abstr.) **(Dut)**

[Lowering of diastolic blood pressure < or = 90 mmHg should not be attempted, except in type 2 diabetics; the 'Hypertension optimal treatment' (HOT) trial (comment)] Wesseling H. **Ned Tijdschr Geneeskd** 1999 Jun 5; 143(23):1188-91 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1197-201. **(Dut)**

[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications (see comments)] Wolffenbuttel BH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1197-201 (20 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1188-91. **(Dut)**

[Efficacy and safety of indapamide 1.5 mg sustained release coated tablets in the therapy of arterial hypertension] Asmar R. **Ann Cardiol Angeiol (Paris)** 1998 Feb; 47(2):94-104 (Eng. Abstr.) **(Fre)**

[Study of the efficacy and safety of fosinopril in general practice in 19,435 hypertensive patients (FLIGHT Study)] Berdah J, et al. **Ann Cardiol Angeiol (Paris)** 1998 Mar; 47(3):169-75 (Eng. Abstr.) **(Fre)**

[The pharmaco-economics of the treatment of arterial hypertension: data and controversies] Rorive G, et al. **Bull Mem Acad R Med Belg** 1998;153(7-9):317-21; discussion 322-4 (Eng. Abstr.) **(Fre)**

[Hypotensive effects of a methanol extract of Bidens pilosa Linn on hypertensive rats] Dimo T, et al. **C R Acad Sci III** 1999 Apr;322(4):323-9 (Eng. Abstr.) **(Fre)**

[Choice of first line treatment for arterial hypertension: should one avoid dihydropyridines in diabetic patients?] Chatellier G, et al. **Diabetes Metab** 1998 Sep;24(4):370-5 (18 ref.) (Eng. Abstr.) **(Fre)**

[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension] Beaufils M, et al. **Drugs** 1998;56 Suppl 2:11-21 (30 ref.) (Eng. Abstr.) **(Fre)**

[Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension] Krivitzky A, et al. **Drugs** 1998;56 Suppl 2:31-43 (38 ref.) (Eng. Abstr.) **(Fre)**

[Hypertension: a new treatment combined with acetylsalicylic acid] Vervaeren J. **J Pharm Belg** 1998 Sep-Oct;53(5):309-14 **(Fre)**

[Antihypertensive treatment in type 1 diabetes and diabetic nephropathy] Chantrel F, et al. **Nephrologie** 1999; 20(4):203-8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Essential arterial hypertension treated with rilmenidin : what dose for what patient?] Amah G. **Presse Med** 1999 Jan 9;28(1):11-6 (Eng. Abstr.) **(Fre)**

[A case of typical flushing of atypical origin (letter)] Durand JM, et al. **Presse Med** 1999 Feb 13;28(6):281 **(Fre)**

[How far should arterial pressure in hypertension be lowered?] Mahé I, et al. **Presse Med** 1998 Nov 7;27(34):1736 **(Fre)**

[New requirements in the primary treatment of arterial hypertension: why do we need fixed low-dose combination therapy?] Vaisse B, et al. **Presse Med** 1999 Mar 6; 28(9):500-6 (Eng. Abstr.) **(Fre)**

[Double-blind placebo-controlled European trial for systolic hypertension--and prevention of dementia] Tzourio C. **Rev Epidemiol Sante Publique** 1999 Apr;47(2):191-2 **(Fre)**

[Which calcium antagonists for hypertension?] Degaute JP. **Rev Med Brux** 1998 Sep;19(4):A389-92 (12 ref.) (Eng. Abstr.) **(Fre)**

[Aging and regression of cardiac hypertrophy in the hypertensive patient] Du Cailar G, et al. **Rev Med Interne** 1998 Dec;19(12):870-7 (Eng. Abstr.) **(Fre)**

[Pharma-clinics. The drug of the month. Candesartan (Atacand)] Kulbertus H. **Rev Med Liege** 1999 Jun; 54(6):557-60 (18 ref.) (Eng. Abstr.) **(Fre)**

[Management of patients with hypertension resistant to treatment] Girerd X, et al. **Rev Prat** 1999 Mar 1; 49(5):527-31 (Eng. Abstr.) **(Fre)**

[Therapeutic trials in arterial hypertension] Gueyffier F. **Rev Prat** 1999 Mar 1;49(5):512-8 (Eng. Abstr.) **(Fre)**

[Treatment strategies in essential arterial hypertension] Waeber B. **Rev Prat** 1999 Mar 1;49(5):520-5 (Eng. Abstr.) **(Fre)**

[Families of antihypertensive drugs and blood pressure exercise profiles in black Africans at the National University Hospital of Cotonou] Attolou V, et al. **Sante** 1998 Sep-Oct;8(5):357-60 (Eng. Abstr.) **(Fre)**

[The goal in treating arterial hypertension] Waeber B, et al. **Schweiz Med Wochenschr** 1999 Jan 12;129(1-2):14-6 (9 ref.) **(Fre)**

[Fixed antihypertensive drug combinations] Waeber B. **Ther Umsch** 1999 Jan;56(1):33-6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations] Andréjak M, et al. **Therapie** 1998 May-Jun; 53(3):291-300 (60 ref.) (Eng. Abstr.) **(Fre)**

[Blood pressure regulation in stroke. Current aspects. 105th Congress of the German Society for Internal Medicine, Wiesbaden 12 April 1999] **Dtsch Med Wochenschr** 1999 Jul 9;124(27 Suppl):1-4 **(Ger)**

[Antihypertensive medication and sleep] Grote L. **Dtsch Med Wochenschr** 1998 Nov 13;123(46):1389-94 (50 ref.) **(Ger)**

[Antihypertensive therapy using a combination of angiotensin-1 receptor inhibitors and angiotensin-converting enzyme inhibitors (letter; comment)] Schute L. **Dtsch Med Wochenschr** 1998 Oct 23; 123(43):1295. Comment on: Dtsch Med Wochenschr 1998 May 22;123(21):681. **(Ger)**

[What blood pressure goal is sensible? Treatment of arterial hypertension--current results of the HOT Study (Hypertension Optimal Treatment Study)] Barenbrock M, et al. **Fortschr Med** 1998 Jul 20;116(20-21):35-7 **(Ger)**

[How can we lower blood pressure safely and effectively?] Dominiak P. **Fortschr Med** 1999 Feb 28;117(6):32-3 **(Ger)**

[Is everything clear in achieving blood pressure control? Consequences from the HOT Study for treatment of hypertension in general practice (interview by Eckhard Böttchen-Bühler)] Kolloch RE, et al. **Fortschr Med** 1998 Oct 20;116(29):43-6 **(Ger)**

[Study on intervention in arterial hypertension. Recommendations by experts and practical antihypertensive therapy. German Hypertension League] Trenkwalder P. **Fortschr Med** 1999 Feb 28;117(6):24, 25-8, 30 passim (Eng. Abstr.) **(Ger)**

[Combination therapy with ACE inhibitors and angiotensin receptor antagonists] Kisters K. **Internist (Berl)** 1999 Jun; 40(6):678-9 **(Ger)**

[A 73-year-old patient with hypertensive crisis. Was the use of calcium antagonist nifedipine justified?] Wenzel UO, et al. **Internist (Berl)** 1999 Feb;40(2):205-9 **(Ger)**

[Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension] Schmidt BM, et al. **Med Klin** 1998 Dec 15; 93(12):701-6 (Eng. Abstr.) **(Ger)**

[Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations] Siepmann M, et al. **Med Klin** 1998 Dec 15;93(12):733-7 (57 ref.) **(Ger)**

[New objectives in hypertensive therapy (editorial)] Heinzl S. **Med Monatsschr Pharm** 1999 Feb;22(2):29 **(Ger)**

[Therapy of the hypertensive crisis] Ziegler R. **Med Monatsschr Pharm** 1999 Jun;22(6):190-1 **(Ger)**

[Single daily dose of calcium antagonist is enough. Advantage for compliance and blood pressure lowering] von Renteln-Kruse W. **MMW Fortschr Med** 1999 Jun 17; 141(24):49 **(Ger)**

[Regression of left ventricular hypertrophy with antihypertensive therapy] Follath F. **Ther Umsch** 1998 Sep; 55(9):539-41 (Eng. Abstr.) **(Ger)**

[Calcium antagonists in cardiovascular diseases--a valuable controversy, but unnecessary panic] Messerli FH. **Ther Umsch** 1999 Jan;56(1):43-8 (31 ref.) (Eng. Abstr.) **(Ger)**

[Calcium antagonists and hypertension: in search of absolute certainty (editorial)] Mayer G. **Wien Klin Wochenschr** 1998 Oct 2;110(18):621-4 (16 ref.) **(Ger)**

[Results after PTCA. Therapy of essential hypertension with additional effects] **Z Kardiol** 1998 Nov;87(11 Suppl Therapie):1-4 **(Ger)**

[Sublingual nitroglycerin or intravenous enalaprilat in preclinical treatment of hypertensive patients with pulmonary edema] Hirschl MM, et al. **Z Kardiol** 1999 Mar; 88(3):208-14 (Eng. Abstr.) **(Ger)**

[Comparative study of the reno-protective effect of short- and long-acting antihypertensive agents in IgA

nephropathy] Vas T, et al. **Orv Hetil** 1999 Sep 5; 140(36):1991–5 (Eng. Abstr.) **(Hun)**

[Arterial hypertension and cardiac pathology. Diagnostic and therapeutic guidelines presented by the Joint Commission of the ANMCO–SIC–SIIA. Assoziane Nazionale Medici Cardiologi Ospedalieri. Società Italiana di Cardiologia. Società Italiana dell'Ipertensione Arteriosa] Agabiti–Rosei E, et al. **G Ital Cardiol** 1999 Mar;29(3):341–56 **(Ita)**

[Pre– and postoperative treatment of hypertensive crisis] Veglio F, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):22–7 (17 ref.) **(Ita)**

[The pharmacotherapy of arterial hypertension and the prevention of cardiovascular events. From evidence–based medicine to the new therapeutic opportunities] Taddei S. **Recenti Prog Med** 1999 Jan;90(1):4–8 (15 ref.) **(Ita)**

[Treatment of hypertension with complications] Abe I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):277–84 (5 ref.) **(Jpn)**

[Current topics on hypertension. At the conclusion of the 1998 meeting of the WHO/ISH Guideline Committee on the management of mild hypertension] Arakawa K. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):303–4 **(Jpn)**

[A message from JNCVI (Joint National Committee–VI) on the treatment of hypertension] Haneda T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):247–54 (5 ref.) **(Jpn)**

[Hypertension therapy and molecular biology––with special reference to renin–angiotensin system] Matsubara H. **Nippon Naika Gakkai Zasshi** 1999 May 10;88(5):920–7 (23 ref.) **(Jpn)**

[Antihypertensive treatment considering the home– and ambulatory blood pressure determination] Nagai K, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):262–8 (11 ref.) **(Jpn)**

[Treatment of hypertension in the aged] Shimada K. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):285–90 (5 ref.) **(Jpn)**

[New trends in management and treatment of hypertension (JNC–VI and the current status in Japan)] Shimamoto K. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):401–5 (8 ref.) **(Jpn)**

[Timing for the start of antihypertensive therapy and the antihypertensive goal] Tsukiyama H, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):269–76 (5 ref.) **(Jpn)**

[Selection of antihypertensive agents in relation to organ protection] Uehara Y. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):291–8 (7 ref.) **(Jpn)**

[Comparison with other antihypertensive drugs, especially with ACEI] Hiwada K. **Nippon Rinsho** 1999 May; 57(5):1187–93 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The usefulness of a new class antihypertensive drug, angiotensin II receptor antagonist,- for essential hypertension] Rakugi H, et al. **Nippon Rinsho** 1999 May; 57(5):1141–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Angiotensin II receptor antagonists: a review of the development and future perspective] Saito I, et al. **Nippon Rinsho** 1999 May;57(5):1015–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Multicenter prospective survey of prognosis of hypertensive elderly outpatient under antihypertensive treatment––morbidity and mortality of cardiovascular diseases and cancer] Ogihara T, et al. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):342–52 (Eng. Abstr.) **(Jpn)**

[The HOT–debate, and so what? (letter)] Dyrdal A. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):999–1000 **(Nor)**

[Therapeutic goals for blood pressure in the press] Gulbrandsen P, et al. **Tidsskr Nor Laegeforen** 1998 Aug 30;118(20):3101 **(Nor)**

[Therapeutic targets for hypertension in the new media. An optimal antihypertensive therapy] Kjeldsen SE. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3665 **(Nor)**

[An overview of hypertension studies with calcium antagonists] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1999 May 20;119(13):1878–82 (36 ref.) (Eng. Abstr.) **(Nor)**

[The HOT study. Can increased therapeutic intensity be dangerous?] Klovning A, et al. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4405–6 **(Nor)**

[The HOT study (letter)] Klovning A, et al. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):407 **(Nor)**

[Has the HOT study taught us something new?] Thelle DS. **Tidsskr Nor Laegeforen** 1999 Jan 30;119(3):353 **(Nor)**

[Therapeutic targets in the management of blood pressure are constant (letter)] Wensaas KA. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4413–4 **(Nor)**

[Clinical pharmacology of hypotensive drugs acting on central imidazoline receptors] Drzewoski J, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):561–9 (35 ref.) **(Pol)**

[Views on the use of calcium channel blockers in the treatment of heart ischemia and hypertension (editorial)] Halawa B. **Pol Merkuriusz Lek** 1998 Sep;5(27):107–10 (36 ref.) (Eng. Abstr.) **(Pol)**

[Cytoprotection of the endothelium cells in primary hypertension] Kwiecień J. **Pol Merkuriusz Lek** 1998 Sep; 5(27):151–4 (28 ref.) (Eng. Abstr.) **(Pol)**

[Antihypertensive drug therapy in relation to lipid disorders] Kawecka–Jaszcz K, et al. **Przegl Lek** 1998;55(2):85–8 (18 ref.) (Eng. Abstr.) **(Pol)**

[Copper, zinc and vitamin C concentrations in polymorphonuclear granulocytes after administration of therapeutic doses of nifedipine in patients with primary hypertension] Misiewicz A, et al. **Wiad Lek** 1998; 51(11–12):480–3 (Eng. Abstr.) **(Pol)**

[Antihypertensive treatment. Prescription and cost of drugs. Survey in a tertiary care hospital] Akashi D, et al. **Arq Bras Cardiol** 1998 Jul;71(1):55–7 (Eng. Abstr.) **(Por)**

[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension] Luna RL, et al. **Arq Bras Cardiol** 1998 Oct; 71(4):601–8 (Eng. Abstr.) **(Por)**

[Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study] Santello JL, et al. **Arq Bras Cardiol** 1998 Nov;71(5):713–6 (Eng. Abstr.) **(Por)**

[The additional efficacy of the nifedipine–diuretic combination depends on the potency of the drug administered first and not the sequence of administration. A double blind study in salt–sensitive black hypertensives] Damasceno A, et al. **Rev Port Cardiol** 1999 Jan;18(1):9–19 (Eng. Abstr.) **(Por)**

[Recommended article of the month: Effects of intensive blood–pressure lowering and low–dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial (editorial)] Maldonado J. **Rev Port Cardiol** 1998 Oct;17(10):843–4 **(Por)**

[Is the J–curve important in the treatment of the patient with arterial hypertension?] Nazaré J. **Rev Port Cardiol** 1999 Apr;18(4):401–4 (17 ref.) (Eng. Abstr.) **(Por)**

[Therapy of arterial hypertension with angiotensin receptor blockers] Nobre FL. **Rev Port Cardiol** 1999 Apr; 18(4):407–12 (23 ref.) (Eng. Abstr.) **(Por)**

[Effect of Polyosm preparation on the viscoelastic properties of the craniospinal system in the model of acute hypertensive encephalopathy] Plotnikov MB, et al. **Biull Eksp Biol Med** 1999 May;127(5):499–502 **(Rus)**

[New approaches in correcting disorders of higher integrative brain functions in the pharmacotherapy of arterial hypertension with propranolol] Petrov VI, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):10–2 (Eng. Abstr.) **(Rus)**

[Effects of angiotensin II receptors antagonist losartan on metabolism and morphofunctional condition myocardium in hypertensive patients] Didenko VA, et al. **Klin Med (Mosk)** 1998;76(9):33–7 **(Rus)**

[Prestarium treatment of essential hypertension] Kakhnovskii IM, et al. **Klin Med (Mosk)** 1998;76(9):52–4 (Eng. Abstr.) **(Rus)**

[Optimization of hypotensive therapy in hypertensive patients with new beta–1 selective long–acting adrenoblocker] Karazhanova LK, et al. **Klin Med (Mosk)** 1998;76(8):40–2 (Eng. Abstr.) **(Rus)**

[24 hour arterial pressure monitoring vs occasional measurements in comparative assessment of hypotensive treatment efficacy] Mazur ES, et al. **Klin Med (Mosk)** 1999; 77(7):50–2 (Eng. Abstr.) **(Rus)**

[Hemodynamic chronosensitivity to metopress–retard in patients with stage ii hypertension] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1998;76(10):42–4 (Eng. Abstr.) **(Rus)**

[Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1998;76(12):49–51 (Eng. Abstr.) **(Rus)**

[Clinical effect of prostenon in patients with resistant arterial hypertension and target organs complications] Zelnalov FM. **Klin Med (Mosk)** 1999;77(4):13–5 **(Rus)**

[Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan] Koval' SN, et al. **Lik Sprava** 1999 Mar;(2):117–20 (Eng. Abstr.) **(Rus)**

[The Berlipril and Retalzem treatment of hypertension patients: the dynamics of the clinico–hemodynamic indices and of the vasodilating humoral factors] Koval' SN, et al. **Lik Sprava** 1999 Jan–Feb;(1):113–7 (Eng. Abstr.) **(Rus)**

[The effect of enalapril maleate on the lipid peroxidation processes and on the body's antioxidant system in patients with hypertension] Shapovalova SA. **Lik Sprava** 1999 Jan–Feb;(1):41–4 (Eng. Abstr.) **(Rus)**

[The rational selection of beta–blockers in the treatment of hypertension] **Ter Arkh** 1999;71(2):57–64 **(Rus)**

[Betaxolol treatment of hypertension in postmenopausal women] Bystrova MM, et al. **Ter Arkh** 1999;71(6):67–9 (Eng. Abstr.) **(Rus)**

[Treatment of mild and moderate hypertension with enalapril (multicenter study of enap and enap N in Ukraine)] Dziak GV, et al. **Ter Arkh** 1999;71(1):31–4 (Eng. Abstr.) **(Rus)**

[Current conception of arterial hypertension treatment in pregnancy] Eliseev OM. **Ter Arkh** 1998;70(9):29–35 (0 ref.) **(Rus)**

[New prospects in the treatment of arterial hypertension. Antagonist of angiotensin II valsartan (diovan)] Ivleva AIa. **Ter Arkh** 1998;70(9):85–8 (26 ref.) **(Rus)**

[The hypotensive effect and tolerance of valsartan (Diovan) in hypertension in a general clinical practice] Ivleva AIa, et al. **Ter Arkh** 1999;71(2):67–70 (Eng. Abstr.) **(Rus)**

[Changes in blood pressure 24 hour monitoring data and quality of life in patients with systolic hypertension treated with arifon] Kobalova ZhD, et al. **Ter Arkh** 1998;70(9):67–9 (Eng. Abstr.) **(Rus)**

[Ramipril effects on 24 hour profile of blood pressure in patients with mild and moderate hypertension] Kukushkin SK, et al. **Ter Arkh** 1998;70(9):69–71 (Eng. Abstr.) **(Rus)**

[Isoptin. Evolution of views from Fleckenstein to the present days] Makolkin VI, et al. **Ter Arkh** 1998;70(10):79–81 **(Rus)**

[Long–term monotherapy with prestarium, anap and lomir in patients with mild and moderate arterial hypertension: clinical efficacy, hemodynamics and morphofunctional parameters of heart] Nesterov IuI, et al. **Ter Arkh** 1998; 70(9):64–7 (Eng. Abstr.) **(Rus)**

[Diovan efficacy and tolerance in mild and moderate hypertension] Zakirova AN, et al. **Ter Arkh** 1999;71(4):41–4 (Eng. Abstr.) **(Rus)**

[Celiprolol improves glucose metabolism in essential hypertension] Okša A, et al. **Vnitr Lek** 1998 Feb;44(2):63–7 (Eng. Abstr.) **(Slo)**

[Fixed–dosage combinations in the treatment of hypertension] Muiño Miguez A, et al. **An Med Interna** 1999 Feb; 16(2):92–6 (31 ref.) (Eng. Abstr.) **(Spa)**

[Has the control of arterial hypertension improved in recent years?] Boj Casajuana J, et al. **Aten Primaria** 1999 May 15;23(8):507–8 **(Spa)**

[Evaluation of 3 strategies to improve therapeutic compliance of patients with essential hypertension (letter)] Pertusa Martinez S, et al. **Aten Primaria** 1998 Dec;22(10):670–1 **(Spa)**

[The use of drugs as a risk factor for poorly controlled arterial hypertension] Sanfélix Genovés J, et al. **Aten Primaria** 1998 Sep 30;22(5):293–7 (Eng. Abstr.) **(Spa)**

[Should we continue to lower arterial blood pressure with calcium antagonists? (letter)] Sempere Verdú E, et al. **Aten Primaria** 1998 Nov 15;22(8):540–2 **(Spa)**

[Comments on guide No. 1, the Adult Program (letter)] Sobrino E, et al. **Aten Primaria** 1998 Sep 30;22(5):324 **(Spa)**

[Relationship between sympathetic activity and response to treatment with atenolol in hypertensive patients. Investigation group of the study of efficiency and tolerance of atenolol in hypertensive patients with increase in the sympathetic activity] de la Sierra A. **Med Clin (Barc)** 1999 Jun 19;113(2):41–5 (Eng. Abstr.) **(Spa)**

[Antihypertensive drugs in primary care (letter)] Gérvas J, et al. **Med Clin (Barc)** 1998 Sep 5;111(6):236–7 **(Spa)**

[Relationship between medical treatment compliance and the degree of control in patients with high blood pressure, non–insulin dependent diabetes mellitus and dyslipidemia] Piñeiro F, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):565–7 (Eng. Abstr.) **(Spa)**

[Evidence–based medicine and anti–hypertensive treatments (letter; comment)] Zambrana Garcia JL, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):597. Comment on: Med Clin (Barc) 1998 Feb 28;110(7):247–53. Comment on: Med Clin (Barc) 1998 Feb 28;110(7):259–62. **(Spa)**

[Ketoconazole in the control of arterial hypertension in Cushing's syndrome] Calvo Romero JM, et al. **Rev Clin Esp** 1999 Jan;199(1):25–7 (Eng. Abstr.) **(Spa)**

[Repercussions in clinical practice of the results of the HOT (Hypertension Optimal Treatment) study] Coca A. **Rev Esp Cardiol** 1999 Jun;52(6):375–80 (Eng. Abstr.) **(Spa)**

[New guidelines from the World Health Organization and the International Society of Hypertension for the management of hypertension: toward common guidelines (editorial)] Suárez C, et al. **Rev Esp Cardiol** 1999 Jun; 52(6):381–2 **(Spa)**

[New multicentric studies in hypertension] Román O. **Rev Med Chil** 1998 Oct;126(10):1238–46 (63 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Pharmacoeconomic issues in antihypertensive therapy. Giles TD. **Am J Cardiol** 1999 Jul 22;84(2A):25K–28K (10 ref.)

The cost of treating hypertension: can we keep it under control without compromising the level of care? Moser M. **Am J Hypertens** 1998 Aug;11(8 Pt 2):120S–127S; discussion 135S–137S (29 ref.)

ACE inhibitor switch in an indigent community clinic [letter] Knight MR, et al. **Ann Pharmacother** 1999 Jul–Aug; 33(7–8):872–3

An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Ramsey SD, et al. **J Am Board Fam Pract** 1999 Mar–Apr;12(2):105–14

Establishing a cost estimation model for hypertension and its related diseases in Taiwan. Yang MC, et al. **J Formos Med Assoc** 1999 Jun;98(6):394–402

The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. Hughes D, et al. **J Hum Hypertens** 1998 Aug;12(8):533–7

Long–term cost and life–expectancy consequences of hypertension [see comments] Kiiskinen U, et al. **J Hypertens** 1998 Aug;16(8):1103–12. Comment in: J Hypertens 1998 Aug;16(8):1099–100.

Long–term cost and life–expectancy consequences of hypertension [comment] Simpson FO. **J Hypertens** 1998 Aug;16(8):1099–100. Comment on: J Hypertens 1998 Aug;16(8):1103–12.

[Socioeconomic and quality of life repercussions of arterial hypertension] Selke B, et al. **Drugs** 1998;56 Suppl 2:45–53

(38 ref.) (Eng. Abstr.) **(Fre)**

[Antihypertensive treatment. Prescription and cost of drugs. Survey in a tertiary care hospital] Akashi D, et al. **Arq Bras Cardiol** 1998 Jul;71(1):55–7 (Eng. Abstr.) **(Por)**

[Description of costs and effectiveness of a hypertension control program in primary care] Bonet Plá A, et al. **Aten Primaria** 1998 Nov 15;22(8):497–504 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

alpha-Tocopherol increased nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats. Newaz MA, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):839–44

In vivo regulation of protein-serine kinases by insulin in skeletal muscle of fructose-hypertensive rats. Bhanot S, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E299–307

Combined SSCP and heteroduplex analysis of the human plasma membrane Ca(2+)-ATPase isoform 1 in patients with essential hypertension. Benkwitz C, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):515–20

Aldosterone stimulates Na,K-ATPase activity in basolateral membrane of rat kidney. Seok JH, et al. **Biochem Mol Biol Int** 1998 Aug;45(5):879–85

Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Fukai T, et al. **Circ Res** 1999 Jul 9;85(1):23–8

Interstrain differences in angiotensin I-converting enzyme mRNA and activity levels. Comparison between stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. Costerousse O, et al. **Clin Exp Hypertens** 1999 May;21(4):377–93

Decrease with age in frequency of the homozygous deletional angiotensin-converting enzyme genotype in hypertensive patients. Cheung BM, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):928–31

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Wallis EJ, et al. **Clin Pharmacol Ther** 1998 Oct;64(4):439–49

Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Margolius HS. **Clin Rev Allergy Immunol** 1998 Winter;16(4):337–49 (57 ref.)

Relationship between neuropathy, hypertension and red blood cell Na/K ATPase in patients with insulin-dependent diabetes mellitus. Jannot MF, et al. **Diabetes Metab** 1999 Mar;25(1):35–42

Structure and mechanism of action and inhibition of steroid dehydrogenase enzymes involved in hypertension. Duax WL, et al. **Endocr Res** 1998 Aug-Nov;24(3–4):521–9

Vascular mitogen-activated protein kinase activity is enhanced via angiotensin system in spontaneously hypertensive rats. Kubo T, et al. **Eur J Pharmacol** 1999 May 21;372(3):279–85

Renal effects of cP450 arachidonate metabolites in the Lyon hypertensive rat. Monneret G, et al. **Fundam Clin Pharmacol** 1999;13(2):226–31

Insulin resistance and angiotensin converting enzyme polymorphism in Japanese hypertensive subjects. Yamamoto J, et al. **Hypertens Res** 1999 Jul;22(2):81–4

Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. Healy DP, et al. **Hypertension** 1999 Feb;33(2):740–5

Renal 11beta-hydroxysteroid dehydrogenase in genetically salt-sensitive hypertensive rats. Takeda Y, et al. **Hypertension** 1998 Dec;32(6):1077–82

Regulation of the genes for 11beta-hydroxysteroid dehydrogenase type 1 and type 2 in the kidney of the Dahl rat. Franco-Saenz R, et al. **J Hypertens** 1999 Aug; 17(8):1089–93

Decrease in glutamic acid decarboxylase level in the hypothalamus of spontaneously hypertensive rats. Horn EM, et al. **J Hypertens** 1998 May;16(5):625–33

No linkage of the lipoprotein lipase locus to hypertension in Caucasians. Hunt SC, et al. **J Hypertens** 1999 Jan; 17(1):39–43

Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats. Liu Y, et al. **J Hypertens** 1998 Aug;16(8):1165–73

Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. Montgomery HE, et al. **J Hypertens** 1998 May;16(5):635–43

Differentially-altered vascular guanylate cyclase isoforms in experimental hypertensive rats. Lee J, et al. **J Korean Med Sci** 1999 Aug;14(4):386–92

Evidence for the involvement of protein kinase C in depression of endothelium-dependent vascular responses in spontaneously hypertensive rats. Soloviev AI, et al. **J Vasc Res** 1998 Sep-Oct;35(5):325–31

Altered renal expression of nitric oxide synthase isozymes in spontaneously hypertensive rats. Kim SW, et al. **Korean J Intern Med** 1999 Jan;14(1):21–6

Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats. Seki T, et al. **Life Sci** 1999;65(10):1077–86

[Expression of mitogen-activated protein kinase in hypertrophic myocardium in SHRsp] Wang M, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):680–2 (Eng. Abstr.) **(Chi)**

[Polymorphism of angiotensin-converting enzyme and endothelial nitric oxide synthase genes in people with arterial hypertension, left ventricular hypertrophy, and hypertrophic cardiomyopathy] Stepanov VA, et al. **Genetika** 1998 Nov;34(11):1578–81 (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia. Pontiroli AE, et al. **Acta Diabetol** 1998 Oct;35(3):130–6

Some aspects of the pattern of systemic hypertension in the adult population of Gassim, Saudi Arabia: age distribution of the subsets of hypertensives. Soyannwo MA, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):17–21

Contrasting influence of the living environment and gender on systemic hypertension in Saudi population of Gassim, Saudi Arabia. Soyannwo MA, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3–4):145–52

Weight cycling, weight gain, and risk of hypertension in women. Field AE, et al. **Am J Epidemiol** 1999 Sep 15; 150(6):573–9

Plasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Zheng ZJ, et al. **Am J Epidemiol** 1999 Sep 1;150(5):492–500

Epidemiology of risk in hypertensives: experience in treated patients. Alderman MH, et al. **Am J Hypertens** 1998 Jul; 11(7):874–6

Prevalence of hypertension in chronic cocaine users. Brecklin CS, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1279–83

Detection, treatment, and control of adult hypertension in northwest Indiana. Ispat Inland/United Steelworkers of America Health Care Network. Elliott WJ, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):830–4

Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study. Monitorización Ambulatoria de la Presión Arterial (MAPA)-Area 5 Working Group. Martinez MA, et al. **Am J Hypertens** 1999 Mar;12(3):251–9

Microalbuminuria and hypertension in nondiabetic Japanese men. Nishijo M, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):16–20

Prevention of cardiovascular disease in hypertensive patients with normal renal function. Wright JT Jr, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S66–79 (121 ref.)

Relationship between birthweight and blood pressure in childhood. Yiu V, et al. **Am J Kidney Dis** 1999 Feb; 33(2):253–60

Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Tomura S, et al. **Am J Nephrol** 1999;19(1):13–20

The contribution of baseline weight and weight gain to blood pressure change in African Americans: the Pitt County Study. Curtis AB, et al. **Ann Epidemiol** 1998 Nov; 8(8):497–503

Influence of calcium intake on gestational hypertension. Ortega RM, et al. **Ann Nutr Metab** 1999;43(1):37–46

Repair of coarctation of the aorta during infancy minimizes the risk of late hypertension. Seirafi PA, et al. **Ann Thorac Surg** 1998 Oct;66(4):1378–82

Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents. SAGE (Systematic Assessment of Geriatric Drug Use via Epidemiology) Study Group [see comments] Gambassi G, et al. **Arch Intern Med** 1998 Nov 23;158(21):2377–85. Comment in: Arch Intern Med 1999 Jul 26;159(4):1621–2.

Prevalence of high blood pressure and associated coronary risk factors in an adult population of Mexico City. Yamamoto-Kimura L, et al. **Arch Med Res** 1998 Winter; 29(4):341–9

The prevalence of isolated systolic hypertension in patients 60 years of age and over attending Australian general practitioners [see comments] Howes LG, et al. **Blood Press** 1998 May;7(3):139–43. Comment in: Blood Press 1998 May;7(3):131–2.

Emergence of Western diseases in the tropical world: the experience with chronic cardiovascular diseases. Forrester T, et al. **Br Med Bull** 1998;54(2):463–73 (22 ref.)

High amplitude of R waves in electrocardiograms, and overload related to heaviness of work in the population of maritime workers. Waśkiewicz J. **Bull Inst Marit Trop Med Gdynia** 1998;49(1-4):77–85

Hypertension in Canada. Carew M, et al. **Can Fam Physician** 1999 Jul;45:1756–8, 1766–9 **(Eng, Fre)**

The diagnosis of renal cell cancer in relation to hypertension (United States). Rosenberg L, et al. **Cancer Causes Control** 1998 Dec;9(6):611–4

Hypertension in the elderly. Cushman WC, et al. **Cardiol Clin** 1999 Feb;17(1):79–92, viii (54 ref.)

Hemodynamic instability following carotid endarterectomy does not affect early discharge. Scheinman M, et al. **Cardiovasc Surg** 1998 Oct;6(5):470–4

Effect of hypertension on mortality in Pima Indians. Sievers ML, et al. **Circulation** 1999 Jul 6;100(1):33–40

Trends in the prevalence and treatment of hypertension in Halifax County from 1985 to 1995 [see comments] Wolf HK, et al. **CMAJ** 1999 Sep 21;161(6):699–704. Comment in: CMAJ 1999 Sep 21;161(6):713–4.

Hypertension in the transplanted patient. Zeier M, et al. **Contrib Nephrol** 1998;124:146–57; discussion 158–65 (86 ref.)

Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Collado-Mesa F, et al. **Diabet Med** 1999 Jan;16(1):41–8

Glucose intolerance and associated factors in the Fergana Valley, Uzbekistan. King H, et al. **Diabet Med** 1998 Dec; 15(12):1052–62

Association of waist circumference with risk of hypertension and type 2 diabetes in Nigerians, Jamaicans, and African-Americans [see comments] Okosun IS, et al. **Diabetes Care** 1998 Nov;21(11):1836–42. Comment in: Diabetes Care 1999 May;22(5):876–7.

Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Suematsu C, et al. **Diabetes Care** 1999 Feb; 22(2):228–32

Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study [comment] Yarbrough DE, et al. **Diabetes Care** 1998 Oct;21(10):1652–8. Comment on: Diabetes Care 1998 Jan;21(1):157–9. Comment on: Diabetes Care 1998 Jan;21(1):179–82.

Peripheral neuropathy, hypertension, foot ulcers and amputations among Saudi Arabian patients with type 2 diabetes. Nielsen JV. **Diabetes Res Clin Pract** 1998 Jul; 41(1):63–9

Hypertensive disorders of pregnancy at Umtata General Hospital: perinatal and maternal outcomes. Buga GA, et al. **East Afr Med J** 1999 Apr;76(4):217–22

The prevalence of hypertension and the state of cardiovascular health in Venezuela and surrounding nations. Hernández-Hernández R, et al. **Ethn Dis** 1998 Autumn;8(3):398–405

Blood pressure and hypertension in rural and urban Sierra Leoneans. Lisk DR, et al. **Ethn Dis** 1999 Spring-Summer; 9(2):254–63

The prevalence of hypertension and the status of cardiovascular health in South Africa. Seedat YK. **Ethn Dis** 1998 Autumn;8(3):394–7

Status of health and prevalence of hypertension in Brazil. Yunis C, et al. **Ethn Dis** 1998 Autumn;8(3):406–12

Regional disparities in cardiovascular risk factors in France: a five-year analysis of the GAZEL cohort. Tran PD, et al. **Eur J Epidemiol** 1998 Sep;14(6):535–43

Non-traumatic intracerebral hemorrhage in young adults living in Guayaquil, Ecuador (South America): analysis of 151 patients. Del Brutto OH, et al. **Funct Neurol** 1999 Jan-Mar;14(1):21–8

Smoking, hemoglobin concentration and pregnancy-induced hypertension. Rasmussen S, et al. **Gynecol Obstet Invest** 1998;46(4):225–31

Blood pressure change in Africa: case study from Nigeria. Kaufman JS, et al. **Hum Biol** 1999 Aug;71(4):641–57

The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Salha O, et al. **Hum Reprod** 1999 Sep;14(9):2268–73

Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Banegas JR, et al. **Hypertension** 1998 Dec;32(6):998–1002

Arterial hypertension in correlation with age and body mass index in some occupational groups in the harbour of Rijeka, Croatia. Skrobonja A, et al. **Ind Health** 1998 Oct; 36(4):312–7

Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Singh RB, et al. **Int J Cardiol** 1998 Sep 1;66(1):65–72

Increased blood pressure in adolescents who were small for gestational age at birth: a cohort study in Brazil. Barros FC, et al. **Int J Epidemiol** 1999 Aug;28(4):676–81

High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Fagot-Campagna A, et al. **Int J Epidemiol** 1998 Oct; 27(5):808–13

Association of fetal gender with pregnancy-induced hypertension and pre-eclampsia. Makhseed M, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):55–6

Obesity, body fat distribution and body build: their relation to blood pressure and prevalence of hypertension. Kroke A, et al. **Int J Obes Relat Metab Disord** 1998 Nov; 22(11):1062–70

Supplement. Obesity, hypertension, insulin resistance and lipid disorders: cross-sectional and longitudinal studies in Japanese adolescents and middle-aged men. Hirose H, et al. **Intern Med** 1999 Feb;38(2):198–200 (17 ref.)

Managing obesity in patients with comorbidities. Franz MJ. **J Am Diet Assoc** 1998 Oct;98(10 Suppl 2):S39–43 (50 ref.)

Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. Mendelson G, et al. **J Am Geriatr Soc** 1999 May;47(5):597–9

Long-term morbidity and mortality trials with amlodipine. Oparil S. **J Cardiovasc Pharmacol** 1999;33 Suppl 2:S1–6 (25 ref.)

Prevalence of hypertension in a Mexican population according to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. González-Villalpando C, et al. **J Cardiovasc Risk** 1999 Jun;6(3):177–81

Development of blood pressure and the incidence of hypertension in men and women over an 18-year period: results of the Nijmegen Cohort Study. Bakx JC, et al. **J Clin Epidemiol** 1999 Jun;52(6):531–8

Prevalence of hypertension in patients with type II diabetes in referral versus primary care clinics. Moore WV, et al.

J Diabetes Complications 1998 Nov-Dec;12(6):302-6

Relationship of occupation to blood pressure among middle-aged Japanese men--the significance of the differences in body mass index and alcohol consumption. Takashima Y, et al. **J Epidemiol** 1998 Oct;8(4):216-26

An inverse relation between blood pressure and birth weight among 5 year old children from Soweto, South Africa. Levitt NS, et al. **J Epidemiol Community Health** 1999 May; 53(5):264-8

High effort, low reward, and cardiovascular risk factors in employed Swedish men and women: baseline results from the WOLF Study. Peter R, et al.
J Epidemiol Community Health 1998 Sep;52(9):540-7

Trends in the prevalence of isolated systolic hypertension in the middle-aged population in 1972-1992. Antikainen RL, et al. **J Hum Hypertens** 1999 Jul;13(7):485-91

The frequency and functional impact of hypertension overlapping on hypertrophic cardiomyopathy: comparison between older and younger patients. Dimitrow PP, et al. **J Hum Hypertens** 1998 Sep;12(9):633-4

Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Dyer AR, et al.
J Hum Hypertens 1999 Jan;13(1):13-21

Genetic epidemiology of essential hypertension. Gavras I, et al. **J Hum Hypertens** 1999 Apr;13(4):225-9 (60 ref.)

Blood pressure, hypertension and correlates in urbanised workers in Ibadan, Nigeria: a revisit. Kadiri S, et al.
J Hum Hypertens 1999 Jan;13(1):23-7

Prevalence and determinants of hypertension in an un-industrialised rural population of North India. Malhotra P, et al. **J Hum Hypertens** 1999 Jul;13(7):467-72

Obesity and hypertension among college-educated black women in the United States. Rosenberg L, et al.
J Hum Hypertens 1999 Apr;13(4):237-41

Hypertension in black South Africans. Seedat YK.
J Hum Hypertens 1999 Feb;13(2):96-103 (79 ref.)

The epidemiology of elevated blood pressure as an estimate for hypertension in Aydin, Turkey. Sönmez HM, et al.
J Hum Hypertens 1999 Jun;13(6):399-404

The epidemiology of the association between hypertension and menopause. Staessen JA, et al. **J Hum Hypertens** 1998 Sep;12(9):587-92 (56 ref.)

Hypertension, serum insulin, obesity and the metabolic syndrome. Wannamethee SG, et al. **J Hum Hypertens** 1998 Nov;12(11):735-41

Hypertension in the elderly with advanced locomotive disability. Wilmańska J. **J Hum Hypertens** 1998 Sep; 12(9):639-40

Hypertension is associated with a high risk of cancer. Xie L, et al. **J Hum Hypertens** 1999 May;13(5):295-301

Prevalence of hypertension in a Bangladeshi adult population. Zaman M, et al. **J Hum Hypertens** 1999 Aug;13(8):547-9 (7 ref.)

Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Folsom AR, et al. **J Hypertens** 1998 Nov;16(11):1579-83

Hypertension in master endurance athletes. Hernelahti M, et al. **J Hypertens** 1998 Nov;16(11):1573-7

Ambulatory blood pressure in the hypertensive population: patterns and prevalence of hypertensive subforms [see comments] Owens P, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1735-43. Comment in: J Hypertens 1998 Dec;16(12 Pt 1):1719-20.

Hypertension and long-term cancer incidence and mortality among Swedish men. Rosengren A, et al. **J Hypertens** 1998 Jul;16(7):933-40

Hypertension in children. Kumar A. **J Indian Med Assoc** 1998 Aug;96(8):249-51

Epidemiological study of blood pressure in domestic cats. Bodey AR, et al. **J Small Anim Pract** 1998 Dec; 39(12):567-73

Re: A randomized controlled trial to assess the incidence of new onset hypertension in patients after shock wave lithotripsy for asymptomatic renal calculi [letter; comment] Frauscher F, et al. **J Urol** 1999 Sep;162(3 Pt 1):806. Comment on: J Urol 1998 Oct;160(4):1241-3.

Hypertension as cause of end-stage renal disease: lessons from international registries. Valderrábano F, et al.
Kidney Int Suppl 1998 Dec;68:S60-6 (3 ref.)

High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Cappuccio FP, et al. **Lancet** 1999 Sep 18;354(9183):971-5

Hypertension in dialysis patients. Bellinghieri G, et al.
Miner Electrolyte Metab 1999 Jan-Apr;25(1-2):84-9 (32 ref.)

Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989 [see comments] Mosterd A, et al. **N Engl J Med** 1999 Apr 22;340(16):1221-7. Comment in: N Engl J Med 1999 Apr 22;340(16):1279-80.

Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Cocchi R, et al.
Nephrol Dial Transplant 1999 Jun;14(6):1536-40

Association of midlife blood pressure to late-life cognitive decline and brain morphology. Swan GE, et al.
Neurology 1998 Oct;51(4):986-93

Hypertension and related risk factors in type 2 diabetes mellitus. Lunetta M, et al. **Panminerva Med** 1998 Sep; 40(3):169-73

Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. Marini R, et al.
Rev Rhum Engl Ed 1999 Jun;66(6):303-9

Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
Siewert-Delle A. **Scand J Urol Nephrol Suppl** 1999; 199:1-36

The puzzle of hypertension in African-Americans. Cooper RS, et al. **Sci Am** 1999 Feb;280(2):56-63

Stroke was predicted by dimensions of quality of life in treated hypertensive men. Agewall S, et al. **Stroke** 1998 Nov;29(11):2329-33

Angiotensin converting enzyme gene polymorphism in renal transplant patients with IgA nephropathy: relationship with graft function and prevalence of hypertension. Di Paolo S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1357-8

Chronic diseases: the new epidemic. Wilks R, et al.
West Indian Med J 1998 Dec;47 Suppl 4:40-4

The association between extent of employment and hypertension among women participants of the Second National Health and Nutrition Survey. Rose KM, et al.
Women Health 1999;29(3):13-29

[A community-based survey on hypertension in the medium-aged-elderly in Jiuxianqiao area Beijing] Lu H, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Oct;19(5):294-6 (Eng. Abstr.) **(Chi)**

[Study on health status of 3,333 old people in Chengdu City, Sichuan Province] Shi Z, et al.
Chung Hua Liu Hsing Ping Hsueh Tsa Chih 1998 Feb; 19(1):15-7 (Eng. Abstr.) **(Chi)**

[A study on the relationship of primary hypertension in elderly and their quality of life in Changsha City] Zhou Y, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1998 Feb;19(1):24-6 (Eng. Abstr.) **(Chi)**

[A prevalence study on risk factors of cardiovascular disease during childhood] Feng N, et al.
Chung Hua Yu Fang I Hsueh Tsa Chih 1997 Jan;31(1):27-30 (Eng. Abstr.) **(Chi)**

[The prevalence of hypertension, diabetes mellitus and hyperlipemia among 1369 subjects for physical examination in Changsha] Duan Y, et al.
Hunan I Ko Ta Hsueh Hsueh Pao 1997;22(5):407-10 (Eng. Abstr.) **(Chi)**

[Survey of smoking and human health in Guangdong province] Wu J, et al. **Wei Sheng Yen Chiu** 1997 May; 26(3):192-5 (Eng. Abstr.) **(Chi)**

[Hypertension and hysterectomy in Danish women] Settnes A, et al. **Ugeskr Laeger** 1999 Jun 21;161(25):3845-9 (Eng. Abstr.) **(Dan)**

[Incidental high blood pressure in family practice: due to hypertension and/or left ventricular hypertrophy in more than half of the patients] Boekhout I, et al.
Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2404-8 (Eng. Abstr.) **(Dut)**

Cclinical study of vscular risk factors in the adult in the Thiadiaye rural environment] Kane A, et al.
Dakar Med 1997;42(2):77-82 (Eng. Abstr.) **(Fre)**

[Arterial hypertension in Senegal: epidemiological aspects, clinical features, and therapeutic management problems] Kane A, et al. **Dakar Med** 1995;40(2):157-61 (13 ref.) (Eng. Abstr.) **(Fre)**

[Current aspects of arterial hypertension: hypertension in the aged] Belmin J. **Presse Med** 1999 Apr 24;28(16):862-9 (87 ref.) (Eng. Abstr.) **(Fre)**

[Arterial hypertension and left ventricular hypertrophy: a 40-year follow-up in a Framingham cohort study] Vallée JP. **Presse Med** 1999 Sep 11;28(26):1421-2 **(Fre)**

[Hypertension in pregnancy. Retrospective epidemiologic study] Franchi M, et al. **Minerva Ginecol** 1999 May; 51(5):183-7 (Eng. Abstr.) **(Ita)**

[Epidemiological study on the relationship between hypertension and dental disease in Japanese factory workers] Ogawa Y, et al. **Sangyo Eiseigaku Zasshi** 1998 Nov;40(6):235-40 (Eng. Abstr.) **(Jpn)**

[New concepts in the pathogenesis of essential hypertension] Zbroch E, et al. **Przegl Lek** 1999;56(4):281-5 (65 ref.) (Eng. Abstr.) **(Pol)**

[Prevalence of systemic arterial hypertension in the population of +Passo Fundo (Brazil) metropolitan area] Trindade IS, et al. **Arq Bras Cardiol** 1998 Aug;71(2):127-30 (Eng. Abstr.) **(Por)**

[Blood pressure among tannery workers] Cordeiro R, et al.
Rev Saude Publica 1998 Oct;32(5):467-76 (Eng. Abstr.) **(Por)**

[The role of heredity in the prevalence of arterial hypertension and its risk factors] Dmitrenko SA.
Lik Sprava 1999 Apr-May;(3):53-5 (Eng. Abstr.) **(Rus)**

[Arterial hypertension in transportation workers: epidemiology, aspects of health management, transportation safety, unresolved problems] Elgarov AA, et al. **Med Tr Prom Ekol** 1998;(8):29-31 **(Rus)**

[Gestational arterial hypertension: clinico-epidemiological study] Vikhliaeva EM, et al. **Ter Arkh** 1998;70(10):29-32 (Eng. Abstr.) **(Rus)**

[Diversity in studies of the prevalence of systemic arterial hypertension] Rodriguez Saldaña J, et al.
Arch Inst Cardiol Mex 1998 Mar-Apr;68(2):130-9 (Eng. Abstr.) **(Spa)**

[White coat and non-dipper hypertension in patients recently diagnosed with mild hypertension] Abásolo Galdós RM, et al. **Aten Primaria** 1999 Apr 15;23(6):332-8 (Eng. Abstr.) **(Spa)**

[Prevalence of hypertension in 3154 young students] Ennis IL, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):483-91 (Eng. Abstr.) **(Spa)**

[Risk markers and high blood pressure. The Cienfuegos global project. Longitudinal study 1992-1994] Alvarez Li FC, et al. **Rev Invest Clin** 1999 May-Jun;51(3):151-8 (Eng. Abstr.) **(Spa)**

[Prevalence of arterial hypertension and related factors in a marginated rural population] Guerrero-Romero JF, et al. **Salud Publica Mex** 1998 Jul-Aug;40(4):339-46 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Blood pressure pattern in Saudi population of Gassim. Soyannwo MA, et al. **Afr J Med Med Sci** 1998 Mar-Jun; 27(1-2):107-16

A rational approach to the treatment of hypertension in special populations. Hall WD. **Am Fam Physician** 1999 Jul; 60(1):156-62 (33 ref.)

Na,Li-countertransport and ethnicity [letter; comment] Hardman TC, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):433-5. Comment on: Am J Hypertens 1998 Aug;11(8 Pt 1):935-41.

The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study. Oparil S.
Am J Hypertens 1998 Nov;11(11 Pt 2):192S-194S

What is the role of obesity in hypertension and target organ injury in African Americans? Jones DW.
Am J Med Sci 1999 Mar;317(3):147-51 (17 ref.)

Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. Hall WD, et al.
Arch Intern Med 1998 Oct 12;158(18):2029-34

The health status and characteristics of hypertensives in Guam. Pinhey TK. **Asia Pac J Public Health** 1995; 8(3):177-80

Beneficial impact of the homelands movement on health outcomes in central Australian aborigines. McDermott R, et al. **Aust N Z J Public Health** 1998 Oct;22(6):653-8

Association of waist circumference with risk of hypertension and type 2 diabetes in Nigerians, Jamaicans, and African-Americans [see comments] Okosun IS, et al.
Diabetes Care 1998 Nov;21(11):1836-42. Comment in: Diabetes Care 1999 May;22(5):876-7.

Examination of factor structure of the cognitive representations of hypertension scale for ethnic equivalence. Scisney-Matlock M, et al. **Ethn Dis** 1999 Winter;9(1):33-47

Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men [see comments] Haq IU, et al. **Heart** 1999 Jan;81(1):40-6. Comment in: Heart 1999 Jul;82(1):114-5.

Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective. Brownley KA, et al.
Hum Biol 1999 Aug;71(4):607-39 (211 ref.)

Heterogeneity of genetic control of blood pressure in ethnically different populations. Livshits G, et al.
Hum Biol 1999 Aug;71(4):685-708

Decreased beta2 adrenergic mediated venodilatation in Native Americans. Vajo Z, et al. **Int Angiol** 1998 Dec; 17(4):276-81

Age, body mass index and 2-hour plasma glucose are the major determinants of blood pressure in Chinese women newly diagnosed to have glucose intolerance. Ko GT, et al. **Int J Cardiol** 1999 Apr 30;69(1):33-9

Racial differences in aortic stiffness in normotensive and hypertensive adults. Ferreira AV, et al. **J Hypertens** 1999 May;17(5):631-7

A population study of ethnic variations in the angiotensin-converting enzyme I/D polymorphism: relationships with gender, hypertension and impaired glucose metabolism. Sagnella GA, et al. **J Hypertens** 1999 May;17(5):657-64

The relationship between health status and blood pressure in urban African Americans. DeForge BR, et al.
J Natl Med Assoc 1998 Nov;90(11):658-64

Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. Prisant LM, et al.
J Natl Med Assoc 1999 Jan;91(1):40-8

Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The Barbados Eye Study. Leske MC, et al. **Ophthalmology** 1999 Jan;106(1):35-41

Physical activity and incident hypertension in black and white adults: the Atherosclerosis Risk in Communities Study. Pereira MA, et al. **Prev Med** 1999 Mar;28(3):304-12

John Henryism, gender, and arterial blood pressure in an African American community. Dressler WW, et al.
Psychosom Med 1998 Sep-Oct;60(5):620-4

Obstetric and neonatal outcome following chronic hypertension in pregnancy among different ethnic groups. Lydakis C, et al. **QJM** 1998 Dec;91(12):837-44

[Hypertension in the Negro patient] Timmers GJ, et al.
Ned Tijdschr Geneeskd 1999 Jan 30;143(5):229-34 (37 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Evidence for an association between birth weight and blood pressure. Hindmarsh PC, et al. **Acta Paediatr Suppl** 1999

Feb;88(428):66-9 (24 ref.)
The effects of high dietary calcium on salt-induced hypertension in rats. Adegunloye BJ, et al. **Afr J Med Med Sci** 1996 Sep;25(3):285-91
Contrasting influence of the living environment and gender on systemic hypertension in Saudi population of Gassim, Saudi Arabia. Soyannwo MA, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):145-52
Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months. Gerdts E, et al. **Am J Hypertens** 1998 Oct;11(10):1178-87
Decreased membrane Mg2+ concentrations in a subgroup of hypertensives: membrane model for the pathogenesis of primary hypertension. Kisters K, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1390-3
Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. Levine TB, et al. **Am J Hypertens** 1998 Sep;11(9):1041-7
Higher cholesterol and insulin levels in pregnancy are associated with increased risk for pregnancy-induced hypertension. Solomon CG, et al. **Am J Hypertens** 1999 Mar;12(3):276-82
Is there a role for the ob gene product leptin in essential hypertension? Suter PM, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1305-11
A high sucrose, high linoleic acid diet potentiates hypertension in the Dahl salt sensitive rat. Zhang HY, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):183-7
Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease [editorial] Johnson RJ, et al. **Am J Kidney Dis** 1999 Feb;33(2):225-34 (82 ref.)
Nephrolithiasis and risk of hypertension in women. Madore F, et al. **Am J Kidney Dis** 1998 Nov;32(5):802-7
Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Mailloux LU, et al. **Am J Kidney Dis** 1998 Nov;32(5):705-19 (139 ref.)
Mechanism of erythropoietin-induced hypertension. Vaziri ND. **Am J Kidney Dis** 1999 May;33(5):821-8 (50 ref.)
Relationship between birthweight and blood pressure in childhood. Yiu V, et al. **Am J Kidney Dis** 1999 Feb;33(2):253-60
Hypertension in the hemodialysis population [letter] Zager P. **Am J Kidney Dis** 1999 Aug;34(2):400
Elevated ambulatory blood pressure in 20 subjects with Williams syndrome. Broder K, et al. **Am J Med Genet** 1999 Apr 23;83(5):356-60
Hypertension due to coexisting pheochromocytoma and aldosterone-producing adrenal cortical adenoma. Miyazawa K, et al. **Am J Nephrol** 1998;18(6):547-50
Pregnancy and renal tubular acidosis. Rowe TF, et al. **Am J Perinatol** 1999;16(4):189-91
Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Pollock DM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1719-23
Neonatal uninephrectomy causes hypertension in adult rats. Woods LL. **Am J Physiol** 1999 Apr;276(4 Pt 2):R974-8
Exaggerated cardiovascular response to anaesthesia--a case for investigation. Jones SE, et al. **Anaesthesia** 1999 Sep;54(9):882-4
Thalamic hemorrhage following carotid endarterectomy-induced labile blood pressure: controlling the liability with clonidine--a case report. Ejaz AA, et al. **Angiology** 1999 Apr;50(4):327-30 (7 ref.)
Coronary artery aneurysms, aortic dissection, and hypertension secondary to primary aldosteronism: a rare triad. A case report. Safi AM, et al. **Angiology** 1999 Jun;50(6):503-8
Postabdominoplasty hypertension: augmentation in the pressure systems? [letter] Dickerman RD, et al. **Ann Plast Surg** 1999 May;42(5):572-4
Maternal size at birth and the development of hypertension during pregnancy: a test of the Barker hypothesis. Klebanoff MA, et al. **Arch Intern Med** 1999 Jul 26;159(14):1607-12
Renovasculopathies of hypertension in Hispanic residents of Dallas, Texas. Tracy RE, et al. **Arch Med Res** 1999 Jan-Feb;30(1):40-8
Renal infarction presenting as hypertension following resection of a follicular dendritic sarcoma [letter] Grant J, et al. **Aust N Z J Med** 1999 Apr;29(2):280-1
Manifestation of oxidative stress in the pathogenesis of arterial hypertension in ISIAH rats. Yelinova VI, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):450-3
Intrauterine programming of hypertension: the role of the renin-angiotensin system. Langley-Evans SC, et al. **Biochem Soc Trans** 1999 Feb;27(2):88-93 (49 ref.)
Hypertension in reflux nephropathy. Goonasekera CD, et al. **BJU Int** 1999 Apr;83 Suppl 3:1-12 (165 ref.)
Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect. Hernández-delRey R, et al. **Blood Press Monit** 1998;3(6):331-7
Salt and hypertension in end-stage renal disease [editorial] Kooman JP, et al. **Blood Purif** 1998;16(6):301-11 (69 ref.)
Twins and the fetal origins hypothesis. Patterns of growth retardation differ in twins and singletons [letter] Doyle D, et al. **BMJ** 1999 Aug 21;319(7208):517; discussion 517-8
Twins and the fetal origins hypothesis. Many variables differ between twins and singleton infants. [letter] Phillips DI, et al. **BMJ** 1999 Aug 21;319(7208):517; discussion 517-8
Twins and the fetal origins hypothesis. Fetal insult may cause vascular changes and growth retardation [letter] Ross CN. **BMJ** 1999 Aug 21;319(7208):517-8
Are spouses of patients with hypertension at increased risk of having hypertension? A population-based case-control study. Hippisley-Cox J, et al. **Br J Gen Pract** 1998 Sep;48(434):1580-3
Physical activity and metabolic cardiovascular syndrome [comment] Tremblay A. **Br J Nutr** 1998 Sep;80(3):215-6 . Comment on: Br J Nutr 1998 Sep;80(3):235-41.
Functional evidence of alpha1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. Villalobos-Molina R, et al. **Br J Pharmacol** 1999 Apr;126(7):1534-6
Symptomatic venous hypertension because of occult iliofemoral deep vein thrombosis: a report of two cases. Bautista E, et al. **Cardiovasc Surg** 1998 Dec;6(6):598-603
White coat hypertension: time for action [editorial; comment] Pickering TG. **Circulation** 1998 Nov 3;98(18):1834-6 (17 ref.). Comment on: Circulation 1998 Nov 3;98(18):1892-7.
Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Singh JP, et al. **Circulation** 1999 Apr 13;99(14):1831-6
Alterations in the local myocardial motion pattern in patients suffering from pressure overload due to aortic stenosis. Stuber M, et al. **Circulation** 1999 Jul 27;100(4):361-8
Diabetes, microalbuminuria and hypertension. Sheth JJ. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):61-8 (27 ref.)
Role of androgens in mediating hypertension and renal injury. Reckelhoff JF, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):127-31
Angiotensin hypertension. Blaine EH, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S16-20
Structure-function relationships of aldosterone synthase and 11 beta-hydroxylase enzymes: implications for human hypertension. Fisher A, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S42-6
Role of dopamine in the pathogenesis of hypertension. Jose PA, et al. **Clin Exp Pharmacol Physiol Suppl** 1999 Apr;26:S10-3 (63 ref.)
Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Peschke B, et al. **Clin Nephrol** 1999 May;51(5):290-5
In utero programming of chronic disease. Barker DJ. **Clin Sci (Colch)** 1998 Aug;95(2):115-28
Hypertension in the transplanted patient. Zeier M, et al. **Contrib Nephrol** 1998;124:146-57; discussion 158-65 (86 ref.)
The role of endothelin in hypertension. Rothermund L, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):451-6 (51 ref.)
Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction? Silverberg DS, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):353-7 (39 ref.)
Epidemiology of risk factors for hypertension: implications for prevention and therapy. Kornitzer M, et al. **Drugs** 1999 May;57(5):695-712 (189 ref.)
Fetal and neonatal hypertension in twin-twin transfusion syndrome: a case report. Baud O, et al. **Fetal Diagn Ther** 1998 Jul-Aug;13(4):223-6
Potassium supplementation induces beneficial cardiovascular changes during rest and stress in salt sensitive individuals. West SG, et al. **Health Psychol** 1999 May;18(3):229-40
Hyponatremic-hypertensive syndrome with renal ischemia: an underrecognized disorder. Agarwal M, et al. **Hypertension** 1999 Apr;33(4):1020-4
Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. Cervenka L, et al. **Hypertension** 1999 Aug;34(2):176-80
11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hatakeyama H, et al. **Hypertension** 1999 May;33(5):1179-84
Both brain angiotensin II and "ouabain" contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Huang BS, et al. **Hypertension** 1998 Dec;32(6):1028-33
Alexithymia: a facet of essential hypertension. Jula A, et al. **Hypertension** 1999 Apr;33(4):1057-61
Arterial stiffness and the development of hypertension. The ARIC study. Liao D, et al. **Hypertension** 1999 Aug;34(2):201-6
Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Makaritsis KP, et al. **Hypertension** 1999 Jan;33(1):14-7
State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Mark AL, et al. **Hypertension** 1999 Jan;33(1 Pt 2):537-41 (40 ref.)
Normotensive salt sensitivity: effects of race and dietary potassium. Morris RC Jr, et al. **Hypertension** 1999 Jan;33(1):18-23
Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Muntzel MS, et al. **Hypertension** 1999 May;33(5):1135-40
Effect of magnesium deficiency on autonomic circulatory regulation in conscious rats. Murasato Y, et al. **Hypertension** 1999 Aug;34(2):247-52
Early cardiac changes after menopause. Schillaci G, et al. **Hypertension** 1998 Oct;32(4):764-9
Salt-sensitive hypertension induced by sensory denervation: introduction of a new model. Wang DH, et al. **Hypertension** 1998 Oct;32(4):649-53
Acute and late effects of tritium beta particles on rats exposed to tritiated water as infants. Yamada K, et al. **In Vivo** 1999 Mar-Apr;13(2):141-5
Hematocrit correlates with blood pressure in young male office workers. Nishikido N, et al. **Ind Health** 1999 Jan;37(1):76-81
QT dispersion as a marker of left ventricular mass in essential hypertension. Maheshwari VD, et al. **Indian Heart J** 1998 Jul-Aug;50(4):414-7
Unilateral adrenal medullary hyperplasia: another form of curable hypertension? Bailey J, et al. **Int J Clin Pract** 1999 Mar;53(2):149-51
Regarding Maor et al. IJROBP 41:647-650; 1998 [letter; comment] Dewit L, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):939-40. Comment on: Int J Radiat Oncol Biol Phys 1998 Jun 1;41(3):647-50.
A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism. Shimada T, et al. **Intern Med** 1999 Aug;38(8):655-9
Impairment of the nitric oxide-mediated vasodilator response to mental stress in hypertensive but not in hypercholesterolemic patients. Cardillo C, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1207-13
Hypertensive patients and diabetes: a high-risk population. Bilo HJ, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 2:S1-8 (65 ref.)
Cardiovascular disease and the kidney: an epidemiologic overview. Zanchetti A, et al. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S1-6; discussion S41-3 (44 ref.)
The lack of association between hypertension and hypothyroidism in a primary care setting. Bergus GR, et al. **J Hum Hypertens** 1999 Apr;13(4):231-5
Secondary hypertension and clinical genetics: usual presentation with unusual diagnosis. Cappuccio FP, et al. **J Hum Hypertens** 1999 Jan;13(1):79-80
A man with severe, transient hypertension due to acute renal infarction. Fay MF, et al. **J Hum Hypertens** 1999 May;13(5):343-4
Diabetes and hypertension: an era of clarity or confusion? Fox C. **J Hum Hypertens** 1999 Apr;13 Suppl 2:S9-17; discussion S25-8 (26 ref.)
Reflux nephropathy and hypertension. Goonasekera CD, et al. **J Hum Hypertens** 1998 Aug;12(8):497-504 (128 ref.)
Obesity and blood pressure in the elderly free-living population. Gryglewska B, et al. **J Hum Hypertens** 1998 Sep;12(9):645-7
Persistent hypertensive non-dipper triggered by panic disorder [letter] Hoshide S, et al. **J Hum Hypertens** 1999 Mar;13(3):215
Secondary hypertension in the elderly. Januszewicz W, et al. **J Hum Hypertens** 1998 Sep;12(9):603-6 (30 ref.)
Hypertension in thoracic transplant recipients. Jenkins GH, et al. **J Hum Hypertens** 1998 Dec;12(12):813-23 (124 ref.)
Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension. Kuroda S, et al. **J Hum Hypertens** 1999 Apr;13(4):257-62
White coat hypertension: a recognised syndrome with uncertain implications. Landray MJ, et al. **J Hum Hypertens** 1999 Jan;13(1):5-8 (20 ref.)
Prevalence and determinants of hypertension in an un-industrialised rural population of North India. Malhotra P, et al. **J Hum Hypertens** 1999 Jul;13(7):467-72
Abdominal obesity in the United States: prevalence and attributable risk of hypertension. Okosun IS, et al. **J Hum Hypertens** 1999 Jul;13(7):425-30
Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? Owens PE, et al. **J Hum Hypertens** 1998 Nov;12(11):743-8
Intensive blood pressure/glucose control in type 2 diabetes: why is it so difficult to decrease coronary heart disease? Reaven GM. **J Hum Hypertens** 1999 Apr;13 Suppl 2:S19-23; discussion S25-8 (20 ref.)
Introduction to 'hypertension in transplant recipients'. Singer DR, et al. **J Hum Hypertens** 1998 Dec;12(12):811
Arterial hypertension due to occlusion of the adrenal vein in the rat is strain-dependent. Abramczyk P, et al. **J Hypertens** 1998 Sep;16(9):1249-51
Effects of weight cycling on urinary catecholamines: sympathoadrenal role in refeeding hypertension. Ernsberger P, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2001-5
Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. Fang TC, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1767-74
Role of the sympathetic nervous system in human hypertension. Grassi G. **J Hypertens** 1998 Dec;16(12 Pt 2):1979-87 (60 ref.)
Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. Hayakawa H, et al. **J Hypertens** 1999 May;17(5):611-9
The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. Hirose H, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2007-12
Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats. Liu Y, et al. **J Hypertens** 1998 Aug;16(8):1165-73

Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. Nishimura M, et al. **J Hypertens** 1998 Aug;16(8):1175-85

Uric acid as a cardiovascular risk factor in arterial hypertension [editorial] Puig JG, et al. **J Hypertens** 1999 Jul;17(7):869-72

Does the Sabra hypertension-prone rat represent a model of salt or mineralocorticoid sensitivity? Yagil Y, et al. **J Hypertens** 1998 Oct;16(10):1481-4

Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. Rantala AO, et al. **J Intern Med** 1999 Feb;245(2):163-74

Paroxysmal tachycardia and hypertension with or without ventricular fibrillation during laparoscopic adrenalectomy: two case reports in patients with noncatecholamine-secreting adrenocortical adenomas. Cheong MA, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):277-81

An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. Mavromoustakos T, et al. **J Med Chem** 1999 May 20; 42(10):1714-22

Dietary salt intake, blood pressure and the kidney in hypertensive patients with non-insulin dependent diabetes mellitus. Campese VM, et al. **J Nephrol** 1998 Nov-Dec; 11(6):289-95

The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. Dessi-Fulgheri P, et al. **J Nephrol** 1998 Nov-Dec; 11(6):296-9 (11 ref.)

Medullary compression and hypertension [letter; comment] Coley SC, et al. **J Neurosurg** 1998 Nov;89(5):894-5. Comment on: J Neurosurg 1998 Feb;88(2):226-31.

Hypertension and virilization caused by a unique desoxycorticosterone- and androgen-secreting adrenal adenoma. Soranno D, et al. **J Pediatr Endocrinol Metab** 1999 Mar-Apr;12(2):215-20

Accelerated risk of hypertensive blood pressure recordings among Alzheimer caregivers. Shaw WS, et al. **J Psychosom Res** 1999 Mar;46(3):215-27

Exogenous 25-hydroxycholecalciferol does not attenuate salt-induced hypertension. Thierry-Palmer M, et al. **J Steroid Biochem Mol Biol** 1998 Nov;67(3):193-9

Posttraumatic hypertension secondary to adrenal hemorrhage mimicking pheochromocytoma: case report. Schmidt J, et al. **J Trauma** 1999 May;46(5):973-5

Hypertension/hypotension in dialysis [letter; comment] Charra B, et al. **Kidney Int** 1999 Mar;55(3):1128. Comment on: Kidney Int 1998 Aug;54(2):561-9.

Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Ismail N, et al. **Kidney Int** 1999 Jan; 55(1):1-28 (304 ref.)

Embryo transfer in the rat as a tool to determine genetic components of the gestational environment. Kubisch HM, et al. **Lab Anim Sci** 1999 Feb;49(1):90-4

The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic. O'Brien E, et al. **Lancet** 1998 Nov 21; 352(9141):1700-2

Mineralocorticoid hypertension. Stewart PM. **Lancet** 1999 Apr 17;353(9161):1341-7 (65 ref.)

Fetal exposure to a maternal low protein diet impairs nephrogenesis and promotes hypertension in the rat. Langley-Evans SC, et al. **Life Sci** 1999;64(11):965-74

Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Zavaroni I, et al. **Metabolism** 1999 Aug;48(8):989-94

Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Csiky B, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):86-90

Extra-adrenal functional paraganglioma (phaeochromocytoma) associated with renal-artery stenosis in a pregnant woman. Del Giudice A, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2920-3

Intriguing presentation of scleroderma renal crisis (scleroderma renal crisis sine scleroderma sine hypertension). Korzets Z, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2953-6

White coat hypertension in haemodialysis: the role of nurses' dresses. Stragier A. **Nephrol Dial Transplant** 1999 Apr; 14(4):861-2

Hypertension in the transplanted patient. Zeier M, et al. **Nephron** 1998 Nov;80(3):257-68 (86 ref.)

Hypertension in Leigh syndrome--a case report. Narita T, et al. **Neuropediatrics** 1998 Oct;29(5):265-7

Alcohol, blood pressure and hypertension. Keil U, et al. **Novartis Found Symp** 1998;216:125-44; discussion 144-51 (92 ref.)

Symptoms associated with mobile phone use: addendum [letter; comment] Hocking B. **Occup Med (Lond)** 1998 Oct; 48(7):472. Comment on: Occup Med (Lond) 1998 Sep;48(6):357-60.

Postoperative hypertension effect of carotid sinus denervation. Ko C, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):150-2

Endothelins in hypertension and kidney diseases. Ivić MA, et al. **Pathol Biol (Paris)** 1998 Nov;46(9):723-30 (80 ref.)

Severe hypertensive sequelae in a child with Seckel syndrome (bird-like dwarfism). Sorof JM, et al. **Pediatr Nephrol** 1999 May;13(4):343-6

Hypertension in continuous ambulatory peritoneal dialysis patients: what do we know and what can we do about it? Cheigh JS, et al. **Perit Dial Int** 1999;19 Suppl 2:S138-43 (37 ref.)

Interaction of Genetic and Environmental Factors in the Etiology of Hypertension. Satellite Symposium to the 17th Meeting of the International Society of Hypertension. Prague, Czech Republic, June 4, 1998. Abstracts. **Physiol Res** 1998;47(5):33P-53P

Dietary salt reduction in hypertension--what is the evidence and why is it still controversial? Chrysant GS, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):23-38 (73 ref.)

Special considerations in the therapy of diabetic hypertension. Guzmán CB, et al. **Prog Cardiovasc Dis** 1999 May-Jun;41(6):461-70 (75 ref.)

Obesity and hypertension. Mikhail N, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):39-58 (152 ref.)

Anxiety but not depression is associated with elevated blood pressure in a community group of French elderly. Paterniti S, et al. **Psychosom Med** 1999 Jan-Feb;61(1):77-83

The syndrome of apparent mineralocorticoid excess [editorial] Cooper M, et al. **QJM** 1998 Jul;91(7):453-5

Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Melo LG, et al. **Regul Pept** 1999 Feb 5;79(2-3):109-15

Relationship between shift work and onset of hypertension in a cohort of manual workers. Morikawa Y, et al. **Scand J Work Environ Health** 1999 Apr;25(2):100-4

Endocrine causes of hypertension in pregnancy--when to start looking for zebras. Keely E. **Semin Perinatol** 1998 Dec;22(6):471-84 (98 ref.)

Approach to a patient with suspected primary aldosteronism. Loh KC. **Singapore Med J** 1999 May;40(5):371-4

Arterial hypertension in adults after surgical treatment of aortic coarctation. Kaemmerer H, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):121-5

Salt and hypertension at the close of the millenium. Luft FC. **Wien Klin Wochenschr** 1998 Jul 31;110(13-14):459-66 (55 ref.)

Stress and hypertension. Kulkarni S, et al. **WMJ** 1998 Dec; 97(11):34-8 (25 ref.)

[The role of insulin resistance in the clustering of cardiovascular risk factors] Guo D, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Apr;36(4):250-2 (Eng. Abstr.) **(Chi)**

[Relationship between blood glucose, insulin and hypertension in 60 obese children] Guo X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jan;32(1):25-7 (Eng. Abstr.) **(Chi)**

[Transient arterial hypertension following an adder bite in a six six-year-old boy] Krue S, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):49-50 (Eng. Abstr.) **(Dan)**

[Salt and hypertension. The most current research on molecular biology increases the knowledge of the connection] Tindholdt TT, et al. **Ugeskr Laeger** 1999 Apr 26;161(17):2507-9 **(Dan)**

[11 beta-hydroxysteroid-dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism] Kerstens MN, et al. **Ned Tijdschr Geneeskd** 1999 Mar 6;143(10):509-14 (47 ref.) (Eng. Abstr.) **(Dut)**

[Adrenal medullary hyperplasia: a rare etiology of arterial hypertension--report of a case] Boissy C, et al. **Ann Pathol** 1999 Mar;19(1):38-41 (Eng. Abstr.) **(Fre)**

[Hypertensive manifestation of an acute intestinal intussusception] Paget C, et al. **Arch Pediatr** 1999 Jun; 6(6):640-2 (Eng. Abstr.) **(Fre)**

[Pathogenesis and epidemiology of arterial hypertension] Pardell H, et al. **Drugs** 1998;56 Suppl 2:1-10 (41 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac manifestations of Takayasu's arteritis: apropos of 5 cases] Abid-Allah M, et al. **Rev Med Interne** 1999 Jun; 20(6):476-82 (Eng. Abstr.) **(Fre)**

[Hypertension induced by sleep apnea--diagnosis and therapy] Sanner B, et al. **Fortschr Med** 1999 Apr 20; 117(11):35-7 **(Ger)**

[The "Franz Gross Science Price 1998". Endogenous messenger substances in essential hypertension?] Zidek W. **Fortschr Med** 1999 Mar 20;117(8):45-6 **(Ger)**

[Reducing concomitant illnesses of morbid obesity after gastric banding] Wolff S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1017-9 (Eng. Abstr.) **(Ger)**

[Therapy refractory arterial hypertension] Gürke T. **Schweiz Rundsch Med Prax** 1998 Nov 26;87(48):1662-3 **(Ger)**

[Arterial hypertension with concomitant hypokalemia] Nordmann A. **Schweiz Rundsch Med Prax** 1998 Nov 4; 87(45):1517-8 **(Ger)**

[Hirsutism. Polycystic ovaries with suspected metabolic syndrome] Zwimpfer J. **Schweiz Rundsch Med Prax** 1999 Jun 10;88(24):1093-5 **(Ger)**

[Hypertension is a frequent illness (editorial)] Ferrari P. **Ther Umsch** 1999 Jan;56(1):3-4 **(Ger)**

[Hypertension in the elderly] Perrig M, et al. **Ther Umsch** 1999 Jan;56(1):19-24 (19 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension in childhood and adolescence] von Vigier RO, et al. **Ther Umsch** 1999 Jan;56(1):12-8 (35 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension in chronic kidney failure: a volume-dependent pathology or a disease due to malnutrition?] Iannetti E, et al. **G Ital Cardiol** 1999 Mar; 29(3):284-90 (Eng. Abstr.) **(Ita)**

[A case of pheochromocytoma detected by hypertensive crisis immediately after drip infusion urography] Inoue K, et al. **Hinyokika Kiyo** 1999 May;45(5):331-3 (Eng. Abstr.) **(Jpn)**

[Hypertension and vasoactive substances] Hirata Y. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):217-22 (4 ref.) **(Jpn)**

[New aspects of environmental factors leading to hypertension] Ishimitsu T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):207-16 (61 ref.) **(Jpn)**

[Progress in diagnosis of secondary hypertension] Saito I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):236-40 (5 ref.) **(Jpn)**

[Role of impaired glucose tolerance in the progression of hypertension] Takagi Y, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov;35(11):830-8 (Eng. Abstr.) **(Jpn)**

[A case of hypertensive encephalopathy secondary to nephrotic syndrome] Okumura K, et al. **No To Hattatsu** 1999 Mar;31(2):159-64 (Eng. Abstr.) **(Jpn)**

[Causes and consequences of mild hypertension] Omvik P. **Tidsskr Nor Laegeforen** 1998 Nov 20;118(28):4396-8 (36 ref.) **(Nor)**

[Nicotine and cardiovascular complications of chronic hypertensive disease] Goldman J, et al. **Przegl Lek** 1998; 55(2):74-6 (23 ref.) (Eng. Abstr.) **(Pol)**

[New concepts in the pathogenesis of essential hypertension] Zbroch E, et al. **Przegl Lek** 1999;56(4):281-5 (65 ref.) (Eng. Abstr.) **(Pol)**

[An anthropological investigation of old age and concepts concerning arterial hypertension] Carvalho F, et al. **Cad Saude Publica** 1998 Jul-Sep;14(3):617-21 (Eng. Abstr.) **(Por)**

[Smoking, endothelium and hypertension] Gogin EE. **Klin Med (Mosk)** 1998;76(11):10-3 **(Rus)**

[Regional arterial hypertension: its theoretical premises and clinical aspects] Martynets PA, et al. **Lik Sprava** 1999 Mar; (2):3-7 (30 ref.) **(Rus)**

[Role of autonomic nervous system in pathogenesis and clinical manifestation of arterial hypertension in Icenko-Cushing disease] Martynov IuS, et al. **Ter Arkh** 1998;70(10):21-4 (Eng. Abstr.) **(Rus)**

[Role of cell membrane abnormalities in the etiology of arterial hypertension] Vershinina AM, et al. **Ter Arkh** 1998; 70(12):24-8 (Eng. Abstr.) **(Rus)**

[Arterial hypertension in diabetes mellitus: pathogenesis and treatment (review)] Zimin IuV. **Ter Arkh** 1998;70(10):15-20 **(Rus)**

[Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients] Kreze A Jr, et al. **Vnitr Lek** 1999 Jan;45(1):17-21 (Eng. Abstr.) **(Slo)**

[Arterial hypertension and lipid metabolism] Cia Gómez P, et al. **An Med Interna** 1999 Jun;16(6):315-20 (61 ref.) (Eng. Abstr.) **(Spa)**

[White coat hypertension: clinical performance after its primary care diagnosis] Márquez Contreras E, et al. **Aten Primaria** 1999 Jun 30;24(2):92-6 (Eng. Abstr.) **(Spa)**

[The intrathoracic hypertension syndrome in a breath-hold diver (letter)] Sala-Sanjaume J, et al. **Med Clin (Barc)** 1998 Dec 12;111(20):798 **(Spa)**

[Arterial hypertension and disorders of hydrocarbon metabolism] González Maqueda I, et al. **Rev Esp Cardiol** 1998;51 Suppl 4:3-14 (Eng. Abstr.) **(Spa)**

[Congenital cyanotic heart disease and peripheral neurogenic tumor] Diez L, et al. **Rev Esp Med Nucl** 1999;18(1):43-6 (Eng. Abstr.) **(Spa)**

[Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements] Fardella CE, et al. **Rev Med Chil** 1999 May;127(5):604-10 (41 ref.) (Eng. Abstr.) **(Spa)**

[Mineralocorticoid hypertension. A new form of secondary hypertension? (editorial)] Román O. **Rev Med Chil** 1999 May;127(5):511-3 (Eng. Abstr.) **(Spa)**

GENETICS

Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular prognosis. Mensah GA, et al. **Am J Cardiol** 1999 Sep 1; 84(5):583-8

Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Li A, et al. **Am J Hum Genet** 1998 Aug;63(2):370-9

Telomeres and essential hypertension. Aviv A, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):427-32 (56 ref.)

HpaII polymorphism in the atrial natriuretic peptide gene and hypertension. Cheung BM, et al. **Am J Hypertens** 1999 May;12(5):524-7

Sympathetic nerve activity and insulin sensitivity in normotensive offspring of hypertensive parents. Hausberg M, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1312-20

Potassium supplementation and urinary kallikrein excretion in normotensive offspring of hypertensive parents [letter] Krmar RT, et al. **Am J Hypertens** 1998 Dec;11(12):1497

Will angiotensin converting enzyme genotype, receptor mutation identification, and other miracles of molecular biology permit reduction of NNT? Materson BJ.

Am J Hypertens 1998 Aug;11(8 Pt 2):138S–142S (40 ref.)
Genetic determination of plasma aldosterone levels in essential hypertension. Pojoga L, et al. **Am J Hypertens** 1998 Jul;11(7):856–60
Family history of essential hypertension versus obesity as risk factors for hypertension in adolescents. Simsolo RB, et al. **Am J Hypertens** 1999 Mar;12(3):260–3
A T1083C polymorphism in the human adenosine A2a receptor gene is not associated with essential hypertension. Soma M, et al. **Am J Hypertens** 1998 Dec;11(12):1492–4
Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Touyz RM, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):757–65
Susceptibility to apoptosis measured by MYC, BCL-2, and BAX expression in arterioles and capillaries of adult spontaneously hypertensive rats. Vega F, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):815–20
The Gly460Trp variant of alpha-adducin is not associated with hypertension in white Anglo-Australians. Wang WY, et al. **Am J Hypertens** 1999 Jun;12(6):632–6
Early captopril treatment prevents hypertrophydependent gene expression in hearts of SHR. Chen S, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1511–7
Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Jacinto SM, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F315–22
Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR. Katovich MJ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1260–4
Salt-sensitive hypertension in ANP knockout mice is prevented by AT1 receptor antagonist losartan. Melo LG, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R624–30
Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. Orlov SN, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):C511–36 (307 ref.)
Effect of subunit composition and Liddle's syndrome mutations on biosynthesis of ENaC. Prince LS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1346–51
Effect of ovariectomy in heart failure-prone SHHF/Mcc-facp rats. Sharkey LC, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1968–76
Blood pressure and the T174M and M235T polymorphisms of the angiotensinogen gene. Niu T, et al. **Ann Epidemiol** 1999 May;9(4):245–53
The relationship between apolipoprotein E, dementia, and vascular illness. Marin DB, et al. **Atherosclerosis** 1998 Sep; 140(1):173–80
The D allele of the angiotensin-converting enzyme gene contributes towards blood LDL-cholesterol levels and the presence of hypertension. Oren I, et al. **Atherosclerosis** 1999 Aug;145(2):267–71
Combined SSCP and heteroduplex analysis of the human plasma membrane Ca(2+)-ATPase isoform 1 in patients with essential hypertension. Benkwitz C, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):515–20
Phenotypic selection: a successful strategy to fix major genes of hypertension. Klöting I, et al. **Biochem Mol Biol Int** 1999 May;47(5):735–42
Abnormalities in insulin sensitivity, vascular resistance and erythrocyte cation transport are independent genetic traits in familial hypertension. Ferrari P, et al. **Blood Press** 1999; 8(2):102–9
Enhanced angiotensin II stimulates renal disorders in transgenic Tsukuba hypertensive mice. Kai T, et al. **Blood Press** 1998 Jul;7(4):247–50
Hyperinsulinemia and dyslipidemia in non-obese, normotensive offspring of hypertensive parents in northern India. Misra A, et al. **Blood Press** 1998 Nov;7(5–6):286–90
Identification of upregulated genes in the thymus of spontaneously hypertensive rats by cDNA representational difference analysis. Zhao XS, et al. **Blood Press** 1998 Nov; 7(5–6):316–23
A case of McLeod syndrome with chronic renal failure. Jeren-Strujić B, et al. **Blood Purif** 1998;16(6):336–40
Inherited predisposition to hypertension confounds the effect of low birthweight [letter; comment] Walker BR, et al. **BMJ** 1999 Apr 3;318(7188):943. Comment on: BMJ 1998 Mar 14;316(7134):834–7. Comment on: BMJ 1998 Sep 5;317(7159):680.
Twin mothers, pregnancy hypertension and pre-eclampsia. Thornton JG, et al. **Br J Obstet Gynaecol** 1999 Jun; 106(6):570–5
Absence of hypertensive retinopathy in a Turkish kindred with autosomal dominant hypertension and brachydactyly. Hattenbach LO, et al. **Br J Ophthalmol** 1998 Dec; 82(12):1363–5
Genetic basis of cerebrovascular accidents associated with hypertension. Rubattu S, et al. **Cardiologia** 1999 May; 44(5):433–7 (33 ref.)
Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Kojda G, et al. **Cardiovasc Res** 1999 Apr;42(1):206–13
Cloning and expression of a novel partial cDNA related to hypertension. Chen KH, et al. **Chin Med J (Engl)** 1998 Apr;111(4):383–4
A high level of CCAAT-enhancer binding protein-delta expression is a major determinant for markedly elevated differential gene expression of the platelet-derived growth factor-alpha receptor in vascular smooth muscle cells of genetically hypertensive rats. Kitami Y, et al. **Circ Res** 1999 Jan 8-22;84(1):64–73
Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Rehemudula D, et al. **Circ Res** 1999 Mar 19;84(5):605–10
In vivo transfer of a beta 2-adrenergic receptor gene into the pressure-overloaded rat heart enhances cardiac response to beta-adrenergic agonist. Kawahira Y, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II262–7; discussion II267–8
Decrease with age in frequency of the homozygous deletional angiotensin-converting enzyme genotype in hypertensive patients. Cheung BM, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):928–31
Gene related to stroke in stroke-prone spontaneously hypertensive rats. Ikeda K, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):566–7
Physiological genetics: application to hypertension research. Jacob HJ. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):530–5 (18 ref.)
Genetic analysis in Dahl salt-sensitive rats. Kato N. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):539–40 (20 ref.)
Effects of quantitative trait loci for lipid phenotypes in the rat are influenced by age. Kovács P, et al. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):1004–7
The A1166C mutation in the angiotensin II type 1 receptor and hypertension in the elderly. Liyou N, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):525–6
From animal models to humans. Nabika T. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):541–3 (12 ref.)
Analysis in spontaneously hypertensive rats. Nara Y, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):536–8
Implication of hypertensive rat models for primordial nutritional prevention of cardiovascular diseases. Yamori Y. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):568–72 (35 ref.)
Scanning the genome for essential hypertension loci. Morris BJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov; 25:S72–8 (77 ref.)
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population. Frossard PM, et al. **Clin Genet** 1998 Oct; 54(4):285–93
SacI identifies a biallelic polymorphism in the coding sequence of the gamma subunit of the epithelial sodium channel (ENaC): a candidate gene for hypertension. Viaplana R, et al. **Clin Genet** 1998 Jul;54(1):104–5
Lower 24-h blood pressure regimen in subjects with a familial genealogy of longevity. Cugini P, et al. **Clin Ter** 1998 Nov-Dec;149(6):419–23
New genetic concepts in hypertensive cardiovascular disease. Dominiczak AF, et al. **Curr Opin Cardiol** 1998 Sep; 13(5):304–11 (65 ref.)
New contributions to clinical hypertension from molecular biology. Krieger JE. **Curr Opin Cardiol** 1998 Sep; 13(5):312–6 (50 ref.)
Assignment of GUCY1B2, the human homologue of a candidate gene for hypertension, to chromosome bands 13q14.2-->q14.3 by in situ hybridization. Malterer A, et al. **Cytogenet Cell Genet** 1999;85(3–4):256–7
Increased familial history of arterial hypertension, coronary heart disease, and renal disease in Brazilian type 2 diabetic patients with diabetic nephropathy. Canani LH, et al. **Diabetes Care** 1998 Sep;21(9):1545–50
Genetics of hypertension. Therapeutic implications. O'Byrne S, et al. **Drugs** 1998 Aug;56(2):203–14 (51 ref.)
Mutations in the carboxy terminus of the beta and gamma subunits of the epithelial sodium channel are not present in patients with hypertensive crisis. Födinger M, et al. **Eur J Clin Invest** 1998 Sep;28(9):707–11
Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus. Pavlovic M, et al. **Eur J Pediatr** 1999 Jan;158(1):18–23
Renal effects of cP450 arachidonate metabolites in the Lyon hypertensive rat. Monneret G, et al. **Fundam Clin Pharmacol** 1999;13(2):226–31
Accuracy of proband reported family history: the NHLBI Family Heart Study (FHS). Bensen JT, et al. **Genet Epidemiol** 1999;17(2):141–50
Genome scan and congenic strains for blood pressure QTL using Dahl salt-sensitive rats. Garrett MR, et al. **Genome Res** 1998 Jul;8(7):711–23
Beta3-adrenergic receptor gene polymorphism is not associated with hypertension in NIDDM patients without nephropathy. Baba T, et al. **Horm Metab Res** 1998 Oct; 30(10):629–32
The genetic basis of hypertension: progress and opportunities. Caulfield M, et al. **Hosp Med** 1998 Jan;59(1):37–40 (16 ref.)
Molecular aspects of blood pressure regulation. Crews DE, et al. **Hum Biol** 1999 Aug;71(4):475–503 (95 ref.)
Blood pressure: genetic and environmental influences. Gerber LM, et al. **Hum Biol** 1999 Aug;71(4):467–73
Heterogeneity of genetic control of blood pressure in ethnically different populations. Livshits G, et al. **Hum Biol** 1999 Aug;71(4):685–708
An MboI two-allele polymorphism may implicate the human renin gene in primary hypertension. Frossard PM, et al. **Hypertens Res** 1998 Sep;21(3):221–5
Angiotensinogen and angiotensin-converting enzyme genotypes, and day and night blood pressures in elderly Japanese hypertensives. Kario K, et al. **Hypertens Res** 1999 Jul;22(2):95–103
Lack of sex-specific effects on the association between angiotensin-converting enzyme gene polymorphism and hypertension in Japanese. Sugiyama T, et al. **Hypertens Res** 1999 Mar;22(1):55–9
Genetic vulnerability of cortical neurons isolated from stroke-prone spontaneously hypertensive rats in hypoxia and oxygen reperfusion. Tagami M, et al. **Hypertens Res** 1999 Mar;22(1):23–9
Insulin resistance and angiotensin converting enzyme polymorphism in Japanese hypertensive subjects. Yamamoto J, et al. **Hypertens Res** 1999 Jul;22(2):81–4
Telemetry for cardiovascular monitoring in a pharmacological study: new approaches to data analysis. Anderson NH, et al. **Hypertension** 1999 Jan;33(1 Pt 2):248–55
Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. Baima J, et al. **Hypertension** 1999 Jul;34(1):4–7
G-Protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Beige J, et al. **Hypertension** 1999 Apr;33(4):1049–51
G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. Benjafield AV, et al. **Hypertension** 1998 Dec;32(6):1094–7
Glucagon receptor gene mutation (Gly40Ser) in human essential hypertension: the PEGASE study. Brand E, et al. **Hypertension** 1999 Jul;34(1):15–7
The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Brand E, et al. **Hypertension** 1999 May;33(5):1175–8
Genes encoding atrial and brain natriuretic peptides as candidates for sensitivity to brain ischemia in stroke-prone hypertensive rats. Brosnan MJ, et al. **Hypertension** 1999 Jan;33(1 Pt 2):290–7
Race and hypertension: science and nescience [see comments] Cooper RS, et al. **Hypertension** 1998 Nov;32(5):813–6. Comment in: Hypertension 1998 Nov;32(5):817–9.
Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Corvol P, et al. **Hypertension** 1999 Jun; 33(6):1324–31 (68 ref.)
Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Davies E, et al. **Hypertension** 1999 Feb;33(2):703–7
Renal mechanoreceptor dysfunction: an intermediate phenotype in spontaneously hypertensive rats. DiBona GF, et al. **Hypertension** 1999 Jan;33(1 Pt 2):472–5
p53-mediated upregulation of BAX gene transcription is not involved in Bax-alpha protein overexpression in the left ventricle of spontaneously hypertensive rats. Fortuño MA, et al. **Hypertension** 1999 Jun;33(6):1348–52
Successful isolation of a rat chromosome 1 blood pressure quantitative trait locus in reciprocal congenic strains [see comments] Frantz SA, et al. **Hypertension** 1998 Oct; 32(4):639–46. Comment in: Hypertension 1998 Oct;32(4):647–8.
Association of an apolipoprotein B gene marker with essential hypertension. Frossard PM, et al. **Hypertension** 1999 Apr; 33(4):1052–6
Different frequencies of inducible nitric oxide synthase genotypes in older hypertensives. Glenn CL, et al. **Hypertension** 1999 Apr;33(4):927–32
Maternal hypertension and progeny blood pressure: role of aldosterone and 11beta-HSD. Gomez-Sanchez EP, et al. **Hypertension** 1999 Jun;33(6):1369–73
Exercise training-induced blood pressure and plasma lipid improvements in hypertensives may be genotype dependent. Hagberg JM, et al. **Hypertension** 1999 Jul; 34(1):18–23
G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. Hegele RA, et al. **Hypertension** 1998 Oct;32(4):688–92
Isolation of a chromosome 1 region that contributes to high blood pressure and salt sensitivity [see comments] Iwai N, et al. **Hypertension** 1998 Oct;32(4):636–8. Comment in: Hypertension 1998 Oct;32(4):647–8.
Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Jia H, et al. **Hypertension** 1999 Jul;34(1):8–14
Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Kainulainen K, et al. **Hypertension** 1999 Mar;33(3):844–9
G protein beta3 subunit variant and essential hypertension in Japanese. Kato N, et al. **Hypertension** 1998 Nov; 32(5):935–8
Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Kato N, et al. **Hypertension** 1999 Apr;33(4):933–6
Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Kerr S, et al. **Hypertension** 1999 Jun;33(6):1353–8
TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Li B, et al. **Hypertension** 1999 Jan;33(1 Pt 2):271–5
High stress responsivity predicts later blood pressure only in combination with positive family history and high life stress. Light KC, et al. **Hypertension** 1999 Jun; 33(6):1458–64
Adducin polymorphism affects renal proximal tubule

reabsorption in hypertension. Manunta P, et al. **Hypertension** 1999 Feb;33(2):694–7

Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Mervaala EM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):389–95

Genetic, biochemical, and clinical studies of patients with A328V or R213C mutations in 11betaHSD2 causing apparent mineralocorticoid excess. Morineau G, et al. **Hypertension** 1999 Sep;34(3):435–41

Increased central angiotensin and osmotic responses in the Ren-2 transgenic rat. Nishioka T, et al. **Hypertension** 1999 Jan;33(1 Pt 2):385–8

Angiotensinogen gene polymorphisms M235T/T174M: no excess transmission to hypertensive Chinese. Niu T, et al. **Hypertension** 1999 Feb;33(2):698–702

Linkage analysis of candidate genes and gene-gene interactions in chinese hypertensive sib pairs. Niu T, et al. **Hypertension** 1999 Jun;33(6):1332–7

Is there a racial predisposition to hypertension? [editorial; comment] O'Donnell CJ, et al. **Hypertension** 1998 Nov; 32(5):817–9. Comment on: Hypertension 1998 Nov;32(5):813–6.

Variable renal atrial natriuretic factor gene expression in hypertension. Ogawa T, et al. **Hypertension** 1999 Jun; 33(6):1342–7

Parental hyperdynamic circulation predicts insulin resistance in offspring: The Tecumseh Offspring Study. Palatini P, et al. **Hypertension** 1999 Mar;33(3):769–74

Genomics and hypertension: concepts, potentials, and opportunities. Pratt RE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):238–47 (73 ref.)

The Sa gene: what does it mean? [comment] Rapp J. **Hypertension** 1998 Oct;32(4):647–8. Comment on: Hypertension 1998 Oct;32(4):636–8. Comment on: Hypertension 1998 Oct;32(4):639–46.

Concordant genetic and physiological data are required for candidate genes [letter; comment] Rapp JP. **Hypertension** 1998 Dec;32(6):1104–5. Comment on: Hypertension 1998 Apr;31(4):918–24.

Maximum-likelihood generalized heritability estimate for blood pressure in Nigerian families. Rotimi CN, et al. **Hypertension** 1999 Mar;33(3):874–8

Effect of chromosome 19 transfer on blood pressure in the spontaneously hypertensive rat. St. Lezin E, et al. **Hypertension** 1999 Jan;33(1 Pt 2):256–60

Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Sharma P, et al. **Hypertension** 1998 Oct;32(4):676–82

Nitric oxide synthase genes: candidate genes among many others [editorial] Soubrier F. **Hypertension** 1999 Apr; 33(4):924–6

Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Tamaki S, et al. **Hypertension** 1999 Jan;33(1 Pt 2):266–70

Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Wang ZQ, et al. **Hypertension** 1999 Jan;33(1):96–101

Role of chromosome X in the Sabra rat model of salt-sensitive hypertension. Yagil C, et al. **Hypertension** 1999 Jan;33(1 Pt 2):261–5

Insulin sensitivity in obese normotensive adults: influence of family history of hypertension. Grandi AM, et al. **Int J Obes Relat Metab Disord** 1998 Sep;22(9):910–4

Donor and recipient family histories of hypertension influence renal impairment and blood pressure during acute rejections. Guidi E, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2102–7

Quantitative trait loci for blood pressure exist near the IGF-1, the Liddle syndrome, the angiotensin II-receptor gene and the renin loci in man. Nagy Z, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1709–16

Gene targeting approaches to analyzing hypertension. Takahashi N, et al. **J Am Soc Nephrol** 1999 Jul; 10(7):1598–605 (50 ref.)

Cystic fibrosis transmembrane conductance regulator inhibits epithelial Na+ channels carrying Liddle's syndrome mutations. Hopf A, et al. **J Biol Chem** 1999 May 14; 274(20):13894–9

Genetic determinants of blood pressure regulation. Ambler SK, et al. **J Cardiovasc Nurs** 1999 Jul;13(4):59–77; quiz 127–8 (67 ref.)

Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. Nakagawa H, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):28–33

Regulation of aortic atrial natriuretic factor and angiotensinogen in experimental hypertension. Ogawa T, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):1001–8

Genetic markers: genes involved in human hypertension. Marian AJ. **J Cardiovasc Risk** 1997 Oct-Dec;4(5–6):341–5 (38 ref.)

Cerebral ischemia produces laddered DNA fragments distinct from cardiac ischemia and archetypal apoptosis. MacManus JP, et al. **J Cereb Blood Flow Metab** 1999 May;19(5):502–10

Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. Mulatero P, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3996–4001

Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. Abriel H, et al. **J Clin Invest** 1999 Mar;103(5):667–73

Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. Kotelevtsev Y, et al. **J Clin Invest** 1999 Mar;103(5):683–9

Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. Pravenec M, et al. **J Clin Invest** 1999 Jun;103(12):1651–7

Genetic epidemiology of essential hypertension. Gavras I, et al. **J Hum Hypertens** 1999 Apr;13(4):225–9 (60 ref.)

Linkage of Gordon's syndrome to the long arm of chromosome 17 in a region recently linked to familial essential hypertension [see comments] O'Shaughnessy KM, et al. **J Hum Hypertens** 1998 Oct;12(10):675–8. Comment in: J Hum Hypertens 1998 Oct;12(10):663–4.

Gordon's syndrome, renal tubule, chromosome 17 and essential hypertension: a credible link? [comment] Soubrier F. **J Hum Hypertens** 1998 Oct;12(10):663–4. Comment on: J Hum Hypertens 1998 Oct;12(10):675–8.

Angiotensin-converting enzyme gene polymorphism in Nepal. Umemura S, et al. **J Hum Hypertens** 1998 Aug; 12(8):527–31

Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. Brand E, et al. **J Hypertens** 1998 Nov;16(11):1627–33

Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. Celentano A, et al. **J Hypertens** 1998 Jul;16(7):985–91

M235T polymorphism of the angiotensinogen gene and hypertension in Chinese. Cheung BM, et al. **J Hypertens** 1998 Aug;16(8):1137–40

In search of hypertension genes in Dahl salt-sensitive rats. Deng AY. **J Hypertens** 1998 Dec;16(12 Pt 1):1707–17 (82 ref.)

Genetics of experimental hypertension. Dominiczak AF, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1859–69 (60 ref.)

Hypertension: genes and environment. Hamet P, et al. **J Hypertens** 1998 Apr;16(4):397–418 (293 ref.)

A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. Ishikawa M, et al. **J Hypertens** 1999 Jun;17(6):807–16

Angiotensinogen gene and essential hypertension in the Japanese: extensive association study and meta-analysis on six reported studies. Kato N, et al. **J Hypertens** 1999 Jun; 17(6):757–63

Increased blood pressure reactivity in children of borderline hypertensive fathers. Lemne CE. **J Hypertens** 1998 Sep; 16(9):1243–8

Insulin receptor exon 11+/- isoform mRNA in spontaneously hypertensive and adrenocorticotropin-hypertensive rats. Lou Y, et al. **J Hypertens** 1998 Jul;16(7):1009–14

Molecular genetics of human hypertension. Luft FC. **J Hypertens** 1998 Dec;16(12 Pt 2):1871–8 (52 ref.)

Lower than normal expression of brain nitric oxide synthase gene in the hypothalamus of deoxycorticosterone acetate-salt hypertensive rats. Nanbu A, et al. **J Hypertens** 1998 Apr;16(4):495–502

Polymorphisms of the gamma subunit of the epithelial Na+ channel in essential hypertension. Persu A, et al. **J Hypertens** 1999 May;17(5):639–45

Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians. Schorr U, et al. **J Hypertens** 1999 Apr;17(4):475–9

G protein beta3 subunit 825T allele and its potential association with obesity in hypertensive individuals. Siffert W, et al. **J Hypertens** 1999 Aug;17(8):1095–8

Renin-angiotensin system and fibronectin gene expression in Dahl Iwai salt-sensitive and salt-resistant rats. Tamura K, et al. **J Hypertens** 1999 Jan;17(1):81–9

Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population. Tonolo G, et al. **J Hypertens** 1999 Jan; 17(1):33–8

Genetic analysis of the epithelial sodium channel in Liddle's syndrome. Uehara Y, et al. **J Hypertens** 1998 Aug; 16(8):1131–5

Cosegregation of spontaneously hypertensive rat renin gene with elevated blood pressure in an F2 generation. Yu H, et al. **J Hypertens** 1998 Aug;16(8):1141–7

Metabolic consequences of the West African diaspora: lessons from the thrifty gene. Osei K. **J Lab Clin Med** 1999 Feb; 133(2):98–111 (65 ref.)

Glucocorticoid receptor polymorphism in genetic hypertension. Kenyon CJ, et al. **J Mol Endocrinol** 1998 Aug;21(1):41–50

Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding. Clemow DB, et al. **J Urol** 1999 Apr;161(4):1372–7

Collagen I and III and mechanical properties of conduit arteries in rats with genetic hypertension. Chamiot Clerc P, et al. **J Vasc Res** 1999 Mar-Apr;36(2):139–46

G proteins and hypertension. Siffert W. **Kidney Blood Press Res** 1998;21(2–4):262–3 (15 ref.)

Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kantachuvesiri S, et al. **Kidney Int** 1999 Aug;56(2):414–20

Retrotransposons transcribed preferentially in proximal tubules of salt-hypertensive rats. Nagase M, et al. **Kidney Int** 1999 Mar;55(3):995–1004

Embryo transfer in the rat as a tool to determine genetic components of the gestational environment. Kubisch HM, et al. **Lab Anim Sci** 1999 Feb;49(1):90–4

Confirmation needed for genes for hypertension [comment] Colhoun H. **Lancet** 1999 Apr 10;353(9160):1200–1. Comment on: Lancet 1999 Apr 10;353(9160):1222–5.

Sympathetic and platelet adrenergic activity and salt sensitivity: an experimental study. Somova L, et al. **Methods Find Exp Clin Pharmacol** 1998 Oct;20(8):657–65

Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. Sankaranarayanan K, et al. **Mutat Res** 1999 Jan;436(1):21–57 (291 ref.)

Relationship between a genetic predisposition to hypertension, blood pressure levels and pain sensitivity. Guasti L, et al. **Pain** 1999 Sep;82(3):311–7

Screening for the Gly40Ser mutation in the glucagon receptor gene among patients with type 2 diabetes or essential hypertension in Taiwan. Huang CN, et al. **Pancreas** 1999 Mar;18(2):151–5

The spontaneously hypertensive rat: a model to dissect cellular defects in glucose and fatty acid metabolism. Aitman TJ, et al. **Pathol Biol (Paris)** 1998 Nov;46(9):693–4 (6 ref.) **(Eng, Fre)**

Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Neel JV, et al. **Perspect Biol Med** 1998 Autumn;42(1):44–74 (167 ref.)

The TGR(mRen2)27 transgenic rat model of hypertension. Engler S, et al. **Regul Pept** 1998 Oct 16;77(1–3):3–8 (53 ref.)

Cardiorenal destiny: the role of genes and environmental factors. Ingelfinger JR, et al. **Semin Nephrol** 1999 Mar; 19(2):201–10 (87 ref.)

Hypertension. Warnock DG. **Semin Nephrol** 1999 Jul; 19(4):374–80 (55 ref.)

Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Grandone E, et al. **Thromb Haemost** 1999 Mar;81(3):349–52

A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Yoshida H, et al. **Thromb Haemost** 1998 Sep;80(3):372–5

Congenic strains for genetic analysis of hypertension and dyslipidemia in the spontaneously hypertensive rat. Pravenec M, et al. **Transplant Proc** 1999 May;31(3):1555–6

[A study of correlation between essential hypertension and HLA-DQA1 alleles] Sun N, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1998 Oct 10;15(5):288–90 (Eng. Abstr.) **(Chi)**

[Angiotensin 1-converting enzyme gene insertion/deletion polymorphism in patients with coronary artery disease and essential hypertension and its nucleotide sequence] Tan H, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Jun;16(3):145–8 (Eng. Abstr.) **(Chi)**

[Genetic analysis of familial hypertension] Sun D, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):108–11 (Eng. Abstr.) **(Chi)**

[The study of mutation in exon 17 of insulin receptor gene in essential hypertensive pedigrees] Pang L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):83–8 (Eng. Abstr.) **(Chi)**

[Absence of point mutation in the third intracellular loop of alpha 1B- and alpha 1D adrenergic receptor in the aortae of spontaneously hypertensive rats] Xu KM, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):102–4 (Eng. Abstr.) **(Chi)**

[Stroke and hypertension: challenge for molecular medicine] Kreutz R. **Fortschr Med** 1998 Aug 20;116(22–23):40 **(Ger)**

[Single gene forms of hypertension. Glucocorticoid suppressible aldosteronism, Liddle syndrome et al.] Rettig R. **Fortschr Med** 1998 Aug 20;116(22–23):38 **(Ger)**

[Genetic research makes new ways for preventing hypertension possible (editorial)] Rettig R. **Fortschr Med** 1998 Aug 20;116(22–23):37 **(Ger)**

[Genetics of salt sensitivity. In which patients is salt restriction effective?] Sharma AM. **Fortschr Med** 1998 Aug 20;116(22–23):39 **(Ger)**

[Molecular genetics of hypertension in the human] Ferrari P. **Ther Umsch** 1999 Jan;56(1):5–11 (47 ref.) (Eng. Abstr.) **(Ger)**

[Case of nonfamilial idiopathic Liddle syndrome] Takeda I, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):339–41 **(Jpn)**

[Progress in genetic study of hypertension] Umemura S, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):198–206 (6 ref.) **(Jpn)**

[Gene polymorphisms and cardiovascular diseases in the elderly] Higaki J, et al. **Nippon Ronen Igakkai Zasshi** 1999 Apr;36(4):242–4 **(Jpn)**

[Endothelial nitric oxide synthase gene polymorphism and hypertension] Yasujima M, et al. **Rinsho Byori** 1998 Dec; 46(12):1199–204 (Eng. Abstr.) **(Jpn)**

[Analysis of polymorphisms Sma (Hpa II) and Sca I gene precursors of atrial natriuretic peptide (ANP) in patients with essential hypertension] Widecka K, et al. **Pol Arch Med Wewn** 1998 Jul;100(1):27–34 (Eng. Abstr.) **(Pol)**

[Genetic markers of hypertension] Chistiakov DA, et al. **Genetika** 1999 May;35(5):565–73 (99 ref.) (Eng. Abstr.) **(Rus)**

[The role of heredity in the prevalence of arterial hypertension and its risk factors] Dmitrenko SA. **Lik Sprava** 1999 Apr-May;(3):53-5 (Eng. Abstr.) **(Rus)**

[Genetic aspects in pathogenesis and treatment of arterial hypertension] Makolkin VI, et al. **Ter Arkh** 1999; 71(4):68-71 (56 ref.) **(Rus)**

[Genetic polymorphisms of the renin-angiotensin system and essential hypertension] Fernández-Llama P, et al. **Med Clin (Barc)** 1999 May 1;112(15):561-4 (35 ref.) (Eng. Abstr.) **(Spa)**

[The effect of the angiotensinogen M235T and the angiotensin-converting enzyme I/D polymorphisms on arterial hypertension and other cardiovascular risk factors] Pamies Andreu E, et al. **Med Clin (Barc)** 1999 Jul 10; 113(5):164-8 (Eng. Abstr.) **(Spa)**

[Insertion/deletion polymorphism of the gene encoding for angiotensin-converting enzyme and microalbuminuria in essential arterial hypertension] Rovira E, et al. **Med Clin (Barc)** 1999 May 29;112(19):726-30 (Eng. Abstr.) **(Spa)**

[The contribution of molecular biology to genetic arterial hypertension (editorial)] Repetto HA. **Medicina (B Aires)** 1999;59(1):109-10 **(Spa)**

HISTORY

Inference of the existence of high blood pressure as a cause of renal disease in the mid-19th century: observations on vascular structures in the kidney. Newton NM, et al. **Am J Nephrol** 1999;19(2):323-32

Stamps in cardiology. Miniature sheets(2). Davies MK, et al. **Heart** 1999 Jul;82(1):4

Hypertension : the second five years [editorial] Frohlich ED, et al. **Hypertension** 1999 Mar;33(3):767-8

50th anniversary historical article. Hypertension. Dustan HP. **J Am Coll Cardiol** 1999 Mar;33(3):595-7

Historical evolution of angiotensin II receptor blockers: therapeutic advantages. Gavras H. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S255-7

An historical and critical review of the articles on blood pressure published in Psychosomatic Medicine between 1939 and 1997. Engel BT. **Psychosom Med** 1998 Nov-Dec; 60(6):682-96 (208 ref.)

IMMUNOLOGY

Antiphospholipid antibodies in chronic hypertension: the value of screening during pregnancy. Parry S, et al. **Am J Perinatol** 1998;15(9):527-31

Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Wu R, et al. **Hypertension** 1999 Jan;33(1):53-9

Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Lynch A, et al. **Obstet Gynecol** 1999 Feb;93(2):193-8

[Antiphospholipid antibodies in hypertension] Mutalova EG, et al. **Ter Arkh** 1998;70(12):38-9 **(Rus)**

METABOLISM

Muscle GLUT-4 and insulin binding to erythrocytes and to adipose, liver and muscle tissue in genetically hypertensive obese rats and in their lean siblings: effect of long lasting terguride treatment. Golda V, et al. **Acta Medica (Hradec Kralove)** 1998;41(3):125-30

In the dose range of 0.5-2.0 mg/kg, acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies. Vainio M, et al. **Acta Obstet Gynecol Scand** 1999 Feb;78(2):82-8

Catecholamines in pericardial fluid of normotensive, spontaneously hypertensive and reserpine-treated rats. Klemola R, et al. **Acta Physiol Scand** 1999 Mar;165(3):293-7

Insulin resistance and systemic hypertension. Osei K. **Am J Cardiol** 1999 Jul 8;84(1A):33J-36J (20 ref.)

Na+ and Mg2+ contents in smooth muscle cells in spontaneously hypertensive rats. Kisters K, et al. **Am J Hypertens** 1999 Jun;12(6):648-52

Effects of aging on the insulin actions for the glucose metabolism and renal function in normotensives and essential hypertensives. Miyazaki Y, et al. **Am J Hypertens** 1998 Sep;11(9):1056-64

Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Tsuda K, et al. **Am J Hypertens** 1998 Dec; 11(12):1475-9

Abnormalities of membrane function and lipid metabolism in hypertension: a review. Zicha J, et al. **Am J Hypertens** 1999 Mar;12(3):315-31 (217 ref.)

Vasoactive mediators in pregnancy-induced hypertensive disorders: a longitudinal study. Paarlberg KM, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1559-64

Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Bergman MR, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H543-50

Genetic control of renal thiazide receptor response to dietary NaCl and hypertension. Fanestil DD, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R901-4

Enhanced ET(A)-receptor-mediated inhibition of K(v) channels in hypoxic hypertensive rat pulmonary artery myocytes. Li KX, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H363-70

Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. Orlov SN, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):C511-36 (307 ref.)

Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Oyekan AO, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R766-75

ANG II-induced Ca(2+) increase in smooth muscle cells from SHR is regulated by actin and microtubule networks. Samain E, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H834-41

Localization and quantitation of cardiac annexins II, V, and VI in hypertensive guinea pigs. Trouvé P, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1159-66

Redistribution of Na+/H+ exchanger isoform NHE3 in proximal tubules induced by acute and chronic hypertension. Yip KP, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F565-75

Impact of cardiovascular reactions using the impedance cardiography method in borderline hypertension. Nawarycz T, et al. **Ann N Y Acad Sci** 1999 Apr 20; 873:174-81

Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats. Fukuda N, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1210-7

Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase. Haefliger JA, et al. **Arterioscler Thromb Vasc Biol** 1999 Jul;19(7):1615-22

Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Jager A, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):617-24

Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Hodgson JM, et al. **Atherosclerosis** 1999 Jul;145(1):167-72

Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies. Brude IR, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):183-91

Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension. Katori M, et al. **Biol Res** 1998;31(3):143-9 (22 ref.)

Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Friedman JE, et al. **Blood Press** 1998;Suppl 3:32-9

Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Hansson L. **Blood Press** 1998;Suppl 3:20-2 (19 ref.)

Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Seccia TM, et al. **Blood Press** 1999;8(1):57-64

Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Varani K, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):167-72

A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome [see comments] Wareham NJ, et al. **Br J Nutr** 1998 Sep;80(3):235-41. Comment in: Br J Nutr 1998 Sep;80(3):215-6.

Glycosylated haemoglobin and hypertension arising in pregnancy. Roberts RN, et al. **Br J Obstet Gynaecol** 1998 Oct;105(10):1122-4

Recurrent calcium stones in Gordon's syndrome. Stratton JD, et al. **Br J Urol** 1998 Dec;82(6):925

Visualisation of AMPA binding sites in the brain stem of normotensive and hypertensive rats. Ashworth-Preece MA, et al. **Brain Res** 1999 Jul 10;834(1-2):186-9

Autoradiographic visualisation of axonal transport of adenosine A1 receptors along the rat vagus nerve and characterisation of adenosine A1 receptor binding in the dorsal vagal complex of hypertensive and normotensive rats. Krstew E, et al. **Brain Res** 1998 Aug 17;802(1-2):61-8

Rapid disappearance of zinc positive terminals in focal brain ischemia. Sørensen JC, et al. **Brain Res** 1998 Nov 23; 812(1-2):265-9

Increased NPY activity in the PVN contributes to food-restriction induced reductions in blood pressure in aortic coarctation hypertensive rats. VanNess JM, et al. **Brain Res** 1999 Mar 13;821(2):263-9

Increased nerve growth factor mRNA stability may underlie elevated nerve growth factor secretion from hypertensive vascular smooth muscle cells. Sherer TB, et al. **Brain Res Mol Brain Res** 1998 Nov 20;62(2):167-74

Abnormal transport of inorganic phosphate in left ventricular mitochondria from spontaneously hypertensive rats. Seccia TM, et al. **Cardiologia** 1999 Aug;44(8):719-25

Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension: relationship with adenylyl cyclase. Marcil J, et al. **Cardiovasc Res** 1998 Aug; 39(2):492-505

Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. Numaguchi Y, et al. **Cardiovasc Res** 1999 Mar;41(3):682-8

Effects of growth rate and cell density on nerve growth factor secretion in cultures of vascular and bladder smooth muscle cells from hypertensive and hyperactive rats. Clemow DB, et al. **Cell Tissue Res** 1998 Dec;294(3):431-8

The relationship between insulin resistance and abnormality of cellular calcium metabolism in patients with essential hypertension. Fu Y, et al. **Chin Med J (Engl)** 1997 Nov; 110(11):891-2

Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Cerqueira PM, et al. **Chirality** 1999;11(7):591-7

Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats. Hu WY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):507-12

Mapping of preproenkephalin mRNA in brain of spontaneously hypertensive rats. Yin X, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Mar;17(2):111-4

Expression of preproopiomelanocortin mRNA and preprodynorphin mRNA in brain of spontaneously hypertensive rats. Yin X, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):391-4

The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Davisson RL, et al. **Circ Res** 1998 Nov 16;83(10):1047-58

Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Ruetten H, et al. **Circ Res** 1999 Sep 17;85(6):534-41

Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Kakoki M, et al. **Circulation** 1999 Mar 9;99(9):1242-8

Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Lamb HJ, et al. **Circulation** 1999 May 4;99(17):2261-7

Platelet sodium/hydrogen exchanger activity in normotensives and hypertensives. Sagnella GA, et al. **Clin Chim Acta** 1999 May;283(1-2):105-18

Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Lebel M, et al. **Clin Exp Hypertens** 1998 Nov;20(8):939-51

Effect of nifedipine and enalapril on insulin-induced glucose disposal in spontaneous hypertensive and diabetic rats. Mehta AA, et al. **Clin Exp Hypertens** 1999 Jan-Feb; 21(1-2):51-9

Thapsigargin-insensitive calcium pools in vascular smooth muscle cells. Neusser M, et al. **Clin Exp Hypertens** 1999 May;21(4):395-405

Sulphatides in the brain of spontaneously hypertensive rats. Vitaioli L, et al. **Clin Exp Hypertens** 1999 Apr;21(3):263-74

Altered nuclear protein binding to the first intron of the renin gene of the spontaneously hypertensive rat. Yu H, et al. **Clin Exp Hypertens** 1998 Nov;20(8):817-32

Effect of cross-fostering on neonatal sodium balance and adult blood pressure in the spontaneously hypertensive rat. Gouldsborough I, et al. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):1024-31

Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. Itoh H, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):558-60

The nitric oxide system and cortisol-induced hypertension in humans. Kelly JJ, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):945-6

Is a hypertensinogenic factor present in the kidney of hypertensive dahl rats? Zhou MS, et al. **Clin Exp Pharmacol Physiol** 1998 Oct;25(10):800-4

Clinical pharmacokinetics of nisoldipine coat-core [published erratum appears in Clin Pharmacokinet 1998 Nov;35(5):390] Heinig R. **Clin Pharmacokinet** 1998 Sep; 35(3):191-208 (75 ref.)

Angiotensin II increases the release of endothelin-1 from human cultured endothelial cells but does not regulate its circulating levels. Ferri C, et al. **Clin Sci (Colch)** 1999 Mar; 96(3):261-70

Increased Na+ and decreased Mg2+ intracellular concentrations in vascular smooth muscle cells from spontaneously hypertensive rats. Kisters K, et al. **Clin Sci (Colch)** 1998 Nov;95(5):583-7

Basal nitric oxide production is impaired in offspring of patients with essential hypertension. McAllister AS, et al. **Clin Sci (Colch)** 1999 Aug;97(2):141-7

Na-dependent changes in intracellular Ca in spontaneously hypertensive rat hearts. Anderson SE, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Jul; 123(3):299-309

Insulin-receptor binding characteristics in perfused SHR and WKY rat hearts. Bikhazi AB, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jul;120(1):127-36

The role of L-arginine in hypertension and nephrotoxicity. Klahr S. **Curr Opin Nephrol Hypertens** 1998 Sep; 7(5):547-50 (25 ref.)

Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats. Kim SH, et al. **Drug Metab Dispos** 1999 Jun;27(6):710-6

The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Gehr TW, et al. **Eur J Clin Pharmacol** 1999 Jun;55(4):269-77

Antihypertensive effect of insulin via nitric oxide production in the Zucker diabetic fatty rat, an animal model for non-insulin-dependent diabetes mellitus. Kawaguchi M, et al. **Eur J Endocrinol** 1999 Apr;140(4):341-9

Renin-like immunoreactivity in uterus and placenta from normotensive and hypertensive pregnancies. Hanssens M, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec; 81(2):177-84

Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats. Aihara H, et al. **Eur J Pharmacol** 1999 May 28;373(1):35–40

Hydralazine prevents endothelial dysfunction, but not the increase in superoxide production in nitric oxide–deficient hypertension [published erratum appears in Eur J Pharmacol 1999 Feb 19;367(2–3):437] Bauersachs J, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):77–81

Sodium balance and hypertension: rare genetic disorders expose pathogenic mechanisms. Burnier M. **Exp Nephrol** 1998 Nov–Dec;6(6):496–501 (29 ref.)

Exercise gas transport determinants in elderly normotensive and hypertensive humans. Petrella RJ, et al. **Exp Physiol** 1999 Jan;84(1):79–91

Nicardipine normalizes elevated levels of antioxidant activity in response to xanthine oxidase–induced oxidative stress in hypertensive rat heart. Carlos DM, et al. **Free Radic Res** 1998 Aug;29(2):143–50

Endothelial dysfunction in DOCA–salt hypertension: possible involvement of prostaglandin endoperoxides. Cordellini S. **Gen Pharmacol** 1999 Mar;32(3):315–20

Lack of deficiency in extracellular and intralymphocyte free Mg2+ in genetically hypertensive rats. Sasaki N. **Hiroshima J Med Sci** 1999 Mar;48(1):1–8

Effect of hypertension and captopril treatment on the vasopressin in the rat median eminence and posterior lobe of the hypophysis. An immunohistochemical study. Castañeyra–Perdomo A, et al. **Histol Histopathol** 1999 Jan; 14(1):45–9

Serum and placental lipid peroxides in chronic hypertension during pregnancy with and without superimposed preeclampsia. Gratacós E, et al. **Hypertens Pregnancy** 1999; 18(2):139–46

Epithelial sodium channel activity is not increased in hypertension in whites. Baker EH, et al. **Hypertension** 1999 Apr;33(4):1031–5

Altered adrenal sensitivity to angiotensin II in low–renin essential hypertension [see comments] Fisher ND, et al. **Hypertension** 1999 Sep;34(3):388–94. Comment in: Hypertension 1999 Sep;34(3):395–7.

Angiotensin II type 1 receptor antagonist downregulates nonmuscle myosin heavy chains in spontaneously hypertensive rat aorta. Fujii K, et al. **Hypertension** 1999 Apr;33(4):975–80

Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II–induced hypertension. Harrison–Bernard LM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):340–6

Pathophysiological roles of endothelin–1 in Dahl salt–sensitive hypertension. Ikeda T, et al. **Hypertension** 1999 Sep;34(3):514–9

Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Kerr S, et al. **Hypertension** 1999 Jun;33(6):1353–8

Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate–salt–induced hypertension in rats. Matsumura Y, et al. **Hypertension** 1999 Feb;33(2):759–65

Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Pasquié JL, et al. **Hypertension** 1999 Mar;33(3):830–4

Dopamine–1 receptor coupling defect in renal proximal tubule cells in hypertension. Sanada H, et al. **Hypertension** 1999 Apr;33(4):1036–42

Handling 22NaCl by the blood–brain barrier and kidney: its relevance to salt–induced hypertension in dahl rats. Simchon S, et al. **Hypertension** 1999 Jan;33(1 Pt 2):517–23

Activation of the Na(+)-H+ exchanger modulates angiotensin II–stimulated Na(+)–dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension. Touyz RM, et al. **Hypertension** 1999 Sep; 34(3):442–9

Low–renin and nonmodulating essential hypertension [editorial; comment] Warnock DG. **Hypertension** 1999 Sep; 34(3):395–7. Comment on: Hypertension 1999 Sep;34(3):388–94.

Dopamine D1 receptor and protein kinase C isoforms in spontaneously hypertensive rats. Yao LP, et al. **Hypertension** 1998 Dec;32(6):1049–53

Endothelium–derived contracting factor in carotid artery of hypertensive Dahl rats. Zhou MS, et al. **Hypertension** 1999 Jul;34(1):39–43

Erythrocyte sodium and Na+, K(+)-ATPase activity in untreated hypertensives and their first degree relatives. Sudhakar K, et al. **Indian J Biochem Biophys** 1998 Dec; 35(6):382–4

Renal size and composition in hypertensive, obese rabbits. Dwyer TM, et al. **Int J Obes Relat Metab Disord** 1998 Sep;22(9):935–8

Dopamine D2–like receptors in the kidney of spontaneously hypertensive rats: a radioligand binding assay and light microscope autoradiography study. Barili P, et al. **J Auton Pharmacol** 1998 Apr;18(2):89–97

Impact of diseases on detoxication. Blouin RA, et al. **J Biochem Mol Toxicol** 1999;13(3–4):215–8 (27 ref.)

Inhibition of the epithelial Na+ channel by interaction of Nedd4 with a PY motif deleted in Liddle's syndrome. Goulet CC, et al. **J Biol Chem** 1998 Nov 6;273(45):30012–7

A novel inhibitory effect on prostacyclin synthesis of coupling factor 6 extracted from the heart of spontaneously hypertensive rats. Osanai T, et al. **J Biol Chem** 1998 Nov 27;273(48):31778–83

Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. Elisaf M, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):60–3

Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2. Lerch M, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):527–33

Angiotensin II AT1–receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. Strawn WB, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):341–51

Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. Abriel H, et al. **J Clin Invest** 1999 Mar;103(5):667–73

Differential regulation of IGF–I, its receptor and GH receptor mRNAs in the right ventricle and caval vein in volume–loaded genetically hypertensive and normotensive rats. Wickman A, et al. **J Endocrinol** 1999 May; 161(2):263–71

Modulation of nitric oxide improves cyclosporin A–induced hypertension in rats and primates. Bartholomeusz B, et al. **J Hum Hypertens** 1998 Dec;12(12):839–44

Effect of protein kinase C and insulin on Na+/H+ exchange in red blood cells of essential hypertensives. Ceolotto G, et al. **J Hum Hypertens** 1999 May;13(5):321–7

Slower activation of insulin action in hypertension associated with obesity. Biolo G, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1783–8

Differential distribution of apolipoprotein E in young and aged spontaneously hypertensive and stroke–prone rats. Chiang AN, et al. **J Hypertens** 1999 Jun;17(6):793–800

Reduced intestinal epithelial cell brush border membrane calcium transport in spontaneously hypertensive rats. de Gooyer TE, et al. **J Hypertens** 1999 Jun;17(6):777–84

Effect of endothelin blockade on pressure natriuresis in nitric oxide–deficient hypertensive rats. Fortepiani LA, et al. **J Hypertens** 1999 Feb;17(2):287–91

Contribution of synthetic phenotype on the enhanced angiotensin II–generating system in vascular smooth muscle cells from spontaneously hypertensive rats. Fukuda N, et al. **J Hypertens** 1999 Aug;17(8):1099–107

Parathyroid hormone–related protein expression in vascular smooth muscle of spontaneously hypertensive rats: evidence for lack of response to angiotensin II. Garcia SI, et al. **J Hypertens** 1998 Oct;16(10):1467–74

Altered sodium pump alpha and gamma subunit gene expression in nephron segments from hypertensive rats. Hayward AL, et al. **J Hypertens** 1999 Aug;17(8):1081–7

Overexpression of vascular endothelin–1 and endothelin–A receptors in a fructose–induced hypertensive rat model. Juan CC, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1775–82

Sodium transport and exchange in spontaneously hypertensive rats [letter] Kisters K, et al. **J Hypertens** 1999 May;17(5):715

Increased mechanosensitive currents in aortic endothelial cells from genetically hypertensive rats. Köhler R, et al. **J Hypertens** 1999 Mar;17(3):365–71

Elevated fasting insulin predicts incident hypertension: the ARIC study. Atherosclerosis Risk in Communities Study Investigators. Liese AD, et al. **J Hypertens** 1999 Aug; 17(8):1169–77

Insulin receptor exon 11+/– isoform mRNA in spontaneously hypertensive and adrenocorticotropin–hypertensive rats. Lou Y, et al. **J Hypertens** 1998 Jul;16(7):1009–14

Cardiovascular kinin–generating capability in hypertensive fructose–fed rats. Miatello RM, et al. **J Hypertens** 1998 Sep;16(9):1273–7

Alterations to the nitric oxide pathway in the spontaneously hypertensive rat. Nava E, et al. **J Hypertens** 1998 May; 16(5):609–15

Neural mechanisms in human obesity–related hypertension. Rumantir MS, et al. **J Hypertens** 1999 Aug;17(8):1125–33

Anti–oxidant status and lipid peroxidation in patients with essential hypertension. Russo C, et al. **J Hypertens** 1998 Sep;16(9):1267–71

Diminished expression of renal dopamine D1A receptors in the kidney inner medulla of the spontaneously hypertensive rat. Sidhu A, et al. **J Hypertens** 1998 May;16(5):601–8

Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats. Szczepańska–Sadowska E, et al. **J Hypertens** 1998 Oct; 16(10):1505–14

Genetic analysis of the epithelial sodium channel in Liddle's syndrome. Uehara Y, et al. **J Hypertens** 1998 Aug; 16(8):1131–5

Alteration of association of agonist–activated renal D1(A) dopamine receptors with G proteins in proximal tubules of the spontaneously hypertensive rat. Uh M, et al. **J Hypertens** 1998 Sep;16(9):1307–13

Increased oxidative stress in renal proximal tubules of the spontaneously hypertensive rat: a mechanism for defective dopamine D1A receptor/G–protein coupling. White BH, et al. **J Hypertens** 1998 Nov;16(11):1659–65

Cross–talk between cardiac kappa–opioid and beta–adrenergic receptors in developing hypertensive rats. Yu XC, et al. **J Mol Cell Cardiol** 1999 Mar;31(3):597–605

Effect of long–term ACE inhibition on myocardial tissue in hypertensive stroke–prone rats. Zimmermann R, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1447–56

Stress–induced changes of gene expression in the paraventricular nucleus are enhanced in spontaneously hypertensive rats. Imaki T, et al. **J Neuroendocrinol** 1998 Aug;10(8):635–43

Effects of restraint stress and spontaneous hypertension on neuropeptide Y neurones in the brainstem and arcuate nucleus. Krukoff TL, et al. **J Neuroendocrinol** 1999 Sep; 11(9):715–23

Single– and multiple–dose mibefradil pharmacokinetics in normal and hypertensive subjects. Welker HA. **J Pharm Pharmacol** 1998 Sep;50(9):983–7

Low–dose angiotensin II reduces urinary cyclic AMP excretion in spontaneously hypertensive, but not normotensive, rats: independence from hypertension and renal hemodynamic effects of angiotensin. Jackson EK, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):115–23

Modulation by angiotensin II of isoproterenol–induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats. Mokkapatti R, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):223–31

Renal effects of an acute NaCl load in chronic nitric oxide blockade–induced hypertensive rats. Rodriguez–Pérez JC, et al. **J Physiol Biochem** 1998 Sep;54(3):127–33

A decrease in the amount and function of inhibitory GTP–binding protein in the resistance small artery from spontaneously hypertensive rats. Masutani M, et al. **Jpn J Pharmacol** 1999 Feb;79(2):185–93

Epithelial sodium channel and its implication in the control of blood pressure. Hummler E. **Kidney Blood Press Res** 1998;21(2–4):253–5 (14 ref.)

Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague–Dawley and transgenic (mRen–2)27 rats. Campbell DJ, et al. **Kidney Int** 1999 Jul;56(1):211–21

Abnormal regulation of proximal tubule renin mRNA in the Dahl/Rapp salt–sensitive rat. Tank JE, et al. **Kidney Int** 1998 Nov;54(5):1608–16

Impaired capacity for endogenous fibrinolysis in essential hypertension [letter] Hrafnkelsdóttir T, et al. **Lancet** 1998 Nov 14;352(9140):1597–8

High salt intake differentially regulates kidney angiotensin IV AT4 receptors in Wistar–Kyoto and spontaneously hypertensive rats. Grove KL, et al. **Life Sci** 1999; 64(20):1811–8

Alterations in heart and kidney membrane phospholipids in hypertension as observed by 31P nuclear magnetic resonance. Chi Y, et al. **Lipids** 1998 Oct;33(10):1023–30

Changes in tissue polyunsaturated fatty acids with age, in spontaneously hypertensive rats. Delachambre MC, et al. **Lipids** 1998 Aug;33(8):795–801

Preliminary communication on intralymphocyte ionized magnesium in hypertensive patients under treatment with beta–blockers. Pastori C, et al. **Magnes Res** 1999 Mar; 12(1):49–55

Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long–term treatment with enalapril and losartan. Caldiz CI, et al. **Metabolism** 1999 Aug;48(8):1041–6

Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt–sensitive rats. Mori Y, et al. **Metabolism** 1999 Sep;48(9):1089–95

Long–term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH–corpulent rat with non–insulin–dependent diabetes mellitus and hypertension. Striffler JS, et al. **Metabolism** 1998 Oct;47(10):1199–204

Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin–1 levels in men with essential hypertension and normotensive controls. Surdacki A, et al. **Metabolism** 1999 Jul;48(7):887–91

Insulin secretion and biosynthesis by the perfused pancreas of spontaneously hypertensive rats. Tanigawa K, et al. **Metabolism** 1999 Jan;48(1):3–6

Abnormal central serotonergic activities in spontaneously hypertensive rats (SHR). Kim SJ, et al. **Methods Find Exp Clin Pharmacol** 1998 Jul–Aug; 20(6):473–8

Hypertension, calcium channel and pyridoxine (vitamin B6). Dakshinamurti K, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):137–48 (68 ref.)

Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Zemel MB. **Mol Cell Biochem** 1998 Nov; 188(1–2):129–36 (69 ref.)

Identification of Cd36 (Fat) as an insulin–resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats [see comments] Aitman TJ, et al. **Nat Genet** 1999 Jan;21(1):76–83. Comment in: Nat Genet 1999 Jan;21(1):61–2.

Release of serotonin in the locus coeruleus of normotensive and spontaneously hypertensive rats (SHR). Kaehler ST, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):460–5

Phosphorylation of transcription factor cyclic–AMP response element binding protein mediates c–fos induction elicited by sustained hypertension in rat nucleus tractus solitarii. Chan JY, et al. **Neuroscience** 1999;88(4):1199–212

L–type calcium channels modulate the regression of left ventricular hypertrophy after ace–inhibition in genetic hypertension. Vulpis V, et al. **Pharmacol Res** 1998 Oct; 38(4):317–22

Renal dopamine receptors in health and hypertension. Jose PA, et al. **Pharmacol Ther** 1998 Nov;80(2):149–82 (477 ref.)

Pharmacokinetics of eprosartan in healthy subjects, patients

with hypertension, and special populations. Bottorff MB, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):73S-78S (10 ref.)

Dietary salt reduction in hypertension--what is the evidence and why is it still controversial? Chrysant GS, et al. **Prog Cardiovasc Dis** 1999 Jul-Aug;42(1):23-38 (73 ref.)

The cellular ionic basis of hypertension and allied clinical conditions. Resnick L. **Prog Cardiovasc Dis** 1999 Jul-Aug; 42(1):1-22 (132 ref.)

Nitric oxide in cyclosporine A-induced hypertension: endothelin receptors gene expression. Oriji GK. **Prostaglandins Leukot Essent Fatty Acids** 1999 Jul; 61(1):41-4

Effect of docosahexaenoic acid on intracellular calcium dynamics in vascular smooth muscle cells from normotensive and genetically hypertensive rats. Hirafuji M, et al. **Res Commun Mol Pathol Pharmacol** 1998 Oct; 102(1):29-42

Monoamine responses to acute and chronic aerobic exercise in normotensive and hypertensive subjects. Arida RM, et al. **Rev Paul Med** 1998 Jan-Feb;116(1):1618-24

[The relationship between insulin resistance and abnormalities of cellular calcium metabolism and cell membrane abnormalities in patients with essential hypertension] Fu Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Jun;77(6):443-6 (Eng. Abstr.) **(Chi)**

[Alteration of inositol phosphate metabolism in aortic smooth muscle cells from spontaneously hypertensive rat] Hu SJ, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):95-8 (Eng. Abstr.) **(Chi)**

[L-arginine transport in cultured vascular smooth muscle cells of spontaneously hypertensive rats and effect of liposome on the transport] Yao XH, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):67-72 (Eng. Abstr.) **(Chi)**

[The "Dieter Klaus Price for Hypertension Research 199". Central angiotensin II is important for blood pressure regulation] Böhm M, et al. **Fortschr Med** 1999 Mar 20; 117(8):47-8 **(Ger)**

[The quantification of energy-rich phosphates in healthy and damaged heart muscle by SLOOP 31P-MR spectroscopy. Spatial localization with optimal pointspread function] Beer M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):65-8 (Eng. Abstr.) **(Ger)**

[The effects of angiotensin II receptor antagonists on glucose, lipid, and uric acid metabolism in essential hypertensives] Takizawa H, et al. **Nippon Rinsho** 1999 May;57(5):1137-40 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Studies of lymphocyte membrane transport of sodium in patients with essential hypertension] Negrusz-Kawecka M. **Pol Merkuriusz Lek** 1999 Mar;6(33):125-7 (Eng. Abstr.) **(Pol)**

[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension] Morugova TV, et al. **Eksp Klin Farmakol** 1999 Mar-Apr;62(2):39-42 (Eng. Abstr.) **(Rus)**

[Noradrenaline synthesis during the first week of life and development of inherited stress-induced arterial hypertension in rats] Maslova LN, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov;84(11):1207-13 (Eng. Abstr.) **(Rus)**

[Urate affection of kidneys and metabolic disturbances in hypertensive patients] Donskov AS, et al. **Ter Arkh** 1999; 71(6):53-6 (Eng. Abstr.) **(Rus)**

[Disruption of saturated fatty acids in cells in the pathogenesis of essential hypertension] Titov VN. **Vopr Med Khim** 1998 Jul-Aug;44(4):317-30 (85 ref.) (Eng. Abstr.) **(Rus)**

[Changes in calcium metabolism in arterial hypertension] López-Miranda González V, et al. **Med Clin (Barc)** 1998 Nov 28;111(18):701-9 (152 ref.) **(Spa)**

MORTALITY

Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris. Tenenbaum A, et al. **Am J Cardiol** 1999 Aug 1;84(3):294-8

Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role? Bursztyn M, et al. **Geriatr Nephrol Urol** 1999;9(1):5-10

Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Linz W, et al. **Hypertension** 1999 Aug;34(2):291-5

Hypertension in diet versus pharmacologically treated diabetics: mortality over a 5-year follow-up. Tenenbaum A, et al. **Hypertension** 1999 Apr;33(4):1002-7

Long-term cost and life-expectancy consequences of hypertension [see comments] Kiiskinen U, et al. **J Hypertens** 1998 Aug;16(8):1103-12. Comment in: J Hypertens 1998 Aug;16(8):1099-100.

Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. Ohkubo T, et al. **J Hypertens** 1998 Jul;16(7):971-5

Long-term cost and life-expectancy consequences of hypertension [comment] Simpson FO. **J Hypertens** 1998 Aug;16(8):1099-100. Comment on: J Hypertens 1998 Aug;16(8):1103-12.

Low diastolic blood pressure and mortality in a population-based cohort of 16913 hypertensive patients in North Karelia, Finland. Tuomilehto J, et al. **J Hypertens** 1998 Sep;16(9):1235-42

Old patients with hypertension. A 25-year observational study of a geographically defined population (Dalby), aged 67 years at entry. Lidfeldt J, et al. **J Intern Med** 1998 Dec; 244(6):469-78

Hypertension in the haemodialysis population: any relationship to 2-years survival? [see comments] Salem MM. **Nephrol Dial Transplant** 1999 Jan;14(1):125-8. Comment in: Nephrol Dial Transplant 1999 Jan;14(1):28-30.

Hypertension and AIDS leading causes of SA maternal deaths. Jones JS. **S Afr Med J** 1998 Oct;88(10):1289

[Multicenter prospective survey of prognosis of hypertensive elderly outpatient under antihypertensive treatment--morbidity and mortality of cardiovascular diseases and cancer] Ogihara T, et al. **Nippon Ronen Igakkai Zasshi** 1999 May;36(5):342-52 (Eng. Abstr.) **(Jpn)**

[Hypertension-related mortality and arterial pressure in Spain] Banegas Banegas JR, et al. **Med Clin (Barc)** 1999 Apr 17;112(13):489-94 (Eng. Abstr.) **(Spa)**

[Influence of risk factors and pharmacological treatment on mortality in patients with essential hypertension] Román O, et al. **Rev Med Chil** 1998 Jul;126(7):745-52 (Eng. Abstr.) **(Spa)**

NURSING

Evaluating mild to moderate hypertension. Tobin LJ. **Nurse Pract** 1999 May;24(5):22, 25-6, 29-30 passim; quiz 42-3 (42 ref.)

PATHOLOGY

Microinfarction as a result of hypertension in a primate model of cerebrovascular disease. Kemper T, et al. **Acta Neuropathol (Berl)** 1999 Sep;98(3):295-303

Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Sharrett AR, et al. **Am J Epidemiol** 1999 Aug 1;150(3):263-70

Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Sharifi AM, et al. **Am J Hypertens** 1998 Sep;11(9):1108-16

Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Shigematsu Y, et al. **Am J Hypertens** 1998 Oct; 11(10):1171-7

Susceptibility to apoptosis measured by MYC, BCL-2, and BAX expression in arterioles and capillaries of adult spontaneously hypertensive rats. Vega F, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):815-20

Noninvasive measurement of the human brachial artery pressure-area relation in collapse and hypertension. Drzewiecki G, et al. **Ann Biomed Eng** 1998 Nov-Dec; 26(6):965-74

Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Liu JE, et al. **Ann Intern Med** 1999 Oct 19;131(8):564-72

Factors underlying the increase in carotid intima-media thickness in borderline hypertensives. Pauletto P, et al. **Arterioscler Thromb Vasc Biol** 1999 May;19(5):1231-7

Astrocytic demise precedes delayed neuronal death in focal ischemic rat brain. Liu D, et al. **Brain Res Mol Brain Res** 1999 May 7;68(1-2):29-41

Vascular remodelling of resistance vessels: can we define this? Mulvany MJ. **Cardiovasc Res** 1999 Jan;41(1):9-13 (34 ref.)

Inhibitory effect of antisense basic fibroblast growth factor oligonucleotides on proliferation of cultured aortic smooth muscle cells induced by angiotensin II in SHR rats. Li GH, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):132-5

Proliferation of aortic smooth muscle cells and renin-angiotensin system in SHR rats. Wang XY, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Mar;19(2):136-40

Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers. Chen NG, et al. **Circulation** 1999 Aug 31;100(9):940-3

Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Yu HC, et al. **Circulation** 1998 Dec 8;98(23):2621-8

Hypertension mechanisms causing stroke. Johansson BB. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):563-5 (21 ref.)

Sarcoplasmic reticulum in vascular cells in hypertension and during proliferation. Lompré AM. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):553-7 (24 ref.)

Effect of hypertension, diabetes and other cardiovascular risk factors on kidney size in middle-aged adults. Päivänsalo MJ, et al. **Clin Nephrol** 1998 Sep;50(3):161-8

Apoptosis in hypertensive heart disease. Diez J, et al. **Curr Opin Cardiol** 1998 Sep;13(5):317-25 (77 ref.)

Weight change, ideal weight and hypertension. Huang Z, et al. **Curr Opin Nephrol Hypertens** 1999 May;8(3):343-6 (36 ref.)

Altered regulation of smooth muscle cell proliferation and apoptosis in small arteries of spontaneously hypertensive rats. Díez J, et al. **Eur Heart J** 1998 Jul;19 Suppl G:G29-33

A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Kawaguchi M, et al. **Heart Vessels** 1997;12(6):267-74

The incidence and development of periarteritis nodosa in testicular arterioles and mesenteric arteries of spontaneously hypertensive rats. Saito N, et al. **Hypertens Res** 1999 Jul;22(2):105-12

Structural skin capillary rarefaction in essential hypertension. Antonios TF, et al. **Hypertension** 1999 Apr;33(4):998-1001

Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats. Giummelly P, et al. **Hypertension** 1999 Aug;34(2):207-11

Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Onodera T, et al. **Hypertension** 1998 Oct;32(4):753-7

Gender-related differences in myocyte remodeling in progression to heart failure. Tamura T, et al. **Hypertension** 1999 Feb;33(2):676-80

The penis is not protected--in hypertension there are vascular changes in the penis which are similar to those in other vascular beds. Okabe H, et al. **Int J Impot Res** 1999 Jun;11(3):133-40

Renal size and composition in hypertensive, obese rabbits. Dwyer TM, et al. **Int J Obes Relat Metab Disord** 1998 Sep;22(9):935-8

Remodeling of retinal capillaries in the diabetic hypertensive rat. Dosso AA, et al. **Invest Ophthalmol Vis Sci** 1999 Sep; 40(10):2405-10

Quantitative examination of the cardiac myocytes in hypertensive rats under chronic inhibition of nitric oxide synthesis. Pereira LM, et al. **J Biomed Sci** 1998 Sep-Oct; 5(5):363-9

Left ventricular chamber and wall mechanics in the presence of concentric geometry. de Simone G, et al. **J Hypertens** 1999 Jul;17(7):1001-6

Renal afferent arteriolar structure in the genetically hypertensive (GH) rat and the ability of losartan and enalapril to cause structural remodelling. Ledingham JM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1945-52

Large artery structure and function in hypertension and end-stage renal disease. London GM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1931-8 (84 ref.)

Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Rossi MA. **J Hypertens** 1998 Jul; 16(7):1031-41

Increased hindlimb leukocyte concentration in a chronic rodent model of venous hypertension. Hahn TL, et al. **J Surg Res** 1999 Jan;81(1):38-41

Effect of amlodipine on the growth of vascular smooth muscle cells of spontaneously hypertensive rats. Tang J, et al. **J Tongji Med Univ** 1997;17(3):165-7

Clinical and morphologic features of hypertrophic cardiomyopathy in elderly patients 85 years or older. Lai ZY, et al. **Jpn Heart J** 1999 Mar;40(2):155-64

Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Bhutto IA, et al. **Life Sci** 1999; 64(3):PL27-39

Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. Mulvany MJ. **Metabolism** 1998 Dec;47(12 Suppl 1):20-3 (38 ref.)

The heterogeneity of vascular findings in the kidneys of patients with benign essential hypertension. Tracy RE. **Nephrol Dial Transplant** 1999 Jul;14(7):1634-9 (18 ref.)

Forebrain white matter in spontaneously hypertensive rats: a quantitative image analysis study. Sabbatini M, et al. **Neurosci Lett** 1999 Apr 9;265(1):5-8

Stereology and immunohistochemistry of the myocardium in experimental hypertension: long-term and low-dosage administration of inhibitor of the nitric oxide synthesis. Gomes Pessanha M, et al. **Pathobiology** 1999;67(1):26-33

Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Topouchian J, et al. **Stroke** 1999 May;30(5):1056-64

Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Pereira LM, et al. **Virchows Arch** 1998 Oct; 433(4):369-73

The contribution of nitric oxide to renal vascular wall thickening in rats with L-NAME-induced hypertension. Yoneyama T, et al. **Virchows Arch** 1998 Dec;433(6):549-57

[White matter changes of corpus callosum in normotensive and hypertensive rats following bilateral carotid artery stenosis] Nishiyama Y, et al. **Nippon Ika Daigaku Zasshi** 1998 Dec;65(6):450-8 (Eng. Abstr.) **(Jpn)**

[Experimental anatomo-pathologic study in the myocardium of animals with arterial hypertension caused via a nitric oxide synthesis blocker] Xavier-Vidal R, et al. **Rev Port Cardiol** 1999 Apr;18(4):381-91 (Eng. Abstr.) **(Por)**

[Changes in suprachiasmatic and paraventricular hypothalamic nuclei in essential hypertension] Goncharuk VD, et al. **Arkh Patol** 1999 May-Jun;61(3):7-10 (Eng. Abstr.) **(Rus)**

[Hyperplastic changes and aldosterone content in the adrenal cortex in essential hypertension and primary aldosteronism] Sokolova RI, et al. **Arkh Patol** 1999 May-Jun;61(3):11-4 (Eng. Abstr.) **(Rus)**

[Morphologic characteristics of the juxtaglomerular apparatus of the kidney in rats with hereditary stress induced arterial hypertension (HSIAH)] Kazarinov NP, et al. **Biull Eksp Biol Med** 1999 May;127(5):576-9 **(Rus)**

[The structural and functional levels of the vascular system and brain pathology in atherosclerosis and arterial

hypertension (experience with systems analysis)] Vereshchagin NV, et al. **Vestn Ross Akad Med Nauk** 1999; (5):3–8 **(Rus)**

[The diameter of the infrarenal aorta in hypertensive patients with organic involvement (letter; comment)] Mediavilla Garcia JD, et al. **Med Clin (Barc)** 1999 Apr 10;112(12):477 . Comment on: Med Clin (Barc) 1998 Mar 7;110(8):318. **(Spa)**

[Arterial hypertension, cardiomegaly, heart failure and interstitial pulmonary images (clinical conference)] **Medicina (B Aires)** 1998;58(5 Pt 1):515–21 **(Spa)**

PHYSIOPATHOLOGY

How to study sympatho-vagal balance in arterial hypertension and the effect of antihypertensive drugs? Presciuttini B, et al. **Acta Cardiol** 1998;53(3):143–52 (67 ref.)

Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Calò L, et al. **Acta Diabetol** 1998 Jul;35(2):96–100

Effects of endothelin receptor type A antagonism and nitric oxide synthase inhibition on cerebral blood flow in hypertensive rats. Granstam SO, et al. **Acta Physiol Scand** 1998 Oct;164(2):213–8

Responses to noradrenaline of tail arteries in hypertensive, hypotensive and normotensive rats under different regimens of perfusion: role of the myogenic response. Machkov VV, et al. **Acta Physiol Scand** 1998 Aug; 163(4):331–7

The effect of Losartan on red blood cell deformability and tissue oxygenation in patients with arterial hypertension. Cicco G, et al. **Adv Exp Med Biol** 1998;454:663–6

Symptoms reported by elderly patients with isolated systolic hypertension: baseline data from the SYST-EUR trial. Systolic Hypertension in Europe. Bulpitt CJ, et al. **Age Ageing** 1999 Jan;28(1):15–22

Blood pressure rhythm and prevalence of vascular events in hypertensive subjects. Di Iorio A, et al. **Age Ageing** 1999 Jan;28(1):23–8

Acute hemodynamic effects of ethanol in conscious spontaneously hypertensive and normotensive rats. El-Mas MM, et al. **Alcohol Clin Exp Res** 1999 Feb;23(2):285–92

Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Karpanou EA, et al. **Am Heart J** 1998 Nov; 136(5):765–8

Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Aurigemma GP, et al. **Am J Cardiol** 1999 Mar 1;83(5):792–4, A10

Hypertension, heart failure, and endothelial function. Drexler H. **Am J Cardiol** 1998 Nov 19;82(10A):20S–22S (16 ref.)

Influence of age and gender on exercise training-induced blood pressure reduction in systemic hypertension. Ishikawa K, et al. **Am J Cardiol** 1999 Jul 15;84(2):192–6

Insulin resistance and systemic hypertension. Osei K. **Am J Cardiol** 1999 Jul 8;84(1A):33J–36J (20 ref.)

Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). Palmieri V, et al. **Am J Cardiol** 1999 Sep 1;84(5):558–62

Midwall fractional shortening is an independent predictor of left ventricular diastolic dysfunction in asymptomatic patients with systemic hypertension. Schussheim AE, et al. **Am J Cardiol** 1998 Nov 1;82(9):1056–9

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Webb DJ, et al. **Am J Cardiol** 1999 Mar 4;83(5A):21C–28C

Marital cohesion and ambulatory blood pressure in early hypertension. Baker B, et al. **Am J Hypertens** 1999 Feb; 12(2 Pt 1):227–30

Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril. Bauduceau B, et al. **Am J Hypertens** 1998 Sep; 11(9):1065–73

Renal perfusion pressure is an important determinant of sodium and calcium excretion in DOC-salt hypertension. Brands MW, et al. **Am J Hypertens** 1998 Oct; 11(10):1199–207

Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Buğra Z, et al. **Am J Hypertens** 1998 Oct;11(10):1164–70

Relationship between vitamin D3 and peripheral circulation in moderate essential arterial hypertension [letter; comment] Duprez D, et al. **Am J Hypertens** 1999 Mar; 12(3):332. Comment on: Am J Hypertens 1998 Jun;11(6 Pt 1):659–66.

Altered angiotensin II-induced small artery contraction during the development of hypertension in spontaneously hypertensive rats. Endemann D, et al. **Am J Hypertens** 1999 Jul;12(7):716–23

Effects of intrarenal infusion of 17-octadecynoic acid on renal antihypertensive mechanisms in anesthetized rabbits. Evans RG, et al. **Am J Hypertens** 1998 Jul;11(7):803–12

Association between resting heart rate and hypertension treatment in a general population. Ferrières J, et al. **Am J Hypertens** 1999 Jun;12(6):628–31

Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Fogari R, et al. **Am J Hypertens** 1998 Oct;11(10):1244–7

Resting diastolic function and left ventricular mass are related to exercise capacity in hypertensive men but not in women. Gharavi AG, et al. **Am J Hypertens** 1998 Oct;11(10):1252–7

The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Gibbons GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):177S–181S (25 ref.)

Strict dietary sodium reduction worsens insulin sensitivity by increasing sympathetic nervous activity in patients with primary hypertension. Gomi T, et al. **Am J Hypertens** 1998 Sep;11(9):1048–55

Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats. Higashiura K, et al. **Am J Hypertens** 1999 Jun;12(6):596–602

Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Jacobi J, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):418–22

Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Jiang J, et al. **Am J Hypertens** 1998 Oct; 11(10):1222–31

Self-reported blood pressure reliability problems exaggerated [letter; comment] Kaplan NM. **Am J Hypertens** 1999 May; 12(5):538–9; discussion 540. Comment on: Am J Hypertens 1998 Dec;11(12):1413–7. Comment on: Am J Hypertens 1998 Dec;11(12):1418–9.

Effects of potassium supplementation on office, home, and 24-h blood pressure in patients with essential hypertension. Kawano Y, et al. **Am J Hypertens** 1998 Oct;11(10):1141–6

Myth and fact: reliability of self-reported blood pressures [editorial] [see comments] Krakoff LR. **Am J Hypertens** 1998 Dec;11(12):1418–9. Comment in: Am J Hypertens 1999 May;12(5):538–9; discussion 540. Comment in: Am J Hypertens 1999 May;12(5):539–40.

Effects of insufficient sleep on blood pressure in hypertensive patients: a 24-h study. Lusardi P, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):63–8

Reliability of reporting self-measured blood pressure values by hypertensive patients [see comments] Mengden T, et al. **Am J Hypertens** 1998 Dec;11(12):1413–7. Comment in: Am J Hypertens 1999 May;12(5):538–9; discussion 540. Comment in: Am J Hypertens 1999 May;12(5):539–40.

What is the value of home (self) blood pressure monitoring in patients with hypertensive heart disease? Mengden T, et al. **Am J Hypertens** 1998 Jul;11(7):813–9

Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Messer-Létienne I, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):398–404

Effects of aging on the insulin actions for the glucose metabolism and renal function in normotensives and essential hypertensives. Miyazaki Y, et al. **Am J Hypertens** 1998 Sep;11(9):1056–64

Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Nawarskas JJ, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):784–9

Blunted nocturnal fall in blood pressure and oxidative stress in men and women with essential hypertension. Pierdomenico SD, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):356–63

The effect of caffeine on ambulatory blood pressure in hypertensive patients. Rachima-Maoz C, et al. **Am J Hypertens** 1998 Dec;11(12):1426–32

Cold acclimation-induced increase of systolic blood pressure in rats is associated with volume expansion. Roukoyatkina NI, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):54–62

The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Thaler I, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):341–7

Determinants of circadian blood pressure rhythm in essential hypertension. Uzu T, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):35–9

Effects of age and hypertension on cardiac responses to the alpha1-agonist phenylephrine in humans. White M, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):151–8

Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. White WB, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):806–14

Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. White WB. **Am J Hypertens** 1999 Feb;12(2 Pt 2):50S–55S (17 ref.)

Isolated clinic hypertension is not an innocent phenomenon: effect on the carotid artery structure. Zakopoulos N, et al. **Am J Hypertens** 1999 Mar;12(3):245–50

Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Fujii T, et al. **Am J Kidney Dis** 1999 Jan;33(1):29–35

Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients [see comments] Rahman M, et al. **Am J Kidney Dis** 1999 Mar;33(3):498–506 . Comment in: Am J Kidney Dis 1999 Mar;33(3):492–4.

Effects of alcohol restriction on 24-hour ambulatory blood pressure in Japanese men with hypertension. Kawano Y, et al. **Am J Med** 1998 Oct;105(4):307–11

What is the role of dietary sodium and potassium in hypertension and target organ injury? He J, et al. **Am J Med Sci** 1999 Mar;317(3):152–9 (50 ref.)

What is the role of obesity in hypertension and target organ injury in African Americans? Jones DW. **Am J Med Sci** 1999 Mar;317(3):147–51 (17 ref.)

Hemodynamic patterns of women with chronic hypertension during pregnancy. Fukushima T. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1584–92

Variation in cerebral perfusion pressure with different hypertensive states in pregnancy. Williams KP, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1200–3

Impact of pregnancy-induced hypertension on fetal growth. Xiong X, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):207–13

Optic nerve blood flow in glaucoma: effect of systemic hypertension. Grunwald JE, et al. **Am J Ophthalmol** 1999 May;127(5):516–22

Sympathetic control of BP and BP variability in borderline hypertensive rats on high- vs. low-salt diet. Brown DR, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R650–7

Arterial baroreflex resetting mediates postexercise reductions in arterial pressure and heart rate. Chandler MP, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1627–34

Altered regulation of bladder nerve growth factor and neurally mediated hyperactive voiding. Clemow DB, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1279–86

Short- and long-term enalapril affect renal medullary hemodynamics in the spontaneously hypertensive rat. Dukacz SA, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R10–6

Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Florian JA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H976–83

Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats. Giulumian AD, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1613–8

Effect of behavioral stress on coronary artery relaxation altered with aging in BHR. Giulumian AD, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R435–40

Arterial chemoreflex in conscious normotensive and hypertensive adult rats. Hayward LF, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1215–22

Exaggerated Ca2+ signaling in preglomerular arteriolar smooth muscle cells of genetically hypertensive rats. Iversen BM, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F260–70

Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Jacinto SM, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):F315–22

Effect of amiloride analogs on DOCA-salt-induced hypertension in rats. Keep RF, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2215–20

Differential catecholamine responses to protein intake in healthy and hypertensive subjects. Kuchel O. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1164–73

Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. Kvam FI, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F576–84

Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats. Miyata N, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1667–73

Insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Nava P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H399–404

Renal arteriolar Na+/Ca2+ exchange in salt-sensitive hypertension. Nelson LD, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 2):F567–73

High dietary salt alters arteriolar myogenic responsiveness in normotensive and hypertensive rats. Nurkiewicz TR, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2095–104

Role of central AT1 and V1 receptors in cardiovascular adaptation to hemorrhage in SD and renin TGR rats. Paczwa P, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H1918–26

Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Persson K, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1366–73

Isradipine and insulin sensitivity in hypertensive rats. Pitre M, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):E1038–48

Primary and adaptive changes of A-type K+ currents in sympathetic neurons from hypertensive rats. Robertson WP, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1758–65

Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertensive rats. Shan ZZ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1200–6

Sympathetic nervous system activity and alpha-adrenergic responsiveness in older hypertensive humans. Supiano MA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):E519–28

Renal effects of leptin in normotensive, hypertensive, and obese rats. Villarreal D, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R2056–60

Characterization of acute reversible systemic hypertension in a model of heme protein-induced renal injury. Warden DH, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):F58–65

5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Watts SW, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H944–52

Altered muscle metabolism associated with vasoconstriction in spontaneously hypertensive rats. Ye JM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1007–15

The effects of clonidine on sensitivity to phenylephrine and nitroprusside in patients with essential hypertension recovering from surgery. Parlow JL, et al. **Anesth Analg** 1999 Jun;88(6):1239–43

Cardiac baroreflex during the postoperative period in patients with hypertension: effect of clonidine [see comments] Parlow JL, et al. **Anesthesiology** 1999 Mar;90(3):681–92.

Comment in: Anesthesiology 1999 Mar;90(3):651–3.
Effect of isoflurane on in situ vascular smooth muscle transmembrane potential in spontaneous hypertension. Stekiel TA, et al. **Anesthesiology** 1999 Jul;91(1):207–14
Acetylcholine–mediated vasodilatation and tissue–type plasminogen activator release in normal and hypertensive men. Dell'Omo G, et al. **Angiology** 1999 Apr;50(4):273–82
Venoarteriolar response to experimental venous hypertension in legs with chronic venous insufficiency and in healthy legs, measured using a double–wavelength laser Doppler technique. Malanin K, et al. **Angiology** 1998 Sep; 49(9):729–33
Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild–to–moderate hypertension. Martina B, et al. **Angiology** 1998 Nov;49(11):897–901
Peripheral vascular resistance limits exercise functional capacity of mild hypertensives. Modesti PA, et al. **Angiology** 1999 Jun;50(6):473–8
Cardiovascular and behavioral response to social confrontation: measuring real–life stress in the laboratory. Larkin KT, et al. **Ann Behav Med** 1998 Fall;20(4):294–301
Noninvasive measurement of the human brachial artery pressure–area relation in collapse and hypertension. Drzewiecki G, et al. **Ann Biomed Eng** 1998 Nov–Dec; 26(6):965–74
Effects of agmatine on the cardiovascular system of spontaneously hypertensive rats. Schäfer U, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:97–101
The role of diastolic blood pressure when treating isolated systolic hypertension. Somes GW, et al. **Arch Intern Med** 1999 Sep 27;159(17):2004–9
Interaction of Viagra with the NO donors molsidomine and RE 2047 with regard to antithrombotic and blood pressure lowering activities [published erratum appears in Arch Pharm (Weinheim) 1999 Jun;332(6):222] Rehse K, et al. **Arch Pharm (Weinheim)** 1999 May;332(5):182–4
Chronic endothelin–1 improves nitric oxide–dependent flow–induced dilation in resistance arteries from normotensive and hypertensive rats. Henrion D, et al. **Arterioscler Thromb Vasc Biol** 1999 Sep;19(9):2148–53
Antihypertensive effects of the novel potassium channel activator SKP–450 and its major metabolites in rats. Shin HS, et al. **Arzneimittelforschung** 1998 Oct;48(10):969–78
Hypertension in the elderly. Kendall MJ. **Basic Res Cardiol** 1998;93 Suppl 2:43–6
Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Müller–Wieland D, et al. **Basic Res Cardiol** 1998;93 Suppl 2:131–4 (16 ref.)
Interaction between insulin and AT1 receptor. Relevance for hypertension and arteriosclerosis. Nickenig G, et al. **Basic Res Cardiol** 1998;93 Suppl 2:135–9 (26 ref.)
Hypertension and the renin–angiotensin system—evidence from genetic and transgenic studies. Rothermund L, et al. **Basic Res Cardiol** 1998;93 Suppl 2:1–6 (32 ref.)
Effects of cytosolic Ca2+ on membrane voltage and conductance of cultured mesangial cells from stroke–prone spontaneously hypertensive rats and WKY rats. Nakagawa K, et al. **Biochem Biophys Res Commun** 1999 Mar 16; 256(2):273–7
Hypertension augments ethanol–induced depression of cell shortening and intracellular Ca(2+) transients in adult rat ventricular myocytes. Ren J, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):202–8
Intrauterine programming of hypertension: the role of the renin–angiotensin system. Langley–Evans SC, et al. **Biochem Soc Trans** 1999 Feb;27(2):88–93 (49 ref.)
Endothelin ET(B) receptor–mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate–salt–induced hypertensive rats. Hashimoto N, et al. **Biol Pharm Bull** 1998 Aug; 21(8):800–4
Endothelin: role in hypertension. Schiffrin EL. **Biol Res** 1998; 31(3):199–208 (69 ref.)
Cellular and functional aspects of the renal kallikrein system in health and disease. Vio CP, et al. **Biol Res** 1998; 31(3):305–22 (127 ref.)
Influence of vascular load on plasma endothelin–1, cytokines and catecholamine levels in essential hypertensives. Cottone S, et al. **Blood Press** 1998 May;7(3):144–8
Importance of the blood pressure–heart rate relationship. Folkow B, et al. **Blood Press** 1998 May;7(3):133–8 (30 ref.)
Factors influencing left ventricular mass in salt sensitive and salt resistant essential hypertensive patients. Gerdts E, et al. **Blood Press** 1998 Jul;7(4):223–30
The growing importance of systolic blood pressure [editorial; comment] Hansson L, et al. **Blood Press** 1998 May; 7(3):131–2. Comment on: Blood Press 1998 May;7(3):139–42.
Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Julius S, et al. **Blood Press** 1998;Suppl 3:5–13 (129 ref.)
Effects of propranolol on cardiovascular and neurohumoral actions of alcohol in hypertensive patients [see comments] Kawano Y, et al. **Blood Press** 1999;8(1):37–42. Comment in: Blood Press 1999 ;8(1):3–4.
Sympathetic control of circulation in hypertension and congestive heart failure. Lanfranchi A, et al. **Blood Press** 1998;Suppl 3:40–5 (39 ref.)
Selective increase of the contractile response to endothelin–1 in subcutaneous arteries from patients with essential hypertension. Lind H, et al. **Blood Press** 1999;8(1):9–15
Muscle sympathetic vasoconstrictor activity in hydrocortisone–induced hypertension in humans. Macefield VG, et al. **Blood Press** 1998 Jul;7(4):215–22
Skeletal muscle angiotensin–converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. Reneland R, et al. **Blood Press** 1999; 8(1):16–22
Evaluation of Meditech ABPM–04 ambulatory blood pressure measuring device according to the British Hypertension Society protocol. Barna I, et al. **Blood Press Monit** 1998;3(6):363–8
Validation of two devices for self–measurement of blood pressure by elderly patients according to the revised British Hypertension Society protocol: the Omron HEM–722C and HEM–735C. Bortolotto LA, et al. **Blood Press Monit** 1999 Feb;4(1):21–5
Accuracy and 'range of uncertainty' of oscillometric blood pressure monitors around the upper arm and the wrist. Dieterle T, et al. **Blood Press Monit** 1998;3(6):339–46
Validation of the Omron F3 blood pressure measuring device for use in the finger through simultaneous invasive comparative measurements according to the German Institute for Validation (DIN) 58130 protocol. Eckert S, et al. **Blood Press Monit** 1998;3(6):347–51
Individualized versus standardized analysis of ambulatory blood pressure profile: relationship with left ventricular characteristics. Grandi AM, et al. **Blood Press Monit** 1999 Feb;4(1):7–11
Home blood pressure measurement: reproducibility and relationship with left ventricular mass. Kok RH, et al. **Blood Press Monit** 1999 Apr;4(2):65–9
Evaluation of the Profilomat II ambulatory blood pressure system according to the protocols of the British Hypertension Society and the Association for the Advancement of Medical Instrumentation. Mee F, et al. **Blood Press Monit** 1998;3(6):353–61
The effect of crossing legs on blood pressure: a randomized single–blind cross–over study. Peters GL, et al. **Blood Press Monit** 1999 Apr;4(2):97–101
Is greater than normal nocturnal heart rate in children with renal scars a predictor of reflux nephropathy? Pomeranz A, et al. **Blood Press Monit** 1998;3(6):369–72
Effects of nicardipine on ventriculo–arterial coupling in humans. Tanaka K, et al. **Br J Anaesth** 1998 Aug; 81(2):180–5
Decreased vascular permeability response to substance P in airways of genetically hypertensive rats. Bakhle YS, et al. **Br J Pharmacol** 1999 Feb;126(4):933–8
Role of iNOS in the vasodilator responses induced by L–arginine in the middle cerebral artery from normotensive and hypertensive rats. Briones AM, et al. **Br J Pharmacol** 1999 Jan;126(1):111–20
The bradykinin B1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Emanueli C, et al. **Br J Pharmacol** 1999 Apr;126(8):1769–76
Impaired function of alpha–2 adrenoceptors in smooth muscle of mesenteric arteries from spontaneously hypertensive rats. Feres T, et al. **Br J Pharmacol** 1998 Nov;125(6):1144–9
Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients. Hutri–Kähönen N, et al. **Br J Pharmacol** 1999 Aug;127(7):1735–43
Spontaneously hypertensive rats cholinergic hyper–responsiveness: central and peripheral pharmacological mechanisms. Lazartigues E, et al. **Br J Pharmacol** 1999 Aug;127(7):1657–65
Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved. Rodriguez–Martinez MA, et al. **Br J Pharmacol** 1998 Nov;125(6):1329–35
Endothelium–derived relaxing, contracting and hyperpolarizing factors of mesenteric arteries of hypertensive and normotensive rats. Sunano S, et al. **Br J Pharmacol** 1999 Feb;126(3):709–16
Rectifying effect of exercise on hypertension in spontaneously hypertensive rats via a calcium–dependent dopamine synthesizing system in the brain. Akiyama K, et al. **Brain Res** 1999 Mar 27;823(1–2):154–60
Spontaneous activity and barosensitivity of the barosensitive neurons in the rostral ventrolateral medulla of hypertensive rats induced by transection of aortic depressor nerves. Han YM, et al. **Brain Res** 1998 Dec 7;813(2):262–7
Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypothalamic nucleus of spontaneously hypertensive rats. Kagiyama S, et al. **Brain Res** 1999 May 22;829(1–2):120–4
Expression of preprogalanin mRNA following acute and chronic restraint stress in brains of normotensive and hypertensive rats. Sweerts BW, et al. **Brain Res Mol Brain Res** 1999 May 21;69(1):113–23
Baroreflex control of sympathetic activity in experimental hypertension. Irigoyen MC, et al. **Braz J Med Biol Res** 1998 Sep;31(9):1213–20 (49 ref.)
Calcium channel blockers attenuate cardiovascular responses to tracheal extubation in hypertensive patients. Fujii Y, et al. **Can J Anaesth** 1998 Jul;45(7):655–9
Diltiazem–lidocaine combination for the attenuation of cardiovascular responses to tracheal intubation in hypertensive patients. Fujii Y, et al. **Can J Anaesth** 1998 Oct;45(10):933–7
Impaired endothelial function in hypertensive elderly patients evaluated by high resolution ultrasonography. Kimura Y, et al. **Can J Cardiol** 1999 May;15(5):563–8 (36 ref.)
Germline polymorphisms in cardiovascular medicine. Is that the whole story? Marsden PA. **Can J Cardiol** 1999 Apr; 15 Suppl B:11B–12B
Tear propagation in isolated, pressurized porcine thoracic aortas. Roach MR, et al. **Can J Cardiol** 1999 May; 15(5):569–75
Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate–salt hypertension. K.–Laflamme A, et al. **Can J Physiol Pharmacol** 1998 Jun; 76(6):665–75
Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Blacher J, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):409–14
Effect of low–dose manidipine on ambulatory blood pressure in very elderly hypertensives. Fogari R, et al. **Cardiovasc Drugs Ther** 1999 May;13(3):243–8
Squeezing tubes: a case of remodeling and regulation: coronary reserve in hypertensive heart disease. Schwartzkopff B, et al. **Cardiovasc Res** 1998 Oct;40(1):4–8 (30 ref.)
Acetaldehyde depresses myocardial contraction and cardiac myocyte shortening in spontaneously hypertensive rats: role of intracellular Ca2+. Brown RA, et al. **Cell Mol Biol (Noisy–le–grand)** 1999 Jun;45(4):453–65
Attenuation of cardiac but not vascular component in baroreflex of spontaneously hypertensive rats. Han CJ, et al. **Chin J Physiol** 1998 Jun 30;41(2):107–12
Development of inverse circadian blood pressure pattern in transgenic hypertensive TGR(mREN2)27 rats. Witte K, et al. **Chronobiol Int** 1999 May;16(3):293–303
Disparate effects of captopril on hypertension and blood vessel. Chen DG, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Mar;17(2):133–8
Superoxide released to high intra–arteriolar pressure reduces nitric oxide–mediated shear stress– and agonist–induced dilations. Huang A, et al. **Circ Res** 1998 Nov 2;83(9):960–5
Cyclosporine attenuates pressure–overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure [see comments] Meguro T, et al. **Circ Res** 1999 Apr 2;84(6):735–40. Comment in: Circ Res 1999 Apr 2;84(6):741–3.
Mitogen–activated protein/extracellular signal–regulated kinase inhibition attenuates angiotensin II–mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Touyz RM, et al. **Circ Res** 1999 Mar 19;84(5):505–15
Failure of calcineurin inhibitors to prevent pressure–overload left ventricular hypertrophy in rats [see comments] Zhang W, et al. **Circ Res** 1999 Apr 2;84(6):722–8. Comment in: Circ Res 1999 Apr 2;84(6):741–3.
Effects of chronic heparin administration on coronary vascular adaptation to hypertension and ventricular hypertrophy in sheep. Flanagan MF, et al. **Circulation** 1999 Aug 31;100(9):981–7
Single–unit sympathetic discharge : quantitative assessment in human hypertensive disease. Greenwood JP, et al. **Circulation** 1999 Sep 21;100(12):1305–10
Regular aerobic exercise augments endothelium–dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium–derived nitric oxide. Higashi Y, et al. **Circulation** 1999 Sep 14;100(11):1194–202
Cardiovascular outcome in white–coat versus sustained mild hypertension: a 10–year follow–up study [see comments] Khattar RS, et al. **Circulation** 1998 Nov 3;98(18):1892–7. Comment in: Circulation 1998 Nov 3;98(18):1834–6.
Alterations in the local myocardial motion pattern in patients suffering from pressure overload due to aortic stenosis. Stuber M, et al. **Circulation** 1999 Jul 27;100(4):361–8
Vasodilation to bradykinin is mediated by an ouabain–sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Taddei S, et al. **Circulation** 1999 Sep 28;100(13):1400–5
Left ventricular filling in the hypertensive patient: long–term course and influence of treatment. Gosse P, et al. **Clin Cardiol** 1999 Jul;22(7):472–6
Enhanced nitric oxide synthesis reverses salt–induced alterations in blood flow and cGMP levels. Bayorh MA, et al. **Clin Exp Hypertens** 1999 May;21(4):333–52
Daily exercise enhances acetylcholine–induced dilation in mesenteric and hindlimb vasculature of hypertensive rats. Chen Y, et al. **Clin Exp Hypertens** 1999 May;21(4):353–76
Antihypertensive drugs and the nervous system: ACE–inhibitors restore oscillatory potentials in hypertensives. Cosenzi A, et al. **Clin Exp Hypertens** 1999 Apr;21(3):223–31
Effect of the vasodilatory beta–blocker, nipradilol, and Ca–antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Kosegawa I, et al. **Clin Exp Hypertens** 1998 Oct;20(7):751–61
Platelet thrombus formation in microvessels of young spontaneously hypertensive rats. Lominadze D, et al. **Clin Exp Hypertens** 1998 Nov;20(8):917–37
Function of the isolated perfused kidneys from young or adult rats with post–DOCA–salt hypertension. Vanecková I, et al. **Clin Exp Hypertens** 1999 May;21(4):407–21
Diabetes and hypertension: experimental models for pharmacological studies. van Zwieten PA. **Clin Exp Hypertens** 1999 Jan–Feb;21(1–2):1–16

Sympathetic and respiratory responses to hypoxia in essential hypertension. Yu BH, et al. **Clin Exp Hypertens** 1999 Apr; 21(3):249–62

Effect of steroid hormones on blood pressure. Dodic M, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):550–2

Effect of cross-fostering on neonatal sodium balance and adult blood pressure in the spontaneously hypertensive rat. Gouldsborough I, et al. **Clin Exp Pharmacol Physiol** 1998 Dec;25(12):1024–31

Effects of nitric oxide synthase inhibition and endothelin ETA receptor blockade on haemodynamics in hypertensive rats. Granstam SO, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):693–701

Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. Kai T, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):206–11

Effects of BDF 9148 on the action potentials and contractions of left ventricles from normo- and hypertensive rats. Nand V, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):212–9

Chaotic characteristics of renal nerve peak interval sequence in normotensive and hypertensive rats. Zhang T, et al. **Clin Exp Pharmacol Physiol** 1998 Nov;25(11):896–903

Prevalence and correlates of blood pressure elevation in children with Guillain-Barré syndrome. Cooper WO, et al. **Clin Pediatr (Phila)** 1998 Oct;37(10):621–4

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Hempel G, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):622–35

The effects of ramipril on sympathetic nervous system function in older patients with hypertension. Lee CC, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):420–7

Reproducibility of abnormal heart rate variability indices: the case of hypertensive sleep apnoea syndrome. Salo TM, et al. **Clin Physiol** 1999 May;19(3):258–68

Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Goetz RM, et al. **Clin Sci (Colch)** 1999 Aug;97(2):165–74

Acute hypertension impairs endothelium-dependent vasodilation [see comments] Millgård J, et al. **Clin Sci (Colch)** 1998 Jun;94(6):601–7. Comment in: Clin Sci (Colch) 1999 Feb;96(2):217–8.

Autonomic modulation of heart rate and blood pressure in hypertensive subjects with symptoms of anxiety. Piccirillo G, et al. **Clin Sci (Colch)** 1998 Jul;95(1):43–52

Suppression of post-glucose hyperinsulinaemia does not affect blood pressure in either normotensive or hypertensive subjects. Savage MW, et al. **Clin Sci (Colch)** 1998 Jun;94(6):609–14

Who are the non-dippers? A better definition via the blood pressure circadian rhythm. Cugini P, et al. **Clin Ter** 1998 Sep-Oct;149(5):343–9

A comparison of the cutaneous microvascular properties of the spontaneously hypertensive rat and the Wistar-Kyoto rat. Rendell MS, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 Apr; 122(4):399–406

Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs. Absher PM, et al. **Coron Artery Dis** 1999 Sep;10(6):413–20

The role of endothelin in hypertension. Rothermund L, et al. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):451–6 (51 ref.)

Neural mechanisms in nitric-oxide-deficient hypertension. Sander M, et al. **Curr Opin Nephrol Hypertens** 1999 Jan; 8(1):61–73 (165 ref.)

Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. Nielsen FS, et al. **Diabet Med** 1999 Jul; 16(7):555–62

Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Ferri C, et al. **Diabetes** 1999 Aug; 48(8):1623–30

Differential glucose tolerance in dipper and nondipper essential hypertension: the implications of circadian blood pressure regulation on glucose tolerance in hypertension. Chen JW, et al. **Diabetes Care** 1998 Oct;21(10):1743–8

Association between central adiposity and multimetabolic syndrome in a special cohort of women with prior gestational diabetes [letter; comment] Kerényi Z, et al. **Diabetes Care** 1999 May;22(5):876–7. Comment on: Diabetes Care 1998 Nov;21(11):1836–42.

Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Liao D, et al. **Diabetes Care** 1998 Dec; 21(12):2116–22

Hypertension in women with gestational diabetes. Roberts R. **Diabetes Care** 1998 Aug;21 Suppl 2:B27–32 (42 ref.)

Arterial hypertension and glycemia in non-diabetic subjects: is there an association independent of obesity? Kroke A, et al. **Diabetes Metab Res Rev** 1999 Mar-Apr;15(2):99–105

Oscillatory potentials of the electroretinogram in hypertensive patients with different antihypertensive treatment. Ravalico G, et al. **Doc Ophthalmol** 1997–98; 94(4):321–6

Association of insulin resistance to electrocardiographic changes in non obese Asian Indian subjects with hypertension. Marita AR, et al. **Endocr Res** 1998 May; 24(2):215–33

Endothelial dysfunction in the aorta of transgenic rats harboring the mouse Ren-2 gene. Arnet UA, et al. **Endothelium** 1999;6(3):175–84

Aerobic exercise attenuates blood pressure reactivity to cold pressor test in normotensive, young adult African-American women. Bond V, et al. **Ethn Dis** 1999 Winter;9(1):104–10

Renin and hemodynamic responses to exercise in borderline hypertensives. Headley SA, et al. **Ethn Dis** 1998 Autumn; 8(3):312–8

Hypertensive left ventricular hypertrophy is linked to an enhanced catecholamine response to submaximal exercise. Kinugawa T, et al. **Eur J Clin Invest** 1999 Jul;29(7):594–602

Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs. Massart PE, et al. **Eur J Clin Invest** 1998 Oct;28(10):798–806

Neonatal neutropenia associated with maternal hypertension poses a risk for nosocomial infection. Gray PH, et al. **Eur J Pediatr** 1999 Jan;158(1):71–3

Comparison of the vascular relaxant effects of ATP-dependent K+ channel openers on aorta and pulmonary artery isolated from spontaneously hypertensive and Wistar-Kyoto rats. Kwan YW, et al. **Eur J Pharmacol** 1999 Jan 22;365(2–3):241–51

Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Nurminen ML, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):61–7

Enhanced endothelium-independent vasodilator response to calcitonin gene-related peptide in hypertensive rats. Tomobe YI, et al. **Eur J Pharmacol** 1998 Jun 26; 351(3):351–5

Differential effects of tyrosine kinase inhibitors on contraction and relaxation of the aortas of normotensive and hypertensive rats. Zerrouk A, et al. **Eur J Pharmacol** 1999 Jun 11;374(1):49–58

The relationship between cardiac output and posthyperventilation hyperpnoea in patients with essential hypertension. Bellofiore S, et al. **Eur Respir J** 1998 Nov; 12(5):1160–3

Vascular remodeling in hypertensive transgenic mice. Nishijo N, et al. **Exp Anim** 1999 Jul;48(3):203–8

Endothelin-1 and relaxation of the rat aorta during pregnancy in nitroarginine-induced hypertension. Dieye AM, et al. **Fundam Clin Pharmacol** 1999;13(2):204–12

Hemodynamic basis of blood pressure variability in normotensive and spontaneously hypertensive rats. Janssen BJ. **Fundam Clin Pharmacol** 1998;12 Suppl 1:11s–16s

Soman-induced hypertension in conscious rats is mediated by prolonged central muscarinic stimulation. Létienne R, et al. **Fundam Clin Pharmacol** 1999;13(4):468–74

Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Bushehri N, et al. **Geriatr Nephrol Urol** 1998;8(2):95–100

Modernization, stress, and blood pressure: new directions in research. Dressler WW. **Hum Biol** 1999 Aug;71(4):583–605 (65 ref.)

Blood pressure: genetic and environmental influences. Gerber LM, et al. **Hum Biol** 1999 Aug;71(4):467–73

Relationship of body size and body mass to blood pressure: sex-specific and developmental influences. Gerber LM, et al. **Hum Biol** 1999 Aug;71(4):505–28 (113 ref.)

Blood pressure and age in cross-cultural perspective. Stevenson DR. **Hum Biol** 1999 Aug;71(4):529–51 (126 ref.)

Gestational hypertension but not pre-eclampsia is associated with insulin resistance syndrome characteristics. Caruso A, et al. **Hum Reprod** 1999 Jan;14(1):219–23

Meeting summary for NASSHP, July 17–19, 1998. North American Society for the Study of Hypertension in Pregnancy. **Hypertens Pregnancy** 1999;18(2):iii–xi

Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hamada M, et al. **Hypertens Res** 1998 Dec; 21(4):227–34

Impaired nitric oxide-independent dilation of renal afferent arterioles in spontaneously hypertensive rats. Hayashi K, et al. **Hypertens Res** 1999 Mar;22(1):31–7

Endothelin-1 facilitates synaptic transmission in the nucleus tractus solitarii in normotensive rats but not in spontaneously hypertensive rats. Hirooka Y, et al. **Hypertens Res** 1999 Mar;22(1):43–8

Calcium channel blockers shorten the periodicity of ultradian variation in blood pressure in patients with essential hypertension. Kawamura H, et al. **Hypertens Res** 1998 Sep; 21(3):179–86

Reduction in blood pressure with a sodium-reduced, potassium- and magnesium-enriched mineral salt in subjects with mild essential hypertension. Kawasaki T, et al. **Hypertens Res** 1998 Dec;21(4):235–43

Evidence suggesting that lateral parabrachial nucleus is responsible for enhanced medullary cholinergic activity in hypertension. Kubo T, et al. **Hypertens Res** 1998 Sep; 21(3):201–7

Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Osaki Y, et al. **Hypertens Res** 1998 Sep;21(3):169–73

Influence of mild to moderate obesity on left ventricular stress filling pattern in hypertension. Seto S, et al. **Hypertens Res** 1998 Dec;21(4):245–50

The myocardial beta-adrenergic system in spontaneously hypertensive heart failure (SHHF) rats. Anderson KM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):402–7

Assessment of arterial compliance by carotid midwall strain-stress relation in hypertension. Bella JN, et al. **Hypertension** 1999 Mar;33(3):793–9

Role of endothelin in the increased vascular tone of patients with essential hypertension. Cardillo C, et al. **Hypertension** 1999 Feb;33(2):753–8

Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Davies E, et al. **Hypertension** 1999 Feb;33(2):703–7

Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. de Simone G, et al. **Hypertension** 1999 Mar;33(3):800–5

Low calorie diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Dessi-Fulgheri P, et al. **Hypertension** 1999 Feb;33(2):658–62

Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension. Di Wang H, et al. **Hypertension** 1999 May;33(5):1225–32

Renin activity and blood pressure in response to chronic episodic hypoxia. Fletcher EC, et al. **Hypertension** 1999 Aug;34(2):309–14

Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Fortuño A, et al. **Hypertension** 1999 Jul;34(1):138–43

Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension. Gelband CH, et al. **Hypertension** 1999 Jan; 33(1 Pt 2):360–5

Alpha1- and alpha2-adrenoceptor control of sodium transport reverses in developing hypertension. Gesek FA. **Hypertension** 1999 Jan;33(1 Pt 2):524–9

A test of the "epinephrine hypothesis" in humans. Goldstein DS, et al. **Hypertension** 1999 Jan;33(1):36–43

Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension. Higashi Y, et al. **Hypertension** 1999 Jan;33(1 Pt 2):591–7

Neuronal nitric oxide synthase-dependent afferent arteriolar function in angiotensin II-induced hypertension. Ichihara A, et al. **Hypertension** 1999 Jan;33(1 Pt 2):462–6

Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Intengan HD, et al. **Hypertension** 1999 Jan;33(1 Pt 2):569–74

Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats. Intengan HD, et al. **Hypertension** 1998 Oct;32(4):770–7

Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Kakoki M, et al. **Hypertension** 1999 Jan;33(1 Pt 2):467–71

Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Kohara K, et al. **Hypertension** 1999 Jan;33(1 Pt 2):565–8

Microvascular responses to ischemia/reperfusion in normotensive and hypertensive rats. Kurose I, et al. **Hypertension** 1999 Aug;34(2):212–6

Irbesartan reduces QT dispersion in hypertensive individuals. Lim PO, et al. **Hypertension** 1999 Feb;33(2):713–8

Hypertension-induced end-organ damage : A new transgenic approach to an old problem. Luft FC, et al. **Hypertension** 1999 Jan;33(1 Pt 2):212–8 (76 ref.)

Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype. Makaritsis KP, et al. **Hypertension** 1999 Sep;34(3):403–7

Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Manunta P, et al. **Hypertension** 1999 Sep;34(3):450–6

State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Mark AL, et al. **Hypertension** 1999 Jan;33(1 Pt 2):537–41 (40 ref.)

Elastic properties and composition of the aortic wall in old spontaneously hypertensive rats. Marque V, et al. **Hypertension** 1999 Sep;34(3):415–22

Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Muiesan ML, et al. **Hypertension** 1999 Jan;33(1 Pt 2):575–80

Activation of the brain angiotensin system by in vivo human angiotensin-converting enzyme gene transfer in rats. Nakamura S, et al. **Hypertension** 1999 Aug;34(2):302–8

Role of nitric oxide in cyclosporine A-induced hypertension. Oriji GK, et al. **Hypertension** 1998 Nov;32(5):849–55

Long-term effects of angiotensin-converting enzyme inhibition on renal medullary neutral lipid in spontaneously hypertensive rats. O'Sullivan JB, et al. **Hypertension** 1999 May;33(5):1214–7

Microalbuminuria and transcapillary albumin leakage in essential hypertension. Pedrinelli R, et al. **Hypertension** 1999 Sep;34(3):491–5

Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety. Piccirillo G, et al. **Hypertension** 1999 Aug;34(2):242–6

Diastolic dysfunction and baroreflex sensitivity in hypertension. Pitzalis MV, et al. **Hypertension** 1999 May; 33(5):1141–5

Structural autoregulation of terminal vascular beds: vascular adaptation and development of hypertension. Pries AR, et al. **Hypertension** 1999 Jan;33(1):153–61

Decreased flow-induced dilation and increased production

of cGMP in spontaneously hypertensive rats. Qiu HY, et al. **Hypertension** 1998 Dec;32(6):1098–103
Nitric oxide dependent vasodilation in young spontaneously hypertensive rats. Radaelli A, et al. **Hypertension** 1998 Oct; 32(4):735–9
Effects of coffee on ambulatory blood pressure in older men and women: A randomized controlled trial. Rakic V, et al. **Hypertension** 1999 Mar;33(3):869–73
Effect of ACE inhibitor on DOCA–salt– and aortic coarctation–induced hypertension in mice: do kinin B2 receptors play a role? Rhaleb NE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):329–34
Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Ribstein J, et al. **Hypertension** 1999 Jan;33(1):90–5
Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Sakata K, et al. **Hypertension** 1999 Jun; 33(6):1447–52
Two–week administration of tempol attenuates both hypertension and renal excretion of 8–Iso prostaglandin f2alpha. Schnackenberg CG, et al. **Hypertension** 1999 Jan; 33(1 Pt 2):424–8
Structural vascular changes in hypertension: role of angiotensin II, dietary sodium supplementation, blood pressure, and time. Simon G, et al. **Hypertension** 1998 Oct; 32(4):654–60
Prolonged L–arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Susic D, et al. **Hypertension** 1999 Jan;33(1 Pt 2):451–5
Local renal medullary L–NAME infusion enhances the effect of long–term angiotensin II treatment. Szentiványi M Jr, et al. **Hypertension** 1999 Jan;33(1 Pt 2):440–5
Role of neuronal nitric oxide synthase in Dahl salt–sensitive hypertension. Tan DY, et al. **Hypertension** 1999 Jan;33(1 Pt 2):456–61
Relation between body fat–corrected ECG voltage and ambulatory blood pressure in patients with essential hypertension. Tochikubo O, et al. **Hypertension** 1999 May; 33(5):1159–63
Antihypertensive mechanisms underlying a novel salt–sensitive hypertensive model induced by sensory denervation. Wang DH, et al. **Hypertension** 1999 Jan;33(1 Pt 2):499–503
I1–imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Wenzel RR, et al. **Hypertension** 1998 Dec;32(6):1022–7
Roles of AT1 and AT2 receptors in the hypertensive Ren–2 gene transgenic rat kidney. Zhuo J, et al. **Hypertension** 1999 Jan;33(1 Pt 2):347–53
A new physiological approach to control essential hypertension. Selvamurthy W, et al. **Indian J Physiol Pharmacol** 1998 Apr;42(2):205–13
Event related evoked potentials in hypertensive subjects. Tandon OP, et al. **Indian J Physiol Pharmacol** 1997 Jan; 41(1):79–82
Echocardiographic features and QT dispersion in borderline isolated systolic hypertension in the elderly. Ural D, et al. **Int J Cardiol** 1999 Mar 15;68(3):317–23
Diastolic function and insulin resistance in essential hypertension. Zemva A, et al. **Int J Cardiol** 1998 Oct 30; 66(3):293–7
Post–beta–receptor defect in isolated hearts of obese–hypertensive rabbits. Carroll JF. **Int J Obes Relat Metab Disord** 1999 Aug;23(8):863–6
Obesity and hypertension: from pathophysiology to treatment. Kolanowski J. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:42–6 (38 ref.)
Risk for hypertension and diminished pain sensitivity in women: autonomic and daily correlates. D'Antono B, et al. **Int J Psychophysiol** 1999 Jan;31(2):175–87
Effects of race, sex, and socioeconomic status upon cardiovascular stress responsivity and recovery in youth. Jackson RW, et al. **Int J Psychophysiol** 1999 Jan; 31(2):111–9
Use of radial artery applanation tonometry and a generalized transfer function to determine aortic pressure augmentation in subjects with treated hypertension. Cameron JD, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1214–20
Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension. Virdis A, et al. **J Am Coll Cardiol** 1999 May; 33(6):1677–84
Contribution of reflection of pressure wave on central systolic blood pressure in older hypertensive patients [letter] Kohara K, et al. **J Am Geriatr Soc** 1999 Apr; 47(4):499
Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. Riondino S, et al. **J Am Geriatr Soc** 1999 Aug;47(8):943–7
Insulin effects on the left ventricle in older hypertensive subjects. Scuteri A, et al. **J Am Geriatr Soc** 1999 Jun; 47(6):727–9
Left ventricular diastolic properties of hypertensive patients measured by pulsed tissue Doppler imaging. Oki T, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1106–12
Pressure–natriuresis and –diuresis in transgenic rats harboring both human renin and human angiotensinogen genes. Dehmel B, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2212–22
Donor and recipient family histories of hypertension influence renal impairment and blood pressure during acute rejections. Guidi E, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2102–7
Evidence against elevated sympathetic vasoconstrictor activity in borderline hypertension. Schobel HP, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1581–7
Daytime blood pressure elevation after nocturnal hypoxia. Arabi Y, et al. **J Appl Physiol** 1999 Aug;87(2):689–98
Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep. Campbell AR, et al. **J Appl Physiol** 1999 Jan;86(1):139–51
Endothelial dysfunction in hypertension. Shimokawa H. **J Atheroscler Thromb** 1998;4(3):118–27 (104 ref.)
Chaos and spectral analyses of heart rate variability during head–up tilting in essential hypertension. Kagiyama S, et al. **J Auton Nerv Syst** 1999 May 28;76(2–3):153–8
Chronopharmacological dependence of antihypertensive effects of the imidazoline–like drugs in stroke–prone spontaneously hypertensive rats. Medvedev OS, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):170–6
Effects of myocardial hypertrophy on neural reflexes controlling cardiovascular function. Meyrelles SS, et al. **J Auton Nerv Syst** 1998 Nov 10;73(2–3):135–42
Theoretical study of the effect of stress, dependent remodeling on arterial geometry under hypertensive conditions [letter] Chaudhry HR. **J Biomech** 1999 May; 32(5):551; 553
A model for geometric and mechanical adaptation of arteries to sustained hypertension. Rachev A, et al. **J Biomech Eng** 1998 Feb;120(1):9–17
Predicting peak oxygen uptake among older patients with chronic illness. Dominick KL, et al. **J Cardiopulm Rehabil** 1999 Mar–Apr;19(2):81–9
Impaired renal vascular response to a D1–like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats. de Vries PA, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):191–8
Effects of fetal and neonatal renin–angiotensin system blockade in Lyon hypertensive rats. Florin M, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):549–53
Nitric oxide–dependent vasodilator mechanism is not impaired by hypertension but is diminished with aging in the rat aorta. Imaoka Y, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):756–61
Adrenaline responsiveness in mild hypertension: no evidence for altered beta–adrenoceptor sensitivity. Kahan T, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):753–9
The endothelium as prognostic factor and therapeutic target: what criteria should we apply? Kaplan NM. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S78–80 (10 ref.)
Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade–induced hypertensive rats. Kobayashi N, et al. **J Cardiovasc Pharmacol** 1999 Aug;34(2):173–81
Effects of L–type calcium channel activation on renal vascular resistances in the Lyon hypertensive rat. Le Roy AL, et al. **J Cardiovasc Pharmacol** 1999 Jan;33(1):65–9
Ethanol selectively counteracts hypotension evoked by central I(1)–imidazoline but not alpha2–adrenergic receptor activation in spontaneously hypertensive rats. El–Mas MM, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):382–9
Dietary NaCl–induced hypertension in uninephrectomized Wistar–Kyoto rats: role of kidney function. Mozaffari MS, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):814–21
Differences in responses to norepinephrine and adenosine triphosphate in isolated, perfused mesenteric vascular beds between normotensive and spontaneously hypertensive rats. Naito Y, et al. **J Cardiovasc Pharmacol** 1998 Nov; 32(5):807–18
Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR–SP. Nakamura K, et al. **J Cardiovasc Pharmacol** 1999 Jun; 33(6):876–82
In vivo left ventricular function and collagen expression in aldosterone/salt–induced hypertension. Ramirez–Gil JF, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):927–34
Total arterial compliance in ambulatory hypertension during selective beta1–adrenergic receptor blockade and angiotensin–converting enzyme inhibition. Soma J, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):273–9
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. Surdacki A, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):652–8
Endothelial dysfunction in hypertension: fact or fancy? Taddei S, et al. **J Cardiovasc Pharmacol** 1998;32 Suppl 3:S41–7 (73 ref.)
Platelet–derived growth factor–induced vasodilatation in mesenteric resistance arteries by nitric oxide: blunted response in spontaneous hypertension. Takase H, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):223–8
Effects of long–term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. Tofovic SP, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):360–6
Relationship between hyperinsulinemia and ambulatory blood pressure monitoring of lean and overweight male hypertensives. Feldstein CA, et al. **J Cardiovasc Risk** 1998 Feb;5(1):25–30
Ambulatory blood pressure and risk factors for coronary heart disease in black and Indian medical students. Morar N, et al. **J Cardiovasc Risk** 1998 Oct–Dec;5(5–6):313–8
Cerebral vasodilatation causing acute intracranial hypertension: a method for noninvasive assessment. Schmidt B, et al. **J Cereb Blood Flow Metab** 1999 Sep; 19(9):990–6
Hypertension in women. August P, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1862–6 (52 ref.)
Hypertension in pregnancy: a potential window into long–term cardiovascular risk in women. Seely EW. **J Clin Endocrinol Metab** 1999 Jun;84(6):1858–61 (27 ref.)
Sustained hemodynamic effects of the selective dopamine–1 agonist, fenoldopam, during 48–hour infusions in hypertensive patients: a dose–tolerability study. Taylor AA, et al. **J Clin Pharmacol** 1999 May;39(5):471–9
Activation of neuropeptide FF neurons in the brainstem nucleus tractus solitarius following cardiovascular challenge and opiate withdrawal. Jhamandas JH, et al. **J Comp Neurol** 1998 Dec 14;402(2):210–21
Growth hormone and the metabolic syndrome. Johannsson G, et al. **J Endocrinol Invest** 1999;22(5 Suppl):41–6 (42 ref.)
Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. Gentilini P, et al. **J Hepatol** 1999 Apr; 30(4):632–8
Plasma insulin, plasminogen activator inhibitor, and ankle–brachial systolic blood pressure ratio in overweight hypertensive subjects. Achimastos A, et al. **J Hum Hypertens** 1999 May;13(5):329–35
A meta–analysis of randomised controlled trials (RCT) among healthy normotensive and essential hypertensive elderly patients to determine the effect of high salt (NaCl) diet of blood pressure. Alam S, et al. **J Hum Hypertens** 1999 Jun;13(6):367–74
White coat hypertension and pregnancy outcome. Bar J, et al. **J Hum Hypertens** 1999 Aug;13(8):541–5
A longitudinal study of vessel wall properties in normotensive and hypertensive renal transplant recipients. Barenbrock M, et al. **J Hum Hypertens** 1998 Oct; 12(10):707–11
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. Conlin PR, et al. **J Hum Hypertens** 1998 Oct; 12(10):693–9
Reversed day–night ambulatory blood pressure profile and blunted heart rate variability of unknown cause in a hypertensive patient. De Backer TL, et al. **J Hum Hypertens** 1999 Jul;13(7):493–4
Lisinopril versus enalapril: evaluation of trough:peak ratio by ambulatory blood pressure monitoring. Diamant M, et al. **J Hum Hypertens** 1999 Jun;13(6):405–12
The heart in the hypertensive elderly. Grodzicki T, et al. **J Hum Hypertens** 1998 Sep;12(9):593–7 (51 ref.)
Does the 'J–curve' still hold in the post 'HOT' era? Grossman E. **J Hum Hypertens** 1998 Nov;12(11):729–30
Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J–curve concept in hypertension. Ibsen H. **J Hum Hypertens** 1998 Nov; 12(11):731–2
Postexercise decrease in arterial blood pressure, total peripheral resistance and in circulatory responses to brief hyperoxia in subjects with mild essential hypertension. Izdebska E, et al. **J Hum Hypertens** 1998 Dec;12(12):855–60
Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits. Kocemba J, et al. **J Hum Hypertens** 1998 Sep;12(9):621–6 (51 ref.)
Studies on cardiac sympathovagal balance and large artery distensibility in patients with untreated essential hypertension. Kosch M, et al. **J Hum Hypertens** 1999 May; 13(5):315–9
Silent myocardial ischaemia in patients with essential arterial hypertension and non–insulin dependent diabetes mellitus. Lubaszewski W, et al. **J Hum Hypertens** 1999 May; 13(5):309–13
Captopril, but not nifedipine, improves endothelium–dependent vasodilation in hypertensive patients. Millgård J, et al. **J Hum Hypertens** 1998 Aug; 12(8):511–6
Blood pressure and other risk factors before the onset of myocardial infarction in hypertensive patients. Minami J, et al. **J Hum Hypertens** 1998 Oct;12(10):713–8
Twenty–four hour ambulatory blood pressure monitoring in young and elderly hypertensive subjects. Musialik D, et al. **J Hum Hypertens** 1998 Sep;12(9):641–2
Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? Owens PE, et al. **J Hum Hypertens** 1998 Nov;12(11):743–8
Blood pressure changes at the Dead Sea (a low altitude area). Paran E, et al. **J Hum Hypertens** 1998 Aug;12(8):551–5
Dissociation between albuminuria and insulinaemia in hypertensive and atherosclerotic men. Pedrinelli R, et al. **J Hum Hypertens** 1999 Feb;13(2):129–34
Homocysteine, hypertension and stroke. Perry IJ. **J Hum Hypertens** 1999 May;13(5):289–93 (42 ref.)
Spectral analysis of heart rate variability in elderly non–dipper hypertensive patients. Rizzo V, et al. **J Hum Hypertens** 1999 Jun;13(6):393–8
The epidemiology of the association between hypertension and menopause. Staessen JA, et al. **J Hum Hypertens** 1998 Sep;12(9):587–92 (56 ref.)
Ambulatory systolic blood pressure patterns in elderly hypertensives. Traub YM. **J Hum Hypertens** 1998 Aug; 12(8):547–9

Reproducibility of ambulatory blood pressure monitoring in daily practice. van der Steen MS, et al. **J Hum Hypertens** 1999 May;13(5):303–8

Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. Vanmolkot FH, et al. **J Hum Hypertens** 1999 Aug; 13(8):559–63

Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. Yamazaki T, et al. **J Hum Hypertens** 1999 Jan;13 Suppl 1:S43–7; discussion S49–50 (32 ref.)

End tidal CO2 is an independent determinant of systolic blood pressure in women. Anderson DE, et al. **J Hypertens** 1999 Aug;17(8):1073–80

Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. Baan J Jr, et al. **J Hypertens** 1998 Sep;16(9):1299–305

Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infarction. Berton G, et al. **J Hypertens** 1998 Apr;16(4):525–30

Influence of age and end-stage renal disease on the stiffness of carotid wall material in hypertension. Blacher J, et al. **J Hypertens** 1999 Feb;17(2):237–44

Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension. Bracht C, et al. **J Hypertens** 1999 Mar;17(3):357–63

Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. Celentano A, et al. **J Hypertens** 1998 Jul;16(7):985–91

Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. Cohn JN. **J Hypertens** 1998 Dec;16(12 Pt 2):2117–24 (53 ref.)

Blood pressure control in a hypertension hospital clinic. Cuspidi C, et al. **J Hypertens** 1999 Jun;17(6):835–41

Left ventricular chamber and wall mechanics in the presence of concentric geometry. de Simone G, et al. **J Hypertens** 1999 Jul;17(7):1001–6

Interaction between lifetime captopril treatment and NaCl-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. Fang Z, et al. **J Hypertens** 1999 Jul;17(7):983–91

Eicosanoids and membrane properties in arteries of aged spontaneously hypertensive rats. Fujii K, et al. **J Hypertens** 1999 Jan;17(1):75–80

Myocardial diastolic impairment caused by left ventricular hypertrophy involves basal septum more than other walls: analysis by pulsed Doppler tissue imaging. Galderisi M, et al. **J Hypertens** 1999 May;17(5):685–93

Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. Gosse P, et al. **J Hypertens** 1998 Apr; 16(4):531–5

Role of the sympathetic nervous system in human hypertension. Grassi G. **J Hypertens** 1998 Dec;16(12 Pt 2):1979–87 (60 ref.)

Sympathetic nerve discharge in normal pregnancy and pregnancy-induced hypertension [see comments] [published erratum appears in J Hypertens 1998 Aug;16(8):1219] Greenwood JP, et al. **J Hypertens** 1998 May;16(5):617–24. Comment in: J Hypertens 1998 May;16(5):569–7 0.

Hypercapnic cerebral blood flow in spontaneously hypertensive rats. Heinert G, et al. **J Hypertens** 1998 Oct; 16(10):1491–8

The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. Hirose H, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2007–12

Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. Hishiki S, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2101–8

Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1. Intengan HD, et al. **J Hypertens** 1998 Dec; 16(12 Pt 2):1907–12

Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice. Kai T, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2045–9

Plasma levels of natriuretic peptides and adrenomedullin in elderly hypertensive patients: relationships to 24 h blood pressure. Kario K, et al. **J Hypertens** 1998 Sep;16(9):1253–9

Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. Kastarinen MJ, et al. **J Hypertens** 1998 Sep;16(9):1379–87

Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. Khder Y, et al. **J Hypertens** 1998 Nov;16(11):1619–25

Hyper-responsiveness to angiotensin II is related to cardiac structural adaptation in hypertensive subjects. Klingbeil AU, et al. **J Hypertens** 1999 Jun;17(6):825–33

Angiogenesis and hypertension. le Noble FA, et al. **J Hypertens** 1998 Nov;16(11):1563–72 (103 ref.)

Effect of postural changes on cardiovascular responses to static exercise in hypertensive human beings. Legramante JM, et al. **J Hypertens** 1999 Jan;17(1):99–105

Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. Lip GY, et al. **J Hypertens** 1999 Aug;17(8):1203–7

Large artery structure and function in hypertension and end-stage renal disease. London GM, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1931–8 (84 ref.)

Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. Maeso R, et al. **J Hypertens** 1998 May; 16(5):665–72

Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. Marceau M, et al. **J Hypertens** 1998 May;16(5):673–9

Indapamide improves flow-induced dilation in hypertensive rats with a high salt intake. Matrougui K, et al. **J Hypertens** 1998 Oct;16(10):1485–90

Biomechanical properties and chemical composition of the aorta in genetic hypertensive rats. Mizutani K, et al. **J Hypertens** 1999 Apr;17(4):481–7

Functional characterization of endothelin receptors in hypertensive resistance vessels. Montagnani M, et al. **J Hypertens** 1999 Jan;17(1):45–52

Power spectral analysis of the heart rate in hypertensive patients with and without left ventricular hypertrophy: the effect of a left ventricular mass reduction. Muiesan ML, et al. **J Hypertens** 1998 Nov;16(11):1641–50

Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. Nishimura M, et al. **J Hypertens** 1998 Aug;16(8):1175–85

Significance of sympathetic nervous system in sodium-induced nocturnal hypertension. Okuguchi T, et al. **J Hypertens** 1999 Jul;17(7):947–57

Ambulatory blood pressure in the hypertensive population: patterns and prevalence of hypertensive subforms [see comments] Owens P, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1735–43. Comment in: J Hypertens 1998 Dec;16(12 Pt 1):1719–20.

Ambulatory blood pressure predicts end-organ damage only in subjects with reproducible recordings. HARVEST Study Investigators. Hypertension and Ambulatory Recording Venetia Study. Palatini P, et al. **J Hypertens** 1999 Apr;17(4):465–73

White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study [see comments] Palatini P, et al. **J Hypertens** 1998 Jul;16(7):977–84. Comment in: J Hypertens 1999 Jan;17(1):148–9.

Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients. Petretta M, et al. **J Hypertens** 1999 May;17(5):707–13

Isolated clinic hypertension [letter] Pierdomenico SD, et al. **J Hypertens** 1998 May;16(5):713–4

Role of endogenous nitric oxide in the nucleus tratus solitarii on baroreflex control of heart rate in spontaneously hypertensive rats. Pontieri V, et al. **J Hypertens** 1998 Dec; 16(12 Pt 2):1993–9

Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Pontremoli R, et al. **J Hypertens** 1999 Jul;17(7):993–1000

U46619-mediated vasoconstriction of the fetal placental vasculature in vitro in normal and hypertensive pregnancies. Read MA, et al. **J Hypertens** 1999 Mar; 17(3):389–96

Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. Rhéaume C, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):2085–9

Left ventricular systolic function in primary aldosteronism and hypertension. Rossi GP, et al. **J Hypertens** 1998 Dec; 16(12 Pt 2):2075–7

Impact of arterial elastance as a measure of vascular load on left ventricular geometry in hypertension. Saba PS, et al. **J Hypertens** 1999 Jul;17(7):1007–15

Relationship between small-artery structure and systolic, diastolic and pulse pressure in essential hypertension. Schiffrin EL, et al. **J Hypertens** 1999 Mar;17(3):381–7

Endothelin and endothelin antagonists in hypertension. Schiffrin EL. **J Hypertens** 1998 Dec;16(12 Pt 2):1891–5 (69 ref.)

Hypertensive disorders of pregnancy: a dysregulation of the sympathetic nervous system? [comment] Schobel HP, et al. **J Hypertens** 1998 May;16(5):569–70. Comment on: J Hypertens 1998 May;16(5):617–24.

Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. Seux ML, et al. **J Hypertens** 1998 Jul;16(7):963–9

Comparison of cardiovascular responses to intra-hippocampal mu, delta and kappa opioid agonists in spontaneously hypertensive rats and isolation-induced hypertensive rats. Shen S, et al. **J Hypertens** 1999 Apr; 17(4):497–505

Analysis of circadian blood pressure rhythm and target-organ damage in stroke-prone spontaneously hypertensive rats. Shimamura T, et al. **J Hypertens** 1999 Feb;17(2):211–20

Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy: the Cardioscreening Study. Stramba-Badiale M, et al. **J Hypertens** 1998 May;16(5):681–8

Assessing the coronary circulation in hypertension. Strauer BE, et al. **J Hypertens** 1998 Sep;16(9):1221–33 (163 ref.)

Nephroprotective effect of antihypertensive drugs in essential hypertension. Susic D, et al. **J Hypertens** 1998 May; 16(5):555–67 (182 ref.)

Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. Taddei S, et al. **J Hypertens** 1998 Apr;16(4):447–56

Regular walking increases peak limb vasodilatory capacity of older hypertensive humans: implications for arterial structure. Tanaka H, et al. **J Hypertens** 1998 Apr; 16(4):423–8

Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats. Teisman AC, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1759–65

Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Tsuchihashi T, et al. **J Hypertens** 1999 Jul;17(7):917–22

Low diastolic blood pressure and mortality in a population-based cohort of 16913 hypertensive patients in North Karelia, Finland. Tuomilehto J, et al. **J Hypertens** 1998 Sep;16(9):1235–42

Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. Verdecchia P, et al. **J Hypertens** 1998 Sep;16(9):1335–43

Changes in short-term variability of blood pressure and heart rate during the development of obesity-associated hypertension in high-fat fed dogs. Verwaerde P, et al. **J Hypertens** 1999 Aug;17(8):1135–43

Regulation of vascular type 1 angiotensin II receptor in hypertension and sodium loading: role of angiotensin II. Wang DH, et al. **J Hypertens** 1998 Apr;16(4):467–75

Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. Watanabe K, et al. **J Hypertens** 1999 Aug;17(8):1161–8

Sympatho-adrenal mechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine? Bobik A, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S51–4 (32 ref.)

Noradrenaline spillover and microneurography measurements in patients with primary hypertension. Jennings GL. **J Hypertens Suppl** 1998 Aug;16(3):S35–8 (41 ref.)

Can good surrogate end-points predict the prognosis of hypertensive patients? Mancia G, et al. **J Hypertens Suppl** 1998 Oct;16(5):S3–7 (38 ref.)

Clinical relevance blood pressure variability. Parati G, et al. **J Hypertens Suppl** 1998 Aug;16(3):S25–33 (34 ref.)

Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. Pénicaud L, et al. **J Hypertens Suppl** 1998 Aug;16(3):S45–9

Insulin resistance may or may not play a role in blood pressure regulation [letter; comment] Reaven GM. **J Intern Med** 1998 Oct;244(4):359–60. Comment on: J Intern Med 1997 Nov;242(5):407–12.

Secondary endothelial dysfunction: hypertension and heart failure. Boulanger CM. **J Mol Cell Cardiol** 1999 Jan; 31(1):39–49 (120 ref.)

Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. Zimmermann R, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1447–56

The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. Dessi-Fulgheri P, et al. **J Nephrol** 1998 Nov-Dec; 11(6):296–9 (11 ref.)

Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. Sakata K, et al. **J Nucl Med** 1999 Jan;40(1):6–11

Absence of hypertension: a bad prognostic sign in placental abruption [letter; comment] Mahale AR. **J Obstet Gynaecol Res** 1999 Feb;25(1):69–70. Comment on: J Obstet Gynaecol Res 1997 Jun;23(3):267–71.

Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats. Brynne L, et al. **J Pharmacol Exp Ther** 1999 Aug; 290(2):664–71

Angiotensin II-induced renal vasoconstriction in genetic hypertension. Jackson EK, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):329–34

Magnetic resonance imaging analysis of left ventricular function in normal and spontaneously hypertensive rats. Wise RG, et al. **J Physiol (Lond)** 1998 Dec 15;513 (Pt 3):873–87

Ca(2+)-sensitivity of portal vein circular muscle from normotensive and hypertensive rats. Shimamura K, et al. **J Smooth Muscle Res** 1998 Feb;34(1):23–34

Implication of ENaC in salt-sensitive hypertension. Hummler E. **J Steroid Biochem Mol Biol** 1999 Apr-Jun; 69(1–6):385–90 (49 ref.)

Collagen I and III and mechanical properties of conduit arteries in rats with genetic hypertension. Chamiot Clerc P, et al. **J Vasc Res** 1999 Mar-Apr;36(2):139–46

Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats. Endo Y, et al. **J Vasc Res** 1998 Nov-Dec; 35(6):421–7

Evidence for the involvement of protein kinase C in depression of endothelium-dependent vascular responses in spontaneously hypertensive rats. Soloviev AI, et al. **J Vasc Res** 1998 Sep-Oct;35(5):325–31

Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. Staessen JA, et al. **JAMA** 1999 Aug 11; 282(6):539–46

Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human

renin-angiotensin system in double transgenic mice with hypertension. Kai T, et al. **Jpn Circ J** 1998 Aug; 62(8):599–603.

Long-term effects of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients. Matoba M, et al. **Jpn Circ J** 1998 Dec;62(12):900–2.

Relations of vascular calcium channels with blood pressure and endothelium in hypertension and with aging. Hui C, et al. **Jpn Heart J** 1999 Mar;40(2):209–25.

Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. Kishida H, et al. **Jpn Heart J** 1999 Jan;40(1):31–44.

Therapeutic effects of a calcium antagonist, lacidipine, on stroke-prone spontaneously hypertensive rats with cerebrovascular lesions. Funato H, et al. **Jpn J Pharmacol** 1999 Jul;80(3):199–208.

Long-term treatment with angiotensin converting enzyme inhibitor restores reduced calcitonin gene-related peptide-containing vasodilator nerve function in mesenteric artery of spontaneously hypertensive rats. Kawasaki H, et al. **Jpn J Pharmacol** 1999 Feb;79(2):221–9.

Effects of exogenous [Arg8]-vasopressin on borderline-hypertensive Hiroshima rats. Teranishi Y, et al. **Jpn J Pharmacol** 1999 Feb;79(2):251–5.

Epithelial sodium channel and its implication in the control of blood pressure. Hummler E. **Kidney Blood Press Res** 1998;21(2-4):253–5 (14 ref.)

Does leptin play a role in the pathogenesis of essential hypertension? Kokot F, et al. **Kidney Blood Press Res** 1999; 22(3):154–60.

Nitric oxide-dependent renal vasodilatation is not altered in rat with rHuEpo-induced hypertension. Migliori M, et al. **Kidney Blood Press Res** 1999;22(3):140–5.

Target blood pressure in the treatment of essential hypertension. Rahn KH, et al. **Kidney Blood Press Res** 1998;21(2-4):271–3 (10 ref.)

Insulin-like growth factor I in essential hypertension [clinical conference] Diez J. **Kidney Int** 1999 Feb;55(2):744–59.

Microalbuminuria in essential hypertension. Rodicio JL, et al. **Kidney Int Suppl** 1998 Dec;68:S51–4 (63 ref.)

Intralymphocyte free magnesium and calcium and insulin tolerance test in a group of essential hypertensive patients. Delva P, et al. **Life Sci** 1998;63(16):1405–15.

Paradoxical effects of intracerebroventricular low-dose opioid antagonists in SHR with chronic pain. Kolaric S, et al. **Life Sci** 1999;65(4):395–402.

High flaxseed (linseed) diet restores endothelial function in the mesenteric arterial bed of spontaneously hypertensive rats. Talom RT, et al. **Life Sci** 1999;64(16):1415–25.

The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopaussal women. Beljic T, et al. **Maturitas** 1998 Jun 17;29(3):229–38.

Essential hypertension is lymphatic: a working hypothesis. Mękarski JE. **Med Hypotheses** 1998 Aug;51(2):101–3.

Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. Juan CC, et al. **Metabolism** 1999 Apr;48(4):465–71.

Acute elevations in salt intake and reduced renal mass hypertension compromise arteriolar dilation in rat cremaster muscle. Frisbee JC, et al. **Microvasc Res** 1999 May;57(3):273–83.

Capillary blood cell velocity in finger nailfold: effect of enalapril and mibefradil in patients with mild to moderate hypertension. Martina B, et al. **Microvasc Res** 1999 Mar; 57(2):94–9.

Hypertension in dialysis patients. Bellinghieri G, et al. **Miner Electrolyte Metab** 1999 Jan-Apr;25(1-2):84–9 (32 ref.)

Systolic hypertension: the nephrologist's point of view. Cirillo M, et al. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):69–72 (19 ref.)

Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension. Wookey PJ, et al. **Miner Electrolyte Metab** 1998;24(6):389–99 (113 ref.)

Expression of vascular endothelial growth factor during the development of cardiac hypertrophy in spontaneously hypertensive rats. McAinsh AM, et al. **Mol Cell Biochem** 1998 Oct;187(1-2):141–6.

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects [see comments] Gainer JV, et al. **N Engl J Med** 1998 Oct 29;339(18):1285–92. Comment in: N Engl J Med 1999 Mar 25;340(12):967; discussion 968–9. Comment in: N Engl J Med 1999 Mar 25;340(12):967–8; discussion 968–9. Comment in: N Engl J Med 1999 Mar 25;340(12):968–9.

Sympathetic overactivity in hypertensive patients with chronic renal disease [editorial; comment] Remuzzi G. **N Engl J Med** 1999 Apr 29;340(17):1360–1. Comment on: N Engl J Med 1999 Apr 29;340(17):1321–8.

Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Brochu E, et al. **Nephrol Dial Transplant** 1999 Aug; 14(8):1881–8.

Adenosine receptor antagonism in the prevention of acute cyclosporine A-nephrotoxicity in normal, diabetic and hypertensive rats. Heyne N, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:23–4.

Sodium proton exchanger (NHE) isoforms--potential relevance to hypertension and its complications [editorial] Ng LL. **Nephrol Dial Transplant** 1998 Dec;13(12):2994–6 (21 ref.)

Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Pontremoli R, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):360–5.

Maintenance of normal agonist-induced endothelium-dependent relaxation in uraemic and hypertensive resistance vessels. Thuraisingham RC, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):70–5.

Risk factors associated with hypertensive nephrosclerosis [editorial] Bleyer AJ, et al. **Nephron** 1999;82(3):193–8 (45 ref.)

Renal vascular resistance in essential hypertension [letter] Galesic K, et al. **Nephron** 1998 Nov;80(3):363–4.

Hypertension as an etiopathological factor in the development of cerebral atrophy in hemodialyzed patients. Savazzi GM, et al. **Nephron** 1999 Jan;81(1):17–24.

Role of atrial natriuretic peptide in the development of arterial hypertension in patients with pubertal hypothalamic syndrome. Krivchenko TP, et al. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):435–7.

Strain differences in Fos expression following airpuff startle in Spontaneously Hypertensive and Wistar Kyoto rats. Palmer AA, et al. **Neuroscience** 1999 Mar;89(3):965–78.

Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition. Pereira LM, et al. **Pathol Res Pract** 1999;195(3):177–81.

Exercise in hypertensive children and adolescents: any harm done? Alpert BS. **Pediatr Cardiol** 1999 Jan-Feb;20(1):66–9; discussion 70 (17 ref.)

Increased arterial stiffness in children with a parental history of hypertension. Meaney E, et al. **Pediatr Cardiol** 1999 May-Jun;20(3):203–5.

Vascular endothelium and nitric oxide in childhood hypertension. Goonasekera CD, et al. **Pediatr Nephrol** 1998 Oct;12(8):676–89 (230 ref.)

Severe hypertensive sequelae in a child with Seckel syndrome (bird-like dwarfism). Sorof JM, et al. **Pediatr Nephrol** 1999 May;13(4):343–6.

White coat hypertension in two adolescents. Yamaguchi Y, et al. **Pediatr Nephrol** 1999 Jan;13(1):60–2.

Hyper-responsiveness of adrenal sympathetic nerve activity in spontaneously hypertensive rats to ganglionic blockade, mental stress and neuronglucopenia. Zhang W, et al. **Pflugers Arch** 1998 Dec;437(1):56–60.

The behavior of spontaneously hypertensive and Wistar Kyoto rats under a paced fixed consecutive number schedule of reinforcement. Evenden J, et al. **Pharmacol Biochem Behav** 1999 May;63(1):71–82.

Endothelial dysfunction and hypertensive vasoconstriction. De Artinano AA, et al. **Pharmacol Res** 1999 Aug; 40(2):113–24 (143 ref.)

Cocaine-induced hypertension: role of the peripheral sympathetic system. Mo W, et al. **Pharmacol Res** 1999 Aug; 40(2):139–45.

Possible mechanisms of salt-induced hypertension in Dahl salt-sensitive rats. Bayorh MA, et al. **Physiol Behav** 1998 Dec 1;65(3):563–8.

Body fluid distribution in rats with cold-induced hypertension. Sun Z, et al. **Physiol Behav** 1999 Jan 1-15; 65(4-5):879–84.

Regional haemodynamic differences between normotensive and spontaneously hypertensive rats--a microsphere study. Granstam SO, et al. **Physiol Res** 1998;47(1):9–15.

Influence of age on inotropic response to insulin and insulin-like growth factor I in spontaneously hypertensive rats: role of nitric oxide. Ren J, et al. **Proc Soc Exp Biol Med** 1999 May;221(1):46–52.

Differential chronergy of propranolol effects on heart rate in healthy and hypertensive subjects. Ruiz-Vega H, et al. **Proc West Pharmacol Soc** 1998;41:71–2.

Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Cohn JN. **Prog Cardiovasc Dis** 1999 May-Jun;41(6):441–50 (53 ref.)

Asymmetrical changes in blood-brain barrier permeability during pentylenetetrazol-induced seizures and in acute hypertension. Oztaş B. **Psychiatry Res** 1998 May 20; 82(2):129–33.

Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. al'Absi M, et al. **Psychosom Med** 1998 Jul-Aug;60(4):521–7.

Salt in hypertension: physiological and molecular aspects. Gavras I, et al. **Recent Prog Horm Res** 1998;53:1–6 (46 ref.)

Insulin resistance and impaired endothelium-dependent renal vasodilatation in fructose-fed hypertensive rats. Kamata K, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb; 103(2):195–210.

Impaired endothelium-dependent relaxation in mesenteric arteries of reduced renal mass hypertensive rats. Kimura K, et al. **Scand J Clin Lab Invest** 1999 May;59(3):199–204.

Long-term renal function in primary hypertension. An epidemiological and pathophysiological study. Siewert-Delle A. **Scand J Urol Nephrol Suppl** 1999; 199:1–36.

Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Raij L. **Semin Nephrol** 1999 May; 19(3):296–303 (58 ref.)

Effects of cholic acid on blood pressure and production of vascular aldosterone and corticosterone. Wu P, et al. **Steroids** 1999 Apr;64(4):291–5.

Decreases in blood pressure and sympathetic nerve activity by microvascular decompression of the rostral ventrolateral medulla in essential hypertension. Morimoto S, et al. **Stroke** 1999 Aug;30(8):1707–10.

Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation. Sobey CG, et al. **Stroke** 1999 Sep; 30(9):1933–40; discussion 1941.

Sleep apnoea and autonomic function. Zwillich CW. **Thorax** 1998 Oct;53 Suppl 3:S20–4 (34 ref.)

Increased heart rate and haemostatic balance disorders pre-exist the established hypertension [letter] Makris TK, et al. **Thromb Haemost** 1999 Apr;81(4):664–5.

Hypertension in kidney transplantation recipients: effect on long-term renal allograft survival. Kim HC, et al. **Transplant Proc** 1998 Nov;30(7):3906–7.

Baroreceptor-heart rate reflex sensitivity enhancement after urinary bladder distention in essential hypertensives. Bardelli M, et al. **Urol Res** 1999 Apr;27(2):153–6.

Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension. Cardillo C, et al. **Vasc Med** 1998;3(2):138–44 (79 ref.)

Occurrence and relevance of postprandial hypotension in patients with essential hypertension. Mitro P, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):320–5.

Index of myocardial performance using Doppler-derived parameters in the evaluation of left ventricular function in patients with essential hypertension. Kang SM, et al. **Yonsei Med J** 1998 Oct;39(5):446–52.

[Electrocardiographic signs of atrial overload in hypertension] Ouyang BA, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):503–7 (Eng. Abstr.) **(Chi)**

[Late ventricular potentials in patients with arterial hypertension] Franc P, et al. **Vnitr Lek** 1998 Nov; 44(11):637–41 (Eng. Abstr.) **(Cze)**

[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus] Vítovec J, et al. **Vnitr Lek** 1998 Jun;44(6):336–41 (Eng. Abstr.) **(Cze)**

[Are the antagonists of angiotensin II AT1 receptors protectors of the kidney?] Deray G. **Arch Mal Coeur Vaiss** 1999 Jul;92(7):903–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Hypertension at pregnancy] Krzesinski JM. **Rev Med Liege** 1999 May;54(5):415–23 (Eng. Abstr.) **(Fre)**

[Mechanisms of essential arterial hypertension] Joly D, et al. **Rev Prat** 1999 Mar 1;49(5):477–81 (Eng. Abstr.) **(Fre)**

[Associations between viscoelastic properties of large arteries and their extracellular matrix composition in abdominal aortic aneurysms in humans] Boutouyrie P, et al. **Therapie** 1999 Jan-Feb;54(1):85–91 (Eng. Abstr.) **(Fre)**

[Endurance training in hypertension is effective. Which form of sports, frequency and intensity of training? When should adjuvant chemotherapy be considered?] Ketelhut RG. **Fortschr Med** 1998 Dec 10;116(34):26–8, 30–2 (Eng. Abstr.) **(Ger)**

[Significance of a life style change in arterial hypertension] Müller JF, et al. **Fortschr Med** 1998 Dec 10;116(34):20–5 (Eng. Abstr.) **(Ger)**

[Chinese meditation pattern. Qi Gong: to learn from tigers and bears. Series: relaxation technic 1. Centers of vital energy] Wagner B. **Fortschr Med** 1999 Mar 20;117(8):55 **(Ger)**

[New objectives in hypertensive therapy (editorial)] Heinzl S. **Med Monatsschr Pharm** 1999 Feb;22(2):29 **(Ger)**

[Emotional irritability and anxiety in salt-sensitive persons at risk for essential hypertension] Buchholz K, et al. **Psychother Psychosom Med Psychol** 1999 Aug;49(8):284–9 (Eng. Abstr.) **(Ger)**

[Intravenous adenosine infusion in the assessment of coronary flow reserve in hypertension. Transesophageal Doppler echocardiographic study] Lengyel M, et al. **Orv Hetil** 1999 Mar 7;140(10):523–7 (45 ref.) (Eng. Abstr.) **(Hun)**

[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension] Mancia G, et al. **Ann Ital Med Int** 1997 Oct-Dec;12(4):217–22 (42 ref.) (Eng. Abstr.) **(Ita)**

[Silent myocardial ischemia: clinical relevance in hypertensive patients] Stramba-Badiale M. **Cardiologia** 1998 Jun;43 Suppl 1:29–31 (27 ref.) **(Ita)**

["The individual pressure profile" in clinical practice (letter)] Bossa P. **G Ital Cardiol** 1998 Sep;28(9):1042–3 **(Ita)**

[Physiopathology and clinical aspects of hypertensive crisis] Pinna G, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):28–36 (29 ref.) **(Ita)**

[Therapy and physiopathology of hypertension in elderly (letter)] Fujii J. **J Cardiol** 1998 Dec;32(6):407 **(Jpn)**

[The role of nitric oxide in deoxycorticosterone acetate-salt hypertensive rats] Ishii T, et al. **Nippon Jinzo Gakkai Shi** 1999 Apr;41(2):43–8 (Eng. Abstr.) **(Jpn)**

[Hypertension and insulin] Kushiro T, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):223–9 (18 ref.) **(Jpn)**

[Differences in exercise blood pressure response between dipper and non-dipper elderly patients with essential hypertension] Yin D, et al.

Nippon Ronen Igakkai Zasshi 1998 Nov;35(11):845–50 (Eng. Abstr.) **(Jpn)**

[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats] **Karasawa A, et al. Nippon Yakurigaku Zasshi** 1999 May; 113(5):317–26 (Eng. Abstr.) **(Jpn)**

[Polymorphism of the ACE gene and left ventricular morphology and function in patients with borderline, mild and moderate hypertension] Swierblewska E, et al. **Pol Arch Med Wewn** 1998 Mar;99(3):203–10 (Eng. Abstr.) **(Pol)**

[Some parameters of hemostasis and fibrinolysis in diabetic patients] Telejko B, et al. **Pol Arch Med Wewn** 1998 Aug; 100(2):133–8 (Eng. Abstr.) **(Pol)**

[Evaluation of the signal-to-noise ratio--"Kullback information"--in the spectrum of cardiointervals in arterial hypertension patients depending on cosmophysical factors] Agulova LP, et al. **Biofizika** 1998 Jul–Aug;43(4):659–65 (Eng. Abstr.) **(Rus)**

[Effect of enalapril on cerebral circulation and its autoregulation in hypertensive rats] Adzhienko LM, et al. **Biull Eksp Biol Med** 1999 Jun;127(6):642–4 **(Rus)**

[Characteristics of the vascular reactivity in hypertensive NISAG rats] Balakireva LA, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):136–8 **(Rus)**

[The blood rheological profiles of patients with arterial hypertension and a hyperviscosity syndrome] Murav'ev AV, et al. **Fiziol Cheloveka** 1998 Jul–Aug;24(4):113–7 **(Rus)**

[Cardio-hemodynamic effects of domestic adrenergic beta-antagonist proxodolol in hypertension in patients with pacemaker] Iskenderov BG, et al. **Klin Med (Mosk)** 1999; 77(4):29–31 (Eng. Abstr.) **(Rus)**

[Effect of the maternal environment on blood pressure and startle reflex in rats with inherited hypertension] Amstislavskiĭ SIa, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Aug;84(8):783–90 (Eng. Abstr.) **(Rus)**

[Changes of arterial bed in essential hypertension and treatment policy] Gogin EE. **Ter Arkh** 1999;71(1):64–7 **(Rus)**

[The connection between late ventricular potentials and ventricular arrhythmias in hypertension patients with different forms of myocardial hypertrophy] Gusarov GV, et al. **Ter Arkh** 1998;70(8):48–52 (Eng. Abstr.) **(Rus)**

[Coronary artery function and myocardial perfusion in patients with ischemic heart disease isolated and in combination with arterial hypertension] Kuzin AI, et al. **Ter Arkh** 1999;71(2):70–2 (Eng. Abstr.) **(Rus)**

[Clinical significance of blood pressure variability in hypertension] Mazur ES, et al. **Ter Arkh** 1999;71(1):22–5 (Eng. Abstr.) **(Rus)**

[Aortic wall distensibility and the structure and function of the left ventricle in aged persons with isolated systolic hypertension] Ivanović-Krstić B, et al. **Srp Arh Celok Lek** 1999 Jan–Feb;127(1–2):10–5 (Eng. Abstr.) **(Scc)**

[Provocation and measurement of retrograde pulsatile wave velocity in normal subjects and patients with systemic hypertension] Sánchez Torres G, et al. **Arch Inst Cardiol Mex** 1999 Jan–Feb;69(1):47–54 (Eng. Abstr.) **(Spa)**

[Ambulatory arterial pressure and left ventricular hypertrophy in untreated hypertensive patients] Pascual JM, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):166–70 (Eng. Abstr.) **(Spa)**

[Blood pressure regulation by potassium channels] Orias M. **Medicina (B Aires)** 1998;58(4):429–32 (Eng. Abstr.) **(Spa)**

[The characteristics of the sympathico-adrenal and kinin systems in engineers in the early stages of arterial hypertension] Zholov VM. **Lik Sprava** 1999 Apr–May; (3):65–8 (Eng. Abstr.) **(Ukr)**

PREVENTION & CONTROL

Does desflurane alter left ventricular function when used to control surgical stimulation during aortic surgery? Eyraud D, et al. **Acta Anaesthesiol Scand** 1999 Aug;43(7):737–43

The effect of i.v. enalaprilat in chronically treated hypertensive patients during cardiac surgery. Schuetz WH, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):929–35

Dietary calcium and blood pressure [comment] [see comments] Drüeke TB. **Am J Hypertens** 1999 Jan;12(1 Pt 1):96–8 (19 ref.). Comment on: Am J Hypertens 1999 Jan;12(1 Pt 1):84–92. Comment in: Am J Hypertens 1999 Jan;12(1 Pt 1):82–3.

Social and economic factors as obstacles to blood pressure control. Lang T. **Am J Hypertens** 1998 Jul;11(7):900–2

A population-based survey of drug treatment efficacy by the French National Committee for the Control of Arterial Hypertension. Mallion JM, et al. **Am J Hypertens** 1998 Jul;11(7):903–4

Reducing hypertension-associated cardiorenal risk: the role of heart rate, left ventricular hypertrophy regression, and renoprotection. Materson BJ. **Am J Hypertens** 1999 Jan; 12(1 Pt 2):1S–2S (4 ref.)

Optimal blood pressure levels. Pickering TG. **Am J Hypertens** 1998 Jul;11(7):877–8

An attempt to improve blood pressure control in the French population: information and outcome awareness at the general practitioner level. Poggi L, et al. **Am J Hypertens** 1998 Jul;11(7):905–8

Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Touyz RM, et al. **Am J Hypertens** 1999 Aug;12(8 Pt 1):757–65

Strategies for improving blood pressure control. Weber MA. **Am J Hypertens** 1998 Jul;11(7):897–9

Blood pressure control in dialysis patients: importance of the lag phenomenon. Charra B, et al. **Am J Kidney Dis** 1998 Nov;32(5):720–4 (28 ref.)

Salt-sensitive hypertension in ANP knockout mice is prevented by AT1 receptor antagonist losartan. Melo LG, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R624–30

Renal medullary interstitial infusion of L-arginine prevents hypertension in Dahl salt-sensitive rats. Miyata N, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1667–73

Hypertension control and access to medical care in the inner city. Kotchen JM, et al. **Am J Public Health** 1998 Nov; 88(11):1696–9

Dexmedetomidine failed to block the acute hyperdynamic response to electroconvulsive therapy. Fu W, et al. **Anesthesiology** 1999 Feb;90(2):422–4

Postexercise vasodilatation reduces diastolic blood pressure responses to stress. West SG, et al. **Ann Behav Med** 1998 Spring;20(2):77–83

Walking to work and the risk for hypertension in men: the Osaka Health Survey. Hayashi T, et al. **Ann Intern Med** 1999 Jul 6;131(1):21–6

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Yoshimoto T, et al. **Atherosclerosis** 1999 Aug;145(2):333–40

Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial. FRACOG and the ACT Study Group. Crowther CA, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):12–8

Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet. Mervaala E, et al. **Blood Press** 1999;8(1):49–56

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [see comments] **BMJ** 1998 Sep 12;317(7160):713–20 . Comment in: BMJ 1998 Sep 12;317(7160):691–2. Comment in: BMJ 1998 Sep 12;317(7160):693–4. Comment in: BMJ 1999 Mar 6;318(7184):667; discussion 667–8. Comment in: BMJ 1999 Mar 6;318(7184):667–8.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [see comments] [published erratum appears in BMJ 1999 Jan 2;318(7175):29] **BMJ** 1998 Sep 12;317(7160):703–13. Comment in: BMJ 1998 Sep 12;317(7160):691–2. Comment in: BMJ 1998 Sep 12;317(7160):693–4. Comment in: ACP J Club 1999 Jan–Feb;130(1):4–5. Comment in: BMJ 1999 Mar 6;318(7184):666–7; discussion 667–8. Comment in: BMJ 1999 Mar 6;318(7184):667; discussion 667–8. Comment in: BMJ 1999 Mar 6;318(7184):667–8.

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group [see comments] **BMJ** 1998 Sep 12;317(7160):720–6. Comment in: BMJ 1998 Sep 12;317(7160):691–2. Comment in: BMJ 1998 Sep 12;317(7160):693–4. Comment in: ACP J Club 1999 Jan–Feb;4–5. Comment in: BMJ 1999 Mar 6;318(7184):667–8.

Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Ito H, et al. **Br J Pharmacol** 1999 Feb;126(3):613–20

Guidelines set new definitions, update treatment for hypertension [news] **Bull World Health Organ** 1999; 77(3):293

Will lifestyle modifications reduce blood pressure? [editorial; comment] Campbell NR. **Can Fam Physician** 1999 Jul; 45:1640–5. Comment on: Can Fam Physician 1999 Jul;45 :1750–5, 1760–5. **(Eng, Fre)**

Lifestyle approaches to managing high blood pressure. New Canadian guidelines [see comments] Petrella RJ. **Can Fam Physician** 1999 Jul;45:1750–5, 1760–5. Comment in: Can Fam Physician 1999 Jul;45 :1640–5. **(Eng, Fre)**

Adherence to management of high blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Chockalingam A, et al. **Can J Public Health** 1998 Sep–Oct;89(5):I5–11 **(Eng, Fre)**

United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Nasr CE, et al. **Cleve Clin J Med** 1999 Apr;66(4):247–53

Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Goyal RK. **Clin Exp Hypertens** 1999 Jan–Feb;21(1–2):167–79 (44 ref.)

Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients. Kuriyama S, et al. **Clin Exp Hypertens** 1999 Apr; 21(3):213–22

Predictive preventive medicine for hypertensive cardiovascular disease. Proceedings of satellite symposium to WHO Forum 97. Kyoto, Japan, October 1997. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):527–80

Kidney denervation combined with elimination of adrenal-renal portal circulation prevents the development of hypertension in spontaneously hypertensive rats. Abramczyk P, et al. **Clin Exp Pharmacol Physiol** 1999 Jan; 26(1):32–4

Effects of voluntary exercise and L-arginine on thrombogenesis and microcirculation in stroke-prone spontaneously hypertensive rats. Noguchi T, et al. **Clin Exp Pharmacol Physiol** 1999 Apr;26(4):330–5

Lifestyle modifications to prevent and control hypertension. 6. Recommendations on potassium, magnesium and calcium. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Burgess E, et al. **CMAJ** 1999 May 4;160(9 Suppl):S35–45

Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Campbell NR, et al. **CMAJ** 1999 May 4;160(9 Suppl):S1–6

Lifestyle modifications to prevent and control hypertension. 3. Recommendations on alcohol consumption. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Campbell NR, et al. **CMAJ** 1999 May 4;160(9 Suppl):S13–20

Lifestyle changes to prevent and control hypertension: do they work? A summary of the Canadian consensus conference. Campbell NR, et al. **CMAJ** 1999 May 4; 160(9):1341–3

Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Cléroux J, et al. **CMAJ** 1999 May 4;160(9 Suppl):S21–8

Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Fodor JG, et al. **CMAJ** 1999 May 4;160(9 Suppl):S29–34

Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Leiter LA, et al. **CMAJ** 1999 May 4;160(9 Suppl):S7–12

Lifestyle modifications to prevent and control hypertension. 7. Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Spence JD, et al. **CMAJ** 1999 May 4;160(9 Suppl):S46–50

Aerobic exercise attenuates blood pressure reactivity to cold pressor test in normotensive, young adult African-American women. Bond V, et al. **Ethn Dis** 1999 Winter;9(1):104–10

Effect of Ca2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat. de Oliveira CF, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):195–200

Sympathectomy prevents fructose-induced hyperinsulinemia and hypertension. Verma S, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):R1–4

Effects of chronic treatment with (+)-nicotine on the stress-induced hypertension and downregulation of central nicotinic receptors in rats: comparative study with (-)-nicotine. Takita M, et al. **Gen Pharmacol** 1999 Jul; 33(1):29–33

The case for combination therapy in achieving blood pressure targets. **Hosp Med** 1999 Jan;60(1):50

Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancy-induced hypertension. Rogers MS, et al. **Hypertens Pregnancy** 1999;18(2):165–72

Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Blezer EL, et al. **Hypertension** 1999 Jan;33(1):137–44

Detection and control of high blood pressure in the community : Do we need a wake-up call? Meissner I, et al. **Hypertension** 1999 Sep;34(3):466–71

Renal intramedullary infusion of L-arginine prevents reduction of medullary blood flow and hypertension in Dahl salt-sensitive rats. Miyata N, et al. **Hypertension** 1999 Jan;33(1 Pt 2):446–50

Clonidine prevents insulin resistance and hypertension in obese dogs. Rocchini AP, et al. **Hypertension** 1999 Jan;33(1 Pt 2):548–53

New guidelines for prevention, detection, evaluation and treatment of high blood pressure. Glick M. **J Am Dent Assoc** 1998 Nov;129(11):1588–94

Participants' evaluation of a weight-loss program.

Mattfeldt-Beman MK, et al. **J Am Diet Assoc** 1999 Jan; 99(1):66-71

The effects of aerobic exercise and T'ai Chi on blood pressure in older people: results of a randomized trial. Young DR, et al. **J Am Geriatr Soc** 1999 Mar;47(3):277-84

Blood pressure control in kidney transplant recipients: influence of immunosuppression. Gerhardt U, et al. **J Auton Pharmacol** 1999 Feb;19(1):49-54

Lacidipine prevents the hypertension and renal and cardiac changes induced by high-fructose diet in WKY rats. Cosenzi A, et al. **J Cardiovasc Pharmacol** 1999 Mar; 33(3):485-91

Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension. López-Hernández FJ, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):748-55

Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. Siragy HM, et al. **J Clin Invest** 1999 Jul;104(2):181-8

Tight blood pressure control in type 2 diabetes. Wroth T, et al. **J Fam Pract** 1998 Dec;47(6):412-3

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO, et al. **J Heart Lung Transplant** 1999 Apr;18(4):336-45

Dietary salt restriction in pregnancy an outmoded practice [comment] Churchill D. **J Hum Hypertens** 1999 Mar; 13(3):157-8 (9 ref.). Comment on: J Hum Hypertens 1999 Mar;13(3):159-66.

Prevalence, awareness, treatment and control of arterial hypertension in an elderly population in Belgium [see comments] De Backer G, et al. **J Hum Hypertens** 1998 Oct;12(10):701-6. Comment in: J Hum Hypertens 1998 Oct;12(10):665-6.

Exercise and hypertension [comment] Fagard R. **J Hum Hypertens** 1999 Jun;13(6):359-60 (22 ref.). Comment on: J Hum Hypertens 1999 Jun;13(6):361-6.

Overestimation of the prevalence of hypertension in the population [letter; comment] Klungel OH, et al. **J Hypertens** 1998 Nov;16(11):1702-3. Comment on: J Hypertens 1998 Jun;16(6):747-52.

Awareness of hypertension among a north Indian population. Gupta AK, et al. **J Indian Med Assoc** 1998 Oct; 96(10):298-9, 311

Calcium supplementation in pregnancy to prevent pregnancy induced hypertension (PIH). Yabes-Almirante C. **J Perinat Med** 1998;26(5):347-53 (39 ref.)

Exogenous 25-hydroxycholecalciferol does not attenuate salt-induced hypertension. Thierry-Palmer M, et al. **J Steroid Biochem Mol Biol** 1998 Nov;67(3):193-9

JAMA patient page: blood pressure. **JAMA** 1999 Feb 3; 281(5):484

Advances in the treatment of hypertension [see comments] Pickering TG. **JAMA** 1999 Jan 13;281(2):114-6. Comment in: JAMA 1999 Jun 2;281(21):1988-9.

Blood-pressure control preserves renal function [news] Frankel DH. **Lancet** 1998 May 23;351(9115):1562

Hypertension guidelines for diabetic patients [letter] Simmons D. **N Z Med J** 1999 Jul 23;112(1092):281-2

Monitoring your blood pressure. **Postgrad Med** 1999 May 1;105(5):209-10

Physical activity and incident hypertension in black and white adults: the Atherosclerosis Risk in Communities Study. Pereira MA, et al. **Prev Med** 1999 Mar;28(3):304-12

Development of a community-based diabetes and hypertension preventive program. Wang CY, et al. **Public Health Nurs** 1998 Dec;15(6):406-14

What should we do about blood pressure and stroke? [editorial] Potter JF. **QJM** 1999 Feb;92(2):63-6

More salt, please. The DASH Steering Committee [letter] Moore TJ, et al. **Science** 1998 Nov 6;282(5391):1049-51

[Disease control in the 21st century in China] Chen NQ. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1997 Jun; 18(3):174-6 (8 ref.) **(Chi)**

[A survey on prevalence of hypertension in Macao area] Leong HC, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Jul; 32(4):219-21 (Eng. Abstr.) **(Chi)**

[The 'Diabetes mellitus type 2' guideline (first revision) of the Dutch College of General Practitioners: response from internal medicine] Erkelens DW. **Ned Tijdschr Geneeskd** 1999 Aug 14;143(33):1686-8 (Eng. Abstr.) **(Dut)**

[Ambulatory 24-hour blood pressure monitoring] **Dtsch Med Wochenschr** 1998 Nov 20;123(47):1426-30 **(Ger)**

[Patients demand more information about hypertension from their physician] Böttcher-Bühler E. **Fortschr Med** 1999 Jan 20;117(1-2):31-2 **(Ger)**

[A project of the Ministry of Health for iodine prophylaxis in Italy: Salt in food for the prophylaxis of iodine deficiency and the prevention of hypertension] Marabelli R, et al. **Ann Ist Super Sanita** 1998;34(3):367-70 (Eng. Abstr.) **(Ita)**

[Prevention of hypertensive crisis by narcosis induction in vascular surgery] Loguercio G, et al. **Minerva Anestesiol** 1981 Jul;47(7):401-3 (16 ref.) **(Ita)**

[Circulatory changes at the time of anesthetic induction and endotracheal intubation--comparison of thiamylal induction group and propofol induction group] Igarashi M, et al. **Masui** 1998 Oct;47(10):1193-9 (Eng. Abstr.) **(Jpn)**

[A clinical analysis of fetoplacental blood flow in prognosis of fetal emergency in pregnancies complicated by hypertension] Wydra D, et al. **Ginekol Pol** 1998 Nov; 69(11):789-94 (Eng. Abstr.) **(Pol)**

[The role of neurohormonal mechanisms in the etiopathogenesis of essential hypertension] Zyśko D, et al. **Pol Merkuriusz Lek** 1998 Sep;5(27):157-61 (29 ref.) (Eng. Abstr.) **(Pol)**

[The comparative assessment of follow-up for hypertensive patients] Nesterov IuI, et al. **Klin Med (Mosk)** 1999; 77(6):23-5 (Eng. Abstr.) **(Rus)**

[Preventive chronotherapy with capoten in hypertensive outpatients] Zaslavskaia RM, et al. **Klin Med (Mosk)** 1999; 77(3):39-41 (Eng. Abstr.) **(Rus)**

[Description of costs and effectiveness of a hypertension control program in primary care] Bonet Plá A, et al. **Aten Primaria** 1998 Nov 15;22(8):497-504 (Eng. Abstr.) **(Spa)**

[Treatment of the hypertensive response during coronary surgery: comparison of high-dose propofol to propofol with nitroprusside] Olmos M, et al. **Rev Esp Anestesiol Reanim** 1998 Oct;45(8):326-32 (Eng. Abstr.) **(Spa)**

[Commentary on the 6th Report of the American National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (editorial)] Vallés Belsué F. **Rev Esp Cardiol** 1999 Jan;52(1):1-4 (Eng. Abstr.) **(Spa)**

[Role of pediatricians in the prevention of adult hypertension] Lagomarsino E. **Rev Med Chil** 1999 Mar;127(3):349-57 (43 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Management of high casual blood pressure in a disaster situation: the 1995 Hanshin-Awaji earthquake [letter] Kario K. **Am J Hypertens** 1998 Sep;11(9):1138-9

Assessing patient wellness: new perspectives on quality of life and compliance. Williams GH. **Am J Hypertens** 1998 Nov;11(11 Pt 2):186S-191S (27 ref.)

Anxiety and coronary heart disease: a synthesis of epidemiological, psychological, and experimental evidence. Kubzansky LD, et al. **Ann Behav Med** 1998 Spring; 20(2):47-58 (140 ref.)

Cardiovascular and behavioral response to social confrontation: measuring real-life stress in the laboratory. Larkin KT, et al. **Ann Behav Med** 1998 Fall;20(4):294-301

Psychological changes accompanying and mediating stress-management training for essential hypertension. García-Vera MP, et al. **Appl Psychophysiol Biofeedback** 1998 Sep;23(3):159-78 (47 ref.)

Religion and hypertension: testing alternative explanations among immigrants. Walsh A. **Behav Med** 1998 Fall; 24(3):122-30

Diminished salt appetite in spontaneously hypertensive rats following local administration of the angiotensin II antagonist saralasin in the median preoptic area. Tanaka J, et al. **Behav Pharmacol** 1997 Dec;8(8):752-6

No impaired cognitive function in treated patients with mild-moderate hypertension compared to normotensive controls. Nilsson P, et al. **Blood Press** 1998 Jul;7(4):209-13

Survey of white coat hypertension. Definition differs from others [letter; comment] Kario K, et al. **BMJ** 1999 Feb 20;318(7182):535. Comment on: BMJ 1998 Aug 29;317(7158):565-70.

The white coat effect in hypertensive pregnancy: much ado about nothing? Brown MA, et al. **Br J Obstet Gynaecol** 1999 May;106(5):474-80

Prevalence and predictors of white-coat response in patients with treated hypertension [see comments] MacDonald MB, et al. **CMAJ** 1999 Aug 10;161(3):265-9. Comment in: CMAJ 1999 Aug 10;161(3):275-6.

Withholding treatment in white-coat hypertension: wishful thinking [editorial; comment] Spence JD. **CMAJ** 1999 Aug 10;161(3):275-6. Comment on: CMAJ 1999 Aug 10;161(3):265-9.

Lifestyle modifications to prevent and control hypertension. 7. Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Spence JD, et al. **CMAJ** 1999 May 4;160(9 Suppl):S46-50

Compliance of patients with hypertension and associated factors. Kyngäs H, et al. **J Adv Nurs** 1999 Apr;29(4):832-9

Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur trial. Syst-Eur Trial Investigators. Fletcher AE, et al. **J Hypertens** 1998 Aug;16(8):1117-24

Psychobehavioral factors involved in the isolated office hypertension: comparison with stress-induced hypertension. Munakata M, et al. **J Hypertens** 1998 Apr; 16(4):419-22

Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. Seux ML, et al. **J Hypertens** 1998 Jul;16(7):963-9

Differences in behavior profile between normotensive subjects and patients with white-coat and sustained hypertension. Coelho R, et al. **J Psychosom Res** 1999 Jan; 46(1):15-27

Defensiveness and essential hypertension. Mann SJ, et al. **J Psychosom Res** 1998 Aug;45(2):139-48

White coat hypertension in haemodialysis: the role of nurses' dresses. Stragier A. **Nephrol Dial Transplant** 1999 Apr; 14(4):861-2

Lifestyle and the development of hypertension: a 3-year follow-up study of middle-aged Japanese male office workers. Nakanishi N, et al. **Occup Med (Lond)** 1999 Feb; 49(2):109-14

Effect of family responsibilities and job strain on ambulatory blood pressure among white-collar women. Brisson C, et al. **Psychosom Med** 1999 Mar-Apr;61(2):205-13

Relationship of physical symptoms and mood to perceived and actual blood pressure in hypertensive men: a repeated-measures design. Brondolo E, et al. **Psychosom Med** 1999 May-Jun;61(3):311-8

Blood pressure reactivity and marital distress in employed women. Carels RA, et al. **Psychosom Med** 1998 Sep-Oct; 60(5):639-43

John Henryism, gender, and arterial blood pressure in an African American community. Dressler WW, et al. **Psychosom Med** 1998 Sep-Oct;60(5):620-4

Anger expression and incident hypertension. Everson SA, et al. **Psychosom Med** 1998 Nov-Dec;60(6):730-5

Ambulatory blood pressure responses and the circumplex model of mood: a 4-day study. Jacob RG, et al. **Psychosom Med** 1999 May-Jun;61(3):319-33

A longitudinal study of job strain and ambulatory blood pressure: results from a three-year follow-up. Schnall PL, et al. **Psychosom Med** 1998 Nov-Dec;60(6):697-706

Stroke was predicted by dimensions of quality of life in treated hypertensive men. Agewall S, et al. **Stroke** 1998 Nov;29(11):2329-33

[Psychosocial stress as trigger for hypertension] Schrader J. **MMW Fortschr Med** 1999 Jun 17;141(24):43-4 **(Ger)**

[Emotional irritability and anxiety in salt-sensitive persons at risk for essential hypertension] Buchholz K, et al. **Psychother Psychosom Med Psychol** 1999 Aug;49(8):284-9 (Eng. Abstr.) **(Ger)**

[Isolated office hypertension] Kuwajima I. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):241-6 (14 ref.) **(Jpn)**

[The influence of 5-week relaxation therapy on psychological state of patients with borderline hypertension] Sharma VK, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):323-5 (Eng. Abstr.) **(Pol)**

[The adverse effects of antihypertensive therapy: the perception of patients] Miguel JM, et al. **Rev Port Cardiol** 1999 Feb;18(2):123-30 (Eng. Abstr.) **(Por)**

RADIOGRAPHY

Renal artery aneurysms and hypertension. Lebel M, et al. **J Hum Hypertens** 1998 Nov;12(11):765-6

[The X-ray characteristics of the status of the heart and vessels in patients with arterial hypertension exacerbated by a myocardial infarct] Tsallagova ZS, et al. **Vestn Rentgenol Radiol** 1998 Mar-Apr;(2):14-8 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

Washout of I-123 meta-iodobenzylguanidine for assessing cardiac sympathetic activity with progression of hypertension in Dahl salt-sensitive rats. Takatsu H, et al. **J Nucl Cardiol** 1999 Mar-Apr;6(2):204-10

Enalapril plus frusemide MAG3 scintigraphy in hypertensive patients with atherosclerosis and moderate renal insufficiency. Caglar M, et al. **Nucl Med Commun** 1998 Dec;19(12):1135-40

RADIOTHERAPY

[The effect of low-intensity laser radiation in the infrared and red ranges on arterial pressure regulation in patients with borderline hypertension] Shuvalova IN, et al. **Lik Sprava** 1998 Oct-Nov;(7):141-3 (Eng. Abstr.) **(Rus)**

REHABILITATION

The magnitude and duration of ambulatory blood pressure reduction following acute exercise [see comments] Wallace JP, et al. **J Hum Hypertens** 1999 Jun;13(6):361-6. Comment in: J Hum Hypertens 1999 Jun;13(6):359-60.

[Air baths in the treatment of hypertension at the sanatorium stage] Kremnev IuA, et al. **Voen Med Zh** 1999 May; 320(5):40-4 **(Rus)**

[The effect of phyto-air ionization on the main homeostatic systems in patients with neurocirculatory dystonia and essential hypertension] Boriak VP. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar-Apr;(2):6-9 (Eng. Abstr.) **(Rus)**

[The efficacy of psychotherapy with biofeedback in the rehabilitation of hypertension patients] Golubev MV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec; (6):16-8 (Eng. Abstr.) **(Rus)**

[The comparative characteristics of the clinico-physiological action of electromagnetic radiation in the milli- and nanometer ranges in hypertension] Kunitsyna LA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Sep-Oct;(5):5-7 (Eng. Abstr.) **(Rus)**

SURGERY

Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Zazgornik J, et al. **Am J Hypertens** 1998 Nov; 11(11 Pt 1):1364-70

Preload assessment in patients with an open abdomen. Cheatham ML, et al. **J Trauma** 1999 Jan;46(1):16–22

Ventrolateral medullary decompression in essential hypertension [letter; comment] Kaplan NM. **Lancet** 1998 Nov 7;352(9139):1549–50. Comment on: Lancet 1998 Aug 8;352(9126):446–9.

Neurovascular decompression of the left ventrolateral medulla as a treatment of hypertension in a patient with renal artery stenosis [see comments] Anding K, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3253–7. Comment in: Ned Tijdschr Geneeskd 1999 Jun 26;143(26):1398.

Microvascular decompression of the left lateral medulla oblongata for severe refractory neurogenic hypertension [letter; comment] Segal R. **Neurosurgery** 1999 Jan; 44(1):232–3. Comment on: Neurosurgery 1998 Jul;43(1):1–6; discussion 6–9.

Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Proye CA, et al. **Surgery** 1998 Dec; 124(6):1128–33

[Surgical treatment of symptomatic arterial hypertension] Nikonenko AS, et al. **Klin Khir** 1998;(7):12–4 (Eng. Abstr.) **(Rus)**

[Shunting operations in the hypertensive hydrocephalic syndrome in children with developmental defects of the central nervous system] Sufianov AA, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):7–11 (Eng. Abstr.) **(Rus)**

THERAPY

Current hypertension control is just not good enough [editorial; comment] Dustan HP. **Am Fam Physician** 1998 Oct 15;58(6):1292, 1295–6. Comment on: Am Fam Physician 1998 Oct 15;58(6):1323–30.

A rational approach to the treatment of hypertension in special populations. Hall WD. **Am Fam Physician** 1999 Jul; 60(1):156–62 (33 ref.)

Treatment of hypertension: insights from the JNC-VI report [see comments] Kaplan NM. **Am Fam Physician** 1998 Oct 15;58(6):1323–30 (11 ref.). Comment in: Am Fam Physician 1998 Oct 15;58(6):1292, 1295–6.

Hypertension treatment and the prevention of coronary heart disease in the elderly. Moser M. **Am Fam Physician** 1999 Mar 1;59(5):1248–56 (21 ref.)

Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid. Phillips MI. **Am J Cardiol** 1998 Nov 19;82(10A):60S–62S (8 ref.)

Treatment of raised blood pressure in the population. Workshop proceedings. Paris, France, December 11, 1996. **Am J Hypertens** 1998 Jul;11(7):871–908

Health and disease management: what is it and where is it going? What is the role of health and disease management in hypertension? Bernard DB, et al. **Am J Hypertens** 1998 Aug;11(8 Pt 2):103S–108S; discussion 109S–111S (9 ref.)

Number needed to treat: solid science or a path to pernicious rationing? Black HR, et al. **Am J Hypertens** 1998 Aug;11(8 Pt 2):128S–134S; discussion 135S–137S (30 ref.)

Hypertension specialists: ready or not, here we come [editorial] Krakoff LR. **Am J Hypertens** 1999 Feb;12(2 Pt 1):242–3

The cost of treating hypertension: can we keep it under control without compromising the level of care? Moser M. **Am J Hypertens** 1998 Aug;11(8 Pt 2):120S–127S; discussion 135S–137S (29 ref.)

Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk. Sheps SG. **Am J Hypertens** 1999 Aug;12(8 Pt 2):65S–72S

Hypertension in the dialysis patient [editorial; comment] CO Mailloux LU. **Am J Kidney Dis** 1999 Aug;34(2):359–61. Comment on: Am J Kidney Dis 1999 Aug;34(2):218–21.

Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor [see comments] Ozkahya M, et al. **Am J Kidney Dis** 1999 Aug; 34(2):218–21. Comment in: Am J Kidney Dis 1999 Aug;34(2):359–61.

The location of chronic pregnancy hypertension on the vasoconstriction-volume spectrum: working hypothesis. Hon EH. **Am J Obstet Gynecol** 1999 Jul;181(1):137–42

Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR. Katovich MJ, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):H1260–4

Is antisense gene therapy a step in the right direction in the control of hypertension? [editorial] Raizada MK, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H423–32 (54 ref.)

Linking community-based blood pressure measurement to clinical care: a randomized controlled trial of outreach and tracking by community health workers. Krieger J, et al. **Am J Public Health** 1999 Jun;89(6):856–61

Psychological changes accompanying and mediating stress-management training for essential hypertension. García-Vera MP, et al. **Appl Psychophysiol Biofeedback** 1998 Sep;23(3):159–78 (47 ref.)

Failure of alcohol reduction to lower blood pressure in the PATHS trial. Prevention and Treatment of Hypertension Study [letter; comment] Bulpitt CJ, et al. **Arch Intern Med** 1999 Jan 25;159(2):195–6. Comment on: Arch Intern Med 1998 Jun 8;158(11):1197–207.

Elderly stroke prevention program(ESP2)--Results of a quality assurance program for the management of hypertension in the elderly in Australian general practices. Beckinsale P, et al. **Aust Fam Physician** 1998 Aug; 27(8):703–7

Targets in hypertension. Going nowhere or gone as far as we can go? Jennings GL, et al. **Aust N Z J Med** 1999 Apr;29(2):189–96 (35 ref.)

Hypertension management in practice--priorities and problems [editorial] Hedner T, et al. **Blood Press** 1998 Nov; 7(5–6):260–1

Implementing clinical guidelines in the treatment of hypertension in general practice. Hetlevik I, et al. **Blood Press** 1998 Nov;7(5–6):270–6

Low-dose diuretic and/or dietary sodium restriction when blood pressure is resistant to ACE inhibitor. Wing LM, et al. **Blood Press** 1998 Nov;7(5–6):299–307

1999 World Health Organization--International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Sub-Committee. **Blood Press Suppl** 1999;1:9–43

The 1999 WHO-ISH Guidelines for the Management of Hypertension--new targets, new treatment and a comprehensive approach to total cardiovascular risk reduction [editorial] Hansson L, et al. **Blood Press Suppl** 1999;1:3–5

Fortnightly review: management of hypertension in pregnancy. Magee LA, et al. **BMJ** 1999 May 15; 318(7194):1332–6 (49 ref.)

British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity [editorial; comment] Psaty BM, et al. **BMJ** 1999 Sep 4; 319(7210):589–90. Comment on: BMJ 1999 Sep 4;319(7210):630–5.

British Hypertension Society guidelines for hypertension management 1999: summary [see comments] Ramsay LE, et al. **BMJ** 1999 Sep 4;319(7210):630–5. Comment in: BMJ 1999 Sep 4;319(7210):589–90.

Auditing the management of hypertension in British general practice: a critical literature review. Cranney M, et al. **Br J Gen Pract** 1998 Jul;48(432):1424–8 (35 ref.)

Hypertension--A case for lifestyle modification. Steele B. **Can J Cardiol** 1999 Jun;15(6):657–60 **(Eng, Fre)**

Adherence to non-pharmacologic therapy for hypertension: problems and solutions. Fodor G, et al. **Can J Public Health** 1998 Sep–Oct;89(5):I12–5

Principles of combination therapy for hypertension: what we learn from the HOT and other studies--a personal point of view. Opie LH. **Cardiovasc Drugs Ther** 1998 Oct; 12(5):425–9 (25 ref.)

How effective is exercise training for the treatment of hypertension? Petrella RJ. **Clin J Sport Med** 1998 Jul; 8(3):224–31

Exercise training for the treatment of hypertension: a review. Tipton CM. **Clin J Sport Med** 1999 Apr;9(2):104 (5 ref.)

Management of acute severe hypertension and encephalopathy. Mabie WC. **Clin Obstet Gynecol** 1999 Sep; 42(3):519–31 (73 ref.)

Hypertension. Witlin AG, et al. **Clin Obstet Gynecol** 1998 Sep;41(3):533–44 (25 ref.)

Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease [published erratum appears in CMAJ 1999 Jul 13;161(1):21] Perreault S, et al. **CMAJ** 1999 May 18;160(10):1449–55

Bibliography. Current world literature. Clinical trials. **Curr Opin Cardiol** 1998 Sep;13(5):B203–5

The management of hypertension in a diabetic pregnancy. Pearson DW, et al. **Diabetes Metab Res Rev** 1999 Mar–Apr; 15(2):146–51

Hypertension: therapeutic approach to weight loss, exercise, and salt intake. Butler RN, et al. **Geriatrics** 1999 May; 54(5):42, 45–6, 49–50 passim contd

Detection, adherence and control of hypertension for the prevention of strokes: a systematic review. Ebrahim S. **Health Technol Assess** 1998;2(11):i–iv, 1–78 (260 ref.)

Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective. Brownley KA, et al. **Hum Biol** 1999 Aug;71(4):607–39 (211 ref.)

Exercise training-induced blood pressure and plasma lipid improvements in hypertensives may be genotype dependent. Hagberg JM, et al. **Hypertension** 1999 Jul; 34(1):18–23

Is gene therapy for hypertension possible? [editorial] Phillips MI. **Hypertension** 1999 Jan;33(1):8–13 (48 ref.)

A new physiological approach to control essential hypertension. Selvamurthy W, et al. **Indian J Physiol Pharmacol** 1998 Apr;42(2):205–13

Hypertension: setting the treatment targets--a consensus emerges [editorial] Jackson G. **Int J Clin Pract** 1999 Mar; 53(2):87–8

Obesity and hypertension: from pathophysiology to treatment. Kolanowski J. **Int J Obes Relat Metab Disord** 1999 Feb;23 Suppl 1:42–6 (38 ref.)

Qigong and hypertension: a critique of research. Mayer M. **J Altern Complement Med** 1999 Aug;5(4):371–82 (90 ref.)

Therapeutic benefits of qigong exercises in combination with drugs. Sancier KM. **J Altern Complement Med** 1999 Aug; 5(4):383–9 (38 ref.).

The effects of two aerobic training intensities on ambulatory blood pressure in hypertensive patients: results of a randomized trial. Moreira WD, et al. **J Clin Epidemiol** 1999 Jul;52(7):637–42

Laparoscopic evacuation of a subcapsular renal hematoma causing symptomatic hypertension. Graham CW, et al. **J Endourol** 1998 Dec;12(6):551–3

Hypertension in community-dwelling elders from a statewide study: implications for nonpharmacologic therapy. Ciesla JR, et al. **J Health Care Poor Underserved** 1998 Feb; 9(1):62–75

The role of the hypertension specialist [see comments] Beevers DG. **J Hum Hypertens** 1998 Oct;12(10):659–61 (16 ref.). Comment in: J Hum Hypertens 1999 Feb;13(2):151–2.

Does the 'J-curve' still hold in the post 'HOT' era? Grossman E. **J Hum Hypertens** 1998 Nov;12(11):729–30

Hypertension in diabetes: a good opportunity to practise evidence-based medicine? A commentary on the UKPDS. United Kingdom Prospective Diabetes Study. Ibrahim HA, et al. **J Hum Hypertens** 1999 Apr;13(4):221–3 (14 ref.)

The role of the hypertension specialists. ASH Working Committee [letter; comment] Krakoff LR. **J Hum Hypertens** 1999 Feb;13(2):151–2. Comment on: J Hum Hypertens 1998 Oct;12(10):659–61.

A 4-year evaluation of blood pressure management in Trinidad and Tobago. Mahabir D, et al. **J Hum Hypertens** 1999 Jul;13(7):455–9

Non-pharmacological treatment of hypertension: a survey of 2150 general practitioners and internists [letter] Schorr U, et al. **J Hum Hypertens** 1998 Aug;12(8):571–2

Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men [letter; comment] Ikeda U, et al. **J Hypertens** 1998 Oct;16(10):1555. Comment on: J Hypertens 1998 Apr;16(4):537–41.

A community-based case management model for hypertension and diabetes. Ginn M, et al. **J Miss State Med Assoc** 1999 Jul;40(7):226–8

Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. Ebrahim S, et al. **J Public Health Med** 1998 Dec;20(4):441–8

Physiologic effects of externally applied continuous negative abdominal pressure for intra-abdominal hypertension. Bloomfield G, et al. **J Trauma** 1999 Jun;46(6):1009–14; discussion 1014–6

Nephrology. Reducing mortality and increasing awareness. Schieppati A, et al. **Lancet** 1998 Dec 19–26;352 Suppl 4:SIV20 (5 ref.)

Does the blood pressure need lowering? Johnson AG. **Med J Aust** 1999 Jun 21;170(12):609–15 (42 ref.)

Evaluation and treatment of hypertension in active individuals. Orbach P, et al. **Med Sci Sports Exerc** 1998 Oct;30(10 Suppl):S354–66

Hypertensive cardiomyopathy relieved by pacing? [letter; comment] DeSilvey DL. **Mil Med** 1999 May;164(5):318. Comment on: Mil Med 1998 Dec;163(12):861–3.

Management of hypertension in renal disease. Marcantoni C, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):80–3 (14 ref.)

Nonpharmacologic interventions successfully treat hypertension in older persons. Feldman EB. **Nutr Rev** 1998 Nov;56(11):341–3 (10 ref.)

Controlling isolated systolic hypertension. No time to be complacent. Pentz WH. **Postgrad Med** 1999 May 1; 105(5):95–6, 99–100, 105–6 passim (25 ref.)

Turning up the heat on hypertension. It's time to be more aggressive in finding and treating this silent killer. Sorrentino MJ. **Postgrad Med** 1999 May 1;105(5):82–4, 89–93 (19 ref.)

Nonpharmacologic therapy in hypertension: from single components to overall dietary management. McCarron DA, et al. **Prog Cardiovasc Dis** 1999 May–Jun;41(6):451–60 (89 ref.)

The management of hypertensive disease in black patients. Gibbs CR, et al. **QJM** 1999 Apr;92(4):187–92 (57 ref.)

Implementing clinical guidelines in the treatment of hypertension in general practice. Evaluation of patient outcome related to implementation of a computer-based clinical decision support system. Hetlevik I, et al. **Scand J Prim Health Care** 1999 Mar;17(1):35–40

[Arterial hypertension, non-drug treatment and cardiovascular risk] Blacher J, et al. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):81–5 (Eng. Abstr.) **(Fre)**

[Absolute risk and treatment decisions in hypertensive patients] Cambou JP. **Rev Prat** 1999 Mar 1;49(5):503–9 (Eng. Abstr.) **(Fre)**

[Effect of a standardized acupuncture treatment on complains, blood pressure and serum lipids of hypertensive, postmenopausal women. A randomized, controlled clinical study] Kraft K, et al. **Forsch Komplementarmed** 1999 Apr; 6(2):74–9 (Eng. Abstr.) **(Ger)**

[Non-medical therapy of arterial hypertension--hemodynamic and long-term therapy] Winterfeld HJ. **Forsch Komplementarmed** 1999 Feb; 6(1):58–9 **(Ger)**

[The Hypertension Ligue on criticism of its recommendations. Emphasis on Ca-antagonists!] **MMW Fortschr Med** 1999 Jun 17;141(24):46 **(Ger)**

[Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension] Agabiti-Rosei E, et al. **Cardiologia** 1999 Mar;44(3):299–312 (312 ref.) **(Ita)**

[Physiopathology and clinical aspects of hypertensive crisis] Pinna G, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):28–36 (29 ref.) **(Ita)**

HYPERTENSION

[Care of hypertension among the aged] Washio S. **Nippon Koshu Eisei Zasshi** 1999 Apr;46(4):328 **(Jpn)**

[Evidence-based medicine for Japanese that is necessary now (editorial)] Ishii M. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):195-7 **(Jpn)**

[Planning individualized therapeutic approaches for hypertensive patients] Matsuoka H. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):406-10 (13 ref.) **(Jpn)**

[Trend in antihypertensive therapy: discussion] Matsuoka H, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):305-25 **(Jpn)**

[Life style modification for the treatment of hypertension] Matsuura H. **Nippon Naika Gakkai Zasshi** 1999 Feb 10; 88(2):255-61 (5 ref.) **(Jpn)**

[Current topics on hypertension. Possibility for gene therapy] Morishita R, et al. **Nippon Naika Gakkai Zasshi** 1999 Feb 10;88(2):299-302 (5 ref.) **(Jpn)**

[The influence of 5-week relaxation therapy on arterial blood pressure in patients with borderline hypertension] Sharma VK, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):319-22 (Eng. Abstr.) **(Pol)**

[The influence of 5-week relaxation therapy on psychological state of patients with borderline hypertension] Sharma VK, et al. **Pol Merkuriusz Lek** 1998 Jun;4(24):323-5 (Eng. Abstr.) **(Pol)**

[High blood pressure among bank employees in Rio de Janeiro. Life-style and treatment] Chor D. **Arq Bras Cardiol** 1998 Nov;71(5):653-60 (Eng. Abstr.) **(Por)**

[Arterial hypertension in transportation workers: epidemiology, aspects of health management, transportation safety, unresolved problems] Elgarov AA, et al. **Med Tr Prom Ekol** 1998;(8):29-31 **(Rus)**

[Genetic aspects in pathogenesis and treatment of arterial hypertension] Makolkin VI, et al. **Ter Arkh** 1999; 71(4):68-71 (56 ref.) **(Rus)**

[Experience in using acupuncture reflexotherapy combined with weight-reducing diet therapy in hypertension] Vukolova ZP, et al. **Ter Arkh** 1998;70(8):41-5 (Eng. Abstr.) **(Rus)**

[Arterial hypertension in diabetes mellitus: pathogenesis and treatment (review)] Zimin IuV. **Ter Arkh** 1998;70(10):15-20 **(Rus)**

[Isolated systolic arterial hypertension in the elderly] Ivanović-Krstić B, et al. **Srp Arh Celok Lek** 1998 Mar-Apr; 126(3-4):125-9 (39 ref.) (Eng. Abstr.) **(Scc)**

[Life style changes in hypertension patients. Members of the Working Group on Arterial Hypertension of the Societat Catalana de Medicina de Família i Comunitària] Coll de Tuero G, et al. **Aten Primaria** 1998 Nov 30;22(9):596-8, 600-2, 604-6 (50 ref.) **(Spa)**

[The variability in the care for diabetic and hypertensive patients as a function of the styles of a physician's practice] Mira JJ, et al. **Aten Primaria** 1999 Feb 15;23(2):73-81 (Eng. Abstr.) **(Spa)**

[Clinical competence of the family doctor in systemic arterial hypertension] Garcia Hernández A, et al. **Rev Invest Clin** 1999 Mar-Apr;51(2):93-8 (Eng. Abstr.) **(Spa)**

[Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia] Vázquez-Chávez C, et al. **Rev Invest Clin** 1998 Nov-Dec; 50(6):491-6 (Eng. Abstr.) **(Spa)**

[Advances in the treatment of hypertension] Román O. **Rev Med Chil** 1999 Apr;127(4):472-80 (54 ref.) (Eng. Abstr.) **(Spa)**

[Cryopuncture in the treatment of stage-II essential hypertension in middle-aged and elderly subjects] Holovakha LM. **Lik Sprava** 1998 Oct-Nov;(7):144-5 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Determinants of left ventricular mass in early hypertension. Baker B, et al. **Am J Hypertens** 1998 Oct;11(10):1248-51

Increased myocardial ultrasonic reflectivity is associated with extreme hypertensive left ventricular hypertrophy: a tissue characterization study in humans. Lucarini AR, et al. **Am J Hypertens** 1998 Dec;11(12):1442-9

Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Shigematsu Y, et al. **Am J Hypertens** 1998 Oct; 11(10):1171-7

Determination of elevated jugular venous pressure by real-time ultrasound [letter] Lipton BM. **Ann Emerg Med** 1999 Jul;34(1):115

Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hamada M, et al. **Hypertens Res** 1998 Dec; 21(4):227-34

Ultrasonic myocardial texture versus Doppler analysis in hypertensive heart: a preliminary study. Di Bello V, et al. **Hypertension** 1999 Jan;33(1):66-73

Changes in cardiac diastolic dimensions precede hypertrophy in early stages of hypertension. Lemme C, et al. **J Hum Hypertens** 1998 Oct;12(10):679-83

Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines? [see comments] Abergel E, et al. **J Hypertens** 1999 Jun; 17(6):817-24. Comment in: J Hypertens 1999 Jun;17(6):735-6.

Guidelines for arterial hypertension: the echocardiography controversy [comment] de Simone G. **J Hypertens** 1999 Jun;17(6):735-6 (10 ref.). Comment on: J Hypertens 1999 Jun;17(6):817-24.

Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive [see comments] Jullien V, et al. **J Hypertens** 1998 Jul; 16(7):1043-7. Comment in: J Hypertens 1998 Nov;16(11):1703-4.

Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. Zanchetti A, et al. **J Hypertens** 1998 Jul;16(7):949-61

Intima-media thickness of carotid arteries in borderline hypertensives. Pitha J, et al. **J Neuroimaging** 1999 Jan; 9(1):19-22

Index of myocardial performance using Doppler-derived parameters in the evaluation of left ventricular function in patients with essential hypertension. Kang SM, et al. **Yonsei Med J** 1998 Oct;39(5):446-52

[A preliminary evaluation on transcranial Dopplor ultrasonic scanning for differentiation of symptoms and signs in patients with ganyang shangkangzheng] Hu S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):131-3 (Eng. Abstr.) **(Chi)**

[Current aspects of arterial hypertension. Doppler echocardiography. Value and indications] Amah G, et al. **Presse Med** 1999 Apr 24;28(16):875-8 (Eng. Abstr.) **(Fre)**

[White-coat arterial hypertension and stable borderline essential arterial hypertension. An ultrasonic study of the carotid arteries] Prencipe G, et al. **Minerva Cardioangiol** 1998 May;46(5):149-55 (Eng. Abstr.) **(Ita)**

[Morpho-functional cardiac evaluation in young normotensive children of hypertensive patients. A prospective Doppler-echocardiographic study] de Almeida CM, et al. **Arq Bras Cardiol** 1998 Nov;71(5):681-6 (Eng. Abstr.) **(Por)**

URINE

Renal perfusion pressure is an important determinant of sodium and calcium excretion in DOC-salt hypertension. Brands MW, et al. **Am J Hypertens** 1998 Oct; 11(10):1199-207

Urinary sodium and potassium profile of blacks and whites in relation to education in two different geographic urban areas. TOMHS Research Group. Treatment of Mild Hypertension Study. Ganguli MC, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):69-72

Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension. Gerber LM, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1321-7

Circadian rhythm of urinary endothelin-1 excretion in mild hypertensive patients. Hwang YS, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1344-51

Changes in plasma and urinary norepinephrine following transdermal clonidine in spontaneously hypertensive rats. Ishii R, et al. **Arzneimittelforschung** 1998 Aug;48(8):811-7

Urinary excretion of nitric oxide, cyclic GMP, and catecholamines during rest and activity period in transgenic hypertensive rats. Globig S, et al. **Chronobiol Int** 1999 May; 16(3):305-14

Increased oxidative DNA damage in stroke-prone spontaneously hypertensive rats. Negishi H, et al. **Clin Exp Pharmacol Physiol** 1999 May-Jun;26(5-6):482-4

Urinary excretion of Tamm-Horsfall protein in normotensive and hypertensive elderly patients. Dulawa J, et al. **J Hum Hypertens** 1998 Sep;12(9):635-7

Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. Bigazzi R, et al. **J Hypertens** 1998 Sep;16(9):1325-33

Rapid progression to end-stage renal disease in young hypertensive African Americans with proteinuria. Obialo CI, et al. **J Natl Med Assoc** 1998 Nov;90(11):649-55

Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. Sierra M, et al. **Kidney Int Suppl** 1998 Dec;68:S10-3

Urinary glycosaminoglycans and their relationship to microalbuminuria in arterial hypertension [letter] Pérez-Blanco FJ, et al. **Nephron** 1999;81(4):444-5

Differential response of angiotensin peptides in the urine of hypertensive animals. Yamada K, et al. **Regul Pept** 1999 Mar 17;80(1-2):57-66

Comparison of urinary excretion of albumin and alpha-1-antitrypsin in patients with arterial hypertension. Lisowska-Myjak B, et al. **Scand J Clin Lab Invest** 1999 Apr;59(2):93-7

A study of Tamm-Horsfall protein excretion in hypertensive patients and type 1 diabetic patients. Torffvit O, et al. **Scand J Urol Nephrol** 1999 Jun;33(3):187-91

VETERINARY

Evaluation of the white-coat effect in cats. Belew AM, et al. **J Vet Intern Med** 1999 Mar-Apr;13(2):134-42

Inter- and intraindividual variation in Doppler ultrasonic indirect blood pressure measurements in healthy cats. Sparkes AH, et al. **J Vet Intern Med** 1999 Jul-Aug; 13(4):314-8

Non-invasive blood pressure measurements in cats: clinical significance of hypertension associated with chronic renal failure. Mishina M, et al. **J Vet Med Sci** 1998 Jul;60(7):805-8

Diagnosis and treatment of systemic hypertension. Brown SA, et al. **Vet Clin North Am Small Anim Pract** 1998 Nov; 28(6):1481-94, ix (41 ref.)

Obesity in dogs: effects on renal function, blood pressure, and renal disease. Joles JA. **Vet Q** 1998 Oct;20(4):117-20 (56 ref.)

HYPERTENSION-EDEMA-PROTEINURIA GESTOSIS see **GESTOSIS, EPH**

HYPERTENSION, GOLDBLATT see **HYPERTENSION, RENOVASCULAR**

HYPERTENSION, MALIGNANT

Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Pavlakis SG, et al. **J Child Neurol** 1999 May;14(5):277-81 (36 ref.)

COMPLICATIONS

Posterior leukoencephalopathy syndrome may not be reversible. Antunes NL, et al. **Pediatr Neurol** 1999 Mar; 20(3):241-3

Expression of 90-kDa heat shock protein within regenerative tubular cells in a patient with acute oliguric renal failure due to malignant hypertension. Komatsuda A, et al. **Ren Fail** 1999 Jan;21(1):113-7

Haematospermia associated with malignant hypertension. Bhaduri S, et al. **Sex Transm Infect** 1999 Jun;75(3):200

[Hypertensive encephalopathy associated with malignant and resistant hypertension] Mangiafico RA, et al. **Minerva Cardioangiol** 1998 Sep;46(9):347-8 **(Ita)**

DIAGNOSIS

Hypertensive crisis. How to tell if it's an emergency or an urgency. Bales A. **Postgrad Med** 1999 May 1;105(5):119-26, 130 (17 ref.)

[Malignant hypertension in a young man with renal artery occlusion diagnosed with magnetic resonance angiography] Postma CT, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1102-5 (Eng. Abstr.) **(Dut)**

[Scleroderma renal crisis. 7 cases and review of the literature] Bonnet F, et al. **Ann Med Interne (Paris)** 1998 Sep; 149(5):243-50 (45 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up. Nakamoto H, et al. **Hypertens Res** 1999 Jul; 22(2):75-80

[On the contribution U.O. Wenzel, B.Pfalzer, I.Meinertz, R.A. Stahl (1999). A 73-year old woman with hypertensive crisis. Internist 40:205-9. Case report (letter)] Lücke C. **Internist (Berl)** 1999 Aug;40(8):880-1 **(Ger)**

ETIOLOGY

Noradrenaline-producing renal-cell carcinoma: a unique cause of endocrine hypertension. Thomas MC, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1811-4

Malignant hypertension and paraganglioma in a 14-year-old girl. Andiran N, et al. **Pediatr Hematol Oncol** 1999 Jan-Feb; 16(1):67-70

[Hemobilia of gallbladder origin manifesting as malignant hypertension (letter)] Seguin P, et al. **Presse Med** 1998 May 23-30;27(19):913 **(Fre)**

PATHOLOGY

Images in clinical medicine. Malignant hypertension. Perazella MA, et al. **N Engl J Med** 1998 Dec 31; 339(27):1985

THERAPY

Hypertensive crisis. How to tell if it's an emergency or an urgency. Bales A. **Postgrad Med** 1999 May 1;105(5):119-26, 130 (17 ref.)

HYPERTENSION, OCULAR see **OCULAR HYPERTENSION**

HYPERTENSION, PORTAL

see related
PORTASYSTEMIC SHUNT, SURGICAL

A cautionary note regarding glycyrrhiza (licorice root) [letter] Stolpman D, et al. **Am J Gastroenterol** 1999 Feb; 94(2):540-1

The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Jones FD, et al. **Anesthesiology** 1999 Feb;90(2):626-9

An experimental model of liver damage and portal hypertension induced by a single dose of monocrotaline. Perazzo J, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):432-5

Portal hypertension: state of the art. Gatta A, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):326-45 (199 ref.)

[Establishment of a new rat model of portal hypertension by intraportal injection of microspheres] Li XA, et al.

Chung Hua Wai Ko Tsa Chih 1997 Jan;35(1):52-5 (Eng. Abstr.) **(Chi)**

[A case of Cruveilhier-Baumgarten syndrome] Nakasone H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr; 96(4):437-9 **(Jpn)**

BLOOD

Should measurements of hemodynamics in portal hypertension be dynamic? [editorial; comment] Calès P. **J Hepatol** 1998 Nov;29(5):829-31. Comment on: J Hepatol 1998 Nov;29(5):772-8.

[Perioperative plasma amino acid spectrum analysis in portal hypertensive cirrhotic patients undergoing portacaval H-graft shunt] Zhu J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 May;35(5):299-301 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

[Clinical case of the month. Hepatoportal sclerosis in a patient treated with azathioprine] Roland S, et al. **Rev Med Liege** 1998 Aug;53(8):450-3 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

A spontaneous portosystemic shunt from the left gastric vein to the left renal vein caused by portal hypertension. Dick E, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):502-3

Varicosities of the paravertebral plexus of veins associated with nocturnal spinal pain as imaged by magnetic resonance venography: a brief report. LaBan MM, et al. **Am J Phys Med Rehabil** 1999 Jan-Feb;78(1):72-6 (23 ref.)

Comparative study of 2 variants of a modified esophageal transection in the Sugiura-Futagawa operation. Mercado MA, et al. **Arch Surg** 1998 Oct;133(10):1046-9

Bile duct obstruction due to portal biliopathy in extrahepatic portal hypertension: surgical management [letter; comment] Siddiqui MN. **Br J Surg** 1999 Jan;86(1):138. Comment on: Br J Surg 1998 Mar;85(3):326-9.

Massive gastrointestinal bleeding from colonic varices in a patient with portal hypertension. Naef M, et al. **Dig Surg** 1998;15(6):709-12

Endoscopic ligation for bleeding rectal varices in a child with primary extrahepatic portal hypertension. Uno Y, et al. **Endoscopy** 1998 Nov;30(9):S107-8

Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Kouroumalis EA, et al. **Eur J Gastroenterol Hepatol** 1998 Jun;10(6):509-12

Delayed healing of acetic-acid-induced gastric ulcer in portal hypertensive rats. Baatar D, et al. **Eur Surg Res** 1999; 31(4):340-6

Prognostic value of early measurements of portal pressure in acute variceal bleeding. Moitinho E, et al. **Gastroenterology** 1999 Sep;117(3):626-31

Endosonographic, endoscopic, and histologic evaluation of alterations in the rectal venous system in patients with portal hypertension. Dhiman RK, et al. **Gastrointest Endosc** 1999 Feb;49(2):218-27

Cholangiopathy associated with portal hypertension: diagnostic evaluation and clinical implications. Malkan GH, et al. **Gastrointest Endosc** 1999 Mar;49(3 Pt 1):344-8

Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Spahr L, et al. **Gut** 1999 May;44(5):739-42

Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Loinaz C, et al. **Hepatogastroenterology** 1998 Sep-Oct;45(23):1787-94

Do alterations in the rate of gastric emptying after injection sclerotherapy for oesophageal varices play any role in the development of portal hypertensive gastropathy? Balan KK, et al. **HPB Surg** 1999;11(3):141-8; discussion 148-50

Therapeutic options for bleeding portal hypertensive gastropathy [editorial; comment] Panés J, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):977-9. Comment on: J Gastroenterol Hepatol 1998 Oct;13(10):1061-7.

Portal-hypertensive gastropathy. Toyonaga A, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):865-77 (191 ref.)

The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy [see comments] Urata J, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1061-7. Comment in: J Gastroenterol Hepatol 1998 Oct;13(10):977-9.

Endotoxemia: an unnecessary but aggravating condition in portal hypertension? [editorial; comment] Sogni P, et al. **J Hepatol** 1999 Jun;30(6):1160-2. Comment on: J Hepatol 1999 Jun;30(6):1105-11.

Successful pregnancy in a woman with secondary biliary cirrhosis with portal hypertension from recurrent pyogenic cholangitis. A case report. Fung TY, et al. **J Reprod Med** 1999 May;44(5):475-7

Effect of mesocaval interposition shunting and repeated sclerotherapy on blood levels of gastrointestinal regulatory peptides, amino acids, and lysosomal enzymes--a prospective randomised trial. Isaksson B, et al. **Liver** 1999 Feb;19(1):3-11

Portal hypertensive enteropathy in biliary atresia. Hasegawa T, et al. **Pediatr Surg Int** 1998 Oct;13(8):602-4

Non-cirrhotic portal fibrosis associated with pulmonary arteriovenous communication and pulmonary arterial hypertension. Chongsrisawat V, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):76-9

Management of portal hypertension-related bleeding. Vargas HE, et al. **Surg Clin North Am** 1999 Feb;79(1):1-22 (107 ref.)

TIPS allowing for an endoscopic mucosal resection of early gastric cancer in a cirrhotic patient with severe hypertensive gastropathy: report of a case. Guglielmi A, et al. **Surg Today** 1999;29(9):902-5

Portopulmonary hypertension and the liver transplant candidate. Kuo PC, et al. **Transplantation** 1999 Apr 27; 67(8):1087-93 (41 ref.)

[Helicobacter pylori and congestive gastropathy] Dai L, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Mar;7(1):22-3 (Eng. Abstr.) **(Chi)**

[Surgical handling of primary hepatic carcinoma with severe cirrhosis and portal hypertension] Li T, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):500-2 (Eng. Abstr.) **(Chi)**

[A rare case of gastric bleeding due to left-sided portal hypertension] Terrinoni V, et al. **G Chir** 1999 Apr; 20(4):185-7 (9 ref.) (Eng. Abstr.) **(Ita)**

[Portal hypertensive gastropathy and colopathy] Ohashi K, et al. **Nippon Rinsho** 1998 Sep;56(9):2369-75 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Portal hypertensive gastropathy] Toyonaga A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):619-26 (32 ref.) **(Jpn)**

[An autopsied case of idiopathic portal hypertension accompanied by right heart failure secondary to pulmonary hypertension] Zenda T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1151-6 **(Jpn)**

[Splenic blood circulation in liver cirrhosis with portal hypertension syndrome] Bulanov KI. **Klin Khir** 1998; (8):29-31 (Eng. Abstr.) **(Rus)**

[Is diuretic-resistant ascites reversible in patients with liver cirrhosis amd portal hypertension?] Mansurov AA, et al. **Klin Khir** 1998;(11):48-9 **(Rus)**

[Systemic affections in cytomegaloviral infection (cytomegaloviral disease) (case report)] Kuznetsova OP, et al. **Ter Arkh** 1998;70(11):33-5 **(Rus)**

[Quo vadis the azygo-portal disconnection] Olejník J, et al. **Rozhl Chir** 1999 Jan;78(1):26-8 (Eng. Abstr.) **(Slo)**

DIAGNOSIS

Correlation between serum-ascites albumin concentration gradient and endoscopic parameters of portal hypertension. Torres E, et al. **Am J Gastroenterol** 1998 Nov;93(11):2172-8

Primary pulmonary hypertension or portopulmonary hypertension? [letter; comment] Gossage JR. **Chest** 1998 Oct;114(4):1224-5. Comment on: Chest 1997 Aug;112(2):551-3.

Pregnancy and its outcome in patients with noncirrhotic portal hypertension. Kochhar R, et al. **Dig Dis Sci** 1999 Jul;44(7):1356-61

Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. Assy N, et al. **Gastrointest Endosc** 1999 Jun; 49(6):690-4

Colonic polypoid lesions: an unusual endoscopic presentation of portal hypertensive colonopathy. Huang WH, et al. **Gastrointest Endosc** 1999 Aug;50(2):283-5

Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Steinlauf AF, et al. **Hepatology** 1999 Apr;29(4):1070-3

AISF practice guidelines for portal hypertension. Committee for Portal Hypertension of the Italian Association for the Study of the Liver (AISF). **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):224-34 (66 ref.)

[PGA index: a way to screen for portal hypertension in an asymptomatic alcoholic patient (letter)] Latrive JP, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):977-9 **(Fre)**

[The forming of distal splenorenal anastomosis in conjunction with gastroesophageal junction suturing during treatment of the portal hypertension syndrome in children] Volosiuk AIe. **Klin Khir** 1999;(4):16-8 (Eng. Abstr.) **(Ukr)**

DRUG THERAPY

Modulation of intravariceal pressure with pentoxifylline: a possible new approach in the treatment of portal hypertension. Eleftheriadis E, et al. **Am J Gastroenterol** 1998 Dec;93(12):2431-5

The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Ramsay MA, et al. **Anesthesiology** 1999 Jan;90(1):299-301

Beta-blockers. Bursey RF. **Can J Gastroenterol** 1998 Nov-Dec;12(8):542-3

Aminoguanidine ameliorates splanchnic hyposensitivity to glypressin in a haemorrhage-transfused rat model of portal hypertension. Chu CJ, et al. **Clin Sci (Colch)** 1998 Nov; 95(5):629-36

Haemodynamic effects of 8-day octreotide and prazosin administration in portal hypertensive rats. Lin HC, et al. **Eur J Clin Invest** 1998 Aug;28(8):622-8

Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution. García-Tsao G. **Gastroenterology** 1999 Sep;117(3):740-2

Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Bañares R, et al. **Hepatology** 1999 Jul;30(1):79-83

Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Schneider AW, et al. **Hepatology** 1999 Feb;29(2):334-9

Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. Jenkins SA, et al. **HPB Surg** 1998;11(1):13-21

Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats. Van de Casteele M, et al. **J Hepatol** 1999 Aug;31(2):300-5

Propranolol and portal hypertension: should kids be on the block? [editorial; comment] Schreiber RA. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):10-1. Comment on: J Pediatr Gastroenterol Nutr 1999 Jul;29(1):12-7.

Propranolol in prevention of portal hypertensive hemorrhage in children: a pilot study [see comments] Shashidhar H, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul;29(1):12-7. Comment in: J Pediatr Gastroenterol Nutr 1999 Jul;29(1):10-1.

Effects of tetramethylpyrazine on portal hypertensive rats. Chang FC, et al. **J Pharm Pharmacol** 1998 Aug;50(8):881-4

Portal hypotensive effects of combined terlipressin and DL-028, a synthetic alpha 1 adrenoceptor antagonist administration on anesthetized portal hypertensive rats. Huang YT, et al. **Liver** 1999 Apr;19(2):129-34

Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Findlay JY, et al. **Liver Transpl Surg** 1999 Sep;5(5):362-5

Drug treatment of portal hypertension. Anand BS. **Natl Med J India** 1998 Jul-Aug;11(4):173-7 (66 ref.)

Hemodynamic effects of 8-day DL-028 and octreotide administration in rats with portal hypertension. Huang YT, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1303-9

Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Piscaglia F, et al. **Ultrasound Med Biol** 1999 Jul;25(6):923-32 (90 ref.)

[Beta-blockers and portal hypertension: in search of the ideal (editorial)] Bandi JC, et al. **Acta Gastroenterol Latinoam** 1998;28(4):313-4 **(Spa)**

[Terlipressin in the treatment of portal hypertension (see comments)] Escorsell A, et al. **Gastroenterol Hepatol** 1998 Nov;21(9):452-8 (57 ref.). Comment in: Gastroenterol Hepatol 1999 May;22(5):258-60. **(Spa)**

[Terlipressin in the treatment of portal hypertension (letter; comment)] Primo J, et al. **Gastroenterol Hepatol** 1999 May; 22(5):258-60. Comment on: Gastroenterol Hepatol 1998 Nov;21(9):452-8. **(Spa)**

ENZYMOLOGY

NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Wiest R, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G1043-51

Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Fernandez M, et al. **Hepatology** 1999 Jun;29(6):1672-9

Abnormal regulation of aortic NOS2 and NOS3 activity and expression from portal vein-stenosed rats after lipopolysaccharide administration. Heller J, et al. **Hepatology** 1999 Sep;30(3):698-704

EPIDEMIOLOGY

Bleeding isolated gastric varices: a retrospective analysis. Nagral S, et al. **Indian J Gastroenterol** 1999 Apr-Jun; 18(2):69-72

ETIOLOGY

Portal vein invasion by intrahepatic peripheral cholangiocarcinoma: a rare cause of portal hypertension. Soyer P, et al. **AJR Am J Roentgenol** 1998 Nov; 171(5):1413-4

Portal hypertension due to traumatic hepatic arterioportal fistula: report of successful embolization. Kirchgatterer A, et al. **Eur J Gastroenterol Hepatol** 1998 Dec;10(12):1057-9

Masked polycythaemia vera in a patient with extrahepatic portal venous obstruction. Pati HP, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):883-5

Intractable gastrointestinal bleeding caused by pancreatic arteriovenous malformation: successful treatment with transjugular intrahepatic portosystemic shunt. Hayashi N, et al. **Eur J Radiol** 1998 Sep;28(2):164-6

Arterioportal fistula with portal hypertension after liver trauma and resection: a case report and review of the literature. Wolf S, et al. **Hepatogastroenterology** 1998 May-Jun;45(21):821-6 (24 ref.)

Cardiac anomalies associated with extrahepatic portal venous obstruction [letter] Gopanpallikar AM, et al. **Indian Pediatr** 1998 Nov;35(11):1143-4

Severe portal hypertension due to congenital hepatoportal arteriovenous fistula associated with intrahepatic portal vein aneurysm. Altuntaş B, et al. **J Clin Ultrasound** 1998 Sep;26(7):357-60

Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. Debray D, et al. **J Hepatol** 1999 Jul;31(1):77-83

Portal hypertension secondary to arterio-portal fistulae: two unusual cases. Aithal GP, et al. **Liver** 1999 Aug;19(4):343-7

Portal hypertension due to extensive hepatic cysts in autosomal dominant polycystic kidney disease. Misra A, et al. **South Med J** 1999 Jun;92(6):626-7

[PGA index: a way to screen for portal hypertension in an

asymptomatic alcoholic patient (letter)] Latrive JP, et al. **Gastroenterol Clin Biol** 1998 Nov;22(11):977–9 **(Fre)**

[Portal hypertension and neutrocytic ascites in POEMS syndrome] Stepani P, et al. **Gastroenterol Clin Biol** 1998 Dec;22(12):1093–7 (Eng. Abstr.) **(Fre)**

[Gaucher's disease type I: an infrequent cause of portal hypertension] Cano Ruiz A, et al. **An Med Interna** 1998 Sep;15(9):483–4 (Eng. Abstr.) **(Spa)**

[Sinusoidal portal hypertension secondary to nodular regenerative hyperplasia of the liver] Gento Peña E, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):183–5 (18 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

[The development of portal hypertension surgery in Ukraine] Saenko VF, et al. **Klin Khir** 1999;(6):53–6 **(Rus)**

IMMUNOLOGY

Analysis of adhesion molecules in patients with idiopathic portal hypertension. Yamaguchi N, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):364–9

METABOLISM

Reduced adrenomedullin expression in gastric mucosa of portal hypertensive rats after ethanol-induced injury. Tomikawa M, et al. **Ann Surg** 1999 Jul;230(1):38–44

The effect of portal hypertension on transforming growth factor-alpha and epidermal growth factor receptor in the gastric mucosa of rats. Wang JY, et al. **Int Surg** 1998 Jul–Sep;83(3):220–3

A quantitative study on vascular angiotensin II receptors in rats with portal hypertension. Li J, et al. **J Tongji Med Univ** 1997;17(4):235–8

Immunohistochemical analysis of EGF-R in gastric mucosa in portal hypertensive with cirrhosis. Yang Z. **J Tongji Med Univ** 1997;17(4):232–4

Norepinephrine uptake modifications in circumventricular organs, pons and myelencephalic areas and nuclei in prehepatic portal hypertensive rats. Fernández B, et al. **Neurochem Int** 1999 Mar;34(3):177–81

PARASITOLOGY

Systemic hemodynamic changes in mansonic schistosomiasis with portal hypertension treated by azygoportal disconnection and splenectomy. de Cleva R, et al. **Am J Gastroenterol** 1999 Jun;94(6):1632–7

PATHOLOGY

The role of nitric oxide in the inhibition of gastric epithelial proliferation in portal hypertensive rats. Baatar D, et al. **J Hepatol** 1999 Jun;30(6):1099–104

Pulmonary vascular morphological changes in cirrhotic patients undergoing liver transplantation. Lamps LW, et al. **Liver Transpl Surg** 1999 Jan;5(1):57–64

Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. Kondo F, et al. **Pathol Res Pract** 1998; 194(7):487–95

[A case of idiopathic portal hypertension complicated with multiple focal nodular hyperplasia (FNH) like lesions] Eda Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr; 96(4):431–6 **(Jpn)**

PHYSIOPATHOLOGY

Liver abnormalities and portal hypertension in Ullrich-Turner syndrome [letter] Garavelli L, et al. **Am J Med Genet** 1998 Nov 2;80(2):180–2

Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Muñoz J, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G687–93

Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Shah V, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G463–8

NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Wiest R, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G1043–51

Vasoconstrictor responsiveness of portal hypertensive vessels. Cahill PA. **Clin Sci (Colch)** 1999 Jan;96(1):3–4

Portal hypertension increases vasoconstrictor responsiveness of rat aorta [see comments] Connolly C, et al. **Clin Sci (Colch)** 1999 Jan;96(1):41–7. Comment in: Clin Sci (Colch) 1999 Jan;96(1):3–4.

Effect of long-term octreotide and isosorbide dinitrate on haemodynamics in rats with portal vein stenosis. Lin HC, et al. **Clin Sci (Colch)** 1998 Jun;94(6):645–50

Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension. Vlavianos P, et al. **Clin Sci (Colch)** 1999 May;96(5):475–81

Impaired adaptive cytoprotection to ethanol-induced damage in gastric mucosa of portal hypertensive rats. Ninomiya K, et al. **Dig Dis Sci** 1999 Jun;44(6):1254–60

Presinusoidal portal hypertension does not affect hepatic artery resistance index. Erden A, et al. **Eur Radiol** 1999; 9(6):1131–4

Measurement of collateral circulation blood flow in anesthetized portal hypertensive rats. Oberti F, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep;22(8–9):697–704

Liver circulation in the development of portal hypertension. Clemens MG. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1429–33 (61 ref.)

Pathophysiology of portal hypertension. Lebrec D, et al. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1426–8 (16 ref.)

Portal hypertension: cytokines and endothelins. Reichen J. **Hepatogastroenterology** 1999 Jun;46 Suppl 2:1434–6 (39 ref.)

Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Chan CC, et al. **Hepatology** 1999 Sep;30(3):630–5

Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hori N, et al. **Hepatology** 1998 Dec;28(6):1467–73

Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Kamath PS, et al. **Hepatology** 1999 Aug;30(2):401–7

Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Panés J, et al. **Hepatology** 1999 Aug;30(2):445–53

Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Sumanovski LT, et al. **Hepatology** 1999 Apr; 29(4):1044–9

Splanchnic arterial Doppler parameters in portal hypertension [letter; comment] Valgimigli M, et al. **Hepatology** 1999 May;29(5):1610. Comment on: Hepatology 1998 Oct;28(4):932–6.

Portal hemodynamics in chronic liver disease. Nagral A, et al. **Indian J Gastroenterol** 1999 Apr–Jun;18(2):78–83 (73 ref.)

Cardiovascular actions of nitric oxide synthase inhibition in the portal hypertensive rat. McDaid J, et al. **J Auton Pharmacol** 1998 Dec;18(6):357–62

The effect of short stature, portal hypertension, and cholestasis on growth hormone resistance in children with liver disease. Holt RI, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3277–82

Upright posture blunts postprandial splanchnic hyperemia in patients with cirrhosis and portal hypertension [see comments] Iwao T, et al. **J Gastroenterol** 1999 Jun; 34(3):359–65. Comment in: J Gastroenterol 1999 Jun;34(3):428–30.

Blood digestion-induced splanchnic hyperemia and portal blood flow in portal hypertensive rats and the role of octreotide. Kotzampassi K, et al. **J Gastroenterol** 1998 Oct; 33(5):678–83

Gastric mucosal blood flow and hepatic perfusion index in patients with portal hypertensive gastropathy. Gupta R, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):921–6

A selective cyclo-oxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury. Tsugawa K, et al. **J Gastroenterol Hepatol** 1999 Jul;14(7):642–51

Evidence against a role for endotoxin in the hyperdynamic circulation of rats with prehepatic portal hypertension [see comments] Chu CJ, et al. **J Hepatol** 1999 Jun;30(6):1105–11 . Comment in: J Hepatol 1999 Jun;30(6):1160–2.

Vascular nitric oxide production during the development of two experimental models of portal hypertension. Gadano AC, et al. **J Hepatol** 1999 May;30(5):896–903

Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. Schneider AW, et al. **J Hepatol** 1999 May; 30(5):876–81

Portal levels of the isoprostane F2 alpha-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients. Praticò D, et al. **J Investig Med** 1998 Dec;46(9):430–4

Acute portal hypertension increases ileal vulnerability to platelet-activating factor in rats. Sakaguchi T, et al. **J Surg Res** 1999 Sep;86(1):116–22

99mTC sulphur colloid phagocytosis by the mononuclear phagocytic system (MPS) of rats with portal hypertension. Duval-Araujo I, et al. **Minerva Chir** 1999 Jun;54(6):403–9

[Effects of radix Salviae miltiorrhizae on hemodynamics of portal hypertension: clinical and experimental study] Li X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jul;36(7):450–3 (Eng. Abstr.) **(Chi)**

[An experiment study of reversed pulmonary hypertension with inhaled nitric oxide on smoke inhalation injury] Qi S, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Jan;35(1):56–8 (Eng. Abstr.) **(Chi)**

[Portal-systemic shunting and hemodynamics of prehepatic portal hypertensive rat models] Zhou YB, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):244–7 (Eng. Abstr.) **(Chi)**

[Effect of phentolamine on portal pressure in cirrhotic patients with portal hypertension] Zhu J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Feb;35(2):92–4 (Eng. Abstr.) **(Chi)**

[Nitric oxide, vasodilatation and cirrhosis: a double (dys)equilibrium] Sogni P, et al. **Gastroenterol Clin Biol** 1999 Jan;23(1):101–4 **(Fre)**

[Angiographic aspects of the hepatic veins in portal hypertension in schistosomiasis. The importance in assessing the hepatic vein pressure] Widman A, et al. **Arq Gastroenterol** 1998 Jul–Sep;35(3):157–63 (Eng. Abstr.) **(Por)**

[Evaluation of propranolol response by catheterization and Doppler ultrasonography in patients with cirrhosis] Castaño G, et al. **Acta Gastroenterol Latinoam** 1998; 28(4):291–7 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Can clamping of splenic vessels prevent abrupt increase of portal vein pressure and migration of transplanted hepatocytes to the liver after intrasplenic hepatocyte transplantation? Kim WH, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2425–9

RADIOGRAPHY

Segmental portal hypertension due to splenic vein obstruction: imaging findings and diagnostic pitfalls in four cases. Lenthall R, et al. **Clin Radiol** 1999 Aug;54(8):540–4

Altered intrahepatic pathway of para-umbilical vein in portal hypertension. Ohhira M, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):691–5

SURGERY

Systemic hemodynamic changes in mansonic schistosomiasis with portal hypertension treated by azygoportal disconnection and splenectomy. de Cleva R, et al. **Am J Gastroenterol** 1999 Jun;94(6):1632–7

Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Trotter JF, et al. **Am J Gastroenterol** 1998 Oct;93(10):1891–4

Surgical technique for inferior mesenteric vein to renal vein shunt in portal hypertension. Deshmukh N, et al. **Am J Surg** 1999 Jul;178(1):55–6

Transjugular intrahepatic portosystemic shunt (TIPS) for variceal bleeding in portal hypertension: comparison of emergency and elective interventions. Gerbes AL, et al. **Dig Dis Sci** 1998 Nov;43(11):2463–9

Transjugular intrahepatic portosystemic stent-shunt (TIPSS): technique and indications. Kauffmann GW, et al. **Eur Radiol** 1999;9(4):685–92 (18 ref.)

Use of adrenal vein conduit for splenorenal shunts: a case report. Kulkarni VM, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):2033–4

Decision-analysis of transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt for portal hypertension. Zacks SL, et al. **Hepatology** 1999 May; 29(5):1399–405

Reoperations for bleeding portal hypertension. Surgical rescue of surgical failures. Mercado MA, et al. **HPB Surg** 1999;11(3):151–5

Results of surgical treatment (modified Sugiura-Futagawa operation) of portal hypertension associated to complete splenomesoportal thrombosis and cirrhosis. Mercado MA, et al. **HPB Surg** 1999;11(3):157–62

Results of a modified sugiura's devascularisation in the management of "unshuntable" portal hypertension. Shah SR, et al. **HPB Surg** 1999;11(4):235–9

Late clinical, biochemical, endoscopic and electroencephalographic evaluation of patients with schistosomal portal hypertension treated with distal splenorenal shunt. Lopes Filho G de J, et al. **Int Surg** 1998 Jan–Mar;83(1):42–7

A technique for distal splenoadrenal shunting in pediatric portal hypertension. Mazariegos GV, et al. **J Am Coll Surg** 1998 Dec;187(6):634–6

Role of transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension in pediatric patients. Heyman MB, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep; 29(3):240–9 (44 ref.)

Transjugular intrahepatic portosystemic shunt after complete obstruction of portal vein. Yamagami T, et al. **J Vasc Interv Radiol** 1999 May;10(5):575–8

Shunt versus transplantation. Langnas AN. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S105–7 (12 ref.)

Distal splenorenal shunt with splenopancreatic disconnection for portal hypertension in biliary atresia. Hasegawa T, et al. **Pediatr Surg Int** 1999;15(2):92–6

Current status of transjugular intrahepatic portosystemic shunts. Patel NH, et al. **Postgrad Med J** 1998 Dec; 74(878):716–20 (62 ref.)

Biliary complications in liver transplantation for cystic fibrosis. Chavez-Cartaya R, et al. **Transplant Proc** 1999 Sep;31(6):2411–2

[Combined surgical treatment of portal hypertension] Kala Z, et al. **Rozhl Chir** 1998 Oct;77(10):445–9 (Eng. Abstr.) **(Cze)**

Surgery for portal hypertension and transjugular intrahepatic portosystemic shunts in Germany: results of a national survey] Wolff M, et al. **Chirurg** 1999 Apr;70(4):447–52 (Eng. Abstr.) **(Ger)**

[Portal hypertension and variceal bleeding: shunt in concomitant or general prehepatic block] Hirner A, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:443–50 (25 ref.) (Eng. Abstr.) **(Ger)**

[Variceal hemorrhage in portal hypertension: role of surgery in the acute and elective situation] Krähenbühl L, et al. **Schweiz Med Wochenschr** 1999 Apr 24;129(16):631–8 (70 ref.) (Eng. Abstr.) **(Ger)**

[Transjugular intrahepatic portosystemic shunt in treatment of portal hypertension] Tarazov PG. **Khirurgiia (Mosk)** 1999;(7):64–9 (80 ref.) **(Rus)**

[Is surgery for portal hypertension a contraindication for liver transplantation?] Poves I, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):382–5 (Eng. Abstr.) **(Spa)**

[A pathogenetic validation of a method for correcting portal hypertension] Vaida RI, et al. **Klin Khir** 1998;(9–10):20–2 (Eng. Abstr.) **(Ukr)**

THERAPY

Interventional radiologic treatment for idiopathic portal hypertension. Hirota S, et al. **Cardiovasc Intervent Radiol** 1999 Jul-Aug;22(4):311-4

Variceal bleeding and portal hypertension: still a therapeutic challenge? Bohnacker S, et al. **Endoscopy** 1999 Jan; 31(1):26-37 (58 ref.)

Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests. Baron A, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2315-21

AISF practice guidelines for portal hypertension. Committee for Portal Hypertension of the Italian Association for the Study of the Liver (AISF). **Ital J Gastroenterol Hepatol** 1999 Apr;31(3):224-34 (66 ref.)

Portal decompression by transjugular intrahepatic portosystemic shunt and changes in serum-ascites albumin gradient. Younossi ZM, et al. **J Clin Gastroenterol** 1998 Sep;27(2):149-51

Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. Debray D, et al. **J Hepatol** 1999 Jul;31(1):77-83

Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Findlay JY, et al. **Liver Transpl Surg** 1999 Sep;5(5):381-7

Successful treatment of bleeding duodenal varices by balloon-occluded retrograde transvenous obliteration: a transjugular venous approach. Ohta M, et al. **Surgery** 1999 Sep;126(3):581-3

[Treatment of portal hypertension] Calès P, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):353-4 (3 ref.) **(Fre)**

[Intrahepatic portocaval shunt as a new method for treating and prevention of bleeding from esophageal varices in portal hypertension] Wróblewski T, et al. **Przegl Lek** 1998; 55(9):469-74 (19 ref.) (Eng. Abstr.) **(Pol)**

[The conservative therapy of acute esophagogastric hemorrhages in portal hypertension patients] Eramishantsev AK, et al. **Klin Med (Mosk)** 1998;76(7):33-7 **(Rus)**

[Evaluation of the hemodynamic effects of tumor necrosis factor alpha factor in rats with portal hypertension using the radioactive microsphere technique] Pérez-Páramo M, et al. **Rev Esp Med Nucl** 1998;17(4):294-301 (Eng. Abstr.) **(Spa)**

[Endoscopic sclerosing as an alternative method of treatment of the portal hypertension syndrome in children] Palkina IS, et al. **Klin Khir** 1999;(5):14-5 (Eng. Abstr.) **(Ukr)**

[The forming of distal splenorenal anastomosis in conjunction with gastroesophageal junction suturing during treatment of the portal hypertension syndrome in children] Volosiuk AIe. **Klin Khir** 1999;(4):16-8 (Eng. Abstr.) **(Ukr)**

ULTRASONOGRAPHY

Correlation of duplex sonography findings and portal pressure in 375 patients with portal hypertension. Haag K, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):631-5

Grayscale and pulsed Doppler characteristics of non-cirrhotic portal fibrosis: a preliminary report. Sinha R. **Clin Radiol** 1999 Mar;54(3):156-9

Portohepatic vascular pathology and liver disease: diagnosis and monitoring. Bolondi L, et al. **Eur J Ultrasound** 1998 Jul;7 Suppl 3:S41-52 (41 ref.)

EUS analysis of collateral veins inside and outside the esophageal wall in portal hypertension. Irisawa A, et al. **Gastrointest Endosc** 1999 Sep;50(3):374-80

Use of color Doppler EUS in assessing azygos blood flow for patients with portal hypertension. Lee YT, et al. **Gastrointest Endosc** 1999 Jul;50(1):47-52

Observation of thoracic duct morphology in portal hypertension by endoscopic ultrasound. Parasher VK, et al. **Gastrointest Endosc** 1998 Dec;48(6):588-92

Splenorenal shunt blood flow by transit-time ultrasound as an index of collateral circulation in portal hypertensive rats. Calès P, et al. **Hepatology** 1998 Nov;28(5):1269-74

Splanchnic arterial Doppler parameters in portal hypertension [letter; comment] Valgimigli M, et al. **Hepatology** 1999 May;29(5):1610. Comment on: Hepatology 1998 Oct;28(4):932-6.

Hepatobiliary and pancreatic: Extrahepatic portal vein obstruction and cavernous transformation. Matsutani S, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1077-9

Doppler evaluation of the effects of pharmacological treatment of portal hypertension. Piscaglia F, et al. **Ultrasound Med Biol** 1999 Jul;25(6):923-32 (90 ref.)

[Doppler-duplex ultrasonography in the diagnosis of cavernous portal vein] Perišić M, et al. **Srp Arh Celok Lek** 1998 Sep-Oct;126(9-10):368-73 (Eng. Abstr.) **(Scc)**

[Contribution of Doppler ultrasonography to the study of natural history of portal hypertension (editorial)] Delgado Blanco MB, et al. **Rev Esp Enferm Dig** 1998 Nov; 90(11):767-70 **(Spa)**

[Usefulness of ultrasonography in the diagnosis of portal hypertension] Fernández Pérez FJ, et al. **Rev Esp Enferm Dig** 1998 Nov;90(11):806-12 (31 ref.) (Eng. Abstr.) **(Spa)**

HYPERTENSION, PULMONARY

see related
PULMONARY HEART DISEASE

The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Jones FD, et al. **Anesthesiology** 1999 Feb;90(2):626-9

Nitric oxide and pulmonary hypertension. Sperling RT, et al. **Coron Artery Dis** 1999 Jul;10(5):287-94 (119 ref.)

Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. Karlsson H, et al. **Thromb Res** 1998 Jun 1;90(5):223-8

[Primary pulmonary hypertension] Svendsen UG, et al. **Ugeskr Laeger** 1999 Feb 15;161(7):935-40 (28 ref.) (Eng. Abstr.) **(Dan)**

BLOOD

High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements? Schulz O, et al. **Am Heart J** 1999 May; 137(5):887-94

Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Patole S, et al. **Biol Neonate** 1998 Nov;74(5):345-50

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Langleben D, et al. **Circulation** 1999 Jun 29;99(25):3266-71

Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Kakishita M, et al. **Clin Sci (Colch)** 1999 Jan;96(1):33-9

Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Hoeper MM, et al. **Eur Respir J** 1998 Dec;12(6):1446-9

Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension. Tutar HE, et al. **Int J Cardiol** 1999 Jul 1;70(1):57-62

Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Celik G, et al. **Respiration** 1998;65(4):289-94

Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. Ignatescu M, et al. **Thromb Haemost** 1998 Aug;80(2):231-2

[Changes of nitric oxide and endothelin content in pulmonary hypertension during early stage of cecal ligation and puncture in rabbits] Wan M, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):180, 142 **(Chi)**

[The changes of plasma endothelin concentration and its clinical significance in pulmonary hypertension associated with congenital heart defects] Zhang S, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):425-7 (Eng. Abstr.) **(Chi)**

CHEMICALLY INDUCED

Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Archer SL, et al. **Am J Respir Crit Care Med** 1998 Oct; 158(4):1061-7

Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Tuder RM, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1999-2001

The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administration. Ralley FE. **Anesth Analg** 1999 Mar;88(3):505-7

Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. Strother J, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):539-40

Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension [letter] Morse JH, et al. **Chest** 1999 Sep;116(3):847

Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Rothman RB, et al. **Circulation** 1999 Aug 24;100(8):869-75

Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade. Hanaoka M, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):145-51

High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Delcroix M, et al. **Eur Respir J** 1998 Aug;12(2):271-6

Lung injury from intratracheal and inhalation exposures to residual oil fly ash in a rat model of monocrotaline-induced pulmonary hypertension. Kodavanti UP, et al. **J Toxicol Environ Health** 1999 Aug 27;57(8):543-63

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Schultze AE, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):271-346 (381 ref.)

Primary pulmonary hypertension and anorectic drugs [letter; comment] Louis WJ. **N Engl J Med** 1999 Feb 11; 340(6):480-2. Comment on: N Engl J Med 1996 Aug 29;335(9):609-16.

Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1. Barman SA, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):183-7

[Pulmonary hypertension and heart valve diseases induced by fenfluramine? Hypothesis or certitude? Myth or reality? (editorial)] Godeau P, et al. **Rev Med Interne** 1998 Oct; 19(10):700-3 **(Fre)**

[Appetite depressants and pulmonary hypertension] Hellermann J, et al. **Ther Umsch** 1998 Sep;55(9):548-50 (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Primary pulmonary hypertension in a patient with HIV infection. Conraads VM, et al. **Acta Cardiol** 1998; 53(6):367-9

Pulmonary hypertension in patients with thalassemia major [letter] Derchi G, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):384

Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension. Hinderliter AL, et al. **Am J Cardiol** 1999 Aug 15;84(4):481-4, A10

Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension. Kawut SM, et al. **Am J Cardiol** 1999 Mar 15;83(6):984-6, A10

A case of congenital mumps infection complicated with persistent pulmonary hypertension. Takahashi Y, et al. **Am J Perinatol** 1998 Jul;15(7):409-12

Pulmonary hypertension and major surgery. Rodriguez RM, et al. **Anesth Analg** 1998 Oct;87(4):812-5

Inoperable pulmonary vascular disease in infants with congenital heart disease. Yamaki S, et al. **Ann Thorac Surg** 1998 Nov;66(5):1565-70

Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with and without pulmonary hypertension. Varan B, et al. **Arch Dis Child** 1999 Jul; 81(1):49-52

Thrombolysis with resolution of pulmonary hypertension in a heart transplant candidate. Lick S, et al. **Chest** 1999 Mar; 115(3):896-7

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Rosenzweig EB, et al. **Circulation** 1999 Apr 13;99(14):1858-65

Vanishing pulmonary hypertension in mixed connective tissue disease. Lahaye IE, et al. **Clin Rheumatol** 1999; 18(1):45-7

Management of postoperative chylothorax with nitric oxide: a critical review [editorial; comment] Mavroudis C. **Crit Care Med** 1999 May;27(5):877 (4 ref.). Comment on: Crit Care Med 1999 May;27(5):1022-4.

Hyperuricaemia in patients with right or left heart failure. Hoeper MM, et al. **Eur Respir J** 1999 Mar;13(3):682-5

Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure. Crilley JG, et al. **Heart** 1998 Dec;80(6):620-2

Primary pulmonary hypertension and its life prognosis [editorial; comment] Kunieda T. **Intern Med** 1999 Jan; 38(1):1-2 (18 ref.). Comment on: Intern Med 1999 Jan;38(1):12-6.

Cardiopulmonary dysfunction in cirrhosis. Liu H, et al. **J Gastroenterol Hepatol** 1999 Jun;14(6):600-8 (87 ref.)

Pulmonary hypertension in a child with juvenile-type autosomal recessive polycystic kidney disease. Huh J, et al. **J Korean Med Sci** 1999 Aug;14(4):451-4

Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. Farber HW, et al. **J Rheumatol** 1999 May; 26(5):1195-6

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 4-1999. A 38-year-old woman with increasing pulmonary hypertension after delivery [clinical conference] **N Engl J Med** 1999 Feb 11; 340(6):455-64

Non-cirrhotic portal fibrosis associated with pulmonary arteriovenous communication and pulmonary arterial hypertension. Chongsrisawat V, et al. **Southeast Asian J Trop Med Public Health** 1998 Mar; 29(1):76-9

A successful case of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension with a thrombus in the right ventricle. Masuda M, et al. **Surg Today** 1999;29(5):478-81

Portopulmonary hypertension and the liver transplant candidate. Kuo PC, et al. **Transplantation** 1999 Apr 27; 67(8):1087-93 (41 ref.)

[Primary pulmonary arterial hypertension associated with primary biliary cirrhosis (letter)] Koenig A, et al. **Presse Med** 1998 Sep 12;27(26):1329 **(Fre)**

[Ventricular septal defect associated with pulmonary hypertension in monozygotic twins--a case report with surgical repair] Kobayashi M, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1152-5 (Eng. Abstr.) **(Jpn)**

[A one-staged operation for mitral regurgitation and giant bulla in a patient with severe pulmonary hypertension: report of a case] Shirasawa B, et al. **Kyobu Geka** 1999 Jul; 52(7):592-4 (Eng. Abstr.) **(Jpn)**

[An autopsied case of idiopathic portal hypertension accompanied by right heart failure secondary to pulmonary hypertension] Zenda T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct;95(10):1151-6 **(Jpn)**

CONGENITAL

Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Shehata SM, et al. **Thorax** 1999 May;54(5):427-31

DIAGNOSIS

Primary pulmonary hypertension with fatal outcome in a

young woman and review of the literature. De Backer TL, et al. **Acta Cardiol** 1999 Feb;54(1):31–9 (40 ref.)
Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Hoeper MM, et al.
Am J Respir Crit Care Med 1999 Aug;160(2):535–41
Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Ong YY, et al.
Asian Pac J Allergy Immunol 1998 Jun–Sep;16(2–3):81–6
Primary pulmonary hypertension or portopulmonary hypertension? [letter; comment] Gossage JR. **Chest** 1998 Oct;114(4):1224–5. Comment on: Chest 1997 Aug;112(2):551–3.
A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension [see comments] Robbins IM, et al. **Chest** 1998 Nov; 114(5):1269–75. Comment in: Chest 1998 Nov;114(5):1234–5.
khree-dimensional contrast-enhanced magnetic resonance angiography in a patient with chronic thromboembolic pulmonary hypertension before and after thromboendarterectomy. Kreitner KF, et al. **Circulation** 1999 Mar 2;99(8):1101
Airway responsiveness to inhaled albuterol in patients with pulmonary hypertension. O'Hagan AR, et al.
Clin Pediatr (Phila) 1999 Jan;38(1):27–33 (41 ref.)
Pulmonary hypertension associated with human immunodeficiency virus infection. Report of two cases and review of the literature. Fiorencis R, et al.
G Ital Cardiol 1998 Dec;28(12):1404–8 (24 ref.)
Imaging in primary pulmonary hypertension. Chugh IM, et al. **Indian J Chest Dis Allied Sci** 1998 Jul–Sep;40(3):195–9
Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. Bossone E, et al.
J Am Coll Cardiol 1999 May;33(6):1662–6
MRI evaluation of right ventricular pressure overload in chronic obstructive pulmonary disease. Marcus JT, et al.
J Magn Reson Imaging 1998 Sep–Oct;8(5):999–1005
Congenital neonatal myotonic dystrophy with persistent pulmonary hypertension and coma: a difficult diagnosis. Cantagrel S, et al. **J Perinat Med** 1999;27(2):136–7
Two cases of primary pulmonary hypertension diagnosed during pregnancy. Takeuchi K, et al. **J Perinat Med** 1998; 26(3):248–51
Pulmonary veno-occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent. Hussein A, et al. **Klin Padiatr** 1999 Mar–Apr;211(2):92–5
Non-invasive estimation of pulmonary arterial hypertension in chronic obstructive pulmonary disease. Spiropoulos K, et al. **Lung** 1999;177(2):65–75
Diagnosing and treating primary pulmonary hypertension. Frazier SK. **Nurse Pract** 1999 Sep;24(9):18, 21–2, 25–6 passim; quiz 42–3 (43 ref.)
Inhalation of low-dose nitric oxide to evaluate pulmonary vascular reactivity in children with congenital heart disease. Yasuda T, et al. **Pediatr Cardiol** 1999 Jul–Aug; 20(4):278–82
Technetium-99m hexamethyl propylenamine oxime lung clearance in the estimation of pulmonary hypertension in congenital heart disease: A preliminary comparative study with cardiac catheterization and pathology. Yener A, et al. **Pediatr Cardiol** 1999 Jul–Aug;20(4):271–7
Recent advances in the treatment of pediatric pulmonary artery hypertension. Barst RJ. **Pediatr Clin North Am** 1999 Apr;46(2):331–45 (41 ref.)
Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging--preliminary experience. Mousseaux E, et al. **Radiology** 1999 Sep;212(3):896–902
Pulmonary hypertension in systemic lupus erythematosus. Shen JY, et al. **Rheumatol Int** 1999;18(4):147–51
[Clinical analysis in seventy-two patients with chronic thromboembolic pulmonary hypertension] Cheng X, et al. **Chung Hua Nei Ko Tsa Chih** 1997 May;36(5):321–4 (Eng. Abstr.) **(Chi)**
[Severe pulmonary hypertension in systemic lupus erythematosus. The successful therapy of an unusual manifestation] Beckh S, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):618–23 (13 ref.) (Eng. Abstr.) **(Ger)**
[Exertional dyspnea in HIV infection] Krautheim A.
Schweiz Rundsch Med Prax 1998 Nov 4;87(45):1512–5 **(Ger)**
[Persistent pulmonary opacification as a sequela of portopulmonary shunt in portal vein thrombosis] Meyer RG, et al. **Z Gastroenterol** 1998 Nov;36(11):971–5 (18 ref.) (Eng. Abstr.) **(Ger)**
[Estimation of pulmonary hypertension in lung and valvular heart diseases by perfusion lung scintigraphy] Fujii T, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):458–65 (Eng. Abstr.) **(Jpn)**
[Primary pulmonary hypertension in children] Hankø E, et al. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):512–4 (Eng. Abstr.) **(Nor)**
[Use of nitric oxide in the evaluation of pulmonary arterial hypertension] Garcia y Otero A, et al.
Arch Inst Cardiol Mex 1998 Sep–Oct;68(5):426–30 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Inhaled nitric oxide therapy in pregnancy complicated by pulmonary hypertension. Robinson JN, et al.
Am J Obstet Gynecol 1999 Apr;180(4):1045–6
Right ventricular size is acutely decreased by inhaled nitric oxide in newborns with pulmonary hypertension. Day RW.
Am J Perinatol 1998 Jul;15(7):445–51
Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury. Jacobs BR, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1536–42
Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Olschewski H, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):600–7
Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Ziegler JW, et al.
Am J Respir Crit Care Med 1998 Nov;158(5 Pt 1):1388–95
Unsuccessful treatment of pulmonary hypertension by inhaled nitric oxide and aerosolized prostacyclin [letter] Tibballs J, et al. **Anaesth Intensive Care** 1999 Jun; 27(3):316–7
Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension. Aranda M, et al. **Anesth Analg** 1999 Jul;89(1):152–8
Inhaled nitric oxide and nifedipine have similar effects on lung cGMP levels in rats. Horstman DJ, et al.
Anesth Analg 1999 Oct;89(4):932–7
The use of nitric oxide for managing catastrophic pulmonary vasoconstriction arising from protamine administration. Ralley FE. **Anesth Analg** 1999 Mar;88(3):505–7
The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Ramsay MA, et al. **Anesthesiology** 1999 Jan;90(1):299–301
Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. McLaughlin VV, et al. **Ann Intern Med** 1999 May 4;130(9):740–3
Epoprostenol in primary pulmonary hypertension. Herner SJ, et al. **Ann Pharmacother** 1999 Mar;33(3):340–7 (23 ref.)
Pulmonary hypertension and diffuse macular edema responsive to acetazolamide [letter] Hammond CJ, et al.
Arch Ophthalmol 1998 Nov;116(11):1535–6
Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Patole S, et al. **Biol Neonate** 1998 Nov;74(5):345–50
Anaesthesia for caesarean section in the presence of severe primary pulmonary hypertension. O'Hare R, et al.
Br J Anaesth 1998 Nov;81(5):790–2
Inhaled and exhaled nitric oxide. Thébaud B, et al.
Cell Mol Life Sci 1999 Jul;55(8–9):1103–12 (87 ref.)
A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension [see comments] Robbins IM, et al. **Chest** 1998 Nov; 114(5):1269–75. Comment in: Chest 1998 Nov;114(5):1234–5.
Role of inhaled nitric oxide in treatment of neonatal pulmonary hypertension. Abman SH.
Chung Kuo Yao Li Hsueh Pao 1997 Nov;18(6):542–5
Update on clinical trials with inhaled nitric oxide. Frostell CG. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):539–41
Vasodilator therapy for primary pulmonary hypertension in children. Barst RJ, et al. **Circulation** 1999 Mar 9; 99(9):1197–208
Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Langleben D, et al.
Circulation 1999 Jun 29;99(25):3266–71
Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Rosenzweig EB, et al.
Circulation 1999 Apr 13;99(14):1858–65
L-arginine and substance P reverse the pulmonary endothelial dysfunction caused by congenital heart surgery. Schulze-Neick I, et al. **Circulation** 1999 Aug 17; 100(7):749–55
Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension [letter] Kawaguchi Y, et al.
Clin Exp Rheumatol 1998 Jul–Aug;16(4):510
Management of postoperative chylothorax with nitric oxide: a case report [see comments] Berkenbosch JW, et al.
Crit Care Med 1999 May;27(5):1022–4. Comment in: Crit Care Med 1999 May;27(5):877.
Inhaled nitric oxide and pulmonary vascular resistance [editorial; comment] Bigatello LM, et al. **Crit Care Med** 1999 Sep;27(9):2060–1. Comment on: Crit Care Med 1999 Sep;27(9):1953–7.
Effects of inhaled nitric oxide on pulmonary hemodynamics in a porcine model of endotoxin shock [see comments] Lambermont B, et al. **Crit Care Med** 1999 Sep;27(9):1953–7. Comment in: Crit Care Med 1999 Sep;27(9):2060–1.
Discordant effects of alkalosis on elevated pulmonary vascular resistance and vascular reactivity in lamb lungs. Moreira GA, et al. **Crit Care Med** 1999 Sep;27(9):1838–42
Inhaled nitric oxide and inhaled prostaglandin E1: effect on left ventricular contractility when used for treatment of experimental pulmonary hypertension. Krieg P, et al.
Eur J Cardiothorac Surg 1998 Nov;14(5):494–502
Effect of nitric oxide inhalation on pulmonary hypertensive crisis in a case of aortic origin of the right pulmonary artery [letter] Ikemoto Y, et al. **Eur J Pediatr** 1998 Aug;157(8):697
Effects of the endothelin ET(A) receptor antagonist, TA-0201, on pulmonary arteries isolated from hypoxic rats. Itoh H, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):233–8
Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Yoshihara F, et al.
Eur J Pharmacol 1998 Aug 14;355(1):33–9
Pulmonary hypertension in high-altitude chronic hypoxia: response to nifedipine. Antezana AM, et al.
Eur Respir J 1998 Nov;12(5):1181–5
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension [see comments] Sitbon O, et al. **Eur Respir J** 1998 Aug;12(2):265–70. Comment in: Eur Respir J 1998 Aug;12(2):263–4.
Vasodilators in the treatment of primary pulmonary hypertension [editorial; comment] Weir EK, et al.
Eur Respir J 1998 Aug;12(2):263–4. Comment on: Eur Respir J 1998 Aug;12(2):265–70.
Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure. Crilley JG, et al. **Heart** 1998 Dec;80(6):620–2
Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Higenbottam T, et al. **Heart** 1998 Aug;80(2):151–5
Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Krowka MJ, et al. **Hepatology** 1999 Sep; 30(3):641–8
Unpredictable response to vasodilator therapy in primary pulmonary hypertension. Schmiedt MI, et al.
Int J Clin Pharmacol Ther 1998 Aug;36(8):435–40
Inhaled prostacyclin: from pulmonary hypertension to splanchnic hypoperfusion. Brienza N.
Intensive Care Med 1998 Nov;24(11):1228–30
Severe hypoxemia and pulmonary hypertension during orthotopic liver transplantation: a successful use of inhaled nitric oxide [letter] Girardis M, et al.
Intensive Care Med 1999 Jun;25(6):638
Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation. Munich Lung Transplant Group. Kemming GI, et al. **Intensive Care Med** 1998 Nov; 24(11):1173–80
Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Schulze-Neick I, et al.
Intensive Care Med 1999 Jan;25(1):76–80
Antioxidants attenuate chronic hypoxic pulmonary hypertension. Lai YL, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):714–20
The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. Pamboukian SV, et al. **J Heart Lung Transplant** 1999 Apr; 18(4):367–71
Diltiazem reduces pulmonary arterial pressures in recurrent pulmonary hypertension associated with pulmonary hypoplasia. Islam S, et al. **J Pediatr Surg** 1999 May; 34(5):712–4
Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. Kodama K, et al. **J Pharmacol Exp Ther** 1999 Aug; 290(2):748–52
Long-term inhalation of nitric oxide for a patient with primary pulmonary hypertension. Koh E, et al.
Jpn Circ J 1998 Dec;62(12):940–2
Inhaled nitric oxide in patients with pulmonary hypertension due to valvular heart disease and chronic lung disease. Sakane M, et al. **Jpn Circ J** 1998 Dec;62(12):877–82
Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Findlay JY, et al.
Liver Transpl Surg 1999 Sep;5(5):362–5
Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Mok MY, et al.
Lupus 1999;8(4):328–31
Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Tam LS, et al. **Lupus** 1998; 7(7):495–7
Pulmonary hypertension in pregnancy: treatment with pulmonary vasodilators. Easterling TR, et al.
Obstet Gynecol 1999 Apr;93(4):494–8
Infant lung function after inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Dobyns EL, et al. **Pediatr Pulmonol** 1999 Jul;28(1):24–30
Inhaled nitric oxide, oxygen, and alkalosis: dose-response interactions in a lamb model of pulmonary hypertension. Heidersbach RS, et al. **Pediatr Pulmonol** 1999 Jul;28(1):3–11
How do we safely use inhaled nitric oxide? [letter; comment] Clark RH. **Pediatrics** 1999 Aug;104(2 Pt 1):296–7. Comment on: Pediatrics 1999 Aug;104(2 Pt 1):231–6.
Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn [see comments] Davidson D, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):231–6. Comment in: Pediatrics 1999 Aug;104(2 Pt 1):296–7.
Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Beck JR, et al. **Perfusion** 1999 Jan;14(1):37–42
Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension. Patterson KW, et al. **Pharmacology** 1999 May;58(5):246–51
Use of epoprostenol (Flolan) in the management of primary pulmonary hypertension [news] Kayser SR.

Prog Cardiovasc Nurs 1998 Summer;13(3):39–41, 45

The effect of the ETA receptor antagonist (CI–1020) in rats with established hypoxic pulmonary hypertension. Sheedy W, et al. **Pulm Pharmacol Ther** 1998 Apr–Jun;11(2–3):173–6

Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis. Parameswaran K, et al. **Respir Med** 1999 Feb;93(2):75–8

Inhaled nitric oxide and high concentrations of oxygen in pediatrics patients with congenital cardiopathy and pulmonary hypertension: report of five cases. de Carvalho WB, et al. **Rev Paul Med** 1998 Jan–Feb;116(1):1602–5

Sustained improvement of performance and haemodynamics with long–term aerosolised prostacyclin therapy in severe pulmonary hypertension. Stricker H, et al. **Schweiz Med Wochenschr** 1999 Jun 19;129(24):923–7

Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Bellotto F, et al. **Thorax** 1999 Apr;54(4):372–4

Pulmonary hypertension: its assessment and treatment. Brij S, et al. **Thorax** 1999 Aug;54 Suppl 2:S28–32 (34 ref.)

Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease. Omar HA, et al. **W V Med J** 1999 Mar–Apr;95(2):74–5

[Clinical efficacy of prolonged therapy with NO on patients with pulmonary hypertension] He JG, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):762–4 (Eng. Abstr.) **(Chi)**

[Present status of researches on pulmonary hypertension] Liu WZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Apr;17(4):248–50 (27 ref.) **(Chi)**

[Effectiveness of continuous intravenous prostaglandin E 1 against pulmonary hypertension] Satomi K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 May;36(5):421–7 (Eng. Abstr.) **(Jpn)**

[Effectiveness of enap and oliphen combined treatment of chronic pulmonary hypertension] Shkol'nik MA, et al. **Klin Med (Mosk)** 1999;77(6):26–7 **(Rus)**

[Treatment of primary pulmonary hypertension: one hundred years of search and disappointments] Belenkov IuN. **Ter Arkh** 1998;70(9):16–8 **(Rus)**

[The use of aspirin in patients with primary pulmonary hypertension] Chazova IE, et al. **Ter Arkh** 1998;70(8):45–8 (Eng. Abstr.) **(Rus)**

[Effectiveness of adenosine as a pulmonary vasodilator during weaning from extracorporeal circulation after mitral valve replacement in a patient with severe pulmonary hypertension] Charco Mora P, et al. **Rev Esp Anestesiol Reanim** 1999 May;46(5):223–5 (Eng. Abstr.) **(Spa)**

[Primary pulmonary hypertension. Treatment with prostacyclin I2 (epoprostenol) (letter)] Vicente R, et al. **Rev Esp Anestesiol Reanim** 1999 Jun–Jul;46(6):274 **(Spa)**

EMBRYOLOGY

Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Hanson KA, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L931–41

Acute intrauterine pulmonary hypertension impairs endothelium–dependent vasodilation in the ovine fetus. Storme L, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):575–81

ENZYMOLOGY

Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Black SM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1643–51

Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Tyler RC, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):L297–303

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Tuder RM, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1925–32

Expression of nitric oxide synthase isoforms (NOS II and NOS III) in adult rat lung in hyperoxic pulmonary hypertension. Steudel W, et al. **Cell Tissue Res** 1999 Feb; 295(2):317–29

Mast cell chymase in pulmonary hypertension. Mitani Y, et al. **Thorax** 1999 Jan;54(1):88–90

[Role of pulmonary arterial angiotensin converting enzyme in development of hypoxic pulmonary hypertension] Cai C, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Aug;20(4):215–7 (Eng. Abstr.) **(Chi)**

[The relationship between the activity of phospholipase A2 and acute hypoxic pulmonary arterial pressure] Li HP, et al. **Sheng Li Hsueh Pao** 1997 Dec;49(6):685–9 (Eng. Abstr.) **(Chi)**

EPIDEMIOLOGY

Pulmonary embolism: one–year follow–up with echocardiography doppler and five–year survival analysis [see comments] Ribeiro A, et al. **Circulation** 1999 Mar 16; 99(10):1325–30. Comment in: Circulation 1999 Mar 16;99(10):1280–3.

Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. Li EK, et al. **J Rheumatol** 1999 Sep;26(9):1923–9

ETIOLOGY

Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Garcia–Manero G, et al. **Am J Hematol** 1999 Feb;60(2):130–5

E–4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Hanasato N, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L225–32

Bacterial lipopolysaccharide induction of the prostaglandin G/H synthase 2 gene causes thromboxane–dependent pulmonary hypertension in rabbits. Delong P, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):493–9

Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. Niijima M, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1766–72

Development of pulmonary hypertension after lung volume reduction surgery. Weg IL, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):552–6

Resuscitation of the injured patient with polymerized stroma–free hemoglobin does not produce systemic or pulmonary hypertension. Johnson JL, et al. **Am J Surg** 1998 Dec;176(6):612–7

Pulmonary hypertension after splenectomy? Hoeper MM, et al. **Ann Intern Med** 1999 Mar 16;130(6):506–9

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. McLaughlin VV, et al. **Ann Intern Med** 1999 May 4;130(9):740–3

Pulmonary hypertension during beating heart coronary surgery: intermittent inferior vena cava snaring. Dagenais F, et al. **Ann Thorac Surg** 1999 Sep;68(3):1094–5

Increased pulmonary blood flow produces endothelial cell dysfunction in neonatal swine. Vitvitsky EV, et al. **Ann Thorac Surg** 1998 Oct;66(4):1372–7

Congenital diaphragmatic hernia. A cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Thebaud B, et al. **Biol Neonate** 1998 Nov; 74(5):323–36 (106 ref.)

Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Fraser KL, et al. **Chest** 1999 May;115(5):1321–8

Pulmonary hypertension in a 45–year–old woman with recurrent deep venous thromboses. O'Brien JD, et al. **Chest** 1999 Aug;116(2):560–3

Aminorex to fen/phen: an epidemic foretold. Fishman AP. **Circulation** 1999 Jan 5–12;99(1):156–61 (55 ref.)

Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Robbins IM, et al. **Circulation** 1998 Oct 27; 98(17):1769–75

Manifestations of scleroderma pulmonary disease. Minai OA, et al. **Clin Chest Med** 1998 Dec;19(4):713–31, viii–ix (168 ref.)

Putative mediator role of endothelin–1 in asthma and other lung diseases. Hay DW. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):168–71 (35 ref.)

Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: reversibility of pulmonary hypertension after transplantation. Tarquino M, et al. **Clin Pediatr (Phila)** 1998 Aug;37(8):505–9

Pulmonary hypertension in collagen vascular disease. Palevsky HI, et al. **Compr Ther** 1999 Mar;25(3):133–43 (87 ref.)

High and low pulmonary vascular resistance in heart transplant candidates. A 5–year follow–up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Lindelöw B, et al. **Eur Heart J** 1999 Jan;20(2):148–56

Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Labrune P, et al. **Eur J Pediatr** 1999 Sep;158(9):734–9

Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Vogel M, et al. **Heart** 1999 Jul;82(1):30–3

Chronic thromboembolic pulmonary hypertension. Lang IM. **Indian Heart J** 1999 Jan–Feb;51(1):27–30 (17 ref.)

Pulmonary hypertensive crisis as an initial manifestation of intracranial arteriovenous malformation with aneurysm of the vein of Galen [letter] Huh J, et al. **Int J Cardiol** 1998 Sep 1;66(1):107–9

Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation. Munich Lung Transplant Group. Kemming GI, et al. **Intensive Care Med** 1998 Nov; 24(11):1173–80

Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. Mal H, et al. **J Hepatol** 1999 Aug;31(2):360–4

Alveolar capillary dysplasia: an emerging syndrome [letter; comment] Thibeault DW, et al. **J Pediatr** 1999 May; 134(5):661–2. Comment on: J Pediatr 1998 Jul;133(1):157–61.

Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. Zenker M, et al. **J Perinat Med** 1998;26(3):231–4

Pulmonary capillary hemangiomatosis as cause of pulmonary hypertension in a young woman with systemic lupus erythematosus [letter] Fernández–Alonso J, et al. **J Rheumatol** 1999 Jan;26(1):231–3

Progressive pulmonary vascular disease after pulmonary artery banding and total correction in a case of ventricular septal defect and pulmonary hypertension. Yamaki S, et al. **Jpn J Thorac Cardiovasc Surg** 1999 May;47(5):229–33

Pulmonary veno–occlusive disease, antiphospholipid antibody and pulmonary hypertension in an adolescent. Hussein A, et al. **Klin Padiatr** 1999 Mar–Apr;211(2):92–5

Augmented vasoreactivity in adult life associated with perinatal vascular insult. Sartori C, et al. **Lancet** 1999 Jun 26;353(9171):2205–7

Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Mok MY, et al. **Lupus** 1999;8(4):328–31

Pulmonary hypertension in systemic lupus erythematosus [letter] [published erratum appears in Mayo Clin Proc 1999 Sep;74(9):950] Cheng TO. **Mayo Clin Proc** 1999 Aug; 74(8):845

Pulmonary hypertension in acute respiratory distress syndrome. Leeman M. **Monaldi Arch Chest Dis** 1999 Apr; 54(2):146–9 (29 ref.)

Post–Mustard procedure pulmonary venous obstruction: An opportunity for anatomic correction with a one–stage arterial switch. Reisman M, et al. **Pediatr Cardiol** 1999 Jul–Aug;20(4):301–3

Pulmonary arteriovenous shunting and pulmonary artery hypertension in children with liver disease. Bernard O. **Pediatr Pulmonol Suppl** 1999;18:88–90

The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS). Wu JM, et al. **Pediatr Pulmonol Suppl** 1999;18:205–8

Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high–risk cardiac surgery. Beck JR, et al. **Perfusion** 1999 Jan;14(1):37–42

How to manage secondary pulmonary hypertension. Ricciardi MJ, et al. **Postgrad Med** 1999 Feb;105(2):183–90; quiz 229 (7 ref.)

An unusual cause of pulmonary hypertension and right heart failure. Orme S, et al. **Postgrad Med J** 1998 Nov; 74(877):697–8

Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. Stratton RJ, et al. **QJM** 1998 Aug;91(8):561–6

Pulmonary hypertension in systemic lupus erythematosus. Shen JY, et al. **Rheumatol Int** 1999;18(4):147–51

Development of advanced pulmonary vascular disease in D–transposition of the great arteries after the neonatal arterial switch operation. Rivenes SM, et al. **Tex Heart Inst J** 1998;25(3):201–5

Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Egermayer P, et al. **Thorax** 1999 Feb;54(2):161–8 (186 ref.)

Pulmonary hypertension secondary to neurofibromatosis: intimal fibrosis versus thromboembolism. Samuels N, et al. **Thorax** 1999 Sep;54(9):858–9

[Primary pulmonary hypertension in an HIV–seropositive patient (letter)] Lambiotte F, et al. **Presse Med** 1999 Mar 20;28(11):582 **(Fre)**

[A rare case of severe pulmonary artery hypertension. Thrombosing pulmonary microangiopathy due to tumor] Perrin C, et al. **Rev Mal Respir** 1998 Sep;15(4):545–7 (Eng. Abstr.) **(Fre)**

[Short–duration nocturnal hypoxemia and persistent pulmonary hypertension] Weitzenblum E, et al. **Rev Mal Respir** 1998 Dec;15(6):743–51 (Eng. Abstr.) **(Fre)**

[Pulmonary artery hypertension and obstructive sleep apnea. Pathophysiology and clinical relevance] Steiner S, et al. **Internist (Berl)** 1999 Jul;40(7):739–46 (61 ref.) **(Ger)**

[Pulmonary hypertension in rheumatic diseases] Manganelli P, et al. **Minerva Med** 1999 Mar;90(3):59–72 (149 ref.) (Eng. Abstr.) **(Ita)**

[Chronic thromboembolic pulmonary hypertension associated with initial pulmonary involvement in Takayasu arteritis] Kashiwabara K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):633–7 (Eng. Abstr.) **(Jpn)**

[Primary Sjögren's syndrome with pulmonary hypertension] Usui K, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 May; 36(5):478–81 (Eng. Abstr.) **(Jpn)**

[State of cardiopulmonary hemodynamics in patients with mucoviscidosis according to Doppler echocardiography] Perlei VE, et al. **Ter Arkh** 1999;71(3):51–4 (Eng. Abstr.) **(Rus)**

GENETICS

Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Klinger JR, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L868–74

Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension [letter] Morse JH, et al. **Chest** 1999 Sep;116(3):847

Factor V Leiden is not common in patients diagnosed with primary pulmonary hypertension. Elliott CG, et al. **Eur Respir J** 1998 Nov;12(5):1177–80

The pulmonary circulation of homozygous or heterozygous eNOS–null mice is hyperresponsive to mild hypoxia. Fagan KA, et al. **J Clin Invest** 1999 Jan;103(2):291–9

ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders [letter] Morrell NW, et al. **Lancet** 1999 Mar 6;353(9155):814

[Interstitial lung diseases with pulmonary hypertension associated with epidermolysis bullosa in an infant] Doeker B, et al. **Klin Padiatr** 1998 Sep–Oct;210(5):340–4 (Eng. Abstr.) **(Ger)**

HYPERTENSION, PULMONARY

HISTORY

Historical perspective: surgery for chronic thromboembolic disease. Daily PO, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):143–51

METABOLISM

Expression and function of atrial myosin light chain 1 in the porcine right ventricle of normal and pulmonary hypertensive animals. Morano M, et al. **Adv Exp Med Biol** 1998;453:481–8; discussion 488–9

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Cool CD, et al. **Am J Pathol** 1999 Aug;155(2):411–9

Chronic activation of neurokinin-1 receptor induces pulmonary hypertension in rats. Chen LW, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1543–51

Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Frasch HF, et al. **Am J Physiol** 1999 Feb; 276(2 Pt 1):L304–10

Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Partovian C, et al. **Am J Physiol** 1998 Dec; 275(6 Pt 2):H1948–56

Microvessel precursor smooth muscle cells express head-inserted smooth muscle myosin heavy chain (SM-B) isoform in hyperoxic pulmonary hypertension. Jones R, et al. **Cell Tissue Res** 1999 Mar;295(3):453–65

Alpha1-adrenergic hypothesis for pulmonary hypertension. Salvi SS. **Chest** 1999 Jun;115(6):1708–19 (106 ref.)

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Yuan JX, et al. **Circulation** 1998 Oct 6;98(14):1400–6

Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Lutz J, et al. **Clin Chem Lab Med** 1999 Apr; 37(4):423–8

Acetylcholine-induced endothelium-derived contracting factor in hypoxic pulmonary hypertensive rats. Maruyama J, et al. **J Appl Physiol** 1999 May;86(5):1687–95

Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? MacLean MR. **J Lab Clin Med** 1999 Aug;134(2):105–14 (133 ref.)

[Expression and distribution of bFGF in rat lung tissue of chronic hypoxic pulmonary hypertension] Yan H, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Dec; 20(6):344–6 (Eng. Abstr.) **(Chi)**

[Changes of PDGF-alpha and beta receptor gene expression in hypoxic rat pulmonary vessels] Huang Q, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Dec; 19(6):470–3 (Eng. Abstr.) **(Chi)**

[Role of endothelial-derived nitric oxide and its synthase in the development of hypoxic pulmonary hypertension in rat] Lin H, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):163–7 (Eng. Abstr.) **(Chi)**

MORTALITY

Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Nagaya N, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):487–92

Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Lopes AA, et al. **Chest** 1998 Nov;114(5):1276–82

Prognoses of primary pulmonary hypertension and chronic majorvessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Kunieda T, et al. **Intern Med** 1999 Jul;38(7):543–6

Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980–1990 [see comments] Okada O, et al. **Intern Med** 1999 Jan;38(1):12–6. Comment in: Intern Med 1999 Jan;38(1):1–2.

PATHOLOGY

Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Cool CD, et al. **Am J Pathol** 1999 Aug;155(2):411–9

Vascular endothelium viability and function after total cardiopulmonary bypass in neonatal piglets. Serraf A, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):544–51

Morphology of the elastic pulmonary arteries in pulmonary hypertension: a quantitative study. McLeod KA, et al. **Cardiol Young** 1999 Jul;9(4):364–70

Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. Soriano CM, et al. **Chest** 1999 Aug; 116(2):564–6

Tetrandrine inhibited chronic "inflammatory" pulmonary hypertension in rats. Wang HL, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):401–4

[Properties of potassium channels in pulmonary arterial smooth muscle cells in hypoxic pulmonary hypertension (editorial)] Chen W. **Chung Hua Nei Ko Tsa Chih** 1997; 36(1):5–6 **(Chi)**

[Effect of L-arg and SNP on pulmonary arterial pressure and vascular structural changes of chronically hypoxic rats] Lin H, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Jun; 19(3):179–84 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Factors determining normalization of pulmonary vascular resistance following successful balloon mitral valvotomy. Gamra H, et al. **Am J Cardiol** 1999 Feb 1;83(3):392–5

Reverse aortic arch flow secondary to severe pulmonary hypertension in the neonate. Lane J, et al. **Am J Perinatol** 1999;16(3):143–9

Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Black SM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1643–51

Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Hanson KA, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L931–41

Pulmonary artery endothelium-dependent vasodilation is impaired in a chicken model of pulmonary hypertension. Martinez-Lemus LA, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R190–7

Hypoxia inhibits increased ETB receptor-mediated NO synthesis in hypertensive rat lungs. Sato K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L571–81

alpha-smooth-muscle actin and microvascular precursor smooth-muscle cells in pulmonary hypertension. Jones R, et al. **Am J Respir Cell Mol Biol** 1999 Apr;20(4):582–94

Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Botney MD. **Am J Respir Crit Care Med** 1999 Feb;159(2):361–4 (35 ref.)

Anesthetic management of the parturient with systemic lupus erythematosus, pulmonary hypertension, and pulmonary edema. Cuenco J, et al. **Anesthesiology** 1999 Aug; 91(2):568–70

Integrity of the pericardium. Its beneficial effects on the protection of the right ventricle in the presence of acute pulmonary hypertension. Borrego JM, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):332–5

Molecular and functional mechanisms of right ventricular adaptation in chronic pulmonary hypertension. Chen EP, et al. **Ann Thorac Surg** 1999 Apr;67(4):1053–8

Effects of chronic pulmonary overcirculation on pulmonary vasomotor tone. Parviz M, et al. **Ann Thorac Surg** 1999 Feb;67(2):522–7

L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Fagan JM, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):100–3

Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Eddahibi S, et al. **Br J Pharmacol** 1998 Oct;125(4):681–8

Improvement of pulmonary hypertension after liver transplantation. Schott R, et al. **Chest** 1999 Jun; 115(6):1748–9

NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Zhao L, et al. **Circulation** 1999 Feb 9;99(5):605–7

Ventilatory inefficiency for carbon dioxide during exercise in patients with pulmonary hypertension. Reybrouck T, et al. **Clin Physiol** 1998 Jul;18(4):337–44

Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Carteaux JP, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):346–52

Pulmonary hypertensive effects of lung inflation in chronic hypoxia: a study in rats. Barer GR, et al. **Eur Respir J** 1998 Aug;12(2):277–83

Hyperuricaemia in patients with right or left heart failure. Hoeper MM, et al. **Eur Respir J** 1999 Mar;13(3):682–5

Proximal pulmonary emboli modify right ventricular ejection pattern. Torbicki A, et al. **Eur Respir J** 1999 Mar; 13(3):616–21

The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Riedel B. **Int Anesthesiol Clin** 1999 Spring;37(2):55–79 (141 ref.)

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. Atz AM, et al. **J Am Coll Cardiol** 1999 Mar;33(3):813–9

Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. Hill LL, et al. **J Appl Physiol** 1999 Apr;86(4):1160–4

Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy. Quaife RA, et al. **J Card Fail** 1999 Mar; 5(1):46–54

Differential roles of endothelin-1 in the development of secondary pulmonary hypertension in patients with left heart failure with or without acute exacerbation. Sasaki T, et al. **J Card Fail** 1999 Mar;5(1):38–45

Effect of inhaled nitric oxide on left ventricular and pulmonary vascular function [letter; comment] Krohn BG. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):195–6. Comment on: J Thorac Cardiovasc Surg 1998 Mar;115(3):700–8.

Estimation of left ventricular function in right ventricular volume and pressure overload. Detection of early left ventricular dysfunction by Tei index. Kim WH, et al. **Jpn Heart J** 1999 Mar;40(2):145–54

Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Sakuma F, et al. **Lung** 1999;177(2):77–88

Does acute volume overloading in the setting of left ventricular dysfunction and pulmonary hypertension affect the defibrillation threshold? Vigh AG, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):759–64

Exercise testing in children with primary pulmonary hypertension. Garofano RP, et al. **Pediatr Cardiol** 1999 Jan-Feb;20(1):61–4; discussion 65 (25 ref.)

Altered endothelial function in lambs with pulmonary hypertension and acute lung injury. Fineman JR, et al. **Pediatr Pulmonol** 1999 Mar;27(3):147–56

New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Abman SH. **Pediatr Pulmonol Suppl** 1999;18:201–4 (18 ref.)

Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Rubin LJ. **Pediatr Pulmonol Suppl** 1999;18:194–7 (16 ref.)

Effects of nebulized nitroprusside on pulmonary and systemic hemodynamics during pulmonary hypertension in piglets. Meadow W, et al. **Pediatr Res** 1998 Aug;44(2):181–6

Inhibition of endogenous nitric oxide synthesis potentiates the effects of sodium nitroprusside but not of adenosine in experimental pulmonary hypertension. Wall MH, et al. **Pharmacology** 1999 Jan;58(1):34–43

Nonlinear indicial response of complex nonstationary oscillations as pulmonary hypertension responding to step hypoxia. Huang W, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1834–9

Regulation of endothelin-1 at rest and during a short steady-state exercise in 21 COPD patients. Faller M, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):151–7

Endothelin-1: a mediator of pulmonary hypertension? MacLean MR. **Pulm Pharmacol Ther** 1998 Apr-Jun; 11(2-3):125–32 (95 ref.)

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat. Underwood DC, et al. **Pulm Pharmacol Ther** 1999;12(1):13–26

Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Voelkel NF, et al. **Pulm Pharmacol Ther** 1997 Oct-Dec;10(5-6):231–41 (104 ref.)

ET-1 infusion increases systemic vascular resistance and depresses cardiac output in patients with chronic hypoxaemia and pulmonary hypertension. Franco-Cereceda A, et al. **Scand Cardiovasc J** 1999; 33(3):151–6

Pulmonary artery pressure variation in patients with connective tissue disease: 24 hour ambulatory pulmonary artery pressure monitoring. Raeside DA, et al. **Thorax** 1998 Oct;53(10):857–62

Role of NO in recovery from neonatal hypoxic pulmonary hypertension. Tulloh RM, et al. **Thorax** 1999 Sep; 54(9):796–804

Alteration in lung particle translocation, macrophage function, and microfilament arrangement in monocrotaline-treated rats. Madl AK, et al. **Toxicol Appl Pharmacol** 1998 Nov;153(1):28–38

Reversal of impaired calcium homeostasis in the rat diaphragm subjected to Monocrotaline-induced pulmonary hypertension. Kanj NA, et al. **Toxicol Lett** 1999 Apr 12; 105(3):177–82

[Pulmonary hemodynamic and gas exchange effects of various oxygen concentrations in patients with severe pulmonary hypertension primarily affecting the pulmonary vasculature] Sato K, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jun;37(6):449–57 (Eng. Abstr.) **(Jpn)**

[Left ventricular function in pulmonary arterial hypertension] Khomaziuk VA. **Lik Sprava** 1998 Dec;(8):58–61 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Hanasato N, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L225–32

Removing the causes of pulmonary hypertension [letter; comment] Krohn BG. **Ann Thorac Surg** 1998 Nov; 66(5):1862–3. Comment on: Ann Thorac Surg 1998 Feb;65(2):340–5.

Cardiac surgery and inhaled nitric oxide: indication and follow-up (2–4 years). Yahagi N, et al. **Artif Organs** 1998 Oct;22(10):886–91

Inhaled nitric oxide does not alter pulmonary or cardiac effects of fat embolism in dogs after cemented arthroplasty. Byrick RJ, et al. **Can J Anaesth** 1999 Jun;46(6):605–12

The pathophysiology and management of perioperative pulmonary hypertension with specific emphasis on the period following cardiac surgery. Riedel B. **Int Anesthesiol Clin** 1999 Spring;37(2):55–79 (141 ref.)

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. Geraci MW, et al. **J Clin Invest** 1999 Jun;103(11):1509–15

Dietary retinol inhibits inflammatory responses of rats treated with monocrotaline. Swamidas GP, et al. **J Nutr** 1999 Jul; 129(7):1285–90

[Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline] Jin X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Dec;21(12):751–2, 763 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Pericardial thickening or effusion in patients with pulmonary artery hypertension: a CT study. Baque-Juston MC, et al. **AJR Am J Roentgenol** 1999 Feb;172(2):361–4

Pulmonary cholesterol granulomas in patients with pulmonary artery hypertension: chest radiographic and CT findings. Nolan RL, et al. **AJR Am J Roentgenol** 1999 May; 172(5):1317–9

Right ventricular myocardial bridge in a patient with pulmonary hypertension--a case report. Gurewitch J, et al. **Angiology** 1999 Apr;50(4):345–7 (6 ref.)

CT measurement of main pulmonary artery diameter. Edwards PD, et al. **Br J Radiol** 1998 Oct;71(850):1018–20

Can pulmonary venous hypertension be graded by the chest radiograph? Sharma S, et al. **Clin Radiol** 1998 Dec; 53(12):899–902

Recurrent chest opacities in a patient with thromboembolic pulmonary hypertension. Wakamatsu K, et al. **Respiration** 1998;65(6):492–4

RADIONUCLIDE IMAGING

Pulmonary embolism: a follow-up study of the relation between the degree of right ventricle overload and the extent of perfusion defects. Ribeiro A, et al. **J Intern Med** 1999 Jun;245(6):601–10

Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. Nagaya N, et al. **J Nucl Med** 1998 Oct;39(10):1676–80

Images in clinical medicine. Right-to-left shunt on a lung scan. Moses CA, et al. **N Engl J Med** 1999 Mar 18; 340(11):857

SURGERY

Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Rothman A, et al. **Am J Cardiol** 1999 Sep 15;84(6):682–6

Long-term outcome after pulmonary thromboendarterectomy. Archibald CJ, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):523–8

Cardiac transplantation with single-lung pulmonary hypertension [letter; comment] Murphy DA, et al. **Ann Thorac Surg** 1999 Feb;67(2):592. Comment on: Ann Thorac Surg 1998 Mar;65(3):823–5.

Heart-lung transplantation for primary pulmonary hypertension. Whyte RI, et al. **Ann Thorac Surg** 1999 Apr; 67(4):937–41; discussion 941–2

Improved exposure of the pulmonary arteries for thromboendarterectomy. Zund G, et al. **Ann Thorac Surg** 1998 Nov;66(5):1821–3

Successful surgical treatment of thromboembolic pulmonary hypertension [letter] Slade MG, et al. **Aust N Z J Med** 1998 Aug;28(4):469–70

Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction. Soriano CM, et al. **Chest** 1999 Aug; 116(2):564–6

Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. Dartevelle P, et al. **Eur J Cardiothorac Surg** 1999 Jul;16(1):38–43

Clamshell or sternotomy for double lung or heart-lung transplantation? Macchiarini P, et al. **Eur J Cardiothorac Surg** 1999 Mar;15(3):333–9

Pulmonary thromboendarterectomy: an advance in the treatment of chronic thromboembolic pulmonary hypertension. McKane CL. **Heart Lung** 1998 Sep-Oct; 27(5):293–6 (11 ref.)

Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension. Birsan T, et al. **J Heart Lung Transplant** 1999 Apr;18(4):304–9

Single or double lung transplantation for pulmonary hypertension [letter; comment] Park SJ, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):404–5. Comment on: J Thorac Cardiovasc Surg 1998 Feb;115(2):397–402; discussion 402–3.

Outcome after pulmonary thromboendarterectomy. Archibald CJ, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):164–71 (31 ref.)

Evaluation of patients with suspected chronic thromboembolic pulmonary hypertension. Auger WR, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):179–90 (42 ref.)

Postoperative management of the patient undergoing pulmonary thromboendarterectomy. Fedullo PF, et al. **Semin Thorac Cardiovasc Surg** 1999 Apr;11(2):172–8

Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension [editorial] Dunning J, et al. **Thorax** 1999 Sep;54(9):755–6

Reversibility of pulmonary hypertension in patients evaluated for orthotopic heart transplantation: importance in the postoperative morbidity and mortality. Espinoza C, et al. **Transplant Proc** 1999 Sep;31(6):2503–4

Extracorporeal membrane oxygenation support for single-lung transplantation in patients with primary pulmonary hypertension. Ko WJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):166–8

Usefulness of nitric oxide inhalation for management of right ventricular failure after heart transplantation in patients with pretransplant pulmonary hypertension. Paniagua MJ, et al. **Transplant Proc** 1999 Sep;31(6):2505–6

Heterotopic heart transplantation for severe pulmonary hypertension. Wang SS, et al. **Transplant Proc** 1998 Nov; 30(7):3408–9

[Pulmonary thromboendarterectomy with video-angioscopy and circulatory arrest: an alternative to cardiopulmonary transplantation and post-embolism pulmonary artery hypertension] Dartevelle P, et al. **Chirurgie** 1998 Feb; 123(1):32–40 (Eng. Abstr.) **(Fre)**

[Surgical treatment for chronic pulmonary hypertension] Haverich A, et al. **Internist (Berl)** 1999 Jul;40(7):764–71 (35 ref.) **(Ger)**

[Heterotropic heart transplantation in young patients with elevated pulmonary vascular resistance] Gamba A, et al. **G Ital Cardiol** 1999 Aug;29(8):918–24 (Eng. Abstr.) **(Ita)**

THERAPY

Preoperative management of pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial septal defect. Atz AM, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1224–8

Primary pulmonary hypertension in childhood. Haworth SG. **Arch Dis Child** 1998 Nov;79(5):452–5 (33 ref.)

Initial steps toward consensus in the management of primary pulmonary hypertension [editorial; comment] Koniaris L. **Chest** 1998 Nov;114(5):1234–5. Comment on: Chest 1998 Nov;114(5):1269–75.

Long-term therapy for pulmonary hypertension in children. Dent CL, et al. **Curr Opin Pediatr** 1999 Jun;11(3):218–22 (27 ref.)

Recognition and management of pulmonary hypertension. Wanstall JC, et al. **Drugs** 1998 Dec;56(6):989–1007 (163 ref.)

Pulmonary vascular disease in pregnancy [letter] Oakley CM. **J Am Coll Cardiol** 1999 Jan;33(1):287

Pulmonary hypertension--advances in medical and surgical interventions. McLaughlin VV, et al. **J Heart Lung Transplant** 1998 Aug;17(8):739–43 (27 ref.)

Treatments for severe pulmonary hypertension. Higenbottam T, et al. **Lancet** 1999 Jan 30;353(9150):338–40 (19 ref.)

Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Findlay JY, et al. **Liver Transpl Surg** 1999 Sep;5(5):381–7

Diagnosing and treating primary pulmonary hypertension. Frazier SK. **Nurse Pract** 1999 Sep;24(9):18, 21–2, 25–6 passim; quiz 42–3 (43 ref.)

Inhalation of low-dose nitric oxide to evaluate pulmonary vascular reactivity in children with congenital heart disease. Yasuda T, et al. **Pediatr Cardiol** 1999 Jul–Aug; 20(4):278–82

Recent advances in the treatment of pediatric pulmonary artery hypertension. Barst RJ. **Pediatr Clin North Am** 1999 Apr;46(2):331–45 (41 ref.)

New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Abman SH. **Pediatr Pulmonol Suppl** 1999;18:201–4 (18 ref.)

How to manage secondary pulmonary hypertension. Ricciardi MJ, et al. **Postgrad Med** 1999 Feb;105(2):183–90; quiz 229 (7 ref.)

How to manage primary pulmonary hypertension. Giving hope to patients with a life-threatening illness. Ricciardi MJ, et al. **Postgrad Med** 1999 Mar;105(3):45–8, 51–6 (16 ref.)

Nonlinear indicial response of complex nonstationary oscillations as pulmonary hypertension responding to step hypoxia. Huang W, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1834–9

Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Borst MM, et al. **Respiration** 1999;66(3):225–32

Treatment of pulmonary hypertension secondary to connective tissue diseases. Sanchez O, et al. **Thorax** 1999 Mar;54(3):273–7 (60 ref.)

[Vasotropic therapy and artificial respiration for pulmonary hypertension] Grimminger F, et al. **Internist (Berl)** 1999 Jul;40(7):747–55 (16 ref.) **(Ger)**

[Effect of inhaled nitric oxide on the first 24 hours of assisted respiration in the critically ill child] López-Herce Cid J, et al. **An Esp Pediatr** 1999 Mar;50(3):253–8 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Recommendations for diagnosis, evaluation, and monitoring of patients with Gaucher disease [letter; comment] Elstein D, et al. **Arch Intern Med** 1999 Jun 14;159(11):1254–5. Comment on: Arch Intern Med 1998 Sep 14;158(16):1754–60.

False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Vachiéry JL, et al. **Eur Respir J** 1998 Dec;12(6):1476–8

Echocardiographic features of primary pulmonary hypertension. Bossone E, et al. **J Am Soc Echocardiogr** 1999 Aug;12(8):655–62

Echocardiographic assessment of pulmonary hypertension in Gaucher's disease [see comments] Elstein D, et al. **Lancet** 1998 May 23;351(9115):1544–6. Comment in: Lancet 1998 Jul 18;352(9123):240.

[Effect of nitric oxide on the doppler profile of the anterior cerebral artery in the newborn (letter)] Patural H, et al. **Arch Pediatr** 1999 Jan;6(1):107 **(Fre)**

[Pulmonary hypertension in patients with left ventricular dysfunction studied with contrast-enhanced Doppler echocardiography: relations with diastolic parameters and prognostic implications] Dini FL, et al. **Cardiologia** 1998 Sep;43(9):933–45 (Eng. Abstr.) **(Ita)**

[Three week stay at a height of 3700–4200 m. causes mild pulmonary hypertension in healthy men] Palasiewicz G, et al. **Pneumonol Alergol Pol** 1998;66(11–12):545–50 (Eng. Abstr.) **(Pol)**

URINE

Urinary cGMP concentrations in severe primary pulmonary hypertension. Bogdan M, et al. **Thorax** 1998 Dec; 53(12):1059–62

VETERINARY

Chronic experimental fumonisin intoxication of calves. Baker DC, et al. **J Vet Diagn Invest** 1999 May;11(3):289–92

Haemodynamic effects of ATP in dogs during hypoxia-induced pulmonary hypertension. Driessen B, et al. **J Vet Pharmacol Ther** 1999 Jun;22(3):213–9

Evidence of mitochondrial dysfunction in broilers with pulmonary hypertension syndrome (Ascites): effect of t-butyl hydroperoxide on hepatic mitochondrial function, glutathione, and related thiols. Cawthon D, et al. **Poult Sci** 1999 Jan;78(1):114–24

Influence of feed deprivation on ventilation and gas exchange in broilers: relationship to pulmonary hypertension syndrome. Fedde MR, et al. **Poult Sci** 1998 Nov; 77(11):1704–10

Electrocardiographic evaluation of broilers following unilateral occlusion of an extrapulmonary primary bronchus. Kirby YK, et al. **Poult Sci** 1999 Feb;78(2):242–54

Electrocardiographic and genetic evaluation of giant jungle fowl, broilers, and their reciprocal crosses following unilateral bronchus occlusion. Kochera Kirby Y, et al. **Poult Sci** 1999 Jan;78(1):125–34

Evaluation of minimally invasive indices for predicting ascites susceptibility in three successive hatches of broilers exposed to cool temperatures. Wideman RF Jr, et al. **Poult Sci** 1998 Oct;77(10):1565–73

Thromboxane mimics the pulmonary but not systemic vascular responses to bolus HCl injections in broiler chickens. Wideman RF Jr, et al. **Poult Sci** 1999 May; 78(5):714–21

Broiler breeder survivors of chronic unilateral pulmonary artery occlusion produce progeny resistant to pulmonary hypertension syndrome (ascites) induced by cool temperatures. Wideman RF Jr, et al. **Poult Sci** 1999 Mar; 78(3):404–11

VIROLOGY

Role of human immunodeficiency virus in primary pulmonary hypertension--case reports. Pellicelli AM, et al. **Angiology** 1998 Dec;49(12):1005–11

Primary pulmonary hypertension associated with human immunodeficiency virus infection. Golpe R, et al. **Postgrad Med J** 1998 Jul;74(873):400–4 (47 ref.)

HYPERTENSION, PULMONARY, OF NEWBORN, PERSISTENT see **PERSISTENT FETAL CIRCULATION SYNDROME**

HYPERTENSION, RENAL

Hypertension in patients with chronic renal disease. Mailloux LU, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S120–41 (229 ref.)

Klaus Thurau Festschrift. Renal Hemodynamics: Cellular and Molecular Determinants. Bavaria, September 18–21, 1997. **Kidney Int Suppl** 1998 Sep;67:S1–249

BLOOD

Characterization of subtypes of hypertension in CAPD patients by cyclic guanosine monophosphate. Lang SM, et al. **Perit Dial Int** 1999 Mar-Apr;19(2):143–7

[Levels of 1,25-dihydroxyvitamin D3 concentration in renal venous blood serum of patients with renovascular hypertension caused by unilateral renal artery stenosis] Kiersztejn M, et al. **Pol Arch Med Wewn** 1998 Apr; 99(4):281–6 (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Rapidly resorptive exudative retinal detachment in a patient with renogenic hypertension: case report. Liao HP, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):324–7

The reappearing kidney: an unusual complication of renal biopsy. Kingdon E, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1758–60

DIAGNOSIS

Renal morphology in essential hypertension: analysis of 1177 unselected cases. Bohle A, et al. **Kidney Int Suppl** 1998 Sep;67:S205–6

[Renal hypertension in children and adolescents (editorial)] Wyszyńska T, et al. **Pol Arch Med Wewn** 1998 Sep; 100(3):188–95 **(Pol)**

[The place of radionuclide methods in diagnostic imaging of renovascular hypertension] Pilecki S, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):220–3 (22 ref.) (Eng. Abstr.) **(Pol)**

[Ambulatory monitoring of arterial pressure in a group of children with reflux nephropathy of different degrees]

Jiménez-Hereza JM, et al. **An Esp Pediatr** 1998 Nov; 49(5):461-6 (34 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Current strategies for management of hypertensive renal disease. Moore MA, et al. **Arch Intern Med** 1999 Jan 11; 159(1):23-8 (74 ref.)

The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats. Anderson IK, et al. **Br J Pharmacol** 1998 Nov;125(6):1236-46

Successful combined therapy of nifedipine and diltiazem for severe hypertension in a maintenance hemodialysis patient [letter] Ikeda Y, et al. **Clin Nephrol** 1999 Feb;51(2):127-8

Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats. Casellas D, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S230-3

Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. Cervenka L, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S197-201

Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. Plum J, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2223-34

Antihypertensive activity and pharmacokinetics of KD3-671, a nonpeptide AT1-receptor antagonist, in renal hypertensive dogs. Takata Y, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):834-44

Optimizing antihypertensive therapy in patients with diabetic nephropathy. Ritz E, et al. **J Hypertens Suppl** 1998 Sep; 16(7):S17-22 (54 ref.)

Treatment of renovascular disease and of renovascular hypertension. Bernini G, et al. **J Nephrol** 1998 Nov-Dec; 11(6):311-7 (35 ref.)

Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. Chabielska E, et al. **J Physiol Pharmacol** 1999 Mar; 50(1):99-109

Angiotensin II receptor antagonists in hypertension. Burnier M, et al. **Kidney Int Suppl** 1998 Dec;68:S107-11 (33 ref.)

Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. del Castillo D, et al. **Kidney Int Suppl** 1998 Dec;68:S135-9

Comparison of losartan and amlodipine in renally impaired hypertensive patients. Fernández-Andrade C, et al. **Kidney Int Suppl** 1998 Dec;68:S120-4

Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Martinez-Castelao A, et al. **Kidney Int Suppl** 1998 Dec; 68:S130-4

Evaluation of the Losartan in Hemodialysis (ELHE) Study. Saracho R, et al. **Kidney Int Suppl** 1998 Dec;68:S125-9

Renoprotective effects of captopril in hypertension induced by nitric oxide synthase inhibition in experimental nephritis. Uhlenius N, et al. **Nephron** 1999 Feb;81(2):221-9

Efficacy of amlodipine in pediatric patients with hypertension. Tallian KB, et al. **Pediatr Nephrol** 1999 May; 13(4):304-10

Therapeutic concepts of proteinuria and intra-glomerular hypertension. Woo KT. **Singapore Med J** 1998 Jun; 39(6):271-2 (8 ref.)

[Antihypertensive therapy in diabetes mellitus] Hess B. **Ther Umsch** 1999 Jan;56(1):25-32 (42 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Hypertension and impaired renal angiotensin II response in rats after chronic neuronal nitric oxide synthase inhibition. Persson AE, et al. **Kidney Int Suppl** 1998 Sep;67:S216-7 (22 ref.)

ETIOLOGY

Ask-Upmark kidney associated with renal and extrarenal arterial aneurysms. Marwali MR, et al. **Am J Kidney Dis** 1999 Apr;33(4):e4

A comparison of the development of renal hypertension in male and female rats. Okuniewski R, et al. **Clin Sci (Colch)** 1998 Oct;95(4):445-51

Neurofibromatosis type 1 associated with systemic vasculopathy. Amorosi B, et al. **Eur J Dermatol** 1998 Jun; 8(4):271-3

Renovascular hypertension and prolonged encephalopathy associated with moyamoya disease [letter] Bayrakci B, et al. **Eur J Pediatr** 1999 Apr;158(4):342

Hypertension in end-stage renal disease. Martinez-Maldonado M. **Kidney Int Suppl** 1998 Dec; 68:S67-72 (43 ref.)

Salt: blood pressure, the kidney, and other harmful effects. MacGregor GA. **Nephrol Dial Transplant** 1998 Oct; 13(10):2471-9 (32 ref.)

Noradrenaline-producing renal-cell carcinoma: a unique cause of endocrine hypertension. Thomas MC, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1811-4

[Arterial hypertension due to compression of the renal artery, revealing ovarian cancer] Jan F, et al. **Presse Med** 1999 Apr 24;28(16):841-4 (Eng. Abstr.) **(Fre)**

[64-year-old patient with dyspnea at rest and rapidly progressing renal failure. Systemic sclerosis with interstitial lung disease and renal crisis] Hellmich B, et al. **Internist (Berl)** 1998 Oct;39(10):1062-8 **(Ger)**

[Percutaneous revascularization of renal artery stenosis. Balloon angioplasty vs. stent implantation] Blum U, et al. **Radiologe** 1999 Feb;39(2):135-43 (42 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension due to perirenal hematoma after renal percutaneous biopsy] Wanic-Kossowska M. **Pol Arch Med Wewn** 1998 Nov;100(5):454-7 (Eng. Abstr.) **(Pol)**

[Renal hypertension in children and adolescents (editorial)] Wyszyńska T, et al. **Pol Arch Med Wewn** 1998 Sep; 100(3):188-95 **(Pol)**

[Role of renin-angiotensin-aldosterone system in pathogenesis of arterial hypertension in chronic renal failure] Lifshits NL, et al. **Ter Arkh** 1999;71(6):64-7 (Eng. Abstr.) **(Rus)**

[Development of arterial hypertension in urate tubulointerstitial renal damage (editorial)] Mukhin NA, et al. **Ter Arkh** 1999;71(6):23-7 (14 ref.) **(Rus)**

GENETICS

T594M mutation in the ENaC beta subunit and low-renin hypertension in blacks. Warnock DG. **Am J Kidney Dis** 1999 Sep;34(3):579-87

Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat. St Lezin E, et al. **Hypertension** 1999 Aug;34(2):187-91

Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Wang ZQ, et al. **Hypertension** 1999 Jan;33(1):96-101

Cardiorenal destiny: the role of genes and environmental factors. Ingelfinger JR, et al. **Semin Nephrol** 1999 Mar; 19(2):201-10 (87 ref.)

[Single gene forms of hypertension. Glucocorticoid suppressible aldosteronism, Liddle syndrome et al.] Rettig R. **Fortschr Med** 1998 Aug 20;116(22-23):38 **(Ger)**

METABOLISM

Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Kaide J, et al. **Am J Hypertens** 1999 Jun;12(6):611-9

Sodium-potassium pump inhibitor in the mechanism of one-kidney, one wrap hypertension in dogs. Pamnani MB, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Feb;45(1):115-21

Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis. Terziivanov D, et al. **Int J Clin Pharmacol Ther** 1999 Aug; 37(8):404-12

Role of angiotensin II in the renal effects induced by nitric oxide and prostaglandin synthesis inhibition. Llinas MT, et al. **J Am Soc Nephrol** 1997 Apr;8(4):543-50

Angiotensin II, nitric oxide, and end-organ damage in hypertension. Bataineh A, et al. **Kidney Int Suppl** 1998 Dec; 68:S14-9 (55 ref.)

PATHOLOGY

Endogenous immunoreactive ouabain-like and digoxin-like factors in reduced renal mass hypertensive rats. Takada T, et al. **Hypertens Res** 1998 Sep;21(3):193-9

Renal morphology in essential hypertension: analysis of 1177 unselected cases. Bohle A, et al. **Kidney Int Suppl** 1998 Sep;67:S205-6

Glomerulus number and blood pressure in the Prague hypertensive rat. Hellmann H, et al. **Kidney Int Suppl** 1998 Sep;67:S211-2

PHYSIOPATHOLOGY

Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Cerasola G, et al. **Am J Nephrol** 1998;18(5):391-8

Antagonism of ANG II type 1 receptors protects the endothelium during the early stages of renal hypertension in rats. Hoshino J, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1950-7

Current strategies for management of hypertensive renal disease. Moore MA, et al. **Arch Intern Med** 1999 Jan 11; 159(1):23-8 (74 ref.)

The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats. Anderson IK, et al. **Br J Pharmacol** 1998 Nov;125(6):1236-46

Role of sympathetic nervous system in experimental hypertension and diabetes mellitus. Kaul CL. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):95-112

Effects of cicletanine on the progression of renal failure in 5/6 nephrectomized hypertensive rats. Nakamoto H, et al. **Clin Exp Pharmacol Physiol** 1999 Mar;26(3):236-41

Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. Wookey PJ, et al. **Clin Exp Pharmacol Physiol** 1998 Sep;25(9):653-60 (70 ref.)

Prevalence of hypertension in a hemodialysis population. Mittal SK, et al. **Clin Nephrol** 1999 Feb;51(2):77-82

The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Yamaguchi T, et al. **Curr Eye Res** 1999 Jun;18(6):417-22

Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hocher B, et al. **Hypertension** 1999 Mar;33(3):816-22

Effect of sinoaortic deafferentation on renal wrap hypertension. VanNess JM, et al. **Hypertension** 1999 Jan; 33(1 Pt 2):476-81

Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats. Wang CT, et al. **J Am Soc Nephrol** 1997 Apr;8(4):535-42

Renovascular parathyroid hormone-related protein in spontaneously hypertensive rats: dilator or trophic factor? Fiaschi-Taesch N, et al. **Kidney Int Suppl** 1998 Sep; 67:S207-10

The K(ATP) channel opener nicorandil: effect on renal hemodynamics in spontaneously hypertensive and Wistar Kyoto rats. Kawata T, et al. **Kidney Int Suppl** 1998 Sep; 67:S231-3

Tubuloglomerular feedback: its physiological and pathophysiological significance. Kurokawa K. **Kidney Int Suppl** 1998 Sep;67:S71-4 (21 ref.)

Hypertension in end-stage renal disease. Martinez-Maldonado M. **Kidney Int Suppl** 1998 Dec; 68:S67-72 (43 ref.)

Hypertension and impaired renal angiotensin II response in rats after chronic neuronal nitric oxide synthase inhibition. Persson AE, et al. **Kidney Int Suppl** 1998 Sep;67:S216-7 (22 ref.)

A role for endothelin in the pathogenesis of hypertension: fact or fiction? Pinto-Sietsma SJ, et al. **Kidney Int Suppl** 1998 Sep;67:S115-21 (94 ref.)

Age-related changes in blood pressure in the senescence-accelerated mouse (SAM): aged SAMP1 mice manifest hypertensive vascular disease. Han J, et al. **Lab Anim Sci** 1998 Jun;48(3):256-63

Chronic elevations in salt intake and reduced renal mass hypertension compromise mechanisms of arteriolar dilation. Frisbee JC, et al. **Microvasc Res** 1998 Nov;56(3):218-27

Decreased diurnal blood pressure variability and low dehydroepiandrosterone sulfate levels in patients with renal hypertension, and after kidney transplantation. Barna I, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:30-1

Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Ligtenberg G. **Neth J Med** 1999 Jul; 55(1):13-8 (36 ref.)

Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Haefliger JA, et al. **Regul Pept** 1999 Jun 30;82(1-3):35-43

PREVENTION & CONTROL

Preventive effects of Shichimotsu-koka-to on renal lesions in stroke-prone spontaneously hypertensive rats. Higuchi Y, et al. **Biol Pharm Bull** 1998 Sep;21(9):914-8

Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Matsumoto K, et al. **Hypertension** 1999 Aug;34(2):279-84

Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats. Wang CT, et al. **J Am Soc Nephrol** 1997 Apr;8(4):535-42

RADIOGRAPHY

Gadolinium-based contrast and carbon dioxide angiography to evaluate renal transplants for vascular causes of renal insufficiency and accelerated hypertension. Spinosa DJ, et al. **J Vasc Interv Radiol** 1998 Nov-Dec;9(6):909-16

RADIONUCLIDE IMAGING

Interventions in renal scintirenography. Fine EJ. **Semin Nucl Med** 1999 Apr;29(2):128-45 (78 ref.)

THERAPY

Optimizing the benefits of renal artery stenting [editorial; comment] Bittl JA. **Catheter Cardiovasc Interv** 1999 Jun; 47(2):173-4. Comment on: Catheter Cardiovasc Interv 1999 Jun;47(2):167-72.

Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis [see comments] Rocha-Singh KJ, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):167-72. Comment in: Catheter Cardiovasc Interv 1999 Jun;47(2):173-4.

Hypotensive therapy in diabetic renal disease. Czekalski S. **Przegl Lek** 1998;55 Suppl 1:62-4 (13 ref.) **(Eng, Pol)**

[Long-term management of dialysis patients. I. Hypertension and anemia] Schäffer J, et al. **Internist (Berl)** 1999 Jan; 40(1):55-63 (49 ref.) **(Ger)**

HYPERTENSION, RENOVASCULAR

Experimental model of renovascular hypertension. Cao X, et al. **Chin Med J (Engl)** 1998 May;111(5):450-2

BLOOD

[Effect of captopril on platelet cytosolic [Ca2+]i and plasma TXA2/PGI2 in renovascular hypertensive rats] Wei XR, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):89-91

(Eng. Abstr.) **(Chi)**

COMPLICATIONS

Role of nitric oxide in the evolution of renal ischemia in two-kidney, one-clip renovascular hypertension. Nakamoto H, et al. **Hypertens Res** 1998 Dec;21(4):267-77

Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Ehmke H, et al. **Hypertension** 1999 Apr;33(4):954-60

Effect of renovascular hypertension on experimental glomerulonephritis in rats. Wenzel UO, et al. **J Lab Clin Med** 1999 Sep;134(3):292-303

Mesangial hyperplasia in a patient with renovascular hypertension and proteinuria [letter; comment] Schiller A, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2704-5. Comment on: Nephrol Dial Transplant 1998 Jun;13(6):1562-4.

Systemic hypertension accelerates chronic rejection of renal allografts in the rat. Kusaka M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):869

DIAGNOSIS

Gross hematuria of uncommon origin: the nutcracker syndrome. Russo D, et al. **Am J Kidney Dis** 1998 Sep; 32(3):E3

Screening for renal artery stenosis: hypertension and more... Tuttle KR. **Am J Kidney Dis** 1998 Nov;32(5):842-5; discussion 845-7

Captopril test: time over? Lenz T, et al. **J Hum Hypertens** 1999 Jul;13(7):431-5

Screening for renovascular hypertension in a population with relatively low prevalence. Helin KH, et al. **J Hypertens** 1998 Oct;16(10):1523-9

-Radiologic case of the month. Arterial hypertension and ureteral notching- Mourani C, et al. **Arch Pediatr** 1998 Mar;5(3):319-20 **(Fre)**

[Arterial hypertension and rapidly progressing renal failure] Gabutti L, et al. **Ther Umsch** 1999 Jan;56(1):55-60 (Eng. Abstr.) **(Ger)**

[Significance of clinical anamnesis in the preliminary diagnosis of renovascular hypertension] Smoszna J, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):266-8 (Eng. Abstr.) **(Pol)**

[Assessment of active renin instead of plasma renin activity in the renin captopril test] Smoszna J, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):269-70 (Eng. Abstr.) **(Pol)**

[Screening for renovascular hypertension in own material (1986-1998)] Wańkowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):261-5 (Eng. Abstr.) **(Pol)**

[Magnetic resonance tomography and angiography in the assessment of the status of the kidneys and renal arteries in patients with renovascular hypertension] Sergienko IV, et al. **Vestn Rentgenol Radiol** 1998 Jul-Aug;(4):50-9 (101 ref.) **(Rus)**

DRUG THERAPY

Benidipine stimulates nitric oxide synthase and improves coronary circulation in hypertensive rats. Kobayashi N, et al. **Am J Hypertens** 1999 May;12(5):483-91

Effect of chronic therapy with proteolytic enzymes on hypertension-induced renal injury in the rat model of Goldblatt hypertension. Sebeková K, et al. **Am J Nephrol** 1998;18(6):570-6

The antihypertensive effect of garlic (Allium sativum) in the rat two-kidney--one-clip Goldblatt model. Al-Qattan KK, et al. **J Ethnopharmacol** 1999 Aug;66(2):217-22

Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats. Demeilliers B, et al. **J Hypertens** 1998 Jul;16(7):1023-9

Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats. Yoshida K, et al. **J Hypertens** 1998 May;16(5):645-55

Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. Kobayashi S, et al. **J Lab Clin Med** 1999 Feb;133(2):134-43

Current trends in the treatment of hypertension in renal disease. Brown EA. **Przegl Lek** 1998;55 Suppl 1:61

ECONOMICS

Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Xue F, et al. **Radiology** 1999 Aug; 212(2):378-84

ENZYMOLOGY

Regulation of Na,K-ATPase activity in renal basolateral membrane of 1-clip-1-kidney hypertensive rat. Seok JH, et al. **Biochem Mol Biol Int** 1998 Nov;46(4):667-72

Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. Jin D, et al. **J Hypertens** 1998 May;16(5):657-64

ETIOLOGY

Nephropathy and hypertension as manifestations in a 13-y-old girl with primary antiphospholipid syndrome. Ohtomo Y, et al. **Acta Paediatr** 1998 Aug;87(8):903-7 (44 ref.)

Treatment of renal artery stenosis by invasive procedures [letter; comment] Sekkarie M. **Am J Kidney Dis** 1999 Mar; 33(3):613-4. Comment on: Am J Kidney Dis 1998 Oct;32(4):611-22.

The role of hypertension, obesity, and diabetes in causing renal vascular disease. Crook ED. **Am J Med Sci** 1999 Mar;317(3):183-8 (36 ref.)

Retroaortic left renal vein with renal vein hypertension causing hematuria. Gibo M, et al. **Clin Imaging** 1998 Nov-Dec;22(6):422-4

Hypertensive vascular crisis secondary to chronic total renal artery occlusion. Scarpelli PT, et al. **J Nephrol** 1998 Nov-Dec;11(6):325-9

Value of captopril renal scintigraphy in hypertensive patients with renal failure. Fernandez P, et al. **J Nucl Med** 1999 Mar;40(3):412-7

Solitary renal myofibromatosis: an unusual cause of infantile hypertension. Kasaragod AB, et al. **Pediatrics** 1999 May; 103(5):e66

[Renovascular arterial hypertension in the framework of von Recklinghausen's neurofibromatosis. Apropos of a case] Sarkis A, et al. **J Med Liban** 1998 Mar-Apr;46(2):97-9 (Eng. Abstr.) **(Fre)**

[Fibromuscular dysplasia of the renal arteries] Fiquet-Kempf B, et al. **Nephrologie** 1999;20(1):13-8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Acute arterial hypertension caused by dissecting aneurysm of the renal artery] Godon P, et al. **Presse Med** 1998 Apr 4;27(13):612-5 (Eng. Abstr.) **(Fre)**

METABOLISM

Redistribution of Na+/H+ exchanger isoform NHE3 in proximal tubules induced by acute and chronic hypertension. Yip KP, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):F565-75

Increased Na,K,Cl cotransporter and Na, K-ATPase activity of vascular tissue in two-kidney Goldblatt hypertension. Goecke A, et al. **Biol Res** 1998;31(3):263-71

Effects of menidipine on dihydropyridines binding sites in cardiac and cerebral membranes from old rats with left ventricular hypertrophy. Xi T, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May;17(3):235-8

Effects of renovascular hypertension on myocardial protein patterns: analysis by computer-assisted two-dimensional gel electrophoresis. Pleissner KP, et al. **Electrophoresis** 1998 Aug;19(11):2043-50

Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. Song L, et al. **Hypertension** 1999 Feb; 33(2):746-52

Renal angiotensin II receptor regulation and renin-angiotensin system inhibition in one-kidney, one clip hypertensive rats. Amiri F, et al. **J Hypertens** 1999 Feb; 17(2):279-86

The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hypertension. Sánchez-Mendoza A, et al. **J Hypertens** 1998 May; 16(5):697-703

Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats. Yoshida K, et al. **J Hypertens** 1998 May;16(5):645-55

Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Heitzer T, et al. **Kidney Int** 1999 Jan;55(1):252-60

Atrial natriuretic factor in two kidney--two clip renovascular hypertension in the rat. Puyo AM, et al. **Medicina (B Aires)** 1998;58(2):165-70

[Changes in the expression of alpha- and beta-myosin heavy chain gene during the development of renal hypertension in rats] Zheng H, et al. **Sheng Li Hsueh Pao** 1997 Jun; 49(3):344-8 (Eng. Abstr.) **(Chi)**

PATHOLOGY

Histologic characteristics of coronary artery in relation to the renovasculopathies of hypertension. Tracy RE. **Ann Diagn Pathol** 1998 Jun;2(3):159-66

Renal vascular interaction of angiotensin II and prostaglandins in renovascular hypertension. Cruz BV, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):21-7

[Myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of formation of angiotensin II and its interaction with specific receptors] Frolov VA, et al. **Biull Eksp Biol Med** 1999 May;127(5):506-9 **(Rus)**

[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II] Frolov VA, et al. **Dokl Akad Nauk** 1999 May;366(3):413-5 **(Rus)**

PHYSIOPATHOLOGY

Renal artery clipping attenuates the progression of adriamycin nephropathy. Balbi AL, et al. **Am J Hypertens** 1998 Sep;11(9):1124-8

Effects on regional renal blood flow when unclipping a two-kidney, one-clip hypertensive Wistar rat during renal nerve stimulation. Rudenstam J, et al. **Am J Hypertens** 1999 Jun;12(6):620-7

Renocaval pressure gradient indicating left renal venous hypertension [letter] Takebayashi S. **Am J Kidney Dis** 1999 Jan;33(1):224

PDGF-A expression correlates with blood pressure and remodeling in 1K1C hypertensive rat arteries. Dobrian A, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2159-67

Reduced GABA inhibition of sympathetic function in renal-wrapped hypertensive rats. Martin DS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1523-9

Increased sympathetic nerve activity in renovascular hypertension. Johansson M, et al. **Circulation** 1999 May 18;99(19):2537-42

Aspirin renography in diagnosis of unilateral renovascular hypertension. Imanishi M, et al. **Hypertens Res** 1998 Sep; 21(3):209-13

Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Cervenka L, et al. **Hypertension** 1999 Jan;33(1):102-7

Enhanced gamma-aminobutyric acid-B receptor agonist responses and mRNA within the nucleus of the solitary tract in hypertension. Durgam VR, et al. **Hypertension** 1999 Jan;33(1 Pt 2):530-6

Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role? Rhaleb NE, et al. **Hypertension** 1999 Jan;33(1 Pt 2):329-34

Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Siragy HM, et al. **Hypertension** 1999 May;33(5):1237-42

Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Wang JL, et al. **Hypertension** 1999 Jul; 34(1):96-101

Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. Navar LG, et al. **J Am Soc Nephrol** 1999 Apr;10 Suppl 12:S266-72 (65 ref.)

Contrasting renal effects of chronic administrations of enalapril and losartan on one-kidney, one clip hypertensive rats. Demeilliers B, et al. **J Hypertens** 1998 Jul;16(7):1023-9

The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hypertension. Sánchez-Mendoza A, et al. **J Hypertens** 1998 May; 16(5):697-703

Ambulatory blood pressure monitoring in nephrology: focus on BP variability. Covic A, et al. **J Nephrol** 1999 Jul-Aug; 12(4):220-9 (89 ref.)

Increased neuropeptide Y pressor activity in Goldblatt hypertensive rats: in vivo studies with BIBP 3226. Mezzano V, et al. **Peptides** 1998;19(7):1227-32

[Effects of Peucedanum praeruptorum extractum on blood pressure, left ventricular hypertrophy and hemodynamic changes in left ventricular hypertrophied hypertensive rats] Ji Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):676-8 (Eng. Abstr.) **(Chi)**

[Effects of enalapril and taurine on left ventricular hypertrophy and arrhythmia in renovascular hypertensive rat] Tao L, et al. **Yao Hsueh Hsueh Pao** 1996;31(12):891-6 (Eng. Abstr.) **(Chi)**

[Vascular mechanisms of renal fibrosis. Vasculonephropathies and arterial hypertension] Meyrier A. **Bull Acad Natl Med** 1999;183(1):33-45; discussion 45-6 (71 ref.) (Eng. Abstr.) **(Fre)**

[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II] Frolov VA, et al. **Dokl Akad Nauk** 1999 May;366(3):413-5 **(Rus)**

RADIOGRAPHY

Renovascular hypertension. Clinical and diagnostic clues. Morganti A, et al. **Ann Urol (Paris)** 1999;33(3):137-43

RADIONUCLIDE IMAGING

Prediction of response to revascularization in patients with renal artery stenosis by Tc-99m-ethylenedicysteine captopril scintigraphy. Uğur O, et al. **Ann Nucl Med** 1999 Apr;13(2):77-81

The possibility of captopril and aspirin test for the diagnosis of patients with renovascular hypertension [letter] Kostadinova I, et al. **Clin Nephrol** 1999 May;51(5):325

A case of renal artery stenosis after transplantation: can losartan be more accurate than captopril renography? Fuster D, et al. **Clin Nucl Med** 1998 Nov;23(11):731-4

False-positive result of a captopril-enhanced radionuclide renogram in a child secondary to dehydration. Levey CS, et al. **Clin Nucl Med** 1999 Jan;24(1):6-8

Negative captopril renography on patients with renin mediated hypertension due to page kidney and reninoma. Yung BC, et al. **Eur J Radiol** 1999 Jul;31(1):63-8

ACE inhibition scintigraphy in the management of hypertension in children. Chandar JJ, et al. **Pediatr Nephrol** 1999 Aug;13(6):493-500

Radionuclide renography: a personal approach. Taylor A. **Semin Nucl Med** 1999 Apr;29(2):102-27 (104 ref.)

SURGERY

Iliorenal bypass for the treatment of type-3 Takayasu's disease. A case report with 10-year follow-up. Mingoli A, et al. **J Cardiovasc Surg (Torino)** 1999 Feb;40(1):49-53

HYPERTENSION, RENOVASCULAR

Vascular reconstruction in urology. Sorcini A, et al. **Urol Clin North Am** 1999 Feb;26(1):219–34, x–xi (31 ref.)

THERAPY

Autotransplantation and stent implantation for bilateral renal artery fibromuscular dysplasia. Kyoraku Y, et al. **Hypertens Res** 1999 Jul;22(2):141–3

Percutaneous transluminal renal angioplasty in aortoarteritis. Deyu Z, et al. **Int J Cardiol** 1998 Oct 1;66 Suppl 1:S205–11

ACE inhibition scintigraphy in the management of hypertension in children. Chandar JJ, et al. **Pediatr Nephrol** 1999 Aug;13(6):493–500

Outcome and cost comparison of percutaneous transluminal renal angioplasty, renal arterial stent placement, and renal arterial bypass grafting. Xue F, et al. **Radiology** 1999 Aug; 212(2):378–84

Percutaneous transluminal angioplasty in the treatment of renovascular hypertension: sequential prospective study. Miranda Júnior F, et al. **Rev Paul Med** 1998 Jan–Feb; 116(1):1613–7

ULTRASONOGRAPHY

Diagnosis of renovascular disease by extra- and intrarenal Doppler parameters. Malatino LS, et al. **Angiology** 1998 Sep;49(9):707–21

Diagnosis of renal artery stenosis and renovascular hypertension. Karasch T, et al. **Eur J Ultrasound** 1998 Jul; 7 Suppl 3:S27–39 (60 ref.)

Magnetic resonance angiography versus duplex sonography for diagnosing renovascular disease. Leung DA, et al. **Hypertension** 1999 Feb;33(2):726–31

HYPERTEXT see **HYPERMEDIA**

HYPERTHERMIA see **FEVER**

HYPERTHERMIA, INDUCED

Successful pregnancies following laser-induced interstitial thermotherapy (LITT) for treatment of large uterine leiomyomas by a minimally invasive method. Chapman R. **Acta Obstet Gynecol Scand** 1998 Nov;77(10):1024–5

Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma. Rapizzi E, et al. **Am J Ophthalmol** 1999 Apr;127(4):481–2

Cerebral autoregulation during whole-body hypothermia and hyperthermia stimulus. Doering TJ, et al. **Am J Phys Med Rehabil** 1999 Jan–Feb;78(1):33–8

Hyperthermic isolated regional perfusion for the treatment of osteosarcoma in the lower extremity. Nakano H, et al. **Am J Surg** 1999 Jul;178(1):27–32

Mild therapeutic hypothermia for postischemic vasoconstriction in the perfused rat liver. Zar HA, et al. **Anesthesiology** 1999 Apr;90(4):1103–11

Computer simulation of heat and mass transfer in tissue during high-intensity long-range laser irradiation. Director LB, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:56–65

Optimization of temperature distributions for regional hyperthermia based on a nonlinear heat transfer model. Erdmann B, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:36–46

Monitoring temperature-induced changes in tissue during hyperthermia by impedance methods. Gersing E. **Ann N Y Acad Sci** 1999 Apr 20;873:13–20

Blood perfusion measurements in the canine prostate during transurethral hyperthermia. Xu LX, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:21–9

Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells. Pantazis P, et al. **Anticancer Drugs** 1999 Mar;10(3):317–22

Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I–II study. Gilly FN, et al. **Anticancer Res** 1999 May–Jun;19(3B):2317–21

Surgical resection combined with intrathoracic hyperthermic perfusion for thymic carcinoma with an intrathoracic disseminated lesion: a case report. Iyoda A, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):699–702

Does AK-2123 (Senazole) have sensitizing effects on radiation, cisplatin and hyperthermia under aerobic conditions in vitro? Mitsuhashi N, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3463–7

Evidence that irradiation of far-infrared rays inhibits mammary tumour growth in SHN mice. Nagasawa H, et al. **Anticancer Res** 1999 May–Jun;19(3A):1797–800

Schedule-dependent efficiency of thermochemotherapy in vitro with etoposide and heating at 43 degrees C. Pantazis P, et al. **Anticancer Res** 1999 Mar–Apr;19(2A):995–8

Antiviral effect of hyperthermic treatment in rhinovirus infection. Conti C, et al. **Antimicrob Agents Chemother** 1999 Apr;43(4):822–9

Circumscribed choroidal hemangioma managed by transpupillary thermotherapy. Othmane IS, et al. **Arch Ophthalmol** 1999 Jan;117(1):136–7

Thermotherapy for retinoblastoma. Shields CL, et al. **Arch Ophthalmol** 1999 Jul;117(7):885–93

Transpupillary thermotherapy in 50 patients with choroidal melanoma [letter; comment] Valverde-Almohalla S. **Arch Ophthalmol** 1998 Dec;116(12):1697. Comment on: Arch Ophthalmol 1998 Feb;116(2):157–62.

Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Tsiftsis D, et al. **Arch Surg** 1999 May;134(5):545–9; discussion 550

Thermal mud-pack as an anti-inflammatory treatment [letter] Galzigna L, et al. **Biomed Pharmacother** 1998;52(9):408–9

A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. de Wit R, et al. **Br J Cancer** 1999 Jul;80(9):1387–91

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation. van der Zee J, et al. **Br J Cancer** 1999 Feb;79(3–4):483–90

Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Horsman MR, et al. **Br J Cancer Suppl** 1996 Jul;27:S168–71

Tumour pO2 can be increased markedly by mild hyperthermia. Iwata K, et al. **Br J Cancer Suppl** 1996 Jul; 27:S217–21

The effects of aspirin and hypothermia on platelet function in vivo. Michelson AD, et al. **Br J Haematol** 1999 Jan; 104(1):64–8

Dynamic computed tomography predicts tumor temperature and response to thermoradiotherapy in superficial and subsurface tumors. Nagata K, et al. **Cancer** 1999 Jul 1; 86(1):177–85

A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia. Robins HI, et al. **Cancer Chemother Pharmacol** 1999;43(5):409–14

Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma. Takeuchi H, et al. **Cancer Chemother Pharmacol** 1998; 42(6):491–6

Synergism between mild hyperthermia and interferon-beta gene expression. Bouhon IA, et al. **Cancer Lett** 1999 May 24;139(2):153–8

Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts. Kinuya S, et al. **Cancer Lett** 1999 Jun 1;140(1–2):209–18

Heat stress-induced resistance to myocardial infarction in the isolated heart from transgenic [(mREN-2)27] hypertensive rats. Joyeux M, et al. **Cardiovasc Res** 1998 Oct;40(1):124–30

Meeting report on the International Congress on Hyperthermia in Clinical Oncology, Venice 1998. Multhoff G, et al. **Cell Stress Chaperones** 1999 Mar;4(1):54–9

Nuclear matrix as a target for hyperthermic killing of cancer cells. Roti Roti JL, et al. **Cell Stress Chaperones** 1998 Dec; 3(4):245–55 (53 ref.)

Whole-body hyperthermia provides biphasic cardioprotection against ischemia/reperfusion injury in the rat. Yamashita N, et al. **Circulation** 1998 Oct 6; 98(14):1414–21

Thermoradiotherapy in the management of superficial malignant tumors. Engin K, et al. **Clin Cancer Res** 1995 Feb;1(2):139–45 (73 ref.)

The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. Hauck ML, et al. **Clin Cancer Res** 1998 Sep;4(9):2071–7

Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Hauck ML, et al. **Clin Cancer Res** 1997 Jan;3(1):63–70

Decrease of respiratory burst in neutrophils of patients with ankylosing spondylitis by combined radon-hyperthermia treatment. Reinisch N, et al. **Clin Exp Rheumatol** 1999 May–Jun;17(3):335–8

Ukrain and hyperthermia treatment in a patient with Ewing's sarcoma (case report). Aschhoff B. **Drugs Exp Clin Res** 1998;24(5–6):241–2

Intermittent warm blood cardioplegia does not provide adequate myocardial resuscitation after global ischaemia. Ericsson AB, et al. **Eur J Cardiothorac Surg** 1999 Aug; 16(2):233–9

Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Lindnér P, et al. **Eur J Surg Oncol** 1999 Apr; 25(2):179–85

Measurement of serosal temperatures and depth of thermal injury generated by thermal balloon endometrial ablation in ex vivo and in vivo models. Shah AA, et al. **Fertil Steril** 1998 Oct;70(4):692–7

Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Kainuma O, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):1071–7

Reduced-order modeling for hyperthermia: an extended balanced-realization-based approach. Mattingly M, et al. **IEEE Trans Biomed Eng** 1998 Sep;45(9):1154–62

Quantification of the 3-D electromagnetic power absorption rate in tissue during transurethral prostatic microwave thermotherapy using heat transfer model. Zhu L, et al. **IEEE Trans Biomed Eng** 1998 Sep;45(9):1163–72

Methods for providing probe position and temperature information on MR images during interventional procedures. Patel KC, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):794–802

Characterization of mild whole-body hyperthermia protocols using human breast, ovarian, and colon tumors grown in severe combined immunodeficient mice. Repasky EA, et al. **Infect Dis Obstet Gynecol** 1999;7(1–2):91–7

Synergistic interaction of ultrasonic shock waves and hyperthermia in the Dunning prostate tumor R3327-AT1. Huber P, et al. **Int J Cancer** 1999 Jul 2;82(1):84–91

Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression. Stein U, et al. **Int J Cancer** 1999 Jan 5;80(1):5–12

Hyperthermia, cyclosporine A and melphalan cytotoxicity and transport in multidrug resistant cells. Averill DA, et al. **Int J Hyperthermia** 1998 Nov–Dec;14(6):583–8

Where there's smoke, is there fire? [editorial; comment] Brizel DM. **Int J Hyperthermia** 1998 Nov–Dec;14(6):589–91. Comment on: Int J Hyperthermia 1998 Nov–Dec;14(6):593–4.

Effectiveness of RF capacitive hyperthermia combined with radiotherapy for stages III and IV oro–hypopharyngeal cancers: a nonrandomized comparison between thermoradiotherapy and radiotherapy [letter] [see comments] Hiraki Y, et al. **Int J Hyperthermia** 1998 Nov–Dec;14(6):593–4. Comment in: Int J Hyperthermia 1998 Nov–Dec;14(6):589–91.

Effectiveness of RF capacitive hyperthermia combined with radiotherapy for stages III and IV oro–hypopharyngeal cancers: a non-randomized comparison between thermoradiotherapy and radiotherapy. Hiraki Y, et al. **Int J Hyperthermia** 1998 Sep–Oct;14(5):445–57

Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Kanamori S, et al. **Int J Hyperthermia** 1999 Jul–Aug;15(4):267–78

Effect of simultaneous pulsed hyperthermia and pulsed radiation treatment on survival of SiHa cells. Kim CS, et al. **Int J Hyperthermia** 1998 Nov–Dec;14(6):573–81

Relationship between the expression of HLA-DR antigen and the effectiveness of preoperative hyperthermo-chemo-radiotherapy in oesophageal cancer. Kuwano H, et al. **Int J Hyperthermia** 1998 Sep–Oct; 14(5):435–44

Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Leal BZ, et al. **Int J Hyperthermia** 1999 May–Jun;15(3):225–36

Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Masunaga S, et al. **Int J Hyperthermia** 1999 Jan–Feb;15(1):7–16

Potentialities of passive thermoacoustic tomography in hyperthermia. Passechnik VI, et al. **Int J Hyperthermia** 1999 Mar–Apr;15(2):123–44

Hyperthermic sensitization by hematoporphyrin on glioma cells. Saito A, et al. **Int J Hyperthermia** 1998 Sep–Oct; 14(5):503–11

Reduction of tumour blood flow with KB-R8498 potentiates the response of tumours to hyperthermia. Shakil A, et al. **Int J Hyperthermia** 1999 Jan–Feb;15(1):1–6

For the clinical application of thermochemotherapy given at mild temperatures. Urano M, et al. **Int J Hyperthermia** 1999 Mar–Apr;15(2):79–107 (101 ref.)

Hyperlactacidaemia in isolated hyperthermic perfusion of tumour bearing rat limbs: a study of feasibility using a novel infusion solution. Walgenbach S, et al. **Int J Hyperthermia** 1999 Mar–Apr;15(2):109–22

The response of human tumour blood flow to a fractionated course of thermoradiotherapy. Waterman FM, et al. **Int J Hyperthermia** 1998 Sep–Oct;14(5):421–34

Thermal radiosensitization of human tumour cell lines with different sensitivities to 41.1 degrees C. Xu M, et al. **Int J Hyperthermia** 1999 Jul–Aug;15(4):279–90

Cepharanthin enhances thermosensitivity without a resultant reduction in the thermotolerance of a murine mammary carcinoma. Yamamoto M, et al. **Int J Oncol** 1999 Jul; 15(1):95–9

Interaction between low dose-rate irradiation, mild hyperthermia and low-dose caffeine in a human lung cancer cell line. Sakurai H, et al. **Int J Radiat Biol** 1999 Jun;75(6):739–45

The optimal combination of hyperthermia and carbogen breathing to increase tumor oxygenation and radiation response. Griffin RJ, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):865–9

Changes in the noninvasive, in vivo electrical impedance of three xenografts during the necrotic cell-response sequence. McRae DA, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):849–57

Comparison of radiosensitization by 41 degrees C hyperthermia during low dose rate irradiation and during pulsed simulated low dose rate irradiation in human glioma cells. Raaphorst GP, et al. **Int J Radiat Oncol Biol Phys** 1999 Apr 1;44(1):185–8

Changes in oxygenation status and blood flow in a rat tumor model by mild temperature hyperthermia. Shakil A, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):859–65

Immediate versus delayed treatment of perimenopausal bleeding due to benign causes by balloon thermal ablation. Lissak A, et al. **J Am Assoc Gynecol Laparosc** 1999 May; 6(2):145–50

Time-temperature equivalence of heat-induced changes in cells and proteins. Wright NT, et al. **J Biomech Eng** 1998 Feb;120(1):22–6 (29 ref.)

Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. Cho HK, et al. **J Clin Pharmacol** 1999 Apr;39(4):394–401

Effect of fever-like whole-body hyperthermia on lymphocyte spectrin distribution, protein kinase C activity, and uropod formation. Wang XY, et al. **J Immunol** 1999 Mar 15;162(6):3378–87

Heat shock protein antibodies in sarcoma patients undergoing

41.8 degrees C whole body hyperthermia. Katschinski DM, et al. **J Immunother** 1999 Jan;22(1):67–70

High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. Oldhafer KJ, et al. **J Invest Surg** 1998 Nov–Dec;11(6):393–400

Posttranslational arginylation of soluble rat brain proteins after whole body hyperthermia. Bongiovanni G, et al. **J Neurosci Res** 1999 Apr 1;56(1):85–92

Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. Lev-Chelouche D, et al. **J Surg Oncol** 1999 Mar;70(3):185–9

Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. Saeki H, et al. **J Surg Oncol** 1998 Dec; 69(4):224–9

Strategy for prevention of myonephropathic metabolic syndrome (MNMS): comparison of cooling and perfusion. Oue H, et al. **Kobe J Med Sci** 1999 Feb;45(1):13–25

Combined intratumor cisplatinum injection and Nd:YAG laser therapy. Graeber IP, et al. **Laryngoscope** 1999 Mar; 109(3):447–54

Thermal preconditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Ito H, et al. **Life Sci** 1999;64(9):755–61

Quantitative MR temperature monitoring of high-intensity focused ultrasound therapy. Bohris C, et al. **Magn Reson Imaging** 1999 May;17(4):603–10

Effects of hyperthermia on bioenergetic status and phosphorus T1S in human melanoma xenografts monitored by 31P-MRS. Olsen DR, et al. **Magn Reson Imaging** 1999 Sep;17(7):1049–56

Computational techniques for fast hyperthermia temperature optimization. Das SK, et al. **Med Phys** 1999 Feb; 26(2):319–28

Visualization and registration of three-dimensional E-field distributions in annual-phased-array applicators. Wust P, et al. **Med Phys** 1999 Apr;26(4):653–9

Hyperthermia prevents functional, histological and biochemical abnormalities induced during ileitis. Goldhill JM, et al. **Neurogastroenterol Motil** 1999 Feb·11(1):69–76

Enhancement of antitumor effect of hyperthermia with glucose administration in murine mammary carcinoma. Akagi K, et al. **Oncol Rep** 1999 May–Jun;6(3):593–6

Hyperthermia-induced apoptosis occurs both in a p53 gene-dependent and -independent manner in three human gastric carcinoma cell lines. Goto A, et al. **Oncol Rep** 1999 Mar–Apr;6(2):335–9

Thermal behavior of human melanoma cell line in vitro and enhancement of hyperthermic response by bupivacaine. Bruno T, et al. **Oncol Res** 1998;10(3):143–50

Lens transmission by fluorophotometry after brachytherapy and thermotherapy of choroidal melanoma. Weenink AC, et al. **Ophthalmic Res** 1998;30(6):402–6

Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Reichel E, et al. **Ophthalmology** 1999 Oct; 106(10):1908–14

Heat-sensitive liposomes containing cisplatin and localized hyperthermia in treatment of murine tumor. Nishita T. **Osaka City Med J** 1998 Jun;44(1):73–83

Hyperthermia, inducing pancreatic heat-shock proteins, fails to prevent cerulein-induced stress kinase activation. Metzler W, et al. **Pancreas** 1999 Aug;19(2):150–7

Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy. Mongero LB, et al. **Perfusion** 1999 Mar;14(2):141–5

Experimental evaluation of two simple thermal models using transient temperature analysis. Kolios MC, et al. **Phys Med Biol** 1998 Nov;43(11):3325–40

An investigation of the flow dependence of temperature gradients near large vessels during steady state and transient tissue heating. Kolios MC, et al. **Phys Med Biol** 1999 Jun; 44(6):1479–97

Modelling the thermal impact of a discrete vessel tree. Kotte AN, et al. **Phys Med Biol** 1999 Jan;44(1):57–74

Thermal conductivity of uterine tissue in vitro. Olsrud J, et al. **Phys Med Biol** 1998 Aug;43(8):2397–406

A theoretical comparison of energy sources--microwave, ultrasound and laser--for interstitial thermal therapy. Skinner MG, et al. **Phys Med Biol** 1998 Dec;43(12):3535–47

Can histopathology predict treatment outcome following high-energy transurethral microwave thermotherapy of the prostate? Results of a biopsy study. d'Ancona FC, et al. **Prostate** 1999 Jun 15;40(1):28–36

Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia. Masunaga S, et al. **Radiat Med** 1998 Nov–Dec;16(6):441–8

Evaluation of cross-resistance between responses to cisplatin, hyperthermia, and radiation in human glioma cells and eight clones selected for cisplatin resistance. Raaphorst GP, et al. **Radiat Oncol Investig** 1999;7(3):153–7

Thermoradiotherapy with hydralazine: the effect of preirradiation of the tumor bed on blood flow and growth delay of Ehrlich carcinoma. Kozin SV, et al. **Radiat Res** 1999 Jan;151(1):79–84

Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat-shock response. Rau B, et al. **Radiat Res** 1999 Apr;151(4):479–88

Role of DNA-PK subunits in radiosensitization by hyperthermia. Woudstra EC, et al. **Radiat Res** 1999 Aug; 152(2):214–8

Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neck with N2 or N3 metastatic cervical lymph nodes. Serin M, et al. **Radiother Oncol** 1999 Jan;50(1):103–6

Heat shock during rat embryo development in vitro results in decreased mitosis and abundant cell death. Breen JG, et al. **Reprod Toxicol** 1999 Jan–Feb;13(1):31–9

Does transurethral microwave thermotherapy (TUMT) affect emission of semen? Hallin A, et al. **Scand J Urol Nephrol** 1998 May;32(3):211–4

Integrality of benign prostatic hyperplasia tissues after transurethral thermotherapy evidenced by transmittance fourier transform infrared spectroscopy combined with thermal analyzer. Lin SY, et al. **Scand J Urol Nephrol** 1998 Jul;32(4):256–60

Combined treatment of inoperable carcinomas of the uterine cervix with radiotherapy and regional hyperthermia. Results of a phase II trial. Dinges S, et al. **Strahlenther Onkol** 1998 Oct;174(10):517–21

Radiation and/or hyperthermia sensitivity of human melanoma cells grown for several days in media with reduced pH. Zölzer F, et al. **Strahlenther Onkol** 1999 Jul; 175(7):325–32

A multi-gate time-of-flight technique for estimation of temperature distribution in heated tissue: theory and computer simulation. Sun Z, et al. **Ultrasonics** 1999 Feb; 37(2):107–22

Ultrasound technology for hyperthermia. Diederich CJ, et al. **Ultrasound Med Biol** 1999 Jul;25(6):871–87 (138 ref.)

Ultrasound imaging of thermal therapy in in vitro liver. Gertner MR, et al. **Ultrasound Med Biol** 1998 Sep; 24(7):1023–32

[Microwave heating and neoadjuvant chemotherapy for malignant bone tumor] Lu S, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):196–9 (Eng. Abstr.) **(Chi)**

[New philosophy in the treatment of peritoneal carcinomatosis of gastrointestinal origin] Jacquet N. **Bull Mem Acad R Med Belg** 1998;153(10–11):414–25; discussion 425–6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis] François Y, et al. **J Chir (Paris)** 1997 Nov;134(5–6):237–42 (Eng. Abstr.) **(Fre)**

[Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder] Mauroy B, et al. **Prog Urol** 1999 Feb;9(1):69–80 (Eng. Abstr.) **(Fre)**

[Calculation of asymmetric temperature fields in hyperthermia treatment with isolated extremity perfusion] Gantenberg J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:292–3 **(Ger)**

[Local resolution in temperature measurement using nuclear magnetic resonance tomography] Hampke M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:476–7 **(Ger)**

[Hyperthermia-induced priming effect in neutrophil granulocytes] Löer D, et al. **Forsch Komplementarmed** 1999 Apr;6(2):86–8 (Eng. Abstr.) **(Ger)**

[Locoregional recurrence of melanomas of the extremities after hyperthermic extremity perfusion: is reperfusion of value?] Meyer T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1452–4 (Eng. Abstr.) **(Ger)**

[Effect of combined carboplatin and ifosfamide with local hyperthermia on human mouth carcinoma in the animal model] Brücker C, et al. **Mund Kiefer Gesichtschir** 1999 May;3 Suppl 1:S144–6 (Eng. Abstr.) **(Ger)**

[Phase II study on preoperative radio-chemo-thermotherapy in locally advanced rectal carcinoma] Rau B, et al. **Strahlenther Onkol** 1998 Nov;174(11):556–65 (Eng. Abstr.) **(Ger)**

[Thermotherapy in rheumatic diseases] Berliner MN. **Z Arztl Fortbild Qualitatssich** 1999 Jul;93(5):331–4 (Eng. Abstr.) **(Ger)**

[Surgery associated with intraoperative hyperthermia-chemotherapy in the treatment of malignant tumors of the digestive system with peritoneal carcinosis] Caporale A, et al. **G Chir** 1999 May;20(5):241–5 (Eng. Abstr.) **(Ita)**

[Combination effect of hyperthermia and MX2 on cultured glioma cell lines] Mizumatsu S, et al. **Gan To Kagaku Ryoho** 1999 May;26(6):789–95 (Eng. Abstr.) **(Jpn)**

[Thermo-chemotherapy using low-dose CPT-11 in a patient with local recurrence of rectal cancer] Nishida Y, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):549–52 (Eng. Abstr.) **(Jpn)**

[Anti-proliferative effects of heating on the human prostatic carcinoma cells in culture] Nakanoma T, et al. **Hum Cell** 1998 Sep;11(3):167–74 (Eng. Abstr.) **(Jpn)**

[Thermal effect on alpha 1-adrenoceptors in the guinea-pig vas deferens: histological and binding studies] Ogawa M, et al. **Nippon Hinyokika Gakkai Zasshi** 1998 Sep; 89(9):739–48 (Eng. Abstr.) **(Jpn)**

[Dependence of synergism of the combined effect of cisplatin and hyperthermia on the concentration of the drug] Pantiukhina AG, et al. **Tsitologiia** 1999;41(5):420–4 (Eng. Abstr.) **(Rus)**

[Current methods of radiation therapy in patients with prostatic cancer: subtotal body radiation, local hyperthermia] Granov AM, et al. **Vestn Rentgenol Radiol** 1998 Sep–Oct;(5):30–3 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Relevance of a new impedance matching, or subtrap, method for the reduction of pain during hyperthermia. Murata T, et al. **Acta Oncol** 1998;37(5):485–8

Prevention by methylprednisolone of increased circulating tumor necrosis factor-alpha levels and lung injury associated with systemic inflammatory response syndrome due to intraperitoneal hyperthermia. Sumida M, et al. **Anesth Analg** 1999 Apr;88(4):771–6

Enhanced protection of heat shock in myocardial infarction: inhibition of detrimental effect of systemic hyperthermia. Iliodromitis EK, et al. **Cardiovasc Drugs Ther** 1999 May; 13(3):223–31

Misusing forced-air hyperthermia units can burn patients. **Health Devices** 1999 May–Jun;28(5–6):229–30

Study of the cause of the temperature rise at the muscle-bone interface during ultrasound hyperthermia. Fujii M, et al. **IEEE Trans Biomed Eng** 1999 May;46(5):494–504

Indomethacin reduces the skin thermal damage in hyperthermic treatment of experimental malignant tumors. Ostapenko VV, et al. **In Vivo** 1999 May–Jun;13(3):255–7

Hyperthermia in the chick embryo: HSP and possible mechanisms of developmental defects. Buckiová D, et al. **Int J Dev Biol** 1998 Jul;42(5):737–40

The effects of intentional hyperthermia on the Thrombelastograph and the Sonoclot analyser. Pivalizza EG, et al. **Int J Hyperthermia** 1999 May–Jun;15(3):217–23

Effects of whole-body hyperthermia on the canine central nervous system. Takahashi S, et al. **Int J Hyperthermia** 1999 May–Jun;15(3):203–16

Effects of intraoperative irradiation (IORT) and intraoperative hyperthermia (IOHT) on canine sciatic nerve: histopathological and morphometric studies. Vujaskovic Z, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1103–9

Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. Brauer LP, et al. **J Cancer Res Clin Oncol** 1998;124(10):549–54

Necrosis of the urethra and tissue sloughing: a delayed complication after transurethral microwave thermotherapy. Stravodimos KG, et al. **J Endourol** 1998 Aug;12(4):379–80

Dissociation of heat shock proteins expression with ischemic tolerance by whole body hyperthermia in rat heart. Qian YZ, et al. **J Mol Cell Cardiol** 1998 Jun;30(6):1163–72

Thermal burns in diabetic feet. Thng P, et al. **Singapore Med J** 1999 May;40(5):362–4

[Prevention of temporary prostatic obstruction after high-energy microwave thermothery by placement of prostatic bridge catheter] Djavan B, et al. **Prog Urol** 1999 Apr;9(2):261–70 (Eng. Abstr.) **(Fre)**

ECONOMICS

A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Waldén M, et al. **Scand J Urol Nephrol** 1998 May;32(3):204–10

HISTORY

The Nobel chronicles. 1927: Julius Wagner-Jauregg (1857–1940). Raju TN. **Lancet** 1998 Nov 21;352(9141):1714

INSTRUMENTATION

3-D temperature distribution in ultrasound hyperthermia with interstitial waveguide applicator. Jarosz BJ. **Ann N Y Acad Sci** 1998 Sep 11;858:47–55

Technical aspects of microwave thermotherapy. Vrba J, et al. **Bioelectrochem Bioenerg** 1999 May;48(2):305–9

Efficacy and safety of infrared warming of the eyelids. Mori A, et al. **Cornea** 1999 Mar;18(2):188–93

Misusing forced-air hyperthermia units can burn patients. **Health Devices** 1999 May–Jun;28(5–6):229–30

Continuous hyperthermic peritoneal perfusion for peritoneal dissemination of gastric cancer. Akiyama H, et al. **Hepatogastroenterology** 1998 Nov–Dec;45(24):2079–86

Arrays of multielement ultrasound applicators for interstitial hyperthermia. Lee RJ, et al. **IEEE Trans Biomed Eng** 1999 Jul;46(7):880–90

Treatment planning of brain implants using vascular information and a new template technique. De Bree J, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):729–36

Spatial steering with quadruple electrodes in 27 MHz capacitively coupled interstitial hyperthermia. Crezee J, et al. **Int J Hyperthermia** 1999 Mar-Apr;15(2):145–56

An adaptive microwave phased array for targeted heating of deep tumours in intact breast: animal study results. Fenn AJ, et al. **Int J Hyperthermia** 1999 Jan–Feb;15(1):45–61

Technical note: Parasitic thermovoltage in the multithermocouple probe, its explanation and elimination. Hanus J, et al. **Int J Hyperthermia** 1999 Jul–Aug; 15(4):331–7

Non-invasive MR thermometry by 2D spectroscopic imaging of the Pr[MOE-DO3A] complex. Hentschel M, et al. **Int J Hyperthermia** 1998 Sep–Oct;14(5):479–93

A HF EM installation allowing simultaneous whole body

and deep local EM hyperthermia. Mazokhin VN, et al. **Int J Hyperthermia** 1999 Jul-Aug;15(4):309-29

Effect of practical layered dielectric loads on SAR patterns from dual concentric conductor microstrip antennas. Rossetto F, et al. **Int J Hyperthermia** 1998 Nov-Dec; 14(6):553-71

Comparisons between the BSD-2000 Quad Amplifier and a new prototype solid state amplifier for deep regional hyperthermia [letter] Turner PF. **Int J Hyperthermia** 1999 Jul-Aug;15(4):339-43

Design and test of a new multi-amplifier system with phase and amplitude control. Wust P, et al. **Int J Hyperthermia** 1998 Sep-Oct;14(5):459-77

Comparison of the clinical effectiveness of the 433 MHz Lucite cone applicator with that of a conventional waveguide applicator in applications of superficial hyperthermia. Rietveld PJ, et al. **Int J Radiat Oncol Biol Phys** 1999 Feb 1;43(3):681-7

Transrectal ultrasound applicator for prostate heating monitored using MRI thermometry. Smith NB, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1;43(1):217-25

Scanning E-field sensor device for online measurements in annular phased-array systems. Wust P, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 1;43(4):927-37

Real-time control of focused ultrasound heating based on rapid MR thermometry. Vimeux FC, et al. **Invest Radiol** 1999 Mar;34(3):190-3

Percutaneous radiofrequency thermal ablation for liver tumours [letter] Jiao LR. **Lancet** 1999 Jul 31; 354(9176):427-8

MRI-guided radiofrequency thermal ablation of implanted VX2 liver tumors in a rabbit model: demonstration of feasibility at 0.2 T. Merkle EM, et al. **Magn Reson Med** 1999 Jul;42(1):141-9

Ex vivo tissue-type independence in proton-resonance frequency shift MR thermometry. Peters RD, et al. **Magn Reson Med** 1998 Sep;40(3):454-9

Temperature measurement errors with thermocouples inside 27 MHz current source interstitial hyperthermia applicators. Kaatee RS, et al. **Phys Med Biol** 1999 Jun; 44(6):1499-511

Quantitative evaluation of 2 x 2 arrays of Lucite cone applicators in flat layered phantoms using Gaussian-beam-predicted and thermographically measured SAR distributions. Rietveld PJ, et al. **Phys Med Biol** 1998 Aug;43(8):2207-20

[Laser-induced thermotherapy. Technical prerequisites for treatment of malignant liver tumors] Albrecht D, et al. **Chirurg** 1998 Sep;69(9):930-7 (Eng. Abstr.) **(Ger)**

[Optimized laser-induced thermotherapy in treatment of liver metastases of colorectal carcinomas, an interdisciplinary responsibility--a clinical study] Albrecht D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1438-40 (Eng. Abstr.) **(Ger)**

[Thermal laser dosimetry in treatment of liver tumors--correlation of optical tissue parameters with in vivo temperature distribution in VX-2 tumors and healthy liver tissue] Ritz JP, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1445-7 (Eng. Abstr.) **(Ger)**

[Trans-pupillary hyperthermia of malignant choroid melanoma. Initial experiences] Schneider H, et al. **Ophthalmologe** 1998 Nov;95(11):765-70 (Eng. Abstr.) **(Ger)**

METHODS

Relevance of a new impedance matching, or subtrap, method for the reduction of pain during hyperthermia. Murata T, et al. **Acta Oncol** 1998;37(5):485-8

Transpupillary thermotherapy for small choroidal melanoma. Godfrey DG, et al. **Am J Ophthalmol** 1999 Jul;128(1):88-93

Laser-induced thermotherapy combined with hepatic arterial embolization in the treatment of liver tumors in a rat tumor model. Germer CT, et al. **Ann Surg** 1999 Jul;230(1):55-62

Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis. Sayag-Beaujard AC, et al. **Anticancer Res** 1999 Mar-Apr; 19(2B):1375-82

Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile? Olieman AF, et al. **Arch Orthop Trauma Surg** 1998;118(1-2):70-4

Sham treatment compared with 30 or 60 min of thermotherapy for benign prostatic hyperplasia: a randomized study. Brehmer M, et al. **BJU Int** 1999 Aug; 84(3):292-6

Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results. Levy C, et al. **Br J Ophthalmol** 1998 Oct;82(10):1154-8

The predictive value of baseline variables in the treatment of benign prostatic hyperplasia using high-energy transurethral microwave thermotherapy. d'Ancona FC, et al. **Br J Urol** 1998 Dec;82(6):808-13

Pressure-flow studies before and after transurethral microwave thermotherapy of benign prostatic hyperplasia using low- and high-energy protocols. Eliasson T, et al. **Br J Urol** 1998 Oct;82(4):513-9

A new treatment for penile conservation in penile carcinoma: a preliminary study of combined laser hyperthermia, radiation and chemotherapy. Shirahama T, et al. **Br J Urol** 1998 Nov;82(5):687-93

Optimizing transurethral microwave thermotherapy: a model for studying power, blood flow, temperature variations and tissue destruction [letter; comment] Wiksell H, et al. **Br J Urol** 1998 Dec;82(6):934-6. Comment on: Br J Urol 1998 Jun;81(6):811-6.

Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Fujimoto S, et al. **Cancer** 1999 Feb 1;85(3):529-34

Current concepts in the pharmacological management of obesity. Carek PJ, et al. **Drugs** 1999 Jun;57(6):883-904 (125 ref.)

Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a 'cooled-tip needle'. A preliminary clinical experience. Francica G, et al. **Eur J Ultrasound** 1999 May;9(2):145-53

A multifrequency driving system for ultrasound hyperthermia. Lu BY, et al. **IEEE Eng Med Biol Mag** 1999 Sep-Oct;18(5):106-11

Effects of blood perfusion rate on the optimization of RF-capacitive hyperthermia. Fujita S, et al. **IEEE Trans Biomed Eng** 1998 Sep;45(9):1182-6

Impact of nonlinear heat transfer on temperature control in regional hyperthermia. Lang J, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1129-38

Density of viral particles in pre and post Nd: YAG laser hyperthermia therapy and cryotherapy in plantar warts. El-Tonsy MH, et al. **Int J Dermatol** 1999 May;38(5):393-8

Thermotherapy: feasibility study using a single focussed ultrasound transducer. Barkman CA, et al. **Int J Hyperthermia** 1999 Jan-Feb;15(1):63-76

Electromagnetic thermal therapy power optimization for multiple source applicators. Das SK, et al. **Int J Hyperthermia** 1999 Jul-Aug;15(4):291-308

A HF EM installation allowing simultaneous whole body and deep local EM hyperthermia. Mazokhin VN, et al. **Int J Hyperthermia** 1999 Jul-Aug;15(4):309-29

Simultaneous superficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to treatment. Myerson RJ, et al. **Int J Hyperthermia** 1999 Jul-Aug;15(4):251-66

Optimization of pelvic heating rate distributions with electromagnetic phased arrays. Paulsen KD, et al. **Int J Hyperthermia** 1999 May-Jun;15(3):157-86 (26 ref.)

The measurement of fringing fields in a radio-frequency hyperthermia array with emphasis on bolus size. Wiersma J, et al. **Int J Hyperthermia** 1998 Nov-Dec;14(6):535-51

Efficacy of transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia. Namiki K, et al. **Int J Urol** 1999 Jul;6(7):341-5

Multidisciplinary treatment, including laser hyperthermia, for extensive regional metastasis of a penile tumor. Shirahama T, et al. **Int J Urol** 1999 Jan;6(1):53-5

Evaluation of temperature distribution during hyperthermic treatment in biliary tumors: a computational approach. Rivolta B, et al. **J Biomech Eng** 1999 Apr;121(2):141-7

Importance of thermal dose and antenna location in transurethral microwave thermotherapy for benign prostatic hyperplasia. Eliasson T, et al. **J Endourol** 1998 Dec;12(6):581-9

A porcine model for investigation of hyperthermic isolated liver perfusion. Lang H, et al. **J Invest Surg** 1998 Nov-Dec; 11(6):401-8

Sensitization to hyperthermia by intracellular acidification of C6 glioma cells. Kitai R, et al. **J Neurooncol** 1998 Sep; 39(3):197-203

Free-flap evolution after hyperthermic regional chemotherapy in the isolated limb for malignant melanoma. Goldschmidt D, et al. **J Reconstr Microsurg** 1998 Aug; 14(6):397-9

Interstitial laser hyperthermia, a new method in the management of fibroadenoma of the breast: A pilot study. Basu S, et al. **Lasers Surg Med** 1999;25(2):148-52

In situ temperature measurements with thermocouple probes during laser interstitial thermotherapy (LITT): quantification and correction of a measurement artifact. Manns F, et al. **Lasers Surg Med** 1998;23(2):94-103

Surgeons use new technique to "melt" liver tumors [news] **Oncology (Huntingt)** 1999 Apr;13(4):540

Perfusion and thermal field during hyperthermia. Experimental measurements and modelling in recurrent breast cancer. Guiot C, et al. **Phys Med Biol** 1998 Oct; 43(10):2831-43

Temperature measurement errors with thermocouples inside 27 MHz current source interstitial hyperthermia applicators. Kaatee RS, et al. **Phys Med Biol** 1999 Jun; 44(6):1499-511

MRI thermometry in phantoms by use of the proton resonance frequency shift method: application to interstitial laser thermotherapy. Olsrud J, et al. **Phys Med Biol** 1998 Sep;43(9):2597-613

Comparison of four magnetic resonance methods for mapping small temperature changes. Wlodarczyk W, et al. **Phys Med Biol** 1999 Feb;44(2):607-24

Evaluation of segmentation algorithms for generation of patient models in radiofrequency hyperthermia. Wust P, et al. **Phys Med Biol** 1998 Nov;43(11):3295-307

Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Madersbacher S, et al. **Prostate** 1998 Nov 1;37(3):174-81

Laser-induced thermotherapy for the treatment of liver metastasis. Correlation of gadolinium-DTPA-enhanced MRI with histomorphologic findings to determine criteria for follow-up monitoring. Germer C, et al. **Surg Endosc** 1998 Nov;12(11):1317-25

The treatment of malignancy by hyperthermia. Christophi C, et al. **Surg Oncol** 1998 Jul-Aug;7(1-2):83-90 (93 ref.)

Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Bozzetti F, et al. **Tumori** 1998 Jul-Aug;84(4):483-8 (75 ref.)

Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Buscarini L, et al. **Ultraschall Med** 1999 Apr;20(2):47-53

[Hyperthermia in combination with chemotherapy in gynecological cancers (comment)] Rietbroek RC, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):85-8 (24 ref.) (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):76-80. **(Dut)**

[Hyperthermia in combination with radiotherapy (see comments)] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):76-80 (21 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jan 9;143(2):75-8. **(Dut)**

[Re-irradiation with hyperthermia in patients with recurrent breast cancer] van der Zee J, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9;143(2):80-4 (23 ref.) (Eng. Abstr.) **(Dut)**

[Transpupillary thermotherapy of choroidal melanoma] Schneider H, et al. **Klin Monatsbl Augenheilkd** 1999 Feb; 214(2):90-5 (Eng. Abstr.) **(Ger)**

[Anesthetic management of patients with malignant pleural effusion undergoing hyperthermic perfusion under thoracoscopy] Kitagawa H, et al. **Masui** 1999 May; 48(5):513-7 (Eng. Abstr.) **(Jpn)**

[Results of application of endolymphatic polychemotherapy and local supra-high frequency hyperthermia in comprehensive treatment of rectal cancer] Kolesnik EA. **Klin Khir** 1998;(8):32-3 (Eng. Abstr.) **(Rus)**

[Treatment of malignant choroidal melanoma with transpupillary thermotherapy using the diode laser] Strmeň P, et al. **Cesk Slov Oftalmol** 1999 May;55(3):176-80 (27 ref.) **(Slo)**

[Many therapeutic alternatives in prostatic hyperplasia. TUMT is not so effective as TURP, but better than drug therapy] Ekman P. **Lakartidningen** 1999 Aug 25; 96(34):3504-5 **(Swe)**

[Research and development called for thermotherapy of prostatic hyperplasia] Hallin A. **Lakartidningen** 1999 Aug 25;96(34):3520-2 (30 ref.) (Eng. Abstr.) **(Swe)**

STANDARDS

Increased heating efficiency of hyperthermia using an ultrasound contrast agent: a phantom study. Fujishiro S, et al. **Int J Hyperthermia** 1998 Sep-Oct;14(5):495-502

VETERINARY

The effects of extracorporeal whole body hyperthermia on the functional and phenotypic features of canine peripheral blood mononuclear cells (PBMC). Kearns RJ, et al. **Clin Exp Immunol** 1999 Apr;116(1):188-92

HYPERTHERMIA, LOCAL see **HYPERTHERMIA, INDUCED**

HYPERTHERMIA, MALIGNANT see **MALIGNANT HYPERTHERMIA**

HYPERTHERMIA, THERAPEUTIC see **HYPERTHERMIA, INDUCED**

HYPERTHYROIDISM

see related
ANTITHYROID AGENTS
LONG-ACTING THYROID STIMULATOR

Thyroid conditions in older patients. Khaira JS, et al. **Practitioner** 1999 Mar;243(1596):214-8, 221 (7 ref.)

Thyroid hyperfunction during pregnancy. Glinoer D. **Thyroid** 1998 Sep;8(9):859-64 (20 ref.)

[Thyrotoxic periodic paralysis] Hansen PS, et al. **Ugeskr Laeger** 1999 Aug 2;161(31):4411-2 (Eng. Abstr.) **(Dan)**

[Hyperthyroidism. Etiology, physiopathology, diagnosis, evolution, treatment] Wemeau JL. **Rev Prat** 1998 Jun 15; 48(12):1377-84 (3 ref.) **(Fre)**

BLOOD

Plasma lipoprotein (a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects. Erem C, et al. **Acta Cardiol** 1999 Apr;54(2):77-81

Prolonged suppressed thyroid-stimulating hormone levels in hyperthyroidism in a neonate born to a mother with Graves' disease. Hojo M, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):483-5

Screening for thyroid disease [letter; comment] Hortin GL. **Ann Intern Med** 1999 Jan 19;130(2):161; discussion 162. Comment on: Ann Intern Med 1998 Jul 15;129(2):141-3. Comment on: Ann Intern Med 1998 Jul 15;129(2):144-58.

Elevation of plasma leptin concentrations in obese hyperinsulinaemic hypothyroidism before and after

treatment. Kautzky-Willer A, et al. **Eur J Clin Invest** 1999 May;29(5):395-403
Role of thyroid hormones on serum leptin levels. Sesmilo G, et al. **Eur J Endocrinol** 1998 Oct;139(4):428-30
Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine. Zulewski H, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):190-4
The status of retinoids in women suffering from hyper- and hypothyroidism: interrelationship between vitamin A, beta-carotene and thyroid hormones. Goswami UC, et al. **Int J Vitam Nutr Res** 1999 Mar;69(2):132-5
Serum cytokines in thyrotoxicosis. Siddiqi A, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):435-9
Effects of vitamin E and vitamin C supplementation on plasma lipid peroxidation and on oxidation of apolipoprotein B-containing lipoproteins in experimental hyperthyroidism. Dirican M, et al. **J Med Invest** 1999 Feb; 46(1-2):29-33
The effect of methimazole on the oxidant and antioxidant system in patients with hyperthyroidism. Ademoğlu E, et al. **Pharmacol Res** 1998 Aug;38(2):93-6
Normal serum concentrations of sex hormone binding-globulin in patients with hyperthyroidism due to subacute thyroiditis. Vierhapper H, et al. **Thyroid** 1998 Dec; 8(12):1107-11
[Markers of endothelial stimulation in hyperthyroidism] Rość D, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):79-81 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Transient hyperthyroidism in a patient taking dietary supplements containing kelp. Eliason BC. **J Am Board Fam Pract** 1998 Nov-Dec;11(6):478-80
Amiodarone and thyroid disease [editorial] Hain SF, et al. **Nucl Med Commun** 1999 Feb;20(2):111-3
A case of lithium-associated hyperthyroidism [letter] Yamagishi S, et al. **Postgrad Med J** 1999 Mar;75(881):188-9
Femoral fracture and iatrogenic hyperthyroidism in spinal cord injury. Valayer-Chaleat E, et al. **Spinal Cord** 1998 Aug;36(8):593-5
Risks of iodine-induced hyperthyroidism after correction of iodine deficiency by iodized salt. Delange F, et al. **Thyroid** 1999 Jun;9(6):545-56
[Hyperthyroidism induced by iodine-containing radiologic contrast media (letter; comment)] Borm JJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29;142(35):1969-70. Comment on: Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1641-4. **(Dut)**
[Hyperthyroidism induced by iodinated roentgen contrast media (see comments)] van Guldener C, et al. **Ned Tijdschr Geneeskd** 1998 Jul 18;142(29):1641-4 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Aug 29;142(35):1969-70. **(Dut)**
[Hyperthyroidism due to the improper use of povidone-iodine] Pagliaricci S, et al. **Ann Ital Med Int** 1999 Apr-Jun;14(2):124-6 (10 ref.) (Eng. Abstr.) **(Ita)**
[Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function] Biondi B, et al. **Cardiologia** 1999 May;44(5):443-9 (Eng. Abstr.) **(Ita)**
[Iodine-induced hyperthyroidism after cadexomer iodine treatment of leg ulcers] Michanek A, et al. **Lakartidningen** 1998 Dec 9;95(50):5755-6 (Eng. Abstr.) **(Swe)**

COMPLICATIONS

Blastocyst implantation: effect of thyroidectomy and thyroxine replacement in the rat. Bolarinwa AF, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):135-7
Secondary osteoporosis. Gennari C, et al. **Aging (Milano)** 1998 Jun;10(3):214-24 (146 ref.)
The effect of thyroid hormone on skeletal integrity. Greenspan SL, et al. **Ann Intern Med** 1999 May 4; 130(9):750-8 (81 ref.)
Thyroid cancer with concurrent hyperthyroidism. Chao TC, et al. **Arch Surg** 1999 Feb;134(2):130-4
Effects of thyroid hormone on the sorbitol pathway in streptozotocin-induced diabetic rats. Shinohara R, et al. **Biochim Biophys Acta** 1998 Nov 27;1425(3):577-86
Evaluation of risk in autonomously functioning thyroid nodules. Mann K. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S23-6 (43 ref.)
Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes inspidus and hyperthyroidism. Wada S, et al. **Intern Med** 1999 Jun; 38(6):486-90
Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. Kobori H, et al. **J Endocrinol** 1999 Jan;160(1):43-7
Amyotrophic lateral sclerosis syndrome and hyperthyroidism: report of 4 patients. Chotmongkol V. **J Med Assoc Thai** 1999 Jun;82(6):615-8
Spontaneous resolution of upper eyelid retraction in thyroid orbitopathy. von Brauchitsch DK, et al. **J Neuroophthalmol** 1999 Jun;19(2):122-4
Subclinical hyperthyroidism and hyperkinetic behavior in children. Suresh PA, et al. **Pediatr Neurol** 1999 Mar; 20(3):192-4
Oxidative stress in the development of diabetes during hyperthyroidism [letter] Kocic R, et al. **Postgrad Med J** 1998 Jun;74(872):381
Cardiac risks of hyperthyroidism in the elderly. Kahaly GJ, et al. **Thyroid** 1998 Dec;8(12):1165-9 (25 ref.)
Subclinical hyperthyroidism. Koutras DA. **Thyroid** 1999 Mar; 9(3):311-5 (42 ref.)
[Severe osteoporosis during glucocorticoid therapy] Aitio ML, et al. **Duodecim** 1995;111(20):1949-53 **(Fin)**
[Hyperthyroidism and diabetes mellitus: analysis of 10 African cases] Sidibé EH, et al. **Ann Endocrinol (Paris)** 1999 Mar;60(1):33-9 (Eng. Abstr.) **(Fre)**
[Hyperthyroidism and cancer of the thyroid. What incidence and what severity? (letter; comment)] Mellière D. **Chirurgie** 1999 Jun;124(3):346-7. Comment on: Chirurgie 1998 Dec;123(6):604-8. **(Fre)**
[Rheumatoid hyperthyroidism. Another observation (letter; comment) (see comments)] Denès E, et al. **Presse Med** 1999 Jan 23;28(3):132-3. Comment on: Presse Med 1998 Sep 12;27(26):1324-6. Comment in: Presse Med 1999 Apr 24;28(16):846. **(Fre)**
[On thyrotoxic heart failure (letter; comment)] Maunand B. **Presse Med** 1999 Apr 24;28(16):846. Comment on: Presse Med 1999 Jan 23;28(3):132-3. **(Fre)**
[Heart and thyroid] Col V, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):481-5 (24 ref.) **(Fre)**
[Extra-thyroidal accompanying and resulting diseases] Stiefelhagen P. **Med Monatsschr Pharm** 1999 Jul; 22(7):220-2 **(Ger)**
[Hyperthyroidism and cholestasis: a case report] Gurioli L, et al. **Ann Ital Med Int** 1998 Oct-Dec;13(4):244-7 (Eng. Abstr.) **(Ita)**
[Severe anemia due to hyperthyroidism (letter)] Grau A, et al. **An Med Interna** 1999 Jan;16(1):50 (10 ref.) **(Spa)**
[Hyperthyroidism and anemia of chronic disorders (letter)] Raya Sánchez JM, et al. **An Med Interna** 1998 Aug; 15(8):453-4 **(Spa)**
[Thyroid function and difficult to manage asthma] Jerez FR, et al. **Arch Bronconeumol** 1998 Oct;34(9):429-32 (Eng. Abstr.) **(Spa)**
[Hyperthyroidism and atrial fibrillation (letter)] Calvo Romero JM. **Rev Clin Esp** 1999 Jul;199(7):482-3 **(Spa)**

CONGENITAL

Prolonged suppressed thyroid-stimulating hormone levels in hyperthyroidism in a neonate born to a mother with Graves' disease. Hojo M, et al. **Acta Paediatr Jpn** 1998 Oct;40(5):483-5
Alterations of neonatal thyroid function. Grüters A, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):17-22 (29 ref.)
Autosomal dominant nonautoimmune hyperthyroidism. Clinical features-diagnosis-therapy. Führer D, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S10-5 (25 ref.)
Fetal and neonatal hyperthyroidism. Zimmerman D. **Thyroid** 1999 Jul;9(7):727-33 (98 ref.)
[Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects] Polak M. **Arch Pediatr** 1998;5 Suppl 4:375S-379S (32 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Hyperthyroidism in a renal transplant recipient. Peces R, et al. **Am J Nephrol** 1998;18(6):560-1
Hyperthyroidism with gynaecomastia as the initial complaint: a case report. Ho HK, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):594-6 (12 ref.)
Never too old for thyroid problems. Phillips PJ, et al. **Aust Fam Physician** 1999 Feb;28(2):163-4
The measurement of antithyroid autoantibodies in the diagnosis and management of thyroid autoimmune disease. Kraiem Z. **Clin Rev Allergy Immunol** 1998 Fall; 16(3):219-25 (33 ref.)
Diagnostic items and treatment of Plummer's disease: a study on 180 patients. Messina G, et al. **Clin Ter** 1998 May-Jun; 149(3):191-5
Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine. Zulewski H, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):190-4
Hyperthyroidism: multiple possibilities in the female patient. Daniels GH. **Int J Fertil Womens Med** 1999 Jan-Feb; 44(1):6-11 (22 ref.)
A rational request behavior: the development of prediction instruments regarding thyroid function tests in primary care. Dupuits FM, et al. **Methods Inf Med** 1999 Mar; 38(1):31-6
Subclinical hyperthyroidism. Koutras DA. **Thyroid** 1999 Mar; 9(3):311-5 (42 ref.)
Hyperthyroidism in pregnancy: diagnosis and treatment. Masiukiewicz US, et al. **Thyroid** 1999 Jul;9(7):647-52 (62 ref.)
Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Polak M. **Thyroid** 1998 Dec;8(12):1171-7 (43 ref.)
[Polyarthralgia disclosing hyperthyroidism. Two case reports (see comments)] Molinier S, et al. **Presse Med** 1998 Sep 12;27(26):1324-6 (Eng. Abstr.). Comment in: Presse Med 1999 Jan 23;28(3):132-3. **(Fre)**
[Subclinical thyroid disorders: strategies] Duprey J. **Rev Med Interne** 1999;20 Suppl 1:16S-18S **(Fre)**
[Hypokalemic periodic paralysis revealing hyperthyroidism (letter)] Haymann JP, et al. **Rev Med Interne** 1999 Aug; 20(8):720-2 **(Fre)**
[Diagnosis of latent hyperthyroidism] Saller B, et al. **Internist (Berl)** 1999 Jan;40(1):112 **(Ger)**
[Is there a need for treatment in subclinical hypo- and hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369-73 (15 ref.) (Eng. Abstr.) **(Ger)**
[Pregnancy and hyperthyroidism] Sax B, et al. **Z Geburtshilfe Neonatol** 1999 Jan-Feb;203(1):29-35 (32 ref.) (Eng. Abstr.) **(Ger)**
[Atrial fibrillation and hyperthyroidism. The results of a retrospective study] Donatelli M, et al. **Minerva Cardioangiol** 1998 May;46(5):157-62 (Eng. Abstr.) **(Ita)**
[Hyperthyroidism and pregnancy] Michalska J, et al. **Ginekol Pol** 1998 Dec;69(12):1016-9 (Eng. Abstr.) **(Pol)**
[Hypertransaminemia secondary to hyperthyroidism (letter)] Rosillo González A, et al. **Aten Primaria** 1999 May 15; 23(8):505-7 **(Spa)**

DRUG THERAPY

The impact of propylthiouracil therapy on lipid peroxidation and antioxidant status parameters in hyperthyroid patients. Seven A, et al. **Acta Med Okayama** 1999 Feb;53(1):27-30
Biochemical evaluation of oxidative stress in propylthiouracil treated hyperthyroid patients. Effects of vitamin C supplementation. Seven A, et al. **Clin Chem Lab Med** 1998 Oct;36(10):767-70
Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Olkawa M, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):171-6
Thymidine kinase activity in homogenates of rat thyroid lobes from euthyroid, hypothyroid and/or hyperthyroid rats incubated with EGF: studies ex vivo in vitro. Karbownik M, et al. **Endocr Regul** 1999 Mar;33(1):17-23
Vitamin D and retinoids in parathyroid glands (review). Hellman P, et al. **Int J Mol Med** 1999 Apr;3(4):355-61 (79 ref.)
Outcome of treatment of hyperthyroidism. Bringmann IM, et al. **J Endocrinol Invest** 1999 Apr;22(4):250-6
Role of colestipol in the treatment of hyperthyroidism. Hagag P, et al. **J Endocrinol Invest** 1998 Dec;21(11):725-31
Differential TCM treatment of hyperthyroidism. Wei Z. **J Tradit Chin Med** 1997 Sep;17(3):178-83
Subclinical hyperthyroidism and hyperkinetic behavior in children. Suresh PA, et al. **Pediatr Neurol** 1999 Mar; 20(3):192-4
[Reversible left intraventricular obstruction after treatment of pheochromocytoma and hyperthyroidism] Gandolfini MP, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12):1513-8 (Eng. Abstr.) **(Fre)**
[Teratogenicity of carbimazole (letter)] Velin P, et al. **Arch Pediatr** 1998 Nov;5(11):1289 **(Fre)**
[Radioactive iodine therapy in thyrotoxicoses] Ben Slimene MF, et al. **Tunis Med** 1999 Apr;77(4):191-4 (12 ref.) **(Fre)**
[Monosymptomatic hyperthyroidism and TSH-producing adenoma: successful therapy with octreotide] Mayinger B, et al. **Dtsch Med Wochenschr** 1999 Jan 29;124(4):73-8 (Eng. Abstr.) **(Ger)**
[Reduced antithyroid agents as a result of radioiodine therapy? (editorial)] Sabri O, et al. **Nuklearmedizin** 1999; 38(4):3-6 **(Ger)**
[Hyperthyroidism in Graves' disease--antithyroid drug treatment] Schumm-Draeger PM. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:41-5 (16 ref.) (Eng. Abstr.) **(Ger)**
[Experience with ambulatory radioiodine therapy of hyperthyroidism] Róka R, et al. **Orv Hetil** 1999 Jun 6; 140(23):1291-5 (Eng. Abstr.) **(Hun)**
[Sweet syndrome following therapeutic use of granulocyte colony stimulating factor] Veres K, et al. **Orv Hetil** 1999 May 9;140(19):1059-61 (Eng. Abstr.) **(Hun)**
[Safety of antithyroid drugs in pregnancy] Agustí A. **Med Clin (Barc)** 1999 Feb 20;112(6):236 **(Spa)**
[Treatment of Basedow-Graves' hyperthyroidism: retrospective analysis after 30 years] Pineda G, et al. **Rev Med Chil** 1998 Aug;126(8):953-62 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Fetal and neonatal hyperthyroidism. Zimmerman D. **Thyroid** 1999 Jul;9(7):727-33 (98 ref.)

ENZYMOLOGY

Bepridil reducing levothyroxine-induced enhancement of mitochondria Ca2+ Mg(2+)-ATPase activity in rat cerebrum. Chen DD, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep;17(5):432-4
Hyperthyroidism facilitates cardiac fatty acid oxidation through altered regulation of cardiac carnitine palmitoyltransferase: studies in vivo and with cardiac myocytes. Sugden MC, et al. **Horm Metab Res** 1999 May; 31(5):300-6

EPIDEMIOLOGY

Epidemiology of functional autonomy. Bauch K. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S16-22

Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Lin CC, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):516-21

Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Laurberg P, et al. **Thyroid** 1999 Jan;9(1):33-8

[Hyperthyroidism in people over 50 years of age in Senegal. Study of 31 cases observed over a 14-year period] Sidibe EH, et al. **Rev Med Interne** 1998 Apr;19(4):237-41 (Eng. Abstr.) **(Fre)**

ETIOLOGY

Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease. Berisso GA, et al. **Bone Marrow Transplant** 1999 May;23(10):1091-2

A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis. Alings AM, et al. **J Endocrinol Invest** 1998 Nov;21(10):703-6

TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. Fischler MP, et al. **J Endocrinol Invest** 1999 Jan;22(1):64-5

Hypokalaemic periodic paralysis mimicking Guillain-Barré syndrome [letter] Warren JD, et al. **Med J Aust** 1998 Sep 21;169(6):342

Hyperthyroidism: a novel feature of the tubulointerstitial nephritis and uveitis syndrome. Paul E, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):314-7

Thyrotoxicosis and low radioactive iodine uptake in a woman with Graves' disease. Wägner AM, et al. **Postgrad Med J** 1999 Feb;75(880):125-6

Hyperthyroidism due to papillary carcinoma of the thyroid--a case report. Sarda AK, et al. **Singapore Med J** 1999 Mar;40(3):157-9

Struma ovarii and hyperthyroidism. Dunzendorfer T, et al. **Thyroid** 1999 May;9(5):499-502

Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Hershman JM. **Thyroid** 1999 Jul;9(7):653-7 (42 ref.)

Hyperthyroidism due to lymphoma involving the thyroid gland in a patient with acquired immunodeficiency syndrome: case report and review of the literature. Samuels MH, et al. **Thyroid** 1998 Aug;8(8):673-7 (41 ref.)

[Hyperthyroidism and cancer of the thyroid (see comments)] Daou R. **Chirurgie** 1998 Dec;123(6):604-8 (Eng. Abstr.). Comment in: Chirurgie 1999 Jun;124(3):346-7. **(Fre)**

[Postpartum thyroiditis: a silent entity (letter)] Dourthe LM, et al. **Presse Med** 1999 Feb 20;28(7):339 **(Fre)**

[A recalcitrant hypercalcemia] Jégo A, et al. **Rev Med Interne** 1998;19 Suppl 2:299s-300s **(Fre)**

[Hypophyseal thyrotropin adenomas at Yaounde (Cameroon). Analysis of two case reports: improvement with somatostatin analogue (SMS 201-995)] Nouedoui C, et al. **Tunis Med** 1999 Mar;77(3):154-8 **(Fre)**

[Hyperthyroidism caused by a TSH producing pituitary adenoma] Prasch F, et al. **Acta Med Austriaca** 1999; 26(1):32-6 (Eng. Abstr.) **(Ger)**

[Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study] Weiss M, et al. **Med Klin** 1999 May 15;94(5):239-44 (Eng. Abstr.) **(Ger)**

[Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies] Rink T, et al. **Nuklearmedizin** 1999;38(5):156-9 (Eng. Abstr.) **(Ger)**

[Hyperthyroidism--advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments] Meier CA. **Ther Umsch** 1999 Jul;56(7):364-8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism and acute renal failure in partial bladder mole] Rönisch G, et al. **Zentralbl Gynakol** 1999; 121(2):88-91 (Eng. Abstr.) **(Ger)**

[Disorders caused by mutations of the thyrotropin receptor] Kosugi S. **Nippon Rinsho** 1998 Jul;56(7):1856-60 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

TSH receptor gene mutations and familial gestational hyperthyroidism. Asteria C. **Eur J Endocrinol** 1999 Aug; 141(2):93-4

Autosomal dominant nonautoimmune hyperthyroidism. Clinical features-diagnosis-therapy. Führer D, et al. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S10-5 (25 ref.)

FISH analysis of 1cen-1q12 breakage, chromosome 1 numerical abnormalities and centromeric content of micronuclei in buccal cells from thyroid cancer and hyperthyroidism patients treated with radioactive iodine. Ramirez MJ, et al. **Mutagenesis** 1999 Jan;14(1):121-7

Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. Rodien P, et al. **N Engl J Med** 1998 Dec 17;339(25):1823-6

Anomaly of chromosome 18 complicated with diabetes mellitus and hyperthyroidism. Nishimura Y, et al. **Pediatr Int** 1999 Apr;41(2):177-80

Non-autoimmune hyper- and hypothyroidism due to mutations in the thyrotropin receptor gene. Vassart G. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:23-4 (11 ref.)

[Activating mutations of the TSH receptor: a synthesis highlighting certain pediatric aspects] Polak M. **Arch Pediatr** 1998;5 Suppl 4:375S-379S (32 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Physiologic effects of active immunization with triiodothyronine in rats] Martianov AA, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):497-501 **(Rus)**

METABOLISM

The impact of propylthiouracil therapy on lipid peroxidation and antioxidant status parameters in hyperthyroid patients. Seven A, et al. **Acta Med Okayama** 1999 Feb;53(1):27-30

Modulation of Ca2+ transient decay by tension and Ca2+ removal in hyperthyroid myocardium. Ishikawa T, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H289-99

Bulbospinal serotonergic activity during changes in thyroid status. Henley WN, et al. **Can J Physiol Pharmacol** 1998 Dec;76(12):1120-31

Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Pachucki J, et al. **Circ Res** 1999 Sep 17;85(6):498-503

Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Olkawa M, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):171-6

The effect of formulation on radioiodide thyroid uptake in the hyperthyroid cat. Yu MD, et al. **Drug Dev Ind Pharm** 1999 May;25(5):565-70

The effect of hypo- and hyperthyroidism on uterine and cervical collagens and glycosidases in albino rats. Gladson M, et al. **Endocr Res** 1999 Feb;25(1):129-37

Novel translational repressor (NAT-1) expression is modified by thyroid state and age in brain and liver. Shah GN, et al. **Eur J Endocrinol** 1998 Dec;139(6):649-53

Liver microsomal parameters related to oxidative stress and antioxidant systems in hyperthyroid rats subjected to acute lindane treatment. Simon Giavarotti KA, et al. **Free Radic Res** 1998 Jul;29(1):35-42

Interaction of hyperthyroidism and hindlimb suspension on skeletal myosin heavy chain expression. Haddad F, et al. **J Appl Physiol** 1998 Dec;85(6):2227-36

Thyroid status affects the rat cardiac beta-adrenoceptor system transiently and time-dependently. Zwaveling J, et al. **J Auton Pharmacol** 1998 Feb;18(1):1-11

G proteins, beta-adrenoreceptors and beta-adrenergic responsiveness in immature and adult rat ventricular myocardium: influence of neonatal hypo- and hyperthyroidism. Novotny J, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):761-72

Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment. Andersen V, et al. **Scand J Gastroenterol** 1999 Jun;34(6):618-22

Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Gürlek A, et al. **Thyroid** 1999 Jun;9(6):539-43

[Pharmacokinetics of beta blockers in hyperthyroidism. Therapeutic relevance] Bouvier N, et al. **Therapie** 1998 Nov-Dec;53(6):523-31 (51 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Hyperthyroidism in elderly patients. Bailes BK. **AORN J** 1999 Jan;69(1):254-8

PATHOLOGY

Inflammation of the cardiac conduction system in a case of hyperthyroidism. Ortmann C, et al. **Int J Legal Med** 1999; 112(4):271-4

Body weight and body composition changes after treatment of hyperthyroidism. Lönn L, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4269-73

Mechanism of hyperthyroidism-induced renal hypertrophy in rats. Kobori H, et al. **J Endocrinol** 1998 Oct;159(1):9-14

[Hyperthyroidism and thyroid carcinoma--coincidence or association?] Oertli D, et al. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1910-4 (26 ref.) (Eng. Abstr.) **(Ger)**

[Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism] Derwahl M. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:25-8 (35 ref.) (Eng. Abstr.) **(Ger)**

[Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function] Biondi B, et al. **Cardiologia** 1999 May;44(5):443-9 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Alterations of neonatal thyroid function. Grüters A, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):17-22 (29 ref.)

In vivo regulation of beta-MHC gene in rodent heart: role of T3 and evidence for an upstream enhancer. Wright CE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C883-91

Left atrial systolic time interval in hyperthyroidism. Dazai Y. **Angiology** 1999 Jul;50(7):591-8

Circadian blood pressure and heart rate profiles in normotensive patients with mild hyperthyroidism. Kohno I, et al. **Chronobiol Int** 1998 Jul;15(4):337-47

Contribution of the autonomic nervous system to blood pressure and heart rate variability changes in early experimental hyperthyroidism. Safa-Tisseront V, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):247-55

Vitamin D and retinoids in parathyroid glands (review). Hellman P, et al. **Int J Mol Med** 1999 Apr;3(4):355-61 (79 ref.)

Ineffective cardiorespiratory function in hyperthyroidism. Kahaly GJ, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):4075-8

Stress echocardiography in hyperthyroidism. Kahaly GJ, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2308-13

Anorectal physiology and transit in patients with disorders of thyroid metabolism. Deen KI, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):384-7

Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism. Safa-Tisseront V, et al. **J Hypertens** 1998 Dec;16(12 Pt 2):1989-92

The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions. Brittsan AG, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1725-37

Thermogenesis and fatty acid composition of brown adipose tissue in rats rendered hyperthyroid and hypothyroid-with special reference to docosahexaenoic acid. Saha SK, et al. **Jpn J Physiol** 1998 Oct;48(5):355-64

Antioxidant-sensitive shortening of ventricular action potential in hyperthyroid rats is independent of lipid peroxidation. Venditti P, et al. **Mol Cell Endocrinol** 1998 Jul 25;142(1-2):15-23

Influence of hyperthyroidism on the activity of liver nitric oxide synthase in the rat. Fernández V, et al. **Nitric Oxide** 1997;1(6):463-8

[Thyrotoxic neuromyopathies] Sidibe EH, et al. **Rev Neurol (Paris)** 1998 May;154(4):330-3 (Eng. Abstr.) **(Fre)**

[Hyperfunction and hypofunction of the thyroid gland] Lauven PM. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):33 **(Ger)**

[Hyperfunction and hypofunction of the thyroid gland from the anesthesiologist's viewpoint] Röper A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):34-7 (16 ref.) **(Ger)**

[Evaluation of autonomic nervous system function with heart rate variability analysis in patients with hyperthyroidism and during euthyroidism after pharmacologic and surgical treatment] Barczyński M, et al. **Folia Med Cracov** 1997; 38(3-4):27-35 (Eng. Abstr.) **(Pol)**

RADIONUCLIDE IMAGING

Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Thompson GB, et al. **Arch Surg** 1999 Jul; 134(7):699-704; discussion 704-5

Thyroid scintigraphy in hyperthyroidism. Klopper J. **S Afr Med J** 1999 May;89(5):523

[Results of TcTUs-optimized radioiodine therapy in multifocal and disseminated autonomy] Dunkelmann S, et al. **Nuklearmedizin** 1999;38(5):131-9 (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism [see comments] Barrington SF, et al. **Eur J Nucl Med** 1999 Jul;26(7):686-92. Comment in: Eur J Nucl Med 1999 Jul;26(7):683-5.

Radioiodine (131I) treatment of hyperthyroidism: radiation protection and quality assurance [editorial; comment] Reiners C, et al. **Eur J Nucl Med** 1999 Jul;26(7):683-5. Comment on: Eur J Nucl Med 1999 Jul;26(7):686-92.

Radioiodine treatment of Plummer's disease. Moser E. **Exp Clin Endocrinol Diabetes** 1998;106 Suppl 4:S63-5 (29 ref.)

Recommended restrictions after 131I therapy: measured doses in family members. Mathieu I, et al. **Health Phys** 1999 Feb;76(2):129-36

Thyroid function and energy intake during weight gain following treatment of hyperthyroidism. Abid M, et al. **J Am Coll Nutr** 1999 Apr;18(2):189-93

Outcome of treatment of hyperthyroidism. Bringmann IM, et al. **J Endocrinol Invest** 1999 Apr;22(4):250-6

Concerns about risks of irradiation during pregnancy [letter; comment] Osmanagaoglu K, et al. **J Nucl Med** 1998 Dec; 39(12):2194-5. Comment on: J Nucl Med 1998 Feb;39(2):357-61.

Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Franklyn JA, et al. **Lancet** 1999 Jun 19;353(9170):2111-5

Malignant ophthalmopathy presenting one week after radioiodine treatment of hyperthyroidism. Burmeister LA, et al. **Thyroid** 1999 Feb;9(2):189-92

[Radioiodine (131I) as the only treatment of hyperthyroidism. Results of 10 years of experience] Hennen G, et al. **Rev Med Liege** 1999 Jul;54(7):611-7 (Eng. Abstr.) **(Fre)**

[Results of TcTUs-optimized radioiodine therapy in multifocal and disseminated autonomy] Dunkelmann S, et al. **Nuklearmedizin** 1999;38(5):131-9 (Eng. Abstr.) **(Ger)**

[Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients] Khandani A, et al. **Nuklearmedizin** 1999;38(5):140-3 (Eng. Abstr.) **(Ger)**

[First results of radioiodine therapy of multifocal and disseminated thyroid gland autonomy and use of a TcTUs-adapted dose concept] Oexle C, et al. **Nuklearmedizin** 1998;37(6):192–6 (Eng. Abstr.) **(Ger)**

[Reduced antithyroid agents as a result of radioiodine therapy? (editorial)] Sabri O, et al. **Nuklearmedizin** 1999; 38(4):3–6 **(Ger)**

SURGERY

Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Thompson GB, et al. **Arch Surg** 1999 Jul; 134(7):699–704; discussion 704–5

The role of surgery in primary hyperthyroidism. Weetman AP. **J R Soc Med** 1998;91 Suppl 33:7–11 (36 ref.)

[Operative and anesthesiologic problems in hyperthyroidism from the viewpoint of the internist] Herrmann J. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):39–43 (6 ref.) **(Ger)**

[Hyperthyroidism from the viewpoint of the surgeon] Thermann M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):38–9 (5 ref.) **(Ger)**

[Surgical procedure for hyperthyroidism in children and adolescents] Witte J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1048–50 (Eng. Abstr.) **(Ger)**

[Surgery for hyperthyroidism] Lorenz K, et al. **Ther Umsch** 1999 Jul;56(7):385–9 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Graves ophthalmopathy [letter; comment] Haddad HM. **Arch Ophthalmol** 1999 May;117(5):700. Comment on: Arch Ophthalmol 1998 Aug;116(8):1106–7.

Diagnostic items and treatment of Plummer's disease: a study on 180 patients. Messina G, et al. **Clin Ter** 1998 May–Jun; 149(3):191–5

Hyperthyroidism: multiple possibilities in the female patient. Daniels GH. **Int J Fertil Womens Med** 1999 Jan–Feb; 44(1):6–11 (22 ref.)

Long-term outcomes of treatment of hyperthyroidism in Ireland. Leary AC, et al. **Ir J Med Sci** 1999 Jan–Mar; 168(1):47–52

Treatment of hyperthyroidism in Down syndrome: case report and review of the literature. Ali FE, et al. **Res Dev Disabil** 1999 Jul–Aug;20(4):297–303 (20 ref.)

Hyperthyroidism in pregnancy: diagnosis and treatment. Masiukiewicz US, et al. **Thyroid** 1999 Jul;9(7):647–52 (62 ref.)

[Pharmacokinetics of beta blockers in hyperthyroidism. Therapeutic relevance] Bouvier N, et al. **Therapie** 1998 Nov–Dec;53(6):523–31 (51 ref.) (Eng. Abstr.) **(Fre)**

[Exophthalmos--what now?] Heufelder AE, et al. **Ther Umsch** 1999 Jul;56(7):408–14 (09 ref.) (Eng. Abstr.) **(Ger)**

[Is there a need for treatment in subclinical hypo- and hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369–73 (15 ref.) (Eng. Abstr.) **(Ger)**

[Hyperthyroidism--advantages and disadvantages of pharmacologic, surgical, and radioactive iodine treatments] Meier CA. **Ther Umsch** 1999 Jul;56(7):364–8 (9 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of autonomic nervous system function with heart rate variability analysis in patients with hyperthyroidism and during euthyroidism after pharmacologic and surgical treatment] Barczyński M, et al. **Folia Med Cracov** 1997; 38(3–4):27–35 (Eng. Abstr.) **(Pol)**

[Practical aspects of iodine-131 therapy of hyperthyroidism] Rogowski F, et al. **Pol Merkuriusz Lek** 1999 Jun; 6(36):347–51 (36 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of hyperthyroidism (editorial)] Donoso J. **Rev Med Chil** 1998 Aug;126(8):895–7 (Eng. Abstr.) **(Spa)**

VETERINARY

Effects of induced hypothyroidism or hyperthyroidism on growth and reproductive performance of Brahman heifers. Thrift TA, et al. **J Anim Sci** 1999 Jul;77(7):1833–43

Spontaneous hyperthyroidism in an aged male and female Macaca mulatta. Brammer DW, et al. **J Med Primatol** 1998 Dec;27(6):273–7

Use of propranolol and potassium iodate in the presurgical management of hyperthyroid cats. Foster DJ, et al. **J Small Anim Pract** 1999 Jul;40(7):307–15

Evaluation of environmental, nutritional, and host factors in cats with hyperthyroidism. Kass PH, et al. **J Vet Intern Med** 1999 Jul–Aug;13(4):323–9

Hyperthyroidism associated with a thyroid adenocarcinoma in a 21-year-old gelding. Ramirez S, et al. **J Vet Intern Med** 1998 Nov–Dec;12(6):475–7

Overexpression of c-Ras in hyperplasia and adenomas of the feline thyroid gland: an immunohistochemical analysis of 34 cases. Merryman JI, et al. **Vet Pathol** 1999 Mar; 36(2):117–24

[Radioiodine therapy in veterinary medicine: treatment of hyperthyroidism in a cat] Reinartz P, et al. **Nuklearmedizin** 1999;38(1):31–4 (Eng. Abstr.) **(Ger)**

HYPERTHYROXINEMIA

COMPLICATIONS

Immunologic and biochemical factors in hyperemesis gravidarum with or without hyperthyroxinemia. Leylek OA, et al. **Gynecol Obstet Invest** 1999;47(4):229–34

[Hyperthyroxinemia and clinical euthyroidism. Report of one case] López JM, et al. **Rev Med Chil** 1999 Feb; 127(2):197–201 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Gestational transient hyperthyroxinaemia (GTH): screening for thyroid function in 23,163 pregnant women using dried blood spots. Tanaka S, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):325–9

[Pseudohyperthyroxinemia in endemic sprue--reversibility with a gluten-free diet] Bätge B, et al. **Dtsch Med Wochenschr** 1998 Oct 23;123(43):1269–73 (Eng. Abstr.) **(Ger)**

GENETICS

Structural investigations of a new familial dysalbuminemic hyperthyroxinemia genotype. Petersen CE, et al. **Clin Chem** 1999 Aug;45(8 Pt 1):1248–54

HYPERTONIC GLUCOSE SOLUTION see **GLUCOSE SOLUTION, HYPERTONIC**

HYPERTONIC SALINE SOLUTION see **SALINE SOLUTION, HYPERTONIC**

HYPERTONIC SOLUTION, GLUCOSE see **GLUCOSE SOLUTION, HYPERTONIC**

HYPERTONIC SOLUTION, SALINE see **SALINE SOLUTION, HYPERTONIC**

HYPERTONIC SOLUTIONS

A clinical trial of hypertonic saline nasal spray [letter; comment] Carlston M. **Arch Fam Med** 1999 Mar–Apr; 8(2):100. Comment on: Arch Fam Med 1998 Jan–Feb;7(1):39–43.

Hypothermic preservation of isolated rat lungs in modified bicarbonate buffer, EuroCollins solution or St Thomas' Hospital cardioplegic solution. Featherstone RL, et al. **Eur J Cardiothorac Surg** 1998 Nov;14(5):508–15

Acute and chronic effects of hyperosmolality on mRNA and protein expression and the activity of Na-K-ATPase in the IMCD. Takayama M, et al. **Exp Nephrol** 1999 Jul–Aug; 7(4):295–305

Rebound intracranial hypertension in dogs after resuscitation with hypertonic solutions from hemorrhagic shock accompanied by an intracranial mass lesion. Prough DS, et al. **J Neurosurg Anesthesiol** 1999 Apr;11(2):102–11

Hypertonic-hyperoncotic solutions in open-heart surgery. Tølløfsrud S, et al. **Perfusion** 1998 Sep;13(5):289–96 (43 ref.)

Cellular response to osmotic stress in the renal medulla. Beck FX, et al. **Pflugers Arch** 1998 Nov;436(6):814–27 (153 ref.)

University of Wisconsin versus Eurocollins solution for kidney preservation: analysis of clinical outcome. Alshaibani K, et al. **Transplant Proc** 1998 Nov;30(7):3681–2

Preservation with a retrograde second flushing of Eurocollins in clinical lung transplantation. Alvarez A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1088–90

Transalveolar fluid absorption ability in rat lungs preserved with Euro-Collins solution and EP4 solution [published erratum appears in Transplantation 1999 Aug 15;68(3):454] Sugita M, et al. **Transplantation** 1999 Feb 15;67(3):349–54

ADMINISTRATION & DOSAGE

Hyponatraemia after orthopaedic surgery. Rigorous audit and introduction of guidelines decreased hospital's figures [letter] Marino A, et al. **BMJ** 1999 Aug 21;319(7208):515; discussion 516

Preimplantation retrograde pneumoplegia in clinical lung transplantation. Venuta F, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):107–14

Renal failure in surgical patients. Treatment with intravenous essential amino acids and hypertonic glucose. Dudrick SJ, et al. **Surgery** 1970 Jul;68(1):180–5; discussion 185–6

PHARMACOLOGY

Preoptic recess noradrenergic receptors control modification of baroreflex sensitivity by hypertonicity. Bealer SL. **Am J Physiol** 1999 Jan;276(1 Pt 2):R44–51

In vivo and in vitro induction of c-fos in avian exocrine salt gland cells. Hildebrandt JP, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):C951–7

Characterization of the hypertonically induced tyrosine phosphorylation of erythrocyte band 3. Minetti G, et al. **Biochem J** 1998 Oct 15;335 (Pt 2):305–11

Comparison of euro-collins solution, low-potassium dextran solution containing glucose, and ET-kyoto solution for lung preservation in an extracorporeal rat lung perfusion model. Bando T, et al. **Eur Surg Res** 1998;30(5):297–304

Facilitation of gastric motility induced by portal infusion of hyper- and hypotonic solution in rats. Kobashi M, et al. **J Auton Nerv Syst** 1998 Nov 10;73(2–3):156–62

Z/I and A-band lattice spacings in frog skeletal muscle: effects of contraction and osmolarity. Irving TC, et al. **J Muscle Res Cell Motil** 1998 Oct;19(7):811–23

Superior protection in orthotopic rat lung transplantation with cyclic adenosine monophosphate and nitroglycerin-containing preservation solution. Kayano K, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):135–44

Hypertonicity prevents lipopolysaccharide-stimulated CD11b/CD18 expression in human neutrophils in vitro: role for p38 inhibition. Rizoli SB, et al. **J Trauma** 1999 May;46(5):794–8; discussion 798–9

Roles of vasopressin and hypertonicity in basolateral Na/K/2Cl cotransporter expression in rat kidney inner medullary collecting duct cells. Anzai N, et al. **Jpn J Physiol** 1999 Apr;49(2):201–6

Hypertonicity-induced accumulation of organic osmolytes in papillary interstitial cells. Burger-Kentischer A, et al. **Kidney Int** 1999 Apr;55(4):1417–25

Adaptation of Madin-Darby canine kidney cells to hypertonic medium: an electron microprobe analysis. Borgmann S, et al. **Kidney Int Suppl** 1998 Sep;67:S133–5

A comparison of the new preservation solution Celsior to Euro-Collins and University of Wisconsin solutions in lung reperfusion injury. Roberts RF, et al. **Transplantation** 1999 Jan 15;67(1):152–5

Evaluation of in vivo and in vitro quality of apheresis-collected RBC stored for 42 days. Holme S, et al. **Vox Sang** 1998;75(3):212–7

HYPERTRICHOSIS

see related
HIRSUTISM

COMPLICATIONS

Acquired trichomegaly of the eyelashes in a child with human immunodeficiency virus infection [letter] Patrizi A, et al. **J Eur Acad Dermatol Venereol** 1998 Jul;11(1):89–91

CONGENITAL

Congenital hypertrichosis, osteochondrodysplasia, and cardiomegaly: Cantú syndrome. Robertson SP, et al. **Am J Med Genet** 1999 Aug 6;85(4):395–402

Shaving: a simple and effective treatment for moderate congenital hypertrichosis. Plantin P, et al. **Eur J Dermatol** 1998 Apr–May;8(3):189–90

DIAGNOSIS

Simultaneous occurrence of segmental odontomaxillary dysplasia and Becker's nevus. Jones AC, et al. **J Oral Maxillofac Surg** 1999 Oct;57(10):1251–4 (17 ref.)

DRUG THERAPY

Depilation in a 6-month-Old with hypertrichosis: A case report. Wendelin DS, et al. **Pediatr Dermatol** 1999 Jul–Aug; 16(4):311–3

GENETICS

A new case of Ambras syndrome associated with a paracentric inversion (8) (q12; q22). Balducci R, et al. **Clin Genet** 1998 Jun;53(6):466–8

PATHOLOGY

Nevoid hypertrichosis with multiple patches of hair that underwent almost complete spontaneous resolution. Dudding TE, et al. **Am J Med Genet** 1998 Sep 23; 79(3):195–6 (12 ref.)

SURGERY

Solar-induced postinflammatory hyperpigmentation after laser hair removal. Hasan AT, et al. **Dermatol Surg** 1999 Feb;25(2):113–5

THERAPY

Hair removal with a non-coherent filtered flashlamp intense pulsed light source. Weiss RA, et al. **Lasers Surg Med** 1999; 24(2):128–32

Optical hair removal. Ort RJ, et al. **Semin Cutan Med Surg** 1999 Jun;18(2):149–58 (42 ref.)

[Androgenetic alopecia, hirsutism and hypertrichosis] Trüeb RM, et al. **Ther Umsch** 1999 Apr;56(4):219–24 (21 ref.) (Eng. Abstr.) **(Ger)**

HYPERTRIGLYCERIDEMIA

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Grundy SM. **Am J Cardiol** 1999 May 13; 83(9B):25F–29F (63 ref.)

Recurrent excessive transient hypertriglyceridaemia [letter] Meissner T, et al. **Eur J Pediatr** 1999 Aug;158(8):683

BLOOD

Effects of hypertriglyceridemia on platelet counts in automated hematologic analysis [letter] Kabutomori O, et al. **Ann Intern Med** 1999 Mar 2;130(5):452

Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Pownall HJ, et al. **Arch Intern Med** 1999 May 10;159(9):981–7

HYPERTRIGLYCERIDEMIA

Comparison of 2 homogeneous high-density lipoprotein cholesterol assays. Hoang MP, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):1005-9

In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase. Chung BH, et al. **Atherosclerosis** 1998 Dec;141(2):209-25

Quantification of lipoprotein(a) and apolipoprotein(a) in plasma and lipoprotein fractions in the hypertriglyceridemic state. Reblin T, et al. **Atherosclerosis** 1999 Jul;145(1):71-9

Monounsaturated diet lowers LDL oxidisability in type IIb and type IV dyslipidemia without affecting coenzyme Q10 and vitamin E contents. Svegliati Baroni S, et al. **Biofactors** 1999;9(2-4):325-30

Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol [letter; comment] von Eckardstein A, et al. **Circulation** 1999 Apr 13;99(14):1925. Comment on: Circulation 1998 Mar 24;97(11):1029-36.

Effects of postprandial hyperlipemia on the vitamin E content of lipoproteins. GERBAP section Lipoprotéines. Groupe d'Evaluation et de Recherche de l'Assistance Publique des Hôpitaux de Paris. Couderc R, et al. **Clin Chim Acta** 1998 Oct;277(2):141-52

HDL metabolism in hypertriglyceridemic states: an overview. Lamarche B, et al. **Clin Chim Acta** 1999 Aug; 286(1-2):145-61 (74 ref.)

Studies in hypertriglyceridaemia. VI: Serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. Asplund-Carlson A, et al. **J Intern Med** 1999 Mar; 245(3):247-52

Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-gamma. Whitman SC, et al. **J Lipid Res** 1999 Jun;40(6):1017-28

(n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. Tinker LF, et al. **J Nutr** 1999 Jun;129(6):1126-34

n-3 fatty acids and human lipoprotein metabolism: an update. Harris WS. **Lipids** 1999;34 Suppl:S257-8

Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Karpe F, et al. **Metabolism** 1999 Mar;48(3):301-7

Hemostatic factors in hypertriglyceridemic men: effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate. Orth M, et al. **Thromb Res** 1999 Jun 15;94(6):341-51

[Comparison of LDL-C values measured with the automated method and the ultracentrifugation method in severe hypertriglyceridemia, and prevalence and life-style of patients with hypertriglyceridemia] Okubo S, et al. **Rinsho Byori** 1999 Mar;47(3):275-80 (Eng. Abstr.) **(Jpn)**

[Hypertriglyceridemia during active intercurrent infections in HIV-infected patients] Montero A, et al. **Gac Med Mex** 1999 Jan-Feb;135(1):5-9 (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients [letter] Hewitt RG, et al. **AIDS** 1999 May 7;13(7):868-9

Marked hypertriglyceridaemia associated with ritonavir therapy [letter] Sullivan AK, et al. **AIDS** 1998 Jul 30; 12(11):1393-4

Clozapine-associated elevation in serum triglycerides. Gaulin BD, et al. **Am J Psychiatry** 1999 Aug;156(8):1270-2

Olanzapine-induced elevation of plasma triglyceride levels [letter] Sheitman BB, et al. **Am J Psychiatry** 1999 Sep; 156(9):1471-2

Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia. Amin SB, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):795-800

The use of soy protein isolate to reduce the severity of 13-cis retinoic acid-induced hypertriglyceridemia. Radcliffe JD, et al. **Cancer Detect Prev** 1998;22(6):526-32

Ritonavir, triglycerides, and pancreatitis. Perry RC, et al. **Clin Infect Dis** 1999 Jan;28(1):161-2

Severe hypertriglyceridaemia in a non-diabetic patient after alpha-interferon [letter] Elisaf M, et al. **Eur J Gastroenterol Hepatol** 1999 Apr;11(4):463

Tamoxifen and hypertriglyceridemia [letter] [see comments] Jonkers GH. **Neth J Med** 1999 Aug;55(2):84-5. Comment in: Neth J Med 1999 Aug;55(2):47-9.

Partial replacement of dietary casein with soy protein isolate can reduce the severity of retinoid-induced hypertriglyceridemia. Radcliffe JD, et al. **Plant Foods Hum Nutr** 1998;52(2):97-108

Drug-induced hypertriglyceridemia with and without pancreatitis. Keung YK, et al. **South Med J** 1999 Sep; 92(9):912-4 (22 ref.)

Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Brattström C, et al. **Transplant Proc** 1998 Dec;30(8):3950-1

[Severe hypertriglyceridemia induced by tamoxifen] Taira M, et al. **Nippon Ronen Igakkai Zasshi** 1998 Nov; 35(11):858-60 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Epidemiology of hypertriglyceridemia and cardiovascular disease. Austin MA. **Am J Cardiol** 1999 May 13; 83(9B):13F-16F

Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Brewer HB Jr. **Am J Cardiol** 1999 May 13;83(9B):3F-12F (116 ref.)

Triglycerides as a risk factor for coronary artery disease. Sprecher DL. **Am J Cardiol** 1998 Dec 17; 82(12A):49U-56U; discussion 85U-86U (20 ref.)

Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia [letter] [see comments] Ford P, et al. **Anaesth Intensive Care** 1998 Oct;26(5):598. Comment in: Anaesth Intensive Care 1999 Feb;27(1):117.

Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia [letter; comment] Ho KM, et al. **Anaesth Intensive Care** 1999 Feb;27(1):117. Comment on: Anaesth Intensive Care 1998 Oct;26(5):598.

Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol [letter; comment] von Eckardstein A, et al. **Circulation** 1999 Apr 13;99(14):1925. Comment on: Circulation 1998 Mar 24;97(11):1029-36.

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Gianturco SH, et al. **Clin Cardiol** 1999 Jun;22(6 Suppl):II7-14 (55 ref.)

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Hodis HN, et al. **Clin Cardiol** 1999 Jun;22(6 Suppl):II15-20 (15 ref.)

Autonomic neuropathy in Type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Gottsäter A, et al. **Diabet Med** 1999 Jan;16(1):49-54

Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia. Tai ES, et al. **Diabetes** 1999 May;48(5):1088-92

Dyslipidemia of central obesity and insulin resistance. Brunzell JD, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C10-3 (69 ref.)

Hypertriglyceridemia may cause a subclinical peripheral neuropathy. Drory VE, et al. **Electromyogr Clin Neurophysiol** 1999 Jan-Feb;39(1):39-41

Spuriously normal amylase levels in a patient with acute pancreatitis secondary to hypertriglyceridemia. Okerberg K, et al. **J Am Board Fam Pract** 1999 Jan-Feb;12(1):68-70

Hypertriglyceridaemia in mild hypertension: impact on cardiovascular and hormonal reactivity under different stress tests. Scheuch K, et al. **J Hum Hypertens** 1999 Aug; 13(8):533-9

Studies in hypertriglyceridaemia. VI: Serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. Asplund-Carlson A, et al. **J Intern Med** 1999 Mar; 245(3):247-52

[Serum triglycerides as a risk factor for atherosclerosis] Stalenhoef AF. **Ned Tijdschr Geneeskd** 1999 Feb 6; 143(6):284-7 (20 ref.) (Eng. Abstr.) **(Dut)**

[Hypertriglyceridemia in acute pancreatitis: cause or epiphenomenon? (editorial)] Ammann RW. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1239-41 **(Ger)**

[Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis] Henzen C, et al. **Schweiz Med Wochenschr** 1999 Sep 4;129(35):1242-8 (Eng. Abstr.) **(Ger)**

[Hypertriglyceridemias] Silva JM, et al. **Rev Port Cardiol** 1999 Apr;18(4):419-29 (107 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

[What about hyperglycerolemia? (letter)] Casamayou H, et al. **Presse Med** 1999 Jan 9;28(1):17 **(Fre)**

DIET THERAPY

Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils. Harris WS. **Clin Cardiol** 1999 Jun;22(6 Suppl):II40-3 (11 ref.)

Dietary counselling effectively improves lipid levels in patients with endogenous hypertriglyceridemia: emphasis on weight reduction and alcohol limitation. de Man FH, et al. **Eur J Clin Nutr** 1999 May;53(5):413-8

Fish oil in hypertriglyceridemia: safety and recommendations. Connor WE. **Lipids** 1999;34 Suppl:S271

Equal antithrombotic and triglyceride-lowering effectiveness of eicosapentaenoic acid-rich and docosahexaenoic acid-rich fish oil supplements. Howe PR, et al. **Lipids** 1999; 34 Suppl:S307-8

DRUG THERAPY

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients [letter] Hewitt RG, et al. **AIDS** 1999 May 7;13(7):868-9

Role of fibrates in the management of hypertriglyceridemia. Rader DJ, et al. **Am J Cardiol** 1999 May 13;83(9B):30F-35F (58 ref.)

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Davidson MH, et al. **Arch Intern Med** 1999 Sep 13;159(16):1893-900

Effects of fibric acid derivatives and metformin on postprandial lipemia. Weintraub MS, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S71-5

Pharmacologic management of triglycerides. Hunninghake DB. **Clin Cardiol** 1999 Jun;22(6 Suppl):II44-8 (10 ref.)

Relevance of the reduction of triglycerides in the prevention of coronary heart disease. Kesäniemi YA. **Curr Opin Lipidol** 1998 Dec;9(6):571-4 (19 ref.)

Therapy and clinical trials [editorial] Ogunko A, et al. **Curr Opin Lipidol** 1998 Dec;9(6):617-8

Beneficial effects of acarbose on familiar hypertriglyceridemias. Malaguarnera M, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):441-5

Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. Kugiyama K, et al. **J Am Coll Cardiol** 1999 May;33(6):1512-8

Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. Jabbar MA, et al. **J Am Coll Nutr** 1998 Oct;17(5):458-61

Safety and efficacy of Omacor in severe hypertriglyceridemia. Harris WS, et al. **J Cardiovasc Risk** 1997 Oct-Dec;4(5-6):385-91

Serum homocysteine increases after therapy with fenofibrate or bezafibrate [letter] Dierkes J, et al. **Lancet** 1999 Jul 17; 354(9174):219-20

n-3 fatty acids and human lipoprotein metabolism: an update. Harris WS. **Lipids** 1999;34 Suppl:S257-8

Exogenous estrogens, antiestrogens and lipid metabolism [editorial; comment] Dullaart RP. **Neth J Med** 1999 Aug; 55(2):47-9. Comment on: Neth J Med 1999 Aug;55(2):84-5.

Tamoxifen and hypertriglyceridemia [letter] [see comments] Jonkers GH. **Neth J Med** 1999 Aug;55(2):84-5. Comment in: Neth J Med 1999 Aug;55(2):47-9.

Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients. Lee MS, et al. **Perit Dial Int** 1999 May-Jun;19(3):280-3

Hypotriglyceridaemic activity of Ficus carica leaves in experimental hypertriglyceridaemic rats. Pérez C, et al. **Phytother Res** 1999 May;13(3):188-91

[Benfluorex (Mediator): non-insulin-dependent diabetes and hypertriglyceridemia] Drain P. **Journ Annu Diabetol Hotel Dieu** 1998;:339-46 (15 ref.) **(Fre)**

[Treatment of combined hyperlipidemia: fibrate and/or statin?] Scheen AJ. **Rev Med Liege** 1999 Jul;54(7):583-7 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The epidemiology of triglyceride as a coronary artery disease risk factor. Miller M. **Clin Cardiol** 1999 Jun;22(6 Suppl):II1-6 (22 ref.)

Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Miller M. **Eur Heart J** 1998 Jul;19 Suppl H:H18-22 (26 ref.)

ETIOLOGY

Hyperlipidaemia in hyperuricaemia and gout. Emmerson B. **Ann Rheum Dis** 1998 Sep;57(9):509-10

Very-low fat diets [letter] Baschetti R. **Circulation** 1999 Aug 31;100(9):1013; discussion 1014-5

Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Hoffer MJ, et al. **Eur J Clin Invest** 1998 Oct;28(10):807-12

[A study of hypertriglyceridemia occurring in patients with chronic hepatitis C during administration of interferon beta] Kioka K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Apr;96(4):392-7 (Eng. Abstr.) **(Jpn)**

GENETICS

Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Axelsen M, et al. **Ann Intern Med** 1999 Jul 6; 131(1):27-31

Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. Grenett HE, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov; 18(11):1803-9

Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Ishiyama-Shigemoto S, et al. **Diabetologia** 1999 Jan;42(1):98-101

Defect in long-term activation of phosphatidylinositol 3-kinase by insulin in vivo: studies in insulin-resistant hHTg rats. Sebokova E, et al. **Endocr Regul** 1999 Jun; 33(2):49-54

The familial chylomicronemia syndrome. Santamarina-Fojo S. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):551-67, viii (146 ref.)

Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. Boisfer E, et al. **J Biol Chem** 1999 Apr 23;274(17):11564-72

METABOLISM

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Davidson MH, et al.

Arch Intern Med 1999 Sep 13;159(16):1893–900

Effects of fibric acid derivatives and metformin on postprandial lipemia. Weintraub MS, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S71–5

A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome [see comments] Wareham NJ, et al. **Br J Nutr** 1998 Sep;80(3):235–41. Comment in: Br J Nutr 1998 Sep;80(3):215–6.

The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. White DA, et al. **Br J Nutr** 1998 Sep;80(3):219–29 (67 ref.)

Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Hodis HN, et al. **Clin Cardiol** 1999 Jun;22(6 Suppl):II15–20 (15 ref.)

Propofol and hypertriglyceridemia: no problem? [letter; comment] Barrachina F, et al. **Crit Care Med** 1999 Jan; 27(1):224–5. Comment on: Crit Care Med 1997 Dec;25(12):1976–81.

Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. Quaschning T, et al. **J Am Soc Nephrol** 1999 Feb;10(2):332–41

Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. Huang Y, et al. **J Biol Chem** 1998 Oct 9;273(41):26388–93

The fatty liver dystrophy mutant mouse: microvesicular steatosis associated with altered expression levels of peroxisome proliferator-regulated proteins. Rehnmark S, et al. **J Lipid Res** 1998 Nov;39(11):2209–17

Exogenous estrogens, antiestrogens and lipid metabolism [editorial; comment] Dullaart RP. **Neth J Med** 1999 Aug; 55(2):47–9. Comment on: Neth J Med 1999 Aug;55(2):84–5.

Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate. Nagyová A, et al. **Physiol Res** 1998;47(3):185–90

PATHOLOGY

Images in clinical medicine. Lipemia retinalis. Fred HL, et al. **N Engl J Med** 1999 Jun 24;340(25):1969

PHYSIOPATHOLOGY

Insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Nava P, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H399–404

Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. Lewis TV, et al. **J Am Coll Cardiol** 1999 Mar;33(3):805–12

Postprandial hypertriglyceridemia induced by saturated vs. monounsaturated fatty acids is related to reduced hepatic lipoprotein receptors binding in NZW rabbits. Harbis A, et al. **Lipids** 1999;34 Suppl:S125–6

PREVENTION & CONTROL

Association of etretinate and fish oil in psoriasis therapy. Inhibition of hypertriglyceridemia resulting from retinoid therapy after fish oil supplementation. Frati C, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:151–3

The use of soy protein isolate to reduce the severity of 13-cis retinoic acid-induced hypertriglyceridemia. Radcliffe JD, et al. **Cancer Detect Prev** 1998;22(6):526–32

Fish oil in hypertriglyceridemia: safety and recommendations. Connor WE. **Lipids** 1999;34 Suppl:S271

Equal antithrombotic and triglyceride-lowering effectiveness of eicosapentaenoic acid-rich and docosahexaenoic acid-rich fish oil supplements. Howe PR, et al. **Lipids** 1999; 34 Suppl:S307–8

Triglyceride-lowering effect of n-3 long chain polyunsaturated fatty acid: eicosapentaenoic acid vs. docosahexaenoic acid. Weber P. **Lipids** 1999;34 Suppl:S269

RADIONUCLIDE IMAGING

Insulin action on heart and skeletal muscle FDG uptake in patients with hypertriglyceridaemia. Yokoyama I, et al. **J Nucl Med** 1999 Jul;40(7):1116–21

THERAPY

Plasmapheresis in the management of pancreatitis related to hypertriglyceridaemia [letter] [see comments] Ford P, et al. **Anaesth Intensive Care** 1998 Oct;26(5):598. Comment in: Anaesth Intensive Care 1999 Feb;27(1):117.

HYPERTRIGLYCERIDEMIA, FAMILIAL see **HYPERLIPOPROTEINEMIA TYPE IV**

HYPERTROPHY

CHEMICALLY INDUCED

Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. Peiró C, et al. **Br J Pharmacol** 1998 Oct;125(4):637–44

Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD+ pathway. Shin M, et al. **Toxicol Appl Pharmacol** 1999 Jul 1;158(1):71–80

The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51

DIAGNOSIS

Clinical differentiation between Proteus syndrome and hemihyperplasia: description of a distinct form of hemihyperplasia. Biesecker LG, et al. **Am J Med Genet** 1998 Oct 2;79(4):311–8

EPIDEMIOLOGY

Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Hoyme HE, et al. **Am J Med Genet** 1998 Oct 2;79(4):274–8 (43 ref.)

ETIOLOGY

Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. Ushio-Fukai M, et al. **J Biol Chem** 1999 Aug 6;274(32):22699–704

PATHOLOGY

The quantitative distinction of hyperplasia from hypertrophy in hepatomegaly induced in the rat liver by phenobarbital. Carthew P, et al. **Toxicol Sci** 1998 Jul;44(1):46–51

HYPERTROPHY, LEFT VENTRICULAR

Hemodynamics and left ventricular mass regression following implantation of the Toronto SPV stentless porcine valve. Bach DS, et al. **Am J Cardiol** 1998 Nov 15;82(10):1214–9

Screening and treatment for cardiovascular disease in patients with chronic renal disease. Murphy SW, et al. **Am J Kidney Dis** 1998 Nov;32(5 Suppl 3):S184–99 (141 ref.)

Why is left ventricular hypertrophy so predictive of morbidity and mortality? Benjamin EJ, et al. **Am J Med Sci** 1999 Mar;317(3):168–75 (79 ref.)

Determinants of left ventricular mass in a French male population. Thomas F, et al. **Blood Press** 1999;8(2):79–84

Home blood pressure measurement: reproducibility and relationship with left ventricular mass. Kok RH, et al. **Blood Press Monit** 1999 Apr;4(2):65–9

Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Manunta P, et al. **Hypertension** 1999 Sep;34(3):450–6

BLOOD

Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. Masciotra S, et al. **Circ Res** 1999 Jun 25;84(12):1453–8

Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population [see comments] Schirmer H, et al. **Eur Heart J** 1999 May;20(10):755–63. Comment in: Eur Heart J 1999 May;20(10):712–4.

Further defining the role for natriuretic peptide levels in clinical practice [editorial; comment] Struthers AD. **Eur Heart J** 1999 May;20(10):712–4. Comment on: Eur Heart J 1999 May;20(10):755–63.

CHEMICALLY INDUCED

Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use. Dickerman RD, et al. **Cardiology** 1998 Oct;90(2):145–8

COMPLICATIONS

The combination of risk factors for sudden death in a resuscitated elderly patient with an exceptional cause of left ventricular hypertrophy. Tavernier R, et al. **Acta Cardiol** 1999 Feb;54(1):41–3

Left ventricular hypertrophy as a risk factor in hypertension. Balogun MO, et al. **Afr J Med Med Sci** 1996 Sep; 25(3):277–83 (67 ref.)

Association of left ventricular dilatation and hypertrophy with chronotropic incompetence in the Framingham Heart Study. Lauer MS, et al. **Am Heart J** 1999 May;137(5):903–9

Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2,384 older persons. Aronow WS, et al. **Am J Cardiol** 1999 Aug 15;84(4):468–9, A9

Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Kohara K, et al. **Am J Cardiol** 1999 Feb 1; 83(3):367–70

Mechanisms and models in heart failure: A combinatorial approach. Mann DL. **Circulation** 1999 Aug 31; 100(9):999–1008 (78 ref.)

Arrhythmogenic effect of ventriculography in patients with left ventricular dilation and/or hypertrophy. Serafi AS, et al. **Clin Sci (Colch)** 1998 Oct;95(4):453–8

QT dispersion as a marker of left ventricular mass in essential hypertension. Maheshwari VD, et al. **Indian Heart J** 1998 Jul-Aug;50(4):414–7

Left ventricular hypertrophy and sudden death [editorial; comment] [see comments] Frohlich ED. **J Am Coll Cardiol** 1998 Nov;32(5):1460–2. Comment on: J Am Coll Cardiol 1998 Nov;32(5):1454–9. Comment in: J Am Coll Cardiol 1999 Jun;33(7):2089.

Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death [see comments] Haider AW, et al. **J Am Coll Cardiol** 1998 Nov; 32(5):1454–9. Comment in: J Am Coll Cardiol 1998 Nov;32(5):1460–2. Comment in: J Am Coll Cardiol 1999 Jun;33(7):2089.

Left ventricular hypertrophy and sudden death [letter; comment] Spencer CG, et al. **J Am Coll Cardiol** 1999 Jun; 33(7):2089. Comment on: J Am Coll Cardiol 1998 Nov;32(5):1454–9. Comment on: J Am Coll Cardiol 1998 Nov;32(5):1460–2.

Association of electrocardiographic left ventricular hypertrophy with the incidence of new congestive heart failure. Aronow WS, et al. **J Am Geriatr Soc** 1998 Oct; 46(10):1280–1

Comparison based on age of baseline electrocardiographic abnormalities in non-Q-wave myocardial infarction. VANQWISH Trial Research Investigators. Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital. Stratmann HG, et al. **J Am Geriatr Soc** 1999 Jul;47(7):870–2

Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. Watanabe K, et al. **J Hypertens** 1999 Aug;17(8):1153–60

Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction. Huang MW, et al. **J Surg Res** 1999 Sep;86(1):89–96

Left ventricular hypertrophy in renal failure. Amann K, et al. **Kidney Int Suppl** 1998 Dec;68:S78–85 (43 ref.)

Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Lopez-Gomez JM, et al. **Kidney Int Suppl** 1998 Dec;68:S92–8 (74 ref.)

Hypertensive cardiomyopathy relieved by pacing? [letter; comment] DeSilvey DL. **Mil Med** 1999 May;164(5):318. Comment on: Mil Med 1998 Dec;163(12):861–3.

Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Ecder T, et al. **Nephrol Dial Transplant** 1999 May;14(5):1113–6

[Left ventricular hypertrophy and cardiovascular risk in hypertension] Amabile G. **Ann Cardiol Angeiol (Paris)** 1998 Feb;47(2):86–90 (52 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of the cardiovascular risk in hypertensive patients: left ventricular hypertrophy] Gosse P, et al. **Arch Mal Coeur Vaiss** 1998 Sep;91 Suppl:19–22 (18 ref.) (Eng. Abstr.) **(Fre)**

[Dipyridamole-echocardiography and thallium exercise myocardial scintigraphy in the diagnosis of obstructive coronary or microvascular disease in hypertensive patients with left ventricular hypertrophy and angina] Astarita C, et al. **G Ital Cardiol** 1998 Sep;28(9):996–1004 (Eng. Abstr.) **(Ita)**

[Presence and severity of carotid atherosclerosis in asymptomatic hypertension patients with left ventricular hypertrophy] Guarini P, et al. **G Ital Cardiol** 1999 Aug; 29(8):910–4 (Eng. Abstr.) **(Ita)**

[Influence of left ventricular wall thickening on myocardial injury in aortic valve replacement] Hosono M, et al. **Kyobu Geka** 1998 Dec;51(13):1099–103 (Eng. Abstr.) **(Jpn)**

[Myocardial hypertrophy and coronary insufficiency as a cause of arrhythmia in patients with hypertension] Israpilov MM, et al. **Ter Arkh** 1999;71(4):37–40 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Insulin resistance syndrome and left ventricular mass in an elderly population (The Rotterdam Study). Rheeder P, et al. **Am J Cardiol** 1999 Jul 15;84(2):233–6, A9

Electrocardiographic left ventricular hypertrophy in chest pain patients: differentiation from acute coronary ischemic events. Brady WJ. **Am J Emerg Med** 1998 Nov;16(7):692–6

Utility of electrocardiogram for predicting increased left ventricular mass in asymptomatic men at risk for cardiovascular disease. Denarié N, et al. **Am J Hypertens** 1998 Jul;11(7):861–5

Medium-term determinants of left ventricular mass index after stentless aortic valve replacement. Jin XY, et al. **Ann Thorac Surg** 1999 Feb;67(2):411–6

Influence of cigarette smoking on the electrocardiographic diagnosis of left ventricular hypertrophy in arterial hypertension. Schillaci G, et al. **G Ital Cardiol** 1999 Jan; 29(1):34–8

Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension. Tomita S, et al. **Hypertens Res** 1998 Dec;21(4):259–66

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Dahlöf B, et al. **Hypertension** 1998 Dec;32(6):989–97

QT dispersion as a marker of left ventricular mass in essential hypertension. Maheshwari VD, et al. **Indian Heart J** 1998 Jul-Aug;50(4):414–7

Electrocardiographic left ventricular hypertrophy by five criteria among civil servants in Benin City, Nigeria: prevalence and correlates. Huston SL, et al. **Int J Cardiol** 1999 Jul 1;70(1):1–14

Comparison based on age of baseline electrocardiographic abnormalities in non-Q-wave myocardial infarction. VANQWISH Trial Research Investigators. Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital. Stratmann HG, et al. **J Am Geriatr Soc** 1999 Jul;47(7):870–2

Physical finding: pulsus alternans. Talley JD.

J Ark Med Soc 1999 May;95(12):541-2

Left ventricular mass in hypertrophic cardiomyopathy: assessment by three-dimensional and geometric MR methods. Soler R, et al. **J Comput Assist Tomogr** 1999 Jul-Aug;23(4):577-82

Electrocardiographic patterns of patients with echocardiographically determined biventricular hypertrophy. Jain A, et al. **J Electrocardiol** 1999 Jul; 32(3):269-73

Value of ambulatory intra-arterial blood pressure monitoring in the long-term prediction of left ventricular hypertrophy and carotid atherosclerosis in essential hypertension [see comments] Khattar RS, et al. **J Hum Hypertens** 1999 Feb; 13(2):111-6. Comment in: J Hum Hypertens 1999 Feb;13(2):81-3.

Prediction of cardiovascular damage in hypertensive patients: clinic or ambulatory blood pressures? [comment] Stanton AV. **J Hum Hypertens** 1999 Feb;13(2):81-3 (11 ref.). Comment on: J Hum Hypertens 1999 Feb;13(2):111-6.

Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. Gosse P, et al. **J Hypertens** 1998 Apr; 16(4):531-5

Detection of left ventricular enlargement by electrocariography. Tamama K, et al. **J Med** 1998; 29(3-4):231-6

Urinary albumin excretion in hospitalized patients with acute myocardial infarction. Prevalence of microalbuminuria and correlation to left ventricle wall thickness. Taskiran M, et al. **Scand Cardiovasc J** 1998;32(3):163-6

Cardiac dysrrhthmia in systemic disease. Quek SC, et al. **Singapore Med J** 1998 Sep;39(9):426-7

[Cardiac manifestations of polymyositis. Apropos of 2 Senegalese cases] Cloatre G, et al. **Rev Med Interne** 1998 Apr;19(4):265-70 (Eng. Abstr.) **(Fre)**

[Electro-cardiographic correlation in the diagnosis of left ventricular hypertrophy] Domingos H, et al. **Arq Bras Cardiol** 1998 Jul;71(1):31-5 (Eng. Abstr.) **(Por)**

[Late ventricular potentials in left ventricular hypertrophy in patients with stage-II hypertension] Israpilov MM, et al. **Ter Arkh** 1999;71(2):64-6 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Effects of spironolactone-altizide on left ventricular hypertrophy. Degre S, et al. **Acta Cardiol** 1998;53(5):261-7

Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Schlaich MP, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1394-404 (90 ref.)

Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Park CW, et al. **Am J Kidney Dis** 1999 Jan;33(1):73-81

Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Kohno M, et al. **Am J Med** 1999 May;106(5):544-9

Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits. Rials SJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1216-24

Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Massimetti C, et al. **Blood Purif** 1998;16(6):317-24

Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. Cheung BM, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):179-87

Regression of left ventricular hypertrophy: what are appropriate therapeutic objectives? Sheridan DJ, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):125-30 (84 ref.)

Single-drug therapy and reduction of left ventricular mass in hypertension. Gottdiener JS. **Cardiologia** 1998 Nov; 43(11):1177-83 (68 ref.)

Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. Thürmann PA. **Cardiology** 1999; 91 Suppl 1:3-7

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Mitsunami K, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):469-74

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension [letter; comment] Gottdiener JS. **Circulation** 1999 Aug 10;100(6):685-6. Comment on: Circulation 1998 Nov 10;98(19):2037-42.

Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Matter CM, et al. **Circulation** 1999 May 11;99(18):2396-401

Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system [editorial; comment] Pitt B. **Circulation** 1998 Nov 10;98(19):1987-9 (20 ref.). Comment on: Circulation 1998 Nov 10;98(19):2037-42.

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension [see comments] Thürmann PA, et al. **Circulation** 1998 Nov 10;98(19):2037-42. Comment in: Circulation 1998 Nov 10;98(19):1987-9.

Left ventricular mass regression with amlodipine in elderly hypertensives. Singh NK, et al. **Clin Exp Hypertens** 1999 Jan-Feb;21(1-2):113-9

Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients [letter; comment] Lièvre M, et al. **Diabetes Care** 1999 Jan; 22(1):178-9. Comment on: Diabetes Care 1998 May;21(5):804-9.

Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Sato A, et al. **Hypertens Res** 1999 Mar;22(1):17-22

Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. Gaudio C, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):760-8

Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. Thürmann PA. **J Cardiovasc Pharmacol** 1999;33 Suppl 1:S33-6; discussion S41-3

Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy [comment] Gibbs CR, et al. **J Hum Hypertens** 1998 Aug;12(8):493-5. Comment on: J Hum Hypertens 1996 Nov;10(11):729-34. Comment on: J Hum Hypertens 1998 Aug;12(8):505-10.

Effects of losartan on hypertension and left ventricular mass: a long-term study [see comments] Tedesco MA, et al. **J Hum Hypertens** 1998 Aug;12(8):505-10. Comment in: J Hum Hypertens 1998 Aug;12(8):493-5.

Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with nilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. Sadowski Z, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S55-62

Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. Tomita S, et al. **Jpn Heart J** 1999 Jan;40(1):55-63

Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients. Wu SG, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Feb; 15(2):62-8

Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Ecder T, et al. **Nephrol Dial Transplant** 1999 May;14(5):1113-6

L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension. Vulpis V, et al. **Pharmacol Res** 1998 Oct; 38(4):317-22

Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function--a pilot study. Gosse P, et al. **Therapie** 1999 Mar-Apr;54(2):217-22

[Clinical study on combined treatment of shuizhi tuyuan powder and nifedipine in treating hypertension patients complicated with left ventricular hypertrophy] Wei AY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov;16(11):652-4 (Eng. Abstr.) **(Chi)**

[Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil] Li G, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):419-21, 424 (Eng. Abstr.) **(Chi)**

[Regression of left ventricular hypertrophy with antihypertensive therapy] Follath F. **Ther Umsch** 1998 Sep; 55(9):539-41 (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin [see comments] Ding B, et al. **Circ Res** 1999 Apr 2;84(6):729-34 . Comment in: Circ Res 1999 Apr 2;84(6):741-3.

Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. Kantor PF, et al. **J Am Coll Cardiol** 1999 May;33(6):1724-34

The sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene promoter activity is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. Aoyagi T, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):919-26

EPIDEMIOLOGY

Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Levin A, et al. **Am J Kidney Dis** 1999 Jul;34(1):125-34

High amplitude of R waves in electrocardiograms, and overload related to heaviness of work in the population of maritime workers. Waskiewicz J. **Buil Inst Marit Trop Med Gdynia** 1998;49(1-4):77-85

Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy. Sato A, et al. **Diabetologia** 1999 Jan;42(1):76-80

Left ventricular hypertrophy: a population perspective [editorial; comment] Mayet J, et al. **Eur Heart J** 1999 Mar; 20(6):400-1. Comment on: Eur Heart J 1999 Mar;20(6):429-38.

Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study [see comments] Schirmer H, et al. **Eur Heart J** 1999 Mar;20(6):429-38. Comment in: Eur Heart J 1999 Mar;20(6):400-1.

Left ventricular hypertrophy in northern and Siberian populations. Malyutina S, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:312-5

Prevalence and patterns of left ventricular hypertrophy in patients with predialysis chronic renal failure. Ha SK, et al. **J Korean Med Sci** 1998 Oct;13(5):488-94

Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989 [see comments] Mosterd A, et al. **N Engl J Med** 1999 Apr 22;340(16):1221-7. Comment in: N Engl J Med 1999 Apr 22;340(16):1279-80.

Anemia during the predialysis period: A key to cardiac damage in renal failure. Silverberg D, et al. **Nephron** 1998 Sep;80(1):1-5 (72 ref.)

[Incidental high blood pressure in family practice: due to hypertension and/or left ventricular hypertrophy in more than half of the patients] Boekhout I, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2404-8 (Eng. Abstr.) **(Dut)**

[Arterial hypertension and left ventricular hypertrophy: a 40-year follow-up in a Framingham cohort study] Vallée JP. **Presse Med** 1999 Sep 11;28(26):1421-2 **(Fre)**

ETHNOLOGY

Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Chapman JN, et al. **Am J Hypertens** 1999 May;12(5):437-42

ETIOLOGY

Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Celentano A, et al. **Am J Cardiol** 1999 Apr 15;83(8):1196-200

Left ventricular morphology in elite female resistance-trained athletes. Haykowsky MJ, et al. **Am J Cardiol** 1998 Oct 1;82(7):912-4

Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Buğra Z, et al. **Am J Hypertens** 1998 Oct;11(10):1164-70

Cardiovascular abnormalities in never-treated hypertensives according to nondipper status. Ferrara AL, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1352-7

Left ventricular contractile performance, ventriculoarterial coupling, and left ventricular efficiency in hypertensive patients with left ventricular hypertrophy. Nitenberg A, et al. **Am J Hypertens** 1998 Oct;11(10):1188-98

What is the role of dietary sodium and potassium in hypertension and target organ injury? He J, et al. **Am J Med Sci** 1999 Mar;317(3):152-9 (50 ref.)

Natural history of congenital pulmonary valvar stenosis: an echo and Doppler cardiographic study. Gielen H, et al. **Cardiol Young** 1999 Mar;9(2):129-35

Left ventricular hypertrophy and parathyroid hormone: a causal connection? [letter; comment] Schlüter KD, et al. **Cardiovasc Res** 1998 Aug;39(2):523-4. Comment on: Cardiovasc Res 1998 Jan;37(1):34-41.

Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin [see comments] Ding B, et al. **Circ Res** 1999 Apr 2;84(6):729-34 . Comment in: Circ Res 1999 Apr 2;84(6):741-3.

Impaired force-frequency relations in patients with hypertensive left ventricular hypertrophy. A possible physiological marker of the transition from physiological to pathological hypertrophy. Inagaki M, et al. **Circulation** 1999 Apr 13;99(14):1822-30

Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Perticone F, et al. **Circulation** 1999 Apr 20;99(15):1991-6

Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Rohrbach S, et al. **Circulation** 1999 Jul 27; 100(4):407-12

Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Schunkert H, et al. **Circulation** 1999 May 4;99(17):2255-60

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension [see comments] Thürmann PA, et al. **Circulation** 1998 Nov 10;98(19):2037-42. Comment in: Circulation 1998 Nov 10;98(19):1987-9.

Symmetric and asymmetric left ventricular hypertrophy in patients with end-stage renal failure on long-term hemodialysis. Straumann E, et al. **Clin Cardiol** 1998 Sep; 21(9):672-8

Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Piovesan A, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):321-8

The heart in arterial hypertension [editorial] Verdecchia P, et al. **G Ital Cardiol** 1999 Jul;29(7):769-80 (81 ref.)

Ventricular dilatation in the absence of ACE inhibitors: influence of haemodynamic and neurohormonal variables following myocardial infarction. Walsh JT, et al. **Heart** 1999 Jan;81(1):33-9

Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Devereux RB, et al. **Hypertens Res** 1999 Mar;22(1):1-9 (85 ref.)

ET(A) receptor antagonist ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis. Nakamura T, et al. **Hypertens Res** 1998 Dec;21(4):251-7

Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension. Tomita S, et al.

Hypertens Res 1998 Dec;21(4):259–66

Clues for understanding the pathogenesis of left ventricular hypertrophy in chronic uremia [editorial] Cannella G, et al. **Int J Artif Organs** 1998 Jul;21(7):378–83

Anemia and blood pressure correction obtained by daily hemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients [letter] Fagugli RM, et al. **Int J Artif Organs** 1998 Jul;21(7):429–31

Optimal management of hypertensive patients with LVH and dyslipidaemia. Plouin PF. **Int J Clin Pract Suppl** 1998 Nov; 98:9–12

A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism. Shimada T, et al. **Intern Med** 1999 Aug; 38(8):655–9

RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. Rogers JH, et al. **J Clin Invest** 1999 Sep;104(5):567–76

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? Gosse P, et al. **J Hum Hypertens** 1999 Aug;13(8):505–9

Changes in cardiac diastolic dimensions precede hypertrophy in early stages of hypertension. Lemme C, et al. **J Hum Hypertens** 1998 Oct;12(10):679–83

Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. Gamble G, et al. **J Hypertens** 1998 Sep;16(9):1389–95

Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. Grimm D, et al. **J Hypertens** 1998 Sep;16(9):1345–55

Type A behavior is associated with an increased risk of left ventricular hypertrophy in male patients with essential hypertension. Munakata M, et al. **J Hypertens** 1999 Jan; 17(1):115–20

Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Rossi MA. **J Hypertens** 1998 Jul; 16(7):1031–41

The importance of left ventricular hypertrophy in human hypertension. Kahan T. **J Hypertens Suppl** 1998 Sep; 16(7):S23–9 (40 ref.)

Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with nilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. Sadowski Z, et al. **J Hypertens Suppl** 1998 Aug; 16(3):S55–62

Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. Blacher J, et al. **J Nephrol** 1999 Jul–Aug;12(4):248–55

Decreased left ventricular filling pressure 8 months after corrective surgery in a 55-year-old man with tetralogy of Fallot: adaptation for increased preload. Iga K, et al. **Jpn Circ J** 1999 Feb;63(2):145–7

Relationship between microalbuminuria, left ventricular mass and function in essential hypertension. Wu SG, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):536–41

Long-term evolution of cardiomyopathy in dialysis patients. Foley RN, et al. **Kidney Int** 1998 Nov;54(5):1720–5

Echocardiography in systemic lupus erythematosus [see comments] Kalke S, et al. **Lupus** 1998;7(8):540–4. Comment in: Lupus 1999;8(3):250.

Hypertensive left ventricular hypertrophy with left ventricular outflow tract obstructive physiology: a case of successful treatment with dual-chamber pacing [see comments] Wicks AB, et al. **Mil Med** 1998 Dec; 163(12):861–3. Comment in: Mil Med 1999 May;164(5):318.

Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. Turcani M, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):225–33

Left ventricular hypertrophy in hypertension [editorial; comment] Dunn FG, et al. **N Engl J Med** 1999 Apr 22; 340(16):1279–80. Comment on: N Engl J Med 1999 Apr 22;340(16):1221–7.

Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Starc TJ, et al. **Pediatrics** 1999 Aug; 104(2):e14

A cross-sectional study on the relationship between depression and left ventricular hypertrophy. Takemura Y, et al. **Prev Med** 1998 Nov-Dec;27(6):787–91

[Left ventricular hypertrophy remodeling in hypertension] Hu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Jun; 36(6):424–6 (19 ref.) **(Chi)**

[Aging and regression of cardiac hypertrophy in the hypertensive patient] Du Cailar G, et al. **Rev Med Interne** 1998 Dec;19(12):870–7 (Eng. Abstr.) **(Fre)**

[Significance of left ventricular hypertrophy in hypertension] Ghanem WM, et al. **Vnitr Lek** 1998 Sep;44(9):513–7 (Eng. Abstr.) **(Slo)**

[Cardiac manifestations of primary hypothyroidism. Determinant factors and treatment response] González Vilchez F, et al. **Rev Esp Cardiol** 1998 Nov;51(11):893–900 (Eng. Abstr.) **(Spa)**

GENETICS

Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular prognosis. Mensah GA, et al. **Am J Cardiol** 1999 Sep 1; 84(5):583–8

Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Estacio RO, et al. **Am J Hypertens** 1999 Jun;12(6):637–42

Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension. Jeng JR. **Am J Hypertens** 1999 May; 12(5):443–50

Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Osono E, et al. **Am J Kidney Dis** 1998 Nov;32(5):725–30

Familial hypertrophic cardiomyopathy: a paradigm of the cardiac hypertrophic response to injury. Marian AJ, et al. **Ann Med** 1998 Aug;30 Suppl 1:24–32 (74 ref.)

Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. Vaziri ND, et al. **Biochim Biophys Acta** 1999 Jan 4;1436(3):577–84

Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. Masciotra S, et al. **Circ Res** 1999 Jun 25;84(12):1453–8

Variants of renin-angiotensin system genes and echocardiographic left ventricular mass. Kauma H, et al. **Eur Heart J** 1998 Jul;19(7):1109–17

AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Osterop AP, et al. **Hypertension** 1998 Nov;32(5):825–30

Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes. Karjalainen J, et al. **J Am Coll Cardiol** 1999 Aug;34(2):494–9

Maternally transmitted susceptibility to non-insulin-dependent diabetes mellitus and left ventricular hypertrophy. Momiyama Y, et al. **J Am Coll Cardiol** 1999 Apr;33(5):1372–8

Familial predisposition of left ventricular hypertrophy. Schunkert H, et al. **J Am Coll Cardiol** 1999 May; 33(6):1685–91

A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. Ishikawa M, et al. **J Hypertens** 1999 Jun;17(6):807–16

A simple and efficient method for the isolation of differentially expressed genes. Mahadeva H, et al. **J Mol Biol** 1998 Dec 18;284(5):1391–8

The sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene promoter activity is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. Aoyagi T, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):919–26

[Relationship between genotype of angiotensin converting enzyme gene and left ventricular hypertrophy in Chinese hypertensives] Shen D, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1998 Dec 10;15(6):364–6 (Eng. Abstr.) **(Chi)**

METABOLISM

Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. Vaziri ND, et al. **Biochim Biophys Acta** 1999 Jan 4;1436(3):577–84

Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Brooks G, et al. **Cardiovasc Res** 1998 Aug;39(2):301–11 (112 ref.)

Myocardial insulin resistance in cardiac hypertrophy [editorial; comment] Verma S, et al. **Cardiovasc Res** 1999 Apr;42(1):12–4. Comment on: Cardiovasc Res 1999 Apr;42(1):246–53.

Effect of chronic captopril treatment on circulating and tissue renin-angiotensin system in SHR rats. Hu WY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):507–12

Inhibition of beta-myosin heavy chain gene expression in pressure overload rat heart by losartan and captopril. Ling Q, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):63–6

Effects of praeruptorine C on the intracellular free calcium in normal and hypertrophied rat ventricular myocytes. Sun L, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May; 18(3):251–4

Effects of menidipine on dihydropyridines binding sites in cardiac and cerebral membranes from old rats with left ventricular hypertrophy. Xi T, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May;17(3):235–8

Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Rohrbach S, et al. **Circulation** 1999 Jul 27; 100(4):407–12

Serial changes in sarcoplasmic reticulum gene expression in volume-overloaded cardiac hypertrophy in the rat: effect of an angiotensin II receptor antagonist. Hashida H, et al. **Clin Sci (Colch)** 1999 Apr;96(4):387–95

Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy. Böhm M, et al. **Hypertension** 1998 Nov;32(5):831–7

Altered effects of acetylcholine on cyclic AMP and GMP induced changes in O2 consumption of hypertrophic dog cardiac myocytes. Gong GX, et al. **J Auton Pharmacol** 1999 Feb;19(1):19–28

Effects of chronic adenosine uptake blockade on adrenergic responsiveness and left ventricular chamber function in pressure overload hypertrophy in the rat. Chung ES, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1813–22

Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. Grimm D, et al. **J Hypertens** 1998 Sep;16(9):1345–55

Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. Mujumdar VS, et al. **J Hypertens** 1999 Feb;17(2):261–70

Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition. Clair MJ, et al. **J Mol Cell Cardiol** 1998 Nov;30(11):2355–64

Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: II. Cytoskeletal remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):319–31

Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: III. Intercalated disc remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb;31(2):333–43

Functional and metabolic evaluation of the hypertrophied heart using MRI and 31P-MRS. Lamb HJ, et al. **MAGMA** 1998 Sep;6(2–3):168–70

[The quantification of energy-rich phosphates in healthy and damaged heart muscle by SLOOP 31P-MR spectroscopy. Spatial localization with optimal pointspread function] Beer M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):65–8 (Eng. Abstr.) **(Ger)**

MORTALITY

Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study [see comments] Vantrimpont P, et al. **Eur Heart J** 1998 Oct;19(10):1552–63. Comment in: Eur Heart J 1998 Oct;19(10):1423–4.

PATHOLOGY

Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Jacobi J, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):418–22

Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Gatzka CD, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):514–6

Apoptosis in hypertensive heart disease. Diez J, et al. **Curr Opin Cardiol** 1998 Sep;13(5):317–25 (77 ref.)

Grading, staging and scoring of left-ventricular hypertrophy, left-ventricular dilatation, asymptomatic left-ventricular dysfunction and chronic heart failure. Field ML, et al. **Eur Heart J** 1999 Sep;20(17):1224–33

Increased insulin-like growth factor-1 protein in human left ventricular hypertrophy. Pauliks LB, et al. **Exp Mol Pathol** 1999 Apr;66(1):53–8

Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats. Sugimoto K, et al. **Hypertens Res** 1998 Sep;21(3):163–8

Left ventricular geometric remodeling and residual stress in the rat heart. Omens JH, et al. **J Biomech Eng** 1998 Dec; 120(6):715–9

Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction. Wei S, et al. **J Card Fail** 1999 Jun;5(2):117–26

Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Rossi MA. **J Hypertens** 1998 Jul; 16(7):1031–41

Analysis of circadian blood pressure rhythm and target-organ damage in stroke-prone spontaneously hypertensive rats. Shimamura T, et al. **J Hypertens** 1999 Feb;17(2):211–20

Torsades de pointes in a case of hypertrophic cardiomyopathy with special reference to the pathologic findings of the heart including the conduction system. Kuboki K, et al. **Jpn Heart J** 1999 Mar;40(2):233–8

Clinical and morphologic features of hypertrophic cardiomyopathy in elderly patients 85 years or older. Lai ZY, et al. **Jpn Heart J** 1999 Mar;40(2):155–64

[Mitral valve prolapse (letter)] Krause D. **Dtsch Med Wochenschr** 1999 Apr 16;124(15):475 **(Ger)**

[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II] Frolov VA, et al. **Dokl Akad Nauk** 1999 May;366(3):413–5 **(Rus)**

PHYSIOPATHOLOGY

QT dispersion in exercise-induced myocardial hypertrophy. Halle M, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):309–12

Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Karpanou EA, et al. **Am Heart J** 1998 Nov; 136(5):765–8

QT dispersion in athletic left ventricular hypertrophy. Mayet J, et al. **Am Heart J** 1999 Apr;137(4 Pt 1):678–81

Evaluation of extent of shortening versus velocity of shortening at the endocardium and midwall in hypertensive heart disease. Aurigemma GP, et al. **Am J Cardiol** 1999 Mar 1;83(5):792–4, A10

Relations of diastolic left ventricular filling to systolic

chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). Palmieri V, et al. **Am J Cardiol** 1999 Sep 1;84(5):558–62

QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Stolt A, et al. **Am J Cardiol** 1999 Aug 1;84(3):364–6, A9

Reducing hypertension-associated cardiorenal risk: the role of heart rate, left ventricular hypertrophy regression, and renoprotection. Materson BJ. **Am J Hypertens** 1999 Jan; 12(1 Pt 2):1S–2S (4 ref.)

Central vasopressin is modulated by chronic blockade of the renin–angiotensin system in experimental left ventricular hypertrophy. Muders F, et al. **Am J Hypertens** 1999 Mar; 12(3):311–4

Left ventricular contractile performance, ventriculoarterial coupling, and left ventricular efficiency in hypertensive patients with left ventricular hypertrophy. Nitenberg A, et al. **Am J Hypertens** 1998 Oct;11(10):1188–98

Effect of treadmill exercise on transmural distribution of blood flow in hypertrophied left ventricle. Duncker DJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1274–82

Effect of NO on transmural distribution of blood flow in hypertrophied left ventricle during exercise. Duncker DJ, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):H1305–12

Role of K(+)(ATP) channels and adenosine in regulation of coronary blood flow in the hypertrophied left ventricle. Melchert PJ, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):H617–25

Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits. Rials SJ, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):H1216–24

B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Magga J, et al. **Ann Med** 1998 Aug;30 Suppl 1:39–45 (73 ref.)

Force-frequency relation in patients with left ventricular hypertrophy and failure. Kass DA. **Basic Res Cardiol** 1998; 93 Suppl 1:108–16

Factors influencing left ventricular mass in salt sensitive and salt resistant essential hypertensive patients. Gerdts E, et al. **Blood Press** 1998 Jul;7(4):223–30

Modification of left ventricular hypertrophy by chronic etomixir treatment. Turcani M, et al. **Br J Pharmacol** 1999 Jan;126(2):501–7

Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts. Naim KL, et al. **Can J Physiol Pharmacol** 1998 Jun;76(6):605–12

Outflow acceleration assessed by continuous-wave doppler echocardiography in left ventricular hypertrophy: an analysis of 103 consecutive cases. Faber L, et al. **Cardiology** 1998 Dec;90(3):220–6

Effects of 1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino) propane hydrochloride on heart function, lactate dehydrogenase and its isoenzymes in rats with cardiac hypertrophy. Zhang ZB, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):54–7

Reduced subendocardial ryanodine receptors and consequent effects on cardiac function in conscious dogs with left ventricular hypertrophy. Hittinger L, et al. **Circ Res** 1999 May 14;84(9):999–1006

Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure [see comments] Meguro T, et al. **Circ Res** 1999 Apr 2;84(6):735–40. Comment in: Circ Res 1999 Apr 2;84(6):741–3.

Signaling in myocardial hypertrophy: life after calcineurin? [comment] [see comments] Sugden PH. **Circ Res** 1999 Apr 2;84(6):633–46 (202 ref.). Comment on: Circ Res 1999 Apr 2;84(6):623–32. Comment in: Circ Res 1999 Apr 2;84(6):741–3.

Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats [see comments] Zhang W, et al. **Circ Res** 1999 Apr 2;84(6):722–8. Comment in: Circ Res 1999 Apr 2;84(6):741–3.

Relations of left ventricular mass to fat-free and adipose body mass: the strong heart study. The Strong Heart Study Investigators. Bella JN, et al. **Circulation** 1998 Dec 8; 98(23):2538–44

Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Condorelli G, et al. **Circulation** 1999 Jun 15; 99(23):3071–8

Effects of chronic heparin administration on coronary vascular adaptation to hypertension and ventricular hypertrophy in sheep. Flanagan MF, et al. **Circulation** 1999 Aug 31;100(9):981–7

Impaired force-frequency relations in patients with hypertensive left ventricular hypertrophy. A possible physiological marker of the transition from physiological to pathological hypertrophy. Inagaki M, et al. **Circulation** 1999 Apr 13;99(14):1822–30

Mechanisms and models in heart failure: A combinatorial approach. Mann DL. **Circulation** 1999 Aug 31; 100(9):999–1008 (78 ref.)

Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Gatzka CD, et al. **Clin Exp Pharmacol Physiol** 1999 Jul;26(7):514–6

Both leg blood flow and the femoral blood flow pattern are related to left ventricular mass in elderly men. Lind L, et al. **Clin Physiol** 1999 May;19(3):275–6

Influence of posture and handgrip on the QT interval in left ventricular hypertrophy and in chronic heart failure. Davey P. **Clin Sci (Colch)** 1999 Apr;96(4):403–7

Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats. Ikeda S, et al. **Clin Sci (Colch)** 1999 Aug;97(2):239–46

Impaired systolic and diastolic function and ventricular arrhythmia are common in normotensive healthy elderly men with left ventricular hypertrophy. Andrén B, et al. **Coron Artery Dis** 1999;10(2):111–7

Hypertensive left ventricular hypertrophy is linked to an enhanced catecholamine response to submaximal exercise. Kinugawa T, et al. **Eur J Clin Invest** 1999 Jul;29(7):594–602

Conduction velocity and gap junction resistance in hypertrophied, hypoxic guinea-pig left ventricular myocardium. Cooklin M, et al. **Exp Physiol** 1998 Nov; 83(6):763–70

A new physiological method for heart rate correction of the QT interval. Davey P. **Heart** 1999 Aug;82(2):183–6

Long axis function in disease [editorial] Henein MY, et al. **Heart** 1999 Mar;81(3):229–31

A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Okajima Y, et al. **Heart** 1998 Sep;80(3):292–5

Direct effects of colchicine on myocardial function: studies in hypertrophied and failing spontaneously hypertensive rats. Cicogna AC, et al. **Hypertension** 1999 Jan;33(1):60–5

Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. Morimoto A, et al. **Hypertension** 1999 May;33(5):1146–52

Gender differences in molecular remodeling in pressure overload hypertrophy. Weinberg EO, et al. **J Am Coll Cardiol** 1999 Jul;34(1):264–73

Left ventricular geometric remodeling and residual stress in the rat heart. Omens JH, et al. **J Biomech Eng** 1998 Dec; 120(6):715–9

Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide. Gillis AM, et al. **J Cardiovasc Electrophysiol** 1998 Sep;9(9):988–97

Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. Zabel M, et al. **J Cardiovasc Electrophysiol** 1998 Dec;9(12):1279–84

Comparison of left ventricular hypertrophy expression in patients with hypertrophic cardiomyopathy on the basis of sex. Dimitrow PP, et al. **J Cardiovasc Risk** 1998 Apr; 5(2):85–7

A novel serum protein of molecular weight 182 kDa: a molecular marker for an early detection of increased left ventricular mass in patients with cardiac hypertrophy. Rajamanickam C, et al. **J Cardiovasc Risk** 1998 Oct–Dec; 5(5–6):335–8

Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy [comment] Gibbs CR, et al. **J Hum Hypertens** 1998 Aug;12(8):493–5. Comment on: J Hum Hypertens 1996 Nov;10(11):729–34. Comment on: J Hum Hypertens 1998 Aug;12(8):505–10.

The heart in the hypertensive elderly. Grodzicki T, et al. **J Hum Hypertens** 1998 Sep;12(9):593–7 (51 ref.)

Myocardial diastolic impairment caused by left ventricular hypertrophy involves basal septum more than other walls: analysis by pulsed Doppler tissue imaging. Galderisi M, et al. **J Hypertens** 1999 May;17(5):685–93

Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. Gerritsen TA, et al. **J Hypertens** 1998 May;16(5):689–96

Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. Lip GY, et al. **J Hypertens** 1999 Aug;17(8):1203–7

Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. Marceau M, et al. **J Hypertens** 1998 May;16(5):673–9

Power spectral analysis of the heart rate in hypertensive patients with and without left ventricular hypertrophy: the effect of a left ventricular mass reduction. Muiesan ML, et al. **J Hypertens** 1998 Nov;16(11):1641–50

Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Pontremoli R, et al. **J Hypertens** 1999 Jul;17(7):993–1000

Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. Jennings G, et al. **J Hypertens Suppl** 1998 Oct;16(6):S29–34

QT interval measurement: Q to TApex or Q to TEnd? Davey PP. **J Intern Med** 1999 Aug;246(2):145–9

Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. Baba HA, et al. **J Mol Cell Cardiol** 1999 Feb; 31(2):445–55

Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. Martinez ML, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1617–25

Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: I. Regional hemodynamics and myocyte remodeling. Wang X, et al. **J Mol Cell Cardiol** 1999 Feb; 31(2):307–17

Properties of ventricular myocytes isolated from the hypertrophied and failing hearts of spontaneously hypertensive rats. Emanuel K, et al. **J Physiol Pharmacol** 1999 Jun;50(2):243–58

Influence of aortic valve replacement, prosthesis type, and size on functional outcome and ventricular mass in patients with aortic stenosis. Bech-Hanssen O, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):57–65

Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. Kishida H, et al. **Jpn Heart J** 1999 Jan;40(1):31–44

Left ventricular hypertrophy in renal failure. Amann K, et al. **Kidney Int Suppl** 1998 Dec;68:S78–85 (43 ref.)

Sodium, angiotensin II, blood pressure, and cardiac hypertrophy. Morgan TO, et al. **Kidney Int Suppl** 1998 Sep;67:S213–5

Functional and metabolic evaluation of the hypertrophied heart using MRI and 31P-MRS. Lamb HJ, et al. **MAGMA** 1998 Sep;6(2–3):168–70

Lack of correlation between ventricular late potentials and left ventricular mass in top-level male athletes. Biffi A, et al. **Med Sci Sports Exerc** 1999 Mar;31(3):359–61

Expression of vascular endothelial growth factor during the development of cardiac hypertrophy in spontaneously hypertensive rats. McAinsh AM, et al. **Mol Cell Biochem** 1998 Oct;187(1–2):141–6

Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. Turcani M, et al. **Mol Cell Biochem** 1998 Nov; 188(1–2):225–33

Ambulatory monitoring and clinic BP measurements for predicting left ventricular mass in patients with chronic renal diseases [letter; comment] Zoccali C, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):240–1. Comment on: Nephrol Dial Transplant 1997 Apr;12(4):724–8.

Relationships between transmembrane action potential changes and simultaneous changes in electrocardiograms of rats after a one-month aortic pressure overload. Lessard Y, et al. **Physiol Res** 1997;46(4):257–69

Plasma noradrenaline and neuropeptide-Y may not be of primary importance in the pathophysiology of cardiac involvement in systemic sclerosis. Kazzam E, et al. **Scand J Rheumatol** 1999;28(4):238–43

[Effects of m-Nif and Nif on left ventricle hypertrophy in rats induced by partial ligation of abdominal aorta] Rao MR, et al. **Yao Hsueh Hsueh Pao** 1996;31(9):647–51 (Eng. Abstr.) **(Chi)**

[Effects of enalapril and taurine on left ventricular hypertrophy and arrhythmia in renovascular hypertensive rat] Tao L, et al. **Yao Hsueh Hsueh Pao** 1996;31(12):891–6 (Eng. Abstr.) **(Chi)**

[Cardiac hypertrophy and coronary reserve in endurance athletes] Toraa M, et al. **Can J Appl Physiol** 1999 Feb; 24(1):87–95 (Eng. Abstr.) **(Fre)**

[Doppler tissue imaging: a new method in the study of diastolic function in left ventricular hypertrophy] Vezù L, et al. **G Ital Cardiol** 1999 Jan;29(1):63–71 (Eng. Abstr.) **(Ita)**

[Morphofunctional characteristics of myocardial hypertrophy in rabbits with vasorenal arterial hypertension during pharmacological blockade of angiotensin II] Frolov VA, et al. **Dokl Akad Nauk** 1999 May;366(3):413–5 **(Rus)**

[The connection between late ventricular potentials and ventricular arrhythmias in hypertension patients with different forms of myocardial hypertrophy] Gusarov GV, et al. **Ter Arkh** 1998;70(8):48–52 (Eng. Abstr.) **(Rus)**

[Ambulatory arterial pressure and left ventricular hypertrophy in untreated hypertensive patients] Pascual JM, et al. **Med Clin (Barc)** 1999 Feb 13;112(5):166–70 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Effect of hormone replacement therapy on left ventricular hypertrophy. Lim WK, et al. **Am J Cardiol** 1999 Apr 1; 83(7):1132–4, A9

Clinical trials of single-drug therapy for the cardiac effects of hypertension. Gottdiener JS. **Am J Hypertens** 1999 Jan; 12(1 Pt 2):12S–18S (68 ref.)

Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Agabiti-Rosei E, et al. **Blood Press** 1998 May;7(3):160–9

Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats [see comments] Zhang W, et al. **Circ Res** 1999 Apr 2;84(6):722–8. Comment in: Circ Res 1999 Apr 2;84(6):741–3.

Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Rohde LE, et al. **Circulation** 1999 Jun 15;99(23):3063–70

Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Ali SM, et al. **Coron Artery Dis** 1998;9(12):815–21

ET(A) receptor antagonist ameliorates nephrosclerosis and left ventricular hypertrophy induced in rat by prolonged inhibition of nitric oxide synthesis. Nakamura T, et al. **Hypertens Res** 1998 Dec;21(4):251–7

Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in

renovascular hypertensive rats. Ehmke H, et al. **Hypertension** 1999 Apr;33(4):954–60

Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. McDonald KM, et al. **J Card Fail** 1998 Sep;4(3):203–12

The influence of different antihypertensive drugs on left ventricular hypertrophy in a population sample of elderly men [see comments] Andrén B, et al. **J Hum Hypertens** 1999 Aug;13(8):499–504. Comment in: J Hum Hypertens 1999 Aug;13(8):497–8.

Antihypertensive agents and left ventricular hypertrophy with 'usual' care in the population setting [comment] Lip GY. **J Hum Hypertens** 1999 Aug;13(8):497–8 (11 ref.). Comment on: J Hum Hypertens 1999 Aug;13(8):449–504.

Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rat. Jalil JE, et al. **Life Sci** 1999;64(18):1603–12

Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats. Seki T, et al. **Life Sci** 1999;65(10):1077–86

Passive smoking induced hypertrophy of the left ventricle: effect of captopril. Simko F, et al. **Pharmazie** 1999 Apr; 54(4):314

Effect of captopril on the development of left ventricular hypertrophy in rabbits with aortic insufficiency. Simko F, et al. **Physiol Res** 1997;46(6):419–25

[Effects of Peucedanum praeruptorum extractum on blood pressure, left ventricular hypertrophy and hemodynamic changes in left ventricular hypertrophied hypertensive rats] Ji Y, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1996 Nov; 16(11):676–8 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Reproducibility of right and left ventricular volume measurements by electron-beam CT in patients with congestive heart failure. Schmermund A, et al. **Int J Card Imaging** 1998 Jun;14(3):201–9

Improved densitometric analysis of ventricular volumes in on-line digital cardiac imaging. Lehmkuhl H, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):7–12

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? Gosse P, et al. **J Hum Hypertens** 1999 Aug;13(8):505–9

RADIONUCLIDE IMAGING

False-positive defects in technetium-99m sestamibi myocardial single-photon emission tomography in healthy athletes with left ventricular hypertrophy. Bartram P, et al. **Eur J Nucl Med** 1998 Sep;25(9):1308–12

SURGERY

Left ventricular mass regression after implantation of St. Jude Medical cardiac valves in small aortic roots. Murakami T, et al. **Artif Organs** 1998 Sep;22(9):740–5

THERAPY

Growth hormone: a new therapy for heart failure? Saccà L. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):217–31 (83 ref.)

Ventricular pacing with premature excitation for treatment of hypertensive-cardiac hypertrophy with cavity-obliteration [see comments] Kass DA, et al. **Circulation** 1999 Aug 24;100(8):807–12. Comment in: Circulation 1999 Aug 24;100(8):786–8.

Hypertensive cardiomyopathy relieved by pacing? [letter; comment] DeSilvey DL. **Mil Med** 1999 May;164(5):318. Comment on: Mil Med 1998 Dec;163(12):861–3.

Hypertensive left ventricular hypertrophy with left ventricular outflow tract obstructive physiology: a case of successful treatment with dual-chamber pacing [see comments] Wicks AB, et al. **Mil Med** 1998 Dec; 163(12):861–3. Comment in: Mil Med 1999 May;164(5):318.

Left ventricular hypertrophy in daily dialysis. Buoncristiani U, et al. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):90–4

Pacing in distal left ventricular hypertrophic cardiomyopathy. Hintringer F, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1828–30

ULTRASONOGRAPHY

Vascular and cardiac remodeling in world class professional cyclists. Abergel E, et al. **Am Heart J** 1998 Nov; 136(5):818–23

Increased myocardial ultrasonic reflectivity is associated with extreme hypertensive left ventricular hypertrophy: a tissue characterization study in humans. Lucarini AR, et al. **Am J Hypertens** 1998 Dec;11(12):1442–9

Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Bardaji A, et al. **Am J Kidney Dis** 1998 Dec; 32(6):970–5

Normalization of left ventricular dimensions after Ross operation with aortic annular reduction. Niwaya K, et al. **Ann Thorac Surg** 1999 Sep;68(3):812–8; discussion 818–9

Assessment of LV mass by echocardiography [letter; comment] Nidorf M, et al. **Circulation** 1999 Jan 5–12; 99(1):165–6. Comment on: Circulation 1997 Sep 16;96(6):1863–73.

Increased left ventricular mass in normotensive type 1 diabetic patients with diabetic nephropathy. Sato A, et al. **Diabetes Care** 1998 Sep;21(9):1534–9

Determinants of echocardiographically measured left ventricular mass in diabetic patients with or without silent myocardial ischaemia. Sachs RN, et al. **Diabetes Metab** 1999 Jun;25(2):128–36

Echocardiographic evidence of concentric left ventricular enlargement in female weight lifters [see comments] George KP, et al. **Eur J Appl Physiol** 1998 Dec;79(1):88–92 . Comment in: Eur J Appl Physiol 1999 Jul;80(2):169–72.

Echocardiographic evidence of concentric left ventricular enlargement in female weight lifters [letter; comment] Urhausen A, et al. **Eur J Appl Physiol** 1999 Jul;80(2):169–72 . Comment on: Eur J Appl Physiol 1998 Dec;79(1):88–92.

Myocardial regional diastolic dysfunction and left ventricular hypertrophy: insights by pulsed Doppler tissue imaging [editorial] Caso P, et al. **G Ital Cardiol** 1999 Apr;29(4):462–6 (30 ref.)

Echocardiographic assessment of ejection fraction in left ventricular hypertrophy. Wandt B, et al. **Heart** 1999 Aug; 82(2):192–8

Relation between coronary blood flow and left ventricular mass in hypertension: noninvasive quantification of coronary blood flow by thallium-201 myocardial scintigraphy. Hamada M, et al. **Hypertens Res** 1998 Dec; 21(4):227–34

Ultrasonic myocardial texture versus Doppler analysis in hypertensive heart: a preliminary study. Di Bello V, et al. **Hypertension** 1999 Jan;33(1):66–73

Impact of on-line endocardial border detection on determination of left ventricular volume and ejection fraction by transthoracic 3-dimensional echocardiography. Chuang ML, et al. **J Am Soc Echocardiogr** 1999 Jul; 12(7):551–8

Evaluation of regional systolic function in hypertrophic cardiomyopathy and hypertensive heart disease: a three-dimensional echocardiographic study. Frielingsdorf J, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):778–86

Acoustic quantification indexes of left ventricular size and function: effects of signal averaging. Mor-Avi V, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):792–802

Age dependency of left atrial and left ventricular acoustic quantification waveforms for the evaluation of diastolic performance in left ventricular hypertrophy. Spencer KT, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1027–35

Progression of asymmetric pattern of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy accompanied by hypertension in the elderly. Dimitrow PP, et al. **J Hum Hypertens** 1998 Sep;12(9):631–2

Changes in cardiac diastolic dimensions precede hypertrophy in early stages of hypertension. Lemme C, et al. **J Hum Hypertens** 1998 Oct;12(10):679–83

The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients [see comments] Ertürk S, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1912–6. Comment in: Nephrol Dial Transplant 1999 Aug;14(8):1836–41.

A novel method for indexing echocardiographic left ventricular mass in infants, children and adolescents: evaluation of obesity-induced left ventricular hypertrophy. Hashimoto I, et al. **Pediatr Int** 1999 Apr;41(2):126–31

[Incidental high blood pressure in family practice: due to hypertension and/or left ventricular hypertrophy in more than half of the patients] Boekhout I, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2404–8 (Eng. Abstr.) **(Dut)**

[Distinguishing between physiologic hypertrophy in athletes and primary hypertrophic cardiomyopathies. Importance of tissue color Doppler (see comments)] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):201–10 (Eng. Abstr.). Comment in: Arch Mal Coeur Vaiss 1999 Feb;92(2):197–9. **(Fre)**

[Hypertrophic cardiomyopathy and physiologic hypertrophy in athletes: a new diagnostic approach using tissue color Doppler (editorial; comment] Malergue MC. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):197–9. Comment on: Arch Mal Coeur Vaiss 1999 Feb;92(2):201–10. **(Fre)**

[Echocardiographic data from chronic dialysis patients in Dakar] Kane A, et al. **Dakar Med** 1997;42(1):25–9 (Eng. Abstr.) **(Fre)**

[Aging and regression of cardiac hypertrophy in the hypertensive patient] Du Cailar G, et al. **Rev Med Interne** 1998 Dec;19(12):870–7 (Eng. Abstr.) **(Fre)**

[Image of the month. Echographic aspects of apical hypertrophic cardiomyopathy] Appeltants H, et al. **Rev Med Liege** 1999 Mar;54(3):137 **(Fre)**

[Doppler tissue imaging: a new method in the study of diastolic function in left ventricular hypertrophy] Vezù L, et al. **G Ital Cardiol** 1999 Jan;29(1):63–71 (Eng. Abstr.) **(Ita)**

HYPERTROPHY, RIGHT VENTRICULAR

CHEMICALLY INDUCED

Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Frasch HF, et al. **Am J Physiol** 1999 Feb; 276(2 Pt 1):L304–10

Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Schultze AE, et al. **J Toxicol Environ Health B Crit Rev** 1998 Oct-Dec; 1(4):271–346 (381 ref.)

COMPLICATIONS

The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. van Suylen RJ, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1791–5

CONGENITAL

Significance of a Q wave in lead I in the newborn. Robinson BW, et al. **Am J Cardiol** 1999 Sep 1;84(5):615–7, A9

DIAGNOSIS

Electrocardiographic patterns of patients with echocardiographically determined biventricular hypertrophy. Jain A, et al. **J Electrocardiol** 1999 Jul; 32(3):269–73

Radiology of the right ventricle. Boxt LM. **Radiol Clin North Am** 1999 Mar;37(2):379–400 (96 ref.)

DRUG THERAPY

Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. Yoshihara F, et al. **Eur J Pharmacol** 1998 Aug 14;355(1):33–9

ETIOLOGY

Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation. Koide M, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H350–8

Holt-Oram syndrome. Brockhoff CJ, et al. **Circulation** 1999 Mar 16;99(10):1395–6

Asymmetry of right ventricular enlargement in response to tricuspid regurgitation. Reynertson SI, et al. **Circulation** 1999 Aug 3;100(5):465–7

An unusual cause of pulmonary hypertension and right heart failure. Orme S, et al. **Postgrad Med J** 1998 Nov; 74(877):697–8

GENETICS

The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. van Suylen RJ, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1791–5

Metabolic disturbances in male broilers of different strains. 1. Performance, mortality, and right ventricular hypertrophy. Gonzales E, et al. **Poult Sci** 1998 Nov; 77(11):1646–53

METABOLISM

Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Frasch HF, et al. **Am J Physiol** 1999 Feb; 276(2 Pt 1):L304–10

Quantitative analysis of collagens and fibronectin expression in human right ventricular hypertrophy. Peters TH, et al. **Ann N Y Acad Sci** 1999 Jun 30;874:278–85

Hemodynamics and mitochondrial energy metabolism in right heart hypertrophy after acute hypoxic stress. Thürich T, et al. **Arzneimittelforschung** 1999 Mar;49(3):212–20

PATHOLOGY

Tetrandrine inhibited chronic "inflammatory" pulmonary hypertension in rats. Wang HL, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):401–4

PHYSIOPATHOLOGY

Hypoxia inhibits increased ETB receptor-mediated NO synthesis in hypertensive rat lungs. Sato K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):L571–81

Hemodynamics and mitochondrial energy metabolism in right heart hypertrophy after acute hypoxic stress. Thürich T, et al. **Arzneimittelforschung** 1999 Mar;49(3):212–20

Signaling in myocardial hypertrophy: life after calcineurin? [comment] [see comments] Sugden PH. **Circ Res** 1999 Apr 2;84(6):633–46 (202 ref.). Comment on: Circ Res 1999 Apr 2;84(6):623–32. Comment in: Circ Res 1999 Apr 2;84(6):741–3.

A novel serum protein of molecular weight 182 kDa: a molecular marker for an early detection of increased left ventricular mass in patients with cardiac hypertrophy. Rajamanickam C, et al. **J Cardiovasc Risk** 1998 Oct-Dec; 5(5-6):335–8

Induction of cardiac nitric oxide synthase 2 in rats exposed to chronic hypoxia. Rouet-Benzineb P, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1697–708

Contribution of baroreceptors and chemoreceptors to ventricular hypertrophy produced by sino-aortic denervation in rats. Van Vliet BN, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):885–95

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat. Underwood DC, et al. **Pulm Pharmacol Ther** 1999;12(1):13–26

Role of NO in recovery from neonatal hypoxic pulmonary

hypertension. Tulloh RM, et al. **Thorax** 1999 Sep; 54(9):796–804

PREVENTION & CONTROL

Inhaled nitric oxide does not alter pulmonary or cardiac effects of fat embolism in dogs after cemented arthroplasty. Byrick RJ, et al. **Can J Anaesth** 1999 Jun;46(6):605–12

Preventive and therapeutic effects of nitrendipine on hypoxic right ventricular hypertrophy. Xie ZZ, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Jul;17(4):337–40

Dietary retinol inhibits inflammatory responses of rats treated with monocrotaline. Swamidas GP, et al. **J Nutr** 1999 Jul; 129(7):1285–90

[Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline] Jin X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Dec;21(12):751–2, 763 (Eng. Abstr.) **(Chi)**

RADIOGRAPHY

Reproducibility of right and left ventricular volume measurements by electron-beam CT in patients with congestive heart failure. Schmermund A, et al. **Int J Card Imaging** 1998 Jun;14(3):201–9

RADIONUCLIDE IMAGING

Simultaneous assessment of right ventricular function and hypertrophy by Tc-99m MIBI. Nishijima K, et al. **Clin Nucl Med** 1999 Mar;24(3):151–5

Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle. Nagaya N, et al. **J Nucl Med** 1998 Oct;39(10):1676–80

HYPERTROPIA see **STRABISMUS**

HYPERVARIABLE REGION see **IMMUNOGLOBULIN VARIABLE REGION**

HYPERVENTILATION

see related
HYPOCAPNIA

The effect of hyperventilation and hyperoxia on cerebral venous oxygen saturation in patients with traumatic brain injury [see comments] Thiagarajan A, et al. **Anesth Analg** 1998 Oct;87(4):850–3. Comment in: Anesth Analg 1999 Jul;89(1):258.

Effect of nitric oxide synthase inhibitor on allergen- and hyperventilation-induced bronchoconstriction in guinea-pigs. Nogami H, et al. **Eur Respir J** 1998 Dec; 12(6):1318–21

Mental stress test is an effective inducer of vasospastic angina pectoris: comparison with cold pressor, hyperventilation and master two-step exercise test. Yoshida K, et al. **Int J Cardiol** 1999 Jul 31;70(2):155–63

High oxygen delivery and extraction by perfluorocarbon-primed extracorporeal membrane oxygenation do not prevent anaerobic metabolism in rabbits [letter; comment] White JJ. **J Pediatr Surg** 1998 Nov; 33(11):1731. Comment on: J Pediatr Surg 1998 Mar;33(3):422–7.

Investigation of the most effective provocation test for patients with coronary spastic angina: usefulness of accelerated exercise following hyperventilation. Sueda S, et al. **Jpn Circ J** 1999 Feb;63(2):85–90

Addressing the causes of hyperventilation. Nias DK. **Practitioner** 1998 Mar;242(1584):187–91 (4 ref.)

BLOOD

Hyperventilation impairs oxygenation after bidirectional superior cavopulmonary connection. Bradley SM, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II372–6; discussion II376–7

CHEMICALLY INDUCED

Severe agitation and hyperventilation after contrast media application during coronary angiography. Moll S, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):200–1

Hyperventilation following a large-scale hazardous-materials incident. Burgess JL, et al. **Int J Occup Environ Health** 1999 Jul-Sep;5(3):194–7

Epinephrine-induced panic attacks and hyperventilation. van Zijderveld GA, et al. **J Psychiatr Res** 1999 Jan-Feb; 33(1):73–8

COMPLICATIONS

Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Brannan JD, et al. **Am J Respir Crit Care Med** 1998 Oct; 158(4):1120–6

Repetitive hyperpnoea causes peripheral airway obstruction and eosinophilia. Davis MS, et al. **Eur Respir J** 1999 Jul; 14(1):57–62

[Posthyperventilation hypoxia (editorial)] Rabinovich RA, et al. **Medicina (B Aires)** 1999;59(1):111–4 **(Spa)**

DIAGNOSIS

Presence of hyperventilation in patients with asthma-like symptoms but negative asthma test responses: provocation with voluntary hyperventilation and mental stress. Ringsberg KC, et al. **J Allergy Clin Immunol** 1999 Apr; 103(4):601–8

Quantitative topographical analysis of EEG during nonstandardized and standardized hyperventilation. Zwiener U, et al. **J Clin Neurophysiol** 1998 Nov;15(6):521–8

[Tetany, spasmophilia, hyperventilation syndrome: theoretical and therapeutic synthesis] Delvaux M, et al. **Rev Med Liege** 1998 Oct;53(10):610–8 (46 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Accumulation of carbon dioxide under ophthalmic drapes during eye surgery: a comparison of three different drapes. Schlager A. **Anaesthesia** 1999 Jul;54(7):690–4

Exercise-induced hyperventilation: a pseudoasthma syndrome. Hammo AH, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):574–8

The development of hyperventilation in patients with chronic heart failure and Cheyne-Strokes respiration: a possible role of chronic hypoxia. Fanfulla F, et al. **Chest** 1998 Oct; 114(4):1083–90

Abnormal respiratory patterns in childhood cerebral malaria. Crawley J, et al. **Trans R Soc Trop Med Hyg** 1998 May-Jun;92(3):305–8

METABOLISM

Hyperventilation, hyperoxia, and cerebral oxygenation after traumatic brain injury [letter; comment] Savva D. **Anesth Analg** 1999 Jul;89(1):258. Comment on: Anesth Analg 1998 Oct;87(4):850–3.

The effect of respiratory mode on human middle ear pressure. Ikarashi F. **Auris Nasus Larynx** 1998 Dec;25(4):349–54

Effects of hyper- and hypoventilation on gastric and sublingual PCO(2). Pernat A, et al. **J Appl Physiol** 1999 Sep;87(3):933–7

Brain tissue oxygenation during hemorrhagic shock, resuscitation, and alterations in ventilation. Manley GT, et al. **J Trauma** 1999 Feb;46(2):261–7

A man from Surinam... (Hyperventilation after drug abuse: how are the observed acid-base and electrolyte abnormalities interpreted?) [letter; comment] Elisaf MS, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2975–6. Comment on: Nephrol Dial Transplant 1998 Jan;13(1):209–10.

[The mechanism of breathing under the conditions of prolonged voluntary hyperventilation] Bubeev IuA, et al. **Aviakosm Ekolog Med** 1999;33(2):22–6 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The effect of eucapnic and isocapnic volitional hyperventilation upon breathlessness. Binks A, et al. **Adv Exp Med Biol** 1998;450:167–72

Ventilatory responses to hypoxia after 6 hours passive hyperventilation in humans. Ren X, et al. **Adv Exp Med Biol** 1998;450:21–3

Human ventilatory response to immersion of the face in cool water. Stewart LM, et al. **Adv Exp Med Biol** 1998; 450:127–31

The use of hyperventilation in contrast-enhanced MR imaging of brain tumors [letter] Hawley RJ, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul;20(6):1184–5

Alveolar ventilation during hyperventilation by panic disorder patients [letter; comment] Janszky I, et al. **Am J Psychiatry** 1999 Apr;156(4):667–8. Comment on: Am J Psychiatry 1997 Nov;154(11):1557–65.

Hyperventilation with dry air increases airway surface fluid osmolality in canine peripheral airways. Freed AN, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1101–7

Effects of hyperventilation and hypocapnic/normocapnic hypoxemia on renal function and lithium clearance in humans. Videndal Olsen N, et al. **Anesthesiology** 1998 Dec; 89(6):1389–400

Recent insights into hyperventilation from the study of Rett syndrome. Kerr AM, et al. **Arch Dis Child** 1999 Apr; 80(4):384–7 (28 ref.)

Cerebral oxygenation and hemodynamics during hyperventilation and sleep in patients with Rett syndrome. Murakami Y, et al. **Brain Dev** 1998 Dec;20(8):574–8

The effect of hyperventilation on the frequency of Rolandic spikes. Nicholl JS, et al. **Clin Electroencephalogr** 1998 Oct; 29(4):181–2

Lack of interaction of hyperpnoea with methacholine and histamine in asthma. Sompradeekul S, et al. **Clin Sci (Colch)** 1998 Nov;95(5):611–9

Elastase in hyperpnea-induced guinea pig airway constriction. Lai YL, et al. **Eur J Pharmacol** 1998 Oct 23; 359(2-3):171–6

The relationship between cardiac output and posthyperventilation hyperpnoea in patients with essential hypertension. Bellofiore S, et al. **Eur Respir J** 1998 Nov; 12(5):1160–3

A simple breathing circuit minimizing changes in alveolar ventilation during hyperpnoea. Sommer LZ, et al. **Eur Respir J** 1998 Sep;12(3):698–701

Effects of voluntary hyperventilation on cortical sensory responses. Electroencephalographic and magnetoencephalographic studies. Huttunen J, et al. **Exp Brain Res** 1999 Apr;125(3):248–54

Effect of nitric oxide synthase inhibition on hypercapnia-induced hypothermia and hyperventilation. Barros RC, et al. **J Appl Physiol** 1998 Sep;85(3):967–72

Airway obstruction during exercise and isocapnic hyperventilation in asthmatic subjects. Suman OE, et al. **J Appl Physiol** 1999 Sep;87(3):1107–13

Tachykinins in propranolol-augmented, hyperpnoea-induced bronchoconstriction in Taida guinea-pigs: effects of dimethylthiourea. Lin CW, et al. **J Auton Pharmacol** 1998 Jun;18(3):139–47

Ventilatory responses to hypercapnia and hypoxia after 6 h passive hyperventilation in humans. Ren X, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):885–94

Functional imaging of the visual cortex with bold-contrast MRI: hyperventilation decreases signal response. Weckesser M, et al. **Magn Reson Med** 1999 Jan;41(1):213–6

[A dynamic analysis of heart rate variability during hyperventilation] Bludov AA, et al. **Fiziol Cheloveka** 1998 Nov-Dec;24(6):66–71 **(Rus)**

PSYCHOLOGY

Ventilatory response to imagination of exercise and altered perception of exercise load under hypnosis. Thornton JM, et al. **Adv Exp Med Biol** 1998;450:195–7

Presence of hyperventilation in patients with asthma-like symptoms but negative asthma test responses: provocation with voluntary hyperventilation and mental stress. Ringsberg KC, et al. **J Allergy Clin Immunol** 1999 Apr; 103(4):601–8

Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. Funke M, et al. **J Neural Transm Suppl** 1998;53:385–98

Subjective symptoms and breathing pattern at rest and following hyperventilation in anxiety and somatoform disorders. Han JN, et al. **J Psychosom Res** 1998 Dec; 45(6):519–32

[Psychophysiologic aspects of the hyperventilation syndrome] Ostroglazov VG. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):26–34 **(Rus)**

THERAPY

The modification of breathing behavior. Pavlovian and operant control in emotion and cognition. Ley R. **Behav Modif** 1999 Jul;23(3):441–79 (170 ref.)

[Tetany, spasmophilia, hyperventilation syndrome: theoretical and therapeutic synthesis] Delvaux M, et al. **Rev Med Liege** 1998 Oct;53(10):610–8 (46 ref.) (Eng. Abstr.) **(Fre)**

HYPERVITAMINOSIS A

COMPLICATIONS

[Benign intracranial hypertension and chronic hypervitaminosis A (letter; comment)] Bousser MG. **Rev Neurol (Paris)** 1998 Nov;154(11):784–5. Comment on: Rev Neurol (Paris) 1998 Apr;154(3):253–6. **(Fre)**

[Benign intracranial hypertension and chronic hypervitaminosis A (see comments)] Drouet A, et al. **Rev Neurol (Paris)** 1998 Apr;154(3):253–6 (Eng. Abstr.). Comment in: Rev Neurol (Paris) 1998 Nov;154(11):784–5. **(Fre)**

ETIOLOGY

Vitamin A toxicity secondary to excessive intake of yellow-green vegetables, liver and laver. Nagai K, et al. **J Hepatol** 1999 Jul;31(1):142–8

METABOLISM

Alterations in kidney enzyme pattern in acute hypervitaminosis A. Alarcón OM, et al. **Arch Latinoam Nutr** 1998 Jun;48(2):129–33

PATHOLOGY

Local disappearance of epiphyseal growth plates in rats with hypervitaminosis A. Kodaka T, et al. **J Vet Med Sci** 1998 Jul;60(7):815–21

VETERINARY

An old, lame cat with reduced food intake and stiff neck. Watson AD. **Aust Vet J** 1998 Dec;76(12):792, 800–1

HYPESTHESIA

New-onset sensory loss or alteration. Huff JS. **Emerg Med Clin North Am** 1998 Nov;16(4):811–24, vi–vii (16 ref.)

CHEMICALLY INDUCED

Toxic effects of acute inhalation exposure to 1,2,4,5-tetramethylbenzene (durene) in experimental animals. Korsak Z, et al. **Int J Occup Med Environ Health** 1998;11(3):267–72

[Accidental catheterization of the subdural space. Confirmation by radiological study] Tornero Tornero JC, et al. **Rev Esp Anestesiol Reanim** 1999 Mar;46(3):126–9 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Quantitative assessment of facial sensation in leprosy. Premkumar R, et al. **Int J Lepr Other Mycobact Dis** 1998 Sep;66(3):348–55

Numb chin syndrome as first sign of temporal arteritis [letter] Généreau T, et al. **J Rheumatol** 1999 Jun;26(6):1425–6

ETIOLOGY

Meralgia paresthetica secondary to limb length discrepancy: case report. Goel A. **Arch Phys Med Rehabil** 1999 Mar; 80(3):348–9

Blink reflex in trigeminal hypoesthesia caused by a pontine demyelinating lesion [letter] Almárcegui C, et al. **J Neurol** 1999 Feb;246(2):140–1

Pain related behaviour during vincristine-induced neuropathy in rats. Authier N, et al. **Neuroreport** 1999 Apr 6;10(5):965–8

Bicortical versus monocortical osteosynthesis [letter; comment] Meyer RA. **Plast Reconstr Surg** 1999 Apr; 103(5):1538–9. Comment on: Plast Reconstr Surg 1998 Jul;102(1):37–41.

Sensory changes after traditional and ultrasound-assisted liposuction using computer-assisted analysis. Trott SA, et al. **Plast Reconstr Surg** 1999 Jun;103(7):2016–25; discussion 2026–8

[Complications of transpalpebral osseous orbital decompressions in thyroid orbitopathies] Spielmann AC, et al. **J Fr Ophtalmol** 1999 Mar;22(2):194–202 (Eng. Abstr.) **(Fre)**

[Lower limb monoplegia and dissociated hypoesthesia after peridural anesthesia] Fernández MF, et al. **Rev Neurol (Paris)** 1999 Sep;155(8):598–600 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Change in corneal sensitivity following laser in situ keratomileusis. Kim WS, et al. **J Cataract Refract Surg** 1999 Mar;25(3):368–73

Impaired peripheral somatosensory function in children with Prader-Willi syndrome. Brandt BR, et al. **Neuropediatrics** 1998 Jun;29(3):124–6

Topographical features of cutaneous tactile hypoesthetic and hyperesthetic abnormalities in chronic pain. Moriwaki K, et al. **Pain** 1999 May;81(1–2):1–6 (43 ref.)

Blood pressure-related hypoalgesia in bulimia nervosa. Girdler SS, et al. **Psychosom Med** 1998 Nov–Dec; 60(6):736–43

[Postoperative sensitivity of vascular pedicles latissimus dorso transplant without neural anastomosis] Schultes G, et al. **Mund Kiefer Gesichtschir** 1998 Sep;2(5):238–41 (Eng. Abstr.) **(Ger)**

SURGERY

[Transplantation of the vascular pedicled thoracicus longus nerve for recovering sensory capacities in the mentalis nerve supply region] Schultes G, et al. **Mund Kiefer Gesichtschir** 1999 Jan;3(1):1–5 (Eng. Abstr.) **(Ger)**

HYPHEMA

CHEMICALLY INDUCED

Hyphema after peribulbar anesthesia for cataract surgery in Fuchs' heterochromic iridocyclitis. Belfort R Jr, et al. **Ocul Immunol Inflamm** 1998 Mar;6(1):57–8

COMPLICATIONS

Hyphema in a neonate [letter] Taugher P. **J Pediatr Ophthalmol Strabismus** 1999 May–Jun;36(3):109

Factors associated with the poor final visual outcome after traumatic hyphema. Cho J, et al. **Korean J Ophthalmol** 1998 Dec;12(2):122–9

DRUG THERAPY

Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Kim MH, et al. **Ophthalmic Surg Lasers** 1998 Sep;29(9):762–6

Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. Rahmani B, et al. **Ophthalmology** 1999 Feb; 106(2):375–9

Traumatic hyphema and patient outcomes--an oversight [letter; comment] Shiuey Y, et al. **Ophthalmology** 1998 Dec; 105(12):2165. Comment on: Ophthalmology 1998 May;105(5):851–5.

ETIOLOGY

Hyphema associated with pupillary dilation in a patient with exfoliation glaucoma and warfarin therapy. Greenfield DS, et al. **Am J Ophthalmol** 1999 Jul;128(1):98–100

Spontaneous hyphaema in hereditary haemorrhagic telangiectasia [letter] Cota NR, et al. **Br J Ophthalmol** 1998 Sep;82(9):1093

An analysis of risk for secondary hemorrhage in traumatic hyphema. Rahmani B, et al. **Ophthalmology** 1999 Feb; 106(2):380–5

[Traumatic hyphema due to contusion. 40 cases] Hammami B, et al. **J Fr Ophtalmol** 1998 Dec;21(10):741–5 (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Effect of melanin on traumatic hyphema in rabbits. Lai WW, et al. **Arch Ophthalmol** 1999 Jun;117(6):789–93

PREVENTION & CONTROL

Photocoagulation of iris nevus to control recurrent hyphema. Todd KC, et al. **Am J Ophthalmol** 1999 Aug;128(2):244–6

SURGERY

Consultation section. Cataract surgical problem. **J Cataract Refract Surg** 1999 Apr;25(4):467–73

THERAPY

[Traumatic hyphema due to contusion. 40 cases] Hammami B, et al. **J Fr Ophtalmol** 1998 Dec;21(10):741–5 (Eng. Abstr.) **(Fre)**

HYPHOCHYTRIUM see **RHINOSPORIDIUM**

HYPHOMYCETES see **MITOSPORIC FUNGI**

HYPNOSIS

Hypnotherapy: an effective treatment modality for trichotillomania. Cohen HA, et al. **Acta Paediatr** 1999 Apr; 88(4):407–10

Improving tolerance of MR imaging with medical hypnosis [letter] Simon EP. **AJR Am J Roentgenol** 1999 Jun; 172(6):1694–5

Using hypnosis to accelerate the healing of bone fractures: a randomized controlled pilot study. Ginandes CS, et al. **Altern Ther Health Med** 1999 Mar;5(2):67–75

Hypnosis vs randomization [letter] Sutcher H. **Altern Ther Health Med** 1998 Nov;4(6):22

Hypnosis in the treatment of hyperemesis gravidarum [letter] Simon EP. **Am Fam Physician** 1999 Jul;60(1):56, 61

Future developments in professional hypnosis training: a review and critique of available training with consideration for development of a nationally coordinated program. Dane JR, et al. **Am J Clin Hypn** 1998 Jul;41(1):38–54

Standards of training in clinical hypnosis: preparing professionals for the 21st century. Elkins GR, et al. **Am J Clin Hypn** 1998 Jul;41(1):55–64

Hypnosis enhances recall memory: a test of forced and non-forced conditions. Fligstein D, et al. **Am J Clin Hypn** 1998 Apr;40(4):297–305

The need for clinically relevant research [editorial] Hammond DC. **Am J Clin Hypn** 1998 Jul;41(1):2–9

Using hypnosis to help deaf children help themselves: report of two cases. Kohen DP, et al. **Am J Clin Hypn** 1998 Apr; 40(4):288–96

A graduate school curriculum in clinical hypnosis. Oster MI. **Am J Clin Hypn** 1998 Jul;41(1):65–74

Childbirth preparation through hypnosis: the hypnoreflexogenous protocol. Schauble PG, et al. **Am J Clin Hypn** 1998 Apr;40(4):273–83

Professional training in the practice of hypnosis--the Australian experience. Stanley RO, et al. **Am J Clin Hypn** 1998 Jul;41(1):29–37

Facilitating facilitators' facilitation: experience with a model for teaching leaders of hypnosis practice groups. Wark D, et al. **Am J Clin Hypn** 1998 Jul;41(1):75–83

Training in clinical hypnosis, a historical perspective: the Montana experience. Watkins JG. **Am J Clin Hypn** 1998 Jul;41(1):10–7

Clinical training in Ericksonian hypnosis. Yapko MD, et al. **Am J Clin Hypn** 1998 Jul;41(1):18–28

Hypnotic technique for sedation of patients during upper gastrointestinal endoscopy. Zimmerman J. **Am J Clin Hypn** 1998 Apr;40(4):284–7

Dependence of explicit and implicit memory on hypnotic state in trauma patients [see comments] Lubke GH, et al. **Anesthesiology** 1999 Mar;90(3):670–80. Comment in: Anesthesiology 1999 Mar;90(3):648–60.

Bilateral neck exploration under hypnosedation: a new standard of care in primary hyperparathyroidism? Meurisse M, et al. **Ann Surg** 1999 Mar;229(3):401–8

The treatment of irritable bowel syndrome with hypnotherapy. Galovski TE, et al. **Appl Psychophysiol Biofeedback** 1998 Dec;23(4):219–32

Functional neuroanatomy of hypnotic state. Maquet P, et al. **Biol Psychiatry** 1999 Feb 1;45(3):327–33

Hypnosis in dermatology. Bellini MA. **Clin Dermatol** 1998 Nov–Dec;16(6):725–6 (7 ref.)

Hypnotic recall: a positive criterion in the differential diagnosis between epileptic and pseudoepileptic seizures. Kuyk J, et al. **Epilepsia** 1999 Apr;40(4):485–91

Autonomic responses to suggestions for cold and warmth in hypnosis. Kistler A, et al. **Forsch Komplementarmed** 1999 Feb;6(1):10–4

Cortical event-related potentials show the structure of hypnotic suggestions is crucial. Barabasz A, et al. **Int J Clin Exp Hypn** 1999 Jan;47(1):5–22

Posthypnotic amnesia for material learned before hypnosis. Bryant RA, et al. **Int J Clin Exp Hypn** 1999 Jan;47(1):46–64

Intentional and spontaneous imagery in hypnosis: the phenomenology of hypnotic responding. Comey G, et al. **Int J Clin Exp Hypn** 1999 Jan;47(1):65–85

Psychophysiological correlates of hypnosis and hypnotic susceptibility. de Pascalis V. **Int J Clin Exp Hypn** 1999 Apr;47(2):117–43 (104 ref.)

Responsiveness to direct versus indirect hypnotic procedures: the role of resistance as a predictor variable. Groth-Marnat G, et al. **Int J Clin Exp Hypn** 1998 Oct;46(4):324–33

Expectancy and suggestibility: are the effects of environmental enhancement due to detection? Kirsch I, et al. **Int J Clin Exp Hypn** 1999 Jan;47(1):40–5

Imagery and hypnotizability revisited. Kogon MM, et al. **Int J Clin Exp Hypn** 1998 Oct;46(4):363–70

Measuring change in the subjective experience of hypnosis. McConkey KM, et al. **Int J Clin Exp Hypn** 1999 Jan; 47(1):23–39

Primary process, hypnotic dreams, and the hidden observer: hypnosis versus alert imagining. Pinnell CM, et al. **Int J Clin Exp Hypn** 1998 Oct;46(4):351–62

Infant communication and the development of hypnotic responsivity. Vandenberg B. **Int J Clin Exp Hypn** 1998 Oct;46(4):334–50 (70 ref.)

Constitutional rights and hypnotically elicited testimony. Newman AW, et al. **J Am Acad Psychiatry Law** 1999; 27(1):149–54

Cerebral mechanisms of hypnotic induction and suggestion. Rainville P, et al. **J Cogn Neurosci** 1999 Jan;11(1):110–25

Hypnosis for pediatric fracture reduction. Iserson KV. **J Emerg Med** 1999 Jan–Feb;17(1):53–6

Self-fulfilling prophecy and hypnotic response are not the same thing. Benham G, et al. **J Pers Soc Psychol** 1998 Dec; 75(6):1604–13

Hypnosis makes headway in the clinic [news] Larkin M. **Lancet** 1999 Jan 30;353(9150):386

Dissociation of sensory and affective dimensions of pain using hypnotic modulation. Rainville P, et al. **Pain** 1999 Aug; 82(2):159–71

Confirming false memories: social construction of "useful" meanings. Fourie DP. **Percept Mot Skills** 1998 Oct; 87(2):536–8

Encoding and recall of parsed stories in hypnosis. Muzur A, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):963–71

Effects of hypnotizability on performance of a Stroop task and event-related potentials. Nordby H, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):819–30

Hypnotic induction profiles, contextual innuendo, and delayed intrusion errors for a narrative: searching for mediating variables. O'Gorman KA, et al. **Percept Mot Skills** 1998 Oct;87(2):587–93

Physiological and psychological effects of active-alert hypnosis. DeVos HM, et al. **Psychol Rep** 1999 Jun;84(3 Pt 2):1123–6

Rhythmical changes of the cutaneous blood flow in the forehead region under the condition of hypnoid relaxation. Mück-Weymann M, et al. **Vasa** 1998 Nov;27(4):220–3

[Hypnosis for smoking cessation] Tønnesen P, et al. **Ugeskr Laeger** 1999 Jul 26;161(30):4270–2 (10 ref.) **(Dan)**

[Hypnosis and self-hypnosis administered and taught by nurses for relief of chronic pain: a controlled clinical trial] Buchser E. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:41–3 (Eng. Abstr.) **(Ger)**

[Clinical hypnotherapy/self-hypnosis for unspecified, chronic and episodic headache without migraine and other defined headaches in children and adolescents] Gysin T. **Forsch Komplementarmed** 1999 Feb;6 Suppl 1:44–6 (Eng. Abstr.) **(Ger)**

[Hypnosis is efficient in functional intestinal disease] Sjöberg M, et al. **Lakartidningen** 1999 Apr 14;96(15):1845–7 **(Swe)**

[Self-hypnosis against fear in connection with labor? (letter; comment)] Swedhner B. **Lakartidningen** 1999 Sep 8; 96(36):3760. Comment on: Lakartidningen 1999 May 12;96(19):2322–4. **(Swe)**

HISTORY

Hysteria, hypnosis, and moral sense in French 19th-century forensic psychiatry. The Eyraud-Bompard case. Plas R. **Int J Law Psychiatry** 1998 Fall;21(4):397–407

EMDR and Mesmerism: a comparative historical analysis. McNally RJ. **J Anxiety Disord** 1999 Jan–Apr; 13(1–2):225–36

METHODS

Biofeedback, cognitive-behavioral methods, hypnosis: "alternative psychotherapy"? Panconesi E, et al. **Clin Dermatol** 1998 Nov–Dec;16(6):709–10 (3 ref.)

Clinical hypnosis versus cognitive behavioral training for pain management with pediatric cancer patients undergoing bone marrow aspirations. Liossi C, et al. **Int J Clin Exp Hypn** 1999 Apr;47(2):104–16

Medical hypnosis and orthopedic hand surgery: pain perception, postoperative recovery, and therapeutic comfort. Mauer MH, et al. **Int J Clin Exp Hypn** 1999 Apr; 47(2):144–61

Brief modification of suggestibility and hypnotic analgesia: too good to be true? Milling LS, et al. **Int J Clin Exp Hypn** 1999 Apr;47(2):91–103

Hypnotically induced control of nausea: a preliminary report. Renouf D. **J Psychosom Res** 1998 Sep;45(3):295–6 (13 ref.)

Hypnosis using a communication device to increase magnetic resonance imaging tolerance with a claustrophobic patient. Simon EP. **Mil Med** 1999 Jan;164(1):71–2

HYPNOSIS

Hypnosis in a case of long-standing idiopathic itch. Rucklidge JJ, et al. **Psychosom Med** 1999 May-Jun; 61(3):355-8

What if your patient prefers an alternative pain control method? Self-hypnosis in the control of pain. Nickelson C, et al. **South Med J** 1999 May;92(5):521-3

[Hypnosis and its application in surgery] Faymonville ME, et al. **Rev Med Liege** 1998 Jul;53(7):414-8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Clinical hypnosis. Current status of theory and empirical aspects] Revenstorf D.
Psychother Psychosom Med Psychol 1999 Jan;49(1):5-13 (68 ref.) (Eng. Abstr.) **(Ger)**

HYPNOSIS, DENTAL

[Hypnosis lightens everyday practice (news)] Trechslin F. **Schweiz Monatsschr Zahnmed** 1998;108(9):888-91, 925-8 **(Ger, Fre)**

HYPNOTICS AND SEDATIVES

see related
HISTAMINE H1 ANTAGONISTS
TRANQUILIZING AGENTS

Hallucinogen, opiate, sedative and stimulant use and abuse in a population-based sample of female twins. Kendler KS, et al. **Acta Psychiatr Scand** 1999 May;99(5):368-76

Iatrogenic sedative dependence and abuse--have doctors learnt caution? [editorial] Lader M. **Addiction** 1998 Aug; 93(8):1133-5

Remifentanil for regional anesthesia [letter; comment] Federolf GK. **Anesth Analg** 1999 Aug;89(2):535. Comment on: Anesth Analg 1999 Jan;88(1):134-40.

Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Weerts EM, et al. **Behav Pharmacol** 1998 May; 9(3):285-97

Guidelines for training in patient monitoring and sedation and analgesia. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1998 Dec;48(6):669-71

Verbal communication: what do critical care nurses say to their unconscious or sedated patients? Elliott R, et al.
J Adv Nurs 1999 Jun;29(6):1412-20

Sedation with xylazine and lumbosacral epidural administration of lidocaine and xylazine for umbilical surgery in calves. Lewis CA, et al.
J Am Vet Med Assoc 1999 Jan 1;214(1):89-95

Analgesia and sedation in the critically ill--a practical approach. Piccolo R, et al. **S Afr J Surg** 1999 Feb; 37(1):15-20

[Unsatisfied craving: zolpidem (Stilnox) dependence syndrome] Hofmann M, et al. **Psychiatr Prax** 1998 Nov; 25(6):313 **(Ger)**

[Llamas--sedation and anesthesia (review article)] Neiger-Aeschbacher G. **Schweiz Arch Tierheilkd** 1999; 141(7):307-18 (34 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Pitrosky B, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R812-28

Dexmedetomidine failed to block the acute hyperdynamic response to electroconvulsive therapy. Fu W, et al.
Anesthesiology 1999 Feb;90(2):422-4

Paroxysmal sneezing during local anesthesia for ocular surgery with thiopentone hypnosis [letter] Wessels IF, et al. **Can J Anaesth** 1999 Jun;46(6):617

Continuous i.v. sedation and mechanical ventilation [letter; comment] Hersch M, et al. **Chest** 1999 Apr;115(4):1220. Comment on: Chest 1998 Aug;114(2):541-8.

Sedation and anesthesia of pet rabbits. Borkowski R, et al. **Clin Tech Small Anim Pract** 1999 Feb;14(1):44-9 (21 ref.)

Sedation and chemical restraint in the dog and cat. Karas AZ. **Clin Tech Small Anim Pract** 1999 Feb;14(1):15-26 (11 ref.)

Adjuncts to analgesia. Sedation and neuromuscular blockade. Lowson SM, et al. **Crit Care Clin** 1999 Jan;15(1):119-41, vii (132 ref.)

Sedation: if you do not know where you are going, any road will get you there [editorial; comment] Lieberman J, et al. **Crit Care Med** 1999 Jul;27(7):1395-6. Comment on: Crit Care Med 1999 Jul;27(7):1325-9.

Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients [see comments] Riker RR, et al. **Crit Care Med** 1999 Jul;27(7):1325-9. Comment in: Crit Care Med 1999 Jul;27(7):1395-6.

Pain management and weaning from narcotics and sedatives. Ganea GR, et al. **Curr Opin Pediatr** 1999 Jun;11(3):207-12 (29 ref.)

Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Hajak G, et al.
Eur Arch Psychiatry Clin Neurosci 1998;248(3):148-56

Analgesia and sedation with propofol-NSAIDs for day-hospital extracorporeal shock wave lithotripsy (ESWL). Iannarone C, et al.
Eur Rev Med Pharmacol Sci 1997 Nov-Dec;1(6):203-6

The influence of an instruction on the stimulus effects of drugs in humans. Johanson CE, et al.
Exp Clin Psychopharmacol 1998 Nov;6(4):427-32

Who should sedate a pediatric patient? Gupta P.
Indian Pediatr 1998 Aug;35(8):805-7

Xenon suppresses the hypnotic arousal in response to surgical stimulation. Nakata Y, et al. **J Clin Anesth** 1999 Jun; 11(4):305-9

Sedatives in late-stage Alzheimer's disease [letter] Mange MS. **J Okla State Med Assoc** 1998 Oct;91(7):411

Oxygen saturation during esophagogastroduodenoscopy in children: general anesthesia versus intravenous sedation [letter; comment] Sabra S, et al.
J Pediatr Gastroenterol Nutr 1999 Apr;28(4):455. Comment on: J Pediatr Gastroenterol Nutr 1998 Aug;27(2):172-5.

Pilot evaluation of hypnotic medication during acute traumatic stress response. Mellman TA, et al.
J Trauma Stress 1998 Jul;11(3):563-9

[Guideline for administration of sedatives and analgesics by physicians who are not anesthesiologists. National Organization for Quality Assurance in Hospitals (see comments)] Knape JT, et al. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1098-102 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 May 22;143(21):1077-9. **(Dut)**

[Is there a rational need for sleeping pills of group B?] Hartvig P, et al. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2070 **(Nor)**

[Terminal care sedation] Kaasa S. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2542-3 **(Nor)**

[Collegial support to improve prescription patterns for addictive preparations] von Hanno T, et al.
Tidsskr Nor Laegeforen 1999 Jun 30;119(17):2520-5 (Eng. Abstr.) **(Nor)**

[Oral dormicum premedication of children in day surgery] Ostreikov IF, et al. **Anesteziol Reanimatol** 1999 May-Jun; (3):12-4 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Pregnancy outcome following first-trimester exposure to zopiclone: a prospective controlled cohort study. Diav-Citrin O, et al. **Am J Perinatol** 1999;16(4):157-60

Relaxation to assist sleep medication withdrawal. Lichstein KL, et al. **Behav Modif** 1999 Jul;23(3):379-402

Hepatotoxicity associated with zolpidem treatment. Karsenti D, et al. **BMJ** 1999 May 1;318(7192):1179

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Hindmarch I, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:133-42 (42 ref.)

Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Kay GG, et al. **Clin Exp Allergy** 1999 Jul;29 Suppl 3:147-50 (19 ref.)

Non-traumatic rhabdomyolysis with gluteal ulcer. Yotsuyanagi T, et al. **Clin Exp Dermatol** 1998 May; 23(3):113-5

Use of phenothiazines as sedatives in children: what are the risks? Dyer KS, et al. **Drug Saf** 1999 Aug;21(2):81-90 (47 ref.)

Adverse drug interactions in dental practice: interactions associated with local anesthetics, sedatives and anxiolytics. Part IV of a series. Moore PA. **J Am Dent Assoc** 1999 Apr;130(4):541-54 (70 ref.)

Association of road-traffic accidents with benzodiazepine use [letter; comment] MacDonald TM. **Lancet** 1998 Dec 19-26; 352(9145):2019-20. Comment on: Lancet 1998 Oct 24;352(9137):1324-5.

Zolpidem tartrate and somnambulism. Harazin J, et al.
Mil Med 1999 Sep;164(9):669-70

Melatonin-induced withdrawal emergent dyskinesia and akathisia. Giladi N, et al. **Mov Disord** 1999 Mar;14(2):381-2

[Zopiclone and delirium: a case report (letter)] David M, et al. **Therapie** 1998 Jan-Feb;53(1):78-80 **(Fre)**

[Safety profile of zolpidem: two studies of 3805 patients by Swiss practitioners] Ganzoni E, et al.
Schweiz Rundsch Med Prax 1999 Jun 24;88(25-26):1120-7 (Eng. Abstr.) **(Ger)**

[Risk of abuse when using zopiclone (letter)] Irgens A.
Tidsskr Nor Laegeforen 1998 Aug 30;118(20):3180 **(Nor)**

ANALYSIS

Determination of embutramide and pentobarbital in meat and bone meal by gas chromatography-mass spectrometry. Hooijerink D, et al. **Analyst** 1998 Dec;123(12):2513-6

Determination of bromvalerylurea and its metabolites in biological samples by frit-fast atom bombardment liquid chromatography-mass spectrometry. Tsuchihashi H, et al. **J Anal Toxicol** 1998 Nov-Dec;22(7):591-5

ANTAGONISTS & INHIBITORS

Zolpidem 10 mg given at daytime is not antagonized by 300 mg caffeine in man. Mattila MJ, et al.
Eur J Clin Pharmacol 1998 Jul;54(5):421-5

BLOOD

Stereoselective binding of zopiclone to human plasma proteins. Fernandez C, et al. **Chirality** 1999;11(2):129-32

[Detection of zopiclone in many drivers--a sign of misuse or abuse] Bramness JG, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20;119(19):2820-1 (Eng. Abstr.) **(Nor)**

CHEMICAL SYNTHESIS

Synthesis and biological activities of dibenzyl dipiperazine diquaternary ammonium salts. Li RT, et al.
Arch Pharm (Weinheim) 1999 May;332(5):179-81

Synthesis and sedative-hypnotic effects of N3-allyl- and N1-allyl-5,6-substituted 2-thiouracil derivatives in mice. Dramiński M, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1370-3

Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. Estrada E, et al.
J Comput Aided Mol Des 1998 Nov;12(6):583-95

CHEMISTRY

Physicochemical characterization and in vivo properties of Zolpidem in solid dispersions with polyethylene glycol 4000 and 6000. Trapani G, et al. **Int J Pharm** 1999 Jul 5;184(1):121-30

The scientific basis for the reputed activity of Valerian. Houghton PJ. **J Pharm Pharmacol** 1999 May;51(5):505-12

METABOLISM

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Von Moltke LL, et al. **Br J Clin Pharmacol** 1999 Jul;48(1):89-97

Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Chouinard G, et al. **Cell Mol Neurobiol** 1999 Aug;19(4):533-52 (90 ref.)

Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Becquemont L, et al. **Drug Metab Dispos** 1999 Sep;27(9):1068-73

Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Kawashima K, et al.
Drug Metab Dispos 1999 Mar;27(3):422-8

Debromination of (alpha-bromoiso-valeryl)urea catalysed by rat blood. Kitamura S, et al. **J Pharm Pharmacol** 1999 Jan; 51(1):73-8

Reductive debromination of (alpha-bromoiso-valeryl)urea by intestinal bacteria. Kitamura S, et al.
J Pharm Pharmacol 1999 Jan;51(1):79-84

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity [see comments] Parman T, et al. **Nat Med** 1999 May;5(5):582-5. Comment in: Nat Med 1999 May;5(5):489-90. Comment in: Nat Med 1999 Jul;5(7):715. Comment in: Nat Med 1999 Aug;5(8):853.

Production of the sedative triterpene galphimine B in Galphimia glauca tissue culture. Osuna L, et al.
Planta Med 1999 Mar;65(2):149-52

PHARMACOKINETICS

Zaleplon pharmacokinetics and absolute bioavailability. Rosen AS, et al. **Biopharm Drug Dispos** 1999 Apr; 20(3):171-5

Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. Darwish M, et al.
J Clin Pharmacol 1999 Jul;39(7):670-4

Zolpidem distribution in postmortem cases. Levine B, et al.
J Forensic Sci 1999 Mar;44(2):369-71

Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Rush CR, et al.
Psychopharmacology (Berl) 1999 Jul;145(1):39-51

PHARMACOLOGY

Sensitivity to ethanol across development in rats: comparison to [3H]zolpidem binding. Moy SS, et al.
Alcohol Clin Exp Res 1998 Oct;22(7):1485-92

Ontogeny of rapid tolerance to the hypnotic effects of ethanol. Silveri MM, et al. **Alcohol Clin Exp Res** 1999 Jul; 23(7):1180-4

Action of ethanol and zolpidem on gamma-aminobutyric acid responses from cerebellar Purkinje neurons: relationship to beta-adrenergic receptor input. Yang X, et al.
Alcohol Clin Exp Res 1998 Nov;22(8):1655-61

Sedative effects of intramuscular administration of a low dose of romifidine in dogs. Lemke KA. **Am J Vet Res** 1999 Feb;60(2):162-8

Cardiorespiratory effects of a tiletamine/zolazepam-ketamine-detomidine combination in horses. Muir WW 3rd, et al. **Am J Vet Res** 1999 Jun; 60(6):770-4

Isobolographic analysis of propofol-thiopental hypnotic interaction in surgical patients. Vinik HR, et al.
Anesth Analg 1999 Mar;88(3):667-70

Studies on the sedative and hypnotic effects of oleamide in mice. Yang JY, et al. **Arzneimittelforschung** 1999 Aug; 49(8):663-7

Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Mintzer MZ, et al. **Behav Pharmacol** 1998 Nov;9(7):545-59

The effects of new hypnotic drugs in rats trained to discriminate ethanol. Sanger DJ. **Behav Pharmacol** 1997 Aug;8(4):287-92

Characterization of the electrophysiological and pharmacological effects of 4-iodo-2,6-diisopropylphenol, a propofol analogue devoid of sedative-anaesthetic properties. Sanna E, et al. **Br J Pharmacol** 1999 Mar; 126(6):1444-54

Synthesis and sedative-hypnotic effects of N3-allyl- and N1-allyl-5,6-substituted 2-thiouracil derivatives in mice. Dramiński M, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1370-3

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Greenblatt DJ, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):661-71

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Greenblatt DJ, et al. **Clin Pharmacol Ther** 1998 Nov;64(5):553–61

The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Lambert DM, et al. **Curr Med Chem** 1999 Aug;6(8):757–73 (119 ref.)

Response patterns of the Spanish version of the 49-item short form of the Addiction Research Center Inventory after the use of sedatives, stimulants, and opioids. Arasteh K, et al. **Drug Alcohol Depend** 1999 Jun 1;55(1–2):117–25

Electrophysiological and behavioral effects of Tyr-D-Arg-Phe-Sar on locus coeruleus neurons of the rat. Yang YR, et al. **Eur J Pharmacol** 1998 Jun 12; 351(1):23–30

Different effects of L-type and T-type calcium channel blockers on the hypnotic potency of triazolam and zolpidem in rats. Takahashi H, et al. **Eur Neuropsychopharmacol** 1999 Jun;9(4):317–21

The effects of benzodiazepine (triazolam), cyclopyrrolone (zopiclone) and imidazopyridine (zolpidem) hypnotics on the frequency of hippocampal theta activity and sleep structure in rats. Yoshimoto M, et al. **Eur Neuropsychopharmacol** 1999 Jan;9(1–2):29–35

Low-level steady-state auditory evoked potentials: effects of rate and sedation on detectability. Dobie RA, et al. **J Acoust Soc Am** 1998 Dec;104(6):3482–8

Influence of ondansetron on thiopental hypnotic requirements. Kostopanagiotou G, et al. **J Clin Pharmacol** 1998 Sep;38(9):825–9

The endogenous lipid oleamide activates serotonin 5-HT7 neurons in mouse thalamus and hypothalamus. Thomas EA, et al. **J Neurochem** 1999 Jun;72(6):2370–8

Reduction of zolpidem sensitivity in a freeze lesion model of neocortical dysgenesis. Defazio RA, et al. **J Neurophysiol** 1999 Jan;81(1):404–7

GABAA receptor subunit composition and functional properties of Cl- channels with differential sensitivity to zolpidem in embryonic rat hippocampal cells. Maric D, et al. **J Neurosci** 1999 Jun 15;19(12):4921–37

Inhibition of nitric oxide metabolism enhances the hypnotic-anesthetic action of the alpha2-adrenoceptor agonist dexmedetomidine in vivo. Tonner PH, et al. **J Neurosurg Anesthesiol** 1999 Jan;11(1):37–41

Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. McLeod RL, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):43–50

Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. Griebel G, et al. **J Psychopharmacol** 1998;12(4):356–65

Effects of ginseng on ethanol induced sedation in mice. Koo MW. **Life Sci** 1999;64(2):153–60

Development of congenics for hypnotic sensitivity to ethanol by QTL-marker-assisted counter selection. Bennett B, et al. **Mamm Genome** 1998 Dec;9(12):969–74

Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Cheer JF, et al. **Neuropharmacology** 1999 Apr;38(4):533–41

Characterization of the hypnotic properties of oleamide. Basile AS, et al. **Neuroreport** 1999 Apr 6;10(5):947–51

Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Homanics GE, et al. **Pharmacol Biochem Behav** 1999 May;63(1):21–6

Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Rush CR. **Pharmacol Biochem Behav** 1998 Nov;61(3):253–69 (154 ref.)

Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats. Silvestre JS, et al. **Pharmacol Biochem Behav** 1999 Sep;64(1):1–5

Evaluation of semicarbazones for anticonvulsant and sedative-hypnotic properties. Pandeya SN, et al. **Pharmazie** 1999 Apr;54(4):300–2

Combination of open field and elevated plus-maze: a suitable test battery to assess strain as well as treatment differences in rat behavior. Schmitt U, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Oct; 22(7):1197–215

The hypnotic effects of melatonin treatment on diurnal sleep in humans. Matsumoto M. **Psychiatry Clin Neurosci** 1999 Apr;53(2):243–5

Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Bocca ML, et al. **Psychopharmacology (Berl)** 1999 Apr;143(4):373–9

The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Fernandes C, et al. **Psychopharmacology (Berl)** 1999 Aug; 145(3):251–9

Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Wiley JL, et al. **Psychopharmacology (Berl)** 1998 Dec;140(4):503–9

Use of midlatency auditory-evoked potentials as indicator of unconsciousness in the dog: characterisation of the effects of acepromazine-thiopentone, medetomidine-thiopentone and medetomidine-butorphanol-midazolam combinations. Pypendop B, et al. **Res Vet Sci** 1999 Aug;67(1):35–9

Thalidomide increases both REM and stage 3–4 sleep in human adults: a preliminary study. Kanbayashi T, et al. **Sleep** 1999 Feb 1;22(1):113–5

Reversal of sedative and clinicophysiological effects of epidural xylazine and detomidine with atipamezole and yohimbine in buffaloes (Bubalus bubalis). Tiwari SK, et al. **Vet Rec** 1998 Nov 7;143(19):529–32

The effect of sedation on gastric emptying of a liquid marker in ponies. Doherty TJ, et al. **Vet Surg** 1999 Sep-Oct; 28(5):375–9

Detomidine-propofol anesthesia for abdominal surgery in horses. Matthews NS, et al. **Vet Surg** 1999 May-Jun; 28(3):196–201

Comparison of sedative effects of medetomidine-midazolam, acepromazine-butorphanol and midazolam-butorphanol in dogs. Kojima K, et al. **Zentralbl Veterinarmed A** 1999 Apr; 46(3):141–8

[Methods of sleep induction for EEG recordings: comparison between three hypnotics and natural sleep] Takasaka Y, et al. **No To Hattatsu** 1999 Mar;31(2):153–8 (Eng. Abstr.) **(Jpn)**

[Effect of etomidate and thiopental on the onset of rocuronium action] Muñoz Letelier H, et al. **Rev Esp Anestesiol Reanim** 1999 Jun-Jul;46(6):252–5 (Eng. Abstr.) **(Spa)**

POISONING

[An autopsy case of poisoning by neuropsychopharmaceuticals including zopiclone] Yamazaki M, et al. **Nippon Hoigaku Zasshi** 1998 Aug; 52(4):245–52 (Eng. Abstr.) **(Jpn)**

STANDARDS

Comparison of five sedation scoring systems by means of auditory evoked potentials [see comments] Schulte-Tamburen AM, et al. **Intensive Care Med** 1999 Apr;25(4):377–82. Comment in: Intensive Care Med 1999 Apr;25(4):350–2.

THERAPEUTIC USE

A survey of hypnotic use in geriatric institutions in Sogn og Fjordane, Norway. Schjøtt J, et al. **Aging (Milano)** 1999 Feb;11(1):50–5

Effect of pharmaceutical services on adherence to criteria-for-use guidelines in the operating room. Higgins B, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):977–82 (7 ref.)

The safety and effectiveness of remifentanil as an adjunct sedative for regional anesthesia [see comments] Lauwers M, et al. **Anesth Analg** 1999 Jan;88(1):134–40. Comment in: Anesth Analg 1999 Aug;89(2):535.

The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Goldberg D, et al. **Br J Gen Pract** 1998 Dec; 48(437):1840–4

Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit [see comments] Devlin JW, et al. **Crit Care Med** 1999 Jul;27(7):1271–5. Comment in: Crit Care Med 1999 Jul;27(7):1384–5.

The ideal sedation assessment tool: an elusive instrument [editorial; comment] Wittbrodt ET. **Crit Care Med** 1999 Jul;27(7):1384–5. Comment on: Crit Care Med 1999 Jul;27(7):1271–5.

Anxiolytic and hypnotic use by general hospital inpatients. The impact of psychopathology and general medical conditions. Pélissolo A, et al. **Gen Hosp Psychiatry** 1999 Mar-Apr;21(2):79–86

Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Hajak G, et al. **Int Clin Psychopharmacol** 1998 Jul;13(4):157–67

Use of hypnotics among patients in geriatric institutions. Opedal K, et al. **Int J Geriatr Psychiatry** 1998 Dec; 13(12):846–51

Sedation for the critically ill. Sydow M, et al. **Intensive Care Med** 1999 Jun;25(6):634–6 (4 ref.)

The effect of a dissociative dose of ketamine on the bispectral index (BIS) during propofol hypnosis. Friedberg BL. **J Clin Anesth** 1999 Feb;11(1):4–7

Oral clonidine for sedation and analgesia in a burn patient. Kariya N, et al. **J Clin Anesth** 1998 Sep;10(6):514–7

Remifentanil for conscious sedation and analgesia during awake fiberoptic tracheal intubation: a case report with pharmacokinetic simulations. Reusche MD, et al. **J Clin Anesth** 1999 Feb;11(1):64–8

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. Elie R, et al. **J Clin Psychiatry** 1999 Aug;60(8):536–44

Piezoelectric lithotripsy of ureteral stones: influence of shockwave frequency on sedation and therapeutic efficiency. Robert M, et al. **J Endourol** 1999 Apr; 13(3):157–60

Commentary: sedation in response to refractory existential distress: walking the fine line. Cherny NI. **J Pain Symptom Manage** 1998 Dec;16(6):404–6

Sedation for uncontrolled symptoms in a South African hospice [see comments] Fainsinger RL, et al. **J Pain Symptom Manage** 1998 Sep;16(3):145–52. Comment in: J Pain Symptom Manage 1999 Jun;17(6):448–9.

Commentary: a case of "terminal sedation" in the family. Rosen EJ. **J Pain Symptom Manage** 1998 Dec;16(6):406–7

Case presentation: "terminal sedation" and existential distress. [clinical conference] Shaiova L. **J Pain Symptom Manage** 1998 Dec;16(6):403–4

From the Food and Drug Administration. Henney JE. **JAMA** 1999 Oct 6;282(13):1218

Development of a nurse-led sedation service for paediatric magnetic resonance imaging. Sury MR, et al. **Lancet** 1999 May 15;353(9165):1667–71

Zolpidem in progressive supranuclear palsy [letter] Daniele A, et al. **N Engl J Med** 1999 Aug 12;341(7):543–4

Sedation for pediatric imaging studies. Hopkins KL, et al. **Neuroimaging Clin N Am** 1999 Feb;9(1):1–10 (47 ref.)

Ethanol as a hypnotic in insomniacs: self administration and effects on sleep and mood. Roehrs T, et al. **Neuropsychopharmacology** 1999 Mar;20(3):279–86

Use of anxiolytics and hypnotics in gynecological, surgical and medical departments of general hospitals. Wancata J, et al. **Pharmacopsychiatry** 1998 Sep;31(5):178–86

Concomitant therapy with anxiolytics or hypnotics and maintenance of initial SSRI therapy. Shields SA, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1298–303

Zolpidem for insomnia related to PTSD [letter] Dieperink ME, et al. **Psychiatr Serv** 1999 Mar;50(3):421

The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Pat-Horenczyk R, et al. **Psychopharmacology (Berl)** 1998 Dec;140(4):450–7

Removal of a foreign body lodged in the larynx using morphine as a sedative. Boye-Hansen T, et al. **Resuscitation** 1998 Sep;38(3):197–8

Withdrawal of Immobilon LA [letter] Fletcher J. **Vet Rec** 1999 Jul 3;145(1):27–8

[What are the indications and what are the modalities of sedation and curarization except for the specific treatment of intracranial hypertension?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):79–84 (28 ref.) **(Fre)**

[Use of hypnotics in children: description and analysis] Pélissolo A, et al. **Arch Pediatr** 1999 Jun;6(6):625–30 (Eng. Abstr.) **(Fre)**

[Alcoholism: withdrawal syndrome. Diagnosis, treatment] Deffond D, et al. **Rev Prat** 1999 Jun 15;49(12):1337–9 **(Fre)**

[The German Cardiovascular Disease Prevention Study: social gradient in use of drugs with a potentially addictive nature. An analysis of selected indications groups] Breckenkamp J, et al. **Med Klin** 1999 Jun 15;94(6):306–13 (Eng. Abstr.) **(Ger)**

[Changes in sedative therapy?] Shnädelbach S. **Med Monatsschr Pharm** 1998 Dec;21(12):391–2 (7 ref.) **(Ger)**

[Safety profile of zolpidem: two studies of 3805 patients by Swiss practitioners] Ganzoni E, et al. **Schweiz Rundsch Med Prax** 1999 Jun 24;88(25–26):1120–7 (Eng. Abstr.) **(Ger)**

[Acute pain, analgesia and sedation in children (V): analgesia and sedation in pediatric intensive care] Valdivielso Serna A, et al. **An Esp Pediatr** 1998 Aug;49(2):193–208 (76 ref.) **(Spa)**

[Sleep disorders and the consumption of hypnotics on the island of Mallorca] Cañellas Dols F, et al. **Rev Clin Esp** 1998 Nov;198(11):719–25 (Eng. Abstr.) **(Spa)**

HYPNOTICS, BARBITURATE see **SEDATIVES, BARBITURATE**

HYPNOTICS, NONBARBITURATE see **SEDATIVES, NONBARBITURATE**

HYPOACTIVE SEXUAL DESIRE DISORDER see **SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL**

HYPOALDOSTERONISM

Hyper- and hypoaldosteronism. Torpy DJ, et al. **Vitam Horm** 1999;57:177–216 (122 ref.)

CHEMICALLY INDUCED

Megestrol acetate therapy and secondary adrenal suppression. Naing KK, et al. **Cancer** 1999 Sep 15; 86(6):1044–9

COMPLICATIONS

Erythropoietin deficiency in hyporeninemia. Donnelly S, et al. **Am J Kidney Dis** 1999 May;33(5):947–53

DIAGNOSIS

Hyperkalemic renal tubular acidosis. Shah SM, et al. **Indian Pediatr** 1998 Dec;35(12):1224–7

GENETICS

Homozygous deletion of arginine-173 in the CYP11B2 gene in a girl with congenital hypoaldosteronism. Corticosterone methyloxidase deficiency type II. Peter M, et al. **Horm Res** 1998;50(4):222–5

Hypertension. Warnock DG. **Semin Nephrol** 1999 Jul; 19(4):374–80 (55 ref.)

PATHOLOGY

Prominent medial hypertrophy of renal arterioles in an infant with hyporeninemic hypoaldosteronism. Tsuchida S, et al. **Pediatr Nephrol** 1999 Apr;13(3):230–2

HYPOALDOSTERONISM, HYPORENINEMIC see

HYPOALDOSTERONISM, HYPORENINEMIC

HYPOALDOSTERONISM

HYPOALPHALIPOPROTEINEMIA, FAMILIAL see **TANGIER DISEASE**

HYPOBETALIPOPROTEINEMIA

BLOOD

Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Ahmed A, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2598–9

COMPLICATIONS

Asymptomatic elevation of aminotransferase levels and fatty liver secondary to heterozygous hypobetalipoproteinemia. Ahmed A, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2598–9

GENETICS

Donor splice mutation (665 + 1 G—T) in familial hypobetalipoproteinemia with no detectable apoB truncation. Pulai JI, et al. **Am J Med Genet** 1998 Nov 16; 80(3):218–20

Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the framingham offspring population. Welty FK, et al.
Arterioscler Thromb Vasc Biol 1998 Nov;18(11):1745–51

A case of McLeod syndrome with chronic renal failure. Jeren-Strujić B, et al. **Blood Purif** 1998;16(6):336–40

Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Lonardo A, et al. **Dig Dis Sci** 1998 Nov;43(11):2489–92 (46 ref.)

A gene-targeted mouse model for familial hypobetalipoproteinemia. Low levels of apolipoprotein B mRNA in association with a nonsense mutation in exon 26 of the apolipoprotein B gene. Kim E, et al.
J Biol Chem 1998 Dec 18;273(51):33977–84

Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. Wu J, et al. **J Lipid Res** 1999 May;40(5):955–9

HYPOCALCEMIA

[Hypocalcemia] Garabédian M. **Rev Prat** 1998 Jun 1; 48(11):1201–6 (10 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients. Borrego MJ, et al.
Am J Kidney Dis 1999 Sep;34(3):456–63

Parathyroid hormone is not a key hormone in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in rats [see comments] Wang W, et al.
Eur J Clin Invest 1999 Apr;29(4):309–20. Comment in: Eur J Clin Invest 1999 Apr;29(4):274–7.

CHEMICALLY INDUCED

Symptomatic hypocalcemia from oral sodium phosphate: a report of two cases [see comments] Boivin MA, et al.
Am J Gastroenterol 1998 Dec;93(12):2577–9. Comment in: Am J Gastroenterol 1999 Jul;94(7):1991–2.

Hyperphosphatemia–hypocalcemia in gastroschisis [letter; comment] Pfitzer L, et al. **Am J Gastroenterol** 1999 Jul; 94(7):1991–2. Comment on: Am J Gastroenterol 1998 Dec;93(12):2577–9.

Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Meier-Kriesche HU, et al.
Am J Kidney Dis 1999 Apr;33(4):e8

Pulmonary injury after ski wax inhalation exposure. Bracco D, et al. **Ann Emerg Med** 1998 Nov;32(5):616–9

Hypocalcemia associated with alendronate [letter] Schussheim DH, et al. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):329

Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients [letter] Chong G, et al.
Aust N Z J Med 1999 Feb;29(1):96–7

Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Sims EC, et al.
Clin Oncol (R Coll Radiol) 1998;10(6):407–9

Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy [letter] De Schepper J, et al.
Eur J Pediatr 1999 Sep;158(9):765–6

Dynamic tests of parathyroid hormone secretion using hemodialysis and calcium infusion cannot be compared. Moysés RM, et al. **Kidney Int** 1999 Aug;56(2):659–65

[Hypocalcemia in a patient treated with estramustine (letter)] Vatan R, et al. **Presse Med** 1999 Jun 5;28(20):1070–1 **(Fre)**

COMPLICATIONS

Ophthalmoplegia: an unusual manifestation of hypocalcemia [letter] Marinella MA. **Am J Emerg Med** 1999 Jan; 17(1):105–6

Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: possible culprits for postcountershock arrhythmias? Niemann JT, et al.
Ann Emerg Med 1999 Jul;34(1):1–7

Non-convulsive status epilepticus in a patient with hypocalcemia. Kline CA, et al. **J Emerg Med** 1998 Sep–Oct; 16(5):715–8

Symptomatic hypocalcaemia in hypermagnesaemia-induced hypoparathyroidism, during magnesium tocolytic therapy--possible involvement of the calcium-sensing receptor. Mayan H, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1764–6

DIAGNOSIS

Bilateral femoral neck fractures secondary to hypocalcemic seizures in a skeletally immature patient. Blanco JS, et al.
Am J Orthop 1999 Mar;28(3):187–8

A case of factitious normocalcaemia [letter] Liu D, et al.
Ann Clin Biochem 1999 Jul;36 (Pt 4):530–1

Early postoperative calcium levels as predictors of hypocalcemia. Adams J, et al. **Laryngoscope** 1998 Dec; 108(12):1829–31

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Urologe A** 1999 May;38(3):285–95 (6 ref.) **(Ger)**

[Hypocalcemia and bone deformities in an infant] González Vicent M, et al. **An Esp Pediatr** 1998 Sep;49(3):311–2 **(Spa)**

[Evaluation of diagnostic tests for hypocalcemia in critically ill newborns] Serret-Montoya J, et al. **Rev Invest Clin** 1998 Nov–Dec;50(6):471–6 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Bone, parathyroid hormone and the response to the rapid induction of hypocalcaemia [comment] Felsenfeld AJ.
Eur J Clin Invest 1999 Apr;29(4):274–7. Comment on: Eur J Clin Invest 1999 Apr;29(4):309–20.

Parathyroid hormone is not a key hormone in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in rats [see comments] Wang W, et al.
Eur J Clin Invest 1999 Apr;29(4):309–20. Comment in: Eur J Clin Invest 1999 Apr;29(4):274–7.

Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Sela-Brown A, et al.
Mol Endocrinol 1998 Aug;12(8):1193–200

ETIOLOGY

Hypocalcemia as a complication of radioiodine therapy. Winslow CP, et al. **Am J Otolaryngol** 1998 Nov–Dec; 19(6):401–3 (15 ref.)

Hypocalcemic tetany in a toddler with undiagnosed rickets. Duplechin RY, et al. **Ann Emerg Med** 1999 Sep; 34(3):399–402

A 42-year-old man with microcytic anemia and hypocalcemia. Matteoni CA, et al. **Cleve Clin J Med** 1999 May;66(5):270–2

Hypocalcemia due to spontaneous infarction of parathyroid adenoma and osteomalacia in a patient with primary hyperparathyroidism. Otsuka F, et al. **Endocr J** 1998 Oct; 45(5):617–23

Neonatal hypocalcaemia associated with rotavirus diarrhoea. Foldenauer A, et al. **Eur J Pediatr** 1998 Oct;157(10):838–42

Clinical implications of hypocalcemia in malaria. Prabha MR, et al. **Indian J Med Res** 1998 Aug;108:62–5

Phototherapy induced hypocalcemia [letter] Jain BK, et al.
Indian Pediatr 1998 Jun;35(6):566–7

Hypocalcemia induced during major and minor abdominal surgery in humans. Lepage R, et al.
J Clin Endocrinol Metab 1999 Aug;84(8):2654–8

Consumption of soft drinks with phosphoric acid as a risk factor for the development of hypocalcemia in postmenopausal women. Fernando GR, et al.
J Clin Epidemiol 1999 Oct;52(10):1007–10

Postoperative hypocalcemia in patients who did or did not undergo parathyroid autotransplantation during thyroidectomy: a comparative study. Lo CY, et al.
Surgery 1998 Dec;124(6):1081–6; discussion 1086–7

[A 63-year-old patient with worsening general condition, bone demineralization, hypocalcemia and excess parathyroid hormone: late manifestations of pseudohypohyperparathyroidism] Pickenpack A, et al.
Dtsch Med Wochenschr 1999 May 7;124(18):551–5 (Eng. Abstr.) **(Ger)**

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Internist (Berl)** 1998 Aug;39(8):825–30 (6 ref.) **(Ger)**

[Surgery of nodular goiter: postoperative hypocalcemia in relation to extent of resection and manipulation of the parathyroid glands] Rimpl I, et al.
Langenbecks Arch Chir Suppl Kongressbd 1998;115:1063–6 (Eng. Abstr.) **(Ger)**

[Total thyroidectomy with identification of parathyroid glands. Functional implications] Giovannini C, et al.
Ann Ital Chir 1999 May–Jun;70(3):393–6, commentary 397–8 (Eng. Abstr.) **(Ita)**

GENETICS

A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. Okazaki R, et al.
J Clin Endocrinol Metab 1999 Jan;84(1):363–6

Extracellular "calcistat" in health and disease [comment] Pearce S. **Lancet** 1999 Jan 9;353(9147):83–4. Comment on: Lancet 1999 Jan 9;353(9147):112–5.

METABOLISM

Formation and mineralization of murine molar roots with hypocalcaemia induced by a low-calcium diet and the changes after returning to a normal diet. Furuta T, et al.
Arch Oral Biol 1999 Aug;44(8):629–39

Effect of hypocalcaemia on glucose metabolism in hyperketonaemic piglets. Schlumbohm C, et al.
Exp Physiol 1999 Jul;84(4):707–23

PHYSIOPATHOLOGY

Bone, parathyroid hormone and the response to the rapid induction of hypocalcaemia [comment] Felsenfeld AJ.
Eur J Clin Invest 1999 Apr;29(4):274–7. Comment on: Eur J Clin Invest 1999 Apr;29(4):309–20.

Effect of rate of calcium reduction and a hypocalcemic clamp on parathyroid hormone secretion: a study in dogs. Estepa JC, et al. **Kidney Int** 1999 May;55(5):1724–33

[Activity of Purkinje cells from the cerebellum of young and adult rats during hypercalcemia] Chaban TV, et al.
Zh Evol Biokhim Fiziol 1998 Nov–Dec;34(6):670–4 **(Rus)**

PREVENTION & CONTROL

Randomized trial of magnesium administration to prevent hypocalcemia in infants of diabetic mothers. Mehta KC, et al. **J Perinatol** 1998 Sep–Oct;18(5):352–6

Hypocalcemia secondary to citrate toxicity [letter] McCarthy LJ, et al. **Ther Apher** 1998 Aug;2(3):249

THERAPY

Reversal of hypocalcemia and decreased afterload in sepsis. Effect on myocardial systolic and diastolic function. Kovacs A, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1990–8

VETERINARY

Rumen motility during induced hyper- and hypocalcaemia. Jørgensen RJ, et al. **Acta Vet Scand** 1998;39(3):331–8

Hypocalcemia and hyperphosphatemia due to primary hypoparathyroidism in a six-month-old kitten. Bassett JR.
J Am Anim Hosp Assoc 1998 Nov–Dec;34(6):503–7

Comparison of bone resorption markers during hypocalcemia in dairy cows. Liesegang A, et al. **J Dairy Sci** 1998 Oct; 81(10):2614–22

Hypocalcemia induced by intravenous administration of disodium ethylenediaminotetraacetate and its effects on excretion of calcium in urine of cows fed a high chloride diet. Schonewille JT, et al. **J Dairy Sci** 1999 Jun; 82(6):1317–24

Post partum subclinical hypocalcaemia and effects on ovarian function and uterine involution in a dairy herd. Kamgarpour R, et al. **Vet J** 1999 Jul;158(1):59–67

Hypocalcaemia in 23 ataxic/recumbent ewes: clinical signs and likelihood ratios. Cockcroft PD, et al. **Vet Rec** 1999 May 8;144(19):529–32

Pathological changes in the myocardium of hypocalcaemic parturient cows. Yamagishi N, et al. **Vet Rec** 1999 Jan 16; 144(3):67–72

Effects of EDTA-induced hypocalcaemia and stress on plasma TNF-alpha, IL-1-ra, G-CSF, GM-CSF and S-100 in dairy cows. Riond JL, et al. **Vet Res Commun** 1999 Aug; 23(5):299–306

[Clinical findings and differential diagnosis in ketosis and hypocalcemia in sheep] Bickhardt K, et al.
DTW Dtsch Tierarztl Wochenschr 1998 Nov;105(11):413–9 (Eng. Abstr.) **(Ger)**

VIROLOGY

Hypocalcaemia in HIV infection and AIDS. Kuehn EW, et al. **J Intern Med** 1999 Jan;245(1):69–73

HYPOCAPNIA

see related
ALKALOSIS, RESPIRATORY

ETIOLOGY

Hypocapnia does not alter hepatic blood flow or oxygen consumption in patients with head injury. Ichai C, et al.
Crit Care Med 1998 Oct;26(10):1725–30

METABOLISM

Splanchnic hemodynamics and gut mucosal-arterial PCO(2) gradient during systemic hypocapnia. Guzman JA, et al.
J Appl Physiol 1999 Sep;87(3):1102–6

PHYSIOPATHOLOGY

Cerebral hemodynamic changes during sustained hypocapnia in severe head injury: can hyperventilation cause cerebral ischemia? Ausina A, et al. **Acta Neurochir Suppl (Wien)** 1998;71:1–4

Dynamics of the cerebral blood flow response to sustained euoxic hypocapnia in humans. Poulin MJ, et al.
Adv Exp Med Biol 1998;450:43–4

Preserved hypocapnic pial arteriolar constriction during

hyperammonemia by glutamine synthetase inhibition. Hirata T, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H456–63

Effects of hyperventilation and hypocapnic/normocapnic hypoxemia on renal function and lithium clearance in humans. Videndal Olsen N, et al. **Anesthesiology** 1998 Dec; 89(6):1389–400

Alterations in respiratory neuronal activities in the medullary 'pre-Bötzinger' region in hypocapnia. St.-John WM. **Respir Physiol** 1998 Nov;114(2):119–31

Blockade of ATP-sensitive potassium channels in cerebral arterioles inhibits vasoconstriction from hypocapnic alkalosis in cats. Wei EP, et al. **Stroke** 1999 Apr;30(4):851–3; discussion 854

HYPOCHLORHYDRIA see **ACHLORHYDRIA**

HYPOCHLORITE see **HYPOCHLOROUS ACID**

HYPOCHLOROUS ACID

CHEMISTRY

Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Hawkins CL, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):539–48

Degradation of hyaluronic acid, poly- and monosaccharides, and model compounds by hypochlorite: evidence for radical intermediates and fragmentation. Hawkins CL, et al. **Free Radic Biol Med** 1998 Jun;24(9):1396–410

METABOLISM

Chlorination and nitration of soy isoflavones. Boersma BJ, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):265–75

Identification of the factors affecting the rate of deactivation of hypochlorous acid by melatonin. Dellegar SM, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):431–9

Structure of dicarboxyl malto-oligomers isolated from hypochlorite-oxidised potato starch studied by 1H and 13C NMR spectroscopy. Teleman A, et al. **Carbohydr Res** 1999 Feb 28;315(3–4):286–92

Linoleic acid hydroperoxide favours hypochlorite- and myeloperoxidase-induced lipid peroxidation. Panasenko OM, et al. **Free Radic Res** 1999 Jun;30(6):479–87

Modification of red cell membrane lipids by hypochlorous acid and haemolysis by preformed lipid chlorohydrins. Carr AC, et al. **Redox Rep** 1997 Oct-Dec;3(5–6):263–71

PHARMACOLOGY

Reactive oxygen species are partially involved in the bacteriocidal action of hypochlorous acid. Dukan S, et al. **Arch Biochem Biophys** 1999 Jul 15;367(2):311–6

Hypochlorous acid activates the tumor suppressor protein p53 in cultured human skin fibroblasts. Vile GF, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):51–6

Loss of 3-nitrotyrosine on exposure to hypochlorous acid: implications for the use of 3-nitrotyrosine as a bio-marker in vivo. Whiteman M, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):168–72

Hypochlorous acid-induced DNA base modification: potentiation by nitrite: biomarkers of DNA damage by reactive oxygen species. Whiteman M, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):572–6

Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins. Hazell LJ, et al. **Biochem J** 1999 May 1;339 (Pt 3):489–95

Modulation of peroxynitrite- and hypochlorous acid-induced inactivation of alpha1-antiproteinase by mercaptoethylguanidine. Whiteman M, et al. **Br J Pharmacol** 1999 Apr;126(7):1646–52

Modification of beta-adrenoceptors and adenylyl cyclase in hearts perfused with hypochlorous acid. Persad S, et al. **Can J Physiol Pharmacol** 1998 Oct-Nov;76(10–11):961–6

Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. Bergt C, et al. **FEBS Lett** 1999 Jun 11;452(3):295–300

Degradation of hypochlorite-damaged glucose-6-phosphate dehydrogenase by the 20S proteasome. Ullrich O, et al. **Free Radic Biol Med** 1999 Sep;27(5–6):487–92

Reduction of faecal coliform, coliform and heterotrophic plate count bacteria in the household kitchen and bathroom by disinfection with hypochlorite cleaners. Rusin P, et al. **J Appl Microbiol** 1998 Nov;85(5):819–28

Disinfection of hospital waste sludge using hypochlorite and chlorine dioxide. Tsai CT, et al. **J Appl Microbiol** 1999 May;86(5):827–33

Oxidation regulates the inflammatory properties of the murine S100 protein S100A8. Harrison CA, et al. **J Biol Chem** 1999 Mar 26;274(13):8561–9

The effect of the oxidant hypochlorous acid on the L-type calcium current in isolated ventricular cardiomyocytes. Hammerschmidt S, et al. **J Mol Cell Cardiol** 1998 Sep; 30(9):1855–67

Alterations in cardiac membrane beta-adrenoceptors and adenylyl cyclase due to hypochlorous acid. Persad S, et al. **J Mol Cell Cardiol** 1999 Jan;31(1):101–11

Isolation of Salmonella resistant to hypochlorous acid from a poultry abattoir. Mokgatla RM, et al. **Lett Appl Microbiol** 1998 Dec;27(6):379–82

Which conditions promote a remanent (persistent) bactericidal activity of chlorine covers? Gottardi W, et al. **Zentralbl Hyg Umweltmed** 1998 Dec;201(4–5):325–35

TOXICITY

Inhibition of PMN- and HOCl-induced vascular injury in isolated rabbit lungs by acetylsalicylic acid: a possible link between neutrophil-derived oxidative stress and eicosanoid metabolism? Wahn H, et al. **Biochim Biophys Acta** 1998 Oct 22;1408(1):55–66

HYPOCHOLESTEREMIC AGENTS see **ANTICHOLESTEREMIC AGENTS**

HYPOCHONDRIASIS

The relationship of hypochondriasis to anxiety disorders [see comments] Noyes R Jr. **Gen Hosp Psychiatry** 1999 Jan-Feb;21(1):8–17 (87 ref.). Comment in: Gen Hosp Psychiatry 1999 Jan-Feb;21(1):5–7.

Hypochondriasis, somatization, and perceived health and utilization of health care services. Hollifield M, et al. **Psychosomatics** 1999 Sep-Oct;40(5):380–6

CLASSIFICATION

Hypochondriasis vs. anxiety disorders: why should we care? [editorial; comment] Fallon B. **Gen Hosp Psychiatry** 1999 Jan-Feb;21(1):5–7. Comment on: Gen Hosp Psychiatry 1999 Jan-Feb;21(1):8–17.

DIAGNOSIS

Long-term outcome of hypochondriacal personality disorder. Tyrer P, et al. **J Psychosom Res** 1999 Feb; 46(2):177–85

[Hypochondriasis] Van Boeijen CA, et al. **Ned Tijdschr Geneeskd** 1998 Aug 15;142(33):1849–51 (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Risperidone for the treatment of monosymptomatic hypochondriacal psychosis [letter] Cetin M, et al. **J Clin Psychiatry** 1999 Aug;60(8):554

SSRI antidepressants are effective for treating delusional hypochondriasis [letter] Perkins RJ. **Med J Aust** 1999 Feb 1;170(3):140–1

PSYCHOLOGY

Exploratory and confirmatory factor analytic investigations of the Illness Attitudes Scale in a nonclinical sample. Hadjistavropoulos HD, et al. **Behav Res Ther** 1999 Jul; 37(7):671–84

Hypochondriacal concerns, symptom reporting and secondary gain mechanisms. Ferguson E. **Br J Med Psychol** 1998 Sep;71 (Pt 3):281–95

Cognitive aspects of hypochondriasis and the somatization syndrome. Rief W, et al. **J Abnorm Psychol** 1998 Nov; 107(4):587–95

Long-term outcome of hypochondriacal personality disorder. Tyrer P, et al. **J Psychosom Res** 1999 Feb; 46(2):177–85

Hypochondriasis and somatization related to personality and attitudes toward self. Hollifield M, et al. **Psychosomatics** 1999 Sep-Oct;40(5):387–95

Attentional correlates of illness anxiety in a non-clinical sample. Vervaeke GA, et al. **Psychother Psychosom** 1999; 68(1):22–5

THERAPY

Two psychological treatments for hypochondriasis. A randomised controlled trial. Clark DM, et al. **Br J Psychiatry** 1998 Sep;173:218–25

Zero progress with hypochondriasis [see comments] Ben-Tovim DI, et al. **Lancet** 1998 Dec 5;352(9143):1798–9 . Comment in: Lancet 1999 Feb 20;353(9153):671–2; discussion 672–3. Comment in: Lancet 1999 Feb 20;353(9153):672–3.

A specific treatment for hypochondriasis? [letter; comment] Clark DM, et al. **Lancet** 1999 Feb 20;353(9153):671–2; discussion 672–3. Comment on: Lancet 1998 Dec 5;352(9143):1798–9.

A specific treatment for hypochondriasis? [letter; comment] Tyrer P, et al. **Lancet** 1999 Feb 20;353(9153):672–3. Comment on: Lancet 1998 Dec 5;352(9143):1798–9.

[Hypochondriasis] Van Boeijen CA, et al. **Ned Tijdschr Geneeskd** 1998 Aug 15;142(33):1849–51 (Eng. Abstr.) **(Dut)**

HYPOCOTYL

ENZYMOLOGY

Molecular cloning and characterization of a new basic peroxidase cDNA from soybean hypocotyls infected with Phytophthora sojae f.sp. glycines. Yi SY, et al. **Mol Cells** 1998 Oct 31;8(5):556–64

GROWTH & DEVELOPMENT

Control of hypocotyl elongation in Arabidopsis thaliana by photoreceptor interaction. Hennig L, et al. **Planta** 1999 Apr;208(2):257–63

METABOLISM

Expansins are conserved in conifers and expressed in hypocotyls in response to exogenous auxin. Hutchison KW, et al. **Plant Physiol** 1999 Jul;120(3):827–32

PHYSIOLOGY

Regulation of differential growth in the apical hook of Arabidopsis. Raz V, et al. **Development** 1999 Aug; 126(16):3661–8

HYPOCREALES

CLASSIFICATION

Genetic and morphological characterization of Cladobotryum species causing cobweb disease of mushrooms. McKay GJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):606–10

Osteoarthritis caused by Neocosmospora vasinfecta. Kac G, et al. **Med Mycol** 1999 Jun;37(3):213–7

ENZYMOLOGY

Influence of temperature and pH on cellulase activity and stability in Nectria catalinensis. Pardo AG, et al. **Rev Argent Microbiol** 1999 Jan-Mar;31(1):31–5

GENETICS

Genetic and morphological characterization of Cladobotryum species causing cobweb disease of mushrooms. McKay GJ, et al. **Appl Environ Microbiol** 1999 Feb;65(2):606–10

A complex group I intron in Nectria galligena rDNA [comment] Johansen S, et al. **Microbiology** 1999 Mar;145 (Pt 3):516–7. Comment on: Microbiology 1998 Aug;144 (Pt 8):2367–72.

METABOLISM

On the absence of the glyceraldehyde 3-phosphate/pyruvate pathway for isoprenoid biosynthesis in fungi and yeasts. Disch A, et al. **FEMS Microbiol Lett** 1998 Nov 15; 168(2):201–8

HYPODERMYIASIS

VETERINARY

Efficacy of a pour-on formulation of doramectin against lice, mites, and grubs of cattle. Rooney KA, et al. **Am J Vet Res** 1999 Apr;60(4):402–4

Deer hypodermosis. Martinez-Moreno FJ, et al. **Parassitologia** 1997 Dec;39(4):419–22 (16 ref.)

Hypoderma lineatum antigen and anti-Przhevalskiana silenus antibodies: cross-reactivity and antibody kinetics in naturally infested goats. Otranto D, et al. **Parassitologia** 1998 Sep;40(3):325–31

The prevalence of bovine hypodermosis in Greece. Papadopoulos E, et al. **Parassitologia** 1997 Dec;39(4):431–3

Activity of moxidectin 1% injectable solution against first instar Hypoderma spp. in cattle and effects on antibody kinetics. Boulard C, et al. **Vet Parasitol** 1998 Jun 15; 77(2–3):205–10

Serodiagnosis of goat warble fly infestation by Przhevalskiana silenus with a commercial ELISA kit. Otranto D, et al. **Vet Rec** 1999 Jun 26;144(26):726–9

Annual warble fly survey, 1998/99 [letter] Phipps P, et al. **Vet Rec** 1999 Jul 3;145(1):26–7

Warble fly status of Great Britain in 1998 [letter] Webster K. **Vet Rec** 1998 Dec 12;143(24):668

HYPODONTIA see **ANODONTIA**

HYPODYNAMIA see **HYPOKINESIA**

HYPOESTHESIA see **HYPESTHESIA**

HYPOGALACTIA see **LACTATION DISORDERS**

HYPOGAMMAGLOBULINEMIA see **AGAMMAGLOBULINEMIA**

HYPOGASTRIC PLEXUS

Examination of nodal metastases by a clearing method supports pelvic plexus preservation in rectal cancer surgery. Hida J, et al. **Dis Colon Rectum** 1999 Apr; 42(4):510–4

Superior hypogastric plexus block successfully treats severe penile pain after transurethral resection of the prostate. Rosenberg SK, et al. **Reg Anesth Pain Med** 1998 Nov–Dec; 23(6):618–20

ANATOMY & HISTOLOGY

Preganglionic fibers in the rat hypogastric nerve project bilaterally to pelvic ganglia. Harji F, et al. **Anat Rec** 1998 Oct;252(2):229–34

Anatomical studies of the autonomic nervous system in the human pelvis by the whole-mount staining method: left-right communicating nerves between bilateral pelvic plexuses. Taguchi K, et al. **J Urol** 1999 Jan;161(1):320–5

History of the neurobiology of the pelvis. Burnett AL, et

HYPOGASTRIC PLEXUS

al. **Urology** 1999 Jun;53(6):1082–9

INJURIES

A plea for preservation of the pelvic autonomic nerves [letter] Maas K, et al. **Lancet** 1999 Aug 28;354(9180):772–3

PATHOLOGY

[Structural changes in the pelvic plexus in cold stress] Lapsha VI, et al. **Morfologiia** 1998;114(5):39–43 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Effects of hypogastric neurectomy on escape responses to uterine distention in the rat. Temple JL, et al. **Pain** 1999 Aug;Suppl 6:S13–20

Mounting and brief noncontact exposure of males to receptive females facilitate reflexive erection in rats, even after hypogastric nerve section. Sachs BD, et al. **Physiol Behav** 1998 Dec 1;65(3):413–21

HYPOGLOSSAL NERVE

Dumbbell-shaped hypoglossal neurinoma: surgical removal via a dorsolateral transcondylar approach. A case report and review of the literature. Spinnato S, et al. **Acta Neurochir (Wien)** 1998;140(8):827–32 (63 ref.)

Synchronous schwannomas of the hypoglossal nerve and cervical sympathetic chain. Karpati RL, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1505–7

Neuromuscular oropharyngeal dysphagia secondary to bone metastases. Shames D, et al. **Conn Med** 1998 Aug; 62(8):451–3

A rare case of hypoglossal nerve palsy complicating a head injury. Shweikh AM, et al. **J Accid Emerg Med** 1998 Nov; 15(6):427–9

Internal carotid artery dissection causes hypoglossal nerve palsy: CT, MRI, and angiographic findings. Boukobza M, et al. **J Neuroimaging** 1998 Oct;8(4):244–6

Intracranial neuroma of the hypoglossal nerve: diagnosis and management. Case report and review of the literature [letter] Lamaida E, et al. **Rev Neurol (Paris)** 1998 May; 154(4):348–9

[Paralysis of the hypoglossal nerve after orotracheal intubation for general anesthesia] Drouet A, et al. **Ann Fr Anesth Reanim** 1999 Aug;18(7):811–2 **(Fre)**

[Collet-Sicard syndrome disclosing periarteritis nodosa] Krystkowiak P, et al. **Rev Neurol (Paris)** 1998 Nov; 154(11):777–9 (Eng. Abstr.) **(Fre)**

[Lower cranial nerve involvement as the initial manifestation of Lyme borreliosis] Velázquez JM, et al. **Neurologia** 1999 Jan;14(1):36–7 (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

The nuclei innervating digastric muscle do not project to the hypoglossal nucleus in the rat. Kang TC, et al. **Anat Histol Embryol** 1999 Mar;28(1):39–40

The hypoglossal nuclear complex in reindeer. Krakowska I. **Folia Morphol (Warsz)** 1998;57(3):205–12

BLOOD SUPPLY

The blood supply of the hypoglossal nerve and its relevance to carotid endarterectomy. Fernando DA, et al. **Cardiovasc Surg** 1999 Apr;7(3):287–91

Persistent primitive hypoglossal artery visualized on three-dimensional computerized tomography angiography. Case illustration. Maeshima S, et al. **J Neurosurg** 1998 Dec; 89(6):1069

Severe stenosis of the internal carotid artery presenting as loss of consciousness due to the presence of a primitive hypoglossal artery: a case report. Katoh M, et al. **Surg Neurol** 1999 Mar;51(3):310–2

CHEMISTRY

Ultrastructure of enkephalin- and substance P-immunoreactive axon terminals in the hypoglossal nucleus of the chicken. Wang J, et al. **Eur J Histochem** 1998;42(3):227–35

CYTOLOGY

Substance P-immunoreactive boutons closely appose inspiratory protruder hypoglossal motoneurons in the cat. Gatti PJ, et al. **Brain Res** 1999 Jul 10;834(1–2):155–9

DRUG EFFECTS

Cranial nerve X and XII paralysis (Tapia's syndrome) after an interscalene brachial plexus block for a left shoulder Mumford procedure. Johnson TM, et al. **Anesthesiology** 1999 Jan;90(1):311–2

Modulation of motoneuron N-methyl-D-aspartate receptors by the inhibitory neurotransmitter glycine. Berger AJ, et al. **J Physiol Paris** 1999 Jan-Apr;93(1-2):23–7

ENZYMOLOGY

IPP isomerase, an enzyme of mevalonate pathway, is preferentially expressed in postnatal cortical neurons and induced after nerve transection. Morihara T, et al. **Brain Res Mol Brain Res** 1999 Apr 20;67(2):231–8

INJURIES

A sequence-specific splicing activator, tra2beta, is up-regulated in response to nerve injury. Kiryu-Seo S, et al. **Brain Res Mol Brain Res** 1998 Nov 20;62(2):220–3

Up-regulation of thioredoxin expression in motor neurons after nerve injury. Mansur K, et al. **Brain Res Mol Brain Res** 1998 Nov 12;62(1):86–91

Expressed-sequence-tag approach to identify differentially expressed genes following peripheral nerve axotomy. Tanabe K, et al. **Brain Res Mol Brain Res** 1999 Jan 22; 64(1):34–40

Discordant expression of c-Ret and glial cell line-derived neurotrophic factor receptor alpha-1 mRNAs in response to motor nerve injury in neonate rats. Tsujino H, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):298–303

Dimethylarginine dimethylaminohydrolase (DDAH) as a nerve-injury-associated molecule: mRNA localization in the rat brain and its coincident up-regulation with neuronal NO synthase (nNOS) in axotomized motoneurons. Nakagomi S, et al. **Eur J Neurosci** 1999 Jun;11(6):2160–6

Hypoglossal nerve injury as a complication of anterior surgery to the upper cervical spine. Sengupta DK, et al. **Eur Spine J** 1999;8(1):78–80 (10 ref.)

Expression of gicerin, a novel cell adhesion molecule, is upregulated in the astrocytes after hypoglossal nerve injury in rats. Li BS, et al. **Neurosci Lett** 1999 Feb 5;260(3):149–52

Cranial and cervical nerve injuries after carotid endarterectomy: a prospective study. Ballotta E, et al. **Surgery** 1999 Jan;125(1):85–91

[Bilateral hypoglossal nerve paralysis as isolated neurological symptom after craniocerebral trauma] Noppeney U, et al. **Nervenarzt** 1999 Apr;70(4):357–8 (Eng. Abstr.) **(Ger)**

METABOLISM

Substance P in the hypoglossal nucleus of the rat. Hinrichsen CF, et al. **Arch Oral Biol** 1999 Aug;44(8):683–91

Reciprocal changes in the expression of Bcl-2 and Bax in hypoglossal nucleus after axotomy in adult rats: possible involvement in the induction of neuronal cell death. Baba N, et al. **Brain Res** 1999 May 8;827(1–2):122–9

PATHOLOGY

Sublingual hypoglossal neurilemmoma. Case report. Drevelengas A, et al. **Aust Dent J** 1998 Oct;43(5):311–4

[XII cranial nerve pseudoneurinoma due to spontaneous fibrous transformation of an aneurysm of the vertebral artery] Meziti L, et al. **J Neuroradiol** 1998 Dec;25(4):307–11 (Eng. Abstr.) **(Fre)**

[Immunohistochemical studies on neuronal changes in brain stem nucleus of forensic autopsied cases. I. Various cases of asphyxia and respiratory disorder] Kubo S, et al. **Nippon Hoigaku Zasshi** 1998 Dec;52(6):345–9 (Eng. Abstr.) **(Jpn)**

[Immunohistochemical studies on neuronal changes in brain stem nucleus of forensic autopsied cases. II. Sudden infant death syndrome] Kubo S, et al. **Nippon Hoigaku Zasshi** 1998 Dec;52(6):350–4 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Differential suppression of upper airway motor activity during carbachol-induced, REM sleep-like atonia. Fenik V, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1013–24

Neuronal supernumerary and dendritic sprouting of the nucleus ambiguus after chronic alteration of peripheral targets in cats. Chang ST, et al. **Brain Res** 1998 Sep 14; 805(1–2):144–54

Substance P-immunoreactive boutons closely appose inspiratory protruder hypoglossal motoneurons in the cat. Gatti PJ, et al. **Brain Res** 1999 Jul 10;834(1–2):155–9

Developmental modulation of mouse hypoglossal nerve inspiratory output in vitro by noradrenergic receptor agonists. Selvaratnam SR, et al. **Brain Res** 1998 Sep 14; 805(1–2):104–15

Influences of neck afferents on sympathetic and respiratory nerve activity. Bolton PS, et al. **Brain Res Bull** 1998 Nov 15;47(5):413–9

Development of the facial and hypoglossal motor nuclei in the neonatal Brazilian opossum brain. Swanson JJ, et al. **Brain Res Dev Brain Res** 1999 Feb 5;112(2):159–72

Expressed-sequence-tag approach to identify differentially expressed genes following peripheral nerve axotomy. Tanabe K, et al. **Brain Res Mol Brain Res** 1999 Jan 22; 64(1):34–40

Discordant expression of c-Ret and glial cell line-derived neurotrophic factor receptor alpha-1 mRNAs in response to motor nerve injury in neonate rats. Tsujino H, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):298–303

Organization of the motor centres for the innervation of different muscles of the tongue: a neuromorphological study in the frog. Matesz C, et al. **Eur J Morphol** 1999 Apr;37(2–3):190–4

Effect of upper airway negative pressure on proprioceptive afferents from the tongue. Brancatisano A, et al. **J Appl Physiol** 1999 Apr;86(4):1396–401

Gamma-aminobutyric acid-induced responses in acutely dissociated neurons from the rat sacral dorsal commissural nucleus. Xu TL. **J Auton Nerv Syst** 1999 Feb 15; 75(2–3):156–63

Voltage-activated K+ currents of hypoglossal motoneurons in a brain stem slice preparation from the neonatal rat. Lape R, et al. **J Neurophysiol** 1999 Jan;81(1):140–8

Regenerative process after experimental injury of hypoglossal nerves in guinea pigs. Tanaka H, et al. **J Oral Sci** 1998 Dec;40(4):147–52

Endogenous calcium buffering in motoneurones of the nucleus hypoglossus from mouse. Lips MB, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):105–17

Bilateral cortical representation of the intrinsic lingual muscles. Chen CH, et al. **Neurology** 1999 Jan 15;52(2):411–3

Microglial reaction in some CNS nuclei following nerves transection in BALB/c and interferon-gamma gene knockout mice. Ng YK, et al. **Neurosci Lett** 1999 Mar 12; 262(3):207–10

Neural connections of the pontine reticular formation, which connects reciprocally with the nucleus prepositus hypoglossi in the rat. Iwasaki H, et al. **Neuroscience** 1999; 93(1):195–208

Hypoglossal canal size and hominid speech. DeGusta D, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1800–4

[Brainstem segmental arrangement of sucking rhythm generators for trigeminal, facial and hypoglossal motoneurons] Nakajima M. **Kokubyo Gakkai Zasshi** 1999 Mar;66(1):88–97 (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Hereditary absence of complement C5 in adult mice influences Wallerian degeneration, but not retrograde responses, following injury to peripheral nerve. Liu L, et al. **J Peripher Nerv Syst** 1999;4(2):123–33

Hypoglossal vertebral entrapment syndrome [letter] Salvi F, et al. **Muscle Nerve** 1999 Feb;22(2):288–9

RADIATION EFFECTS

MR features of the denervated tongue in radiation induced neuropathy. King AD, et al. **Br J Radiol** 1999 Apr; 72(856):349–53

RADIONUCLIDE IMAGING

Dual-isotope SPECT diagnosis of a skull-base metastasis causing isolated unilateral hypoglossal nerve palsy. Fukumoto M, et al. **Ann Nucl Med** 1998 Aug;12(4):213–6

SURGERY

Dumb-bell hypoglossal neurinoma with intra- and extracranial paravertebral expansion. Bunc G, et al. **Acta Neurochir (Wien)** 1998;140(11):1209–10

Significance of trigeminal sensory input on regrowth of hypoglossal and facial motoneurons after hypoglossal facial anastomosis in rats. Streppel M, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):790–6

Hypoglossal nerve transfer for laryngeal reinnervation: a preliminary study. Paniello RC, et al. **Ann Otol Rhinol Laryngol** 1999 Mar;108(3):239–44

A skull base extradural hypoglossal neurilemmoma resected via an extended posterolateral approach. Myatt HM, et al. **J Laryngol Otol** 1998 Nov;112(11):1052–7 (18 ref.)

Surgical anatomy for direct hypoglossal-facial nerve side-to-end "anastomosis". Asaoka K, et al. **J Neurosurg** 1999 Aug;91(2):268–75

Hypoglossal-facial nerve side-to-end anastomosis [letter; comment] Asaoka K, et al. **J Neurosurg** 1999 Jul; 91(1):163–4. Comment on: J Neurosurg 1999 Jan;90(1):27–34.

New technique of side-to-end hypoglossal-facial nerve attachment with translocation of the infratemporal facial nerve [see comments] Darrouzet V, et al. **J Neurosurg** 1999 Jan;90(1):27–34. Comment in: J Neurosurg 1999 Jul;91(1):163–4.

Initial report on the limited value of hypoglossal nerve transfer to treat brachial plexus root avulsions. Malessy MJ, et al. **J Neurosurg** 1999 Oct;91(4):601–4

Gains and losses of the XII-VII component of the "baby-sitter" procedure: a morphometric analysis. Kalantarian B, et al. **J Reconstr Microsurg** 1998 Oct; 14(7):459–71

[Analytical study of the treatment of facial paralysis by hypoglossal-facial anastomosis. Apropos of 25 cases] Gousheh J, et al. **Ann Chir Plast Esthet** 1998 Oct; 43(5):548–53 (Eng. Abstr.) **(Fre)**

[Hypoglossal-facial anastomosis. A report of 60 cases] Pellat JL, et al. **Ann Chir Plast Esthet** 1997 Feb;42(1):37–43 (Eng. Abstr.) **(Fre)**

[Clinical and electrophysiologic studies of facial nerve function after hypoglossal-facial nerve anastomosis] Riemann R, et al. **Laryngorhinootologie** 1999 May; 78(5):244–53 (69 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

Facial nerve reconstruction and facial reanimation following oncologic surgery. Cheney ML, et al. **Head Neck** 1999 May;21(3):276–84

ULTRASTRUCTURE

Quantitative analysis of the dendritic architectures of cat hypoglossal motoneurons stained intracellularly with horseradish peroxidase. Fukunishi Y, et al. **J Comp Neurol** 1999 Mar 15;405(3):345–58

HYPOGLYCEMIA

Diabetic hypoglycaemia and the dental patient. Jowett NI, et al. **Br Dent J** 1998 Nov 14;185(9):439–42

Hypoglycemia and reduction of the insulin requirement as a sign of celiac disease in children with IDDM [letter] Iafusco D, et al. **Diabetes Care** 1998 Aug;21(8):1379–81

Cerebral metabolic response to hypoglycemia in severe intrauterine growth-retarded rat pups. Lin CH, et al. **Early Hum Dev** 1998 Aug 28;52(1):1–11

JAMA Patient Page: diabetes. **JAMA** 1999 Aug 25;282(8):806

Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes. Clarke WL, et al. **JAMA** 1999 Aug 25;282(8):750–4

[Hypoglycemia. Diagnostic assessment and guidelines for emergencies and drug therapy] Slama G. **Rev Prat** 1998 Oct 15;48(16):1821–6 **(Fre)**

BLOOD

Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Adler GK, et al. **Am J Med** 1999 May; 106(5):534–43

Counterregulatory hormones oscillate during steady-state hypoglycemia. Genter P, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):E821–9

Cognitive function and mood after profound nocturnal hypoglycaemia in prepubertal children with conventional insulin treatment for diabetes. Matyka KA, et al. **Arch Dis Child** 1999 Aug;81(2):138–42

Autoregulation of glucose production in health and disease. Tappy L, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):161–4 (34 ref.)

Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Levy CJ, et al. **Diabetes Care** 1998 Aug;21(8):1330–8

Dramatic recovery of counter-regulatory hormone response to hypoglycaemia after intensive insulin therapy in poorly controlled Type I diabetes mellitus [letter] Kaneto H, et al. **Diabetologia** 1998 Aug;41(8):982–3

Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Hizuka N, et al. **Endocr J** 1998 Apr;45 Suppl:S61–5

Hyperinsulinaemic hypoglycaemia associated with persistent hyperammonaemia. Kitaura J, et al. **Eur J Pediatr** 1999 May;158(5):410–3

Hypoglycemia-associated hyperammonemia caused by impaired expression of ornithine cycle enzyme genes in C/EBPalpha knockout mice. Kimura T, et al. **J Biol Chem** 1998 Oct 16;273(42):27505–10

Counterregulatory response to hypoglycemia differs according to the insulin delivery route, but does not affect glucose production in normal humans. Lewis GF, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1037–46

Human insulin induces a higher glucagon response to induced hypoglycemia in short normal children, compared to porcine insulin. Kanaka-Gantenbein C, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb;12(1):39–46

Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. Gutiérrez MA, et al. **J Rheumatol** 1999 Feb;26(2):277–81

Insulin-induced hypoglycemia does not impair the surge of luteinizing hormone secretion in the proestrous rat. Kawaguchi M, et al. **Neurosci Lett** 1998 Nov 13; 256(3):131–4

Rise in plasma oxidized glutathione by experimental hypoglycemia. Jiang ZL, et al. **Tohoku J Exp Med** 1999 Jan;187(1):59–64

CHEMICALLY INDUCED

Round table on hypoglycaemia in diabetic children. Soltész G. **Acta Paediatr Suppl** 1998 Oct;425:25–9

Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):89–94

Insulin hypoglycemia and growth hormone secretion in sheep: a paradox revisited. Jaffe CA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E253–8

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Mullins ME, et al. **Ann Emerg Med** 1999 Jan;33(1):129–30. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Robertson WO. **Ann Emerg Med** 1999 Jan;33(1):130–1. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.

Hypoglycemic effect of water-soluble polysaccharide from Auricularia auricula-judae Quel. on genetically diabetic KK-Ay mice. Yuan Z, et al. **Biosci Biotechnol Biochem** 1998 Oct;62(10):1898–903

Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. Takhar J, et al. **Can J Clin Pharmacol** 1999 Spring;6(1):12–4

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Stahl M, et al. **Diabet Med** 1999 Jul;16(7):586–90

Renal glucose production during insulin-induced hypoglycemia in humans. Cersosimo E, et al. **Diabetes** 1999 Feb;48(2):261–6

Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication [letter] Cooper JW. **Diabetes Care** 1998 Dec;21(12):2197–8

Hypoglycemia associated with maprotiline in a patient with type I diabetes [letter] Isotani H, et al. **Diabetes Care** 1999 May;22(5):862–3

Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Mohn A, et al. **Diabetes Care** 1999 Jan; 22(1):27–32

No increase of hypoglycaemia upon transfer of aged longstanding type 1 diabetic patients to human insulin: a prospective randomized study. The Investigators of the Transfert Study. Altman JJ, et al. **Diabetes Metab** 1998 Nov;24(5):419–23

Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Schiel R, et al. **Diabetes Metab** 1998 Dec;24(6):509–14

Relative hypoglycemia of rectal insulin suppositories containing deoxycholic acid, sodium taurocholate, polycarbophil, and their combinations in diabetic rabbits. Hosny EA. **Drug Dev Ind Pharm** 1999 Jun;25(6):745–52

Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? Kovacs GT, et al. **Horm Res** 1999;51(4):193–200

Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. Gasperi M, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2633–7

Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175–8 (11 ref.)

Intensive diabetes therapy in childhood: is it achievable? Is it desirable? Is it safe? [letter; comment] Becker DJ, et al. **J Pediatr** 1999 Apr;134(4):392–4. Comment on: J Pediatr 1999 Apr;134(4):503–6.

Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. Shojania K, et al. **J Rheumatol** 1999 Jan;26(1):195–6

Hypoglycemia induced by interaction between clarithromycin and disopyramide. Iida H, et al. **Jpn Heart J** 1999 Jan;40(1):91–6

Type 1 diabetes mellitus in early childhood: glycemic control and associated risk of hypoglycemic reactions [see comments] Lteif AN, et al. **Mayo Clin Proc** 1999 Mar; 74(3):211–6. Comment in: Mayo Clin Proc 1999 Mar;74(3):309–11.

Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats. Khamaisi M, et al. **Metabolism** 1999 Apr;48(4):504–10

Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Moriguchi T, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):101–4

Preoperative hypoglycaemia, propranolol and the Jervell and Lange-Nielsen syndrome. Baines DB, et al. **Paediatr Anaesth** 1999;9(2):156–8

Hypoglycemia and propranolol in pediatric behavioral disorders. Chavez H, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1290–2

[Factitious insulinoma] Blans MC, et al. **Ned Tijdschr Geneeskd** 1998 Sep 26;142(39):2154–6 (Eng. Abstr.) **(Dut)**

[Reevaluation of hypoglycemic risk in the course of intensive insulin therapy] Selam JL. **Journ Annu Diabetol Hotel Dieu** 1998;:257–80 (106 ref.) **(Fre)**

[Hypoglycemia due to cibenzoline: role of hyperinsulinism (letter)] Yazbeck R, et al. **Presse Med** 1999 May 22–29; 28(19):1017–8 **(Fre)**

[Co-trimoxazole administration: a rare cause of hypoglycemia in elderly persons] Rutschmann OT, et al. **Schweiz Med Wochenschr** 1998 Aug 4;128(31-32):1171–4 (23 ref.) (Eng. Abstr.) **(Fre)**

[Life-threatening alcoholic hypoglycemia in subjects free of diabetes mellitus] Bokarev IN, et al. **Klin Med (Mosk)** 1999; 77(3):29–32 **(Rus)**

COMPLICATIONS

Secondary adrenal failure in a young woman presenting as hypoglycaemic coma [letter; comment] al-Jubouri MA. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):114–5. Comment on: Ann Clin Biochem 1998 Jul;35 (Pt 4):545–8.

Plasma glucose alone does not predict neurologic dysfunction in hypoglycemic nondiabetic subjects. Osorio I, et al. **Ann Emerg Med** 1999 Mar;33(3):291–8

Long-term neurological dysfunction and neonatal hypoglycaemia after diabetic pregnancy. Stenninger E, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov; 79(3):F174–9

Brain imaging in neonatal hypoglycaemia. Traill Z, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F145–7

Hypokalaemia during insulin-induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency. Davies JS, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):217–20

Hemiplegia hypoglycaemia syndrome. Vanpee D, et al. **Eur J Emerg Med** 1999 Jun;6(2):157–9

Treatment of hyperinsulinaemic hypoglycaemia with nifedipine. Eichmann D, et al. **Eur J Pediatr** 1999 Mar; 158(3):204–6

Hyperinsulinaemic hypoglycaemia associated with persistent hyperammonaemia. Kitaura J, et al. **Eur J Pediatr** 1999 May;158(5):410–3

The effect of maternal hypothermia on the fetal heart rate. Aboud E, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):163–4

Recurrent, refractory hypoglycemia presenting as a behavioral disorder in an older woman [letter] Dharmarajan TS, et al. **J Am Geriatr Soc** 1999 Mar; 47(3):380–1

Case report: Insulin-like growth factor II expression in hepatocellular carcinoma with alcoholic liver fibrosis accompanied by hypoglycaemia. Yamaguchi M, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):47–51

Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants [see comments] Duvanel CB, et al. **J Pediatr** 1999 Apr;134(4):492–8. Comment in: J Pediatr 1999 Apr;134(4):389–91.

The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study [see comments] Rovet JF, et al. **J Pediatr** 1999 Apr;134(4):503–6 . Comment in: J Pediatr 1999 Apr;134(4):392–4.

Severe hypoglycemia in Spanish diabetic children and adolescents. Study Group of Infantile Diabetes of the Spanish Paediatric Endocrinology Society. López MJ, et al. **J Pediatr Endocrinol Metab** 1999 Jan-Feb;12(1):85–7

Use of CS spray in hypoglycaemia [letter] O'Brien S, et al. **Lancet** 1999 Aug 28;354(9180):779

Silent myocardial ischemia induced by hypoglycemia. Pezzilli R, et al. **Panminerva Med** 1998 Dec;40(4):347–9

Cranial MRI of neurologically impaired children suffering from neonatal hypoglycaemia. Murakami Y, et al. **Pediatr Radiol** 1999 Jan;29(1):23–7

Hyperphagia induced by hypoglycemia in rats is independent of leptin and hypothalamic neuropeptide Y (NPY). Dryden S, et al. **Peptides** 1998;19(9):1549–55

Nesidioblastosis with hyperinsulinemic hypoglycemia in adults: report of two cases. Eriguchi N, et al. **Surg Today** 1999;29(4):361–3

Alternating transient dense hemiplegia due to episodes of hypoglycemia. Wattoo MA, et al. **West J Med** 1999 Mar; 170(3):170–1

[Hypoglycemic coma of long duration] Berger A, et al. **Rev Med Suisse Romande** 1999 Jan;119(1):49–53 (20 ref.) **(Fre)**

[Rare neurological disorders and hypoglycemia. 3 cases] Rothmann C, et al. **Rev Neurol (Paris)** 1998 Jan;154(1):58–9 (Eng. Abstr.) **(Fre)**

CONGENITAL

Histochemical, clinical, and in vitro beta cell responses in a neonate with persistent hyperinsulinaemic hypoglycaemia of infancy. Panesar NS, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F141–4

Outcome of neonatal hypoglycaemia. Complete data are needed [letter] Cornblath M, et al. **BMJ** 1999 Jan 16; 318(7177):194–5

Neonatal hyperinsulinism. Schwitzgebel VM, et al. **Clin Perinatol** 1998 Dec;25(4):1015–38, viii (78 ref.)

DIAGNOSIS

Hypoglycaemia in children with type 1 diabetes mellitus. Chiarelli F, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):31–4 (17 ref.)

Anthropometric indices in singleton term neonates and their possible value in predicting some metabolic problems: a preliminary study. Nte A, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):171–3

Hypoglycemia masquerading as acute psychosis and acute cocaine intoxication [letter] Brady WJ Jr, et al. **Am J Emerg Med** 1999 May;17(3):318–9

Amniotic fluid insulin levels identify the fetus at risk of neonatal hypoglycaemia. Fraser RB, et al. **Diabet Med** 1999 Jul;16(7):568–72

Propranolol in hypoglycaemia unawareness. Chalon S, et al. **Diabetes Metab** 1999 Mar;25(1):23–6

Prospective assessment of severe hypoglycaemia in diabetic children and adolescents with impaired and normal awareness of hypoglycaemia. Barkai L, et al. **Diabetologia** 1998 Aug;41(8):898–903

Recognizing factitious hypoglycemia in the family practice setting. Waickus CM, et al. **J Am Board Fam Pract** 1999 Mar-Apr;12(2):133–6

Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. Service FJ, et al. **J Clin Endocrinol Metab** 1999 May; 84(5):1582–9

Neonatal hypoglycemia: a little goes a long way [letter; comment] Cowett RM. **J Pediatr** 1999 Apr;134(4):389–91 (17 ref.). Comment on: J Pediatr 1999 Apr;134(4):492–8.

Abnormal electroencephalogram at diagnosis of insulin-dependent diabetes mellitus may predict severe symptoms of hypoglycemia in children. Tupola S, et al.

J Pediatr 1998 Dec;133(6):792–4

Childhood hypoglycemia in an urban emergency department: epidemiology and a diagnostic approach to the problem. Pershad J, et al. **Pediatr Emerg Care** 1998 Aug;14(4):268–71

Symptomatic hypoglycemia in otherwise healthy, breastfed term newborns. Moore AM, et al. **Pediatrics** 1999 Apr; 103(4 Pt 1):837–9

Insulinoma masquerading as factitious hypoglycemia. Baddley JW, et al. **South Med J** 1998 Nov;91(11):1067–9

[CNS symptoms caused by hypoglycemia: frequent misdiagnosis: "stroke". Pitfall of the neuroglycopenia syndrome] Holstein A, et al. **MMW Fortschr Med** 1999 Jun 3;141(22):42–4 (Eng. Abstr.) **(Ger)**

[Results of five year care of newborns born from diabetic mothers] Mikulska M, et al. **Ginekol Pol** 1998 Dec; 69(12):1103–9 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Hypoglycaemic neuropathy in BB/Wor rats treated with insulin implants: electron microscopic observations. Mohseni S, et al. **Acta Neuropathol (Berl)** 1998 Aug; 96(2):151–6

Differences in respiratory metabolism during treatment of hypoglycemia in infants of diabetic mothers and small-for-gestational-age infants. Kinnala A, et al. **Am J Perinatol** 1998 Jun;15(6):363–7

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Roach P, et al. **Clin Ther** 1999 Mar;21(3):523–34

Treatment of hyperinsulinaemic hypoglycaemia with nifedipine. Eichmann D, et al. **Eur J Pediatr** 1999 Mar; 158(3):204–6

Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Touati G, et al. **Eur J Pediatr** 1998 Aug; 157(8):628–33

Influence of the antioxidants vitamin E and idebenone on retinal cell injury mediated by chemical ischemia, hypoglycemia, or oxidative stress. Rego AC, et al. **Free Radic Biol Med** 1999 Jun;26(11–12):1405–17

Treatment of hemangiopericytoma-induced hypoglycemia with growth hormone and corticosteroids [letter] Gullo D, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1758–9

EPIDEMIOLOGY

Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Stahl M, et al. **Diabet Med** 1999 Jul;16(7):586–90

Severe hypoglycaemia in children and adolescents during multiple-dose insulin therapy. Tupola S, et al. **Diabet Med** 1998 Aug;15(8):695–9

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Brunelle BL, et al. **Diabetes Care** 1998 Oct;21(10):1726–31

Risk factors of severe hypoglycaemia in adult patients with Type I diabetes--a prospective population based study. Mühlhauser I, et al. **Diabetologia** 1998 Nov;41(11):1274–82

Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Gürlek A, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):220–4

Hypoglycemia and insulin analogues: is there a reduction in the incidence? Heinemann L. **J Diabetes Complications** 1999 Mar–Apr;13(2):105–14 (53 ref.)

Severe hypoglycemia in Spanish diabetic children and adolescents. Study Group of Infantile Diabetes of the Spanish Paediatric Endocrinology Society. López MJ, et al. **J Pediatr Endocrinol Metab** 1999 Jan–Feb;12(1):85–7

Ambulance visits for severe hypoglycaemia in insulin-treated diabetes [see comments] Daniels A, et al. **N Z Med J** 1999 Jun 25;112(1090):225–8. Comment in: N Z Med J 1999 Jun 25;112(1090):219–21.

Hypoglycaemia in type 1 diabetes [comment] Manning PJ. **N Z Med J** 1999 Jun 25;112(1090):219–21. Comment on: N Z Med J 1999 Jun 25;112(1090):225–8.

ETIOLOGY

Prevention and treatment of hypoglycaemia unawareness in type 1 diabetes mellitus. Bolli GB. **Acta Diabetol** 1998 Dec; 35(4):183–93 (50 ref.)

Anti-insulin antibodies may cause hypoglycaemia following pancreas transplantation. Larsen J, et al. **Acta Diabetol** 1998 Dec;35(4):172–5

Post-transplantation hypoglycaemia in type 1 diabetic pancreas allograft recipients. Osei K. **Acta Diabetol** 1998 Dec;35(4):176–82 (29 ref.)

Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Detlofson I, et al. **Acta Paediatr** 1999 Jun; 88(6):595–7

Practical aspects of managing preschool children with type 1 diabetes. Kiess W, et al. **Acta Paediatr Suppl** 1998 Oct; 425:67–71 (38 ref.)

Hypoglycemia in multiple trauma victims. Brady WJ, et al. **Am J Emerg Med** 1999 Jan;17(1):4–5

Neuroglycopenic and other symptoms in patients with insulinomas. Dizon AM, et al. **Am J Med** 1999 Mar; 106(3):307–10

Hypoketotic hypoglycemic coma in a 21-month-old child. Hostetler MA, et al. **Ann Emerg Med** 1999 Sep;34(3):394–8

Severe and recurrent fasting hypoglycemia due to growth hormone deficiency? [letter] Fukui M, et al. **Arch Intern Med** 1999 Sep 13;159(16):1954–5

Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes. Collin M, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):134–7

Hepatic and pulmonary metastases from a meningeal hemangiopericytoma and severe hypoglycemia due to abnormal secretion of insulin-like growth factor: a case report. Grunenberger F, et al. **Cancer** 1999 May 15; 85(10):2245–8

Malignant hypoglycemia associated with a large mesenchymal tumor: case report and review of the literature. Rose MG, et al. **Cancer J Sci Am** 1999 Jan–Feb; 5(1):48–51 (17 ref.)

Glucocorticoid therapy for nonislet cell tumour hypoglycaemia (NICTH) [letter] McNulty SJ, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):546

Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Teale JD, et al. **Clin Endocrinol (Oxf)** 1998 Oct; 49(4):491–8

Occult hypoglycemia caused by hemodialysis. Jackson MA, et al. **Clin Nephrol** 1999 Apr;51(4):242–7

Spontaneous hypoglycaemia after pancreas transplantation in Type 1 diabetes mellitus. Battezzati A, et al. **Diabet Med** 1998 Dec;15(12):991–6

Hypoglycaemic symptoms reported by children with type 1 diabetes mellitus and by their parents. Ross LA, et al. **Diabet Med** 1998 Oct;15(10):836–43

A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Otonkoski T, et al. **Diabetes** 1999 Feb;48(2):408–15

Reduced beta-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Korytkowski MT, et al. **Diabetes Care** 1998 Nov;21(11):1939–43

Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Kovatchev BP, et al. **Diabetes Care** 1998 Nov; 21(11):1870–5

Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Meyer C, et al. **Diabetes Care** 1998 Nov;21(11):1960–6

Hypoglycemia after pancreas transplantation. Redmon JB, et al. **Diabetes Care** 1998 Nov;21(11):1944–50

Transient hypoglycemic hemiparesis in children with IDDM [letter] Spallino L, et al. **Diabetes Care** 1998 Sep; 21(9):1567–8

An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats. Chang SL, et al. **Diabetologia** 1999 Feb; 42(2):250–5

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Toft-Nielsen M, et al. **Diabetologia** 1998 Oct;41(10):1180–6

Helicobacter pylori-induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia. Açbay O, et al. **Dig Dis Sci** 1999 Sep;44(9):1837–42

Maternal epidermal growth factor deficiency causes fetal hypoglycemia and intrauterine growth retardation in mice: possible involvement of placental glucose transporter GLUT3 expression. Kamei Y, et al. **Endocrinology** 1999 Sep;140(9):4236–43

Hypoglycaemia associated with a solitary fibrous tumour of the pleura. Chaugle H, et al. **Eur J Cardiothorac Surg** 1999 Jan;15(1):84–6

Risk factors of hypoglycemia in premature infants. Zanardo V, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):63–7

Primary liver hemangiopericytoma associated with hypoglycemia: report of a second case. Campion JP, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1944–8

Persistent hyperinsulinemic hypoglycemia of infancy. Desai MP, et al. **Indian Pediatr** 1998 Apr;35(4):317–28

Insulinoma with hyperproinsulinemia during hypoglycemia and loss of expression of vacuolar-type H(+)-ATPase (V-ATPase) in the tumor tissue. Hiura A, et al. **Int J Pancreatol** 1999 Feb;25(1):11–6

Late intraoperative hypoglycemia in a patient with Russell-Silver syndrome [letter] Tomiyama H, et al. **J Clin Anesth** 1999 Feb;11(1):80–2

Insulinoma/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. Soga J, et al. **J Exp Clin Cancer Res** 1998 Dec;17(4):379–88

Acinar cell carcinoma of the pancreas associated with hypoglycemia: involvement of "big" insulin-like growth factor-II. Mizuta Y, et al. **J Gastroenterol** 1998 Oct; 33(5):761–5

Manifestations of hypercholesterolaemia, hypoglycaemia, erythrocytosis and hypercalcaemia in patients with hepatocellular carcinoma: report of two cases. Chu CW, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):807–10

Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose. de Lonlay P, et al. **J Pediatr** 1999 Sep;135(3):379–83

Failure to detect preterm infants at risk of hypoglycemia before discharge. Hume R, et al. **J Pediatr** 1999 Apr; 134(4):499–502

Foregut dysmotility complicating persistent hyperinsulinaemic hypoglycaemia of infancy. Cade A, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):355–8

Re: Severe hypoglycaemia in insulin-dependent diabetes mellitus: living to tell the tale (lessons to be learned: a case study approach) [letter; comment] Kiln MR. **J R Soc Health** 1998 Jun;118(3):192–3. Comment on: J R Soc Health 1997 Dec;117(6):377–80.

Management of the young child with diabetes mellitus: how do we measure success? [editorial; comment] White NH. **Mayo Clin Proc** 1999 Mar;74(3):309–11. Comment on: Mayo Clin Proc 1999 Mar;74(3):211–6.

Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia. Cowett RM, et al. **Metabolism** 1999 May;48(5):568–74

Tumor-induced hypoglycemia [editorial; comment] Le Roith D. **N Engl J Med** 1999 Sep 2;341(10):757–8. Comment on: N Engl J Med 1999 Sep 2;341(10):733–6.

Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix [see comments] Seckl MJ, et al. **N Engl J Med** 1999 Sep 2;341(10):733–6. Comment in: N Engl J Med 1999 Sep 2;341(10):757–8.

The causes of neonatal hypoglycemia [editorial; comment] Stanley CA, et al. **N Engl J Med** 1999 Apr 15; 340(15):1200–1. Comment on: N Engl J Med 1999 Apr 15;340(15):1169–75.

Brainstem dysfunction in chiari malformation presenting as profound hypoglycemia: presentation of four cases, review of the literature, and conjecture as to mechanism. Rekate HL, et al. **Neurosurgery** 1999 Aug;45(2):386–91 (22 ref.)

Causes, management and morbidity of acute hypoglycaemia in adults requiring hospital admission. Hart SP, et al. **QJM** 1998 Jul;91(7):505–10

Metastatic malignant meningioma of the liver with hypoglycemia: report of a case. Nabeya Y, et al. **Surg Today** 1998;28(9):953–8

Liver transplantation for metastatic hemangiopericytoma associated with hypoglycemia. Adams J, et al. **Transplantation** 1999 Feb 15;67(3):488–9

Hypoglycaemic shock: normal or abnormal response to injury? [letter] Gill G. **Trop Doct** 1999 Apr;29(2):117

Attenuation of brain hyperbaric oxygen toxicity by fasting is not related to ketosis. Chavko M, et al. **Undersea Hyperb Med** 1999 Summer;26(2):99–103

[Persistent hyperinsulinemic hypoglycemia in the newborn and infants] de Lonlay-Debeney P, et al. **Arch Pediatr** 1998 Dec;5(12):1347–52 (30 ref.) (Eng. Abstr.) **(Fre)**

[Transitory hyperinsulinism with hypoglycemia in asphyxia neonatorum (letter; comment)] Sann L. **Arch Pediatr** 1999 Feb;6(2):228. Comment on: Arch Pediatr 1997 Dec;4(12):1213–6. **(Fre)**

[Hypoglycemia secondary to IGF-II hypersecretion in the course of metastatic colonic adenocarcinoma] Larvol L, et al. **Gastroenterol Clin Biol** 1998 Oct;22(10):835–6 **(Fre)**

[Severe hypoglycemia secondary to localized pleural fibrous mesothelioma (letter)] Luque-Sánchez F, et al. **Arch Bronconeumol** 1999 Feb;35(2):102–3 **(Spa)**

GENETICS

Hypoglycaemic symptoms described by diabetic children and their parents. Chiarelli F, et al. **Acta Diabetol** 1998 Jul; 35(2):81–4

Loss of imprinted genes and paternal SUR1 mutations lead to hyperinsulinism in focal adenomatous hyperplasia. Fournet JC, et al. **Ann Endocrinol (Paris)** 1998;59(6):485–91

Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia. Mahalingam B, et al. **Diabetes** 1999 Sep;48(9):1698–705

A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Otonkoski T, et al. **Diabetes** 1999 Feb;48(2):408–15

Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. Liu S, et al. **J Clin Invest** 1999 Jan;103(2):207–13

Clinical and molecular heterogeneity of familial hyperinsulinism [letter; comment] Glaser B, et al. **J Pediatr** 1998 Dec;133(6):801–2. Comment on: J Pediatr 1998 Jan;132(1):9–14.

The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice [see comments] Calogero S, et al. **Nat Genet** 1999 Jul;22(3):276–80. Comment in: Nat Genet 1999 Jul;22(3):215–7.

Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Terauchi Y, et al. **Nat Genet** 1999 Feb;21(2):230–5

Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. Ferrand-Drake M, et al. **Neuroscience** 1999; 90(4):1325–38

IMMUNOLOGY

Insulin autoimmune syndrome (IAS, Hirata disease). Uchigata Y, et al. **Ann Med Interne (Paris)** 1999 Apr; 150(3):245–53 (47 ref.)

Induction of hypothermia, hypoglycemia and hyperinsulinemia after acute leptin immunoneutralization in overnight fasted mice. Martinez-Ansó E, et al.

Int J Mol Med 1998 Dec;2(6):681–3

METABOLISM

Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR, et al. **Afr J Med Med Sci** 1996 Sep;25(3):243–9

Effects of beta-adrenergic blockade on hepatic and renal glucose production during hypoglycemia in conscious dogs. Cersosimo E, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E792–7

Brain O2 consumption and glutamate release during hypoglycemic coma in piglets are temperature sensitive. Ichord RN, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2053–62

Insulin hypoglycemia and growth hormone secretion in sheep: a paradox revisited. Jaffe CA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E253–8

Insulin induced hypoglycaemia: comparison of glucose and glycerol concentrations in plasma and microdialysate from subcutaneous adipose tissue. Kamel A, et al. **Arch Dis Child** 1999 Jan;80(1):42–5

Increase in glucose transporter densities of Glut3 and decrease of glucose utilization in rat brain after one week of hypoglycemia. Duelli R, et al. **Brain Res** 1999 Jun 12; 831(1–2):254–62

Effects of glucose and related substrates on the recovery of the electrical activity of gonadotropin-releasing hormone pulse generator which is decreased by insulin-induced hypoglycemia in the estrogen-primed ovariectomized rat. He D, et al. **Brain Res** 1999 Feb 27;820(1–2):71–6

Involvement of P2 purinoceptors and the nitric oxide pathway in [3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. Juránvi Z, et al. **Brain Res** 1999 Mar 27;823(1–2):183–90

Synergistic effect of counterregulatory hormones during insulin-induced hypoglycemia in rats: participation of lipolysis and gluconeogenesis to hyperglycemia. Souza HM, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep; 17(5):455–9

Renal glucose production during insulin-induced hypoglycemia in humans. Cersosimo E, et al. **Diabetes** 1999 Feb;48(2):261–6

Opposite effects of acute hypoglycemia and acute hyperglycemia on glucose transport and glucose transporters in perfused rat skeletal muscle. Mathoo JM, et al. **Diabetes** 1999 Jun;48(6):1281–8

Brain substrate utilisation during acute hypoglycaemia. Wahren JP6, et al. **Diabetologia** 1999 Jul;42(7):812–8

Changes in the extracellular levels of glutamate and aspartate during ischemia and hypoglycemia. Effects of hypothermia. Boris-Möller F, et al. **Exp Brain Res** 1998 Aug; 121(3):277–84

Rat cultured astrocytes release guanine-based purines in basal conditions and after hypoxia/hypoglycemia. Ciccarelli R, et al. **Glia** 1999 Jan;25(1):93–8

Lipolytic response during spontaneous hypoglycaemia in insulin-dependent diabetic subjects. Hagström-Toft E, et al. **Horm Metab Res** 1998 Sep;30(9):586–93

Importance of phosphodiesterase 3 for the lipolytic response in adipose tissue during insulin-induced hypoglycemia in normal man. Moberg E, et al. **Horm Metab Res** 1998 Nov; 30(11):684–8

Comment--do glucocorticoids mediate the hypoglycemia-induced rise in insulin-like growth factor binding protein-1? [letter; comment] Baxter RC, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2259–61. Comment on: J Clin Endocrinol Metab 1998 Dec;83(12):4426–30.

Protective effect of insulin against hypoglycemia-associated counterregulatory failure. Fruehwald-Schultes B, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1551–7

Blood-brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. Simpson IA, et al. **J Neurochem** 1999 Jan;72(1):238–47

Inhibition of luteinizing hormone secretion and expression of c-fos and corticotrophin-releasing factor genes in the paraventricular nucleus during insulin-induced hypoglycaemia in sheep. Adam CL, et al. **J Neuroendocrinol** 1998 Oct;10(10):777–83

Lower arterial glucose concentrations in lambs with aortopulmonary shunts after an 18-hour fast. Beaufort-Krol GC, et al. **Metabolism** 1999 Sep; 48(9):1082–8

Individualized low-dose growth hormone (GH) treatment in GH-deficient adults with childhood-onset disease: metabolic effects during fasting and hypoglycemia. Bülow B, et al. **Metabolism** 1999 Aug;48(8):1003–10

Muscle damage induced by experimental hypoglycemia. Jiang ZL, et al. **Metabolism** 1998 Dec;47(12):1472–6

Recurrent hypoglycemia does not impair the cortisol response to adrenocorticotropin infusion in healthy humans. Welt CK, et al. **Metabolism** 1998 Oct; 47(10):1252–7

Effect of starvation and insulin-induced hypoglycemia on oxidative stress scavenger system and electron transport chain complexes from rat brain, liver, and kidney. Bhardwaj SK, et al. **Mol Chem Neuropathol** 1998 Jun–Aug; 34(2–3):157–68

Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. Féry F, et al. **N Engl J Med** 1999 Mar 18;340(11):852–6

Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. Ferrand-Drake M, et al. **Neuroscience** 1999; 90(4):1325–38

[Effects of stimulation and damage of afferent nerves on the glucose and free fatty acid levels in the rat blood under various glycemic conditions] Spiridonov VK, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Dec;84(12):1333–8 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Hypoglycaemic neuropathy in BB/Wor rats treated with insulin implants: electron microscopic observations. Mohseni S, et al. **Acta Neuropathol (Berl)** 1998 Aug; 96(2):151–6

BDNF and NGF afford in vitro neuroprotection against ethanol combined with acute ischemia and chronic hypoglycemia. Mitchell JJ, et al. **Dev Neurosci** 1999; 21(1):68–75

Insulin-induced hypoglycemia elicits thymocyte apoptosis in the rat. Morishita S, et al. **Diabetes Res Clin Pract** 1998 Apr;40(1):1–7

NGF-induced cytotoxicity in PC12 cells in a hypoglycemic environment. Chung JM, et al. **Neuroreport** 1998 Aug 3; 9(11):2495–500

Cerebral magnetic resonance imaging and ultrasonography findings after neonatal hypoglycemia. Kinnala A, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):724–9

PHYSIOPATHOLOGY

Ernst-Friedrich-Pfeiffer-Memorial lecture. Hypoglycaemia associated syndrome. Amiel SA. **Acta Diabetol** 1998 Dec; 35(4):226–31 (66 ref.)

Hypoglycaemic symptoms described by diabetic children and their parents. Chiarelli F, et al. **Acta Diabetol** 1998 Jul; 35(2):81–4

Evidence that the gastrointestinal tract is involved in glucose homeostasis. Alada AR, et al. **Afr J Med Med Sci** 1996 Sep;25(3):243–9

Hypoglycemia and torpor in Siberian hamsters. Dark J, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R776–81

Effects of estrogen and estrous cycle on glucocorticoid and catecholamine responses to stress in sheep. Komesaroff PA, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):E671–8

Forearm norepinephrine spillover during standing, hyperinsulinemia, and hypoglycemia. Paramore DS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E872–81

The role of sympathetic arousal in discrimination of insulin-produced hypoglycemia. Duncan PM, et al. **Behav Pharmacol** 1997 Oct;8(5):389–95

Hypoglycaemia leads to an increased QT interval in normal men. Eckert B, et al. **Clin Physiol** 1998 Nov;18(6):570–5

Increased splanchnic blood flow after hypoglycaemia in diabetic and normal man: evidence against glucagon as a mediator. Parker DR, et al. **Clin Sci (Colch)** 1999 Feb; 96(2):179–84

Physiological control of splanchnic blood flow by adrenaline: studies during acute hypoglycaemia in man. Parker DR, et al. **Clin Sci (Colch)** 1999 Jun;96(6):623–9

Physiological significance of behavioral hypothermia in hypoglycemic frogs (Rana catesbeiana). Rocha PL, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Apr; 119(4):957–61

Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats. Borg MA, et al. **Diabetes** 1999 Mar;48(3):584–7

Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Fanelli CG, et al. **Diabetes** 1998 Dec;47(12):1920–7

Effects of recurrent hypoglycemia on brainstem function in diabetic BB rats: protective adaptation during acute hypoglycemia. Jacob RJ, et al. **Diabetes** 1999 Jan; 48(1):141–5

Hypoglycemia per se stimulates sympathetic neural as well as adrenomedullary activity, but, unlike the adrenomedullary response, the forearm sympathetic neural response is not reduced after recent hypoglycemia. Paramore DS, et al. **Diabetes** 1999 Jul;48(7):1429–36

Durable reversal of hypoglycemia unawareness in type 1 diabetes [letter] Dagogo-Jack S, et al. **Diabetes Care** 1999 May;22(5):866–7

Effect of hypoglycemia on beta-adrenergic sensitivity in normal and type 1 diabetic subjects. Fritsche A, et al. **Diabetes Care** 1998 Sep;21(9):1505–10

Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Kinsley BT, et al. **Diabetes Care** 1999 Jul; 22(7):1022–8

Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Matyka KA, et al. **Diabetes Care** 1999 Jul;22(7):1144–50

Hypoglycemic urticaria revisited [letter] Sacerdote AS. **Diabetes Care** 1999 May;22(5):861

No differences in attentional functioning between type 1 diabetic patients with and without a history of severe hypoglycemia [letter] Snoek FJ, et al. **Diabetes Care** 1998 Sep;21(9):1568–9

Long-term follow-up of insulin-dependent diabetes mellitus patients with recurrent episodes of severe hypoglycaemia. Oskarsson P, et al. **Diabetes Res Clin Pract** 1999 Jun; 44(3):165–74

Fetal heart-rate monitoring during maternal hypoglycaemic coma: a case report. Matias A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):223–5

Arrest of pulsatile luteinizing hormone (LH) secretion during insulin-induced hypoglycemia (IIH): improvement by intrahypothalamic perfusion with glucose. Rodriguez M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(4):257–61

Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects. Meinhold J, et al. **Horm Metab Res** 1998 Nov;30(11):694–7

Pre-exercise ingestion of carbohydrate and transient hypoglycemia during exercise. Kuipers H, et al. **Int J Sports Med** 1999 May;20(4):227–31

Response of the pituitary-adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome. Gennarelli G, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):76–81

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Landstedt-Hallin L, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3140–5

Hypoglycemia unawareness in a patient with dumping syndrome: report of a case. Bellini F, et al. **J Endocrinol Invest** 1998 Jul–Aug;21(7):463–7

Hepatic amino- to urea-N clearance and forearm amino-N exchange during hypoglycemic and euglycemic hyperinsulinemia in normal man. Grøfte T, et al. **J Hepatol** 1999 May;30(5):819–25

Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Landstedt-Hallin L, et al. **J Intern Med** 1999 Sep;246(3):299–307

Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia. Cowett RM, et al. **Metabolism** 1999 May;48(5):568–74

Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Moriguchi T, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):101–4

Appraisal of mood and personality during hypoglycaemia in human subjects. McCrimmon RJ, et al. **Physiol Behav** 1999 Aug 1;67(1):27–33

Anger state during acute insulin-induced hypoglycaemia. McCrimmon RJ, et al. **Physiol Behav** 1999 Aug 1;67(1):35–9

PREVENTION & CONTROL

Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Detlofson I, et al. **Acta Paediatr** 1999 Jun; 88(6):595–7

The evidence for insulin lispro [letter; comment] Grossman LD. **CMAJ** 1999 Jun 1;160(11):1551–2. Comment on: CMAJ 1998 Feb 24;158(4):506–11. Comment on: CMAJ 1998 Dec 1;159(11):1353–5.

How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Bolli GB. **Diabetes Care** 1999 Mar;22 Suppl 2:B43–52 (44 ref.)

Relation of fibre intake to HbA1c and the prevalence of severe ketoacidosis and severe hypoglycaemia. EURODIAB IDDM Complications Study Group. Buyken AE, et al. **Diabetologia** 1998 Aug;41(8):882–90

Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Kentrup H, et al. **Eur J Pediatr** 1999 Jun;158(6):455–9

Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? Kovacs GT, et al. **Horm Res** 1999;51(4):193–200

Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Riddell MC, et al. **Int J Sport Nutr** 1999 Mar;9(1):24–34

Bedtime uncooked cornstarch supplement prevents nocturnal hypoglycaemia in intensively treated type 1 diabetes subjects. Axelsen M, et al. **J Intern Med** 1999 Mar; 245(3):229–36

The snack is critical for the blood glucose profile during treatment with regular insulin preprandially. Orre-Pettersson AC, et al. **J Intern Med** 1999 Jan; 245(1):41–5

PSYCHOLOGY

Ernst-Friedrich-Pfeiffer-Memorial lecture. Hypoglycaemia associated syndrome. Amiel SA. **Acta Diabetol** 1998 Dec; 35(4):226–31 (66 ref.)

Prevention and treatment of hypoglycaemia unawareness in type 1 diabetes mellitus. Bolli GB. **Acta Diabetol** 1998 Dec; 35(4):183–93 (50 ref.)

The perception of safe driving ability during hypoglycemia in patients with type 1 diabetes mellitus. Weinger K, et al. **Am J Med** 1999 Sep;107(3):246–53

Biopsychobehavioral model of risk of severe hypoglycemia. Self-management behaviors. Clarke WL, et al. **Diabetes Care** 1999 Apr;22(4):580–4

Patients' stories and clinical care. Uniting the unique and the universal? [editorial; comment] Feudtner C. **J Gen Intern Med** 1998 Dec;13(12):846–9. Comment on: J Gen Intern Med 1998 Dec;13(12):799–804.

Living with hypoglycemia [see comments] Ritholz MD, et al. **J Gen Intern Med** 1998 Dec;13(12):799–804. Comment in: J Gen Intern Med 1998 Dec;13(12):846–9.

Effect of acute hypoglycemia on visual information processing in adults with type 1 diabetes mellitus. Ewing FM, et al. **Physiol Behav** 1998 Jul;64(5):653–60

HYPOGLYCEMIA

Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey. Chen MD, et al. **Psychoneuroendocrinology** 1998 Jul;23(5):497-503

RADIONUCLIDE IMAGING

Technetium-99m-HMPAO brain SPECT in neonates with hypoglycemic encephalopathy. Chiu NT, et al. **J Nucl Med** 1998 Oct;39(10):1711-3

SURGERY

Pancreatic exocrine and endocrine function after pancreatectomy for persistent hyperinsulinaemic hypoglycaemia of infancy. Cade A, et al. **Arch Dis Child** 1998 Nov;79(5):435-9

Partial or near total pancreatectomy for persistent neonatal hyperinsulinaemic hypoglycaemia: the pathologist's role [letter; comment] Cox P. **Histopathology** 1999 Jan;34(1):78 Comment on: Histopathology 1998 Jan;32(1):15-9.

THERAPY

Out-of-hospital treatment of hypoglycemia: refusal of transport and patient outcome. Socransky SJ, et al. **Acad Emerg Med** 1998 Nov;5(11):1080-5

Hypoglycaemia in children with type 1 diabetes mellitus. Chiarelli F, et al. **Acta Paediatr Suppl** 1999 Jan;88(427):31-4 (17 ref.)

Long-term follow up of persistent hyperinsulinaemic hypoglycaemia of infancy. Cresto JC, et al. **Arch Dis Child** 1998 Nov;79(5):440-4

Clinical features of neonates with hyperinsulinism [letter] Hawdon JM, et al. **N Engl J Med** 1999 Aug 26;341(9):701-2

VETERINARY

Profound postanesthetic hypoglycemia attributable to glucocorticoid deficiency in 2 dogs. Lane IF, et al. **Can Vet J** 1999 Jul;40(7):497-500

Hypothermia, hypoglycemia, and hypothyrosis associated with poult enteritis and mortality syndrome. Doerfler RE, et al. **Poult Sci** 1998 Aug;77(8):1103-9

HYPOGLYCEMIC AGENTS

Insulin hypoglycemia and growth hormone secretion in sheep: a paradox revisited. Jaffe CA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):E253-8

Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Venturini F, et al. **Ann Pharmacother** 1999 Mar;33(3):281-8

Nephrectomy decreases amylin and pramlintide clearance in rats. Vine W, et al. **Horm Metab Res** 1998 Aug;30(8):514-7

Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Moriguchi T, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):101-4

Mitigation of the somnolence of insulin-induced hypoglycemia by a vasopressin V1 receptor antagonist in the rhesus monkey. Chen MD, et al. **Psychoneuroendocrinology** 1998 Jul;23(5):497-503

[24 years later....] Brogard JM. **Rev Med Interne** 1998 Oct; 19(10):751-2 **(Fre)**

[Amaryl and alapryl: 2 paronymous drugs (letter)] Navarro Sanz JJ, et al. **Aten Primaria** 1998 Dec;22(10):669-70 **(Spa)**

ADMINISTRATION & DOSAGE

Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Glynn RJ, et al. **Am J Epidemiol** 1999 Mar 15;149(6):541-9

Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets. Leaf E, et al. **Am J Health Syst Pharm** 1999 Mar 1; 56(5):454-6

Hyponatremia: evaluating the correction factor for hyperglycemia. Hillier TA, et al. **Am J Med** 1999 Apr; 106(4):399-403

Insulin pens and acute deterioration in blood glucose control [letter] Albareda M, et al. **Arch Intern Med** 1999 Jan 11; 159(1):100

Effects of fibric acid derivatives and metformin on postprandial lipemia. Weintraub MS, et al. **Atherosclerosis** 1998 Dec;141 Suppl 1:S71-5

Type 2 diabetes mellitus and Aboriginal Australians. Options for oral therapy in the control of glyceamia. Bell D. **Aust Fam Physician** 1998 Nov;27(11):1017-20 (44 ref.)

Diabetes mellitus management in general practice: where are we? [letter] Staff M. **Aust Fam Physician** 1999 Aug; 28(8):775

In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. Shimokawa T, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):374-8

Preparation and characterization of enteric microspheres containing bovine insulin by a w/o/w emulsion solvent evaporation method. Nagareya N, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1613-7

Pulmonary administration of insulin as an aerosol [letter] Inoue K, et al. **Chest** 1999 Aug;116(2):581-2

Insulin by inhalation? [letter] Mecikalski M. **Chest** 1999 Aug; 116(2):581

The effect of vitamin E supplementation on erythrocyte osmotic fragility in diabetic patients. Tütüncü NB, et al. **Clin Hemorheol Microcirc** 1999;20(3):201-7

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Todd JF, et al. **Clin Sci (Colch)** 1998 Sep;95(3):325-9

Plasma endothelin-1 and total insulin exposure in diabetes mellitus. Wollesen F, et al. **Clin Sci (Colch)** 1999 Aug; 97(2):149-56

Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Roach P, et al. **Clin Ther** 1999 Mar;21(3):523-34

Preliminary experience of the DIAS computer model in providing insulin dose advice to patients with insulin dependent diabetes. Cavan DA, et al. **Comput Methods Programs Biomed** 1998 May;56(2):157-64

Cutis/subcutis thickness at insulin injection sites and localization of simulated insulin boluses in children with type 1 diabetes mellitus: need for individualization of injection technique? Birkebaek NH, et al. **Diabet Med** 1998 Nov;15(11):965-71

Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Riemens SC, et al. **Diabetes** 1999 Aug;48(8):1631-7

Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Lteif AN, et al. **Diabetes Care** 1999 Jan;22(1):137-40

Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Rassam AG, et al. **Diabetes Care** 1999 Jan; 22(1):133-6

Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients [letter] Rave K, et al. **Diabetes Care** 1999 May;22(5):865-6

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Renner R, et al. **Diabetes Care** 1999 May;22(5):784-8

Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Scheen AJ, et al. **Diabetes Metab** 1999 Jun;25(2):157-62

Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. Yuen VG, et al. **Diabetes Res Clin Pract** 1999 Jan;43(1):9-19

Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. Hosny EA, et al. **Drug Dev Ind Pharm** 1998 Mar;24(3):307-11

Recent approaches in insulin delivery. Trehan A, et al. **Drug Dev Ind Pharm** 1998 Jul;24(7):589-97 (83 ref.)

Relating in vitro/in vivo data of two controlled-release metformin formulations. Yuen KH, et al. **Drug Dev Ind Pharm** 1999 May;25(5):613-8

Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. Thomsen HS, et al. **Eur Radiol** 1999;9(4):738-40

Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Barichello JM, et al. **Int J Pharm** 1999 Jul 20;184(2):189-98

Ocular devices for the controlled systemic delivery of insulin: in vitro and in vivo dissolution. Lee YC, et al. **Int J Pharm** 1999 Apr 20;181(1):71-7

Insulin induces dephosphorylation of eukaryotic initiation factor 2alpha and restores protein synthesis in vulnerable hippocampal neurons after transient brain ischemia. Sullivan JM, et al. **J Cereb Blood Flow Metab** 1999 Sep; 19(9):1010-9

Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. Guerci B, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2673-8

An investigation into antidiabetic medication prescribing in South Africa. Truter I. **J Clin Pharm Ther** 1998 Dec; 23(6):417-22

Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. Akiyoshi K, et al. **J Controlled Release** 1998 Aug 14;54(3):313-20

Modulating insulin-release profile from pH/thermosensitive polymeric beads through polymer molecular weight. Ramkissoon-Ganorkar C, et al. **J Controlled Release** 1999 Jun 2;59(3):287-98

Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. Roger P, et al. **J Diabetes Complications** 1999 Mar-Apr;13(2):62-7

Cardiovascular regulation during insulin infusion into the carotid or vertebral artery in dogs. Hildebrandt DA, et al. **J Hypertens** 1999 Feb;17(2):251-60

Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. Bando Y, et al. **J Int Med Res** 1999 Mar-Apr; 27(2):53-64

Recurrent hypoglycaemia in multiple myeloma: a case of Munchausen syndrome by proxy in an elderly patient. Ben-Chetrit E, et al. **J Intern Med** 1998 Aug;244(2):175-8 (11 ref.)

2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor. Wolkowicz PE, et al. **J Mol Cell Cardiol** 1999 Aug;31(8):1405-12

Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. Chiarelli F, et al. **J Pediatr** 1999 Apr;134(4):486-91

Physical stress testing of insulin suspensions and solutions. Shnek DR, et al. **J Pharm Sci** 1998 Nov;87(11):1459-65

The UK Prospective Diabetes Study [letter; comment] Bailey CJ, et al. **Lancet** 1998 Dec 12;352(9144):1932; discussion 1934. Comment on: Lancet 1998 Sep 12;352(9131):837-53. Comment on: Lancet 1998 Sep 12;352(9131):854-65.

The UK Prospective Diabetes Study [letter; comment] Evans M. **Lancet** 1998 Dec 12;352(9144):1932-3; discussion 1934 . Comment on: Lancet 1998 Sep 12;352(9131):837-53. Comment on: Lancet 1998 Sep 12;352(9131):854-65.

The UK Prospective Diabetes Study [letter; comment] Good CB. **Lancet** 1998 Dec 12;352(9144):1933; discussion 1934. Comment on: Lancet 1998 Sep 12;352(9131):837-53. Comment on: Lancet 1998 Sep 12;352(9131):854-65.

Implantable insulin pumps. Selam JL. **Lancet** 1999 Jul 17; 354(9174):178-9

Pharmacokinetics of methyl palmoxirate, an inhibitor of beta-oxidation, in rats and humans. Chang MC, et al. **Life Sci** 1998;63(20):PL297-302

Designer insulins: moving closer to convenient and physiological replacement of insulin [editorial; comment] Boyages SC. **Med J Aust** 1999 Apr 19;170(8):349-50. Comment on: Med J Aust 1999 Apr 19;170(8):364-7.

Oral agents in type 2 diabetes: where to now? [editorial] Campbell LV, et al. **Med J Aust** 1999 Jul 19;171(2):64-5

Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Paolisso G, et al. **Metabolism** 1999 Jun;48(6):755-62

Dose-response relationship of insulin to glucose fluxes in the awake and unrestrained mouse. Shen HQ, et al. **Metabolism** 1999 Aug;48(8):965-70

Metformin hydrochloride all right before, but not after, contrast medium administration [letter; comment] Rasuli P, et al. **Radiology** 1998 Nov;209(2):586-7. Comment on: Radiology 1995 Nov;197(2):545. Comment on: Radiology 1995 Nov;197(2):545-6.

Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Scott JF, et al. **Stroke** 1999 Apr;30(4):793-9

[Clinical report of 60 cases of diabetic cardio-vascular autonomous neuropathy by stasis removing treatment of combined traditional and Western medicine] Huang SM, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Oct;17(10):594-6 (Eng. Abstr.) **(Chi)**

[The short-acting insulin analog Lispro (Humalog) in the treatment of diabetes--comparison of preprandial and postprandial administration and comparison with treatment using Humulin R] Perušičová J, et al. **Vnitr Lek** 1998 Jul; 44(7):409-14 (Eng. Abstr.) **(Cze)**

[Insulin injections: techniques and plans] Soltani D, et al. **Presse Med** 1998 Jul 4-11;27(24):1247-50 (Eng. Abstr.) **(Fre)**

["Good" blood glucose values, "bad" HbA1c] Osterwalder P, et al. **Schweiz Rundsch Med Prax** 1998 Sep 23; 87(39):1260-2 **(Ger)**

[Minor differences in outcome comparing early vs. later initiation of medicamentous blood glucose control in type 2 diabetic patients] Ritzman P. **Schweiz Rundsch Med Prax** 1999 Aug 15;88(31-32):1289-90 **(Ger)**

[Step-wise drug therapy in type 2 diabetes mellitus] König K, et al. **Z Arztl Fortbild Qualitatssich** 1998 Sep; 92(7):467-73 (33 ref.) (Eng. Abstr.) **(Ger)**

[An assessment of neuronal regeneration in neural anastomoses by synthetic guide and biological systems and insulin administration: an experimental study in the rat] Vellucci R, et al. **G Chir** 1999 Jun-Jul;20(6-7):316-24 (Eng. Abstr.) **(Ita)**

[Short-term intensive insulin therapy as a method of overcoming secondary failure of sulfonylureas in patients with type 2 diabetes (non-insulin-dependent)] Jedynasty K, et al. **Pol Arch Med Wewn** 1998 Jun;99(6):442-51 (Eng. Abstr.) **(Pol)**

[The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy] Strokov IA, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(6):18-22 (Eng. Abstr.) **(Rus)**

[Treatment of type 2 diabetes. Early detection of secondary oral treatment failure is important] Clauson P, et al. **Lakartidningen** 1999 Jan 20;96(3):176-81 (19 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Advisory panel hears contradictory evidence, backs keeping troglitazone on market [news] Miller JL. **Am J Health Syst Pharm** 1999 May 1;56(9):840, 842

Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Mullins ME, et al. **Ann Emerg Med** 1999 Jan;33(1):129-30. Comment on: Ann

Emerg Med 1998 Jun;31(6):773–6.
Delayed hypoglycemia after ingestion of a single glipizide tablet [letter; comment] Robertson WO. **Ann Emerg Med** 1999 Jan;33(1):130–1. Comment on: Ann Emerg Med 1998 Jun;31(6):773–6.
Severe hepatotoxicity associated with troglitazone [letter; comment] Herrine SK, et al. **Ann Intern Med** 1999 Jan 19;130(2):163–4. Comment on: Ann Intern Med 1998 Jul 1;129(1):36–8. Comment on: Ann Intern Med 1998 Jul 1;129(1):38–41.
Troglitazone-associated hepatic failure [letter; comment] Misbin RI. **Ann Intern Med** 1999 Feb 16;130(4 Pt 1):330 . Comment on: Ann Intern Med 1998 Jul 1;129(1):36–8. Comment on: Ann Intern Med 1998 Jul 1;129(1):38–41. Comment on: Ann Intern Med 1998 Dec 15;129(12):1080.
Fatal hepatotoxicity associated with troglitazone [letter; comment] [see comments] Vella A, et al. **Ann Intern Med** 1998 Dec 15;129(12):1080. Comment on: Ann Intern Med 1998 May 15;128(10):871. Comment in: Ann Intern Med 1999 Feb 16;130(4 Pt 1):330.
Drug-induced hypoglycemic coma in 102 diabetic patients. Ben-Ami H, et al. **Arch Intern Med** 1999 Feb 8;159(3):281–4
Significant weight gain with rezulin therapy [letter] Gorson DM. **Arch Intern Med** 1999 Jan 11;159(1):99
Pulmonary edema associated with troglitazone therapy [letter] Hirsch IB, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1811
Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Zapęcka-Dubno B, et al. **Arzneimittelforschung** 1999 Apr;49(4):330–4
Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. Takhar J, et al. **Can J Clin Pharmacol** 1999 Spring;6(1):12–4
Metformin and contrast media--a dangerous combination? McCartney MM, et al. **Clin Radiol** 1999 Jan;54(1):29–33 (37 ref.)
Safety of metformin in Type 2 diabetes mellitus [editorial] Baigent C, et al. **Diabet Med** 1999 Feb;16(2):89–90
Metformin-associated lactic acidosis: a rare or very rare clinical entity? Chan NN, et al. **Diabet Med** 1999 Apr; 16(4):273–81 (123 ref.)
Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Stahl M, et al. **Diabet Med** 1999 Jul;16(7):586–90
Severe hypoglycaemia in children and adolescents during multiple-dose insulin therapy. Tupola S, et al. **Diabet Med** 1998 Aug;15(8):695–9
Acarbose-associated hepatotoxicity [letter] Andrade RJ, et al. **Diabetes Care** 1998 Nov;21(11):2029–30 (11 ref.)
Lactic acidosis rates in type 2 diabetes [see comments] [published erratum appears in Diabetes Care 1998 Dec;21(12):2203] Brown JB, et al. **Diabetes Care** 1998 Oct; 21(10):1659–63. Comment in: Diabetes Care 1998 Oct;21(10):1587–8. Comment in: Diabetes Care 1999 Mar;22(3):532–3. Comment in: Diabetes Care 1999 Jun;22(6):1010–1.
Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient [letter; comment] Chan NN, et al. **Diabetes Care** 1999 Jan;22(1):178. Comment on: Diabetes Care 1998 Aug;21(8):1364–5.
Metformin and lactic acidosis [letter; comment] Cohen RD, et al. **Diabetes Care** 1999 Jun;22(6):1010–1. Comment on: Diabetes Care 1998 Oct;21(10):1587–8. Comment on: Diabetes Care 1998 Oct;21(10):1659–63.
Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication [letter] Cooper JW. **Diabetes Care** 1998 Dec;21(12):2197–8
Effect of fiber intake and meal pattern on gastrointestinal symptoms with acarbose [letter; comment] Harrower AD, et al. **Diabetes Care** 1999 Jul;22(7):1227. Comment on: Diabetes Care 1998 Oct;21(10):1612–8.
Early preprandial hypoglycemia after administration of insulin lispro [letter; comment] Iafusco D, et al. **Diabetes Care** 1998 Oct;21(10):1777–8. Comment on: Diabetes Care 1998 Apr;21(4):570–3.
Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient [letter] [see comments] al-Jebawi AF, et al. **Diabetes Care** 1998 Aug;21(8):1364–5 . Comment in: Diabetes Care 1999 Jan;22(1):178.
Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Response to Kitzmiller et al [comment] [published erratum appears in Diabetes Care 1999 Jul;22(7):1229] Jovanovic L. **Diabetes Care** 1999 May; 22(5):846–8. Comment on: Diabetes Care 1999 May;22(5):874–6.
Lactic acidosis in metformin therapy. Relationship between plasma metformin concentration and renal function [letter] Lalau JD, et al. **Diabetes Care** 1998 Aug;21(8):1366–7
Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Mohn A, et al. **Diabetes Care** 1999 Jan; 22(1):27–32
An autopsy case of troglitazone-induced fulminant hepatitis. Shibuya A, et al. **Diabetes Care** 1998 Dec;21(12):2140–3
Metformin and lactic acidosis: guilt by association? [editorial; comment] [see comments] Stacpoole PW. **Diabetes Care** 1998 Oct;21(10):1587–8. Comment on: Diabetes Care 1998 Oct;21(10):1659–63. Comment in: Diabetes Care 1999 Mar;22(3):532–3. Comment in: Diabetes Care 1999 Jun;22(6):1010–1.
On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions. Stern MP. **Diabetes Care** 1999 May;22(5):844–5
Marked weight loss in a type 2 diabetic patient treated with acarbose [letter] Yoo WH, et al. **Diabetes Care** 1999 Apr; 22(4):645–6
Risk factors of severe hypoglycaemia in adult patients with Type I diabetes--a prospective population based study. Mühlhauser I, et al. **Diabetologia** 1998 Nov;41(11):1274–82
Management of antidiabetic medications in overdose. Spiller HA. **Drug Saf** 1998 Nov;19(5):411–24 (104 ref.)
Epidemiology of adverse drug reactions in the elderly by drug class. Beyth RJ, et al. **Drugs Aging** 1999 Mar; 14(3):231–9 (76 ref.)
Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Gürlek A, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):220–4
Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro. Reichel A, et al. **Exp Clin Endocrinol Diabetes** 1998;106(3):168–72
Diabetes and coronary artery disease: time to stop taking the tablets? [editorial] Connaughton M, et al. **Heart** 1998 Aug;80(2):108–9
Three diabetic cases of acute dizziness due to initial administration of voglibose. Bando Y, et al. **Intern Med** 1998 Sep;37(9):753–6
Lipoatrophy induced by recombinant human insulin injection. Murao S, et al. **Intern Med** 1998 Dec; 37(12):1031–3
Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. Garratt KN, et al. **J Am Coll Cardiol** 1999 Jan;33(1):119–24
Sulfonylurea drugs and cardiovascular mortality [letter] O'Keefe JH Jr, et al. **J Am Coll Cardiol** 1999 Sep;34(3):958
Glibenclamide-induced hypoglycemic coma in 51 older patients with type 2 diabetes mellitus [letter] Ben-Ami H, et al. **J Am Geriatr Soc** 1999 May;47(5):631–3
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Landstedt-Hallin L, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3140–5
Rezulin (troglitazone) greatly increases cyclosporine metabolism [letter] Frantz RP, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1037–8
Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. Aarsand AK, et al. **J Intern Med** 1998 Aug;244(2):169–74
Bedtime uncooked cornstarch supplement prevents nocturnal hypoglycaemia in intensively treated type 1 diabetes subjects. Axelsen M, et al. **J Intern Med** 1999 Mar; 245(3):229–36
Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Landstedt-Hallin L, et al. **J Intern Med** 1999 Sep;246(3):299–307
Intensive diabetes therapy in childhood: is it achievable? Is it desirable? Is it safe? [letter; comment] Becker DJ, et al. **J Pediatr** 1999 Apr;134(4):392–4. Comment on: J Pediatr 1999 Apr;134(4):503–6.
Adverse effects of human insulin [letter; comment] Hirst J. **Lancet** 1998 Nov 21;352(9141):1710. Comment on: Lancet 1998 Aug 29;352(9129):665.
The UK Prospective Diabetes Study [letter; comment] Kerner W. **Lancet** 1998 Dec 12;352(9144):1934. Comment on: Lancet 1998 Sep 12;352(9131):837–53. Comment on: Lancet 1998 Sep 12;352(9131):854–65.
Acarbose-induced generalised erythema multiforme [letter] Kono T, et al. **Lancet** 1999 Jul 31;354(9176):396–7
Type 1 diabetes mellitus in early childhood: glycemic control and associated risk of hypoglycemic reactions [see comments] Lteif AN, et al. **Mayo Clin Proc** 1999 Mar; 74(3):211–6. Comment in: Mayo Clin Proc 1999 Mar;74(3):309–11.
Pleuropulmonary disease in a man with diabetes who was treated with troglitazone [letter] Koshida H, et al. **N Engl J Med** 1998 Nov 5;339(19):1400–1
Metformin-induced hemolysis with jaundice [letter; comment] Lin KD, et al. **N Engl J Med** 1998 Dec 17; 339(25):1860–1. Comment on: N Engl J Med 1996 Feb 29;334(9):574–9.
NIH opens conflict-of-interest investigation [news] Cimons M. **Nat Med** 1999 Feb;5(2):129–30
Metabolic acidosis. Darwich MS, et al. **Postgrad Med J** 1998 Jul;74(873):427–8
[Reevaluation of hypoglycemic risk in the course of intensive insulin therapy] Selam JL. **Journ Annu Diabetol Hotel Dieu** 1998;:257–80 (106 ref.) **(Fre)**
[Interaction between converting enzyme inhibitors and hypoglycemic sulfonamides or insulin] Girardin E, et al. **Presse Med** 1998 Nov 28;27(37):1914–23 (48 ref.) (Eng. Abstr.) **(Fre)**
[Hepatotoxic reaction associated with metformin and chlorpropamide treatment (letter)] Crespo Valadés E, et al. **Rev Clin Esp** 1999 Feb;199(2):118–9 **(Spa)**

ANALYSIS

Development and validation of liquid chromatography and capillary electrophoresis methods for acarbose determination in pharmaceutical tablets. Cherkaoui S, et al. **J Pharm Biomed Anal** 1998 Dec;18(4–5):729–35

BLOOD

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Festa A, et al. **Arterioscler Thromb Vasc Biol** 1999 Mar;19(3):562–8
Sensitive RIA for the specific determination of insulin lispro. Bowsher RR, et al. **Clin Chem** 1999 Jan;45(1):104–10
New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin. Gershonov E, et al. **Diabetes** 1999 Jul;48(7):1437–42
Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Lalau JD, et al. **Drug Saf** 1999 Apr; 20(4):377–84
Systemic exposure to rosiglitazone is unaltered by food. Freed MI, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):53–6
Insulin- or morphine-injection? Immunohistochemical contribution to the elucidation of a case. Wehner F, et al. **Forensic Sci Int** 1998 Aug 12;95(3):241–6
Determination of metformin in plasma by high-performance liquid chromatography after ultrafiltration. Vesterqvist O, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1–2):299–304
Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Paolisso G, et al. **Metabolism** 1999 Jun;48(6):755–62
Determination of plasma metformin by a new cation-exchange HPLC technique. Bonfigli AR, et al. **Ther Drug Monit** 1999 Jun;21(3):330–4

CHEMICAL SYNTHESIS

Synthesis of sulfonylurea conjugated copolymer via PEO spacer and its in vitro short-term bioactivity in insulin secretion from islets of Langerhans. Hwang JS, et al. **Biomaterials** 1998 Jul;19(13):1189–95
Synthesis and biological activity of novel thiazolidinediones. Prabhakar C, et al. **Bioorg Med Chem Lett** 1998 Oct 6; 8(19):2725–30
Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif [published erratum appears in Bioorg Med Chem Lett 1998 Aug 4;8(15):2059] Reddy KA, et al. **Bioorg Med Chem Lett** 1998 May 5; 8(9):999–1002
Synthesis and hypoglycemic effect of chrysin derivatives. Shin JS, et al. **Bioorg Med Chem Lett** 1999 Mar 22; 9(6):869–74
Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Hongu M, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1545–55
Hypoglycemic prodrugs of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid. Aicher TD, et al. **J Med Chem** 1999 Jan 14;42(1):153–63
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents. Aicher TD, et al. **J Med Chem** 1998 Nov 5;41(23):4556–66
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. Cobb JE, et al. **J Med Chem** 1998 Dec 3;41(25):5055–69
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety. Collins JL, et al. **J Med Chem** 1998 Dec 3;41(25):5037–54
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. Henke BR, et al. **J Med Chem** 1998 Dec 3;41(25):5020–36
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl) piperazines and isosteric analogues of imidazoline. Le Bihan G, et al. **J Med Chem** 1999 May 6;42(9):1587–603
Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones. Lohray BB, et al. **J Med Chem** 1999 Jul 15;42(14):2569–81
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. Reddy KA, et al. **J Med Chem** 1999 Jun 3;42(11):1927–40
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives. Reddy KA, et al. **J Med Chem** 1999 Aug 26;42(17):3265–78
4-(trans-4-Methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent. Shinkai H, et al. **J Med Chem** 1998 Dec 31;41(27):5420–8
PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. Wrobel J, et al. **J Med Chem** 1999 Aug 26;42(17):3199–202

HYPOGLYCEMIC AGENTS

CHEMISTRY

1-Isobutyl-2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-3-indoleacetic acid. Deepthi S, et al. **Acta Crystallogr C** 1999 Jan 15;55 (Pt 1):100-2

Gliclazide. Parvez M, et al. **Acta Crystallogr C** 1999 Jan 15;55 (Pt 1):74-5

Troglitazone, an euglycemic antidiabetic drug. Vyas K, et al. **Acta Crystallogr C** 1999 Mar 15;55 (Pt 3):411-3

Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. Kulkarni SS, et al. **Bioorg Med Chem** 1999 Jul;7(7):1475-85

(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Nomura M, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):533-8

USAN Council. List No.417. New names. Insulin Aspart. **Clin Pharmacol Ther** 1999 Jul;66(1):103

Physicochemical characterization of glybuzole polymorphs and their pharmaceutical properties. Otsuka M, et al. **Drug Dev Ind Pharm** 1999 Feb;25(2):197-203

Preparation and dissolution rate of gliquidone-PVP K30 solid dispersions. Martnez P, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun;23(2):113-7

Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods. Hwang SH, et al. **Int J Pharm** 1999 Mar 1;179(1):85-95

Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior. Kimura K, et al. **J Pharm Sci** 1999 Apr;88(4):385-91

Hypoglycaemic avoidance, technology, and knowledge [letter; comment] Wolff F. **Lancet** 1998 Nov 7;352(9139):1549. Comment on: Lancet 1998 Aug 15;352(9127):502-3.

CLASSIFICATION

[Type 2 diabetes: new therapeutic perspectives] Bouhanick B, et al. **Presse Med** 1998 Dec 12;27(39):2015-24 (36 ref.) (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Metformin and contrast media [letter; comment] Hammond DI, et al. **Clin Radiol** 1998 Dec;53(12):933-4. Comment on: Clin Radiol 1998 Apr;53(4):310.

Contra-indications to metformin therapy are largely disregarded. Holstein A, et al. **Diabet Med** 1999 Aug;16(8):692-6

Review of management of type 2 diabetes mellitus. Yap WS, et al. **J Clin Pharm Ther** 1998 Dec;23(6):457-65

DIAGNOSTIC USE

The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities. Graci S, et al. **J Endocrinol Invest** 1999 Jun;22(6):472-5

Enhanced neuroendocrine response to insulin tolerance test performed under increased ambient temperature. Ježová D, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):412-7

ECONOMICS

Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Brown RR. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S24-7

Diabetes care and cost of pharmacotherapy versus medical services. Grace KA, et al. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S27-9

Patient outcomes after formulary conversion from immediate-release to extended-release glipizide tablets. Leaf E, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):454-6

Drug utilization in a hospital general medical outpatient clinic with particular reference to antihypertensive and antidiabetic drugs. Yuen YH, et al. **J Clin Pharm Ther** 1998 Aug;23(4):287-94

HISTORY

Effects of postprandial administration of insulin on food intake by the white rat and the mechanism of appetite for energy (first published in French in 1956) [classical article] Le Magnen J, et al. **Appetite** 1999 Aug;33(1):8-13

IMMUNOLOGY

Effect of intrathymic administration of mycobacterial heat shock protein 65 and peptide p277 on the development of diabetes in NOD mice: caution required in vaccination studies. Funda DP, et al. **APMIS** 1998 Oct;106(10):1009-16

An epitaph for sulfated insulin: immunologic profile of the last patients as they are switched from sulfated beef to human insulin [letter] Carpentier A, et al. **Diabetes Care** 1998 Sep;21(9):1571-2

IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. Rothe H, et al. **J Immunol** 1999 Aug 1;163(3):1230-6

ISOLATION & PURIFICATION

Purification and characterization of Moran 20K from Morus alba. Kim ES, et al. **Arch Pharm Res** 1999 Feb;22(1):9-12

A potent anti-diabetic agent from Kalopanax pictus. Park HJ, et al. **Arch Pharm Res** 1998 Feb;21(1):24-9

METABOLISM

Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. Ashfield R, et al. **Diabetes** 1999 Jun;48(6):1341-7

Role of focal adhesion kinase in MAP kinase activation by insulin-like growth factor-I or insulin. Arbet-Engels C, et al. **FEBS Lett** 1999 Jul 9;454(3):252-6

Insulin exposure and unifying aging. Parr T. **Gerontology** 1999 May-Jun;45(3):121-35 (152 ref.)

Big deal about a little insulin [news] Flier JS. **Nat Med** 1999 Jun;5(6):614-5

PHARMACOKINETICS

Pharmacokinetics of the antihyperglycemic agent metformin in cats. Michels GM, et al. **Am J Vet Res** 1999 Jun;60(6):738-42

Oral bioavailability and pharmacokinetics of the new insulin sensitizer DRF-2189 in Wistar rats. Jajoo HK, et al. **Arzneimittelforschung** 1999 Feb;49(2):133-6

Sex-dependent pharmacokinetics and in vitro reductive metabolism of acetohexamide in Wistar-Imamichi rats. Imamura Y, et al. **Biol Pharm Bull** 1999 Apr;22(4):435-8

Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Hatorp V, et al. **Clin Ther** 1999 Apr;21(4):702-10

Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Rave K, et al. **Diabet Med** 1998 Sep;15(9):747-51

Effect of physicochemical variables of regular insulin formulations on their absorption from the subcutaneous tissue. Polaschegg E. **Diabetes Res Clin Pract** 1998 Apr;40(1):39-44

Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. Schneider RP, et al. **Drug Metab Dispos** 1998 Nov;26(11):1149-59

Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs. Schneider RP, et al. **Drug Metab Dispos** 1998 Nov;26(11):1160-6

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Home PD, et al. **Eur J Clin Pharmacol** 1999 May;55(3):199-203

Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Ott P, et al. **Eur J Clin Pharmacol** 1998 Sep;54(7):567-71

The effect of stress on the pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats. Abd Elaziz MA, et al. **Eur J Drug Metab Pharmacokinet** 1998 Jul-Sep;23(3):371-6

Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Frick A, et al. **Eur J Pharm Biopharm** 1998 Nov;46(3):305-11

Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Hatorp V, et al. **Int J Clin Pharmacol Ther** 1998 Dec;36(12):636-41

Bioequivalence of a generic metformin tablet preparation. Yuen KH, et al. **Int J Clin Pharmacol Ther** 1999 Jul;37(7):319-22

Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. Hatorp V, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1475-8

Efflux transport of tolbutamide across the blood-brain barrier. Takanaga H, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1027-33

20beta-hydroxysteroid dehydrogenase catalyzes ketone-reduction of acetohexamide, an oral antidiabetic drug, in liver microsomes of adult male rats. Takada H, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):504-7

Pharmacokinetics of methyl palmoxirate, an inhibitor of beta-oxidation, in rats and humans. Chang MC, et al. **Life Sci** 1998;63(20):PL297-302

Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Aisenpreis U, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:5-6

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects. Courtois P, et al. **Res Commun Mol Pathol Pharmacol** 1999 Feb;103(2):211-22

[Preparation and utility of glibenclamide suppository for hospital use] Takahashi Y, et al. **Yakugaku Zasshi** 1998 Sep;118(9):401-7 (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport. Hansen BF, et al. **Acta Diabetol** 1998 Jul;35(2):101-3

Insulin impairs the anticonvulsive activity of carbamazepine against maximal electroshock-induced seizures in mice. Alaraj M, et al. **Acta Neurobiol Exp (Warsz)** 1998;58(4):283-6

Effects of magnesium and glucose, insulin, potassium (GIK) solution on the action potential parameters of guinea-pig atrial muscle. Ingemansson MP, et al. **Acta Physiol Scand** 1998 Oct;164(2):173-9

Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Cushman SW, et al. **Adv Exp Med Biol** 1998;441:63-71 (74 ref.)

Effects of glucagon, glucose, adrenaline and insulin infusion on blood glucose level in the common African toad (bufo regularis). Oyebola DD, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):89-94

Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Fujishima S, et al. **Am J Hypertens** 1998 Sep;11(9):1134-7

Effects of aging on the insulin actions for the glucose metabolism and renal function in normotensives and essential hypertensives. Miyazaki Y, et al. **Am J Hypertens** 1998 Sep;11(9):1056-64

Insulin regulation of renal glucose metabolism in humans. Cersosimo E, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E78-84

Calorie restriction increases cell surface GLUT-4 in insulin-stimulated skeletal muscle. Dean DJ, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E957-64

Wortmannin inhibits insulin-stimulated activation of protein phosphatase 1 in rat cardiomyocytes. De Luca JP, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1520-6

Synergistic actions of insulin and troglitazone on contractility in endothelium-denuded rat aortic rings. Goud C, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):E882-7

STZ-induced diabetes decreases and insulin normalizes POMC mRNA in arcuate nucleus and pituitary in rats. Kim EM, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1320-6

Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Lima FB, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E934-41

Hormonal regulation of stearoyl coenzyme-A desaturase 1 activity and gene expression in primary cultures of chicken hepatocytes. Lefevre P, et al. **Arch Biochem Biophys** 1999 Aug 15;368(2):329-37

Hypolipemic and hypoglycemic activities of Prunus davidiana in high fat-fed rats. Choi JS, et al. **Arch Pharm Res** 1991 Mar;14(1):44-7

A potent anti-diabetic agent from Kalopanax pictus. Park HJ, et al. **Arch Pharm Res** 1998 Feb;21(1):24-9

The effect of the new oral hypoglycemic agent A-4166 on glucose turnover in the high fat diet-induced and/or in the hereditary insulin resistance of rats. Klimeš I, et al. **Arch Physiol Biochem** 1998 Oct;106(4):325-32

Effect of insulin on farnesyltransferase gene transcription and mRNA stability. Goalstone ML, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):243-7

Cellular and molecular mechanisms involved in insulin's potentiation of glycogen synthase activity by metformin. Detaille D, et al. **Biochem Pharmacol** 1999 Nov 1;58(9):1475-86

Prevention of dexamethasone-induced insulin resistance by metformin. Thomas CR, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1145-50

Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Davies GF, et al. **Biochim Biophys Acta** 1999 Aug 12;1451(1):122-31

Insulin inhibits surfactant protein A and B gene expression in the H441 cell line. Miakotina OL, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):60-70

Expression and regulation of the insulin-like growth factor-1 receptor by growing and quiescent H4IIE hepatoma. Zahradka P, et al. **Biochim Biophys Acta** 1998 Oct 15;1375(1-2):131-9

Actions of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic db/db mice. Ishikawa Y, et al. **Biol Pharm Bull** 1998 Sep;21(9):928-33

Lipogenic action of the novel oral antidiabetic agent HQL-975 in genetically obese diabetic KK-Ay mice. Ishikawa Y, et al. **Biol Pharm Bull** 1999 Jun;22(6):572-6

Antidiabetic mechanism of Bakumondo-inshi. Miura T, et al. **Biol Pharm Bull** 1999 Apr;22(4):388-90

Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. Kulkarni SS, et al. **Bioorg Med Chem** 1999 Jul;7(7):1475-85

(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Nomura M, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):533-8

Differential activity of rosiglitazone enantiomers at PPAR gamma. Parks DJ, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3657-8

Synthesis and biological activity of novel thiazolidinediones. Prabhakar C, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2725-30

Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes. Sum FW, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):1921-6

Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Friedman JE, et al. **Blood Press** 1998;Suppl 3:32-9

Insulin modifies the glucose response to mental stress independently of forearm blood flow. Høieggen A, et al. **Blood Press** 1998 Nov;7(5-6):291-8

Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Kobayashi J, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):433-9

Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. Anello M, et al.

Br J Pharmacol 1999 Aug;127(8):1883–91

JTT–608 restores impaired early insulin secretion in diabetic Goto–Kakizaki rats. Ohta T, et al. **Br J Pharmacol** 1999 Apr;126(7):1674–80

Acute troglitazone action in isolated perfused rat liver. Preininger K, et al. **Br J Pharmacol** 1999 Jan;126(1):372–8

Enantioselective inhibition of the biotransformation and pharmacological actions of isoidide dinitrate by diphenyleneiodonium sulphate. Ratz JD, et al. **Br J Pharmacol** 1999 Jan;126(1):61–8

JTT–501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non–genetic insulin–resistant models. Shibata T, et al. **Br J Pharmacol** 1998 Dec; 125(8):1744–50

Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin. Smith AJ, et al. **Br J Pharmacol** 1999 Jan;126(1):79–86

Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC–555. Upton R, et al. **Br J Pharmacol** 1998 Dec;125(8):1708–14

Neurophysiological changes in the central and peripheral nervous system of streptozotocin–diabetic rats. Course of development and effects of insulin treatment. Biessels GJ, et al. **Brain** 1999 Apr;122 (Pt 4):757–68

Insulin induces tyrosine phosphorylation of the insulin receptor and SHC, and SHC/GRB2 association in cerebellum but not in forebrain cortex of rats. de L A Fernandes ML, et al. **Brain Res** 1999 Apr 24;826(1):74–82

Intra–septal injections of glucose and glibenclamide attenuate galanin–induced spontaneous alternation performance deficits in the rat. Stefani MR, et al. **Brain Res** 1998 Nov 30;813(1):50–6

Different effects of insulin and 2–deoxy–D–glucose administration on tyrosine hydroxylase gene expression in the locus coeruleus and the adrenal medulla in rats. Rusnák M, et al. **Brain Res Bull** 1998 Jul 15;46(5):447–52

Glucose and tolbutamide trigger transients of Ca2+ in single pancreatic beta–cells exposed to tetraethylammonium. Eberhardson M, et al. **Cell Calcium** 1999 May;25(5):355–60

Na(+)–glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4'–dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Hongu M, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1545–55

Antidiabetic principles of natural medicines. III. Structure–related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Matsuda H, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep; 46(9):1399–403

Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Kawasaki J, et al. **Circulation** 1998 Dec 1;98(22):2446–52

Troglitazone inhibits voltage–dependent calcium currents in guinea pig cardiac myocytes. Nakajima T, et al. **Circulation** 1999 Jun 8;99(22):2942–50

Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats. Kosegawa I, et al. **Clin Exp Hypertens** 1999 Apr; 21(3):199–211

Glipizide treatment of post–transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Sagedal S, et al. **Clin Transplant** 1998 Dec;12(6):553–6

The evidence for insulin lispro [letter; comment] Grossman LD. **CMAJ** 1999 Jun 1;160(11):1551–2. Comment on: CMAJ 1998 Feb 24;158(4):506–11. Comment on: CMAJ 1998 Dec 1;159(11):1353–5.

Dehydroepiandrosterone suppresses the elevated hepatic glucose–6–phosphatase and fructose–1,6–bisphosphatase activities in C57BL/Ksj–db/db mice: comparison with troglitazone. Aoki K, et al. **Diabetes** 1999 Aug; 48(8):1579–85

An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose–fed rats. Faure P, et al. **Diabetes** 1999 Feb;48(2):353–7

Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP–sensitive K+ channel activity. Kawaki J, et al. **Diabetes** 1999 Oct;48(10):2001–6

Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin–induced diabetes and effects of metformin. Large V, et al. **Diabetes** 1999 Jun; 48(6):1251–7

A novel insulin sensitizer acts as a coligand for peroxisome proliferator–activated receptor–alpha (PPAR–alpha) and PPAR–gamma: effect of PPAR–alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Murakami K, et al. **Diabetes** 1998 Dec;47(12):1841–7

NH2–terminally modified gastric inhibitory polypeptide exhibits amino–peptidase resistance and enhanced antihyperglycemic activity. O'Harte FP, et al. **Diabetes** 1999 Apr;48(4):758–65

Metformin but not glyburide prevents high glucose–induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Ren J, et al. **Diabetes** 1999 Oct;48(10):2059–65

Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Shimoyama M, et al. **Diabetes** 1999 Mar;48(3):609–15

Sulfonylureas enhance exocytosis from pancreatic beta–cells by a mechanism that does not involve direct activation of protein kinase C. Tian YA, et al. **Diabetes** 1998 Nov; 47(11):1722–6

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator–activated receptor–gamma. Wang M, et al. **Diabetes** 1999 Feb;48(2):254–60

The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Joseph SE, et al. **Diabetes Care** 1998 Dec;21(12):2098–102

Troglitazone reduces free fatty acid–induced insulin resistance in perfused rat hindquarter. Mokuda O, et al. **Diabetes Metab** 1998 Sep;24(4):362–4

Effects of regular insulin or insulin LISPRO on glucose metabolism after an oral glucose load in patients with type 2 diabetes mellitus. Paquot N, et al. **Diabetes Metab** 1998 Dec;24(6):523–8

Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Wiernsperger NF. **Diabetes Metab** 1999 Jun;25(2):110–27 (174 ref.)

Inhibition of tumor necrosis factor–alpha with anti–diabetic agents. Fukuzawa M, et al. **Diabetes Res Clin Pract** 1999 Mar;43(3):147–54

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Kado S, et al. **Diabetes Res Clin Pract** 1998 Jul;41(1):49–55

Pioglitazone–induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Hallakou S, et al. **Diabetologia** 1998 Aug;41(8):963–8

A new antidiabetic agent (JTT–501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Maegawa H, et al. **Diabetologia** 1999 Feb;42(2):151–9

Rosiglitazone. Balfour JA, et al. **Drugs** 1999 Jun;57(6):921–30; discussion 931–2 (66 ref.)

Insulin aspart. Simpson KL, et al. **Drugs** 1999 May; 57(5):759–65; discussion 766–7 (18 ref.)

Defect in long–term activation of phosphatidylinositol 3–kinase by insulin in vivo: studies in insulin–resistant hHTg rats. Sebokova E, et al. **Endocr Regul** 1999 Jun; 33(2):49–54

Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D–glucose. Louchami K, et al. **Endocrine** 1998 Jun; 8(3):247–50

The new antidiabetic drug MCC–555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Liu LS, et al. **Endocrinology** 1998 Nov;139(11):4531–9

Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Zierath JR, et al. **Endocrinology** 1998 Dec;139(12):5034–41

Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Malaisse WJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:21–9 (34 ref.)

Pharmacological intervention: the antidiabetic approach. Melander A. **Eur J Clin Invest** 1998 Sep;28 Suppl 2:23–5; discussion 25–6 (24 ref.)

Troglitazone has no effect on red cell mass or other erythropoietic parameters. Young MM, et al. **Eur J Clin Pharmacol** 1999 Apr;55(2):101–4

Apoptotic cell death of proliferating neuroepithelial cells in the embryonic retina is prevented by insulin. Díaz B, et al. **Eur J Neurosci** 1999 May;11(5):1624–32

Effect of gliclazide treatment on insulin secretion and beta–cell mass in non–insulin dependent diabetic Goto–Kakisaki rats. Dachicourt N, et al. **Eur J Pharmacol** 1998 Nov 20;361(2–3):243–51

Glucose–dependent insulinotropic effects of JTT–608, a novel antidiabetic compound. Furukawa N, et al. **Eur J Pharmacol** 1999 Apr 23;371(1):51–8

Differential effects of insulin–sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Knock GA, et al. **Eur J Pharmacol** 1999 Feb 26; 368(1):103–9

Pancreatic islet responsiveness to D–glucose after repeated administration of repaglinide. Laghmich A, et al. **Eur J Pharmacol** 1998 May 8;348(2–3):265–70

Effect of 1,1–dimethyl–2–[2–morpholinophenyl]guanidine fumarate on pancreatic islet function. Louchami K, et al. **Eur J Pharmacol** 1998 Jul 10;352(2–3):289–97

The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Lupi R, et al. **Eur J Pharmacol** 1999 Jan 8;364(2–3):205–9

Troglitazone inhibits alpha1–adrenoceptor–induced DNA synthesis in vascular smooth muscle cells. Nishio E, et al. **Eur J Pharmacol** 1999 Jun 11;374(1):127–35

Possible mechanisms for insulin–induced attenuation of the antinociceptive effect of [D–Ala2, N–MePhe4, Gly–ol5]enkephalin. Ohsawa M, et al. **Eur J Pharmacol** 1999 Jun 4;373(2–3):181–6

JTT–608 controls blood glucose by enhancement of glucose–stimulated insulin secretion in normal and diabetes mellitus rats. Ohta T, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):91–9

Effect of the new imidazoline derivative S–22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Pelé–Tounian A, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):81–7

Comparison of the efficacy of glibenclamide and glimepiride in reperfusion–induced arrhythmias in rats. El–Reyani NE, et al. **Eur J Pharmacol** 1999 Jan 22;365(2–3):187–92

Triglyceride–lowering effect of a novel insulin–sensitizing agent, JTT–501. Shibata T, et al. **Eur J Pharmacol** 1999 May 28;373(1):85–91

Pharmacological profiles of a novel oral antidiabetic agent, JTT–501, an isoxazolidinedione derivative. Shibata T, et al. **Eur J Pharmacol** 1999 Jan 8;364(2–3):211–9

Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin–induced diabetic rats. Tanaka Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):17–22

The influence of streptozotocin–induced diabetes and the antihyperglycaemic agent metformin on the contractile characteristics and the membrane potential of the rat diaphragm. McGuire M, et al. **Exp Physiol** 1998 Jul; 83(4):481–7

Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues. Tüzün S, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):436–41

Role of ERK1/ERK2 and p70S6K pathway in insulin signalling of protein synthesis. Sale EM, et al. **FEBS Lett** 1999 Mar 5;446(1):122–6

Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes. Giorgini AE, et al. **Horm Metab Res** 1999 Jan;31(1):1–4

Insulin potentiating effect on development of alloxan diabetes and its prevention by the Ca–channel blocker nicardipine. Katsumata K, et al. **Horm Metab Res** 1998 Sep;30(9):557–8

YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3–L1 adipocytes. Shimaya A, et al. **Horm Metab Res** 1998 Sep; 30(9):543–8

Metformin attenuates salt–induced hypertension in spontaneously hypertensive rats. Muntzel MS, et al. **Hypertension** 1999 May;33(5):1135–40

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Sung BH, et al. **Hypertension** 1999 Jul;34(1):83–8

Effects of glyburide–cyclosporin A interaction on interleukin–2 production in rats. Sireci G, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):583–98

Hypoglycemic activity of Cajanus cajan (seeds) in mice. Amalraj T, et al. **Indian J Exp Biol** 1998 Oct;36(10):1032–3

Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Fujimura S, et al. **Int J Oncol** 1998 Dec;13(6):1263–7

Comparison of short–term diet and exercise on insulin action in individuals with abnormal glucose tolerance. Arciero PJ, et al. **J Appl Physiol** 1999 Jun;86(6):1930–5

State–space models of insulin and glucose responses to diets of varying nutrient content in men and women. Holtschlag DJ, et al. **J Appl Physiol** 1998 Sep;85(3):935–45

Alterations of heart function and Na+–K+–ATPase activity by etomoxir in diabetic rats. Kato K, et al. **J Appl Physiol** 1999 Mar;86(3):812–8

Mechanisms of insulin resistance in non–oxidative glucose metabolism: the role of glycogen synthase. Beck–Nielsen H. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):255–79 (39 ref.)

Central role of the adipocyte in insulin resistance. Bergman RN, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):205–21 (38 ref.)

Insulin regulates expression of metabolic genes through divergent signaling pathways. Hall RK, et al. **J Basic Clin Physiol Pharmacol** 1999;10(2):119–33 (47 ref.)

Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. Larner J, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):127–37

The role of insulin and other hormones in the regulation of amino acid and protein metabolism in humans. Miers WR, et al. **J Basic Clin Physiol Pharmacol** 1998; 9(2–4):235–53 (86 ref.)

Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. Nestler JE. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):197–204

Insulin unexpectedly increases the glucose 6–phosphate Ka of skeletal muscle glycogen synthase in calorie–restricted monkeys. Ortmeyer HK, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):309–23

Glucose and tolbutamide induce apoptosis in pancreatic beta–cells. A process dependent on intracellular Ca2+ concentration. Efanova IB, et al. **J Biol Chem** 1998 Dec 11;273(50):33501–7

Dominant negative forms of Akt (protein kinase B) and atypical protein kinase Clambda do not prevent insulin inhibition of phosphoenolpyruvate carboxykinase gene transcription. Kotani K, et al. **J Biol Chem** 1999 Jul 23; 274(30):21305–12

Coordinate regulation of the alpha(2)–macroglobulin signaling receptor and the low density lipoprotein receptor–related protein/alpha(2)–macroglobulin receptor by insulin. Misra UK, et al. **J Biol Chem** 1999 Sep 3; 274(36):25785–91

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator–activated receptor gamma–activating properties. Reginato MJ, et al. **J Biol Chem** 1998 Dec 4;273(49):32679–84

Inhibitor–1 is not required for the activation of glycogen synthase by insulin in skeletal muscle. Scrimgeour AG, et al. **J Biol Chem** 1999 Jul 23;274(30):20949–52

Insulin activates protein kinases C–zeta and C–lambda by an autophosphorylation–dependent mechanism and stimulates their translocation to GLUT4 vesicles and other membrane fractions in rat adipocytes. Standaert ML, et al. **J Biol Chem** 1999 Sep 3;274(36):25308–16

ADP-ribosylation factor 6 (ARF6) defines two insulin-regulated secretory pathways in adipocytes. Yang CZ, et al. **J Biol Chem** 1999 Sep 3;274(36):25297-300

Protective effect of insulin against hypoglycemia-associated counterregulatory failure. Fruehwald-Schultes B, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1551-7

Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol. Koup JR, et al. **J Clin Pharmacol** 1998 Sep;38(9):815-8

Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. Loi CM, et al. **J Clin Pharmacol** 1999 Apr;39(4):410-7

Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety. Young MA, et al. **J Clin Pharmacol** 1998 Sep;38(9):819-24

Transforming growth factor alpha with insulin stimulates cell proliferation in vivo in adult rat vestibular sensory epithelium. Kuntz AL, et al. **J Comp Neurol** 1998 Sep 28; 399(3):413-23

Induction of cell growth by insulin and insulin-like growth factor-I is associated with Jun expression in the otic vesicle. León Y, et al. **J Comp Neurol** 1998 Aug 31;398(3):323-32

Evaluation of the hypoglycaemic effect of Memecylon umbellatum in normal and alloxan diabetic mice. Amalraj T, et al. **J Ethnopharmacol** 1998 Oct;62(3):247-50

Preliminary studies on the inorganic constituents of some indigenous hypoglycaemic herbs on oral glucose tolerance test. Kar A, et al. **J Ethnopharmacol** 1999 Feb;64(2):179-84

Pharmacological characterisation of the antihyperglycaemic properties of Tinospora crispa extract. Noor H, et al. **J Ethnopharmacol** 1998 Aug;62(1):7-13

4-Hydroxybenzoic acid: a hypoglycemic constituent of aqueous extract of Pandanus odorus root. Peungvicha P, et al. **J Ethnopharmacol** 1998 Aug;62(1):79-84

Troglitazone, a new antidiabetic agent, decreases cyclosporine level [letter] Park MH, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1139-40

Modulatory effect of insulin on release of calcium from human fibroblasts by angiotensin II. Ceolotto G, et al. **J Hypertens** 1998 Apr;16(4):487-93

Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. Williams S, et al. **J Hypertens** 1998 May; 16(5):705-11

Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. Edvardsson U, et al. **J Lipid Res** 1999 Jul; 40(7):1177-84

Repaglinide and related hypoglycemic benzoic acid derivatives. Grell W, et al. **J Med Chem** 1998 Dec 17; 41(26):5219-46

Antidiabetic effects of a dietary supplement "Pancreas Tonic". Rao RM, et al. **J Natl Med Assoc** 1998 Oct;90(10):614-8

Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. Ryu BR, et al. **J Neurobiol** 1999 Jun 15;39(4):536-46

Insulin causes a transient tyrosine phosphorylation of NR2A and NR2B NMDA receptor subunits in rat hippocampus. Christie JM, et al. **J Neurochem** 1999 Apr;72(4):1523-8

Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. Lesort M, et al. **J Neurochem** 1999 Feb; 72(2):576-84

Effect of glucose administration on contusion volume after moderate cortical impact injury in rats. Cherian L, et al. **J Neurotrauma** 1998 Dec;15(12):1059-66

Effect of emeriamine, an inhibitor of fatty acid oxidation, on metabolic fate of a geometrical isomer of linoleic acid in perfused rat liver. Fukuda N, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Aug;44(4):525-35

Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture. Yokoyama T, et al. **J Ocul Pharmacol Ther** 1999 Feb;15(1):73-83

Pharmacological modulation of endothelial function by insulin in the rat aorta. Laight DW, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1117-20

Insulin lispro: in-vivo potency determination by intravenous administration in conscious rabbits. Lin S, et al. **J Pharm Pharmacol** 1999 Mar;51(3):301-6

Biphasic insulin-releasing effect of BTS 67 582 in rats. Storey DA, et al. **J Pharm Pharmacol** 1998 Dec;50(12):1357-60

A new insulin-mimetic vanadyl complex, (N-pyridylmethylaspartate)oxovanadium(IV) with VO(N2O2) coordination mode, and evaluation of its effect on uptake of D-glucose by Ehrlich ascites tumour cells. Tawa R, et al. **J Pharm Pharmacol** 1999 Feb;51(2):119-24

Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). Ernsberger P, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):139-47

Troglitazone inhibits bicarbonate secretion in rat and human duodenum. Hosokawa M, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1080-4

Novel terpenoid-type quinones isolated from Pycnanthus angolensis of potential utility in the treatment of type 2 diabetes. Luo J, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):529-34

Inhibition of gastric emptying by triterpene saponin, momordin Ic, in mice: roles of blood glucose, capsaicin-sensitive sensory nerves, and central nervous system. Matsuda H, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):729-34

Insulinotropic effect of new glibenclamide isosteres. Ouedraogo R, et al. **J Pharmacol Exp Ther** 1999 May; 289(2):625-31

Insulin occludes leptin activation of ATP-sensitive K+ channels in rat CRI-G1 insulin secreting cells. Harvey J, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):695-706

Insulin stimulation of rat ventricular K+ currents depends on the integrity of the cytoskeleton. Shimoni Y, et al. **J Physiol (Lond)** 1999 Feb 1;514 (Pt 3):735-45

Possible mechanism of hypoglycemic effect of 4-hydroxybenzoic acid, a constituent of Pandanus odorus root. Peungvicha P, et al. **Jpn J Pharmacol** 1998 Nov; 78(3):395-8

Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Cortes P, et al. **Kidney Int** 1998 Dec;54(6):1985-98

Changes in the liver protein pattern of female Wistar rats treated with the hypoglycemic agent SDZ PGU 693. Arce A, et al. **Life Sci** 1998;63(25):2243-50

Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Fujiwara T, et al. **Life Sci** 1998; 63(22):2039-47

Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein. Kahn NN. **Life Sci** 1998;63(22):2031-8

A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate. McCarty MF. **Med Hypotheses** 1999 Feb;52(2):89-93 (41 ref.)

Troglitazone and vascular reactivity: role of glucose and calcium. Ali SS, et al. **Metabolism** 1999 Jan;48(1):125-30

Insulin has a biphasic effect on the ability of human chorionic gonadotropin to induce ovarian cysts in the rat. Bogovich K, et al. **Metabolism** 1999 Aug;48(8):995-1002

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Burcelin R, et al. **Metabolism** 1999 Feb;48(2):252-8

Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Ciampelli M, et al. **Metabolism** 1999 Feb;48(2):167-72

Increased dependence of glucose production on peripheral insulin in diabetic depancreatized dogs. Giacca A, et al. **Metabolism** 1999 Feb;48(2):153-60

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Kawai T, et al. **Metabolism** 1999 Sep;48(9):1102-7

Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone. Matsumoto K, et al. **Metabolism** 1999 Jan;48(1):1-2

BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Pill J, et al. **Metabolism** 1999 Jan;48(1):34-40

Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Russell JC, et al. **Metabolism** 1999 Jun;48(6):701-6

Glucose-6-phosphatase mRNA levels in kidney isolated tubule suspensions are increased by dexamethasone and decreased by insulin. Simonnet H. **Metabolism** 1999 Aug; 48(8):1052-6

15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene. Sinha D, et al. **Metabolism** 1999 Jun;48(6):786-91

Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Yamagishi S, et al. **Microvasc Res** 1999 May;57(3):329-39

Vanadium and diabetes. Poucheret P, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):73-80 (67 ref.)

Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes. Pugazhenthi S, et al. **Mol Cell Biochem** 1998 May;182(1-2):185-91

Differential influence of fasting and BM13.907 treatment on growth and phenotype of pressure overloaded rat heart. Rupp H, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):209-15

GLUT2 and glucokinase expression is coordinately regulated by sulfonylurea. Porzio O, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1-2):155-61

Big deal about a little insulin [news] Flier JS. **Nat Med** 1999 Jun;5(6):614-5

Sulfonylureas stimulate renin secretion from the perfused kidney of the rat. Ochi H, et al. **Nephron** 1999 Jan; 81(1):67-71

Troglitazone. Is it all over? Wagenaar LJ, et al. **Neth J Med** 1999 Jul;55(1):4-12 (57 ref.)

Rapid actions of insulin on sensory nerve function. Delaney CA, et al. **Neuroreport** 1998 Aug 24;9(12):2775-9

Glucose plus insulin infusion improves cerebral outcome after asphyxial cardiac arrest. Katz LM, et al. **Neuroreport** 1998 Oct 26;9(15):3363-7

Electron microscopic study of intercalated duct cells in the chicken pancreatic islet and effects of tolbutamide administration. Mutoh K, et al. **Okajimas Folia Anat Jpn** 1998 Dec;75(5):231-7

P-glycoprotein inhibition by glibenclamide and related compounds. Golstein PE, et al. **Pflugers Arch** 1999 Apr; 437(5):652-60

Direct effects of tolbutamide on mitochondrial function, intracellular Ca2+ and exocytosis in pancreatic beta-cells. Smith PA, et al. **Pflugers Arch** 1999 Mar;437(4):577-88

Insulin modulation of ATP-sensitive K+ channel of rat skeletal muscle is impaired in the hypokalaemic state. Tricarico D, et al. **Pflugers Arch** 1999 Jan;437(2):235-40

The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. Tanira MO, et al. **Pharmacol Res** 1999 May;39(5):349-56

Insulin reversal of impaired nitrergic transmission in the anococcygeus muscle from diabetic rats. Way KJ, et al. **Pharmacology** 1999 Sep;59(3):115-26

Studies on Securigera securidacea (L.) Deg. et Dörfl. (Fabaceae) seeds, an antidiabetic Egyptian folk medicine. Ali AA, et al. **Pharmazie** 1998 Oct;53(10):710-5

The effect of chard (Beta vulgaris L. var. cicla) on the skin of streptozotocin induced diabetic rats. Tunali T, et al. **Pharmazie** 1998 Sep;53(9):638-40

Insulin affects dopamine overflow in the nucleus accumbens and the striatum. Potter GM, et al. **Physiol Behav** 1999 Jan 1-15;65(4-5):811-6

Hypoglycemic, anticomplement and anti-HIV activities of Spathodea campanulata stem bark. Niyonzima G, et al. **Phytomedicine** 1999 Mar;6(1):45-9

Analgesic, antiinflammatory and hypoglycaemic activities of Sida cordifolia. Kanth VR, et al. **Phytother Res** 1999 Feb; 13(1):75-7

Effect of parsley (Petroselinum crispum) on the skin of STZ induced diabetic rats. Tunali T, et al. **Phytother Res** 1999 Mar;13(2):138-41

Hypoglycaemic activity of an HMG-containing flavonoid glucoside, chamaemeloside, from Chamaemelum nobile. König GM, et al. **Planta Med** 1998 Oct;64(7):612-4

Hypotensive, hypoglycaemic and toxicological studies on the flavonol C-glycoside shamimin from Bombax ceiba. Saleem R, et al. **Planta Med** 1999 May;65(4):331-4

Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes. Dabros W, et al. **Pol J Pathol** 1998;49(2):67-76

Insulin increases near-membrane but not global Ca2+ in isolated skeletal muscle. Bruton JD, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3281-6

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Higa M, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11513-8

Effects of gliquidone on D-glucose metabolism in rat pancreatic islets depend on hexose concentration. Picton S, et al. **Res Commun Mol Pathol Pharmacol** 1998 Nov; 102(2):99-112

Glycogen concentration in human skeletal muscle: effect of prolonged insulin and glucose infusion. Hansen BF, et al. **Scand J Med Sci Sports** 1999 Aug;9(4):209-13

Discovery of a small molecule insulin mimetic with antidiabetic activity in mice [see comments] Zhang B, et al. **Science** 1999 May 7;284(5416):974-7. Comment in: Science 1999 May 7;284(5416):886.

[Experimental study on berberin raised insulin sensitivity in insulin resistance rat models] Gao CR, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Mar; 17(3):162-4 (Eng. Abstr.) **(Chi)**

[Hypoglycemic effect of Rhodiola sachalinensis A. Bor. polysaccharides: comparison of administration in different ways] Chem X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Nov;21(11):685-7 inside back cover (Eng. Abstr.) **(Chi)**

[Experimental studies of jiantang oral solution on reducing glycemia] Chen Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):397-400 (Eng. Abstr.) **(Chi)**

[ATP-sensitive potassium channels and substances affecting them] Pospíšilová Y. **Vnitr Lek** 1998 Jul;44(7):435-8 (Eng. Abstr.) **(Cze)**

[Continuous blood glucose monitoring: the acute effect of acarbose on blood glucose variations] Herrmann BL, et al. **Med Klin** 1998 Nov 15;93(11):651-5 (Eng. Abstr.) **(Ger)**

[In-vivo 1H-MR spectroscopy: the determination of the intra- and extramyocellular lipid content depending on the insulin effect in the direct offspring of type-2 diabetics] Brechtel K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Aug;171(2):113-20 (Eng. Abstr.) **(Ger)**

[Optimizing pharmacotherapeutic aspects of pharmacokinetic and pharmacodynamic drug properties in the elderly] Orzechowska-Juzwenko K. **Przegl Lek** 1998;55(11):607-10 (23 ref.) (Eng. Abstr.) **(Pol)**

[Hypoglycemic activity of Bouvardia terniflora, Brickellia veronicaefolia, and Parmentiera edulis] Pérez-Gutiérrez RM, et al. **Salud Publica Mex** 1998 Jul-Aug;40(4):354-8 (Eng. Abstr.) **(Spa)**

POISONING

Consequences of metformin intoxication [letter] Lalau JD, et al. **Diabetes Care** 1998 Nov;21(11):2036-7

THERAPEUTIC USE

Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment. Tovi J, et al. **Acta Neurol Scand** 1998 Nov;98(5):346-53

Hypoglycaemic neuropathy in BB/Wor rats treated with insulin implants: electron microscopic observations. Mohseni S, et al. **Acta Neuropathol (Berl)** 1998 Aug; 96(2):151-6

Neuropathy in diabetic BB/Wor rats treated with insulin implants. Mohseni S, et al. **Acta Neuropathol (Berl)** 1998 Aug;96(2):144–50

Hypoglycaemic activity of alpha, alpha trehalose–6–phosphate. Oke JM, et al. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):219–23

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy [letter] Saint–Marc T, et al. **AIDS** 1999 May 28; 13(8):1000–2

Cost–effectiveness and clinical outcomes of metformin or insulin add–on therapy in adults with type 2 diabetes. Brown RR. **Am J Health Syst Pharm** 1998 Dec 15;55(24 Suppl 4):S24–7

Safety of insulin lispro: pooled data from clinical trials. Glazer NB, et al. **Am J Health Syst Pharm** 1999 Mar 15; 56(6):542–7

Advisory panel hears contradictory evidence, backs keeping troglitazone on market [news] Miller JL. **Am J Health Syst Pharm** 1999 May 1;56(9):840, 842

Effects of metformin in patients with poorly controlled, insulin–treated type 2 diabetes mellitus. A randomized, double–blind, placebo–controlled trial. Avilés–Santa L, et al. **Ann Intern Med** 1999 Aug 3;131(3):182–8

Intensive therapy preserves insulin secretion [letter; comment] Charles–Marcel ZL. **Ann Intern Med** 1998 Dec 1;129(11):914. Comment on: Ann Intern Med 1998 Apr 1;128(7):517–23.

Pharmacologic therapy for type 2 diabetes mellitus. DeFronzo RA. **Ann Intern Med** 1999 Aug 17; 131(4):281–303 (175 ref.)

Intensive therapy preserves insulin secretion [letter; comment] Gumpel RC. **Ann Intern Med** 1998 Dec 1; 129(11):913–4. Comment on: Ann Intern Med 1998 Apr 1;128(7):517–23.

On the treatment of diabetes mellitus with glucagon–like peptide–1. Holst JJ, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:336–43 (37 ref.)

Respiratory quotient in patients with non–insulin–dependent diabetes mellitus treated with insulin and oral hypoglycemic agents. Nakaya Y, et al. **Ann Nutr Metab** 1998;42(6):333–40

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Campbell RK. **Ann Pharmacother** 1998 Oct;32(10):1044–52 (42 ref.)

Comment: troglitazone [letter; comment] Fraser CG, et al. **Ann Pharmacother** 1998 Oct;32(10):1111–2. Comment on: Ann Pharmacother 1998 Mar;32(3):337–48.

Comment: troglitazone drug interactions [letter; comment] Terra SG, et al. **Ann Pharmacother** 1998 Oct;32(10):1111 . Comment on: Ann Pharmacother 1998 Mar;32(3):337–48.

Cardiovascular effects of troglitazone. Umland EM, et al. **Ann Pharmacother** 1999 Feb;33(2):229–32 (18 ref.)

Cytokine production in NOD mice on prophylactic insulin therapy. Strandell E, et al. **APMIS** 1999 Apr;107(4):413–9

Treatment of psoriasis with troglitazone therapy [letter] Pershadsingh HA, et al. **Arch Dermatol** 1998 Oct; 134(10):1304–5

Partial remission phase of diabetes in children younger than age 10 years. Muhammad BJ, et al. **Arch Dis Child** 1999 Apr;80(4):367–9

Lung local defense in experimental diabetes mellitus and the effect of 11,20–dihydroxyecdysone in combination with maninil. Najmutdinova DK, et al. **Arch Insect Biochem Physiol** 1999;41(3):144–7

Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Emanuele N, et al. **Arch Intern Med** 1998 Dec 7–21;158(22):2485–90

Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG–CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Shiomi M, et al. **Atherosclerosis** 1999 Feb; 142(2):345–53

Vasculo–protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Yoshimoto T, et al. **Atherosclerosis** 1999 Aug;145(2):333–40

New antidiabetic compounds, mangiferin and its glucoside. Ichiki H, et al. **Biol Pharm Bull** 1998 Dec;21(12):1389–90

Secondary prevention in acute myocardial infarction. Long term insulin treatment is important in secondary prevention in diabetic patients [letter] Nightingale A, et al. **BMJ** 1998 Oct 24;317(7166):1153

Traditional plant treatments for diabetes mellitus: pharmaceutical foods. Day C. **Br J Nutr** 1998 Jul;80(1):5–6

Actions of the traditional anti–diabetic plant, Agrimony eupatoria (agrimony): effects on hyperglycaemia, cellular glucose metabolism and insulin secretion. Gray AM, et al. **Br J Nutr** 1998 Jul;80(1):109–14

Potent antihyperglycaemic property of a new imidazoline derivative S–22068 (PMS 847) in a rat model of NIDDM. Pelé–Tounian A, et al. **Br J Pharmacol** 1998 Aug; 124(8):1591–6

The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC–555 treatment. Pickavance L, et al. **Br J Pharmacol** 1998 Oct; 125(4):767–70

Guidelines for using insulin lispro. Toth EL, et al. **Can Fam Physician** 1998 Nov;44:2444–9 (42 ref.)

Humalog—human kindling? [editorial] MacInnis BJ. **Can J Ophthalmol** 1998 Oct;33(6):303–5 (7 ref.)
(Eng, Fre)

Pancreatic islet transplantation, but not intensive insulin therapy, corrects the pulmonary vascular complications of streptozotocin diabetes. Russ RD, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):407–17

The rescue effect of 15–deoxyspergualin on intraperitoneal microencapsulated xenoislets. Hsu BR, et al. **Cell Transplant** 1999 May–Jun;8(3):307–15

Effects of insulin therapy on non–insulin–dependent diabetics with secondary oral hypoglycemic agent failure. Peng YS, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Sep;21(3):271–6

Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study [news] Laakso M. **Circulation** 1999 Feb 2;99(4):461–2

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long–term results from the Diabetes and Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Malmberg K, et al. **Circulation** 1999 May 25;99(20):2626–32

Thiazolidinediones—the new insulin enhancers. Jha RJ. **Clin Exp Hypertens** 1999 Jan–Feb;21(1–2):157–66 (19 ref.)

The emerging role of thiazolidinediones in the treatment of diabetes–mellitus and related disorders. Subramaniam S. **Clin Exp Hypertens** 1999 Jan–Feb;21(1–2):121–36 (37 ref.)

Nonsteroidal anti–inflammatories (NSAIDS), oral hypoglycemics, and topical steroids. An overview. Guadara J, et al. **Clin Podiatr Med Surg** 1998 Oct; 15(4):687–703, vi (36 ref.)

Ten–year follow–up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Brown JB, et al. **Clin Ther** 1999 Jun;21(6):1045–57

A retrospective chart review of uncontrolled use of metformin as an add–on therapy in type 2 diabetes. Johnson M, et al. **Clin Ther** 1998 Jul–Aug;20(4):691–8

The evidence for insulin lispro [letter; comment] [see comments] McCormack J, et al. **CMAJ** 1998 Dec 1; 159(11):1353–5. Comment on: CMAJ 1998 Feb 24;158(4):506–11. Comment in: CMAJ 1999 Jun 1;160(11):1551–2.

DIAS–NIDDM—a model–based decision support system for insulin dose adjustment in insulin–treated subjects with NIDDM. Tudor RS, et al. **Comput Methods Programs Biomed** 1998 May;56(2):175–91

New therapeutic approaches to reversing insulin resistance. Sonnenberg GE, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):551–5 (51 ref.)

The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus. Ammari F, et al. **Diabet Med** 1999 Feb; 16(2):142–6

Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia [letter] Bardini G, et al. **Diabet Med** 1998 Aug;15(8):706

Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Buysschaert M, et al. **Diabet Med** 1999 Feb; 16(2):147–53

Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Colombel A, et al. **Diabet Med** 1999 Apr;16(4):319–24

Thiazolidinediones: a new class of antidiabetic drugs. Day C. **Diabet Med** 1999 Mar;16(3):179–92 (140 ref.)

Medium–term hypoglycaemic effects of two different oral formulations of gliclazide [letter] Galeone F, et al. **Diabet Med** 1999 Jul;16(7):618–9

Long–term efficacy of humalog in subjects with Type 1 diabetes mellitus. Garg SK, et al. **Diabet Med** 1999 May; 16(5):384–7

Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Goddijn PP, et al. **Diabet Med** 1999 Jan;16(1):23–30

Time–action profile of the soluble, fatty acid acylated, long–acting insulin analogue NN304. Heinemann L, et al. **Diabet Med** 1999 Apr;16(4):332–8

Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well–being in patients with Type 1 diabetes mellitus. Henriksen JE, et al. **Diabet Med** 1999 Apr;16(4):312–8

What is the role of between meal snacks with intensive basal bolus regimens using preprandial lispro? Kong N, et al. **Diabet Med** 1999 Apr;16(4):325–31

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Kumar S, et al. **Diabet Med** 1998 Sep;15(9):772–9

Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy. Lafrance L, et al. **Diabet Med** 1998 Nov;15(11):972–8

Effect of metformin on patients with impaired glucose tolerance. Li CL, et al. **Diabet Med** 1999 Jun;16(6):477–81

Long–term effectiveness of a new alpha–glucosidase inhibitor (BAY m1099–miglitol) in insulin–treated type 2 diabetes mellitus. Mitrakou A, et al. **Diabet Med** 1998 Aug; 15(8):657–60

Metformin treatment leads to an increase in basal, but not insulin–stimulated, glucose disposal in obese patients with impaired glucose tolerance. Morel Y, et al. **Diabet Med** 1999 Aug;16(8):650–5

Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes. Mortensen HB, et al. **Diabet Med** 1998 Sep;15(9):752–9

Normalization of fasting glycaemia by intravenous GLP–1 ([7–36 amide] or [7–37]) in type 2 diabetic patients. Nauck MA, et al. **Diabet Med** 1998 Nov;15(11):937–45

Repaglinide—prandial glucose regulator: a new class of oral antidiabetic drugs. Owens DR. **Diabet Med** 1998;15 Suppl 4:S28–36 (16 ref.)

Adding metformin versus insulin dose increase in insulin–treated but poorly controlled Type 2 diabetes mellitus: an open–label randomized trial. Relimpio F, et al. **Diabet Med** 1998 Dec;15(12):997–1002

Effects of insulin administration in a group of high–risk, non–diabetic, first–degree relatives of Type 1 diabetic patients: an open pilot trial. Rodriguez–Villar C, et al. **Diabet Med** 1999 Feb;16(2):160–3

Resolution of lipohypertrophy following change of short–acting insulin to insulin lispro (Humalog). Roper NA, et al. **Diabet Med** 1998 Dec;15(12):1063–4

Relationship between HLA–DQ and –DR genotypes and clinical characteristics in a French population of Type 1 diabetic patients. Zevaco–Mattei C, et al. **Diabet Med** 1999 Mar;16(3):201–6

Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Beisswenger PJ, et al. **Diabetes** 1999 Jan; 48(1):198–202

Insulin B–chain reactive CD4+ regulatory T–cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T–cells. Bergerot I, et al. **Diabetes** 1999 Sep;48(9):1720–9

Effects of streptozotocin–induced diabetes and of insulin treatment on homocysteine metabolism in the rat. Jacobs RL, et al. **Diabetes** 1998 Dec;47(12):1967–70

Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Kramer L, et al. **Diabetes** 1998 Dec;47(12):1909–14

Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Tang Y, et al. **Diabetes** 1999 Sep;48(9):1830–5

The thiazolidinedione rosiglitazone (BRL–49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Walker AB, et al. **Diabetes** 1999 Jul;48(7):1448–53

Glucose–lowering and insulin–sensitizing actions of exendin–4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Young AA, et al. **Diabetes** 1999 May; 48(5):1026–34

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin [see comments] Abbasi F, et al. **Diabetes Care** 1998 Aug;21(8):1301–5. Comment in: Diabetes Care 1999 Jan;22(1):179–80.

Vanadyl sulfate does not enhance insulin action in patients with type 1 diabetes [letter] Aharon Y, et al. **Diabetes Care** 1998 Dec;21(12):2194–5

Metformin lowers lipoprotein(a) levels [letter; comment] Bell DS, et al. **Diabetes Care** 1998 Nov;21(11):2028. Comment on: Diabetes Care 1999 May;22(5):859.

Troglitazone interferes with gemfibrozil's lipid–lowering action [letter] Bell DS, et al. **Diabetes Care** 1998 Nov; 21(11):2028–9

An interaction between digoxin and acarbose [letter] Ben–Ami H, et al. **Diabetes Care** 1999 May;22(5):860–1

Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria. Berg TJ, et al. **Diabetes Care** 1998 Aug;21(8):1295–300

Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Berger M, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C71–5 (40 ref.)

Switching insulin–sensitizing agents in patients with type 2 diabetes who require insulin [letter] Blonde L, et al. **Diabetes Care** 1999 Jun;22(6):1004–6

American Diabetes Association Annual Meeting, 1998. More on the treatment of type 2 diabetes [news] Bloomgarden ZT. **Diabetes Care** 1999 Feb;22(2):357–61

The European Association for the Study of Diabetes Annual Meeting, 1998. Treatment of type 2 diabetes and the pathogenesis of complications. Bloomgarden ZT. **Diabetes Care** 1999 Jul;22(7):1209–15

Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Boyne MS, et al. **Diabetes Care** 1999 Apr; 22 Suppl 3:C45–53 (95 ref.)

Meta–analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Brunelle BL, et al. **Diabetes Care** 1998 Oct;21(10):1726–31

Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Buse JB. **Diabetes Care** 1999 Apr;22 Suppl 3:C65–70 (29 ref.)

Troglitazone use in insulin–treated type 2 diabetic patients. The Troglitazone Insulin Study Group [see comments] Buse JB, et al. **Diabetes Care** 1998 Sep;21(9):1455–61. Comment in: Diabetes Care 1998 Sep;21(9):1389–90.

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Charles MA, et al. **Diabetes Care** 1998 Nov;21(11):1967–72

2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications [letter] Chatterjee S, et al. **Diabetes Care** 1999 Jul; 22(7):1226-7

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Chiasson JL, et al. **Diabetes Care** 1998 Oct;21(10):1720-5

Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Ciofetta M, et al. **Diabetes Care** 1999 May;22(5):795-800

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Damsbo P, et al. **Diabetes Care** 1999 May;22(5):789-94

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin. Damsbo P, et al. **Diabetes Care** 1998 Sep;21(9):1489-94

Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes [letter] Darmon P, et al. **Diabetes Care** 1998 Sep;21(9):1575

Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Emoto M, et al. **Diabetes Care** 1999 May; 22(5):818-22

Oral agent therapy in the treatment of type 2 diabetes. Feinglos MN, et al. **Diabetes Care** 1999 Apr;22 Suppl 3:C61-4 (23 ref.)

Aminotransferase activity and acarbose treatment in patients with type 2 diabetes [letter] Gentile S, et al. **Diabetes Care** 1999 Jul;22(7):1217-8

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Goldberg RB, et al. **Diabetes Care** 1998 Nov;21(11):1897-903

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Heinemann L, et al. **Diabetes Care** 1998 Nov;21(11):1910-4

Metformin added to insulin therapy in poorly controlled type 2 diabetes [letter] Hirsch IB. **Diabetes Care** 1999 May; 22(5):854

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Holman RR, et al. **Diabetes Care** 1999 Jun;22(6):960-4

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Home PD, et al. **Diabetes Care** 1998 Nov;21(11):1904-9

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group [see comments] Horton ES, et al. **Diabetes Care** 1998 Sep;21(9):1462-9. Comment in: Diabetes Care 1998 Sep;21(9):1389-90.

LDL cholesterol and troglitazone therapy [letter; comment] Howard BV, et al. **Diabetes Care** 1998 Dec;21(12):2201-3 . Comment on: Diabetes Care 1998 May;21(5):796-9.

Hypoglycemia and reduction of the insulin requirement as a sign of celiac disease in children with IDDM [letter] Iafusco D, et al. **Diabetes Care** 1998 Aug;21(8):1379-81

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Imano E, et al. **Diabetes Care** 1998 Dec;21(12):2135-9

Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Johansen K. **Diabetes Care** 1999 Jan; 22(1):33-7

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Kelley DE, et al. **Diabetes Care** 1998 Dec;21(12):2056-61

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes [published erratum appears in Diabetes Care 1999 Mar;22(3):536] Kelly IE, et al. **Diabetes Care** 1999 Feb;22(2):288-93

Metformin and lipoprotein(a) levels [letter; comment] Kiayias JA, et al. **Diabetes Care** 1999 May;22(5):859. Comment on: Diabetes Care 1998 Nov;21(11):2028.

Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy [letter] [see comments] Kitzmiller JL, et al. **Diabetes Care** 1999 May;22(5):874-6 . Comment in: Diabetes Care 1999 May;22(5):846-8.

Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Koivisto VA, et al. **Diabetes Care** 1999 Mar; 22(3):459-62

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Lalli C, et al. **Diabetes Care** 1999 Mar;22(3):468-77

Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus. Langer O. **Diabetes Care** 1998 Aug;21 Suppl 2:B91-8 (61 ref.)

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. Launay B, et al. **Diabetes Care** 1998 Oct;21(10):1627-31

Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Lebovitz HE. **Diabetes Care** 1999 Apr;22 Suppl 3:C41-4 (36 ref.)

Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Lindholm A, et al. **Diabetes Care** 1999 May; 22(5):801-5

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Littorin B, et al. **Diabetes Care** 1999 Mar;22(3):409-12

Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Matyka KA, et al. **Diabetes Care** 1999 Jul;22(7):1144-50

Effect of troglitazone on body fat distribution in type 2 diabetic patients. Mori Y, et al. **Diabetes Care** 1999 Jun; 22(6):908-12

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Moses R, et al. **Diabetes Care** 1999 Jan;22(1):119-24

Metformin and fatty acids [letter; comment] Muntoni S. **Diabetes Care** 1999 Jan;22(1):179-80. Comment on: Diabetes Care 1998 Aug;21(8):1301-5.

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Nauck MA, et al. **Diabetes Care** 1998 Nov;21(11):1925-31

Troglitazone directly increases HDL cholesterol levels. Nozue T, et al. **Diabetes Care** 1999 Feb;22(2):355-6

Troglitazone's effect on lipoprotein(a) levels [letter] Ovalle F, et al. **Diabetes Care** 1999 May;22(5):859-60

Glycemic control in type 1 diabetes. A cross-sectional study in 1,200 Belgian patients [letter; comment] Paris I, et al. **Diabetes Care** 1998 Dec;21(12):2200-1. Comment on: Diabetes Care 1998 Jul;21(7):1146-53.

Keep metformin guidelines intact [letter; comment] Peters AL, et al. **Diabetes Care** 1999 Mar;22(3):532-3. Comment on: Diabetes Care 1998 Oct;21(10):1587-8. Comment on: Diabetes Care 1998 Oct;21(10):1659-63.

Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. Rabasa-Lhoret R, et al. **Diabetes Care** 1999 May; 22(5):667-73

Overview of current therapeutic options: session summary. Riddle MC. **Diabetes Care** 1999 Apr;22 Suppl 3:C76-8

Learning to use troglitazone [editorial; comment] Riddle MC. **Diabetes Care** 1998 Sep;21(9):1389-90 (14 ref.). Comment on: Diabetes Care 1998 Sep;21(9):1455-61. Comment on: Diabetes Care 1998 Sep;21(9):1462-9.

Determinants of the quality of life of patients with diabetes under intensified insulin therapy. Rose M, et al. **Diabetes Care** 1998 Nov;21(11):1876-85

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Rosenstock J, et al. **Diabetes Care** 1998 Dec;21(12):2050-5

Long-acting insulin analogs. Rosskamp RH, et al. **Diabetes Care** 1999 Mar;22 Suppl 2:B109-13 (39 ref.)

First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization. Selby JV, et al. **Diabetes Care** 1999 Jan;22(1):38-44

Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients [see comments] Shimizu H, et al. **Diabetes Care** 1998 Sep;21(9):1470-4. Comment in: Diabetes Care 1999 Jul;22(7):1227-8.

Antidiabetic treatment trends in a cohort of elderly people with diabetes. The cardiovascular health study, 1989-1997. Smith NL, et al. **Diabetes Care** 1999 May;22(5):736-42

Incidence of lactic acidosis in metformin users. Stang M, et al. **Diabetes Care** 1999 Jun;22(6):925-7

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Toft-Nielsen MB, et al. **Diabetes Care** 1999 Jul;22(7):1137-43

Metformin as adjuvant to insulin therapy in type 2 diabetic patients [letter; comment] Vanamo R. **Diabetes Care** 1999 Mar;22(3):528. Comment on: Diabetes Care 1996 Jun;19(6):671-2. Comment on: Diabetes Care 1998 May;21(5):701-5.

Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. van der Does FE, et al. **Diabetes Care** 1998 Dec;21(12):2085-93

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate [see comments] Wolever TM, et al. **Diabetes Care** 1998 Oct;21(10):1612-8. Comment in: Diabetes Care 1999 Jul;22(7):1227.

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Wolffenbuttel BH, et al. **Diabetes Care** 1999 Mar; 22(3):463-7

Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group. Zinman B, et al. **Diabetes Care** 1999 Apr; 22(4):603-8

Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion. Meyer L, et al. **Diabetes Metab** 1998 Dec;24(6):544-6

Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Scheen AJ. **Diabetes Metab** 1998 Sep;24(4):311-20 (79 ref.)

Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Schiel R, et al. **Diabetes Metab** 1998 Dec;24(6):509-14

Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update. Weyer C, et al. **Diabetes Metab** 1999 Mar;25(1):11-21 (94 ref.)

Treating obese patients with poorly controlled diabetes: confessions of an insulin therapist. Kerr D, et al. **Diabetes Metab Res Rev** 1999 May-Jun;15(3):219-25 (34 ref.)

The evolving role of alpha-glucosidase inhibitors. Göke B, et al. **Diabetes Metab Rev** 1998 Sep;14 Suppl 1:S31-8 (60 ref.)

The use of Acarbose in Type 2 diabetic patients in secondary failure: effects on glycaemic control and diet induced thermogenesis. Brooks B, et al. **Diabetes Res Clin Pract** 1998 Dec;42(3):175-80

Insulin therapy in type 2 diabetic patients: effects on arterial blood pressure and endothelin-1 plasma levels. Flores L, et al. **Diabetes Res Clin Pract** 1998 Sep;41(3):151-5

Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro. Hirsch IB, et al. **Diabetes Res Clin Pract** 1998 Sep;41(3):197-202

Actions of the novel oral antidiabetic agent HQL-975 in insulin-resistant non-insulin-dependent diabetes mellitus model animals. Ishikawa Y, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):101-11

Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Kadiri A, et al. **Diabetes Res Clin Pract** 1998 Jul;41(1):15-23

Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Kawamori R, et al. **Diabetes Res Clin Pract** 1998 Jul; 41(1):35-43

Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Kuzuya T, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):121-9

Repaglinide versus glyburide: a one-year comparison trial. Marbury T, et al. **Diabetes Res Clin Pract** 1999 Mar; 43(3):155-66

Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Mertes G. **Diabetes Res Clin Pract** 1998 Apr;40(1):63-70

Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study. Sels JP, et al. **Diabetes Res Clin Pract** 1998 Aug;41(2):139-45

Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Takamura T, et al. **Diabetes Res Clin Pract** 1999 May;44(2):107-14

Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. Yamakita T, et al. **Diabetes Res Clin Pract** 1998 Dec;42(3):205-8

Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Bruno G, et al. **Diabetologia** 1999 Mar;42(3):297-301

Insulin increases serum leptin concentrations in children and adolescents with newly diagnosed type I diabetes mellitus with and without ketoacidosis. Flück CE, et al. **Diabetologia** 1999 Sep;42(9):1067-70

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Mäkimattila S, et al. **Diabetologia** 1999 Apr; 42(4):406-12

Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. Hosny EA, et al. **Drug Dev Ind Pharm** 1998 Mar;24(3):307-11

Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Evans A, et al. **Drug Saf** 1999 Jul;21(1):7-22 (85 ref.)

A risk-benefit assessment of metformin in type 2 diabetes mellitus. Howlett HC, et al. **Drug Saf** 1999 Jun; 20(6):489-503 (183 ref.)

Drug therapy of postprandial hyperglycaemia. Mooradian AD, et al. **Drugs** 1999 Jan;57(1):19-29 (95 ref.)

Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Plosker GL, et al. **Drugs** 1999 Mar; 57(3):409-38 (159 ref.)

Repaglinide [published erratum appears in Drugs Aging 1999 Jul;15(1):28] Balfour JA, et al. **Drugs Aging** 1998 Aug; 13(2):173-80 (32 ref.)

Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance. Rabasa-Lhoret R, et al. **Drugs Aging** 1998 Aug; 13(2):131-43 (91 ref.)

Overweight and increased diabetes susceptibility in neonatally insulin-treated adult rats. Harder T, et al. **Endocr Regul** 1999 Mar;33(1):25-31

In vivo insulin signaling in the myocardium of streptozotocin-diabetic rats: opposite effects of diabetes on insulin stimulation of glycogen synthase and c-Fos. Wang PH, et al. **Endocrinology** 1999 Mar;140(3):1141-50

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide [see comments] Klepzig H, et al.

Eur Heart J 1999 Mar;20(6):439–46. Comment in: Eur Heart J 1999 Mar;20(6):403–5.

Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon [see comments] Tomai F, et al. **Eur Heart J** 1999 Feb;20(3):196–202. Comment in: Eur Heart J 1999 Feb;20(3):167–8.

Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist [editorial; comment] Wikström G, et al. **Eur Heart J** 1999 Mar;20(6):403–5 (15 ref.). Comment on: Eur Heart J 1999 Mar;20(6):439–46.

Current therapeutic options in type 2 diabetes. Heine RJ. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:17–20 (43 ref.)

Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Owens DR. **Eur J Clin Invest** 1999 Jun;29 Suppl 2:30–7 (39 ref.)

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Landgraf R, et al. **Eur J Clin Pharmacol** 1999 May;55(3):165–71

The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. Scorpiglione N, et al. **Eur J Clin Pharmacol** 1999 Jun; 55(4):239–49

Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study? Lopez-Liuchi JV, et al. **Eur J Endocrinol** 1999 Jan;140(1):4–6 (11 ref.)

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. Unlühizarci K, et al. **Eur J Endocrinol** 1999 Jan;140(1):56–61

Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Kentrup H, et al. **Eur J Pediatr** 1999 Jun;158(6):455–9

Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy. Kashiwagi K, et al. **Eur Neurol** 1999;41(3):171–2

The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Laube H, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):231–3

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. De Leo V, et al. **Fertil Steril** 1999 Aug;72(2):282–5

Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. Elkind-Hirsch KE, et al. **Fertil Steril** 1999 May;71(5):943–7

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Hasegawa I, et al. **Fertil Steril** 1999 Feb;71(2):323–7

Type 2 diabetes: glycemic targets and oral therapies for older patients. Lardinois CK. **Geriatrics** 1998 Nov;53(11):22–3, 27–8, 33–4 passim (29 ref.)

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Borm AK, et al. **Horm Metab Res** 1999 Aug;31(8):472–5

Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Ishida H, et al. **Horm Metab Res** 1998 Nov;30(11):673–8

Failure of sulfonylureas in type 2 diabetes [letter; comment] Yildiz BO, et al. **Horm Metab Res** 1999 Apr;31(4):293–4 . Comment on: Horm Metab Res 1998 Feb;30(2):108–10.

Hypoglycemic effect of Biophytum sensitivum in the alloxan diabetic rabbits. Puri D, et al. **Indian J Physiol Pharmacol** 1998 Jul;42(3):401–6

Therapeutic potentials of fenugreek [letter] Puri D. **Indian J Physiol Pharmacol** 1998 Jul;42(3):423–4

The impact of pharmacotherapy on weight management in type 2 diabetes. Hauner H. **Int J Obes Relat Metab Disord** 1999 Jun;23 Suppl 7:S12–7 (44 ref.)

Effects of insulin treatment on diabetes-induced alterations in endothelin receptors in rat ureter. Saito M, et al. **Int J Urol** 1999 Jul;6(7):361–8

Insulin therapy in cats. Greco DS. **J Am Anim Hosp Assoc** 1999 Jul–Aug;35(4):269–70

Insulin resistance: site of the primary defect or how the current and the emerging therapies work. Kolaczynski JW, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2–4):281–94 (63 ref.)

Leptin before and after insulin therapy in children with new-onset type 1 diabetes. Hanaki K, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1524–6

Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1510–2

Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. Glynn RJ, et al. **J Clin Epidemiol** 1999 Aug;52(8):781–90

Evaluation of drug usage and expenditure in a hospital diabetes clinic. Wu SY, et al. **J Clin Pharm Ther** 1998 Feb; 23(1):49–56

Hypoglycemia and insulin analogues: is there a reduction in the incidence? Heinemann L. **J Diabetes Complications** 1999 Mar-Apr;13(2):105–14 (53 ref.)

Triple oral antidiabetic therapy. Kaye TB. **J Diabetes Complications** 1998 Nov-Dec;12(6):311–3

Patient and family reflections on the use of subcutaneous insulin to prevent diabetes: a retrospective evaluation from a pilot prevention trial. Tercyak KP, et al. **J Diabetes Complications** 1998 Sep-Oct;12(5):279–86

Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. Oleandri SE, et al. **J Endocrinol Invest** 1999 Feb; 22(2):134–40

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? Trischitta V, et al. **J Endocrinol Invest** 1998 Dec; 21(11):744–7

Hypoglycaemic activity of Syzigium cumini seeds: effect on lipid peroxidation in alloxan diabetic rats. Prince PS, et al. **J Ethnopharmacol** 1998 May;61(1):1–7

United Kingdom prospective diabetes study results are in [news] Genuth S. **J Fam Pract** 1998 Nov;47(5 Suppl):S27

An evaluation of new agents in the treatment of type 2 diabetes. Zimmerman BR, et al. **J Fam Pract** 1998 Nov; 47(5 Suppl):S37–43 (35 ref.)

Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. Williams S, et al. **J Hypertens** 1998 May; 16(5):705–11

Diabetes mellitus and aging. Banerjee S, et al. **J Indian Med Assoc** 1998 May;96(5):147–8, 164 (9 ref.)

Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. Saito N, et al. **J Int Med Res** 1998 Oct-Nov;26(5):219–32

The snack is critical for the blood glucose profile during treatment with regular insulin preprandially. Orre-Pettersson AC, et al. **J Intern Med** 1999 Jan; 245(1):41–5

Maprouneacin, a new daphnane diterpenoid with potent antihyperglycemic activity from Maprounea africana. Carney JR, et al. **J Nat Prod** 1999 Feb;62(2):345–7

Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. Gray AM, et al. **J Nutr** 1998 Dec;128(12):2319–23

Glucose disturbances and regulation with glibenclamide in thalassemia. Ladis V, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:871–8

Metformin therapy for diabetes in Prader-Willi syndrome. Chan NN, et al. **J R Soc Med** 1998 Nov;91(11):598

Effects of diabetes and insulin treatment of diabetic rats on hyaluronan and hyaluronectin production in injured aorta. Chajara A, et al. **J Vasc Res** 1999 May-Jun;36(3):209–21

Effect of immediate-release glipizide on hypoglycemic vulnerability in fasted, elderly patients with type 2 diabetes [letter] Burge MR, et al. **JAMA** 1999 Mar 24–31; 281(12):1084–5

Excessive weight gain and effects on lipids with intensive therapy of type 1 diabetes [letter; comment] Freedland ES. **JAMA** 1998 Dec 16;280(23):1991–2. Comment on: JAMA 1998 Jul 8;280(2):140–6.

From the Food and Drug Administration. Henney JE. **JAMA** 1999 Sep 8;282(10):932

Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial [see comments] Testa MA, et al. **JAMA** 1998 Nov 4;280(17):1490–6. Comment in: JAMA 1999 Jun 2;281(21):1985; discussion 1986. Comment in: JAMA 1999 Jun 2;281(21):1985–6. Comment in: JAMA 1999 Jun 2;281(21):1987–8.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Turner RC, et al. **JAMA** 1999 Jun 2;281(21):2005–12

Excessive weight gain and effects on lipids with intensive therapy of type 1 diabetes [letter; comment] Wei M. **JAMA** 1998 Dec 16;280(23):1991; discussion 1991–2. Comment on: JAMA 1998 Jul 8;280(2):140–6.

Insulin lispro--a review. Muzaffer Z, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):212–4 (13 ref.)

Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients. Niazi R, et al. **JPMA J Pak Med Assoc** 1998 Nov;48(11):336–8

UKPDS: what was the question? UK Prospective Diabetes Study [letter] Turner R, et al. **Lancet** 1999 Aug 14; 354(9178):600

Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. Ogawa J, et al. **Life Sci** 1999;65(12):1287–96

Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics. McCarty MF. **Med Hypotheses** 1998 Nov;51(5):399–403

United Kingdom Prospective Diabetes Study: the end of the beginning? [editorial] Davis TM. **Med J Aust** 1998 Nov 16;169(10):511–2

Insulin lispro: experience in a private practice setting [see comments] Stocks AE. **Med J Aust** 1999 Apr 19; 170(8):364–7. Comment in: Med J Aust 1999 Apr 19;170(8):349–50.

Miglitol for type 2 diabetes mellitus. **Med Lett Drugs Ther** 1999 May 21;41(1053):49–50

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Glueck CJ, et al. **Metabolism** 1999 Apr;48(4):511–9

Synergistic interaction of magnesium and vanadate on glucose metabolism in diabetic rats. Matsuda M, et al. **Metabolism** 1999 Jun;48(6):725–31

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Nyholm B, et al. **Metabolism** 1999 Jul;48(7):935–41

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Tessier D, et al. **Metabolism** 1999 Jul;48(7):897–903

Scientist denies role in conflict investigation [news] Dove A. **Nat Med** 1999 Oct;5(10):1098

No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study. Ligtenberg PC, et al. **Neth J Med** 1999 Aug;55(2):59–63

Troglitazone. Is it all over? Wagenaar LJ, et al. **Neth J Med** 1999 Jul;55(1):4–12 (57 ref.)

Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Wolffenbuttel BH, et al. **Neth J Med** 1999 Feb;54(2):63–9

Understanding new pharmacologic therapy for type 2 diabetes. Gutowski C. **Nurse Pract** 1999 Jun;24(6):15–8, 21–2, 24–5; quiz 26–7

Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose [published erratum appears in Obes Res 1999 Mar;7(2):232] Axen KV, et al. **Obes Res** 1999 Jan;7(1):83–9

Continuous subcutaneous insulin injection for a case of mitochondrial cytopathy with diabetes mellitus requiring a large amount of insulin. Kuno T, et al. **Pediatr Int** 1999 Feb;41(1):97–100

The role of troglitazone in treating the insulin resistance syndrome. Granberry MC, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):973–87 (112 ref.)

Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Guay DR. **Pharmacotherapy** 1998 Nov-Dec;18(6):1195–204 (35 ref.)

Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus. Swidan SZ, et al. **Pharmacotherapy** 1998 Sep-Oct;18(5):961–72 (86 ref.)

Hypoglycaemic activity of four plants used in Chilean popular medicine. Lemus I, et al. **Phytother Res** 1999 Mar; 13(2):91–4

Insulin versus oral agents for 'steroid-induced' diabetes [letter; comment] Carolan J. **Postgrad Med** 1999 May 1; 105(5):36. Comment on: Postgrad Med 1998 Nov;104(5):163–6, 171, 175–6.

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Turner NC, et al. **Prog Drug Res** 1998;51:33–94 (370 ref.)

Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Fanghänel G, et al. **Rev Invest Clin** 1998 Sep-Oct;50(5):389–94

New lead found to a possible "insulin pill" [news; comment] Gura T. **Science** 1999 May 7;284(5416):886. Comment on: Science 1999 May 7;284(5416):974–7.

Metformin reduces circulating factor VII concentrations in patients with type 2 diabetes mellitus [letter] Grant PJ. **Thromb Haemost** 1998 Jul;80(1):209–10

[Proper use of oral hypoglycemic agents (editorial)] Qian R. **Chung Hua Nei Ko Tsa Chih** 1997 Mar;36(3):149–50 **(Chi)**

[Effect of jiangtangkang on blood glucose, sensitivity of insulin and blood viscosity in non-insulin dependent diabetes mellitus] Chen SH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Nov; 17(11):666–8 (Eng. Abstr.) **(Chi)**

[Clinical study of glibenclamide in combination with kelening treatment in non-insulin dependent diabetes mellitus] Zhou P. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):29–31 (Eng. Abstr.) **(Chi)**

[Short-acting insulin analogs (letter; comment)] Van Doorn LG. **Ned Tijdschr Geneeskd** 1998 Aug 15;142(33):1886–7. Comment on: Ned Tijdschr Geneeskd 1998 May 16;142(20):1165–6. **(Dut)**

[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications (see comments)] Wolffenbuttel BH, et al. **Ned Tijdschr Geneeskd** 1999 Jun 5;143(23):1197–201 (20 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jun 5;143(23):1188–91. **(Dut)**

[So-called "functional" insulin therapy] Sachon C, et al. **Diabetes Metab** 1998 Dec;24(6):556–9 **(Fre)**

[Role of acarbose in the treatment of diabetes mellitus] Scheen AJ. **Diabetes Metab** 1998 Sep;24(4):385–90 (36 ref.) **(Fre)**

[Is it possible to predict the success of an intensified program of insulin therapy?] Bott U, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:289–313 **(Fre)**

[Effects of pramlintide, an analog of amylin, on the regulation of glycemia] Girard J. **Journ Annu Diabetol Hotel Dieu** 1998;:315–20 (38 ref.) **(Fre)**

[Ultimate treatment of type 2 diabetes: intensive insulin therapy or bariatric surgery? Scheen AJ, et al. **Journ Annu Diabetol Hotel Dieu** 1998;:81–97 (97 ref.) **(Fre)**

[New classification and diagnostic criteria of diabetes.

HYPOGLYCEMIC AGENTS

Interview with Prof. B. Charbonnel] Charbonnel B. **Presse Med** 1999 Feb 20;28(7):354–7 **(Fre)**

[From insulin secretion to insulin therapy] Soltani D, et al. **Presse Med** 1998 Jul 4–11;27(24):1240–6 (Eng. Abstr.) **(Fre)**

[Insulin injections: techniques and plans] Soltani D, et al. **Presse Med** 1998 Jul 4–11;27(24):1247–50 (Eng. Abstr.) **(Fre)**

[Monitoring of the insulin treated diabetic] Soltani D, et al. **Presse Med** 1998 Jul 4–11;27(24):1251–4 (Eng. Abstr.) **(Fre)**

[Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes] André P. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):93–5 **(Fre)**

[New developments in the treatment of diabetes and hyperlipidemias] Ducobu J. **Rev Med Brux** 1998 Sep; 19(4):A379–85 (17 ref.) (Eng. Abstr.) **(Fre)**

[Diabetes mellitus associated with protease inhibitors in HIV infected patients (letter)] Bardonnet K, et al. **Rev Med Interne** 1998 Sep;19(9):675–6 **(Fre)**

[Drug clinics. How I treat various metabolic diseases treated by a drug intervention that targets the intestine] Scheen AJ. **Rev Med Liege** 1998 Nov;53(11):646–50 (Eng. Abstr.) **(Fre)**

[Insulin in the treatment of type 2 diabetes] Meyer L, et al. **Rev Prat** 1999 Jan 1;49(1):51–5 (29 ref.) (Eng. Abstr.) **(Fre)**

[Oral antidiabetic drugs] Tauber JP. **Rev Prat** 1999 Jan 1; 49(1):46–50 (27 ref.) (Eng. Abstr.) **(Fre)**

[United Kingdom Prospective Diabetes Study: facts and questions] Spinas GA. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2043–6 (5 ref.) **(Ger)**

[Which form of therapy (insulin therapy or oral antidiabetics) is best for a patient with newly diagnosed type 2 diabetes mellitus?] Lehmann R. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1368–9 **(Ger)**

[Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data] Galeone F, et al. **Minerva Endocrinol** 1998 Sep;23(3):71–5 (Eng. Abstr.) **(Ita)**

[Therapeutic utility of biguanides in the treatment of NIDDM] Fujimoto S. **Nippon Rinsho** 1999 Mar; 57(3):657–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

[alpha-Glucosidase inhibitor] Ishida H. **Nippon Rinsho** 1999 Mar;57(3):669–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Insulin-sensitizing agents] Kadowaki T. **Nippon Rinsho** 1999 Mar;57(3):688–94 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Non-SU, insulin secretagogues] Kikuchi M. **Nippon Rinsho** 1999 Mar;57(3):702–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Rapid-acting insulin analogues] Matsuda A, et al. **Nippon Rinsho** 1999 Mar;57(3):709–18 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Use of sulfonylurea (SU) in the treatment of diabetes mellitus] Tasaka Y. **Nippon Rinsho** 1999 Mar;57(3):663–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Sulfonylurea drug--a new sulfonylurea drug for type 2 diabetes] Toyota T. **Nippon Rinsho** 1999 Mar;57(3):695–701 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Insulin-sensitizing agent] Yamanouchi T. **Nippon Rinsho** 1999 Mar;57(3):675–80 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Morning blood glucose determination in the monitoring of metabolic control in type 2 elderly diabetic cases treated by oral hypoglycemic agents] Ohba K, et al. **Nippon Ronen Igakkai Zasshi** 1999 Feb;36(2):122–7 (Eng. Abstr.) **(Jpn)**

[Sulodexide in the treatment of right hand necrosis in diabetic patient performing exchanges of continuous ambulatory peritoneal dialysis (CAPD) by himself] Olszowska A, et al. **Pol Merkuriusz Lek** 1998 Nov;5(29):301–3 (Eng. Abstr.) **(Pol)**

[The pathogenetic characteristics and the possible ways for the pharmacological correction of insulin-dependent diabetes mellitus] Chernov IuN, et al. **Eksp Klin Farmakol** 1999 May-Jun;62(3):60–6 (135 ref.) (Eng. Abstr.) **(Rus)**

[Sulodexide in the treatment of diabetic nephropathy] Rasovskii BL, et al. **Klin Med (Mosk)** 1998;76(7):40–2 (Eng. Abstr.) **(Rus)**

[Delayed-type hypersensitivity in insulin-dependent diabetes mellitus and effects of short-action insulins produced by different pharmaceutical firms] Zhuk EA, et al. **Ter Arkh** 1998;70(12):46–9 (Eng. Abstr.) **(Rus)**

[Factors influencing the prescription of insulin and oral antidiabetics in primary care] Olveira G, et al. **Aten Primaria** 1999 Mar 31;23(5):260–7 (Eng. Abstr.) **(Spa)**

[New drugs in the treatment of type-2 diabetes mellitus] Zárate-Treviño A, et al. **Gac Med Mex** 1999 Jan-Feb; 135(1):91–4 (16 ref.) **(Spa)**

[Medication use in diabetes mellitus (VI). Economics and effectiveness of insulin and sulfonyl-urea combination therapy compared with conventional two daily doses] Costa B, et al. **Med Clin (Barc)** 1998 Nov 7;111(15):568–72 (Eng. Abstr.) **(Spa)**

[Thiazolidenediones, diabetes and adipogenesis (editorial)] Moreno L, et al. **Med Clin (Barc)** 1999 Apr 10; 112(12):457–8 (19 ref.) **(Spa)**

[Intensive insulin treatment improves metabolic control and preserves residual insulin secretion at 5 years from the diagnosis of type-1 diabetes mellitus (letter)] Pérez Maraver M, et al. **Med Clin (Barc)** 1998 Dec 5;111(19):758 **(Spa)**

[Gastrointestinal peptides among new therapeutic agents used in type 2 diabetes] Efendic S, et al. **Lakartidningen** 1999 Feb 24;96(8):888–92 (15 ref.) (Eng. Abstr.) **(Swe)**

[Limited effect of antidiabetics on type 2 diabetes (letter; comment)] Lindeberg S. **Lakartidningen** 1998 Dec 2; 95(49):5605–6. Comment on: Lakartidningen 1998 Nov 4;95(45):4983–4, 4987. Comment on: Lakartidningen 1998 Nov 11;95(46):5128–9. **(Swe)**

TOXICITY

Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart. Dali V. **Arzneimittelforschung** 1999 May;49(5):463–70

Insulin-induced hypoglycemia elicits thymocyte apoptosis in the rat. Morishita S, et al. **Diabetes Res Clin Pract** 1998 Apr;40(1):1–7

Acarbose and acetaminophen: a dangerous combination? [letter] Ahr HJ, et al. **Hepatology** 1999 Jul;30(1):341–2

Acarbose and acetaminophen- a dangerous combination? [letter; comment] Sato A. **Hepatology** 1999 Jun;29(6):1914 Comment on: Hepatology 1999 Jan;29(1):161–5. Comment on: Hepatology 1999 Jan;29(1):285–7.

Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. Juan CC, et al. **Metabolism** 1999 Apr;48(4):465–71

HYPOGLYCINS

POISONING

Epidemic of fatal encephalopathy in preschool children in Burkina Faso and consumption of unripe ackee (Blighia sapida) fruit [see comments] Meda HA, et al. **Lancet** 1999 Feb 13;353(9152):536–40. Comment in: Lancet 1999 Feb 13;353(9152):536–40. Comment in: Lancet 1999 May 8;353(9164):1622–3. Comment in: Lancet 1999 May 8;353(9164):1623.

HYPOGONADISM

BLOOD

Pituitary glycoprotein hormone a-subunit secretion by cirrhotic patients. Oliveira MC, et al. **Braz J Med Biol Res** 1999 Jan;32(1):73–7

Hypergonadotropic hypogonadism in a 3-year-old girl with blepharophimosis, ptosis, and epicanthus inversus syndrome [see comments] Ogata T, et al. **Horm Res** 1998 Sep; 50(3):190–2. Comment in: Horm Res 1998;50(6):341.

Antimüllerian hormone in patients with hypogonadotropic hypogonadism. Young J, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2696–9

Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Jockenhövel F, et al. **Metabolism** 1999 May;48(5):590–6

[Analysis of liver function in patients with Turner syndrome (TS) and in patients with secondary hypogonadism with estrogen and estrogen- progestagens replacement therapy: a preliminary report] Rujner J, et al. **Ginekol Pol** 1999 May; 70(5):338–42 (Eng. Abstr.) **(Pol)**

CHEMICALLY INDUCED

Can growth hormone treatment in boys without growth hormone deficiency impair testicular function? [see comments] Bertelloni S, et al. **J Pediatr** 1999 Sep; 135(3):367–70. Comment in: J Pediatr 1999 Sep;135(3):278–9.

A red flag unfurled? Growth hormone treatment and testicular function [editorial; comment] Frasier SD. **J Pediatr** 1999 Sep;135(3):278–9 (11 ref.). Comment on: J Pediatr 1999 Sep;135(3):367–70.

Blockade of the hypothalamic-pituitary-testicular axis with a GnRH antagonist in the neonatal marmoset monkey: changes in Leydig cell ultrastructure. Prince FP, et al. **Tissue Cell** 1998 Dec;30(6):651–61

COMPLICATIONS

Ejaculatory failure and hypogonadotrophic hypogonadism caused by haemochromatosis. Stopforth HB, et al. **BJU Int** 1999 Apr;83(6):728

Hypergonadotropic hypogonadism in a 3-year-old girl with blepharophimosis, ptosis, and epicanthus inversus syndrome [see comments] Ogata T, et al. **Horm Res** 1998 Sep; 50(3):190–2. Comment in: Horm Res 1998;50(6):341.

Effect of venesection on bone mineral density in an eugonadal woman with haemochromatosis. Hibbert EJ, et al. **J Gastroenterol Hepatol** 1999 Feb;14(2):176–8

A microdeletion within DAX-1 in X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism. Wang J, et al. **J Investig Med** 1999 May; 47(5):232–5

Pituitary deficiency and lack of gonads in an XY pseudohermaphrodite with beta 39/lepore haemoglobinopathy. Saviano A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:997–9

Sexual dysfunction in the United States [letter] Rosen RC, et al. **JAMA** 1999 Oct 6;282(13):1229

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Curran MJ, et al. **Urology** 1999 Feb;53(2):423–4

[Gorham disease in he course of osteoporosis caused by hypogonadism (letter)] Rolland Y, et al. **Presse Med** 1999 Apr 3;28(13):690 **(Fre)**

[Testosterone and atherosclerosis in males during andropause] Mędraś M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):205–7 (12 ref.) (Eng. Abstr.) **(Pol)**

[Multiple nodular heterotopias and Kallman's syndrome (letter)] Falero MP, et al. **Rev Neurol** 1998 Dec; 27(160):1067–8 **(Spa)**

CONGENITAL

Novel DAX1 mutations in X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism. Bassett JH, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):69–75

Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. Bin-Abbas B, et al. **J Pediatr** 1999 May;134(5):579–83

Should boys with micropenis be reared as girls? [editorial] Calikoglu AS. **J Pediatr** 1999 May;134(5):537–8

DIAGNOSIS

Evaluation of the pituitary gland in idiopathic hypogonadotropic hypogonadism. Jayasundar R, et al. **Acta Radiol** 1999 Jan;40(1):88–94

Response of the free alpha-subunit to GnRH distinguishes individuals with 'functional' from those with permanent hypogonadotropic hypogonadism. Mainieri AS, et al. **Horm Res** 1998;50(4):212–6

Magnetic resonance imaging of the pituitary gland in patients with secondary hypogonadism due to transfusional hemochromatosis. Sparacia G, et al. **MAGMA** 1999 May; 8(2):87–90

[Testosterone and atherosclerosis in males during andropause] Mędraś M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):205–7 (12 ref.) (Eng. Abstr.) **(Pol)**

[On the healthy male aging: hormonal aspects] Mędraś M, et al. **Pol Merkuriusz Lek** 1999 Apr;6(34):208–10 (22 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Absence of effect of recombinant growth hormone to classic gonadotropin treatment on spermatogenesis of patients with severe hypogonadotropic hypogonadism. Giagulli VA. **Arch Androl** 1999 Jul-Aug;43(1):47–53

Current status of testosterone replacement therapy in men. Winters SJ. **Arch Fam Med** 1999 May-Jun;8(3):257–63 (41 ref.)

Androgen therapy in AIDS wasting. Dobs AS. **Baillieres Clin Endocrinol Metab** 1998 Oct;12(3):379–90 (63 ref.)

Androgen receptor immunoreactivity in specific neural regions in normal and hypogonadal male mice: effect of androgens. Apostolinas S, et al. **Brain Res** 1999 Jan 30; 817(1–2):19–24

Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Behre HM, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):629–35

L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency. Lado-Abeal J, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):203–7

Experience with transdermal testosterone replacement therapy for hypogonadal men. Parker S, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):57–62

Clinical course of long term treatment with intermittent subcutaneous injection of LHRH in combination with GH replacement in a male patient with hypothalamic hypogonadism due to disruption of the pituitary stalk. Mori T, et al. **Endocr J** 1998 Apr;45 Suppl:S155–8

Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Behre HM, et al. **Eur J Endocrinol** 1999 May;140(5):414–9

Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Barrio R, et al. **Fertil Steril** 1999 Feb;71(2):244–8

Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Tripathy D, et al. **Horm Metab Res** 1998 Oct;30(10):642–5

GH/IGF-I axis in azoospermia in primary and secondary hypogonadism: a study before and during replacement therapy. Carani C, et al. **Int J Androl** 1999 Jun;22(3):184–9

Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. Strawford A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Feb 1;20(2):137–46

A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. Zhang GY, et al. **J Androl** 1998 Nov-Dec;19(6):761–8

Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. Caron P, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):990–6

Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. Rabkin JG, et al. **J Clin Psychopharmacol** 1999 Feb; 19(1):19–27

Hormonal replacement therapy with HCG and HU-FSH in thalassaemic patients affected by hypogonadotropic hypogonadism. Cisternino M, et al.
J Pediatr Endocrinol Metab 1998;11 Suppl 3:885-90

Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. De Sanctis V, et al.
J Pediatr Endocrinol Metab 1998;11 Suppl 3:891-900

Human chorionic gonadotrophin therapy in hypogonadal thalassaemic patients with osteopenia: increase in bone mineral density. Perniola R, et al.
J Pediatr Endocrinol Metab 1998;11 Suppl 3:995-6

Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Jockenhövel F, et al. **Metabolism** 1999 May;48(5):590-6

Endocrine aspects of ageing in the male. Gooren LJ.
Mol Cell Endocrinol 1998 Oct 25;145(1-2):153-9 (48 ref.)

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Curran MJ, et al.
Urology 1999 Feb;53(2):423-4

[Hypogonadotropic hypogonadism treated with HCG monotherapy: report of 3 cases] Mukouyama H, et al.
Hinyokika Kiyo 1999 Mar;45(3):195-8 (Eng. Abstr.)
(Jpn)

ETIOLOGY

Patterns of gonadal dysfunction following bone marrow transplantation. Mertens AC, et al.
Bone Marrow Transplant 1998 Aug;22(4):345-50

Rathke's cleft cyst as a cause of growth hormone deficiency and micropenis. Setian N, et al. **Childs Nerv Syst** 1999 May; 15(5):271-3

Hypogonadotropic hypogonadism. Hayes FJ, et al.
Endocrinol Metab Clin North Am 1998 Dec;27(4):739-63, vii (94 ref.)

Isolated hypogonadotropic hypogonadism in Rathke's cleft cyst: case report. Trincado P, et al. **J Child Neurol** 1998 Aug;13(8):402-5

[Nutritional hypogonadism] Bringer J, et al. **Rev Prat** 1999 Jun 15;49(12):1291-6 (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of hypogonadotropism in males and females] Young J, et al. **Rev Prat** 1999 Jun 15;49(12):1283-9 (Eng. Abstr.) **(Fre)**

[Hemochromatosis--a rare cause of hypogonadism] Rishaug U, et al. **Tidsskr Nor Laegeforen** 1999 Aug 20; 119(19):2818-9 (Eng. Abstr.) **(Nor)**

GENETICS

Physiologic and genetic insights into the pathophysiology and management of hypogonadotropic hypogonadism. Hall JE. **Ann Endocrinol (Paris)** 1999 Jul;60(2):93-101 (45 ref.)

A syndrome of congenital ichthyosis, hypogonadism, small stature, facial dysmorphism, scoliosis and myogenic dystrophy. Stoll C, et al. **Ann Genet** 1999;42(1):45-50

Novel DAX1 mutations in X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism. Bassett JH, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):69-75

Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Seminara SB, et al. **Endocr Rev** 1998 Oct; 19(5):521-39 (215 ref.)

MEHMO (mental retardation, epileptic seizures, hypogonadism and -genitalism, microcephaly, obesity), a novel syndrome: assignment of disease locus to xp21.1-p22.13. Steinmüller R, et al. **Eur J Hum Genet** 1998 May-Jun;6(3):201-6

Long-term restoration of gonadal activity with xenografts of preoptic area tissue in hypogonadal (hpg) mice. Wood MJ, et al. **Genet Res** 1998 Dec;72(3):229-36

Cat eye syndrome with hypogonadotropic hypogonadism. Masukawa H, et al. **Intern Med** 1998 Oct;37(10):853-6

Resistance of hypogonadic patients with mutated GnRH receptor genes to pulsatile GnRH administration. Caron P, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):990-6

The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. de Roux N, et al.
J Clin Endocrinol Metab 1999 Feb;84(2):567-72

A microdeletion within DAX-1 in X-linked adrenal hypoplasia congenita and hypogonadotrophic hypogonadism. Wang J, et al. **J Investig Med** 1999 May; 47(5):232-5

Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX1 gene. Merke DP, et al. **N Engl J Med** 1999 Apr 22;340(16):1248-52

[Genetic anomalies of the gonadotropic axis] de Roux N, et al. **Rev Prat** 1999 Jun 15;49(12):1277-82 (Eng. Abstr.) **(Fre)**

[29-year-old patient with gynecomastia and small testis] Brand S, et al. **Internist (Berl)** 1999 Apr;40(4):437-41 **(Ger)**

IMMUNOLOGY

Epiphenomenal antiovarian antibodies in hypogonadotropic hypogonadism [letter] Demirel LC, et al.
Int J Gynaecol Obstet 1995 Jun;49(3):333-4

METABOLISM

Effects of fenfluramine on ejaculatory function, luteinizing hormone and testosterone levels in men with hypogonadotropic hypogonadism and premature ejaculation. Cohen PG, et al. **Int Clin Psychopharmacol** 1999 Mar;14(2):91-4

Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. Mauras N, et al. **J Bone Miner Res** 1999 Apr;14(4):577-82

The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity. Cohen PG.
Med Hypotheses 1999 Jan;52(1):49-51

Bone mass and metabolism in Whipple's disease: the role of hypogonadism. Di Stefano M, et al.
Scand J Gastroenterol 1998 Nov;33(11):1180-5

PHYSIOPATHOLOGY

Physiologic and genetic insights into the pathophysiology and management of hypogonadotropic hypogonadism. Hall JE. **Ann Endocrinol (Paris)** 1999 Jul;60(2):93-101 (45 ref.)

Absence of effect of recombinant growth hormone to classic gonadotropin treatment on spermatogenesis of patients with severe hypogonadotropic hypogonadism. Giagulli VA.
Arch Androl 1999 Jul-Aug;43(1):47-53

Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men--effect of adrenal stimulation and implications for detection of testosterone abuse. Kicman AT, et al.
Clin Endocrinol (Oxf) 1999 May;50(5):661-8

Predictive value of serum follicle-stimulating hormone levels in the differentiation between hypogonadotropic hypogonadism and constitutional delay of puberty. Odink RJ, et al. **Horm Res** 1998;49(6):279-87

Concerning the article by Ogata et al. Hypergonadotrophic hypogonadism in a 3-year-old girl with blepharophimosis, ptosis, and epicanthus inversus syndrome [letter; comment] Wales JK. **Horm Res** 1998;50(6):341. Comment on: Horm Res 1998 Sep;50(3):190-2.

Event-related brain potentials in male hypogonadism. Ozata M, et al. **J Endocrinol Invest** 1999 Jul-Aug;22(7):508-13

[Testicular hypogonadisms] Lejeune H. **Rev Prat** 1999 Jun 15;49(12):1303-8 (Eng. Abstr.) **(Fre)**

THERAPY

Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. Bin-Abbas B, et al. **J Pediatr** 1999 May;134(5):579-83

[Analysis of liver function in patients with Turner syndrome (TS) and in patients with secondary hypogonadism with estrogen and estrogen- progestagens replacement therapy: a preliminary report] Rujner J, et al. **Ginekol Pol** 1999 May; 70(5):338-42 (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

A case of anaphylactic reaction caused by exposure to a latex probe cover in transvaginal ultrasound scanning [letter] Fry A, et al. **Ultrasound Obstet Gynecol** 1999 May;13(5):373

HYPOGRAVITY

see related
WEIGHTLESSNESS

Alteration of eye movements and motion perception in microgravity. Clément G. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):161-72 (61 ref.)

Perception of spatial orientation in microgravity. Glasauer S, et al. **Brain Res Brain Res Rev** 1998 Nov;28(1-2):185-93 (34 ref.)

Reference frames and internal models for visuo-manual coordination: what can we learn from microgravity experiments? McIntyre J, et al.
Brain Res Brain Res Rev 1998 Nov;28(1-2):143-54 (77 ref.)

Body orientation and control of coordinated movements in microgravity. Massion J, et al.
Brain Res Brain Res Rev 1998 Nov;28(1-2):83-91 (48 ref.)

Interaction of vestibular, somatosensory and visual signals for postural control and motion perception under terrestrial and microgravity conditions--a conceptual model. Mergner T, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):118-35 (67 ref.)

Post-spaceflight orthostatic intolerance: possible relationship to microgravity-induced plasticity in the vestibular system. Yates BJ, et al. **Brain Res Brain Res Rev** 1998 Nov; 28(1-2):73-82 (61 ref.)

Changes in lower limb volume in humans during parabolic flight. Bailliart O, et al. **J Appl Physiol** 1998 Dec; 85(6):2100-5

Three molecular mechanisms to explain some biological effects of electromagnetic fields and hypogravity. Menéndez RG. **Med Hypotheses** 1999 Mar;52(3):239-45 (44 ref.)

[The use of microfluorimetric analysis for the studies of the influence of changed gravity on isolated lymphocytes in the spleen of the mouse] Turovetskiĭ VB, et al.
Aviakosm Ekolog Med 1999;33(2):12-5 (Eng. Abstr.)
(Rus)

[Beta-guanidinopropionic acid prevents decrease in muscle performance and reduction in mitochondrial enzymes activation under gravitation unloading in rats] Nasledov GA, et al. **Dokl Akad Nauk** 1998 Nov;363(1):126-9
(Rus)

HYPOHIDROSIS

COMPLICATIONS

Congenital insensitivity to pain with anhidrosis: ocular and systemic manifestations. Yagev R, et al.
Am J Ophthalmol 1999 Mar;127(3):322-6

Congenital insensitivity to pain with anhidrosis: report of a 68-day-old case [letter] Sipahi T, et al. **Eur J Pediatr** 1999 Mar;158(3):268-9

Unsuccessful surgical treatment of hip dislocation in congenital sensory neuropathy with anhidrosis. A case report. Köster G, et al. **J Bone Joint Surg Br** 1999 Jan; 81(1):102-5

A novel point mutation affecting the tyrosine kinase domain of the TRKA gene in a family with congenital insensitivity to pain with anhidrosis. Yotsumoto S, et al.
J Invest Dermatol 1999 May;112(5):810-4

ETIOLOGY

Focal (segmental) dyshidrosis in syringomyelia. Sudo K, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):106-8

Hereditary insensitivity to pain with anhidrosis. Berkovitch M, et al. **Pediatr Neurol** 1998 Sep;19(3):227-9

GENETICS

Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. Mardy S, et al. **Am J Hum Genet** 1999 Jun;64(6):1570-9

A novel point mutation affecting the tyrosine kinase domain of the TRKA gene in a family with congenital insensitivity to pain with anhidrosis. Yotsumoto S, et al.
J Invest Dermatol 1999 May;112(5):810-4

PATHOLOGY

The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. Lao LM, et al. **J Dermatol Sci** 1998 Nov;18(2):109-17

Congenital insensitivity to pain with anhidrosis: a case report. Kim JS, et al. **J Korean Med Sci** 1999 Aug;14(4):460-4

RADIONUCLIDE IMAGING

Cardiac sympathetic denervation in Ross syndrome demonstrated by MIBG-SPECT. Druschky K, et al.
J Auton Nerv Syst 1999 May 28;76(2-3):184-7

HYPOKALEMIA

Potassium and anaesthesia. Reddy VG. **Singapore Med J** 1998 Nov;39(11):511-6 (56 ref.)

[Hypokalemia. Etiology, physiopathology, diagnosis, treatment] Dussaule JC, et al. **Rev Prat** 1998 Oct 1; 48(15):1697-703 (3 ref.) **(Fre)**

BLOOD

Hypokalemia alters sex hormone and gonadotropin levels: evidence that FSH may be required for luteinization. Tejada F, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):E1037-45

Treatment of hypokalemia [letter; comment] Robertson JI. **N Engl J Med** 1999 Jan 14;340(2):155. Comment on: N Engl J Med 1998 Aug 13;339(7):451-8.

CHEMICALLY INDUCED

Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Ruml LA, et al.
Am J Kidney Dis 1999 Jul;34(1):107-13

Should we fear "health foods"? [letter] Feingold RM.
Arch Intern Med 1999 Jul 12;159(13):1502

High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. Haris A, et al.
Exp Clin Endocrinol Diabetes 1998;106(5):431-4

11 beta HSD and the mechanism of gossypol-induced hypokalemia [letter; comment] Michael AE.
Int J Androl 1998 Oct;21(5):313. Comment on: Int J Androl 1998 Feb;21(1):2-7. Comment on: Int J Androl 1998 Feb;21(1):8-12.

Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa. Ishikawa S, et al. **Int J Eat Disord** 1999 Jul;26(1):111-4

Hypokalemia with syncope caused by habitual drinking of oolong tea. Aizaki T, et al. **Intern Med** 1999 Mar; 38(3):252-6

Rapid reversal of life-threatening toluene-induced hypokalemia with hemodialysis. Gerkin RD Jr, et al.
J Emerg Med 1998 Sep-Oct;16(5):723-5

Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. Eriksson JW, et al.
J Intern Med 1999 Mar;245(3):307-10

Iatrogenic hypercalcaemia, hypokalaemia and metabolic alkalosis in a lady with vena cava thrombosis--beware of overzealous diuretic treatment. Böhmig GA, et al.
Nephrol Dial Transplant 1999 Mar;14(3):782-4

Hypokalemia, hyperreninemia and osteoporosis in a patient ingesting large amounts of cider vinegar [letter] Lhotta K,

et al. **Nephron** 1998 Oct;80(2):242–3
Hypokalemia and salbutamol therapy in asthma. Hung CH, et al. **Pediatr Pulmonol** 1999 Jan;27(1):27–31
Renal tubular acidosis, hypokalemic paralysis, rhabdomyolysis, and acute renal failure--a rare presentation of Chinese herbal nephropathy. Lee CT, et al. **Ren Fail** 1999 Mar;21(2):227–30
[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake] Gaul C, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):483–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Hypokalemic paralysis in furosemide therapy and simultaneous laxative abuse] Rudolf J, et al. **Med Klin** 1999 Jul 15;94(7):391–4 (Eng. Abstr.) **(Ger)**
[Itraconazole-induced hypokalemia in a patient with pulmonary aspergilloma] Sasaki E, et al. **Nihon Kokyuki Gakkai Zasshi** 1999 Jan;37(1):36–40 (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Hypokalemic periodic paralysis associated with hypophosphatemia in a patient with hyperinsulinemia. Ogawa T, et al. **Am J Med Sci** 1999 Jul;318(1):69–72
Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Manoukian MA, et al. **Arch Intern Med** 1999 Mar 22;159(6):601–6
C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Berthet M, et al. **Circulation** 1999 Mar 23; 99(11):1464–70
Acute renal failure due to hypokalemic rhabdomyolysis in Gitelman's syndrome. Nishihara G, et al. **Clin Nephrol** 1998 Nov;50(5):330–2 (9 ref.)
Unusual ECG after syncope in an elderly woman. Hancock EW. **Hosp Pract (Off Ed)** 1999 Jul 15;34(7):11–2
Latent tetany associated with the hypokalaemia of Conn's syndrome. Davies JS, et al. **Int J Clin Pract** 1998 Jul–Aug; 52(5):347–8
Prominent bifid T waves observed in the QT prolongation caused by complete atrioventricular blockade in a hypokalemic diabetic patient. Oka-Manabe S, et al. **J Electrocardiol** 1999 Jul;32(3):289–92
Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. Eriksson JW, et al. **J Intern Med** 1999 Mar;245(3):307–10
Recurrent calcium oxalate urolithiasis in a man with familial periodic paralysis and hypokalemia. Zitella A, et al. **J Urol** 1999 Jun;161(6):1899
Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter Study of Perioperative Ischemia Research Group. Wahr JA, et al. **JAMA** 1999 Jun 16;281(23):2203–10
Severe hypokalemic myopathy in Gitelman's syndrome [letter] Tang NL, et al. **Muscle Nerve** 1999 Apr;22(4):545–7
Hypokalaemia-induced acute renal failure. Menahem SA, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2216–8
Bilateral vocal fold paralysis caused by familial hypokalemic periodic paralysis. Rosen CA, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):785–6
Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Hayashi Y, et al. **Pacing Clin Electrophysiol** 1999 Apr;22(4 Pt 1):672–4
Hypokalemic paralysis. Bello O, et al. **Pediatr Emerg Care** 1998 Dec;14(6):409–10
Hypokalemia and agitation in acute psychotic patients. Hatta K, et al. **Psychiatry Res** 1999 Apr 19;86(1):85–8
Preponderance of hypokalaemia as a cause of acute onset quadriparesis in northern India/southern Nepal. Thomas SM, et al. **Trop Doct** 1999 Jul;29(3):148–51
[Intraoperative problems with cardiac rhythm in relation to hypokalemia and the administration of atropine (letter)] Cazals C, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):467–8 **(Fre)**
[A rare case of hypokalemic thyrotoxic periodic paralysis in a Caucasian patient with Basedow's disease] Messina G, et al. **Recenti Prog Med** 1999 Jul–Aug;90(7–8):392–3 (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Photo quiz. A subtle ECG. Gentry BC, et al. **Am Fam Physician** 1999 May 1;59(9):2581–2
Electrocardiographic abnormalities in combined hypercalcaemia and hypokalaemia--case report. Chia BL, et al. **Ann Acad Med Singapore** 1998 Jul;27(4):567–9 (6 ref.)
Hypokalaemic periodic paralysis mimicking Guillain-Barré syndrome [letter] Warren JD, et al. **Med J Aust** 1998 Sep 21;169(6):342
Chronic hypokalaemia in young women--it is not always abuse of diuretics. Persu A, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1021–5
Bilateral vocal fold paralysis caused by familial hypokalemic periodic paralysis. Rosen CA, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):785–6
Creatinine, electrolytes and urea--do I hear much groaning? Swanepoel CR. **S Afr Med J** 1999 Mar;89(3):251–4
[Periodic hypokalemic paralysis disclosing thyrotoxicosis] Penisson-Besnier I, et al. **Presse Med** 1998 Sep 26; 27(28):1430–1 (Eng. Abstr.) **(Fre)**
[Thyrotoxic hypokalemic periodic paralysis in a male Kurd] Gamper G, et al. **Acta Med Austriaca** 1998;25(3):106–8 (17 ref.) (Eng. Abstr.) **(Ger)**
[Distal renal tubular acidosis or only renal failure and diuretics-induced hypokalemia? (letter; comment)] Gøransson L. **Tidsskr Nor Laegeforen** 1999 Jun 10; 119(15):2239–40. Comment on: Tidsskr Nor Laegeforen 1999 Apr 30;119(11):1610–2. **(Nor)**

DRUG THERAPY

The effect of varying molar ratios of potassium-magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Ruml LA, et al. **J Clin Pharmacol** 1998 Nov; 38(11):1035–41
The calcium channel blocker verapamil in hypokalemic periodic paralysis [letter] Links TP, et al. **Muscle Nerve** 1998 Nov;21(11):1564–5
Treatment of hypokalemia [letter; comment] [published erratum appears in N Engl J Med 1999 Feb 25;340(8):663] Agarwal A, et al. **N Engl J Med** 1999 Jan 14;340(2):154–5; discussion 155. Comment on: N Engl J Med 1998 Aug 13;339(7):451–8.
[The usefulness of Aspargin for supplementing potassium and magnesium in ethanol dependent patients] Pach J, et al. **Przegl Lek** 1999;56(6):472–4 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Thyrotoxic periodic paralysis in Mexican mestizo patients: a clinical, biochemical and HLA-serological study. Nellen H, et al. **Arch Med Res** 1999 Jan–Feb;30(1):74–6
Is hypokalaemic periodic paralysis more prevalent in Maori? [letter] Fink JN, et al. **Aust N Z J Med** 1998 Aug; 28(4):477–8

ETIOLOGY

Hypokalemic periodic paralysis associated with hypophosphatemia in a patient with hyperinsulinemia. Ogawa T, et al. **Am J Med Sci** 1999 Jul;318(1):69–72
Hypokalaemic, hyperchloraemic metabolic acidosis requiring ventilation. Dunn SR, et al. **Anaesthesia** 1999 Jun; 54(6):566–8
Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Hill AG, et al. **Aust N Z J Surg** 1998 Dec;68(12):856–8
Sudden periodic paralysis: rare manifestation of thyrotoxicosis. Ramirez Rivera J, et al. **Bol Asoc Med P R** 1998 Apr–Jun;90(4–6):88–90
Hypokalaemia during insulin-induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency. Davies JS, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):217–20
Thyroid hypokalemic periodic paralysis. Nida ME, et al. **J Am Osteopath Assoc** 1998 Dec;98(12):694–5
Electrolyte monitoring in patients undergoing peripheral blood stem cell collection. Perseghin P, et al. **J Clin Apheresis** 1999;14(1):14–7
Hypokalaemic paralysis revealing Sjögren syndrome in an elderly man. al-Jubouri MA, et al. **J Clin Pathol** 1999 Feb; 52(2):157–8
Muscle pain after exercise. Nielsen C, et al. **Lancet** 1999 Mar 27;353(9158):1062
Hypothermia-induced hypokalemia. Zydlewski AW, et al. **Mil Med** 1998 Oct;163(10):719–21
Leptospirosis associated with hypokalaemia and thick ascending limb dysfunction. Lin CL, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):193–5
The unusual diabetic patient with advanced renal insufficiency on ACE inhibitors. What is the explanation for her persisting hypokalaemia? Morales E, et al. **Nephrol Dial Transplant** 1999 May;14(5):1313–4
Severe hypokalaemia and respiratory arrest due to renal tubular acidosis in a patient with Sjögren syndrome. Ohtani H, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2201–3
The syndrome of apparent mineralocorticoid excess [editorial] Cooper M, et al. **QJM** 1998 Jul;91(7):453–5
Severe muscle weakness due to hypokalemia as a manifestation of small-cell carcinoma. Konstantinidis A, et al. **Respiration** 1999;66(3):269–72
Hypokalemic nephropathy and nephrogenic diabetes insipidus due to excessive consumption of a soft drink. Buridi A, et al. **South Med J** 1998 Nov;91(11):1079–82
[Hypokalemic periodic paralysis revealing hyperthyroidism (letter)] Haymann JP, et al. **Rev Med Interne** 1999 Aug; 20(8):720–2 **(Fre)**
[Disorders of potassium balance] Gross P, et al. **Internist (Berl)** 1998 Aug;39(8):810–4 (11 ref.) **(Ger)**
[Arterial hypertension with concomitant hypokalemia] Nordmann A. **Schweiz Rundsch Med Prax** 1998 Nov 4; 87(45):1517–8 **(Ger)**

GENETICS

Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Lemmink HH, et al. **Kidney Int** 1998 Sep;54(3):720–30
The molecular basis of hypokalaemic alkalosis: Bartter's and Gitelman's syndromes [editorial] Bhandari S, et al. **Nephron** 1998 Dec;80(4):373–9 (60 ref.)
Molecular basis of hypokalemic myopathy caused by 17alpha-hydroxylase/17,20-lyase deficiency. Satoh J, et al. **Neurology** 1998 Dec;51(6):1748–51
The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes. Bhandari S. **Postgrad Med J** 1999 Jul;75(885):391–6 (65 ref.)

METABOLISM

Temporal responses of oxidative vs. glycolytic skeletal muscles to K+ deprivation: Na+ pumps and cell cations. Thompson CB, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1411–9
The relationship between distal tubular proton secretion and dietary potassium depletion: evidence for up-regulation of H+ -ATPase. Bailey M, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1435–40
The molecular basis of hypokalaemic alkalosis: Bartter's and Gitelman's syndromes [editorial] Bhandari S, et al. **Nephron** 1998 Dec;80(4):373–9 (60 ref.)
Insulin modulation of ATP-sensitive K+ channel of rat skeletal muscle is impaired in the hypokalaemic state. Tricarico D, et al. **Pflugers Arch** 1999 Jan;437(2):235–40

PHYSIOPATHOLOGY

Photo quiz. A subtle ECG. Gentry BC, et al. **Am Fam Physician** 1999 May 1;59(9):2581–2
Anesthetic management of familial hypokalemic periodic paralysis during parturition. Viscomi CM, et al. **Anesth Analg** 1999 May;88(5):1081–2
Echocardiographic findings of the heart resembling dilated cardiomyopathy during hypokalemic myopathy due to licorice-induced pseudoaldosteronism [letter] Hasegawa J, et al. **Cardiovasc Drugs Ther** 1998 Dec;12(6):599–600
Dysfunction of sensory nerves during attacks of hypokalemic periodic paralysis. Inshasi JS, et al. **Neuromuscul Disord** 1999 Jun;9(4):227–31
[Cushing syndrome by ectopic ACTH secretion: analysis of the physiopathologic mechanism of hypokalemia. Report of two cases] Campusano C, et al. **Rev Med Chil** 1999 Mar; 127(3):332–6 (Eng. Abstr.) **(Spa)**

URINE

Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia. Melnick JZ, et al. **Kidney Int** 1998 Nov;54(5):1670–4

VETERINARY

Hypokalaemia in cattle [letter; comment] Michell AR. **Vet Rec** 1998 Nov 7;143(19):540. Comment on: Vet Rec 1998 Oct 31;143(18):503–7.
Description of 14 cases of bovine hypokalaemia syndrome [see comments] Sattler N, et al. **Vet Rec** 1998 Oct 31; 143(18):503–7. Comment in: Vet Rec 1998 Nov 7;143(19):540.

HYPOKINESIA

CHEMICALLY INDUCED

Valproic acid intoxication in a patient with bipolar disorder and chronic uremia [letter] Lapierre O, et al. **Can J Psychiatry** 1999 Mar;44(2):188

COMPLICATIONS

Suspension "hypokinesia/hypodynamia" may decrease bone mass by stimulating osteoclast production in ovariectomized mice. Kawata T, et al. **J Nutr Sci Vitaminol (Tokyo)** 1998 Oct;44(5):581–90
[The development of the syndrome of congestive parenchymatous organs under conditions of short-term hypokinesia] Bednenko VS, et al. **Aviakosm Ekolog Med** 1999;33(3):25–31 (Eng. Abstr.) **(Rus)**
[The effect of a two-week anti-orthostatic hypokinesia on the cardiac function and on the latter's regulation in monkeys] Korol'kov VI, et al. **Aviakosm Ekolog Med** 1998; 32(3):30–7 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Ambulatory quantitative assessment of body position, bradykinesia, and hypokinesia in Parkinson's disease. Dunnewold RJ, et al. **J Clin Neurophysiol** 1998 May; 15(3):235–42
Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398–403 (70 ref.)
Bradykinesia and impairment of EEG desynchronization in Parkinson's disease. Brown P, et al. **Mov Disord** 1999 May; 14(3):423–9
[Specific aspects of the nervous system and brain blood supply in women during prolonged anti-orthostatic hypokinesia] Chumak OB, et al. **Aviakosm Ekolog Med** 1999;33(2):9–12 (Eng. Abstr.) **(Rus)**
[The main clinico-neurological syndromes of prolonged hypokinesia] Tizul ALa. **Aviakosm Ekolog Med** 1999; 33(3):9–12 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Sex differences in effects of opioid blockade on stress-induced freezing behavior. Klein LC, et al. **Pharmacol Biochem Behav** 1998 Dec;61(4):413–7
Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in

depressed patients with blunted affect and psychomotor retardation. Jouvent R, et al. **Psychiatry Res** 1998 Jul 13; 79(3):267–75

[The effect of GABA-ergic agents on the electrolyte balance under hypokinesia] Akopian VP, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):62–4 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

[The influence of hypokinesia on the mother-fetus system] Serova LV, et al. **Aviakosm Ekolog Med** 1999;33(2):5–9 (Eng. Abstr.) **(Rus)**

ETIOLOGY

Episodically remitting akinetic mutism following subarachnoid hemorrhage. Burruss JW, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter;11(1):100–2

Bradykinesia and impairment of EEG desynchronization in Parkinson's disease. Brown P, et al. **Mov Disord** 1999 May; 14(3):423–9

Severe akinetic syndrome resulting from a bilateral basal ganglia lesion following bone marrow transplantation. Pirker W, et al. **Mov Disord** 1999 May;14(3):525–8

Hypoactive delirium as a clinical symptom of intestinal perforation. Morita T, et al. **Psychosomatics** 1999 Mar–Apr; 40(2):130–1

METABOLISM

Daily copper supplement effects on copper balance in trained subjects during prolonged restriction of muscular activity. Zorbas YG, et al. **Biol Trace Elem Res** 1999 Aug; 69(2):81–98

Magnesium loading effect on magnesium deficiency in endurance-trained subjects during prolonged restriction of muscular activity. Zorbas YG, et al. **Biol Trace Elem Res** 1998 Aug;63(2):149–66

Potassium loading effect on potassium balance in athletes during prolonged restriction of muscular activity. Zorbas YG, et al. **Biol Trace Elem Res** 1999 Oct;70(1):1–19

Fluid electrolyte changes during prolonged restriction of motor activity in rat. Zorbas YG, et al. **J Physiol Biochem** 1998 Mar;54(1):33–40

[Comparative analysis of changes in rats organisms exposed to microgravity and head-down suspension] Il'in EA, et al. **Aviakosm Ekolog Med** 1998;32(6):43–50 (Eng. Abstr.) **(Rus)**

[GABA reuptake by rat brain slices in hypokinesia and under the influence of cinnarizine and flunarizine] Mirzoian NR, et al. **Eksp Klin Farmakol** 1998 Sep–Oct;61(5):15–7 (Eng. Abstr.) **(Rus)**

PATHOLOGY

Bone tissue changes in rats during prolonged restriction of motor activity. Zorbas YG, et al. **Physiol Chem Phys Med NMR** 1998;30(2):219–28

Morphometric examination of glomerulus and juxta glomerural system of rat kidney during prolonged restriction of motor activity. Zorbas YG, et al. **Physiol Chem Phys Med NMR** 1998;30(2):229–37

PHYSIOPATHOLOGY

The physiological consequences of bed rest and inactivity. Krasnoff J, et al. **Adv Ren Replace Ther** 1999 Apr; 6(2):124–32 (47 ref.)

Daily hyperhydration effect on electrolyte deficiency of endurance-trained subjects during prolonged hypokinesia. Zorbas YG, et al. **Biol Trace Elem Res** 1998 Summer; 64(1–3):259–73

Effect of hindlimb unloading on interlimb coordination during treadmill locomotion in the rat. Canu MH, et al. **Eur J Appl Physiol** 1998 Nov;78(6):509–15

Voluntary movements and event-related potentials in Parkinsonians (stages 1–2). Suvorov N, et al. **Int J Psychophysiol** 1999 Jan;31(2):95–110

Progressive bradykinesia and hypokinesia of ocular pursuit in Parkinson's disease. Lekwuwa GU, et al. **J Neurol Neurosurg Psychiatry** 1999 Jun;66(6):746–53

Magnesium supplements' effect on magnesium balance in athletes during prolonged restriction of muscular activity. Zorbas YG, et al. **Kidney Blood Press Res** 1999; 22(3):146–53

Pathophysiology of chorea and bradykinesia in Huntington's disease. Berardelli A, et al. **Mov Disord** 1999 May; 14(3):398–403 (70 ref.)

Short-term reorganization of the rat somatosensory cortex following hypodynamia-hypokinesia. Langlet C, et al. **Neurosci Lett** 1999 May 7;266(2):145–8

Water and electrolyte excretion in rats during prolonged restriction of motor activity and chronic hyperhydration. Zorbas YG, et al. **Physiol Chem Phys Med NMR** 1998; 30(1):99–111

[Effect of antiorthostatic pre-training on transcapillary turnover of fluids in extra- and intracranial vessels of rats in antiorthostatic hypokinesia] Medvedev OS, et al. **Aviakosm Ekolog Med** 1998;32(4):17–21 (Eng. Abstr.) **(Rus)**

[Effect of training to antiorthostatic hypokinesia on parameters of the central hemodynamics in rats] Bychkova Elu, et al. **Biull Eksp Biol Med** 1998 Sep;126(9):289–93 **(Rus)**

PREVENTION & CONTROL

[Prevention of respiratory muscles deconditioning and deterioration of aerobic working capacity in prolonged weightlessness and hypokinesia] Baranov VM, et al. **Aviakosm Ekolog Med** 1998;32(6):36–42 (Eng. Abstr.) **(Rus)**

THERAPY

Decrease in akinesia seems to result from chronic electrical stimulation in the external (GPe) rather than internal (Gpi) pallidum [letter; comment] Hariz MI. **Mov Disord** 1999 May;14(3):536–40. Comment on: Mov Disord 1998 Jul;13(4):648–52.

HYPOLIPOPROTEINEMIA

CHEMICALLY INDUCED

Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Rait JL. **Aust N Z J Ophthalmol** 1999 Feb; 27(1):57–64 (60 ref.)

DIAGNOSIS

[How I study a patient with a low concentration of HDL cholesterol] Scheen AJ. **Rev Med Liege** 1998 Nov; 53(11):711–4 (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Mechanistic studies of high-density lipoproteins. Kashyap ML. **Am J Cardiol** 1998 Dec 17;82(12A):42U–48U; discussion 85U–86U (26 ref.)

High density lipoprotein: are elevated levels desirable and achievable? Bisgaier CL, et al. **Curr Pharm Des** 1998 Feb; 4(1):53–70 (361 ref.)

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Rubins HB, et al. **N Engl J Med** 1999 Aug 5;341(6):410–8

[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol] Scheen AJ. **Rev Med Liege** 1998 Dec; 53(12):727–31 (Eng. Abstr.) **(Fre)**

GENETICS

Genetics of lipoprotein disorders. Davignon J, et al. **Endocrinol Metab Clin North Am** 1998 Sep;27(3):521–50 (244 ref.)

Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Yamakawa-Kobayashi K, et al. **Hum Mol Genet** 1999 Feb;8(2):331–6

METABOLISM

Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Franceschini G, et al. **Arterioscler Thromb Vasc Biol** 1999 May; 19(5):1257–62

THERAPY

Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase. Brousseau ME, et al. **J Lipid Res** 1998 Aug; 39(8):1558–67

HYPOMENORRHEA see **MENSTRUATION DISORDERS**

HYPOMINERALIZATION, TOOTH see **TOOTH DEMINERALIZATION**

HYPONATREMIA

They should have reviewed the obstetric literature [letter] Goodlin RC. **Am J Obstet Gynecol** 1999 Jul;181(1):230–1

Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Siegel AJ, et al. **Harv Rev Psychiatry** 1998 Nov–Dec;6(4):190–200 (53 ref.)

Hyponatremia: how to approach this confusing abnormality [editorial; comment] Oiso Y. **Intern Med** 1998 Nov; 37(11):907–8 (7 ref.). Comment on: Intern Med 1998 Nov;37(11):950–4.

Hyponatraemia--a prospective analysis of surgical patients. Madiba TE, et al. **S Afr J Surg** 1998 Aug;36(3):78–81

[Hypo-osmolar hyponatremic syndromes: physiopathology and clinical aspects] Garini G, et al. **Recenti Prog Med** 1999 Feb;90(2):100–8 (43 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Oster JR, et al. **Arch Intern Med** 1999 Feb 22; 159(4):333–6 (23 ref.)

Dual facets of hyponatraemia and arginine vasopressin in patients with ACTH deficiency. Yamamoto T, et al. **Clin Endocrinol (Oxf)** 1998 Dec;49(6):785–92

CHEMICALLY INDUCED

Seizure and hyponatraemia after overdose of trazadone [letter] Vanpee D, et al. **Am J Emerg Med** 1999 Jul; 17(4):430–1

Diuretic-induced hyponatremia. Spital A. **Am J Nephrol** 1999;19(4):447–52 (48 ref.)

Comment: hyponatremia with venlafaxine [letter; comment] Boyd IW. **Ann Pharmacother** 1998 Sep;32(9):981–2. Comment on: Ann Pharmacother 1998 Jan;32(1):49–51.

Hyponatremic seizure in a child using desmopressin for nocturnal enuresis [letter; comment] Schwartz ID. **Arch Pediatr Adolesc Med** 1998 Oct;152(10):1037–8. Comment on: Arch Pediatr Adolesc Med 1998 Mar;152(3):290–2.

Could this be a drug side effect? Phillips PJ, et al. **Aust Fam Physician** 1999 Mar;28(3):269–70

An unusually rapid onset of hyponatraemia following paroxetine [letter] Paul S, et al. **Aust N Z J Med** 1998 Dec;28(6):840

Syndrome of inappropriate antidiuretic hormone [letter; comment] Goldman MB. **Biol Psychiatry** 1999 Feb 15; 45(4):515. Comment on: Biol Psychiatry 1998 Mar 15;43(6):466–7.

Care required when prescribing carbamazepine [letter; comment] Zakrzewska JM. **Br Dent J** 1998 Nov 28; 185(10):500–1. Comment on: Br Dent J 1998 Sep 26;185(6):276–8.

Drug-induced hyponatraemia in elderly patients [letter; comment] Schwab M, et al. **Br J Clin Pharmacol** 1999 Jul; 48(1):105–6. Comment on: Br J Clin Pharmacol 1999 Feb;47(2):211–7.

Hyponatremia and amlodipine therapy [letter] Malaterre HR, et al. **Cardiovasc Drugs Ther** 1999 Apr;13(2):171–2

Lung cancer and drug-induced severe hyponatremia [clinical conference] Chintanadilok J, et al. **Geriatr Nephrol Urol** 1998;8(3):161–5

Hynonatremia in elderly psychiatric inpatients [letter] Critchlow S. **Int J Geriatr Psychiatry** 1998 Nov; 13(11):816–8

Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis. Apakama DC, et al. **J Accid Emerg Med** 1999 May;16(3):229–30

Hyponatremia in an older patient [letter] Kelly RE, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1037–8

Sertraline-induced hyponatremia in an older patient [letter] [published erratum appears in J Am Geriatr Soc 1999 Mar;47(3):365] Levsky ME, et al. **J Am Geriatr Soc** 1998 Dec;46(12):1582–3

Increased sensitivity to thyroid hormone replacement therapy followed by hyponatremia and eosinophilia in a patient with long-standing young-onset primary hypothyroidism. Fujikawa M, et al. **J Endocrinol Invest** 1999 Jun; 22(6):476–80

Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. Kirchner V, et al. **J Psychopharmacol** 1998;12(4):396–400 (52 ref.)

Lessons to be learned: a case study approach diuretic therapy and a laxative causing electrolyte and water imbalance, loss of attention, a fall and subsequent fractures of the tibia and fibula in an elderly lady. Sankar NS, et al. **J R Soc Health** 1998 Aug;118(4):237–40

Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use. O'Connor A, et al. **N Z Med J** 1999 Jul 9;112(1091):255–6

Severe hyponatraemia in an amiloride/hydrochlorothiazide-treated patient [see comments] van Assen S, et al. **Neth J Med** 1999 Mar; 54(3):108–13. Comment in: Neth J Med 1999 Mar;54(3):101–4.

Hyponatraemia and seizures after ecstasy use. Holmes SB, et al. **Postgrad Med J** 1999 Jan;75(879):32–3

Hyponatremia associated with paroxetine use [letter] Madhusoodanan S, et al. **South Med J** 1999 Aug;92(8):843

[Hyponatremia and benazepril (letter)] Goutorbe R, et al. **Rev Med Interne** 1998 Jul;19(7):519–20 **(Fre)**

[Hyponatremia and probable inappropriate secretion of antidiuretic hormone due to citalopram (letter)] Pradalier A, et al. **Therapie** 1998 Nov–Dec;53(6):600–2 **(Fre)**

[Transient psychosis in lisinopril-induced hyponatremia] Giupponi G, et al. **Psychiatr Prax** 1998 Jul;25(4):204 **(Ger)**

[Recurrent hyponatremia, neurological symptoms and long-term administration of levomepromazine] Münzer T, et al. **Schweiz Rundsch Med Prax** 1999 Feb 4;88(6):237–41 (Eng. Abstr.) **(Ger)**

[Carbamazepine induced hyponatremia] Inamura T, et al. **No Shinkei Geka** 1999 Jan;27(1):85–7 (Eng. Abstr.) **(Jpn)**

[Severe hyponatremia during treatment with fluoxetine] Miranda M, et al. **Rev Med Chil** 1999 Mar;127(3):337–40 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Profound hyponatraemia in quadriplegia. Watson ID, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):673–6

Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine. Wicki J, et al. **Ann Pharmacother** 1998 Sep;32(9):892–5

Hypertonic 3% saline infusion by nasogastric tube for the treatment of severe symptomatic hyponatremia. Hoover B, et al. **Clin Pediatr (Phila)** 1999 Jan;38(1):55–7

Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis. Apakama DC, et al. **J Accid Emerg Med** 1999 May;16(3):229–30

Chronic hyponatremia exacerbates ammonia-induced brain

edema in rats after portacaval anastomosis. Córdoba J, et al. **J Hepatol** 1998 Oct;29(4):589–94

Cortical sclerosis presenting with dementia as a sequel of rapid correction of hyponatraemia. Lebrun C, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):685–6

Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. Ayus JC, et al. **JAMA** 1999 Jun 23–30; 281(24):2299–304

Hypoxia is the cause of brain damage in hyponatremia [editorial] Knochel JP. **JAMA** 1999 Jun 23–30; 281(24):2342–3

Recurrent symptomatic hyponatremia associated with priapism in paraplegia [letter] Ghosh AK. **Nephron** 1998 Oct;80(2):231

Hyponatremia–associated rhabdomyolysis. Trimarchi H, et al. **Nephron** 1999;82(3):274–7 (33 ref.)

Extrapontine myelinolysis in a nine–year–old child. Oztürk F, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):579–84

DIAGNOSIS

MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. Leadbetter RA, et al. **Am J Psychiatry** 1999 Jun;156(6):958–60

Use of a handheld, battery–operated chemistry analyzer for evaluation of heat–related symptoms in the backcountry of Grand Canyon National Park: a brief report. Backer HD, et al. **Ann Emerg Med** 1999 Apr;33(4):418–22

Exaggerated urinary excretion of aquaporin–2 in the pathological state of impaired water excretion dependent upon arginine vasopressin. Saito T, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4034–40

Severe hyponatraemia in an amiloride/hydrochlorothiazide–treated patient [see comments] van Assen S, et al. **Neth J Med** 1999 Mar; 54(3):108–13. Comment in: Neth J Med 1999 Mar;54(3):101–4.

Creatinine, electrolytes and urea––do I hear much groaning? Swanepoel CR. **S Afr Med J** 1999 Mar;89(3):251–4

[Disturbances of effective osmolality regulation in disorders of the central nervous system and possible methods of monitoring] Balik M, et al. **Cas Lek Cesk** 1998 Aug 24; 137(16):488–92 (0 ref.) (Eng. Abstr.) **(Cze)**

[Schizophreniform psychosis with polydipsia and electrolyte imbalance in multiple sclerosis] Dieterle L, et al. **Nervenarzt** 1998 Aug;69(8):698–701 (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Nasogastric tube delivery of 3% saline to correct hyponatremia [letter] Robertson WO. **Clin Pediatr (Phila)** 1999 Sep;38(9):562

Microencapsulated NaCl for oral salt–replacement therapy in infants [letter] Claviez A, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1513–4

Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. Suarez JI, et al. **J Neurosurg Anesthesiol** 1999 Jul;11(3):178–84

Disorders of sodium balance [letter; comment] Kelly J. **Lancet** 1998 Oct 3;352(9134):1146–7. Comment on: Lancet 1998 Jul 18;352(9123):220–8.

Disorders of sodium balance [letter; comment] Ostoja–Chrzastowski W, et al. **Lancet** 1998 Oct 3; 352(9134):1147. Comment on: Lancet 1998 Jul 18;352(9123):220–8.

The role of fludrocortisone in a child with cerebral salt wasting. Sakarcan A, et al. **Pediatr Nephrol** 1998 Nov; 12(9):769–71

EPIDEMIOLOGY

Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people [see comments] Wilkinson TJ, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):211–7. Comment in: Br J Clin Pharmacol 1999 Jul;48(1):105–6.

Prevalence and severity of hyponatremia and hypercreatininemia in short–term uncomplicated hypothyroidism. Baajafer FS, et al. **J Endocrinol Invest** 1999 Jan;22(1):35–9

ETIOLOGY

Recent advances in the understanding of water metabolism in heart failure. Schrier RW, et al. **Adv Exp Med Biol** 1998; 449:415–26 (78 ref.)

Emergency! Hyponatremia. De Jong MJ. **Am J Nurs** 1998 Dec;98(12):36

Dilutional hyponatremia in pre–eclampsia. Hayslett JP, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1312–6

Acute hyponatraemia secondary to cerebral salt wasting syndrome in a patient with tuberculous meningitis. Ti LK, et al. **Anaesth Intensive Care** 1998 Aug;26(4):420–3

Hyponatraemia after orthopaedic surgery. General journals must not alienate particular specialties [letter] Harrington P. **BMJ** 1999 Aug 21;319(7208):514; discussion 516

Hyponatraemia after orthopaedic surgery. Hypotonic solutions should be used infrequently [letter] Hoffbrand B. **BMJ** 1999 Aug 21;319(7208):515–6

Hyponatraemia after orthopaedic surgery [editorial] Lane N, et al. **BMJ** 1999 May 22;318(7195):1363–4

Hyponatraemia after orthopaedic surgery. Rigorous audit and introduction of guidelines decreased hospital's figures [letter] Marino A, et al. **BMJ** 1999 Aug 21;319(7208):515; discussion 516

Hyponatraemia after orthopaedic surgery. Laboratory must play a part in patients' management [letter] Mojiminiyi OA. **BMJ** 1999 Aug 21;319(7208):515; discussion 516

Hyponatraemia after orthopaedic surgery. Failsafe system is needed [letter] Severn AM, et al. **BMJ** 1999 Aug 21; 319(7208):514; discussion 516

Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people [see comments] Wilkinson TJ, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):211–7. Comment in: Br J Clin Pharmacol 1999 Jul;48(1):105–6.

Iatrogenic acute hyponatraemia in a college athlete. Herfel R, et al. **Br J Sports Med** 1998 Sep;32(3):257–8

The frequency, aetiology and outcome of severe hyponatraemia in adult hospitalised patients. Erasmus RT, et al. **Cent Afr J Med** 1998 Jun;44(6):154–8

An unusual cause of hyponatraemia [letter] Bradley MD, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):680–2

Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Hensen J, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):431–9

Hyponatremia due to inappropriate secretion of antidiuretic hormone in a patient with systemic lupus erythematosus [clinical conference] Elisaf MS, et al. **Clin Exp Rheumatol** 1999 Mar–Apr;17(2):223–6

Hyponatremic–hypertensive syndrome with renal ischemia: an underrecognized disorder. Agarwal M, et al. **Hypertension** 1999 Apr;33(4):1020–4

Asymptomatic hyponatremia due to inappropriate secretion of antidiuretic hormone as the first sign of a small cell lung cancer in an elderly man [see comments] Kamoi K, et al. **Intern Med** 1998 Nov;37(11):950–4. Comment in: Intern Med 1998 Nov;37(11):907–8.

Hyponatremia in a patient with chronic inflammatory disease. Murakami T, et al. **Intern Med** 1998 Sep;37(9):792–5

Severe hyponatremia caused by hypothalamic adrenal insufficiency [see comments] Shibata T, et al. **Intern Med** 1999 May;38(5):426–32. Comment in: Intern Med 1999 May;38(5):382–3.

Preventing hyponatremic encephalopathy [letter] Brooks PG. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):446–8

Clozapine restores water balance in schizophrenic patients with polydipsia–hyponatremia syndrome. Canuso CM, et al. **J Neuropsychiatry Clin Neurosci** 1999 Winter; 11(1):86–90

Hyponatremia in ultradistance triathletes. Speedy DB, et al. **Med Sci Sports Exerc** 1999 Jun;31(6):809–15

Disturbances in plasma sodium in patients with war head injuries. Bačić A, et al. **Mil Med** 1999 Mar;164(3):214–7

Death from hyponatremia as a result of acute water intoxication in an Army basic trainee. Garigan TP, et al. **Mil Med** 1999 Mar;164(3):234–8

Hyponatraemia as the presenting feature of isolated thyrotropin deficiency. Yoshioka T, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):423–5

Severe hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. A rare initial presentation of tuberculosis [letter] Usalan C, et al. **Nephron** 1998 Oct;80(2):237–8

Beer drinker's hyponatraemia: a case report [see comments] Hettema ME, et al. **Neth J Med** 1999 Mar;54(3):105–7. Comment in: Neth J Med 1999 Mar;54(3):101–4.

Hyponatraemia. Comments on two case reports [comment] Racasan S, et al. **Neth J Med** 1999 Mar;54(3):101–4. Comment on: Neth J Med 1999 Mar;54(3):105–7. Comment on: Neth J Med 1999 Mar;54(3):108–13.

Hyponatraemia: biochemical and clinical perspectives. Gill G, et al. **Postgrad Med J** 1998 Sep;74(875):516–23

[Generalized convulsions in a patient with polydipsia and severe hyponatremia] Mølgaard O. **Ugeskr Laeger** 1999 Jul 26;161(30):4295–6 (Eng. Abstr.) **(Dan)**

[Sodium and water balance for clinical routine practice] Luft FC. **Internist (Berl)** 1998 Aug;39(8):804–9 (9 ref.) **(Ger)**

[Disorders of sodium and water balance. Diagnosis and therapy.] Rüchardt A, et al. **Internist (Berl)** 1999 Aug; 40(8):W861–71 (9 ref.) **(Ger)**

[Unusual cause of hyponatremia] Lahaye T. **Schweiz Rundsch Med Prax** 1999 Apr 22;88(17):777–9 **(Ger)**

[Hyponatremia and lung edema in endometrium ablation with rollerball ablation] Klinzing S, et al. **Zentralbl Gynakol** 1999;121(2):98–100 (Eng. Abstr.) **(Ger)**

[Hyponatremia in patients with subarachnoid hemorrhage] Ori C. **Minerva Anestesiol** 1998 May;64(5):235–8 (5 ref.) (Eng. Abstr.) **(Ita)**

[Hyponatremia and inflammation] Ohta M, et al. **Rinsho Byori** 1999 May;47(5):408–16 (Eng. Abstr.) **(Jpn)**

[Hyponatremia in the postoperative period after a neurosurgical tumor condition] Carrascosa AJ, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):40–4 (Eng. Abstr.) **(Spa)**

METABOLISM

Hyponatremia in the rat in the absence of positive water balance. Gowrishankar M, et al. **J Am Soc Nephrol** 1997 Apr;8(4):524–9

NURSING

Emergency! Hyponatremia. De Jong MJ. **Am J Nurs** 1998 Dec;98(12):36

PATHOLOGY

The role of taurine in the regulation of brain cell volume in chronically hyponatraemic rats. Law RO. **Neurochem Int** 1998 Nov;33(5):467–72

PHYSIOPATHOLOGY

Brain adaptation to acute hyponatremia in young rats. Silver SM, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1595–9

Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management. Gowrishankar M, et al. **Clin Nephrol** 1998 Dec;50(6):352–60 (60 ref.)

The role of antidiuretic hormone in hyponatremia in adrenal insufficiency––is the guideline for the diagnosis of syndrome of inappropriate secretion of the antidiuretic hormone appropriate? [editorial; comment] Demura R. **Intern Med** 1999 May;38(5):382–3. Comment on: Intern Med 1999 May;38(5):426–32.

Severe hyponatremia caused by hypothalamic adrenal insufficiency [see comments] Shibata T, et al. **Intern Med** 1999 May;38(5):426–32. Comment in: Intern Med 1999 May;38(5):382–3.

Electrical and mechanical abnormalities in the heart of a schizophrenic patient with hyponatremia derived from water intoxication. Yanagi N, et al. **J Cardiol** 1998 Sep; 32(3):197–204

Asymptomatic hyponaturemia in a patient with mild head injury due to syndrome of inappropriate diuretic hormone––a case report. Ishibashi A, et al. **Kurume Med J** 1999;46(2):123–5

[Hyponatremia: a classical approach (editorial)] Kanfer A. **Nephrologie** 1998;19(8):465–7 (12 ref.) **(Fre)**

[Hyponatremia, toward a logical approach: the balance of tonicity (published erratum appears in Nephrologie 1999;20(1):51)] Mallié JP, et al. **Nephrologie** 1998; 19(8):469–80 (44 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of acute hyponatremia by mannitol: an unanticipated mechanism. Gowrishankar M, et al. **Clin Nephrol** 1998 Nov;50(5):295–300

Preventing hyponatremic encephalopathy [letter] Brooks PG. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):446–8

Cost reduction strategies in burn nutrition services: adjustments in dietary treatment of patients with hyponatremia and hypophosphatemia. Mathews JJ, et al. **J Burn Care Rehabil** 1999 Jan–Feb;20(1 Pt 1):80–4; discussion 77–9

THERAPY

Total paracentesis in cirrhotic patients with tense ascites and dilutional hyponatremia. Vila MC, et al. **Am J Gastroenterol** 1999 Aug;94(8):2219–23

Successful treatment of severe hyponatremia in a patient with renal failure using continuous venovenous hemodialysis. Bender FH. **Am J Kidney Dis** 1998 Nov;32(5):829–31

Review of investigation and management of severe hyponatraemia in a hospital population [see comments] Crook MA, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):158–62. Comment in: Ann Clin Biochem 1999 Jul;36(Pt 4):531–2.

Review of investigation and management of severe hyponatraemia in a hospital population [letter; comment] al–Jubouri MA. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):531–2 . Comment on: Ann Clin Biochem 1999 Mar;36(Pt 2):158–62.

Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Soupart A, et al. **Clin Nephrol** 1999 Jun;51(6):383–6

Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. Ayus JC, et al. **JAMA** 1999 ' Jun 23–30; 281(24):2299–304

Hypoxia is the cause of brain damage in hyponatremia [editorial] Knochel JP. **JAMA** 1999 Jun 23–30; 281(24):2342–3

VETERINARY

Severe neurologic sequelae in a dog after treatment of hypoadrenal crisis. Brady CA, et al. **J Am Vet Med Assoc** 1999 Jul 15;215(2):222–5, 210

HYPOPARATHYROIDISM

COMPLICATIONS

Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. Kowdley KV, et al. **Am J Med Sci** 1999 May;317(5):273–7

A rapidly progressive cataract in a patient with autoimmune hypoparathyroidism and acute liver and renal failure. Haviv YS, et al. **Am J Nephrol** 1999;19(4):523–6

Idiopathic hypoparathyroidism associated with adult rheumatoid arthritis. Salvador G, et al. **Clin Rheumatol** 1999;18(4):334–6

Primary hypomagnesemia caused by isolated magnesium

malabsorption: atypical case in adult. Jin-no Y, et al. **Intern Med** 1999 Mar;38(3):261-5

Non-convulsive status epilepticus in a patient with hypocalcemia. Kline CA, et al. **J Emerg Med** 1998 Sep-Oct; 16(5):715-8

Symptomatic hypocalcaemia in hypermagnesaemia-induced hypoparathyroidism, during magnesium tocolytic therapy--possible involvement of the calcium-sensing receptor. Mayan H, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1764-6

[Case of hypothyroidism and hypoparathyroidism discovered by fainting spells] Kunisada K, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2314-5 **(Jpn)**

[Treatment of patient with burns, suffering from hypoparathyroidism] Grishchenko AV, et al. **Khirurgiia (Mosk)** 1998;(10):62-3 **(Rus)**

DIAGNOSIS

Untreated idiopathic hypoparathyroidism associated with infant congenital and perinatal abnormalities [letter] Kaneko N, et al. **Intern Med** 1999 Jan;38(1):75

Pseudohypoparathyroidism: from bedside to bench and back. Levine MA. **J Bone Miner Res** 1999 Aug;14(8):1255-60 (70 ref.)

Pregnancy unmasking hypoparathyroidism. Jabbar A, et al. **JPMA J Pak Med Assoc** 1998 Aug;48(8):250-1

[Calcinosis of the basal ganglia and hypoparathyroidism] Schäfer M, et al. **Nervenarzt** 1998 Oct;69(10):873-8 (Eng. Abstr.) **(Ger)**

[Bilateral unclear papilledema] Grasbon T, et al. **Ophthalmologe** 1998 Sep;95(9):652-3 **(Ger)**

DRUG THERAPY

A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. Winer KK, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3480-6

Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol. Boots JM, et al. **Neth J Med** 1999 Jan;54(1):16-20

ETIOLOGY

Relative hypoparathyroidism and adynamic bone disease. Mucsi I, et al. **Am J Med Sci** 1999 Jun;317(6):405-9 (44 ref.)

Hypocalcemia as a complication of radioiodine therapy. Winslow CP, et al. **Am J Otolaryngol** 1998 Nov-Dec; 19(6):401-3 (15 ref.)

Hypoparathyroidism after the treatment of laryngopharyngeal carcinoma. Mortimore S, et al. **J Laryngol Otol** 1998 Nov;112(11):1058-60

Hypoparathyroidism, intracranial calcification, and seizures 61 years after thyroid surgery. Reddy ST, et al. **Tenn Med** 1999 Sep;92(9):341-2

[Total thyroidectomy with identification of parathyroid glands. Functional implications] Giovannini C, et al. **Ann Ital Chir** 1999 May-Jun;70(3):393-6, commentary 397-8 (Eng. Abstr.) **(Ita)**

GENETICS

BsmI polymorphism of the vitamin D receptor gene in hyperparathyroid or hypoparathyroid dialysis patients. Tagliabue J, et al. **Am J Clin Pathol** 1999 Sep;112(3):366-70

Autosomal dominant familial hypoparathyroidism and sensorineural deafness without renal dysplasia. Watanabe T, et al. **Eur J Endocrinol** 1998 Dec;139(6):631-4

Localisation of X linked recessive idiopathic hypoparathyroidism to a 1.5 Mb region on Xq26-q27. Trump D, et al. **J Med Genet** 1998 Nov;35(11):905-9

METABOLISM

Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. Duan Y, et al. **J Clin Endocrinol Metab** 1999 Feb; 84(2):718-22

PREVENTION & CONTROL

New technique of parathyroidectomy to prevent parathyromatosis and hypoparathyroidism. Pérez-Ruiz L, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1553-5

SURGERY

Cultured parathyroid cells allotransplantation without immunosuppression for treatment of intractable hypoparathyroidism. Tołłoczko T, et al. **Ann Transplant** 1996;1(1):51-3

Parathyroid-thyroid transplantation without flushing or perfusion. Yuxin C, et al. **Transplant Proc** 1998 Nov; 30(7):2931-2

VETERINARY

Primary hypoparathyroidism in two horses. Hudson NP, et al. **Aust Vet J** 1999 Aug;77(8):504-8

Hypocalcemia and hyperphosphatemia due to primary hypoparathyroidism in a six-month-old kitten. Bassett JR. **J Am Anim Hosp Assoc** 1998 Nov-Dec;34(6):503-7

HYPOPHARYNGEAL NEOPLASMS

T-cell non-Hodgkin's lymphoma of the larynx and hypopharynx. Pak MW, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):335-6

CHEMISTRY

Cyclin D1 expression as a prognostic factor in advanced hypopharyngeal carcinoma. Nishimura G, et al. **J Laryngol Otol** 1998 Jun;112(6):552-5

Metalloproteinases and their inhibitors in squamous cell carcinoma of the hypopharynx: indicators of individual tumor aggressiveness. Heissenberg MC, et al. **Otolaryngol Pol** 1998;52(5):521-6

Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Bárdos H, et al. **Thromb Haemost** 1998 Nov;80(5):767-72

COMPLICATIONS

[Problematic intubation in the patient with laryngeal-hypopharyngeal carcinoma. Retrograde controlled fiber bronchoscopy technique] Bissinger U, et al. **HNO** 1998 Jul;46(7):666-71 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Atypical squamous cell carcinoma of the larynx and hypopharynx: radiologic features and pathologic correlation. Becker M, et al. **Eur Radiol** 1998;8(9):1541-51

Well-differentiated liposarcoma of the hypopharynx. Fahmy FF, et al. **J Laryngol Otol** 1998 Sep;112(9):880-2 (7 ref.)

Imaging of squamous cell carcinoma of the hypopharynx. Pameijer FA, et al. **Semin Ultrasound CT MR** 1998 Dec; 19(6):476-91 (57 ref.)

[A rare case of metastatic tumor in the neck with unknown primary focus] Jurkiewicz D, et al. **Otolaryngol Pol** 1998; 52(6):731-3 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Sequential chemotherapy and radiotherapy for organ preservation in advanced resectable nonlaryngeal head and neck cancer. Khan A, et al. **Am J Clin Oncol** 1999 Aug; 22(4):403-7

Induction chemotherapy followed by concomitant chemoradiation for cervical esophageal cancer [letter] Ampil FL, et al. **Am J Gastroenterol** 1999 Aug;94(8):2325-6

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Bensadoun RJ, et al. **Int J Radiat Oncol Biol Phys** 1998 Sep 1; 42(2):237-45

EPIDEMIOLOGY

Carcinoma of the hypopharynx: analysis of incidence and survival in Sweden over a 30-year period. Wahlberg PC, et al. **Head Neck** 1998 Dec;20(8):714-9

IMMUNOLOGY

[Dendritic cells, T- and B-lymphocytes and macrophages in supraglottic and glottic squamous epithelial carcinoma. Location and correlation with prognosis of the illness] Jecker P, et al. **HNO** 1999 May;47(5):466-71 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Franklin S, et al. **Arch Otolaryngol Head Neck Surg** 1999 Feb;125(2):177-82

Angiocentric T-cell lymphoma: an extensive lesion involving the posterior tongue, hypopharynx and supraglottis. Thorp MA, et al. **J Laryngol Otol** 1999 Mar;113(3):263-5

Upper aerodigestive tract liposarcoma: report on four cases and literature review. Mandell DL, et al. **Laryngoscope** 1999 Aug;109(8):1245-52 (28 ref.)

[The clinical and pathological features of the hypopharyngeal lipomas] Gao Z, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Feb; 19(1):78-80 (Eng. Abstr.) **(Chi)**

[Squamous epithelial carcinoma-associated necrolytic migratory erythema] Möhrenschlager M, et al. **Hautarzt** 1999 Mar;50(3):198-202 (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Quiz case 1. Cavernous hemangioma of the hypopharynx. Thorp MA, et al. **Arch Otolaryngol Head Neck Surg** 1999 Sep;125(9):1036, 1038

RADIONUCLIDE IMAGING

The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Stokkel MP, et al. **Eur J Nucl Med** 1999 Jul;26(7):767-73

RADIOTHERAPY

Sequential chemotherapy and radiotherapy for organ preservation in advanced resectable nonlaryngeal head and neck cancer. Khan A, et al. **Am J Clin Oncol** 1999 Aug; 22(4):403-7

Radical radiotherapy for squamous cell carcinoma of the larynx, oropharynx and hypopharynx: patterns of recurrence, treatment and survival. Jones AS, et al. **Clin Otolaryngol** 1998 Dec;23(6):496-511

Parathyroid and thyroid function five years after treatment of laryngeal and hypopharyngeal carcinoma. Thorp MA, et al. **Clin Otolaryngol** 1999 Apr;24(2):104-8

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Bensadoun RJ, et al. **Int J Radiat Oncol Biol Phys** 1998 Sep 1; 42(2):237-45

[New knowledge about late sequelae of radiochemotherapy (comment)] Budach W. **HNO** 1998 Aug;46(8):708-11. Comment on: HNO 1998 Aug;46(8):731-8. **(Ger)**

SECONDARY

[A rare case of metastatic tumor in the neck with unknown primary focus] Jurkiewicz D, et al. **Otolaryngol Pol** 1998; 52(6):731-3 (Eng. Abstr.) **(Pol)**

SECRETION

Minimally invasive surgery for recurrent neuroendocrine carcinoma of the supraglottic larynx. Machens A, et al. **Eur Arch Otorhinolaryngol** 1999;256(5):242-6

SURGERY

Parathyroid and thyroid function five years after treatment of laryngeal and hypopharyngeal carcinoma. Thorp MA, et al. **Clin Otolaryngol** 1999 Apr;24(2):104-8

Carotid artery resection and reconstruction in patients with squamous cell carcinomas of the neck. Iván L, et al. **Eur Arch Otorhinolaryngol** 1999;256(3):145-7

Minimally invasive surgery for recurrent neuroendocrine carcinoma of the supraglottic larynx. Machens A, et al. **Eur Arch Otorhinolaryngol** 1999;256(5):242-6

Free-flap reconstruction for laryngeal preservation after partial laryngectomy in patients with extended tumors of the oropharynx and hypopharynx. Schwager K, et al. **Eur Arch Otorhinolaryngol** 1999;256(6):280-2

Primary placement of a voice prosthesis on transposed colon after total pharyngolaryngoesophagectomy. Parise O Jr, et al. **Head Neck** 1999 Jul;21(4):363-5

Reconstructive techniques currently used following resection of hypopharyngeal carcinoma. Ayshford CA, et al. **J Laryngol Otol** 1999 Feb;113(2):145-8

A third decade's experience with the gastric pull-up operation for hypopharyngeal carcinoma: changing patterns of use. Hartley BE, et al. **J Laryngol Otol** 1999 Mar;113(3):241-3

Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma. Wilson LD, et al. **Laryngoscope** 1998 Oct;108(10):1504-8

Prefabricated free jejunal transfer: a new reconstructive technique for high pharyngeal defects. Nakatsuka T, et al. **Plast Reconstr Surg** 1999 Feb;103(2):458-64

Head and neck cancer implantation at the percutaneous endoscopic gastrostomy exit site. A case report and a review. Potochny JD, et al. **Surg Endosc** 1998 Nov; 12(11):1361-5

Free jejunal graft autotransplantation should be revascularized within 3 hours. Hikida S, et al. **Transplant Proc** 1998 Nov;30(7):3446-8

[Reconstruction of the hypopharyngeal and cervical esophagus using flap of epiglottis] Hong Y, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Oct; 11(10):446-8 (Eng. Abstr.) **(Chi)**

[The usage of allograft nasal septal cartilage in partial laryngectomy] Huang Z, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Oct; 11(10):449-50 (Eng. Abstr.) **(Chi)**

[U-shaped free jejunum transplant] Germain MA, et al. **Ann Chir** 1998;52(10):978-82 (Eng. Abstr.) **(Fre)**

[Pathological deglutition pattern after tumor surgery of the oro- and hypopharynx. Analysis by differentiated deglutition] Oursin C, et al. **HNO** 1999 Mar;47(3):167-71 (Eng. Abstr.) **(Ger)**

[Resection and replacement of the cervical esophagus and hypopharynx--an interdisciplinary responsibility for visceral, micro- and ENT surgeons] Kiene J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1505-8 (Eng. Abstr.) **(Ger)**

[Invasive carcinomas of the hypopharynx with esophageal involvement--multidisciplinary treatment concept] Schilling MK, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1499-501 (Eng. Abstr.) **(Ger)**

[The Janeway laparoscopic gastrostomy in palliative surgery] Strauss T, et al. **Zentralbl Chir** 1998;123(10):1160-3 (Eng. Abstr.) **(Ger)**

[Delto-pectoral flap in reconstruction of esophagus after laryngectomy] Jurkiewicz D, et al. **Otolaryngol Pol** 1997; 51 Suppl 25:57-9 (Eng. Abstr.) **(Pol)**

[Surgical treatment of hypopharyngeal cancer: reconstructive methods] Ziętek E, et al. **Otolaryngol Pol** 1998;52(3):251-7 (Eng. Abstr.) **(Pol)**

[Supraglottic laryngectomy: 3-year and 5-year results] Herranz González-Botas J, et al.

HYPOPHARYNGEAL NEOPLASMS

Acta Otorrinolaringol Esp 1999 May;50(4):269–75 (Eng. Abstr.) **(Spa)**

THERAPY

Cytotoxic and anti-proliferative effects of high-energy pulsed ultrasound (HEPUS) on human squamous cell carcinoma cells as compared to connective tissue fibroblasts. Iro H, et al. **Eur Arch Otorhinolaryngol** 1998; 255(8):420–6

Effectiveness of RF capacitive hyperthermia combined with radiotherapy for stages III and IV oro-hypopharyngeal cancers: a non-randomized comparison between thermoradiotherapy and radiotherapy. Hiraki Y, et al. **Int J Hyperthermia** 1998 Sep–Oct;14(5):445–57

Hypoparathyroidism after the treatment of laryngopharyngeal carcinoma. Mortimore S, et al. **J Laryngol Otol** 1998 Nov;112(11):1058–60

[Interdisciplinary multi-modality therapy of advanced hypopharyngeal and proximal esophageal carcinomas] Fass J, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1502–4 (Eng. Abstr.) **(Ger)**

[Carcinoma of the hypopharynx and esophagus] Marzetti F. **Acta Otorhinolaryngol Ital** 1998 Jun;18(3):133–4 **(Ita)**

[Clinical study of hypopharyngeal carcinoma] Asakura K, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Oct; 101(10):1276–82 (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Cytotoxic and anti-proliferative effects of high-energy pulsed ultrasound (HEPUS) on human squamous cell carcinoma cells as compared to connective tissue fibroblasts. Iro H, et al. **Eur Arch Otorhinolaryngol** 1998; 255(8):420–6

VIROLOGY

Expression of Epstein-Barr virus in mesopharyngeal and hypopharyngeal carcinomas [see comments] Shimakage M, et al. **Hum Pathol** 1999 Sep;30(9):1071–6. Comment in: Hum Pathol 1999 Sep;30(9):1001–3.

HYPOPHARYNX

Complication of Bullard laryngoscope: dislodgment of blade-extender resulting in an upper airway foreign body [letter] Marshall KA. **Anesthesiology** 1998 Dec;89(6):1604–5

Synovial sarcoma of the larynx and hypopharynx [clinical conference] Dei Tos AP, et al. **Ann Otol Rhinol Laryngol** 1998 Dec;107(12):1080–5

Life threatening airway obstruction: a hazard of concealed eating disorders. Jones TM, et al. **J Accid Emerg Med** 1998 Sep;15(5):332–3

CHEMISTRY

[24 hour pH monitoring of the hypopharymx] Schlottmann A, et al. **HNO** 1999 Feb;47(2):112–6 (Eng. Abstr.) **(Ger)**

INJURIES

Transection of the base of the tongue caused by penetrating injury. Steinig JP, et al. **Am Surg** 1999 Feb;65(2):133–4

Duodenal obstruction secondary to bay leaf impaction [letter] Tsang TK, et al. **Ann Intern Med** 1999 Apr 20;130(8):701–2

Hypopharyngeal perforation after blunt neck trauma: case report and review of the literature. Jacobs I, et al. **J Trauma** 1999 May;46(5):957–8 (4 ref.)

Intraoral blunt carotid injury in an adult: case report and review of the literature. Mikulaschek A, et al. **J Trauma** 1999 Jul;47(1):179–82 (43 ref.)

Neonatal pharyngeal pseudodiverticulum mimicking esophageal atresia. Cason DL, et al. **South Med J** 1998 Dec;91(12):1163–6 (17 ref.)

INNERVATION

Recurrent and superior laryngeal nerves: a new look with implications for the esophageal surgeon. Liebermann-Meffert DM, et al. **Ann Thorac Surg** 1999 Jan; 67(1):217–23

PATHOLOGY

Synovial sarcoma of the larynx and hypopharynx [clinical conference] Dei Tos AP, et al. **Ann Otol Rhinol Laryngol** 1998 Dec;107(12):1080–5

Enhanced regeneration response of laryngeal and hypopharyngeal mucosa with accelerated hyperfractionated radiation therapy for glottic cancers. Mariya Y, et al. **Radiat Med** 1998 Nov–Dec;16(6):469–72

A case of pleomorphic lipoma of the hypopharynx. Arista-Nasr J, et al. **Rev Invest Clin** 1998 May–Jun; 50(3):259–61

PHYSIOLOGY

Laryngopharyngeal sensory discrimination testing and the laryngeal adductor reflex. Aviv JE, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):725–30

PHYSIOPATHOLOGY

First results on daytime submandibular electrostimulation of suprahyoidal muscles to prevent night-time hypopharyngeal collapse in obstructive sleep apnea syndrome. Wiltfang J, et al. **Int J Oral Maxillofac Surg** 1999 Feb;28(1):21–5

RADIOGRAPHY

Utility of radiographs in the evaluation of pediatric upper airway obstruction. Walner DL, et al. **Ann Otol Rhinol Laryngol** 1999 Apr;108(4):378–83

[Swallowed tools] Reiss M, et al. **HNO** 1998 Nov; 46(11):942–3 **(Ger)**

SURGERY

Surgical management of the hypopharyngeal airway in sleep disordered breathing. Troell RJ, et al. **Otolaryngol Clin North Am** 1998 Dec;31(6):979–1012 (55 ref.)

Galeal pedicle flap of the occipital region for pharynx reconstruction: anatomic and clinical considerations. de Magalhães RP, et al. **Plast Reconstr Surg** 1998 Nov; 102(6):2124–8

One-stage reconstruction of defects in the hypopharyngeal region with free flaps. Ninković M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1999 Mar; 33(1):31–9

[Reconstruction of the hypopharyngeal and cervical esophagus using flap of epiglottis] Hong Y, et al. **Lin Chuang Erh Pi Yen Hou Ko Tsa Chih** 1997 Oct; 11(10):446–8 (Eng. Abstr.) **(Chi)**

HYPOPHOSPHATASIA

COMPLICATIONS

Molecular diagnosis of hypophosphatasia with severe periodontitis. Watanabe H, et al. **J Periodontol** 1999 Jun; 70(6):688–91

ENZYMOLOGY

Characterization of eleven novel mutations (M45L, R119H, 544delG, G145V, H154Y, C184Y, D289V, 862+5A, 1172delC, R411X, E459K) in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in patients with severe hypophosphatasia. Mutations in brief no. 217. Online. Taillandier A, et al. **Hum Mutat** 1999;13(2):171–2

GENETICS

Correlations of genotype and phenotype in hypophosphatasia. Zurutuza L, et al. **Hum Mol Genet** 1999 Jun;8(6):1039–46

Hypophosphatasia: identification of five novel missense mutations (G507A, G705A, A748G, T1155C, G1320A) in the tissue-nonspecific alkaline phosphatase gene among Japanese patients. Goseki-Sone M, et al. **Hum Mutat** 1998; Suppl 1:S263–7

Characterization of eleven novel mutations (M45L, R119H, 544delG, G145V, H154Y, C184Y, D289V, 862+5A, 1172delC, R411X, E459K) in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in patients with severe hypophosphatasia. Mutations in brief no. 217. Online. Taillandier A, et al. **Hum Mutat** 1999;13(2):171–2

Expression of the mutant (1735T-DEL) tissue-nonspecific alkaline phosphatase gene from hypophosphatasia patients. Goseki-Sone M, et al. **J Bone Miner Res** 1998 Dec; 13(12):1827–34

Analysis of localization of mutated tissue-nonspecific alkaline phosphatase proteins associated with neonatal hypophosphatasia using green fluorescent protein chimeras. Cai G, et al. **J Clin Endocrinol Metab** 1998 Nov; 83(11):3936–42

METABOLISM

Red-cell thiamine pyrophosphate levels in hypophosphatasia. Iqbal SJ, et al. **J Inherit Metab Dis** 1999 Feb;22(1):95–6

PATHOLOGY

Lethal hypophosphatasia, spur type: case report and fetopathological study. Vandevijver N, et al. **Genet Couns** 1998;9(3):205–9

HYPOPHOSPHATEMIA

[Regulation of phosphatemia and hypophosphatemia] Essig M, et al. **Rev Prat** 1998 Jun 1;48(11):1218–25 (13 ref.) (Eng. Abstr.) **(Fre)**

[Severe hypophosphatemia--an overlooked condition?] Haukeland JW, et al. **Tidsskr Nor Laegeforen** 1999 Feb 10;119(4):538–40 (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Severe hypophosphataemia in paracetamol-induced oliguric renal failure. Eckardt KU, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):2013–4

COMPLICATIONS

Hypokalemic periodic paralysis associated with hypophosphatemia in a patient with hyperinsulinemia. Ogawa T, et al. **Am J Med Sci** 1999 Jul;318(1):69–72

Rickets and secondary craniosynostosis associated with long-term antacid use in an infant [letter] [see comments] Shetty AK, et al. **Arch Pediatr Adolesc Med** 1998 Dec; 152(12):1243–5 (19 ref.). Comment in: Arch Pediatr Adolesc Med 1998 Dec;152(12):1168–9.

Disturbance of consciousness associated with hypophosphatemia in a chronically alcoholic patient [see comments] Funabiki Y, et al. **Intern Med** 1998 Nov; 37(11):958–61. Comment in: Intern Med 1998 Nov;37(11):911–2.

Severe hypophosphatemia in children with kwashiorkor is associated with increased mortality [see comments] Manary MJ, et al. **J Pediatr** 1998 Dec;133(6):789–91. Comment in: J Pediatr 1998 Dec;133(6):722–4.

Severe muscle weakness secondary to paraneoplastic hypophosphatemia in neuroblastoma. Kats S, et al. **Neth J Med** 1998 Nov;53(5):207–11

Chronic fatigue syndrome [letter; comment] Baschetti R. **Postgrad Med J** 1998 Nov;74(877):701. Comment on: Postgrad Med J 1998 Apr;74(870):229–32.

CONGENITAL see HYPOPHOSPHATEMIA, FAMILIAL

DIAGNOSIS

Hypophosphatemia as atypical panic disorder: a case study. Kligler B. **J Am Board Fam Pract** 1999 Jan–Feb;12(1):65–7

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Urologe A** 1999 May;38(3):285–95 (6 ref.) **(Ger)**

DRUG THERAPY

Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Bugg NC, et al. **Anaesthesia** 1998 Sep;53(9):895–902 (64 ref.)

Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets. Kruse K, et al. **Eur J Pediatr** 1998 Nov;157(11):894–900

Growth and bone mineral density in a child with X-linked hypophosphatemic rickets: early response to treatment. Sugiyama T, et al. **J Bone Miner Metab** 1999;17(2):137–40

A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. Econs MJ, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3459–62

EPIDEMIOLOGY

Hypophosphataemia in general practice patients. Guy JM, et al. **Ann Clin Biochem** 1999 Jan;36 (Pt 1):37–42

High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. Håglin L, et al. **J Intern Med** 1999 Jul;246(1):45–52

ETIOLOGY

Polyclonal hyperglobulinemia and spurious hypophosphatemia [letter] Malhotra A, et al. **Ann Intern Med** 1999 Aug 17;131(4):314

Hemodialysis-induced hypophosphatemia in a normophosphatemic patient dialyzed for ethylene glycol poisoning: treatment with phosphorus-enriched hemodialysis. Chow MT, et al. **Artif Organs** 1998 Oct; 22(10):905–7

Hypophosphatemia and encephalopathy in alcoholics [editorial; comment] Nagata N. **Intern Med** 1998 Nov; 37(11):911–2. Comment on: Intern Med 1998 Nov;37(11):958–61.

Hypophosphatemia in patients with chronic renal failure during total parenteral nutrition [letter; comment] Druml W, et al. **JPEN J Parenter Enteral Nutr** 1999 Jan–Feb; 23(1):45–6. Comment on: JPEN J Parenter Enteral Nutr 1998 Mar–Apr;22(2):102–4.

Magnesium and phosphorus [letter; comment] Davenport A. **Lancet** 1998 Oct 31;352(9138):1475–6. Comment on: Lancet 1998 Aug 1;352(9125):391–6.

Eating disorders [letter] Bravender T. **N Engl J Med** 1999 Aug 19;341(8):615–6

[Disorders of calcium and phosphate homeostasis] Fliser D, et al. **Internist (Berl)** 1998 Aug;39(8):825–30 (6 ref.) **(Ger)**

GENETICS

Familial adult onset X-linked hypophosphataemic osteomalacia (report of a family; clinical and experimental studies). Radó JP, et al. **Acta Physiol Hung** 1997–98; 85(3):199–214

1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Ecarot B, et al. **Endocrinology** 1999 Mar;140(3):1192–9

Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Mornet E, et al. **Eur J Hum Genet** 1998 Jul–Aug;6(4):308–14

Mutational analysis of PHEX gene in X-linked hypophosphatemia. Dixon PH, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3615–23

A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. Econs MJ, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3459–62

Evidence for Phex haploinsufficiency in murine X-linked hypophosphatemia. Wang L, et al. **Mamm Genome** 1999 Apr;10(4):385–9

Isoproterenol increases renal tubular reabsorption of phosphate in X-linked hypophosphatemic (Hyp) mice. Thornton LR, et al. **Miner Electrolyte Metab** 1999 May-Jun;25(3):204-9
X-linked hypophosphataemia: a homologous disorder in humans and mice. Tenenhouse HS. **Nephrol Dial Transplant** 1999 Feb;14(2):333-41 (88 ref.)
PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Blydt-Hansen TD, et al. **Pediatr Nephrol** 1999 Sep; 13(7):607-11

METABOLISM

Bone metabolism and bone mineral density in childhood hypophosphatasia. Girschick HJ, et al. **Bone** 1999 Sep; 25(3):361-7
Protein-RNA interactions determine the stability of the renal NaPi-2 cotransporter mRNA and its translation in hypophosphatemic rats. Moz Y, et al. **J Biol Chem** 1999 Sep 3;274(36):25266-72
PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Blydt-Hansen TD, et al. **Pediatr Nephrol** 1999 Sep; 13(7):607-11

MICROBIOLOGY

High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. Håglin L, et al. **J Intern Med** 1999 Jul;246(1):45-52

MORTALITY

Severe hypophosphatemia in children with kwashiorkor is associated with increased mortality [see comments] Manary MJ, et al. **J Pediatr** 1998 Dec;133(6):789-91. Comment in: J Pediatr 1998 Dec;133(6):722-4.

PHYSIOPATHOLOGY

Severe hypophosphataemia and insulin resistance in diabetic ketoacidosis [letter] Ravenscroft AJ, et al. **Anaesthesia** 1999 Feb;54(2):198

PREVENTION & CONTROL

Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis. Emelife-Obi C, et al. **Clin Nephrol** 1998 Aug; 50(2):131-3
Cost reduction strategies in burn nutrition services: adjustments in dietary treatment of patients with hyponatremia and hypophosphatemia. Mathews JJ, et al. **J Burn Care Rehabil** 1999 Jan-Feb;20(1 Pt 1):80-4; discussion 77-9

THERAPY

Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Yu AW, et al. **Artif Organs** 1992 Aug;16(4):414-6

HYPOPHOSPHATEMIA, FAMILIAL

The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Malloy PJ, et al. **Endocr Rev** 1999 Apr;20(2):156-88 (273 ref.)

COMPLICATIONS

[Growth hormone treatment of familial hypophosphatemic rickets] Saggese G, et al. **Arch Pediatr** 1998;5 Suppl 4:360S-363S (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Epidermal naevus syndrome and hypophosphataemic rickets: description of a patient with central nervous system anomalies and review of the literature. Olivares JL, et al. **Eur J Pediatr** 1999 Feb;158(2):103-7 (19 ref.)
[Farmer with osteomalacia?] Schlumpf U, et al. **Schweiz Med Wochenschr** 1998 Aug 22;128(34):1267 **(Ger)**

DRUG THERAPY

A trial of growth hormone therapy in well-controlled hypophosphataemic rickets. Cameron FJ, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):577-82
Growth hormone and bone diseases. Tanaka H. **Endocr J** 1998 Apr;45 Suppl:S47-52 (8 ref.)
High-dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia. Haris A, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):431-4

EPIDEMIOLOGY

Impact of demographic distribution and population growth rate on haplotypic diversity linked to a disease gene and their consequences for the estimation of recombination rate: example of a French Canadian population. Austerlitz F, et al. **Genet Epidemiol** 1999;16(1):2-14

GENETICS

New insights into the pathogenesis of inherited phosphate wasting disorders. Econs MJ. **Bone** 1999 Jul;25(1):131-5 (59 ref.)
The role of the PHEX gene (PEX) in families with X-linked hypophosphataemic rickets. Rowe PS. **Curr Opin Nephrol Hypertens** 1998 Jul;7(4):367-76 (108 ref.)
Impact of demographic distribution and population growth rate on haplotypic diversity linked to a disease gene and their consequences for the estimation of recombination rate: example of a French Canadian population. Austerlitz F, et al. **Genet Epidemiol** 1999;16(1):2-14
Genetic screening for X-linked hypophosphatemic mice and ontogenic characterization of the defect in the renal sodium-phosphate transporter. Muller YL, et al. **Pediatr Res** 1998 Nov;44(5):633-8
[Vitamin D-resistant rickets (editorial)] Dumas R. **Arch Pediatr** 1999 Jul;6(7):715-9 (15 ref.) **(Fre)**

METABOLISM

[Vitamin D-resistant rickets (editorial)] Dumas R. **Arch Pediatr** 1999 Jul;6(7):715-9 (15 ref.) **(Fre)**

PATHOLOGY

Hypophosphatemic rickets accompanying congenital microvillous atrophy. Kagitani K, et al. **J Bone Miner Res** 1998 Dec;13(12):1946-52

THERAPY

The effect of osteotomy on bowing and height in children with X-linked hypophosphatemia. Rohmiller MT, et al. **J Pediatr Orthop** 1999 Jan-Feb;19(1):114-8

HYPOPHOSPHOROUS ACIDS see **PHOSPHINIC ACIDS**

HYPOPHYSECTOMY

see related
PITUITARY IRRADIATION

Effect of pituitary microsurgery on acromegaly complicated nephrotic syndrome with focal segmental glomerulosclerosis: report of a rare clinical case. Yoshida H, et al. **Am J Kidney Dis** 1999 Jun;33(6):1158-63
Effect of hypophysectomy on the proliferation and differentiation of rat bone marrow stromal cells. Yeh JK, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):E34-42
Sevoflurane increases lumbar cerebrospinal fluid pressure in normocapnic patients undergoing transsphenoidal hypophysectomy. Talke P, et al. **Anesthesiology** 1999 Jul; 91(1):127-30
Long-term growth after hypophyseal stalk transection and hypophysectomy of beef calves. Anderson LL, et al. **Endocrinology** 1999 May;140(5):2405-14
Effects of prolactin and growth hormone on plasma immunoglobulin M levels of hypophysectomized rainbow trout, Oncorhynchus mykiss. Yada T, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):46-52
Inhibitory effect of plasma obtained from hypophysectomized and control women on the assay of bioactive luteinizing hormone. Galeraud-Denis I, et al. **Hum Reprod** 1999 Feb; 14(2):312-7
Failure of IGF-I infusion to promote growth in Zn deficient hypophysectomized rats. Cha MC, et al. **J Trace Elem Med Biol** 1998 Nov;12(3):141-7
Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Abe T, et al. **Neurosurgery** 1999 Jul;45(1):1-10
Hypophysectomy, high tumor necrosis factor levels, and hemoglobinemia in lethal endotoxemic shock. Bloom O, et al. **Shock** 1998 Dec;10(6):395-400
Neuromyotonia of the abducens nerve after hypophysectomy and radiation. Bacskulin A, et al. **Strabismus** 1999 Mar; 7(1):37-40

ADVERSE EFFECTS

Delayed visual deterioration after surgery for pituitary adenoma. Czech T, et al. **Acta Neurochir (Wien)** 1999; 141(1):45-51
Subcutaneous sarcoidosis following hypophysectomy for pituitary microadenoma inducing Cushing's disease [letter] Marzano AV, et al. **Int J Dermatol** 1998 Oct;37(10):798

INSTRUMENTATION

Endoscopic transseptal transsphenoidal hypophysectomy with three-dimensional intraoperative localization technology. Moses RL, et al. **Laryngoscope** 1999 Mar; 109(3):509-12
[Transnasal microsurgery using a micro-pressure-suction-irrigation system for pituitary adenomas] Abe T, et al. **No Shinkei Geka** 1999 Mar; 27(3):225-31 (Eng. Abstr.) **(Jpn)**

METHODS

A combined, minimally invasive transnasal approach to the sella turcica. Nasseri SS, et al. **Am J Rhinol** 1998 Nov-Dec; 12(6):409-16
Endoscopic pituitary surgery: an in vivo model for transnasal transsphenoidal hypophysectomy. Jarrahy R, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):211-9
Transnasal transsphenoidal hypophysectomy: choice of approach for the otolaryngologist. Dew LA, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):824-7
[Endonasal sequelae after hypophysectomy] Soldati D, et al. **Ann Otolaryngol Chir Cervicofac** 1998 May;115(2):49-53 (Eng. Abstr.) **(Fre)**
[Unilateral endonasal approach to hypophyseal adenomas] Guarnieri J, et al. **Neurochirurgie** 1998 Dec;44(5):312-5 (Eng. Abstr.) **(Fre)**
[Use of endoscopy in pituitary surgery] Hazan A, et al. **Neurochirurgie** 1998 Dec;44(5):327-30 (Eng. Abstr.) **(Fre)**
[Transnasal microsurgery using a micro-pressure-suction-irrigation system for pituitary adenomas] Abe T, et al. **No Shinkei Geka** 1999 Mar; 27(3):225-31 (Eng. Abstr.) **(Jpn)**
[Visual acuity outcome and recurrence in large or huge pituitary adenomas operated with transcranial approach: comparison between frontotemporal and interhemispheric approaches] Kurokawa Y, et al. **No Shinkei Geka** 1998 Sep; 26(9):813-21 (Eng. Abstr.) **(Jpn)**
[Extradural temporopolar approach for giant pituitary adenomas invading the cavernous sinus and parasellar regions] Tamiya T, et al. **No Shinkei Geka** 1998 Sep; 26(9):803-11 (Eng. Abstr.) **(Jpn)**

HYPOPHYSIS see **PITUITARY GLAND**

HYPOPIGMENTATION

CHEMICALLY INDUCED

Hypopigmentation along subcutaneous veins following intrakeloid triamcinolone injection: a case report and review of literature. Kumar P, et al. **Burns** 1998 Aug; 24(5):487-8 (11 ref.)
Linear lymphatic hypopigmentation after intralesional corticosteroid injection: report of two cases. George WM. **Cutis** 1999 Jul;64(1):61-4
Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata. Nasca MR, et al. **Eur J Dermatol** 1998 Mar;8(2):125-6
Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction. English JC 3rd, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):801-3
Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. Roehm PC, et al. **J Neuroophthalmol** 1999 Mar;19(1):7-9

COMPLICATIONS

Bilateral iris sector heterochromia with or without Hirschsprung's disease [letter] Lai JS, et al. **Eye** 1998;12 (Pt 6):1024-7
Localized hypopigmented mycosis fungoides in a 12-year-old caucasian boy. Grunwald MH, et al. **J Dermatol** 1999 Jan;26(1):70-1
[Granulomatous skin lesions in Griscelli disease] Eyer D, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):727-8 **(Fre)**

CONGENITAL

CHILD syndrome with linear eruptions, hypopigmented bands, and verruciform xanthoma. Hashimoto K, et al. **Pediatr Dermatol** 1998 Sep-Oct;15(5):360-6

DRUG THERAPY

Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Pagnoni A, et al. **Acta Derm Venereol** 1999 Jul;79(4):305-10

ETIOLOGY

Acyclovir can abort rejection of punch grafts in herpes-simplex-induced lip leucoderma [letter] Malakar S, et al. **Dermatology** 1999;199(1):75
Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Nagasaki Y, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):465-73
Hypopigmented mycosis fungoides associated with human T cell lymphotropic virus type I tax in a pediatric patient. Zucker-Franklin D, et al. **Pediatrics** 1999 May;103(5 Pt 1):1039-45

GENETICS

The Sox10(Dom) mouse: modeling the genetic variation of Waardenburg-Shah (WS4) syndrome. Southard-Smith EM, et al. **Genome Res** 1999 Mar;9(3):215-25
The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. Feng L, et al. **Hum Mol Genet** 1999 Feb; 8(2):323-30

PARASITOLOGY

Independent evaluation of onchocerciasis rapid assessment methods in Benue State, Nigeria. Whitworth JA, et al. **Trop Med Int Health** 1999 Jan;4(1):26-30

PATHOLOGY

Nevus anemicus. Ahkami RN, et al. **Dermatology** 1999; 198(4):327-9 (28 ref.)
Nevus depigmentosus and inflammatory linear epidermal

HYPOPIGMENTATION

nevus--an unusual combination with a note on histology. Ogunbiyi AO, et al. **Int J Dermatol** 1998 Aug;37(8):600–2
Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. Lee HS, et al. **J Am Acad Dermatol** 1999 Jan;40(1):21–6
Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. Wallace ML, et al. **J Cutan Pathol** 1998 Aug;25(7):375–9
Congenital poikiloderma with unusual hypopigmentation and acral blistering at birth. Ogunbiyi AO, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):54–8 (11 ref.)
Skin patches heralding relapse in a treated case of neuritic leprosy [letter] Singh G, et al. **Lepr Rev** 1998 Dec; 69(4):400–1
Independent evaluation of onchocerciasis rapid assessment methods in Benue State, Nigeria. Whitworth JA, et al. **Trop Med Int Health** 1999 Jan;4(1):26–30

PHYSIOPATHOLOGY

Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. Wallace ML, et al. **J Cutan Pathol** 1998 Aug;25(7):375–9

THERAPY

Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Nagasaki Y, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):465–73

HYPOPITUITARISM

Sheehan's syndrome in Saudi Arabia. Banzal S, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):181–2
A 30-year-old man with hypopituitarism. Wolfert A, et al. **Tenn Med** 1999 Mar;92(3):98–9

BLOOD

Hypokalaemia during insulin-induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency. Davies JS, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):217–20
Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults. Nørrelund H, et al. **Growth Horm IGF Res** 1999 Feb;9(1):52–60

COMPLICATIONS

Complete heart block caused by primary Sjögren's syndrome and hypopituitarism [letter] Baumgart DC, et al. **Ann Rheum Dis** 1998 Oct;57(10):635
Lymphocytic hypophysitis associated with dacryoadenitis: an autoimmunologically mediated syndrome. Joussen AM, et al. **Arch Ophthalmol** 1999 Jul;117(7):959–62
Cardiovascular disease and risk factors in adults with hypopituitarism. Beshyah SA, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):1–15 (145 ref.)
Cardiovascular mortality among pituitary insufficient patients [letter; comment] Erfurth EM, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):271–2. Comment on: Clin Endocrinol (Oxf) 1997 Jan;46(1):75–81. Comment on: Clin Endocrinol (Oxf) 1998 Apr;48(4):525–6.
A case of autoimmune hypophysitis associated with asymptomatic primary biliary cirrhosis. Nishiki M, et al. **Endocr J** 1998 Oct;45(5):697–700
Psychosis associated with hypopituitarism. Leo RJ, et al. **Gen Hosp Psychiatry** 1998 Jul;20(4):248–54
High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Erfurth EM, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:21–4
Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment. Pfeifer M, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:25–30
Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes insipidus and hyperthyroidism. Wada S, et al. **Intern Med** 1999 Jun; 38(6):486–90
Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. Colao A, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1919–24
Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism. Cordido F, et al. **J Clin Endocrinol Metab** 1998 Dec;83(12):4350–4
Concurrent central diabetes insipidus and panhypopituitarism in a German shepherd dog. Ramsey IK, et al. **J Small Anim Pract** 1999 Jun;40(6):271–4
[Anesthetic management of a child with Lenz dysplasia associated with panhypopituitarism] Oobayashi C, et al. **Masui** 1998 Sep;47(9):1118–21 (Eng. Abstr.) **(Jpn)**

CONGENITAL

Behçet's disease with gastrointestinal involvement associated with myelodysplasia in a patient with congenital panhypopituitarism. Della Rossa A, et al. **Clin Rheumatol** 1998;17(6):515–7
A case of congenital hypopituitarism: difficulty in the diagnosis of ACTH deficiency due to high serum cortisol levels from a hypothyroid state. Nanao K, et al. **Endocr J** 1999 Feb;46(1):183–6
Pituitary dysfunction, morbidity and mortality with congenital midline malformation of the cerebrum. Cameron FJ, et al. **Eur J Pediatr** 1999 Feb;158(2):97–102
Aplasia of right internal carotid artery and hypopituitarism. Kjellin IB, et al. **Pediatr Radiol** 1999 Aug;29(8):586–8; discussion 585
[Neuro-MR-findings in primary panhypopituitarism] Fellner F, et al. **Rontgenpraxis** 1998;51(7):243–7 (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Evaluation of the pituitary gland in idiopathic hypogonadotropic hypogonadism. Jayasundar R, et al. **Acta Radiol** 1999 Jan;40(1):88–94
MR findings in growth hormone deficiency: correlation with severity of hypopituitarism. Kornreich L, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1495–9
Optic nerve hypoplasia with isolated tortuosity of the retinal veins: a marker of endocrinopathy. Hellström A, et al. **Arch Ophthalmol** 1999 Jul;117(7):880–4
A case of congenital hypopituitarism: difficulty in the diagnosis of ACTH deficiency due to high serum cortisol levels from a hypothyroid state. Nanao K, et al. **Endocr J** 1999 Feb;46(1):183–6
Evolution of childhood central diabetes insipidus into panhypopituitarism with a large hypothalamic mass: is 'lymphocytic infundibuloneurohypophysitis' in children a different entity? Maghnie M, et al. **Eur J Endocrinol** 1998 Dec;139(6):635–40
Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency. Van den Broeck J, et al. **Horm Res** 1999;51(1):1–9 (74 ref.)
Hypertrophic cranial pachymeningitis and lymphocytic hypophysitis in Sjögren's syndrome. Li JY, et al. **Neurology** 1999 Jan 15;52(2):420–3
[Headache, general malaise and left-side ptosis] Kissling S, et al. **Schweiz Rundsch Med Prax** 1998 Aug 26; 87(35):1109–12 (Eng. Abstr.) **(Ger)**
[The empty sella turcica syndrome associated with hypopituitarism (letter)] Barrios Fayula JL, et al. **An Med Interna** 1999 Feb;16(2):108–9 **(Spa)**

DRUG THERAPY

How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Chrisoulidou A, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):261–79 (52 ref.)
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Abs R, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):703–13
High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Erfurth EM, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:21–4
Effects of recombinant human growth hormone on height and skeletal maturation in growth hormone-deficient children with and without severe pretreatment bone age delay. Frindik JP, et al. **Horm Res** 1999;51(1):15–9
Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. Drake WM, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3913–9
Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults. Johnston DG, et al. **J Endocrinol Invest** 1999;22(5 Suppl):37–40 (19 ref.)
Two hot topics in the field of GH therapy: quality of life in hypopituitary adults, and clinical implications of the somatopause. Report from an interactive discussion. Jørgensen JO. **J Endocrinol Invest** 1999;22(5 Suppl):150–6 (26 ref.)
Effect of low-dosage recombinant human growth hormone therapy on pulmonary function in hypopituitary patients with adult-onset growth hormone deficiency. Meineri I, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):423–7
Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Bengtsson BA, et al. **Lancet** 1999 Jun 5;353(9168):1898–9
Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Hayes FJ, et al. **Metabolism** 1999 Mar;48(3):308–13
Treatment of hypopituitarism in infancy. Effect on head circumference growth. Di Maio S, et al. **Minerva Pediatr** 1999 Apr;51(4):89–92

ENZYMOLOGY

Sexual dimorphism in 11 beta hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects [see comments] Weaver JU, et al. **Clin Endocrinol (Oxf)** 1998 Jul; 49(1):13–20. Comment in: Clin Endocrinol (Oxf) 1998 Jul;49(1):9–10.

ETIOLOGY

Optic nerve hypoplasia with posterior pituitary ectopia: male predominance and nonassociation with breech delivery. Brodsky MC. **Am J Ophthalmol** 1999 Feb;127(2):238–9
Rathke's cleft cyst as a cause of growth hormone deficiency and micropenis. Setian N, et al. **Childs Nerv Syst** 1999 May; 15(5):271–3
Lymphocytic hypophysitis with central diabetes insipidus and consequent panhypopituitarism preceding a multifocal, intracranial germinoma in a prepubertal girl. Bettendorf M, et al. **Eur J Pediatr** 1999 Apr;158(4):288–92
A case of Cushing's disease revealed six years after postpartum hypopituitarism. Kamoi K, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2718–23
Clinical and molecular characterization of a Brazilian patient with Pit-1 deficiency. Arnhold IJ, et al. **J Pediatr Endocrinol Metab** 1998 Sep-Oct;11(5):623–30
[Sheehan's syndrome: a recurrent obstetrical complication] Conreux F, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):430–5 (Eng. Abstr.) **(Fre)**
[Panhypopituitarism disclosing empty sella turcica syndrome] Schmoor P, et al. **Rev Med Interne** 1998 Aug;19(8):565–7 (Eng. Abstr.) **(Fre)**
[Disorders of endocrine function after brain tumor therapy in childhood] Marx M, et al. **Strahlenther Onkol** 1999 Jul; 175(7):305–8 (30 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Cat eye syndrome with hypogonadotropic hypogonadism. Masukawa H, et al. **Intern Med** 1998 Oct;37(10):853–6
Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene. Rosenbloom AL, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):50–7

METABOLISM

Why is the retention of gonadotrophin secretion common in children with panhypopituitarism due to septo-optic dysplasia? Nanduri VR, et al. **Eur J Endocrinol** 1999 Jan; 140(1):48–50
Very-low-density lipoprotein apolipoprotein B100 kinetics in adult hypopituitarism. Chrisoulidou A, et al. **Metabolism** 1999 Aug;48(8):1057–62

MICROBIOLOGY

Relapsing Whipple's disease presenting with hypopituitarism. Brändle M, et al. **Clin Endocrinol (Oxf)** 1999 Mar; 50(3):399–403

MORTALITY

Life expectancy following surgery for pituitary tumours. Bates AS, et al. **Clin Endocrinol (Oxf)** 1999 Mar;50(3):315–9
Mortality and hypopituitarism. Stewart PM, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:15–9 (33 ref.)

PATHOLOGY

MR findings in pituitary haemosiderosis. Ambrosetto P, et al. **Pediatr Radiol** 1998 May;28(5):288–9
[Hypopituitarism and shock in an 88 year old woman (clinical conference)] **Medicina (B Aires)** 1998;58(6):741–6 **(Spa)**

PHYSIOPATHOLOGY

Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Evans LM, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):457–64
Sheehan's syndrome of more than 30 years' duration: an endocrine and MRI study of 6 cases. Otsuka F, et al. **Endocr J** 1998 Aug;45(4):451–8 (27 ref.)
Growth hormone binding protein correlates strongly with leptin and percentage body fat in GH-deficient adults, is increased by GH replacement but does not predict IGF-I response. Florkowski CM, et al. **Growth Horm IGF Res** 1999 Feb;9(1):35–40
Effect of low-dosage recombinant human growth hormone therapy on pulmonary function in hypopituitary patients with adult-onset growth hormone deficiency. Meineri I, et al. **J Endocrinol Invest** 1998 Jul-Aug;21(7):423–7
Regression of acromegaly following pituitary apoplexy [letter] Thomas N, et al. **Neurol India** 1999 Jun;47(2):161–2

PSYCHOLOGY

How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults? Chrisoulidou A, et al. **Baillieres Clin Endocrinol Metab** 1998 Jul;12(2):261–79 (52 ref.)

RADIOGRAPHY

Influence of age on the clinical presentation of prolactinomas in male patients. Delgrange E, et al. **Gerontology** 1999 May-Jun;45(3):160–4

THERAPY

[Reduced incidence of side-effects of growth hormone substitution in 404 patients with hypophyseal insufficiency. Results of a multicenter indications study] Wüster C, et al. **Med Klin** 1998 Oct 15;93(10):585–91 (Eng. Abstr.) **(Ger)**

VETERINARY

Concurrent central diabetes insipidus and panhypopituitarism

in a German shepherd dog. Ramsey IK, et al. **J Small Anim Pract** 1999 Jun;40(6):271–4
Pituitary function and morphology in two German shepherd dogs with congenital dwarfism. Hamann F, et al. **Vet Rec** 1999 Jun 5;144(23):644–6

HYPOPLASTIC LEFT HEART SYNDROME

Obstetric management of 219 infants with hypoplastic left heart syndrome. Reis PM, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1150–4
Hypoplastic left heart in cerebrocostomandibular syndrome [letter] Kirk E, et al. **J Med Genet** 1998 Oct;35(10):879
Response to "Induced early delivery of a fetus with hypophastic left heart: a moral choice when neither surgery nor abortion is an acceptable option" [letter; comment] Panicola MR. **J Perinatol** 1998 Jul–Aug;18(4):332–3. Comment on: J Perinatol 1997 Jul–Aug;17(4):314–7.

BLOOD

Handling complexity in oxygen delivery in the univentricular circulation [letter; comment] Francis DP, et al. **Circulation** 1999 Jul 13;100(2):213–4. Comment on: Circulation 1998 Oct 6;98(14):1407–13.

COMPLICATIONS

Preoperative management of pulmonary venous hypertension in hypoplastic left heart syndrome with restrictive atrial septal defect. Atz AM, et al. **Am J Cardiol** 1999 Apr 15; 83(8):1224–8
Survival in neonatal biventricular repair of left-sided cardiac obstructive lesions associated with hypoplastic left ventricle. Blaufox AD, et al. **Am J Cardiol** 1998 Nov 1; 82(9):1138–40, A10
Hypoplastic left heart syndrome with right aortic arch, bilateral arterial ducts and origin of the left subclavian artery from the left pulmonary artery. Patel CR, et al. **Cardiol Young** 1999 May;9(3):331–4
Left heart hypoplasia in neonates having congenital diaphragmatic hernia and treated with ECMO [letter; comment] Baumgart S, et al. **J Pediatr Surg** 1998 Dec; 33(12):1848. Comment on: J Pediatr Surg 1998 Jun;33(6):943–5.
Outcome of infants with hypoplastic left heart and Turner syndromes. Reis PM, et al. **Obstet Gynecol** 1999 Apr; 93(4):532–5
Left ventricular outflow obstruction. Fedderly RT. **Pediatr Clin North Am** 1999 Apr;46(2):369–84 (37 ref.)

DIAGNOSIS

Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally. Kumar RK, et al. **Am J Cardiol** 1999 Jun 15;83(12):1649–53
Obstetric management in 219 cases of infants with hypoplastic left heart syndrome [letter] Gilles JM, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):226
Outcome analysis and quality assessment. Autopsy Committee of the College of American Pathologists. Bennett AT, et al. **Arch Intern Med** 1999 Jul 12; 159(13):1399–400
Case of the month: incidental and not-so-incidental findings. Havlik DM, et al. **Arch Intern Med** 1999 Aug 9–23; 159(15):1655–6
Prenatally diagnosed hypoplastic left heart syndrome—outcomes after postnatal surgery. Munn MB, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):147–50

EPIDEMIOLOGY

Decreased prevalence of hypoplastic left heart syndrome in Malta. Grech V. **Pediatr Cardiol** 1999 Sep–Oct;20(5):355–7

GENETICS

Trisomy 16q in a female newborn with a de novo X;16 translocation and hypoplastic left heart. Bacino CA, et al. **Am J Med Genet** 1999 Jan 15;82(2):128–31
Familial association of congenital left heart abnormalities and sustained fetal arrhythmia. Hajdú J, et al. **Pediatr Cardiol** 1999 Sep–Oct;20(5):368–70

PATHOLOGY

Growth characteristics of the aortic arch after the Norwood operation. Mahle WT, et al. **J Am Coll Cardiol** 1998 Dec; 32(7):1951–4
The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome. Rychik J, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):554–60

PHYSIOPATHOLOGY

Hypoplastic left heart syndrome: duration of survival without surgical intervention. Hoshino K, et al. **Am Heart J** 1999 Mar;137(3):535–42
Estimation of oxygen delivery in newborns with a univentricular circulation [see comments] Barnea O, et al. **Circulation** 1998 Oct 6;98(14):1407–13. Comment in: Circulation 1999 Jul 13;100(20:213–4. Comment in: Circulation 1999 Aug 10;100(6):687–8.
Left heart hypoplasia and neonatal aortic arch obstruction: is the Rhodes left ventricular adequacy score applicable? Tani LY, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):81–6

SURGERY

Survival in neonatal biventricular repair of left-sided cardiac obstructive lesions associated with hypoplastic left ventricle. Blaufox AD, et al. **Am J Cardiol** 1998 Nov 1; 82(9):1138–40, A10
Left ventricular growth in selected hypoplastic left ventricles: outcome after repair of coarctation of aorta. Alboliras ET, et al. **Ann Thorac Surg** 1999 Aug; 68(2):549–55
Norwood procedure without circulatory arrest. Imoto Y, et al. **Ann Thorac Surg** 1999 Aug;68(2):559–61
Use of the "chimney patch" technique for Norwood stage I procedures. Plunkett MD, et al. **Ann Thorac Surg** 1998 Oct;66(4):1438–9
Biventricular repair in neonates with hypoplastic left heart complex. Tchervenkov CI, et al. **Ann Thorac Surg** 1998 Oct;66(4):1350–7
Sternal wound and mediastinal infections in infants with congenital heart disease. Kearns B, et al. **Cardiol Young** 1999 May;9(3):280–4
Norwood reconstruction [letter; comment] [see comments] Adderley RJ. **CMAJ** 1999 Feb 9;160(3):313. Comment on: CMAJ 1998 Nov 17;159(10):1285–7. Comment in: CMAJ 1999 May 18;160(10):1433.
Norwood reconstruction [letter; comment] Ross DB. **CMAJ** 1999 May 18;160(10):1433. Comment on: CMAJ 1999 Feb 9;160(3):313.
Results after Norwood procedure and subsequent cavopulmonary anastomoses for typical hypoplastic left heart syndrome and similar complex cardiovascular malformations. Breymann T, et al. **Eur J Cardiothorac Surg** 1999 Aug;16(2):117–24
Growth characteristics of the aortic arch after the Norwood operation. Mahle WT, et al. **J Am Coll Cardiol** 1998 Dec; 32(7):1951–4
Biventricular repair approach in ducto-dependent neonates with hypoplastic but morphologically normal left ventricle. Serraf A, et al. **J Am Coll Cardiol** 1999 Mar;33(3):827–34
Anesthesia for an infant with hypoplastic left heart syndrome undergoing reconstruction of a systemic pulmonary shunt under extracorporeal membrane oxygenation [letter] Miyashita T, et al. **J Cardiothorac Vasc Anesth** 1998 Aug; 12(4):497–8
Heart transplantation for hypoplastic left heart syndrome: modified technique for reducing circulatory arrest time. Vricella LA, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1167–71
Prenatally diagnosed hypoplastic left heart syndrome--outcomes after postnatal surgery. Munn MB, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):147–50
Successful modified Norwood operation for hypoplastic left heart syndrome in neonatal period: the first reported case in Thailand. Benjacholamas V, et al. **J Med Assoc Thai** 1998 Oct;81(10):803–6
Left heart hypoplasia in neonates having congenital diaphragmatic hernia and treated with ECMO [letter; comment] Baumgart S, et al. **J Pediatr Surg** 1998 Dec; 33(12):1848. Comment on: J Pediatr Surg 1998 Jun;33(6):943–5.
The modified Norwood procedure for hypoplastic left heart syndrome: early to intermediate results of 120 patients with particular reference to aortic arch repair. Ishino K, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):920–30
Modified hemi-Fontan procedure on the beating heart. Schmid FX, et al. **J Thorac Cardiovasc Surg** 1999 Jan; 117(1):188–90
Surgical treatment for hypoplastic left heart syndrome. Bove EL. **Jpn J Thorac Cardiovasc Surg** 1999 Feb;47(2):47–56
Innominate artery steal syndrome after stage I palliation for hypoplastic left heart syndrome. Garabedian CP, et al. **Pediatr Cardiol** 1998 Nov–Dec;19(6):458–62
Early developmental outcome after the Norwood procedure for hypoplastic left heart syndrome. Kern JH, et al. **Pediatrics** 1998 Nov;102(5):1148–52
[Hypoplastic left heart syndrome (general review)] Tláskal T, et al. **Rozhl Chir** 1999 May;78(5):199–206 (46 ref.) (Eng. Abstr.) **(Cze)**
[Hypoplastic left-heart syndrome. Initial intensive care experiences with the Norwood operation in Vienna] Golej J, et al. **Wien Klin Wochenschr** 1999 Jan 15;111(1):26–32 (Eng. Abstr.) **(Ger)**
[Norwood procedure to hypoplastic left heart syndrome] Sano S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec; 46(12):1311–6 (Eng. Abstr.) **(Jpn)**

THERAPY

Balloon angioplasty for recurrent coarctation of the aorta in patients following staged palliation for hypoplastic left heart syndrome. Zellers TM. **Am J Cardiol** 1999 Jul 15; 84(2):231–3, A9
Managing disagreements in the management of short bowel and hypoplastic left heart syndrome. Cooper TR, et al. **Pediatrics** 1999 Oct;104(4):e48

ULTRASONOGRAPHY

Left heart hypoplasia and neonatal aortic arch obstruction: is the Rhodes left ventricular adequacy score applicable? Tani LY, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):81–6

HYPOPOTASSEMIA see **HYPOKALEMIA**

HYPOPROCONVERTINEMIA see **FACTOR VII DEFICIENCY**

HYPOPROTEINEMIA

see related
PROTEIN-LOSING ENTEROPATHIES

DRUG THERAPY

Treatment of complications due to peritoneal dialysis for chronic renal failure with traditional Chinese medicine. Wei L, et al. **J Tradit Chin Med** 1999 Mar;19(1):3–9

ETIOLOGY

A 13-year-old girl with hyperlipoproteinaemia type IIb and low plasma protein levels. Stozicky F, et al. **Eur J Pediatr** 1999 May;158(5):427–8
Hypoproteinemia caused by tricuspid regurgitation: report of a case. Sekine S, et al. **Surg Today** 1998;28(12):1287–9
[Molecular mechanism and therapy of hypoalbuminemia in peritoneal infection] Li W, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Feb;35(2):100–3 (Eng. Abstr.) **(Chi)**

PHYSIOPATHOLOGY

Spontaneous remission of hypertrophic lymphocytic gastritis associated with hypoproteinemia. Amenomori M, et al. **Intern Med** 1998 Dec;37(12):1019–22

HYPOPROTHROMBINEMIAS

[Congenital hypoprothrombinemia/dysprothrombinemia] Takamatsu J. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):456–9 (11 ref.) **(Jpn)**

CONGENITAL

Congenital deficiencies and abnormalities of prothrombin. Girolami A, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):557–69 (84 ref.)

DIAGNOSIS

Multiplex PCR for one-step determination of the G20210A variation and the factor V Leiden mutation by denaturing gradient gel electrophoresis (DGGE) [letter] Patri S, et al. **Thromb Haemost** 1999 Feb;81(2):313–4

DRUG THERAPY

O/W lipid emulsions for parenteral drug delivery. IV. Changes in the pharmacokinetics and pharmacodynamics of a highly lipophilic drug, menatetrenone. Sakaeda T, et al. **J Drug Target** 1998;6(3):183–9

ETIOLOGY

Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Galli M, et al. **Blood** 1999 Apr 1;93(7):2149–57 (82 ref.)
Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature. Erkan D, et al. **Lupus** 1999; 8(7):560–4 (31 ref.)
Celiac disease and hypoprothrombinemia. Hussaini SH, et al. **Nutrition** 1999 May;15(5):389–91

GENETICS

Congenital deficiencies and abnormalities of prothrombin. Girolami A, et al. **Blood Coagul Fibrinolysis** 1998 Oct; 9(7):557–69 (84 ref.)
Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Poort SR, et al. **Blood Coagul Fibrinolysis** 1998 Nov;9(8):761–4
Prothrombin carora: hypoprothrombinaemia caused by substitution of Tyr-44 by Cys. Sun WY, et al. **Br J Haematol** 1999 Jun;105(3):670–2
Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR. Mitterer M, et al. **Haematologica** 1999 Mar;84(3):204–7
Inherited prothrombotic states and ischaemic stroke in childhood [see comments] Ganesan V, et al. **J Neurol Neurosurg Psychiatry** 1998 Oct;65(4):508–11. Comment in: J Neurol Neurosurg Psychiatry 1998 Nov;65(5):617. Comment in: J Neurol Neurosurg Psychiatry 1999 Jun;66(6):806.
The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Gardemann A, et al. **Thromb Haemost** 1999 Feb;81(2):208–13

IMMUNOLOGY

Acquired hypoprothrombinemia related to high titres of antiprotein-phospholipid antibodies [letter] de Larrañaga G, et al. **Thromb Haemost** 1999 Feb;81(2):317–8

HYPOREFLEXIA

HYPOREFLEXIA see **REFLEX, ABNORMAL**

HYPOSALIVATION see **XEROSTOMIA**

HYPOSENSITIZATION THERAPY see **DESENSITIZATION, IMMUNOLOGIC**

HYPOSPADIAS

COMPLICATIONS

Extraurogenital congenital anomalies associated with hypospadias: retrospective review of 700 patients [letter] Latifoğlu O, et al. **Ann Plast Surg** 1998 Nov;41(5):570–1

The incidence of intersexuality in children with cryptorchidism and hypospadias: stratification based on gonadal palpability and meatal position. Kaefer M, et al. **J Urol** 1999 Sep;162(3 Pt 2):1003–6; discussion 1006–7

Incomplete hypospadiac urethral duplication with posterior urethral valves. Ramanujam TM, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):134–7 (12 ref.)

Perineal–mound defects. Sharma AK, et al. **Pediatr Surg Int** 1999;15(3–4):227–9 (6 ref.)

[Keratosis follicularis spinulosa decalvans associated with patent ductus arteriosus and hypospadia in an Asiatic patient] Harth W, et al. **Hautarzt** 1999 Apr;50(4):295–8 (Eng. Abstr.) **(Ger)**

[The treatment of hypospadias complexes] Woodard JR, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):561–8 (19 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Value of uroflowmetry in a long–term follow–up study in hypospadias surgery] Saggiomo G, et al. **Minerva Pediatr** 1998 Nov;50(11):461–5 (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Microphallic hypospadias--the use of human chorionic gonadotropin and testosterone before surgical repair [editorial; comment] Husmann DA. **J Urol** 1999 Oct; 162(4):1440–1. Comment on: J Urol 1999 Oct;162(4):1435–9.

Preoperative treatment with human chorionic gonadotropin in infancy decreases the severity of proximal hypospadias and chordee [see comments] Koff SA, et al. **J Urol** 1999 Oct;162(4):1435–9. Comment in: J Urol 1999 Oct;162(4):1440–1.

[Hypoplasia of the penis: etiologic diagnosis and results of treatment with delayed–action testosterone] Velásquez–Urzola A, et al. **Arch Pediatr** 1998 Aug; 5(8):844–50 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

5alpha–reductase type 2 mutations are present in some boys with isolated hypospadias. Silver RI, et al. **J Urol** 1999 Sep;162(3 Pt 2):1142–5

EPIDEMIOLOGY

Sexual differentiation and environmental endocrine disrupters. Toppari J, et al. **Baillieres Clin Endocrinol Metab** 1998 Apr;12(1):143–56 (67 ref.)

The incidence of hypospadias in two English cities: a case–control comparison of possible causal factors. Chambers EL, et al. **BJU Int** 1999 Jul;84(1):95–8

International trends in rates of hypospadias and cryptorchidism. Paulozzi LJ. **Environ Health Perspect** 1999 Apr;107(4):297–302

Cryptorchidism and hypospadias in sons of gardeners and farmers. Weidner IS, et al. **Environ Health Perspect** 1998 Dec;106(12):793–6

Risk factor patterns for cryptorchidism and hypospadias [see comments] Akre O, et al. **Epidemiology** 1999 Jul;10(4):364–9 . Comment in: Epidemiology 1999 Jul;10(4):352–4.

Epidemiology of cryptorchidism and hypospadias [editorial; comment] Møller H, et al. **Epidemiology** 1999 Jul; 10(4):352–4. Comment on: Epidemiology 1999 Jul;10(4):364–9.

Hypospadias trends in two US surveillance systems. Rise in prevalence of hypospadias. Canning DA. **J Urol** 1999 Jan; 161(1):366

Hypospadias is related to birth weight in discordant monozygotic twins. Fredell L, et al. **J Urol** 1998 Dec;160(6 Pt 1):2197–9

In vitro fertilization is associated with an increased risk of hypospadias. Silver RI, et al. **J Urol** 1999 Jun;161(6):1954–7

Risk factors for cryptorchidism and hypospadias. Weidner IS, et al. **J Urol** 1999 May;161(5):1606–9

ETIOLOGY

Homozygous alpha–thalassemia associated with hypospadias in three survivors. Fung TY, et al. **Am J Med Genet** 1999 Jan 29;82(3):225–7

Three cases of congenital growth hormone deficiency with micropenis and hypospadias: what does growth hormone have to do with it? Urzola A, et al. **Horm Res** 1999; 51(2):101–4

GENETICS

Homozygous alpha–thalassemia associated with hypospadias in three survivors. Fung TY, et al. **Am J Med Genet** 1999 Jan 29;82(3):225–7

The novel contiguous gene syndrome of myotubular myopathy (MTM1), male hypogenitalism and deletion in Xq28:report of the first familial case. Bartsch O, et al. **Cytogenet Cell Genet** 1999;85(3–4):310–4

True hermaphroditism associated with microphthalmia. Hayashi T, et al. **Eur J Endocrinol** 1999 Jan;140(1):62–5

Homozygous alpha–thalassaemia and hypospadias--common aetiology or incidental association? Long–term survival of Hb Bart's hydrops syndrome leads to new aspects for counselling of alpha–thalassaemic traits. Dame C, et al. **Eur J Pediatr** 1999 Mar;158(3):217–20

5alpha–reductase type 2 mutations are present in some boys with isolated hypospadias. Silver RI, et al. **J Urol** 1999 Sep;162(3 Pt 2):1142–5

Ambiguity of the external genitalia in an infant with Down syndrome: gender assignment and ethical implications. Jospe N, et al. **Ment Retard** 1999 Jun;37(3):232–6

Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene. Köhler B, et al. **Pediatr Res** 1999 Feb;45(2):187–90

Screening for mutations in candidate genes for hypospadias. Nordenskjöld A, et al. **Urol Res** 1999;27(1):49–55

[Undescended testis and hypospadia in sex chromosomal aberrations] Raff R, et al. **Klin Padiatr** 1998 Nov–Dec; 210(6):400–5 (Eng. Abstr.) **(Ger)**

NURSING

Hypospadias repair in the 1990s. Ellsworth P, et al. **AORN J** 1999 Jan;69(1):148–53, 155–6, 159–61

PATHOLOGY

Analysis of meatal location in 1,244 healthy men. Definition of the normal site justifies the need for meatal advancement in pediatric anterior hypospadias cases. Uygur MC, et al. **Pediatr Surg Int** 1999;15(2):119–20

Glans penis in hypospadias [letter] Ramaswamy CN. **Plast Reconstr Surg** 1998 Oct;102(5):1776–7

SURGERY

X–shaped meatoplasty and uretheral advancement for distal hypospadias treatment [letter] Songür E, et al. **Ann Plast Surg** 1999 Jul;43(1):103–4

Hypospadias repair in the 1990s. Ellsworth P, et al. **AORN J** 1999 Jan;69(1):148–53, 155–6, 159–61

An axially vascularized metal–based flap for the repair of hypospadias [letter; comment] Aubert J. **BJU Int** 1999 May; 83(7):879. Comment on: Br J Urol 1998 Nov;82(5):698–703.

Sexuality after hypospadias repair. Bracka A. **BJU Int** 1999 Apr;83 Suppl 3:29–33 (21 ref.)

An axially vascularized metal–based flap for the repair of hypospadias [letter; comment] Chiari G, et al. **BJU Int** 1999 May;83(7):879. Comment on: Br J Urol 1998 Nov;82(5):698–703.

Complications of the preputial island flap–tube urethroplasty. Elbakry A. **BJU Int** 1999 Jul;84(1):89–94

Hypospadias repair by skin flaps: a comparison of onlay preputial island flaps with either Mathieu's meatal–based or Duckett's tubularized preputial flaps. Ghali AM. **BJU Int** 1999 Jun;83(9):1032–8

The use of a dorsal buccal mucosal graft with urethral plate incision (Snodgrass) for hypospadias salvage. Hayes MC, et al. **BJU Int** 1999 Mar;83(4):508–9

Tubularization of the incised urethral plate (Snodgrass procedure) for primary hypospadias surgery. Sugarman ID, et al. **BJU Int** 1999 Jan;83(1):88–90

Balanitis xerotica obliterans complicating hypospadias repair. Kumar MV, et al. **Br J Plast Surg** 1999 Jan;52(1):69–71

An investigation into the role of waterproofing in a two–stage hypospadias repair. Telfer JR, et al. **Br J Plast Surg** 1998 Oct;51(7):542–6

An axially vascularized meatal–based flap for the repair of hypospadias [see comments] Elbakry A, et al. **Br J Urol** 1998 Nov;82(5):698–703. Comment in: BJU Int 1999 May;83(7):879.

Abnormal prostatic utricle configuration in hypospadias and intersex patients. Ciftçi AO, et al. **Eur J Pediatr Surg** 1999 Jun;9(3):167–72

One–stage repair of hypospadias--experience with 856 cases. Abu–Arafeh W, et al. **Eur Urol** 1998 Oct;34(4):365–7

Surgical repair of anterior hypospadias with fish–mouth meatus and intact prepuce based on anatomical characteristics. Nonomura K, et al. **Eur Urol** 1998 Oct; 34(4):368–71

Treatment of hypospadias: an update of current practice. Soomro NA, et al. **Hosp Med** 1998 Jul;59(7):553–6 (30 ref.)

Fistula advancement operation in the treatment of selected cases of persistently recurrent urethrocutaneous fistula following distal penile hypospadias repair. Marzouk E. **Int J Urol** 1999 Mar;6(3):135–8

A combined tubularized/onlay graft technique for total correction of severe hypospadias. Joseph VT. **J Pediatr Surg** 1999 Jun;34(6):992–5

Pedicled external spermatic fascia flap for urethroplasty in hypospadias and closure of urethrocutaneous fistula. Yamataka A, et al. **J Pediatr Surg** 1998 Dec;33(12):1788–9

A novel inert collagen matrix for hypospadias repair. Atala A, et al. **J Urol** 1999 Sep;162(3 Pt 2):1148–51

Newer concepts in the management of hypospadias and its complications. Canning DA. **J Urol** 1999 Oct;162(4):1560

Chordee correction by corporal rotation: the split and roll technique. Decter RM. **J Urol** 1999 Sep;162(3 Pt 2):1152–4; discussion 1155

Distal hypospadias repair by the modified Thiersch–Duplay technique with or without hinging the urethral plate: a near ideal way to correct distal hypospadias. Decter RM, et al. **J Urol** 1999 Sep;162(3 Pt 2):1156–8

Re: Tubularized incised plate hypospadias repair for proximal hypospadias [letter; comment] Elbakry A. **J Urol** 1999 Apr; 161(4):1286. Comment on: J Urol 1998 Jun;159(6):2129–31.

Tunica vaginalis onlay urethroplasty as a salvage repair. Joseph DB, et al. **J Urol** 1999 Sep;162(3 Pt 2):1146–7

Preoperative treatment with human chorionic gonadotropin in infancy decreases the severity of proximal hypospadias and chordee [see comments] Koff SA, et al. **J Urol** 1999 Oct;162(4):1435–9. Comment in: J Urol 1999 Oct;162(4):1440–1.

Penile torque after the use of tunica vaginalis blanket wrap as an aid in hypospadias repair. Pattaras JG, et al. **J Urol** 1999 Mar;161(3):934–5

Does tubularized incised plate hypospadias repair create neourethral strictures? Snodgrass W. **J Urol** 1999 Sep;162(3 Pt 2):1159–61

Coronal cuff: a problem site for buccal mucosal grafts. Yerkes EB, et al. **J Urol** 1999 Oct;162(4):1442–4

Laser ablation of urethral hair. Neal DE Jr, et al. **Lasers Surg Med** 1999;24(4):261–3

Urethral mobilization and meatal advancement: a surgical principle in hypospadias repair. Hamdy H, et al. **Pediatr Surg Int** 1999;15(3–4):240–2

Analysis of meatal location in 1,244 healthy men. Definition of the normal site justifies the need for meatal advancement in pediatric anterior hypospadias cases. Uygur MC, et al. **Pediatr Surg Int** 1999;15(2):119–20

Lessons from 197 Mathieu hypospadias repairs performed at a single institution. Uygur MC, et al. **Pediatr Surg Int** 1998 Dec;14(3):192–4

The use of eccentric circummeatal–based flap with combined limited urethral mobilization technique for distal hypospadias repair. Türken A, et al. **Plast Reconstr Surg** 1999 Feb;103(2):525–30

Buccal mucosal graft for hypospadias repairs. Payne CE, et al. **Tech Urol** 1998 Dec;4(4):173–6

Current trends in hypospadias repair. Borer JG, et al. **Urol Clin North Am** 1999 Feb;26(1):15–37, vii (83 ref.)

Tubularized incised plate hypospadias repair: indications, technique, and complications. Snodgrass WT. **Urology** 1999 Jul;54(1):6–11 (32 ref.)

[Correction of hypospadias. What is new in the past 10 years?] Valla JS, et al. **Ann Chir** 1998;52(10):1043–8 **(Fre)**

[Urethral fistulas after surgical treatment of hypospadias. Apropos of a series of 74 cases] Dubois R, et al. **Prog Urol** 1998 Dec;8(6):1029–34 (Eng. Abstr.) **(Fre)**

[Repair of anterior hypospadias with transurethral vesical catheter: comparison of ambulatory surgery with the "between 2 diapers" catheter and traditional hospitalization] Mondet F, et al. **Prog Urol** 1999 Feb;9(1):107–11 (Eng. Abstr.) **(Fre)**

[Penile disassembly technique: a new approach in the surgical reconstruction of hypospadias] Perovic SV, et al. **Prog Urol** 1999 Apr;9(2):371–9 (Eng. Abstr.) **(Fre)**

[Correction of hypospadias] Bianchi M. **Arch Ital Urol Androl** 1998 Dec;70(5):219–22 (Eng. Abstr.) **(Ita)**

[Value of uroflowmetry in a long–term follow–up study in hypospadias surgery] Saggiomo G, et al. **Minerva Pediatr** 1998 Nov;50(11):461–5 (Eng. Abstr.) **(Ita)**

[Use of polyurethane Bioclusive foil from Johnson and Johnson, as a dressing after surgery for hypospadias in children] Skrobisz P, et al. **Wiad Lek** 1998;51 Suppl 3:120–3 (Eng. Abstr.) **(Pol)**

[A rare and little–known form of hypospadias] Derevianko TI, et al. **Urol Nefrol (Mosk)** 1998 Sep–Oct;(5):46–7 (Eng. Abstr.) **(Rus)**

[The surgical treatment of distal hypospadias] Cendron M. **Arch Esp Urol** 1998 Jul–Aug;51(6):539–49 (25 ref.) (Eng. Abstr.) **(Spa)**

[Proximal hypospadias] Mollard P, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):551–9 (18 ref.) (Eng. Abstr.) **(Spa)**

[The treatment of hypospadias complexes] Woodard JR, et al. **Arch Esp Urol** 1998 Jul–Aug;51(6):561–8 (19 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Prenatal diagnosis of isolated hypospadias. Devesa R, et al. **Prenat Diagn** 1998 Aug;18(8):779–88

HYPOSTASIS, GENETIC see **EPISTASIS, GENETIC**

HYPOTENSION

see related
SYNCOPE, VASOVAGAL

[Local reduced pressure in the treatment of infantile cerebral palsy] Gerasimov IG, et al. **Zh Nevrol Psikhiatr Im S S Korsakova** 1998;98(9):41–2 **(Rus)**

BLOOD

Vasopressor hormone response following mesenteric traction during major abdominal surgery. Brinkmann A, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):948–56

Changes of plasma L-arginine levels in spontaneously hypertensive rats under induced hypotension. Prados P, et al. **Biomed Chromatogr** 1999 Feb;13(1):27–32

CHEMICALLY INDUCED

Effects of trimetaphan-induced deliberate hypotension on human cochlear blood flow. Tono T, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;539:40–3

Estrogen-dependent hypotensive effects of ethanol in conscious female rats. El-Mas MM, et al. **Alcohol Clin Exp Res** 1999 Apr;23(4):624–32

Efficacy of bretylium tosylate for ventricular tachycardia. Chandrasekaran S, et al. **Am J Cardiol** 1999 Jan 1; 83(1):115–7, A9

Severe hypotension and bradycardia associated with verapamil and clarithromycin [letter] Kaeser YA, et al. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2417–8

Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. Guillén EL, et al. **Am J Kidney Dis** 1998 Jul;32(2):E4

Beta-blocker eyedrops and nocturnal arterial hypotension. Hayreh SS, et al. **Am J Ophthalmol** 1999 Sep;128(3):301–9

Refractory hypotension after induction of anesthesia in a patient chronically treated with angiotensin receptor antagonists. Brabant SM, et al. **Anesth Analg** 1999 Oct; 89(4):887–8

Indigo carmine-induced severe hypotension. Nguyen AC, et al. **Anesth Analg** 1998 Nov;87(5):1194–5

Cold urticaria associated with intraoperative hypotension and facial edema. Ariño P, et al. **Anesthesiology** 1999 Mar; 90(3):907–9

Intrathecal sufentanil produces sensory changes without hypotension in male volunteers [letter; comment] Chado HN. **Anesthesiology** 1999 Apr;90(4):1229–30. Comment on: Anesthesiology 1998 Jul;89(1):73–8.

Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass. Falase BA, et al. **Ann Thorac Surg** 1999 Apr;67(4):1158–9

Systemic hypotension on withdrawal from inhaled nitric oxide in an adult patient with acute respiratory distress syndrome [letter] Buratti T, et al. **Crit Care Med** 1999 Feb; 27(2):441

Propofol toxicity in critically ill pediatric patients: show us the proof [editorial; comment] Susla GM. **Crit Care Med** 1998 Dec;26(12):1959–60 (15 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2087–92.

Involvement of spinal dopamine receptors in mediation of the hypotensive and bradycardic effects of systemic quinpirole in anaesthetised rats. Lahlou S. **Eur J Pharmacol** 1998 Jul 24;353(2–3):227–37

Lack of hypotensive effect of chronically infused proadrenomedullin N-terminal 20 peptide in rats. Matsui E, et al. **Horm Metab Res** 1998 Sep;30(9):555–6

Endogenous B1 receptor mediated hypotension produced by contact system activation in the presence of endotoxemia. Schmid A, et al. **Immunopharmacology** 1998 Aug; 40(2):131–7

Clonidine overdose. Karnawat BS, et al. **Indian Pediatr** 1998 Nov;35(11):1119–21

Dobutamine-induced hypotension is an independent predictor for mortality in patients with left ventricular dysfunction following myocardial infarction. Wang CH, et al. **Int J Cardiol** 1999 Mar 15;68(3):297–302

First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Navookarasu NT, et al. **Int J Clin Pract** 1999 Jan–Feb;53(1):25–30

Alprazolam and hypotension [letter] Ranieri P, et al. **Int J Geriatr Psychiatry** 1999 May;14(5):401–2

Superior mesenteric artery dilatation alone does not account for glucose-induced hypotension in human sympathetic denervation. Puvi-Rajasingham S, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2–3):184–91

Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit. Head GA, et al. **J Hypertens** 1998 Apr;16(4):503–17

Hypotensive response to captopril: a potential pitfall of scintigraphic assessment for renal artery stenosis. Stavropoulos SW, et al. **J Nucl Med** 1999 Mar;40(3):406–11

Mannitol osmotherapy in haemodynamically stable head injury patients—risk of sudden hypotension—a case report. Choudhary GN, et al. **JPMA J Pak Med Assoc** 1998 Jul; 48(7):220–1

Incidence of hypotension and bradycardia during integrated epidural/general anaesthesia. An epidemiologic observational study on 1200 consecutive patients. Italian Study Group on Integrated Anaesthesia. Fanelli G, et al. **Minerva Anestesiol** 1998 Jul–Aug;64(7–8):313–9

Autologous blood transfusion and hypotensive anesthesia for rotational acetabular osteotomy. Yoshida K, et al. **Nagoya J Med Sci** 1998 Oct;61(3–4):131–5

Paradoxical hypotension during dobutamine infusion for myocardial perfusion scintigraphy. Ergün EL, et al. **Nuklearmedizin** 1998;37(8):268–71

Enantioselective synthesis and pharmacological evaluation of a new type of verapamil analog with hypotensive and calcium antagonist activities. Holland HL, et al. **Pharm Res** 1999 Feb;16(2):281–7

Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor—results of the drug utilization observation studies. Delini-Stula A, et al. **Pharmacopsychiatry** 1999 Mar;32(2):61–7

Another report of adverse reactions to immediate-release nifedipine. Fami MJ, et al. **Pharmacotherapy** 1998 Sep–Oct; 18(5):1133–5

Labetalol-induced hypotension decreases blood loss during uncontrolled hemorrhage. Gurevich B, et al. **Resuscitation** 1998 Jul;38(1):25–32

Hypotensive shock as a complication of infracyanine green injection. Bonte CA, et al. **Retina** 1998;18(5):476–7

Induction of a critical elevation of povidone-iodine absorption in the treatment of a burn patient: report of a case. Aiba M, et al. **Surg Today** 1999;29(2):157–9 (10 ref.)

[Severe flecainide acetate poisoning. Apropos of a case] Maury P, et al. **Arch Mal Coeur Vaiss** 1999 Feb;92(2):273–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Hypotension in acyclovir therapy] Wolters H, et al. **Schweiz Rundsch Med Prax** 1998 Nov 19;87(47):1614–8 (Eng. Abstr.) **(Ger)**

[Bromocriptine for the suppression of lactation and severe hypotension (letter)] Palop Larrea V, et al. **Aten Primaria** 1999 Apr 30;23(7):447–8 **(Spa)**

COMPLICATIONS

Adrenal dysfunction in hemodynamically unstable patients in the emergency department. Rivers EP, et al. **Acad Emerg Med** 1999 Jun;6(6):626–30

Induction of antenatal periventricular leukomalacia by hemorrhagic hypotension in the chronically instrumented fetal sheep. Matsuda T, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):725–30

Intracranial hypotension with parkinsonism, ataxia, and bulbar weakness. Pakiam AS, et al. **Arch Neurol** 1999 Jul; 56(7):869–72

Anoxic-hypotensive brain injury: neuropsychological performance at 1 month as an indicator of recovery. Kaplan CP. **Brain Inj** 1999 Apr;13(4):305–10

Congenital paraplegia following maternal hypotension. Suri S, et al. **Dev Med Child Neurol** 1999 Apr;41(4):273–4

Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Torpy DJ, et al. **Neuroimmunomodulation** 1999 May–Jun;6(3):182–6

[Anterior ischemic optic neuropathy after systemic hypotension and anemia] Koos MJ, et al. **Oftalmologia** 1998; 44(3):79–83 (33 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

A 9-year-old girl with chronic fatigue. Diagnosis: neurally mediated hypotension. Massin MM, et al. **Eur J Pediatr** 1999 Sep;158(9):761–2

Sampling intervals to record severe hypotensive and hypoxic episodes in anesthetised patients. Derrick JL, et al. **J Clin Monit Comput** 1998 Jul;14(5):347–51

[Acute postoperative pancreatitis and hypertension of the pancreatic vascular system during hemorrhage in the course of the experiment] Uzhva VP. **Klin Khir** 1999; (5):42–4 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Intradialytic dobutamine therapy in maintenance hemodialysis patients with persistent hypotension. Anand U, et al. **Am J Nephrol** 1999;19(4):459–63

Epidural phenylephrine attenuates hypotension induced by alkalinized lidocaine epidural anesthesia. Cheng JK, et al. **Anesth Analg** 1999 Jun;88(6):1322–6

Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Eyraud D, et al. **Anesth Analg** 1999 May;88(5):980–4

Vasopressin and postcardiopulmonary bypass refractory hypotension [letter; comment] Licker M, et al. **Anesth Analg** 1999 Mar;88(3):695. Comment on: Anesth Analg 1998 Jun;86(6):1207–9.

Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage. Talmor D, et al. **Anesth Analg** 1999 Oct;89(4):950–6

Mechanisms of blood pressure increase induced by dopamine in hypotensive preterm neonates. Zhang J, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F99–F104

Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Morales D, et al. **Circulation** 1999 Jul 20;100(3):226–9

Role of corticosteroids in neonatal blood pressure homeostasis. Sasidharan P. **Clin Perinatol** 1998 Sep; 25(3):723–40, xi (160 ref.)

Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following endotoxin administration in rats. Wang D, et al. **J Biomed Sci** 1999 Jan;6(1):28–35

Single-dose dexamethasone treatment of hypotension in preterm infants. Gaissmaier RE, et al. **J Pediatr** 1999 Jun; 134(6):701–5

Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. Yiu P, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):195–6

Bradycardia and hypotension associated with severe hemorrhage are reversed by morphine given centrally or peripherally in anesthetized rats. Ohnishi M, et al. **J Trauma** 1998 Dec;45(6):1024–30

Prevention of the hemorrhagic hypotension-induced hepatic arterial vasoconstriction by L-arginine and naloxone. Benyó Z, et al. **Shock** 1999 May;11(5):342–6

[Octreotide and a serotonin-secreting glomus tumor] García Galán F, et al. **Rev Esp Anestesiol Reanim** 1999 May; 46(5):219–22 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period. Kang ES, et al. **Am J Med Sci** 1999 Jan;317(1):9–21

EPIDEMIOLOGY

Hemodynamic instability following carotid endarterectomy does not affect early discharge. Scheinman M, et al. **Cardiovasc Surg** 1998 Oct;6(5):470–4

Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. Guo Z, et al. **J Am Geriatr Soc** 1999 Jun;47(6):723–6

Incidence of hypotension and bradycardia during integrated epidural/general anaesthesia. An epidemiologic observational study on 1200 consecutive patients. Italian Study Group on Integrated Anaesthesia. Fanelli G, et al. **Minerva Anestesiol** 1998 Jul–Aug;64(7–8):313–9

Occurrence and relevance of postprandial hypotension in patients with essential hypertension. Mitro P, et al. **Wien Klin Wochenschr** 1999 Apr 23;111(8):320–5

[Prevalence of hypotension and symptomatic, orthostatic dysregulation in a patient sample of a medical polyclinic] Bernard A, et al. **Schweiz Rundsch Med Prax** 1999 Mar 25;88(13):547–58 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Hypotensive ischemic optic neuropathy and peritoneal dialysis. Jackson TL, et al. **Am J Ophthalmol** 1999 Jul; 128(1):109–11

Hypotension induced by exercise is associated with enhanced release of adenyl purines from aged rat artery. Hashimoto M, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H970–5

Postexercise hypotension is mediated by reductions in sympathetic nerve activity. Kulics JM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H27–32

Unusual cause of intraoperative hypotension diagnosed with transoesophageal echocardiography in a patient with renal cell carcinoma. Plowman AN, et al. **Anaesth Intensive Care** 1999 Feb;27(1):63–5

Transient hypotension as a complication of monitoring transcervical motor evoked potentials. Hays SR, et al. **Anesthesiology** 1999 Jan;90(1):314–7

Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. van Kraaij DJ, et al. **Arch Intern Med** 1999 Jul 26;159(14):1599–605

Complement activation as a cause of transient hypotension during plasmapheresis. Shiga Y, et al. **Artif Organs** 1998 Dec;22(12):1067–9

Relative underestimation of fluid removal during hemodialysis hypotension measured by whole body bioimpedance. Zaluska WT, et al. **ASAIO J** 1998 Nov–Dec; 44(6):823–7

Systemic vascular resistance in intradialytic hypotension determined by means of impedance cardiography. Straver B, et al. **Blood Purif** 1998;16(5):281–9

An 87-year-old man with hypotension and confusion after cystoscopy. Yende S, et al. **Chest** 1999 May;115(5):1449–51

Hypotensive response during dobutamine stress echocardiography in coronary patients: a common event of well-functioning left ventricle. Rallidis LS, et al. **Clin Cardiol** 1998 Oct;21(10):747–52

The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. van der Sande FM, et al. **Clin Nephrol** 1998 Nov;50(5):301–8

Postprandial hypotension is associated with asymptomatic cerebrovascular damage in essential hypertensive patients. Kohara K, et al. **Hypertension** 1999 Jan;33(1 Pt 2):565–8

Dialysis-induced hypotension [editorial] Copley JB, et al. **Int J Artif Organs** 1998 Aug;21(8):440–2

Dialysis hypotension [editorial] Leunissen KM. **Int J Artif Organs** 1998 Dec;21(12):771–3

Dialysis hypotension and splanchnic circulation [editorial] Yu AW, et al. **Int J Artif Organs** 1998 Dec;21(12):774–7

Effect of gender and left ventricular dysfunction on the incidence of hypotension induced by dobutamine stress echocardiography. Khanal S, et al. **J Am Soc Echocardiogr** 1998 Dec;11(12):1134–8

Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. Brauer LP, et al. **J Cancer Res Clin Oncol** 1998;124(10):549–54

Sudden hypotension associated with cardiopulmonary bypass: way out of the diagnostic dilemma [letter] Grubitzsch H, et al. **J Cardiothorac Vasc Anesth** 1999 Apr; 13(2):240

Vasoplegic syndrome after open heart surgery. Gomes WJ, et al. **J Cardiovasc Surg (Torino)** 1998 Oct;39(5):619–23

HYPOTENSION

The effects of exercise intensity on post exercise hypotension. MacDonald J, et al. **J Hum Hypertens** 1999 Aug; 13(8):527–31

Precipitous decrease in blood pressure in acute ischemic stroke patients during transesophageal echocardiography: a case study from the adult brain attack database. Shephard T, et al. **J Neurosci Nurs** 1998 Aug;30(4):261–4

Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. Kovacich JC, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):154–62

Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. Yiu P, et al. **J Thorac Cardiovasc Surg** 1999 Jul;118(1):195–6

From the Food and Drug Administration. Nightingale SL. **JAMA** 1999 Jun 2;281(21):1978

Hypertension/hypotension in dialysis [letter; comment] Charra B, et al. **Kidney Int** 1999 Mar;55(3):1128. Comment on: Kidney Int 1998 Aug;54(2):561–9.

The management of hypotension in dialyzed patients. Zucchelli P, et al. **Miner Electrolyte Metab** 1999 Jan–Apr; 25(1–2):105–8 (20 ref.)

Intradialytic hypotension: new insights into the mechanism of vasovagal syncope [editorial] Ligtenberg G, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2745–7

Dialysis hypotension: do we see light at the end of the tunnel? Passauer J, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3024–9 (35 ref.)

Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension. Ligtenberg G. **Neth J Med** 1999 Jul; 55(1):13–8 (36 ref.)

Plasma expanders used to treat or prevent hypotension can themselves cause hypotension. Walker SR, et al. **Postgrad Med J** 1998 Aug;74(874):492–3

Frequency of hypotension during conventional or asymmetric hyperbaric spinal block. Casati A, et al. **Reg Anesth Pain Med** 1999 May–Jun;24(3):214–9

Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Tsuboi Y, et al. **Ther Apher** 1998 Nov;2(4):297–9

Hypotensive reactions during transfusion: is bradykinin the culprit? [letter; comment] Colman RW, et al. **Transfusion** 1999 Jan;39(1):107–9. Comment on: Transfusion 1996 Oct;36(10):939–41. Comment on: Transfusion 1998 Apr;38(4):410; discussion 413–5. Comment on: Transfusion 1998 Apr;38(4):410–1; discussion 413–5. Comment on: Transfusion 1998 Apr;38(4):411–2; discussion 413–5.

Arterial blood pressure in adult Nigerian sickle cell anaemia patients. Aderibigbe A, et al. **West Afr J Med** 1999 Apr–Jun;18(2):114–8

[Spinal anesthesia and von Bezold-Jarisch reflex? (letter)] Amrouni K, et al. **Ann Fr Anesth Reanim** 1999 Apr; 18(4):468–9 **(Fre)**

[With regard to a "blood-patch" in post-lumbar puncture syndrome (letter; comment)] Seebacher J, et al. **Rev Neurol (Paris)** 1998 May;154(4):350–1. Comment on: Rev Neurol (Paris) 1997 Oct;153(10):605–8. **(Fre)**

[Efficacy of diltiazem in uremic hemodialyzed patients with isolated diastolic dysfunction and dialysis hypotensive crisis] Cice G, et al. **Cardiologia** 1999 Mar;44(3):289–94 (Eng. Abstr.) **(Ita)**

GENETICS

Blood pressure and the T174M and M235T polymorphisms of the angiotensinogen gene. Niu T, et al. **Ann Epidemiol** 1999 May;9(4):245–53

Hypotension and reduced nitric oxide–elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase [see comments] Ohashi Y, et al. **J Clin Invest** 1998 Dec 15;102(12):2061–71. Comment in: J Clin Invest 1998 Dec 15;102(12):2033–4.

Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Schinke M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3975–80

METABOLISM

Fos expression in brain stem nuclei of pregnant rats after hydralazine-induced hypotension. Curtis KS, et al. **Am J Physiol** 1999 Aug;277(2 Pt 2):R532–40

Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Cicala C, et al. **Circulation** 1999 May 18;99(19):2590–7

N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. Knutsen LJ, et al. **J Med Chem** 1999 Sep 9;42(18):3463–77

Comparison of effects of hypotension and handling stress on the release of noradrenaline and dopamine in the locus coeruleus and medial prefrontal cortex of the rat. Kawahara Y, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):42–9

Peripheral oxygenation in hypotensive preterm babies. Wardle SP, et al. **Pediatr Res** 1999 Mar;45(3):343–9

PATHOLOGY

Pathologic characterization of hypotensive C57BL/6J-agt: angiotensinogen-deficient C57BL/6J mice. Taniguchi K, et al. **Int J Mol Med** 1998 Mar;1(3):583–7

PHYSIOPATHOLOGY

Responses to noradrenaline of tail arteries in hypertensive, hypotensive and normotensive rats under different regimens of perfusion: role of the myogenic response. Machkov VV, et al. **Acta Physiol Scand** 1998 Aug; 163(4):331–7

Effect of hemorrhagic hypotension on hydroxyl radicals in cat brain. Song D, et al. **Adv Exp Med Biol** 1998;454:173–80

Postprandial hypotension: evaluation by ambulatory blood pressure monitoring. Kohara K, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1358–63

Neurally mediated hypotension and chronic fatigue syndrome. Rowe PC, et al. **Am J Med** 1998 Sep 28; 105(3A):15S–21S (55 ref.)

Activation of spinal opioid receptors contributes to hypotension after hemorrhage in conscious rats. Ang KK, et al. **Am J Physiol** 1999 May;276(5 Pt 2):H1552–8

Metabolism of cAMP to adenosine: role in vasodilation of rat pial artery in response to hypotension. Hong KW, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H376–82

Postexercise hypotension is mediated by reductions in sympathetic nerve activity. Kulics JM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):H27–32

Effects of systemic hypotension on postnatal intestinal circulation: role of angiotensin. Nowicki PT, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G341–52

Cardiovascular afferent signals and drinking in response to hypotension in dogs. Thrasher TN, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R795–801

Effects of isoflurane anesthesia on pulmonary vascular response to K+ ATP channel activation and circulatory hypotension in chronically instrumented dogs. Fujiwara Y, et al. **Anesthesiology** 1999 Mar;90(3):799–811

Hemodynamic effects of prostaglandins and catecholamines in graded reduction of pulmonary flow during venoarterial bypass in awake goats. Takewa Y, et al. **ASAIO J** 1999 Jan–Feb;45(1):79–82

Nitric oxide limits the eicosanoid-dependent bronchoconstriction and hypotension induced by endothelin-1 in the guinea-pig. Lewis K, et al. **Br J Pharmacol** 1999 Jan;126(1):93–102

Hypotension dilates pial arteries by KATP and kca channel activation. Armstead WM. **Brain Res** 1999 Jan 16; 816(1):158–64

Neurons in the hypothalamic paraventricular nucleus that project to the rostral ventrolateral medulla are not activated by hypotension. Badoer E. **Brain Res** 1998 Aug 10;801(1–2):224–7

Differential recruitment of hypothalamic neuroendocrine and ventrolateral medulla catecholamine cells by non-hypotensive and hypotensive hemorrhages. Buller KM, et al. **Brain Res** 1999 Jul 10;834(1–2):42–54

Role of bradykinin in postprandial hypotension in humans. Tumilero S, et al. **Braz J Med Biol Res** 1999 Jun; 32(6):777–81

Neurally mediated hypotension and autonomic dysfunction measured by heart rate variability during head-up tilt testing in children with chronic fatigue syndrome. Stewart J, et al. **Clin Auton Res** 1998 Aug;8(4):221–30

Impaired sympathetic response before intradialytic hypotension: a study based on spectral analysis of heart rate and pressure variability. Pelosi G, et al. **Clin Sci (Colch)** 1999 Jan;96(1):23–31

Electrocortical brain activity during hypoxia and hypotension in anesthetized newborn lambs. van de Bor M, et al. **Early Hum Dev** 1999 Jul;55(3):237–45

Hypotension following mild bouts of resistance exercise and submaximal dynamic exercise. MacDonald JR, et al. **Eur J Appl Physiol** 1999 Jan;79(2):148–54

Dialysis hypotension [editorial] Leunissen KM. **Int J Artif Organs** 1998 Dec;21(12):771–3

Intradialytic hypotension in relation to pre-existent autonomic dysfunction in hemodialysis patients. Straver B, et al. **Int J Artif Organs** 1998 Dec;21(12):794–801

Dialysis hypotension and splanchnic circulation [editorial] Yu AW, et al. **Int J Artif Organs** 1998 Dec;21(12):774–7

Comparative analysis of systemic and coronary hemodynamics during sevoflurane- and isoflurane-induced hypotension in dogs. Tomiyasu S, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):741–7

Endogenous angiotensin II and bradykinin delay and attenuate the hypotension after N-type calcium channel blockade in conscious rabbits. Whorlow SL, et al. **J Cardiovasc Pharmacol** 1998 Dec;32(6):951–61

Moderate hypothermia reduces hypotensive, but not hypercapnic vasodilation of pial arterioles in rats. Irikura K, et al. **J Cereb Blood Flow Metab** 1998 Dec;18(12):1294–7

Activation of neuropeptide FF neurons in the brainstem nucleus tractus solitarius following cardiovascular challenge and opiate withdrawal. Jhamandas JH, et al. **J Comp Neurol** 1998 Dec 14;402(2):210–21

Mediation of humoral catecholamine secretion by the renin-angiotensin system in hypotensive rainbow trout (Oncorhynchus mykiss). Bernier NJ, et al. **J Endocrinol** 1999 Mar;160(3):351–63

The effects of exercise intensity on post exercise hypotension. MacDonald J, et al. **J Hum Hypertens** 1999 Aug; 13(8):527–31

Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit. Head GA, et al. **J Hypertens** 1998 Apr;16(4):503–17

Fentanyl infusion preserves cerebral blood flow during decreased arterial blood pressure after traumatic brain injury in cats. Bedell EA, et al. **J Neurotrauma** 1998 Nov; 15(11):985–92

Hepatocellular dysfunction after severe hypotension in the absence of blood loss is associated with the increased IL-6 and PGE2. Wang P, et al. **J Surg Res** 1998 Dec; 80(2):136–42

Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. Kovacich JC, et al. **J Thorac Cardiovasc Surg** 1999 Jul; 118(1):154–62

Hypotension does not alter the antinociceptive effect of nifedipine. Wong CH, et al. **Life Sci** 1998;63(24):PL343–8

Pituitary-adrenal and parasympathetic function in chronic schizophrenic patients with postoperative ileus or hypotension. Kudoh A, et al. **Neuropsychobiology** 1999; 39(3):125–30

Cerebral blood-flow responses to induced hypotension and to CO2 inhalation in patients with major cerebral artery occlusive disease: a positron-emission tomography study. Nishimura S, et al. **Neuroradiology** 1999 Feb;41(2):73–9

GABA may function tonically via GABA(A) receptors to inhibit hypotension and bradycardia by L-DOPA microinjected into depressor sites of the nucleus tractus solitarii in anesthetized rats. Honjo K, et al. **Neurosci Lett** 1999 Feb 12;261(1–2):93–6

Distribution of neurons projecting to the rostral ventrolateral medullary pressor region that are activated by sustained hypotension. Horiuchi J, et al. **Neuroscience** 1999; 89(4):1319–29

Hypotension activates neuropeptide Y-containing neurons in the rat medulla oblongata. McLean KJ, et al. **Neuroscience** 1999;92(4):1377–87

Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Hayreh SS, et al. **Ophthalmologica** 1999; 213(2):76–96

Triosephosphate isomerase deficiency in a child with congenital hemolytic anemia and severe hypotonia. Linarello RE, et al. **Pediatr Hematol Oncol** 1998 Nov–Dec; 15(6):553–6

Near infrared spectroscopy detects cerebral ischemia during hypotension in piglets. Tsuji M, et al. **Pediatr Res** 1998 Oct;44(4):591–5

Ultrawide-band electromagnetic pulses induced hypotension in rats. Lu ST, et al. **Physiol Behav** 1999 Jan 1–15; 65(4–5):753–61

Contingent negative variation and cognitive performance in hypotension. Costa M, et al. **Psychophysiology** 1998 Nov; 35(6):737–44

Nocturnal hypotension: role in glaucoma progression. Graham SL, et al. **Surv Ophthalmol** 1999 Jun;43 Suppl 1:S10–6 (64 ref.)

An inhibitor of angiotensin converting enzyme (enalapril) augments endotoxin-induced hypotension in the pig. Kiiski R, et al. **Ups J Med Sci** 1999;104(2):163–76

[Postprandial hypotension] Alcântara C, et al. **Rev Port Cardiol** 1999 Jun;18(6):595–8 (Eng. Abstr.) **(Por)**

[Vasoconstrictor responses of the tail artery in rats with regional arterial hypotension] Vlasova MA, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):11–3 **(Rus)**

PREVENTION & CONTROL

Prevention of hypotension after spinal anesthesia for cesarean section: dextran 40 versus lactated Ringer's solution. Lin CS, et al. **Acta Anaesthesiol Sin** 1999 Jun;37(2):55–9

Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Cruz DN, et al. **Am J Kidney Dis** 1999 May;33(5):920–6

A comparison of three fluid-vasopressor regimens used to prevent hypotension during subarachnoid anaesthesia in the elderly. Yap JC, et al. **Anaesth Intensive Care** 1998 Oct; 26(5):497–502

The use of metoprolol and glycopyrrolate to prevent hypotensive/bradycardic events during shoulder arthroscopy in the sitting position under interscalene block. Liguori GA, et al. **Anesth Analg** 1998 Dec;87(6):1320–5

Furosemide withdrawal improves postprandial hypotension in elderly patients with heart failure and preserved left ventricular systolic function. van Kraaij DJ, et al. **Arch Intern Med** 1999 Jul 26;159(14):1599–605

Systemic hypotensive response to protamine following chronic inhibition of nitric oxide synthase in rats [see comments] Komatsu H, et al. **Can J Anaesth** 1998 Dec; 45(12):1186–9. Comment in: Can J Anaesth 1998 Dec;45(12):1144–7.

Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Cruz DN, et al. **Clin Nephrol** 1998 Aug;50(2):101–7

Prevention of hypotension after induction of anesthesia after preoperative tune-up. A preliminary report of the Groningen Tune-up Study [see comments] Girbes AR, et al. **Neth J Med** 1999 Jun;54(6):215–20. Comment in: Neth J Med 1999 Jun;54(6):213–4.

Preoperative optimisation of oxygen delivery. Intensive care moves into preventive medicine [editorial; comment] van der Hoeven JG, et al. **Neth J Med** 1999 Jun;54(6):213–4 . Comment on: Neth J Med 1999 Jun;54(6):215–20.

Frequency of hypotension during conventional or asymmetric hyperbaric spinal block. Casati A, et al.

Reg Anesth Pain Med 1999 May-Jun;24(3):214-9

The use of the Haemonetic Rapid Infusion System (RIS) has dramatically reduced the duration and frequency of significant intraoperative hypotension and hypothermia that can occur in major cases [letter; comment] Minore WS. **Resuscitation** 1997 Nov;35(3):273-4. Comment on: Resuscitation 1996 Apr;31(2):127-33.

[Treatment of the acute phase of a brain injury] Ohman J. **Duodecim** 1995;111(21):2001-6 (33 ref.) **(Fin)**

[Prevention of arterial hypotension during spinal anesthesia using intramuscular ephedrine in older people] Di Roio C, et al. **Ann Fr Anesth Reanim** 1997;16(5):483-7 (Eng. Abstr.) **(Fre)**

[Practice of spinal anesthesia in a developing country: usefulness of vascular preloading with a 7.5% hypertonic saline solution (see comments)] Durasnel P, et al. **Ann Fr Anesth Reanim** 1999 Jun;18(6):631-5 (Eng. Abstr.) . Comment in: Ann Fr Anesth Reanim 1999 Jun;18(6):619-20. Comment in: Ann Fr Anesth Reanim 1999 Jun;18(6):621-2. **(Fre)**

[Preloading with 500 ml of Hartmann's solution lessens the incidence and severity of hypotension and reduces the need for ephedrine after epidural anesthesia in ambulatory patients] Rama-Maceiras P, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):14-8 (Eng. Abstr.) **(Spa)**

THERAPY

A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. Emili S, et al. **Am J Kidney Dis** 1999 Jun;33(6):1107-14

Assessing fluid responsiveness by the systolic pressure variation in mechanically ventilated patients. Systolic pressure variation as a guide to fluid therapy in patients with sepsis-induced hypotension [editorial; comment] Perel A. **Anesthesiology** 1998 Dec;89(6):1309-10. Comment on: Anesthesiology 1998 Dec;89(6):1313-21.

Systolic pressure variation as a guide to fluid therapy in patients with sepsis-induced hypotension [see comments] Tavernier B, et al. **Anesthesiology** 1998 Dec;89(6):1313-21 . Comment in: Anesthesiology 1998 Dec;89(6):1309-10.

Worsening hypotension in a 60-year-old man requiring intra-aortic balloon counterpulsation. Parrillo J. **Chest** 1999 Sep;116(3):801-2

Clonidine overdose. Karnawat BS, et al. **Indian Pediatr** 1998 Nov;35(11):1119-21

Evidence of profiled hemodialysis efficacy in the treatment of intradialytic hypotension. Coli L, et al. **Int J Artif Organs** 1998 Jul;21(7):398-402

Hypertonic saline resuscitation. Rocha e Silva M. **Medicina (B Aires)** 1998;58(4):393-402 (186 ref.)

The management of hypotension in dialyzed patients. Zucchelli P, et al. **Miner Electrolyte Metab** 1999 Jan-Apr; 25(1-2):105-8 (20 ref.)

VETERINARY

Adrenocortical and metabolic responses to dobutamine infusion during halothane anaesthesia in ponies. Taylor PM. **J Vet Pharmacol Ther** 1998 Aug;21(4):282-7

Effects of hypertonic saline infusion on the adrenocortical response to thiopental-halothane anesthesia in sheep after premedication with acepromazine. Taylor PM. **Vet Surg** 1999 Jan-Feb;28(1):77-82

HYPOTENSION, CONTROLLED

Is it feasible to use magnesium sulphate as a hypotensive agent in oral and maxillofacial surgery? Sanders GM, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):780-5

Acute normovolaemic haemodilution vs controlled hypotension for reducing the use of allogeneic blood in patients undergoing radical prostatectomy [see comments] Boldt J, et al. **Br J Anaesth** 1999 Feb;82(2):170-4. Comment in: Br J Anaesth 1999 Feb;82(2):161-3.

Intraoperative conservation of red cell mass: controlled hypotension or haemodilution--not necessarily mutually exclusive? [editorial; comment] Levack ID, et al. **Br J Anaesth** 1999 Feb;82(2):161-3. Comment on: Br J Anaesth 1999 Feb;82(2):170-4.

Cerebral oxygenation during prostaglandin E1 induced hypotension. Kadoi Y, et al. **Can J Anaesth** 1998 Sep; 45(9):860-4

Effects of controlled hypotension with sevoflurane anaesthesia on hepatic function of surgical patients. Fukusaki M, et al. **Eur J Anaesthesiol** 1999 Feb;16(2):111-6

The incidence of venous thromboembolism after total hip arthroplasty: a specific hypotensive epidural anesthesia protocol. Westrich GH, et al. **J Arthroplasty** 1999 Jun; 14(4):456-63

Renal function in patients during and after hypotensive anesthesia with sevoflurane [see comments] Hara T, et al. **J Clin Anesth** 1998 Nov;10(7):539-45. Comment in: J Clin Anesth 1998 Nov;10(7):531-8.

Efficacy of induced hypotension in the surgical treatment of large cavernous sinus cavernomas. Ohata K, et al. **J Neurosurg** 1999 Apr;90(4):702-8

Inhibition of physiologic stress responses by regional nerve block during orthognathic surgery under hypotensive anesthesia. Noma T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Nov;86(5):511-5

[Acidosis, hypoxia and hypotension in abdominal chemotherapy with blockade of arterial and venous circulation (stop flow)] Bartucci S, et al. **Minerva Anestesiol** 1999 Jan-Feb;65(1-2):45-52 (Eng. Abstr.) **(Ita)**

[Subarachnoid hemorrhage: protective hypotension in delayed surgery] Massei R, et al. **Minerva Anestesiol** 1998 May;64(5):209-10 (Eng. Abstr.) **(Ita)**

[Brain damage caused by hypotensive anesthesia? Both the anesthetic technique and the anesthetic agent must be chosen with care] Frithz G. **Lakartidningen** 1999 Mar 3; 96(9):1010-2 (25 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Asystole under hypotensive epidural anesthesia [letter; comment] Sharrock NE. **Anesth Analg** 1998 Oct;87(4):982 Comment on: Anesth Analg 1998 Apr;86(4):847-9.

HISTORY

An early approach to controlled hypotension: Felice Visalli and the "pneumoanemizator." De Caro GM, et al. **J Neurosurg Anesthesiol** 1999 Jan;11(1):53-6

METHODS

Clinical application of diadenosine tetraphosphate (Ap4A:F-1500) for controlled hypotension. Kikuta Y, et al. **Acta Anaesthesiol Scand** 1999 Jan;43(1):82-6

I.v. clonidine: does it work as a hypotensive agent with inhalation anaesthesia? Lee J, et al. **Br J Anaesth** 1999 Apr; 82(4):639-40

Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. Melendez JA, et al. **J Am Coll Surg** 1998 Dec;187(6):620-5

Endovascular repair of a descending thoracic aortic aneurysm: a tip for systemic pressure reduction. Hata M, et al. **J Vasc Surg** 1999 Mar;29(3):551-3

Labetalol-induced hypotension decreases blood loss during uncontrolled hemorrhage. Gurevich B, et al. **Resuscitation** 1998 Jul;38(1):25-32

HYPOTENSION, ORTHOSTATIC

Orthostatic hypotension and cognitive decline in older people. Viramo P, et al. **J Am Geriatr Soc** 1999 May; 47(5):600-4

CHEMICALLY INDUCED

A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension. Takata Y, et al. **Biol Pharm Bull** 1999 May;22(5):457-62

Long lasting, grade IV, orthostatic hypotension after a single cycle combination chemotherapy with paclitaxel and cisplatin [letter] Vassilomanolakis M, et al. **Eur J Cancer** 1998 Jul;34(8):1295

Syncope in a 65-year-old woman after nitrate ingestion. Chong Y, et al. **Fukuoka Igaku Zasshi** 1998 Sep;89(9):282-6

Benign prostatic hyperplasia: maximizing treatment with alpha blockers. Lowenthal DT, et al. **Geriatrics** 1998 Oct; 53 Suppl 2:S4-28

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Churchyard A, et al. **Mov Disord** 1999 Mar; 14(2):246-51

Orthostatic hypotension in an elderly patient. Allcock L, et al. **Postgrad Med J** 1998 Nov;74(877):685-7

COMPLICATIONS

Clinical and laboratory indices that enhance the diagnosis of postural tachycardia syndrome. Novak V, et al. **Mayo Clin Proc** 1998 Dec;73(12):1141-50

Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: an overview of classification, clinical evaluation, and management. Grubb BP, et al. **Pacing Clin Electrophysiol** 1999 May;22(5):798-810 (77 ref.)

Orthostatic intolerance in adolescent chronic fatigue syndrome. Stewart JM, et al. **Pediatrics** 1999 Jan; 103(1):116-21

[Image of the month. What collapse!] Scheen AJ. **Rev Med Liege** 1998 Dec;53(12):725-6 **(Fre)**

DIAGNOSIS

Should primary care patients be screened for orthostatic hypotension? Hale WA, et al. **J Fam Pract** 1999 Jul; 48(7):547-52 (26 ref.)

Diagnosis of orthostatic hypotension [letter; comment] Boddaert J, et al. **Lancet** 1998 Nov 21;352(9141):1705-6. Comment on: Lancet 1998 Aug 8;352(9126):458.

An unusual jaw tremor with characteristics of primary orthostatic tremor. Schrag A, et al. **Mov Disord** 1999 May; 14(3):528-30

Assessment of orthostatic blood pressure: measurement technique and clinical applications. Carlson JE. **South Med J** 1999 Feb;92(2):167-73 (68 ref.)

[Diagnosis of orthostatic hypotension] Oldenburg O, et al. **Dtsch Med Wochenschr** 1999 Jun 25;124(25-26):799-801 (21 ref.) **(Ger)**

[Multi-system atrophy or symptomatic orthostatic hypotension] Pryszmont M, et al. **Neurol Neurochir Pol** 1998 Nov-Dec;32(6):1533-7 (Eng. Abstr.) **(Pol)**

[Orthostatic intolerance. A review and clinical case] Freitas J, et al. **Rev Port Cardiol** 1998 Sep;17(9):715-20 (5 ref.) (Eng. Abstr.) **(Por)**

[Specific aspects of the nervous system and brain blood supply in women during prolonged anti-orthostatic hypokinesia] Chumak OB, et al. **Aviakosm Ekolog Med** 1999;33(2):9-12 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Moderate sodium restriction does not alter lower body negative pressure tolerance. Davrath LR, et al. **Aviat Space Environ Med** 1999 Jun;70(6):577-82

Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. Montastruc JL, et al. **Fundam Clin Pharmacol** 1998;12(4):398-402

L-threo-3,4-dihydroxyphenylserine enhances the orthostatic responses of plasma renin activity and angiotensin II in multiple system atrophy. Yoshizawa T, et al. **J Neurol** 1999 Mar;246(3):193-7

EPIDEMIOLOGY

[Prevalence of hypotension and symptomatic, orthostatic dysregulation in a patient sample of a medical polyclinic] Bernard A, et al. **Schweiz Rundsch Med Prax** 1999 Mar 25;88(13):547-58 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Orthostatic hypotension in Alzheimer's disease: result or cause of brain dysfunction? Siennicki-Lantz A, et al. **Aging (Milano)** 1999 Jun;11(3):155-60

Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. Laederach-Hofmann K, et al. **Am J Med** 1999 Jan; 106(1):50-8

The use of oral vasopressors in the management of autonomic dysfunction and orthostatic hypotension. Wittbrodt ET, et al. **Ann Pharmacother** 1999 May;33(5):565-71

Postural hypotension: causes, clinical features, investigation, and management. Mathias CJ, et al. **Annu Rev Med** 1999; 50:317-36 (55 ref.)

Postural hypotension and postural dizziness in patients with non-insulin-dependent diabetes. Wu JS, et al. **Arch Intern Med** 1999 Jun 28;159(12):1350-6

Head-out immersion in the non-human primate: a model of cardiovascular deconditioning during microgravity. Cornish KG, et al. **Aviat Space Environ Med** 1999 Aug; 70(8):773-9

Moderate sodium restriction does not alter lower body negative pressure tolerance. Davrath LR, et al. **Aviat Space Environ Med** 1999 Jun;70(6):577-82

Orthostatic intolerance, blood pressure and its variability. Halmai L, et al. **Fundam Clin Pharmacol** 1998;12 Suppl 1:35s-41s

Autonomic dysfunction and orthostatic hypotention caused by vitamin B12 deficiency [letter] Toru S, et al. **J Neurol Neurosurg Psychiatry** 1999 Jun;66(6):804-5

Continuous drop type of orthostatic hypotension [letter] Yokota T, et al. **J Neurol Neurosurg Psychiatry** 1999 Aug; 67(2):255-6

Postural hypotension and electrolyte disturbances in a 61-year-old man. Ranganath LR, et al. **Postgrad Med J** 1999 Mar;75(881):185-7

[Orthostatic hypotension due to autonomous nervous system dysfunction. Review of different syndromes and their treatment] Grubb BP, et al. **Arch Mal Coeur Vaiss** 1999 Jan;92(1):43-52 (33 ref.) (Eng. Abstr.) **(Fre)**

[Orthostatic hypotension revealing vitamin B12 deficiency] Girard P, et al. **Rev Neurol (Paris)** 1998 May;154(4):342-4 (Eng. Abstr.) **(Fre)**

[Does constitutional hypotension exist?] Pechère-Bertschi A, et al. **Ther Umsch** 1999 Jan;56(1):49-54 (14 ref.) (Eng. Abstr.) **(Fre)**

[Shy-Drager syndrome: a rare cause of orthostatic hypotension] Oldenburg O, et al. **Dtsch Med Wochenschr** 1999 Jan 8;124(1-2):8-12 (Eng. Abstr.) **(Ger)**

GENETICS

Autosomal dominant orthostatic hypotensive disorder maps to chromosome 18q. DeStefano AL, et al. **Am J Hum Genet** 1998 Nov;63(5):1425-30

Mitochondrial DNA mutations in patients with orthostatic hypotension. Schwartz F, et al. **Am J Med Genet** 1999 Sep 10;86(2):145-50

METABOLISM

Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Jacob G, et al. **Circulation** 1999 Apr 6;99(13):1706-12

MORTALITY

Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Masaki KH, et al. **Circulation** 1998 Nov 24;98(21):2290-5

PHYSIOPATHOLOGY

Altered sympathetic and vagal modulations of the cardiovascular system in patients with pheochromocytoma: their relations to orthostatic hypotension. Munakata M, et

al. **Am J Hypertens** 1999 Jun;12(6):572–80
Effects of standing on cerebrovascular resistance in patients with idiopathic orthostatic intolerance. Jacob G, et al. **Am J Med** 1999 Jan;106(1):59–64
Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. Laederach-Hofmann K, et al. **Am J Med** 1999 Jan; 106(1):50–8
Orthostatic intolerance. A historical introduction to the pathophysiological mechanisms. Streeten DH. **Am J Med Sci** 1999 Feb;317(2):78–87 (55 ref.)
Prognosis of diastolic and systolic orthostatic hypotension in older persons. Luukinen H, et al. **Arch Intern Med** 1999 Feb 8;159(3):273–80 (35 ref.)
Female exposure to high G: chronic adaptations of cardiovascular functions. Convertino VA, et al. **Aviat Space Environ Med** 1998 Sep;69(9):875–82
Head-out immersion in the non-human primate: a model of cardiovascular deconditioning during microgravity. Cornish KG, et al. **Aviat Space Environ Med** 1999 Aug; 70(8):773–9
Abnormal myocardial adrenergic nerve function in orthostatic hypotension. Nakamura M, et al. **Cardiology** 1998 Dec;90(3):236–8
Diagnosis of tachycardia syndromes associated with orthostatic symptoms. Braune S, et al. **Clin Auton Res** 1999 Apr;9(2):97–101
Assessment of capillary fluid shifts during orthostatic stress in normal subjects and subjects with orthostatic intolerance. Brown CM, et al. **Clin Auton Res** 1999 Apr;9(2):69–73
A prospective study of orthostatic blood pressure in diabetic patients. de Kanter M, et al. **Clin Auton Res** 1998 Aug; 8(4):189–93
Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Mtinangi BL, et al. **Clin Auton Res** 1998 Aug; 8(4):231–5
Femoral to cerebral arterial blood flow redistribution and femoral vein distension during orthostatic tests after 4 days in the head-down tilt position or confinement. Arbeille P, et al. **Eur J Appl Physiol** 1998 Aug;78(3):208–18
Raised cerebrovascular resistance in idiopathic orthostatic intolerance: evidence for sympathetic vasoconstriction. Jordan J, et al. **Hypertension** 1998 Oct;32(4):699–704
Effects of bilateral vestibular lesions on orthostatic tolerance in awake cats. Jian BJ, et al. **J Appl Physiol** 1999 May; 86(5):1552–60
Orthostatic intolerance in the chronic fatigue syndrome. Schondorf R, et al. **J Auton Nerv Syst** 1999 Feb 15; 75(2–3):192–201
Predictors of medication use, compliance and symptoms of hypotension in a community-based sample of elderly men and women. Cohen I, et al. **J Clin Pharm Ther** 1998 Dec; 23(6):423–32
Patterns of orthostatic intolerance: the orthostatic tachycardia syndrome and adolescent chronic fatigue. Stewart JM, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):218–25
Pathophysiological basis of orthostatic hypotension in autonomic failure. Smit AA, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:1–10 (131 ref.)
Circadian variations of renal sodium handling in patients with orthostatic hypotension. Pechère-Bertschi A, et al. **Kidney Int** 1998 Oct;54(4):1276–82
Water drinking and the heart [letter; comment] Senard JM, et al. **Lancet** 1999 Jun 5;353(9168):1971–2. Comment on: Lancet 1999 Feb 27;353(9154):723.
Clinical and laboratory indices that enhance the diagnosis of postural tachycardia syndrome. Novak V, et al. **Mayo Clin Proc** 1998 Dec;73(12):1141–50

PREVENTION & CONTROL

Novel therapeutic strategy against central baroreflex failure: a bionic baroreflex system. Sato T, et al. **Circulation** 1999 Jul 20;100(3):299–304
Increased orthostatic tolerance following moderate exercise training in patients with unexplained syncope. Mtinangi BL, et al. **Heart** 1998 Dec;80(6):596–600
Acute pulmonary edema associated with placement of waist-high, custom-fit compression stockings [see comments] McCardell CS, et al. **Mayo Clin Proc** 1999 May; 74(5):478–80. Comment in: Mayo Clin Proc 1999 Sep;74(9):946.
[The effect of a two-week anti-orthostatic hypokinesia on the cardiac function and on the latter's regulation in monkeys] Korol'kov VI, et al. **Aviakosm Ekolog Med** 1998; 32(3):30–7 (Eng. Abstr.) **(Rus)**
[Problem of orthostatic intolerance in astronauts and perspectives for its pharmacological prevention] Shashkov VS, et al. **Aviakosm Ekolog Med** 1998;32(4):13–7 (Eng. Abstr.) **(Rus)**

REHABILITATION

Exercise training in orthostatic intolerance [editorial] Hainsworth R. **QJM** 1998 Nov;91(11):715–7
[Effect of antiorthostatic pre-training on transcapillary turnover of fluids in extra- and intracranial vessels of rats in antiorthostatic hypokinesia] Medvedev OS, et al. **Aviakosm Ekolog Med** 1998;32(4):17–21 (Eng. Abstr.) **(Rus)**

SURGERY

Orthostatic hypotension improved after bilateral carotid endarterectomy--case report. Akiyama Y, et al. **Neurol Med Chir (Tokyo)** 1999 Feb;39(2):153–6

THERAPY

Haemodynamic analysis of efficacy of compression hosiery in elderly fallers with orthostatic hypotension [letter] Henry R, et al. **Lancet** 1999 Jul 3;354(9172):45–6
A potent pressor response elicited by drinking water [letter] [see comments] Jordan J, et al. **Lancet** 1999 Feb 27; 353(9154):723. Comment in: Lancet 1999 Jun 5;353(9168):1971–2.

HYPOTENSION, POSTURAL see **HYPOTENSION, ORTHOSTATIC**

HYPOTHALAMIC AREA, ANTERIOR

CYTOLOGY

Distribution of neurons in the anterior hypothalamic nucleus activated by blood pressure changes in the rat. Wyss JM, et al. **Brain Res Bull** 1999 Jun;49(3):163–72

PHYSIOLOGY

Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Szymusiak R, et al. **Brain Res** 1998 Aug 24;803(1-2):178–88
Distribution of neurons in the anterior hypothalamic nucleus activated by blood pressure changes in the rat. Wyss JM, et al. **Brain Res Bull** 1999 Jun;49(3):163–72

HYPOTHALAMIC AREA, LATERAL

CHEMISTRY

Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. Elias CF, et al. **J Comp Neurol** 1998 Dec 28;402(4):442–59

CYTOLOGY

Testosterone increases the number of substance P-like immunoreactive neurons in a specific sub-division of the lateral hypothalamus of the weakly electric, brown ghost knifefish, Apteronotus leptorhynchus. Dulka JG, et al. **Brain Res** 1999 Apr 24;826(1):1–9
Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. Broberger C, et al. **J Comp Neurol** 1998 Dec 28; 402(4):460–74

DRUG EFFECTS

Interactions between sulpiride infusions within the perifornical region of the lateral hypothalamus and the nucleus accumbens on measures of locomotor activity and conditioned place preference. Morutto SL, et al. **Behav Pharmacol** 1998 Jul;9(4):345–55
Effects of the alpha antagonists and agonists injected into the lateral hypothalamus on the water and sodium intake induced by angiotensin II injection into the subfornical organ. Araújo Almeida NA, et al. **Brain Res Bull** 1999 Mar 15;48(5):521–5
Inhibitory effects of 5-hydroxytryptamine microinjection into thalamic nucleus submedius on rat tail flick reflex are mediated by 5-HT2 receptors. Xiao DQ, et al. **Neurosci Lett** 1999 Jan 29;260(2):85–8

IMMUNOLOGY

Lateral hypothalamus modulates the intrinsic splenic natural killer cell activity in rats. Iimori H, et al. **Neuroimmunomodulation** 1998 Sep-Oct;5(5):221–5

METABOLISM

Lateral hypothalamic NMDA receptor subunits NR2A and/or NR2B mediate eating: immunochemical/behavioral evidence. Khan AM, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R880–91
Dehydration modifies somal CRH immunoreactivity in the rat hypothalamus: an immunocytochemical study in the absence of colchicine. Kay-Nishiyama C, et al. **Brain Res** 1999 Mar 20;822(1-2):251–5
Distinct patterns of neuropeptide gene expression in the lateral hypothalamic area and arcuate nucleus are associated with dehydration-induced anorexia. Watts AG, et al. **J Neurosci** 1999 Jul 15;19(14):6111–21
Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area. Griffond B, et al. **Neurosci Lett** 1999 Mar 5;262(2):77–80
Preprohypocretin (orexin) and prolactin-like immunoreactivity are coexpressed by neurons of the rat lateral hypothalamic area. Risold PY, et al. **Neurosci Lett** 1999 Jan 15;259(3):153–6
A search for the metabolic signal that sensitizes lateral hypothalamic self-stimulation in food-restricted rats. Cabeza De Vaca S, et al. **Physiol Behav** 1998 Jun 1; 64(3):251–60

PATHOLOGY

Cytoskeletal alterations in the human tuberal hypothalamus related to argyrophilic grain disease. Schultz C, et al. **Acta Neuropathol (Berl)** 1998 Dec;96(6):596–602
Pick's disease: cytoskeletal changes in the hypothalamic lateral tuberal nucleus. Braak H, et al. **Brain Res** 1998 Aug 17;802(1-2):119–24
Morphological alterations of hypothalamic nuclei due to intrahypothalamic hyperinsulinism in newborn rats. Plagemann A, et al. **Int J Dev Neurosci** 1999 Feb; 17(1):37–44

PHYSIOLOGY

Involvement of the parafascicular nucleus in the facilitative effect of intracranial self-stimulation on active avoidance in rats. Massanés-Rotger E, et al. **Brain Res** 1998 Oct 19; 808(2):220–31
Feeding response to central orexins. Sweet DC, et al. **Brain Res** 1999 Mar 13;821(2):535–8
Role of glutamate in the amygdala and lateral hypothalamus in conditioned taste aversion. Tucci S, et al. **Brain Res** 1998 Nov 30;813(1):44–9
Lateral hypothalamic serotonin inhibits nucleus accumbens dopamine: implications for sexual satiety. Lorrain DS, et al. **J Neurosci** 1999 Sep 1;19(17):7648–52
Self-stimulation of lateral hypothalamus and ventral tegmentum increases the levels of noradrenaline, dopamine, glutamate, and AChE activity, but not 5-hydroxytryptamine and GABA levels in hippocampus and motor cortex. Shankaranarayana Rao BS, et al. **Neurochem Res** 1998 Aug;23(8):1053–9
Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Elias CF, et al. **Neuron** 1999 Aug;23(4):775–86
CCK-8 inhibits ingestive behavior in rats with lateral hypothalamic 6-OHDA lesions. Qian M, et al. **Neuroreport** 1998 Aug 24;9(12):2763–7
Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Moriguchi T, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):101–4
Infusion of nicotine into the LHA enhances dopamine and 5-HT release and suppresses food intake. Yang ZJ, et al. **Pharmacol Biochem Behav** 1999 Sep;64(1):155–9
Effects of NMDA lesions of the medial basal forebrain on LH and VTA self-stimulation. Arvanitogiannis A, et al. **Physiol Behav** 1999 Jan 1-15;65(4-5):805–10
A search for the metabolic signal that sensitizes lateral hypothalamic self-stimulation in food-restricted rats. Cabeza De Vaca S, et al. **Physiol Behav** 1998 Jun 1; 64(3):251–60

PHYSIOPATHOLOGY

Gastric mucosal erosion produced by NMDA microinfusions in the lateral hypothalamus: effect of selective knife cuts. Landeira-Fernandez J, et al. **Behav Brain Res** 1999 Jul; 102(1-2):51–60
Feeding pattern in obese Zucker rats after dopaminergic and serotonergic LHA grafts. Meguid MM, et al. **Neuroreport** 1999 Apr 6;10(5):1049–53

HYPOTHALAMIC DISEASES

Oral-facial-digital syndrome with hypothalamic hamartoma, postaxial ray hypoplasia of the limbs, and vagino-cystic communication: a new variant? Fujiwara I, et al. **Am J Med Genet** 1999 Mar 12;83(2):77–81
Pallister-Hall syndrome [letter; comment] Biesecker LG, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):556. Comment on: Otolaryngol Head Neck Surg 1997 Jan;116(1):129–33.
Hypothalamic hamartoma associated with multiple congenital abnormalities. Two patients and a review of reported cases. Tsugu H, et al. **Pediatr Neurosurg** 1998 Dec; 29(6):290–6 (31 ref.)

BLOOD

Gonadotrophin and prolactin secretory dynamics in girls with normal puberty, idiopathic precocious puberty and precocious puberty due to hypothalamic hamartoma. Uriarte MM, et al. **Clin Endocrinol (Oxf)** 1998 Sep; 49(3):363–8
Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea. Petraglia F, et al. **Fertil Steril** 1998 Nov;70(5):907–12
Nocturnal TSH surge and TRH test response in the evaluation of thyroid axis in hypothalamic pituitary disorders in childhood. Gruñeiro-Papendieck L, et al. **Horm Res** 1998;50(5):252–7

COMPLICATIONS

Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. de Brito VN, et al. **Arch Dis Child** 1999 Mar;80(3):231–4
Hypothalamic obesity: multiple routes mediated by loss of function in medial cell groups. Choi S, et al. **Endocrinology** 1999 Sep;140(9):4081–8
Rats with hypothalamic obesity are insensitive to central

leptin injections. Choi S, et al. **Endocrinology** 1999 Oct; 140(10):4426–33

Induction of ovulation with clomiphene citrate in combination with metoclopramide in patients with amenorrhea of hypothalamic origin. Mendes MC, et al. **Gynecol Endocrinol** 1999 Jun;13(3):149–54

Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. Grinspoon S, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2049–55

Elevated nocturnal melatonin is a consequence of gonadotropin-releasing hormone deficiency in women with hypothalamic amenorrhea. Kadva A, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3653–62

Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. Perkins RB, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1905–11

Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. Warren MP, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):873–7

Diabetes insipidus arising from hypothalamic diffuse axonal injury. Case illustration. Song JK, et al. **J Neurosurg** 1999 Jun;90(6):1141

[A case of hypothalamic hamartoma manifesting gelastic seizure and multifocal independent seizure foci] Kitajima K, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):305–10 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Hamartoma of the suprasellar cistern in a 5-year-old girl. Boto GR, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):131–3

Cranial MR imaging findings in Waardenburg syndrome: anophthalmia, and hypothalamic hamartoma. Sener RN. **Comput Med Imaging Graph** 1998 Sep–Oct;22(5):409–11

How reliable is the short synacthen test for the investigation of the hypothalamic-pituitary-adrenal axis? Bangar V, et al. **Eur J Endocrinol** 1998 Dec;139(6):580–3

Clinical usefulness of the low dose ACTH test [see comments] Patel L, et al. **J Endocrinol Invest** 1999 May; 22(5):401–4 (19 ref.). Comment in: J Endocrinol Invest 1999 Jun;22(6):492–5.

The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. Arita K, et al. **J Neurosurg** 1999 Aug; 91(2):212–20 (63 ref.)

Diabetes insipidus arising from hypothalamic diffuse axonal injury. Case illustration. Song JK, et al. **J Neurosurg** 1999 Jun;90(6):1141

DRUG THERAPY

L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency. Lado-Abeal J, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):203–7

Clinical course of long term treatment with intermittent subcutaneous injection of LHRH in combination with GH replacement in a male patient with hypothalamic hypogonadism due to disruption of the pituitary stalk. Mori T, et al. **Endocr J** 1998 Apr;45 Suppl:S155–8

Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate. Garty BZ, et al. **Eur J Pediatr** 1999 May;158(5):367–70

Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. Feuillan PP, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):44–9

Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist [see comments] Lustig RH, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):162–8. Comment in: J Pediatr 1999 Aug;135(2 Pt 1):142–4.

ETIOLOGY

Multisystem Langerhans cell histiocytosis [letter; comment] Vázquez JA, et al. **Acta Paediatr** 1999 Mar;88(3):349–50. Comment on: Acta Paediatr 1998 Jan;87(1):112–4.

Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Couzinet B, et al. **Clin Endocrinol (Oxf)** 1999 Feb; 50(2):229–35

METABOLISM

Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. Féry F, et al. **N Engl J Med** 1999 Mar 18;340(11):852–6

PHYSIOPATHOLOGY

Paradoxical response to valproic acid in a patient with a hypothalamic hamartoma. Stecker MM, et al. **Ann Pharmacother** 1998 Nov;32(11):1168–72

Evaluation of adrenal function in patients with hypothalamic and pituitary disorders: comparison of serum cortisol, urinary free cortisol and the human-corticotrophin releasing hormone test with the insulin tolerance test. Dullaart RP, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):465–71

A rose is a rose is a rose--or is it? [editorial; comment] Zeitler P. **J Pediatr** 1999 Aug;135(2 Pt 1):142–4. Comment on: J Pediatr 1999 Aug;135(2 Pt 1):162–8.

Role of atrial natriuretic peptide in the development of arterial hypertension in patients with pubertal hypothalamic syndrome. Krivchenko TP, et al. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):435–7

RADIONUCLIDE IMAGING

Hypothalamic hamartomas and gelastic epilepsy: a spectroscopic study. Tasch E, et al. **Neurology** 1998 Oct; 51(4):1046–50

SURGERY

Hamartoma of the suprasellar cistern in a 5-year-old girl. Boto GR, et al. **Childs Nerv Syst** 1999 Mar;15(2–3):131–3

VETERINARY

Adipsia and hypernatraemia in a dog with focal hypothalamic granulomatous meningoencephalitis. Mackay BM, et al. **Aust Vet J** 1999 Jan;77(1):14–7

HYPOTHALAMIC HORMONES

see related
PITUITARY HORMONES, POSTERIOR

[Discovery of prolactin-releasing peptide in the brain] Oda H, et al. **Tanpakushitsu Kakusan Koso** 1999 Jun;44(7):881–6 (24 ref.) **(Jpn)**

ANALYSIS

Prolactin-releasing peptide-immunoreactivity in A1 and A2 noradrenergic neurons of the rat medulla. Chen C, et al. **Brain Res** 1999 Mar 20;822(1–2):276–9

Survival of rat MCH (melanin-concentrating hormone) neurons in hypothalamus slice culture: histological, pharmacological and molecular studies. Bayer L, et al. **Cell Tissue Res** 1999 Jul;297(1):23–33

Immunocytochemical localization of prolactin-releasing peptide in the rat brain. Maruyama M, et al. **Endocrinology** 1999 May;140(5):2326–33

ANTAGONISTS & INHIBITORS

Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat. Sahu A. **Endocrinology** 1998 Nov;139(11):4739–42

BIOSYNTHESIS

Antisense expression of the human pro-melanin-concentrating hormone genes. Miller CL, et al. **Brain Res** 1998 Aug 24;803(1–2):86–94

Synthesis of new peptides with prolactin-releasing activity by a combination of recombinant DNA technology and a cysteine-specific cyanylation reaction. Nishimura O, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep;46(9):1490–2

Melanin-concentrating hormone-producing neurons in birds. Cardot J, et al. **J Comp Neurol** 1999 Aug 23;411(2):239–56

Cellular localization of prolactin-releasing peptide messenger RNA in the rat brain. Minami S, et al. **Neurosci Lett** 1999 Apr 30;266(1):73–5

Rat diencephalic neurons producing melanin-concentrating hormone are influenced by ascending cholinergic projections. Bayer L, et al. **Neuroscience** 1999; 91(3):1087–101

BLOOD

Distribution and characterization of immunoreactive prolactin-releasing peptide (PrRP) in rat tissue and plasma. Matsumoto H, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):264–8

GENETICS

Antisense expression of the human pro-melanin-concentrating hormone genes. Miller CL, et al. **Brain Res** 1998 Aug 24;803(1–2):86–94

Survival of rat MCH (melanin-concentrating hormone) neurons in hypothalamus slice culture: histological, pharmacological and molecular studies. Bayer L, et al. **Cell Tissue Res** 1999 Jul;297(1):23–33

Characterization of a cDNA encoding a precursor of Carassius RFamide, structurally related to a mammalian prolactin-releasing peptide. Satake H, et al. **FEBS Lett** 1999 Mar 12;446(2–3):247–50

Radiation hybrid mapping of the two highly homologous human-variant pMCHL genes by PCR-SSCP. Miller CL, et al. **Genome Res** 1998 Jul;8(7):737–40

ISOLATION & PURIFICATION

Isolation and identification of melanin-concentrating hormone as the endogenous ligand of the SLC-1 receptor. Shimomura Y, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):622–6

The quest for novel bioactive peptides utilizing orphan seven-transmembrane-domain receptors. Hinuma S, et al. **J Mol Med** 1999 Jun;77(6):495–504 (64 ref.)

METABOLISM

Distribution and characterization of immunoreactive prolactin-releasing peptide (PrRP) in rat tissue and plasma. Matsumoto H, et al. **Biochem Biophys Res Commun** 1999 Apr 13;257(2):264–8

Isolation and identification of melanin-concentrating hormone as the endogenous ligand of the SLC-1 receptor. Shimomura Y, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):622–6

Melanin-concentrating hormone and neuropeptide EI projections from the lateral hypothalamic area and zona incerta to the medial septal nucleus and spinal cord: a study using multiple neuronal tracers. Bittencourt JC, et al. **Brain Res** 1998 Sep 14;805(1–2):1–19

Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1). Bächner D, et al. **FEBS Lett** 1999 Sep 3; 457(3):522–4

Cellular localization and role of prohormone convertases in the processing of pro-melanin concentrating hormone in mammals. Viale A, et al. **J Biol Chem** 1999 Mar 5; 274(10):6536–45

Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. Broberger C, et al. **J Comp Neurol** 1998 Dec 28; 402(4):460–74

Synthesis and characterization of new radioligands for the mammalian melanin-concentrating hormone (MCH) receptor. Hintermann E, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1–4):411–22

Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Chambers J, et al. **Nature** 1999 Jul 15;400(6741):261–5

Molecular characterization of the melanin-concentrating-hormone receptor. Saito Y, et al. **Nature** 1999 Jul 15;400(6741):265–9

Identification of synaptic metabolites of dynorphin A (1-8) by electrospray ionization and tandem mass spectrometry. Prokai L, et al. **Rapid Commun Mass Spectrom** 1998; 12(22):1796–800

PHARMACOLOGY

Stimulation of prolactin release by prolactin-releasing peptide in rats. Matsumoto H, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):321–4

Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Tritos NA, et al. **Diabetes** 1998 Nov; 47(11):1687–92

Gender-biased activity of the novel prolactin releasing peptides: comparison with thyrotropin releasing hormone reveals only pharmacologic effects. Samson WK, et al. **Endocrine** 1998 Dec;9(3):289–91

Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat. Sahu A. **Endocrinology** 1998 Nov;139(11):4739–42

Behavioral effects of neuropeptide E-I (NEI) in the female rat: interactions with alpha-MSH, MCH and dopamine. Gonzalez MI, et al. **Peptides** 1998;19(6):1007–16

PHYSIOLOGY

Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. Elias CF, et al. **J Comp Neurol** 1998 Dec 28;402(4):442–59

Mice lacking melanin-concentrating hormone are hypophagic and lean. Shimada M, et al. **Nature** 1998 Dec 17;396(6712):670–4

HYPOTHALAMIC NEOPLASMS

COMPLICATIONS

Autonomic and hormonal ictal changes in gelastic seizures from hypothalamic hamartomas. Cerullo A, et al. **Electroencephalogr Clin Neurophysiol** 1998 Nov; 107(5):317–22

Hypercalcemia in an euthyroid patient with secondary hypoadrenalism and diabetes insipidus due to hypothalamic tumor. Hotta M, et al. **Endocr J** 1998 Dec;45(6):773–8

Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes inspidus and hyperthyroidism. Wada S, et al. **Intern Med** 1999 Jun; 38(6):486–90

Hypothalamic juvenile pilocytic astrocytoma presenting with intracerebral hemorrhage. Hwang SL, et al. **J Formos Med Assoc** 1998 Nov;97(11):784–7

DIAGNOSIS

Ictal bradycardia in a patient with a hypothalamic hamartoma: a stereo-EEG study. Kahane P, et al. **Epilepsia** 1999 Apr;40(4):522–7

Evolution of childhood central diabetes insipidus into panhypopituitarism with a large hypothalamic mass: is 'lymphocytic infundibuloneurohypophysitis' in children a different entity? Maghnie M, et al. **Eur J Endocrinol** 1998 Dec;139(6):635–40

PATHOLOGY

AgNOR staining may reflect the growth potential of pilocytic astrocytomas. Dirven CM, et al.

Childs Nerv Syst 1999 Aug;15(8):384–8
Spontaneous remission of chiasmatic/hypothalamic masses in neurofibromatosis type 1: report of two cases. Gottschalk S, et al. **Neuroradiology** 1999 Mar;41(3):199–201

PHYSIOPATHOLOGY

An association of hypothalamic hamartoma, central precocious puberty and juvenile granulosa cell tumour in early childhood. Feilberg Jørgensen N, et al. **Horm Res** 1998;49(6):292–4

RADIOTHERAPY

Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Cappelli C, et al. **Arch Dis Child** 1998 Oct;79(4):334–8

SECONDARY

Polyuria in a patient with fibrosing alveolitis. Meghjee SP, et al. **Postgrad Med J** 1999 Jan;75(879):55–7

SURGERY

Hypothalamic gliomas. Dolenc VV.
Adv Tech Stand Neurosurg 1999;25:161–94 (57 ref.)
Computer simulation of a neurosurgical operation: craniotomy for hypothalamic hamartoma. Sgouros S, et al. **Childs Nerv Syst** 1998 Jul;14(7):322–7
Management of recurrent pilocytic astrocytoma with leptomeningeal dissemination in childhood. Tamura M, et al. **Childs Nerv Syst** 1998 Nov;14(11):617–22 (19 ref.)
[Gelastic seizures treated by partial resection of a hypothalamic hamartoma] Watanabe T, et al.
No Shinkei Geka 1998 Oct;26(10):923–8 (Eng. Abstr.) **(Jpn)**

HYPOTHALAMIC NUCLEUS, DORSOMEDIAL see **DORSOMEDIAL HYPOTHALAMIC NUCLEUS**

HYPOTHALAMIC NUCLEUS, VENTROMEDIAL see **VENTROMEDIAL HYPOTHALAMIC NUCLEUS**

HYPOTHALAMIC PARAVENTRICULAR NUCLEUS see **PARAVENTRICULAR HYPOTHALAMIC NUCLEUS**

HYPOTHALAMIC RELEASE-INHIBITING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

HYPOTHALAMIC RELEASING HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE**

HYPOTHALAMO-HYPOPHYSEAL SYSTEM

see related
PITUITARY HORMONE-RELEASING HORMONES
Psychological and endocrine correlates of chronic pelvic pain associated with adhesions. Heim C, et al.
J Psychosom Obstet Gynaecol 1999 Mar;20(1):11–20
[Liver and endocrine system. Part II: pituitary-gonadal axis and adrenal gland activity disturbances] Marek B, et al. **Wiad Lek** 1998;51(7–8):352–9 (23 ref.) (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Elchebly M, et al. **Nat Genet** 1999 Mar; 21(3):330–3
[Diabetes insipidus with a hypothalamo-hypophyseal morphologic anomaly during a pregnancy] Fluteau-Nadler S, et al. **Presse Med** 1998 Jun 20;27(22):1095–8 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. Sawchenko PE.
J Comp Neurol 1998 Dec 28;402(4):435–41 (70 ref.)

CHEMISTRY

Localization of endothelin-like immunoreactivity in the hypothalamo-neurohypophysial system of the rat after ischemia. Gajkowska B, et al. **Folia Neuropathol** 1996; 34(4):173–7
Adrenomedullin-like immunoreactivity in the rat hypothalamo-neurohypophysial tract. Ueta Y, et al.
Peptides 1999;20(2):199–204

CYTOLOGY

Neurophysiology of magnocellular neuroendocrine cells: recent advances. Hatton GI, et al. **Prog Brain Res** 1998; 119:77–99 (130 ref.)

DRUG EFFECTS

Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Farren CK, et al.
Alcohol Clin Exp Res 1999 Mar;23(3):502–8
Effects of prenatal exposure to alcohol on the release of adenocorticotropic hormone, corticosterone, and proinflammatory cytokines. Kim CK, et al.
Alcohol Clin Exp Res 1999 Jan;23(1):52–9
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Schluger JH, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1430–6
Interaction of ethanol and nitric oxide in the hypothalamic-pituitary-gonadal axis in the male rat. Shi Q, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1754–62
Effect of nitric oxide synthase inhibitors on preventing ethanol-induced suppression of the hypothalamic-pituitary-gonadal axis in the male rat. Shi Q, et al. **Alcohol Clin Exp Res** 1998 Nov;22(8):1763–70
Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease. Asthana S, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun; 13(2):102–8
Intracerebroventricular injection of anti-Fas activates the hypothalamus-pituitary-adrenal axis and induces peripheral interleukin-6 and serum amyloid A in mice: comparison with other ligands of the tumor necrosis factor/nerve growth factor receptor superfamily. Benigni F, et al. **Am J Pathol** 1998 Nov;153(5):1377–81
Adrenal suppression secondary to inhaled fluticasone propionate. Taylor AV, et al.
Ann Allergy Asthma Immunol 1999 Jul;83(1):68–70
Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. Gianotti L, et al.
Biol Psychiatry 1999 Feb 1;45(3):334–9
Dorsomedial hindbrain participation in glucoprivic feeding response to 2DG but not 2DG-induced hyperglycemia or activation of the HPA axis. Edmonds BK, et al.
Brain Res 1998 Aug 10;801(1–2):21–8
Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Lacosta S, et al. **Brain Res** 1999 Feb 13;818(2):291–303
Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic-pituitary-adrenal axis and sympathetic nervous system. Woiciechowsky C, et al. **Brain Res** 1999 Jan 23;816(2):563–71
Effects of halothane and methoxyflurane on the hypothalamic-pituitary-adrenal axis in rat. Karuri AR, et al. **Brain Res Bull** 1998 Oct;47(3):205–9
The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis. Raab C, et al. **Clin Endocrinol (Oxf)** 1999 Jan;50(1):37–44
Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Sorkness CA, et al.
Clin Ther 1999 Feb;21(2):353–67
Effects of repeated injections of interleukin 1beta or lipopolysaccharide on the HPA axis in the newborn rat. Bumiller A, et al. **Cytokine** 1999 Mar;11(3):225–30
Relationships between environmental organochlorine contaminant residues, plasma corticosterone concentrations, and intermediary metabolic enzyme activities in Great Lakes herring gull embryos. Lorenzen A, et al. **Environ Health Perspect** 1999 Mar;107(3):179–86
Influence of body mass on the hypothalamic-pituitary-adrenal-axis response to naloxone in patients with polycystic ovary syndrome. Guido M, et al. **Fertil Steril** 1999 Mar;71(3):462–7
Oxidant anti-oxidant imbalance and effects of ethanol. Rivier C. **Front Biosci** 1999 Jun 1;4:D514–9 (59 ref.)
Persistent effects of prenatal, neonatal, or adult treatment with flutamide on the hypothalamic-pituitary-adrenal stress response of adult male rats. McCormick CM, et al. **Horm Behav** 1999 Feb;35(1):90–101
Hypothalamic-pituitary-adrenal axis suppression associated with the use of inhaled fluticasone propionate [see comments] Duplantier JE, et al.
J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):699–700. Comment in: J Allergy Clin Immunol 1999 Jun;103(6):1224.
Effect of fluticasone propionate nasal spray on the hypothalamic-pituitary-adrenal axis [letter; comment] Lipworth B, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):537–8. Comment on: J Allergy Clin Immunol 1998 Aug;102(2):191–7.
Systemic effects of intranasal corticosteroids [letter; comment] Storms WW. **J Allergy Clin Immunol** 1999 Jan; 103(1 Pt 1):177–8. Comment on: J Allergy Clin Immunol 1998 Apr;101(4 Pt 1):470–4.
Systemic effects of inhaled fluticasone propionate [letter; comment] Thompson JR, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1224. Comment on: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):699–700.
Measures of hypothalamic-pituitary-adrenal function in patients with asthma treated with inhaled glucocorticoids: clinical and research implications. Wolthers OD, et al.
J Asthma 1999 Sep;36(6):477–86 (119 ref.)
The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities. Maghnie M, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3886–9
Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. Toogood AA, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):131–6
Epiphenomenal, causal, or correlational--more on the mechanism(s) of action of antidepressants [editorial] Shader RI, et al. **J Clin Psychopharmacol** 1998 Aug;18(4):265–7 (26 ref.)
The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies [letter; comment] Fernández-Fernández FJ, et al. **J Intern Med** 1999 Jul;246(1):122–3. Comment on: J Intern Med 1998 Nov;244(5):411–6.
The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies [see comments] Kauppila M, et al.
J Intern Med 1998 Nov;244(5):411–6. Comment in: J Intern Med 1999 Jul;246(1):122–3.
Hyperactivity of hypothalamic pituitary axis in neonatal clomipramine model of depression. Prathiba J, et al.
J Neural Transm 1998;105(10–12):1335–9
Long-lasting deficient dexamethasone suppression of hypothalamic-pituitary-adrenocortical activation following peripheral CRF challenge in socially defeated rats. Buwalda B, et al. **J Neuroendocrinol** 1999 Jul; 11(7):513–20
Evidence that cholecystokinin receptors are not involved in the hypothalamic-pituitary-adrenal response to intraperitoneal administration of interleukin-1beta. Day HE, et al. **J Neuroendocrinol** 1999 Jul;11(7):561–8
Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. Jensen JB, et al.
J Neuroendocrinol 1999 Jun;11(6):465–71
Endogenous alpha-MSH modulates the hypothalamic-pituitary-adrenal response to the cytokine interleukin-1beta. Papadopoulos AD, et al.
J Neuroendocrinol 1999 Apr;11(4):315–9
Cocaine-reinforced responding in rhesus monkeys: pharmacological attenuation of the hypothalamic-pituitary-adrenal axis response. Broadbear JH, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1347–55
Effects of response contingent and noncontingent cocaine injection on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Broadbear JH, et al.
J Pharmacol Exp Ther 1999 Jul;290(1):393–402
The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic-pituitary-adrenal axis responses. Mellon RD, et al.
J Pharmacol Exp Ther 1999 Feb;288(2):635–42
Blockade of nitric oxide formation impairs adrenergic-induced ACTH and corticosterone secretion. Bugajski J, et al. **J Physiol Pharmacol** 1999 Jun;50(2):327–34
Effects of acute inhalation exposure to isoamyl nitrite on the hypothalamo-pituitary-adrenal axis in male Sprague-Dawley rats. Ramanathan VM, et al.
J Toxicol Environ Health 1998 Nov 13;55(5):345–58
Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Wong ML, et al. **Life Sci** 1999; 65(4):PL53–8
Effects of methanol extract of Chansu on hypothalamic-pituitary-testis function in rats. Wang SW, et al. **Metabolism** 1998 Oct;47(10):1211–6
Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Wang J, et al.
Neurochem Int 1998 Aug;33(2):143–54
Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo-pituitary-adrenocortical axis. Barkhudaryan N, et al. **Neurochem Res** 1999 Sep;24(9):1169–80 (183 ref.)
Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Betancur C, et al.
Neuropsychopharmacology 1998 Oct;19(4):322–32
Hypothalamic-pituitary-adrenocortical and gonadal axes and sympathoadrenal activity of adult male rats prenatally exposed to morphine. Dutriez-Casteloot I, et al.
Neurosci Lett 1999 Mar 19;263(1):1–4
Interactions between glucocorticoids and the growth hormone-insulin-like growth factor axis. Tönshoff B, et al. **Pediatr Transplant** 1997 Nov;1(2):183–9 (62 ref.)
Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma. Debeljuk L, et al. **Peptides** 1999; 20(2):285–99 (139 ref.)
Lactic acid does not directly activate hypothalamic-pituitary corticotroph function. Petrides JS, et al.
Proc Soc Exp Biol Med 1999 Feb;220(2):100–5
Effects of rearing condition on HPA axis response to fluoxetine and desipramine treatment over repeated social separations in young rhesus monkeys. Clarke AS, et al.
Psychiatry Res 1998 Jun 15;79(2):91–104
High-dose naloxone (1.0 mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone. Martin-Del-Campo AF, et al. **Psychoneuroendocrinology** 1998 May;23(4):413–24
Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Kirschbaum C, et al.
Psychosom Med 1999 Mar–Apr;61(2):154–62
Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Thompson PJ, et al.
Respir Med 1998 Jun;92 Suppl A:33–9
Blockade of the hypothalamic-pituitary-testicular axis with a GnRH antagonist in the neonatal marmoset monkey: changes in Leydig cell ultrastructure. Prince FP, et al.

Tissue Cell 1998 Dec;30(6):651-61

Neuroendocrine and reproductive effects of contemporary-use pesticides. Cooper RL, et al. **Toxicol Ind Health** 1999 Jan-Mar;15(1-2):26-36 (44 ref.)

[Effect of three kinds (tonifying kidney, invigorating spleen, promoting blood circulation) recipes on the hypothalamus-pituitary-adrenal-thymus (HPAT) axis and CRF gene expression] Zhong LY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jan; 17(1):39-41 (Eng. Abstr.) **(Chi)**

[Withdrawing corticosteroid therapy: the stress of the last milligrams...] Dupond JL, et al. **Presse Med** 1999 Jan 23; 28(3):140-2 (Eng. Abstr.) **(Fre)**

[Influence of salmon calcitonin on changes in thyroid hormone concentration and on TSH secretion. II.] Bodzenta E, et al. **Pol Arch Med Wewn** 1998 Sep; 100(3):205-11 (Eng. Abstr.) **(Pol)**

EMBRYOLOGY

A model for the development of the hypothalamic-pituitary axis: transcribing the hypophysis. Kioussi C, et al. **Mech Dev** 1999 Mar;81(1-2):23-35 (82 ref.)

ENZYMOLOGY

Choline acetyltransferase immunoreactivity in the hypothalamoneurohypophysial system of the lamprey. Pombal MA, et al. **Eur J Morphol** 1999 Apr;37(2-3):103-6

Effects of oestrogen upon nitric oxide synthase NADPH-diaphorase activity in the hypothalamo-neurohypophysial system of the rat. Wang H, et al. **Neuroscience** 1999 Jan;88(1):151-8

IMMUNOLOGY

Mechanisms mediating the influence of alcohol on the hypothalamic-pituitary-adrenal axis responses to immune and nonimmune signals. Ogilvie K, et al. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):243S-247S (31 ref.)

Central nervous system activation following peripheral chemical sympathectomy: implications for neural-immune interactions. Callahan TA, et al. **Brain Behav Immun** 1998 Sep;12(3):230-41

The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta. Wang J, et al. **Brain Res** 1999 Jan 9;815(2):337-48

Hypophyseal-pituitary-adrenal axis in autoimmune and rheumatic diseases. Athreya BH, et al. **Immunol Res** 1998; 18(2):93-102 (56 ref.)

Glutamate augments retrovirus-induced immunodeficiency through chronic stimulation of the hypothalamic-pituitary-adrenal axis. Espey MG, et al. **J Immunol** 1999 Apr 15; 162(8):4998-5002

Differential immune responses in mice with left- and right-turning preference. Kim D, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):164-71

Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov-Dec;5(6):277-87 (61 ref.)

Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Chrousos GP, et al. **Neuroimmunomodulation** 1998 Nov-Dec;5(6):288-308 (70 ref.)

The effect of depressive symptomatology on plasma cortisol responses to acute bicycle exercise among post-menopausal women. van der Pompe G, et al. **Psychiatry Res** 1999 Jan 18;85(1):113-7

[Liver and endocrine system. Part I: pituitary-thyroid axis activity disorders] Marek B, et al. **Wiad Lek** 1998; 51(5-6):271-6 (23 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Adrenocortical responses and family history of alcoholism. Wand GS, et al. **Alcohol Clin Exp Res** 1999 Jul; 23(7):1185-90

Hypothalamus, anterior pituitary and adrenal gland involvement in the activation of adrenocorticotropin and corticosterone secretion by gastrin-releasing peptide. Garrido MM, et al. **Brain Res** 1999 May 15;828(1-2):20-6

Prenatal dexamethasone treatment does not prevent alterations of the hypothalamic pituitary adrenal axis in steroid 21-hydroxylase deficient mice. Tajima T, et al. **Endocrinology** 1999 Jul;140(7):3354-62

Evaluation of hypothalamic-pituitary-adrenocortical hormones and inflammatory cytokines in patients with persistent vegetative state. Munno I, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):519-29

Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids [see comments] Cutolo M, et al. **J Rheumatol** 1999 Feb;26(2):282-8. Comment in: J Rheumatol 1999 Feb;26(2):247-50.

Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. Gutiérrez MA, et al. **J Rheumatol** 1999 Feb;26(2):277-81

Immune challenge-stimulated hypophysiotropic corticotropin-releasing hormone messenger RNA expression is associated with an induction of neurotensin messenger RNAs without alteration of vasopressin messenger RNAs. Juaneda C, et al. **Neuroscience** 1999; 93(1):393-400

Microtubule-associated protein-2 in the hypothalamo-neurohypophysial system: low-molecular-weight microtubule-associated protein-2 in pituitary astrocytes. Matsunaga W, et al. **Neuroscience** 1999; 88(4):1289-97

Thyroid axis sustaining hypothesis of posttraumatic stress disorder [editorial; comment] Prange AJ Jr. **Psychosom Med** 1999 Mar-Apr;61(2):139-40. Comment on: Psychosom Med 1999 Mar-Apr;61(2):131-8.

PATHOLOGY

Prenatal dexamethasone treatment does not prevent alterations of the hypothalamic pituitary adrenal axis in steroid 21-hydroxylase deficient mice. Tajima T, et al. **Endocrinology** 1999 Jul;140(7):3354-62

Preliminary observations of the cytological structure of the hypothalamo-neurohypophyseal magnocellular neuroendocrine system in field voles after acute thermal stress. Sawicki B, et al. **Folia Histochem Cytobiol** 1999; 37(2):73-4

Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Elchebly M, et al. **Nat Genet** 1999 Mar; 21(3):330-3

PHYSIOLOGY

Do neonatal pain and stress program the brain's response to future stimuli? [comment] Winberg J. **Acta Paediatr** 1998 Jul;87(7):723-5. Comment on: Acta Paediatr 1998 Jul;87(7):774-9.

Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. Burbach JP, et al. **Adv Exp Med Biol** 1998;449:29-37 (59 ref.)

Gaseous neurotransmitter modulation of vasopressin and oxytocin release. Forsling ML, et al. **Adv Exp Med Biol** 1998;449:191-2

Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Gainer H. **Adv Exp Med Biol** 1998; 449:15-27 (59 ref.)

Local protein synthesis in magnocellular dendrites. Basic elements and their response to hyperosmotic stimuli. Ma D, et al. **Adv Exp Med Biol** 1998;449:55-7

Regulation of vasopressin release by ionotropic glutamate receptor agonists. Morsette DJ, et al. **Adv Exp Med Biol** 1998;449:129-30

Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Lenczowski MJ, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):R652-8

Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro. Rossi NF. **Am J Physiol** 1998 Oct;275(4 Pt 1):E687-93

Proceedings of the 1st International Conference on the Neuroendocrine Immune Basis of the Rheumatic Diseases. Genova, Italy, September 18-20, 1998. **Ann N Y Acad Sci** 1999 Jun 22;876:xi-xv, 1-433

Adaptive interactions between cytokines and the hypothalamic-pituitary-gonadal axis. Cannon JG. **Ann N Y Acad Sci** 1998 Sep 29;856:234-42 (64 ref.)

Neuroendocrine immune basis of the rheumatic diseases. Cutolo M, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:xi-xv

Individual variation in hypothalamus-pituitary-adrenal responsiveness of rats to endotoxin and interleukin-1 beta. Lenczowski MJ, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:139-47 (52 ref.)

Effects of 60 Hz magnetic field exposure on the pineal and hypothalamic-pituitary-gonadal axis in the Siberian hamster (Phodopus sungorus). Wilson BW, et al. **Bioelectromagnetics** 1999;20(4):224-32

Something fishy in the rat brain: molecular genetics of the hypothalamo-neurohypophysial system. Murphy D, et al. **Bioessays** 1998 Sep;20(9):741-9 (62 ref.)

Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. Posener JA, et al. **Biol Psychiatry** 1999 Jan 15;45(2):222-8

Prolactin activates all three populations of hypothalamic neuroendocrine dopaminergic neurons in ovariectomized rats. DeMaria JE, et al. **Brain Res** 1999 Aug 7; 837(1-2):236-41

Activation of the hypothalamic-pituitary axis in adrenalectomised rats: potentiation by chronic stress. Marti O, et al. **Brain Res** 1999 Mar 6;821(1):1-7

Hypothalamic oxytocin in the developing ovine fetus: interaction with pituitary-adrenocortical function. Matthews SG. **Brain Res** 1999 Feb 27;820(1-2):92-100

Area postrema removal abolishes stimulatory effects of intravenous interleukin-1beta on hypothalamic-pituitary-adrenal axis activity and c-fos mRNA in the hypothalamic paraventricular nucleus. Lee HY, et al. **Brain Res Bull** 1998 Aug;46(6):495-503

Early vs. late maternal deprivation differentially alters the endocrine and hypothalamic responses to stress. van Oers HJ, et al. **Brain Res Dev Brain Res** 1998 Dec 7; 111(2):245-52

Regulation of hypothalamic somatostatin and growth hormone releasing hormone mRNA levels by inhibin. Carro E, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1-2):191-4

Osmotic activation of the hypothalamo-neurohypophysial system reversibly downregulates the NMDA receptor subunit, NR2B, in the supraoptic nucleus of the hypothalamus. Curras-Collazo MC, et al. **Brain Res Mol Brain Res** 1999 Jul 5;70(2):187-96

Thyroid and fertility. Mayer G, et al. **Coll Antropol** 1998 Jun;22(1):17-21 (38 ref.)

Alterations in hypothalamic-pituitary-adrenal function associated with captivity in Gambel's white-crowned sparrows (Zonotrichia leucophrys gambelii). Romero LM, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Jan;122(1):13-20

Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Lincoln GA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Jun;119(3):283-94 (78 ref.)

Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus [see comments] Björntorp P, et al. **Diabet Med** 1999 May;16(5):373-83. Comment in: Diabet Med 1999 May;16(5):355-7.

Behavior and pituitary-adrenal function in large white and Meishan pigs. Désautés C, et al. **Domest Anim Endocrinol** 1999 May;16(4):193-205

Effect of exogenous FSH on ovulation rate in homozygous carriers or noncarriers of the Booroola FecB gene after hypothalamic-pituitary disconnection or after treatment with a GnRH agonist. Hudson NL, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):69-80

Estradiol and gonadotropin-releasing hormone (GnRH) interact to increase GnRH receptor expression in ovariectomized ewes after hypothalamic-pituitary disconnection. Kirkpatrick BL, et al. **Endocrine** 1998 Jun; 8(3):225-9

Nonresponsiveness of the rat hypothalamo-pituitary-adrenocortical axis to parturition-related events: inhibitory action of endogenous opioids. Wigger A, et al. **Endocrinology** 1999 Jun; 140(6):2843-9

The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function. Ambrosi B, et al. **Eur J Endocrinol** 1998 Dec;139(6):575-9

On the meaning of low-dose ACTH(1-24) tests to assess functionality of the hypothalamic-pituitary-adrenal axis. Darmon P, et al. **Eur J Endocrinol** 1999 Jan;140(1):51-5

Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Krysiak R, et al. **Eur J Endocrinol** 1999 Feb;140(2):130-6 (65 ref.)

Hypothalamus-pituitary-adrenal activity during human sleep: a coordinating role for the limbic hippocampal system. Born J, et al. **Exp Clin Endocrinol Diabetes** 1998; 106(3):153-63 (81 ref.)

Physiological regulation of hypothalamic TRH transcription in vivo is T3 receptor isoform specific. Guissouma H, et al. **FASEB J** 1998 Dec;12(15):1755-64

Animal models of CRH deficiency. Venihaki M, et al. **Front Neuroendocrinol** 1999 Apr;20(2):122-45 (144 ref.)

Endocrine changes in critically ill patients. Van den Berghe G. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:77-81 (28 ref.)

Insulin receptors and signal transduction proteins in the hypothalamo-hypophyseal system: a review on morphological findings and functional implications. Unger JW, et al. **Histol Histopathol** 1998 Oct;13(4):1215-24 (74 ref.)

Hypothalamo-hypophysial connection revisited [editorial] **Indian J Physiol Pharmacol** 1998 Apr;42(2):153-4

The interactions between hypothalamic-pituitary-adrenal axis activity, testosterone, insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Rosmond R, et al. **Int J Obes Relat Metab Disord** 1998 Dec;22(12):1184-96

Neuroendocrine system and mental function in sedentary and endurance-trained elderly males. Strüder HK, et al. **Int J Sports Med** 1999 Apr;20(3):159-66

Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. Li JT, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):622-9

Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis. Veldhuis JD. **J Androl** 1999 Jan-Feb;20(1):1-17 (141 ref.)

Birth by caesarian section alters postnatal function of the hypothalamic-pituitary-adrenal axis in young pigs. Daniel JA, et al. **J Anim Sci** 1999 Mar;77(3):742-9

Effects of oral chlortetracycline and dietary protein level on plasma concentrations of growth hormone and thyroid hormones in beef steers before and after challenge with a combination of thyrotropin-releasing hormone and growth hormone-releasing hormone. Rumsey TS, et al. **J Anim Sci** 1999 Aug;77(8):2079-87

Adrenocorticotropic hormone and cortisol in calves after corticotropin-releasing hormone. Veissier I, et al. **J Anim Sci** 1999 Aug;77(8):2047-53

Comment on comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease [letter] Oelkers W. **J Clin Endocrinol Metab** 1999 Aug;84(8):2973-4

Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. Sawchenko PE. **J Comp Neurol** 1998 Dec 28;402(4):435-41 (70 ref.)

Review: Central non-glucocorticoid inhibitors of the

hypothalamo-pituitary-adrenal axis. Jessop DS. **J Endocrinol** 1999 Feb;160(2):169-80 (139 ref.)

Hyper-reactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behaviour. Landgraf R, et al. **J Neuroendocrinol** 1999 Jun;11(6):405-7

Apomorphine-susceptible and apomorphine-unsusceptible Wistar rats differ in their susceptibility to inflammatory and infectious diseases: a study on rats with group-specific differences in structure and reactivity of hypothalamic-pituitary-adrenal axis. Kavelaars A, et al. **J Neurosci** 1997 Apr 1;17(7):2580-4

Alterations in the hypothalamic pituitary adrenal axis during pregnancy and the placental clock that determines the length of parturition. Smith R. **J Reprod Immunol** 1998 Aug;39(1-2):215-20 (16 ref.)

Modeling the involvement of the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes in autoimmune and stress-related rheumatic syndromes in women. Crofford LJ, et al. **J Womens Health** 1999 Mar;8(2):203-15 (58 ref.)

Hypothalamic-pituitary-adrenal axis and sympathetic nervous system activities in Pima Indians and Caucasians. Tataranni PA, et al. **Metabolism** 1999 Mar;48(3):395-9

Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans. Deuschle M, et al. **Neuroendocrinology** 1998 Nov; 68(5):355-60

Hypothalamic-pituitary-gonadal axis in the mutant weaver mouse. Schwartz NB, et al. **Neuroendocrinology** 1998 Dec; 68(6):374-85

Immunoneuroendocrine connectivity: the paradigm of the thymus-hypothalamus/pituitary axis. Savino W, et al. **Neuroimmunomodulation** 1999 Jan-Apr;6(1-2):126-36 (151 ref.)

Brief predator odour exposure activates the HPA axis independent of locomotor changes. Perrot-Sinal TS, et al. **Neuroreport** 1999 Mar 17;10(4):775-80

Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis. Nussdorfer GG, et al. **Peptides** 1998;19(8):1443-67 (346 ref.)

Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Turnbull AV, et al. **Physiol Rev** 1999 Jan;79(1):1-71 (1004 ref.)

Lactic acid does not directly activate hypothalamic-pituitary corticotroph function. Petrides JS, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):100-5

Neurophysiology of magnocellular neuroendocrine cells: recent advances. Hatton GI, et al. **Prog Brain Res** 1998; 119:77-99 (130 ref.)

The human hypothalamo-neurohypophysial system in health and disease. Swaab DF. **Prog Brain Res** 1998;119:577-618 (297 ref.)

The magnocellular neurons of the hypothalamo-neurohypophyseal system display remarkable neuropeptidergic phenotypes leading to novel insights in neuronal cell biology. van Leeuwen FW, et al. **Prog Brain Res** 1998;119:115-26 (62 ref.)

Corticosteroid hormones and neuronal vulnerability: towards identification of candidate vulnerability genes. Vreugdenhil E, et al. **Prog Brain Res** 1998;117:9-22 (92 ref.)

Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour. Neumann ID, et al. **Psychoneuroendocrinology** 1998 Jul;23(5):449-63

Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Posener JA, et al. **Psychoneuroendocrinology** 1998 May;23(4):371-83

Stress and the developing limbic-hypothalamic-pituitary-adrenal axis. Vázquez DM. **Psychoneuroendocrinology** 1998 Oct;23(7):663-700 (110 ref.)

The rapid low-dose (1 microgram) cosyntropin test in the immediate postoperative period: results in elderly subjects after major abdominal surgery. Richards ML, et al. **Surgery** 1999 Apr;125(4):431-40

A model for pharmacokinetics and physiological feedback among hormones of the testicular-pituitary axis in adult male rats: a framework for evaluating effects of endocrine active compounds. Barton HA, et al. **Toxicol Sci** 1998 Oct; 45(2):174-87

[Thinking of study on neuroendocrino-immunological network of integrated traditional and Western medicine] Cai DF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jul; 17(7):442-5 **(Chi)**

[Effects of different intensity endurance training on hypothalamus-pituitary regulatory function] Guo J, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 May; 13(2):121-3 (Eng. Abstr.) **(Chi)**

[Physiology and exploration of the gonadotropic axis] Chabbert-Buffet N, et al. **Rev Prat** 1999 Jun 15; 49(12):1270-6 (Eng. Abstr.) **(Fre)**

[Thyroid hormone production and its regulation] Thomopoulos P. **Rev Prat** 1998 Nov 15;48(18):1987-91 (Eng. Abstr.) **(Fre)**

[Glucocorticoid resistance syndrome and hypothalamo-pituitary-adrenal axis] Arai K. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):396-401 (36 ref.) **(Jpn)**

[Interaction central GABA-B receptors with serotoninergic brain system during regulation of the hypothalamo-hypophyseal-testicular axis by the negative feedback mechanism in rats] Amikishieva AV, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May-Jun; 84(5-6):474-9 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Effects of prenatal ethanol exposure on hypothalamic-pituitary-adrenal responses to chronic cold stress in rats. Kim CK, et al. **Alcohol Clin Exp Res** 1999 Feb;23(2):301-10

Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Adler GK, et al. **Am J Med** 1999 May; 106(5):534-43

Direct evidence of acute stress-induced facilitation of ACTH response to subsequent stress in rats. Andrés R, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R863-8

Defective ACTH response to stress in previously stressed rats: dependence on glucocorticoid status. Martí O, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R869-77

Desmopressin, ovine CRH, and low-dose ACTH tests: tools for the study of the hypothalamic-pituitary-adrenal axis in premenopausal rheumatoid arthritis patients. Foppiani L, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:83-7

Differential effects of psychological and immunological challenge on the hypothalamo-pituitary-adrenal axis function in adjuvant-induced arthritis. Harbuz MS, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:43-52 (28 ref.)

Perturbations of hypothalamic-pituitary-gonadal axis and adrenal androgen functions in rheumatoid arthritis: an odyssey of hormonal relationships to the disease. Masi AT, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:53-62; discussion 62-3 (27 ref.)

Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Mück-Seler D, et al. **Biol Psychiatry** 1999 Jun 1;45(11):1433-9

Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancy. Jenkins PJ, et al. **Br J Cancer** 1999 Aug;80(11):1815-9

Reaction of sleep-wakefulness cycle to stress is related to differences in hypothalamo-pituitary-adrenal axis reactivity in rat. Bouyer JJ, et al. **Brain Res** 1998 Aug 31; 804(1):114-24

The low dose (1 microgram) ACTH test--when and how to use it [letter; comment] Dickstein G. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):135. Comment on: Clin Endocrinol (Oxf) 1997 Jul;47(1):51-60. Comment on: Clin Endocrinol (Oxf) 1997 Sep;47(3):297-304.

Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Fernández-Real JM, et al. **Clin Endocrinol (Oxf)** 1998 Jul;49(1):53-61

A comparison of the naloxone test with the insulin stress test in patients following transsphenoidal surgery. McAllister AS, et al. **Clin Endocrinol (Oxf)** 1999 Feb; 50(2):261-5

Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Tsagarakis S, et al. **Clin Endocrinol (Oxf)** 1998 Aug;49(2):165-71

The metabolic syndrome: all in the mind? [editorial; comment] O'Rahilly SP. **Diabet Med** 1999 May;16(5):355-7 . Comment on: Diabet Med 1999 May;16(5):373-83.

The neurobiology of social phobia. Bell CJ, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249 Suppl 1:S11-8 (53 ref.)

The role of high- and low-dose corticotropin tests in the diagnosis of secondary adrenal insufficiency. Oelkers W. **Eur J Endocrinol** 1998 Dec;139(6):567-70 (22 ref.)

The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis. Scott LV, et al. **Funct Neurol** 1999 Jan-Mar;14(1):3-11 (59 ref.)

Perturbations of the hypothalamic-pituitary-adrenal axis and the metabolic syndrome in ageing. Björntorp P, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:121-3 (14 ref.)

Nitric oxide in the stress axis. López-Figueroa MO, et al. **Histol Histopathol** 1998 Oct;13(4):1243-52 (90 ref.)

Does a positive oestrogen feedback on the hypothalamic-pituitary axis exist concurrently with a defective testosterone feedback in Klinefelter's syndrome? Goh VH, et al. **Horm Res** 1998 Sep;50(3):160-5

Evaluation of hypothalamic-pituitary-adrenal axis in amenorrhoeic women with insulin-dependent diabetes. la Marca A, et al. **Hum Reprod** 1999 Feb;14(2):298-302

Function of the hypothalamic adrenal axis in patients with fibromyalgia syndrome undergoing mud-pack treatment. Bellometti S, et al. **Int J Clin Pharmacol Res** 1999; 19(1):27-33

The role of antidiuretic hormone in hyponatremia in adrenal insufficiency--is the guideline for the diagnosis of syndrome of inappropriate secretion of the antidiuretic hormone appropriate? [editorial; comment] Demura R. **Intern Med** 1999 May;38(5):382-3. Comment on: Intern Med 1999 May;38(5):426-32.

Severe hyponatremia caused by hypothalamic adrenal insufficiency [see comments] Shibata T, et al. **Intern Med** 1999 May;38(5):426-32. Comment in: Intern Med 1999 May;38(5):382-3.

Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease [see comments] Abdu TA, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):838-43. Comment in: J Clin Endocrinol Metab 1999 Mar;84(3):835-7.

Differential hypothalamic-pituitary-adrenal axis reactivity to psychological and physical stress. Singh A, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):1944-8

Personality disorders in relation to anthropometric, endocrine and metabolic factors. Rosmond R, et al. **J Endocrinol Invest** 1999 Apr;22(4):279-88

Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. Rosmond R, et al. **J Hypertens** 1998 Dec;16(12 Pt 1):1721-6

Learning to cope with repeated stress. Leng G, et al. **J Physiol (Lond)** 1998 Jul 15;510 (Pt 2):331

Chronic insomnia and activity of the stress system: a preliminary study. Vgontzas AN, et al. **J Psychosom Res** 1998 Jul;45(1 Spec No):21-31

Hypofunction of the stress axis in Sjögren's syndrome. Johnson EO, et al. **J Rheumatol** 1998 Aug;25(8):1508-14

Assessment of hypothalamic-pituitary function by hormonal pulsatility, gonadotropin-releasing hormone and thyrotropin-releasing hormone testing in women with euprolactinemic secondary amenorrhea. Lin KC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Nov; 14(11):698-705

Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Gutiérrez MA, et al. **Lupus** 1998;7(6):404-8

The hypothalamic-pituitary response in SLE. Regulation of prolactin, growth hormone and cortisol release. Rovenský J, et al. **Lupus** 1998;7(6):409-13

Does the impairment of the hypothalamic-pituitary-gonadal axis in anorexia nervosa depend on increased sensitivity to endogenous melatonin? Pawlikowski M, et al. **Med Hypotheses** 1999 Feb;52(2):111-3 (15 ref.)

Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits. Raber J. **Mol Neurobiol** 1998 Aug;18(1):1-22 (246 ref.)

The hypothalamo-pituitary-adrenal axis [letter] Sridhar GR. **Natl Med J India** 1998 Jul-Aug;11(4):201

Ventral subiculum regulates hypothalamo-pituitary-adrenocortical and behavioural responses to cognitive stressors. Herman JP, et al. **Neuroscience** 1998 Sep;86(2):449-59

The human hypothalamo-neurohypophysial system in health and disease. Swaab DF. **Prog Brain Res** 1998;119:577-618 (297 ref.)

Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Sinha SS, et al. **Psychiatry Res** 1999 May 31;86(2):93-8

Effects of Alzheimer's disease and gender on the hypothalamic-pituitary-adrenal axis response to lumbar puncture stress. Petrie EC, et al. **Psychoneuroendocrinology** 1999 May;24(4):385-95

Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. al'Absi M, et al. **Psychosom Med** 1998 Jul-Aug;60(4):521-7

Burnout, perceived stress, and cortisol responses to awakening. Pruessner JC, et al. **Psychosom Med** 1999 Mar-Apr;61(2):197-204

Hypothalamo-pituitary-adrenal axis and growth hormone axis in patients with rheumatoid arthritis. Demir H, et al. **Scand J Rheumatol** 1999;28(1):41-6

The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. Crofford LJ. **Z Rheumatol** 1998;57 Suppl 2:67-71 (32 ref.)

[Neuroendocrine disorders cause stress-related disease. "Civilization syndrome" is a growing health problem] Björntorp P, et al. **Lakartidningen** 1999 Feb 24;96(8):893-6 (21 ref.) (Eng. Abstr.) **(Swe)**

RADIATION EFFECTS

The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies [letter; comment] Fernández-Fernández FJ, et al. **J Intern Med** 1999 Jul;246(1):122-3. Comment on: J Intern Med 1998 Nov;244(5):411-6.

SECRETION

Seasonal regulation of prolactin secretion in hypophyseal stalk transected beef calves. Cho SJ, et al. **Anim Reprod Sci** 1998 Oct 9;52(4):253-65

The corticotropin-release inhibitory factor hypothesis: a review of the evidence for the existence of inhibitory as well as stimulatory hypophysiotropic regulation of adrenocorticotropin secretion and biosynthesis. Engler D, et al. **Endocr Rev** 1999 Aug;20(4):460-500 (462 ref.)

Increased ACTH and corticosterone secretion induced by different methods of paradoxical sleep deprivation. Suchecki D, et al. **J Sleep Res** 1998 Dec;7(4):276-81

HYPOTHALAMUS

Spontaneous involution of a diencephalic astrocytoma. Kernan JC, et al. **Pediatr Neurosurg** 1998 Sep;29(3):149-53 (25 ref.)

[Orexins--new hypothalamic peptides that stimulate appetite] Meister B, et al. **Lakartidningen** 1998 Dec 16; 95(51-52):5885-7 (10 ref.) (Eng. Abstr.) **(Swe)**

ANATOMY & HISTOLOGY

Projections of the mediolateral part of the lateral septum to the hypothalamus, revealed by Fos expression and axonal tracing in rats. Varoqueaux F, et al. **Anat Embryol (Berl)** 1998 Mar;199(3):249–63

Hypothalamopontine projections in the rat: anterograde axonal transport studies utilizing light and electron microscopy. Liu H, et al. **Anat Rec** 1999 Aug 1; 255(4):428–51

Laterally asymmetrical cell number in a sexually dimorphic nucleus in the gerbil hypothalamus is correlated with vocal emission rates. Holman SD, et al. **Behav Neurosci** 1998 Aug; 112(4):979–90

Species-specific differences in the corticohypothalamic connections of lizards. Hoogland PV, et al. **Eur J Morphol** 1999 Apr;37(2–3):85–8 (13 ref.)

Organization of the ophidian amygdala: chemosensory pathways to the hypothalamus. Martinez-Marcos A, et al. **J Comp Neurol** 1999 Sep 13;412(1):51–68

Topographic organization of connections between the hypothalamus and prefrontal cortex in the rhesus monkey. Rempel-Clower NL, et al. **J Comp Neurol** 1998 Aug 31; 398(3):393–419

Morphofunctional specialization of the main and accessory magnocellular neuroendocrine nuclei of the hypothalamus. Grinevich VV, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):710–4

CHEMISTRY

Innate differences of neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the amygdala between selectively bred rats with high and low alcohol preference. Hwang BH, et al. **Alcohol Clin Exp Res** 1999 Jun; 23(6):1023–30

Family history of alcoholism and hypothalamic opioidergic activity. Wand GS, et al. **Arch Gen Psychiatry** 1998 Dec; 55(12):1114–9

Distribution of estrogen receptor-beta messenger ribonucleic acid in the male sheep hypothalamus. Hileman SM, et al. **Biol Reprod** 1999 Jun;60(6):1279–84

Immunohistochemical localization of the angiotensin II type 1 receptor in human hypothalamus and brainstem. Benarroch EE, et al. **Brain Res** 1998 Nov 23;812(1–2):292–6

Leptin receptors in estrogen receptor-containing neurons of the female rat hypothalamus. Diano S, et al. **Brain Res** 1998 Nov 23;812(1–2):256–9

Immunohistochemical demonstration of serotonin-containing axons in the hypothalamus of the white-footed mouse, Peromyscus leucopus. Phelix CF, et al. **Brain Res** 1998 Oct 19;808(2):197–219

Localization of ATP-gated P2X2 receptor immunoreactivity in the rat hypothalamus. Xiang Z, et al. **Brain Res** 1998 Dec 7;813(2):390–7

Effects of mu, kappa, and delta opioid receptor agonists and antagonists on rat hypothalamic noradrenergic neurotransmission. Yilmaz B, et al. **Brain Res Bull** 1999 Mar 15;48(5):491–5

Evidence of altered hypothalamic pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice. Guan XM, et al. **Brain Res Mol Brain Res** 1998 Aug 31; 59(2):273–9

Immunohistochemical localization and biochemical characterization of two novel decapeptides derived from POMC-A in the trout hypothalamus. Tollemer H, et al. **Cell Tissue Res** 1999 Mar;295(3):409–17

Luteinizing hormone-releasing hormone quantified in tissues and slice explant cultures of postnatal rat hypothalami. Maurer JA, et al. **Endocrinology** 1999 Feb;140(2):791–9

Distribution of fibroblast growth factor-5 in rat hypothalamus, and its possible role as a regulator of feeding behaviour. Li AJ, et al. **Eur J Neurosci** 1999 Apr; 11(4):1362–8

Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis. Lozeva V, et al. **Inflamm Res** 1999 Feb; 48(2):81–5

Expression of the galanin receptor subtype Gal-R2 mRNA in the rat hypothalamus. Mitchell V, et al. **J Chem Neuroanat** 1999 Jun;16(4):265–77

Pre- and posthatch developmental changes in hypothalamic thyrotropin-releasing hormone and somatostatin concentrations and in circulating growth hormone and thyrotropin levels in the chicken. Geris KL, et al. **J Endocrinol** 1998 Nov;159(2):219–25

Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. Romijn HJ, et al. **J Histochem Cytochem** 1999 Feb;47(2):229–36

Hormonal regulation of progesterone receptor mRNA expression in the hypothalamus of whiptail lizards: regional and species differences. Godwin J, et al. **J Neurobiol** 1999 May;39(2):287–93

Serotonin 5-HT7 receptors binding to rat hypothalamic membranes [letter; comment] Mennini T, et al. **J Neurochem** 1999 Feb;72(2):883–4. Comment on: J Neurochem 1998 Sep;71(3):1271–9.

Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. Håkansson M, et al. **J Neuroendocrinol** 1999 Aug; 11(8):653–63

Immunocytochemical localization of prostaglandin EP3 receptor in the rat hypothalamus. Nakamura K, et al. **Neurosci Lett** 1999 Jan 29;260(2):117–20

Localization of the preprosomatostatin-mRNA by in situ hybridization in the ewe hypothalamus. Bruneau G, et al. **Peptides** 1998;19(10):1749–58

The localization of pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactivity in the hypothalamo-pituitary region of an elasmobranch, stingray, Dasyatis akajei. Matsuda K, et al. **Peptides** 1998; 19(7):1263–7

CART peptide analysis by Western blotting. Kuhar MJ, et al. **Synapse** 1999 Sep 1;33(3):163–71

CYTOLOGY

Immunohistochemical demonstration of serotonin-containing axons in the hypothalamus of the white-footed mouse, Peromyscus leucopus. Phelix CF, et al. **Brain Res** 1998 Oct 19;808(2):197–219

Survival of rat MCH (melanin-concentrating hormone) neurons in hypothalamus slice culture: histological, pharmacological and molecular studies. Bayer L, et al. **Cell Tissue Res** 1999 Jul;297(1):23–33

Feedback effects of placental lactogens on prolactin levels and Fos-related antigen immunoreactivity of tuberoinfundibular dopaminergic neurons in the arcuate nucleus during pregnancy in the rat. Lee Y, et al. **Endocrinology** 1999 May;140(5):2159–66

The neuronal structure of paramamillary nuclei in Bison bonasus: Nissl and Golgi pictures. Robak A, et al. **Folia Morphol (Warsz)** 1998;57(2):105–19

The morphology and cell structure of some nuclei in tuberal region of bison bonasus. Robak A, et al. **Folia Morphol (Warsz)** 1998;57(4):309–14

Leptin sensitive neurons in the hypothalamus. Baskin DG, et al. **Horm Metab Res** 1999 May;31(5):345–50 (83 ref.)

Septal complex of the telencephalon of lizards: III. Efferent connections and general discussion. Font C, et al. **J Comp Neurol** 1998 Nov 30;401(4):525–48

Prefrontal cortical projections to the hypothalamus in macaque monkeys [see comments] Ongür D, et al. **J Comp Neurol** 1998 Nov 30;401(4):480–505. Comment in: J Comp Neurol 1998 Nov 30;401(4):429–36.

Early synaptogenesis in vitro: role of axon target distance. van den Pol AN, et al. **J Comp Neurol** 1998 Oct 5; 399(4):541–60

Steroid-induced developmental plasticity in hypothalamic astrocytes: implications for synaptic patterning. Mong JA, et al. **J Neurobiol** 1999 Sep 15;40(4):602–19 (153 ref.)

Effects of osmotic pressure and brain-derived neurotrophic factor on the survival of postnatal hypothalamic oxytocinergic and vasopressinergic neurons in dissociated cell culture. Kusano K, et al. **J Neuroendocrinol** 1999 Feb; 11(2):145–52

Developmental aspects and mechanisms of rat caudal hypothalamic neuronal responses to hypoxia. Horn EM, et al. **J Neurophysiol** 1999 Apr;81(4):1949–59

Gonadal steroids promote glial differentiation and alter neuronal morphology in the developing hypothalamus in a regionally specific manner. Mong JA, et al. **J Neurosci** 1999 Feb 15;19(4):1464–72

Innervation and control of the adenohypophysis by hypothalamic peptidergic neurons in teleost fishes: EM immunohistochemical evidence. Batten TF, et al. **Microsc Res Tech** 1999 Jan 1;44(1):19–35

Control of rat hypothalamic pro-opiomelanocortin neurons by a circadian clock that is entrained by the daily light-off signal. Jamali KA, et al. **Neuroscience** 1999;93(3):1051–61

Cortistatin affects glutamate sensitivity in mouse hypothalamic neurons through activation of sst2 somatostatin receptor subtype. Vasilaki A, et al. **Neuroscience** 1999 Jan;88(2):359–64

Properties of T-type calcium current in enkephalinergic neurones in guinea-pig hypothalamic slices. Niespodziany I, et al. **Pflugers Arch** 1999 May;437(6):871–80

Vasopressin and sensory circumventricular organs. Jurzak M, et al. **Prog Brain Res** 1998;119:221–45 (181 ref.)

Origin of the serotonergic innervation to the rat dorsolateral hypothalamus: retrograde transport of cholera toxin and upregulation of tryptophan hydroxylase mRNA expression following selective nerve terminals lesion. Ljubic-Thibal V, et al. **Synapse** 1999 Jun 1;32(3):177–86

DRUG EFFECTS

Effect of voltage-dependent calcium channel blockers on ethanol-induced beta-endorphin release from hypothalamic neurons in primary cultures. De A, et al. **Alcohol Clin Exp Res** 1999 May;23(5):850–5

Effects of ethanol on alpha-adrenergic and beta-adrenergic agonist-stimulated beta-endorphin release and cAMP production in hypothalamic cells in primary cultures. De A, et al. **Alcohol Clin Exp Res** 1999 Jan;23(1):46–51

Alcohol rapidly lowers plasma testosterone levels in the rat: evidence that a neural brain-gonadal pathway may be important for decreased testicular responsiveness to gonadotropin. Rivier C. **Alcohol Clin Exp Res** 1999 Jan; 23(1):38–45

Metabolic, gastrointestinal, and CNS neuropeptide effects of brain leptin administration in the rat. van Dijk G, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1425–33

Hypothalamic hypocretin/orexin and neuropeptide Y: divergent interaction with energy depletion and leptin. Beck B, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):119–22

Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. de Miguel R, et al. **Biochem Pharmacol** 1998 Nov 15;56(10):1331–8

The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Bing C, et al. **Br J Pharmacol** 1999 May;127(1):35–42

Bidirectional effects of the neuroactive steroid tetrahydrodeoxycorticosterone on GABA-activated Cl- currents in cultured rat hypothalamic neurons. Wetzel CH, et al. **Br J Pharmacol** 1999 Jun;127(4):863–8

Gold-thioglucose-induced hypothalamic lesions inhibit metabolic modulation of light-induced circadian phase shifts in mice. Challet E, et al. **Brain Res** 1999 Apr 3; 824(1):18–27

Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Dunn-Meynell AA, et al. **Brain Res** 1998 Dec 14;814(1–2):41–54

Corticotropin-releasing hormone expression is the major target for glucocorticoid feedback-control at the hypothalamic level. Kretz O, et al. **Brain Res** 1999 Feb 13;818(2):488–91

Advantage of double labeled in situ hybridization for detecting the effects of glucocorticoids on the mRNAs of protooncogenes and neural peptides (TRH) in cultured hypothalamic neurons. Luo LG, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):201–8

Specificity of interleukin-1beta-induced changes in monoamine concentrations in hypothalamic nuclei: blockade by interleukin-1 receptor antagonist. MohanKumar SM, et al. **Brain Res Bull** 1998 Sep 1; 47(1):29–34

Effects of brain testosterone implants on appetitive and consummatory components of male sexual behavior in Japanese quail. Riters LV, et al. **Brain Res Bull** 1998 Sep 1;47(1):69–79

Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Gundlah C, et al. **Brain Res Mol Brain Res** 1999 Jan 8;63(2):325–39

Effects of prolactin on expression of the mRNAs encoding the immediate early genes zif/268 (NGF1-A), nur/77 (NGF1-B), c-fos and c-jun in the hypothalamus. Sagrillo CA, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1–2):62–8

Magnolol decreases body temperature by reducing 5-hydroxytryptamine release in the rat hypothalamus. Hsieh MT, et al. **Clin Exp Pharmacol Physiol** 1998 Oct; 25(10):813–7

Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Haque MS, et al. **Diabetes** 1999 Sep;48(9):1706–12

Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus. Tritos NA, et al. **Diabetes** 1998 Nov; 47(11):1687–92

Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Fitzpatrick SL, et al. **Endocrinology** 1999 Sep; 140(9):3928–37

Brain-derived neurotrophic factor and neurotrophin-3 enhance somatostatin gene expression through a likely direct effect on hypothalamic somatostatin neurons. Rage F, et al. **Endocrinology** 1999 Feb;140(2):909–16

Tumor necrosis factor-alpha induces apoptosis in immortalized hypothalamic neurons: involvement of ceramide-generating pathways. Sortino MA, et al. **Endocrinology** 1999 Oct;140(10):4841–9

Effects of the antihistaminergic drugs diphenhydramine and zolantidine on vestibular-induced hypothalamic neuronal activity in the guinea pig. Inokuchi A, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S22–6

Leptin stimulates prostaglandin E2 and F2alpha, but not nitric oxide production in neonatal rat hypothalamus. Brunetti L, et al. **Eur J Pharmacol** 1999 Mar 26; 369(3):299–304

Leptin inhibits norepinephrine and dopamine release from rat hypothalamic neuronal endings. Brunetti L, et al. **Eur J Pharmacol** 1999 May 21;372(3):237–40

Gender-selective effects of ethanol dependence on NMDA receptor subunit expression in cerebral cortex, hippocampus and hypothalamus. Devaud LL, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):331–4

In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Jansen FP, et al. **Eur J Pharmacol** 1998 Dec 4;362(2–3):149–55

Effects of memantine alone and with acute 'binge' cocaine on hypothalamic-pituitary-adrenal activity in the rat. Zhou Y, et al. **Eur J Pharmacol** 1998 Jul 3;352(1):65–71

Region specific expression of NMDA receptor NR1 subunit mRNA in hypothalamus and pons following chronic morphine treatment. Zhu H, et al. **Eur J Pharmacol** 1999 Jan 15;365(1):47–54

Effects of the GABA-A receptor agonist and antagonist on the in vitro release of hypothalamic catecholamines: apparent parallelism between these effects and the LHRH secretion in adult male rats. Feleder C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):80–4

Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Halliday GM, et al. **Exp Neurol** 1999 Jul; 158(1):155–63

Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. Emilsson V, et al. **FEBS Lett** 1999 Jul 16;455(1–2):170–4

Effect of age on the response of the hypothalamo–pituitary–ovarian axis to a combined oral contraceptive. Fitzgerald C, et al. **Fertil Steril** 1999 Jun; 71(6):1079–84

Cardiovascular responses evoked by carbachol microinjection into the posterior hypothalamus involves ganglionic nicotinic and muscarinic mechanisms. Methvin JM, et al. **J Auton Pharmacol** 1998 Jun;18(3):177–87

The growth hormone secretagogue hexarelin stimulates the hypothalamo–pituitary–adrenal axis via arginine vasopressin. Korbonits M, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2489–95

Developing hypothalamic dopaminergic neurones as potential targets for environmental estrogens. Christian M, et al. **J Endocrinol** 1999 Mar;160(3):R1–6

Antidepressants inhibit the glucocorticoid stimulation of thyrotropin releasing hormone expression in cultured hypothalamic neurons. Jackson IM, et al. **J Investig Med** 1998 Dec;46(9):470–4

The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. Korbonits M, et al. **J Neuroendocrinol** 1999 Jul;11(7):521–8

The effects of oestrogen and progesterone on serotonin and its metabolite in the lateral septum, medial preoptic area and ventromedial hypothalamic nucleus of female rats. Lu H, et al. **J Neuroendocrinol** 1998 Dec;10(12):919–26

Effect of IL-1alpha on the release of norepinephrine in rat hypothalamus. Kaur D, et al. **J Neuroimmunol** 1998 Oct 1;90(2):122–7

Kainate acts at presynaptic receptors to increase GABA release from hypothalamic neurons. Liu QS, et al. **J Neurophysiol** 1999 Aug;82(2):1059–62

Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. Raap DK, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):98–106

Effect of acute delta9-THC treatment on hypothalamic catecholamines and sexual behaviour in male rats. Hernández-Tristán R, et al. **J Physiol Biochem** 1999 Mar; 55(1):53–4

Long-term exposure of hypothalamic explants to melatonin alters the release of gonadotrophin releasing hormone and the density of melatonin binding sites in the pars tuberalis of the male mink (Mustela vison). Messager S, et al. **J Pineal Res** 1999 Jan;26(1):17–27

Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Corchero J, et al. **Life Sci** 1999;64(11):905–11

Short-term glucocorticoid administration decreases both hypothalamic and pituitary galanin synthesis in the adult male rat. Brogan RS, et al. **Metabolism** 1999 Jun; 48(6):792–6

Dexamethasone rapidly regulates TRH mRNA levels in hypothalamic cell cultures: interaction with the cAMP pathway. Pérez-Martinez L, et al. **Neuroendocrinology** 1998 Nov;68(5):345–54

The effect of leptin on feeding-regulating neurons in the rat hypothalamus. Funahashi H, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):117–20

Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Pérez de la Mora M, et al. **Neurosci Lett** 1999 Jan 15;259(3):181–5

Leptin effects on feeding-related hypothalamic and peripheral neuronal activities in normal and obese rats. Shiraishi T, et al. **Nutrition** 1999 Jul–Aug;15(7–8):576–9

Somatostatin decreases somatostatin messenger ribonucleic acid levels in the rat periventricular nucleus. Aguila MC. **Peptides** 1998;19(9):1573–9

Oleoyl-estrone does not alter hypothalamic neuropeptide Y in Zucker lean and obese rats. Cabot C, et al. **Peptides** 1998;19(9):1631–5

Prostaglandin E2 mediates activation of hypothalamic histamine by interleukin-1beta in rats. Kang M, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):88–93

Effects of chronic nicotine treatment and withdrawal on hypothalamic proopiomelanocortin gene expression and neuroendocrine regulation. Rasmussen DD. **Psychoneuroendocrinology** 1998 Apr;23(3):245–59

Post-session sulpiride infusions within the perifornical region of the lateral hypothalamus enhance consolidation of associative learning. Phillips GD, et al. **Psychopharmacology (Berl)** 1998 Dec;140(3):354–64

NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. McMinn JE, et al. **Regul Pept** 1998 Sep 25; 75–76:425–31

Nicotine's effect on hypothalamic neurotransmitters and appetite regulation. Miyata G, et al. **Surgery** 1999 Aug; 126(2):255–63

[Chronically administered midazolam does not have neurodegenerative effects] Montón J, et al. **Rev Med Univ Navarra** 1999 Jan–Mar;43(1):17–23 (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Regulation of hypothalamic arginine vasopressin messenger ribonucleic acid and pituitary arginine vasopressin content in fetal sheep: effects of acute tonicity alterations and fetal maturation. Zhao X, et al. **Am J Obstet Gynecol** 1998 Oct; 179(4):899–905

Ontogeny of estrogen sulfatase activity in ovine fetal hypothalamus, hippocampus, and brain stem. Purinton SC, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1647–52

Lectin staining in the basal nucleus (Meynert) and the hypothalamic tuberomamillary nucleus of the developing human prosencephalon. Paul A, et al. **Anat Rec** 1998 Sep; 252(1):149–58

Morphogenesis of the hypothalamus and hypophysis: their association, dissociation and reassociation before and after "Rathke". Kawamura K, et al. **Arch Histol Cytol** 1998 Aug; 61(3):189–98 (49 ref.)

Effect of ethanol on calcium regulation in rat fetal hypothalamic cells in culture. Simasko SM, et al. **Brain Res** 1999 Apr 3;824(1):89–96

Novel strategy yields candidate Gsh-1 homeobox gene targets using hypothalamus progenitor cell lines. Li H, et al. **Dev Biol** 1999 Jul 1;211(1):64–76

The regulation of prolactin receptor messenger ribonucleic acid levels in the sheep liver before birth: relative roles of the fetal hypothalamus, cortisol, and the external photoperiod. Phillips ID, et al. **Endocrinology** 1999 May; 140(5):1966–71

Expression of the medaka (Oryzias latipes) Ol-Rx3 paired-like gene in two diencephalic derivatives, the eye and the hypothalamus. Deschet K, et al. **Mech Dev** 1999 May;83(1–2):179–82

Six6 (Optx2) is a novel murine Six3-related homeobox gene that demarcates the presumptive pituitary/hypothalamic axis and the ventral optic stalk. Jean D, et al. **Mech Dev** 1999 Jun;84(1–2):31–40

Ontogenic development of prolactin immunoreactive neurons in the rat lateral hypothalamus. Grillon S, et al. **Neuropeptides** 1998 Aug;32(4):327–32

Analysis of synaptotagmin I–IV messenger RNA expression and developmental regulation in the rat hypothalamus and pituitary. Xi D, et al. **Neuroscience** 1999 Jan;88(2):425–35

ENZYMOLOGY

The effects of continuous light and darkness on the activity of monoamine oxidase A and B in the hypothalamus, ovaries and uterus of rats. Cvijić G, et al. **Acta Physiol Hung** 1997–98;85(3):269–76

Distribution and regulation of aromatase activity in the ram hypothalamus and amygdala. Roselli CE, et al. **Brain Res** 1998 Nov 16;811(1–2):105–10

3,5jcyclic adenosine monophosphate mediates the salmon calcitonin-induced increase in hypothalamic tyrosine hydroxylase activity. Arbogast LA, et al. **Endocrinology** 1999 Jul;140(7):3273–81

Androgenic regulation of hypothalamic aromatase activity in prepubertal and postpubertal male golden hamsters. Romeo RD, et al. **Endocrinology** 1999 Jan;140(1):112–7

Inducible expression of tryptophan hydroxylase without serotonin synthesis in hypothalamic dopaminergic neurons. Vanhatalo S, et al. **Exp Neurol** 1999 Jun;157(2):305–16

Aromatic L-amino acid decarboxylase- and tyrosine hydroxylase-immunohistochemistry in the adult human hypothalamus. Kitahama K, et al. **J Chem Neuroanat** 1998 Dec;16(1):43–55

Decrease in glutamic acid decarboxylase level in the hypothalamus of spontaneously hypertensive rats. Horn EM, et al. **J Hypertens** 1998 May;16(5):625–33

Aromatase in developing sensory systems of the rat brain. Horvath TL, et al. **J Neuroendocrinol** 1999 Feb;11(2):77–84

Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. Mancuso C, et al. **J Neuroimmunol** 1999 Oct 29; 99(2):189–94

Absence of increased hypothalamic nitric oxide synthase gene expression during the preovulatory LH surge in middle-aged rats. Sahu A. **Neuroreport** 1998 Dec 21; 9(18):4019–23

Reduced nicotinamide adenine dinucleotide phosphate-diaphorase activity in the paraventricular nucleus of the rat hypothalamus is modulated by estradiol. Sánchez F, et al. **Neurosci Lett** 1998 Sep 4;253(2):75–8

GROWTH & DEVELOPMENT

Development and organization of the hypophysiotropic hypothalamus driving the pituitary-gonadal axis in the rhesus monkey. Plant TM, et al. **Ann Endocrinol (Paris)** 1999 Jul;60(2):60–6 (43 ref.)

Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites. Statnick MA, et al. **Brain Res** 1998 Nov 9;810(1–2):16–26

Perinatal changes in hypothalamic N-methyl-D-aspartate receptors and their relationship to gonadotropin-releasing hormone neurons. Adams MM, et al. **Endocrinology** 1999 May;140(5):2288–96

Steroid-induced developmental plasticity in hypothalamic astrocytes: implications for synaptic patterning. Mong JA, et al. **J Neurobiol** 1999 Sep 15;40(4):602–19 (153 ref.)

Ontogeny and sexual differentiation of somatostatin biosynthesis and secretion in the hypothalamic periventricular-median eminence pathway. Murray HE, et al. **J Neuroendocrinol** 1999 Jan;11(1):35–42

Developmental sex differences in estrogen receptor-beta mRNA expression in the mouse hypothalamus/preoptic region. Karolczak M, et al. **Neuroendocrinology** 1998 Oct; 68(4):229–34

Developmental and hormonal regulation of thermosensitive neuron potential activity in rat brain. Belugin S, et al. **Thyroid** 1999 Aug;9(8):837–43

IMMUNOLOGY

The interleukin-1 type I receptor is expressed in human hypothalamus. Hammond EA, et al. **Brain** 1999 Sep;122 (Pt 9):1697–707

Do only circulating pyrogenic cytokines act as mediators in the febrile response? A hypothesis. Netea MG, et al. **Eur J Clin Invest** 1999 Apr;29(4):351–6 (52 ref.)

Inhibition of heme oxygenase in the central nervous system potentiates endotoxin-induced vasopressin release in the rat. Mancuso C, et al. **J Neuroimmunol** 1999 Oct 29; 99(2):189–94

Neuroimmunomodulatory actions of hypothalamic interferon-alpha. Hori T, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3–4):172–7 (63 ref.)

Role of nitric oxide and carbon monoxide in modulating the ACTH response to immune and nonimmune signals. Rivier C. **Neuroimmunomodulation** 1998 May-Aug;5(3–4):203–13 (65 ref.)

METABOLISM

Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. van de Nes JA, et al. **Acta Neuropathol (Berl)** 1998 Aug;96(2):129–38

Hypothalamic transcription factors and the regulation of the hypothalamo-neurohypophysial system. Burbach JP, et al. **Adv Exp Med Biol** 1998;449:29–37 (59 ref.)

Cell-specific gene expression in oxytocin and vasopressin magnocellular neurons. Gainer H. **Adv Exp Med Biol** 1998; 449:15–27 (59 ref.)

The area postrema modulates hypothalamic fos responses to intragastric hypertonic saline in conscious rats. Carlson SH, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1921–7

Central Fos expression in fetal and adult sheep after intraperitoneal hypertonic saline. Caston-Balderrama A, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):H725–35

Sleep deprivation increases rat hypothalamic growth hormone-releasing hormone mRNA. Zhang J, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1755–61

Induction of multiple pituitary adenylate cyclase activating polypeptide (PACAP) transcripts through alternative cleavage and polyadenylation of proPACAP precursor mRNA. Harakall SA, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:367–74

Hypothalamic beta-endorphin concentrations are decreased in animal models of autoimmune disease. Sacerdote P, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:305–8

Changes in hypothalamic agouti-related protein (AGRP), but not alpha-MSH or pro-opiomelanocortin concentrations in dietary-obese and food-restricted rats. Harrold JA, et al. **Biochem Biophys Res Commun** 1999 May 19; 258(3):574–7

Sex difference and testosterone modulation of pheromone-induced NeuronalFos in the Ferret's main olfactory bulb and hypothalamus. Kelliher KR, et al. **Biol Reprod** 1998 Dec;59(6):1454–63

Insulin-like growth factor-I, insulin-like growth factor-binding proteins, and gonadotropins in the hypothalamic-pituitary axis and serum of nutrient-restricted ewes. Snyder JL, et al. **Biol Reprod** 1999 Jul;61(1):219–24

Pindolol-insensitive [3H]-5-hydroxytryptamine binding in the rat hypothalamus; identity with 5-hydroxytryptamine7 receptors. Clemett DA, et al. **Br J Pharmacol** 1999 May; 127(1):236–42

Effects of ethanol on basal and adenosine-induced increases in beta-endorphin release and intracellular cAMP levels in hypothalamic cells. Boyadjieva N, et al. **Brain Res** 1999 Apr 3;824(1):112–8

Gold-thioglucose-induced hypothalamic lesions inhibit metabolic modulation of light-induced circadian phase shifts in mice. Challet E, et al. **Brain Res** 1999 Apr 3; 824(1):18–27

Reciprocal changes in hypothalamic receptor binding and circulating leptin in anorectic tumor-bearing rats. Chance WT, et al. **Brain Res** 1998 Aug 24;803(1–2):27–33

The effect of neurointermediate lobe denervation on hypothalamic neuroendocrine dopaminergic neurons. DeMaria JE, et al. **Brain Res** 1998 Sep 21;806(1):89–94

The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior. Hagan MM, et al. **Brain Res** 1998 Sep 14;805(1–2):20–8

Reduced glucose-induced neuronal activation in the hypothalamus of diet-induced obese rats. Levin BE, et al. **Brain Res** 1998 Oct 19;808(2):317–9

Hypothalamic oxytocin in the developing ovine fetus:

interaction with pituitary-adrenocortical function. Matthews SG. **Brain Res** 1999 Feb 27;820(1-2):92-100

Expression of Fos immunoreactivity in rat brain during dehydration: effect of duration and timing of water deprivation. Morien A, et al. **Brain Res** 1999 Jan 16; 816(1):1-7

Perinatal elevation of hypothalamic insulin, acquired malformation of hypothalamic galaninergic neurons, and syndrome x-like alterations in adulthood of neonatally overfed rats. Plagemann A, et al. **Brain Res** 1999 Jul 31; 836(1-2):146-55

Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites. Statnick MA, et al. **Brain Res** 1998 Nov 9;810(1-2):16-26

Hypothalamic galanin: control by signals of fat metabolism. Wang J, et al. **Brain Res** 1998 Aug 31;804(1):7-20

Combination of immunohistochemical and in situ hybridization methods to reveal tyrosine hydroxylase and oxytocin and vasopressin mRNAs in magnocellular neurons of obese Zucker rats. Fetissov SO, et al. **Brain Res Brain Res Protoc** 1999 Apr;4(1):36-43

Effects of mu and kappa opioid receptor antagonists on glucoprivic induction of Fos immunoreactivity in the rat preoptic area and hypothalamus. Briski KP, et al. **Brain Res Bull** 1999 Jun;49(3):181-7

Altered hypothalamic c-Fos-like immunoreactivity in diet-induced obese mice. Lin S, et al. **Brain Res Bull** 1999 Jun;49(3):215-9

Effects of alcohol on the synthesis and expression of hypothalamic peptides. Madeira MD, et al. **Brain Res Bull** 1999 Jan 1;48(1):3-22 (218 ref.)

Differential regulation of glucocorticoid receptor messenger RNA (GR-mRNA) by maternal deprivation in immature rat hypothalamus and limbic regions. Avishai-Eliner S, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):265-8

Ontogeny of the GNRH-, glutaminase- and glutamate decarboxylase-gene expression in the hypothalamus of female rats. Roth C, et al. **Brain Res Dev Brain Res** 1998 Sep 10;110(1):105-14

Effect of pre- and postnatal nicotine exposure on vasopressinergic system in rats. Zbuzek VK, et al. **Brain Res Dev Brain Res** 1999 Feb 5;112(2):229-35

The influence of gender and age on neonatal rat hypothalamic 5-HT1A and 5-HT2A receptors. Ferrari PF, et al. **Cell Mol Neurobiol** 1999 Dec;19(6):775-84

Sheep 5HT2A receptors: partial cloning of the coding sequence and mRNA localization by in situ hybridization in the ewe hypothalamus. Pelletier J, et al. **Cell Tissue Res** 1999 Feb;295(2):231-9

Divergent effects of intracerebroventricular and peripheral leptin administration on feeding and hypothalamic neuropeptide Y in lean and obese (fa/fa) Zucker rats. Dryden S, et al. **Clin Sci (Colch)** 1999 Mar;96(3):307-12

Effects of short-term dehydration on plasma osmolality, levels of arginine vasotocin and its hypothalamic gene expression in the laying hen. Saito N, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Nov; 121(3):235-9

Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Baskin DG, et al. **Diabetes** 1999 Apr; 48(4):828-33

Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Ebihara K, et al. **Diabetes** 1999 Oct;48(10):2028-33

Altered energy balance causes selective changes in melanocortin-4(MC4-R), but not melanocortin-3 (MC3-R), receptors in specific hypothalamic regions: further evidence that activation of MC4-R is a physiological inhibitor of feeding. Harrold JA, et al. **Diabetes** 1999 Feb;48(2):267-71

The anti-gonadotropic effects of cytokines: the role of neuropeptides. Kalra PS, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):321-32 (55 ref.)

Expression of activin and follistatin in the rat hypothalamus: anatomical association with gonadotropin-releasing hormone neurons and possible role of central activin in the regulation of luteinizing hormone release. MacConell LA, et al. **Endocrine** 1998 Dec;9(3):233-41

Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Bergen HT, et al. **Endocrinology** 1998 Nov;139(11):4483-8

Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Bjørbaek C, et al. **Endocrinology** 1999 May;140(5):2035-43

The human growth hormone-releasing hormone transgenic mouse as a model of modest obesity: differential changes in leptin receptor (OBR) gene expression in the anterior pituitary and hypothalamus after fasting and OBR localization in somatotrophs. Cai A, et al. **Endocrinology** 1999 Aug;140(8):3609-14

Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Fitzpatrick SL, et al. **Endocrinology** 1999 Sep; 140(9):3928-37

Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Mizuno TM, et al. **Endocrinology** 1999 Feb;140(2):814-7

Fasting regulates hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelanocortin in diabetic mice independent of changes in leptin or insulin. Mizuno TM, et al. **Endocrinology** 1999 Oct;140(10):4551-7

The effects of estrogen and progesterone on corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid levels in the paraventricular nucleus and supraoptic nucleus of the rhesus monkey. Roy BN, et al. **Endocrinology** 1999 May;140(5):2191-8

Interaction between hypothalamic dopaminergic and opioidergic systems in the photoperiodic regulation of pulsatile luteinizing hormone secretion in sheep. Tortonese DJ. **Endocrinology** 1999 Feb;140(2):750-7

Daily changes in hypothalamic gene expression of neuropeptide Y, galanin, proopiomelanocortin, and adipocyte leptin gene expression and secretion: effects of food restriction. Xu B, et al. **Endocrinology** 1999 Jun; 140(6):2868-75

Effects of DPDPE (a specific delta-opioid receptor agonist) and naloxone on hypothalamic monoamine concentrations during the pre-ovulatory LH surge in the rat. Yilmaz B, et al. **Eur J Endocrinol** 1998 Nov;139(5):546-51

The paraventricular organ of mormyrid fish: uptake or release of intraventricular biogenic amines? Meek J. **Eur J Morphol** 1999 Apr;37(2-3):107-11

Leptin stimulates prostaglandin E2 and F2alpha, but not nitric oxide production in neonatal rat hypothalamus. Brunetti L, et al. **Eur J Pharmacol** 1999 Mar 26; 369(3):299-304

Methamphetamine alters prodynorphin gene expression and dynorphin A levels in rat hypothalamus. Romualdi P, et al. **Eur J Pharmacol** 1999 Jan 22;365(2-3):183-6

Effects of age on GABA turnover rates in specific hypothalamic areas in female rats. Jarry H, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):59-62

Cellular mechanism of pulsatile LHRH release. Terasawa E. **Gen Comp Endocrinol** 1998 Dec;112(3):283-95 (135 ref.)

Levels of monoamine and amino acid neurotransmitters in the developing male mouse hypothalamus and in histotypic hypothalamic cultures. Miranda-Contreras L, et al. **Int J Dev Neurosci** 1998 Aug;16(5):403-12

Hypothalamic expression of neuropeptide-Y in the New Zealand obese mouse. Rizk NM, et al. **Int J Obes Relat Metab Disord** 1998 Dec;22(12):1172-7

Effects of corticosteroids on hypothalamic adrenocortical regulation, on responses to neural stimuli and the pathways involved. Feldman S. **Isr J Med Sci** 1973;9 Suppl:106-13 (35 ref.)

Influence of voluntary exercise on hypothalamic norepinephrine. Lambert GW, et al. **J Appl Physiol** 1998 Sep;85(3):962-6

The effects of hormone replacement therapy on hypothalamic neuropeptide gene expression in a primate model of menopause. Abel TW, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2111-8

Experimentally induced lysosomal dysfunction disrupts processing of hypothalamic releasing factors. Bi X, et al. **J Comp Neurol** 1998 Nov 23;401(3):382-94

Nitric oxide synthase in the guinea pig preoptic area and hypothalamus: distribution, effect of estrogen, and colocalization with progesterone receptor. Warembourg M, et al. **J Comp Neurol** 1999 May 3;407(2):207-27

The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. Edwards CM, et al. **J Endocrinol** 1999 Mar; 160(3):R7-12

Transcriptional changes in hypothalamic vasoactive intestinal peptide during a photo-induced reproductive cycle in the turkey. Chaiseha Y, et al. **J Mol Endocrinol** 1998 Dec; 21(3):267-75

Expression of the vasotocin gene in the hypothalamus of intact and osmotically stimulated bullfrogs during metamorphosis. Hyodo S. **J Mol Endocrinol** 1999 Jun; 22(3):305-12

Increased expression of both short and long forms of prolactin receptor mRNA in hypothalamic nuclei of lactating rats. Pi XJ, et al. **J Mol Endocrinol** 1999 Aug; 23(1):13-22

Molecular cloning, genomic organization and selective expression of bombesin receptor subtype 3 in the sheep hypothalamus and pituitary. Whitley JC, et al. **J Mol Endocrinol** 1999 Aug;23(1):107-16

Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. King PJ, et al. **J Neurochem** 1999 Aug; 73(2):641-6

Serotonin 5-HT7 receptors binding to rat hypothalamic membranes [letter; comment] Mennini T, et al. **J Neurochem** 1999 Feb;72(2):883-4. Comment on: J Neurochem 1998 Sep;71(3):1271-9.

The endogenous lipid oleamide activates serotonin 5-HT7 neurons in mouse thalamus and hypothalamus. Thomas EA, et al. **J Neurochem** 1999 Jun;72(6):2370-8

Thyroid hormones and estrogen affect oxytocin gene expression in hypothalamic neurons. Dellovade TL, et al. **J Neuroendocrinol** 1999 Jan;11(1):1-10

Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. Diano S, et al. **J Neuroendocrinol** 1998 Sep;10(9):647-50

Photo-induction of hypothalamic gonadotrophin releasing hormone-I mRNA in the domestic chicken: a role for oestrogen? Dunn IC, et al. **J Neuroendocrinol** 1999 May; 11(5):371-5

Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotrophin-releasing hormone agonist in the rat hypothalamus. Han YG, et al. **J Neuroendocrinol** 1999 Mar; 11(3):195-201

Stationary organotypic cultures of oxytocin and vasopressin magnocellular neurones from rat and mouse hypothalamus. House SB, et al. **J Neuroendocrinol** 1998 Nov;10(11):849-61

Growth hormone-releasing hormone receptor (GHRH-R) and growth hormone secretagogue receptor (GHS-R) mRNA levels during postnatal development in male and female rats. Kamegai J, et al. **J Neuroendocrinol** 1999 Apr; 11(4):299-306

Anorectic effect of pituitary adenylate cyclase activating polypeptide (PACAP) in rats: lack of evidence for involvement of hypothalamic neuropeptide gene expression. Mizuno Y, et al. **J Neuroendocrinol** 1998 Aug; 10(8):611-6

Correlation of hypothalamic somatostatin mRNA expression and peptide content with secretion: sexual dimorphism and differential regulation by gonadal factors. Murray HE, et al. **J Neuroendocrinol** 1999 Jan;11(1):27-33

Increased prolactin receptor immunoreactivity in the hypothalamus of lactating rats. Pi XJ, et al. **J Neuroendocrinol** 1999 Sep;11(9):693-705

Differential regulation of hypothalamic tuberoinfundibular dopamine neurones in two dwarf rat models with contrasting changes in pituitary prolactin. Thomas GB, et al. **J Neuroendocrinol** 1999 Mar;11(3):229-36

Proopiomelanocortin mRNA levels in ovine hypothalamus are not reduced at the time of the preovulatory luteinising hormone surge. Walsh JP, et al. **J Neuroendocrinol** 1998 Oct;10(10):803-8

Hypothalamic beta-endorphin concentrations are decreased in animals models of autoimmune disease. Sacerdote P, et al. **J Neuroimmunol** 1999 Jun 1;97(1-2):129-33

Changes in neuropeptide Y receptors and pro-opiomelanocortin in the anorexia (anx/anx) mouse hypothalamus. Broberger C, et al. **J Neurosci** 1999 Aug 15;19(16):7130-9

T-lymphocyte activation increases hypothalamic and amygdaloid expression of CRH mRNA and emotional reactivity to novelty. Kusnecov AW, et al. **J Neurosci** 1999 Jun 1;19(11):4533-43

Promoter transgenics reveal multiple gonadotropin-releasing hormone-I-expressing cell populations of different embryological origin in mouse brain. Skynner MJ, et al. **J Neurosci** 1999 Jul 15;19(14):5955-66

Glutamate inhibits GABA excitatory activity in developing neurons. van den Pol AN, et al. **J Neurosci** 1998 Dec 15; 18(24):10749-61

Quantitative analysis of gene expression in organotypic slice-explant cultures by particle-mediated gene transfer. Thomas A, et al. **J Neurosci Methods** 1998 Oct 1; 84(1-2):181-91

Neuropeptide Y and corticotropin-releasing hormone concentrations within specific hypothalamic regions of lean but not ob/ob mice respond to food-deprivation and refeeding. Jang M, et al. **J Nutr** 1998 Dec;128(12):2520-5

Influence of nitric oxide synthase inhibitors on the vasopressin-induced pituitary-adrenocortical activity and hypothalamic catecholamine levels. Bugajski J, et al. **J Physiol Pharmacol** 1998 Dec;49(4):617-26

A review of endocrine changes in anorexia nervosa. Støving RK, et al. **J Psychiatr Res** 1999 Mar-Apr;33(2):139-52 (219 ref.)

Leptin changes Ca2+/calmodulin-dependent response and up-regulates the gene expression of calcineurin in rat hypothalamus. Morishita T, et al. **Life Sci** 1998; 63(20):PL311-5

Three TRH-like molecules are released from rat hypothalamus in vitro. Méndez M, et al. **Neurochem Res** 1999 Jul;24(7):815-23

Transcription factor STAT3 in leptin target neurons of the rat hypothalamus. Håkansson ML, et al. **Neuroendocrinology** 1998 Dec;68(6):420-7

Growth hormone-dependent regulation of pituitary GH secretagogue receptor (GHS-R) mRNA levels in the spontaneous dwarf Rat. Kamegai J, et al. **Neuroendocrinology** 1998 Nov;68(5):312-8

In vitro secretion of gonadotropin-releasing hormone (GnRH) and [hydroxyproline9]GnRH from the rat hypothalamus exhibits a differential sensitivity to castration and second messengers. Rochdi L, et al. **Neuroendocrinology** 1998 Oct;68(4):281-92

Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. McCann SM, et al. **Neuroimmunomodulation** 1998 May-Aug;5(3-4):193-202 (55 ref.)

Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat. Corchero J, et al. **Neuropharmacology** 1999 Mar;38(3):433-9

Histamine and tumor necrosis factor-alpha production from purified rat brain mast cells mediated by substance P. Cocchiara R, et al. **Neuroreport** 1999 Feb 25;10(3):575-8

Metabotropic glutamate receptor in vasopressin, CRF and VIP hypothalamic neurones. Kocsis K, et al. **Neuroreport** 1998 Dec 21;9(18):4029-33

Identification of two novel diurnal genes by screening of a rat brain cDNA library. Patten C, et al. **Neuroreport** 1998 Dec 1;9(17):3935-41

Hypothalamic insulin and neuropeptide Y in the offspring of gestational diabetic mother rats. Plagemann A, et al. **Neuroreport** 1998 Dec 21;9(18):4069–73

The daily pattern of Fos synthesis by hypothalamic pro-opiomelanocortin neurons is unaffected by adrenalectomy in the rat. Jamali KA, et al. **Neurosci Lett** 1998 Jul 3;250(2):119–22

Transforming growth factor beta2 is able to modify mRNA levels and release of luteinizing hormone-releasing hormone in a immortalized hypothalamic cell line (GT1-1). Messi E, et al. **Neurosci Lett** 1999 Aug 6;270(3):165–8

Neuronal activity in the mediobasal hypothalamus of hibernating jerboas (Jaculus orientalis). El Quezzani S, et al. **Neurosci Lett** 1999 Jan 22;260(1):13–6

Hypothalamic neuropeptide Y and plasma leptin after long-term high-fat feeding in the rat. Stricker-Krongrad A, et al. **Neurosci Lett** 1998 Oct 2;254(3):157–60

Heatstroke induces c-fos expression in the rat hypothalamus. Tsay HJ, et al. **Neurosci Lett** 1999 Feb 26;262(1):41–4

Atrial natriuretic factor does not affect norepinephrine catabolism in rat hypothalamus and adrenal medulla. Vatta MS, et al. **Neurosci Lett** 1998 Sep 11;253(3):151–4

Comparison of the expression of two immediate early gene proteins, FosB and Fos in the rat preoptic area, hypothalamus and brainstem during pregnancy, parturition and lactation. Lin SH, et al. **Neurosci Res** 1998 Dec; 32(4):333–41

Developmental sex differences in amino acid neurotransmitter levels in hypothalamic and limbic areas of rat brain. Davis AM, et al. **Neuroscience** 1999 90(4):1471–82

D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Javed A, et al. **Neuroscience** 1999 Mar; 90(3):851–8

Differential increase in Fos immunoreactivity in hypothalamic and septal nuclei by arginine8-vasopressin and desglycinamide9-arginine8-vasopressin. Lança AJ, et al. **Neuroscience** 1999;91(4):1331–41

Hypo-osmolarity stimulates and high sodium concentration inhibits thyrotropin-releasing hormone secretion from rat hypothalamus. Nikodémová M, et al. **Neuroscience** 1999; 88(4):1299–306

Effect of progesterone on tachykinin concentrations in the hypothalamus and anterior pituitary of female siberian hamsters. Debeljuk L, et al. **Peptides** 1999;20(3):353–60

Hypothalamic NPY status during positive energy balance and the effects of the NPY antagonist, BW 1229U91, on the consumption of highly palatable energy-rich diet. Widdowson PS, et al. **Peptides** 1999;20(3):367–72

Changes in hypothalamic calmodulin concentration induced by perinatal hormone manipulation in the rat. Rodriguez-Medina MA, et al. **Pharmacol Biochem Behav** 1998 Dec;61(4):445–50

Increased GABA-gated chloride ion influx in the hypothalamus of low-anxiety rats. Imamura M, et al. **Physiol Behav** 1998 Jun 1;64(3):415–7

Determination, using microdialysis, of hypothalamic serotonin variations in response to different macronutrients. Rouch C, et al. **Physiol Behav** 1999 Jan 1-15;65(4-5):653–7

Stimulatory effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on cyclic AMP formation in the hypothalamus and cerebral cortex of four avians and rat. Nowak JZ, et al. **Pol J Pharmacol** 1999 Jan-Feb; 51(1):87–91

Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Date Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19; 96(2):748–53

Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Wang ZW, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10373–8

Hypothalamic neuropeptide Y content and mRNA expression in weanling rats subjected to dietary manipulations during fetal and neonatal life. Kozak R, et al. **Regul Pept** 1998 Sep 25;75-76:397–402

Neuropeptide Y (NPY) neurons in the arcuate nucleus (ARH) and dorsomedial nucleus (DMH), areas activated during lactation, project to the paraventricular nucleus of the hypothalamus (PVH). Li C, et al. **Regul Pept** 1998 Sep 25;75-76:93–100

NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. McMinn JE, et al. **Regul Pept** 1998 Sep 25; 75-76:425–31

Disturbance of the reproductive axis induced by negative energy balance. Judd SJ. **Reprod Fertil Dev** 1998; 10(1):65–72 (67 ref.)

Downregulation of 5-HT1A receptors in rat hypothalamus and dentate gyrus after "binge" pattern cocaine administration. Perret G, et al. **Synapse** 1998 Oct; 30(2):166–71

Physiological and pathophysiological aspects of thyrotropin-releasing hormone gene expression in the human hypothalamus. Fliers E, et al. **Thyroid** 1998 Oct; 8(10):921–8 (45 ref.)

Feeding and body-weight regulation by hypothalamic neuropeptides--mediation of the actions of leptin. Inui A. **Trends Neurosci** 1999 Feb;22(2):62–7 (83 ref.)

[Effect of zuogui wan on the contents of hypothalamic monoaminic transmitters and body weight in rats treated with monosodium glutamate neonatally] Liu YF, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Nov; 17(11):673–5 (Eng. Abstr.) **(Chi)**

[Effects of the fruit of Rubus chingii Hu on hypothalamus-pituitary-sex gland axis in rats] Chen K, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Sep;21(9):560–2 inside back cover (Eng. Abstr.) **(Chi)**

[Effect of active constituents of Herba Epimedii on hypothalamic monoamine neurotransmitters and other brain functions in aging rats] Meng X, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Nov;21(11):683–5 inside back cover (Eng. Abstr.) **(Chi)**

[Effect of stressful stimulations on hypothalamic vasopressin mRNA level of rats] Lu LM, et al. **Sheng Li Hsueh Pao** 1997 Oct;49(5):594–8 (Eng. Abstr.) **(Chi)**

[Changes in densities of hypothalamic mu opioid receptor during cupric acete-induced preovulatory lh surge in rabbit] Yang SP, et al. **Sheng Li Hsueh Pao** 1997 Jun; 49(3):354–8 (Eng. Abstr.) **(Chi)**

[Effect of thyroid stimulating hormone on the functional condition of nonapeptidergic cells in the rat hypothalamus in vitro] Glazova MV, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):378–80 **(Rus)**

[Effects of thyroliberin on nonapeptidergic cells in the rat hypothalamus slides] Glazova MV, et al. **Biull Eksp Biol Med** 1999 May;127(5):526–8 **(Rus)**

[Participation of monoaminergic hypothalamus cells in the regulation of the stressor body reaction in process of aging] Chernigovskaia EV, et al. **Zh Evol Biokhim Fiziol** 1999 Jan-Feb;35(1):48–52 **(Rus)**

PATHOLOGY

Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. van de Nes JA, et al. **Acta Neuropathol (Berl)** 1998 Aug;96(2):129–38

Hypothalamic hamartoma: report of a case with unusual histologic features. Sharma MC, et al. **Am J Surg Pathol** 1998 Dec;22(12):1538–41

Diabetes insipidus arising from hypothalamic diffuse axonal injury. Case illustration. Song JK, et al. **J Neurosurg** 1999 Jun;90(6):1141

Magnetic resonance imaging evaluation of the pituitary gland and hypothalamus in thalassaemic children with elevated serum ferritin levels. Lau KY, et al. **J Paediatr Child Health** 1998 Oct;34(5):463–6

Reversible MRI abnormalities in an unusual paediatric presentation of Wernicke's encephalopathy. Sparacia G, et al. **Pediatr Radiol** 1999 Aug;29(8):581–4

PHYSIOLOGY

Differential central and peripheral release of vasopressin and oxytocin in response to swim stress in rats. Engelmann M, et al. **Adv Exp Med Biol** 1998;449:175–7 (15 ref.)

Electrophysiological studies of oxytocin neurons in organotypic slice cultures. Jourdain P, et al. **Adv Exp Med Biol** 1998;449:135–45

Intrahypothalamic vasopressin release. An inhibitor of systemic vasopressin secretion? Ludwig M, et al. **Adv Exp Med Biol** 1998;449:163–73 (50 ref.)

Progesterone regulates hypothalamic oxytocin mRNA levels through gamma aminobutyric acid. Thomas A, et al. **Adv Exp Med Biol** 1998;449:123–5

Reduced GABA inhibition of sympathetic function in renal-wrapped hypertensive rats. Martin DS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1523–9

Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Smith BK, et al. **Am J Physiol** 1999 Sep;277(3 Pt 2):R802–11

Stimulation of rat hypothalamus by microdialysis with K+: increase of ACh release elevates plasma glucose. Takahashi A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):R1647–53

Hypothalamic neurons. Mechanisms of sensitivity to temperature. Boulant JA. **Ann N Y Acad Sci** 1998 Sep 29; 856:108–15 (16 ref.)

Brown adipose tissue. More than an effector, of thermogenesis? Cannon B, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:171–87 (67 ref.)

Is there appetite after GLP-1 and PACAP? Christophe J. **Ann N Y Acad Sci** 1998 Dec 11;865:323–35 (88 ref.)

Pituitary adenylate cyclase activating peptide (PACAP) in the retinohypothalamic tract: a daytime regulator of the biological clock. Hannibal J, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:197–206

Neuroendocrine interactions between galanin, opioids, and neuropeptide Y in the control of reproduction and appetite. Kalra SP, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:236–40 (25 ref.)

Differential functions of hypothalamic galanin cell grows in the regulation of eating and body weight. Leibowitz SF. **Ann N Y Acad Sci** 1998 Dec 21;863:206–20 (127 ref.)

Locomotion and head scanning initiated by hypothalamic stimulation are inversely related. Sinnamon HM, et al. **Ann N Y Acad Sci** 1998 Nov 16;860:560–2

Hypothalamic control of amino acid appetite. Torii K, et al. **Ann N Y Acad Sci** 1998 Nov 30;855:417–25 (22 ref.)

Role of the medial preoptic area/anterior hypothalamus in the control of masculine sexual behavior. Paredes RG, et al. **Annu Rev Sex Res** 1997;8:68–101 (176 ref.)

Time course of VMN lesion effects on lordosis and ultrasound production in hamsters. Gibson BM, et al. **Behav Neurosci** 1998 Oct;112(5):1236–46

Aggressive experience affects the sensitivity of neurons towards pharmacological treatment in the hypothalamic attack area. Haller J, et al. **Behav Pharmacol** 1998 Sep; 9(5-6):469–75

Evidence that hypothalamic neurotensin signals leptin effects on feeding behavior in normal and fat-preferring rats. Beck B, et al. **Biochem Biophys Res Commun** 1998 Nov 27; 252(3):634–8

Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Leibowitz SF, et al. **Biol Psychiatry** 1998 Nov 1;44(9):851–64 (166 ref.)

Twenty-four hour rhythms of hypothalamic corticotropin-releasing hormone, thyrotropin-releasing hormone, growth hormone-releasing hormone and somatostatin in rats injected with Freund's adjuvant. Esquifino AI, et al. **Biol Signals Recept** 1999 May-Jun; 8(3):178–90

Is there a geniculohypothalamic tract in primates? A comparative immunohistochemical study in the circadian system of strepsirhine and haplorhine species. Chevassus-au-Louis N, et al. **Brain Res** 1998 Sep 14; 805(1-2):213–9

Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Szymusiak R, et al. **Brain Res** 1998 Aug 24;803(1-2):178–88

The organization of chemically characterized afferents to the perivascular neuronal groups of the hypothalamic magnocellular neurosecretory system in the rat. Duan X, et al. **Brain Res Bull** 1998 Jul 15;46(5):409–15

Time-dependent GABA-ergic activity in olfactory bulb and hypothalamus of proestrous rats. Grigorjev C, et al. **Brain Res Bull** 1999 Apr;48(6):569–72

Neurotransmission in the medulla mediating insular cortical and lateral hypothalamic sympathetic responses. Butcher KS, et al. **Can J Physiol Pharmacol** 1998 Jul-Aug; 76(7-8):737–46

Growth hormone-releasing peptide (GHRP). Bowers CY. **Cell Mol Life Sci** 1998 Dec;54(12):1316–29 (62 ref.)

Restoration of circadian behavior by anterior hypothalamic grafts containing the suprachiasmatic nucleus: graft/host interconnections. Sollars PJ, et al. **Chronobiol Int** 1998 Sep; 15(5):513–33 (104 ref.)

Effects of Coriolus versicolor polysaccharides peptides on electric activity of mediobasal hypothalamus and on immune function in rats. Yu GD, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May;17(3):271–4

Angiotensin II type 1 receptor-mediated inhibition of K+ channel subunit kv2.2 in brain stem and hypothalamic neurons. Gelband CH, et al. **Circ Res** 1999 Feb 19; 84(3):352–9

Interaction of circulating hormones with the brain: the roles of the subfornical organ and the organum vasculosum of the lamina terminalis. McKinley MJ, et al. **Clin Exp Pharmacol Physiol Suppl** 1998 Nov;25:S61–7 (47 ref.)

Responsiveness of the hypothalamo-pituitary-interrenal axis in an amphibian (Bufo terrestris) exposed to coal combustion wastes. Hopkins WA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Feb;122(2):191–6

Leptin, the hypothalamus and the regulation of adiposity. Harrold JA, et al. **Curr Opin Lipidol** 1998 Aug;9(4):295–9 (30 ref.)

Developmental studies for identification of the inhibitory center of melanotropes in the toad, Bufo japonicus. Kouki T, et al. **Dev Growth Differ** 1998 Dec;40(6):651–8

Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus [see comments] Björntorp P, et al. **Diabet Med** 1999 May;16(5):373–83. Comment in: Diabet Med 1999 May;16(5):355–7.

Altered hypothalamic function in response to glucose ingestion in obese humans. Matsuda M, et al. **Diabetes** 1999 Sep;48(9):1801–6

Hypothalamic control of gonadotropin secretion by LHRH, FSHRF, NO, cytokines, and leptin. McCann SM, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):333–44 (53 ref.)

Growth hormone inhibits its own secretion by acting on the hypothalamus through its receptors on neuropeptide Y neurons in the arcuate nucleus and somatostatin neurons in the periventricular nucleus. Minami S, et al. **Endocr J** 1998 Apr;45 Suppl:S19–26 (35 ref.)

Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Kalra SP, et al. **Endocr Rev** 1999 Feb;20(1):68–100 (412 ref.)

Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. Auernhammer CJ, et al. **Endocrinology** 1999 Apr; 140(4):1559–66

Hypothalamic mediated action of free fatty acid on growth hormone secretion in sheep. Briard N, et al. **Endocrinology** 1998 Dec;139(12):4811–9

Leptin signaling in the hypothalamus of normal rats in vivo. McCowen KC, et al. **Endocrinology** 1998 Nov; 139(11):4442–7

Brain-derived neurotrophic factor and neurotrophin-3

enhance somatostatin gene expression through a likely direct effect on hypothalamic somatostatin neurons. Rage F, et al. **Endocrinology** 1999 Feb;140(2):909–16

Characterization of expression of hypothalamic appetite-regulating peptides in obese hyperleptinemic brown adipose tissue-deficient (uncoupling protein-promoter-driven diphtheria toxin A) mice. Tritos NA, et al. **Endocrinology** 1998 Nov;139(11):4634–41

Effects of the antihistaminergic drugs diphenhydramine and zolantidine on vestibular-induced hypothalamic neuronal activity in the guinea pig. Inokuchi A, et al. **Eur Arch Otorhinolaryngol** 1999;256 Suppl 1:S22–6

Visualization of local afferent inputs to magnocellular oxytocin neurons in vitro. Jourdain P, et al. **Eur J Neurosci** 1999 Jun;11(6):1960–72

Opposing roles for dopamine D1 and D2 receptors in the regulation of hypothalamic tuberoinfundibular dopamine neurons. Durham RA, et al. **Eur J Pharmacol** 1998 Aug 21;355(2–3):141–7

Attractin more interest in weight regulation [news] Walsh JH. **Gastroenterology** 1999 Aug;117(2):294

Growth hormone (GH) secretagogues and neuroendocrine regulation of GH secretion. Dickson SL, et al. **Growth Horm IGF Res** 1999 Apr;9 Suppl A:89–91 (20 ref.)

Leptin and neuropeptide Y gene expression in human placenta: ontogeny and evidence for similarities to hypothalamic regulation. Dötsch J, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2755–8

Postmortem tracing reveals the organization of hypothalamic projections of the suprachiasmatic nucleus in the human brain. Dai J, et al. **J Comp Neurol** 1998 Oct 12; 400(1):87–102

Cells of origin of the trigeminohypothalamic tract in the rat. Malick A, et al. **J Comp Neurol** 1998 Oct 12;400(1):125–44

Identification and characterization of estrogen receptor alpha-containing neurons projecting to the vicinity of the gonadotropin-releasing hormone perikarya in the rostral preoptic area of the rat. Simonian SX, et al. **J Comp Neurol** 1999 Aug 23;411(2):346–58

Is the primitive regulation of pituitary prolactin (tPRL177 and tPRL188) secretion and gene expression in the euryhaline tilapia (Oreochromis mossambicus) hypothalamic or environmental? Shepherd BS, et al. **J Endocrinol** 1999 Apr;161(1):121–9

Gender-dependent characteristics of the hypothalamo-corticotrope axis function in glucocorticoid-replete and glucocorticoid-depleted rats. Chisari AN, et al. **J Endocrinol Invest** 1998 Dec; 21(11):737–43

Hyperglycemic effect of a neurotoxic fraction (F3) from Naja haje venom: role of hypothalamo-pituitary adrenal axis (HPA). el-Fiky MA. **J Nat Toxins** 1999 Jun;8(2):203–12

Observations on the orexigenic hypothalamic neuropeptide Y-system in neonatally overfed weanling rats. Plagemann A, et al. **J Neuroendocrinol** 1999 Jul;11(7):541–6

Adrenal responsiveness and the timing of parturition in hypothalamo-pituitary disconnected ovine foetuses with and without constant adrenocorticotrophin infusion. Poore KR, et al. **J Neuroendocrinol** 1999 May;11(5):343–9

Persistent effects of maternal deprivation on HPA regulation can be reversed by feeding and stroking, but not by dexamethasone. van Oers HJ, et al. **J Neuroendocrinol** 1999 Aug;11(8):581–8

Spontaneous action potentials initiate rhythmic intercellular calcium waves in immortalized hypothalamic (GT1-1) neurons. Costantin JL, et al. **J Neurophysiol** 1999 Jul; 82(1):429–35

Physiological studies of spinohypothalamic tract neurons in the lumbar enlargement of monkeys. Zhang X, et al. **J Neurophysiol** 1999 Aug;82(2):1054–8

Maternal aggression is reduced in neuronal nitric oxide synthase-deficient mice. Gammie SC, et al. **J Neurosci** 1999 Sep 15;19(18):8027–35

Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. Horvath TL, et al. **J Neurosci** 1999 Feb 1;19(3):1072–87

Nitric oxide stimulates ACTH secretion and the transcription of the genes encoding for NGFI-B, corticotropin-releasing factor, corticotropin-releasing factor receptor type 1, and vasopressin in the hypothalamus of the intact rat. Lee S, et al. **J Neurosci** 1999 Sep 1;19(17):7640–7

Differences in the properties of ionotropic glutamate synaptic currents in oxytocin and vasopressin neuroendocrine neurons. Stern JE, et al. **J Neurosci** 1999 May 1; 19(9):3367–75

Density of transient K+ current influences excitability in acutely isolated vasopressin and oxytocin neurones of rat hypothalamus. Fisher TE, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):423–32

Properties of C1 and other ventrolateral medullary neurones with hypothalamic projections in the rat. Verberne AJ, et al. **J Physiol (Lond)** 1999 Jun 1;517 (Pt 2):477–94

Activation and degeneration during aging: a morphometric study of the human hypothalamus. Zhou JN, et al. **Microsc Res Tech** 1999 Jan 1;44(1):36–48 (90 ref.)

D5 dopamine receptors mediate estrogen-induced stimulation of hypothalamic atrial natriuretic factor neurons. Lee D, et al. **Mol Endocrinol** 1999 Feb;13(2):344–52

Leptin and the hypothalamus: neuroendocrine regulation of food intake [news] Mantzoros CS. **Mol Psychiatry** 1999 Jan;4(1):8–12, 6–7

Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Hahn TM, et al. **Nat Neurosci** 1998 Aug;1(4):271–2

Expression of hypothalamic peptides in mice lacking neuronal nitric oxide synthase: reduced beta-END immunoreactivity in the arcuate nucleus. Bernstein HG, et al. **Neuroendocrinology** 1998 Dec;68(6):403–11

Leptin activates hypothalamic CART neurons projecting to the spinal cord. Elias CF, et al. **Neuron** 1998 Dec; 21(6):1375–85

From lesions to leptin: hypothalamic control of food intake and body weight. Elmquist JK, et al. **Neuron** 1999 Feb; 22(2):221–32 (133 ref.)

Identification of two novel diurnal genes by screening of a rat brain cDNA library. Patten C, et al. **Neuroreport** 1999 Apr 6;10(5):1155–61

Responses of hypothalamic neurons to stimulation of the vestibular nerve and lateral vestibular nucleus in the rabbit. Grigoryan SS, et al. **Neurosci Behav Physiol** 1999 Jan-Feb; 29(1):61–6

The hypothalamus: cross-roads of endocrine and behavioural regulation in grooming and aggression. Kruk MR, et al. **Neurosci Biobehav Rev** 1998;23(2):163–77 (122 ref.)

The effect of leptin on feeding-regulating neurons in the rat hypothalamus. Funahashi H, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):117–20

Autoregulation of histamine release in medulla oblongata via H3-receptors in rabbits. Kanamaru M, et al. **Neurosci Res** 1998 May;31(1):53–60

Infant cold exposure changes Fos expression to acute cold stimulation in adult hypothalamic brain regions. Miyata S, et al. **Neurosci Res** 1998 Jul;31(3):219–25

Distribution of neurons projecting to the rostral ventrolateral medullary pressor region that are activated by sustained hypotension. Horiuchi J, et al. **Neuroscience** 1999; 89(4):1319–29

Hypothalamic serotonergic activity correlates better with brain temperature than with sleep-wake cycle and muscle tone in rats. Imeri L, et al. **Neuroscience** 1999;89(4):1241–6

Hypothalamic A14 and A15 catecholamine cells provide the dopaminergic innervation to the supraoptic nucleus in rat: a combined retrograde tracer and immunohistochemical study. van Vulpen EH, et al. **Neuroscience** 1999; 93(2):675–80

A brain Na+, K+-ATPase inhibitor (endobain E) enhances norepinephrine release in rat hypothalamus. Vatta M, et al. **Neuroscience** 1999 May;90(2):573–9

Neuropeptides, the hypothalamus and obesity: insights into the central control of body weight. Thorburn AW, et al. **Pathology** 1998 Aug;30(3):229–36 (109 ref.)

Neural substrates for leptin and neuropeptide Y (NPY) interaction: hypothalamic sites associated with inhibition of NPY-induced food intake. Yokosuka M, et al. **Physiol Behav** 1998 Jun 1;64(3):331–8

Hypothalamic neuropeptide Y mRNA is increased after feed restriction in growing broilers. Boswell T, et al. **Poult Sci** 1999 Aug;78(8):1203–7

Molecular and functional remodeling of electrogenic membrane of hypothalamic neurons in response to changes in their input. Tanaka M, et al. **Proc Natl Acad Sci U S A** 1999 Feb 2;96(3):1088–93

Activin antiserum infused into the lateral hypothalamic area affects operant behavior of rats fed lysine-deficient diet. Hawkins RL, et al. **Proc Soc Exp Biol Med** 1998 Nov; 219(2):149–53

Prostaglandin E2 mediates activation of hypothalamic histamine by interleukin-1beta in rats. Kang M, et al. **Proc Soc Exp Biol Med** 1999 Feb;220(2):88–93

Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Ferreira MF, et al. **Psychoneuroendocrinology** 1998 Nov;23(8):1005–13

Effect of novel environmental stimuli on rat behaviour and central noradrenaline function measured by in vivo microdialysis. McQuade R, et al. **Psychopharmacology (Berl)** 1999 Aug;145(4):393–400

A pontine-hypothalamic temperature difference correlated with cutaneous and respiratory heat loss. Parmeggiani PL, et al. **Respir Physiol** 1998 Oct;114(1):49–56

Developmental and hormonal regulation of thermosensitive neuron potential activity in rat brain. Belugin S, et al. **Thyroid** 1999 Aug;9(8):837–43

Hypothalamic thyrotropin-releasing hormone and thyrotropin biological activity. Persani L. **Thyroid** 1998 Oct;8(10):941–6 (45 ref.)

Hypothalamic interleukin-1 in physiology and pathology. Tringali G, et al. **Toxicol Lett** 1998 Dec 28;102–103:295–9 (22 ref.)

[Effect of injection of cholecystokinin into the nucleus tractus solitarius on extrasystoles induced by hypothalamic stimulation in rabbits] Li X, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):49 **(Chi)**

[Role of substance P in pressor response of lateral hypothamus-perifornical region to glutamate] Wang Y, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Nov;13(4):337–41 (Eng. Abstr.) **(Chi)**

[Involvement of nucleus amygdaloideus centralis, lateral hypothalamus/perifornical region and nucleus paraventricularis in insular cortex-pressor response] Gu YH, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):221–6 (Eng. Abstr.) **(Chi)**

[Whole-cell recordings of the supraoptic nucleus neurons from rat hypothalamic slices in vitro] Liu QS, et al. **Sheng Li Hsueh Pao** 1997 Aug;49(4):467–70 (Eng. Abstr.) **(Chi)**

[Hypothalamic LHRH pulse generator] Jiang ZY. **Sheng Li Ko Hsueh Chin Chan** 1996 Oct;27(4):347–9 (10 ref.) **(Chi)**

[From Claude Bernard to the regulatory system between the hypothalamus and the periphery: implications for homeostasis of body weight and obesity] Jeanrenaud B, et al. **C R Seances Soc Biol Fil** 1998;192(5):829–41 (48 ref.) (Eng. Abstr.) **(Fre)**

[Understanding the action of the circadian clock: from phenomenologic ideas to molecular activity] Serviere J. **C R Seances Soc Biol Fil** 1998;192(4):683–710 (120 ref.) (Eng. Abstr.) **(Fre)**

[An autoregulatory system of growth hormone secretion] Minami S. **Nippon Ika Daigaku Zasshi** 1998 Oct; 65(5):409–12 (14 ref.) **(Jpn)**

[Paraventriculovagal path of carbohydrate homeostasis regulation--a perspective biological model in studies on neuroimmunoendocrine interactions] Akmaev IG. **Biull Eksp Biol Med** 1999 Feb;127(2):124–8 (35 ref.) **(Rus)**

[The role of the posterior hypothalamus in the regulation of paradoxical sleep] Suntsova NV, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Nov;84(11):1165–73 (Eng. Abstr.) **(Rus)**

[Motivational-emotional conflict: systemogenesis of goal-directed behavioral act] Kotov AV. **Vestn Ross Akad Med Nauk** 1999;(6):20–5 (10 ref.) (Eng. Abstr.) **(Rus)**

[Interaction between vasopressinergic cells of the hypothalamus neurosecretion centers and the thyroid gland in rats] Krasnovskaia IA, et al. **Zh Evol Biokhim Fiziol** 1998 Nov-Dec;34(6):683–9 **(Rus)**

[The escape reactions in cats during electrical stimulation of the hypothalamus leading to the occurrence of aggressive behavior] Nikulin VV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar-Apr; 49(2):211–9 (Eng. Abstr.) **(Rus)**

[Convergence studies of hypothalamic neurons] Kravtsov PIa, et al. **Fiziol Zh** 1999;45(1-2):127–33 (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Rinaman L. **Am J Physiol** 1999 Aug;277(2 Pt 2):R582–90

Hypothalamic galanin is upregulated during hyperphagia. Kalra PS, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:432–4

Infertility in a line of mice with the high growth mutation is due to luteal insufficiency resulting from disruption at the hypothalamic-pituitary axis. Cargill SL, et al. **Biol Reprod** 1999 Jul;61(1):283–7

Differential recruitment of hypothalamic neuroendocrine and ventrolateral medulla catecholamine cells by non-hypotensive and hypotensive hemorrhages. Buller KM, et al. **Brain Res** 1999 Jul 10;834(1–2):42–54

Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone. De Marinis L, et al. **Clin Endocrinol (Oxf)** 1999 Jun;50(6):741–7

Chronic ethanol drinking and food deprivation affect rat hypothalamic-pituitary-thyroid axis and TRH in septum. Nikodémová M, et al. **Endocrine** 1998 Oct;9(2):213–8

Experimental induction of intermale aggressive behavior in limbic epileptic rats by weak, complex magnetic fields: implications for geomagnetic activity and the modern habitat? St-Pierre LS, et al. **Int J Neurosci** 1998 Dec; 96(3–4):149–59

The midnight to morning urinary cortisol increment is an accurate, noninvasive method for assessment of the hypothalamic-pituitary-adrenal axis. Kong WM, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3093–8

Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. Hall JE, et al. **J Endocrinol Invest** 1998 Oct;21(9):602–11 (67 ref.)

Is the hypothalamic-pituitary-adrenal axis really hyperactivated in visceral obesity? [comment] Kopelman PG. **J Endocrinol Invest** 1999 Jan;22(1):76–9 (17 ref.). Comment on: J Endocrinol Invest 1998 Apr;21(4):268–71.

Hypothalamic dysfunction in acute head-injured patients with stress ulcer. Hwang SL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Sep; 14(9):554–60

Sudden infant death syndrome: hypothalamic failure to sense elevated blood pyrogens. Reid GM, et al. **Med Hypotheses** 1999 Jun;52(6):569–75 (69 ref.)

Differences between men and women as regards the effects of protein-energy malnutrition on the hypothalamic-pituitary-gonadal axis. Lado-Abeal J, et al. **Nutrition** 1999 May;15(5):351–8

Separation induced changes in squirrel monkey hypothalamic-pituitary-adrenal physiology resemble aspects of hypercortisolism in humans. Lyons DM, et al. **Psychoneuroendocrinology** 1999 Feb;24(2):131–42

Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant

hypothalamic-releasing hormones. Riedel W, et al. **Z Rheumatol** 1998;57 Suppl 2:81-7

[The activity of the monoaminergic systems of the rat hypothalamus in acute stress after chronic stressing] Zaretskii DV, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1999 Mar-Apr; 49(2):313-20 (Eng. Abstr.) **(Rus)**

RADIONUCLIDE IMAGING

PET demonstration of hypothalamic activation in cluster headache. Goadsby PJ, et al. **Neurology** 1999 Apr 22; 52(7):1522

SECRETION

Gonadotrophin-releasing hormone and oxytocin secretion from the hypothalamus in vitro during pro-oestrus: the effects of time of day and melatonin. Evans JJ, et al. **Brain Res Bull** 1999 Jan 1;48(1):93-7

The drop in plasma thyrotropin concentrations in fasted chickens is caused by an action at the level of the hypothalamus: role of corticosterone. Geris KL, et al. **Domest Anim Endocrinol** 1999 May;16(4):231-7

Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. Krsmanovic LZ, et al. **Endocrinology** 1999 Mar;140(3):1423-31

Effects of the GABA-A receptor agonist and antagonist on the in vitro release of hypothalamic catecholamines: apparent parallelism between these effects and the LHRH secretion in adult male rats. Feleder C, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):80-4

Arrest of pulsatile luteinizing hormone (LH) secretion during insulin-induced hypoglycemia (IIH): improvement by intrahypothalamic perfusion with glucose. Rodriguez M, et al. **Exp Clin Endocrinol Diabetes** 1999;107(4):257-61

Supraphysiological hyperinsulinemia acutely increases hypothalamic-pituitary-adrenal secretory activity in humans. Fruehwald-Schultes B, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3041-6

Indirect assessment of pulsatile gonadotropin-releasing hormone release in agonadal prepubertal rhesus monkeys (Macaca mulatta). Suter KJ, et al. **J Endocrinol** 1999 Jan; 160(1):35-41

Effects of diabetes and estradiol on norepinephrine release in female rat hypothalamus, preoptic area and cortex. Karkanias GB, et al. **Neuroendocrinology** 1998 Jul; 68(1):30-6

Interrelations between sleep and the somatotropic axis. Van Cauter E, et al. **Sleep** 1998 Sep 15;21(6):553-66 (129 ref.)

TRANSPLANTATION

Restoration of circadian behavior by anterior hypothalamic grafts containing the suprachiasmatic nucleus: graft/host interconnections. Sollars PJ, et al. **Chronobiol Int** 1998 Sep; 15(5):513-33 (104 ref.)

ULTRASTRUCTURE

Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins. Raap DK, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):561-7

[The role of certain sections of the central nervous system in the genesis of sudden death] Dubrovin IA, et al. **Sud Med Ekspert** 1999 Jul-Aug;42(4):19-21 (Eng. Abstr.) **(Rus)**

HYPOTHALAMUS, ANTERIOR

ANATOMY & HISTOLOGY

The medial preoptic and anterior hypothalamic regions of the rhesus monkey: cytoarchitectonic comparison with the human and evidence for sexual dimorphism. Byne W. **Brain Res** 1998 May 18;793(1-2):346-50

CYTOLOGY

Connections of the precommissural nucleus. Canteras NS, et al. **J Comp Neurol** 1999 May 24;408(1):23-45

Large somal size is associated with the expression of galanin but not with neuronal birthdate in the sexually dimorphic male nucleus of ferret's preoptic area/anterior hypothalamus. Park JJ, et al. **Neuroendocrinology** 1998 Oct; 68(4):235-43

Age-related changes in oxytocinergic neurosecretory cells in the accessory magnocellular neuroendocrine nuclei of the hypothalamus in rats. Bazhanova ED, et al. **Neurosci Behav Physiol** 1998 Jul-Aug;28(4):354-6

DRUG EFFECTS

A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Heal DJ, et al. **Br J Pharmacol** 1998 Sep; 125(2):301-8

Diurnal variation in 5-HT1B autoreceptor function in the anterior hypothalamus in vivo: effect of chronic antidepressant drug treatment. Sayer TJ, et al. **Br J Pharmacol** 1999 Apr;126(8):1777-84

Continuous infusion of proinflammatory cytokines into the brain to study brain cytokine induced local and systemic immune effects. Schöning B, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):217-22

Differential regulation of vasopressin gene expression in the hypothalamus of endotoxin-treated 14-day-old rat. Boros A, et al. **Life Sci** 1999;65(4):PL47-52

GROWTH & DEVELOPMENT

Mechanisms for the regulation of gonadotropin-releasing hormone gene expression in the developing mouse. Gore AC, et al. **Endocrinology** 1999 May;140(5):2280-7

Large somal size is associated with the expression of galanin but not with neuronal birthdate in the sexually dimorphic male nucleus of ferret's preoptic area/anterior hypothalamus. Park JJ, et al. **Neuroendocrinology** 1998 Oct; 68(4):235-43

IMMUNOLOGY

Anterior hypothalamic interleukin-1 receptors are involved in mediation of fever during bacterial sepsis in rats. Gourine AV, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:266-9

Interleukin-6 and tumor necrosis factor-alpha during fever induced by bacterial infection. Rudolph K, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:300-3

METABOLISM

Expression of mRNAs for vasopressin, oxytocin and corticotrophin releasing hormone in the hypothalamus, and of cyclooxygenases-1 and -2 in the cerebral vasculature, of endotoxin-challenged pigs. Vellucci SV, et al. **Neuropeptides** 1998 Oct;32(5):439-46

PHYSIOLOGY

Gonadal steroid-dependent GAL-IR cells within the medial preoptic nucleus (MPN) and the stimulatory effects of GAL within the MPN on sexual behaviors. Bloch GJ, et al. **Ann N Y Acad Sci** 1998 Dec 21;863:188-205 (88 ref.)

Control of REM sleep: an aspect of the regulation of physiological homeostasis. Zamboni G, et al. **Arch Ital Biol** 1999 Aug;137(4):249-62 (43 ref.)

The medial preoptic and anterior hypothalamic regions of the rhesus monkey: cytoarchitectonic comparison with the human and evidence for sexual dimorphism. Byne W. **Brain Res** 1998 May 18;793(1-2):346-50

Lesions of the medial preoptic area/anterior hypothalamus (MPOA/AH) modify partner preference in male rats. Paredes RG, et al. **Brain Res** 1998 Nov 30;813(1):1-8

The preoptic area/anterior hypothalamus of different strains of mice: sex differences and development. Brown AE, et al. **Brain Res Dev Brain Res** 1999 Jun 2;115(2):171-82

Synergism between interleukin-6 and interleukin-1beta in hypothalamic serotonin release: a reverse in vivo microdialysis study in F344 rats. Wu Y, et al. **Eur Cytokine Netw** 1999 Mar;10(1):57-64

Hypothalamic involvement in the regulation of maternal behaviour in the rat: inhibitory roles for the ventromedial hypothalamus and the dorsal/anterior hypothalamic areas. Bridges RS, et al. **J Neuroendocrinol** 1999 Apr;11(4):259-66

HYPOTHALAMUS, INFUNDIBULAR see **HYPOTHALAMUS, MIDDLE**

HYPOTHALAMUS, MEDIAL see **HYPOTHALAMUS, MIDDLE**

HYPOTHALAMUS, MIDDLE

ANATOMY & HISTOLOGY

Lateral evaginations from the third ventricle into the rat mediobasal hypothalamus: an amplification of the ventricular route. Amat P, et al. **Neuroscience** 1999; 88(3):673-7

CHEMISTRY

Galanin-R1 receptor in anterior and mid-hypothalamus: distribution and regulation. Landry M, et al. **J Comp Neurol** 1998 Sep 28;399(3):321-40

Special relationship of gamma-aminobutyric acid to the ventromedial nucleus of the hypothalamus during embryonic development. Tobet SA, et al. **J Comp Neurol** 1999 Mar 1;405(1):88-98

Estrogen receptor immunoreactivity in prepubertal and adult male Syrian hamsters. Romeo RD, et al. **Neurosci Lett** 1999 Apr 23;265(3):167-70

CYTOLOGY

Connections of the precommissural nucleus. Canteras NS, et al. **J Comp Neurol** 1999 May 24;408(1):23-45

DRUG EFFECTS

Changes in mediobasal hypothalamic dopamine and GABA release: a possible mechanism underlying taurine-induced prolactin secretion. Arias P, et al. **Amino Acids** 1998; 15(1-2):5-11

Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Satoh N, et al. **Diabetes** 1999 Sep;48(9):1787-93

Conjugated estradiol increases female sexual receptivity in response to oxytocin infused into the medial preoptic area and medial basal hypothalamus. Caldwell JD, et al. **Horm Behav** 1999 Feb;35(1):38-46

Leptin effects on the expression of type-2 CRH receptor mRNA in the ventromedial hypothalamus in the rat. Nishiyama M, et al. **J Neuroendocrinol** 1999 Apr; 11(4):307-14

Effects of cholinergic agonists and antagonists on interleukin-2-induced corticotropin-releasing hormone release from the mediobasal hypothalamus. Karanth S, et al. **Neuroimmunomodulation** 1999 May-Jun;6(3):168-74

L-Deprenyl stimulates the release of catecholamines in the rat medial basal hypothalamus in vivo. ThyagaRajan S, et al. **Neurosci Lett** 1999 Jul 30;270(2):79-82

EMBRYOLOGY

Phytoestrogens alter hypothalamic calbindin-D28k levels during prenatal development. Taylor H, et al. **Brain Res Dev Brain Res** 1999 May 14;114(2):277-81

Androgen-dependent modulation of calbindin-D28K in hypothalamic tissue during prenatal development. Watson MA, et al. **Neurosci Res** 1998 Sep;32(1):97-101

Dopamine turnover in the mediobasal hypothalamus in rat fetuses. Melnikova V, et al. **Neuroscience** 1999 Mar; 89(1):235-41

METABOLISM

Photoperiodic effects on gonadotropin-releasing hormone (GnRH) content and the GnRH-immunoreactive neuronal system of male Siberian hamsters. Bernard DJ, et al. **Biol Reprod** 1999 Feb;60(2):272-6

Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: role of the serotonin transporter and terminal autoreceptors. Maswood S, et al. **Brain Res** 1999 Jun 12;831(1-2):146-54

The development of POMC gene expression in the medial basal hypothalamus of prepubertal rats. Mann PE, et al. **Brain Res Dev Brain Res** 1999 Aug 5;116(1):21-8

Hypothalamic glucose sensor: similarities to and differences from pancreatic beta-cell mechanisms. Yang XJ, et al. **Diabetes** 1999 Sep;48(9):1763-72

Changes in mediobasal hypothalamic gonadotropin-releasing hormone messenger ribonucleic acid levels induced by mating or ovariectomy in a reflex ovulator, the ferret. Bakker J, et al. **Endocrinology** 1999 Feb;140(2):595-602

Changes in extracellular LHRH and beta-endorphin-like immunoreactivity in the nucleus infundibularis-median eminence of anestrous ewes under stress condition. Tomaszewska D, et al. **J Neural Transm** 1999; 106(3-4):265-74

Differential regulation of the expression of corticotropin-releasing factor receptor type 2 (CRF2) in hypothalamus and amygdala of the immature rat by sensory input and food intake. Eghbal-Ahmadi M, et al. **J Neurosci** 1999 May 15;19(10):3982-91

Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Luo S, et al. **Neuroendocrinology** 1998 Jul;68(1):1-10

L-Deprenyl stimulates the release of catecholamines in the rat medial basal hypothalamus in vivo. ThyagaRajan S, et al. **Neurosci Lett** 1999 Jul 30;270(2):79-82

Dopamine turnover in the mediobasal hypothalamus in rat fetuses. Melnikova V, et al. **Neuroscience** 1999 Mar; 89(1):235-41

NPY messenger RNA is increased in medial hypothalamus of anorectic tumor-bearing rats. Chance WT, et al. **Regul Pept** 1998 Sep 25;75-76:347-53

PHYSIOLOGY

Rhythmicity of beta-endorphinergic neuronal activity in the mediobasal hypothalamus during pregnancy in the rat. Lee Y, et al. **Brain Res** 1999 Aug 7;837(1-2):152-60

Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat. Luo B, et al. **Brain Res** 1998 Jun 15;796(1-2):27-37

Involvement of interleukin-2 in analgesia produced by Coriolus versicolor polysaccharide peptides. Gong S, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):67-70

Rapid increase in circulating leptin in ventromedial hypothalamus-lesioned rats: role of hyperinsulinemia and implication for upregulation mechanism. Suga A, et al. **Diabetes** 1999 Oct;48(10):2034-8

Neuropeptide Y and tuberoinfundibular dopamine activities are altered during lactation: role of prolactin. Li C, et al. **Endocrinology** 1999 Jan;140(1):118-23

Rat uncoupling protein 2 (UCP2): expression in obese ventromedial hypothalamus (VMH)-lesioned animals. Strobel A, et al. **Int J Obes Relat Metab Disord** 1998 Nov; 22(11):1121-6

Postmortem anterograde tracing of intrahypothalamic projections of the human dorsomedial nucleus of the hypothalamus. Dai J, et al. **J Comp Neurol** 1998 Nov 9; 401(1):16-33

Hypothalamic involvement in the regulation of maternal behaviour in the rat: inhibitory roles for the ventromedial hypothalamus and the dorsal/anterior hypothalamic areas. Bridges RS, et al. **J Neuroendocrinol** 1999 Apr;11(4):259-66

GABAB receptor-mediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development. Obrietan K, et al.

J Neurophysiol 1999 Jul;82(1):94–102

Lateral evaginations from the third ventricle into the rat mediobasal hypothalamus: an amplification of the ventricular route. Amat P, et al. **Neuroscience** 1999; 88(3):673–7

SECRETION

Combined effect of obesity and aging on feeding-induced monoamine release in the rostromedial hypothalamus of the Zucker rat. Lemierre S, et al.
Int J Obes Relat Metab Disord 1998 Oct;22(10):993–9

beta-Endorphin blocks luteinizing hormone-releasing hormone release by inhibiting the nitricoxidergic pathway controlling its release. Faletti AG, et al.
Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1722–6

HYPOTHALAMUS, POSTERIOR

DRUG EFFECTS

Nitric oxide modulates the release of serotonin in the rat hypothalamus. Kaehler ST, et al. **Brain Res** 1999 Jul 24; 835(2):346–9

METABOLISM

The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Ferraro L, et al. **Neuropsychopharmacology** 1999 Apr;20(4):346–56

Increased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin. Ma SX, et al. **Nitric Oxide** 1999;3(2):153–61

PHYSIOLOGY

Sucrose rich diet modifies thermogenic response to injection of muscimol into the posterior hypothalamus in the rat. Monda M, et al. **Acta Physiol Scand** 1998 Aug; 163(4):379–84

Memory improvement by post-trial injection of lidocaine into the tuberomammillary nucleus, the source of neuronal histamine. Frisch C, et al. **Neurobiol Learn Mem** 1999 Sep; 72(2):69–77

An L-dopaergic relay from the posterior hypothalamic nucleus to the rostral ventrolateral medulla and its cardiovascular function in anesthetized rats. Nishihama M, et al. **Neuroscience** 1999;92(1):123–35

HYPOTHALAMUS, SUPRAOPTIC see **HYPOTHALAMUS, ANTERIOR**

HYPOTHERMIA

see related
REWARMING

Childhood deaths and cargo barriers in cars. Byard RW, et al. **J Paediatr Child Health** 1999 Aug;35(4):409–10

Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428 - positron emission tomography studies. Melega WP, et al. **Neurosci Lett** 1998 Dec 11; 258(1):17–20

Hypothermia causes a reversible, p53-mediated cell cycle arrest in cultured fibroblasts. Matijasevic Z, et al.
Oncol Res 1998;10(11–12):605–10

Cold injuries. Protecting your patients from the dangers of hypothermia and frostbite. Kanzenbach TL, et al.
Postgrad Med 1999 Jan;105(1):72–8 (8 ref.)

[Mild intraoperative hypothermia. Another risk factor for postoperative complications] Rosenberg J, et al.
Ugeskr Laeger 1999 May 17;161(20):2935–8 (29 ref.) (Eng. Abstr.) **(Dan)**

BLOOD

The alveolar-arterial difference in oxygen tension increases with temperature-corrected determination during moderate hypothermia. Hansen D, et al. **Anesth Analg** 1999 Mar;88(3):538–41

Acute severe hemodilution to a hemoglobin of 1.3 g/dl tolerated in the presence of mild hypothermia [letter] Koehntop DE, et al. **Anesthesiology** 1999 Jun;90(6):1798–9

CHEMICALLY INDUCED

Less core hypothermia when anesthesia is induced with inhaled sevoflurane than with intravenous propofol. Ikeda T, et al. **Anesth Analg** 1999 Apr;88(4):921–4

Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Varty GB, et al. **Behav Pharmacol** 1998 Sep;9(5–6):445–55

Cholecystokinin and morphine-induced hypothermia. Rezayat M, et al. **Eur Neuropsychopharmacol** 1999 Mar; 9(3):219–25

3-Nitropropionic acid (3-NPA) produces hypothermia and inhibits histochemical labeling of succinate dehydrogenase (SDH) in rat brain. Nony PA, et al. **Metab Brain Dis** 1999 Jun;14(2):83–94

Magnesium sulfate, maternal hypothermia, and fetal bradycardia with loss of heart rate variability. Cardosi RJ, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):691–3

Nitrous oxide-induced hypothermia in the rat: acute and chronic tolerance. Ramsay DS, et al.
Pharmacol Biochem Behav 1999 Jan;62(1):189–96

Ontogeny of ethanol-induced locomotor activity and hypothermia differences in selectively bred FAST and SLOW mice. Wood RD, et al.
Pharmacol Biochem Behav 1999 Feb;62(2):339–47

Influence of fluoroquinolones on the central action of ethanol. Strzelec JS, et al. **Pol J Pharmacol** 1999 Jan–Feb; 51(1):71–8

Behavioral thermoregulatory response to maitotoxin in mice. Gordon CJ, et al. **Toxicon** 1998 Oct;36(10):1341–7

COMPLICATIONS

Platelet cold agglutinins and cardiac surgery hypothermia [letter] Bizzaro N. **Am J Hematol** 1999 Jan;60(1):80

Hypothermia does not result in more complications after colon surgery. Barone JE, et al. **Am Surg** 1999 Apr; 65(4):356–9

Thermal injury with pulse oximeter probe in hypothermic patient. Pulse oximeter probe burn in hypothermia [letter] Pandey CK, et al. **Can J Anaesth** 1999 Sep;46(9):908–9

Episodic spontaneous hyperhidrosis hypothermia in human immunodeficiency virus-positive patients. Okechukwu CN, et al. **Clin Infect Dis** 1999 Jul;29(1):210

Hypothermia and acute renal failure in the elderly. Durakovic Z, et al. **Coll Antropol** 1998 Jun;22(1):135–40

Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group [see comments] Arons MM, et al. **Crit Care Med** 1999 Apr; 27(4):699–707. Comment in: Crit Care Med 1999 Apr;27(4):669–70.

The effect of maternal hypothermia on the fetal heart rate. Aboud E, et al. **Int J Gynaecol Obstet** 1999 Aug;66(2):163–4

Electrocardiographic changes in unintentional hypothermia--the J wave [letter] Janssens U, et al.
Intensive Care Med 1998 Oct;24(10):1118–9

Left ventricular dysfunction following rewarming from experimental hypothermia. Tveita T, et al.
J Appl Physiol 1998 Dec;85(6):2135–9

Wischnewski ulcers and acute pancreatitis in two hospitalized patients with cirrhosis, portal vein thrombosis, and hypothermia. Wolf DA, et al. **J Forensic Sci** 1999 Sep; 44(5):1082–5

Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries. Holcomb JB, et al. **J Trauma** 1999 Aug;47(2):233–40; discussion 240–2

Ketaset-Rompun extends the temporal gradient for hypothermia-induced retrograde amnesia. Metzger MM, et al. **Physiol Behav** 1999 Jul;66(5):737–40

An unconscious diabetic patient. Ozawa Y, et al.
Postgrad Med J 1998 Sep;74(875):549–50

[Hypothermia lower than 32 degrees C responsible for thrombopenia and leukopenia in the course of polymyositis (letter)] Michel F, et al. **Presse Med** 1998 Oct 24; 27(32):1626–7 **(Fre)**

DIAGNOSIS

Accidental hypothermia. Hanania NA, et al.
Crit Care Clin 1999 Apr;15(2):235–49 (53 ref.)

Hypothermia: an easy-to-miss, dangerous disorder in winter weather. Ballester JM, et al. **Geriatrics** 1999 Feb;54(2):51–2, 55–7 (10 ref.)

Continuous core temperature monitoring of search and rescue divers during extreme conditions [see comments] White LJ, et al. **Prehosp Emerg Care** 1998 Oct–Dec;2(4):280–4. Comment in: Prehosp Emerg Care 1998 Oct–Dec;2(4):330–3.

[Cold and humid time...] Hausfater P, et al.
Rev Med Interne 1999;20 Suppl 2:283s–284s **(Fre)**

[Accidental hypothermia] Le Conte P, et al. **Rev Prat** 1998 Feb 1;48(3):343–5 **(Fre)**

[Use of a CO-oximeter for forensic diagnosis of hypothermia] Shimizu K, et al. **Nippon Hoigaku Zasshi** 1998 Jun; 52(3):196–201 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Does capsaicin affect physiologic and thermal responses of males during immersion in 22 degrees C? Glickman-Weiss EL, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1095–9

Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Malone DT, et al. **Br J Pharmacol** 1998 Aug;124(7):1419–24

Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group [see comments] Arons MM, et al. **Crit Care Med** 1999 Apr; 27(4):699–707. Comment in: Crit Care Med 1999 Apr;27(4):669–70.

The effects of ibuprofen on eicosanoid synthesis in sepsis [editorial; comment] Fletcher JR. **Crit Care Med** 1999 Apr; 27(4):669–70 (11 ref.). Comment on: Crit Care Med 1999 Apr;27(4):699–707.

ENZYMOLOGY

Elevated serum creatine kinase and MB isoenzyme levels in hypothermia--a brief case report [editorial] Landesman KA, et al. **Conn Med** 1999 Feb;63(2):67

EPIDEMIOLOGY

The epidemiology of cold injury in Antarctica. Cattermole TJ. **Aviat Space Environ Med** 1999 Feb;70(2):135–40

Hypothermia in critically ill trauma patients. Rutherford EJ, et al. **Injury** 1998 Oct;29(8):605–8

ETIOLOGY

Intraoperative hypothermia and ventricular shunt infections [published erratum appears in Acta Neurochir (Wien) 1998;140(8):882] Gerszten PC, et al.
Acta Neurochir (Wien) 1998;140(6):591–4

Platelet cold agglutinins and cardiac surgery hypothermia [letter] Bizzaro N. **Am J Hematol** 1999 Jan;60(1):80

Cooling effect of continuous renal replacement therapy in critically ill patients. Yagi N, et al. **Am J Kidney Dis** 1998 Dec;32(6):1023–30

Evidence supporting involvement of leukotrienes in LPS-induced hypothermia in mice. Paul L, et al.
Am J Physiol 1999 Jan;276(1 Pt 2):R52–8

Hypothermia in newborns at Shimla. Kaushik SL, et al.
Indian Pediatr 1998 Jul;35(7):652–6

Normal developmental outcome following exposure and hypothermia in a new-born infant [letter] Healy J, et al.
Ir Med J 1998 Dec;91(6):216–7

Hypothermia in trauma patients. Peng RY, et al.
J Am Coll Surg 1999 Jun;188(6):685–96 (107 ref.)

Severe hypothermic injury to the foot and ankle caused by continuous cryocompression therapy. Høiness PR, et al.
Knee Surg Sports Traumatol Arthrosc 1998;6(4):253–5 (14 ref.)

Fentanyl analgesia increases the incidence of postoperative hypothermia in neonates. Okada Y, et al.
Pediatr Surg Int 1998 Sep;13(7):508–11

Collapse and hypothermia in an elderly woman in early summer. Morris RO, et al. **Postgrad Med J** 1999 Jul; 75(885):441–2

Core temperature changes during open and laparoscopic colorectal surgery. Luck AJ, et al. **Surg Endosc** 1999 May; 13(5):480–3

Hypothermia: a potential risk of CO2 insufflation? [editorial; comment] MacFadyen BV Jr. **Surg Endosc** 1999 Feb; 13(2):99–100. Comment on: Surg Endosc 1999 Feb;13(2):101–5. Comment on: Surg Endosc 1999 Feb;13(2):106–8.

A quadriplegic man with hypothermia and thrombocytopenia. Jeanpierre CA, et al. **WMJ** 1999 Jan–Feb;98(1):52–3

Computer simulation of hypothermia during "damage control" laparotomy. Hirshberg A, et al. **World J Surg** 1999 Sep;23(9):960–5

[Severe hypothermia in a tropical setting] Tchoua R, et al.
Med Trop (Mars) 1998;58(2):158–60 (Eng. Abstr.) **(Fre)**

[Extracorporeal circulation for warming in severe accidental hypothermia. 3 cases] Demaria R, et al. **Presse Med** 1998 Apr 11;27(14):664–6 (Eng. Abstr.) **(Fre)**

[Accidental hypothermia (letter)] Molvaer OI.
Tidsskr Nor Laegeforen 1999 Jun 20;119(16):2392 **(Nor)**

[Accidental intraoperative whole-body hypothermia: the mechanisms of its occurrence and of self-warming] Romanov MA. **Anesteziol Reanimatol** 1998 Jul–Aug; (4):65–72 (145 ref.) **(Rus)**

IMMUNOLOGY

Effects of mild perioperative hypothermia on cellular immune responses. Beilin B, et al. **Anesthesiology** 1998 Nov; 89(5):1133–40

Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Ben-Eliyahu S, et al. **Anesthesiology** 1999 Sep;91(3):732–40

Induction of hypothermia, hypoglycemia and hyperinsulinemia after acute leptin immunoneutralization in overnight fasted mice. Martinez-Ansó E, et al.
Int J Mol Med 1998 Dec;2(6):681–3

METABOLISM

Cold stress increases lipolysis, FFA Ra and TG/FFA cycling in humans. Vallerand AL, et al.
Aviat Space Environ Med 1999 Jan;70(1):42–50

Mitochondrial permeability transition during hypothermic to normothermic reperfusion in rat liver demonstrated by the protective effect of cyclosporin A. Leducq N, et al.
Biochem J 1998 Dec 1;336 (Pt 2):501–6

Hypothermia attenuates hyperglycolysis in the periphery of ischemic core in rat brain. Tohyama Y, et al.
Exp Brain Res 1998 Oct;122(3):333–8

Hypothermia ameliorates ischemic brain damage and suppresses the release of extracellular amino acids in both normo- and hyperglycemic subjects. Li PA, et al.
Exp Neurol 1999 Jul;158(1):242–53

Hypothermic stress leads to activation of Ras-Erk signaling. Chan EY, et al. **J Clin Invest** 1999 May;103(9):1337–44

Effects of hypothermic hypoxia on anaerobic energy metabolism in isolated anuran livers. Fedorow CA, et al.
J Comp Physiol [B] 1998 Dec;168(8):555–61

Profound systemic hypothermia and release of neurotransmitter amino acids [letter; comment] Miyamoto TA, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):406–8. Comment on: J Thorac Cardiovasc Surg 1995 Jul;110(1):27–35.

HYPOTHERMIA

The time-course of DNA fragmentation in the choroid plexus and the CA1 region following transient global ischemia in the rat brain. The effect of intra-ischemic hypothermia. Ferrand-Drake M, et al. **Neuroscience** 1999;93(2):537-49

Effects of adrenalectomy on 8-OH-DPAT induced hypothermia in mice. McAllister-Williams RH, et al. **Psychopharmacology (Berl)** 1999 Feb;142(1):73-7

Superoxide dismutase activity and the effect of N-methyl-D-aspartate antagonists on lipid peroxidation in the early phase of cold injury. Kiris T, et al. **Res Exp Med (Berl)** 1999 Apr;198(6):341-7

MORTALITY

From the Centers for Disease Control and Prevention. Hypothermia-related deaths--Georgia, January 1996-December 1997, and United States, 1979-1995. **JAMA** 1999 Jan 13;281(2):124-5

Hypothermia-related deaths--Georgia, January 1996-December 1997, and United States, 1979-1995 [published erratum appears in MMWR Morb Mortal Wkly Rep 1999 Jan 29;48(3):60] **MMWR Morb Mortal Wkly Rep** 1998 Dec 11; 47(48):1037-40

NURSING

Warming up to better surgical outcomes. Hudson G, et al. **AORN J** 1999 Jan;69(1):247-8, 251-3

PATHOLOGY

Glial cell swelling--effect of hypothermia. Plesnila N, et al. **Acta Neurochir Suppl (Wien)** 1999;73:63-6

What happens in freezing bodies? Experimental study of histological tissue change caused by freezing injuries. Schäfer AT, et al. **Forensic Sci Int** 1999 Jun 28; 102(2-3):149-58

PHYSIOPATHOLOGY

Evidence supporting involvement of leukotrienes in LPS-induced hypothermia in mice. Paul L, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R52-8

Intraoperative phenylephrine infusion decreases the magnitude of redistribution hypothermia. Ikeda T, et al. **Anesth Analg** 1999 Aug;89(2):462-5

The effect of graded postischemic spinal cord hypothermia on neurological outcome and histopathology after transient spinal ischemia in rat. Kakinohana M, et al. **Anesthesiology** 1999 Mar;90(3):789-98

Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Varty GB, et al. **Behav Pharmacol** 1998 Sep;9(5-6):445-55

Effect of hypothermia on kainic acid-induced limbic seizures: an electroencephalographic and 14C-deoxyglucose autoradiographic study. Maeda T, et al. **Brain Res** 1999 Feb 13;818(2):228-35

Hatchling painted turtles (Chrysemys picta) survive only brief freezing of their bodily fluids. Attaway MB, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Jul; 120(3):405-8

Physiological significance of behavioral hypothermia in hypoglycemic frogs (Rana catesbeiana). Rocha PL, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1998 Apr; 119(4):957-61

Spontaneous activity of preoptic neurons in slice preparations of the hypothalamus of European hamsters (Cricetus cricetus) and Wistar rats under different states of hypothermia. Hashimoto M, et al. **Cryobiology** 1998 Nov; 37(3):254-62

Thermoregulatory responses of the newborn pig during experimentally induced hypothermia and rewarming. Lossec G, et al. **Exp Physiol** 1998 Sep;83(5):667-78

Hypothermia related changes in electrocortical activity at stepwise increase of intracranial pressure in piglets. Fritz H, et al. **Exp Toxicol Pathol** 1999 Feb;51(2):163-71

Immune changes in humans during cold exposure: effects of prior heating and exercise. Brenner IK, et al. **J Appl Physiol** 1999 Aug;87(2):699-710

Cold stress alters characteristics of sympathetic nerve discharge bursts. Kenney MJ, et al. **J Appl Physiol** 1999 Aug;87(2):732-42

Exertional fatigue, sleep loss, and negative energy balance increase susceptibility to hypothermia. Young AJ, et al. **J Appl Physiol** 1998 Oct;85(4):1210-7

The implications of hypothermia for early tracheal extubation following cardiac surgery. Leslie K, et al. **J Cardiothorac Vasc Anesth** 1998 Dec;12(6 Suppl 2):30-4; discussion 41-4 (59 ref.)

Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats. Colbourne F, et al. **J Cereb Blood Flow Metab** 1999 Jul;19(7):742-9

Moderate hypothermia reduces hypotensive, but not hypercapnic vasodilation of pial arterioles in rats. Irikura K, et al. **J Cereb Blood Flow Metab** 1998 Dec;18(12):1294-7

Regional blood flow response to hypothermia in premature, newborn, and neonatal piglets. Powell RW, et al. **J Pediatr Surg** 1999 Jan;34(1):193-8

Simultaneous measurement of brain and core temperature in the rat during fever, hyperthermia, hypothermia and sleep. Sundgren-Andersson AK, et al. **Neuroimmunomodulation** 1998 Sep-Oct;5(5):241-7

Alterations in swim stress-induced analgesia and hypothermia following serotonergic or NMDA antagonists in the rostral ventromedial medulla of rats. Hopkins E, et al. **Physiol Behav** 1998 Jun 1;64(3):219-25

Neuromodulators and hypoxic hypothermia in the rat. Gautier H, et al. **Respir Physiol** 1998 Jun;112(3):315-24

[Osborn wave in hypothermia] Igual M, et al. **Schweiz Med Wochenschr** 1999 Feb 13;129(6):241 **(Ger)**

[Effects of neo-kyotorphin and delta sleep-inducing peptide on the rectal temperature in rats in the norm, during hypothermia and self-warming] Pavlov Iu, et al. **Biull Eksp Biol Med** 1998 Jul;126(7):113-5 **(Rus)**

[Resuming of thermoregulation in rats during deep hypothermia with EDTA without rewarming the body] Arokina NK. **Ross Fiziol Zh Im I M Sechenova** 1998 Aug; 84(8):806-13 (Eng. Abstr.) **(Rus)**

[The functional activity, energetics and survival of the heart under hypothermia] Aliukhin IuS. **Usp Fiziol Nauk** 1998 Jul-Sep;29(3):66-78 (52 ref.) (Eng. Abstr.) **(Rus)**

[Can the nervous system functions of mammals be restored during deep cooling without warming? New facts and the evolution of views] Ivanov KP. **Usp Fiziol Nauk** 1999 Jan-Mar;30(1):73-89 (68 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Oesophageal heat exchanger in the prevention of perioperative hypothermia [letter; comment] Bräuer A, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1232-3. Comment on: Acta Anaesthesiol Scand 1998 Mar;42(3):348-52.

Forced-air warming blanket and surgical access [letter] Tuckey J. **Anaesthesia** 1999 Jan;54(1):97-8

Intraoperative burns secondary to warmed i.v. bags: a warning. Rosenfield LK, et al. **Anesthesiology** 1999 Feb; 90(2):616-8

Warming up to better surgical outcomes. Hudson G, et al. **AORN J** 1999 Jan;69(1):247-8, 251-3

Design and evaluation of a portable rigid forced-air warming cover for prehospital transport of cold patients. Giesbrecht GG, et al. **Aviat Space Environ Med** 1998 Dec; 69(12):1200-3

Improved high altitude hypoxic tolerance and amelioration of anorexia and hypophagia in rats on oral glutamate supplementation. Kumar D, et al. **Aviat Space Environ Med** 1999 May;70(5):475-9

Cognitive performance over 7 days in a distressed submarine. Slaven GM, et al. **Aviat Space Environ Med** 1999 Jun; 70(6):604-8

Pharmacological vasodilatation improves efficiency of rewarming from hypothermic cardiopulmonary bypass. Deakin CD, et al. **Br J Anaesth** 1998 Aug;81(2):147-51

Covering the head and face maintains intraoperative core temperature. Kamitani K, et al. **Can J Anaesth** 1999 Jul; 46(7):649-52

Thermodynamic modelling of hypothermia. Brandon Bravo LJ. **Eur J Emerg Med** 1999 Jun;6(2):123-7

Preventing hypothermia: convective and intravenous fluid warming versus convective warming alone. Smith CE, et al. **J Clin Anesth** 1998 Aug;10(5):380-5

Thermal management of the low birth weight infant: a cornerstone of neonatology [editorial; comment] Narendran V, et al. **J Pediatr** 1999 May;134(5):529-31. Comment on: J Pediatr 1999 May;134(5):547-51.

Effect of polyethylene occlusive skin wrapping on heat loss in very low birth weight infants at delivery: a randomized trial [see comments] Vohra S, et al. **J Pediatr** 1999 May; 134(5):547-51. Comment in: J Pediatr 1999 May;134(5):529-31.

Reduction of laparoscopic-induced hypothermia, postoperative pain and recovery room length of stay by pre-conditioning gas with the Insuflow device: a prospective randomized controlled multi-center study. Ott DE, et al. **JSLS** 1998 Oct-Dec;2(4):321-9

Efficacy and safety of heat exchanger added to venovenous bypass circuit during orthotopic liver transplantation. Neelakanta G, et al. **Liver Transpl Surg** 1998 Nov; 4(6):506-9

The use of the Haemonetic Rapid Infusion System (RIS) has dramatically reduced the duration and frequency of significant intraoperative hypotension and hypothermia that can occur in major cases [letter; comment] Minore WS. **Resuscitation** 1997 Nov;35(3):273-4. Comment on: Resuscitation 1996 Apr;31(2):127-33.

Humidified gas prevents hypothermia induced by laparoscopic insufflation: a randomized controlled study in a pig model [see comments] Bessell JR, et al. **Surg Endosc** 1999 Feb;13(2):101-5. Comment in: Surg Endosc 1999 Feb;13(2):99-100.

A randomized controlled trial to determine the effects of humidified carbon dioxide insufflation during thoracoscopy. Mouton WG, et al. **Surg Endosc** 1999 Apr; 13(4):382-5

[Level 1 systems in clinical practice] Amicucci G, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):46-8 **(Ita)**

[Consequences of perioperative hypothermia] Berti M, et al. **Minerva Anestesiol** 1999 May;65(5 Suppl 1):42-5 (25 ref.) **(Ita)**

[Transdermal nitroglycerin before induction of anesthesia prevents redistribution hypothermia in patients under general anesthesia] Morioka N, et al. **Masui** 1998 Dec; 47(12):1459-63 (Eng. Abstr.) **(Jpn)**

SURGERY

Severe accidental hypothermia: rewarming strategy using a veno-venous bypass system and a convective air warmer. Bräuer A, et al. **Intensive Care Med** 1999 May;25(5):520-3

THERAPY

Forced hot air rewarming in hypothermic patients with cardiocirculatory arrest? [letter; comment] Mair P, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):1018-20. Comment on: Acta Anaesthesiol Scand 1997 Nov;41(10):1359-64.

Forward blood flow during cardiopulmonary resuscitation in patients with severe accidental hypothermia. An echocardiographic study. Mair P, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1139-44

Accidental hypothermia. Hanania NA, et al. **Crit Care Clin** 1999 Apr;15(2):235-49 (53 ref.)

Hypothermia and extracorporeal rewarming: the journey toward a less invasive, more accessible methodology [editorial; comment] Josephs JD, et al. **Crit Care Med** 1998 Dec;26(12):1944-5 (9 ref.). Comment on: Crit Care Med 1998 Dec;26(12):2016-20.

Continuous venovenous rewarming: results from a juvenile animal model [see comments] Seigler RS, et al. **Crit Care Med** 1998 Dec;26(12):2016-20. Comment in: Crit Care Med 1998 Dec;26(12):1944-5.

Enhanced thermogenesis in rats by a composite Indian herbal preparation-I and its mechanism of action. Kumar R, et al. **J Altern Complement Med** 1999 Jun;5(3):245-51

Recovery from mild hypothermia can be accelerated by mechanically distending blood vessels in the hand. Grahn D, et al. **J Appl Physiol** 1998 Nov;85(5):1643-8

Can recovery from mild hypothermia be accelerated so much by mechanically distending locally heated blood vessels? [letter] Oakley EH. **J Appl Physiol** 1999 Aug;87(2):867-8

A non-invasive means to effectively restore normothermia in cold stressed individuals: a preliminary report. Soreide E, et al. **J Emerg Med** 1999 Jul-Aug;17(4):725-30

Randomised study of skin-to-skin versus incubator care for rewarming low-risk hypothermic neonates [letter] Christensson K, et al. **Lancet** 1998 Oct 3;352(9134):1115

Severe accidental hypothermia successfully treated by warmed peritoneal lavage. Visetti E, et al. **Minerva Anestesiol** 1998 Oct;64(10):471-5

Accidental hypothermia in a child. Balagna R, et al. **Paediatr Anaesth** 1999;9(4):342-4

The Mt. Tyndall incident. Braude D, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):167-9

Severe accidental hypothermia: the need for prolonged aggressive resuscitative efforts. Kulkarni RG, et al. **Prehosp Emerg Care** 1999 Jul-Sep;3(3):254-9

The utility of traditional prehospital interventions in maintaining thermostasis. Watts DD, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):115-22

Scottish Hypothermia and Rewarming Project (SHARP) [letter] Gordon MW, et al. **Scott Med J** 1998 Aug;43(4):105

Freezing to death--the treatment of accidental hypothermia in the Scottish mountains. Grant P, et al. **Scott Med J** 1998 Apr;43(2):36-7 (4 ref.)

Hypothermia in trauma patients [editorial; comment] Segers MJ. **Unfallchirurg** 1998 Oct;101(10):741. Comment on: Unfallchirurg 1998 Oct;101(10):742-9.

Hypothermia in trauma patients [see comments] Segers MJ, et al. **Unfallchirurg** 1998 Oct;101(10):742-9. Comment in: Unfallchirurg 1998 Oct;101(10):741.

[Hypothermia in traumatology] Rousseau JM, et al. **Ann Fr Anesth Reanim** 1997;16(7):885-94 (69 ref.) (Eng. Abstr.) **(Fre)**

[Accidental hypothermia] Le Conte P, et al. **Rev Prat** 1998 Feb 1;48(3):343-5 **(Fre)**

[Cardiopulmonary resuscitation. The effect of severe hypothermia on clinical outcome] Lamperti M, et al. **Minerva Anestesiol** 1998 Oct;64(10):459-64 (Eng. Abstr.) **(Ita)**

VETERINARY

Hypothermia, hypoglycemia, and hypothyrosis associated with poult enteritis and mortality syndrome. Doerfler RE, et al. **Poult Sci** 1998 Aug;77(8):1103-9

Warming with a forced air warming blanket minimizes anesthetic-induced hypothermia in cats. Machon RG, et al. **Vet Surg** 1999 Jul-Aug;28(4):301-10

HYPOTHERMIA, INDUCED

see related

REWARMING

Effect of prostaglandin E1 and nitroglycerin on portal venous flow during hypothermic extracorporeal circulation: assessment by transesophageal echography. Iribe G, et al. **Acta Anaesthesiol Scand** 1999 May;43(5):520-5

Effects of dopamine in lung-transplanted pigs at 32 degrees C. Roscher R, et al. **Acta Anaesthesiol Scand** 1999 Aug; 43(7):715-21

Effects of mild and moderate hypothermia on cerebral metabolism and glutamate in an experimental head injury. Mori K, et al. **Acta Neurochir Suppl (Wien)** 1998;71:222-4

Significance of multimodal cerebral monitoring under moderate therapeutic hypothermia for severe head injury. Nakamura T, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:85-7

Comparative effects of hypothermia, barbiturate, and

osmotherapy for cerebral oxygen metabolism, intracranial pressure, and cerebral perfusion pressure in patients with severe head injury. Nara I, et al.
Acta Neurochir Suppl (Wien) 1998;71:22–6

Effects of systemic hypothermia and selective brain cooling on ischemic brain damage and swelling. Park CK, et al.
Acta Neurochir Suppl (Wien) 1998;71:225–8

Moderate hypothermia and brain temperature in patients with severe middle cerebral artery infarction. Schwab S, et al.
Acta Neurochir Suppl (Wien) 1998;71:131–4

The chronic cell death with DNA fragmentation after post-ischaemic hypothermia in the gerbil hippocampus. Nakamura T, et al. **Acta Neurochir (Wien)** 1999; 141(4):407–12; discussion 412–3

Systemic hypothermia following compression injury of rat spinal cord: reduction of plasma protein extravasation demonstrated by immunohistochemistry. Yu WR, et al.
Acta Neuropathol (Berl) 1999 Jul;98(1):15–21

Influence of the sympathetic nervous system on renal function during hypothermia. Broman M, et al.
Acta Physiol Scand 1998 Jul;163(3):241–9

Cerebral autoregulation during whole-body hypothermia and hyperthermia stimulus. Doering TJ, et al.
Am J Phys Med Rehabil 1999 Jan–Feb;78(1):33–8

Ischemic preconditioning and myocardial hypothermia in rabbits with prolonged coronary artery occlusion. Hale SL, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):H2029–34

Segment VIII resection of the cirrhotic liver under continuous pringle maneuver with in situ cooling followed by temporary portal decompression. Kim YI, et al.
Am J Surg 1999 Mar;177(3):244–6

Muscle-sparing minithoracotomy with intercostal nerve cryoanalgesia: an improved method for major lung resections. Tovar EA, et al. **Am Surg** 1998 Nov; 64(11):1109–15

Induced hypothermia in the postoperative management of refractory cardiac failure following paediatric cardiac surgery. Deakin CD, et al. **Anaesthesia** 1998 Sep; 53(9):848–53

The effectiveness of rapidly infused intravenous fluids for inducing moderate hypothermia in neurosurgical patients. Baumgardner JE, et al. **Anesth Analg** 1999 Jul;89(1):163–9

Cryoanalgesia: effect on postherniorrhaphy pain. Callesen T, et al. **Anesth Analg** 1998 Oct;87(4):896–9

Changing temperature management for cardiopulmonary bypass. Cook DJ. **Anesth Analg** 1999 Jun;88(6):1254–71 (166 ref.)

The effect of hematocrit on cerebral blood flow velocity in neonates and infants undergoing deep hypothermic cardiopulmonary bypass. Gruber EM, et al.
Anesth Analg 1999 Aug;89(2):322–7

The effects of prostaglandin E1 on intraoperative temperature changes and the incidence of postoperative shivering during deliberate mild hypothermia for neurosurgical procedures. Kawaguchi M, et al.
Anesth Analg 1999 Feb;88(2):446–51

Cerebrovascular cytokine responses during coronary artery bypass surgery: specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass. Nandate K, et al. **Anesth Analg** 1999 Oct;89(4):823–8

The effects of moderate hypothermia and intrathecal tetracaine on glutamate concentrations of intrathecal dialysate and neurologic and histopathologic outcome in transient spinal cord ischemia in rabbits. Wakamatsu H, et al. **Anesth Analg** 1999 Jan;88(1):56–62

Differential immediate-early gene expression in ovine brain after cardiopulmonary bypass and hypothermic circulatory arrest. Bokesch PM, et al. **Anesthesiology** 1998 Oct; 89(4):961–8

Direct expiratory gas analysis after hypothermic cardiopulmonary bypass. Moriyama S, et al.
Ann Thorac Cardiovasc Surg 1999 Jun;5(3):150–5

Recovery from metabolic impairments after hypothermic cardiopulmonary bypass: postoperative changes in arterial-venous carbon dioxide tension difference. Utoh J, et al. **Ann Thorac Cardiovasc Surg** 1999 Feb;5(1):27–30

Influence of cardiopulmonary bypass perfusion temperature on neurologic and hematologic function after coronary artery bypass grafting. Engelman RM, et al.
Ann Thorac Surg 1999 Jun;67(6):1547–55; discussion 1556

Cardiovascular effects of induced hypothermia after lung transplantation. Eriksson LT, et al. **Ann Thorac Surg** 1999 Mar;67(3):804–9

Retrospective study of somatosensory evoked potential monitoring in deep hypothermic circulatory arrest. Ghariani S, et al. **Ann Thorac Surg** 1999 Jun;67(6):1915–8; discussion 1919–21

Effects of hypothermic and normothermic cardiopulmonary bypass on brain oxygenation. Kadoi Y, et al.
Ann Thorac Surg 1999 Jul;68(1):34–9

Intermittent perfusion protects the brain during deep hypothermic circulatory arrest. Langley SM, et al.
Ann Thorac Surg 1999 Jul;68(1):4–12; discussion 12–3

Spinal cord protection during aortic cross-clamping using retrograde venous perfusion. Parrino PE, et al.
Ann Thorac Surg 1999 Jun;67(6):1589–94; discussion 1594–5

Delayed impairment of cerebral oxygenation after deep hypothermic circulatory arrest in children. Pesonen EJ, et al. **Ann Thorac Surg** 1999 Jun;67(6):1765–70

Aprotinin in deep hypothermic circulatory arrest. Smith CR, et al. **Ann Thorac Surg** 1999 Jul;68(1):278–86 (66 ref.)

Increased intracerebral excitatory amino acids and nitric oxide after hypothermic circulatory arrest. Tseng EE, et al. **Ann Thorac Surg** 1999 Feb;67(2):371–6

Optimal blood flow for cooled brain at 20 degrees C. Watanabe T, et al. **Ann Thorac Surg** 1999 Sep;68(3):864–9

Clinical application of the M-numbers of aortic cannulas during hypothermic cardiopulmonary bypass in pediatric patients. Kim WG, et al. **Artif Organs** 1999 Apr; 23(4):369–72

The effects of pulsatile versus nonpulsatile perfusion on blood viscoelasticity before and after deep hypothermic circulatory arrest in a neonatal piglet model. Undar A, et al. **Artif Organs** 1999 Aug;23(8):717–21

Mild hypothermia reduces infarct size in the beating rabbit heart: a practical intervention for acute myocardial infarction? Miki T, et al. **Basic Res Cardiol** 1998 Oct; 93(5):372–83

Hypothermic neuroprotection of peripheral nerve of rats from ischaemia-reperfusion injury. Mitsui Y, et al.
Brain 1999 Jan;122 (Pt 1):161–9

Effect of postischaemic hypothermia on the mitochondrial damage induced by ischaemia and reperfusion in the gerbil. Canevari L, et al. **Brain Res** 1999 Jan 30;817(1–2):241–5

Characterization of postischemic behavioral deficits in gerbils with and without hypothermic neuroprotection. Colbourne F, et al. **Brain Res** 1998 Aug 24;803(1–2):69–78

Diazepam-induced neuroprotection: dissociating the effects of hypothermia following global ischemia. Dowden J, et al. **Brain Res** 1999 May 22;829(1–2):1–6

Hypothermic neuroprotection of peripheral nerve of rats from ischemia-reperfusion injury: intraischemic vs. reperfusion hypothermia. Mitsui Y, et al. **Brain Res** 1999 May 8;827(1–2):63–9

Consecutive in vivo measurement of nitric oxide in transient forebrain ischemic rat under normothermia and hypothermia. Sugimura T, et al. **Brain Res** 1998 Oct 19; 808(2):313–6

The effect of head cooling on the physiological responses and resultant neural damage to global hemispheric hypoxic ischemia in prostaglandin E2 treated rats. Thornhill J, et al. **Brain Res** 1999 Apr 17;825(1–2):36–45

Neonatal cryoanesthesia affects the morphology of the visual cortex in the adult rat. Nuñez JL, et al.
Brain Res Dev Brain Res 1998 Nov 1;111(1):89–98

The effect of hypothermia on the expression of neurotrophin mRNA in the hippocampus following transient cerebral ischemia in the rat. Boris-Möller F, et al.
Brain Res Mol Brain Res 1998 Dec 10;63(1):163–73

Lidocaine prolongs the safe duration of circulatory arrest during deep hypothermia in dogs. Zhou Y, et al.
Can J Anaesth 1998 Jul;45(7):692–8

Myocardial temperature reduction attenuates necrosis after prolonged ischemia in rabbits. Hale SL, et al.
Cardiovasc Res 1998 Dec;40(3):502–7

Influence of normothermic systemic perfusion temperature on cold myocardial protection during coronary artery bypass surgery. Birdi I, et al. **Cardiovasc Surg** 1999 Apr; 7(3):369–74

Cerebral blood flow and oxygen metabolism during cardiopulmonary bypass with moderate hypothermic selective cerebral perfusion. Igari T, et al.
Cardiovasc Surg 1999 Jan;7(1):106–11

Hippocampal neuronal death following deep hypothermic circulatory arrest in dogs: involvement of apoptosis. Kin H, et al. **Cardiovasc Surg** 1999 Aug;7(5):558–64

Does hypothermia prevent cerebral ischaemia during cardiopulmonary bypass? McCleary AJ, et al.
Cardiovasc Surg 1999 Jun;7(4):425–31

Moderately hypothermic cardiopulmonary bypass and selective cerebral perfusion in ascending aorta and aortic arch surgery. Preliminary experience in twenty-two patients. Testolin L, et al. **Cardiovasc Surg** 1998 Aug; 6(4):398–405

Hypothermia prevents biphasic glutamate release and corresponding neuronal degeneration after transient spinal cord ischemia in the rat. Ishikawa T, et al.
Cell Mol Neurobiol 1999 Apr;19(2):199–208

Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery? Talwalkar NG, et al. **Chest** 1999 Jan;115(1):135–9

Effect of mild hypothermia on the changes of cerebral blood flow, brain blood barrier and neuronal injuries following reperfusion of focal cerebral ischemia in rats. Huang F, et al. **Chin Med J (Engl)** 1998 Apr;111(4):368–72

Neurological function after deep hypothermic circulatory arrest in the rat. Kawaguchi AT, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II385–9; discussion II390

High-volume continuous hemofiltration during cardiopulmonary bypass attenuates pulmonary dysfunction in neonatal lambs after deep hypothermic circulatory arrest. Nagashima M, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II378–84

Hypothermia induced by atypical neuroleptics. Schwaninger M, et al. **Clin Neuropharmacol** 1998 Nov–Dec;21(6):344–6 (15 ref.)

Computer simulation and spatial modelling in heart surgery. Trobec R, et al. **Comput Biol Med** 1998 Jul;28(4):393–403

Treatment of traumatic brain injury with hypothermia. Biagas KV, et al. **Curr Opin Pediatr** 1998 Jun;10(3):271–7 (45 ref.)

The size of the splenium of the rat corpus callosum: influence of hormones, sex ratio, and neonatal cryoanesthesia. Nuñez JL, et al. **Dev Psychobiol** 1998 Dec;33(4):295–303

The 'pharmacology' of neuronal rescue with cerebral hypothermia. Gunn AJ, et al. **Early Hum Dev** 1998 Nov; 53(1):19–35 (90 ref.)

Elevated serum levels of S-100 after deep hypothermic arrest correlate with duration of circulatory arrest. Astudillo R, et al. **Eur J Cardiothorac Surg** 1996;10(12):1107–12; discussion 1113

Myocardial protection by pressure- and volume-controlled continuous hypothermic coronary perfusion in combination with Esmolol and nitroglycerine for correction of congenital heart defects in pediatric risk patients. Borowski A, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):243–9

Is hypothermia necessary in pediatric cardiac surgery? [letter] Corno AF, et al. **Eur J Cardiothorac Surg** 1999 Jan; 15(1):110–1

Induced hypothermia as salvage treatment for refractory cardiac failure following paediatric cardiac surgery. Dalrymple-Hay MJ, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):515–8

Changes in the extracellular levels of glutamate and aspartate during ischemia and hypoglycemia. Effects of hypothermia. Boris-Möller F, et al. **Exp Brain Res** 1998 Aug; 121(3):277–84

Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Büki A, et al.
Exp Neurol 1999 Sep;159(1):319–28

Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Dietrich WD, et al. **Exp Neurol** 1999 Aug;158(2):444–50

Effects of hypothermia and lamotrigine on trace-conditioned learning after global cerebral ischemia in rabbits. Kwon JY, et al. **Exp Neurol** 1999 Sep;159(1):105–13

Mild hypothermia modifies ammonia-induced brain edema in rats after portacaval anastomosis. Córdoba J, et al.
Gastroenterology 1999 Mar;116(3):686–93

Normothermic cardiopulmonary bypass & post-operative blood loss. Chauhan S, et al. **Indian J Med Res** 1998 Aug; 108:66–70

Increase in leukotrienes in the coronary circulation by cooling: a study in the anesthetized dog. Ytrehus K, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:316–9

Effect of nitric oxide synthase inhibition on hypercapnia-induced hypothermia and hyperventilation. Barros RC, et al. **J Appl Physiol** 1998 Sep;85(3):967–72

Noninvasive infrared spectroscopy as a monitor of retrograde cerebral perfusion during deep hypothermia [letter] Blas ML, et al. **J Cardiothorac Vasc Anesth** 1999 Apr;13(2):244–5

The effect of three different doses of tranexamic acid on blood loss after cardiac surgery with mild systemic hypothermia (32 degrees C). Karski JM, et al.
J Cardiothorac Vasc Anesth 1998 Dec;12(6):642–6

Assessment of arteriovenous blood flow during retrograde cerebral perfusion. Loubser PG.
J Cardiothorac Vasc Anesth 1999 Apr;13(2):173–5

Warming the core after cardiac surgery [letter; comment] Ponte J. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):496 . Comment on: J Cardiothorac Vasc Anesth 1997 Oct;11(6):708–11.

Case 4—1998. Cardiopulmonary bypass and hypothermic circulatory arrest for basilar artery aneurysm clipping [clinical conference] Weiss L, et al.
J Cardiothorac Vasc Anesth 1998 Aug;12(4):473–9

Ischemic threshold during cold blood cardioplegic arrest: monitoring with tissue pH and pO2. Carrier M, et al.
J Cardiovasc Surg (Torino) 1998 Oct;39(5):593–7

Blood flow rate in normal and tumor-bearing rats in conscious state, under urethane anesthesia, and during systemic hypothermia. Sakaeda T, et al. **J Drug Target** 1998;6(4):261–72

Effects of moderate hypothermia on constitutive and inducible nitric oxide synthase activities after traumatic brain injury in the rat. Chatzipanteli K, et al.
J Neurochem 1999 May;72(5):2047–52

Fulminant form of acute disseminated encephalomyelitis: successful treatment with hypothermia. Takata T, et al.
J Neurol Sci 1999 May 1;165(1):94–7

Hypothermia and head injury [letter; comment] Cruz J.
J Neurosurg 1999 Mar;90(3):607–8. Comment on: J Neurosurg 1998 Aug;89(2):206–11.

Hypothermia: depression of tricarboxylic acid cycle flux and evidence for pentose phosphate shunt upregulation. Kaibara T, et al. **J Neurosurg** 1999 Feb;90(2):339–47

Influence of rewarming conditions after hypothermia in gerbils with transient forebrain ischemia. Nakamura T, et al. **J Neurosurg** 1999 Jul;91(1):114–20

Influence of early posttraumatic hypothermia therapy on local cerebral blood flow and glucose metabolism after fluid-percussion brain injury. Zhao W, et al.
J Neurosurg 1999 Mar;90(3):510–9

Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans. Aibiki M, et al. **J Neurotrauma** 1999 Mar; 16(3):225–32

Mechanisms of excitatory amino acid release in contused brain tissue: effects of hypothermia and in situ administration of Co2+ on extracellular levels of glutamate. Maeda T, et al. **J Neurotrauma** 1998 Sep; 15(9):655–64

Completion rates and feasibility of outcome measures: experience in a multicenter clinical trial of systemic

hypothermia for severe head injury. Scheibel RS, et al. **J Neurotrauma** 1998 Sep;15(9):685–92

Systemic hypothermia after spinal cord compression injury in the rat: does recorded temperature in accessible organs reflect the intramedullary temperature in the spinal cord? Westergren H, et al. **J Neurotrauma** 1998 Nov; 15(11):943–54

L-[1–11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. van Ginkel RJ, et al. **J Nucl Med** 1999 Feb;40(2):262–7

Corneal cooling and rehydration during photorefractive keratectomy to reduce postoperative corneal haze. Stein HA, et al. **J Refract Surg** 1999 Mar–Apr;15(2 Suppl):S232–3

Is alpha-stat management still justified for deep hypothermic circulatory arrest in adults? [letter] Miyamoto TA, et al. **J Thorac Cardiovasc Surg** 1999 Sep;118(3):569–70

Regional cerebral blood flow and regional glucose use during rewarding after hypothermic cardiopulmonary bypass [letter; comment] Miyamoto TA, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1228–9. Comment on: J Thorac Cardiovasc Surg 1998 Sep;116(3):503–10.

Left subclavian artery as a site of proximal aortic perfusion for hypothermic repair of thoracic and thoracoabdominal aneurysms [letter; comment] Moriyama Y, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):408–9. Comment on: J Thorac Cardiovasc Surg 1998 Jan;115(1):162–7.

Oxygenation strategy and neurologic damage after deep hypothermic circulatory arrest. I. Gaseous microemboli. Nollert G, et al. **J Thorac Cardiovasc Surg** 1999 Jun; 117(6):1166–71

Oxygenation strategy and neurologic damage after deep hypothermic circulatory arrest. II. hypoxic versus free radical injury. Nollert G, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1172–9

Postischemic hyperthermia exacerbates neurologic injury after deep hypothermic circulatory arrest. Shum-Tim D, et al. **J Thorac Cardiovasc Surg** 1998 Nov;116(5):780–92

Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries. Ishikawa K, et al. **J Trauma** 1999 Jun; 46(6):999–1007; discussion 1007–8

Effects of local cooling on microvascular hemodynamics and leukocyte adhesion in the striated muscle of hamsters. Thorlacius H, et al. **J Trauma** 1998 Oct;45(4):715–9

Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision [see comments] Safi HJ, et al. **J Vasc Surg** 1998 Oct;28(4):591–8 . Comment in: J Vasc Surg 1999 Jul;30(1):196–7.

Regarding "Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision" [letter; comment] Westaby S. **J Vasc Surg** 1999 Jul;30(1):196–7. Comment on: J Vasc Surg 1998 Oct;28(4):591–8.

Catecholaminergic mechanisms-mediated hypothermia induced by magnolol in rats. Hsieh MT, et al. **Jpn J Pharmacol** 1998 Dec;78(4):501–4

Hypothermic circulatory arrest and hypothermic perfusion for extensive disease of the thoracic and thoracoabdominal aorta. Kouchoukos NT. **Jpn J Thorac Cardiovasc Surg** 1999 Jan;47(1):1–5

Increased portal endothelin-1 level is associated with the liver function after cardiopulmonary bypass in rabbits: influence of hypothermia on the damage. Wakiyama H, et al. **Kobe J Med Sci** 1997 Dec;43(6):245–57

Results of surgical treatment for thoracoabdominal aneurysm using cardiopulmonary bypass under moderate hypothermia and selective visceral artery perfusion. Yamashita C, et al. **Kobe J Med Sci** 1998 Dec;44(5–6):191–7

Hypothermia reduces neurologic deficits associated with placement of a vascular prosthesis in the abdominal aorta of rabbits. Tolwani RJ, et al. **Lab Anim Sci** 1998 Jun; 48(3):282–7

Localised cerebral phosphorus-31 MR spectroscopy in man before and immediately after coronary bypass surgery with hypothermic cardiopulmonary bypass. Wilson JA, et al. **Metab Brain Dis** 1998 Sep;13(3):191–200

Circulatory arrest with profound hypothermia during the surgical treatment of large internal carotid artery aneurysm--case report. Taki W, et al. **Neurol Med Chir (Tokyo)** 1998 Nov;38(11):725–9

Effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia on cerebral blood flow and metabolism, lactate, and extracellular glutamate in experimental head injury. Mori K, et al. **Neurol Res** 1998 Dec;20(8):719–26

Postischemic hypothermia induced by eugenol protects hippocampal neurons from global ischemia in gerbils. Won MH, et al. **Neurosci Lett** 1998 Sep 25;254(2):101–4

Mild hypothermia--a revived countermeasure against ischemic neuronal damages. Kataoka K, et al. **Neurosci Res** 1998 Oct;32(2):103–17 (151 ref.)

Neuroprotective effect of mild hypothermia cannot be explained in terms of a reduction of glutamate release during ischemia. Yamamoto H, et al. **Neuroscience** 1999; 91(2):501–9

Resection of a large arteriovenous fistula of the brain using low-flow deep hypothermic cardiopulmonary bypass: technical case report. Bendok BR, et al. **Neurosurgery** 1999 Apr;44(4):888–90; discussion 890–1

Mild hypothermia as a protective therapy during intracranial aneurysm surgery: a randomized prospective pilot trial. Hindman BJ, et al. **Neurosurgery** 1999 Jan;44(1):23–32; discussion 32–3

Hypothermic circulatory arrest in neurovascular surgery: evolving indications and predictors of patient outcome [letter] Sekhar LN, et al. **Neurosurgery** 1999 Mar; 44(3):686–7

Influence of a forced air warming system on morbidly obese patients undergoing Roux-en-Y gastric bypass. Mason DS, et al. **Obes Surg** 1998 Aug;8(4):453–60

Convective warming blankets improve peroperative heat preservation in congenital heart surgery. Schlünzen L, et al. **Paediatr Anaesth** 1998;8(5):397–401

Choreoathetosis after cardiac surgery with hypothermia and extracorporeal circulation. Gherpelli JL, et al. **Pediatr Neurol** 1998 Aug;19(2):113–8

Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Gunn AJ, et al. **Pediatrics** 1998 Nov;102(5):1098–106

Brain hypothermia and QT interval [letter; comment] Gunn TR, et al. **Pediatrics** 1999 May;103(5 Pt 1):1079. Comment on: Pediatrics 1998 Oct;102(4 Pt 1):885–92.

Evaluation of hypothermia-induced analgesia and influence of opioid antagonists in leopard frogs (Rana pipiens). Suckow MA, et al. **Pharmacol Biochem Behav** 1999 May; 63(1):39–43

Low body temperature affects associative processes in long-trace conditioned flavor aversion. Misanin JR, et al. **Physiol Behav** 1998 Dec 1;65(3):581–90

The physiological response to norepinephrine during hypothermia and rewarming. Weiss SJ, et al. **Resuscitation** 1998 Dec;39(3):189–95

Preliminary clinical outcome study of mild resuscitative hypothermia after out-of-hospital cardiopulmonary arrest. Yanagawa Y, et al. **Resuscitation** 1998 Oct-Nov; 39(1–2):61–6

Effects of moderate hypothermia on leukocyte- endothelium interaction in the rat pial microvasculature after transient middle cerebral artery occlusion. Ishikawa M, et al. **Stroke** 1999 Aug;30(8):1679–86

Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia: effects on neurologic outcome, infarct size, apoptosis, and inflammation. Maier CM, et al. **Stroke** 1998 Oct;29(10):2171–80

Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Schmid-Elsaesser R, et al. **Stroke** 1999 Sep; 30(9):1891–9

Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction [see comments] Schwab S, et al. **Stroke** 1998 Dec;29(12):2461–6. Comment in: Stroke 1999 May;30(5):1153.

Effect of the no-flow interval and hypothermia on cerebral blood flow and metabolism during cardiopulmonary resuscitation in dogs. Shaffner DH, et al. **Stroke** 1998 Dec; 29(12):2607–15

Mild hypothermia for temporary brain ischemia during cardiopulmonary support systems: report of three cases. Yamashita C, et al. **Surg Today** 1999;29(2):182–5

Application of retrograde cerebral perfusion and moderate systemic hypothermic circulatory arrest for cavoatrial tumor resection. Beltz MS, et al. **Tech Urol** 1999 Jun; 5(2):87–91

Platelet activation and cytokine production during hypothermic cardiopulmonary bypass--a possible correlation? Ferroni P, et al. **Thromb Haemost** 1998 Jul; 80(1):58–64

[Experimental study prevention of reperfusion injury of skeletal muscle by local hypothermia and its clinical application] An H, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Jan;11(1):52–5 (Eng. Abstr.) **(Chi)**

[Must we avoid hyperthermia? Using what modalities? Indications and modalities of therapeutic hypothermia.] **Ann Fr Anesth Reanim** 1999 Jan;18(1):138–41 **(Fre)**

[Protective effect of hypothermia in cerebral ischemia] Clavier N. **Ann Fr Anesth Reanim** 1999 May;18(5):593–8 (69 ref.) (Eng. Abstr.) **(Fre)**

[Sensitivity, specificity, and impact on the surgical strategy of the perioperative neuromonitoring of somatic evoked potentials in vascular surgery performed with circulatory arrest under deep hypothermia] Ghariani S, et al. **Neurophysiol Clin** 1998 Sep;28(4):335–41 (Eng. Abstr.) **(Fre)**

[Gaseous oxygen for protection and conditioning of organs during ischemia] Isselhard W, et al. **Zentralbl Chir** 1999; 124(4):252–9 (70 ref.) (Eng. Abstr.) **(Ger)**

[Therapeutic applications of hypothermia in intensive care] Faenza S, et al. **Minerva Anestesiol** 1999 Jun;65(6):367–71 (26 ref.) (Eng. Abstr.) **(Ita)**

[Unreliability of pulse oximetry in hypothermic children after cardiovascular surgery with deep hypothermic circulation] Picardo S, et al. **Minerva Anestesiol** 1998 Oct;64(10):427–30 (Eng. Abstr.) **(Ita)**

[A report of 4 cases of aortic operation using open proximal anastomosis under the hypothermic circulatory arrest and left lateral exposure] Doi K, et al. **Kyobu Geka** 1999 Aug; 52(9):751–5 (Eng. Abstr.) **(Jpn)**

[Cerebral protection and update on hypothermic therapy] Kataoka Y. **Masui** 1998 Dec;47 Suppl:S27–32 (23 ref.) **(Jpn)**

[Effect of deliberate mild hypothermia on the incidence of surgical-wound infection and duration of hospitalization in neurosurgical patients] Kawaraguchi Y, et al. **Masui** 1999 Mar;48(3):232–7 (Eng. Abstr.) **(Jpn)**

[Epidural regional hypothermia for prevention of paraplegia in experimental aortic clamping] Radoňak J, et al. **Rozhl Chir** 1999 Mar;78(3):109–13 (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Effects of preservation of rat lungs in a hypothermic medium on alveolar morphology. Arbak S, et al. **Acta Histochem** 1999 Jul;101(3):341–9

Pharmacological vasodilatation improves efficiency of rewarming from hypothermic cardiopulmonary bypass. Deakin CD, et al. **Br J Anaesth** 1998 Aug;81(2):147–51

Developmental and neurological status of children at 4 years of age after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. Bellinger DC, et al. **Circulation** 1999 Aug 3;100(5):526–32

Impaired oxygen utilization during rapid cooling on cardiopulmonary bypass. Irita K, et al. **Fukuoka Igaku Zasshi** 1999 Jan;90(1):14–22

A novel sialyl Lewis X analog attenuates cerebral injury after deep hypothermic circulatory arrest. Shin'oka T, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1204–11

Hypothermia-induced hypokalemia. Zydlewski AW, et al. **Mil Med** 1998 Oct;163(10):719–21

Experimental models of hypothermic circulatory arrest. Vannucci RC, et al. **Semin Pediatr Neurol** 1999 Mar; 6(1):48–54 (30 ref.)

Intraoperative hypothermia is an independent risk factor for early cytomegalovirus infection in liver transplant recipients. Paterson DL, et al. **Transplantation** 1999 Apr 27;67(8):1151–5

[Influence of cryotherapy on the concentration of malondialdehyde in rats serum] Xie X, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(5):428–30 (Eng. Abstr.) **(Chi)**

[Ventricular fibrillation during mild hypothermic therapy in a patient undergoing neurosurgery] Kawaguchi M, et al. **Masui** 1999 May;48(5):537–41 (Eng. Abstr.) **(Jpn)**

[The blood sugar levels after hypothermic cardiopulmonary bypass in diabetic patients: their relation to preoperative values of hemoglobin-A1c and medication] Kihara M, et al. **Masui** 1999 Feb;48(2):172–5 (Eng. Abstr.) **(Jpn)**

[Severe late effects of esophageal cancer treated by simultaneous intraluminal hyperthermo-brachytherapy: a case report] Ii N, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Dec; 58(14):831–3 (Eng. Abstr.) **(Jpn)**

METHODS

Profound hypothermia and circulatory arrest with skull base approaches for treatment of complex posterior circulation aneurysms. Sullivan BJ, et al. **Acta Neurochir (Wien)** 1999; 141(1):1–11; discussion 11–2

Prevention of oxidative stress due to tourniquet application. Analysis of the effects of local hypothermia and systemic allopurinol administration. Erdoğan D, et al. **Acta Orthop Belg** 1999 Jun;65(2):164–9

Features and outcomes of classic heat stroke [letter; comment] Graham BS. **Ann Intern Med** 1999 Apr 6; 130(7):613–4; discussion 614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Features and outcomes of classic heat stroke [letter; comment] Slovis CM. **Ann Intern Med** 1999 Apr 6; 130(7):614–5. Comment on: Ann Intern Med 1998 Aug 1;129(3):173–81.

Cerebral metabolic suppression during hypothermic circulatory arrest in humans. McCullough JN, et al. **Ann Thorac Surg** 1999 Jun;67(6):1895–9; discussion 1919–21

Mild or moderate hypothermia but not increased oxygen breathing prolongs survival during lethal uncontrolled hemorrhagic shock in rats, with monitoring of visceral dysoxia. Takasu A, et al. **Crit Care Med** 1999 Aug; 27(8):1557–64

Effect of mild hypothermia during cardiopulmonary bypass on erythrocytic hemoglobin oxygen delivery. Leone BJ, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):393–6

Myocardial hypothermia: a potential therapeutic technique for acute regional myocardial ischemia. Hale SL, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):405–13 (29 ref.)

Mild hypothermia: an alternative to deep hypothermia for achieving neuroprotection. Bell TE, et al. **J Cardiovasc Nurs** 1998 Oct;13(1):34–44 (35 ref.)

Multiple organ harvesting from a single donor for transplantation. A comparison of simple cooling technique and bypass technique. Takahashi T, et al. **J Cardiovasc Surg (Torino)** 1999 Jun;40(3):347–53

Efficacy of hypothermic perfusion using University of Wisconsin solution in extended hepatectomy with hepatic inflow occlusion in a canine model. Ohya T, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):781–5

Little benefit from mild hypothermia therapy for severely head injured patients with low intracranial pressure. Shiozaki T, et al. **J Neurosurg** 1999 Aug;91(2):185–91

Mild hypothermia. Tommasino C, et al. **J Neurosurg Sci** 1998 Mar;42(1 Suppl 1):37–8 (13 ref.)

Hypothermia bed system for stroke patients. Technical note. Kawamura S, et al. **Neurol Med Chir (Tokyo)** 1999 Jun; 39(6):466–9; discussion 469–70

The use of hypothermia: a role in the treatment of neonatal asphyxia? Wagner CL, et al. **Pediatr Neurol** 1999 Jul; 21(1):429–43 (117 ref.)

Selective hypothermia in repair of aneurysms of the descending aorta. Cooley DA, et al. **Tex Heart Inst J** 1999; 26(2):103–6

[Selective brain cooling] Corrard F. **Arch Pediatr** 1999 Jan; 6(1):87–92 (26 ref.) (Eng. Abstr.) **(Fre)**

[Moderate hypothermia for the treatment of malignant middle cerebral artery infarct] Schwab S, et al. **Nervenarzt** 1999 Jun;70(6):539–46 (Eng. Abstr.) **(Ger)**

[Near-infrared spectroscopy during hypothermic selective cerebral perfusion—a clinical study of its value] Ito T, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Dec;46(12):1260–6 (Eng. Abstr.) **(Jpn)**

[Surface-induced mild hypothermia anesthesia for hepatectomy in a patient with a giant hemangioma of the liver (Kasabach-Merritt syndrome)] Wake M, et al. **Masui** 1998 Nov;47(11):1344–9 (Eng. Abstr.) **(Jpn)**

[The brain hypothermia therapy for prevention of vegetation after severe brain injury] Hayashi N. **Nippon Geka Gakkai Zasshi** 1999 Jul;100(7):443–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Effect of hypothermia on lactate acidosis in experimental ischemia of rat brain] Ostrowski RP, et al. **Neurol Neurochir Pol** 1998 Nov–Dec;32(6):1385–95 (Eng. Abstr.) **(Pol)**

[The experimental and clinical validation of intraoperative local abdominal hypothermia in mechanical trauma to the abdomen] Anisimov AIu. **Vestn Khir Im I I Grek** 1998; 157(4):62–5 (Eng. Abstr.) **(Rus)**

[Renal cryopreservation in 2 renal transplant patients undergoing aortic surgery] Muñoz Ramirez P, et al. **Rev Esp Anestesiol Reanim** 1999 Apr;46(4):173–5 (Eng. Abstr.) **(Spa)**

VETERINARY

Circulatory arrest under hypothermic anesthesia using abdominal cavity cooling. Fujiki M, et al. **J Vet Med Sci** 1998 Nov;60(11):1237–42

A comparative study between hypothermic and normothermic cardiopulmonary bypass in open heart surgery in dogs—effects on systemic hemodynamics. Shibazaki A, et al. **J Vet Med Sci** 1999 Apr;61(4):331–6

HYPOTHYROIDISM

see related
CRETINISM
MYXEDEMA

Hypothyroidism in elderly patients. Bailes BK. **AORN J** 1999 May;69(5):1026–30

Lipomatous myelomeningocele, athyrotic hypothyroidism, and sensorineural deafness: a new form of syndromal deafness? Peters HL, et al. **J Med Genet** 1998 Nov; 35(11):948–50

Maternal hypothyroidism and fetal development [editorial; comment] Utiger RD. **N Engl J Med** 1999 Aug 19; 341(8):601–2. Comment on: N Engl J Med 1999 Aug 19;341(8):549–55.

Thyroid conditions in older patients. Khaira JS, et al. **Practitioner** 1999 Mar;243(1596):214–8, 221 (7 ref.)

BLOOD

Plasma lipoprotein (a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects. Erem C, et al. **Acta Cardiol** 1999 Apr;54(2):77–81

Maternal and neonatal thyroid status in Saki, Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):57–61

Screening for thyroid disease [letter; comment] Dieter RS. **Ann Intern Med** 1999 Jan 19;130(2):162. Comment on: Ann Intern Med 1998 Jul 15;129(2):144–58.

Factors involved in the rate of fall of thyroid stimulating hormone in treated hypothyroidism [letter; comment] Swift PG, et al. **Arch Dis Child** 1998 Aug;79(2):200–1. Comment on: Arch Dis Child 1997 Dec;77(6):526–7.

Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Kreisman SH, et al. **Arch Intern Med** 1999 Jan 11;159(1):79–82

The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Bindels AJ, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):217–20

Low cholesterol in severe hypothyroidism? [letter] Wägner AM, et al. **Endocr J** 1999 Apr;46(2):347–8

Mechanism of hypothyroidism action on insulin-like growth factor-I and -II from neonatal to adult rats: insulin mediates thyroid hormone effects in the neonatal period. Ramos S, et al. **Endocrinology** 1998 Dec;139(12):4782–92

Elevation of plasma leptin concentrations in obese hyperinsulinaemic hypothyroidism before and after treatment. Kautzky-Willer A, et al. **Eur J Clin Invest** 1999 May;29(5):395–403

Role of thyroid hormones on serum leptin levels. Sesmilo G, et al. **Eur J Endocrinol** 1998 Oct;139(4):428–30

The status of retinoids in women suffering from hyper- and hypothyroidism: interrelationship between vitamin A, beta-carotene and thyroid hormones. Goswami UC, et al. **Int J Vitam Nutr Res** 1999 Mar;69(2):132–5

Low growth hormone-binding protein in infants with congenital hypothyroidism. Cassio A, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3643–6

Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. Weintraub M, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2532–6

Liver function in cirrhotic patients in the euthyroid versus the hypothyroid state. Oren R, et al. **J Clin Gastroenterol** 1998 Dec;27(4):339–41

Kinetics of red blood cell T3 uptake in hypothyroidism with or without hormonal replacement, in the rat. Moreau X, et al. **J Endocrinol Invest** 1999 Apr;22(4):257–61

Serum lipoproteins and apolipoprotein E in infants with congenital hypothyroidism. Ciomartan T, et al. **Pediatr Int** 1999 Jun;41(3):249–52

Thyroid hormones modulate serum leptin levels: observations in thyrotoxic and hypothyroid women. Diekman MJ, et al. **Thyroid** 1998 Dec;8(12):1081–6

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

[Changes in thrombocyte aggregation in primary hypothyroidism] Lazúrová I, et al. **Vnitr Lek** 1998 Jul; 44(7):383–6 (Eng. Abstr.) **(Slo)**

[Vomiting and hypertransaminesemia as presenting form of hypothyroidism] Conde Martel A, et al. **Rev Esp Enferm Dig** 1998 Oct;90(10):728–9 **(Spa)**

[Increased level of TSH can be a sign of adrenal cortex failure. Not necessarily thyroid gland disease] Sjöberg S, et al. **Lakartidningen** 1999 Feb 3;96(5):464–5 (20 ref.) **(Swe)**

CEREBROSPINAL FLUID

L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Sjöberg S, et al. **Eur J Endocrinol** 1998 Nov;139(5):493–7

CHEMICALLY INDUCED

Neonatal transient hypothyroidism: aetiological study. Italian Collaborative Study on Transient Hypothyroidism. Weber G, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul; 79(1):F70–2

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Ghilardi G, et al. **Br J Rheumatol** 1998 Dec;37(12):1349–51

Promoting effects of kojic acid due to serum TSH elevation resulting from reduced serum thyroid hormone levels on development of thyroid proliferative lesions in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Mitsumori K, et al. **Carcinogenesis** 1999 Jan;20(1):173–6

Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis. Soumakis SA, et al. **Clin Infect Dis** 1998 Oct;27(4):910–1

Amiodarone compared with iodine exhibits a potent and persistent inhibitory effect on TSH-stimulated cAMP production in vitro: a possible mechanism to explain amiodarone-induced hypothyroidism. Pitsiavas V, et al. **Eur J Endocrinol** 1999 Mar;140(3):241–9

Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. Kleiner J, et al. **J Clin Psychiatry** 1999 Apr;60(4):249–55 (96 ref.)

Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases. Grosso S, et al. **J Endocrinol Invest** 1998 Nov;21(10):699–702

Is thyroxine during lithium therapy necessary? [see comments] Lazarus JH. **J Endocrinol Invest** 1998 Dec; 21(11):784–6 (15 ref.). Comment in: J Endocrinol Invest 1999 Mar;22(3):220–2.

Influence of dietary iodine on drug-induced hypothyrodism in the rat. Beyssen ML, et al. **J Pharm Pharmacol** 1999 Jun;51(6):745–50

Effect of lithium maintenance therapy on thyroid and parathyroid function. Kusalic M, et al. **J Psychiatry Neurosci** 1999 May;24(3):227–33

Central hypothyroidism associated with retinoid X receptor-selective ligands. Sherman SI, et al. **N Engl J Med** 1999 Apr 8;340(14):1075–9

Amiodarone and thyroid disease [editorial] Hain SF, et al. **Nucl Med Commun** 1999 Feb;20(2):111–3

Possible involvement of hypothyroidism as a cause of lithium-induced sinus node dysfunction. Numata T, et al. **Pacing Clin Electrophysiol** 1999 Jun;22(6 Pt 1):954–7

[Attempted suicide with 400 thyroxine pills: what happened to the physician-patient relationship?] Martin-du Pan RC. **Rev Med Suisse Romande** 1999 Jun;119(6):493–6 (Eng. Abstr.) **(Fre)**

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[A particular case of iodine-induced hypothyroidism] Nifosi G. **Minerva Endocrinol** 1998 Sep;23(3):93–7 (Eng. Abstr.) **(Ita)**

[Effects of low doses of ionizing radiation and induced hypothyroidism on the course of pregnancy and the development of the offspring in rats] Izmest'eva OS, et al. **Radiats Biol Radioecol** 1998 Nov–Dec;38(6):833–40 (Eng. Abstr.) **(Rus)**

[Postoperative complications in a case of iatrogenic hypothyroidism induced by diet drugs] Fernández Torres B, et al. **Rev Esp Anestesiol Reanim** 1998 Oct;45(8):349–52 (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Moderate renal failure in association with prolonged acquired hypothyroidism in children. Al-Fifi S, et al. **Acta Paediatr** 1999 Jul;88(7):715–7

Blastocyst implantation: effect of thyroidectomy and thyroxine replacement in the rat. Bolarinwa AF, et al. **Afr J Med Med Sci** 1997 Sep–Dec;26(3–4):135–7

Thrombotic thrombocytopenic purpura and hypothyroidism [letter] Durand JM, et al. **Am J Hematol** 1999 May; 61(1):83–4

The influence of maternal hypothyroidism and radioactive iodine on rat embryonal development: thyroid C-cells. Usenko VS, et al. **Anat Rec** 1999 Sep 1;256(1):7–13

Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Hussein WI, et al. **Ann Intern Med** 1999 Sep 7;131(5):348–51

Sleep apnoea in hypothyroidism [letter] Park KE, et al. **Aust N Z J Med** 1998 Oct;28(5):665–6

Palmoplantar keratoderma associated with hypothyroidism [letter] Miller JJ, et al. **Br J Dermatol** 1998 Oct;139(4):741–2 (7 ref.)

Acute respiratory alkalosis associated with low minute ventilation in a patient with severe hypothyroidism. Lee HT, et al. **Can J Anaesth** 1999 Feb;46(2):185–9

Disturbances of menstruation in hypothyroidism. Krassas GE, et al. **Clin Endocrinol (Oxf)** 1999 May;50(5):655–9

Thyroid hormones and neurodevelopment [comment] Lazarus JH. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):147–8. Comment on: Clin Endocrinol (Oxf) 1999 Feb;50(2):149–55.

Reversible cerebral hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia caused by hypothyroidism. Kinuya S, et al. **Clin Nucl Med** 1999 Sep; 24(9):666–8

Kocher-Debré Sémélaigne syndrome. Tashko V, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):113–5

Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Kuroki R, et al. **Dermatology** 1999;198(2):164–6

Effect of propylthiouracil induced hypothyroidism in developing rat cerebellum: comparison of cerebellar parameters in five day old normal and treated rat pups. Mwangi DK. **East Afr Med J** 1998 Oct;75(10):602–8

A case of congenital hypopituitarism: difficulty in the diagnosis of ACTH deficiency due to high serum cortisol levels from a hypothyroid state. Nanao K, et al. **Endocr J** 1999 Feb;46(1):183–6

Dermal mucinosis and musculoskeletal symptoms simulating polymyositis as a presenting sign of hypothyroidism. Ohtsuka T, et al. **Eur J Dermatol** 1999 Apr–May;9(3):227–9

A focused approach to anemia. Carmel R. **Hosp Pract (Off Ed)** 1999 Feb 15;34(2):71–8, 81–5, 89–90; discussion 90–1

Kocher-Debré-Sémélaigne syndrome. Luiz N. **Indian Pediatr** 1998 Nov;35(11):1115–6

Cold-induced urticaria associated with hypothyroidism [letter] Mahmoudi M, et al. **J Am Osteopath Assoc** 1999 Aug;99(8):394

Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. Biondi B, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2064–7

Outcome of a baby born from a mother with acquired juvenile hypothyroidism having undetectable thyroid hormone concentrations. Yasuda T, et al. **J Clin Endocrinol Metab** 1999 Aug;84(8):2630–2

Liver function in cirrhotic patients in the euthyroid versus the hypothyroid state. Oren R, et al. **J Clin Gastroenterol** 1998 Dec;27(4):339–41

Onycholysis and thyroid disease: report of three cases. Nakatsui T, et al. **J Cutan Med Surg** 1998 Jul;3(1):40–2

Prevalence and severity of hyponatremia and hypercreatininemia in short-term uncomplicated hypothyroidism. Baajafer FS, et al. **J Endocrinol Invest** 1999 Jan;22(1):35–9

The lack of association between hypertension and hypothyroidism in a primary care setting. Bergus GR, et al. **J Hum Hypertens** 1999 Apr;13(4):231–5

Hypothyroidism with multiple serous effusions [letter] Agarwal MP, et al. **J Indian Med Assoc** 1998 Sep;96(9):289

An unusual cause of obstructive sleep apnoea presenting during pregnancy. Taibah K, et al. **J Laryngol Otol** 1998 Dec;112(12):1189–91

Congenital hypothyroidism and immunodeficiency: evidence for an endocrine-immune interaction. Pillay K. **J Pediatr Endocrinol Metab** 1998 Nov–Dec;11(6):757–61

Pituitary deficiency and lack of gonads in an XY pseudohermaphrodite with beta 39/lepore haemoglobinopathy. Saviano A, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:997–9

Child psychosis due to hypothyroidism. Smith AL, et al. **J R Soc Med** 1998 Oct;91(10):537–8

Polymorphic ventricular tachycardia in a patient with adrenal insufficiency and hypothyroidism. Izumi C, et al. **Jpn Circ J** 1998 Jul;62(7):543–5

Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child [see comments] Haddow JE, et al. **N Engl J Med** 1999 Aug 19;341(8):549–55. Comment in: N Engl J Med 1999 Aug 19;341(8):601–2.

Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism [letter] Clouâtre Y, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1047–8

Fibrillary glomerulonephritis occurring in association with

hereditary angioneurotic oedema, pernicious anaemia and hypothyroidism. Whitaker G, et al.
Nephrol Dial Transplant 1998 Jul;13(7):1822–4

Myocardial 123I-MIBG kinetics in acutely hypothyroid patients with differentiated thyroid carcinoma. Maini CL, et al. **Nucl Med Commun** 1999 Aug;20(8):719–26

Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Kessel I, et al. **Pediatrics** 1999 Jan;103(1):E9

Compensated hypothyroidism [letter] Jolobe OM.
Postgrad Med J 1999 Jul;75(885):445

Collapse and hypothermia in an elderly woman in early summer. Morris RO, et al. **Postgrad Med J** 1999 Jul; 75(885):441–2

Compensated hypothyroidism [letter] Pradhan SC, et al.
Postgrad Med J 1999 Jul;75(885):445

Primary thyroid failure and diarrhoea. Sugiultjoglu F, et al.
Postgrad Med J 1998 Jun;74(872):371–2

Pericardial tamponade in a 65-year-old woman. Usalan C, et al. **Postgrad Med J** 1999 Mar;75(881):183–4

Development of Graves' hyperthyroidism from primary hypothyroidism in a case of thyroid hemiagenesis. Bando Y, et al. **Thyroid** 1999 Feb;9(2):183–7

Severe short-term hypothyroidism is not associated with an increased incidence of myocardial ischemia as assessed by thallium-201 stress/rest myocardial scintigraphy. Prasch F, et al. **Thyroid** 1999 Feb;9(2):155–8

Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Rodolico C, et al. **Thyroid** 1998 Nov;8(11):1033–8

[Isolated ascites revealing a hypothyroidism. Study of 2 cases] Desramé J, et al. **Gastroenterol Clin Biol** 1998 Aug–Sep; 22(8–9):732–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Anasarca and hypothyroidism (letter)] Sidibe EH, et al.
Med Trop (Mars) 1998;58(2):207–8 **(Fre)**

[Ascites and iron-deficiency anemia revealing hypothyroidism (letter)] Francoual J, et al. **Presse Med** 1998 Oct 17;27(31):1578–9 **(Fre)**

[Heart and thyroid] Col V, et al.
Rev Med Suisse Romande 1999 Jun;119(6):481–5 (24 ref.) **(Fre)**

[Low T3 syndrome] Maréchaud R. **Rev Prat** 1998 Nov 15; 48(18):2018–22 (Eng. Abstr.) **(Fre)**

[Extra-thyroidal accompanying and resulting diseases] Stiefelhagen P. **Med Monatsschr Pharm** 1999 Jul; 22(7):220–2 **(Ger)**

[Effects of thyroid hormone replacement therapy on nocturnal apnea in elderly patients with hypothyroidism] Teramoto S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul; 36(7):590–4 (Eng. Abstr.) **(Jpn)**

[Case of hypothyroidism and hypoparathyroidism discovered by fainting spells] Kunisada K, et al.
Nippon Naika Gakkai Zasshi 1998 Nov 10;87(11):2314–5 **(Jpn)**

[Hypothyroidism in patients treated for laryngeal cancer: preliminary results] Romero A, et al.
Acta Otorrinolaringol Esp 1999 Apr;50(3):205–10 (34 ref.) (Eng. Abstr.) **(Spa)**

[Cardiac manifestations of primary hypothyroidism. Determinant factors and treatment response] González Vilchez F, et al. **Rev Esp Cardiol** 1998 Nov;51(11):893–900 (Eng. Abstr.) **(Spa)**

CONGENITAL

Massive pericardial effusion in an adult case of congenital hypothyroidism due to a sublingual thyroid. Isobe M, et al. **Acta Cardiol** 1998;53(2):101–3

Congenital hypothyroidism, seasonality and consanguinity in the West Midlands, England. Hall SK, et al.
Acta Paediatr 1999 Feb;88(2):212–5

Alterations of neonatal thyroid function. Grüters A, et al.
Acta Paediatr Suppl 1999 Feb;88(428):17–22 (29 ref.)

Maternal and neonatal thyroid status in Saki, Nigeria. Ojule AC, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):57–61

Young–Simpson syndrome: further delineation of a distinct syndrome with congenital hypothyroidism, congenital heart defects, facial dysmorphism, and mental retardation. Masuno M, et al. **Am J Med Genet** 1999 May 7;84(1):8–11

Congenital anomalies associated with congenital hypothyroidism. Stoll C, et al. **Ann Genet** 1999;42(1):17–20

Screening for congenital hypothyroidism in cognitively delayed children. al-Qudah AA. **Ann Trop Paediatr** 1998 Dec;18(4):285–8

Structural defects of a Pax8 mutant that give rise to congenital hypothyroidism. Tell G, et al. **Biochem J** 1999 Jul 1;341 (Pt 1):89–93

Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Pohlenz J, et al. **Biochimie** 1999 May; 81(5):469–76 (25 ref.)

The screening for mutations in the thyroglobulin cDNA from six patients with congenital hypothyroidism. van de Graaf SA, et al. **Biochimie** 1999 May;81(5):425–32

Familial occurrence of congenital hypothyroidism due to lingual thyroid gland. El-Desouki MI, et al.
Clin Nucl Med 1999 Jun;24(6):421–3

Unusual appearance of lingual thyroid in congenital hypothyroidism. Strain J, et al. **Clin Nucl Med** 1998 Jul; 23(7):460

Thyroid function in premature infants. The hypothyroxinemia of prematurity. Fisher DA.
Clin Perinatol 1998 Dec;25(4):999–1014, viii (53 ref.)

Congenital hypothyroidism screening in the West Bank: a test case for screening in developing regions. Sack J, et al. **Horm Res** 1998 Sep;50(3):151–4

Low growth hormone-binding protein in infants with congenital hypothyroidism. Cassio A, et al.
J Clin Endocrinol Metab 1998 Oct;83(10):3643–6

A search for the possible molecular mechanisms of thyroid dysgenesis: sex ratios and associated malformations. Devos H, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2502–6

A novel mutation in the sodium/iodide symporter gene in the largest family with iodide transport defect. Kosugi S, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3248–53

A novel mutation in the human thyroid peroxidase gene resulting in a total iodide organification defect. Kotani T, et al. **J Endocrinol** 1999 Feb;160(2):267–73

Intellectual outcomes of patients with congenital hypothyroidism not detected by neonatal screening. Hsiao PH, et al. **J Formos Med Assoc** 1999 Jul;98(7):512–5

Neonatal screening for congenital hypothyroidism in Mexico: experience, obstacles, and strategies. Vela M, et al.
J Med Screen 1999;6(2):77–9

Pertechnetate scintigraphy in primary congenital hypothyroidism. Sfakianakis GN, et al. **J Nucl Med** 1999 May;40(5):799–804

Has perchlorate in drinking water increased the rate of congenital hypothyroidism? Lamm SH, et al.
J Occup Environ Med 1999 May;41(5):409–11

Congenital hypothyroidism screening in Oklahoma: a change in follow-up recommendations for 1999. King P, et al.
J Okla State Med Assoc 1999 Jan;92(1):42–3

Increased TSH levels in neonates with congenital malformations [letter; comment] Narchi H, et al.
J Pediatr 1999 Feb;134(2):252–3. Comment on: J Pediatr 1998 Apr;132(4):726–30.

Collodion baby concomitant with congenital hypothyroidism: a patient report and review of the literature. Kurtoğlu S, et al.
J Pediatr Endocrinol Metab 1998 Jul–Aug;11(4):569–73 (24 ref.)

Congenital hypothyroidism and immunodeficiency: evidence for an endocrine–immune interaction. Pillay K.
J Pediatr Endocrinol Metab 1998 Nov–Dec;11(6):757–61

Bone metabolism in children with congenital hypothyroidism--a longitudinal study. Verrotti A, et al.
J Pediatr Endocrinol Metab 1998 Nov–Dec;11(6):699–705

Evaluation and characterization of congenital hypothyroidism in rdw dwarf rats. Umezu M, et al.
Lab Anim Sci 1998 Oct;48(5):496–501

Thyroid function in mothers of hypothyroid newborns. Dussault JH, et al. **Obstet Gynecol** 1999 Jan;93(1):15–20

Thyroxine inversely regulates serum intermediate density lipoprotein levels in children with congenital hypothyroidism. Asami T, et al. **Pediatr Int** 1999 Jun; 41(3):266–9

Serum lipoproteins and apolipoprotein E in infants with congenital hypothyroidism. Ciomartan T, et al.
Pediatr Int 1999 Jun;41(3):249–52

Assessment of skeletal maturation in infants: comparison between two methods in hypothyroid patients. Paesano PL, et al. **Pediatr Radiol** 1998 Aug;28(8):622–6

Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin-releasing hormone treatment. TRH Collaborative Trial Participants. Ballard PL, et al. **Pediatr Res** 1998 Nov;44(5):642–9

Congenital hypothyroidism and nonimmune hydrops fetalis: associated? Kessel I, et al. **Pediatrics** 1999 Jan;103(1):E9

Hypomania in a patient with congenital familial hypothyroidism and mild mental retardation. Mahendran R. **Singapore Med J** 1999 Jun;40(6):425–7

Congenital hypothyroid screening using cord blood TSH. Wu LL, et al. **Singapore Med J** 1999 Jan;40(1):23–6

Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control. Delange F. **Thyroid** 1998 Dec;8(12):1185–92 (43 ref.)

Congenital hypothyroidism: etiologies, diagnosis, and management. LaFranchi S. **Thyroid** 1999 Jul;9(7):735–40 (27 ref.)

Structural analysis of the thyrotropin receptor in four patients with congenital hypothyroidism due to thyroid hypoplasia. Nogueira CR, et al. **Thyroid** 1999 Jun;9(6):523–9

Congenital hypothyroidism: long-term outcome. Rovet JF. **Thyroid** 1999 Jul;9(7):741–8

[Results of national evaluation tests (primary schools) of CE2 and 6th classes of 73 students with congenital hypothyroidism screened at birth] Toublanc JE, et al.
Arch Pediatr 1998 Mar;5(3):255–63 (Eng. Abstr.) **(Fre)**

[Congenital hypothyroidism] Léger J. **Rev Prat** 1998 Nov 15;48(18):2001–5 (Eng. Abstr.) **(Fre)**

[Congenital hypothyroidism: causes for delayed initiation of treatment] Doeker B, et al. **Klin Padiatr** 1999 May–Jun; 211(3):161–4 (Eng. Abstr.) **(Ger)**

[Results of screening of congenital hypothyroidism and iodine excess in neonatal age] Cassio A, et al.
Ann Ist Super Sanita 1998;34(3):337–41 (Eng. Abstr.) **(Ita)**

[Re-evaluation of the diagnosis in congenital hypothyroidism] Costa P, et al. **Ann Ist Super Sanita** 1998; 34(3):343–7 (Eng. Abstr.) **(Ita)**

[Areas in Calabria with an elevated incidence of congenital hypothyroidism and iodine content of drinking water] Di Martino MT, et al. **Ann Ist Super Sanita** 1998;34(3):425–8 (Eng. Abstr.) **(Ita)**

[Transient congenital hypothyroidism: physiopathology and clinica] Montanelli L, et al. **Ann Ist Super Sanita** 1998; 34(3):321–9 (25 ref.) (Eng. Abstr.) **(Ita)**

[Transient congenital hypothyroidism in iodine deficiency areas. Gruppo di Studio per il Registro Nazionale degli Ipotiroidei Congeniti] Olivieri A, et al.
Ann Ist Super Sanita 1998;34(3):331–6 (Eng. Abstr.) **(Ita)**

[A case report of glomerulocystic kidney disease with hypothyroidism in a new born infant] Satomura K, et al.
Nippon Jinzo Gakkai Shi 1998 Nov;40(8):602–6 (Eng. Abstr.) **(Jpn)**

[Neonatal transient hypothyroidism] Arisaka O, et al.
Nippon Rinsho 1999 Aug;57(8):1784–7 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Neuro-cognitive condition of 8 year old children with congenital hypothyroidism treated early] Alvarez M, et al. **Rev Neurol** 1999 Apr 1–15;28(7):701–6 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Moderate renal failure in association with prolonged acquired hypothyroidism in children. Al-Fifi S, et al.
Acta Paediatr 1999 Jul;88(7):715–7

Screening for neonatal hyperbilirubinaemia and ABO alloimmunization at the time of testing for phenylketonuria and congenital hypothyreosis. Meberg A, et al.
Acta Paediatr 1998 Dec;87(12):1269–74

Hypothyroidism presenting as acute cardiac tamponade with viral pericarditis. Gupta R, et al. **Am J Emerg Med** 1999 Mar;17(2):176–8

Screening for hypothyroidism in sleep apnea. Skjodt NM, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):732–5

Screening for thyroid disease [letter; comment] Friedman MN. **Ann Intern Med** 1999 Jan 19;130(2):161–2. Comment on: Ann Intern Med 1998 Jul 15;129(2):141–3.

Dermal mucinosis and musculoskeletal symptoms simulating polymyositis as a presenting sign of hypothyroidism. Ohtsuka T, et al. **Eur J Dermatol** 1999 Apr–May;9(3):227–9

Blunted nocturnal TSH surge does not indicate central hypothyroidism in patients after pituitary surgery. Mönig H, et al. **Exp Clin Endocrinol Diabetes** 1999;107(1):89–92

Nocturnal TSH surge and TRH test response in the evaluation of thyroid axis in hypothalamic pituitary disorders in childhood. Gruñeiro-Papendieck L, et al.
Horm Res 1998;50(5):252–7

Congenital hypothyroidism screening in the West Bank: a test case for screening in developing regions. Sack J, et al. **Horm Res** 1998 Sep;50(3):151–4

Carpal tunnel syndrome: is it work-related? [published erratum appears in Hosp Pract (Off Ed) 1999 Apr 15;34(4):63] Atcheson SG. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):49–56; quiz 147 (8 ref.)

Recognizing the faces of hypothyroidism. Mazzaferri EL, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):93–6, 101–5, 109; discussion 109–10

Kocher-Debré-Sémélaigne syndrome. Luiz N.
Indian Pediatr 1998 Nov;35(11):1115–6

In vivo and in vitro regulation of thyroid leukemia inhibitory factor (LIF): marker of hypothyroidism. Ren SG, et al.
J Clin Endocrinol Metab 1999 Aug;84(8):2883–7

Headache and bilateral visual loss in a young hypothyroid Indian man. Wiesli P, et al. **J Endocrinol Invest** 1999 Feb; 22(2):141–3

Neonatal screening for congenital hypothyroidism in Mexico: experience, obstacles, and strategies. Vela M, et al.
J Med Screen 1999;6(2):77–9

Congenital hypothyroidism screening in Oklahoma: a change in follow-up recommendations for 1999. King P, et al.
J Okla State Med Assoc 1999 Jan;92(1):42–3

Semiautomated enzyme immunoassay of thyrotropin as a mass screening test for neonatal hypothyroidism. Miyai K, et al. **Pediatr Res** 1984 Dec;18(12):1289–92

Maternal hypothyroidism: recognition and management. Brent GA. **Thyroid** 1999 Jul;9(7):661–5 (29 ref.)

Screening for congenital hypothyroidism used as an indicator of the degree of iodine deficiency and of its control. Delange F. **Thyroid** 1998 Dec;8(12):1185–92 (43 ref.)

Application of ThyroChek in the assessment of the various degrees of hypothyroidism [letter] Duntas LH, et al.
Thyroid 1999 Aug;9(8):847–8

Stapedial reflex: a biological index found to be abnormal in clinical and subclinical hypothyroidism. Goulis DG, et al.
Thyroid 1998 Jul;8(7):583–7

Congenital hypothyroidism: long-term outcome. Rovet JF.
Thyroid 1999 Jul;9(7):741–8

[Frequency of newly detected hypothyroidism in lipid clinics] Szabó M, et al. **Vnitr Lek** 1998 Nov;44(11):642–5 (Eng. Abstr.) **(Cze)**

[Subclinical thyroid disorders: strategies] Duprey J.
Rev Med Interne 1999;20 Suppl 1:16S–18S **(Fre)**

[Thyrotropic deficiency] Chanson P. **Rev Prat** 1998 Nov 15; 48(18):2023–6 (Eng. Abstr.) **(Fre)**

[Congenital hypothyroidism] Léger J. **Rev Prat** 1998 Nov 15;48(18):2001–5 (Eng. Abstr.) **(Fre)**

[Diagnosis of hypothyroidism in the adult] Nunez S, et al.
Rev Prat 1998 Nov 15;48(18):1993–8 (Eng. Abstr.) **(Fre)**

[Long-term study of subclinical hypothyroidism: spontaneous course and predictors of manifest hypothyroidism] Huber G, et al.
Schweiz Med Wochenschr 1998 Nov 28;128(48):1902–5 (Eng. Abstr.) **(Ger)**

[Is there a need for treatment in subclinical hypo- and

hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369–73 (15 ref.) (Eng. Abstr.) **(Ger)**

[Hypothyroidism coexisting with pregnancy] Milczek T, et al. **Ginekol Pol** 1998 Dec;69(12):1093–6 (9 ref.) (Eng. Abstr.) **(Pol)**

[The carpal tunnel syndrome and hypothyroidism (letter)] Cruz JM, et al. **An Med Interna** 1999 Jul;16(7):386 **(Spa)**

[Hypothyroidism in the elderly patient: its clinical significance and difficulties in diagnosis and treatment] Díez JJ. **Med Clin (Barc)** 1998 Dec 5;111(19):742–50 (166 ref.) **(Spa)**

[Hypothyroidism presenting as intestinal pseudo-obstruction (letter)] Pila Pérez R, et al. **Rev Esp Enferm Dig** 1998 Dec; 90(12):887–8 **(Spa)**

DRUG THERAPY

Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Hussein WI, et al. **Ann Intern Med** 1999 Sep 7;131(5):348–51

Screening for thyroid disease [letter; comment] Zelmanovitz F. **Ann Intern Med** 1999 Jan 19;130(2):161; discussion 162 . Comment on: Ann Intern Med 1998 Jul 15;129(2):144–58.

Zinc sulfate supplementation improves thyroid function in hypozincemic Down children. Bucci I, et al. **Biol Trace Elem Res** 1999 Mar;67(3):257–68

Headache in hypothyroidism. Prevalence and outcome under thyroid hormone therapy. Moreau T, et al. **Cephalalgia** 1998 Dec;18(10):687–9

Reversible hypothyroidism in empty sella syndrome: a case report. Otsuka F, et al. **Endocr J** 1998 Jun;45(3):385–91

Severe juvenile hypothyroidism: treatment with GH and GnRH agonist in addition to thyroxine. Watanabe T, et al. **Endocr J** 1998 Apr;45 Suppl:S159–62

Thymidine kinase activity in homogenates of rat thyroid lobes from euthyroid, hypothyroid and/or hyperthyroid rats incubated with EGF: studies ex vivo in vitro. Karbownik M, et al. **Endocr Regul** 1999 Mar;33(1):17–23

L-thyroxine treatment and neurotransmitter levels in the cerebrospinal fluid of hypothyroid patients: a pilot study. Sjöberg S, et al. **Eur J Endocrinol** 1998 Nov;139(5):493–7

Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine. Zulewski H, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):190–4

L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. Pines A, et al. **Gynecol Endocrinol** 1999 Jun;13(3):196–201

Catch-up growth after childhood-onset substitution in primary hypothyroidism: is it a guide towards optimal growth hormone treatment in idiopathic growth hormone deficiency? Ranke MB, et al. **Horm Res** 1998;50(5):264–70

Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. Ferretti E, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):924–9

Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. Weintraub M, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2532–6

Evaluation of thyroid function in north Indians with alopecia areata: response to intravenous injection of 100 micrograms thyrotropin releasing hormone (TRH). Sharma VK, et al. **J Dermatol** 1999 Jun;26(6):339–42

Increased sensitivity to thyroid hormone replacement therapy followed by hyponatremia and eosinophilia in a patient with long-standing young-onset primary hypothyroidism. Fujikawa M, et al. **J Endocrinol Invest** 1999 Jun; 22(6):476–80

Experience with low-dose replacement therapy in the initial management of severe pediatric acquired primary hypothyroidism. Slyper AH, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):543–7

Superovulation of immature hypothyroid rdw rats by thyroxine therapy and the development of eggs after in vitro fertilization. Jiang JY, et al. **J Reprod Fertil** 1999 May;116(1):19–24

Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism [see comments] Bunevicius R, et al. **N Engl J Med** 1999 Feb 11;340(6):424–9. Comment in: N Engl J Med 1999 Feb 11;340(6):469–70.

Thyroid hormone replacement--one hormone or two? [editorial; comment] Toft AD. **N Engl J Med** 1999 Feb 11;340(6):469–70. Comment on: N Engl J Med 1999 Feb 11;340(6):424–9.

Thyroxine inversely regulates serum intermediate density lipoprotein levels in children with congenital hypothyroidism. Asami T, et al. **Pediatr Int** 1999 Jun; 41(3):266–9

Levothyroxine replacement therapy in central hypothyroidism: a practice report. Carrozza V, et al. **Pharmacotherapy** 1999 Mar;19(3):349–55

Management of the unexpected result: compensated hypothyroidism. Benediktsson R, et al. **Postgrad Med J** 1998 Dec;74(878):729–32 (27 ref.)

Neonatal hypothyroidism: treatment and outcome. Van Vliet G. **Thyroid** 1999 Jan;9(1):79–84 (54 ref.)

Thyroxine replacement attenuates hypothyroxinemia, hearing loss, and motor deficits following developmental exposure to Aroclor 1254 in rats. Goldey ES, et al. **Toxicol Sci** 1998 Sep;45(1):94–105

[Should LT3 be added to L-thyroxine in replacement therapy of hypothyroidism?] Massol J, et al. **Presse Med** 1999 Sep 4;28(25):1363–4 **(Fre)**

[Treatment of hypothyroidism] Massol J. **Rev Prat** 1998 Nov 15;48(18):2027–33 (Eng. Abstr.) **(Fre)**

[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism] Gerber H, et al. **Ther Umsch** 1999 Jul; 56(7):374–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Neuro-cognitive condition of 8 year old children with congenital hypothyroidism treated early] Alvarez M, et al. **Rev Neurol** 1999 Apr 1–15;28(7):701–6 (Eng. Abstr.) **(Spa)**

ECONOMICS

[Critical evaluation of a cost-effectiveness analysis] Sendi PP, et al. **Schweiz Rundsch Med Prax** 1998 Dec 3; 87(49):1695–702 **(Ger)**

ENZYMOLOGY

DNA topoisomerase I activity in regenerating liver of hypothyroid rats. Merlo M, et al. **Boll Soc Ital Biol Sper** 1998 Jan-Feb;74(1–2):9–14

Hypothyroidism leads to a decreased expression of mitochondrial F0F1-ATP synthase in rat liver. Guerrieri F, et al. **J Bioenerg Biomembr** 1998 Jun;30(3):269–76

Stimulation of Na,K-ATPase by hypothyroidism in the thyroid gland. LeGrow AB, et al. **J Endocrinol** 1999 Mar; 160(3):453–60

Expression of type 2 iodothyronine deiodinase in hypothyroid rat brain indicates an important role of thyroid hormone in the development of specific primary sensory systems. Guadaño-Ferraz A, et al. **J Neurosci** 1999 May 1;19(9):3430–9

Serum creatine kinase levels in overt and subclinical hypothyroidism. Beyer IW, et al. **Thyroid** 1998 Nov; 8(11):1029–31

EPIDEMIOLOGY

Congenital hypothyroidism, seasonality and consanguinity in the West Midlands, England. Hall SK, et al. **Acta Paediatr** 1999 Feb;88(2):212–5

Association of hypothyroidism and obstructive sleep apnea. Kapur VK, et al. **Am J Respir Crit Care Med** 1998 Nov; 158(5 Pt 1):1379–83

Congenital anomalies associated with congenital hypothyroidism. Stoll C, et al. **Ann Genet** 1999;42(1):17–20

Hypothyroidism: its incidence and prevalence in adults older than 55 years of age in an acute rehabilitation unit. Cristian A, et al. **Arch Phys Med Rehabil** 1999 Apr;80(4):468–9

The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Bindels AJ, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):217–20

Juvenile hypothyroidism among two populations exposed to radioiodine. Goldsmith JR, et al. **Environ Health Perspect** 1999 Apr;107(4):303–8

Has perchlorate in drinking water increased the rate of congenital hypothyroidism? Lamm SH, et al. **J Occup Environ Med** 1999 May;41(5):409–11

Screening for hypothyroidism in infertile women. Lincoln SR, et al. **J Reprod Med** 1999 May;44(5):455–7

Postnatal care and women's health [letter; comment] Lazarus JH, et al. **Lancet** 1999 May 1;353(9163):1532. Comment on: Lancet 1999 Jan 30;353(9150):343–4.

Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Lin CC, et al. **Perit Dial Int** 1998 Sep-Oct;18(5):516–21

Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Laurberg P, et al. **Thyroid** 1999 Jan;9(1):33–8

Increased risk of maternal thyroid failure with pregnancy progression in an iodine deficient area with major iodine deficiency disorders. Vermiglio F, et al. **Thyroid** 1999 Jan; 9(1):19–24

ETHNOLOGY

Subclinical hypothyroidism in a biethnic, urban community. Lindeman RD, et al. **J Am Geriatr Soc** 1999 Jun;47(6):703–9

Prevalence of hypothyroidism among Arabs with rheumatoid arthritis [letter] Al-Awadhi AM, et al. **Rheumatology (Oxford)** 1999 May;38(5):472–3

ETIOLOGY

Multisystem Langerhans cell histiocytosis [letter; comment] Vázquez JA, et al. **Acta Paediatr** 1999 Mar;88(3):349–50. Comment on: Acta Paediatr 1998 Jan;87(1):112–4.

Diffuse necrosis of the thyroid presenting as hypothyroidism after laryngectomy. Aikawa H, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):248–9

Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity [letter] Posner EB, et al. **Arch Dis Child** 1999 Sep;81(3):283

Concealed hypothyroidism in patients with myeloperoxidase antineutrophili cytoplasmic autoantibodies-(MPO-ANCA) positive renal disease. Tanaka A, et al. **Clin Nephrol** 1999 Aug;52(2):91–5

Evaluation of thyroid function in north Indians with alopecia areata: response to intravenous injection of 100 micrograms thyrotropin releasing hormone (TRH). Sharma VK, et al. **J Dermatol** 1999 Jun;26(6):339–42

Primary hypothyroidism-associated TSH-secreting pituitary adenoma/hyperplasia presenting as a bleeding nasal mass and extremely elevated TSH level. Ghannam NN, et al. **J Endocrinol Invest** 1999 Jun;22(6):419–23

Biochemical hypothyroidism secondary to iodine deficiency is associated with poor school achievement and cognition in Bangladeshi children. Huda SN, et al. **J Nutr** 1999 May; 129(5):980–7

Atrioventricular block in a patient with growth hormone deficiency during growth hormone therapy. Okada T, et al. **Pediatr Int** 1999 Feb;41(1):90–3

Bilateral nephrectomy reverses hypothyroidism in congenital nephrotic syndrome. Chadha V, et al. **Pediatr Nephrol** 1999 Apr;13(3):209–11

Hypothyroldism in a neonate following excision of a cervical teratoma. Chowdhary SK, et al. **Pediatr Surg Int** 1998 Dec; 14(3):212–3

Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies. Chung HK, et al. **Thyroid** 1999 Apr;9(4):393–9

Radioiodine and pregnancy. Gorman CA. **Thyroid** 1999 Jul; 9(7):721–6 (45 ref.)

[Treatment of endocrine orbital disease by elimination of the thyroid gland. The effect of unsuccessful elimination, severe pretibial myxedema and persistence of hypothyroidism after removal in long-term results] Váňa S, et al. **Vnitr Lek** 1998 Jul;44(7):387–90 (Eng. Abstr.) **(Cze)**

[Hypothyroidism induced by drugs, radiotherapy, and surgery] Caron P. **Rev Prat** 1998 Nov 15;48(18):2013–7 (Eng. Abstr.) **(Fre)**

[Prolonged post-anesthesia recovery in hemodialysis-induced hypothyroidism] Nibler R, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1998 Dec; 33(12):810–2 (Eng. Abstr.) **(Ger)**

[Hormonal function of the thyroid gland after therapy for laryngeal cancer] Tarnowska C, et al. **Otolaryngol Pol** 1999; 53(3):289–92 (Eng. Abstr.) **(Pol)**

GENETICS

Genetic basis of congenital hypothyroidism: abnormalities in the TSHbeta gene, the PIT1 gene, and the NIS gene. Tatsumi K, et al. **Clin Chem Lab Med** 1998 Aug; 36(8):659–62

Vitrification of two-cell rat embryos derived from immature hypothyroid rdw rats by in vitro fertilization in ethylene glycol-based solutions. Jiang JY, et al. **Cryobiology** 1999 Mar;38(2):160–4

Missense mutation (C1263R) in the thyroglobulin gene causes congenital goiter with mild hypothyroidism by impaired intracellular transport. Hishinuma A, et al. **Endocr J** 1998 Jun;45(3):315–27

Linkage analysis excludes familial congenital hypothyroidism from chromosome 21. Ahlbom BE, et al. **Genet Couns** 1998; 9(4):265–70

A search for the possible molecular mechanisms of thyroid dysgenesis: sex ratios and associated malformations. Devos H, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2502–6

A novel mutation in the sodium/iodide symporter gene in the largest family with iodide transport defect. Kosugi S, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3248–53

A premature stopcodon in thyroglobulin messenger RNA results in familial goiter and moderate hypothyroidism. van de Graaf SA, et al. **J Clin Endocrinol Metab** 1999 Jul; 84(7):2537–42

New genetic mechanism associated with thyroid-related diseases [news] **Oncology (Huntingt)** 1999 Jul;13(7):938

Severe congenital hypothyroidism due to a homozygous mutation of the betaTSH gene. Biebermann H, et al. **Pediatr Res** 1999 Aug;46(2):170–3

Effect of primary congenital hypothyroidism upon expression of genes mediating murine brain glucose uptake. Khan JY, et al. **Pediatr Res** 1999 May;45(5 Pt 1):718–25

Non-autoimmune hyper- and hypothyroidism due to mutations in the thyrotropin receptor gene. Vassart G. **Z Arztl Fortbild Qualitatssich** 1999 Apr;93 Suppl 1:23–4 (11 ref.)

IMMUNOLOGY

Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Laurberg P, et al. **Eur J Endocrinol** 1998 Dec;139(6):584–6

Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. Costagliola S, et al. **FEBS Lett** 1998 Oct 9;436(3):427–33

Skeletal muscle disturbances may precede clinical and laboratory evidence of autoimmune hypothyroidism [letter] Rodolico C, et al. **J Neurol** 1998 Aug;245(8):555–6

Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy. Ueta Y, et al. **Thyroid** 1999 Feb;9(2):179–82

[Autoimmune hypothyroidism] Wémeau JL, et al. **Rev Prat** 1998 Nov 15;48(18):2006–12 (Eng. Abstr.) **(Fre)**

[Idiopathic myxedema and blocking type antibodies to TSH receptor] Mitsuma T. **Nippon Rinsho** 1999 Aug; 57(8):1759–63 (20 ref.) (Eng. Abstr.) **(Jpn)**

HYPOTHYROIDISM

METABOLISM

Effect of experimentally induced hypothyroidism on sulfate renal transport in rats. Sagawa K, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):F164–71

Thyroid hormone status and membrane n–3 fatty acid content influence mitochondrial proton leak. Pehowich DJ. **Biochim Biophys Acta** 1999 Apr 21;1411(1):192–200

Improved suppression by dietary taurine of the fecal excretion of bile acids from hypothyroid rats. Mochizuki H, et al. **Biosci Biotechnol Biochem** 1999 Apr;63(4):753–5

Malondialdehyde binding of rat cerebral proteins is reduced in experimental hypothyroidism. Chehade J, et al. **Brain Res** 1999 May 22;829(1–2):201–3

Bulbospinal serotonergic activity during changes in thyroid status. Henley WN, et al. **Can J Physiol Pharmacol** 1998 Dec;76(12):1120–31

Thyroid function in premature infants. The hypothyroxinemia of prematurity. Fisher DA. **Clin Perinatol** 1998 Dec;25(4):999–1014, viii (53 ref.)

Effect of propylthiouracil-induced hypothyroidism on the onset of skeletal muscle necrosis in dystrophin-deficient mdx mice. McArdle A, et al. **Clin Sci (Colch)** 1998 Jul; 95(1):83–9

The effect of hypo- and hyperthyroidism on uterine and cervical collagens and glycosidases in albino rats. Gladson M, et al. **Endocr Res** 1999 Feb;25(1):129–37

Effects of contractile activity and hypothyroidism on nuclear hormone receptor mRNA isoforms in rat skeletal muscle. Schuler MJ, et al. **Eur J Biochem** 1999 Sep;264(3):982–8

Thyroid gland function and growth in IGF binding protein-1 transgenic mice. Modric T, et al. **Eur J Endocrinol** 1999 Aug;141(2):149–59

Novel translational repressor (NAT-1) expression is modified by thyroid state and age in brain and liver. Shah GN, et al. **Eur J Endocrinol** 1998 Dec;139(6):649–53

Adenosine regulates renal nitric oxide production in hypothyroid rats. Franco M, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1681–8

Changes in satellite cell content and myosin isoforms in low-frequency-stimulated fast muscle of hypothyroid rat. Putman CT, et al. **J Appl Physiol** 1999 Jan;86(1):40–51

Thyroid status affects the rat cardiac beta-adrenoceptor system transiently and time-dependently. Zwaveling J, et al. **J Auton Pharmacol** 1998 Feb;18(1):1–11

Tri-iodothyronine increases insulin-like growth factor binding protein-2 expression in cultured hepatocytes from hypothyroid rats. Demori I, et al. **J Endocrinol** 1999 Jun; 161(3):465–74

Modulation of human thyrotropin oligosaccharide structures--enhanced proportion of sialylated and terminally galactosylated serum thyrotropin isoforms in subclinical and overt primary hypothyroidism. Trojan J, et al. **J Endocrinol** 1998 Sep;158(3):359–65

G proteins, beta-adrenoreceptors and beta-adrenergic responsiveness in immature and adult rat ventricular myocardium: influence of neonatal hypo- and hyperthyroidism. Novotny J, et al. **J Mol Cell Cardiol** 1999 Apr;31(4):761–72

Bone metabolism in children with congenital hypothyroidism--a longitudinal study. Verrotti A, et al. **J Pediatr Endocrinol Metab** 1998 Nov–Dec;11(6):699–705

Ontogeny of renal renin in congenital hypothyroid rats. Montiel M, et al. **Life Sci** 1999;65(3):263–9

Inhibition of concanavalin A-induced acute T cell dependent hepatic damage in mice by hypothyroidism. Shirin H, et al. **Liver** 1999 Jun;19(3):206–11

Hormonal regulation of 18S RNA, leptin mRNA, and leptin release in adipocytes from hypothyroid rats. Fain JN, et al. **Metabolism** 1998 Dec;47(12):1455–61

Diverse effects of mild and potent goitrogens on blood–brain barrier nutrient transport. Raghunath M, et al. **Neurochem Int** 1998 Aug;33(2):173–7

Bioequivalence of levothyroxine tablets administered to a target population in steady state. Cerutti R, et al. **Pharmacol Res** 1999 Mar;39(3):193–201

Structural analysis of the thyrotropin receptor in four patients with congenital hypothyroidism due to thyroid hypoplasia. Nogueira CR, et al. **Thyroid** 1999 Jun;9(6):523–9

NURSING

Hypothyroidism. Goldsmith C. **Am J Nurs** 1999 Jun; 99(6):42–3

PATHOLOGY

Thyroid gland function and growth in IGF binding protein-1 transgenic mice. Modric T, et al. **Eur J Endocrinol** 1999 Aug;141(2):149–59

Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. Bosch RF, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):156–65

Hypothyroidism in the rat results in decreased soleus motoneurone soma size. Bakels R, et al. **Neurosci Lett** 1998 Oct 2;254(3):149–52

PHYSIOPATHOLOGY

Effects of L-thyroxine and zinc therapy on wound healing in hypothyroid rats. Erdoğan M, et al. **Acta Chir Belg** 1999 Apr;99(2):72–7

Alterations of neonatal thyroid function. Grüters A, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):17–22 (29 ref.)

Electrophysiological mechanisms by which hypothyroidism delays repolarization in guinea pig hearts. Bosch RF, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H211–20

In vivo regulation of beta-MHC gene in rodent heart: role of T3 and evidence for an upstream enhancer. Wright CE, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):C883–91

Macro-orchidism in juvenile hypothyroidism. Panidis DK, et al. **Arch Androl** 1999 Mar–Apr;42(2):85–7

DNA topoisomerase I activity in regenerating liver of hypothyroid rats. Merlo M, et al. **Boll Soc Ital Biol Sper** 1998 Jan–Feb;74(1–2):9–14

Cardiac function at rest in hypothyroidism evaluated by equilibrium radionuclide angiography. Tielens ET, et al. **Clin Endocrinol (Oxf)** 1999 Apr;50(4):497–502

Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. Bruck R, et al. **Dig Dis Sci** 1999 Jun; 44(6):1228–35

Development of compensatory thermogenesis in response to overfeeding in hypothyroid rats. Curcio C, et al. **Endocrinology** 1999 Aug;140(8):3438–43

The influence of low doses 131I-induced maternal hypothyroidism on the development of rat embryos. Usenko V, et al. **Exp Toxicol Pathol** 1999 May;51(3):223–7

Effects of induced hypothyroidism on weight gains, lactation, and reproductive performance of primiparous Brahman cows. Thrift TA, et al. **J Anim Sci** 1999 Jul;77(7):1844–50

The role of somatostatin (octreotide) in the regulation of melatonin secretion in healthy volunteers and in patients with primary hypothyroidism. Wikner J, et al. **J Endocrinol Invest** 1999 Jul–Aug;22(7):527–34

Anorectal physiology and transit in patients with disorders of thyroid metabolism. Deen KI, et al. **J Gastroenterol Hepatol** 1999 Apr;14(4):384–7

The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions. Brittsan AG, et al. **J Mol Cell Cardiol** 1999 Sep;31(9):1725–37

Thermogenesis and fatty acid composition of brown adipose tissue in rats rendered hyperthyroid and hypothyroid-with special reference to docosahexaenoic acid. Saha SK, et al. **Jpn J Physiol** 1998 Oct;48(5):355–64

Hypothyroidism-evoked shifts in hippocampal adrenergic receptors: implications to ischemia-induced hippocampal damage. Hemmings SJ, et al. **Mol Cell Biochem** 1998 Aug; 185(1–2):161–9

Development of cholinergic neurons in rat brain regions: dose-dependent effects of propylthiouracil-induced hypothyroidism. Sawin S, et al. **Neurotoxicol Teratol** 1998 Nov–Dec;20(6):627–35

The influence of hypothyroidism on wound healing. An experimental study. Natori J, et al. **Nippon Ika Daigaku Zasshi** 1999 Jun;66(3):176–80

The influence of hypothyroidism and thyroid replacement therapy on stimulated parotid flow rates. Dixit PS, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jan;87(1):55–60

Persistent infantile hypothyroidism attributable to thyroxine-binding globulin deficiency. Carrel AL, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):312–4

Electrodermal activity in hypothyroid patients and healthy subjects. Dolu N, et al. **Thyroid** 1999 Aug;9(8):787–90

[A central nerve conduction study in hypothyroidism: before and after thyroxine replacement] Lai CL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Dec; 14(12):743–50 (Eng. Abstr.) **(Chi)**

[Hyperfunction and hypofunction of the thyroid gland] Lauven PM. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):33 **(Ger)**

[Hyperfunction and hypofunction of the thyroid gland from the anesthesiologist's viewpoint] Röper A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jan; 34(1):34–7 (16 ref.) **(Ger)**

[Thyroid disease in ageing] Hashizume K. **Nippon Ronen Igakkai Zasshi** 1998 Sep;35(9):662–4 (10 ref.) **(Jpn)**

PREVENTION & CONTROL

Is thyroxine during lithium therapy necessary? [comment] Bartalena L, et al. **J Endocrinol Invest** 1999 Mar;22(3):220–2 (12 ref.). Comment on: J Endocrinol Invest 1998 Dec;21(11):784–6.

Congenital hypothyroid screening using cord blood TSH. Wu LL, et al. **Singapore Med J** 1999 Jan;40(1):23–6

PSYCHOLOGY

School attainments in children with congenital hypothyroidism detected by neonatal screening and treated early in life. Bargagna S, et al. **Eur J Endocrinol** 1999 May; 140(5):407–13

Postpartum depression and thyroid antibody status. Harris B. **Thyroid** 1999 Jul;9(7):699–703 (42 ref.)

[Attempted suicide with 400 thyroxine pills: what happened to the physician-patient relationship?] Martin-du Pan RC. **Rev Med Suisse Romande** 1999 Jun;119(6):493–6 (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Familial occurrence of congenital hypothyroidism due to lingual thyroid gland. El-Desouki MI, et al. **Clin Nucl Med** 1999 Jun;24(6):421–3

Pertechnetate scintigraphy in primary congenital hypothyroidism. Sfakianakis GN, et al. **J Nucl Med** 1999 May;40(5):799–804

Myocardial 123I-MIBG kinetics in acutely hypothyroid patients with differentiated thyroid carcinoma. Maini CL, et al. **Nucl Med Commun** 1999 Aug;20(8):719–26

THERAPY

School attainments in children with congenital hypothyroidism detected by neonatal screening and treated early in life. Bargagna S, et al. **Eur J Endocrinol** 1999 May; 140(5):407–13

Congenital hypothyroidism: etiologies, diagnosis, and management. LaFranchi S. **Thyroid** 1999 Jul;9(7):735–40 (27 ref.)

[Is there a need for treatment in subclinical hypo- and hyperthyroidism?] Lerch M, et al. **Ther Umsch** 1999 Jul; 56(7):369–73 (15 ref.) (Eng. Abstr.) **(Ger)**

URINE

Measurement of urinary iodine excretion to reveal iodine excess in neonatal transient hypothyroidism. Bona G, et al. **J Pediatr Endocrinol Metab** 1998 Nov–Dec;11(6):739–43

VETERINARY

Effect of hypothyroidism on blood lipid concentrations in horses. Frank N, et al. **Am J Vet Res** 1999 Jun;60(6):730–3

Hemodynamic effects of thyroidectomy in sedentary horses. Vischer CM, et al. **Am J Vet Res** 1999 Jan;60(1):14–21

Clinical hypothyroidism associated with trimethoprim-sulfadiazine administration in a dog. Gookin JL, et al. **J Am Vet Med Assoc** 1999 Apr 1;214(7):1028–31, 1021

Change in serum thyroid-stimulating hormone concentration in response to administration of thyrotropin-releasing hormone to healthy dogs, hypothyroid dogs, and euthyroid dogs with concurrent disease. Scott-Moncrieff JC, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1435–8

Effects of induced hypothyroidism or hyperthyroidism on growth and reproductive performance of Brahman heifers. Thrift TA, et al. **J Anim Sci** 1999 Jul;77(7):1833–43

Idiopathic pulmonary fibrosis in a Staffordshire bull terrier with hypothyroidism. Corcoran BM, et al. **J Small Anim Pract** 1999 Apr;40(4):185–8

Evaluation of serum free thyroxine and thyrotropin concentrations in the diagnosis of canine hypothyroidism. Dixon RM, et al. **J Small Anim Pract** 1999 Feb;40(2):72–8

Is it possible to diagnose canine hypothyroidism? Panciera DL. **J Small Anim Pract** 1999 Apr;40(4):152–7

Thyroid-stimulating hormone stimulation tests in cardiomyopathic Doberman pinschers: a retrospective study. Calvert CA, et al. **J Vet Intern Med** 1998 Sep–Oct; 12(5):343–8

Effect of 131I-induced hypothyroidism on indices of reproductive function in adult male dogs. Johnson C, et al. **J Vet Intern Med** 1999 Mar–Apr;13(2):104–10

Hypothermia, hypoglycemia, and hypothyrosis associated with poult enteritis and mortality syndrome. Doerfler RE, et al. **Poult Sci** 1998 Aug;77(8):1103–9

Canine serum thyroglobulin autoantibodies in health, hypothyroidism and non-thyroidal illness. Dixon RM, et al. **Res Vet Sci** 1999 Jun;66(3):243–6

VIROLOGY

Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. Ghilardi G, et al. **Br J Rheumatol** 1998 Dec;37(12):1349–51

HYPOTONIC SOLUTIONS

Mechanisms of Na+–K+ pump regulation in cardiac myocytes during hyposmolar swelling. Bewick NL, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1091–9

Effects of anion channel blockers on hyposmotically induced amino acid release from the in vivo rat cerebral cortex. Estevez AY, et al. **Neurochem Res** 1999 Mar;24(3):447–52

Volume changes induced by osmotic stress in freshly isolated rat hippocampal neurons. Aitken PG, et al. **Pflugers Arch** 1998 Nov;436(6):991–8

Cell swelling causes the action potential duration to shorten in guinea-pig ventricular myocytes by activating IKATP. Priebe L, et al. **Pflugers Arch** 1998 Nov;436(6):894–8

ADMINISTRATION & DOSAGE

Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Tsujitani S, et al. **Oncology** 1999 Jul;57(1):77–82

ADVERSE EFFECTS

Transurethral resection syndrome: effect of the introduction into clinical practice of a new method for monitoring fluid absorption [see comments] Konrad C, et al. **J Clin Anesth** 1998 Aug;10(5):360–5. Comment in: J Clin Anesth 1998 Aug;10(5):357–9.

PHARMACOKINETICS

Ethanol monitoring of fluid absorption in anesthesiology practice [editorial; comment] Hahn RG. **J Clin Anesth** 1998

Aug;10(5):357–9. Comment on: J Clin Anesth 1998 Aug;10(5):360–5.

PHARMACOLOGY

Hypotonic-stimulated taurine efflux in skate erythrocytes: regulation by tyrosine phosphatase activity. Musch MW, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1677–86

Effects of hypotonic swelling on the cellular distribution and expression of pI(Cln) in human nonpigmented ciliary epithelial cells. Sánchez-Torres J, et al. **Curr Eye Res** 1999 Jun;18(6):408–16

Facilitation of gastric motility induced by portal infusion of hyper- and hypotonic solution in rats. Kobashi M, et al. **J Auton Nerv Syst** 1998 Nov 10;73(2–3):156–62

Z/I and A-band lattice spacings in frog skeletal muscle: effects of contraction and osmolarity. Irving TC, et al. **J Muscle Res Cell Motil** 1998 Oct;19(7):811–23

Volume regulation following hypotonic shock in isolated crypts of mouse distal colon. Mignen O, et al. **J Physiol (Lond)** 1999 Mar 1;515 (Pt 2):501–10

[Detection of irregular anti-erythrocyte antibodies using the indirect antiglobulin test in a low-ionic-strength medium. Immunohematology Group of the French Blood Transfusion Society] Mannessier L, et al. **Transfus Clin Biol** 1999 Jun;6(3):174–9 (Eng. Abstr.) **(Fre)**

HYPOTRICHIDA

GENETICS

Evolution of the scrambled germline gene encoding alpha-telomere binding protein in three hypotrichous ciliates. Prescott JD, et al. **Chromosoma** 1998 Nov; 107(5):293–303

Separation of micronuclear DNA of Stylonychia lemnae by pulsed-field electrophoresis and identification of a DNA molecule with a high copy number. Maercker C, et al. **Genome Res** 1999 Jul;9(7):654–61

Invention and mystery in hypotrich DNA. Prescott DM. **J Eukaryot Microbiol** 1998 Nov-Dec;45(6):575–81 (40 ref.)

Messenger RNA in dormant cells of Sterkiella histriomuscorum (Oxytrichiade): indentification of putative regulatory gene transcripts. Tourancheau AB, et al. **Protist** 1999 Aug;150(2):137–47

HYPOTRICHOSIS

T-2 toxin-induced acute skin lesions in Wistar-derived hypotrichotic WBN/ILA-Ht rats. Albarenque SM, et al. **Histol Histopathol** 1999 Apr;14(2):337–42

CONGENITAL

Marie Unna hereditary hypotrichosis. Argenziano G, et al. **Eur J Dermatol** 1999 Jun;9(4):278–80

Lectin histochemistry of dorsal skin of Wistar-derived hypotrichotic WBN/Ila-Ht rats. Iwamoto S, et al. **Exp Anim** 1998 Jul;47(3):183–7

Congenital hypotrichosis. de Berker D. **Int J Dermatol** 1999 May;38 Suppl 1:25–33 (17 ref.)

A sporadic case of congenital hypotrichosis simplex of the scalp: difficulties in diagnosis and classification. Cambiaghi S, et al. **Pediatr Dermatol** 1999 Jul-Aug;16(4):301–4

DIAGNOSIS

Ectodermal dysplasia with hypodontia in a set of Nigerian twins--a case report. Denloye OO, et al. **Afr J Med Med Sci** 1996 Sep;25(3):299–301

GENETICS

The gene for hypotrichosis of Marie Unna maps between D8S258 and D8S298: exclusion of the hr gene by cDNA and genomic sequencing. van Steensel M, et al. **Am J Hum Genet** 1999 Aug;65(2):413–9

PATHOLOGY

Morphological and morphometrical study on the dorsal skin of Wistar and WBN/ILA-Ht rats in their developing stage. Evaluation of the proliferation and apoptotic processes. Iwamoto S, et al. **Histol Histopathol** 1998 Oct;13(4):981–8

Multiple follicular hamartomas with sweat gland and sebaceous differentiation, vermiculate atrophoderma, milia, hypotrichosis, and late development of multiple basal cell carcinomas. Pujol RM, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 2):853–7

VETERINARY

Lectin histochemistry of dorsal skin of Wistar-derived hypotrichotic WBN/Ila-Ht rats. Iwamoto S, et al. **Exp Anim** 1998 Jul;47(3):183–7

Inheritance of the "rat-tail" syndrome and its effect on calf performance. Schalles RR, et al. **J Anim Sci** 1999 May; 77(5):1144–7

HYPOVENTILATION

BLOOD

Functional magnetic resonance imaging of regional cerebral blood oxygenation changes during breath holding. Kastrup A, et al. **Stroke** 1998 Dec;29(12):2641–5

CONGENITAL

The control of breathing with reference to congenital central hypoventilation syndrome. Child F, et al. **J R Soc Med** 1998 Sep;91(9):479–83 (20 ref.)

DIAGNOSIS

Functional magnetic resonance imaging of regional cerebral blood oxygenation changes during breath holding. Kastrup A, et al. **Stroke** 1998 Dec;29(12):2641–5

ETIOLOGY

Central alveolar hypoventilation in neurosarcoidosis. Kim H, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1467–8

Infantile lipid storage myopathy with nocturnal hypoventilation shows abnormal low-affinity muscle carnitine uptake in vitro. Vergani L, et al. **Neuromuscul Disord** 1999 Jul;9(5):320–2

Vocal cord paralysis and hypoventilation in a patient with suspected Leigh disease. Lin YC, et al. **Pediatr Neurol** 1999 Mar;20(3):223–5

METABOLISM

The effect of respiratory mode on human middle ear pressure. Ikarashi F. **Auris Nasus Larynx** 1998 Dec;25(4):349–54

Effects of hyper- and hypoventilation on gastric and sublingual PCO(2). Pernat A, et al. **J Appl Physiol** 1999 Sep;87(3):933–7

Brain tissue oxygenation during hemorrhagic shock, resuscitation, and alterations in ventilation. Manley GT, et al. **J Trauma** 1999 Feb;46(2):261–7

PHYSIOPATHOLOGY

Cardiorenal effects of behavioral inhibition of breathing. Anderson DE. **Biol Psychol** 1998 Sep;49(1–2):151–63 (42 ref.)

The control of breathing with reference to congenital central hypoventilation syndrome. Child F, et al. **J R Soc Med** 1998 Sep;91(9):479–83 (20 ref.)

[Diaphragm pacing in chronic hypoventilation] Kroworsch B, et al. **Med Klin** 1999 Apr;94(1 Spec No):91–2 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Ketamine antagonises alfentanil-induced hypoventilation in healthy male volunteers. Persson J, et al. **Acta Anaesthesiol Scand** 1999 Aug;43(7):744–52

RADIOGRAPHY

[Unilateral hypoventilation in the adult patient] Toral Marin J, et al. **Rev Clin Esp** 1999 Jul;199(7):467–8 **(Spa)**

REHABILITATION

[Noninvasive intermittent self-ventilation as a palliative measure in amyotrophic lateral sclerosis] Schlamp V, et al. **Nervenarzt** 1998 Dec;69(12):1074–82 (Eng. Abstr.) **(Ger)**

THERAPY

Nasal mask ventilation in children [letter; comment] Marcus CL, et al. **Chest** 1998 Dec;114(6):1794–5. Comment on: Chest 1998 May;113(5 Suppl):289S–344S.

HYPOVENTILATION, CENTRAL ALVEOLAR see **SLEEP APNEA SYNDROMES**

HYPOVOLEMIC SHOCK see **SHOCK**

HYPOXANTHINE

ANALOGS & DERIVATIVES see HYPOXANTHINES

ANALYSIS

Are elevated cerebrospinal fluid levels of IL-6 in sudden unexplained deaths, infectious deaths and deaths due to heart/lung disease in infants and children due to hypoxia? Vege A, et al. **Acta Paediatr** 1998 Aug;87(8):819–24

Tissue hypoxanthine reflects gut vulnerability in porcine endotoxin shock [see comments] Oldner A, et al. **Crit Care Med** 1999 Apr;27(4):790–7. Comment in: Crit Care Med 1999 Apr;27(4):690–1.

Hypoxanthine levels in vitreous humor: a study of influencing factors in sudden infant death syndrome. Opdal SH, et al. **Pediatr Res** 1998 Aug;44(2):192–6

BLOOD

Effects of hypoxic exercise conditioning on work capacity, lactate, hypoxanthine and hormonal factors in men. Mori M, et al. **Clin Exp Pharmacol Physiol** 1999 Apr;26(4):309–14

Plasma hypoxanthine levels during crystalloid and blood cardioplegias: warm blood cardioplegia increases hypoxanthine levels with a greater risk of oxidative stress. Quinlan GJ, et al. **J Cardiovasc Surg (Torino)** 1999 Feb; 40(1):65–9

Can oxypurines plasma levels classify the type of physical exercise? Bianchi GP, et al. **J Sports Med Phys Fitness** 1999 Jun;39(2):123–7

METABOLISM

Nucleobase transport in opossum kidney epithelial cells and Xenopus laevis oocytes: the characterisation, structure-activity relationship of uracil analogues and oocyte expression studies of sodium-dependent and -independent hypoxanthine uptake. Shayeghi M, et al. **Biochim Biophys Acta** 1999 Jan 12;1416(1–2):109–18

Elevated hypoxanthine in endotoxic shock [editorial; comment] Alston TA. **Crit Care Med** 1999 Apr;27(4):690–1 (12 ref.). Comment on: Crit Care Med 1999 Apr;27(4):790–7.

Protein kinase C and intracellular calcium are involved in follicle-stimulating hormone-mediated meiotic resumption of cumulus cell-enclosed porcine oocytes in hypoxanthine-supplemented medium. Su YQ, et al. **Mol Reprod Dev** 1999 May;53(1):51–8

PHARMACOLOGY

Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro. Marshman E, et al. **Clin Cancer Res** 1998 Nov;4(11):2895–902

Precursors of the purine backbone augment the inhibitory action of hypoxanthine and dibutyryl cAMP on mouse oocyte maturation. Downs SM. **J Exp Zool** 1998 Oct 15; 282(3):376–84

The antiproliferative and cell cycle effects of 5,6,7,8-tetrahydro-N5,N10-carbonylfolic acid, an inhibitor of methylenetetrahydrofolate dehydrogenase, are potentiated by hypoxanthine. Tonkinson JL, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):315–21

HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

HYPOXANTHINE OXIDASE see **XANTHINE OXIDASE**

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE

see related
LESCH-NYHAN SYNDROME

ANTAGONISTS & INHIBITORS

Bacterial complementation as a means to test enzyme-ligand interactions. Canyuk B, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):181–6

Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases [see comments] Li CM, et al. **Nat Struct Biol** 1999 Jun; 6(6):582–7. Comment in: Nat Struct Biol 1999 Jun;6(6):502–4.

BLOOD

HPRT- mutant T cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis. Cannons JL, et al. **Arthritis Rheum** 1998 Oct;41(10):1772–82

DNA sequence analysis of hprt mutants persisting in peripheral blood of cynomolgus monkeys more than two years after ENU treatment. Harbach PR, et al. **Environ Mol Mutagen** 1999;33(1):42–8

CHEMISTRY

A 1.4 A crystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma cruzi. Focia PJ, et al. **Biochemistry** 1998 Oct 27;37(43):15066–75

Approaching the transition state in the crystal structure of a phosphoribosyltransferase. Focia PJ, et al. **Biochemistry** 1998 Dec 8;37(49):17120–7

Understanding substrate specificity in human and parasite phosphoribosyltransferases through calculation and experiment. Pitera JW, et al. **Biochemistry** 1999 Aug 10; 38(32):10298–306

The 2.0 A structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor [see comments] Shi W, et al. **Nat Struct Biol** 1999 Jun;6(6):588–93. Comment in: Nat Struct Biol 1999 Jun;6(6):502–4.

Forming and inhibiting PRT active sites [news; comment] [published erratum appears in Nat Struct Biol 1999 Jul;6(7):706] Smith JL. **Nat Struct Biol** 1999 Jun;6(6):502–4 . Comment on: Nat Struct Biol 1999 Jun;6(6):582–7. Comment on: Nat Struct Biol 1999 Jun;6(6):588–93.

Ternary complex structure of human HGPRTase, PRPP, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. Balendiran GK, et al. **Protein Sci** 1999 May;8(5):1023–31

DEFICIENCY

Purine metabolism in female heterozygotes for hypoxanthine-guanine phosphoribosyltransferase deficiency. Puig JG, et al. **Eur J Clin Invest** 1998 Nov; 28(11):950–7

The molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in French families;

report of two novel mutations. Liu G, et al. **Hum Mutat** 1998;Suppl 1:S88–90

Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase manifesting as acute renal damage [see comments] Hikita M, et al. **Intern Med** 1998 Nov;37(11):945–9. Comment in: Intern Med 1998 Nov;37(11):905–6.

Partial hypoxanthine phosphoribosyltransferase deficiency: unrecognized until adult ages [editorial; comment] Kamatani N. **Intern Med** 1998 Nov;37(11):905–6 (11 ref.) . Comment on: Intern Med 1998 Nov;37(11):945–9.

Abnormal purine and pyrimidine nucleotide content in primary astroglia cultures from hypoxanthine-guanine phosphoribosyltransferase-deficient transgenic mice. Pelled D, et al. **J Neurochem** 1999 Mar;72(3):1139–45

Hypoxanthine-guanine phosphoribosyltransferase deficiency and erythrocyte synthesis of pyridine coenzymes. Micheli V, et al. **Life Sci** 1999;64(26):2479–87

Bone marrow transplantation does not ameliorate the neurologic symptoms in mice deficient in hypoxanthine guanine phosphoribosyl transferase (HPRT). Wojcik BE, et al. **Metab Brain Dis** 1999 Mar;14(1):57–65

No self-injurious behavior was found in HPRT-deficient mice treated with 9-ethyladenine. Edamura K, et al. **Pharmacol Biochem Behav** 1998 Oct;61(2):175–9

[Establishment of mutant strain from human lung cancer cell (A549) with characteristics of resistance to 8-AG and HGPRT deficiency] Xiao Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(2):113–5 (Eng. Abstr.) **(Chi)**

[Physiopathology of neurological signs of hypoxanthine-guanine phosphoribosyltransferase deficiency] Torres-Jimenez R, et al. **Rev Neurol** 1998 Dec; 27(160):1050–4 (35 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. Chen T, et al. **Carcinogenesis** 1999 Feb;20(2):269–77

GENETICS

Gene-specific damage produced by topoisomerase inhibitors in human lung cancer cells and peripheral mononuclear cells as assayed by polymerase chain reaction-stop assay. Oshita F, et al. **Anticancer Res** 1998 Sep–Oct; 18(5A):3389–93

Bacterial complementation as a means to test enzyme-ligand interactions. Canyuk B, et al. **Appl Microbiol Biotechnol** 1998 Aug;50(2):181–6

Altering the purine specificity of hypoxanthine-guanine-xanthine phosphoribosyltransferase from Tritrichomonas foetus by structure-based point mutations in the enzyme protein. Munagala NR, et al. **Biochemistry** 1998 Nov 24;37(47):16612–9

Temporal, spatial and tissue-specific expression of a myogenin-lacZ transgene targeted to the Hprt locus in mice. Vivian JL, et al. **Biotechniques** 1999 Jul;27(1):154–62

Prospective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy. Sawada M, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Aug;7(8):711–7

Hprt lymphocyte mutant frequency in relation to DNA adduct formation in rats fed the hepatocarcinogen 2-acetylaminofluorene. Beland FA, et al. **Cancer Lett** 1999 Sep 1;143(2):249–55

Failure to complement abnormal phenotypes of simian virus 40-transformed Werner syndrome cells by introduction of a normal human chromosome 8. Kodama S, et al. **Cancer Res** 1998 Nov 15;58(22):5188–95

Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Glaab WE, et al. **Carcinogenesis** 1998 Nov;19(11):1931–7

MSH3 deficiency is not sufficient for a mutator phenotype in Chinese hamster ovary cells. Hinz JM, et al. **Carcinogenesis** 1999 Feb;20(2):215–20

Hprt mutant frequency and aromatic DNA adduct level in non-smoking and smoking lung cancer patients and population controls. Hou SM, et al. **Carcinogenesis** 1999 Mar;20(3):437–44

Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Philip PA, et al. **Clin Cancer Res** 1996 Feb; 2(2):303–10

Association among somatic HPRT mutant frequency, peripheral blood T-lymphocyte clonality, and serologic parameters of disease activity in children with juvenile onset dermatomyositis. Abramson LS, et al. **Clin Immunol** 1999 Apr;91(1):61–7

Selection of hprt mutant T cells as surrogates for dividing cells reveals a restricted T cell receptor BV repertoire in insulin-dependent diabetes mellitus. Falta MT, et al. **Clin Immunol** 1999 Mar;90(3):340–51

Genotyping metabolic polymorphisms in a cohort of Caucasians and single strand conformation polymorphism analysis of point mutations in human hprt exons 7 and 8. Krause G, et al. **Electrophoresis** 1998 Oct;19(14):2380–8

PCR-directed DNA sequencing of "nondeletion" HPRT-mutants induced by bleomycin in CHO K1-BH4 cells. An J, et al. **Environ Mol Mutagen** 1998;32(3):244–50

Molecular analysis of in vivo mutations induced by N-ethyl-N-nitrosourea in the autosomal Tk and the X-linked Hprt genes of mouse lymphocytes. Dobrovolsky VN, et al. **Environ Mol Mutagen** 1999;34(1):30–8

DNA sequence analysis of hprt mutants persisting in peripheral blood of cynomolgus monkeys more than two years after ENU treatment. Harbach PR, et al. **Environ Mol Mutagen** 1999;33(1):42–8

Culture and propagation of Hprt mutant T-lymphocytes isolated from mouse spleen. Meng Q, et al. **Environ Mol Mutagen** 1998;32(3):236–43

Transition mutations at CpG dinucleotides are the most frequent in vivo spontaneous single-based substitution mutation in the human HPRT gene. O'Neill JP, et al. **Environ Mol Mutagen** 1998;32(2):188–91 (15 ref.)

Lack of response to multiple genotoxic agents at the hprt locus in peripheral blood T-lymphocytes of cynomolgus monkeys. Zimmer DM, et al. **Environ Mol Mutagen** 1999; 33(2):123–31

Purine metabolism in female heterozygotes for hypoxanthine-guanine phosphoribosyltransferase deficiency. Puig JG, et al. **Eur J Clin Invest** 1998 Nov; 28(11):950–7

Influence of sex, smoking and age on human hprt mutation frequencies and spectra. Curry J, et al. **Genetics** 1999 Jul; 152(3):1065–77

Molecular characterization of two deletion events involving Alu-sequences, one novel base substitution and two tentative hotspot mutations in the hypoxanthine phosphoribosyltransferase (HPRT) gene in five patients with Lesch-Nyhan syndrome. Tvrdik T, et al. **Hum Genet** 1998 Sep;103(3):311–8

Different somatic and germline HPRT1 mutations promote use of a common, cryptic intron 1 splice site. Mutation in brief no. 259. Online [corrected and republished article originally printed in Hum Mutat 1999;13(6):504–5] Colgin LM, et al. **Hum Mutat** 1999;14(1):92

Ialpha exon-replacement mice synthesize a spliced HPRT-C(alpha) transcript which may explain their ability to switch to IgA. Inhibition of switching to IgG in these mice. Qiu G, et al. **Int Immunol** 1999 Jan;11(1):37–46

Pgk1 and Hprt gene activity in the peri-implantation mouse embryo is influenced by the parental origin of the X-chromosome. Sturm K, et al. **Int J Dev Biol** 1999 Jan; 43(1):69–73

Mutation of the repeat number of the HPRTB locus and structure of rare intermediate alleles. Mertens G, et al. **Int J Legal Med** 1999;112(3):192–4

RBE-LET relationships for cell inactivation and mutation induced by low energy protons in V79 cells: further results at the LNL facility. Belli M, et al. **Int J Radiat Biol** 1998 Oct;74(4):501–9

Expression of the Methanobacterium thermoautotrophicum hpt gene, encoding hypoxanthine (Guanine) phosphoribosyltransferase, in Escherichia coli. Sauer J, et al. **J Bacteriol** 1999 Mar;181(6):1958–62

The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. Arnaudeau C, et al. **J Mol Biol** 1999 Jun 25;289(5):1231–8

Influence of age and strain on striatal dopamine loss in a genetic mouse model of Lesch-Nyhan disease. Jinnah HA, et al. **J Neurochem** 1999 Jan;72(1):225–9

Long-term exposure to a magnetic field (5 mT at 60 Hz) increases X-ray-induced mutations. Miyakoshi J, et al. **J Radiat Res (Tokyo)** 1999 Mar;40(1):13–21

Identification of a new single nucleotide substitution on the hypoxanthine-guanine phosphoribosyltransferase gene (HPRT(Tsou) from a Taiwanese aboriginal family with severe gout. Chang SJ, et al. **J Rheumatol** 1999 Aug; 26(8):1802–7

Hypoxanthine phosphoribosyltransferase cDNA in gerbils (Meriones unguiculatus). Mai Z, et al. **Lab Anim Sci** 1998 Apr;48(2):179–83

5-azacytidine induces transgene silencing by DNA methylation in Chinese hamster cells. Broday L, et al. **Mol Cell Biol** 1999 Apr;19(4):3198–204

Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Elder RH, et al. **Mol Cell Biol** 1998 Oct; 18(10):5828–37

DNA loop domains in a 1.4-Mb region around the human hprt gene mapped by cleavage mediated by nuclear matrix-associated topoisomerase II. Fajkus J, et al. **Mol Gen Genet** 1998 Dec;260(5):410–6

Detection of a novel splice variant of the hypoxanthine-guanine phosphoribosyl transferase gene in human oocytes and preimplantation embryos: implications for a RT-PCR-based preimplantation diagnosis of Lesch-Nyhan syndrome. Daniels R, et al. **Mol Hum Reprod** 1998 Aug;4(8):785–9

Complex hprt deletion events are recovered after exposure of human lymphoblastoid cells to high-LET carbon and neon ion beams. Kagawa Y, et al. **Mutagenesis** 1999 Mar; 14(2):199–205

The effect of folate deficiency on the hprt mutational spectrum in Chinese hamster ovary cells treated with monofunctional alkylating agents. Branda RF, et al. **Mutat Res** 1999 Jun 30;427(2):79–87

Rapid characterization of mutations in amplified human hprt cDNA by polyacrylamide gel electrophoresis. Garganta F, et al. **Mutat Res** 1998 Nov;406(1):33–43

Specificity of mutations induced by methyl methanesulfonate in mismatch repair-deficient human cancer cell lines. Glaab WE, et al. **Mutat Res** 1999 Jun 30;427(2):67–78

Specificity of mutations in the PMS2-deficient human tumor cell line HEC-1-A. Kato T, et al. **Mutat Res** 1998 Dec 3;422(2):279–83

Biomarkers in long survivors of pediatric acute lymphoblastic leukemia patients: late effects of cancer chemotherapy. Koishi S, et al. **Mutat Res** 1998 Dec 3;422(2):213–22

Evidence that most radiation-induced HPRT mutants are generated directly by the initial radiation exposure. Leonhardt EA, et al. **Mutat Res** 1999 May 3;426(1):23–30

Mutagenicity of 1,3-butadiene at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats. Meng Q, et al. **Mutat Res** 1999 Aug 11; 429(1):107–25

Mutagenicity of the racemic mixtures of butadiene monoepoxide and butadiene diepoxide at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats. Meng Q, et al. **Mutat Res** 1999 Aug 11; 429(1):127–40

Polymerase chain reaction-based deletion screening of bisulfite (sulfur dioxide)-enhanced gpt-mutants in CHO-AS52 cells. Meng Z, et al. **Mutat Res** 1999 Mar 10; 425(1):81–5

Aflatoxin B1-induced Hprt mutations in splenic lymphocytes of Fischer 344 rats. Results of an intermittent feeding trial. Morris SM, et al. **Mutat Res** 1999 Jan 25;423(1-2):33–8

Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum. O'Neill JP, et al. **Mutat Res** 1998 Nov;411(3):179–214 (98 ref.)

Use of cryopreserved peripheral mononuclear blood cells in biomonitoring. Risom L, et al. **Mutat Res** 1999 Apr 6; 440(2):131–8

Misrejoining of DNA double-strand breaks in primary and transformed human and rodent cells: a comparison between the HPRT region and other genomic locations. Rothkamm K, et al. **Mutat Res** 1999 Apr 9;433(3):193–205

Deletion-pattern analysis of alpha-particle and X-ray induced mutations at the HPRT locus of V79 Chinese hamster cells. Schmidt P, et al. **Mutat Res** 1998 Nov 3; 421(2):149–61

Comparison of HepG2 feeder cells generated by exposure to gamma-rays, X-rays, UV-C light or mitomycin C for ability to activate 7,12-dimethylbenz[a]anthracene in a cell-mediated Chinese hamster V79/HGPRT mutation assay. Schrader TJ. **Mutat Res** 1999 Jan 25;423(1-2):137–48

Triethylene glycol dimethacrylate induces large deletions in the hprt gene of V79 cells. Schweikl H, et al. **Mutat Res** 1999 Jan 2;438(1):71–8

Elevated frequencies of hypoxanthine phosphoribosyltransferase lymphocyte mutants are detected in Russian liquidators 6 to 10 years after exposure to radiation from the Chernobyl nuclear power plant accident. Thomas CB, et al. **Mutat Res** 1999 Feb 2; 439(1):105–19

Targeted gene knockout mediated by triple helix forming oligonucleotides. Majumdar A, et al. **Nat Genet** 1998 Oct; 20(2):212–4

Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke [see comments] Finette BA, et al. **Nat Med** 1998 Oct;4(10):1144–51. Comment in: Nat Med 1998 Oct;4(10):1119–20.

The chicken HPRT gene: a counter selectable marker for the DT40 cell line. Fukagawa T, et al. **Nucleic Acids Res** 1999 May 1;27(9):1966–9

CAG-polyglutamine-repeat mutations: independence from gene context. Ordway JM, et al. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1083–8 (34 ref.)

Gender-specific frequency of background somatic mutations at the hypoxanthine phosphoribosyltransferase locus in cord blood T lymphocytes from preterm newborns. Yoshioka M, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):586–91

Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome. Lowenstein PR, et al. **Prog Brain Res** 1998;117:485–501 (113 ref.)

Increase in radiation-induced HPRT gene mutation frequency after nonthermal exposure to nonionizing 60 Hz electromagnetic fields. Walleczek J, et al. **Radiat Res** 1999 Apr;151(4):489–97

[Effect of beta-carotene on 60Co-gamma-induced mutation at T-lymphocyte hypoxanthine-guanine phosphoribosyl transferase locus in rats] Ni QG, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Nov;18(6):535–6 (Eng. Abstr.) **(Chi)**

METABOLISM

Limited proteolysis of a trypanosomal hypoxanthine phosphoribosyltransferase yields crystals that diffract X-rays to near atomic resolution. Nieves-Alicea R, et al. **Biochim Biophys Acta** 1998 Nov 10;1388(2):500–5

Point mutations in the guanine phosphoribosyltransferase from Giardia lamblia modulate pyrophosphate binding and enzyme catalysis. Page JP, et al. **Eur J Biochem** 1999 Feb; 259(3):565–71

6-thioguanine resistance in a human colon carcinoma cell line with unaltered levels of hypoxanthine guanine phosphoribosyltransferase activity. Bemi V, et al.

Int J Cancer 1999 Aug 12;82(4):556–61

Purification and characterization of Plasmodium falciparum hypoxanthine–guanine–xanthine phosphoribosyltransferase and comparison with the human enzyme. Keough DT, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):29–41

HYPOXANTHINES

CHEMISTRY

N2-amination of guanine to 2-hydrazinohypoxanthine, a novel in vivo nucleic acid modification produced by the hepatocarcinogen 2-nitropropane. Sodum RS, et al. **Chem Res Toxicol** 1998 Dec;11(12):1453–9

HYPOXEMIA see **ANOXEMIA**

HYPOXIA see **ANOXIA**

HYPOXIA, CELLULAR see **CELL HYPOXIA**

HYPSARRHYTHMIA see **SPASMS, INFANTILE**

HYSTERECTOMY

Respiration during emergence from anaesthesia with desflurane/N2O vs. desflurane/air for gynaecological laparoscopy. Einarsson SG, et al. **Acta Anaesthesiol Scand** 1998 Nov;42(10):1192–8

Epidural anesthesia combined with propofol sedation for abdominal hysterectomy in a patient with amyotrophic lateral sclerosis--a case report. Chen LK, et al. **Acta Anaesthesiol Sin** 1998 Jun;36(2):103–6

Benign glandular cells in posthysterectomy vaginal smears. Tambouret R, et al. **Acta Cytol** 1998 Nov–Dec;42(6):1403–8

Compliance to estrogen treatment one to three years after hysterectomy and bilateral salpingooophorectomy. The cohort's lifestyle, knowledge of ERT, benefits etc. Hée P. **Acta Obstet Gynecol Scand** 1999 Jul;78(6):534–9

Histopathological factors influencing pelvic lymph node metastases in two or more sites in patients with cervical carcinoma undergoing radical hysterectomy. Kamura T, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):452–7

Successful management of malignant hyperthermia susceptibility during cesarean hysterectomy for postpartum hemorrhage. Wu YC, et al. **Acta Obstet Gynecol Scand** 1999 Sep;78(8):738–9

Prescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil. Heineck I, et al. **Am J Infect Control** 1999 Jun; 27(3):296–300

Prospective randomized clinical trial of laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy. Falcone T, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):955–62

The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Fox J, et al. **Am J Obstet Gynecol** 1999 May;180(5):1104–9

Role of androgens in surgical menopause. Gelfand MM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):325–7 (10 ref.)

Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women <30 years old. MacDonald SR, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1360–3

Laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy: a prospective, randomized, multicenter study. Marana R, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):270–5

Planned cesarean hysterectomy: A preferred alternative to separate operations. Seago DP, et al. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1385–93

Patient profile 2: surgical menopause. Sonder HM. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 2):328

Vaginal hysterectomy for the woman with a moderately enlarged uterus weighing 200 to 700 grams. Unger JB. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1337–44

Recurrent cervical carcinoma after primary radical surgery. Wang CJ, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):518–24

Functional outcomes and satisfaction after abdominal hysterectomy. Weber AM, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):530–5

Intra-operative bradycardia in gynaecological surgery [letter; comment] Buggy D. **Anaesthesia** 1998 Aug;53(8):824–5. Comment on: Anaesthesia 1997 Dec;52(12):1221–4.

Mucosal host defence response to hysterectomy assessed by saliva analyses: a comparison of propofol and isoflurane anaesthesia. Lähteenmäki M, et al. **Anaesthesia** 1998 Nov; 53(11):1067–73

Perioperative dextromethorphan reduces postoperative pain after hysterectomy. Henderson DJ, et al. **Anesth Analg** 1999 Aug;89(2):399–402

Pulmonary hypertension and major surgery. Rodriguez RM, et al. **Anesth Analg** 1998 Oct;87(4):812–5

Adjuvant chemotherapy in "high risk" patients after Wertheim hysterectomy--10-year survivals. Sivanesaratnam V. **Ann Acad Med Singapore** 1998 Sep; 27(5):622–6

Outcome of early cervical carcinoma treated by Wertheim hysterectomy with selective postoperative radiotherapy. Tay SK, et al. **Ann Acad Med Singapore** 1998 Sep; 27(5):613–7

The stimulatory effect of VIP on progesterone release in rats after adrenalectomy, ovariectomy, and hysterectomy: influence of VIP and PACAP38 on progesterone release in rats after ovariectomy and hysterectomy. Wasilewska-Dziubinska E, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:556–60

The retained ovary and the residual ovary syndrome [editorial; comment] Allen DG. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):446–7. Comment on: Aust N Z J Obstet Gynaecol 1998 Nov;38(4):447–8.

Is it better to avoid urethral catheterization at hysterectomy and caesarean section? Barnes JS. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):315–6

Hysterectomy with ovarian conservation: effect on bone mineral density. Larcos G. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):452–4

'Acute' residual ovary syndrome [see comments] Rane A, et al. **Aust N Z J Obstet Gynaecol** 1998 Nov;38(4):447–8 . Comment in: Aust N Z J Obstet Gynaecol 1998 Nov;38(4):446–7.

Tramadol or morphine administered during operation: a study of immediate postoperative effects after abdominal hysterectomy. Coetzee JF, et al. **Br J Anaesth** 1998 Nov; 81(5):737–41

Dextromethorphan and pain after total abdominal hysterectomy. McConaghy PM, et al. **Br J Anaesth** 1998 Nov;81(5):731–6

The effect of malnutrition on the metabolic response to surgery. Emery PW, et al. **Br J Nutr** 1999 Feb;81(2):115–20

A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. Aberdeen Endometrial Ablation Trials Group [see comments] **Br J Obstet Gynaecol** 1999 Apr;106(4):360–6. Comment in: Br J Obstet Gynaecol 1999 Aug;106(8):876.

Enterobius vermicularis threadworm infestation of paraovarian tissue in a woman who has had a hysterectomy. Dundas KC, et al. **Br J Obstet Gynaecol** 1999 Jun; 106(6):605–7

Pharmacokinetics of three doses of epidural ropivacaine during hysterectomy and comparison with bupivacaine. Sandler AN, et al. **Can J Anaesth** 1998 Sep;45(9):843–9

Time of peritoneal cavity exposure influences postoperative glucose production. Schricker T, et al. **Can J Anaesth** 1999 Apr;46(4):352–8

Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Sakuragi N, et al. **Cancer** 1999 Apr 1;85(7):1547–54

Ultrasonographic evaluation of hysterectomized patients with and without concomitant adnexectomy? Pardo J, et al. **Clin Exp Obstet Gynecol** 1998;25(4):133–4

Columnar and metaplastic cells in vault smears: cytologic and colposcopic study. Sodhani P, et al. **Cytopathology** 1999 Apr;10(2):122–6; discussion 131

Endometrial intraepithelial carcinoma diagnosed by brush cytology and p53 immunostaining, and confirmed by hysterectomy. Maksem JA, et al. **Diagn Cytopathol** 1998 Oct;19(4):284–7

The secretory patterns of growth hormone in pregnant and hysterectomized ewes. Al-Gubory KH, et al. **Eur J Endocrinol** 1999 Jul;141(1):83–9

Routine retroperitoneal drainage is not required for uncomplicated pelvic lymphadenectomy for uterine cancer. Patsner B. **Eur J Gynaecol Oncol** 1999;20(2):87–9

Is there an effect of perioperative blood transfusion on the outcome of radical hysterectomy with lymphadenectomy for cervical cancer in South Africa? Wolterbeek JH, et al. **Eur J Gynaecol Oncol** 1998;19(5):458–63

Effects of topical honey on post-operative wound infections due to gram positive and gram negative bacteria following caesarean sections and hysterectomies. Al-Waili NS, et al. **Eur J Med Res** 1999 Mar 26;4(3):126–30

Pre-operative ultrasonographic evaluation of nongravid, enlarged uteri--correlation with bimanual examination. Dekel A, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):205–7

Recurrence and survival analyses of 1,115 cervical cancer patients treated with radical hysterectomy. Yuan C, et al. **Gynecol Obstet Invest** 1999;47(2):127–32

Re: Estape et al.: Close vaginal margins as a prognostic factor after radical hysterectomy [letter; comment] Beitler JJ. **Gynecol Oncol** 1999 Feb;72(2):267. Comment on: Gynecol Oncol 1998 Mar;68(3):229–32.

Prospective trial of aggressive postoperative bowel stimulation following radical hysterectomy. Fanning J, et al. **Gynecol Oncol** 1999 Jun;73(3):412–4

Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Lahousen M, et al. **Gynecol Oncol** 1999 May;73(2):196–201

Modified radical hysterectomy in the treatment of early squamous cervical cancer. Magrina JF, et al. **Gynecol Oncol** 1999 Feb;72(2):183–6

A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study [see comments] Sedlis A, et al. **Gynecol Oncol** 1999 May; 73(2):177–83. Comment in: Gynecol Oncol 1999 May;73(2):175–6.

Laparoscopic assisted vaginal hysterectomy/laparoscopic hysterectomy. Wakabayashi MT. **Hawaii Med J** 1999 Jan; 58(1):12–4 (25 ref.)

Morphological changes in hysterectomies after endometrial ablation. Tresserra F, et al. **Hum Reprod** 1999 Jun; 14(6):1473–7

Chronic plasma cell endometritis in hysterectomy specimens of HIV-infected women: a retrospective analysis. Kerr-Layton JA, et al. **Infect Dis Obstet Gynecol** 1998; 6(4):186–90

Bilateral tubo-ovarian abscesses four years after total abdominal hysterectomy. Mendez LE, et al. **Infect Dis Obstet Gynecol** 1998;6(3):138–40

Recurrence of gynecologic malignancy at the vaginal vault after hysterectomy. Heller DS, et al. **Int J Gynaecol Obstet** 1999 Feb;64(2):159–62

Abnormal urodynamic findings after radical hysterectomy or pelvic irradiation for cervical cancer. Lin HH, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):169–74

Arterial embolization for bleeding following hysterectomy for intractable postpartum hemorrhage. Oei PL, et al. **Int J Gynaecol Obstet** 1998 Jul;62(1):83–6

Conservative treatment of vaginal vault granulation tissue following total abdominal hysterectomy. Saropala N, et al. **Int J Gynaecol Obstet** 1998 Jul;62(1):55–8

Occult carcinoma discovered after simple hysterectomy treated with postoperative radiotherapy. Crane CH, et al. **Int J Radiat Oncol Biol Phys** 1999 Mar 15;43(5):1049–53 (16 ref.)

Prognostic factors in patients with with locally advanced cervical cancer treated with radical hysterectomy and adjuvant radiotherapy. Frigerio L, et al. **Int Surg** 1998 Jul-Sep;83(3):265–70

100 total laparoscopic hysterectomies in private practice in Brazil. Jaenisch JB, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):169–71

Leptin and the perioperative neuroendocrinological stress response. Kain ZN, et al. **J Clin Endocrinol Metab** 1999 Jul;84(7):2438–42

Vaginal evisceration. Ferrera PC, et al. **J Emerg Med** 1999 Jul-Aug;17(4):665–7

Cancer reduces the metabolic response of muscle to surgical stress in the rat. de Blaauw I, et al. **J Surg Res** 1998 Nov; 80(1):94–101

A survey of gynecologists' attitudes regarding decision making in the management of non-cancerous conditions that frequently result in hysterectomy. Dolan JG, et al. **Med Decis Making** 1999 Apr-Jun;19(2):186–92

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma [see comments] Keys HM, et al. **N Engl J Med** 1999 Apr 15;340(15):1154–61. Comment in: N Engl J Med 1999 Apr 15;340(15):1198–200.

Quality of life among women undergoing hysterectomies. Rowe MK, et al. **Obstet Gynecol** 1999 Jun;93(6):915–21

Predictive value for infection of febrile morbidity after vaginal surgery. Shackelford DP, et al. **Obstet Gynecol** 1999 Jun;93(6):928–31

Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2-positive patient. Spear SL, et al. **Plast Reconstr Surg** 1999 Feb;103(2):548–53; discussion 554–5

Preoperative irradiation therapy and radical hysterectomy: prognostic value of tumor regression after initial irradiation of squamous cell carcinoma of the cervix. Coelho FR, et al. **Rev Paul Med** 1998 May-Jun;116(3):1700–9

Adjuvant radiotherapy after radical hysterectomy of the cervical cancer. Prognostic factors and complications. Chatani M, et al. **Strahlenther Onkol** 1998 Oct; 174(10):504–9

Management of postoperative radiation injury of the urinary bladder by hyperbaric oxygen (HBO). Peusch-Dreyer D, et al. **Strahlenther Onkol** 1998 Nov;174 Suppl 3:99–100

Loss prevention case of the month. Possible vs. appropriate. Avery JK. **Tenn Med** 1999 Mar;92(3):88–9

A study of an educational intervention to decrease inappropriate preoperative autologous blood donation: its effectiveness and the effect on subsequent transfusion rates in elective hysterectomy. Kanter MH, et al. **Transfusion** 1999 Aug;39(8):801–7

Women's knowledge about the physical and emotional changes associated with menopause. Fox-Young S, et al. **Women Health** 1999;29(2):37–51

[Disorders in sexual function following hysterectomy] Popov I, et al. **Akush Ginekol (Sofiia)** 1998;37(3):38–41 (Eng. Abstr.) **(Bul)**

[Strategies in antibiotic prophylaxis in abdominal hysterectomy] Tsankova M, et al. **Akush Ginekol (Sofiia)** 1998;37(1):25–7 (Eng. Abstr.) **(Bul)**

[Hospitalization and convalescence after hysterectomy. Open or laparoscopic surgery?] Møller C, et al. **Ugeskr Laeger** 1999 Aug 16;161(33):4620–4 (26 ref.) (Eng. Abstr.) **(Dan)**

[Vaginal hysterectomy in fibroma. Apropos of 453 cases. Retrospective comparison with 509 cases of abdominal hysterectomy] el Ghaoui A, et al. **Ann Chir** 1999; 53(3):201–5 (Eng. Abstr.) **(Fre)**

[Malignant melanoma of the uterine cervix. Apropos of a case, with total colpo-hysterectomy and vaginal reconstruction using a rectus abdominis flap] Salle E, et

al. **Ann Chir** 1998;52(1):93–6 **(Fre)**

[Outcome of patients treated with intra-peritoneal immunochemotherapy for ovarian cancer] Zylberberg B, et al. **Contracept Fertil Sex** 1998 Nov;26(11):790–9 (Eng. Abstr.) **(Fre)**

[Surgical hysteroscopy or hysterectomy in the treatment of benign uterine lesions. What to choose in 1998?] Herman P, et al. **Rev Med Liege** 1998 Dec;53(12):756–61 (Eng. Abstr.) **(Fre)**

[Indications and results of abdominal hysterectomies (report of 250 cases)] Terras K, et al. **Tunis Med** 1999 Feb; 77(2):87–94 **(Fre)**

[Preemptive effects caused by co-analgesia with ketamine in gynecological laparotomies?] Heinke W, et al. **Anaesthesiol Reanim** 1999;24(3):60–4 (Eng. Abstr.) **(Ger)**

[Prevention of postoperative nausea and vomiting after hysterectomy with oral dolasetron, intravenous dehydrobenzperidol or a combination of both substances] Triem JG, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):340–4 (Eng. Abstr.) **(Ger)**

[The effects of hormone replacement therapy on ovarian function in premenopausal women after hysterectomy] Kuckatz C, et al. **Zentralbl Gynakol** 1999;121(5):223–7 (Eng. Abstr.) **(Ger)**

[Appropriate duration of postoperative pain relief by continuous epidural infusion in patients receiving hysterectomy or ovarian tumor resection: comparison of three methods] Sawada N, et al. **Masui** 1999 Mar; 48(3):244–50 (Eng. Abstr.) **(Jpn)**

[Local vaginal immunity in patients with uterine myoma before and after hysterectomy] Adamian LV, et al. **Biull Eksp Biol Med** 1998 Oct;126(10):436–40 **(Rus)**

[Radical hysterectomy with pelvic lymphadenectomy in patients with carcinoma of the uterine cervix—3 years' experience] Bošković V, et al. **Srp Arh Celok Lek** 1998 May-Jun;126(5–6):183–7 (Eng. Abstr.) **(Scc)**

[Changes in body weight and the distribution of adipose tissue in hysterectomized postmenopausal patients on estrogen replacement therapy] Carranza Lira S, et al. **Ginecol Obstet Mex** 1999 Jul;67:346–8 (Eng. Abstr.) **(Spa)**

[Gynecologic hysterectomy. Current concepts] Fernández del Castillo C. **Ginecol Obstet Mex** 1999 Aug;67:349–52 **(Spa)**

ADVERSE EFFECTS

Follow-up after repair of vaginal vault prolapse with abdominal colposacropexy. Pilsgaard K, et al. **Acta Obstet Gynecol Scand** 1999 Jan;78(1):66–70

Ovarian vein thrombosis: a common incidental finding in patients who have undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy with retroperitoneal lymph node dissection. Yassa NA, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):45–7

Risk adjustment for complications of hysterectomy: limitations of routinely collected administrative data. Myers ER, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):567–75

Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group. Roy S, et al. **Am J Surg** 1998 Dec;176(6A Suppl):62S–66S

A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery [see comments] Varrassi G, et al. **Anesth Analg** 1999 Mar;88(3):611–6. Comment in: Anesth Analg 1999 Sep;89(3):805.

Comparison of complications of vaginal hysterectomy in patients with leiomyomas and in patients with adenomyosis. Furuhashi M, et al. **Arch Gynecol Obstet** 1998; 262(1–2):69–73

Transvaginal sacrospinous colpopexy for posthysterectomy vault prolapse. Hewson AD. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):318–24

Chronic pain as the main presenting symptom of depression following hysterectomy in old age. Singh S, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):127–30

Is there a hormonal basis to hysterectomy-related depression? Khastgir G, et al. **Br J Obstet Gynaecol** 1999 Jul; 106(7):620–2

Evaluation of perioperative stress after laparoscopic and abdominal hysterectomy in premalignant and malignant disease of the uterine cervix and corpus. Holub Z, et al. **Clin Exp Obstet Gynecol** 1999;26(1):12–5

The risk of breast cancer following reproductive surgery [see comments] Kreiger N, et al. **Eur J Cancer** 1999 Jan; 35(1):97–101. Comment in: Eur J Cancer 1999 Jan;35(1):12–3.

Reproductive surgery, menopause and breast cancer risk [editorial; comment] La Vecchia C. **Eur J Cancer** 1999 Jan;35(1):12–3. Comment on: Eur J Cancer 1999 Jan;35(1):97–101.

Bilateral ureteric obstruction following vaginal hysterectomy: oedema of the bladder can be a rare cause. Timmerhuis OA, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):95–7

Transvaginal evisceration of small bowel after radical hysterectomy and pelvic lymphadenectomy. Dawlatly B, et al. **Gynecol Oncol** 1999 Apr;73(1):165–6 (5 ref.)

The value of intra-operative cystoscopy at the time of laparoscopic hysterectomy. Ribeiro S, et al. **Hum Reprod** 1999 Jul;14(7):1727–9

Early repair of injury to the ureter or bladder after hysterectomy. Kostakopoulos A, et al. **Int Urol Nephrol** 1998;30(4):445–50

One-year cohort of abdominal, vaginal, and laparoscopic hysterectomies: complications and subjective outcomes. Meltomaa SS, et al. **J Am Coll Surg** 1999 Oct;189(4):389–96

Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. Thom DH, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1411–7 (98 ref.)

Timing of hysterectomy surgery during the menstrual cycle--impact of menstrual cycle phase on rate of complications: preliminary study [published erratum appears in J Am Osteopath Assoc 1999 Mar;99(3):176] Baron DA, et al. **J Am Osteopath Assoc** 1999 Jan;99(1):25–7

Symptomatic cervical macrocyst as a late complication of subtotal hysterectomy. A case report. Pelosi MA 3rd, et al. **J Reprod Med** 1999 Jun;44(6):567–70

Testosterone deficiency: a key factor in the increased cardiovascular risk to women following hysterectomy or with natural aging? Rako S. **J Womens Health** 1998 Sep; 7(7):825–9

Hysterectomy, ovarian failure and depression [letter; comment] Carranza-Lira S. **Menopause** 1999 Summer; 6(2):180–1. Comment on: Menopause 1998 Summer;5(2):113–22.

[The bikini incision: nice, but not without painful complications (see comments)] Huikeshoven FJ, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1481–3 (11 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 3;142(40):2218. **(Dut)**

ECONOMICS

Long-term economic evaluation of resectoscopic endometrial ablation versus hysterectomy for the treatment of menorrhagia. Hidlebaugh DA, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):351–6

Laparoscopic supracervical hysterectomy vs. abdominal hysterectomy in a community hospital. A cost comparison. Simon NV, et al. **J Reprod Med** 1999 Apr;44(4):339–45

Supracervical and total abdominal hysterectomy trends in New York State: 1990–1996. Sills ES, et al. **J Urban Health** 1998 Dec;75(4):903–10

Costs of hysterectomy: does surgical approach make a difference? Cohen MM, et al. **J Womens Health** 1998 Sep; 7(7):885–92

HISTORY

An historical perspective of natural and surgical menopause. Utian WH. **Menopause** 1999 Summer;6(2):83–6 (26 ref.)

[100 years of the Wertheim operation--Ernst Wertheim between myth and reality] Köhler G. **Zentralbl Gynakol** 1999;121(3):121–5 (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Radical hysterectomy with the endoscopic stapler. Brewer CA, et al. **Gynecol Oncol** 1998 Oct;71(1):50–2

METHODS

Pain and pulmonary function following laparoscopic and abdominal hysterectomy: a randomized study. Ellström M, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):923–8

New retroperitoneal culdoplasty and colpopexy at the time of laparoscopic total abdominal hysterectomy (L-TAH). Ostrzenski A. **Acta Obstet Gynecol Scand** 1998 Nov; 77(10):1017–21

Bloodless surgery: establishment of a program for the special medical needs of the Jehovah's witness community--the gynecologic surgery experience at a community hospital. deCastro RM. **Am J Obstet Gynecol** 1999 Jun;180(6 Pt 1):1491–8

Laparoscopic lymphadenectomy and vaginal or laparoscopic hysterectomy with bilateral salpingo-oophorectomy for endometrial cancer: morbidity and survival. Magrina JF, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):376–81

Wertheim's hysterectomy after neoadjuvant carboplatin-based chemotherapy in patients with cervical cancer stage IIB and IIIB. Meden H, et al. **Anticancer Res** 1998 Nov-Dec;18(6B):4575–9

Hysterectomy and myomectomy by laparotomy. West CP. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):317–35 (41 ref.)

Recurrent pain after hysterectomy and bilateral salpingo-oophorectomy for endometriosis: evaluation of laparoscopic excision of residual endometriosis. Clayton RD, et al. **Br J Obstet Gynaecol** 1999 Jul;106(7):740–4

A leiomyomatous perineal hernia? Jermy KV, et al. **Br J Obstet Gynaecol** 1999 May;106(5):507–8

Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomised controlled trial. Vercellini P, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1148–54

Hysterectomy: indications, surgical routes, cases for adnexal or cervical conservation. Cosson M, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Sep;80(1):5–15 (60 ref.)

Modified radical hysterectomy for early Ib cervical cancer. Yang YC, et al. **Gynecol Oncol** 1999 Aug;74(2):241–4

Laparoscopic hemi-hysterectomy in treatment of a didelphic uterus with a hypoplastic cervix and obstructed hemivagina. Lee CL, et al. **Hum Reprod** 1999 Jul; 14(7):1741–3

The value of intra-operative cystoscopy at the time of laparoscopic hysterectomy. Ribeiro S, et al. **Hum Reprod** 1999 Jul;14(7):1727–9

Prospective randomized comparison between an open and closed vaginal cuff in abdominal hysterectomy. Aharoni A, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):29–32

Laparoscopic radical hysterectomy with pelvic lymphadenectomy for early, invasive cervical carcinoma. Kim DH, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov; 5(4):411–7

Hand-assisted laparoscopy for complex hysterectomy. Pelosi MA, et al. **J Am Assoc Gynecol Laparosc** 1999 May; 6(2):183–8

Minilaparoscopic hysterectomy. Wattiez A, et al. **J Am Assoc Gynecol Laparosc** 1999 Feb;6(1):97–100

Timing of hysterectomy surgery during the menstrual cycle--impact of menstrual cycle phase on rate of complications: preliminary study [published erratum appears in J Am Osteopath Assoc 1999 Mar;99(3):176] Baron DA, et al. **J Am Osteopath Assoc** 1999 Jan;99(1):25–7

Rational type of laparoscopic hysterectomy and safety in anesthetic profiles. Song J, et al. **J Obstet Gynaecol Res** 1999 Feb;25(1):55–61

Alternatives to total abdominal hysterectomy. Carter JE. **J Soc Laparoendosc Surg** 1997 Jul-Sep;1(3):259–62 (8 ref.)

Laparoscopic hysterectomy with automatic stapling devices. Kumar KM, et al. **J Soc Laparoendosc Surg** 1997 Jan-Mar; 1(1):65–9

Problems related to the cervical stump at follow-up in laparoscopic supracervical hysterectomy. van der Stege JG, et al. **JSLS** 1999 Jan-Mar;3(1):5–7

A multicenter randomized comparison of laparoscopically assisted vaginal hysterectomy and abdominal hysterectomy in abdominal hysterectomy candidates [letter; comment] Patsner B. **Obstet Gynecol** 1999 Jan;93(1):160; discussion 161. Comment on: Obstet Gynecol 1998 Sep;92(3):321–6.

A multicenter randomized comparison of laparoscopically assisted vaginal hysterectomy and abdominal hysterectomy in abdominal hysterectomy candidates [letter; comment] Spellacy WN. **Obstet Gynecol** 1999 Jan;93(1):160–1. Comment on: Obstet Gynecol 1998 Sep;92(3):321–6.

Laparoscopic hysterectomy. Hawe JA, et al. **Semin Laparosc Surg** 1999 Jun;6(2):80–9 (45 ref.)

Abdominal, laparoscopic, and vaginal hysterectomy with bilateral salpingo-oophorectomy: a feasibility study for further evaluation in randomized trials. Nwosu CR, et al. **Surg Endosc** 1999 Feb;13(2):148–50

Surgical procedure for specific pathogen free piglet production by modified terminal hysterectomy. Muñoz A, et al. **Transplant Proc** 1999 Sep;31(6):2627–9

Ultrasonography of the ureter during laparoscopic, abdominal and radical hysterectomy. Helin HL, et al. **Ultrasound Obstet Gynecol** 1998 Sep;12(3):207–10

[Results of laparoscopic assisted vaginal hysterectomy in the Ikazia Hospital at Rotterdam, 1993–1997 (letter; comment)] Brölmann HA, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31; 142(44):2431–2. Comment on: Ned Tijdschr Geneeskd 1998 Aug 15;142(33):1873–6. **(Dut)**

[Hysterectomies for benign pathology: is there a place for laparoscopic surgery?] Anquetil C, et al. **Contracept Fertil Sex** 1999 Apr;27(4):291–7 (Eng. Abstr.) **(Fre)**

[Is vaginal hysterectomy important for large uterus of more than 500 g? Comparison with laparotomy] Switala I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct; 27(6):585–92 (Eng. Abstr.) **(Fre)**

[Laparoscopic Galvin-TeLinde hysterectomy for treatment of a microinvasive cervical carcinoma] Skręt A, et al. **Zentralbl Gynakol** 1999;121(5):250–4 (Eng. Abstr.) **(Ger)**

[Obstetric hysterectomy] Powolny M, et al. **Ginekol Pol** 1998 Sep;69(9):693–7 (Eng. Abstr.) **(Pol)**

[The modern approach to hysterectomy] Stanojević D, et al. **Srp Arh Celok Lek** 1998 Mar-Apr;126(3–4):148–50 (Eng. Abstr.) **(Scc)**

[Vaginally assisted laparoscopic hysterectomy vs. abdominal hysterectomy. Initial experience] Gayón-Vera E, et al. **Ginecol Obstet Mex** 1999 Apr;67:164–8 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Chronic pain as the main presenting symptom of depression following hysterectomy in old age. Singh S, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):127–30

The effect of gynecological surgery on sexual desire. Galyer KT, et al. **J Sex Marital Ther** 1999 Apr-Jun;25(2):81–8

Lack of influence of hysterectomy on meal size and meal number in Fischer-344 rats. Varma M, et al. **Physiol Behav** 1999 Jun;66(4):559–65

REHABILITATION

Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. Stead ML, et al. **Br J Obstet Gynaecol** 1999 Jan;106(1):50–4

STANDARDS

Swiss consensus guidelines for hysterectomy. Swiss Society of Gynecology and Obstetrics, Switzerland. Schilling J,

et al. **Int J Gynaecol Obstet** 1999 Mar;64(3):297–305

Outcomes in abdominal hysterectomy patients with benign disease. Use of physician–developed clinical protocols. D'Amato LO Jr, et al. **J Reprod Med** 1998 Nov; 43(11):975–85

STATISTICS & NUMERICAL DATA

Predictors of hysterectomy: an Australian study. Treloar SA, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):945–54

Risk of hysterectomy after 1000 consecutive endometrial laser ablations. Phillips G, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):897–903

High frequency of hysterectomies and appendectomies in fibromyalgia compared with rheumatoid arthritis: a pilot study. ter Borg EJ, et al. **Clin Rheumatol** 1999;18(1):1–3

Emergency peripartum hysterectomy at the Princess Badeea Teaching Hospital in north Jordan. Abu–Heija AT, et al. **J Obstet Gynaecol Res** 1999 Jun;25(3):193–5

Hysterectomy in Rhode Island. Verma A, et al. **Med Health R I** 1999 Apr;82(4):127–30

[Hypertension and hysterectomy in Danish women] Settnes A, et al. **Ugeskr Laeger** 1999 Jun 21;161(25):3845–9 (Eng. Abstr.) **(Dan)**

[Hysterectomies for benign pathology: is there a place for laparoscopic surgery?] Anquetil C, et al. **Contracept Fertil Sex** 1999 Apr;27(4):291–7 (Eng. Abstr.) **(Fre)**

TRENDS

Supracervical hysterectomy: back to the future? Jones DED, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):513–5 (2 ref.)

Hysterectomy fractions in New South Wales, 1971–2006. Taylor R, et al. **Aust N Z J Public Health** 1998 Dec; 22(7):759–64

UTILIZATION

Abdominal hysterectomy practice patterns in the United States. Sills ES, et al. **Int J Gynaecol Obstet** 1998 Dec; 63(3):277–83

Supracervical and total abdominal hysterectomy trends in New York State: 1990–1996. Sills ES, et al. **J Urban Health** 1998 Dec;75(4):903–10

[Hysterectomy for a benign lesion: can the vaginal route be used in all cases?] Martin X, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May; 28(2):124–30 (Eng. Abstr.) **(Fre)**

[Is hysterectomy rate too high? Rates falling—new drug and surgical alternatives?] Strobel E. **Fortschr Med** 1998 Aug 30;116(24):34–6 **(Ger)**

VETERINARY

Changes in cortisol concentration in response to stress and postoperative pain in client–owned cats and correlation with objective clinical variables. Smith JD, et al. **Am J Vet Res** 1999 Apr;60(4):432–6

In favor of pediatric neutering [letter; comment] Phillips I. **Can Vet J** 1998 Jul;39(7):397. Comment on: Can Vet J 1998 Apr;39(4):242–3.

An ethicist's commentary on the case of the pregnant dog brought in for a spay and found to be pregnant. Rollin BE. **Can Vet J** 1998 Jul;39(7):399

Partial colonic obstruction following ovariohysterectomy: a report of three cases. Coolman BR, et al. **J Am Anim Hosp Assoc** 1999 Mar–Apr;35(2):169–72

Animal behavior case of the month. Aggression that began 4 days after ovariohysterectomy. Misner TL, et al. **J Am Vet Med Assoc** 1998 Nov 1;213(9):1260–2

Changes in plasma cortisol concentrations in bitches in response to different combinations of halothane and butorphanol, with or without ovariohysterectomy. Fox SM, et al. **Res Vet Sci** 1998 Sep–Oct;65(2):125–33

Comparison of transdermal fentanyl and intramuscular oxymorphone on post–operative behaviour after ovariohysterectomy in dogs. Kyles AE, et al. **Res Vet Sci** 1998 Nov–Dec;65(3):245–51

Neutering pet rabbits [letter; comment] [see comments] Lester–Cockx L. **Vet Rec** 1999 Mar 6;144(10):271. Comment on: Vet Rec 1999 Feb 20;144(8):216. Comment in: Vet Rec 1999 Mar 20;144(12):328.

Neutering pet rabbits [letter; comment] Meredith A, et al. **Vet Rec** 1999 Mar 20;144(12):328. Comment on: Vet Rec 1999 Feb 20;144(8):216. Comment on: Vet Rec 1999 Mar 6;144(10):271.

Comparison of pethidine, buprenorphine and ketoprofen for postoperative analgesia after ovariohysterectomy in the cat. Slingsby LS, et al. **Vet Rec** 1998 Aug 15;143(7):185–9

Efficacy and kinetics of carprofen, administered preoperatively or postoperatively, for the prevention of pain in dogs undergoing ovariohysterectomy. Lascelles BD, et al. **Vet Surg** 1998 Nov–Dec;27(6):568–82

HYSTERECTOMY, VAGINAL

The effect of the learning curve on the duration and peri–operative complications of laparoscopically assisted vaginal hysterectomy. Ikhena SE, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):632–5

Comparison of ureteral and cervical descents during vaginal hysterectomy for uterine prolapse. DeLancey JO, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1405–8; discussion 1409–10

A trial of vaginal route for hysterectomy [letter] Sheth SS. **Am J Obstet Gynecol** 1999 Jul;181(1):227–8

Vaginal hysterectomy in women with history of previous cesarean delivery. Unger JB, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1473–8

Uterovaginal prolapse associated with rectal prolapse. Kriplani A, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug; 38(3):325–6

Brachytherapy and vaginal hysterectomy for low–stage uterine cervix carcinoma. Cravello L, et al. **Gynecol Oncol** 1999 Jan;72(1):102–6 (43 ref.)

Laparoscopic loop ligatures for bladder repair during laparoscopic surgery. Yin CS, et al. **Int J Gynaecol Obstet** 1999 Jul;66(1):47–9

Vaginal hysterectomy for correcting genital prolapse. Long–term evaluation. Marana HR, et al. **J Reprod Med** 1999 Jun;44(6):529–34

The Gupta–Frank clamp for salpingo–oophorectomy at vaginal hysterectomy [letter; comment] Currie JL. **Obstet Gynecol** 1998 Dec;92(6):1058. Comment on: Obstet Gynecol 1998 Jul;92(1):144–7.

Laparoscopically assisted vaginal hysterectomy. Shwayder JM. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):169–87 (76 ref.)

How can laparoscopic management assist radiation treatment in cervix carcinoma? Gerbaulet A, et al. **Radiother Oncol** 1999 Apr;51(1):9–13

[Rational laparoscopic intervention in laparoscopically–assisted vaginal hysterectomy (LAVH): prospective study] Kužel D, et al. **Ceska Gynekol** 1999 Apr; 64(2):96–9 (Eng. Abstr.) **(Cze)**

[Hospitalization and convalescence after hysterectomy. Open or laparoscopic surgery?] Møller C, et al. **Ugeskr Laeger** 1999 Aug 16;161(33):4620–4 (26 ref.) (Eng. Abstr.) **(Dan)**

[Laparoscopy–assisted hysterectomy and laparoscopic preparation. Apropos of a series of 177 cases] Darai E, et al. **Ann Chir** 1998;52(1):29–35 (Eng. Abstr.) **(Fre)**

[Vaginal hysterectomy in fibroma. Apropos of 453 cases. Retrospective comparison with 509 cases of abdominal hysterectomy] el Ghaoui A, et al. **Ann Chir** 1999; 53(3):201–5 (Eng. Abstr.) **(Fre)**

[Vaginal hysterectomy for non–prolapse uterus] Blanc B, et al. **Bull Acad Natl Med** 1999;183(1):107–15 (Eng. Abstr.) **(Fre)**

[Total vaginal hysterectomy for genital prolapse apropos of 10 cases] Dia A, et al. **Dakar Med** 1998;43(1):118–21 (Eng. Abstr.) **(Fre)**

[Is vaginal hysterectomy important for large uterus of more than 500 g? Comparison with laparotomy] Switala I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct; 27(6):585–92 (Eng. Abstr.) **(Fre)**

[Bologna procedure in stress urinary incontinence with stage III cystocele (with or without vaginal hysterectomy)] el Khader K, et al. **Prog Urol** 1999 Feb;9(1):81–7 (Eng. Abstr.) **(Fre)**

[Prolapse of the small intestine through a surgically closed introitus vaginae after vaginal hysterectomy followed by subsequent colpectomy] Meierhöfer J, et al. **Zentralbl Gynakol** 1998;120(9):468–70 (Eng. Abstr.) **(Ger)**

[Vaginally assisted laparoscopic hysterectomy vs. abdominal hysterectomy. Initial experience] Gayón–Vera E, et al. **Ginecol Obstet Mex** 1999 Apr;67:164–8 (Eng. Abstr.) **(Spa)**

[Colposuspension of the sacrospinal ligament] Neri Ruz ES, et al. **Ginecol Obstet Mex** 1998 Oct;66:407–10 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

A multi–center study of intrathecal neostigmine for analgesia following vaginal hysterectomy. Lauretti GR, et al. **Anesthesiology** 1998 Oct;89(4):913–8

Re: Bleeding associated with vaginal hysterectomy [letter; comment] Hill B. **Aust N Z J Obstet Gynaecol** 1998 Aug; 38(3):356–7. Comment on: Aust N Z J Obstet Gynaecol 1997 Nov;37(4):457–61.

Re: Bleeding associated with vaginal hysterectomy [letter; comment] Seman E. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):359. Comment on: Aust N Z J Obstet Gynaecol 1997 Nov;37(4):457–61.

Ultrasound detection of vault haematoma following vaginal hysterectomy [letter; comment] Tincello DG. **Br J Obstet Gynaecol** 1998 Dec;105(12):1336–7. Comment on: Br J Obstet Gynaecol 1998 Feb;105(2):211–5.

One–year cohort of abdominal, vaginal, and laparoscopic hysterectomies: complications and subjective outcomes. Meltomaa SS, et al. **J Am Coll Surg** 1999 Oct;189(4):389–96

Small bowel obstruction secondary to stapled laparoscopically assisted vaginal hysterectomy. Huntington TR, et al. **Surg Endosc** 1999 Mar;13(3):246–9

ECONOMICS

Laparoscopic–assisted vaginal hysterectomy superfluous? [letter; comment] [see comments] Dippenaar J. **S Afr Med J** 1998 Dec;88(12):1534. Comment on: S Afr Med J 1998 Jun;88(6):733. Comment in: S Afr Med J 1999 Apr;89(4):362, 364–5.

Laparoscopic–assisted vaginal hysterectomy superfluous? [letter; comment] Rösemann GW. **S Afr Med J** 1999 Apr; 89(4):362, 364–5. Comment on: S Afr Med J 1998 Dec;88(12):1534.

[Evaluation of direct hospital and extra–hospital cost of operative hysteroscopy and vaginal hysterectomy] Cravello L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul; 28(4):335–42 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

New techniques using the ultrasonic scalpel in laparoscopic hysterectomy. Kauko M. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):303–5

METHODS

Randomized comparison of three surgical methods used at the time of vaginal hysterectomy to prevent posterior enterocele. Cruikshank SH, et al. **Am J Obstet Gynecol** 1999 Apr;180(4):859–65

Laparoscopically assisted vaginal hysterectomy versus total abdominal hysterectomy: a prospective, randomized, multicenter study. Marana R, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):270–5

Laparoscopic–assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges [see comments] Gemignani ML, et al. **Gynecol Oncol** 1999 Apr; 73(1):5–11. Comment in: Gynecol Oncol 1999 Apr;73(1):1–3.

Vaginal removal of the benign nonprolapsed uterus: experience with 300 consecutive operations. Figueiredo O, et al. **Obstet Gynecol** 1999 Sep;94(3):348–51

Abdominal, laparoscopic, and vaginal hysterectomy with bilateral salpingo–oophorectomy: a feasibility study for further evaluation in randomized trials. Nwosu CR, et al. **Surg Endosc** 1999 Feb;13(2):148–50

[Results of laparoscopically assisted vaginal hysterectomies in the Ikazia Ziekenhuis, Rotterdam, 1993–1997 (letter; comment)] De Blok S. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):174–5. Comment on: Ned Tijdschr Geneeskd 1998 Aug 15;142(33):1873–6. **(Dut)**

[Results of laparoscopic assisted vaginal hysterectomy in Ikazia Hospital at Rotterdam, 1993–1997 (letter)] Molendijk LW, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2432 **(Dut)**

[Results from laparoscopically assisted vaginal hysterectomy in the Ikazia Hospital, Rotterdam, 1993–1997 (see comments)] Prinsen AK, et al. **Ned Tijdschr Geneeskd** 1998 Aug 15;142(33):1873–6 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2431–2. **(Dut)**

UTILIZATION

How to increase the proportion of hysterectomies performed vaginally. Davies A, et al. **Am J Obstet Gynecol** 1998 Oct; 179(4):1008–12

How to increase the proportion of vaginal hysterectomies–bipolar coagulation [letter] Weyl BP. **Am J Obstet Gynecol** 1999 Sep;181(3):768

[Hysterectomy for a benign lesion: can the vaginal route be used in all cases?] Martin X, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 May; 28(2):124–30 (Eng. Abstr.) **(Fre)**

HYSTERIA

Coke adds life, but cannot always explain it [editorial] **Lancet** 1999 Jul 17;354(9174):173

COMPLICATIONS

Patterns of hysterical hemianopia. Keane JR. **Neurology** 1998 Oct;51(4):1230–1

DIAGNOSIS

Hysteria—a chameleon or a fossil? Bhatia MS, et al. **Indian J Med Sci** 1998 Jun;52(6):227–30 (24 ref.)

[Pseudohysteria in patients with melancholia] Krauz A. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(2):51–6 (78 ref.) **(Rus)**

HISTORY

Hysteria, hypnosis, and moral sense in French 19th–century forensic psychiatry. The Eyraud–Bompard case. Plas R. **Int J Law Psychiatry** 1998 Fall;21(4):397–407

Surgical therapy as treatment for hysteria in Italy: 1880–1889. Vanni D, et al. **Ital J Anat Embryol** 1998 Oct–Dec; 103(4):177–82

Freud and castration: a new look into the origins of psychoanalysis. Bonomi C. **J Am Acad Psychoanal** 1998 Spring;26(1):29–49

PSYCHOLOGY

Getting in on the act: the hysterical solution. Britton R. **Int J Psychoanal** 1999 Feb;80 (Pt 1):1–14

[Clinical aspects of hysteria at the psychiatric clinic of the Fann University Hospital Center. Apropos of a prospective study of 121 cases] Thiam MH, et al. **Dakar Med** 1998; 43(1):41–4 (11 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical therapy as treatment for hysteria in Italy: 1880–1889. Vanni D, et al. **Ital J Anat Embryol** 1998 Oct–Dec;

HYSTERIA

103(4):177–82

THERAPY

Getting in on the act: the hysterical solution. Britton R. **Int J Psychoanal** 1999 Feb;80 (Pt 1):1–14

Acupuncture treatment of hysteric aphonia--a report of 27 cases. Shen X. **J Tradit Chin Med** 1998 Dec;18(4):253–5

HYSTERIA, CONVERSION see **CONVERSION DISORDER**

HYSTERIA, DISSOCIATIVE see **DISSOCIATIVE DISORDERS**

HYSTERICAL PERSONALITY see **HISTRIONIC PERSONALITY DISORDER**

HYSTEROSALPINGOGRAPHY

Diagnostic quality in hysterosalpingography. Comparison between iodixanol and iotrolan. Lindequist S, et al. **Acta Radiol** 1998 Nov;39(6):730–3

Complex uterine surgery: a cooperative role for interventional radiology with hysteroscopic surgery. Sanders BH, et al. **Fertil Steril** 1998 Nov;70(5):952–5

Comparison of hysterosalpingography and laparoscopy in predicting fertility outcome. Mol BW, et al. **Hum Reprod** 1999 May;14(5):1237–42

Tubal catheterization and selective salpingography. Gazzera C, et al. **Rays** 1998 Oct–Dec;23(4):735–41

Radiologic imaging of the fallopian tubes. Valentini AL, et al. **Rays** 1998 Oct–Dec;23(4):662–72 **(Eng, Ita)**

[Selective salpingography in the treatment of infertility caused by proximal tubal obstruction: apropos of 122 cases treated in Dakar] Ba SD, et al. **Sante** 1999 Mar–Apr; 9(2):81–4 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Dynamic studies of fallopian tube physiology in human infertility--state of the art [letter; comment] van der Weiden RM, et al. **Fertil Steril** 1998 Oct;70(4):786–7. Comment on: Fertil Steril 1998 Feb;69(2):216–20.

INSTRUMENTATION

[A fluoroscopy-controlled transcervical fallopian tube recanalization] Schmitz-Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):229–31 **(Ger)**

METHODS

Vaginal sonosalpingography in the evaluation of tubal patency. Inki P, et al. **Acta Obstet Gynecol Scand** 1998 Nov;77(10):978–82

Radiologic usefulness of hysterosalpingography after bladder filling. Bae JI, et al. **AJR Am J Roentgenol** 1999 Mar; 172(3):765–6

Patient dosimetry in hysterosalpingography: a comparative study. Gregan AC, et al. **Br J Radiol** 1998 Oct; 71(850):1058–61

Patterns of uterine enhancement with helical CT. Kaur H, et al. **Eur J Radiol** 1998 Oct;28(3):250–5

HYSTEROSCOPY

see related
HYSTEROSALPINGOGRAPHY

Transvaginal sonohysterography and hysteroscopy in the evaluation of female infertility, habitual abortion or metrorrhagia. A comparative study. Grønlund L, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):415–8

Hysteroscopy and gas embolism [letter] Gorton P. **Anaesth Intensive Care** 1999 Jun;27(3):319

Paracervical anaesthesia in outpatient hysteroscopy: a randomised double-blind placebo-controlled trial. Lau WC, et al. **Br J Obstet Gynaecol** 1999 Apr;106(4):356–9

Vaginoscopy using hysteroscope for diagnosis of vaginal bleeding during childhood: case report. Shui LT, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):344–7

Office hysteroscopy. Valle RF. **Clin Obstet Gynecol** 1999 Jun;42(2):276–89 (20 ref.)

Hysteroscopic cervical canal shaving: a new therapy for cervical stenosis before embryo transfer in patients undergoing in vitro fertilization. Noyes N. **Fertil Steril** 1999 May;71(5):965–6

Complex uterine surgery: a cooperative role for interventional radiology with hysteroscopic surgery. Sanders BH, et al. **Fertil Steril** 1998 Nov;70(5):952–5

Patient's acceptance of outpatient hysteroscopy. Lau WC, et al. **Gynecol Obstet Invest** 1999;47(3):191–3

Experience with isotonic 2.2% glycine as distension medium for hysteroscopic endomyometrial resection. Tapper AM, et al. **Gynecol Obstet Invest** 1999;47(4):263–7

Does hysteroscopy improve upon the sensitivity of dilation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? [letter; comment] Loffer FD. **Gynecol Oncol** 1999 Apr;73(1):171. Comment on: Gynecol Oncol 1998 Jan;68(1):4–7.

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Mourits MJ, et al. **Gynecol Oncol** 1999 Apr;73(1):21–6

Total corporal synechiae due to tuberculosis carry a very poor prognosis following hysteroscopic synechialysis. Bukulmez O, et al. **Hum Reprod** 1999 Aug;14(8):1960–1

Hysteroscopic treatment of severe Asherman's syndrome and subsequent fertility. Capella-Allouc S, et al. **Hum Reprod** 1999 May;14(5):1230–3

Routine use of saline hysterosonography in 500 consecutive, unselected, infertile women. Hamilton JA, et al. **Hum Reprod** 1998 Sep;13(9):2463–73

Falloposcopy in conjunction with laparoscopy: possibilities and limitations. Lundberg S, et al. **Hum Reprod** 1998 Jun; 13(6):1490–2

Efficacy of preoperative medical treatment in facilitating hysteroscopic endometrial resection, myomectomy and metroplasty: literature review. Parazzini F, et al. **Hum Reprod** 1998 Sep;13(9):2592–7 (22 ref.)

Should hysteroscopy be a part of the basic infertility workup? Shushan A, et al. **Hum Reprod** 1999 Aug;14(8):1923–4

Value of postoperative treatment after cutting of a broad base intrauterine septum. Assaf A. **Int J Gynaecol Obstet** 1999 Mar;64(3):315–6

Management of septate uterus by flexible hysteroscopy and Nd:YAG laser. Jourdain O, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):159–62

Hysteroscopic endometrial ablation without endometrial preparation. Yin CS, et al. **Int J Gynaecol Obstet** 1998 Aug; 62(2):167–72

Comparison of ultrasonography and hysteroscopy in the diagnosis of intrauterine lesions in infertile women. Fabres C, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):375–8

Operative hysteroscopy in physiologic distention media. Isaacson KB, et al. **J Am Assoc Gynecol Laparosc** 1999 Feb;6(1):113–8

Outpatient diagnostic hysteroscopy. Valli E, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):397–402

Adenomyosis: diagnosis by hysteroscopic endomyometrial biopsy, correlation of incidence and severity with menorrhagia. Goswami A, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):281–4

A prospective randomized study comparing hysteroscopy and curettage (H & C) under local anaesthesia (LA) and general anaesthesia (GA) in Chinese population. Kun KY, et al. **J Obstet Gynaecol Res** 1999 Apr;25(2):119–27

Paracervical anesthesia for hysteroscopy and endometrial biopsy in postmenopausal women. A randomized, double-blind, placebo-controlled study. Cicinelli E, et al. **J Reprod Med** 1998 Dec;43(12):1014–8

Successful treatment of advanced interstitial pregnancy with methotrexate and hysteroscopy. A case report. Groutz A, et al. **J Reprod Med** 1998 Aug;43(8):719–22

Comparison of office hysteroscopy, transvaginal ultrasonography and endometrial biopsy in evaluation of abnormal uterine bleeding [published erratum appears in J Soc Laparoendosc Surg 1997 Oct–Dec;1(4):395] Pal L, et al. **J Soc Laparoendosc Surg** 1997 Apr–Jun;1(2):125–30

Hysteroscopic resection of cervical nerve sheath tumor. Goldfarb RS, et al. **JSLS** 1999 Apr–Jun;3(2):145–7

Implementation of an outpatient hysteroscopy clinic at Waikato Women's Hospital report of the first 60 cases. Roman JD, et al. **N Z Med J** 1999 Jul 9;112(1091):253–5

Uterine fluid irrigation and absorption in hysteroscopic endometrial ablation. Baskett TF, et al. **Obstet Gynecol** 1998 Dec;92(6):976–8

A randomized controlled trial of vaginal misoprostol for cervical priming before hysteroscopy. Preutthipan S, et al. **Obstet Gynecol** 1999 Sep;94(3):427–30

Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Varasteh NN, et al. **Obstet Gynecol** 1999 Aug;94(2):168–71

Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Vercellini P, et al. **Obstet Gynecol** 1999 Sep;94(3):341–7

Hysteroscopy in the management of abnormal uterine bleeding. Cooper JM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):217–36 (65 ref.)

Ultrasound guidance during endoscopic procedures. Letterie GS. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):63–82 (48 ref.)

Laparoscopy and hysteroscopy. Schenk LM, et al. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):1–22, v (61 ref.)

Endoscopic myomectomy. Laparoscopy and hysteroscopy. Tulandi T, et al. **Obstet Gynecol Clin North Am** 1999 Mar; 26(1):135–48, viii (65 ref.)

Endoscopy of the uterus and its congenital malformations. Cinque B, et al. **Rays** 1998 Oct–Dec;23(4):617–24 **(Eng, Ita)**

Hysteroscopic diagnosis of uterine intracavitary disorders. Gaglione R, et al. **Rays** 1998 Oct–Dec;23(4):655–61 **(Eng, Ita)**

[Hysteroscopy--a high standard or standard examination method? (Analysis of 690 diagnostic hysteroscopies)] Kovář P. **Ceska Gynekol** 1998 Oct;63(5):418–22 **(Cze)**

[Contribution of hysteroscopic surgery for the treatment of postmenopausal metrorrhagia] Cravello L, et al. **Presse Med** 1998 Sep 5;27(25):1267–71 (Eng. Abstr.) **(Fre)**

[Role of diagnostic hysteroscopy in the exploration of postmenopausal metrorrhagia] Roger V, et al. **Presse Med** 1998 Sep 5;27(25):1294–5 (6 ref.) (Eng. Abstr.) **(Fre)**

[Surgical hysteroscopy or hysterectomy in the treatment of benign uterine lesions. What to choose in 1998?] Herman P, et al. **Rev Med Liege** 1998 Dec;53(12):756–61 (Eng. Abstr.) **(Fre)**

[Total hysteroscopic endometrium resection: a critical analysis of indications, technique and results] Burmucic R, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):119–30 (Eng. Abstr.) **(Ger)**

[Ambulatory hysteroscopy in evaluation of postmenopausal bleeding] Wieser F, et al. **Wien Klin Wochenschr** 1999 Apr 9;111(7):289–93 (Eng. Abstr.) **(Ger)**

[Hysteroscopic diagnosis and treatment of endometrial polyps] Bacskó G, et al. **Orv Hetil** 1999 Sep 12; 140(37):2041–5 (Eng. Abstr.) **(Hun)**

[A hysteroscopic and anatomicopathological study in women with breast cancer] Gonçalves MA, et al. **Minerva Ginecol** 1998 Sep;50(9):341–6 (Eng. Abstr.) **(Ita)**

[Osseous metaplasia of the endometrium as a cause of infertility. Hysteroscopic approach] García León F, et al. **Ginecol Obstet Mex** 1999 Jan;67:37–41 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Carbon dioxide embolism following diagnostic hysteroscopy. Sherlock S, et al. **Anaesth Intensive Care** 1998 Dec; 26(6):674–6

Management of hysteroscopic surgery complications. Morrison DM. **AORN J** 1999 Jan;69(1):194–7, 199–209; quiz 210, 213–5, 21 (35 ref.)

Gas embolism during hysteroscopy. Nishiyama T, et al. **Can J Anaesth** 1999 Apr;46(4):379–81

Relief of pain and/or spasm during diagnostic hysteroscopy? [letter; comment] Stefanidis K. **Fertil Steril** 1999 Apr; 71(4):776. Comment on: Fertil Steril 1998 Aug;70(2):378–80.

Hysteroscopic dissemination of endometrial carcinoma. Rose PG, et al. **Gynecol Oncol** 1998 Oct;71(1):145–6

Embolic vascular seeding of endometrial adenocarcinoma, a complication of hysteroscopic endometrial biopsy. Workman RD, et al. **Gynecol Oncol** 1999 Feb;72(2):261–4

Preventing hyponatremic encephalopathy [letter] Brooks PG. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):446–8

Vision disturbances after operative hysteroscopy. Motashaw ND, et al. **J Am Assoc Gynecol Laparosc** 1999 May; 6(2):213–5

Uterine rupture after hysteroscopic metroplasty and labor induction. A case report. Gabriele A, et al. **J Reprod Med** 1999 Jul;44(7):642–4

Complications of hysteroscopy. Isaacson KB. **Obstet Gynecol Clin North Am** 1999 Mar;26(1):39–51

[Mechanical and metabolic complications of hysteroscopic surgery: report of a retrospective study of 352 procedures] Castaing N, et al. **Contracept Fertil Sex** 1999 Mar; 27(3):210–5 (Eng. Abstr.) **(Fre)**

ECONOMICS

Long-term economic evaluation of resectoscopic endometrial ablation versus hysterectomy for the treatment of menorrhagia. Hidlebaugh DA, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):351–6

[Evaluation of direct hospital and extra-hospital cost of operative hysteroscopy and vaginal hysterectomy] Cravello L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul; 28(4):335–42 (Eng. Abstr.) **(Fre)**

HISTORY

The early history of hysteroscopy. Siegle AM. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):329–32

INSTRUMENTATION

Evaluation of a disinfection procedure for hysteroscopes contaminated by hepatitis C virus. Sartor C, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):434–6

Hysteroscopic cervical polypectomy with a polyp snare. Goudas VT, et al. **J Am Assoc Gynecol Laparosc** 1999 May; 6(2):195–7

Initial experience with a physiologic morcellating resectoscope. Kresch AJ, et al. **J Am Assoc Gynecol Laparosc** 1998 Nov;5(4):419–21

Use of rigid hysteroscope for extraction of foreign bodies embedded in lower urinary tract. Szlyk GR, et al. **J Endourol** 1999 Feb;13(1):47–8

[The disinfection of non-autoclavable hysteroscopes in gynecology. Proposition of a protocol and organization of its management] Cravello L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul;28(4):381–3 (Eng. Abstr.) **(Fre)**

[Therapy of recurrent menorrhagia--Cavaterm balloon coagulation versus roller-ball endometrium coagulation--a prospective randomized comparative study] Römer T. **Zentralbl Gynakol** 1998;120(10):511–4 (Eng. Abstr.) **(Ger)**

METHODS

Hysteroscopic metroplasty in diethylstilboestrol-exposed and hypoplastic uterus: a report on 24 cases. Garbin O, et al. **Hum Reprod** 1998 Oct;13(10):2751–5

Precise measurements of intrauterine vascular structures at

hysteroscopy in menorrhagia and during Norplant use. Hickey M, et al. **Hum Reprod** 1998 Nov;13(11):3190–6

Office mini-hysteroscopy. Campo R, et al. **Hum Reprod Update** 1999 Jan–Feb;5(1):73–81 (36 ref.)

Hysteroscopic resection of endometrial hyperplasia. Cianferoni L, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):151–4

Fertility after hysteroscopic resection of submucous myomas. Giatras K, et al. **J Am Assoc Gynecol Laparosc** 1999 May; 6(2):155–8

Hysteroscopic cervical cannulation under ultrasound guidance. A case report. Goudas VT, et al. **J Reprod Med** 1998 Aug;43(8):696–8

Safe and effective fluid management by automated gravitation during hysteroscopy. Tomazevic T, et al. **J Soc Laparoendosc Surg** 1998 Jan–Mar;2(1):51–5

Fluoroscopically guided hysteroscopic division of adhesions in severe Asherman syndrome. Broome JD, et al. **Obstet Gynecol** 1999 Jun;93(6):1041–3

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**

[Role of hysteroscopic treatment of the septate uterus resulting in primary sterility] Porcu G, et al. **Contracept Fertil Sex** 1998 Nov;26(11):764–7 **(Fre)**

[The value of hysteroscopy after repeated implantation failures with in vitro fertilization] Schiano A, et al. **Contracept Fertil Sex** 1999 Feb;27(2):129–32 (Eng. Abstr.) **(Fre)**

[Hysteroscopic myomectomy. Functional results with an average follow-up of 6 years] Cravello L, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):593–7 (Eng. Abstr.) **(Fre)**

[Contrast hysterosonography: an efficient means of investigation in gynecology. Review of the literature] van den Brûle FA, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Nov; 27(7):655–64 (59 ref.) (Eng. Abstr.) **(Fre)**

[The role of hysteroscopy in the diagnosis of infertility in materials of the 2nd Gynecological Clinic of the Medical Academy in Lódz] Sobkiewicz S, et al. **Ginekol Pol** 1998 Dec;69(12):1146–9 (Eng. Abstr.) **(Pol)**

[The effectiveness of hysteroscopic intrauterine septum resection in terms of reproductive outcome] Szamatowicz J, et al. **Ginekol Pol** 1998 Oct;69(10):757–60 (Eng. Abstr.) **(Pol)**

[Catheterization of the tubal ostium using hysteroscopy under laparoscopic guidance] Salazar López-Ortiz C, et al. **Ginecol Obstet Mex** 1999 Feb;67:64–71 (44 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Management of hysteroscopic surgery complications. Morrison DM. **AORN J** 1999 Jan;69(1):194–7, 199–209; quiz 210, 213–5, 21 (35 ref.)

HYSTRIX see **RODENTIA**

HZE PARTICLES see **COSMIC RADIATION**

I BLOOD-GROUP SYSTEM

IMMUNOLOGY

Pancreatic tumour marker anti-mucin antibody CAM 17.1 reacts with a sialyl blood group antigen, probably I, which is expressed throughout the human gastrointestinal tract. Eccleston DW, et al. **Digestion** 1998 Nov–Dec;59(6):665–70

Cold-induced augmentation of I blood group antigen interactions with galactophilic lectins. Sudakevitz D, et al. **Zentralbl Bakteriol** 1999 Apr;289(2):147–54

I-CELL DISEASE see **MUCOLIPIDOSIS**

IA ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IA-LIKE ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IA-LIKE ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IAIMS see **INTEGRATED ADVANCED INFORMATION MANAGEMENT SYSTEMS**

IAP ELEMENTS see **GENES, INTRACISTERNAL A-PARTICLE**

IAP PERTUSSIS TOXIN see **PERTUSSIS TOXINS**

IATROGENIC DISEASE

see related
DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT

Simultaneous subarachnoid hemorrhage and carotid cavernous fistula after rupture of a paraclinoid aneurysm during balloon-assisted coil embolization. Phatouros CC, et al. **AJNR Am J Neuroradiol** 1999 Jun–Jul;20(6):1100–2

The outcomes for patients with incidental lesions: serendipitous or iatrogenic? Westbrook JI, et al. **AJR Am J Roentgenol** 1998 Nov;171(5):1193–6 (53 ref.)

Treatment of iatrogenic previable premature rupture of membranes with intra-amniotic injection of platelets and cryoprecipitate (amniopatch): preliminary experience. Quintero RA, et al. **Am J Obstet Gynecol** 1999 Sep; 181(3):744–9

Clinical presentation and management of iatrogenic colon perforations [letter; comment] Agalar F, et al. **Am J Surg** 1999 May;177(5):442. Comment on: Am J Surg 1996 Nov;172(5):454–7; discussion 457–8.

Iatrogenic gallbladder perforation during laparoscopic cholecystectomy: etiology and sequelae. Hui TT, et al. **Am Surg** 1999 Oct;65(10):944–8

Iatrogenic oesophageal perforations: a clinical review [letter; comment] Shukla KK. **Ann R Coll Surg Engl** 1999 Mar; 81(2):140. Comment on: Ann R Coll Surg Engl 1998 Mar;80(2):115–8.

Iatrogenic mammary arteriovenous fistula caused by sternal wire. Silva J, et al. **Ann Thorac Surg** 1998 Oct;66(4):1398–9

Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. Shimizu S, et al. **Arch Neurol** 1999 Mar;56(3):357–62 (22 ref.)

Iatrogenic posterior tibial nerve division during ankle arthroscopy. Freedman DM, et al. **Arthroscopy** 1998 Oct; 14(7):769–72

Lesson of the week: exacerbating cervical spine injury by applying a hard collar. Papadopoulos MC, et al. **BMJ** 1999 Jul 17;319(7203):171–2

Iatrogenic isolated isoleucine deficiency as the cause of an acrodermatitis enteropathica-like syndrome. Bosch AM, et al. **Br J Dermatol** 1998 Sep;139(3):488–91

Iatrogenic acute hyponatraemia in a college athlete. Herfel R, et al. **Br J Sports Med** 1998 Sep;32(3):257–8

Iatrogenic ureteric injuries: approaches to etiology and management. Watterson JD, et al. **Can J Surg** 1998 Oct; 41(5):379–82

Intraarterial ethanol for the management of iatrogenic renal artery pseudoaneurysm. Singh B, et al. **Cathet Cardiovasc Diagn** 1998 Dec;45(4):442–4

Iatrogenic coronary artery stenosis following coronary stenting. Hamby RI, et al. **Catheter Cardiovasc Interv** 1999 Apr;46(4):393–7; discussion 398

Therapeutic embolization for unusual iatrogenic complications related to coronary revascularization. Thomas WJ, et al. **Catheter Cardiovasc Interv** 1999 Apr; 46(4):457–62

Tracheal lacerations after intubation [letter; comment] Molins L, et al. **Chest** 1998 Dec;114(6):1793–4. Comment on: Chest 1997 Sep;112(3):774–8.

Duropleural fistula manifested as a large pleural transudate: an unusual complication of transthoracic diskectomy. Monla-Hassan J, et al. **Chest** 1998 Dec;114(6):1786–9

Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Soupart A, et al. **Clin Nephrol** 1999 Jun;51(6):383–6

Iatrogenic neonatal mercury poisoning from Mercurochrome treatment of a large omphalocele. Mullins ME, et al. **Clin Pediatr (Phila)** 1999 Feb;38(2):111–2

Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology. Lee KW, et al. **Conn Med** 1999 Jul;63(7):399–403 (24 ref.)

Distribution and pathophysiology of acute lobar collapse in the pediatric intensive care unit [see comments] Thomas K, et al. **Crit Care Med** 1999 Aug;27(8):1594–7. Comment in: Crit Care Med 1999 Aug;27(8):1677–9.

Ureteric injuries [editorial; comment] Magoha GA. **East Afr Med J** 1999 Apr;76(4):181–3. Comment on: East Afr Med J 1999 Apr;76(4):184–8.

Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Sato K, et al. **Endocr J** 1998 Aug;45(4):431–9 (44 ref.)

Subtotal cystectomy as a complication of infant hernia repair. Koot VC, et al. **Eur J Surg** 1998 Nov;164(11):873–4

Stent-graft treatment of iatrogenic iliac artery perforations: report of three cases. Nyman U, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):259–63 (18 ref.)

Iatrogenic carotid artery pseudoaneurysm treated by an autologous vein-covered stent. Van Nieuwenhove Y, et al. **Eur J Vasc Endovasc Surg** 1998 Sep;16(3):262–5

Main stem subocclusion shortly after aortic valve replacement. Van Langenhove G, et al. **Heart** 1998 Nov; 80(5):530–1

Polypropylene mesh repair of iatrogenic thigh hernias. Richards H, et al. **Injury** 1998 Jul;29(6):478

Traditional bone setter's gangrene. Onuminya JE, et al. **Int Orthop** 1999;23(2):111–2

Percutaneous treatment of rare latrogenic arteriovenous fistulas of the lower limbs. Bürger T, et al. **Int Surg** 1998 Jul–Sep;83(3):198–201

Iatrogenic reno-jejunal fistula. Aragona F, et al. **Int Urol Nephrol** 1999;31(1):35–8

Kinetics of procalcitonin in iatrogenic sepsis [letter] Brunkhorst FM, et al. **Intensive Care Med** 1998 Aug; 24(8):888–9

Iatrogenic injury of the spinal accessory nerve. Results of repair. Nakamichi K, et al. **J Bone Joint Surg Am** 1998 Nov;80(11):1616–21

Delayed onset keratectasia following laser in situ keratomileusis [see comments] Geggel HS, et al. **J Cataract Refract Surg** 1999 Apr;25(4):582–6. Comment in: J Cataract Refract Surg 1999 Apr;25(4):453–4.

The riddle of iatrogenic keratectasia [editorial; comment] Koch DD. **J Cataract Refract Surg** 1999 Apr;25(4):453–4

. Comment on: J Cataract Refract Surg 1999 Apr;25(4):582–6.

Iatrogenic entrapped nasogastric tube with endoscopic removal [letter] Han HF, et al. **J Clin Gastroenterol** 1999 Jul;29(1):103–4

An unusual complication of an ankle arthroscopy and its management. Schmidt RG, et al. **J Foot Ankle Surg** 1999 Mar–Apr;38(2):147–9

Would physicians override a do-not-resuscitate order when a cardiac arrest is iatrogenic? Casarett DJ, et al. **J Gen Intern Med** 1999 Jan;14(1):35–8

Complete avulsion of the distal posterior interosseous nerve during wrist arthroscopy: a possible cause of persistent pain after arthroscopy. del Piñal F, et al. **J Hand Surg [Am]** 1999 Mar;24(2):240–2

Acute angle closure glaucoma precipitated by intranasal application of cocaine. Hari CK, et al. **J Laryngol Otol** 1999 Mar;113(3):250–1

Iatrogenic osteonecrosis of the maxilla caused by laser injury. Cassatly MG, et al. **J Oral Maxillofac Surg** 1999 Feb; 57(2):184–6

Iatrogenic avascular necrosis of the hip in young children: a long-term follow-up. Gore DR. **J Pediatr Orthop** 1999 Sep–Oct;19(5):635–40

Adverse events in health care: setting priorities based on economic evaluation. Rigby K, et al. **J Qual Clin Pract** 1999 Mar;19(1):7–12

Ureteric injuries: diagnosis, management, and outcome. Ghali AM, et al. **J Trauma** 1999 Jan;46(1):150–8

Iatrogenic brachiocephalic arteriovenous fistula: description of a fatal complication after cardiac pacemaker lead extraction [letter] Cirillo RL Jr, et al. **J Vasc Interv Radiol** 1998 Nov–Dec;9(6):1029–30

Severe hypothermic injury to the foot and ankle caused by continuous cryocompression therapy. Høiness PR, et al. **Knee Surg Sports Traumatol Arthrosc** 1998;6(4):253–5 (14 ref.)

Arterial injury during revision total knee replacement. A case report. Metzdorf A, et al. **Knee Surg Sports Traumatol Arthrosc** 1999;7(4):246–8

Combined endolaryngeal and external approaches for iatrogenic glottic web. Hsiao TY. **Laryngoscope** 1999 Aug; 109(8):1347–50

Iatrogenic superior gluteal mononeuropathy. Donofrio PD, et al. **Muscle Nerve** 1998 Dec;21(12):1794–6

Iatrogenic hyperkalaemia--points to consider in diagnosis and management. Siamopoulos KC, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2402–6

Shunt surgery induced iatrogenic CSF cyst presenting as a mass lesion [letter] Babu HV, et al. **Neurol India** 1999 Jun; 47(2):160–1

Iatrogenic vertebrobasilar insufficiency after surgery of the subclavian or brachial artery: review of three cases. Amar AP, et al. **Neurosurgery** 1998 Dec;43(6):1450–7; discussion 1457–8

Hypertensive encephalopathy as a complication of hyperdynamic therapy for vasospasm: report of two cases. Amin-Hanjani S, et al. **Neurosurgery** 1999 May; 44(5):1113–6

Complications and their management in tympanomastoid surgery. Mancini F, et al. **Otolaryngol Clin North Am** 1999 Jun;32(3):567–83 (56 ref.)

A comparative study of iatrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Kouyanou K, et al. **Pain** 1998 Jun;76(3):417–26

Peripherally inserted central venous catheter fracture and embolization to the lung. Kossoff EH, et al. **Pediatr Emerg Care** 1998 Dec;14(6):403–5 (11 ref.)

Multiple fungal brain abscess in a child with acute myeloblastic leukemia. Erduran E, et al. **Pediatr Hematol Oncol** 1998 Sep–Oct;15(5):463–6

A conversation on medical injury. Leape LL, et al. **Public Health Rep** 1999 Jul–Aug;114(4):302–17

Iatrogenic vascular trauma. Nehler MR, et al. **Semin Vasc Surg** 1998 Dec;11(4):283–93 (74 ref.)

[Iatrogenic peripheral nerve injuries and its repair] Song X, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 May;12(3):133–4 (Eng. Abstr.) **(Chi)**

[Hyperplasia and endocrine neoplasms associated with gastritis] Monges G. **Ann Pathol** 1998;18(5 Suppl):104–6 **(Fre)**

[Behcet's disease and iatrogenic arterial complications: importance of pre-operative noninvasive explorations] Saliou C, et al. **J Mal Vasc** 1999 Jun;24(3):221–4 (Eng. Abstr.) **(Fre)**

[Accidental vitamin D poisoning in an infant (letter)] Ailal F, et al. **Med Trop (Mars)** 1998;58(2):206–7 **(Fre)**

[Iatrogenic aseptic meningitis (letter)] Bonnotte B, et al. **Presse Med** 1998 Jun 20;27(22):1102 **(Fre)**

[Iatrogenic nosocomial drug-induced conditions: where is the risk? (editorial)] Schmitt E. **Presse Med** 1999 May 15; 28(18):970–2 **(Fre)**

[2 cases of iatrogenic oral streptococcal infection: meningitis and spondylodiscitis] Molinier S, et al. **Rev Med Interne** 1998 Aug;19(8):568–70 (Eng. Abstr.) **(Fre)**

[Iatrogenic thyroid disorders] Wemeau JL. **Rev Med Interne** 1999;20 Suppl 1:19S–20S **(Fre)**

[Iatrogenic Creutzfeld-Jakob disease. Significance of cases observed after extracted growth hormone treatment

(editorial)] Billette de Villemeur T. **Rev Neurol (Paris)** 1998 Oct;154(10):651-2 **(Fre)**

[Iatrogenic agranulocytosis. Etiology, diagnosis, treatment] Sébahoun G. **Rev Prat** 1999 Jun 15;49(12):1355-60 **(Fre)**

[Iatrogenic rupture of the left mainstem bronchus in tracheobronchial intubation] Dal Corso B, et al. **Minerva Anestesiol** 1998 Dec;64(12):581-5 (Eng. Abstr.) **(Ita)**

[Accidental esophageal intubation] Frova G. **Minerva Anestesiol** 1998 Nov;64(11):483-7 (10 ref.) **(Ita)**

[Neurologic disorders caused by adverse effects of drugs--with special reference to iatrogenic nervous system diseases of the current interest] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1885-91 (26 ref.) **(Jpn)**

[Iatrogenic prion disease] Kuroda Y. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):230-3 (12 ref.) **(Jpn)**

[Medico-expert qualification of iatrogenic diseases] Belikov ES. **Arkh Patol** 1998 Jul-Aug;60(4):50-2 (Eng. Abstr.) **(Rus)**

[The problem of iatrogenesis] Rusakov VI. **Khirurgiia (Mosk)** 1998;(8):45-8 (Eng. Abstr.) **(Rus)**

[Iatrogenic pathology--a current forensic medical problem] Sergeev IuD, et al. **Sud Med Ekspert** 1998 Nov-Dec; 41(6):3-8 (19 ref.) (Eng. Abstr.) **(Rus)**

[Iatrogenic complications in tracheal intubation and tracheostomy] Gorbunov VA. **Voen Med Zh** 1999 Mar; 320(3):32-4 **(Rus)**

[Colonic perforation in percutaneous surgery of the kidney. Report of two cases] Pinos Paul MA, et al. **Actas Urol Esp** 1999 Jun;23(6):542-5 (Eng. Abstr.) **(Spa)**

[Analysis of the neurologic consultations in an oncologic hospital: contributions of neuro-oncology] Porta-Etessam J, et al. **Neurologia** 1999 Jun-Jul;14(6):266-74 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Adverse events of procedural sedation and analgesia in a pediatric emergency department. Peña BM, et al. **Ann Emerg Med** 1999 Oct;34(4 Pt 1):483-91

Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Darchy B, et al. **Arch Intern Med** 1999 Jan 11;159(1):71-8

Does the Complications Screening Program flag cases with process of care problems? Using explicit criteria to judge processes. Iezzoni LI, et al. **Int J Qual Health Care** 1999 Apr;11(2):107-18

Frequency, consequences and prevention of adverse drug events. Bates DW. **J Qual Clin Pract** 1999 Mar;19(1):13-7

The nature and extent of drug-related hospitalisations in Australia. Roughead EE. **J Qual Clin Pract** 1999 Mar; 19(1):19-22 (8 ref.)

Towards safer drug use in general practice. Steven ID, et al. **J Qual Clin Pract** 1999 Mar;19(1):47-50

The association of quality of care and occurrence of in-hospital, treatment-related complications. Geraci JM, et al. **Med Care** 1999 Feb;37(2):140-8

Screening inpatient quality using post-discharge events. Iezzoni LI, et al. **Med Care** 1999 Apr;37(4):384-98

An analysis of the causes of adverse events from the Quality in Australian Health Care Study. Wilson RM, et al. **Med J Aust** 1999 May 3;170(9):411-5

[Patients admitted to the intensive care unit for iatrogenic disease. Risk factors and consequences] Darchy B, et al. **Rev Med Interne** 1998 Jul;19(7):470-8 (Eng. Abstr.) **(Fre)**

[Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance] Imbs JL, et al. **Therapie** 1999 Jan-Feb;54(1):21-7 (Eng. Abstr.) **(Fre)**

[Prospective study on admissions for iatrogenic adverse effects in the emergency service of hospital university center in Poitiers] Perault MC, et al. **Therapie** 1999 Jan-Feb;54(1):183-5 (Eng. Abstr.) **(Fre)**

[Iatrogeny in hospitalized elderly patients] Carvalho-Filho ET, et al. **Rev Saude Publica** 1998 Feb;32(1):36-42 (Eng. Abstr.) **(Por)**

[Iatrogenic vascular lesions after cardiac catheterization] Manuel-Rimbau E, et al. **Rev Esp Cardiol** 1998 Sep; 51(9):750-5 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

A worthy goal--less iatrogenics [letter; comment] Fricker JP. **Am J Orthod Dentofacial Orthop** 1999 May;115(5):13A . Comment on: Am J Orthod Dentofacial Orthop 1998 Dec;114(6):668-74.

The recurrent laryngeal nerve related to thyroid surgery. Sturniolo G, et al. **Am J Surg** 1999 Jun;177(6):485-8

Prevention of iatrogenic illness: adverse drug reactions and nosocomial infections in hospitalized older adults. Riedinger JL, et al. **Clin Geriatr Med** 1998 Nov; 14(4):681-98 (48 ref.)

Accidental iatrogenic intoxications by cytotoxic drugs: error analysis and practical preventive strategies. Zernikow B, et al. **Drug Saf** 1999 Jul;21(1):57-74

Screening for adverse events [see comments] Karson AS, et al. **J Eval Clin Pract** 1999 Feb;5(1):23-32. Comment in: J Eval Clin Pract 1999 Feb;5(1):1-4.

Commentary: current status and future directions in acute pediatric pain assessment and treatment [comment] Blount RL, et al. **J Pediatr Psychol** 1999 Apr;24(2):150-2. Comment on: J Pediatr Psychol 1999 Apr;24(2):131-45.

Commentary on "Treatments that work in pediatric psychology: Procedure-related pain" [comment] Dahlquist LM. **J Pediatr Psychol** 1999 Apr;24(2):153-4. Comment on: J Pediatr Psychol 1999 Apr;24(2):131-45.

Commentary: well-established treatments for procedure-related pain: issues for future research and policy implications [comment] Manne S. **J Pediatr Psychol** 1999 Apr;24(2):147-9. Comment on: J Pediatr Psychol 1999 Apr;24(2):131-45.

Empirically supported treatments in pediatric psychology: procedure-related pain [see comments] Powers SW. **J Pediatr Psychol** 1999 Apr;24(2):131-45 (32 ref.). Comment in: J Pediatr Psychol 1999 Apr;24(2):147-9. Comment in: J Pediatr Psychol 1999 Apr;24(2):150-2. Comment in: J Pediatr Psychol 1999 Apr;24(2):153-4.

Incidents and accidents in health care: it's time! [editorial; comment] Runciman WB. **J Qual Clin Pract** 1999 Mar; 19(1):1-2. Comment on: J Qual Clin Pract 1999 Mar;19(1):5.

The risk of paraplegia through medical treatment. Bacher T, et al. **Spinal Cord** 1999 Mar;37(3):172-82

[Total hip arthroplasty. Risk factors and prevention of iatrogenic vascular complications] Feugier P, et al. **Ann Chir** 1999;53(2):127-35 (Eng. Abstr.) **(Fre)**

[Iatrogenic dysphagia with severe consequences: simple preventive measures (letter)] Karsenti D, et al. **Presse Med** 1999 Feb 6;28(5):232 **(Fre)**

[Prevention of avoidable iatrogenic effects: the obligation for vigilance (editorial)] Queneau P, et al. **Presse Med** 1998 Sep 5;27(25):1280-2 (Eng. Abstr.) **(Fre)**

[Assessment of preventable iatrogenic drug therapy: methodology. Round Table No 2 at Giens XIII] Imbs JL, et al. **Therapie** 1998 Jul-Aug;53(4):365-70 (18 ref.) (Eng. Abstr.) **(Fre)**

[Dealing with errors in medicine] Schoenenberger RA, et al. **Schweiz Rundsch Med Prax** 1998 Dec 24; 87(51-52):1793-7 (23 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Iatrogenic hyperadrenocorticism in 28 dogs. Huang HP, et al. **J Am Anim Hosp Assoc** 1999 May-Jun;35(3):200-7

IBDV see **INFECTIOUS BURSAL DISEASE VIRUS**

IBOGAINE

Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]benzothiophenes. Efange SM, et al. **J Med Chem** 1998 Nov 5;41(23):4486-91

ANALOGS & DERIVATIVES

Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain. Zubaran C, et al. **Neuropsychopharmacology** 1999 Jul; 21(1):119-26

18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Glick SD, et al. **Psychopharmacology (Berl)** 1998 Oct; 139(3):274-80

PHARMACOLOGY

Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice. Yu X, et al. **Brain Res** 1999 Mar 27;823(1-2):213-6

The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes. Wells GB, et al. **Brain Res Bull** 1999 Apr;48(6):641-7

Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Fryer JD, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):88-92

Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Szumlinski KK, et al. **Pharmacol Biochem Behav** 1999 Jul;63(3):457-64

Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice. Sunder Sharma S, et al. **Pharmacology** 1998 Nov;57(5):229-32

Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. Helsley S, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Feb; 23(2):317-26

Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats. Szumlinski KK, et al. **Psychopharmacology (Berl)** 1999 Jul;145(2):227-33

IBOTENIC ACID

ANALOGS & DERIVATIVES

Synthesis and pharmacology of N-alkylated derivatives of the excitotoxin ibotenic acid. Madsen U, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1563-8

PHARMACOLOGY

Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. Levin ED, et al. **Brain Res Cogn Brain Res** 1999 Jan; 7(3):405-10

Eye movement deficits following ibotenic acid lesions of the nucleus prepositus hypoglossi in monkeys II. Pursuit, vestibular, and optokinetic responses. Kaneko CR. **J Neurophysiol** 1999 Feb;81(2):668-81

GFAPbeta mRNA expression in the normal rat brain and after neuronal injury. Condorelli DF, et al. **Neurochem Res** 1999 May;24(5):709-14

Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Becker A, et al. **Psychopharmacology (Berl)** 1999 Jun;144(4):333-8

THERAPEUTIC USE

Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. Lieberman DM, et al. **J Neurosurg** 1999 May;90(5):928-34

TOXICITY

Differential alterations in basal and D-amphetamine-induced behavioural pattern following 6-OHDA or ibotenic acid lesions into the dorsal striatum. Antoniou K, et al. **Behav Brain Res** 1998 Dec;97(1-2):13-28

Long-term evolution of excitotoxic cortical dysgenesis induced in the developing rat brain. Redecker C, et al. **Brain Res Dev Brain Res** 1998 Jul 1;109(1):109-13

Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192-IgG saporin lesions of the nucleus basalis magnocellularis. Bednar I, et al. **Int J Dev Neurosci** 1998 Nov-Dec;16(7-8):661-8

Effects of ibotenate hippocampal and extrahippocampal destruction on delayed-match and -nonmatch-to-sample behavior in rats. Hampson RE, et al. **J Neurosci** 1999 Feb 15;19(4):1492-507

IBR-IPV VIRUS see **HERPESVIRUS 1, BOVINE**

IBUPROFEN

Dissolution studies on tablets of ibuprofen using chitosan. Ilango R, et al. **Indian J Exp Biol** 1999 May;37(5):505-8

[Effect of tableting conditions on the sticking of tablet using ibuprofen] Aoki S, et al. **Yakugaku Zasshi** 1998 Nov; 118(11):511-8 (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Doyle G, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):897-906

Effect of dosage form on stereoisomeric inversion of ibuprofen in volunteers. Aiba T, et al. **Biol Pharm Bull** 1999 Jun;22(6):616-22

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. McMillan DC, et al. **Br J Cancer** 1999 Feb; 79(3-4):495-500

Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Tegeder I, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):357-68

Cataplasm-based controlled drug delivery: development and optimization of a novel formulation. Agarwal V, et al. **Drug Dev Ind Pharm** 1999 May;25(5):659-65

Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Ghosh LK, et al. **Drug Dev Ind Pharm** 1998 May;24(5):473-7

New controlled-release ibuprofen tablets. Palmieri GF, et al. **Drug Dev Ind Pharm** 1999 May;25(5):671-7

Anti-inflammatory doses of ibuprofen: effect on neutrophils and exercise-induced muscle injury. Pizza FX, et al. **Int J Sports Med** 1999 Feb;20(2):98-102

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Paracetamol or ibuprofen in febrile children. Carley S. **J Accid Emerg Med** 1999 Mar;16(2):137-39 (15 ref.)

The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. Kellstein DE, et al. **J Clin Pharmacol** 1999 May;39(5):520-32

Preparation and in vitro release studies of ibuprofen-loaded films and microspheres made from graft copolymers of poly(L-lactic acid) on acrylic backbones. Gallardo A, et al. **J Controlled Release** 1998 Nov 13;55(2-3):171-9

Additive analgesic effects of oxycodone and ibuprofen in the oral surgery model. Dionne RA. **J Oral Maxillofac Surg** 1999 Jun;57(6):673-8

Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. Huang A, et al. **J Urol** 1999 Oct;162(4):1396-8

[Prophylactic use of prostaglandin synthesis inhibitors in connection with IUD insertion] Jensen HH, et al. **Ugeskr Laeger** 1998 Nov 23;160(48):6958-61 (Eng. Abstr.) **(Dan)**

[Can local therapy of joint syndrome with Dolgit cream be used as an alternative to systemic nonsteroid antiinflammatory drugs in rheumatic diseases?] Nasonov VA, et al. **Ter Arkh** 1998;70(11):64-6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Gastrointestinal safety and tolerance of ibuprofen at

maximum over-the-counter dose. Doyle G, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):897-906

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Lanza FL, et al. **Aliment Pharmacol Ther** 1999 Jun;13(6):761-7

Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. Bell EA, et al. **Ann Pharmacother** 1999 Jun;33(6):693-6

Ibuprofen causing acute renal failure in children: reply to Moghal et al [letter; comment] Bhowmik D. **Clin Nephrol** 1998 Nov;50(5):336. Comment on: Clin Nephrol 1998 May;49(5):293-5.

A calcium channel blocker and ibuprofen overdose. Cimpello LB, et al. **Curr Opin Pediatr** 1998 Jun;10(3):303-7

Desipramine and ibuprofen [letter] Gillette DW. **J Am Acad Child Adolesc Psychiatry** 1998 Nov;37(11):1129

Nonsteroidal anti-inflammatory drug-induced ulceration diagnosed on barium enema. Crosby JC, et al. **J Clin Gastroenterol** 1998 Sep;27(2):156-7

The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. Kellstein DE, et al. **J Clin Pharmacol** 1999 May;39(5):520-32

Effect of caffeine on ibuprofen-induced gastric mucosal damage in rats. Koyama R, et al. **J Pharm Pharmacol** 1999 Jul;51(7):817-24

Acute nonoliguric renal failure in children associated with nonsteroidal antiinflammatory agents. Schaller S, et al. **Pediatr Emerg Care** 1998 Dec;14(6):416-8 (20 ref.)

The safety of acetaminophen and ibuprofen among children younger than two years old. Lesko SM, et al. **Pediatrics** 1999 Oct;104(4):e39

A case-control study of necrotizing fasciitis during primary varicella. Zerr DM, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):783-90

[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake] Gaul C, et al. **Dtsch Med Wochenschr** 1999 Apr 23;124(16):483-6 (15 ref.) (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Influence of water activity on the enantioselective esterification of (R,S)-ibuprofen by Candida antarctica lipase B in solventless media. Pepin P, et al. **Biotechnol Bioeng** 1999 May 20;63(4):502-5

Chiral discrimination in the transport of ketoprofen and ibuprofen esters through an aqueous phase mediated by various serum albumins. Nakagawa H, et al. **Chirality** 1999; 11(5-6):516-9

Methoxybutropate microencapsulation by gelatin-acacia complex coacervation. Palmieri GF, et al. **Drug Dev Ind Pharm** 1999 Apr;25(4):399-407

Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum. Stoye I, et al. **Eur J Pharm Biopharm** 1998 Sep;46(2):191-200

ANALYSIS

Separation of ibuprofen, codeine phosphate, their degradation products and impurities by capillary electrophoresis. II. Validation. Stubberud KP, et al. **J Chromatogr A** 1998 Nov 20;826(1):95-102

CHEMISTRY

Absorption of ibuprofen coated by anhydrous silicic acid. Aoki S, et al. **Chem Pharm Bull (Tokyo)** 1998 Dec; 46(12):1914-7

The dissolution and complexing properties of ibuprofen and ketoprofen when mixed with N-methylglucamine. de Villiers MM, et al. **Drug Dev Ind Pharm** 1999 Aug; 25(8):967-72

Preparation and release of ibuprofen from polyacrylamide gels. Hussain MD, et al. **Drug Dev Ind Pharm** 1999 Mar; 25(3):265-71

Ibuprofen agglomerates preparation by phase separation. Jbilou M, et al. **Drug Dev Ind Pharm** 1999 Mar; 25(3):297-305

Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen. Khan GM, et al. **Drug Dev Ind Pharm** 1998 May;24(5):463-71

Study of interaction between drug enantiomers and serum albumin by capillary electrophoresis. Ding Y, et al. **Electrophoresis** 1999 Jul;20(9):1890-4

Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum. Stoye I, et al. **Eur J Pharm Biopharm** 1998 Sep;46(2):191-200

Studies on drug release kinetics from ibuprofen-carbomer hydrophilic matrix tablets: influence of co-excipients on release rate of the drug. Khan GM, et al. **J Controlled Release** 1999 Feb 1;57(2):197-203

Formulation and in vitro evaluation of ibuprofen-Carbopol 974P-NF controlled release matrix tablets. III: Influence of co-excipients on release rate of the drug. Khan GM, et al. **J Controlled Release** 1998 Jul 31;54(2):185-90

Ibuprofen release kinetics from controlled-release tablets granulated with aqueous polymeric dispersion of ethylcellulose II: influence of several parameters and coexcipients. Majid Khan G, et al. **J Controlled Release** 1998 Dec 4;56(1-3):127-34

Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres. Perumal D, et al. **J Microencapsul** 1999 Jul-Aug;16(4):475-87

Effect of production variables on the physical characteristics of ibuprofen-loaded polystyrene microparticles. Tamilvanan S, et al. **J Microencapsul** 1999 Jul-Aug; 16(4):411-8

Dissolution of ibuprofen enantiomers from coprecipitates and suspensions containing chiral excipients. Janjikhel RK, et al. **Pharm Dev Technol** 1999 Jan;4(1):9-17

Confocal Raman-spectroscopy: analytical approach to solid dispersions and mapping of drugs. Breitenbach J, et al. **Pharm Res** 1999 Jul;16(7):1109-13

ISOLATION & PURIFICATION

Resolution of enantiomers of ibuprofen by liquid chromatography: a review. Bhushan R, et al. **Biomed Chromatogr** 1998 Nov-Dec;12(6):309-16 (39 ref.)

Direct enantiomeric resolution of some 2-arylpropionic acids using (-)-brucine-impregnated thin-layer chromatography. Bhushan R, et al. **Biomed Chromatogr** 1999 Jun;13(4):276-8

Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen. Khan GM, et al. **Drug Dev Ind Pharm** 1998 May;24(5):463-71

Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc, and PEG-talc as dispersion carriers. Khan GM, et al. **Drug Dev Ind Pharm** 1998 May;24(5):455-62

METABOLISM

Effect of water content on enzyme activity and enantioselectivity of lipase-catalyzed esterification of racemic ibuprofen in organic solvents. Xie YC, et al. **Ann N Y Acad Sci** 1998 Dec 13;864:570-5

Stereoselective allosteric binding interaction on human serum albumin between ibuprofen and lorazepam acetate. Fitos I, et al. **Chirality** 1999;11(2):115-20

PHARMACOKINETICS

Influence of water activity on the enantioselective esterification of (R,S)-ibuprofen by Candida antarctica lipase B in solventless media. Pepin P, et al. **Biotechnol Bioeng** 1999 May 20;63(4):502-5

Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Jamali F, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):391-6

Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram. Lapatto-Reiniluoto O, et al. **Br J Clin Pharmacol** 1999 Aug;48(2):148-53

Absorption of ibuprofen coated by anhydrous silicic acid. Aoki S, et al. **Chem Pharm Bull (Tokyo)** 1998 Dec; 46(12):1914-7

Application of microdialysis for the determination of muscle and subcutaneous tissue concentrations after oral and topical ibuprofen administration. Tegeder I, et al. **Clin Pharmacol Ther** 1999 Apr;65(4):357-68

Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Ghosh LK, et al. **Drug Dev Ind Pharm** 1998 May;24(5):473-7

Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release. Halsas M, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun; 23(2):190-6

Comparative bioavailability study of codeine and ibuprofen after administration of the two products alone or in association to 24 healthy volunteers. Laneury JP, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun; 23(2):185-9

Transformation of a liposomal dispersion containing ibuprofen lysinate and phospholipids into mixed micelles - physico-chemical characterization and influence on drug permeation through excised human stratum corneum. Stoye I, et al. **Eur J Pharm Biopharm** 1998 Sep;46(2):191-200

Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy volunteers. Eller N, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):414-7

The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. Scott CS, et al. **J Pediatr** 1999 Jan;134(1):58-63

Pharmacokinetics of ibuprofen in patients with cystic fibrosis. Murry DJ, et al. **Pharmacotherapy** 1999 Mar;19(3):340-5

Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Thai QA, et al. **Stroke** 1999 Jan;30(1):140-7

PHARMACOLOGY

Effect of the cyclo-oxygenase blocker ibuprofen on cerebral blood volume and cerebral blood flow during normocarbia and hypercarbia in newborn piglets. Pellicer A, et al. **Acta Paediatr** 1999 Jan;88(1):82-8

Spinal action of ketorolac, S(+)- and R(-)-ibuprofen on non-noxious activation of the catechol oxidation in the rat locus coeruleus: evidence for a central role of prostaglandins in the strychnine model of allodynia. Hall SR, et al. **Anesthesiology** 1999 Jan;90(1):165-73

Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Fowler CJ, et al. **Arch Biochem Biophys** 1999 Feb 15;362(2):191-6

Ibuprofen: new explanation for an old phenomenon. Stuhlmeier KM, et al. **Biochem Pharmacol** 1999 Feb 1; 57(3):313-20

Intestinal permeability before and after ibuprofen in families of children with Crohn's disease. Zamora SA, et al. **Can J Gastroenterol** 1999 Jan-Feb;13(1):31-6

Effects of dexamethasone, ibuprofen, and ligustrazini on lipopolysaccharides-induced tumor necrosis factor alpha production. Qiu HB, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):67-70

Effects of dexamethasone and ibuprofen on LPS-induced gene expression of TNF alpha, IL-1 beta, and MIP-1 alpha in rat lung. Qiu HB, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):165-8

The effects of ibuprofen on eicosanoid synthesis in sepsis [editorial; comment] Fletcher JR. **Crit Care Med** 1999 Apr; 27(4):669-70 (11 ref.). Comment on: Crit Care Med 1999 Apr;27(4):699-707.

Inhibition of cytokine production and adhesion molecule expression by ibuprofen is without effect on transendothelial migration of monocytes. Menzel EJ, et al. **Inflammation** 1999 Jun;23(3):275-86

Effects of acetaminophen and ibuprofen on renal function in anesthetized normal and sodium-depleted dogs. Colletti AE, et al. **J Appl Physiol** 1999 Feb;86(2):592-7

Effects of acetaminophen and ibuprofen on renal function in the stressed kidney. Farquhar WB, et al. **J Appl Physiol** 1999 Feb;86(2):598-604

Effects of ibuprofen on arylamine N-acetyltransferase activity in human colon tumor cells. Chung JG, et al. **J Appl Toxicol** 1999 Jan-Feb;19(1):1-6

Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. Brown RD, et al. **J Pharmacokinet Biopharm** 1998 Oct;26(5):559-79

Ibuprofen-induced changes in sulfate renal transport. Sagawa K, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):1092-7

Down-regulation of nitric oxide production by ibuprofen in human volunteers. Vandivier RW, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1398-403

POISONING

Combined antipyretic therapy: another potential source of chronic acetaminophen toxicity [letter; comment] Mofenson HC, et al. **J Pediatr** 1998 Nov;133(5):712-4. Comment on: J Pediatr 1997 Feb;130(2):300-4. Comment on: J Pediatr 1998 Jan;132(1):5-8. Comment on: J Pediatr 1998 Jan;132(1):22-7.

THERAPEUTIC USE

Parents' fear regarding fever and febrile seizures. van Stuijvenberg M, et al. **Acta Paediatr** 1999 Jun;88(6):618-22

No effective prophylaxis of heterotopic ossification with short-term ibuprofen. Koorevaar CT, et al. **Arch Orthop Trauma Surg** 1999;119(3-4):183-5

The comparative efficacy of aceclofenac and ibuprofen in postoperative pain after third molar surgery. Seymour RA, et al. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):375-9

Analgesic efficacy of a combination of hydrocodone with ibuprofen in postoperative pain. Wideman GL, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):66-76

Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group [see comments] Arons MM, et al. **Crit Care Med** 1999 Apr; 27(4):699-707. Comment in: Crit Care Med 1999 Apr;27(4):669-70.

Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Sandrini G, et al. **Int J Clin Pharmacol Res** 1998;18(3):145-50

Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats. Pollock DM, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S116-9

Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. Gendelman HE, et al. **J Infect Dis** 1998 Oct;178(4):1000-7

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Rice GP, et al. **Neurology** 1999 Jun 10;52(9):1893-5

Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Harris RE, et al. **Oncol Rep** 1999 Jan-Feb;6(1):71-3

Ibuprofen for tonsillectomy pain in children: efficacy and complications. Harley EH, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):492-6

Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Bickel A, et al. **Pain** 1998 Jun; 76(3):317-25

Reevaluation of antipyretics in children with enteric fever. Noyola DE, et al. **Pediatr Infect Dis J** 1998 Aug; 17(8):691-5

Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences. van Stuijvenberg M, et al. **Pediatrics** 1998

IBUPROFEN

Nov;102(5):E51

Ibuprofen attenuates cardiopulmonary dysfunction by modifying vascular tone in endotoxemia. Heidemann SM, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar; 60(3):181–5

Corticosteroids and ibuprofen in cystic fibrosis [letter] Balfour-Lynn IM, et al. **Thorax** 1999 Jul;54(7):657

Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years. Nwanyanwu OC, et al. **Trans R Soc Trop Med Hyg** 1999 Jan–Feb; 93(1):84

[Brufen on the eve of the 21st century] Karateev DE. **Ter Arkh** 1998;70(12):78–80 (22 ref.) **(Rus)**

[Will administration of omega-3 unsaturated fatty acids reduce the use of nonsteroidal antirheumatic agents in children with chronic juvenile arthritis?] Vargová V, et al. **Cas Lek Cesk** 1998 Nov 2;137(21):651–3 (Eng. Abstr.) **(Slo)**

[Congenital chloridorrhea: adjuvant therapy with ibuprofen and ranitidine] Martinón-Torres F, et al. **An Esp Pediatr** 1999 Jun;50(6):619–22 (19 ref.) **(Spa)**

TOXICITY

The effects of high-dose ibuprofen and pancreatic enzymes on the intestine of the rat. Kimura RE, et al. **J Pediatr Gastroenterol Nutr** 1999 Aug;29(2):178–83

URINE

Separatory determination of diastereomeric ibuprofen glucuronides in human urine by liquid chromatography/electrospray ionization-mass spectrometry. Ikegawa S, et al. **Biomed Chromatogr** 1998 Nov–Dec;12(6):317–21

ICAM-1 see **INTERCELLULAR ADHESION MOLECULE-1**

ICE

Effects of a novel ice-cooling technique on work in protective clothing at 28 degrees C, 23 degrees C, and 18 degrees C WBGTs. Muir IH, et al. **Am Ind Hyg Assoc J** 1999 Jan–Feb;60(1):96–104

The effectiveness of ice as a topical anesthetic for the insertion of intravenous catheters. Richman PB, et al. **Am J Emerg Med** 1999 May;17(3):255–7

Three-dimensional behavior of ice crystals and biological cells during freezing of cell suspensions. Ishiguro H, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:235–44

Effects of glycerol on intracellular ice formation and dehydration of onion epidermis. Tsuruta T, et al. **Ann N Y Acad Sci** 1998 Sep 11;858:217–26

Health effects resulting from nitrogen dioxide exposure in an indoor ice arena. Rosenlund M, et al. **Arch Environ Health** 1999 Jan–Feb;54(1):52–7

The ice-binding site of sea raven antifreeze protein is distinct from the carbohydrate-binding site of the homologous C-type lectin. Loewen MC, et al. **Biochemistry** 1998 Dec 22;37(51):17745–53

Alternative roles for putative ice-binding residues in type I antifreeze protein. Loewen MC, et al. **Biochemistry** 1999 Apr 13;38(15):4743–9

Subzero water permeability parameters of mouse spermatozoa in the presence of extracellular ice and cryoprotective agents. Devireddy RV, et al. **Biol Reprod** 1999 Sep;61(3):764–75

Cluster of unintentional carbon monoxide poisonings presenting to the emergency departments in Kingston, Ontario during 'ice storm 98'. Hartling L, et al. **Can J Public Health** 1998 Nov–Dec;89(6):388–90

The injury experience observed in two emergency departments in Kingston, Ontario during 'ice storm 98'. Hartling L, et al. **Can J Public Health** 1999 Mar–Apr; 90(2):95–8

Crystallization of ice in aqueous solutions of glycerol and dimethyl sulfoxide 2: ice crystal growth kinetics. Hey JM, et al. **Cryobiology** 1998 Sep;37(2):119–30

Identification of a novel ice-nucleating bacterium of Antarctic origin and its ice nucleation properties. Obata H, et al. **Cryobiology** 1999 Mar;38(2):131–9

Effects of cryoprotectants and ice-seeding temperature on intracellular freezing and survival of human oocytes. Trad FS, et al. **Hum Reprod** 1999 Jun;14(6):1569–77

A method to study intracellular ice nucleation. Tatsutani K, et al. **J Biomech Eng** 1998 Feb;120(1):27–31

Soil hydric characteristics and environmental ice nuclei influence supercooling capacity of hatchling painted turtles Chrysemys picta. Costanzo JP, et al. **J Exp Biol** 1998 Nov; 201 (Pt 22):3105–12

An ice test for the diagnosis of myasthenia gravis. Golnik KC, et al. **Ophthalmology** 1999 Jul;106(7):1282–6

UV irradiation of polycyclic aromatic hydrocarbons in ices: production of alcohols, quinones, and ethers [see comments] Bernstein MP, et al. **Science** 1999 Feb 19; 283(5405):1135–8. Comment in: Science 1999 Feb 19;283(5405):1123–4.

No ice on the moon? [letter] Eshleman VR, et al. **Science** 1999 Jul 23;285(5427):531–2

Life in ice-covered oceans. Gaidos EJ, et al. **Science** 1999 Jun 4;284(5420):1631–3

Topography of the lunar poles from radar interferometry: a survey of cold trap locations. Margot JL, et al. **Science** 1999 Jun 4;284(5420):1658–60

Permafrost comes alive for Siberian researchers [news] Stone R. **Science** 1999 Oct 1;286(5437):36–7

Observations of the north polar region of Mars from the Mars orbiter laser altimeter. Zuber MT, et al. **Science** 1998 Dec 11;282(5396):2053–60

Sledding injuries in the southeastern United States. Major CP, et al. **South Med J** 1999 Feb;92(2):193–6

[Grey (Halcichoerus grypus) and common (Phoca vitulina) seals in Murman: adaptation to ice and ecological differentiation in subpopulations] Kondakov AA. **Dokl Akad Nauk** 1999 Jan;364(2):274–6 **(Rus)**

[A radiation hygiene assessment of the use of the deicing preparation Kama-M in Moscow] Loginov AA, et al. **Gig Sanit** 1999 May–Jun;(3):20–2 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Fat necrosis after ice application for supraventricular tachycardia termination. Craig JE, et al. **J Pediatr** 1998 Dec;133(6):727

ANALYSIS

Recent evolution of the multi-isotopic radioactive content in ice of Livingston Island, Antarctica. Baeza A, et al. **Bull Environ Contam Toxicol** 1999 Aug;63(2):139–49

STANDARDS

Microbial, physical, and chemical quality of packaged ice in Florida. Schmidt RH, et al. **J Food Prot** 1999 May; 62(5):526–31

ICE CREAM

Reducing ice cream energy density does not condition decreased acceptance or engender compensation following repeated exposure. Specter SE, et al. **Eur J Clin Nutr** 1998 Oct;52(10):703–10

MICROBIOLOGY

Consequences in Georgia of a nationwide outbreak of Salmonella infections: what you don't know might hurt you. Mahon BE, et al. **Am J Public Health** 1999 Jan; 89(1):31–5

Characterization of Listeria monocytogenes from an ice cream plant by serotyping and pulsed-field gel electrophoresis. Miettinen MK, et al. **Int J Food Microbiol** 1999 Feb 18;46(3):187–92

ICE HOCKEY see **HOCKEY**

ICE PROTEASE see **CASPASE 1**

ICE SKATING see **SKATING**

ICHTHYOSIFORM ERYTHRODERMA, BULLOUS CONGENITAL see **HYPERKERATOSIS, EPIDERMOLYTIC**

ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL

COMPLICATIONS

Ichthyosiform erythroderma and cardiomyopathy: report of two cases and review of the literature. Hoeger PH, et al. **Br J Dermatol** 1998 Dec;139(6):1055–9 (22 ref.)

GENETICS

Novel and recurrent mutations in keratin 10 causing bullous congenital ichthyosiform erythroderma. McLean WH, et al. **Exp Dermatol** 1999 Apr;8(2):120–3

ULTRASONOGRAPHY

Three-dimensional ultrasonography of congenital ichthyosis. Benoit B. **Ultrasound Obstet Gynecol** 1999 May;13(5):380

ICHTHYOSIFORM ERYTHRODERMA, NONBULLOUS CONGENITAL see **ICHTHYOSIS, LAMELLAR**

ICHTHYOSIS

Harlequin ichthyosis: report of one case. Lai SW, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov–Dec;39(6):412–4

Association in the same patient of autosomal dominant progressive external ophthalmoplegia with multiple mtDNA deletions and X-linked ichthyosis: clinical, biochemical, histological, submicroscopic and molecular genetic study. Federico A, et al. **J Submicrosc Cytol Pathol** 1998 Oct;30(4):521–6

Ichthyosis in a nutshell. Shwayder T. **Pediatr Rev** 1999 Jan; 20(1):5–12 (10 ref.)

[KID syndrome (keratitis, ichthyosis and deafness)] André N, et al. **Arch Pediatr** 1999 Mar;6(3):302–6 (29 ref.) (Eng. Abstr.) **(Fre)**

[The harlequin baby. Apropos of a case] Megarbane A. **J Med Liban** 1998 Mar–Apr;46(2):106–8 (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Recurrent bacterial vaginosis and Netherton's syndrome. Nicholls S, et al. **Int J STD AIDS** 1999 Mar;10(3):202–3

Ichthyosis and psoriasis in a patient with Down syndrome. Nomura K. **J Dermatol** 1999 Aug;26(8):538–40

DIAGNOSIS

[The fully-symptomatic Netherton syndrome in the 11-year-old boy] Macura-Gina M, et al. **Wiad Lek** 1998; 51(11–12):531–4 (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Ichthyosis bullosa of Siemens: a topical therapy option [letter] Sanclemente G, et al. **Arch Dermatol** 1999 Feb;135(2):217–8

ETIOLOGY

CD30-positive cutaneous anaplastic large cell lymphoma with ichthyosis acquisita. Zamolo G, et al. **Tumori** 1999 Jan–Feb;85(1):71–4

GENETICS

A glutamate to lysine mutation at the end of 2B rod domain of keratin 2e gene in ichthyosis bullosa of Siemens. Yang JM, et al. **Acta Derm Venereol** 1998 Nov;78(6):417–9

A syndrome of congenital ichthyosis, hypogonadism, small stature, facial dysmorphism, scoliosis and myogenic dystrophy. Stoll C, et al. **Ann Genet** 1999;42(1):45–50

A novel in situ method for the detection of deficient transglutaminase activity in the skin. Raghunath M, et al. **Arch Dermatol Res** 1998 Nov;290(11):621–7

Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. de Boer J, et al. **Cancer Res** 1999 Jul 15;59(14):3489–94

A hyperkeratotic linear lesion in a girl with KID syndrome. A further example of early allelic loss?[letter] Restano L, et al. **Eur J Dermatol** 1999 Mar;9(2):142–3

A novel mutation in the 1A domain of keratin 2e in ichthyosis bullosa of Siemens. Arin MJ, et al. **J Invest Dermatol** 1999 Mar;112(3):380–2

A novel insertional mutation in loricrin in Vohwinkel's Keratoderma. Armstrong DK, et al. **J Invest Dermatol** 1998 Oct;111(4):702–4

A novel helix termination mutation in keratin 10 in annular epidermolytic ichthyosis, a variant of bullous congenital ichthyosiform erythroderma. Suga Y, et al. **J Invest Dermatol** 1998 Dec;111(6):1220–3

The pattern of inheritance in KID syndrome [letter] Restano L, et al. **Pediatr Dermatol** 1999 Mar–Apr;16(2):164–5

IMMUNOLOGY

Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Stryk S, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):19–22

PATHOLOGY

Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Fartasch M, et al. **Arch Dermatol** 1999 Jul; 135(7):823–32

Specific skin lesions occurring in a patient with Hodgkin's lymphoma. Pagliaro JA, et al. **Australas J Dermatol** 1999 Feb;40(1):41–3

The molecular basis of inherited disorders of keratinization. Dunnill MG. **Hosp Med** 1998 Jan;59(1):17–22

Severe congenital ichthyosis of the neonate. Akiyama M. **Int J Dermatol** 1998 Oct;37(10):722–8 (67 ref.)

Ichthyosiform sarcoidosis. Cather JC, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):862–5

[A case of keratitis, ichthyosis, and deafness syndrome with Hutchinson's triad-like symptoms] Takechi K, et al. **Nippon Ganka Gakkai Zasshi** 1999 Apr;103(4):322–6 (Eng. Abstr.) **(Jpn)**

ICHTHYOSIS, LAMELLAR

Harlequin fetus: a case report. Moreau S, et al. **Surg Radiol Anat** 1999;21(3):215–6

COMPLICATIONS

Unusual hyperpigmentation developing in congenital reticular ichthyosiform erythroderma (ichthyosis variegata). Brusasco A, et al. **Br J Dermatol** 1998 Nov; 139(5):893–6

Collodion baby concomitant with congenital hypothyroidism: a patient report and review of the literature. Kurtoğlu S, et al. **J Pediatr Endocrinol Metab** 1998 Jul–Aug;11(4):569–73 (24 ref.)

DIAGNOSIS

Prenatal diagnosis of harlequin ichthyosis by the examination of keratinized hair canals and amniotic fluid cells at 19 weeks' estimated gestational age. Akiyama M, et al. **Prenat Diagn** 1999 Feb;19(2):167–71

GENETICS

Bleomycin-induced chromosome aberrations in lymphocytes

derived from patients with lamellar ichthyosis. Vernole P, et al. **Cancer Genet Cytogenet** 1999 Jan 15;108(2):154–7
Lamellar ichthyosis: further narrowing, physical and expression mapping of the chromosome 2 candidate locus. Parmentier L, et al. **Eur J Hum Genet** 1999 Jan;7(1):77–87
Strong founder effect for a transglutaminase 1 gene mutation in lamellar ichthyosis and congenital ichthyosiform erythroderma from Norway. Pigg M, et al. **Eur J Hum Genet** 1998 Nov–Dec;6(6):589–96
Identification of mutations in the transglutaminase 1 gene in lamellar ichthyosis. Tok J, et al. **Exp Dermatol** 1999 Apr;8(2):128–33
[Dorfman–Chanarin syndrome] Kaassis C, et al. **Ann Dermatol Venereol** 1998 May;125(5):317–9 (Eng. Abstr.) **(Fre)**

METABOLISM

Differential patterns of filaggrin expression in lamellar ichthyosis. Peña Penabad C, et al. **Br J Dermatol** 1998 Dec; 139(6):958–64
Altered expression of immunoreactive involucrin in lamellar ichthyosis. Peña–Penabad C, et al. **Eur J Dermatol** 1999 Apr–May;9(3):197–201

ICHTHYOSIS, SEX-LINKED see **ICHTHYOSIS, X-LINKED**

ICHTHYOSIS VULGARIS

DIAGNOSIS

Dermacase. Ichthyosis vulgaris. Adams SP. **Can Fam Physician** 1998 Dec;44:2645, 2652
Are atopy and palm–sole hyperlinearity clinical tools in the differential diagnosis between ichthyosis vulgaris and X–linked ichthyosis? [letter; comment] Cuevas–Covarrubias SA, et al. **J Dermatol** 1998 Aug; 25(8):556–7. Comment on: J Dermatol 1996 Sep;23(9):594–7.

GENETICS

Higher prevalence of X–linked ichthyosis vs. ichthyosis vulgaris in Mexico [letter] Cuevas–Covarrubias SA, et al. **Int J Dermatol** 1999 Jul;38(7):555–6

METABOLISM

The pH gradient over the stratum corneum differs in X–linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"? Ohman H, et al. **J Invest Dermatol** 1998 Oct;111(4):674–7

ICHTHYOSIS, X-LINKED

DIAGNOSIS

Most "sporadic" cases of X–linked ichthyosis are not de novo mutations. Cuevas–Covarrubias SA, et al. **Acta Derm Venereol** 1999 Mar;79(2):143–4
Are atopy and palm–sole hyperlinearity clinical tools in the differential diagnosis between ichthyosis vulgaris and X–linked ichthyosis? [letter; comment] Cuevas–Covarrubias SA, et al. **J Dermatol** 1998 Aug; 25(8):556–7. Comment on: J Dermatol 1996 Sep;23(9):594–7.

ENZYMOLOGY

Absence of male–pattern baldness in men with X–linked recessive ichthyosis? A hypothesis to be challenged. Happle R, et al. **Dermatology** 1999;198(3):231–2

GENETICS

Most "sporadic" cases of X–linked ichthyosis are not de novo mutations. Cuevas–Covarrubias SA, et al. **Acta Derm Venereol** 1999 Mar;79(2):143–4
Linear lesions reflecting lyonization in women heterozygous for IFAP syndrome (ichthyosis follicularis with atrichia and photophobia). König A, et al. **Am J Med Genet** 1999 Aug 6;85(4):365–8
Steroid sulfatase activity in leukocytes: a comparative study in 45,X; 46,Xi(Xq) and carriers of steroid sulfatase deficiency. Miranda–Duarte A, et al. **Biochem Mol Biol Int** 1999 Jan;47(1):137–42
An atypical contiguous gene syndrome: molecular studies in a family with X–linked Kallmann's syndrome and X–linked ichthyosis. Maya–Nuñez G, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):157–62
Analysis of an interstitial deletion in a patient with Kallmann syndrome, X–linked ichthyosis and mental retardation. Weissörtel R, et al. **Clin Genet** 1998 Jul;54(1):45–51
Higher prevalence of X–linked ichthyosis vs. ichthyosis vulgaris in Mexico [letter] Cuevas–Covarrubias SA, et al. **Int J Dermatol** 1999 Jul;38(7):555–6

METABOLISM

The pH gradient over the stratum corneum differs in X–linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"? Ohman H, et al. **J Invest Dermatol** 1998 Oct;111(4):674–7
[X–linked ichthyosis: development of a new cellular and metabolic model of cholesterol sulfate] Levade T. **Ann Dermatol Venereol** 1998 Nov;125 Suppl 2:S37–8 **(Fre)**

PATHOLOGY

Linear lesions reflecting lyonization in women heterozygous for IFAP syndrome (ichthyosis follicularis with atrichia and photophobia). König A, et al. **Am J Med Genet** 1999 Aug 6;85(4):365–8
Ocular findings in ichthyosis follicularis, atrichia, and photophobia syndrome. Cursiefen C, et al. **Arch Ophthalmol** 1999 May;117(5):681–4

PHYSIOPATHOLOGY

Recessive x–linked ichthyosis: role of cholesterol–sulfate accumulation in the barrier abnormality. Zettersten E, et al. **J Invest Dermatol** 1998 Nov;111(5):784–90

ICI–46474 see **TAMOXIFEN**

ICI–66082 see **ATENOLOL**

ICOSAHEDRAL CYTOPLASMIC DEOXYRIBOVIRUSES see **IRIDOVIRIDAE**

ICRF–159 see **RAZOXANE**

ICSH see **LH**

ICSH RECEPTORS see **RECEPTORS, LH**

ICTALURIDAE

Determination of flumequine in channel catfish by liquid chromatography with fluorescence detection. Plakas SM, et al. **J AOAC Int** 1999 May–Jun;82(3):614–9

ANATOMY & HISTOLOGY

Descending neural projections to the spinal cord in the channel catfish, Ictalurus punctatus. New JG, et al. **Anat Rec** 1998 Oct;252(2):235–53
Non–enzymatic isolation and culture of channel catfish hepatocytes. Seddon WL, et al. **Comp Biochem Physiol A Mol Integr Physiol** 1999 May; 123(1):9–15

BLOOD

Seasonal values of selected blood parameters of farm–raised channel catfish (Ictalurus punctatus) in the Mississippi Delta. Leard AT, et al. **J Vet Diagn Invest** 1998 Oct; 10(4):344–9
Molecular and functional characterization of channel catfish (Ictalurus punctatus) neutrophil collagenase. Noya M, et al. **Vet Immunol Immunopathol** 1999 Mar 1;67(4):303–16

GENETICS

Transcribed dinucleotide microsatellites and their associated genes from channel catfish Ictalurus punctatus. Liu Z, et al. **Biochem Biophys Res Commun** 1999 May 27; 259(1):190–4
Identification and characterization of the tumor suppressor p53 in channel catfish (Ictalurus punctatus). Luft JC, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1998 Aug; 120(4):675–82
MHC class I genes of the channel catfish: sequence analysis and expression. Antao AB, et al. **Immunogenetics** 1999 Apr; 49(4):303–11
Structure and genomic organization of a second cluster of immunoglobulin heavy chain gene segments in the channel catfish. Ghaffari SH, et al. **J Immunol** 1999 Feb 1; 162(3):1519–29
T–cell receptors in channel catfish: structure and expression of TCR alpha and beta genes [published erratum appears in Mol Immunol 1998 Dec;35(18):1219] Wilson MR, et al. **Mol Immunol** 1998 Jun;35(9):545–57
Intraindividual sequence diversity and a hierarchical approach to the study of mitochondrial DNA mutations. Chen JZ, et al. **Mutat Res** 1999 Jul 30;434(3):205–17

IMMUNOLOGY

Induction of target cell apoptosis by channel catfish cytotoxic cells. Hogan RJ, et al. **Cell Immunol** 1999 Aug 1; 195(2):110–8
Identification of a channel catfish, Ictalurus punctatus (Rafinesque), leukocyte–specific leucine zipper protein. Xue L, et al. **Dev Comp Immunol** 1999 Mar–Apr; 23(2):149–63
Structure and genomic organization of a second cluster of immunoglobulin heavy chain gene segments in the channel catfish. Ghaffari SH, et al. **J Immunol** 1999 Feb 1; 162(3):1519–29

METABOLISM

An enzyme–linked immunosorbent assay for estrogenicity using primary hepatocyte cultures from the channel catfish (Ictalurus punctatus). Monteverdi GH, et al. **Arch Environ Contam Toxicol** 1999 Jul;37(1):62–9
Biomarker assessment of the effects of coal strip–mine contamination on channel catfish. Martin LK Jr, et al. **Ecotoxicol Environ Saf** 1998 Nov;41(3):307–20
Cloning, in vitro expression, and novel phylogenetic classification of a channel catfish estrogen receptor. Xia Z, et al. **Gen Comp Endocrinol** 1999 Mar;113(3):360–8
The interaction of chlorinated alicyclic insecticides with brain GABA(A) receptors in channel catfish (Ictalurus punctatus). Carr RL, et al. **J Toxicol Environ Health** 1999 Apr 23;56(8):543–53

MICROBIOLOGY

Characterization of Listeria monocytogenes isolated from channel catfish (Ictalurus punctatus). Wang C, et al. **Am J Vet Res** 1998 Sep;59(9):1125–8
Production of monoclonal antibodies to Listeria monocytogenes and their application to determine the virulence of isolates from channel catfish. Erdenlig S, et al. **Appl Environ Microbiol** 1999 Jul;65(7):2827–32
Prevalence and characteristics of Aeromonas species isolated from processed channel catfish. Wang C, et al. **J Food Prot** 1999 Jan;62(1):30–4
Quantitative PCR for Listeria monocytogenes with colorimetric detection. Wang C, et al. **J Food Prot** 1999 Jan;62(1):35–9

PHYSIOLOGY

Biomarkers of oxidative stress and genotoxicity in livers of field–collected brown bullhead, Ameiurus nebulosus. McFarland VA, et al. **Arch Environ Contam Toxicol** 1999 Aug;37(2):236–41
Amino acid–activated channels in the catfish taste system. Kumazawa T, et al. **Biophys J** 1998 Dec;75(6):2757–66
Differential projections of ciliated and microvillous olfactory receptor cells in the catfish, Ictalurus punctatus. Morita Y, et al. **J Comp Neurol** 1998 Sep 7;398(4):539–50
Intracellular pH regulation in hepatocytes isolated from three teleost species. Furimsky M, et al. **J Exp Zool** 1999 Sep 1;284(4):361–7
Transcriptional activities in the pituitaries of channel catfish before and after induced ovulation by injection of carp pituitary extract as revealed by expressed sequence tag analysis. Karsi A, et al. **J Mol Endocrinol** 1998 Oct; 21(2):121–9
Odorant receptor gene expression in catfish taste tissue. Medler KF, et al. **Neuroreport** 1998 Dec 21;9(18):4103–7

VIROLOGY

Cloning and expression of a putative glycoprotein gene of channel catfish virus using baculovirus expression system. Kucuktas H, et al. **Dis Aquat Organ** 1998 Nov 30; 34(3):231–7
Detection of channel catfish virus DNA in latently infected catfish. Gray WL, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1817–22
Channel catfish virus gene 50 encodes a secreted, mucin–like glycoprotein. Vanderheijden N, et al. **Virology** 1999 Apr 25;257(1):220–7

ICTALURUS see **ICTALURIDAE**

ICTERUS see **JAUNDICE**

ICTERUS GRAVIS NEONATORUM see **ERYTHROBLASTOSIS, FETAL**

IDARUBICIN

ADMINISTRATION & DOSAGE

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. **Br J Haematol** 1998 Oct;103(1):100–9
Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Nousiainen T, et al. **Eur J Haematol** 1998 Nov;61(5):347–53
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Chiodini B, et al. **Leuk Lymphoma** 1999 May;33(5–6):485–97
[Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse] Wakazono Y, et al. **Rinsho Ketsueki** 1998 Jul;39(7):499–505 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Successful emergency operation for massive hemorrhage due to jejunal angiodysplasia after intensive chemotherapy in a patient with refractory anemia with excess of blasts] Morita K, et al. **Rinsho Ketsueki** 1998 Jul;39(7):526–31 (Eng. Abstr.) **(Jpn)**

BLOOD

Determination of idarubicin and idarubicinol in rat plasma using reversed–phase high–performance liquid chromatography and fluorescence detection. Kuhlmann O, et al. **J Chromatogr B Biomed Sci Appl** 1999 May 28; 728(2):279–82

IDARUBICIN

CHEMISTRY

Solution structure of iron(III)-anthracycline complexes. Fiallo MM, et al. **J Med Chem** 1999 Jul 29;42(15):2844-51

PHARMACOKINETICS

Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells. Kessel M, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):369-73

Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. Pea F, et al. **Eur J Clin Pharmacol** 1999 Jul;55(5):361-8

Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. Berg SL, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):26-30

PHARMACOLOGY

Modification of membrane fluidity and depolarization by some anthracyclines in different cell lines. Pacilio C, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4027-34

Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells. Fukushima T, et al. **Leuk Res** 1999 Jan;23(1):37-42

Idarubicin DNA intercalation is reduced by MRP1 and not Pgp. Smeets ME, et al. **Leukemia** 1999 Sep;13(9):1390-8

Topoisomerase poisoning activity of novel disaccharide anthracyclines. Guano F, et al. **Mol Pharmacol** 1999 Jul; 56(1):77-84

THERAPEUTIC USE

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial. Schneller F, et al. **Ann Hematol** 1998 Nov; 77(5):225-9

FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Deane M, et al. **Bone Marrow Transplant** 1998 Dec;22(12):1137-43

Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells. Locke VL, et al. **Br J Haematol** 1999 Jul;106(1):86-91

Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Roovers DJ, et al. **Leuk Res** 1999 Jun;23(6):539-48

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Archimbaud E, et al. **Leukemia** 1999 Jun; 13(6):843-9

Idarubicin-anti-CD3 reduces vascular disease in mouse cardiac allografts. Mottram PL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1414-5

[Clinical effect of idarubicin on malignant lymphoma] Urabe A, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1275-82 (Eng. Abstr.) **(Jpn)**

TOXICITY

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Hu XF, et al. **Br J Cancer** 1999 Feb;79(5-6):831-7

IDAZOXAN

ANALOGS & DERIVATIVES

Attenuation of tolerance to opioid-induced antinociception by idazoxan and other I2-ligands. Boronat MA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:359-63

alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. Zhang W, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1286-92

Tonic adrenergic and serotonergic inhibition of a withdrawal reflex in rabbits subjected to different levels of surgical preparation. Ogilvie J, et al. **Neuroscience** 1999; 89(4):1247-58

METABOLISM

1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. Wood DH, et al. **Eur J Pharmacol** 1998 Jul 17; 353(1):97-103

Characterization of [3H]idazoxan binding proteins in solubilized membranes from rabbit and human liver. Remaury A, et al. **J Auton Nerv Syst** 1998 Oct 15; 72(2-3):111-7

PHARMACOKINETICS

Identification of human I1 receptors and their relationship to alpha 2-adrenoceptors. Dontenwill M, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:123-34

Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Olmos G, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:144-60

Pentamidine is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 receptors. Wood DH, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:110-3

PHARMACOLOGY

Attenuation of tolerance to opioid-induced antinociception by idazoxan and other I2-ligands. Boronat MA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:359-63

Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Regunathan S, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:410-9

Importance of imidazoline receptors in the cardiovascular responses of clonidine in sinoaortic denervated rats. Ricci D, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:290-4

Imidazolines and the pancreatic B-cell. Actions and binding sites. Rustenbeck I, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:229-40

Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels. Ugedo L, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:365-8

The effects of the alpha 2 adrenoceptor blocker idazoxan on defeat-induced immobility and plasma corticosterone in rats is antagonized by administration of adrenocorticotrophin-antiserum. Haller J, et al. **Behav Pharmacol** 1997 Jun;8(2-3):269-73

Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Boronat MA, et al. **Br J Pharmacol** 1998 Sep;125(1):175-85

Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Hertel P, et al. **Eur J Pharmacol** 1999 Apr 29;371(2-3):153-8

Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Martel J, et al. **Exp Neurol** 1998 Dec;154(2):595-601

The effects of idazoxan on reaction times, eye movements and the mood of healthy volunteers and patients with upper respiratory tract illnesses. Smith A, et al. **J Psychopharmacol** 1999;13(2):148-51

Inhibition of astroglial nitric oxide synthase type 2 expression by idazoxan. Feinstein DL, et al. **Mol Pharmacol** 1999 Feb; 55(2):304-8

Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine. Middleton HC, et al. **Psychopharmacology (Berl)** 1999 Aug;145(4):401-11

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Hertel P, et al. **Science** 1999 Oct 1;286(5437):105-7

IDDM see **DIABETES MELLITUS, INSULIN-DEPENDENT**

IDENTIFICATION (PSYCHOLOGY)

The identity status of African Americans in middle adolescence: a reexamination of Watson and Protinsky (1991). Forbes S, et al. **Adolescence** 1998 Winter; 33(132):845-9

Posttraumatic stress disorder and identification in disaster workers [see comments] Ursano RJ, et al. **Am J Psychiatry** 1999 Mar;156(3):353-9. Comment in: Am J Psychiatry 1999 Mar;156(3):349-51.

Shall we ever know the whole truth about projective identification? [letter] Massidda GB. **Int J Psychoanal** 1999 Apr;80 (Pt 2):365-7

Who influenced whom? And how?--a brief series of notes on E. Weiss, M. Klein (and I. Svevo) and the so-called 'origins' of 'projective and introjective identification' [letter] Steiner R. **Int J Psychoanal** 1999 Apr;80 (Pt 2):367-75

The professional identity of the nurse: concept analysis and development. Ohlén J, et al. **J Adv Nurs** 1998 Oct; 28(4):720-7 (40 ref.)

The patient who assumed his analyst's identity. Goldberg C. **J Am Acad Psychoanal** 1999 Summer;27(2):177-89

Imitation and identification in autism. Hobson RP, et al. **J Child Psychol Psychiatry** 1999 May;40(4):649-59

Dangerous misidentification of people due to flashback phenomena in posttraumatic stress disorder. Silva JA, et al. **J Forensic Sci** 1998 Nov;43(6):1107-11

Ethnic identity development of internationally adopted children and adolescents: implications for family therapists. Friedlander ML. **J Marital Fam Ther** 1999 Jan;25(1):43-60 (69 ref.)

Induction, identification or folie à deux? Psychodynamics and genesis of Munchausen syndromes by proxy and false allegations of sexual abuse in adolescents. Günter M. **Med Law** 1998;17(3):359-79

Relationship between identification with the role of sport fan and trait aggression. Wann DL, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1296-8

Trauma and identity through two generations of the Holocaust. Hogman F. **Psychoanal Rev** 1998 Aug; 85(4):551-78

Emotional congruence in sexual offenders against children. Wilson RJ. **Sex Abuse** 1999 Jan;11(1):33-47

IDENTIFICATION, SOCIAL see **SOCIAL IDENTIFICATION**

IDENTITY CRISIS

Does assisted reproduction make an impact on the identity and self-image of infertile couples? Daniels KR. **J Assist Reprod Genet** 1999 Feb;16(2):57-9 (12 ref.)

Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59-62 (19 ref.)

IDIOCY see **MENTAL RETARDATION**

IDIOPATHIC CD4-POSITIVE T-LYMPHOCYTOPENIA see **T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE**

IDIOPATHIC HYPERCATABOLIC HYPOPROTEINEMIA see **PROTEIN-LOSING ENTEROPATHIES**

IDIOPATHIC HYPEREOSINOPHILIC SYNDROME see **HYPEREOSINOPHILIC SYNDROME**

IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS see **CARDIOMYOPATHY, HYPERTROPHIC**

IDIOPATHIC HYPERTROPHIC SUBVALVULAR STENOSIS see **CARDIOMYOPATHY, HYPERTROPHIC**

IDIOPATHIC INTRACRANIAL HYPERTENSION see **PSEUDOTUMOR CEREBRI**

IDIOPATHIC THROMBOCYTOPENIC PURPURA see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

IDIOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN IDIOTYPES**

IDITOL DEHYDROGENASE

ANTAGONISTS & INHIBITORS

Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy. Schmidt RE, et al. **J Neuropathol Exp Neurol** 1998 Dec;57(12):1175-89

BIOSYNTHESIS

Expression of aldose reductase, sorbitol dehydrogenase and Na+/myo-inositol and Na+/Cl-/betaine transporter mRNAs in individual cells of the kidney during changes in the diuretic state. Burger-Kentischer A, et al. **Pflugers Arch** 1999 Jan;437(2):248-54

Expression of Na+/Cl-/betaine and Na+/myo-inositol transporters, aldose reductase and sorbitol dehydrogenase in macula densa cells of the kidney. Burger-Kentischer A, et al. **Pflugers Arch** 1998 Oct;436(5):807-9

CHEMISTRY

Tandem mass spectrometry of alcohol dehydrogenase and related biomolecules. Griffiths WJ. **Adv Exp Med Biol** 1999; 463:305-10

GENETICS

Rat renal expression of mRNA coding for aldose reductase and sorbitol dehydrogenase and its osmotic regulation in inner medullary collecting duct cells. Grunewald RW, et al. **Cell Physiol Biochem** 1998;8(6):293-303

Sorbitol dehydrogenase of Drosophila. Gene, protein, and expression data show a two-gene system. Luque T, et al. **J Biol Chem** 1998 Dec 18;273(51):34293-301

Structural and evolutionary characterization of the human sorbitol dehydrogenase gene duplication. Carr IM, et al. **Mamm Genome** 1998 Dec;9(12):1042-8

Cloning of NAD-dependent sorbitol dehydrogenase from apple fruit and gene expression. Yamada K, et al. **Plant Cell Physiol** 1998 Dec;39(12):1375-9

METABOLISM

Structural and functional properties of a yeast xylitol dehydrogenase, a Zn2+-containing metalloenzyme similar to medium-chain sorbitol dehydrogenases. Lunzer R, et al. **Biochem J** 1998 Nov 15;336 (Pt 1):91-9

The use of fluoro- and deoxy-substrate analogs to examine binding specificity and catalysis in the enzymes of the sorbitol pathway. Scott ME, et al. **Carbohydr Res** 1998 Dec 15;313(3-4):247-53

Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Sato S, et al. **Invest Ophthalmol Vis Sci** 1999 Mar;40(3):697-704

IDOXURIDINE

ADMINISTRATION & DOSAGE

Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. McGinn CJ, et al. **Clin Cancer Res** 1996 Aug;2(8):1299-305

Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Williams JA, et

al. **Int J Radiat Oncol Biol Phys** 1998 Oct 1;42(3):631-9

Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain. Reza MS, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):789-801

CHEMISTRY

Synthesis and characterisation of poly(D,L-lactic acid)-idoxuridine conjugate. Rimoli MG, et al. **J Controlled Release** 1999 Mar 8;58(1):61-8

Iodo-2'-deoxyuridine (IUdR) and 125IUdR loaded biodegradable microspheres for controlled delivery to the brain. Reza MS, et al. **J Microencapsul** 1998 Nov-Dec; 15(6):789-801

DIAGNOSTIC USE

Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. Chiou RK, et al. **J Urol** 1999 Jul; 162(1):58-62

METABOLISM

In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Kinsella TJ, et al. **Clin Cancer Res** 1996 Jun;2(6):981-9

5-Iododeoxyuridine-125I incorporation in vivo after exposure to a 50 Hz magnetic field. Svedenstål BM, et al. **In Vivo** 1998 Sep-Oct;12(5):531-4

PHARMACOKINETICS

Targeting tumors with iodine-123 labeled deoxyuridine: distribution and DNA binding. Thakur ML, et al. **Cancer Detect Prev** 1999;23(1):72-7

Development of 5-iodo-2'-deoxyuridine milling process to reduce initial burst release from PLGA microparticles. Gèze A, et al. **Int J Pharm** 1999 Feb 15;178(2):257-68

Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers. Geze A, et al. **J Controlled Release** 1999 Apr 19;58(3):311-22

PHARMACOLOGY

Inhibition of condensation in human chromosomes induced by the thymidine analogue 5-iododeoxyuridine. Ott G, et al. **Chromosome Res** 1998 Sep;6(6):495-9

Correlation between cell reproductive death and chromosome aberrations assessed by FISH for low and high doses of radiation and sensitization by iodo-deoxyuridine in human SW-1573 cells. Franken NA, et al. **Int J Radiat Biol** 1999 Mar;75(3):293-9

Effect of 3 growth control substances on foreign body sarcomagenesis: IFN, IUdR, MGBG. Mhic Iomhair M, et al. **Ir J Med Sci** 1999 Jan-Mar;168(1):42-4

Increased chromosome exchange frequencies in iodo-deoxyuridine-sensitized human SW-1573 cells after gamma-irradiation. Franken NA, et al. **Oncol Rep** 1999 Jan-Feb;6(1):59-63

TOXICITY

Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Fauth E, et al. **Mutat Res** 1999 Apr 6;440(2):147-56

IDURONATE SULFATASE

GENETICS

Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Vafiadaki E, et al. **Arch Dis Child** 1998 Sep;79(3):237-41

A deletion involving exons 2-4 in the iduronate-2-sulfatase gene of a patient with intermediate Hunter syndrome. Bonuccelli G, et al. **Clin Genet** 1998 Jun;53(6):474-7

Homologous nonallelic recombinations between the iduronate-sulfatase gene and pseudogene cause various intragenic deletions and inversions in patients with mucopolysaccharidosis type II. Bunge S, et al. **Eur J Hum Genet** 1998 Sep-Oct;6(5):492-500

Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients. Karsten S, et al. **Hum Genet** 1998 Dec;103(6):732-5

Detection of four novel mutations in the iduronate-2-sulfatase gene. Mutations in brief no. 123. Online. Balzano N, et al. **Hum Mutat** 1998;11(4):333

Mutations in the iduronate-2-sulfatase gene in 12 Spanish patients with Hunter disease. Gort L, et al. **Hum Mutat** 1998;Suppl 1:S66-8

Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: characterisation of 6 novel mutations. Mutation in brief no. 249. Online. Hartog C, et al. **Hum Mutat** 1999;14(1):87

Identification of 6 new mutations in the iduronate sulfatase gene. Mutation in brief no. 233. Online. Vallance HD, et al. **Hum Mutat** 1999;13(4):338

Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). Li P, et al. **J Med Genet** 1999 Jan;36(1):21-7

Reassessment of biochemically determined Hunter syndrome carrier status by DNA testing. Timms KM, et al. **J Med Genet** 1998 Aug;35(8):646-9

Quantification of X-chromosome inactivation patterns using RT-PCR of the polymorphic iduronate-2-sulphatase gene and correlation of the results obtained with DNA-based techniques. Harrison CN, et al. **Leukemia** 1998 Nov; 12(11):1834-9

Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome. Stroncek DF, et al. **Transfusion** 1999 Apr;39(4):343-50

IDURONATESULFATE SULFOHYDROLASE see **IDURONATE SULFATASE**

IDURONIC ACID

ANALOGS & DERIVATIVES

Synthesis of a 3-deoxy-L-iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence. Lei PS, et al. **Bioorg Med Chem** 1998 Aug;6(8):1337-46

CHEMICAL SYNTHESIS

Synthesis of a 3-deoxy-L-iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence. Lei PS, et al. **Bioorg Med Chem** 1998 Aug;6(8):1337-46

METABOLISM

Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. Kobayashi M, et al. **J Biol Chem** 1999 Apr 9;274(15):10474-80

IDURONIDASE

see related **MUCOPOLYSACCHARIDOSIS I**

CHEMISTRY

Structural determination of oligosaccharides from recombinant iduronidase released with peptide N-glycanase F using fluorophore-assisted carbohydrate electrophoresis. Hague C, et al. **Electrophoresis** 1998 Nov; 19(15):2612-20

DEFICIENCY

Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Lutzko C, et al. **Blood** 1999 Mar 15;93(6):1895-905

Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Lutzko C, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1521-32

GENETICS

Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Lutzko C, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1521-32

Mobilization and transduction of peripheral blood progenitor cells in patients with mucopolysaccharidosis I. Hubel A, et al. **J Hematother** 1998 Dec;7(6):505-14

Identification and characterization of the molecular lesion causing mucopolysaccharidosis type I in cats. He X, et al. **Mol Genet Metab** 1999 Jun;67(2):106-12

METABOLISM

Mucopolysaccharidosis type I: characterization of novel mutations affecting alpha-L-iduronidase activity. Lee-Chen GJ, et al. **Clin Genet** 1999 Jul;56(1):66-70

IFN-GAMMA-INDUCING FACTOR see **INTERLEUKIN-18**

IFOSFAMIDE

L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Badary OA. **Exp Nephrol** 1999 Jul-Aug; 7(4):323-7

ADMINISTRATION & DOSAGE

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) [see comments] Buesa JM, et al. **Ann Oncol** 1998 Aug;9(8):871-6. Comment in: Ann Oncol 1999 Jan;10(1):123-4.

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Fuchs N, et al. **Ann Oncol** 1998 Aug;9(8):893-9

Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide? [letter; comment] Yalçin S. **Ann Oncol** 1999 Jan;10(1):123-4. Comment on: Ann Oncol 1998 Aug;9(8):871-6.

Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J, et al. **Bone Marrow Transplant** 1999 Mar;23(5):413-9

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. Prince HM, et al. **Bone Marrow Transplant** 1999 Mar;23(5):427-35

Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. Comandone A, et al. **J Chemother** 1998 Oct; 10(5):385-93

Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. Ferrari S, et al. **J Chemother** 1998 Dec;10(6):484-91

Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. Craft A, et al. **J Clin Oncol** 1998 Nov;16(11):3628-33

Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study. Mantovani G, et al. **Oncol Rep** 1998 Nov-Dec;5(6):1499-505

Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer. Soh LT, et al. **Singapore Med J** 1998 Aug;39(8):357-8

ADVERSE EFFECTS

Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide. Ferrari S, et al. **Anticancer Drugs** 1999 Jan;10(1):25-31

Increased urinary losses of carnitine during ifosfamide chemotherapy. Marthaler NP, et al. **Cancer Chemother Pharmacol** 1999;44(2):170-2

A 47-year-old man with leiomyosarcoma and altered mental status. Gurm HS, et al. **Cleve Clin J Med** 1999 Jan; 66(1):15-7

A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Bitran JD, et al. **Clin Cancer Res** 1995 Feb;1(2):185-8

Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. Foxall PJ, et al. **Clin Cancer Res** 1997 Sep;3(9):1507-18

Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. Loebstein R, et al. **J Clin Pharmacol** 1999 May;39(5):454-61

Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Rossi R, et al. **Med Pediatr Oncol** 1999 Mar;32(3):177-82

Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm. Lehrich RW, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):226-30

[Ifosfamide-related encephalopathy. Report of two cases] Dourthe LM, et al. **Rev Med Interne** 1999 Mar;20(3):264-6 (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes. Kerbusch T, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1-2):275-84

Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions. Gilard V, et al. **J Med Chem** 1999 Jul 15; 42(14):2542-60

Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. Yazawa Y, et al. **J Orthop Sci** 1999;4(3):231-7

Unexpected electrophysiological effects of D-19575, a new cytostatic drug. Kleta R, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:18-20

ANALYSIS

Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Minoia C, et al. **Rapid Commun Mass Spectrom** 1998;12(20):1485-93

BLOOD

Determination of ifosfamide by HPLC using on-line sample preparation. Zolezzi C, et al. **J Chemother** 1999 Feb; 11(1):69-73

CHEMISTRY

Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions. Gilard V, et al. **J Med Chem** 1999 Jul 15; 42(14):2542-60

IFOSFAMIDE

METABOLISM

High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. Huang Z, et al. **Anal Biochem** 1999 Aug 15;273(1):117-25

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Crommentuyn KM, et al. **Cancer Treat Rev** 1998 Oct;24(5):345-66 (91 ref.)

Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Granvil CP, et al. **Drug Metab Dispos** 1999 Apr;27(4):533-41

Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Roy P, et al. **Drug Metab Dispos** 1999 Jun; 27(6):655-66

Differential in vitro hepatic and intestinal metabolism of ifosfamide in the rat. Lu H, et al. **Xenobiotica** 1998 Aug; 28(8):779-84

PHARMACOKINETICS

Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2. Passe P, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):837-42

Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Jounaidi Y, et al. **Cancer Res** 1998 Oct 1;58(19):4391-401

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Yule SM, et al. **Clin Cancer Res** 1997 Nov;3(11):1985-92

Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. Comandone A, et al. **J Chemother** 1998 Oct; 10(5):385-93

PHARMACOLOGY

Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Hartley JM, et al. **Clin Cancer Res** 1999 Mar; 5(3):507-12

Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Mulders TM, et al. **Clin Cancer Res** 1995 Dec;1(12):1525-36

Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. Reinhart WH, et al. **Eur J Haematol** 1999 Apr; 62(4):223-30

Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. Löhr M, et al. **J Mol Med** 1999 Apr;77(4):393-8

Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. Yazawa Y, et al. **J Orthop Sci** 1999;4(3):231-7

THERAPEUTIC USE

Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. Fernberg JO, et al. **Acta Orthop Scand Suppl** 1999 Jun;285:62-8

Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Karle P, et al. **Adv Exp Med Biol** 1998; 451:97-106

Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Müller P, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:337-51

Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Santoro A. **Ann Oncol** 1999 Feb;10(2):151-4

High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence? [editorial; comment] Verweij J. **Ann Oncol** 1998 Aug;9(8):807-9. Comment on: Ann Oncol 1998 Aug;9(8):870-84. Comment on: Ann Oncol 1998 Aug;9(8):917-9.

Single-agent ifosfamide in the treatment of anthracycline-refractory adult sarcomas. Lopez M, et al. **Clin Ter** 1998 Sep-Oct;149(5):331-3

Comments on: Should patients with advanced soft tissue sarcomas be treated with chemotherapy? Arbiter: Van Hoesel, Q.G.C.M. Eur J Cancer 1998, 34(7), 964-965 [letter; comment] De Pas T. **Eur J Cancer** 1999 Feb; 35(2):327. Comment on: Eur J Cancer 1998 Jun;34(7):958-65.

Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). Simşek T, et al. **Eur J Gynaecol Oncol** 1998;19(4):405-7

Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). Reinhardt W, et al. **Exp Clin Endocrinol Diabetes** 1999;107(3):177-82

Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Löhr M, et al. **Gene Ther** 1998 Aug;5(8):1070-8

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. Paulsen F, et al. **J Cancer Res Clin Oncol** 1999 Jul;125(7):411-8

Ifosfamide in malignant mesothelioma: a phase II study. Andersen MK, et al. **Lung Cancer** 1999 Apr;24(1):39-43

Pilot study of daily ifosfamide 1 g/m2 until grade III granulocytopenia as second-line chemotherapy for anthracycline-pretreated advanced soft tissue sarcoma. Babovic N, et al. **Tumori** 1998 Nov-Dec;84(6):677-80

Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study. Bisagni G, et al. **Tumori** 1998 Nov-Dec;84(6):659-61

TOXICITY

2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Sood C, et al. **Br J Cancer Suppl** 1996 Jul;27:S287-93

Induction of specific-locus and dominant lethal mutations in male mice by ifosfamide (Holoxan). Ehling UH, et al. **Genet Res** 1998 Dec;72(3):177-83

Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. Springate J, et al. **In Vitro Cell Dev Biol Anim** 1999 Jun;35(6):314-7

Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. Brauer LP, et al. **J Cancer Res Clin Oncol** 1998;124(10):549-54

Taurine attenuates fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Badary OA. **Oncol Res** 1998;10(7):355-60

IGA

Expression, purification and biochemical characterization of recombinant murine secretory component: a novel tool in mucosal immunology. Crottet P, et al. **Biochem J** 1999 Jul 15;341 (Pt 2):299-306

Nomenclature of immunoglobulin A and other proteins of the mucosal immune system. IUIS/WHO Subcommittee on IgA Nomenclature. **Bull World Health Organ** 1998; 76(4):427-8

Linear IgA bullous dermatosis in a patient with acute lymphocytic leukemia: possible involvement of granulocyte colony-stimulating factor. Kano Y, et al. **Eur J Dermatol** 1999 Mar;9(2):122-5

Intercellular IgA dermatosis. Ongenae KC, et al. **Eur J Dermatol** 1999 Mar;9(2):85-94 (66 ref.)

Characterization of the human myeloid IgA Fc receptor 1 (CD89) gene in a cosmid clone. van Vuuren AJ, et al. **Immunogenetics** 1999 Jun;49(6):586-9

Lack of SC/pIgR-mediated epithelial transport of a human polymeric IgA devoid of J chain: in vitro and in vivo studies. Vaerman JP, et al. **Immunology** 1998 Sep;95(1):90-6

Linear IgA disease--a review of four patients. Elling SV, et al. **Ir Med J** 1998 Oct-Nov;91(5):167-8

Drug-induced linear IgA bullous dermatosis probably induced by furosemide. Cerottini JP, et al. **J Am Acad Dermatol** 1999 Jul;41(1):103-5

Chronic bullous disease of childhood: successful treatment with dicloxacillin. Siegfried EC, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):797-800

Linear IgA bullous dermatosis associated with ulcerative colitis. Chi HI, et al. **J Dermatol** 1999 Mar;26(3):150-3

Depot sulfonamid associated linear IgA bullous dermatosis with erythema multiforme-like clinical features. Tonev S, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):165-8

Linear IgA disease histopathologically and clinically masquerading as lichen planus. Cohen DM, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):196-201

Treatment of linear IgA bullous dermatosis of childhood with colchicine. Ang P, et al. **Pediatr Dermatol** 1999 Jan-Feb; 16(1):50-2

Monoclonal gammopathy of the immunoglobulin A class in a two-year-old girl with ataxia telangiectasia. McDonald PS, et al. **Pediatr Dev Pathol** 1998 Jul-Aug;1(4):319-21

Association of lymphocytic colitis with linear IgA dermatosis. Stüber E, et al. **Z Gastroenterol** 1999 Jun; 37(6):519-23

[Linear IgA dermatosis in an adult with clinical signs of Stevens-Johnson syndrome] Schneck B, et al. **Hautarzt** 1999 Apr;50(4):288-91 (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Johansson JE, et al. **Bone Marrow Transplant** 1999 Jul;24(1):35-9

Combined administration of IgA and IgG anti-Thy-1 antibodies enhances renal inflammation in rats. Van Dixhoorn MG, et al. **Kidney Int** 1999 Jun;55(6):2299-309

ANALYSIS

A clinical and histologic study of 37 cases of immunoglobulin A-associated vasculitis. Magro CM, et al. **Am J Dermatopathol** 1999 Jun;21(3):234-40

Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice [see comments] Rostami K, et al. **Am J Gastroenterol** 1999 Apr;94(4):888-94. Comment in: Am J Gastroenterol 1999 Apr;94(4):869-71.

IgA antiglomerular basement membrane disease associated with bronchial carcinoma and monoclonal gammopathy. Maes B, et al. **Am J Kidney Dis** 1999 Feb;33(2):E3 (24 ref.)

Hantavirus-specific IgG, IgM, and IgA in acute and chronic renal disease versus congenital renal disease in the United States. Patnaik M, et al. **Am J Kidney Dis** 1999 Apr; 33(4):734-7

Enzyme-linked immunosorbent assay for IgA antibodies to Trypanosoma cruzi in congenital infection. Di Pentima MC, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):211-4

Dermatitis herpetiformis: coeliac disease of the skin [editorial] Reunala T. **Ann Med** 1998 Oct;30(5):416-8 (20 ref.)

Toxic eruption in a woman with chronic arthritis. Abate KL, et al. **Arch Dermatol** 1999 Jan;135(1):81-6

IgA multiple myeloma presenting as an acquired bullous disorder. Wong DA, et al. **Australas J Dermatol** 1999 Feb; 40(1):31-4

Anti-Kp 90 IgA antibodies in the diagnosis of active tuberculosis. Arikan S, et al. **Chest** 1998 Nov;114(5):1253-7

Predominant immunoglobulin A response to phase II antigen of Coxiella burnetii in acute Q fever. Fournier PE, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):173-7

IgA basement membrane zone autoantibodies in bullous pemphigoid detect epidermal antigens of 270-280 kDa, 230 kDa, and 180 kDa molecular weight by immunoblotting. Kirtschig G, et al. **Clin Exp Dermatol** 1999 Jul;24(4):302-7

Desquamative gingivitis and balanitis--linear IgA disease or cicatricial pemphigoid? Kirtschig G, et al. **Clin Exp Dermatol** 1998 Jul;23(4):173-7

Sarcoidosis in a patient with linear IgA disease. Porter WM, et al. **Clin Exp Dermatol** 1999 Mar;24(2):67-70

Relationship between mucosal levels of Helicobacter pylori-specific IgA, interleukin-8 and gastric inflammation. Zhang QB, et al. **Clin Sci (Colch)** 1999 Apr;96(4):409-14

Linear IgA disease and ulcerative colitis. De Simone C, et al. **Eur J Dermatol** 1998 Jan-Feb;8(1):48-50

Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA? Wallon M, et al. **Eur J Pediatr** 1999 Aug;158(8):645-9

Elevation of specific immunoglobulin A antibodies to both allergen and bacterial antigen in induced sputum from asthmatics [see comments] Nahm DH, et al. **Eur Respir J** 1998 Sep;12(3):540-5. Comment in: Eur Respir J 1998 Sep;12(3):517-8.

The protective effect of breast feeding in relation to sudden infant death syndrome (SIDS): III. Detection of IgA antibodies in human milk that bind to bacterial toxins implicated in SIDS. Gordon AE, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):175-82

Immunoelectron microscopic study of the conjunctiva in cicatricial pemphigoid. Robin H, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):39-44

Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease. Seissler J, et al. **Horm Metab Res** 1999 Jun;31(6):375-9

The effect of exercising to exhaustion at different intensities on saliva immunoglobulin A, protein and electrolyte secretion. Blannin AK, et al. **Int J Sports Med** 1998 Nov; 19(8):547-52

Tissue transglutaminase antibodies for coeliac disease screening [see comments] Brusco G, et al. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):496-7. Comment in: Ital J Gastroenterol Hepatol 1998 Oct;30(5):498-9.

Serologic screening for coeliac disease--time for tissue transglutaminase test? [comment] Collin P. **Ital J Gastroenterol Hepatol** 1998 Oct;30(5):498-9. Comment on: Ital J Gastroenterol Hepatol 1998 Oct;30(5):496-7.

Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. Moulin B, et al. **J Am Soc Nephrol** 1999 Mar;10(3):519-28

Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). Westerhuis R, et al. **J Am Soc Nephrol** 1999 Apr;10(4):770-8

A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. Yoshikawa N, et al. **J Am Soc Nephrol** 1999 Jan;10(1):101-9

A patient with a refractory cutaneous bullous eruption [clinical conference] Nousari HC, et al. **J Cutan Med Surg** 1999 Apr;3(4):201-4

Chlamydia trachomatis and male infertility: chlamydia-IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response. Ochsendorf FR, et al. **J Eur Acad Dermatol Venereol** 1999 Mar; 12(2):143-52

Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. Fujioka H, et al. **J Exp Med** 1998 Oct 5;188(7):1223-9

High frequency of antigliadin antibodies and absence of antireticulin and antiendomysium antibodies in patients with ulcerative colitis. Kull K, et al. **J Gastroenterol** 1999 Feb;34(1):61-5

Prevalence of specific IgA and IgM anti-HBc antibodies compared with HBV DNA in the sera of HBsAg chronic carriers. Elsana S, et al. **J Hum Virol** 1997 Nov-Dec; 1(1):52-7

Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. Hildesheim A, et al. **J Immunol Methods** 1999 May 27;225(1-2):131-43

Self-sampled and air-dried cervicovaginal secretions can be used for analyses of mucosal antibodies. Hordnes K, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):151-9

Absorption of IgG does not enhance toxoplasma IgM and IgA immunoblotting. Chatterton JM, et al. **J Med Microbiol** 1999 Jun;48(6):593-5

Human colostrum contains IgA antibodies reactive to enteropathogenic Escherichia coli virulence-associated proteins: intimin, BfpA, EspA, and EspB. Loureiro I, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):166-71

IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus [letter; comment] Samarkos M, et al. **J Rheumatol** 1998 Nov;25(11):2283-4. Comment on: J Rheumatol 1998 Jan;25(1):74-8.

Isotype- and subclass-specific responses to infection and reinfection with parainfluenza-3 virus: comparison of the diagnostic potential of ELISAs detecting seroconversion and specific IgM and IgA. Graham DA, et al. **J Vet Diagn Invest** 1999 Mar;11(2):127-33

Comparison of the immunogold labeling of single light chains and whole immunoglobulins with anti-kappa on LR-white and epoxy sections. Brorson SH. **Micron** 1998 Dec; 29(6):439-43

IgA-gliadin antibodies, IgA-containing circulating immune complexes, and IgA glomerular deposits in wasting marmoset syndrome. Schroeder C, et al. **Nephrol Dial Transplant** 1999 Aug;14(8):1875-80

Serum and salivary antiendomysium antibodies in the screening of coeliac disease. Di Leo M, et al. **Panminerva Med** 1999 Mar;41(1):68-71

Indirect immunofluorescence for of anti-jejunum antibody detection in celiac disease: comparison among different antigenic substrates. Sategna-Guidetti C, et al. **Panminerva Med** 1998 Dec;40(4):261-3

Effect of music and auditory stimuli on secretory immunoglobulin A (IgA). Charnetski CJ, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1163-70

Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Jönsson T, et al. **Rheumatol Int** 1998;18(3):119-22

Catastrophic antiphospholipid syndrome associated with anti-beta-2-glycoprotein I IgA [letter] Abinader A, et al. **Rheumatology (Oxford)** 1999 Jan;38(1):84-5

A new immunoelectron microscopy approach for the detection of immunoglobulin and complement deposits in epoxy-embedded renal biopsies. Brorson SH, et al. **Ultrastruct Pathol** 1998 Nov-Dec;22(6):449-57

Determination of salivary and serum immunoglobulin concentrations in the cat. Harley R, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2-4):99-112

[Characterization of specific IgG, IgM, IgA and IgE isotypes in profound candidiasis] Toubas D, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):329-36 (Eng. Abstr.) **(Fre)**

[Effect of sulfur salt-bromine-iodine thermal waters on albumin and IgA concentrations in nasal secretions] Staffieri A, et al. **Acta Otorhinolaryngol Ital** 1998 Aug; 18(4):233-8 (Eng. Abstr.) **(Ita)**

[Correlation of serum IgA levels with serum IgG levels, erythrocyte sedimentation rate and platelet counts in 98 patients with rheumatoid arthritis] Nishiya K, et al. **Rinsho Byori** 1999 Jul;47(7):665-8 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Intraocular anti-Toxoplasma gondii IgA antibody production in patients with ocular toxoplasmosis. Ronday MJ, et al. **Am J Ophthalmol** 1999 Mar;127(3):294-300

Benzylpenicillin induced specific non-IgE antibody response in mice. Zhang L, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):531-4

Immunoglobulin A in asthma: friend or foe? [editorial; comment] Hiemstra PS. **Eur Respir J** 1998 Sep;12(3):517-8 (20 ref.). Comment on: Eur Respir J 1998 Sep;12(3):540-5.

Developmental regulation of immunoglobulin mRNA processing and the IgA response: establishing a paradigm. Lebman DA, et al. **Immunol Res** 1999;20(1):43-53 (55 ref.)

IgA production in MHC class II-deficient mice is primarily a function of B-1a cells. Snider DP, et al. **Int Immunol** 1999 Feb;11(2):191-8

Effect of bifidobacteria feeding on fecal flora and production of immunoglobulins in lactating mouse. Fukushima Y, et al. **Int J Food Microbiol** 1999 Feb 18;46(3):193-7

Intestinal IgA- and IgM-producing cells are not decreased in marathon runners. Nilssen DE, et al. **Int J Sports Med** 1998 Aug;19(6):425-31

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. Bontkes HJ, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):409-17

Two stages of increased IgA transfer during lactation in the marsupial, trichosurus vulpecula (Brushtail possum). Adamski FM, et al. **J Immunol** 1999 May 15; 162(10):6009-15

Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. Coffin SE, et al. **J Immunol** 1999 Sep 15;163(6):3064-70

Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. Hiroi T, et al. **J Immunol** 1999 Jan 15;162(2):821-8

The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. Hougs L, et al. **J Immunol** 1999 Jan 1;162(1):224-37

Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. Yanagita M, et al. **J Immunol** 1999 Mar 15; 162(6):3559-65

CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu-->S alpha and sequential S mu-->S gamma, S gamma-->S alpha DNA recombination. Zan H, et al. **J Immunol** 1998 Nov 15;161(10):5217-25

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):93-103

Recombinant porcine IFN-gamma potentiates the secondary IgG and IgA responses to an inactivated suid herpesvirus-1 vaccine and reduces postchallenge weight loss and fever in pigs. Vandenbroeck K, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):739-44

Fish oil feeding delays influenza virus clearance and impairs production of interferon-gamma and virus-specific immunoglobulin A in the lungs of mice [published erratum appears in J Nutr 1999 Jun;129(6):1237] Byleveld PM, et al. **J Nutr** 1999 Feb;129(2):328-35

Cytokine mRNA expression in lymphoid organs associated with the expression of IgA response in the rat. Petitprez K, et al. **Scand J Immunol** 1999 Jan;49(1):14-20

Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Lundholm P, et al. **Vaccine** 1999 Apr 9;17(15-16):2036-42

Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Verweij WR, et al. **Vaccine** 1998 Dec; 16(20):2069-76

Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Nesburn AB, et al. **Virology** 1998 Dec 5;252(1):200-9

BLOOD

Chronic urticaria and IgA myeloma [letter] Lipsker D, et al. **Acta Derm Venereol** 1998 Sep;78(5):395

Malaria parasitaemia and immunoglobulin levels in paired maternal-cord sera from south western Nigeria. Achidi EA, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):167-70

Serum IgA antibodies to human gut luminal aspirates and human liver in alcoholic liver disease. Douds AC, et al. **Alcohol Clin Exp Res** 1998 Oct;22(7):1383-8

Comparison of carbohydrate-deficient transferrin, immunoglobulin A antibodies reactive with acetaldehyde-modified protein and acetaldehyde-modified albumin with conventional markers of alcohol consumption. Worrall S, et al. **Alcohol Clin Exp Res** 1998 Dec;22(9):1921-6

Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Coles KA, et al. **Am J Cardiol** 1999 Oct 1;84(7):825-8

Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody [see comments] Fervenza FC, et al. **Am J Kidney Dis** 1999 Sep;34(3):549-55. Comment in: Am J Kidney Dis 1999 Sep;34(3):565-8.

The emerging spectrum of IgA-mediated renal diseases: is there an IgA variant of Goodpasture's syndrome? [editorial; comment] Lee SM, et al. **Am J Kidney Dis** 1999 Sep; 34(3):565-8. Comment on: Am J Kidney Dis 1999 Sep;34(3):549-55.

Significantly increased frequency of baseline IgA anti-type II collagen positivity in the placebo group in a study of oral type II collagen treatment of rheumatoid arthritis: comment on the article by Barnett et al [letter; comment] Masi AT, et al. **Arthritis Rheum** 1999 Mar;42(3):585-7. Comment on: Arthritis Rheum 1998 Feb;41(2):290-7.

Endomysial antibody detection using human umbilical cord tissue as substrate: reactivity of cells in Wharton's jelly. Feighery C, et al. **Br J Biomed Sci** 1998 Jun;55(2):107-10

IgA class serum antibodies against three different Klebsiella serotypes in ankylosing spondylitis. Mäki-Ikola O, et al. **Br J Rheumatol** 1998 Dec;37(12):1299-302

Detection of IgA against Epstein-Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein. Shu CH, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jun;62(6):350-5

Antibody to ras proteins in patients with colon cancer. Takahashi M, et al. **Clin Cancer Res** 1995 Oct;1(10):1071-7

Reference values of serum IgA subclasses in caucasian adults by immunonephelometry. Berth M, et al. **Clin Chem** 1999 Feb;45(2):309-10

LD-IgG, IgA, IgM complex in a postburn patient. Liu Z, et al. **Clin Chim Acta** 1999 Jul;285(1-2):195-8

Co-incidental presentation of IgA lambda multiple myeloma and pleural involvement with IgM kappa non-Hodgkin's lymphoma. Manley R, et al. **Clin Lab Haematol** 1999 Feb; 21(1):61-3

The immunoglobulin A antibody response in clinical subsets of mucous membrane pemphigoid. Egan CA, et al. **Dermatology** 1999;198(4):330-5

Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Wirsing von König CH, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):341-5

Autoantibodies to tissue transglutaminase as predictors of celiac disease [see comments] Dieterich W, et al. **Gastroenterology** 1998 Dec;115(6):1317-21. Comment in: Gastroenterology 1998 Dec;115(6):1584-94.

Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Halttunen T, et al. **Gastroenterology** 1999 Mar;116(3):566-72

Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease [see comments] Sulkanen S, et al. **Gastroenterology** 1998 Dec; 115(6):1322-8. Comment in: Gastroenterology 1998 Dec;115(6):1584-94.

Evidence for a site-specific fucosylation of N-linked oligosaccharide of immunoglobulin A1 from normal human serum. Tanaka A, et al. **Glycoconj J** 1998 Oct; 15(10):995-1000

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219-29

Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer. Tsavaris N, et al. **Int J Biol Markers** 1998 Apr-Jun;13(2):87-91

Elevated blood levels of soluble tumor necrosis factor receptors in nasopharyngeal carcinoma: correlation with humoral immune response to lytic replication of Epstein-Barr virus. Feng P, et al. **Int J Oncol** 1999 Jul; 15(1):167-72

Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. Khan IU, et al. **J Am Acad Dermatol** 1999 Mar;40(3):485-8

Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. Bazzigaluppi E, et al. **J Autoimmun** 1999 Feb; 12(1):51-6

Lack of value of specific IgA detection in the postnatal diagnosis of congenital toxoplasmosis. Faure AK, et al. **J Clin Lab Anal** 1999;13(1):27-30

Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test. Gutiérrez J, et al. **J Clin Lab Anal** 1999; 13(1):1-4

Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA. Gutiérrez J, et al. **J Clin Lab Anal** 1999;13(2):65-8

Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome. Lewis S, et al. **J Clin Lab Anal** 1998;12(5):293-7

Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. Ritchie RF, et al. **J Clin Lab Anal** 1998; 12(6):363-70

Reference distributions for immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature. Ritchie RF, et al. **J Clin Lab Anal** 1998;12(6):371-7

Development of specific immunoglobulins G, M, and A following primary Toxoplasma gondii infection in pregnant women. Jenum PA, et al. **J Clin Microbiol** 1998 Oct; 36(10):2907-13

Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. Voeten JT, et al. **J Clin Microbiol** 1998 Dec;36(12):3527-31

Clinical relevance of serum immunoglobulin A antibodies to Epstein-Barr virus envelope glycoprotein gp350 in nasopharyngeal carcinoma patients [letter] Xu JW, et al. **J Clin Microbiol** 1998 Dec;36(12):3740

IgA anti-tissue transglutaminase as a diagnostic marker of gluten sensitive enteropathy. Lock RJ, et al. **J Clin Pathol** 1999 Apr;52(4):274-7

Linear IgA bullous dermatosis with circulating IgG autoantibodies to the 230 kD epidermal antigen. Honoki K, et al. **J Dermatol** 1998 Aug;25(8):503-9

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. Mazzoli S, et al. **J Infect Dis** 1999 Sep;180(3):871-5

Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinemia. Quezada A, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun;9(3):178-82

Tissue transglutaminase: the Holy Grail for the diagnosis of

celiac disease, at last? [editorial: comment] Fasano A. **J Pediatr** 1999 Feb;134(2):134–5. Comment on: J Pediatr 1999 Feb;134(2):166–71.

IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease [see comments] Troncone R, et al. **J Pediatr** 1999 Feb;134(2):166–71. Comment in: J Pediatr 1999 Feb;134(2):134–5.

High prevalence of silent celiac disease in preschool children screened with IgA/IgG antiendomysium antibodies. Korponay-Szabó IR, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):26–30

Levels of immunoglobulins and complement C3 in protein-energy malnutrition [letter] Mishra OP, et al. **J Trop Pediatr** 1999 Jun;45(3):179–81

Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group. Shimizu K, et al. **Jpn J Cancer Res** 1999 Mar;90(3):355–60

Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and abeta2 glycoprotein-I is the most frequent isotype. Diri E, et al. **Lupus** 1999; 8(4):263–8

Exposed peptide core of IgA1 hinge region in IgA nephropathy. Kokubo T, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):81–5

Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Roodnat JI, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):353–9

Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Ho S, et al. **Oral Oncol** 1998 Nov;34(6):491–5

Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after Helicobacter pylori eradication. Kato S, et al. **Pediatrics** 1999 Aug;104(2):e22

A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of schistosoma mansoni. Kanamura HY, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr; 40(2):85–91

IgM and IgA antibody responses in 12 cases of human acquired toxoplasmosis. Takahashi EE, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov-Dec;39(6):327–31

Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. Witte T, et al. **Rheumatol Int** 1998;18(2):63–9

Improved method for serological testing in celiac disease--IgA anti-endomysium antibody test: a comparison between monkey oesophagus and human umbilical cord as substrate in indirect immunofluorescence test. Amara W, et al. **Scand J Clin Lab Invest** 1998 Nov;58(7):547–54

Serum IgA antibodies from patients with coeliac disease react strongly with human brain blood-vessel structures. Pratesi R, et al. **Scand J Gastroenterol** 1998 Aug;33(8):817–21

IgA antiphospholipid antibodies [letter; comment] Keil LB, et al. **Thromb Haemost** 1999 Feb;81(2):319–20. Comment on: Thromb Haemost 1998 Feb;79(2):282–5.

Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity in living donor renal transplant recipients: a pilot study. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):2977–8

Sustained decrease of serum anti-galactose alpha 1-3-galactose antibodies in baboons by removing aerobic gram-negative bacteria from the bowel. Manez R, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):947–8

Serum immunoglobulin and immunoglobulin G subclasses in children with allergic colitis. Ojuawo A, et al. **West Afr J Med** 1998 Jul-Sep;17(3):206–9

[Diagnostic value of serum IGA-fibronectin aggregates to IGA nephropathy] Wei L, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):83–6 (Eng. Abstr.) **(Chi)**

[Dosage of the antibody antigliadin in first degree relatives of celiac patients] Nunes CR, et al. **Arq Gastroenterol** 1998 Jan-Mar;35(1):69–73 (Eng. Abstr.) **(Por)**

[Pulmonary involvement in IgA multiple myeloma. A case report and review of the literature (letter)] Conesa Bernal C, et al. **Arch Bronconeumol** 1999 Jan;35(1):54–5 (6 ref.) **(Spa)**

[Immunoproliferative disease of the small intestine. A case of polymeric IgA with evolution to lymphoma] Martin Guerrero JM, et al. **Gastroenterol Hepatol** 1998 Aug-Sep; 21(7):335–8 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Study of the relationship between sticky human serum IgA1 and its O-glycan glycoform. Iwase H, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):472–7

Rapid structural characterisation of a murine monoclonal IgA alpha chain: heterogeneity in the oligosaccharide structures at a specific site in samples produced in different bioreactor systems. Schweikart F, et al. **J Biotechnol** 1999 Apr 15; 69(2-3):191–201

Aggregated human serum immunoglobulin A1 induced by neuraminidase treatment had a lower number of O-linked sugar chains on the hinge portion. Iwase H, et al. **J Chromatogr B Biomed Sci Appl** 1999 Mar 5;724(1):1–7

A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor-mediated secretion. Hexham JM, et al. **J Exp Med** 1999 Feb 15;189(4):747–52

The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. Boehm MK, et al. **J Mol Biol** 1999 Mar 12;286(5):1421–47

Structural features of IgA molecules which contribute to IgA nephropathy. Feehally J, et al. **J Nephrol** 1999 Mar-Apr; 12(2):59–65 (30 ref.)

CLASSIFICATION

Nomenclature of immunoglobulin A and other proteins of the mucosal immune system. IUIS/WHO Subcommittee on IgA Nomenclature. **Eur J Immunol** 1999 Mar; 29(3):1057–8

Nomenclature of immunoglobulin A and other proteins of the mucosal immune system. IUIS/WHO subcommittee on IgA nomenclature. **J Immunol Methods** 1999 Mar 4; 223(2):263–4

IgA class antibodies and flow cytometric cross-matching in renal transplantation. Doran TJ, et al. **Transplantation** 1999 Jan 27;67(2):309–14

DEFICIENCY see IGA DEFICIENCY

GENETICS

The regulatory effects of all-trans-retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. Tokuyama H, et al. **Cell Immunol** 1999 Feb 25;192(1):41–7

Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Wang Z, et al. **Clin Immunol** 1999 Jun;91(3):263–70

Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin. Johansen FE, et al. **Eur J Immunol** 1999 May;29(5):1701–8

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219–29

Ialpha exon-replacement mice synthesize a spliced HPRT-C(alpha) transcript which may explain their ability to switch to IgA. Inhibition of switching to IgG in these mice. Qiu G, et al. **Int Immunol** 1999 Jan;11(1):37–46

The major phase-variable outer membrane protein of Escherichia coli structurally resembles the immunoglobulin A1 protease class of exported protein and is regulated by a novel mechanism involving Dam and oxyR. Henderson IR, et al. **J Bacteriol** 1999 Apr;181(7):2132–41

CBF alpha3 (AML2) is induced by TGF-beta1 to bind and activate the mouse germline Ig alpha promoter. Shi MJ, et al. **J Immunol** 1998 Dec 15;161(12):6751–60

In vitro induction of the expression of multiple IgA isotype genes in rabbit B cells by TGF-beta and IL-2. Spieker-Polet H, et al. **J Immunol** 1999 May 1; 162(9):5380–8

The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Greer MR, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):1980–3

IMMUNOLOGY

Antigen-specific IgA response of NALT and cervical lymph node cells in antigen-primed rats. Asakura K, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):859–63

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. Kaul R, et al. **AIDS** 1999 Jan 14; 13(1):23–9

IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Ots M, et al. **Am J Nephrol** 1999;19(4):453–8

Pathogenesis of IgA nephropathy. Feehally J, et al. **Ann Med Interne (Paris)** 1999 Feb;150(2):91–8 (39 ref.)

Route and type of nutrition influence IgA-mediating intestinal cytokines. Wu Y, et al. **Ann Surg** 1999 May; 229(5):662–7; discussion 667–8

Inhibition of Entamoeba histolytica proteolytic activity by human salivary IgA antibodies. Guerrero-Manriquez GG, et al. **APMIS** 1998 Nov;106(11):1088–94

The IgG2a/IgA produced by the murine T560 B lymphoma that arose during a graft-versus-host reaction is polyreactive and somatically mutated. Phillips-Quagliata JM, et al. **Autoimmunity** 1999;29(3):215–33

Adenoviral-mediated gene transfer of interleukin-6 in rat lung enhances antiviral immunoglobulin A and G responses in distinct tissue compartments. Xing Z, et al. **Biochem Biophys Res Commun** 1999 May 10;258(2):332–5

Thiol-disulfide redox buffers maintain a structure of immunoglobulin A that is essential for optimal in vitro binding to secretory component. Jones RM, et al. **Biochim Biophys Acta** 1998 Dec 8;1429(1):265–74

The localization of target antigens and autoantibodies in linear IgA disease is variable: correlation of immunogold electron microscopy and immunoblotting. Zhou S, et al. **Br J Dermatol** 1998 Oct;139(4):591–7

Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. Lindholt JS, et al. **Br J Surg** 1999 May; 86(5):634–8

T cell and cytokine regulation of the IgA response. Lycke N. **Chem Immunol** 1998;71:209–34 (130 ref.)

Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Lakos G, et al. **Clin Exp Immunol** 1999 Sep;117(3):574–9

Elevation of serum IgA in spondyloarthropathies and IgA nephropathy and its pathogenic role. Montenegro V, et al. **Curr Opin Rheumatol** 1999 Jul;11(4):265–72 (103 ref.)

Antibody-mediated protection of mucosal surfaces. Corthesy B, et al. **Curr Top Microbiol Immunol** 1999;236:93–111 (130 ref.)

Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells. Yawalkar N, et al. **Dermatology** 1999;199(1):25–30

Use of immunoglobulin A-antiendomysial antibody to screen for celiac disease in North American children with type 1 diabetes. Fraser-Reynolds KA, et al. **Diabetes Care** 1998 Nov;21(11):1985–9

Evidence of transient IgA anti-endomysial antibody positivity in a patient with Graves' disease. Carroccio A, et al. **Digestion** 1999 Jan-Feb;60(1):86–8

Intercellular IgA vesiculopustular dermatosis [letter] Cordoliani F. **Eur J Dermatol** 1998 Mar;8(2):137

Human amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin. Quan CP, et al. **Eur J Immunol** 1998 Dec;28(12):4001–9

HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Uchio E, et al. **Exp Eye Res** 1998 Dec; 67(6):719–27

Experimental murine IgA nephropathy following passive administration of vomitoxin-induced IgA monoclonal antibodies. Yan D, et al. **Food Chem Toxicol** 1998 Dec; 36(12):1095–106

Systemic and local immune responses against Helicobacter pylori urease in patients with chronic gastritis: distinct IgA and IgG productive sites. Futagami S, et al. **Gut** 1998 Aug; 43(2):168–75

Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Mestecky J, et al. **Gut** 1999 Jan;44(1):2–5

Anti-DNA IgA autoantibodies are spontaneously generated in mouse Peyer's patches. Shimoda M, et al. **Immunology** 1998 Oct;95(2):200–7

A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the human challenge model of urethral infection. Johannsen DB, et al. **Infect Immun** 1999 Jun;67(6):3009–13

Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. Way SS, et al. **Infect Immun** 1999 Apr;67(4):2001–4

Cat-specific IgA antibodies in breast milk from atopic and non-atopic mothers: detection of Fel d 1-IgG immune complexes in cord blood and sera. Casas R, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):317–8

Epstein-Barr virus genomes are found predominantly in IgA-positive B cells in the blood of healthy carriers. Ehlin-Henriksson B, et al. **Int J Cancer** 1999 Sep 24; 83(1):50–4

Captopril-triggered linear IgA bullous dermatosis. Friedman IS, et al. **Int J Dermatol** 1998 Aug;37(8):608–12 (20 ref.)

An IgA-binding peptide derived from a streptococcal surface protein. Johnsson E, et al. **J Biol Chem** 1999 May 21; 274(21):14521–4

Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. Tomana M, et al. **J Clin Invest** 1999 Jul;104(1):73–81

Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice. Tejada-Simon MV, et al. **J Dairy Sci** 1999 Apr;82(4):649–60

Analysis of signal transduction pathways regulating cytokine-mediated Fc receptor activation on human eosinophils. Bracke M, et al. **J Immunol** 1998 Dec 15; 161(12):6768–74

Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils. Motegi Y, et al. **J Immunol** 1998 Oct 15;161(8):4340–6

Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Roux KH, et al. **J Immunol** 1998 Oct 15;161(8):4083–90

Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis. Koga M, et al. **J Neuroimmunol** 1999 May 3;96(2):245–50

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. Zeitlin L, et al. **J Reprod Immunol** 1998 Oct; 40(1):93–101

Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. Tajima C, et al. **J Rheumatol** 1998 Sep;25(9):1730–6

Significance of IgA antiphospholipid antibodies. Wilson WA, et al. **Lupus** 1998;7 Suppl 2:S110–3 (34 ref.)

Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature. Nousari HC, et al. **Medicine (Baltimore)** 1999 Jan;78(1):1–8 (34 ref.)

Uteroglobin is essential in preventing immunoglobulin A nephropathy in mice. Zheng F, et al. **Nat Med** 1999 Sep; 5(9):1018–25

Prevalence of IgA-antiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Carlsson AK, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1248–52

In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies

assembled and produced in CHO cells. Berdoz J, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3029–34

Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. van Doornum G, et al. **Sex Transm Infect** 1998 Oct;74(5):354–60

[Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test] Meyer F, et al. **Transfus Clin Biol** 1999 Jul;6(4):221–6 (Eng. Abstr.) **(Fre)**

[Detection of anti-IgA alloantibody in a case of non-hemolytic transfusion reaction] Nishiya K, et al. **Rinsho Ketsueki** 1999 Mar;40(3):236–9 (Eng. Abstr.) **(Jpn)**

[A case report of selective IgA deficiency in rheumatoid arthritis and anti-IgA antibody induced anaphylactic transfusion] Miwa Y, et al. **Ryumachi** 1998 Oct;38(5):735–40 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The effect of intrabronchial specific immunotherapy on certain immunologic parameters in asthmatic patients with allergic to house mites] Zietkowski Z. **Pol Merkuriusz Lek** 1999 May;6(35):236–8 (Eng. Abstr.) **(Pol)**

ISOLATION & PURIFICATION

Study of the relationship between sticky human serum IgA1 and its O-glycan glycoform. Iwase H, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):472–7

Using distilled water for the extraction of mucosal antibodies and the subsequent application in RSV neutralization test. Hu KF, et al. **J Immunoassay** 1998 May–Aug; 19(2–3):209–22

A synthetic ligand for IgA affinity purification. Palombo G, et al. **J Mol Recognit** 1998 Winter;11(1–6):243–6

[Isolation of glomerular IgA deposits from biopsied kidney tissues of patients with IgA nephritis and analysis of the antibody specificity of IgA] Ogawa Y. **Hokkaido Igaku Zasshi** 1999 May;74(3):217–30 (Eng. Abstr.) **(Jpn)**

METABOLISM

Bacterial degradation of immunoglobulin A1 in relation to periodontal diseases. Grønbaek Frandsen EV. **APMIS Suppl** 1999;87:1–54 (333 ref.)

Oxidation of alpha1-proteinase inhibitor by the myeloperoxidase-hydrogen peroxidase system promotes binding to immunoglobulin A. Scott LJ, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):562–7

Characterising lectin binding to the O-linked sugars of immunoglobulin A1. Carpenter GH, et al. **Biochem Soc Trans** 1998 Nov;26(4):S384

Peritoneal B-1 cells switch in vivo to IgA and these IgA antibodies can bind to bacteria of the normal intestinal microflora. Kroese FG, et al. **Curr Top Microbiol Immunol** 1999;246:343–9; discussion 350 (25 ref.)

Transcytosis of immunoglobulin A in the mouse enterocyte occurs through glycolipid raft- and rab17-containing compartments. Hansen GH, et al. **Gastroenterology** 1999 Mar;116(3):610–22

Preferential enhancement of B cell IgA secretion by intestinal epithelial cell-derived cytokines and interleukin-2. Goodrich ME, et al. **Immunol Invest** 1999 Jan;28(1):67–75

The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. van Egmond M, et al. **Immunol Lett** 1999 May 3;68(1):83–7

Evaluation of immunoglobulin A1 (IgA1) protease and IgA1 protease-inhibitory activity in human female genital infection with Neisseria gonorrhoeae. Hedges SR, et al. **Infect Immun** 1998 Dec;66(12):5826–32

Pyloric atresia with junctional epidermolysis bullosa (PA-JEB) syndrome: absence of detectable beta4 integrin and reduced expression of epidermal linear IgA dermatosis antigen. Kim JN, et al. **Int J Dermatol** 1999 Jun; 38(6):467–70

Protein kinase C regulates NO-cGMP pathway in muscarinic receptor activation by HIV+-IgA. Sales ME, et al. **Int J Mol Med** 1999 Jun;3(6):633–7

Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. Allen AC, et al. **J Am Soc Nephrol** 1999 Aug;10(8):1763–71

Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. Hiki Y, et al. **J Am Soc Nephrol** 1999 Apr;10(4):760–9

IgA interaction with carboxy-terminal 43-kD fragment of fibronectin in IgA nephropathy. Waga S, et al. **J Am Soc Nephrol** 1999 Feb;10(2):256–63

Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. Malmborg AC, et al. **J Autoimmun** 1998 Oct;11(5):573–80

Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. Launay P, et al. **J Biol Chem** 1999 Mar 12; 274(11):7216–25

Identification of residues in the CH2/CH3 domain interface of IgA essential for interaction with the human fcalpha receptor (FcalphaR) CD89. Pleass RJ, et al. **J Biol Chem** 1999 Aug 13;274(33):23508–14

Inability of intact cells of Treponema denticola to degrade human serum proteins IgA, IgG and albumin. Hollmann R, et al. **J Clin Periodontol** 1999 Jul;26(7):477–9

Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. Lycke N, et al. **J Immunol** 1999 Jul 15; 163(2):913–9

Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece. Sørensen V, et al. **J Immunol** 1999 Mar 15;162(6):3448–55

Identification of residues in the first domain of human Fc alpha receptor essential for interaction with IgA. Wines BD, et al. **J Immunol** 1999 Feb 15;162(4):2146–53

Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. Cauci S, et al. **J Infect Dis** 1998 Dec;178(6):1698–706

Increased sialylation of polymeric immunoglobulin A1: mechanism of selective glomerular deposition in immunoglobulin A nephropathy? Leung JC, et al. **J Lab Clin Med** 1999 Feb;133(2):152–60

Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy. Allen AC. **J Nephrol** 1999 Mar–Apr;12(2):76–84 (46 ref.)

Vitamin A prevents the decline in immunoglobulin A and Th2 cytokine levels in small intestinal mucosa of protein-malnourished mice. Nikawa T, et al. **J Nutr** 1999 May;129(5):934–41

Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. Franklin RD, et al. **J Reprod Immunol** 1999 Mar; 42(2):93–106

Degradations of human immunoglobulins and hemoglobin by a 60 kDa cysteine proteinase of Trichomonas vaginalis. Min DY, et al. **Korean J Parasitol** 1998 Dec;36(4):261–8

Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. van Zandbergen G, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3058–64

Glomerulonephritis without IgA deposits in a case of Henoch-Schönlein purpura. Tanaka H, et al. **Pediatr Nephrol** 1999 Sep;13(7):597–9

IL-6 cerebrospinal fluid levels are related to laryngeal IgA and epithelial HLA-DR response in sudden infant death syndrome. Vege A, et al. **Pediatr Res** 1999 Jun;45(6):803–9

[IgG, IgA, Bence Jones protein (BJP) myeloma] Takahashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):403–7 (20 ref.) **(Jpn)**

[Proteolysis of immunoglobulins--biologically-active supplement in a fermented milk in gastrointestinal system of rats] Gmoshinskii IV, et al. **Vopr Pitan** 1998;(4):5–8 (Eng. Abstr.) **(Rus)**

[Submandibular secretion of immunoglobulins IgA and IgG in peripheral paralysis of the facial nerve] Ristić B, et al. **Med Pregl** 1998 Sep–Oct;51(9–10):400–3 (Eng. Abstr.) **(Scr)**

PHARMACOLOGY

IgA induced activation of human mesangial cells: independent of FcalphaR1 (CD 89). Diven SC, et al. **Kidney Int** 1998 Sep;54(3):837–47

Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Oesser S, et al. **Res Exp Med (Berl)** 1999 Apr;198(6):325–39

PHYSIOLOGY

Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. Kokubo T, et al. **J Am Soc Nephrol** 1998 Nov; 9(11):2048–54

Mucosal immunity to influenza without IgA: an IgA knockout mouse model. Mbawuike IN, et al. **J Immunol** 1999 Mar 1;162(5):2530–7

Effect of IgA1 protease on the ability of secretory IgA1 antibodies to inhibit the adherence of Streptococcus mutans. Tyler BM, et al. **Microbiol Immunol** 1998; 42(7):503–8

THERAPEUTIC USE

Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Johansson JE, et al. **Bone Marrow Transplant** 1999 Jul;24(1):35–9

Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Brooks D, et al. **Clin Cancer Res** 1995 Nov;1(11):1259–65

Immunoglobulins in anergic patients: choice of patients, identification of dependent variables, and importance of study [editorial; comment] Christou NV. **Crit Care Med** 1999 Jul;27(7):1387–8. Comment on: Crit Care Med 1999 Jul;27(7):1281–7.

Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery [see comments] Kress HG, et al. **Crit Care Med** 1999 Jul;27(7):1281–7. Comment in: Crit Care Med 1999 Jul;27(7):1387–8.

Monoclonal IgA antibodies protect against Acanthamoeba keratitis. Leher H, et al. **Exp Eye Res** 1999 Jul;69(1):75–84

[Use of octagam and pentaglobin in the treatment of severe sepsis in the neonatal period] Barinov AV, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):59–60 (Eng. Abstr.) **(Rus)**

IGA DEFICIENCY

The transfusion needs of an autologous bone marrow transplant patient with IgA deficiency. Meena-Leist CE, et al. **Transfusion** 1999 May;39(5):457–9

[Selective IgA deficiency] Sugai S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):213–5 (9 ref.) **(Jpn)**

BLOOD

Serum immunoglobulin A deficiency in relapsing inflammatory demyelinating polyneuropathy [letter] Vital A, et al. **Muscle Nerve** 1999 Apr;22(4):543–5

COMPLICATIONS

Lymphoid hyperplasia of the lung and Evans' syndrome in IgA deficiency [letter] Roca B, et al. **Am J Med** 1999 Jan; 106(1):121–2

The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Aittoniemi J, et al. **Clin Exp Immunol** 1999 Jun;116(3):505–8

Celiac disease and selective IgA deficiency in a girl with atypical Turner syndrome [letter; comment] [see comments] Schewior S, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar; 28(3):353–4. Comment on: J Pediatr Gastroenterol Nutr 1998 May;26(5):496–9. Comment in: J Pediatr Gastroenterol Nutr 1999 Jul;29(1):107–8.

Type A immunoglobulin deficiency presenting as a mixed polymicrobial brain abscess: case report. Ruebenacker CA, et al. **Neurosurgery** 1999 Feb;44(2):411–4

[Jacobsen's syndrome, thrombopenia and humoral immunodeficiency] Sirvent N, et al. **Arch Pediatr** 1998 Dec; 5(12):1338–40 (Eng. Abstr.) **(Fre)**

[A case report of selective IgA deficiency in rheumatoid arthritis and anti-IgA antibody induced anaphylactic transfusion] Miwa Y, et al. **Ryumachi** 1998 Oct;38(5):735–40 (22 ref.) (Eng. Abstr.) **(Jpn)**

[IgA deficiency, cryoglobulinemia and carpal tunnel syndrome (letter)] Rodriguez Cuartero A, et al. **An Med Interna** 1999 May;16(5):266–7 **(Spa)**

DIAGNOSIS

Identifying immunoglobulin-A--deficient children and adults does not necessarily help the serologic diagnosis of coeliac disease. Lock RJ, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):81–3

[IgA deficiency: clinical and laboratory evaluation of 60 patients from the "Instituto da Criança"] Grumach AS, et al. **Rev Assoc Med Bras** 1998 Oct–Dec;44(4):277–82 (Eng. Abstr.) **(Por)**

ETHNOLOGY

Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. al-Attas RA, et al. **J Clin Immunol** 1998 Sep;18(5):368–71

ETIOLOGY

Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. Harriman GR, et al. **J Immunol** 1999 Mar 1; 162(5):2521–9

Recurrent infections in haemodialysis patients--do not forget selective immunoglobulin A deficiency. Kuo MC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3220–2

GENETICS

Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Wang Z, et al. **Clin Immunol** 1999 Jun;91(3):263–70

Genetic basis of abnormal B cell development. Conley ME, et al. **Curr Opin Immunol** 1998 Aug;10(4):399–406 (76 ref.)

HLA antigens and haplotypes in IgA-deficient Brazilian paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281–5

Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. van Ginkel FW, et al. **J Immunol** 1999 Aug 15;163(4):1951–7

A putative susceptibility locus on chromosome 18 is not a major contributor to human selective IgA deficiency: evidence from meiotic mapping of 83 multiple-case families. Vořechovský I, et al. **J Immunol** 1999 Aug 15; 163(4):2236–42

IMMUNOLOGY

Fucosidosis: immunological studies and chronological neuroradiological changes. Ismail EA, et al. **Acta Paediatr** 1999 Feb;88(2):224–7

The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Aittoniemi J, et al. **Clin Exp Immunol** 1999 Jun;116(3):505–8

Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Wang Z, et al. **Clin Immunol** 1999 Jun;91(3):263–70

HLA antigens and haplotypes in IgA-deficient Brazilian

paediatric patients. Gerbase-Delima M, et al. **Eur J Immunogenet** 1998 Aug;25(4):281-5
Effects of tobacco smoking on salivary immunoglobulin levels in immunodeficiency. Norhagen Engström G, et al. **Eur J Oral Sci** 1998 Dec;106(6):986-91
Mucosal immunity to influenza without IgA: an IgA knockout mouse model. Mbawuike IN, et al. **J Immunol** 1999 Mar 1;162(5):2530-7
Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. van Ginkel FW, et al. **J Immunol** 1999 Aug 15;163(4):1951-7
Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Stryk S, et al. **Pediatr Dermatol** 1999 Jan-Feb;16(1):19-22
[Rare hyperimmunoglobulinemia E syndromes] Katchourine I, et al. **Rev Med Interne** 1998 Mar;19(3):185-91 (29 ref.) (Eng. Abstr.) **(Fre)**

IGA, EXOCRINE see **IGA, SECRETORY**

IGA GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, IGA**

IGA NEPHROPATHY see **GLOMERULONEPHRITIS, IGA**

IGA, SECRETORY

Partitioning the mortality risk associated with inadequate passive transfer of colostral immunoglobulins in dairy calves. Tyler JW, et al. **J Vet Intern Med** 1999 Jul-Aug; 13(4):335-7

ANALYSIS

Intestinal antibodies against gliadin, tissue-transglutaminase, beta-lactoglobulin, and ovalbumin in patients with irritable bowel syndrome. Wahnschaffe U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:280-4
Immunohistochemical localization of secretory immunoglobulins in the main excretory duct of the human submandibular gland. Perra MT, et al. **Arch Histol Cytol** 1998 Dec;61(5):427-32
Relaxation training and breast milk secretory IgA [see comments] O'Connor ME, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1065-70. Comment in: Arch Pediatr Adolesc Med 1999 Jun;153(6):654-5.
Secretory IgA epitopes in basal tears of extended-wear soft contact lens wearers and in non-lens wearers. Pearce DJ, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):221-3
Bright light exposure during the daytime affects circadian rhythms of urinary melatonin and salivary immunoglobulin A. Park SJ, et al. **Chronobiol Int** 1999 May;16(3):359-71
Decreased Helicobacter pylori-specific gastric secretory IgA antibodies in infected patients. Birkholz S, et al. **Digestion** 1998 Nov-Dec;59(6):638-45
Salivary SIgA and SIgA 1 in coeliac disease, inflammatory bowel disease and controls. Warner RH, et al. **Ir J Med Sci** 1999 Jan-Mar;168(1):33-5
Cervical secretory immunoglobulin A in adolescent girls. Ellen JM, et al. **J Adolesc Health** 1999 Aug;25(2):150-4
A simple and reproducible method for collecting nasal secretions in frail elderly adults, for measurement of virus-specific IgA. Walsh EE, et al. **J Infect Dis** 1999 May; 179(5):1268-73
Periodontal conditions and salivary immunoglobulins in individuals with Down syndrome. Barr-Agholme M, et al. **J Periodontol** 1998 Oct;69(10):1119-23
The effects of high-intensity intermittent exercise on saliva IgA, total protein and alpha-amylase. Walsh NP, et al. **J Sports Sci** 1999 Feb;17(2):129-34
Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. Watarai S, et al. **J Vet Med Sci** 1998 Sep;60(9):1047-50
Submandibular and lacrimal gland immunoglobulin in the C3H.MRL-Faslpr autoimmune mouse model of Sjögren's syndrome. Trune DR, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1729-32
Salivary IgA levels and infection risk in elite swimmers. Gleeson M, et al. **Med Sci Sports Exerc** 1999 Jan; 31(1):67-73
Tear secretory IgA: evaluation of usefulness as a diagnostic marker in herpetic keratitis. Pramod NP, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):61-7
Salivary immunoglobulin A levels of persons who have stopped smoking. Griesel AG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):170-3
Secretory immune response in patients with intestinal amoebiasis. Ortiz-Ortiz L, et al. **Parasite Immunol** 1998 Oct;20(10):503-7
Effect of restorative treatment on mutans streptococci and IgA antibodies. Gregory RL, et al. **Pediatr Dent** 1998 Jul-Aug;20(4):273-7
Secretory immunoglobulin A is a component of the human milk fat globule membrane. Schroten H, et al. **Pediatr Res** 1999 Jan;45(1):82-6

BIOSYNTHESIS

Strategies for mucosal vaccine development. Boyaka PN, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):35-45 (117 ref.)
Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. De Haan L, et al. **Immunology** 1999 Aug; 97(4):706-13
Production and characterization of recombinant IgA. Chintalacharuvu KR, et al. **Immunotechnology** 1999 Mar; 4(3-4):165-74 (54 ref.)
Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions. Ekström J, et al. **Vaccine** 1999 Jun 4; 17(20-21):2690-701
A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms. Carol H, et al. **Vet Immunol Immunopathol** 1998 Sep 16; 65(1):29-41

BLOOD

A study on secretory IgA in malnourished children with chronic diarrhoea associated with parasitic infections. Marei MA, et al. **J Egypt Soc Parasitol** 1998 Dec; 28(3):907-13

CHEMISTRY

Secretory immunoglobulins A from human milk possess affinity to oligonucleotides and nucleic acids. Kit YY, et al. **Biochemistry (Mosc)** 1999 Jan;64(1):40-6

CLASSIFICATION

Nomenclature of immunoglobulin A and other proteins of the mucosal immune system. IUIS/WHO Subcommittee on IgA Nomenclature. **Eur J Immunol** 1999 Mar; 29(3):1057-8
Salivary IgA subclasses and infection risk in elite swimmers. Gleeson M, et al. **Immunol Cell Biol** 1999 Aug;77(4):351-5

DRUG EFFECTS

Secretory immunoglobulin A and cardiovascular reactions to mental arithmetic, cold pressor, and exercise: effects of beta-adrenergic blockade. Winzer A, et al. **Psychophysiology** 1999 Sep;36(5):591-601

GENETICS

Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin. Johansen FE, et al. **Eur J Immunol** 1999 May;29(5):1701-8

IMMUNOLOGY

Hemorrhagic shock impairs mucosal immunity to gut-derived antigens. Saini MS, et al. **Am Surg** 1999 Jul; 65(7):637-42
Secretory IgA epitopes in basal tears of extended-wear soft contact lens wearers and in non-lens wearers. Pearce DJ, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):221-3
Secretory immunity in defense against cariogenic mutans streptococci. Russell MW, et al. **Caries Res** 1999;33(1):4-15 (105 ref.)
Production and characterization of recombinant IgA. Chintalacharuvu KR, et al. **Immunotechnology** 1999 Mar; 4(3-4):165-74 (54 ref.)
Humoral immunity to commensal oral bacteria in human infants: salivary secretory immunoglobulin A antibodies reactive with Streptococcus mitis biovar 1, Streptococcus oralis, Streptococcus mutans, and Enterococcus faecalis during the first two years of life. Cole MF, et al. **Infect Immun** 1999 Apr;67(4):1878-86
Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Brandt ER, et al. **Int Immunol** 1999 Apr;11(4):569-76
Impact of oral immunization with Acanthamoeba antigens on parasite adhesion and corneal infection. Leher H, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2337-43
Salivary sIgA response in HIV-1 infection. Skott P, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):73-80
Synergistic effect of hyperoxia and immunoglobulin A on mucosal barrier defense. Diebel LN, et al. **J Trauma** 1999 Mar;46(3):374-8; discussion 378-9

METABOLISM

Secretory immunoglobulin A from human milk catalyzes milk protein phosphorylation. Nevinsky GA, et al. **Appl Biochem Biotechnol** 1998 Oct;75(1):77-91
Relaxation training and levels of secretory IgA in breast milk [letter; comment] Friedman E. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):654-5. Comment on: Arch Pediatr Adolesc Med 1998 Nov;152(11):1065-70.
Phosphorylation of lipids tightly bound to secretory immunoglobulin A in antibody fractions from human breast milk possessing protein kinase activity. Kit YY, et al. **Biochemistry (Mosc)** 1998 Jun;63(6):719-24
Expression of a local immune defense system in the female genital tract. An immunohistochemical study. Kondi-Paphitis A, et al. **Eur J Gynaecol Oncol** 1999; 20(2):141-3
Interleukin-4 and interferon-gamma synergistically increase secretory component gene expression, but are additive in stimulating secretory immunoglobulin A release by Calu-3 airway epithelial cells. Loman S, et al. **Immunology** 1999 Apr;96(4):537-43
Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, et al. **Infect Immun** 1999 May;67(5):2531-9
The relationship between salivary secretory immunoglobulin A and cortisol: neuroendocrine response to awakening and the diurnal cycle. Hucklebridge F, et al. **Int J Psychophysiol** 1998 Dec;31(1):69-76
Secretory immunoglobulin A heavy chain presents Galbeta1-3GalNAc binding structures for Actinomyces naeslundii genospecies 1. Bratt P, et al. **J Dent Res** 1999 Jun;78(6):1238-44
Reduced amount of secretory component of IgA secretion in tears of patients with atopic dermatitis. Toshitani A, et al. **J Dermatol Sci** 1999 Feb;19(2):134-8
Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab')2: a possible implication for mucosal defense. Crottet P, et al. **J Immunol** 1998 Nov 15;161(10):5445-53
Binding of Clostridium difficile toxin A to human milk secretory component. Dallas SD, et al. **J Med Microbiol** 1998 Oct;47(10):879-88
Secretion and excretion of immunoglobulin A to cecum and feces differ with type of indigestible saccharides. Kudoh K, et al. **J Nutr Sci Vitaminol (Tokyo)** 1999 Apr; 45(2):173-81
The influence of nerves on the secretion of immunoglobulin A into submandibular saliva in rats. Carpenter GH, et al. **J Physiol (Lond)** 1998 Oct 15;512 (Pt 2):567-73
Degradations of human immunoglobulins and hemoglobin by a 60 kDa cysteine proteinase of Trichomonas vaginalis. Min DY, et al. **Korean J Parasitol** 1998 Dec;36(4):261-8
Depression in the quantity of intestinal secretory IgA and in the expression of the polymeric immunoglobulin receptor in caloric deficiency of the weanling mouse. Ha CL, et al. **Lab Invest** 1998 Oct;78(10):1255-66
Secretory immunoglobulin A and cardiovascular activity during mental arithmetic and paced breathing. Ring C, et al. **Psychophysiology** 1999 Sep;36(5):602-9
Over-expression of the murine polymeric immunoglobulin receptor gene in the mammary gland of transgenic mice. de Groot N, et al. **Transgenic Res** 1999 Apr;8(2):125-35
[Occurrence of clinical strains of Klebsiella pneumoniae inactivating secretory IgA] Agapova OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec; (6):80-1 **(Rus)**

PHARMACOLOGY

Effect of tear-specific immunoglobulin A on the adhesion of Pseudomonas aeruginosa I to contact lenses. Lan J, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3-4):218-20
Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. Woerly G, et al. **J Exp Med** 1999 Aug 16; 190(4):487-95

PHYSIOLOGY

Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice. Parr MB, et al. **Immunology** 1998 Oct; 95(2):208-13
Roles of glycoproteins and oligosaccharides found in human vaginal fluid in bacterial adherence. Rajan N, et al. **Infect Immun** 1999 Oct;67(10):5027-32
Role of mucosal IgA in the resistance to Acanthamoeba keratitis. Leher HF, et al. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2666-73
A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor-mediated secretion. Hexham JM, et al. **J Exp Med** 1999 Feb 15;189(4):747-52
Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. Hocini H, et al. **J Infect Dis** 1999 May;179 Suppl 3:S448-53 (35 ref.)
Effect of IgA1 protease on the ability of secretory IgA1 antibodies to inhibit the adherence of Streptococcus mutans. Tyler BM, et al. **Microbiol Immunol** 1998; 42(7):503-8

URINE

Expression of the polymeric immunoglobulin receptor and excretion of secretory IgA in the postischemic kidney. Rice JC, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F666-73
Urinary secretory IgA after nutritional rehabilitation. Teodósio MR, et al. **Braz J Med Biol Res** 1999 Apr; 32(4):421-6
A study on secretory IgA in malnourished children with chronic diarrhoea associated with parasitic infections. Marei MA, et al. **J Egypt Soc Parasitol** 1998 Dec; 28(3):907-13
Assessment of mucosal immune response in genitourinary tract using urine. Kohno T, et al. **Microbiol Immunol** 1999; 43(3):253-8

IGD

Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International

Hyper-IgD Study Group [see comments] Drenth JP, et al. **Nat Genet** 1999 Jun;22(2):178–81. Comment in: Nat Genet 1999 Jun;22(2):121–2.
Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome [see comments] Houten SM, et al. **Nat Genet** 1999 Jun;22(2):175–7. Comment in: Nat Genet 1999 Jun;22(2):121–2.
[Pseudo-periodic disease with hyperimmunoglobulinemia D: a never-ending story with probable prenatal onset] Grouteau E, et al. **Arch Pediatr** 1998 Mar;5(3):280–4 (Eng. Abstr.) **(Fre)**
[Fever that came from the North] Oziol E, et al. **Rev Med Interne** 1999;20 Suppl 2:236s–238s **(Fre)**

ANALYSIS

IL-5 induces IgG1 isotype switch recombination in mouse CD38-activated sIgD-positive B lymphocytes. Mizoguchi C, et al. **J Immunol** 1999 Mar 1;162(5):2812–9
Clinical features, autoantibody activity, and survival in nine Tunisian patients with IgD myeloma [letter] Zitouni M, et al. **Rev Rhum Engl Ed** 1999 Feb;66(2):122
[IgD-type multiple myeloma with confirmation of improvement in renal pathology achieved by chemotherapy] Otsubo H, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1560–2 **(Jpn)**

BLOOD

Crescentic glomerulonephritis in hyper IgD syndrome. Tsimaratos M, et al. **Pediatr Nephrol** 1999 Feb;13(2):132–4
[IgD myeloma] Takahashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):408–10 (7 ref.) **(Jpn)**

CEREBROSPINAL FLUID

CNS tumours: oligoclonal immunoglobulin D in cerebrospinal fluid and serum. Mavra M, et al. **Acta Neurol Scand** 1999 Aug;100(2):117–8

GENETICS

Immunoglobulins D and M multiple myeloma variants are heavily mutated. Juge-Morineau N, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2501–6
Differential regulation of transcription termination occurring at two different sites on the micro-delta gene complex. Kim M, et al. **Int Immunol** 1999 May;11(5):813–24
Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. Zan H, et al. **J Immunol** 1999 Mar 15; 162(6):3437–47
Probing the natural antibody repertoire by combinatorial cloning of IgM and IgD isotypes in phage display vectors. Burioni R, et al. **Res Virol** 1998 Sep-Oct;149(5):321–5
Molecular cloning and phylogenetic analysis of the Atlantic salmon immunoglobulin D gene. Hordvik I, et al. **Scand J Immunol** 1999 Aug;50(2):202–10

IMMUNOLOGY

Anti-D treatment for chronic immune thrombocytopenic purpura: clinical and laboratory aspects. Sagripanti A, et al. **Biomed Pharmacother** 1998;52(7–8):293–7
Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Lunde E, et al. **Nat Biotechnol** 1999 Jul;17(7):670–5
Allergen-specific IgE and IgGd antibodies in atopic and normal dogs. Lian TM, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):203–23

METABOLISM

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. Klein U, et al. **J Exp Med** 1998 Nov 2;188(9):1679–89

PHYSIOLOGY

Facilitated antigen presentation by B cells expressing IgD when responding T cells express IgD-receptors. Wu Y, et al. **Cell Immunol** 1999 Mar 15;192(2):194–202

IGE

see related
RECEPTORS, IGE

30 Years with IgE. Proceedings of an international symposium on basic and clinical aspects of atopic allergy. Stockholm, Sweden, 1–2 September 1998. **Allergy** 1998; 53(45 Suppl):5–97
Spray-drying performance of a bench-top spray dryer for protein aerosol powder preparation. Maa YF, et al. **Biotechnol Bioeng** 1998 Nov 5;60(3):301–9
Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471. Wheeler DJ, et al. **Immunology** 1998 Sep;95(1):105–10
[Tracheobronchial aspergillosis in a patient with Buckley's syndrome (letter)] Barel R, et al. **Presse Med** 1998 Oct 3;27(29):1477 **(Fre)**

ANALYSIS

Self-assembled monolayer-based piezoelectric crystal immunosensor for the quantification of total human immunoglobulin E. Su X, et al. **Anal Biochem** 1999 Aug 15;273(1):66–72
Utility of antibody in identifying individuals who have or will develop anhydride-induced respiratory disease. Grammer L, et al. **Chest** 1998 Oct;114(4):1199–202
Comparison of skin-prick test and specific serum IgE determination for the diagnosis of latex allergy [see comments] Blanco C, et al. **Clin Exp Allergy** 1998 Aug; 28(8):971–6. Comment in: Clin Exp Allergy 1999 Jan;29(1):133–4.
Dermatophagoides sp. and IgE anti-D. pteronyssinus and D. farinae detection in a Venezuelan community at more than 2000 m above the sea level. Rangel A, et al. **Clin Exp Allergy** 1998 Sep;28(9):1100–3
Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Meyer FJ, et al. **Eur Respir J** 1998 Oct;12(4):996–7
Presence of anti-ovalbumin IgE antibody in the sera of laboratory-reared squirrel monkeys (Saimiri sciureus) fed quail eggs. Imaoka K, et al. **Exp Anim** 1998 Jul;47(3):195–7
Chemical respiratory allergy. IgE and the relevance of predictive test methods: a commentary. Kimber I, et al. **Hum Exp Toxicol** 1998 Oct;17(10):537–40 (23 ref.)
IgE antibodies to prohevein, hevein, and rubber elongation factor in children with latex allergy. Ylitalo L, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):659–64
Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. Scheule AM, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):348–53
Fibroin allergy. IgE mediated hypersensitivity to silk suture materials. Kurosaki S, et al. **Nippon Ika Daigaku Zasshi** 1999 Feb;66(1):41–4
Evidence of possible localized specific immunoglobulin E production in middle ear fluid as demonstrated by ELISA testing. Hurst DS, et al. **Otolaryngol Head Neck Surg** 1999 Sep;121(3):224–30
IgE antibody during infection with the ovine abomasal nematode, Teladorsagia circumcincta: primary and secondary responses in serum and gastric lymph of sheep. Huntley JF, et al. **Parasite Immunol** 1998 Nov; 20(11):565–71
Variability of the intestinal immunoglobulin E response of rats to infection with Trichinella spiralis, Heligmosomoides polygyrus or Nippostrongylus brasiliensis. Negrao-Correa D, et al. **Parasite Immunol** 1999 Jun;21(6):287–97
Clinical food hypersensitivity: the relevance of duodenal immunoglobulin E-positive cells. Caffarelli C, et al. **Pediatr Res** 1998 Oct;44(4):485–90
[Measurement of total IgE in tears : the adaptation of an immunoenzyme technique and the value of investigating locally produced IgE in the diagnosis of chronic conjunctivitis] Batellier L, et al. **Ann Biol Clin (Paris)** 1999 Jul-Aug;57(4):469–73 (Eng. Abstr.) **(Fre)**
[Characterization of specific IgG, IgM, IgA and IgE isotypes in profound candidiasis] Toubas D, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):329–36 (Eng. Abstr.) **(Fre)**
[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis] Bourcier T, et al. **J Fr Ophtalmol** 1998 Mar;21(3):209–13 (Eng. Abstr.) **(Fre)**
[The comparative study of LUMIWARD immunoassay system and CAP RAST system for determination of specific IgE antibody against mite in infantile atopic dermatitis] Miyoshi M, et al. **Arerugi** 1998 Aug;47(8):744–8 (Eng. Abstr.) **(Jpn)**
[An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease] Sato A, et al. **Nippon Rinsho** 1999 Aug;57(8):1904–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Total allergen-specific IgE antibodies in the serum and skin reactivity induced by a mixture of pollens in allergic individuals] Paranos S, et al. **Vojnosanit Pregl** 1998 Nov-Dec;55(6):605–9 (Eng. Abstr.) **(Scc)**

BIOSYNTHESIS

Development of immunoglobulins to venoms during specific immunotherapy. Palma-Carlos ML, et al. **Allerg Immunol (Paris)** 1999 Mar;31(3):71–2
Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells. Challa A, et al. **Allergy** 1999 Jun;54(6):576–83
Involvement of carbohydrate on phospholipase A2, a bee-venom allergen, in in vivo antigen-specific IgE synthesis in mice. Okano M, et al. **Allergy** 1999 Aug; 54(8):811–8
Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Spiegelberg HL, et al. **Allergy** 1998;53(45 Suppl):93–7
Regulation of IgE synthesis: the molecular basis and implications for clinical modulation. Bacharier LB, et al. **Allergy Asthma Proc** 1999 Jan-Feb;20(1):1–8 (58 ref.)
Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):212–6
Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Kimata H. **Ann Allergy Asthma Immunol** 1999 Mar; 82(3):293–5
The effect of feeding carrots on immunoglobulin E production and anaphylactic response in mice. Akiyama H, et al. **Biol Pharm Bull** 1999 Jun;22(6):551–5
IgE responses to bluetongue virus (BTV) serotype 11 after immunization with inactivated BTV and challenge infection. Odeón AC, et al. **Comp Immunol Microbiol Infect Dis** 1999 Apr;22(2):145–62
Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Ball T, et al. **Eur J Immunol** 1999 Jun;29(6):2026–36
Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Bohle B, et al. **Eur J Immunol** 1999 Jul;29(7):2344–53
Segregation analysis of the specific response to allergens: a recessive major gene controls the specific IgE response to Timothy grass pollen. Dizier MH, et al. **Genet Epidemiol** 1999;16(3):305–15
Asiasari radix inhibits immunoglobulin E production on experimental models in vitro and in vivo. Kim HM, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):469–81
STAT6, NF-kappaB and C/EBP in CD23 expression and IgE production. Tinnell SB, et al. **Int Immunol** 1998 Oct; 10(10):1529–38
Oral administration of hot water extracts of Chlorella vulgaris reduces IgE production against milk casein in mice. Hasegawa T, et al. **Int J Immunopharmacol** 1999 May; 21(5):311–23
Effect of systemic beta-agonist therapy on IgE production in allergic subjects in vivo. Corne JM, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):727–31
Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome. Garraud O, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):333–40
Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E. Miller RL, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):503–11
Engagement of the B-cell antigen receptor by antigen negatively regulates IgE production by antigen-specific B cells. Oshiba A, et al. **J Allergy Clin Immunol** 1999 Feb; 103(2 Pt 1):341–8
Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. Sigman K, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):421–7
Lipopolysaccharide augments IgG and IgE responses of mice to the latex allergen Hev b 5. Slater JE, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):977–83
Influenza A virus infection increases IgE production and airway responsiveness in aerosolized antigen-exposed mice. Suzuki S, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):732–40
Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. De Sanctis GT, et al. **J Clin Invest** 1999 Feb; 103(4):507–15
Fur mites induce dermatitis associated with IgE hyperproduction in an inbred strain of mice, NC/Kuj. Morita E, et al. **J Dermatol Sci** 1999 Jan;19(1):37–43
Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse. Ouadahi S, et al. **J Drug Target** 1998; 5(5):365–78
Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. Akdis M, et al. **J Immunol** 1999 Jul 1; 163(1):466–75
IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. Chiaramonte MG, et al. **J Immunol** 1999 Jan 15;162(2):920–30
Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia, and airway hyperresponsiveness in mice. Kato Y, et al. **J Immunol** 1999 Jun 15;162(12):7470–9
IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. Matsumoto M, et al. **J Immunol** 1999 Jan 15;162(2):1056–63
Cutting edge: dominant effect of Ile50Val variant of the human IL-4 receptor alpha-chain in IgE synthesis. Mitsuyasu H, et al. **J Immunol** 1999 Feb 1;162(3):1227–31
CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. Nagumo H, et al. **J Immunol** 1998 Dec 15; 161(12):6496–502
Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. Mizushima Y, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):849–57
STAT6-deficient mice exhibit normal induction of murine AIDS and expression of immunoglobulin E following infection with LP-BM5 murine leukemia viruses. Morse HC 3rd, et al. **J Virol** 1999 Aug;73(8):7093–5
Molecular identification of a 21.7 kDa schistosoma japonicum antigen as a target of the human IgE response. Hafalla

JC, et al. **Mol Biochem Parasitol** 1999 Jan 5;98(1):157–61

Occupational IgE sensitisation to phytase, a phosphatase derived from Aspergillus niger. Dockes G, et al. **Occup Environ Med** 1999 Jul;56(7):454–9

Lactic dehydrogenase virus inhibits allergic immunoglobulin E production: in vivo molecular analysis of cytokines. Morimoto M, et al. **Scand J Immunol** 1999 Aug;50(2):211–4

Interleukin-13 and human immunoglobulin E production in severe combined immunodeficiency mice transplanted with human peripheral blood lymphocytes. Steinsvik TE, et al. **Scand J Immunol** 1999 Jan;49(1):67–72

Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid. Isaka M, et al. **Vaccine** 1999 Feb 26;17(7–8):944–8

[Immunologic basis of bronchial asthma] Simon HU, et al. **Internist (Berl)** 1999 Aug;40(8):849–54 (34 ref.) **(Ger)**

[Allergy: allergens, induction and IgE synthesis regulation] Gushchin IS. **Patol Fiziol Eksp Ter** 1999 Jan–Mar;(1):24–32 (17 ref.) **(Rus)**

BLOOD

Seasonal increase in specific IgE in serum induced by natural Japanese cedar pollen exposure in asymptomatic and symptomatic sensitized individuals. Kakinoki Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:152–5

Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis. Washio Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:126–32

Clinical evaluation of lumiward immunoassay system for detection of specific IgE associated with allergic rhinitis. Yamada K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:169–77

Respiratory symptoms, skin disorders and serum IgE levels in farm workers. Bener A, et al. **Allerg Immunol (Paris)** 1999 Feb;31(2):52–6

Determination of total and specific IgE using UNICAP 100: comparative study with the CAP system. Cots P, et al. **Allergol Immunopathol (Madr)** 1998 Sep–Oct;26(5):223–7

Skin tests or in vitro tests? [editorial; comment] Muñoz-López F. **Allergol Immunopathol (Madr)** 1998 Sep–Oct;26(5):203–8. Comment on: Allergol Immunopathol (Madr) 1998 Sep–Oct;26(5):228–33. **(Eng, Spa)**

A novel dipstick developed for rapid Bet v 1-specific IgE detection: recombinant allergen immobilized via a monoclonal antibody to crystalline bacterial cell-surface layers. Breitwieser A, et al. **Allergy** 1998 Aug;53(8):786–93

IgE antibodies specific for carbohydrates in a patient allergic to gum arabic (Acacia senegal). Fötisch K, et al. **Allergy** 1998 Nov;53(11):1043–51

IgE levels in surgery: effect of ranitidine and prednisolone. Kampen GT, et al. **Allergy** 1999 Feb;54(2):171–6

Wheat allergy: diagnostic accuracy of skin prick and patch tests and specific IgE. Majamaa H, et al. **Allergy** 1999 Aug; 54(8):851–6

Cow's milk allergy: diagnostic accuracy of skin prick and patch tests and specific IgE. Majamaa H, et al. **Allergy** 1999 Apr;54(4):346–51

Pertussis IgE and atopic disease. Nilsson L, et al. **Allergy** 1998 Dec;53(12):1195–201

Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Noh GW, et al. **Allergy** 1998 Dec;53(12):1202–7

Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. Paganelli R, et al. **Allergy** 1998 Aug;53(8):763–8

Injection of anti-IgE antibodies will suppress IgE and allergic symptoms. Patalano F. **Allergy** 1999 Feb; 54(2):103–10 (43 ref.)

Prevalence of latex-specific IgE in blood donors: an Italian survey. Senna GE, et al. **Allergy** 1999 Jan;54(1):80–1

The patch test, skin prick test, and serum milk-specific IgE as diagnostic tools in cow's milk allergy in infants. Vanto T, et al. **Allergy** 1999 Aug;54(8):837–42

A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Baldini M, et al. **Am J Respir Cell Mol Biol** 1999 May;20(5):976–83

The relationship of skin test positivity, high serum total IgE levels, and peripheral blood eosinophilia to symptomatic and asymptomatic airway hyperresponsiveness. Jansen DF, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):924–31

Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Rakes GP, et al. **Am J Respir Crit Care Med** 1999 Mar;159(3):785–90

Influence of sex and age on serum total immunoglobulin E concentration in Beagles. Racine BP, et al. **Am J Vet Res** 1999 Jan;60(1):93–7

Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):160–4

Serum cytokines and increased total serum IgE in alcoholics. González-Quintela A, et al. **Ann Allergy Asthma Immunol** 1999 Jul;83(1):61–7

Occupational asthma and IgE sensitization to cellulase in a textile industry worker. Kim HY, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):174–8

Lymphocyte membrane antigen expression and intracellular cytokine patterns in an asymptomatic patient with persistently high serum levels of IgE. Krampera M, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):144–8

A patient with persistent wheezing, sinusitis, elevated IgE, and eosinophilia [clinical conference] Robinson J, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):144–9

Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Masamoto T, et al. **Ann Otol Rhinol Laryngol** 1999 Feb;108(2):169–76

Definitive diagnosis of nut allergy. Armstrong D, et al. **Arch Dis Child** 1999 Feb;80(2):175–7

Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Ohashi Y, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1337–46

The value of a single skin prick testing for specific IgE Dermatophagoides pteronyssinus to distinguish atopy from non-atopic asthmatic children in the tropics. Santoso H. **Asian Pac J Allergy Immunol** 1998 Jun–Sep;16(2–3):69–74

Comparison of intradermal testing and serum testing for allergen-specific IgE using monoclonal IgE antibodies in 84 atopic dogs. Mueller RS, et al. **Aust Vet J** 1999 May; 77(5):290–4

Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. Gao PS, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):425–9

Immunological aspects of human schistosomiasis. Butterworth AE. **Br Med Bull** 1998;54(2):357–68 (40 ref.)

Evaluation of a particle-enhanced turbidimetric immunoassay for the measurement of immunoglobulin E in an ILab 900 analyzer. Guaita S, et al. **Clin Chem** 1999 Sep;45(9):1557–61

Total immunoglobulin E levels and dengue infection on San Andrés Island, Colombia. Miguez-Burbano MJ, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):624–6

Allergy to complex salts of platinum in refinery workers: prospective evaluations of IgE and Phadiatop status. Calverley AE, et al. **Clin Exp Allergy** 1999 May; 29(5):703–11

Do inhaled corticosteroids reduce serum IgE levels? The answer is maybe but how relevant is the question? [editorial; comment] Corne J. **Clin Exp Allergy** 1999 Mar; 29(3):294–7. Comment on: Clin Exp Allergy 1999 Mar;29(3):357–61.

Predicting the impairment and accelerated decline of lung function – the role of immunoglobulin E [editorial; comment] Dow L. **Clin Exp Allergy** 1998 Oct;28(10):1174–7. Comment on: Clin Exp Allergy 1998 Oct;28(10):1210–8.

Relation between IgG antibodies to foods and IgE antibodies to milk, egg, cat, dog and/or mite in a cross-sectional study [see comments] Eysink PE, et al. **Clin Exp Allergy** 1999 May;29(5):604–10. Comment in: Clin Exp Allergy 1999 May;29(5):576–8.

Reference values of total serum IgE and their significance in the diagnosis of allergy among the young adult Kuwaiti population. Ezeamuzie CI, et al. **Clin Exp Allergy** 1999 Mar;29(3):375–81

Vbeta8+ T lymphocytes are essential in the regulation of airway hyperresponsiveness and bronchoalveolar eosinophilia but not in allergen-specific IgE in a murine model of allergic asthma [see comments] Hofstra CL, et al. **Clin Exp Allergy** 1998 Dec;28(12):1571–80. Comment in: Clin Exp Allergy 1998 Dec;28(12):1449–53.

Unreliability of IgE/IgG4 antibody testing as a diagnostic tool in food intolerance [see comments] Jenkins M, et al. **Clin Exp Allergy** 1998 Dec;28(12):1526–9. Comment in: Clin Exp Allergy 1998 Dec;28(12):1457–9.

Comparison of skin prick test and specific IgE determination for the diagnosis of latex allergy [letter; comment] Niggemann B. **Clin Exp Allergy** 1999 Jan;29(1):133–4. Comment on: Clin Exp Allergy 1998 Aug;28(8):971–6.

Effects of inhaled beclomethasone dipropionate on serum IgE levels and clinical symptoms in atopic asthma [see comments] Ohrui T, et al. **Clin Exp Allergy** 1999 Mar; 29(3):357–61. Comment in: Clin Exp Allergy 1999 Mar;29(3):294–7.

Head circumference at birth and maternal factors related to cord blood total IgE. Oryszczyn MP, et al. **Clin Exp Allergy** 1999 Mar;29(3):334–41

The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD [see comments] Renkema TE, et al. **Clin Exp Allergy** 1998 Oct; 28(10):1210–8. Comment in: Clin Exp Allergy 1998 Oct;28(10):1174–7.

Cow's milk protein-specific IgE concentrations in two age groups of milk-allergic children and in children achieving clinical tolerance. Sicherer SH, et al. **Clin Exp Allergy** 1999 Apr;29(4):507–12

Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide. Jarman ER, et al. **Clin Exp Immunol** 1999 Feb;115(2):221–8

High IgE in rheumatoid arthritis (RA) patients is complexed with anti-IgE autoantibodies. Millauer N, et al. **Clin Exp Immunol** 1999 Jan;115(1):183–8

Unclassified endogenous eczema. MacKenzie-Wood AR, et al. **Contact Dermatitis** 1999 Jul;41(1):18–21

Immunoblot analysis of components of barley recognized by IgE antibodies in sera from pig farm workers. Chiung YM, et al. **Electrophoresis** 1998 Jun;19(8–9):1317–8

Relationship between cholinergic airway tone and serum immunoglobulin E in human subjects. Endoh N, et al. **Eur Respir J** 1998 Jul;12(1):71–4

Indication of linkage of serum IgE levels to the interleukin-4 gene and exclusion of the contribution of the (-590 C to T) interleukin-4 promoter polymorphism to IgE variation. Dizier MH, et al. **Genet Epidemiol** 1999;16(1):84–94

Elevation of serum IgE level and peripheral eosinophil count during T lymphocyte-directed gene therapy for ADA deficiency: implication of Tc2-like cells after gene transduction procedure. Kawamura N, et al. **Immunol Lett** 1998 Nov;64(1):49–53

IgE and tumor necrosis factor in malaria infection. Perlmann P, et al. **Immunol Lett** 1999 Jan;65(1–2):29–33 (43 ref.)

Eosinophilia, IgE production, and cytokine production by lung T cells in surface CD4-deficient mutant mice infected with Toxocara canis. Takamoto M, et al. **Immunology** 1998 Sep;95(1):97–104

Pilot study on histamine release from basophils of atopic individuals with low specific IgE serum levels against casein. Amon U, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S43–4

Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. Crameri R, et al. **Int Immunol** 1998 Aug;10(8):1211–6

Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer. Tsavaris N, et al. **Int J Biol Markers** 1998 Apr–Jun;13(2):87–91

Measurement of murine IgE antibody responses to dust mite allergens by in vitro assay. Ma Y, et al. **Int J Mol Med** 1999 Jun;3(6):621–4

Ascaris-specific IgE and allergic sensitization in a cohort of school children in the former East Germany. Dold S, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):414–20

Relation of latex-specific IgE titer and symptoms in patients allergic to latex. Kim KT, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):671–7

Skin reactivity to inhalant allergens, total serum IgE levels, and bronchial responsiveness to methacholine are increased in parents of nonatopic asthmatic children. Kim YK, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):311–6

Eosinophil involvement and serum IgE level in HIV-1-infected children. Onorato J, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):245–7

Total serum IgE and its association with asthma symptoms and allergic sensitization among children. Sherrill DL, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):28–36

Alterations of T-lymphocyte subsets, soluble IL-2 receptor, and IgE in peripheral blood of children with acute asthma attacks. Shi HZ, et al. **J Allergy Clin Immunol** 1999 Mar; 103(3 Pt 1):388–94

Serum levels of anti-Staphylococcus aureus-specific IgE in patients with atopic dermatitis. Yamada H, et al. **J Clin Lab Immunol** 1996;48(4):167–75

An assessment of the role of Candida albicans antigen in atopic dermatitis. Morita E, et al. **J Dermatol** 1999 May; 26(5):282–7

Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. Hofstra CL, et al. **J Immunol** 1998 Nov 1;161(9):5054–60

Does IgE bind to and activate eosinophils from patients with allergy? Kita H, et al. **J Immunol** 1999 Jun 1; 162(11):6901–11

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. Saini SS, et al. **J Immunol** 1999 May 1;162(9):5624–30

Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. van Neerven RJ, et al. **J Immunol** 1999 Sep 1;163(5):2944–52

Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. Neva FA, et al. **J Infect Dis** 1998 Dec;178(6):1856–9

Increased type 2 cytokine expression by both CD4+ CD45RO+ T cells and CD8+ CD45RO+ T cells in blood circulation is associated with high serum IgE but not with atopic dermatitis. Sato A, et al. **J Invest Dermatol** 1998 Dec;111(6):1079–84

Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. Valenta R, et al. **J Invest Dermatol** 1998 Dec; 111(6):1178–83

Patterns of immunoglobulin E sensitization to chironomids in exposed and unexposed subjects. Galindo PA, et al. **J Investig Allergol Clin Immunol** 1999 Mar–Apr;9(2):117–22

DNase I hypersensitive sites in human I epsilon region of immunoglobulin heavy chain genes abnormally induced by interleukin-4 in B-lymphocytes of atopic patients with high levels of serum IgE. Kondo N, et al. **J Investig Allergol Clin Immunol** 1998 Jul–Aug;8(4):234–8

Multiple sclerosis with mite antigen-specific IgE. Kira J, et al. **J Neurol Sci** 1998 May 7;157(2):138–42

The influence of chronic yogurt consumption on immunity. Van de Water J, et al. **J Nutr** 1999 Jul;129(7 Suppl):1492S–5S

Immunoglobulin E antibody against environmental allergens in subjects with trimellitic anhydride-induced asthma.

Sikora R, et al. **J Occup Environ Med** 1999 Mar;41(3):190–4
Serum IgE levels during the first 6 years of life. Kulig M, et al. **J Pediatr** 1999 Apr;134(4):453–8
High serum IgE levels are associated with selective proteinuria in glomerulonephritis [letter] Pall AA, et al. **Kidney Int** 1999 Jul;56(1):351–3
Eosinophil and IgE responses of IL-5 transgenic mice experimentally infected with Nippostrongylus brasiliensis. Chai JY, et al. **Korean J Parasitol** 1999 Jun;37(2):93–9
Variation of antigenicity and serological reaction to Pneumocystis carinii in Korea. Park HY, et al. **Korean J Parasitol** 1999 Jun;37(2):109–15
Decline in total serum IgE after treatment for tuberculosis. Adams JF, et al. **Lancet** 1999 Jun 12;353(9169):2030–3
IgE multiple myeloma. Macro M, et al. **Leuk Lymphoma** 1999 Feb;32(5–6):597–603 (42 ref.)
IgE and IgG4 antibodies in subjects reinfected with Schistosoma mansoni in an endemic area of northeast Brazil. Gomes YM, et al. **Mem Inst Oswaldo Cruz** 1998; 93 Suppl 1:183–4
Measurement of specific IgEs in the diagnosis of drug allergy. Anania A. **Panminerva Med** 1999 Jun;41(2):115–7
Toxocara infestations in humans: symptomatic course of toxocarosis correlates significantly with levels of IgE/anti-IgE immune complexes. Obwaller A, et al. **Parasite Immunol** 1998 Jul;20(7):311–7
Influence of the genetic background and parasite load of mice on the immune response developed against nymphs of Ixodes ricinus. Christe M, et al. **Parasitol Res** 1999 Jul; 85(7):557–61
Reduced plasma c-AMP levels in children with atopic dermatitis. Salpietro DC, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):130–2
Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels. Yu G, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):133–8
Dystrophic epidermolysis bullosa associated with eosinophilic infiltrate and elevated serum IgE. Grunwald MH, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):16–8 (14 ref.)
The relationship between serum ACE activity and total IgE levels in patients with bronchial asthma. Tutluoglu B, et al. **Pneumoftiziologia** 1998 Apr–Jun;47(2):95–7
Serum antibody titers in a systemic lytic therapy with streptokinase. Hohage H, et al. **South Med J** 1998 Nov; 91(11):1019–23
Modelling the cause of dependency with application to filaria infection. Houwing-Duistermaat JJ, et al. **Stat Med** 1998 Dec 30;17(24):2939–54
Elevated immunoglobulin E (IgE) levels in children with exposure to environmental lead. Lutz PM, et al. **Toxicology** 1999 May 3;134(1):63–78
Serum immunoglobulin and immunoglobulin G subclasses in children with allergic colitis. Ojuawo A, et al. **West Afr J Med** 1998 Jul–Sep;17(3):206–9
Evaluation of a commercial ELISA test for the detection of allergen-specific IgE antibodies in atopic dogs. Ginel PJ, et al. **Zentralbl Veterinarmed [B]** 1998 Sep;45(7):421–5
[Technical test of the AlaSat system] Lavigne JP, et al. **Ann Biol Clin (Paris)** 1998 Sep–Oct;56(5):590–2 **(Fre)**
[Reagin sensitizations and date of birth. Differences in function according to family history] de Montis G. **Arch Pediatr** 1999 Mar;6(3):259–62 (Eng. Abstr.) **(Fre)**
[IgE levels in cord blood in an area of the Veneto region] Tenderini ML, et al. **Minerva Pediatr** 1998 May; 50(5):157–61 (Eng. Abstr.) **(Ita)**
[Antigen specific immunoglobulin E to grass and weed pollens in the plasma of patients with seasonal allergic rhinitis] Silny W, et al. **Otolaryngol Pol** 1999;53(1):55–8 (Eng. Abstr.) **(Pol)**
[Anti-RS viral IgE in respiratory syncytial viral infection in adult patients with a complicated course of bronchitis] Krivitskaia VZ, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug; (4):56–61 (Eng. Abstr.) **(Rus)**
[Interleukin 4, total and allergen-specific immunoglobulin E antibodies in the blood of individuals with an atopic constitution] Paranos S, et al. **Srp Arh Celok Lek** 1998 Mar–Apr;126(3–4):92–6 (Eng. Abstr.) **(Scc)**
[Relation between the total plasma IgE concentration and the prevalence of the various RAST (radioallergosorbent) classes of allergy (see comments)] San Martin Ciges E, et al. **Allergol Immunopathol (Madr)** 1998 Sep–Oct; 26(5):228–33 (Eng. Abstr.). Comment in: Allergol Immunopathol (Madr) 1998 Sep–Oct;26(5):203–8. **(Spa)**
[Total serum IgE values in two different populations of asthmatics with different levels of environmental contamination] Ortíz Quintero JL, et al. **Rev Alerg Mex** 1998 Jul–Aug;45(4):87–91 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structure/function studies on IgE as a basis for the development of rational IgE antagonists. Helm BA, et al. **Allergy** 1998;53(45 Suppl):77–82
Characterization of IgE and IgG epitopes on ovomucoid using egg-white-allergic patients' sera. Zhang JW, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):124–7
Characterization of residues in human IgE and IgG binding site by chemical modification of ovomucoid third domain. Zhang JW, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):610–3
Quantifying aggregation of IgE–FcepsilonRI by multivalent antigen. Hlavacek WS, et al. **Biophys J** 1999 May; 76(5):2421–31
Ligand binding by antibody IgE Lb4: assessment of binding site preferences using microcalorimetry, docking, and free energy simulations. Sotriffer CA, et al. **Biophys J** 1999 Jun; 76(6):2966–77
The structural basis of human IgE–Fc receptor interactions. Sayers I, et al. **Clin Exp Allergy** 1999 May;29(5):585–94 (92 ref.)
Prediction of an anti-IgE binding site on IgE. Wright JD, et al. **Protein Eng** 1998 Jun;11(6):421–7
An immunoglobulin-like fold in a major plant allergen: the solution structure of Phl p 2 from timothy grass pollen. De Marino S, et al. **Structure Fold Des** 1999 Aug 15; 7(8):943–52
Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis. Helm BA, et al. **Technol Health Care** 1998 Sep;6(2–3):195–207

CLASSIFICATION

Measles virus infection synergizes with IL-4 in IgE class switching. Imani F, et al. **J Immunol** 1999 Feb 1; 162(3):1597–602

GENETICS

Molecular regulation of IgE switching: let's walk hand in hand. Monticelli S, et al. **Allergy** 1998;53(45 Suppl):6–8
Suggestive evidence for genetic linkage between IgE phenotypes and chromosome 14q markers. Mansur AH, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1796–802
Primary sequence and molecular model of the variable region of a mouse monoclonal anti-Der p 1 antibody showing a similar epitope specificity as human IgE. McElveen JE, et al. **Clin Exp Allergy** 1998 Nov;28(11):1427–34
Clonally related IgE and IgG4 transcripts in blood lymphocytes of patients with asthma reveal differing patterns of somatic mutation. Snow RE, et al. **Eur J Immunol** 1998 Oct;28(10):3354–61
Establishment of antigen-specific IgE transgenic mice to study pathological and immunobiological roles of IgE in vivo. Matsuoka K, et al. **Int Immunol** 1999 Jun;11(6):987–94
Genetic influences of chromosomes 5q31–q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):449–53
Genetic regulation of Dermatophagoides pteronyssinus-specific IgE responsiveness: a genome-wide multipoint linkage analysis in families recruited through 2 asthmatic sibs. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):436–42
Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):443–8
Measles virus infection synergizes with IL-4 in IgE class switching. Imani F, et al. **J Immunol** 1999 Feb 1; 162(3):1597–602

IMMUNOLOGY

Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness--a murine model. Hamelmann E, et al. **Allergy** 1999 Apr; 54(4):297–305 (51 ref.)
Treatment of allergic airways disease with anti-IgE. Holgate ST, et al. **Allergy** 1998;53(45 Suppl):83–8 (62 ref.)
Simultaneous IgE-mediated urticaria and contact dermatitis from latex. Mahmoudi M, et al. **Allergy** 1998 Oct; 53(10):1009–10
Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma. Menz G, et al. **Allergy** 1998;53(45 Suppl):15–21 (57 ref.)
Detection of IgE antibody to a radiocontrast medium [see comments] Mita H, et al. **Allergy** 1998 Dec;53(12):1133–40 . Comment in: Allergy 1998 Dec;53(12):1111–3.
Cow's milk IgE and IgG antibody responses to cow's milk formulas. Oldaeus G, et al. **Allergy** 1999 Apr;54(4):352–7
Allergy to bumblebee venom. II. IgE cross-reactivity between bumblebee and honeybee venom. Stapel SO, et al. **Allergy** 1998 Aug;53(8):769–77
Progressive eosinophilia and elevated IgE in enterobiasis. Villarreal O, et al. **Allergy** 1999 Jun;54(6):646–8
Differential effects of endogenous and exogenous interferon-gamma on immunoglobulin E, cellular infiltration, and airway responsiveness in a murine model of allergic asthma. Hofstra CL, et al. **Am J Respir Cell Mol Biol** 1998 Nov;19(5):826–35
ATP modulates anti-IgE-induced release of histamine from human lung mast cells. Schulman ES, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):530–7
Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma. Wilder JA, et al. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1326–34
Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Fahy JV, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):1023–7
Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Hamelmann E, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):934–41
Evaluation of IgE-sensitization to fungi in HIV-positive patients with eczematous skin reactions. Nissen D, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):153–9
IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus. Morton S, et al. **Ann Rheum Dis** 1998 Nov;57(11):660–3
Mouse Langerhans cells do not express the high-affinity receptor for IgE. Hayashi S, et al. **Arch Dermatol Res** 1999 Apr;291(4):241–3
Differential effect of ebselen on compound 48/80- and anti-IgE-induced histamine release from rat peritoneal mast cells. Tchoumkeu-Nzouessa GC, et al. **Biochem Pharmacol** 1998 Dec 1;56(11):1525–8
Toward an in vitro test for the diagnosis of allergy to penicillins. Synthesis, characterization, and use of beta-lactam and beta-lactam metabolite poly-L-lysines which recognize human IgE antibodies. Bolzacchini E, et al. **Bioconjug Chem** 1999 May–Jun;10(3):332–7
Inhibitory mechanisms of glycoprotein fraction derived from Miscanthus sinensis for the immediate phase response of an IgE-mediated cutaneous reaction. Watanabe C, et al. **Biol Pharm Bull** 1999 Jan;22(1):26–30
Kinetics of adhesion of IgE-sensitized rat basophilic leukemia cells to surface-immobilized antigen in Couette flow. Swift DG, et al. **Biophys J** 1998 Nov;75(5):2597–611
It's spring, and thoughts turn to...allergies. Metzger H. **Cell** 1999 Apr 30;97(3):287–90 (20 ref.)
Serological characteristics of peanut allergy. Clarke MC, et al. **Clin Exp Allergy** 1998 Oct;28(10):1251–7
A role for the hepatobiliary system in IgE-mediated intestinal inflammation in the rat [see comments] Collins AM, et al. **Clin Exp Allergy** 1999 Feb;29(2):262–70. Comment in: Clin Exp Allergy 1999 Feb;29(2):155–8.
Impaired NK1.1+ T cells do not prevent the development of an IgE-dependent allergic phenotype [see comments] Daser A, et al. **Clin Exp Allergy** 1998 Aug;28(8):950–5. Comment in: Clin Exp Allergy 1998 Aug;28(8):908–10.
Systemic immune response to specific immunotherapy [editorial; comment] Ebner C. **Clin Exp Allergy** 1998 Jul; 28(7):781–3. Comment on: Clin Exp Allergy 1998 Jul;28(7):791–8.
Is allergy increasing?--early life influences. Howarth PH. **Clin Exp Allergy** 1998 Dec;28 Suppl 6:2–7 (35 ref.)
IgE and T-cell responses to high-molecular weight allergens from bee venom. Kettner A, et al. **Clin Exp Allergy** 1999 Mar;29(3):394–401
IgE reactivity and cross-reactivity of Japanese monkeys (Macaca fuscata) to Japanese cedar (Cryptomeria japonica) and cypress (Chamaecyparis obtusa) pollen allergens. Kobayashi C, et al. **Clin Exp Allergy** 1999 Jun;29(6):856–61
Phase-contrast microscopic studies using cinematographic techniques and scanning electron microscopy on IgE-mediated degranulation of cultured human mast cells. Kurosawa M, et al. **Clin Exp Allergy** 1998 Aug; 28(8):1007–12
IgE-Fc epsilonRI-mast cell axis in the allergic cycle. Pawankar R, et al. **Clin Exp Allergy** 1998 Aug;28 Suppl 3:6–14
The role of IgE in asthma. Yssel H, et al. **Clin Exp Allergy** 1998 Nov;28 Suppl 5:104–9; discussion 117–8 (71 ref.)
Aspergillus fumigatus antigen exposure results in pulmonary airway resistance in wild-type but not in IL-4 knockout mice. Kurup VP, et al. **Clin Immunol** 1999 Mar;90(3):404–10
Occupational IgE-mediated contact urticaria from diphenylmethane-4,4-diisocyanate (MDI). Kanerva L, et al. **Contact Dermatitis** 1999 Jul;41(1):50–1
Autoallergy: a pathogenetic factor in atopic dermatitis? Valenta R, et al. **Curr Probl Dermatol** 1999;28:45–50 (38 ref.)
Rat urinary proteins binding human IgE detected by chemiluminescence. Bayard C, et al. **Electrophoresis** 1998 Jul;19(10):1642–8
Functional Fc epsilonRI engagement by a second secretory IgE isoform detected in humans. Lorenzi R, et al. **Eur J Immunol** 1999 Mar;29(3):936–45
Suppression of immediate and late responses to antigen by a non-anaphylactogenic anti-IgE antibody in a murine model of asthma. Haile S, et al. **Eur Respir J** 1999 May; 13(5):961–9
Allergen mimotopes in food enhance type I allergic reactions in mice. Jensen-Jarolim E, et al. **FASEB J** 1999 Sep; 13(12):1586–92
Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. Natter S, et al. **FASEB J** 1998 Nov;12(14):1559–69
Role of CD86 (B7-2) in triggering of antigen-specific IgE antibody response by lipopolysaccharide. Jiang GZ, et al. **FEMS Immunol Med Microbiol** 1998 Aug;21(4):303–11
Identification of Cannabis pollens using an allergic patient's immunoglobulin E and purification and characterization of allergens in Cannabis pollens. Tanaka H, et al. **Forensic Sci Int** 1998 Nov 9;97(2–3):139–53
The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Philips JR, et al. **Immunol Cell Biol** 1999 Apr; 77(2):121–6
Reciprocal effects of interleukin-4 and interferon-gamma on immunoglobulin E-mediated mast cell degranulation: a role

for nitric oxide but not peroxynitrite or cyclic guanosine monophosphate. Deschoolmeester ML, et al. **Immunology** 1999 Jan;96(1):138–44

Immunoglobulin E suppression and cytokine modulation in mice orally tolerized to beta-lactoglobulin. Pecquet S, et al. **Immunology** 1999 Feb;96(2):278–85

Reactivity of the immunoglobulin E in bovine gelatin-sensitive children to gelatins from various animals. Sakaguchi M, et al. **Immunology** 1999 Feb;96(2):286–90

Oral tolerance induced to house dust mite extract in naive and sensitized mice: evaluation of immunoglobulin G anti-immunoglobulin E autoantibodies and IgG-IgE complexes. Sato MN, et al. **Immunology** 1998 Oct; 95(2):193–9

Antibody mimicking an anti-E antibody that binds to patient's E negative red cells. Morio A, et al. **Immunopharmacol Immunotoxicol** 1999 May;21(2):221–31

Sequence-specific antibodies against human IgE isoforms induced by an epitope display system. Lorenzi R, et al. **Immunotechnology** 1999 Mar;4(3–4):267–72

Prevention of occupational allergy caused by exposure to acid anhydrides. Yokota K, et al. **Ind Health** 1999 Jul; 37(3):281–8 (53 ref.)

Natural immunity to Ascaris lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. McSharry C, et al. **Infect Immun** 1999 Feb;67(2):484–9

Role of adult worm antigen-specific immunoglobulin E in acquired immunity to Schistosoma mansoni infection in baboons. Nyindo M, et al. **Infect Immun** 1999 Feb; 67(2):636–42

Prostanoid DP receptor activation inhibits anti-IgE induced histamine release from rat peritoneal mast cells. Chan CL, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S29–30

Analysis of anti-IgE and allergen induced human basophil activation by flow cytometry. Comparison with histamine release. Sainte-Laudy J, et al. **Inflamm Res** 1998 Oct; 47(10):401–8

Effect of Y-24180, an antagonist at platelet-activating factor (PAF) receptors, on IgE-mediated cutaneous reactions in mice. Yamaguchi S, et al. **Inflamm Res** 1998 Dec; 47(12):506–11

Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Akdis CA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):140–4 (23 ref.)

IgE-mediated reactions to autoantigens in allergic diseases. Appenzeller U, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):193–6

TNF-alpha and IL-5 gene induction in IgE plus antigen-stimulated mast cells require common and distinct signaling pathways. Baumruker T, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):108–11

Modification of a major peanut allergen leads to loss of IgE binding. Burks AW, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):313–4

Protein and allergen analysis of latex mattresses. Chardin H, et al. **Int Arch Allergy Immunol** 1999 Jul;119(3):239–46

IgE binding capacity of synthetic and recombinant peptides of the major storage mite (Lepidoglyphus destructor) allergen, Lep d 2. Elfman LH, et al. **Int Arch Allergy Immunol** 1998 Nov;117(3):167–73

IgE inhibition as a therapy for allergic disease. Jardieu PM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):112–5 (12 ref.)

Nonapeptides selected by phage display mimic the binding sites of monoclonal antibodies BIP1 and BIP4 on Bet v 1, the major birch pollen allergen. Jensen-Jarolim E, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):224–5

The importance of recombinant allergens for diagnosis and therapy of IgE-mediated allergies. Kraft D, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):171–6

IgE-related peptide mimotopes. Basic structures for anti-allergy vaccine development. Kricek F, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):222–3

An in vitro model for the allergen-IgE-FcARI interaction. Laffer S, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):116–8

Corn allergens: IgE antibody reactivity and cross-reactivity with rice, soy, and peanut. Lehrer SB, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):298–9

Role of IgE for the onset of allergic cutaneous response caused by simple chemical hapten in mice. Nagai H, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):285–6

Antigen interaction and heat inactivation expose new epitopes on human IgE. Pachlopnik JM, et al. **Int Arch Allergy Immunol** 1998 Dec;117(4):231–8

Endogenous superallergen protein Fv interacts with the VH3 region of IgE to induce cytokine secretion from human basophils. Patella V, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):197–9

Implications of the grass group I allergens on the sensitization and provocation process. Petersen A, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):411–3

IgE-binding epitopes of shrimp tropomyosin, the major allergen Pen a 1. Reese G, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):300–1

Effects of structure modifications on IgE binding properties of serum albumins. Restani P, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):113–9

Identification of the Schistosoma japonicum 22.6-kDa antigen as a major target of the human IgE response: similarity of IgE-binding epitopes to allergen peptides. Santiago ML, et al. **Int Arch Allergy Immunol** 1998 Oct; 117(2):94–104

Mimotope and anti-idiotypic vaccines to induce an anti-IgE response. Stadler BM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):119–21

CD8 T-lymphocyte-mediated regulation of ovalbumin-specific murine IgE responses. Thomas MJ, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):289–91

IgE downmodulates stem cell factor-driven mast cell development from cultured peripheral blood mononuclear cells. Welker P, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):292–3

Establishment of antigen-specific IgE transgenic mice to study pathological and immunobiological roles of IgE in vivo. Matsuoka K, et al. **Int Immunol** 1999 Jun;11(6):987–94

Risk of asthma in the general Spanish population attributable to specific immunoresponse. Spanish Group of the European Community Respiratory Health Survey. Soriano JB, et al. **Int J Epidemiol** 1999 Aug;28(4):728–34

Reduction of latex aeroallergens and latex-specific IgE antibodies in sensitized workers after removal of powdered natural rubber latex gloves in a hospital. Allmers H, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):841–6

Role of gamma/delta T cells in a patient with CD4+CD3- lymphocytosis, hypereosinophilia, and high levels of IgE. Bank I, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):621–30

Diagnostic performance of Food and Drug Administration-cleared serologic assays for natural rubber latex-specific IgE antibody. The Multi-Center Latex Skin Testing Study Task Force. Hamilton RG, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):925–30

Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):449–53

Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test. Collaborative Study on the Genetics of Asthma (CSGA). Hizawa N, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):443–8

IgE reactivity to Api g 1, a major celery allergen, in a Central European population is based on primary sensitization by Bet v 1. Hoffmann-Sommergruber K, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):478–84

Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes. Hong SJ, et al. **J Allergy Clin Immunol** 1999 Aug; 104(2 Pt 1):473–8

A murine model of IgE-mediated cow's milk hypersensitivity. Li XM, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):206–14

Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. Niederberger V, et al. **J Allergy Clin Immunol** 1998 Oct; 102(4 Pt 1):579–91

An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production. Pullerits T, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):843–9

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. Sabroe RA, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):484–93

The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. Wantke F, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):642–8

Repeated intratracheal inoculation of house dust mite (Dermatophagoides farinae) induces pulmonary eosinophilic inflammation and IgE antibody production in mice. Yu CK, et al. **J Allergy Clin Immunol** 1999 Jul; 104(1):228–36

Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. Sabroe RA, et al. **J Am Acad Dermatol** 1999 Mar;40(3):443–50

Trichophyton antigens associated with IgE antibodies and delayed type hypersensitivity. Sequence homology to two families of serine proteinases. Woodfolk JA, et al. **J Biol Chem** 1998 Nov 6;273(45):29489–96

The immunoglobulin-like modules Cepsilon3 and alpha2 are the minimal units necessary for human IgE-FcepsilonRI interaction. Vangelista L, et al. **J Clin Invest** 1999 Jun; 103(11):1571–8

Adjuvant activities of pyrene, anthracene, fluoranthene and benzo(a)pyrene in production of anti-IgE antibody to Japanese cedar pollen allergen in mice. Kanoh T, et al. **J Clin Lab Immunol** 1996;48(4):133–47

Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. Cui J, et al. **J Exp Med** 1999 Sep 20;190(6):783–92

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. Haselden BM, et al. **J Exp Med** 1999 Jun 21;189(12):1885–94

Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. Ujike A, et al. **J Exp Med** 1999 May 17;189(10):1573–9

Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. Hayek B, et al. **J Immunol** 1998 Dec 15; 161(12):7031–9

Inhibition by dexamethasone of antigen-induced c-Jun N-terminal kinase activation in rat basophilic leukemia cells. Hirasawa N, et al. **J Immunol** 1998 Nov 1; 161(9):4939–43

Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Roux KH, et al. **J Immunol** 1998 Oct 15;161(8):4083–90

Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. Valenta R, et al. **J Invest Dermatol** 1998 Dec; 111(6):1178–83

Determinations of Par j 1 by a competitive enzyme immunoassay using human specific IgE and IgG. Validation by skin prick testing. Boluda L, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):207–13

Further characterization of IgE-binding antigens in kiwi, with particular emphasis on glycoprotein allergens. Fahlbusch B, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec;8(6):325–32

Extracts from various mite species contain cross-reactive and noncross-reactive IgE epitopes. A RAST inhibition study. Garcia-Robaina JC, et al. **J Investig Allergol Clin Immunol** 1998 Sep-Oct;8(5):285–9

Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy. Rogala B, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun;9(3):183–9

Comparison of basophil histamine releasability between atopic and nonatopic asthmatics. Son JW, et al. **J Korean Med Sci** 1999 Apr;14(2):153–8

Potential effect of the administration of substance P and allergen therapy on immunoglobulin E-mediated allergic reactions in human subjects. Patterson R, et al. **J Lab Clin Med** 1999 Feb;133(2):189–99

Soy allergy in infants and children with IgE-associated cow's milk allergy. Zeiger RS, et al. **J Pediatr** 1999 May; 134(5):614–22

Analysis of human IgE epitope of Der f 2 with anti-Der f 2 mouse monoclonal antibodies. Nishiyama C, et al. **Mol Immunol** 1999 Jan;36(1):53–60

Toxocara infestations in humans: symptomatic course of toxocarosis correlates significantly with levels of IgE/anti-IgE immune complexes. Obwaller A, et al. **Parasite Immunol** 1998 Jul;20(7):311–7

Therapy of allergic pulmonary diseases with anti-IgE antibodies. A review. Fick RB. **Pediatr Pulmonol Suppl** 1999;18:115–7 (17 ref.)

Low responsiveness to immunization with immunoglobulin E/antigen and immunoglobulin G/antigen complexes in H-2Ab mice. Gustavsson S, et al. **Scand J Immunol** 1999 Jul;50(1):45–51

Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis. Helm BA, et al. **Technol Health Care** 1998 Sep;6(2–3):195–207

Effects of anti-IgE in asthmatic subjects. Frew AJ. **Thorax** 1998 Aug;53 Suppl 2:S52–7 (44 ref.)

Allergen-specific IgE and IgGd antibodies in atopic and normal dogs. Lian TM, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):203–23

Studies on pulmonary and systemic Aspergillus fumigatus-specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD). Schmallenbach KH, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):245–56

Use of muscle exudates for the detection of anti-gE antibodies to Aujeszky's disease virus. Le Potier MF, et al. **Vet Rec** 1998 Oct 3;143(14):385–7

Identification and purification of IgE-reactive proteins in German cockroach extract. Yong TS, et al. **Yonsei Med J** 1999 Jun;40(3):283–9

Identification of IgE-reacting Clonorchis sinensis antigens. Yong TS, et al. **Yonsei Med J** 1999 Apr;40(2):178–83

[Circannual rhythm of the risk of IgE-dependent sensitization to acari depending on the birth date. Interpretation and practical consequences in prevention] de Montis G. **Bull Acad Natl Med** 1998;182(8):1697–705; discussion 1705–7 (Eng. Abstr.) **(Fre)**

[Rare hyperimmunoglobulinemia E syndromes] Katchourine I, et al. **Rev Med Interne** 1998 Mar;19(3):185–91 (29 ref.) (Eng. Abstr.) **(Fre)**

[A cross-reactivity of Candida albicans at the serum IgE level to the other yeast species] Kanbe T, et al. **Arerugi** 1998 Dec;47(12):1237–9 (10 ref.) **(Jpn)**

[Evaluation of changes in the course of seasonal allergic nasal mucosa inflammation] Jurkiewicz D. **Otolaryngol Pol** 1998; 52(3):363–5 (Eng. Abstr.) **(Pol)**

[Antigen specific immunoglobulin E to grass and weed pollens in the plasma of patients with seasonal allergic rhinitis] Silny W, et al. **Otolaryngol Pol** 1999;53(1):55–8 (Eng. Abstr.) **(Pol)**

[IgE mediated food allergy: pathomechanism, clinical picture and perspectives of new therapy] Romański B.

Pol Merkuriusz Lek 1998 Dec;5(30):379–83 (Eng. Abstr.) **(Pol)**

[The effect of intrabronchial specific immunotherapy on certain immunologic parameters in asthmatic patients with allergic to house mites] Ziętkowski Z.
Pol Merkuriusz Lek 1999 May;6(35):236–8 (Eng. Abstr.) **(Pol)**

[Round Table: Immunological urticaria mediated by IgE] Eseverri JL, et al. **Allergol Immunopathol (Madr)** 1999 Mar–Apr;27(2):104–11 (28 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Affinity purification of mouse monoclonal IgE using a protein A mimetic ligand (TG19318) immobilized on solid supports. Palombo G, et al. **J Mol Recognit** 1998 Winter; 11(1–6):247–9

METABOLISM

Human conjunctival mast cells: expression of Fc epsilonRI, c-kit, ICAM-1, and IgE. Stahl JL, et al.
Arch Ophthalmol 1999 Apr;117(4):493–7

Characterization of a novel allergen, a major IgE-binding protein from Aspergillus flavus, as an alkaline serine protease. Yu CJ, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):669–75

Ligand binding by antibody IgE Lb4: assessment of binding site preferences using microcalorimetry, docking, and free energy simulations. Sotriffer CA, et al. **Biophys J** 1999 Jun; 76(6):2966–77

Fecal tumor necrosis factor alpha, eosinophil cationic protein and IgE levels in infants with cow's milk allergy and gastrointestinal manifestations. Kapel N, et al.
Clin Chem Lab Med 1999 Jan;37(1):29–32

Association studies on beta2-adrenoceptor polymorphisms and enhanced IgE responsiveness in an atopic population. Deichmann KA, et al. **Clin Exp Allergy** 1999 Jun; 29(6):794–9

The structural basis of human IgE–Fc receptor interactions. Sayers I, et al. **Clin Exp Allergy** 1999 May;29(5):585–94 (92 ref.)

Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. Niederberger V, et al. **FASEB J** 1999 May;13(8):843–56

The membrane-proximal part of FcepsilonRIalpha contributes to human IgE and antibody binding—implications for a general structural motif in Fc receptors. Nechansky A, et al. **FEBS Lett** 1998 Dec 18; 441(2):225–30

IgE binding capacity of synthetic and recombinant peptides of the major storage mite (Lepidoglyphus destructor) allergen, Lep d 2. Elfman LH, et al.
Int Arch Allergy Immunol 1998 Nov;117(3):167–73

IgE-binding and histamine-release capabilities of the main carbohydrate component isolated from the major allergen of olive tree pollen, Ole e 1. Batanero E, et al.
J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):147–53

Human IgE-binding epitopes of the latex allergen Hev b 5. Beezhold DH, et al. **J Allergy Clin Immunol** 1999 Jun; 103(6):1166–72

The human recombinant histamine releasing factor: functional evidence that it does not bind to the IgE molecule. Wantke F, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):642–8

Fine structure analysis of interaction of FcepsilonRI with IgE. Hulett MD, et al. **J Biol Chem** 1999 May 7; 274(19):13345–52

Fc epsilon RI on dendritic cells: a receptor, which links IgE mediated allergic reaction and T cell mediated cellular response. Shibaki A. **J Dermatol Sci** 1998 May;20(1):29–38 (90 ref.)

Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. Choi IH, et al. **J Exp Med** 1998 Nov 2;188(9):1587–92

Production of a chimeric form of CD23 that is oligomeric and blocks IgE binding to the Fc epsilonRI. Kelly AE, et al. **J Immunol** 1998 Dec 15;161(12):6696–704

Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. Patella V, et al. **J Immunol** 1998 Nov 15;161(10):5647–55

"Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. Schramm G, et al.
J Immunol 1999 Feb 15;162(4):2406–14

Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. Hofer MF, et al.
J Invest Dermatol 1999 Feb;112(2):171–6

N-glycosylation influences epitope expression and receptor binding structures in human IgE. Björklund JE, et al.
Mol Immunol 1999 Feb;36(3):213–21

Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Chen CL, et al. **Pharm Res** 1999 Jan;16(1):117–22

IgE binding patterns to German cockroach whole body extract in Korean atopic asthmatic children. Lee SY, et al. **Yonsei Med J** 1998 Oct;39(5):409–16

[IgE myeloma] Nakano T, et al.
Ryoikibetsu Shokogun Shirizu 1998;(22 Pt 3):413–6 (14 ref.) **(Jpn)**

PHARMACOLOGY

Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy. Moneret-Vautrin DA, et al.
Ann Allergy Asthma Immunol 1999 Jan;82(1):33–40

Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. MacGlashan D Jr, et al.
J Allergy Clin Immunol 1999 Aug;104(2 Pt 1):492–8

Interleukin-3 or immunoglobulin E promotes expression of protein kinase C delta gene in murine mast cells. Kim HM, et al. **Pharmacol Res** 1999 Aug;40(2):147–51

PHYSIOLOGY

The role of IgE in the pathogenesis of atopic dermatitis. Bruijnzeel-Koomen C. **Allergy** 1998;53(46 Suppl):29–30

Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Sayers I, et al. **Biochemistry** 1998 Nov 17;37(46):16152–64

A novel function for transforming growth factor-beta1: upregulation of the expression and the IgE-independent extracellular release of a mucosal mast cell granule-specific beta-chymase, mouse mast cell protease-1. Miller HR, et al. **Blood** 1999 May 15;93(10):3473–86

Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the Fc epsilon RI. Erdei A, et al. **Immunol Lett** 1999 May 3; 68(1):79–82

IL-4-dependent IgE class switching in an anti-trinitrophenyl B-cell hybridoma after engagement of antigen receptors. Hikida M, et al. **Immunol Lett** 1999 Feb;65(3):161–6

Anaphylactic response to parasite antigens: IgE and IgG1 independently induce death in Trichinella-infected mice. Bruschi F, et al. **Int Arch Allergy Immunol** 1999 Aug; 119(4):291–6

The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE. Kisselgof AB, et al. **Int Immunol** 1998 Sep;10(9):1377–84

gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. Lu-Kuo JM, et al. **J Biol Chem** 1999 Feb 26;274(9):5791–6

Role of TGF-beta 1 on the IgE-dependent anaphylaxis reaction. Kim HM, et al. **J Immunol** 1999 Apr 15; 162(8):4960–5

Fc epsilonRI-mediated induction of TNF-alpha gene expression in the RBL-2H3 mast cell line: regulation by a novel NF-kappaB-like nuclear binding complex. Pelletier C, et al. **J Immunol** 1998 Nov 1;161(9):4768–76

Macrophage colony-stimulating factor stimulates synthesis and secretion of a mouse homolog of a human IgE-dependent histamine-releasing factor by macrophages in vitro and in vivo. Teshima S, et al. **J Immunol** 1998 Dec 1;161(11):6356–66

IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. Yamaguchi M, et al. **J Immunol** 1999 May 1;162(9):5455–65

Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Kershaw MH, et al.
Oncol Res 1998;10(3):133–42

IGE-MEDIATED HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

IGE RECEPTORS see **RECEPTORS, IGE**

IGF-BINDING PROTEIN 1 see **INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1**

IGF-BINDING PROTEIN 2 see **INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2**

IGF-BINDING PROTEIN 3 see **INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3**

IGF-BINDING PROTEIN 4 see **INSULIN LIKE GROWTH-FACTOR-BINDING PROTEIN 4**

IGF-BINDING PROTEIN 5 see **INSULIN-LIKE GROWTH-FACTOR-BINDING-PROTEIN 5**

IGF-BINDING PROTEIN 6 see **INSULIN-LIKE-GROWTH-FACTOR-BINDING PROTEIN 6**

IGF-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGF-I see **INSULIN-LIKE GROWTH FACTOR I**

IGF-I RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

IGF-II see **INSULIN-LIKE GROWTH FACTOR II**

IGF-II RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

IGFBP see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGFBP-1 see **INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1**

IGFBP-2 see **INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2**

IGFBP-3 see **INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3**

IGFBP-4 see **INSULIN LIKE GROWTH-FACTOR-BINDING PROTEIN 4**

IGFBP-5 see **INSULIN-LIKE GROWTH-FACTOR-BINDING-PROTEIN 5**

IGFBP-6 see **INSULIN-LIKE-GROWTH-FACTOR-BINDING PROTEIN 6**

IGG

see related
RECEPTORS, IGG

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter] Brion PH, et al.
Ann Intern Med 1999 Oct 19;131(8):634

Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Kobayashi H, et al. **Bioconjug Chem** 1999 Jan-Feb; 10(1):103–11

Prevention of necrotizing enterocolitis in extremely low birth weight infants by IgG feeding? Richter D, et al.
Eur J Pediatr 1998 Nov;157(11):924–5

Ultrasensitive immune complex transfer enzyme immunoassay of HIV-1 p24 antigen with less serum interference using 2,4-dinitrophenyl-anti-HIV-1 p24 IgG and indirectly immobilized (anti-2,4-dinitrophenyl group) Fab. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(3):126–32

Chemiluminescence of ABEI-labelled IgG triggered by the N-chloramine-H(2)O(2)-p-iodophenol system. Olszowski S, et al. **Luminescence** 1999 May-Jun;14(3):139–45

Molecular mapping of influenza virus RNA polymerase by site-specific antibodies. Masunaga K, et al. **Virology** 1999 Mar 30;256(1):130–41

[Case of cardiac amyloidosis associated with IgG-K multiple myeloma in the framework of restrictive myocardiopathy] Baldassarre S, et al. **Cardiologia** 1999 Feb;44(2):193–7 (Eng. Abstr.) **(Ita)**

[Systemic Buschke's scleredema with cardiomyopathy, monoclonal IgG kappa gammopathy and amyloidosis. Case report with autopsy] Paz RA, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):501–3 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

IgG-coated erythrocytes augment the lipopolysaccharidestimulated increase in serum tumor necrosis factor-alpha. Richard CA, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R171–7

Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG. Dams ET, et al. **Ann Surg** 1999 Apr;229(4):551–7

Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Johansson JE, et al. **Bone Marrow Transplant** 1999 Jul;24(1):35–9

Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Trehu EG, et al. **Clin Cancer Res** 1996 Aug;2(8):1341–51

Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model. Blumenthal RD, et al. **Eur J Cancer** 1999 May;35(5):815–24

IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. Wagner E, et al. **J Immunol** 1999 Sep 15;163(6):3549–58

Sustained delivery of immunoglobulins from polymer microsources on a narrow surface of the developing rat brain. Doulazmi M, et al. **J Neurosci Methods** 1998 Oct 1;84(1-2):17–28

High-dose immunoglobulin G therapy for fulminant myocarditis. Takeda Y, et al. **Jpn Circ J** 1998 Nov; 62(11):871–2

Combined administration of IgA and IgG anti-Thy-1 antibodies enhances renal inflammation in rats. Van Dixhoorn MG, et al. **Kidney Int** 1999 Jun;55(6):2299–309

Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Kuwabara S, et al. **Neurology** 1998 Dec;51(6):1656–60

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Nussenblatt RB, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7462–6

Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with

antibody deficiency syndromes. Costa-Carvalho BT, et al. **Rev Paul Med** 1998 Sep-Oct;116(5):1815-20

ADVERSE EFFECTS

Adult respiratory distress syndrome after experimental intravenous gamma-globulin concentrate and monocyte-reactive IgG antibodies [letter] Dooren MC, et al. **Lancet** 1998 Nov 14;352(9140):1601-2

ANALYSIS

Measurement of platelet antibodies: where do we stand? Winiarski J. **Acta Paediatr Suppl** 1998 Jun;424:51-3 (11 ref.)

Compartmentalization of the IgG immune response to HIV-1 in breast milk. Becquart P, et al. **AIDS** 1999 Jul 30; 13(11):1323-31

Posttransplantation cytotoxic immunoglobulin G is associated with a high rate of acute allograft dysfunctions in heart transplant recipients. Leprince P, et al. **Am Heart J** 1999 Sep;138(3 Pt 1):586-92

Hantavirus-specific IgG, IgM, and IgA in acute and chronic renal disease versus congenital renal disease in the United States. Patnaik M, et al. **Am J Kidney Dis** 1999 Apr; 33(4):734-7

High sensitivity immunoassays using particulate fluorescent labels. Hall M, et al. **Anal Biochem** 1999 Aug 1; 272(2):165-70

Operation of acoustic plate mode immunosensors in complex biological media. Dahint R, et al. **Anal Chem** 1999 Aug 1;71(15):3150-6

Colloidal Au-enhanced surface plasmon resonance immunosensing. Lyon LA, et al. **Anal Chem** 1998 Dec 15; 70(24):5177-83

A diagnostic ELISA for visceral leishmaniasis, based on antigen from media conditioned by Leishmania donovani promastigotes. Martin SK, et al. **Ann Trop Med Parasitol** 1998 Jul;92(5):571-7

Prevalence of IgG-class antibodies against hepatitis E virus in a community of the southern Amazon: a randomized survey. Souto FJ, et al. **Ann Trop Med Parasitol** 1998 Jul; 92(5):623-5

Immunohistochemical localization of secretory immunoglobulins in the main excretory duct of the human submandibular gland. Perra MT, et al. **Arch Histol Cytol** 1998 Dec;61(5):427-32

Central retinal vein occlusion in a patient with IgG lambda monoclonal gammopathy. Enzenauer RW, et al. **Arch Ophthalmol** 1999 Jan;117(1):134-5

Anti-[(H2A/2B)-DNA]] IgG supports the diagnosis of procainamide-induced arthritis or pleuritis. Lau CC, et al. **Arthritis Rheum** 1999 Jun;42(6):1300-1

Detection of functional groups and antibodies on microfabricated surfaces by confocal microscopy. Nashat AH, et al. **Biotechnol Bioeng** 1998 Oct 20;60(2):137-46

Levels of serum immunoglobulin G, CSF IgG and IgG index in acute bacterial meningitis. Giasuddin AS, et al. **Br J Biomed Sci** 1998 Dec;55(4):253-7

Possible presence of enhancing antibodies in idiopathic thrombocytopenic purpura. Yang YY, et al. **Br J Haematol** 1999 Jan;104(1):69-80

Anti-U and haemolytic disease of the fetus and newborn. Smith G, et al. **Br J Obstet Gynaecol** 1998 Dec; 105(12):1318-21

Utility of antibody in identifying individuals who have or will develop anhydride-induced respiratory disease. Grammer L, et al. **Chest** 1998 Oct;114(4):1199-202

Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Gan J, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):236-42

Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group. Dorrucci M, et al. **Eur J Epidemiol** 1999 Apr;15(4):317-22

Immunoelectron microscopic study of the conjunctiva in cicatricial pemphigoid. Robin H, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jan;237(1):39-44

Helicobacter pylori-seronegative gastric carcinoma: a subset of gastric carcinoma with distinct clinicopathologic features. Wu MS, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2432-6

IgG, albumin, and sCD44 in whole-gut lavage fluid are useful clinical markers for assessing the presence and activity of pouchitis. Stallmach A, et al. **Int J Colorectal Dis** 1999 Feb;14(1):35-40

Sensitivity of indirect immunofluorescence and immunoblotting for the detection of intercellular antibodies in endemic pemphigus foliaceus (fogo selvagem). Rowilson-Cunha P, et al. **Int J Dermatol** 1999 Jan; 38(1):41-5

The effect of human immunodeficiency virus-1 infection and stunting on measles immunoglobulin-G levels in children vaccinated against measles in Uganda. Waibale P, et al. **Int J Epidemiol** 1999 Apr;28(2):341-6

IgG and IgM antibodies of Herpes Simplex Virus type-1 and type-2 in 233 maternal and neonatal sera. Dong Z, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):69-70

Serum markers of treatment success in leprosy. MacLean S, et al. **Int J Lepr Other Mycobact Dis** 1999 Mar; 67(1):19-23

HUB1 is an autoantigen frequently eliciting humoral immune response in patients with adult T cell leukemia. Itoh M, et al. **Int J Oncol** 1999 Apr;14(4):703-8

Exposure to cow's milk during the first 3 months of life is associated with increased levels of IgG subclass antibodies to beta-lactoglobulin to 8 years. Jenmalm MC, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):671-8

Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. Abbate M, et al. **J Am Soc Nephrol** 1999 Apr;10(4):804-13

Improved survival and amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1 knockout mice. Janssen U, et al. **J Am Soc Nephrol** 1998 Oct;9(10):1805-14

Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1. Moulin B, et al. **J Am Soc Nephrol** 1999 Mar;10(3):519-28

Use of mammary gland and colostral characteristics for prediction of colostral IgG1 concentration and intramammary infection in Holstein cows. Maunsell FP, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1817-23

Performance characteristics of an enzyme-linked immunosorbent assay for determining salivary immunoglobulin G response to Helicobacter pylori. De Pascalis R, et al. **J Clin Microbiol** 1999 Feb;37(2):430-2

Detection of rubella virus-specific immunoglobulin G in saliva by an amplification-based enzyme-linked immunosorbent assay using monoclonal antibody to fluorescein isothiocyanate. Vyse AJ, et al. **J Clin Microbiol** 1999 Feb;37(2):391-5

Bovine immunoglobulin G, beta-lactoglobulin, alpha-lactalbumin and serum albumin in colostrum and milk during the early post partum period. Levieux D, et al. **J Dairy Res** 1999 Aug;66(3):421-30

A case of nonscarring inflammatory epidermolysis bullosa acquisita: characterization of IgG autoantibodies by immunofluorescence, immunoblotting and immunogold electron microscopy. Honoki K, et al. **J Dermatol** 1998 Oct;25(10):666-72

Immune thrombocytopenia due to Tranilast (Rizaben): detection of drug-dependent platelet-associated IgG. Nagae S, et al. **J Dermatol** 1998 Nov;25(11):706-9

Swab-based enzyme immunoassay system for detection of meat residues on food contact surfaces as a hygiene monitoring tool. Blais BW. **J Food Prot** 1999 Apr; 62(4):386-9

High frequency of antigliadin antibodies and absence of antireticulin and antiendomysium antibodies in patients with ulcerative colitis. Kull K, et al. **J Gastroenterol** 1999 Feb;34(1):61-5

Evaluation of a new immunochromatographic test for Helicobacter pylori IgG antibodies in elderly symptomatic patients [see comments] Shirin H, et al. **J Gastroenterol** 1999 Feb;34(1):7-10. Comment in: J Gastroenterol 1999 Feb;34(1):145-6.

Detection of biomolecules in the near-infrared spectral region via a fiber-optic immunosensor. Daneshvar MI, et al. **J Immunol Methods** 1999 Jun 24;226(1-2):119-28

Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. Hildesheim A, et al. **J Immunol Methods** 1999 May 27;225(1-2):131-43

Self-sampled and air-dried cervicovaginal secretions can be used for analyses of mucosal antibodies. Hordnes K, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):151-9

Periodontal conditions and salivary immunoglobulins in individuals with Down syndrome. Barr-Agholme M, et al. **J Periodontol** 1998 Oct;69(10):1119-23

Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. Scheule AM, et al. **J Thorac Cardiovasc Surg** 1999 Aug;118(2):348-53

Enzyme-linked immunosorbent assay for detection of feline herpesvirus 1 IgG in serum, aqueous humor, and cerebrospinal fluid. Dawson DA, et al. **J Vet Diagn Invest** 1998 Oct;10(4):315-9

Submandibular and lacrimal gland immunoglobulin in the C3H.MRL-Faslpr autoimmune mouse model of Sjögren's syndrome. Trune DR, et al. **Laryngoscope** 1998 Nov;108(11 Pt 1):1729-32

Reproducibility of alkaline antigens of Leishmania major-like and Leishmania (V.) braziliensis evaluated by IgG-ELISA. Comparison of antigens added of a protein inhibitor (PMSF) or not. Celeste BJ, et al. **Rev Inst Med Trop Sao Paulo** 1998 Sep-Oct;40(5):287-90

Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA). Skov M, et al. **Thorax** 1999 Jan;54(1):44-50

Comparative mapping of cloned human and murine antithyroglobulin antibodies: recognition by human antibodies of an immunodominant region. Estienne V, et al. **Thyroid** 1998 Aug;8(8):643-6

Measles antibody levels in a vaccinated population in Brazil. Cox MJ, et al. **Trans R Soc Trop Med Hyg** 1998 Mar-Apr; 92(2):227-30

Determination of salivary and serum immunoglobulin concentrations in the cat. Harley R, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2-4):99-112

Comparison of polyclonal, monoclonal and protein G peroxidase conjugates in an enzyme-linked immunosorbent assay for the diagnosis of Brucella ovis in sheep. Marin CM, et al. **Vet Rec** 1998 Oct 3;143(14):390-4

[Characterization of specific IgG, IgM, IgA and IgE isotypes in profound candidiasis] Toubas D, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):329-36 (Eng. Abstr.) **(Fre)**

[Development of an enzyme-linked immunosorbent assay (ELISA) for detection of IgM and IgG antibodies to lipopolysaccharide of Escherichia coli O157] Sugawara N, et al. **Kansenshogaku Zasshi** 1999 Jun;73(6):593-9 (Eng. Abstr.) **(Jpn)**

[Prevalence of serum IgG antibody against Bartonella henselae in an asymptomatic Japanese population] Tsuneoka H, et al. **Kansenshogaku Zasshi** 1999 Jan; 73(1):90-1 **(Jpn)**

[Efficacy of immunized milk for preventing viral infection] Yoshida H, et al. **Kansenshogaku Zasshi** 1999 Feb; 73(2):122-9 (Eng. Abstr.) **(Jpn)**

[Correlation of serum IgA levels with serum IgG levels, erythrocyte sedimentation rate and platelet counts in 98 patients with rheumatoid arthritis] Nishiya K, et al. **Rinsho Byori** 1999 Jul;47(7):665-8 (Eng. Abstr.) **(Jpn)**

[The number of plasma exchanges in Guillain-Barré syndrome: evaluation by the removal rate of immunoglobulin G] Tagawa Y, et al. **Rinsho Shinkeigaku** 1998 Oct-Nov;38(10-11):951-4 (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Development of immunoglobulins to venoms during specific immunotherapy. Palma-Carlos ML, et al. **Allerg Immunol (Paris)** 1999 Mar;31(3):71-2

Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Kimata H. **Ann Allergy Asthma Immunol** 1999 Mar; 82(3):293-5

Effects of specific humoral immunity on DNA-adduct formation in Swiss mice treated with benzo[alpha]pyrene. Galati R, et al. **Anticancer Res** 1999 May-Jun; 19(3A):2101-4

Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Kanda N, et al. **Arthritis Rheum** 1999 Feb; 42(2):328-37

Adjuvant effect of grifolan on antibody production in mice. Adachi Y, et al. **Biol Pharm Bull** 1998 Sep;21(9):974-7

Overexpression of a cytosolic chaperone to improve solubility and secretion of a recombinant IgG protein in insect cells. Ailor E, et al. **Biotechnol Bioeng** 1998 Apr 20-May 5;58(2-3):196-203

IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Rodolfo M, et al. **Cancer Res** 1998 Dec 15;58(24):5812-7

Benzylpenicillin induced specific non-IgE antibody response in mice. Zhang L, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):531-4

In vitro production of IgG4 by peripheral blood mononuclear cells (PBMC): the contribution of committed B cells. de Boer BA, et al. **Clin Exp Immunol** 1998 Nov;114(2):252-7

CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras. Murphy WJ, et al. **Clin Immunol** 1999 Jan;90(1):22-7

IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides [published erratum appears in Clin Infect Dis 1999 Jan;28(1):164] Musher DM, et al. **Clin Infect Dis** 1998 Dec;27(6):1487-90

Comparison of adjuvants with respect to serum IgG antibody response in orally immunized chickens. Hoshi S, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jan;22(1):63-9

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Ball T, et al. **Eur J Immunol** 1999 Jun;29(6):2026-36

Interleukin-1beta partially alleviates cyclosporin A-induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo. Dalai SK, et al. **Immunology** 1998 Sep;95(1):83-9

Oral tolerance induced to house dust mite extract in naive and sensitized mice: evaluation of immunoglobulin G anti-immunoglobulin E autoantibodies and IgG-IgE complexes. Sato MN, et al. **Immunology** 1998 Oct; 95(2):193-9

Different stimulating effects of complement C3b and complete Freund's adjuvant on antibody response. Villiers MB, et al. **Immunopharmacology** 1999 May;42(1-3):151-7

pFab-CMV, a single vector system for the rapid conversion of recombinant Fabs into whole IgG1 antibodies. Sanna PP, et al. **Immunotechnology** 1999 Mar;4(3-4):185-8

The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 correlates with mild and brief arthritis. Akin E, et al. **Infect Immun** 1999 Jan;67(1):173-81

Bovine CD4(+) T-lymphocyte clones specific for rhoptry-associated protein 1 of Babesia bigemina stimulate enhanced immunoglobulin G1 (IgG1) and IgG2 synthesis. Brown WC, et al. **Infect Immun** 1999 Jan;67(1):155-64

CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge. Brown WC, et al. **Infect Immun** 1998 Nov;66(11):5406-13

The J558 VH CDR3 region contributes little to antibody avidity; however, it is the recognition element for cognate

T cell control of the alpha(1-->3) dextran-specific antibody response. Clemens A, et al. **Int Immunol** 1998 Dec;10(12):1931-42

IgG1 production by sIgD+ splenic B cells and peritoneal B-1 cells in response to IL-5 and CD38 ligation. Yasue T, et al. **Int Immunol** 1999 Jun;11(6):915-23

Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome. Garraud O, et al. **J Allergy Clin Immunol** 1999 Feb;103(2 Pt 1):333-40

Estrogen enhances immunoglobulin production by human PBMCs. Kanda N, et al. **J Allergy Clin Immunol** 1999 Feb; 103(2 Pt 1):282-8

Lipopolysaccharide augments IgG and IgE responses of mice to the latex allergen Hev b 5. Slater JE, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):977-83

Properties of whole human IgG molecules produced by the expression of cloned anti-DNA antibody cDNA in mammalian cells. Rahman MAA, et al. **J Autoimmun** 1998 Dec;11(6):661-9

Changes during subclone development and ageing of human antibody-producing recombinant CHO cells. Strutzenberger K, et al. **J Biotechnol** 1999 Apr 15; 69(2-3):215-26

Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. Igartua M, et al. **J Controlled Release** 1998 Dec 4; 56(1-3):63-73

Evaluation of basal membrane antibody (immunoglobulin G) formation after high-energy shockwave application in rats. Sarica K, et al. **J Endourol** 1998 Dec;12(6):505-8

Modulation of the humoral immune response by antibody-mediated antigen targeting to complement receptors and Fc receptors. Baiu DC, et al. **J Immunol** 1999 Mar 15;162(6):3125-30

Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. Bonifacio E, et al. **J Immunol** 1999 Jul 1;163(1):525-32

Characteristics of the strong antibody response to mycobacterial Hsp70: a primary, T cell-dependent IgG response with no evidence of natural priming or gamma delta T cell involvement. Bonorino C, et al. **J Immunol** 1998 Nov 15;161(10):5210-6

Cloning the antibody response in humans with inflammatory central nervous system disease: analysis of the expressed IgG repertoire in subacute sclerosing panencephalitis brain reveals disease-relevant antibodies that recognize specific measles virus antigens. Burgoon MP, et al. **J Immunol** 1999 Sep 15;163(6):3496-502

High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. Coccia MA, et al. **J Immunol** 1998 Nov 15; 161(10):5772-80

Cutting edge: mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. Faquim-Mauro EL, et al. **J Immunol** 1999 Oct 1;163(7):3572-6

The p65 subunit of NF-kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3. Horwitz BH, et al. **J Immunol** 1999 Feb 15;162(4):1941-6

Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. Kohm AP, et al. **J Immunol** 1999 May 1; 162(9):5299-308

Evidence of alternative or concomitant use of perforin- and Fas-dependent pathways in a T cell-mediated negative regulation of Ig production. Majlessi L, et al. **J Immunol** 1999 Apr 15;162(8):4391-8

A soluble form of IL-13 receptor alpha 1 promotes IgG2a and IgG2b production by murine germinal center B cells. Poudrier J, et al. **J Immunol** 1999 Aug 1;163(3):1153-61

Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. Qin D, et al. **J Immunol** 1998 Nov 1;161(9):4549-54

In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. Wu ZQ, et al. **J Immunol** 1999 Jul 15;163(2):659-67

Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. Yip HC, et al. **J Immunol** 1999 Apr 1; 162(7):3942-9

A bidirectional phage display vector for the selection and mass transfer of polyclonal antibody libraries. Den W, et al. **J Immunol Methods** 1999 Jan 1;222(1-2):45-57

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):93-103

Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA). Wang L, et al. **J Immunol Methods** 1999 Jan 1; 222(1-2):93-9

Recombinant porcine IFN-gamma potentiates the secondary IgG and IgA responses to an inactivated suid herpesvirus-1 vaccine and reduces postchallenge weight loss and fever in pigs. Vandenbroeck K, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):739-44

Cell replication rates and processes concerning antibody production in vitro are not influenced by 2.45-GHz microwaves at physiologically normal temperatures. van Dorp R, et al. **Methods** 1998 Jun;15(2):151-9

CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Schofield L, et al. **Science** 1999 Jan 8;283(5399):225-9

Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov-Dec; 22(6):421-9 (26 ref.)

Human antibody responses to A and C capsular polysaccharides, IgA1 protease and transferrin-binding protein complex stimulated by infection with Neisseria meningitidis of subgroup IV-1 or ET-37 complex. Brieske N, et al. **Vaccine** 1999 Feb 26;17(7-8):731-44

Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Naess LM, et al. **Vaccine** 1999 Feb 26;17(7-8):754-64

Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Verweij WR, et al. **Vaccine** 1998 Dec; 16(20):2069-76

IgG isotype specific immune response in rats infected with Fasciola hepatica. Paz A, et al. **Vet Parasitol** 1998 Nov 16;79(3):229-37

BLOOD

A case of cat scratch disease diagnosed by serologic tests specific for Bartonella henselae [letter] Koga T, et al. **Acta Derm Venereol** 1998 Nov;78(6):477

Does class switching contribute to remission in bullous pemphigoid? [see comments] Modre B, et al. **Acta Derm Venereol** 1999 Mar;79(2):127-31. Comment in: Acta Derm Venereol 1999 Mar;79(2):97.

Serologic response to Bartonella henselae in patients with cat scratch disease and in sick and healthy children. Not T, et al. **Acta Paediatr** 1999 Mar;88(3):284-9

The prevalence and related symptomatology of Helicobacter pylori in children with recurrent abdominal pain. Wewer V, et al. **Acta Paediatr** 1998 Aug;87(8):830-5

Immunoglobulin G subclasses in wheezing infants. Karaman O, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):564-6

Flow cytometric analysis of IgG reactive to parasitized red blood cell membrane antigens in Plasmodium falciparum-immune individuals. Drame I, et al. **Acta Trop** 1999 Jul 30;73(2):175-81

Therapy-induced antibodies to interferon-alpha 2a recognise its receptor-binding site. Liptáková H, et al. **Acta Virol** 1998 Nov;42(5):279-84

Malaria parasitaemia and immunoglobulin levels in paired maternal-cord sera from south western Nigeria. Achidi EA, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):167-70

Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. Coles KA, et al. **Am J Cardiol** 1999 Oct 1;84(7):825-8

Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Glueck CJ, et al. **Am J Cardiol** 1999 May 15;83(10):1490-4, A8

Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies. Al-Assi MT, et al. **Am J Gastroenterol** 1999 Sep;94(9):2367-72

Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Marchildon P, et al. **Am J Gastroenterol** 1999 Aug; 94(8):2105-8

Decrease in serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin [letter] Sanaka M, et al. **Am J Gastroenterol** 1999 Jul;94(7):1983-4

Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Chappell CL, et al. **Am J Trop Med Hyg** 1999 Jan; 60(1):157-64

Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Leal-Herrera Y, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):587-92

Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels. de Martino M, et al. **Ann Allergy Asthma Immunol** 1999 Aug;83(2):160-4

Sensitive enzyme immunoassay for anti-beta-lactoglobulin IgG in serum. Hirota K, et al. **Ann Clin Biochem** 1998 Sep; 35 (Pt 5):649-55

Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ridker PM, et al. **Ann Intern Med** 1999 Oct 19; 131(8):573-7

Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with chronic maxillary sinusitis. Brook I, et al. **Ann Otol Rhinol Laryngol** 1999 Mar;108(3):293-5

Serologic study of the working mechanisms of immunotherapy for children with perennial allergic rhinitis. Ohashi Y, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1337-46

Rubella antibody in antenatal clinic patients [letter] Sintchenko V, et al. **Aust N Z J Med** 1999 Apr;29(2):284

Covalent coupling of immunoglobulin G to self-assembled monolayers as a method for immobilizing the interfacial-recognition layer of a surface plasmon resonance immunosensor. Disley DM, et al. **Biosens Bioelectron** 1998 Nov 15;13(11):1213-25

Primary recurrent miscarriages: anti-beta2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test [letter; comment] Mercier E, et al. **Blood** 1998 Oct 15;92(8):2993-4. Comment on: Blood 1998 Mar 15;91(6):1999-2004.

The IgG1/G2 subclass shift--a sensitive, tissue non-specific marker for malignancy. Diagnostic performance with squamous cell carcinoma of the head and neck. Anderhuber W, et al. **Br J Cancer** 1999 Apr;79(11-12):1777-81

Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR. Mitchell LA, et al. **Can J Public Health** 1998 Sep-Oct;89(5):325-8

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Mosolits S, et al. **Cancer Immunol Immunother** 1999 Feb;47(6):315-20

Short-term exposure of rodents to diesel exhausts: usefulness for studies of genotoxic and immunotoxic effects. Nilsen A, et al. **Chem Biol Interact** 1999 Mar 1;118(1):19-38

Enzyme-linked immunosorbent assay for detection of IgG against penicillins in children. Zhang L, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 May;17(3):274-7

Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Ridker PM, et al. **Circulation** 1999 Mar 9;99(9):1161-4

Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Ridker PM, et al. **Circulation** 1998 Dec 22-29;98(25):2796-9

Lactate dehydrogenase-immunoglobulin G complex in the serum of the postburn patient. Liu Z, et al. **Clin Chem** 1998 Nov;44(11):2368-9

A case of multiple myeloma IgG(lambda)type with low molecular weight kappa light chain. Imoto M, et al. **Clin Chim Acta** 1998 Sep 14;277(1):99-105

LD-IgG, IgA, IgM complex in a postburn patient. Liu Z, et al. **Clin Chim Acta** 1999 Jul;285(1-2):195-8

Immunoglobulin subclass distribution and diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in Indian kala-azar patients. Anam K, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):231-5

Increases in the levels of Coxiella burnetii-specific immunoglobulin G1 and G3 antibodies in acute Q fever and chronic Q fever. Capo C, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):814-6

Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Helfand RF, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):178-80

Evaluation of recombinant dense granule antigen 7 (GRA7) of Toxoplasma gondii for detection of immunoglobulin G antibodies and analysis of a major antigenic domain. Jacobs D, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):24-9

Effects of ginseng treatment on neutrophil chemiluminescence and immunoglobulin G subclasses in a rat model of chronic Pseudomonas aeruginosa pneumonia. Song Z, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):882-7

Early biomarkers of allergic disease in children [editorial; comment] Arshad SH, et al. **Clin Exp Allergy** 1999 May; 29(5):576-8. Comment on: Clin Exp Allergy 1999 May;29(5):604-10.

Relation between IgG antibodies to foods and IgE antibodies to milk, egg, cat, dog and/or mite in a cross-sectional study [see comments] Eysink PE, et al. **Clin Exp Allergy** 1999 May;29(5):604-10. Comment in: Clin Exp Allergy 1999 May;29(5):576-8.

Unreliability of IgE/IgG4 antibody testing as a diagnostic tool in food intolerance [see comments] Jenkins M, et al. **Clin Exp Allergy** 1998 Dec;28(12):1526-9. Comment in: Clin Exp Allergy 1998 Dec;28(12):1457-9.

The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Aittoniemi J, et al. **Clin Exp Immunol** 1999 Jun;116(3):505-8

Distribution of IgG subclasses in antimonial unresponsive Indian kala-azar patients. Chatterjee M, et al. **Clin Exp Immunol** 1998 Dec;114(3):408-13

Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Lacombe C, et al. **Clin Immunol** 1999 Jan;90(1):128-32

Serum IgG antibody response to pertussis toxin in persons for whom pertussis vaccination failed depends upon the number of antigens in the vaccine [editorial; comment] Cherry JD. **Clin Infect Dis** 1999 Mar;28(3):560-1. Comment on: Clin Infect Dis 1999 Mar;28(3):552-9.

Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Feldman S, et al. **Clin Infect Dis** 1998 Aug;27(2):388-90

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis [see comments] Trollfors B, et al. **Clin Infect Dis** 1999 Mar;28(3):552-9. Comment in: Clin Infect Dis 1999 Mar;28(3):560-1.

Renal involvement in essential monoclonal (type I) IgG cryoglobulinemia [letter] Grcevska L, et al.

Clin Nephrol 1998 Sep;50(3):200–2

Measurement of human serum IgG antibodies or a surrogate is sufficient to standardize (predict efficacy) vaccines. Robbins JB, et al. **Dev Biol Stand** 1998;95:221–2

Specificity of low anti-Toxoplasma IgG titers with IMx and AxSYM Toxo IgG assays. Cimon B, et al. **Diagn Microbiol Infect Dis** 1998 Sep;32(1):65–7

Can screening for IgG antibodies against Helicobacter pylori be used in clinical practice? Omit endoscopy in seropositive or seronegative patients? Werdmuller BF, et al. **Dig Dis Sci** 1998 Oct;43(10):2296–300

Seroprevalence of IgG antibodies to the chlamydia-like microorganism 'Simkania Z' by ELISA. Friedman MG, et al. **Epidemiol Infect** 1999 Feb;122(1):117–23

Transplacental transfer of measles and total IgG. Gonçalves G, et al. **Epidemiol Infect** 1999 Apr;122(2):273–9

Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II. Wang LC, et al. **Eur J Clin Invest** 1999 Mar;29(3):232–7

Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Wirsing von König CH, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):341–5

Prevalence of IgM and IgG antibodies to Toxoplasma gondii in blood donors in the Czech Republic. Svobodová V, et al. **Eur J Epidemiol** 1998 Dec;14(8):803–5

Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Leyendeckers H, et al. **Eur J Immunol** 1999 Apr;29(4):1406–17

Acute motor axonal neuropathy associated with IgM anti-GM1 following Mycoplasma pneumoniae infection. Heckmann JG, et al. **Eur Neurol** 1999;41(3):175–6

Detection of IgG and IgM to meningococcal outer membrane proteins in relation to carriage of Neisseria meningitidis or Neisseria lactamica. Kremastinou J, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):73–8

Strain variation in the IgG1 antibody response to proteins administered intranasally in the mouse. Blaikie L, et al. **Food Chem Toxicol** 1999 Aug;37(8):897–904

A low-grade MALT lymphoma in the form of colonic lymphoid hyperplasia with an increased serum IgG2. Chiba M, et al. **Gastrointest Endosc** 1998 Dec;48(6):626–31

Does quantitative serologic testing for Helicobacter pylori predict peptic ulcer disease in cirrhosis? Tsai CJ. **Gastrointest Endosc** 1999 Sep;50(3):381–6

Serum level of IgG autoantibodies against oxidized low density lipoproteins and lag-phase of serum oxidation in coronary heart disease--inverse correlation. Bakalova R, et al. **Gen Physiol Biophys** 1999 Mar;18(1):87–97

Detection of disease-specific augmentation of abnormal immunoglobulin G in sera of patients with rheumatoid arthritis. Tang W, et al. **Glycoconj J** 1998 Sep;15(9):929–34

Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Murray LJ, et al. **Heart** 1999 Mar; 81(3):239–44

Cytomegalovirus seropositivity and incident ischaemic heart disease in the Caerphilly prospective heart disease study. Strachan DP, et al. **Heart** 1999 Mar;81(3):248–51

Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease. Seissler J, et al. **Horm Metab Res** 1999 Jun;31(6):375–9

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219–29

Diagnosis of tuberculous meningitis by detection of antigen and antibodies in CSF and sera. Srivastava KL, et al. **Indian Pediatr** 1998 Sep;35(9):841–50

Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Schwerer B, et al. **Infect Immun** 1999 May;67(5):2414–20

Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Zhang MX, et al. **Infect Immun** 1998 Oct;66(10):4845–50

Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer. Tsavaris N, et al. **Int J Biol Markers** 1998 Apr-Jun;13(2):87–91

Childhood bullous pemphigoid: report of a case with characterization of the targeted antigens. Trüeb RM, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):338–44 (31 ref.)

Spaceflight and development of immune responses. Sonnenfeld G, et al. **J Appl Physiol** 1998 Oct;85(4):1429–33

Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. Bazzigaluppi E, et al. **J Autoimmun** 1999 Feb; 12(1):51–6

Immunoglobulin G insulin autoantibodies in BABYDIAB offspring appear postnatally: sensitive early detection using a protein A/G-based radiobinding assay. Naserke HE, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1239–43

Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test. Gutiérrez J, et al. **J Clin Lab Anal** 1999; 13(1):1–4

Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA. Gutiérrez J, et al. **J Clin Lab Anal** 1999;13(2):65–8

Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome. Lewis S, et al. **J Clin Lab Anal** 1998;12(5):293–7

Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. Ritchie RF, et al. **J Clin Lab Anal** 1998; 12(6):363–70

Reference distributions for immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature. Ritchie RF, et al. **J Clin Lab Anal** 1998;12(6):371–7

Detection of Toscana virus-specific immunoglobulins G and M by an enzyme-linked immunosorbent assay based on recombinant viral nucleoprotein. Ciufolini MG, et al. **J Clin Microbiol** 1999 Jun;37(6):2010–2

Indirect enzyme-linked immunosorbent assay for detection of immunoglobulin G reactive with a recombinant protein expressed from the gene encoding the 116-kilodalton protein of Mycoplasma pneumoniae. Duffy MF, et al. **J Clin Microbiol** 1999 Apr;37(4):1024–9

Clinical comparison of the Treponema pallidum CAPTIA syphilis-G enzyme immunoassay with the fluorescent treponemal antibody absorption immunoglobulin G assay for syphilis testing. Halling VW, et al. **J Clin Microbiol** 1999 Oct;37(10):3233–4

Development of specific immunoglobulins G, M, and A following primary Toxoplasma gondii infection in pregnant women. Jenum PA, et al. **J Clin Microbiol** 1998 Oct; 36(10):2907–13

Detection by enzyme immunoassay of serum immunoglobulin G antibodies that recognize specific Cryptosporidium parvum antigens. Priest JW, et al. **J Clin Microbiol** 1999 May;37(5):1385–92

Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2. Vallari AS, et al. **J Clin Microbiol** 1998 Dec;36(12):3657–61

Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. Voeten JT, et al. **J Clin Microbiol** 1998 Dec;36(12):3527–31

Rapid and sensitive detection of immunoglobulin M (IgM) and IgG antibodies against canine distemper virus by a new recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay. von Messling V, et al. **J Clin Microbiol** 1999 Apr;37(4):1049–56

Increased sialylation of oligosaccharides on IgG paraproteins--a potential new tumour marker in multiple myeloma. Fleming SC, et al. **J Clin Pathol** 1998 Nov; 51(11):825–30

The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae. Wong YK, et al. **J Clin Pathol** 1999 Feb;52(2):99–102

Evaluation of a fully automated glycoprotein G-2 based assay for the detection of HSV-2 specific IgG antibodies in serum and plasma. Groen J, et al. **J Clin Virol** 1999 May; 12(3):193–200

Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections. Schubert J, et al. **J Clin Virol** 1998 Dec;11(3):161–72

Seroprevalence of toxoplasmosis in Jodhpur, India. Joshi YR, et al. **J Commun Dis** 1998 Mar;30(1):32–7

Linear IgA bullous dermatosis with circulating IgG autoantibodies to the 230 kD epidermal antigen. Honoki K, et al. **J Dermatol** 1998 Aug;25(8):503–9

Human desmocollin 1a transiently expressed in COS-7 cells and NIH 3T3-3 cells is reacted by IgG4 antibodies in a pemphigus foliaceus serum. Dmochowski M, et al. **J Dermatol Sci** 1999 Sep;21(1):42–8

Evaluation of specific immunoglobulin G avidity enzyme linked immunosorbent assay (IgG avidity ELISA) in diagnosis of early and chronic Schistosomiasis mansoni. el Zayyat EA, et al. **J Egypt Soc Parasitol** 1998 Dec; 28(3):739–52

Antibody coating approach involving gamma globulins from non-immunized animal and second antibody antiserum. Petrou PS, et al. **J Immunoassay** 1998 Nov;19(4):271–93

A one-step solid phase immunoassay for simultaneous detection of serum IgG and IgM antibodies to Borrelia burgdorferi. Schønau A, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):9–17

Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. Breukels MA, et al. **J Infect Dis** 1999 May;179(5):1152–6

Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. Busico KM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S102–7

IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen. Venturoli S, et al. **J Infect Dis** 1998 Dec;178(6):1826–9

IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis [letter] Chimanovitch I, et al. **J Invest Dermatol** 1999 Jul;113(1):140–2

Importance of IgG4 determination in in vitro immunotherapy follow-up of inhalant allergens. Oehling AK, et al. **J Investig Allergol Clin Immunol** 1998 Nov-Dec;8(6):333–9

Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinemia. Quezada A, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun;9(3):178–82

Serum antibodies to human herpesvirus 7, human herpesvirus 6 and cytomegalovirus in patients with idiopathic facial nerve palsy or sudden deafness. Takasaki T, et al. **J Laryngol Otol** 1998 Jul;112(7):617–21

Seroprevalence of antibodies to hepatitis E virus in the normal blood donor population and two aboriginal communities in Malaysia. Seow HF, et al. **J Med Virol** 1999 Oct;59(2):164–8

Maintenance of high-avidity rubella-specific IgG antibody and titres in recent HIV seroconvertors and in patients progressing to the AIDS-related complex and AIDS. Thomas HI, et al. **J Med Virol** 1999 Jul;58(3):273–9

Autoreactive IgG to intracellular proteins in sera of MS patients. Lu F, et al. **J Neuroimmunol** 1999 Sep 1; 99(1):72–81

Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. Di Troia A, et al. **J Neurol Sci** 1999 Mar 15;164(1):64–71

Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: their association with cranial nerve dysfunction. Koga M, et al. **J Neurol Sci** 1999 Mar 15;164(1):50–5

IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease [see comments] Troncone R, et al. **J Pediatr** 1999 Feb;134(2):166–71. Comment in: J Pediatr 1999 Feb;134(2):134–5.

High prevalence of silent celiac disease in preschool children screened with IgA/IgG antiendomysium antibodies. Korponay-Szabó IR, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):26–30

Testing for serum IgG antibodies to Helicobacter pylori cytotoxin-associated protein detects children with higher grades of gastric inflammation. Luzza F, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):302–7

Elevated serum Chlamydia trachomatis IgG antibodies. Association with decreased implantation rates in GIFT Sharara FI, et al. **J Reprod Med** 1999 Jul;44(7):581–6

Evaluation of serum levels of IgG subclasses and anti-ribosyl-ribitolphosphate IgG and IgG2 in children with Haemophilus influenzae b meningitis. IshigamiMiyake TT, et al. **J Trop Pediatr** 1999 Jun;45(3):130–4

Levels of immunoglobulins and complement C3 in protein-energy malnutrition [letter] Mishra OP, et al. **J Trop Pediatr** 1999 Jun;45(3):179–81

An IgG avidity ELISA to discriminate between recent and chronic Neospora caninum infection. Björkman C, et al. **J Vet Diagn Invest** 1999 Jan;11(1):41–4

Seroneutralization of porcine reproductive and respiratory syndrome virus correlates with antibody response to the GP5 major envelope glycoprotein. Gonin P, et al. **J Vet Diagn Invest** 1999 Jan;11(1):20–6

Detection of low serum immunoglobulin concentrations in clinically ill calves. Tyler JW, et al. **J Vet Intern Med** 1999 Jan-Feb;13(1):40–3

Prediction of serum IgG1 concentration in beef calves based on age and serum gamma-glutamyl-transferase activity. Wilson LK, et al. **J Vet Intern Med** 1999 Mar-Apr; 13(2):123–5

Prevalence of Helicobacter pylori antibodies in endoscopy personnel and non-medical volunteers of Karachi. Abbas Z, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):201–3

CLO antibody assay--can it be an alternate to endoscopy and biopsy? Mehdi I, et al. **JPMA J Pak Med Assoc** 1998 Jul;48(7):203–5

Markers of chronic infection and inflammation. Are they important in cases with chronic coronary heart disease. Kaftan HA, et al. **Jpn Heart J** 1999 May;40(3):275–80

Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group. Shimizu K, et al. **Jpn J Cancer Res** 1999 Mar;90(3):355–60

Shift in the IgG subclass distribution in patients with lung cancer. Klotz M, et al. **Lung Cancer** 1999 Apr;24(1):25–30

A comparative study on IgG-ELISA, IgM-IFT and Kato-Katz methods for epidemiological purposes in a low endemic area for schistosomiasis. da Silva RM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:279–82

IgE and IgG4 antibodies in subjects reinfected with Schistosoma mansoni in an endemic area of northeast Brazil. Gomes YM, et al. **Mem Inst Oswaldo Cruz** 1998; 93 Suppl 1:183–4

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura [see comments] Tsai HM, et al. **N Engl J Med** 1998 Nov 26; 339(22):1585–94. Comment in: N Engl J Med 1998 Nov 26;339(22):1629–31. Comment in: N Engl J Med 1999 Apr 29;340(17):1368–9.

Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome. Mizoguchi K. **Neurol Res** 1998 Oct;20(7):617–24

Antibodies to prothrombin in patients with Sneddon's syndrome. Kalashnikova LA, et al. **Neurology** 1999 Jul 13; 53(1):223–5

Bilateral optic neuropathy with IgGkappa multiple myeloma improved after myeloablative chemotherapy. Lieberman FS, et al. **Neurology** 1999 Jan 15;52(2):414–6

Isolated internal ophthalmoplegia associated with immunoglobulin G anti-GQ1b antibody [letter; comment] Yuki N, et al. **Neurology** 1998 Nov;51(5):1515–6. Comment on: Neurology 1998 Jan;50(1):307.

Study of IgG antibodies to Pseudomonas aeruginosa in early cystic fibrosis infection. Giordano A, et al. **New Microbiol** 1998 Oct;21(4):375–8

Serodiagnosis of acute toxoplasmosis using a recombinant form of the dense granule antigen GRA6 in an enzyme-linked immunosorbent assay. Redlich A, et al. **Parasitol Res** 1998 Sep;84(9):700–6

IgG subclass antibody responses to birch pollen in sibling pairs discordant for atopy. Härfast B, et al. **Pediatr Allergy Immunol** 1998 Nov;9(4):208–14

Prevalence of Bartonella henselae immunoglobulin G antibodies in Singaporean cats. Nasirudeen AM, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):276–8

IgG subclass/IgM ratio and response to therapy in focal segmental glomerulonecrosis. Fu LW, et al. **Pediatr Nephrol** 1998 Nov;12(9):761–3

Probable false positive coccidioidal serologic results in patients with cystic fibrosis. Dosanjh A, et al. **Pediatr Transplant** 1998 Nov;2(4):313–7

Long-term follow-up study of serum immunoglobulin G and immunoglobulin A antibodies after Helicobacter pylori eradication. Kato S, et al. **Pediatrics** 1999 Aug;104(2):e22

Direct and correlated response to divergent selection for serum immunoglobulin M and G levels in chickens. Sarker N, et al. **Poult Sci** 1999 Jan;78(1):1–7

Immunoglobulin G concentration and neonatal survival of goat kids delivered in a pen or on open range. Mellado M, et al. **Prev Vet Med** 1998 Dec 1;37(1–4):33–9

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Chackerian B, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2373–8

Evolution of IgG antibody response against Toxoplasma gondii tissue cyst in acute and chronic human infections. Villavedra M, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr;40(2):77–84

Agalactosyl IgG is elevated in patients with active spondyloarthropathy. Leirisalo-Repo M, et al. **Rheumatol Int** 1999;18(5–6):171–6

Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Lerang F, et al. **Scand J Gastroenterol** 1998 Jul;33(7):710–5

Preparation of IgG subclass allotypes from polyclonal IgG. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):395–8

Altered pattern of connectivity in serum immunoglobulins from pemphigus vulgaris patients. Pacheco-García U, et al. **Scand J Immunol** 1999 Apr;49(4):424–30

IgG subclass-specific antibodies in Chlamydia pneumoniae infections. Anttila T, et al. **Scand J Infect Dis** 1998; 30(4):381–6

IgG seroprevalence of Lyme borreliosis in the population of the Aland Islands in Finland. Carlsson SA, et al. **Scand J Infect Dis** 1998;30(5):501–3

Use of delipidized antigens of Taenia solium metacestodes in IgG-ELISA for detection of neurocysticercosis. Dekumyoy P, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):572–8

IgG response to some mycobacterial antigens in selected leprosy patients. Rafi A. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):567–71

Modelling the cause of dependency with application to filaria infection. Houwing-Duistermaat JJ, et al. **Stat Med** 1998 Dec 30;17(24):2939–54

Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Newman PM, et al. **Thromb Haemost** 1998 Aug; 80(2):292–7

Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. Hotchkiss CE, et al. **Toxicol Appl Pharmacol** 1999 Jul 15;158(2):152–60

Evaluation by enzyme-linked immunosorbent assay of IgG anti-D and IgG subclass concentrations in immunoglobulin preparations. Ahaded A, et al. **Transfusion** 1999 May; 39(5):515–21

IgG titer, subclass, and light-chain phenotype of pregnancy-induced HPA-5b antibodies that cause or do not cause neonatal alloimmune thrombocytopenia. Kurz M, et al. **Transfusion** 1999 Apr;39(4):379–82

Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays. Watkins NA, et al. **Transfusion** 1999 Jul;39(7):781–9

Removal of anti-donor antibody by double-filtration plasmapheresis to prevent chronic rejection in kidney transplantation. Abe M, et al. **Transplant Proc** 1998 Nov; 30(7):3108–9

Sustained decrease of serum anti-galactose alpha 1-3-galactose antibodies in baboons by removing aerobic gram-negative bacteria from the bowel. Manez R, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):947–8

The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Przybylowski P, et al. **Transplantation** 1999 Jan 27; 67(2):258–62

Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies. Susskind B, et al. **Transplantation** 1998 Dec 27;66(12):1823–6

Anti-filarial IgG4 in men and women living in Brugia malayi-endemic areas. Haarbrink M, et al. **Trop Med Int Health** 1999 Feb;4(2):93–7

Specific IgG to gelatin in children with systemic immediate- and nonimmediate-type reactions to measles, mumps and rubella vaccines. Miyazawa H, et al. **Vaccine** 1999 Apr 23; 17(17):2176–80

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Schröder U, et al. **Vaccine** 1999 Apr 9; 17(15–16):2096–103

IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Soininen A, et al. **Vaccine** 1999 Apr 9;17(15–16):1889–97

Prevalence of antibodies to Neospora caninum in dogs. Cheadle MA, et al. **Vet Parasitol** 1999 Sep 1;85(4):325–30

Prevalence of IgG and IgM antibodies specific to Toxoplasma gondii in cats. Svobodová V, et al. **Vet Parasitol** 1998 Dec 31;80(2):173–6

Lack of humoral and cellular responses against glutathione S-transferases in Fasciola hepatica experimentally infected sheep. Moreau E, et al. **Vet Res** 1998 Nov-Dec; 29(6):585–91

A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Hadley AG. **Vox Sang** 1998;74 Suppl 2:375–83 (79 ref.)

Serum immunoglobulin and immunoglobulin G subclasses in children with allergic colitis. Ojuawo A, et al. **West Afr J Med** 1998 Jul-Sep;17(3):206–9

[Effect of chaihu guizhi decoction on the immunoglobulin and IgG subgroup in children with recurrent respiratory tract infection] Li ZH, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Nov; 17(11):653–4 (Eng. Abstr.) **(Chi)**

[Cell-mediated and humoral immunity in human rabies] Fang Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(3):279–80 **(Chi)**

[Detection of the level of serum IgG antibody to hepatitis E virus] Xie Y, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):223–5 (Eng. Abstr.) **(Chi)**

[Inhibition effect of hypoxia on humoral immunity of rats] Bai HB, et al. **Sheng Li Hsueh Pao** 1997 Apr;49(2):167–72 (Eng. Abstr.) **(Chi)**

[Property of antibody avidity in the detection of toxoplasmosis seroconversion] Robert-Gangneux F, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):586–9 **(Fre)**

[Comparative analysis of 2 diagnostic methods of human loiasis: IgG4 serology and nested PCR] Touré FS, et al. **Bull Soc Pathol Exot** 1999 Jul;92(3):167–70 (Eng. Abstr.) **(Fre)**

[Circulating antibodies against an epitope of the heat-shock protein 60kDA of chlamydia trachomatis in infertile couples. Relation with surface chlamydia trachomatis anti-antigen antibody and E. coli anti-HSP60 antibody and human anti-HSP60] Witkin SS, et al. **Contracept Fertil Sex** 1998 Nov;26(11):suppl I-VI **(Fre)**

[Comparison of two techniques for detection of anti-Plasmodium falciparum antibodies: Falciparum-spot IF (Biomérieux) and Malaria IgG Celisa (BMD). Preliminary results] Assal A, et al. **Transfus Clin Biol** 1999 Apr;6(2):119–23 (Eng. Abstr.) **(Fre)**

[Interpretation of borreliosis serology. Step-wise diagnosis--introduction to case examples] Hassler D, et al. **Fortschr Med** 1998 Oct 20;116(29):20–2, 24 (16 ref.) **(Ger)**

[Serology in herpes infection] Einsele H, et al. **Internist (Berl)** 1999 May;40(5):565–6 **(Ger)**

[Incidence of increased serum Helicobacter pylori IgG antibodies in children with and without chronic abdominal pain] Blümel P, et al. **Klin Padiatr** 1998 Sep-Oct; 210(5):366–9 (Eng. Abstr.) **(Ger)**

[Quantitative changes in the immunoglobulin G subclass system--a reliable tumor marker in squamous epithelial carcinoma in the area of the head-neck] Anderhuber W, et al. **Laryngorhinootologie** 1998 Oct;77(10):564–8 (Eng. Abstr.) **(Ger)**

[Guillain-Barré syndrome with cerebellar symptoms and elevated serum anti-GD1b IgG antibody] Araki T, et al. **Rinsho Shinkeigaku** 1999 May;39(5):527–30 (Eng. Abstr.) **(Jpn)**

[A case of pharyngeal-cervical-branchial variant of Guillain-Barré syndrome with IgG anti-GT1a antibody] Nagano K, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):333–5 (5 ref.) (Eng. Abstr.) **(Jpn)**

[A case of atypical Guillain-Barré syndrome exclusively showing multiple cranial nerve palsy with an elevation of anti-GQ1b and anti-GT1a IgG antibodies] Ohori N, et al. **Rinsho Shinkeigaku** 1998 Sep;38(9):843–5 (Eng. Abstr.) **(Jpn)**

[Evaluation of the usefulness of the ELISA method for determining the level of enterovirus antibodies in serum and cerebrospinal fluid] Binduga I, et al. **Med Dosw Mikrobiol** 1998;50(3–4):277–84 (Eng. Abstr.) **(Pol)**

[Diagnostic value of IgG antibody levels against 38 kDa mycobacterial antigen] Demkow U, et al. **Pneumonol Alergol Pol** 1998;66(11–12):509–16 (Eng. Abstr.) **(Pol)**

[Evaluation of the correlation between the level of IgG antibodies against mycobacterial A60-antigen and tuberculin reactivity in persons without a history of tuberculosis and in active pulmonary tuberculosis patients] Siemińska A, et al. **Pol Arch Med Wewn** 1998 Nov; 100(5):426–30 (Eng. Abstr.) **(Pol)**

[Anti-measles igg concentration in maternal blood and in umbilical cord blood: according to the mother's vaccination status] Gonçalves G, et al. **Acta Med Port** 1998 Oct; 11(10):847–53 (Eng. Abstr.) **(Por)**

[Dosage of the antibody antigliadin in first degree relatives of celiac patients] Nunes CR, et al. **Arq Gastroenterol** 1998 Jan-Mar;35(1):69–73 (Eng. Abstr.) **(Por)**

[Non-Hodgkin lymphoma in adults. Protein profile of CSF and serum in 25 patients] Mielli SR, et al. **Arq Neuropsiquiatr** 1998 Dec;56(4):769–71 (Eng. Abstr.) **(Por)**

[Immunoenzyme assay for detection of natural antibodies against vasopressin in systemic lupus erythematosus] Miagkova MA, et al. **Klin Lab Diagn** 1999 Apr;(4):20–4 (Eng. Abstr.) **(Rus)**

[The development and certification of the Hepabest anti-HBc IgG test system for detecting antibodies to the core antigen of the hepatitis B virus] Iaroslavtseva OA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):49–52 (Eng. Abstr.) **(Rus)**

[The enzymatic activity of IgG preparations in viral hepatitis] Zhil'sov IV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug;(4):73–7 (Eng. Abstr.) **(Rus)**

[Usefulness of determining low-avidity IgG antibodies in the diagnosis of primary rubella infection in pregnant women] Lafarga B, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):413–8 (Eng. Abstr.) **(Spa)**

[Estimation of IgG Adenovirus antibody titers using a standard curve and an indirect ultramicroELISA essay] Laferté J, et al. **Rev Cubana Med Trop** 1996;48(2):102–8 (Eng. Abstr.) **(Spa)**

[The standardization of an ultramicro ELISA assay for the detection of IgG antibodies to the respiratory syncytial virus] Savón C, et al. **Rev Cubana Med Trop** 1996; 48(3):161–2 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

IgG index in acute idiopathic peripheral facial palsy. Inci IO, et al. **Acta Neurol Scand** 1999 Feb;99(2):117–20

Oligoclonal bands and blood--cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. Hampel H, et al. **Alzheimer Dis Assoc Disord** 1999 Jan;13(1):9–19

Polyclonal antibodies from blood and cerebrospinal fluid of patients with multiple sclerosis effectively hydrolyze DNA and RNA. Baranovskii AG, et al. **Biochemistry (Mosc)** 1998 Nov;63(11):1239–48

Diagnosis of tuberculous meningitis by detection of antigen and antibodies in CSF and sera. Srivastava KL, et al. **Indian Pediatr** 1998 Sep;35(9):841–50

Can CSF predict the course of optic neuritis? Frederiksen JL. **Mult Scler** 1998 Jun;4(3):132–5

Higher levels of antibodies against the psoriasis-associated antigen pso p27 in cerebrospinal fluid from patients with low back pain and sciatica. Zwart JA, et al. **Spine** 1999 Feb 15;24(4):373–7

[Value of antibody titers for diagnosis of neuroborreliosis] Woessner R, et al. **Nervenarzt** 1998 Aug;69(8):694–7 (Eng. Abstr.) **(Ger)**

[Chronic Cryptococcal meningitis with CSF oligoclonal IgG band in a patient with Claude syndrome] Kawanishi R, et al. **Rinsho Shinkeigaku** 1998 Apr;38(4):314–8 (Eng. Abstr.) **(Jpn)**

[The evaluation of humoral immunity response in subacute sclerosing panencephalitis (SSPE)] Sobczyk W, et al. **Neurol Neurochir Pol** 1999 Jan-Feb;33(1):79–85 (Eng. Abstr.) **(Pol)**

CHEMISTRY

Sugar printing rheumatic diseases: a potential method for disease differentiation using immunoglobulin G oligosaccharides. Watson M, et al. **Arthritis Rheum** 1999 Aug;42(8):1682–90

Changes in the galactose content of IgG during humoral immune responses. Lastra GC, et al. **Autoimmunity** 1998; 28(1):25–30

Characterization of residues in human IgE and IgG binding site by chemical modification of ovomucoid third domain. Zhang JW, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):610–3

Characterization of IgE and IgG epitopes on ovomucoid using egg-white-allergic patients' sera. Zhang JW, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):124–7

Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. Leibiger H, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):529–38

Affinity purification of human IgG using immobilised, mutated immunoglobulin-binding domains from protein A of Staphylococcus aureus. Brown NL, et al. **Biochem Soc Trans** 1998 Aug;26(3):S249

Fragment reconstitution of a small protein: folding energetics of the reconstituted immunoglobulin binding domain B1 of streptococcal protein G. Honda S, et al. **Biochemistry** 1999 Jan 26;38(4):1203–13

Hydrogen bonding and equilibrium protium–deuterium fractionation factors in the immunoglobulin G binding domain of protein G. Khare D, et al. **Biochemistry** 1999 Mar 30;38(13):3918–25

Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH–like sequence of human immunoglobulin G1. Navolotskaya EV, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):758–64

Structural changes of IgG induced by heat treatment and by adsorption onto a hydrophobic Teflon surface studied by circular dichroism spectroscopy. Vermeer AW, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):1–12

Analysis of nonlinear quenching of terbium(III):dipicolinic acid complex fluorescence by chelators and chelate–conjugated macromolecules. Sanny CG, et al. **Bioconjug Chem** 1999 Jan–Feb;10(1):141–5

Competitive protein adsorption as observed by surface plasmon resonance. Green RJ, et al. **Biomaterials** 1999 Feb; 20(4):385–91

Proteins and cells on PEG immobilized silicon surfaces. Zhang M, et al. **Biomaterials** 1998 May;19(10):953–60

A chromatographic method for the production of a human immunoglobulin G solution for intravenous use. Tanaka K, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1375–81

Human IgG2 constant region enhances in vivo stability of anti–tenascin antibody 81C6 compared with its murine parent. Reist CJ, et al. **Clin Cancer Res** 1998 Oct; 4(10):2495–502

USAN Council. List No.418. New names. Etanercept. **Clin Pharmacol Ther** 1999 Aug;66(2):209

Monospecific antipeptide antibody to cytochrome P–450 2B6. Stresser DM, et al. **Drug Metab Dispos** 1999 Apr; 27(4):517–25

Metal–catalyzed oxidation of immunoglobulin G impairs Fc receptor–mediated binding to macrophages. Margiloff L, et al. **Free Radic Biol Med** 1998 Nov 1;25(7):780–5

Binding of avidin modified antibody to biotinylated metal supported membranes and liposomes changes the physical properties of lipid bilayer. Hianik T, et al. **Gen Physiol Biophys** 1998 Sep;17(3):239–52

N–Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Cabanes–Macheteau M, et al. **Glycobiology** 1999 Apr;9(4):365–72

Structural changes in the oligosaccharide moiety of human IgG with aging. Shikata K, et al. **Glycoconj J** 1998 Jul; 15(7):683–9

Glycosylation of human IgG–Fc: influences on structure revealed by differential scanning micro–calorimetry. Ghirlando R, et al. **Immunol Lett** 1999 May 3;68(1):47–52

IgG–Fc–mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Jefferis R, et al. **Immunol Rev** 1998 Jun; 163:59–76 (93 ref.)

Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. Yamaguchi Y, et al. **J Biomol NMR** 1998 Oct; 12(3):385–94

Pharmacokinetics and organ distribution of cationized colchicine–specific IgG and Fab fragments in rat. Hong G, et al. **J Pharm Sci** 1999 Jan;88(1):147–53

Controlled release of human immunoglobulin G. 1. Release kinetics studies. Wang CH, et al. **J Pharm Sci** 1999 Feb; 88(2):215–20

Controlled release of human immunoglobulin G. 2. Morphological characterization. Wang CH, et al. **J Pharm Sci** 1999 Feb;88(2):221–8

The Nobel chronicles. 1972: Gerald M Edelman (b 1929) and Rodney R Porter (1917–85). Raju TN. **Lancet** 1999 Sep 18;354(9183):1040

Transfer of 131I and fluoresceinyl sialic acid derivatives into the oligosaccharide chains of IgG: a new method for site–specific labeling of antibodies. Schwarz U, et al. **Nucl Med Biol** 1999 May;26(4):383–8

Homogeneous immunoconjugates for boron neutron–capture therapy: design, synthesis, and preliminary characterization. Guan L, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13206–10

Effect of selected substances on heat–induced aggregation of albumin, IgG and lysozyme. Saso L, et al. **Res Commun Mol Pathol Pharmacol** 1998 Oct;102(1):15–28

Antibodies against macaque monoclonal immunoglobulin G in rheumatoid arthritis. Fortenfant F, et al. **Scand J Immunol** 1999 Jan;49(1):88–95

CLASSIFICATION

Does class switching contribute to remission in bullous pemphigoid? [see comments] Modre B, et al. **Acta Derm Venereol** 1999 Mar;79(2):127–31. Comment in: Acta Derm Venereol 1999 Mar;79(2):97.

Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1–capsids is a possible predictor for the regression of HPV16–positive cervical intraepithelial neoplasia. Matsumoto K, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):128–31

IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines. Parkkali T, et al. **Bone Marrow Transplant** 1999 Sep;24(6):671–8

Monitoring allergen immunotherapy of pollen–allergic patients: the ratio of allergen–specific IgG4 to IgG1 correlates with clinical outcome. Gehlhar K, et al. **Clin Exp Allergy** 1999 Apr;29(4):497–506

The significance of IgG subclasses and mannan–binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Aittoniemi J, et al. **Clin Exp Immunol** 1999 Jun;116(3):505–8

Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Lacombe C, et al. **Clin Immunol** 1999 Jan;90(1):128–32

Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease. Gouni–Berthold I, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1720–3

Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Schwerer B, et al. **Infect Immun** 1999 May;67(5):2414–20

IL–5 induces IgG1 isotype switch recombination in mouse CD38–activated sIgD–positive B lymphocytes. Mizoguchi C, et al. **J Immunol** 1999 Mar 1;162(5):2812–9

Urine IgG2/IgG4–ratio indicates the significance of the charge selective properties of the glomerular capillary wall for the macromolecular transport in glomerular diseases. Tencer J, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1425–9

IgG subclass deficiency and the day–care generation. Lawton AR. **Pediatr Infect Dis J** 1999 May;18(5):462–6 (32 ref.)

Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice. Katayama S, et al. **Vaccine** 1999 Jun 4; 17(20–21):2733–9

Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Naess LM, et al. **Vaccine** 1999 Feb 26;17(7–8):754–64

[Immunoglobulin subclass defects in patients with therapy refractor chronic rhinosinusitis] May A, et al. **HNO** 1999 Jan;47(1):19–24 (Eng. Abstr.) **(Ger)**

DEFICIENCY see IGG DEFICIENCY

DIAGNOSTIC USE

Imaging experimental intraabdominal abscesses with 99mTc–PEG liposomes and 99mTc–HYNIC IgG. Dams ET, et al. **Ann Surg** 1999 Apr;229(4):551–7

Detection of adducts of bromobenzene 3,4–oxide with rat liver microsomal protein sulfhydryl groups using specific antibodies. Rombach EM, et al. **Chem Res Toxicol** 1999 Feb;12(2):159–63

Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Buijs WC, et al. **Eur J Nucl Med** 1998 Nov;25(11):1552–61

Specific IgG avidity--a supplementary assay in serological screening for toxoplasmosis in pregnancy [letter] Logar J, et al. **J Infect** 1999 Jan;38(1):61–3

Technetium–99m–labeled liposomes to image experimental colitis in rabbits: comparison with technetium–99m–HMPAO–granulocytes and technetium–99m–HYNIC–IgG. Dams ET, et al. **J Nucl Med** 1998 Dec;39(12):2172–8

Dynamic distribution and dosimetric evaluation of human non–specific immunoglobulin G labelled with 111In or 99Tcm. Buijs WC, et al. **Nucl Med Commun** 1998 Aug; 19(8):743–51

Polyclonal, nonspecific 111In–IgG scintigraphy in the evaluation of complicated osteomyelitis and septic arthritis. Molina–Murphy IL, et al. **Q J Nucl Med** 1999 Mar; 43(1):29–37

[Radiolabelling of human IgG with ultraviolet light having its own reactor [letter]] Barreras V, et al. **Rev Esp Med Nucl** 1999 Jun;18(3):225–6 **(Spa)**

DRUG EFFECTS

Depletion of neutralising antibodies resensitises a secondary non–responder to botulinum A neurotoxin. Naumann M, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):924–7

GENETICS

Clonality and germinal centre B–cell derivation of Hodgkin/Reed–Sternberg cells in Hodgkin's disease. Küppers R, et al. **Ann Oncol** 1998;9 Suppl 5:S17–20 (36 ref.)

IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice. Ichikawa M, et al. **Cell Immunol** 1999 Feb 1; 191(2):97–104

The regulatory effects of all–trans–retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL–5 and inhibits IgG1 switching. Tokuyama H, et al. **Cell Immunol** 1999 Feb 25;192(1):41–7

Molecular characterization of immunoglobulin G4 gene isoallotypes. Brusco A, et al. **Eur J Immunogenet** 1998 Oct; 25(5):349–55

Genetic origin of IgG antibodies cloned by phage display and anti–idiotypic panning from three patients with autoimmune thrombocytopenia. Jendreyko N, et al. **Eur J Immunol** 1998 Dec;28(12):4236–47

Clonally related IgE and IgG4 transcripts in blood lymphocytes of patients with asthma reveal differing patterns of somatic mutation. Snow RE, et al. **Eur J Immunol** 1998 Oct;28(10):3354–61

N–Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Cabanes–Macheteau M, et al. **Glycobiology** 1999 Apr;9(4):365–72

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219–29

Persistent and secondary adenovirus–mediated hepatic gene expression using adenovirus vector containing CTLA4IgG [see comments] Nakagawa I, et al. **Hum Gene Ther** 1998 Aug 10;9(12):1739–45. Comment in: Hum Gene Ther 1998 Aug 10;9(12):1699–700.

Analysis of gamma4 germline transcription in human B cells. Agresti A, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr; 118(2–4):279–81

Ialpha exon–replacement mice synthesize a spliced HPRT–C(alpha) transcript which may explain their ability to switch to IgA. Inhibition of switching to IgG in these mice. Qiu G, et al. **Int Immunol** 1999 Jan;11(1):37–46

T–cell–epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Fagerberg J, et al. **Int J Cancer** 1999 Mar 1;80(5):671–80

Cloning and functional analysis of anti–double strand DNA IgG autoantibodies using the phage–display method. Suzuki M, et al. **Int J Mol Med** 1999 Apr;3(4):385–90

Properties of whole human IgG molecules produced by the expression of cloned anti–DNA antibody cDNA in mammalian cells. Rahman MAA, et al. **J Autoimmun** 1998 Dec;11(6):661–9

Processing of switch transcripts is required for targeting of antibody class switch recombination. Hein K, et al. **J Exp Med** 1998 Dec 21;188(12):2369–74

Polymarker, HLA–DQA1, and D1S80 allele frequency data in Chamorro and Filipino populations from Guam. Budowle B, et al. **J Forensic Sci** 1998 Nov;43(6):1195–8

Regulation of T cell activation in vitro and in vivo by targeting the OX40–OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40–IgG fusion protein, but not with an OX40 ligand–IgG fusion protein. Higgins LM, et al. **J Immunol** 1999 Jan 1; 162(1):486–93

A single–chain IL–12 IgG3 antibody fusion protein retains antibody specificity and IL–12 bioactivity and demonstrates antitumor activity. Peng LS, et al. **J Immunol** 1999 Jul 1;163(1):250–8

Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Roux KH, et al. **J Immunol** 1998 Oct 15;161(8):4083–90

A bidirectional phage display vector for the selection and mass transfer of polyclonal antibody libraries. Den W, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):45–57

Gene therapy by transforming growth factor–beta receptor–IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis [see comments] Isaka Y, et al. **Kidney Int** 1999 Feb;55(2):465–75 . Comment in: Kidney Int 1999 Feb;55(2):740–1.

Isolation and sequence of a cDNA coding for the heavy chain constant region of IgG from the Australian brushtail possum, Trichosurus vulpecula. Belov K, et al. **Mol Immunol** 1999 Jun;36(8):535–41

Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy–chain antibodies. Nguyen VK, et al. **Mol Immunol** 1999 Jun;36(8):515–24

Regulation of the germline immunoglobulin Cgamma1 promoter by CD40 ligand and IL–4: dual role for tandem NF–kappaB binding sites. Warren WD, et al. **Mol Immunol** 1999 Jan;36(1):31–44

Immunoglobulin G Fc–receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Myhr KM, et al. **Neurology** 1999 Jun 10;52(9):1771–6

Expression and ligand binding assays of soluble cytokine receptor–immunoglobulin fusion proteins. Brown SJ, et al. **Protein Expr Purif** 1998 Oct;14(1):120–4

The specificity of synovial IgM rheumatoid factors (RF) for genetically engineered IgG antibodies is not affected by the method used to immortalize RF–producing B cells. Bonagura VR, et al. **Scand J Immunol** 1999 Jan; 49(1):106–11

Characterization of the three immunoglobulin G subclasses of macaques. Calvas P, et al. **Scand J Immunol** 1999 Jun; 49(6):595–610

Fc gamma receptor allotypes in children with bacterial meningitis. A preliminary study. Tezcan I, et al. **Turk J Pediatr** 1998 Oct–Dec;40(4):533–8

IMMUNOLOGY

Rabbit IgG antibodies against cord red blood cell membranes bind to complement receptor 1 (CD35). Giuliani AL, et al. **Acta Haematol** 1998 Dec;100(3):123–9

Role of complement in immune or idiopathic thrombocytopenic purpura. Hed J. **Acta Paediatr Suppl** 1998 Jun;424:37–40 (20 ref.)

Binding reaction of aflatoxin B1 with immunoglobulin G against aflatoxin B1–bovine serum albumin complex. Odunola OA, et al. **Afr J Med Med Sci** 1998 Mar–Jun;

27(1-2):1-4
Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. Challita-Eid PM, et al.
AIDS Res Hum Retroviruses 1998 Dec 20;14(18):1617-24
Cow's milk IgE and IgG antibody responses to cow's milk formulas. Oldaeus G, et al. **Allergy** 1999 Apr;54(4):352-7
Benign monoclonal gammopathy turning to AL amyloidosis after kidney transplantation. Dysseleer A, et al.
Am J Kidney Dis 1999 Jul;34(1):166-9
Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Shi YP, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):135-41
Extraction of sp18 family membrane proteins on posterior head of bull sperm and the effect of anti-sp18 IgG on sperm motility and murine in vitro fertilization. Gou KM, et al.
Anim Biotechnol 1998;9(2):149-53
Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Kusunoki S, et al. **Ann Neurol** 1999 Mar; 45(3):400-3
Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity. Woo BH, et al. **Arch Pharm Res** 1994 Dec; 17(6):452-7
Changes in the galactose content of IgG during humoral immune responses. Lastra GC, et al. **Autoimmunity** 1998; 28(1):25-30
The IgG2a/IgA produced by the murine T560 B lymphoma that arose during a graft-versus-host reaction is polyreactive and somatically mutated. Phillips-Quagliata JM, et al. **Autoimmunity** 1999;29(3):215-33
Bullous pemphigoid IgG2 and IgG4 antibodies have a capability to inhibit a transient increase of intracellular Ca2+ induced by bullous pemphigoid IgG1 antibody. Suzuki M, et al. **Autoimmunity** 1999;30(2):85-91
Production of a rabbit anti-cockatiel immunoglobulin G and characterization of its cross-reactivities with immunoglobulin G of other psittacine species. Baghian A, et al. **Avian Dis** 1999 Jan-Mar;43(1):48-54
Adenoviral-mediated gene transfer of interleukin-6 in rat lung enhances antiviral immunoglobulin A and G responses in distinct tissue compartments. Xing Z, et al.
Biochem Biophys Res Commun 1999 May 10;258(2):332-5
Fc gamma receptors in negative signaling--as potential candidates for the antibody induced regulation of humoral responses. Bell CG. **Biochem Soc Trans** 1998 Aug; 26(3):S202
FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Meyer D, et al. **Blood** 1998 Dec 1; 92(11):3997-4002
The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. van Vugt MJ, et al. **Blood** 1999 Jul 15; 94(2):808-17
Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). Lazarova Z, et al. **Br J Dermatol** 1998 Nov;139(5):791-7
Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. Fischer P, et al. **Br J Haematol** 1999 Jun;105(3):626-40
Platelet-bound immunogloblins before and after platelet transfusion: measurement of in vivo binding. Levin MD, et al. **Br J Haematol** 1999 Feb;104(2):397-402
Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Zhu M, et al. **Br J Haematol** 1999 Apr;105(1):102-9
A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells. Andersson E, et al. **Cancer Immunol Immunother** 1999 Jan;47(5):249-56
Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. LaTemple DC, et al.
Cancer Res 1999 Jul 15;59(14):3417-23
Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Moro M, et al. **Cancer Res** 1999 Jun 1;59(11):2650-6
It's spring, and thoughts turn to...allergies. Metzger H. **Cell** 1999 Apr 30;97(3):287-90 (20 ref.)
A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo. Cullen CM, et al. **Cell Immunol** 1999 Feb 25; 192(1):54-62
An ELISA for the H-subunit of human ferritin which employs a combination of rabbit poly- and mice monoclonal antibodies and an enzyme labeled anti-mouse-IgG. Vaisman B, et al. **Clin Chem Lab Med** 1999 Feb;37(2):121-5
Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Kroon FP, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):352-5
Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Narita M, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):799-803
Relationship between allergic status and specificity of IgG antibody to inhaled allergens: the grass pollen model. Michils A, et al. **Clin Exp Allergy** 1999 Jun;29(6):832-9
IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease. Skyllouriotis P, et al.
Clin Exp Immunol 1999 Feb;115(2):236-47
IgG-mediated anaphylaxis via Fc gamma receptor in CD40-deficient mice. Wakayama H, et al.
Clin Exp Immunol 1998 Nov;114(2):154-60
Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis. Ichikawa Y, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):709-15
High anti-golgi autoantibody levels: an early sign of autoimmune disease? Bizzaro N, et al. **Clin Rheumatol** 1999; 18(4):346-8
Hyperacute rejection from antibody against class II HLA antigens. Ghasemian SR, et al. **Clin Transplant** 1998 Dec; 12(6):569-71
Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study. Kalogeropoulos CD, et al.
Doc Ophthalmol 1998;95(2):109-20
Development and comparison of assays for measuring immunospecific antibody response in serum of chickens and rabbits immunized with human immunoglobulin G. Bollen LS, et al. **Electrophoresis** 1998 Oct;19(14):2419-22
Human preformed IgG combining with membrane-bound porcine serotransferrin lyse porcine endothelial cells through antibody-dependent cellular cytotoxicity. Atia N, et al. **Eur J Immunol** 1998 Dec;28(12):3917-28
Isolation and characterization of natural human IgG with a morphine-like activity. Macé G, et al.
Eur J Immunol 1999 Mar;29(3):997-1003
Human amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin. Quan CP, et al.
Eur J Immunol 1998 Dec;28(12):4001-9
IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. Rückert R, et al.
Eur J Immunol 1998 Oct;28(10):3312-20
Deaggregated homologous immunoglobulin-peptide conjugates induce peptide-specific T cell nonresponsiveness in vivo. Seddon B, et al.
Eur J Immunol 1998 Dec;28(12):4313-24
HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Uchio E, et al. **Exp Eye Res** 1998 Dec; 67(6):719-27
Allergen mimotopes in food enhance type I allergic reactions in mice. Jensen-Jarolim E, et al. **FASEB J** 1999 Sep; 13(12):1586-92
Production and partial characterization of anti-cord factor (trehalose-6,6'-dimycolate) IgG antibody in rabbits recognizing mycolic acid subclasses of Mycobacterium tuberculosis or Mycobacterium avium. Fujiwara N, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):141-9
IgG antibodies to Lewis type 2 antigens in serum of H. pylori-infected and noninfected blood donors of different Lewis(a,b) blood-group phenotype. Kurtenkov O, et al.
FEMS Immunol Med Microbiol 1999 Jun;24(2):227-32
Identification of antibodies directed against O-acetylated sialic acids in visceral leishmaniasis: its diagnostic and prognostic role. Chatterjee M, et al. **Glycoconj J** 1998 Dec; 15(12):1141-7
Sialyl Lewis(x) expression on IgG in rheumatoid arthritis and other arthritic conditions: a preliminary study. Goodarzi MT, et al. **Glycoconj J** 1998 Dec;15(12):1149-54
Systemic and local immune responses against Helicobacter pylori urease in patients with chronic gastritis: distinct IgA and IgG productive sites. Futagami S, et al. **Gut** 1998 Aug; 43(2):168-75
Gradual loss of IgG antibodies against GB virus C/hepatitis G virus in a patient with AIDS. Nerurkar VR, et al.
Hawaii Med J 1998 Dec;57(12):733-4
Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells. Jelley-Gibbs DM, et al. **Hum Immunol** 1999 Jun;60(6):469-78
The human uniqueness of HIV: innate immunity and the viral Tat protein. Rodman TC, et al. **Hum Immunol** 1999 Aug; 60(8):631-9
Immunoglobulin double isotype-producing hybridomas isolated from an autoimmune (NZB x NZW)F1 mouse. Payelle-Brogard B, et al. **Hybridoma** 1998 Jun;17(3):289-97
The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Philips JR, et al. **Immunol Cell Biol** 1999 Apr; 77(2):121-6
The influence of antibody functional affinity on the effector functions involved in the clearance of circulating immune complexes anti-BSA IgG/BSA. Marzocchi-Machado CM, et al. **Immunol Invest** 1999 Mar-May;28(2-3):89-101
Immunoglobulin G subclass responses in mice immunized with plasmid DNA encoding the CFA/I fimbria of enterotoxigenic Escherichia coli. Alves AM, et al.
Immunol Lett 1998 Jul;62(3):145-9
Effect of pregnancy and placental factors on the quality of humoral immune response. Gentile T, et al.
Immunol Lett 1998 Jul;62(3):151-7
DNA-mobility shift assay and the detection of anti-DNA IgG in systemic lupus erythematosus patients. Keyhani J, et al. **Immunol Lett** 1998 Jun;62(2):81-6
Paradoxical behavior of asymmetric IgG antibodies. Margni RA, et al. **Immunol Rev** 1998 Jun;163:77-87 (61 ref.)
Dominant recognition of a cross-reactive B-cell epitope in Mycobacterium leprae 10 K antigen by immunoglobulin G1 antibodies across the disease spectrum in leprosy. Hussain R, et al. **Immunology** 1999 Apr;96(4):620-7
Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Schuurman J, et al.
Immunology 1999 Aug;97(4):693-8
Transplacental transfer of H. influenzae type b antibody. John TJ. **Indian Pediatr** 1998 Sep;35(9):919-20
Biased immunoglobulin G1 isotype responses induced in cattle with DNA expressing msp1a of Anaplasma marginale. Arulkanthan A, et al. **Infect Immun** 1999 Jul; 67(7):3481-7
Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Lottenbach KR, et al. **Infect Immun** 1999 Sep;67(9):4935-8
Dominance of immunoglobulin G2c in the antiphosphorylcholine response of rats infected with Trichinella spiralis. Peters PJ, et al. **Infect Immun** 1999 Sep; 67(9):4661-7
The apparent monovalency of human IgG4 is due to bispecificity. Aalberse RC, et al.
Int Arch Allergy Immunol 1999 Feb-Apr;118(2-4):187-9
Cat-specific IgA antibodies in breast milk from atopic and non-atopic mothers: detection of Fel d 1-IgG immune complexes in cord blood and sera. Casas R, et al.
Int Arch Allergy Immunol 1999 Feb-Apr;118(2-4):317-8
Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction. Eibensteiner P, et al.
Int Arch Allergy Immunol 1999 Feb-Apr;118(2-4):190-2
Is complement activation a factor in bronchial asthma? Glovsky MM, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):330-2
The real value of IgG4 determination in immunotherapy follow-up. Oehling A, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):366-7
Monoclonal IgG antibodies influence the migration patterns of lymphocytes in vivo. Yousaf N, et al.
Int Arch Allergy Immunol 1999 Jan;118(1):59-66
Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Tempero RM, et al.
Int J Cancer 1999 Feb 9;80(4):595-9
Specificity of polyclonal anti-p53 IgG for isolation of the soluble p53 antigen from human serum. Sandler B, et al.
Int J Mol Med 1998 Apr;1(4):767-70
Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. Metlas R, et al.
J Acquir Immune Defic Syndr 1999 Aug 1;21(4):266-70
Specific IgG response to monomeric and polymeric diphenylmethane diisocyanate conjugates in subjects with respiratory reactions to isocyanates. Aul DJ, et al.
J Allergy Clin Immunol 1999 May;103(5 Pt 1):749-55
Anti-epiligrin cicatricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5. Fujimoto W, et al. **J Am Acad Dermatol** 1999 Apr; 40(4):637-9
American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis. Xue W.
J Am Acad Dermatol 1999 Sep;41(3 Pt 1):462-3
Latex immunoassays: comparative studies on covalent and physical immobilization of antibodies. II. IgG. Molina-Bolivar JA, et al. **J Biomater Sci Polym Ed** 1998; 9(10):1103-13
Targeting of functional antibody-CD59 fusion proteins to a cell surface. Zhang HF, et al. **J Clin Invest** 1999 Jan; 103(1):55-61
Predictive value of maternal-IgG avidity for congenital human cytomegalovirus infection. Bodéus M, et al.
J Clin Virol 1999 Jan;12(1):3-8
Repeat direct immunofluorescence (DIF) test, using, 1 M NaCl treated skin, in the subepidermal autoimmune bullous diseases that contain IgG at the dermal epidermal junction. Barnadas MA, et al. **J Cutan Pathol** 1999 Jan;26(1):37-41
Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. Ujike A, et al. **J Exp Med** 1999 May 17;189(10):1573-9
Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. Bartemes KR, et al. **J Immunol** 1999 Mar 1; 162(5):2982-9
Analysis of signal transduction pathways regulating cytokine-mediated Fc receptor activation on human eosinophils. Bracke M, et al. **J Immunol** 1998 Dec 15; 161(12):6768-74
Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. Isaacs JD, et al. **J Immunol** 1998 Oct 15;161(8):3862-9
Deletion of bone marrow stromal cell antigen-1 (CD157) gene impaired systemic thymus independent-2 antigen-induced IgG3 and mucosal TD antigen-elicited IgA responses. Itoh M, et al. **J Immunol** 1998 Oct 15; 161(8):3974-83

Regulation of monocyte survival in vitro by deposited IgG: role of macrophage colony-stimulating factor. Marsh CB, et al. **J Immunol** 1999 May 15;162(10):6217-25

Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Roux KH, et al. **J Immunol** 1998 Oct 15;161(8):4083-90

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model. Humphreys DP, et al. **J Immunol Methods** 1998 Aug 1;217(1-2):1-10

Two high-affinity monoclonal IgG2a antibodies with differing thermodynamic stability demonstrate distinct antigen-induced changes in protein A-binding affinity. Kravchuk ZI, et al. **J Immunol Methods** 1998 Aug 1; 217(1-2):131-41

A simple method for determining K(A)s of both low and high affinity IgG antibodies. O'Hare T, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):161-7

In vivo biotinylated recombinant antibodies: high efficiency of labelling and application to the cloning of active anti-human IgG1 Fab fragments. Sibler AP, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):129-40

Humoral immunity status in neonates born to pre-eclamptic toxaemia mothers. Das S, et al. **J Indian Med Assoc** 1998 Mar;96(3):77-9

Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. Lazzarotto T, et al. **J Infect Dis** 1998 Oct;178(4):1145-9

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. Pungor E Jr, et al. **J Interferon Cytokine Res** 1998 Dec;18(12):1025-30

Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. Aoyama Y, et al. **J Invest Dermatol** 1999 Jan;112(1):67-71

Determinations of Par j 1 by a competitive enzyme immunoassay using human specific IgE and IgG. Validation by skin prick testing. Boluda L, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):207-13

Presence of specific IgG antibody to grain dust does not go with respiratory symptoms. Park HS, et al. **J Korean Med Sci** 1999 Feb;14(1):39-44

IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome [letter] Kashihara K, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov;65(5):799

Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. Naumann M, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):924-7

Antiganglioside antibodies in various episodes in a patient with recurrent Guillain-Barré syndrome [letter] Tagawa Y, et al. **J Neurol Neurosurg Psychiatry** 1998 Dec;65(6):952

Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. Rowe DB, et al. **J Neurosci Res** 1998 Sep 1;53(5):551-8

Differences of IgG and IgM antibodies to phospholipids and APTT among non-pregnant and pregnant women. Shimano S, et al. **J Obstet Gynaecol Res** 1998 Aug; 24(4):299-304

Development of a polyclonal antibody with defined specificity against synthetic peptides from the N-myc oncoprotein using multiple antigen peptide and hemocyanin conjugation methods. Yang HW, et al. **J Pediatr Surg** 1999 Mar;34(3):454-60

Pharmacokinetic mechanisms for obtaining high renal coelimination of phencyclidine and a monoclonal antiphencyclidine antigen-binding fragment of immunoglobulin G in the rat. Proksch JW, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):616-24

Human serum beta2-microglobulin levels: correlation with total serum IgG and placental IgG transfer in HIV-infected and non-HIV infected individuals. de Moraes-Pinto MI, et al. **J Reprod Immunol** 1999 Mar;42(2):167-74

Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. Zeitlin L, et al. **J Reprod Immunol** 1998 Oct; 40(1):93-101

Placental transfer of IgG antibodies against Haemophilus influenzae type b capsular polysaccharide in Brazilian term and preterm newborns. Nagao AT, et al. **J Trop Pediatr** 1999 Jun;45(3):171-3

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. MacDonald NE, et al. **JAMA** 1998 Nov 18;280(19):1685-9

Errors in reported association between Tamm-Horsfall protein and IgG [letter] Rhodes DC, et al. **Kidney Int** 1999 Aug;56(2):759

Polyethylene glycol augments thyroid cAMP responses by fragments from protease-digested TSAb or TSBAb-IgG. Yamashiro K, et al. **Life Sci** 1999;64(13):1109-16

IgG, IgG1 and IgM response in Trichinella spiralis-infected mice treated with 4-deoxypyridoxine or fed a Vitamin B6-deficient diet. Frydas S, et al. **Mol Cell Biochem** 1999 Apr;194(1-2):47-52

The second and third extracellular domains of FcgammaR1 (CD64) confer the unique high affinity binding of IgG2a. Hulett MD, et al. **Mol Immunol** 1998 Oct;35(14-15):989-96

Axonal involvement at the common entrapment sites in Guillain-Barré syndrome with IgG anti-GM1 antibody. Kuwabara S, et al. **Muscle Nerve** 1999 Jul;22(7):840-5

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Umaña P, et al. **Nat Biotechnol** 1999 Feb;17(2):176-80

Recurrent multifocal demyelinating neuropathy with febrile illness and IgG subset deficiency. Likosky DJ, et al. **Neurology** 1999 Jun 10;52(9):1902-5

IgG subclass recognition of Loa loa antigens and their correlation with clinical status in individuals from Gabon. Akue JP, et al. **Parasite Immunol** 1998 Aug;20(8):387-93

Protective immunity in the rat model of congenital toxoplasmosis and the potential of excreted-secreted antigens as vaccine components. Zenner L, et al. **Parasite Immunol** 1999 May;21(5):261-72

The effect of maternally derived immunoglobulin G on the risk of respiratory disease in heifers during the first 3 months of life. Virtala AM, et al. **Prev Vet Med** 1999 Mar 12;39(1):25-37

Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Kang Y, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8609-14

Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Karlsson MC, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2; 96(5):2244-9

Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Wang B, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1627-32

Characterization of the three immunoglobulin G subclasses of macaques. Calvas P, et al. **Scand J Immunol** 1999 Jun; 49(6):595-610

Low responsiveness to immunization with immunoglobulin E/antigen and immunoglobulin G/antigen complexes in H-2Ab mice. Gustavsson S, et al. **Scand J Immunol** 1999 Jul;50(1):45-51

Low levels of IgG antibodies against pneumocystis carinii among HIV-infected patients. Laursen AL, et al. **Scand J Infect Dis** 1998;30(5):495-9

Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. van Doornum G, et al. **Sex Transm Infect** 1998 Oct;74(5):354-60

Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Tuhrim S, et al. **Stroke** 1999 Aug; 30(8):1561-5

Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus--possible association with thrombotic and thrombocytopenic complications. Nojima J, et al. **Thromb Haemost** 1999 Mar; 81(3):436-41

Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Rauch J, et al. **Thromb Haemost** 1998 Dec;80(6):936-41

Development and evaluation of the neutralizing capacity of horse antivenom against the Brazilian spider Loxosceles intermedia. Braz A, et al. **Toxicon** 1999 Sep;37(9):1323-8

An association between antibodies specific for endothelial cells and renal transplant failure. Perrey C, et al. **Transpl Immunol** 1998 Jun;6(2):101-6

Significance of anti-Gal IgG in chronic xenograft rejection. Galili U. **Transplant Proc** 1999 Feb-Mar;31(1-2):940-1 (14 ref.)

Induction of resistance against Schistosoma mansoni infection by passive transfer of an IgG2a monoclonal antibody. Attallah AM, et al. **Vaccine** 1999 May 4;17(18):2306-10

Anti-haemolysin IgG1 to IgG2 ratios correlate with haemolysin neutralization titres and lung lesion scores in Actinobacillus pleuropneumoniae infected pigs. Furesz SE, et al. **Vaccine** 1998 Dec;16(20):1971-5

A novel epitope R7V common to all HIV-1 isolates is recognized by neutralizing IgG found in HIV-infected patients and immunized rabbits. Galéa P, et al. **Vaccine** 1999 Mar 17;17(11-12):1454-61

Studies on pulmonary and systemic Aspergillus fumigatus-specific IgE and IgG antibodies in horses affected with chronic obstructive pulmonary disease (COPD). Schmallenbach KH, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3-4):245-56

Novel feline autoimmune blistering disease resembling bullous pemphigoid in humans: IgG autoantibodies target the NC16A ectodomain of type XVII collagen (BP180/BPAG2). Olivry T, et al. **Vet Pathol** 1999 Jul; 36(4):328-35

Comparison of the immunoglobulin-G-specific seroreactivity of different recombinant antigens of the human herpesvirus 8. Lang D, et al. **Virology** 1999 Jul 20;260(1):47-54

IgG, but not IgM, mediates hyperacute rejection in hepatic xenografting. Schraa EO, et al. **Xenotransplantation** 1999 May;6(2):110-6

IgG western blot as a confirmatory test in early syphilis. Marangoni A, et al. **Zentralbl Bakteriol** 1999 Apr; 289(2):125-33

[Degranulation of eosinophils by IgG antibody to Candida antigen] Ikeda Y, et al. **Arerugi** 1999 May;48(5):546-53 (Eng. Abstr.) **(Jpn)**

[The evaluation of humoral immunity response in subacute sclerosing panencephalitis (SSPE)] Sobczyk W, et al. **Neurol Neurochir Pol** 1999 Jan-Feb;33(1):79-85 (Eng. Abstr.) **(Pol)**

[Subclasses of IgG (IgG1-IgG4) in children during specific immunotherapy] Trofimowicz A, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):354-6 (Eng. Abstr.) **(Pol)**

[The effect of intrabronchial specific immunotherapy on certain immunologic parameters in asthmatic patients with allergic to house mites] Ziętkowski Z. **Pol Merkuriusz Lek** 1999 May;6(35):236-8 (Eng. Abstr.) **(Pol)**

[Vasopressin: secondary immune response and antigen-specific suppressants] Igonina NA, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):60-2 **(Rus)**

[Immunoglobulin avidity in the diagnosis acute infectious processes] Maroto Vela MC. **An R Acad Nac Med (Madr)** 1998;115(2):519-30; discussion 530-7 **(Spa)**

ISOLATION & PURIFICATION

Sedimentation equilibrium analysis of interference optical data by systematic noise decomposition. Schuck P. **Anal Biochem** 1999 Aug 1;272(2):199-208

Affinity purification of human IgG using immobilised, mutated immunoglobulin-binding domains from protein A of Staphylococcus aureus. Brown NL, et al. **Biochem Soc Trans** 1998 Aug;26(3):S249

IgG and hybridoma partitioning in aqueous two-phase systems containing a dye-ligand. Zijlstra GM, et al. **Bioseparation** 1998;7(2):117-26

Anti-epiligrin cicatricial pemphigoid: a case associated with gastric carcinoma and features resembling epidermolysis bullosa acquisita. Fujimoto W, et al. **Br J Dermatol** 1998 Oct;139(4):682-7

Purification and quantitation of tumor necrosis factor receptor immunoadhesin using a combination of immunoaffinity and reversed-phase chromatography. Battersby JE, et al. **J Chromatogr B Biomed Sci Appl** 1999 May 14;728(1):21-33

Purification of immunoglobulins G by protein A/G affinity membrane chromatography. Dancette OP, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19;723(1-2):61-8

Structure of the IgG-binding ligand of the T-gel. Scoble JA, et al. **J Mol Recognit** 1998 Winter;11(1-6):119-20

Immunoadsorption therapy for paraneoplastic syndromes. Batchelor TT, et al. **J Neurooncol** 1998 Nov;40(2):131-6

Separation and quantitation of monoclonal antibodies in cell growth medium using capillary zone electrophoresis. Dai HJ, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1143-53

Release and preparation of intact and unreduced N-linked oligosaccharides from Sf-9 insect cells. Wolff MW, et al. **Prep Biochem Biotechnol** 1999 Feb;29(1):1-21

Part of prekallikrein removed from human plasma together with IgG--immunoblot experiments and functional tests. Briseid K, et al. **Scand J Clin Lab Invest** 1999 Feb; 59(1):55-63

Comparison of the adsorption ability between tryptophan and modified tryptophan columns. Odaka M, et al. **Ther Apher** 1997 Nov;1(4):353-5

Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain-Barré syndrome: is it equivalent to plasma exchange? Tagawa Y, et al. **Ther Apher** 1997 Nov; 1(4):336-9

An evaluation of oral-fluid collection devices for the determination of rubella antibody status in a rural Ethiopian community. Nokes DJ, et al. **Trans R Soc Trop Med Hyg** 1998 Nov-Dec;92(6):679-85

[Studies on properties of cross-reacting anti-A,B antibodies in group O sera] Ago K. **Nippon Hoigaku Zasshi** 1998 Oct; 52(5):319-30 (Eng. Abstr.) **(Jpn)**

[Isolation of anti-Cryptococcus neoformans immunoglobulin G] Illnait Zaragozi MT, et al. **Rev Cubana Med Trop** 1998; 50(1):27-30 (Eng. Abstr.) **(Spa)**

METABOLISM

The effect of silicone ocular surgical devices on serum IgG binding to silicones. Shaikh S, et al. **Am J Ophthalmol** 1998 Dec;126(6):798-804

Effect of high arterial carbon dioxide tension on efficiency of immunoglobulin G absorption in calves. Drewry JJ, et al. **Am J Vet Res** 1999 May;60(5):609-14

Localization of IgG in the normal and dystrophic rat retina after laser lesions. Chu Y, et al. **Aust N Z J Ophthalmol** 1999 Apr;27(2):117-25

Human breast milk immunoglobulins G hydrolyze nucleotides. Semenov DV, et al. **Biochemistry (Mosc)** 1998 Aug;63(8):935-43

Human Fcgamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Sondermann P, et al. **Biol Chem** 1999 Jun;380(6):717-21

Functional role of sialic acid in IgG binding to microvillus membranes in neonatal rat intestine. Gill RK, et al. **Biol Neonate** 1999 Jul;76(1):55-64

Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates. Jackson TL, et al. **Br J Cancer** 1999 Aug;80(11):1747-53

Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.

Gillies SD, et al. **Cancer Res** 1999 May 1;59(9):2159–66

Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Newkirk MM, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1129–38

Anti-betalactoglobulin IgG antibodies bind to a specific profile of epitopes when patients are allergic to cow's milk proteins. Duchateau J, et al. **Clin Exp Allergy** 1998 Jul; 28(7):824–33

Galactosylation of serum IgG and autoantibodies in murine models of autoimmune haemolytic anaemia. Barker RN, et al. **Clin Exp Immunol** 1999 Sep;117(3):449–54

Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Richter WF, et al. **Drug Metab Dispos** 1999 Jan;27(1):21–5

Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Armour KL, et al. **Eur J Immunol** 1999 Aug;29(8):2613–24

IgG transport across trophoblast-derived BeWo cells: a model system to study IgG transport in the placenta. Ellinger I, et al. **Eur J Immunol** 1999 Mar;29(3):733–44

Modulation of the chemotactic peptide- and immunoglobulin G-triggered respiratory burst in human neutrophils by exogenous and endogenous adenosine. Zalavary S, et al. **Eur J Pharmacol** 1998 Aug 7;354(2–3):215–25

Binding of human IgG and F(ab')2 and Fc fragments to cultured trophoblast cells from human term placenta. Ugele B, et al. **Exp Cell Res** 1998 Oct 10;244(1):137–46

Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Margiloff L, et al. **Free Radic Biol Med** 1998 Nov 1;25(7):780–5

The effect on IgG glycosylation of altering beta1, 4-galactosyltransferase-1 activity in B cells. Keusch J, et al. **Glycobiology** 1998 Dec;8(12):1215–20

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Warny M, et al. **Gut** 1999 Feb;44(2):212–7

The influence of the hinge region length in binding of human IgG to human Fcgamma receptors. Redpath S, et al. **Hum Immunol** 1998 Nov;59(11):720–7

The antigen binding domain of non-idiotypic human anti-F(ab')2 autoantibodies: study of their interaction with IgG hinge region epitopes. Welschof M, et al. **Hum Immunol** 1999 Apr;60(4):282–90

Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Ghirlando R, et al. **Immunol Lett** 1999 May 3;68(1):47–52

Biochemical analysis and crystallisation of Fc gamma RIIa, the low affinity receptor for IgG. Powell MS, et al. **Immunol Lett** 1999 May 3;68(1):17–23

Amidolytic and peptidolytic activities of immunoglobulin G present in sera from patients with rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus. Matsuura K, et al. **Immunology** 1998 Sep;95(1):26–30

Arachidonic acid, but not its metabolites, is essential for FcgammaR-stimulated intracellular killing of Staphylococcus aureus by human monocytes. Zheng L, et al. **Immunology** 1999 Jan;96(1):90–7

Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes. Gorgani NN, et al. **Int Immunol** 1999 Aug;11(8):1275–82

Interaction of IgG immunoglobulins with the guinea pig peritoneal macrophage Fc gamma receptors. Effect on the association of the receptors with the membrane skeleton and the cytoskeleton. Sokal I, et al. **Int J Biochem Cell Biol** 1998 Dec;30(12):1353–65

111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Hassan R, et al. **Int J Cancer** 1999 Feb 9;80(4):559–63

Regulation of RANTES and ICAM-1 expression in murine mesangial cells. Satriano JA, et al. **J Am Soc Nephrol** 1997 Apr;8(4):596–603

Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. Chapman TL, et al. **J Biol Chem** 1999 Mar 12; 274(11):6911–9

The effects of alpha 2-antiplasmin complex and alpha 2-antiplasmin on the secretion of IgG and IgM by cultured human mononuclear cells. Zhabin SG, et al. **J Clin Lab Immunol** 1997;49(2):77–82

Inability of intact cells of Treponema denticola to degrade human serum proteins IgA, IgG and albumin. Hollmann R, et al. **J Clin Periodontol** 1999 Jul;26(7):477–9

Controlled release of a model protein from enzymatically degrading dextran microspheres. Franssen O, et al. **J Controlled Release** 1999 May 20;59(2):219–28

IgG transcytosis is accelerated but its pathway is not disrupted by Brefeldin-A. Ichimura T. **J Electron Microsc (Tokyo)** 1999;48(1):47–53

Differential binding of IgG and of a HIV gp41 peptide by the B chain and A chain globular head sequences of C1q, respectively. Kojouharova MS, et al. **J Immunol** 1998 Oct 15;161(8):4325–31

Fc gamma receptor-mediated activation of phospholipase D regulates macrophage phagocytosis of IgG-opsonized particles. Kusner DJ, et al. **J Immunol** 1999 Feb 15; 162(4):2266–74

Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction. Juhlin P, et al. **J Intern Med** 1999 May;245(5):483–8

Absorption of IgG does not enhance toxoplasma IgM and IgA immunoblotting. Chatterton JM, et al. **J Med Microbiol** 1999 Jun;48(6):593–5

Identification of peptides that bind to the constant region of a humanized IgG1 monoclonal antibody using phage display. Ehrlich GK, et al. **J Mol Recognit** 1998 Winter; 11(1–6):121–5

Structure of the IgG-binding ligand of the T-gel. Scoble JA, et al. **J Mol Recognit** 1998 Winter;11(1–6):119–20

Analysis of the endocytic pathway upon intracellular transport of IgG molecules through Fc receptors. Athanassakis I, et al. **J Recept Signal Transduct Res** 1999 Jan-Jul;19(1–4):143–54

Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. Franklin RD, et al. **J Reprod Immunol** 1999 Mar; 42(2):93–106

Degradations of human immunoglobulins and hemoglobin by a 60 kDa cysteine proteinase of Trichomonas vaginalis. Min DY, et al. **Korean J Parasitol** 1998 Dec;36(4):261–8

Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I. Zhang L, et al. **Microbiology** 1999 Jan;145 (Pt 1):177–83

A study of the interactions between an IgG-binding domain based on the B domain of staphylococcal protein A and rabbit IgG. Brown NL, et al. **Mol Biotechnol** 1998 Aug; 10(1):9–16

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases [see comments] Yu Z, et al. **N Engl J Med** 1999 Jan 21;340(3):227–8 (9 ref.). Comment in: N Engl J Med 1999 Jul 1;341(1):57–8.

Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Stabila PF, et al. **Nat Biotechnol** 1998 Dec;16(13):1357–60

Nephrotic syndrome secondary to primary immunoglobulin-G mesangioproliferative glomerulonephritis [letter] Sepandj F, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1889–90

Preparation, biodistribution, and dosimetry of 188Re-labeled MoAb ior cea1 and its F(ab')2 fragments by avidin-biotin strategy. Ferro-Flores G, et al. **Nucl Med Biol** 1999 Jan; 26(1):57–62

Fc-binding molecules specific for human IgG1 and IgG3 are present in Echinococcus granulosus protoscoleces. Baz A, et al. **Parasite Immunol** 1998 Sep;20(9):399–404

Dissection of the protein G B1 domain binding site for human IgG Fc fragment. Sloan DJ, et al. **Protein Sci** 1999 Aug; 8(8):1643–8

A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Raeder R, et al. **Res Microbiol** 1998 Sep;149(8):539–48

Suppression of immunoglobulin secretion by soluble annexin II. Aarli A, et al. **Scand J Immunol** 1998 Nov;48(5):522–6

Protein-protein interactions between native Ro52 and immunoglobulin G heavy chain. Yang Y, et al. **Scand J Immunol** 1999 Jun;49(6):620–8

Mechanisms of allergy and chemical sensitivity. Meggs WJ. **Toxicol Ind Health** 1999 Apr-Jun;15(3–4):331–8 (56 ref.)

Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Ismail M, et al. **Toxicon** 1998 Nov;36(11):1523–8

Influence of growth conditions on expression of immunoglobulin G binding in group A streptococci. Burova LA, et al. **Zentralbl Bakteriol** 1998 Dec; 288(4):479–89

[Transcytosis of immunoglobulin IgG] Ichimura T. **Kaibogaku Zasshi** 1998 Dec;73(6):595–602 (56 ref.) (Eng. Abstr.) **(Jpn)**

[IgG, IgA, Bence Jones protein (BJP) myeloma] Takahashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):403–7 (20 ref.) **(Jpn)**

[Proteolysis of immunoglobulins--biologically-active supplement in a fermented milk in gastrointestinal system of rats] Gmoshinskii IV, et al. **Vopr Pitan** 1998;(4):5–8 (Eng. Abstr.) **(Rus)**

[Submandibular secretion of immunoglobulins IgA and IgG in peripheral paralysis of the facial nerve] Ristić B, et al. **Med Pregl** 1998 Sep-Oct;51(9–10):400–3 (Eng. Abstr.) **(Scr)**

PHARMACOLOGY

Comparative study on the ability of IgG and F(ab')2 antivenoms to neutralize lethal and myotoxic effects induced by Micrurus nigrocinctus (coral snake) venom. León G, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):266–71

Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Buchwald B, et al. **Ann Neurol** 1998 Dec; 44(6):913–22

Bullous pemphigoid IgG2 and IgG4 antibodies have a capability to inhibit a transient increase of intracellular Ca2+ induced by bullous pemphigoid IgG1 antibody. Suzuki M, et al. **Autoimmunity** 1999;30(2):85–91

Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: effects of physostigmine and FG 7142. McGaughy J, et al. **Behav Neurosci** 1998 Dec; 112(6):1519–25

Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1. Navolotskaya EV, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):758–64

Mechanism of the augmentative effect of high polyethylene glycol (PEG) concentrations on the thyroid stimulating activity in TSAb-IgG using a porcine thyroid cell assay. Yamashiro K, et al. **Endocr Res** 1999 Feb;25(1):67–75

TrkA activation in the rat visual cortex by antirat trkA IgG prevents the effect of monocular deprivation. Pizzorusso T, et al. **Eur J Neurosci** 1999 Jan;11(1):204–12

Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor. Di Cerbo A, et al. **J Clin Endocrinol Metab** 1999 Sep; 84(9):3283–92

Growth responses of coliform bacteria to purified immunoglobulin G from cows immunized with ferric enterobactin receptor FepA. Lin J, et al. **J Dairy Sci** 1999 Jan;82(1):86–92

Inhibition of nonspecific binding of fluorescent-labelled antibodies to human eosinophils. Mahmudi-Azer S, et al. **J Immunol Methods** 1998 Aug 1;217(1–2):113–9

Antibodies against cysteine string proteins inhibit evoked neurotransmitter release at Xenopus neuromuscular junctions. Poage RE, et al. **J Neurophysiol** 1999 Jul; 82(1):50–9

Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells. Engisch KL, et al. **J Neurosci** 1999 May 1;19(9):3384–95

Immobilized IgG and fibrinogen differentially affect the cytoskeletal organization and bactericidal function of adherent neutrophils. De La Cruz C, et al. **J Surg Res** 1998 Nov;80(1):28–34

Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels [see comments] Offen D, et al. **Neurology** 1998 Oct;51(4):1100–3. Comment in: Neurology 1999 Apr 22;52(7):1520–1.

Effect of intravenous immunoglobulin G on the TNFalpha-mediated hepatic microvascular inflammatory response. Ito Y, et al. **Shock** 1999 Apr;11(4):291–5

Induction of endothelial cell adhesion molecules by serum and immunoglobulins G from a patient with vasculitis and monoclonal gammapathy: potential relevance to vasculitis. Dupuy E, et al. **Thromb Haemost** 1998 Sep;80(3):477–80

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan-Feb;27(1):78–86 (75 ref.)

Presence of IgG exhibiting a morphine-like activity in therapeutic intravenous immunoglobulins. Macé G, et al. **Transplant Proc** 1998 Dec;30(8):3949

Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children. Savo AM, et al. **Transplant Proc** 1999 Feb-Mar;31(1–2):1182–3

PHYSIOLOGY

Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Mazel JA, et al. **Circulation** 1999 Apr 13; 99(14):1914–8

Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Di Simone N, et al. **Hum Reprod** 1999 Feb;14(2):489–95

Antibody feedback suppression: towards a unifying concept? Heyman B. **Immunol Lett** 1999 May 3;68(1):41–5 (48 ref.)

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Jefferis R, et al. **Immunol Rev** 1998 Jun; 163:59–76 (93 ref.)

Anaphylactic response to parasite antigens: IgE and IgG1 independently induce death in Trichinella-infected mice. Bruschi F, et al. **Int Arch Allergy Immunol** 1999 Aug; 119(4):291–6

Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the mu-opioid receptor. Macé G, et al. **J Biol Chem** 1999 Jul 16;274(29):20079–82

Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus. Butko P, et al. **J Immunol** 1999 Sep 1;163(5):2761–8

IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. Wernersson S, et al. **J Immunol** 1999 Jul 15;163(2):618–22

Protein kinase C and a calcium-independent phospholipase are required for IgG-mediated phagocytosis by Mono-Mac-6 cells. Karimi K, et al. **J Leukoc Biol** 1999 Jun;65(6):854–62

Accelerated elimination from the circulation of homologous aged red blood cells in rats bearing anti-spectrin antibodies. Graldi G, et al. **Mech Ageing Dev** 1999 Feb 1;107(1):21–36

Inhibition of complement-mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin. Kojima T, et al. **Transplantation** 1999 Feb 27;67(4):637–8

RADIATION EFFECTS

Cell replication rates and processes concerning antibody production in vitro are not influenced by 2.45-GHz

microwaves at physiologically normal temperatures. van Dorp R, et al. **Methods** 1998 Jun;15(2):151–9

THERAPEUTIC USE

Novel therapies for Helicobacter pylori infection. Opekun AR, et al. **Aliment Pharmacol Ther** 1999 Jan;13(1):35–42

Etanercept marketed for moderate, severe rheumatoid arthritis [news] **Am J Health Syst Pharm** 1998 Dec 15; 55(24):2593

The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody–positive women undergoing in vitro fertilization. Sher G, et al. **Am J Reprod Immunol** 1998 Aug;40(2):74–82

Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Herting E, et al. **Am J Respir Crit Care Med** 1999 Jun; 159(6):1862–7

Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Pittet D, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):852–7

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Moreland LW, et al. **Ann Intern Med** 1999 Mar 16;130(6):478–86

Intravenous injection of an immunoconjugate (anti–PSA–IgG conjugated to 5–fluoro–2'–deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Sinha AA, et al. **Anticancer Res** 1999 Mar–Apr; 19(2A):893–902

Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Barekzi NA, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1609–15

Anti–D treatment for chronic immune thrombocytopenic purpura: clinical and laboratory aspects. Sagripanti A, et al. **Biomed Pharmacother** 1998;52(7–8):293–7

Gut mucosa barrier preservation by orally administered IgA–IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Johansson JE, et al. **Bone Marrow Transplant** 1999 Jul;24(1):35–9

Mathematical and experimental analysis of localization of anti–tumour antibody–enzyme conjugates. Jackson TL, et al. **Br J Cancer** 1999 Aug;80(11):1747–53

Tumor necrosis factor inhibitors for rheumatoid arthritis. Jones RE, et al. **Bull Rheum Dis** 1999;48(3):1–4 (16 ref.)

Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Felts AG, et al. **Burns** 1999 Aug; 25(5):415–23

Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Yang XD, et al. **Cancer Res** 1999 Mar 15;59(6):1236–43

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure [see comments] Deswal A, et al. **Circulation** 1999 Jun 29;99(25):3224–6. Comment in: Circulation 1999 Jun 29;99(25):3213–4.

TNF–alpha and heart failure. The difference between proof of principle and hypothesis testing [editorial; comment] Francis GS. **Circulation** 1999 Jun 29;99(25):3213–4. Comment on: Circulation 1999 Jun 29;99(25):3224–6.

Immune responses in patients with T–cell lymphoma treated with an anti–idiotype antibody mimicking a highly restricted T–cell antigen. Foon KA, et al. **Clin Cancer Res** 1995 Nov;1(11):1285–94

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Goldstein NI, et al. **Clin Cancer Res** 1995 Nov;1(11):1311–8

Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Goldenberg MM. **Clin Ther** 1999 Jan;21(1):75–87; discussion 1–2 (50 ref.)

Etanercept: a review of its use in rheumatoid arthritis. Jarvis B, et al. **Drugs** 1999 Jun;57(6):945–66 (115 ref.)

Comparative anticancer effects of vaccination and dietary factors on experimentally–induced cancers. Zusman I. **In Vivo** 1998 Nov–Dec;12(6):675–89 (186 ref.)

A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Flynn AA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1; 43(1):183–9

Radiotoxicity of systemically administered 211At–labeled human/mouse chimeric monoclonal antibody: a long–term survival study with histologic analysis. McLendon RE, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):491–9

Etanercept: a new option in the management of RA. Lovell CM. **J Am Pharm Assoc (Wash)** 1999 May–Jun;39(3):412–4

Maximum–tolerated dose, toxicity, and efficacy of (131)I–Lym–1 antibody for fractionated radioimmunotherapy of non–Hodgkin's lymphoma. DeNardo GL, et al. **J Clin Oncol** 1998 Oct;16(10):3246–56

An IgG3–IL–2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. Penichet ML, et al. **J Interferon Cytokine Res** 1998 Aug;18(8):597–607

Inhibitors of tumor necrosis factor for rheumatoid arthritis. Moreland LW. **J Rheumatol** 1999 May;26 Suppl 57:7–15 (20 ref.)

Etanercept in rheumatoid arthritis [letter; comment] Cook DA, et al. **N Engl J Med** 1999 Jun 24;340(25):2000; discussion 2001. Comment on: N Engl J Med 1999 Jan 28;340(4):253–9.

Etanercept in rheumatoid arthritis [letter; comment] Escalante A, et al. **N Engl J Med** 1999 Jun 24;340(25):2000; discussion 2001. Comment on: N Engl J Med 1999 Jan 28;340(4):253–9. Comment on: N Engl J Med 1999 Jan 28;340(4):310–2.

Etanercept in rheumatoid arthritis [letter; comment] Ferraccioli GF, et al. **N Engl J Med** 1999 Jun 24; 340(25):2000–1. Comment on: N Engl J Med 1999 Jan 28;340(4):253–9.

Anticytokine therapy--a new era in the treatment of rheumatoid arthritis? [editorial; comment] [see comments] O'Dell JR. **N Engl J Med** 1999 Jan 28;340(4):310–2. Comment on: N Engl J Med 1999 Jan 28;340(4):253–9. Comment in: N Engl J Med 1999 Jun 24;340(25):2000; discussion 2001.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments] Weinblatt ME, et al. **N Engl J Med** 1999 Jan 28;340(4):253–9. Comment in: N Engl J Med 1999 Jan 28;340(4):310–2. Comment in: N Engl J Med 1999 Jun 24;340(25):2000; discussion 2001. Comment in: N Engl J Med 1999 Jun 24;340(25):2000–1.

Protective effects of C5a blockade in sepsis. Czermak BJ, et al. **Nat Med** 1999 Jul;5(7):788–92

TNF neutralization in MS: results of a randomized, placebo–controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group [see comments] **Neurology** 1999 Aug 11;53(3):457–65. Comment in: Neurology 1999 Aug 11;53(3):444–5.

A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Otero R, et al. **Toxicon** 1999 Jun;37(6):895–908

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Ekberg H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):267–8

Anti–TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Feldman M, et al. **Transplant Proc** 1998 Dec;30(8):4126–7 (9 ref.)

Prolongation of rat fetal pancreas allograft survival using a nondepleting anti–CD4 monoclonal antibody W3/25. Muller CJ, et al. **Transplant Proc** 1998 Dec;30(8):4180–3

Daclizumab rapidly saturates interleukin–2 receptor–alpha (CD25) on lymph node lymphocytes in children. Savo AM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1182–3

Can antibody prophylaxis allow sparing of other immunosuppressives? Vincenti F, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1246–8

Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Vincenti F. **Transplant Proc** 1999 Sep;31(6):2206–7

Cytomegalovirus infections after treatment with daclizumab, an anti IL–2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Hengster P, et al. **Transplantation** 1999 Jul 27;68(2):310–3

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B, et al. **Transplantation** 1999 Jan 15;67(1):110–5

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH–1 in acute leukemia: graft–versus–host disease and graft–versus–leukemia effect. Novitzky N, et al. **Transplantation** 1999 Feb 27;67(4):620–6

CTLA4IgG treatment induces long–term acceptance of rat small bowel allografts. Tarumi K, et al. **Transplantation** 1999 Feb 27;67(4):520–5

Treatment advances in rheumatoid arthritis. Arriola ER, et al. **West J Med** 1999 May;170(5):278–81 (16 ref.)

TOXICITY

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Ryan AM, et al. **Toxicol Pathol** 1999 Jan–Feb;27(1):78–86 (75 ref.)

URINE

Proteinuria selectivity index based upon alpha 2–macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases. Technical note. Tencer J, et al. **Kidney Int** 1998 Dec;54(6):2098–105

Urine IgG2/IgG4–ratio indicates the significance of the charge selective properties of the glomerular capillary wall for the macromolecular transport in glomerular diseases. Tencer J, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1425–9

IGG DEFICIENCY

[IgG3 deficiency] Ochiai S. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):543–6 (12 ref.) **(Jpn)**

[Selective IgG deficiency--IgG subclass deficiency] Sugai S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):218–20 (15 ref.) **(Jpn)**

BLOOD

Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Lacombe C, et al. **Clin Immunol** 1999 Jan;90(1):128–32

COMPLICATIONS

Immediate hypersensitivity in adults with IgG deficiency and recurrent respiratory infections. Popa V, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):567–73

Monoclonal gammopathy: benign or not? [letter] Wong P, et al. **Aust N Z J Med** 1999 Apr;29(2):278–9

Recurrent parotitis and isolated IgG3 subclass deficiency [letter] Marsman WA, et al. **Eur J Pediatr** 1999 Aug; 158(8):684

[IgG subclass deficiency and recurrent infections] Sakiyama Y. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug; 21(4):145–9 (16 ref.) **(Jpn)**

DIAGNOSIS

Immunoglobulin G subclasses in wheezing infants. Karaman O, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):564–6

[Immunoglobulin subclass defects in patients with therapy refractor chronic rhinosinusitis] May A, et al. **HNO** 1999 Jan;47(1):19–24 (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

IgG subclass deficiency and the day–care generation. Lawton AR. **Pediatr Infect Dis J** 1999 May;18(5):462–6 (32 ref.)

ETHNOLOGY

Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia. al–Attas RA, et al. **J Clin Immunol** 1998 Sep;18(5):368–71

IMMUNOLOGY

Immunodeficiency due to a unique protracted developmental delay in the B–cell lineage. Goldman AS, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):161–7

Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Stryk S, et al. **Pediatr Dermatol** 1999 Jan–Feb;16(1):19–22

IGG RECEPTORS see **RECEPTORS, IGG**

IGM

Anti–myelin–associated glycoprotein antibodies predict the development of neuropathy in asymptomatic patients with IgM monoclonal gammopathy. Meucci N, et al. **Ann Neurol** 1999 Jul;46(1):119–22

An aggressive form of polyarticular arthritis in a man with CD154 mutation (X–linked hyper–IgM syndrome). Webster EA, et al. **Arthritis Rheum** 1999 Jun;42(6):1291–6

Immunological reconstitution by allogeneic bone marrow transplantation in a child with the X–linked hyper–IgM syndrome. Kawai S, et al. **Eur J Pediatr** 1999 May; 158(5):394–7

Contrasting roles of mannan–specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Zhang MX, et al. **Infect Immun** 1998 Dec;66(12):6027–9

Fulminant ulcerative colitis associated with both masseter muscle myositis and immunoglobulin M nephropathy. Ishiwada N, et al. **Pediatr Int** 1999 Aug;41(4):385–8

The X–linked hyperimmunoglobulin M syndrome. Fuleihan RL. **Semin Hematol** 1998 Oct;35(4):321–31 (96 ref.)

[Detection of antibodies binding to myelin in 75 neuropathies associated with IgM gammopathy] Campant RM, et al. **Ann Biol Clin (Paris)** 1999 Jan–Feb;57(1):69–75 (Eng. Abstr.) **(Fre)**

[Monoclonal IGM interference during measurement of reactive protein C and ferritin by immunonephelometry] Granouillet R, et al. **Ann Biol Clin (Paris)** 1998 Jul–Aug; 56(4):485–6 **(Fre)**

[Measurement of complement C4 fraction in Array 360: beware of monoclonal IgM! (see comments)] Parent X. **Ann Biol Clin (Paris)** 1998 Mar–Apr;56(2):209–10. Comment in: Ann Biol Clin (Paris) 1998 Sep–Oct;56(5):623–5. Comment in: Ann Biol Clin (Paris) 1999 Mar–Apr;57(2):238–9. **(Fre)**

[Necrobiotic xanthogranulomatosis: a cutaneous manifestation of a monoclonal IgM gammopathy] Sève P, et al. **Rev Med Interne** 1998 May;19(5):338–40 (Eng. Abstr.) **(Fre)**

[X–linked hyper IgM syndrome] Kimura N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):460–3 (22 ref.) **(Jpn)**

[Benign IgM gammopathy] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):537–9 (8 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Sustained delivery of immunoglobulins from polymer microsources on a narrow surface of the developing rat brain. Doulazmi M, et al. **J Neurosci Methods** 1998 Oct 1;84(1–2):17–28

ANALYSIS

IgM myeloma: case report with immunophenotypic profile.

Haghighi B, et al. **Am J Hematol** 1998 Dec;59(4):302–8

Hantavirus-specific IgG, IgM, and IgA in acute and chronic renal disease versus congenital renal disease in the United States. Patnaik M, et al. **Am J Kidney Dis** 1999 Apr; 33(4):734–7

Intestinal antibodies against gliadin, tissue-transglutaminase, beta-lactoglobulin, and ovalbumin in patients with irritable bowel syndrome. Wahnschaffe U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:280–4

Immunohistochemical localization of secretory immunoglobulins in the main excretory duct of the human submandibular gland. Perra MT, et al. **Arch Histol Cytol** 1998 Dec;61(5):427–32

Preliminary studies on the use of solid-phase immunosorbent techniques for the rapid detection of Wesselsbron virus (WSLV) IgM by haemagglutination-inhibition. Baba SS, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jan; 22(1):71–9

IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus related disease? [letter; comment] Fisher NC. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):355–6. Comment on: Eur J Gastroenterol Hepatol 1997 Jul;9(7):661–3.

Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA? Wallon M, et al. **Eur J Pediatr** 1999 Aug;158(8):645–9

IgG and IgM antibodies of Herpes Simplex Virus type-1 and type-2 in 233 maternal and neonatal sera. Dong Z, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):69–70

Prevalence of specific IgA and IgM anti-HBc antibodies compared with HBV DNA in the sera of HBsAg chronic carriers. Elsana S, et al. **J Hum Virol** 1997 Nov-Dec; 1(1):52–7

An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice. Arai K, et al. **J Immunol Methods** 1998 Aug 1; 217(1-2):79–85

Absorption of IgG does not enhance toxoplasma IgM and IgA immunoblotting. Chatterton JM, et al. **J Med Microbiol** 1999 Jun;48(6):593–5

Periodontal conditions and salivary immunoglobulins in individuals with Down syndrome. Barr-Agholme M, et al. **J Periodontol** 1998 Oct;69(10):1119–23

Isotype- and subclass-specific responses to infection and reinfection with parainfluenza-3 virus: comparison of the diagnostic potential of ELISAs detecting seroconversion and specific IgM and IgA. Graham DA, et al. **J Vet Diagn Invest** 1999 Mar;11(2):127–33

Evaluation of an IgM-specific indirect enzyme-linked immunosorbent assay for serodiagnosis of bovine respiratory syncytial virus infection: influence of IgM rheumatoid factor on test results with field sera. Graham DA, et al. **J Vet Diagn Invest** 1998 Oct;10(4):331–7

Diagnosis of dengue infection by detecting specific immunoglobulin M antibodies in saliva samples. Artimos de Oliveira S, et al. **J Virol Methods** 1999 Jan;77(1):81–6

Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Jónsson T, et al. **Rheumatol Int** 1998;18(3):119–22

Evaluation of Meridian ImmunoCard Mycoplasma test for the detection of Mycoplasma pneumoniae-specific IgM in paediatric patients. Matas L, et al. **Scand J Infect Dis** 1998; 30(3):289–93

Salivary diagnosis of measles for surveillance: a clinic-based study in Niterói, state of Rio de Janeiro, Brazil. Oliveira SA, et al. **Trans R Soc Trop Med Hyg** 1998 Nov-Dec; 92(6):636–8

Determination of salivary and serum immunoglobulin concentrations in the cat. Harley R, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2-4):99–112

[Low concentration monoclonal IgM and demyelinating peripheral neuropathy] Dehan C, et al. **Ann Biol Clin (Paris)** 1999 Mar-Apr;57(2):221–3 **(Fre)**

[Characterization of specific IgG, IgM, IgA and IgE isotypes in profound candidiasis] Toubas D, et al. **Ann Biol Clin (Paris)** 1998 May-Jun;56(3):329–36 (Eng. Abstr.) **(Fre)**

[Development of an enzyme-linked immunosorbent assay (ELISA) for detection of IgM and IgG antibodies to lipopolysaccharide of Escherichia coli O157] Sugawara N, et al. **Kansenshogaku Zasshi** 1999 Jun;73(6):593–9 (Eng. Abstr.) **(Jpn)**

[The presence of antibodies to Borrelia burgdorferi associated with immunologic complexes in sera of foresters] Sobieszczańska BM, et al. **Med Dosw Mikrobiol** 1998; 50(1-2):97–103 (Eng. Abstr.) **(Pol)**

[Filter paper sampling for the detection of anti-hepatitis A IgM antibodies] Rodriguez Lay LA, et al. **Rev Cubana Med Trop** 1998;50(1):42–7 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Benzylpenicillin induced specific non-IgE antibody response in mice. Zhang L, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):531–4

Normal CD40-mediated activation of monocytes and dendritic cells from patients with hyper-IgM syndrome due to a CD40 pathway defect in B cells. Revy P, et al. **Eur J Immunol** 1998 Nov;28(11):3648–54

IgM antibodies to P1 cytoadhesin of Mycoplasma pneumoniae are part of the natural antibody repertoire expressed early in life. Ben-Aissa-Fennira F, et al. **Immunol Lett** 1998 Aug;63(1):59–62

Heterogeneity in the ability of cytotoxic murine NK cell clones to enhance Ig secretion in vitro. Vos Q, et al. **Int Immunol** 1999 Feb;11(2):159–68

Phenotypic and functional characterization of a panel of cytotoxic murine NK cell clones that are heterogeneous in their enhancement of Ig secretion in vitro. Vos Q, et al. **Int Immunol** 1998 Aug;10(8):1093–101

Intestinal IgA- and IgM-producing cells are not decreased in marathon runners. Nilssen DE, et al. **Int J Sports Med** 1998 Aug;19(6):425–31

Estrogen enhances immunoglobulin production by human PBMCs. Kanda N, et al. **J Allergy Clin Immunol** 1999 Feb; 103(2 Pt 1):282–8

Leukocyte transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome. Atkinson TP, et al. **J Clin Immunol** 1998 Nov;18(6):430–9

Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. Leiva LE, et al. **J Clin Immunol** 1998 Jul;18(4):283–90

Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. Kohm AP, et al. **J Immunol** 1999 May 1; 162(9):5299–308

Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. Levin SD, et al. **J Immunol** 1999 Jan 15;162(2):677–83

IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. Oliver AM, et al. **J Immunol** 1999 Jun 15;162(12):7198–207

Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. Pérez-Melgosa M, et al. **J Immunol** 1999 Aug 1;163(3):1123–7

CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. Subauste CS, et al. **J Immunol** 1999 Jun 1;162(11):6690–700

Autoimmunity develops in lupus-prone NZB mice despite normal T cell tolerance. Wither J, et al. **J Immunol** 1998 Nov 1;161(9):4555–62

Method for the preparation of bispecific F(ab')2mu fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments. Morimoto K, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):43–50

Induction of anti-thymocyte/T lymphocyte antibodies in mice injected with lipopolysaccharides from periodontopathic bacteria. Kaneko T, et al. **J Periodontal Res** 1999 Feb;34(2):105–12

Heuristic models of the intermonomeric disulfide bonding process. Evans DA, et al. **J Theor Biol** 1998 Dec 21; 195(4):505–24

Evaluation of the primary humoral immune response following exposure of male rats to 17beta-estradiol or flutamide for 15 days. Ladics GS, et al. **Toxicol Sci** 1998 Nov;46(1):75–82

Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov-Dec; 22(6):421–9 (26 ref.)

Influence of concurrent BVDV infection on the IgM response of calves experimentally infected with bovine respiratory syncytial virus. Graham DA, et al. **Vet Rec** 1998 Aug 15;143(7):198–9

BLOOD

Monozygotic twin brothers with primary immunodeficiency presenting with metastatic adenocarcinoma of unknown primary. Wood LA, et al. **Acta Oncol** 1998;37(7-8):771–2

Serologic response to Bartonella henselae in patients with cat scratch disease and in sick and healthy children. Not T, et al. **Acta Paediatr** 1999 Mar;88(3):284–9

Malaria parasitaemia and immunoglobulin levels in paired maternal-cord sera from south western Nigeria. Achidi EA, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):167–70

Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Glueck CJ, et al. **Am J Cardiol** 1999 May 15;83(10):1490–4, A8

Evaluation of an IgM immunoblot kit for dengue diagnosis. Kuno G, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):757–62

Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM. Bordigoni P, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1111–4

Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. Kato T, et al. **Bone Marrow Transplant** 1999 May;23(10):1081–3

Fresh vs aged benzylpenicillin on non-IgE responses in mice. Zhang L, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan; 19(1):74–6

An IgM paraprotein causing a falsely low result in an enzymatic assay for acetaminophen [letter] Hullin DA. **Clin Chem** 1999 Jan;45(1):155–7

LD-IgG, IgA, IgM complex in a postburn patient. Liu Z, et al. **Clin Chim Acta** 1999 Jul;285(1-2):195–8

Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Helfand RF, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):178–80

Acquired C1 inhibitor deficiency associated with systemic lupus erythematosus, secondary antiphospholipid syndrome and IgM monoclonal paraproteinaemia. Nagy L, et al. **Clin Rheumatol** 1999;18(1):56–8

Enteroviral RNA and IgM antibodies in early pregnancy and risk for childhood-onset IDDM in offspring [letter] Dahlquist GG, et al. **Diabetes Care** 1999 Feb;22(2):364–5

Prevalence of IgM and IgG antibodies to Toxoplasma gondii in blood donors in the Czech Republic. Svobodová V, et al. **Eur J Epidemiol** 1998 Dec;14(8):803–5

CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization. de Saint Basile G, et al. **Eur J Immunol** 1999 Jan;29(1):367–73

Dynamics of serum IgM autoreactive repertoires following immunization: strain specificity, inheritance and association with autoimmune disease susceptibility. Fesel C, et al. **Eur J Immunol** 1998 Nov;28(11):3616–29

Necrotizing toxoplasmic encephalitis in a child with the X-linked hyper-IgM syndrome. Tsuge I, et al. **Eur J Pediatr** 1998 Sep;157(9):735–7

Detection of IgG and IgM to meningococcal outer membrane proteins in relation to carriage of Neisseria meningitidis or Neisseria lactamica. Kremastinou J, et al. **FEMS Immunol Med Microbiol** 1999 May;24(1):73–8

Effects of prolactin and growth hormone on plasma immunoglobulin M levels of hypophysectomized rainbow trout, Oncorhynchus mykiss. Yada T, et al. **Gen Comp Endocrinol** 1999 Jul;115(1):46–52

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219–29

Preliminary evaluation of the potential prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with gastric cancer. Tsavaris N, et al. **Int J Biol Markers** 1998 Apr-Jun;13(2):87–91

Measles IgM immunoreactivity in patients with inflammatory bowel disease [see comments] Balzola FA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):378–82. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):383–4.

CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand. Seyama K, et al. **J Biol Chem** 1999 Apr 16;274(16):11310–20

Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine. Takahashi T, et al. **J Clin Immunol** 1998 Jul;18(4):299–305

Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA. Gutiérrez J, et al. **J Clin Lab Anal** 1999;13(2):65–8

Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen. Hashida S, et al. **J Clin Lab Anal** 1998;12(6):329–36

Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta2glycoprotein I in patients with antiphospholipid syndrome. Lewis S, et al. **J Clin Lab Anal** 1998;12(5):293–7

Reference distributions for immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature. Ritchie RF, et al. **J Clin Lab Anal** 1998;12(6):371–7

Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. Ritchie RF, et al. **J Clin Lab Anal** 1998; 12(6):363–70

Evaluation of hemagglutinin protein-specific immunoglobulin M for diagnosis of measles by an enzyme-linked immunosorbent assay based on recombinant protein produced in a high-efficiency mammalian expression system. Bouche FB, et al. **J Clin Microbiol** 1998 Dec;36(12):3509–13

Immunoglobulin M antibody test to detect genogroup II Norwalk-like virus infection. Brinker JP, et al. **J Clin Microbiol** 1999 Sep;37(9):2983–6

Development and evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay based on the 18-kilodalton matrix protein for diagnosis of primary EBV infection. Chan KH, et al. **J Clin Microbiol** 1998 Nov;36(11):3359–61

Detection of Toscana virus-specific immunoglobulins G and M by an enzyme-linked immunosorbent assay based on recombinant viral nucleoprotein. Ciufolini MG, et al. **J Clin Microbiol** 1999 Jun;37(6):2010–2

Development of specific immunoglobulins G, M, and A following primary Toxoplasma gondii infection in pregnant women. Jenum PA, et al. **J Clin Microbiol** 1998 Oct; 36(10):2907–13

Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM. Lazzarotto T, et al. **J Clin Microbiol** 1998 Nov;36(11):3337–41

Evaluation of the MRL diagnostics dengue fever virus IgM capture ELISA and the PanBio Rapid Immunochromatographic Test for diagnosis of dengue fever in Jamaica. Palmer CJ, et al. **J Clin Microbiol** 1999 May;37(5):1600–1

International multicenter evaluation of the clinical utility of a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human serum specimens. Smits HL, et al. **J Clin Microbiol** 1999 Sep;37(9):2904–9

Evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay using a synthetic convergent peptide library, or mixotope, for diagnosis of

primary EBV infection. Tranchand-Bunel D, et al. **J Clin Microbiol** 1999 Jul;37(7):2366-8

Rapid and sensitive detection of immunoglobulin M (IgM) and IgG antibodies against canine distemper virus by a new recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay. von Messling V, et al. **J Clin Microbiol** 1999 Apr;37(4):1049-56

Diagnosis of Mycoplasma pneumoniae pneumonia in childrea. Waris ME, et al. **J Clin Microbiol** 1998 Nov; 36(11):3155-9

Evaluation of two novel enzyme immunoassays using recombinant antigens to detect cytomegalovirus-specific immunoglobulin M in sera from pregnant women. Daiminger A, et al. **J Clin Virol** 1999 Aug;13(3):161-71

IgM antibodies in hospitalized children with febrile illness during an inter-epidemic period of measles, in Somalia. Nur YA, et al. **J Clin Virol** 1999 Jan;12(1):21-5

Seroprevalence of toxoplasmosis in Jodhpur, India. Joshi YR, et al. **J Commun Dis** 1998 Mar;30(1):32-7

Hepatitis C virus infection-associated non-cryoglobulinaemic monoclonal IgMkappa gammopathy responsive to interferon-alpha treatment. Schott P, et al. **J Hepatol** 1998 Aug;29(2):310-5

Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome. Lacroix-Desmazes S, et al. **J Immunol** 1999 May 1;162(9):5601-8

A one-step solid phase immunoassay for simultaneous detection of serum IgG and IgM antibodies to Borrelia burgdorferi. Schønau A, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):9-17

A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. Porwancher R. **J Infect Dis** 1999 Apr;179(4):1021-4

IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Negro F, et al. **J Med Virol** 1998 Nov;56(3):224-9

Anti-GM2 IgM antibodies: clinical correlates and reactivity with a human neuroblastoma cell line. Cavanna B, et al. **J Neuroimmunol** 1999 Feb 1;94(1-2):157-64

Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. Di Troia A, et al. **J Neurol Sci** 1999 Mar 15;164(1):64-71

Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: their association with cranial nerve dysfunction. Koga M, et al. **J Neurol Sci** 1999 Mar 15;164(1):50-5

The 301 to 314 amino acid residue of beta-tubulin is not a target epitope for serum IgM antibodies in chronic inflammatory demyelinating polyneuropathy. Tagawa Y, et al. **J Neurol Sci** 1999 Feb 1;163(1):44-6

Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. Cunningham CK, et al. **J Pediatr** 1999 May;134(5):584-8

Levels of immunoglobulins and complement C3 in protein-energy malnutrition [letter] Mishra OP, et al. **J Trop Pediatr** 1999 Jun;45(3):179-81

Seroneutralization of porcine reproductive and respiratory syndrome virus correlates with antibody response to the GP5 major envelope glycoprotein. Gonin P, et al. **J Vet Diagn Invest** 1999 Jan;11(1):20-6

Evaluation of an immunofluorescent antibody test to detect bovine herpesvirus 1-specific IgM. Graham DA, et al. **J Vet Diagn Invest** 1999 Jul;11(4):324-9

IgM antibodies to Schistosoma mansoni gut-associated antigens for the study of schistosomiasis transmission in Ribeirão Pires, São Paulo. Camargo-Neves VL, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:273-8

A comparative study on IgG-ELISA, IgM-IFT and Kato-Katz methods for epidemiological purposes in a low endemic area for schistosomiasis. da Silva RM, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:279-82

Immunofluorescence test on Schistosoma mansoni worm paraffin sections (IgM-IFT) for the study of schistosomiasis transmission in Campinas, São Paulo, Brazil. Lima VL, et al. **Mem Inst Oswaldo Cruz** 1998;93 Suppl 1:283-7

IgM paraproteinemia in a patient with primary lateral sclerosis. Desai J, et al. **Neuromuscul Disord** 1999 Jan; 9(1):38-40

IgG subclass/IgM ratio and response to therapy in focal segmental glomerulonecrosis. Fu LW, et al. **Pediatr Nephrol** 1998 Nov;12(9):761-3

Probable false positive coccidioidal serologic results in patients with cystic fibrosis. Dosanjh A, et al. **Pediatr Transplant** 1998 Nov;2(4):313-7

Direct and correlated response to divergent selection for serum immunoglobulin M and G levels in chickens. Sarker N, et al. **Poult Sci** 1999 Jan;78(1):1-7

Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Baumgarth N, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2250-5

Detection of IgM antibodies to Schistosoma mansoni gut-associated antigens for the study of the dynamics of schistosomiasis transmission in an endemic area with low worm burden. Kanamura HY, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):225-31

A comparative epidemiologic study of specific antibodies (IgM and IgA) and parasitological findings in an endemic area of low transmission of schistosoma mansoni. Kanamura HY, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr; 40(2):85-91

Laboratory diagnosis of acute human parvovirus B19 infection by specific IgM detection. Nascimento JP, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):265-6

IgM and IgA antibody responses in 12 cases of human acquired toxoplasmosis. Takahashi EE, et al. **Rev Inst Med Trop Sao Paulo** 1997 Nov-Dec;39(6):327-31

Anti M. leprae IgM antibody determination by ultramicroimmunoenzymatic (UMELISA HANSEN) for the diagnosis and monitoring leprosy. Torrella A, et al. **Rev Inst Med Trop Sao Paulo** 1998 May-Jun;40(3):177-81

Structured reactions of serum IgM repertoires to immunization are dependent on major histocompatibility complex genes. Fesel C, et al. **Scand J Immunol** 1999 Mar; 49(3):251-7

Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Näsman Björk I, et al. **Scand J Immunol** 1999 Jul; 50(1):73-82

Altered pattern of connectivity in serum immunoglobulins from pemphigus vulgaris patients. Pacheco-García U, et al. **Scand J Immunol** 1999 Apr;49(4):424-30

Successful plasmapheresis in the not-so-benign Bickerstaff's brain stem encephalitis associated with anti-GQ1b antibody. Shimokawa M, et al. **Ther Apher** 1998 Aug; 2(3):240-2

Sustained decrease of serum anti-galactose alpha 1-3-galactose antibodies in baboons by removing aerobic gram-negative bacteria from the bowel. Manez R, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):947-8

Reduction of anti-Gal alpha 1-3Gal natural antibodies in sera of alpha 1,3-galactosyltransferase-deficient mice receiving Gal-positive bone marrow transplantation. Ohdan H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):945-6

The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Przybylowski P, et al. **Transplantation** 1999 Jan 27; 67(2):258-62

Prevalence of IgG and IgM antibodies specific to Toxoplasma gondii in cats. Svobodová V, et al. **Vet Parasitol** 1998 Dec 31;80(2):173-6

Detection of IgM antibodies against a recombinant nucleocapsid protein of canine distemper virus in dog sera using a dot-blot assay. Barben G, et al. **Zentralbl Veterinarmed A** 1999 Mar;46(2):115-21

[Protein quantification in the presence of monoclonal IgM (letter; comment) (see comments)] Pontet F. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):623-5. Comment on: Ann Biol Clin (Paris) 1998 Mar-Apr;56(2):209-10. Comment in: Ann Biol Clin (Paris) 1999 Mar-Apr;57(2):238-9. **(Fre)**

[Monoclonal IgM and falsely increased result of complement C4 determination (letter; comment)] Watine J. **Ann Biol Clin (Paris)** 1999 Mar-Apr;57(2):238-9. Comment on: Ann Biol Clin (Paris) 1998 Mar-Apr;56(2):209-10. Comment on: Ann Biol Clin (Paris) 1998 Sep-Oct;56(5):623-5. **(Fre)**

[Interpretation of borreliosis serology. Step-wise diagnosis--introduction to case examples] Hassler D, et al. **Fortschr Med** 1998 Oct 20;116(29):20-2, 24 (16 ref.) **(Ger)**

[Serology in herpes infection] Einsele H, et al. **Internist (Berl)** 1999 May;40(5):565-6 **(Ger)**

[A case of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome with positive anti-galactocerebroside (Gal-C) IgM antibody] Kasuya J, et al. **Rinsho Shinkeigaku** 1999 May;39(5):538-41 (Eng. Abstr.) **(Jpn)**

[A case of multiple sclerosis associated with myelin associated glycoprotein neuropathy] Nakane S, et al. **Rinsho Shinkeigaku** 1998 Dec;38(12):1042-8 (Eng. Abstr.) **(Jpn)**

[IgM myeloma] Hayashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):411-2 (10 ref.) **(Jpn)**

[Immunodeficiency with hyper-IgM] Sugai S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):210-2 (9 ref.) **(Jpn)**

[Evaluation of the usefulness of the ELISA method for determining the level of enterovirus antibodies in serum and cerebrospinal fluid] Binduga I, et al. **Med Dosw Mikrobiol** 1998;50(3-4):277-84 (Eng. Abstr.) **(Pol)**

[Immunological indicators (IgM and C-reactive protein) in neonatal infections] Vaz FA, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):185-95 (Eng. Abstr.) **(Por)**

[Immunoenzyme assay for detection of natural antibodies against vasopressin in systemic lupus erythematosus] Miagkova MA, et al. **Klin Lab Diagn** 1999 Apr;(4):20-4 (Eng. Abstr.) **(Rus)**

[The determination of class-M immunoglobulins in the latex agglutination reaction] Vorob'eva ZG, et al. **Klin Lab Diagn** 1999 May;(5):54-6 (Eng. Abstr.) **(Rus)**

[Class M immunoglobulins from blood serum of patients with systemic lupus erythematosus effectively cleave RNA] Andrievskaia OA, et al. **Mol Biol (Mosk)** 1998 Sep-Oct; 32(5):908-15 **(Rus)**

[Prospective study of the positive IgM value against Toxoplasma gondii in the analytical determination of pregnancy. Analysis of the fetal results (letter)] Jordá B, et al. **Med Clin (Barc)** 1998 Sep 19;111(8):317 **(Spa)**

[A comparison of the results obtained in IgM serology and anti-Coxsackie A9 (strain 47) neutralization in cases of epidemic neuropathy and their contacts] Ribas MA, et al. **Rev Cubana Med Trop** 1995;47(1):50-3 (Eng. Abstr.) **(Spa)**

[The immunoassay of IgM antibodies in samples clinically suspected of measles] Ribas Antúnez MA, et al. **Rev Cubana Med Trop** 1998;50(2):105-9 (Eng. Abstr.) **(Spa)**

CEREBROSPINAL FLUID

Human African trypanosomiasis: a latex agglutination field test for quantifying IgM in cerebrospinal fluid. Lejon V, et al. **Bull World Health Organ** 1998;76(6):553-8

CHEMISTRY

Interference of IgM paraproteins in the Olympus AU800 uric acid assay. Langman LJ, et al. **Clin Biochem** 1998 Oct; 31(7):517-21

Occurrence of heavy chain of 7S IgM half-molecule whose NH2-terminal sequence is identical with that of kappa light chain sequence in patients with Waldenstrom macroglobulinemia. Imoto M, et al. **Clin Chim Acta** 1999 Apr;282(1-2):77-88

Varied redox forms of teleost IgM: an alternative to isotypic diversity? Kaattari S, et al. **Immunol Rev** 1998 Dec; 166:133-42 (60 ref.)

Structural aspects of human IgM antibodies expressed in chronic B lymphocytic leukemia. Ramsland PA, et al. **Immunotechnology** 1999 Mar;4(3-4):217-29

Primary structure of the antigen-binding domains of a human oligodendrocyte-reactive IgM monoclonal antibody derived from a patient with multiple sclerosis. Kirschning E, et al. **J Neuroimmunol** 1999 Sep 1;99(1):122-30

Biogenesis and function of IgM: the role of the conserved mu-chain tailpiece glycans. de Lalla C, et al. **Mol Immunol** 1998 Sep;35(13):837-45

The specificity of synovial IgM rheumatoid factors (RF) for genetically engineered IgG antibodies is not affected by the method used to immortalize RF-producing B cells. Bonagura VR, et al. **Scand J Immunol** 1999 Jan; 49(1):106-11

DEFICIENCY

[Jacobsen's syndrome, thrombopenia and humoral immunodeficiency] Sirvent N, et al. **Arch Pediatr** 1998 Dec; 5(12):1338-40 (Eng. Abstr.) **(Fre)**

[Selective IgM deficiency] Sugai S. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):216-7 (13 ref.) **(Jpn)**

DIAGNOSTIC USE

The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate. Pantuck AJ, et al. **Br J Urol** 1998 Sep;82(3):426-30

DRUG EFFECTS

Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Kato I, et al. **Eur J Epidemiol** 1998 Sep;14(6):621-6

GENETICS

Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization. Gokmen E, et al. **Blood** 1998 Oct 15;92(8):2802-14

Immunoglobulins D and M multiple myeloma variants are heavily mutated. Juge-Morineau N, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2501-6

Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Saini SS, et al. **Eur J Immunol** 1999 Aug;29(8):2420-6

Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hatagima A, et al. **Hum Biol** 1999 Apr;71(2):219-29

Differential regulation of transcription termination occurring at two different sites on the micro-delta gene complex. Kim M, et al. **Int Immunol** 1999 May;11(5):813-24

Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line. Takami Y, et al. **J Biol Chem** 1999 Aug 20; 274(34):23977-90

Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. Messmer BT, et al. **J Immunol** 1999 Feb 15; 162(4):2184-92

IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. Shiokawa S, et al. **J Immunol** 1999 May 15;162(10):6060-70

Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. Zan H, et al. **J Immunol** 1999 Mar 15; 162(6):3437-47

Levels of polyadenylation factor CstF-64 control IgM heavy

chain mRNA accumulation and other events associated with B cell differentiation. Takagaki Y, et al. **Mol Cell** 1998 Dec;2(6):761–71

Identification of a stem–loop structure important for polyadenylation at the murine IgM secretory poly(A) site. Phillips C, et al. **Nucleic Acids Res** 1999 Jan 15;27(2):429–38

Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions. Sakai E, et al.
Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1526–31

Probing the natural antibody repertoire by combinatorial cloning of IgM and IgD isotypes in phage display vectors. Burioni R, et al. **Res Virol** 1998 Sep–Oct;149(5):321–5

[Amplification and sequencing of heavy chain variable region (VH) gene of a human monoclonal antibody (CM–1) with specificity to breast cancer] Chen L, et al.
Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao 1997 Apr; 19(2):150–3 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Partial characterization of two lymphocyte-specific natural autoantibodies isolated from newborn mice. Cervenak J, et al. **Acta Microbiol Immunol Hung** 1999;46(1):53–62

Cytomegalovirus is not associated with IgM anti–myelin–associated glycoprotein/sulphate–3–glucuronyl paragloboside antibody–associated neuropathy. Lunn MP, et al.
Ann Neurol 1999 Aug;46(2):267–70

Accelerated clearance of polyethylene glycol–modified proteins by anti–polyethylene glycol IgM. Cheng TL, et al. **Bioconjug Chem** 1999 May–Jun;10(3):520–8

The 78C --> T (T254M) XHIM mutation: lack of a tight phenotype–genotype relationship [letter] de Vries E, et al. **Blood** 1999 Aug 15;94(4):1488–90

Evidence for an upper affinity threshold for anti–IgM–induced apoptosis in a human B–cell lymphoma. Mongini PK, et al. **Blood** 1998 Nov 15;92(10):3756–71

V(H) gene analysis of IgM–secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Sahota SS, et al. **Blood** 1999 Aug 1;94(3):1070–6

A fatal case of autoimmune thrombocytopenia with an IgM anti–GPIb/IX following one antigen mismatched unrelated donor bone marrow transplantation. Kottaridis PD, et al. **Bone Marrow Transplant** 1999 Apr;23(7):739–41

Correction of neutropenia and hypogammaglobulinemia in X–linked hyper–IgM syndrome by allogeneic bone marrow transplantation. Scholl PR, et al.
Bone Marrow Transplant 1998 Dec;22(12):1215–8

Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B–cells. Cragg MS, et al.
Br J Cancer 1999 Feb;79(5–6):850–7

Delayed haemolytic transfusion reaction due to anti–M antibody. Sancho JM, et al. **Br J Haematol** 1998 Oct; 103(1):268–9

Rejection of tumors of the B cell lineage by idiotype–vaccinated mice. Haimovich J, et al.
Cancer Immunol Immunother 1999 Feb;47(6):330–6

Binding of modified fragments of the Shigella dysenteriae type 1 O–specific polysaccharide to monoclonal IgM 3707 E9 and docking of the immunodeterminant to its modeled Fv. Miller CE, et al. **Carbohydr Res** 1998 Jul;309(3):219–26

Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15. Ball ED, et al. **Clin Cancer Res** 1995 Sep;1(9):965–72

Severe cold agglutinin disease and cryoglobulinemia secondary to a monoclonal anti–Pr2 IgM lambda cryoagglutinin. Ciejka JZ, et al. **Clin Exp Rheumatol** 1999 Mar–Apr;17(2):227–31

Ontogeny of lymphoid organs and immunoglobulin producing cells in Atlantic cod (Gadus morhua L.). Schrøder MB, et al. **Dev Comp Immunol** 1998 Sep–Dec; 22(5–6):507–17

Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study. Kalogeropoulos CD, et al.
Doc Ophthalmol 1998;95(2):109–20

Identification of HSP–60 as the specific antigen of IgM produced by BRG–lymphoma cells. Musante L, et al.
Electrophoresis 1999 Apr–May;20(4–5):1092–7

Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti–IgM. Lin CK, et al. **Exp Cell Res** 1998 Oct 10;244(1):1–13

Human monoclonal IgM DJ binds to ssDNA and human commensal bacteria. Dimitrijević LA, et al.
Hum Antibodies 1999;9(1):37–45

The human uniqueness of HIV: innate immunity and the viral Tat protein. Rodman TC, et al. **Hum Immunol** 1999 Aug; 60(8):631–9

Immunoglobulin double isotype–producing hybridomas isolated from an autoimmune (NZB x NZW)F1 mouse. Payelle–Brogard B, et al. **Hybridoma** 1998 Jun;17(3):289–97

Varied redox forms of teleost IgM: an alternative to isotypic diversity? Kaattari S, et al. **Immunol Rev** 1998 Dec; 166:133–42 (60 ref.)

Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross–reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain–Barré syndrome. Prendergast MM, et al. **Infect Immun** 1999 Jul;67(7):3698–701

Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Zhong Z, et al.
Infect Immun 1999 Aug;67(8):4119–27

A new paradigm of T cell allergy: requirement for the B–1 cell subset. Askenase PW, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):145–9

CpG oligodeoxynucleotides rescue BKS–2 immature B cell lymphoma from anti–IgM–mediated growth inhibition by up–regulation of egr–1. Han SS, et al. **Int Immunol** 1999 Jun;11(6):871–9

Heterogeneity of antibody specificity in Taiwanese patients with polyneuropathy and IgM paraproteinemia. Lin KP, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):441–5

Defects of T–cell effector function and post–thymic maturation in X–linked hyper–IgM syndrome. Jain A, et al. **J Clin Invest** 1999 Apr;103(8):1151–8

Diagnostic value of anti–hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. Casino C, et al.
J Clin Microbiol 1999 Aug;37(8):2726–8

Improvement of immunoglobulin M capture immunoassay specificity: toxoplasma antibody detection method as a model. Tuuminen T, et al. **J Clin Microbiol** 1999 Jan; 37(1):270–3

A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. Boes M, et al.
J Exp Med 1998 Dec 21;188(12):2381–6

Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. Hughey CT, et al. **J Immunol** 1998 Oct 15; 161(8):4091–7

Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Roux KH, et al.
J Immunol 1998 Oct 15;161(8):4083–90

An 11–amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c–Jun N–terminal kinase, activation of MAPKAP kinase–2, phosphorylation of I kappa B alpha, and protection of WEHI–231 cells from anti–IgM–induced growth arrest. Sutherland CL, et al.
J Immunol 1999 Apr 15;162(8):4720–30

Generation of acetylcholine receptor–specific human T cell lines using heterobifunctional antibody–targeted antigen presentation. Wang D, et al. **J Neuroimmunol** 1999 Sep 1;99(1):114–21

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Wilson HC, et al.
J Neurol Neurosurg Psychiatry 1999 May;66(5):575–80

Differences of IgG and IgM antibodies to phospholipids and APTT among non–pregnant and pregnant women. Shimano S, et al. **J Obstet Gynaecol Res** 1998 Aug; 24(4):299–304

Fatal autoimmune hemolytic anemia in a child due to warm–reactive immunoglobulin M antibody. Friedmann AM, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct; 20(5):502–5

Establishment and characterization of a novel ALL–L3 cell line (BALM–18): induction of apoptosis by anti–IgM and inhibition of apoptosis by bone marrow stroma cells. Matsuo Y, et al. **Leuk Res** 1999 Jun;23(6):559–68

Antisense macrophage migration inhibitory factor (MIF) prevents anti–IgM mediated growth arrest and apoptosis of a murine B cell line by regulating cell cycle progression. Takahashi A, et al. **Microbiol Immunol** 1999;43(1):61–7

IgG, IgG1 and IgM response in Trichinella spiralis–infected mice treated with 4–deoxypirydoxine or fed a Vitamin B6–deficient diet. Frydas S, et al. **Mol Cell Biochem** 1999 Apr;194(1–2):47–52

IgM/IgA nephropathy in callitrichids: antigen studies. Brack M, et al. **Nephron** 1999;82(3):221–31

IgM antibody–related polyneuropathies: B–cell depletion chemotherapy using Rituximab. Levine TD, et al.
Neurology 1999 May 12;52(8):1701–4

Antibody–mediated red blood cell agglutination resulting in spontaneous echocardiographic contrast. Miller MR, et al.
Pediatr Cardiol 1999 Jul–Aug;20(4):287–9

IgM anti–dsDNA antibodies in systemic lupus erythematosus–negative association with nephritis. SLE Study Group. Witte T, et al. **Rheumatol Int** 1998;18(3):85–91

Bruton's tyrosine–kinase–deficient murine B lymphocytes fail to enter S phase when stimulated with anti–immunoglobulin plus interleukin–4. Forssell J, et al.
Scand J Immunol 1999 Feb;49(2):155–61

Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. van Doornum G, et al.
Sex Transm Infect 1998 Oct;74(5):354–60

Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Tuhrim S, et al. **Stroke** 1999 Aug; 30(8):1561–5

Demonstration of IgM antibodies of high affinity within the anti–Galalpha1–3Gal antibody repertoire. Lee J, et al.
Transplantation 1998 Oct 27;66(8):1117–9

Field evaluation of a one–step dipstick assay for the diagnosis of human leptospirosis in the Seychelles. Yersin C, et al.
Trop Med Int Health 1999 Jan;4(1):38–45

IgG, but not IgM, mediates hyperacute rejection in hepatic xenografting. Schraa EO, et al. **Xenotransplantation** 1999 May;6(2):110–6

[IgM kappa lymphoma with antisulfatide antibodies revealed by cervical motor neuropathy simulating amyotrophic lateral sclerosis] Baud P, et al. **Rev Med Interne** 1998 Apr; 19(4):275–8 (Eng. Abstr.) **(Fre)**

[Vasopressin: secondary immune response and antigen–specific suppressants] Igonina NA, et al.
Biull Eksp Biol Med 1999 Jan;127(1):60–2 **(Rus)**

[Infectious endocarditis: immune disorders, differentiated therapy] Tatarchenko IP, et al. **Ter Arkh** 1999;71(4):44–7 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Affinity purification of immunoglobulin M using a novel synthetic ligand. Palombo G, et al.
J Chromatogr B Biomed Sci Appl 1998 Sep 11;715(1):137–45

Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmapheresis in Guillain–Barré syndrome: is it equivalent to plasma exchange? Tagawa Y, et al. **Ther Apher** 1997 Nov; 1(4):336–9

METABOLISM

Up–regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Burrows FJ, et al. **Clin Cancer Res** 1995 Dec;1(12):1623–34

CD21high IgMhigh splenic B cells enriched in the marginal zone: distinct phenotypes and functions. Martin F, et al.
Curr Top Microbiol Immunol 1999;246:45–50; discussion 51–2 (9 ref.)

Pre–mRNA splicing of IgM exons M1 and M2 is directed by a juxtaposed splicing enhancer and inhibitor. Kan JL, et al. **Genes Dev** 1999 Feb 15;13(4):462–71

IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Olafsen T, et al.
Immunotechnology 1998 Oct;4(2):141–53

The effects of alpha 2–antiplasmin complex and alpha 2–antiplasmin on the secretion of IgG and IgM by cultured human mononuclear cells. Zhabin SG, et al.
J Clin Lab Immunol 1997;49(2):77–82

Human immunoglobulin (Ig)M + IgD + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. Klein U, et al. **J Exp Med** 1998 Nov 2;188(9):1679–89

Peptide ligands that bind IgM antibodies and block interaction with antigen. Glee PM, et al. **J Immunol** 1999 Jul 15;163(2):826–33

Two human neonatal IgM antibodies encoded by different variable–region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. Messmer BT, et al. **J Immunol** 1999 Feb 15; 162(4):2184–92

Fine specificity of ligand–binding domain 1 in the polymeric Ig receptor: importance of the CDR2–containing region for IgM interaction. Røe M, et al. **J Immunol** 1999 May 15;162(10):6046–52

Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece. Sørensen V, et al. **J Immunol** 1999 Mar 15;162(6):3448–55

Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. Cauci S, et al.
J Infect Dis 1998 Dec;178(6):1698–706

Membrane anchoring of calnexin facilitates its interaction with its targets. Ho SC, et al. **Mol Immunol** 1999 Jan; 36(1):1–12

Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells. Marches R, et al.
Proc Natl Acad Sci U S A 1999 Jul 20;96(15):8711–5

Suppression of immunoglobulin secretion by soluble annexin II. Aarli A, et al. **Scand J Immunol** 1998 Nov;48(5):522–6

[Proteolysis of immunoglobulins--biologically–active supplement in a fermented milk in gastrointestinal system of rats] Gmoshinskii IV, et al. **Vopr Pitan** 1998;(4):5–8 (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Anti–Fas IgM monoclonal antibody enhances apoptosis induced by low–dose cytosine arabinoside. Nakamura S, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):197–204

Immunoglobulin M–enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Rieben R, et al. **Blood** 1999 Feb 1;93(3):942–51

Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. David K, et al. **Cancer Res** 1999 Aug 1;59(15):3768–75

Complement–mediated anti–HIV–1 effect induced by human IgM monoclonal antibody against ganglioside GM2. Wu X, et al. **J Immunol** 1999 Jan 1;162(1):533–9

Differential apoptotic susceptibility to anti–Fas IgM and anticancer drugs in a human endometrial adenocarcinoma cell line HHUA on laminin and type I collagen. Chang L, et al. **Osaka City Med J** 1998 Dec;44(2):173–80

Protective capacity of a IgM/IgA–enriched polyclonal immunoglobulin–G preparation in endotoxemia. Oesser S, et al. **Res Exp Med (Berl)** 1999 Apr;198(6):325–39

PHYSIOLOGY

Membrane IgM–stimulated human B lymphocytes succumb to activation–related apoptosis at a G1-->S transition:

influence of ligand affinity and valency. Mongini PK, et al. **Cell Immunol** 1998 Sep 15;188(2):137–50

Intestinal reperfusion injury is mediated by IgM and complement. Williams JP, et al. **J Appl Physiol** 1999 Mar; 86(3):938–42

Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. Hocini H, et al. **J Infect Dis** 1999 May;179 Suppl 3:S448–53 (35 ref.)

Biogenesis and function of IgM: the role of the conserved mu-chain tailpiece glycans. de Lalla C, et al. **Mol Immunol** 1998 Sep;35(13):837–45

THERAPEUTIC USE

Immunoglobulins in anergic patients: choice of patients, identification of dependent variables, and importance of study [editorial; comment] Christou NV. **Crit Care Med** 1999 Jul;27(7):1387–8. Comment on: Crit Care Med 1999 Jul;27(7):1281–7.

Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery [see comments] Kress HG, et al. **Crit Care Med** 1999 Jul;27(7):1281–7. Comment in: Crit Care Med 1999 Jul;27(7):1387–8.

Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Vassilev T, et al. **Eur J Immunol** 1999 Aug;29(8):2436–42

A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. Fleuridor R, et al. **J Infect Dis** 1998 Oct;178(4):1213–6

Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Novitzky N, et al. **Transplantation** 1999 Feb 27;67(4):620–6

Inhibition of liver metastases from neuraminidase-treated colon 26 cells by an anti-Thomsen-Friedenreich-specific monoclonal antibody. Shigeoka H, et al. **Tumour Biol** 1999 May-Jun;20(3):139–46

[Use of octagam and pentaglobin in the treatment of severe sepsis in the neonatal period] Barinov AV, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):59–60 (Eng. Abstr.) **(Rus)**

URINE

Proteinuria selectivity index based upon alpha 2-macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases. Technical note. Tencer J, et al. **Kidney Int** 1998 Dec;54(6):2098–105

IGUANAS

Serratia marcescens cellulitis following an iguana bite. Hsieh S, et al. **Clin Infect Dis** 1999 May;28(5):1181–2

ANATOMY & HISTOLOGY

Growth and morphometrics of green iguanas (Iguana iguana) fed four levels of dietary protein. Donoghue S, et al. **J Nutr** 1998 Dec;128(12 Suppl):2587S–2589S

GENETICS

Molecular tests of phylogenetic taxonomies: a general procedure and example using four subfamilies of the lizard family Iguanidae. Schulte JA, et al. **Mol Phylogenet Evol** 1998 Dec;10(3):367–76

GROWTH & DEVELOPMENT

Growth and morphometrics of green iguanas (Iguana iguana) fed four levels of dietary protein. Donoghue S, et al. **J Nutr** 1998 Dec;128(12 Suppl):2587S–2589S

METABOLISM

Tissue and plasma enzyme activities in juvenile green iguanas. Wagner RA, et al. **Am J Vet Res** 1999 Feb;60(2):201–3

MICROBIOLOGY

Simultaneous occurrence of Salmonella arizonae in a sulfur crested cockatoo (Cacatua galerita galerita) and iguanas. Orós J, et al. **Avian Dis** 1998 Oct-Dec;42(4):818–23

PARASITOLOGY

Isolation and identification by partial sequencing of the 18S ribosomal gene of free-living amoebae from necrotic tissue of Basiliscus plumifrons (Sauria: Iguanidae). Walochnik J, et al. **Parasitol Res** 1999 Jul;85(7):601–3

PHYSIOLOGY

Behavior of juvenile lizards (Iguana iguana) in a conflict between temperature regulation and palatable food. Balasko M, et al. **Brain Behav Evol** 1998;52(6):257–62

VIROLOGY

Replication of reptilian paramyxovirus in avian host systems. Ahne W, et al. **Zentralbl Veterinarmed [B]** 1999 Feb; 46(1):57–62

IKE PHAGE see **INOVIRUS**

IL-1 see **INTERLEUKIN-1**

IL-1 ALPHA see **INTERLEUKIN-1**

IL-1 BETA see **INTERLEUKIN-1**

IL-1 BETA-CONVERTING ENZYME see **CASPASE 1**

IL-1 RECEPTORS see **RECEPTORS, INTERLEUKIN-1**

IL-2 see **INTERLEUKIN-2**

IL-2 RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

IL-3 see **INTERLEUKIN-3**

IL-3 RECEPTORS see **RECEPTORS, INTERLEUKIN-3**

IL-4 see **INTERLEUKIN-4**

IL-4 RECEPTORS see **RECEPTORS, INTERLEUKIN-4**

IL-5 see **INTERLEUKIN-5**

IL-6 see **INTERLEUKIN-6**

IL-6 RECEPTORS see **RECEPTORS, INTERLEUKIN-6**

IL-7 see **INTERLEUKIN-7**

IL-7 RECEPTORS see **RECEPTORS, INTERLEUKIN-7**

IL-8 see **INTERLEUKIN-8**

IL-9 see **INTERLEUKIN-9**

IL-10 see **INTERLEUKIN-10**

IL-11 see **INTERLEUKIN-11**

IL-12 see **INTERLEUKIN-12**

IL-13 see **INTERLEUKIN-13**

IL-15 see **INTERLEUKIN-15**

IL-16 see **INTERLEUKIN-16**

IL-17 see **INTERLEUKIN-17**

IL-18 see **INTERLEUKIN-18**

ILARVIRUS

GENETICS

Genome activation in alfamo- and ilarviruses. Jaspars EM. **Arch Virol** 1999;144(5):843–63 (95 ref.)

Differentiation among isolates of prunus necrotic ringspot virus by transcript conformation polymorphism. Rosner A, et al. **J Virol Methods** 1998 Sep;74(1):109–15

ISOLATION & PURIFICATION

Ilarvirus isolation and RNA extraction. Guo D, et al. **Methods Mol Biol** 1998;81:171–81

METABOLISM

In vitro evidence for RNA binding properties of the coat protein of prunus necrotic ringspot ilarvirus and their comparison to related and unrelated viruses. Pallás V, et al. **Arch Virol** 1999;144(4):797–803

PHYSIOLOGY

Alfalfa mosaic virus and ilarviruses: involvement of coat protein in multiple steps of the replication cycle. Bol JF. **J Gen Virol** 1999 May;80 (Pt 5):1089–102 (100 ref.)

ILEAL CONDUIT see **URINARY DIVERSION**

ILEAL DISEASES

[Acquired jejunal and ileal diverticula (Meckel's excluded)] Huguenin A, et al. **Ann Chir** 1999;53(6):522–6 (28 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

CT findings of isolated small bowel angioedema due to iodinated radiographic contrast medium reaction. Kim SH, et al. **Abdom Imaging** 1999 Mar-Apr;24(2):117–9

Ulcer on Bauhin's valve induced by oral iron therapy. Stolte M, et al. **Endoscopy** 1999 Mar;31(3):S15–6

Use of intraoperative enteroscopy to diagnose nonsteroidal anti-inflammatory drug injury to the small intestine. Achanta KK, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):544–6

All-trans retinoic acid-induced vasculitis and hemonecrosis of the ileum in a patient with acute promyelocytic leukemia [letter] Yamada K, et al. **Leukemia** 1999 Apr;13(4):647–8

[An ileal ulcer and diaphragm-type colonic stenosis due to diclofenac] Aguirre Palacio A, et al. **Gastroenterol Hepatol** 1999 May;22(5):232–4 (21 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Painless intussusception and altered mental status. Birkhahn R, et al. **Am J Emerg Med** 1999 Jul;17(4):345–7

Giant omphalocele filled by a duplication cyst. Kiriştioğlu I, et al. **Eur J Pediatr Surg** 1998 Oct;8(5):315–6

Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease [see comments] Brink MA, et al. **Gastroenterology** 1999 Jun; 116(6):1420–7. Comment in: Gastroenterology 1999 Jun;116(6):1492–4.

Lipomatosis of the small intestine and colon associated with intussusception in the ileocecal region. Tatsuguchi A, et al. **Gastrointest Endosc** 1999 Jan;49(1):118–21

Intussusception at the onset of acute lymphoblastic leukemia in a child. Kumari TP, et al. **Indian Pediatr** 1998 May; 35(5):470–2

An unusual case of ileocaecal tuberculosis in an 80-year-old Caucasian male. Kelly J, et al. **Int J Clin Pract** 1999 Jan-Feb;53(1):77–9

Spontaneous jejunoileal fistula associated with intestinal strangulation [letter] Umehara M, et al. **J Clin Gastroenterol** 1999 Apr;28(3):281–2

Multiple tubercular ulcer perforation of ileum in an AIDS patient: case report. Deb T, et al. **J Commun Dis** 1998 Sep; 30(3):175–8

Idiopathic localized dilatation of the ileum. A rare cause of gastrointestinal haemorrhage in an adult. Simpson S, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1234–6

[Primary chronic ulcerative jejunoileitis complicated by hemophagocytic syndrome] Galoo E, et al. **Gastroenterol Clin Biol** 1999 Jun-Jul;23(6–7):783–7 (Eng. Abstr.) **(Fre)**

[Colonic involvement in ileal Crohn's disease] Peschard S, et al. **Gastroenterol Clin Biol** 1998 Jun-Jul;22(6–7):594–600 (Eng. Abstr.) **(Fre)**

[A case of ileal diverticulum with a foreign body manifested by digestive tract bleeding] Yoshikawa K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug;96(8):969–72 **(Jpn)**

[Association of small intestine multiple diverticula with "kissing" ulcers] Temnyshev SV. **Khirurgiia (Mosk)** 1999; (2):56 **(Rus)**

[Aberrant pancreas in ileum as the cause of anemia (letter)] Bernardos J, et al. **Rev Esp Enferm Dig** 1998 Sep; 90(9):668–9 **(Spa)**

DIAGNOSIS

Extensive reflux of air during enema for intussusception without reduction: case report. Murakami JW, et al. **Can Assoc Radiol J** 1998 Oct;49(5):334–5

Answer to case of the month #57. Gallstone ileus. Zander DR, et al. **Can Assoc Radiol J** 1998 Oct;49(5):344–7

Use of intraoperative enteroscopy to diagnose nonsteroidal anti-inflammatory drug injury to the small intestine. Achanta KK, et al. **Gastrointest Endosc** 1999 Apr;49(4 Pt 1):544–6

Polypoid vascular malformations of the small intestine. Krinsky ML, et al. **Gastrointest Endosc** 1998 Nov; 48(5):530–3

Ileocecal tuberculosis. Raufman JP, et al. **Gastrointest Endosc** 1998 Dec;48(6):617

Two way push videoenteroscopy in investigation of small bowel disease. Bouhnik Y, et al. **Gut** 1998 Aug;43(2):280–4

Enterogenous duplication cyst presenting as obstructed inguinal hernia. Iyer S, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):123

Acute intermittent abdominal pain. Brown DF, et al. **J Emerg Med** 1998 Sep-Oct;16(5):751–3

Enterovesical fistula complicating pregnancy. A case report. Forsnes EV, et al. **J Reprod Med** 1999 Mar;44(3):297–8

Percutaneous cecostomy as access for small-bowel endoscopy. Rattner Z, et al. **J Vasc Interv Radiol** 1998 Nov-Dec;9(6):968–70

Ileosigmoid knotting in a 6-year-old child. Meier DE, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):407–8

Small-bowel pandiverticulosis--a potential source of recurrent gastrointestinal bleeding. Report of a case and review of the literature. Hazzan D, et al. **Scand J Gastroenterol** 1998 Dec;33(12):1321–3

A rare case of intestinal tuberculosis in a child. Poddar B, et al. **Trop Gastroenterol** 1999 Apr-Jun;20(2):88–9

[Comparison of push-type endoscopy and barium transit study of the small intestine in digestive bleeding and unexplained iron-deficiency anemia] Cellier C, et al. **Gastroenterol Clin Biol** 1998 May;22(5):491–4 (Eng. Abstr.) **(Fre)**

[Gastrointestinal hemorrhage in a 22-year-old patient] Wiest GH, et al. **Med Klin** 1999 Jun 15;94(6):338 **(Ger)**

[Diagnosis of gallstone ileus] Aschoff AJ, et al. **Z Gastroenterol** 1998 Sep;36(9):853–8 (49 ref.) (Eng. Abstr.) **(Ger)**

[Obstruction of terminal ileum due to heterotopic gastric mucosa] Atik FA, et al. **Rev Assoc Med Bras** 1998 Oct-Dec;44(4):340–3 (Eng. Abstr.) **(Por)**

[Nodular lymphoid hyperplasia of the colon and terminal ileum. Case report] Peršić M, et al. **Lijec Vjesn** 1998 Mar-Apr;120(3–4):62–4 (Eng. Abstr.) **(Scr)**

EMBRYOLOGY

[Meconium peritonitis and feto-fetal transfusion syndrome] Melissari M, et al. **Pathologica** 1999 Feb;91(1):25-30 (Eng. Abstr.) **(Ita)**

ETIOLOGY

Ileal obstruction caused by idiopathic sclerosing encapsulating peritonitis. Kim MY, et al. **Abdom Imaging** 1999 Jan-Feb;24(1):82-4

Intussusception in Peutz-Jeghers syndrome: sonographic findings. Naganuma H, et al. **Abdom Imaging** 1999 Jul-Aug; 24(4):333-5

Separate sac of peritoneum: a case of an unusual cause of intestinal obstruction. Petrakis I, et al. **Am J Gastroenterol** 1999 Feb;94(2):518-9

Radiological case of the month. Intermittent ileocolic intussusception caused by an unusual choristoma. Iuchtman M, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):763-4

Gallstone ileus with impaction at the neck of a Meckel's diverticulum. Nakamoto Y, et al. **Br J Radiol** 1998 Dec; 71(852):1320-2

False-negative FDG PET imaging in a patient with metastatic melanoma and ileal intussusception. Alibazoglu H, et al. **Clin Nucl Med** 1999 Feb;24(2):129

Adult ileocolic intussusception as presenting finding of primary large bowel lymphoma. Gotian A, et al. **Dig Dis** 1999;17(1):62

Acute necrotizing Meckel diverticulitis due to biliary enterolithiasis. Emparan C, et al. **Dig Surg** 1998; 15(4):369-71

Postoperative intussusception in childhood: case report. Ameh EA. **East Afr Med J** 1999 Jan;76(1):54-5

Transvaginal evisceration of small bowel after radical hysterectomy and pelvic lymphadenectomy. Dawlatly B, et al. **Gynecol Oncol** 1999 Apr;73(1):165-6 (5 ref.)

Small bowel obstruction following blunt abdominal trauma. Lane TM, et al. **Injury** 1998 Jul;29(6):484-5

Small bowel obstruction as a complication of laparoscopic extraperitoneal inguinal hernia repair. Eugene JR, et al. **J Am Osteopath Assoc** 1998 Sep;98(9):510-1

Small intestinal ulceration secondary to carcinoid tumour arising in a Meckel's diverticulum. McCluggage WG, et al. **J Clin Pathol** 1999 Jan;52(1):72-4

Intussusception following a baby walker injury. Conners GP, et al. **J Emerg Med** 1999 Mar-Apr;17(2):269-71

Acute gallbladder distension and recurrent small bowel intussusception in a child with celiac disease. González JA, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):444-5

Intussusception caused by blunt abdominal trauma. Brooks A, et al. **J Trauma** 1999 Jul;47(1):156-7

Small bowel obstruction caused by intussusception after the ingestion of a plastic clip. Beall DP, et al. **Md Med J** 1999 Jan-Feb;48(1):23-5

Unusual vascular dysplasia presenting as an intra-abdominal catastrophe. Menon P, et al. **Pediatr Surg Int** 1999 Jul; 15(5-6):440-1

Delayed mid-ileal perforation secondary to acute-on-chronic ischaemia after a diagnostic colonoscopy. Chau TN, et al. **Scand J Gastroenterol** 1998 Sep;33(9):1002-4

Small bowel obstruction secondary to stapled laparoscopically assisted vaginal hysterectomy. Huntington TR, et al. **Surg Endosc** 1999 Mar;13(3):246-9

Ileal volvulus on internal hernia following left laparoscopic-assisted hemicolectomy. Elio A, et al. **Surg Laparosc Endosc** 1998 Dec;8(6):477-8

Enterocutaneous fistula as a postoperative complication of laparoscopic inguinal hernia repair. Klein AM, et al. **Surg Laparosc Endosc** 1999 Jan;9(1):60-2

Ovarian carcinoma with fistula formation to the sigmoid colon and ileum: report of a case. Kim SJ, et al. **Surg Today** 1999;29(5):449-52

Laparoscopic ileocecal resection for Crohn's disease associated with intestinal stenosis and ileorectal fistula. Watanabe M, et al. **Surg Today** 1999;29(5):446-8

Coloenteric fistula from chicken-bone perforation of the sigmoid colon. Read TE, et al. **Surgery** 1999 Mar; 125(3):354-6

Retained surgical sponge: an unusual cause of malabsorption. Sinha SK, et al. **Trop Gastroenterol** 1999 Jan-Mar; 20(1):42-4

[Small-bowel duplication, apropos of a case in a child] Wandaogo A, et al. **Dakar Med** 1998;43(1):126-8 (Eng. Abstr.) **(Fre)**

[A case of intestinal obstruction after migration of esophageal endoprosthesis] Berti S, et al. **Minerva Chir** 1999 Jun; 54(6):433-6 (Eng. Abstr.) **(Ita)**

[Cystic lymphangioma of the mesentery. A case of intestinal obstruction and a brief review of the literature] Fundarò S, et al. **Minerva Chir** 1998 Nov;53(11):939-42 (19 ref.) (Eng. Abstr.) **(Ita)**

[Endometriosis of the ileum and colon complicated by intestinal obstruction. Report of two cases] Croce P, et al. **Minerva Ginecol** 1999 May;51(5):189-92 (Eng. Abstr.) **(Ita)**

[Entero-vesical fistula caused by a foreign body] Garritano A, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):125-7 (Eng. Abstr.) **(Ita)**

[Dermoid cyst with thyroid follicle perforated into bladder and ileum: a case report] Suzuki M, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 May;90(5):586-9 (Eng. Abstr.) **(Jpn)**

[Uncommon cause of acute intestinal obstruction] Astakhov GI, et al. **Khirurgiia (Mosk)** 1998;(12):56 **(Rus)**

[Acute intestinal obstruction with foreign body] Sten'ko VG, et al. **Khirurgiia (Mosk)** 1999;(3):64 **(Rus)**

[Crohn disease with recurrent free intestinal perforation (letter)] del Olmo Martínez ML, et al. **Gastroenterol Hepatol** 1999 May;22(5):258 (5 ref.) **(Spa)**

[Severe lower digestive hemorrhage in Crohn's disease] Ortiz V, et al. **Gastroenterol Hepatol** 1999 Jan;22(1):18-21 (15 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Familial idiopathic intussusception: a report of two families. Kurzbart E, et al. **J Pediatr Surg** 1999 Mar;34(3):493-4

MICROBIOLOGY

Single-layer closure for typhoid perforations of the small intestine: case report. Connolly DP, et al. **East Afr Med J** 1998 Jul;75(7):439-40

PARASITOLOGY

Bowel perforation with Taenia saginata [letter] Jain PK, et al. **Indian Pediatr** 1998 Aug;35(8):797

PATHOLOGY

Heterotopic pancreas as lead point in intussusception: new variant of vitellointestinal tract malformation. Abel R, et al. **Pediatr Dev Pathol** 1999 Jul-Aug;2(4):367-70

[2 case reports of inflammatory tumors of the ileocecal part of the intestine] Cherkasov VA, et al. **Vestn Khir Im I I Grek** 1999;158(3):81-2 **(Rus)**

[Chronic non granulomatous ulcerative jejunitis] Elizalde Apestegui IR, et al. **Gastroenterol Hepatol** 1998 Aug-Sep; 21(7):342-5 (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Protective effects of a culture supernatant of Lactobacillus acidophilus and antioxidants on ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Bing SR, et al. **Microbiol Immunol** 1998;42(11):745-53

RADIOGRAPHY

Ileal actinomycosis in a patient with AIDS. Litt HI, et al. **AJR Am J Roentgenol** 1999 May;172(5):1297-9

CT diagnosis of ileal diverticulitis. Macari M, et al. **Clin Imaging** 1998 Jul-Aug;22(4):243-5

Crohn's disease presenting as intermittent ileocolic intussusception. Kihiczak D, et al. **Clin Pediatr (Phila)** 1998 Oct;37(10):635-8

Pain after small bowel meal and pneumocolon: a randomized controlled trial of carbon dioxide versus air insufflation. Gellett LR, et al. **Clin Radiol** 1999 Jun;54(6):381-3

Quiz case 2. Intestinal occlusion due to a fragment of gastric phytobenzoar impacted in an intestinal loop. Hidalgo A, et al. **Eur J Radiol** 1998 Sep;28(2):114-6

Chronic intussusception in childhood. Schulman H, et al. **Eur Radiol** 1998;8(8):1455-6

[Ileal crohn disease associated with serous cystadenoma of the ovary] Chagnon S, et al. **J Radiol** 1998 Dec; 79(12):1534-5 **(Fre)**

[Computerized tomography in the study of jejuno-ileal perforations. Personal case load] Pinto A, et al. **Radiol Med (Torino)** 1998 Dec;96(6):602-6 (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Scintigraphy of ileal hemorrhage from metastasis of renal cell carcinoma. Nguyen BD, et al. **Clin Nucl Med** 1998 Jul;23(7):464-5

[99mTc pertechnetate scintigraphy and premedication for the search for ectopic gastric mucosa in Meckel's diverticulum] Rampin L, et al. **Minerva Chir** 1998 Nov;53(11):877-82 (Eng. Abstr.) **(Ita)**

[Scintigraphic studies in abdominal vascular diseases] Estorch Cabrera M. **Rev Esp Med Nucl** 1998;17(5):372-9 **(Spa)**

SURGERY

Single-layer closure for typhoid perforations of the small intestine: case report. Connolly DP, et al. **East Afr Med J** 1998 Jul;75(7):439-40

Transvaginal evisceration of small bowel after radical hysterectomy and pelvic lymphadenectomy. Dawlatly B, et al. **Gynecol Oncol** 1999 Apr;73(1):165-6 (5 ref.)

A case of Crohn's disease with recurrent massive life-threatening hemorrhage from terminal ileum. Egawa T, et al. **Hepatogastroenterology** 1999 May-Jun; 46(27):1695-8

Carcinoid tumor of the ileum with intestinal obstruction. Nozoe T, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1013-5

Transient pseudo-hypoaldosteronism following resection of the ileum: normal level of lymphocytic aldosterone receptors outside the acute phase. Vantyghem MC, et al. **J Endocrinol Invest** 1999 Feb;22(2):122-7

Laparoscopy in the treatment of intussusception in children. Poddoubnyi IV, et al. **J Pediatr Surg** 1998 Aug; 33(8):1194-7

The prognostic factors in typhoid ileal perforation: a prospective study of 50 cases [letter; comment] Loefler IJ. **J R Coll Surg Edinb** 1998 Oct;43(5):359-60. Comment on: J R Coll Surg Edinb 1997 Dec;42(6):395-9.

Acute small bowel obstruction due to ileal endometriosis: a case report and literature review. Wickramasekera D, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):59-60 (7 ref.)

Postoperative complications after surgery for typhoid perforation in children in Ghana. Abantanga FA, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):55-8

Ileosigmoid knotting in a 6-year-old child. Meier DE, et al. **Pediatr Surg Int** 1999 Jul;15(5-6):407-8

The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn's disease. Yamamoto T, et al. **Surg Today** 1999;29(6):579-80

[Intestinal invagination and HIV infection] Halkic N, et al. **Ann Chir** 1999;53(6):531-4 **(Fre)**

[The treatment procedure in cholelithic intestinal obstruction] Ivashchenko VV, et al. **Klin Khir** 1998;(9-10):13-5 (Eng. Abstr.) **(Rus)**

[Intestinal invagination in the adult] Piñero Madrona A, et al. **Gastroenterol Hepatol** 1998 Oct;21(8):398-400 (Eng. Abstr.) **(Spa)**

THERAPY

Reduction of intussusception in children using sonographic guidance. Peh WC, et al. **AJR Am J Roentgenol** 1999 Oct; 173(4):985-8

Embolization of the vasa recta in acute lower gastrointestinal hemorrhage: A report of five cases. Ledermann HP, et al. **Cardiovasc Intervent Radiol** 1999 Jul-Aug;22(4):315-20

Intussusception in infants and children: feasibility of ambulatory management. Le Masne A, et al. **Eur J Pediatr** 1999 Sep;158(9):707-10

Enteroliths in a Kock continent ileostomy: endoscopic diagnosis and management. Geller A, et al. **Gastrointest Endosc** 1998 Sep;48(3):306-8

Idiopathic intussusception: the role of laparoscopy. Hay SA, et al. **J Pediatr Surg** 1999 Apr;34(4):577-8

[Diffuse jejuno-ileitis of Crohn's disease: a separate form of the disease?] Touze I, et al. **Gastroenterol Clin Biol** 1999 Mar;23(3):307-11 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Intussusception in Peutz-Jeghers syndrome: sonographic findings. Naganuma H, et al. **Abdom Imaging** 1999 Jul-Aug; 24(4):333-5

[Ultrasonography in the diagnosis of enterocutaneous fistula in Crohn's disease] Cerro P, et al. **Radiol Med (Torino)** 1998 Sep;96(3):214-7 (Eng. Abstr.) **(Ita)**

VETERINARY

Ileocecocolic intussusception in a one-month-old llama. Costarella CE, et al. **J Am Vet Med Assoc** 1999 Jun 1; 214(11):1672-3, 1640

What is your diagnosis? Small intestinal obstruction as a result of incarceration in a diaphragmatic hernia. Ethell MT, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):321-2

Parietal hernia of the small intestine into the epiploic foramen of a horse. Hammock PD, et al. **J Am Vet Med Assoc** 1999 May 1;214(9):1354-6, 1334-5

Comparison of the effects of Clostridium perfringens type D culture supernates in ligated intestinal loops of goats and sheep. Uzal FA, et al. **J Comp Pathol** 1999 Aug; 121(2):127-38

Multiple persistent vitelline duct cysts in a dog. Frazier KS, et al. **Vet Pathol** 1998 Nov;35(6):541-2

Surgical reduction of ileal impactions in the horse: 28 cases. Hanson RR, et al. **Vet Surg** 1998 Nov-Dec;27(6):555-60

[Cecal intussusception in calves] Doll K, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1998 Sep; 26(5):247-53 (Eng. Abstr.) **(Ger)**

ILEAL NEOPLASMS

COMPLICATIONS

Synchronous occurrence of carcinoid tumour of the appendix and T-cell lymphoma of the ileum. A case report with review of the literature. Lindboe CF, et al. **APMIS** 1999 May;107(5):523-8

Tuberculosis and lymphoma of the ileum: unusual association and challenge to diagnosis. Lam KY, et al. **Aust N Z J Surg** 1999 Jul;69(7):543-4

Malignant gastrointestinal stromal tumor of the small intestine: rare complication of acute disseminated intravascular coagulation without hematogenous metastasis. Nishimura M, et al. **Dig Dis Sci** 1998 Oct; 43(10):2271-7

Coincidence of Crohn's disease and a high-risk gastrointestinal stromal tumor of the terminal ileum. Pfeffel F, et al. **Digestion** 1999 Jul-Aug;60(4):363-6

Metastases from a regressed malignant melanoma as a cause of haemoperitoneum. Wong LS, et al. **Eur J Surg Oncol** 1999 Apr;25(2):227

Biclonal lymphoplasmacytic immunocytoma associated with Crohn's disease. Hara T, et al. **Intern Med** 1999 Jun; 38(6):500-3

Familial adenomatous polyposis: a case report and histologic mucin study. Mimura T, et al. **J Clin Gastroenterol** 1999 Jun;28(4):372-6 (39 ref.)

A case of ureteric obstruction, retroperitoneal fibrosis, and

carcinoid tumour. Dev S, et al. **Postgrad Med J** 1999 Jan; 75(879):38–40

[A rare form of intestinal perforation: adenocarcinoma of the ileum. Presentation of a clinical case] Cossavella D, et al. **Minerva Chir** 1998 May;53(5):431–3 (Eng. Abstr.) **(Ita)**

[Ileal angiolipoma in a patient with multisystemic manifestations of tuberous sclerosis: diagnosis with computerized tomography] Ferrozzi F, et al. **Radiol Med (Torino)** 1998 Oct;96(4):403–5 **(Ita)**

[Spontaneous peripelvic urine extravasation associated with ileocecal cancer: a case report] Nakayama M, et al. **Hinyokika Kiyo** 1999 Jan;45(1):53–5 (Eng. Abstr.) **(Jpn)**

[A case report of intussusception due to an inflammatory fibroid polyp in the ileum] Kida H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Nov;95(11):1240–3 **(Jpn)**

DIAGNOSIS

Tuberculosis and lymphoma of the ileum: unusual association and challenge to diagnosis. Lam KY, et al. **Aust N Z J Surg** 1999 Jul;69(7):543–4

Small bowel carcinoid presenting as a barolith. Regan JK, et al. **Clin Imaging** 1999 Jan–Feb;23(1):22–5

Adenocarcinoid of ileum and appendix, incidentally discovered during exploratory laparotomy for gastric MALT lymphoma, with subsequent diffuse prostatic metastases: report of a case with light, immunohistochemical, and electron microscopic studies. McGregor DH, et al. **Dig Dis Sci** 1999 Jan;44(1):87–95

Coincidence of Crohn's disease and a high-risk gastrointestinal stromal tumor of the terminal ileum. Pfeffel F, et al. **Digestion** 1999 Jul–Aug;60(4):363–6

Squamous cell carcinoma in an ileal conduit. Yamada Y, et al. **Int J Urol** 1998 Nov;5(6):613–4

Anaplastic and sarcomatoid carcinoma of the small intestine: an unusual tumor. Agrawal S, et al. **J Clin Gastroenterol** 1999 Jul;29(1):99–101

Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids. Cunningham RT, et al. **J Pathol** 1999 Feb;187(3):321–5

Cystic lymphangioma in an asymptomatic newborn: an uncommon localization in the ileum. Haber HP, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):446–8

A case of solitary cavernous hemangioma of the small intestine with recurrent clinical anemic attacks in childhood. Sakaguchi M, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):342–3

[The stepchild of intestinal diagnosis. Evaluation of radiologic methods in the diagnosis of leiomyoma of the small intestine] Keberle M, et al. **Aktuelle Radiol** 1998 Nov; 8(6):253–9 (Eng. Abstr.) **(Ger)**

[Primary neoplasms of the jejunum-ileum. The clinico-diagnostic and surgical therapy considerations: the clinical cases and a retrospective study of our experience] Calabrese L, et al. **Acta Biomed Ateneo Parmense** 1998; 69(3–4):73–95 (Eng. Abstr.) **(Ita)**

[Carcinoid tumor presenting as intestinal necrosis (letter)] Zazpe C, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):889–90 **(Spa)**

EPIDEMIOLOGY

Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. Stang A, et al. **Br J Cancer** 1999 Jul;80(9):1440–4

Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Bernardis V, et al. **Digestion** 1999 Jan–Feb;60(1):82–5 (16 ref.)

Incidence of neoplastic polyps in ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy. Grady W. **Gastrointest Endosc** 1998 Dec; 48(6):647–50

ETIOLOGY

Intra-abdominal angiosarcomatosis after radiotherapy. Suzuki F, et al. **J Gastroenterol Hepatol** 1999 Mar; 14(3):289–92

[Ileocolic linitis in Crohn's disease] Dumontier I, et al. **Gastroenterol Clin Biol** 1998 Jun–Jul;22(6–7):642–5 (Eng. Abstr.) **(Fre)**

[Enterovesical fistula in patient with Crohn disease] Erdozain JC, et al. **Rev Esp Enferm Dig** 1998 Oct;90(10):726–8 **(Spa)**

PATHOLOGY

Measurement of gut diamine oxidase activity. Diamine oxidase as a new biologic marker of colorectal proliferation? Raithel M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:262–6

Endoscopic diagnosis of ileocecal mucosa-associated lymphoid tissue lymphoma. Hasegawa N, et al. **Gastrointest Endosc** 1999 Jul;50(1):115–7 (7 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30–1999. An 86-year-old man with gastrointestinal bleeding and small-bowel obstruction [clinical conference] **N Engl J Med** 1999 Sep 30;341(14):1063–71

Signet-ring cell carcinoma of the ileum: report of a case and review of the Japanese literature. Iizawa H, et al. **Surg Today** 1998;28(11):1168–71 (14 ref.)

[Leiomyosarcoma of the terminal ileum] Villanueva Sáenz E, et al. **Rev Gastroenterol Mex** 1998 Jul–Sep;63(3):170 **(Spa)**

PHYSIOPATHOLOGY

Increased intestinal non-substance P tachykinin concentrations in malignant midgut carcinoid disease. Makridis C, et al. **J Gastroenterol Hepatol** 1999 May; 14(5):500–7

RADIOGRAPHY

[A case of intestinal lymphoma of the last ileal loop] Savastano M, et al. **Radiol Med (Torino)** 1999 May; 97(5):435–7 **(Ita)**

[Computerized tomography findings in intestinal carcinoid] Vinci R, et al. **Radiol Med (Torino)** 1998 Sep;96(3):209–13 (Eng. Abstr.) **(Ita)**

[A case of lymphangioma of the small intestine] Ishikawa N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Aug; 96(8):959–63 **(Jpn)**

RADIONUCLIDE IMAGING

Stromal tumor causing small intestinal bleeding: scintigraphic localization. Chandramouly BS, et al. **Clin Nucl Med** 1999 Mar;24(3):204–5

[Neuroendocrine carcinoma] Kacl GM, et al. **Schweiz Med Wochenschr** 1998 Nov 28;128(48):1915 **(Ger)**

SECONDARY

Small bowel metastases from primary carcinoma of the lung: clinical findings and outcome. Berger A, et al. **Am J Gastroenterol** 1999 Jul;94(7):1884–7

Scintigraphy of ileal hemorrhage from metastasis of renal cell carcinoma. Nguyen BD, et al. **Clin Nucl Med** 1998 Jul;23(7):464–5

Metastases from a regressed malignant melanoma as a cause of haemoperitoneum. Wong LS, et al. **Eur J Surg Oncol** 1999 Apr;25(2):227

SURGERY

Carcinoid tumor of the ileum with intestinal obstruction. Nozoe T, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):1013–5

ULTRASONOGRAPHY

Inflammatory fibroid polyp presenting with intestinal invagination: sonographic and correlative imaging findings. Dicle O, et al. **J Clin Ultrasound** 1999 Feb;27(2):89–91

ILEAL RESERVOIRS see **PROCTOCOLECTOMY, RESTORATIVE**

ILEITIS

BLOOD

Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Barbier M, et al. **Gut** 1998 Dec;43(6):783–90

CHEMICALLY INDUCED

Regional variation in the histological appearance of the small and large intestine of the rat following acute and chronic administration of Melo's Conquer Mixture. Didia BC, et al. **West Afr J Med** 1999 Apr–Jun;18(2):110–3

DIAGNOSIS

Cutaneous larva migrans, sacroileitis, and optic neuritis caused by an unidentified organism acquired in Thailand. Potasman I, et al. **J Travel Med** 1998 Dec;5(4):223–5

DRUG THERAPY

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Prantera C, et al. **Gastroenterology** 1999 Mar;116(3):521–6

Glutamine attenuates leukocyte-endothelial cell adhesion in indomethacin-induced intestinal inflammation in the rat. Arndt H, et al. **JPEN J Parenter Enteral Nutr** 1999 Jan–Feb;23(1):12–8

ETIOLOGY

Ileitis terminalis in a patient with Henoch–Schönlein purpura. Ortego-Centeno N, et al. **Dig Dis Sci** 1999 Aug; 44(8):1590–3

Prospective evaluation of transabdominal bowel sonography in the diagnosis of intestinal obstruction in Crohn's disease: comparison with plain abdominal film and small bowel enteroclysis. Kohn A, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):153–7

METABOLISM

Differential inflammatory modulation of canine ileal longitudinal and circular muscle cells. Shi XZ, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):G341–50

Mechanism of inhibition of Na+-bile acid cotransport during chronic ileal inflammation in rabbits. Sundaram U, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1259–65

Corticosteroids reverse the inhibition of Na-glucose cotransport in the chronically inflamed rabbit ileum. Sundaram U, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G211–8

Correlation of desensitisation of platelet activating factor (PAF) receptors with intensity of inflammation and intestinal PAF content during experimental ileitis in guinea pig. Jeanneton O, et al. **Gut** 1998 Sep;43(3):356–64

MICROBIOLOGY

Mycobacterium avium infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis. Kim SY, et al. **J Med Microbiol** 1998 Aug; 47(8):725–31

Intestinal ulceration, obstruction, and haemorrhage in congenital syphilis. Ajayi NA, et al. **Pediatr Surg Int** 1999 Jul;15(5–6):391–3

PARASITOLOGY

Cutaneous larva migrans, sacroileitis, and optic neuritis caused by an unidentified organism acquired in Thailand. Potasman I, et al. **J Travel Med** 1998 Dec;5(4):223–5

PATHOLOGY

Hyperthermia prevents functional, histological and biochemical abnormalities induced during ileitis. Goldhill JM, et al. **Neurogastroenterol Motil** 1999 Feb;11(1):69–76

Regional variation in the histological appearance of the small and large intestine of the rat following acute and chronic administration of Melo's Conquer Mixture. Didia BC, et al. **West Afr J Med** 1999 Apr–Jun;18(2):110–3

PHYSIOPATHOLOGY

Hyperthermia prevents functional, histological and biochemical abnormalities induced during ileitis. Goldhill JM, et al. **Neurogastroenterol Motil** 1999 Feb;11(1):69–76

SURGERY

[Tuberculous ileotyphlitis] Dantsig II, et al. **Khirurgiia (Mosk)** 1999;(6):64 **(Rus)**

ULTRASONOGRAPHY

Prospective evaluation of transabdominal bowel sonography in the diagnosis of intestinal obstruction in Crohn's disease: comparison with plain abdominal film and small bowel enteroclysis. Kohn A, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):153–7

VETERINARY

Effect of peroral anti-bacterial antiserum treatment on intestinal immune parameters of germ-free piglets intragastrically infected with virulent Salmonella typhimurium or enteropathogenic E. coli. Trebichavský I, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):55–65

Control of porcine proliferative enteropathy by oral administration of chlortetracycline. McOrist S, et al. **Vet Rec** 1999 Jan 9;144(2):48–9

ILEITIS, REGIONAL see **CROHN DISEASE**

ILEITIS, TERMINAL see **CROHN DISEASE**

ILEOANAL POUCHES see **PROCTOCOLECTOMY, RESTORATIVE**

ILEOCECAL VALVE

Painless intussusception and altered mental status. Birkhahn R, et al. **Am J Emerg Med** 1999 Jul;17(4):345–7

Adult ileocolic intussusception as presenting finding of primary large bowel lymphoma. Gotian A, et al. **Dig Dis** 1999;17(1):62

Ulcer on Bauhin's valve induced by oral iron therapy. Stolte M, et al. **Endoscopy** 1999 Mar;31(3):S15–6

Treatment of total colonic aganglionosis by a modified Martin procedure--a preliminary report. Ajuluchuku EU, et al. **Eur J Pediatr Surg** 1998 Oct;8(5):317–9

Ileocecal tuberculosis. Raufman JP, et al. **Gastrointest Endosc** 1998 Dec;48(6):617

Lipomatosis of the small intestine and colon associated with intussusception in the ileocecal region. Tatsuguchi A, et al. **Gastrointest Endosc** 1999 Jan;49(1):118–21

Acute intermittent abdominal pain. Brown DF, et al. **J Emerg Med** 1998 Sep–Oct;16(5):751–3

Radiographic findings in intussusception. Moats T. **J Emerg Med** 1999 Mar–Apr;17(2):335–6

Intussusception in an infant with acute lymphoblastic leukemia: a case report and review of the literature. Manglani MV, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct;20(5):467–8

PATHOLOGY

Endoscopic diagnosis of ileocecal mucosa-associated lymphoid tissue lymphoma. Hasegawa N, et al. **Gastrointest Endosc** 1999 Jul;50(1):115–7 (7 ref.)

PHYSIOLOGY

Role of the ileocecal junction in the motor response to intestinal resection. Thompson JS, et al. **J Gastrointest Surg** 1998 Mar-Apr;2(2):174-85

RADIOGRAPHY

Intussusception in infants: an emergency in diagnosis and treatment. Roeyen G, et al. **Eur J Emerg Med** 1999 Mar; 6(1):73-6

SURGERY

The importance of ileocaecal integrity in the arthritic complications of Crohn's disease. Orchard TR, et al. **Inflamm Bowel Dis** 1999 May;5(2):92-7

[Antibacterial treatment in patients after extended bowel resection with ileo-cecal valve removal--personal experience] Paluszkiewicz P, et al. **Pol Arch Med Wewn** 1998 Nov;100(5):437-41 (Eng. Abstr.) **(Pol)**

[Tuberculous ileotyphlitis] Dantsig II, et al. **Khirurgiia (Mosk)** 1999;(6):64 **(Rus)**

[The treatment procedure in cholelithic intestinal obstruction] Ivashchenko VV, et al. **Klin Khir** 1998;(9-10):13-5 (Eng. Abstr.) **(Rus)**

ILEOCOLITIS see **CROHN DISEASE**

ILEOJEJUNAL BYPASS see **JEJUNOILEAL BYPASS**

ILEOSTOMY

Techniques and complications of ileostomy takedown. Phang PT, et al. **Am J Surg** 1999 Jun;177(6):463-6

Another case of high gentamicin clearance and volume of distribution in a patient with high output ileostomy [letter] McDonald S. **Aust N Z J Med** 1998 Dec;28(6):847-8

How large should a skin trephine be for an end stoma? Nguyen MH, et al. **Aust N Z J Surg** 1999 Sep;69(9):675-6

The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers. Burggraaf J, et al. **Br J Clin Pharmacol** 1998 Sep;46(3):207-14

Conversion of failed ileal pouch-anal anastomosis to continent ileostomy. Behrens DT, et al. **Dis Colon Rectum** 1999 Apr;42(4):490-5; discussion 495-6

Continent ileostomy can be offered as an option to patients who fail the ileal pouch-anal anastomosis (IPAA) [letter] Behrens DT, et al. **Dis Colon Rectum** 1999 May;42(5):686

Retrograded high-amylose corn starch reduces cholic acid excretion from the small bowel in ileostomy subjects. Langkilde AM, et al. **Eur J Clin Nutr** 1998 Nov; 52(11):790-5

Loop ileostomy: technical aspects and complications. Carlsen E, et al. **Eur J Surg** 1999 Feb;165(2):140-3; discussion 144

Intraluminal bypass instead of covering ileostomy in ileal pouch-anal anastomosis. Gyrtrup HJ, et al. **Eur J Surg** 1998 Oct;164(10):791-2

Crohn's colitis: the fate of the rectum. Geoghegan JG, et al. **Int J Colorectal Dis** 1998;13(5-6):256-9

Defunctioning loop ileostomy: a prospective audit. O'Toole GC, et al. **J Am Coll Surg** 1999 Jan;188(1):6-9

Familial adenomatous polyposis: a case report and histologic mucin study. Mimura T, et al. **J Clin Gastroenterol** 1999 Jun;28(4):372-6 (39 ref.)

Plum stones: an unusual cause of ileostomy obstruction demonstrated by sonography. Jain M, et al. **J Clin Ultrasound** 1998 Oct;26(8):416-7

Selective increase in gastric mucosal mRNA encoding basolateral Na-K-2Cl cotransporter following ileostomy in the rat. Hallonquist H, et al. **J Gastrointest Surg** 1998 May-Jun;2(3):238-43

Absorption and urinary excretion of the coffee diterpenes cafestol and kahweol in healthy ileostomy volunteers. De Roos B, et al. **J Intern Med** 1998 Dec;244(6):451-60

Nondigestibility characteristics of inulin and oligofructose in humans. Andersson HB, et al. **J Nutr** 1999 Jul;129(7 Suppl):1428S-30S (24 ref.)

Restorative proctocolectomy in children with ulcerative colitis utilizing rectal mucosectomy with or without diverting ileostomy. Dolgin SE, et al. **J Pediatr Surg** 1999 May;34(5):837-9; discussion 839-40

Long-term outcome of total colectomy and ileostomy for Crohn disease. Yamamoto T, et al. **Scand J Gastroenterol** 1999 Mar;34(3):280-6

[Stoma physiology] Stern J, et al. **Chirurg** 1999 Jun; 70(6):627-34 (35 ref.) (Eng. Abstr.) **(Ger)**

[A method for reducing the risk of infection in newborn and premature infants with stomas] Schäfer K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1172-4 (Eng. Abstr.) **(Ger)**

[Principles of rehabilitation of patients with ileostomy] Palmeri R, et al. **Chir Ital** 1997;49(4-5):43-6 (13 ref.) (Eng. Abstr.) **(Ita)**

[Pregnancy and delivery in a patient after ileocystoplasty] Majek A, et al. **Ginekol Pol** 1998 Oct;69(10):771-4 (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Temporary decompression after colorectal surgery: randomized comparison of loop ileostomy and loop colostomy [letter; comment] Torkington J, et al. **Br J Surg** 1998 Oct;85(10):1452. Comment on: Br J Surg 1998 Jan;85(1):76-9.

Complications of abdominal stoma surgery. Shellito PC. **Dis Colon Rectum** 1998 Dec;41(12):1562-72 (113 ref.)

Amikacin gel administration in the treatment of peristomal dermatitis. La Torre F, et al. **Drugs Exp Clin Res** 1998; 24(3):153-7

Arterial thrombosis: a complication of loop ileostomy. Ashkan K, et al. **Eur J Gastroenterol Hepatol** 1998 Sep; 10(9):795-6

Colonic resection in trauma: colostomy versus anastomosis. Murray JA, et al. **J Trauma** 1999 Feb;46(2):250-4

[Abdominal skin affection caused by ectopic gut mucosa] Ainsworth AP, et al. **Ugeskr Laeger** 1999 May 31; 161(22):3300-1 (Eng. Abstr.) **(Dan)**

INSTRUMENTATION

[Laparoscopic stoma technique] Schlemminger R, et al. **Chirurg** 1999 Jun;70(6):656-61 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Stoma creation for fecal diversion: is the laparoscopic technique appropriate? Schwandner O, et al. **Int J Colorectal Dis** 1998;13(5-6):251-5

Mucous fistula refeeding in neonates with short bowel syndrome. Al-Harbi K, et al. **J Pediatr Surg** 1999 Jul; 34(7):1100-3

The role of intestinal stoma in patients with spinal cord injury. Kelly SR, et al. **Spinal Cord** 1999 Mar;37(3):211-4

Initial experience using a catheterizable ileovesicostomy (Monti procedure) in children. Cain MP, et al. **Urology** 1998 Nov;52(5):870-3

[The continent ileostomy. Current indications, techniques and results] Ecker KW. **Chirurg** 1999 Jun;70(6):635-42 (Eng. Abstr.) **(Ger)**

[Permanent stomata] Falkenberg B, et al. **Chirurg** 1999 Jun; 70(6):643-9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Loop enterostomy] Rosen HR, et al. **Chirurg** 1999 Jun; 70(6):650-5 (38 ref.) (Eng. Abstr.) **(Ger)**

[What patient needs which stoma?] Säuberli H, et al. **Zentralbl Chir** 1998;123(12):1370-4 (9 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Coming of age with an ostomy. Life with a stoma may be especially difficult for teens. O'Brien BK. **Am J Nurs** 1999 Aug;99(8):71-6

PSYCHOLOGY

Coming of age with an ostomy. Life with a stoma may be especially difficult for teens. O'Brien BK. **Am J Nurs** 1999 Aug;99(8):71-6

ILEUM

see related
ILEOSTOMY

The clinical significance of acquired jejunoileal diverticula. de Bree E, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2523-8

Rapunzel syndrome--a case report. Singla SL, et al. **Am J Gastroenterol** 1999 Jul;94(7):1970-1

Adenosquamous carcinoma of the small intestine. Report of a case and review of the literature. Ngo N, et al. **Arch Pathol Lab Med** 1999 Aug;123(8):739-42 (32 ref.)

Phytobezoar: a rare cause of intestinal obstruction. Rubin M, et al. **Dig Surg** 1998;15(1):52-4

Rapunzel syndrome [letter] Sarin YK. **Indian Pediatr** 1998 Jul;35(7):682-3

Intra-abdominal abscess due to patient non-compliance after construction of an ileal neobladder: case report and review of the literature. Doehn C, et al. **Int J Urol** 1999 May; 6(5):264-7 (12 ref.)

An unusual foreign body in the bowel lumen causing obstruction in a neonate. Tander B, et al. **J Pediatr Surg** 1999 Aug;34(8):1289-90

Small bowel obstruction caused by intussusception after the ingestion of a plastic clip. Beall DP, et al. **Md Med J** 1999 Jan-Feb;48(1):23-5

Sponge bezoar: a rare cause of abdominal pain. McAlinden MG, et al. **Ulster Med J** 1999 May;68(1):36-7

Successful closure of neovesicocutaneous fistula with fibrin glue. Morita T, et al. **Urol Int** 1998;61(2):130-1

Use of a laparoscopic insufflation port for ileal conduit endoscopy. Chang DT, et al. **Urology** 1999 Feb;53(2):412-3

[Outcome of nonspecific right iliac fossa pain syndromes] Groebli Y, et al. **Ann Chir** 1998;52(10):959-64 (Eng. Abstr.) **(Fre)**

[Incarceration and ileus of small bowel in omental bursa] Frolov BA. **Khirurgiia (Mosk)** 1999;(1):60 **(Rus)**

[Acute intestinal obstruction with foreign body] Stenko VG, et al. **Khirurgiia (Mosk)** 1999;(3):64 **(Rus)**

[Intestinal perforation caused by a foreign body (letter)] Martinez Turnes A, et al. **Rev Esp Enferm Dig** 1998 Oct; 90(10):731-2 **(Spa)**

ABNORMALITIES

Increased frequency of cystic fibrosis among infants with jejunoileal atresia. Roberts HE, et al. **Am J Med Genet** 1998 Aug 6;78(5):446-9

Jejunoileal atresia: a 27-year experience. Sato S, et al. **J Pediatr Surg** 1998 Nov;33(11):1633-5

[Small-bowel duplication, apropos of a case in a child] Wandaogo A, et al. **Dakar Med** 1998;43(1):126-8 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Arrangement of the tunica muscularis in the ileal papilla of swine. Prado IM, et al. **Anat Anz** 1999 Jul;181(4):339-44

BLOOD SUPPLY

Cellular pathways of mast cell- and capsaicin-sensitive nerve-evoked ileal submucosal arteriolar dilations. Atwood L, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1063-72

The role of mast cell degranulation in ischaemia-reperfusion-induced mucosal injury in the small intestine. Boros M, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):79-84

Dopexamine attenuates flow motion in ileal mucosal arterioles in normotensive sepsis [see comments] Madorin WS, et al. **Crit Care Med** 1999 Feb;27(2):394-400. Comment in: Crit Care Med 1999 Feb;27(2):257-8.

Ileal varices associated with recurrent bleeding in a patient with liver cirrhosis. Ohtani T, et al. **J Gastroenterol** 1999 Apr;34(2):264-8 (12 ref.)

Low-volume resuscitation with a hemoglobin-based oxygen carrier after hemorrhage improves gut microvascular oxygenation in swine. van Iterson M, et al. **J Lab Clin Med** 1998 Nov;132(5):421-31

IL-6 knock-out mice exhibit resistance to splanchnic artery occlusion shock. Cuzzocrea S, et al. **J Leukoc Biol** 1999 Sep;66(3):471-80

Microvascular oxygen pressure in the pig intestine during haemorrhagic shock and resuscitation. Sinaasappel M, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):245-53

The abdominoinguinal incision: the equivalent of thoracoabdominal incision for the lower quadrants of the abdomen. Karakousis CP. **J Surg Oncol** 1998 Dec; 69(4):249-57

Indomethacin-induced disturbances in villous microcirculation in the rat ileum. Ruh J, et al. **Microvasc Res** 1999 Sep;58(2):137-43

Small-bowel volvulus during treatment for renal tumors. Yule SM, et al. **Pediatr Hematol Oncol** 1998 Sep-Oct; 15(5):455-8

Delayed mid-ileal perforation secondary to acute-on-chronic ischaemia after a diagnostic colonoscopy. Chau TN, et al. **Scand J Gastroenterol** 1998 Sep;33(9):1002-4

[Aneurysm rupture of the ileocolic artery, multiple aneurysms, renal arteriovenous fistula and fatal aortic rupture in Ehlers-Danlos syndrome, subtype IV] Heiss U, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):608-10 **(Ger)**

CHEMISTRY

Identification and characterization of a novel rat triosephosphate isomerase gene in remnant ileum after massive small bowel resection. Wang Y, et al. **Dig Dis Sci** 1999 Jan;44(1):25-32

Contractile protein isoforms of single and cultured smooth muscle cells from guinea pig ileum. Iijima M, et al. **J Smooth Muscle Res** 1998 Oct-Dec;34(5-6):193-205

A comparative study of the backbone dynamics of two closely related lipid binding proteins: bovine heart fatty acid binding protein and porcine ileal lipid binding protein. Lücke C, et al. **Mol Cell Biochem** 1999 Feb;192(1-2):109-21

Short-chain fatty acids present in the ileum inhibit fasting gastrointestinal motility in conscious pigs. Cuche G, et al. **Neurogastroenterol Motil** 1999 Jun;11(3):219-25

CYTOLOGY

The expression and activation of EGF and c-NEU receptors are increased in enterocytes during intestinal adaptation. Falcone RA Jr, et al. **J Pediatr Surg** 1999 May;34(5):663-7

The effect of epidermal growth factor on differentiation of isolated enterocytes after small bowel resection. Falcone RA Jr, et al. **J Pediatr Surg** 1999 Jan;34(1):209-13

DRUG EFFECTS

Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Izzo AA, et al. **Br J Pharmacol** 1998 Aug;124(7):1363-8

Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum. Romanelli L, et al. **Br J Pharmacol** 1999 Jun;127(4):909-18

Microtubule cytoskeleton involvement in muscarinic suppression of voltage-gated calcium channel current in guinea-pig ileal smooth muscle. Unno T, et al. **Br J Pharmacol** 1999 Aug;127(7):1703-11

GABA(B) receptor antagonism by 7-MBFG, a benzo[b]furan analogue of baclofen, in central and peripheral tissues. Ong J, et al. **Can J Physiol Pharmacol** 1998 Jul-Aug; 76(7-8):798-801

An action of erythromycin in the intestine that is not mediated via motilin receptors. Furness JB, et al.

Clin Exp Pharmacol Physiol 1999 Feb;26(2):100–4

Dopexamine attenuates flow motion in ileal mucosal arterioles in normotensive sepsis [see comments] Madorin WS, et al. **Crit Care Med** 1999 Feb;27(2):394–400. Comment in: Crit Care Med 1999 Feb;27(2):257–8.

The difference in the inhibitory mechanisms of papaverine on vascular and intestinal smooth muscles. Kaneda T, et al. **Eur J Pharmacol** 1998 Aug 21;355(2–3):149–57

Pharmacological evidence that neuropeptides mediate part of the actions of scorpion venom on the guinea pig ileum. Matos IM, et al. **Eur J Pharmacol** 1999 Mar 5; 368(2–3):231–6

Comparison of gamma-aminobutyric acid effects in different parts of the cat ileum. Pencheva N, et al. **Eur J Pharmacol** 1999 Feb 26;368(1):49–56

Pertussis toxin increases isoproterenol induced relaxation in field-stimulated ileum [published erratum appears in Eur J Pharmacol 1999 May 21;372(3):329] Sawyer G, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):81–4

Different pathways for Ca2+ mobilization by angiotensin II and carbachol in the circular muscle of the guinea-pig ileum. Shimuta SI, et al. **Eur J Pharmacol** 1999 Feb 12; 367(1):59–66

Pharmacological characterization of histamine H3 receptors in human saphenous vein and guinea pig ileum. Valentine AF, et al. **Eur J Pharmacol** 1999 Jan 29;366(1):73–8

Apparent digestibility and glycaemic responses to an experimental induced viscosity dietary fibre incorporated into an enteral formula fed to dogs cannulated in the ileum. Murray SM, et al. **Food Chem Toxicol** 1999 Jan;37(1):47–56

Ileal and colonic contractions by endothelin-1 in experimentally induced paralytic ileus in rats. Tekin E, et al. **Gen Pharmacol** 1999 Jun;32(6):631–5

A substance P receptor antagonist (FK 888) modifies gut alterations induced by ionizing radiation. Esposito V, et al. **Int J Radiat Biol** 1998 Nov;74(5):625–32

Interactions of new and conventional H3-antagonists with non-histaminergic receptors involved in neurogenic and myogenic contractile responses of guinea-pig ileum. Barocelli E, et al. **J Auton Pharmacol** 1999 Feb;19(1):7–17

Antihistaminic and anticholinergic activity of barberry fruit (Berberis vulgaris) in the guinea-pig ileum. Shamsa F, et al. **J Ethnopharmacol** 1999 Feb;64(2):161–6

Tyrosine kinase regulatory action on ileal muscarinic effects of IFN-gamma. Sales ME, et al. **J Interferon Cytokine Res** 1999 Apr;19(4):375–82

Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. Massimino SP, et al. **J Nutr** 1998 Oct;128(10):1786–93

An investigation of the actions of the essential oils of Manuka (Leptospermum scoparium) and Kanuka (Kunzea ericoides), Myrtaceae on guinea-pig smooth muscle. Lis-Balchin M, et al. **J Pharm Pharmacol** 1998 Jul; 50(7):809–11

Pharmacological properties of pteleprenine, a quinoline alkaloid extracted from Orixa japonica, on guinea-pig ileum and canine left atrium. Seya K, et al. **J Pharm Pharmacol** 1998 Jul;50(7):803–7

Comparison of functional antagonism between isoproterenol and M2 muscarinic receptors in guinea pig ileum and trachea. Ostrom RS, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):969–76

Effects of Dai-kenchu-to on intestinal obstruction following laparotomy. Hayakawa T, et al. **J Smooth Muscle Res** 1999 Apr;35(2):47–54

Acute portal hypertension increases ileal vulnerability to platelet-activating factor in rats. Sakaguchi T, et al. **J Surg Res** 1999 Sep;86(1):116–22

Potentiation by neurotensin of carbachol-induced tension development in beta-escin-skinned smooth muscle of guinea-pig ileum. Unno T, et al. **J Vet Med Sci** 1998 Nov; 60(11):1227–32

Relationship between muscarinic autoinhibition and the inhibitory effect of morphine on acetylcholine release from myenteric plexus of guinea pig ileum. Nishiwaki H, et al. **Jpn J Pharmacol** 1998 Aug;77(4):271–8

Relationship between inhibitory effect of endogenous opioid via mu-receptors and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum. Nishiwaki H, et al. **Jpn J Pharmacol** 1998 Aug; 77(4):279–86

Inhibitory effect of endomorphin-1 and -2 on acetylcholine release from myenteric plexus of guinea pig ileum. Nishiwaki H, et al. **Jpn J Pharmacol** 1998 Sep;78(1):83–6

Selective 5-hydroxytryptamine3 (5-HT3) receptor blocking activity of KB-R6933, a novel benzimidazole derivative. Ozaki A, et al. **Jpn J Pharmacol** 1999 May;80(1):25–32

Indomethacin-induced disturbances in villous microcirculation in the rat ileum. Ruh J, et al. **Microvasc Res** 1999 Sep;58(2):137–43

Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Capasso A. **Neuropharmacology** 1999 Jun;38(6):871–7

The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations. Dobson CL, et al. **Pharm Res** 1999 Jan; 16(1):92–6

Fluoroquinolone-induced motor changes in the guinea-pig isolated ileum. Di Nucci A, et al. **Pharmacol Toxicol** 1998 Dec;83(6):263–9

Impairment of GABA-mediated contractions of rat isolated ileum by experimental diabetes. Ozdem SS, et al. **Pharmacology** 1999 Sep;59(3):165–70

Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and Chelidonium majus extracts on isolated guinea-pig ileum [letter] Hiller KO, et al. **Planta Med** 1998 Dec;64(8):758–60

Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets. Endo T, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jun;100(3):243–53

Effects of cadmium chloride on the paracellular barrier function of intestinal epithelial cell lines. Duizer E, et al. **Toxicol Appl Pharmacol** 1999 Mar 1;155(2):117–26

ENZYMOLOGY

Ileal nitric oxide formation is altered in the young rat in response to endotoxin: effects of exposure to alcohol in utero. Weisbrodt NW, et al. **Alcohol** 1999 Apr;17(3):247–51

The role of xanthine oxidase in platelet activating factor induced intestinal injury in the rat. Qu XW, et al. **Gut** 1999 Feb;44(2):203–11

Distribution of NADPH diaphorase-positive neurons in the enteric nervous system of the rabbit intestine. Junquera C, et al. **Neurochem Res** 1998 Oct;23(10):1233–40

Corticotropin-releasing hormone acts on guinea pig ileal smooth muscle via protein kinase A. Duridanova DB, et al. **Pflugers Arch** 1999 Jul;438(2):205–12

[The effect of dexamethasone and thyroxine on the ratio of membrane and soluble forms of intestinal disaccharidases in ontogenesis of rats] Gordova LA, et al. **Dokl Akad Nauk** 1999 Mar;365(1):135–7 **(Rus)**

GROWTH & DEVELOPMENT

Phenotypic comparison of ileal intraepithelial lymphocyte populations of suckling and weaned calves. Wyatt CR, et al. **Vet Immunol Immunopathol** 1999 Feb 22;67(3):213–22

IMMUNOLOGY

Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta. Rocha MFG, et al. **Infect Immun** 1998 Oct;66(10):4910–6

INJURIES

Ileal penetration by a Multiload-Cu 375 intrauterine contraceptive device. A case report with review of the literature [published erratum appears in Contraception 1998 Dec;58(6):following 389] Chen CP, et al. **Contraception** 1998 Nov;58(5):295–304 (36 ref.)

[Perforation of the small intestine after nephro-uretero-lithotripsy by ESWL--a rare complication] Kurtz V, et al. **Chirurg** 1999 Mar;70(3):306–7 (Eng. Abstr.) **(Ger)**

INNERVATION

Evidence for NO. redox form of nitric oxide as nitrergic inhibitory neurotransmitter in gut. Goyal RK, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G1185–92

Analysis of fast synaptic pathways in myenteric plexus of guinea pig ileum. LePard KJ, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G529–38

Involvement of nitric oxide in extrinsic nervous control of ileal contractile activity. Mizhorkova Z, et al. **Brain Res Bull** 1998 Sep 15;47(2):151–4

NADPH-diaphorase positive myenteric neurons in the ileum of guinea-pig, rat, rabbit and cat: a comparative study. Wilhelm M, et al. **Eur J Morphol** 1998 Jul;36(3):143–52

Structural, neuronal, and functional adaptive changes in atrophic rat ileum. Ekelund KM, et al. **Gut** 1999 Aug; 45(2):236–45

Depletion of the enteric nervous system by gene targeting results in haemorrhagic necrosis of the ileum. MacDonald TT. **Gut** 1998 Dec;43(6):742–3

Abnormalities of nerve fibers in the circular muscle of patients with slow transit constipation. Porter AJ, et al. **Int J Colorectal Dis** 1998;13(5–6):208–16

The topography, architecture and structure of the enteric nervous system in the jejunum and ileum of cattle. Balemba OB, et al. **J Anat** 1999 Jul;195 (Pt 1):1–9

The effects of age on the overall population and on sub-populations of myenteric neurons in the rat small intestine. Johnson RJ, et al. **J Anat** 1998 May;192 (Pt 4):479–88

The three-dimensional structure of myenteric neurons in the guinea-pig ileum. Hanani M, et al. **J Auton Nerv Syst** 1998 Jun 30;71(1):1–9

The role of histamine H1, H2 and H3 receptors on enteric ascending synaptic transmission in the guinea pig ileum. Izzo AA, et al. **J Pharmacol Exp Ther** 1998 Dec; 287(3):952–7

Topographical and electrophysiological characteristics of highly excitable S neurones in the myenteric plexus of the guinea-pig ileum. Smith TK, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):817–30

Evidence that inhibitory motor neurons of the guinea-pig small intestine exhibit fast excitatory synaptic potentials mediated via P2X receptors. Johnson PJ, et al. **Neurosci Lett** 1999 May 14;266(3):169–72

Substance P immunoreactive nerves and interstitial cells of Cajal in the rat and guinea-pig ileum. A histochemical and quantitative study. Vannucchi MG, et al. **Neurosci Lett** 1999 Jun 11;268(1):49–52

Ascending neural pathways in the isolated guinea-pig ileum: effect of muscarinic M1, M2 and M3 cholinergic antagonists. Izzo AA, et al. **Neuroscience** 1999; 91(4):1575–80

Neurokinin B- and substance P-like immunoreactivity are co-localized in enteric nerves of rat ileum. Yunker AM, et al. **Regul Pept** 1999 Mar 17;80(1–2):67–74

METABOLISM

Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Akhter S, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):C136–44

Prostaglandin-induced recovery of barrier function in porcine ileum is triggered by chloride secretion. Blikslager AT, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G28–36

Effects of pH changes on systems ASC and B in rabbit ileum. Munck BG, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G173–84

Transcobalamin II synthesized in the intestinal villi facilitates transfer of cobalamin to the portal blood. Quadros EV, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):G161–6

Corticosteroids reverse the inhibition of Na-glucose cotransport in the chronically inflamed rabbit ileum. Sundaram U, et al. **Am J Physiol** 1999 Jan;276(1 Pt 1):G211–8

Assessment of net postprandial protein utilization of 15N-labelled milk nitrogen in human subjects. Bos C, et al. **Br J Nutr** 1999 Mar;81(3):221–6

Assessment of apparent ileal digestibility of amino acids and nitrogen in cottonseed and soyabean meals fed to pigs determined using ileal dissection under halothane anaesthesia or following carbon dioxide-stunning. Prawirodigdo S, et al. **Br J Nutr** 1998 Aug;80(2):183–91

Characterization and tissue location of the neural adenosine receptor in the rat ileum. Coupar IM. **Br J Pharmacol** 1999 Mar;126(5):1269–75

In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Croci T, et al. **Br J Pharmacol** 1998 Dec;125(7):1393–5

NPY receptor subtype in the rabbit isolated ileum. Félétou M, et al. **Br J Pharmacol** 1999 Jun;127(3):795–801

[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum. Hemedah M, et al. **Br J Pharmacol** 1999 Jan;126(1):179–88

Spermine affects intestinal in vitro permeability to different-sized molecules in rats. Osman NE, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):211–6

Morphological and immunohistochemical changes in intestinal mucosa and PYY release following total colectomy with ileal pouch-anal anastomosis in dogs. Imamura M, et al. **Dig Dis Sci** 1999 May;44(5):1000–7

Secretion of human meprin from intestinal epithelial cells depends on differential expression of the alpha and beta subunits. Lottaz D, et al. **Eur J Biochem** 1999 Jan; 259(1–2):496–504

Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. McClean S, et al. **Eur J Pharm Sci** 1998 Apr;6(2):153–63

The small intestine can both absorb and glucuronidate luminal flavonoids. Spencer JP, et al. **FEBS Lett** 1999 Sep 17;458(2):224–30

Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Söderholm JD, et al. **Gastroenterology** 1999 Jul;117(1):65–72

Correlation of desensitisation of platelet activating factor (PAF) receptors with intensity of inflammation and intestinal PAF content during experimental ileitis in guinea pig. Jeanneton O, et al. **Gut** 1998 Sep;43(3):356–64

Regulation of ileal bile acid transport: desirability of measuring transport function as well as transporter activity [letter; comment] Hofmann AF. **Hepatology** 1999 Apr; 29(4):1335–7. Comment on: Hepatology 1998 Oct;28(4):1081–7.

Collagen synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors. Verhofstad MH, et al. **Int J Exp Pathol** 1998 Oct;79(5):321–8

The effect of feeding level and physiological status on total flow and amino acid composition of endogenous protein at the distal ileum in swine. Stein HH, et al. **J Anim Sci** 1999 May;77(5):1180–7

Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter. Saeki T, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):846–51

Changes in fecal fat excretion from allo-intestine transplanted rats after discontinuance of immunosuppressive agents. Saito T, et al. **J Gastroenterol** 1999 Apr;34(2):182–8

Effect of gut transposition on the expression of the endocrine gene neurotensin. Wang XM, et al. **J Gastrointest Surg** 1998 May-Jun;2(3):230–7

Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters. Kramer W, et al. **J Lipid Res** 1999 Sep; 40(9):1604–17

Apparent ileal nitrogen and amino acid digestibility of a moist cat food. Hendriks WH, et al. **J Nutr** 1998 Dec;128(12 Suppl):2801S–2S

The 15N amino acid dilution method allows the

determination of the real digestibility and of the ileal endogenous losses of the respective amino acid in pigs. Hess V, et al. **J Nutr** 1998 Nov;128(11):1969–77

The current 15N–leucine infusion technique is not suitable for quantitative measurements of ileal endogenous amino acid flows in pigs. Leterme P, et al. **J Nutr** 1998 Nov; 128(11):1961–8

Fermentable dietary fiber increases GLP–1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. Massimino SP, et al. **J Nutr** 1998 Oct;128(10):1786–93

Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats. Ogino Y, et al. **J Pharm Pharmacol** 1999 Jul;51(7):811–5

A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M3 muscarinic receptors in guinea pig ileum and transfected cells. Ehlert FJ, et al. **J Pharmacol Exp Ther** 1999 May;289(2):981–92

Hexose transport in the apical and basolateral membranes of enterocytes in chickens adapted to high and low NaCl intakes. Garriga C, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):189–99

Regulation of intracellular pH during H+–coupled oligopeptide absorption in enterocytes from guinea–pig ileum. Hayashi H, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):573–86

Microvascular oxygen pressure in the pig intestine during haemorrhagic shock and resuscitation. Sinaasappel M, et al. **J Physiol (Lond)** 1999 Jan 1;514 (Pt 1):245–53

GABA(A) receptor subunit messenger RNA expression in the enteric nervous system of the rat: implications for functional diversity of enteric GABA(A) receptors. Poulter MO, et al. **Neuroscience** 1999;93(3):1159–65

Surface hydrophobicity is increased in the ileum and proximal colon of cystic fibrosis mice. Chung C, et al. **Pediatr Res** 1999 Aug;46(2):174–8

Transforming growth factor–beta levels in maternal milk and expression in postnatal rat duodenum and ileum. Penttila IA, et al. **Pediatr Res** 1998 Oct;44(4):524–31

Neurokinin B– and substance P–like immunoreactivity are co–localized in enteric nerves of rat ileum. Yunker AM, et al. **Regul Pept** 1999 Mar 17;80(1–2):67–74

Ammonium transport in the intestine chronically exposed to urine: is it reduced over time? Grocela JA, et al. **Urology** 1999 Aug;54(2):373–6

[The role of zinc in the iliac absorption of various L–tryptophane forms in chickens] Basova NA, et al. **Ross Fiziol Zh Im I M Sechenova** 1999 Feb;85(2):305–11 (Eng. Abstr.) **(Rus)**

[Alternative paths of zinc transepithelial transport in the small intestine] Berzin' NI, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Jul;84(7):687–93 (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Darfeuille–Michaud A, et al. **Gastroenterology** 1998 Dec;115(6):1405–13

Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Boudeau J, et al. **Infect Immun** 1999 Sep;67(9):4499–509

Invasiveness of Salmonella serotypes Typhimurium, Choleraesuis and Dublin for rabbit terminal ileum in vitro. Bolton AJ, et al. **J Med Microbiol** 1999 Sep;48(9):801–10

Mycobacterium avium infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis. Kim SY, et al. **J Med Microbiol** 1998 Aug; 47(8):725–31

A histotoxin produced by Salmonella. Lodge JM, et al. **J Med Microbiol** 1999 Sep;48(9):811–8

Presence of eubacteria in biopsies from Crohn's disease inflammatory lesions as determined by 16S rRNA gene–based PCR. Tiveljung A, et al. **J Med Microbiol** 1999 Mar;48(3):263–8

The significance of the difference in bacterial adherence between bladder and ileum using rat ileal augmented bladder. Nakano Y, et al. **J Urol** 1999 Jul;162(1):243–7

Inactivation of the gene (cpe) encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe–positive C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. Sarker MR, et al. **Mol Microbiol** 1999 Sep;33(5):946–58

PARASITOLOGY

Recovery of Oxyuris equi eggs from hemomelasma ilei lesions on ileal serosa of a Thoroughbred yearling filly. Tolliver SC, et al. **Vet Parasitol** 1999 Jan 28;80(4):353–7

PATHOLOGY

Histomorphology of an ileal orthotopic neobladder: 24 Year's follow–up. Gatti R, et al. **Acta Anat (Basel)** 1998; 163(4):179–83

Desiccant recovered, Crohn's disease discovered. Wu ML, et al. **Am J Gastroenterol** 1998 Dec;93(12):2595–7

Structural, neuronal, and functional adaptive changes in atrophic rat ileum. Ekelund KM, et al. **Gut** 1999 Aug; 45(2):236–45

The role of xanthine oxidase in platelet activating factor induced intestinal injury in the rat. Qu XW, et al. **Gut** 1999 Feb;44(2):203–11

Acute small bowel obstruction due to ileal endometriosis: a case report and literature review. Wickramasekera D, et al. **J R Coll Surg Edinb** 1999 Feb;44(1):59–60 (7 ref.)

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30–1999. An 86–year–old man with gastrointestinal bleeding and small–bowel obstruction [clinical conference] **N Engl J Med** 1999 Sep 30;341(14):1063–71

TNF–alpha, nitric oxide and IFN–gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Liesenfeld O, et al. **Parasite Immunol** 1999 Jul;21(7):365–76

Cautionary note on the use of end–labelling DNA fragments for detection of apoptosis. Wolvekamp MC, et al. **Pathology** 1998 Aug;30(3):267–71

Comparison of jejunal and ileal surveillance biopsies in a porcine model of intestinal transplantation. Raofi V, et al. **Transplantation** 1999 Jul 27;68(2):188–91

[Leiomyosarcoma of the terminal ileum] Villanueva Sáenz E, et al. **Rev Gastroenterol Mex** 1998 Jul–Sep;63(3):170 **(Spa)**

PHYSIOLOGY

Role of transcellular pathway in ileal Ca2+ absorption: stimulation by low–Ca2+ diet. Auchère D, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G951–6

Endogenous interstitial adenosine in isolated myenteric neural networks varies inversely with prevailing PO2. Deshpande NA, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G875–85

Basal pressure patterns and reflexive motor responses in the human ileocolonic junction. Dinning PG, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G331–40

Cholinergic and GABAergic regulation of nitric oxide synthesis in the guinea pig ileum. Hebeiss K, et al. **Am J Physiol** 1999 Apr;276(4 Pt 1):G862–6

Slow waves in circular muscle of porcine ileum: structural and electrophysiological studies. Jiménez M, et al. **Am J Physiol** 1999 Feb;276(2 Pt 1):G393–406

Roles of IL–1 and TNF in the decreased ileal muscle contractility induced by lipopolysaccharide. Lodato RF, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1356–62

Visual parameters define the phase and the load of contractions in isolated guinea pig ileum. Schulze–Delrieu K. **Am J Physiol** 1999 Jun;276(6 Pt 1):G1417–24

GLP–2 augments the adaptive response to massive intestinal resection in rat. Scott RB, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):G911–21

NPY receptor subtype in the rabbit isolated ileum. Félétou M, et al. **Br J Pharmacol** 1999 Jun;127(3):795–801

Roles of neuronal NK1 and NK3 receptors in synaptic transmission during motility reflexes in the guinea–pig ileum. Johnson PJ, et al. **Br J Pharmacol** 1998 Aug; 124(7):1375–84

Characterization of beta–adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1–, beta2– and beta3–adrenoceptors in rat ileum. Roberts SJ, et al. **Br J Pharmacol** 1999 Jun;127(4):949–61

Glucagonlike peptide–1 (GLP–1) participation in ileal brake induced by intraluminal peptones in rat. Giralt M, et al. **Dig Dis Sci** 1999 Feb;44(2):322–9

Tachykinins stimulate release of peptide hormones (glucagon–like peptide–1) and paracrine (somatostatin) and neurotransmitter (vasoactive intestinal polypeptide) from porcine ileum through NK–1 receptors. Schmidt PT, et al. **Dig Dis Sci** 1999 Jul;44(7):1273–81

Factors affecting outcome following proximal and distal intestinal resection in the dog: an examination of the relative roles of mucosal adaptation, motility, luminal factors, and enteric peptides. Thompson JS, et al. **Dig Dis Sci** 1999 Jan;44(1):63–74

Up–regulation of microsphere transport across the follicle–associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a. Meynell HM, et al. **FASEB J** 1999 Apr;13(6):611–9

Effect of estradiol on rat ileum. Pines A, et al. **Gen Pharmacol** 1998 Nov;31(5):735–6

Apparent ileal and total–tract nutrient digestion by pigs as affected by dietary nondigestible oligosaccharides. Houdijk JG, et al. **J Anim Sci** 1999 Jan;77(1):148–58

Impedance analysis for the determination of epithelial and subepithelial resistance in intestinal tissues. Gitter AH, et al. **J Biochem Biophys Methods** 1998 Sep 24;37(1–2):35–46

Contractile activity of circular smooth muscle in rats one year after small bowel transplantation: differing adaptive response of the jejunum and ileum to denervation. Shibata C, et al. **J Gastrointest Surg** 1998 Sep–Oct;2(5):463–72

Pituitary adenylate cyclase–activating peptide as a neurotransmitter in the canine ileal circular muscle. Fox–Threlkeld JA, et al. **J Pharmacol Exp Ther** 1999 Jul; 290(1):66–75

Characterization of prejunctional and postjunctional muscarinic receptors of the ascending reflex contraction in rat ileum. Kurjak M, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):893–900

Initiation of peristalsis by circumferential stretch of flat sheets of guinea–pig ileum. Brookes SJ, et al. **J Physiol (Lond)** 1999 Apr 15;516 (Pt 2):525–38

Contractile activity in intestinal muscle evokes action potential discharge in guinea–pig myenteric neurons. Kunze WA, et al. **J Physiol (Lond)** 1999 Jun 1;517 (Pt 2):547–61

Does the guinea–pig ileum obey the 'law of the intestine'? Spencer N, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):889–98

Potentiating actions of lanthanum on ACh–induced cation current in guinea–pig ileal smooth muscle cells. Inoue R, et al. **J Smooth Muscle Res** 1998 Apr;34(2):69–81

Functional role of M2 muscarinic receptors in the guinea pig ileum. Ehlert FJ, et al. **Life Sci** 1995;56(11–12):965–71 (26 ref.)

Distinct functional muscarinic receptors in guinea–pig gallbladder, ileum and atria. Karaalp A, et al. **Pharmacol Res** 1999 May;39(5):389–95

Ileal short–chain fatty acids inhibit transpyloric flow in pigs. Cuche G, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):149–55

[Adrenergic mechanism of the stimulation of the small intestine motor activity] Ovsiannikov VI. **Ross Fiziol Zh Im I M Sechenova** 1998 Sep;84(9):920–30 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Cryptosporidium parvum infection in suckling rats: impairment of mucosal permeability and Na(+)–glucose cotransport. Capet C, et al. **Exp Parasitol** 1999 Feb; 91(2):119–25

Response of wild–type mutants of Vibrio cholerae O1 possessing different combinations of virulence genes in the ligated rabbit ileal loop and in Ussing chambers: evidence for the presence of additional secretogen. Koley H, et al. **J Med Microbiol** 1999 Jan;48(1):51–7

Acute portal hypertension increases ileal vulnerability to platelet–activating factor in rats. Sakaguchi T, et al. **J Surg Res** 1999 Sep;86(1):116–22

Recombinant growth hormone's effects on the strength and thickness of radiation–injured ileal anastomoses: a rat model. Silver DF, et al. **J Surg Res** 1999 Jul;85(1):66–70

Altered myoelectrical activity in noninflamed ileum of rats with colitis induced by trinitrobenzene sulphonic acid. Aube AC, et al. **Neurogastroenterol Motil** 1999 Feb; 11(1):55–62

Impairment of GABA–mediated contractions of rat isolated ileum by experimental diabetes. Ozdem SS, et al. **Pharmacology** 1999 Sep;59(3):165–70

RADIATION EFFECTS

A substance P receptor antagonist (FK 888) modifies gut alterations induced by ionizing radiation. Esposito V, et al. **Int J Radiat Biol** 1998 Nov;74(5):625–32

RADIOGRAPHY

Desiccant recovered, Crohn's disease discovered. Wu ML, et al. **Am J Gastroenterol** 1998 Dec;93(12):2595–7

Small bowel enteroclysis in surgically treated obesity. Coppola V, et al. **Radiol Med (Torino)** 1998 Nov; 96(5):466–9

SECRETION

Abnormal patterns of mucin secretion in ileal neobladder mucosa: evidence of preneoplastic lesion? Parenti A, et al. **Eur Urol** 1999 Feb;35(2):98–101

[Signal transduction of serotonin release from enterochromaffin cells in mouse ileal crypts] Hirafuji M, et al. **Nippon Yakurigaku Zasshi** 1998 Oct;112 Suppl 1:133P–137P (Eng. Abstr.) **(Jpn)**

SURGERY

GLP–2 augments the adaptive response to massive intestinal resection in rat. Scott RB, et al. **Am J Physiol** 1998 Nov; 275(5 Pt 1):G911–21

Reperfusion injury delays healing of intestinal anastomosis in a rat. Kuzu MA, et al. **Am J Surg** 1998 Oct;176(4):348–51

Role of T cells in mucosal transformation of ileoanal pouches. Stallmach A, et al. **Ann N Y Acad Sci** 1998 Nov 17; 859:231–6

An ileal enterotomy for colonic lavage and primary anastomosis in left colon obstruction also used to defunction anastomosis [letter; comment] **Reasbeck PG. Ann R Coll Surg Engl** 1998 Nov;80(6):447–8. Comment on: Ann R Coll Surg Engl 1998 Jul;80(4):249.

Check the stapler before use. Polglase AL, et al. **Aust N Z J Surg** 1999 May;69(5):402–3

Effects of early postoperative 5–fluorouracil and ageing on the healing capacity of experimental intestinal anastomoses. Stoop MJ, et al. **Br J Surg** 1998 Nov;85(11):1535–8

Cholylsarcosine for bile acid deficiency caused by ileal resection [letter] Popović OS, et al. **Dig Dis Sci** 1999 Sep; 44(9):1931–2

Factors affecting outcome following proximal and distal intestinal resection in the dog: an examination of the relative roles of mucosal adaptation, motility, luminal factors, and enteric peptides. Thompson JS, et al. **Dig Dis Sci** 1999 Jan;44(1):63–74

Use of a jejunal pouch with ileal interposition in salvage surgery after restorative proctocolectomy. Dehni N, et al. **Dis Colon Rectum** 1998 Dec;41(12):1587–9

Conservative surgical management of perforating Crohn's disease: side–to–side enteroenteric neoileocolic anastomosis: report of two cases. Poggioli G, et al. **Dis Colon Rectum** 1998 Dec;41(12):1577–80

Comparison of ileal pouch–anal anastomosis and ileorectal anastomosis in patients with familial adenomatous

polyposis. Soravia C, et al. **Dis Colon Rectum** 1999 Aug; 42(8):1028–33; discussion 1033–4

Functional outcome of conversion of ileorectal anastomosis to ileal pouch–anal anastomosis in patients with familial adenomatous polyposis and ulcerative colitis. Soravia C, et al. **Dis Colon Rectum** 1999 Jul;42(7):903–8

Functional evaluation of different ileal neobladders and ureteral reimplantation techniques. Minervini R, et al. **Eur Urol** 1998 Sep;34(3):198–202

Molecular analysis of the adaptive response of intestinal bile acid transport after ileal resection in the rat [see comments] Coppola CP, et al. **Gastroenterology** 1998 Nov; 115(5):1172–8. Comment in: Gastroenterology 1998 Nov;115(5):1291–4.

Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Buts JP, et al. **Gut** 1999 Jul; 45(1):89–96

Management of pouchitis [letter; comment] Coran AG. **Inflamm Bowel Dis** 1998 Nov;4(4):333. Comment on: Inflamm Bowel Dis 1998 May;4(2):165–6; discussion 170–1. Comment on: Inflamm Bowel Dis 1998 May;4(2):167–9; discussion 170–1.

Ileal pouch with an umbilical stoma: a continent mechanism created by the extramural tunnel technique. Kato H, et al. **Int J Urol** 1998 Sep;5(5):487–9

Ileocecocolic intussusception in a one-month-old llama. Costarella CE, et al. **J Am Vet Med Assoc** 1999 Jun 1; 214(11):1672–3, 1640

Appendico-ileo-vesical fistula. Kawamura YJ, et al. **J Gastroenterol** 1998 Dec;33(6):868–71

Enterocyte apoptosis is increased following small bowel resection. Helmrath MA, et al. **J Gastrointest Surg** 1998 Jan–Feb;2(1):44–9

Effect of gut transposition on the expression of the endocrine gene neurotensin. Wang XM, et al. **J Gastrointest Surg** 1998 May–Jun;2(3):230–7

Limited ileal resection in infancy: the long-term consequences. Davies BW, et al. **J Pediatr Surg** 1999 Apr; 34(4):583–7

The expression and activation of EGF and c-NEU receptors are increased in enterocytes during intestinal adaptation. Falcone RA Jr, et al. **J Pediatr Surg** 1999 May;34(5):663–7

Recombinant growth hormone's effects on the strength and thickness of radiation-injured ileal anastomoses: a rat model. Silver DF, et al. **J Surg Res** 1999 Jul;85(1):66–70

Long-term outcome of incontinent ileovesicostomy management of severe lower urinary tract dysfunction. Leng WW, et al. **J Urol** 1999 Jun;161(6):1803–6

Xylose absorption and metabolic status in urinary intestinal orthotopic reservoir: ileocecal compared with ileal neobladder. Racioppi M, et al. **J Urol** 1998 Nov; 160(5):1655–7

Epidermal growth factor and human growth hormone induce two sodium-dependent arginine transport systems after massive enterectomy. Iannoli P, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep–Oct;22(5):326–30

Complications of ileal cannulation in cats. Mawby DI, et al. **Lab Anim Sci** 1999 Aug;49(4):406–10

Internal mammary blood supply for ileo–colon interposition in esophagogastroplasty: a case report. Zonta A, et al. **Microsurgery** 1998;18(8):472–5

Ilial transposition and enteroglucagon/GLP-1 in obesity (and diabetic?) surgery. Mason EE. **Obes Surg** 1999 Jun; 9(3):223–8 (35 ref.)

Long-term results of strictureplasty without synchronous resection for jejunoileal Crohn's disease. Yamamoto T, et al. **Scand J Gastroenterol** 1999 Feb;34(2):180–4

Cosmesis and body image after laparoscopic-assisted and open ileocolic resection for Crohn's disease. Dunker MS, et al. **Surg Endosc** 1998 Nov;12(11):1334–40

The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn's disease. Yamamoto T, et al. **Surg Today** 1999;29(6):579–80

Stapled functional end-to-end anastomosis in Crohn's disease. Yamamoto T, et al. **Surg Today** 1999;29(7):679–81

Adaptation after small bowel resection is attenuated by sialoadenectomy: the role for endogenous epidermal growth factor. Helmrath MA, et al. **Surgery** 1998 Nov; 124(5):848–54

Utilising an ileal segment in the posterior urethral replacement procedures using anal sphincter to provide continence in dogs. Yilmaz Y, et al. **Tohoku J Exp Med** 1998 Aug;185(4):263–70

[Long-term results of ileo–rectal anastomosis in familial polyposis] Sváb J, et al. **Rozhl Chir** 1999 Apr;78(4):150–3 (Eng. Abstr.) **(Cze)**

[Laparoscopic ileocecal resection in Crohn disease] Jess P, et al. **Ugeskr Laeger** 1999 Mar 1;161(9):1258–60 (Eng. Abstr.) **(Dan)**

[Surgical treatment of constipation] Hiltunen KM, et al. **Duodecim** 1995;111(20):1955–9 (17 ref.) **(Fin)**

[Ileo–anal reservoir technique] Mariani P, et al. **J Chir (Paris)** 1998 May;135(2):75–8 **(Fre)**

[Laparoscopic creation of stomas--an ideal single indication in minimally invasive surgery] Marusch F, et al. **Chirurg** 1999 Jul;70(7):785–8 (Eng. Abstr.) **(Ger)**

[Cholysarkosin in treatment of bile acid deficiency syndrome] Weinand I, et al. **Z Gastroenterol** 1999 Jul;37(7):675–7 **(Ger)**

[Intestinal anastomosis in urology: comparison of methods] Diana M, et al. **Ann Ital Chir** 1999 Jan–Feb;70(1):91–5 (Eng. Abstr.) **(Ita)**

[Orthotopic ileal neobladder: technical procedures and long-term follow-up] Leidi GL, et al. **Arch Ital Urol Androl** 1999 Jun;71(3):165–70 (Eng. Abstr.) **(Ita)**

[Ileotransversoanastomosis end-to-end in right-sided hemicolectomy] Timofeev IuM, et al. **Khirurgiia (Mosk)** 1999;(1):39–40 (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

Ureter and bladder replacement following radical cystectomy. Csata S, et al. **Acta Chir Hung** 1998; 37(1–2):107–10

Bilateral ureteric replacement with ileum. Répássy D, et al. **Acta Chir Hung** 1998;37(1–2):119–23

Morphometric parameters of ileal revascularized grafts of the cervical portion of the oesophagus in dogs. Milenin O, et al. **Ann Chir Gynaecol** 1999;88(1):29–34

Transversely tubularized ileal segments for the Mitrofanoff or Malone antegrade colonic enema procedures: the Monti principle [letter] Gerharz EW, et al. **Br J Urol** 1998 Sep; 82(3):460–1

Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women [letter; comment] Kelly JD, et al. **Br J Urol** 1998 Oct; 82(4):609–10. Comment on: Br J Urol 1998 Apr;81(4):569–73.

Contractile activity of circular smooth muscle in rats one year after small bowel transplantation: differing adaptive response of the jejunum and ileum to denervation. Shibata C, et al. **J Gastrointest Surg** 1998 Sep–Oct;2(5):463–72

Comparison of ileal and jejunal transplantation after 50% proximal intestinal resection. Thompson JS, et al. **J Surg Res** 1999 Jan;81(1):91–4

New concepts of histological changes in experimental augmentation cystoplasty: insights into the development of neoplastic transformation at the enterovesical and gastrovesical anastomosis. Gitlin JS, et al. **J Urol** 1999 Sep; 162(3 Pt 2):1096–100

The significance of the difference in bacterial adherence between bladder and ileum using rat ileal augmented bladder. Nakano Y, et al. **J Urol** 1999 Jul;162(1):243–7

Ileal ureteral substitution in reconstructive urological surgery: is an antireflux procedure necessary? Waldner M, et al. **J Urol** 1999 Aug;162(2):323–6 (20 ref.)

Intestinal transplant between two of identical triplets [letter] Calne RY, et al. **Lancet** 1997 Oct 11;350(9084):1077–8

Living-related small bowel transplantation: the first case in Japan [see comments] Uemoto S, et al. **Pediatr Transplant** 1998 Feb;2(1):40–4. Comment in: Pediatr Transplant 1998 Feb;2(1):1–2.

Living-related donor small bowel transplantation: first case in Japan. Fujimoto Y, et al. **Transplant Proc** 1998 Nov; 30(7):3441–2

Voiding function of orthotopic ileal neobladder in women. Arai Y, et al. **Urology** 1999 Jul;54(1):44–9

Wall-incorporated antireflux valve in ileal bladder substitutes: first clinical experience in 17 patients. Elbakry A. **Urology** 1998 Dec;52(6):1020–5

[Results of the surgical treatment of severe caustic pharyngo–esophageal stenosis. The value of complete reconstruction of the pharynx by transposition of the ileum and colon] Popovici Z. **Chirurgie** 1998 Dec;123(6):552–9 (Eng. Abstr.) **(Fre)**

[Ileo–cecal segment as stomach substitute] Harder F, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:66–71 (Eng. Abstr.) **(Ger)**

[Anti-reflux ureteral grafting to the ileum by the Hassan Abol-Enein technique used in augmentation cystoplasty. Preliminary remarks] Komasara L, et al. **Wiad Lek** 1998; 51 Suppl 3:77–82 (Eng. Abstr.) **(Pol)**

ILEUS see **INTESTINAL OBSTRUCTION**

ILIAC ANEURYSM

COMPLICATIONS

Ureteropelvic urinary extravasation due to iliac artery aneurysm. Obrand DI, et al. **Ann Vasc Surg** 1998 Sep; 12(5):468–70

Rupture of an iliac artery pseudo-aneurysm into a ureter. Levi N, et al. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):264–5 (14 ref.)

Persistent sciatic artery: report of an original aneurysm-associated case. Papon X, et al. **Surg Radiol Anat** 1999;21(2):151–3

[Hypogastric arterial aneurysms associated with abdominal aortic aneurysms] Mellière D, et al. **J Mal Vasc** 1998 Dec; 23(5):342–8 (Eng. Abstr.) **(Fre)**

[Ilio femoral thrombosis: an infrequent complication of an aortic and iliac aneurysm. Report of two cases] Mertens R, et al. **Rev Med Chil** 1999 Apr;127(4):459–62 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Isolated iliac artery aneurysms in patients with or without previous abdominal aortic aneurysm repair. Dosluoglu HH, et al. **Am J Surg** 1999 Aug;178(2):129–32

Hematuria from arteriovesical fistula: unusual presentation of ruptured iliac artery aneurysm. Goff CD, et al. **Am Surg** 1999 May;65(5):421–2

ETIOLOGY

A solitary iliac artery aneurysm caused by Candida infection. Report of a case. Tsunezuka Y, et al. **J Cardiovasc Surg (Torino)** 1998 Aug;39(4):437–9

Isolated iliac artery aneurysms with associated hydronephrosis. O'Driscoll D, et al. **J R Coll Surg Edinb** 1999 Jun;44(3):197–9

[Rupture of an atherosclerotic aneurysm of the common iliac artery] Istomin AA. **Arkh Patol** 1999 Jan–Feb;61(1):46–7 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Digital aortography showing extensive aneurysmal aortoiliac disease and severe proximal renal artery stenosis in a patient with a history of acute myocardial infarction. Missouris CG, et al. **J Hum Hypertens** 1999 Apr;13(4):283–4

[Arteriography in critical changes in the iliac arterial bed] Karev AV, et al. **Vestn Khir Im I I Grek** 1999;158(1):58–61 (Eng. Abstr.) **(Rus)**

SURGERY

Awake aortic aneurysm repair in patients with severe pulmonary disease. McGregor WE, et al. **Am J Surg** 1999 Aug;178(2):121–4

Two-stage operation for multiple aneurysms of the thoracic aorta, abdominal aorta, and left common iliac artery in an octogenarian. Kudaka M, et al. **Ann Thorac Cardiovasc Surg** 1999 Apr;5(2):133–6

Endovascular treatment of aortoiliac aneurysms: made-to-measure stent-grafts increase feasibility. Koskas F, et al. **Ann Vasc Surg** 1999 May;13(3):239–46

Isolated hypogastric artery aneurysms. Zimmer PW, et al. **Ann Vasc Surg** 1999 Sep;13(5):545–9 (18 ref.)

Intestinal ischaemia after aortoiliac surgery--a case-control study within the Swedvasc Registry. Björck M. **Eur J Surg Suppl** 1998;(581):37–9

Isolated iliac artery aneurysms. Levi N, et al. **Eur J Vasc Endovasc Surg** 1998 Oct;16(4):342–4

Endovascular graft repair of ruptured aortoiliac aneurysms. Ohki T, et al. **J Am Coll Surg** 1999 Jul;189(1):102–12; discussion 112–3

Exclusion of internal iliac arterial aneurysm concomitant with abdominal aortic aneurysm repair. Urayama H, et al. **J Cardiovasc Surg (Torino)** 1999 Apr;40(2):243–7

Endovascular treatment of internal iliac artery aneurysms. Henry M, et al. **J Endovasc Surg** 1998 Nov;5(4):345–8

Internal to external iliac artery stent-graft: a new technique for vessel exclusion. Hoffer EK, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1067–73

Aortoiliac aneurysms: endoluminal repair--clinical evidence for a fully supported stent-graft. Silberzweig JE, et al. **Radiology** 1998 Oct;209(1):111–6

Successful treatment of bilateral deep femoral aneurysms and multiple iliac aneurysms associated with severe aortic valve disease: report of a case. Kuniyoshi Y, et al. **Surg Today** 1998;28(11):1206–9

Successful simultaneous operation of concomitant early gastric cancer, transverse colon cancer, and a common iliac artery aneurysm. Nakata Y, et al. **Surg Today** 1999; 29(8):782–4

[Hypogastric arterial aneurysms associated with abdominal aortic aneurysms] Mellière D, et al. **J Mal Vasc** 1998 Dec; 23(5):342–8 (Eng. Abstr.) **(Fre)**

[The value of a fabric-coated self-expanding stent in iliac arterial occlusions or aneurysms--the primary and long-term results] Scheinert D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):302–9 (Eng. Abstr.) **(Ger)**

THERAPY

Transluminal repair of an infrarenal aortoiliac aneurysm by a combination of bifurcated and branched stent grafts [see comments] Iwase T, et al. **Catheter Cardiovasc Interv** 1999 Aug;47(4):491–4. Comment in: Catheter Cardiovasc Interv 1999 Aug;47(4):495.

Endovascular repair of iliac aneurysms following aortoiliac surgery. Vraux H, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):442–5 (9 ref.)

Isolated iliac artery aneurysm: treatment by percutaneous stent-graft placement. Sharma S, et al. **Indian Heart J** 1998 May–Jun;50(3):337–40

Transcatheter arterial embolization for impending rupture of an isolated internal iliac artery aneurysm complicated with disseminated intravascular coagulation. Takatori M, et al. **Intern Med** 1999 Jan;38(1):27–30

Percutaneous embolization of an isolated hypogastric artery aneurysm. A case report. Battaglia L, et al. **J Cardiovasc Surg (Torino)** 1998 Dec;39(6):761–3

Transcatheter embolization of internal iliac artery aneurysms. Mori M, et al. **J Vasc Interv Radiol** 1999 May;10(5):591–7

Percutaneous stent-graft for treatment of isolated iliac aneurysm. Bhargava B, et al. **Tex Heart Inst J** 1998; 25(3):220–1

[A coated stent as alternative therapy for stopping a tumor-induced arrosive hemorrhage] Steudel A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):324–6 (10 ref.) **(Ger)**

[Intravascular treatment of iliac aneurysms] Mancuso M, et al. **Radiol Med (Torino)** 1998 Oct;96(4):384–8 (Eng. Abstr.) **(Ita)**

ILIAC ARTERY

Evaluation of maximum neointima proliferation and plaque morphology in iliac self-expanding nitinol stents with intravascular sonography. Schwarzenberg H, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1627-30

Diabetic versus nondiabetic limb-threatening ischemia: outcome of percutaneous iliac intervention. Spence LD, et al. **AJR Am J Roentgenol** 1999 May;172(5):1335-41

Arterial occlusions as a presenting feature of acute promyelocytic leukemia. Rolston DD, et al. **Am J Clin Oncol** 1998 Oct;21(5):436-7

Cocaine-induced thrombosis of common iliac and popliteal arteries. Mirzayan R, et al. **Ann Vasc Surg** 1998 Sep; 12(5):476-81

Directional atherectomy in iliac stent failure: clinical technique and histopathologic correlation. Ettles DF, et al. **Cardiovasc Intervent Radiol** 1998 Nov-Dec;21(6):475-80

Primary stent placement for recanalization of iliac artery occlusions: using a self-expanding spiral stent. Kim JK, et al. **Cardiovasc Intervent Radiol** 1999 Jul-Aug; 22(4):278-81

Temporary Strecker stent for management of acute dissection in popliteal and crural arteries. Manke C, et al. **Cardiovasc Intervent Radiol** 1999 Mar-Apr;22(2):141-3

Primary stenting for complex atherosclerotic plaques in aortic and iliac stenoses. Onal B, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):386-92

Placement of a PTFE-covered Wallstent through a 12 Fr sheath for the exclusion of a common iliac artery aneurysm. Reddy SG, et al. **Cardiovasc Intervent Radiol** 1999 Mar-Apr;22(2):152-4

A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures. Reekers JA. **Cardiovasc Intervent Radiol** 1998 Sep-Oct; 21(5):431-3

Options in the surgical management of aorto-iliac occlusive disease: a changing perspective. Rutherford RB. **Cardiovasc Surg** 1999 Jan;7(1):5-12 (36 ref.)

Septic endarteritis and fatal iliac wall rupture after endovascular stenting of the common iliac artery. Schachtrupp A, et al. **Cardiovasc Surg** 1999 Mar;7(2):183-6

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Kumar A, et al. **Circulation** 1999 Mar 16;99(10):1363-9

Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. Becker BN, et al. **Clin Transplant** 1999 Aug;13(4):349-55

Isolated iliac artery stenosis as a cause of kidney graft dysfunction post-transplant. Humar A, et al. **Clin Transplant** 1998 Oct;12(5):406-8

Chronic iliac artery occlusion: treatment with the Strecker stent after PTA. Lupattelli L, et al. **Eur J Radiol** 1998 Aug;28(1):80-5

An unusual case of haematuria treated by endoluminal repair. Asham EH, et al. **Eur J Vasc Endovasc Surg** 1999 Jan; 17(1):89-90

A minimally invasive technique allowing ligation of the internal iliac artery during endovascular repair of aortic aneurysms with an aorto-uni-iliac device. Gough MJ, et al. **Eur J Vasc Endovasc Surg** 1998 Dec;16(6):535-6

A complication of the tapered aortouni-iliac graft for endovascular aneurysm repair. Robinson J, et al. **Eur J Vasc Endovasc Surg** 1999 Apr;17(4):366-8

Percutaneous placement of stents in chronic iliac and aortic occlusive disease. Uher P, et al. **Eur J Vasc Endovasc Surg** 1999 Aug;18(2):114-21

Aortoiliac reconstructive surgery based upon the results of duplex scanning. van der Zaag ES, et al. **Eur J Vasc Endovasc Surg** 1998 Nov;16(5):383-9

Intimal sarcoma of the left iliac artery [letter] Weickert U, et al. **Histopathology** 1998 Sep;33(3):286-7

Catheter-induced vasospasm in the right external iliac and femoral arteries during a cardiac diagnostic procedure. Ergene O, et al. **Int J Card Imaging** 1999 Jun;15(3):189-93

Percutaneous endoluminal treatment of iliac occlusions: long-term follow-up in 105 patients. Henry M, et al. **J Endovasc Surg** 1998 Aug;5(3):228-35

Angioplasty of lower limb arterial stenoses under ultrasound guidance: single-center experience. Ramaswami G, et al. **J Endovasc Surg** 1999 Feb;6(1):52-8

Effects of nitinol Strecker stent placement on vascular response in normal and stenotic porcine iliac arteries. Froelich JJ, et al. **J Vasc Interv Radiol** 1999 Mar; 10(3):329-38

Endovascular graft-related iliac artery infection. Sheeran SR, et al. **J Vasc Interv Radiol** 1999 Jul-Aug;10(7):877-82

Detection of distal emboli in patients with peripheral arterial stenosis before and after iliac angioplasty: a prospective study. Al-Hamali S, et al. **J Vasc Surg** 1999 Feb; 29(2):345-51

Infrarenal aortic surgery with a 3-day hospital stay: A report on success with a clinical pathway. Podore PC, et al. **J Vasc Surg** 1999 May;29(5):787-92

Regarding "Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost" [letter; comment] Wang WY. **J Vasc Surg** 1999 Feb;29(2):387-9. Comment on: J Vasc Surg 1998 Jul;28(1):94-101; discussion 101-3.

Magnetic resonance imaging of the abdominal aorta and iliac vessels using combined 3-D gadolinium-enhanced MRA and gadolinium-enhanced fat-suppressed spoiled gradient echo sequences. Kelekis NL, et al. **Magn Reson Imaging** 1999 Jun;17(5):641-51

Spontaneous iliac artery dissection in a kidney transplantation treated with and endovascular stent [letter] Esteban RJ, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1610

Arteriovenous fistula as a complication of lumbar disc surgery: case report. Santos E, et al. **Neuroradiology** 1998 Jul;40(7):459-61

Increased prostacyclin production after percutaneous transluminal angioplasty of the iliac artery for atherosclerosis obliterans. Onohara T, et al. **Panminerva Med** 1999 Mar;41(1):1-4

Internal iliac artery embolisation for intractable bladder haemorrhage in the peri-operative phase. Gujral S, et al. **Postgrad Med J** 1999 Mar;75(881):167-8

Iliofemoral arterial occlusive disease: contrast-enhanced MR angiography for preinterventional evaluation and follow-up after stent placement. Link J, et al. **Radiology** 1999 Aug;212(2):371-7

External iliac artery occlusion in posterior spinal surgery. Akagi S, et al. **Spine** 1999 Apr 15;24(8):823-5

Percutaneous transluminal angioplasty and stenting for iliac artery occlusive disease. Hood DB, et al. **Surg Clin North Am** 1999 Jun;79(3):575-96 (34 ref.)

Iliac artery pseudoaneurysm following renal transplantation presenting as lumbosacral plexopathy. Luzzio CC, et al. **Transplantation** 1999 Apr 15;67(7):1077-8

[Treatment of iliac artery stenosis and obliteration by transluminal angioplasty] Hassen-Khodja R, et al. **Chirurgie** 1998 Jun;123(3):287-91 (Eng. Abstr.) **(Fre)**

[Aneurysm of the iliac artery in an elderly subject. Role of treatment with covered endoprosthesis] Rojas M, et al. **Presse Med** 1998 Nov 28;27(37):1890-2 (Eng. Abstr.) **(Fre)**

[The Perflex stent, a new balloon-expandable vascular stent: the initial clinical results] Schürmann K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 May;170(5):497-502 (Eng. Abstr.) **(Ger)**

[Results of "cross-over implantation of Palmaz-stents" with cross-over sheaths] Steinkamp HJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):209-13 (Eng. Abstr.) **(Ger)**

[The death of Thomas Mann: consequence of erroneous angiologic diagnosis?] Bollinger A. **Wien Med Wochenschr** 1999;149(2-4):30-2 (Eng. Abstr.) **(Ger)**

[Occlusion of the common iliac artery caused by mycotic endocarditis] Veraldi GF, et al. **Ann Ital Chir** 1998 May-Jun;69(3):379-82; discussion 382-3 (Eng. Abstr.) **(Ita)**

[Endovascular treatment of obstructive lesions of the iliac arteries. Results and complications] Zaccaria A, et al. **Minerva Cardioangiol** 1998 Sep;46(9):325-6 **(Ita)**

[Percutaneous mechanical revascularization of chronic iliac artery occlusion with "first intention" stent placement] Petronelli S, et al. **Radiol Med (Torino)** 1998 Jul-Aug; 96(1-2):92-7 (Eng. Abstr.) **(Ita)**

[Uretero-external iliac artery fistula: a case report] Kawabata G, et al. **Hinyokika Kiyo** 1998 Nov;44(11):829-32 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Uretero-iliac fistula] Herranz Amo F, et al. **Arch Esp Urol** 1998 Oct;51(8):818-20 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Extrauterine pelvic arteriovenous malformation mimicking the clinical presentation of structural heart disease. Chen SC, et al. **Int J Cardiol** 1999 Jun 1;69(3):305-8

A case of pelvic arteriovenous malformation in a male. Tanaka M, et al. **Int J Urol** 1999 Jul;6(7):374-6

Percutaneous treatment of rare latrogenic arteriovenous fistulas of the lower limbs. Bürger T, et al. **Int Surg** 1998 Jul-Sep;83(3):198-201

MR angiography of persistent sciatic artery. Lin CW, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1119-21

Fetal internal iliac artery: case report and embryologic review. Shortell CK, et al. **J Vasc Surg** 1998 Dec; 28(6):1112-4

Persistent sciatic artery: report of an original aneurysm-associated case. Papon X, et al. **Surg Radiol Anat** 1999;21(2):151-3

Pelvic arteriovenous malformation mimicking seminal vesicle cyst. Richards SL, et al. **Urology** 1999 Feb;53(2):420-2

[Diagnosis and therapy of second aortoenteric fistulas: results of 16 patients] Müller BT, et al. **Chirurg** 1999 Apr; 70(4):415-21 (Eng. Abstr.) **(Ger)**

[Novel endoluminal stents for the treatment of arterial fistulas and perforations] Vorwerk D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Nov;169(5):526-31 (Eng. Abstr.) **(Ger)**

[Acute thromboembolic occlusion of the A. poplitea and of the trifurcation originating from a persistent primitive A. ischiadica] Zähringer M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jul;171(1):79-81 **(Ger)**

ANATOMY & HISTOLOGY

A statistical study of the branching of the human internal iliac artery. Yamaki K, et al. **Kurume Med J** 1998; 45(4):333-40

Transverse subgluteal-ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432-41 (65 ref.)

Anatomic basis of iliac crest flap pedicled on the iliolumbar artery. Chen RS, et al. **Surg Radiol Anat** 1999;21(2):103-7

CYTOLOGY

Regional distribution in human of a novel aortic collagen-associated microfibrillar protein. Chew DK, et al. **Exp Mol Pathol** 1999 Apr;66(1):59-65

DRUG EFFECTS

17 beta-estradiol reduces glycoxidative damage in the artery wall. Walsh BA, et al. **Arterioscler Thromb Vasc Biol** 1999 Apr;19(4):840-6

Local effect of three nonionic contrast media on the arterial blood flow velocity during iliofemoral arteriography. Zwaan M, et al. **Invest Radiol** 1999 Jan;34(1):5-12

Differences of antagonism for a selective alpha1D-adrenoceptor antagonist BMY 7378 in the rabbit thoracic aorta and iliac artery. Satoh M, et al. **J Smooth Muscle Res** 1998 Aug;34(4):151-8

The influence of a novel antioxidant fatty acid on the development of stenosis after balloon injury. Dyrøy E, et al. **Lipids** 1999;34 Suppl:S339

INJURIES

Recreational bicycling and injury to the external iliac artery. Roth JW, et al. **Am Surg** 1999 May;65(5):460-3 (24 ref.)

Vascular complications of the intraaortic balloon pump in patients undergoing open heart operations: 15-year experience. Arafa OE, et al. **Ann Thorac Surg** 1999 Mar; 67(3):645-51

Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Janiszewski M, et al. **Cardiovasc Res** 1998 Aug;39(2):327-38

Strain differences in neointimal hyperplasia in the rat. Assadnia S, et al. **Circ Res** 1999 Jun 11;84(11):1252-7

Arterial response to mild balloon injury in the normal rabbit: evidence for low proliferation rate in the adventitia. Le Feuvre C, et al. **Coron Artery Dis** 1998;9(12):805-14

Stent-graft treatment of iatrogenic iliac artery perforations: report of three cases. Nyman U, et al. **Eur J Vasc Endovasc Surg** 1999 Mar;17(3):259-63 (18 ref.)

Implications for port placement of deep circumflex iliac artery damage at laparoscopy. Reid GD, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):221-3

Management of injuries to great vessels during laparoscopy. Ruiz A, et al. **J Am Assoc Gynecol Laparosc** 1999 Feb; 6(1):101-4

Common and external iliac artery injuries associated with pelvic fractures. Carrillo EH, et al. **J Orthop Trauma** 1999 Jun-Jul;13(5):351-5

Temporary arterial shunts to maintain limb perfusion after arterial injury: an animal study. Dawson DL, et al. **J Trauma** 1999 Jul;47(1):64-71

Psoralen and long wavelength ultraviolet radiation as an adjuvant therapy for prevention of intimal hyperplasia and constrictive remodeling after balloon dilation: a study in the rabbit iliac artery. Perrée J, et al. **Lasers Surg Med** 1998;23(5):281-90

The influence of a novel antioxidant fatty acid on the development of stenosis after balloon injury. Dyrøy E, et al. **Lipids** 1999;34 Suppl:S339

Combined catheter embolization and femorofemoral bypass for pseudoaneurysm of the right external iliac artery: report of a case. Watarida S, et al. **Surg Today** 1999;29(1):83-5

[Temporary balloon occlusion as therapy of uncontrollable arterial hemorrhage in multiple trauma patients] Rieger J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):80-3 (Eng. Abstr.) **(Ger)**

[Novel endoluminal stents for the treatment of arterial fistulas and perforations] Vorwerk D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Nov;169(5):526-31 (Eng. Abstr.) **(Ger)**

[Arterial vascular injuries in hip prosthesis implantation] Krenzien J, et al. **Zentralbl Chir** 1998;123(11):1292-6 (Eng. Abstr.) **(Ger)**

[Vascular complications during laparoscopy. An analysis of a personal case] Esposito C, et al. **Minerva Chir** 1999 Mar; 54(3):163-5 (9 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Arterial heparin deposition: role of diffusion, convection, and extravascular space. Lovich MA, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2236-42

High accumulation of calcium and phosphorus in human iliac arteries. Tohno S, et al. **Biol Trace Elem Res** 1999 Oct; 70(1):41-9

Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels. Falkenberg M, et al. **Eur J Vasc Endovasc Surg** 1998 Oct;16(4):276-83

Expression of IGF-1, IGF-1 receptor and TGF-beta following balloon angioplasty in atherosclerotic and normal rabbit iliac arteries: an immunocytochemical study. Grant MB, et al. **Regul Pept** 1999 Jan 1;79(1):47-53

ILIAC ARTERY

MICROBIOLOGY

Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases. Ouchi K, et al. **J Med Microbiol** 1998 Oct; 47(10):907-13

PATHOLOGY

Leriche's syndrome with total perfusion of the left lower extremity by way of the left internal mammary artery. Arnold JR. **Am J Cardiol** 1998 Oct 15;82(8):997-9

Hyperhomocysteinemia, aortic thrombus, and peripheral arterial emboli--a case report. Sindhav JB, et al. **Angiology** 1999 Jul;50(7):599-603

Intravascular ultrasound and histology in in vitro assessment of iliac artery angioplasty. van Lankeren W, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):50-5

External iliac artery endofibrosis in a young cyclist. Abraham P, et al. **Circulation** 1999 Aug 3;100(5):e38

Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group. Bosch JL, et al. **Circulation** 1999 Jun 22;99(24):3155-60

Intraluminal signal intensity of iliac artery stents investigated by contrast-enhanced three-dimensional MR angiography. Amano Y, et al. **Comput Med Imaging Graph** 1998 Jan-Feb; 22(1):9-12

Arterial damage induced by cryopreservation is irreversible following organ culture. Bellón JM, et al. **Eur J Vasc Endovasc Surg** 1999 Feb;17(2):136-43

Thickness, taper, and ellipticity in the aortoiliac bifurcation of patients aged 1 day to 76 years. MacLean NF, et al. **Heart Vessels** 1998;13(2):95-101

Local gene delivery within the media of rabbit iliac arteries by using the infiltrator intramural delivery device. Teiger E, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):726-32

The effect of nonporous PTFE-covered stents on intimal hyperplasia following balloon arterial injury in minipigs. Yuan JG, et al. **J Endovasc Surg** 1998 Nov;5(4):349-58

Impact of different hemodynamic criteria for stent placement after suboptimal iliac angioplasty. Dutch Iliac Stent Trial Study Group. Kamphuis AG, et al. **J Vasc Interv Radiol** 1999 Jun;10(6):741-6

Histopathologic evaluation of an expanded polytetrafluoroethylene-nitinol stent endoprosthesis in canine iliofemoral arteries. Virmani R, et al. **J Vasc Interv Radiol** 1999 Apr;10(4):445-56

Psoralen and long wavelength ultraviolet radiation as an adjuvant therapy for prevention of intimal hyperplasia and constrictive remodeling after balloon dilation: a study in the rabbit iliac artery. Perrée J, et al. **Lasers Surg Med** 1998;23(5):281-90

Aortoiliac and lower extremity arteries: comparison of three-dimensional dynamic contrast-enhanced subtraction MR angiography and conventional angiography. Sueyoshi E, et al. **Radiology** 1999 Mar;210(3):683-8

Angiographic arterial occlusion and extra-anatomical vascular bypass for the management of a ureteral-iliac fistula: case report and review of the literature. Gheiler EL, et al. **Urol Int** 1998 Oct;61(1):62-6 (33 ref.)

[Comparison of magnetic resonance angiography with injection of gadolinium and conventional arteriography of the ilio-femoral arteries] Perrier E, et al. **J Radiol** 1998 Dec;79(12):1493-8 (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Characterization of the "silent" 5-HT1B receptors of rabbit iliac artery. Yildiz O, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:259

Daily exercise enhances acetylcholine-induced dilation in mesenteric and hindlimb vasculature of hypertensive rats. Chen Y, et al. **Clin Exp Hypertens** 1999 May;21(4):353-76

Visualization of flow patterns from stents and stent-grafts in an in vitro flow-model. Müller-Hülsbeck S, et al. **Invest Radiol** 1998 Oct;33(10):762-70

PHYSIOPATHOLOGY

Elastic response of human iliac arteries in-vitro to balloon angioplasty using high-resolution CT. Medynsky AO, et al. **J Biomech** 1998 Aug;31(8):747-51

Ligation of internal iliac arteries in pelvic haemorrhage. Das BN, et al. **J Obstet Gynaecol Res** 1998 Aug;24(4):251-4

Combination of pressure and velocity parameters in the non-invasive diagnosis of aorto-iliac disease. Fronek A, et al. **Vasc Med** 1999;4(2):77-81

RADIOGRAPHY

Local effect of three nonionic contrast media on the arterial blood flow velocity during iliofemoral arteriography. Zwaan M, et al. **Invest Radiol** 1999 Jan;34(1):5-12

Spiral CT angiography versus aortography in the assessment of aortoiliac length in patients undergoing endovascular abdominal aortic aneurysm repair. Armon MP, et al. **J Endovasc Surg** 1998 Aug;5(3):222-7

Common and external iliac artery injuries associated with pelvic fractures. Carrillo EH, et al. **J Orthop Trauma** 1999 Jun-Jul;13(5):351-5

Special exhibit for the SCVIR Annual Meeting Film Panel Session: diagnosis and discussion of cases 5-8. Society of Cardiovascular & Interventional Radiology. Case 6. Blue-toe syndrome secondary to embolization from a complex right common iliac artery plaque containing fresh thrombus material. LaBerge JM, et al. **J Vasc Interv Radiol** 1999 May;10(5):653, 658-61

Gadolinium-enhanced three-dimensional MR angiography of the entire aorta and iliac arteries with dynamic manual table translation. Earls JP, et al. **Radiology** 1998 Dec; 209(3):844-9

Penile arteriography. Borge MA. **Tech Urol** 1999 Jun; 5(2):81-6 (9 ref.)

Quantification of iliac artery stenoses: a methodological comparative study between intravascular ultrasound, arteriography and duplex scanning. Vogt KC, et al. **Ultrasound Med Biol** 1998 Sep;24(7):963-70

[Arteriography in critical changes in the iliac arterial bed] Karev AV, et al. **Vestn Khir Im I I Grek** 1999;158(1):58-61 (Eng. Abstr.) **(Rus)**

SURGERY

Analysis of endovascular graft treatment for aortoiliac occlusive disease: what is its role based on midterm results? Wain RA, et al. **Ann Surg** 1999 Aug;230(2):145-51

Iliac to popliteal artery bypass through the iliac wing: An alternative extracavitary route for management of complex groin injuries. Donayre CE, et al. **Ann Vasc Surg** 1999 Mar; 13(2):209-15 (23 ref.)

Role of direct revascularization of the internal iliac artery during aortoiliac surgery. Hassen-Khodja R, et al. **Ann Vasc Surg** 1998 Nov;12(6):550-6

May-Thurner syndrome: management by endovascular surgical techniques. Heniford BT, et al. **Ann Vasc Surg** 1998 Sep;12(5):482-6

Aortoiliac reconstruction and kidney transplantation: a multicenter study. Pittaluga P, et al. **Ann Vasc Surg** 1998 Nov;12(6):529-36

Revascularization of internal iliac arteries during aortoiliac surgery: a multicenter study. Pittaluga P, et al. **Ann Vasc Surg** 1998 Nov;12(6):537-43

Combined use of iliac artery angioplasty and infrainguinal revascularization for treatment of multilevel atherosclerotic disease. Siskin G, et al. **Ann Vasc Surg** 1999 Jan;13(1):45-51

Single and tandem stents in sheep iliac arteries: is there a difference in patency? Schürmann K, et al. **Cardiovasc Intervent Radiol** 1998 Sep-Oct;21(5):411-8

Femoral anastomotic aneurysms: pathogenic factors, clinical presentations and treatment. A study of 142 cases. Demarche M, et al. **Cardiovasc Surg** 1999 Apr;7(3):315-22

Arterial reconstruction with vascular clips is safe and quicker than sutured repair. Pikoulis E, et al. **Cardiovasc Surg** 1998 Dec;6(6):573-8

Metallic artifacts of coronary and iliac arteries stents in MR angiography and contrast-enhanced CT. Amano Y, et al. **Clin Imaging** 1999 Mar-Apr;23(2):85-9

Semiclosed iliac recanalisation by an inguinal approach--modified surgical techniques integrating interventional procedures. Schröder A, et al. **Eur J Vasc Endovasc Surg** 1998 Dec;16(6):501-8

Endovascular repair of iliac aneurysms following aortoiliac surgery. Vraux H, et al. **Eur J Vasc Endovasc Surg** 1999 May;17(5):442-5 (9 ref.)

Prophylactic internal iliac artery ligation in gynecologic pelvic surgery. Gharoro EP, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):307-9

Common and external iliac artery injuries associated with pelvic fractures. Carrillo EH, et al. **J Orthop Trauma** 1999 Jun-Jul;13(5):351-5

Internal to external iliac artery stent-graft: a new technique for vessel exclusion. Hoffer EK, et al. **J Vasc Interv Radiol** 1999 Sep;10(8):1067-73

Preliminary results with a new vascular basket occluder in swine. Kónya A, et al. **J Vasc Interv Radiol** 1999 Sep; 10(8):1043-9

Iliac-to-isolated hepatic artery bypass in the treatment of intestinal angina: two cases. Cavallaro A, et al. **J Vasc Surg** 1998 Dec;28(6):1115-9

Video-assisted crossover iliofemoral obturator bypass grafting: a minimally invasive approach to extra-anatomic lower limb revascularization. Geier B, et al. **J Vasc Surg** 1999 Apr;29(4):730-3

Descending thoracic aorta to iliofemoral artery bypass grafting: a role for primary revascularization for aortoiliac occlusive disease? Passman MA, et al. **J Vasc Surg** 1999 Feb;29(2):249-58

Early complications of femorofemoral crossover bypass grafts after aorta uni-iliac endovascular repair of abdominal aortic aneurysms. Walker SR, et al. **J Vasc Surg** 1998 Oct; 28(4):647-50

Aortomonoiliac endovascular grafting combined with femorofemoral bypass: an acceptable compromise or a preferred solution? Chuter TA, et al. **Semin Vasc Surg** 1999 Sep;12(3):176-81

A double bifurcated graft for abdominal aorta and bilateral iliac artery reconstruction. Akiyama K, et al. **Surg Today** 1999;29(4):313-6

Surgery for descending thoracic aortic anastomotic aneurysms with a temporary external bypass method. Miyata T, et al. **Surg Today** 1999;29(2):129-36

Renal transplantation in patients with a vascular aortoiliac prosthesis. Coosemans W, et al. **Transplant Proc** 1999 Jun; 31(4):1925-7

Ex vivo reno-vascular reconstruction in living kidney transplantation. Kawase T, et al. **Transplant Proc** 1998 Nov; 30(7):2993-4

Various vascular procedures in kidney transplantations. Moon I, et al. **Transplant Proc** 1998 Nov;30(7):3006

Mesenteric infarction after aortoiliac surgery on the basis of 1752 operations from the National Vascular Registry. Järvinen O, et al. **World J Surg** 1999 Mar;23(3):243-7

[Bilateral aneurysm of the common iliac artery and kidney pelvic ectopia: endovascular treatment] Lopez Trapero V, et al. **J Mal Vasc** 1999 Feb;24(1):42-4 (Eng. Abstr.) **(Fre)**

[Iliaco-ureteral fistula and its treatment with a stent graft] Krenzien J, et al. **Chirurg** 1998 Sep;69(9):977-80 (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of second aortoenteric fistulas: results of 16 patients] Müller BT, et al. **Chirurg** 1999 Apr; 70(4):415-21 (Eng. Abstr.) **(Ger)**

[The infected arterial stent] Müller G, et al. **Chirurg** 1998 Aug;69(8):872-6 (Eng. Abstr.) **(Ger)**

[Results of 31 laparoscopic interventions of the aorto-iliac vessels for arterial occlusive disease] Barbera L, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:528-31 (Eng. Abstr.) **(Ger)**

[The value of a fabric-coated self-expanding stent in iliac arterial occlusions or aneurysms--the primary and long-term results] Scheinert D, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Sep;169(3):302-9 (Eng. Abstr.) **(Ger)**

[Preservation of pelvic vascularization in surgery of aneurysms of the abdominal aorta] Cardia G, et al. **Minerva Cardioangiol** 1998 Sep;46(9):276-9 **(Ita)**

[Evaluation of factors influencing the result of surgical treatment in patients with ruptured aneurysm of the abdominal aorta and iliac arteries] Grączewski J. **Ann Acad Med Stetin** 1998;44:101-14 (Eng. Abstr.) **(Pol)**

[Aortoiliac graft infection as a diagnostic and treatment problem] Gutowski P. **Ann Acad Med Stetin** 1998;Suppl 41:1-72 (143 ref.) (Eng. Abstr.) **(Pol)**

[Extraanatomical bypass as a reoperation in complication of major artery injury] Lokhvitskii SV, et al. **Khirurgiia (Mosk)** 1999;(1):55-6 **(Rus)**

TRANSPLANTATION

Dissection of an iliac artery conduit to liver allograft: treatment with an endovascular stent. Stein M, et al. **Liver Transpl Surg** 1999 May;5(3):252-4

Preserved vascular homograft for revascularization of pediatric liver transplant: a clinical, histological, and bacteriological study. Martinez JA, et al. **Transplantation** 1999 Sep 15;68(5):672-7

[Biomechanical study of the vasomotor system of the arterial smooth muscle after long-term cryopreservation of a human arterial graft at two different temperatures -80and -150C] Cardon A, et al. **J Mal Vasc** 1999 May;24(2):118-25 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Angle dependence of intravascular ultrasound imaging and its feasibility in tissue characterization of human atherosclerotic tissue. Hiro T, et al. **Am Heart J** 1999 Mar; 137(3):476-81

Intravascular ultrasound and histology in in vitro assessment of iliac artery angioplasty. van Lankeren W, et al. **Cardiovasc Intervent Radiol** 1999 Jan;22(1):50-5

The use of the echo-enhancing agent Levovist does not influence the estimation of the degree of vascular stenosis calculated from peak systolic velocity ratio, diameter reduction and cross section area reduction. Kröger K, et al. **Eur J Ultrasound** 1998 Sep;8(1):17-24

Does Dopplersignal enhancement with Levovist improve the diagnostic confidence of duplex scanning of the iliac arteries?--(A pilot study with correlation to intravascular ultrasound). Vogt KC, et al. **Eur J Ultrasound** 1998 Aug; 7(3):159-65

Effect and outcome of balloon angioplasty and stenting of the iliac arteries evaluated by intravascular ultrasound. Vogt KJ, et al. **Eur J Vasc Endovasc Surg** 1999 Jan; 17(1):47-55

Surgical transluminal iliac angioplasty with selective stenting: long-term results assessed by means of duplex scanning. Becquemin JP, et al. **J Vasc Surg** 1999 Mar;29(3):422-9

Ultrasonographic screening for arterial occlusive disease in the pelvis and lower extremities. Hirai T, et al. **Radiat Med** 1998 Nov-Dec;16(6):411-6

Quantification of iliac artery stenoses: a methodological comparative study between intravascular ultrasound, arteriography and duplex scanning. Vogt KC, et al. **Ultrasound Med Biol** 1998 Sep;24(7):963-70

The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle. Engmann L, et al. **Ultrasound Obstet Gynecol** 1999 Jan;13(1):26-33

ILIAC VEIN

Treatment of venous outflow stenoses in thigh grafts with Wallstents. Funaki B, et al. **AJR Am J Roentgenol** 1999 Jun;172(6):1591-6

Safety and efficacy of catheter-directed thrombolysis for iliofemoral venous thrombosis. Grossman C, et al. **AJR Am J Roentgenol** 1999 Mar;172(3):667-72 (42 ref.)

Aneurysm of the iliofemoral vein. Fourneau I, et al. **Ann Vasc Surg** 1998 Nov;12(6):605–8 (18 ref.)
Thrombolytic therapy: the treatment of choice for iliac vein thrombosis in the presence of kidney transplant. Tamim W, et al. **Ann Vasc Surg** 1999 Jul;13(4):436–8
Treatment of May–Thurner syndrome with catheter-directed thrombolysis and stent placement, complicated by heparin-induced thrombocytopenia. Seidensticker D, et al. **Cardiovasc Surg** 1998 Dec;6(6):607–13 (29 ref.)
Percutaneous ilio-caval thrombectomy with the Amplatz device: preliminary results. Gandini R, et al. **Eur Radiol** 1999;9(5):951–8
Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. Kirchmaier CM, et al. **Int Angiol** 1998 Sep;17(3):135–45
Psoas abscess associated with iliac vein thrombosis and piriformis and gluteal abscesses. Arai Y, et al. **Int J Urol** 1999 May;6(5):257–9
Treatment of acute neonatal vascular injuries--the utility of multiple interventions. Friedman J, et al. **J Pediatr Surg** 1999 Jun;34(6):940–5
Challenging the role of cremasteric reflux in the pathogenesis of varicocele using a new venographic approach. Franco G, et al. **J Urol** 1999 Jan;161(1):117–21
Iliofemoral venous thrombolysis after failed surgical thrombectomy [letter] Rundback JH, et al. **J Vasc Interv Radiol** 1998 Sep–Oct;9(5):852–3
Unilateral iliac vein occlusion, caused by bladder enlargement, simulating deep venous thrombosis. Ducharme SE, et al. **J Vasc Surg** 1999 Apr;29(4):724–6
Magnetic resonance imaging of the abdominal aorta and iliac vessels using combined 3-D gadolinium-enhanced MRA and gadolinium-enhanced fat-suppressed spoiled gradient echo sequences. Kelekis NL, et al. **Magn Reson Imaging** 1999 Jun;17(5):641–51
Arteriovenous fistula as a complication of lumbar disc surgery: case report. Santos E, et al. **Neuroradiology** 1998 Jul;40(7):459–61
Transiliac catheterization of the inferior vena cava for long-term venous access in children. Ikeda S, et al. **Pediatr Surg Int** 1998 Nov;14(1–2):140–1
Use of the Amplatz thrombectomy device for severe deep venous thrombosis. Houry D, et al. **South Med J** 1999 Sep; 92(9):915–7
Iliac vein blood sampling in wild, culled roe deer (Capreolus capreolus). Urquhart KA. **Vet Rec** 1999 Mar 27;144(13):353
[Successful lysis therapy of inferior vena cava and iliofemoral venous thrombosis in heparin-induced thrombocytopenia type II (letter; comment)] Fischer KG. **Dtsch Med Wochenschr** 1999 Jan 8;124(1–2):32–3. Comment on: Dtsch Med Wochenschr 1997 Aug 1;122(31–32):965–8. **(Ger)**
[Skin necrosis in the front foot area during anticoagulation with phenprocoumon] Schmidt M, et al. **Dtsch Med Wochenschr** 1999 Jun 11;124(23):727–30 (Eng. Abstr.) **(Ger)**
[Ilio femoral thrombosis: an infrequent complication of an aortic and iliac aneurysm. Report of two cases] Mertens R, et al. **Rev Med Chil** 1999 Apr;127(4):459–62 (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Extrauterine pelvic arteriovenous malformation mimicking the clinical presentation of structural heart disease. Chen SC, et al. **Int J Cardiol** 1999 Jun 1;69(3):305–8
Percutaneous treatment of rare latrogenic arteriovenous fistulas of the lower limbs. Bürger T, et al. **Int Surg** 1998 Jul–Sep;83(3):198–201
Retrocaval ureter and preaortic iliac venous confluence in a patient with an abdominal aortic aneurysm. Shindo S, et al. **Surg Radiol Anat** 1999;21(2):147–9
Right iliac vein agenesis, varicosities, and widespread hemangiomas: report of a rare case. Kutsal A, et al. **Tex Heart Inst J** 1999;26(2):149–51

INJURIES

Non-surgical retrieval of a bullet embolus from the right heart. Kaushik VS, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):55–7
Leech therapy in the management of acute venous congestion of an infant's lower limb. Weinfeld AB, et al. **Plast Reconstr Surg** 1998 Oct;102(5):1611–4
[Vascular complications during laparoscopy. An analysis of a personal case] Esposito C, et al. **Minerva Chir** 1999 Mar; 54(3):163–5 (9 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Catheter-directed thrombolysis in acute, infected iliofemoral venous thrombosis. McCollom VE, et al. **J Vasc Interv Radiol** 1998 Nov–Dec;9(6):941–4
Relief of obstructive pelvic venous symptoms with endoluminal stenting. Blättler W, et al. **J Vasc Surg** 1999 Mar;29(3):484–8
[The iliac vein occlusion] Baeshko AA, et al. **Klin Khir** 1999; (4):19–21 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Central venous pressure from common iliac vein reflects right atrial pressure. Alzeer A, et al. **Can J Anaesth** 1998 Aug; 45(8):798–801

SURGERY

May–Thurner syndrome: management by endovascular surgical techniques. Heniford BT, et al. **Ann Vasc Surg** 1998 Sep;12(5):482–6
Spontaneous common iliac vein rupture: a case report. DePass IE. **Can J Surg** 1998 Dec;41(6):473–5 (13 ref.)
New trends in the surgical and endovascular reconstructions of large veins for nonmalignant chronic venous occlusive disease. Alimi YS, et al. **Curr Opin Cardiol** 1998 Sep; 13(5):375–83 (51 ref.)
Influence of ligation of the internal iliac veins on the venous plexuses around the sacrum. Hata M, et al. **J Orthop Sci** 1998;3(5):264–71
Venous bypass and valve reconstruction: long-term efficacy. Eklof BG, et al. **Vasc Med** 1998;3(2):157–64 (43 ref.)
[Reconstructive surgery of the cavo-ilio-femoral segment in acute occlusion] Alemany J, et al. **Zentralbl Chir** 1999; 124(1):37–41 (Eng. Abstr.) **(Ger)**
[Stent implantation after thrombectomy of pelvic veins. Indications, results] Mickley V, et al. **Zentralbl Chir** 1999; 124(1):12–7 (Eng. Abstr.) **(Ger)**
[Ligation of iliac internal arteries in advanced endometrial cancer] Warelis M, et al. **Ginekol Pol** 1997 Nov; 68(11):565–6 (Eng. Abstr.) **(Pol)**
[Treatment of iliac vein thrombosis by use of filter placed in the inferior cava vein in a female patient after reoperation of meningioma of the smaller section of the sphenoid bone] Gościński I, et al. **Neurol Neurochir Pol** 1998 May–Jun; 32(3):689–97 (Eng. Abstr.) **(Pol)**
[An iliac-mesenteric-atrial shunt in the Budd-Chiari syndrome with extensive thrombosis of the inferior vena cava] Bancu S, et al. **Chirurgia (Bucur)** 1998 May–Jun; 93(3):165–9 (7 ref.) (Eng. Abstr.) **(Rum)**

TRANSPLANTATION

Selective distal splenorenal shunt without requiring splenopancreatic disconnection with the use of the external iliac vein graft: a preliminary report. Kato K, et al. **Surgery** 1999 Sep;126(3):577–80
Preserved vascular homograft for revascularization of pediatric liver transplant: a clinical, histological, and bacteriological study. Martinez JA, et al. **Transplantation** 1999 Sep 15;68(5):672–7

ULTRASONOGRAPHY

[Iliac vein insufficiency syndrome. Clinical contribution] Belardi P, et al. **Minerva Cardioangiol** 1998 Jun;46(6):211–4 (Eng. Abstr.) **(Ita)**

ILIUM

Bone metastasis of intracranial germinoma. Itami J, et al. **Acta Oncol** 1999;38(2):267–8
Malignant haemangioendothelioma of bone in a HbSC disease patient--a case report. Shokunbi WA, et al. **Afr J Med Med Sci** 1996 Sep;25(3):293–6
Intrapelvic cyst formation after hip arthroplasty with a carbon fibre-reinforced polyethylene socket. Korkala O, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):113–5 (8 ref.)
Functional results after partial pelvic resection in Ewing's sarcoma of the ilium. Porsch M, et al. **Arch Orthop Trauma Surg** 1999;119(3–4):199–204
Histomorphometry and bone biomarkers in cynomolgus females: a study in young, mature, and old monkeys. Lees CJ, et al. **Bone** 1999 Jan;24(1):25–8
A 90-year-old woman presenting with hip pain [clinical conference] Banaszkiewicz P, et al. **Clin Orthop** 1999 Jan; (358):250–4, 257–8
Primary angiosarcoma of bone in Paget's disease. Boulanger V, et al. **Eur J Surg Oncol** 1998 Dec;24(6):611–3
Idiopathic iliopsoas bursitis [letter] Salmerón I, et al. **Eur Radiol** 1999;9(1):175
Fortuitous diagnosis of iliac osteomyelitis: septic arthritis of the hip in the neonate. Duffy TN, et al. **J Am Osteopath Assoc** 1998 Dec;98(12):689–92
Primary iliac muscle abscess due to Staphylococcus aureus. Liu KY, et al. **J Formos Med Assoc** 1999 Jun;98(6):452–4
Chondrosarcoma and myositis ossificans. Le Roux DA. **J Manipulative Physiol Ther** 1998 Nov–Dec;21(9):640–8
Chondromyxoid fibroma of bone presenting as chronic back pain [published erratum appears in J Manipulative Physiol Ther 1999 Feb;22(2):122] Schmidt RG, et al. **J Manipulative Physiol Ther** 1998 Oct;21(8):564–7
Polyradiculoneuropathy revealing a solitary plasmacytoma of the ilium. A new case-report. Niamane R, et al. **Rev Rhum Engl Ed** 1999 Apr;66(4):229–31
Ewing's sarcoma of the ilium mimicking sacroiliitis [letter] Al-Adsani A, et al. **Rheumatology (Oxford)** 1999 Aug; 38(8):792–3
Bifocal sclerosing osteosarcoma: unusual presentation and course. Abramovici L, et al. **Skeletal Radiol** 1998 Aug; 27(8):449–52
Parosteal osteoma of the iliac bone [letter; comment] Ehara S. **Skeletal Radiol** 1998 Nov;27(11):650. Comment on: Skeletal Radiol 1998 Mar;27(3):161–3.
Clear cell chondrosarcoma of the pelvis in a skeletally immature patient. Ishida T, et al. **Skeletal Radiol** 1999 May; 28(5):290–3
[L5 sciatica caused by the compression of the lumbo-sacral trunk of osseous origin at the sacro-iliac level. Treatment by an antero-lateral subperitoneal approach] Chataigner H, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Jul; 84(4):377–80 (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Differences in the iliolumbar ligament and the transverse process of the L5 vertebra in young white and black people. Hanson P, et al. **Acta Anat (Basel)** 1998;163(4):218–23
Relationship between foo: length and the inter anterior superior iliac distance. Waikakul S, et al. **Injury** 1998 Dec; 29(10):763–7
Bone marrow composition and bone microarchitecture and turnover in blacks and whites. Schnitzler CM, et al. **J Bone Miner Res** 1998 Aug;13(8):1300–7

CHEMISTRY

Scanning small angle X-ray scattering analysis of human bone sections. Rinnerthaler S, et al. **Calcif Tissue Int** 1999 May;64(5):422–9

DRUG EFFECTS

Effects of recombinant human bone morphogenetic protein-2 on differentiation of cells isolated from human bone, muscle, and skin. Kawasaki K, et al. **Bone** 1998 Sep; 23(3):223–31

EMBRYOLOGY

Iliac angle as a marker for Down syndrome in second-trimester fetuses: CT measurement. Zook PD, et al. **Radiology** 1999 May;211(2):447–51

IMMUNOLOGY

Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Mitchell EA, et al. **Eur J Immunol** 1998 Oct;28(10):3066–74

INJURIES

Stress fracture of the iliac wing due to bone insufficiency. Report of a case [letter; comment] Françon C, et al. **Rev Rhum Engl Ed** 1998 Oct;65(10):598–600 (11 ref.). Comment on: Rev Rhum Engl Ed 1997 Oct;64(10):542–8. Comment on: Rev Rhum Engl Ed 1997 Dec;64(12):853–4.
[A new type of iliac fracture caused by bone insufficiency] el Maghraoui A, et al. **Presse Med** 1999 Jun 19; 28(22):1161–3 (Eng. Abstr.) **(Fre)**
[Pathological fracture of the ala of the ilium as the form of presentation of an adenocarcinoma of unknown origin (letter)] Iglesias D, et al. **An Med Interna** 1999 Jan;16(1):55 **(Spa)**

INNERVATION

Relationship of the nerve with the iliac crest [letter] Maigne JY, et al. **Clin Orthop** 1999 Mar;(360):270–2

METABOLISM

Age-related changes in the biochemical properties of human cancellous bone collagen: relationship to bone strength. Bailey AJ, et al. **Calcif Tissue Int** 1999 Sep;65(3):203–10

PATHOLOGY

Correlations between bone histopathology and serum biochemistry in uremic patients on chronic hemodialysis. Canavese C, et al. **Int J Artif Organs** 1998 Aug;21(8):443–50
What is your diagnosis? An aggressive bony lesion in the left ilium and severe degenerative changes in the right coxal joint and lumbosacral disk space. Randell SC, et al. **J Am Vet Med Assoc** 1999 Feb 1;214(3):331–2
A new test for estimating iliotibial band contracture [letter; comment] Sunil TM. **J Bone Joint Surg Br** 1999 Mar; 81(2):370–1. Comment on: J Bone Joint Surg Br 1998 May;80(3):474–5.
Iliac cancellous bone in drug addicts: a histomorphometric study. Schiwy-Bochat KH, et al. **J Forensic Sci** 1999 Mar; 44(2):249–52
Histomorphometric study of iliac bones in cervical myelopathy with ossification of the posterior longitudinal ligament. Aita I, et al. **J Orthop Sci** 1998;3(6):324–9
Bone scan and bone biopsy in the detection of skeletal metastases. Ron IG, et al. **Oncol Rep** 1999 Jan–Feb; 6(1):185–8
Structural mechanisms of bone loss in iliac biopsies: comparison between rheumatoid arthritis and postmenopausal osteoporosis. Hanyu T, et al. **Rheumatol Int** 1999;18(5–6):193–200

PHYSIOPATHOLOGY

Can an anomalous lumbo-sacral or lumbo-iliac articulation cause low back pain? A retrospective study of 12 cases. Avimadje M, et al. **Rev Rhum Engl Ed** 1999 Jan;66(1):35–9 (6 ref.)

RADIOGRAPHY

Analysis of trabecular microarchitecture of human iliac bone using microcomputed tomography in patients with hip arthrosis with or without vertebral fracture. Ito M, et al.

Bone 1998 Aug;23(2):163–9

Iliac angle as a marker for Down syndrome in second-trimester fetuses: CT measurement. Zook PD, et al. **Radiology** 1999 May;211(2):447–51

[Picture of the month. Iatrogenic hernia] Larsen CG, et al. **Ugeskr Laeger** 1999 Mar 29;161(13):1934 **(Dan)**

[Air in the bone? Diagnosis and treatment of a pneumatocyst of the ilium. Apropos of a case] Colineau X, et al. **J Radiol** 1998 Dec;79(12):1503–5 (Eng. Abstr.) **(Fre)**

[Reference values for development of the iliac crest apophysis (Risser sign)] Diedrichs V, et al. **Z Orthop Ihre Grenzgeb** 1998 May–Jun;136(3):226–9 (Eng. Abstr.) **(Ger)**

SURGERY

Enterocutaneous fistula: a complication of posterior iliac bone graft harvesting not previously described. Dösoğlu M, et al. **Acta Neurochir (Wien)** 1998;140(10):1089–92

A prospective study of trephined bone grafts of the tibial shaft and iliac crest. Ilankovan V, et al. **Br J Oral Maxillofac Surg** 1998 Dec;36(6):434–9

Critical size defect in the goat's os ilium. A model to evaluate bone grafts and substitutes. Anderson ML, et al. **Clin Orthop** 1999 Jul;(364):231–9

Alveolar soft part sarcoma involving the ilium. A case report. Durkin RC, et al. **Clin Orthop** 1999 Feb;(359):197–202 (21 ref.)

Bilateral posterior pelvic resection osteotomies in patients with exstrophy of the bladder. Gugenheim JJ, et al. **Clin Orthop** 1999 Jul;(364):70–5

An aiming device for pin fixation at the iliac crest for external fixation in unstable pelvic fracture. Waikakul S, et al. **Injury** 1998 Dec;29(10):757–62

TRANSPLANTATION

The surgical treatment of osteonecrosis of the femoral head with an osteochondral allograft. Meyers MH. **Acta Orthop Belg** 1999;65 Suppl 1:66–7

Repair of osteochondral defects with autogenous callo-osseous grafts. Takahashi S, et al. **Acta Orthop Belg** 1999;65 Suppl 1:136–41

Can autologous bone culture predict spinal fusion capacity? Christensen FB, et al. **Eur Spine J** 1999;8(1):54–60

Sacrospinalis muscle-pedicle bone graft in posterolateral fusion for spondylolisthesis. Baksi DP. **Int Orthop** 1998; 22(4):234–40

Long-term follow-up of the vascularized iliac bone graft. Ikeda K, et al. **Microsurgery** 1998;18(7):419–23

Vascularized iliac bone graft for displaced femoral neck fractures in young adults. Chang MC, et al. **Orthopedics** 1999 May;22(5):493–9

Direct repair of spondylolysis without spondylolisthesis, using a rod-screw construct and bone grafting of the pars defect. Gillet P, et al. **Spine** 1999 Jun 15;24(12):1252–6

Optimal selection and preparation of fresh frozen corticocancellous allografts for cervical interbody spinal fusion. Kummer FJ, et al. **Spine** 1998 Nov 1;23(21):2295–8

Minimum 5-year follow-up of anterior column structural allografts in the thoracic and lumbar spine. Molinari RW, et al. **Spine** 1999 May 15;24(10):967–72

Anatomic basis of iliac crest flap pedicled on the iliolumbar artery. Chen RS, et al. **Surg Radiol Anat** 1999;21(2):103–7

[Free autologous iliac graft in femoral head osteonecrosis] van Elegem P. **Acta Orthop Belg** 1999;65 Suppl 1:62–5 (Eng. Abstr.) **(Fre)**

[Treatment of substance loss of the bones of the leg in traumatology by transfer of the free vascularized iliac crest. Apropos of 13 cases] Legré R, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 May; 84(3):264–71 (Eng. Abstr.) **(Fre)**

[Osseous reconstruction of the patella with screwed autologous graft in the course of repeat prosthesis of the knee] Tabutin J. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Jul; 84(4):363–7 (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Three-dimensional power Doppler sonography of tumor vascularity. Hirai T, et al. **Radiat Med** 1998 Sep–Oct; 16(5):353–7

The second-trimester fetal iliac angle as a sign of Down's syndrome. Shipp TD, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):15–8

Can fetal iliac bone measurement be used as a marker for Down's syndrome screening? Zoppi MA, et al. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):19–22

ULTRASTRUCTURE

Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies [see comments] Roschger P, et al. **Bone** 1998 Oct;23(4):319–26. Comment in: Bone 1999 Jun;24(6):619–21.

The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Boyde A, et al. **Calcif Tissue Int** 1999 Mar;64(3):185–90

Bone marrow composition and bone microarchitecture and turnover in blacks and whites. Schnitzler CM, et al. **J Bone Miner Res** 1998 Aug;13(8):1300–7

VIROLOGY

Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction. Mee AP, et al. **Bone** 1998 Aug;23(2):171–5

ILIZAROV TECHNIQUE

see related

OSTEOGENESIS, DISTRACTION

Ilizarov circular external fixator for open olecranon fractures--a report of 3 cases. Aktuglu K, et al. **Acta Orthop Scand** 1999 Feb;70(1):93–6

Failed treatment of congenital pseudoarthrosis of the tibia--a case of Ilizarov-transportation of proximal tibia with arthrodesis to talus. Velan GJ, et al. **Acta Orthop Scand** 1998 Aug;69(4):433–4

Non-free osteoplasty of the mandible in maxillofacial gunshot wounds: mandibular reconstruction by compression-osteodistraction. Shvyrkov MB, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):261–7

Correction of post burns contracture of wrist with Ilizarov method. Madhuri V, et al. **Burns** 1998 Sep;24(6):576–8

The Ilizarov method. Orthopedic and soft tissue applications. Gugenheim JJ Jr. **Clin Plast Surg** 1998 Oct;25(4):567–78 (68 ref.)

Temporary muscle weakness in the early phase of distraction during femoral lengthening. Clinical and electromyographical observations. Oey PL, et al. **Electromyogr Clin Neurophysiol** 1999 Jun;39(4):217–20

Joint distraction as treatment for ankle osteoarthritis. van Roermund PM, et al. **Instr Course Lect** 1999;48:249–54 (20 ref.)

Treatment of tibial bone defects with the Ilizarov circular external fixator in high-velocity gunshot wounds. Atesalp AS, et al. **Int Orthop** 1998;22(6):343–7

Spontaneous healing of an atrophic pseudoarthrosis during femoral lengthening. A case report with six-year follow-up. Song HR, et al. **Int Orthop** 1999;23(2):126–7

Tibial bone defects treated by internal bone transport using the Ilizarov method. Song HR, et al. **Int Orthop** 1998; 22(5):293–7

Chondrodiatasis in a patient with spondyloepimetaphyseal dysplasia using the Ilizarov technique: successful correction of an angular deformity with ensuing ossification of a large metaphyseal lesion. A case report. Valdivia GG, et al. **Int Orthop** 1998;22(6):400–3

Use of Ilizarov external fixation for a periprosthetic supracondylar femur fracture. Simon RG, et al. **J Arthroplasty** 1999 Jan;14(1):118–21

Biomechanical properties of tendons during lower-leg lengthening in dogs using the Ilizarov method. Fink B, et al. **J Biomech** 1999 Aug;32(8):763–8

The Ilizarov technique for treatment of sequelae of childhood-acquired bone and joint infection. Wang CT, et al. **J Formos Med Assoc** 1999 Mar;98(3):175–82

Lengthening of pediatric forearm deformities using the Ilizarov technique: functional and cosmetic results. Raimondo RA, et al. **J Hand Surg [Am]** 1999 Mar; 24(2):331–8

Correction of soft tissue contractures of the wrist using the Ilizarov technique. Niall DM, et al. **J Hand Surg [Br]** 1998 Aug;23(4):442–4

Salvage of open tibial fracture with segmental loss of tibial nerve: case report and review of the literature. Higgins TF, et al. **J Orthop Trauma** 1999 Jun–Jul;13(5):380–5 (14 ref.)

Simultaneous ipsilateral femoral and tibial lengthening with the Ilizarov method. Curran AR, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):386–90

Behavior of tendons during lower-leg lengthening in dogs using the Ilizarov method. Fink B, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):380–5

Leg lengthening in spinal dysraphism. Haddad FS, et al. **J Pediatr Orthop** 1999 May–Jun;19(3):391–3

Ilizarov applications in the pediatric foot [letter; comment] Kara CS. **J Pediatr Orthop** 1998 Sep–Oct;18(5):695–6. Comment on: J Pediatr Orthop 1997 Nov–Dec;17(6):796–802.

[Use of Ilizarov fixator in the treatment of post-osteomyelitis pseudoarthroses in children] Zehi K, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1999 Jun; 85(3):231–7 (Eng. Abstr.) **(Fre)**

[Mandibular distraction using a dynamic osteosynthesis system: MD-DOS. Concepts and surgical technic] Mommaerts MY, et al. **Rev Stomatol Chir Maxillofac** 1998 Dec;99(5–6):223–30 (Eng. Abstr.) **(Fre)**

[A case of infected tibial pseudoarthrosis treated by Ilizarov method complicated by supracondylar traumatic fracture of the femur] Palczewski D, et al. **Chir Narzadow Ruchu Ortop Pol** 1998;63(4):395–8 (Eng. Abstr.) **(Pol)**

[Distraction osteosynthesis in occlusive diseases of the limb arteries] Shevtsov VI, et al. **Khirurgiia (Mosk)** 1998; (11):17–21 (Eng. Abstr.) **(Rus)**

[Current trends and problems in the measurement of limb loading parameters during transosseous osteosynthesis using external fixation devices] Shuts SA, et al. **Med Tekh** 1999 Jul–Aug;(4):21–30 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Lengthening of the tibia over an intramedullary nail, using the Ilizarov external fixator. Major complications and slow consolidation in 9 lengthenings. Kristiansen LP, et al. **Acta Orthop Scand** 1999 Jun;70(3):271–4

Distalization of the patella during tibial callus distraction. Eingartner C, et al. **Arch Orthop Trauma Surg** 1998; 117(6–7):397–8

High complication rate of reconstruction using Ilizarov bone transport method in patients with bone sarcomas. Ozaki T, et al. **Arch Orthop Trauma Surg** 1998;118(3):136–9

Post operative swelling in Ilizarov leg lengthening. Sharp RJ, et al. **Injury** 1998 Nov;29(9):717–8

[Personality changes in children treated by the Ilizarov device] Tarczyńska M, et al. **Pol Merkuriusz Lek** 1999 Jun; 6(36):317–21 (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

Lengthening of the tibia over an intramedullary nail, using the Ilizarov external fixator. Major complications and slow consolidation in 9 lengthenings. Kristiansen LP, et al. **Acta Orthop Scand** 1999 Jun;70(3):271–4

Salvage of contaminated fractures of the distal humerus with thin wire external fixation. Ring D, et al. **Clin Orthop** 1999 Feb;(359):203–8

Fracture reduction and deformity correction with the hexapod Ilizarov fixator. Seide K, et al. **Clin Orthop** 1999 Jun;(363):186–95

Repeatability of goniometer measurements of the knee in patients wearing an Ilizarov external fixator: a clinic-based study. Barker KL, et al. **Clin Rehabil** 1999 Apr;13(2):156–63

Estimation of artifacts induced by the Ilizarov device in quantitative computed tomographic analysis of tibiae. Salmas MG, et al. **Injury** 1998 Nov;29(9):711–6

The treatment of infected non-union of the tibia by compression-distraction techniques using the Ilizarov external fixator. Hosny G, et al. **Int Orthop** 1998; 22(5):298–302

Ilizarov's technique used to expand skin from a groin flap. Low CK, et al. **J Hand Surg [Br]** 1999 Jun;24(3):361–2

Use of modified Ilizarov olive wires as pushing wires. Atkins RM, et al. **J Orthop Trauma** 1998 Aug;12(6):436–8

Ilizarov external fixation in the management of bilateral, highly complex blast injuries of lower extremities: a report of two cases. Lerner A, et al. **J Orthop Trauma** 1998 Aug; 12(6):442–5

[Focus debridement of chronic sequestered talus osteomyelitis by TCNC arthrodesis. A new technique with ring fixateur] Weber M, et al. **Unfallchirurg** 1999 May; 102(5):402–5 (Eng. Abstr.) **(Ger)**

VETERINARY

Fracture treatment with circular external fixation. Marcellin-Little DJ. **Vet Clin North Am Small Anim Pract** 1999 Sep; 29(5):1153–70, vii (43 ref.)

Distraction osteogenesis. Welch RD, et al. **Vet Clin North Am Small Anim Pract** 1999 Sep; 29(5):1187–205, vii–viii (51 ref.)

ILLEGITIMACY

[In children, social determinants of health are changing (letter)] Berthier M, et al. **Arch Pediatr** 1999 May;6(5):594 **(Fre)**

HISTORY

Interacting factors affecting illegitimacy in preindustrial northern England. Scott S, et al. **J Biosoc Sci** 1997 Apr; 29(2):151–69

PREVENTION & CONTROL

The 'illegitimacy bonus' and state efforts to reduce out-of wedlock births. Donovan P. **Fam Plann Perspect** 1999 Mar–Apr;31(2):94–7

STATISTICS & NUMERICAL DATA

Changing patterns of extramarital conceptions in the Czech Republic, 1960–93. Stloukal L. **J Biosoc Sci** 1997 Oct; 29(4):471–89

TRENDS

Changing patterns of extramarital conceptions in the Czech Republic, 1960–93. Stloukal L. **J Biosoc Sci** 1997 Oct; 29(4):471–89

ILLICIT DRUG TESTING see **SUBSTANCE ABUSE DETECTION**

ILLICIT DRUGS see **STREET DRUGS**

ILLITERACY see **EDUCATIONAL STATUS**

ILLNESS BEHAVIOR see **SICK ROLE**

ILLNESS DAYS see **SICK LEAVE**

ILLUMINATING GAS POISONING see **CARBON MONOXIDE POISONING**

ILLUMINATION see **LIGHTING**

ILLUSIONS

Testing for glaucoma with the frequency-doubling illusion in the whole, macular and eccentric visual fields. Maddess T, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug; 27(3-4):194-6

Frequency, probability, and prediction: easy solutions to cognitive illusions? Griffin D, et al. **Cognit Psychol** 1999 Feb;38(1):48-78

Illusory inferences: a novel class of erroneous deductions [see comments] Johnson-Laird PN, et al. **Cognition** 1999 Jul 30;71(3):191-229. Comment in: Cognition 1999 Jul 30;71(3):187-9.

The writing of clinical papers: the analyst as illusionist. Plaut F. **J Anal Psychol** 1999 Jul;44(3):375-93; discussion 395-8

Perceptual independence of size and weight by dynamic touch. Amazeen EL.
J Exp Psychol Hum Percept Perform 1999 Feb;25(1):102-19

A sublexical locus for repetition blindness: evidence from illusory words. Morris AL, et al.
J Exp Psychol Hum Percept Perform 1999 Aug; 25(4):1060-75

This way up: illusions and internal models in the vestibular system [news] Snyder L. **Nat Neurosci** 1999 May;2(5):396-8

Why cars in the next lane seem to go faster. Redelmeier DA, et al. **Nature** 1999 Sep 2;401(6748):35

Auditory cortical responses in the cat to sounds that produce spatial illusions. Xu L, et al. **Nature** 1999 Jun 17; 399(6737):688-91

Is a common grouping mechanism involved in the phenomena of illusory continuity and stream segregation? Bregman AS, et al. **Percept Psychophys** 1999 Feb; 61(2):195-205

The surface-weight illusion: on the contribution of grip force to perceived heaviness. Rinkenauer G, et al.
Percept Psychophys 1999 Jan;61(1):23-30

The effect of timing and spatial separation on the velocity of auditory apparent motion. Strybel TZ, et al.
Percept Psychophys 1998 Nov;60(8):1441-51

Linear-vection chronometry along spinal and sagittal axes in erect man. Giannopulu I, et al. **Perception** 1998; 27(3):363-72

Stimulus eccentricity and spatial frequency interact to determine circular vection. Palmisano S, et al.
Perception 1998;27(9):1067-77

Engaging in "illusory control" during repeated risk-taking. Dixon MR, et al. **Psychol Rep** 1998 Dec;83(3 Pt 1):959-62

Second-order motions contribute to vection. Gurnsey R, et al. **Vision Res** 1998 Sep;38(18):2801-16

ETIOLOGY

Auditory illusions caused by a small lesion in the right medial geniculate body. Fukutake T, et al. **Neurology** 1998 Nov; 51(5):1469-71

PHYSIOLOGY

Neural substrates of the tilt illusion. Wenderoth P, et al.
Aust N Z J Ophthalmol 1999 Jun-Aug;27(3-4):271-4

The consciousness of sight. Zeman A. **BMJ** 1998 Dec 19-26; 317(7174):1696-7 (11 ref.)

Illusions as neuro-signs. Wade N. **Curr Biol** 1998 Oct 22; 8(21):R743

Illusory self-motion and motion sickness: a model for brain-gut interactions and nausea. Koch KL.
Dig Dis Sci 1999 Aug;44(8 Suppl):53S-57S (25 ref.)

Optic flow illusion and single neuron behaviour reconciled by a population model. Lappe M, et al. **Eur J Neurosci** 1999 Jul;11(7):2323-31

Antagonist motor responses correlate with kinesthetic illusions induced by tendon vibration. Calvin-Figuière S, et al. **Exp Brain Res** 1999 Feb;124(3):342-50

The influence of visual illusions on grasp position. Ellis RR, et al. **Exp Brain Res** 1999 Mar;125(2):109-14

Object size effects on initial lifting forces under microgravity conditions. Kingma I, et al. **Exp Brain Res** 1999 Feb; 124(4):422-8

Are perception and action affected differently by the Titchener circles illusion? Pavani F, et al.
Exp Brain Res 1999 Jul;127(1):95-101

Pointing movements are affected by size-contrast illusions. van Donkelaar P. **Exp Brain Res** 1999 Apr;125(4):517-20

Illusory arm movements activate cortical motor areas: a positron emission tomography study. Naito E, et al.
J Neurosci 1999 Jul 15;19(14):6134-44

Do animals see what we see? [news; comment] Ohzawa I. **Nat Neurosci** 1999 Jul;2(7):586-8. Comment on: Nat Neurosci 1999 Jul;2(7):660-3.

Neural bases of an auditory illusion and its elimination in owls. Saberi K, et al. **Nat Neurosci** 1999 Jul;2(7):656-9

Visual interactions in the path of apparent motion. Yantis S, et al. **Nat Neurosci** 1998 Oct;1(6):508-12

The unfolding of an auditory illusion. Butler RA.
Perspect Biol Med 1999 Winter;42(2):157-73

Neural gain changes subserving perceptual acuity. Jones LF, et al. **Somatosens Mot Res** 1998;15(3):190-9

The effect of orientation on the clarity of Hermann grid illusory lines. Goldthwaite D, et al. **Spat Vis** 1999; 12(4):461-5

[The formation of a set based on illusory representations and during the perception of concrete visual stimuli] Kostandov EA. **Fiziol Cheloveka** 1999 Jan-Feb;25(1):5-14 **(Rus)**

PSYCHOLOGY

Cognitive moderators of children's adjustment to stressful divorce events: the role of negative cognitive errors and positive illusions. Mazur E, et al. **Child Dev** 1999 Jan-Feb; 70(1):231-45

The perceived intentionality of groups. Bloom P, et al.
Cognition 1999 May 3;71(1):B1-9

Sex related effect of unilateral brain lesions on the perception of the Mueller-Lyer illusion. Grabowska A, et al.
Cortex 1999 Apr;35(2):231-41

Illusory tip-of-the-tongue states. Schwartz BL. **Memory** 1998 Nov;6(6):623-42

Illusory contours and spatial neglect. Vuilleumier P, et al.
Neuroreport 1998 Aug 3;9(11):2481-4

Musical hallucinations and palinacousis. Terao T, et al.
Psychopathology 1999 Mar-Apr;32(2):57-9

Cognitive psychopathology of problem gambling. Toneatto T. **Subst Use Misuse** 1999 Sep;34(11):1593-604 (29 ref.)

ILLUSTRATED BOOKS see **BOOKS, ILLUSTRATED**

ILLUSTRATION, MEDICAL see **MEDICAL ILLUSTRATION**

ILOPROST

[The repair of injured brain by implanting embryonic cortical brain tissue preserved in Iloprost solution at 4 degrees C: experimental study] Liu H, et al.
Chung Hua Wai Ko Tsa Chih 1997 Jan;35(1):22-5 (Eng. Abstr.) **(Chi)**

ADMINISTRATION & DOSAGE

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Olschewski H, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):600-7

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Black CM, et al.
Br J Rheumatol 1998 Sep;37(9):952-60

Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Mok MY, et al.
Lupus 1999;8(4):328-31

Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Hoeper MM, et al.
Respir Med 1999 Jan;93(1):62-4

Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Stricker H, et al.
Schweiz Med Wochenschr 1999 Jun 19;129(24):923-7

[Our experience in using a synthetic prostacyclin analog in the treatment of critical ischemia of the extremities] Centorrino T, et al. **G Chir** 1998 Oct;19(10):399-403 (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. Turcato S, et al.
Br J Pharmacol 1999 Feb;126(4):845-7

Selective formation of Gsalpha-MHC I complexes after desensitization of human platelets with iloprost. Ferreira P, et al. **Eur J Biochem** 1999 Jan;259(1-2):167-74

Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo. Aitchison KA, et al. **Eur J Pharmacol** 1999 Jun 11;374(1):59-69

Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost. Clapp LH, et al. **Eur J Pharmacol** 1998 Sep 4; 356(2-3):215-24

The protective effect of iloprost, a PGL2 analogue, on ultratructure of ischemic and reperfused myocardial myocytes. Fitzl G, et al. **Exp Toxicol Pathol** 1999 Jan; 51(1):81-8

Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages. D'Acquisto F, et al. **FEBS Lett** 1998 Nov 27;440(1-2):76-80

Effects of PGI2 and analogues (taprostene, iloprost) on oxidation of native and glycated LDL. Sobal G, et al.
Life Sci 1999;65(12):1237-46

Preservation of myocardial metabolism in acute coronary artery occlusions with retrograde coronary sinus perfusion and iloprost. Katircioğlu SF, et al.
Prostaglandins Leukot Essent Fatty Acids 1998 Sep; 59(3):169-74

THERAPEUTIC USE

Acute oliguric renal failure associated with unilateral renal embolism: a successful treatment with iloprost. Levin M, et al. **Am J Nephrol** 1998;18(5):444-7

Prognostic aspects of TcPO2 in iloprost treatment as an alternative to amputation. Chomard D, et al. **Angiology** 1999 Apr;50(4):283-8

Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40--a case report. Gouny P, et al. **Angiology** 1999 Jul;50(7):605-6

Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al [letter; comment] Braun J, et al. **Arthritis Rheum** 1999 Jan;42(1):196-8. Comment on: Arthritis Rheum 1998 Mar;41(3):559-60.

The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Mazzone A, et al.
Eur J Clin Invest 1999 Jan;29(1):1-5

Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III. Arosio E, et al. **Eur Rev Med Pharmacol Sci** 1998 Mar-Apr; 2(2):53-9

Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Higenbottam T, et al. **Heart** 1998 Aug;80(2):151-5

Dopexamine unloads the impaired right ventricle better than iloprost, a prostacyclin analog, after coronary artery surgery. Honkonen EL, et al.
J Cardiothorac Vasc Anesth 1998 Dec;12(6):647-53

Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year. Biasi D, et al. **Rev Rhum Engl Ed** 1998 Dec; 65(12):745-50

Antithrombotic stent coatings: hirudin/iloprost combination. Alt E, et al. **Semin Interv Cardiol** 1998 Sep-Dec; 3(3-4):177-83 (40 ref.)

[Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency] Cappelli R, et al. **Minerva Cardioangiol** 1999 Mar;47(3):81-8 (30 ref.) (Eng. Abstr.) **(Ita)**

IMAGE ANALYSIS, COMPUTER-ASSISTED see **IMAGE PROCESSING, COMPUTER-ASSISTED**

IMAGE CYTOMETRY

Image cytometry in early graft-versus-host disease. Fleming MG, et al. **Am J Dermatopathol** 1998 Oct;20(5):459-62

Preneoplastic oral lesions: the clinical value of image cytometry DNA analysis, p53 and p21/WAF1 expression. Högmo A, et al. **Anticancer Res** 1998 Sep-Oct; 18(5B):3645-50

[Cytometry and cell sorting] Unsöld E.
Biomed Tech (Berl) 1998;43 Suppl:442-5 **(Ger)**

INSTRUMENTATION

Artificial neural network-aided image analysis system for cell counting. Sjöström PJ, et al. **Cytometry** 1999 May 1; 36(1):18-26

[Assessment of cervical dysplasia with DNA image cytometry] Böcking A, et al. **Pathologe** 1999 Jan; 20(1):25-33 (Eng. Abstr.) **(Ger)**

METHODS

Path reconstruction as a tool for actin filament speed determination in the in vitro motility assay. Hamelink W, et al. **Anal Biochem** 1999 Aug 15;273(1):12-9

Influence of sampling practices on the appearance of DNA image histograms of prostate cells in FNAB samples. Buhmeida A, et al. **Anal Cell Pathol** 1999;18(2):95-102

The effect of primary fixation with standard postfixation and the duration of hydrolysis on nuclear features in image cytometry. Flezar M, et al. **Anal Cell Pathol** 1998; 17(3):131-44

Machine vision in the detection of prostate lesions in histologic sections. Bartels PH, et al.
Anal Quant Cytol Histol 1998 Oct;20(5):358-64

Automated feature extraction and identification of colon carcinoma. Esgiar AN, et al. **Anal Quant Cytol Histol** 1998 Aug;20(4):297-301

Laser scanning cytometry quantification of estrogen receptors in breast cancer. Gorczyca W, et al.
Anal Quant Cytol Histol 1998 Dec;20(6):470-6

Automated histometry in quantitative prostate pathology. Hamilton PW, et al. **Anal Quant Cytol Histol** 1998 Oct; 20(5):443-60 (48 ref.)

Image cytometric nuclear DNA quantitation of paragangliomas in tissue sections. Prognostic significance. Held EL, et al. **Anal Quant Cytol Histol** 1997 Dec; 19(6):501-6

Application of confocal scanning laser microscopy to 3-D DNA image cytometry of prostatic lesions. Irinopoulou T, et al. **Anal Quant Cytol Histol** 1998 Oct;20(5):351-7

Use of image cytometry to classify biliary and ampullary adenocarcinomas. Yeaton P, et al.
Anal Quant Cytol Histol 1998 Dec;20(6):509-16

Fluorescence-based analysis of DNA ploidy and cell proliferation within fine-needle samplings of breast tumors: a new approach using automated image cytometry. Truong K, et al. **Cancer** 1998 Oct 25;84(5):309-16

Analysis of apoptosis by laser scanning cytometry. Bedner E, et al. **Cytometry** 1999 Mar 1;35(3):181-95 (120 ref.)

In vitro motility evaluation of aggregated cancer cells by means of automatic image processing. De Hauwer C, et al. **Cytometry** 1999 May 1;36(1):1-10

Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC). Deptala A, et al.
Cytometry 1998 Nov 1;33(3):376-82

Comparison of flow and laser scanning cytometry for the assay of cell proliferation in human solid tumors. Rew DA,

IMAGE CYTOMETRY

et al. **Cytometry** 1998 Nov 1;33(3):355–61

Application of laser scanning cytometry to the analysis of chromosomal aberrations induced by benzo[a]pyrene in CHO-WBLT cells. Satoh T, et al. **Cytometry** 1999 Apr 1;35(4):363–8

Development and validation of a computerized cytomorphometric method to assess the maturation of vaginal epithelial cells. van der Laak JA, et al. **Cytometry** 1999 Mar 1;35(3):196–202

Image analysis enhancement of the laser scanning cytometer. Woltmann G, et al. **Cytometry** 1998 Nov 1;33(3):362–5

Cytologic score and DNA-image analysis in the classification of borderline breast lesions: a prospective study on 47 fine-needle aspirates. Gherardi G, et al. **Diagn Cytopathol** 1999 Apr;20(4):212–8

Clinical value of DNA image cytometry in effusions with atypia. Thunnissen FB, et al. **Diagn Cytopathol** 1999 Aug; 21(2):112–6

Laser-scanning cytometry: A new instrumentation with many applications. Darzynkiewicz Z, et al. **Exp Cell Res** 1999 May 25;249(1):1–12 (52 ref.)

Comparison of eight histomorphometric methods for measuring trabecular bone architecture by image analysis on histological sections. Chappard D, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):303–12

Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Tomita K, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr; 359(4):249–55

An automated image cytometry system for monitoring DNA ploidy and other cell features of radiotherapy and chemotherapy patients. Zhang Y, et al. **Radiat Med** 1999 Jan-Feb;17(1):47–57

[Thyroid glands as an object of morphometric study] Khmel'nitskaiaOK, et al. **Arkh Patol** 1998 Jul-Aug; 60(4):47–9 (Eng. Abstr.) **(Rus)**

STANDARDS

1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations for quality assurance. European Society for Analytical Cellular Pathology. Giroud F, et al. **Anal Cell Pathol** 1998; 17(4):201–8

1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Haroske G, et al. **Anal Cell Pathol** 1998; 17(4):189–200

Standardisation of DNA quantitation by image analysis: quality control of instrumentation. Puech M, et al. **Cytometry** 1999 May 1;36(1):11–7

IMAGE ENHANCEMENT

see related
RADIOGRAPHIC IMAGE ENHANCEMENT
SUBTRACTION TECHNIQUE

Contrast-enhanced MR angiography. Maki JH, et al. **Abdom Imaging** 1998 Sep-Oct;23(5):469–84 (89 ref.)

Rare-MR-urography--a new diagnostic method in autosomal recessive polycystic kidney disease. Kern S, et al. **Acta Radiol** 1999 Sep;40(5):543–4

MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T. Keiper MD, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1489–93

Nitrate-enhanced thallium 201 single-photon emission computed tomography imaging in hibernating myocardium [see comments] Oudiz RJ, et al. **Am Heart J** 1999 Aug; 138(2 Pt 1):369–75. Comment in: Am Heart J 1999 Aug;138(2 Pt 1):206–9.

Is nitroglycerin useful for the enhancement of viability detection with myocardial perfusion imaging? [editorial; comment] Sias TM, et al. **Am Heart J** 1999 Aug;138(2 Pt 1):206–9 (26 ref.). Comment on: Am Heart J 1999 Aug;138(2 Pt 1):369–75.

Subendocardial enhancement in gadolinium-diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging in aortic stenosis. Ochiai K, et al. **Am J Cardiol** 1999 May 15; 83(10):1443–6

Ultrasound echo-enhancers in the evaluation of endovascular prostheses. Giannoni MF, et al. **Cardiovasc Surg** 1999 Aug; 7(5):532–8

Evaluation of contrast agents for delineation of vessel wall boundary by intracoronary ultrasound after coronary angioplasty in human. Nishino M, et al. **Catheter Cardiovasc Interv** 1999 May;47(1):6–13

Development of a 3-D measurement and evaluation system for facial forms with a liquid crystal range finder. Yamada T, et al. **Comput Methods Programs Biomed** 1999 Feb; 58(2):159–73

Assessment of left ventricular wall motion and delineation of the endocardial border after intravenous injection of Infoson during dobutamine stress echocardiography. Ikonomidis I, et al. **Coron Artery Dis** 1998;9(9):567–76

The combination of magnetic resonance angiography and computational fluid dynamics: a critical review. Long Q, et al. **Crit Rev Biomed Eng** 1998;26(4):227–74 (125 ref.)

Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Shimizu J, et al. **Dig Dis Sci** 1999 Jul;44(7):1330–7

Detection of coronary artery bypass graft patency by contrast enhanced magnetic resonance angiography. Brenner P, et al. **Eur J Cardiothorac Surg** 1999 Apr;15(4):389–93

High-resolution magnetic resonance angiography of the internal carotid artery: 2D vs 3D TOF in stenotic disease. Carriero A, et al. **Eur Radiol** 1998;8(8):1370–2

Contrast mechanisms in MR imaging. Nitz WR, et al. **Eur Radiol** 1999;9(6):1032–46 (35 ref.)

Water enhanced "non-paralytic" transcutaneous ultrasound of the normal gastric wall layers (WETCUS). Abdel Bagi ME, et al. **Hepatogastroenterology** 1998 Nov-Dec; 45(24):2051–4

New ultrasound contrast agents for left ventricular and myocardial opacification. Kasprzak JD, et al. **Herz** 1998 Dec;23(8):474–82 (62 ref.)

Detection of lines and boundaries in speckle images--application to medical ultrasound. Czerwinski RN, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):126–36 (37 ref.)

Harmonic imaging: echocardiographic enhanced contrast intensity and duration. Allen MR, et al. **Int J Card Imaging** 1999 Jun;15(3):215–20

3D contrast-enhanced MR angiography using fluoroscopic triggering and an elliptical centric view order. Riederer SJ, et al. **Int J Card Imaging** 1999 Apr;15(2):117–29

Contrast enhanced body magnetic resonance angiography [see comments] Stillman AE. **Int J Card Imaging** 1999 Apr; 15(2):131–7. Comment in: Int J Card Imaging 1999 Apr;15(2):115.

Gadolinium contrast-enhanced three-dimensional MRA of peripheral arteries with multiple bolus injection: scan optimization in vitro and in vivo [see comments] Westenberg JJ, et al. **Int J Card Imaging** 1999 Apr; 15(2):161–73. Comment in: Int J Card Imaging 1999 Apr;15(2):115.

Optimization of gadolinium-enhanced magnetic resonance angiography using an automated bolus-detection algorithm (MR SmartPrep). Original investigation. Ho VB, et al. **Invest Radiol** 1998 Sep;33(9):515–23 (25 ref.)

Optimizing three-dimensional gadolinium-enhanced magnetic resonance angiography. Original investigation. Maki JH, et al. **Invest Radiol** 1998 Sep;33(9):528–37

The future of contrast-enhanced magnetic resonance angiography. Are blood pool agents needed? [editorial] [published erratum appears in Invest Radiol 1999 Jan;34(1):82] Mühler A. **Invest Radiol** 1998 Sep; 33(9):709–14 (16 ref.)

Determinants of image appearance in contrast-enhanced magnetic resonance angiography. A review. Saloner D. **Invest Radiol** 1998 Sep;33(9):488–95 (15 ref.)

Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment. Caiati C, et al. **J Am Coll Cardiol** 1999 Jul;34(1):122–30

In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. Demos SM, et al. **J Am Coll Cardiol** 1999 Mar;33(3):867–75

Noninvasive assessment of coronary flow reserve with transthoracic signal-enhanced Doppler echocardiography. Lambertz H, et al. **J Am Soc Echocardiogr** 1999 Mar; 12(3):186–95

Dobutamine stress echocardiography: improved endocardial border definition and wall motion analysis with tissue harmonic imaging. Zaglavara T, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):706–13

A case for electronic manipulation of medical images? Barry CJ, et al. **J Audiov Media Med** 1999 Mar;22(1):15–20

Evaluation of brain activity in FDG PET studies. Fahey FH, et al. **J Comput Assist Tomogr** 1998 Nov-Dec; 22(6):953–61

Electron microscopic observations and X-ray microanalysis of a multinucleated giant cell. Bay BH, et al. **J Electron Microsc (Tokyo)** 1998;47(4):359–61

Detection of perivenous inflammation in a rat model of venous thrombosis using MRV. Londy FJ, et al. **J Invest Surg** 1999 May-Jun;12(3):151–6

Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. Cheng LL, et al. **J Magn Reson** 1998 Nov;135(1):194–202

Image-based reduction of artifacts in multishot echo-planar imaging. Hennel F. **J Magn Reson** 1998 Oct;134(2):206–13

Signal dynamics in magnetic resonance imaging of the lung with hyperpolarized noble gases. Möller HE, et al. **J Magn Reson** 1998 Nov;135(1):133–43

A simple approach for ultraclean multisite selective excitation using excitation sculpting. Parella T, et al. **J Magn Reson** 1998 Nov;135(1):50–3

MRI edge enhancement as a diffusive discord of spin phase structure. Stepišnik J, et al. **J Magn Reson** 1999 Mar; 137(1):154–60

Heteronuclear cross polarization for enhanced sensitivity of in vivo 13C MR spectroscopy on a clinical 1.5 T MR system. van den Bergh AJ, et al. **J Magn Reson** 1998 Nov; 135(1):93–8

Selective detection of biexponential relaxation in isotropic solutions by mixed coherence filtering NMR. Yamada H, et al. **J Magn Reson** 1998 Nov;135(1):99–103

Gradient- and sensitivity-enhanced heteronuclear multiple-quantum correlation spectroscopy. Zhu G, et al. **J Magn Reson** 1998 Nov;135(1):232–5

Single-shot diffusion-weighted RARE sequence: application for temperature monitoring during hyperthermia session. Il'yasov KA, et al. **J Magn Reson Imaging** 1998 Nov-Dec; 8(6):1296–305

Diagnosis of MCA-occlusion and monitoring of systemic thrombolytic therapy with contrast enhanced transcranial duplex-sonography. Mäurer M, et al. **J Neuroimaging** 1999 Apr;9(2):99–101

Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. Filippi M, et al. **J Neurol Sci** 1998 Aug 14;159(2):162–5

Echo-enhanced Doppler sonography of focal nodular hyperplasia of the liver. Uggowitzer MM, et al. **J Ultrasound Med** 1999 Jul;18(7):445–51; quiz 453–4

Generalised calculation of NMR imaging edge effects arising from restricted diffusion in porous media. Callaghan PT, et al. **Magn Reson Imaging** 1998 Jun-Jul;16(5–6):471–8

Perfusion imaging of the human lung using flow-sensitive alternating inversion recovery with an extra radiofrequency pulse (FAIRER). Mai VM, et al. **Magn Reson Imaging** 1999 Apr;17(3):355–61

Characterization of human head vasculature by percolation parameters. Weis J, et al. **Magn Reson Imaging** 1999 Apr; 17(3):411–5

The effect of residual Nyquist ghost in quantitative echo-planar diffusion imaging. Porter DA, et al. **Magn Reson Med** 1999 Aug;42(2):385–92

Quantification of myocardial perfusion by MRI after coronary occlusion. Vallée JP, et al. **Magn Reson Med** 1998 Aug;40(2):287–97

Image enhancement by noncontrast harmonic echocardiography. Part II. Quantitative assessment with use of contrast-to-speckle ratio. Belohlavek M, et al. **Mayo Clin Proc** 1998 Nov;73(11):1066–70

Image enhancement by noncontrast harmonic echocardiography. Part I. Qualitative assessment of endocardial visualization. Mulvagh SL, et al. **Mayo Clin Proc** 1998 Nov;73(11):1062–5

Real-time equalization of region-of-interest fluoroscopic images using binary masks. Rudin S, et al. **Med Phys** 1999 Jul;26(7):1359–64

Effect of microwave irradiation on antibody labeling efficiency when applied to ultrathin cryosections through fixed biological material. Chicoine L, et al. **Microsc Res Tech** 1998 Jul 1;42(1):24–32

Comparison of 3D BOLD functional MRI with spiral acquisition at 1.5 and 4.0 T. Yang Y, et al. **Neuroimage** 1999 Apr;9(4):446–51

Diffuse meningeal enhancement in patients with overdraining, long-standing ventricular shunts. Hochman MS, et al. **Neurology** 1999 Jan 15;52(2):406–9

Enhanced cervical MRI in identifying intracranial dural arteriovenous fistulae with spinal perimedullary venous drainage. Chen CJ, et al. **Neuroradiology** 1998 Jun; 40(6):393–7

Viral cochleitis with gadolinium enhancement of the cochlea on magnetic resonance imaging scan. Fitzgerald DC, et al. **Otolaryngol Head Neck Surg** 1999 Jul;121(1):130–2

Computer-aided radiation therapy simulation: image intensifier spatial distortion correction for large field of view digital fluoroscopy. Cosby NS, et al. **Phys Med Biol** 1998 Aug;43(8):2265–78

Locating blood vessels in retinal images by piece-wise threshold probing of a matched filter response. Hoover A, et al. **Proc AMIA Symp** 1998;:931–5

Renal blood flow in pigs: changes depicted with contrast-enhanced harmonic US imaging during acute urinary obstruction. Claudon M, et al. **Radiology** 1999 Sep; 212(3):725–31

Cystic fibrosis: combined hyperpolarized 3He-enhanced and conventional proton MR imaging in the lung--preliminary observations. Donnelly LF, et al. **Radiology** 1999 Sep; 212(3):885–9

Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT--a comparative study. Loyer EM, et al. **Radiology** 1999 Sep;212(3):866–75

Brain lesions: when should fluid-attenuated inversion-recovery sequences be used in MR evaluation? Okuda T, et al. **Radiology** 1999 Sep;212(3):793–8

Abdominal MR imaging with a volumetric interpolated breath-hold examination. Rofsky NM, et al. **Radiology** 1999 Sep;212(3):876–84

Computer-enhanced mitral valve surgery: toward a total endoscopic procedure. Falk V, et al. **Semin Thorac Cardiovasc Surg** 1999 Jul;11(3):244–9

Contrast-enhanced transcranial color-coded sonography in acute hemispheric brain infarction. Postert T, et al. **Stroke** 1999 Sep;30(9):1819–26

Computer-assisted photographic image enhancement and modification in ophthalmology. Augsburger JJ. **Trans Am Ophthalmol Soc** 1998;96:295–304; discussion 304–7

Neural network correction of ultrasonic C-scan images. Hutchins DA, et al. **Ultrasonics** 1999 Apr;37(4):263–72

Fetal neurosonography: should it be routine? Should it be detailed? [editorial] Monteagudo A. **Ultrasound Obstet Gynecol** 1998 Jul;12(1):1–5

[Comparison of three fat suppression sequences for the detection of vertebral detection. Turbo STIR, phase contrast gradient-echo, and MISTEC-Chopper after gadolinium injection] Cottier JP, et al. **J Neuroradiol** 1998

Jul;25(2):129-35 (Eng. Abstr.) **(Fre)**

[Improved structure identification with tissue Doppler echocardiography] Bartel T, et al. **Herz** 1998 Dec; 23(8):499-505 (Eng. Abstr.) **(Ger)**

[Asynchrony of ventricular contraction and relaxation--pathophysiologically recognized phenomenon, now can be clinically assessed] Bruch C, et al. **Herz** 1998 Dec;23(8):506-15 (47 ref.) (Eng. Abstr.) **(Ger)**

[Noninvasive determination of coronary flow reserve with signal enhanced high resolution transthoracic Doppler color echocardiography] Lambertz H, et al. **Herz** 1998 Dec;23(8):516-25 (Eng. Abstr.) **(Ger)**

[Progress in diagnostic imaging in the area of the pancreas (CT, MRI, MR-angio, hydro-CT, MR cholangiopancreatography)] Gerhardt P. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:274-80 (16 ref.) (Eng. Abstr.) **(Ger)**

[Detection of patent foramen ovale. Transesophageal echocardiography and transcranial Doppler sonography with ultrasound contrast media are "supplementary, not competing, diagnostic methods"] Heckmann JG, et al. **Med Klin** 1999 Jul 15;94(7):367-70 (Eng. Abstr.) **(Ger)**

[Visualization of renal arteries and value of color-coded duplex sonography in renal artery stenoses using an ultrasound signal enhancing agent (published erratum appears in Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1998 Dec;169(6):681-2)] Hortling N, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):397-401 (Eng. Abstr.) **(Ger)**

[Dynamic MR-mammography in invasive lobular breast cancer] Sittek H, et al. **Rontgenpraxis** 1998;51(7):235-42 (Eng. Abstr.) **(Ger)**

[A case of clinically diagnosed Creutzfeldt-Jakob disease with serial MRI diffusion weighted images] Hirose Y, et al. **Rinsho Shinkeigaku** 1998 Aug;38(8):779-82 (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

New method to obtain ultrasonic angle independent Doppler color images using a sector transducer. Fei DY, et al. **Ann Biomed Eng** 1999 Mar-Apr;27(2):187-93

Normalization of RNA hybridization signals by means of SYBR green II-stained 28S or 18S ribosomal RNA and a phosphor imager. Spiess AN, et al. **Biotechniques** 1999 Jan;26(1):46-8, 50

Butterworth equations for homomorphic filtering of images. Adelmann HG. **Comput Biol Med** 1998 Mar;28(2):169-81

Toshiba's approach to the digital catheterization laboratory--full-digital system with DVD and network. Fujii S. **Int J Card Imaging** 1998;14 Suppl 1:27-30

Dynamic changes in the shape of the triangular fibrocartilage complex during rotation demonstrated with high resolution magnetic resonance imaging. Nakamura T, et al. **J Hand Surg [Br]** 1999 Jun;24(3):338-41

Asymmetric adiabatic pulses for NH selection. Hwang TL, et al. **J Magn Reson** 1999 May;138(1):173-7

Evolution strategy optimization for adiabatic pulses in MRI. Lunati E, et al. **J Magn Reson** 1999 May;138(1):48-53

Intrahepatic arterioportal fistula: gadolinium-enhanced 3D magnetic resonance angiography findings and angiographic embolization with steel coils. Balci NC, et al. **Magn Reson Imaging** 1999 Apr;17(3):475-8

High-resolution, multiple gradient-echo functional MRI at 1.5 T. Barth M, et al. **Magn Reson Imaging** 1999 Apr; 17(3):321-9

Lesion load measurements in multiple sclerosis: the effect of incorporating magnetization transfer contrast in fast-FLAIR sequence. Filippi M, et al. **Magn Reson Imaging** 1999 Apr;17(3):459-61

A hybrid technique for spectroscopic imaging with reduced truncation artifact. Metzger G, et al. **Magn Reson Imaging** 1999 Apr;17(3):435-43

Intracranial black-blood MR angiography with high-resolution 3D fast spin echo. Alexander AL, et al. **Magn Reson Med** 1998 Aug;40(2):298-310

Myocardial velocity gradient imaging by phase contrast MRI with application to regional function in myocardial ischemia. Arai AE, et al. **Magn Reson Med** 1999 Jul; 42(1):98-109

Composite image formation in z-shimmed functional MR imaging. Constable RT, et al. **Magn Reson Med** 1999 Jul; 42(1):110-7

Fast T1 mapping on a whole-body scanner. Deichmann R, et al. **Magn Reson Med** 1999 Jul;42(1):206-9

Simultaneous correction for interscan patient motion and geometric distortions in echoplanar imaging. Ernst T, et al. **Magn Reson Med** 1999 Jul;42(1):201-5

A programmable pre-emphasis system. Gach HM, et al. **Magn Reson Med** 1998 Sep;40(3):427-31

Integrated MRI assessment of regional function and perfusion in canine myocardial infarction. Kraitchman DL, et al. **Magn Reson Med** 1998 Aug;40(2):311-26

Cerebral blood flow measurement by dynamic contrast MRI using singular value decomposition with an adaptive threshold. Liu HL, et al. **Magn Reson Med** 1999 Jul; 42(1):167-72

A 16-element phased-array head coil. Porter JR, et al. **Magn Reson Med** 1998 Aug;40(2):272-9

Enhancement of BOLD-contrast sensitivity by single-shot multi-echo functional MR imaging. Posse S, et al. **Magn Reson Med** 1999 Jul;42(1):87-97

Reduced circular field-of-view imaging. Scheffler K, et al. **Magn Reson Med** 1998 Sep;40(3):474-80

Simultaneous highly selective MR water and fat imaging using a simple new type of spectral-spatial excitation. Schick F. **Magn Reson Med** 1998 Aug;40(2):194-202

Quantitative assessment of improved homogeneity using higher-order shims for spectroscopic imaging of the brain. Spielman DM, et al. **Magn Reson Med** 1998 Sep; 40(3):376-82

High-resolution diffusion imaging with DIFRAD-FSE (diffusion-weighted radial acquisition of data with fast spin-echo) MRI. Trouard TP, et al. **Magn Reson Med** 1999 Jul;42(1):11-8

A study of injected dose for brain mapping on the ECAT HR+: activation maps for a parametric verbal working memory task. Isoardi RA, et al. **Neuroimage** 1999 Jan; 9(1):145-53

Intracranial vascular stenosis and occlusion: comparison of 3D time-of-flight and 3D phase-contrast MR angiography. Oelerich M, et al. **Neuroradiology** 1998 Sep;40(9):567-73

Fast fluid-attenuated inversion-recovery imaging: first experience with a 3D version in epilepsy. Wieshmann UC, et al. **Neuroradiology** 1998 Aug;40(8):483-9

Shape-based grey-level image interpolation. Chuang KS, et al. **Phys Med Biol** 1999 Jun;44(6):1565-77

Can inversion-recovery gradient- and spin-echo T2-weighted MR imaging be an alternative to fast spin-echo imaging with fat suppression? [letter; comment] Kanematsu M, et al. **Radiology** 1999 Jul;212(1):291. Comment on: Radiology 1998 Nov;209(2):427-34.

Sonography under Daylight Conditions. Bleck JS, et al. **Ultraschall Med** 1998 Dec;19(6):259-64

[Ultrasonography] Leray P, et al. **J Radiol** 1999 Jul;80(7 Suppl):791-6 **(Fre)**

[Technique for ultrasound imaging with contrast media using nonlinearity and time variance] Wilkening W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:18-9 **(Ger)**

[Improved endocardium imaging using modified transthoracic echocardiography with the second harmonic frequency (tissue harmonic imaging)] Becher H, et al. **Herz** 1998 Dec;23(8):467-73 (25 ref.) (Eng. Abstr.) **(Ger)**

[Topographic imaging of head and neck soft tissues by an new sectional imaging method in ultrasound diagnosis] Jecker P, et al. **Laryngorhinootologie** 1998 Oct; 77(10):547-50 (Eng. Abstr.) **(Ger)**

[Diffusion-weighted imaging in acute stroke] Jakob PM, et al. **Nervenarzt** 1998 Aug;69(8):683-93 (63 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of acute subarachnoid hemorrhage--MRI with 0.5 Tesla with FLAIR sequence] Kopsa W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):355-9 (Eng. Abstr.) **(Ger)**

[Detection of focal lung lesions with magnetic resonance tomography using T2-weighted ultrashort turbo-spin-echo-sequence in comparison with spiral computerized tomography] Lutterbey G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):365-9 (Eng. Abstr.) **(Ger)**

[Virtual endoscopy of the upper urinary tract based on contrast-enhanced MR urography data sets] Nolte-Ernsting CC, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):550-6 (Eng. Abstr.) **(Ger)**

[Determination of contour clarity in contrast-enhanced MR angiography: definition and clinical evaluation exemplified by ECG-triggered imaging of the thoracic aorta] Rodenwaldt J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Dec;169(6):616-21 (Eng. Abstr.) **(Ger)**

[Acute spinal epidural hematoma--comments on MRI diagnosis using fluid-attenuated inversion recovery sequence (FLAIR)] Textor HJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):231-2 **(Ger)**

[Improved B-image diagnosis with harmonic imaging] Schoelgens C. **Ultraschall Med** 1998 Oct;19(5):M70-5 **(Ger)**

[Trends and values in technical aspects of ultrasound diagnosis equipment (editorial)] Zweifel HJ. **Ultraschall Med** 1998 Oct;19(5):195 **(Ger)**

[Breath-hold MR cholangiopancreatography with 2D and 3D-FASE sequence at 0.5 tesla: evaluation based on measurements of signal intensity ratio and contrast-to-noise ratio] Ichikawa T, et al. **Nippon Rinsho** 1998 Nov; 56(11):2817-24 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Comparative studies of breath-hold magnetic resonance cholangiopancreatography (MRCP) between different two sequences and between 1.0T and 1.5T units] Yasui M, et al. **Nippon Rinsho** 1998 Nov;56(11):2849-53 (Eng. Abstr.) **(Jpn)**

[The use of computer technology and digital photography in the work of a forensic medical expertise bureau] Novoselov VP, et al. **Sud Med Ekspert** 1999 Mar-Apr; 42(2):35-6 (Eng. Abstr.) **(Rus)**

METHODS

Open MRI-guided neurosurgery. Seifert V, et al. **Acta Neurochir (Wien)** 1999;141(5):455-64

Schistosomal myelopathy: relevance and limits of contrast-enhanced magnetic resonance imaging in spinal cord infections. Goffette S, et al. **Acta Neurol Belg** 1998 Sep;98(3):289-91

Doppler ultrasound assessment of TIPS patency and function--the need for echo enhancers. Skjoldbye B, et al. **Acta Radiol** 1998 Nov;39(6):675-9

Comparison of the contrast enhancement pattern in two different T1-weighted 3-D sequences in MR imaging of the breast. Wiberg MK, et al. **Acta Radiol** 1998 Nov; 39(6):680-5

MR angiography with ultrashort echo time in cerebral aneurysms treated with Guglielmi detachable coils. Gönner F, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1324-8

Technique for arterial-phase contrast-enhanced three-dimensional MR angiography of the carotid and vertebral arteries. Isoda H, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1241-4

Nasal airway volumetric measurement using segmented HRCT images and acoustic rhinometry. Prasun D, et al. **Am J Rhinol** 1999 Mar-Apr;13(2):97-103

Noninvasive delineation of normal right ventricular contractile motion with magnetic resonance imaging myocardial tagging. Klein SS, et al. **Ann Biomed Eng** 1998 Sep-Oct;26(5):756-63

A new UV-visible confocal laser scanning microspectrofluorometer designed for spectral cellular imaging. Favard C, et al. **Biospectroscopy** 1999;5(2):101-15

The use of optical coherence tomography in macular diseases. Stalmans P, et al. **Bull Soc Belge Ophtalmol** 1999;272:15-30

Tumor-enhancement effect of a Mn3+ metalloporphyrin derivative (ATN-4T) in magnetic resonance imaging. Kobayashi M, et al. **Cancer Lett** 1999 Mar 22;137(1):83-9

The "hug" view: an image that results in optimal visualization of the upper posterior thorax. Freeman L, et al. **Clin Nucl Med** 1999 Jan;24(1):63

The usefulness of Tc-99m DMSA SPECT and three-dimensional surface rendering in an asymptomatic patient with a single kidney in the pelvis. Leitha T. **Clin Nucl Med** 1998 Jul;23(7):414-6

Application of computer animation techniques for presenting biomechanical research results. Baca A. **Comput Biol Med** 1998 Jul;28(4):449-54

Interactive dynamic navigation for virtual endoscopy. Ramaswamy K, et al. **Comput Biol Med** 1999 Sep; 29(5):303-31

Automatic segmentation of contours of corneal cells. Sanchez-Marin FJ. **Comput Biol Med** 1999 Jul;29(4):243-58

Intraluminal signal intensity of iliac artery stents investigated by contrast-enhanced three-dimensional MR angiography. Amano Y, et al. **Comput Med Imaging Graph** 1998 Jan-Feb; 22(1):9-12

Surface matching of multimodality image volumes by a fuzzy elastic registration technique. Butt A, et al. **Comput Med Imaging Graph** 1998 Jan-Feb;22(1):13-23

Image analysis enhancement of the laser scanning cytometer. Woltmann G, et al. **Cytometry** 1998 Nov 1;33(3):362-5

Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI. Rovaris M, et al. **Eur Neurol** 1999;41(3):123-7

Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Coffin CM, et al. **Eur Radiol** 1999;9(3):444-9

Optimizing liver contrast in helical liver CT: value of a real-time bolus-triggering technique. Dinkel HP, et al. **Eur Radiol** 1998;8(9):1608-12

Software for 3-D visualization/analysis of optic-disc images. Yogesan K, et al. **IEEE Eng Med Biol Mag** 1999 Jan-Feb; 18(1):43-9

Edge detection in medical images using a genetic algorithm [letter] Gudmundsson M, et al. **IEEE Trans Med Imaging** 1998 Jun;17(3):469-74

Reversible decorrelation method for progressive transmission of 3-D medical image. Kim YS, et al. **IEEE Trans Med Imaging** 1998 Jun;17(3):383-94

Speckle reduction and contrast enhancement of echocardiograms via multiscale nonlinear processing. Zong X, et al. **IEEE Trans Med Imaging** 1998 Aug;17(4):532-40

The DICOM image formatting standard: its role in echocardiography and angiography. Thomas JD. **Int J Card Imaging** 1998;14 Suppl 1:1-6 (13 ref.)

Enhancing diagnostic ultrasound programs utilizing wide-area image management technology. Martin BD, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:691-3

Accuracy evaluation of fusion of CT, MR, and spect images using commercially available software packages (SRS PLATO and IFS). Mongioj V, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1;43(1):227-34

Contrast-enhanced magnetic resonance angiography of peripheral vessels. Different contrast agent applications and sequence strategies: a review. Boos M, et al. **Invest Radiol** 1998 Sep;33(9):538-46 (27 ref.)

Contrast-enhanced magnetic resonance angiography of the renal arteries. Original investigation. Hany TF, et al. **Invest Radiol** 1998 Sep;33(9):653-9

Contrast-enhanced magnetic resonance angiography of the pulmonary vasculature. A review. Kauczor HU. **Invest Radiol** 1998 Sep;33(9):606-17 (65 ref.)

Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation. Knollmann FD, et al. **Invest Radiol** 1998 Sep;33(9):637-43

Gadolinium-enhanced three-dimensional magnetic resonance angiography of the thoracic aorta and arch vessels. A review. Krinsky G. **Invest Radiol** 1998 Sep; 33(9):587–605 (82 ref.)

Gadolinium-enhanced fast three-dimensional angiography of the neck: technical aspect. Leclerc X, et al. **Invest Radiol** 1999 Mar;34(3):204–10

Contrast-enhanced magnetic resonance imaging of the coronary arteries. A review. Li D, et al. **Invest Radiol** 1998 Sep;33(9):578–86 (54 ref.)

Contrast-enhanced magnetic resonance angiography of cerebral arteries. A review. Parker DL, et al. **Invest Radiol** 1998 Sep;33(9):560–72

Contrast-enhanced magnetic resonance angiography. Potential applications and pitfalls in magnetic resonance angiography-guided therapy: a review. Schild HH, et al. **Invest Radiol** 1998 Sep;33(9):524–7 (12 ref.)

D-galactose-based signal-enhanced color Doppler sonography of breast tumors and tumorlike lesions. Schroeder RJ, et al. **Invest Radiol** 1999 Feb;34(2):109–15

Contrast-enhanced magnetic resonance angiography of the cervical arteries. A review. Steffens JC, et al. **Invest Radiol** 1998 Sep;33(9):573–7

Gadolinium-enhanced magnetic resonance venography of the portal venous system prior to transjugular intrahepatic portosystemic shunts and liver transplantation. Original investigation. Wilson MW, et al. **Invest Radiol** 1998 Sep; 33(9):644–52

Gadolinium-enhanced magnetic resonance angiography of the aorta. A review. Yamada CY, et al. **Invest Radiol** 1998 Sep;33(9):618–27 (17 ref.)

Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. Hundley WG, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1426–32

Real-time visualization of myocardial perfusion and wall thickening in human beings with intravenous ultrasonographic contrast and accelerated intermittent harmonic imaging. Porter TR, et al. **J Am Soc Echocardiogr** 1999 Apr;12(4):266–71

Measuring collagen fiber orientation: a two-dimensional quantitative macroscopic technique. Dickey JP, et al. **J Biomech Eng** 1998 Aug;120(4):537–40

Diagnosis of herniated intervertebral disc assisted by 3-dimensional, multiaxial, magnetic resonance imaging. Hsieh MS, et al. **J Formos Med Assoc** 1999 May; 98(5):347–55

T2-weighted MRI of the uterus: fast spin echo vs. breath-hold fast spin echo. Ascher SM, et al. **J Magn Reson Imaging** 1999 Mar;9(3):384–90

Detection of residual quadrupolar interaction in the human breast in vivo using sodium-23 multiple quantum spectroscopy. Duvvuri U, et al. **J Magn Reson Imaging** 1999 Mar;9(3):391–4

Transfer insensitive labeling technique (TILT): application to multislice functional perfusion imaging. Golay X, et al. **J Magn Reson Imaging** 1999 Mar;9(3):454–61

Pelvic floor descent: dynamic MR imaging using a half-Fourier RARE sequence. Gufler H, et al. **J Magn Reson Imaging** 1999 Mar;9(3):378–83

Sub-millimeter fMRI at 1.5 Tesla: correlation of high resolution with low resolution measurements. Hoogenraad FG, et al. **J Magn Reson Imaging** 1999 Mar;9(3):475–82

Quantitative analysis of cerebral microvascular hemodynamics with T2-weighted dynamic MR imaging. Koshimoto Y, et al. **J Magn Reson Imaging** 1999 Mar; 9(3):462–7

MRI geometric distortion: a simple approach to correcting the effects of non-linear gradient fields. Langlois S, et al. **J Magn Reson Imaging** 1999 Jun;9(6):821–31

Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla. Loubeyre P, et al. **J Magn Reson Imaging** 1999 Mar;9(3):447–53

Diagnostic benefit of echocontrast enhancement for the insufficient transtemporal bone window. Nabavi DG, et al. **J Neuroimaging** 1999 Apr;9(2):102–7

Serial gadolinium-enhanced and magnetization transfer imaging to investigate the relationship between the duration of blood-brain barrier disruption and extent of demyelination in new multiple sclerosis lesions [letter] Silver N, et al. **J Neurol** 1999 Aug;246(8):728–30

Lumen reduction measurements of the internal carotid artery before and after Levovist enhancement: reproducibility and agreement with angiography. Elgersma OE, et al. **J Ultrasound Med** 1999 Mar;18(3):191–201

Dodecafluoropentane ultrasonic contrast enhancement in carotid diagnosis: preliminary results. Gahn G, et al. **J Ultrasound Med** 1999 Feb;18(2):101–8

Doppler sonographic enhancement of hepatic hemangiomas and hepatocellular carcinomas after perflenapent emulsion: preliminary study. Lopez-Ben R, et al. **J Ultrasound Med** 1999 Feb;18(2):109–16

Signal-enhanced color Doppler sonography of deep venous thrombosis in the lower limbs and pelvis. Puls R, et al. **J Ultrasound Med** 1999 Mar;18(3):185–90

Diode laser-induced thermal damage evaluation on the retina with a liposome dye system. Desmettre TJ, et al. **Lasers Surg Med** 1999;24(1):61–8

On- and off-resonance spin-lock MR imaging of normal human brain at 0.1 T: possibilities to modify image contrast. Ramadan UA, et al. **Magn Reson Imaging** 1998 Dec; 16(10):1191–9

Two methods for semi-automated quantification of changes in ventricular volume and their use in schizophrenia. Saeed N, et al. **Magn Reson Imaging** 1998 Dec;16(10):1237–47

Method for improved multiband excitation profiles using the Shinnar-Le Roux transform. Cunningham CH, et al. **Magn Reson Med** 1999 Sep;42(3):577–84

Segmented k-space fast cardiac imaging using an echo-train readout. Epstein FH, et al. **Magn Reson Med** 1999 Mar; 41(3):609–13

3D z-shim method for reduction of susceptibility effects in BOLD fMRI. Glover GH. **Magn Reson Med** 1999 Aug; 42(2):290–9

Improved device definition in interventional magnetic resonance imaging using a rotated stripes keyhole acquisition. Hwang KP, et al. **Magn Reson Med** 1999 Sep; 42(3):554–60

Motion correction in fMRI via registration of individual slices into an anatomical volume. Kim B, et al. **Magn Reson Med** 1999 May;41(5):964–72

Improving contrast and tracking of tags in cardiac magnetic resonance images. Koerkamp MA, et al. **Magn Reson Med** 1999 May;41(5):973–82

In vivo gradient echo microimaging of rodent spinal cord at 7 T. Meyerand ME, et al. **Magn Reson Med** 1998 Nov; 40(5):789–91

In vivo neuronal tract tracing using manganese-enhanced magnetic resonance imaging. Pautler RG, et al. **Magn Reson Med** 1998 Nov;40(5):740–8

Intimate combination of low- and high-resolution image data: I. Real-space PET and (1)H(2)O MRI, PETAMRI. Sammi MK, et al. **Magn Reson Med** 1999 Aug;42(2):345–60

Toward high-resolution myocardial tagging. Stuber M, et al. **Magn Reson Med** 1999 Mar;41(3):639–43

Functional imaging of the visual cortex with bold-contrast MRI: hyperventilation decreases signal response. Weckesser M, et al. **Magn Reson Med** 1999 Jan;41(1):213–6

Motion-selective encoding for fast cine imaging. Yang GZ, et al. **Magn Reson Med** 1999 Sep;42(3):430–5

Automatic segmentation of magnetic resonance images of the trans-femoral residual limb. Douglas TS, et al. **Med Eng Phys** 1998 Dec;20(10):756–63

A method for quantifying time dependent changes in MR signal intensity of articular cartilage as a function of tissue deformation in intact joints. Stammberger T, et al. **Med Eng Phys** 1998 Dec;20(10):741–9

Measuring actin dynamics in endothelial cells. McGrath JL, et al. **Microsc Res Tech** 1998 Dec 1;43(5):385–94

Contrast-enhanced carotid MR angiography. Imaging principles and physics. Foo TK, et al. **Neuroimaging Clin N Am** 1999 May;9(2):263–84

Fast FLAIR MRI in childhood white-matter abnormalities. Demaerel P, et al. **Neuroradiology** 1998 Jun;40(6):355–8

Do acute lesions of Wernicke's encephalopathy show contrast enhancement? Report of three cases and review of the literature. Mascalchi M, et al. **Neuroradiology** 1999 Apr;41(4):249–54 (20 ref.)

MRI of acute cerebral infarcts, increased contrast enhancement with continuous infusion of gadolinium. Merten CL, et al. **Neuroradiology** 1999 Apr;41(4):242–8

Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. Nelson SJ, et al. **NMR Biomed** 1999 May;12(3):123–38 (119 ref.)

Ultrasound myocardial tissue characterization by integrated backscatter in children treated with anthracyclines. Goens MB, et al. **Pediatr Cardiol** 1999 Jul-Aug;20(4):264–70

Hepatic enhancement analysis in children using smart prep monitoring for 2 : 1 pitch helical scanning. Vade A, et al. **Pediatr Radiol** 1999 Sep;29(9):689–93

Shape-based grey-level image interpolation. Chuang KS, et al. **Phys Med Biol** 1999 Jun;44(6):1565–77

Analytical propagation of errors in dynamic SPECT: estimators, degrading factors, bias and noise. Kadrmas DJ, et al. **Phys Med Biol** 1999 Aug;44(8):1997–2014

Image/patient registration from (partial) projection data by the Fourier phase matching method. Lu W, et al. **Phys Med Biol** 1999 Aug;44(8):2029–48

A study of artefacts in simultaneous PET and MR imaging using a prototype MR compatible PET scanner. Slates RB, et al. **Phys Med Biol** 1999 Aug;44(8):2015–27

Estimation of blood perfusion using ultrasound. Jansson T, et al. **Proc Inst Mech Eng [H]** 1999;213(2):91–106 (110 ref.)

Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Yamada I, et al. **Radiology** 1999 Mar;210(3):617–23

Indocyanine green angiography: an evaluation of image enhancement for the identification of occult choroidal neovascular membranes. Maberley DA, et al. **Retina** 1999; 19(1):37–44

Pachymeningeal gadolinium enhancement of the lumbar region secondary to neuraxis hypotension. Fedder SL. **Spine** 1999 Mar 1;24(5):463–4

Effect of acquisition rate on liver and portal vein enhancement with microbubble contrast. Sirlin CB, et al. **Ultrasound Med Biol** 1999 Mar;25(3):331–8

Comparison of spin echo, gradient echo and fat saturation magnetic resonance imaging sequences for imaging the canine elbow. Snaps FR, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec;39(6):518–23

[Application of T1-weighted images by contrast-enhanced frequency-selective presaturation in magnetic resonance imaging] Zhou G, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):265–7 (Eng. Abstr.) **(Chi)**

[Contrast-enhanced magnetic resonance angiography] Leiner T, et al. **Ned Tijdschr Geneeskd** 1999 May 22; 143(21):1087–93 (27 ref.) (Eng. Abstr.) **(Dut)**

[Ultrasonography] Leray P, et al. **J Radiol** 1999 Jul;80(7 Suppl):791–6 **(Fre)**

[Abdominal and pelvic segmented T1-weighted echo-planar imaging and MRI. Comparison with T1-TSE and T2-UTSE sequences] Maubon A, et al. **J Radiol** 1999 Mar; 80(3):291–6 (Eng. Abstr.) **(Fre)**

[Color duplex ultrasonography of the intracranial vertebro-basilar system: improved imaging by echo signal enhancement] Brunner-Beeg F, et al. **Ultraschall Med** 1999 Jun;20(3):83–6 (Eng. Abstr.) **(Ger)**

[Differentiation between benign and malignant breast lesions using fat-suppressed dynamic MR imaging] Koshiishi T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Jul; 58(8):433–40 (Eng. Abstr.) **(Jpn)**

[Double oblique MR images of the shoulder: comparison with conventional images] Sasaki T, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Jul; 58(8):426–32 (Eng. Abstr.) **(Jpn)**

[Evaluation of the cystic duct and cysticohepatic junction with MR cholangiography: comparison of various techniques and clinical evaluation with respiratory-triggered three-dimensional multislab technique] Tsunoda M, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Jul;58(8):420–5 (Eng. Abstr.) **(Jpn)**

[Efficacy of dynamic susceptibility contrast MRI using echo-planar imaging in differential diagnosis of breast tumors] Yoshino A. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Jul;58(8):441–6 (Eng. Abstr.) **(Jpn)**

[Object analysis of cervical lymph nodes using MRI turbo-STIR sequence in cases of head and neck tumors] Okita W, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1999 Jan; 102(1):1–7 (Eng. Abstr.) **(Jpn)**

[Optimization of pulse sequences for MR cholangiopancreatography with FASE] Akiyama H, et al. **Nippon Rinsho** 1998 Nov;56(11):2813–6 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical usefulness of fat suppression technique for MR cholangiopancreatography (MRCP)] Dohke M, et al. **Nippon Rinsho** 1998 Nov;56(11):2870–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

[FASE (fast advanced spin echo)] Higashi M. **Nippon Rinsho** 1998 Nov;56(11):2783–91 (20 ref.) (Eng. Abstr.) **(Jpn)**

[HASTE: features and clinical applications] Imura C. **Nippon Rinsho** 1998 Nov;56(11):2778–82 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Maximum intensity projection (MIP) and multiplanar reformation (MPR) for post-processing cholangiopancreatographic data set--clinical application and pitfalls] Isogai S, et al. **Nippon Rinsho** 1998 Nov; 56(11):2760–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness of T2-weighted images using single shot fast spin echo (SSFSE) pulse sequence for the evaluation of pancreatobiliary diseases: comparison with MRCP using SSFSE] Kadoya M, et al. **Nippon Rinsho** 1998 Nov; 56(11):2836–41 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Efficacy of multidirection MRCP] Koike S, et al. **Nippon Rinsho** 1998 Nov;56(11):2808–12 (0 ref.) (Eng. Abstr.) **(Jpn)**

[PSIF/CE-FAST (fast gradient echo) and TSE (turbo spin echo)] Miyazaki T, et al. **Nippon Rinsho** 1998 Nov; 56(11):2773–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[MR cholangiopancreatography using respiratory triggered half-Fourier RARE technique] Morimoto A, et al. **Nippon Rinsho** 1998 Nov;56(11):2859–64 (Eng. Abstr.) **(Jpn)**

[Characteristics and detectability of RARE technique] Murata K, et al. **Nippon Rinsho** 1998 Nov;56(11):2799–802 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Ultrafast CT, MRI] Nakanishi T, et al. **Nippon Rinsho** 1998 Oct;56(10):2544–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Optimal scan parameters of MRCP using HASTE] Nishio H, et al. **Nippon Rinsho** 1998 Nov;56(11):2803–7 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Single shot fast spin echo (SSFSE)] Nozaki A. **Nippon Rinsho** 1998 Nov;56(11):2792–7 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Elimination of artifacts in MRCP: technical consideration] Ohgi K, et al. **Nippon Rinsho** 1998 Nov;56(11):2854–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[MR cholangiopancreatography with single-shot fast-spin-echo sequences] Shiratori Y, et al. **Nippon Rinsho** 1998 Nov;56(11):2842–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical efficacy of suppression and visualization of the duodenal fluid in MR cholangiopancreatography using ferric ammonium citrate] Takahara T, et al. **Nippon Rinsho** 1998 Nov;56(11):2865–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Demonstration of normal bile duct and pancreatic duct with MR cholangiopancreatography] Toda J, et al. **Nippon Rinsho** 1998 Nov;56(11):2830–5 (Eng. Abstr.) **(Jpn)**

[MR-cholangiopancreatography using three-dimensional Fourier transfer fast asymmetric spin-echo method (3DFT-FASE)--clinical evaluation] Yamakawa K, et al. **Nippon Rinsho** 1998 Nov;56(11):2825-9 (Eng. Abstr.) **(Jpn)**

[Clinical application of multi-shot diffusion EPI in neurological disease] Ishihara T, et al. **Rinsho Shinkeigaku** 1998 May;38(5):453-6 (Eng. Abstr.) **(Jpn)**

[Two cases with chronic inflammatory demyelinating polyneuropathy showing high signal and enlargement of the brachial plexus in short TI inversion recovery of MRI] Sato H, et al. **Rinsho Shinkeigaku** 1999 Apr;39(4):471-4 (Eng. Abstr.) **(Jpn)**

[Ultrasound contrast agents] Drop A. **Ann Univ Mariae Curie Sklodowska [Med]** 1997;52:167-71 (9 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Technology assessment of magnetic resonance angiography. Why pretty pictures are not enough: an overview. Flamm CR. **Invest Radiol** 1998 Sep;33(9):547-52 (19 ref.)

IMAGE INTERPRETATION, COMPUTER-ASSISTED

Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. Kohlberger PD, et al. **Anticancer Res** 1999 May-Jun;19(3B):2189-93

A fuzzy clustering based segmentation system as support to diagnosis in medical imaging. Masulli F, et al. **Artif Intell Med** 1999 Jun;16(2):129-47

Observer variation in cytologic grading for cervical dysplasia of Papanicolaou smears with the PAPNET testing system. Doornewaard H, et al. **Cancer** 1999 Aug 25;87(4):178-83

Chromatic distortion during angioscopy: assessment and correction by quantitative colorimetric angioscopic analysis. Lehmann KG, et al. **Cathet Cardiovasc Diagn** 1998 Oct;45(2):191-201

Image quality assessment: a timely look [editorial] Laskey WK, et al. **Catheter Cardiovasc Interv** 1999 Feb;46(2):125-6

Automated Papanicolaou smear analysis as a screening tool for female lower genital tract malignancies. Ku NN. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):41-3 (6 ref.)

Cellular automata and follicle recognition problem and possibilities of using cellular automata for image recognition purposes. Viher B, et al. **Int J Med Inf** 1998 Apr;49(2):231-41

Three-dimensional color Doppler: a new approach for quantitative assessment of mitral regurgitant jets. De Simone R, et al. **J Am Soc Echocardiogr** 1999 Mar; 12(3):173-85

How accurate is visual assessment of synchronicity in myocardial motion? An In vitro study with computer-simulated regional delay in myocardial motion: clinical implications for rest and stress echocardiography studies. Kvitting JP, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):698-705

A comparison of the interpretation of digitized and videotape recorded echocardiograms. Segar DS, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):714-9

Dobutamine stress echocardiography: improved endocardial border definition and wall motion analysis with tissue harmonic imaging. Zaglavara T, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):706-13

Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. Belien JA, et al. **J Clin Pathol** 1999 Mar; 52(3):184-92

A breast density index for digital mammograms based on radiologists' ranking. Boone JM, et al. **J Digit Imaging** 1998 Aug;11(3):101-15

Differentiation of small hyperechoic renal cell carcinoma from angiomyolipoma: computer-aided tissue echo quantification. Sim JS, et al. **J Ultrasound Med** 1999 Apr; 18(4):261-4

In the next decade automated computer analysis will be an accepted sole method to separate "normal" from "abnormal" radiological images. Hoffman KR, et al. **Med Phys** 1999 Jan;26(1):1-4

Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Zaidi H. **Med Phys** 1999 Apr; 26(4):574-608 (288 ref.)

Image analysis and pattern recognition for computer supported skin tumor diagnosis. Handels H, et al. **Medinfo** 1998;9 Pt 2:1056-62

Development of videostrobokymography for the quantitative analysis of laryngeal vibratory pattern. Lee JS, et al. **Medinfo** 1998;9 Pt 2:1022-4

Computer-supported diagnosis of melanoma in profilometry. Handels H, et al. **Methods Inf Med** 1999 Mar;38(1):43-9

Computer-assisted electrocardiography in structured diagnosis of acute myocardial infarction. Porela P, et al. **Scand Cardiovasc J** 1999;33(2):89-96

[Are the procedures in hematology always rational? Considerations] Churý Z. **Vnitr Lek** 1998 May;44(5):294-6 (Eng. Abstr.) **(Cze)**

[High-resolution virtual laryngoscopy based on spiral CT data] Aschoff AJ, et al. **Radiologe** 1998 Oct;38(10):810-5 (47 ref.) (Eng. Abstr.) **(Ger)**

[Imaging in intensive care. Methods, indications, diagnostic signs. I] Bankier A, et al. **Radiologe** 1998 Nov;38(11):972-86 **(Ger)**

[Morphologic image processing operators: reduction of partial volume effects for improved 3D visualization of CT data] Beier J, et al. **Radiologe** 1998 Oct;38(10):860-6 (Eng. Abstr.) **(Ger)**

[Computer-assisted diagnosis based on computer-based image interpretation and 3D-visualization] Schuhmann D, et al. **Radiologe** 1998 Oct;38(10):799-809 (47 ref.) (Eng. Abstr.) **(Ger)**

[Expert systems and automatic diagnostic systems in histopathology--a review] Tamai S. **Rinsho Byori** 1999 Feb;47(2):126-31 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Computer diagnosis of postmenopausal osteoporosis] Vasil'ev AI, et al. **Vopr Onkol** 1998;44(6):729-32 **(Rus)**

INSTRUMENTATION

[High resolution methods for monitoring eye position] Hutten H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:108-9 **(Ger)**

[Therapy evaluation in dermatology by comparative color measurements] Meffert B, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:82-3 **(Ger)**

[3D segmenting method for volume quantification of ECT (emission-computed tomography) data] Schmitt T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:70-1 **(Ger)**

[Digital data collection based on "DICOM Supplement Structured Reporting" in radiology] von Gehlen S, et al. **Biomed Tech (Berl)** 1998;43 Suppl:46-7 **(Ger)**

[Volumetric brain findings in late depression. A study with quantified magnetic resonance tomography] Pantel J, et al. **Nervenarzt** 1998 Nov;69(11):968-74 (Eng. Abstr.) **(Ger)**

METHODS

Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Marsigliante S, et al. **Cancer Lett** 1999 May 3;139(1):33-41

Tissue architecture analysis in prostate cancer and its precursors: An innovative approach to computerized histometry. Bartels PH, et al. **Eur Urol** 1999;35(5-6):484-91 (8 ref.)

Description of shapes in CT images. The usefulness of time-series modeling techniques for identifying organs. Mir AH, et al. **IEEE Eng Med Biol Mag** 1999 Jan-Feb; 18(1):79-84

Enhancement and associative restoration of electronic portal images in radiotherapy. Krell G, et al. **Int J Med Inf** 1998 Apr;49(2):157-71

Chiropractic biophysics digitized radiographic mensuration analysis of the anteroposterior lumbopelvic view: a reliability study. Troyanovich SJ, et al. **J Manipulative Physiol Ther** 1999 Jun;22(5):309-15

[Stepwise analysis of cerebral blood flow SPECT imaging on standard brain atlas in patients with dementia of Alzheimer's type] Kumakura Y, et al. **Kaku Igaku** 1998 Nov;35(9):843-8 (Eng. Abstr.) **(Jpn)**

IMAGE PROCESSING, COMPUTER-ASSISTED

Three-dimensional endoluminal ultrasound: a new method for the evaluation of gastrointestinal tumors [see comments] Hünerbein M, et al. **Abdom Imaging** 1999 Sep-Oct; 24(5):445-8. Comment in: Abdom Imaging 1999 Sep-Oct;24(5):449-51.

MR virtual endoscopy of the pancreaticobiliary tract: a feasible technique? Neri E, et al. **Abdom Imaging** 1999 May-Jun;24(3):289-91

Three-dimensional intraluminal sonography in the evaluation of gastrointestinal diseases [comment] Nesje SO, et al. **Abdom Imaging** 1999 Sep-Oct;24(5):449-51 (29 ref.). Comment on: Abdom Imaging 1999 Sep-Oct;24(5):445-8.

Impact of double helical CT and three-dimensional CT arteriography on surgical planning for hepatic transplantation. Nghiem HV, et al. **Abdom Imaging** 1999 May-Jun;24(3):278-84

Report of the Working Group on Digital Mammography: Computer-Aided Diagnosis and 3D Image Analysis and Display. Cambridge, Massachusetts, USA. October 8-9, 1998. **Acad Radiol** 1999 Jun;6 Suppl 5:S223-56

The inevitability of 3D visualization: technology trends and cost/benefit. Argiro V. **Acad Radiol** 1998 Sep;5 Suppl 2:S432-3

Radiologic volumetry on a personal computer with a stereologic method. Kao SC, et al. **Acad Radiol** 1998 Oct; 5(10):665-9

Automated calculation of the centerline of the human colon on CT images. Samara Y, et al. **Acad Radiol** 1999 Jun; 6(6):352-9

A study of the solar effect on actinic keratoses by quantification of elastic fibres using an image analysis system. Cho CG, et al. **Acta Derm Venereol** 1999 Jul; 79(4):278-80

Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Savolainen L, et al. **Acta Derm Venereol** 1998 Nov; 78(6):466-7

An image analysis strategy to determine the distribution of cell types in spleen sections. Carol M, et al. **Acta Histochem** 1999 Jul;101(3):281-91

Three-dimensional computerized tomography in the presurgical evaluation of Chiari malformations. Duffau H, et al. **Acta Neurochir (Wien)** 1998;140(5):429-35; discussion 435-6

Cerebral aneurysm associated with persistent primitive olfactory artery aneurysm. Nozaki K, et al. **Acta Neurochir (Wien)** 1998;140(4):397-401; discussion 401-2 (11 ref.)

Three-dimensional displacement of the hip joint after triple pelvic osteotomy. A postmortem radiostereometric study. de Kleuver M, et al. **Acta Orthop Scand** 1998 Dec; 69(6):585-9

Bone age in 116 untreated patients with Turner's syndrome rated by a computer-assisted method (CASAS). Schwarze CP, et al. **Acta Paediatr** 1998 Nov;87(11):1146-50

3D surface rendering of images from multiple MR pulse sequences in the pre-operative evaluation of hepatic lesions. Bjerner T, et al. **Acta Radiol** 1998 Nov; 39(6):698-700

2D inflow MR angiography in severe chronic leg ischemia. Eklöf H, et al. **Acta Radiol** 1998 Nov;39(6):663-8

Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Kvistad KA, et al. **Acta Radiol** 1999 Jan;40(1):45-51

Timing adjustment in gadolinium MR angiography by raw data recombination. Technical note. Smedby O, et al. **Acta Radiol** 1999 Jul;40(4):462-4

Form and function of mammalian lung: analysis by scientific computing. Kriete A. **Adv Anat Embryol Cell Biol** 1998; 145:III-IX, 1-105

Use of surgical wands in neurosurgery. Zamorano L, et al. **Adv Tech Stand Neurosurg** 1998;24:77-128 (64 ref.)

The role of the computer imaging system in modern aesthetic plastic surgery. Bronz G. **Aesthetic Plast Surg** 1999 May-Jun;23(3):159-63

Osseous anatomy of the pterygopalatine fossa. Daniels DL, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1423-32

Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. Fazekas F, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):637-42

Triple-technique (MR imaging, single-photon emission CT, and CT) coregistration for image-guided surgical evaluation of patients with intractable epilepsy. Hogan RE, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul;20(6):1054-8

Curved planar reformatted CT angiography: usefulness for the evaluation of aneurysms at the carotid siphon. Ochi T, et al. **AJNR Am J Neuroradiol** 1999 Jun-Jul; 20(6):1025-30

Virtual MR cholangiography. Dubno B, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1547-50

Virtual endoscopy: what's in a name? [see comments] Johnson CD, et al. **AJR Am J Roentgenol** 1998 Nov; 171(5):1201-2. Comment in: AJR Am J Roentgenol 1998 Nov;171(5):1185. Comment in: AJR Am J Roentgenol 1999 May;172(5):1452.

Virtual bronchoscopy in children: early clinical experience. Konen E, et al. **AJR Am J Roentgenol** 1998 Dec; 171(6):1699-702

Quantitative analysis of pulmonary emphysema: three-dimensional fractal analysis of single-photon emission computed tomography images obtained with a carbon particle radioaerosol. Nagao M, et al. **AJR Am J Roentgenol** 1998 Dec;171(6):1657-63

A day in the court of lexicon: virtual endoscopy [editorial; comment] [see comments] Rogers LF. **AJR Am J Roentgenol** 1998 Nov;171(5):1185. Comment on: AJR Am J Roentgenol 1998 Nov;171(5):1201-2. Comment in: AJR Am J Roentgenol 1999 May;172(5):1452.

Three-dimensional MR coronary angiography using the navigator technique compared with conventional coronary angiography. Sandstede JJ, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):135-9

Three-dimensional helical CT of pulmonary arteries in infants and children with congenital heart disease. Westra SJ, et al. **AJR Am J Roentgenol** 1999 Jul;173(1):109-15

Virtual endoscopy of the gastrointestinal system outside the colon. Wood BJ, et al. **AJR Am J Roentgenol** 1998 Nov; 171(5):1367-72

Virtual endoscopy using perspective volume-rendered three-dimensional sonographic data: technique and clinical applications. Yuh EL, et al. **AJR Am J Roentgenol** 1999 May;172(5):1193-7

Intravenous three-dimensional coronary angiography using contrast enhanced electron beam computed tomography. Budoff MJ, et al. **Am J Cardiol** 1999 Mar 15;83(6):840-5

Ablation of right and left ectopic atrial tachycardias using a three-dimensional nonfluoroscopic mapping system. Natale A, et al. **Am J Cardiol** 1998 Oct 15;82(8):989-92

Measuring maximal percent area stenosis poststent placement with intracoronary Doppler and the continuity equation and correlation with intracoronary ultrasound and angiography. Al Suwaidi J, et al. **Am J Cardiol** 1999 Sep 15;84(6):650-4

Virtual microscopy and the Internet as telepathology consultation tools. A study of gastrointestinal biopsy specimens. Singson RP, et al. **Am J Clin Pathol** 1999 Jun; 111(6):792-5

Morphing and warping. Part I. Halazonetis DJ. **Am J Orthod Dentofacial Orthop** 1999 Apr;115(4):466-77

Morphing and warping: Part II. Halazonetis DJ. **Am J Orthod Dentofacial Orthop** 1999 Jun;115(6):706–8

Presentations with Dentofacial Planner images. Hegarty D. **Am J Orthod Dentofacial Orthop** 1999 Jul;116(1):114–6

Imaging in the orthodontic office (and beyond). Scholz RP. **Am J Orthod Dentofacial Orthop** 1998 Oct;114(4):464–6

Capturing data from three-dimensional surfaces using fuzzy landmarks. Valeri CJ, et al. **Am J Phys Anthropol** 1998 Sep;107(1):113–24

Computer-assisted image analysis of intratumoral vessel density in mammary tumors from dogs. Griffey SM, et al. **Am J Vet Res** 1998 Oct;59(10):1238–42

Quantification of eumelanin and pheomelanin: stereologic image analysis method. Donois E, et al. **Anal Quant Cytol Histol** 1998 Aug;20(4):275–87

Discrimination of esophageal dysplasia with progression and nonprogression. High-resolution image analysis for surrogate end point biomarkers. Zhou B, et al. **Anal Quant Cytol Histol** 1998 Dec;20(6):500–8

Increase in odontoclast nuclei number by cell fusion: a three-dimensional reconstruction of cell fusion of human odontoclasts. Domon T, et al. **Anat Rec** 1998 Nov; 252(3):462–71

Three-dimensional direction and interrelationship of prisms in cuspal and cervical enamel of dog tooth. Hanaizumi Y, et al. **Anat Rec** 1998 Nov;252(3):355–68

Quality assessment of computer-assisted semen analysis (CASA) in the andrology laboratory. Krause W, et al. **Andrologia** 1999 May;31(3):125–9 (23 ref.)

Digital image analysis of erythema development after experimental thermal injury to human skin: effect of postburn topical local anesthetics (EMLA). Mattsson U, et al. **Anesth Analg** 1999 May;88(5):1131–6

Comparison of preferences in lip position using computer animated imaging. Hier LA, et al. **Angle Orthod** 1999 Jun; 69(3):231–8

Estimation of tendon moment arms from three-dimensional magnetic resonance images. Wilson DL, et al. **Ann Biomed Eng** 1999 Mar-Apr;27(2):247–56

Diagnosis of subtle focal dysplastic lesions: curvilinear reformatting from three-dimensional magnetic resonance imaging. Bastos AC, et al. **Ann Neurol** 1999 Jul;46(1):88–94

Three-dimensional navigation in otorhinolaryngological surgery with the viewing wand. Freysinger W, et al. **Ann Otol Rhinol Laryngol** 1998 Nov;107(11 Pt 1):953–8

Virtual laryngoscopy. Fried MP, et al. **Ann Otol Rhinol Laryngol** 1999 Mar;108(3):221–6

The mysterious case of persistent malocclusion. Tang C, et al. **Ann Plast Surg** 1998 Oct;41(4):420–1

Assessment of mitral regurgitant jets by three-dimensional color Doppler. De Simone R, et al. **Ann Thorac Surg** 1999 Feb;67(2):494–9

Computerized tomographic angiography scan following carotid endarterectomy. Marro B, et al. **Ann Vasc Surg** 1998 Sep;12(5):451–6

Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. Kohlberger PD, et al. **Anticancer Res** 1999 May-Jun;19(3B):2189–93

Quantitative digital image analysis applied to demonstrate the stratified distribution of involucrin in organ cultured human skin. Kivinen PK, et al. **Arch Dermatol Res** 1999 Apr;291(4):217–23

DNA ploidy determination of early molar pregnancies by image analysis: comparison to histologic classification. Gschwendtner A, et al. **Arch Pathol Lab Med** 1998 Nov; 122(11):1000–4

Three-dimensional imaging of mitral and tricuspid annuli for total artificial heart implantation. Komoda T, et al. **Artif Organs** 1992 Oct;16(5):496–501

Observation of eardrum movements during quasi-static pressure changes by high-speed digital imaging. Vorwerk U, et al. **Audiol Neurootol** 1999 May-Aug;4(3–4):150–5

Computerized assessment of the mastoid air cell system. Isono M, et al. **Auris Nasus Larynx** 1999 Apr;26(2):139–45

New software for lens retro-illumination digital image analysis. Gershenzon A, et al. **Aust N Z J Ophthalmol** 1999 Jun-Aug;27(3–4):170–2

Beyond the "hot-and-cold" game: a demonstration of computer-controlled shaping. Silva FJ. **Behav Res Methods Instrum Comput** 1999 Feb;31(1):63–73

Morphing techniques for manipulating face images. Steyvers M. **Behav Res Methods Instrum Comput** 1999 May; 31(2):359–69 (14 ref.)

Computer quantification of intracellular gold particles. Bisland SK, et al. **Biotechniques** 1999 Mar;26(3):494–500

Identification of relative protein bands in polyacrylamide gel electrophoresis (PAGE) using a multi-resolution snake algorithm. Gürcan MN, et al. **Biotechniques** 1999 Jun; 26(6):1162–6, 1168–9

The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Ulrich D, et al. **Bone** 1999 Jul;25(1):55–60

Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Fenton BM, et al. **Br J Cancer** 1999 Feb; 79(3–4):464–71

Comparison between laser scanning tomography and computerised image analysis of the optic disc. Azuara-Blanco A, et al. **Br J Ophthalmol** 1999 Mar; 83(3):295–8

A vision-based three-dimensional capture system for maxillofacial assessment and surgical planning. Ayoub AF, et al. **Br J Oral Maxillofac Surg** 1998 Oct;36(5):353–7

Predictive models for difficult laryngoscopy and intubation. A clinical, radiologic and three-dimensional computer imaging study. Naguib M, et al. **Can J Anaesth** 1999 Aug; 46(8):748–59

Computer-assisted restriction endonuclease analysis of plasmid DNA in field strains of Salmonella enteritidis. Rychlik I, et al. **Can J Microbiol** 1998 Dec;44(12):1183–5

Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis. Boone CW, et al. **Cancer Surv** 1998; 32:133–47 (40 ref.)

Development of coronary aneurysm after cutting balloon angioplasty: assessment by intracoronary ultrasound. Bertrand OF, et al. **Cathet Cardiovasc Diagn** 1998 Aug; 44(4):449–52

Cine PACS: preprint. Balter S. **Catheter Cardiovasc Interv** 1999 May;47(1):85–90

Discrimination of osteoarthritic and rheumatoid human synovial cells in culture by nuclear image analysis. Delage B, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Jun; 45(4):445–52

A computer-assisted system for reconstructing and interpreting the dynamic three-dimensional relationships of the outer surface, nucleus and pseudopods of crawling cells. Wessels D, et al. **Cell Motil Cytoskeleton** 1998; 41(3):225–46

Three-dimensional reconstruction of the human central sulcus reveals a morphological correlate of the hand area. Sastre-Janer FA, et al. **Cereb Cortex** 1998 Oct-Nov; 8(7):641–7

Real-time bronchoscope tip localization enables three-dimensional CT image guidance for transbronchial needle aspiration in swine. Solomon SB, et al. **Chest** 1998 Nov;114(5):1405–10

Examination of the transverse tubular system in living cardiac rat myocytes by 2-photon microscopy and digital image-processing techniques. Soeller C, et al. **Circ Res** 1999 Feb 19;84(3):266–75

Four-dimensional cardiac image by helical computed tomography. Koyama Y, et al. **Circulation** 1999 Oct 12; 100(15):e61–2

Electron beam computed tomographic angiography and 3-dimensional reconstruction of a stented saphenous vein graft. Reiner JS, et al. **Circulation** 1999 Jun 22;99(24):E16

Virtual bronchoscopy. Haponik EF, et al. **Clin Chest Med** 1999 Mar;20(1):201–17 (46 ref.)

Electronic imaging in cytopathology. Kurtycz DF. **Clin Lab Med** 1998 Sep;18(3):585–98, vii (17 ref.)

Computer-assisted light microscopy in evaluating urinary red blood cell morphology [letter; comment] Oktenli G, et al. **Clin Nephrol** 1999 Feb;51(2):130–1. Comment on: Clin Nephrol 1997 Apr;47(4):271–2.

Virtual anthropology (VA): methodological aspects of linear and volume measurements--first results. Weber GW, et al. **Coll Antropol** 1998 Dec;22(2):575–84

Development of computer-aided surgery for otorhinolaryngology. Klimek L, et al. **Comput Aided Surg** 1998;3(4):194–201

Stereolithography versus milled three-dimensional models: comparison of production method, indication, and accuracy. Santler G, et al. **Comput Aided Surg** 1998; 3(5):248–56

Intraoperative navigation for breast cancer surgery using 3D ultrasound images. Tamaki Y, et al. **Comput Aided Surg** 1999;4(1):37–44

VoxeLine: a software program for 3D real-time visualization of biomedical images. Diallo B, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):275–89

Computerized evaluation of mammographic image quality using phantom images. Dougherty G. **Comput Med Imaging Graph** 1998 Sep-Oct;22(5):365–73

Non-invasive image acquisition and advanced processing in optical bioimaging. Farkas DL, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):89–102

3D visualization library for multimodal medical images. Heinonen T, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):267–73

Towards a microMRI atlas of mouse development. Jacobs RE, et al. **Comput Med Imaging Graph** 1999 Jan-Feb; 23(1):15–24

Interstitial lung diseases: evaluation of the performance of a computerized analysis system versus observers. Kido S, et al. **Comput Med Imaging Graph** 1999 Mar-Apr; 23(2):103–10

Statistical shape model based segmentation of medical images. Neumann A, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):133–43

A Markov random field model for bony tissue classification. Pardo-López JM, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):169–78

Evaluation and progression analysis of pulmonary tuberculosis from digital chest radiographs. Sarkar S, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):145–55

Magnetic resonance imaging of embryos: an Internet resource for the study of embryonic development. Smith BR, et al. **Comput Med Imaging Graph** 1999 Jan-Feb;23(1):33–40

Computer-assisted three-dimensional reconstruction and motion analysis of living, crawling cells. Soll DR. **Comput Med Imaging Graph** 1999 Jan-Feb;23(1):3–14

Multilevel adaptive process control of acquisition and post-processing of computed radiographic images in picture archiving and communication system environment. Zhang J, et al. **Comput Med Imaging Graph** 1998 Jan-Feb; 22(1):31–40

Divergent X-ray projections may under certain conditions be treated as parallel projections. Edholm PR, et al. **Comput Methods Programs Biomed** 1998 Aug-Sep; 57(1–2):91–4

Magnetic resonance image processing and structured grid generation of a human abdominal bifurcation. Long Q, et al. **Comput Methods Programs Biomed** 1998 Jun; 56(3):249–59

Building quantitative stereology data files with scion image, a public domain image processing and analysis software. Xu YH, et al. **Comput Methods Programs Biomed** 1999 May; 59(2):131–42

Computer-assisted morphometry of cell-substratum contacts. Weber I. **Croat Med J** 1999 Sep;40(3):334–9

Functional genomics: learning to think about gene expression data. Brent R. **Curr Biol** 1999 May 6;9(9):R338–41 (9 ref.)

Digital echocardiography. Main ML, et al. **Curr Opin Cardiol** 1998 Nov;13(6):404–8 (22 ref.)

Automated breast tumor diagnosis and grading based on wavelet chromatin texture description. Weyn B, et al. **Cytometry** 1998 Sep 1;33(1):32–40

Relation between proton magnetic resonance spectroscopy within 18 hours of birth asphyxia and neurodevelopment at 1 year of age. Hanrahan JD, et al. **Dev Med Child Neurol** 1999 Feb;41(2):76–82

Beyond retinal screening: digital imaging in the assessment and follow-up of patients with diabetic retinopathy. Kerr D, et al. **Diabet Med** 1998 Oct;15(10):878–82

Quantitative image cell analysis of cytologic smears for DNA ploidy in renal parenchymal neoplasms. Akhtar M, et al. **Diagn Cytopathol** 1999 Sep;21(3):223–9

Accuracy comparison between PAPNET diagnoses and conventional diagnoses in an Italian cervical cytology laboratory. Ghidoni D, et al. **Diagn Cytopathol** 1998 Oct; 19(4):279–83

Improved quality-control detection of false-negative Pap smears using the Autopap 300 QC system. Marshall CJ, et al. **Diagn Cytopathol** 1999 Mar;20(3):170–4

Clinical value of DNA image cytometry in effusions with atypia. Thunnissen FB, et al. **Diagn Cytopathol** 1999 Aug; 21(2):112–6

Two-dimensional gel analysis of protein expression in ovarian tumors shows a low degree of intratumoral heterogeneity. Alaiya AA, et al. **Electrophoresis** 1999 Apr-May;20(4–5):1039–46

Computer-assisted gait analysis in equine orthopaedic practice: the case for inverse dynamic analysis [editorial; comment] van den Bogert AJ. **Equine Vet J** 1998 Sep; 30(5):362–3. Comment on: Equine Vet J 1998 Sep;30(5):384–9.

When is a lifting movement too asymmetric to identify low-back loading by 2-D analysis? Kingma I, et al. **Ergonomics** 1998 Oct;41(10):1453–61

Three-dimensional color Doppler for assessing mitral regurgitation during valvuloplasty. De Simone R, et al. **Eur J Cardiothorac Surg** 1999 Feb;15(2):127–33

Role of computer-assisted analysis of the corneal endothelium in vitreoretinal surgery with intraocular silicone oil injection: a technical report. Fruschelli M, et al. **Eur J Histochem** 1998;42(4):321–5

A multivariate approach to registration of dissimilar tomographic images. Andersson JL, et al. **Eur J Nucl Med** 1999 Jul;26(7):718–33

Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection. Zimny M, et al. **Eur J Nucl Med** 1999 Aug;26(8):818–23

A computerized analysis of the relation between the occlusal enamel caries lesion and the demineralized dentin. Bjørndal L, et al. **Eur J Oral Sci** 1999 Jun;107(3):176–82

Space analysis: a comparison between sonic digitization (DigiGraph Workstation) and the digital caliper. Mok KH, et al. **Eur J Orthod** 1998 Dec;20(6):653–61

Investigation of the pellet-distribution in single tablets via image analysis. Wagner KG, et al. **Eur J Pharm Biopharm** 1999 Jan;47(1):79–85

Increasing spiral CT benefits with postprocessing applications. Kirchgeorg MA, et al. **Eur J Radiol** 1998 Aug; 28(1):39–54 (81 ref.)

Quantitative assessment of angiogenesis in the chick embryo and its chorioallantoic membrane by computerised analysis of angiographic images. Nikiforidis G, et al. **Eur J Radiol** 1999 Feb;29(2):168–79

Multiresolution texture based adaptive clustering algorithm for breast lesion segmentation. Boukerroui D, et al. **Eur J Ultrasound** 1998 Nov;8(2):135–44

Stereoscopic visualization of three-dimensional ultrasonic data applied to breast tumours. Hernandez A, et al. **Eur J Ultrasound** 1998 Sep;8(1):51–65

Echo planar perfusion imaging with high spatial and temporal resolution: methodology and clinical aspects. Bitzer M, et al. **Eur Radiol** 1999;9(2):221–9

Optimized preoperative planning of calcaneal fractures using spiral computed tomography. Freund M, et al. **Eur Radiol** 1999;9(5):901–6

Accessory cardiac bronchus: 3D CT demonstration in nine

cases. Ghaye B, et al. **Eur Radiol** 1999;9(1):45–8 (21 ref.)
K-space sampling strategies. Hennig J. **Eur Radiol** 1999; 9(6):1020–31 (28 ref.)
Intrathoracic rib demonstrated by helical CT with three-dimensional reconstruction. Laufer L, et al. **Eur Radiol** 1999;9(1):60–1
Phase-contrast MR angiography of peripheral arteries: technique and clinical application. Reimer P, et al. **Eur Radiol** 1999;9(1):122–7
3D MR gastrography: exoscopic and endoscopic analysis of the stomach. Schmid MR, et al. **Eur Radiol** 1999;9(1):73–7
Evaluation of the carotid and vertebral arteries: comparison of 3D SCTA and IA-DSA-work in progress. Seemann MD, et al. **Eur Radiol** 1999;9(1):105–12
Three-dimensional cholangio-spiral CT demonstration of a post-traumatic bile leak in a child. Wicky S, et al. **Eur Radiol** 1999;9(1):99–102
Imaging of airway cells [editorial] Puchelle E, et al. **Eur Respir J** 1998 Jul;12(1):3–5
DNA content and chromatin texture of benzo[a]pyrene-transformed human breast epithelial cells as assessed by image analysis. de Campos Vidal B, et al. **Exp Cell Res** 1998 Oct 10;244(1):77–82
Morphometric analysis of LPS-stimulated human monocytes by computer-assisted image analysis. Madeja Z, et al. **Folia Biol (Krakow)** 1998;46(3–4):123–8
Morphometric analysis of pancreatic carcinoma by computer-assisted image analysis. Wolnicka A, et al. **Folia Biol (Krakow)** 1998;46(1–2):7–15
The amygdaloid body of the rabbit--a morphometric study using image analyser. Dziewiątkowski J, et al. **Folia Morphol (Warsz)** 1998;57(2):93–103
Genome size determination in peronosporales (Oomycota) by Feulgen image analysis. Voglmayr H, et al. **Fungal Genet Biol** 1998 Dec;25(3):181–95
Development of a topographic analysis system for manometric studies in the gastrointestinal tract. Clouse RE, et al. **Gastrointest Endosc** 1998 Oct;48(4):395–401
Preoperative assessment of extrahepatic bile duct carcinoma using three-dimensional intraductal US. Tamada K, et al. **Gastrointest Endosc** 1999 Oct;50(4):548–54
Genetic and environmental contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of adolescent twins. McGregor B, et al. **Genet Epidemiol** 1999;16(1):40–53
High resolution in vivo intra-arterial imaging with optical coherence tomography. Fujimoto JG, et al. **Heart** 1999 Aug;82(2):128–33
Image-guided neurosurgery. Wadley J, et al. **Hosp Med** 1999 Jan;60(1):34–8 (15 ref.)
Multidimensional wavelet analysis of functional magnetic resonance images. Brammer MJ. **Hum Brain Mapp** 1998; 6(5–6):378–82
Analysis of brain activation patterns using a 3-D scale-space primal sketch. Lindeberg T, et al. **Hum Brain Mapp** 1999; 7(3):166–94
Three-dimensional linear and nonlinear transformations: an integration of light microscopical and MRI data. Schormann T, et al. **Hum Brain Mapp** 1998;6(5–6):339–47
Flow cytometric and quantitative image cell analysis of DNA ploidy in renal chromophobe cell carcinoma. Akhtar M, et al. **Hum Pathol** 1998 Nov;29(11):1181–8
Ultrasonic myocardial texture versus Doppler analysis in hypertensive heart: a preliminary study. Di Bello V, et al. **Hypertension** 1999 Jan;33(1):66–73
Detecting membrane lipid microdomains by two-photon fluorescence microscopy. Parasassi T, et al. **IEEE Eng Med Biol Mag** 1999 Sep–Oct;18(5):92–9
A real-time experimental prototype for enhancement of vision rehabilitation using auditory substitution. Capelle C, et al. **IEEE Trans Biomed Eng** 1998 Oct;45(10):1279–93
Characterization of cell deformation and migration using a parametric estimation of image motion. Germain F, et al. **IEEE Trans Biomed Eng** 1999 May;46(5):584–600
Bone image segmentation. Liu ZQ, et al. **IEEE Trans Biomed Eng** 1999 May;46(5):565–73
Comments on "Hall effect imaging". Roth BJ, et al. **IEEE Trans Biomed Eng** 1998 Oct;45(10):1294–5; discussion 1295–6
Three-dimensional wound surface area calculations with a CAD surface element model. Tuch DS, et al. **IEEE Trans Biomed Eng** 1998 Nov;45(11):1397–400
Three-dimensional electrical impedance tomography based on the complete electrode model. Vauhkonen PJ, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1150–60
Adaptive template filtering for signal-to-noise ratio enhancement in magnetic resonance imaging [letter] Ahn CB, et al. **IEEE Trans Med Imaging** 1999 Jun;18(6):549–59
Coupled B-snake grids and constrained thin-plate splines for analysis of 2-D tissue deformations from tagged MRI. Amini AA, et al. **IEEE Trans Med Imaging** 1998 Jun; 17(3):344–56
Energy dependence of nonstationary scatter subtraction--restoration in high resolution PET. Bentourkia M, et al. **IEEE Trans Med Imaging** 1999 Jan; 18(1):66–73
Registration of real and CT-derived virtual bronchoscopic images to assist transbronchial biopsy. Bricault I, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):703–14
Validation of object-induced MR distortion correction for frameless stereotactic neurosurgery. Dean D, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):810–6
Predicting error in rigid-body point-based registration. Fitzpatrick JM, et al. **IEEE Trans Med Imaging** 1998 Oct; 17(5):694–702
A task-specific evaluation of three-dimensional image interpolation techniques. Grevera GJ, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):137–43
Anatomy-based registration of CT-scan and intraoperative X-ray images for guiding a surgical robot. Guéziec A, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):715–28
Iterative reconstruction of single-shot spiral MRI with off resonance. Harshbarger TB, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):196–205
Gradient-based iterative image reconstruction scheme for time-resolved optical tomography. Hielscher AH, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):262–71
Anatomical model matching with fuzzy implicit surfaces for segmentation of thoracic volume scans. Lelieveldt BP, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):218–30
Registration of head CT images to physical space using a weighted combination of points and surfaces. Maurer CR Jr, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):753–61
Fast implementations of algebraic methods for three-dimensional reconstruction from cone-beam data. Mueller K, et al. **IEEE Trans Med Imaging** 1999 Jun; 18(6):538–48
Anti-aliased three-dimensional cone-beam reconstruction of low-contrast objects with algebraic methods. Mueller K, et al. **IEEE Trans Med Imaging** 1999 Jun;18(6):519–37
Quasi-bandlimited properties of radon transforms and their implications for increasing angular sampling densities. Pan X. **IEEE Trans Med Imaging** 1998 Jun;17(3):395–406
Automated atlas integration and interactive three-dimensional visualization tools for planning and guidance in functional neurosurgery. St-Jean P, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):672–80
Image guidance of breast cancer surgery using 3-D ultrasound images and augmented reality visualization. Sato Y, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):681–93
Segmentation of digitized dermatoscopic images by two-dimensional color clustering. Schmid P. **IEEE Trans Med Imaging** 1999 Feb;18(2):164–71
Off-resonance correction of MR images. Schomberg H. **IEEE Trans Med Imaging** 1999 Jun;18(6):481–95
Image guidance of endovascular interventions on a clinical MR scanner. van der Weide R, et al. **IEEE Trans Med Imaging** 1998 Oct;17(5):779–85
Reconstruction of the human cerebral cortex from magnetic resonance images. Xu C, et al. **IEEE Trans Med Imaging** 1999 Jun;18(6):467–80
A unified reconstruction framework for both parallel-beam and variable focal-length fan-beam collimators by a Cormack-type inversion of exponential radon transform. You J, et al. **IEEE Trans Med Imaging** 1999 Jan;18(1):59–65
A method of scoring automated visual fields to determine field constriction causing blindness. Dandona L, et al. **Indian J Ophthalmol** 1998 Jun;46(2):93–6
Computer generated odontoid peg "fracture", a cause for concern? Collier A, et al. **Injury** 1998 Nov;29(9):719–23
Sesamoid displacement: a rare cause of 'clicking thumb'. Deshmukh NV, et al. **Injury** 1999 Mar;30(2):141–3
The effect of B-mode ultrasonic image standardisation on the echodensity of symptomatic and asymptomatic carotid bifurcation plaques. Elatrozy T, et al. **Int Angiol** 1998 Sep; 17(3):179–86
Effects of sauna on sperm movement characteristics of normal men measured by computer-assisted sperm analysis. Saikhun J, et al. **Int J Androl** 1998 Dec;21(6):358–63
Fourier analysis of electron micrographs of positively stained collagen fibrils: application to type I and II collagen typing. Ronzière MC, et al. **Int J Biol Macromol** 1998 Oct; 23(3):207–13
Analysis of flow patterns using MRI see comments] Buonocore MH, et al. **Int J Card Imaging** 1999 Apr; 15(2):99–103. Comment in: Int J Card Imaging 1999 Apr;15(2):97.
Impact of presence of abnormal wall motion on echocardiographic determination of left ventricular function with automated boundary detection technique: re-evaluation. Zhang GC, et al. **Int J Card Imaging** 1998 Aug;14(4):253–9
Objective computerized fetal heart rate analysis. Bernardes J, et al. **Int J Gynaecol Obstet** 1998 Aug;62(2):141–7
The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Anttila MA, et al. **Int J Gynecol Pathol** 1999 Jan; 18(1):42–51
The teaching of computer programming and digital image processing in radiography. Allan GL, et al. **Int J Med Inf** 1998 Jun;50(1–3):139–43
Extending a teleradiology system by tools for visualization and volumetric analysis through a plug-in mechanism. Evers H, et al. **Int J Med Inf** 1999 Feb–Mar;53(2–3):265–75
Virtual planning of liver resections: image processing, visualization and volumetric evaluation. Glombitza G, et al. **Int J Med Inf** 1999 Feb–Mar;53(2–3):225–37
A review of compression methods for medical images in PACS. Strintzis MG. **Int J Med Inf** 1998 Oct–Dec; 52(1–3):159–65
Genomic alterations in human meningiomas detected by restriction landmark genomic scanning and immunohistochemical studies. Inui T, et al. **Int J Oncol** 1999 Sep;15(3):459–66
Comparison of computer workstation with light box for detecting setup errors from portal images. Boxwala AA, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):711–6
Virtual reality of the lower urinary tract in women. Stenzl A, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(4):248–53 (42 ref.)
Three-dimensional coronary magnetic resonance angiography with injection of extracellular contrast medium. Sakuma H, et al. **Invest Radiol** 1999 Aug; 34(8):503–8
Objective evaluation of regional left ventricular wall motion during dobutamine stress echocardiographic studies using segmental analysis of color kinesis images. Koch R, et al. **J Am Coll Cardiol** 1999 Aug;34(2):409–19
Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. Prinzen FW, et al. **J Am Coll Cardiol** 1999 May;33(6):1735–42
Double-oblique free-breathing high resolution three-dimensional coronary magnetic resonance angiography. Stuber M, et al. **J Am Coll Cardiol** 1999 Aug; 34(2):524–31
New real-time interactive cardiac magnetic resonance imaging system complements echocardiography. Yang PC, et al. **J Am Coll Cardiol** 1998 Dec;32(7):2049–56
A methodologic issue for ophthalmic telemedicine: image quality and its effect on diagnostic accuracy and confidence. Briggs R, et al. **J Am Optom Assoc** 1998 Sep; 69(9):601–5
Quantitative assessment of chronic aortic regurgitation with 3-dimensional echocardiographic reconstruction: comparison with electromagnetic flowmeter measurements. Acar P, et al. **J Am Soc Echocardiogr** 1999 Feb;12(2):138–48
Effects of myocardial fiber orientation in echocardiography: quantitative measurements and computer simulation of the regional dependence of backscattered ultrasound in the parasternal short-axis view. Holland MR, et al. **J Am Soc Echocardiogr** 1998 Oct;11(10):929–37
Regional wall motion assessment in stress echocardiography by tissue Doppler bull's-eyes. Hunziker PR, et al. **J Am Soc Echocardiogr** 1999 Mar;12(3):196–202
How accurate is visual assessment of synchronicity in myocardial motion? An In vitro study with computer-simulated regional delay in myocardial motion: clinical implications for rest and stress echocardiography studies. Kvitting JP, et al. **J Am Soc Echocardiogr** 1999 Sep;12(9):698–705
A simplified, practical echocardiographic approach for 3-dimensional surfacing and quantitation of the left ventricle: clinical application in patients with abnormally shaped hearts. Mele D, et al. **J Am Soc Echocardiogr** 1998 Nov;11(11):1001–12
Comparison of MPEG digital video with super VHS tape for diagnostic echocardiographic readings. Soble JS, et al. **J Am Soc Echocardiogr** 1998 Aug;11(8):819–25
Feasibility of real-time 3-dimensional treadmill stress echocardiography. Zwas DR, et al. **J Am Soc Echocardiogr** 1999 May;12(5):285–9
Computer-generated three-dimensional reconstructions of serially sectioned mouse embryos. Kaufman MH, et al. **J Anat** 1998 Oct;193 (Pt 3):323–36 (24 ref.)
Vascularisation in adipose depots surrounding immune-stimulated lymph nodes. Macqueen HA, et al. **J Anat** 1999 Jan;194 (Pt 1):33–8
Identifying homologous anatomical landmarks on reconstructed magnetic resonance images of the human cerebral cortical surface. Maudgil DD, et al. **J Anat** 1998 Nov;193 (Pt 4):559–71
Factors involved in the 'rotation' of the human embryonic stomach around its longitudinal axis: computer-assisted morphometric analysis. Nebot-Cegarra J, et al. **J Anat** 1999 Jan;194 (Pt 1):61–9
The central canal of the human spinal cord: a computerised 3-D study. Storer KP, et al. **J Anat** 1998 May;192 (Pt 4):565–72
Computer-aided interactive three-dimensional reconstruction of the embryonic human heart. Whiten S, et al. **J Anat** 1998 Oct;193 (Pt 3):337–45 (13 ref.)
Coupling of image analysis and tenderness classification to simultaneously evaluate carcass cutability, longissimus area, subprimal cut weights, and tenderness of beef. Shackelford SD, et al. **J Anim Sci** 1998 Oct;76(10):2631–40
A method to increase the sensitive range of pressure sensitive film. Atkinson PJ, et al. **J Biomech** 1998 Sep;31(9):855–9
Measurement of sarcomere length during fast contraction of muscle fibers by digital image analysis. Hajjar M, et al. **J Biomech** 1999 Jul;32(7):737–42
Fast and accurate automated measurements in digitized stereophotogrammetric radiographs. Vrooman HA, et al. **J Biomech** 1998 May;31(5):491–8
Confocal imaging of flows in artificial venular bifurcations. Hitt DL, et al. **J Biomech Eng** 1999 Apr;121(2):170–7
Physiological investigations by image analysis. Pons MN, et al. **J Biotechnol** 1998 Oct 19;65(1):3–14
Trabecular bone mineral and calculated structure of human bone specimens scanned by peripheral quantitative computed tomography: relation to biomechanical properties. Jiang Y, et al. **J Bone Miner Res** 1998 Nov; 13(11):1783–90
Improved densitometric analysis of ventricular volumes in on-line digital cardiac imaging. Lehmkuhl H, et al. **J Cardiovasc Surg (Torino)** 1996 Dec;37(6 Suppl 1):7–12

Robustness of anatomically guided pixel-by-pixel algorithms for partial volume effect correction in positron emission tomography. Strul D, et al. **J Cereb Blood Flow Metab** 1999 May;19(5):547–59

Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. Belien JA, et al. **J Clin Pathol** 1999 Mar; 52(3):184–92

Quantitative assessment of gastric atrophy using the syntactic structure analysis. Zaitoun AM, et al. **J Clin Pathol** 1998 Dec;51(12):895–900

Evaluation of tetracycline fiber therapy with digital image analysis. Fourmousis I, et al. **J Clin Periodontol** 1998 Sep; 25(9):737–45

Semi-automated measurement of motility of human subgingival microflora by image analysis. Ojima M, et al. **J Clin Periodontol** 1998 Aug;25(8):612–6

Activity-dependent refinement in the goldfish retinotectal system is mediated by the dynamic regulation of processes withdrawal: an in vivo imaging study. Johnson FA, et al. **J Comp Neurol** 1999 Apr 19;406(4):548–62

Three-dimensional reconstruction of the antennal lobe in Drosophila melanogaster. Laissue PP, et al. **J Comp Neurol** 1999 Mar 22;405(4):543–52

A probabilistic ribbon model for shape analysis of the cerebral sulci: application to the central sulcus. Manceaux-Demiau A, et al. **J Comput Assist Tomogr** 1998 Nov-Dec; 22(6):962–71

Local maximum intensity projection (LMIP): a new rendering method for vascular visualization. Sato Y, et al. **J Comput Assist Tomogr** 1998 Nov-Dec;22(6):912–7

Confocal reflectance imaging of folliculitis in vivo: correlation with routine histology. Gonzalez S, et al. **J Cutan Pathol** 1999 Apr;26(4):201–5

Three-dimensional reconstruction in dermatopathology--a personal computer-based system. Matsumura T, et al. **J Cutan Pathol** 1999 Apr;26(4):197–200

Digital images in dermatology and the Dermatology Online Atlas on the World Wide Web. Diepgen TL, et al. **J Dermatol** 1998 Dec;25(12):782–7 (20 ref.)

Web-based viewing of picture archiving and communications systems images--Part II: The effect of compression on speed of transmission. Bennett WF, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):116–8

Angiographic film subtraction using a laser digitizer and computer processing. Boone JM, et al. **J Digit Imaging** 1998 Nov;11(4):159–67

Radiologist evaluation of a multispectral image compression algorithm for magnetic resonance images. Cahill PT, et al. **J Digit Imaging** 1998 Aug;11(3):126–36

Evaluating the potential and problems of three-dimensional computed tomography measurements of arterial stenosis. Ebert DS, et al. **J Digit Imaging** 1998 Aug;11(3):151–7

Clinical evaluation of irreversible data compression for computed radiography of the chest. Egashira K, et al. **J Digit Imaging** 1998 Nov;11(4):176–81

Application of artificial neural networks for quantitative analysis of image data in chest radiographs for detection of interstitial lung disease. Ishida T, et al. **J Digit Imaging** 1998 Nov;11(4):182–92

Perceived fidelity of compressed and reconstructed radiological images: a preliminary exploration of compression, luminance, and viewing distance. Pilgram TK, et al. **J Digit Imaging** 1998 Nov;11(4):168–75

Contrast limited adaptive histogram equalization image processing to improve the detection of simulated spiculations in dense mammograms. Pisano ED, et al. **J Digit Imaging** 1998 Nov;11(4):193–200

Clinical evaluation of irreversible data compression for computed radiography of the hand. Uchida K, et al. **J Digit Imaging** 1998 Aug;11(3):121–5

Computer-assisted enhancement permits the use of five nanometer gold probes in low magnification transmission electron microscopy. Broomall K. **J Electron Microsc (Tokyo)** 1998;47(4):355–7

Automatic acquisition of fiducial markers and alignment of images in tilt series for electron tomography. Ress D, et al. **J Electron Microsc (Tokyo)** 1999;48(3):277–87

Advances in digital imaging during endoscopic surgery. Aslan P, et al. **J Endourol** 1999 May;13(4):251–5

Three-dimensional endoluminal ultrasonography of the ureter. Bagley DH, et al. **J Endourol** 1998 Oct;12(5):411–6

Digital still image recording during video endoscopy. Bruno D, et al. **J Endourol** 1999 Jun;13(5):353–6; discussion 356–7

New visualization techniques for in utero surgery: amnioscopy with a three-dimensional head-mounted display and a computer-controlled endoscope. Calvano CJ, et al. **J Endourol** 1998 Oct;12(5):407–10

Video superimposition at the C.A. Pound Laboratory 1987 to 1992. Austin D. **J Forensic Sci** 1999 Jul;44(4):695–9

Determination of the size of a foreign body in the eye using image analysis of its roentgenogram. Pilin A, et al. **J Forensic Sci** 1999 Jan;44(1):214–9

Computer morphometry for quantitative measurement of liver fibrosis: comparison with Knodell's score, colorimetry and conventional description reports. Lin XZ, et al. **J Gastroenterol Hepatol** 1998 Jan;13(1):75–80

The use of video-imaging to assess the sub-lethal impact of plant secondary compounds on Schistosoma mansoni miracidia. Lyddiard JR, et al. **J Helminthol** 1998 Sep; 72(3):237–41

Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. Lehr HA, et al. **J Histochem Cytochem** 1999 Jan; 47(1):119–26

Accurate guidance for percutaneous access to a specific target in soft tissues: preclinical study of computer-assisted pericardiocentesis. Chavanon O, et al. **J Laparoendosc Adv Surg Tech A** 1999 Jun;9(3):259–66

Off-resonance effects in two-dimensional NQR spectroscopy using a single crystal. Ajithkumar TG, et al. **J Magn Reson** 1998 Nov;135(1):165–8

Reference deconvolution in the frequency domain. Goez M, et al. **J Magn Reson** 1999 Jan;136(1):69–75

15N-edited three-dimensional NOESY-HMQC with water flipback: enhancement of weak labile 1H resonances of protein side chains contacting DNA. Gruschus JM, et al. **J Magn Reson** 1998 Nov;135(1):87–92

Composite pulsed field gradients with refocused chemical shifts and short recovery time. Hu H, et al. **J Magn Reson** 1999 Jan;136(1):54–62

Distributed parallel processing for multidimensional maximum entropy reconstruction. Li KB, et al. **J Magn Reson** 1998 Sep;134(1):161–3

Measurement of dipolar couplings for methylene and methyl sites in weakly oriented macromolecules and their use in structure determination. Ottiger M, et al. **J Magn Reson** 1998 Oct;134(2):365–9

Orientational constraints derived from hydrated powder samples by two-dimensional PISEMA. Tian F, et al. **J Magn Reson** 1998 Nov;135(1):227–31

Spectral parameter estimation by an iterative quadratic maximum likelihood method. Zhu G, et al. **J Magn Reson** 1998 Nov;135(1):37–43

Subungual glomus tumor: combined use of MRI and three-dimensional contrast MR angiography. Boudghene FP, et al. **J Magn Reson Imaging** 1998 Nov-Dec; 8(6):1326–8

Locally focused MRI of interventions. Kuperman VY, et al. **J Magn Reson Imaging** 1998 Nov-Dec;8(6):1288–95

Application and validation of three-dimensional data sets from a phase contrast MR angiography for preoperative computer simulation of brain tumors. Mamata H, et al. **J Magn Reson Imaging** 1999 Jul;10(1):102–6

Spiral reconstruction by regridding to a large rectilinear matrix: a practical solution for routine systems. Oesterle C, et al. **J Magn Reson Imaging** 1999 Jul;10(1):84–92

Contrast-enhanced 3D MRA with centric ordering in k space: a preliminary clinical experience in imaging the abdominal aorta and renal and peripheral arterial vasculature [letter] Riederer SJ. **J Magn Reson Imaging** 1998 Nov-Dec;8(6):1355

MRI of patellar articular cartilage: evaluation of an optimized gradient echo sequence (3D-DESS). Ruehm S, et al. **J Magn Reson Imaging** 1998 Nov-Dec;8(6):1246–51

Localization of a ventricular tachycardia-focus with multichannel magnetocardiography and three-dimensional current density reconstruction. Müller HP, et al. **J Med Eng Technol** 1999 May-Jun;23(3):108–15

A new approach to computer guidance in orthopedic surgery using real time volume rendering. Liener UC, et al. **J Med Syst** 1999 Feb;23(1):35–40

Quantitative imaging and statistical analysis of fluorescence in situ hybridization (FISH) of Aureobasidium pullulans. Spear RN, et al. **J Microbiol Methods** 1999 Mar; 35(2):101–10

Four-dimensional factor analysis of confocal image sequences (4D-FAMIS) to detect and characterize low copy numbers of human papillomavirus DNA by FISH in HeLa and SiHa cells. Kahn E, et al. **J Microsc** 1999 Mar;193 (Pt 3):227–43

Three-dimensional morphometry in scanning electron microscopy: a technique for accurate dimensional and angular measurements of microstructures using stereopaired digitized images and digital image analysis. Minnich B, et al. **J Microsc** 1999 Jul;195 (Pt 1):23–33

Segmentation of confocal microscope images of cell nuclei in thick tissue sections. Ortiz de Solórzano C, et al. **J Microsc** 1999 Mar;193 (Pt 3):212–26

Three dimensional image restoration in fluorescence lifetime imaging microscopy. Squire A, et al. **J Microsc** 1999 Jan; 193 (Pt 1):36–49

The role of image-guided technology in the surgical planning and resection of gliomas. Barnett GH. **J Neurooncol** 1999 May;42(3):247–58 (62 ref.)

Cellular proliferation in pilocytic and diffuse astrocytomas. Giannini C, et al. **J Neuropathol Exp Neurol** 1999 Jan; 58(1):46–53

Peripheral synapses at identified mechanosensory neurons in spiders: three-dimensional reconstruction and GABA immunocytochemistry. Fabian-Fine R, et al. **J Neurosci** 1999 Jan 1;19(1):298–310

Three-dimensional relationships between hippocampal synapses and astrocytes. Ventura R, et al. **J Neurosci** 1999 Aug 15;19(16):6897–906

Semi-automated analysis of NMDA-mediated toxicity in digitised colour images from rat hippocampus. Manahan-Vaughan D, et al. **J Neurosci Methods** 1998 Jul 1;82(1):85–95

Digitized image analysis reveals diffuse abnormalities in normal-appearing white matter during acute experimental autoimmune encephalomyelitis. Kawczak JA, et al. **J Neurosci Res** 1998 Nov 1;54(3):364–72

Clinical review of attenuation-corrected cardiac SPECT. Corbett JR, et al. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):54–68 (109 ref.)

An introduction to attenuation correction. Miles J, et al. **J Nucl Cardiol** 1999 Jul-Aug;6(4):449–57 (39 ref.)

Parametric mapping of cerebral blood flow deficits in Alzheimer's disease: a SPECT study using HMPAO and image standardization technique. Imran MB, et al. **J Nucl Med** 1999 Feb;40(2):244–9

Global spatial normalization of human brain using convex hulls. Lancaster JL, et al. **J Nucl Med** 1999 Jun; 40(6):942–55

Attenuation compensation in 99mTc SPECT brain imaging: a comparison of the use of attenuation maps derived from transmission versus emission data in normal scans. Licho R, et al. **J Nucl Med** 1999 Mar;40(3):456–63

Frequency encoding for simultaneous display of multimodality images. Quarantelli M, et al. **J Nucl Med** 1999 Mar;40(3):442–7

Integrated visualization of functional and anatomic brain data: a validation study. Stokking R, et al. **J Nucl Med** 1999 Feb;40(2):311–6

Anatomic validation of spatial normalization methods for PET. Sugiura M, et al. **J Nucl Med** 1999 Feb;40(2):317–22

Superresolution and convergence properties of the expectation-maximization algorithm for maximum-likelihood deconvolution of incoherent images. Conchello JA. **J Opt Soc Am A Opt Image Sci Vis** 1998 Oct;15(10):2609–19

Prediction of human observer performance by numerical observers: an experimental study. Narayan TK, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 Mar;16(3):679–93

Independent-component analysis of skin color image. Tsumura N, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 Sep;16(9):2169–76

Total least-squares reconstruction with wavelets for optical tomography. Zhu W, et al. **J Opt Soc Am A Opt Image Sci Vis** 1998 Oct;15(10):2639–50

Getting the picture correctly [letter; comment] Sarver DM. **J Oral Maxillofac Surg** 1999 Jun;57(6):754. Comment on: J Oral Maxillofac Surg 1998 Sep;56(9):1021–2.

Development of X-ray TV M-mode and reconstructed ultrasound M-mode methods for investigating tongue movement during swallowing in humans. Kawashima S, et al. **J Oral Sci** 1999 Mar;41(1):1–4

Optimizing calvarial bone graft harvesting with the SIM/Plant software system. Gerencer R, et al. **J Otolaryngol** 1999 Jun;28(3):173–7

Acetabular development after Salter's innominate osteotomy for congenital dislocation of the hip: evaluation by three-dimensional quantitative method. Takashi S, et al. **J Pediatr Orthop** 1998 Nov-Dec;18(6):802–6

Computer-assisted densitometric image analysis of digital subtraction images: in vivo error of the method and effect of thresholding. Brägger U, et al. **J Periodontol** 1998 Sep; 69(9):967–74

Use of digital cameras for radiographs: how to get the best pictures. Whitehouse RW. **J R Soc Med** 1999 Apr; 92(4):178–82 (6 ref.)

Photofilters for dimensional contrast sensitivity improvement in patients with corneal haze after photorefractive keratectomy. Shadenkov D, et al. **J Refract Surg** 1999 Mar-Apr;15(2 Suppl):S263–4

Results of AutoPap system-assisted and manual cytologic screening. A comparison. Wertlake P. **J Reprod Med** 1999 Jan;44(1):11–7

Low-resolution density maps from atomic models: how stepping "back" can be a step "forward". Belnap DM, et al. **J Struct Biol** 1999 Apr-May;125(2-3):166–75

Web-based telemicroscopy. Hadida-Hassan M, et al. **J Struct Biol** 1999 Apr-May;125(2-3):235–45 (29 ref.)

JavaScope: A Web-based TEM control interface. Kisseberth N, et al. **J Struct Biol** 1999 Apr-May;125(2-3):229–34

A data mining approach for analyzing density maps representing macromolecular structures. Ravantti JJ, et al. **J Struct Biol** 1999 Apr-May;125(2-3):216–22

Intraoperative evaluation of myocardial revascularization during minimally invasive direct coronary artery bypass by means of ultrasonic integrated backscatter. Hirata N, et al. **J Thorac Cardiovasc Surg** 1999 Jun;117(6):1215–7

Normal splenic volumes estimated using three-dimensional ultrasonography. De Odorico I, et al. **J Ultrasound Med** 1999 Mar;18(3):231–6

Computerized digital image processing on radiographs of canine filariosis. Miyatake K, et al. **J Vet Med Sci** 1999 Mar;61(3):245–50

In-vivo three-dimensional ultrasound reconstructions of embryos and early fetuses. Blaas HG, et al. **Lancet** 1998 Oct 10;352(9135):1182–6

Computer-aided three-dimensional reconstruction and measurement of the optic canal and intracanalicular structures. Tao H, et al. **Laryngoscope** 1999 Sep; 109(9):1499–502

Modeling laser treatment of port wine stains with a computer-reconstructed biopsy. Pfefer TJ, et al. **Lasers Surg Med** 1999;24(2):151–66

3D spin-lock imaging of human gliomas. Aronen HJ, et al. **Magn Reson Imaging** 1999 Sep;17(7):1001–10

Quantitation of atherosclerosis by magnetic resonance imaging and 3-D morphology operators. Hänni M, et al. **Magn Reson Imaging** 1999 May;17(4):585–91

Assessment of the pore geometry of stereolithographic models by high resolution MRI. Issa B, et al.

Magn Reson Imaging 1998 Jun-Jul;16(5-6):651-3

A post-processing technique for displaying vessels from routine fast-spin-echo images: MRI-derived angiography. Kao YH, et al. **Magn Reson Imaging** 1999 Sep;17(7):1057-63

MR imaging of flow with locally high spatial resolution. Kuperman VY, et al. **Magn Reson Imaging** 1999 Jun; 17(5):699-704

Characterisation of fluid flow through porous media using three-dimensional microimaging and pulsed gradient stimulated echo NMR. Manz B, et al. **Magn Reson Imaging** 1998 Jun-Jul;16(5-6):673-5

MR virtual endoscopy of the pancreaticobiliary tract. Neri E, et al. **Magn Reson Imaging** 1999 Jan;17(1):59-67

Quantitative magnetic resonance imaging of fresh and frozen-thawed trout. Nott KP, et al. **Magn Reson Imaging** 1999 Apr;17(3):445-55

Visualisation of structure and flow in packed beds. Sederman AJ, et al. **Magn Reson Imaging** 1998 Jun-Jul; 16(5-6):497-500

Interobserver reproducibility of quantitative cartilage measurements: comparison of B-spline snakes and manual segmentation. Stammberger T, et al. **Magn Reson Imaging** 1999 Sep;17(7):1033-42

Re: Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain Simmons et al 1996, vol. 16, pages 319-330 1998 [letter; comment] Wardlaw JM, et al. **Magn Reson Imaging** 1999 Apr;17(3):483-7. Comment on: Magn Reson Imaging 1998 Apr;16(3):319-30.

Characterization of human head vasculature by percolation parameters. Weis J, et al. **Magn Reson Imaging** 1999 Apr; 17(3):411-5

Projection-reconstruction reduced [correction of reduces] FOV imaging [published erratum appears in Magn Reson Imaging 1999 Jul;17(6):945] Weiss S, et al. **Magn Reson Imaging** 1999 May;17(4):517-25

Switchable multicoil array for MR micro-imaging of breast lesions. Artemov D, et al. **Magn Reson Med** 1999 Mar; 41(3):569-74

Analytic approach to the design of transverse gradient coils with co-axial return paths. Bowtell R, et al. **Magn Reson Med** 1999 Mar;41(3):600-8

The effect of ouabain on water diffusion in the rat hippocampal slice measured by high resolution NMR imaging. Buckley DL, et al. **Magn Reson Med** 1999 Jan; 41(1):137-42

Visualizing blood flow patterns using streamlines, arrows, and particle paths. Buonocore MH. **Magn Reson Med** 1998 Aug;40(2):210-26

Perfusion-based functional magnetic resonance imaging with single-shot RARE and GRASE acquisitions. Crelier GR, et al. **Magn Reson Med** 1999 Jan;41(1):132-6

A technique for determining the spatial relationship between the rotator cuff and the subacromial space in arm abduction using MRI and 3D image processing. Graichen H, et al. **Magn Reson Med** 1998 Oct;40(4):640-3

MR phase-contrast flow measurement with limited spatial resolution in small vessels: value of model-based image analysis. Hoogeveen RM, et al. **Magn Reson Med** 1999 Mar; 41(3):520-8

Proton spectroscopy without water suppression: the oversampled J-resolved experiment. Hurd RE, et al. **Magn Reson Med** 1998 Sep;40(3):343-7

3D coronary artery imaging with phase reordering for improved scan efficiency. Jhooti P, et al. **Magn Reson Med** 1999 Mar;41(3):555-62

Sampling errors in projection reconstruction MRI. Joseph PM. **Magn Reson Med** 1998 Sep;40(3):460-6

Three-dimensional 87Rb imaging of isolated pig hearts: effects of regional ischemia. Kupriyanov VV, et al. **Magn Reson Med** 1998 Aug;40(2):175-9

3D time-resolved contrast-enhanced MR DSA: advantages and tradeoffs. Mistretta CA, et al. **Magn Reson Med** 1998 Oct;40(4):571-81

Sampling density compensation in MRI: rationale and an iterative numerical solution. Pipe JG, et al. **Magn Reson Med** 1999 Jan;41(1):179-86

MR fluoroscopy using projection reconstruction multi-gradient-echo (prMGE) MRI. Rasche V, et al. **Magn Reson Med** 1999 Aug;42(2):324-34

Feature space analysis of MRI. Soltanian-Zadeh H, et al. **Magn Reson Med** 1998 Sep;40(3):443-53

Functional imaging by I0- and T2*-parameter mapping using multi-image EPI. Speck O, et al. **Magn Reson Med** 1998 Aug;40(2):243-8

Determination of 3D cartilage thickness data from MR imaging: computational method and reproducibility in the living. Stammberger T, et al. **Magn Reson Med** 1999 Mar; 41(3):529-36

Effects of acceleration, jerk, and field inhomogeneities on vessel positions in magnetic resonance angiography. Stefansic JD, et al. **Magn Reson Med** 1998 Aug; 40(2):261-71

Partial Fourier reconstruction for three-dimensional gradient echo functional MRI: comparison of phase correction methods. Stenger VA, et al. **Magn Reson Med** 1998 Sep; 40(3):481-90

Locally focused 3D coronary imaging using volume-selective RF excitation. Yang GZ, et al. **Magn Reson Med** 1999 Jan;41(1):171-8

Computerised volumetric analysis of lesions in multiple sclerosis using new semi-automatic segmentation software. Dastidar P, et al. **Med Biol Eng Comput** 1999 Jan; 37(1):104-7

Image processing in stereotactic planning: volume visualization and image registration. Pelizzari CA. **Med Dosim** 1998 Fall;23(3):137-45 (39 ref.)

An integrated system for the production of field shaping devices in radiotherapy. Gueorguieva K, et al. **Med Eng Phys** 1999 Jan;21(1):45-51

Regularization of blood motion fields by modified Navier-Stokes equations. Tura A, et al. **Med Eng Phys** 1999 Jan;21(1):27-36

A method for approximating the density of maximum-likelihood and maximum a posteriori estimates under a Gaussian noise model. Abbey CK, et al. **Med Image Anal** 1998 Dec;2(4):395-403

Development and preliminary evaluation of VISLAN, a surgical planning and guidance system using intra-operative video imaging. Colchester AC, et al. **Med Image Anal** 1996 Mar;1(1):73-90

Segmentation of brain tissue from magnetic resonance images. Kapur T, et al. **Med Image Anal** 1996 Jun;1(2):109-27

Cardiac material markers from tagged MR images. Kerwin WS, et al. **Med Image Anal** 1998 Dec;2(4):339-53

Automatic construction of eigenshape models by direct optimization. Kotcheff AC, et al. **Med Image Anal** 1998 Dec;2(4):303-14

Deformable models in medical image analysis: a survey. McInerney T, et al. **Med Image Anal** 1996 Jun;1(2):91-108 (129 ref.)

Comparison of edge-based and ridge-based registration of CT and MR brain images. Maintz JB, et al. **Med Image Anal** 1996 Jun;1(2):151-61

Analysis of left ventricular wall motion based on volumetric deformable models and MRI-SPAMM. Park J, et al. **Med Image Anal** 1996 Mar;1(1):53-71

A robust point-matching algorithm for autoradiograph alignment. Rangarajan A, et al. **Med Image Anal** 1997 Sep; 1(4):379-98

Segmentation of 2-D and 3-D objects from MRI volume data using constrained elastic deformations of flexible Fourier contour and surface models. Székely G, et al. **Med Image Anal** 1996 Mar;1(1):19-34

Symbolic representation and visual querying of left ventricular image sequences. Baroni M, et al. **Med Inform Internet Med** 1999 Jan-Mar;24(1):33-52

A network-based training environment: a medical image processing paradigm. Costaridou L, et al. **Med Inform (Lond)** 1998 Oct-Dec;23(4):277-87

A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Mikolajczyk K, et al. **Med Inform (Lond)** 1998 Jul-Sep;23(3):207-14

New classes of helical weighting algorithms with applications to fast CT reconstruction. Besson G. **Med Phys** 1998 Aug; 25(8):1521-32

Systematic distortions in magnetic position digitizers. Birkfellner W, et al. **Med Phys** 1998 Nov;25(11):2242-8

Reduced partial volume artifacts using spiral computed tomography and an integrating interpolator. Heuscher DJ, et al. **Med Phys** 1999 Feb;26(2):276-86

Helical CT reconstruction with longitudinal filtration. Hu H, et al. **Med Phys** 1998 Nov;25(11):2130-8

Multi-slice helical CT: scan and reconstruction. Hu H. **Med Phys** 1999 Jan;26(1):5-18

A 10 MV x-ray zero-area tissue-maximum ratio expression constructed by taking into account depth and off-axis beam quality change. Iwasaki A. **Med Phys** 1998 Nov; 25(11):2209-14

An artificial neural net and error backpropagation to reconstruct single photon emission computerized tomography data. Knoll P, et al. **Med Phys** 1999 Feb; 26(2):244-8

Optical processing architecture and its potential application for digital and analog radiography. Liu H, et al. **Med Phys** 1999 Apr;26(4):648-52

Resolution degradation due to K-characteristic photon absorption in dual phosphor image receptors. McLean D. **Med Phys** 1999 Apr;26(4):643-7

Maximum likelihood estimation in calibrating a stereo camera setup. Muijtjens AM, et al. **Med Phys** 1999 Feb;26(2):310-8

Astigmatic single photon emission computed tomography imaging with a displaced center of rotation. Wang H, et al. **Med Phys** 1998 Aug;25(8):1493-501

Visualization and registration of three-dimensional E-field distributions in annual-phased-array applicators. Wust P, et al. **Med Phys** 1999 Apr;26(4):653-9

Modeling of polychromatic attenuation using computed tomography reconstructed images. Yan CH, et al. **Med Phys** 1999 Apr;26(4):631-42

Relevance of accurate Monte Carlo modeling in nuclear medical imaging. Zaidi H. **Med Phys** 1999 Apr; 26(4):574-608 (288 ref.)

Facial reconstruction: a case report and review of development of techniques. Stoney MB, et al. **Med Sci Law** 1999 Jan;39(1):49-60

An architecture for implementing customizable medical image processing systems. Demiris AM, et al. **Medinfo** 1998;9 Pt 2:1100-4

Technical aspects of virtual liver resection planning. Glombitza G, et al. **Medinfo** 1998;9 Pt 2:1041-5

Compression of color medical images in gastrointestinal endoscopy: a review. Kim CY. **Medinfo** 1998;9 Pt 2:1046-50 (22 ref.)

Web based 3-D medical image visualization on the PC. Kim N, et al. **Medinfo** 1998;9 Pt 2:1105-10

A marker-free system for the analysis of movement disabilities. Legrand L, et al. **Medinfo** 1998;9 Pt 2:1066-70

Application of a 3D display system for biplane cerebral angiography. Ooe Y, et al. **Medinfo** 1998;9 Pt 2:1013-6

Complete left ventricular wall motion estimation from cascaded MRI-SPAMM data. Park J, et al. **Medinfo** 1998; 9 Pt 2:1063-5

Detection of compact low-chromatin areas in cell nuclei images. Zganec M, et al. **Medinfo** 1998;9 Pt 2:1017-21

Image processing and analysis of fluorescent labelled cytoskeleton. Buño I, et al. **Micron** 1998 Dec;29(6):445-9

Direct methods in electron crystallography: image processing and solving incommensurate structures. Fan HF. **Microsc Res Tech** 1999 Jul 15;46(2):104-16

Product review: lucis image processing software. Johnson JE Jr. **Microsc Res Tech** 1999 Apr 1;45(1):59-61

Optimized evaluation of a pulsed 2.09 microns holmium:YAG laser impact on the rat brain and 3 D-histomorphometry of the collateral damage. Ludwig HC, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):217-22

Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia. Gala JL, et al. **Mod Pathol** 1999 Apr;12(4):391-9

Real-time imaging of the axonal transport of granules containing a tissue plasminogen activator/green fluorescent protein hybrid. Lochner JE, et al. **Mol Biol Cell** 1998 Sep; 9(9):2463-76

Normal thoracoabdominal motion. Scano G. **Monaldi Arch Chest Dis** 1999 Jun;54(3):287-8

One-step resection and reconstruction of the mandible using computer-aided techniques--experimental and clinical results. Stojadinovic S, et al. **Mund Kiefer Gesichtschir** 1999 May;3 Suppl 1:S151-3

Technical report: automated classification of first and second cycle metaphases. Huber R, et al. **Mutat Res** 1998 Nov 9;419(1-3):27-32

High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner. Hanzel DK, et al. **Nat Biotechnol** 1999 Jan; 17(1):53-7

Local interaction fields and adaptive regularizers for surface reconstruction and image relaxation. Yang Z, et al. **Network** 1998 Feb;9(1):19-37

JPEG quality transcoding using neural networks trained with a perceptual error measure. Lazzaro J, et al. **Neural Comput** 1999 Jan 1;11(1):267-96

Mixtures of probabilistic principal component analyzers. Tipping ME, et al. **Neural Comput** 1999 Feb 15;11(2):443-82

Interactive image-guided pituitary surgery. An experience of 101 procedures. Sandeman D, et al. **Neurochirurgie** 1998 Dec;44(5):331-8

High-dimensional image registration using symmetric priors. Ashburner J, et al. **Neuroimage** 1999 Jun;9(6 Pt 1):619-28

Localization of cardiac-induced signal change in fMRI. Dagli MS, et al. **Neuroimage** 1999 Apr;9(4):407-15

Generalizable patterns in neuroimaging: how many principal components? Hansen LK, et al. **Neuroimage** 1999 May; 9(5):534-44

Functional MRI of human brain during breath holding by BOLD and FAIR techniques. Li TQ, et al. **Neuroimage** 1999 Feb;9(2):243-9

MRI-Based topographic parcellation of human cerebral white matter and nuclei II. Rationale and applications with systematics of cerebral connectivity. Makris N, et al. **Neuroimage** 1999 Jan;9(1):18-45

MRI-Based topographic parcellation of human cerebral white matter. Meyer JW, et al. **Neuroimage** 1999 Jan; 9(1):1-17

Three distinct ventral occipitotemporal regions for reading and object naming. Moore CJ, et al. **Neuroimage** 1999 Aug; 10(2):181-92

Phase navigator correction in 3D fMRI improves detection of brain activation: quantitative assessment with a graded motor activation procedure. Ramsey NF, et al. **Neuroimage** 1998 Oct;8(3):240-8

Neuronal mechanisms of perceptual learning: changes in human brain activity with training in orientation discrimination. Schiltz C, et al. **Neuroimage** 1999 Jan; 9(1):46-62

Three-dimensional MRI atlas of the human cerebellum in proportional stereotaxic space. Schmahmann JD, et al. **Neuroimage** 1999 Sep;10(3 Pt 1):233-60

Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Signorini M, et al. **Neuroimage** 1999 Jan;9(1):63-80

In vitro evaluation of brain lesioning electrodes (Leksell) using a computer-assisted video system. Eriksson O, et al. **Neurol Res** 1999 Jan;21(1):89-95

Neurosurgical simulation and navigation with three-dimensional computer graphics. Hayashi N, et al. **Neurol Res** 1999 Jan;21(1):60-6

A comparison of manual and semi-automated methods in the assessment of axonal injury. Gentleman SM, et al. **Neuropathol Appl Neurobiol** 1999 Feb;25(1):41-7

Computer-assisted three-dimensional reconstruction of the corticospinal system as a reference for CT and MRI. Buhmann C, et al. **Neuroradiology** 1998 Sep;40(9):549-57

Association of an intracranial arteriovenous malformation and a meningioma. Castillo M, et al. **Neuroradiology** 1998 Sep;40(9):574–6 (30 ref.)

Carotid stenosis: a comparison between MR and spiral CT angiography. Magarelli N, et al. **Neuroradiology** 1998 Jun; 40(6):367–73

Magnetic resonance angiography in patients with acute stroke treated by local thrombolysis. Ohue S, et al. **Neuroradiology** 1998 Aug;40(8):536–40

Virtual MRI endoscopy of the intracranial cerebrospinal fluid spaces. Shigematsu Y, et al. **Neuroradiology** 1998 Oct; 40(10):644–50

Three-dimensional CT angiography of intracranial vasospasm following subarachnoid haemorrhage. Takagi R, et al. **Neuroradiology** 1998 Oct;40(10):631–5

Pitfalls in the use of spiral CT for identification of intracranial aneurysms. Young N, et al. **Neuroradiology** 1999 Feb; 41(2):93–9

Forebrain white matter in spontaneously hypertensive rats: a quantitative image analysis study. Sabbatini M, et al. **Neurosci Lett** 1999 Apr 9;265(1):5–8

Fast and slow recovery phases of goldfish behavior after transection of the optic nerve revealed by a computer image processing system. Kato S, et al. **Neuroscience** 1999; 93(3):907–14

Use of preoperative computed tomography-angiography in cranial remodeling: technical note. Simmons NE, et al. **Neurosurgery** 1998 Oct;43(4):970–2; discussion 972–3

Comparison of ordered subsets expectation maximization and Chang's attenuation correction method in quantitative cardiac SPET: a phantom study. Dey D, et al. **Nucl Med Commun** 1998 Dec;19(12):1149–57

Automatic motion correction in dynamic radionuclide renography using image registration. Lee KJ, et al. **Nucl Med Commun** 1998 Dec;19(12):1159–67

Organising multi-dimensional biological image information: the BioImage Database. Carazo JM, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):280–3

Expression scanning of an array of growth control genes in human tumor cell lines. Bertucci F, et al. **Oncogene** 1999 Jul 1;18(26):3905–12

Quantification of palpebral fissure shape in severe congenital blepharoptosis. Cruz AA, et al. **Ophthal Plast Reconstr Surg** 1999 Jul;15(4):232–5

Image analysis of implanted rigid and foldable intraocular lenses in human eyes using Scheimpflug photography. Klos KM, et al. **Ophthalmic Res** 1999;31(2):130–3

Quantitative image sequence analysis of fundus fluorescein angiography. Berger JW. **Ophthalmic Surg Lasers** 1999 Jan; 30(1):72–3

Factors affecting image acquisition during scanning laser polarimetry [letter; comment] Holló G. **Ophthalmic Surg Lasers** 1999 Jan;30(1):74. Comment on: Ophthalmic Surg Lasers 1998 Jul;29(7):545–51.

Virtual endoscopy in otorhinolaryngology by postprocessing of helical computed tomography. Pototschnig C, et al. **Otolaryngol Head Neck Surg** 1998 Nov;119(5):536–9

Wavelet-assisted volume ray casting. He T. **Pac Symp Biocomput** 1998;:153–64

Automated assay of gene expression at cellular resolution. Kosman D, et al. **Pac Symp Biocomput** 1998;:6–17

Human precision of operating a digitizing board: implications for electrocardiogram measurements. Malik M, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1656–62

Magnetic electroanatomical mapping for ablation of focal atrial tachycardias. Marchlinski F, et al. **Pacing Clin Electrophysiol** 1998 Aug;21(8):1621–35 (22 ref.)

Use of a real-time three-dimensional magnetic navigation system for radiofrequency ablation of accessory pathways. Worley SJ. **Pacing Clin Electrophysiol** 1998 Aug; 21(8):1636–45 (5 ref.)

Changing distribution of islets in the developing human pancreas: a computer-assisted three-dimensional reconstruction study. Watanabe T, et al. **Pancreas** 1999 May;18(4):349–54

MRI multiplanar reconstruction in the assessment of congenital talipes equinovarus. Wang C, et al. **Pediatr Radiol** 1999 Apr;29(4):262–7

Evaluation of the accuracy and precision of lung aerosol deposition measurements from planar radionuclide imaging using simulation. Fleming JS, et al. **Phys Med Biol** 1998 Aug;43(8):2423–9

Spatial regularization applied to factor analysis of medical image sequences (FAMIS). Frouin F, et al. **Phys Med Biol** 1999 Sep;44(9):2289–306

Measurement of electrical current density distribution in a simple head phantom with magnetic resonance imaging. Gamba HR, et al. **Phys Med Biol** 1999 Jan;44(1):281–91

Combining various projection access schemes with the algebraic reconstruction technique for low-contrast detection in computed tomography. Guan H, et al. **Phys Med Biol** 1998 Aug;43(8):2413–21

Application of a fuzzy pattern classifier to decision making in portal verification of radiotherapy. Leszczynski K, et al. **Phys Med Biol** 1999 Jan;44(1):253–69

Accuracy of digitization using automated and manual methods. Wilson DJ, et al. **Phys Ther** 1999 Jun;79(6):558–66

STESYS software for computer-assisted stereology. Karen P, et al. **Physiol Res** 1998;47(4):271–8

Three-dimensional computed tomographic analysis of the primary nasal deformity in 3-month-old infants with complete unilateral cleft lip and palate. Fisher DM, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1826–34

Digital images in the diagnosis of wound healing problems. Roth AC, et al. **Plast Reconstr Surg** 1999 Feb;103(2):483–6

Nondestructive prediction method for yolk:albumen ratio in chicken eggs by computer image analysis. Kuchida K, et al. **Poult Sci** 1999 Jun;78(6):909–13

Incorporating constraint-based shape models into an interactive system for functional brain mapping. Hinshaw KP, et al. **Proc AMIA Symp** 1998;:921–5

Quantification of interdigitation at bone cement/cancellous bone interfaces in cemented femoral reconstructions. Maher SA, et al. **Proc Inst Mech Eng [H]** 1999;213(4):347–54

On the efficiency of stereologic volumetry as commonly implemented for three-dimensional digital images. Black KJ. **Psychiatry Res** 1999 Feb 22;90(1):55–64

Multimodal imaging of residual function and compensatory resource allocation in cortical atrophy: a case study of parietal lobe function in a patient with Huntington's disease [corrected and republished article originally printed in Psychiatry Res 1998 Nov 9;84(1):27–35] Dierks T, et al. **Psychiatry Res** 1999 Feb 22;90(1):67–75

Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements. Pezawas LM, et al. **Psychiatry Res** 1998 Sep 28; 83(3):139–47

Measuring facial expressions by computer image analysis. Bartlett MS, et al. **Psychophysiology** 1999 Mar;36(2):253–63

Interactive fusion of three-dimensional images of upper abdominal CT and FDG PET with no body surface markers. Inagaki H, et al. **Radiat Med** 1999 Mar–Apr; 17(2):155–63

Volume-rendered three-dimensional spiral CT: musculoskeletal applications. Pretorius ES, et al. **Radiographics** 1999 Sep–Oct;19(5):1143–60

Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Anzai Y, et al. **Radiology** 1999 Jul; 212(1):285–90

Display modes for CT colonography. Part II. Blinded comparison of axial CT and virtual endoscopic and panoramic endoscopic volume-rendered studies. Beaulieu CF, et al. **Radiology** 1999 Jul;212(1):203–12

Improvement of radiologists' characterization of mammographic masses by using computer-aided diagnosis: an ROC study. Chan HP, et al. **Radiology** 1999 Sep; 212(3):817–27

Technical solution for an interactive functional MR imaging examination: application to a physiologic interview and the study of cerebral physiology. Frank JA, et al. **Radiology** 1999 Jan;210(1):260–8

Display modes for CT colonography. Part I. Synthesis and insertion of polyps into patient CT data. Karadi C, et al. **Radiology** 1999 Jul;212(1):195–201

Measurement of brain structures with artificial neural networks: two- and three-dimensional applications. Magnotta VA, et al. **Radiology** 1999 Jun;211(3):781–90

Cross-sectional nodal atlas: a tool for the definition of clinical target volumes in three-dimensional radiation therapy planning. Martinez-Monge R, et al. **Radiology** 1999 Jun; 211(3):815–28

Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging--preliminary experience. Mousseaux E, et al. **Radiology** 1999 Sep;212(3):896–902

Spiral CT angiography of the pulmonary circulation. Remy-Jardin M, et al. **Radiology** 1999 Sep;212(3):615–36 (132 ref.)

Pulmonary perfusion: respiratory-triggered three-dimensional MR imaging with arterial spin tagging--preliminary results in healthy volunteers. Roberts DA, et al. **Radiology** 1999 Sep;212(3):890–5

Abdominal MR imaging with a volumetric interpolated breath-hold examination. Rofsky NM, et al. **Radiology** 1999 Sep;212(3):876–84

Utility of three-dimensional planning for axillary node coverage with breast-conserving radiation therapy: early experience. Smitt MC, et al. **Radiology** 1999 Jan; 210(1):221–6

Submillimeter three-dimensional coronary MR angiography with real-time navigator correction: comparison of navigator locations. Stuber M, et al. **Radiology** 1999 Aug; 212(2):579–87

Breath-hold MR cholangiopancreatography with three-dimensional, segmented, echo-planar imaging and volume rendering. Wielopolski PA, et al. **Radiology** 1999 Jan;210(1):247–52

ROC curve analysis in the evaluation of contrast-enhanced color Doppler US [letter; comment] Winehouse J, et al. **Radiology** 1999 Sep;212(3):911–2. Comment on: Radiology 1998 Aug;208(2):485–9.

Computerized image analysis of lung expansion patterns in surfactant treated immature newborn rabbits. Berggren P, et al. **Respir Physiol** 1999 Jan 1;115(1):45–53

ENT aspects of the mummification of the head in ancient Egypt: an imaging study. Motamed M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):337–9

Computer-assisted electrocardiography in structured diagnosis of acute myocardial infarction. Porela P, et al. **Scand Cardiovasc J** 1999;33(2):89–96

Morphometry in digital photographs: a promising technique for assessing patients with cleft lip and palate. Becker M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1998 Sep; 32(3):295–9

Clinical examination compared with morphometry of digital photographs for evaluation of repaired cleft lips. Becker M, et al. **Scand J Plast Reconstr Surg Hand Surg** 1998 Sep; 32(3):301–6

Quantitative imaging in electron and confocal microscopies for applications in biology. Bonnet N, et al. **Scanning Microsc** 1996;10(1):85–101; discussion 101–2

Difference mapping cryo-EM. Peters R, et al. **Science** 1999 Feb 19;283(5405):1133

CT bronchoscopy. Hopper KD. **Semin Ultrasound CT MR** 1999 Feb;20(1):10–5 (22 ref.)

Virtual colonoscopy. Vining DJ. **Semin Ultrasound CT MR** 1999 Feb;20(1):56–60 (11 ref.)

Helical computed tomography and three-dimensional reconstruction of a bipedicular developmental anomaly of the C2 vertebra. Power DM, et al. **Spine** 1999 May 15; 24(10):984–6

Neuronavigation--impact on operating time. Alberti O, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):44–8

Head-mounted display system for microneurosurgery. Chen JC, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):25–32

Volumegraph (overlaid three-dimensional image-guided navigation). Clinical application of augmented reality in neurosurgery. Iseki H, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):18–24

Can neuronavigation contribute to standardization of selective amygdalohippocampectomy? Van Roost D, et al. **Stereotact Funct Neurosurg** 1997;69(1–4 Pt 2):239–42

Image-guided neurosurgery with intraoperative MRI: update of frameless stereotaxy and radicality control. Wirtz CR, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):39–43

Automatic embolus detection by a neural network. Kemény V, et al. **Stroke** 1999 Apr;30(4):807–10

Improved automated detection of embolic signals using a novel frequency filtering approach. Markus H, et al. **Stroke** 1999 Aug;30(8):1610–5

The 3-D monitor and head-mounted display. A quantitative evaluation of advanced laparoscopic viewing technologies. Herron DM, et al. **Surg Endosc** 1999 Aug;13(8):751–5

A simple method of scalp localization using multiplanar reconstruction of MR images. Nakajima S, et al. **Surg Neurol** 1998 Dec;50(6):597–9

Comparison of virtual and fiberoptic bronchoscopy. Liewald F, et al. **Thorac Cardiovasc Surg** 1998 Dec;46(6):361–4

Computer-assisted photographic image enhancement and modification in ophthalmology. Augsburger JJ. **Trans Am Ophthalmol Soc** 1998;96:295–304; discussion 304–7

A new algorithm to align three-dimensional maps of helical structures. Hanein D, et al. **Ultramicroscopy** 1999 Apr; 76(4):233–8

CART: a controlled algebraic reconstruction technique for electron microscope tomography of embedded, sectioned specimen. Jonges R, et al. **Ultramicroscopy** 1999 Apr; 76(4):203–19

SieScape: a new sonographic dimension with fictive images [see comments] Kröger K, et al. **Ultrasound Med Biol** 1998 Oct;24(8):1125–9. Comment in: Ultrasound Med Biol 1999 Jun;25(5):861.

Three-dimensional ultrasound imaging. Nelson TR, et al. **Ultrasound Med Biol** 1998 Nov;24(9):1243–70 (300 ref.)

Second-trimester measurements of placental volume by three-dimensional ultrasound to predict small-for-gestational-age infants. Hafner E, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):97–102

The assessment of ovarian tumor angiogenesis: what does three-dimensional power Doppler add? Kurjak A, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):136–46 (98 ref.)

Fetal liver volume measurement by three-dimensional ultrasonography: a preliminary study. Laudy JA, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):93–6

Interactive classification of porcine Eimeria spp. by computer-assisted image analysis. Plitt A, et al. **Vet Parasitol** 1999 Sep 30;86(2):105–12

Sensitivity testing of veterinary pathogens with a semi-automatic image analysis system compared with tablet diffusion and agar dilution tests. Mevius DJ, et al. **Vet Q** 1999 Jun;21(3):99–104

3D-ultrasound in imaging, diagnosis and follow-up of an atypical hydatid cyst. Ockenga J, et al. **Z Gastroenterol** 1998 Jul;36(7):599–603

[Tri-dimensional computer reconstruction and animated display from serial sections of the Chinese crude drugs] Xiao X, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Jun; 14(2):131–6 (Eng. Abstr.) **(Chi)**

[An improved ISRA algorithm for ECT] Yu Z, et al. **Sheng Wu I Hsueh Kung Cheng Hsueh Tsa Chih** 1997 Mar; 14(1):48–50 (Eng. Abstr.) **(Chi)**

[An imaging system and computer processing of digital images from the Tesla BS500 transmission electron microscope] Vagunda V, et al. **Cesk Patol** 1998 Nov; 34(4):149–53 (Eng. Abstr.) **(Cze)**

[The scientific bases of virtual endoscopy] Coatrieux JL. **Bull Acad Natl Med** 1999;183(3):455–64 (17 ref.) (Eng. Abstr.) **(Fre)**

[3-dimensional imaging of thalamic fractures of the calcaneum. Validation of classifying fractures into 3 forms] Utheza G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1998 Sep;

84(5):440–50 (Eng. Abstr.) **(Fre)**

[Three-dimensional facial reconstruction of computerized tomography images by computer-aided design: example of an anthropologic study] Bou C, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):333–5 (Eng. Abstr.) **(Fre)**

[Geometric modeling and virtual endoscopy of the laryngo-tracheal lumen from computerized tomography images: initial applications to laryngo-tracheal pathology in the child] Giovanni A, et al. **Rev Laryngol Otol Rhinol (Bord)** 1998;119(5):341–6 (Eng. Abstr.) **(Fre)**

[Value of 3D CT in diagnosis and treatment of fractures of the tibial plateau] Blaser PF, et al. **Swiss Surg** 1998;(4):180–6 (Eng. Abstr.) **(Fre)**

[Cellular automated detection for simulation of the impulse transmission with reference to anisotropy] Abdallah O, et al. **Biomed Tech (Berl)** 1998;43 Suppl:490–1 **(Ger)**

[Preprocessing of the Visible Female data] Binhack S, et al. **Biomed Tech (Berl)** 1998;43 Suppl:528–9 **(Ger)**

[Teaching materials from image data of the human body] Bock G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:482–3 **(Ger)**

[Biomechanical 3D-FE model of the human cochlea] Böhnke F, et al. **Biomed Tech (Berl)** 1998;43 Suppl:26–7 **(Ger)**

[Reconstruction of extended electric sources in a thoracic phantom using biomagnetic field measurements] Brauer H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:228–9 **(Ger)**

[Effect of corrective procedures on volume quantification of SPECT data] Foe Owono GD, et al. **Biomed Tech (Berl)** 1998;43 Suppl:470–1 **(Ger)**

[Local resolution in temperature measurement using nuclear magnetic resonance tomography] Hampke M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:476–7 **(Ger)**

[Method for calibrating spiral CT data in contour finding processes in individual fitting of skull implants] Koenen D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:518–9 **(Ger)**

[3D localization of electrodes on and in the human body based on biplanar roentgen images] Maurer W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:474–5 **(Ger)**

[Algorithm for automatic endocardium identification in digital echocardiography image sequences] Santos Conde JE, et al. **Biomed Tech (Berl)** 1998 Jul-Aug;43(7–8):221–6 (Eng. Abstr.) **(Ger)**

[Three-dimensional reconstruction of echocardiographic section images. Methods, clinical value and future perspectives] Franke A, et al. **Dtsch Med Wochenschr** 1998 Oct 16;123(42):1245–9 (23 ref.) **(Ger)**

[Noninvasive determination of coronary flow reserve with signal enhanced high resolution transthoracic Doppler color echocardiography] Lambertz H, et al. **Herz** 1998 Dec;23(8):516–25 (Eng. Abstr.) **(Ger)**

[Painless recurrent cheek swelling. Parotid emphysema (pneumoparotis)] Leuwer A, et al. **HNO** 1998 Aug; 46(8):766–7 **(Ger)**

[Computer-assisted evaluation of aortic aneurysm morphology for choosing the method of therapy] Allenberg JR, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:105–7 (Eng. Abstr.) **(Ger)**

[Control of the patency of coronary artery bypasses with contrast enhanced magnetic resonance angiography] Brenner P, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1308–11 (Eng. Abstr.) **(Ger)**

[Progress in diagnostic imaging in the area of the pancreas (CT, MRI, MR-angio, hydro-CT, MR cholangiopancreatography)] Gerhardt P. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:274–80 (16 ref.) (Eng. Abstr.) **(Ger)**

[Can noninvasive gadolinium 3D MR subtraction angiography of visceral arteries replace conventional intra-arterial catheter angiography?] Krieglstein CF, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1491–3 (Eng. Abstr.) **(Ger)**

[Volumetry of circumscribed liver changes with 3-D ultrasound in comparison with 3-D computerized tomography] Lang H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1478–80 (Eng. Abstr.) **(Ger)**

[3D CT of fractures: comparison of volume and surface reconstruction] Rieker O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Nov;169(5):490–4 (Eng. Abstr.) **(Ger)**

[Possibilities of an open magnetic resonance scanner integration in therapy simulation and three-dimensional radiotherapy planning] Schubert K, et al. **Strahlenther Onkol** 1999 May;175(5):225–31 (Eng. Abstr.) **(Ger)**

[Monitor assessment of digitalized and post-processed portal films compared to conventional films presented on a light box] Wachter S, et al. **Strahlenther Onkol** 1998 Nov; 174(11):589–96 (Eng. Abstr.) **(Ger)**

[3D and color Doppler ultrasound evaluation of cystic space-occupying lesion near the head of the pancreas] Boozari B, et al. **Ultraschall Med** 1998 Dec;19(6):280–5 (Eng. Abstr.) **(Ger)**

[The value of CT in classification and decision making in acetabulum fractures. A systematic analysis] Hüfner T, et al. **Unfallchirurg** 1999 Feb;102(2):124–31 (Eng. Abstr.) **(Ger)**

[Validation of computerized tomography antetorsion angle measurement of the femur] Starker M, et al. **Z Orthop Ihre Grenzgeb** 1998 Sep-Oct;136(5):420–7 (Eng. Abstr.) **(Ger)**

[Application of a semi-automatic ROI setting system for brain PET images to animal PET studies] Kuge Y, et al. **Kaku Igaku** 1998 Oct;35(8):733–40 (Eng. Abstr.) **(Jpn)**

[Clinical experience of image-guided neurosurgery with a frameless navigation system (StealthStation)] Morioka T, et al. **No Shinkei Geka** 1999 Jan;27(1):33–40 (Eng. Abstr.) **(Jpn)**

[Three-dimensional computed tomographic angiography as preoperative examination in the treatment of cerebral aneurysms] De Araujo IS. **Arq Neuropsiquiatr** 1998 Dec; 56(4):798–802 (Eng. Abstr.) **(Por)**

[Computer analysis of microimages of adrenal glands during poisoning with organochlorine compounds] Popuchiev VV, et al. **Biull Eksp Biol Med** 1998 Dec;126(12):666–8 **(Rus)**

[Features of construction and use of digital X-ray apparatuses for lung examinations] Berdiakov GI, et al. **Med Tekh** 1998 Sep-Oct;(5):35–40 **(Rus)**

[An information system for automated cytogenetic image processing: analysis of interphase chromatin of nerve cells of embryonic brain of rats with varying nervous system excitability] Dudkin KN, et al. **Tsitologiia** 1999; 41(3–4):237–49 (Eng. Abstr.) **(Rus)**

[The computer processing of B-echo scanograms of the eye in hemophthalmos] Andzhelova DV, et al. **Vestn Oftalmol** 1998 Sep-Oct;114(5):44–5 (Eng. Abstr.) **(Rus)**

[Use of computer-assisted corneal topography in ophthalmology] Trnavec B, et al. **Cesk Slov Oftalmol** 1999 Jan;55(1):10–3 (Eng. Abstr.) **(Slo)**

[Study of histoenzymatic activity of isocitrate-DH in the hepatic tissue of rats treated with AZT: image analysis] Corcuera Pindado MT, et al. **An Med Interna** 1998 Dec; 15(12):638–41 (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Similarity measurement method for the classification of architecturally differentiated images. Smith Y, et al. **Comput Biomed Res** 1999 Feb;32(1):1–12

ECONOMICS

Digital fundus imaging: a quality and cost comparison with 35-mm film. Prasad S, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):79–82

Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Sonnenberg A, et al. **Am J Gastroenterol** 1999 Aug;94(8):2268–74

INSTRUMENTATION

Volume (three-dimensional) fast spin-echo imaging of the lumbar spine. Maldjian C, et al. **Acad Radiol** 1999 Jun; 6(6):339–42

Determining the utility and effectiveness of the NeoPath AutoPap 300 QC System used routinely. Fetterman B, et al. **Acta Cytol** 1999 Jan-Feb;43(1):13–22

AutoCyte Interactive Screening System. Experience at a university hospital cytology laboratory. Howell LP, et al. **Acta Cytol** 1999 Jan-Feb;43(1):58–64

Image analysis of skin surface contour. Takahashi M. **Acta Derm Venereol Suppl (Stockh)** 1994;185:9–14

Differential diagnosis of NPH and brain atrophy assessed by measurement of intracranial and ventricular CSF volume with 3D FASE MRI. Yoshihara M, et al. **Acta Neurochir Suppl (Wien)** 1998;71:371–4

An experimental approach to image guided skull base surgery employing a microscope-based neuronavigation system. Brinker T, et al. **Acta Neurochir (Wien)** 1998;140(9):883–9

...But will it play in Peoria? [editorial; comment] Brant-Zawadzki M. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1384–5. Comment on: AJNR Am J Neuroradiol 1998 Sep;19(8):1405–13.

Integral and shell-MIP display algorithms in MR and CT three-dimensional models of the brain surface. Casey SO, et al. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1513–21

Contrast-enhanced three-dimensional fast imaging with steady-state precession (FISP) MR angiography of supraaortic vessels: preliminary results [see comments] Leclerc X, et al. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1405–13. Comment in: AJNR Am J Neuroradiol 1998 Sep;19(8):1384–5.

Digital imaging and orthodontics. Coimbra O, et al. **Am J Orthod Dentofacial Orthop** 1999 Jan;115(1):103–5

Observations of laryngeal lesions with a rhinolarynx electronic videoendoscope system and digital image processing. Kawaida M, et al. **Ann Otol Rhinol Laryngol** 1998 Oct;107(10 Pt 1):855–9

Measuring small linear displacements with a three-dimensional video motion analysis system: determining its accuracy and precision. Everaert DG, et al. **Arch Phys Med Rehabil** 1999 Sep;80(9):1082–9

Equivalent dipoles for middle latency auditory evoked potentials using the dipole tracing method. Nakagawa M, et al. **Auris Nasus Larynx** 1999 Jul;26(3):245–56

Visualization of the human larynx: a three-dimensional computer modeling tool. Rubin JS, et al. **Auris Nasus Larynx** 1998 Sep;25(3):303–8

Quantitative laser microscopy in single cells based on ratio-imaging of fluorescent indicators: a critical assessment. Opitz N. **Biomed Tech (Berl)** 1998;43 Suppl:452–3

High-resolution ERD using realistic head geometry. Prüll A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:240–1

Intrinsic optical signals in vitro: a tool to measure alterations in extracellular space with two-dimensional resolution. Holthoff K, et al. **Brain Res Bull** 1998 Dec;47(6):649–55

Condensation pattern (CP) analysis of plant chromosomes by an improved chromosome image analysing system, CHIAS III. Kato S, et al. **Chromosome Res** 1998 Sep; 6(6):473–9

Butterworth equations for homomorphic filtering of images. Adelmann HG. **Comput Biol Med** 1998 Mar;28(2):169–81

A system for computing neuromorphometry from magnetic resonance images. Greenshields IR, et al. **Comput Biol Med** 1999 May;29(3):157–73

Quantification of burn induced extravasation of Evans blue albumin based on digital image analysis. Jönsson A, et al. **Comput Biol Med** 1998 Mar;28(2):153–67

High performance medical image processing in client/server-environments. Mayer A, et al. **Comput Methods Programs Biomed** 1999 Mar;58(3):207–17

Artificial neural network-aided image analysis system for cell counting. Sjöström PJ, et al. **Cytometry** 1999 May 1; 36(1):18–26

Rainbow scale in computer-aided sinus surgery. Christmas DA, et al. **Ear Nose Throat J** 1999 Sep;78(9):670–2

Computerised carotid plaque characterisation [letter; comment] Aly S. **Eur J Vasc Endovasc Surg** 1999 Mar; 17(3):271–2. Comment on: Eur J Vasc Endovasc Surg 1996 May;11(4):414–6.

The correlation between R2' and bone mineral measurements in human vertebrae: an in vitro study. Brismar TB, et al. **Eur Radiol** 1999;9(1):141–4

Amplitude-coded color doppler: clinical applications. Turetschek K, et al. **Eur Radiol** 1999;9(1):115–21 (52 ref.)

Spatiotemporal measurement of free radical elimination in the abdomen using an in vivo ESR-CT imaging system. Togashi H, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):1–8

Y2K compliance report. Problems affecting imaging equipment. **Health Devices** 1999 Sep;28(9):366–8

Hazard report. Falling InfiMed X-ray monitors. **Health Devices** 1999 Jul;28(7):285–7

Detection of bile duct cancer by autofluorescence cholangioscopy: a pilot study. Izuishi K, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):804–7

Liver, spleen and tumor volume measured by personal computer. Lin XZ, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):838–42

A single-pinhole confocal laser scanning microscope for 3-D imaging of biostructures. Diaspro A, et al. **IEEE Eng Med Biol Mag** 1999 Jul-Aug;18(4):106–10

Three-dimensional reconstruction of live embryos using robotic macroscope images. Brodland GW, et al. **IEEE Trans Biomed Eng** 1998 Sep;45(9):1173–81

The impact of vessel and catheter position on the measurement accuracy in catheter-based quantitative coronary angiography. Wunderlich W, et al. **Int J Card Imaging** 1998 Aug;14(4):217–27

Preliminary tests and construction of a computerized quantitative surgical keratometer. Carvalho L, et al. **J Cataract Refract Surg** 1999 Jun;25(6):821–6

Practical aspects of birdcage coils. Doty FD, et al. **J Magn Reson** 1999 May;138(1):144–54

Unambiguous correlations of backbone amide and aliphatic gamma resonances in deuterated proteins. McCallum SA, et al. **J Magn Reson** 1998 Oct;134(2):350–4

Fourier reconstruction as a valid alternative to filtered back projection in iterative applications: implementation of Fourier spectral spatial EPR imaging. Placidi G, et al. **J Magn Reson** 1998 Oct;134(2):280–6

Improved hardware and software for single-crystal NMR spectroscopy. Vosegaard T, et al. **J Magn Reson** 1998 Nov; 135(1):126–32

In vivo 3D localized 13C spectroscopy using modified INEPT and DEPT. Watanabe H, et al. **J Magn Reson** 1998 Oct;134(2):214–22

Measurement accuracy in confocal microscopy. Delorme R, et al. **J Microsc** 1998 Nov;192 (Pt 2):151–62

Endoscopic transseptal transsphenoidal hypophysectomy with three-dimensional intraoperative localization technology. Moses RL, et al. **Laryngoscope** 1999 Mar; 109(3):509–12

Intrahepatic arterioportal fistula: gadolinium-enhanced 3D magnetic resonance angiography findings and angiographic embolization with steel coils. Balci NC, et al. **Magn Reson Imaging** 1999 Apr;17(3):475–8

MR imaging of cervical spine motion with HASTE. Duerinckx AJ, et al. **Magn Reson Imaging** 1999 Apr; 17(3):371–81

Lesion load measurements in multiple sclerosis: the effect of incorporating magnetization transfer contrast in fast-FLAIR sequence. Filippi M, et al. **Magn Reson Imaging** 1999 Apr;17(3):459–61

Quantitative 3D VUSE pulmonary MRA. Friedli JL, et al. **Magn Reson Imaging** 1999 Apr;17(3):363–70

Improvement of the acquisition of a large amount of MR images on a conventional whole body system. Klose U, et al. **Magn Reson Imaging** 1999 Apr;17(3):471–4

A hybrid technique for spectroscopic imaging with reduced truncation artifact. Metzger G, et al. **Magn Reson Imaging** 1999 Apr;17(3):435–43

Optimization of tissue segmentation of brain MR images

based on multispectral 3D feature maps. Mohamed FB, et al. **Magn Reson Imaging** 1999 Apr;17(3):403–9

Three-dimensional magnetic resonance imaging of the interosseous membrane of forearm: a new method using fuzzy reasoning. Nakamura T, et al. **Magn Reson Imaging** 1999 Apr;17(3):463–70

Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Weber OM, et al. **Magn Reson Imaging** 1999 Apr;17(3):417–25

Intracranial black-blood MR angiography with high-resolution 3D fast spin echo. Alexander AL, et al. **Magn Reson Med** 1998 Aug;40(2):298–310

Myocardial velocity gradient imaging by phase contrast MRI with application to regional function in myocardial ischemia. Arai AE, et al. **Magn Reson Med** 1999 Jul; 42(1):98–109

A flexible view ordering technique for high-quality real-time 2DFT MR fluoroscopy. Busse RF, et al. **Magn Reson Med** 1999 Jul;42(1):69–81

Composite image formation in z-shimmed functional MR imaging. Constable RT, et al. **Magn Reson Med** 1999 Jul; 42(1):110–7

Fast T1 mapping on a whole-body scanner. Deichmann R, et al. **Magn Reson Med** 1999 Jul;42(1):206–9

Fast lipid-suppressed MR temperature mapping with echo-shifted gradient-echo imaging and spectral-spatial excitation. de Zwart JA, et al. **Magn Reson Med** 1999 Jul; 42(1):53–9

Simultaneous correction for interscan patient motion and geometric distortions in echoplanar imaging. Ernst T, et al. **Magn Reson Med** 1999 Jul;42(1):201–5

In vivo perfusion measurements in the human placenta using echo planar imaging at 0.5 T. Gowland PA, et al. **Magn Reson Med** 1998 Sep;40(3):467–73

Gradient echo time dependence and quantitative parameter maps for somatosensory activation in rats at 7 T. Grüne M, et al. **Magn Reson Med** 1999 Jul;42(1):118–26

A high-temperature superconducting Helmholtz probe for microscopy at 9.4 T. Hurlston SE, et al. **Magn Reson Med** 1999 May;41(5):1032–8

Non-invasive assessment of axonal fiber connectivity in the human brain via diffusion tensor MRI. Jones DK, et al. **Magn Reson Med** 1999 Jul;42(1):37–41

Integrated MRI assessment of regional function and perfusion in canine myocardial infarction. Kraitchman DL, et al. **Magn Reson Med** 1998 Aug;40(2):311–26

Fast, accurate, and reproducible automatic segmentation of the brain in T1-weighted volume MRI data. Lemieux L, et al. **Magn Reson Med** 1999 Jul;42(1):127–35

Cerebral blood flow measurement by dynamic contrast MRI using singular value decomposition with an adaptive threshold. Liu HL, et al. **Magn Reson Med** 1999 Jul; 42(1):167–72

MRI-guided radiofrequency thermal ablation of implanted VX2 liver tumors in a rabbit model: demonstration of feasibility at 0.2 T. Merkle EM, et al. **Magn Reson Med** 1999 Jul;42(1):141–9

A 16-element phased-array head coil. Porter JR, et al. **Magn Reson Med** 1998 Aug;40(2):272–9

Enhancement of BOLD-contrast sensitivity by single-shot multi-echo functional MR imaging. Posse S, et al. **Magn Reson Med** 1999 Jul;42(1):87–97

Reduced circular field-of-view imaging. Scheffler K, et al. **Magn Reson Med** 1998 Sep;40(3):474–80

Simultaneous highly selective MR water and fat imaging using a simple new type of spectral-spatial excitation. Schick F. **Magn Reson Med** 1998 Aug;40(2):194–202

Quantitative assessment of improved homogeneity using higher-order shims for spectroscopic imaging of the brain. Spielman DM, et al. **Magn Reson Med** 1998 Sep; 40(3):376–82

Amplitude response and stimulus presentation frequency response of human primary visual cortex using BOLD EPI at 4 T. Thomas CG, et al. **Magn Reson Med** 1998 Aug; 40(2):203–9

Prospective MR signal-based cardiac triggering. Vasanawala SS, et al. **Magn Reson Med** 1999 Jul;42(1):82–6

The role of three-dimensional ultrasonography in evaluating the developing fetus. Naylor CS, et al. **MD Comput** 1999 May-Jun;16(3):46–8

Computer evaluation of left ventricular wall motion by means of shape-based tracking and symbolic description. Baroni M. **Med Eng Phys** 1999 Mar;21(2):73–85

Calibration of a portal imaging device for high-precision dosimetry: a Monte Carlo study. Keller H, et al. **Med Phys** 1998 Oct;25(10):1891–902

Optimization of the scintillation detector in a combined 3D megavoltage CT scanner and portal imager. Mosleh-Shirazi MA, et al. **Med Phys** 1998 Oct; 25(10):1880–90

Megavoltage imaging with low Z targets: implementation and characterization of an investigational system. Ostapiak OZ, et al. **Med Phys** 1998 Oct;25(10):1910–8

The use of an electronic portal imaging system to measure portal dose and portal dose profiles [published erratum appears in Med Phys 1999 Feb;26(2):331] Parsaei H, et al. **Med Phys** 1998 Oct;25(10):1903–9

Functional evaluation of telemedicine with super high definition images and B-ISDN. Takeda H, et al. **Medinfo** 1998;9 Pt 1:311–4

Virtual endoscopy (VE) of the basal cisterns: its value in planning the neurosurgical approach. Boor S, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):177–82

Stereotactic-guided microsurgical removal of lesions without cortical appearance planned by three-dimensional CT reconstruction: limits and advantages of the frame-based technique. Callovini GM, et al. **Minim Invasive Neurosurg** 1998 Dec;41(4):187–93

Neuronavigation using an articulated arm with a bayonet probe on a computer graphic composite of magnetic resonance and computerized tomography images. Hayashi N, et al. **Minim Invasive Neurosurg** 1998 Sep;41(3):144–8

Use of interactive-intraoperative guidance during vertebrectomy and anterior spinal fusion with instrumental fixation: technical note. Vinas FC, et al. **Minim Invasive Neurosurg** 1998 Sep;41(3):166–71

Computerized brain tissue classification of magnetic resonance images: a new approach to the problem of partial volume artifact. Bullmore E, et al. **Neuroimage** 1995 Jun; 2(2):133–47

Cortical surface-based analysis. I. Segmentation and surface reconstruction. Dale AM, et al. **Neuroimage** 1999 Feb; 9(2):179–94

Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Fischl B, et al. **Neuroimage** 1999 Feb;9(2):195–207

Detecting structural changes in whole brain based on nonlinear deformations-application to schizophrenia research. Gaser C, et al. **Neuroimage** 1999 Aug;10(2):107–13

A study of injected dose for brain mapping on the ECAT HR+: activation maps for a parametric verbal working memory task. Isoardi RA, et al. **Neuroimage** 1999 Jan; 9(1):145–53

Registration of MR/MR and MR/SPECT brain images by fast stochastic optimization of robust voxel similarity measures. Nikou C, et al. **Neuroimage** 1998 Jul;8(1):30–43

Visualization of magnetoencephalographic data using minimum current estimates. Uutela K, et al. **Neuroimage** 1999 Aug;10(2):173–80

Real-time fMRI paradigm control, physiology, and behavior combined with near real-time statistical analysis. Voyvodic JT. **Neuroimage** 1999 Aug;10(2):91–106

Quantitation of regional cerebral blood flow increases in prefrontal cortex during a working memory task: a steady-state arterial spin-tagging study. Ye FQ, et al. **Neuroimage** 1998 Jul;8(1):44–9

Technical considerations regarding accuracy of the MKM navigation system. An experimental study on impact factors. Kaminsky J, et al. **Neurol Res** 1999 Jun;21(4):420–4

Intracranial vascular stenosis and occlusion: comparison of 3D time-of-flight and 3D phase-contrast MR angiography. Oelerich M, et al. **Neuroradiology** 1998 Sep;40(9):567–73

Fast fluid-attenuated inversion-recovery imaging: first experience with a 3D version in epilepsy. Wieshmann UC, et al. **Neuroradiology** 1998 Aug;40(8):483–9

BrainLab VectorVision Neuronavigation System: technology and clinical experiences in 131 cases. Gumprecht HK, et al. **Neurosurgery** 1999 Jan;44(1):97–104; discussion 104–5

Angeles between A1 and A2 segments of the anterior cerebral artery visualized by three-dimensional computed tomographic angiography and association of anterior communicating artery aneurysms. Kasuya H, et al. **Neurosurgery** 1999 Jul;45(1):89–93; discussion 93–4

Universal calibration of surgical instruments for spinal stereotaxy. Kim KD, et al. **Neurosurgery** 1999 Jan; 44(1):173–7; discussion 177–8

Stereoscopic head-mounted display incorporated into microsurgical procedures: technical note. Levy ML, et al. **Neurosurgery** 1998 Aug;43(2):392–5; discussion 395–6

Intraoperative brain shift and deformation: a quantitative analysis of cortical displacement in 28 cases. Roberts DW, et al. **Neurosurgery** 1998 Oct;43(4):749–58; discussion 758–60

Radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia utilizing nonfluoroscopic electroanatomical mapping. Cooke PA, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1802–9

Electroanatomical mapping and ablation of the substrate supporting intraatrial reentrant tachycardia after palliation for complex congenital heart disease. Dorostkar PC, et al. **Pacing Clin Electrophysiol** 1998 Sep;21(9):1810–9

Fast and exact 2D image reconstruction by means of Chebyshev decomposition and backprojection. Bortfeld T, et al. **Phys Med Biol** 1999 Apr;44(4):1105–20

A large-area ionization chamber for portal image calibration. Partridge M, et al. **Phys Med Biol** 1999 Jan;44(1):271–9

Accurate portal dose measurement with a fluoroscopic electronic portal imaging device (EPID) for open and wedged beams and dynamic multileaf collimation. Pasma KL, et al. **Phys Med Biol** 1998 Aug;43(8):2047–60

Volumetric imaging with ultrasonic spiral CT. Azhari H, et al. **Radiology** 1999 Jul;212(1):270–5

Glenohumeral relationships during physiologic shoulder motion and stress testing: initial experience with open MR imaging and active imaging-plane registration. Beaulieu CF, et al. **Radiology** 1999 Sep;212(3):699–705

Three-dimensional US of the prostate: early experience. Hamper UM, et al. **Radiology** 1999 Sep;212(3):719–23

Brain tumor volume measurement: comparison of manual and semiautomated methods. Joe BN, et al. **Radiology** 1999 Sep; 212(3):811–6

Virtual CT intravascular endoscopy of the aorta: pierced surface and floating shape thresholding artifacts. Neri E, et al. **Radiology** 1999 Jul;212(1):276–9

Simultaneous noninvasive determination of regional myocardial perfusion and oxygen content in rabbits: toward direct measurement of myocardial oxygen consumption at MR imaging. Reeder SB, et al. **Radiology** 1999 Sep; 212(3):739–47

Electrocardiographically gated thin-section CT of the lung. Schoepf UJ, et al. **Radiology** 1999 Sep;212(3):649–54

Laparoscopic visual field. Voice vs foot pedal interfaces for control of the AESOP robot. Allaf ME, et al. **Surg Endosc** 1998 Dec;12(12):1415–8

Intravascular ultrasound elastography. van der Steen AF, et al. **Ultraschall Med** 1998 Oct;19(5):196–201

In vitro evaluation of three-dimensional ultrasonography based on magnetic scanhead tracking. Gilja OH, et al. **Ultrasound Med Biol** 1998 Oct;24(8):1161–7

Imaging of placental vasculature using three-dimensional ultrasound and color power Doppler: a preliminary study. Pretorius DH, et al. **Ultrasound Obstet Gynecol** 1998 Jul; 12(1):45–9

[A new concept in surgery of the digestive tract: surgical procedure assisted by computer, from virtual reality to telemanipulation] Marescaux J, et al. **Chirurgie** 1998 Feb; 123(1):16–24 (Eng. Abstr.) **(Fre)**

[Imaging cranial nerves with inframillimetric T2-weighted MRI] Benoudiba F, et al. **J Radiol** 1998 Jan;79(1):21–5 (Eng. Abstr.) **(Fre)**

[Equipment for modification of nuclear medicine lung diagnosis as triggered SPECT--presentation, phantom studies and clinical value] Andreeff M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:76–7 **(Ger)**

[Possibilities of infrared diaphanoscopy of human teeth] Becker J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:126–7 **(Ger)**

[Analysis of tension distribution in bone matrix on a stressed external fixator bone pin in a two-dimensional model with finite element method of tension optics] Brandt H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:196–7 **(Ger)**

[Segmentation of clinical 4-dimensional magnetic resonance tomography images using active contour models and haptic interaction] Busch NH, et al. **Biomed Tech (Berl)** 1998;43 Suppl:526–7 **(Ger)**

[Development of a 4 camera system for localizing an electrode series on the thorax] de Boer IH, et al. **Biomed Tech (Berl)** 1998;43 Suppl:56–7 **(Ger)**

[Image segmentation and 3D presentation of histological objects] Dramm P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:36 **(Ger)**

[Device for three-dimensional measuring and frequency analysis of electric and magnetic fields] Eichmeier J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:274–5 **(Ger)**

[Rapid neuronal filters in mammography] Eppler W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:40–1 **(Ger)**

[Analytic methods for functional magnetic resonance data] Erné SN, et al. **Biomed Tech (Berl)** 1998;43 Suppl:16–7 **(Ger)**

[Quantifying stenosis and evaluating projection--an online realization in the catheter laboratory] Fischer F, et al. **Biomed Tech (Berl)** 1998;43 Suppl:364–5 **(Ger)**

[Detecting the spatial distribution of QT dispersion in bipolar magnetocardiography with various myocardial infarct sites] Giesler T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:230–1 **(Ger)**

[3-dimensional ultrasound elastography of the female breast: in vitro and in vivo results] Hiltawsky KM, et al. **Biomed Tech (Berl)** 1998;43 Suppl:520–1 **(Ger)**

[Simultaneous control of radiotherapy with heavy ions by positron emission tomography] Hinz R, et al. **Biomed Tech (Berl)** 1998;43 Suppl:30–1 **(Ger)**

[3-dimensional activity analysis with activity sensors for pacemaker therapy] Hoeland K, et al. **Biomed Tech (Berl)** 1998;43 Suppl:368–9 **(Ger)**

[Determining the position of distorted point lattice patterns on the human retina by evaluating monochromatic image errors] Kaemmerer M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:62–3 **(Ger)**

[Classification of cytological smears of the cervix with neuronal methods] Kestler HA, et al. **Biomed Tech (Berl)** 1999 Jan-Feb;44(1-2):17–24 (Eng. Abstr.) **(Ger)**

[Virtual neuro-endoscopy imaging of cerebral aneurysms] Kleinszig G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:20–1 **(Ger)**

[Calibration of volume data from spiral CT images for defining the contour of individually fitted skull implants] Koenen D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:468–9 **(Ger)**

[Imaging cardiac impedance changes in the human thorax using impedance tomography] Li JH, et al. **Biomed Tech (Berl)** 1998;43 Suppl:52–3 **(Ger)**

[A new measuring system for processing ultrasound multi-compression elastograph images of the prostate] Lorenz A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:72–3 **(Ger)**

[Therapy evaluation in dermatology by comparative color measurements] Meffert B, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:82–3 **(Ger)**

[Practical technical measurement problems in determining optical image errors of the human eye with a video-aberroscope] Mierdel P, et al. **Biomed Tech (Berl)** 1998;43 Suppl:60–1 **(Ger)**

[Time and frequency parameters for analysis of IVUS

(intravascular ultrasound) echo signals] Niendorf M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:104–5 **(Ger)**

[A system for detection and imaging geometric values from video images for movement analysis of the human body] Ottósdóttir KE, et al. **Biomed Tech (Berl)** 1998;43 Suppl:522–3 **(Ger)**

[A technique for imaging stretch of human back musculature with ultrasound for supporting the diagnosis of post-discectomy syndrome] Pesavento A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:148–9 **(Ger)**

[Segmentation-based movement estimation in ultrasound images] Reise F, et al. **Biomed Tech (Berl)** 1998;43 Suppl:472–3 **(Ger)**

[Combined video radiography and manometry for evaluating transport function of the esophageal sphincter] Rosenbaum KD, et al. **Biomed Tech (Berl)** 1998;43 Suppl:130–1 **(Ger)**

[3D reconstruction of anatomic structures with the TIM (tomographic imaging) visualization software] Rudolph I, et al. **Biomed Tech (Berl)** 1998;43 Suppl:64–5 **(Ger)**

[Development and evaluation of a diagnostic treadmill for three-dimensional imaging of gait dynamics] Rupp R, et al. **Biomed Tech (Berl)** 1998;43 Suppl:192–3 **(Ger)**

[Optical laboratory tomograph for education and research] Schleicher E, et al. **Biomed Tech (Berl)** 1998;43 Suppl:480–1 **(Ger)**

[Dynamic geometric contour models for segmenting intravascular ultrasound image series in 3-dimensional surface reconstruction of coronary vessel walls] Schmauder M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:22–3 **(Ger)**

[Characterization of an intravascular ultrasound measuring system for vessel wall assessment] Schmidt W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:162–3 **(Ger)**

[3D segmenting method for volume quantification of ECT (emission-computed tomography) data] Schmitt T, et al. **Biomed Tech (Berl)** 1998;43 Suppl:70–1 **(Ger)**

[Evaluation of endoscopic images for 3-dimensional measurement of hollow biological organs] Schubert M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:32–3 **(Ger)**

[Development of an educational program for medical ultrasound examinations: Ultra Trainer] Stallkamp J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:38–9 **(Ger)**

[Intraoperative monitoring of a robot-assisted minimal invasive mitral valve solo-surgery] Stein H, et al. **Biomed Tech (Berl)** 1998;43 Suppl:186–7 **(Ger)**

[Compression of 3- and 4-dimensional medical image data] Steingötter A, et al. **Biomed Tech (Berl)** 1998;43 Suppl:478–9 **(Ger)**

[Segmenting image series based on complex adaptive estimates] Steuer D, et al. **Biomed Tech (Berl)** 1998;43 Suppl:44–5 **(Ger)**

[Development of a measuring system for vital microscopy] Thümmler M, et al. **Biomed Tech (Berl)** 1998;43 Suppl:78–9 **(Ger)**

[High resolution structural imaging of the human ear] Vogel U, et al. **Biomed Tech (Berl)** 1998;43 Suppl:24–5 **(Ger)**

[Digital data collection based on "DICOM Supplement Structured Reporting" in radiology] von Gehlen S, et al. **Biomed Tech (Berl)** 1998;43 Suppl:46–7 **(Ger)**

[Time-efficient and objective diagnosis of muscle function by video analysis with the BMP meter] Walther A. **Biomed Tech (Berl)** 1998;43 Suppl:84–5 **(Ger)**

[ImaView--imaging station for pre-processing tomography image data] Wehmöller M, et al. **Biomed Tech (Berl)** 1998; 43 Suppl:42–3 **(Ger)**

[Comparative assessment of isotropic and anisotropic models of signal transmission in the heart] Werner CD, et al. **Biomed Tech (Berl)** 1998;43 Suppl:98–9 **(Ger)**

[CT-based 3D planning for dental implantology] Wolfram S. **Biomed Tech (Berl)** 1998;43 Suppl:34–5 **(Ger)**

[Measuring para-DC biomagnetic fields of the head using a horizontal modulated patient cot] Wübbeler G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:232–3 **(Ger)**

[Foreshortened imaging: a new method for spatial interpretation and evaluating the view of the coronary region of interest] Wunderlich W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:366–7 **(Ger)**

[Virtual surgical planning and surgical practice for liver surgery (editorial)] Herfarth C. **Chirurg** 1999 Mar; 70(3):231–2 **(Ger)**

[Increasing the quality of preoperative planning and intraoperative application of computer-assisted systems and surgical robots--an experimental study] Jerosch J, et al. **Chirurg** 1998 Sep;69(9):973–6 (Eng. Abstr.) **(Ger)**

[3-dimensional sonography for volume determination of liver tumors--report of initial experiences] Lang H, et al. **Chirurg** 1999 Mar;70(3):246–50 (Eng. Abstr.) **(Ger)**

[3-dimensional (3-D) visualization of the liver for planning extensive liver resections] Oldhafer KJ, et al. **Chirurg** 1999 Mar;70(3):233–8 (Eng. Abstr.) **(Ger)**

[Keratinocyte density of the cornea in vivo. Automated measurement with a modified confocal microscopy MICROPHTHAL] Stave J, et al. **Klin Monatsbl Augenheilkd** 1998 Jul;213(1):38–44 (Eng. Abstr.) **(Ger)**

[Principles and current possibilities of virtual scenarios for surgery planning] Englmeier KH, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:93–100 (Eng. Abstr.) **(Ger)**

[Virtual operations on real patients] Schlag PM, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:101–4 (Eng. Abstr.) **(Ger)**

[Computer assisted localization in endoscopic sinus surgery--state of the art? The Insta Trak system] Luxenberger W, et al. **Laryngorhinootologie** 1999 Jun; 78(6):318–25 (12 ref.) (Eng. Abstr.) **(Ger)**

[Thermographic detection of heat radiation in caloric vestibular function tests] Pau HW, et al. **Laryngorhinootologie** 1999 Apr;78(4):217–21 (Eng. Abstr.) **(Ger)**

[Neuronavigation. Methods and prospects] Wirtz CR, et al. **Nervenarzt** 1998 Dec;69(12):1029–36 (29 ref.) (Eng. Abstr.) **(Ger)**

[Quantifying the damage to conjunctival and corneal cell cultures caused by uv light using CASY (Cell Analysis System). A method for reducing animal experiments] Schmut O, et al. **Ophthalmologe** 1999 Jun;96(6):375–81 (Eng. Abstr.) **(Ger)**

[Combined use of MRI and MR cholangiopancreatography and contrast enhanced dual phase 3-D MR angiography in diagnosis of pancreatic tumors: initial clinical results] Gaa J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):528–33 (Eng. Abstr.) **(Ger)**

[Lymph node imaging with ultra-rapid 3D MR angiography] Georgi M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):218–21 (Eng. Abstr.) **(Ger)**

[Flow quantification of intracardiac shunt volumes using MR phase contrast technique in the breath holding phase] Kalden P, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):378–82 (Eng. Abstr.) **(Ger)**

[Diagnosis of renal artery stenosis in 1.0 T using 3D phase contrast magnetic resonance angiography and dynamic contrast medium perfusion] Miller S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):163–7 (Eng. Abstr.) **(Ger)**

[Optimization of numerical measurement parameters for ECG-triggered MRI snapshot-FLASH myocardial perfusion studies] Nägele T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):89–93 (Eng. Abstr.) **(Ger)**

[Color-coded volume reconstruction for 3-dimensional presentation of CT data] Rieker O, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jan;170(1):109–11 (Eng. Abstr.) **(Ger)**

[Determination of contour clarity in contrast-enhanced MR angiography: definition and clinical evaluation exemplified by ECG-triggered imaging of the thoracic aorta] Rodenwaldt J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Dec;169(6):616–21 (Eng. Abstr.) **(Ger)**

[3-dimensional MR coronary angiography with navigator technique: imaging of the proximal course of a coronary artery anomaly] Sandstede J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1998 Oct;169(4):432–6 (Eng. Abstr.) **(Ger)**

[Panorama ultrasound of the spinal canal with determination of the level of the conus medullaris in newborn infants and infants] Staatz G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):564–7 (Eng. Abstr.) **(Ger)**

[Possibilities of virtual gastrointestinal endoscopy] Fleiter T, et al. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):65–71 (8 ref.) (Eng. Abstr.) **(Ger)**

[New perspectives in 3D MR colonography] Luboldt W, et al. **Schweiz Rundsch Med Prax** 1999 Jan 14;88(3):73–9 (Eng. Abstr.) **(Ger)**

[Ultrasound-controlled anthropometry--on the development of a new method in asymmetry diagnosis] Himmelreich H, et al. **Sportverletz Sportschaden** 1998 Jun;12(2):60–5 (Eng. Abstr.) **(Ger)**

[Ultrasound--already clinically relevant?] Glüer CC, et al. **Ther Umsch** 1998 Nov;55(11):667–75 (34 ref.) (Eng. Abstr.) **(Ger)**

[Transparent 3-D ultrasound in fetal abnormalities] Meinel K, et al. **Ultraschall Med** 1998 Jun;19(3):120–5 (Eng. Abstr.) **(Ger)**

[Ultrasound-controlled stereotactic breast biopsy--description and initial clinical results of a new breast biopsy device] Wunderbaldinger P, et al. **Wien Med Wochenschr** 1998;148(14):325–30 (Eng. Abstr.) **(Ger)**

[Evaluating the pregnant cervix uteri by ultrasound with computer-assisted texture analysis] Wischnik A, et al. **Z Geburtshilfe Neonatol** 1999 May-Jun;203(3):115–9 (Eng. Abstr.) **(Ger)**

[Possibilities and limits of electron beam tomography] Moshage W, et al. **Z Kardiol** 1998 Jul;87(7):522–7 (Eng. Abstr.) **(Ger)**

[Morphometric dual-energy roentgen absorptiometry in follow-up of scoliosis] Hutzelmann A, et al. **Z Orthop Ihre Grenzgeb** 1998 Jul-Aug;136(4):380–2 (Eng. Abstr.) **(Ger)**

[New methods for minimal invasive assessment of uncertain mammography and MRI tomography findings] Heywang-Köbrunner SH, et al. **Zentralbl Chir** 1998;123 Suppl 5:66–9 (Eng. Abstr.) **(Ger)**

[Minimally invasive stereotactic breast biopsy with the "mammotome". Methodology and personal experiences] Laufer U, et al. **Zentralbl Chir** 1998;123 Suppl 5:63–5 (Eng. Abstr.) **(Ger)**

[Combination of mammography with automated ultrasound (Sono-X) in routine diagnosis?] Richter K, et al. **Zentralbl Chir** 1998;123 Suppl 5:37–41 (Eng. Abstr.) **(Ger)**

[The ABBI system as a possibility for evaluating non-palpable lesions] Winzer KJ, et al. **Zentralbl Chir** 1998; 123 Suppl 5:57–62 (Eng. Abstr.) **(Ger)**

METHODS

Electron-beam CT: the effect of using a correction function on coronary artery calcium quantitation. Greaser LE 3rd, et al. **Acad Radiol** 1999 Jan;6(1):40–8

Automation of primary screening for cervical cancer. Sooner or later? [editorial] Bartels PH, et al. **Acta Cytol** 1999 Jan-Feb;43(1):7–12

Utility of residual AutoCyte cervical cytology samples for image analysis. Bishop JW, et al. **Acta Cytol** 1999 Jan-Feb; 43(1):39–46

Semiautomated monolayer preparation of bronchial secretions using AutoCyte PREP. Motherby H, et al. **Acta Cytol** 1999 Jan-Feb;43(1):47–57

A simple image analysis method for evaluating cell binding to derivatized beads. Latham VH, et al. **Acta Histochem** 1999 Jul;101(3):263–70

Postnatal development of Eustachian tube: a computer-aided 3-D reconstruction and measurement study. Suzuki C, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):837–43

Fluid-attenuated inversion-recovery MR imaging in acute and subacute cerebral intraventricular hemorrhage. Bakshi R, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):629–36

The limitations of functional MR imaging: a caveat [editorial; comment] Dillon WP, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):536. Comment on: AJNR Am J Neuroradiol 1999 Apr;20(4):609–12.

Comparison of three-dimensional visualization techniques for depicting the scala vestibuli and scala tympani of the cochlea by using high-resolution MR imaging. Hans P, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1197–206

A new sonographic technique for assessing carotid artery disease: extended-field-of-view imaging [see comments] Hara Y, et al. **AJNR Am J Neuroradiol** 1999 Feb; 20(2):267–70. Comment in: AJNR Am J Neuroradiol 1999 Feb;20(2):187–9.

Proton MR spectroscopy in patients with complex partial seizures: single-voxel spectroscopy versus chemical-shift imaging. Hsu YY, et al. **AJNR Am J Neuroradiol** 1999 Apr;20(4):643–51

Real-time reconstruction and high-speed processing in functional MR imaging. Lee CC, et al. **AJNR Am J Neuroradiol** 1998 Aug;19(7):1297–300

Use of three-dimensional MR angiography for tracking a contrast bolus in the carotid artery [see comments] Melhem ER, et al. **AJNR Am J Neuroradiol** 1999 Feb;20(2):263–6 . Comment in: AJNR Am J Neuroradiol 1999 Feb;20(2):186.

Characterization of differences between multiple sclerosis and normal brain: a global magnetization transfer application. Ostuni JL, et al. **AJNR Am J Neuroradiol** 1999 Mar; 20(3):501–7

MR line scan diffusion imaging of the brain in children. Robertson RL, et al. **AJNR Am J Neuroradiol** 1999 Mar; 20(3):419–25

Newer sequences for spinal MR imaging: smorgasbord or succotash of acronyms? Ross JS. **AJNR Am J Neuroradiol** 1999 Mar;20(3):361–73 (82 ref.)

Evaluation of CSF leaks: high-resolution CT compared with contrast-enhanced CT and radionuclide cisternography. Stone JA, et al. **AJNR Am J Neuroradiol** 1999 Apr; 20(4):706–12

Prognostic value of diastolic filling parameters derived using a novel image processing technique in patients > or = 70 years of age with congestive heart failure. Rich MW, et al. **Am J Cardiol** 1999 Jul 1;84(1):82–6

Strategies for rare-event detection: an approach for automated fetal cell detection in maternal blood. Oosterwijk JC, et al. **Am J Hum Genet** 1998 Dec; 63(6):1783–92

Digital imaging of black and white photomicrographs: impact of file size. Barker NJ, et al. **Am J Surg Pathol** 1998 Nov; 22(11):1411–6

Quantification of ribonucleotide reductase expression in wild-type and hydroxyurea-resistant cell lines employing in situ reverse transcriptase polymerase chain reaction and a computerized image analysis system. Wadler S, et al. **Anal Biochem** 1999 Feb 1;267(1):24–9

Fast-FISH detection and semi-automated image analysis of numerical chromosome aberrations in hematological malignancies. Esa A, et al. **Anal Cell Pathol** 1998; 16(4):211–22

Automatic cell segmentation in cyto- and histometry using dominant contour feature points. Pal U, et al. **Anal Cell Pathol** 1998;17(4):243–50

Full second-order chromatographic/spectrometric data matrices for automated sample identification and component analysis by non-data-reducing image analysis. Nielsen NP, et al. **Anal Chem** 1999 Feb 1;71(3):727–35

Automated feature extraction and identification of colon carcinoma. Esgiar AN, et al. **Anal Quant Cytol Histol** 1998 Aug;20(4):297–301

Image analysis for comparative genomic hybridization based on a karyotyping program for windows. Roth K, et al. **Anal Quant Cytol Histol** 1997 Dec;19(6):461–74

Apoptosis during inner ear development in human and mouse

embryos: an analysis by computer-assisted three-dimensional reconstruction. Nishikori T, et al. **Anat Embryol (Berl)** 1999 Jul;200(1):19-26

New evidence from Le Moustier 1: computer-assisted reconstruction and morphometry of the skull. Ponce de León MS, et al. **Anat Rec** 1999 Apr 1;254(4):474-89

Repeatability and variance analysis on multiple computer-assisted (IVOS) sperm morphology readings. Coetzee K, et al. **Andrologia** 1999 May;31(3):163-8

A practical technique of colour image analysis: applications in experimental research. Chow PK, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):155-8

Measurement of articular cartilage thickness in the articulated knee. Wayne JS, et al. **Ann Biomed Eng** 1998 Jan-Feb; 26(1):96-102

Optical tracking of a microscope for image-guided intranasal sinus surgery. Hauser R, et al. **Ann Otol Rhinol Laryngol** 1999 Jan;108(1):54-62

Multi-label image analysis of secretory cell juxtaposition in the sheep pituitary gland. Ishii T, et al. **Arch Histol Cytol** 1999 May;62(2):119-28

Errors of computer-assisted migration analysis in conventional radiographs of femoral hip implants--an experimental study. Wirtz DC, et al. **Arch Orthop Trauma Surg** 1999;119(1-2):50-6

Methodologic issues for the assessment of reproducibility: comment on the article by Genant et al [letter; comment] Giraudeau B, et al. **Arthritis Rheum** 1999 Jul;42(7):1556-7 . Comment on: Arthritis Rheum 1998 Sep;41(9):1583-90.

A society of goal-oriented agents for the analysis of living cells. Boucher A, et al. **Artif Intell Med** 1998 Sep-Oct; 14(1-2):183-99

Feature selection for optimized skin tumor recognition using genetic algorithms. Handels H, et al. **Artif Intell Med** 1999 Jul;16(3):283-97

Toward objective selection of representative microscope images. Markey MK, et al. **Biophys J** 1999 Apr; 76(4):2230-7

Analysis of dynamic brain imaging data. Mitra PP, et al. **Biophys J** 1999 Feb;76(2):691-708

Solution x-ray scattering-based estimation of electron cryomicroscopy imaging parameters for reconstruction of virus particles. Thuman-Commike PA, et al. **Biophys J** 1999 Apr;76(4):2249-61

A full color system for quantitative assessment of histochemical and immunohistochemical staining patterns. Ma W, et al. **Biotech Histochem** 1999 Jan;74(1):1-9

Digital image processing for rapid analysis of differentially expressed transcripts on high-density cDNA arrays. Adryan B, et al. **Biotechniques** 1999 Jun;26(6):1174-9

Videos, photographs, and patient consent. Digital disguising techniques need to be improved [letter] Welsby PD. **BMJ** 1998 Nov 28;317(7171):1523

Development and validation of an objective method of determining skin erythema to transdermal oestradiol patches. Ross D, et al. **Br J Obstet Gynaecol** 1999 Mar; 106(3):279-83

Digital imaging in the assessment of facial deformity. Fanibunda KB, et al. **Br J Oral Maxillofac Surg** 1999 Apr; 37(2):94-8

Volumetric assessment of carotid artery bifurcation using freehand-acquired, compound 3D ultrasound. Allott CP, et al. **Br J Radiol** 1999 Mar;72(855):289-92

Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Hussain Z, et al. **Br J Radiol** 1999 Mar;72(855):236-45

CT derived Patlak images of the human kidney. Miles KA, et al. **Br J Radiol** 1999 Feb;72(854):153-8

Comparison of three-dimensional virtual endoscopy with bronchoscopy in patients with oesophageal carcinoma infiltrating the tracheobronchial tree. Rapp-Bernhardt U, et al. **Br J Radiol** 1998 Dec;71(852):1271-8

Software implementation of statistical methods for the analysis of structure and patterns in neuroanatomical objects. Baader SL, et al. **Brain Res Brain Res Protoc** 1998 Nov;3(2):173-82

The inverted multilayer perceptron as a consistency measuring device in neuroanatomical image analysis. Josephson E, et al. **Brain Res Brain Res Protoc** 1998 Nov; 3(2):161-72

High resolution quantitation of microvascular plasma perfusion in non-ischemic and ischemic rat brain by laser-scanning confocal microscopy. Morris DC, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):185-91

Intrinsic optical signals in vitro: a tool to measure alterations in extracellular space with two-dimensional resolution. Holthoff K, et al. **Brain Res Bull** 1998 Dec;47(6):649-55

Computerised colour: a technique for the assessment of burn scar hypertrophy. A preliminary report. Davey RB, et al. **Burns** 1999 May;25(3):207-13 (8 ref.)

A cost-effective method for the automatic quantitative analysis of fibroblastic colony-forming units. Dobson K, et al. **Calcif Tissue Int** 1999 Aug;65(2):166-72

Improved assessment of isolated islet tissue volume using digital image analysis. Stegemann JP, et al. **Cell Transplant** 1998 Sep-Oct;7(5):469-78

Three-dimensional visualization and quantification of the mandibular articular surface by optical profilometry. Dirksen D, et al. **Cells Tissues Organs** 1999;164(4):212-20

Real-time imaging of gene expression in single living cells. Rutter GA, et al. **Chem Biol** 1998 Nov;5(11):R285-90 (27 ref.)

Optimal scan delay of arterial phase scanning of hepatic CT using a real-time image reconstruction system. Shimizu T, et al. **Clin Imaging** 1999 Mar-Apr;23(2):107-10

Three-dimensional computed tomographic reconstruction: planning tool for surgery of skull base pathologies. Elolf E, et al. **Comput Aided Surg** 1998;3(2):89-94

Accuracy of registration methods in frameless stereotaxis. Helm PA, et al. **Comput Aided Surg** 1998;3(2):51-6

An edge-sensitive noise reduction algorithm for image processing. Adelmann HG. **Comput Biol Med** 1999 Mar; 29(2):137-45

Automated morphometric analysis in peripheral neuropathies. Campadelli P, et al. **Comput Biol Med** 1999 Mar;29(2):147-56

A 3D deformable surface model for segmentation of objects from volumetric data in medical images. Ghanei A, et al. **Comput Biol Med** 1998 May;28(3):239-53

Unsupervised connectivity-based thresholding segmentation of midsagittal brain MR images. Lee C, et al. **Comput Biol Med** 1998 May;28(3):309-38

Automatic karyotyping of metaphase cells with overlapping chromosomes. Popescu M, et al. **Comput Biol Med** 1999 Jan;29(1):61-82

Evaluation of linear diaphragm-chest expansion models for magnetic resonance imaging motion artifact correction. Priatna A, et al. **Comput Biol Med** 1999 Mar;29(2):111-27

Automated registration of multimodal brain image sets using computer vision methods. Secretta G, et al. **Comput Biol Med** 1999 Sep;29(5):333-59

Automatic segmentation of lung fields on chest radiographic images. Carreira MJ, et al. **Comput Biomed Res** 1999 Jun; 32(3):283-303

Implementation of three-dimensional EEG brain mapping. Heinonen T, et al. **Comput Biomed Res** 1999 Apr; 32(2):123-31

Split-and-merge segmentation of magnetic resonance medical images: performance evaluation and extension to three dimensions. Manousakas IN, et al. **Comput Biomed Res** 1998 Dec;31(6):393-412

Volume-preserving smoothing of three-dimensional surfaces: application to intravascular ultrasound. Zeng C, et al. **Comput Biomed Res** 1998 Oct;31(5):385-92

A wavelet-based method for removal of out-of-plane structures in digital tomosynthesis. Badea C, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):309-15

A geometry-and intensity-based partial volume correction for MRI volumetric studies. Bello F, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):123-32

Self-calibration of a biplane X-ray imaging system for an optimal three dimensional reconstruction. Cheriet F, et al. **Comput Med Imaging Graph** 1999 May-Jun;23(3):133-41

Assessment of left ventricular cardiac shape by the use of volumetric curvature analysis from 3D echocardiography. Duann JR, et al. **Comput Med Imaging Graph** 1999 Mar-Apr;23(2):89-101

Computer-assisted image analysis of small cell lymphoma of the thyroid gland. Comparison of nuclear parameters of small lymphocytes in lymphomas and Hashimoto's thyroiditis. Eldar S, et al. **Comput Med Imaging Graph** 1998 Nov-Dec;22(6):479-88

Techniques for a structural analysis of dermatoscopic imagery. Fleming MG, et al. **Comput Med Imaging Graph** 1998 Sep-Oct;22(5):375-89

Segmentation of the hippocampus from brain MRI using deformable contours. Ghanei A, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):203-16

Correlation of SPECT and PET cardiac images by a surface matching registration technique. Gilardi MC, et al. **Comput Med Imaging Graph** 1998 Sep-Oct;22(5):391-8

Automatic detection of left ventricular borders on electron beam CT sequential cardiac images using an adaptive algorithm. Herment A, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):291-9

Tracking of non-rigid articulatory organs in X-ray image sequences. Höwing F, et al. **Comput Med Imaging Graph** 1999 Mar-Apr;23(2):59-67

A comparison of lossless compression methods for medical images. Kivijärvi J, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):323-39

Comparison of structure extraction methods for in vivo trabecular bone measurements. Laib A, et al. **Comput Med Imaging Graph** 1999 Mar-Apr;23(2):69-74

Three-dimensional modeling of biopsy protocols for localized prostate cancer. Loughlin M, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):229-38

Bladder and rectum volume estimations using CT and stereology. Mazonakis M, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):195-201

Pitfalls in image reconstruction of helical CT angiography: an experimental study. Ogata I, et al. **Comput Med Imaging Graph** 1999 May-Jun;23(3):143-54

A pyramidal approach for automatic segmentation of multiple sclerosis lesions in brain MRI. Pachai C, et al. **Comput Med Imaging Graph** 1998 Sep-Oct;22(5):399-408

3D MR image analysis of the morphology of the rear foot: application to classification of bones. Stindel E, et al. **Comput Med Imaging Graph** 1999 Mar-Apr;23(2):75-83

Quantification of the local heartwall motion by magnetic resonance myocardial tagging. Stuber M, et al. **Comput Med Imaging Graph** 1998 May-Jun;22(3):217-28

Two motion-detection algorithms for projection-reconstruction magnetic resonance imaging: theory and experimental verification. Van de Walle R, et al. **Comput Med Imaging Graph** 1998 Mar-Apr;22(2):115-21

Automatic finite element mesh generation for maxillary second premolar. Lin CL, et al. **Comput Methods Programs Biomed** 1999 Jun;59(3):187-95

High performance medical image processing in client/server-environments. Mayer A, et al. **Comput Methods Programs Biomed** 1999 Mar;58(3):207-17

Image processing techniques for quantitative analysis of skin structures. Sanders JE, et al. **Comput Methods Programs Biomed** 1999 Jun;59(3):167-80

Robust pupil center detection using a curvature algorithm. Zhu D, et al. **Comput Methods Programs Biomed** 1999 Jun; 59(3):145-57

Comparison of recording systems and analysis methods in specular microscopy. Ohno K, et al. **Cornea** 1999 Jul; 18(4):416-23

A versatile image analysis approach for simultaneous chromosome identification and localization of FISH probes. Christian A, et al. **Cytogenet Cell Genet** 1998; 82(3-4):172-9

Automated recognition of patterns characteristic of subcellular structures in fluorescence microscopy images. Boland MV, et al. **Cytometry** 1998 Nov 1;33(3):366-75

In vitro motility evaluation of aggregated cancer cells by means of automatic image processing. De Hauwer C, et al. **Cytometry** 1999 May 1;36(1):1-10

Interactive computer-assisted position acquisition procedure designed for the analysis of organelle movement in pollen tubes. de Win AH, et al. **Cytometry** 1998 Aug 1;32(4):263-7

Signal to noise analysis of multiple color fluorescence imaging microscopy. Garini Y, et al. **Cytometry** 1999 Mar 1;35(3):214-26

Fluorescence-imaging assay for cytotoxic plaque formation and for growth toward confluency of adherent cells. Gericke G, et al. **Cytometry** 1998 Sep 1;33(1):41-6

Automated segmentation of muscle fiber images using active contour models. Klemencic A, et al. **Cytometry** 1998 Aug 1;32(4):317-26

Identification of early apoptosis in feulgen-stained cultured cells in situ by computerized image analysis. Kuo HR, et al. **Cytometry** 1998 Dec 1;33(4):420-7

Single-cell measurement of superoxide anion and hydrogen peroxide production by human neutrophils with digital imaging fluorescence microscopy. Szucs S, et al. **Cytometry** 1998 Sep 1;33(1):19-31

Image analysis enhancement of the laser scanning cytometer. Woltmann G, et al. **Cytometry** 1998 Nov 1;33(3):362-5

Two-dimensional electrophoresis and computer imaging: quantitation of human milk casein. Goldfarb M. **Electrophoresis** 1999 Apr-May;20(4-5):870-4

A computer-assisted two-dimensional gel electrophoresis approach for studying the variations in protein expression related to an induced functional repression of NFkappaB in lymphoblastoid cell lines. Joubert-Caron R, et al. **Electrophoresis** 1999 Apr-May;20(4-5):1017-26

Rapid, high-sensitivity imaging of radiolabeled gels with microchannel plate detectors. Lees JE, et al. **Electrophoresis** 1999 Jul;20(10):2139-43

Semi-automatic segmentation of computed tomographic images in volumetric estimation of nasal airway. Dastidar P, et al. **Eur Arch Otorhinolaryngol** 1999;256(4):192-8

The use of nuclear morphometry for the prediction of survival in patients with advanced cancer of the larynx. Dobroś W, et al. **Eur Arch Otorhinolaryngol** 1999; 256(5):257-61

An image analysis for the quantitative evaluation of K19 positive nodules in rat liver sections. Barboro P, et al. **Eur J Histochem** 1997;41 Suppl 2:91-2

A computer-based technique for cell quantitation: "in vitro" chemotactic migration of endothelial cells. Marenzana M, et al. **Eur J Histochem** 1997;41 Suppl 2:101-2

An automatic classification technique for attenuation correction in positron emission tomography. Bettinardi V, et al. **Eur J Nucl Med** 1999 May;26(5):447-58

Semi-automatic segmentation of gated blood pool emission tomographic images by watersheds:application to the determination of right and left ejection fractions. Mariano-Goulart D, et al. **Eur J Nucl Med** 1998 Sep; 25(9):1300-7

Development of the human temporomandibular joint. Computer-aided 3D-reconstructions. Radlanski RJ, et al. **Eur J Oral Sci** 1999 Feb;107(1):25-34

The helical three-dimensional CT in the diagnosis of torticollis with occipitocondylar hypoplasia. Ilkko E, et al. **Eur J Radiol** 1998 Nov;29(1):55-60

Full-size digitized mammography will probably be a major step forward in breast imaging [editorial] Vanel D. **Eur J Radiol** 1999 Jul;31(1):1

Keratocyte density and size in conscious humans by digital image analysis of confocal images. Prydal JI, et al. **Eye** 1998;12 (Pt 3a):337-42

Ultrastructure of the eukaryotic aminoacyl-tRNA synthetase complex derived from two dimensional averaging and classification of negatively stained electron microscopic images. Norcum MT. **FEBS Lett** 1999 Mar 26; 447(2-3):217-22

Digital imaging in endoscopy [editorial] Korman LY. **Gastrointest Endosc** 1998 Sep;48(3):318-26 (5 ref.)

A computer-based method to quantify the classic pattern of choroidal neovascularization in order to monitor photodynamic therapy. Sickenberg M, et al.

Graefes Arch Clin Exp Ophthalmol 1999 May;237(5):353–60
Gold chloride technique to study articular innervation. A protocol validated through computer-assisted colorimetry. Gómez-Barrena E, et al. **Histol Histopathol** 1999 Jan; 14(1):69–79
A proximal CCD imaging system for high-throughput detection of microarray-based assays. Brignac SJ Jr, et al. **IEEE Eng Med Biol Mag** 1999 Mar–Apr;18(2):120–2
Recurrent nasal tumor detection by dynamic MRI. Huang WC, et al. **IEEE Eng Med Biol Mag** 1999 Jul–Aug; 18(4):100–5
Imaging of current density and current pathways in rabbit brain during transcranial electrostimulation. Joy ML, et al. **IEEE Trans Biomed Eng** 1999 Sep;46(9):1139–49
Three-dimensional microwave tomography: experimental prototype of the system and vector born reconstruction method. Semenov SY, et al. **IEEE Trans Biomed Eng** 1999 Aug;46(8):937–46
Adaptive predictive multiplicative autoregressive model for medical image compression [letter] Chen ZD, et al. **IEEE Trans Med Imaging** 1999 Feb;18(2):181–4
Algebraic reconstruction for magnetic resonance imaging under B0 inhomogeneity. Kadah YM, et al. **IEEE Trans Med Imaging** 1998 Jun;17(3):362–70
Ovarian ultrasound image analysis: follicle segmentation. Krivanek A, et al. **IEEE Trans Med Imaging** 1998 Dec; 17(6):935–44
Wavelet-based lossless compression of coronary angiographic images. Munteanu A, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):272–81
Registration of stereo and temporal images of the retina. Ritter N, et al. **IEEE Trans Med Imaging** 1999 May; 18(5):404–18
Segmentation of medical images using LEGION. Shareef N, et al. **IEEE Trans Med Imaging** 1999 Jan;18(1):74–91
Application of the extremum stack to neurological MRI. Simmons A, et al. **IEEE Trans Med Imaging** 1998 Jun; 17(3):371–82
A robust numerical solution to reconstruct a globally relative shear modulus distribution from strain measurements. Sumi C, et al. **IEEE Trans Med Imaging** 1998 Jun;17(3):419–28
Deformation analysis to detect and quantify active lesions in three-dimensional medical image sequences. Thirion JP, et al. **IEEE Trans Med Imaging** 1999 May;18(5):429–41
Fast spatio-temporal image reconstruction for dynamic PET. Wernick MN, et al. **IEEE Trans Med Imaging** 1999 Mar; 18(3):185–95 (20 ref.)
Retrospective intermodality registration techniques for images of the head: surface-based versus volume-based. West J, et al. **IEEE Trans Med Imaging** 1999 Feb; 18(2):144–50
A multimodal registration algorithm of eye fundus images using vessels detection and Hough transform. Zana F, et al. **IEEE Trans Med Imaging** 1999 May;18(5):419–28
Replicate and technician variation associated with computer aided bull sperm head morphometry analysis (ASMA). Gravance CG, et al. **Int J Androl** 1999 Apr;22(2):77–82
Replacement of cinefilm with a digital archive and review network. Cusma JT, et al. **Int J Card Imaging** 1998 Oct; 14(5):293–300 (10 ref.)
The status of the GE approach to the digital catheterization laboratory. Herro PJ. **Int J Card Imaging** 1998 Oct; 14(5):329–33 (0 ref.)
The Kodak approach to digital cardiovascular imaging laboratories. Pelanek GA. **Int J Card Imaging** 1998 Oct; 14(5):335–42 (2 ref.)
Intracardiac echocardiography: computerized detection of left ventricular borders. Sonka M, et al. **Int J Card Imaging** 1998 Dec;14(6):397–411 (20 ref.)
Computerized system to enhance the clinical diagnosis of pigmented cutaneous malignancies. Landau M, et al. **Int J Dermatol** 1999 Jun;38(6):443–6
A fast and accurate method for registration of MR images of the head. Kotsas P, et al. **Int J Med Inf** 1998 Oct–Dec; 52(1–3):167–82
Mechanical imaging: a new technology for medical diagnostics. Sarvazyan A. **Int J Med Inf** 1998 Apr; 49(2):195–216
Volumetric visualization of head and neck CT data for treatment planning. Lee JS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):693–703
Stereolithographic modelling as an aid to orbital brachytherapy. Poulsen M, et al. **Int J Radiat Oncol Biol Phys** 1999 Jun 1;44(3):731–5
Digital image capture and automated analysis of posterior capsular opacification. Friedman DS, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1715–26
A new method for noninvasive optical sectioning of the chorioretinal vasculature. Shahidi M, et al. **Invest Ophthalmol Vis Sci** 1998 Dec;39(13):2733–43
X-ray digital subtraction angiography to magnetic resonance-digital subtraction angiography using three-dimensional TRICKS. Historical perspective and computer simulations: a review. Mistretta CA, et al. **Invest Radiol** 1998 Sep;33(9):496–505 (43 ref.)
Real-time, 3-dimensional echocardiography acquires all standard 2-dimensional images from 2 volume sets: a clinical demonstration in 45 patients. Takuma S, et al. **J Am Soc Echocardiogr** 1999 Jan;12(1):1–6
Automated mass spectrometry imaging with a matrix-assisted laser desorption ionization time-of-flight instrument. Stoeckli M, et al. **J Am Soc Mass Spectrom** 1999 Jan; 10(1):67–71
Motion analysis of an articulated locomotion model by video and telemetric data. Lugné PC, et al. **J Biomech** 1999 Sep; 32(9):977–81
Finite element analysis of trabecular bone structure: a comparison of image-based meshing techniques. Ulrich D, et al. **J Biomech** 1998 Dec;31(12):1187–92
A method for synchronising digitised video data. Yeadon MR, et al. **J Biomech** 1999 Sep;32(9):983–6
Precise measurement of cat patellofemoral joint surface geometry with multistation digital photogrammetry. Ronsky JL, et al. **J Biomech Eng** 1999 Apr;121(2):196–205
Golgi structure in three dimensions: functional insights from the normal rat kidney cell. Ladinsky MS, et al. **J Cell Biol** 1999 Mar 22;144(6):1135–49
Measurement of motility of Helicobacter pylori, Campylobacter jejuni, and Escherichia coli by real time computer tracking using the Hobson BacTracker. Karim QN, et al. **J Clin Pathol** 1998 Aug;51(8):623–8
Automatic bone segmentation technique for CT angiographic studies. Fiebich M, et al. **J Comput Assist Tomogr** 1999 Jan–Feb;23(1):155–61
Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. Harris G, et al. **J Comput Assist Tomogr** 1999 Jan–Feb;23(1):144–54
High sensitive multiresolution analysis of low-contrast radiologic images based on the digital pseudocoherent holographic interferometry method. Akhmetshin AM. **J Digit Imaging** 1999 May;12(2 Suppl 1):197–8
Finding-specific display presets for computed radiography soft-copy reading. Andriole KP, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):3–5
Computerized analysis of abnormal asymmetry in digital chest radiographs: evaluation of potential utility. Armato SG 3rd, et al. **J Digit Imaging** 1999 Feb;12(1):34–42
Image processing strategies in picture archiving and communication systems. Blume H. **J Digit Imaging** 1999 Feb;12(1):43–7
Optimization of a contrast-detail-based method for electronic image display quality evaluation. Hangiandreou NJ, et al. **J Digit Imaging** 1999 May;12(2):60–7
Seamless multiresolution display of portable wavelet-compressed images. Hovanes ME, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):109–11
A comparison of wavelet and Joint Photographic Experts Group lossy compression methods applied to medical images. Iyriboz TA, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):14–7
Why and how is soft copy reading possible in clinical practice? Mertelmeier T. **J Digit Imaging** 1999 Feb; 12(1):3–11
A new filtering algorithm for medical magnetic resonance and computer tomography images. Stoll E, et al. **J Digit Imaging** 1999 Feb;12(1):23–8
Detection of cancerous masses for screening mammography using discrete wavelet transform-based multiresolution Markov random field. Zheng L, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):18–23
Real-time image reconstruction and display system for MRI using a high-speed personal computer. Haishi T, et al. **J Magn Reson** 1998 Sep;134(1):138–41
Automated peak picking and peak integration in macromolecular NMR spectra using AUTOPSY. Koradi R, et al. **J Magn Reson** 1998 Dec;135(2):288–97
Experimental validation of an automated edge-detection method for a simultaneous determination of the endocardial and epicardial borders in short-axis cardiac MR images: application in normal volunteers. Furber A, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1006–14
Quantification of white matter and gray matter volumes from three-dimensional magnetic resonance volume studies using fuzzy classifiers. Herndon RC, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1097–105
An image registration strategy for multi-echo fMRI. Jonsson T, et al. **J Magn Reson Imaging** 1999 Aug;10(2):154–8
Simultaneous MRI tagging and through-plane velocity quantification: a three-dimensional myocardial motion tracking algorithm. Kuijer JP, et al. **J Magn Reson Imaging** 1999 Mar;9(3):409–19
Optimized outer volume suppression for single-shot fast spin-echo cardiac imaging. Le Roux P, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1022–32
Digital wavelet-encoded MRI: a new wavelet-encoding methodology. Panych LP, et al. **J Magn Reson Imaging** 1998 Sep–Oct;8(5):1135–44
A novel object-independent "balanced" reference scan for echo-planar imaging. Reeder SB, et al. **J Magn Reson Imaging** 1999 Jun;9(6):847–52
A new method for the automatic mesh generation of bone segments from CT data. Viceconti M, et al. **J Med Eng Technol** 1999 Mar–Apr;23(2):77–81
Rapid and convenient method of autoradiography for DNA cloning using digital imaging analysis. Taketani Y, et al. **J Med Invest** 1998 Aug;45(1–4):111–3
In situ imaging of microorganisms in geologic material. Tobin KJ, et al. **J Microbiol Methods** 1999 Sep;37(3):201–13
Star length distribution: a volume-based concept for the characterization of structural anisotropy. Smit TH, et al. **J Microsc** 1998 Sep;191 (Pt 3):249–57
Feature extraction for MRI segmentation. Velthuizen RP, et al. **J Neuroimaging** 1999 Apr;9(2):85–90
3D angiography. Clinical interest. First applications in interventional neuroradiology. Anxionnat R, et al. **J Neuroradiol** 1998 Dec;25(4):251–62
BrainView: a computer program for reconstruction and interactive visualization of 3D data sets. Lohmann K, et al. **J Neurosci Methods** 1998 Oct 1;84(1–2):143–54
Subcellular distribution of delta-opioid receptors in the rat spinal cord: an approach using a three-dimensional reconstruction of confocal series of immunolabelled neurons. Mailly P, et al. **J Neurosci Methods** 1999 Feb 1; 87(1):17–24
Digital video: a tool for correlating neuronal firing patterns with hand motor behavior. Ro JY, et al. **J Neurosci Methods** 1998 Aug 1;82(2):215–31
Quantitation of multiple gene expression by in situ hybridization autoradiography: accurate normalization using Bayes classifier. Zhao W, et al. **J Neurosci Methods** 1999 Apr 1;88(1):63–70
Clinical application of three-dimensional anisotropy contrast magnetic resonance axonography. Technical note. Nakada T, et al. **J Neurosurg** 1999 Apr;90(4):791–5
Quantitative and clinical analysis of SPECT image registration for epilepsy studies. Brinkmann BH, et al. **J Nucl Med** 1999 Jul;40(7):1098–105
Bone SPECT of the spine: a comparison of attenuation correction techniques. Case JA, et al. **J Nucl Med** 1999 Apr;40(4):604–13
Automatic three-dimensional multimodality registration using radionuclide transmission CT attenuation maps: a phantom study. Dey D, et al. **J Nucl Med** 1999 Mar; 40(3):448–55
Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. Habraken JB, et al. **J Nucl Med** 1999 Jul;40(7):1091–7
Using vascular structure for CT-SPECT registration in the pelvis. Hamilton RJ, et al. **J Nucl Med** 1999 Feb; 40(2):347–51
Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. Hermansen F, et al. **J Nucl Med** 1998 Oct;39(10):1696–702
Iterative reconstruction based on median root prior in quantification of myocardial blood flow and oxygen metabolism. Katoh C, et al. **J Nucl Med** 1999 May; 40(5):862–7
Quantitative comparison of three- and two-dimensional PET with human brain studies. Sossi V, et al. **J Nucl Med** 1998 Oct;39(10):1714–9
Effects of the attenuation map used in the Chang algorithm on quantitative SPECT results. Cao Z, et al. **J Nucl Med Technol** 1998 Sep;26(3):178–85
An assessment of the sensitivity of the Cedars-Sinai quantitative gated SPECT software to changes in the reconstruction of the short-axis slices. Fredericks N, et al. **J Nucl Med Technol** 1999 Jun;27(2):123–6
Equivalent blur as a function of spurious response of a sampled imaging system: application to character recognition. Driggers RG, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 May;16(5):1026–33
Separating reflections from images by use of independent component analysis. Farid H, et al. **J Opt Soc Am A Opt Image Sci Vis** 1999 Sep;16(9):2136–45
An opinion survey of reported benefits from the use of stereolithographic models. Erickson DM, et al. **J Oral Maxillofac Surg** 1999 Sep;57(9):1040–3
Three-dimensional reconstruction system for imaging of the temporomandibular joint using magnetic resonance imaging. Motoyoshi M, et al. **J Oral Sci** 1999 Mar;41(1):5–8
Morphologic changes in the ulnar nerve at the elbow with flexion and extension: a magnetic resonance imaging study with 3-dimensional reconstruction. Patel VV, et al. **J Shoulder Elbow Surg** 1998 Jul–Aug;7(4):368–74
Video on the Internet: An introduction to the digital encoding, compression, and transmission of moving image data. Boudier T, et al. **J Struct Biol** 1999 Apr–May; 125(2–3):133–55
A strategy for determining the orientations of refractory particles for reconstruction from cryo-electron micrographs with particular reference to round, smooth-surfaced, icosahedral viruses. Castón JR, et al. **J Struct Biol** 1999 Apr–May;125(2–3):209–15
Cryo-electron-microscopy reconstruction of partially symmetric objects. Rossmann MG, et al. **J Struct Biol** 1999 Apr–May;125(2–3):196–208
A maximum-likelihood approach to single-particle image refinement. Sigworth FJ. **J Struct Biol** 1998;122(3):328–39
Xmdisp--A visualization tool to aid structure determination from electron microscope images. Smith JM. **J Struct Biol** 1999 Apr–May;125(2–3):223–8
Extended field-of-view two-dimensional ultrasonography of the breast: improvement in lesion documentation. Ghate SV, et al. **J Ultrasound Med** 1999 Sep;18(9):597–601
Computer-assisted three-dimensional reconstruction of head and neck tumors. Moharir VM, et al **Laryngoscope** 1998 Nov;108(11 Pt 1):1592–8
On spatially selective RF excitation and its analogy with spiral MR image acquisition. Börnert P, et al. **MAGMA** 1998 Dec;7(3):166–78
Oxygen enhanced MR ventilation imaging of the lung. Chen Q, et al. **MAGMA** 1998 Dec;7(3):153–61
AUTO-SMASH: a self-calibrating technique for SMASH imaging. SiMultaneous Acquisition of Spatial Harmonics.

Jakob PM, et al. **MAGMA** 1998 Nov;7(1):42–54
Motion artifacts reduction in DWI using navigator echoes: a robust and simple correction scheme. Latta P, et al. **MAGMA** 1998 Nov;7(1):21–7
Influence of digital audio filters on image reconstruction in MRI. Vondra V, et al. **MAGMA** 1998 Aug;6(1):70–6
Scanning time efficient slinky for non-contrast MRA at low field. Liu K, et al. **Magn Reson Imaging** 1999 Jun; 17(5):689–98
Removal of extracerebral tissues in dual-echo magnetic resonance images via linear scale-space features. Suckling J, et al. **Magn Reson Imaging** 1999 Feb;17(2):247–56
Determination of normal regional left ventricular function from cine-MR images using a semi-automated edge detection method. Waiter GD, et al. **Magn Reson Imaging** 1999 Jan;17(1):99–107
Closed contour edge detection of blood vessel lumen and outer wall boundaries in black-blood MR images. Yuan C, et al. **Magn Reson Imaging** 1999 Feb;17(2):257–66
An echo-shifted gradient-echo MRI method for efficient diffusion weighting. Delalande C, et al. **Magn Reson Med** 1999 May;41(5):1000–8
Spectral quantitation by principal component analysis using complex singular value decomposition. Elliott MA, et al. **Magn Reson Med** 1999 Mar;41(3):450–5
Rapid iterative reconstruction for echo planar imaging. Foxall DL, et al. **Magn Reson Med** 1999 Sep;42(3):541–7
Flow distortion and signal loss in spiral imaging. Gatehouse PD, et al. **Magn Reson Med** 1999 May;41(5):1023–31
Simple analytic spiral K-space algorithm. Glover GH. **Magn Reson Med** 1999 Aug;42(2):412–5
Quantitative imaging of magnetization transfer using multiple selective pulses. Gochberg DF, et al. **Magn Reson Med** 1999 May;41(5):1065–72
Voxel sensitivity function description of flow-induced signal loss in MR imaging: implications for black-blood MR angiography with turbo spin-echo sequences. Jara H, et al. **Magn Reson Med** 1999 Mar;41(3):575–90
Single-shot half k-space high-resolution gradient-recalled EPI for fMRI at 3 Tesla. Jesmanowicz A, et al. **Magn Reson Med** 1998 Nov;40(5):754–62
Functional MRI of the human brain with GRASE-based BOLD contrast. Jovicich J, et al. **Magn Reson Med** 1999 May;41(5):871–6
Geometric distortion correction in gradient-echo imaging by use of dynamic time warping. Kannengiesser SA, et al. **Magn Reson Med** 1999 Sep;42(3):585–90
Motion correction in fMRI via registration of individual slices into an anatomical volume. Kim B, et al. **Magn Reson Med** 1999 May;41(5):964–72
Improving contrast and tracking of tags in cardiac magnetic resonance images. Koerkamp MA, et al. **Magn Reson Med** 1999 May;41(5):973–82
Polar sampling in k-space: reconstruction effects. Lauzon ML, et al. **Magn Reson Med** 1998 Nov;40(5):769–82 (21 ref.)
Improved visualization of the human lung in 1H MRI using multiple inversion recovery for simultaneous suppression of signal contributions from fat and muscle. Mai VM, et al. **Magn Reson Med** 1999 May;41(5):866–70
Optimization of realtime adaptive navigator correction for 3D magnetic resonance coronary angiography. Nagel E, et al. **Magn Reson Med** 1999 Aug;42(2):408–11
Analysis of functional magnetic resonance imaging data using self-organizing mapping with spatial connectivity. Ngan SC, et al. **Magn Reson Med** 1999 May;41(5):939–46
Color schemes to represent the orientation of anisotropic tissues from diffusion tensor data: application to white matter fiber tract mapping in the human brain. Pajevic S, et al. **Magn Reson Med** 1999 Sep;42(3):526–40
Selection of high-definition 2D virtual profiles with multiple RF pulse excitations along interleaved echo-planar k-space trajectories. Panych LP, et al. **Magn Reson Med** 1999 Feb; 41(2):224–9
Systematic noise compensation for simultaneous multislice acquisition using rosette trajectories (SMART). Peltier SJ, et al. **Magn Reson Med** 1999 May;41(5):1073–6
Motion compensated projection reconstruction. Schäffter T, et al. **Magn Reson Med** 1999 May;41(5):954–63
Signal-to-noise ratio and signal-to-noise efficiency in SMASH imaging. Sodickson DK, et al. **Magn Reson Med** 1999 May;41(5):1009–22
Optimal partial volume estimation in MRI [letter] Soltanian-Zadeh H, et al. **Magn Reson Med** 1999 Sep; 42(3):612–5
In vivo micro-imaging using alternating navigator echoes with applications to cancellous bone structural analysis. Song HK, et al. **Magn Reson Med** 1999 May;41(5):947–53
3D spiral cardiac/respiratory ordered fMRI data acquisition at 3 Tesla. Stenger VA, et al. **Magn Reson Med** 1999 May; 41(5):983–91
Wavelet packet denoising of magnetic resonance images: importance of Rician noise at low SNR. Wood JC, et al. **Magn Reson Med** 1999 Mar;41(3):631–5
Application of the RLGS image analysis tool (RAT) to the construction of a genetic linkage map of recombinant inbred strain SMXA. Sugahara Y, et al. **Mamm Genome** 1999 Jun;10(6):611–6
Technique of distortion correction in endoscopic images using a polynomial expansion. Asari KV, et al. **Med Biol Eng Comput** 1999 Jan;37(1):8–12
Quantification of the morphological features of a full microvascular network. Bidiwala SB, et al. **Med Biol Eng Comput** 1998 Sep;36(5):621–6
Roughness feature of metaphase chromosome spreads and nuclei for automated cell proliferation analysis. Corkidi G, et al. **Med Biol Eng Comput** 1998 Nov;36(6):679–85
Outlining the prostate boundary using the harmonics method. Kwoh CK, et al. **Med Biol Eng Comput** 1998 Nov; 36(6):768–71
Volumetric analysis of CT orbital images. Lutzemberger L, et al. **Med Biol Eng Comput** 1998 Nov;36(6):661–6
Automated sizing of DNA fragments in atomic force microscope images. Spisz TS, et al. **Med Biol Eng Comput** 1998 Nov;36(6):667–72
Computer evaluation of left ventricular wall motion by means of shape-based tracking and symbolic description. Baroni M. **Med Eng Phys** 1999 Mar;21(2):73–85
Three-dimensional computational reconstruction of mixed anatomical tissues following histological preparation. Ferguson SJ, et al. **Med Eng Phys** 1999 Mar;21(2):111–7
Ultrasonic and elasticity imaging to model disease-induced changes in soft-tissue structure. Chaturvedi P, et al. **Med Image Anal** 1998 Dec;2(4):325–38
A three-component deformation model for image-guided surgery. Edwards PJ, et al. **Med Image Anal** 1998 Dec; 2(4):355–67
On-line analysis of echocardiographic image sequences. Giachetti A. **Med Image Anal** 1998 Sep;2(3):261–84
Estimation of three-dimensional cardiac velocity fields: assessment of a differential method and application to three-dimensional CT data. Gorce JM, et al. **Med Image Anal** 1997 Apr;1(3):245–61
Analysis of dynamic MR breast images using a model of contrast enhancement. Hayton P, et al. **Med Image Anal** 1997 Apr;1(3):207–24
The detection and significance of subtle changes in mixed-signal brain lesions by serial MRI scan matching and spatial normalization. Lemieux L, et al. **Med Image Anal** 1998 Sep;2(3):227–42
An approximate bootstrap technique for variance estimation in parametric images. Maitra R. **Med Image Anal** 1998 Dec; 2(4):379–93
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Meyer CR, et al. **Med Image Anal** 1997 Apr;1(3):195–206
A symbolic environment for visualizing activated foci in functional neuroimaging datasets. Rehm K, et al. **Med Image Anal** 1998 Sep;2(3):215–26
The Brain Bench: virtual tools for stereotactic frame neurosurgery. Serra L, et al. **Med Image Anal** 1997 Sep; 1(4):317–29 (28 ref.)
Automated 3-D registration of MR and CT images of the head. Studholme C, et al. **Med Image Anal** 1996 Jun; 1(2):163–75
Image matching as a diffusion process: an analogy with Maxwell's demons. Thirion JP. **Med Image Anal** 1998 Sep; 2(3):243–60
Semiautomatic segmentation of brain exterior in magnetic resonance images driven by empirical procedures and anatomical knowledge. Worth AJ, et al. **Med Image Anal** 1998 Dec;2(4):315–24
Motion and deformation tracking for short-axis echo-planar myocardial perfusion imaging. Yang GZ, et al. **Med Image Anal** 1998 Sep;2(3):285–302
Statistical image reconstruction methods for randoms-precorrected PET scans. Yavuz M, et al. **Med Image Anal** 1998 Dec;2(4):369–78
Image de-noising by integer wavelet transforms and generalized cross validation. Jansen M, et al. **Med Phys** 1999 Apr;26(4):622–30
Linear motion correction in three dimensions applied to dynamic gadolinium enhanced breast imaging. Krishnan S, et al. **Med Phys** 1999 May;26(5):707–14
A wavelet-based algorithm for detecting clustered microcalcifications in digital mammograms. Lado MJ, et al. **Med Phys** 1999 Jul;26(7):1294–305
Optimal noise control in and fast reconstruction of fan-beam computed tomography image. Pan X. **Med Phys** 1999 May; 26(5):689–97
Quantitative evaluation of vessel tracking techniques on coronary angiograms. Sen A, et al. **Med Phys** 1999 May; 26(5):698–706
Effects of lossy compression on lesion detection: predictions of the nonprewhitening matched filter. Zhao B, et al. **Med Phys** 1998 Sep;25(9):1621–4
Digital videomicroscopy and image analysis with automatic classification for detection of thin melanomas. Seidenari S, et al. **Melanoma Res** 1999 Apr;9(2):163–71
Visualizing protein interactions in living cells using digitized GFP imaging and FRET microscopy. Periasamy A, et al. **Methods Cell Biol** 1999;58:293–314 (98 ref.)
Characterization of ocular cellular and extracellular structures using confocal microscopy and computerized three-dimensional reconstruction. Brotchie D, et al. **Methods Enzymol** 1999;307:496–513
Analytical and numerical techniques for evaluation of free radical damage in cultured cells using imaging cytometry and fluorescent indicators. Buxser SE, et al. **Methods Enzymol** 1999;300:256–75
Computer analysis of 2-D images. Appel RD, et al. **Methods Mol Biol** 1999;112:363–81 (12 ref.)
Morphing confocal images and digital movie production. Hazen E. **Methods Mol Biol** 1999;122:421–41 (6 ref.)
New system for image analysis in nailfold capillaroscopy. Hu Q, et al. **Microcirculation** 1999 Sep;6(3):227–35
Combination of digital image analysis and polarization microscopy: theoretical considerations and experimental data. Kocsis K, et al. **Microsc Res Tech** 1998 Dec 15; 43(6):511–7
On the phase problem in electron microscopy: the relationship between structure factors, exit waves, and HREM images. Zou X. **Microsc Res Tech** 1999 Aug 1; 46(3):202–19
Image-guided neurosurgery/neuronavigation/the SurgiScope--reflexions on a theme. Haase J. **Minim Invasive Neurosurg** 1999 Jun;42(2):53–9 (37 ref.)
Quantification of tissue eosinophils and lymphocytes in histologic sections. Bishop JW. **Mod Pathol** 1998 Dec; 11(12):1247–51
Three-dimensional imaging of the yeast actin cytoskeleton through the budding cell cycle. Amberg DC. **Mol Biol Cell** 1998 Dec;9(12):3259–62
Microtubules and microscopes: how the development of light microscopic imaging technologies has contributed to discoveries about microtubule dynamics in living cells. Waterman-Storer CM. **Mol Biol Cell** 1998 Dec; 9(12):3263–71 (44 ref.)
Computer assisted image analysis to assess colonization of recipient seminiferous tubules by spermatogonial stem cells from transgenic donor mice. Dobrinski I, et al. **Mol Reprod Dev** 1999 Jun;53(2):142–8
Group II chaperonin in an open conformation examined by electron tomography. Nitsch M, et al. **Nat Struct Biol** 1998 Oct;5(10):855–7
The variability of human, BOLD hemodynamic responses. Aguirre GK, et al. **Neuroimage** 1998 Nov;8(4):360–9
Neurosurgical tools and techniques--modern image-guided surgery. Haase J. **Neurol Med Chir (Tokyo)** 1998;38 Suppl:303–7
Digital processing of images in physiological studies. Dudkin KN, et al. **Neurosci Behav Physiol** 1999 Mar-Apr; 29(2):161–5
Evaluation of scatter correction using a single isotope for simultaneous emission and transmission data. Phantom and clinical patient studies. Yang J, et al. **Nuklearmedizin** 1999; 38(2):49–55
Comparison of clinical and digital assessment of nuclear optical density. Robman LD, et al. **Ophthalmic Res** 1999; 31(2):119–26
Computer-vision-enabled augmented reality fundus biomicroscopy. Berger JW, et al. **Ophthalmology** 1999 Oct; 106(10):1935–41
Computer-assisted, interactive fundus image processing for macular drusen quantitation. Shin DS, et al. **Ophthalmology** 1999 Jun;106(6):1119–25
Cup-to-disc ratio: ophthalmoscopy versus automated measurement in a general population: The Rotterdam Study. Wolfs RC, et al. **Ophthalmology** 1999 Aug; 106(8):1597–601
Detection of caries with conventional digital imaging and tuned aperture computed tomography using CRT monitor and laptop displays. Abreu M Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):234–8
An in vivo comparison of diagnostic information obtained from tuned-aperture computed tomography and conventional dental radiographic imaging modalities. Webber RL, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Aug;88(2):239–47
Visualizing nerve cells with VolVis. Kaufman A. **Pac Symp Biocomput** 1998;:165–76
Hepatic enhancement analysis in children using smart prep monitoring for 2 : 1 pitch helical scanning. Vade A, et al. **Pediatr Radiol** 1999 Sep;29(9):689–93
Developments in component-based normalization for 3D PET. Badawi RD, et al. **Phys Med Biol** 1999 Feb; 44(2):571–94
Efficient SPECT scatter calculation in non-uniform media using correlated Monte Carlo simulation. Beekman FJ, et al. **Phys Med Biol** 1999 Aug;44(8):N183–92
Fast and exact 2D image reconstruction by means of Chebyshev decomposition and backprojection. Bortfeld T, et al. **Phys Med Biol** 1999 Apr;44(4):1105–20
Pulsed EPR imaging: image reconstruction using selective acquisition sequences. Di Giuseppe S, et al. **Phys Med Biol** 1999 Jun;44(6):N137–44
Cone-beam filtered-backprojection algorithm for truncated helical data. Kudo H, et al. **Phys Med Biol** 1998 Oct; 43(10):2885–909
An investigation of pulse-timing techniques for broadband ultrasonic velocity determination in cancellous bone: a simulation study. Le LH. **Phys Med Biol** 1998 Aug; 43(8):2295–308
Single-slice rebinning method for helical cone-beam CT. Noo F, et al. **Phys Med Biol** 1999 Feb;44(2):561–70
A large-area ionization chamber for portal image calibration. Partridge M, et al. **Phys Med Biol** 1999 Jan;44(1):271–9
Subsets and overrelaxation in iterative image reconstruction. Schmidlin P, et al. **Phys Med Biol** 1999 May;44(5):1385–96
Application of temporal filters to time resolved data in optical tomography. Schweiger M, et al. **Phys Med Biol** 1999 Jul; 44(7):1699–717
Incorporating a priori anatomical information into image

reconstruction in electrical impedance tomography. Dehghani H, et al. **Physiol Meas** 1999 Feb;20(1):87–102
Tomographic reconstruction of the retina using a confocal scanning laser ophthalmoscope. Vieira P, et al. **Physiol Meas** 1999 Feb;20(1):1–19
Vector-field classification in magnetic-resonance angiography. Tovar MA. **Proc AMIA Symp** 1998;:926–30
Measurements of organ volume by ultrasonography. Gilja OH, et al. **Proc Inst Mech Eng [H]** 1999;213(3):247–59 (119 ref.)
Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis. Kay PA, et al. **Prostate** 1998 Dec 1;37(4):270–7
Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound. Loch T, et al. **Prostate** 1999 May 15;39(3):198–204
Dipole analysis of epileptic source generator with manual zero potential shifting method. Tanaka KI, et al. **Psychiatry Clin Neurosci** 1998 Oct;52(5):507–11
Projecting the sulcal pattern of human brains onto a 2D plane--a new approach using potential theory and MRI. Haidekker MA, et al. **Psychiatry Res** 1998 Aug 26; 83(2):75–84
Automated face analysis by feature point tracking has high concurrent validity with manual FACS coding. Cohn JF, et al. **Psychophysiology** 1999 Jan;36(1):35–43
Identification of neural circuits underlying P300 abnormalities in schizophrenia. O'Donnell BF, et al. **Psychophysiology** 1999 May;36(3):388–98 (99 ref.)
Clinical evaluation of three-dimensional MR-cholangiopancreatography using three-dimensional Fourier transform fast asymmetric spin echo method (3DFT-FASE): usefulness of observation by multi-planar reconstruction. Yamakawa K, et al. **Radiat Med** 1999 Jan-Feb;17(1):15–9
Computerized detection of pulmonary nodules on CT scans. Armato SG 3rd, et al. **Radiographics** 1999 Sep-Oct; 19(5):1303–11
Three-dimensional volume rendering of spiral CT data: theory and method. Calhoun PS, et al. **Radiographics** 1999 May-Jun;19(3):745–64
Three-dimensional visualization and analysis methodologies: a current perspective. Udupa JK. **Radiographics** 1999 May-Jun;19(3):783–806 (97 ref.)
Three-dimensional imaging of congenital disorders involving the orbit. Zonneveld FW, et al. **Radiol Clin North Am** 1998 Nov;36(6):1261–79, xii (78 ref.)
Liver window settings at hepatic CT: added value or marginal cost? [editorial; comment] Brink JA. **Radiology** 1999 Mar;210(3):593–4. Comment on: Radiology 1999 Mar;210(3):601–4.
Internal carotid arterial stenosis: CT angiography with volume rendering. Leclerc X, et al. **Radiology** 1999 Mar; 210(3):673–82
Detecting hepatic lesions: the added utility of CT liver window settings [see comments] Mayo-Smith WW, et al. **Radiology** 1999 Mar;210(3):601–4. Comment in: Radiology 1999 Mar;210(3):593–4.
Development of virtual CT cholangiopancreatoscopy. Prassopoulos P, et al. **Radiology** 1998 Nov;209(2):570–4
Aortoiliac and lower extremity arteries: comparison of three-dimensional dynamic contrast-enhanced subtraction MR angiography and conventional angiography. Sueyoshi E, et al. **Radiology** 1999 Mar;210(3):683–8
Automated three-dimensional US frame positioning computed from elevational speckle decorrelation. Tuthill TA, et al. **Radiology** 1998 Nov;209(2):575–82
Unenhanced CT in the evaluation of urinary calculi: application of advanced computer methods. Olcott EW, et al. **Semin Ultrasound CT MR** 1999 Apr;20(2):136–41 (24 ref.)
Measurement of strain distributions within vertebral body sections by texture correlation. Bay BK, et al. **Spine** 1999 Jan 1;24(1):10–7
Spinal biomodeling. D'Urso PS, et al. **Spine** 1999 Jun 15; 24(12):1247–51
Subacromial space width changes during abduction and rotation--a 3-D MR imaging study. Graichen H, et al. **Surg Radiol Anat** 1999;21(1):59–64
A new method of three-dimensional computer assisted reconstruction of the developing biliary tract. Prudhomme M, et al. **Surg Radiol Anat** 1999;21(1):55–8
Segmentation techniques for analysis of bone by three-dimensional computed tomographic imaging. Dufresne T. **Technol Health Care** 1998 Dec;6(5-6):351–9 (10 ref.)
Localisation and characterisation of auditory perception through Functional Magnetic Resonance Imaging. Formisano E, et al. **Technol Health Care** 1998 Sep; 6(2-3):111–23
Measures of complexity for cancellous bone. Gowin W, et al. **Technol Health Care** 1998 Dec;6(5-6):373–90
Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis. Kapadia RD, et al. **Technol Health Care** 1998 Dec; 6(5-6):361–72
Presentation of brain electrical activity distribution on its cortex surface derived from MR images. Kozińska D, et al. **Technol Health Care** 1998 Sep;6(2-3):209–24
Micro-CT examinations of trabecular bone samples at different resolutions: 14, 7 and 2 micron level. Peyrin F, et al. **Technol Health Care** 1998 Dec;6(5-6):391–401
On-line 3D evaluation of left ventricular wall motion in magnetic resonance imaging. Santarelli MF, et al. **Technol Health Care** 1998 Sep;6(2-3):151–7
Mechanical analysis of bone and its microarchitecture based on in vivo voxel images. Ulrich D, et al. **Technol Health Care** 1998 Dec;6(5-6):421–7 (16 ref.)
Assessment of cancellous bone mechanical properties from micro-FE models based on micro-CT, pQCT and MR images. van Rietbergen B, et al. **Technol Health Care** 1998 Dec;6(5-6):413–20
New architectural parameters derived from micro-MRI for the prediction of trabecular bone strength. Wehrli FW, et al. **Technol Health Care** 1998 Dec;6(5-6):307–20 (47 ref.)
Automated analysis of patterns in fluorescence-microscope images. Boland MV, et al. **Trends Cell Biol** 1999 May; 9(5):201–2 (5 ref.)
Rapid calibration for 3-D freehand ultrasound. Prager RW, et al. **Ultrasound Med Biol** 1998 Jul;24(6):855–69
Automatic registration of 3-D ultrasound images. Rohling RN, et al. **Ultrasound Med Biol** 1998 Jul;24(6):841–54
Effect of contrast medium dose and image acquisition timing on ureteral opacification in the normal dog as assessed by computed tomography. Barthez PY, et al. **Vet Radiol Ultrasound** 1998 Nov-Dec;39(6):524–7
[Customized 3D radiographic reconstruction of the human pelvis] Gauvin C, et al. **Ann Chir** 1998;52(8):744–51 (Eng. Abstr.) **(Fre)**
[3-dimensional reconstruction technic using power Doppler. In vitro use on normal and stenosed pulmonary artery bifurcations] Christiaens L, et al. **Arch Mal Coeur Vaiss** 1998 Jun;91(6):759–64 (Eng. Abstr.) **(Fre)**
[Virtual laparoscopic anatomy of the esophagogastric junction] Cadière GB, et al. **Chirurgie** 1998 Dec; 123(6):580–7 (Eng. Abstr.) **(Fre)**
[Spinal cord MRI in multiple sclerosis: comparison of turbo-spin echo sequences and turbo-MRI] Neugroschl C, et al. **J Neuroradiol** 1998 Dec;25(4):263–7 (Eng. Abstr.) **(Fre)**
[Evaluation of a new MRI cholangiography sequence with a half-Fourier acquisition technic] Aubé C, et al. **J Radiol** 1998 Dec;79(12):1487–92 (Eng. Abstr.) **(Fre)**
[Snapping scapula: the value of 3D imaging] Sans N, et al. **J Radiol** 1999 Apr;80(4):379–81 (Eng. Abstr.) **(Fre)**
[The chondrocranium of an 18 mm human embryo. A 3-dimensional computer-assisted reconstruction (see comments)] Bettega G, et al. **Rev Stomatol Chir Maxillofac** 1999 Apr;100(1):6–12 (Eng. Abstr.). Comment in: Rev Stomatol Chir Maxillofac 1999 Apr;100(1):43–4. **(Fre)**
[On the article by G. Bettega and colleagues: "The chondrocranium of an 18 mm human embryo. A 3-dimensional computer-assisted reconstruction" (comment)] Devauchelle B, et al. **Rev Stomatol Chir Maxillofac** 1999 Apr;100(1):43–4. Comment on: Rev Stomatol Chir Maxillofac 1999 Apr;100(1):6–12. **(Fre)**
[Neuronavigation. Computer-assisted neurosurgery] Ostertag CB, et al. **Nervenarzt** 1999 Jun;70(6):517–21 (38 ref.) (Eng. Abstr.) **(Ger)**
[Onco-PET: lesion detection by monitor versus standardized film documentation] Bleckmann C, et al. **Nuklearmedizin** 1999;38(2):56–60 (Eng. Abstr.) **(Ger)**
[Reduction of radiation exposure in PET examinations by data acquisition in the 3D mode] Brix G, et al. **Nuklearmedizin** 1999 Apr;38(3):75–9 (Eng. Abstr.) **(Ger)**
[MR whole-spine recording: computer-assisted simulation of the conventional x-ray technic] König R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Mar;170(3):258–61 (Eng. Abstr.) **(Ger)**
[Computer-based image analysis for experimental and clinical morphology--principles, utilization and marginal limits] Seufert R, et al. **Zentralbl Gynakol** 1999;121(5):260–4 (9 ref.) (Eng. Abstr.) **(Ger)**
[A trial to reduce cardiac motion artifacts on HR-CT images of lung with combined use of subsecond scan and a high temporal resolution reconstruction algorithm] Sakai F, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Aug; 58(9):521–3 (Eng. Abstr.) **(Jpn)**
[Reduction of helical artifact using SmartHelical algorithm] Sakai O, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Aug;58(9):527–30 (Eng. Abstr.) **(Jpn)**
[A histological analysis of the changes experimentally induced by cadmium in cardiac muscle tissue by a computerized method of image analysis] Coucelo JM, et al. **Rev Port Cardiol** 1998 Sep;17(9):735–40 (Eng. Abstr.) **(Por)**
[A method for the contact-free computerized visualization of the movements of the head of the mandible in the temporomandibular joint] Kalivradzhiian ES, et al. **Stomatologiia (Mosk)** 1999;78(2):31–3 (Eng. Abstr.) **(Rus)**
[Potential of the image analyzer "videotest" for performing microphotometric study in cytology] Stein GI, et al. **Tsitologiia** 1998;40(10):913–6 (Eng. Abstr.) **(Rus)**

STANDARDS

Multicenter comparison of manual and automated screening of AutoCyte gynecologic preparations. Bishop JW, et al. **Acta Cytol** 1999 Jan-Feb;43(1):34–8
Standardisation of DNA quantitation by image analysis: quality control of instrumentation. Puech M, et al. **Cytometry** 1999 May 1;36(1):11–7
Y2K compliance report. Problems affecting imaging equipment. **Health Devices** 1999 Sep;28(9):366–8
The DICOM review stations: are they truly different? Goedhart B, et al. **Int J Card Imaging** 1998 Oct; 14(5):317–22 (7 ref.)
A quality assurance phantom for three-dimensional radiation treatment planning. Craig T, et al. **Int J Radiat Oncol Biol Phys** 1999 Jul 1;44(4):955–66
Joslin Vision Network Validation Study: pilot image stabilization phase. Aiello LM, et al. **J Am Optom Assoc** 1998 Nov;69(11):699–710
Image quality degradation by light scattering in display devices. Flynn MJ, et al. **J Digit Imaging** 1999 May; 12(2):50–9
Image quality assurance for CRT display systems--Part II [editorial] Roehrig H. **J Digit Imaging** 1999 May;12(2):49
Image quality assurance for CRT display systems [editorial] Roehrig H. **J Digit Imaging** 1999 Feb;12(1):1–2
Attenuation correction, or the emperor's new clothes? [editorial; comment] Wackers FJ. **J Nucl Med** 1999 Aug; 40(8):1310–2 (18 ref.). Comment on: J Nucl Med 1999 Aug;40(8):1301–9.
Technical considerations regarding accuracy of the MKM navigation system. An experimental study on impact factors. Kaminsky J, et al. **Neurol Res** 1999 Jun;21(4):420–4
Variability in digital assessment of cortical and posterior subcapsular cataract. Robman LD, et al. **Ophthalmic Res** 1999;31(2):110–8
Joint Photographic Experts Group compression of intraoral radiographs for image transmission on the World Wide Web. Yuasa H, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):93–9

STATISTICS & NUMERICAL DATA

Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Lonneux M, et al. **Eur J Nucl Med** 1999 Jun;26(6):591–8
Automated extraction and variability analysis of sulcal neuroanatomy. Le Goualher G, et al. **IEEE Trans Med Imaging** 1999 Mar;18(3):206–17 (47 ref.)
Landmark methods for forms without landmarks: morphometrics of group differences in outline shape. Bookstein FL. **Med Image Anal** 1997 Apr;1(3):225–43
Multiresolution elastic image registration. Kostelec PJ, et al. **Med Phys** 1998 Sep;25(9):1593–604
A method for assessing the accuracy of intersubject registration of the human brain using anatomic landmarks. Grachev ID, et al. **Neuroimage** 1999 Feb;9(2):250–68
Estimation of the probabilities of 3D clusters in functional brain images [see comments] Ledberg A, et al. **Neuroimage** 1998 Aug;8(2):113–28. Comment in: Neuroimage 1998 Aug;8(2):108–12.
The problem of the missing wavelet. Brigner WL. **Percept Mot Skills** 1999 Apr;88(2):496–502

TRENDS

Computers or cytotechnologists? [editorial] Wied GL. **Acta Cytol** 1999 Jan-Feb;43(1):1–3
[Computer assisted localization in endoscopic sinus surgery--state of the art? The Insta Trak system] Luxenberger W, et al. **Laryngorhinootologie** 1999 Jun; 78(6):318–25 (12 ref.) (Eng. Abstr.) **(Ger)**

IMAGE RECONSTRUCTION see **IMAGE PROCESSING, COMPUTER-ASSISTED**

IMAGERY (PSYCHOTHERAPY)

Imagery content during nonpharmacologic analgesia in the procedure suite: where your patients would rather be [see comments] Fick LJ, et al. **Acad Radiol** 1999 Aug; 6(8):457–63. Comment in: Acad Radiol 1999 Aug;6(8):455–6.
The value of tapes for surgery [letter] Naparstek B. **Adv Mind Body Med** 1999 Summer;15(3):157–8
The benefits of visualization. Hoffart MB, et al. **Am J Nurs** 1998 Dec;98(12):44–7
Guided imagery interventions for symptom management. Eller LS. **Annu Rev Nurs Res** 1999;17:57–84 (100 ref.)
Adverse effect of EMDR: a case report [letter] Kaplan R, et al. **Aust N Z J Psychiatry** 1998 Oct;32(5):731–2
Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Walker LG, et al. **Br J Cancer** 1999 Apr;80(1-2):262–8
The role of imagery in sexual arousal disturbances in the male traumatically brain injured individual. Crowe SF, et al. **Brain Inj** 1999 May;13(5):347–54
Intentional and spontaneous imagery in hypnosis: the phenomenology of hypnotic responding. Comey G, et al. **Int J Clin Exp Hypn** 1999 Jan;47(1):65–85
Eye Movement Desensitization and Reprocessing: an analysis of specific versus nonspecific treatment factors. Lohr JM, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):185–207 (133 ref.)
A single session, group study of exposure and Eye Movement Desensitization and Reprocessing in treating Posttraumatic Stress Disorder among Vietnam War veterans: preliminary data. Rogers S, et al. **J Anxiety Disord** 1999 Jan-Apr; 13(1-2):119–30
Cyclic vomiting syndrome: role of a psychiatric inpatient unit in a general children's hospital. Fennig S, et al.

IMAGERY (PSYCHOTHERAPY)

J Pediatr Gastroenterol Nutr 1999 Aug;29(2):207-10

Can emotive imagery aid in tolerating exertion efficiently? Coote D, et al. **J Sports Med Phys Fitness** 1998 Dec; 38(4):344-54

The function of image control in the psychophysiology of posttraumatic stress disorder. Laor N, et al. **J Trauma Stress** 1998 Oct;11(4):679-96

The effects of guided imagery on comfort of women with early stage breast cancer undergoing radiation therapy. Kolcaba K, et al. **Oncol Nurs Forum** 1999 Jan-Feb; 26(1):67-72

A randomized controlled trial of guided imagery in bulimia nervosa. Esplen MJ, et al. **Psychol Med** 1998 Nov; 28(6):1347-57

Visual and mental exploration of visuo-spatial configurations: behavioral and neuroimaging approaches. Cocude M, et al. **Psychol Res** 1999;62(2-3):93-106 (57 ref.)

HISTORY

EMDR and Mesmerism: a comparative historical analysis. McNally RJ. **J Anxiety Disord** 1999 Jan-Apr; 13(1-2):225-36

METHODS

Renewal of object relations through dream-work. Ergorova L. **J Anal Psychol** 1999 Jan;44(1):29-36

Does EMDR work? And if so, why?: a critical review of controlled outcome and dismantling research. Cahill SP, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):5-33 (72 ref.)

The contributions of eye movements to the efficacy of brief exposure treatment for reducing fear of public speaking. Carrigan MH, et al. **J Anxiety Disord** 1999 Jan-Apr; 13(1-2):101-18

Treatment of specific phobias with Eye Movement Desensitization and Reprocessing (EMDR): protocol, empirical status, and conceptual issues. De Jongh A, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):69-85 (54 ref.)

Eye Movement Desensitization and Reprocessing (EMDR) and the anxiety disorders: clinical and research implications of an integrated psychotherapy treatment. Shapiro F. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):35-67 (130 ref.)

Utility of psychophysiological measurement in the diagnosis of posttraumatic stress disorder: results from a Department of Veterans Affairs Cooperative Study. Keane TM, et al. **J Consult Clin Psychol** 1998 Dec;66(6):914-23

A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. Tarrier N, et al. **J Consult Clin Psychol** 1999 Feb; 67(1):13-8

Recognizing and treating dysfunctional grief. Rancour P. **Oncol Nurs Forum** 1998 Sep;25(8):1310-1

STANDARDS

The cognitive dismantling of Eye Movement Desensitization and Reprocessing (EMDR) treatment of Posttraumatic Stress Disorder (PTSD). Cusack K, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):87-99

The relative efficacy and treatment distress of EMDR and a cognitive-behavior trauma treatment protocol in the amelioration of posttraumatic stress disorder. Devilly GJ, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):131-57

Traumatic memories, eye movements, phobia, and panic: a critical note on the proliferation of EMDR. Muris P, et al. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):209-23 (63 ref.)

Treatment fidelity and research on Eye Movement Desensitization and Reprocessing (EMDR). Rosen GM. **J Anxiety Disord** 1999 Jan-Apr;13(1-2):173-84

IMAGERY, GUIDED see **IMAGERY (PSYCHOTHERAPY)**

IMAGINATION

see related

IMAGERY (PSYCHOTHERAPY)

What makes alcohol-dependent individuals early in abstinence crave for alcohol: exposure to the drink, images of drinking, or remembrance of drinks past? Weinstein A, et al. **Alcohol Clin Exp Res** 1998 Sep;22(6):1376-81

Regional cerebral blood flow during script-driven imagery in childhood sexual abuse-related PTSD: A PET investigation. Shin LM, et al. **Am J Psychiatry** 1999 Apr; 156(4):575-84

The contributions of source misattributions, acquiescence, and response bias to children's false memories. McBrien CM, et al. **Am J Psychol** 1998 Winter;111(4):509-28

Traumatic intrusions as 'worse case scenario's'. Merckelbach H, et al. **Behav Res Ther** 1998 Nov;36(11):1075-9

Exposure to disgust-evoking imagery and information processing biases in blood-injection-injury phobia. Sawchuk CN, et al. **Behav Res Ther** 1999 Mar;37(3):249-57

Anger in healthy men: a PET study using script-driven imagery. Dougherty DD, et al. **Biol Psychiatry** 1999 Aug 15;46(4):466-72

Evidence for image-scanning eye movements during transitive inference. Demarais AM, et al. **Biol Psychol** 1998 Nov;49(3):229-47

A cognitive distortion associated with eating disorders: thought-shape fusion. Shafran R, et al. **Br J Clin Psychol** 1999 Jun;38 (Pt 2):167-79

The mental model theory of spatial reasoning re-examined: the role of relevance in premise order. van der Henst JB. **Br J Psychol** 1999 Feb;90 (Pt 1):73-84

Imagined futures: young men's talk about fatherhood and domestic life. Edley N, et al. **Br J Soc Psychol** 1999 Jun; 38 (Pt 2):181-94

A note on state individual differences in accuracy of response imagery: aftereffects and reminiscence. Kohl RM, et al. **Brain Cogn** 1998 Dec;38(3):369-77

Childhood imaginary companionship and mental health in adolescence. Bonne O, et al. **Child Psychiatry Hum Dev** 1999 Summer;29(4):277-86

Mental representations of movements. Brain potentials associated with imagination of eye movements. Höllinger P, et al. **Clin Neurophysiol** 1999 May;110(5):799-805

Physical imagery: kinematic versus dynamic models. Schwartz DL. **Cognit Psychol** 1999 May;38(3):433-64

Imagery and hypnotizability revisited. Kogon MM, et al. **Int J Clin Exp Hypn** 1998 Oct;46(4):363-70

Primary process, hypnotic dreams, and the hidden observer: hypnosis versus alert imagining. Pinnell CM, et al. **Int J Clin Exp Hypn** 1998 Oct;46(4):351-62

Creativity and imagination in autism and Asperger syndrome. Craig J, et al. **J Autism Dev Disord** 1999 Aug;29(4):319-26

Revision of the Word Association Test for assessing associations of patients reporting satanic ritual abuse in childhood. Leavitt F, et al. **J Clin Psychol** 1998 Nov; 54(7):933-43

Reality monitoring in auditory and visual modalities: developmental trends and effects of cross-modal imagery. Markham R, et al. **J Exp Child Psychol** 1999 Jan; 72(1):51-70

Immune neglect: a source of durability bias in affective forecasting. Gilbert DT, et al. **J Pers Soc Psychol** 1998 Sep;75(3):617-38

The inadvertent use of prior knowledge in a generative cognitive task. Marsh RL, et al. **Mem Cognit** 1999 Jan; 27(1):94-105

Corticospinal excitability is specifically modulated by motor imagery: a magnetic stimulation study. Fadiga L, et al. **Neuropsychologia** 1999 Feb;37(2):147-58

Attentional memory and visualization strategies in mental additions. Abbate CS, et al. **Percept Mot Skills** 1998 Dec; 87(3 Pt 1):955-62

Video modeling and imaging training on performance of tennis service of 9- to 12-year-old children. Atienza FL, et al. **Percept Mot Skills** 1998 Oct;87(2):519-29

When does imagery practice enhance performance on a motor task? Bohan M, et al. **Percept Mot Skills** 1999 Apr; 88(2):651-8

A measure of visual imaging capacity: a preliminary study. Campos A. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):1012-4

Capacity for mental imagery and its spontaneous use. Campos A, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):856-8

Vividness of visual and haptic imagery of movement. Campos A, et al. **Percept Mot Skills** 1998 Aug;87(1):271-4

Emotionality of words as related to vividness of imagery and concreteness. Campos A, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1135-40

Action and imagination in the formation of images. Corriss D, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):979-83

Explanatory style among elite ice hockey athletes. Davis H 4th, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):1075-80

Imagery processes in evaluating duration of a ball flight. Féry YA, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1129-30

Men's and women's self-reported ratings of feeling observed. Iizuka Y. **Percept Mot Skills** 1999 Apr;88(2):621

Functional equivalence for response programming of actually performing versus imagining movements. Ito M. **Percept Mot Skills** 1999 Jun;88(3 Pt 1):941-51

An exploratory study of effects of smoking on mental rotation and mental paper-folding task. Iwaki T, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1171-82

Writing Chinese characters and success on Mental Rotation Test. Li C, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1261-70

Split-half reliability of two facial imagery questionnaires. McKelvie SJ. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):953-4

Prevalence of auditory, olfactory, and gustatory experiences in home dreams. Zadra AL, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):819-26

Repressed memories. When are they real? How are they false? Loftus EF, et al. **Psychiatr Clin North Am** 1999 Mar; 22(1):61-70 (29 ref.)

Obsolete terminology constricts imaginative thinking. Goldberger M. **Psychoanal Q** 1999 Jul;68(3):462-6

Aging and deficits in associative memory: what is the role of strategy production? Dunlosky J, et al. **Psychol Aging** 1998 Dec;13(4):597-607

Period duration of physical and imaginary movement sequences affects contralateral amplitude modulation. Heuer H, et al. **Q J Exp Psychol A** 1998 Nov;51(4):755-79

[Images and representations of cancer] Hoerni B, et al. **Encephale** 1998 Dec;24 Spec No 2:53-8 **(Fre)**

[Intuitive dialogue--a way out of emotional blockages with defocusing imagination] Drees A. **Wien Med Wochenschr** 1998;148(6):166-70 (19 ref.) (Eng. Abstr.) **(Ger)**

[The crossover effect of the propositional text representation and the mental model:the role of individual differences in spatial imagery ability] Dutke S. **Z Exp Psychol** 1999; 46(3):164-76 (Eng. Abstr.) **(Ger)**

[Influence of the type of visualization on the construction of mental models during picture and text comprehension] Schnotz W, et al. **Z Exp Psychol** 1999;46(3):217-36 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Feature centrality: naming versus imagining. Sloman SA, et al. **Mem Cognit** 1999 May;27(3):526-37

PHYSIOLOGY

Effects of real and imagined training on voluntary muscle activation during maximal isometric contractions. Herbert RD, et al. **Acta Physiol Scand** 1998 Aug;163(4):361-8

Ventilatory response to imagination of exercise and altered perception of exercise load under hypnosis. Thornton JM, et al. **Adv Exp Med Biol** 1998;450:195-7

Motor learning by imagery is differentially affected in Parkinson's and Huntington's diseases. Yágüez L, et al. **Behav Brain Res** 1999 Jul;102(1-2):115-27

Episodic retrieval activates the precuneus irrespective of the imagery content of word pair associates. A PET study. Krause BJ, et al. **Brain** 1999 Feb;122 (Pt 2):255-63

Corticospinal excitability modulation to hand muscles during movement imagery. Rossini PM, et al. **Cereb Cortex** 1999 Mar;9(2):161-7

Active and passive scene recognition across views. Wang RF, et al. **Cognition** 1999 Mar 1;70(2):191-210

Facilitation of motor evoked potentials (MEPs) in first dorsal interosseous (FDI) muscle is dependent on different motor images. Yahagi S, et al. **Electroencephalogr Clin Neurophysiol** 1998 Oct; 109(5):409-17

Autonomic nervous system responses correlate with mental rehearsal in volleyball training. Roure R, et al. **Eur J Appl Physiol** 1998 Jul;78(2):99-108

Dynamic changes in corticospinal excitability during motor imagery. Hashimoto R, et al. **Exp Brain Res** 1999 Mar; 125(1):75-81

Ataxia reflected in the simulated movements of patients with cerebellar lesions. Kagerer FA, et al. **Exp Brain Res** 1998 Jul;121(2):125-34

Separability of EEG signals recorded during right and left motor imagery using adaptive autoregressive parameters. Pfurtscheller G, et al. **IEEE Trans Rehabil Eng** 1998 Sep; 6(3):316-25

Fear-relevant images as conditioned stimuli for somatic complaints, respiratory behavior, and reduced end-tidal pCO2. Stegen K, et al. **J Abnorm Psychol** 1999 Feb; 108(1):143-52

Enhancement of left-right sensorimotor EEG differences during feedback-regulated motor imagery. Neuper C, et al. **J Clin Neurophysiol** 1999 Jul;16(4):373-82

Patterns of brain activity during visual imagery of letters. Raij T. **J Cogn Neurosci** 1999 May;11(3):282-99

Mental rotation and temporal contingencies. Cohen DJ, et al. **J Exp Anal Behav** 1998 Sep;70(2):203-14

Memory representation of alphabetic position and interval information. Jou J, et al. **J Exp Psychol Learn Mem Cogn** 1999 May;25(3):680-701

The origin of confabulations [news; comment] Shallice T. **Nat Neurosci** 1999 Jul;2(7):588-90. Comment on: Nat Neurosci 1999 Jul;2(7):677-81.

Hypothetical neural mechanism that may play a role in mental rotation: an attractor neural network model. Benusková L, et al. **Network** 1998 Nov;9(4):513-30

Reopening the mental imagery debate: lessons from functional anatomy. Mellet E, et al. **Neuroimage** 1998 Aug; 8(2):129-39 (90 ref.)

Asymmetries between dominant and non-dominant hands in real and imagined motor task performance. Maruff P, et al. **Neuropsychologia** 1999 Mar;37(3):379-84

Human primary visual cortex and lateral geniculate nucleus activation during visual imagery. Chen W, et al. **Neuroreport** 1998 Nov 16;9(16):3669-74

Event-related potentials during mental imagery. Yamamoto S, et al. **Neuroreport** 1998 Oct 26;9(15):3359-62

EEG frequency ranges during perception and mental rotation of two- and three-dimensional objects. Nikolaev AR, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):670-7

Visually guided motor imagery activates sensorimotor areas in humans. Pfurtscheller G, et al. **Neurosci Lett** 1999 Jul 16;269(3):153-6

Differences in spatial visualization as a function of scores on hemisphericity of mathematics teachers. Hassan MM, et al. **Percept Mot Skills** 1999 Apr;88(2):387-90

Autonomic physiological activity in mental rotation tasks. Kalamas AD, et al. **Percept Mot Skills** 1999 Feb; 88(1):211-4

Covert neuromuscular activity of the dominant forearm during visualization of a motor task. Livesay JR, et al. **Percept Mot Skills** 1998 Apr;86(2):371-4

Searching for impossible objects: processing form and attributes in early vision. Donnelly N, et al. **Percept Psychophys** 1999 May;61(4):675-90

Imagery quality estimated by autonomic response is correlated to sporting performance enhancement. Roure R, et al. **Physiol Behav** 1999 Mar;66(1):63-72

On separating processes of event categorization, task preparation, and mental rotation proper in a handedness recognition task. Bajrič J, et al. **Psychophysiology** 1999 May;36(3):399-408

How body asymmetries determine accessibility in spatial

frameworks. Bryant DJ, et al. **Q J Exp Psychol A** 1999 May;52(2):487–508

Recognizing unfamiliar faces: the effects of distinctiveness and view. Newell FN, et al. **Q J Exp Psychol A** 1999 May; 52(2):509–34

Shedding light on visual imagination [news; comment] Barinaga M. **Science** 1999 Apr 2;284(5411):22. Comment on: Science 1999 Apr 2;284(5411):167–70.

The role of area 17 in visual imagery: convergent evidence from PET and rTMS [see comments] [published erratum appears in Science 1999 May 7;284(5416):197] Kosslyn SM, et al. **Science** 1999 Apr 2;284(5411):167–70. Comment in: Science 1999 Apr 2;284(5411):22.

IMAGING, DIAGNOSTIC see **DIAGNOSTIC IMAGING**

IMAGING, MEDICAL see **DIAGNOSTIC IMAGING**

IMAGING TECHNIQUES see **DIAGNOSTIC IMAGING**

IMECROMONE see **HYMECROMONE**

IMIDAMINE see **ANTAZOLINE**

IMIDATES see **IMIDOESTERS**

IMIDAZOLES

Anesthesia of horses with a combination of detomidine, zolazepam, tiletamine, and isoflurane immediately after strenuous treadmill exercise. Rankin DC, et al. **Am J Vet Res** 1999 Jun;60(6):743–8

Proceedings of the 3rd International Symposium on Imidazoline Receptors. Bonn, Germany, July 22–24, 1998. **Ann N Y Acad Sci** 1999 Jun 21;881:1–454

Two types of electrochemical nitric oxide (NO) sensing systems with heat–denatured Cyt C and radical scavenger PTIO. Haruyama T, et al. **Biosens Bioelectron** 1998 Oct 1;13(7–8):763–9

Proteome analysis of polyacrylamide gel–separated proteins visualized by reversible negative staining using imidazole–zinc salts. Castellanos–Serra L, et al. **Electrophoresis** 1999 Apr–May;20(4–5):732–7

Understanding the mechanism of the zinc–ion stains of biomacromolecules in electrophoresis gels: generalization of the reverse–staining technique. Fernandez–Patron C, et al. **Electrophoresis** 1998 Oct;19(14):2398–406

Anesthetic and cardiorespiratory effects of tiletamine–zolazepam–medetomidine in cheetahs. Deem SL, et al. **J Am Vet Med Assoc** 1998 Oct 1;213(7):1022–6

Imidazoline Receptor Workshop. Melbourne, Australia, 10 September 1997. Proceedings. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):73–219

Effects of imidacloprid on adult and larval stages of the flea Ctenocephalides felis after in vivo and in vitro application: a light– and electron–microscopy study. Mehlhorn H, et al. **Parasitol Res** 1999 Aug;85(8–9):625–37

[Imidazole compounds simulated active center of ribonuclease A. Synthesis and RNA cleaving activity] Sil'nikov VN, et al. **Dokl Akad Nauk** 1999 Feb;364(5):690–4 **(Rus)**

ADMINISTRATION & DOSAGE

Dexmedetomidine failed to block the acute hyperdynamic response to electroconvulsive therapy. Fu W, et al. **Anesthesiology** 1999 Feb;90(2):422–4

Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Sega R. **Blood Press** 1999;8(2):114–21

Single infusion of zoledronate in Paget's disease of bone: a placebo–controlled, dose–ranging study. Buckler H, et al. **Bone** 1999 May;24(5 Suppl):81S–85S

The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Kuijpers AL, et al. **Br J Dermatol** 1998 Sep;139(3):380–9

Central moxonidine on water and NaCl intake. Menani JV, et al. **Brain Res Bull** 1999 Jul 1;49(4):273–9

Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure. Shen YT, et al. **Cardiovasc Res** 1998 Aug;39(2):413–22

Combined effects of a mechanical nasal dilator and a topical decongestant on nasal airflow resistance. Lorino AM, et al. **Chest** 1999 Jun;115(6):1514–8

Phase II study of liarozole in advanced non–small cell lung cancer. O'Byrne KJ, et al. **Eur J Cancer** 1998 Aug; 34(9):1463–6

Design and characterization of a surfactant–enriched tablet formulation for oral delivery of a poorly water–soluble immunosuppressive agent. Ruddy SB, et al. **Int J Pharm** 1999 May 25;182(2):173–86

A dose–finding study of zoledronate in hypercalcemic cancer patients. Body JJ, et al. **J Bone Miner Res** 1999 Sep; 14(9):1557–61

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. Hedner T, et al. **J Hypertens** 1999 Jan;17(1):129–36

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. Puig JG, et al. **J Hypertens** 1999 Jul;17(7):1033–9

Effects of chronic oral treatment with imidapril and TCV–116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Tsuchihashi T, et al. **J Hypertens** 1999 Jul;17(7):917–22

Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. Podworny NV, et al. **J Rheumatol** 1999 Sep;26(9):1972–82

Intracellular application of calmidazolium increases Ca2+ current through activation of protein kinase A in cultured vascular smooth muscle cells. Sunagawa M, et al. **J Vasc Res** 1998 Sep–Oct;35(5):303–9

Systemic administration of atipamezole, a selective antagonist of alpha–2 adrenoceptors, facilitates behavioural activity but does not influence short–term or long–term memory in trimethyltin–intoxicated and control rats. Niittykoski M, et al. **Neurosci Biobehav Rev** 1998 Oct;22(6):735–50

Nasal flow limitation in children. Pickering DN, et al. **Pediatr Pulmonol** 1999 Jan;27(1):32–6

[Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting] Marui A, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1112–6 (Eng. Abstr.) **(Jpn)**

[Decongesting effect of tramazoline on nasal airway patency and nasal symptoms as evaluated by acoustic rhinometry: an objective study in 30 allergic and six non–allergic subjects] Takeno S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1998 Jul;101(7):900–7 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Shusterman NH. **Am Heart J** 1999 Sep; 138(3 Pt 2):238–45 (28 ref.)

DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary–relevant dose of 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine. Dingley KH, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jun;8(6):507–12

Allergic contact dermatitis from dimethyl–oxo–propenyl–phenyl–imidazoline. English JS, et al. **Contact Dermatitis** 1998 Nov;39(5):270

Contact dermatitis from clotrimazole with positive patch–test reactions also to croconazole and itraconazole. Erdmann S, et al. **Contact Dermatitis** 1999 Jan;40(1):47–8

Allergic contact dermatitis from goldenrod (Herba solidaginis) after systemic administration. Schätzle M, et al. **Contact Dermatitis** 1998 Nov;39(5):271–2

Polycyclic aromatic hydrocarbons and heterocyclic amines in the diet: the role of red meat. Baghurst PA. **Eur J Cancer Prev** 1999 Jul;8(3):193–9

A review of the safety and tolerability of sertindole. Hale AS. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S65–70 (22 ref.)

Prolonged nocturnal penile tumescence caused by epinastine. Yamanaka M, et al. **Int J Urol** 1999 Mar;6(3):162–3

Dermatosis and associated systemic signs in a cat with thymoma and recently treated with an imidacloprid preparation. Godfrey DR. **J Small Anim Pract** 1999 Jul; 40(7):333–7

Mammary gland carcinogenicity of 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine in Sprague–Dawley rats on high– and low–fat diets. Snyderwine EG, et al. **Nutr Cancer** 1998;31(3):160–7

Safety and tolerability of eprosartan. Gavras I, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):102S–107S (28 ref.)

Efficacy and extrapyramidal side–effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta–analysis of randomized controlled trials. Leucht S, et al. **Schizophr Res** 1999 Jan 4;35(1):51–68

[Cibenzoline–induced acute hepatitis (letter)] Caroli–Bosc FX, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):106–7 **(Fre)**

[Hypoglycemia due to cibenzoline: role of hyperinsulinism (letter)] Yazbeck R, et al. **Presse Med** 1999 May 22–29; 28(19):1017–8 **(Fre)**

[Loss of consciousness during treatment with sertindole] Haberfellner EM. **Psychiatr Prax** 1999 May;26(3):150 **(Ger)**

ANALYSIS

Residue analysis of imazapyr and chlozolinate in water using sunlight. Santoro A, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):33–8

Immunohistochemical detection of imidazolone and N(epsilon)–(carboxymethyl)lysine in aortas of hemodialysis patients. Takayama F, et al. **Cell Mol Biol (Noisy–le–grand)** 1998 Nov;44(7):1101–9

DNA adducts of 2,3–epoxy–4–hydroxynonanal: detection of 7–(1', 2'–dihydroxyheptyl)–3H–imidazo[2,1–i]purine and 1,N6–ethenoadenine by gas chromatography/negative ion chemical ionization/mass spectrometry. Chen HJ, et al. **Chem Res Toxicol** 1998 Dec;11(12):1474–80

Heterocyclic amine levels in cooked meat and the implication for New Zealanders. Thomson B. **Eur J Cancer Prev** 1999 Jul;8(3):201–6

Histochemical staining of chromium with 2–(8–quinolylazo)–4,5–di–p–tolylimidazole. Sumi Y, et al. **Eur J Histochem** 1998;42(4):271–6

Development of monoclonal antibodies to gizzerosine, a toxic component present in fish meal. Becker MI, et al. **Hybridoma** 1998 Aug;17(4):373–81

Determination of glycarbylamide in chicken tissue by high–performance liquid chromatography. Yamamoto Y, et al. **J AOAC Int** 1999 Mar–Apr;82(2):248–50

Capillary electrophoresis determinative and LC–MS confirmatory method for screening selected imidazolinone herbicides from soil. Nejad H, et al. **J Capillary Electrophor** 1998 Jan–Apr;5(1–2):81–7

Development of a sensitive and quantitative analytical method for 1H–4–substituted imidazole histamine H3–receptor antagonists utilizing high–performance liquid chromatography and dabsyl derivatization. Handley MK, et al. **J Chromatogr B Biomed Sci Appl** 1998 Sep 25; 716(1–2):239–49

Determination of imidazole antimycotics in creams by supercritical fluid extraction and derivative UV spectroscopy. Bonazzi D, et al. **J Pharm Biomed Anal** 1998 Oct;18(1–2):235–40

ANTAGONISTS & INHIBITORS

1,5–Bis(4–amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites. Wood DH, et al. **Eur J Pharmacol** 1998 Jul 17; 353(1):97–103

BLOOD

In vivo human metabolism of [2–14C]2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP). Lang NP, et al. **Cancer Lett** 1999 Sep 1;143(2):135–8

Identification of 6–methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography–mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Dervieux T, et al. **Clin Chem** 1998 Dec; 44(12):2511–5

CHEMICAL SYNTHESIS

Glycine derivatives of imidazolones as potential ligands of glycine binding site of NMDA receptors. Part I. Kieć–Kononowicz K, et al. **Acta Pol Pharm** 1998 Sep–Oct; 55(5):381–8

Structure and activity studies on glycine receptor ligands. Part 5. Diphenyl imidazolin–4–one glycinamides. Kieć–Kononowicz K, et al. **Acta Pol Pharm** 1998 Sep–Oct; 55(5):389–96

Novel selective compounds for the investigation of imidazoline receptors. Hudson AL, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:81–91

Imidazo[1,5–b]pyridazine–d4T conjugates: synthesis and anti–human immunodeficiency virus evaluation. Renoud–Grappin M, et al. **Antivir Chem Chemother** 1998 May;9(3):205–23

Synthesis and positive inotropic effects of 1–acyl–5,6–diethoxy–2–methylthiobenzimidazoles. Garalienė V, et al. **Arzneimittelforschung** 1998 Dec; 48(12):1137–42

Synthesis and antimuscarinic activity of a series of 4–(1–Imidazolyl)–2,2–diphenylbutyramides: discovery of potent and subtype–selective antimuscarinic agents. Miyachi H, et al. **Bioorg Med Chem** 1999 Jun;7(6):1151–61

Synthesis and biological evaluation of novel 2–deoxy–4–thio–imidazole nucleosides. Wang Y, et al. **Bioorg Med Chem** 1999 Mar;7(3):481–7

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Adams JL, et al. **Bioorg Med Chem Lett** 1998 Nov 17;8(22):3111–6

4–[(1H–imidazol–4–yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor. Aslanian R, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2263–8

Synthesis of an imidazo[1,2–e]purine–acridine heterodimer for targeting abasic sites in DNA. Belmont P, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):233–6

Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology. Freyne E, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):267–72

C32–O–imidazol–2–yl–methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential. Goulet MT, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2253–8

Synthesis of 13C–dehydrocoelenterazine and model studies on Symplectoteuthis squid bioluminescence. Isobe M, et al. **Bioorg Med Chem Lett** 1998 Oct 20;8(20):2919–24

Synthesis and antitumor activity of 4–phenyl–1–arylsulfonyl imidazolidinones. Jung SH, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1547–50

Alkylation of succinates: synthesis of Ro 32–3555. McClure KF, et al. **Bioorg Med Chem Lett** 1998 Jan 20;8(2):143–6

Novel imidazole derivatives with subtype–selective antimuscarinic activity (2). Miyachi H, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2163–8

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides. Naylor EM, et al. **Bioorg Med Chem Lett** 1999 Mar 8; 9(5):755–8

From histamine to imidazolylalkyl–sulfonamides: the design of a novel series of histamine H3–receptor antagonists. Tozer MJ, et al. **Bioorg Med Chem Lett** 1999 Jul 5;

9(13):1825–30

Syntheses and analgesic activities of some 2-substituted-4,5-diphenyl and 1,2-disubstituted-4,5-diphenyl imidazole derivatives. Işikdağ I, et al. **Boll Chim Farm** 1999 Jan;138(1):24–9

Optically active antifungal azoles. VIII. Synthesis and antifungal activity of 1-[(1R,2R)-2-(2,4-difluoro- and 2-fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- 3-(4-substituted phenyl)-2(1H,3H)-imidazolones and 2-imidazolidinones. Kitazaki T, et al. **Chem Pharm Bull (Tokyo)** 1999 Mar; 47(3):351–9

N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin: synthesis, chemical and enzymatic stability studies. Bak A, et al. **Eur J Pharm Sci** 1999 Mar;7(4):317–23

Synthesis and antimicrobial activity of substituted imidazolidinediones and thioxoimidazolidinones. Albuquerque JF, et al. **Farmaco** 1999 Jan–Feb; 54(1–2):77–82

Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. Ali SM, et al. **J Med Chem** 1999 Mar 11;42(5):903–9

Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase. Anthony NJ, et al. **J Med Chem** 1999 Aug 26;42(17):3356–68

DNA-Directed alkylating agents. 7. Synthesis, DNA interaction, and antitumor activity of bis(hydroxymethyl)- and bis(carbamate)-substituted pyrrolizines and imidazoles. Atwell GJ, et al. **J Med Chem** 1998 Nov 19;41(24):4744–54

1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels. Carling RW, et al. **J Med Chem** 1999 Jul 15;42(14):2706–15

Synthesis of imidazo[1,2-a]pyridines as antiviral agents. Gueiffier A, et al. **J Med Chem** 1998 Dec 3;41(25):5108–12

Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. Jacobsen EJ, et al. **J Med Chem** 1999 Apr 8;42(7):1123–44

Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives. Kovalainen JT, et al. **J Med Chem** 1999 Apr 8;42(7):1193–202

4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity. Krause M, et al. **J Med Chem** 1998 Oct 8;41(21):4171–6

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl) piperazines and isosteric analogues of imidazoline. Le Bihan G, et al. **J Med Chem** 1999 May 6;42(9):1587–603

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. Liverton NJ, et al. **J Med Chem** 1999 Jun 17;42(12):2180–90

Synthesis of 2,8-disubstituted imidazo[1,5-a]pyrimidines with potent antitumor activity. Matsumoto H, et al. **J Med Chem** 1999 May 6;42(9):1661–6

Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl) -N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor. Moloney GP, et al. **J Med Chem** 1999 Jul 15;42(14):2504–26

2-(2-Phenylcyclopropyl)imidazolines: reversed enantioselective interaction at I(1) and I(2) imidazoline receptors. Quaglia W, et al. **J Med Chem** 1999 Jul 29; 42(15):2737–40

Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. Vasudevan A, et al. **J Med Chem** 1999 Apr 22;42(8):1333–40

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity. Williams TM, et al. **J Med Chem** 1999 Sep 23;42(19):3779–84

Synthesis and cytotoxicity of 2-methyl-4, 9-dihydro-1-substituted-1H-imidazo[4,5-g]quinoxaline-4,9-diones and 2,3-disubstituted-5,10-pyrazino[2,3-g]quinoxalinediones. Yoo HW, et al. **J Med Chem** 1998 Nov 19;41(24):4716–22

Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. Tedford CE, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1160–8

Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands. Yates SL, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1151–9

Synthesis, spectral and antimicrobial properties of 5-chloroarylidene aromatic derivatives of imidazoline-4-one. Kieć-Kononowicz K, et al. **Pharmazie** 1998 Oct;53(10):680–4

[SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series] Bonnet PA, et al. **Ann Pharm Fr** 1998;56(4):155–9 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Symmetry breaking during the formation of beta-cyclodextrin-imidazole inclusion compounds: capillary electrophoresis study. Guillaume YC, et al. **Anal Chem** 1999 May 15;71(10):2046–52

Imidazolyl carboxylic acids as mechanistic probes of flavocytochrome P-450 BM3. Noble MA, et al. **Biochemistry** 1998 Nov 10;37(45):15799–807

D221 in thymidylate synthase controls conformation change, and thereby opening of the imidazolidine. Sage CR, et al. **Biochemistry** 1998 Sep 29;37(39):13893–901

Differential pulse polarography and electron spin resonance spectroscopy of nitroxyl free radicals used as ESR-spin probes. Kroll C, et al. **Bioelectrochem Bioenerg** 1999 Feb; 48(1):233–6

Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units. Angiolini M, et al. **Bioorg Med Chem** 1998 Nov;6(11):2013–27

Quantitative structure-activity relationship studies on some nonbenzodiazepine series of compounds acting at the benzodiazepine receptor. Gupta SP, et al. **Bioorg Med Chem** 1998 Nov;6(11):2213–8

Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Lee YS, et al. **Bioorg Med Chem** 1998 Oct; 6(10):1811–9

Molecular structure and stereoelectronic properties of sarmazenil--a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors): comparison with bretazenil and flumazenil. López-Romero B, et al. **Bioorg Med Chem** 1998 Oct;6(10):1745–57

Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models. Pigini M, et al. **Bioorg Med Chem** 1998 Dec; 6(12):2245–60

Analogues of 4,5-bis(3,5-dichlorophenyl)-2-trifluoromethyl-1H-imidazole as potential antibacterial agents. Antolini M, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1023–8

Synthesis of an imidazo[1,2-e]purine-acridine heterodimer for targeting abasic sites in DNA. Belmont P, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):233–6

Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands. Cordi A, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1409–14

Parallel synthesis of 1,2,4-oxadiazoles using CDI activation. Deegan TL, et al. **Bioorg Med Chem Lett** 1999 Jan 18; 9(2):209–12

Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors. Ho GD, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):7–12

2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. Parveen I, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2031–6

State of imidazole side chain of hen lysozyme modified with histamine and Japanese quail lysozyme. A study by immobilized metal ion affinity chromatography. Fukamizo T. **Biosci Biotechnol Biochem** 1998 Nov;62(11):2239–41

Heterocyclic amine formation and the impact of structure on their mutagenicity. Felton JS, et al. **Cancer Lett** 1999 Sep 1;143(2):127–34

Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. Chan SL, et al. **Eur J Pharmacol** 1998 Aug 14;355(1):67–76

Quantitative structure-activity relationship of 4,5-diphenyl-2-(substituted thio)-1H-imidazoles as the inhibitors of acyl CoA: cholesterol acyltransferase. Singh P, et al. **Indian J Biochem Biophys** 1998 Jun;35(3):179–83

Imidazole binding to Rhodobacter capsulatus cytochrome c2. Effect of site-directed mutants on ligand binding. Dumortier C, et al. **J Biol Chem** 1998 Oct 2; 273(40):25647–53

The local minima method (LMM) of pharmacophore determination: a protocol for predicting the bioactive conformation of small, conformationally flexible molecules. Demeter DA, et al. **J Chem Inf Comput Sci** 1998 Nov-Dec; 38(6):1125–36

Preparation of an IMI dye (imidazole functional group) containing a 4-(N,N-dimethylaminosulfonyl)-2,1,3-benzoxadiazole fluorophore for labeling of phosphomonoesters. Lan ZH, et al. **J Chromatogr A** 1999 Jan 29;831(2):325–30

Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis(imidazol)ruthenate(III)]. Trynda-Lemiesz L, et al. **J Inorg Biochem** 1999 Mar; 73(3):123–8

Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. Eriksson MA, et al. **J Med Chem** 1999 Mar 11;42(5):868–81

Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. Smith RH Jr, et al. **J Med Chem** 1998 Dec 17;41(26):5272–86

Novel 2-phenylimidazo[1,2-a]pyridine derivatives as potent and selective ligands for peripheral benzodiazepine receptors: synthesis, binding affinity, and in vivo studies. Trapani G, et al. **J Med Chem** 1999 Sep 23;42(19):3934–41

Investigation of the polymorphism of the angiotensin II antagonist agent MK-996. Jahansouz H, et al. **Pharm Dev Technol** 1999 May;4(2):181–7

Structural determination of metabolites of S-1153, a new, potent, non-nucleoside, anti-HIV agent in rat liver microsomes. Ohkawa T, et al. **Xenobiotica** 1998 Sep; 28(9):877–86

CLASSIFICATION

Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Kodama I, et al. **Jpn Circ J** 1999 Jan;63(1):1–12 (126 ref.)

DIAGNOSTIC USE

Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia. Yamamoto F, et al. **Biol Pharm Bull** 1999 Jun;22(6):590–7

ISOLATION & PURIFICATION

High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Roberge M, et al. **Cancer Res** 1998 Dec 15;58(24):5701–6

Separation and quantitation of azimilide and its putative metabolites by capillary electrophoresis. Bao JJ, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1–2):129–40

METABOLISM

Imidazoline (I2) binding sites in chicken brain. Danbury TC, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:189–92

Evidence for presynaptic high affinity imidazoline-specific binding sites in the bovine brainstem. Heemskerk FM, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:185–8

Imidazoline binding domains on MAO-B. Localization and accessibility. Raddatz R, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:26–31 (17 ref.)

The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Frantz B, et al. **Biochemistry** 1998 Sep 29;37(39):13846–53

Imidazole is a sensitive probe of steric hindrance in the distal pockets of oxygen-binding heme proteins. Mansy SS, et al. **Biochemistry** 1998 Sep 8;37(36):12452–7

Ligand binding to the serotonin 5HT3 receptor studied with a novel fluorescent ligand. Tairi AP, et al. **Biochemistry** 1998 Nov 10;37(45):15850–64

Retention mechanism of imidazoles in connective tissue. IV. Identification of a nucleophilic imidazolone metabolite in rats. Ohta K, et al. **Biol Pharm Bull** 1998 Dec;21(12):1334–7

Retention mechanism of imidazoles in connective tissue. III. Aldehyde adduct formation of a 4(5H)(or5(4H))-imidazolone product in vitro. Ohta K, et al. **Biol Pharm Bull** 1998 Sep;21(9):958–63

Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Lee YS, et al. **Bioorg Med Chem** 1998 Oct; 6(10):1811–9

2-nitroimidazol-5-ylmethyl as a potential bioreductively activated prodrug system: reductively triggered release of the PARP inhibitor 5-bromoisoquinolinone. Parveen I, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2031–6

Influence of antiresorptive agent OST-766 on signal transduction pathways involved in parathyroid hormone action. Morris SA, et al. **Calcif Tissue Int** 1999 Feb; 64(2):148–53

DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Dingley KH, et al. **Cancer Epidemiol Biomarkers Prev** 1999 Jun;8(6):507–12

Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Garner RC, et al. **Cancer Lett** 1999 Sep 1;143(2):161–5

Involvement of free radicals in the formation of heterocyclic amines and prevention by antioxidants. Kikugawa K. **Cancer Lett** 1999 Sep 1;143(2):123–6

Detoxification of carcinogenic aromatic and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative. King RS, et al. **Cancer Lett** 1999 Sep 1; 143(2):167–71

Interspecies differences in metabolism of heterocyclic aromatic amines by rat and human P450 1A2. Turesky RJ, et al. **Cancer Lett** 1999 Sep 1;143(2):109–12

Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Turteltaub KW, et al. **Cancer Lett** 1999 Sep 1;143(2):149–55

Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Crofts FG, et al. **Carcinogenesis** 1998 Nov;19(11):1969–73

Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Lewis AJ, et al. **Carcinogenesis** 1998 Nov;19(11):2049–53

Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Nowell SA, et al.

Carcinogenesis 1999 Jun;20(6):1107–14

N–Acetyltransferase expression and DNA binding of N–hydroxyheterocyclic amines in human prostate epithelium. Wang CY, et al. **Carcinogenesis** 1999 Aug; 20(8):1591–5

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E–3174 [clinical conference] McCrea JB, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):348–52

In vivo studies of gene expression via transient transgenesis using lipid–DNA delivery. McClarrinon M, et al. **DNA Cell Biol** 1999 Jul;18(7):533–47

Characterisation and localisation of [3H]2–(2–benzofuranyl)–2–imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. Lione LA, et al. **Eur J Pharmacol** 1998 Jul 17;353(1):123–35

LK 204–545, a highly selective beta1–adrenoceptor antagonist at human beta–adrenoceptors. Louis SN, et al. **Eur J Pharmacol** 1999 Feb 19;367(2–3):431–5

Affinity isolation of imidazoline binding proteins from rat brain using 5–amino–efaroxan as a ligand. Monks LK, et al. **FEBS Lett** 1999 Mar 19;447(1):61–4

Dietary omega–3 fatty acids as potential inhibitors of carcinogenesis: effect on DNA adduct formation of 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP) in mice and rats. Josyula S, et al. **Food Chem Toxicol** 1999 Apr;37(4):287–96

Imidazoline binding sites and receptors in cardiovascular tissue. Molderings GJ, et al. **Gen Pharmacol** 1999 Jan; 32(1):17–22 (53 ref.)

Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1–imidazoline receptors. Ernsberger P. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):147–54

Does a second generation of centrally acting antihypertensive drugs really exist? Feldman J, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):94–7 (42 ref.)

Relationship between imidazoline and alpha2–adrenoceptors involved in the sympatho–inhibitory actions of centrally acting antihypertensive agents. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):163–9 (40 ref.)

Recent advances in imidazoline receptor research: ligands––localization and isolation––signaling––functional and clinical studies. Head GA, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):74–9 (50 ref.)

Pharmacology and subcellular distribution of [3H]rilmenidine binding sites in rat brain. Hosseini AR, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):129–36

Characterization of a partial cDNA clone detected by imidazoline receptor–selective antisera. Ivanov TR, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):98–110

[3H]Rilmenidine–labelled imidazoline–receptor binding sites co–localize with [3H]2–(benzofuranyl)–2–imidazoline–labelled imidazoline–receptor binding sites and monoamine oxidase–B in rabbit, but not rat, kidney. King PR, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):118–28

Investigation of I1–imidazoline receptors using microphysiometry and molecular modelling. Musgrave IF, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):137–46

Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. Reis DJ, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):80–5 (26 ref.)

Characterization of [3H]idazoxan binding proteins in solubilized membranes from rabbit and human liver. Remaury A, et al. **J Auton Nerv Syst** 1998 Oct 15; 72(2–3):111–7

Imidazoline receptor mediated natriuresis: central and/or peripheral effect? Smyth DD, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2–3):155–62

Glu–857 moderates K+–dependent stimulation and SCH 28080–dependent inhibition of the gastric H,K–ATPase. Rulli SJ, et al. **J Biol Chem** 1999 May 21;274(21):15245–50

Structure and mechanism of formation of human lens fluorophore LM–1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis. Tessier F, et al. **J Biol Chem** 1999 Jul 23;274(30):20796–804

The binding of imidazole in an azurin–like blue–copper site. van Gastel M, et al. **J Biol Inorg Chem** 1999 Jun;4(3):257–65

Molecular characterization and imidacloprid selectivity of nicotinic acetylcholine receptor subunits from the peach–potato aphid Myzus persicae. Huang Y, et al. **J Neurochem** 1999 Jul;73(1):380–9

Moxonidine, a selective alpha2–adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. Fairbanks CA, et al. **J Pharmacol Exp Ther** 1999 Jul; 290(1):403–12

Do alpha 2–adrenoceptors and imidazoline binding sites coexist in the human term placenta? Evidence from direct binding studies. Bagaméry K, et al. **Mol Hum Reprod** 1998 Apr;4(4):387–91

Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Sastre–Coll A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jul; 360(1):50–62

Potential role for imidazole in the rhythmic respiratory activity of the in vitro neonatal rat brainstem. Krause WL, et al. **Neurosci Lett** 1998 Jul 31;251(3):153–6

Effects of chemoprotective agents on the metabolic activation of the carcinogenic arylamines PhIP and 4–aminobiphenyl in human and rat liver microsomes. Hammons GJ, et al. **Nutr Cancer** 1999;33(1):46–52

Effects of dietary conjugated linoleic acid on DNA adduct formation of PhIP and IQ after bolus administration to female F344 rats. Josyula S, et al. **Nutr Cancer** 1998; 32(3):139–45

Inhibition of DNA adduct formation of PhIP in female F344 rats by dietary conjugated linoleic acid. Josyula S, et al. **Nutr Cancer** 1998;32(3):132–8

Bioactivation of the proximal food mutagen 2–hydroxyamino–1–methyl–6–phenylimidazo[4,5–b]pyridine (N–OH–PhIP) to DNA–binding species by human mammary gland enzymes [see comments] Dubuisson JG, et al. **Nutrition** 1998 Sep;14(9):683–6. Comment in: Nutrition 1998 Sep;14(9):710–2.

Effects of moxonidine and clonidine on potassium excretion in Sprague–Dawley rats. Hohage H, et al. **Pharmacol Res** 1999 May;39(5):357–61

Imidazole rescue of a cytosine mutation in a self–cleaving ribozyme [see comments] Perrotta AT, et al. **Science** 1999 Oct 1;286(5437):123–6. Comment in: Science 1999 Oct 1;286(5437):61–2.

Use of polyclonal antibodies against carcinogen–DNA adducts in analysis of carcinogenesis. Shirai T, et al. **Toxicol Lett** 1998 Dec 28;102–103:441–6

Structural determination of metabolites of S–1153, a new, potent, non–nucleoside, anti–HIV agent in rat liver microsomes. Ohkawa T, et al. **Xenobiotica** 1998 Sep; 28(9):877–86

[Direct detoxification of N–acetoxy–PhIP by tea polyphenols: a possible mechanism for chemoprevention against PhIP–DNA adduct formation in vivo] Lin D, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep; 32(5):265–9 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

alpha–2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Khan ZP, et al. **Anaesthesia** 1999 Feb;54(2):146–65 (215 ref.)

Imidazoline (I2) binding sites in chicken brain. Danbury TC, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:189–92

Endogenous indoleamines demonstrate moderate affinity for I2 binding sites. Hudson AL, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:212–6

Novel selective compounds for the investigation of imidazoline receptors. Hudson AL, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:81–91

Pharmacologic and molecular discrimination of I2–imidazoline receptor subtypes. Olmos G, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:144–60

Comparison of crude methanolic CDS extracts from various tissues. Parker CA, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:92–6

Binding of tracizolines to the imidazoline receptor. Role of lipophilicity in quantitative structure–activity relationship models. Pigini M, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:118–22

Binding of the imidazoline ligand 3H–2–benzofuranyl–2–imidazoline (BFI) to human brain and platelets. Potentiation by tranylcypromine and role of MAO isoforms. Steinberg MI, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:193–8

Central I1–imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

Retention mechanism of imidazoles in connective tissue. IV. Identification of a nucleophilic imidazolone metabolite in rats. Ohta K, et al. **Biol Pharm Bull** 1998 Dec;21(12):1334–7

Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Corey A, et al. **Biopharm Drug Dispos** 1999 Mar;20(2):59–68

Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Tenero D, et al. **Biopharm Drug Dispos** 1998 Sep;19(6):351–6

Effect of age and gender on the pharmacokinetics of eprosartan. Tenero DM, et al. **Br J Clin Pharmacol** 1998 Sep;46(3):267–70

Activation of heterocyclic amines by combinations of prostaglandin H synthase–1 and –2 with N–acetyltransferase 1 and 2. Liu Y, et al. **Cancer Lett** 1998 Nov 13;133(1):115–23

Immunohistochemical demonstration of carcinogen–DNA adducts in tissues of rats given 2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine (PhIP): detection in paraffin–embedded sections and tissue distribution. Takahashi S, et al. **Cancer Res** 1998 Oct 1; 58(19):4307–13

The identification of [2–(14)C]2–amino–1–methyl–6–phenylimidazo[4,5–b]pyridine metabolites in humans. Malfatti MA, et al. **Carcinogenesis** 1999 Apr;20(4):705–13

Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose–escalation studies. Wong SL, et al. **J Pharm Sci** 1998 Dec;87(12):1629–31

Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. Karlsson MO, et al. **J Pharmacokinet Biopharm** 1998 Apr;26(2):207–46

Pharmacokinetics of medetomidine and atipamezole in dairy calves: an agonist–antagonist interaction. Ranheim B, et al. **J Vet Pharmacol Ther** 1998 Dec;21(6):428–32

Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD–94–1 study. Lahti RA, et al. **Mol Psychiatry** 1998 Nov;3(6):528–33

In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes. Zhang Y, et al. **Pharmacology** 1999 Mar;58(3):147–59

A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Blum RA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):79S–85S (23 ref.)

Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Bottorff MB, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):73S–78S (10 ref.)

Pharmacokinetics and protein binding of eprosartan in hemodialysis–dependent patients with end–stage renal disease. Kovacs SJ, et al. **Pharmacotherapy** 1999 May; 19(5):612–9

The renal profile of eprosartan. Sica DA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):86S–94S (42 ref.)

Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin–induced diabetes mellitus. Moon CH, et al. **Res Commun Mol Pathol Pharmacol** 1998 Aug; 101(2):147–58

Pharmacokinetics of medetomidine in ponies and elaboration of a medetomidine infusion regime which provides a constant level of sedation. Bettschart–Wolfensberger R, et al. **Res Vet Sci** 1999 Aug;67(1):41–6

[Chemoprotection by green tea against the formation of food–borne carcinogen 2–amino–1–methyl–6–phenylimidazo [4,5–b] pyridine (PhIP)–DNA adducts in rats] Lin D, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):261–4 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats. Zhang X, et al. **Acta Anaesthesiol Scand** 1998 Sep;42(8):1004–9

Spinal effects of the calmodulin inhibitor calmidazolium on dorsal horn neurons in the rat. Menéndez L, et al. **Acta Neurobiol Exp (Warsz)** 1999;59(1):31–5

Does thromboxane A2 synthase inhibitor UK–38485 prevent the vasoconstrictor effects of endothelin–1 on rabbit basilar artery? Baykaner MK, et al. **Acta Neurochir (Wien)** 1999; 141(3):279–85

Effects of dexmedetomidine on rat locus coeruleus and ethanol withdrawal symptoms during intermittent ethanol exposure. Riihioja P, et al. **Alcohol Clin Exp Res** 1999 Mar; 23(3):432–8

Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Martinek J, et al. **Aliment Pharmacol Ther** 1999 Jan; 13(1):27–34

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Brooks DP, et al. **Am Heart J** 1999 Sep;138(3 Pt 2):246–51 (53 ref.)

Effect of luminal angiotensin II receptor antagonists on proximal tubule transport. Quan A, et al. **Am J Hypertens** 1999 May;12(5):499–503

Comparison of sedative effects of romifidine following intravenous, intramuscular, and sublingual administration to horses. Freeman SL, et al. **Am J Vet Res** 1999 Aug; 60(8):954–9

Sedative effects of intramuscular administration of a low dose of romifidine in dogs. Lemke KA. **Am J Vet Res** 1999 Feb;60(2):162–8

Cardiorespiratory effects of a tiletamine/zolazepam–ketamine–detomidine combination in horses. Muir WW 3rd, et al. **Am J Vet Res** 1999 Jun; 60(6):770–4

The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats. Liu Q, et al. **Am Surg** 1999 Jul;65(7):611–6; discussion 617

Dexmedetomidine modulates cardiovascular responses to stimulation of central nervous system pressor sites. Farber NE, et al. **Anesth Analg** 1999 Mar;88(3):617–24

The effect of olprinone compared with milrinone on diaphragmatic muscle function in dogs. Fujii Y, et al. **Anesth Analg** 1999 Sep;89(3):781–5

The effects of clonidine and dexmedetomidine on human neutrophil functions. Nishina K, et al. **Anesth Analg** 1999 Feb;88(2):452–8

The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin–induced pain in rats. Nishiyama T, et al. **Anesth Analg** 1999 Jul;89(1):143–7

Intravenous dexmedetomidine inhibits cerebrovascular dilation induced by isoflurane and sevoflurane in dogs. Ohata H, et al. **Anesth Analg** 1999 Aug;89(2):370–7

Pretreatment with dexmedetomidine: altered indices of anesthetic depth for halothane in the neuraxis of cats. Schmeling WT, et al. **Anesth Analg** 1999 Mar;88(3):625–32

The effects of dexmedetomidine on neuromuscular blockade in human volunteers. Talke PO, et al. **Anesth Analg** 1999 Mar;88(3):633–9

Effect of moxonidine and cilazapril on microcirculation as assessed by finger nailfold capillaroscopy in mild–to–moderate hypertension. Martina B, et al. **Angiology** 1998 Nov;49(11):897–901

Attenuation of tolerance to opioid-induced antinociception by idazoxan and other I2-ligands. Boronat MA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:359-63

Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs. Bousquet P, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:272-8 (19 ref.)

An unexpected central hypertensive effect of the new imidazoline compound benazoline. Bruban V, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:102-5

Protection by imidazol(ine) compounds of L-glutamate neurotoxicity through NMDA receptor blockade. DeGregorio-Rocasolano N, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:452

Effects of imidazoline drugs on tyrosine and tryptophan hydroxylase activity in rat brain in vivo. Esteban S, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:358

Localization of the diuretic effect of moxonidine in the nephron by micropuncture experiments in anesthetized rats. Greven J, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:383-4

Moxonidine acting centrally inhibits airway reflex responses. Haxhiu MA, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:372-82

Dissociation of the effects of intramedullary monoamine neurotoxins on the hypotensive action of moxonidine and on immunodetected imidazoline and alpha 2-receptor proteins. Head GA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:300

Gene substitution/knockout to delineate the role of alpha 2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines. Hein L, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:265-71

Behavioral effects of RS-45041-190, a selective I2 imidazoline ligand, in rats. Jett MF, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:369-71

Structure of new imidazoline derivatives and their cardiovascular effect in rats. Krzystanek E, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:106-9

Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands. Lalies MD, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:114-7

Influence of sinoaortic barodenervation on the hypotensive effects of imidazoline-like drugs in stroke-prone spontaneously hypertensive rats. Medvedev OS, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:295-9

Imidazoline recognition sites and stomach function. Molderings GJ, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:332-43 (56 ref.)

Imidazolines and pancreatic hormone secretion. Morgan NG, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:217-28 (41 ref.)

The renal actions of moxonidine are mediated by atrial natriuretic peptide and involve the opioid receptors. Mukaddam-Daher S, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:385-7

Novel targets and techniques in imidazoline receptor research. Musgrave IF, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:301-12 (51 ref.)

Modulation of MAO activity by imidazoline and guanidine derivatives. Raasch W, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:313-31

Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Regunathan S, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:410-9

Imidazolines and the pancreatic B-cell. Actions and binding sites. Rustenbeck I, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:229-40

Effects of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) on dopamine synthesis in rat striatum in vivo. Sastre-Coll A, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:364

Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Smyth DD, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:344-57 (72 ref.)

Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine. Szabo B, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:253-64

Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels. Ugedo L, et al. **Ann N Y Acad Sci** 1999 Jun 21; 881:365-8

Different modes of action of the imidazoline compound RX871024 in pancreatic beta-cells. Blocking of K+ channels, mobilization of Ca2+ from endoplasmic reticulum, and interaction with exocytotic machinery. Zaitsev SV, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:241-52

alpha 2A-adrenoceptors, not I1-imidazoline receptors, mediate the hypotensive effects of rilmenidine and moxonidine in conscious mice. In vivo and in vitro studies. Zhu QM, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:287-9

In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Torres-Rodríguez JM, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1258-9

Inhibitory effect of 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1H - imidazole on HCMV DNA replication and permissive infection. Johnson RA, et al. **Antiviral Res** 1999 Apr; 41(3):101-11

Inhibitory action of YJA20379, a new proton pump inhibitor on Helicobacter pylori growth and urease. Woo TW, et al. **Arch Pharm Res** 1998 Feb;21(1):6-11

Investigation of serum minimal inhibitory concentrations of some benzimidazole, imidazole and benzothiazole derivatives and their effects on liver and renal functions. Durmaz R, et al. **Arzneimittelforschung** 1998 Dec; 48(12):1179-84

Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971. Hey JA, et al. **Arzneimittelforschung** 1998 Sep;48(9):881-8

Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation. Su J, et al. **Basic Res Cardiol** 1999 Apr; 94(2):128-35

Modeling study of some inhibitors of 17,20-lyase, a component of the enzyme 17 alpha-hydroxylase/17,20-lyase: a novel approach. Ahmed S, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):273-6

Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. Efanova IB, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):162-5

The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Keller D, et al. **Biochem Biophys Res Commun** 1999 Aug 2;261(2):464-71

Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Lal AS, et al. **Biochem Biophys Res Commun** 1999 Jun 7; 259(2):465-70

Synergistic inhibition of carboxypeptidase A by zinc ion and imidazole. Mock WL, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):239-43

The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Mukai E, et al. **Biochem Biophys Res Commun** 1998 Oct 20;251(2):477-81

Ca2+ mobilization in adult rat cardiomyocytes by angiotensin type 1 and 2 receptors. Shao Q, et al. **Biochem Pharmacol** 1998 May 1;55(9):1413-8

Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides. Dickinson LA, et al. **Biochemistry** 1999 Aug 17;38(33):10801-7

Inhibitory effects in vitro of S-[2-carboxy-1-(1H-imidazol-4-yl)ethyl]-glutathione, a proposed metabolite of L-histidine, on gamma-glutamyltransferase activity. Shimizu H, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):112-8

Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models. Pigini M, et al. **Bioorg Med Chem** 1998 Dec; 6(12):2245-60

Analogues of 4,5-bis(3,5-dichlorophenyl)-2-trifluoromethyl-1H-imidazole as potential antibacterial agents. Antolini M, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1023-8

Antiinflammatory 4,5-diarylimidazoles as selective cyclooxygenase inhibitors. Barta TE, et al. **Bioorg Med Chem Lett** 1998 Dec 15;8(24):3443-8

Design, synthesis and structure-activity relationships of novel strychnine-insensitive glycine receptor ligands. Cordi A, et al. **Bioorg Med Chem Lett** 1999 May 17;9(10):1409-14

Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors. Ho GD, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):7-12

Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones. Jung SH, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1547-50

Novel imidazole derivatives with subtype-selective antimuscarinic activity (1). Miyachi H, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1807-12

Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo. Shih NY, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):243-8

8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. Wichmann J, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2343-8

Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Corey A, et al. **Biopharm Drug Dispos** 1999 Mar;20(2):59-68

Moxonidine: pharmacology, clinical pharmacology and clinical profile. Elliott HL. **Blood Press** 1998;Suppl 3:23-7 (20 ref.)

Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Friedman JE, et al. **Blood Press** 1998;Suppl 3:32-9

Cardiovascular effects of novel imidazoline congeners. Shukla S, et al. **Boll Chim Farm** 1998 Jul-Aug; 137(7):229-32

The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Bing C, et al. **Br J Pharmacol** 1999 May;127(1):35-42

Potentiation of barbiturate-induced alterations in presynaptic noradrenergic function in rat frontal cortex by imidazol(in)e alpha2-adrenoceptor agonists. Dalley JW, et al. **Br J Pharmacol** 1998 Oct;125(3):441-6

Effects of hydroxocobalamin and carboxy-PTIO on nitrergic transmission in porcine anococcygeus and retractor penis muscles. Li CG, et al. **Br J Pharmacol** 1999 May; 127(1):172-6

Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets. Mourtada M, et al. **Br J Pharmacol** 1999 Jul;127(5):1279-87

Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Olmos G, et al. **Br J Pharmacol** 1999 Jul;127(6):1317-26

LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy. Potschka H, et al. **Br J Pharmacol** 1998 Nov;125(6):1258-66

2-Phenyl-imidazo[1,2-a]pyridine derivatives as ligands for peripheral benzodiazepine receptors: stimulation of neurosteroid synthesis and anticonflict action in rats. Serra M, et al. **Br J Pharmacol** 1999 May;127(1):177-87

Minor structural changes in nicotinoid insecticides confer differential subtype selectivity for mammalian nicotinic acetylcholine receptors. Tomizawa M, et al. **Br J Pharmacol** 1999 May;127(1):115-22

Pharmacological characterization of Ca2+ entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365. Zhang XF, et al. **Br J Pharmacol** 1999 Jul;127(6):1388-98

Inhibition of platelet-activating factor, intercellular adhesion molecule 1 and platelet endothelial cell adhesion molecule 1 reduces experimental pancreatitis-associated gut endothelial barrier dysfunction. Wang X, et al. **Br J Surg** 1999 Mar;86(3):411-6

Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion. Häberg A, et al. **Brain Res** 1998 Nov 16;811(1-2):63-70

A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Kawasaki-Yatsugi S, et al. **Brain Res** 1998 May 18; 793(1-2):39-46

The biochemical and pharmacological properties of a newly synthesized H+-K+ ATPase inhibitor, 2-dimethylamino-4,5-dihydrothiazolo[4,5:3,4]pyridol-[1,2-a]benzimidazol e. Chung YK, et al. **Can J Physiol Pharmacol** 1998 Sep;76(9):921-9

Romifidine, medetomidine or xylazine before propofol-halothane-N2O anesthesia in dogs. Redondo JI, et al. **Can J Vet Res** 1999 Jan;63(1):31-6

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) retards mammary gland involution in lactating Sprague-Dawley rats. Venugopal M, et al. **Carcinogenesis** 1999 Jul;20(7):1309-14

Differential sensitivity to nickel and SK&F96365 of second messenger-operated and receptor-operated calcium channels in rat submandibular ductal cells. Chaïb N, et al. **Cell Calcium** 1998 Jun;23(6):395-404

Capacitative Ca2+ entry in HL-60 cells: tetrandrine and SK & F 96365 as probes. Leung YM, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Mar;17(2):97-101 (29 ref.)

Effects of moxonidine injected into rostral ventrolateral medulla on blood pressure, heart rate, and renal sympathetic nerve activity in rats. Xu YF, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):415-8

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Hempel G, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):622-35

Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Hegde SS, et al. **Curr Pharm Des** 1998 Dec;4(6):469-79 (57 ref.)

Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Yakubu-Madus FE, et al. **Diabetes** 1999 May; 48(5):1093-100

Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Pan HJ, et al. **Endocrine** 1998 Aug;9(1):39-43

Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Ly LH, et al. **Endocrinology** 1999 May;140(5):2071-6

Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel. Chachin M, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):457-60

Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites. Chan SL, et al. **Eur J Pharmacol** 1998 Aug 14;355(1):67-76

Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Fujimoto S, et al. **Eur J Pharmacol** 1998 Jul 24;353(2-3):239-46

Effect of SK&F 96365 on extracellular Ca2+ -dependent O2- production in neutrophil-like HL-60 cells. Gallois A, et al. **Eur J Pharmacol** 1998 Nov 20;361(2-3):293-8

NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells. Gazi L, et al. **Eur J Pharmacol** 1999 May 21;372(3):R9-10

In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Jansen FP, et al. **Eur J Pharmacol** 1998 Dec 4;362(2-3):149-55

Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Jolkkonen J, et al. **Eur J Pharmacol** 1999 May 7;372(1):31-6

KW-5092, a novel gastrokinetic agent, facilitates luminal serotonin release from the guinea-pig colon. Kojima S. **Eur J Pharmacol** 1999 Jun 11;374(1):113-5

Modulatory effect of imetit, a histamine H3 receptor agonist, on C-fibers, cholinergic fibers and mast cells in rabbit lungs in vitro. Nemmar A, et al. **Eur J Pharmacol** 1999 Apr 23; 371(1):23-30

Na+ channel blocking effects of cibenzoline on guinea-pig ventricular cells. Niwa R, et al. **Eur J Pharmacol** 1998 Jul 10;352(2-3):317-27

Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Nurminen ML, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):61-7

Protective effect of imidaprilat, a new angiotensin-converting enzyme inhibitor against 1-methyl-4-phenylpyridinium ion-induced •OH generation in rat striatum. Obata T. **Eur J Pharmacol** 1999 Jul 28;378(1):39-45

SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells. Parameswaran N, et al. **Eur J Pharmacol** 1999 Apr 23;371(1):75-82

Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Pelé-Tounian A, et al. **Eur J Pharmacol** 1999 Jul 14;377(1):81-7

Effects of epinastine hydrochloride on cholinergic neuro-effector transmission in canine tracheal smooth muscle. Takahashi N, et al. **Eur J Pharmacol** 1998 Sep 25; 358(1):55-61

Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents. Takami M, et al. **Eur J Pharmacol** 1999 Feb 5; 366(2-3):253-9

High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. Tedford CE, et al. **Eur J Pharmacol** 1998 Jun 26; 351(3):307-11

The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum. Watanabe M, et al. **Eur J Pharmacol** 1999 Feb 12; 367(1):19-23

Facilitation of spontaneous defibrillation by moxonidine during regional ischaemia in an isolated working rabbit heart model. Wolk R, et al. **Eur J Pharmacol** 1999 Feb 12;367(1):25-32

Effects of azimilide, a KV(r) and KV(s) blocker, on canine ventricular arrhythmia models. Xue Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):27-35

Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Martel J, et al. **Exp Neurol** 1998 Dec;154(2):595-601

Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. Eyers PA, et al. **FEBS Lett** 1999 May 21; 451(2):191-6

Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580. Kalmes A, et al. **FEBS Lett** 1999 Feb 5;444(1):71-4

Effect of mutagenesis at serine 653 of Arabidopsis thaliana acetohydroxyacid synthase on the sensitivity to imidazolinone and sulfonylurea herbicides. Lee YT, et al. **FEBS Lett** 1999 Jun 11;452(3):341-5

A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. Ridley SH, et al. **FEBS Lett** 1998 Nov 13;439(1-2):75-80

Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats. Kubo E, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Sep;237(9):758-62

Effects of losartan and PD123319 on antigensin II-induced proto-oncogene expression and protein synthesis in cultured neonatal rat cardiac myocytes. Ling Q, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(4):283-6

Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Morsing P, et al. **Hypertension** 1999 Jun;33(6):1406-13

Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Touyz RM, et al. **Hypertension** 1999 Jan;33(1 Pt 2):366-72

I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Wenzel RR, et al. **Hypertension** 1998 Dec;32(6):1022-7

Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS. Patel R, et al. **Inflamm Res** 1999 Jun;48(6):337-43

A comparison of Cetirizine, Ebastine, Epinastine, Fexofenadine, Terfenadine, and Loratadine versus placebo in suppressing the cutaneous response to histamine. Grant JA, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2-4):339-40

gamma-Hydroxybutyric acid, imidazoleacetic acid, cerebral metabolism and induced sleep. Rick JT, et al. **Isr J Med Sci** 1973;9 Suppl:55-62 (12 ref.)

Effects of candesartan and PD123319 on responses to angiotensin II in the anesthetized mouse. Bivalacqua TJ, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S98-100

The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat. Champion HC, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S95-7

Comparison of the baroreceptor-heart rate reflex effects of moxonidine, rilmenidine and clonidine in conscious rabbits. Godwin SJ, et al. **J Auton Nerv Syst** 1998 Oct 15; 72(2-3):195-204

Influence of sino-aortic barodenervation on the cardiovascular effects of imidazoline-like drugs. Medvedev OS, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2-3):205-9

Chronopharmacological dependence of antihypertensive effects of the imidazoline-like drugs in stroke-prone spontaneously hypertensive rats. Medvedev OS, et al. **J Auton Nerv Syst** 1998 Oct 15;72(2-3):170-6

Effects of dexmedetomidine, an alpha2-adrenoceptor agonist, on renal sympathetic nerve activity, blood pressure, heart rate and central venous pressure in urethane-anesthetized rabbits. Xu H, et al. **J Auton Nerv Syst** 1998 Jun 30; 71(1):48-54

Characterization of imidazole as a DNA denaturant by using TGGE of PCR products from a random pool of DNA. Eli P, et al. **J Biochem (Tokyo)** 1999 Apr;125(4):790-4

A chimeric gastric H+,K+-ATPase inhibitable with both ouabain and SCH 28080. Asano S, et al. **J Biol Chem** 1999 Mar 12;274(11):6848-54

Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. Börsch-Haubold AG, et al. **J Biol Chem** 1998 Oct 30;273(44):28766-72

Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. Engelman JA, et al. **J Biol Chem** 1998 Nov 27;273(48):32111-20

An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. Mackay K, et al. **J Biol Chem** 1999 Mar 5;274(10):6272-9

Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. Sennequier N, et al. **J Biol Chem** 1999 Jan 8;274(2):930-8

An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. Sweeney G, et al. **J Biol Chem** 1999 Apr 9;274(15):10071-8

Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. Binkley N, et al. **J Bone Miner Res** 1998 Nov;13(11):1775-82

A novel alpha 2-adrenoceptor antagonist attenuates the early, but preserves the late cardiovascular effects of intravenous dexmedetomidine in conscious dogs. Pagel PS, et al. **J Cardiothorac Vasc Anesth** 1998 Aug;12(4):429-34

Effects of moxonidine on stress-induced peak blood pressure and renal function: a randomized, double-blind, placebo-controlled crossover study. Fauvel JP, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):495-9

Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. McVey MJ, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):703-10

Antihypertensive activity and pharmacokinetics of KD3-671, a nonpeptide AT1-receptor antagonist, in renal hypertensive dogs. Takata Y, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):834-44

1,2-Diarylimidazoles as inhibitors of cyclooxygenase-2: a quantitative structure-activity relationship study. Singh P, et al. **J Enzyme Inhib** 1999;14(4):277-88

Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. Gillies LK, et al. **J Hypertens** 1998 Apr; 16(4):477-86

Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. Brooks DP, et al. **J Hypertens Suppl** 1999 Jun;17(2):S27-32 (63 ref.)

Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. Qi XQ, et al. **J Interv Card Electrophysiol** 1999 Mar; 3(1):61-7

Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice. Fischer W, et al. **J Neural Transm** 1998;105(6-7):587-99

Inhibition of nitric oxide metabolism enhances the hypnotic-anesthetic action of the alpha2-adrenoceptor agonist dexmedetomidine in vivo. Tonner PH, et al. **J Neurosurg Anesthesiol** 1999 Jan;11(1):37-41

Some 1-[(benzofuran-2-yl)methyl]imidazoles as inhibitors of 17 alpha-hydroxylase: 17, 20-lyase (P450 17) and their specificity patterns. Bahshwan SA, et al. **J Pharm Pharmacol** 1998 Oct;50(10):1109-16

Enantioselectivity of some 1-(benzofuran-2-yl)-1-(1-H-imidazol-1-yl) alkanes as inhibitors of P450Arom. Khodarahmi GA, et al. **J Pharm Pharmacol** 1998 Nov;50(11):1321-30

Effects of KW-5092 on antroduodenal coordination and gastric emptying in guinea-pigs. Kishibayashi N, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1045-50

In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. Kohara A, et al. **J Pharm Pharmacol** 1998 Jul;50(7):795-801

Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles. Owen CP, et al. **J Pharm Pharmacol** 1999 Apr;51(4):427-33

The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. Uchiyama K, et al. **J Pharm Pharmacol** 1999 Apr; 51(4):457-64

Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats. Yuasa C, et al. **J Pharm Pharmacol** 1999 Jul;51(7):867-71

Anesthetic profile of dexmedetomidine identified by stimulus-response and continuous measurements in rats. Bol CJ, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):153-60

Cardiopulmonary effects of the alpha2-adrenoceptor agonists medetomidine and ST-91 in anesthetized sheep. Celly CS, et al. **J Pharmacol Exp Ther** 1999 May;289(2):712-20

Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). Ernsberger P, et al. **J Pharmacol Exp Ther** 1999 Jan;288(1):139-47

Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. Fairbanks CA, et al. **J Pharmacol Exp Ther** 1999 Jul; 290(1):403-12

Imidazenil, a positive allosteric GABAA receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens shell without tolerance liability. Giorgetti M, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):58-66

SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. Kankaanranta H, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):621-8

Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. Ligneau X, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):658-66

Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. McLeod RL, et al. **J Pharmacol Exp Ther** 1998 Oct;287(1):43-50

Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. Takahashi M, et al. **J Pharmacol Exp Ther** 1998 Nov;287(2):559-66

Release of nitric oxide within the coeliac plexus is involved in the organization of a gastroduodenal inhibitory reflex in the rabbit. Quinson N, et al. **J Physiol (Lond)** 1999 Aug 15;519 Pt 1:223-34

p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. Cain BS, et al. **J Surg Res** 1999 May 1;83(1):7-12

Comparison of three doses of dexmedetomidine with medetomidine in cats following intramuscular administration. Ansah OB, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):380-7

Selectivity of atipamezole, yohimbine and tolazoline for alpha-2 adrenergic receptor subtypes: implications for clinical reversal of alpha-2 adrenergic receptor mediated sedation in sheep. Schwartz DD, et al. **J Vet Pharmacol Ther** 1998 Oct;21(5):342-7

Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. Kai T, et al. **Jpn Circ J** 1998 Aug; 62(8):599-603

Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology). Kodama I, et al. **Jpn Circ J** 1999 Jan;63(1):1-12 (126 ref.)

Effects of phosphodiesterase inhibitors after coronary artery bypass grafting. Orime Y, et al. **Jpn Circ J** 1999 Feb; 63(2):117-22

An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Harada J, et al. **Jpn J Pharmacol** 1999 Mar;79(3):369-78

YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Ideyama Y, et al. **Jpn J Pharmacol** 1999 Feb;79(2):213-20

Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Hough LB, et al. **Life Sci** 1999;64(5):PL79-86

A synthetic polycation, a copolymer of 1-vinyl-3-methylimidazole iodide with maleic acid diethyl ester, increases passive ionic permeability in erythrocyte membranes modified by fatty acids. Glazunova OO, et al. **Membr Cell Biol** 1998;12(3):401-9

Improvement of chronic hepatic encephalopathy in dogs by the benzodiazepine-receptor partial inverse agonist sarmazenil, but not by the antagonist flumazenil. Meyer HP, et al. **Metab Brain Dis** 1998 Sep;13(3):241-51

General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine. Kakinoki

B, et al. **Methods Find Exp Clin Pharmacol** 1999 Apr; 21(3):179–87

In vitro activity of sertaconazole against Malassezia furfur and pachydermatis in different culture media. Palacin C, et al. **Methods Find Exp Clin Pharmacol** 1998 Jul–Aug; 20(6):451–5

Effects of TU–199, a novel H+, K(+)–ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Uchiyama K, et al. **Methods Find Exp Clin Pharmacol** 1999 Mar;21(2):115–22

Whole–blood assays for evaluation of thromboxane synthase inhibition. Spokas EG, et al. **Methods Mol Biol** 1999; 120:249–56

Conformation–dependent inhibition of gastric H+,K+–ATPase by SCH 28080 demonstrated by mutagenesis of glutamic acid 820. Swarts HG, et al. **Mol Pharmacol** 1999 Mar;55(3):541–7

The gene that determines resistance to tioconazole and to acridine derivatives in Aspergillus nidulans may have a corresponding gene in Trichophyton rubrum. Pereira M, et al. **Mycopathologia** 1998;143(2):71–5

Comparison of the effects of calmidazolium, morphine and bupivacaine on N–methyl–D–aspartate– and septide–induced nociceptive behaviour. Alvarez–Vega M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):628–34

Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Bock C, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Apr; 359(4):262–71

Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats. Haapalinna A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):194–203

Multiple effects of 1–[beta–[3–(4–methoxyphenyl)propoxy]–4–methoxyphenethyl]–1H–imidazole hydrochloride (SKF 96365) on Ca2+ signaling in MDCK cells: depletion of thapsigargin–sensitive Ca2+ store followed by capacitative Ca2+ entry, activation of a direct Ca2+ entry, and inhibition of thapsigargin–induced capacitative Ca2+ entry. Jan CR, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Feb; 359(2):92–101

Ciproxifan and chemically related compounds are highly potent and selective histamine H3–receptor antagonists. Kathmann M, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Dec; 358(6):623–7

Heterogeneous characteristics of imidazoline–induced insulin secretion. Rustenbeck I, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):235–42

Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats. Ni JW, et al. **Neuroreport** 1998 Nov 16;9(16):3719–24

The antiepileptic drug AWD 131–138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Sigel E, et al. **Neurosci Lett** 1998 Apr 3;245(2):85–8

Joint actions of deltamethrin and azole fungicides on honey bee thermoregulation [published erratum appears in Neurosci Lett 1998 Oct 9;255(1):61] Vandame R, et al. **Neurosci Lett** 1998 Jul 17;251(1):57–60

The P38 mitogen–activated protein kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin–1beta on long–term potentiation in the rat dentate gyrus in vitro. Coogan AN, et al. **Neuroscience** 1999;93(1):57–69

Alpha2–adrenoceptor modulation of cortical acetylcholine release in vivo. Tellez S, et al. **Neuroscience** 1999; 89(4):1041–50

Effect of SB 203580 on the activity of c–Raf in vitro and in vivo. Hall–Jackson CA, et al. **Oncogene** 1999 Mar 25; 18(12):2047–54

Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1– and MRP–mediated multidrug resistance. Naito S, et al. **Oncol Res** 1998; 10(3):123–32

Effects of moxonidine and clonidine on potassium excretion in Sprague–Dawley rats. Hohage H, et al. **Pharmacol Res** 1999 May;39(5):357–61

Secretory, biosynthetic and cationic responses to 2–(N–PHENYL–INDOYL)IMIDAZOLE in rat pancreatic islets. Louchami K, et al. **Pharmacol Res** 1998 Oct;38(4):305–10

Correlative alteration of thromboxane A2 with antigen–induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP–1904, an inhibitor of thromboxane synthetase. Takami M, et al. **Pharmacol Res** 1998 Aug;38(2):133–9

In vitro effect of DP–1904, a novel anti–asthma agent, against antigen–induced constriction and TXB2 release from the isolated guinea–pig lung parenchymal tissue. Takami M, et al. **Pharmacol Res** 1998 Aug;38(2):141–7

Effects of imidazoline and non–imidazoline alpha–adrenergic agents on canine platelet aggregation. Hikasa Y, et al. **Pharmacology** 1999 Apr;58(4):171–82

A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Blum RA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):79S–85S (23 ref.)

Review of eprosartan: a new angiotensin II receptor antagonist. Introduction. Hollenberg NK. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):71S–72S

Review of eprosartan: a new angiotensin II receptor antagonist. Summary. Sica DA. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):108S–109S

The renal profile of eprosartan. Sica DA, et al. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):86S–94S (42 ref.)

Carnosine and other imidazole–containing compounds enhance the postdenervation depolarization of the rat diaphragm fibres. Urazaev AKh, et al. **Physiol Res** 1998; 47(4):291–5

Effects of DP–1904, a thromboxane synthetase inhibitor, on the antigen–induced airway hyperresponsiveness and infiltration of inflammatory cells in guinea–pigs. Takami M, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Dec;59(6):407–14

A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Fox T, et al. **Protein Sci** 1998 Nov;7(11):2249–55

Effects of different classes of partial benzodiazepine agonists on punished and unpunished responding in pigeons. Kleven MS, et al. **Psychopharmacology (Berl)** 1999 Jun; 144(4):405–10

Effects of a selective PDE4 inhibitor, D–22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Dent G, et al. **Pulm Pharmacol Ther** 1998 Feb;11(1):13–21

NPY Y1 antagonists: structure–activity relationships of arginine derivatives and hybrid compounds with arpromidine–like partial structures. Aiglstorfer I, et al. **Regul Pept** 1998 Sep 25;75–76:9–21

Characterisation of the cardiovascular pharmacology of medetomidine in the horse and sheep. Bryant CE, et al. **Res Vet Sci** 1998 Sep–Oct;65(2):149–54

Use of midlatency auditory–evoked potentials as indicator of unconsciousness in the dog: characterisation of the effects of acepromazine–thiopentone, medetomidine–thiopentone and medetomidine–butorphanol–midazolam combinations. Pypendop B, et al. **Res Vet Sci** 1999 Aug;67(1):35–9

Are cholinergic pathways involved in the anesthetic response to alpha2 agonists. Buttermann AE, et al. **Toxicol Lett** 1998 Nov 23;100–101:17–22

'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Eglen RM, et al. **Trends Pharmacol Sci** 1998 Sep; 19(9):381–90 (89 ref.)

Reversal of sedative and clinicophysiological effects of epidural xylazine and detomidine with atipamezole and yohimbine in buffaloes (Bubalus bubalis). Tiwari SK, et al. **Vet Rec** 1998 Nov 7;143(19):529–32

Detomidine–propofol anesthesia for abdominal surgery in horses. Matthews NS, et al. **Vet Surg** 1999 May–Jun; 28(3):196–201

Hemodynamic effects of medetomidine in the dog: a dose titration study. Pypendop BH, et al. **Vet Surg** 1998 Nov–Dec;27(6):612–22

Effects of subarachnoid xylazine and medetomidine on haemodynamics and ECG in goats. Kinjavdekar P, et al. **Zentralbl Veterinarmed A** 1999 Jul;46(5):271–5

Comparison of sedative effects of medetomidine–midazolam, acepromazine–butorphanol and midazolam–butorphanol in dogs. Kojima K, et al. **Zentralbl Veterinarmed A** 1999 Apr; 46(3):141–8

[Evaluation of the antinociceptive effect of systemic and epidurally applied xylazine in general anesthesia with isoflurane in dogs and the effect of atipamezole infection on postoperative analgesia] Rector E, et al. **Berl Munch Tierarztl Wochenschr** 1998 Nov–Dec; 111(11–12):438–51 (Eng. Abstr.) **(Ger)**

[Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog] Fujishima K, et al. **Nippon Yakurigaku Zasshi** 1998 Dec;112(6):371–80 (Eng. Abstr.) **(Jpn)**

[Bactericidal properties of copper (II) complexes with 1–alkylimidazole] Radzyminska–Lenarcik E, et al. **Med Dosw Mikrobiol** 1998;50(3–4):269–75 (Eng. Abstr.) **(Pol)**

[Clinical pharmacology of hypotensive drugs acting on central imidazoline receptors] Drzewoski J, et al. **Pol Arch Med Wewn** 1998 Dec;100(6):561–9 (35 ref.) **(Pol)**

[Agonists of the imidazoline receptors] Ol'binskaia LI, et al. **Eksp Klin Farmakol** 1999 Mar–Apr;62(2):68–72 **(Rus)**

POISONING

Ammoniated forage poisoning: concentrations of alkylimidazoles in ammoniated forage and in milk, plasma and urine in sheep and cow. Müller L, et al. **Acta Vet Scand** 1998;39(4):511–4

Effect of charcoal hemoperfusion on clearance of cibenzoline succinate (cifenline) poisoning. Aoyama N, et al. **J Toxicol Clin Toxicol** 1999;37(4):505–8

Acute poisoning with a herbicide containing imazapyr (Arsenal): a report of six cases. Lee HL, et al. **J Toxicol Clin Toxicol** 1999;37(1):83–9

Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child. Holmes JF, et al. **Pediatr Emerg Care** 1999 Jun;15(3):193–4

[Fatal voluntary poisoning with cibenzoline. Failure of conventional therapies] Viallon A, et al. **Presse Med** 1998 Oct 24;27(32):1621–5 (28 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Dickstein K, et al. **Am J Cardiol** 1999 Jun 15;83(12):1638–44

Angiotensin II subtype–1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non–insulin–dependent diabetes mellitus. Uehara Y, et al. **Am J Hypertens** 1999 Jan;12(1 Pt 1):21–7

Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Tappia PS, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):H40–9

Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Myou S, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):817–20

The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2–adrenoceptors. Poree LR, et al. **Anesth Analg** 1998 Oct;87(4):941–8

Central I1–imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine. Van Zwieten PA, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:420–9 (33 ref.)

Post–operative effects of olprinone after coronary artery bypass grafting. Orime Y, et al. **Ann Thorac Cardiovasc Surg** 1998 Dec;4(6):340–6

Systemic administration of atipamezole, an alpha 2–antagonist, can reduce scopolamine–induced hyperactivity in rats. Niittykoski M, et al. **Behav Pharmacol** 1997 Oct;8(5):465–70

Discovery of an imidazopyridine–containing 1,4–benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Keenan RM, et al. **Bioorg Med Chem Lett** 1998 Nov 17; 8(22):3171–6

Potent antihyperglycaemic property of a new imidazoline derivative S–22068 (PMS 847) in a rat model of NIDDM. Pelé–Tounian A, et al. **Br J Pharmacol** 1998 Aug; 124(8):1591–6

The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Miller WH Jr. **Cancer** 1998 Oct 15;83(8):1471–82 (146 ref.)

Antitumor activity of 4–phenyl–1–arylsulfonylimidazolidinone, DW2143. Moon EY, et al. **Cancer Lett** 1999 Jun 1;140(1–2):177–87

Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor–1 levels in patients with essential hypertension. Krespi PG, et al. **Cardiovasc Drugs Ther** 1998 Oct;12(5):463–7

Antifibrillatory efficacy of ersentilide, a novel beta–adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Adamson PB, et al. **Cardiovasc Res** 1998 Oct;40(1):56–63

Selective imidazoline receptor agonists and lipid metabolism [letter] Elisaf M, et al. **Clin Chem Lab Med** 1999 Feb; 37(2):165

Assessment of once–daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. Gradman AH, et al. **Clin Ther** 1999 Mar;21(3):442–53

Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26–week, double–blind, multicentre study. Eprosartan Multinational Study Group. Argenziano L, et al. **Curr Med Res Opin** 1999;15(1):9–14

Effect of long–term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I–II hypertension. Eprosartan Study Group. Diamond JA, et al. **Curr Med Res Opin** 1999;15(1):1–8

Effects of eprosartan versus enalapril in hypertensive patients on the renin–angiotensin–aldosterone system and safety parameters: results from a 26–week, double–blind, multicentre study. Eprosartan Multinational Study Group. Gavras I, et al. **Curr Med Res Opin** 1999;15(1):15–24

Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26–week, double–blind, multicentre study. Eprosartan Multinational Study Group. Levine B. **Curr Med Res Opin** 1999; 15(1):25–32

Safety and tolerability of moxonidine in the treatment of hypertension. Schachter M, et al. **Drug Saf** 1998 Sep; 19(3):191–203 (43 ref.)

Nasal decongestion with imidazoline derivatives: acoustic rhinometry measurements. Hochban W, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):7–12

Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt–sensitive rats. Yoneda H, et al. **Eur J Pharmacol** 1998 Dec 4;362(2–3):213–9

Post–stroke treatment with imidapril reduces learning deficits with less formation of brain oedema in a stroke–prone substrain of spontaneously hypertensive rats. Yabuuchi F, et al. **Fundam Clin Pharmacol** 1999;13(4):475–83

Effect of an alpha(2) agonist (mivazerol) on limiting myocardial ischaemia in stable angina. Fox K, et al. **Heart** 1999 Sep;82(3):383–5

Sertindole in treating schizophrenia [letter] **Hosp Med** 1998 Feb;59(2):165

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Brodsky S, et al. **Hypertension** 1998 Oct;32(4):746–52

Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Matsumoto K, et al. **Hypertension** 1999 Aug;34(2):279–84

Sertindole: a review of clinical efficacy. Kane JM. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S59–63; discussion S63–4 (8 ref.)

The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy. Wehnert A. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S27–30

Efficacy of NND–502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Niwano Y, et al. **Int J Antimicrob Agents** 1999 Aug;12(3):221–8

Terbinafine 1% cream vs. bifonazole 1% cream in the treatment of tinea cruris. Budimulja U. **Int J Dermatol** 1998 Nov;37(11):871–3

Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis. Wang X, et al. **Int J Pancreatol** 1999 Feb;25(1):45–52

EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. Lynch JJ Jr, et al. **J Am Coll Cardiol** 1999 Sep;34(3):876–84

High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. van Veldhuisen DJ, et al. **J Am Coll Cardiol** 1998 Dec;32(7):1811–8

Pharmacologic cardioversion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecainide, and d-sotalol. Wijffels MC, et al. **J Cardiovasc Electrophysiol** 1999 Feb;10(2):178–93

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Friedman HS, et al. **J Clin Oncol** 1998 Dec;16(12):3851–7

Aldose reductase and the development of renal disease in diabetic dogs. Kern TS, et al. **J Diabetes Complications** 1999 Jan–Feb;13(1):10–6

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. Elliott WJ. **J Hum Hypertens** 1999 Jun;13(6):413–7

Management of hypertension: the advent of a new angiotensin II receptor antagonist. Hedner T. **J Hypertens Suppl** 1999 Jun;17(2):S21–5 (28 ref.)

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Rascol O, et al. **Mov Disord** 1998 Jul;13(4):673–6

Hope or hype for lexipafant? [letter; comment] Abu-Zidan FM. **Nature** 1998 Oct 1;395(6701):431. Comment on: Nature 1998 May 28;393(6683):291. Comment on: Nature 1998 May 28;393(6683):299. Comment on: Nature 1998 Jun 11;393(6685):509.

Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Schifitto G, et al. **Neurology** 1999 Jul 22;53(2):391–6

Field study on the insecticidal efficacy of Advantage against natural infestations of dogs with lice. Hanssen I, et al. **Parasitol Res** 1999 Apr;85(4):347–8

Effects of eprosartan on glomerular injury in rats with reduced renal mass. Gandhi M, et al. **Pharmacology** 1999 Aug;59(2):89–94

Clinical efficacy of eprosartan. Weber M. **Pharmacotherapy** 1999 Apr;19(4 Pt 2):95S–101S (12 ref.)

Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Jentsch JD, et al. **Psychopharmacology (Berl)** 1999 Feb;142(1):78–84

YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Shimizu-Sasamata M, et al. **Stroke** 1998 Oct;29(10):2141–8

[Treatment of subglottic laryngitis (pseudocroup): steroids in place of steam (letter; comment)] Engels MA, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2646–7. Comment on: Ned Tijdschr Geneeskd 1998 Jul 18;142(29):1658–62. **(Dut)**

[A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia] Piot O, et al. **Arch Mal Coeur Vaiss** 1998 Dec;91(12):1481–6 (Eng. Abstr.) **(Fre)**

[In vitro determination of the texture of 3 gynecologic antifungal agents: TX 15338 (Monazole, sertaconazole nitrate) and 2 related products (letter)] Cros C, et al. **Presse Med** 1998 Dec 5;27(38):1955 **(Fre)**

[Management of schizophrenic psychoses: a one-year experience with Serdolect] **Fortschr Neurol Psychiatr** 1998 Nov;66(11 Suppl Therapie):1–4 **(Ger)**

[Schizophrenic psychoses: distinct therapeutic advantages of atypical neuroleptics. Serdolect: effective and free of side effects] **Fortschr Neurol Psychiatr** 1998 Oct;66(10 Suppl Schizophre):1–4 **(Ger)**

[Schizophrenic psychoses: distinct therapeutic advantages of atypical neuroleptics. Serdolect is effective and free of side effects] **Psychiatr Prax** 1998 Sep;25(5 Suppl):1–4 **(Ger)**

[Cardiovascular and metabolic diseases. Imidazolin-antagonists and the sympathetic nervous system] **Z Kardiol** 1998 Oct;87(10 Suppl):1–4 **(Ger)**

[The usage of nasal drops Tyzine in otorhinolaryngology] Kozłowski Z, et al. **Otolaryngol Pol** 1997;51 Suppl 25:315–9 (Eng. Abstr.) **(Pol)**

TOXICITY

Antitumor activity of 4,5,6,7-tetrathiocino (1,2-b: 3,4-b') diimidazolyl-1,3,8,10-tetrasubstituted-2,9-dithiones (R4-todit). Pani A, et al. **Anticancer Res** 1998 Nov–Dec; 18(6A):4429–34

Does moxonidine increase cytotoxic activity of ethanol in rats? Preliminary report on the base of the ultrastructural study. Marczewski K, et al. **Arch Immunol Ther Exp (Warsz)** 1998;46(4):241–6

Evaluation of toxicity of beta-tethymustine, a new anticancer compound, in mice. Ghosh M, et al. **Cancer Lett** 1999 Apr 26;138(1–2):107–14

Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Hirose M, et al. **Cancer Lett** 1999 Sep 1;143(2):173–8

Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocylic amines. Kamataki T, et al. **Cancer Lett** 1999 Sep 1;143(2):113–6

Mutagenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the new gpt delta transgenic mouse. Masumura K, et al. **Cancer Lett** 1999 Sep 1; 143(2):241–4

Carcinogenic risk assessment of MeIQx and PhIP in a newborn mouse two-stage tumorigenesis assay. Miyauchi M, et al. **Cancer Lett** 1999 Jul 19;142(1):75–81

Chemoprevention of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced mammary carcinogenesis in rats. Mori H, et al. **Cancer Lett** 1999 Sep 1;143(2):195–8

Genetic analysis of the susceptibility in rats to aberrant crypt foci formation by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine, PhIP. Nakagama H, et al. **Cancer Lett** 1999 Sep 1;143(2):205–9

Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Shirai T, et al. **Cancer Lett** 1999 Sep 1;143(2):217–21

Role of well-done, grilled red meat, heterocyclic amines (HCAs) in the etiology of human cancer. Sinha R, et al. **Cancer Lett** 1999 Sep 1;143(2):189–94

Mammary gland carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats: possible mechanisms. Snyderwine EG. **Cancer Lett** 1999 Sep 1;143(2):211–5 (22 ref.)

Heterocyclic amine mixture carcinogenesis and its enhancement by caffeine in F344 rats. Tsuda H, et al. **Cancer Lett** 1999 Sep 1;143(2):229–34

Chemoprevention studies of heterocyclic amine-induced colon carcinogenesis. Xu M, et al. **Cancer Lett** 1999 Sep 1;143(2):179–83

Carcinogenicity of heterocyclic amines for the pancreatic duct epithelium in hamsters. Yoshimoto M, et al. **Cancer Lett** 1999 Sep 1;143(2):235–9

Cytotoxic and mutagenic response of mismatch repair-defective human cancer cells exposed to a food-associated heterocyclic amine. Glaab WE, et al. **Carcinogenesis** 1999 Mar;20(3):391–4

Strain differences of rats in the susceptibility to aberrant crypt foci formation by 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine: no implication of Apc and Pla2g2a genetic polymorphisms in differential susceptibility. Ishiguro Y, et al. **Carcinogenesis** 1999 Jun;20(6):1063–8

Neonatal exposure to the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. Paulsen JE, et al. **Carcinogenesis** 1999 Jul;20(7):1277–82

Heterocyclic aromatic amines induce DNA strand breaks and cell transformation. Pfau W, et al. **Carcinogenesis** 1999 Apr; 20(4):545–51

Inhibition of DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3-methylimidazo[4,5-f]quinoline by dietary indole-3-carbinol in female rats. He YH, et al. **J Biochem Mol Toxicol** 1999;13(5):239–47

Development and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced aberrant crypt foci in the rat large intestine. Tsukamoto T, et al. **Jpn J Cancer Res** 1999 Jul;90(7):720–5

Genetic analysis of PHIP intestinal mutations in MutaMouse. Lynch AM, et al. **Mutagenesis** 1998 Nov;13(6):601–5

Mutant yields and mutational spectra of the heterocyclic amines MeIQ and PhIP at the S1 locus of human-hamster AL cells with activation by chick embryo liver (CELC) co-cultures. Waldren CA, et al. **Mutat Res** 1999 Mar 10; 425(1):29–46

Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Gao XM, et al. **Neuropsychopharmacology** 1998 Nov; 19(5):428–33

URINE

Urinary excretion of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in White, African-American, and Asian-American men in Los Angeles County. Kidd LC, et al. **Cancer Epidemiol Biomarkers Prev** 1999 May;8(5):439–45

In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Lang NP, et al. **Cancer Lett** 1999 Sep 1;143(2):135–8

No sex difference in the urinary excretion of the histamine metabolite methylimidazoleacetic acid (MeImAA) when corrected for creatinine excretion. Granerus G, et al. **Inflamm Res** 1999 Apr;48 Suppl 1:S92–3

Determination of the histamine metabolite tele-methylimidazoleacetic acid and of creatinine in urine by the same HPLC system. Granerus G, et al. **Inflamm Res** 1999 Feb;48(2):75–80

Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis. Martens-Lobenhoffer J, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 8; 721(1):135–40

IMIDAZOLIDINETHIONE see **ETHYLENETHIOUREA**

IMIDES

A new technique for stripping of polyimide coating from fused-silica capillaries. Lindberg P, et al. **Electrophoresis** 1998 Oct;19(14):2445–6

13C cross-polarization magic angle spinning NMR and gauge-independent atomic orbital, coupled Hartree-Fock calculations of buspirone analogues. Part 2. Hydrochlorides and perchlorates of 1-arylpiperazine-4-alkylimides. Szelejewska-Woźniakowska A, et al. **Solid State Nucl Magn Reson** 1999 Jun;14(1):59–65

CHEMICAL SYNTHESIS

Synthesis of new N-[4-(4-aryl- and 4-heteroaryl-1-piperazinyl)butyl]derivatives of 1-methyl-5-oxobicyclo[2.2.1]heptane-2,3-dicarboximide with an expected anxiolytic activity. Kossakowski J, et al. **Acta Pol Pharm** 1998 Jul–Aug;55(4):315–8

Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, et al. **Bioorg Med Chem** 1998 Aug;6(8):1347–78

Synthesis of N,N'-bis-substituted diimides related to tricyclo [6.2.2.0(1,6)] dodecane with an expected activity on the central nervous system. Turło J, et al. **Farmaco** 1998 Jul 30;53(7):451–4

CHEMISTRY

Diazene--a not so innocent ligand for the binuclear center of cytochrome c oxidase. Liao GL, et al. **Biochemistry** 1998 Nov 3;37(44):15583–92

Models for superoxide dismutases: characterization of mononuclear Cu(II), Fe(III), and Mn(II) complexes with 4',5'-bis(salicylideneimino)benzo-15-crown-5. Güner S, et al. **Bioorg Med Chem** 1999 Feb;7(2):329–33

Effect of conformation on the conversion of cyclo-(1,7)-Gly-Arg-Gly-Asp-Ser-Pro-Asp-Gly-OH to its cyclic imide degradation product. Bogdanowich-Knipp SJ, et al. **J Pept Res** 1999 Jul;54(1):43–53

Conformational study of Ac-Xaa-Pro-NHMe dipeptides: proline puckering and trans/cis imide bond. Kang YK, et al. **J Pept Res** 1999 Jan;53(1):30–40

13C cross-polarization magic angle spinning NMR and gauge-independent atomic orbital, coupled Hartree-Fock calculations of buspirone analogues. Part 2. Hydrochlorides and perchlorates of 1-arylpiperazine-4-alkylimides. Szelejewska-Woźniakowska A, et al. **Solid State Nucl Magn Reson** 1999 Jun;14(1):59–65

Characterization of polyimides by 13C and 1H solid state nuclear magnetic resonance. Varner SJ, et al. **Solid State Nucl Magn Reson** 1998 Sep;12(2–3):71–85

METABOLISM

Cyclic-imide-hydrolyzing activity of D-hydantoinase from Blastobacter sp. strain A17p-4. Soong CL, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1459–62

PHARMACOLOGY

Effect of bimoclomol (N-[2-hydroxy-3-(1-piperidinyl) propoxy]-3 pyridine-carboximidoyl-chloride) on iminodipropionitrile-induced central effects. Tóth E, et al. **Neurochem Int** 1998 Dec;33(6):513–8

THERAPEUTIC USE

Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Costanza ME, et al. **Clin Cancer Res** 1995 Jul;1(7):699–704

IMIDOBENZYLE see **IMIPRAMINE**

IMIDOCARB

ANALOGS & DERIVATIVES

Administration of diminazene aceturate or imidocarb dipropionate for treatment of cytauxzoonosis in cats. Greene CE, et al. **J Am Vet Med Assoc** 1999 Aug 15;

IMIDOCARB

215(4):497–500, 482
Lack of susceptibility of Ehrlichia canis to imidocarb dipropionate in vitro. Kelly PJ, et al. **J S Afr Vet Assoc** 1998 Jun;69(2):55–6

IMIDOESTERS

Optimized conditions to couple two water-soluble biomolecules through alkylamine thiolation and thioetherification. Meunier L, et al. **Bioconjug Chem** 1999 Mar–Apr;10(2):206–12

CHEMICAL SYNTHESIS

Formation of glucoraphanin by chemoselective oxidation of natural glucoerucin: a chemoenzymatic route to sulforaphane. Iori R, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1047–8

CHEMISTRY

Mapping protein-protein interactions with a library of tethered cutting reagents: the binding site of sigma 70 on Escherichia coli RNA polymerase. Traviglia SL, et al. **Biochemistry** 1999 Apr 6;38(14):4259–65
Formation of glucoraphanin by chemoselective oxidation of natural glucoerucin: a chemoenzymatic route to sulforaphane. Iori R, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1047–8

IMINES

Asymmetric imine-ene reactions: diastereofacial selective reactions with chiral glyoxylate-derived alpha-imino esters and asymmetric catalysis of enantiofacial selective reactions with prochiral alpha-imino esters. Mikami K, et al. **Amino Acids** 1998;14(4):311–8

CHEMICAL SYNTHESIS

Synthesis and antibacterial activity of new cephalosporins with lactonyloxyimino moiety. Suh KH, et al. **Arch Pharm Res** 1994 Apr;17(2):87–92
Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase. Ling YZ, et al. **Bioorg Med Chem** 1998 Oct;6(10):1683–93
Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. Jimonet P, et al. **J Med Chem** 1999 Jul 29;42(15):2828–43
Novel (N-ferrocenylmethyl)amines and (N-ferrocenylmethylen)imines derived from vicinal steroid amino alcohols and amines: synthesis, molecular structure, and biological activity. Krieg R, et al. **Steroids** 1998 Oct; 63(10):531–41

CHEMISTRY

Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Chen W, et al. **Biochemistry** 1999 Jun 22;38(25):8159–66
Thioether adducts of a new imine reactive intermediate of the pneumotoxin 3-methylindole. Skordos KW, et al. **Chem Res Toxicol** 1998 Nov;11(11):1326–31
Highly deiminated isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles. Boggs JM, et al. **J Neurosci Res** 1999 Aug 15; 57(4):529–35

METABOLISM

Enzymes that exploit imines--one way or the other. Abell C. **Biochem Soc Trans** 1998 Aug;26(3):310–5 (15 ref.)

PHARMACOKINETICS

Tumor versus vascular photodamage in a rat tumor model. Kessel D, et al. **J Photochem Photobiol B** 1998 Aug 21; 45(1):25–7

PHARMACOLOGY

Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area. Hodges H, et al. **Behav Brain Res** 1999 Feb 15;99(1):81–92
Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase. Ling YZ, et al. **Bioorg Med Chem** 1998 Oct;6(10):1683–93
The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Harries MH, et al. **Br J Pharmacol** 1998 May;124(2):409–15
In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-alpha-methyl-histamine and its prodrug BP 2.94 in the dog. Mazenot C, et al. **Br J Pharmacol** 1999 Jan; 126(1):264–8
The adenylate cyclase inhibitor MDL-12330A has a non-specific effect on glycine transport in Müller cells from the retina. Gadea A, et al. **Brain Res** 1999 Aug 14; 838(1-2):200–4
In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes. Watson JM, et al. **Eur J Pharmacol** 1999 Apr 1;370(1):69–77
Spin-trapping agent alpha-phenyl N-tert-butylnitrone binds to trypsin and enhances heparin-induced inhibition of amidolytic activity and structural degradation of the enzyme. Finotti P, et al. **FEBS Lett** 1999 Jun 18; 453(1-2):159–63
Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Hatcher JP, et al. **Psychopharmacology (Berl)** 1998 Aug;138(3-4):275–82

THERAPEUTIC USE

In vivo and in vitro photodynamic studies with benzochlorin iminium salts delivered by a lipid emulsion. Garbo GM, et al. **Photochem Photobiol** 1998 Oct;68(4):561–8

TOXICITY

Metabolites of acetaminophen trigger Ca2+ release from liver microsomes. Stoyanovsky DA, et al. **Toxicol Lett** 1999 May 20;106(1):23–9

IMINO ACIDS

CHEMICAL SYNTHESIS

Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, et al. **Bioorg Med Chem** 1998 Aug;6(8):1347–78
Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2339–44

CHEMISTRY

Identification and characterization of kinetically competent carbinolamine and alpha-iminoglutarate complexes in the glutamate dehydrogenase-catalyzed oxidation of L-glutamate using a multiwavelength transient state approach. Maniscalco SJ, et al. **Biochemistry** 1998 Oct 13; 37(41):14585–90
Immobilized iminodiacetic acid (IDA)-type Cu2+ -chelating membrane affinity chromatography for purification of bovine liver catalase. Yang L, et al. **Biomed Chromatogr** 1999 May;13(3):229–34
Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, et al. **Bioorg Med Chem** 1998 Aug;6(8):1347–78
Higher order iminodiacetic acid libraries for probing protein-protein interactions. Boger DL, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2339–44
Technetium-99m complexes with steroid-2-aminooxyethyliminodiacetic acid conjugates. Yoda R, et al. **Chem Pharm Bull (Tokyo)** 1999 Mar; 47(3):413–6

DIAGNOSTIC USE

Technetium-99m complex of N-(2-pyridylmethyl)iminodiacetic acid as a new renal radiopharmaceutical. Karube Y, et al. **Ann Nucl Med** 1999 Apr;13(2):127–32
Where did the mass go? Hari JK, et al. **Clin Nucl Med** 1998 Nov;23(11):775–7
Imaging of septate gallbladder. Mrhac L, et al. **Clin Nucl Med** 1999 Mar;24(3):209–10
Focal liver uptake of Tc-99m mebrofenin in a patient with cavernous hemangioma. Oussama N, et al. **Clin Nucl Med** 1998 Jul;23(7):475–7
Evaluation of mebrofenin hepatoscintigraphy in neonatal-onset jaundice. Johnson K, et al. **Pediatr Radiol** 1998 Dec;28(12):937–41
The rim sign. Dorio PJ. **Radiology** 1998 Dec;209(3):801–2

IMIPEMIDE see **IMIPENEM**

IMIPENEM

Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Hellinger WC, et al. **Mayo Clin Proc** 1999 Apr; 74(4):420–34 (218 ref.)

ADMINISTRATION & DOSAGE

Intravenous regional infusion of imipenem for antimicrobial chemoprophylaxis in orthopaedic surgery [letter] Vrettou I, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):801–2
Report of eight cases of pulmonary actinomycosis and their treatment with imipenem-cilastatin. Yew WW, et al. **Monaldi Arch Chest Dis** 1999 Apr;54(2):126–9 (15 ref.)

ADVERSE EFFECTS

Insulin autoimmune syndrome after therapy with imipenem [letter] Lidar M, et al. **Diabetes Care** 1999 Mar;22(3):524–5
Empiric therapy of sepsis in the surgical intensive care unit with broad-spectrum antibiotics for 72 hours does not lead to the emergence of resistant bacteria. Namias N, et al. **J Trauma** 1998 Nov;45(5):887–91
Neurological complication during imipenem/cilastatin therapy in uraemic patients [letter] Campise M. **Nephrol Dial Transplant** 1998 Jul;13(7):1895–6
Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis [letter] Rivera M, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):258–9

ECONOMICS

[Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis] Rodloff AC, et al. **Chirurg** 1998 Oct;69(10):1093–100; discussion 1100 (Eng. Abstr.) **(Ger)**

METABOLISM

[Analysis of secretion into the saliva of cefoxitin (Mefoxin), imipenem (Tienam) and meropenem (Meronem)] Kelentey B, et al. **Fogorv Sz** 1999 Jan;92(1):3–10 (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Resistance of Pseudomonas aeruginosa to imipenem induced by eluates from siliconized latex urinary catheters is related to outer membrane protein alterations. Martinez-Martinez L, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):397–9
Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Ochs MM, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1085–90
Effects of imipenem and meropenem on serum sensitivity and surface hydrophobicity of Klebsiella pneumoniae. Hoštacká A. **Arzneimittelforschung** 1998 Nov;48(11):1101–3
Utility of serial rectal swab cultures for detection of ceftazidime- and imipenem-resistant gram-negative bacilli from patients in the intensive care unit. Arbo MD, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):727–30
Effects of imipenem and meropenem on purine content of endothelial cells. Armbruster C, et al. **Int J Clin Pharmacol Ther** 1999 Feb;37(2):86–9
Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. Coquet L, et al. **J Antimicrob Chemother** 1998 Dec;42(6):755–60
In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. Fuchs PC, et al. **J Antimicrob Chemother** 1999 May; 43(5):703–6
Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network [letter; comment] Jones ME, et al. **J Antimicrob Chemother** 1999 Mar;43(3):429–31 . Comment on: J Antimicrob Chemother 1998 May;41(5):574–6. Comment on: J Antimicrob Chemother 1998 May;41(5):576–7.
In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem. Pragai Z, et al. **J Antimicrob Chemother** 1998 Dec;42(6):821–4
The production of a novel carbapenem-hydrolysing beta-lactamase in Aeromonas veronii biovar sobria, and its association with imipenem resistance [letter] Stunt RA, et al. **J Antimicrob Chemother** 1998 Dec;42(6):835–6
A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan [letter] Stunt RA, et al. **J Antimicrob Chemother** 1998 Aug; 42(2):272–3
Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients. Troillet N, et al. **J Hosp Infect** 1999 May;42(1):37–43
In vitro effect of imipenem on Acinetobacter baumannii. Hoštacká A. **Pharmazie** 1999 Jan;54(1):70–2
A bi-modal transfer of antibiotic resistance by conjugation and transduction from an imipenem-resistant strain of Pseudomonas aeruginosa. Babálová M, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):61–8
Imipenem inhibits in vitro activity of amphotericin B directed against Aspergillus fumigatus. Rath PM, et al. **Zentralbl Bakteriol** 1995 Nov;283(1):69–78
[Effects of prophylactic antibiotic agent on interleukin-6 level in open chest surgery--comparison between imipenem and flomoxef (published erratum appears in Jpn J Antibiot 1998 Oct;51(10):C-1)] Sohma A, et al. **Jpn J Antibiot** 1998 Sep;51(9):576–82 (Eng. Abstr.) **(Jpn)**
[Sensitivity to blood bactericidal activity and hydrophobicity of Acinetobacter baumannii after treatment with imipenem] Hoštacká A. **Epidemiol Mikrobiol Imunol** 1999 Apr; 48(2):67–70 (Eng. Abstr.) **(Slo)**
[Bactericidal activity and capacity for selection of mutants resistant to imipenmen and meropenem in strains of Proteus, Morganella and Providencia] Villar HE, et al. **Enferm Infecc Microbiol Clin** 1998 Jun-Jul;16(6):261–4 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Donahue PE, et al. **Am J Surg** 1998 Dec;176(6A Suppl):53S–61S
Comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients [letter; comment] Borja J, et al. **Clin Infect Dis** 1999 Feb;28(2):406–7. Comment on: Clin Infect Dis 1998 Mar;26(3):576–83.
Combination antibiotic therapy for severe melioidosis [letter;

comment] Simpson AJ, et al. **Clin Infect Dis** 1999 Feb; 28(2):410. Comment on: Clin Infect Dis 1998 Apr;26(4):889–94.
Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Bassi C, et al. **Gastroenterology** 1998 Dec;115(6):1513–7
Imipenem versus targeted therapy in cancer patients. Aoun M, et al. **Int J Antimicrob Agents** 1998 Nov;10(4):263–70
Imipenem for the treatment of melioidosis. Minassian MA, et al. **Int J Antimicrob Agents** 1999 Aug;12(3):263–5
Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. Zanetti G, et al. **Int J Antimicrob Agents** 1999 Feb;11(2):107–13
Cefepime versus imipenem–cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). Biron P, et al. **J Antimicrob Chemother** 1998 Oct;42(4):511–8
Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia [see comments] Caldwell JW, et al. **J Antimicrob Chemother** 1999 Mar;43 Suppl A:129–34. Comment in: J Antimicrob Chemother 1999 Mar;43 Suppl A:115.
Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Newcomb D, et al. **Shock** 1998 Aug;10(2):110–7
[Enzymatic resistance to imipenem in gram-negative bacilli: NMC-A, an original carbapenemase] Boyer-Mariotte S. **Ann Pharm Fr** 1998;56(6):244–9 (43 ref.) (Eng. Abstr.) **(Fre)**
[Comparative activity of cefepime, ceftazidime and imipenem in a mouse infection caused by Klebsiella pneumoniae producing a broad spectrum beta-lactamase] Ronco E, et al. **Pathol Biol (Paris)** 1998 Oct;46(8):651–5 (Eng. Abstr.) **(Fre)**
[Imipenem resistance in Pseudomonas aeruginosa] Fille M, et al. **Wien Klin Wochenschr** 1998 Oct 30;110(20):715–20 (Eng. Abstr.) **(Ger)**
[Imipenem. Evaluation of its role in antibacterial therapy of severe hospital infections] Iakovlev SV. **Antibiot Khimioter** 1999;44(5):33–7 **(Rus)**

IMIPRAMINE

ADMINISTRATION & DOSAGE

[Is there a relationship between clinical efficacy and antidepressant dosage in major depression?] Corruble E, et al. **Encephale** 1999 Jun;25 Spec No 2:39–43; discussion 44–6 (9 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Testicular pain and swelling on withdrawal of imipramine [letter] Perera M, et al. **Br J Psychiatry** 1998 Sep;173:268
Imipramine-induced hyperpigmentation: four cases and a review of the literature. Ming ME, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):159–66 (20 ref.)
Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. Sicari MC, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):290–3
Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. Rousseau A, et al. **Pharmacology** 1998 Nov;57(5):242–8

ANALOGS & DERIVATIVES

Quinone-dependent tertiary amine N-oxide reduction in rat blood. Kitamura S, et al. **Biol Pharm Bull** 1998 Dec; 21(12):1344–7
Biphasic kinetics of imipramine N-oxidation in rat brain microsomes. Narimatsu S, et al. **Biol Pharm Bull** 1999 Mar; 22(3):253–6
A unique tertiary amine N-oxide reduction system composed of quinone reductase and heme in rat liver preparations. Kitamura S, et al. **Drug Metab Dispos** 1999 Jan;27(1):92–7

BLOOD

Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. Rosel P, et al. **J Affect Disord** 1999 Jan-Mar;52(1-3):225–33

METABOLISM

Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine. Thompson CM, et al. **Arch Biochem Biophys** 1998 Nov 1;359(1):115–21
Contribution of flavin-containing monooxygenase and cytochrome P450 to imipramine N-oxidation in rat hepatic microsomes. Narimatsu S, et al. **Biol Pharm Bull** 1999 Jun; 22(6):567–71
Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Yang TJ, et al. **Drug Metab Dispos** 1999 Jan;27(1):102–9
Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. Casis O, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):521–6
Variations in [3H]imipramine and 5-HT2A but not [3H]paroxetine binding sites in suicide brains. Rosel P, et al. **Psychiatry Res** 1998 Jun 30;82(3):161–70

PHARMACOKINETICS

Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. Ragusi C, et al. **Br J Pharmacol** 1998 Sep;125(1):35–40
Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men. Xu ZH, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Sep;17(5):399–402
Altered [3H]imipramine and 5-HT2 but not [3H]paroxetine binding sites in platelets from depressed patients. Rosel P, et al. **J Affect Disord** 1999 Jan-Mar;52(1-3):225–33

PHARMACOLOGY

Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Nowak G, et al. **Biol Trace Elem Res** 1999 Jan;67(1):85–92
Imipramine inhibition of transient K+ current: an external open channel blocker preventing fast inactivation. Kuo CC. **Biophys J** 1998 Dec;75(6):2845–57
Antagonistic effects of trifluoperazine, imipramine, and chlorpromazine against acetylcholine-induced contractions in isolated rat uterus. Balais SY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):97–100
Imipramine blocks the transient outward potassium current in rat ventricular myocytes. Liu QY, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jul;18(4):351–5
Imipramine inhibits soluble enkephalin-degrading aminopeptidase activity in vitro. Gallego M, et al. **Eur J Pharmacol** 1998 Oct 30;360(1):113–6
The effect of arginine-428 mutation on modulation of activity of human liver flavin monooxygenase 3 (FMO3) by imipramine and chlorpromazine. Adali O, et al. **Exp Toxicol Pathol** 1999 Jul;51(4–5):271–6
Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. Zhu J, et al. **J Autoimmun** 1998 Aug;11(4):319–27
Protection of neuronal uptake-1 inhibitors in ischemic and anoxic hearts by norepinephrine-dependent and -independent mechanisms. Du XJ, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):621–8
Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. Boyer PA, et al. **J Mol Neurosci** 1998 Jun;10(3):219–33
Effects of imipramine, an uptake inhibitor, on double-peaked constrictor responses to periarterial nerve stimulation in isolated, perfused canine splenic arteries. Yang XP, et al. **Jpn J Pharmacol** 1999 Apr;79(4):461–6
The effect of prolonged imipramine and electroconvulsive shock treatment on calcium/calmodulin-dependent protein kinase II in the hippocampus of rat brain. Pilc A, et al. **Neuropharmacology** 1999 Apr;38(4):597–603
Ethopharmacology of imipramine in the forced-swimming test: gender differences. Barros HM, et al. **Neurosci Biobehav Rev** 1998;23(2):279–86 (60 ref.)
Block and unblock by imipramine of cloned and mutated P2X2 receptor/channel expressed in Xenopus oocytes. Nakazawa K, et al. **Neurosci Lett** 1999 Apr 2;264(1–3):93–6
Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Yamadera H, et al. **Psychiatry Clin Neurosci** 1998 Aug;52(4):439–43
Effects of chronic mild stress (CMS) and imipramine administration, on spleen mononuclear cell proliferative response, serum corticosterone level and brain norepinephrine content in male mice. Azpiroz A, et al. **Psychoneuroendocrinology** 1999 Apr;24(3):345–61
[Effect of imipramine and ftoracizin on platelet aggregation and smooth muscle contraction of the ureter] Prokopenko PA, et al. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):101–5 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Rational treatment of panic disorder with antidepressants. Mavissakalian MR, et al. **Ann Clin Psychiatry** 1998 Dec; 10(4):185–95 (29 ref.)
Serotonin-induced platelet intracellular Ca2+ responses in untreated depressed patients and imipramine responders in remission. Tomiyoshi R, et al. **Biol Psychiatry** 1999 Apr 15;45(8):1042–8
Effects of panic disorder treatments on personality disorder characteristics. Hofmann SG, et al. **Depress Anxiety** 1998; 8(1):14–20
Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Bandelow B, et al. **Eur Arch Psychiatry Clin Neurosci** 1999;249(1):21–7
Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. Ochsenkühn R, et al. **Int J Androl** 1999 Jun;22(3):173–7
Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo [see comments] Sheikh JI, et al. **Int J Psychiatry Med** 1999; 29(1):107–17. Comment in: Int J Psychiatry Med 1999 ;29(1):91–5.
Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. Joffe RT, et al. **J Affect Disord** 1999 Jan-Mar;52(1-3):257–9
Perceived parenting pattern and response to antidepressants in patients with major depression. Sakado K, et al. **J Affect Disord** 1999 Jan-Mar;52(1-3):59–66
Pharmacotherapy response and diagnostic validity in atypical depression. Sotsky SM, et al. **J Affect Disord** 1999 Aug; 54(3):237–47
Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. Robert R, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jul; 38(7):873–82
An approach to the timely treatment of acute stress disorder. Robert R, et al. **J Burn Care Rehabil** 1999 May-Jun; 20(3):250–8
Prevalence variations in psychotropic treatment of children. Zito JM, et al. **J Child Adolesc Psychopharmacol** 1998; 8(2):99–105
Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. Bruijn JA, et al. **J Clin Psychiatry** 1998 Dec; 59(12):657–63
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Hirschfeld RM, et al. **J Clin Psychiatry** 1998 Dec;59(12):669–75
The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. Keller MB, et al. **J Clin Psychiatry** 1998 Nov;59(11):598–607
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. Miller IW, et al. **J Clin Psychiatry** 1998 Nov; 59(11):608–19
The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. Rush AJ, et al. **J Clin Psychiatry** 1998 Nov;59(11):589–97
The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. Strober M, et al. **J Clin Psychiatry** 1999 Mar;60(3):164–9
Panic disorder: long-term pharmacotherapy and discontinuation. Rickels K, et al. **J Clin Psychopharmacol** 1998 Dec;18(6 Suppl 2):12S–18S (45 ref.)
Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Stewart JW, et al. **J Clin Psychopharmacol** 1998 Dec;18(6):429–34
Dynamic systems theory as a paradigm for the study of change in psychotherapy: an application to cognitive therapy for depression. Hayes AM, et al. **J Consult Clin Psychol** 1998 Dec;66(6):939–47
A re-evaluation of social defeat as an animal model of depression. Marrow LP, et al. **J Psychopharmacol** 1999; 13(2):115–21
Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Gurguis GN, et al. **Neuropsychopharmacology** 1999 Feb; 20(2):162–76
A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Kirli S, et al. **Schizophr Res** 1998 Sep 7;33(1-2):103–11

TOXICITY

Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. Masubuchi Y, et al. **Arch Toxicol** 1999 Apr-May;73(3):147–51
Mechanisms of Ca2+ antagonism in imipramine-induced toxicity of isolated adult rat cardiomyocytes. Watts JA, et al. **Toxicol Appl Pharmacol** 1998 Nov;153(1):95–101

IMITATIVE BEHAVIOR

The ethological analysis of imitation. Miklósi A. **Biol Rev Camb Philos Soc** 1999 Aug;74(3):347–74 (142 ref.)
Social contagion, adolescent sexual behavior, and pregnancy: a nonlinear dynamic EMOSA model [see comments] Rodgers JL, et al. **Dev Psychol** 1998 Sep;34(5):1096–113. Comment in: Dev Psychol 1998 Sep;34(5):1114–6; discussion 1117–8.
Comment on "Social contagion, adolescent sexual behavior, and pregnancy: a nonlinear dynamic EMOSA model" [comment] Stoolmiller M. **Dev Psychol** 1998 Sep; 34(5):1114–6; discussion 1117–8. Comment on: Dev Psychol 1998 Sep;34(5):1096–13.
Immediate imitation and joint attention in young children with autism. Roeyers H, et al. **Dev Psychopathol** 1998 Summer;10(3):441–50
Imitation and identification in autism. Hobson RP, et al. **J Child Psychol Psychiatry** 1999 May;40(4):649–59
Modelling the training effects of kinaesthetic acuity measurement in children. Sims K, et al. **J Child Psychol Psychiatry** 1998 Jul;39(5):731–46
Effects of coaching on malingered motor function profiles. Rapport LJ, et al. **J Clin Exp Neuropsychol** 1998 Feb; 20(1):89–97
Observational learning and the use of retrieval information during the second and third years. Abravanel E, et al. **J Genet Psychol** 1998 Dec;159(4):455–76
The chameleon effect: the perception-behavior link and social interaction. Chartrand TL, et al. **J Pers Soc Psychol** 1999 Jun;76(6):893–910
The modeling of alcohol consumption: a meta-analytic

review. Quigley BM, et al. **J Stud Alcohol** 1999 Jan; 60(1):90–8

Video modeling and imaging training on performance of tennis service of 9- to 12-year-old children. Atienza FL, et al. **Percept Mot Skills** 1998 Oct;87(2):519–29

Perceptual differences in fetal alcohol effect boys performing a modeling task. Meyer MJ. **Percept Mot Skills** 1998 Dec; 87(3 Pt 1):784–6

Does visual perspective matter in imitation? Sambrook TD. **Perception** 1998;27(12):1461–73

[The "Werther effect". Historical origin and background of a phenomenon] Steinberg H. **Psychiatr Prax** 1999 Jan; 26(1):37–42 (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Learning by imitation: a hierarchical approach. Byrne RW, et al. **Behav Brain Sci** 1998 Oct;21(5):667–84; discussion 684–721 (240 ref.)

Factors influencing imitation of manipulatory actions in chimpanzees (Pan troglodytes). Myowa-Yamakoshi M, et al. **J Comp Psychol** 1999 Jun;113(2):128–36

Imitation of the sequential structure of actions by chimpanzees (Pan troglodytes). Whiten A. **J Comp Psychol** 1998 Sep;112(3):270–81

Imitation in eight young infants with Down's syndrome. Heimann M, et al. **Pediatr Res** 1998 Nov;44(5):780–4

From grasping to speech: imitation might provide a missing link [letter; comment] Miklósi A. **Trends Neurosci** 1999 Apr;22(4):151–2. Comment on: Trends Neurosci 1998 May;21(5):188–94.

IMIZIN see **IMIPRAMINE**

IMMEDIATE-EARLY GENES see **GENES, IMMEDIATE-EARLY**

IMMEDIATE-EARLY PROTEINS

ANALYSIS

Colocalization of the herpes simplex virus 1 UL4 protein with infected cell protein 22 in small, dense nuclear structures formed prior to onset of DNA synthesis. Jahedi S, et al. **J Virol** 1999 Jun;73(6):5132–8

BIOSYNTHESIS

Regulation of a novel immediate early response gene, IEX-1, in keratinocytes by 1alpha,25-dihydroxyvitamin D3. Kobayashi T, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):868–73

MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. Winter C, et al. **Brain Res** 1998 Aug 10;801(1–2):198–205

Cocaine and fluoxetine induce the expression of the hVH-5 gene encoding a MAP kinase phosphatase. Thiriet N, et al. **Brain Res Mol Brain Res** 1998 Nov 20;62(2):150–7

Rapid induction and translocation of Egr-1 in response to mechanical strain in vascular smooth muscle cells. Morawietz H, et al. **Circ Res** 1999 Apr 2;84(6):678–87

A viral activator of gene expression functions via the ubiquitin-proteasome pathway. Everett RD, et al. **EMBO J** 1998 Dec 15;17(24):7161–9

Cyclophosphamide cystitis as a model of visceral pain in rats: a c-fos and Krox-24 study at telencephalic levels, with a note on pituitary adenylate cyclase activating polypeptide (PACAP). Bon K, et al. **Exp Brain Res** 1998 Sep; 122(2):165–74

Effect of trichloroethylene on DNA methylation and expression of early-intermediate protooncogenes in the liver of B6C3F1 mice. Tao L, et al. **J Biochem Mol Toxicol** 1999;13(5):231–7

Cyclic strain stress-induced mitogen-activated protein kinase (MAPK) phosphatase 1 expression in vascular smooth muscle cells is regulated by Ras/Rac-MAPK pathways. Li C, et al. **J Biol Chem** 1999 Sep 3;274(36):25273–80

Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells. Metzler B, et al. **J Biol Chem** 1998 Dec 11;273(50):33320–6

Decreased expression and activity of the immediate-early growth response (Egr-1) gene product during cellular senescence. Meyyappan M, et al. **J Cell Physiol** 1999 Apr; 179(1):29–39

Macrophage colony-stimulating factor induces the expression of mitogen-activated protein kinase phosphatase-1 through a protein kinase C-dependent pathway. Valledor AF, et al. **J Immunol** 1999 Sep 1; 163(5):2452–62

Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. O'Neill MF, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):839–46

Temporal and spatial regulation of the expression of BAD2, a MAP kinase phosphatase, during seizure, kindling, and long-term potentiation. Qian Z, et al. **Learn Mem** 1994 Sep–Oct;1(3):180–8

CHEMISTRY

A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Van Sant C, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8184–9

Characterization of the acidic domain of the IE1 regulatory protein from Orgyia pseudotsugata multicapsid nucleopolyhedrovirus. Forsythe IJ, et al. **Virology** 1998 Dec 5;252(1):65–81

GENETICS

Sequences downstream of the RNA initiation site of the HTLV type I long terminal repeat are sufficient for trans-activation by human cytomegalovirus immediate-early proteins. Kim JM, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):545–50

Differential display PCR reveals induction of immediate early genes by vasoactive intestinal peptide in PC12 cells. Eschelbach A, et al. **Ann N Y Acad Sci** 1998 Dec 11; 865:181–8

p22/PACAP response gene 1 (PRG1): a putative target gene for the tumor suppressor p53. Schäfer H, et al. **Ann N Y Acad Sci** 1998 Dec 11;865:27–36

p22/PRG1: a novel early response gene in pancreatic cancer cells regulated by p53 and NF kappa B. Schmidt WE, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:147–56

Characterization of a bovine herpesvirus 4(BHV-4) 1.1-kb RNA and its transactivation by BHV-4 immediate-early 2 gene product. Bermudez-Cruz R, et al. **Arch Virol** 1998; 143(12):2391–412

LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells. Metzler B, et al. **Arterioscler Thromb Vasc Biol** 1999 Aug;19(8):1862–71

A novel immediate early response gene, IEX-1, is induced by ultraviolet radiation in human keratinocytes. Kumar R, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):336–41

The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22(PRG1/IEX-1) and is not expressed in vivo. Schäfer H, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):139–45

Sphingosine 1-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle. Role of endothelial differentiation gene 1, c-Src tyrosine kinase and phosphoinositide 3-kinase. Rakhit S, et al. **Biochem J** 1999 Mar 15;338 (Pt 3):643–9

Increased expression of zif268 mRNA in rat retrosplenial cortex following administration of phencyclidine. Shirayama Y, et al. **Brain Res** 1999 Aug 21;839(1):180–5

MAP kinase phosphatase-1 mRNA is expressed in embryonic sympathetic neurons and is upregulated after NGF stimulation. Peinado-Ramón P, et al. **Brain Res Mol Brain Res** 1998 May;56(1–2):256–67

Radiation-inducible gene therapy. Mauceri HJ, et al. **C R Acad Sci III** 1999 Feb–Mar;322(2–3):225–8 (19 ref.)

Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Goetzl EJ, et al. **Cancer Res** 1999 Sep 15;59(18):4732–7

Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Westphal EM, et al. **Cancer Res** 1999 Apr 1;59(7):1485–91

Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. Everett RD, et al. **EMBO J** 1999 Mar 15;18(6):1526–38

Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Tollet-Egnell P, et al. **Endocrinology** 1999 Aug; 140(8):3693–704

A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Sawicki JA, et al. **Exp Cell Res** 1998 Oct 10;244(1):367–9

Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. Walden PD, et al. **Exp Cell Res** 1998 Nov 25; 245(1):19–26

The ras oncogene inhibits growth factor inducibility of early response genes, and promotes selectively expression of NGFI-A in a PC12 cell line. Cosgaya JM, et al. **FEBS Lett** 1999 Feb 26;445(2–3):329–32

Immediate early response of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein. Lee YH, et al. **FEBS Lett** 1998 Nov 6;438(3):297–300

Molecular cloning of human er1 cDNA and its differential expression in breast tumours and tumour-derived cell lines. Paterno GD, et al. **Gene** 1998 Nov 5;222(1):77–82

High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5. Howard MK, et al. **Gene Ther** 1998 Aug;5(8):1137–47

Cloning of the human interferon-related developmental regulator (IFRD1) gene coding for the PC4 protein, a member of a novel family of developmentally regulated genes. Buanne P, et al. **Genomics** 1998 Jul 15;51(2):233–42

Ier5, a novel member of the slow-kinetics immediate-early genes. Williams M, et al. **Genomics** 1999 Feb 1;55(3):327–34

Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Kawashita Y, et al. **Hum Gene Ther** 1999 Jun 10;10(9):1509–19

Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. Bokemeyer D, et al. **Hypertension** 1998 Oct;32(4):661–7

Comparative analysis of promoters for transient gene expression in cultured mosquito cells. Zhao YG, et al. **Insect Mol Biol** 1999 Feb;8(1):31–8

Evaluation of the AmpliSensor PCR and the SHARP signal detection system for the early prediction of symptomatic CMV infection in solid transplant recipients. Rautenberg P, et al. **J Clin Virol** 1999 Jun;13(1–2):81–94

An analysis of herpes simplex virus gene expression during latency establishment and reactivation. Lachmann RH, et al. **J Gen Virol** 1999 May;80 (Pt 5):1271–82

Translational control of viral and host protein synthesis during the course of herpes simplex virus type 1 infection: evidence that initiation of translation is the limiting step. Laurent AM, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2765–75

Strong conservation of the constitutive activity of the IE1/2 transcriptional control region in wild-type strains of human cytomegalovirus. Sorg G, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):3039–47

Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. Lipscomb EA, et al. **J Neurochem** 1999 Jul;73(1):429–32

Increased intracellular calcium alters myelin gene expression in the N20.1 oligodendroglial cell line. Studzinski DM, et al. **J Neurosci Res** 1999 Sep 1;57(5):633–42

Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. Hobbs WE 2nd, et al. **J Virol** 1999 Oct;73(10):8245–55

A cis repression sequence adjacent to the transcription start site of the human cytomegalovirus US3 gene is required to down regulate gene expression at early and late times after infection. Lashmit PE, et al. **J Virol** 1998 Dec; 72(12):9575–84

Effects of human cytomegalovirus major immediate-early proteins in controlling the cell cycle and inhibiting apoptosis: studies with ts13 cells. Lukac DM, et al. **J Virol** 1999 Apr;73(4):2825–31

Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US1.5 protein. Ogle WO, et al. **J Virol** 1999 May;73(5):4305–15

PCR-RFLP analysis of cytomegalovirus infections associated with bone marrow transplantation in Japanese children. Kawasaki S, et al. **Microbiol Immunol** 1999; 43(4):359–64

A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Verdier F, et al. **Mol Cell Biol** 1998 Oct;18(10):5852–60

Light- and focus-dependent expression of the transcription factor ZENK in the chick retina. Fischer AJ, et al. **Nat Neurosci** 1999 Aug;2(8):706–12

Expression of immediate early gene cyr61 during the differentiation of immortalized embryonic hippocampal neuronal cells. Chung KC, et al. **Neurosci Lett** 1998 Oct 23;255(3):155–8

Circadian and photic regulation of immediate-early gene expression in the hamster suprachiasmatic nucleus. Guido ME, et al. **Neuroscience** 1999 May;90(2):555–71

Expression of c-fos, junB, c-jun, MKP-1 and hsp72 following traumatic neocortical lesions in rats--relation to spreading depression. Hermann DM, et al. **Neuroscience** 1999 Jan;88(2):599–608

Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division. Iacopetti P, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4639–44

Human cytomegalovirus US3 gene expression is regulated by a complex network of positive and negative regulators. Biegalke BJ. **Virology** 1999 Sep 1;261(2):155–64

The early baculovirus he65 promoter: On the mechanism of transcriptional activation by IE1. Kremer A, et al. **Virology** 1998 Sep 30;249(2):336–51

Site-directed mutagenesis of the AcMNPV p143 gene: effects on baculovirus DNA replication. Liu G, et al. **Virology** 1999 Jan 5;253(1):125–36

The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Panagiotidis CA, et al. **Virology** 1999 Mar 30; 256(1):64–74

The defective interfering particles of equine herpesvirus 1 encode an ICP22/ICP27 hybrid protein that alters viral gene regulation. Chen M, et al. **Virus Res** 1999 Feb; 59(2):149–64

A polymorphism in the major immediate-early gene delineates groups among cytomegalovirus clinical isolates. Retière C, et al. **Virus Res** 1998 Sep;57(1):43–51

[Mechanisms of BTG2 activity, a transcriptional target of p53: evidences and hypothesis.] Puisieux A, et al. **Bull Cancer** 1999 Apr;86(4):358–64 (42 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE, et al. **J Immunol** 1999 Jan 1;162(1):560–7

Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. Jenkins DE, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S39–42

Varicella-zoster virus IE63, a virion component expressed

during latency and acute infection, elicits humoral and cellular immunity. Sadzot-Delvaux C, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S43-7

Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. Kern F, et al. **J Virol** 1999 Oct; 73(10):8179-84

Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. Le Roy E, et al. **J Virol** 1999 Aug;73(8):6582-9

Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. Pepperl S, et al. **J Virol** 1998 Nov;72(11):8644-9

Proliferation and MHC-unrestricted bystander lysis by virus-specific cytotoxic T cells following antigen self-presentation. Staege MS, et al. **Med Microbiol Immunol (Berl)** 1998 Jun;187(1):17-21

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Rosenthal KS, et al. **Vaccine** 1999 Feb 12; 17(6):535-42

Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. Brehm M, et al. **Virology** 1999 Apr 10;256(2):258-69

Phenotypic and functional characterization of CD8(+) T cell clones specific for a mouse cytomegalovirus epitope. Fernandez JA, et al. **Virology** 1999 Mar 1;255(1):40-9

[Diagnosis of the active form of cytomegalovirus infection based on determination of IgG antibodies to the immediate-early cytomegalovirus protein by lanthanide immunofluorescence analysis] Pomelova VG, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):89-92 (Eng. Abstr.) **(Rus)**

METABOLISM

Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Stumptner C, et al. **Am J Pathol** 1999 Jun; 154(6):1701-10

In situ RT-PCR detection of Epstein-Barr virus immediate-early transcripts in CD4+ and CD8+ T lymphocytes. Guan M, et al. **Anticancer Res** 1998 Sep-Oct; 18(5A):3171-80

EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16. Okamoto H, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):203-8

The putative apoptosis inhibitor IEX-1L is a mutant nonspliced variant of p22(PRG1/IEX-1) and is not expressed in vivo. Schäfer H, et al. **Biochem Biophys Res Commun** 1999 Aug 19;262(1):139-45

Enzymatic methylation of recombinant TIS21 protein-arginine residues. Lim IK, et al. **Biochem Mol Biol Int** 1998 Aug;45(5):871-8

The CCN family of angiogenic regulators: the integrin connection. Lau LF, et al. **Exp Cell Res** 1999 Apr 10; 248(1):44-57 (101 ref.)

Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. Gatfield J, et al. **Int Immunol** 1998 Nov; 10(11):1665-72

Binding studies with mutants of Zif268. Contribution of individual side chains to binding affinity and specificity in the Zif268 zinc finger-DNA complex. Elrod-Erickson M, et al. **J Biol Chem** 1999 Jul 2;274(27):19281-5

Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. Laderoute KR, et al. **J Biol Chem** 1999 Apr 30;274(18):12890-7

EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. Okamoto H, et al. **J Biol Chem** 1998 Oct 16;273(42):27104-10

Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. Peng Y, et al. **J Biol Chem** 1999 Feb 19;274(8):4513-20

Sp1 and egr-1 have opposing effects on the regulation of the rat Pgp2/mdr1b gene. Thottassery JV, et al. **J Biol Chem** 1999 Jan 29;274(5):3199-206

Angiotensin II-induced tyrosine phosphorylation of signal transducers and activators of transcription 1 is regulated by Janus-activated kinase 2 and Fyn kinases and mitogen-activated protein kinase phosphatase 1. Venema RC, et al. **J Biol Chem** 1998 Nov 13;273(46):30795-800

Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. Verdier F, et al. **J Biol Chem** 1998 Oct 23; 273(43):28185-90

Characterization of the interaction between the baculovirus ssDNA-binding protein (LEF-3) and putative helicase (P143). Evans JT, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):493-500

Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. Johnson RA, et al. **J Gen Virol** 1999 May;80 (Pt 5):1293-303

Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation. Yurochko AD, et al. **J Hum Virol** 1999 Mar-Apr;2(2):81-90

Regulated nuclear localization of the varicella-zoster virus major regulatory protein, IE62. Kinchington PR, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S16-21

A novel cellular protein, p60, interacting with both herpes simplex virus 1 regulatory proteins ICP22 and ICP0 is modified in a cell-type-specific manner and Is recruited to the nucleus after infection. Bruni R, et al. **J Virol** 1999 May;73(5):3810-7

Herpes simplex virus 1 regulatory protein ICP22 interacts with a new cell cycle-regulated factor and accumulates in a cell cycle-dependent fashion in infected cells. Bruni R, et al. **J Virol** 1998 Nov;72(11):8525-31

The C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus protein EB2 is required for its effect on RNA splicing and transport. Buisson M, et al. **J Virol** 1999 May;73(5):4090-100

Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. Hrimech M, et al. **J Virol** 1999 May;73(5):4101-9

Intracellular formation and processing of the heterotrimeric gH-gL-gO (gCIII) glycoprotein envelope complex of human cytomegalovirus. Huber MT, et al. **J Virol** 1999 May;73(5):3886-92

ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. Long MC, et al. **J Virol** 1999 Jul;73(7):5593-604

The baculovirus PE38 protein augments apoptosis induced by transactivator IE1. Prikhod'ko EA, et al. **J Virol** 1999 Aug;73(8):6691-9

The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. Swenson JJ, et al. **J Virol** 1999 Aug;73(8):6540-50

Analysis of the phosphorylation sites of herpes simplex virus type 1 regulatory protein ICP27. Zhi Y, et al. **J Virol** 1999 Apr;73(4):3246-57

Differential nuclear localization of ER1 protein during embryonic development in Xenopus laevis. Luchman HA, et al. **Mech Dev** 1999 Jan;80(1):111-4

Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Babic AM, et al. **Mol Cell Biol** 1999 Apr;19(4):2958-66

All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Lee HY, et al. **Mol Cell Biol** 1999 Mar;19(3):1973-80

Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Matsumoto A, et al. **Mol Cell Biol** 1999 Sep;19(9):6396-407

Activation of the thymidine kinase promoter by herpes simplex virus type 1 immediate early proteins. Kwun HJ, et al. **Mol Cells** 1999 Jun 30;9(3):277-80

Early growth response protein 1 binds to the luteinizing hormone-beta promoter and mediates gonadotropin-releasing hormone-stimulated gene expression. Wolfe MW, et al. **Mol Endocrinol** 1999 May; 13(5):752-63

Thyroid hormone effects on Krox-24 transcription in the post-natal mouse brain are developmentally regulated but are not correlated with mitosis. Ghorbel MT, et al. **Oncogene** 1999 Jan 28;18(4):917-24

A single amino acid substitution in the cyclin D binding domain of the infected cell protein no. 0 abrogates the neuroinvasiveness of herpes simplex virus without affecting its ability to replicate. Van Sant C, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8184-9

Pseudorabies virus (PRV) early protein 0 activates PRV gene transcription in combination with the immediate-early protein IE180 and enhances the infectivity of PRV genomic DNA. Ono E, et al. **Vet Microbiol** 1998 Oct;63(2-4):99-107

Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Adamson AL, et al. **Virology** 1998 Nov 10;251(1):187-97

The gamma2 late glycoprotein K promoter of equine herpesvirus 1 is differentially regulated by the IE and EICP0 proteins. Kim SK, et al. **Virology** 1999 Apr 10; 256(2):173-9

The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter. Panagiotidis CA, et al. **Virology** 1999 Mar 30; 256(1):64-74

Binding of the human cytomegalovirus 80-kDa immediate-early protein (IE2) to minor groove A/T-rich sequences bounded by CG dinucleotides is regulated by protein oligomerization and phosphorylation. Waheed I, et al. **Virology** 1998 Dec 5;252(1):235-57

Stable ubiquitination of the ICP0R protein of herpes simplex virus type 1 during productive infection. Weber PC, et al. **Virology** 1999 Jan 20;253(2):288-98

Self-interaction of the herpes simplex virus type 1 regulatory protein ICP27. Zhi Y, et al. **Virology** 1999 May 10; 257(2):341-51

PHARMACOLOGY

The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. Liu C, et al. **J Biol Chem** 1999 Feb 12;274(7):4400-11

The p56(lck)-interacting protein p62 stimulates transcription via the SV40 enhancer. Rachubinski RA, et al. **J Biol Chem** 1999 Jun 25;274(26):18278-84

Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins [see comments] Burns LJ, et al. **Transplantation** 1999 Jan 15;67(1):137-44. Comment in: Transplantation 1999 Jan 15;67(1):2-3.

PHYSIOLOGY

The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Zhou YF, et al. **Biochem Biophys Res Commun** 1999 Mar 24;256(3):608-13

Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Tanaka K, et al. **Circulation** 1999 Apr 6; 99(13):1656-9

Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. Ancellin N, et al. **J Biol Chem** 1999 Jul 2;274(27):18997-9002

Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. Dorn C, et al. **J Biol Chem** 1999 May 14;274(20):13870-6

Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3). Jedsadayanmata A, et al. **J Biol Chem** 1999 Aug 20; 274(34):24321-7

Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells. Mittelstadt PR, et al. **J Biol Chem** 1999 Jan 29; 274(5):3222-7

Hypoxia-associated induction of early growth response-1 gene expression. Yan SF, et al. **J Biol Chem** 1999 May 21;274(21):15030-40

Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. Leib DA, et al. **J Exp Med** 1999 Feb 15;189(4):663-72

Human cytomegalovirus IE1 protein activates AP-1 through a cellular protein kinase(s). Kim S, et al. **J Gen Virol** 1999 Apr;80 (Pt 4):961-9

The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. Aubert M, et al. **J Virol** 1999 Apr; 73(4):2803-13

The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication. Everett RD, et al. **J Virol** 1999 Jan;73(1):417-26

Amino acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of early lytic cycle genes and synergy with the Epstein-Barr virus R transactivator. Francis A, et al. **J Virol** 1999 Jun; 73(6):4543-51

Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle. Lu M, et al. **J Virol** 1999 Jan;73(1):676-83

Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. Müller S, et al. **J Virol** 1999 Jun; 73(6):5137-43

Colocalization of baculovirus IE-1 and two DNA-binding proteins, DBP and LEF-3, to viral replication factories. Okano K, et al. **J Virol** 1999 Jan;73(1):110-9

Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. Parkinson J, et al. **J Virol** 1999 Jan;73(1):650-7

The CIS/JAB family: novel negative regulators of JAK signaling pathways. Yoshimura A. **Leukemia** 1998 Dec; 12(12):1851-7 (47 ref.)

Interactions between a herpes simplex virus regulatory protein and cellular mRNA processing pathways. Sandri-Goldin RM. **Methods** 1998 Sep;16(1):95-104

Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Liu CH, et al. **Mol Biol Cell** 1999 Apr; 10(4):1179-90

Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Lim IK, et al. **Mol Carcinog** 1998 Sep;23(1):25-35

MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction [see comments] Thomson S, et al. **Semin Cell Dev Biol** 1999 Apr;10(2):205-14 (77 ref.). Comment in: Semin Cell Dev Biol 1999 Apr;10(2):165-7.

Intercellular adhesion molecule-1 expression in endothelial

cells is activated by cytomegalovirus immediate early proteins [comment] Moss P. **Transplantation** 1999 Jan 15; 67(1):2-3 (14 ref.). Comment on: Transplantation 1999 Jan 15;67(1):137-44.

[Mechanisms of BTG2 activity, a transcriptional target of p53: evidences and hypothesis.] Puisieux A, et al. **Bull Cancer** 1999 Apr;86(4):358-64 (42 ref.) (Eng. Abstr.) **(Fre)**

IMMEDIATE RECALL see **MEMORY, SHORT-TERM**

IMMERSION

see related
DIVING
DROWNING

Luminal acid in water-immersion stress and the antiulcer effect of axetazolamide in the rat gastric mucosa. Gutierrez-Cabano CA. **Acta Gastroenterol Latinoam** 1999; 29(1):25-31

Maximal physiological responses to deep water running at thermoneutral temperature. Nakanishi Y, et al. **Appl Human Sci** 1999 Mar;18(2):31-5

Evaluation of a new universal jettison mechanism for helicopter underwater escape. Brooks CJ, et al. **Aviat Space Environ Med** 1999 Aug;70(8):752-8

A hand immersion test under laboratory-controlled usage conditions: the need for sensitive and controlled assessment methods. Paye M, et al. **Contact Dermatitis** 1999 Mar; 40(3):133-8

The effect of dynamic exercise on resting cold thermoregulatory responses measured during water immersion. Kenny GP, et al. **Eur J Appl Physiol** 1999 May; 79(6):495-9

Analysis of salivary DNA evidence from a bite mark on a body submerged in water. Sweet D, et al. **J Forensic Sci** 1999 Sep;44(5):1069-72

Vasopressin, angiotensin II and renal responses during water immersion in hydrated humans. Hammerum MS, et al. **J Physiol (Lond)** 1998 Aug 15;511 (Pt 1):323-30

Whole body cooling by immersion in water at moderate temperatures. Marino F, et al. **J Sci Med Sport** 1998 Jun; 1(2):73-82

Effects of cold water immersion on the symptoms of exercise-induced muscle damage. Eston R, et al. **J Sports Sci** 1999 Mar;17(3):231-8

Visualization of blood vessels without prior perfusion. Zwi LJ, et al. **Microvasc Res** 1999 Jul;58(1):79-82

Effects of immersion in cool water on lung-exhaled nitric oxide at rest and during exercise. Pendergast DR, et al. **Respir Physiol** 1999 Jan 1;115(1):73-81

Effects of hydration on tactile sensation. Verrillo RT, et al. **Somatosens Mot Res** 1998;15(2):93-108

[Intraocular lens calculation and ultrasound biometry: immersion and contact procedures] Hoffmann PC, et al. **Klin Monatsbl Augenheilkd** 1998 Sep;213(3):161-5 **(Eng. Abstr.) (Ger)**

ADVERSE EFFECTS

Face immersion in cold water induces prolongation of the QT interval and T-wave changes in children with nonfamilial long QT syndrome. Yoshinaga M, et al. **Am J Cardiol** 1999 May 15;83(10):1494-7, A8

A few issues about the bionic ear [letter; comment] Ahmadizadeh A. **Arch Otolaryngol Head Neck Surg** 1999 Apr;125(4):477-8. Comment on: Arch Otolaryngol Head Neck Surg 1998 Oct;124(10):1118-21.

Tympanostomy tubes and water exposure: a practical model [see comments] Hebert RL 2nd, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct; 124(10):1118-21. Comment in: Arch Otolaryngol Head Neck Surg 1999 Apr;125(4):477-8.

Head-out immersion in the non-human primate: a model of cardiovascular deconditioning during microgravity. Cornish KG, et al. **Aviat Space Environ Med** 1999 Aug; 70(8):773-9

Effect of glucose-water ingestion on exercise thermoregulation in men dehydrated after water immersion. Dearborn AS, et al. **Aviat Space Environ Med** 1999 Jan;70(1):35-41

The effect of wave motion on dry suit insulation and the responses to cold water immersion. Ducharme MB, et al. **Aviat Space Environ Med** 1998 Oct;69(10):957-64

Does capsaicin affect physiologic and thermal responses of males during immersion in 22 degrees C? Glickman-Weiss EL, et al. **Aviat Space Environ Med** 1998 Nov;69(11):1095-9

The effect of water immersion on postural and visual orientation. Jarchow T, et al. **Aviat Space Environ Med** 1999 Sep;70(9):879-86

Electrical and contractile parameters of muscle in man: effects of 7-day "dry" water immersion. Koryak Y. **Aviat Space Environ Med** 1999 May;70(5):459-64

Thermal and metabolic responses of high and low fat women to cold water immersion. Prisby R, et al. **Aviat Space Environ Med** 1999 Sep;70(9):887-91

Acute renal impairment after immersion and near-drowning. Spicer ST, et al. **J Am Soc Nephrol** 1999 Feb;10(2):382-6

Effect of Saiboku-to, an Oriental Herbal Medicine, on gastric lesion induced by restraint water-immersion stress or by ethanol treatment. Yuzurihara M, et al. **J Pharm Pharmacol** 1999 Apr;51(4):483-90

Habituation of the initial responses to cold water immersion in humans: a central or peripheral mechanism? Tipton MJ, et al. **J Physiol (Lond)** 1998 Oct 15;512 (Pt 2):621-8

[The pharmacological correction of the antioxidant status and of the immunological reactivity of the body during air and immersion cooling] Laskova IL, et al. **Eksp Klin Farmakol** 1999 May-Jun;62(3):44-7 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Comparison of responses of men to immersion in circulating water at 40.0 and 41.5 degrees C. Allison TG, et al. **Aviat Space Environ Med** 1998 Sep;69(9):845-50

The effect of water immersion on postural and visual orientation. Jarchow T, et al. **Aviat Space Environ Med** 1999 Sep;70(9):879-86

Thermal and metabolic responses of high and low fat women to cold water immersion. Prisby R, et al. **Aviat Space Environ Med** 1999 Sep;70(9):887-91

Renal, endocrine, and cardiovascular responses during head-out water immersion in legless men. Tajima F, et al. **Aviat Space Environ Med** 1999 May;70(5):465-70

Water immersion delays the oxygen uptake response to sitting arm-cranking in humans. Hayashi N, et al. **Eur J Appl Physiol** 1999 Jul;80(2):132-8

Temperature dependence of habituation of the initial responses to cold-water immersion. Tipton MJ, et al. **Eur J Appl Physiol** 1998 Aug;78(3):253-7

Influence of immersion on respiratory requirements during 30-min cycling exercise. Bréchat PH, et al. **Eur Respir J** 1999 Apr;13(4):860-6

Heat balance at -5 degrees C after cold water immersion. Rintamäki H, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:738-41

Influence of water immersion stress on peripheral nerve recovery in the rat. Amako M, et al. **J Orthop Sci** 1998; 3(1):32-41

Immersion deaths and swim failure--implications for resuscitation and prevention [comment] Ryan JM. **Lancet** 1999 Aug 21;354(9179):613. Comment on: Lancet 1999 Aug 21;354(9179):626-9.

Immersion deaths and deterioration in swimming performance in cold water [see comments] Tipton M, et al. **Lancet** 1999 Aug 21;354(9179):626-9. Comment in: Lancet 1999 Aug 21;354(9179):613.

Lack of effect of 24 atm abs environment on face immersion bradycardia in human subjects [letter] Shiraki K, et al. **Undersea Hyperb Med** 1998 Fall;25(3):189-90

Subacute effects of inspiratory resistive loading and head-out water immersion on pulmonary function. Thorsen E, et al. **Undersea Hyperb Med** 1999 Fall;26(3):137-41

[The physical work capacity of divers during prolonged deep-water immersions] Novikov VS, et al. **Fiziol Cheloveka** 1998 Jul-Aug;24(4):38-42 **(Rus)**

[The hemodynamics and physical work capacity of divers after prolonged deep-water immersions] Novikov VS, et al. **Voen Med Zh** 1999 Feb;320(2):69-71 **(Rus)**

IMMERSION FOOT

EPIDEMIOLOGY

The epidemiology of cold injury in Antarctica. Cattermole TJ. **Aviat Space Environ Med** 1999 Feb;70(2):135-40

IMMIGRATION see **EMIGRATION AND IMMIGRATION**

IMMOBILIZATION

see related
HYPOKINESIA

No advantage from splinting the wrist after open carpal tunnel release. A randomized study of 82 wrists. Finsen V, et al. **Acta Orthop Scand** 1999 Jun;70(3):288-92

Oxidative stress and haematological changes in immobilized rats. Oishi K, et al. **Acta Physiol Scand** 1999 Jan;165(1):65-9

Suturing versus immobilization of a muscle laceration. A morphological and functional study in a mouse model. Menetrey J, et al. **Am J Sports Med** 1999 Mar-Apr; 27(2):222-9

Early full weightbearing and functional treatment after surgical repair of acute achilles tendon rupture. Speck M, et al. **Am J Sports Med** 1998 Nov-Dec;26(6):789-93

Effects of acepromazine and butorphanol on positive-contrast upper gastrointestinal tract examination in dogs. Scrivani PV, et al. **Am J Vet Res** 1998 Oct; 59(10):1227-33

The Combitube and cervical spine immobilisation [letter; comment] Gwinnutt CL, et al. **Anaesthesia** 1999 Mar; 54(3):304-5. Comment on: Anaesthesia 1998 Oct;53(10):971-4.

Insertion of the Combitube airway with the cervical spine immobilised in a rigid cervical collar [see comments] Mercer MH, et al. **Anaesthesia** 1998 Oct;53(10):971-4. Comment in: Anaesthesia 1999 Mar;54(3):304-5.

Pressure immobilization for neurotoxic snake bites [letter] Winkel KD, et al. **Ann Emerg Med** 1999 Aug;34(2):294-5

Abnormal mitochondria and sarcoplasmic changes in rabbit skeletal muscle induced by immobilization. Leivo I, et al. **APMIS** 1998 Dec;106(12):1113-23

Influenza vaccination in bedridden patients [letter] Fukushima T, et al. **Arch Intern Med** 1999 Feb 8; 159(3):316-7

Bone loss after hip fracture is correlated to the postoperative degree of mobilisation. Zerahn B, et al. **Arch Orthop Trauma Surg** 1998;117(8):453-6

Head movement restriction and postural stability in patients with compensated unilateral vestibular loss. Karlberg M, et al. **Arch Phys Med Rehabil** 1998 Nov;79(11):1448-50

Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Massagli TL, et al. **Arch Phys Med Rehabil** 1999 Sep;80(9):998-1000

Prospective randomized clinical trial comparing the effectiveness of immediate arthroscopic stabilization versus immobilization and rehabilitation in first traumatic anterior dislocations of the shoulder. Kirkley A, et al. **Arthroscopy** 1999 Jul-Aug;15(5):507-14

Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. Sato Y, et al. **Bone** 1999 Mar;24(3):271-5

Decreased spermatogenic and androgenic testicular functions in adult rats submitted to immobilization-induced stress from prepuberty. Almeida SA, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1443-8

Remobilization does not fully restore immobilization induced articular cartilage atrophy. Haapala J, et al. **Clin Orthop** 1999 May;(362):218-29

Sedation and chemical restraint in the dog and cat. Karas AZ. **Clin Tech Small Anim Pract** 1999 Feb;14(1):15-26 (11 ref.)

Effects of hindlimb suspension and androgen treatment on testosterone receptors in rat skeletal muscles. Bricout VA, et al. **Eur J Appl Physiol** 1999 Apr;79(5):443-8

Ureteral catheterization and patient mobilization: is bed restriction mandatory? Leibovici D, et al. **Eur Urol** 1999 Sep;36(3):236-9

Nonoperatively treated displaced bimalleolar and trimalleolar fractures: a 20-year follow-up. Wei SY, et al. **Foot Ankle Int** 1999 Jul;20(7):404-7

Immobilisation stress induced analgesia in diabetic rats. Mahajan AS, et al. **Indian J Physiol Pharmacol** 1997 Jul; 41(3):275-9

The tension cord plaster: a method of immobilising the swollen elbow. Brooks RA, et al. **Injury** 1998 Oct; 29(8):601-3

Setup reproducibility in radiation therapy for lung cancer: a comparison between T-bar and expanded foam immobilization devices. Halperin R, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 1;43(1):211-6

Noninvasive patient fixation for extracranial stereotactic radiotherapy. Lohr F, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):521-7

A non-invasive immobilization system and related quality assurance for dynamic intensity modulated radiation therapy of intracranial and head and neck disease. Tsai JS, et al. **Int J Radiat Oncol Biol Phys** 1999 Jan 15; 43(2):455-67

A comparison of the Sport Stirrup, Malleoloc, and Swede-O ankle orthoses for the foot-ankle kinematics of a rapid lateral movement. Simpson KJ, et al. **Int J Sports Med** 1999 Aug;20(6):396-402

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Immobilisation after first anterior shoulder dislocation. Dollery W. **J Accid Emerg Med** 1998 Nov;15(6):382-3

Position of immobilization after dislocation of the shoulder. A cadaveric study. Itoi E, et al. **J Bone Joint Surg Am** 1999 Mar;81(3):385-90

Sensory afferent properties of immobilised or inflamed rat knees during continuous passive movement. Okamoto T, et al. **J Bone Joint Surg Br** 1999 Jan;81(1):171-7

An antisense oligonucleotide reverses the footshock-induced expression of fos in the rat medial prefrontal cortex and the subsequent expression of conditioned fear-induced immobility. Morrow BA, et al. **J Neurosci** 1999 Jul 1; 19(13):5666-73

Weight-bearing immobilization and early exercise treatment following a grade II lateral ankle sprain. Glasoe WM, et al. **J Orthop Sports Phys Ther** 1999 Jul;29(7):394-9

Comparison of the Nebraska collar, a new prototype cervical immobilization collar, with three standard models. Alberts LR, et al. **J Orthop Trauma** 1998 Aug;12(6):425-30

Closed treatment of hip dislocation in Down syndrome. Greene WB. **J Pediatr Orthop** 1998 Sep-Oct;18(5):643-7

Ankylosing spondylitis: time to focus on ankylosis [editorial] Archer JR, et al. **J Rheumatol** 1999 Apr;26(4):761-4 (37 ref.)

Alpha-chloralose immobilization of rock doves in Ohio. Belant JL, et al. **J Wildl Dis** 1999 Apr;35(2):239-42

Relative efficiency of succinylcholine, xylazine, and carfentanil/xylazine mixtures to immobilize free-ranging moose. Delvaux H, et al. **J Wildl Dis** 1999 Jan;35(1):38-48

Field immobilization and euthanasia of American opossum. Stoskopf MK, et al. **J Wildl Dis** 1999 Jan;35(1):145-9

Restraint of the paca (Agouti paca) with ketamine hydrochloride, acetylpromazine maleate, and atropine sulfate. Pachaly JR, et al. **J Zoo Wildl Med** 1998 Sep; 29(3):303-6

Histamine release induced by immobilization, gentle handling and decapitation from mast cells and its inhibition by nedocromil in rats. Huang ZL, et al. **Jpn J Pharmacol** 1999 Jul;80(3):255-62

Brain catecholaminergic and tryptophan responses to restraint are attenuated by nitric oxide synthase inhibition.

Dunn AJ. **Neurochem Int** 1998 Dec;33(6):551–7
Modified Headholder and operating table for intra-operative MRI in neurosurgery. Wirtz CR, et al. **Neurol Res** 1998 Oct;20(7):658–61
The Ca2+ channel blockade changes the behavioral and biochemical effects of immobilization stress. Mamczarz J, et al. **Neuropsychopharmacology** 1999 Mar;20(3):248–54
Influence of stress duration on the sleep rebound induced by immobilization in the rat: a possible role for corticosterone. Marinesco S, et al. **Neuroscience** 1999; 92(3):921–33
Changes in biomechanical properties of tendons and ligaments from joint disuse. Yasuda K, et al. **Osteoarthritis Cartilage** 1999 Jan;7(1):122–9
The effect of handling and immobilization on the response to acute pain in newborn infants. Porter FL, et al. **Pediatrics** 1998 Dec;102(6):1383–9
Fist position for skin grafting on the dorsal hand: I. Analysis of length of the dorsal hand surgery in hand positions. Burm JS, et al. **Plast Reconstr Surg** 1999 Oct;104(5):1350–5
Current practice in clinical cervical spinal clearance: implication for EMS. Cone DC, et al. **Prehosp Emerg Care** 1999 Jan–Mar;3(1):42–6
Indications for prehospital spinal immobilization. National Association of EMS Physicians Standards and Clinical Practice Committee. Domeier RM. **Prehosp Emerg Care** 1999 Jul–Sep;3(3):251–3 (37 ref.)
The Kendrick extrication device used for pediatric spinal immobilization. Markenson D, et al. **Prehosp Emerg Care** 1999 Jan–Mar;3(1):66–9
Paramedic use of a spinal injury clearance algorithm reduces spinal immobilization in the out-of-hospital setting. Muhr MD, et al. **Prehosp Emerg Care** 1999 Jan–Mar;3(1):1–6
Involvement of 5-HT3 receptors in the prolactin release induced by immobilization stress in rats. Nonaka KO. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):497–503
Calf muscle atrophy and Achilles tendon healing following experimental tendon division and surgery in rats. Comparison of postoperative immobilization of the muscle-tendon complex in relaxed and tensioned positions. Rantanen J, et al. **Scand J Med Sci Sports** 1999 Feb; 9(1):57–61
The efficacy of head immobilization techniques during simulated vehicle motion. Perry SD, et al. **Spine** 1999 Sep 1;24(17):1839–44
Craniospinal axis irradiation in children. Treatment in supine position including field verification as a prerequisite for anesthesia without intubation. Rades D, et al. **Strahlenther Onkol** 1999 Aug;175(8):409–12
[Functional stabilization versus orthopedic immobility in grade-I–II (mild) ankle sprain] Hazañas Ruiz S, et al. **Aten Primaria** 1999 Apr 30;23(7):425–8 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

'Synaptic ribbon' modifications in the pineal gland of the albino rat following 24 hours of immobilization. Martinenz Soriano F, et al. **Acta Anat (Basel)** 1992;145(4):430–3
Disability in older adults. 2: Physical activity as prevention. Carlson JE, et al. **Behav Med** 1999 Winter;24(4):157–68 (78 ref.)
Heightened transcription for enzymes involved in norepinephrine biosynthesis in the rat locus coeruleus by immobilization stress. Serova LI, et al. **Biol Psychiatry** 1999 Apr 1;45(7):853–62
Immobility as a major cause of bone remodeling in residents of a long-stay geriatric ward. Bischoff H, et al. **Calcif Tissue Int** 1999 Jun;64(6):485–9
Immobility and falls. Mahoney JE. **Clin Geriatr Med** 1998 Nov;14(4):699–726 (170 ref.)
Selective melanocortin MC4 receptor blockage reduces immobilization stress-induced anorexia in rats. Vergoni AV, et al. **Eur J Pharmacol** 1999 Mar 12;369(1):11–5
Pulmonary xanthine oxidase activity of rats exposed to prolonged immobilization stress. Kovacheva S, et al. **Gen Physiol Biophys** 1998 Dec;17(4):377–84
Immobilization-dependent bone collagen breakdown appears to increase with time: evidence for a lack of new bone equilibrium in response to reduced load during prolonged bed rest. Fiore CE, et al. **Horm Metab Res** 1999 Jan; 31(1):31–6
Emotional stress and characteristics of brain noradrenaline release in the rat. Tanaka M. **Ind Health** 1999 Apr; 37(2):143–56 (27 ref.)
mRNA levels for alpha-subunit of prolyl 4-hydroxylase and fibrillar collagens in immobilized rat skeletal muscle. Han XY, et al. **J Appl Physiol** 1999 Jul;87(1):90–6
Mechanical loading attenuates bone loss due to immobilization and calcium deficiency. Inman CL, et al. **J Appl Physiol** 1999 Jul;87(1):189–95
Effect of nonweight bearing on tibial bone density measured by QCT in patients with hip surgery. Ito M, et al. **J Bone Miner Metab** 1999;17(1):45–50
Differential effects of a six-day immobilization on newborn rat soleus muscles at two developmental stages. Picquet F, et al. **J Muscle Res Cell Motil** 1998 Oct;19(7):743–55
Different mechanisms of bone metabolism between patients with stroke and with spinal cord injury [letter; comment] Davie MW, et al. **J Neurol Sci** 1999 Feb 1;163(1):99–101 . Comment on: J Neurol Sci 1998 Apr 1;156(2):205–10.
[Peroneal nerve paresis after long-term bed rest in intensive care patients] Wiis J, et al. **Ugeskr Laeger** 1999 Aug 16; 161(33):4641–2 (Eng. Abstr.) **(Dan)**
[Influence of hypodynamia on organism of Japanese quail] Lebedeva ZN, et al. **Aviakosm Ekolog Med** 1999;33(1):24–7 (Eng. Abstr.) **(Rus)**
[Rhabdomyolysis and compartment syndrome associated with drug abuse (letter)] Blanco García S, et al. **Rev Esp Anestesiol Reanim** 1999 Jan;46(1):46–7 **(Spa)**

PHYSIOLOGY

Changes in peak oxygen uptake and plasma volume in fit and unfit subjects following exposure to a simulation of microgravity. Convertino VA. **Acta Physiol Scand** 1998 Nov;164(3):251–7
Effect of immobilization on vitamin D status and bone mass in chronically hospitalized disabled stroke patients. Sato Y, et al. **Age Ageing** 1999 May;28(3):265–9
Adverse effects on rabbit anterior cruciate ligament after knee immobilization: changes in permeability of horseradish peroxidase. Kanda T, et al. **Arch Orthop Trauma Surg** 1998; 117(6–7):307–11
Immobilisation of pinniped species. Lynch MJ, et al. **Aust Vet J** 1999 Mar;77(3):181–5 (39 ref.)
Fiber atrophy, but not changes in acetylcholine receptor expression, contributes to the muscle dysfunction after immobilization. Ibebunjo C, et al. **Crit Care Med** 1999 Feb; 27(2):275–85
mRNA levels for alpha-subunit of prolyl 4-hydroxylase and fibrillar collagens in immobilized rat skeletal muscle. Han XY, et al. **J Appl Physiol** 1999 Jul;87(1):90–6
Plasma catecholamines and plasma corticosterone following restraint stress in juvenile alligators. Lance VA, et al. **J Exp Zool** 1999 May 1;283(6):559–65
Chronic recording of the vestibulo-ocular reflex in the restrained rat using a permanently implanted scleral search coil. Quinn KJ, et al. **J Neurosci Methods** 1998 Apr 30; 80(2):201–8
A chest wall restrictor to study effects on pulmonary function and exercise. 1. Development and validation. Cline CC, et al. **Respiration** 1999;66(2):182–7
A chest wall restrictor to study effects on pulmonary function and exercise. 2. The energetics of restrictive breathing. Gonzalez J, et al. **Respiration** 1999;66(2):188–94
[Pathophysiology of immobilization] Geiger M, et al. **Wien Med Wochenschr** 1999;149(2–4):33–4 (Eng. Abstr.) **(Ger)**
[Neuron reactions of brain structures suppressing motion during development of animal hypnosis in guinea pigs] Milelkovskiĭ BIu, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May–Jun; 84(5–6):436–42 (Eng. Abstr.) **(Rus)**

IMMOBILIZED CELLS see **CELLS, IMMOBILIZED**

IMMOBILIZED ENZYMES see **ENZYMES, IMMOBILIZED**

IMMOTILE CILIA SYNDROME see **CILIARY MOTILITY DISORDERS**

IMMUNE ADHERENCE REACTION

Immune adherence-mediated opsonophagocytosis: the mechanism of Leishmania infection. Dominguez M, et al. **J Exp Med** 1999 Jan 4;189(1):25–35

IMMUNE-ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE-ASSOCIATED ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE COMPLEX see **ANTIGEN-ANTIBODY COMPLEX**

IMMUNE COMPLEX DISEASES

A syndrome of immune complex glomerulonephritis and ophthalmic abnormalities. Amirlak I, et al. **J Med Genet** 1999 Aug;36(8):641–4

CHEMICALLY INDUCED

Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis. Endoh T, et al. **Transfusion** 1999 Mar;39(3):306–9

COMPLICATIONS

Iris crystals in Fuch heterochromic iridocyclitis. Goldstein DA, et al. **Arch Ophthalmol** 1998 Dec;116(12):1692–3
Peliosis of the spleen: an immune-complex disease? Gugger M, et al. **Histopathology** 1998 Oct;33(4):387–9

ETIOLOGY

Autoantibodies against C1q: view on clinical relevance and pathogenic role. Siegert CE, et al. **Clin Exp Immunol** 1999 Apr;116(1):4–8 (58 ref.)
Shunt nephritis: fortuitous diagnosis and confirmation by serology (ASET). Wood H, et al. **Eur J Pediatr Surg** 1998 Dec;8 Suppl 1:66–7
Hepatitis virus and glomerulonephritis [editorial; comment] Yamabe H. **Intern Med** 1998 Oct;37(10):800–1. Comment on: Intern Med 1998 Oct;37(10):836–40.

IMMUNOLOGY

Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft. Adams PL, et al. **Am J Kidney Dis** 1999 Mar;33(3):552–4
Modulation by lipid mediators of immune complex-induced lung inflammation in mice. Steil AA, et al. **Eur J Pharmacol** 1998 Nov 13;361(1):93–9
Failure to induce anti-glomerular basement membrane glomerulonephritis in TNF alpha/beta deficient mice. Ryffel B, et al. **Int J Exp Pathol** 1998 Dec;79(6):453–60

METABOLISM

Lipid mediators, tumor necrosis factor and nitric oxide and their interactions in immune-complex-induced lung injury. Tavares de Lima W, et al. **Eur J Pharmacol** 1998 Sep 25; 358(1):69–75

PATHOLOGY

Development of immune complex trapping: experimental study of lymphoid follicles and germinal centers newly induced by exogenous stimulants in mouse popliteal lymph nodes. Horie K, et al. **Histol Histopathol** 1999 Jan; 14(1):11–21
Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. Heller T, et al. **J Immunol** 1999 Jul 15;163(2):985–94

PHYSIOPATHOLOGY

Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. Czermak BJ, et al. **Am J Pathol** 1999 May; 154(5):1513–24

VETERINARY

Evidence of Pasteurella haemolytica linked immune complex disease in natural and experimental models. McBride JW, et al. **Microb Pathog** 1999 Apr;26(4):183–93

VIROLOGY

B19 virus: an update [editorial] Koduri PR. **Int J Artif Organs** 1998 Jun;21(6):309–11

IMMUNE GLOBULIN, RH see **RHO(D) IMMUNE GLOBULIN**

IMMUNE GLOBULINS see **IMMUNOGLOBULINS**

IMMUNE MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNE PRECIPITATES see **PRECIPITINS**

IMMUNE RESPONSE ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE-RESPONSE ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE-RESPONSE-ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE RESPONSE GENES see **GENES, MHC CLASS II**

IMMUNE RESPONSE, MUCOSAL see **IMMUNITY, MUCOSAL**

IMMUNE RNA MANIPULATION see **IMMUNOTHERAPY, ACTIVE**

IMMUNE SERA

see related
IMMUNIZATION, PASSIVE

Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. Spruth M, et al. **AIDS Res Hum Retroviruses** 1999 Apr 10;15(6):533–43
Urinary and plasma urodilatin measured by a direct RIA using a highly specific antiserum. Meyer M, et al. **Clin Chem** 1998 Dec;44(12):2524–9
Preparation of specific antisera to 15alpha-hydroxyestrogen 15-N-acetylglucosaminides. Nakagomi M, et al. **Steroids** 1999 Jul;64(7):491–6
[Therapeutic sera and immunoglobulins available in France as of 1 January 1998] Roger I, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):477–83 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Additional reports of failure to respond to treatment after rabies exposure in Thailand. Hemachudha T, et al.

Clin Infect Dis 1999 Jan;28(1):143-4

Human rabies postexposure prophylaxis during a raccoon rabies epizootic in New York, 1993 and 1994. Wyatt JD, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):415-23

Pig islet xenografts are susceptible to "anti-pig" but not Gal alpha(1,3)Gal antibody plus complement in Gal o/o mice. McKenzie IF, et al. **J Immunol** 1998 Nov 15;161(10):5116-9

ANALYSIS

[Antigenicity of nine synthetic peptides of human immunodeficiency virus] Mao P, et al. **Chung Hua Nei Ko Tsa Chih** 1997;36(2):105-7 (Eng. Abstr.) **(Chi)**

BIOSYNTHESIS

Model multiple antigenic and homopolymeric peptides from non-repetitive sequences of malaria merozoite proteins elicit biologically irrelevant antibodies. Ramasamy R, et al. **Biochim Biophys Acta** 1999 Jan 6;1453(1):115-25

Production of a polyclonal antibody raised against recombinant flounder p53 protein. Cachot J, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Oct;120(3):351-6

Production and characterization of polyclonal antibodies against cholecalciferol (vitamin D3). Jean J, et al. **J Immunol Methods** 1999 Mar 4;223(2):155-63

Development and characterisation of human 5-HT1B- or 5-HT1D-receptor specific antibodies as unique research tools. Smith D, et al. **J Neurosci Methods** 1998 Apr 30; 80(2):155-61

CHEMISTRY

Development and characterisation of human 5-HT1B- or 5-HT1D-receptor specific antibodies as unique research tools. Smith D, et al. **J Neurosci Methods** 1998 Apr 30; 80(2):155-61

DIAGNOSTIC USE

[The evaluation of antigens and antisera for their use in the serodiagnosis of aspergillosis] Fernández Andreu CM, et al. **Rev Cubana Med Trop** 1995;47(2):118-21 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Shi YP, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):135-41

Human sperm proteome: immunodominant sperm surface antigens identified with sera from infertile men and women. Shetty J, et al. **Biol Reprod** 1999 Jul;61(1):61-9

Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders [see comments] Dalmau J, et al. **Brain** 1999 Jan;122 (Pt 1):27-39. Comment in: Brain 1999 Jan;122 (Pt 1):27-39.

Species specificity of human and murine anti-ZP3 synthetic peptide antisera and use of the antibodies for localization and identification of ZP3 or ZPC domains of functional significance. Hinsch E, et al. **Hum Reprod** 1999 Feb; 14(2):419-28

An antiserum raised against the recombinant cytoplasmic tail of the human CD43 glycoprotein identifies CD43 in many mammalian species. Szlanka T, et al. **Immunology** 1999 Jan; 96(1):74-82

Effects of in vivo administration of adamantylamide dipeptide on bone marrow granulocyte-macrophage hemopoietic progenitor cells (GM-CFC) and on ability of serum of the treated mice to stimulate GM-CFC colony formation in vitro: comparison with muramyl dipeptide and glucan. Vacek A, et al. **Immunopharmacol Immunotoxicol** 1999 Feb; 21(1):1-14

Recombinant Staphylococcus strains as live vectors for the induction of neutralizing anti-diphtheria toxin antisera. Fromen-Romano C, et al. **Infect Immun** 1999 Oct; 67(10):5007-11

The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats. Suzuki S, et al. **J Am Soc Nephrol** 1999 Feb;10(2):264-70

Development of horse polyclonal antiserum inhibiting all in vitro biological functions of human IFN-gamma. Martinelli F, et al. **J Biol Regul Homeost Agents** 1998 Oct-Dec; 12(4):112-8

Expression of heat-shock proteins in Streptococcus pyogenes and their immunoreactivity with sera from patients with streptococcal diseases. Lemos JA, et al. **J Med Microbiol** 1998 Aug;47(8):711-5

Anti-Trypanosoma brucei activity of nonprimate zoo sera. Black SJ, et al. **J Parasitol** 1999 Feb;85(1):48-53

The relationship of ASE-1 and NOR-90 in autoimmune sera. Whitehead CM, et al. **J Rheumatol** 1998 Nov; 25(11):2126-30

Correlation between antigenemia of Paracoccidioides brasiliensis and inhibiting effects of plasma in patients with paracoccidioidomycosis. Sugizaki MF, et al. **Med Mycol** 1999 Aug;37(4):277-84

Neutralizing capacity of antisera raised in horses and rabbits against Crotalus durissus terrificus (South American rattlesnake) venom and its main toxin, crotoxin. Oshima-Franco Y, et al. **Toxicon** 1999 Oct;37(10):1341-57

Evaluation of hyperimmune sera against goat pox viral antigens. Singh RP, et al. **Trop Anim Health Prod** 1998 Aug;30(4):229-32

Effect of peroral anti-bacterial antiserum treatment on intestinal immune parameters of germ-free piglets intragastrically infected with virulent Salmonella typhimurium or enteropathogenic E. coli. Trebichavský I, et al. **Vet Immunol Immunopathol** 1999 Jan 4;67(1):55-65

ISOLATION & PURIFICATION

[The use of minipigs to produce diagnostic sera for the serological identification of bacteria in the genus Morganella] Gurdina VV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):8-10 (Eng. Abstr.) **(Rus)**

[The isolation and comparative characteristics of sera to the enterotoxin of Vibrio cholerae of the serogroups O139 and O1] Mazrukho AB, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr; (2):86-7 **(Rus)**

METABOLISM

Ultrastructural localization of nonstructural and coat proteins of 19 potyviruses using antisera to bacterially expressed proteins of plum pox potyvirus. Riedel D, et al. **Arch Virol** 1998;143(11):2133-58

Non-proteolytic activation of human prorenin by anti-prorenin prosegment (pf#1: 1P-15P) antiserum. Suzuki F, et al. **Biosci Biotechnol Biochem** 1999 Mar; 63(3):550-4

Translocated intimin receptors (Tir) of Shiga-toxigenic Escherichia coli isolates belonging to serogroups O26, O111, and O157 react with sera from patients with hemolytic-uremic syndrome and exhibit marked sequence heterogeneity. Paton AW, et al. **Infect Immun** 1998 Nov; 66(11):5580-6

Immune complexes from vasculitis patients bind to endothelial Fc receptors independent of the allelic polymorphism of FcgammaRIIa. Gröger M, et al. **J Invest Dermatol** 1999 Jul;113(1):56-60

PHARMACOLOGY

Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. Wildbaum G, et al. **J Immunol** 1998 Dec 1;161(11):6368-74

Evaluation of ZP2 domains of functional importance with antisera against synthetic ZP2 peptides. Hinsch E, et al. **J Reprod Fertil** 1998 Nov;114(2):245-51

Effects of peptidase inhibitors, [D-Ala2, Met5]-enkephalinamide and antiserum to methionine-enkephalin microinjected into the caudal periaqueductal gray on morphine withdrawal in rats. Fukunaga Y, et al. **Jpn J Pharmacol** 1998 Dec;78(4):455-61

Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve. Ro LS, et al. **Pain** 1999 Feb;79(2-3):265-74

NA1/NA2 antisera inhibit FcgammaRI- but not FcgammaRII- mediated phagocytosis. Flesch BK, et al. **Vox Sang** 1998;75(3):247-52

Growth inhibitory and bactericidal efficacy of sera from Lyme borreliosis patients on B. burgdorferi strains. Kraiczy P, et al. **Wien Klin Wochenschr** 1998 Dec 23;110(24):886-93

[Effect of various dilutions of the potentiated antibodies to the brain-specific protein S-100 on the post-titanic potentiation in surviving hippocampal slices] Epshtein OI, et al. **Biull Eksp Biol Med** 1999 Mar;127(3):317-20 **(Rus)**

[Effects of the potentiated forms of antibodies to the brain-specific S-100 protein on the integrative brain activity] Epstein OI, et al. **Biull Eksp Biol Med** 1999 May; 127(5):547-9 **(Rus)**

[Reaction of the leech neuron to synaptic activation of various frequencies upon exposure to ganglioside antiserum] Sergeeva SS, et al. **Dokl Akad Nauk** 1998 Sep; 362(2):280-2 **(Rus)**

[Modification of the effects of microwave irradiation on biochemical processes by using foreign protein] Podkovkin VG, et al. **Radiats Biol Radioecol** 1998 Nov-Dec; 38(6):916-9 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Toxicity and immunogenicity of Crotalus durissus terrificus venom treated with different doses of gamma rays. Clissa PB, et al. **Toxicon** 1999 Aug;37(8):1131-41

THERAPEUTIC USE see IMMUNIZATION, PASSIVE

IMMUNE SYSTEM

Integrins in the immune system. Shimizu Y, et al. **Adv Immunol** 1999;72:325-80 (456 ref.)

Cervical Papanicolaou smear abnormalities in inner city Bronx adolescents: prevalence, progression, and immune modifiers. Edelman M, et al. **Cancer** 1999 Aug 25; 87(4):184-9

The role of cytokines of the innate and adaptive immune system in the regulation of insulin resistance [letter; comment] Cseh K, et al. **Diabetologia** 1999 Apr;42(4):497-8 . Comment on: Diabetologia 1998 Oct;41(10):1241-8.

Controlled ovarian hyperstimulation in assisted reproduction: effect on the immune system. Giuliani A, et al. **Fertil Steril** 1998 Nov;70(5):831-5

What do the paralogous regions in the genome tell us about the origin of the adaptive immune system? Kasahara M. **Immunol Rev** 1998 Dec;165:159-75 (114 ref.)

What brought the adaptive immune system to vertebrates?--The jaw hypothesis and the seahorse. Matsunaga T, et al. **Immunol Rev** 1998 Dec;166:177-86 (72 ref.)

6th Annual Congress of the British Society for Immunology. Harrogate, United Kingdom, 1-4 December 1998. Abstracts. **Immunology** 1998 Dec;95 Suppl 1:1-144

Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Kantele A, et al. **Infect Immun** 1998 Dec;66(12):5630-5

Photoimmunology. Selected papers of the 7th Congress of the European Society for Photobiology. Stresa, Italy, 8-13 September 1997. **J Photochem Photobiol B** 1998 Jul 10; 44(2):87-164

Glycosylation and the immune system. Rudd PM, et al. **J Protein Chem** 1998 Aug;17(6):519

Emotion and immunity. Koh KB. **J Psychosom Res** 1998 Aug;45(2):107-15 (86 ref.)

From terra firma to terra plana--danger is shaking the foundations: deconstructing the 'immune system'. Cunliffe J. **Med Hypotheses** 1999 Mar;52(3):213-9

Fit for life in the immune system? Surrogate L chain tests H chains that test L chains. Melchers F. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2571-3

[The senile immune system] Bruunsgaard H, et al. **Ugeskr Laeger** 1999 Aug 23;161(34):4740-3 **(Dan)**

CHEMISTRY

Comparison of intact antibody structures and the implications for effector function. Harris LJ, et al. **Adv Immunol** 1999; 72:191-208 (66 ref.)

Sympathectomy-induced immune changes are not abrogated by the glucocorticoid receptor blocker RU-486. Kruszewska B, et al. **Brain Behav Immun** 1998 Sep; 12(3):181-200

CYTOLOGY

The central effectors of cell death in the immune system. Rathmell JC, et al. **Annu Rev Immunol** 1999;17:781-828 (359 ref.)

Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. Xu W, et al. **Int J Immunopharmacol** 1999 Jul;21(7):463-72

The overlooked "nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. Altomonte M, et al. **J Cell Physiol** 1999 Jun;179(3):251-6 (51 ref.)

The role of amoebocytes in endotoxin-mediated coagulation in the innate immunity of Achatina fulica snails. Biswas C, et al. **Scand J Immunol** 1999 Feb;49(2):131-8

DRUG EFFECTS

Is there evidence for an effect of antidepressant drugs on immune function? Neveu PJ, et al. **Adv Exp Med Biol** 1999; 461:267-81 (92 ref.)

Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Yamauchi K, et al. **Adv Exp Med Biol** 1998;443:261-5

Alcohol-Induced Immunopathology. Proceedings of a symposium. New Orleans, Louisiana, USA. October 17-18, 1997. **Alcohol Clin Exp Res** 1998 Aug;22(5 Suppl):181S-268S

Immunological properties of dehydroepiandrosterone, its conjugates, and metabolites. Bradlow HL, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:91-101

Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT. AOX. geriatric network. Girodon F, et al. **Arch Intern Med** 1999 Apr 12; 159(7):748-54

Sympathectomy-induced immune changes are not abrogated by the glucocorticoid receptor blocker RU-486. Kruszewska B, et al. **Brain Behav Immun** 1998 Sep; 12(3):181-200

MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Roy S, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):190-4

Glutamine: a potentially useful supplement for athletes. Antonio J, et al. **Can J Appl Physiol** 1999 Feb;24(1):1-14 (64 ref.)

Immune function in aged women is improved by ingestion of vitamins C and E. de la Fuente M, et al. **Can J Physiol Pharmacol** 1998 Apr;76(4):373-80

Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Liu FJ, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1168-72

Immunological disorders in men exposed to metallic mercury vapour. A review. Moszczyński P. **Cent Eur J Public Health** 1999 Feb;7(1):10-4 (57 ref.)

Neurodevelopmental, immunological and endocrinological indices of perinatal human exposure to PCBs and dioxins. Weisglas-Kuperus N. **Chemosphere** 1998 Oct-Nov; 37(9-12):1845-53 (55 ref.)

The immunologic evaluation of the Yucheng children. Yu

ML, et al. **Chemosphere** 1998 Oct-Nov;37(9-12):1855-65

The effects of environmental and other chemicals on the human immune system: the emergence of immunotoxicology [editorial; comment] Burchiel SW. **Clin Immunol** 1999 Mar;90(3):285-6. Comment on: Clin Immunol 1999 Mar;90(3):287-301.

A critique of the World Resources Institute's report "Pesticides and the immune system: the public health risks" [see comments] Acquavella J, et al. **Environ Health Perspect** 1998 Feb;106(2):51-4. Comment in: Environ Health Perspect 1998 Feb;106(2):A52-4.

Response to the ACPA's critique [letter; comment] Repetto R, et al. **Environ Health Perspect** 1998 Feb;106(2):A52-4 . Comment on: Environ Health Perspect 1998 Feb;106(2):51-4.

Immune functions in the Fisher rat fed beluga whale (Delphinapterus leucas) blubber from the contaminated St. Lawrence estuary. Lapierre P, et al. **Environ Res** 1999 Feb; 80(2 Pt 2):S104-S112

Oxidant anti-oxidant imbalance and effects of ethanol. Rivier C. **Front Biosci** 1999 Jun 1;4:D514-9 (59 ref.)

Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95). Bhushan A, et al. **Immunol Cell Biol** 1998 Aug;76(4):350-6

Antisense strategies: functions and applications in immunology. Varga LV, et al. **Immunol Lett** 1999 Aug 3;69(2):217-24 (45 ref.)

Immunomodulation by n-3 polyunsaturated fatty acids [letter; comment] Netea MG, et al. **Immunol Today** 1999 Feb;20(2):103. Comment on: Immunol Today 1998 Jun;19(6):244-7.

Immunobiology of zinc and zinc therapy [letter; comment] Reinhold D, et al. **Immunol Today** 1999 Feb;20(2):102-3. Comment on: Immunol Today 1997 Nov;18(11):519-21.

Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. Xu W, et al. **Int J Immunopharmacol** 1999 Jul;21(7):463-72

Effect of beta-agonists on inflammatory cells. Barnes PJ. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S10-7 (109 ref.)

Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. Nel AE, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):539-54 (115 ref.)

Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. Knoflach A, et al. **J Am Soc Nephrol** 1999 May; 10(5):1059-66

Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. Massi P, et al. **J Neuroimmunol** 1998 Dec 1; 92(1-2):60-6

Dietary conjugated linoleic acid influences the immune response of young and old C57BL/6NCrlBR mice. Hayek MG, et al. **J Nutr** 1999 Jan;129(1):32-8

Time-dependent effects of melatonin on immune measurements in male Syrian hamsters. Champney TH, et al. **J Pineal Res** 1998 Oct;25(3):142-6

Health of tree swallows (Tachycineta bicolor) nesting in pesticide-sprayed apple orchards in Ontario, Canada. I. Immunological parameters. Bishop CA, et al. **J Toxicol Environ Health** 1998 Dec 25;55(8):531-59

Systemic effects of ingested nickel on the immune system of nickel sensitised women. Boscolo P, et al. **Life Sci** 1999; 64(17):1485-91

Pharmacological activities of fusaric acid (5-butylpicolinic acid). Wang H, et al. **Life Sci** 1999;65(9):849-56 (46 ref.)

Altered immune function in human newborns after prenatal administration of betamethasone: enhanced natural killer cell activity and decreased T cell proliferation in cord blood. Kavelaars A, et al. **Pediatr Res** 1999 Mar; 45(3):306-12

Late embryonic ritanserin exposure fails to alter normal responses to immune system stimulation in young chicks. Schrott LM, et al. **Pharmacol Biochem Behav** 1999 Sep; 64(1):81-8

Effects of six endodontic cements on the cells of the murine immune system in vitro. Molina-Guarneros JA, et al. **Proc West Pharmacol Soc** 1998;41:47-50

Asbestos toxicity: an immunologic perspective. Rosenthal GJ, et al. **Rev Environ Health** 1999 Jan-Mar;14(1):11-20 (62 ref.)

Metallothionein-null mice are highly susceptible to the hematotoxic and immunotoxic effects of chronic CdCl2 exposure. Liu J, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):98-108

Immune parameters in biological monitoring of pesticide exposure: current knowledge and perspectives. Colosio C, et al. **Toxicol Lett** 1999 Sep 5;108(2-3):285-95 (28 ref.)

Immunotoxicology assessment in the pharmaceutical industry. Dean JH, et al. **Toxicol Lett** 1998 Dec 28; 102-103:247-55

Mandates to develop non-mammalian models for chemical immunotoxicity evaluation: are fish a viable alternate to rodents? Gogal RM Jr, et al. **Toxicol Lett** 1999 Jun 1; 106(2-3):89-92

What are the prospects for regulation in immunotoxicology? Hastings KL. **Toxicol Lett** 1998 Dec 28;102-103:267-70

Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. Kaminski NE. **Toxicol Lett** 1998 Dec 28;102-103:59-63 (26 ref.)

Testing strategies in immunotoxicology. Pallardy M, et al. **Toxicol Lett** 1998 Dec 28;102-103:257-60 (17 ref.)

Immunological parameters in humans exposed to pesticides in the agricultural environment. Stiller-Winkler R, et al. **Toxicol Lett** 1999 Jun 30;107(1-3):219-24

Risk assessment and immunotoxicology. Van Loveren H, et al. **Toxicol Lett** 1998 Dec 28;102-103:261-5 (13 ref.)

Persistent effect of in utero meso-2,3-dimercaptosuccinic acid (DMSA) on immune function and lead-induced immunotoxicity. Chen S, et al. **Toxicology** 1999 Jan 1; 132(1):67-79

Investigation of some immunological functions in a group of asphalt workers exposed to polycyclic aromatic hydrocarbons. Karakaya A, et al. **Toxicology** 1999 Jul 1; 135(1):43-7

Use of immunotoxicity data in health risk assessments: uncertainties and research to improve the process. Selgrade MK. **Toxicology** 1999 Mar 1;133(1):59-72

Effect of chlorpyrifos on immune function in rats. Blakley BR, et al. **Vet Hum Toxicol** 1999 Jun;41(3):140-4

[The influence of alanyl-glutamine on immunologic functions and morbidity in postoperative total parenteral nutrition. Preliminary results of a prospective randomized trial] Jacobi CA, et al. **Zentralbl Chir** 1999;124(3):199-205 (Eng. Abstr.) **(Ger)**

[Vitamin E is beneficial for the immune system in the elderly] Landmark K. **Tidsskr Nor Laegeforen** 1998 Nov 20; 118(28):4403-4 (36 ref.) **(Nor)**

[Regulation of immune processes by peptides of natural origin] Besednova NN. **Antibiot Khimioter** 1999;44(1):31-5 (56 ref.) **(Rus)**

[Microbiological and pharmacodynamics factors defining the clinical effect of antibiotic therapy (editorial)] Iakovlev SV. **Antibiot Khimioter** 1999;44(5):3-5 **(Rus)**

[The effect of platinum-containing cytostatic preparations on the immune and hematopoietic systems] Masnaia NV, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):53-5 (Eng. Abstr.) **(Rus)**

[The effect of the essential fatty acids in mare's milk on the function of the immune system and of nonspecific resistance in rats] Valiev AG, et al. **Vopr Pitan** 1999;68(3):3-6 (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Ontogeny of the fetal immune system: study on pregnancies with Rh-isoimmunization and nonimmune fetal hydrops. Noia G, et al. **Clin Immunol** 1999 Jan;90(1):115-8

Cellular and molecular events that govern the development of the hematopoietic and immune system in the embryo [editorial] Dieterlen-Lièvre F, et al. **Dev Comp Immunol** 1998 May-Jun;22(3):249-52

Induction and early development of the hematopoietic and immune systems in Xenopus. Turpen JB. **Dev Comp Immunol** 1998 May-Jun;22(3):265-78 (71 ref.)

Differential presentation of an altered peptide within fetal central and peripheral organs supports an avidity model for thymic T cell development and implies a peripheral readjustment for activation. Legge KL, et al. **J Immunol** 1999 May 15;162(10):5738-46

Terminal deoxynucleotidyl transferase expression during neonatal life alters D(H) reading frame usage and Ig-receptor-dependent selection of V regions. Marshall AJ, et al. **J Immunol** 1998 Dec 15;161(12):6657-63

Late embryonic ritanserin exposure fails to alter normal responses to immune system stimulation in young chicks. Schrott LM, et al. **Pharmacol Biochem Behav** 1999 Sep; 64(1):81-8

GROWTH & DEVELOPMENT

Reciprocal effects of age and clinical allergy: is there more to be learned? [editorial; comment] Bernstein IL. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):131-2. Comment on: Ann Allergy Asthma Immunol 1999 Feb;82(2):152-6.

Bone marrow transplantation, fetal B-cell repertoire development, and the mechanism of immune reconstitution [letter] Raaphorst FM. **Blood** 1998 Dec 15;92(12):4873-4

Immunisation and the maturation of infant immune responses. Goldblatt D. **Dev Biol Stand** 1998;95:125-32 (21 ref.)

Development of T-B cell collaboration in neonatal mice. Astori M, et al. **Int Immunol** 1999 Mar;11(3):445-51

TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation [comment] Green EA, et al. **J Exp Med** 1999 Apr 5;189(7):1017-20 . Comment on: J Exp Med 1999 Apr 5;189(7):1025-31.

Immune system development and function in prolactin receptor-deficient mice. Bouchard B, et al. **J Immunol** 1999 Jul 15;163(2):576-82

Accelerated development and aging of the immune system in p53-deficient mice. Ohkusu-Tsukada K, et al. **J Immunol** 1999 Aug 15;163(4):1966-72

[Ontogeny of the immune system] Millet V, et al. **Arch Pediatr** 1999;6 Suppl 1:14S-9S (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Integration of neuro-endocrine immune responses in defense of mucosal surfaces. Befus AD, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):26-34 (94 ref.)

Does the immune system of a mouse age faster than the immune system of a human? Aspinall R. **Bioessays** 1999 Jun;21(6):519-24 (61 ref.)

IL-6 knock-out mice show modified basal immune functions, but normal immune responses to stress. Manfredi B, et al. **Brain Behav Immun** 1998 Sep;12(3):201-11

CNS cell populations are protected from virus-induced pathology by distinct arms of the immune system. Drescher KM, et al. **Brain Pathol** 1999 Jan;9(1):21-31

DATELINE Aix-les-bains. Brunner T, et al. **Cell Death Differ** 1998 Jun;5(6):539-46

Changes in immune-endocrine response after surgery. Yamauchi H, et al. **Cytokine** 1998 Jul;10(7):549-54

'Big Bang' emergence of the combinatorial immune system [editorial] Schluter SF, et al. **Dev Comp Immunol** 1999 Mar-Apr;23(2):107-11 (44 ref.)

Endotoxins and endocrine system. Bertók L. **Domest Anim Endocrinol** 1998 Sep;15(5):305-8 (21 ref.)

Immune-endocrine interactions in agricultural species: chromium and its effect on health and performance. Borgs P, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):431-8 (59 ref.)

Immune and endocrine regulation of food intake in sick animals. Johnson RW. **Domest Anim Endocrinol** 1998 Sep; 15(5):309-19 (81 ref.)

Churchill and the immune system of ectothermic vertebrates. Flajnik MF. **Immunol Rev** 1998 Dec;166:5-14 (47 ref.)

Metamorphosis and the amphibian immune system. Rollins-Smith LA. **Immunol Rev** 1998 Dec;166:221-30 (140 ref.)

The overlooked "nonclassical" functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. Altomonte M, et al. **J Cell Physiol** 1999 Jun;179(3):251-6 (51 ref.)

On the role of feedback in promoting conflicting goals of the adaptive immune system. Segel LA, et al. **J Immunol** 1999 Aug 1;163(3):1342-9 (24 ref.)

Differential immune responses in mice with left- and right-turning preference. Kim D, et al. **J Neuroimmunol** 1999 Jan 1;93(1-2):164-71

Binding specificity of hydrolytic catalytic antibody: lessons from the diverse immune system. Wada Y, et al. **J Protein Chem** 1999 Feb;18(2):199-204

The concept of glomerular self-defense. Kitamura M, et al. **Kidney Int** 1999 May;55(5):1639-71 (413 ref.)

Development of the immune system in atopic children. Jenmalm MC, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):5-12 (93 ref.)

Interactions of pathogens with the host immune system: implications for the pathogenesis of reactive arthritis. Sieper J. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):60S-61S; discussion 62S (13 ref.)

Prolactin, the immune response and lupus [editorial] Hughes GR, et al. **Rheumatology (Oxford)** 1999 Apr;38(4):296-7

The role of amoebocytes in endotoxin-mediated coagulation in the innate immunity of Achatina fulica snails. Biswas C, et al. **Scand J Immunol** 1999 Feb;49(2):131-8

[Induction of immune responses by DNA vaccine] Takahashi H. **Uirusu** 1998 Dec;48(2):201-10 (33 ref.) **(Jpn)**

[Environmental pollution and the status of the immune system in children] Rumiantseva EG, et al. **Gig Sanit** 1999 Mar-Apr;(2):24-6 **(Rus)**

[From transplantation of the thymus to molecular reconstruction of the immune system] Arion VIa, et al. **Vestn Ross Akad Med Nauk** 1999;(5):15-9 (20 ref.) (Eng. Abstr.) **(Rus)**

[The evaluation of the human immune system: the complexities and achievements] Pinegin BV, et al. **Vestn Ross Akad Med Nauk** 1999;(5):11-5 (14 ref.) **(Rus)**

[The status of the immunity system in diphtheria] Asfandiiarova NS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):77-80 (Eng. Abstr.) **(Rus)**

[The function of the immune system in patients with diphtheritic myocarditis] Dubyns'ka HM, et al. **Lik Sprava** 1998 Aug;(6):40-4 (Eng. Abstr.) **(Ukr)**

METABOLISM

Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Pestonjamasp VK, et al. **Biochim Biophys Acta** 1998 Nov 2;1394(2-3):249-60

Developmental regulation of immune system gene rearrangement. Cedar H, et al. **Curr Opin Immunol** 1999 Feb;11(1):64-9 (52 ref.)

Changes in immune-endocrine response after surgery. Yamauchi H, et al. **Cytokine** 1998 Jul;10(7):549-54

The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. Cook GA, et al. **FEBS Lett** 1999 Jul 30;456(1):155-9

Expression analysis of the thyrotropin-releasing hormone receptor (TRHR) in the immune system using agonist anti-TRHR monoclonal antibodies. Mellado M, et al. **FEBS Lett** 1999 May 28;451(3):308-14

EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Gräler MH, et al. **Genomics** 1998 Oct 15;53(2):164-9

Expression of growth hormone and insulin-like growth factor in the immune system of children. Yang Y, et al. **Horm Metab Res** 1999 Jun;31(6):380-4

Modulation of the immune response and tumor growth by activated Ras. Weijzen S, et al. **Leukemia** 1999 Apr; 13(4):502-13 (107 ref.)

Metabolism of dietary alpha-linolenic acid vs.

eicosapentaenoic acid in rat immune cell phospholipids during endotoxemia. Palombo JD, et al. **Lipids** 1998 Nov; 33(11):1099–105

Redox regulation of apoptotic cell death in the immune system. Hampton MB, et al. **Toxicol Lett** 1998 Dec 28; 102–103:355–8 (22 ref.)

[Critical involvement of the specific neuroendocrine profile for an adequate T-dependent immune response] Pérez Castro C, et al. **Medicina (B Aires)** 1998;58(2):189–93 (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Sellon RK, et al. **Infect Immun** 1998 Nov;66(11):5224–31

PARASITOLOGY

Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease. Marinho CR, et al. **Infect Immun** 1999 Jan;67(1):308–18

PATHOLOGY

Structural relationships between immune cells and longitudinal muscle during a Trichinella spiralis infection in the rat intestine. Berezin I, et al. **Neurogastroenterol Motil** 1999 Jun;11(3):179–92

[Neuroimmunopathology] Kryzhanovskiĭ GN. **Vestn Ross Akad Med Nauk** 1999;(4):18–20 (17 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The influence of the diet on the maturation of the immune system. Hughes DA. **Allergy** 1998;53(46 Suppl):26–8 (19 ref.)

In praise of pollution. Dossey L. **Altern Ther Health Med** 1999 May;5(3):12–5, 94–100

Adrenal and pituitary hormone patterns after spinal cord injury. Campagnolo DI, et al. **Am J Phys Med Rehabil** 1999 Jul–Aug;78(4):361–6

Influence of photoperiod on immune cell functions in the male Siberian hamster. Yellon SM, et al. **Am J Physiol** 1999 Jan;276(1 Pt 2):R97–R102

Immunomodulatory aspects of transfusion: a once and future risk? Klein HG. **Anesthesiology** 1999 Sep;91(3):861–5 (15 ref.)

Sex hormones and glucocorticoids: interactions with the immune system. Da Silva JA. **Ann N Y Acad Sci** 1999 Jun 22;876:102–17; discussion 117–8 (78 ref.)

Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. Scudeletti M, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:164–79

Further thoughts on the immunomodulatory role of glucocorticoids: comment on the article by Buttgereit et al [letter; comment] Wilckens T. **Arthritis Rheum** 1999 Feb; 42(2):393–6. Comment on: Arthritis Rheum 1998 May;41(5):761–7.

Opioids and the immune system [editorial] Webster NR. **Br J Anaesth** 1998 Dec;81(6):835–6

Differential immune system changes with acute and persistent stress for optimists vs pessimists. Cohen F, et al. **Brain Behav Immun** 1999 Jun;13(2):155–74

Role of serotonin in the immune system and in neuroimmune interactions. Mössner R, et al. **Brain Behav Immun** 1998 Dec;12(4):249–71 (135 ref.)

Human brain-immune relationships: a PET study. Wik G, et al. **Brain Behav Immun** 1998 Sep;12(3):242–6

Cellular responses to moderate and heavy exercise. Nehlsen-Cannarella SL. **Can J Physiol Pharmacol** 1998 May;76(5):485–9 (58 ref.)

The role of the immune system and infection in the effects of psychological factors on the cardiovascular system [letter] Sher L. **Can J Psychiatry** 1998 Nov;43(9):954–5

Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Liu FJ, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1168–72

The role of growth hormone and insulin-like growth factors in the immune system. van Buul-Offers SC, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1083–94 (160 ref.)

Prolactin, growth hormone and the immune system in humans. Velkeniers B, et al. **Cell Mol Life Sci** 1998 Oct; 54(10):1102–8 (75 ref.)

International Conference on Heat-Shock Proteins in Immune Response. Farmington, Connecticut, USA. 12–15 October 1998. Abstracts [published erratum appears in Cell Stress Chaperones 1998 Dec;3(4):272] **Cell Stress Chaperones** 1998 Sep;3 Suppl 1:1–28

New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Uetrecht JP. **Chem Res Toxicol** 1999 May; 12(5):387–95 (92 ref.)

Nutrition, exercise, and immune system function. Nieman DC. **Clin Sports Med** 1999 Jul;18(3):537–48 (86 ref.)

Shared resources between the neural and immune systems: semaphorins join the ranks. Spriggs MK. **Curr Opin Immunol** 1999 Aug;11(4):387–91 (58 ref.)

Cellular camouflage: fooling the immune system with polymers. Scott MD, et al. **Curr Pharm Des** 1998 Dec; 4(6):423–38 (59 ref.)

Cytokine actions in the central nervous system. Benveniste EN. **Cytokine Growth Factor Rev** 1998 Sep–Dec; 9(3–4):259–75 (199 ref.)

Reviewing the potential utility of interleukin-7 as a promoter of thymopoiesis and immune recovery. Or R, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):287–94 (71 ref.)

Cow's milk and type 1 diabetes: the real debate is about mucosal immune function. Harrison LC, et al. **Diabetes** 1999 Aug;48(8):1501–7 (81 ref.)

Monocyte function before and after surgical trauma. Haupt W, et al. **Dig Surg** 1998;15(2):102–4

Cytokines in surgical trauma: cholecystectomy as an example. Reber PU, et al. **Dig Surg** 1998;15(2):92–101 (94 ref.)

Immunoendocrine Interactions: A Comparative View. Proceedings of a workshop. Mariensee, Germany. **Domest Anim Endocrinol** 1998 Sep;15(5):273–456

Environmental modulation of the immune system via the endocrine system. Davis SL. **Domest Anim Endocrinol** 1998 Sep;15(5):283–9 (39 ref.)

Effects of elevated plasma noradrenaline concentration on the immune system in humans. Kappel M, et al. **Eur J Appl Physiol** 1998 Dec;79(1):93–8

Cellular mechanisms and molecules in infection immunity. Papers from the 5th Elsinore Meeting on Infection Immunity. Elsinore, Denmark, 29 May–2 June 1998. **Immunol Lett** 1999 Jan;65(1–2):1–140

Proceedings of the 10th Symposium on Signals and Signal Processing in the Immune System. Balatonöszöd, Hungary, 13–17 September 1998. **Immunol Lett** 1999 May 3; 68(1):1–195

Away with words: commentary on the Atlan–Cohen essay 'Immune information, self-organization and meaning'. Langman RE, et al. **Int Immunol** 1999 Jun;11(6):865–70 (39 ref.)

Is atherosclerosis an overreaction of the immune system? [letter] Seely S. **Int J Cardiol** 1998 Oct 30;66(3):323–4

Erratic behavior of nitric oxide within the immune system: illustrative review of conflicting data and their immunopharmacological aspects. Zidek Z, et al. **Int J Immunopharmacol** 1998 Jul;20(7):319–43 (293 ref.)

Effects of eccentric exercise on the immune system in men. Malm C, et al. **J Appl Physiol** 1999 Feb;86(2):461–8

Site-specific immune regulation in the brain: differential modulation of major histocompatibility complex (MHC) proteins in brainstem vs. hippocampus. Phillips LM, et al. **J Comp Neurol** 1999 Mar 15;405(3):322–33

Immune stress activates putative nitric oxide-producing neurons in rat brain: cumulative effects with restraint. Yang W, et al. **J Comp Neurol** 1999 Mar 15;405(3):380–7

Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. Reiter RJ, et al. **J Mol Med** 1999 Jan; 77(1):36–9 (43 ref.)

Immune regulation within the central nervous system. Xiao BG, et al. **J Neurol Sci** 1998 Apr 15;157(1):1–12 (91 ref.)

Expression of autoimmune disease-related antigens by cells of the immune system. Mor F, et al. **J Neurosci Res** 1998 Oct 15;54(2):254–62

Stress-induced immunomodulation: implications for infectious diseases? Glaser R, et al. **JAMA** 1999 Jun 23–30; 281(24):2268–70

Very low dietary intake of n-3 fatty acids affects the immune function of healthy elderly people. Bechoua S, et al. **Lipids** 1999;34 Suppl:S143

Dietary fatty acids and the immune system. Calder PC. **Lipids** 1999;34 Suppl:S137–40 (59 ref.)

Modulation of stress-induced murine lymphoid tissue involution by age, sex and strain: role of bone marrow. Dominguez-Gerpe L, et al. **Mech Ageing Dev** 1998 Aug 14;104(2):195–205

No man is an island; no island is an island: does the immune network extend beyond the limits of skin? Rewald E, et al. **Med Hypotheses** 1999 Apr;52(4):325–7 (20 ref.)

Pain control in inflammation governed by selectins [see comments] Machelska H, et al. **Nat Med** 1998 Dec; 4(12):1425–8. Comment in: Nat Med 1998 Dec;4(12):1359–60.

Can inflammation relieve pain? [news; comment] Porreca F, et al. **Nat Med** 1998 Dec;4(12):1359–60. Comment on: Nat Med 1998 Dec;4(12):1425–8.

How the immune system puts the brain to sleep [news; comment] Straub RH, et al. **Nat Med** 1999 Aug;5(8):877–9 . Comment on: Nat Med 1999 Aug;5(8):913–8.

Thymus-derived glucocorticoids and the regulation of antigen-specific T-cell development. Tolosa E, et al. **Neuroimmunomodulation** 1999 Jan–Apr;6(1–2):90–6 (70 ref.)

Immunologic complexity in neurons. Darnell RB. **Neuron** 1998 Nov;21(5):947–50 (20 ref.)

Immunonutrition--concluding remarks [editorial] Bengmark S. **Nutrition** 1999 Jan;15(1):57–61

CD95 mediated T cell apoptosis and its relevance to immune deviation. Varadhachary AS, et al. **Oncogene** 1998 Dec 24;17(25):3271–6 (99 ref.)

A brief review of the immune system. Alam R. **Prim Care** 1998 Dec;25(4):727–38 (32 ref.)

DSHP: a "power bar" for sustained immune responses? Satterthwaite AB, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13355–7

Maternal effects on the development of social rank and immunity trade-offs in male laboratory mice (Mus musculus). Barnard CJ, et al. **Proc R Soc Lond B Biol Sci** 1998 Nov 7;265(1410):2087–93

Immunoregulatory mechanisms of the eye. Streilein JW. **Prog Retin Eye Res** 1999 May;18(3):357–70 (44 ref.)

Capacity to produce cytokines during weight restoration in patients with anorexia nervosa. Nagata T, et al. **Psychosom Med** 1999 May–Jun;61(3):371–7

Parasitism, host immune function, and sexual selection. Møller AP, et al. **Q Rev Biol** 1999 Mar;74(1):3–20

Melatonin mediates seasonal adjustments in immune function. Nelson RJ, et al. **Reprod Nutr Dev** 1999 May–Jun; 39(3):383–98 (148 ref.)

Immunomodulation by colony-stimulating factors. Hartung T. **Rev Physiol Biochem Pharmacol** 1999;136:1–164 (644 ref.)

HLA-DM – an endosomal and lysosomal chaperone for the immune system. Vogt AB, et al. **Trends Biochem Sci** 1999 Apr;24(4):150–4 (48 ref.)

[The effect of "cognitive" and "noncognitive" exposures on the sensitivity to stressor hormones and the choice of adaptation strategy] Volchegorskiĭ IA, et al. **Izv Akad Nauk Ser Biol** 1999 Mar–Apr;(2):201–10 (Eng. Abstr.) **(Rus)**

[Regression analysis in the assessment of the state of the immune system] Shchegoleva LS, et al. **Klin Lab Diagn** 1999 Mar;(3):13–5 (Eng. Abstr.) **(Rus)**

[Immune system and immunodeficiency] Sapin MR. **Klin Med (Mosk)** 1999;77(1):5–11 (22 ref.) **(Rus)**

[Secondary immune deficiency (editorial)] Mikhailenko AA, et al. **Ter Arkh** 1998;70(11):5–9 **(Rus)**

[Chronobiology of immune system] Trufakin VA, et al. **Vestn Ross Akad Med Nauk** 1999;(4):40–3 (20 ref.) (Eng. Abstr.) **(Rus)**

[The immunological health of flight personnel: the concept and the approaches to its assessment] Ushakov IB, et al. **Voen Med Zh** 1998 Dec;319(12):43–50 **(Rus)**

[Opioids and the immune system] Núñez G, et al. **Rev Med Chil** 1999 Mar;127(3):341–8 (53 ref.) (Eng. Abstr.) **(Spa)**

[The thyroid and thymus glands and the immune system] Shidlovs'kyĭ VO, et al. **Lik Sprava** 1998 Oct–Nov;(7):21–5 (43 ref.) **(Ukr)**

PHYSIOPATHOLOGY

Immunoendocrinology of preterm labor: the link between corticotropin-releasing hormone and inflammation. Dudley DJ. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S251–6 (62 ref.)

Neuroendocrine immune features of pediatric inflammatory rheumatic diseases. Chikanza IC. **Ann N Y Acad Sci** 1999 Jun 22;876:71–80; discussion 80–2 (47 ref.)

Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. Cutolo M. **Ann N Y Acad Sci** 1999 Jun 22;876:32–41; discussion 41–2 (53 ref.)

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1–11; discussion 11–3 (59 ref.)

Stress and immune dysfunction in Gulf War veterans. Everson MP, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:413–8 (27 ref.)

Differential effects of psychological and immunological challenge on the hypothalamo-pituitary-adrenal axis function in adjuvant-induced arthritis. Harbuz MS, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:43–52 (28 ref.)

In vitro superfusion method to study nerve-immune cell interactions in human synovial membrane in long-standing rheumatoid arthritis or osteoarthritis. Miller LE, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:266–75

The immune system in viral myocarditis: maintaining the balance [editorial; comment] Knowlton KU, et al. **Circ Res** 1999 Sep 17;85(6):559–61 (20 ref.). Comment on: Circ Res 1999 Sep 17;85(6):551–8.

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC, et al. **Curr Opin Rheumatol** 1998 Sep;10(5):417–25 (70 ref.)

Functional relationship between age-related immunodeficiency and learning deterioration. Zhang Y, et al. **Eur J Neurosci** 1998 Dec;10(12):3869–75

The possible role of the immune system in Alzheimer's disease. Marx F, et al. **Exp Gerontol** 1998 Nov–Dec; 33(7–8):871–81 (57 ref.)

Restraint stress-induced immunosuppression by inhibiting leukocyte migration and Th1 cytokine expression during the intraperitoneal infection of Listeria monocytogenes. Zhang D, et al. **J Neuroimmunol** 1998 Dec 1;92(1–2):139–51

Intrathymic immunomodulation and the "infectious" tolerance pathway in allograft recipients. Reemtsen BL, et al. **J Surg Res** 1999 Jun 1;84(1):1–7

Implications of immune-to-brain communication for sickness and pain. Watkins LR, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7710–3 (34 ref.)

Reduced immune function and malnutrition in the elderly. Kawakami K, et al. **Tohoku J Exp Med** 1999 Feb; 187(2):157–71

Differences in immunoactivation between heart and liver transplanted patients. Erez E, et al. **Transplant Proc** 1999 Jun;31(4):1883–4

[The correction of immunoendocrine disorders in patients with hyperplastic processes in the endometrium]

Bespoiasnaia VV. **Lik Sprava** 1998 Jul-Aug;(5):139-42 (Eng. Abstr.) **(Rus)**

[The study of influence of acoustic oscillations on the immunogenesis] Voblikov IG, et al. **Radiats Biol Radioecol** 1998 Jul-Aug;38(4):565-72 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

UV and the Immune System. Round table summary and general discussion. Paris, France, February 6, 1998. Aubin F. **Eur J Dermatol** 1998 Apr-May;8(3):214-6

Immunomodulation by UV light: role of neuropeptides. Luger TA. **Eur J Dermatol** 1998 Apr-May;8(3):198-9 (18 ref.)

Photoprotection and photo-immunosuppression in man. Meunier L. **Eur J Dermatol** 1998 Apr-May;8(3):207-8

Relevance of photo-immunosuppression for viral infections (i.e. human papilloma virus). Vermeer BJ, et al. **Eur J Dermatol** 1998 Apr-May;8(3):205-6 (12 ref.)

Modification of immune response by low dose ionizing radiation: role of apoptosis. Shankar B, et al. **Immunol Lett** 1999 Jun 1;68(2-3):237-45

[Effect of iodine isotope on the hypophyseal-thyroid and immune systems of children residing in radionuclide polluted areas] Chernyshov VP, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):216-20 **(Rus)**

[Disturbances of proliferative properties of cells in the early embryo impair the following development of the nervous, immune, and endocrine systems in the offspring] Filiushkin IV, et al. **Biull Eksp Biol Med** 1998 Aug;126(8):164-6 **(Rus)**

[Post-radiation communicative induction of blood and immunity disorders] Surinov BP, et al. **Patol Fiziol Eksp Ter** 1998 Jul-Sep;(3):7-10 (Eng. Abstr.) **(Rus)**

[A comparative analysis of the action of red and infrared laser radiation and ultrasound on the regeneration of locally irradiated skeletal muscle and on immune system function in the rat] Subkova SM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec;(6):11-6 (Eng. Abstr.) **(Rus)**

[The effect of normobaric hypoxia on the indices of the cardiorespiratory and immune systems in the inhabitants of radiation-contaminated regions] Mel'nyk TO, et al. **Fiziol Zh** 1999;45(1-2):104-13 (Eng. Abstr.) **(Ukr)**

VIROLOGY

CNS cell populations are protected from virus-induced pathology by distinct arms of the immune system. Drescher KM, et al. **Brain Pathol** 1999 Jan;9(1):21-31

Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Kandolf R, et al. **Virus Res** 1999 Aug;62(2):149-58 (46 ref.)

IMMUNE TOLERANCE

see related
GRAFT VS HOST DISEASE
IMMUNOCOMPROMISED HOST
IMMUNOSUPPRESSION

Mixed allogeneic chimerism to induce tolerance to solid organ and cellular grafts. Exner BG, et al. **Acta Haematol** 1999;101(2):78-81 (30 ref.)

T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Stockinger B. **Adv Immunol** 1999; 71:229-65 (255 ref.)

Mucosal immunity in relation to the development of oral tolerance/sensitization. Holt PG. **Allergy** 1998;53(46 Suppl):16-9 (26 ref.)

Jeg-3 human choriocarcinoma-induced immunosuppression: downregulation of interleukin-2, interleukin-2 receptor alpha-chain, and its Jak/Stat signaling pathway. Kilic M, et al. **Am J Reprod Immunol** 1999 Jan;41(1):61-9

Donor-specific tolerance induction in composite tissue allografts. Foster RD, et al. **Am J Surg** 1998 Nov; 176(5):418-21

Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin-12. Marth T, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:290-4

Development and disappearance of tolerance to induction of interferon and tumor necrosis factor response in athletes treated with natural immunostimulant. Inglot AD, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(4):237-44

E7-specific cytotoxic T cell tolerance in HPV-transgenic mice. Borchers A, et al. **Arch Virol** 1999;144(8):1539-56

Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Heino M, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):821-5

Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response. Jones DS, et al. **Bioconjug Chem** 1999 May-Jun;10(3):480-8

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Rosenberg M, et al. **Blood** 1999 Mar 15;93(6):2081-8

In vivo T-lymphocyte tolerance in the absence of thymic clonal deletion mediated by hematopoietic cells. van Meerwijk JP, et al. **Blood** 1999 Jun 1;93(11):3856-62

Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. Petrini P, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S143-6

Risk of allogeneic transfusions. Heiss MM. **Br J Anaesth** 1998 Dec;81 Suppl 1:16-9 (30 ref.)

Keratoacanthomas have an immunosuppressive cytokine environment of increased IL-10 and decreased GM-CSF compared to squamous cell carcinomas. Lowes MA, et al. **Br J Cancer** 1999 Jul;80(10):1501-5

Comparative immunotoxicology of ultraviolet B exposure I. Effects of in vitro and in situ ultraviolet B exposure on the functional activity and morphology of Langerhans cells in the skin of different species. Goettsch W, et al. **Br J Dermatol** 1998 Aug;139(2):230-8

Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Oliveira FM, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1421-4 (20 ref.)

Immune changes induced by exercise in an adverse environment. Shephard RJ. **Can J Physiol Pharmacol** 1998 May;76(5):539-46 (63 ref.)

Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Horiguchi S, et al. **Cancer Res** 1999 Jun 15;59(12):2950-6

Approach to fever in the neutropenic host. Stoupis A, et al. **Cancer Treat Res** 1998;96:77-104 (114 ref.)

Induction of peripheral tolerance in neonatally thymectomized mice by immunization through chemical carcinogen-altered skin. Chen YP, et al. **Cell Immunol** 1998 Nov 1;189(2):99-106

Induction of T cell anergy by high concentrations of immunodominant native peptide is accompanied by IL-10 production and a block in JNK activity. Chou YK, et al. **Cell Immunol** 1998 Sep 15;188(2):125-36

Priming or tolerization of the B- and Th2-dependent immune response by the oral administration of OVA-DNP is determined by the antigen dosage. Franco L, et al. **Cell Immunol** 1998 Nov 25;190(1):1-11

Activation of donor-specific CTL in a tolerant recipient of cardiac allograft. Petersson E, et al. **Cell Immunol** 1998 Oct 10;189(1):19-24

Rheumatoid factor B cell tolerance via autonomous Fas/FasL-independent apoptosis. Warnatz K, et al. **Cell Immunol** 1999 Jan 10;191(1):69-73

Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Pak AS, et al. **Clin Cancer Res** 1995 Jan;1(1):95-103

The immunosuppressive activity of Ascaris suum is due to high molecular weight components. Faquim-Mauro EL, et al. **Clin Exp Immunol** 1998 Nov;114(2):245-51

Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes. Lundin BS, et al. **Clin Exp Immunol** 1999 Apr;116(1):181-7

T-cell reactivity and its predictive role in immunosuppression after burns [see comments] Zedler S, et al. **Crit Care Med** 1999 Jan;27(1):66-72. Comment in: Crit Care Med 1999 Jan;27(1):7-8.

FcR-mediated inhibition of cell activation and other forms of coinhibition. Anderson CC, et al. **Crit Rev Immunol** 1998; 18(6):525-44 (131 ref.)

Immune deficits induced by strenuous exertion under adverse environmental conditions: manifestations and countermeasures. Shephard RJ, et al. **Crit Rev Immunol** 1998;18(6):545-68 (224 ref.)

Immunologic nonresponsiveness to tumors. Antonia SJ, et al. **Crit Rev Oncog** 1998;9(1):35-41 (62 ref.)

Infectious tolerance. Cobbold S, et al. **Curr Opin Immunol** 1998 Oct;10(5):518-24 (74 ref.)

Development and tolerance of natural killer cells. Raulet DH. **Curr Opin Immunol** 1999 Apr;11(2):129-34 (51 ref.)

NOD mice have a generalized defect in their response to transplantation tolerance induction. Markees TG, et al. **Diabetes** 1999 May;48(5):967-74

Functional tolerance for prevention of type 1 diabetes. Baxter AG, et al. **Diabetes Metab Rev** 1998 Sep;14(3):254-6

Problems with inducing tolerance to type 1 diabetes. Beales PE. **Diabetes Metab Rev** 1998 Sep;14(3):257-8

Antigen-specific therapy in NOD mouse. Liddi R. **Diabetes Metab Rev** 1998 Sep;14(3):256-7

Immunomodulation induced by psoralen plus ultraviolet A radiation. Aubin F, et al. **Eur J Dermatol** 1998 Apr-May; 8(3):212-3 (29 ref.)

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Brackmann HH, et al. **Eur J Haematol Suppl** 1998;63:18-23 (15 ref.)

Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. Bachmann MF, et al. **Eur J Immunol** 1999 Jul;29(7):2156-66

Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice. Bercovici N, et al. **Eur J Immunol** 1999 Jan;29(1):345-54

Characterization of anti-DNA B cells that escape negative selection. Bynoe MS, et al. **Eur J Immunol** 1999 Apr; 29(4):1304-13

Neonatal colonization of rats induces immunological tolerance to bacterial antigens. Karlsson MR, et al. **Eur J Immunol** 1999 Jan;29(1):109-18

Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance. Karp CL, et al. **Eur J Immunol** 1998 Oct;28(10):3128-36

Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction. Müller A, et al. **Eur J Immunol** 1998 Nov; 28(11):3488-98

Maternal-fetal tolerance is maintained despite transgene-driven trophoblast expression of MHC class I, and defects in Fas and its ligand. Rogers AM, et al. **Eur J Immunol** 1998 Nov;28(11):3479-87

Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Montón C, et al. **Eur Respir J** 1999 Jul;14(1):218-20

Th2 biased immune response in cases with active Mycobacterium tuberculosis infection and tuberculin anergy. Balikó Z, et al. **FEMS Immunol Med Microbiol** 1998 Nov;22(3):199-204

Inhibition of lymphoproliferative response and its restoration with a glucan immunomodulator in mice with experimental larval toxocarosis. Borošková Z, et al. **Folia Microbiol (Praha)** 1998;43(5):475-6

Enhanced human tumor cell transplantability in a new congenic immunodeficient mouse; KSN-BNX. Ishigaki Y, et al. **Folia Microbiol (Praha)** 1998;43(5):493-4

Oral tolerance in disease. Garside P, et al. **Gut** 1999 Jan; 44(1):137-42 (112 ref.)

Mechanisms of immune escape in viral hepatitis. Rosenberg W. **Gut** 1999 May;44(5):759-64 (78 ref.)

German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Brackmann HH, et al. **Haemophilia** 1999 May;5(3):203-6

Immune tolerance: a synopsis of the international experience. Di Michele DM. **Haemophilia** 1998 Jul;4(4):568-73 (28 ref.)

Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Furukawa H, et al. **Hum Immunol** 1999 Jan;60(1):32-40

Immunoregulation by CD4 T cells in the induction of specific immunological unresponsiveness to alloantigens in vivo: evidence for a reduction in the frequency of alloantigen-specific cytotoxic T cells in vitro. Roelen DL, et al. **Hum Immunol** 1998 Sep;59(9):529-39

Soluble HLA antigens: how it all started. van Rood JJ, et al. **Hum Immunol** 1999 May;60(5):412-3

Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Plebanski M, et al. **Immunity** 1999 Jun;10(6):651-60

Persistent tolerance induced after portal venous injection of allogeneic cells plus cyclophosphamide treatment. Jin T, et al. **Immunobiology** 1999 Jun;200(2):215-26

Oral tolerance by a high dose OVA in BALB/c mice is more pronounced and persistent in Th2-mediated immune responses than in Th1 responses. Kang B, et al. **Immunobiology** 1999 Jun;200(2):264-76

Ubiquitin-like polypeptide inhibits the proliferative response of T cells in vivo. Kondoh T, et al. **Immunobiology** 1999 Feb;200(1):140-9

Nature versus nurture: contributions of developmental programming and the microenvironment to B cell tolerance. Fazekas de St Groth B. **Immunol Cell Biol** 1998 Aug;76(4):369-72

Determinant hierarchy: shaping of the self-directed T cell repertoire, and induction of autoimmunity. Moudgil KD. **Immunol Lett** 1999 Jun 1;68(2-3):251-6

Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Thurau SR, et al. **Immunol Lett** 1999 Jun 1;68(2-3):205-12

Dominant regulation: a common mechanism of monoclonal antibody induced tolerance? Honey K, et al. **Immunol Res** 1999;20(1):1-14 (95 ref.)

Peripheral T-cell tolerance: the contribution of permissive T-cell migration into parenchymal tissues of the neonate. Alferink J, et al. **Immunol Rev** 1999 Jun;169:255-61 (43 ref.)

Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis. Anderton S, et al. **Immunol Rev** 1999 Jun;169:123-37 (78 ref.)

Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein. Goverman J. **Immunol Rev** 1999 Jun;169:147-59 (111 ref.)

Myelin protein expression in lymphoid tissues: implications for peripheral tolerance. Voskuhl RR. **Immunol Rev** 1998 Aug;164:81-92

Cow's milk and type I diabetes: the gut immune system deserves attention. Kolb H, et al. **Immunol Today** 1999 Mar; 20(3):108-10

Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). D'Orazio TJ, et al. **Immunology** 1998 Sep;95(1):47-55

Importance of intrathymic mixed chimerism for the maintenance of skin allograft tolerance across fully allogeneic antigens in mice. Eto M, et al. **Immunology** 1999 Mar;96(3):440-6

Distinct roles for transforming growth factor-beta2 and tumour necrosis factor-alpha in immune deviation elicited by hapten-derivatized antigen-presenting cells. Hecker KH, et al. **Immunology** 1999 Mar;96(3):372-80

Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture. Leshem B, et al. **Immunology** 1998 Nov;95(3):409-18

Elevated major histocompatibility complex class I expression protects T cells from antibody- and macrophage-mediated

deletion. Orlikowsky T, et al. **Immunology** 1998 Nov; 95(3):437–42

Immunoglobulin E suppression and cytokine modulation in mice orally tolerized to beta-lactoglobulin. Pecquet S, et al. **Immunology** 1999 Feb;96(2):278–85

Unresponsiveness following immunization with the T-cell-independent antigen dextran B512. Can it be abrogated? Sverremark E, et al. **Immunology** 1998 Nov; 95(3):402–8

Visualizing the T-cell response elicited by oral administration of soluble protein antigen. Williamson E, et al. **Immunology** 1999 Aug;97(4):565–72

Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Navratil JS, et al. **Immunopharmacology** 1999 May;42(1–3):47–52 (34 ref.)

NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Kastenbauer S, et al. **Infect Immun** 1999 Apr; 67(4):1553–9

Salmonella typhimurium infection in mice induces nitric oxide-mediated immunosuppression through a natural killer cell-dependent pathway. Schwacha MG, et al. **Infect Immun** 1998 Dec;66(12):5862–6

Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Wu-Hsieh BA, et al. **Infect Immun** 1998 Nov;66(11):5520–6

Estrogen-mediated immunosuppression in autoimmune diseases. Jansson L, et al. **Inflamm Res** 1998 Jul; 47(7):290–301 (177 ref.)

Linked suppression in peripheral T cell tolerance to the house dust mite derived allergen Der p 1. Hoyne GF, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):122–4

The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Jones ND, et al. **Int Immunol** 1998 Nov; 10(11):1637–46

Immunosuppressive factors: role in cancer development and progression. Botti C, et al. **Int J Biol Markers** 1998 Apr–Jun;13(2):51–69 (221 ref.)

FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. Favre N, et al. **Int J Cancer** 1999 Jul 30; 82(3):359–67

Host H-2 haplotype modulates the induction of host-versus-graft disease after the induction of neonatal tolerance to H-2 alloantigens. Ramos A, et al. **Int J Mol Med** 1998 Feb;1(2):431–7

Prevalence of and risk factors for tuberculin positivity and skin test anergy in HIV-1-infected and uninfected at-risk women. Women's Interagency HIV Study (WIHS). Anastos K, et al. **J Acquir Immune Defic Syndr** 1999 Jun 1;21(2):141–7

Immunologic tolerance for immune system-mediated diseases. Hackett CJ, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):362–70

Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. Chu CQ, et al. **J Autoimmun** 1999 Feb;12(1):35–42

Tolerance induction by acylated peptides: effect on encephalitogenic T cell lines. St Louis J, et al. **J Autoimmun** 1999 May;12(3):177–89

Minimally invasive surgery induces endotoxin-tolerance in the absence of detectable endotoxemia. Lemaire LC, et al. **J Clin Immunol** 1998 Nov;18(6):414–20

Treatment of an autoimmune disease with "classical" T cell veto: a proposal. Staerz UD, et al. **J Clin Immunol** 1999 Jul;19(4):195–202 (97 ref.)

Tolerance by transplantation: how much is enough, how much is too much? [comment] Platt JL. **J Clin Invest** 1999 Aug;104(3):227–8 (16 ref.). Comment on: J Clin Invest 1999 Aug;104(3):281–90.

Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. Miller C, et al. **J Exp Med** 1999 Jul 5;190(1):53–64

Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy. Min B, et al. **J Exp Med** 1998 Dec 7;188(11):2007–17

Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant. Pulendran B, et al. **J Exp Med** 1998 Dec 7;188(11):2075–82

B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. Stremmel C, et al. **J Exp Med** 1999 Mar 15;189(6):919–30

Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? [editorial; comment] Farrell GC. **J Gastroenterol Hepatol** 1999 Aug;14(8):741–4. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):801–3. Comment on: J Gastroenterol Hepatol 1999 Aug;14(8):804–6.

Induction of donor-specific tolerance to cardiac xenografts in utero. Tanaka SA, et al. **J Heart Lung Transplant** 1998 Sep;17(9):888–91

Oncospheres of Taenia solium and T. saginata asiatica develop into metacestodes in normal and immunosuppressed mice. Wang IC, et al. **J Helminthol** 1999 Jun;73(2):183–6

Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. Bushell A, et al. **J Immunol** 1999 Feb 1; 162(3):1359–66

Tolerance to antigen-presenting cell-depleted islet allografts is CD4 T cell dependent. Coulombe M, et al. **J Immunol** 1999 Mar 1;162(5):2503–10

Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo. Dubois PM, et al. **J Immunol** 1998 Nov 15;161(10):5260–7

Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. Fehniger TA, et al. **J Immunol** 1998 Dec 1;161(11):6433–8

Relationship between chimerism and tolerance in a kidney transplantation model. Fuchimoto Y, et al. **J Immunol** 1999 May 15;162(10):5704–11

Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. Gregerson DS, et al. **J Immunol** 1999 Jul 15; 163(2):1073–80

Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4. Hall BM, et al. **J Immunol** 1998 Nov 15; 161(10):5147–56

The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor beta 2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12. Himmelrich H, et al. **J Immunol** 1998 Dec 1;161(11):6156–63

Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. Homann D, et al. **J Immunol** 1999 Aug 15;163(4):1833–8

Cutting edge: myelin basic protein-specific cytotoxic T cell tolerance is maintained in vivo by a single dominant epitope in H-2k mice. Huseby ES, et al. **J Immunol** 1999 Aug 1; 163(3):1115–8

Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. Ichino M, et al. **J Immunol** 1999 Apr 1; 162(7):3814–8

Peripheral tolerance to class I mismatched renal allografts in miniature swine: donor antigen-activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity. Ierino FL, et al. **J Immunol** 1999 Jan 1; 162(1):550–9

Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. Issazadeh S, et al. **J Immunol** 1999 Jan 15;162(2):761–5

Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. Kaliyaperumal A, et al. **J Immunol** 1999 May 15; 162(10):5775–83

Suppression of antigen-specific Th2 cell-dependent IgM and IgG1 production following norepinephrine depletion in vivo. Kohm AP, et al. **J Immunol** 1999 May 1; 162(9):5299–308

Strain variation in autoimmunity: attempted tolerization of DA rats results in the induction of experimental autoimmune encephalomyelitis. Lenz DC, et al. **J Immunol** 1999 Aug 15;163(4):1763–8

B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance. Liu L, et al. **J Immunol** 1999 Aug 15;163(4):2284–90

Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. Morgan DJ, et al. **J Immunol** 1999 Jul 15; 163(2):723–7

Normal development in porcine thymus grafts and specific tolerance of human T cells to porcine donor MHC. Nikolic B, et al. **J Immunol** 1999 Mar 15;162(6):3402–7

I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. Noorchashm H, et al. **J Immunol** 1999 Jul 15;163(2):743–50

Humoral response suppression observed with CD23 transgenics. Payet ME, et al. **J Immunol** 1999 Jul 1; 163(1):217–23

TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. Phillips TA, et al. **J Immunol** 1999 May 15;162(10):6053–9

IL-4 and IL-10 are both required for the induction of oral tolerance. Rizzo LV, et al. **J Immunol** 1999 Mar 1; 162(5):2613–22

Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. Schmidt CS, et al. **J Immunol** 1999 Sep 1;163(5):2561–7

Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. Shi FD, et al. **J Immunol** 1999 May 15; 162(10):5757–63

Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, et al. **J Immunol** 1998 Nov 1;161(9):4520–9

Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development. Sivakumar PV, et al. **J Immunol** 1999 Jun 15;162(12):6976–80

Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. Smeltz RB, et al. **J Immunol** 1999 Aug 1;163(3):1390–7

Antigen-specific T cell activation and proliferation during oral tolerance induction. Sun J, et al. **J Immunol** 1999 May 15;162(10):5868–75

Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. Tisch R, et al. **J Immunol** 1999 Aug 1;163(3):1178–87

Experimental murine Trypanosoma congolense infections. II. Role of splenic adherent CD3+Thy1.2+ TCR-alpha beta-gamma delta- CD4+8- and CD3+Thy1.2+ TCR-alpha beta- gamma delta- CD4-8- cells in the production of IL-4, IL-10, and IFN-gamma and in trypanosome-elicited immunosuppression. Uzonna JE, et al. **J Immunol** 1998 Dec 1;161(11):6189–97

Linked suppression of skin graft rejection can operate through indirect recognition. Wise MP, et al. **J Immunol** 1998 Dec 1;161(11):5813–6

Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. Zhang HG, et al. **J Immunol** 1999 Feb 1;162(3):1423–30

Tolerization of adult mice to immunodominant proteins before monoclonal antibody production. Lebrón JA, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):59–63

Serum from Entamoeba histolytica-infected gerbils selectively suppresses T cell proliferation by inhibiting interleukin-2 production. Campbell D, et al. **J Infect Dis** 1999 Jun;179(6):1495–501

Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. Agarwal SK, et al. **J Interferon Cytokine Res** 1998 Dec; 18(12):1059–68

Cytokines in the induction and circumvention of peripheral tolerance. Romball CG, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):671–8

Different in vivo tolerogenicity of MHC class I peptides. Fändrich F, et al. **J Leukoc Biol** 1999 Jan;65(1):16–27

Inhibition of autoreactive antibody effects with antibody feedings: a pilot study. Hofmann WW, et al. **J Neuroimmunol** 1999 Apr 1;96(1):1–8

Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. Massi P, et al. **J Neuroimmunol** 1998 Dec 1; 92(1–2):60–6

Severity, time, and beta-adrenergic receptor involvement in surgery-induced immune alterations. Nelson CJ, et al. **J Surg Res** 1998 Dec;80(2):115–22

Immune response and cytokines in septic rats undergoing blood transfusion. Salinas JC, et al. **J Surg Res** 1998 Dec; 80(2):295–9

Immunosuppressive effect of Cryptosporidium baileyi infection on vaccination against avian infectious bronchitis in chicks. Rhee JK, et al. **Korean J Parasitol** 1998 Sep; 36(3):203–6

Verification of immunosuppression in chicks caused by Cryptosporidium baileyi infection using Brucella abortus strain 1119-3. Rhee JK, et al. **Korean J Parasitol** 1998 Dec; 36(4):281–4

Specific tolerance induction and organ transplantation. de Vries-van der Zwan A, et al. **Leuk Lymphoma** 1998 Sep; 31(1–2):131–42 (56 ref.)

Immunologic tolerance: self-nonself discrimination versus costimulatory factors and second signals. Simon Z, et al. **Med Hypotheses** 1998 Jul;51(1):1–3 (11 ref.)

Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma. Mercié P, et al. **Microvasc Res** 1999 Mar; 57(2):208–10

Immunosuppressory mini-regions of HLA-DP and HLA-DR. Szewczuk Z, et al. **Mol Immunol** 1999 Jun; 36(8):525–33

Transplantation of anergic histoincompatible bone marrow cells [letter] de Carvalho Bittencourt M, et al. **N Engl J Med** 1999 Sep 30;341(14):1081–2

Transplantation of anergic histoincompatible bone marrow cells [letter] Gallardo D, et al. **N Engl J Med** 1999 Sep 30;341(14):1082

Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells [see comments] Zhang HG, et al. **Nat Biotechnol** 1998 Nov;16(11):1045–9. Comment in: Nat Biotechnol 1998 Nov;16(11):1011–2.

Much IDO about pregnancy [news] Bonney EA, et al. **Nat Med** 1998 Oct;4(10):1128–9

Lowered leptin slims immune response [news; comment] Flier JS. **Nat Med** 1998 Oct;4(10):1124–5. Comment on: Nat Med 1998 Oct;4(10):1152–6.

Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Matsue H, et al. **Nat Med** 1999 Aug;5(8):930–7

NIAID to begin clinical transplant tolerance trials [news] Novak K. **Nat Med** 1999 May;5(5):470–1

Brain injury and immunosuppression [news; comment] Plata-Salamán CR. **Nat Med** 1998 Jul;4(7):768–9. Comment on: Nat Med 1998 Jul;4(7):808–13.

Azodicarbonamide inhibits T-cell responses in vitro and in

vivo. Tassignon J, et al. **Nat Med** 1999 Aug;5(8):947–50
Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury [see comments] Woiciechowsky C, et al. **Nat Med** 1998 Jul; 4(7):808–13. Comment in: Nat Med 1998 Jul;4(7):768–9.
Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Lord GM, et al. **Nature** 1998 Aug 27;394(6696):897–901
NIMA (non-inherited maternal antigens) versus NIPA (non-inherited paternal antigens) and tolerance of human kidney graft [editorial] Dupont E.
Nephrol Dial Transplant 1999 Mar;14(3):547–8
Proceedings of a symposium on immunological tolerance. London, 8–10 July 1997. **Novartis Found Symp** 1998; 215:1–240
Tolerance induction in mature T lymphocytes. Alferink J, et al. **Novartis Found Symp** 1998;215:191–6; discussion 196–9, 218–30
A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Allison JP, et al.
Novartis Found Symp 1998;215:92–8; discussion 98–102, 186–90 (28 ref.)
Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Anderton SM, et al. **Novartis Found Symp** 1998;215:120–31; discussion 131–6, 186–90
B cell antigen receptor signalling in the balance of tolerance and immunity. Cornall RJ, et al. **Novartis Found Symp** 1998; 215:21–30; discussion 30–40 (38 ref.)
Quantitative and qualitative control of antigen receptor signalling in tolerant B lymphocytes. Healy JI, et al.
Novartis Found Symp 1998;215:137–44; discussion 144–5, 186–90
Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity. Kurts C, et al. **Novartis Found Symp** 1998;215:172–81; discussion 181–90 (20 ref.)
A two-step model for the induction of organ-specific autoimmunity. Limmer A, et al. **Novartis Found Symp** 1998; 215:159–67; discussion 167–71, 186–90
Immunological tolerance. Introduction. Mitchison NA.
Novartis Found Symp 1998;215:1–4
Antigen-specific CD4+ T cells that survive after the induction of peripheral tolerance possess an intrinsic lymphokine production defect. Pape KA, et al.
Novartis Found Symp 1998;215:103–13; discussion 113–9, 186–90 (30 ref.)
Tolerance and determinant hierarchy. Schneider SC, et al. **Novartis Found Symp** 1998;215:54–66; discussion 66–72
T lymphocyte-mediated control of autoimmunity. Shevach EM, et al. **Novartis Found Symp** 1998;215:200–11; discussion 211–30
Mechanisms of peripheral T cell tolerance. van Parijs L, et al. **Novartis Found Symp** 1998;215:5–14; discussion 14–20, 33–40 (23 ref.)
Tolerance induction with CD4 monoclonal antibodies. Waldmann H, et al. **Novartis Found Symp** 1998;215:146–52; discussion 152–8, 186–90 (22 ref.)
The study of self-tolerance using murine haemoglobin as a model self antigen. Williams CB, et al.
Novartis Found Symp 1998;215:41–6; discussion 46–53 (23 ref.)
Immune privilege in the retina. Gregerson DS.
Ocul Immunol Inflamm 1998 Dec;6(4):257–67 (68 ref.)
Immunosuppression in hamsters with progressive visceral leishmaniasis: an evaluation of the role of nitric oxide toward impairment of the lymphoproliferative response. Dasgupta S, et al. **Parasitol Res** 1999 Jul;85(7):594–6
Induction of immunologic tolerance for transplantation. Rossini AA, et al. **Physiol Rev** 1999 Jan;79(1):99–141 (460 ref.)
A two-step, two-signal model for the primary activation of precursor helper T cells. Bretscher PA.
Proc Natl Acad Sci U S A 1999 Jan 5;96(1):185–90
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Sotomayor EM, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11476–81
Antithymocyte globulin and cyclosporin A are synergistic in an experimental transplantation tolerance model in the rat. Olausson M, et al. **Scand J Immunol** 1999 Jan; 49(1):38–44
Heat denaturation of egg-white proteins abrogates the induction of oral tolerance of specific Th2 immune responses in mice. Peng HJ, et al. **Scand J Immunol** 1998 Nov;48(5):491–6
Soluble Fas and soluble Fas ligand proteins in human milk: possible significance in the development of immunological tolerance. Srivastava MD, et al. **Scand J Immunol** 1999 Jan;49(1):51–4
Tolerating differences. Sikorski R, et al. **Science** 1999 Jul 16;285(5426):357–8
HLA-G expression: immune privilege for tumour cells? Cabestre FA, et al. **Semin Cancer Biol** 1999 Feb;9(1):27–36 (49 ref.)
The immunotolerance role of HLA-G. Rouas-Freiss N, et al. **Semin Cancer Biol** 1999 Feb;9(1):3–12 (40 ref.)
The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. Guller S, et al.
Semin Reprod Endocrinol 1999;17(1):39–44 (53 ref.)
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Rothschild C, et al. **Thromb Haemost** 1998 Nov;80(5):779–83
Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Smith MP, et al.
Thromb Haemost 1999 Jan;81(1):35–8
Tolerance induction following allogeneic vascularized bone marrow transplantation--the possible role of microchimerism. Durlik M, et al. **Transpl Int** 1998;11 Suppl 1:S299–302
Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. Horimoto H, et al. **Transpl Int** 1998;11 Suppl 1:S310–2
"Almost tolerance" in the clinic. Calne R.
Transplant Proc 1998 Nov;30(7):3846–8 (10 ref.)
Clinical application of tolerance induction in solid organ transplantation. Cosimi AB. **Transplant Proc** 1999 Jun; 31(4):1803–5 (18 ref.)
Increased IL-4 production and decreased CD40L expression by newborn T cells contribute to transplantation tolerance. Donckier V, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):782–3
Allopeptide-mediated expression of endothelial Fas-ligand (CD95L) in long-term tolerized heterotopic rat heart grafts. Fändrich F, et al. **Transplant Proc** 1999 May; 31(3):1558–9
An alternative model to study intrathymic tolerance induction: the neonatal heart-in-ear transplantation model in the rat. Hillebrands JL, et al. **Transplant Proc** 1999 May; 31(3):1563–6
Strategies for the treatment of intraocular inflammatory disease. Nussenblatt RB, et al. **Transplant Proc** 1998 Dec; 30(8):4124–5 (13 ref.)
Reflections on tolerance, self-tolerance and Felix Milgrom. Rose NR. **Transplant Proc** 1999 May;31(3):1460–3 (34 ref.)
Role of HLA-G in maternal-fetal immune tolerance. Rouas-Freiss N, et al. **Transplant Proc** 1999 Feb-Mar; 31(1–2):724–5
Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al.
Transplant Proc 1999 Feb-Mar;31(1–2):1406–11 (62 ref.)
Induction of tolerance by oral administration of a tolerogenic allochimeric donor/recipient class I MHC protein. Stepkowski SM, et al. **Transplant Proc** 1999 May;31(3):1557
Immunoregulatory role of CD8alpha in the veto effect. Asiedu C, et al. **Transplantation** 1999 Feb 15;67(3):372–80
A nonlethal conditioning approach to achieve engraftment of xenogeneic rat bone marrow in mice and to induce donor-specific tolerance. Neipp M, et al.
Transplantation 1998 Oct 27;66(8):969–75
Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy. Plain KM, et al. **Transplantation** 1999 Feb 27;67(4):605–13
CD2 and CD3 receptor-mediated tolerance: constraints on T cell activation. Punch JD, et al. **Transplantation** 1999 Mar 15;67(5):741–8
Mixed chimerism as an approach for the induction of transplantation tolerance. Wekerle T, et al.
Transplantation 1999 Aug 27;68(4):459–67 (118 ref.)
The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model. Yamada K, et al. **Transplantation** 1999 Aug 27;68(4):485–91
Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Johnson CM, et al.
Tuber Lung Dis 1997;78(5–6):257–61
Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Maassen CB, et al. **Vaccine** 1999 Apr 23;17(17):2117–28
Changes in donor leukocytes during blood storage. Implications on post-transfusion immunomodulation and transfusion-associated GVHD. Mincheff M. **Vox Sang** 1998;74 Suppl 2:189–200
[UV-induced immunosuppression and skin cancers] Meunier L, et al. **Rev Med Interne** 1998 Apr;19(4):247–54 (72 ref.) (Eng. Abstr.) **(Fre)**
[The young hemophiliac, inhibitors and immune tolerance] Rothschild C. **Transfus Clin Biol** 1999 Jun;6(3):191–4 (11 ref.) (Eng. Abstr.) **(Fre)**
[Immune tolerance in pregnancy. Maternal-fetal interactions] Spina V, et al. **Minerva Ginecol** 1998 Dec;50(12):533–7 (Eng. Abstr.) **(Ita)**
[Effect of HIV envelope glycoprotein on the induction of immune dysregulation in HIV infection] Sekigawa I, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Feb;21(1):11–9 (38 ref.) (Eng. Abstr.) **(Jpn)**
[Immunological tolerance and autoimmune disease] Misaki Y, et al. **Nippon Rinsho** 1999 Aug;57(8):1703–9 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Vasopressin: secondary immune response and antigen-specific suppressants] Igonina NA, et al.
Biull Eksp Biol Med 1999 Jan;127(1):60–2 **(Rus)**
[Immunosuppression induced by homologous blood transfusion] Fariñas Guerrero F, et al. **Sangre (Barc)** 1998 Jun;43(3):213–7 (61 ref.) **(Spa)**

DRUG EFFECTS

The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Verhoef CM, et al.
Ann Rheum Dis 1999 Jan;58(1):49–54
Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Yamada J, et al.
Arch Ophthalmol 1998 Oct;116(10):1351–7
Effects of Brazilin on induction of immunological tolerance by sheep red blood cells in C57BL/6 female mice. Mok MS, et al. **Arch Pharm Res** 1998 Dec;21(6):769–73
Effects of resuscitation fluids on T cell immune responses. Sillett HK, et al. **Br J Anaesth** 1998 Aug;81(2):242–3
Extended blood half-life of monomethoxypolyethylene glycol-conjugated hen lysozyme is a key parameter controlling immunological tolerogenicity. So T, et al.
Cell Mol Life Sci 1999 Jul;55(8–9):1187–94
Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides. Saborio DV, et al. **Cell Transplant** 1999 Jul-Aug;8(4):375–81
Recombinant IFN-gamma abrogates allograft tolerance induced by donor-specific blood transfusion by restoring alloantibody production. Josien R, et al. **Eur J Immunol** 1999 Jan;29(1):317–26
Immunogenic and tolerogenic properties of monomethoxypoly(ethylene glycol) conjugated proteins. Caliceti P, et al. **Farmaco** 1999 Jul 30;54(7):430–7
Orally administered cholera toxin prevents murine intestinal T cells from staphylococcal enterotoxin B-induced anergy. Iijima H, et al. **Gastroenterology** 1998 Nov;115(5):1197–204
Clotting factor concentrates and immune function in haemophilic patients. Hoots K, et al. **Haemophilia** 1998 Sep; 4(5):704–13 (85 ref.)
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Tengborn L, et al. **Haemophilia** 1998 Jan;4(1):56–9
Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Williams NA, et al.
Immunol Today 1999 Feb;20(2):95–101 (63 ref.)
Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Myers LK, et al. **Immunology** 1998 Dec;95(4):631–9
The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to
(TJ-41:Bu-Zhong-Yi-Qi-Tang). Li T, et al.
Immunopharmacology 1999 Jun;43(1):11–21
Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. Koblish HK, et al. **J Exp Med** 1998 Nov 2;188(9):1603–10
Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. Wu DY, et al. **J Immunol** 1999 Jun 1; 162(11):6926–33
Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. Agarwal SK, et al. **J Interferon Cytokine Res** 1998 Dec; 18(12):1059–68
In vitro determination of erythema and immunologic protection afforded by sunscreens do not accord with in vivo assessments [letter; comment] Fourtanier A.
J Invest Dermatol 1999 Jan;112(1):119. Comment on: J Invest Dermatol 1998 Aug;111(2):340.
Glucocorticoids protect against suppression of T cell responses in a murine model of acute ethanol exposure and thermal injury by regulating IL-6. Faunce DE, et al.
J Leukoc Biol 1998 Dec;64(6):724–32
Efficacy of micronized titanium dioxide-containing compounds in protection against UVB-induced immunosuppression in humans in vivo. van der Molen RG, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):143–50
The gut cytokine balance as a target of lead toxicity. Goebel C, et al. **Life Sci** 1999;64(24):2207–14
Immunosuppressive effects of silicon phthalocyanine photodynamic therapy. Reddan JC, et al.
Photochem Photobiol 1999 Jul;70(1):72–7
Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Yoshikawa M, et al. **Transplant Proc** 1999 Aug;31(5):1939
Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. Leung W, et al.
Transplantation 1999 Jun 15;67(11):1487–9
[Anticipatory nausea and anticipatory vomiting, food aversion and anticipatory immunomodulation: classical conditioning in cytostatic drug treatment of pediatric chemotherapy patients] Stockhorst U, et al.
Schweiz Rundsch Med Prax 1998 Sep 2;87(36):1140–7 (37 ref.) (Eng. Abstr.) **(Ger)**
[Experimental validation of the use of the radioprotector indometofen for inflammation arrest in the periodontium in an immunodeficiency state] Grigor'ian AS, et al.
Patol Fiziol Eksp Ter 1998 Jul-Sep;(3):15–8 (Eng. Abstr.) **(Rus)**

GENETICS

Insulin expression in the thymus, tolerance, and type 1 diabetes [letter; comment] Pugliese A.
Diabetes Metab Rev 1998 Dec;14(4):325–7. Comment on:

Diabetes Metab Rev 1998 Mar;14(1):95–103.

Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance. Bennett WA, et al. **Early Pregnancy** 1997 Sep;3(3):190–8

Analysis of peripheral immune tolerance uncovers a mouse strain-dependent in situ type of graft tolerance. Mysliwietz J, et al. **Eur J Immunol** 1999 Jan;29(1):150–5

Unresponsiveness of MyD88-deficient mice to endotoxin. Kawai T, et al. **Immunity** 1999 Jul;11(1):115–22

Central T cell tolerance in lupus-prone mice: influence of autoimmune background and the lpr mutation. Fatenejad S, et al. **J Immunol** 1998 Dec 1;161(11):6427–32

Orally induced peripheral nonresponsiveness is maintained in the absence of functional Th1 or Th2 cells. Shi HN, et al. **J Immunol** 1999 May 1;162(9):5143–8

Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells. Sobel ES, et al. **J Immunol** 1999 Feb 15;162(4):2415–21

A rapid and safe plasmid isolation method for efficient engineering of recombinant lactobacilli expressing immunogenic or tolerogenic epitopes for oral administration. Maassen CB. **J Immunol Methods** 1999 Feb 1;223(1):131–6

The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [see comments] Burlingham WJ, et al. **N Engl J Med** 1998 Dec 3;339(23):1657–64. Comment in: N Engl J Med 1998 Dec 3;339(23):1700–2. Comment in: N Engl J Med 1999 Apr 29;340(17):1369–70.

The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors [letter; comment] Opelz G. **N Engl J Med** 1999 Apr 29;340(17):1369–70. Comment on: N Engl J Med 1998 Dec 3;339(23):1657–64.

Transplantation tolerance--the search continues [editorial; comment] Sanfilippo F. **N Engl J Med** 1998 Dec 3; 339(23):1700–2. Comment on: N Engl J Med 1998 Dec 3;339(23):1657–64.

Indications of immunological tolerance in kidney transplantation. Christensen LL, et al. **Tissue Antigens** 1998 Jun;51(6):637–44

Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. LaTemple DC, et al. **Xenotransplantation** 1998 Aug;5(3):191–6

IMMUNOLOGY

Oral tolerance: mechanisms and therapeutic applications. Faria AM, et al. **Adv Immunol** 1999;73:153–264 (566 ref.)

Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Wewers MD, et al. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 1):1543–9

Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion. Josien R, et al. **Blood** 1998 Dec 15;92(12):4539–44

Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327–33 (42 ref.)

Induction of immune tolerance in adult rabbits undergoing heterotopic cardiac transplantation. Yue X, et al. **Chin Med J (Engl)** 1998 May;111(5):387–90

Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications [see comments] Menges T, et al. **Crit Care Med** 1999 Apr; 27(4):733–40. Comment in: Crit Care Med 1999 Apr;27(4):674–5.

Posttraumatic complications and changes in blood lymphocyte populations after multiple trauma [editorial; comment] Moore FA. **Crit Care Med** 1999 Apr;27(4):674–5 (15 ref.). Comment on: Crit Care Med 1999 Apr;27(4):733–40.

Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Gammie JS, et al. **Curr Opin Cardiol** 1999 Mar;14(2):126–32 (52 ref.)

Porokeratosis and immunosuppression. Kanitakis J, et al. **Eur J Dermatol** 1998 Oct-Nov;8(7):459–65 (88 ref.)

Langerhans cells are susceptible to measles virus infection and actively suppress T cell proliferation. Steineur MP, et al. **Eur J Dermatol** 1998 Sep;8(6):413–20

Deaggregated homologous immunoglobulin-peptide conjugates induce peptide-specific T cell nonresponsiveness in vivo. Seddon B, et al. **Eur J Immunol** 1998 Dec;28(12):4313–24

Bystander suppression of occupational hapten sensitization in rats made tolerant to ovalbumin. Pullerits T, et al. **Eur Respir J** 1998 Oct;12(4):889–94

The effect of thymic inoculation to induce tolerance of allogeneic thyroid grafts in the outbred rabbit. Torchia MG, et al. **Histol Histopathol** 1998 Oct;13(4):1061–8

A critical role for complement in maintenance of self-tolerance. Prodeus AP, et al. **Immunity** 1998 Nov; 9(5):721–31

Mucosal tolerance. Weiner HL, et al. **Immunol Lett** 1999 Jun 15;69(1):3–4

Measles: immunosuppression, interleukin-12, and complement receptors. Karp CL. **Immunol Rev** 1999 Apr; 168:91–101 (109 ref.)

Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens. Miller JF, et al. **Immunol Rev** 1998 Oct;165:267–77 (69 ref.)

General and specific immunosuppression caused by antiviral T-cell responses. Zinkernagel RM, et al. **Immunol Rev** 1999 Apr;168:305–15 (78 ref.)

HLA-G: a tolerance molecule from the major histocompatibility complex. Carosella ED, et al. **Immunol Today** 1999 Feb;20(2):60–2 (22 ref.)

Are dendritic cells the key to liver transplant tolerance? Thomson AW, et al. **Immunol Today** 1999 Jan;20(1):27–32 (82 ref.)

Oral tolerance induced to house dust mite extract in naive and sensitized mice: evaluation of immunoglobulin G anti-immunoglobulin E autoantibodies and IgG-IgE complexes. Sato MN, et al. **Immunology** 1998 Oct; 95(2):193–9

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Young MR, et al. **Int J Immunopharmacol** 1999 Apr;21(4):241–52 (35 ref.)

Adoptively transferable tolerance induced by CD45RB monoclonal antibody. Gao Z, et al. **J Am Soc Nephrol** 1999 Feb;10(2):374–81

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation [comment] Sallusto F, et al. **J Exp Med** 1999 Feb 15;189(4):611–4 (33 ref.). Comment on: J Exp Med 1999 Feb 15;189(4):627–35.

Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome. Blank M, et al. **J Immunol** 1998 Nov 15; 161(10):5303–12

Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. Chung Y, et al. **J Immunol** 1999 Oct 1;163(7):3692–8

Human anti-porcine T cell response: blocking with anti-class I antibody leads to hyporesponsiveness and a switch in cytokine production. DerSimonian H, et al. **J Immunol** 1999 Jun 15;162(12):6993–7001

Tolerization of mice to Schistosoma mansoni egg antigens causes elevated type 1 and diminished type 2 cytokine responses and increased mortality in acute infection. Fallon PG, et al. **J Immunol** 1999 Apr 1;162(7):4122–32

Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. Gallichan WS, et al. **J Immunol** 1999 Aug 1;163(3):1696–703

Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. Gorczynski L, et al. **J Immunol** 1999 Jan 15;162(2):774–81

Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions. Kweon MN, et al. **J Immunol** 1999 Feb 15;162(4):1904–9

Induction of allograft tolerance in the absence of Fas-mediated apoptosis. Li XC, et al. **J Immunol** 1999 Sep 1;163(5):2500–7

Impaired T cell proliferation in acute dengue infection. Mathew A, et al. **J Immunol** 1999 May 1;162(9):5609–15

The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. Niimi M, et al. **J Immunol** 1998 Nov 15;161(10):5331–7

Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. Tsitoura DC, et al. **J Immunol** 1999 Sep 1;163(5):2592–600

Plasticity of immune responses suppressing parasitemia during acute Plasmodium chabaudi malaria. Weidanz WP, et al. **J Immunol** 1999 Jun 15;162(12):7383–8

Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. Wolvers DA, et al. **J Immunol** 1999 Feb 15;162(4):1994–8

Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. Zeller JC, et al. **J Immunol** 1999 Oct 1;163(7):3684–91

CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. Zheng XX, et al. **J Immunol** 1999 Apr 15;162(8):4983–90

Mechanisms of ozone-induced inhibitory effect of bronchoalveolar lavage fluid on alveolar macrophage-mediated immunosuppressive activity in rats. Koike E, et al. **J Leukoc Biol** 1999 Jul;66(1):75–82

Infusion of donor leukocytes to induce tolerance in organ allograft recipients. Salgar SK, et al. **J Leukoc Biol** 1999 Aug;66(2):310–4

Plasma concentration of hGH and anti-hGH antibodies after subcutaneous administration of hGH for 3 weeks to immunosuppressed pigs. Agersø H, et al. **J Pharmacol Toxicol Methods** 1999 Feb;41(1):1–8

The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. Hug DH, et al. **J Photochem Photobiol B** 1998 Jul 10; 44(2):117–23 (81 ref.)

Skin allograft survival following intrathymic injection of donor bone marrow. Cober SR, et al. **J Surg Res** 1999 Aug;85(2):204–8

Tolerance of islet allografts induced by orthotopic liver transplantation. Sawada T, et al. **J Surg Res** 1999 Aug; 85(2):209–16

Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. Doan T, et al. **J Virol** 1999 Jul;73(7):6166–70

Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice. von Herrath M, et al. **J Virol** 1999 Jul;73(7):5918–25

Mechanisms of induction of renal allograft tolerance in CD45RB-treated mice. Lazarovits AI, et al. **Kidney Int** 1999 Apr;55(4):1303–10

Sperm survival in the female reproductive tract: presence of immunosuppression or absence of recognition? [see comments] Barratt CL, et al. **Mol Hum Reprod** 1998 Apr; 4(4):309–13 (56 ref.). Comment in: Mol Hum Reprod 1998 Apr;4(4):313–7.

COX-2: promoting tolerance [news; comment] Morteau O. **Nat Med** 1999 Aug;5(8):867–8. Comment on: Nat Med 1999 Aug;5(8):900–6.

Transplantation tolerance: the concept and its applicability. Dong VM, et al. **Pediatr Transplant** 1999 Aug;3(3):181–92 (192 ref.)

Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Kang Y, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8609–14

Complex genetic and environmental relationships between psychological distress, fatigue and immune functioning: a twin study. Hickie I, et al. **Psychol Med** 1999 Mar; 29(2):269–77

TCR peptide-reactive T cells and peripheral tolerance to myelin basic protein. Kumar V. **Res Immunol** 1998 Nov-Dec;149(9):827–34; discussion 852–4, 855–60 (66 ref.)

Bystander suppression in experimental autoimmune encephalomyelitis: where and how does it occur? Racke MK, et al. **Res Immunol** 1998 Nov-Dec;149(9):820–7; discussion 851–2, 855–60 (58 ref.)

Non-responsiveness to mercury-induced autoimmunity in resistant DBA/2 mice is not due to immunosuppression or biased Th1-type response. Hu H, et al. **Scand J Immunol** 1998 Nov;48(5):515–21

The self-nonself discrimination in the context of function. Cohn M. **Theor Med Bioeth** 1998 Sep;19(5):475–84; discussion 485–504 (6 ref.)

Paradigm changes in organ transplantation: a journey toward selflessness? Schaffner KF. **Theor Med Bioeth** 1998 Sep; 19(5):425–40 (55 ref.)

Transplantation tolerance, microchimerism, and the two-way paradigm [see comments] Starzl TE, et al. **Theor Med Bioeth** 1998 Sep;19(5):441–55 (83 ref.). Comment in: Theor Med Bioeth 1998 Sep;19(5):457–73.

Conceptual shifts in immunology: comments on the "two-way paradigm" [comment] Tauber AI. **Theor Med Bioeth** 1998 Sep;19(5):457–73 (39 ref.). Comment on: Theor Med Bioeth 1998 Sep;19(5):441–55.

An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers. de Vries-van der Zwan A, et al. **Transpl Immunol** 1998 Sep;6(3):147–51

Assessment of peripheral tolerance in anti-CD4 treated C57BL/6 mouse heart transplants recipients. Han WR, et al. **Transpl Immunol** 1999 Mar;7(1):37–44

Tolerance induction permits the development of graft-versus-host disease: donor-mediated attack following small bowel transplantation in mixed chimeras. Morrissey NJ, et al. **Transpl Immunol** 1999 Mar;7(1):19–25

All or none peripheral tolerance induction in H-Y antigen-specific TCR transgenic mice. Sheng B, et al. **Transpl Immunol** 1998 Jun;6(2):78–83

Trafficking of APC from liver allografts of Flt3L-treated donors: augmentation of potent allostimulatory cells in recipient lymphoid tissue is associated with a switch from tolerance to rejection. Steptoe RJ, et al. **Transpl Immunol** 1999 Mar;7(1):51–7

Negative response to noninherited maternal antigens confirmed by ELISA. Bishara A, et al. **Transplant Proc** 1999 Jun;31(4):1879–80

Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Chowdhury NC, et al. **Transplantation** 1998 Oct 27;66(8):1059–66

Regulation of immune complexes during infection of mice with lactate dehydrogenase-elevating virus: studies with interferon-gamma gene knockout and tolerant mice. Cafruny WA, et al. **Viral Immunol** 1999;12(2):163–73

[Immunology in medical practice. XXII. T-cells and strategies for tolerance induction] Weenink JJ, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1148–53 (24 ref.) (Eng. Abstr.) **(Dut)**

[Differentiation between "self" and "foreign" by the immune system] Holländer GA. **Schweiz Rundsch Med Prax** 1998 Sep 9;87(37):1167–9 (13 ref.) **(Ger)**

[Mechanisms and applications of oral tolerance] Marth T, et al. **Z Gastroenterol** 1999 Feb;37(2):165–85 (165 ref.) (Eng. Abstr.) **(Ger)**

[The mechanism of donor specific unresponsiveness in renal transplant recipients] Okimoto T, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Jun;21(3):118–28 (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Mixed hematopoietic chimerism induces donor-specific tolerance for lung allografts in rodents. Pham SM, et al. **Am J Respir Crit Care Med** 1999 Jan;159(1):199–205

Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac

allografts. Gammie JS, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II163–8; discussion II168–9

Transplantation without immunosuppression: what the future may hold. Orosz CG. **Cleve Clin J Med** 1999 Jul–Aug; 66(7):395–6

Manipulation of Th responses by oral tolerance. Garcia G, et al. **Curr Top Microbiol Immunol** 1999;238:123–45 (126 ref.)

Immunological aspects of the potential role of dietary carbohydrates and lectins in human health. Kilpatrick DC. **Eur J Nutr** 1999 Jun;38(3):107–17 (99 ref.)

Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Trop S, et al. **Hepatology** 1999 Mar;29(3):746–55

Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Pender MP. **Immunol Cell Biol** 1999 Jun;77(3):216–23 (82 ref.)

Role of cytokines in transplantation tolerance: lessons learned from gene–knockout mice. Lakkis FG. **J Am Soc Nephrol** 1998 Dec;9(12):2361–7 (83 ref.)

Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. Kauma SW, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2188–94

A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K+ channels, Ca2+ signaling, and gene expression in T lymphocytes. Ehring GR, et al. **J Exp Med** 1998 Nov 2;188(9):1593–602

Thymic expression of neuroendocrine self-peptide precursors: role in T cell survival and self-tolerance. Geenen V, et al. **J Neuroendocrinol** 1998 Nov;10(11):811–22 (137 ref.)

Intrathymic immunomodulation and the "infectious" tolerance pathway in allograft recipients. Reemtsen BL, et al. **J Surg Res** 1999 Jun 1;84(1):1–7

Modulation of immune system function by measles virus infection: role of soluble factor and direct infection. Fujinami RS, et al. **J Virol** 1998 Dec;72(12):9421–7

Toward tolerance: lessons learned from liver transplantation. Fung JJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S90–7 (45 ref.)

Structural similarity of two T cell signaling regulators suggests a conserved and interactive mechanism of immunosuppression. Vieira A. **Mol Immunol** 1998 Sep; 35(13):881–4

Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis. Hilliard B, et al. **Mult Scler** 1999 Feb;5(1):2–9

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Frank DA, et al. **Nat Med** 1999 Apr;5(4):444–7

A role for neuropeptides in UVB-induced systemic immunosuppression. Garssen J, et al. **Photochem Photobiol** 1998 Aug;68(2):205–10

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Cohen SS, et al. **Proc Natl Acad Sci U S A** 1999 Sep 14;96(19):10842–7

On the adaptive significance of stress-induced immunosuppression. Råberg L, et al. **Proc R Soc Lond B Biol Sci** 1998 Sep 7;265(1406):1637–41

Oral tolerance and the treatment of rheumatoid arthritis. Weiner HL, et al. **Springer Semin Immunopathol** 1998; 20(1–2):289–308 (126 ref.)

Stress protein-induced immunosuppression: inhibition of cellular immune effector functions following overexpression of haem oxygenase (HSP 32). Woo J, et al. **Transpl Immunol** 1998 Jun;6(2):84–93

A nonhuman primate model for maternal-fetal immune tolerance. Slukvin II, et al. **Transplant Proc** 1999 Jun; 31(4):1844–6

Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Starzl TE, et al. **Transplant Proc** 1999 Jun;31(4):1806–11 (44 ref.)

Transfer of swine major histocompatibility complex class II genes into autologous bone marrow cells of baboons for the induction of tolerance across xenogeneic barriers. Ierino FL, et al. **Transplantation** 1999 Apr 27;67(8):1119–28

Fas ligand, tumor necrosis factor–alpha expression, and apoptosis during allograft rejection and tolerance. Josien R, et al. **Transplantation** 1998 Oct 15;66(7):887–93

Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption. Kozlowski T, et al. **Transplantation** 1999 Jan 15;67(1):18–30

Role of the thymus in transplantation tolerance in miniature swine. III. Surgical manipulation of the thymus interferes with stable induction of tolerance to class I–mismatched renal allografts. Yamada K, et al. **Transplantation** 1999 Apr 27;67(8):1112–9

RADIATION EFFECTS

Ultraviolet B induced suppression of induction of contact sensitivity in human skin is not associated with tumour necrosis factor–alpha–308 or interleukin–10 genetic polymorphisms. Allen MH, et al. **Br J Dermatol** 1998 Aug; 139(2):225–9

Disparate effects of photoprotection on ultraviolet radiation–induced immunosuppression. Bergstresser PR. **Eur J Dermatol** 1998 Apr–May;8(3):203–4 (21 ref.)

Dose-responses for UV-induced suppression of various immune responses. Kim T, et al. **Eur J Dermatol** 1998 Apr–May;8(3):195

Immunosuppression induced by chronic ultraviolet irradiation in humans and its prevention by sunscreens. Moyal D. **Eur J Dermatol** 1998 Apr–May;8(3):209–11

Mechanisms of UV-induced immunosuppression. Link between UV-induced tolerance and apoptosis. Schwarz T. **Eur J Dermatol** 1998 Apr–May;8(3):196–7

Protection against UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamins C and E. Steenvoorden DP, et al. **Int J Radiat Biol** 1999 Jun;75(6):747–55

UVA-induced immune suppression through an oxidative pathway. Iwai I, et al. **J Invest Dermatol** 1999 Jan; 112(1):19–24

Efficacy of micronized titanium dioxide–containing compounds in protection against UVB–induced immunosuppression in humans in vivo. van der Molen RG, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):143–50

UVA-induced immunosuppression. Halliday GM, et al. **Mutat Res** 1998 Nov 9;422(1):139–45

UV-induced immunosuppression in virus infections. Norval M, et al. **Mutat Res** 1998 Nov 9;422(1):131–8 (29 ref.)

A role for neuropeptides in UVB-induced systemic immunosuppression. Garssen J, et al. **Photochem Photobiol** 1998 Aug;68(2):205–10

HIV, UV and immunosuppression. Akaraphanth R, et al. **Photodermatol Photoimmunol Photomed** 1999 Feb; 15(1):28–31 (26 ref.)

IMMUNITY

see related
IMMUNOLOGIC TECHNIQUES
TUMOR ESCAPE

Innate functions of epithelial gamma delta T cells. Havran WL, et al. **Adv Exp Med Biol** 1998;452:29–35 (42 ref.)

DNA vaccines. Mechanisms for generation of immune responses. Liu MA, et al. **Adv Exp Med Biol** 1998; 452:187–91 (20 ref.)

Lymphocyte trafficking and regional immunity. Butcher EC, et al. **Adv Immunol** 1999;72:209–53 (178 ref.)

Interleukin–18: a novel cytokine that augments both innate and acquired immunity. Okamura H, et al. **Adv Immunol** 1998;70:281–312 (112 ref.)

Interleukin–12: a cytokine at the interface of inflammation and immunity. Trinchieri G. **Adv Immunol** 1998;70:83–243 (754 ref.)

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Ghio M, et al. **Blood** 1999 Mar 1;93(5):1770–7

Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha–L–iduronidase deficiency. Lutzko C, et al. **Blood** 1999 Mar 15;93(6):1895–905

Glutamine and the effects of exhaustive exercise upon the immune response. Castell LM, et al. **Can J Physiol Pharmacol** 1998 May;76(5):524–32 (77 ref.)

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589–97 (71 ref.)

Immune changes induced by exercise in an adverse environment. Shephard RJ. **Can J Physiol Pharmacol** 1998 May;76(5):539–46 (63 ref.)

Cold exposure and immune function. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 Sep;76(9):828–36 (77 ref.)

Aging and immune response to exercise. Shinkai S, et al. **Can J Physiol Pharmacol** 1998 May;76(5):562–72 (48 ref.)

Carbohydrate–bearing cell surface receptors involved in innate immunity: interleukin–12 induction by mitogenic and nonmitogenic lectins. Muraille E, et al. **Cell Immunol** 1999 Jan 10;191(1):1–9

Introduction: hormones, blood cells and immunity, with special reference to prolactin, growth hormone and insulin–like growth factor–I. Hooghe–Peters EL, et al. **Cell Mol Life Sci** 1998 Oct;54(10):1057–8

Monocytes/macrophages in diagnosis and immunopathogenesis. Douglas SD. **Clin Diagn Lab Immunol** 1999 May;6(3):283–5

Clinical laboratory immunology: the future. Fahey JL. **Clin Diagn Lab Immunol** 1999 May;6(3):291–2

Stress proteins and immunity mediated by cytotoxic T lymphocytes. Schild H, et al. **Curr Opin Immunol** 1999 Feb; 11(1):109–13 (55 ref.)

Initial and innate responses to viral infections--pattern setting in immunity or disease. Biron CA. **Curr Opin Microbiol** 1999 Aug;2(4):374–81 (76 ref.)

Immunity to Candida albicans: Th1, Th2 cells and beyond. Romani L. **Curr Opin Microbiol** 1999 Aug;2(4):363–7 (56 ref.)

Is type II diabetes mellitus a disease of the innate immune system? [see comments] Pickup JC, et al. **Diabetologia** 1998 Oct;41(10):1241–8 (86 ref.). Comment in: Diabetologia 1999 Apr;42(4):497–8.

The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Spanhaak S, et al. **Eur J Clin Nutr** 1998 Dec;52(12):899–907

9th Walter Brendel Symposium on Applied Immunology and Microcirculation. Axams, Tirol, Austria. February 1–5, 1998. Abstracts. **Eur Surg Res** 1998;30(5):359–69

Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Gerhard I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):301–9 (56 ref.)

Immunological self/nonself discrimination: integration of self vs nonself during cognate T cell interactions with antigen–presenting cells. Mannie MD. **Immunol Res** 1999; 19(1):65–87 (154 ref.)

Integrating innate and adaptive immunity in the whole animal. Lo D, et al. **Immunol Rev** 1999 Jun;169:225–39 (47 ref.)

CD69 and regulation of the immune function. Marzio R, et al. **Immunopharmacol Immunotoxicol** 1999 Aug; 21(3):565–82 (56 ref.)

Rubella immunity in a cohort of pregnant women. McElhaney RD Jr, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):64–6

Prevalence of, antibody response to, and immunity induced by Haemophilus ducreyi hemolysin. Dutro SM, et al. **Infect Immun** 1999 Jul;67(7):3317–28

Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Viret JF, et al. **Infect Immun** 1999 Jul;67(7):3680–5

High level antibody response to retrovirus–associated but not to melanocyte lineage–specific antigens in mice protected against B16 melanoma. Sfondrini L, et al. **Int J Cancer** 1999 Sep 24;83(1):107–12

Immunity to tetanus, diphtheria and poliomyelitis in the adult population of Sweden in 1991. Böttiger M, et al. **Int J Epidemiol** 1998 Oct;27(5):916–25

Immunity in the Swedish population: diphtheria, tetanus and poliomyelitis. Svensson A, et al. **Int J Epidemiol** 1998 Oct; 27(5):909–15

Effects of development of host immunity on the biodistribution of xenogeneic MHC non–restricted cytotoxic T cells: implications for adoptive cell therapy of cancer. Cesano A, et al. **Int J Oncol** 1999 Feb; 14(2):233–44

Influence of exercise mode and carbohydrate on the immune response to prolonged exercise. Henson DA, et al. **Int J Sport Nutr** 1999 Jun;9(2):213–28

Future directions in exercise and immunology: regulation and integration. Mackinnon LT. **Int J Sports Med** 1998 Jul;19 Suppl 3:S205–9; discussion S209–11 (44 ref.)

Exercise immunology: integration and regulation [editorial] Nieman DC. **Int J Sports Med** 1998 Jul;19 Suppl 3:S171

Immune responses in space flight. Sonnenfeld G. **Int J Sports Med** 1998 Jul;19 Suppl 3:S195–202; discussion S202–4 (71 ref.)

Immunonutrition in the critically ill. Jolliet P, et al. **Intensive Care Med** 1999 Jun;25(6):631–3 (3 ref.)

Effect of pen size on behavioral, endocrine, and immune responses of water buffalo (Bubalus bubalis) calves. Grasso F, et al. **J Anim Sci** 1999 Aug;77(8):2039–46

Dendritic cells: a link between innate and adaptive immunity. Palucka K, et al. **J Clin Immunol** 1999 Jan;19(1):12–25 (112 ref.)

Influence of vitamin A supplementation in milk on growth, health, concentrations of vitamins in plasma, and immune parameters of calves. Franklin ST, et al. **J Dairy Sci** 1998 Oct;81(10):2623–32

Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. Perdigón G, et al. **J Dairy Sci** 1999 Jun;82(6):1108–14

A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein. Berney C, et al. **J Exp Med** 1999 Sep 20;190(6):851–60

The influence of chronic yogurt consumption on immunity. Van de Water J, et al. **J Nutr** 1999 Jul;129(7 Suppl):1492S–5S

Immune responses to training: how critical is training volume? Shore S, et al. **J Sports Med Phys Fitness** 1999 Mar;39(1):1–11

Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus. Dittmer U, et al. **J Virol** 1999 Oct;73(10):8435–40

Exacerbated immune stress response during experimental magnesium deficiency results from abnormal cell calcium homeostasis. Malpuech–Brugère C, et al. **Life Sci** 1998; 63(20):1815–22

Presence and functional regulation of cannabinoid receptors in immune cells. Parolaro D. **Life Sci** 1999;65(6–7):637–44 (63 ref.)

Gender differences in some host defense mechanisms. Spitzer JA. **Lupus** 1999;8(5):380–3

Enteral nutrition: just a fuel or an immunity enhancer? Bistrian BR. **Minerva Anestesiol** 1999 Jun;65(6):471–4 (27 ref.)

B cell antigen receptor signalling in the balance of tolerance and immunity. Cornall RJ, et al. **Novartis Found Symp** 1998; 215:21–30; discussion 30–40 (38 ref.)

Beta-carotene and immune function: is it a case of defining the right intake? [editorial] Hughes DA. **Nutrition** 1999 May;15(5):405–7 (15 ref.)

The role of glutamine in modulating the body's immune function [comment] Sriram K. **Nutrition** 1999 Jun;15(6):443 . Comment on: Nutrition 1999 Jun;15(6):439–42.

Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Lillard JW Jr, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):651–6

Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75–8 (16 ref.)
Dietary n–6 and n–3 fatty acids in immunity and autoimmune disease. Harbige LS. **Proc Nutr Soc** 1998 Nov;57(4):555–62 (99 ref.)
Effects of dietary antioxidants on the immune function of middle-aged adults. Hughes DA. **Proc Nutr Soc** 1999 Feb; 58(1):79–84 (45 ref.)
Immune response during disease and recovery in the elderly. Lesourd B. **Proc Nutr Soc** 1999 Feb;58(1):85–98 (155 ref.)
n–3 polyunsaturated fatty acids and immune function. Wu D, et al. **Proc Nutr Soc** 1998 Nov;57(4):503–9 (67 ref.)
Monounsaturated fats and immune function. Yaqoob P. **Proc Nutr Soc** 1998 Nov;57(4):511–20 (34 ref.)
Preliminary data touch off genetic food fight [news] Enserink M. **Science** 1999 Feb 19;283(5405):1094–5
Microbes immunity, and disease. Introduction. Microbe management. Purnell BA, et al. **Science** 1999 May 21; 284(5418):1301
Mast cells and basophils in innate immunity. Abraham SN, et al. **Semin Immunol** 1998 Oct;10(5):373–81 (46 ref.)
Role of early cytokines, including alpha and beta interferons (IFN–alpha/beta), in innate and adaptive immune responses to viral infections. Biron CA. **Semin Immunol** 1998 Oct; 10(5):383–90 (76 ref.)
The complement system and adaptive immunity. Fearon DT. **Semin Immunol** 1998 Oct;10(5):355–61 (74 ref.)
The serum mannose–binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Fraser IP, et al. **Semin Immunol** 1998 Oct;10(5):363–72 (94 ref.)
Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells? Kaiserlian D, et al. **Semin Immunol** 1999 Jun;11(3):217–24 (50 ref.)
An innate sense of danger. Matzinger P. **Semin Immunol** 1998 Oct;10(5):399–415 (86 ref.)
Innate immune recognition and control of adaptive immune responses. Medzhitov R, et al. **Semin Immunol** 1998 Oct; 10(5):351–3 (23 ref.)
Innate and adaptive functions of the CD1 pathway of antigen presentation. Park SH, et al. **Semin Immunol** 1998 Oct; 10(5):391–8 (57 ref.)
Severe injury triggers antigen–specific T–helper cell dysfunction. Kelly JL, et al. **Shock** 1999 Jul;12(1):39–45
Estimation of individual and population vaccination effectiveness from time–to–event data. Haber M, et al. **Stat Med** 1998 Nov 30;17(22):2617–23
A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication. Sietses C, et al. **Surgery** 1999 Jul;126(1):5–9
Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1406–11 (62 ref.)
[Significance of the absorption of macromolecules for the immune response of an organism] Seifert J, et al. **Zentralbl Chir** 1999;124(4):292–7 (Eng. Abstr.) **(Ger)**
[Mechanisms of induction and expression of anti–tuberculous immunity] Mitsuyama M. **Kekkaku** 1998 Nov;73(11):639–44 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of interleukin–1 beta gene in brain after peripheral administration of thymus–dependent and thymus–independent antigens] Grebenshchikov AIu, et al. **Dokl Akad Nauk** 1999 Jun;366(5):712–4 **(Rus)**

DRUG EFFECTS

Effect of plant flavonoids on immune and inflammatory cell function. Middleton E Jr. **Adv Exp Med Biol** 1998; 439:175–82 (27 ref.)
Immunological, hematological, and biochemical responses in immature white–footed mice following maternal Aroclor 1254 exposure: A possible bioindicator. Wu PJ, et al. **Arch Environ Contam Toxicol** 1999 May;36(4):469–76
Dietary effect of EPA–rich and DHA–rich fish oils on the immune function of Sprague–Dawley rats. Hung P, et al. **Biosci Biotechnol Biochem** 1999 Jan;63(1):135–40
Effects of pulsed or continuous infusion of cortisol on immune function in sheep. Rhind SM, et al. **Domest Anim Endocrinol** 1999 Jan;16(1):1–9
Indicators of immunotoxicity in populations of cotton rats (Sigmodon hispidus) inhabiting an abandoned oil refinery. McMurry ST, et al. **Ecotoxicol Environ Saf** 1999 Mar; 42(3):223–35
Effect of MSC on the immune response of mice. Hidvégi M, et al. **Immunopharmacology** 1999 Apr;41(3):183–6
Immune recovery in children with malignancy after cessation of chemotherapy. Mustafa MM, et al. **J Pediatr Hematol Oncol** 1998 Sep–Oct;20(5):451–7
Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy [letter] Gilquin J, et al. **Lancet** 1998 Dec 12; 352(9144):1907–8
Endotoxin opens the Tollgates to innate immunity [news] Ulevitch RJ. **Nat Med** 1999 Feb;5(2):144–5
Immunomodulatory action of class mu–, delta– and kappa–opioid receptor agonists in mice. Kowalski J. **Neuropeptides** 1998 Aug;32(4):301–6
The influence of various factors on immune toxicity assessment of pesticide chemicals. Banerjee BD. **Toxicol Lett** 1999 Jun 30;107(1–3):21–31 (34 ref.)
Acute respiratory exposure of human volunteers to octamethylcyclotetrasiloxane (D4): absence of immunological effects. Looney RJ, et al. **Toxicol Sci** 1998 Aug;44(2):214–20
Comparison of detection sensitivity of immuno– and genotoxicological effects of subacute cypermethrin and permethrin exposure in rats. Institóris L, et al. **Toxicology** 1999 Sep 10;137(1):47–55
[Smoking and immunological status] Zhigacheva IV, et al. **Dokl Akad Nauk** 1999 Jun;366(5):705–7 **(Rus)**
[The hygienic characteristics of the heavy metal pollution of the environment of an industrial region and the immune status of children] Paran'ko NM, et al. **Gig Sanit** 1999 Mar–Apr;(2):51–4 **(Rus)**
[Protective action of leukinferin during radiotherapy of oncologic patients] Rasskazchikova ES, et al. **Radiats Biol Radioecol** 1998 Sep–Oct;38(5):684–9 (Eng. Abstr.) **(Rus)**
[Immunological prognosis of the effectiveness of soybean diet] Pershin BB, et al. **Vopr Pitan** 1999;68(4):14–20 (Eng. Abstr.) **(Rus)**
[Effects of antiatherosclerosis diet including soy protein on the dynamics of clinical, biochemical and immunologic indicators in patients with ischemic heart disease and hypertension] Pogozheva AV, et al. **Vopr Pitan** 1999; 68(4):27–31 (Eng. Abstr.) **(Rus)**

GENETICS

Warner–Lambert/Parke–Davis Award Lecture. Pathological and physiological double–strand breaks: roles in cancer, aging, and the immune system. Lieber MR. **Am J Pathol** 1998 Nov;153(5):1323–32 (73 ref.)
Differences in NK cell function in mice bred for high and low aggression: genetic linkage between complex behavioral and immunological traits? Petitto JM, et al. **Brain Behav Immun** 1999 Jun;13(2):175–86
Interaction and specificity of Rel–related proteins in regulating Drosophila immunity gene expression. Han ZS, et al. **J Biol Chem** 1999 Jul 23;274(30):21355–61
Expression scanning of an array of growth control genes in human tumor cell lines. Bertucci F, et al. **Oncogene** 1999 Jul 1;18(26):3905–12
A factor analysis of associations among self–reported immune related symptoms in a large twin sample. Duffy DL, et al. **Twin Res** 1998 Jun;1(2):71–7
[Genetics of immune response and vaccines of tomorrow] Khaitov RM. **Vestn Ross Akad Med Nauk** 1999;(4):9–18 (56 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Candida albicans mannan– and protein–induced humoral, cellular and cytokine responses in atopic dermatitis patients. Savolainen J, et al. **Clin Exp Allergy** 1999 Jun;29(6):824–31
Molecular anatomy of the immune response. Bell JI. **Immunol Rev** 1998 Jun;163:5–10 (4 ref.)
Host defense molecule polymorphisms influence the risk for immune–mediated complications in chronic granulomatous disease. Foster CB, et al. **J Clin Invest** 1998 Dec 15; 102(12):2146–55
DNA vaccination: transfection and activation of dendritic cells as key events for immunity. Akbari O, et al. **J Exp Med** 1999 Jan 4;189(1):169–78
The elusive immune self: a case of category errors. Tauber AI. **Perspect Biol Med** 1999 Summer;42(4):459–74
Differential display of peptides induced during the immune response of Drosophila: a matrix–assisted laser desorption ionization time–of–flight mass spectrometry study. Uttenweiler–Joseph S, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11342–7
Immunity to Paracoccidioides brasiliensis infection. Calich VL, et al. **Res Immunol** 1998 May–Jun;149(4–5):407–17; discussion 499–500 (60 ref.)
Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. Vázquez RI, et al. **Scand J Immunol** 1999 Jun;49(6):578–84
Exercise and immune function. Recent developments. Nieman DC, et al. **Sports Med** 1999 Feb;27(2):73–80 (55 ref.)
[Reparative processes and immunity] Babaeva AG. **Izv Akad Nauk Ser Biol** 1999 May–Jun;(3):261–9 (63 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Mucosal immunity and inflammation. III. The mucosal antigen barrier: cross talk with mucosal cytokines. Perdue MH. **Am J Physiol** 1999 Jul;277(1 Pt 1):G1–5 (25 ref.)
Epithelial peptide antibiotics. Schröder JM. **Biochem Pharmacol** 1999 Jan 15;57(2):121–34 (137 ref.)
Immune response and iron metabolism. Weiss G, et al. **Br J Anaesth** 1998 Dec;81 Suppl 1:6–9 (35 ref.)
Individual variability and immunity. Cohen JJ. **Brain Behav Immun** 1999 Jun;13(2):76–9 (8 ref.)
Norman Cousins Memorial Lecture 1998. Stress, personal relationships, and immune function: health implications. Kiecolt–Glaser JK. **Brain Behav Immun** 1999 Mar; 13(1):61–72 (57 ref.)
A preliminary description of responses of free–ranging rhesus monkeys to brief capture experiences: behavior, endocrine, immune, and health relationships. Laudenslager ML, et al. **Brain Behav Immun** 1999 Jun;13(2):124–37
Personality and tonic cardiovascular, neuroendocrine, and immune parameters. Miller GE, et al. **Brain Behav Immun** 1999 Jun;13(2):109–23
Worry affects the immune response to phobic fear. Segerstrom SC, et al. **Brain Behav Immun** 1999 Jun; 13(2):80–92
Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. Colaco CA. **Cell Mol Biol (Noisy–le–grand)** 1998 Sep;44(6):883–90 (40 ref.)
Cross–talk between the pineal gland and immune system. Poon AM, et al. **Chin Med J (Engl)** 1998 Jan;111(1):7–11 (70 ref.)
Gut microenvironment and immune function. Bengmark S. **Curr Opin Clin Nutr Metab Care** 1999 Jan;2(1):83–5 (20 ref.)
Insulin–like growth factor–1 (IGF–1) and growth hormone (GH) in immunity and inflammation. Heemskerk VH, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):5–14 (109 ref.)
A new model system to study Norwalk virus immunity [editorial; comment] Matsui SM. **Gastroenterology** 1999 Jul; 117(1):255–7 (26 ref.). Comment on: Gastroenterology 1999 Jul;117(1):40–8.
Previously undetected Chlamydia trachomatis infection, immunity to heat shock proteins and tubal occlusion in women undergoing in–vitro fertilization. Spandorfer SD, et al. **Hum Reprod** 1999 Jan;14(1):60–4
Deficiency of the hematopoietic cell–specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. Roberts AW, et al. **Immunity** 1999 Feb;10(2):183–96
Origins of immunity: transcription factors and homologues of effector genes of the vertebrate immune system expressed in sea urchin coelomocytes. Pancer Z, et al. **Immunogenetics** 1999 Aug;49(9):773–86
Cellular mechanisms and molecules in infection immunity. Papers from the 5th Elsinore Meeting on Infection Immunity. Elsinore, Denmark, 29 May–2 June 1998. **Immunol Lett** 1999 Jan;65(1–2):1–140
Innate Immunity: The Bridge between Adaptive Immunity and Inflammation, December 17, 1998, New York Academy of Sciences, New York, NY, USA. Barton BE. **Inflamm Res** 1999 May;48(5):232–5
Effects of intensive exercise training on immunity in athletes. Pyne DB, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S183–91; discussion S191–4 (101 ref.)
Effect of level of chronic immune system activation on the lactational performance of sows. Sauber TE, et al. **J Anim Sci** 1999 Aug;77(8):1985–93
Effects of spaceflight and PEG–IL–2 on rat physiological and immunological responses. Chapes SK, et al. **J Appl Physiol** 1999 Jun;86(6):2065–76
Effects of resistance training on selected indexes of immune function in elderly women. Flynn MG, et al. **J Appl Physiol** 1999 Jun;86(6):1905–13
Experimental acute hematogenous osteomyelitis in mice. II. Influence of Staphylococcus aureus infection on T–cell immunity. Yoon KS, et al. **J Orthop Res** 1999 May; 17(3):382–91
Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini–symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico [editorial; comment] [see comments] Walker SE, et al. **Lupus** 1998;7(6):371–5 (70 ref.). Comment on: Lupus 1998 ;7(6):420–7. Comment in: Lupus 1999;8(30:251.
Zinc and immunity. Prasad AS. **Mol Cell Biochem** 1998 Nov; 188(1–2):63–9 (52 ref.)
Systems analysis of the neuroimmunological mechanisms of memory. Zhuravlev BV, et al. **Neurosci Behav Physiol** 1999 Jan–Feb;29(1):37–44
The measurement of stress–related immune dysfunction in psychoneuroimmunology. Vedhara K, et al. **Neurosci Biobehav Rev** 1999 May;23(5):699–715 (85 ref.)
Immune challenge–stimulated hypophysiotropic corticotropin–releasing hormone messenger RNA expression is associated with an induction of neurotensin messenger RNAs without alteration of vasopressin messenger RNAs. Juaneda C, et al. **Neuroscience** 1999; 93(1):393–400
Extracellular purines and their receptors in immunoregulation. Review of recent advances. Sitkovsky MV. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):351–7 (12 ref.)
Effects of social status after mixing on immune, metabolic, and endocrine responses in pigs. Tuchscherer M, et al. **Physiol Behav** 1998 Jun 1;64(3):353–60
[Anesthesia and perioperative immune function. Remarks on the work of M. Bauer, H. Rensing and T. Ziegenfuss (Anaesthesist 1998,47:538–556) (letter; comment)] Bauer M. **Anaesthesist** 1998 Nov;47(11):939. Comment on: Anaesthesist 1998 Jul;47(7):538–56. **(Ger)**
[Indices of immunity to endotoxin of gram–negative bacteria in intestinal dysbacteriosis] Kochurko LI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep–Oct;(5):25–7 (Eng. Abstr.) **(Rus)**
[Comparative analysis of general and local immunoreactivity in patients with chronic vulvovaginitis of mixed etiology] Uchevatkina AE, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov–Dec; (6):57–60 (Eng. Abstr.) **(Rus)**
[Anti–pneumococcal immunity in extra–hospital acute pneumonia in children] Vishniakova LA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep–Oct;(5):50–4 (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. Hill LL, et al. **J Exp Med** 1999 Apr 19;189(8):1285–94

Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. Krutmann J. **J Photochem Photobiol B** 1998 Jul 10;44(2):159–64 (39 ref.)

[Radiation and immunity. Interference of ionizing radiation with key immune processes] Iarilin AA. **Radiats Biol Radioecol** 1999 Jan–Feb;39(1):181–9 (57 ref.) (Eng. Abstr.) **(Rus)**

IMMUNITY, ACTIVE

see related

IMMUNOTHERAPY

Regional specialization in the mucosal immune system: what happens in the microcompartments? Brandtzaeg P, et al. **Immunol Today** 1999 Mar;20(3):141–51 (84 ref.)

Phosphorylcholine: friend or foe of the immune system? Harnett W, et al. **Immunol Today** 1999 Mar;20(3):125–9

IMMUNOLOGY

Breastfeeding provides passive and likely long-lasting active immunity [published erratum appears in Ann Allergy Asthma Immunol 1999 May;82(5):478] Hanson LA. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):523–33; quiz 533–4, 537 (155 ref.)

Linking innate and adaptive immunity [news; comment] Palucka K, et al. **Nat Med** 1999 Aug;5(8):868–70. Comment on: Nat Med 1999 Aug;5(8):919–23.

IMMUNITY, CELLULAR

see related

HYPERSENSITIVITY, DELAYED

Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity. Biron CA, et al. **Adv Exp Med Biol** 1998;452:143–9 (32 ref.)

The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii. Sher A, et al. **Adv Exp Med Biol** 1998;452:103–10 (23 ref.)

Current views in intracellular transport: insights from studies in immunology. Hsu VW, et al. **Adv Immunol** 1998; 70:369–415 (259 ref.)

CD4+ T-cell induction and effector functions: a comparison of immunity against soluble antigens and viral infections. Oxenius A, et al. **Adv Immunol** 1998;70:313–67 (280 ref.)

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. Tartaglia J, et al. **AIDS Res Hum Retroviruses** 1998 Oct; 14 Suppl 3:S291–8 (58 ref.)

Investigation of the immunological properties of the bovine viral diarrhea virus protein NS3 expressed by an adenovirus vector in mice. Elahi SM, et al. **Arch Virol** 1999; 144(6):1057–70

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits. Isaguliants MG, et al. **Biochemistry (Mosc)** 1998 May;63(5):551–8

Tissue zinc dynamics during the immune reaction in mice. Verbanac D, et al. **Biol Trace Elem Res** 1998 Nov; 65(2):97–108

Evaluation of cellular immune responses in rhesus monkeys subjected to adenovirus-mediated gene transfer into the cervix. Sarkar AK, et al. **Cancer Gene Ther** 1999 May–Jun; 6(3):220–7

The effects of metal corrosion debris on immune system cells. Donati ME, et al. **Chir Organi Mov** 1998 Oct–Dec; 83(4):387–93 **(Eng, Ita)**

Aging and the immune response to tetanus toxoid: diminished frequency and level of cellular immune reactivity to antigenic stimulation. Schatz D, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):894–6

Apoptosis of Th1-like cells in experimental tuberculosis (TB). Das G, et al. **Clin Exp Immunol** 1999 Feb;115(2):324–8

Comparison of enterovirus-specific cellular immunity in two populations of young children vaccinated with inactivated or live poliovirus vaccines. Juhela S, et al. **Clin Exp Immunol** 1999 Jul;117(1):100–5

Cell-mediated immunity: dealing a direct blow to pathogens. Kaufmann SH. **Curr Biol** 1999 Feb 11;9(3):R97–9 (10 ref.)

Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Brooks-Worrell BM, et al. **Diabetes** 1999 May;48(5):983–8

Neonatal porcine islet cells induce human CD4+, but not CD8+, lymphocyte proliferation and resist cell-mediated cytolytic injury in vitro. Murray AG, et al. **Diabetes** 1999 Sep;48(9):1713–9

Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Heeg K, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):464–9 (54 ref.)

The cellular immune response to Bordetella pertussis in two children with whooping cough. Hafler JP, et al. **Eur J Med Res** 1998 Nov 17;3(11):523–6

Immune response after laparoscopic and conventional Nissen fundoplication. Perttilä J, et al. **Eur J Surg** 1999 Jan; 165(1):21–8

Cellular immune responses in mice infected with the intestinal nematode Trichuris muris. Soltys J, et al. **Exp Parasitol** 1999 May;92(1):40–7

Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen. Smith BF, et al. **Gene Ther** 1998 Jul;5(7):865–8

Macaque lymphocytes transduced by a constitutively expressed interferon beta gene display an enhanced resistance to SIVmac251 infection. Matheux F, et al. **Hum Gene Ther** 1999 Feb 10;10(3):429–40

Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Acha-Orbea H, et al. **Immunol Rev** 1999 Apr;168:287–303 (130 ref.)

Does properdin crosslink the cellular and the humoral immune response? Schwaeble WJ, et al. **Immunol Today** 1999 Jan;20(1):17–21 (44 ref.)

The safety and longevity of DNA vaccines for fish. Kanellos T, et al. **Immunology** 1999 Feb;96(2):307–13

Enhanced in vivo immune responses to bacterial lipopolysaccharide by exogenous CD40 stimulation. Barr TA, et al. **Infect Immun** 1999 Jul;67(7):3637–40

Resistance of virulent Mycobacterium avium to gamma interferon-mediated antimicrobial activity suggests additional signals for induction of mycobacteriostasis. Flórido M, et al. **Infect Immun** 1999 Jul;67(7):3610–8

Cellular immune responses to Neisseria meningitidis in children. Pollard AJ, et al. **Infect Immun** 1999 May; 67(5):2452–63

Longitudinal study of Plasmodium falciparum infection and immune responses in infants with or without the sickle cell trait. Le Hesran JY, et al. **Int J Epidemiol** 1999 Aug; 28(4):793–8

Lymphoproliferative responses of leprosy patients and healthy controls to nitrocellulose-bound M. leprae antigens. Sachdeva G, et al. **Int J Lepr Other Mycobact Dis** 1999 Jun;67(2):133–42

Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. Stumbles PA, et al. **J Exp Med** 1998 Dec 7;188(11):2019–31

Cell-mediated immune responses in cattle vaccinated with a vaccinia virus recombinant expressing the nucleocapsid protein of rinderpest virus. Ohishi K, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1627–34

Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. Brewer JM, et al. **J Immunol** 1998 Oct 15;161(8):4000–7

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. Fehniger TA, et al. **J Immunol** 1999 Apr 15;162(8):4511–20

Murine Langerhans cells cultured under serum-free conditions mature into potent stimulators of primary immune responses in vitro and in vivo. Kociková A, et al. **J Immunol** 1998 Oct 15;161(8):4033–41

High antigen density and IL-2 are required for generation of CD4 effectors secreting Th1 rather than Th0 cytokines. Rogers PR, et al. **J Immunol** 1998 Oct 15;161(8):3844–52

Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. Shibata Y, et al. **J Immunol** 1998 Oct 15;161(8):4283–8

Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. Yeung VP, et al. **J Immunol** 1998 Oct 15;161(8):4146–52

The CD8+ cell phenotype mediating antiviral activity in feline immunodeficiency virus-infected cats is characterized by reduced surface expression of the CD8 beta chain. Bucci JG, et al. **J Infect Dis** 1998 Oct; 178(4):968–77

Cellular immunity to varicella-zoster virus in patients with major depression [published erratum appears in J Infect Dis 1999 Mar;179(3):753] Irwin M, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S104–8

Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. Seo N, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):555–61 (66 ref.)

The cellular immunology of multiple sclerosis. Al-Omaishi J, et al. **J Leukoc Biol** 1999 Apr;65(4):444–52 (68 ref.)

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. Verschoor EJ, et al. **J Virol** 1999 Apr; 73(4):3292–300

Aging and T-cell-mediated immunity. Chakravarti B, et al. **Mech Ageing Dev** 1999 May 17;108(3):183–206 (168 ref.)

Exercise and cellular innate immune function. Woods JA, et al. **Med Sci Sports Exerc** 1999 Jan;31(1):57–66 (121 ref.)

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Gurunathan S, et al. **Nat Med** 1998 Dec;4(12):1409–15

The eosinophil, a Trojan Horse? [editorial] Koenderman L, et al. **Neth J Med** 1999 May;54(5):181–3

Effect of dietary rosemary extract on cell-mediated immunity of young rats. Babu US, et al. **Plant Foods Hum Nutr** 1999; 53(2):169–74

Effect of induced molting in laying hens on production and immune parameters. Alodan MA, et al. **Poult Sci** 1999 Feb; 78(2):171–7

Mice deficient for 5-lipoxygenase, but not leukocyte-type 12-lipoxygenase, display altered immune responses during infection with Schistosoma mansoni. Secor WE, et al. **Prostaglandins Other Lipid Mediat** 1998 Aug; 56(5–6):291–304

Molecular and cellular determinants of immunity to Histoplasma capsulatum. Deepe GS Jr, et al. **Res Immunol** 1998 May–Jun;149(4–5):397–406; discussion 509–10 (60 ref.)

Cells and cytokines in pulmonary cryptococcosis. Huffnagle GB, et al. **Res Immunol** 1998 May–Jun;149(4–5):387–96; discussion 512–4 (80 ref.)

Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals. Mencacci A, et al. **Res Immunol** 1998 May–Jun;149(4–5):352–61; discussion 517–9 (50 ref.)

Protective cell-mediated immunity against Cryptococcus neoformans. Murphy JW. **Res Immunol** 1998 May–Jun; 149(4–5):373–86; discussion 519–22 (90 ref.)

Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Vecchiarelli A, et al. **Res Immunol** 1998 May–Jun; 149(4–5):321–33; discussion 500–3 (130 ref.)

The immune response induced by a split influenza vaccine. Studies on cellular immunity. Alexandrescu V, et al. **Roum Arch Microbiol Immunol** 1997 Jul–Dec; 56(3–4):155–64

Principles of the photodynamic therapy and its impact on the immune system. Vančíková Z. **Sb Lek** 1998;99(1):1–11 (82 ref.)

Apheresis techniques and cellular immunomodulation. Smith JW. **Ther Apher** 1997 Aug;1(3):203–6 (10 ref.)

Response of the cellular immune system to cardiopulmonary bypass is independent of the applied pump type and of the use of heparin-coated surfaces. Misoph M, et al. **Thorac Cardiovasc Surg** 1998 Aug;46(4):222–7

Immune response to influenza vaccination in a large healthy elderly population. Bernstein E, et al. **Vaccine** 1999 Jan; 17(1):82–94

Induction of humoral and cellular immune responses against the nucleocapsid of bovine viral diarrhea virus by an adenovirus vector with an inducible promoter. Elahi SM, et al. **Virology** 1999 Aug 15;261(1):1–7

Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Sanz-Parra A, et al. **Virology** 1999 Jun 20; 259(1):129–34

[Can T-cell immunity in an adult be regenerated?] Plum J. **Verh K Acad Geneeskd Belg** 1999;61(3):457–64; discussion 464–5 (14 ref.) (Eng. Abstr.) **(Dut)**

[Ways of optimizing the teaching of cellular bases of immune reactions in the course of general histology for students of medical universities] Bykov VL. **Morfologiia** 1999; 115(2):73–5 **(Rus)**

DRUG EFFECTS

Effect of 50- and 100-mg vitamin E supplements on cellular immune function in noninstitutionalized elderly persons. Pallast EG, et al. **Am J Clin Nutr** 1999 Jun;69(6):1273–81

Effect of antibiotic pretreatment on immunogenicity of human heart valves and component cells. Johnson DL, et al. **Ann Thorac Surg** 1998 Dec;66(6 Suppl):S221–4

Cimetidine activates interleukin-12, which enhances cellular immunity [letter] Ishikura H, et al. **Blood** 1999 Mar 1; 93(5):1782–3

Acute-sublethal copper effects on phagocytosis and lysozyme activity in the earthworm Amynthas hawayanus. Nusetti O, et al. **Bull Environ Contam Toxicol** 1999 Sep; 63(3):350–6

Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance? McKenna HJ. **Cancer Immunol Immunother** 1999 Sep; 48(6):281–6 (69 ref.)

Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity. Schirrmacher V, et al. **Clin Cancer Res** 1998 Nov; 4(11):2635–45

Effects of fluoride on immune system function [letter; comment] Gibson SL. **Community Dent Health** 1998 Jun; 15(2):121. Comment on: Community Dent Health 1996 Sep;13 Suppl 2:69–71.

Does aluminium stimulate the immune system in male rats after oral exposure? Glynn AW, et al. **Food Addit Contam** 1999 Mar;16(3):129–35

Humoral and cellular immune responses in different rat strains on oral exposure to ovalbumin. Knippels LM, et al. **Food Chem Toxicol** 1999 Aug;37(8):881–8

Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters. Boura P, et al. **Hepatogastroenterology** 1999 Mar–Apr;46(26):799–803

Ethanol impairs major histocompatibility complex (MHC) class II molecule-mediated but not MHC class I molecule-mediated T cell response in alcohol-consuming mice. Chang MP, et al. **Immunopharmacol Immunotoxicol** 1999 Feb;21(1):65–87

Effect of "rasayanas" a herbal drug preparation on cell-mediated immune responses in tumour bearing mice. Kumar VP, et al. **Indian J Exp Biol** 1999 Jan;37(1):23–6

Effect of "rasayanas", a herbal drug preparation on immune responses and its significance in cancer treatment. Kumar VP, et al. **Indian J Exp Biol** 1999 Jan;37(1):27–31

Effect of herbal preparation on immune response of immunosuppressed mice. Sharma SB, et al. **Indian J Physiol Pharmacol** 1997 Jul;41(3):293–6

Effects of zinc supplementation on the immune system and on antibody response to multivalent influenza vaccine in hemodialysis patients. Türk S, et al. **Int J Artif Organs** 1998 May;21(5):274–8

Lifelong treatment with oral DHEA sulfate does not preserve immune function, prevent disease, or improve survival in genetically heterogeneous mice. Miller RA, et al. **J Am Geriatr Soc** 1999 Aug;47(8):960–6

Nickel release from orthodontic arch wires and cellular immune response to various nickel concentrations. Jia W, et al. **J Biomed Mater Res** 1999;48(4):488–95

Studies on the immunomodulatory effects of Boerhaavia diffusa alkaloidal fraction. Mungantiwar AA, et al. **J Ethnopharmacol** 1999 May;65(2):125–31

CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. Gurunathan S, et al. **J Immunol** 1998 Nov 1;161(9):4563–71

Immune alterations associated with epidural analgesia for labor and delivery. Fehder WP, et al. **MCN Am J Matern Child Nurs** 1998 Nov–Dec;23(6):292–9

The effect of rhGH in vitro on donor-specific hyporesponsiveness in pediatric transplantation [see comments] Benfield MR, et al. **Pediatr Transplant** 1997 Aug;1(1):90–7. Comment in: Pediatr Transplant 1998 May;2(2):177.

Effect of tylosin tartrate (Tylan Soluble) on cellular immune responses in chickens. Baba T, et al. **Poult Sci** 1998 Sep; 77(9):1306–11

The effect of immunotoxins directed against CD80 and CD86 on primary T-cell alloresponses. Otten HG, et al. **Tissue Antigens** 1998 Sep;52(3):270–4

Immunotoxicity of pesticides: a review. Voccia I, et al. **Toxicol Ind Health** 1999 Jan–Mar;15(1–2):119–32 (115 ref.)

The vehicle modulates cellular and humoral responses in contact hypersensitivity to oxazolone. van't Erve EH, et al. **Toxicol Sci** 1998 Jul;44(1):39–45

Tilapia (Oreochromis niloticus) dosed with azathioprine display immune effects similar to those seen in mammals, including apoptosis. Gogal RM Jr, et al. **Vet Immunol Immunopathol** 1999 May;68(2–4):209–27

[The polyclonal nature of the immune response to xenobiotics and endobiotics] Bykova AA. **Eksp Klin Farmakol** 1999 Mar–Apr;62(2):43–7 (Eng. Abstr.) **(Rus)**

[Immunity during ampicillin administration against a background of immunosuppression] Sakaeva DD, et al. **Eksp Klin Farmakol** 1998 Nov–Dec;61(6):39–41 (Eng. Abstr.) **(Rus)**

[The immunological reactivity of children living under conditions of the action of low doses of ionizing radiation and of industrial waste] Markevych VE, et al. **Lik Sprava** 1999 Apr–May;(3):49–53 (Eng. Abstr.) **(Ukr)**

GENETICS

Genetic control of the T cell response to Leishmania major infection. Coffman RL, et al. **Adv Exp Med Biol** 1998; 452:61–6 (14 ref.)

Impaired cutaneous immune responses in Thy-1-deficient mice. Beissert S, et al. **J Immunol** 1998 Nov 15; 161(10):5296–302

Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. Wei XQ, et al. **J Immunol** 1999 Sep 1;163(5):2821–8

Natural killer cell frequency and function in pigs selectively bred for high or low antibody and cell-mediated immune response: response to vaccination with modified live transmissible gastroenteritis virus. Raymond C, et al. **Nat Immun** 1998;16(1):18–26

Susceptibility to the biological effects of polyaromatic hydrocarbons is influenced by genes of the major histocompatibility complex. Elmets CA, et al. **Proc Natl Acad Sci U S A** 1998 Dec 8;95(25):14915–9

IMMUNOLOGY

Cytokines are critical in linking the innate and adaptive immune responses to bacterial, fungal, and parasitic infection. Seder RA, et al. **Adv Intern Med** 1999;44:353–88 (163 ref.)

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine. Zuckermann FA, et al. **Adv Vet Med** 1999;41:447–61 (60 ref.)

Vaccination with an ovalbumin/interleukin-4 fusion DNA efficiently induces Th2 cell-mediated immune responses in an ovalbumin-specific manner. Lim YS, et al. **Arch Pharm Res** 1998 Oct;21(5):537–42

Effects of low-level 50 Hz magnetic fields on the level of host defense and on spleen colony formation. Korneva HA, et al. **Bioelectromagnetics** 1999;20(1):57–63

Immunotolerant functions of HLA-G. Carosella ED, et al. **Cell Mol Life Sci** 1999 Mar;55(3):327–33 (42 ref.)

Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus-positive subjects in the United States after a five-dose schedule of Mycobacterium vaccae vaccine. von Reyn CF, et al. **Clin Infect Dis** 1998 Dec;27(6):1517–20

Listeria monocytogenes as a probe to study cell-mediated immunity. Shen H, et al. **Curr Opin Immunol** 1998 Aug; 10(4):450–8 (65 ref.)

Peptide libraries in cellular immune recognition. Uebel S, et al. **Curr Top Microbiol Immunol** 1999;243:1–21 (92 ref.)

Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Taniguchi T, et al. **Eur Cytokine Netw** 1998 Sep;9(3 Suppl):43–8 (48 ref.)

Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Abdel-Wahab M, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1293–6

Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo. Combadière B, et al. **Immunity** 1998 Sep;9(3):305–13

Priming of cytokine release and increased levels of bactericidal permeability-increasing protein in the blood of animal facility workers. Borm PJ, et al. **Int Arch Occup Environ Health** 1999 Aug;72(5):323–9

Effects of summer camp endurance training on non-specific immunity in long-distance runners. Kumae T, et al. **Int J Sports Med** 1999 Aug;20(6):390–5

The impact of soccer training on the immune system. Rebelo AN, et al. **J Sports Med Phys Fitness** 1998 Sep;38(3):258–61

Pulmonary host defenses. Twigg HL 3rd. **J Thorac Imaging** 1998 Oct;13(4):221–33 (88 ref.)

Cell-mediated allergy to a cerebral aneurysm clip: case report [letter] McFadden JT. **Neurosurgery** 1999 Jul;45(1):200–2

Cell-mediated allergy to a cerebral aneurysm clip: case report. Ross IB, et al. **Neurosurgery** 1998 Nov; 43(5):1209–11

Effects of acute and chronic social stress on blood cellular immunity in rats. Stefanski V, et al. **Physiol Behav** 1998 Jul;64(5):733–41

Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. Duke-Cohan JS, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11336–41

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Kafri T, et al. **Proc Natl Acad Sci U S A** 1998 Sep 15;95(19):11377–82

Influence of early postoperative enteral nutrition versus placebo on cell-mediated immunity, as measured with the Multitest CMI. Beier-Holgersen R, et al. **Scand J Gastroenterol** 1999 Jan;34(1):98–102

Innate and adaptive immune responses can be beneficial for CNS repair. Schwartz M, et al. **Trends Neurosci** 1999 Jul; 22(7):295–9 (65 ref.)

Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Arulanandam BP, et al. **Vaccine** 1999 Jan 21;17(3):252–60

[Current views about etiology and pathogenesis of systemic vasculitis: role of autoantibodies and disturbances of cellular immunity (part II)] Nasonov EL, et al. **Klin Med (Mosk)** 1998;76(8):4–9 (90 ref.) **(Rus)**

PHYSIOLOGY

Regulation of IgE synthesis: the molecular basis and implications for clinical modulation. Bacharier LB, et al. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):1–8 (58 ref.)

Effects of mild perioperative hypothermia on cellular immune responses. Beilin B, et al. **Anesthesiology** 1998 Nov; 89(5):1133–40

Socially inhibited individuals show heightened DTH response during intense social engagement. Cole SW, et al. **Brain Behav Immun** 1999 Jun;13(2):187–200

Cellular immune responses against proinsulin: no evidence for enhanced reactivity in individuals with IDDM. Ellis T, et al. **Diabetes** 1999 Feb;48(2):299–303

Cellular immune response to phogrin in the NOD mouse: cloned T-cells cause destruction of islet transplants. Kelemen K, et al. **Diabetes** 1999 Aug;48(8):1529–34

Pathways of development of human dendritic cells. Caux C. **Eur J Dermatol** 1998 Sep;8(6):375–84 (74 ref.)

Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve. Jani A, et al. **Hum Gene Ther** 1999 Mar 20;10(5):787–800

Cell-mediated immunity needed for TB vaccine [news] **Indian J Med Sci** 1998 Nov;52(11):521–2

Influence of the specific immune response on some consistent murine behaviors. Vidal J. **J Gen Psychol** 1999 Apr; 126(2):205–16

The role of vitamin E in T-cell differentiation and the decrease of cellular immunity with aging. Moriguchi S, et al. **J Med Invest** 1998 Aug;45(1–4):1–8 (35 ref.)

Nerve growth factor: a neurotrophin with activity on cells of the immune system. Aloe L, et al. **Microsc Res Tech** 1999 May 15–Jun 1;45(4–5):285–91 (109 ref.)

The effects of psychological stress on leukocyte subset distribution in humans: evidence of immune activation. Maes M, et al. **Neuropsychobiology** 1999;39(1):1–9

The perioperative nutritional concept [editorial; comment] Senkal M. **Nutrition** 1998 Nov–Dec;14(11–12):864–5. Comment on: Nutrition 1998 Nov–Dec;14(11–12):831–5.

Chronic stress in dogs subjected to social and spatial restriction. II. Hormonal and immunological responses. Beerda B, et al. **Physiol Behav** 1999 Apr;66(2):243–54

Infiltration of lymphocytes in the limbic brain following stimulation of subclinical cellular immunity and low dosages of lithium and a cholinergic agent. Cook LL, et al. **Toxicol Lett** 1999 Sep 20;109(1–2):77–85

Blood transfusions downregulate hematopoiesis and subsequently downregulate the immune response. Grzelak I, et al. **Transfusion** 1998 Nov–Dec;38(11–12):1104–14

Immune function in hyperbaric environments, diving, and decompression. Brenner I, et al. **Undersea Hyperb Med** 1999 Spring;26(1):27–39 (115 ref.)

[The immunological health of flight personnel: the concept and the approaches to its assessment] Ushakov IB, et al. **Voen Med Zh** 1998 Dec;319(12):43–50 **(Rus)**

[Leucocyte tartrate-resistant acid phosphatase as marker for the transition of monocyte to macrophage] Grignaschi VJ, et al. **Medicina (B Aires)** 1998;58(6):713–6 (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition. Hug DH, et al. **J Photochem Photobiol B** 1998 Jul 10; 44(2):117–23 (81 ref.)

[The immune status of young school-age children irradiated while in the womb as a result of the accident at the Chernobyl Atomic Electric Power Station] Vdovenko VIu. **Lik Sprava** 1999 Jan–Feb;(1):28–9 (Eng. Abstr.) **(Rus)**

[The immunological reactivity of children living under conditions of the action of low doses of ionizing radiation and of industrial waste] Markevych VE, et al. **Lik Sprava** 1999 Apr–May;(3):49–53 (Eng. Abstr.) **(Ukr)**

IMMUNITY, HUMORAL see **ANTIBODY FORMATION**

IMMUNITY, MATERNALLY-ACQUIRED

see related

IMMUNIZATION, PASSIVE

The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Wesumperuma HL, et al. **Ann Trop Med Parasitol** 1999 Mar;93(2):169–77

Placental antibody transfer: influence of maternal HIV infection and placental malaria. de Moraes-Pinto MI, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov; 79(3):F202–5

ERV-3 envelope expression and congenital heart block: what does a physiological knockout teach us. de Parseval N, et al. **Autoimmunity** 1999;30(2):81–3

Transplacental transmission of serotype-specific pneumococcal antibodies in a Brazilian population. Carvalho BTC, et al. **Clin Diagn Lab Immunol** 1999 Jan; 6(1):50–4

Prenatal immune priming in onchocerciasis-onchocerca volvulus-specific cellular responsiveness and cytokine production in newborns from infected mothers. Soboslay PT, et al. **Clin Exp Immunol** 1999 Jul;117(1):130–7

Passive immunisation of neonatal lambs via colostrum and milk of ewes previously immunised with live attenuated Salmonella typhimurium protects neonatal lambs from experimental salmonellosis. Mukkur TK, et al. **Comp Immunol Microbiol Infect Dis** 1998 Oct;21(4):327–36

Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Siegrist CA, et al. **Eur J Immunol** 1998 Dec;28(12):4138–48

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Linder N, et al. **Infection** 1999 Mar–Apr;27(2):128–31

Nutrient and immunity transfer from cow to calf pre- and postcalving. Quigley JD 3rd, et al. **J Dairy Sci** 1998 Oct; 81(10):2779–90 (139 ref.)

Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections. Montesano MA, et al. **J Exp Med** 1999 Feb 15;189(4):637–45

Serum and intestinal isotype antibody responses to Wa human rotavirus in gnotobiotic pigs are modulated by maternal antibodies. Parreño V, et al. **J Gen Virol** 1999 Jun;80 (Pt 6):1417–28

Two stages of increased IgA transfer during lactation in the marsupial, trichosurus vulpecula (Brushtail possum). Adamski FM, et al. **J Immunol** 1999 May 15; 162(10):6009–15

Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. Miranda ME, et al. **J Immunol** 1998 Nov 1;161(9):5061–9

Effect of passive transfer status and vaccination with Escherichia coli (J5) on mortality in comingled dairy calves. Tyler JW, et al. **J Vet Intern Med** 1999 Jan–Feb; 13(1):36–9

Detection of low serum immunoglobulin concentrations in clinically ill calves. Tyler JW, et al. **J Vet Intern Med** 1999 Jan–Feb;13(1):40–3

Experimental infection of maternally immune pigs with porcine reproductive and respiratory syndrome (PRRS) virus. Shibata I, et al. **J Vet Med Sci** 1998 Dec; 60(12):1285–91

Effects of maternal antibodies on protection and development of antibody responses to human rotavirus in gnotobiotic pigs. Hodgins DC, et al. **J Virol** 1999 Jan;73(1):186–97

Maternal transfer of Hantavirus antibodies in rats. Dohmae K, et al. **Lab Anim Sci** 1998 Aug;48(4):395–7

Neonatal varicella despite maternal immunity [letter] Bendig JW, et al. **Lancet** 1998 Dec 19-26;352(9145):1985-6
Maternal immunization [editorial] Combs BG, et al. **P N G Med J** 1997 Jun;40(2):63-8 (44 ref.)
Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Nohynek H, et al. **Pediatr Infect Dis J** 1999 Jan;18(1):25-30
Dynamics of immunoglobulins at the feto-maternal interface. Saji F, et al. **Rev Reprod** 1999 May;4(2):81-9 (85 ref.)
Antibody response to glycoprotein E after bovine herpesvirus type 1 infection in passively immunised, glycoprotein E-negative calves. Lemaire M, et al. **Vet Rec** 1999 Feb 13;144(7):172-6
Screening programmes for foetomaternal alloimmune thrombocytopenia. Williamson LM. **Vox Sang** 1998;74 Suppl 2:385-9 (32 ref.)
[Efficacy of maternal Salmonella antibodies and experimental oral infection of chicks with Salmonella enteritidis] Methner U, et al. **Berl Munch Tierarztl Wochenschr** 1997 Oct;110(10):373-7 (Eng. Abstr.) **(Ger)**
[Structure and function of serum mannan-binding protein involved in innate immunity] Uemura K, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2428-34 (19 ref.) **(Jpn)**

IMMUNOLOGY

Protective role of maternal antibodies against Haemophilus parasuis infection. Solano-Aguilar GI, et al. **Am J Vet Res** 1999 Jan;60(1):81-7
Maternal immunization. Glezen WP, et al. **Clin Infect Dis** 1999 Feb;28(2):219-24 (51 ref.)
Transplacental transfer of measles and total IgG. Gonçalves G, et al. **Epidemiol Infect** 1999 Apr;122(2):273-9
Transplacental transfer of measles antibody in Delhi. Singh J, et al. **Indian Pediatr** 1998 Dec;35(12):1187-91
Placental transfer of maternal rubella antibodies to full-term and preterm infants. Linder N, et al. **Infection** 1999 May-Jun;27(3):203-7
Helminth- and Bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. Malhotra I, et al. **J Immunol** 1999 Jun 1; 162(11):6843-8
Human serum beta2-microglobulin levels: correlation with total serum IgG and placental IgG transfer in HIV-infected and non-HIV infected individuals. de Moraes-Pinto MI, et al. **J Reprod Immunol** 1999 Mar;42(2):167-74
Transplacental measles immunity [letter; comment] Katz SL. **Pediatr Infect Dis J** 1998 Aug;17(8):763. Comment on: Pediatr Infect Dis J 1998 Apr;17(4):313-6.
Reduced passive measles immunity in infants of mothers who have not been exposed to measles outbreaks. Ohsaki M, et al. **Scand J Infect Dis** 1999;31(1):17-9
Negative response to noninherited maternal antigens confirmed by ELISA. Bishara A, et al. **Transplant Proc** 1999 Jun;31(4):1879-80
Susceptibility to tropical theileriosis of calves born to dams immunized with Theileria annulata (Hisar) cell culture vaccine. Beniwal RK, et al. **Trop Anim Health Prod** 1998 Dec;30(6):341-9
Persistence of passively transferred antibodies in porcine Taenia solium cysticercosis. Cysticercosis Working Group in Peru. Gonzalez AE, et al. **Vet Parasitol** 1999 Sep 30; 86(2):113-8
Assessment of maternal immunity to Cryptosporidium baileyi in chickens. Hornok S, et al. **Vet Parasitol** 1998 Nov 16; 79(3):203-12
Role of acquired immunity and natural age resistance on course of Isospora suis coccidiosis in nursing piglets. Koudela B, et al. **Vet Parasitol** 1999 Mar 31;82(2):93-9

PHYSIOLOGY

Persistence of maternal antibodies against Mycoplasma agassizii in desert tortoise hatchlings. Schumacher IM, et al. **Am J Vet Res** 1999 Jul;60(7):826-31
Tolerance of the fetus by the maternal immune system. Current concepts. Kanellopoulos-Langevin C. **Rev Rhum Engl Ed** 1998 Nov;65(11):603-7 (28 ref.)
HLA-G and pregnancy. Le Bouteiller P. **Rev Rhum Engl Ed** 1998 Nov;65(11):608-10 (21 ref.)

IMMUNITY, MUCOSAL

see related

IGA, SECRETORY

HIV transmission and immune protection at mucosal surfaces. Neutra MR. **Adv Exp Med Biol** 1998;452:169-75 (60 ref.)
Role of macrophage cytokines in mucosal adjuvanticity. Foss DL, et al. **Adv Vet Med** 1999;41:83-104 (67 ref.)
ISCOM: a delivery system for neonates and for mucosal administration. Morein B, et al. **Adv Vet Med** 1999; 41:405-13 (20 ref.)
Cholera toxin B subunit as an immunomodulator for mucosal vaccine delivery. Russell MW, et al. **Adv Vet Med** 1999; 41:105-14 (31 ref.)
Enteric viral infections of pigs and strategies for induction of mucosal immunity. Saif LJ. **Adv Vet Med** 1999;41:429-46 (54 ref.)
Mucosal antibody expression following rapid SIV(Mne) dissemination in intrarectally infected Macaca nemestrina. Kuller L, et al. **AIDS Res Hum Retroviruses** 1998 Oct 10; 14(15):1345-56
Mucosal immunity in relation to the development of oral tolerance/sensitization. Holt PG. **Allergy** 1998;53(46 Suppl):16-9 (26 ref.)
Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review. Russell MW, et al. **Am J Reprod Immunol** 1999 Jul;42(1):58-63 (42 ref.)
Scratching the surface: inroads to a better understanding of airway host defense. Bevins CL. **Am J Respir Cell Mol Biol** 1999 May;20(5):861-3
Integration of neuro-endocrine immune responses in defense of mucosal surfaces. Befus AD, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):26-34 (94 ref.)
Immune-epithelial interactions in host defense. Berin MC, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):16-25 (82 ref.)
Strategies for mucosal vaccine development. Boyaka PN, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):35-45 (117 ref.)
Upregulation of keratinocyte growth factor during T-cell immunity in the gut mucosa. Bajaj-Elliott M, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:184-7
Intestinal antibodies against gliadin, tissue-transglutaminase, beta-lactoglobulin, and ovalbumin in patients with irritable bowel syndrome. Wahnschaffe U, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:280-4
Identification of CMV-specific immunoglobulin production by intestinal biopsies of AIDS patients with CMV enteritis. Zippel T, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:271-5
Increased density of jejunal gammadelta+ T cells in patients having normal mucosa--marker of operative autoimmune mechanisms? Iltanen S, et al. **Autoimmunity** 1999; 29(3):179-87
Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. Tzung SP, et al. **Biol Blood Marrow Transplant** 1998; 4(1):43-8
Immune responsiveness of lymphotoxin-alpha-deficient mice: two reconstitution models. Davis IA, et al. **Cell Immunol** 1998 Nov 1;189(2):116-24
Immunostimulatory DNA is a potent mucosal adjuvant. Horner AA, et al. **Cell Immunol** 1998 Nov 25;190(1):77-82
Accumulation of immunoglobulin-containing cells in the gut mucosa and presence of faecal immunoglobulin in severe combined immunodeficient (scid) mice with T cell-induced inflammatory bowel disease (IBD). Bregenholt S, et al. **Clin Exp Immunol** 1998 Oct;114(1):19-25
Humoral immune responses in periodontal disease may have mucosal and systemic immune features. Kinane DF, et al. **Clin Exp Immunol** 1999 Mar;115(3):534-41
Organization of mucosal lymphoid tissue. Hein WR. **Curr Top Microbiol Immunol** 1999;236:1-15 (28 ref.)
Effector and regulatory lymphoid cells and cytokines in mucosal sites. MacDonald TT. **Curr Top Microbiol Immunol** 1999;236:113-35 (133 ref.)
Bacterial epithelial cell cross talk. Raupach B, et al. **Curr Top Microbiol Immunol** 1999;236:137-61 (82 ref.)
Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Goodrich ME, et al. **Cytokine** 1998 Dec;10(12):948-55
Mucosal responses to parenteral and mucosal vaccines. Kaul D, et al. **Dev Biol Stand** 1998;95:141-6 (10 ref.)
Maturation of B cells in the lamina propria of human gut and bronchi in the first months of human life. El Kaissouni J, et al. **Dev Immunol** 1998;5(3):153-9
Derangement of mucosal barrier function by bacteria colonizing the rat colonic mucosa [see comments] Garcia-Lafuente A, et al. **Eur J Clin Invest** 1998 Dec; 28(12):1019-26. Comment in: Eur J Clin Invest 1998 Dec;28(12):1027-9.
The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Grdic D, et al. **Eur J Immunol** 1999 Jun;29(6):1774-84
Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Mitchell EA, et al. **Eur J Immunol** 1998 Oct;28(10):3066-74
Early induction and augmentation of parasitic antigen-specific antibody-producing B lymphocytes in the non-Peyer's patch region of the small intestine. Wang CH, et al. **Front Biosci** 1998 Nov 1;3:A58-65
Intolerance of the dirty intestine [comment] Macpherson AJ, et al. **Gut** 1999 Jun;44(6):774-5. Comment on: Gut 1999 Jun;44(6):812-18.
Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Mestecky J, et al. **Gut** 1999 Jan;44(1):2-5
The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin. de Haan L, et al. **Immunol Cell Biol** 1998 Jun;76(3):270-9 (95 ref.)
10th International Congress of Mucosal Immunology. Amsterdam, The Netherlands, 27 June-1 July, 1999. Proceedings and abstracts. **Immunol Lett** 1999 Jun 15; 69(1):1-216
Intestinal intraepithelial T lymphocytes. Our T cell horizons are expanding. Nanno M, et al. **Immunol Res** 1998 Aug; 18(1):41-53 (70 ref.)
Immuno-epithelial interactions: cytokine modulation of normal rabbit colonocyte function [letter] Vidrich A, et al. **In Vitro Cell Dev Biol Anim** 1998 Nov-Dec;34(10):743-6
Innate antimicrobial activity of nasal secretions. Cole AM, et al. **Infect Immun** 1999 Jul;67(7):3267-75
Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Seong SY, et al. **Infect Immun** 1999 Jul; 67(7):3587-92
Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Umesaki Y, et al. **Infect Immun** 1999 Jul;67(7):3504-11
Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Viret JF, et al. **Infect Immun** 1999 Jul;67(7):3680-5
The role of the invariant chain in mucosal immunity. Barrera CA, et al. **Int Arch Allergy Immunol** 1998 Oct;117(2):85-93 (88 ref.)
Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres. Cho NH, et al. **J Controlled Release** 1998 Apr 30;53(1-3):215-24
Selection and expansion of CD8alpha/alpha(1) T cell receptor alpha/beta(1) intestinal intraepithelial lymphocytes in the absence of both classical major histocompatibility complex class I and nonclassical CD1 molecules. Park SH, et al. **J Exp Med** 1999 Sep 20; 190(6):885-90
The effect of minimum luminal nutrition on mucosal cellularity and immunity of the gut. Heel KA, et al. **J Gastroenterol Hepatol** 1998 Oct;13(10):1015-9
Serum and intestinal isotype antibody responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. Tô TL, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2661-72
Efficient lymphocyte migration across high endothelial venules of mouse Peyer's patches requires overlapping expression of L-selectin and beta7 integrin. Steeber DA, et al. **J Immunol** 1998 Dec 15;161(12):6638-47
The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7. Williams MB, et al. **J Immunol** 1998 Oct 15;161(8):4227-35
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. Yamamoto M, et al. **J Immunol** 1998 Oct 15;161(8):4115-21
Nomenclature of immunoglobulin A and other proteins of the mucosal immune system. IUIS/WHO subcommittee on IgA nomenclature. J **Immunol Methods** 1999 Mar 4; 223(2):263-4
Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. Kresina TF, et al. **J Infect Dis** 1999 May;179 Suppl 3:S392-6 (4 ref.)
Mucosal immune system of the human genital tract. Mestecky J, et al. **J Infect Dis** 1999 May;179 Suppl 3:S470-4 (58 ref.)
Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis: comments and conference summary. Wahl SM, et al. **J Infect Dis** 1999 May;179 Suppl 3:S397-400
CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection [letter] Williams SB, et al. **J Infect Dis** 1999 May;179(5):1310-2
Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. Brennan FR, et al. **J Virol** 1999 Feb;73(2):930-8
Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes. Hu KF, et al. **Med Microbiol Immunol (Berl)** 1999 May;187(4):191-8
Assessment of mucosal immune response in genitourinary tract using urine. Kohno T, et al. **Microbiol Immunol** 1999; 43(3):253-8
Further characterization of M cells in gut-associated lymphoid tissues of the chicken. Jeurissen SH, et al. **Poult Sci** 1999 Jul;78(7):965-72
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Belyakov IM, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4512-7
Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Strober W, et al. **Scand J Immunol** 1998 Nov;48(5):453-8 (59 ref.)
Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Wilson CL, et al. **Science** 1999 Oct 1;286(5437):113-7
Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Kyd JM, et al. **Vaccine** 1999 Mar 26;17(13-14):1775-81 (49 ref.)
Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Liu XS, et al. **Virology** 1998 Dec 5;252(1):39-45
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Nguyen HH, et al. **Virology** 1999 Feb 1;254(1):50-60
[The intestinal immune system] Reinking RR, et al. **Med Monatsschr Pharm** 1999 Jul;22(7):198-204 (23 ref.) **(Ger)**

IMMUNITY, MUCOSAL

DRUG EFFECTS

Mucosal host defence response to hysterectomy assessed by saliva analyses: a comparison of propofol and isoflurane anaesthesia. Lähteenmäki M, et al. **Anaesthesia** 1998 Nov; 53(11):1067–73

Enhancement of ovalbumin-induced antibody production and mucosal mast cell response by mercury. Watzl B, et al. **Food Chem Toxicol** 1999 Jun;37(6):627–37

Effects of the common cold and intranasal fluticasone propionate treatment on mucosal host defense assessed by human saliva. Lenander-Lumikari M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jun;87(6):695–9

Mucosal and systemic suppression of the immune response to E. histolytica provoked by metronidazole and mebendazole in Balb/c mice. Moreno-Fierros L, et al. **Proc West Pharmacol Soc** 1998;41:99–102

Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein. Coombes AG, et al. **Vaccine** 1999 May 14; 17(19):2410–22

GENETICS

Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. Yang X, et al. **EMBO J** 1999 Mar 1; 18(5):1280–91

IMMUNOLOGY

Breastfeeding provides passive and likely long-lasting active immunity [published erratum appears in Ann Allergy Asthma Immunol 1999 May;82(5):478] Hanson LA. **Ann Allergy Asthma Immunol** 1998 Dec;81(6):523–33; quiz 533–4, 537 (155 ref.)

Antibody-mediated protection of mucosal surfaces. Corthesy B, et al. **Curr Top Microbiol Immunol** 1999;236:93–111 (130 ref.)

Bacterial toxins as mucosal adjuvants. Freytag LC, et al. **Curr Top Microbiol Immunol** 1999;236:215–36 (62 ref.)

Recombinant viruses as vectors for mucosal immunity. Morrow CD, et al. **Curr Top Microbiol Immunol** 1999; 236:255–73 (49 ref.)

Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Kewenig S, et al. **Gastroenterology** 1999 May; 116(5):1115–23

Immune stimulating complexes as mucosal vaccines. Smith RE, et al. **Immunol Cell Biol** 1998 Jun;76(3):263–9 (63 ref.)

A role for mucosal immunity in resistance to HIV infection. Clerici M, et al. **Immunol Lett** 1999 Mar;66(1–3):21–5

Mucosal tolerance. Weiner HL, et al. **Immunol Lett** 1999 Jun 15;69(1):3–4

Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Brandtzaeg P, et al. **Immunol Today** 1999 Jun;20(6):267–77 (111 ref.)

Diversity of antibody-mediated immunity at the mucosal barrier. Bouvet JP, et al. **Infect Immun** 1999 Jun; 67(6):2687–91 (59 ref.)

Pertussis adjuvant prolongs intestinal hypersensitivity. Kosecka U, et al. **Int Arch Allergy Immunol** 1999 Jul; 119(3):205–11

Topical CTLA4-Ig suppresses ongoing mucosal immune response in presensitized murine model of allergic rhinitis. Sato J, et al. **Int Arch Allergy Immunol** 1999 Jul; 119(3):197–204

Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy. Wiedermann U, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):129–32

IgA production in MHC class II-deficient mice is primarily a function of B-1a cells. Snider DP, et al. **Int Immunol** 1999 Feb;11(2):191–8

The innate immune system in cystic fibrosis lung disease [see comments] Bals R, et al. **J Clin Invest** 1999 Feb; 103(3):303–7 (29 ref.). Comment in: J Clin Invest 1999 Feb;103(4):441–5.

Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. Stumbles PA, et al. **J Exp Med** 1998 Dec 7;188(11):2019–31

Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. Klavinskis LS, et al. **J Immunol** 1999 Jan 1; 162(1):254–62

Functional studies on dendritic cells in the respiratory tract and related mucosal tissues. Holt PG, et al. **J Leukoc Biol** 1999 Aug;66(2):272–5 (43 ref.)

Synergistic effect of hyperoxia and immunoglobulin A on mucosal barrier defense. Diebel LN, et al. **J Trauma** 1999 Mar;46(3):374–8; discussion 378–9

Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Lundholm P, et al. **Vaccine** 1999 Apr 9;17(15–16):2036–42

Induction of immune responses in pigs following oral administration of purified F4 fimbriae. Van den Broeck W, et al. **Vaccine** 1999 Apr 9;17(15–16):2020–9

Induction of mucosal immunity with a replication-defective adenoviral recombinant. Xiang Z, et al. **Vaccine** 1999 Apr 9;17(15–16):2003–8

PHYSIOLOGY

Regulation of the mucosal immune response. Ernst PB, et al. **Am J Trop Med Hyg** 1999 Apr;60(4 Suppl):2–9 (90 ref.)

Interactions between epithelial cells and immune cells in the intestine. Strober W. **Ann N Y Acad Sci** 1998 Nov 17; 859:37–45 (19 ref.)

Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Svanborg C, et al. **Curr Opin Microbiol** 1999 Feb;2(1):99–105 (59 ref.)

Immunological aspects of the potential role of dietary carbohydrates and lectins in human health. Kilpatrick DC. **Eur J Nutr** 1999 Jun;38(3):107–17 (99 ref.)

Regional specialization in the mucosal immune system: what happens in the microcompartments? Brandtzaeg P, et al. **Immunol Today** 1999 Mar;20(3):141–51 (84 ref.)

IMMUNITY, NATURAL

Antimicrobial function of human saliva--how important is it for oral health? Tenovuo J. **Acta Odontol Scand** 1998 Oct;56(5):250–6 (89 ref.)

Functional responses of neonatal chicken and turkey heterophils following stimulation by inflammatory agonists. Kogut MH, et al. **Am J Vet Res** 1998 Nov;59(11):1404–8

Hyper-resistance to infection in TIMP-1-deficient mice is neutrophil dependent but not immune cell autonomous. Osiewicz K, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:494–6

The role of host immunocompetence in neuroinvasion of Sindbis virus. Lustig S, et al. **Arch Virol** 1999; 144(6):1159–71

Possible role of reactive oxygen species in antiviral defense. Skulachev VP. **Biochemistry (Mosc)** 1998 Dec; 63(12):1438–40

The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Marshall JD, et al. **Blood** 1999 Aug 1; 94(3):1003–11

Congenital toxoplasma chorioretinitis transmitted by preconceptionally immune women [letter] Dollfus H, et al. **Br J Ophthalmol** 1998 Dec;82(12):1444–5

Innate immunity [editorial] Carroll MC, et al. **Curr Opin Immunol** 1999 Feb;11(1):1–2

Lung surfactant proteins involved in innate immunity. Eggleton P, et al. **Curr Opin Immunol** 1999 Feb;11(1):28–33 (36 ref.)

Mast cells as sentinels of innate immunity. Galli SJ, et al. **Curr Opin Immunol** 1999 Feb;11(1):53–9 (71 ref.)

Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin. Emoto M, et al. **Eur J Immunol** 1999 Feb;29(2):650–9

The human uniqueness of HIV: innate immunity and the viral Tat protein. Rodman TC, et al. **Hum Immunol** 1999 Aug; 60(8):631–9

Functional roles of the lung surfactant proteins SP-A and SP-D in innate immunity. Reid KB. **Immunobiology** 1998 Aug;199(2):200–7 (44 ref.)

Microbe exposure, innate immunity and autoimmunity [letter; comment] Ristori G, et al. **Immunol Today** 1999 Jan; 20(1):54. Comment on: Immunol Today 1998 Mar;19(3):113–6.

Complement diversity: a mechanism for generating immune diversity? Sunyer JO, et al. **Immunol Today** 1998 Nov; 19(11):519–23

Phagocytosis does not play a major role in naturally acquired transmission-blocking immunity to Plasmodium falciparum malaria. Healer J, et al. **Infect Immun** 1999 May; 67(5):2334–9

CD4(+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice. Julia V, et al. **Infect Immun** 1999 Jul;67(7):3641–4

Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Kurtis JD, et al. **Infect Immun** 1999 Jul;67(7):3424–9

Effect of breed (Angus vs Simmental) on immune function and response to a disease challenge in stressed steers and preweaned calves. Engle TE, et al. **J Anim Sci** 1999 Mar; 77(3):516–21

Dendritic cells: a link between innate and adaptive immunity. Palucka K, et al. **J Clin Immunol** 1999 Jan;19(1):12–25 (112 ref.)

A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. Boes M, et al. **J Exp Med** 1998 Dec 21;188(12):2381–6

Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. Rosenkranz AR, et al. **J Immunol** 1998 Dec 15;161(12):6463–7

On the role of feedback in promoting conflicting goals of the adaptive immune system. Segel LA, et al. **J Immunol** 1999 Aug 1;163(3):1342–9 (24 ref.)

Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. Roselaar SE, et al. **J Lipid Res** 1998 Sep;39(9):1740–3

Age-dependent resistance to Cryptosporidium muris (strain MCR) infection in golden hamsters and mice. Rhee JK, et al. **Korean J Parasitol** 1999 Mar;37(1):33–7

Natural immunity and bone and muscle remodelling hormones in the elderly. Mariani E, et al. **Mech Ageing Dev** 1998 May 15;102(2–3):279–92

50th annual meeting of the Society for Natural Immunity. 17th International Natural Killer Cell Workshop. Warrenton, Virginia, USA. October 17–21, 1998. Abstracts. **Nat Immun** 1998;16(2–3):51–126

Nutritional modulation of resistance to infectious diseases. Klasing KC. **Poult Sci** 1998 Aug;77(8):1119–25 (55 ref.)

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Walker PS, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6970–5

Specific and non-specific immunity to Candida albicans: a lesson from genetically modified animals. Mencacci A, et al. **Res Immunol** 1998 May-Jun;149(4–5):352–61; discussion 517–9 (50 ref.)

Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Kemp K, et al. **Scand J Immunol** 1999 Jun;49(6):655–9

Phylogenetic perspectives in innate immunity. Hoffmann JA, et al. **Science** 1999 May 21;284(5418):1313–8 (42 ref.)

Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Wilson CL, et al. **Science** 1999 Oct 1;286(5437):113–7

The effects of injury on the adaptive immune response. Lederer JA, et al. **Shock** 1999 Mar;11(3):153–9 (75 ref.)

Resisting resistance [editorial; comment] Stear MJ, et al. **Vet J** 1999 Mar;157(2):111. Comment on: Vet J 1999 Mar;157(2):148–59.

[Insect lectins and defense mechanism] Natori S. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2435–41 (28 ref.) **(Jpn)**

GENETICS

Brief communication: Resistance to Falciparum malaria in alpha-thalassemia, oxidative stress, and hemoglobin oxidation. Destro-Bisol G, et al. **Am J Phys Anthropol** 1999 Jun;109(2):269–73

A PCR method for typing B-L beta II family (class II MHC) alleles in broiler chickens. Zheng D, et al. **Anim Genet** 1999 Apr;30(2):109–19

Human natural resistance-associated macrophage protein 2: gene cloning and protein identification. Kishi F, et al. **Biochem Biophys Res Commun** 1998 Oct 29;251(3):775–83

Gene-for-gene interactions: bacterial avirulence proteins specify plant disease resistance. Bonas U, et al. **Curr Opin Microbiol** 1999 Feb;2(1):94–8 (59 ref.)

Strong host resistance targeted against a viral suppressor of the plant gene silencing defence mechanism. Li HW, et al. **EMBO J** 1999 May 17;18(10):2683–91

Identification of three putative signal transduction genes involved in R gene-specified disease resistance in Arabidopsis. Warren RF, et al. **Genetics** 1999 May; 152(1):401–12

Disease-resistance related sequences in common bean. Rivkin MI, et al. **Genome** 1999 Feb;42(1):41–7

The full expression of the ity phenotype in ityr mice requires C3 activation by Salmonella lipopolysaccharide. Nishikawa F, et al. **Immunology** 1998 Dec;95(4):640–7

Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Moore RJ, et al. **Nat Med** 1999 Jul; 5(7):828–31

Genetic control of susceptibility to infections with intracellular pathogens. Skamene E. **Pathol Biol (Paris)** 1998 Nov;46(9):689–92 (0 ref.) **(Eng, Fre)**

Impact of genetics on disease resistance. Lamont SJ. **Poult Sci** 1998 Aug;77(8):1111–8 (96 ref.)

The Nramp1 protein and its role in resistance to infection and macrophage function. Canonne-Hergaux F, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):283–9 (56 ref.)

Involvement of specific calmodulin isoforms in salicylic acid-independent activation of plant disease resistance responses. Heo WD, et al. **Proc Natl Acad Sci U S A** 1999 Jan 19;96(2):766–71

Heritable variation in resistance to gastro-intestinal nematodes in an unmanaged mammal population. Smith JA, et al. **Proc R Soc Lond B Biol Sci** 1999 Jun 22; 266(1425):1283–90

Study on scrapie resistance [letter] Baylis M, et al. **Vet Rec** 1998 Aug 8;143(6):176

[Anti-HIV-1 genes; genetic restriction of AIDS pathogenesis by gene variants] Tashiro K, et al. **Nippon Rinsho** 1999 Apr;57(4):967–74 (28 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The hypersensitive response. A programmed cell death associated with plant resistance. Pontier D, et al. **C R Acad Sci III** 1998 Sep;321(9):721–34 (174 ref.)

Innate immunity. Robertson M. **Curr Biol** 1998 Aug 27; 8(17):R595–7 (3 ref.)

Recognition of gram-negative bacteria and endotoxin by the innate immune system. Ulevitch RJ, et al. **Curr Opin Immunol** 1999 Feb;11(1):19–22 (37 ref.)

Neuroimmunoregulation and natural immunity. Berczi I, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):273–81 (30 ref.)

Coordinated host defense through an integration of the neural, immune and haemopoietic systems. Miyan JA, et al. **Domest Anim Endocrinol** 1998 Sep;15(5):297–304 (20 ref.)

The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. Maurer M, et al. **J Exp Med** 1998 Dec 21;188(12):2343–8

Linking innate and adaptive immunity [news; comment]

Palucka K, et al. **Nat Med** 1999 Aug;5(8):868–70. Comment on: Nat Med 1999 Aug;5(8):919–23.

Reduction of natural killer cytotoxic activity in major depression: interaction between depression and cigarette smoking [see comments] Jung W, et al. **Psychosom Med** 1999 May–Jun;61(3):263–70. Comment in: Psychosom Med 1999 May–Jun;61(3):271–2.

Innate and adaptive immune responses can be beneficial for CNS repair. Schwartz M, et al. **Trends Neurosci** 1999 Jul; 22(7):295–9 (65 ref.)

[Immunology in medical practice. XXII. T-cells and strategies for tolerance induction] Weenink JJ, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1148–53 (24 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

The Toll-receptor family and control of innate immunity. Kopp EB, et al. **Curr Opin Immunol** 1999 Feb;11(1):13–8 (48 ref.)

A new theory on the common evolutionary origin of natural immunity, inflammation and stress response: the invertebrate phagocytic immunocyte as an eye-witness. Ottaviani E, et al. **Domest Anim Endocrinol** 1998 Sep; 15(5):291–6 (30 ref.)

Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance against Mycobacterium avium. Gomes MS, et al. **Immunology** 1998 Oct;95(2):165–8

Macrophage NRAMP1 and its role in resistance to microbial infections. Govoni G, et al. **Inflamm Res** 1998 Jul; 47(7):277–84 (65 ref.)

Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. Bohuslav J, et al. **J Clin Invest** 1998 Nov 1;102(9):1645–52

Impact of aging on innate immunity. Pawelec G, et al. **J Leukoc Biol** 1998 Dec;64(6):703–12 (128 ref.)

Inducible defence and the social evolution of herd immunity. Frank SA. **Proc R Soc Lond B Biol Sci** 1998 Oct 7; 265(1408):1911–3

RADIATION EFFECTS

Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Goettsch W, et al. **Environ Health Perspect** 1998 Feb; 106(2):71–7

Radiation-resistant and radiation-sensitive forms of host resistance to polyomavirus. Carroll JP, et al. **J Virol** 1999 Feb;73(2):1213–8

[A new possibility for enhancing natural immunity: a radiation-detoxified endotoxin] Bertók L. **Orv Hetil** 1999 Apr 11;140(15):819–27 (50 ref.) (Eng. Abstr.) **(Hun)**

[The natural resistance of the inhabitants of Kiev 10 years after the accident at the Chernobyl Atomic Electric Power Station] Kindzel'skiĭ LP, et al. **Lik Sprava** 1998 Jul–Aug; (5):47–9 (Eng. Abstr.) **(Rus)**

IMMUNITY, NON-SPECIFIC see **IMMUNITY, NATURAL**

IMMUNIZATION

Prevention of allergies of infants: breast-feeding and special formulas. Influence on the response to immunization. Salvioli GP, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:21–7

Enhancement of nasal clearance of nontypeable Haemophilus influenzae by oral immunization with outer membrane proteins. Suzuki M, et al. **Acta Otolaryngol (Stockh)** 1998 Nov;118(6):864–9

Allergen sensitization of asthmatic and nonasthmatic schoolchildren in Costa Rica. Soto-Quiros M, et al. **Allergy** 1998 Dec;53(12):1141–7

Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Spiegelberg HL, et al. **Allergy** 1998;53(45 Suppl):93–7

What makes a child allergic? Analysis of risk factors for allergic sensitization in preschool children from East and West Germany. Schäfer T, et al. **Allergy Asthma Proc** 1999 Jan–Feb;20(1):23–7

The sensitizing capacity of ginkgolic acids in guinea pigs. Hausen BM. **Am J Contact Dermat** 1998 Sep;9(3):146–8

A new splenic artery Doppler velocimetric index for prediction of severe fetal anemia associated with Rh alloimmunization. Bahado-Singh R, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):49–54

Physicians' immunization knowledge, attitudes, and practices: a valid and internally consistent measurement tool. Prislin R, et al. **Am J Prev Med** 1999 Aug;17(2):151–2

Goblet cell degranulation after antigen challenge in sensitized guinea pigs. Role of neutrophils. Agusti C, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1253–8

Mechanisms of immune sensitization of human bronchus. Rabe KF. **Am J Respir Crit Care Med** 1998 Nov;158(5 Pt 3):S161–70 (64 ref.)

Treatment of gilts with leukocytes from the sire does not improve reproductive performance. Ramsoondar JJ, et al. **Anim Reprod Sci** 1998 Dec 1;54(1):13–21

Control of immune responses by gene immunization. Lee DJ, et al. **Ann Med** 1998 Oct;30(5):460–8 (73 ref.)

Effects of specific humoral immunity on DNA-adduct formation in Swiss mice treated with benzo[alpha]pyrene. Galati R, et al. **Anticancer Res** 1999 May–Jun; 19(3A):2101–4

Varicella: to vaccinate or not to vaccinate? Gershon A. **Arch Dis Child** 1998 Dec;79(6):470–1

Antigen-specific antibody responses in lupus patients following immunization [see comments] Battafarano DF, et al. **Arthritis Rheum** 1998 Oct;41(10):1828–34. Comment in: Arthritis Rheum 1999 Jun;42(6):1307–8.

Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Lamb DJ, et al. **Atherosclerosis** 1999 Mar; 143(1):105–13

Effect of long-term immunization against inhibin on sperm output in bulls. Bame JH, et al. **Biol Reprod** 1999 Jun; 60(6):1360–6

Potential contraceptive use of epididymal proteins: immunization of male rats with epididymal protein DE inhibits sperm fusion ability. Ellerman DA, et al. **Biol Reprod** 1998 Nov;59(5):1029–36

Infertility in female rabbits (Oryctolagus cuniculus) alloimmunized with the rabbit zona pellucida protein ZPB either as a purified recombinant protein or expressed by recombinant myxoma virus. Kerr PJ, et al. **Biol Reprod** 1999 Sep;61(3):606–13

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy. Zagury D, et al. **Biomed Pharmacother** 1999 Mar;53(2):90–2

Immunisation and counselling for Kosovar refugee children [news] Ciment J. **BMJ** 1999 May 15;318(7194):1310

A little bit of measles does you good. Even if measles is eradicated, immunisation may still be desirable in developing countries [editorial] Shann F. **BMJ** 1999 Jul 3;319(7201):4–5

Immunization by subcutaneous implants of polyester-polyurethane sponges coupled with antigen. Lima SL, et al. **Braz J Med Biol Res** 1999 Apr;32(4):443–7

Childhood immunization coverage in zone 3 of Dhaka City: the challenge of reaching impoverished households in urban Bangladesh. Perry H, et al. **Bull World Health Organ** 1998;76(6):565–73

Canada's International Immunization Initiative. Dafoe GH. **Can J Public Health** 1998 Nov–Dec;89(6):364 **(Eng, Fre)**

Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Yaari E, et al. **Chest** 1999 May;115(5):1254–8

Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Luo Z, et al. **Circulation** 1999 Apr 13;99(14):1776–9

Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis. Motin VL, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):356–63

Proteinases and sensitization: house mites and enzyme detergents [editorial; comment] Flindt ML. **Clin Exp Allergy** 1999 Feb;29(2):280–3. Comment on: Clin Exp Allergy 1998 May;28(5):530–3. Comment on: Clin Exp Allergy 1998 May;28(5):561–7.

On early sensitization to allergens and development of respiratory symptoms. Sherrill D, et al. **Clin Exp Allergy** 1999 Jul;29(7):905–11

Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes. Lundin BS, et al. **Clin Exp Immunol** 1999 Apr;116(1):181–7

Physicians may have to "sell" benefits of immunization to sceptical parents. Pinker S. **CMAJ** 1999 Sep 21; 161(6):737–8

Immunisation of preterm infants. Botham SJ, et al. **Commun Dis Intell** 1998 Oct 1;22(10):218–20

Need for vaccination against yellow fever. **Commun Dis Rep CDR Wkly** 1999 Aug 13;9(33):289, 292

Using semantic constraints to help verify the completeness of a computer-based clinical guideline for childhood immunization. Miller DW Jr, et al. **Comput Methods Programs Biomed** 1999 Mar;58(3):267–80

Structure-activity relationships in the murine local lymph node assay for skin sensitization: alpha,beta-diketones. Roberts DW, et al. **Contact Dermatitis** 1999 Jul;41(1):14–7

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367–73 (45 ref.)

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1998 Aug;10(4):453–8 (40 ref.)

Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Vaarala O, et al. **Diabetes** 1999 Jul;48(7):1389–94

Yellow fever vaccine [letter] Arya SC. **Emerg Infect Dis** 1999 May–Jun;5(3):487–9

Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Kita M, et al. **Endocrinology** 1999 Mar;140(3):1392–8

Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. De Melker HE, et al. **Epidemiol Infect** 1998 Dec; 121(3):637–43

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Saelens X, et al. **Eur J Biochem** 1999 Feb;260(1):166–75

The influence of tissue culture on corneal immunogenicity. Gabric N, et al. **Exp Eye Res** 1999 Mar;68(3):277–82

Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Rotman HL, et al. **Exp Parasitol** 1999 Jan;91(1):78–85

Kinetics of peroxidases in guinea pig bone marrow under immunostimulation. Keyhani E, et al. **FEBS Lett** 1999 Jun 11;452(3):233–6

Effect of controlled antigenic stimulation on lymphocyte subsets in pigs and pig fetuses. Reháková Z, et al. **Folia Microbiol (Praha)** 1998;43(5):513–6

Metastatic melanoma: transplenic immunostimulation--a new therapeutical alternative for an ever-challenging disease. Lygidakis NJ, et al. **Hepatogastroenterology** 1999 Jan–Feb; 46(25):148–56

Effect of Bacillus firmus on antibody formation after mucosal and parenteral immunization in mice. Prokesová L, et al. **Immunol Lett** 1998 Dec;64(2–3):161–6

TCR diversity in gammadeltaTCR+ hybridomas derived from mice given portal vein donor-specific pre-immunization and skin allografts. Sun Y, et al. **Immunol Lett** 1998 Dec;64(2–3):85–95

Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Shearer GM, et al. **Immunol Today** 1999 Feb;20(2):66–71 (49 ref.)

Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Böcher WO, et al. **Immunology** 1999 Apr;96(4):634–41

Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Kamath AT, et al. **Immunology** 1999 Apr; 96(4):511–6

CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge. Brown WC, et al. **Infect Immun** 1998 Nov;66(11):5406–13

Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. McDaniel LS, et al. **Infect Immun** 1998 Oct; 66(10):4748–54

Induced immunity against the mosquito Anopheles stephensi Liston (Diptera: Culicidae): effects on mosquito survival and fecundity. Almeida AP, et al. **Int J Parasitol** 1998 Nov; 28(11):1721–31

Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres. Cho NH, et al. **J Controlled Release** 1998 Apr 30;53(1–3):215–24

Concentrated bovine colostral whey proteins from Streptococcus mutans/Strep. sobrinus immunized cows inhibit the adherence of Strep. mutans and promote the aggregation of mutans streptococci. Loimaranta V, et al. **J Dairy Res** 1998 Nov;65(4):599–607

Efficacy of an Escherichia coli J5 bacterin administered to primigravid heifers. Hogan JS, et al. **J Dairy Sci** 1999 May; 82(5):939–43

Growth responses of coliform bacteria to purified immunoglobulin G from cows immunized with ferric enterobactin receptor FepA. Lin J, et al. **J Dairy Sci** 1999 Jan;82(1):86–92

Anti-idiotypic responses of lactating cows immunized with monoclonal antibodies against bovine somatotropin. Roberge S, et al. **J Dairy Sci** 1999 Aug;82(8):1707–15

Heteroclitic immunization induces tumor immunity. Dyall R, et al. **J Exp Med** 1998 Nov 2;188(9):1553–61

Universal rotavirus immunizations: should rotavirus vaccine be recommended for universal use? An opposing view. Ganiats TG. **J Fam Pract** 1999 Feb;48(2):147–8

Universal rotavirus immunizations: should rotavirus vaccine be recommended for universal use? An affirmative view. Zimmerman RK. **J Fam Pract** 1999 Feb;48(2):146–7

Time for changes in immunization: inactivated poliovirus vaccine and a family practice immunization book [editorial; comment] Zimmerman RK. **J Fam Pract** 1999 Aug; 48(8):588–9. Comment on: J Fam Pract 1999 Aug;48(8):594–600.

Influenza immunization among Medicare beneficiaries enrolled in a health maintenance organization: 1994. Florida Medical Quality Assurance, Inc. **J Fla Med Assoc** 1998 Apr;85(1):19–20

Encapsulated xenogeneic hepatocytes remain functional after peritoneal implantation despite immunization of the host. Wen L, et al. **J Hepatol** 1998 Dec;29(6):960–8

Antibody coating approach involving gamma globulins from non-immunized animal and second antibody antiserum. Petrou PS, et al. **J Immunoassay** 1998 Nov;19(4):271–93

Nickel allergy in mice: enhanced sensitization capacity of nickel at higher oxidation states. Artik S, et al. **J Immunol** 1999 Aug 1;163(3):1143–52

Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. Inaba M, et al. **J Immunol** 1999 Aug 1;163(3):1315–20

Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE, et al. **J Immunol** 1999 Jan 1;162(1):560–7

IMMUNIZATION

Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. Schmidt CS, et al. **J Immunol** 1999 Sep 1;163(5):2561-7

Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. Murphy TF, et al. **J Infect Dis** 1998 Dec;178(6):1667-75

Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. Baca-Estrada ME, et al. **J Interferon Cytokine Res** 1999 May;19(5):455-62

Induction of systemic and mucosal immune response in mice immunised with porins of Salmonella typhi. Singh M, et al. **J Med Microbiol** 1999 Jan;48(1):79-88

Immunizations in pregnancy. A public health perspective. Hackley BK. **J Nurse Midwifery** 1999 Mar-Apr; 44(2):106-17 (37 ref.)

Workplace influenza immunization update [letter] Burris J, et al. **J Occup Environ Med** 1999 Jun;41(6):415

Should we be doing more to prevent Group C meningococcal infection in school age children? How can we decide? Round A, et al. **J Public Health Med** 1999 Mar;21(1):8-13

Commentary on "Active immunization against poliomyelitis" [comment] Katz SL. **J Urban Health** 1998 Sep;75(3):600. Comment on: J Urban Health 1998 Sep;75(3):584-99.

Pediatricians alerted to five new vaccines [news] Jefferson T. **JAMA** 1999 Jun 2;281(21):1973-5

Intraduodenal inoculation of adult rabbits for evaluating the immunogenicity of genetically attenuated Vibrio cholerae strains. García Imia L, et al. **Lab Anim Sci** 1998 Oct; 48(5):538-41

Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy. WHO/CHD Immunisation-Linked Vitamin A Supplementation Study Group [published erratum appears in Lancet 1999 Jan 9;353(9147):154] **Lancet** 1998 Oct 17; 352(9136):1257-63

Control of hypercalcaemia of parathyroid carcinoma by immunisation [see comments] Bradwell AR, et al. **Lancet** 1999 Jan 30;353(9150):370-3. Comment in: Lancet 1999 Jan 30;353(9150):340. Comment in: Lancet 1999 Apr 3;353(9159):1188-9.

Delivering prevention: the role of public programs in delivering care to high-risk populations. Roos LL, et al. **Med Care** 1999 Jun;37(6 Suppl):JS264-78

Travel immunizations. Jong EC. **Med Clin North Am** 1999 Jul;83(4):903-22, vi (36 ref.)

Advice for travelers. **Med Lett Drugs Ther** 1999 Apr 23; 41(1051):39-42

Partial protection of mice against Trypanosoma cruzi after immunizing with the TcY 72 antigenic preparation. Gomes YM, et al. **Mem Inst Oswaldo Cruz** 1999 Mar-Apr; 94(2):167-72

Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Christodoulides M, et al. **Microbiology** 1998 Nov;144 (Pt 11):3027-37

The molecular basis of virus crossreactivity and neutralisation after immunisation with optimised chimeric peptides mimicking a putative helical epitope of the measles virus hemagglutinin protein. El Kasmi KC, et al. **Mol Immunol** 1998 Oct;35(14-15):905-18

Therapeutic antibodies elicited by immunization against TNF-alpha. Dalum I, et al. **Nat Biotechnol** 1999 Jul; 17(7):666-9

Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Wang Y, et al. **Nat Med** 1999 Sep;5(9):1004-9

Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Roodnat JI, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):353-9

Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Vella JP, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2027-32

Comparison of indirect fluorescent antibody test and enzyme linked immunosorbent assay in the detection of exposure of cattle to Theileria parva in Kenya. Muraguri GR, et al. **Onderstepoort J Vet Res** 1999 Jun;66(2):119-22

Egg-hatching inhibition in mice immunized with recombinant Schistosoma bovis 28 kDa glutathione S-transferase. Da Costa AV, et al. **Parasite Immunol** 1999 Jul;21(7):341-50

Plasmodium berghei development in irradiated sporozoite-immunized C57BL6 mice. Zechini B, et al. **Parasitology** 1999 Apr;118 (Pt 4):335-8

Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Wasserman RL, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):157-63 (37 ref.)

Duration of immunity to diphtheria and tetanus in young kidney transplant patients. Pedrazzi C, et al. **Pediatr Transplant** 1999 May;3(2):109-14

Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). **Pediatrics** 1999 May;103(5 Pt 1):1064-77 (80 ref.)

Committee on Native American Child Health and Committee on Infectious Diseases. Immunizations for Native American children. American Academy of Pediatrics. **Pediatrics** 1999 Sep;104(3 Pt 1):564-7

Internationally adopted children--immunization status [letter] Miller LC. **Pediatrics** 1999 May;103(5 Pt 1):1078

Influenza immunization of schoolchildren: can we interrupt community epidemics? Poland GA, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1280-2

Pneumococcal vaccine: an update. Wadwa RP, et al. **Pediatrics** 1999 May;103(5 Pt 1):1035-7

Evaluation of the efficacy of intraperitoneal immunization in reducing Salmonella typhimurium infection in chickens. Muir WI, et al. **Poult Sci** 1998 Dec;77(12):1874-83

A mother who opposes immunisation. Gerada C, et al. **Practitioner** 1998 Apr;242(1585):243-5, 247, 250 passim

A message from Preventive Medicine and your physician: Adults need shots, too! **Prev Med** 1998 Nov-Dec;27(6):773

Issues in accommodating national changes and local variation in a computer-based guideline for childhood immunization and in related knowledge maintenance tools. Miller PL, et al. **Proc AMIA Symp** 1998;:563-7

Immunization of rats reduces nicotine distribution to brain. Hieda Y, et al. **Psychopharmacology (Berl)** 1999 Apr; 143(2):150-7

Structured reactions of serum IgM repertoires to immunization are dependent on major histocompatibility complex genes. Fesel C, et al. **Scand J Immunol** 1999 Mar; 49(3):251-7

An immunization against Alzheimer's? [news] Barinaga M. **Science** 1999 Jul 9;285(5425):175, 177

The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. Miura S, et al. **Transplant Proc** 1999 Aug;31(5):1973-5

Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Onodera K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):876-7

Immunization with Escherichia coli-produced soluble MHC class I proteins induces accelerated rejection or prolonged survival of rat cardiac allografts. Perez J, et al. **Transplant Proc** 1999 May;31(3):1560

HLA antibodies present in the sera of sensitized patients awaiting renal transplant are also reactive to swine leukocyte antigens. Naziruddin B, et al. **Transplantation** 1998 Oct 27;66(8):1074-80

Proceedings of the 1st World Congress on Vaccines and Immunization. Istanbul, Turkey, April 26-30, 1998. **Vaccine** 1999 Mar 26;17(13-14):vii, 1583-811

Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Arulanandam BP, et al. **Vaccine** 1999 Jan 21;17(3):252-60

CHILD profile: an immunization registry and more--a new approach to tracking and surveillance. Children's Health, Immunization, Linkages and Development. Baker BJ. **Vaccine** 1998 Nov;16(18):v-vi

Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Nam JH, et al. **Vaccine** 1999 Jan 21;17(3):261-8

DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection. Ruitenberg KM, et al. **Vaccine** 1999 Jan 21;17(3):237-44

Induction of immune responses in pigs following oral administration of purified F4 fimbriae. Van den Broeck W, et al. **Vaccine** 1999 Apr 9;17(15-16):2020-9

Poliomyelitis eradication. Dowdle WR, et al. **Virus Res** 1999 Aug;62(2):185-92 (27 ref.)

Three cases of platelet alloimmunisation associated with the presence of a novel platelet-specific antibody. Masters R, et al. **Vox Sang** 1998;75(3):242-6

[The role of vaccination in the prevention of communicable diseases] Budai J. **Orv Hetil** 1998 Nov 15;139(46):2755-9 (Eng. Abstr.) **(Hun)**

[An attempt to block histamine release from basophils granulocytes with antibodies obtained as a result of long-term immunization] Szymaniak L. **Ann Acad Med Stetin** 1998;44:45-64 (Eng. Abstr.) **(Pol)**

[The impact of immunization against measles on epidemiology of measles in Poland] Janaszek W. **Przegl Epidemiol** 1998;52(4):413-25 (Eng. Abstr.) **(Pol)**

[International conference "Vaccines and Immunization"] Bektimirov TA, et al. **Vopr Virusol** 1999 Mar-Apr; 44(2):95-6 **(Rus)**

[Immunostimulating action of lactobacteria used as the basis of probiotic preparations] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):107-12 (57 ref.) **(Rus)**

[Immunoglobulins of cows of different ages and of their calves] Kravtsiv IuR. **Ukr Biokhim Zh** 1998 Jan-Feb; 70(1):94-8 (Eng. Abstr.) **(Ukr)**

ADVERSE EFFECTS

Randomised controlled trial of sucrose by mouth for the relief of infant crying after immunisation [letter; comment] Abu-Arafeh I, et al. **Arch Dis Child** 1998 Nov;79(5):465-6 . Comment on: Arch Dis Child 1998 May;78(5):453-6.

Randomised controlled trial of sucrose by mouth for the relief of infant crying after immunisation [letter; comment] Choonara I, et al. **Arch Dis Child** 1998 Nov;79(5):466. Comment on: Arch Dis Child 1998 May;78(5):453-6.

Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Goto T, et al. **Infect Immun** 1999 May;67(5):2531-9

Autoimmune disease induced by dendritic cell immunization against leukemia. Roskrow MA, et al. **Leuk Res** 1999 Jun; 23(6):549-57

Infection, immunisation and atherosclerosis: is there a link? Lamb DJ, et al. **Vaccine** 1999 Feb 12;17(6):559-64 (54 ref.)

[Vaccinations and systemic diseases. Vaccinations and immunosuppression] Bouchaud O, et al. **Ann Med Interne (Paris)** 1998 Oct;149(6):351-60 (56 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

Public health in Celtic Britain [letter] Hunter D. **Lancet** 1999 Mar 20;353(9157):1020

INSTRUMENTATION

Use of SoloShot autodestruct syringes compared with disposable syringes, in a national immunization campaign in Indonesia. Nelson CM, et al. **Bull World Health Organ** 1999;77(1):29-33

Safety of injections. WHO-UNICEF policy statement for mass immunization campaigns. **Wkly Epidemiol Rec** 1998 Dec 11;73(50):394-6 **(Eng, Fre)**

LEGISLATION & JURISPRUDENCE

Immunizations for children are covered [news] **J Okla State Med Assoc** 1997 Nov-Dec;90(8):458

METHODS

Adult immunization: principles and practice. Gellin BG, et al. **Adv Intern Med** 1999;44:327-52 (17 ref.)

Cholera toxin B subunit as an immunomodulator for mucosal vaccine delivery. Russell MW, et al. **Adv Vet Med** 1999; 41:105-14 (31 ref.)

Binding reaction of aflatoxin B1 with immunoglobulin G against aflatoxin B1-bovine serum albumin complex. Odunola OA, et al. **Afr J Med Med Sci** 1998 Mar-Jun; 27(1-2):1-4

Liposome entrapped allergen reduces plasma histamine in sensitized mice. Arora N, et al. **Asian Pac J Allergy Immunol** 1998 Jun-Sep;16(2-3):87-91

Neonatal jaundice, animal-based injuries, and immunizations. Davis IJ, et al. **Curr Opin Pediatr** 1999 Aug;11(4):367-73 (45 ref.)

Immunization through dermal delivery of protein-encoding DNA: a role for migratory dendritic cells. Bouloc A, et al. **Eur J Immunol** 1999 Feb;29(2):446-54

Gene gun delivered DNA-based immunizations mediate rapid production of murine monoclonal antibodies to the Flt-3 receptor. Kilpatrick KE, et al. **Hybridoma** 1998 Dec; 17(6):569-76

Differential production of monoclonal antibodies to carbohydrate moiety or peptides moiety of glycoproteins by different routes of immunization. Kimura A, et al. **Hybridoma** 1998 Jun;17(3):245-50

Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization. Mulero-Marchese RD, et al. **Immunogenetics** 1999 Oct;49(11-12):973-80

Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Yamamoto N, et al. **Immunol Cell Biol** 1998 Jun;76(3):237-44

Impact of oral immunization with Acanthamoeba antigens on parasite adhesion and corneal infection. Leher H, et al. **Invest Ophthalmol Vis Sci** 1998 Nov;39(12):2337-43

Idiotypic induction of autoimmunity. Krause I, et al. **J Biol Regul Homeost Agents** 1998 Jul-Sep;12(3):49-52 (46 ref.)

Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Shimizu Y, et al. **J Immunol** 1998 Nov 1;161(9):4520-9

Modulating dendritic cells to optimize mucosal immunization protocols. Williamson E, et al. **J Immunol** 1999 Oct 1; 163(7):3668-75

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. Durrani Z, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):93-103

The effect of route of immunization on mucosal immunity and protection. Lehner T, et al. **J Infect Dis** 1999 May; 179 Suppl 3:S489-92 (19 ref.)

A quantitative comparison of induction and challenge concentrations inducing a 50% positive response in three skin sensitization tests; the guinea pig maximization test, adjuvant and patch test and Buehler test. Nakamura Y, et al. **J Toxicol Sci** 1999 May;24(2):123-31

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury [see comments] Sawa T, et al. **Nat Med** 1999 Apr; 5(4):392-8. Comment in: Nat Med 1999 Apr;5(4):378-9.

Active immunoneutralization of somatostatin in the sheep: effects on gastrointestinal somatostatin expression, storage and secretion. Shulkes A, et al. **Regul Pept** 1999 Jun 30; 82(1-3):59-64

Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge. Heritage PL, et

al. **Vaccine** 1998 Dec;16(20):2010–7

[The excretion pattern and protective capacity in rabbits orally immunized with attenuated strains of Vibrio cholerae O1 biotype El Tor] García Sánchez HM, et al. **Rev Cubana Med Trop** 1998;50(2):115–9 (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Immunization refusal and physician responsibility. Jessee RA. **Arch Pediatr Adolesc Med** 1999 Mar;153(3):312–3

Immunization against monoamine oxidase slows extinction of a conditioned active escape reflex in rats. Buzinova EV, et al. **Neurosci Behav Physiol** 1998 Sep–Oct;28(5):490–2

STANDARDS

APIC position paper: immunization. Association for Professionals in Infection and Epidemiology, Inc. DeCastro MG, et al. **Am J Infect Control** 1999 Feb;27(1):52–3

It's wise to immunize, regardless of what the Web says. Sibbald B. **CMAJ** 1999 Sep 21;161(6):736

Immunization of peacekeeping forces [letter] Steffen R. **Emerg Infect Dis** 1999 May–Jun;5(3):485–6

Comparisons of immunisation accessibility between non–US born and US–born children in New York City. Sun WY, et al. **Public Health** 1998 Nov;112(6):405–8

STATISTICS & NUMERICAL DATA

Parental knowledge, attitudes, and demand regarding a vaccine to prevent varicella. Freeman VA, et al. **Am J Prev Med** 1999 Aug;17(2):153–5

The role of state policies and programs in buffering the effects of poverty on children's immunization receipt. Mayer ML, et al. **Am J Public Health** 1999 Feb;89(2):164–70

Parental attitudes and childhood immunization [letter] Strobino D, et al. **Am J Public Health** 1999 Sep; 89(9):1442–3

Differences in prevalence of allergic sensitization in urban and rural school children. Crimi P, et al. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):252–6

Immunization registries in the United States: implications for the practice of public health in a changing health care system. Wood D, et al. **Annu Rev Public Health** 1999; 20:231–55 (81 ref.)

Impact of community volunteers on immunization rates of children younger than 2 years. Barnes K, et al. **Arch Pediatr Adolesc Med** 1999 May;153(5):518–24

Impact of North Carolina's universal vaccine purchase program by children's insurance status. Freed GL, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):748–54

Measuring immunisation coverage in Australia. A review of the Australian Childhood Immunisation Register. Hull BP, et al. **Aust Fam Physician** 1999 Jan;28(1):55–60

Tetanus immunization status and predictors of immunity in older family practice outpatients. Costa AJ, et al. **J Am Board Fam Pract** 1998 Jul–Aug;11(4):315–7

Child immunisation in Ghana: the effects of family, location and social disparity. Matthews Z, et al. **J Biosoc Sci** 1997 Jul;29(3):327–43

Immunization practices and beliefs of physicians in suburban Cook County, Illinois. Smith SW, et al. **J Community Health** 1999 Feb;24(1):1–11

Design and implementation of a multi–institution immunization registry. Jenders RA, et al. **Medinfo** 1998;9 Pt 1:45–9

An immunisation success story [letter] Pert H. **N Z Med J** 1999 Aug 27;112(1094):327

A statewide survey of immunization rates in Minnesota school age children: implications for targeted assessment and prevention strategies. Ehresmann KR, et al. **Pediatr Infect Dis J** 1998 Aug;17(8):711–6

When acculturation hurts: the case of immunization. Prislin R, et al. **Soc Sci Med** 1998 Dec;47(12):1947–56

TRENDS

Recent trends in vaccine development and immunization. Jaffe CL. **Clin Dermatol** 1999 May–Jun;17(3):339–44 (54 ref.)

MMR vaccine coverage falls in the United Kingdom. **Commun Dis Rep CDR Wkly** 1999 Jan 29;9(5):37

Immunisation of patients with systemic lupus erythematosus: the current state of play. Ioannou Y, et al. **Lupus** 1999; 8(7):497–501 (51 ref.)

UTILIZATION

Managing the shortage of intravenous immune globulin [news] Decker EL, et al. **Am J Health Syst Pharm** 1998 Oct 15;55(20):2090, 2093

Combining state administrative databases and provider records to assess the quality of care for children enrolled in Medicaid. Cotter JJ, et al. **Am J Med Qual** 1999 Mar–Apr;14(2):98–104

Immunization practices [letter] Bradford BJ. **Am J Public Health** 1999 Oct;89(10):1594–5

The impact of physician bonuses, enhanced fees, and feedback on childhood immunization coverage rates. Fairbrother G, et al. **Am J Public Health** 1999 Feb; 89(2):171–5

Immunization status and sociodemographic characteristics: the mediating role of beliefs, attitudes, and perceived control. Prislin R, et al. **Am J Public Health** 1998 Dec; 88(12):1821–6

Barriers to immunisation in general practice. Bailey HD, et al. **Aust N Z J Public Health** 1999 Feb;23(1):6–10

Immunisation uptake, services required and government incentives for users of formal day care. Bond L, et al. **Aust N Z J Public Health** 1999 Aug;23(4):368–76

Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996 [see comments] Lamagni TL, et al. **Commun Dis Public Health** 1999 Sep;2(3):174–7. Comment in: Commun Dis Public Health 1999 Sep;2(3):154–9.

MMR vaccine coverage shows signs of recovery. **Commun Dis Rep CDR Wkly** 1999 Sep 24;9(39):345

It'll only hurt a second? Microeconomic determinants of who gets flu shots. Mullahy J. **Health Econ** 1999 Feb;8(1):9–24

Pretesting Spanish–language educational radio messages to promote timely and complete infant immunization in California. de Nuncio ML, et al. **J Community Health** 1999 Aug;24(4):269–84

Creating alternative immunization clinics to maintain and improve community immunization rates. Horner SD, et al. **J Community Health Nurs** 1999;16(2):121–32

A population–based survey of immunization coverage in children aged 2 years and younger in New South Wales. Sullivan EA, et al. **J Paediatr Child Health** 1998 Aug; 34(4):342–5

Assessing immunization performance of private practitioners in Maine: impact of the assessment, feedback, incentives, and exchange strategy. Massoudi MS, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1218–23

A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Rodewald LE, et al. **Pediatrics** 1999 Jan;103(1):31–8

Predictors of childhood immunization completion in a rural population. Gore P, et al. **Soc Sci Med** 1999 Apr; 48(8):1011–27

Perceived barriers to childhood immunization: a physician and parent survey in a southeastern urban/rural community. Nace NB, et al. **Tenn Med** 1999 Jul;92(7):265–8

Action on low immunization uptake. Azubuike MC, et al. **World Health Forum** 1998;19(4):362–4

VETERINARY

Forty years of canine vaccination. Appel MJ. **Adv Vet Med** 1999;41:309–24 (95 ref.)

DNA immunization: present and future. Babiuk LA, et al. **Adv Vet Med** 1999;41:163–79 (55 ref.)

An epidemiologic approach to evaluating the importance of immunoprophylaxis. Morley PS. **Adv Vet Med** 1999; 41:415–7

Evaluation of protective immunity in gilts inoculated with the NADC–8 isolate of porcine reproductive and respiratory syndrome virus (PRRSV) and challenge–exposed with an antigenically distinct PRRSV isolate. Lager KM, et al. **Am J Vet Res** 1999 Aug; 60(8):1022–7

Safety and efficacy of vaccination of pregnant gilts against porcine reproductive and respiratory syndrome. Mengeling WL, et al. **Am J Vet Res** 1999 Jul;60(7):796–801

Biosafety and antibody responses of adult bison bulls after vaccination with Brucella abortus strain RB51. Olsen SC, et al. **Am J Vet Res** 1999 Jul;60(7):905–8

Effect of immunization against melatonin on prolactin concentrations and the timing of reproductive transitions in ewes. O'Callaghan D, et al. **Domest Anim Endocrinol** 1999 May;16(4):207–17

Immunization of cows with ferric enterobactin receptor from coliform bacteria. Lin J, et al. **J Dairy Sci** 1998 Aug; 81(8):2151–8

Peptide immunization restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes in cynomolgus monkeys. Mavoungou E, et al. **J Med Primatol** 1998 Aug;27(4):202–9

Heligmosomoides polygyrus and Trypanosoma congolense infections in mice: effect of immunisation by abbreviated larval infection. Fakae BB, et al. **Vet Parasitol** 1999 Aug 16;85(1):13–23

Antibody response in goats vaccinated with liposome–adjuvanted Clostridium perfringens type D epsilon toxoid. Uzal FA, et al. **Vet Res Commun** 1999 May; 23(3):143–50

IMMUNIZATION, ACTIVE see **VACCINATION**

IMMUNIZATION, BOOSTER see **IMMUNIZATION, SECONDARY**

IMMUNIZATION, PASSIVE

Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian–human immunodeficiency virus failed to protect against mucosally inoculated virus. Joag SV, et al. **AIDS Res Hum Retroviruses** 1999 Mar 1;15(4):391–4

Active and passive immunization against HIV type 1 infection in chimpanzees. Murthy KK, et al. **AIDS Res Hum Retroviruses** 1998 Oct;14 Suppl 3:S271–6 (36 ref.)

The role of immunoglobulin therapy in allergic diseases. Rabinovitch N, et al. **Allergy** 1999 Jul;54(7):662–8 (28 ref.)

Immune globulin and vaccine therapy to prevent hepatitis A infection. Levy MJ, et al. **Am J Med** 1998 Nov; 105(5):416–23 (97 ref.)

Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction. Nigro G, et al. **Am J Obstet Gynecol** 1999 May;180(5):1222–6

Passive transfer of growth–inhibitory antibodies raised against yeast–expressed recombinant Plasmodium falciparum merozoite surface protein–1(19). Gozalo A, et al. **Am J Trop Med Hyg** 1998 Dec;59(6):991–7

Effect of passive immunization with buffalo follicular fluid antisera on ovarian activity in guinea pigs. Kumar H, et al. **Anim Reprod Sci** 1998 Sep 11;52(3):245–51

Update on emerging infections from the Centers for Disease Control and Prevention. Update rabies postexposure prophylaxis guidelines. **Ann Emerg Med** 1999 May; 33(5):590–7

Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. King SM. **Antiviral Res** 1999 Jan;40(3):115–37 (150 ref.)

Bacterin–induced protection of turkeys against fowl cholera following infection with Bordetella avium. Rimler RB, et al. **Avian Dis** 1998 Oct–Dec;42(4):752–6

Anti–B–cell monoclonal antibody treatment of severe posttransplant B–lymphoproliferative disorder: prognostic factors and long–term outcome. Benkerrou M, et al. **Blood** 1998 Nov 1;92(9):3137–47

Rituxan in the treatment of cold agglutinin disease [letter] Lee EJ, et al. **Blood** 1998 Nov 1;92(9):3490–1

Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti–Candida antibodies in bone marrow transplant recipients. Tollemar J, et al. **Bone Marrow Transplant** 1999 Feb;23(3):283–90

Anti–gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Jacobs E, et al. **Br J Cancer** 1999 May;80(3–4):352–9

An EGP–2/Ep–CAM–expressing transgenic rat model to evaluate antibody–mediated immunotherapy. McLaughlin PM, et al. **Cancer Immunol Immunother** 1999 Sep; 48(6):303–11

Immunity to p53 induced by an idiotypic network of anti–p53 antibodies: generation of sequence–specific anti–DNA antibodies and protection from tumor metastasis. Erez–Alon N, et al. **Cancer Res** 1998 Dec 1;58(23):5447–52

Cerebrospinal fluid filtration and immunoglobulins in multifocal motor neuropathy. Finsterer J, et al. **Clin Neuropathol** 1999 Jan–Feb;18(1):31–6

The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. Green M, et al. **FEMS Immunol Med Microbiol** 1999 Feb;23(2):107–13

Passive protective effect of egg–yolk antibodies against enterotoxigenic Escherichia coli K88+ infection in neonatal and early–weaned piglets. Marquardt RR, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):283–8

Liver graft infection by HBV S–gene mutants in transplant patients receiving long–term HBIg prophylaxis. Santantonio T, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1848–54

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Tillmann HL, et al. **Hepatology** 1999 Jul;30(1):244–56

An OspC–specific monoclonal antibody passively protects mice from tick–transmitted infection by Borrelia burgdorferi B31. Mbow ML, et al. **Infect Immun** 1999 Oct; 67(10):5470–2

Inhibition of neutrophil–mediated acute inflammation injury by an antibody against interleukin–8 (IL–8) Mukaida N, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S151–7

Therapeutic effect of an anti–Fas ligand mAb on lethal graft–versus–host disease. Miwa K, et al. **Int Immunol** 1999 Jun;11(6):925–31

Gamma–globulin inhibits tumor spread in mice. Shoenfeld Y, et al. **Int Immunol** 1999 Aug;11(8):1247–52

The effects of neutrophil depletion on a completely noninvasive model of acute pancreatitis–associated lung injury. Bhatia M, et al. **Int J Pancreatol** 1998 Oct; 24(2):77–83

A nontoxic Pseudomonas exotoxin A induces active immunity and passive protective antibody against Pseudomonas exotoxin A intoxication. Chen TY, et al. **J Biomed Sci** 1999 Sep–Oct;6(5):357–63

Role of anti–Trichinella spiralis antibodies and interferon–gamma in the protection against the enteral phase of experimental trichinosis. Boulos LM, et al. **J Egypt Soc Parasitol** 1998 Dec;28(3):609–20

Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections. Montesano MA, et al. **J Exp Med** 1999 Feb 15;189(4):637–45

Antigenic characterization of pre– and post–liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. Carman WF, et al. **J Hepatol** 1999 Aug;31(2):195–201

The sequential occurrence of viral mutations in a liver transplant recipient re–infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non–response, followed by lamivudine resistance resulting in graft loss. de Man RA, et al. **J Hepatol** 1998 Oct;29(4):669–75

Neonatal exposure to idiotype induces Schistosoma mansoni egg antigen–specific cellular and humoral immune responses. Montesano MA, et al. **J Immunol** 1999 Jul 15;

163(2):898–905

Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. DesJardin JA, et al. **J Infect Dis** 1998 Dec; 178(6):1783–6

Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. Fisher RG, et al. **J Infect Dis** 1999 Sep;180(3):708–13

Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. Johnson SE, et al. **J Infect Dis** 1999 Jul;180(1):133–40

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. Kudoyarova-Zubavichene NM, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S218–23

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. Mupapa K, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S18–23

Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. Yang XD, et al. **J Leukoc Biol** 1999 Sep; 66(3):401–10

Effect of passive immunotherapy on murine gut-derived sepsis caused by Pseudomonas aeruginosa. Matsumoto T, et al. **J Med Microbiol** 1999 Aug;48(8):765–70

Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. Blaes F, et al. **J Neurol** 1999 Apr;246(4):299–303

Inclusion body myositis: immune globulins improve muscle strength, but not abnormal postures [letter] Johannes S, et al. **J Neurol** 1998 Dec;245(12):816–8

Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pradhan S, et al. **J Neurol Sci** 1999 May 1;165(1):56–61

Intraperitoneal administration of cytomegalovirus-hyperimmunoglobulin to the cytomegalovirus-infected fetus. Negishi H, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 1):466–9

Efficacy of serotherapy in scorpion sting: a matched-pair study. Belghith M, et al. **J Toxicol Clin Toxicol** 1999; 37(1):51–7

Serotherapy in scorpion envenomation: a randomised controlled trial. Abroug F, et al. **Lancet** 1999 Sep 11; 354(9182):906–9

Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. Van Zaanen HC, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):551–8

Management of posttransplantation viral hepatitis--hepatitis B. Dickson RC. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S73–8 (40 ref.)

Infliximab (Remicade) for Crohn's disease. **Med Lett Drugs Ther** 1999 Feb 26;41(1047):19–20

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Pegram M, et al. **Oncogene** 1999 Apr 1; 18(13):2241–51

Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Sato N, et al. **Pediatr Int** 1999 Feb;41(1):1–7

Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Menard V, et al. **Pharm Res** 1999 Jul;16(7):1059–66

Animal models of antiphospholipid syndrome. Tincani A, et al. **Rev Rhum Engl Ed** 1998 Nov;65(11):614–8 (42 ref.)

HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Golling M, et al. **Transplant Proc** 1998 Nov;30(7):3316–7

Developing strategies for prevention and treatment of recurrent HBV in liver transplantation. Nery JR, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):485–6

Passive transfer of anti-donor antibodies in a rat lung transplant model. Sano Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):198–9

Down regulation of in vivo and in vitro T cell responses post cytomegalovirus immune globulin intravenous (human) administration in sensitized renal transplant candidates. SivaSai KS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1378–81

Induction of resistance against Schistosoma mansoni infection by passive transfer of an IgG2a monoclonal antibody. Attallah AM, et al. **Vaccine** 1999 May 4;17(18):2306–10

Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization. Chiba N, et al. **Vaccine** 1999 Mar 17;17(11-12):1532–9

Hyperimmune bovine colostrum treatment of moribund Leopard geckos (Eublepharis macularius) infected with Cryptosporidium sp. Graczyk TK, et al. **Vet Res** 1999 Jul-Aug;30(4):377–82

Novel diagnostic and therapeutic strategies with genetically engineered human antibodies. Ouwehand WH, et al. **Vox Sang** 1998;74 Suppl 2:223–32 (53 ref.)

[Pancytopenia in chronic parvovirus B 19 infection, cured by polyvalent immunoglobulins (letter)] Andres E, et al. **Ann Med Interne (Paris)** 1998 Sep;149(5):313–4 **(Fre)**

[Intracellular antibodies: a new therapeutic concept for virus infections and neoplasms] zu Putlitz J, et al. **Dtsch Med Wochenschr** 1999 Mar 26;124(12):357–60 (0 ref.) **(Ger)**

[Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins] Enk AH, et al. **Hautarzt** 1998 Oct;49(10):774–6 (Eng. Abstr.) **(Ger)**

[Immunoglobulin therapy in Gilles de la Tourette syndrome] Müller N, et al. **Nervenarzt** 1997 Nov;68(11):914–6 (Eng. Abstr.) **(Ger)**

[Intravenous immunoglobulins (IVIG) in treatment of an antiphospholipid syndrome in pregnancy] Heilmann L, et al. **Z Geburtshilfe Neonatol** 1998 Jul-Aug;202(4):164–7 (Eng. Abstr.) **(Ger)**

[Anti-Trichomonas activity of metronidazole in the presence of immunobiological preparations] Rubalskii OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):67–70 (Eng. Abstr.) **(Rus)**

[Hepatitis C virus infection among the health personnel and prophylaxis with human immunoglobulin (letter)] Echevarria JM, et al. **Med Clin (Barc)** 1998 Oct 10; 111(11):438–9 **(Spa)**

ADVERSE EFFECTS

Adverse effects of intravenous immunoglobulin therapy. Nydegger UE, et al. **Drug Saf** 1999 Sep;21(3):171–85 (74 ref.)

Hemiplegia as a complication of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin [letter] Tsiouris J, et al. **J Pediatr** 1998 Nov;133(5):717

CONTRAINDICATIONS

[Thiomersal in gammaglobulin for pregnant travellers may not be safe for the fetus. National Coordination Center for Travel Advisory] Schilthuis HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1622 (Eng. Abstr.) **(Dut)**

ECONOMICS

Companies cooperate in emergency supply program for IGIV [news] Landis NT. **Am J Health Syst Pharm** 1999 Apr 1;56(7):599

HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Golling M, et al. **Transplant Proc** 1998 Nov;30(7):3316–7

HISTORY

Doctor Albert Calmette 1863–1933: founder of antivenomous serotherapy and of antituberculous BCG vaccination. Hawgood BJ. **Toxicon** 1999 Sep;37(9):1241–58

INSTRUMENTATION

Long-term use of immunoglobulin infusion device [letter] Webb DB, et al. **Lancet** 1999 Aug 28;354(9180):775

METHODS

Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Zeitlin L, et al. **Emerg Infect Dis** 1999 Jan-Feb;5(1):54–64 (127 ref.)

Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Zhong W, et al. **Eur J Immunol** 1999 Mar;29(3):946–57

Selection of hepatitis B surface "escape" mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Shields PL, et al. **Gut** 1999 Aug;45(2):306–9

Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy. Wild MK, et al. **J Immunol** 1999 Aug 15; 163(4):2064–72

Effects of anti-IgE in asthmatic subjects. Frew AJ. **Thorax** 1998 Aug;53 Suppl 2:S52–7 (44 ref.)

Toxicity and immunogenicity of Crotalus durissus terrificus venom treated with different doses of gamma rays. Clissa PB, et al. **Toxicon** 1999 Aug;37(8):1131–41

Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. McCluskie MJ, et al. **Viral Immunol** 1998;11(4):245–52

VETERINARY

Partitioning the mortality risk associated with inadequate passive transfer of colostral immunoglobulins in dairy calves. Tyler JW, et al. **J Vet Intern Med** 1999 Jul-Aug; 13(4):335–7

Prediction of serum IgG1 concentration in beef calves based on age and serum gamma-glutamyl-transferase activity. Wilson LK, et al. **J Vet Intern Med** 1999 Mar-Apr; 13(2):123–5

IMMUNIZATION PROGRAMS

Public health in managed care: a randomized controlled trial of the effectiveness of postcard reminders. Clayton AE, et al. **Am J Public Health** 1999 Aug;89(8):1235–7

Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Tarr PE, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):163–70

Epidemics of aseptic meningitis due to enteroviruses following national immunization days in Bahrain. Khalfan S, et al. **Ann Trop Paediatr** 1998 Jun;18(2):101–9

Pertussis is increasing in unimmunized infants: is a change in policy needed? Ranganathan S, et al. **Arch Dis Child** 1999 Mar;80(3):297–9

Impact of North Carolina's universal vaccine purchase program by children's insurance status. Freed GL, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):748–54

Australia's contribution to global polio eradication initiatives. D'Souza RM, et al. **Aust N Z J Public Health** 1999 Jun; 23(3):289–94

Rehabilitation of the expanded programme on immunization in Sudan following a poliomyelitis outbreak. ElZein HA, et al. **Bull World Health Organ** 1998;76(4):335–41

Measles: effect of a two-dose vaccination programme in Catalonia, Spain. Godoy P, et al. **Bull World Health Organ** 1999;77(2):132–7

Awareness about a national immunization day programme in the Sunsari district of Nepal. Jha N, et al. **Bull World Health Organ** 1999;77(7):602–6

Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Sutanto A, et al. **Bull World Health Organ** 1999; 77(2):119–26

Are state immunization programs effective? Implications for the children's immunization initiative. Kauf TL. **Clin Ther** 1998 Jul-Aug;20(4):806–19

Improving the uptake of selective neonatal BCG immunisation. Gill J, et al. **Commun Dis Public Health** 1998 Dec;1(4):281–2

Vaccination programme for group C meningococcal infection is launched. **Commun Dis Rep CDR Wkly** 1999 Jul 23;9(30):261, 264

European Forum on Immunization: report of Second General Meeting, Munich, 2–3 June 1997. FitzSimons DW, et al. **Eur J Pediatr** 1999 May;158(5):359–61

Childhood immunisation in the European Union. Confederation of European Specialists in Paediatrics (CESP). Helwig H, et al. **Eur J Pediatr** 1998 Aug; 157(8):676–80

AFP surveillance--let it not be "targetoma". John TJ. **Indian Pediatr** 1998 Dec;35(12):1240–3

Influenza vaccination in long-term-care facilities: structuring programs for success. McArthur MA, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):499–503

Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme. Godoy P, et al. **Int J Epidemiol** 1999 Jun;28(3):558–62

Thirty year trend (1967–1996) in prevalence of poliomyelitis and vaccine coverage in Ballabgarh, Haryana, India. Anand K, et al. **J Epidemiol Community Health** 1998 Dec; 52(12):823–5

Perception and practice regarding pulse polio immunisation in an urban community of Calcutta. Sengupta B, et al. **J Indian Med Assoc** 1998 Aug;96(8):247–8

To reintroduce school BCG or abolish it – the dilemma for the newly formed health authorities [letter] Mukerjee AK, et al. **J Public Health Med** 1998 Dec;20(4):486–7

Measles immunization: early two-doses policy experience. al-Mazrou YY, et al. **J Trop Pediatr** 1999 Apr;45(2):98–104

Epidemiologic consequences of moderate coverage levels of measles vaccine in a district headquarter town (Alwar) in India, 1996. Singh J, et al. **J Trop Pediatr** 1998 Dec; 44(6):369–71

From the Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication--West Africa, 1997-September 1998. **JAMA** 1998 Dec 16;280(23):1980–1

Voucher incentives to increase childhood immunization rates [letter; comment] Golden R. **JAMA** 1999 Feb 24; 281(8):702–3. Comment on: JAMA 1998 Oct 7;280(13):1143–7.

From the Surgeon General. Polio eradication by the year 2000 [news] Satcher D. **JAMA** 1999 Jan 20;281(3):221

Improving vaccination coverage through accelerated measurement and feedback [letter; comment] Schlenker T, et al. **JAMA** 1998 Nov 4;280(17):1482–3. Comment on: JAMA 1997 Feb 26;277(8):631–5.

Vaccines for smallpox [letter] Baxby D. **Lancet** 1999 Jul 31; 354(9176):422–3

Vaccines for smallpox [letter] Blanchard T, et al. **Lancet** 1999 Jul 31;354(9176):422

National immunisation days and global eradication of poliomyelitis [letter] John TJ. **Lancet** 1999 Sep 4; 354(9181):869–70

Can we stop national immunisation days before global eradication of poliomyelitis? [letter] Kobayashi M, et al. **Lancet** 1999 Jun 19;353(9170):2129–30

Yellow fever vaccination [letter] Middleton D. **Lancet** 1999 Jan 9;353(9147):154

Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination. Vitek CR, et al. **Lancet** 1999 Jan 30;353(9150):355–8

Adult immunization: influenza and pneumonia. Maxim R. **Med Health R I** 1999 Jul;82(7):268–9

Progress toward global poliomyelitis eradication--1997–1998. **MMWR Morb Mortal Wkly Rep** 1999 May 28; 48(20):416–21

Vaccination campaign for Kosovar Albanian refugee children--former Yugoslav Republic of Macedonia, April-May, 1999. **MMWR Morb Mortal Wkly Rep** 1999 Sep 17;48(36):799–803

Progress toward poliomyelitis eradication--West Africa, 1997-September 1998. **MMWR Morb Mortal Wkly Rep** 1998 Oct 23;47(41):882-6

The sun sets on the CVI. Children's Vaccine Initiative [news] Birmingham K. **Nat Med** 1999 May;5(5):469-70

Characteristics of families who attend free vaccine fairs. Hambidge SJ, et al. **Pediatrics** 1999 Jul;104(1 Pt 2):158-63

Use of state hospital discharge data to assess the morbidity from rotavirus diarrhea and to monitor the impact of a rotavirus immunization program: A pilot study in Connecticut. Parashar UD, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):489-94

The measles tragedy revisited [letter] Tulchinsky TH. **Public Health** 1998 Nov-Dec;113(6):479-80

More on measles [letter; comment] Miller MA, et al. **Public Health Rep** 1999 Jan-Feb;114(1):4-5. Comment on: Public Health Rep 1998 Nov-Dec;113(6):479-80.

The measles tragedy revisited [letter] [see comments] Tulchinsky TH. **Public Health Rep** 1998 Nov-Dec; 113(6):479-80. Comment in: Public Health Rep 1999 Jan-Feb;114(1):4-5.

NIH scientist to head IVI institute in Korea [news] Baker M. **Science** 1999 Apr 16;284(5413):410

UN to end Children's Vaccine Initiative [news] Gavaghan H. **Science** 1999 Mar 26;283(5410):1992-3

Global immunization for the 21st century [editorial] Nossal GJ. **Science** 1999 Apr 23;284(5414):587

Knowledge, attitude and practice survey on immunization service delivery in Guangxi and Gansu, China. Zhang X, et al. **Soc Sci Med** 1999 Oct;49(8):1125-7

Impact of the hepatitis B mass vaccination program in the southern part of Thailand. Chub-uppakarn S, et al. **Southeast Asian J Trop Med Public Health** 1998 Sep; 29(3):464-8

Immunization and vaccine-preventable illness, United States, 1992 to 1997. Teitelbaum MA, et al. **Stat Bull Metrop Insur Co** 1999 Apr-Jun;80(2):13-20

Immunization program update. Narramore J. **Tenn Med** 1999 Jul;92(7):273

Report on Working Group 1: Albania, Andorra, Canada, France, Italy, Moldova, Portugal, Poland, Romania and Spain. Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S58-60

Universal hepatitis B immunization: infant, and infant plus adolescent immunization [published erratum appears in Vaccine 1999 Apr 9;17(15-16):I] Bonanni P. **Vaccine** 1998 Nov;16 Suppl:S17-22 (13 ref.)

Success stories in the implementation of universal hepatitis B vaccination: an update on Italy [published erratum appears in Vaccine 1999 Apr 9;17(15-16):I-II] Bonanni P, et al. **Vaccine** 1998 Nov;16 Suppl:S38-42 (13 ref.)

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Bresee JS, et al. **Vaccine** 1999 May 4; 17(18):2207-22 (148 ref.)

Hepatitis B immunization programme: Spain. de la Torre J. **Vaccine** 1998 Nov;16 Suppl:S43-4

Report on Working Group 2: Austria, Belgium, Bulgaria, Germany, Greece, Hungary, Malta, Russia, Switzerland, Turkey and Uzbekistan [published erratum appears in Vaccine 1999 May 14;17(19):2472] Grob PJ. **Vaccine** 1998 Nov;16 Suppl:S61-2

Assessing immunization coverage: how and why? Guérin N. **Vaccine** 1998 Nov;16 Suppl:S81-3 (6 ref.)

Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK). Iwarson S. **Vaccine** 1998 Nov;16 Suppl:S63-4

Why the Scandinavian countries have not implemented universal vaccination against hepatitis B. Iwarson S. **Vaccine** 1998 Nov;16 Suppl:S56-7

Status of hepatitis B immunization programmes in 1998. Kane MA. **Vaccine** 1998 Nov;16 Suppl:S104-8 (25 ref.)

The introduction of new vaccines into developing countries. Mahoney RT, et al. **Vaccine** 1999 Feb 26;17(7-8):646-52 (17 ref.)

Progress toward elimination of hepatitis B virus transmission in the United States. Mast EE, et al. **Vaccine** 1998 Nov; 16 Suppl:S48-51 (11 ref.)

Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Mast EE, et al. **Vaccine** 1998 Nov;16 Suppl:S27-9 (7 ref.)

Hepatitis B immunization programme: lessons learnt in Greece. Papaevangelou G. **Vaccine** 1998 Nov;16 Suppl:S45-7

Control of hepatitis B in the United Kingdom. Ramsay M, et al. **Vaccine** 1998 Nov;16 Suppl:S52-5

Opportunities not missed--systematic influenza and pneumococcal immunization in a public inner-city emergency department. Slobodkin D, et al. **Vaccine** 1998 Nov;16(19):1795-802

Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Swartz TA, et al. **Vaccine** 1998 Dec;16(20):2090-5

Universal hepatitis B immunization: young adolescent immunization. Tepper ML. **Vaccine** 1998 Nov;16 Suppl:S23-6 (34 ref.)

The children's vaccine initiative (CVI) and WHO's global programme for vaccines and immunization (GPV). Recommendations from the Scientific Advisory Group of Experts (SAGE). Part II. **Wkly Epidemiol Rec** 1998 Sep 18;73(38):292-5 **(Eng, Fre)**

Progress towards polio eradication, Somalia and southern Sudan. January 1998-June 1999. **Wkly Epidemiol Rec** 1999 Jul 30;74(30):246-52 **(Eng, Fre)**

Pertussis vaccines. **Wkly Epidemiol Rec** 1999 May 7; 74(18):137-43 **(Eng, Fre)**

Japanese encephalitis vaccines. **Wkly Epidemiol Rec** 1998 Oct 30;73(44):337-44 **(Eng, Fre)**

Tracking and improving children's health. Kennedy M. **WMJ** 1998 Sep;97(8):39

[Pneumococcal infection and anti-pneumococcal vaccination programs in Canada] Spika JS, et al. **Presse Med** 1998 May; 27 Suppl 1:39-42 **(Fre)**

[Information strategy for physicians and public health regarding introduction of general hepatitis B vaccination in Switzerland] Bourquin C, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S72-4, S146-8 (Eng. Abstr.) **(Ger, Fre)**

[Hepatitis B vaccination: knowledge and acceptance by Swiss physicians] Gugelmann RJ, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S57-60, S130-3 (Eng. Abstr.) **(Ger, Fre)**

[Hepatitis B vaccination strategies] Kammerlander R, et al. **Soz Praventivmed** 1998;43 Suppl 1:S41-3, S115-7 (Eng. Abstr.) **(Ger, Fre)**

[When competence and creativeness coincide] Thorens JJ, et al. **Soz Praventivmed** 1998;43 Suppl 1:S75-7, S149-51 (Eng. Abstr.) **(Ger, Fre)**

[Practical recommendations for general introduction of hepatitis B vaccination] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S69-71, S143-5 (Eng. Abstr.) **(Ger, Fre)**

[General hepatitis B vaccination in Switzerland: what is the attitude of vaccinating physicians?] Vaudaux B, et al. **Soz Praventivmed** 1998;43 Suppl 1:S47-56, S121-9 (Eng. Abstr.) **(Ger, Fre)**

[Introduction of general hepatitis B vaccination in Switzerland] Zimmermann H, et al. **Soz Praventivmed** 1998; 43 Suppl 1:S65-8, S138-42 (Eng. Abstr.) **(Ger, Fre)**

[Vaccinations and epidemiology] Nassauer KA. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):669-72 (Eng. Abstr.) **(Ger)**

[Viral hepatitis B morbidity in the Trebišov District after introduction of vaccination] Sallaiová M. **Epidemiol Mikrobiol Imunol** 1998 Aug;47(3):93-6 (Eng. Abstr.) **(Slo)**

[Impact of various strategies on the rates of flu vaccination in the elderly] Puig-Barberà J, et al. **Aten Primaria** 1999 Apr 15;23(6):339-45 (Eng. Abstr.) **(Spa)**

[Vaccination against Haemophilus influenzae type b in Uruguay: experience and impact] Ruocco G, et al. **Rev Panam Salud Publica** 1999 Mar;5(3):197-9 (Eng. Abstr.) **(Spa)**

ECONOMICS

Health care incentives in immunisation. Achat H, et al. **Aust N Z J Public Health** 1999 Jun;23(3):285-8 (48 ref.)

Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Edmunds WJ. **Commun Dis Public Health** 1998 Dec;1(4):221-8 (34 ref.)

Economic rate of discount and estimating cost benefit of viral immunisation programmes. West RR. **Rev Med Virol** 1999 Jan-Mar;9(1):51-5 (20 ref.)

Pediatric vaccines. Gates launches $100 million initiative [news] Ferber D. **Science** 1998 Dec 11;282(5396):1971

A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. Bovier PA, et al. **Soc Sci Med** 1999 May; 48(9):1205-20

Sustainable introduction of affordable new vaccines: the targeting strategy. Batson A. **Vaccine** 1998 Nov;16 Suppl:S93-8 (5 ref.)

[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents] Szucs TD, et al. **Med Klin** 1998 Aug 15;93(8):468-77 (Eng. Abstr.) **(Ger)**

[Economic evaluation of various hepatitis B vaccination Strategies in Switzerland] Zurn P, et al. **Soz Praventivmed** 1998;43 Suppl 1:S61-4, S134-7 (Eng. Abstr.) **(Ger, Fre)**

METHODS

Modeling measles, mumps, and rubella: implications for the design of vaccination programs. Gay NJ. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):570-3

A randomized study of tracking with outreach and provider prompting to improve immunization coverage and primary care. Rodewald LE, et al. **Pediatrics** 1999 Jan;103(1):31-8

[Increasing the immunization rate against measles, mumps, and rubella in medical students at the University of Berne] Germann D, et al. **Schweiz Med Wochenschr** 1999 Apr 3; 129(13):499-507 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

"McFlu". The Monroe County, New York, Medicare vaccine demonstration. Barker WH, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):118-27

Providers' perceptions of an immunization registry. Christakis DA, et al. **Am J Prev Med** 1999 Aug; 17(2):147-50

Evaluation of a community-based program to improve infant immunization rates in rural Minnesota. Hellerstedt WL, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):50-7

Jamaica's measles elimination experience. Hirshon JM, et al. **Am J Public Health** 1999 Aug;89(8):1254-5

Randomised controlled trial of the use of a modified postal reminder card on the uptake of measles vaccination. Hawe P, et al. **Arch Dis Child** 1998 Aug;79(2):136-40

Advances and challenges for the expanded programme on immunization. Cutts FT. **Br Med Bull** 1998;54(2):445-61 (64 ref.)

Measles eradication: experience in the Americas. de Quadros CA, et al. **Bull World Health Organ** 1998;76 Suppl 2:47-52

Commentary: smallpox eradication in west and central Africa revisited. Foege WH. **Bull World Health Organ** 1998; 76(3):233-5

Perspectives from the global poliomyelitis eradication initiative. Hull HF, et al. **Bull World Health Organ** 1998; 76 Suppl 2:42-6

Preventing pneumococcal disease: a Canadian consensus conference. 16-18 February 1998. **Can Commun Dis Rep** 1999 Feb 15;25(4):25-35 (0 ref.) **(Eng, Fre)**

Immunisation coverage in Australian children: a systematic review 1990-1998. Lister S, et al. **Commun Dis Intell** 1999 Jun 10;23(6):145-70 (137 ref.)

Strategies to ensure delivery of hepatitis B vaccine to injecting drug users [editorial; comment] Heptonstall J. **Commun Dis Public Health** 1999 Sep;2(3):154-6. Comment on: Commun Dis Public Health 1999 Sep;2(3):174-7.

Influenza immunisation and health care workers and other occupational groups. **Commun Dis Rep CDR Wkly** 1999 Aug 13;9(33):289, 292

Measles in adults in Canada and the United States: implications for measles elimination and eradication. Duclos P, et al. **Int J Epidemiol** 1999 Feb;28(1):141-6 (22 ref.)

Fuzzy logic and measles vaccination: designing a control strategy. Massad E, et al. **Int J Epidemiol** 1999 Jun; 28(3):550-7

Influenza vaccine update. **J Ark Med Soc** 1998 Oct; 95(5):207-8

Creating alternative immunization clinics to maintain and improve community immunization rates. Horner SD, et al. **J Community Health Nurs** 1999;16(2):121-32

Should childhood immunisation be compulsory? Bradley P. **J Med Ethics** 1999 Aug;25(4):330-4

Optimal disease prevention using vaccination depends on a system. Robbins A, et al. **Public Health Rep** 1998 Nov-Dec; 113(6):533-4

Horizons Project wants physicians to increase the rate of influenza/pneumococcal immunizations among elderly blacks. Malone L. **Tenn Med** 1998 Nov;91(11):422-3

Perceived barriers to childhood immunization: a physician and parent survey in a southeastern urban/rural community. Nace NB, et al. **Tenn Med** 1999 Jul;92(7):265-8

A comprehensive assessment of the quality of immunization services in one major area of Dhaka City, Bangladesh. Perry H, et al. **Trop Med Int Health** 1998 Dec;3(12):981-92

A comprehensive influenza campaign in a managed care setting. Pearson DC, et al. **Vaccine** 1998 Nov; 16(18):1718-21

New frontiers in the development of vaccines against enterotoxinogenic (ETEC) and enterohaemorrhagic (EHEC) E. coli infections. Part I. **Wkly Epidemiol Rec** 1999 Apr 2;74(13):98-101 **(Eng, Fre)**

Progress towards poliomyelitis eradication. WHO African Region, January 1998-June 1999. **Wkly Epidemiol Rec** 1999 Jun 25;74(25):201-5 **(Eng, Fre)**

Integration of vitamin A supplementation with immunization. **Wkly Epidemiol Rec** 1999 Jan 8;74(1):1-6 **(Eng, Fre)**

Technical network for logistics in health (Technet). **Wkly Epidemiol Rec** 1999 Apr 30;74(17):129-35 **(Eng, Fre)**

Progress towards polio eradication, Nigeria, 1996-1998. **Wkly Epidemiol Rec** 1999 Apr 23;74(16):121-4 **(Eng, Fre)**

The Children's Vaccine Initiative (CVI) and WHO's global programme for vaccines and immunization (GPV). Recommendations from the scientific advisory group of experts (SAGE). **Wkly Epidemiol Rec** 1998 Sep 25; 73(39):301-3 **(Eng, Fre)**

Progress towards polio eradication, South-East Asia, 1997-1998. **Wkly Epidemiol Rec** 1999 Mar 26;74(12):90-3 **(Eng, Fre)**

[Vaccines for rotavirus infections: efficacy and eventual role of vaccination programs] Ivanoff B, et al. **Arch Pediatr** 1999;6 Suppl 2:330s-331s **(Fre)**

[Expansion of pneumococcal vaccination in industrialized countries: will France join the movement?] Fedson DS, et al. **Presse Med** 1998 May;27 Suppl 1:50-4 **(Fre)**

[Pneumococcal vaccine in Great Britain] Mayon-White D. **Presse Med** 1998 May;27 Suppl 1:46-9 **(Fre)**

[Introduction and implementation of pneumococcal vaccination in Belgium] Peetermans WE. **Presse Med** 1998 May;27 Suppl 1:43-5 **(Fre)**

[Vaccine strategies for the general practitioner. I. Apropos of a research-action] Limme C, et al. **Rev Med Liege** 1998 Sep;53(9):541-52 (14 ref.) (Eng. Abstr.) **(Fre)**

[A new vaccination plan in Mexico (editorial)] Santos Preciado JI. **Salud Publica Mex** 1999 Jan-Feb;41(1):1-2 **(Spa)**

STANDARDS

Canadian Consensus Conference on a National Immunization Records System. **Can Commun Dis Rep** 1998 Sep 1;

IMMUNIZATION PROGRAMS

24(17):137–40 (0 ref.) **(Eng, Fre)**

Varicella serological status of healthcare workers as a guide to whom to test or immunize. Brunell PA, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):355–7

Audit of immunization policy and practice of health care workers within National Health Service Trusts in England and Wales. Verow P, et al. **Occup Med (Lond)** 1999 May; 49(4):211–6

Universal childhood immunization against hepatitis A: whoa! Takayama JI. **West J Med** 1999 Jun;170(6):325–6 (11 ref.)

Rotavirus vaccines. **Wkly Epidemiol Rec** 1999 Feb 5; 74(5):33–8 **(Eng, Fre)**

Progress towards poliomyelitis eradication, India, 1998. **Wkly Epidemiol Rec** 1998 Sep 25;73(39):297–300 **(Eng, Fre)**

STATISTICS & NUMERICAL DATA

Hepatitis B vaccination program at a New York City hospital: seroprevalence, seroconversion, and declination. Louther J, et al. **Am J Infect Control** 1998 Aug;26(4):423–7

Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. Nichol KL. **Am J Med** 1998 Nov; 105(5):385–92

Demonstration of the feasibility of emergency department immunization against influenza and pneumococcus. Slobodkin D, et al. **Ann Emerg Med** 1998 Nov;32(5):537–43

Improving immunization rates in private pediatric practices through physician leadership. Sinn JS, et al. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):597–603

Impact of the media on vaccine uptake in British Columbia's grade 6 hepatitis B immunization program. Bigham M, et al. **Can Commun Dis Rep** 1999 May 15;25(10):89–93; discussion 93–4 **(Eng, Fre)**

MMR vaccine coverage at 24 months stabilises in the UK. **Commun Dis Rep CDR Wkly** 1999 Mar 26;9(13):113, 116

Sentinel surveillance shows small decline in MMR coverage. **Commun Dis Rep CDR Wkly** 1998 Sep 4;8(36):317, 320

Evaluation of a campaign to improve immunization in a rural headstart program. Mayer JP, et al. **J Community Health** 1999 Feb;24(1):13–27

Progress toward poliomyelitis eradication--Afghanistan, 1994–1999. **MMWR Morb Mortal Wkly Rep** 1999 Sep 24; 48(37):825–8

Vaccines for Children program, United States, 1997. Santoli JM, et al. **Pediatrics** 1999 Aug;104(2):e15

No scientific justification to suspend hepatitis B immunization [news] **Public Health Rep** 1998 Nov–Dec;113(6):487

Vaccine coverage [letter; comment] Zell ER, et al. **Public Health Rep** 1999 Jan–Feb;114(1):3–4. Comment on: Public Health Rep 1998 Nov–Dec;113(6):521–6. Comment on: Public Health Rep 1998 Nov–Dec;113(6):527–32.

A comprehensive assessment of the quality of immunization services in one major area of Dhaka City, Bangladesh. Perry H, et al. **Trop Med Int Health** 1998 Dec;3(12):981–92

[Vaccination coverage and risk factors associated to non-vaccination in a urban area of northeastern Brazil, 1994] da Silva AA, et al. **Rev Saude Publica** 1999 Apr; 33(2):147–56 (Eng. Abstr.) **(Por)**

TRENDS

Evolution of the Viral Hepatitis Prevention Board--VHPB. McCloy E, et al. **Vaccine** 1998 Nov;16 Suppl:S7–10 (18 ref.)

From Cannes 1993 to the present. Van Damme P, et al. **Vaccine** 1998 Nov;16 Suppl:S3–6 (11 ref.)

[Vaccination strategies of tomorrow... is it necessary to revaccinate rubella, mumps and rubeola, and when?] Guérin N, et al. **Arch Pediatr** 1998;5 Suppl 2:187s–190s **(Fre)**

[Anti-pneumococcal vaccination in France: future trends] Micoud M. **Presse Med** 1998 May;27 Suppl 1:55–6 **(Fre)**

[World-wide status of hepatitis B vaccination 1998] Kane MA. **Soz Praventivmed** 1998;43 Suppl 1:S44–6, S118–20 (Eng. Abstr.) **(Ger, Fre)**

[General hepatitis B vaccination--a challenge for public health in the year 2000 (editorial)] Raeber PA, et al. **Soz Praventivmed** 1998;43 Suppl 1:S3–4, S78 **(Ger, Fre)**

UTILIZATION

Changes in clinic vaccination coverage after institution of measurement and feedback in 4 states and 2 cities. LeBaron CW, et al. **Arch Pediatr Adolesc Med** 1999 Aug; 153(8):879–86

Does reminder-recall augment the impact of voucher incentives on immunization rates among inner-city infants enrolled in WIC? Special Supplemental Program for Women, Infants, and Children. Hoekstra EJ, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):261–3

Failure to immunize the elderly: a systems problem or a statement of personal values? Fowles JB, et al. **Jt Comm J Qual Improv** 1998 Dec;24(12):704–10

Influenza and pneumococcal vaccine receipt in older persons with chronic disease: a population-based study. Petersen RL, et al. **Med Care** 1999 May;37(5):502–9

Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups. Sarnoff R, et al. **Med Care Res Rev** 1998 Dec; 55(4):432–56

Regional differences in infant immunization against hepatitis B: did intervention work? Takayama JI, et al. **Prev Med** 1999 Feb;28(2):160–6

Motivating factors influencing participation in hepatitis B immunization programs in rural populations. Meert M, et al. **Stat Bull Metrop Insur Co** 1998 Oct–Dec;79(4):2–7

IMMUNIZATION SCHEDULE

Promoting breastfeeding through health education at the time of immunizations: a randomized trial from Guinea Bissau [see comments] Jakobsen MS, et al. **Acta Paediatr** 1999 Jul;88(7):741–7. Comment in: Acta Paediatr 1999 Jul;88(7):703–4.

ACIP issues recommendations to eliminate measles, rubella and congenital rubella syndrome and to control mumps. Rose VL. **Am Fam Physician** 1998 Nov 1;58(7):1682, 1685–6

The 1999 harmonized immunization schedule. Zimmerman RK. **Am Fam Physician** 1999 Jan 1;59(1):203–4, 206

Subpotent vaccine lot recalled, recommendations on supplemental doses issued [news] **Am J Health Syst Pharm** 1999 Mar 15;56(6):504

Minimum time interval adjustment for 4–3–1 immunization rates among two-year-old children. Steiner RP, et al. **Am J Prev Med** 1999 Apr;16(3):189–94

Polio vaccine: is it time for a change? [letter; comment] Salisbury DM. **Arch Dis Child** 1999 Feb;80(2):207. Comment on: Arch Dis Child 1998 Jun;78(6):571–3; discussion 573–4.

Parent and general practitioner preferences for infant immunisation. Reactogenicity or multiple injections? Bartlett MJ, et al. **Aust Fam Physician** 1999 Jan;28 Suppl 1:S22–7

Reasons for delayed compliance with the childhood vaccination schedule and some failings of computerised vaccination registers. Richards A, et al. **Aust N Z J Public Health** 1999 Jun;23(3):315–7

Reimmunization after blood or marrow stem cell transplantation [see comments] Singhal S, et al. **Bone Marrow Transplant** 1999 Apr;23(7):637–46 (87 ref.). Comment in: Bone Marrow Transplant 1999 Apr;23(7):635–6.

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Vance E, et al. **Bone Marrow Transplant** 1998 Oct; 22(8):735–41

Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Groves FD, et al. **Br J Cancer** 1999 Sep;81(1):175–8

Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Chen CC, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 May–Jun;40(3):157–60

Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children. Tseng CY, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1999 May–Jun;40(3):161–5

Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Van Hoecke C, et al. **Clin Infect Dis** 1999 Jun; 28(6):1260–4

Cost-effectiveness analysis of a rotavirus immunization program for the United States. Steele RW. **Clin Pediatr (Phila)** 1998 Dec;37(12):758–9

Do we practice what we teach about childhood immunization in New Jersey? Sharkness CM, et al. **Fam Med** 1998 Nov–Dec;30(10):727–32

BCG vaccination with antitubercular therapy. Amdekar YK. **Indian Pediatr** 1998 Oct;35(10):1046–8

Interval between immunization sessions. John TJ. **Indian Pediatr** 1998 Oct;35(10):1029–30

Pulse and routine immunization against poliomyelitis. John TJ. **Indian Pediatr** 1998 Dec;35(12):1239–40

Need for measles revaccination. John TJ. **Indian Pediatr** 1998 Aug;35(8):789–91

Efficacy of two dose measles vaccination in a community setting. Phadke MA, et al. **Indian Pediatr** 1998 Aug; 35(8):723–5

Knowledge and practice of mothers regarding pulse polio immunization in National Capital Territory of Delhi. Bhasin SK, et al. **J Commun Dis** 1997 Dec;29(4):363–6

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Scheifele DW, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):240–5

Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM). Vidor E, et al. **J Travel Med** 1998 Dec;5(4):167–72

Measles immunization: early two-doses policy experience. al-Mazrou YY, et al. **J Trop Pediatr** 1999 Apr;45(2):98–104

From the Centers for Disease Control and Prevention. Recommended childhood immunization schedule--United States, 1999. **JAMA** 1999 Feb 17;281(7):601–3

Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Somjee S, et al. **Leuk Res** 1999 Apr;23(4):365–7

Recommended childhood immunization schedule--United States, 1999. **MMWR Morb Mortal Wkly Rep** 1999 Jan 15;48(1):12–6

The future of the immunisation schedule: recommendations of a workshop. Mansoor O, et al. **N Z Med J** 1999 Feb 26;112(1082):52–5

Immunisation of preterm babies. Moyes C. **N Z Med J** 1999 Jul 23;112(1092):263–4

Immunisation timeliness for a birth cohort in Christchurch. Christchurch Immunisation Coordination Study Group. Schluter PJ, et al. **N Z Med J** 1998 Sep 11;111(1073):336–40

Varicella: the vaccine and the public health debate. Niederhauser VP. **Nurse Pract** 1999 Mar;24(3):74–6, 79, 83–4 passim (54 ref.)

Immunizations for the immunocompromised child. McFarland E. **Pediatr Ann** 1999 Aug;28(8):487–96 (32 ref.)

More on immunizations [letter; comment] Ritrosky J Jr. **Pediatr Ann** 1999 Jan;28(1):7–8. Comment on: Pediatr Ann 1998 Jun;27(6):335–6.

Recommended immunization practices for pediatric renal transplant recipients. Neu AM, et al. **Pediatr Transplant** 1998 Nov;2(4):263–9 (44 ref.)

Recommended childhood immunization schedule–United States, January–December 1999. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1999 Jan;103(1):182–5

Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Losonsky GA, et al. **Pediatrics** 1999 Feb;103(2):E14

Deficiencies in current childhood immunization indicators. Bolton P, et al. **Public Health** 1998 Nov–Dec;113(6):527–32

Haemophilus influenzae type B vaccine. **S Afr Med J** 1999 Jul;89(7):738

Predictors of childhood immunization completion in a rural population. Gore P, et al. **Soc Sci Med** 1999 Apr; 48(8):1011–27

Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21–40 months of age. degli Atti MC, et al. **Vaccine** 1999 Apr 9;17(15–16):2030–5

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Habermehl P, et al. **Vaccine** 1999 Feb 26;17(7–8):669–74

Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens. Lu MY, et al. **Vaccine** 1999 Jan; 17(1):26–30

Do we need 3 doses of hepatitis B vaccine? Wilson JN, et al. **Vaccine** 1999 Jun 4;17(20–21):2667–73

[Immunization schedule in the European Union] Ovetchkine P, et al. **Arch Pediatr** 1998 Sep;5(9):1036–40 (Eng. Abstr.) **(Fre)**

[Vaccination strategies for the general practitioner. III. Difficulties encountered in practice: various references] Limme C, et al. **Rev Med Liege** 1998 Nov;53(11):685–90 (Eng. Abstr.) **(Fre)**

[The primary antitetanus cycle in adults: the contribution of the Fist Aid Service to the activities of the territorial health service of the city of Pesaro] Massari M, et al. **Ann Ig** 1999 Jan–Feb;11(1):63–70 (Eng. Abstr.) **(Ita)**

[Positive aspects of re-vaccination in adolescence] Silvio VE. **Minerva Pediatr** 1998 Jun;50(6):255–60 **(Ita)**

[The choice of the optimal schedules in the vaccination procedure against influenza in elderly subjects] Burtseva EI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):40–5 (Eng. Abstr.) **(Rus)**

[The coverage of vaccines systematically administered and of a vaccine against Haemophilus influenzae type b prior to its inclusion in the vaccinal calendar in the Valencian Community] Diez Domingo J, et al. **An Esp Pediatr** 1998 Dec;49(6):568–70 (Eng. Abstr.) **(Spa)**

[Seroprevalence of bactericidal anti-meningococcal antibodies in Cantabria 10 months following a vaccination campaign González de Aledo Linos A, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):365–74 (Eng. Abstr.) **(Spa)**

[Evaluation of the campaign on vaccination against meningococcal disease in Galicia. Methodology, advantages and disadvantages. Study of carriers] Malvar Pintos A. **Rev Esp Salud Publica** 1998 Sep–Oct; 72(5):393–400 **(Spa)**

[Efficacy of seroconversion and duration of immunity induced by the meningococcal serogroup C vaccine. Study included in the evaluation of the mass immunization of the population in the age group between 18 months and 19 years in the community of Madrid] Ramírez Fernández R. **Rev Esp Salud Publica** 1998 Sep–Oct;72(5):401–6 **(Spa)**

[Resurgence of the measles epidemic: situation in Minas Gerais, Brazil] Oliveira MT, et al. **Rev Panam Salud Publica** 1998 Oct;4(4):252–7 (Eng. Abstr.) **(Spa)**

IMMUNIZATION, SECONDARY

Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Menzies D. **Am J Respir Crit Care Med** 1999 Jan;159(1):15–21 (58 ref.)

Immunization of transplant recipients [editorial; comment] Ljungman P. **Bone Marrow Transplant** 1999 Apr; 23(7):635–6. Comment on: Bone Marrow Transplant 1999 Apr;23(7):637–46.

Reimmunization after blood or marrow stem cell transplantation [see comments] Singhal S, et al. **Bone Marrow Transplant** 1999 Apr;23(7):637–46 (87 ref.). Comment in: Bone Marrow Transplant 1999

Apr;23(7):635–6.
Update on revaccination protocols. Gumley N. **Can Vet J** 1999 May;40(5):323–4
Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus–infected individuals after revaccination with tetanus toxoid. Kroon FP, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):352–5
Neutralising antibody response to oral poliovirus vaccine after primary immunisation with inactivated poliovirus vaccine. Guérin N, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):815–6
Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Huang LM, et al. **Hepatology** 1999 Mar; 29(3):954–9
Pulse and routine immunization against poliomyelitis. John TJ. **Indian Pediatr** 1998 Dec;35(12):1239–40
Need for measles revaccination. John TJ. **Indian Pediatr** 1998 Aug;35(8):789–91
Efficacy of two dose measles vaccination in a community setting. Phadke MA, et al. **Indian Pediatr** 1998 Aug; 35(8):723–5
An experimental study on the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. Yang Y, et al. **J Epidemiol** 1999 Aug;9(4):209–15
Presence of pentoxifylline during T cell priming increases clonal frequencies in secondary proliferative responses and inhibits apoptosis. Gupta M, et al. **J Immunol** 1999 Jan 15;162(2):689–95
BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge. Kenty G, et al. **J Immunol** 1999 Jul 1; 163(1):232–41
Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. Levin MJ, et al. **J Infect Dis** 1998 Nov;178 Suppl 1:S109–12
Immune response to rabies booster vaccination in subjects who had postexposure treatment more than 5 years previously. Naraporn N, et al. **J Travel Med** 1999 Jun; 6(2):134–6
Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A [published erratum appears in J Travel Med 1998 Sep;5(3):inside front cover] Zuckerman JN, et al. **J Travel Med** 1998 Mar;5(1):18–22
Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Hethcote HW. **Math Biosci** 1999 Apr;158(1):47–73
Timing and effectiveness of requirements for a second dose of measles vaccine. Thomas A, et al. **Pediatr Infect Dis J** 1999 Mar;18(3):266–70
Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Vitek CR, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):620–3
Measles outbreak in Juneau, Alaska, 1996: implications for future outbreak control strategies. Landen MG, et al. **Pediatrics** 1998 Dec;102(6):E71
Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4–7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age. Dagan R, et al. **Vaccine** 1999 Jun 4; 17(20–21):2620–7
Secondary vaccination with vaccinia virus recombinants: role of residual virulence of recombinants and immunogenicity of extrinsic antigens. Kutinová L, et al. **Vaccine** 1999 Mar 5;17(9–10):1186–92
Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice. Sarin PS, et al. **Vaccine** 1999 Jan; 17(1):64–71
A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age. Scheifele DW, et al. **Vaccine** 1999 Feb 12;17(6):543–50
Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Sohn YM, et al. **Vaccine** 1999 May 4;17(18):2259–64
Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Wiström J, et al. **Vaccine** 1999 Apr 23;17(17):2162–5
[Studies on re-immunization with live attenuated hepatitis A vaccine] Liu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 May; 32(3):162–4 (Eng. Abstr.) **(Chi)**
[Trismus and tetanus vaccine] Mayaud C, et al. **Arch Pediatr** 1999 Jul;6(7):752–4 (Eng. Abstr.) **(Fre)**
[Intranasal revaccination of children with live measles vaccine: development of local immunity] Liashenko VA, et al. **Vopr Virusol** 1999 May-Jun;44(3):124–6 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Generalized granuloma annulare and hepatitis B vaccination. Wolf F, et al. **Eur J Dermatol** 1998 Sep;8(6):435–6
Comparative safety of tetanus-diphtheria toxoids booster immunization in students in Grades 6 and 9. Scheifele DW, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1121–6
The plea against annual influenza vaccination? 'The Hoskins' Paradox' revisited. Beyer WE, et al. **Vaccine** 1998 Dec; 16(20):1929–32
Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Gross PA, et al. **Vaccine** 1999 May 4;17(18):2284–9
Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Mark A, et al. **Vaccine** 1999 Apr 9;17(15–16):2067–72

METHODS

Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. Xiang ZQ, et al. **J Immunol** 1999 Jun 1;162(11):6716–23
Booster vaccination at 1 year with a rabies vaccine associated with DTP-IPV in infants living in a rabies endemic country [letter] Lang J, et al. **J Trop Pediatr** 1999 Jun;45(3):181–3

PSYCHOLOGY

A retrospective cohort study of risk factors for missing preschool booster immunisation. Evans MR, et al. **Arch Dis Child** 1998 Aug;79(2):141–4

STANDARDS

Immunogenicity and reactogenicity associated with an 18-month booster dose of a new diphtheria-tetanus-whole cell pertussis vaccine. Nolan T, et al. **J Paediatr Child Health** 1998 Aug;34(4):346–8

TRENDS

Diphtheria booster vaccination: one or two injections? Nicolay U, et al. **Vaccine** 1999 May 4;17(18):2223–8

VETERINARY

Effect of various adjuvants on secondary immune response in chickens. Hilgers LA, et al. **Vet Immunol Immunopathol** 1998 Nov 24;66(2):159–71

IMMUNOACTIVATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADJUVANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADSORBENT TECHNIQUES see **IMMUNOSORBENT TECHNIQUES**

IMMUNOADSORBENTS see **IMMUNOSORBENTS**

IMMUNOASSAY

Use of alkaline phosphatase to correct the underestimation of fosphenytoin concentration in serum measured by phenytoin immunoassays. Dasgupta A, et al. **Am J Clin Pathol** 1999 Apr;111(4):557–62
Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Nomura F, et al. **Am J Gastroenterol** 1999 Mar;94(3):650–4
Differential immunodiagnosis between cystic hydatid disease and other cross-reactive pathologies. Poretti D, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):193–8
Use of colloidal gold surface plasmon resonance peak shift to infer affinity constants from the interactions between protein antigens and antibodies specific for single or multiple epitopes. Englebienne P. **Analyst** 1998 Jul; 123(7):1599–603
Trace level detection of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) by microimmunosensor. Charles PT, et al. **Biosens Bioelectron** 1999 Apr 30;14(4):387–96
A multi-band capillary immunosensor. Misiakos K, et al. **Biosens Bioelectron** 1998 Oct 1;13(7–8):825–30
Evaluation of the Strep A OIA assay versus culture methods: ability to detect different quantities of group A Streptococcus. Kuhn S, et al. **Diagn Microbiol Infect Dis** 1999 Aug;34(4):275–80
Determination of doping methyltestosterone by capillary electrophoresis immunological analysis with thermally reversible hydrogel and laser-induced fluorescence. Zhang XX, et al. **Electrophoresis** 1999 Jul;20(10):1998–2002
Oxaprozin interference with urinary benzodiazepine immunoassays and noninterference with receptor assay. Nishikawa T, et al. **J Anal Toxicol** 1999 Mar-Apr; 23(2):125–6
Rifampicin cross-reacts with opiate immunoassay [letter] van As H, et al. **J Anal Toxicol** 1999 Jan-Feb;23(1):71
Immunoturbidimetric assay of glycated hemoglobin. Metus P, et al. **J Clin Lab Anal** 1999;13(1):5–8
Improvement of immunoglobulin M capture immunoassay specificity: toxoplasma antibody detection method as a model. Tuuminen T, et al. **J Clin Microbiol** 1999 Jan; 37(1):270–3
Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. Cavaco B, et al. **J Endocrinol Invest** 1999 Mar;22(3):203–8
Detection of zooplankton prey in squid paralarvae with immunoassay. Venter JD, et al. **J Immunoassay** 1999 Aug; 20(3):127–49
Development of an immunoassay for urinary galactosylhydroxylysine. Leigh SD, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):169–78
Immunomagnetic concentration of antigens and detection based on a scanning force microscopic immunoassay. Perrin A, et al. **J Immunol Methods** 1999 Apr 22;224(1–2):77–87
Current therapy for chronic rhinitis [letter; comment] Davidson A, et al. **J S C Med Assoc** 1999 May;95(5):208–9 . Comment on: J S C Med Assoc 1998 Dec;94(12):535–8. Comment on: J S C Med Assoc 1998 Dec;94(12):539–41.
A time-resolved fluoroimmunoassay for cortisol in unextracted bovine plasma or serum with optimized procedures to eliminate steroid binding protein interference and to minimize non-specific streptavidin-europium binding. Erkens JH, et al. **J Steroid Biochem Mol Biol** 1998 Oct;67(2):153–61
A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels. Hanemaaijer R, et al. **Matrix Biol** 1998 Dec;17(8–9):657–65
Progressive multifocal leukoencephalopathy in a renal transplant patient diagnosed by JCV-specific DNA amplification and an intrathecal humoral immune response to recombinant virus protein 1. Berner B, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):462–5
Toxicology reviews: immunoassay in detecting drugs of abuse. Cox MN, et al. **Pediatr Emerg Care** 1998 Oct; 14(5):372–5
Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency? [editorial] Lindstedt G, et al. **Scand J Clin Lab Invest** 1998 Oct;58(6):441–58 (97 ref.)
[Analytical evaluation of third generation TSH assay. Application to the exploration of thyrotropin suppression in differentiated thyroid cancer] Charrié A, et al. **Ann Endocrinol (Paris)** 1999 Mar;60(1):40–4 (Eng. Abstr.) **(Fre)**
[Improving the efficacy of tuberculosis immunodiagnosis using anti-human IgG monoclonal antibodies] Avdienko VG, et al. **Klin Lab Diagn** 1999 Jun;(6):22–4, 33–5 (Eng. Abstr.) **(Rus)**

ECONOMICS

Management of sore throats in children: a cost-effectiveness analysis [see comments] Tsevat J, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):681–8 (73 ref.) . Comment in: Arch Pediatr Adolesc Med 1999 Jul;153(7):672–4.
Accuracy and economics of Helicobacter pylori diagnosis. Cutler AF. **Yale J Biol Med** 1998 Mar-Apr;71(2):75–9 (14 ref.)

INSTRUMENTATION

Clinical evaluation of lumiward immunoassay system for detection of specific IgE associated with allergic rhinitis. Yamada K, et al. **Acta Otolaryngol Suppl (Stockh)** 1998; 538:169–77
Clinical analyzers. Immunoassays. Sokoll LJ, et al. **Anal Chem** 1999 Jun 15;71(12):356R–362R (35 ref.)
Performance characteristics of IMMULITE TPS: a comparison with TPS IRMA. Einarsson R, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2743–7
LIAISON Ferritin--an automated chemiluminescent immunoassay for the determination of Ferritin. König B, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2739–41
LIAISON hCG--an automated chemiluminescent immunoassay for the determination of human chorionic gonadotropin (hCG). Oed M, et al. **Anticancer Res** 1999 Jul-Aug;19(4A):2735–7
A contactless surface acoustic wave biosensor. Freudenberg J, et al. **Biosens Bioelectron** 1999 Apr 30;14(4):423–5
Evaluation of Elecsys free triiodothyronine assay: relevance of age-related reference ranges. Sapin R, et al. **Clin Biochem** 1998 Jul;31(5):399–404
Analytical and clinical performance of an automated immunoassay system (Immulite) for estradiol in serum. Rodriguez-Espinosa J, et al. **Clin Chem Lab Med** 1998 Dec; 36(12):969–74
Accuracy of five on-site immunoassay drugs-of-abuse testing devices. Taylor EH, et al. **J Anal Toxicol** 1999 Mar-Apr; 23(2):119–24
[Analytic evaluation of Immage for ten proteins] Giraudeaux V, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):593–8 **(Fre)**

METHODS

A novel dipstick developed for rapid Bet v 1-specific IgE detection: recombinant allergen immobilized via a monoclonal antibody to crystalline bacterial cell-surface layers. Breitwieser A, et al. **Allergy** 1998 Aug;53(8):786–93
Specific IgE antibodies in the diagnosis of atopic disease. Clinical evaluation of a new in vitro test system, UniCAP, in six European allergy clinics. Paganelli R, et al. **Allergy** 1998 Aug;53(8):763–8
A rapid and sensitive quantitative kinase activity assay using a convenient 96-well format. Asthagiri AR, et al. **Anal Biochem** 1999 May 1;269(2):342–7
A microchip-based enzyme assay for protein kinase A. Cohen

CB, et al. **Anal Biochem** 1999 Aug 15;273(1):89–97

An immunological assay for determination of baculovirus titers in 48 hours. Kitts PA, et al. **Anal Biochem** 1999 Mar 15;268(2):173–8

Liposome dehydration on nitrocellulose and its application in a biotin immunoassay. Martorell D, et al. **Anal Biochem** 1999 Jul 1;271(2):177–85

A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Swartzman EE, et al. **Anal Biochem** 1999 Jul 1;271(2):143–51

Immunoprofiling of pectic polysaccharides. Willats WG, et al. **Anal Biochem** 1999 Mar 1;268(1):143–6

An electrochemiluminescence flow-through cell and its applications to sensitive immunoassay using N-(aminobutyl)-N-ethylisoluminol. Arai K, et al. **Anal Chem** 1999 Jun 1;71(11):2237–40

Automated amplified flow immunoassay for cocaine. Bauer CG, et al. **Anal Chem** 1998 Nov 1;70(21):4624–30

Development of a theoretical model for chromatographic-based competitive binding immunoassays with simultaneous injection of sample and label. Hage DS, et al. **Anal Chem** 1999 Aug 1;71(15):2965–75

Immunoassays. Hage DS. **Anal Chem** 1999 Jun 15; 71(12):294R–304R (414 ref.)

Colloidal Au-enhanced surface plasmon resonance immunosensing. Lyon LA, et al. **Anal Chem** 1998 Dec 15; 70(24):5177–83

An array immunosensor for simultaneous detection of clinical analytes. Rowe CA, et al. **Anal Chem** 1999 Jan 15; 71(2):433–9

Liposome immunoassay by long-lived fluorescence detection. Okabayashi Y, et al. **Analyst** 1998 Jun; 123(6):1329–32

Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Keevil BG, et al. **Ann Clin Biochem** 1998 Sep;35 (Pt 5):671–3

Comparison of two methods for measurement of cardiac troponin T in patients with acute myocardial infarction. Oschatz E, et al. **Ann Clin Biochem** 1999 Mar;36 (Pt 2):242–3

Monoclonal antibodies, antigens and molecular diagnostics: a practical overview. Laurino JP, et al. **Ann Clin Lab Sci** 1999 Jul-Sep;29(3):158–66 (21 ref.)

An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. Talwar S, et al. **Biochem Biophys Res Commun** 1999 Aug 11;261(3):567–71

Single-step sandwich immunoassay of myoglobin with bifunctional monoclonal antibodies. Smirnova MB, et al. **Biochemistry (Mosc)** 1999 Jun;64(6):639–47

Synthesis of CpFe(CO)(L) complexes of hydantoin anions (Cp = eta5-C5H5, L = CO, PPh3), and the use of the 5,5-diphenylhydantoin anion complexes as tracers in the nonisotopic immunoassay CMIA of this antiepileptic drug. Vessières A, et al. **Bioconjug Chem** 1999 May-Jun; 10(3):379–85

Advancements toward magneto immunoassays. Kriz K, et al. **Biosens Bioelectron** 1998 Oct 1;13(7–8):817–23

Surface investigations on the development of a direct optical immunosensor. Kröger D, et al. **Biosens Bioelectron** 1998 Nov 1;13(10):1141–7

A membrane-based displacement flow immunoassay. Rabbany SY, et al. **Biosens Bioelectron** 1998 Oct 15; 13(9):939–44

Characterization of immobilization methods for African swine fever virus protein and antibodies with a piezoelectric immunosensor. Uttenthaler E, et al. **Biosens Bioelectron** 1998 Dec 1;13(12):1279–86

Flow microsphere immunoassay-based method of virus quantitation. Samoylova TI, et al. **Biotechniques** 1999 Aug; 27(2):356–61

A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Warner MN, et al. **Br J Haematol** 1999 Mar;104(3):442–7

Performance characteristics of the creatine kinase-MB mass assay on the Vitros ECi analyzer. Christenson RH, et al. **Clin Biochem** 1999 Apr;32(3):237–40

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Scheibenbogen C, et al. **Clin Cancer Res** 1997 Feb;3(2):221–6

Evaluation of an automated immunoassay method for cytokine measurement using the Immulite Immunoassay system. Berthier F, et al. **Clin Chem Lab Med** 1999 May; 37(5):593–9

Difference plots and mountain plots are useful also in comparing CA 125 immunoassay systems manufactured by the same company [letter; comment] Dorizzi RM, et al. **Clin Chem Lab Med** 1998 Jun;36(7):497. Comment on: Eur J Clin Chem Clin Biochem 1997 Aug;35(8):617–23.

Pre-evaluation and system optimization of the Elecsys thyroid electrochemiluminescence immunoassays. Luppa PB, et al. **Clin Chem Lab Med** 1998 Oct;36(10):789–96

Automated prozone effect detection in ferritin homogeneous immunoassays using neural network classifiers. Papik K, et al. **Clin Chem Lab Med** 1999 Apr;37(4):471–6

Clinical evaluation of the CARDIAC STATus, a rapid immunochromatographic assay for simultaneous detection of elevated concentrations of CK-MB and myoglobin in whole blood. Schouten Y, et al. **Clin Chem Lab Med** 1998 Jun;36(7):469–73

Evaluation of the first automated thyroglobulin assay. Vogeser M, et al. **Clin Chem Lab Med** 1999 Feb; 37(2):159–64

Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind). Jortani SA, et al. **Clin Chim Acta** 1999 May;283(1–2):159–69

A simple visual immunoassay (VIA) for the semiquantitative determination of plasma elastase levels. Rojas G, et al. **Clin Chim Acta** 1999 Jun 15;284(1):93–100

Estradiol-17beta measurement in women receiving conjugated estrogens. Dissociation between two commercial methods. Takahashi K, et al. **Clin Chim Acta** 1999 Jun 15;284(1):69–79

Comparison of three different methods for measuring classical pathway complement activity. Jaskowski TD, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):137–9

Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Nasir MS, et al. **Comb Chem High Throughput Screen** 1999 Aug;2(4):177–90 (98 ref.)

The immunoassay of cytokines and growth factors in biological fluids. Kopp W, et al. **Dev Biol Stand** 1999; 97:29–37 (8 ref.)

Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Swanson SJ, et al. **Dev Biol Stand** 1999;97:135–47

A novel visual immunoassay for coeliac disease screening. Garrote JA, et al. **Eur J Clin Invest** 1999 Aug;29(8):697–9

A novel in-situ-zymography technique localizes gelatinolytic activity in human skin to mast cells. Krejci-Papa NC, et al. **Exp Dermatol** 1998 Dec;7(6):321–6

The international standard for platelet-derived growth factor-BB: comparison of candidate preparations by in vitro bioassays and immunoassays. Robinson CJ, et al. **Growth Factors** 1998;16(2):153–60

Reactivity of a dual amplified chlamydia immunoassay with different serovars of Chlamydia trachomatis. Okadome A, et al. **Int J STD AIDS** 1999 Jul;10(7):460–3

Fluid therapy directly interferes with immunoassay for cardiac troponin I. Lagneau F, et al. **Intensive Care Med** 1999 Jun;25(6):625–7

The use of percent free PSA for early detection of prostate cancer. Potter SR, et al. **J Androl** 1999 Jul-Aug; 20(4):449–53 (31 ref.)

Determination of four fluoroquinolones in milk by on-line immunoaffinity capture coupled with reversed-phase liquid chromatography. Holtzapple CK, et al. **J AOAC Int** 1999 May-Jun;82(3):607–13

An immunoaffinity column for the determination of peanut protein in chocolate. Newsome WH, et al. **J AOAC Int** 1999 May-Jun;82(3):666–8

Laser light scattering immunoassay: an improved data analysis by CONTIN method. Antony T, et al. **J Biochem Biophys Methods** 1998 Jun 11;36(2–3):75–85

Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. Halleen JM, et al. **J Bone Miner Res** 1999 Mar;14(3):464–9

Demonstration of the predominant urine osteocalcin fragments detectable by two-site immunoassays. Matikainen T, et al. **J Bone Miner Res** 1999 Mar; 14(3):431–8

Analysis of urinary drugs of abuse by a multianalyte capillary electrophoretic immunoassay. Caslavska J, et al. **J Chromatogr A** 1999 Apr 9;838(1–2):197–211

Noncompetitive immunoassays using protein G affinity capillary chromatography and capillary electrophoresis with laser-induced fluorescence detection. Wang Q, et al. **J Chromatogr A** 1999 Jul 2;848(1–2):139–48

Use of capillary electrophoresis-based competitive immunoassay for a large molecule. Ou JP, et al. **J Chromatogr B Biomed Sci Appl** 1999 Apr 30; 727(1–2):63–71

Evaluation of a rapid immunochromatographic test for detection of antibodies to human immunodeficiency virus. Arai H, et al. **J Clin Microbiol** 1999 Feb;37(2):367–70

Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo. de Baar MP, et al. **J Clin Microbiol** 1999 Jan;37(1):63–7

Rapid immunochromatographic assay for diagnosis of tuberculosis [letter] [see comments] Grobusch MP, et al. **J Clin Microbiol** 1998 Nov;36(11):3443. Comment in: J Clin Microbiol 1999 Jun;37(6):2111–2.

Leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay [letter; comment] Lipson SM. **J Clin Microbiol** 1999 Aug;37(8):2742. Comment on: J Clin Microbiol 1998 Nov;36(11):3410–1.

Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. Weber B, et al. **J Clin Microbiol** 1999 Aug;37(8):2639–47

Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples. Constantine NT, et al. **J Hum Virol** 1997 Nov-Dec;1(1):45–51

Laser light scattering immunoassay for malaria. Bhakat P, et al. **J Immunoassay** 1999 Aug;20(3):103–14

The detection of pyrogens in sera from patients with symptoms of sepsis using an ex vivo whole blood culture assay. Pool EJ, et al. **J Immunoassay** 1999 Feb-May; 20(1–2):1–11

Differentiation between endotoxin and non-endotoxin pyrogens in human albumin solutions using an ex vivo whole blood culture assay. Pool EJ, et al. **J Immunoassay** 1999 Feb-May;20(1–2):79–89

Development of a bispecific monoclonal antibody as a universal immunoprobe for detecting biotinylated macromolecules. Cao Y, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):85–91

Influence of antibody valency in a displacement immunoassay for the quantitation of 2,4-dichlorophenoxyacetic acid. Gerdes M, et al. **J Immunol Methods** 1999 Mar 4; 223(2):217–26

On-line flow displacement immunoassay for fatty acid-binding protein. Kaptein WA, et al. **J Immunol Methods** 1998 Aug 1;217(1–2):103–11

A one-step solid phase immunoassay for simultaneous detection of serum IgG and IgM antibodies to Borrelia burgdorferi. Schønau A, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):9–17

Comparative studies of magnetic particle-based solid phase fluorogenic and electrochemiluminescent immunoassay. Yu H. **J Immunol Methods** 1998 Sep 1;218(1–2):1–8

Immunoassay detection of hepatitis B surface antigen mutants. Coleman PF, et al. **J Med Virol** 1999 Sep; 59(1):19–24

Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance. Puchhammer-Stöckl E, et al. **J Med Virol** 1999 Mar; 57(3):283–9

Immunoreagents based on polymer dispersions for immunochemical assays. Lukin YuV, et al. **J Mol Recognit** 1998 Winter;11(1–6):185–7

A flow immunoassay for studies of human exposure and toxicity in biological samples. Onnerfjord P, et al. **J Mol Recognit** 1998 Winter;11(1–6):182–4

Comparison of different immunoassays and GC-MS screening of benzodiazepines in urine. Augsburger M, et al. **J Pharm Biomed Anal** 1998 Dec;18(4–5):681–7

Chemiluminescence-based detection: principles and analytical applications in flowing streams and in immunoassays. Baeyens WR, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6–7):941–53 (57 ref.)

Fluorescent and electron-microscopy immunoassays employing polyclonal and monoclonal antibodies for detection of goose parvovirus infection. Alexandrov M, et al. **J Virol Methods** 1999 Apr;79(1):21–32

Detection of episomal banana streak badnavirus by IC-PCR. Harper G, et al. **J Virol Methods** 1999 Apr;79(1):1–8

Multicenter evaluation of a new rapid automated human immunodeficiency virus antigen detection assay. Weber B, et al. **J Virol Methods** 1999 Mar;78(1–2):61–70

Detection of doping [letter; comment] Jenkins P. **Lancet** 1999 May 1;353(9163):1532. Comment on: Lancet 1999 Mar 13;353(9156):895.

Detection of doping with human growth hormone [letter] [see comments] Wu Z, et al. **Lancet** 1999 Mar 13; 353(9156):895. Comment in: Lancet 1999 May 1;353(9163):1532.

Engineering a regulatable enzyme for homogeneous immunoassays. Legendre D, et al. **Nat Biotechnol** 1999 Jan; 17(1):67–72

Protein conformation dictates prion strain [news; comment] Aguzzi A. **Nat Med** 1998 Oct;4(10):1125–6. Comment on: Nat Med 1998 Oct;4(10):1157–65.

Eight prion strains have PrP(Sc) molecules with different conformations [see comments] Safar J, et al. **Nat Med** 1998 Oct;4(10):1157–65. Comment in: Nat Med 1998 Oct;4(10):1125–6.

Pseudo-nitzschia in New Zealand and the role of DNA probes and immunoassays in refining marine biotoxin monitoring programmes [see comments] Rhodes L, et al. **Nat Toxins** 1998;6(3–4):105–11. Comment in: Nat Toxins 1998 ;6(3–4):91–2.

Quantification of lamivudine (3TC) by competitive immunoassay. Akeb F, et al. **Nucleosides Nucleotides** 1999 Apr-May;18(4–5):893–6

Methods in determining growth hormone concentrations: an immunofunctional assay. Strasburger CJ. **Pediatrics** 1999 Oct;104(4 Pt 2):1024–8

Prehospital identification of acute coronary ischemia using a troponin T rapid assay. Newman J, et al. **Prehosp Emerg Care** 1999 Apr-Jun;3(2):97–101

Application of region-specific immunoassay for human chromogranin A: substantial clue for detection and measurement of chromogranin A in human plasma. Yanaihara H, et al. **Regul Pept** 1999 Mar 17;80(1–2):83–90

Group testing in presence of classification errors. Gupta D, et al. **Stat Med** 1999 May 15;18(9):1049–68

Interference from digitoxin-like immunoreactive factors reduced in a new monoclonal chemiluminescent digitoxin assay. Datta P, et al. **Ther Drug Monit** 1998 Dec;20(6):663–8

Adaptation of total phenytoin reagent pack for measuring free phenytoin levels with the Abbott AxSYM immunoassay analyzer. Jarzabek JI, et al. **Ther Drug Monit** 1999 Feb;21(1):134–6

Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype. Puppo F, et al. **Tissue Antigens** 1999 Mar; 53(3):253–62

Effectiveness of a highly sensitive chemiluminescent immunoassay in screening for hepatitis B surface antigen

in Japanese blood donors [letter] Sekiguchi S, et al. **Transfusion** 1999 Jun;39(6):660–1
Cytokines: from technology to therapeutics. Mire-Sluis AR. **Trends Biotechnol** 1999 Aug;17(8):319–25 (31 ref.)
Field evaluation of a one-step dipstick assay for the diagnosis of human leptospirosis in the Seychelles. Yersin C, et al. **Trop Med Int Health** 1999 Jan;4(1):38–45
Ultrasonic enhancement of coated particle agglutination immunoassays: influence of particle density and compressibility. Thomas NE, et al. **Ultrasound Med Biol** 1999 Mar;25(3):443–50
Accuracy and economics of Helicobacter pylori diagnosis. Cutler AF. **Yale J Biol Med** 1998 Mar–Apr;71(2):75–9 (14 ref.)
[Comparison of two techniques for detection of anti-Plasmodium falciparum antibodies: Falciparum-spot IF (Biomérieux) and Malaria IgG Celisa (BMD). Preliminary results] Assal A, et al. **Transfus Clin Biol** 1999 Apr;6(2):119–23 (Eng. Abstr.) **(Fre)**
[Development of a serum lipoprotein A-I immunoassay method] Shishino K, et al. **Rinsho Byori** 1999 Jun; 47(6):576–9 (Eng. Abstr.) **(Jpn)**
[Liposomal immunoassay as a method for detecting microorganism antigens and their antibodies] Iarkov SP, et al. **Vestn Ross Akad Med Nauk** 1999;(8):39–43 (Eng. Abstr.) **(Rus)**
[The assessment of the parallelism in the results of measuring an analyzable substance and the calibrator in immunological assays] Shobukhova TS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar–Apr; (2):68–71 (Eng. Abstr.) **(Rus)**

STANDARDS

Human anti-animal antibody interferences in immunological assays. Kricka LJ. **Clin Chem** 1999 Jul;45(7):942–56 (185 ref.)
Quantification of MUC1 in breast cancer patients. A method comparison study. Bon GG, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):67–75
Effect of low urine specific gravity on pregnancy testing. Neinstein L, et al. **J Am Coll Health** 1998 Nov;47(3):138–9
Cytokine immunoassays: recommendations for standardisation, calibration and validation. Wadhwa M, et al. **J Immunol Methods** 1998 Oct 1;219(1–2):1–5
[Standardized description of biology analyzers. Automated Version of Immunoanalysis] Gruson A. **Ann Biol Clin (Paris)** 1998 Mar;56 Spec No:3–34 **(Fre)**

VETERINARY

Cross-reactivity of an automated human haptoglobin immunoturbidimetric assay for detection of haptoglobin in swine serum. Wiedmeyer CE, et al. **J Vet Diagn Invest** 1999 May;11(3):295–7

IMMUNOASSAY, ENZYME see **IMMUNOENZYME TECHNIQUES**

IMMUNOASSAY, FLUORESCENCE POLARIZATION see **FLUORESCENCE POLARIZATION IMMUNOASSAY**

IMMUNOBLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLASTIC LYMPHADENOPATHY

COMPLICATIONS

Immunoblastic lymphadenopathy-like T cell lymphoma evolving into a massive plasma cell proliferation with biclonal paraproteinemia. Higuchi T, et al. **Acta Haematol** 1998 Dec;100(3):151–5
[Immunoblastic lymphadenopathy-like T cell lymphoma with high levels of serum interleukin-6, cold agglutinin disease, and immune thrombocytopenia] Takayanagi N, et al. **Rinsho Ketsueki** 1998 Nov;39(11):1109–14 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

A man with a swollen leg and abnormal globulins. Parnassa DT, et al. **Hosp Pract (Off Ed)** 1999 Mar 15;34(3):15–6, 22
Immunoblastic lymphadenopathy-like T-cell lymphoma complicated by multiple gastrointestinal involvement. Kaneki T, et al. **J Gastroenterol** 1999 Apr;34(2):253–9

DRUG THERAPY

Angioimmunoblastic lymphadenopathy: treatment in three cases. [letter; comment] Sánchez M, et al. **Acta Haematol** 1998 Dec;100(3):164–5. Comment on: Acta Haematol 1998;99(2):57–64.
The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Sallah S, et al. **Br J Haematol** 1999 Jan;104(1):163–5
Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Pautier P, et al. **Leuk Lymphoma** 1999 Feb; 32(5–6):545–52 (28 ref.)

IMMUNOBLASTIC LYMPHOSARCOMA, DIFFUSE see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLASTOMA see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLOTTING

see related
IMMUNOCHEMISTRY

Proteins of rat serum: I. Establishing a reference two-dimensional electrophoresis map by immunodetection and microbore high performance liquid chromatography-electrospray mass spectrometry. Haynes P, et al. **Electrophoresis** 1998 Jun;19(8–9):1484–92
Highly cationic anti-DNA antibodies in patients with lupus nephritis analyzed by two-dimensional electrophoresis and immunoblotting. Kohro-Kawata J, et al. **Electrophoresis** 1998 Jun;19(8–9):1511–5
Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. Garinis G, et al. **J Clin Lab Anal** 1999;13(3):122–5
Isoelectricfocusing and reverse blotting as a diagnostic tool in pediatric HIV infection. del Bono V, et al. **J Clin Virol** 1998 Dec;11(3):203–10
Development of a dot blot neutralizing assay for HHV-6 and HHV-7 using specific monoclonal antibodies. Tsukazaki T, et al. **J Virol Methods** 1998 Aug;73(2):141–9
Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Mikami K, et al. **Jpn J Cancer Res** 1998 Sep;89(9):910–5
[Immunoblotting for the serodiagnosis of syphilis. A candidate to replace the Nelson-Mayer test] Pâris-Hamelin A, et al. **Ann Pharm Fr** 1999 Jan;57(1):68–75 (Eng. Abstr.) **(Fre)**

METHODS

Immunoblotting analysis of schwannomin/merlin in human schwannomas. Harwalkar JA, et al. **Am J Otol** 1998 Sep; 19(5):654–9
Evaluation of an IgM immunoblot kit for dengue diagnosis. Kuno G, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):757–62
Determination of protein carbonyl groups by immunoblotting. Robinson CE, et al. **Anal Biochem** 1999 Jan 1;266(1):48–57
Nonradioactive multi-sample protein-protein interaction assay using an epitope tagging technique. Solinas G, et al. **Biotechniques** 1999 Feb;26(2):246–9
Differential expression of double-band apolipoprotein(a) phenotypes in healthy Spanish subjects detected by SDS-agarose immunoblotting. Martin S, et al. **Clin Chim Acta** 1998 Oct;277(2):191–205
Development of an antigen spot test for detection of coronavirus in bovine fecal samples. Gaber F, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):542–4
Specific anti-toxoplasmic IgG antibody immunoblot profiles in patients with AIDS-associated Toxoplasma encephalitis. Raffi F, et al. **Diagn Microbiol Infect Dis** 1999 May; 34(1):51–6
Accurate detection of both glycoproteins and total proteins on blots: control of side reactions occurring after periodate oxidation of proteins. Bouchez-Mahiout I, et al. **Electrophoresis** 1999 Jun;20(7):1412–7
The combination of Indian ink staining with immunochemiluminescence detection allows precise identification of antigens on blots: application to the study of glycosylated barley storage proteins. Eynard L, et al. **Electrophoresis** 1998 Jun;19(8–9):1394–6
Immunoblotting of multiple antigenic peptides. Kurien BT, et al. **Electrophoresis** 1998 Jul;19(10):1659–61
Impact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study. Kist M, et al. **FEMS Immunol Med Microbiol** 1999 Jun;24(2):239–42
Standardization of a dot blot immunoassay for antigen detection in cases of pulmonary tuberculosis & its evaluation with respect to the conventional techniques. Deodhar L, et al. **Indian J Med Res** 1998 Sep;108:75–9
Sensitivity of indirect immunofluorescence and immunoblotting for the detection of intercellular antibodies in endemic pemphigus foliaceus (fogo selvagem). Rowilson-Cunha P, et al. **Int J Dermatol** 1999 Jan; 38(1):41–5
Evaluation of a line immunoblot assay for detection of antibodies recognizing extractable nuclear antigens. Prince HE, et al. **J Clin Lab Anal** 1998;12(5):320–4
Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. Buisson M, et al. **J Clin Microbiol** 1999 Aug; 37(8):2709–14
Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay. Schröter M, et al. **J Clin Microbiol** 1999 Aug;37(8):2576–80
Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. Ter Meulen J, et al. **J Clin Microbiol** 1998 Nov;36(11):3143–8
Comparison of four serological tests to determine the CagA or VacA status of Helicobacter pylori strains. Yamaoka Y, et al. **J Clin Microbiol** 1998 Nov;36(11):3433–4
An immunoblotting procedure comprising O = 9,12 and H = d antigens as an alternative to the Widal agglutination assay. Chart H, et al. **J Clin Pathol** 1998 Nov;51(11):854–6
The impact of HCV genotypes on seroreactivity against HCV antigens immobilized on the RIBA 3.0 SIA [letter] Jain N, et al. **J Hepatol** 1999 Jan;30(1):173
Immunoblotting technique for the detection of allergens of Aspergillus fumigatus: influence of Nonidet P-40 on the sensitivity. Wijnands LM, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun;9(3):195–6
GB virus C/hepatitis G virus infection in hemodialysis patients: determination of seroprevalence by a four-antigen recombinant immunoblot assay. Schröter M, et al. **J Med Virol** 1999 Mar;57(3):230–4
Dot immunobinding assay for detection of bovine herpesvirus 4 antibodies in rabbits. Essmail M, et al. **J Vet Diagn Invest** 1999 May;11(3):237–9
Serodiagnosis of equine piroplasmosis, dourine, and glanders using an arrayed immunoblotting method. Katz JB, et al. **J Vet Diagn Invest** 1999 May;11(3):292–4
TCID50 determination by an immuno dot blot assay as exemplified in a study of storage conditions of infectious pancreatic necrosis virus. Svensson L, et al. **J Virol Methods** 1999 Jun;80(1):17–24
Electroblotting of proteins from 2-D polyacrylamide gels. Dunn MJ. **Methods Mol Biol** 1999;112:313–8 (16 ref.)
Immunoaffinity identification of 2-DE separated proteins. Magi B, et al. **Methods Mol Biol** 1999;112:431–43 (52 ref.)
Detection of plant RNA viruses by nonisotopic dot-blot hybridization. Pallás V, et al. **Methods Mol Biol** 1998; 81:461–8
A recombinant Toscana virus nucleoprotein in a diagnostic immunoblot test system. Schwarz TF, et al. **Res Virol** 1998 Nov-Dec;149(6):413–8
Dot enzyme-linked immunosorbent assay (dot-ELISA) for schistosomiasis diagnosis using dacron as solid-phase. Montenegro SM, et al. **Rev Soc Bras Med Trop** 1999 Mar-Apr;32(2):139–43
A comparative evaluation of the sensitivity of five anti-hepatitis C virus immunoblot assays. Couroucé AM, et al. **Vox Sang** 1998;74(4):217–24
Genospecies and their influence on immunoblot results. Wilske B, et al. **Wien Klin Wochenschr** 1998 Dec 23; 110(24):882–5 (20 ref.)
Supplementary anti-hepatitis C virus (HCV) testing with 2nd and 3rd generation recombinant immunoblot assay and matrix applied to enzyme immunoassay positive sera and comparison with HCV-RNA detection. Engel PM, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):267–75
[Anti-HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot] Dubois F, et al. **Ann Biol Clin (Paris)** 1998 Jul-Aug;56(4):417–26 (11 ref.) (Eng. Abstr.) **(Fre)**
[Retrospective study of the value of the RIBA-3 test in 68 patients with discordant serologies with regard to hepatitis C obtained with third generation ELISA tests. Is there still a value in RIBA-3?] Cecille A, et al. **Pathol Biol (Paris)** 1999 May;47(5):508–11 (Eng. Abstr.) **(Fre)**
[Detection of isotype-specific autoantibodies to calpastatin in sera from patients with rheumatic diseases using heat-treated HeLa cell extract as an antigen source for immunoblotting] Takada R, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug;21(4):150–8 (Eng. Abstr.) **(Jpn)**
[Membrane-filtration immunoassay: reagents, methods and the diagnostic and technical means for detection] Khramov EN, et al. **Vestn Ross Akad Med Nauk** 1999;(8):20–6 (Eng. Abstr.) **(Rus)**

STANDARDS

[A retrospective study of the expediency of performing the immunoblot in conducting expert diagnosis at a center for the prevention and control of AIDS] Matveeva EM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan-Feb; (1):62–3 (Eng. Abstr.) **(Rus)**

IMMUNOBLOTTING, WESTERN see **BLOTTING, WESTERN**

IMMUNOCHEMISTRY

see related
IMMUNOBLOTTING
IMMUNOLOGIC TECHNIQUES

METHODS

Identification of oxidized proteins based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunochemical detection, isoelectric focusing, and microsequencing. Yan LJ, et al. **Anal Biochem** 1998 Oct 1;263(1):67–71
Immunofiltration: a methodology for preconcentration and determination of organic pollutants. Morais S, et al. **Anal Chem** 1999 May 1;71(9):1905–9
A novel microtiter plate based method for identification of B-cell epitopes. Gregorius K, et al. **J Pept Sci** 1999 Feb; 5(2):75–82

IMMUNOCOMPETENCE

Erythema multiforme-like eruptions induced by cytomegalovirus infection in an immunocompetent adult [letter] Koga T, et al. **Acta Derm Venereol** 1999 Mar; 79(2):166

Proximal white subungual onychomycosis in the immunocompetent patient: report of two cases and review of the literature [letter] Weinberg JM, et al. **Acta Derm Venereol** 1999 Jan;79(1):81-2 (10 ref.)

Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucémies et Autres Maladies du Sang (GOELAMS). Camilleri-Broët S, et al. **Am J Clin Pathol** 1998 Nov;110(5):607-12

Scopulariopsis: an invasive nasal infection. Jabor MA, et al. **Am J Rhinol** 1998 Sep-Oct;12(5):367-71 (8 ref.)

Changes in skin and nasal sensitivity to allergens and the course of rhinitis; a long-term follow-up study [see comments] Simola M, et al. **Ann Allergy Asthma Immunol** 1999 Feb;82(2):152-6. Comment in: Ann Allergy Asthma Immunol 1999 Feb;82(2):131-2.

Epstein-Barr virus meningoencephalitis with a lymphoma-like response in an immunocompetent host. Schellinger PD, et al. **Ann Neurol** 1999 May;45(5):659-62

Discovering the origins of immunological competence. Miller JF. **Annu Rev Immunol** 1999;17:1-17

Overt chorioretinitis after patient acquired toxoplasmosis in an immunocompetent subject [letter] Marx-Chemla C, et al. **Br J Ophthalmol** 1998 Dec;82(12):1446-7

Disseminated Pseudallescheria boydii infection in a nonimmunocompromised host. Khurshid A, et al. **Chest** 1999 Aug;116(2):572-4

Invasive sinusitis and cerebritis due to Curvularia clavata in an immunocompetent adult. Ebright JR, et al. **Clin Infect Dis** 1999 Mar;28(3):687-9

Disseminated adenovirus disease in immunocompromised and immunocompetent children. Munoz FM, et al. **Clin Infect Dis** 1998 Nov;27(5):1194-200

Fatal cytomegalovirus infection in a patient without evidence of prior immunodeficiency. Nyong'o A, et al. **Clin Infect Dis** 1998 Sep;27(3):659-60

Candida arthritis in an immunocompetent patient without predisposing factors. Calvo Romero JM, et al. **Clin Rheumatol** 1998;17(5):393-4

Lymphadenitis due to Mycobacterium terrae in an immunocompetent patient [letter] Shimizu T, et al. **Dermatology** 1999;198(1):97-8

Acute cytomegalovirus meningomyelitis in an immunocompetent patient. De Socio GV, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):885-7

Immune selection in murine tumors. A study of MCA induced sarcomas in normal and immunodeficient mice. Engel AM, et al. **Folia Microbiol (Praha)** 1998;43(5):483-6

Differences in thermoregulation between immunocompetent and immunodeficient hairless mice exposed to mild cold. Funda DP, et al. **Folia Microbiol (Praha)** 1998;43(5):487-9

Enhancement by mild cold stress of the antibody forming capacity in euthymic and athymic hairless mice. Sima P, et al. **Folia Microbiol (Praha)** 1998;43(5):521-3

Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Allende LM, et al. **Immunology** 1998 Aug;94(4):543-51

Murine model of Bartonella henselae infection in the immunocompetent host. Regnath T, et al. **Infect Immun** 1998 Nov;66(11):5534-6

Haemophilus aphrophilus meningitis complicated by hydrocephalus in an immunocompetent adult. Adeyemi-Doro FA, et al. **Infection** 1998 Nov-Dec; 26(6):405-7

Meningoencephalitis caused by human herpesvirus-6 in an immunocompetent adult patient: case report and review of the literature. Torre D, et al. **Infection** 1998 Nov-Dec; 26(6):402-4 (28 ref.)

Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Ben-Eliyahu S, et al. **Int J Cancer** 1999 Mar 15; 80(6):880-8

Risk of asthma in the general Spanish population attributable to specific immunoresponse. Spanish Group of the European Community Respiratory Health Survey. Soriano JB, et al. **Int J Epidemiol** 1999 Aug;28(4):728-34

Intrabronchial Aspergillus nidulans infection in an immunocompetent man. Yano S, et al. **Intern Med** 1999 Apr;38(4):372-5

Invasive sinus aspergillosis in apparently immunocompetent hosts. Clancy CJ, et al. **J Infect** 1998 Nov;37(3):229-40 (33 ref.)

GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. Lefrère JJ, et al. **J Med Virol** 1999 Sep; 59(1):32-7

Epstein-Barr virus DNA in cerebrospinal fluid from an immunocompetent man with herpes simplex virus encephalitis. Portolani M, et al. **J Neurovirol** 1998 Aug; 4(4):461-4

Cyclosporiasis in a traveler returning from South America. Drenaggi D, et al. **J Travel Med** 1998 Sep;5(3):153-5

Cytomegalovirus mononucleosis with decreased H2O2 production of neutrophil in an immunocompetent adult. Watanabe H, et al. **Kansenshogaku Zasshi** 1998 Sep; 72(9):939-44

Growth and development of Gymnophalloides seoi in immunocompetent and immunosuppressed C3H/HeN mice. Chai JY, et al. **Korean J Parasitol** 1999 Mar; 37(1):21-6

Corynebacterium bovis infection in immunocompetent hirsute mice [see comments] Gobbi A, et al. **Lab Anim Sci** 1999 Apr;49(2):209-11. Comment in: Lab Anim Sci 1999 Apr;49(2):132-3.

Simultaneous infection of immunocompetent individuals with multiple cytomegalovirus strains [letter; comment] Numazaki K, et al. **Lancet** 1998 Nov 21;352(9141):1710. Comment on: Lancet 1998 Oct 17;352(9136):1280-1.

The inter-relation of maternal immune competence, HIV-1 viral load, and nutritional status in preventing vertical transmission: an alternative to chemoprophylaxis? Moran PJ, et al. **Med Hypotheses** 1998 Nov;51(5):389-97

Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Pearson PA, et al. **Ophthalmology** 1999 Jan;106(1):148-53

Immune competence involving the natural killer cell lineage promotes placental growth. Guimond M, et al. **Placenta** 1999 Jul-Aug;20(5-6):441-50

Cytomegalovirus infection associated with ulcerative colitis in immunocompetent individuals. Rachima C, et al. **Postgrad Med J** 1998 Aug;74(874):486-9

A tradeoff between immunocompetence and sexual ornamentation in domestic fowl. Verhulst S, et al. **Proc Natl Acad Sci U S A** 1999 Apr 13;96(8):4478-81

Unusual radiological presentation and rapid fatal progression of invasive pulmonary aspergillosis in an immunocompetent young patient. Parameswaran K, et al. **Respirology** 1999 Sep;4(3):287-90

The lymphoid system and its role in maintaining immunocompetence. Workman ML. **Semin Oncol Nurs** 1998 Nov;14(4):248-55 (22 ref.)

Aspergillus spondylodiscitis in an immunocompetent paraplegic patient. Schubert M, et al. **Spinal Cord** 1998 Nov;36(11):800-3 (7 ref.)

Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:326-31

[Severe community-acquired pneumonia in immunocompetent children] Fayon M, et al. **Arch Pediatr** 1998;5 Suppl 1:49s-56s (46 ref.) (Eng. Abstr.) **(Fre)**

[Fatal fulminating hepatitis due to Herpes simplex virus type 2 in a young immunocompetent female] Chauveau E, et al. **Med Trop (Mars)** 1999;59(1):58-60 (Eng. Abstr.) **(Fre)**

[Cerebral abscess during a severe form of Salmonella typhimurium bacteremia in an immunocompetent patient] Broux C, et al. **Presse Med** 1998 May 23-30;27(19):909-10 (Eng. Abstr.) **(Fre)**

[Cerebral and pulmonary miliary tuberculosis in an immunocompetent patient: aggravation in an adequately treated patient] Gavazzi G, et al. **Presse Med** 1998 Jun 6;27(20):958-62 (Eng. Abstr.) **(Fre)**

[Disseminated tuberculosis in non-immunocompromised host: three case reports] Charfi MR, et al. **Rev Med Interne** 1998 Dec;19(12):917-20 (Eng. Abstr.) **(Fre)**

[How to increase immune response in HIV-infected patients] Gürtler L. **Fortschr Med** 1998 Nov 30;116(33):6 **(Ger)**

[Secondary immune deficiency (editorial)] Mikhailenko AA, et al. **Ter Arkh** 1998;70(11):5-9 **(Rus)**

[Pneumocystis carinii pneumonia in an immunocompetent patient after paraquat spraying (letter)] Lillo A, et al. **An Med Interna** 1999 Jul;16(7):381 (9 ref.) **(Spa)**

[Severe thrombocytopenia secondary to cytomegalovirus infection in an immunocompetent adult (letter)] López Vivancos J, et al. **An Med Interna** 1998 Oct;15(10):561-2 (8 ref.) **(Spa)**

[Cytomegalovirus granulomatous hepatitis in an immunocompetent patient] de la Serna-Higuera C, et al. **Gastroenterol Hepatol** 1999 May;22(5):230-1 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

[Impact of delta-9-tetrahydrocannabinol and its metabolites on the immune system] Masset D, et al. **Acta Clin Belg Suppl** 1999;1:39-43 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Variation in the immune status of two Australian pig breeds. Nguyen VP, et al. **Aust Vet J** 1998 Sep;76(9):613-7

Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status--a study in ex vivo-isolated endothelial cells. Liliensiek B, et al. **Blood** 1998 Nov 1;92(9):3394-404

IMMUNOLOGY

Defense mechanisms against infections. Reynolds HY. **Curr Opin Pulm Med** 1999 May;5(3):136-42 (61 ref.)

Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. Way SS, et al. **Infect Immun** 1999 Apr;67(4):2001-4

Immunocompetence of human microvascular brain endothelial cells: cytokine regulation of IL-1beta, MCP-1, IL-10, sICAM-1 and sVCAM-1. Frigerio S, et al. **J Neurol** 1998 Nov;245(11):727-30

Immunological competence and nutritional status in patients with lung cancer. Shirai R, et al. **Lung** 1998;176(6):363-70

Collagen-bound alpha1-microglobulin in normal and healed tissues and its effect on immunocompetent cells. Santin M, et al. **Scand J Immunol** 1999 Sep;50(3):289-95

Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Thomas CF Jr, et al. **Semin Respir Infect** 1998 Dec;13(4):289-95 (34 ref.)

Host-pathogen relationship: evasion from control [editorial] Dierich MP. **Wien Klin Wochenschr** 1999 Jun 4; 111(11):417-8

Dynamics of immune escape in HIV infection. Wodarz D, et al. **Wien Klin Wochenschr** 1999 Jun 4;111(11):419-27 (46 ref.)

[The modulating effect of physical factors during their action on immunocompetent organs] Babov KD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jan-Feb;(1):41-4 (56 ref.) **(Rus)**

PHYSIOLOGY

Immunosuppressive effect of vestibulo-cerebellar lesion in rats. Ghoshal D, et al. **Neurosci Lett** 1998 Nov 27; 257(2):89-92

IMMUNOCOMPROMISED HOST

Diverticulosis and diverticulitis in the immunocompromised patients. Detry O, et al. **Acta Chir Belg** 1999 May-Jun; 99(3):100-2 (15 ref.)

Respiratory distress due to tracheal aspergillosis in a severely immunocompromised patient. Lévy V, et al. **Acta Haematol** 1998;100(2):85-7

Cryptosporidiosis in immunocompromised patients in a Turkish university hospital. Arikan S, et al. **Acta Microbiol Immunol Hung** 1999;46(1):33-40

Bacillary angiomatosis in immunocompromised patients. Gasquet S, et al. **AIDS** 1998 Oct 1;12(14):1793-803 (37 ref.)

Fungal spinal osteomyelitis in the immunocompromised patient: MR findings in three cases. Williams RL, et al. **AJNR Am J Neuroradiol** 1999 Mar;20(3):381-5

Cytomegalovirus-infected cells in routinely prepared peripheral blood films of immunosuppressed patients. Pooley RJ Jr, et al. **Am J Clin Pathol** 1999 Jul;112(1):108-12

Prevention of infection in the immunocompromised host. Risi GF, et al. **Am J Infect Control** 1998 Dec;26(6):594-604; quiz 605-6 (76 ref.)

Bilateral acute retinal necrosis caused by cytomegalovirus in an immunocompromised patient. Akpek EK, et al. **Am J Ophthalmol** 1999 Jan;127(1):93-5

Raw shellfish consumption among renal disease patients. A risk factor for severe Vibrio vulnificus infection. Gholami P, et al. **Am J Prev Med** 1998 Oct;15(3):243-5

Epstein-Barr virus-associated leiomyosarcoma of the thyroid in a child with congenital immunodeficiency: a case report. Tulbah A, et al. **Am J Surg Pathol** 1999 Apr;23(4):473-6

Cryptococcal prostatic abscess in an immunocompromised patient: a case report and review of the literature. Yip SK, et al. **Ann Acad Med Singapore** 1998 Nov;27(6):873-6 (28 ref.)

Pathology of human immunodeficiency virus infection: noninfectious conditions. Klassen MK, et al. **Ann Diagn Pathol** 1997 Oct;1(1):57-64 (58 ref.)

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Tasker SA, et al. **Ann Intern Med** 1999 Sep 21;131(6):430-3

Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: case report and review of the literature. Breathnach O, et al. **Ann Oncol** 1999 Apr;10(4):461-5 (28 ref.)

Possible interaction between cyclosporine and chloramphenicol [letter] Bui L, et al. **Ann Pharmacother** 1999 Feb;33(2):252-3

Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Lazarus HM, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1192-7

Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Duan J, et al. **Antiviral Res** 1998 Oct;39(3):189-97

Symmetrical hemorrhagic bullae in an immunocompromised host. Johnson DS, et al. **Arch Dermatol** 1999 Aug; 135(8):983-4, 986-7

Left vocal cord paralysis as a primary manifestation of invasive pulmonary aspergillosis in a nonimmunocompromised host. Nakahira M, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jun;125(6):691-3 (6 ref.)

Oral candidiasis in children with immune suppression: clinical appearance and therapeutic considerations. Flaitz CM, et al. **ASDC J Dent Child** 1999 May-Jun;66(3):161-6, 154

Spread of influenza A virus infection in hospitalised patients with cancer [letter] Schepetiuk S, et al. **Aust N Z J Med** 1998 Aug;28(4):475-6

Crusted scabies in two immunocompromised children: successful treatment with oral ivermectin. Patel A, et al. **Australas J Dermatol** 1999 Feb;40(1):37-40

Aspergillus fumigatus strains recovered from

immunocompromised patients (ICP): subtyping of strains by RAPD analysis. Khan ZK, et al. **Biochem Mol Biol Int** 1998 Oct;46(3):537–48

Deep cutaneous infection with Mycobacterium avium–intracellulare complex in an immunosuppressed patient with dermatomyositis [letter] Bedlow AJ, et al. **Br J Dermatol** 1998 Nov;139(5):920–2

The treatment of Merkel cell carcinoma and its association with immunosuppression [letter] Plunkett TA, et al. **Br J Dermatol** 1998 Aug;139(2):345–6

The Koebner phenomenon in Kaposi's sarcoma in a renal transplant recipient [letter] Seçkin D, et al. **Br J Dermatol** 1998 Aug;139(2):346–8

Cellulitis due to Escherichia coli in three immunocompromised subjects. Yoon TY, et al. **Br J Dermatol** 1998 Nov;139(5):885–8 (19 ref.)

Progressive outer retinal necrosis in a patient with cutaneous non-Hodgkin's T cell lymphoma (Sézary syndrome) [letter] Njoo FL, et al. **Br J Ophthalmol** 1998 Oct;82(10):1218–9

An unusual manifestation of encephalitozoonosis in chinchilla rabbits. Levkut M, et al. **Can Vet J** 1998 Sep;39(9):576–7

Antimicrobial therapy in immunocompromised patients: infectious complications of solid tumors. Zuger A. **Cancer Invest** 1999;17(3):220–2

Prevention of infection in immunocompromised hosts. Noskin GA. **Cancer Treat Res** 1998;96:223–46 (92 ref.)

Pharmacologic considerations with antimicrobials used in oncology. Postelnick M, et al. **Cancer Treat Res** 1998; 96:247–82 (146 ref.)

Role of the clinical microbiology laboratory in the diagnosis of infections. Thomson RB Jr, et al. **Cancer Treat Res** 1998; 96:143–65 (29 ref.)

Recent advances in the management of viral infections. Wingard JR. **Cancer Treat Res** 1998;96:183–200 (119 ref.)

The challenge of invasive fungal infection. de Pauw BE, et al. **Chemotherapy** 1999 Jun;45 Suppl 1:1–14 (66 ref.)

Mycobacterial infections in lung transplant recipients. Kesten S, et al. **Chest** 1999 Mar;115(3):741–5

Recognition of the immunocompromised patient. Gutierrez MG, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):1–18 (48 ref.)

Malignancies associated with the immunocompromised state. Katariya K, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):63–77, viii (57 ref.)

Aspergillus and other fungi. Robinson LA. **Chest Surg Clin N Am** 1999 Feb;9(1):193–225, x (86 ref.)

Opportunistic thoracic infections. Bacteria, viruses, and protozoa. Talbot EA, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):167–92, ix–x (91 ref.)

The initial pulmonary evaluation of the immunocompromised patient. Walsh FW, et al. **Chest Surg Clin N Am** 1999 Feb; 9(1):19–38 (95 ref.)

Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed. Stewart T, et al. **Clin Cancer Res** 1997 Jan;3(1):51–5

Central nervous system infections due to Stomatococcus mucilaginosus in immunocompromised hosts. Goldman M, et al. **Clin Infect Dis** 1998 Nov;27(5):1241–6 (13 ref.)

Infections due to nontuberculous mycobacteria in children with leukemia. Levendoglu-Tugal O, et al. **Clin Infect Dis** 1998 Nov;27(5):1227–30

Disseminated adenovirus disease in immunocompromised and immunocompetent children. Munoz FM, et al. **Clin Infect Dis** 1998 Nov;27(5):1194–200

Conventional respiratory viruses recovered from immunocompromised patients: clinical considerations. Rabella N, et al. **Clin Infect Dis** 1999 May;28(5):1043–8

Bacteremia due to motile Enterococcus species: clinical features and outcomes. Ratanasuwan W, et al. **Clin Infect Dis** 1999 May;28(5):1175–7

Primary cutaneous aspergillosis—an emerging infection among immunocompromised patients [editorial; comment] Walsh TJ. **Clin Infect Dis** 1998 Sep;27(3):453–7. Comment on: Clin Infect Dis 1998 Sep;27(3):437–52. Comment on: Clin Infect Dis 1998 Sep;27(3):641–3. Comment on: Clin Infect Dis 1998 Sep;27(3):643–4.

Emphysematous cystitis: possible side-effect of cyclophosphamide therapy [letter] Abuzarad H, et al. **Clin Nephrol** 1998 Dec;50(6):394–6

CT and MRI manifestations of central nervous system infection following allogeneic bone marrow transplantation. Coley SC, et al. **Clin Radiol** 1999 Jun; 54(6):390–7

Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. Kleindienst R, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):65–7

Human parvovirus B19 infection in organ transplant recipients. Marchand S, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):17–24 (63 ref.)

Phaeohyphomycosis in kidney transplant patients. Mesa A, et al. **Clin Transplant** 1999 Jun;13(3):273–6

Cryptosporidium in water and the immunocompromised. **Commun Dis Rep CDR Wkly** 1999 Aug 13;9(33):289, 292

Diagnosis of respiratory viruses in cancer and transplant patients. Englund JA, et al. **Curr Clin Top Infect Dis** 1999; 19:30–59 (121 ref.)

Treatment of fungal infections in neutropenic children [see comments] Lehrnbecher T, et al. **Curr Opin Pediatr** 1999 Feb;11(1):47–55 (112 ref.). Comment in: Curr Opin Pediatr 1999 Feb;11(1):31–2.

Respiratory infections in immunocompromised patients. Barry SM, et al. **Curr Opin Pulm Med** 1999 May; 5(3):168–73 (50 ref.)

Infections in solid organ transplant recipients. Kibbler CC. **Curr Top Pathol** 1999;92:19–35 (83 ref.)

Subcutaneous Fusarium foot abscess in a renal transplant patient. Girardi M, et al. **Cutis** 1999 May;63(5):267–70

Disseminated cutaneous protothecosis in an immunocompromised host: a case report and literature review. Wirth FA, et al. **Cutis** 1999 Mar;63(3):185–8 (48 ref.)

Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy. Degraeve C, et al. **Dermatology** 1999; 198(2):162–3

Cryptosporidia and microsporidia—waterborne diseases in the immunocompromised host. Franzen C, et al. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):245–62 (140 ref.)

Goussia carpelli (Protozoa: Coccidia) infection in stressed and immunosuppressed common carp Cyprinus carpio. Steinhagen D, et al. **Dis Aquat Organ** 1998 Nov 30; 34(3):199–204

Perianal lymphoma in a heterosexual and nonimmunocompromised patient: report of a case and review of the literature. Smith DL 2nd, et al. **Dis Colon Rectum** 1999 Jul;42(7):952–4 (13 ref.)

Preventing zoonotic diseases in immunocompromised persons: the role of physicians and veterinarians. Grant S, et al. **Emerg Infect Dis** 1999 Jan–Feb;5(1):159–63

Fever in the immunocompromised host. Mendelson M. **Emerg Med Clin North Am** 1998 Nov;16(4):761–79, vi (59 ref.)

Non-tuberculous mycobacterial infection in children with cancer. Graham JC, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jun;17(6):394–7

Three cases of tuberculosis after heart transplantation in Spain. Muñoz RM, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):801–6 (15 ref.)

A case of Listeria murray/grayi bacteremia in a patient with advanced Hodgkin's disease. Todeschini G, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):808–10

Management of infections due to the varicella-zoster virus. 11th consensus conference on anti-infectious therapy of the French-speaking Society of Infectious Diseases (SPILF). Peyramond D, et al. **Eur J Dermatol** 1998 Sep; 8(6):397–402 (0 ref.)

Dietary nucleosides and nucleotides reduce Cryptosporidium parvum infection in dexamethasone immunosuppressed adult mice. Adjei AA, et al. **Exp Parasitol** 1999 Jul; 92(3):199–208

Conjunctival carcinoma in an immunosuppressed patient [letter] Ansari EA, et al. **Eye** 1998;12 (Pt 5):891–3

9th International Workshop on Immunodeficient Animals (IWIDA). Prague, Czech Republic, June 15–18, 1997. Proceedings and abstracts. **Folia Microbiol (Praha)** 1998; 43(5):471–559

Legionella sp pneumonia in patients with hematologic diseases. A study of 10 episodes from a series of 67 cases of pneumonia [letter] Fernández-Avilés F, et al. **Haematologica** 1999 May;84(5):474–5

Listeria meningitis presenting in an immunocompetent adult patient [see comments] Kelly J, et al. **Hosp Med** 1999 Feb; 60(2):140–1. Comment in: Hosp Med 1999 Feb;60(2):80–1.

Nosocomial transmission of opportunistic infections. Gerberding JL. **Infect Control Hosp Epidemiol** 1998 Aug; 19(8):574–7 (31 ref.)

Pneumonia in the compromised host including cancer patients and transplant patients. Collin BA, et al. **Infect Dis Clin North Am** 1998 Sep;12(3):781–805, xi (160 ref.)

Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients. Krivoy N, et al. **Infection** 1998 Nov–Dec;26(6):396–8

Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. Sterling TR, et al. **Int J Tuberc Lung Dis** 1999 Mar;3(3):248–54

Healthy pets, healthy people. Wong SK, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):335–8

The immunocompromised host and risk for cardiovascular infection. Schell HM. **J Cardiovasc Nurs** 1999 Jan; 13(2):31–48 (50 ref.)

Systemic infection of an immunocompromised patient with Methylobacterium zatmanii. Hornei B, et al. **J Clin Microbiol** 1999 Jan;37(1):248–50

Massilia timonae gen. nov., sp. nov., isolated from blood of an immunocompromised patient with cerebellar lesions. La Scola B, et al. **J Clin Microbiol** 1998 Oct;36(10):2847–52

Detection and typing of human papillomaviruses in mucosal and cutaneous biopsies from immunosuppressed and immunocompetent patients and patients with epidermodysplasia verruciformis: a unified diagnostic approach. Surentheran T, et al. **J Clin Pathol** 1998 Aug; 51(8):606–10

Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised. Baldanti F, et al. **J Clin Virol** 1998 Jul 24;11(1):51–60 (45 ref.)

Detection of Microsporidia by different staining techniques. Awadalla HN, et al. **J Egypt Soc Parasitol** 1998 Dec; 28(3):729–38

Preliminary identification of an intestinal coccidian parasite in man. el Naga IF, et al. **J Egypt Soc Parasitol** 1998 Dec; 28(3):807–14

Rhodotorula rubra fungaemia in an immunosuppressed patient. Papadogeorgakis H, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):169–70

Hepatitis viruses under immunosuppressive agents. Liaw YF. **J Gastroenterol Hepatol** 1998 Jan;13(1):14–20 (75 ref.)

Upper limb Escherichia coli cellulitis in the immunocompromised. Brzozowski D, et al. **J Hand Surg [Br]** 1997 Oct;22(5):679–80

The Bouchier report--a recommendation too far? Cunningham R. **J Hosp Infect** 1999 Apr;41(4):261–2

Invasive yeast infections other than Candida spp. in acute leukaemia. Krcmery V, et al. **J Hosp Infect** 1999 Mar; 41(3):181–94 (101 ref.)

Mycobacterium szulgai osteomyelitis. Hurr H, et al. **J Infect** 1998 Sep;37(2):191–2

Listeria monocytogenes meningitis in a penicillin-allergic paediatric renal transplant patient. Weston VC, et al. **J Infect** 1998 Jul;37(1):77–8

Development and distribution of pathologic lesions are related to immune status and tissue deposition of human granulocytic ehrlichiosis agent-infected cells in a murine model system. Bunnell JE, et al. **J Infect Dis** 1999 Aug; 180(2):546–50

Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. Hudnall SD, et al. **J Infect Dis** 1998 Dec;178(6):1791–4

Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals. Opal SM, et al. **J Infect Dis** 1998 Oct;178(4):1205–8

GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. Kumar R, et al. **J Leukoc Biol** 1999 Jan;65(1):102–8

Infected ovarian cyst in a homozygous beta-thalassemic patient. Sukcharoen N, et al. **J Med Assoc Thai** 1999 May; 82(5):511–4

Respiratory virus infections in immunocompromised patients [editorial] Muir D, et al. **J Med Microbiol** 1998 Jul; 47(7):561–2

Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. Peret Filho LA, et al. **J Med Microbiol** 1998 Feb;47(2):111–6

Actinomyces and nocardia infections in immunocompromised and nonimmunocompromised patients. Dominguez DC, et al. **J Natl Med Assoc** 1999 Jan;91(1):35–9

Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. Kappagoda C, et al. **J Paediatr Child Health** 1999 Aug;35(4):341–5

Pneumocystis carinii pneumonia: pitfalls of prophylaxis. Massie RJ, et al. **J Paediatr Child Health** 1998 Oct; 34(5):477–9

Endemic fungal pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1999 Jan;14(1):1–8 (52 ref.)

Noninfectious lung disease in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1999 Jan;14(1):9–24 (94 ref.)

Pulmonary infections in immunocompromised patients who do not have acquired immunodeficiency syndrome: a systematic approach. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):234–46 (106 ref.)

Opportunistic fungal pneumonia. Connolly JE Jr, et al. **J Thorac Imaging** 1999 Jan;14(1):51–62 (60 ref.)

Viral and Pneumocystis carinii infections of the lung in the immunocompromised host. McGuinness G, et al. **J Thorac Imaging** 1999 Jan;14(1):25–36 (46 ref.)

Pulmonary disease in the immunocompromised child. Pennington DJ, et al. **J Thorac Imaging** 1999 Jan; 14(1):37–50 (72 ref.)

Susceptibility of immunodeficient gene-knockout mice to urinary tract infection. Jones-Carson J, et al. **J Urol** 1999 Jan;161(1):338–41

Role of fibreoptic bronchoscopy in the management of immunocompromised patients with pulmonary infiltrates. Hussain SF, et al. **JPMA J Pak Med Assoc** 1998 Oct; 48(10):311–2

Which type of underlying disease facilitates cytomegalovirus infection? Comparison of benign disease, hematopoietic malignancy, and post-bone-marrow or renal transplantation status by using the first standardized objective PCR test for cytomegalovirus detection. Hiyoshi M, et al. **Kansenshogaku Zasshi** 1999 Feb;73(2):144–8

Growth and development of Gymnophalloides seoi in immunocompetent and immunosuppressed C3H/HeN mice. Chai JY, et al. **Korean J Parasitol** 1999 Mar; 37(1):21–6

Trends in infection morbidity in a pediatric oncology ward, 1986–1995. Wehl G, et al. **Med Pediatr Oncol** 1999 May; 32(5):336–43

Microwave-stimulated Jones-Marres method for staining fungi in brain tissue of immunocompromised patients. Boon ME, et al. **Methods** 1998 Jun;15(2):141–9

VIII Meeting of the European Society for Immunodeficiencies, ESID'98. V Meeting of the International Patient Organisation of Primary Immunodeficiencies, IPOPI '98. III Meeting of the

International Nursing Group for Immunodeficiencies, INGID '98. Rhodes, Hellas, October 8–11, 1998. Abstracts. **Mol Immunol** 1998 Aug;35(11–12):623–818

PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients. Chryssanthou E, et al. **Mycoses** 1999;42(4):239–47

Reappearance of hepatitis B 10 years after kidney transplantation [letter] Kidd-Ljunggren K, et al. **N Engl J Med** 1999 Jul 8;341(2):127–8

Fever in immunocompromised patients. Pizzo PA. **N Engl J Med** 1999 Sep 16;341(12):893–900 (32 ref.)

Pseudomonas folliculitis from a spa pool in an immunocompromised patient [letter; comment] Corbett R. **N Z Med J** 1999 Feb 26;112(1082):59. Comment on: N Z Med J 1998 Oct 9;111(1075):389.

Herpes varicella zoster encephalitis in immunocompromised patients. Weaver S, et al. **Neurology** 1999 Jan 1;52(1):193–5

Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen--Chaetomium atrobrunneum: case report. Guppy KH, et al. **Neurosurgery** 1998 Dec;43(6):1463–9 (42 ref.)

Subcutaneous phaeohyphomycosis caused by Phaeoacremonium rubrigenum in an immunosuppressed patient. Matsui T, et al. **Nippon Ishinkin Gakkai Zasshi** 1999;40(2):99–102

The effect of chemotherapy on the supragingival plaque of pediatric cancer patients. Sixou JL, et al. **Oral Oncol** 1998 Nov;34(6):476–83

Bilateral acute coalescent mastoiditis in an immunocompromised infant with a rare leukocyte adhesion deficiency. Martinez SA, et al. **Otolaryngol Head Neck Surg** 1999 Jun;120(6):926–8

Trichomonas tenax empyema in an immunocompromised patient with advanced cancer. Shiota T, et al. **Parasite** 1998 Dec;5(4):375–7

Immunizations for the immunocompromised child. McFarland E. **Pediatr Ann** 1999 Aug;28(8):487–96 (32 ref.)

Preoperative diagnosis of Mycobacterium avium lymphadenitis in two immunocompetent children by polymerase chain reaction of gastric aspirates. Haas WH, et al. **Pediatr Infect Dis J** 1998 Nov;17(11):1016–20

Ochrobactrum anthropi bacteremia associated with a catheter in an immunocompromised child and review of the pediatric literature. Saavedra J, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):658–60 (9 ref.)

Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Furth SL, et al. **Pediatr Transplant** 1997 Aug;1(1):37–42

Combination antifungal therapy for invasive aspergillosis infection in liver transplant recipients: report of two patients. Bajjoka IE, et al. **Pharmacotherapy** 1999 Jan; 19(1):118–23

The lung in the immunocompromised patient. Infectious complications Part 1. Baughman RP. **Respiration** 1999; 66(2):95–109 (179 ref.)

Pulmonary malignancies in the immunocompromised patient. Cadranel J, et al. **Respiration** 1999;66(4):289–309 (231 ref.)

Rhinocerebral mycosis in immunocompromised patients. A case report and review of the literature. Schmidt JM, et al. **Rhinology** 1998 Jun;36(2):90–3

Lymphocytes in host defense against Pneumocystis carinii. Beck JM, et al. **Semin Respir Infect** 1998 Dec;13(4):330–8 (62 ref.)

Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii. Hughes WT. **Semin Respir Infect** 1998 Dec;13(4):283–8 (33 ref.)

Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Limper AH. **Semin Respir Infect** 1998 Dec;13(4):339–47 (77 ref.)

Cutaneous tuberculosis mimicking cellulitis in an immunosuppressed patient. Chin PW, et al. **Singapore Med J** 1999 Jan;40(1):44–5

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. Link K, et al. **South Med J** 1999 Jul; 92(7):728–31 (42 ref.)

Rifampicin as treatment for pruritus in malignant cholestasis: an example of an improper indication for anti-infective drugs [letter] Castagnola E, et al. **Support Care Cancer** 1999 May;7(3):160

Acute parvovirus infection in a heart transplant recipient. Bisognano JD, et al. **Transplant Proc** 1999 Aug; 31(5):2159–60

Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Dengler TJ, et al. **Transplantation** 1998 Nov 27;66(10):1340–7

A cluster of suspected Pneumocystis carinii Pneumonia following intensive chemotherapy in a Belfast haematology unit. Ong YL, et al. **Ulster Med J** 1998 Nov;67(2):104–9

A case of intestinal Mycobacterium simiae infection in an SIV-infected immunosuppressed rhesus monkey. Didier A, et al. **Vet Pathol** 1999 May;36(3):249–52

[New oncogenic viruses in human pathology] Brousset P, et al. **Ann Pathol** 1998;18(5 Suppl):76–7 **(Fre)**

[Extrapulmonary tuberculosis in the central western region. Retrospective study of 217 cases (Gericco 1991–1993)] Denis-Delpierre N, et al. **Presse Med** 1998 Feb 28; 27(8):341–6 (Eng. Abstr.) **(Fre)**

[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**

[Geotrichum capitatum infection in a neutropenic patient. Apropos of a case and review of the literature] Fouassier M, et al. **Rev Med Interne** 1998 Jun;19(6):431–3 (13 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary cavitated opacity in immunocompromised patient] Lamour C, et al. **Rev Pneumol Clin** 1998 Feb; 54(1):38–41 (Eng. Abstr.) **(Fre)**

[A neutropenic acute myeloid leukemia patient complicated with chronic otitis media due to Aspergillus niger and yeast-like fungi caused by superinfection] Itoh K, et al. **Kansenshogaku Zasshi** 1999 Jun;73(6):618–22 (Eng. Abstr.) **(Jpn)**

[A case of cutaneous tuberculosis associated with steroid therapy for mixed connective tissue disease] Yagi T, et al. **Kekkaku** 1998 Sep;73(9):557–62 (Eng. Abstr.) **(Jpn)**

[Epidural abscess associated with epidural block in a patient with immunosuppressive disease] Yamaguchi M, et al. **Masui** 1999 May;48(5):506–8 (Eng. Abstr.) **(Jpn)**

[Case of systemic erythematodes on long-term care with repeated development of severe cytomegalovirus infection] Masago R, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1555–6 **(Jpn)**

[Endogenous infection] Matsumoto T, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):399–402 (8 ref.) **(Jpn)**

[Immunosuppressive measles encephalitis] Nihei K. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):63–4 (5 ref.) **(Jpn)**

[Recommended vaccines and immunoglobulins for immunocompromised patients] Bricks LF. **Rev Saude Publica** 1998 Jun;32(3):281–94 (75 ref.) (Eng. Abstr.) **(Por)**

[Recommendations for the use of the varicella vaccine in immunosuppressed patients (editorial)] Ruiz Contreras J, et al. **An Esp Pediatr** 1999 Feb;50(2):113–8 **(Spa)**

[Which are the vaccines that human immunodeficiency virus infected patients must receive?] Valencia Ortega ME, et al. **An Med Interna** 1998 Aug;15(8):439–42 (36 ref.) (Eng. Abstr.) **(Spa)**

[Macrolide prophylaxis in patients with HIV-1 infection or other forms of immunosuppression] García Alcaide F, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 1:59–65 (40 ref.) **(Spa)**

[Chlamydia as the agent responsible for disease in the immunosuppressed and transplanted patient] Muñoz García-Paredes P, et al. **Rev Clin Esp** 1998 Sep;198 Suppl 1:35–9 (61 ref.) **(Spa)**

[Herpesvirus detection in immunocompromised patients with meningoencephalitis by the polymerase chain reaction technic] Kouri V, et al. **Rev Cubana Med Trop** 1998; 50(3):186–90 (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Restricted isotypic antibody reactivity to hepatitis C virus synthetic peptides in immunocompromised patients. Devesa M, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):279–81

Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency. Kimura K, et al. **Eur J Immunol** 1999 May;29(5):1532–42

Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. Heuer JG, et al. **J Immunother** 1999 Jul; 22(4):324–35

High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. Nelson KE, et al. **J Infect Dis** 1999 Aug;180(2):337–43

Bacterial pneumonia in immunocompromised patients. Conces DJ Jr. **J Thorac Imaging** 1998 Oct;13(4):261–70 (81 ref.)

Mycobacterial infection in immunocompromised patients. Washington L, et al. **J Thorac Imaging** 1998 Oct; 13(4):271–81 (66 ref.)

Primary subcutaneous nocardial infection in a SLE patient. Balbir-Gurman A, et al. **Lupus** 1999;8(2):164–7

Diffuse pulmonary infiltrates in immunocompromised patients. Fijen JW, et al. **Neth J Med** 1999 Jul;55(1):23–8

Expression of interleukin-2 receptor, CD25, on CD4 lymphocytes in response to varicella-zoster virus antigen among patients with malignancies immunized with live attenuated varicella vaccine. Oitani K. **Pediatr Int** 1999 Feb;41(1):32–6

[Study of different pattern of immuno-modulatory mechanism by tonifying kidney and invigorating spleen] Shen ZY, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):351–3 (Eng. Abstr.) **(Chi)**

[Pulmonary infections in immune deficiency states. Immunosuppression and its consequences] Lebargy F. **Presse Med** 1998 May 23–30;27(19):921–2 **(Fre)**

[Methods of investigation in pulmonary infections] Milosevic D, et al. **Presse Med** 1998 May 23–30;27(19):924–6 (19 ref.) **(Fre)**

[Pneumocystis carinii is still a dangerous opportunist. The infection is continuously a threat to immunocompromised patients] Olsson M, et al. **Lakartidningen** 1999 Jan 27; 96(4):328–31 (60 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOLOGY

Healing times of pedal ulcers in diabetic immunosuppressed patients after transplantation. Sinacore DR. **Arch Phys Med Rehabil** 1999 Aug;80(8):935–40

Endogenous hematopoietic reconstitution induced by human umbilical cord blood cells in immunocompromised mice: implications for adoptive therapy. Rameshwar P, et al. **Exp Hematol** 1999 Jan;27(1):176–85

The lung in the immunocompromised patient. Infectious complications part 2. Tamm M. **Respiration** 1999; 66(3):199–207 (77 ref.)

IMMUNOCONJUGATES

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study. Riva P, et al. **Acta Oncol** 1999;38(3):351–9

Production and characterization of a bivalent single chain Fv/alkaline phosphatase conjugate specific for the hemocyanin of the scorpion Androctonus australis. Mousli M, et al. **Biochim Biophys Acta** 1998 Oct 23;1425(2):348–60

Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. King HD, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):279–88

Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Miller CR, et al. **Cancer Res** 1998 Dec 15;58(24):5738–48

ADMINISTRATION & DOSAGE

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Sievers EL, et al. **Blood** 1999 Jun 1;93(11):3678–84

Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley RB, et al. **Cancer Res** 1999 Aug 15;59(16):3998–4003

Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging. Panousis C, et al. **Drugs Aging** 1999 Jul;15(1):1–13 (88 ref.)

CHEMISTRY

Conjugation, immunoreactivity, and immunogenicity of calix[4]arenes; model study to potential calix[4]arene-based Ac3+ chelators. Grote Gansey MH, et al. **Bioconjug Chem** 1999 Jul-Aug;10(4):613–23

Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Peterson JJ, et al. **Bioconjug Chem** 1999 Jul-Aug;10(4):553–7

Synthesis of cancer peptide antigen-lipid A analog conjugates for synthetic vaccines. Ikeda K, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr;47(4):563–8

Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Bendas G, et al. **Int J Pharm** 1999 Apr 20;181(1):79–93

Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Hudson AJ, et al. **Int J Pharm** 1999 May 10;182(1):49–58

Evaluation of methods for large scale preparation of antibody ligand conjugates. Wu C, et al. **Nucl Med Biol** 1999 Apr; 26(3):339–42

Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Wang M, et al. **Protein Eng** 1998 Dec;11(12):1277–83

IMMUNOLOGY

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Ragupathi G, et al. **Cancer Immunol Immunother** 1999 Apr;48(1):1–8

Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Yao TJ, et al. **Clin Cancer Res** 1999 Jan;5(1):77–81

Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: disulfide-linked epitopes, multiple injections, and role of CD4(+) cells. Ballard JD, et al. **Infect Immun** 1998 Oct;66(10):4696–9

Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Wiedermann U, et al. **Int Immunol** 1999 Jul;11(7):1131–8

Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Omelyanenko V, et al. **Pharm Res** 1999 Jul; 16(7):1010–9

METABOLISM

Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Gillies SD, et al. **Cancer Res** 1999 May 1;59(9):2159–66

Incorporation of 15N from ammonium into the N-linked oligosaccharides of an immunoadhesin glycoprotein expressed in Chinese hamster ovary cells. Gawlitzek M, et al. **Glycobiology** 1999 Feb;9(2):125–31

Targetability of novel immunoliposomes prepared by a new

antibody conjugation technique. Bendas G, et al. **Int J Pharm** 1999 Apr 20;181(1):79–93

Preparation, biodistribution, and dosimetry of 188Re-labeled MoAb ior cea1 and its F(ab')2 fragments by avidin-biotin strategy. Ferro-Flores G, et al. **Nucl Med Biol** 1999 Jan; 26(1):57–62

Strategies to reduce renal radioactivity levels of antibody fragments. Arano Y. **Q J Nucl Med** 1998 Dec;42(4):262–70 (61 ref.)

PHARMACOKINETICS

An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Davies Q, et al. **Br J Obstet Gynaecol** 1999 Jan;106(1):31–7

Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Li Q, et al. **Cancer Immunol Immunother** 1998 Nov; 47(3):121–30

Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Arano Y, et al. **Cancer Res** 1999 Jan 1;59(1):128–34

Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. DeNardo GL, et al. **Clin Cancer Res** 1998 Oct;4(10):2483–90

Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Foss FM, et al. **Clin Cancer Res** 1998 Nov;4(11):2691–700

Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial. Macey DJ, et al. **Clin Cancer Res** 1997 Sep; 3(9):1547–55

In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Waurzyniak B, et al. **Clin Cancer Res** 1997 Jun;3(6):881–90

Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Hudson AJ, et al. **Int J Pharm** 1999 May 10;182(1):49–58

Enhanced effects of monoclonal antibody carboplatin immunoconjugates uptake and anti-tumor effects with angiotensin II and tumor necrosis factor. Takeda A, et al. **J Chemother** 1999 Apr;11(2):137–43

Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Morales-Morales A, et al. **Nucl Med Biol** 1999 Apr;26(3):275–9

Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Quadri SM, et al. **Q J Nucl Med** 1998 Dec;42(4):250–61

PHARMACOLOGY

Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells. Erben U, et al. **Cancer Res** 1999 Jun 15;59(12):2924–30

Synthesis of cancer peptide antigen-lipid A analog conjugates for synthetic vaccines. Ikeda K, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr;47(4):563–8

The selective cytotoxicity of cobra venom factor immunoconjugate on cultured human nasopharyngeal carcinoma cell line. Wang XM, et al. **Hum Exp Toxicol** 1999 Feb;18(2):71–6

Influence of immunoadjuvants and a promiscous T-cell determinant on the immunogenicity of RESA peptide antigen of P. falciparum. Chaba B, et al. **Int J Immunopharmacol** 1998 Jun;20(6):259–73

Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Yao Z, et al. **Nucl Med Biol** 1998 Aug; 25(6):557–60

A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation. Ruef J, et al. **Thromb Haemost** 1999 Jul; 82(1):109–14

THERAPEUTIC USE

New non-cytotoxic approaches to ovarian cancer. Kaye SB, et al. **Ann Oncol** 1999;10 Suppl 1:65–8 (26 ref.)

Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Sinha AA, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):893–902

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Juweid ME, et al. **Cancer** 1999 Apr 15; 85(8):1828–42

Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts. Kinuya S, et al. **Cancer Lett** 1999 Jun 1;140(1-2):209–18

Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Flavell DJ, et al. **Cancer Res** 1998 Dec 15;58(24):5787–94

Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Stan AC, et al. **Cancer Res** 1999 Jan 1;59(1):115–21

Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Vrouenraets MB, et al. **Cancer Res** 1999 Apr 1;59(7):1505–13

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Kumar A, et al. **Circulation** 1999 Mar 16;99(10):1363–9

Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). DeNardo GL, et al. **Clin Cancer Res** 1997 Jan;3(1):71–9

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Divgi CR, et al. **Clin Cancer Res** 1998 Nov; 4(11):2729–39

Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Multani PS, et al. **Clin Cancer Res** 1998 Nov;4(11):2599–604

Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Patrick TA, et al. **Int J Cancer** 1998 Nov 9; 78(4):470–9

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S, et al. **J Infect Dis** 1999 Jun; 179(6):1565–8

Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. Han Y, et al. **J Infect Dis** 1999 Jun; 179(6):1477–84

Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2. Yamamoto A, et al. **Oncol Rep** 1999 Jan-Feb;6(1):179–84

Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Hu Z, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8161–6

Neuroprotection with noninvasive neurotrophin delivery to the brain. Wu D, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):254–9

Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Kennel SJ, et al. **Radiat Res** 1999 Mar;151(3):244–56

[Monoclonal antibodies and immunoconjugates: new prospects in the treatment of non-Hodgkin's lymphomas] Sack A, et al. **Strahlenther Onkol** 1999 Apr;175(4):192–3 **(Ger)**

TOXICITY

Cytotoxic effect of binar cisplatin immunoconjugate. Plotnikov VM. **Adv Exp Med Biol** 1998;451:151–2

In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Waurzyniak B, et al. **Clin Cancer Res** 1997 Jun;3(6):881–90

Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Wang B, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1627–32

IMMUNOCONTRACEPTION see **CONTRACEPTION, IMMUNOLOGIC**

IMMUNOCYTOADHERENCE see **ROSETTE FORMATION**

IMMUNOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNODEFICIENCY, COMMON VARIABLE see **COMMON VARIABLE IMMUNODEFICIENCY**

IMMUNODEFICIENCY, SEVERE COMBINED see **SEVERE COMBINED IMMUNODEFICIENCY**

IMMUNODEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNODEFICIENCY VIRUS, BOVINE

Seroprevalence of bovine immunodeficiency virus in dairy and beef cattle herds in Korea. Cho KO, et al. **J Vet Med Sci** 1999 May;61(5):549–51

Seroprevalence to bovine immunodeficiency virus and lack of association with leukocyte counts in Italian dairy cattle. Cavirani S, et al. **Prev Vet Med** 1998 Dec 1;37(1-4):147–57

ENZYMOLOGY

Natural selection of the Pol gene of bovine immunodeficiency virus. Cooper CR, et al. **Virology** 1999 Mar 15; 255(2):294–301

GENETICS

Overexpression and purification of an immunologically reactive His-BIV capsid fusion protein. Betemps D, et al. **Protein Expr Purif** 1999 Apr;15(3):258–64

IMMUNOLOGY

Development of a Western blot assay for detection of bovine immunodeficiency-like virus using capsid and transmembrane envelope proteins expressed from recombinant baculovirus. Abed Y, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):168–72

The antibody response of cattle infected with bovine immunodeficiency virus to peptides of the viral transmembrane protein. Scobie L, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):237–43

AIDS campaigner on trial for testing vaccine on people [news] Kumar S. **Lancet** 1999 May 15;353(9165):1686

Effects of long-term infection with bovine immunodeficiency virus and/or bovine leukemia virus on antibody and lymphocyte proliferative responses in cattle. Isaacson JA, et al. **Vet Immunol Immunopathol** 1998 Jul 31;64(3):249–66

ISOLATION & PURIFICATION

Development of a Western blot assay for detection of bovine immunodeficiency-like virus using capsid and transmembrane envelope proteins expressed from recombinant baculovirus. Abed Y, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):168–72

Seroprevalence and field isolation of bovine immunodeficiency virus. Meas S, et al. **J Vet Med Sci** 1998 Nov;60(11):1195–202

METABOLISM

RNA bulge entropies in the unbound state correlate with peptide binding strengths for HIV-1 and BIV TAR RNA because of improved conformational access. Lustig B, et al. **Nucleic Acids Res** 1998 Nov 15;26(22):5212–7

PATHOGENICITY

Lymphadenopathy and non-suppurative meningo-encephalitis in calves experimentally infected with bovine immunodeficiency-like virus (FL112). Munro R, et al. **J Comp Pathol** 1998 Aug;119(2):121–34

Bovine immunodeficiency virus and analogies with human immunodeficiency virus. Straub OC, et al. **Leukemia** 1999 Apr;13 Suppl 1:S106–9

Infection of rabbits with R29 strain of bovine immunodeficiency virus: virulence, immunosuppression, and progressive mesenteric lymphadenopathy. Kalvatchev Z, et al. **Viral Immunol** 1998;11(3):159–66

PHYSIOLOGY

Investigation of the cellular tropism of bovine immunodeficiency-like virus. Heaton PR, et al. **Res Vet Sci** 1998 Jul-Aug;65(1):33–40

IMMUNODEFICIENCY VIRUS, FELINE

Feline immunodeficiency virus envelope protein (FIVgp120) causes electrophysiological alterations in rats. Prospéro-Garcia O, et al. **Brain Res** 1999 Jul 31; 836(1-2):203–9

Effects of feline immunodeficiency virus on cognition and behavioral function in cats. Steigerwald ES, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):411–9

Epidemiology of feline foamy virus and feline immunodeficiency virus infections in domestic and feral cats: a seroepidemiological study. Winkler IG, et al. **J Clin Microbiol** 1999 Sep;37(9):2848–51

Neuron loss and axon reorganization in the dentate gyrus of cats infected with the feline immunodeficiency virus. Mitchell TW, et al. **J Comp Neurol** 1999 Sep 6; 411(4):563–77

Neurotoxic effects of feline immunodeficiency virus, FIV-PPR. Gruol DL, et al. **J Neurovirol** 1998 Aug; 4(4):415–25

Horizontal transmission of feline immunodeficiency virus with semen from seropositive cats. Jordan HL, et al. **J Reprod Immunol** 1998 Dec;41(1-2):341–57

Feline immunodeficiency virus associated myopathy in the adult cat. Podell M, et al. **Muscle Nerve** 1998 Dec; 21(12):1680–5

CLASSIFICATION

Feline immunodeficiency virus subtype C is prevalent in northern part of Taiwan. Uema M, et al. **J Vet Med Sci** 1999 Feb;61(2):197–9

DRUG EFFECTS

Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency

virus replication. Egberink HF, et al. **J Virol** 1999 Aug; 73(8):6346–52

Antiviral properties of a crude extract from a green alga Caulerpa taxifolia (Vahl) C. Agardh. Nicoletti E, et al. **Phytother Res** 1999 May;13(3):245–7

The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. Mortola E, et al. **Vet Res Commun** 1998 Dec;22(8):553–63

ENZYMOLOGY

Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme. Tasara T, et al. **Biochemistry** 1999 Feb 2;38(5):1633–42

Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem. Dunn BM, et al. **Biopolymers** 1999;51(1):69–77

Methodology for protein–ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system. Dominy BN, et al. **Proteins** 1999 Aug 15; 36(3):318–31

GENETICS

Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Klein D, et al. **Electrophoresis** 1999 Feb;20(2):291–9

Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. de Parseval A, et al. **J Virol** 1999 Jan;73(1):608–17

Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. Johnston JC, et al. **J Virol** 1999 Jun; 73(6):4991–5000

Interspecies transmission of feline immunodeficiency virus from the domestic cat to the Tsushima cat (Felis bengalensis euptilura) in the wild. Nishimura Y, et al. **J Virol** 1999 Sep;73(9):7916–21

Phylogeographic patterns of feline immunodeficiency virus genetic diversity in the domestic cat. Carpenter MA, et al. **Virology** 1998 Nov 25;251(2):234–43

The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Lockridge KM, et al. **Virology** 1999 Aug 15;261(1):25–30

Genetic heterogeneity of env gene of feline immunodeficiency virus obtained from multiple districts in Japan. Nishimura Y, et al. **Virus Res** 1998 Sep; 57(1):101–12

GROWTH & DEVELOPMENT

Protein degradation and apoptotic death in lymphocytes during Fiv infection: activation of the ubiquitin–proteasome proteolytic system. Piedimonte G, et al. **Exp Cell Res** 1999 May 1;248(2):381–90

Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. Karlas JA, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):761–5

IMMUNOLOGY

Analysis of the protective immunity induced by feline immunodeficiency virus vaccination. Hosie MJ, et al. **Adv Vet Med** 1999;41:325–32 (28 ref.)

Binding of feline immunodeficiency viral gag–p24 polypeptide to nonimmune Igs. Amici A, et al. **Immunol Lett** 1998 Jun;62(2):93–7

Mucosal infection and vaccination against feline immunodeficiency virus. Stokes CR, et al. **J Biotechnol** 1999 Aug 20;73(2–3):213–21 (40 ref.)

Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. Karlas JA, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):761–5

Cytokine response in multiple lymphoid tissues during the primary phase of feline immunodeficiency virus infection. Dean GA, et al. **J Virol** 1998 Dec;72(12):9436–40

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. Mazzetti P, et al. **J Virol** 1999 Jan;73(1):1–10

Attempt to modify the immune response developed against FIV gp120 protein by preliminary FIV DNA injection. Cuisinier AM, et al. **Vaccine** 1999 Feb 5;17(5):415–25

Feline immunodeficiency virus (FIV)-associated lymphoma: a potential role for immune dysfunction in tumourigenesis. Beatty JA, et al. **Vet Immunol Immunopathol** 1998 Oct 23; 65(2–4):309–22

Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Karlas JA, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2–4):353–65

Cellular composition, coronavirus antigen expression and production of specific antibodies in lesions in feline infectious peritonitis. Kipar A, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2–4):243–57

ISOLATION & PURIFICATION

Feline immunodeficiency virus is shed in semen from experimentally and naturally infected cats. Jordan HL, et al. **AIDS Res Hum Retroviruses** 1998 Aug 10; 14(12):1087–92

Seroepidemiological survey of feline retrovirus infections in domestic and leopard cats in northern Vietnam in 1997. Miyazawa T, et al. **J Vet Med Sci** 1998 Nov;60(11):1273–5

Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. Leutenegger CM, et al. **J Virol Methods** 1999 Mar;78(1–2):105–16

METABOLISM

Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus. Richardson J, et al. **J Virol** 1999 May;73(5):3661–71

PATHOGENICITY

A thermoresistant strain of feline immunodeficiency virus (FIV) with an altered cytopathic effect and a restricted cell tropism. Alix C, et al. **Arch Virol** 1998;143(11):2093–107

Neurotoxicity of FIV and FIV envelope protein in feline cortical cultures. Bragg DC, et al. **Brain Res** 1999 Jan 23; 816(2):431–7

Cytokine response in multiple lymphoid tissues during the primary phase of feline immunodeficiency virus infection. Dean GA, et al. **J Virol** 1998 Dec;72(12):9436–40

In vivo monocyte tropism of pathogenic feline immunodeficiency viruses. Dow SW, et al. **J Virol** 1999 Aug;73(8):6852–61

The role of in vitro-induced lymphocyte apoptosis in feline immunodeficiency virus infection: correlation with different markers of disease progression. Holznagel E, et al. **J Virol** 1998 Nov;72(11):9025–33

Neurovirulence in feline immunodeficiency virus–infected neonatal cats is viral strain specific and dependent on systemic immune suppression. Power C, et al. **J Virol** 1998 Nov;72(11):9109–15

The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Willett BJ, et al. **Mol Membr Biol** 1999 Jan–Mar;16(1):67–72 (47 ref.)

PHYSIOLOGY

Shedding of feline immunodeficiency virus in semen of domestic cats during acute infection. Jordan HL, et al. **Am J Vet Res** 1999 Feb;60(2):211–5

A thermoresistant strain of feline immunodeficiency virus (FIV) with an altered cytopathic effect and a restricted cell tropism. Alix C, et al. **Arch Virol** 1998;143(11):2093–107

Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes. Flynn JN, et al. **Immunology** 1999 Feb;96(2):220–9

Feline CD8+ T cell non-cytolytic anti-feline immunodeficiency virus activity mediated by a soluble factor(s). Hohdatsu T, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2729–35

Inhibition of apoptosis and virus replication in feline immunodeficiency virus–infected cells by N-acetylcysteine and ascorbic acid. Mortola E, et al. **J Vet Med Sci** 1998 Nov;60(11):1187–93

Effect of interleukin-12 and interleukin-10 on the virus replication and apoptosis in T-cells infected with feline immunodeficiency virus. Mortola E, et al. **J Vet Med Sci** 1998 Nov;60(11):1181–5

Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. Brelot A, et al. **J Virol** 1999 Apr;73(4):2576–86

Differential cell tropism of feline immunodeficiency virus molecular clones in vivo. Dean GA, et al. **J Virol** 1999 Apr;73(4):2596–603

Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus: implications for vector development. Johnston J, et al. **J Virol** 1999 Mar; 73(3):2491–8

Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. Pistello M, et al. **J Virol** 1999 Feb;73(2):1518–27

Effect of feline immunodeficiency virus on cytokine response to Listeria monocytogenes in vivo. Dean GA, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2–4):125–38

FIV infection of IL-2-dependent and -independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation. Lerner DL, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2–4):277–97

Temperature sensitivity of two different steps in the viral life cycle of feline immunodeficiency virus. Alix C, et al. **Virology** 1999 Jan 20;253(2):309–18

The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Lockridge KM, et al. **Virology** 1999 Aug 15;261(1):25–30

IMMUNODEFICIENCY VIRUSES, PRIMATE see **LENTIVIRUSES, PRIMATE**

IMMUNODIAGNOSIS see **IMMUNOLOGIC TESTS**

IMMUNODIFFUSION

METHODS

Detecting anti-SSA and anti-SSB antibodies in routine analysis: a comparison between double immunodiffusion and immunoblotting. Yago M, et al. **Ann Clin Biochem** 1999 May;36 (Pt 3):365–71

Single radial immunodiffusion as a method for the assay of the acellular pertussis vaccine components, pertussis toxoid, filamentous haemagglutinin and pertactin. Xing DK, et al. **Biologicals** 1998 Sep;26(3):217–24

Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea. Schultz JC. **J Clin Lab Anal** 1999;13(2):82–9

[The determination of immunoglobulins on the erythrocyte surface by using a gel test] Levina AA, et al. **Klin Lab Diagn** 1999 Jul;(7):24, 33–4 **(Rus)**

IMMUNODOMINANT EPITOPES

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. Cavacini LA, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1271–80

Human p53(264–272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Petersen TR, et al. **Cancer Lett** 1999 Apr 1;137(2):183–91

T cell responses to the putative dominant autoepitope in primary biliary cirrhosis (PBC). Palmer JM, et al. **Clin Exp Immunol** 1999 Apr;116(1):133–9

The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Vanderlugt CL, et al. **Immunol Rev** 1998 Aug;164:63–72 (58 ref.)

Epitope dominance: evidence for reciprocal determinant spreading to glutamic acid decarboxylase in non-obese diabetic mice. Zechel MA, et al. **Immunol Rev** 1998 Aug; 164:111–8 (33 ref.)

Identification of immunodominant regions within the C-terminal cell binding domain of intimin alpha and intimin beta from enteropathogenic Escherichia coli. Adu-Bobie J, et al. **Infect Immun** 1998 Dec;66(12):5643–9

Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Fattom AI, et al. **Infect Immun** 1998 Oct;66(10):4588–92

Immunodominant peptide epitopes of allergen, Asp f 1 from the fungus Aspergillus fumigatus. Kurup VP, et al. **Peptides** 1998;19(9):1469–77

ADMINISTRATION & DOSAGE

Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice. Hirahara K, et al. **J Allergy Clin Immunol** 1998 Dec;102(6 Pt 1):961–7

ANALYSIS

An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. Kuwana M, et al. **Arthritis Rheum** 1999 Jun;42(6):1179–88

BIOSYNTHESIS

A rapid and safe plasmid isolation method for efficient engineering of recombinant lactobacilli expressing immunogenic or tolerogenic epitopes for oral administration. Maassen CB. **J Immunol Methods** 1999 Feb 1;223(1):131–6

CHEMISTRY

Trypanosoma cruzi: conformational preferences of antigenic peptides bearing the immunodominant epitope of the B13 antigen. Duranti MA, et al. **Exp Parasitol** 1999 Sep; 93(1):38–44

Crystallization of the immunodominant outer membrane protein OmpC; the first protein crystals from Salmonella typhi, a human pathogen. Arockiasamy A, et al. **FEBS Lett** 1999 Jun 25;453(3):380–2

The p29 and p35 immunodominant antigens of Neospora caninum tachyzoites are homologous to the family of surface antigens of Toxoplasma gondii. Howe DK, et al. **Infect Immun** 1998 Nov;66(11):5322–8

Characterization of a 34-kilodalton protein of Mycobacterium leprae that is isologous to the immunodominant 34-kilodalton antigen of Mycobacterium paratuberculosis. Silbaq FS, et al. **Infect Immun** 1998 Nov; 66(11):5576–9

The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731–752) is uniquely directed against a conformational epitope. Buratti E, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2709–16

Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus. Eden PA, et al. **J Immunol** 1999 Apr 15;162(8):4502–10

Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease [see comments] Hellmark T, et al. **Kidney Int** 1999 Mar;55(3):936–44.

Comment in: Kidney Int 1999 Mar;55(3):1120–2.
[Spatial structure of the rp142 peptide containing the immunodominant epitope of the HIV–1 gp120 protein. A theoretical study] Andrianov AM, et al. **Biofizika** 1999 Jan–Feb;44(1):10–7 (Eng. Abstr.) **(Rus)**

GENETICS

Positional cloning and molecular characterization of an immunodominant cytotoxic determinant of the mouse H3 minor histocompatibility complex. Zuberi AR, et al. **Immunity** 1998 Nov;9(5):687–98
Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Eckels DD, et al. **Int Immunol** 1999 Apr;11(4):577–83
Molecular cloning and epitope analysis of the peanut allergen Ara h 3. Rabjohn P, et al. **J Clin Invest** 1999 Feb; 103(4):535–42
Immunodominant B–cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. Zibert A, et al. **J Hepatol** 1999 Feb;30(2):177–84
Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease [see comments] Hellmark T, et al. **Kidney Int** 1999 Mar;55(3):936–44. Comment in: Kidney Int 1999 Mar;55(3):1120–2.
Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Nara PL, et al. **Vaccine** 1998 Nov;16(19):1780–7 (80 ref.)

IMMUNOLOGY

Non–structural determinants of immunogenicity and the B cell co–receptors, CD19, CD21, and CD22. Fearon DT. **Adv Exp Med Biol** 1998;452:181–4 (44 ref.)
Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides. Londos–Gagliardi D, et al. **AIDS Res Hum Retroviruses** 1999 Jul 1;15(10):909–20
Characterization of monoclonal antibodies to an immunodominant protein of the etiologic agent of human granulocytic ehrlichiosis. Ravyn MD, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):171–6
Induction of a multiple sclerosis–like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Slavin A, et al. **Autoimmunity** 1998; 28(2):109–20
Immunoreactivity of apolipoprotein B–100 and binding to LDL–receptor of phospholipase A2–treated low density lipoproteins. Korotaeva AA, et al. **Biochemistry (Mosc)** 1998 Dec;63(12):1430–7
Behavior of a short preS1 epitope on the surface of hepatitis B core particles. Borisova G, et al. **Biol Chem** 1999 Mar; 380(3):315–24
Shaping the repertoire of cytotoxic T–lymphocyte responses: explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens. Pion S, et al. **Blood** 1999 Feb 1;93(3):952–62
Epitope specificity of the monoclonal anticytokeratin antibody TS1. Johansson A, et al. **Cancer Res** 1999 Jan 1;59(1):48–51
An antigen–targeted approach to adoptive transfer therapy of cancer. Valmori D, et al. **Cancer Res** 1999 May 1; 59(9):2167–73
Binding of modified fragments of the Shigella dysenteriae type 1 O–specific polysaccharide to monoclonal IgM 3707 E9 and docking of the immunodeterminant to its modeled Fv. Miller CE, et al. **Carbohydr Res** 1998 Jul;309(3):219–26
Selection–dominant and nonaccessible epitopes on cell–surface receptors revealed by cell–panning with a large phage antibody library. Hoogenboom HR, et al. **Eur J Biochem** 1999 Mar;260(3):774–84
Plasma autoantibodies against platelet glycoprotein IIb/IIIa from patients with autoimmune thrombocytopenic purpura may recognize different antigenic determinants. Berchtold P, et al. **Eur J Haematol** 1998 Oct;61(4):223–8
Identification of immunodominant epitopes in the filamentous hemagglutinin of Bordetella pertussis. Piatti G. **FEMS Immunol Med Microbiol** 1999 Mar;23(3):235–41
A novel epitope (pentapeptide) in the human hemoglobin beta chain. Endo M, et al. **Hemoglobin** 1998 Jul; 22(4):321–31
Binding specificity of a class II–restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, et al. **Hum Immunol** 1998 Dec;59(12):783–93
Immunogenic epitopes of Salmonella typhi GroEL heat shock protein reactive with both monoclonal antibody and patients sera. Panchanathan V, et al. **Immunol Lett** 1998 Jun;62(2):105–9
Cross–reactive epitope mimics in a fragmented–genome phage display library derived from the rickettsia, Cowdria ruminantium. Fehrsen J, et al. **Immunotechnology** 1999 Mar; 4(3–4):175–84
Polarization of the immune response to the single immunodominant epitope of p38, a major Schistosoma mansoni egg antigen, generates Th1– or Th2–type cytokines and granulomas. Chen Y, et al. **Infect Immun** 1999 Sep;67(9):4570–7
Molecular fine–specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic–peptide–based serodiagnostic assays. Greijer AE, et al. **J Clin Microbiol** 1999 Jan;37(1):179–88
Location of neutralizing epitopes on the G protein of bovine ephemeral fever rhabdovirus. Kongsuwan K, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2573–81
Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. Bergmann CC, et al. **J Immunol** 1999 Sep 15;163(6):3379–87
Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen–specific regulation. Bonifacio E, et al. **J Immunol** 1999 Jul 1;163(1):525–32
Biochemical and immunogenetic analysis of an immunodominant peptide (Bödom1) encoded by the classical H7 minor histocompatibility locus. Eden PA, et al. **J Immunol** 1999 Apr 15;162(8):4502–10
Human transaldolase and cross–reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. Esposito M, et al. **J Immunol** 1999 Oct 1;163(7):4027–32
Cutting edge: myelin basic protein–specific cytotoxic T cell tolerance is maintained in vivo by a single dominant epitope in H–2k mice. Huseby ES, et al. **J Immunol** 1999 Aug 1; 163(3):1115–8
Heterogeneity of the T cell response to immunodominant determinants within hen eggwhite lysozyme of individual syngeneic hybrid F1 mice: implications for autoimmunity and infection. Moudgil KD, et al. **J Immunol** 1998 Dec 1;161(11):6046–53
Diversity of the fine specificity displayed by HLA–A*0201–restricted CTL specific for the immunodominant Melan–A/MART–1 antigenic peptide [published erratum appears in J Immunol 1999 Jul 15;163(2):1093] Valmori D, et al. **J Immunol** 1998 Dec 15; 161(12):6956–62
Mutations in immunodominant T cell epitopes derived from the nonstructural 3 protein of hepatitis C virus have the potential for generating escape variants that may have important consequences for T cell recognition. Wang H, et al. **J Immunol** 1999 Apr 1;162(7):4177–83
Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. Wolpert EZ, et al. **J Immunol** 1998 Nov 1; 161(9):4499–505
Tolerization of adult mice to immunodominant proteins before monoclonal antibody production. Lebrón JA, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):59–63
Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens. Grufman P, et al. **J Leukoc Biol** 1999 Aug;66(2):268–71
Antibody responses to an immunodominant nonstructural 1 synthetic peptide in patients with dengue fever and dengue hemorrhagic fever. Huang JH, et al. **J Med Virol** 1999 Jan;57(1):1–8
HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. Jolivet–Reynaud C, et al. **J Med Virol** 1998 Dec; 56(4):300–9
Cytotoxic T–lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. Schell TD, et al. **J Virol** 1999 Jul;73(7):5981–93
The cytotoxic T–cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. Wallace ME, et al. **J Virol** 1999 Sep;73(9):7619–26
Recognition of a dominant epitope in bovine heat–shock protein 70 in inner ear disease. Bloch DB, et al. **Laryngoscope** 1999 Apr;109(4):621–5
Analysis of human IgE epitope of Der f 2 with anti–Der f 2 mouse monoclonal antibodies. Nishiyama C, et al. **Mol Immunol** 1999 Jan;36(1):53–60
Characterization of variable immunodominant antigens of Cowdria ruminantium by ELISA and immunoblots. Perez JM, et al. **Parasite Immunol** 1998 Dec;20(12):613–22
Epitope specificities and antibody responses to the EG95 hydatid vaccine. Woollard DJ, et al. **Parasite Immunol** 1998 Nov;20(11):535–40
Cloning and characterization of a 150 kDa microsphere antigen of Theileria parva that is immunologically cross–reactive with the polymorphic immunodominant molecule (PIM). Skilton RA, et al. **Parasitology** 1998 Oct; 117 (Pt 4):321–30
Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Laub R, et al. **Thromb Haemost** 1999 Jan;81(1):39–44
Comparative mapping of cloned human and murine antithyroglobulin antibodies: recognition by human antibodies of an immunodominant region. Estienne V, et al. **Thyroid** 1998 Aug;8(8):643–6
Antibodies against Tityus discrepans venom do not abolish the effect of Tityus serrulatus venom on the rat sodium and potassium channels. Borges A, et al. **Toxicon** 1999 Jun; 37(6):867–81
The V3 loop based multi–epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV–1 isolates. Gómez CE, et al. **Vaccine** 1999 May 4;17(18):2311–9
Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Nara PL, et al. **Vaccine** 1998 Nov;16(19):1780–7 (80 ref.)
A single amino acid variation within an immunodominant AKR/Gross MuLV cytotoxic T–lymphocyte epitope leads to a loss in immunogenicity. Kim V, et al. **Viral Immunol** 1998;11(4):197–213
Phenotypic and functional characterization of CD8(+) T cell clones specific for a mouse cytomegalovirus epitope. Fernandez JA, et al. **Virology** 1999 Mar 1;255(1):40–9
The effect of low–profile serine substitutions in the V3 loop of HIV–1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM, et al. **Virology** 1998 Nov 10; 251(1):59–70
Immune response to the immunodominant epitope of mouse hepatitis virus is polyclonal, but functionally monospecific in C57Bl/6 mice. Pewe L, et al. **Virology** 1999 Mar 1; 255(1):106–16
Characterization of the immunodominant cross–reacting epitope of visna maedi virus and caprine arthritis–encephalitis virus capsid antigen. Rosati S, et al. **Virus Res** 1999 Jun;61(2):177–83
An immunodominant epitope on 40 kilodalton outer membrane protein is conserved among different strains of Haemophilus (Histophilus) somnus. Silva SV, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):449–56
[Synthesis and immunogenic properties of peptides––fragments of the immunodominant regions of the VP1 protein of the Asia–1 type of foot– and–mouth disease virus] Petrov VN, et al. **Bioorg Khim** 1998 Dec; 24(12):899–905 (Eng. Abstr.) **(Rus)**
[Study of antigenic determinants of Yersinia pestis lipopolysaccharide using monoclonal antibodies] Fedorova VA, et al. **Mol Gen Mikrobiol Virusol** 1998;(3):22–6 (Eng. Abstr.) **(Rus)**
[Characterization of structure and antigenic activity of lipopolysaccharides of genus Francisella] Maslova NN, et al. **Mol Gen Mikrobiol Virusol** 1998;(3):26–9 (Eng. Abstr.) **(Rus)**

METABOLISM

Rapid release and unusual stability of immunodominant peptide 45–89 from citrullinated myelin basic protein. Cao L, et al. **Biochemistry** 1999 May 11;38(19):6157–63
Elucidation and role of critical residues of immunodominant peptide associated with T cell–mediated parasitic disease. Hernandez HJ, et al. **J Immunol** 1999 Oct 1;163(7):3877–82
A common TCR V–D–J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. Hong J, et al. **J Immunol** 1999 Sep 15;163(6):3530–8
Cross–recognition of two middle T protein epitopes by immunodominant polyoma virus–specific CTL. Wilson CS, et al. **J Immunol** 1999 Apr 1;162(7):3933–41
IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. Perriard J, et al. **J Invest Dermatol** 1999 Feb;112(2):141–7
Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1. Merat R, et al. **J Virol** 1999 Jul;73(7):5698–706
The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader–derived T cell epitope. Gallimore A, et al. **Mol Immunol** 1998 Jul;35(10):581–91

PHARMACOLOGY

Opposite effects of immunotherapy with ovalbumin and the immunodominant T–cell epitope on airway eosinophilia and hyperresponsiveness in a murine model of allergic asthma. Janssen EM, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):21–9
Tolerization of adult mice to immunodominant proteins before monoclonal antibody production. Lebrón JA, et al. **J Immunol Methods** 1999 Jan 1;222(1–2):59–63

PHYSIOLOGY

Antigen interaction and heat inactivation expose new epitopes on human IgE. Pachlopnik JM, et al. **Int Arch Allergy Immunol** 1998 Dec;117(4):231–8

IMMUNOELECTROBLOTTING see **IMMUNOBLOTTING**

IMMUNOELECTRON MICROSCOPY see **MICROSCOPY, IMMUNOELECTRON**

IMMUNOELECTROOSMOPHORESIS see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOELECTROPHORESIS

see related
BLOOD PROTEIN ELECTROPHORESIS

Development and comparison of assays for measuring immunospecific antibody response in serum of chickens and rabbits immunized with human immunoglobulin G. Bollen LS, et al. **Electrophoresis** 1998 Oct;19(14):2419–22
[Quantitation and heterogeneity of serum alpha 2–macroglobulin] Mashiko T, et al. **Rinsho Byori** 1999 May; 47(5):473–8 (Eng. Abstr.) **(Jpn)**

IMMUNOELECTROPHORESIS

METHODS

Comparison of capillary zone and immunosubtraction with agarose gel and immunofixation electrophoresis for detecting and identifying monoclonal gammopathies. Litwin CM, et al. **Am J Clin Pathol** 1999 Sep;112(3):411-7

Unusually slow-migrating albumin variants: rapid confirmation using immunofixation. Ooi DS, et al. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):514-5

Sequence of testing for monoclonal gammopathies. Kyle RA. **Arch Pathol Lab Med** 1999 Feb;123(2):114-8 (17 ref.)

Multimodal application of lectin affinity electrophoresis of alpha-fetoprotein. Taketa K. **Electrophoresis** 1998 Jul; 19(10):1774-9 (28 ref.)

Isolation of peroxisome subpopulations from rat liver by means of immune free-flow electrophoresis. Völkl A, et al. **Electrophoresis** 1998 Jun;19(7):1140-4

IMMUNOELECTROPHORESIS, COUNTERCURRENT see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOELECTROPHORESIS, CROSSOVER see **COUNTERIMMUNOELECTROPHORESIS**

IMMUNOENZYME TECHNIQUES

Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing [letter] Diaz RS, et al. **AIDS** 1999 Jul 30;13(11):1417-8

Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. Nkengasong JN, et al. **AIDS** 1998 Aug 20;12(12):1405-12

Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. Sullivan PS, et al. **AIDS** 1999 Jan 14;13(1):89-96

Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies. Reisner BS, et al. **Am J Clin Pathol** 1999 Apr; 111(4):503-6

Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces: a prospective pilot study. Trevisani L, et al. **Am J Gastroenterol** 1999 Jul;94(7):1830-3

Expression immunoassay based on antibodies labeled with a deoxyribonucleic acid fragment encoding the alpha-peptide of beta-galactosidase. White SR, et al. **Analyst** 1998 Jun;123(6):1309-14

Sensitive enzyme immunoassay for anti-beta-lactoglobulin IgG in serum. Hirota K, et al. **Ann Clin Biochem** 1998 Sep; 35 (Pt 5):649-55

Fast-in situ hybridization and immunoenzymatic color pigment detection of mouse bone marrow micronucleus. Kolanko CJ, et al. **Biotech Histochem** 1999 May;74(3):111-5

An on-line method for the measurement of total protein output in biological fluids and secretory tissues after stimulation of intrinsic nerves and identification of neurotransmitters using immunohistochemical techniques. Adeghate E, et al. **Brain Res Brain Res Protoc** 1999 Jan; 3(3):270-7

Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Okuda H, et al. **Cancer** 1999 Feb 15;85(4):812-8

Determination of serum tetranectin: technical and clinical evaluation of three sandwich immunoassays. Thougaard AV, et al. **Clin Chim Acta** 1998 Aug 10;276(1):19-34

Diagnosis of Lyme borreliosis by a whole-blood gamma interferon assay for cell-mediated immune responses [letter] Sikand VK, et al. **Clin Diagn Lab Immunol** 1999 May; 6(3):445

An enzyme immunoassay for intrinsic factor in urine. Waters HM, et al. **Clin Lab Haematol** 1999 Jun;21(3):169-72

Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. De Miguel P, et al. **Cytokine** 1999 Sep;11(9):722-7

Millipore filter cell block preparation: an alternative to cell block in nongynecologic specimens of limited cellularity. Baloch ZW, et al. **Diagn Cytopathol** 1999 Jun;20(6):389-92

Development and clinical application of a highly sensitive enzyme immunoassay (EIA) for human growth hormone-releasing hormone (hGHRH) in plasma. Katakami H, et al. **Endocr J** 1998 Apr;45 Suppl:S67-70

Multicentre evaluation of a commercial test for the rapid diagnosis of Clostridium difficile-mediated antibiotic-associated diarrhoea. Bentley AH, et al. **Eur J Clin Microbiol Infect Dis** 1998 Nov;17(11):788-90

Evaluation of a new serologic test for diagnosis of Helicobacter pylori infection in children. Raymond J, et al. **Eur J Clin Microbiol Infect Dis** 1999 Mar;18(3):192-8

Comparison of three assays for HIV antibodies detection in urine to be applied to epidemiological setting. Carducci A, et al. **Eur J Epidemiol** 1999 Jul;15(6):545-8

BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Irani J, et al. **Eur Urol** 1999 Feb;35(2):89-92

Immunohistochemical detection of fibronectin in postmortem incised wounds of porcine skin. Grellner W, et al. **Forensic Sci Int** 1998 Nov 9;97(2-3):109-16

Absence of Helicobacter pylori in dental plaque determined by immunoperoxidase. Savoldi E, et al. **Helicobacter** 1998 Dec;3(4):283-7

Vector alkaline phophatase substrate Blue III: one substrate for brightfield histochemistry and high-resolution fluorescence imaging by confocal laser scanning microscopy. Hollinshead M, et al. **Histochem J** 1998 Aug; 30(8):577-81

Immunoassay of human Neisseria meningitidis serogroup A antibody. Diakun KR, et al. **Immunol Invest** 1998 Jul-Sep; 27(4-5):203-20

Serodiagnosis of neuroborreliosis: comparison of reliability of three confirmatory assays. Kaiser R, et al. **Infection** 1999 May-Jun;27(3):177-82

Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Seo HS, et al. **Int J Cancer** 1998 Dec 9;78(6):760-5

Detection of Chlamydia trachomatis antibodies by 2 novel tests: rELISA and peptide EIA. Paukku M, et al. **Int J STD AIDS** 1998 Oct;9(10):604-7

Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Arai Y, et al. **Int J Urol** 1998 Nov;5(6):550-5

Benzodiazepines: toxic serum concentrations in positive enzyme immunoassay responses. Divanon F, et al. **J Anal Toxicol** 1998 Nov-Dec;22(7):559-66

Validation of an automated microplate enzyme immunoassay for screening of postmortem blood for drugs of abuse. Spiehler VR, et al. **J Anal Toxicol** 1998 Nov-Dec; 22(7):573-9

Ultrasensitive immune complex transfer enzyme immunoassay of HIV-1 p24 antigen with less serum interference using 2,4-dinitrophenyl-anti-HIV-1 p24 IgG and indirectly immobilized (anti-2,4-dinitrophenyl group) Fab. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(3):126-32

Use of indirectly immobilized recombinant p17 antigen for detection of antibodies to HIV-1 by enzyme immunoassay. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(1):9-18

Comparison of enzyme immunoassay and reverse transcriptase PCR for identification of serotype G9 rotaviruses. Coulson BS, et al. **J Clin Microbiol** 1999 Oct; 37(10):3187-93

Semiquantitative species-specific detection of Bartonella henselae and Bartonella quintana by PCR-enzyme immunoassay. Sander A, et al. **J Clin Microbiol** 1999 Oct; 37(10):3097-101

Evaluation of a fully automated glycoprotein G-2 based assay for the detection of HSV-2 specific IgG antibodies in serum and plasma. Groen J, et al. **J Clin Virol** 1999 May; 12(3):193-200

Typing of rabies virus isolates by DNA enzyme immunoassay. Sabouraud A, et al. **J Clin Virol** 1999 Jan; 12(1):9-19

Polymacron enzyme immunoassay system for detection of naturally contaminating Salmonella in foods, feeds, and environmental samples. Blais BW, et al. **J Food Prot** 1998 Sep;61(9):1187-90

The detection of cocaine in hair specimens using micro-plate enzyme immunoassay. Moore C, et al. **J Forensic Sci** 1999 May;44(3):609-12

Improved detection of apoptotic cells using a modified in situ TUNEL technique. Cuello-Carrión FD, et al. **J Histochem Cytochem** 1999 Jun;47(6):837-9

Enhanced in situ detection of beta-glucuronidase activity in murine tissue. Kopen GC, et al. **J Histochem Cytochem** 1999 Jul;47(7):965-8

Microwave staining of enteric neurons using cuprolinic blue (Quinolinic phthalocyanin) combined with enzyme histochemistry and peroxidase immunohistochemistry. Van Ginneken CJ, et al. **J Histochem Cytochem** 1999 Jan; 47(1):13-22

Immunoglobulin and enzyme-conjugated dextran polymers enhance u-PAR staining intensity of carcinoma cells in peripheral blood smears. Werther K, et al. **J Histochem Cytochem** 1999 Jul;47(7):959-64

Efficacy of Directigen RSV testing in patient management following admission from a paediatric emergency department. Lipson SM, et al. **J Hosp Infect** 1999 Apr; 41(4):323-9

The development of an enzyme immunometric assay for LH and the effects of the methods on the immunoreactivity of the conjugates. Akman S, et al. **J Immunoassay** 1998 May-Aug;19(2-3):113-28

Two-site enzyme immunometric assays for determination of native and denatured beta-lactoglobulin. Negroni L, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):25-37

A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. Power CA, et al. **J Immunol Methods** 1999 Jul 30;227(1-2):99-107

Application of electronmicroscopy, enzyme immunoassay, and RT-PCR to monitor an outbreak of astrovirus type 1 in a paediatric bone marrow transplant unit. Cubitt WD, et al. **J Med Virol** 1999 Mar;57(3):313-21

Filtration capture immunoassay for bacteria: optimization and potential for urinalysis. Mazenko RS, et al. **J Microbiol Methods** 1999 Jun;36(3):157-65

A novel two-site enzyme immunoassay reveals the regional distributions of and developmental changes in GluR1 and NMDAR1 protein contents in the rat brain. Ibaraki K, et al. **J Neurochem** 1999 Jul;73(1):408-17

Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. Kaufmann O, et al. **J Pathol** 1998 Oct;186(2):165-8

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. Gürtler L, et al. **J Virol Methods** 1998 Nov;75(1):27-38

An immunochemical focus assay to quantify replication competent and defective viruses involved in murine acquired immunodeficiency syndrome. Hügin AW, et al. **J Virol Methods** 1999 Feb;77(2):217-24

Rapid detection and identification of two lineages of influenza B strains with monoclonal antibodies. Nakagawa N, et al. **J Virol Methods** 1999 Apr;79(1):113-20

Detection and quantification of cell-free Epstein-Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay. Zingg W, et al. **J Virol Methods** 1999 May; 79(2):141-8

Overview of antigen detection through enzymatic activity. Bratthauer GL. **Methods Mol Biol** 1999;115:181-90 (17 ref.)

The peroxidase-antiperoxidase (PAP) method and other all-immunologic detection methods. Bratthauer GL. **Methods Mol Biol** 1999;115:191-201 (8 ref.)

Identification of mycoplasmas by dot immunobinding on membrane filtration (MF dot). Poumarat F. **Methods Mol Biol** 1998;104:113-8 (19 ref.)

Avidin-biotin labeling of cellular antigens in cryostat-sectioned tissue. Raffeld M, et al. **Methods Mol Biol** 1999;115:215-22 (7 ref.)

Immunohistochemical staining of fixed tissues. Scanziani E. **Methods Mol Biol** 1998;104:133-40 (15 ref.)

Detection of adhesion molecules by immunohistochemistry on human and murine tissue sections. Stoppacciaro A, et al. **Methods Mol Biol** 1999;96:93-106 (25 ref.)

Determination of the endothelial barrier function in vitro. Van Nieuw Amerongen GP, et al. **Methods Mol Biol** 1999; 96:183-9 (15 ref.)

Immunohistochemical retrieval of the principal HIV antigens p24, gp41, and gp120 in formalin fixed tissue: an investigation using HIV infected lymphoblasts and postmortem brain tissue from AIDS cases. Morrison HL, et al. **Mol Pathol** 1998 Aug;51(4):227-31

Immunostaining of dystrophin using catalyzed signal amplification [letter] Hoshino S, et al. **Muscle Nerve** 1999 Sep;22(9):1298-9

Occult cervical metastases: immunoperoxidase analysis of the pathologically negative neck. Enepekides DJ, et al. **Otolaryngol Head Neck Surg** 1999 May;120(5):713-7

Detection of Helicobacter pylori in faeces with a new enzyme immunoassay method: preliminary results [letter] Trevisani L, et al. **Scand J Gastroenterol** 1998 Aug;33(8):893-4

False-positive enzyme immunoassay test results for Chlamydia trachomatis because of contact of the collection swab with agar. Sales V, et al. **Sex Transm Dis** 1998 Sep; 25(8):418-20

Enzyme immunoassay for the measurement of 17alpha-estradiol 17-N-acetylglucosaminide in rabbit urine. Nakagomi M, et al. **Steroids** 1999 Apr;64(4):301-7

Comparison of four immunoassays for the detection of lorazepam in urine. Meatherall R, et al. **Ther Drug Monit** 1998 Dec;20(6):673-5

A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders. Bos R, et al. **Thromb Haemost** 1999 Jan;81(1):54-9

Evaluation of third generation anti-HCV enzyme immunoassays. Panigrahi AK, et al. **Trop Gastroenterol** 1998 Jul-Sep;19(3):105-7

Supplementary anti-hepatitis C virus (HCV) testing with 2nd and 3rd generation recombinant immunoblot assay and matrix applied to enzyme immunoassay positive sera and comparison with HCV-RNA detection. Engel PM, et al. **Zentralbl Bakteriol** 1998 Oct;288(2):267-75

[VIDAS Stallertest: clinico-biological evaluation of a new global test for respiratory allergy] Felden F, et al. **Pathol Biol (Paris)** 1998 Dec;46(10):819-23 (Eng. Abstr.) **(Fre)**

[Comparison of the MTP immunoassay with EMIT in blood screening for drugs] Käferstein H, et al. **Arch Kriminol** 1998 Nov-Dec;202(5-6):165-72 (Eng. Abstr.) **(Ger)**

[Comparative study of results of serological diagnosis of Lyme borreliosis by indirect immunofluorescence and immunoenzyme analysis] Kufko IT, et al. **Klin Lab Diagn** 1999 Mar;(3):34-7 (Eng. Abstr.) **(Rus)**

[Development of a two-site immunoassay using polyclonal antibodies for determination of lactoferrin in human blood] Laktionov PP, et al. **Vopr Med Khim** 1999 Mar-Apr; 45(2):170-7 (Eng. Abstr.) **(Rus)**

[Evaluation of the effectiveness of substance for diagnosing rotaviral infection under field conditions] Karpovich LG, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):82-5 (Eng. Abstr.) **(Rus)**

[Immunoenzyme test-system for the detection of Vibrio cholerae 0139] Fedorova VA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):77-80 (Eng. Abstr.) **(Rus)**

[Use of Brucellar protein antigen synthesized in Escherichia coli cells in the enzyme immunoassay] Zheludkov MM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):74-7 (Eng. Abstr.) **(Rus)**

[Immunocytochemistry techniques for the diagnosis of hematologic neoplasms] Diaz de Domingo NB, et al. **Medicina (B Aires)** 1999;59(1):11-6 (Eng. Abstr.) **(Spa)**

[Validation in Havana City, Cuba of ENZYMEBA, an immunoassay for detecting Entamoeba histolytica in feces] Fonte Galindo L, et al. **Rev Cubana Med Trop** 1998; 50(1):18–21 (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Flow-through membrane-based enzyme immunoassay for rapid detection of ochratoxin A in wheat. De Saeger S, et al. **J Food Prot** 1999 Jan;62(1):65–9

[The comparative study of LUMIWARD immunoassay system and CAP RAST system for determination of specific IgE antibody against mite in infantile atopic dermatitis] Miyoshi M, et al. **Arerugi** 1998 Aug;47(8):744–8 (Eng. Abstr.) **(Jpn)**

METHODS

Advances in immunohistochemical techniques: toward making things simpler, cheaper, more sensitive, and more reproducible [published erratum appears in Adv Anat Pathol 1998 Nov;5(6):399] Chan JK. **Adv Anat Pathol** 1998 Sep;5(5):314–25 (55 ref.)

Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay. Elimination of negative interference by monitoring free digoxin concentrations. Dasgupta A, et al. **Am J Clin Pathol** 1999 Mar;111(3):406–10

Development of a highly sensitive enzyme immunoassay for human calcitonin using solid phase coupled with multiple antibodies. Isomura M, et al. **Ann Clin Biochem** 1999 Sep; 36 (Pt 5):629–35

Practical applications of immunohistochemistry in hematolymphoid neoplasms. Chu PG, et al. **Ann Diagn Pathol** 1999 Apr;3(2):104–33 (287 ref.)

Human tetranectin: methodological and clinical studies. Høgdall CK. **APMIS Suppl** 1998;86:1–31

An amperometric enzyme-linked immunosensor for Nitrobacter. Sandén B, et al. **Appl Microbiol Biotechnol** 1998 Dec;50(6):710–6

Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Homburger HA, et al. **Arch Pathol Lab Med** 1998 Nov;122(11):993–9

A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Tan EM, et al. **Arthritis Rheum** 1999 Mar;42(3):455–64

Specific sandwich-type enzyme immunoassays for smooth muscle constricting novel 31-amino acid endothelins. Okishima N, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):1–5

A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings. Jacobs MV, et al. **Br J Cancer** 1999 Sep;81(1):114–21

Production and characterization of monoclonal antibodies specific for Leptospira borgpetersenii serovar hardjo type hardjobovis and Leptospira interrogans serovar hardjo type hardjoprajitno. Surujballi O, et al. **Can J Vet Res** 1999 Jan; 63(1):62–8

A new enzyme immunoassay for PCDD/F TEQ screening in environmental samples: comparison to micro-EROD assay and to chemical analysis. Li W, et al. **Chemosphere** 1999 Jun;38(14):3313–8

Parent cyclosporine in whole blood by monoclonal fluorescence polarization immunoassay for axsym and monoclonal enzyme-multiplied immunoassay for cobas-fara. de Cos MA, et al. **Clin Biochem** 1998 Nov; 31(8):681–5

Determination of tumor necrosis factor-alpha (TNF-alpha) in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay. Petrovas C, et al. **Clin Biochem** 1999 Jun;32(4):241–7

Validation of an automated enzyme immunoassay for Interleukin-6 for routine clinical use. Fraunberger P, et al. **Clin Chem Lab Med** 1998 Oct;36(10):797–801

Antibody interference with the Abbott AxSym immunoassay for thyroid-stimulating hormone. Landau-Levine M, et al. **Clin Chim Acta** 1999 Mar;281(1–2):177–80

Comparison of three different methods for measuring classical pathway complement activity. Jaskowski TD, et al. **Clin Diagn Lab Immunol** 1999 Jan;6(1):137–9

Evaluation of newly developed immunoperoxidase monolayer assays for detection of antibodies against bovine herpesvirus 4. Wellenberg GJ, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):447–51

Detection of Epstein-Barr virus-specific antibodies by an automated enzyme immunoassay. Performance evaluation and cost analysis. Tang YW, et al. **Diagn Microbiol Infect Dis** 1998 Aug;31(4):549–54

Evidence-based diagnosis of Lyme disease. Davidson MM, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):484–9

Discrepancy between results of a commercial enzyme immunoassay kit and immunofluorescence staining for detection of respiratory syncytial virus antigen. Holter E, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):595–6

Hybridocytochemical detection of mRNA for calcitonin, CGRP, somatostatin and NPY in cultured cells of medullary thyroid carcinoma using immunomax technique. Kasprzak A, et al. **Folia Histochem Cytobiol** 1999; 37(2):59–60

Application of biotinylated tyramine to amplify reactions with horseradish peroxidase labelling. Surowiak P, et al. **Folia Histochem Cytobiol** 1999;37(2):57–8

The detection of cotinine in hydrolyzed meconium samples. Dempsey D, et al. **Forensic Sci Int** 1999 Jun 28; 102(2–3):167–71

A sandwich enzyme immunoassay for human muscle-specific beta-enolase and its application for the determination of skeletal muscle injury. Matsuda H, et al. **Forensic Sci Int** 1999 Jan 25;99(3):197–208

Concentration dependent and adverse effects in immunohistochemistry using the tyramine amplification technique. Mengel M, et al. **Histochem J** 1999 Mar; 31(3):195–200

A novel immunohistochemical detection system using mirror image complementary antibodies (MICA). Mangham DC, et al. **Histopathology** 1999 Aug;35(2):129–33

Monoclonal antibodies to progesterone: characterization and selection for enzyme immunoassay in bovine milk. Waldmann A. **Hybridoma** 1999 Jun;18(3):289–96

Changes in testicular transferrin concentrations measured by enzyme immunoassay after FSH administration to beagle dogs. Kawakami E, et al. **Int J Androl** 1999 Aug; 22(4):224–8

Enzyme immunoassay detection of Cryptosporidium parvum inhibition by sinefungin in sporozoite infected HCT-8 enterocytic cells. Gargala G, et al. **Int J Parasitol** 1999 May;29(5):703–9

Improvement of the specificity of enzyme immunoassays for the detection of rotavirus and adenovirus in fecal specimens. Rabenau H, et al. **Intervirology** 1998; 41(2–3):55–62

V3 serotyping of HIV-1 infection: correlation with genotyping and limitations. Plantier JC, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1999 Apr 15;20(5):432–41

Direct semiquantitative screening of drugs of abuse in serum and whole blood by means of CEDIA DAU urine immunoassays. Iwersen-Bergmann S, et al. **J Anal Toxicol** 1999 Jul-Aug;23(4):247–56

Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen. Hashida S, et al. **J Clin Lab Anal** 1998;12(6):329–36

Sensitive enzyme immunoassay of antibodies to HIV-1 p17 antigen using indirectly immobilized recombinant p17 for diagnosis of HIV-1 infection. Ishikawa S, et al. **J Clin Lab Anal** 1998;12(6):343–50

Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin. Kohno T, et al. **J Clin Lab Anal** 1998;12(6):356–62

Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1–34): application to pharmacokinetic study on intranasal parathyroid hormone (1–34) in human. Kohno T, et al. **J Clin Lab Anal** 1998;12(5):268–75

Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate. Wu JT, et al. **J Clin Lab Anal** 1998;12(5):298–303

Rapid identification of Candida species with species-specific DNA probes. Elie CM, et al. **J Clin Microbiol** 1998 Nov; 36(11):3260–5

Diagnosis of Mycoplasma pneumoniae pneumonia in children. Waris ME, et al. **J Clin Microbiol** 1998 Nov; 36(11):3155–9

Comparison of different scoring systems for immunohistochemical staining. Adams EJ, et al. **J Clin Pathol** 1999 Jan;52(1):75–7

An enzyme linked immunoassay using recombinant antigens for differentiation of primary from secondary or past CMV infections in pregnancy. Daminger A, et al. **J Clin Virol** 1998 Aug 20;11(2):93–102

Optimization of the immunohistochemical demonstration of keratins in paraffin wax-embedded mouse skin. Pérez-Martínez C, et al. **J Comp Pathol** 1998 Aug; 119(2):177–81

Swab-based enzyme immunoassay system for detection of meat residues on food contact surfaces as a hygiene monitoring tool. Blais BW. **J Food Prot** 1999 Apr; 62(4):386–9

Blood grouping of mixed bloodstains using immunocytochemical methods. Bunai Y, et al. **J Forensic Sci** 1999 Jan;44(1):100–4

Development of an immunoassay for monitoring the levels of ciprofloxacin in patient samples. Snitkoff GG, et al. **J Immunoassay** 1998 Nov;19(4):227–38

Enzyme immunoassays for measuring complement-dependent prevention of immune precipitation (PIP) and solubilization of preformed antigen-antibody complexes (SOL). Arason GJ, et al. **J Immunol Methods** 1999 Feb 1;223(1):37–46

Monitoring of intracellular levels of 5'-monophosphate-AZT using an enzyme immunoassay. Goujon L, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):19–30

Construction of a specific and sensitive sandwich enzyme immunoassay for 20 kDa human growth hormone. Hashimoto Y, et al. **J Immunol Methods** 1998 Dec 1; 221(1–2):77–85

Advantage of recombinant borrelial proteins for serodiagnosis of neuroborreliosis. Kaiser R, et al. **J Med Microbiol** 1999 Jan;48(1):5–10

A kinetic enzyme immunoassay for the quantitation of antibodies to a humanized monoclonal antibody in human serum. Thurmond LM, et al. **J Pharm Biomed Anal** 1998 Apr;16(8):1317–28

A new enzyme immunoassay to detect antibodies to arboviruses in the blood of wild birds. Chiles RE, et al. **J Vector Ecol** 1998 Dec;23(2):123–35

A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. Lee MS, et al. **J Virol Methods** 1999 Mar; 78(1–2):209–17

Polymerase chain reaction-based enzyme immunoassay for quantitation of telomerase activity: application to colorectal cancers. Cheng AJ, et al. **Jpn J Cancer Res** 1999 Mar; 90(3):280–5

Enzyme immunoassays (EIAs) of eicosanoids. Yin K, et al. **Methods Mol Biol** 1999;120:107–18

Restriction of peroxidase-mediated antibody reactivity to single neurons by local hydrogen peroxide production. Shayan H, et al. **Neuroscience** 1999 Mar;89(1):279–90

A sensitive sandwich enzyme immunoassay for calcitonin gene-related peptide (CGRP): characterization and application. Frobert Y, et al. **Peptides** 1999;20(2):275–84

Detection of Chlamydia trachomatis in vaginal specimens from female commercial sex workers using a new improved enzyme immunoassay. Tanaka M, et al. **Sex Transm Infect** 1998 Dec;74(6):435–8

17Beta-hydroxy-11alpha-(3'-sulfanylpropyl)oxy-estra-1,3,5(10)- trien-3-yl sulfamate--a novel hapten structure: toward the development of a specific enzyme immunoassay (EIA) for estra-1,3,5(10)-triene-3-yl sulfamates. Schwarz S, et al. **Steroids** 1999 Jul;64(7):460–71

Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation. Brunet M, et al. **Ther Drug Monit** 1998 Dec;20(6):676–9

Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA. Lynch DM, et al. **Tumour Biol** 1998;19(6):421–38

[Detection of anti-Chlamydia trachomatis antibody by means of enzyme immunoassay using synthetic peptide antigen] Bannai H, et al. **Kansenshogaku Zasshi** 1999 Jul;73(7):633–9 (Eng. Abstr.) **(Jpn)**

[Detection of Clostridium difficile toxin A from stool specimens by an enzyme immunoassay kit] Kato N, et al. **Kansenshogaku Zasshi** 1999 May;73(5):467–72 (Eng. Abstr.) **(Jpn)**

[Rapid and simple method for the detection of shigatoxins (STxs)] Kobayashi K, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):213–7 (Eng. Abstr.) **(Jpn)**

STANDARDS

CDTect-RIA and CDTect-EIA for determination of serum carbohydrate-deficient transferrin compared. Arndt T, et al. **Alcohol Alcohol** 1998 Nov-Dec;33(6):639–45

Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Lim LC, et al. **Am J Clin Pathol** 1999 Mar;111(3):363–9

Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Apple FS, et al. **Clin Chem** 1999 Feb;45(2):206–12

Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Koskinen S, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):817–22

Quantification of MUC1 in breast cancer patients. A method comparison study. Bon GG, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Mar;83(1):67–75

Disopyramide cross-reactivity in a commercial immunoassay reagent for methadone [letter] Moorman P, et al. **J Anal Toxicol** 1999 Jul-Aug;23(4):299–300

Impact of assay parameters on the accuracy of free PSA test: source and stability of calibrator, calibration curve fitting, and level of total PSA in the serum. Liu GH, et al. **J Clin Lab Anal** 1998;12(5):304–9

Use of alcohol fixed cytospins protected by 10% polyethylene glycol in immunocytology external quality assurance. Maxwell P, et al. **J Clin Pathol** 1999 Feb; 52(2):141–4

Evaluation of the commercial microparticle enzyme immunoassay [letter; comment] Taylor-Robinson D, et al. **Sex Transm Infect** 1998 Jun;74(3):231. Comment on: Genitourin Med 1997 Dec;73(6):498–502.

VETERINARY

Development of a simple enzyme immunoassay for blood haptoglobin concentration in cattle and its application in improving food safety. Saini PK, et al. **Am J Vet Res** 1998 Sep;59(9):1101–7

Development of a sensitive enzymeimmunoassay (EIA) for FSH determination in bovine plasma. Prakash BS, et al. **Anim Reprod Sci** 1999 Apr 31;55(3–4):183–92

A modified immunoperoxidase assay for detection of antibody porcine reproductive and respiratory syndrome (PRRS) virus in swine sera. Takashima H, et al. **J Vet Med Sci** 1999 Feb;61(2):195–6

Detection of antibodies against Actinobacillus pleuropneumoniae serotypes 1, 2, 5 and 7 using the immunohistochemical staining. Takashima H, et al.

IMMUNOENZYME TECHNIQUES

J Vet Med Sci 1999 Jun;61(6):713–6
A non-competitive chemiluminescence enzyme immunoassay for the equine acute phase protein serum amyloid A (SAA) -- a clinically useful inflammatory marker in the horse. Hultén C, et al. **Vet Immunol Immunopathol** 1999 May; 68(2–4):267–81

IMMUNOFLUORESCENCE ANTIBODY TEST, DIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, DIRECT**

IMMUNOFLUORESCENCE ANTIBODY TEST, INDIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT**

IMMUNOFLUORESCENCE MICROSCOPY see **MICROSCOPY, FLUORESCENCE**

IMMUNOFLUORESCENCE TECHNIQUE see **FLUORESCENT ANTIBODY TECHNIQUE**

IMMUNOFLUORESCENCE TECHNIQUE, DIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, DIRECT**

IMMUNOFLUORESCENCE TECHNIQUE, INDIRECT see **FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT**

IMMUNOFLUOROMETRIC ASSAY see **FLUOROIMMUNOASSAY**

IMMUNOGENETICS

Immunogenetic properties of genes. Wahren B. **Acta Oncol** 1999;38(3):309–11
The American Society for Histocompatibility and Immunogenetics 24th annual meeting. Vancouver, British Columbia, Canada. October 10–15, 1998. Abstracts. **Hum Immunol** 1998;59 Suppl 1:1–170
European Federation for Immunogenetics 13th Conference. Heraklion, Crete, Greece, April 13–17, 1999. Abstracts. **Hum Immunol** 1999;60 Suppl 1:S1–121
IMGT/LIGM-DB: a systematized approach for ImMunoGeneTics database coherence and data distribution improvement. Giudicelli V, et al. **Ismb** 1998;6:59–68
Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene. Ohtake Y, et al. **Jpn J Cancer Res** 1999 Apr; 90(4):460–8
Immunophenotypic and immunogenotypic characteristics of TCRgammadelta+ T cell acute lymphoblastic leukemia. Langerak AW, et al. **Leukemia** 1999 Feb;13(2):206–14
IMGT, the international ImMunoGeneTics database: a new design for immunogenetics data access. Giudicelli V, et al. **Medinfo** 1998;9 Pt 1:351–5
IMGT, the international ImMunoGeneTics database. Lefranc MP, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):209–12
[Immunogenetic markers of erythrocyte systems in Armenians of Nagornil Karabakh] Nersisian VM, et al. **Genetika** 1998 Aug;34(8):1134–7 (Eng. Abstr.) **(Rus)**

EDUCATION

Educational programme of Slovak Foundation: Education in Immunogenetics and its collaboration with the NATO. North Atlantic Treaty Organization. Bencová M. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S119–20

HISTORY

Erik Thorsby is 60. Vartdal F. **Tissue Antigens** 1998 Jul; 52(1):96–8

METHODS

Utility of immunophenotypic and immunogenotypic analysis in the study of necrotic lymph nodes. Vega F, et al. **Virchows Arch** 1999 Mar;434(3):245–8

TRENDS

[Immunogenetic achievements for medicine] Khaitov RM, et al. **Vestn Ross Akad Med Nauk** 1999;(4):35–9 (22 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOGENS, SYNTHETIC see **VACCINES, SYNTHETIC**

IMMUNOGLOBULIN ALLOTYPES

BIOSYNTHESIS

Nucleotide sequences specific for nonnominal immunoglobulin allotypes in rheumatoid arthritis patients and in normal individuals and their expression in synovial tissue of rheumatoid arthritis patients. Bjarnadottir M, et al. **Exp Clin Immunogenet** 1999;16(1):8–16

BLOOD

Preparation of IgG subclass allotypes from polyclonal IgG. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):395–8

CLASSIFICATION

GM and KM immunoglobulin allotypes in a Spanish Pyrenean population: Val d'Aran. Giraldo MP, et al. **Ann Hum Biol** 1998 Sep-Oct;25(5):453–65

GENETICS

Genetic diversity in northern Spain (Basque Country and Cantabria): GM and KM variation related to demographic histories. Esteban E, et al. **Eur J Hum Genet** 1998 Jul–Aug; 6(4):315–24
Molecular characterization of immunoglobulin G4 gene isoallotypes. Brusco A, et al. **Eur J Immunogenet** 1998 Oct; 25(5):349–55
Immunoglobulin allotypes among the Bicolanos of Sorsogon province, Luzon, Philippines: implications of phenotypes for filariasis. Kron MA, et al. **Exp Clin Immunogenet** 1999; 16(2):65–71
Epistatic effects of genes encoding tumor necrosis factor-alpha, immunoglobulin allotypes, and HLA antigens on susceptibility to non-insulin-dependent (type 2) diabetes mellitus. Pandey JP, et al. **Immunogenetics** 1999 Sep; 49(10):860–4
Identification of rabbit immunoglobulin latent Ckappa1 allotype genes alters the concept of allelic inheritance. Wolf B, et al. **Mol Immunol** 1998 Oct;35(14–15):965–76
[The association of genetic markers in two related swine breeds] Kniazev SP, et al. **Genetika** 1999 May;35(5):674–80 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Allotype immunoglobulin enhances alkaline phosphatase activity: implications for the inflammatory response. Shinozaki T, et al. **J Lab Clin Med** 1998 Oct;132(4):320–8

IMMUNOGLOBULIN CLASS SWITCHING

Does class switching contribute to remission in bullous pemphigoid? [see comments] Modre B, et al. **Acta Derm Venereol** 1999 Mar;79(2):127–31. Comment in: Acta Derm Venereol 1999 Mar;79(2):97.
Molecular regulation of IgE switching: let's walk hand in hand. Monticelli S, et al. **Allergy** 1998;53(45 Suppl):6–8
Immunoglobulin switch recombination may occur by a DNA end-joining mechanism. Kenter A, et al. **Ann N Y Acad Sci** 1999 May 18;870:206–17
The IgG2a/IgA produced by the murine T560 B lymphoma that arose during a graft-versus-host reaction is polyreactive and somatically mutated. Phillips-Quagliata JM, et al. **Autoimmunity** 1999;29(3):215–33
VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Aarts WM, et al. **Blood** 1998 Nov 15; 92(10):3857–64
V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Sahota SS, et al. **Blood** 1999 Aug 1;94(3):1070–6
DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Vaandrager JW, et al. **Blood** 1998 Oct 15; 92(8):2871–8
IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice. Ichikawa M, et al. **Cell Immunol** 1999 Feb 1; 191(2):97–104
Ialpha exon-replacement mice synthesize a spliced HPRT-C(alpha) transcript which may explain their ability to switch to IgA. Inhibition of switching to IgG in these mice. Qiu G, et al. **Int Immunol** 1999 Jan;11(1):37–46
Processing of switch transcripts is required for targeting of antibody class switch recombination. Hein K, et al. **J Exp Med** 1998 Dec 21;188(12):2369–74
Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. Manis JP, et al. **J Exp Med** 1998 Oct 19;188(8):1421–31
The p65 subunit of NF-kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3. Horwitz BH, et al. **J Immunol** 1999 Feb 15;162(4):1941–6
Localization of splenic B cells activated for switch recombination by in situ hybridization with Igamma1 switch transcript and Rad51 probes. Peakman MC, et al. **J Immunol** 1998 Oct 15;161(8):4008–15
Ig heavy chain expression and class switching in vitro from an allele lacking the 3' enhancers DNase I-hypersensitive hs3A and hs1,2. Saleque S, et al. **J Immunol** 1999 Mar 1;162(5):2791–803
In vitro system for immunoglobulin class switching using BHK cells transfected with murine recombinant CD40 ligand. Fukushima K, et al. **J Vet Med Sci** 1999 Jun; 61(6):615–9
Position-dependent inhibition of class-switch recombination by PGK-neor cassettes inserted into the immunoglobulin heavy chain constant region locus. Seidl KJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3000–5
Characterization of CD40-dependent immunoglobulin class switching. Ström L, et al. **Scand J Immunol** 1999 May; 49(5):523–32

DRUG EFFECTS

The regulatory effects of all-trans-retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. Tokuyama H, et al. **Cell Immunol** 1999 Feb 25;192(1):41–7
IL-4-dependent IgE class switching in an anti-trinitrophenyl B-cell hybridoma after engagement of antigen receptors. Hikida M, et al. **Immunol Lett** 1999 Feb;65(3):161–6
IL-5 induces IgG1 isotype switch recombination in mouse CD38-activated sIgD-positive B lymphocytes. Mizoguchi C, et al. **J Immunol** 1999 Mar 1;162(5):2812–9
CBF alpha3 (AML2) is induced by TGF-beta1 to bind and activate the mouse germline Ig alpha promoter. Shi MJ, et al. **J Immunol** 1998 Dec 15;161(12):6751–60

GENETICS

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Kuipers J, et al. **Cancer Genet Cytogenet** 1999 Mar; 109(2):99–107
Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. Ehrenstein MR, et al. **EMBO J** 1999 Jun 15;18(12):3484–90
Defective immunoglobulin class switching in Vav-deficient mice is attributable to compromised T cell help. Gulbranson-Judge A, et al. **Eur J Immunol** 1999 Feb; 29(2):477–87
AML and Ets proteins regulate the I alpha1 germ-line promoter. Xie XQ, et al. **Eur J Immunol** 1999 Feb; 29(2):488–98
Target specificity of immunoglobulin class switch recombination is not determined by nucleotide sequences of S regions. Kinoshita K, et al. **Immunity** 1998 Dec; 9(6):849–58
Apparent trans-chromosomal antibody class switch in mice bearing an Igh(a) mu-chain transgene on an Igh(b) genetic background. Willers J, et al. **Immunobiology** 1999 Feb; 200(1):150–64
Analysis of gamma4 germline transcription in human B cells. Agresti A, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2–4):279–81
Germline transcription and recombination of a murine VDJmudeltagamma1 transgene. Cunningham K, et al. **Int Immunol** 1998 Aug;10(8):1027–37
An extrachromosomal switch recombination substrate reveals kinetics and substrate requirements of switch recombination in primary murine B cells. Petry K, et al. **Int Immunol** 1999 May;11(5):753–63
An expressed neo(r) cassette provides required functions of the 1gamma2b exon for class switching. Seidl KJ, et al. **Int Immunol** 1998 Nov;10(11):1683–92
The liaison of isotype class switch and mismatch repair: an illegitimate affair [comment] Kenter AL. **J Exp Med** 1999 Aug 2;190(3):307–10 (26 ref.). Comment on: J Exp Med 1999 Aug 2;190(3):323–30.
Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes [see comments] Schrader CE, et al. **J Exp Med** 1999 Aug 2;190(3):323–30 . Comment in: J Exp Med 1999 Aug 2;190(3):307–10.
Switch recombination in a transfected plasmid occurs preferentially in a B cell line that undergoes switch recombination of its chromosomal Ig heavy chain genes. Stavnezer J, et al. **J Immunol** 1999 Aug 15;163(4):2028–40
Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. Zan H, et al. **J Immunol** 1999 Mar 15; 162(6):3437–47
CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu-->S alpha and sequential S mu-->S gamma, S gamma-->S alpha DNA recombination. Zan H, et al. **J Immunol** 1998 Nov 15;161(10):5217–25

IMMUNOLOGY

Toward a role of dendritic cells in the germinal center reaction: triggering of B cell proliferation and isotype switching. Dubois B, et al. **J Immunol** 1999 Mar 15; 162(6):3428–36
Comparison of an anti-HSV-2 monoclonal IgG and its IgA switch variant for topical immunoprotection of the mouse vagina. Zeitlin L, et al. **J Reprod Immunol** 1998 Oct; 40(1):93–101

PHYSIOLOGY

CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. Nagumo H, et al. **J Immunol** 1998 Dec 15; 161(12):6496–502

IMMUNOGLOBULIN CONSTANT REGION

CHEMISTRY

Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Olsen KE,

et al. **Biochem Biophys Res Commun** 1998 Oct 20; 251(2):642–7

Human IgG2 constant region enhances in vivo stability of anti–tenascin antibody 81C6 compared with its murine parent. Reist CJ, et al. **Clin Cancer Res** 1998 Oct; 4(10):2495–502

A human immunoglobulin (Ig)A calpha3 domain motif directs polymeric Ig receptor–mediated secretion. Hexham JM, et al. **J Exp Med** 1999 Feb 15;189(4):747–52

GENETICS

DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B–cell neoplasia: aberrant CH gene rearrangements in follicle center–cell lymphoma. Vaandrager JW, et al. **Blood** 1998 Oct 15; 92(8):2871–8

Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Rack KA, et al. **Genes Chromosomes Cancer** 1998 Nov;23(3):220–6

Organization of the equine immunoglobulin heavy chain constant region genes; III. Alignment of c mu, c gamma, c epsilon and c alpha genes. Wagner B, et al. **Immunobiology** 1998 Jul;199(1):105–18

Opposite orientation of the alpha– and upsilon–chain constant region genes in the immunoglobulin heavy chain locus of the duck. Magor KE, et al. **Immunogenetics** 1999 Jul; 49(7–8):692–5

The p65 subunit of NF–kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3. Horwitz BH, et al. **J Immunol** 1999 Feb 15;162(4):1941–6

Organisation of the equine immunoglobulin constant heavy chain genes. II. Equine cgamma genes. Overesch G, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3–4):273–87

IMMUNOLOGY

The structure of an entire noncovalent immunoglobulin kappa light–chain dimer (Bence–Jones protein) reveals a weak and unusual constant domains association. Roussel A, et al. **Eur J Biochem** 1999 Feb;260(1):192–9

Novel tetravalent and bispecific IgG–like antibody molecules combining single–chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. Alt M, et al. **FEBS Lett** 1999 Jul 2;454(1–2):90–4

METABOLISM

Evidence that C1q binds specifically to CH2–like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Kovacs H, et al. **Biochemistry** 1998 Dec 22;37(51):17865–74

Identification of peptides that bind to the constant region of a humanized IgG1 monoclonal antibody using phage display. Ehrlich GK, et al. **J Mol Recognit** 1998 Winter; 11(1–6):121–5

PHARMACOLOGY

Inhibition of cytoplasmic antigen, glucose– 6–phosphate dehydrogenase, by VH–CH1, an intracellular Fd fragment antibody derived from a semisynthetic Fd fragment phage display library. Mulligan–Kehoe MJ, et al. **J Mol Biol** 1999 May 28;289(1):41–55

PHYSIOLOGY

Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. Harriman GR, et al. **J Immunol** 1999 Mar 1; 162(5):2521–9

Inhibition of complement–mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin. Kojima T, et al. **Transplantation** 1999 Feb 27;67(4):637–8

IMMUNOGLOBULIN ENHANCER–BINDING PROTEIN
see **NF–KAPPA B**

IMMUNOGLOBULIN FRAGMENTS

The regulated expression of an intrabody produces a mutant phenotype in Drosophila. Hassanzadeh Gh G, et al. **FEBS Lett** 1998 Oct 16;437(1–2):81–6

A chimeric receptor that selectively targets membrane–bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Hombach A, et al. **Gene Ther** 1999 Feb;6(2):300–4

High–density immobilization of an antibody fragment to a carboxymethylated dextran–linked biosensor surface. Howell S, et al. **J Mol Recognit** 1998 Winter;11(1–6):200–3

DNA vaccines with single–chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments] King CA, et al. **Nat Med** 1998 Nov;4(11):1281–6. Comment in: Nat Med 1998 Nov;4(11):1239–40.

BIOSYNTHESIS

Production and characterization of an anti–(MUC1 mucin) recombinant diabody. Denton G, et al. **Cancer Immunol Immunother** 1999 Apr;48(1):29–38

High level accumulation of single–chain variable fragments in the cytosol of transgenic Petunia hybrida. De Jaeger G, et al. **Eur J Biochem** 1999 Jan;259(1–2):426–34

Expression and characterization of bispecific single–chain Fv fragments produced in transgenic plants. Fischer R, et al. **Eur J Biochem** 1999 Jun;262(3):810–6

Bioprocess monitoring: an optical biosensor for rapid bioproduct analysis. Gill A, et al. **J Biotechnol** 1998 Oct 19;65(1):69–80

Intracellular and cell surface displayed single–chain diabodies. Kontermann RE, et al. **J Immunol Methods** 1999 Jun 24;226(1–2):179–88

Method for the preparation of bispecific F(ab')2mu fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments. Morimoto K, et al. **J Immunol Methods** 1999 Apr 22;224(1–2):43–50

Bacterial surface display of an anti–pollutant antibody fragment. Dhillon JK, et al. **Lett Appl Microbiol** 1999 May; 28(5):350–4

Transient expression of a tumor–specific single–chain fragment and a chimeric antibody in tobacco leaves. Vaquero C, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11128–33

Escherichia coli skp chaperone coexpression improves solubility and phage display of single–chain antibody fragments. Hayhurst A, et al. **Protein Expr Purif** 1999 Apr; 15(3):336–43

Recent advances in the large–scale production of antibody fragments using lower eukaryotic microorganisms. Frenken LG, et al. **Res Immunol** 1998 Jul–Aug;149(6):589–99 (1 ref.)

In vitro production of recombinant antibody fragments in Pichia pastoris. Pennell CA, et al. **Res Immunol** 1998 Jul–Aug;149(6):599–603

[Expression of chimeric single–chain antibody with specificity for HBsAg in E. coli] Pan H, et al. **I Chuan Hsueh Pao** 1999;26(1):87–91 (Eng. Abstr.) **(Chi)**

CHEMISTRY

Production, crystallization and diffraction to atomic resolution of an antibody Fv specific for the blood–group A oligosaccharide antigen. Patenaude SI, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(2 (Pt 6)):1456–9

Production and characterisation of a recombinant single–chain anti ErbB2–clavin immunotoxin. D'Alatri L, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3369–73

Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Wörn A, et al. **Biochemistry** 1999 Jul 6; 38(27):8739–50

Site–specific modification of a single–chain antibody using a novel glyoxylyl–based labeling reagent. Zhao ZG, et al. **Bioconjug Chem** 1999 May–Jun;10(3):424–30

Expression and characterization of bispecific single–chain Fv fragments produced in transgenic plants. Fischer R, et al. **Eur J Biochem** 1999 Jun;262(3):810–6

Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Braden BC, et al. **Immunol Rev** 1998 Jun; 163:45–57 (44 ref.)

Mitogenic properties of a bispecific single–chain Fv–Ig fusion generated from CD2–specific mAb to distinct epitopes. Connelly RJ, et al. **Int Immunol** 1998 Dec;10(12):1863–72

Backbone and C beta assignments of the anti–gp120 antibody Fv fragment complexed with an antigenic peptide [letter] Tugarinov V, et al. **J Biomol NMR** 1999 Feb;13(2):193–4

Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen. Jäger M, et al. **J Mol Biol** 1999 Feb 5;285(5):2005–19

The pH–dependent structural variation of complementarity–determining region H3 in the crystal structures of the Fv fragment from an anti–dansyl monoclonal antibody. Nakasako M, et al. **J Mol Biol** 1999 Aug 6;291(1):117–34

Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. Ramm K, et al. **J Mol Biol** 1999 Jul 9; 290(2):535–46

Crystal structure of a ternary complex between human chorionic gonadotropin (hCG) and two Fv fragments specific for the alpha and beta–subunits. Tegoni M, et al. **J Mol Biol** 1999 Jun 25;289(5):1375–85

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage–displayed antibody fragments. Huls GA, et al. **Nat Biotechnol** 1999 Mar;17(3):276–81

Exposed peptide core of IgA1 hinge region in IgA nephropathy. Kokubo T, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):81–5

Ribosome display efficiently selects and evolves high–affinity antibodies in vitro from immune libraries. Hanes J, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14130–5

scFv multimers of the anti–neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Atwell JL, et al. **Protein Eng** 1999 Jul;12(7):597–604

[Antibody radiolabeling with technetium–99m] Perera A, et al. **Rev Esp Med Nucl** 1998;17(4):302–9 (63 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSTIC USE

Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Viti F, et al. **Cancer Res** 1999 Jan 15; 59(2):347–52

Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Bartolomei M, et al. **Eur J Nucl Med** 1998 Nov;25(11):1489–94

GENETICS

Analysis of V(H)–D–J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Gellrich S, et al. **Arthritis Rheum** 1999 Feb;42(2):240–7

Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. zu Putlitz J, et al. **Biochem Biophys Res Commun** 1999 Feb 24;255(3):785–91

Binding characteristics of anti–atrazine monoclonal antibodies and their fragments synthesised in bacteria and plants. Strachan G, et al. **Biosens Bioelectron** 1998 Sep 15; 13(6):665–73

Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Barnes MN, et al. **Clin Cancer Res** 1996 Jul;2(7):1089–95

Sequence analysis of a monoclonal antibody specific for the preS2 region of hepatitis B surface antigen, and the cloning, expression and characterisation of its single–chain Fv construction. Passafiume M, et al. **FEBS Lett** 1998 Dec 28;441(3):407–12

Production of a functional single chain antibody attached to the surface of a plant virus. Smolenska L, et al. **FEBS Lett** 1998 Dec 28;441(3):379–82

Antibodies: from genes to targeted cancer gene therapy [editorial] Hawkins RE, et al. **Gene Ther** 1998 Dec; 5(12):1581–3

Human single–chain Fv fragments from a combinatorial library using the loxP–Cre recombination system. Biard–Piechaczyk M, et al. **Hum Antibodies** 1999;9(1):67–77

Cloning and expression of a single–chain Fv fragment specific for the human interleukin 18 receptor. Nishida Y, et al. **Hybridoma** 1998 Dec;17(6):577–80

Expression levels of B cell surface immunoglobulin regulate efficiency of allelic exclusion and size of autoreactive B–1 cell compartment. Watanabe N, et al. **J Exp Med** 1999 Aug 16;190(4):461–69

Intrabody construction and expression. II. A synthetic catalytic Fv fragment. Ohage EC, et al. **J Mol Biol** 1999 Sep 3;291(5):1129–34

Retrovirus targeting by tropism restriction to melanoma cells. Martin F, et al. **J Virol** 1999 Aug;73(8):6923–9

Selection of immunoglobulin diversity gene reading frames in B cell lymphoproliferative disorders. Stamatopoulos K, et al. **Leukemia** 1999 Apr;13(4):601–4

Filamentous bacteriophage display of a bifunctional protein A::scFv fusion. Li Y, et al. **Mol Biotechnol** 1998 Jun; 9(3):187–93

Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti–p53 single chain Fv fragments. Caron de Fromentel C, et al. **Oncogene** 1999 Jan 14;18(2):551–7

A tumor specific single chain antibody dependent gene expression system. Mary MN, et al. **Oncogene** 1999 Jan 14;18(2):559–64

Recent advances in the large–scale production of antibody fragments using lower eukaryotic microorganisms. Frenken LG, et al. **Res Immunol** 1998 Jul–Aug;149(6):589–99 (1 ref.)

[Construction of expressing vector for phage display scFv and a mouse unspecified antibody library] Zhang WG, et al. **I Chuan Hsueh Pao** 1999;26(2):99–106 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis. Kortt AA, et al. **Anal Biochem** 1999 Aug 15;273(1):133–41

Single–chain antibodies in pancreatic cancer. Colcher D, et al. **Ann N Y Acad Sci** 1999 Jun 30;880:263–80 (56 ref.)

Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. van der Linden RH, et al. **Biochim Biophys Acta** 1999 Apr 12; 1431(1):37–46

A monoclonal antibody directed against the non–toxic subunit of a dimeric phospholipase A2 neurotoxin, crotoxin, neutralizes its toxicity. Choumet V, et al. **Biol Chem** 1998 Jul;379(7):899–906

Production and characterization of an anti–(MUC1 mucin) recombinant diabody. Denton G, et al. **Cancer Immunol Immunother** 1999 Apr;48(1):29–38

Cytotoxic and antitumor activity of a recombinant tumor necrosis factor–B1(Fv) fusion protein on LeY antigen–expressing human cancer cells. Scherf U, et al. **Clin Cancer Res** 1996 Sep;2(9):1523–31

The mode of action of Y13–259 scFv fragment intracellularly expressed in mammalian cells. Cardinale A, et al. **FEBS Lett** 1998 Nov 20;439(3):197–202

Di–, tri– and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. Le Gall F, et al. **FEBS Lett** 1999 Jun 18;453(1–2):164–8

Retention of neutralising activity by recombinant anti–pneumolysin antibody fragments. Garcia M, et al.

IMMUNOGLOBULIN FRAGMENTS

FEMS Immunol Med Microbiol 1998 Nov;22(3):225–31
Development of neutralising human recombinant antibodies to pertussis toxin. Williamson P, et al.
FEMS Immunol Med Microbiol 1999 Apr;23(4):313–9
Human single-chain Fv fragments from a combinatorial library using the loxP-Cre recombination system. Biard-Piechaczyk M, et al. **Hum Antibodies** 1999;9(1):67–77
Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies [see comments] Mhashilkar AM, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1453–67. Comment in: Hum Gene Ther 1999 Jun 10;10(9):1425–7.
Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Prechl J, et al.
Immunopharmacology 1999 May;42(1–3):159–65
Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses. Franconi R, et al. **Immunotechnology** 1999 Mar;4(3–4):189–201
An scFv phage clone that binds to human beta2-microglobulin. Jwang B, et al. **Immunotechnology** 1999 Mar;4(3–4):231–6
Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Cirino NM, et al. **Infect Immun** 1999 Jun;67(6):2957–63
Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay. Luo D, et al. **J Biotechnol** 1998 Oct 27; 65(2–3):225–8
Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. Annenkov AE, et al. **J Immunol** 1998 Dec 15;161(12):6604–13
The rate of dissociation between antibody and antigen determines the efficiency of antibody-mediated antigen presentation to T cells. Guermonprez P, et al.
J Immunol 1998 Nov 1;161(9):4542–8
A yeast surface display system for the discovery of ligands that trigger cell activation. Cho BK, et al.
J Immunol Methods 1998 Nov 1;220(1–2):179–88
Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate for one-step immunodetection in molecular hybridization. Muller BH, et al.
J Immunol Methods 1999 Jul 30;227(1–2):177–85
T cell activation by monoclonal antibodies bound to tumor cells by a cell surface displayed single-chain antibody. Rode HJ, et al. **J Immunol Methods** 1999 Apr 22; 224(1–2):151–60
Open sandwich ELISA with V(H)-/V(L)-alkaline phosphatase fusion proteins. Suzuki C, et al.
J Immunol Methods 1999 Apr 22;224(1–2):171–84
A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy. Thompson JE, et al. **J Immunol Methods** 1999 Jul 30;227(1–2):17–29
Construction and characterization of a humanized single chain Fv antibody fragment against the main immunogenic region of the acetylcholine receptor. Papanastasiou D, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):182–95
High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. Tsantili P, et al. **J Neuroimmunol** 1999 Feb 1;94(1–2):15–27
Strain specific recombinant antibodies to potato virus Y potyvirus. Boonham N, et al. **J Virol Methods** 1998 Oct; 74(2):193–9
Characterization of a new intrabody directed against the N-terminal region of human p53. Cohen PA, et al.
Oncogene 1998 Nov 12;17(19):2445–56
Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. McCormick AA, et al.
Proc Natl Acad Sci U S A 1999 Jan 19;96(2):703–8
Antibody BCF2 against scorpion toxin Cn2 from Centuroides noxius Hoffmann: primary structure and three-dimensional model as free Fv fragment and complexed with its antigen. Selisko B, et al. **Proteins** 1999 Oct 1;37(1):130–43
Calculation of HyHel10-lysozyme binding free energy changes: effect of ten point mutations. Sharp KA.
Proteins 1998 Oct 1;33(1):39–48
Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3 [published erratum appears in Scand J Immunol 1999 Aug;50(2):232] Hombach A, et al. **Scand J Immunol** 1998 Nov;48(5):497–501
Exploiting antibody-based technologies to manage environmental pollution. Harris B. **Trends Biotechnol** 1999 Jul;17(7):290–6 (64 ref.)

ISOLATION & PURIFICATION

Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Wörn A, et al. **Biochemistry** 1999 Jul 6; 38(27):8739–50
Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies. Hombach A, et al.
J Immunol Methods 1998 Sep 1;218(1–2):53–61
The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries. MacKenzie R, et al. **J Immunol Methods** 1998 Nov 1;220(1–2):39–49
Monitoring of scFv selected by phage display using detection of scFv-pIII fusion proteins in a microtiter scale assay. Mersmann M, et al. **J Immunol Methods** 1998 Nov 1; 220(1–2):51–8
Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. Tsumoto K, et al. **J Immunol Methods** 1998 Oct 1; 219(1–2):119–29

METABOLISM

Toward selection of internalizing antibodies from phage libraries. Becerril B, et al.
Biochem Biophys Res Commun 1999 Feb 16;255(2):386–93
Stability of a single-chain Fv antibody fragment when exposed to a high shear environment combined with air-liquid interfaces. Harrison JS, et al.
Biotechnol Bioeng 1998 Aug 20;59(4):517–9
High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Roovers RC, et al. **Br J Cancer** 1998 Dec;78(11):1407–16
Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Li Q, et al. **Cancer Immunol Immunother** 1998 Nov; 47(3):121–30
Binding of modified fragments of the Shigella dysenteriae type 1 O-specific polysaccharide to monoclonal IgM 3707 E9 and docking of the immunodeterminant to its modeled Fv. Miller CE, et al. **Carbohydr Res** 1998 Jul;309(3):219–26
Protein LA, a novel hybrid protein with unique single-chain Fv antibody- and Fab-binding properties. Svensson HG, et al. **Eur J Biochem** 1998 Dec 1;258(2):890–6
IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Olafsen T, et al.
Immunotechnology 1998 Oct;4(2):141–53
Underglycosylation of IgA1 hinge plays a certain role for its glomerular deposition in IgA nephropathy. Hiki Y, et al. **J Am Soc Nephrol** 1999 Apr;10(4):760–9
Receptor-mediated targeting of fluorescent probes in living cells. Farinas J, et al. **J Biol Chem** 1999 Mar 19; 274(12):7603–6
Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system. Kobayashi H, et al. **J Nucl Med** 1999 Aug;40(8):1381–91
Therapeutic antibody fragments with prolonged in vivo half-lives. Chapman AP, et al. **Nat Biotechnol** 1999 Aug; 17(8):780–3
Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Schmidt M, et al. **Oncogene** 1999 Mar 4;18(9):1711–21
Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Hanes J, et al.
Proc Natl Acad Sci U S A 1998 Nov 24;95(24):14130–5
Strategies to reduce renal radioactivity levels of antibody fragments. Arano Y. **Q J Nucl Med** 1998 Dec;42(4):262–70 (61 ref.)
Pharmacokinetics and biodistribution of genetically-engineered antibodies. Colcher D, et al.
Q J Nucl Med 1998 Dec;42(4):225–41 (164 ref.)

PHARMACOLOGY

Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Arano Y, et al. **Cancer Res** 1999 Jan 1;59(1):128–34
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Reiter Y, et al. **Clin Cancer Res** 1996 Feb; 2(2):245–52 (62 ref.)
Intrathymic function of the human cortical epithelial cell surface antigen gp200-MR6: single-chain antibodies to evolutionarily conserved determinants disrupt mouse thymus development. Palmer DB, et al. **Immunology** 1999 Feb;96(2):236–45

THERAPEUTIC USE

Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Pfosser A, et al. **Int J Cancer** 1999 Feb 9;80(4):612–6
Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Tripathi PK, et al. **Mol Immunol** 1998 Sep;35(13):853–63
Therapeutic antibody fragments with prolonged in vivo half-lives. Chapman AP, et al. **Nat Biotechnol** 1999 Aug; 17(8):780–3
[Use of antibodies or their fragments for the treatment of tumors] Douillard JY, et al. **Bull Cancer** 1998 Nov; 85(11):951–9 (29 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOGLOBULIN GENES see **GENES, IMMUNOGLOBULIN**

IMMUNOGLOBULIN GM ALLOTYPES

Susceptibility to coeliac disease in Tunisian children and GM immunoglobulin allotypes. Bouguerra F, et al.
Eur J Immunogenet 1999 Aug;26(4):293–7

CLASSIFICATION

GM and KM immunoglobulin allotypes in a Spanish Pyrenean population: Val d'Aran. Giraldo MP, et al.
Ann Hum Biol 1998 Sep–Oct;25(5):453–65

GENETICS

Genetic B-cell variation based on immunoglobulin heavy G-chain (Gm) genes. Oxelius VA. **Scand J Immunol** 1999 Apr;49(4):345–6 (10 ref.)

IMMUNOGLOBULIN IDIOTYPES

Idiotype usage by polyclonally activated B cells in experimental autoimmunity and infection. Sutmuller M, et al. **Clin Exp Immunol** 1999 Feb;115(2):275–80
Preferential IgH V4-34 gene segment usage in particular subtypes of B-cell lymphoma detected by antibody 9G4. Funkhouser WK, et al. **Hum Pathol** 1998 Nov; 29(11):1317–21

ADMINISTRATION & DOSAGE

Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections. Montesano MA, et al.
J Exp Med 1999 Feb 15;189(4):637–45

ANALYSIS

Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. European Concerted Action on the Immunogenetics of SLE. Galeazzi M, et al.
Clin Exp Rheumatol 1998 Nov-Dec;16(6):717–20

BLOOD

Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus. Isenberg DA, et al.
Ann Rheum Dis 1998 Sep;57(9):566–70

CHEMISTRY

Immunogenic properties of an anti-DNA antibody-derived peptide, 88H.64–80: location of a dominant idiotope defined by T and B cells. Ward FJ, et al. **J Autoimmun** 1998 Oct; 11(5):439–47

GENETICS

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Fagerberg J, et al. **Int J Cancer** 1999 Mar 1;80(5):671–80

IMMUNOLOGY

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. Reichardt VL, et al.
Blood 1999 Apr 1;93(7):2411–9
Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis. Erez-Alon N, et al. **Cancer Res** 1998 Dec 1;58(23):5447–52
Evidence of idiotypic modulation in the immune response to gp43, the major antigenic component of Paracoccidioides brasiliensis in both mice and humans. Souza AR, et al. **Clin Exp Immunol** 1998 Oct;114(1):40–8
Thyroglobulin monoclonal antibody cross-reacting with thyroperoxidase induces in syngeneic mice anti-idiotypic monoclonal antibodies with dual autoantigen binding properties. The intertope hypothesis. Duthoit C, et al.
Eur J Immunol 1999 May;29(5):1626–34
Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg). Macias A, et al. **Hybridoma** 1999 Jun;18(3):263–72
Idiotype-specific inhibition of LFA-1-mediated cell adhesion by anti-idiotype x anti-LFA-1 bispecific antibodies. Kollet O, et al. **Immunol Lett** 1998 Jul; 62(3):171–6
Immunoglobulin variable regions as idiotype vaccines. Hefty PS, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):27–37, vi (57 ref.)
Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Nussbaum G, et al. **Infect Immun** 1999 Sep;67(9):4469–76
Immunogenic properties of an anti-DNA antibody-derived peptide, 88H.64–80: location of a dominant idiotope defined by T and B cells. Ward FJ, et al. **J Autoimmun** 1998 Oct; 11(5):439–47
Characterization of the I-E(d)--restricted peptide recognized by an anti-idiotypic CD4+ T cell line. Masaki H, et al.
J Clin Lab Immunol 1997;49(1):1–14
Neonatal exposure to idiotype induces Schistosoma mansoni egg antigen-specific cellular and humoral immune responses. Montesano MA, et al. **J Immunol** 1999 Jul 15; 163(2):898–905
DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. Syrengelas AD, et al. **J Immunol** 1999 Apr 15;162(8):4790–5

Monoclonal anti-idiotype antibody mimicking the pesticide binding site of cutinase: potential for broad specificity organophosphate recognition. Ward CM, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):197-202

Molecular basis for the lack of mimicry of Brucella polysaccharide antigens by Ab2gamma antibodies. Young NM, et al. **Mol Immunol** 1999 Apr;36(6):339-47

Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine. Mellstedt H, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):211-5 (21 ref.)

Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3 [published erratum appears in Scand J Immunol 1999 Aug;50(2):232] Hombach A, et al. **Scand J Immunol** 1998 Nov;48(5):497-501

Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Wen YJ, et al. **Scand J Immunol** 1999 Sep;50(3):296-301

Idiotypic vaccination as therapy for multiple myeloma. Kwak LW, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):34-7 (15 ref.)

[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)] Wagner U, et al. **Zentralbl Gynakol** 1999;121(4):190-5 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Massaia M, et al. **Blood** 1999 Jul 15; 94(2):673-83

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments] Bendandi M, et al. **Nat Med** 1999 Oct;5(10):1171-7. Comment in: Nat Med 1999 Oct;5(10):1124.

Cancer vaccine strategies get bigger and better [news; comment] de Gruijl TD, et al. **Nat Med** 1999 Oct; 5(10):1124-5. Comment on: Nat Med 1999 Oct;5(10):1171-7.

Idiotypic vaccination as therapy for multiple myeloma. Kwak LW, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):34-7 (15 ref.)

IMMUNOGLOBULIN ISOTYPES

Serum and intestinal isotype antibody responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. Tô TL, et al. **J Gen Virol** 1998 Nov;79 (Pt 11):2661-72

Multiple myeloma. A model of nature. Van Camp B, et al. **Pathol Biol (Paris)** 1999 Feb;47(2):87-8

ANALYSIS

Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis. Ichikawa Y, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):709-15

[Detection of isotype-specific autoantibodies to calpastatin in sera from patients with rheumatic diseases using heat-treated HeLa cell extract as an antigen source for immunoblotting] Takada R, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug;21(4):150-8 (Eng. Abstr.) **(Jpn)**

[Distribution of IgG subclasses and their biological activity in bioglobulin] Bucholc B, et al. **Med Dosw Mikrobiol** 1998; 50(1-2):105-13 (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Latex allergy: characterization of major allergens and isotypic expression. Chardin H, et al. **Allergy** 1999 Aug; 54(8):872-7

Defective antibody production in patients with rheumatoid arthritis and bronchiectasis. Snowden N, et al. **Clin Rheumatol** 1999;18(2):132-5

Antigenic stimuli do not influence thymic B lymphocytes: a morphological and functional study in germ-free and conventionally reared piglets. Cukrowska B, et al. **Dev Immunol** 1998;6(3-4):171-8

The liaison of isotype class switch and mismatch repair: an illegitimate affair [comment] Kenter AL. **J Exp Med** 1999 Aug 2;190(3):307-10 (26 ref.). Comment on: J Exp Med 1999 Aug 2;190(3):323-30.

Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes [see comments] Schrader CE, et al. **J Exp Med** 1999 Aug 2;190(3):323-30 . Comment in: J Exp Med 1999 Aug 2;190(3):307-10.

Cutting edge: mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. Faquim-Mauro EL, et al. **J Immunol** 1999 Oct 1;163(7):3572-6

The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. Hougs L, et al. **J Immunol** 1999 Jan 1;162(1):224-37

In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. Wu ZQ, et al. **J Immunol** 1999 Jul 15;163(2):659-67

In situ hybridization analysis of immunoglobulin heavy chain variable gene expression with family specific oligonucleotide probes. Rundle CH, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):31-52

Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. Fischer JE, et al. **J Infect Dis** 1999 Sep;180(3):714-9

Different antiamebic antibody isotype patterns in the large and small intestine after local and systemic immunization of mice with glutaraldehyde fixed Entamoeba histolytica trophozoites. Moreno-Fierros L, et al. **Life Sci** 1999; 64(13):1079-89

Expression of IgH chain genes in antibody response to ragweed and purified Amb a 1: evidence for differential regulation of isotype production. Allauzen S, et al. **Mol Immunol** 1999 Jun;36(9):587-98

Immunoglobulin-secreting cells in cord blood: effects of Epstein-Barr virus and interleukin-4. Gudmundsson KO, et al. **Scand J Immunol** 1999 Jul;50(1):21-4

Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Rajananthanan P, et al. **Vaccine** 1999 Feb 26;17(7-8):715-30

Isotype-specific immune responses in murine experimental anisakiasis. Perteguer MJ, et al. **Zentralbl Veterinarmed [B]** 1998 Dec;45(10):603-10

BLOOD

Antibody isotype responses, infection and re-infection for Schistosoma japonicum in a marshland area of China. Li YS, et al. **Acta Trop** 1999 Jul 30;73(2):79-92

Skin-test reactivity and isotype-specific immune responses to recombinant Asp f 3, a major allergen of Aspergillus fumigatus. Hemmann S, et al. **Clin Exp Allergy** 1998 Jul; 28(7):860-7

Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Lacombe C, et al. **Clin Immunol** 1999 Jan;90(1):128-32

Progression to type 1 diabetes is associated with a change in the immunoglobulin isotype profile of autoantibodies to glutamic acid decarboxylase (GAD65). Childhood Diabetes in Finland Study Group. Petersen JS, et al. **Clin Immunol** 1999 Feb;90(2):276-81

Systemic levels of cytokines and GAD-specific autoantibodies isotypes in Chinese IDDM patients. Ng WY, et al. **Diabetes Res Clin Pract** 1999 Feb;43(2):127-35

Characterization of human immunoglobulin (Ig) isotype and IgG subclass response to Bartonella henselae infection. McGill SL, et al. **Infect Immun** 1998 Dec;66(12):5915-20

Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes. Harriman GR, et al. **J Immunol** 1999 Mar 1; 162(5):2521-9

Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. Hutchins WA, et al. **J Infect Dis** 1999 Jun;179(6):1433-40

Specificity, isotype, and titer distribution of anticardiolipin antibodies in CNS diseases. D'Olhaberriague L, et al. **Neurology** 1998 Nov;51(5):1376-80

Experimental Angiostrongylus costaricensis infection in mice: immunoglobulin isotype responses and parasite-specific antigen recognition after primary low-dose infection. Geiger SM, et al. **Parasitol Res** 1999 Mar;85(3):200-5

Immunoglobulin isotype identification in red cell antibodies using flow cytometry. Price WR, et al. **Transfusion** 1999 Jul;39(7):756-62

CHEMISTRY

The interaction between F3 immunoglobulin domains and protein tyrosine phosphatases zeta/beta triggers bidirectional signalling between neurons and glial cells. Revest JM, et al. **Eur J Neurosci** 1999 Apr;11(4):1134-47

DRUG EFFECTS

The regulatory effects of all-trans-retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. Tokuyama H, et al. **Cell Immunol** 1999 Feb 25;192(1):41-7

GENETICS

The liaison of isotype class switch and mismatch repair: an illegitimate affair [comment] Kenter AL. **J Exp Med** 1999 Aug 2;190(3):307-10 (26 ref.). Comment on: J Exp Med 1999 Aug 2;190(3):323-30.

Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes [see comments] Schrader CE, et al. **J Exp Med** 1999 Aug 2;190(3):323-30 . Comment in: J Exp Med 1999 Aug 2;190(3):307-10.

In vitro induction of the expression of multiple IgA isotype genes in rabbit B cells by TGF-beta and IL-2. Spieker-Polet H, et al. **J Immunol** 1999 May 1; 162(9):5380-8

IMMUNOLOGY

Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Lakos G, et al. **Clin Exp Immunol** 1999 Sep;117(3):574-9

Isotype controls--time to let go? [comment] O'Gorman MR, et al. **Cytometry** 1999 Apr 15;38(2):78-80. Comment on: Cytometry 1998 Dec 15;34(6):280-3.

Prognostic significance of the immunological variant in patients with multiple myeloma. Goranova V, et al. **Folia Med (Plovdiv)** 1999;41(1):164-7

Immunoglobulin double isotype-producing hybridomas isolated from an autoimmune (NZB x NZW)F1 mouse. Payelle-Brogard B, et al. **Hybridoma** 1998 Jun;17(3):289-97

Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis. Rehman J, et al. **Immunol Lett** 1999 Jun 1;68(2-3):391-5

Immunoglobulin isotype distribution of antinuclear antibodies in dogs with leishmaniasis. Lucena R, et al. **Res Vet Sci** 1998 Nov-Dec;65(3):205-7

Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Arvieux J, et al. **Thromb Haemost** 1998 Sep;80(3):393-8

Antigen-specific cytokine and antibody isotype profiles induced by mucosal and systemic immunization with recombinant adenoviruses. Papp Z, et al. **Viral Immunol** 1999;12(2):107-16

IMMUNOGLOBULIN JOINING REGION

see related
GENES, IMMUNOGLOBULIN

GENETICS

Rapid simultaneous amplification and detection of the MBR/JH chromosomal translocation by fluorescence melting curve analysis [see comments] Bohling SD, et al. **Am J Pathol** 1999 Jan;154(1):97-103. Comment in: Am J Pathol 1999 Jan;154(1):7-9.

Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Krangel MS, et al. **Immunol Rev** 1998 Oct;165:131-47 (181 ref.)

A targeted deletion of a region upstream from the Jkappa cluster impairs kappa chain rearrangement in cis in mice and in the 103/bcl2 cell line. Cocea L, et al. **J Exp Med** 1999 May 3;189(9):1443-50

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Pott C, et al. **Leukemia** 1998 Oct;12(10):1630-7

Intermolecular V(D)J recombination is prohibited specifically at the joining step. Han JO, et al. **Mol Cell** 1999 Mar;3(3):331-8

Formation of coding joints in V(D)J recombination-inducible severe combined immune deficient pre-B cell lines. Chang Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):191-6

Investigation of the molecular changes during chemotherapy in non-Hodgkin's lymphoma. Yazici H, et al. **Res Commun Mol Pathol Pharmacol** 1998 Jun;100(3):301-11

IMMUNOLOGY

Monoclonal autoantibodies from patients with autoimmune diseases: synovial fluid B lymphocytes of a patient with rheumatoid arthritis produced an IgG lambda antibody recognizing J-sequences of Ig kappa chains in a conformation-dependent way. von Landenberg P, et al. **Immunobiology** 1999 Jun;200(2):205-14

IMMUNOGLOBULIN-PRODUCING CELLS see **ANTIBODY-PRODUCING CELLS**

IMMUNOGLOBULIN-SECRETING CELLS see **ANTIBODY-PRODUCING CELLS**

IMMUNOGLOBULIN SWITCH REGION

Discordance between IgA switching at the DNA level and IgA expression at the mRNA level in IgA-deficient patients. Wang Z, et al. **Clin Immunol** 1999 Jun;91(3):263-70

GENETICS

Immunoglobulin class switch recombination: will genetics provide new clues to mechanism? Maizels N. **Am J Hum Genet** 1999 May;64(5):1270-5 (42 ref.)

Target specificity of immunoglobulin class switch recombination is not determined by nucleotide sequences of S regions. Kinoshita K, et al. **Immunity** 1998 Dec; 9(6):849-58

G4 DNA binding by LR1 and its subunits, nucleolin and hnRNP D, A role for G-G pairing in immunoglobulin switch recombination. Dempsey LA, et al. **J Biol Chem** 1999 Jan 8;274(2):1066-71

Processing of switch transcripts is required for targeting of antibody class switch recombination. Hein K, et al. **J Exp Med** 1998 Dec 21;188(12):2369-74

The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites. Schaffer A, et al. **J Immunol** 1999 May 1;162(9):5327-36

Switch recombination in a transfected plasmid occurs preferentially in a B cell line that undergoes switch recombination of its chromosomal Ig heavy chain genes. Stavnezer J, et al. **J Immunol** 1999 Aug 15;163(4):2028-40

Aberrant rearrangements of the immunoglobulin heavy chain

switch region in chronic B-cell leukemia. Crossen PE, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):559-65

Isolation and characterisation of recombination events involving immunoglobulin heavy chain switch regions in multiple myeloma using long distance vectorette PCR (LDV-PCR). Proffitt J, et al. **Leukemia** 1999 Jul; 13(7):1100-7

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Gabrea A, et al. **Mol Cell** 1999 Jan;3(1):119-23

IMMUNOGLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

IMMUNOGLOBULIN VARIABLE REGION

see related

BINDING SITES, ANTIBODY

A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas. Ohtomo T, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4311-5

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments] Damle RN, et al. **Blood** 1999 Sep 15; 94(6):1840-7. Comment in: Blood 1999 Sep 15;94(6):1837-9.

Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Benhar I, et al. **Clin Cancer Res** 1995 Sep;1(9):1023-9

H3-rules: identification of CDR-H3 structures in antibodies. Shirai H, et al. **FEBS Lett** 1999 Jul 16;455(1-2):188-97

Preferential IgH V4-34 gene segment usage in particular subtypes of B-cell lymphoma detected by antibody 9G4. Funkhouser WK, et al. **Hum Pathol** 1998 Nov; 29(11):1317-21

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments] King CA, et al. **Nat Med** 1998 Nov;4(11):1281-6. Comment in: Nat Med 1998 Nov;4(11):1239-40.

ANALYSIS

Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Ridgway JB, et al. **Cancer Res** 1999 Jun 1;59(11):2718-23

BIOSYNTHESIS

Isolation and recombinant expression of an MHV-JHM neutralising monoclonal antibody. Kolb AF, et al. **Adv Exp Med Biol** 1998;440:657-64

Procaryotic expression of single-chain variable-fragment (scFv) antibodies: secretion in L-form cells of Proteus mirabilis leads to active product and overcomes the limitations of periplasmic expression in Escherichia coli. Rippmann JF, et al. **Appl Environ Microbiol** 1998 Dec; 64(12):4862-9

Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. Fischer R, et al. **Eur J Biochem** 1999 Jun;262(3):810-6

Bioprocess monitoring: an optical biosensor for rapid bioproduct analysis. Gill A, et al. **J Biotechnol** 1998 Oct 19;65(1):69-80

Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Gao C, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6025-30

BLOOD

Light chain deposition disease detected by antisera to a variable region of the kappa1 light chain subgroup. Takeda S, et al. **Nephron** 1998 Oct;80(2):162-5

CHEMISTRY

Construction and characterization of a quadruplex DNA selective single-chain autoantibody from a viable motheaten mouse hybridoma with homology to telomeric DNA binding proteins. Brown JC, et al. **Biochemistry** 1998 Nov 17;37(46):16338-48

Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Wörn A, et al. **Biochemistry** 1999 Jul 6; 38(27):8739-50

Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc. Kim IS, et al. **Bioconjug Chem** 1999 May-Jun;10(3):447-53

Design of novel porphyrin-binding peptides based on antibody CDR. Takahashi M, et al. **Bioorg Med Chem Lett** 1998 Aug 4;8(15):2023-6

Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Tan PH, et al. **Biophys J** 1998 Sep;75(3):1473-82

Structural relationship of lambda-type light chains with AL amyloidosis. Alim MA, et al. **Clin Immunol** 1999 Mar; 90(3):399-403

Expression and characterization of bispecific single-chain Fv fragments produced in transgenic plants. Fischer R, et al. **Eur J Biochem** 1999 Jun;262(3):810-6

A single-chain antibody fragment is functionally expressed in the cytoplasm of both Escherichia coli and transgenic plants. Tavladoraki P, et al. **Eur J Biochem** 1999 Jun; 262(2):617-24

Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Braden BC, et al. **Immunol Rev** 1998 Jun; 163:45-57 (44 ref.)

Glimpses at the recognition of peptide/MHC complexes by T-cell antigen receptors. Mazza G, et al. **Immunol Rev** 1998 Jun;163:187-96 (34 ref.)

Preferred CDRH3 lengths for antibodies with defined specificities. Johnson G, et al. **Int Immunol** 1998 Dec; 10(12):1801-5

Anti-V3 and anti-IgG antibodies of healthy individuals share complementarity structures. Metlas R, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21(4):266-70

Structural models of antibody variable fragments: a method for investigating binding mechanisms. Petit S, et al. **J Comput Aided Mol Des** 1998 Mar;12(2):147-63

Algorithmic determination of core positions in the VL and VH domains of immunoglobulin molecules. Gelfand I, et al. **J Comput Biol** 1998 Fall;5(3):467-77

Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. Coloma MJ, et al. **J Immunol** 1999 Feb 15; 162(4):2162-70

Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. Shan D, et al. **J Immunol** 1999 Jun 1; 162(11):6589-95

Conformational analysis of the first observed non-proline cis-peptide bond occurring within the complementarity determining region (CDR) of an antibody. Bates PA, et al. **J Mol Biol** 1998 Dec 4;284(3):549-55

Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen. Jäger M, et al. **J Mol Biol** 1999 Feb 5;285(5):2005-19

Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies. Lamminmäki U, et al. **J Mol Biol** 1999 Aug 20; 291(3):589-602

The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge. Langedijk AC, et al. **J Mol Biol** 1998;283(1):95-110

The pH-dependent structural variation of complementarity-determining region H3 in the crystal structures of the Fv fragment from an anti-dansyl monoclonal antibody. Nakasako M, et al. **J Mol Biol** 1999 Aug 6;291(1):117-34

Intrabody construction and expression. I. The critical role of VL domain stability. Ohage E, et al. **J Mol Biol** 1999 Sep 3;291(5):1119-28

Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. Ramm K, et al. **J Mol Biol** 1999 Jul 9; 290(2):535-46

Novel mechanisms control the folding and assembly of lambda5/14.1 and VpreB to produce an intact surrogate light chain. Minegishi Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3041-6

Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding. de Haard HJ, et al. **Protein Eng** 1998 Dec; 11(12):1267-76

Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Delagrave S, et al. **Protein Eng** 1999 Apr;12(4):357-62

Geometric invariant core for the V(L) and V(H) domains of immunoglobulin molecules. Gelfand I, et al. **Protein Eng** 1998 Nov;11(11):1015-25

Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Wang M, et al. **Protein Eng** 1998 Dec;11(12):1277-83

A domain flip as a result of a single amino-acid substitution. Pokkuluri PR, et al. **Structure** 1998 Aug 15;6(8):1067-73

GENETICS

Transcripts of immunoglobulin germline mu: an amplified myeloid and B-lymphoid common gene program in various leukemias. Dong L, et al. **Acta Haematol** 1999; 101(3):119-23

Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients. Bolhuis RL, et al. **Adv Exp Med Biol** 1998; 451:547-55

Toward targeted killing of tumor-specific antigen-producing cancer cells by retrovirus displaying a single chain variable fragment antibody. Konishi H, et al. **Adv Exp Med Biol** 1998;451:405-10

An automated method for the analysis of T-cell receptor repertoires. Rapid RT-PCR fragment length analysis of the T-cell receptor beta chain complementarity-determining region 3. Lue C, et al. **Am J Clin Pathol** 1999 May;111(5):683-90

Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation [see comments] Matolcsy A, et al. **Am J Pathol** 1998 Nov;153(5):1609-14. Comment in: Am J Pathol 1998 Nov;153(5):1341-6.

Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells [comment] Müller-Hermelink HK, et al. **Am J Pathol** 1998 Nov;153(5):1341-6 (59 ref.). Comment on: Am J Pathol 1998 Nov;153(5):1609-14.

Polymorphism of the beta chain of the high affinity immunoglobulin E receptor (FcepsilonRI-beta) in South African black and white asthmatic and nonasthmatic individuals [letter] Hollá L, et al. **Am J Respir Crit Care Med** 1999 Aug;160(2):756-7

A bacterial signal peptidase enhances processing of a recombinant single chain antibody fragment in insect cells. Ailor E, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):444-50

VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Aarts WM, et al. **Blood** 1998 Nov 15; 92(10):3857-64

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments] Hamblin TJ, et al. **Blood** 1999 Sep 15; 94(6):1848-54. Comment in: Blood 1999 Sep 15;94(6):1837-9.

Mutational status of Ig V(H) genes provides clinically valuable information in B-cell chronic lymphocytic leukemia [comment] Naylor M, et al. **Blood** 1999 Sep 15; 94(6):1837-9. Comment on: Blood 1999 Sep 15;94(6):1840-7. Comment on: Blood 1999 Sep 15;94(6):1848-54.

V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Sahota SS, et al. **Blood** 1999 Aug 1;94(3):1070-6

V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Thompsett AR, et al. **Blood** 1999 Sep 1;94(5):1738-46

Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease. Vockerodt M, et al. **Blood** 1998 Oct 15;92(8):2899-907

V(H) gene analysis of Burkitt's lymphoma in children from north-western Iran. Chapman CJ, et al. **Br J Haematol** 1998 Dec;103(4):1116-23

Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Hughes-Jones NC, et al. **Br J Haematol** 1999 Jun;105(3):811-6

Primary sequence and molecular model of the variable region of a mouse monoclonal anti-Der p 1 antibody showing a similar epitope specificity as human IgE. McElveen JE, et al. **Clin Exp Allergy** 1998 Nov;28(11):1427-34

Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation. Elagib KE, et al. **Clin Exp Immunol** 1999 Aug;117(2):388-94

Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Krenn V, et al. **Clin Exp Immunol** 1999 Jan;115(1):168-75

Sequence analysis of V(4-34)-encoded antibodies from single B cells of two patients with systemic lupus erythematosus (SLE). Mockridge CI, et al. **Clin Exp Immunol** 1998 Oct; 114(1):129-36

Somatic mutation of immunoglobulin V(H)6 genes in human infants. Ridings J, et al. **Clin Exp Immunol** 1998 Oct; 114(1):33-9

Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythematosus. Dörner T, et al. **Clin Immunol** 1999 Aug;92(2):188-96

V(D)J recombination: on the cutting edge. Oettinger MA. **Curr Opin Cell Biol** 1999 Jun;11(3):325-9 (40 ref.)

V(D)J hypermutation and receptor revision: coloring outside the lines. Kelsoe G. **Curr Opin Immunol** 1999 Feb; 11(1):70-5 (53 ref.)

Light chain variable region diversity in Atlantic cod (Gadus morhua L.). Widholm H, et al. **Dev Comp Immunol** 1999 Apr;23(3):231-40

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Mayer A, et al. **Eur J Cancer** 1998 Jun; 34(7):968-76

Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Gabay C, et al. **Eur J Haematol** 1999 Sep; 63(3):180-91

V(H) gene family utilization in different B-cell lymphoma subgroups. Rosenquist R, et al. **Eur J Haematol** 1999 Feb; 62(2):123-8

The murine Cd48 gene: allelic polymorphism in the IgV-like region. Cabrero JG, et al. **Eur J Immunogenet** 1998 Dec; 25(6):421-3

V(H) gene replacement occurs in the spleen and bone marrow of non-autoimmune quasi-monoclonal mice. Bertrand FE, et al. **Eur J Immunol** 1998 Oct;28(10):3362-70

Accessibility changes across the mouse Igh-V locus during B cell development. Haines BB, et al. **Eur J Immunol** 1998 Dec;28(12):4228-35

Genetic origin of IgG antibodies cloned by phage display and anti-idiotypic panning from three patients with autoimmune thrombocytopenia. Jendreyko N, et al. **Eur J Immunol** 1998 Dec;28(12):4236-47

Early anti-nucleosome autoantibodies from a single

MRL+/+ mouse: fine specificity, V gene structure and pathogenicity. Jovelin F, et al. **Eur J Immunol** 1998 Nov; 28(11):3411–22

Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Saini SS, et al. **Eur J Immunol** 1999 Aug;29(8):2420–6

The variable genes and gene families of the mouse immunoglobulin kappa locus. Thiebe R, et al. **Eur J Immunol** 1999 Jul;29(7):2072–81

Restriction–PCR fingerprinting of the immunoglobulin VH repertoire: direct detection of an immune response and global analysis of B cell clonality. White HN. **Eur J Immunol** 1998 Oct;28(10):3268–79

The human immunoglobulin heavy variable genes. Pallarès N, et al. **Exp Clin Immunogenet** 1999;16(1):36–60 (61 ref.)

Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. Chardès T, et al. **FEBS Lett** 1999 Jun 11;452(3):386–94

Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination. Choumet V, et al. **FEBS Lett** 1999 Jul 16;455(1–2):18–22

Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein [published erratum appears in FEBS Lett 1999 Jan 22;443(1):80] Hassanzadeh GH G, et al. **FEBS Lett** 1998 Oct 16;437(1–2):75–80

Polymorphic sites in human mitochondrial DNA control region sequences: population data and maternal inheritance. Baasner A, et al. **Forensic Sci Int** 1998 Dec 21;98(3):169–78

Multiplex amplification of mitochondrial DNA for human and species identification in forensic evaluation. Bataille M, et al. **Forensic Sci Int** 1999 Jan 25;99(3):165–70

Report of the European DNA Profiling Group (EDNAP)—an investigation of the hypervariable STR loci ACTBP2, APOAI1 and D11S554 and the compound loci D12S391 and D1S1656. Gill P, et al. **Forensic Sci Int** 1998 Dec 21;98(3):193–200

Cloning, bacterial synthesis, and characterization of immunoglobulin variable regions of a monoclonal antibody specific for the hepatitis B virus X protein. zu Putlitz J, et al. **Gene** 1998 Oct 9;221(1):143–9

Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Okuda M, et al. **Hepatology** 1999 Jan; 29(1):217–22

Human single-chain Fv fragments from a combinatorial library using the loxP–Cre recombination system. Biard–Piechaczyk M, et al. **Hum Antibodies** 1999;9(1):67–77

Multiple geographic sources of region V 9-bp deletion haplotypes in Brazilians. Alves–Silva J, et al. **Hum Biol** 1999 Apr;71(2):245–59

Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Yang Q, et al. **Hum Gene Ther** 1998 Sep 1; 9(13):1929–37

Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region. Hashimoto Y, et al. **Hum Pathol** 1999 May;30(5):581–7

Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Miranda RN, et al. **Hum Pathol** 1999 Mar; 30(3):306–12

TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Sale JE, et al. **Immunity** 1998 Dec;9(6):859–69

Sequence and diversity of T-cell receptor beta-chain V and J genes of the owl monkey Aotus nancymaae. Vecino W, et al. **Immunogenetics** 1999 Aug;49(9):792–9

A unifying hypothesis for the molecular mechanism of somatic mutation and gene conversion in rearranged immunoglobulin variable genes. Blanden RV, et al. **Immunol Cell Biol** 1998 Jun;76(3):288–93 (36 ref.)

PCR amplification of murine immunoglobulin germline V genes: strategies for minimization of recombination artefacts. Zylstra P, et al. **Immunol Cell Biol** 1998 Oct; 76(5):395–405

Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. Kotlan B, et al. **Immunol Lett** 1999 Feb;65(3):143–51

Developmental regulation of V(D)J recombination at the TCR alpha/delta locus. Krangel MS, et al. **Immunol Rev** 1998 Oct;165:131–47 (181 ref.)

Accessibility control of variable region gene assembly during T-cell development. Sleckman BP, et al. **Immunol Rev** 1998 Oct;165:121–30 (59 ref.)

Characteristics of IgVH genes used by human intestinal plasma cells from childhood. Boursier L, et al. **Immunology** 1999 Aug;97(4):558–64

Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. Dunn–Walters DK, et al. **Immunology** 1998 Nov; 95(3):339–45

Co-existence of somatic hypermutation and gene conversion in hypervariable regions of single Igkappa clones. Liu J, et al. **Immunology** 1998 Oct;95(2):291–301

Complementarity-determining region (CDR) implantation: a theme of recombination. Söderlind E, et al. **Immunotechnology** 1999 Mar;4(3–4):279–85 (25 ref.)

Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues. Reason DC, et al. **Infect Immun** 1999 Feb;67(2):994–7

Promoter-associated displacement of hypermutations. Wu P, et al. **Int Immunol** 1998 Aug;10(8):1131–8

Heteroplasmic substitutions in the mitochondrial DNA control region in mother and child samples. Hühne J, et al. **Int J Legal Med** 1999;112(1):27–30

Increased utilization of the VH6 gene family in patients with autoimmune idiopathic thrombocytopenic purpura. van Dijk–Härd I, et al. **J Autoimmun** 1999 Feb;12(1):57–63

Analysis of T cell receptor Vbeta gene usage during the course of disease in patients with chronic hepatitis B. Dou HY, et al. **J Biomed Sci** 1998 Nov–Dec;5(6):428–34

High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen. Sánchez L, et al. **J Biotechnol** 1999 Jun 11;72(1–2):13–20

Mainly unmutated V(H) genes rearranged in B cells forming germinal centers in a cutaneous pleomorphic T-cell lymphoma. Golembowski S, et al. **J Cutan Pathol** 1999 Jan;26(1):6–12

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. Klein U, et al. **J Exp Med** 1998 Nov 2;188(9):1679–89

The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus [see comments] Matsuda F, et al. **J Exp Med** 1998 Dec 7; 188(11):2151–62. Comment in: J Exp Med 1998 Dec 7;188(11):1973–5.

Forensic evidence based on mtDNA from dog and wolf hairs. Savolainen P, et al. **J Forensic Sci** 1999 Jan;44(1):77–81

Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire. Farner NL, et al. **J Immunol** 1999 Feb 15;162(4):2137–45

Multiple sites of V lambda diversification in cattle. Lucier MR, et al. **J Immunol** 1998 Nov 15;161(10):5438–44

Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. Messmer BT, et al. **J Immunol** 1999 Feb 15; 162(4):2184–92

Decreased frequency of rearrangement due to the synergistic effect of nucleotide changes in the heptamer and nonamer of the recombination signal sequence of the V kappa gene A2b, which is associated with increased susceptibility of Navajos to Haemophilus influenzae type b disease. Nadel B, et al. **J Immunol** 1998 Dec 1;161(11):6068–73

Hypermutation in Ig V genes from mice deficient in the MLH1 mismatch repair protein. Phung QH, et al. **J Immunol** 1999 Mar 15;162(6):3121–4

Biased VH gene usage in early lineage human B cells: evidence for preferential Ig gene rearrangement in the absence of selection. Rao SP, et al. **J Immunol** 1999 Sep 1;163(5):2732–40

Gene conversion and hypermutation during diversification of VH sequences in developing splenic germinal centers of immunized rabbits. Schiaffella E, et al. **J Immunol** 1999 Apr 1;162(7):3984–95

Analyses of single B cells by polymerase chain reaction reveal rearranged VH with germline sequences in spleens of immunized adult rabbits: implications for B cell repertoire maintenance and renewal. Sehgal D, et al. **J Immunol** 1998 Nov 15;161(10):5347–56

Predicting regional mutability in antibody V genes based solely on di- and trinucleotide sequence composition. Shapiro GS, et al. **J Immunol** 1999 Jul 1;163(1):259–68

IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. Shiokawa S, et al. **J Immunol** 1999 May 15;162(10):6060–70

The dual phases of the response to neonatal exposure to a VH family-restricted staphylococcal B cell superantigen. Silverman GJ, et al. **J Immunol** 1998 Nov 15; 161(10):5720–32

Characteristics of sequences around individual nucleotide substitutions in IgVH genes suggest different GC and AT mutators. Spencer J, et al. **J Immunol** 1999 Jun 1; 162(11):6596–601

Antibody repertoire development in fetal and neonatal piglets. I. Four VH genes account for 80 percent of VH usage during 84 days of fetal life. Sun J, et al. **J Immunol** 1998 Nov 1;161(9):5070–8

B lymphocyte selection and age-related changes in VH gene usage in mutant Alicia rabbits. Zhu X, et al. **J Immunol** 1999 Sep 15;163(6):3313–20

In situ hybridization analysis of immunoglobulin heavy chain variable gene expression with family specific oligonucleotide probes. Rundle CH, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):31–52

Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies. Lamminmäki U, et al. **J Mol Biol** 1999 Aug 20; 291(3):589–602

Intrabody construction and expression. II. A synthetic catalytic Fv fragment. Ohage EC, et al. **J Mol Biol** 1999 Sep 3;291(5):1129–34

An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. Reiter Y, et al. **J Mol Biol** 1999 Jul 16;290(3):685–98

Enhanced evolvability in immunoglobulin V genes under somatic hypermutation. Cowell LG, et al. **J Mol Evol** 1999 Jul;49(1):23–6

Somatic hypermutation and B-cell malignancies. Spencer JO, et al. **J Pathol** 1999 Jan;187(2):158–63 (54 ref.)

Retrovirus targeting by tropism restriction to melanoma cells. Martin F, et al. **J Virol** 1999 Aug;73(8):6923–9

Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma. Nakamura N, et al. **Lab Invest** 1999 Aug;79(8):925–33

Primary diffuse large B cell lymphoma of the stomach: analysis of somatic mutations in the rearranged immunoglobulin heavy chain variable genes indicates antigen selection. Driessen A, et al. **Leukemia** 1999 Jul; 13(7):1085–92

Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Fais F, et al. **Leukemia** 1999 Jul;13(7):1093–9

Immunoglobulin light chain variable region genes in multiple myeloma [letter; comment] Kosmas C, et al. **Leukemia** 1999 May;13(5):827–30. Comment on: Leukemia 1998 Apr;12(4):601–9.

Sequencing of antibodies. Jarrin A, et al. **Methods Mol Biol** 1999;96:21–8 (5 ref.)

Intermolecular V(D)J recombination is prohibited specifically at the joining step. Han JO, et al. **Mol Cell** 1999 Mar;3(3):331–8

Evidence that immunoglobulin VH–DJ recombination does not require germ line transcription of the recombining variable gene segment. Angelin–Duclos C, et al. **Mol Cell Biol** 1998 Nov;18(11):6253–64

Analysis of mice with single and multiple copies of transgenes reveals a novel arrangement for the lambda5–VpreB1 locus control region. Sabbattini P, et al. **Mol Cell Biol** 1999 Jan; 19(1):671–9

The RAG-HMG1 complex enforces the 12/23 rule of V(D)J recombination specifically at the double-hairpin formation step. West RB, et al. **Mol Cell Biol** 1998 Nov; 18(11):6408–15

Motif-specific probes identify individual genes and detect somatic mutations. Glas AM, et al. **Mol Immunol** 1999 Jun; 36(9):599–610

Frequent N addition and clonal relatedness among immunoglobulin lambda light chains expressed in rheumatoid arthritis synovia and PBL, and the influence of V lambda gene segment utilization on CDR3 length. Bridges SL Jr. **Mol Med** 1998 Aug;4(8):525–53

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma [see comments] Bräuninger A, et al. **N Engl J Med** 1999 Apr 22;340(16):1239–47. Comment in: N Engl J Med 1999 Apr 22;340(16):1280–2.

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity [see comments] Biragyn A, et al. **Nat Biotechnol** 1999 Mar; 17(3):253–8. Comment in: Nat Biotechnol 1999 Mar;17(3):226–7.

Improving antibody affinity by mimicking somatic hypermutation in vitro. Chowdhury PS, et al. **Nat Biotechnol** 1999 Jun;17(6):568–72

The role of components of recombination signal sequences in immunoglobulin gene segment usage: a V81x model. Larijani M, et al. **Nucleic Acids Res** 1999 Jun 1; 27(11):2304–9

Conserved T cell receptor complementarity-determining region 3 of ocular T cells in mice with experimental autoimmune uveoretinitis. Uehara R, et al. **Ophthalmic Res** 1999;31(4):249–55

Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral B cell neoplasms and B cell chronic lymphocytic leukemia in the japanese population. Nakamura N, et al. **Pathol Int** 1999 Jul; 49(7):595–600

Analysis of variable (diversity) joining recombination in DNAdependent protein kinase (DNA–PK)-deficient mice reveals DNA–PK-independent pathways for both signal and coding joint formation. Bogue MA, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15559–64

Formation of coding joints in V(D)J recombination-inducible severe combined immune deficient pre-B cell lines. Chang Y, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):191–6

Defect in IgV gene somatic hypermutation in common variable immuno-deficiency syndrome. Levy Y, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13135–40

Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Mao S, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6953–8

Novel mechanisms control the folding and assembly of lambda5/14.1 and VpreB to produce an intact surrogate light chain. Minegishi Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3041–6

Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites. Seidl KJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2262–7

Fifty-million-year-old polymorphism at an immunoglobulin variable region gene locus in the rabbit evolutionary lineage. Su C, et al. **Proc Natl Acad Sci U S A** 1999 Aug

17;96(17):9710-5
Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs. Smallshaw JE, et al. **Protein Eng** 1999 Jul; 12(7):623-30
pSKAP/S: An expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. Griep RA, et al. **Protein Expr Purif** 1999 Jun;16(1):63-9
Repertoire shift occurs during the memory maintenance phase of the immune responses and is not affinity-driven. Andersson K, et al. **Scand J Immunol** 1999 Jan;49(1):1-6
Oligoclonality of TCRint cells with a low diversity of TCR complementarity-determining region 3 in mice with graft-versus-host disease. Sugahara S, et al. **Scand J Immunol** 1998 Dec;48(6):592-604
T-cell receptor variable gene analysis of renal allograft-infiltrating cells in biopsy specimens using a nonradioisotopic micromethod. Obata F, et al. **Transplantation** 1998 Nov 27;66(10):1389-92
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Reiter Y, et al. **Trends Biotechnol** 1998 Dec;16(12):513-20 (54 ref.)
Comparison of amino acid sequences in hypervariable region-1 of hepatitis C virus clones between human inocula and the infected chimpanzee sera. Sugitani M, et al. **Virus Res** 1998 Aug;56(2):177-82
[Cloning and sequencing of variable region genes of HAb25 McAb against hepatocellular carcinoma] Hu C, et al. **Chung Hua Kan Tsang Ping Tsa Chih** 1999 Jun;7(2):101-3 (Eng. Abstr.) **(Chi)**
[Amplification and sequencing of heavy chain variable region (VH) gene of a human monoclonal antibody (CM-1) with specificity to breast cancer] Chen L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):150-3 (Eng. Abstr.) **(Chi)**
[Dynamics of the diversity of the Asian Mongoloid population mitochondrial gene pool from data on the variability of hypervariable segment I] Derenko MV, et al. **Mol Biol (Mosk)** 1998 Sep-Oct;32(5):782-7 **(Rus)**

IMMUNOLOGY

The T-cell receptor Vbeta repertoire of nickel-specific T cells. Zollner TM, et al. **Arch Dermatol Res** 1998 Jul; 290(7):397-401
T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides [see comments] Moreland LW, et al. **Arthritis Rheum** 1998 Nov;41(11):1919-29. Comment in: Arthritis Rheum 1998 Nov;41(11):1906-10.
SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis [published erratum appears in Biochem Biophys Res Commun 1999 May 27;259(1):230] Sakurai N, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):223-30
Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. van der Linden RH, et al. **Biochim Biophys Acta** 1999 Apr 12; 1431(1):37-46
A monoclonal antibody directed against the non-toxic subunit of a dimeric phospholipase A2 neurotoxin, crotoxin, neutralizes its toxicity. Choumet V, et al. **Biol Chem** 1998 Jul;379(7):899-906
Expression of recombinant Lym-1 single-chain Fv in Escherichia coli. Bin Song K, et al. **Biotechnol Appl Biochem** 1998 Oct;28 (Pt 2):163-7
Regional variation in the lamina propria T cell receptor V beta repertoire in normal human colon. Bennet JD, et al. **Clin Immunol** 1999 Jan;90(1):38-46
Characterization of CD4+ T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Price PW, et al. **Eur J Immunol** 1999 Mar;29(3):1051-6
A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. Mousli M, et al. **FEBS Lett** 1999 Jan 15;442(2-3):183-8
Development of neutralising human recombinant antibodies to pertussis toxin. Williamson P, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):313-9
A human monoclonal antibody encoded by the V4-34 gene segment recognises melanoma-associated ganglioside via CDR3 and FWR1. Thomas MD, et al. **Hum Antibodies** 1999;9(2):95-106
Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies [see comments] Mhashilkar AM, et al. **Hum Gene Ther** 1999 Jun 10; 10(9):1453-67. Comment in: Hum Gene Ther 1999 Jun 10;10(9):1425-7.
Anti-idiotypic monoclonal Ig specific for an anti-laminin Ig heavy chain transgene variable region. Foster MH, et al. **Hybridoma** 1998 Aug;17(4):323-9
'Naïve' and 'memory' CD4+ T-cells and T-cell receptor (TCR) V beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. King DJ, et al. **Immunol Lett** 1999 Mar;66(1-3):199-206
Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition. de Haard H, et al. **Immunotechnology** 1999 Mar;4(3-4):203-15
Functional expression in bacteria and plants of an scFv antibody fragment against tospoviruses. Franconi R, et al. **Immunotechnology** 1999 Mar;4(3-4):189-201
A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library. Hall BL, et al. **Immunotechnology** 1998 Oct;4(2):127-40
An scFv phage clone that binds to human beta2-microglobulin. Jwang B, et al. **Immunotechnology** 1999 Mar;4(3-4):231-6
Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Tan PH, et al. **Immunotechnology** 1998 Oct;4(2):107-14
Immunoglobulin variable regions as idiotype vaccines. Hefty PS, et al. **Infect Dis Clin North Am** 1999 Mar;13(1):27-37, vi (57 ref.)
Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues. Reason DC, et al. **Infect Immun** 1999 Feb;67(2):994-7
The J558 VH CDR3 region contributes little to antibody avidity; however, it is the recognition element for cognate T cell control of the alpha(1-->3) dextran-specific antibody response. Clemens A, et al. **Int Immunol** 1998 Dec;10(12):1931-42
MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW, et al. **Int J Mol Med** 1998 Jan; 1(1):157-62
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. Kaminski MJ, et al. **J Biol Chem** 1999 Feb 26; 274(9):5597-604
A bacterial single-chain Fv antibody fragment that inhibits binding of its parental anti-E-selectin monoclonal antibody to activated human endothelial cells. Casalvilla R, et al. **J Biotechnol** 1999 Jun 11;72(1-2):1-12
Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay. Luo D, et al. **J Biotechnol** 1998 Oct 27; 65(2-3):225-8
A yeast surface display system for the discovery of ligands that trigger cell activation. Cho BK, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):179-88
Open sandwich ELISA with V(H)-/V(L)-alkaline phosphatase fusion proteins. Suzuki C, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):171-84
Coxsackievirus and adenovirus receptor amino-terminal immunoglobulin V-related domain binds adenovirus type 2 and fiber knob from adenovirus type 12. Freimuth P, et al. **J Virol** 1999 Feb;73(2):1392-8
Strain specific recombinant antibodies to potato virus Y potyvirus. Boonham N, et al. **J Virol Methods** 1998 Oct; 74(2):193-9
Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Cochet O, et al. **Mol Immunol** 1998 Dec;35(17):1097-110
Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. McCall AM, et al. **Mol Immunol** 1999 May;36(7):433-45
Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx. Mao S, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6953-8
Antibody affinity maturation using bacterial surface display. Daugherty PS, et al. **Protein Eng** 1998 Sep;11(9):825-32
The role of surface lysines in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. Kobayashi H, et al. **Protein Eng** 1998 Nov;11(11):1089-92
Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Starovasnik MA, et al. **Protein Sci** 1999 Jul;8(7):1423-31
Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3 [published erratum appears in Scand J Immunol 1999 Aug;50(2):232] Hombach A, et al. **Scand J Immunol** 1998 Nov;48(5):497-501
Characterization of the T-cell receptor V-beta repertoire in Kawasaki disease. Mancia L, et al. **Scand J Immunol** 1998 Oct;48(4):443-9
Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Potter KN, et al. **Scand J Immunol** 1999 Jul;50(1):14-20
Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Wen YJ, et al. **Scand J Immunol** 1999 Sep;50(3):296-301
Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. Rahman A, et al. **Semin Arthritis Rheum** 1998 Dec;28(3):141-54 (76 ref.)

ISOLATION & PURIFICATION

Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Wörn A, et al. **Biochemistry** 1999 Jul 6; 38(27):8739-50
The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries. MacKenzie R, et al. **J Immunol Methods** 1998 Nov 1;220(1-2):39-49
Monitoring of scFv selected by phage display using detection of scFv-pIII fusion proteins in a microtiter scale assay. Mersmann M, et al. **J Immunol Methods** 1998 Nov 1; 220(1-2):51-8
Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. Tsumoto K, et al. **J Immunol Methods** 1998 Oct 1; 219(1-2):119-29

METABOLISM

Toward selection of internalizing antibodies from phage libraries. Becerril B, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):386-93
Probing the interaction between a high-affinity single-chain Fv and a pyrimidine (6-4) pyrimidone photodimer by site-directed mutagenesis. Kobayashi H, et al. **Biochemistry** 1999 Jan 12;38(2):532-9
High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Roovers RC, et al. **Br J Cancer** 1998 Dec;78(11):1407-16
IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Olafsen T, et al. **Immunotechnology** 1998 Oct;4(2):141-53
Analysis of kappa light chain contribution to anti-DNA antibody activity of a human VH4-21-encoded monoclonal antibody (NE-1) by antibody-phage display technique. Katsube Y, et al. **Int J Mol Med** 1998 May;1(5):863-8
Increased T-cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: a potential role for microbial superantigens. Hauk PJ, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):37-45
Structural models of antibody variable fragments: a method for investigating binding mechanisms. Petit S, et al. **J Comput Aided Mol Des** 1998 Mar;12(2):147-63
DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain. Chen Y, et al. **J Immunol** 1999 Apr 15;162(8):4663-70
Mapping the major interaction between binding protein and Ig light chains to sites within the variable domain. Davis DP, et al. **J Immunol** 1999 Oct 1;163(7):3842-50
Mu-surrogate light chain physicochemical interactions of the human preB cell receptor: implications for VH repertoire selection and cell signaling at the preB cell stage. Gauthier L, et al. **J Immunol** 1999 Jan 1;162(1):41-50
Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. Patella V, et al. **J Immunol** 1998 Nov 15;161(10):5647-55
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. Reinhold U, et al. **J Invest Dermatol** 1999 May;112(5):744-50
Intrabody construction and expression. I. The critical role of VL domain stability. Ohage E, et al. **J Mol Biol** 1999 Sep 3;291(5):1119-28
Replacements in the exposed loop of the T15 antibody VH CDR2 affect carrier recognition of PC-containing pathogens. Brown M, et al. **Mol Immunol** 1999 Feb; 36(3):205-11
Serum starvation induced secondary V lambda J lambda rearrangement in a human plasma B cell line. Haruta H, et al. **Mol Immunol** 1999 Feb;36(3):177-85
Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. Potter KN, et al. **Mol Immunol** 1998 Dec; 35(18):1179-87
Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs. Smallshaw JE, et al. **Protein Eng** 1999 Jul; 12(7):623-30
Pharmacokinetics and biodistribution of genetically-engineered antibodies. Colcher D, et al. **Q J Nucl Med** 1998 Dec;42(4):225-41 (164 ref.)

PHARMACOLOGY

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Kuan CT, et al. **Clin Cancer Res** 1999 Jun;5(6):1539-49
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Barth S, et al. **Int J Mol Med** 1998 Jan;1(1):249-56
Inhibition of cytoplasmic antigen, glucose- 6-phosphate dehydrogenase, by VH-CH1, an intracellular Fd fragment antibody derived from a semisynthetic Fd fragment phage display library. Mulligan-Kehoe MJ, et al. **J Mol Biol** 1999 May 28;289(1):41-55

PHYSIOLOGY

Downregulation of the expression of the main immunoglobulin V(H) family in HIV-infected patients: modulation by triple combination therapy [letter] David D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;

15(3):315–6
Functional knock-out of c-myb by an intracellular anti-c-Myb single-chain antibody. Kasono K, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):124–30
Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. de Inés C, et al. **J Immunol** 1999 Oct 1;163(7):3948–56

THERAPEUTIC USE

Extending genetic vaccines with chemokines [news; comment] Kipps T, et al. **Nat Biotechnol** 1999 Mar; 17(3):226–7. Comment on: Nat Biotechnol 1999 Mar;17(3):253–8.

IMMUNOGLOBULINS

see related

PARAPROTEINEMIAS

Managing the shortage of intravenous immune globulin [news] Decker EL, et al. **Am J Health Syst Pharm** 1998 Oct 15;55(20):2090, 2093
Reusability of avidin-biotinylated immunoglobulin Y columns in immunoaffinity chromatography. Kim HO, et al. **Anal Biochem** 1999 Mar 15;268(2):383–97
Iris crystals in Fuchs' heterochromic iridocyclitis. Zamir E, et al. **Arch Ophthalmol** 1998 Oct;116(10):1394
Hepatitis B maternal screening, infant vaccination, and infant prophylaxis practices in North Carolina. Pierce RL, et al. **Arch Pediatr Adolesc Med** 1999 Jun;153(6):619–23
Hepatitis G virus in intramuscular and intravenous immunoglobulin products manufactured in Europe [letter] Cristiano K, et al. **Transfusion** 1999 Apr;39(4):428
[Dynamics of immunoglobulin production in non infected children born from HIV-1 infected mothers: effect of zidovudine] Resino S, et al. **Med Clin (Barc)** 1999 May 1;112(15):568–71 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. Negishi H, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):466–9
Intravenous immunoglobulin in the treatment of refractory adult Still's disease [letter] Mahmud T, et al. **J Rheumatol** 1999 Sep;26(9):2067–8
Case 21-1998: rabies [letter; comment] Wilde H. **N Engl J Med** 1999 Jan 7;340(1):64–5; discussion 65. Comment on: N Engl J Med 1998 Jul 9;339(2):105–12.
Postinfectious pandysautonomia with complete recovery after intravenous immunoglobulin therapy. Venkataraman S, et al. **Neurology** 1998 Dec;51(6):1764–5
Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics)] Canfield SD, et al. **Pediatr Ann** 1999 Aug;28(8):507–14
Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Sarker SA, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1149–54
Successful postexposure rabies prophylaxis after erroneous starting treatment. Haviv J, et al. **Prev Med** 1999 Jul; 29(1):28–31
A study of human rabies immune globulin manufactured by the Thai Red Cross. Chantanakajornfung A, et al. **Vaccine** 1999 Feb 26;17(7–8):979–81
Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Walter EB, et al. **Vaccine** 1999 Mar 17;17(11–12):1468–73
[Recommended vaccines and immunoglobulins for immunocompromised patients] Bricks LF. **Rev Saude Publica** 1998 Jun;32(3):281–94 (75 ref.) (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

Adverse effects of intravenous immunoglobulin therapy. Nydegger UE, et al. **Drug Saf** 1999 Sep;21(3):171–85 (74 ref.)
Immunoglobulin transmits hepatitis C. True or false? [letter; comment] Piazza M. **Hepatology** 1999 Jan;29(1):299–300. Comment on: Hepatology 1997 Sep;26(3):521–6.
Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. Barrett S, et al. **J Hepatol** 1999 Jun;30(6):979–83
[Marked thrombocytopenia after high-dose intravenous gamma globulin in a pregnant woman with idiopathic thrombocytopenic purpura] Shimano S, et al. **Rinsho Ketsueki** 1999 Apr;40(4):318–23 (Eng. Abstr.) **(Jpn)**

ANALYSIS

Human serum albumin and immunoglobulin on Dracunculus medinensis. Bloch P, et al. **Acta Trop** 1999 Jul 30; 73(2):135–41
Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Smith JD, et al. **Ann Clin Lab Sci** 1998 Sep–Oct;28(5):280–2
Procedures for the evaluation of monoclonal immunoglobulins. Keren DF. **Arch Pathol Lab Med** 1999 Feb;123(2):126–32 (18 ref.)
Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Emad A, et al. **Chest** 1999 May;115(5):1346–51
Mucosal immunity in extrinsic allergic alveolitis: salivary immunoglobulins and antibody against inhaled avian antigens among pigeon breeders. McSharry C, et al. **Clin Exp Allergy** 1999 Jul;29(7):957–64
Immunoglobulin levels and autoantibody titers in women with hyperprolactinaemia [letter] Alves J, et al. **Clin Exp Rheumatol** 1998 Jul–Aug;16(4):515–6
A novel member of the Ig superfamily, RPE7, expressed on the retinal pigment epithelial cell and Müller cell of the bovine retina. Yoshimoto M, et al. **Exp Eye Res** 1998 Sep; 67(3):331–40
Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid. Bastian A, et al. **Gene Ther** 1999 Apr;6(4):637–42
Angiomatosis of skin with local intravascular immunoglobulin deposits, associated with monoclonal gammopathy. A potential cutaneous marker for B-chronic lymphocytic leukemia. A report of unusual case with immunohistochemical and immunofluorescence correlation and review of the literature. Salama SS, et al. **J Cutan Pathol** 1999 Apr;26(4):206–12 (32 ref.)
Immunoglobulin- and complement-coated bacteria in pus from peritonsillar abscesses. Lilja M, et al. **J Laryngol Otol** 1998 Jul;112(7):634–8
The assembly of immunoglobulin-like modules in titin: implications for muscle elasticity. Improta S, et al. **J Mol Biol** 1998 Dec 4;284(3):761–77
Selective augmentation of antibodies in various mucosal regions, after intranasal immunization with diphtheria in mice. Gizurarson S, et al. **J Pharm Sci** 1998 Nov; 87(11):1267–9
Effects of ageing and oestrogen on the localization of immunoglobulin-containing cells in the chicken ovary. Barua A, et al. **J Reprod Fertil** 1998 Sep;114(1):11–6
Immunohistochemical localization of antigen presenting cells in liver from patients with primary biliary cirrhosis; highly restricted distribution of CD83-positive activated dendritic cells. Tanimoto K, et al. **Pathol Res Pract** 1999; 195(3):157–62
The effect of nonspecific immunostimulation of pregnant mares with 1,3/1,6 glucan and levamisole on the immunoglobulins levels in colostrum, selected indices of nonspecific cellular and humoral immunity in foals in neonatal and postnatal period. Krakowski L, et al. **Vet Immunol Immunopathol** 1999 Mar 29;68(1):1–11
Elevation of immunoglobulin deposition in the synovial membrane of dogs with cranial cruciate ligament rupture. Lawrence D, et al. **Vet Immunol Immunopathol** 1998 Sep 16;65(1):89–96
[Multiple sclerosis and oligoclonal bands in tears (letter)] Forzy G, et al. **Ann Biol Clin (Paris)** 1999 Mar–Apr; 57(2):240 **(Fre)**
[Recurrent aphthous stomatitis: which role for viruses, food, and dental materials?] Galliani EA, et al. **Ann Ital Med Int** 1998 Jul–Sep;13(3):152–6 (Eng. Abstr.) **(Ita)**
[Status of local immunity in populations of regions with microbiological and chemical enterprises] Litovskaia AV, et al. **Gig Sanit** 1998 Sep–Oct;(5):52–4 **(Rus)**
[Laboratory diagnosis of immunological disorders in rheumatoid arthritis] Potemkina EE, et al. **Klin Lab Diagn** 1999 Mar;(3):10–2 **(Rus)**
[The immunoglobulin content in the saliva of children living under different radioecological conditions] Mel'nichenko EM, et al. **Stomatologiia (Mosk)** 1999;78(2):12–4 (Eng. Abstr.) **(Rus)**
[Monoclonal component in visceral leishmaniasis: a rare association that can lead to misdiagnosis] García Menéndez L, et al. **Rev Clin Esp** 1998 Aug;198(8):517–20 (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Expression, crystallization and preliminary X-ray analysis of the two amino-terminal Ig domains of the neural cell adhesion molecule (NCAM). Kasper C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Sep;55 (Pt 9):1598–600
Effect of dietary antioxidants on serum lipid contents and immunoglobulin productivity of lymphocytes in Sprague-Dawley rats. Kaku S, et al. **Biosci Biotechnol Biochem** 1999 Mar;63(3):575–6
In vitro reconstitution of human B-cell ontogeny: from CD34(+) multipotent progenitors to Ig-secreting cells. Fluckiger AC, et al. **Blood** 1998 Dec 15;92(12):4509–20
Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Goodrich ME, et al. **Cytokine** 1998 Dec;10(12):948–55
In vitro immunoglobulin response of fetal B-cells is influenced by perinatal infections and antibiotic treatment: a study in preterm infants [see comments] Cukrowska B, et al. **Eur J Pediatr** 1999 Jun;158(6):463–8. Comment in: Eur J Pediatr 1999 Jun;158(6):444–5.
Improved fusion partners transfected with DNA fragment encoding IL-11 on generation of human B lymphocyte hybridomas. Zhu Y, et al. **Hum Antibodies** 1999;9(1):1–7
Effects of type I/type II interferons and transforming growth factor-beta on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression. Estes DM, et al. **Immunology** 1998 Dec;95(4):604–11
Ganglioside GT1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Kanda N, et al. **Immunology** 1999 Apr;96(4):628–33
The effects of nonsteroidal anti-inflammatory drugs on immune functions of human peripheral blood mononuclear cells. Tanaka K, et al. **Immunopharmacology** 1998 Nov; 40(3):209–17
HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Mallet V, et al. **Int Immunol** 1999 Jun;11(6):889–98
Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen or Peyer's patches in mice. Yoshikawa M, et al. **Int J Immunopharmacol** 1998 Jan–Mar;20(1–3):29–38
Ganglioside GQ1b enhances Ig production by human PBMCs. Kanda N, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):813–20
Identification of a phosphopeptide in bovine alpha s1-casein digest as a factor influencing proliferation and immunoglobulin production in lymphocyte cultures. Hata I, et al. **J Dairy Res** 1998 Nov;65(4):569–78
Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. Lai YH, et al. **J Immunol** 1999 Jan 1;162(1):78–87
Humoral response suppression observed with CD23 transgenics. Payet ME, et al. **J Immunol** 1999 Jul 1; 163(1):217–23
IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. Wernersson S, et al. **J Immunol** 1999 Jul 15;163(2):618–22
Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation. Connor EM, et al. **J Leukoc Biol** 1999 Mar;65(3):349–55
Transforming growth factor-beta impairs postburn immunoglobulin production by limiting B-cell proliferation, but not cellular synthesis. Nishimura T, et al. **J Trauma** 1999 May;46(5):881–5
Construction and purification of adhesion molecule immunoglobulin chimeric proteins. Moll T, et al. **Methods Mol Biol** 1999;96:77–84 (10 ref.)
CD40L activation of dendritic cells down-regulates DORA, a novel member of the immunoglobulin superfamily. Bates EE, et al. **Mol Immunol** 1998 Jun;35(9):513–24
MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Sellebjerg F, et al. **Mult Scler** 1998 Jun;4(3):127–31
[The proliferative response and immunoglobulin production in peripheral blood lymphocytes stimulated with Japanese cedar pollen antigens] Hayashi T, et al. **Arerugi** 1999 Apr; 48(4):414–24 (Eng. Abstr.) **(Jpn)**
[Immunoglobulin production by human peripheral B cells against Staphylococcus aureus] Miyashita T, et al. **Kansenshogaku Zasshi** 1998 Dec;72(12):1269–74 (Eng. Abstr.) **(Jpn)**
[Intrathecal humoral immune response in pediatric patients with meningoencephalitis due to Coxsackie B5] Dorta-Contreras AJ, et al. **Rev Neurol** 1999 Apr 16–30; 28(8):739–41 (Eng. Abstr.) **(Spa)**

BLOOD

Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase. Martínez-Brú C, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):601–8
Chlamydia pneumoniae and possible relationship to asthma. Serum immunoglobulins and histamine release in patients and controls. Larsen FO, et al. **APMIS** 1998 Oct; 106(10):928–34
Influence of dietary nucleotides on plasma immunoglobulin levels and lymphocyte subsets of preterm infants. Navarro J, et al. **Biofactors** 1999;10(1):67–76
Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Dahl IM, et al. **Blood** 1999 Jun 15;93(12):4144–8
Production of serum immunoglobulins and T cell antigen binding molecules specific for cow's milk antigens in adults intolerant to cow's milk. Little CH, et al. **Clin Immunol Immunopathol** 1998 Nov;89(2):160–70
Exercise-associated hypogammaglobulinemia. Fricker PA, et al. **Clin J Sport Med** 1999 Jan;9(1):46–8
Cerebrospinal fluid filtration and immunoglobulins in multifocal motor neuropathy. Finsterer J, et al. **Clin Neuropathol** 1999 Jan–Feb;18(1):31–6
Serum immunoglobulin and soluble IL-2 receptor levels in small intestinal overgrowth with indigenous gut flora. Riordan SM, et al. **Dig Dis Sci** 1999 May;44(5):939–44
The influence of antibody and complement removal with a Ig-Therasorb column in a xenogeneic working heart model. Brenner P, et al. **Eur J Cardiothorac Surg** 1999 May; 15(5):672–9
Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndrome. Abramov Y, et al. **Fertil Steril** 1999 Jan;71(1):102–5
Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease. Gouni-Berthold I, et al. **Hepatogastroenterology** 1999 May–Jun;46(27):1720–3
Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active

antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Daniel V, et al. **Immunol Lett** 1999 Aug 3;69(2):283-9

A sequential study of circulating immune complexes, complement and immunoglobulins in borderline tuberculoid leprosy patients with and without reactions. Ramanathan VD, et al. **Indian J Lepr** 1998 Apr-Jun; 70(2):153-60

Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Schwerer B, et al. **Infect Immun** 1999 May;67(5):2414-20

Immune response and airway reactivity in wild and IL-4 knockout mice exposed to latex allergens. Xia JQ, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):23-9

Correlation of applied kinesiology muscle testing findings with serum immunoglobulin levels for food allergies. Schmitt WH Jr, et al. **Int J Neurosci** 1998 Dec; 96(3-4):237-44

Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. Bakri Hassan A, et al. **J Autoimmun** 1998 Oct;11(5):503-8

Serum levels of immunoglobulins in children with recurrent otitis media. Hirata CH, et al. **J Investig Allergol Clin Immunol** 1999 Mar-Apr;9(2):106-9

Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Aittoniemi J, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):381-5

Age-related loss of immunoregulatory function in peripheral blood CD8 T cells. Crisi GM, et al. **Mech Ageing Dev** 1998 Jul 15;103(3):235-54

The concentration of immunoglobulins A, G, and M in serum of patients with periodontal disease. Bokor-Bratić M. **Med Pregl** 1998 Jul-Aug;51(7-8):310-4 **(Eng, Scr)**

Simultaneous elevation of serum amylase and lipase levels due to multiclass immunoglobulin-bound enzymes in a patient with alcoholic liver cirrhosis. Yuki T, et al. **Pancreas** 1999 May;18(4):418-9

Serum beta2-microglobulin and immunoglobulin levels in young hemodialysis patients. Dixit MP, et al. **Pediatr Nephrol** 1999 Feb;13(2):139-42

Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Fruman DA, et al. **Science** 1999 Jan 15;283(5400):393-7

Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Koll RA. **Ther Apher** 1998 May;2(2):147-52

[Analytic evaluation of Immage for ten proteins] Giraudeaux V, et al. **Ann Biol Clin (Paris)** 1998 Sep-Oct;56(5):593-8 **(Fre)**

[Serum immunoglobulin concentrations and autoantibodies in patients with Yusho] Tsuji H, et al. **Fukuoka Igaku Zasshi** 1999 May;90(5):147-9 (Eng. Abstr.) **(Jpn)**

[The effects of occupational exposure to nitrogen dioxide (NO2) on the immunological parameters in workers] Rutowski J, et al. **Med Pr** 1998;49(4):341-51 (Eng. Abstr.) **(Pol)**

[Gastrointestinal cancer antigen and immunoglobulins G, A, M in patients with head cancer] Adamiak G, et al. **Otolaryngol Pol** 1998;52(6):655-60 (Eng. Abstr.) **(Pol)**

[Changes of selected immunological parameters after cardiopulmonary bypass in postop period] Bystryk L, et al. **Pol Merkuriusz Lek** 1999 Jun;6(36):313-6 (Eng. Abstr.) **(Pol)**

[The effect of various occupational exposures to microwave radiation on the concentrations of immunoglobulins and T lymphocyte subsets] Moszczyński P, et al. **Wiad Lek** 1999;52(1-2):30-4 (Eng. Abstr.) **(Pol)**

[Fetal plasma contains blood coagulation factor XIIIa inhibitor which is not found in normal human plasma] Mit'kevich OV, et al. **Biull Eksp Biol Med** 1999 Feb; 127(2):189-93 **(Rus)**

[The determination of immunoglobulins on the erythrocyte surface by using a gel test] Levina AA, et al. **Klin Lab Diagn** 1999 Jul;(7):24, 33-4 **(Rus)**

[The role of the lungs in regulating the generation of active forms of oxygen by the phagocytes, the concentration of immunoglobulins and the complement activity] Kogan AKh, et al. **Patol Fiziol Eksp Ter** 1999 Jul-Sep;(3):9-14 (Eng. Abstr.) **(Rus)**

[Immunoglobulins of cows of different ages and of their calves] Kravtsiv IuR. **Ukr Biokhim Zh** 1998 Jan-Feb; 70(1):94-8 (Eng. Abstr.) **(Ukr)**

CEREBROSPINAL FLUID

CNS tumours: oligoclonal immunoglobulin D in cerebrospinal fluid and serum. Mavra M, et al. **Acta Neurol Scand** 1999 Aug;100(2):117-8

The significance of oligoclonal bands in multiple sclerosis in Japan: relevance of immunogenetic backgrounds. Fukazawa T, et al. **J Neurol Sci** 1998 Jun 30;158(2):209-14

[Intrathecal humoral immune response in pediatric patients with meningoencephalitis due to Coxsackie B5] Dorta-Contreras AJ, et al. **Rev Neurol** 1999 Apr 16-30; 28(8):739-41 (Eng. Abstr.) **(Spa)**

CHEMISTRY

Expression, crystallization and preliminary X-ray analysis of the two amino-terminal Ig domains of the neural cell adhesion molecule (NCAM). Kasper C, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Sep;55 (Pt 9):1598-600

A convenient microscale colorimetric method for terminal galactose on immunoglobulins. Raju TS, et al. **Biochem Biophys Res Commun** 1999 Jul 22;261(1):196-201

Purification of Ig-fusion proteins from medium containing Ig. Sakurai T, et al. **Biotechniques** 1998 Sep;25(3):382-5

The N-terminal region of tapasin is required to stabilize the MHC class I loading complex. Bangia N, et al. **Eur J Immunol** 1999 Jun;29(6):1858-70

MuSC, a novel member of the immunoglobulin superfamily, is expressed in neurons of a subset of cranial sensory ganglia in the mouse embryo. Sekine-Aizawa Y, et al. **Eur J Neurosci** 1998 Sep;10(9):2810-24

Association between the first two immunoglobulin-like domains of the neural cell adhesion molecule N-CAM. Atkins AR, et al. **FEBS Lett** 1999 May 21;451(2):162-8

Molecular cloning of a human cDNA IGSF3 encoding an immunoglobulin-like membrane protein: expression and mapping to chromosome band 1p13. Saupe S, et al. **Genomics** 1998 Sep 15;52(3):305-11

Analogy and solution scattering modelling: new structural strategies for the multidomain proteins of complement, cartilage and the immunoglobulin superfamily. Perkins SJ, et al. **Immunol Rev** 1998 Jun;163:237-50 (50 ref.)

Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Wang J, et al. **Immunol Rev** 1998 Jun;163:197-215 (104 ref.)

Ig-hepta, a novel member of the G protein-coupled hepta-helical receptor (GPCR) family that has immunoglobulin-like repeats in a long N-terminal extracellular domain and defines a new subfamily of GPCRs. Abe J, et al. **J Biol Chem** 1999 Jul 9; 274(28):19957-64

Engineered assembly of intertwined oligomers of an immunoglobulin chain. Hayes MV, et al. **J Mol Biol** 1999 Jan 29;285(4):1857-67

Universally conserved positions in protein folds: reading evolutionary signals about stability, folding kinetics and function. Mirny LA, et al. **J Mol Biol** 1999 Aug 6; 291(1):177-96

Development of reversed passive latex agglutination for detection of Thai cobra (Naja kaouthia) venom. Khow O, et al. **J Nat Toxins** 1999 Jun;8(2):213-20

Conservation of cys-cys trp structural triads and their geometry in the protein domains of immunoglobulin superfamily members. Ioerger TR, et al. **Mol Immunol** 1999 Apr;36(6):373-86

Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nagata T, et al. **Nat Struct Biol** 1999 Jul;6(7):615-9

Wrapper, a novel member of the Ig superfamily, is expressed by midline glia and is required for them to ensheath commissural axons in Drosophila. Noordermeer JN, et al. **Neuron** 1998 Nov;21(5):991-1001

The immunoglobulin fold family: sequence analysis and 3D structure comparisons. Halaby DM, et al. **Protein Eng** 1999 Jul;12(7):563-71

Polyethylene glycol-induced immunoglobulin precipitation may cause invalidation of antiglobulin tests [letter] Polski JM, et al. **Transfusion** 1999 May;39(5):537-9

CLASSIFICATION

Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Schwerer B, et al. **Infect Immun** 1999 May;67(5):2414-20

DEFICIENCY

Lack of systemic anaphylaxis and aeroallergen-induced airway plasma extravasation in allergic immunoglobulin-deficient mice. Korsgren M, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):67-73

Inhibition of acute cardiac allograft rejection in immunoglobulin-deficient mice. Wasowska BA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):136

DIAGNOSTIC USE

Scintigraphic assessment of disease activity in psoriatic arthritis with 99m-Tc-labelled non-specific polyclonal human immunoglobulin G. Liberatore M, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:118

Tc-99m dextran and Tc-99m HIG findings in patients with ulcerative colitis. Sarikaya I, et al. **Clin Nucl Med** 1999 Apr;24(4):243-7

Technetium-99m human immunoglobulin imaging in patients with subacromial impingement or adhesive capsulitis. Clunie GP, et al. **Clin Rheumatol** 1998;17(5):419-21

Measurement of lymphatic function with technetium-99m-labelled polyclonal immunoglobulin. Svensson W, et al. **Eur J Nucl Med** 1999 May;26(5):504-10

Evaluation of 99Tcm-HIG as a lymphoscintigraphic agent in rabbits. Ergün EL, et al. **Nucl Med Commun** 1998 Jul; 19(7):665-70

DRUG EFFECTS

The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Rinkardt NE, et al. **Can J Vet Res** 1999 Jan; 63(1):18-24

ECONOMICS

Companies cooperate in emergency supply program for IGIV [news] Landis NT. **Am J Health Syst Pharm** 1999 Apr 1;56(7):599

HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Golling M, et al. **Transplant Proc** 1998 Nov;30(7):3316-7

GENETICS

Phylogenetic emergence and molecular evolution of the immunoglobulin family. Marchalonis JJ, et al. **Adv Immunol** 1998;70:417-506 (378 ref.)

Evolution of immunoglobulin and T-cell receptor gene assembly. Lewis SM. **Ann N Y Acad Sci** 1999 May 18; 870:58-67 (35 ref.)

Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering. Meroni L, et al. **Clin Immunol** 1999 Sep;92(3):276-84

Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Thomassen E, et al. **Cytokine** 1999 Jun;11(6):389-99

The murine Cd48 gene: allelic polymorphism in the IgV-like region. Cabrero JG, et al. **Eur J Immunogenet** 1998 Dec; 25(6):421-3

NILR-1, a novel immunoglobulin-like receptor expressed by neutrophilic granulocytes, is encoded by a leukocyte receptor gene complex on rat chromosome 1. Berg SF, et al. **Eur J Immunol** 1999 Jun;29(6):2000-6

Elucidation of the genetic basis of the antigen presentation defects in the mutant cell line .220 reveals polymorphism and alternative splicing of the tapasin gene. Copeman J, et al. **Eur J Immunol** 1998 Nov;28(11):3783-91

Molecular evolution of immunoglobulin and fibronectin domains in titin and related muscle proteins. Kenny PA, et al. **Gene** 1999 May 17;232(1):11-23

Deregulation of BCL6 in non-Hodgkin lymphoma by insertion of IGH sequences in complex translocations involving band 3q27. Chaganti SR, et al. **Genes Chromosomes Cancer** 1998 Dec;23(4):328-36

Molecular cloning of a human cDNA IGSF3 encoding an immunoglobulin-like membrane protein: expression and mapping to chromosome band 1p13. Saupe S, et al. **Genomics** 1998 Sep 15;52(3):305-11

Identification of the Tapasin gene in the chicken major histocompatibility complex. Frangoulis B, et al. **Immunogenetics** 1999 Apr;49(4):328-37

The mouse Cd83 gene: structure, domain organization, and chromosome localization. Twist CJ, et al. **Immunogenetics** 1998 Nov-Dec;48(6):383-93

Mutational pattern of the nurse shark antigen receptor gene (NAR) is similar to that of mammalian Ig genes and to spontaneous mutations in evolution: the translesion synthesis model of somatic hypermutation. Diaz M, et al. **Int Immunol** 1999 May;11(5):825-33

Expression of soluble human signaling lymphocytic activation molecule in vivo. Isomäki P, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):114-8

Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing. Li S, et al. **J Biol Chem** 1999 Mar 26;274(13):8649-54

OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin superfamily. Patel N, et al. **J Biol Chem** 1999 Aug 6;274(32):22729-38

NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. Cantoni C, et al. **J Exp Med** 1999 Mar 1;189(5):787-96

The site of a missense mutation in the extracellular Ig or FN domains of L1CAM influences infant mortality and the severity of X linked hydrocephalus. Michaelis RC, et al. **J Med Genet** 1998 Nov;35(11):901-4

Structural analysis of the sixth immunoglobulin-like domain of mouse neural cell adhesion molecule L1 and its interactions with alpha(v)beta3, alpha(IIb)beta3, and alpha5beta1 integrins. Blaess S, et al. **J Neurochem** 1998 Dec;71(6):2615-25

Gene mutation responsible for fatal EBV complication discovered [news] McCarthy M. **Lancet** 1998 Oct 3; 352(9134):1125

Genomic structure and chromosomal localization of the mouse gene Punc. Salbaum JM. **Mamm Genome** 1999 Feb; 10(2):107-11

cDNA cloning of the CEPUS, a secreted type of neural glycoprotein belonging to the immunoglobulin-like opioid binding cell adhesion molecule (OBCAM) subfamily. Kim DS, et al. **Mol Cells** 1999 Jun 30;9(3):270-6

Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen-driven reactions in the absence of germinal centers. Diaz M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14343-8

Polymorphism of TAPASIN and its linkage disequilibria with HLA class II genes in the Japanese population.

Furukawa H, et al. **Tissue Antigens** 1998 Sep;52(3):279–81

IMMUNOLOGY

Immobilized chicken antibodies improve the detection of serum antigens with surface plasmon resonance (SPR). Vikinge TP, et al. **Biosens Bioelectron** 1998 Dec 1; 13(12):1257–62

Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post–exposure rabies vaccination under the 2–1–1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Lang J, et al. **Bull World Health Organ** 1998;76(5):491–5

Mechanisms of resistance against B–cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T–cell immunity. Sternas LA, et al. **Cancer Treat Res** 1999;99:267–73 (25 ref.)

MAdCAM–1 dependent colonization of developing lymph nodes involves a unique subset of CD4+CD3– hematolymphoid cells. Mebius RE, et al. **Cell Adhes Commun** 1998;6(2–3):97–103 (50 ref.)

Qualitative immunoglobulin abnormalities in HIV–positive patients: long–term follow–up. Pontet F, et al. **Clin Chem Lab Med** 1998 Jun;36(7):493–6

Enhancement of lectin pathway haemolysis by immunoglobulins. Suankratay C, et al. **Clin Exp Immunol** 1999 Sep;117(3):435–41

Inhibition of IL–12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD). Takata Y, et al. **Clin Exp Immunol** 1998 Nov;114(2):311–9

HLA–A*0201 presents TAP–dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. Lewis JW, et al. **Eur J Immunol** 1998 Oct;28(10):3214–20

Activating interactions in human NK cell recognition: the role of 2B4–CD48. Nakajima H, et al. **Eur J Immunol** 1999 May;29(5):1676–83

General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia–inducible factor 1alpha. Camenisch G, et al. **FASEB J** 1999 Jan;13(1):81–8

Novel tetravalent and bispecific IgG–like antibody molecules combining single–chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. Alt M, et al. **FEBS Lett** 1999 Jul 2;454(1–2):90–4

Preliminary investigation of lethally toxic sera of sudden infant death syndrome victims and neutralisation by commercially available immunoglobulins and adult sera. Sayers NM, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):193–8

Binding of feline immunodeficiency viral gag–p24 polypeptide to nonimmune Igs. Amici A, et al. **Immunol Lett** 1998 Jun;62(2):93–7

Role of different lymphocyte subpopulations in the formation of non–specific immunoglobulins induced by antigen injection. Chernyshova IN, et al. **Immunol Lett** 1999 Apr 1;67(2):113–6

A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Früh K, et al. **Immunol Rev** 1999 Apr;168:157–66 (76 ref.)

Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Wang J, et al. **Immunol Rev** 1998 Jun;163:197–215 (104 ref.)

Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram–negative septicemia. Wenisch C, et al. **Infection** 1999 May–Jun;27(3):183–6

gp49B1 and its related family of counterregulatory receptors of the immunoglobulin superfamily. Katz HR. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):177–9

High–affinity antibodies from hen's–egg yolks against human mannose–6–phosphate/insulin–like growth–factor–II receptor (M6P/IGFII–R): characterization and potential use in clinical cancer studies. Lemamy GJ, et al. **Int J Cancer** 1999 Mar 15;80(6):896–902

Natural antibodies in childhood: development, individual stability, and injury effect indicate a contribution to immune memory. Mirilas P, et al. **J Clin Immunol** 1999 Mar; 19(2):109–15

Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. Singh RR, et al. **J Clin Invest** 1998 Nov 15;102(10):1841–9

2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. Brown MH, et al. **J Exp Med** 1998 Dec 7;188(11):2083–90

ChT1, an Ig superfamily molecule required for T cell differentiation. Katevuo K, et al. **J Immunol** 1999 May 15; 162(10):5685–94

Differential modulation of human immunoglobulin isotype production by the neuropeptides substance P, NKA and NKB. Braun A, et al. **J Neuroimmunol** 1999 Jun 1; 97(1–2):43–50

Mathematical model of a virus–neutralizing immunglobulin response. Funk GA, et al. **J Theor Biol** 1998 Nov 7; 195(1):41–52

Possible role of disturbed Na+ homeostasis in mouse vas deferens contractile hyperreactivity after immunological sensitization. Souilem O, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Oct; 358(4):474–82

The use of chicken IgY in a double antibody sandwich ELISA for detecting African horsesickness virus. Du Plessis DH, et al. **Onderstepoort J Vet Res** 1999 Mar; 66(1):25–8

Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: possible role in antigen–driven reactions in the absence of germinal centers. Diaz M, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14343–8

Bovine herpesvirus 1–induced apoptotic cell death: role of glycoprotein D. Hanon E, et al. **Virology** 1999 Apr 25; 257(1):191–7

IgY antiporcine endothelial cell antibodies effectively block human antiporcine xenoantibody binding. Fryer J, et al. **Xenotransplantation** 1999 May;6(2):98–109

[Humoral immunity] Pasquali JL, et al. **Rev Prat** 1998 Feb 1;48(3):337–42 **(Fre)**

[Gastrointestinal cancer antigen and immunoglobulins G, A, M in patients with head cancer] Adamiak G, et al. **Otolaryngol Pol** 1998;52(6):655–60 (Eng. Abstr.) **(Pol)**

[Dynamics of the interaction of polyreactive immunoglobulins with immobilized antigens] Bobrovnik SA. **Ukr Biokhim Zh** 1998 Nov–Dec;70(6):135–43 (Eng. Abstr.) **(Rus)**

[Assessment of general and local immunity in children with affected lymphadenoid throat ring] Kovaleva LM, et al. **Vestn Otorinolaringol** 1999;(4):15–7 (Eng. Abstr.) **(Rus)**

[Agglutination of hen egg–yolk immunoglobulins (IgY) against Salmonella enterica, serovar enteritidis] Terzolo HR, et al. **Rev Argent Microbiol** 1998 Apr–Jun;30(2):84–92 (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Virus validation of pH 4–treated human immunoglobulin products produced by the Cohn fractionation process. Bos OJ, et al. **Biologicals** 1998 Dec;26(4):267–76

Three methods of capillary electrophoresis compared with high–resolution agarose gel electrophoresis for serum protein electrophoresis. Jenkins MA. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1–2):49–58

Micropurification and two–dimensional polyacrylamide gel electrophoresis of immunoglobulins for studying the clonal diversity of antigen–specific antibodies. Layer A, et al. **J Immunol Methods** 1999 Jul 30;227(1–2):137–48

A simplified procedure for the isolation of immunoglobulins from human serum using a novel type of thiophilic gel at low salt concentration. Scholz GH, et al. **J Immunol Methods** 1998 Oct 1;219(1–2):109–18

Immunoglobulin specificity of TG19318: a novel synthetic ligand for antibody affinity purification. Fassina G, et al. **J Mol Recognit** 1998 Winter;11(1–6):128–33

A novel immunoglobulin superfamily junctional molecule expressed by antigen presenting cells, endothelial cells and platelets. Malergue F, et al. **Mol Immunol** 1998 Dec; 35(17):1111–9

Expressed immunoglobulin repertoire of LPS–stimulated splenocytes of unimmunized mice as studied by two–dimensional gel electrophoresis. Nezlin R, et al. **Mol Immunol** 1998 Dec;35(17):1089–96

METABOLISM

The level of human decidua–associated protein (hDP) 200, identified as a monoclonal rheumatoid factor in the fallopian tube. Halperin R, et al. **Am J Reprod Immunol** 1999 Apr;41(4):253–6

Enrichment of immunoglobulin binding Plasmodium falciparum–infected erythrocytes using anti–immunoglobulin–coated magnetic beads. Heddini A, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):663–6

Atherosclerosis and the immune system [letter; comment] Niculescu F, et al. **Arch Intern Med** 1999 Feb 8;159(3):315 Comment on: Arch Intern Med 1998 Jul 13;158(13):1395–6. Comment on: Arch Intern Med 1998 Jul 13;158(13):1434–9.

Bile immunoglobulins and blockage of biliary endoprosthesis: an immunohistochemical study. Chan FK, et al. **Biomed Pharmacother** 1998;52(9):403–7

Novel modified tripeptide inhibitors of alpha 4 beta 7 mediated lymphoid cell adhesion to MAdCAM–1. Shroff HN, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1601–6

Effect of dietary fats and sesamin on the lipid metabolism and immune function of Sprague–Dawley rats. Gu JY, et al. **Biosci Biotechnol Biochem** 1998 Oct;62(10):1917–24

Proliferation and immunoglobulin secretion of lymphoblastoid cell lines are differently affected by soluble cytokines. Pistillo MP, et al. **Cell Prolif** 1994 Jun; 27(6):293–305

How to extinguish lymphocyte activation, immunotyrosine–based inhibition motif (ITIM)–bearing molecules a solution? Blery M, et al. **Clin Chem Lab Med** 1999 Mar;37(3):187–91 (54 ref.)

Accumulation of immunoglobulin–containing cells in the gut mucosa and presence of faecal immunoglobulin in severe combined immunodeficient (scid) mice with T cell–induced inflammatory bowel disease (IBD). Bregenholt S, et al. **Clin Exp Immunol** 1998 Oct;114(1):19–25

Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. Schoenhals GJ, et al. **EMBO J** 1999 Feb 1; 18(3):743–53

The N–terminal region of tapasin is required to stabilize the MHC class I loading complex. Bangia N, et al. **Eur J Immunol** 1999 Jun;29(6):1858–70

Novel chondroitin sulfate–modified ligands for L–selectin on lymph node high endothelial venules. Derry CJ, et al. **Eur J Immunol** 1999 Feb;29(2):419–30

Binding of human secretory leukocyte protease inhibitor in uterine cervical mucus to immunoglobulins: pathophysiology in immunologic infertility and local immune defense. Hirano M, et al. **Fertil Steril** 1999 Jun; 71(6):1108–14

Effects of intermittent vomitoxin exposure on body weight, immunoglobulin levels and haematuria in the B6C3F1 mouse. Banotai C, et al. **Food Chem Toxicol** 1999 Apr; 37(4):343–50

Intrauterine levels of human decidua–associated protein (hDP) 200 in normal pregnancy and missed abortion. Halperin R, et al. **Gynecol Obstet Invest** 1998;46(3):150–2

Cloning and expression of new receptors belonging to the immunoglobulin superfamily from the marine sponge Geodia cydonium. Blumbach B, et al. **Immunogenetics** 1999 Aug;49(9):751–63

The non–specific binding of immunoglobulins to silicone implant materials: the lack of a detectable silicone specific antibody. White KL Jr, et al. **Immunol Invest** 1998 Jul–Sep; 27(4–5):221–35

Trafficking of the Igalpha/Igbeta heterodimer with membrane Ig and bound antigen to the major histocompatibility complex class II peptide–loading compartment. Brown BK, et al. **J Biol Chem** 1999 Apr 16;274(16):11439–46

Proteins bound to polyethylene components in patients who have aseptic loosening after total joint arthroplasty. A preliminary report [see comments] Wooley PH, et al. **J Bone Joint Surg Am** 1999 May;81(5):616–23. Comment in: J Bone Joint Surg Am 1999 May;81(5):599–602.

Neurotractin, a novel neurite outgrowth–promoting Ig–like protein that interacts with CEPU–1 and LAMP. Marg A, et al. **J Cell Biol** 1999 May 17;145(4):865–76

Identification of an adhesion molecule expressed on adult T cell leukemia cells derived from a patient with gastrointestinal involvement: implication for a possible role of integrin beta 7 in leukemic cell infiltration into intestinal mucosa. Chen H, et al. **J Clin Immunol** 1999 May; 19(3):186–93

Effects of lactic acid bacteria ingestion of basal cytokine mRNA and immunoglobulin levels in the mouse. Tejada–Simon MV, et al. **J Food Prot** 1999 Mar; 62(3):287–91

Orientation of the Ig domains of CD8 alpha beta relative to MHC class I. Devine L, et al. **J Immunol** 1999 Jan 15; 162(2):846–51

Identification of the 2B4 molecule as a counter–receptor for CD48. Latchman Y, et al. **J Immunol** 1998 Dec 1; 161(11):5809–12

Fc–mediated nonspecific binding between fibronectin–binding protein I of Streptococcus pyogenes and human immunoglobulins. Medina E, et al. **J Immunol** 1999 Sep 15;163(6):3396–402

CDw150 associates with src–homology 2–containing inositol phosphatase and modulates CD95–mediated apoptosis. Mikhalap SV, et al. **J Immunol** 1999 May 15; 162(10):5719–27

Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma–chain. Nakajima H, et al. **J Immunol** 1999 Jan 1;162(1):5–8

Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain. Suh WK, et al. **J Immunol** 1999 Feb 1;162(3):1530–40

Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. McQuillen DP, et al. **J Infect Dis** 1999 Jan; 179(1):124–35

Granulocyte–macrophage colony–stimulating factor modulates tapasin expression in human neutrophils. El Ouakfaoui S, et al. **J Leukoc Biol** 1999 Feb;65(2):205–10

Ability to remove immunoglobulins and anti–ganglioside antibodies by plasma exchange, double–filtration plasmapheresis and immunoadsorption. Tagawa Y, et al. **J Neurol Sci** 1998 Apr 15;157(1):90–5

Serum antibody levels and avidities to Escherichia coli O antigens and poliovirus type 1 antigen are increased in children treated for malignant disease. Abrahamsson J, et al. **Med Pediatr Oncol** 1999 Jun;32(6):416–20

Expression of immunoglobulin superfamily members on the lymphatic endothelium of inflamed human small intestine. Sawa Y, et al. **Microvasc Res** 1999 Mar;57(2):100–6

The X–linked lymphoproliferative–disease gene product SAP regulates signals induced through the co–receptor SLAM [see comments] Sayos J, et al. **Nature** 1998 Oct 1; 395(6701):462–9. Comment in: Nature 1998 Oct 1;395(6701):441, 443–4.

Glomerular deposition of mannose–binding lectin in human glomerulonephritis. Lhotta K, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):881–6

The interactions of the cytokine–binding homology region and immunoglobulin–like domains of gp130 with oncostatin M: implications for receptor complex formation. Staunton D, et al. **Protein Eng** 1998 Nov;11(11):1093–102

Selective modulation of B–cell activation markers CD86 and I–Ak on murine draining lymph node cells following allergen or irritant treatment. Gerberick GF, et al. **Toxicol Appl Pharmacol** 1999 Sep 1;159(2):142–51

IMMUNOGLOBULINS

Simultaneous occurrence of Hodgkin's disease, nodal Langerhans' cell histiocytosis and multiple myeloma IgA(kappa). Ibarrola de Andrés C, et al. **Virchows Arch** 1999 Mar;434(3):259–62

PHARMACOLOGY

Histones evoke thymocyte death in vitro; histone-binding immunoglobulins decrease their cytotoxicity. Abakushin DN, et al. **Biochemistry (Mosc)** 1999 Jun;64(6):693–8

Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein. Swiniarski H, et al. **Clin Immunol** 1999 Sep;92(3):235–45

Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants? Bialek R, et al. **Infection** 1998 Nov-Dec;26(6):375–8

The comparative potency of cholesterol crystallization-effector proteins in supersaturated model bile systems: association with vesicle transformation. Hattori Y, et al. **J Gastroenterol Hepatol** 1998 Nov; 13(11):1161–70

Hyperimmune globulin prophylaxis for cytomegalovirus infection in renal transplantation [letter] Wirnsberger GH, et al. **Nephron** 1999;81(3):368–9

PHYSIOLOGY

Physiological aspects of the immunoglobulin superfamily in invertebrates. Mendoza HL, et al. **Dev Comp Immunol** 1999 Jun-Jul;23(4–5):359–74 (72 ref.)

MAdCAM-1 costimulates T cell proliferation exclusively through integrin alpha4beta7, whereas VCAM-1 and CS-1 peptide use alpha4beta1: evidence for "remote" costimulation and induction of hyperresponsiveness to B7 molecules. Lehnert K, et al. **Eur J Immunol** 1998 Nov; 28(11):3605–15

From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Korganow AS, et al. **Immunity** 1999 Apr;10(4):451–61

Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. Csencsits KL, et al. **J Immunol** 1999 Aug 1;163(3):1382–9

THERAPEUTIC USE see IMMUNIZATION, PASSIVE

IMMUNOGLOBULINS, ALPHA-CHAIN

ANALYSIS

Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Magnac C, et al. **Hematol Cell Ther** 1999 Feb;41(1):13–8

BIOSYNTHESIS

Modifications of Igalpha and Igbeta expression as a function of B lineage differentiation. Benlagha K, et al. **J Biol Chem** 1999 Jul 2;274(27):19389–96

CHEMISTRY

Rapid structural characterisation of a murine monoclonal IgA alpha chain: heterogeneity in the oligosaccharide structures at a specific site in samples produced in different bioreactor systems. Schweikart F, et al. **J Biotechnol** 1999 Apr 15; 69(2–3):191–201

GENETICS

Target specificity of immunoglobulin class switch recombination is not determined by nucleotide sequences of S regions. Kinoshita K, et al. **Immunity** 1998 Dec; 9(6):849–58

Opposite orientation of the alpha- and upsilon-chain constant region genes in the immunoglobulin heavy chain locus of the duck. Magor KE, et al. **Immunogenetics** 1999 Jul; 49(7–8):692–5

The distribution of human TCR junctional region lengths shifts with age in both CD4 and CD8 T cells. Hall MA, et al. **Int Immunol** 1998 Oct;10(10):1407–19

Conserved T-cell receptor beta chain CDR3 sequences in IgA nephropathy biopsies. Wu H, et al. **Kidney Int** 1999 Jan;55(1):109–19

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Pott C, et al. **Leukemia** 1998 Oct;12(10):1630–7

Oligoclonality of TCRint cells with a low diversity of TCR complementarity-determining region 3 in mice with graft-versus-host disease. Sugahara S, et al. **Scand J Immunol** 1998 Dec;48(6):592–604

IMMUNOLOGY

Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy. Kostense S, et al. **AIDS** 1998 Dec 24; 12(18):F235–40

In-vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma. Wen YJ, et al. **Br J Haematol** 1998 Dec;103(3):663–8

Idiosyncratic alterations of TCR size distributions affecting both CD4 and CD8 T cell subsets in aging mice. Mosley RL, et al. **Cell Immunol** 1998 Oct 10;189(1):10–8

Does the CDR3 of the heavy chain determine the specificity of autoantibodies in systemic lupus erythematosus? Yazici ZA, et al. **J Autoimmun** 1998 Oct;11(5):477–83

IMMUNOGLOBULINS, DELTA-CHAIN

GENETICS

Terminal deoxynucleotidyl transferase expression during neonatal life alters D(H) reading frame usage and Ig-receptor-dependent selection of V regions. Marshall AJ, et al. **J Immunol** 1998 Dec 15;161(12):6657–63

IMMUNOGLOBULINS, EPSILON-CHAIN

GENETICS

A highly sensitive and specific assay using a novel human growth hormone cDNA reporter gene regulated by the human interleukin-4 inducible germline epsilon transcript promoter. Jenh CH, et al. **J Immunol Methods** 1998 Aug 1;217(1–2):87–95

DNase I hypersensitive sites in human I epsilon region of immunoglobulin heavy chain genes abnormally induced by interleukin-4 in B-lymphocytes of atopic patients with high levels of serum IgE. Kondo N, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):234–8

IMMUNOLOGY

Sequence-specific antibodies against human IgE isoforms induced by an epitope display system. Lorenzi R, et al. **Immunotechnology** 1999 Mar;4(3–4):267–72

IMMUNOGLOBULINS, FAB

A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas. Ohtomo T, et al. **Anticancer Res** 1998 Nov-Dec;18(6A):4311–5

Structure-binding relationships for the interaction between a vancomycin monoclonal antibody Fab fragment and a library of vancomycin analogues and tracers. Adamczyk M, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):176–85

Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: improved immunogene approach. Chen J, et al. **Cancer Gene Ther** 1998 Nov-Dec;5(6):357–64

Ultrasensitive immune complex transfer enzyme immunoassay of HIV-1 p24 antigen with less serum interference using 2,4-dinitrophenyl-anti-HIV-1 p24 IgG and indirectly immobilized (anti-2,4-dinitrophenyl group) Fab. Ishikawa S, et al. **J Clin Lab Anal** 1999;13(3):126–32

Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study. Yamamoto K, et al. **Surg Today** 1999;29(2):190–3

Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Crowe JE, et al. **Virology** 1998 Dec 20; 252(2):373–5

Sequence and specificity analysis of recombinant human Fab anti-Rh D isolated by phage display. Miescher S, et al. **Vox Sang** 1998;75(4):278–87

[Production of various antibodies and single chain Fv molecule against signal-transducing proteins] Kurose H, et al. **Nippon Yakurigaku Zasshi** 1998 Jul;112(1):59–68 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. Califf RM. **Am Heart J** 1999 Jul;138(1 Pt 2):S12–5

Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. Brener SJ, et al. **Am J Cardiol** 1999 Sep 15;84(6):728–30, A8

Abciximab vials as multidose containers [letter] [see comments] Yee WP, et al. **Am J Health Syst Pharm** 1998 Oct 1;55(19):2026–7. Comment in: Am J Health Syst Pharm 1999 Mar 1;56(5):477.

Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Bera TK, et al. **Cancer Res** 1999 Aug 15;59(16):4018–22

Vasoseal hemostasis following coronary interventions with Abciximab. Lunney L, et al. **Cathet Cardiovasc Diagn** 1998 Aug;44(4):405–6

Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A. **Conn Med** 1999 Aug;63(8):483–7

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. van den Merkhof LF, et al. **J Am Coll Cardiol** 1999 May; 33(6):1528–32

Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Hézard N, et al. **Thromb Haemost** 1999 Jun;81(6):869–73

[The value of Abciximab in stent implantation clearly proven] **Z Kardiol** 1999 Jun;88(6 Suppl):1–4 **(Ger)**

ADVERSE EFFECTS

Readministration of abciximab: interim report of the ReoPro readministration registry. Tcheng JE, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S33–8

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Peter K, et al. **Am J Cardiol** 1999 Sep 1;84(5):519–24

Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Sundlof DW, et al. **Am J Cardiol** 1999 Jun 1;83(11):1569–71, A7

Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Jubelirer SJ, et al. **Am J Hematol** 1999 Jul;61(3):205–8 (11 ref.)

Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab [letter] [see comments] Alvarez JM, et al. **Aust N Z J Med** 1998 Aug;28(4):463–4. Comment in: Aust N Z J Med 1998 Oct;28(5):583–4.

Possible anaphylactic reaction to abciximab. Guzzo JA, et al. **Catheter Cardiovasc Interv** 1999 Sep;48(1):71–3

Images in cardiovascular medicine: pseudothrombocytopenia after abciximab (ReoPro) treatment. Moll S, et al. **Circulation** 1999 Sep 28;100(13):1460

Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Joseph T, et al. **Clin Cardiol** 1998 Nov;21(11):851–2

Surgical implications of platelet glycoprotein IIb-IIIa inhibition [letter] Duke C, et al. **J Thorac Cardiovasc Surg** 1998 Dec;116(6):1083–4

Coronary stenting and use of abciximab [letter; comment] Alvarez JM. **Lancet** 1998 Oct 17;352(9136):1311–2. Comment on: Lancet 1998 Jul 11;352(9122):87–92.

Coronary stenting and use of abciximab [letter; comment] Mohl W, et al. **Lancet** 1998 Oct 17;352(9136):1312. Comment on: Lancet 1998 Jul 11;352(9122):87–92.

Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists [letter; comment] Stiegler HM, et al. **Lancet** 1999 Apr 3;353(9159):1185. Comment on: Lancet 1999 Jan 16;353(9148):227–31.

Abciximab and alveolar hemorrhage [letter; comment] Khanlou H, et al. **N Engl J Med** 1998 Dec 17; 339(25):1861–3. Comment on: N Engl J Med 1994 Apr 7;330(14):956–61. Comment on: N Engl J Med 1997 Jun 12;336(24):1689–96.

[Cardiac tamponade after coronary angioplasty induced by treatment with ReoPro (see comments)] Cappelletti A, et al. **G Ital Cardiol** 1999 Mar;29(3):312–4 (Eng. Abstr.). Comment in: G Ital Cardiol 1999 Apr;29(4):467–71. **(Ita)**

BIOSYNTHESIS

Bacterial expression of a neutralizing mouse monoclonal antibody Fab fragment to a 150-kilodalton surface antigen of Entamoeba histolytica. Tachibana H, et al. **Am J Trop Med Hyg** 1999 Jan;60(1):35–40

Expression of a recombinant Fab antibody fragment against cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Kaplan D, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):53–8

Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display. Coomber DW, et al. **J Immunol** 1999 Aug 15;163(4):2276–83

A vector for the expression of recombinant monoclonal Fab fragments in bacteria. Burioni R, et al. **J Immunol Methods** 1998 Aug 1;217(1–2):195–9

Method for the preparation of bispecific F(ab')2mu fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments. Morimoto K, et al. **J Immunol Methods** 1999 Apr 22;224(1–2):43–50

Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low-density lipoprotein receptor-binding site of human apolipoprotein E. Raffaï R, et al. **Protein Expr Purif** 1999 Jun;16(1):84–90

Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Schmaljohn C, et al. **Virology** 1999 May 25;258(1):189–200

BLOOD

Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind). Jortani SA, et al. **Clin Chim Acta** 1999 May;283(1–2):159–69

Effect of digoxin fab antibody on the measurement of total and free digitoxin by fluorescence polarization and a new chemiluminescent immunoassay. Dasgupta A, et al. **Ther Drug Monit** 1999 Apr;21(2):251–5

CHEMISTRY

Use of streptococcal protein G in obtaining crystals of an antibody Fab fragment in complex with a meningococcal antigen. Derrick JP, et al.
Acta Crystallogr D Biol Crystallogr 1999 Jan;55 (Pt 1):314–6

Crystallization and preliminary X-ray data for the human transthyretin–retinol–binding protein (RBP) complex bound to an anti–RBP Fab. Malpeli G, et al.
Acta Crystallogr D Biol Crystallogr 1999 Jan;55 (Pt 1):276–8

Crystallization and preliminary X-ray diffraction analysis of antigen–binding fragments which are specific for antigenic conformations of sialic acid homopolymers. Patenaude SI, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Sep 1;54 (Pt 5):1005–7

Structure of a monoclonal 2E8 Fab antibody fragment specific for the low-density lipoprotein–receptor binding region of apolipoprotein E refined at 1.9 A. Trakhanov S, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jan;55 (Pt 1):122–8

Removal of pyrogens by filtration? [letter; comment] Turco SJ. **Am J Health Syst Pharm** 1999 Mar 1;56(5):477. Comment on: Am J Health Syst Pharm 1998 Oct 1;55(19):2026–7.

Conformational change in an anti–integrin antibody: structure of OPG2 Fab bound to a beta 3 peptide. Kodandapani R, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):61–6

Detection of molecular interactions by using a new peptide–displaying bacteriophage biosensor. Ramirez E, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):801–5

In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. Saviranta P, et al.
Bioconjug Chem 1998 Nov–Dec;9(6):725–35

Validity of unbound digoxin measurements by immunoassays in presence of antidote (Digibind). Jortani SA, et al.
Clin Chim Acta 1999 May;283(1–2):159–69

Head–to–tail dimers and interdomain flexibility revealed by the crystal structure of HIV–1 capsid protein (p24) complexed with a monoclonal antibody Fab. Berthet–Colominas C, et al. **EMBO J** 1999 Mar 1; 18(5):1124–36

Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. Lim K, et al. **J Biol Chem** 1998 Oct 30; 273(44):28576–82

The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. Boehm MK, et al. **J Mol Biol** 1999 Mar 12;286(5):1421–47

A comparison of the crystallographic structures of two catalytic antibodies with esterase activity. Buchbinder JL, et al. **J Mol Biol** 1998 Oct 9;282(5):1033–41

Crystal structures of a rat anti–CD52 (CAMPATH–1) therapeutic antibody Fab fragment and its humanized counterpart. Cheetham GM, et al. **J Mol Biol** 1998 Nov 20;284(1):85–99

Structure and functional implications of the polymerase active site region in a complex of HIV–1 RT with a double–stranded DNA template–primer and an antibody Fab fragment at 2.8 A resolution. Ding J, et al.
J Mol Biol 1998 Dec 11;284(4):1095–111

Crystal structure at 1.95 A resolution of the breast tumour–specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition. Dokurno P, et al. **J Mol Biol** 1998 Dec 4;284(3):713–28

1.9 A structure of the therapeutic antibody CAMPATH–1H fab in complex with a synthetic peptide antigen. James LC, et al. **J Mol Biol** 1999 Jun 4;289(2):293–301

Pharmacokinetics and organ distribution of cationized colchicine–specific IgG and Fab fragments in rat. Hong G, et al. **J Pharm Sci** 1999 Jan;88(1):147–53

Structure of an activity suppressing Fab fragment to cytochrome P450 aromatase: insights into the antibody–antigen interactions. Sawicki MW, et al.
Mol Immunol 1999 May;36(7):423–32

188Re DD–3B6/22 Fab' for use in therapy of ovarian cancer: labelling and animal studies. Schmidt PF, et al.
Nucl Med Biol 1998 Oct;25(7):639–49

Crystal structure of Taq DNA polymerase in complex with an inhibitory Fab: the Fab is directed against an intermediate in the helix–coil dynamics of the enzyme. Murali R, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13; 95(21):12562–7

Efficient site specific removal of a C–terminal FLAG fusion from a Fab' using copper(II) ion catalysed protein cleavage. Humphreys DP, et al. **Protein Eng** 1999 Feb;12(2):179–84

Quantitative evaluation of the chicken lysozyme epitope in the HyHEL–10 Fab complex: free energies and kinetics. Rajpal A, et al. **Protein Sci** 1998 Sep;7(9):1868–74

Kinetic epitope mapping of the chicken lysozyme.HyHEL–10 Fab complex: delineation of docking trajectories. Taylor MG, et al. **Protein Sci** 1998 Sep; 7(9):1857–67

Class–directed structure determination: foundation for a protein structure initiative. Terwilliger TC, et al.
Protein Sci 1998 Sep;7(9):1851–6 (54 ref.)

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA, et al. **Structure** 1998 Sep 15;6(9):1153–67

HIV gp120: double lock strategy foils host defences. Sattentau QJ. **Structure** 1998 Aug 15;6(8):945–9 (27 ref.)

Dual conformations for the HIV–1 gp120 V3 loop in complexes with different neutralizing fabs. Stanfield R, et al. **Structure Fold Des** 1999 Feb 15;7(2):131–42

DIAGNOSTIC USE

Use of abciximab–modified thrombelastography in patients undergoing cardiac surgery. Kettner SC, et al.
Anesth Analg 1999 Sep;89(3):580–4

Immunoscintigraphy of venous thrombi: clinical effectiveness of a new antifibrin D–dimer monoclonal antibody. Ciavolella M, et al. **Angiology** 1999 Feb;50(2):103–9

Human monoclonal antibodies: a tool for cancer detection in vivo. Ditzel HJ. **APMIS Suppl** 1999;94:5–42 (242 ref.)

Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. Kobayashi H, et al. **J Nucl Med** 1999 May;40(5):837–45

Biodistribution and localization of radiolabeled NR–LU–10 Fab fragment in human breast cancer xenografts. Burak WE Jr, et al. **Nucl Med Biol** 1998 Oct;25(7):633–7

ECONOMICS

Economic issues in glycoprotein IIb/IIIa receptor therapy. Hillegass WB, et al. **Am Heart J** 1999 Jul;138(1 Pt 2):S24–32 (28 ref.)

Economics and cost–effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. Mark DB, et al. **Am Heart J** 1999 May; 137(5):S123–5

Cost and outcomes analysis of abciximab use in a community teaching hospital. Abernathy GB, et al.
Am J Health Syst Pharm 1998 Dec 15;55(24 Suppl 4):S35–7

[An economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health–care context] Lorenzoni R, et al. **G Ital Cardiol** 1999 Mar; 29(3):269–76 (Eng. Abstr.) **(Ita)**

GENETICS

Expression of a recombinant Fab antibody fragment against cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Kaplan D, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):53–8

Cloning, expression, and characterization of the Fab fragment of the anti–lysozyme antibody HyHEL–5. Wibbenmeyer JA, et al. **Biochim Biophys Acta** 1999 Mar 19; 1430(2):191–202

Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)–alpha induces significant tumor regression. Wright P, et al.
Cancer Gene Ther 1998 Nov–Dec;5(6):371–9

Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti–epidermal growth factor receptor antibody: immunogene approach. Chen J, et al. **Hum Gene Ther** 1998 Dec 10;9(18):2673–81

Generation of human Fab monoclonal antibodies against preS1 of hepatitis B virus using repertoire cloning. Choi IH, et al. **Hybridoma** 1998 Dec;17(6):535–40

Recombinant human monoclonal Fab fragments against rotavirus from phage display combinatorial libraries. Itoh K, et al. **J Biochem (Tokyo)** 1999 Jan;125(1):123–9

A large non–immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. de Haard HJ, et al. **J Biol Chem** 1999 Jun 25;274(26):18218–30

Application of a recombinant Fab fragment from a phage display library for sensitive detection of a target antigen by an inhibition ELISA system. Itoh K, et al.
J Immunol Methods 1999 Feb 1;223(1):107–14

Bacterial expression of a human recombinant monoclonal antibody fab fragment against hepatitis B surface antigen. Maeda F, et al. **J Med Virol** 1999 Aug;58(4):338–45

Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus–specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. Burgoon MP, et al.
J Neuroimmunol 1999 Feb 1;94(1–2):204–11

Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor–specific Fab immunogene. Ohtake Y, et al. **Jpn J Cancer Res** 1999 Apr; 90(4):460–8

Gene silencing results in instability of antibody production in transgenic plants. De Neve M, et al. **Mol Gen Genet** 1999 Jan;260(6):582–92

Anti–CD34+ Fabs generated against hematopoietic stem cells in HIV–derived combinatorial immunoglobulin library suggest antigen–selected autoantibodies. Rubinstein DB, et al. **Mol Immunol** 1998 Oct;35(14–15):955–64

Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low–density lipoprotein receptor–binding site of human apolipoprotein E. Raffaï R, et al. **Protein Expr Purif** 1999 Jun;16(1):84–90

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA, et al. **Structure** 1998 Sep 15;6(9):1153–67

Cloning and expression of recombinant antibody Fab genes of anti–c–myc peptide. Li L, et al. **Transplant Proc** 1998 Nov;30(7):2929–30

IMMUNOLOGY

Crystallization of two hCG–specific monoclonal antibody fragments. Fotinou C, et al.
Acta Crystallogr D Biol Crystallogr 1998 May 1;54 (Pt 3):405–6

Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat–treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero–cell rabies vaccine. Lang J, et al. **Acta Trop** 1998 Jul 30; 70(3):317–33

Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis. Kortt AA, et al. **Anal Biochem** 1999 Aug 15;273(1):133–41

Ricin A immunotoxins of IgG and Fab of anti–CALLA monoclonal antibody: effect of water soluble long–chain SPDP on conjugate yield, immunoselectivity and cytotoxicity. Woo BH, et al. **Arch Pharm Res** 1994 Dec; 17(6):452–7

Fc gamma receptors in negative signaling––as potential candidates for the antibody induced regulation of humoral responses. Bell CG. **Biochem Soc Trans** 1998 Aug; 26(3):S202

Kinetic analysis of the effect on Fab binding of identical substitutions in a peptide and its parent protein. Choulier L, et al. **Biochemistry** 1999 Mar 23;38(12):3530–7

A combinatorial phage display library for the generation of specific Fab fragments recognizing human spermatozoa and inhibiting fertilizing capacity in vitro. Clayton R, et al.
Biol Reprod 1998 Nov;59(5):1180–6

A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells. Andersson E, et al. **Cancer Immunol Immunother** 1999 Jan;47(5):249–56

Preparation of recombinant human monoclonal antibody Fab fragments specific for Entamoeba histolytica. Tachibana H, et al. **Clin Diagn Lab Immunol** 1999 May;6(3):383–7

Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T–cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B–cell lineage leukemia and lymphoma. Brandl M, et al. **Exp Hematol** 1999 Aug; 27(8):1264–70

Dual specificity antibodies using a double–stranded oligonucleotide bridge. Chaudri ZN, et al. **FEBS Lett** 1999 Apr 30;450(1–2):23–6

Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2 dimers, monomers, and monovalent F(ab). Mahoney RJ, et al. **Hum Immunol** 1999 Jun;60(6):492–9

The antigen binding domain of non–idiotypic human anti–F(ab')2 autoantibodies: study of their interaction with IgG hinge region epitopes. Welschof M, et al.
Hum Immunol 1999 Apr;60(4):282–90

Generation of human Fab monoclonal antibodies against preS1 of hepatitis B virus using repertoire cloning. Choi IH, et al. **Hybridoma** 1998 Dec;17(6):535–40

Expression of a human IgG4 antibody, BAB2, with specificity for the major Birch pollen allergen, Bet v 1 in Escherichia coli: recombinant BAB2 Fabs enhance the allergic reaction. Eibensteiner P, et al.
Int Arch Allergy Immunol 1999 Feb–Apr;118(2–4):190–2

MHC class II–independent, Vbeta–specific activation of T cells by superantigen mutants fused to anti–tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW, et al. **Int J Mol Med** 1998 Jan; 1(1):157–62

Bactericidal antibody recognition of meningococcal PorA by induced fit. Comparison of liganded and unliganded Fab structures. van den Elsen J, et al. **J Biol Chem** 1999 Jan 15;274(3):1495–501

Latex immunoassays: comparative studies on covalent and physical immobilization of antibodies. I. F(ab')2 fragments. Molina–Bolivar JA, et al. **J Biomater Sci Polym Ed** 1998; 9(10):1089–101

A recombinant Fab neutralizes dengue virus in vitro. Thullier P, et al. **J Biotechnol** 1999 Apr 15;69(2–3):183–90

Human neutralizing human immunodeficiency virus type 2–specific Fab molecules generated by phage display. Björling E, et al. **J Gen Virol** 1999 Aug;80 (Pt 8):1987–93

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model. Humphreys DP, et al.
J Immunol Methods 1998 Aug 1;217(1–2):1–10

In vivo biotinylated recombinant antibodies: high efficiency of labelling and application to the cloning of active anti–human IgG1 Fab fragments. Sibler AP, et al.
J Immunol Methods 1999 Apr 22;224(1–2):129–40

Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus–specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. Burgoon MP, et al.
J Neuroimmunol 1999 Feb 1;94(1–2):204–11

Targeted adeno–associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody [published erratum appears in Nat Biotechnol 1999 Apr;17(4):393] Bartlett JS, et al. **Nat Biotechnol** 1999 Feb;17(2):181–6

A new subtraction technique for molecular cloning of rare antiviral antibody specificities from phage display libraries. Burioni R, et al. **Res Virol** 1998 Sep–Oct;149(5):327–30

Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity in living donor renal transplant recipients: a pilot study. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):2977–8

Flexibility of the major antigenic loop of foot-and-mouth disease virus bound to a Fab fragment of a neutralising antibody: structure and neutralisation. Verdaguer N, et al. **Virology** 1999 Mar 15;255(2):260–8

Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH, et al. **Vox Sang** 1998;74 Suppl 2:483–7 (36 ref.)

ISOLATION & PURIFICATION

Characterization of each isoform of a F(ab')2 by capillary electrophoresis. Vincentelli R, et al. **J Chromatogr** 1993 Jul 9;641(2):383–90

Reopro removal during cardiopulmonary bypass using a hemoconcentrator. Poullis M, et al. **J Thorac Cardiovasc Surg** 1999 May;117(5):1032–4

Isolation of human anti-branched chain alpha-oxo acid dehydrogenase-E2 recombinant antibodies by Ig repertoire cloning in idiopathic dilated cardiomyopathy. Lee S, et al. **Mol Cells** 1999 Feb 28;9(1):25–30

A molecular approach for isolating high-affinity Fab fragments that are useful in blood group serology. Czerwinski M, et al. **Transfusion** 1999 Apr;39(4):364–71

[Isolation, crystallization, and preliminary x-ray study of a Fab fragment of monoclonal antibody against human interleukin-2 and its complex with antigenic peptide] Mikhailova Iu, et al. **Bioorg Khim** 1999 Apr;25(4):247–52 (Eng. Abstr.) **(Rus)**

METABOLISM

Human breast milk immunoglobulins G hydrolyze nucleotides. Semenov DV, et al. **Biochemistry (Mosc)** 1998 Aug;63(8):935–43

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Gu DL, et al. **Cancer Res** 1999 Jun 1;59(11):2608–14

The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Kobayashi H, et al. **Cancer Res** 1999 Jan 15;59(2):422–30

Subcellular localization of estradiol receptor in MCF7 cells studied with nanogold-labelled antibody fragments. Kessels MM, et al. **Eur J Histochem** 1998;42(4):259–70

pFab-CMV, a single vector system for the rapid conversion of recombinant Fabs into whole IgG1 antibodies. Sanna PP, et al. **Immunotechnology** 1999 Mar;4(3–4):185–8

Enhancement of tumor uptakes by stabilized Fab homo-oligomers of a chimeric monoclonal antibody against carcinoembryonic antigen. Kamigaki T, et al. **Int J Oncol** 1999 Jan;14(1):139–44

Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab')2: a possible implication for mucosal defense. Crottet P, et al. **J Immunol** 1998 Nov 15;161(10):5445–53

Biodistribution of filamentous phage-Fab in nude mice. Yip YL, et al. **J Immunol Methods** 1999 May 27;225(1–2):171–8

Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. Ding J, et al. **J Mol Biol** 1998 Dec 11;284(4):1095–111

Gene silencing results in instability of antibody production in transgenic plants. De Neve M, et al. **Mol Gen Genet** 1999 Jan;260(6):582–92

Biodistribution and localization of radiolabeled NR-LU-10 Fab fragment in human breast cancer xenografts. Burak WE Jr, et al. **Nucl Med Biol** 1998 Oct;25(7):633–7

In vivo stability and metabolism of 99Tcm-labelled anti-CD4 monoclonal antibodies and Fab' fragments. Kinne RW, et al. **Nucl Med Commun** 1999 Jan;20(1):67–75

Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis. List B, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15351–5

Time- and dose-dependent digoxin redistribution by digoxin-specific antigen binding fragments in a rat model. Renard C, et al. **Toxicology** 1999 Sep 20;137(2):117–27

Pharmacokinetics of 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Ismail M, et al. **Toxicon** 1998 Nov;36(11):1523–8

Membrane fusion by surrogate receptor-bound influenza haemagglutinin. Millar BM, et al. **Virology** 1999 May 10; 257(2):415–23

PHARMACOLOGY

Potential non-glycoprotein IIb/IIIa effects of abciximab. Coller BS. **Am Heart J** 1999 Jul;138(1 Pt 2):S1–5 (50 ref.)

Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Kaide J, et al. **Am J Hypertens** 1999 Jun;12(6):611–9

A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia Russelii Russelii): a preliminary dose-finding and pharmacokinetic study. Ariaratnam CA, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):259–65

Comparative study on the ability of IgG and F(ab')2 antivenoms to neutralize lethal and myotoxic effects induced by Micrurus nigrocinctus (coral snake) venom. León G, et al. **Am J Trop Med Hyg** 1999 Aug;61(2):266–71

A combinatorial phage display library for the generation of specific Fab fragments recognizing human spermatozoa and inhibiting fertilizing capacity in vitro. Clayton R, et al. **Biol Reprod** 1998 Nov;59(5):1180–6

Abciximab binding to glycoprotein IIb–IIa and protein tyrosine phosphorylation in human platelets [letter; comment] Cazes E, et al. **Blood** 1999 Jun 1;93(11):4019–20 . Comment on: Blood 1998 Nov 1;92(9):3240–9.

Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Nurden P, et al. **Blood** 1999 Mar 1;93(5):1622–33

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors [see comments] Peter K, et al. **Blood** 1998 Nov 1;92(9):3240–9. Comment in: Blood 1999 Jun 1;93(11):4019–20.

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. **Circulation** 1999 Aug 24;100(8):799–806

Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Harder S, et al. **Circulation** 1999 Sep 14; 100(11):1175–81

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Quinn M, et al. **Circulation** 1999 May 4;99(17):2231–8

Pharmacology of the intravenous platelet receptor glycoprotein IIb–IIIa antagonists. Kleiman NS. **Coron Artery Dis** 1998;9(9):603–16 (104 ref.)

A risk-benefit assessment of abciximab in angioplasty. Kleiman NS. **Drug Saf** 1999 Jan;20(1):43–57 (77 ref.)

Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. Mickelson JK, et al. **J Am Coll Cardiol** 1999 Jan; 33(1):97–106

Disulfide cross-linked Fab-aggregates: preparation and biodistribution. Dalkara S, et al. **J Drug Target** 1998; 6(1):45–52

Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear [letter] Goto S, et al. **Lancet** 1999 Mar 6;353(9155):809

Vipera palaestinae antivenin. Moroz C. **Public Health Rev** 1998;26(3):233–6 (8 ref.)

Effect of glycoprotein IIb–IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M, et al. **Thromb Haemost** 1998 Dec; 80(6):994–1001

In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Mak KH, et al. **Thromb Haemost** 1998 Dec;80(6):989–93

Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Coiffic A, et al. **Thromb Res** 1999 Jul 15; 95(2):83–91

Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Pedicord DL, et al. **Thromb Res** 1998 Jun 15;90(6):247–58

[Abciximab-induced thrombopenia during treatment of acute coronary syndromes by angioplasty] Pinton P. **Ann Cardiol Angeiol (Paris)** 1998 May;47(5):351–8 (Eng. Abstr.) **(Fre)**

[Expression of inducible nitric oxide synthase in the carotid of rats after endothelial skinning: the effects of platelets and treatment with abciximab] González-Fernández F, et al. **Rev Esp Cardiol** 1999 Jun;52(6):422–8 (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. Tepe G, et al. **AJR Am J Roentgenol** 1999 May;172(5):1343–6

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. Anderson KM, et al. **Am Heart J** 1999 May;137(5):S129–32

Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Dangas G, et al. **Am Heart J** 1999 Jul;138(1 Pt 1):49–54

Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Haase KK, et al. **Am Heart J** 1999 Feb; 137(2):234–40

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy. Schrogie JJ. **Am Heart J** 1999 May;137(5):S126–8

Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Thel MC, et al. **Am Heart J** 1999 Feb;137(2):264–73

Usefulness of abciximab for treatment of early coronary artery stent thrombosis. Casserly IP, et al. **Am J Cardiol** 1998 Oct 15;82(8):981–5

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Kereiakes DJ, et al. **Am J Cardiol** 1999 Aug 15;84(4):391–5

Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM. **Am J Cardiol** 1998 Oct 22;82(8B):36P–42P (24 ref.)

Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO–III trial). Global Use of Strategies To Open occluded coronary arteries. Miller JM, et al. **Am J Cardiol** 1999 Oct 1; 84(7):779–84

Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET). Topol EJ. **Am J Cardiol** 1998 Oct 22;82(8B):63P–68P (21 ref.)

Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. Reed SD, et al. **Am J Health Syst Pharm** 1998 Nov 15;55(22):2409–14

A novel Fab-based antivenom for the treatment of mass bee attacks. Jones RG, et al. **Am J Trop Med Hyg** 1999 Sep; 61(3):361–6

Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria. Looareesuwan S, et al. **Am J Trop Med Hyg** 1999 Jul;61(1):26–33

Abciximab and the risk of bleeding during emergency cardiac operations [letter; comment] Arjomand H, et al. **Ann Thorac Surg** 1999 Jan;67(1):292–3. Comment on: Ann Thorac Surg 1998 Feb;65(2):465–9.

Recurrent and persistent coagulopathy following pit viper envenomation. Boyer LV, et al. **Arch Intern Med** 1999 Apr 12;159(7):706–10

Expression of markers of platelet activation and the interpatient variation in response to abciximab. Bihour C, et al. **Arterioscler Thromb Vasc Biol** 1999 Feb;19(2):212–9

Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates. Deitch JS, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov;18(11):1730–7

Monitoring platelet GPIIb/IIIa antagonist therapy. Coller BS. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S81–6 (40 ref.)

The effects of specific antibody fragments on the 'irreversible' neurotoxicity induced by Brown snake (Pseudonaja) venom. Jones RG, et al. **Br J Pharmacol** 1999 Feb; 126(3):581–4

Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty. McGregor M, et al. **Can J Cardiol** 1999 Feb;15(2):201–7

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Behr TM, et al. **Cancer Res** 1999 Jun 1;59(11):2635–43

Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Galassi AR, et al. **Cardiologia** 1999 Jul;44(7):639–45

Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis. Berkompas DC. **Cathet Cardiovasc Diagn** 1998 Nov;45(3):272–4

Abciximab readministration: A single-operator community-hospital experience. Arjomand H, et al. **Catheter Cardiovasc Interv** 1999 Jul;47(3):294–6; discussion 297

Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin [see comments] Cantor WJ, et al. **Catheter Cardiovasc Interv** 1999 Mar;46(3):352–5. Comment in: Catheter Cardiovasc Interv 1999 Mar;46(3):356.

Rescue PTCA complicated by pulmonary artery rupture after tPA and abciximab. Chadow HL, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):89–91

Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). Chamberlin JR, et al. **Catheter Cardiovasc Interv** 1999 Jun;47(2):143–7; discussion 148

Options to heparin anticoagulation for cardiac interventions [editorial; comment] Kahn JK. **Catheter Cardiovasc Interv** 1999 Mar;46(3):356. Comment on: Catheter Cardiovasc Interv 1999 Mar;46(3):352–5.

Adjunctive abciximab improves outcomes during recanalization of totally occluded saphenous vein grafts using transluminal extraction atherectomy. Sullebarger JT, et al. **Catheter Cardiovasc Interv** 1999 Jan;46(1):107–10

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Antman EM, et al. **Circulation** 1999 Jun 1;99(21):2720–32

Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Klootwijk P, et al. **Circulation** 1998 Oct 6; 98(14):1358–64

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG

trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM, et al. **Circulation** 1999 Apr 20;99(15):1951-8

Images in cardiovascular medicine. Rapid dissolution of massive intracoronary thrombosis with platelet glycoprotein IIb/IIIa receptor inhibitor. Rerkpattanapipat P, et al. **Circulation** 1999 Jun 8;99(22):2965

Recombinant F(ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Debinski W, et al. **Clin Cancer Res** 1995 Sep;1(9):1015-22

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Cannon CP. **Clin Cardiol** 1999 Aug;22(8 Suppl):IV30-6 (31 ref.)

Digibind and free digoxin [letter; comment] Rainey P. **Clin Chem** 1999 May;45(5):719-21. Comment on: Clin Chem 1998 Sep;44(9):1947-50.

Abciximab. An updated review of its use in ischaemic heart disease [published erratum appears in Drugs 1999 Jan;57(1):91] Foster RH, et al. **Drugs** 1998 Oct;56(4):629-65 (163 ref.)

Antibodies against type II phospholipase A2 prevent renal injury due to ischemia and reperfusion in rats. Takasaki J, et al. **FEBS Lett** 1998 Dec 4;440(3):377-81

Platelet IIb/IIIa antagonists followed by delayed stent implantation. A new treatment for vein graft lesions containing massive thrombus. Robinson N, et al. **Heart** 1999 Apr;81(4):434-7

Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. Azar RR, et al. **J Am Coll Cardiol** 1998 Dec; 32(7):1996-2002

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. Ellis SG, et al. **J Am Coll Cardiol** 1998 Nov 15;32(6):1619-23

Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. Koch KC, et al. **J Am Coll Cardiol** 1999 Mar 15; 33(4):998-1004

The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Narins CR, et al. **J Am Coll Cardiol** 1999 Mar;33(3):647-53

Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph. Greilich PE, et al. **J Cardiothorac Vasc Anesth** 1999 Feb; 13(1):58-64

Efficacy of abciximab induced platelet blockade using a rapid point of care assay. Kereiakes DJ, et al. **J Thromb Thrombolysis** 1999 Jun;7(3):265-76

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Hamm CW, et al. **N Engl J Med** 1999 May 27;340(21):1623-9

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM, et al. **N Engl J Med** 1999 Jul 29;341(5):319-27

188Re DD-3B6/22 Fab' for use in therapy of ovarian cancer: labelling and animal studies. Schmidt PF, et al. **Nucl Med Biol** 1998 Oct;25(7):639-49

Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization [letter] Lempert TE, et al. **Stroke** 1999 Mar; 30(3):693-5

Comparative studies on the antiplatelet effects of a humanized anti-platelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions. Kuwahara M, et al. **Thromb Haemost** 1998 Jul;80(1):28-31

Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Brubacher JR, et al. **Toxicon** 1999 Jun;37(6):931-42

Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. Calderón-Aranda ES, et al. **Toxicon** 1999 May;37(5):771-82

Clinical safety of a polyvalent F(ab')2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l'Ouest) Investigators. Chippaux JP, et al. **Trans R Soc Trop Med Hyg** 1998 Nov-Dec; 92(6):657-62

[Abciximab: a new antiplatelet agent for use in coronary angioplasty] van den Brand MJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12;142(50):2728-32 (Eng. Abstr.) **(Dut)**

[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents] Pinton P. **Therapie** 1998 Jul-Aug; 53(4):341-7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies] **Internist (Berl)** 1998 Dec;39(12 Suppl Plattchena):1-4 **(Ger)**

[Therapy of unstable angina pectoris. Thrombocyte aggregation inhibition improves chances for survival] **Z Kardiol** 1998 Aug;87(8 Suppl Thrombozy):1-3 **(Ger)**

[Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA--treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA] Laubenthal FC, et al. **Z Kardiol** 1999 Feb;88(2):141-6 (Eng. Abstr.) **(Ger)**

[Initial experience with the use of abciximab in the salvage treatment of acute coronary thrombosis in the Hemodynamics Laboratory] Rubboli A, et al. **Cardiologia** 1998 Nov;43(11):1221-9 (Eng. Abstr.) **(Ita)**

[Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk] Matos V, et al. **Rev Port Cardiol** 1998 Dec;17(12):1001-5 (Eng. Abstr.) **(Por)**

[Abciximab (ReoPro) in primary angioplasty] Pereira H, et al. **Rev Port Cardiol** 1998 Nov;17(11):903-7 (Eng. Abstr.) **(Por)**

ULTRASTRUCTURE

Single-molecule imaging of human insulin receptor ectodomain and its Fab complexes. Tulloch PA, et al. **J Struct Biol** 1999 Mar;125(1):11-8

IMMUNOGLOBULINS, FC

see related
RECEPTORS, FC

BIOSYNTHESIS

Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. DeNardo SJ, et al. **Hybridoma** 1999 Feb;18(1):13-21

CHEMISTRY

Changes in the galactose content of IgG during humoral immune responses. Lastra GC, et al. **Autoimmunity** 1998; 28(1):25-30

Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Martin WL, et al. **Biochemistry** 1999 Sep 28; 38(39):12639-47

Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Sánchez LM, et al. **Biochemistry** 1999 Jul 20; 38(29):9471-6

Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Ghirlando R, et al. **Immunol Lett** 1999 May 3;68(1):47-52

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Jefferis R, et al. **Immunol Rev** 1998 Jun; 163:59-76 (93 ref.)

Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. Yamaguchi Y, et al. **J Biomol NMR** 1998 Oct; 12(3):385-94

The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling. Boehm MK, et al. **J Mol Biol** 1999 Mar 12;286(5):1421-47

GENETICS

Protein targeting in the analysis of learning and memory: a potential alternative to gene targeting. Gerlai R, et al. **Exp Brain Res** 1998 Nov;123(1-2):24-35

IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. Zheng XX, et al. **J Immunol** 1999 Oct 1; 163(7):4041-8

Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis [see comments] Isaka Y, et al. **Kidney Int** 1999 Feb;55(2):465-75 . Comment in: Kidney Int 1999 Feb;55(2):740-1.

The CTLA-4 gene is expressed in placental fibroblasts. Kaufman KA, et al. **Mol Hum Reprod** 1999 Jan;5(1):84-7

High level expression and secretion of Fc-X fusion proteins in mammalian cells. Lo KM, et al. **Protein Eng** 1998 Jun; 11(6):495-500

CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis. Gonzalez-Escribano MF, et al. **Tissue Antigens** 1999 Mar;53(3):296-300

Effect of adenovirus-mediated gene transfer with CTLA4-Ig gene in organ transplantation. Hayashi S, et al. **Transplant Proc** 1999 Aug;31(5):1944-5

IMMUNOLOGY

Changes in the galactose content of IgG during humoral immune responses. Lastra GC, et al. **Autoimmunity** 1998; 28(1):25-30

Fc-dependent immune regulation. Enhancement and/suppression directed by antibody-engaging functional Fc receptors (FcR). Bell CG. **Biochem Soc Trans** 1998 Aug; 26(3):S200

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. Alt M, et al. **FEBS Lett** 1999 Jul 2;454(1-2):90-4

Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. DeNardo SJ, et al. **Hybridoma** 1999 Feb;18(1):13-21

Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. Casares S, et al. **J Exp Med** 1999 Aug 16;190(4):543-53

Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Knechtle SJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):27S-28S

METABOLISM

Molecular modeling and experimental approaches toward designing a minimalist protein having Fc-binding activity of Staphylococcal protein A. Sengupta J, et al. **Biochem Biophys Res Commun** 1999 Mar 5;256(1):6-12

A minimized Fc binding peptide from protein A induces immunocyte proliferation and evokes Th1-type response in mice. Sinha P, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):141-7

Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Sánchez LM, et al. **Biochemistry** 1999 Jul 20; 38(29):9471-6

Binding of human IgG and F(ab')2 and Fc fragments to cultured trophoblast cells from human term placenta. Ugele B, et al. **Exp Cell Res** 1998 Oct 10;244(1):137-46

Immunoglobulin-derived polypeptides enter the regulated secretory pathway in AtT-20 cells. Castle AM, et al. **FEBS Lett** 1998 Nov 20;439(3):341-5

Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Ghirlando R, et al. **Immunol Lett** 1999 May 3;68(1):47-52

Expression and characterization of a DNase I-Fc fusion enzyme. Dwyer MA, et al. **J Biol Chem** 1999 Apr 2; 274(14):9738-43

Novel peptides binding to the Fc-portion of immunoglobulins obtained from a combinatorial phage display peptide library. Krook M, et al. **J Immunol Methods** 1998 Dec 1;221(1-2):151-7

Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Stabila PF, et al. **Nat Biotechnol** 1998 Dec;16(13):1357-60

Dissection of the protein G B1 domain binding site for human IgG Fc fragment. Sloan DJ, et al. **Protein Sci** 1999 Aug; 8(8):1643-8

PHARMACOLOGY

Soluble vascular cell adhesion molecule (VCAM)-Fc fusion protein induces leukotriene C4 secretion in platelet-activating factor-stimulated eosinophils. Tsuruta R, et al. **J Leukoc Biol** 1999 Jan;65(1):71-9

PHYSIOLOGY

IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Jefferis R, et al. **Immunol Rev** 1998 Jun; 163:59-76 (93 ref.)

Fc-mediated nonspecific binding between fibronectin-binding protein I of Streptococcus pyogenes and human immunoglobulins. Medina E, et al. **J Immunol** 1999 Sep 15;163(6):3396-402

THERAPEUTIC USE

Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy. Novak EJ, et al. **Transplantation** 1998 Dec 27;66(12):1732-5

IMMUNOGLOBULINS, GAMMA-CHAIN

ADVERSE EFFECTS

[Thiomersal in gammaglobulin for pregnant travellers may not be safe for the fetus. National Coordination Center for Travel Advisory] Schilthuis HJ, et al. **Ned Tijdschr Geneeskd** 1999 Jul 31;143(31):1622 (Eng. Abstr.) **(Dut)**

ANALYSIS

Electrophoretic analyses in a case of monoclonal gamma chain disease. Tissot JD, et al. **Electrophoresis** 1998 Jul; 19(10):1771-3

BLOOD

[Atypical chronic myeloid leukemia presenting with trilineage dysplasia and IgG (lambda) type monoclonal gammopathy] Itoh K, et al. **Rinsho Ketsueki** 1999 Feb; 40(2):129-34 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, et al. **Eur J Immunol** 1999 Jan;29(1):189-95

IMMUNOGLOBULINS, GAMMA-CHAIN

GENETICS

Characterization of CD40-dependent immunoglobulin class switching. Ström L, et al. **Scand J Immunol** 1999 May; 49(5):523-32

IMMUNOLOGY

Natural killer and T cells of innate and adaptive immunity: lymphoid compartments with different requirements for common gamma chain-dependent cytokines. Di Santo JP, et al. **Immunol Rev** 1998 Oct;165:29-38 (85 ref.)

Localization of splenic B cells activated for switch recombination by in situ hybridization with Igamma1 switch transcript and Rad51 probes. Peakman MC, et al. **J Immunol** 1998 Oct 15;161(8):4008-15

Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Cochet O, et al. **Mol Immunol** 1998 Dec;35(17):1097-110

METABOLISM

Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Kovacs H, et al. **Biochemistry** 1998 Dec 22;37(51):17865-74

N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, et al. **Eur J Immunol** 1999 Jan;29(1):189-95

Loss of SDF-1 receptor expression during positive selection in the thymus. Suzuki G, et al. **Int Immunol** 1998 Aug; 10(8):1049-56

PHYSIOLOGY

Activation of Fc epsilon RI inhibits the pyruvate kinase through direct interaction with the gamma-chain. Oak MH, et al. **Int Arch Allergy Immunol** 1999 Jun;119(2):95-100

IMMUNOGLOBULINS, HEAVY-CHAIN

see related

HEAVY CHAIN DISEASE

Fit for life in the immune system? Surrogate L chain tests H chains that test L chains. Melchers F. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2571-3

[Biclonal gammopathy] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):540-2 (9 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Production of high affinity autoantibodies in autoimmune New Zealand Black/New Zealand white F1 mice targeted with an anti-DNA heavy chain. Friedmann D, et al. **J Immunol** 1999 Apr 15;162(8):4406-16

BIOSYNTHESIS

Localization of a cyclopentenone prostaglandin to the endoplasmic reticulum and induction of BiP mRNA. Takahashi S, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):35-42

Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. Kim NS, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):679-88

Expression of IgH chain genes in antibody response to ragweed and purified Amb a 1: evidence for differential regulation of isotype production. Allauzen S, et al. **Mol Immunol** 1999 Jun;36(9):587-98

Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Gao C, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6025-30

CHEMISTRY

Occurrence of heavy chain of 7S IgM half-molecule whose NH2-terminal sequence is identical with that of kappa light chain sequence in patients with Waldenstrom macroglobulinemia. Imoto M, et al. **Clin Chim Acta** 1999 Apr;282(1-2):77-88

H3-rules: identification of CDR-H3 structures in antibodies. Shirai H, et al. **FEBS Lett** 1999 Jul 16;455(1-2):188-97

Preferred CDRH3 lengths for antibodies with defined specificities. Johnson G, et al. **Int Immunol** 1998 Dec; 10(12):1801-5

Algorithmic determination of core positions in the VL and VH domains of immunoglobulin molecules. Gelfand I, et al. **J Comput Biol** 1998 Fall;5(3):467-77

The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge. Langedijk AC, et al. **J Mol Biol** 1998;283(1):95-110

BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Lee YK, et al. **Mol Biol Cell** 1999 Jul;10(7):2209-19

Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Hanes J, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14130-5

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Atwell JL, et al. **Protein Eng** 1999 Jul;12(7):597-604

Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding. de Haard HJ, et al. **Protein Eng** 1998 Dec; 11(12):1267-76

A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Decanniere K, et al. **Structure** 1999 Apr 15;7(4):361-70

GENETICS

Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin disease. Izban KF, et al. **Am J Clin Pathol** 1998 Nov;110(5):599-606

How reliable is histologic examination of bone marrow trephine biopsy specimens for the staging of non-Hodgkin lymphoma? A study of hairy cell leukemia and mantle cell lymphoma involvement of the bone marrow trephine specimen by histologic, immunohistochemical, and polymerase chain reaction techniques. Pittaluga S, et al. **Am J Clin Pathol** 1999 Feb;111(2):179-84

Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation [see comments] Matolcsy A, et al. **Am J Pathol** 1998 Nov;153(5):1609-14. Comment in: Am J Pathol 1998 Nov;153(5):1341-6.

Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells [comment] Müller-Hermelink HK, et al. **Am J Pathol** 1998 Nov;153(5):1341-6 (59 ref.). Comment on: Am J Pathol 1998 Nov;153(5):1609-14.

Susceptibility to multiple sclerosis and the immunoglobulin heavy chain gene cluster [letter] Feakes R, et al. **Ann Neurol** 1998 Dec;44(6):984

Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes. Botsonis T, et al. **Anticancer Res** 1999 May-Jun; 19(3B):2211-20

Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogeneous IgH gene rearrangement. Buggage RR, et al. **Arch Ophthalmol** 1999 Sep;117(9):1239-42

Localization of a cyclopentenone prostaglandin to the endoplasmic reticulum and induction of BiP mRNA. Takahashi S, et al. **Biochem J** 1998 Oct 1;335 (Pt 1):35-42

VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Aarts WM, et al. **Blood** 1998 Nov 15; 92(10):3857-64

Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Bräuninger A, et al. **Blood** 1999 Apr 15; 93(8):2679-87

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Chesi M, et al. **Blood** 1998 Nov 1;92(9):3025-34

Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization. Gokmen E, et al. **Blood** 1998 Oct 15;92(8):2802-14

Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments] Hamblin TJ, et al. **Blood** 1999 Sep 15; 94(6):1848-54. Comment in: Blood 1999 Sep 15;94(6):1837-9.

Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Morrison AM, et al. **Blood** 1998 Nov 15;92(10):3865-78

Mutational status of Ig V(H) genes provides clinically valuable information in B-cell chronic lymphocytic leukemia [comment] Naylor M, et al. **Blood** 1999 Sep 15; 94(6):1837-9. Comment on: Blood 1999 Sep 15;94(6):1840-7. Comment on: Blood 1999 Sep 15;94(6):1848-54.

V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Sahota SS, et al. **Blood** 1999 Aug 1;94(3):1070-6

Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Szczepański T, et al. **Blood** 1999 Jun 15; 93(12):4079-85

A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Szczepek AJ, et al. **Blood** 1998 Oct 15; 92(8):2844-55

V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Thompsett AR, et al. **Blood** 1999 Sep 1;94(5):1738-46

DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Vaandrager JW, et al. **Blood** 1998 Oct 15; 92(8):2871-8

Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease. Vockerodt M, et al. **Blood** 1998 Oct 15;92(8):2899-907

FISH detection of chromosome 14q32/IgH translocations: evaluation in follicular lymphoma. Rack KA, et al. **Br J Haematol** 1998 Nov;103(2):495-504

Molecular analysis of bcl-1/IgH junctional sequences in mantle cell lymphoma: potential mechanism of the t(11;14) chromosomal translocation. Stamatopoulos K, et al. **Br J Haematol** 1999 Apr;105(1):190-7

Immunoglobulins D and M multiple myeloma variants are heavily mutated. Juge-Morineau N, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2501-6

Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation. Elagib KE, et al. **Clin Exp Immunol** 1999 Aug;117(2):388-94

Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Krenn V, et al. **Clin Exp Immunol** 1999 Jan;115(1):168-75

Somatic mutation of immunoglobulin V(H)6 genes in human infants. Ridings J, et al. **Clin Exp Immunol** 1998 Oct; 114(1):33-9

Detection of immunoglobulin heavy chain gene rearrangements by polymerase chain reaction analysis on lymph node imprints and fine-needle aspirate smears: a comparison of five different imprint preparations. Torlakovic E, et al. **Diagn Cytopathol** 1999 Jun;20(6):333-8

Polymerase chain reaction-single-strand conformational polymorphism analysis of antigen receptor rearrangements in monitoring therapeutic effect in childhood ALL. Thunberg U, et al. **Diagn Mol Pathol** 1998 Jun;7(3):146-51

Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. Muto A, et al. **EMBO J** 1998 Oct 1;17(19):5734-43

V(H) gene family utilization in different B-cell lymphoma subgroups. Rosenquist R, et al. **Eur J Haematol** 1999 Feb; 62(2):123-8

Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia. Rosenquist R, et al. **Eur J Haematol** 1999 Sep;63(3):171-9

V(H) gene replacement occurs in the spleen and bone marrow of non-autoimmune quasi-monoclonal mice. Bertrand FE, et al. **Eur J Immunol** 1998 Oct;28(10):3362-70

Synergies between regulatory elements of the immunoglobulin heavy chain locus and its palindromic 3' locus control region. Chauveau C, et al. **Eur J Immunol** 1998 Oct;28(10):3048-56

Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. Dörner T, et al. **Eur J Immunol** 1998 Oct; 28(10):3384-96

Accessibility changes across the mouse Igh-V locus during B cell development. Haines BB, et al. **Eur J Immunol** 1998 Dec;28(12):4228-35

Expression of an immunoglobulin heavy chain transgene in macrophage as well as lymphocyte lineages in vivo. Pasare C, et al. **Eur J Immunol** 1999 Apr;29(4):1219-27

Restriction-PCR fingerprinting of the immunoglobulin VH repertoire: direct detection of an immune response and global analysis of B cell clonality. White HN. **Eur J Immunol** 1998 Oct;28(10):3268-79

AML and Ets proteins regulate the I alpha1 germ-line promoter. Xie XQ, et al. **Eur J Immunol** 1999 Feb; 29(2):488-98

The human immunoglobulin heavy variable genes. Pallarès N, et al. **Exp Clin Immunogenet** 1999;16(1):36-60 (61 ref.)

The human immunoglobulin heavy diversity (IGHD) and joining (IGHJ) segments. Ruiz M, et al. **Exp Clin Immunogenet** 1999;16(3):173-84

Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. Chardès T, et al. **FEBS Lett** 1999 Jun 11;452(3):386-94

Insertion of the IgH locus 3' regulatory palindrome in expression vectors warrants sure and efficient expression in stable B cell transfectants. Chauveau C, et al. **Gene** 1998 Nov 19;222(2):279-85

The region 3' to Calpha1 gene of human IG heavy chain displays a polymorphic duplicated sequence and encodes an RNA associated with polysomes. Frezza D, et al. **Gene** 1998 Sep 28;219(1-2):19-24

Selectable in-vivo recombination to increase antibody library size--an improved phage display vector system. Zahra DG, et al. **Gene** 1999 Feb 4;227(1):49-54

High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Avet-Loiseau H, et al. **Genes Chromosomes Cancer** 1999 Jan;24(1):9-15

Vector-hexamer PCR isolation of all insert ends from a YAC contig of the mouse Igh locus. Herring CD, et al. **Genome Res** 1998 Jun;8(6):673-81

WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma [published erratum appears in Hum Mol Genet 1998 Sep;7(9):1527] Stec I, et al. **Hum Mol Genet** 1998 Jul;

7(7):1071-82
Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR/DGGE. Brady SP, et al. **Hum Pathol** 1999 Feb;30(2):130-6
Multiple lymphomatous polyposis of the gastrointestinal tract is a heterogenous group that includes mantle cell lymphoma and follicular lymphoma: analysis of somatic mutation of immunoglobulin heavy chain gene variable region. Hashimoto Y, et al. **Hum Pathol** 1999 May;30(5):581-7
Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Miranda RN, et al. **Hum Pathol** 1999 Mar; 30(3):306-12
ETS protein-dependent accessibility changes at the immunoglobulin mu heavy chain enhancer. Nikolajczyk BS, et al. **Immunity** 1999 Jul;11(1):11-20
Organization of the equine immunoglobulin heavy chain constant region genes; III. Alignment of c mu, c gamma, c epsilon and c alpha genes. Wagner B, et al. **Immunobiology** 1998 Jul;199(1):105-18
A long form of the skate IgX gene exhibits a striking resemblance to the new shark IgW and IgNARC genes. Anderson MK, et al. **Immunogenetics** 1999 Jan;49(1):56-67
Ig heavy chain of the sturgeon Acipenser baeri: cDNA sequence and diversity. Lundqvist ML, et al. **Immunogenetics** 1998 Nov-Dec;48(6):372-82
Opposite orientation of the alpha- and upsilon-chain constant region genes in the immunoglobulin heavy chain locus of the duck. Magor KE, et al. **Immunogenetics** 1999 Jul; 49(7-8):692-5
Analysis of clonal diversity in mouse immunoglobulin heavy chain genes selected for size of the antigen combining site. Raaphorst FM, et al. **Immunol Invest** 1998 Dec; 27(6):355-65
The impact of ancestral tetraploidy on antibody heterogeneity in salmonid fishes. Hordvik I. **Immunol Rev** 1998 Dec;166:153-7 (28 ref.)
Antibodies of sharks: revolution and evolution. Marchalonis JJ, et al. **Immunol Rev** 1998 Dec;166:103-22 (109 ref.)
Transcriptional enhancers and the evolution of the IgH locus. Magor BG, et al. **Immunol Today** 1999 Jan;20(1):13-7 (35 ref.)
Strong intrinsic biases towards mutation and conservation of bases in human IgVH genes during somatic hypermutation prevent statistical analysis of antigen selection. Dunn-Walters DK, et al. **Immunology** 1998 Nov; 95(3):339-45
The effects of E mu, 3'alpha (hs 1,2) and 3'kappa enhancers on mutation of an Ig-VDJ-Cgamma2a Ig heavy gene in cultured B cells. Lin MM, et al. **Int Immunol** 1998 Aug; 10(8):1121-9
Ialpha exon-replacement mice synthesize a spliced HPRT-C(alpha) transcript which may explain their ability to switch to IgA. Inhibition of switching to IgG in these mice. Qiu G, et al. **Int Immunol** 1999 Jan;11(1):37-46
An expressed neo(r) cassette provides required functions of the 1gamma2b exon for class switching. Seidl KJ, et al. **Int Immunol** 1998 Nov;10(11):1683-92
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Fagerberg J, et al. **Int J Cancer** 1999 Mar 1;80(5):671-80
Immunoglobulin VH gene expression among extranodal marginal zone B-cell lymphomas of the ocular adnexa. Coupland SE, et al. **Invest Ophthalmol Vis Sci** 1999 Mar; 40(3):555-62
Corneal transplantation in antibody-deficient hosts. Goslings WR, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):250-3
Increased utilization of the VH6 gene family in patients with autoimmune idiopathic thrombocytopenic purpura. van Dijk-Härd I, et al. **J Autoimmun** 1999 Feb;12(1):57-63
Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line. Takami Y, et al. **J Biol Chem** 1999 Aug 20; 274(34):23977-90
Role of the intronic elements in the endogenous immunoglobulin heavy chain locus. Either the matrix attachment regions or the core enhancer is sufficient to maintain expression. Wiersma EJ, et al. **J Biol Chem** 1999 Feb 19;274(8):4858-62
B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development. Lam KP, et al. **J Exp Med** 1999 Aug 16;190(4):471-7
Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. Manis JP, et al. **J Exp Med** 1998 Oct 19;188(8):1421-31
The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus [see comments] Matsuda F, et al. **J Exp Med** 1998 Dec 7; 188(11):2151-62. Comment in: J Exp Med 1998 Dec 7;188(11):1973-5.
Rearrangement and expression of immunoglobulin light chain genes can precede heavy chain expression during normal B cell development in mice. Novobrantseva TI, et al. **J Exp Med** 1999 Jan 4;189(1):75-88
Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. Dörner T, et al. **J Immunol** 1999 Jul 15; 163(2):1027-36
Structure and genomic organization of a second cluster of immunoglobulin heavy chain gene segments in the channel catfish. Ghaffari SH, et al. **J Immunol** 1999 Feb 1; 162(3):1519-29
AIDS primary central nervous system lymphoma: molecular analysis of the expressed VH genes and possible implications for lymphomagenesis. Julien S, et al. **J Immunol** 1999 Feb 1;162(3):1551-8
Ig heavy chain complex-linked genes influence the immunc response in a murine cryptococcal infection. Lovchik JA, et al. **J Immunol** 1999 Oct 1;163(7):3907-13
B cell deletion, anergy, and receptor editing in "knock in" mice targeted with a germline-encoded or somatically mutated anti-DNA heavy chain. Pewzner-Jung Y, et al. **J Immunol** 1998 Nov 1;161(9):4634-45
Biased VH gene usage in early lineage human B cells: evidence for preferential Ig gene rearrangement in the absence of selection. Rao SP, et al. **J Immunol** 1999 Sep 1;163(5):2732-40
Ig heavy chain expression and class switching in vitro from an allele lacking the 3' enhancers DNase I-hypersensitive hs3A and hs1,2. Saleque S, et al. **J Immunol** 1999 Mar 1;162(5):2791-803
The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites. Schaffer A, et al. **J Immunol** 1999 May 1;162(9):5327-36
Gene conversion and hypermutation during diversification of VH sequences in developing splenic germinal centers of immunized rabbits. Schiaffella E, et al. **J Immunol** 1999 Apr 1;162(7):3984-95
Analyses of single B cells by polymerase chain reaction reveal rearranged VH with germline sequences in spleens of immunized adult rabbits: implications for B cell repertoire maintenance and renewal. Sehgal D, et al. **J Immunol** 1998 Nov 15;161(10):5347-56
IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. Shiokawa S, et al. **J Immunol** 1999 May 15;162(10):6060-70
The dual phases of the response to neonatal exposure to a VH family-restricted staphylococcal B cell superantigen. Silverman GJ, et al. **J Immunol** 1998 Nov 15; 161(10):5720-32
Characteristics of sequences around individual nucleotide substitutions in IgVH genes suggest different GC and AT mutators. Spencer J, et al. **J Immunol** 1999 Jun 1; 162(11):6596-601
Switch recombination in a transfected plasmid occurs preferentially in a B cell line that undergoes switch recombination of its chromosomal Ig heavy chain genes. Stavnezer J, et al. **J Immunol** 1999 Aug 15;163(4):2028-40
Antibody repertoire development in fetal and neonatal piglets. I. Four VH genes account for 80 percent of VH usage during 84 days of fetal life. Sun J, et al. **J Immunol** 1998 Nov 1;161(9):5070-8
Germline structure and differential utilization of Igha and Ighb VH10 genes. Whitcomb EA, et al. **J Immunol** 1999 Feb 1;162(3):1541-50
Antigen-induced somatic diversification of rabbit IgH genes: gene conversion and point mutation. Winstead CR, et al. **J Immunol** 1999 Jun 1;162(11):6602-12
B lymphocyte selection and age-related changes in VH gene usage in mutant Alicia rabbits. Zhu X, et al. **J Immunol** 1999 Sep 15;163(6):3313-20
In situ hybridization analysis of immunoglobulin heavy chain variable gene expression with family specific oligonucleotide probes. Rundle CH, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):31-52
DNase I hypersensitive sites in human I epsilon region of immunoglobulin heavy chain genes abnormally induced by interleukin-4 in B-lymphocytes of atopic patients with high levels of serum IgE. Kondo N, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):234-8
An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. Reiter Y, et al. **J Mol Biol** 1999 Jul 16;290(3):685-98
Rearranged patterns of IgH and TcR gamma genes in patients with acute lymphoblastic leukemia. Li S, et al. **J Tongji Med Univ** 1997;17(4):206-8
Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma. Nakamura N, et al. **Lab Invest** 1999 Aug;79(8):925-33
Aberrant rearrangements of the immunoglobulin heavy chain switch region in chronic B-cell leukemia. Crossen PE, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):559-65
Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia. Spencer A, et al. **Leuk Lymphoma** 1999 Jan; 32(3-4):299-307
Clonal analysis of B-cell leukemias and lymphomas using the polymerase chain reaction for the third complementarity determining region of the IgH gene: a study of 75 cases from Nagasaki Japan. Sugahara K, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):387-93
Primary diffuse large B cell lymphoma of the stomach: analysis of somatic mutations in the rearranged immunoglobulin heavy chain variable genes indicates antigen selection. Driessen A, et al. **Leukemia** 1999 Jul; 13(7):1085-92
Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Pott C, et al. **Leukemia** 1998 Oct;12(10):1630-7
Selection of immunoglobulin diversity gene reading frames in B cell lymphoproliferative disorders. Stamatopoulos K, et al. **Leukemia** 1999 Apr;13(4):601-4
Splenic marginal zone cell lymphoma associated with clonal B-cell populations showing different immunoglobulin heavy chain sequences. Elenitoba-Johnson KS, et al. **Mod Pathol** 1998 Sep;11(9):905-13
Evidence that a single replication fork proceeds from early to late replicating domains in the IgH locus in a non-B cell line. Ermakova OV, et al. **Mol Cell** 1999 Mar; 3(3):321-30
Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Gabrea A, et al. **Mol Cell** 1999 Jan;3(1):119-23
Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation. Takagaki Y, et al. **Mol Cell** 1998 Dec;2(6):761-71
The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes. Madisen L, et al. **Mol Cell Biol** 1998 Nov;18(11):6281-92
Temporal expression of a V(H) promoter-Cmu transgene linked to the IgH HS1,2 enhancer. Andersson T, et al. **Mol Immunol** 1999 Jan;36(1):19-29
Motif-specific probes identify individual genes and detect somatic mutations. Glas AM, et al. **Mol Immunol** 1999 Jun; 36(9):599-610
Molecular analysis of the heavy chain of antibodies that recognize the capsular polysaccharide of Neisseria meningitidis in hu-PBMC reconstituted SCID mice and in the immunized human donor. Smithson SL, et al. **Mol Immunol** 1999 Feb;36(2):113-24
The role of components of recombination signal sequences in immunoglobulin gene segment usage: a V81x model. Larijani M, et al. **Nucleic Acids Res** 1999 Jun 1; 27(11):2304-9
Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions. Sakai E, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1526-31
Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites. Seidl KJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2262-7
Position-dependent inhibition of class-switch recombination by PGK-neor cassettes inserted into the immunoglobulin heavy chain constant region locus. Seidl KJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3000-5
Induction of Ig light chain gene rearrangement in heavy chain-deficient B cells by activated Ras. Shaw AC, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2239-43
Organisation of the equine immunoglobulin constant heavy chain genes. II. Equine cgamma genes. Overesch G, et al. **Vet Immunol Immunopathol** 1998 Dec 11;66(3-4):273-87
[Amplification and sequencing of heavy chain variable region (VH) gene of a human monoclonal antibody (CM-1) with specificity to breast cancer] Chen L, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):150-3 (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. van der Linden RH, et al. **Biochim Biophys Acta** 1999 Apr 12; 1431(1):37-46
Ontogeny of lymphoid organs and immunoglobulin producing cells in Atlantic cod (Gadus morhua L.). Schrøder MB, et al. **Dev Comp Immunol** 1998 Sep-Dec; 22(5-6):507-17
Anti-idiotypic monoclonal Ig specific for an anti-laminin Ig heavy chain transgene variable region. Foster MH, et al. **Hybridoma** 1998 Aug;17(4):323-9
Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis. Manoutcharian K, et al. **Infect Immun** 1999 Sep; 67(9):4764-70
The J558 VH CDR3 region contributes little to antibody avidity; however, it is the recognition element for cognate T cell control of the alpha(1-->3) dextran-specific antibody response. Clemens A, et al. **Int Immunol** 1998 Dec;10(12):1931-42
The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. Kaminski MJ, et al. **J Biol Chem** 1999 Feb 26; 274(9):5597-604
Open sandwich ELISA with V(H)-/V(L)-alkaline phosphatase fusion proteins. Suzuki C, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):171-84
Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. de Wildt RM, et al. **J Mol Biol** 1999 Jan 22;285(3):895-901
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Lee HS, et al. **Mol Immunol** 1999 Jan;36(1):61-71
Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Transue TR, et al. **Proteins** 1998 Sep 1;32(4):515-22

Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Potter KN, et al. **Scand J Immunol** 1999 Jul;50(1):14–20

Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma. Wen YJ, et al. **Scand J Immunol** 1999 Sep;50(3):296–301

METABOLISM

Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Kovacs H, et al. **Biochemistry** 1998 Dec 22;37(51):17865–74

Improving the efficacy of antibody–interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Gillies SD, et al. **Cancer Res** 1999 May 1;59(9):2159–66

The in vivo association of BiP with newly synthesized proteins is dependent on the rate and stability of folding and not simply on the presence of sequences that can bind to BiP. Hellman R, et al. **J Cell Biol** 1999 Jan 11; 144(1):21–30

Secretory immunoglobulin A heavy chain presents Galbeta1-3GalNAc binding structures for Actinomyces naeslundii genospecies 1. Bratt P, et al. **J Dent Res** 1999 Jun;78(6):1238–44

DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain. Chen Y, et al. **J Immunol** 1999 Apr 15;162(8):4663–70

Mu-surrogate light chain physicochemical interactions of the human preB cell receptor: implications for VH repertoire selection and cell signaling at the preB cell stage. Gauthier L, et al. **J Immunol** 1999 Jan 1;162(1):41–50

Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection. Lovchik JA, et al. **J Immunol** 1999 Oct 1;163(7):3907–13

Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. Patella V, et al. **J Immunol** 1998 Nov 15;161(10):5647–55

Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain alpha3 domain. Suh WK, et al. **J Immunol** 1999 Feb 1;162(3):1530–40

BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Lee YK, et al. **Mol Biol Cell** 1999 Jul;10(7):2209–19

Replacements in the exposed loop of the T15 antibody VH CDR2 affect carrier recognition of PC-containing pathogens. Brown M, et al. **Mol Immunol** 1999 Feb; 36(3):205–11

Peptide ligand structure influences the exchange of beta2-microglobulin by cell surface Kb. Cook JR, et al. **Mol Immunol** 1998 Oct;35(14–15):929–34

Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. Potter KN, et al. **Mol Immunol** 1998 Dec; 35(18):1179–87

PHARMACOLOGY

Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1. Navolotskaya EV, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):758–64

Inhibition of cytoplasmic antigen, glucose- 6-phosphate dehydrogenase, by VH-CH1, an intracellular Fd fragment antibody derived from a semisynthetic Fd fragment phage display library. Mulligan-Kehoe MJ, et al. **J Mol Biol** 1999 May 28;289(1):41–55

PHYSIOLOGY

Downregulation of the expression of the main immunoglobulin V(H) family in HIV-infected patients: modulation by triple combination therapy [letter] David D, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):315–6

IMMUNOGLOBULINS, INTRAVENOUS

Gastrointestinal involvement in Behçet's syndrome [letter] Beales IL. **Am J Gastroenterol** 1998 Dec;93(12):2633

A chromatographic method for the production of a human immunoglobulin G solution for intravenous use. Tanaka K, et al. **Braz J Med Biol Res** 1998 Nov;31(11):1375–81

A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Hern S, et al. **Clin Exp Dermatol** 1998 Jul;23(4):185–8

Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Jindal KK. **Kidney Int Suppl** 1999 Jun;70:S33–40 (27 ref.)

Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Sherer Y, et al. **Lupus** 1999;8(4):324–7

Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Sater RA, et al. **Neurology** 1998 Dec;51(6 Suppl 5):S9–15 (97 ref.)

Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Nishikawa M, et al. **Pediatr Neurol** 1999 Aug;21(2):583–6

Protective capacity of a IgM/IgA-enriched polyclonal immunoglobulin-G preparation in endotoxemia. Oesser S, et al. **Res Exp Med (Berl)** 1999 Apr;198(6):325–39

Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome [editorial] Hughes RA. **Ther Apher** 1997 May;1(2):129–30 (14 ref.)

Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation [published erratum appears in Ther Alpher 1997 Nov;1(4):388–9] Robinson JA, et al. **Ther Apher** 1997 May;1(2):147–51

Sequential plasmapheresis and intravenous immunoglobulin therapy for refractory myasthenia gravis: case report. Yeh JH, et al. **Ther Apher** 1999 Aug;3(3):271–4

Hepatitis G virus in intramuscular and intravenous immunoglobulin products manufactured in Europe [letter] Cristiano K, et al. **Transfusion** 1999 Apr;39(4):428

[Therapeutic sera and immunoglobulins available in France as of 1 January 1998] Roger I, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):477–83 (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Alpay F, et al. **Acta Paediatr** 1999 Feb;88(2):216–9

Successful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. Chuhjo T, et al. **Am J Hematol** 1999 Mar; 60(3):222–4

Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Majluf-Cruz A, et al. **Am J Hematol** 1998 Oct;59(2):127–32

High-dose intravenous immunoglobulin in cutaneous lupus erythematosus [letter] Généreau T, et al. **Arch Dermatol** 1999 Sep;135(9):1124–5

Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Sullivan KM, et al. **Biol Blood Marrow Transplant** 1998; 4(1):20–6

Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Abdel-Mageed A, et al. **Bone Marrow Transplant** 1999 May;23(9):929–32

Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma [see comments] Landwehr LP, et al. **Chest** 1998 Nov;114(5):1349–56. Comment in: Chest 1999 Jun;116(1):267–8.

Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system. Aukrust P, et al. **Clin Exp Immunol** 1999 Jan;115(1):136–43

In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Sewell WA, et al. **Clin Exp Immunol** 1999 Jun;116(3):509–15

Intrauterine anemia due to parvovirus B19: successful treatment with intravenous immunoglobulins [letter] Rugolotto S, et al. **Haematologica** 1999 Jul;84(7):668–9

Tetanus: still "inexcusable". Mysliwiec AG, et al. **Hawaii Med J** 1998 Nov;57(11):689–90

Massive immunoglobulin treatment in women with four or more recurrent spontaneous primary abortions of unexplained aetiology. Yamada H, et al. **Hum Reprod** 1998 Sep;13(9):2620–3

Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Levy Y, et al. **Int Arch Allergy Immunol** 1999 Jul;119(3):231–8

High-dose immunoglobulin G therapy for fulminant myocarditis. Takeda Y, et al. **Jpn Circ J** 1998 Nov; 62(11):871–2

I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Sharief MK, et al. **Neurology** 1999 Jun 10;52(9):1833–8

Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Burns JC, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1144–8

Effectiveness of RSV-IVIG in premature infants: success in the home [letter; comment] Hayes C, et al. **Pediatrics** 1999 Mar;103(3):698–9. Comment on: Pediatrics 1998 Feb;101(2):320–1.

Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Ginevri F, et al. **Transpl Int** 1998;11 Suppl 1:S130–4

[Comment on the contribution by Alexander H. Enk and Jürgen Knop. "Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins" (letter)] Luther H, et al. **Hautarzt** 1999 May;50(5):372–4 **(Ger)**

[The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy] Kubori T, et al. **No To Shinkei** 1999 Feb; 51(2):127–35 (Eng. Abstr.) **(Jpn)**

[Effect of human immunoglobulin preparation in resistance to immunosuppressive therapy in a male patient with nephrotic syndrome] Moskaleva ES, et al. **Ter Arkh** 1999; 71(6):75–6 **(Rus)**

ADVERSE EFFECTS

Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Mathy I, et al. **Acta Neurol Belg** 1998 Dec;98(4):347–51 (34 ref.)

Recurrent lymphocytic pleural effusion after intravenous immunoglobulin [letter] Bolanos-Meade J, et al. **Am J Hematol** 1999 Mar;60(3):248–9

Acute renal failure after large doses of intravenous immune globulin. Haskin JA, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):800–3

Facial vasculitic rash associated with intravenous immunoglobulin. Howse M, et al. **BMJ** 1998 Nov 7; 317(7168):1291

Coincidence of neonatal alloimmune thrombocytopenia and maternal anti-D immunization: case report [letter] Klüter H, et al. **Br J Haematol** 1998 Sep;102(5):1383–4

Immune globulin intravenous products--notice to hospitals [news] Hogan V. **CMAJ** 1999 Apr 6;160(7):1051–2, 1055–6 **(Eng, Fre)**

Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disorders. Stangel M, et al. **Eur Neurol** 1998 Oct;40(3):173–4

Compatibility problems after intravenous immunoglobulin--a case report. Sulochana PV, et al. **Indian J Pathol Microbiol** 1998 Oct;41(4):495–8

A likelihood-based method of identifying contaminated lots of blood product. Reilly M, et al. **Int J Epidemiol** 1999 Aug;28(4):787–92

Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. Berkovitch M, et al. **Int J Immunopharmacol** 1999 Jun; 21(6):411–5

Lichenoid/Interface cutaneous eruptions to IVIg with the primary infusion may be related to the re-regulation of anti-idiotype network. Smith KJ, et al. **J Cutan Med Surg** 1998 Oct;3(2):96–101

Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985–1998. **MMWR Morb Mortal Wkly Rep** 1999 Jun 25;48(24):518–21

The renal risks of high-dose intravenous immunoglobulin treatment [editorial] Stahl M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2182–5 (24 ref.)

Prolonged acute renal failure after i.v. immunoglobulin therapy in the refeeding phase of anorexia nervosa. Stahl M, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2364–7

Henoch-Schönlein nephritis. Adverse effect of treatment with intravenous immunoglobulin [letter] Villarreal IR, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):795–7

Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Boyce TG, et al. **Pediatr Infect Dis J** 1998 Nov; 17(11):1054–6

[Unusual skin reaction after intravenous infusion of polyvalent immunoglobulins: 3 case reports (letter)] Leclech C, et al. **Presse Med** 1999 Mar 13;28(10):531 **(Fre)**

[Aseptic meningitis during treatment with very low doses of intravenous immunoglobulins (letter)] Attout H, et al. **Rev Med Interne** 1998 Feb;19(2):140–1 **(Fre)**

[Acute renal insufficiency and cerebral infarction during high-dose intravenous immunoglobulin therapy] Chatot-Henry C, et al. **Rev Med Interne** 1998 Dec; 19(12):914–6 (Eng. Abstr.) **(Fre)**

[Acute renal failure due to immunoglobulins (letter)] Peyrade F, et al. **Rev Med Interne** 1998 Oct;19(10):746–7 **(Fre)**

ANALYSIS

[Anti-verotoxin-neutralizing antibody in intravenous gammaglobulin preparations] Adachi E, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):808–12 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

[Distribution of IgG subclasses and their biological activity in bioglobulin] Bucholc B, et al. **Med Dosw Mikrobiol** 1998; 50(1–2):105–13 (Eng. Abstr.) **(Pol)**

ECONOMICS

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants [see comments] Joffe S, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):419–27. Comment in: Pediatrics 1999 Sep;104(3 Pt 1):559–60.

RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? [comment] Moler FW. **Pediatrics** 1999 Sep;104(3 Pt 1):559–60. Comment on: Pediatrics 1999 Sep;104(3 Pt 1):419–27.

IMMUNOLOGY

Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Teeling JL, et al. **Clin Exp Immunol** 1998 Nov;114(2):264–70

Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2 dimers, monomers, and monovalent F(ab). Mahoney RJ, et al. **Hum Immunol** 1999 Jun;60(6):492–9

Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg).

Macias A, et al. **Hybridoma** 1999 Jun;18(3):263–72
Atypical C-ANCA following high dose intravenous immunoglobulin. Jolles S, et al. **J Clin Pathol** 1999 Mar; 52(3):177–80
Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Näsman Björk I, et al. **Scand J Immunol** 1999 Jul; 50(1):73–82
Anti-Rh D activity of commercial intravenous immunoglobulin preparations. Turner CE, et al. **Vox Sang** 1999;76(1):55–8

ISOLATION & PURIFICATION

Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Troccoli NM, et al. **Biologicals** 1998 Dec;26(4):321–9
New methods for inactivation of lipid-enveloped and non-enveloped viruses. Miekka SI, et al. **Haemophilia** 1998 Jul;4(4):402–8
Virus reduction in the preparation of intravenous immune globulin: in vitro experiments. Chandra S, et al. **Transfusion** 1999 Mar;39(3):249–57
GB virus C/hepatitis G virus and intravenous immunoglobulins. Nübling C, et al. **Vox Sang** 1998; 75(3):189–92

PHARMACOKINETICS

Technetium-99m labelling of human immunoglobulin and preliminary clinical evaluation in tumour patients. Varvarigou AD, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun; 23(2):267–72
Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299–305

PHARMACOLOGY

Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Xu C, et al. **Am J Pathol** 1998 Oct;153(4):1257–66
Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Reagan WJ, et al. **Am J Vet Res** 1998 Dec;59(12):1568–74
Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Rieben R, et al. **Blood** 1999 Feb 1;93(3):942–51
Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Vassilev TL, et al. **Blood** 1999 Jun 1;93(11):3624–31
Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model. Bruss JB, et al. **Clin Diagn Lab Immunol** 1999 Jul;6(4):464–70
Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. Salmun LM, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):810–5
Intravenous immunoglobulin inhibits IgE production in human B lymphocytes. Sigman K, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):421–7
Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. Spahn JD, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):421–6
Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. Stangel M, et al. **J Neuroimmunol** 1999 May 3;96(2):228–33
Hepatitis C virus genotypes and the influence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients. Rodrigues A, et al. **Transpl Int** 1998;11 Suppl 1:S115–8
Presence of IgG exhibiting a morphine-like activity in therapeutic intravenous immunoglobulins. Macé G, et al. **Transplant Proc** 1998 Dec;30(8):3949
[Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome] Marcinkiewicz J, et al. **Przegl Lek** 1998;55(11):611–3 (27 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

[Distribution of IgG subclasses and their biological activity in bioglobulin] Bucholc B, et al. **Med Dosw Mikrobiol** 1998; 50(1–2):105–13 (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Severe steroid-dependent asthma with IgG-2 deficiency and recurrent sinusitis: response to treatment with high-dose intravenous immunoglobulin. Loza Cortina C. **Allergol Immunopathol (Madr)** 1999 May-Jun;27(3):165–7
The role of immunoglobulin therapy in allergic diseases. Rabinovitch N, et al. **Allergy** 1999 Jul;54(7):662–8 (28 ref.)
Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Koduri PR, et al. **Am J Hematol** 1999 May; 61(1):16–20
Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Majluf-Cruz A, et al. **Am J Hematol** 1998 Oct;59(2):127–32
Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjögren's syndrome [letter] Dupond JL, et al. **Am J Med** 1999 Jan;106(1):125
The treatment of refractory uveitis with intravenous immunoglobulin. Rosenbaum JT, et al. **Am J Ophthalmol** 1999 May;127(5):545–9
Intravenous immune globulin in autoimmune uveitis [letter] Karmochkine M, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1078–9
Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases. Baronci C, et al. **Ann Ist Super Sanita** 1998;34(4):457–61
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Hadden RD, et al. **Ann Neurol** 1998 Nov; 44(5):780–8
Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. King SM. **Antiviral Res** 1999 Jan;40(3):115–37 (150 ref.)
Is the routine use of intravenous immunoglobulin treatment in neurologic disorders justified? No. Karussis D, et al. **Arch Neurol** 1999 Aug;56(8):1028–32 (89 ref.)
Intravenous immunoglobulin treatment in neurologic disorders: yes. Sorensen PS. **Arch Neurol** 1999 Aug; 56(8):1025–7 (52 ref.)
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Stangel M, et al. **Arch Neurol** 1999 Jun;56(6):661–3 (21 ref.)
Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Guy J, et al. **Arch Ophthalmol** 1999 Apr;117(4):471–7 (36 ref.)
Impact of respiratory syncytial virus immune globulin in 1996–1997: a local controlled comparison. Redding GJ, et al. **Arch Pediatr Adolesc Med** 1999 May;153(5):503–7
Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis. Boonyaleepun S, et al. **Asian Pac J Allergy Immunol** 1999 Mar;17(1):59–62
Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Phan TG, et al. **Australas J Dermatol** 1999 Aug;40(3):153–7
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Federici AB, et al. **Blood** 1998 Oct 15;92(8):2707–11
Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Jan-Inge Henter for the Histiocyte Society. Imashuku S, et al. **Blood** 1999 Mar 15; 93(6):1869–74
Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Müller F, et al. **Blood** 1998 Nov 15;92(10):3721–9
Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Ottolini MG, et al. **Bone Marrow Transplant** 1999 Jul;24(1):41–5
Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin [letter] Harman KE, et al. **Br J Dermatol** 1998 Dec;139(6):1126–7
Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IVIgG and steroids [letter] Summerfield GP, et al. **Br J Haematol** 1998 Sep;102(5):1380–1
Chronic demyelinating polyneuropathy in pregnancy treated with intravenous immunoglobulin. Nwosu EC, et al. **Br J Obstet Gynaecol** 1999 Feb;106(2):174–6
A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Apak RA, et al. **Brain Dev** 1999 Jun;21(4):279–82
IGIV in neurology--evidence and recommendations. Bril V, et al. **Can J Neurol Sci** 1999 May;26(2):139–52 (92 ref.)
The use of prophylactic intravenous immunoglobulin therapy in very low birthweight infants. Chou YH, et al. **Chang Keng I Hsueh Tsa Chih** 1998 Dec;21(4):371–6
IV immunoglobulin for asthma? [letter; comment] Weinberger M. **Chest** 1999 Jul;116(1):267–8. Comment on: Chest 1998 Nov;114(5):1349–56.
Supplemental immune globulins in sepsis. Werdan K. **Clin Chem Lab Med** 1999 Mar;37(3):341–9 (56 ref.)
Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy. Creamer D, et al. **Clin Exp Dermatol** 1999 Jul;24(4):273–4
Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy [letter] Wollina U, et al. **Clin Exp Dermatol** 1998 Nov;23(6):292–3
Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa [letter; comment] Gedalia A, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):767. Comment on: Clin Exp Rheumatol 1998 Mar-Apr;16(2):187–9.
Is steroid-dependent asthma a disease treatable with intravenous immunoglobulin? [editorial; comment] Ballow M. **Clin Immunol** 1999 May;91(2):123–5. Comment on: Clin Immunol 1999 May;91(2):126–33.
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma [see comments] Kishiyama JL, et al. **Clin Immunol** 1999 May;91(2):126–33 . Comment in: Clin Immunol 1999 May;91(2):123–5.
Clinical uses of intravenous immunoglobulin in pregnancy. Clark AL. **Clin Obstet Gynecol** 1999 Jun;42(2):368–80 (97 ref.)
Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Arahata H, et al. **Clin Rheumatol** 1999; 18(1):77–81
Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Huang JL, et al. **Clin Rheumatol** 1998;17(4):349–52
Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Sherer Y, et al. **Clin Rheumatol** 1999;18(2):170–3
Immunoglobulins in anergic patients: choice of patients, identification of dependent variables, and importance of study [editorial; comment] Christou NV. **Crit Care Med** 1999 Jul;27(7):1387–8. Comment on: Crit Care Med 1999 Jul;27(7):1281–7.
Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin A- and immunoglobulin M-enriched preparation in anergic patients undergoing cardiac surgery [see comments] Kress HG, et al. **Crit Care Med** 1999 Jul;27(7):1281–7. Comment in: Crit Care Med 1999 Jul;27(7):1387–8.
Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Campbell DE, et al. **Cytokine** 1999 May; 11(5):359–65
Cutaneous granulomatous lesions in common variable immunodeficiency: complete resolution after intravenous immunoglobulins. Pujol RM, et al. **Dermatology** 1999; 198(2):156–8
Chronic steadily progressive central and peripheral predominantly motor demyelination, involving the cranial nerves, responsive to immunoglobulins. Bentes C, et al. **Electromyogr Clin Neurophysiol** 1999 Jan-Feb;39(1):33–7
Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? Falcini F, et al. **Endothelium** 1999;6(3):209–15
Peri-operative immune-modulation with intravenous immunoglobulins. Dominioni L. **Eur J Anaesthesiol** 1998 Nov;15(6):734–5
Pregnancy and multiple sclerosis: a 2-year experience. Orvieto R, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Feb;82(2):191–4
Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. Somerset DA, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):227–9
High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy? Sztajzel R, et al. **Eur Neurol** 1999; 41(3):153–8
Acute renal failure complicating high-dose intravenous immunoglobulin therapy for acquired haemophilia. McColl MD, et al. **Haemophilia** 1999 Mar;5(2):124–6
Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Mazzucconi MG, et al. **Haemophilia** 1999 Mar;5(2):132–4
Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Adler R, et al. **Hepatology** 1999 Apr; 29(4):1299–305
Guillain-Barré syndrome: recent advances. Hadden RD, et al. **Hosp Med** 1998 Jan;59(1):55–60 (17 ref.)
Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Jablonowska B, et al. **Hum Reprod** 1999 Mar;14(3):838–41
Recovery from myasthenic crisis after use of IVIG therapy. Jain K, et al. **Indian Pediatr** 1998 Sep;35(9):901–3
Gamma-globulin inhibits tumor spread in mice. Shoenfeld Y, et al. **Int Immunol** 1999 Aug;11(8):1247–52
Do we have a less severe form of Kawasaki disease or is it the gammaglobulin effect? Abushaban L, et al. **Int J Cardiol** 1999 Apr 30;69(1):71–6
Successful treatment of adult-onset Henoch-Schönlein purpura nephritis with high-dose immunoglobulins. Kusuda A, et al. **Intern Med** 1999 Apr;38(4):376–9
Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. Dirschka T, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):789–90
Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris [letter] Jolles S, et al. **J Am Acad Dermatol** 1999 Mar;40(3):499–500
Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. Jolles S, et al. **J Am Acad Dermatol** 1999 Jan;40(1):121–3
Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. Khan IU, et al. **J Am Acad Dermatol** 1999 Mar;40(3):485–8
Severe Guillain-Barré syndrome associated with Campylobacter jejuni infection with failure to respond to plasmapheresis and immunoglobulin. Allen A, et al.

J Am Board Fam Pract 1999 May-Jun;12(3):249-52

Intravenous immune globulin in the therapy of peripartum cardiomyopathy. Bozkurt B, et al. **J Am Coll Cardiol** 1999 Jul;34(1):177-80

Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. DelGiudice-Asch G, et al. **J Autism Dev Disord** 1999 Apr;29(2):157-60

Treatment of children with autism with intravenous immunoglobulin [letter; comment] Gupta S. **J Child Neurol** 1999 Mar;14(3):203-5. Comment on: J Child Neurol 1998 Feb;13(2):79-82.

High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response. Winder A, et al. **J Clin Immunol** 1998 Sep;18(5):330-4

Intravenous immunoglobulin therapy: confounding effects on serological screening for toxoplasmosis during pregnancy. Pelloux H, et al. **J Clin Microbiol** 1999 Oct;37(10):3423-4

Necrotizing ulcerative periodontitis associated with severe congenital immunodeficiency in a prepubescent subject: clinical findings and response to intravenous immunoglobulin treatment. Batista EL Jr, et al. **J Clin Periodontol** 1999 Aug;26(8):499-504

Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. Sadayama T, et al. **J Dermatol** 1999 Jul;26(7):457-9

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. Pisani BA, et al. **J Heart Lung Transplant** 1999 Jul;18(7):701-6

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. Stiehm ER, et al. **J Infect Dis** 1999 Mar;179(3):567-75

Intravenous immune globulin (i.v.IG) therapy in steroid-resistant atopic dermatitis. Noh G, et al. **J Korean Med Sci** 1999 Feb;14(1):63-8

Rapid recovery of a child with Guillain-Barré syndrome using intravenous immunoglobulins. Shah M, et al. **J La State Med Soc** 1998 Nov;150(11):533-7

Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. Blaes F, et al. **J Neurol** 1999 Apr;246(4):299-303

Use of human intravenous immunoglobulin in lower motor neuron syndromes. Ellis CM, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):15-9

Intravenous immunoglobulin dependent inflammatory radiculopathy presenting as lumbar canal stenosis [letter] Hillier CE, et al. **J Neurol Neurosurg Psychiatry** 1998 Nov; 65(5):802-3

Immune thrombocytopenic purpura: why treat? [editorial; comment] Nugent DJ. **J Pediatr** 1999 Jan;134(1):3-4 (15 ref.). Comment on: J Pediatr 1999 Jan;134(1):21-6.

Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. Quartier P, et al. **J Pediatr** 1999 May;134(5):589-96

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. Simoes EA, et al. **J Pediatr** 1998 Oct;133(4):492-9

Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. Tagher RJ, et al. **J Pediatr** 1999 Feb;134(2):233-5

Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin [see comments] Tarantino MD, et al. **J Pediatr** 1999 Jan;134(1):21-6. Comment in: J Pediatr 1999 Jan;134(1):3-4.

Evans syndrome: successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide [letter; comment] Gombakis N, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):248-9. Comment on: J Pediatr Hematol Oncol 1997 Sep-Oct;19(5):433-7.

Successful treatment of severe muscle necrosis with intravenous immunoglobulin. McRorie E, et al. **J Rheumatol** 1999 Jun;26(6):1411-3

Changes in cardiac troponin I in Kawasaki disease before and after treatment with intravenous gammaglobulin. Kim M, et al. **Jpn Circ J** 1998 Jul;62(7):479-82

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [letter] Boletis JN, et al. **Lancet** 1999 Aug 14;354(9178):569-70

Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Gordon C, et al. **Lupus** 1998; 7(7):429-33 (52 ref.)

Fetomaternal alloimmune thrombocytopenia treated with intragam [letter] Dawkins B, et al. **Med J Aust** 1999 May 3;170(9):451-2

Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998. **MMWR Morb Mortal Wkly Rep** 1999 Mar 5;48(8):159-62

Human rabies prevention--United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Morb Mortal Wkly Rep 1999 Jan 15;48(1):16] **MMWR Morb Mortal Wkly Rep** 1999 Jan 8;48(RR-1):1-21

Response to therapy in demyelinating motor neuropathy. Markson L, et al. **Muscle Nerve** 1998 Dec;21(12):1769-71

Respiratory syncytial virus immune globulin and conflict of interest [letter; comment] Groothuis JR. **N Engl J Med** 1998 Nov 26;339(22):1644. Comment on: N Engl J Med 1993 Nov 18;329(21):1524-30.

Mechanism of intravenous immune globulin therapy [letter; comment] Spellberg B. **N Engl J Med** 1999 Jul 1; 341(1):57-8. Comment on: N Engl J Med 1999 Jan 21;340(3):227-8.

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases [see comments] Yu Z, et al. **N Engl J Med** 1999 Jan 21;340(3):227-8 (9 ref.). Comment in: N Engl J Med 1999 Jul 1;341(1):57-8.

Second response to immunoglobulin in recurrent Guillain-Barré syndrome. Nagappan R, et al. **N Z Med J** 1998 Nov 13;111(1077):433-4

Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Dalakas MC. **Neurology** 1998 Dec;51(6 Suppl 5):S37-45 (30 ref.)

Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Dalakas MC. **Neurology** 1998 Dec;51(6 Suppl 5):S2-8 (69 ref.)

Intravenous immunoglobulin treatment in multiple sclerosis [letter; comment] Francis G. **Neurology** 1999 Jan 1; 52(1):214. Comment on: Neurology 1998 Feb;50(2):398-402.

Intravenous immunoglobulin treatment in multiple sclerosis [letter; comment] [published erratum appears in Neurology 1999 Jun 10;52(9):1952] Gadoth N, et al. **Neurology** 1999 Jan 1;52(1):214-5. Comment on: Neurology 1998 Feb;50(2):398-402.

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Hahn AF. **Neurology** 1998 Dec;51(6 Suppl 5):S16-21 (31 ref.)

Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Howard JF Jr. **Neurology** 1998 Dec;51(6 Suppl 5):S30-6 (73 ref.)

Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Leach JP, et al. **Neurology** 1999 Mar 10;52(4):738-42

Intravenous immunoglobulins in multiple sclerosis. Lisak RP. **Neurology** 1998 Dec;51(6 Suppl 5):S25-9 (42 ref.)

Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Qureshi AI, et al. **Neurology** 1999 Feb;52(3):629-32

Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Sater RA, et al. **Neurology** 1998 Dec;51(6 Suppl 5):S9-15 (97 ref.)

Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Clark AL, et al. **Obstet Gynecol** 1999 Mar;93(3):437-41

Human immunoglobulin preparations for intravenous use prevent endotoxin-induced uveitis in rats. Obrador E, et al. **Ophthalmic Res** 1999;31(1):59-67

Critical pharmacologic management in the emergency department. Rosenberg NM, et al. **Pediatr Emerg Care** 1998 Oct;14(5):376-9

Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Bruss JB, et al. **Pediatr Infect Dis J** 1999 Jun;18(6):505-11

Monoclonal antibodies against respiratory syncytial virus. Givner LB. **Pediatr Infect Dis J** 1999 Jun;18(6):541-2

Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. Sato N, et al. **Pediatr Int** 1999 Feb;41(1):1-7

IVIG in Landau-Kleffner syndrome [letter; comment] Mikati M, et al. **Pediatr Neurol** 1998 Nov;19(5):399-400. Comment on: Pediatr Neurol 1998 Feb;18(2):165-8.

Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Furth S, et al. **Pediatr Transplant** 1999 May; 3(2):146-9

Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Jordan SC, et al. **Pediatr Transplant** 1998 May; 2(2):92-105 (61 ref.)

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. **Pediatrics** 1998 Nov;102(5):1211-6

Demyelinative brainstem encephalitis responsive to intravenous immunoglobulin therapy. Assa A, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):301-3

A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. Körber J, et al. **Scand J Gastroenterol** 1998 Oct;33(10):1113-7

Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation. Bengtsson A, et al. **Scand J Immunol** 1998 Nov;48(5):509-14

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Viard I, et al. **Science** 1998 Oct 16;282(5388):490-3

Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. Levy Y, et al. **South Med J** 1999 Apr;92(4):412-4

Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. Haupt WF, et al. **Ther Apher** 1997 Feb; 1(1):55-7

Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Hosokawa T, et al. **Ther Apher** 1998 Nov; 2(4):288-91

Mechanisms of immunomodulatory action of intravenous immunoglobulin in autoimmune and systemic inflammatory diseases [editorial] Vassilev T, et al. **Ther Apher** 1997 Feb; 1(1):38-41 (22 ref.)

Evaluation of an enzyme-linked immunosorbent assay kit (GTI PakPlus) for the detection of antibodies against human platelet antigens. Lucas GF, et al. **Transfus Med** 1999 Mar;9(1):63-7

Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Theodorakis J, et al. **Transpl Int** 1998;11 Suppl 1:S86-9

Successful treatment of autoimmune hemolytic anemia with intravenous immunoglobulin in a patient with AIDS. González CA. **Transplant Proc** 1998 Dec;30(8):4151-2

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Jordan SC, et al. **Transplantation** 1998 Sep 27;66(6):800-5

The treatment of patients with autoimmune thrombocytopenia with intravenous IgG-anti-D. Engelfriet CP, et al. **Vox Sang** 1999;76(4):250-5

[Immunotherapy as part of comprehensive therapy in abdominal reoperations with septic complications] Vyhnánek F, et al. **Acta Medica (Hradec Kralove) Suppl** 1997;40(2):97-100 (Eng. Abstr.) **(Cze)**

[Treatment of chronic autoimmune urticaria using polyvalent immunoglobulins] Lacour JP, et al. **Ann Dermatol Venereol** 1998 Sep;125(9):641-4 **(Fre)**

[Polyvalent immunoglobins in general pediatrics: what place, what risk, and what cost?] Dommergues JP, et al. **Arch Pediatr** 1999;6 Suppl 2:397s-399s **(Fre)**

[Severe newborn icterus due to Rhesus incompatibility. Treatment with intravenous immunoglobulins (letter)] Sebag O, et al. **Arch Pediatr** 1999 Mar;6(3):345 **(Fre)**

[Substitution therapy for deficiencies in antibody production by immunoglobulins] Strengers PF. **Arch Pediatr** 1999;6 Suppl 2:423s-424s **(Fre)**

[Intravenous polyclonal immunoglobulins (IVIG): what use in transplantation?] Haymann JP, et al. **Nephrologie** 1999; 20(3):139-43 (28 ref.) (Eng. Abstr.) **(Fre)**

[Treatment with intravenous polyvalent immunoglobulins for autoimmune diseases in children] Karmochkine M. **Presse Med** 1998 Jun 27;27(23):1153-8 (49 ref.) (Eng. Abstr.) **(Fre)**

["Stiff-man" syndrome treated with intravenous immunoglobulins (letter)] Sevrin C, et al. **Rev Neurol (Paris)** 1998 Jun;154(5):431 **(Fre)**

[Functional mechanisms of intravenous immunoglobulins] Lories RJ, et al. **Acta Clin Belg** 1998 Dec;53(6):360-6 (46 ref.) (Eng. Abstr.) **(Ger)**

[Comment on the report "Successful treatment of Lyell's syndrome with intravenous immunoglobulins". ("Gehört-gelesen-nachgefragt") Hautarzt (1998) 49:950-951 (letter)] Mockenhaupt M, et al. **Hautarzt** 1999 Jul;50(7):513-4 **(Ger)**

[Pathogenesis research with clinical application. Successful treatment of Lyell's syndrome with intravenous immunoglobulin] Petzoldt D, et al. **Hautarzt** 1998 Dec; 49(12):950 **(Ger)**

[Treatment with immunoglobulins] Junker U. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):105-9 (24 ref.) (Eng. Abstr.) **(Ger)**

[Fluctuations in Guillain-Barré syndrome related with intravenous human immunoglobulin (triphasic course): case report] Dourado ME, et al. **Arq Neuropsiquiatr** 1998 Sep; 56(3A):476-9 (Eng. Abstr.) **(Por)**

[Use of octagam and pentaglobin in the treatment of severe sepsis in the neonatal period] Barinov AV, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):59-60 (Eng. Abstr.) **(Rus)**

[Intravenous immunoglobulin in combined therapy for children with juvenile rheumatoid arthritis (evaluation of therapeutical efficiency and factors that influence them)] Shaikov AV, et al. **Vestn Ross Akad Med Nauk** 1998; (12):36-9 (Eng. Abstr.) **(Rus)**

[Treatment of idiopathic thrombopenic purpura in adolescents by intravenous immunoglobulin (letter)] Rodriguez Cuartero A, et al. **An Med Interna** 1998 Dec; 15(12):675-6 **(Spa)**

[Treatment of lupus crisis with IgIV] Vázquez García MJ, et al. **Rev Alerg Mex** 1998 Nov-Dec;45(6):143-6 (Eng. Abstr.) **(Spa)**

[Intravenous immunoglobulin therapy is more and more common. The increasing tempo can force a prioritization of patients, scientists are warning] Orn P. **Lakartidningen** 1999 May 5;96(18):2186-9 **(Swe)**

TOXICITY

Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin. Urra JM, et al. **Transplant Proc** 1998 Dec; 30(8):4177-9

IMMUNOGLOBULINS, J-CHAIN

Lack of SC/pIgR-mediated epithelial transport of a human polymeric IgA devoid of J chain: in vitro and in vivo studies. Vaerman JP, et al. **Immunology** 1998 Sep;95(1):90–6

GENETICS

Recombinant expression of polymeric IgA: incorporation of J chain and secretory component of human origin. Johansen FE, et al. **Eur J Immunol** 1999 May;29(5):1701–8

The human immunoglobulin kappa variable (IGKV) genes and joining (IGKJ) segments. Barbié V, et al. **Exp Clin Immunogenet** 1998;15(3):171–83

The mouse (Mus musculus) immunoglobulin kappa variable (IGKV) genes and joining (IGKJ) segments. Martinez C, et al. **Exp Clin Immunogenet** 1998;15(3):184–93

The human immunoglobulin heavy diversity (IGHD) and joining (IGHJ) segments. Ruiz M, et al. **Exp Clin Immunogenet** 1999;16(3):173–84

Sequence and diversity of T-cell receptor beta-chain V and J genes of the owl monkey Aotus nancymaae. Vecino W, et al. **Immunogenetics** 1999 Aug;49(9):792–9

Myocyte enhancer factor-related B-MEF2 is developmentally expressed in B cells and regulates the immunoglobulin J chain promoter. Rao S, et al. **J Biol Chem** 1998 Oct 2;273(40):26123–9

Extensive junctional diversity in Ig light chain genes from early B cell progenitors of mu MT mice. Bentolila LA, et al. **J Immunol** 1999 Feb 15;162(4):2123–8

Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire. Farner NL, et al. **J Immunol** 1999 Feb 15;162(4):2137–45

Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. Lycke N, et al. **J Immunol** 1999 Jul 15; 163(2):913–9

IMMUNOLOGY

B cell-specific activator protein prevents two activator factors from binding to the immunoglobulin J chain promoter until the antigen-driven stages of B cell development. Wallin JJ, et al. **J Biol Chem** 1999 May 28; 274(22):15959–65

IMMUNOGLOBULINS, KAPPA-CHAIN

[Necrobiotic xanthogranulomatosis: a cutaneous manifestation of a monoclonal IgM gammopathy] Sève P, et al. **Rev Med Interne** 1998 May;19(5):338–40 (Eng. Abstr.) **(Fre)**

[Case of cardiac amyloidosis associated with IgG-K multiple myeloma in the framework of restrictive myocardiopathy] Baldassarre S, et al. **Cardiologia** 1999 Feb;44(2):193–7 (Eng. Abstr.) **(Ita)**

[Systemic Buschke's scleredema with cardiomyopathy, monoclonal IgG kappa gammopathy and amyloidosis. Case report with autopsy] Paz RA, et al. **Medicina (B Aires)** 1998;58(5 Pt 1):501–3 (Eng. Abstr.) **(Spa)**

ANALYSIS

Comparison of the immunogold labeling of single light chains and whole immunoglobulins with anti-kappa on LR-white and epoxy sections. Brorson SH. **Micron** 1998 Dec; 29(6):439–43

Comparative mapping of cloned human and murine antithyroglobulin antibodies: recognition by human antibodies of an immunodominant region. Estienne V, et al. **Thyroid** 1998 Aug;8(8):643–6

BIOSYNTHESIS

Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov-Dec; 22(6):421–9 (26 ref.)

BLOOD

Recurrent Goodpasture's disease due to a monoclonal IgA-kappa circulating antibody [see comments] Fervenza FC, et al. **Am J Kidney Dis** 1999 Sep;34(3):549–55. Comment in: Am J Kidney Dis 1999 Sep;34(3):565–8.

The emerging spectrum of IgA-mediated renal diseases: is there an IgA variant of Goodpasture's syndrome? [editorial; comment] Lee SM, et al. **Am J Kidney Dis** 1999 Sep; 34(3):565–8. Comment on: Am J Kidney Dis 1999 Sep;34(3):549–55.

Co-incidental presentation of IgA lambda multiple myeloma and pleural involvement with IgM kappa non-Hodgkin's lymphoma. Manley R, et al. **Clin Lab Haematol** 1999 Feb; 21(1):61–3

Light chain deposition disease detected by antisera to a variable region of the kappa1 light chain subgroup. Takeda S, et al. **Nephron** 1998 Oct;80(2):162–5

Bilateral optic neuropathy with IgGkappa multiple myeloma improved after myeloablative chemotherapy. Lieberman FS, et al. **Neurology** 1999 Jan 15;52(2):414–6

CHEMISTRY

1.7 A structure of the stabilized REIv mutant T39K. Application of local NCS restraints. Usón I, et al. **Acta Crystallogr D Biol Crystallogr** 1999 Jun;55 (Pt 6):1158–67

Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Olsen KE, et al. **Biochem Biophys Res Commun** 1998 Oct 20; 251(2):642–7

Occurrence of heavy chain of 7S IgM half-molecule whose NH2-terminal sequence is identical with that of kappa light chain sequence in patients with Waldenstrom macroglobulinemia. Imoto M, et al. **Clin Chim Acta** 1999 Apr;282(1–2):77–88

Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition. de Haard H, et al. **Immunotechnology** 1999 Mar;4(3–4):203–15

Reproducing the natural evolution of protein structural features with the selectively infective phage (SIP) technology. The kink in the first strand of antibody kappa domains. Spada S, et al. **J Mol Biol** 1998 Oct 23; 283(2):395–407

Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Déret S, et al. **Protein Eng** 1999 Apr;12(4):363–9

GENETICS

Selective PCR amplification of functional immunoglobulin light chain from hybridoma containing the aberrant MOPC 21-derived V kappa by PNA-mediated PCR clamping. Cochet O, et al. **Biotechniques** 1999 May;26(5):818–20, 822

Multiplex PCR reaction for the detection and identification of immunoglobulin kappa deleting element rearrangements in B-lineage leukaemias. Stolz F, et al. **Br J Haematol** 1999 Aug;106(2):486–90

Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythematosus. Dörner T, et al. **Clin Immunol** 1999 Aug;92(2):188–96

Regulation of c-myc and immunoglobulin kappa gene transcription by promoter-proximal pausing of RNA polymerase II. Schneider EE, et al. **Curr Top Microbiol Immunol** 1999;246:225–31 (32 ref.)

Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Gabay C, et al. **Eur J Haematol** 1999 Sep; 63(3):180–91

The central part of the mouse immunoglobulin kappa locus. Kirschbaum T, et al. **Eur J Immunol** 1999 Jul;29(7):2057–64

Induction of the Igkappa 3' enhancer by distinct pathways can be inhibited by cross-linking of the CD40 receptor. Meyer KB. **Eur J Immunol** 1999 Mar;29(3):872–7

The 5' part of the mouse immunoglobulin kappa locus. Röschenthaler F, et al. **Eur J Immunol** 1999 Jul; 29(7):2065–71

Characteristics of the immunoglobulin Vkappa genes, pseudogenes, relics and orphons in the mouse genome. Schäble KF, et al. **Eur J Immunol** 1999 Jul;29(7):2082–6

The variable genes and gene families of the mouse immunoglobulin kappa locus. Thiebe R, et al. **Eur J Immunol** 1999 Jul;29(7):2072–81

The human immunoglobulin kappa variable (IGKV) genes and joining (IGKJ) segments. Barbié V, et al. **Exp Clin Immunogenet** 1998;15(3):171–83

The mouse (Mus musculus) immunoglobulin kappa variable (IGKV) genes and joining (IGKJ) segments. Martinez C, et al. **Exp Clin Immunogenet** 1998;15(3):184–93

Contribution of interleukin 1beta and KM loci to alopecia areata. Galbraith GM, et al. **Hum Hered** 1999 Mar; 49(2):85–9

Co-existence of somatic hypermutation and gene conversion in hypervariable regions of single Igkappa clones. Liu J, et al. **Immunology** 1998 Oct;95(2):291–301

Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues. Reason DC, et al. **Infect Immun** 1999 Feb;67(2):994–7

The effects of E mu, 3'alpha (hs 1,2) and 3'kappa enhancers on mutation of an Ig-VDJ-Cgamma2a Ig heavy gene in cultured B cells. Lin MM, et al. **Int Immunol** 1998 Aug; 10(8):1121–9

Lambda5 is required for rearrangement of the Ig kappa light chain gene in pro-B cell lines. Miyazaki T, et al. **Int Immunol** 1999 Aug;11(8):1195–202

Promoter-associated displacement of hypermutations. Wu P, et al. **Int Immunol** 1998 Aug;10(8):1131–8

Spi-C, a novel Ets protein that is temporally regulated during B lymphocyte development. Bemark M, et al. **J Biol Chem** 1999 Apr 9;274(15):10259–67

Developmental regulation of the kappa locus involves both positive and negative sequence elements in the 3' enhancer that affect synergy with the intron enhancer. Liu X, et al. **J Biol Chem** 1999 Feb 5;274(6):3285–93

A targeted deletion of a region upstream from the Jkappa cluster impairs kappa chain rearrangement in cis in mice and in the 103/bcl2 cell line. Cocea L, et al. **J Exp Med** 1999 May 3;189(9):1443–50

Extensive junctional diversity in Ig light chain genes from early B cell progenitors of mu MT mice. Bentolila LA, et al. **J Immunol** 1999 Feb 15;162(4):2123–8

Decreased frequency of rearrangement due to the synergistic effect of nucleotide changes in the heptamer and nonamer of the recombination signal sequence of the V kappa gene A2b, which is associated with increased susceptibility of Navajos to Haemophilus influenzae type b disease. Nadel B, et al. **J Immunol** 1998 Dec 1;161(11):6068–73

Evidence that the Igkappa gene MAR regulates the probability of premature V-J joining and somatic hypermutation. Yi M, et al. **J Immunol** 1999 May 15; 162(10):6029–39

A targeted kappa immunoglobulin gene containing a deletion of the nuclear matrix association region exhibits spontaneous hyper-recombination in pre-B cells. Hale MA, et al. **Mol Immunol** 1998 Jul;35(10):609–20

Identification of rabbit immunoglobulin latent Ckappa1 allotype genes alters the concept of allelic inheritance. Wolf B, et al. **Mol Immunol** 1998 Oct;35(14–15):965–76

The salt dependence of DNA recognition by NF-kappaB p50: a detailed kinetic analysis of the effects on affinityand specificity. Hart DJ, et al. **Nucleic Acids Res** 1999 Feb 15; 27(4):1063–9

IMMUNOLOGY

Benign monoclonal gammopathy turning to AL amyloidosis after kidney transplantation. Dysseleer A, et al. **Am J Kidney Dis** 1999 Jul;34(1):166–9

Monoclonal autoantibodies from patients with autoimmune diseases: synovial fluid B lymphocytes of a patient with rheumatoid arthritis produced an IgG lambda antibody recognizing J-sequences of Ig kappa chains in a conformation-dependent way. von Landenberg P, et al. **Immunobiology** 1999 Jun;200(2):205–14

Vernier zone residue 4 of mouse subgroup II kappa light chains is a critical determinant for antigen recognition. de Haard H, et al. **Immunotechnology** 1999 Mar;4(3–4):203–15

Polysaccharide binding potential of the human A2 or A18 kappa light chain homologues. Reason DC, et al. **Infect Immun** 1999 Feb;67(2):994–7

Analysis of kappa light chain contribution to anti-DNA antibody activity of a human VH4-21-encoded monoclonal antibody (NE-1) by antibody-phage display technique. Katsube Y, et al. **Int J Mol Med** 1998 May;1(5):863–8

Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Cochet O, et al. **Mol Immunol** 1998 Dec;35(17):1097–110

Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Lee HS, et al. **Mol Immunol** 1999 Jan;36(1):61–71

Gene targeting of the KI-KII sequence elements in a model pre-B cell line: effects on germline transcription and rearrangement of the kappa locus. Liu X, et al. **Mol Immunol** 1999 May;36(7):461–9

DNA immunization by intramuscular injection or gene gun induces specific IgG antibodies against a Schistosoma japonicum 22 kDa antigen, Sj22, when fused to the murine Ig K-chain secretory leader sequence. Waine GJ, et al. **Parasite Immunol** 1999 Jan;21(1):53–6

[IgM kappa lymphoma with antisulfatide antibodies revealed by cervical motor neuropathy simulating amyotrophic lateral sclerosis] Baud P, et al. **Rev Med Interne** 1998 Apr; 19(4):275–8 (Eng. Abstr.) **(Fre)**

[Urine free light chains kappa in multiple sclerosis] Michałowska-Wender G, et al. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):311–9 (Eng. Abstr.) **(Pol)**

METABOLISM

Interactions between a single immunoglobulin-binding domain of protein L from Peptostreptococcus magnus and a human kappa light chain. Beckingham JA, et al. **Biochem J** 1999 May 15;340 (Pt 1):193–9

Immunoglobulin-derived polypeptides enter the regulated secretory pathway in AtT-20 cells. Castle AM, et al. **FEBS Lett** 1998 Nov 20;439(3):341–5

A young woman from Somalia with acute renal failure. Goosens AN, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1832–4

URINE

A case of multiple myeloma IgG(lambda)type with low molecular weight kappa light chain. Imoto M, et al. **Clin Chim Acta** 1998 Sep 14;277(1):99–105

Hepatitis C virus infection-associated non-cryoglobulinaemic monoclonal IgMkappa gammopathy responsive to interferon-alpha treatment. Schott P, et al. **J Hepatol** 1998 Aug;29(2):310–5

Free light chains in multiple sclerosis urine. Mehta PD, et al. **Mult Scler** 1998 Jun;4(3):254–6

[Urine free light chains kappa in multiple sclerosis] Michałowska-Wender G, et al. **Neurol Neurochir Pol** 1999 Mar-Apr;33(2):311–9 (Eng. Abstr.) **(Pol)**

IMMUNOGLOBULINS, LAMBDA-CHAIN

[Lambda light chain deposition disease without renal involvement (letter)] Armengou A, et al. **Med Clin (Barc)** 1998 Sep 26;111(9):358–9 **(Spa)**

ANALYSIS

Lambda light chain induced nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia. Bate KL, et al. **Am J Kidney Dis** 1998 Dec;32(6):E3

Central retinal vein occlusion in a patient with IgG lambda

monoclonal gammopathy. Enzenauer RW, et al. **Arch Ophthalmol** 1999 Jan;117(1):134-5

Comparative mapping of cloned human and murine antithyroglobulin antibodies: recognition by human antibodies of an immunodominant region. Estienne V, et al. **Thyroid** 1998 Aug;8(8):643-6

BIOSYNTHESIS

Monoclonal autoantibodies from patients with autoimmune diseases: synovial fluid B lymphocytes of a patient with rheumatoid arthritis produced an IgG lambda antibody recognizing J-sequences of Ig kappa chains in a conformation-dependent way. von Landenberg P, et al. **Immunobiology** 1999 Jun;200(2):205-14

Organ-specific (localized) synthesis of Ig light chain amyloid. Hamidi Asl K, et al. **J Immunol** 1999 May 1;162(9):5556-60

Senescent BALB/c mice exhibit decreased expression of lambda5 surrogate light chains and reduced development within the pre-B cell compartment. Sherwood EM, et al. **J Immunol** 1998 Nov 1;161(9):4472-5

Plural immunoglobulin synthesis in a single cell: an ultrastructural study of two cases with three M-proteins. Saito N, et al. **Ultrastruct Pathol** 1998 Nov-Dec; 22(6):421-9 (26 ref.)

BLOOD

A case of multiple myeloma IgG(lambda)type with low molecular weight kappa light chain. Imoto M, et al. **Clin Chim Acta** 1998 Sep 14;277(1):99-105

Co-incidental presentation of IgA lambda multiple myeloma and pleural involvement with IgM kappa non-Hodgkin's lymphoma. Manley R, et al. **Clin Lab Haematol** 1999 Feb; 21(1):61-3

GENETICS

Light chain shifting: identification of a human plasma cell line actively undergoing light chain replacement. Tachibana H, et al. **Blood** 1999 Jan 1;93(1):198-207

Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Krenn V, et al. **Clin Exp Immunol** 1999 Jan;115(1):168-75

The immunoglobulin lambda light chain enhancer consists of three modules which synergize in activation of transcription. Asenbauer H, et al. **Eur J Immunol** 1999 Feb; 29(2):713-24

Allelic polymorphisms and RFLP in the human immunoglobulin lambda light chain locus. Lefranc MP, et al. **Hum Genet** 1999 May;104(5):361-9

Antibodies of sharks: revolution and evolution. Marchalonis JJ, et al. **Immunol Rev** 1998 Dec;166:103-22 (109 ref.)

Lambda5 is required for rearrangement of the Ig kappa light chain gene in pro-B cell lines. Miyazaki T, et al. **Int Immunol** 1999 Aug;11(8):1195-202

Extensive junctional diversity in Ig light chain genes from early B cell progenitors of mu MT mice. Bentolila LA, et al. **J Immunol** 1999 Feb 15;162(4):2123-8

Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. Dörner T, et al. **J Immunol** 1999 Jul 15; 163(2):1027-36

Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire. Farner NL, et al. **J Immunol** 1999 Feb 15;162(4):2137-45

Marsupial light chains: complexity and conservation of lambda in the opossum Monodelphis domestica. Lucero JE, et al. **J Immunol** 1998 Dec 15;161(12):6724-32

Multiple sites of V lambda diversification in cattle. Lucier MR, et al. **J Immunol** 1998 Nov 15;161(10):5438-44

Mef2 proteins, required for muscle differentiation, bind an essential site in the Ig lambda enhancer. Satyaraj E, et al. **J Immunol** 1998 Nov 1;161(9):4795-802

Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia [letter] Sánchez-García I, et al. **Leukemia** 1999 Mar;13(3):485-7

Analysis of mice with single and multiple copies of transgenes reveals a novel arrangement for the lambda5-VpreB1 locus control region. Sabbattini P, et al. **Mol Cell Biol** 1999 Jan; 19(1):671-9

Frequent N addition and clonal relatedness among immunoglobulin lambda light chains expressed in rheumatoid arthritis synovia and PBL, and the influence of V lambda gene segment utilization on CDR3 length. Bridges SL Jr. **Mol Med** 1998 Aug;4(8):525-53

IMMUNOLOGY

Severe cold agglutinin disease and cryoglobulinemia secondary to a monoclonal anti-Pr2 IgM lambda cryoagglutinin. Ciejka JZ, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):227-31

Necrobiotic xanthogranuloma with monoclonal gammopathy of the IgG lambda type. Nestle FO, et al. **Dermatology** 1999;198(4):434-5

A human immunoglobulin lambda locus is similarly well expressed in mice and humans. Popov AV, et al. **J Exp Med** 1999 May 17;189(10):1611-20

METABOLISM

The in vivo association of BiP with newly synthesized proteins is dependent on the rate and stability of folding and not simply on the presence of sequences that can bind to BiP. Hellman R, et al. **J Cell Biol** 1999 Jan 11; 144(1):21-30

URINE

Free light chains in multiple sclerosis urine. Mehta PD, et al. **Mult Scler** 1998 Jun;4(3):254-6

IMMUNOGLOBULINS, LIGHT-CHAIN

Fit for life in the immune system? Surrogate L chain tests H chains that test L chains. Melchers F. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2571-3

[Biclonal gammopathy] Maseki N. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):540-2 (9 ref.) **(Jpn)**

ANALYSIS

Treatment of AL amyloidosis with 4'-Iodo-4'-deoxydoxorubicin: an update [letter] Merlini G, et al. **Blood** 1999 Feb 1;93(3):1112-3

Cerebrovascular involvement in systemic AA and AL amyloidosis: a clear haematogenic pattern. Schröder R, et al. **Virchows Arch** 1999 Jun;434(6):551-60

[Determination of total proteinuria: a comparative study of automated trichloracetic acid and pyrogallol red techniques for samples with monoclonal light chains] Le Bricon T, et al. **Ann Biol Clin (Paris)** 1998 Nov-Dec;56(6):719-23 **(Fre)**

BIOSYNTHESIS

Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis. Krakauer M, et al. **Acta Neurol Scand** 1998 Sep;98(3):161-5

Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. Kim NS, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):679-88

Diversity of Ig light chain variable region gene expression in fetal lambs. Hein WR, et al. **Int Immunol** 1998 Sep; 10(9):1251-9

Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Gao C, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6025-30

BLOOD

IgG titer, subclass, and light-chain phenotype of pregnancy-induced HPA-5b antibodies that cause or do not cause neonatal alloimmune thrombocytopenia. Kurz M, et al. **Transfusion** 1999 Apr;39(4):379-82

CHEMISTRY

Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Olsen KE, et al. **Biochem Biophys Res Commun** 1998 Oct 20; 251(2):642-7

Occurrence of heavy chain of 7S IgM half-molecule whose NH2-terminal sequence is identical with that of kappa light chain sequence in patients with Waldenstrom macroglobulinemia. Imoto M, et al. **Clin Chim Acta** 1999 Apr;282(1-2):77-88

Structural relationship of lambda-type light chains with AL amyloidosis. Alim MA, et al. **Clin Immunol** 1999 Mar; 90(3):399-403

The structure of an entire noncovalent immunoglobulin kappa light-chain dimer (Bence-Jones protein) reveals a weak and unusual constant domains association. Roussel A, et al. **Eur J Biochem** 1999 Feb;260(1):192-9

Algorithmic determination of core positions in the VL and VH domains of immunoglobulin molecules. Gelfand I, et al. **J Comput Biol** 1998 Fall;5(3):467-77

Intrabody construction and expression. I. The critical role of VL domain stability. Ohage E, et al. **J Mol Biol** 1999 Sep 3;291(5):1119-28

Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Hanes J, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14130-5

Novel mechanisms control the folding and assembly of lambda5/14.1 and VpreB to produce an intact surrogate light chain. Minegishi Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3041-6

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Atwell JL, et al. **Protein Eng** 1999 Jul;12(7):597-604

Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Déret S, et al. **Protein Eng** 1999 Apr;12(4):363-9

Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Raffen R, et al. **Protein Sci** 1999 Mar;8(3):509-17

DIAGNOSTIC USE

Recombinant light chain of human monoclonal antibody HB4C5 as a potentially useful lung cancer-targeting vehicle. Nishimura E, et al. **Hum Antibodies** 1999; 9(2):111-24

GENETICS

Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals. Shiokawa S, et al. **Am J Pathol** 1998 Nov;153(5):1393-400

Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Bräuninger A, et al. **Blood** 1999 Apr 15; 93(8):2679-87

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments] Damle RN, et al. **Blood** 1999 Sep 15; 94(6):1840-7. Comment in: Blood 1999 Sep 15;94(6):1837-9.

Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes. Krenn V, et al. **Clin Exp Immunol** 1999 Jan;115(1):168-75

Light chain variable region diversity in Atlantic cod (Gadus morhua L.). Widholm H, et al. **Dev Comp Immunol** 1999 Apr;23(3):231-40

Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. Chardes T, et al. **FEBS Lett** 1999 Jun 11;452(3):386-94

Selectable in-vivo recombination to increase antibody library size--an improved phage display vector system. Zahra DG, et al. **Gene** 1999 Feb 4;227(1):49-54

The immunoglobulin light chain in poikilothermic vertebrates. Pilström L, et al. **Immunol Rev** 1998 Dec; 166:123-32 (86 ref.)

Diversity of Ig light chain variable region gene expression in fetal lambs. Hein WR, et al. **Int Immunol** 1998 Sep; 10(9):1251-9

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Fagerberg J, et al. **Int J Cancer** 1999 Mar 1;80(5):671-80

Rearrangement and expression of immunoglobulin light chain genes can precede heavy chain expression during normal B cell development in mice. Novobrantseva TI, et al. **J Exp Med** 1999 Jan 4;189(1):75-88

Immunoglobulin light chain variable region genes in multiple myeloma [letter; comment] Kosmas C, et al. **Leukemia** 1999 May;13(5):827-30. Comment on: Leukemia 1998 Apr;12(4):601-9.

Detection of immunoglobulin light chain mRNA by in situ hybridisation using biotinylated tyramine signal amplification. King G, et al. **Mol Pathol** 1999 Feb; 52(1):47-50

Novel mechanisms control the folding and assembly of lambda5/14.1 and VpreB to produce an intact surrogate light chain. Minegishi Y, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3041-6

Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding. Xiang J, et al. **Protein Eng** 1999 May;12(5):417-21

IMMUNOLOGY

Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Perfetti V, et al. **Bone Marrow Transplant** 1999 Feb;23(4):323-7

Open sandwich ELISA with V(H)-/V(L)-alkaline phosphatase fusion proteins. Suzuki C, et al. **J Immunol Methods** 1999 Apr 22;224(1-2):171-84

Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. de Wildt RM, et al. **J Mol Biol** 1999 Jan 22;285(3):895-901

Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Lee HS, et al. **Mol Immunol** 1999 Jan;36(1):61-71

METABOLISM

A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival. Christou L, et al. **Acta Haematol** 1999; 101(4):202-5

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Gertz MA, et al. **Am J Hematol** 1999 Jun;61(2):115-9

In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Isaac J, et al. **Amyloid** 1998 Dec;5(4):238-46

DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain. Chen Y, et al. **J Immunol** 1999 Apr 15;162(8):4663-70

Mapping the major interaction between binding protein and Ig light chains to sites within the variable domain. Davis DP, et al. **J Immunol** 1999 Oct 1;163(7):3842-50

Cutting edge: proteasome involvement in the degradation of unassembled Ig light chains. O'Hare T, et al. **J Immunol** 1999 Jul 1;163(1):11-4

Intrabody construction and expression. I. The critical role of VL domain stability. Ohage E, et al. **J Mol Biol** 1999 Sep 3;291(5):1119-28

BiP and immunoglobulin light chain cooperate to control

the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Lee YK, et al. **Mol Biol Cell** 1999 Jul;10(7):2209–19

Spleen localization of light chain deposition disease associated with sea blue histiocytosis, revealed by spontaneous rupture. de Lajarte-Thirouard AS, et al. **Virchows Arch** 1999 May;434(5):463–5

[Light chain deposition disease as a cause of renal failure] Wohl P, et al. **Cas Lek Cesk** 1998 Nov 30;137(23):721–4 (Eng. Abstr.) **(Cze)**

[Light chain deposition disease] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1998;(22 Pt 3):585–7 (14 ref.) **(Jpn)**

PHARMACOLOGY

Glomerulopathic light chain–mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo. Herrera GA, et al. **Ultrastruct Pathol** 1999 Mar–Apr; 23(2):107–26

PHYSIOLOGY

The importance of the light chain for the epitope specificity of human anti-U1 small nuclear RNA autoantibodies present in systemic lupus erythematosus patients. Hoet RM, et al. **J Immunol** 1999 Sep 15;163(6):3304–12

URINE

Multiple narrow bands in urine protein electrophoresis [letter] Roach BM, et al. **Clin Chem** 1999 May;45(5):716–8

IMMUNOGLOBULINS, MU-CHAIN

BIOSYNTHESIS

Method for the preparation of bispecific F(ab')2mu fragments from mouse monoclonal antibodies of the immunoglobulin M class and characterization of the fragments. Morimoto K, et al. **J Immunol Methods** 1999 Apr 22;224(1–2):43–50

CHEMISTRY

The human (PsiL+mu–) proB complex: cell surface expression and biochemical structure of a putative transducing receptor. Lemmers B, et al. **Blood** 1999 Jun 15;93(12):4336–46

Biogenesis and function of IgM: the role of the conserved mu-chain tailpiece glycans. de Lalla C, et al. **Mol Immunol** 1998 Sep;35(13):837–45

GENETICS

The human (PsiL+mu–) proB complex: cell surface expression and biochemical structure of a putative transducing receptor. Lemmers B, et al. **Blood** 1999 Jun 15;93(12):4336–46

Nuclear matrix attachment regions confer long-range function upon the immunoglobulin mu enhancer. Fernández LA, et al. **Cold Spring Harb Symp Quant Biol** 1998;63:515–24

The molecular basis of multiple vector insertion by gene targeting in mammalian cells. Ng P, et al. **Genetics** 1999 Mar;151(3):1143–55

Target specificity of immunoglobulin class switch recombination is not determined by nucleotide sequences of S regions. Kinoshita K, et al. **Immunity** 1998 Dec; 9(6):849–58

ETS protein-dependent accessibility changes at the immunoglobulin mu heavy chain enhancer. Nikolajczyk BS, et al. **Immunity** 1999 Jul;11(1):11–20

Apparent trans-chromosomal antibody class switch in mice bearing an Igh(a) mu-chain transgene on an Igh(b) genetic background. Willers J, et al. **Immunobiology** 1999 Feb; 200(1):150–64

Evolutionary variation of immunoglobulin mu heavy chain RNA processing pathways: origins, effects, and implications. Ross DA, et al. **Immunol Rev** 1998 Dec; 166:143–51 (37 ref.)

Extensive junctional diversity in Ig light chain genes from early B cell progenitors of mu MT mice. Bentolila LA, et al. **J Immunol** 1999 Feb 15;162(4):2123–8

Exploring functional redundancy in the immunoglobulin mu heavy-chain gene enhancer. Dang W, et al. **Mol Cell Biol** 1998 Nov;18(11):6870–8

Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements. Mayeda A, et al. **Mol Cell Biol** 1999 Mar;19(3):1853–63

Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins. Tian G, et al. **Mol Cell Biol** 1999 Apr;19(4):2946–57

Cux/CDP homeoprotein is a component of NF-muNR and represses the immunoglobulin heavy chain intronic enhancer by antagonizing the bright transcription activator. Wang Z, et al. **Mol Cell Biol** 1999 Jan;19(1):284–95

Effect of upstream RNA processing on selection of mu S versus mu M poly(A) sites. Abuodeh R, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5417–24

IMMUNOLOGY

A tumor necrosis factor-induced model of human primary demyelinating diseases develops in immunodeficient mice. Kassiotis G, et al. **Eur J Immunol** 1999 Mar;29(3):912–7

METABOLISM

Mu-surrogate light chain physicochemical interactions of the human preB cell receptor: implications for VH repertoire selection and cell signaling at the preB cell stage. Gauthier L, et al. **J Immunol** 1999 Jan 1;162(1):41–50

Effect of upstream RNA processing on selection of mu S versus mu M poly(A) sites. Abuodeh R, et al. **Nucleic Acids Res** 1998 Dec 1;26(23):5417–24

PHYSIOLOGY

Biogenesis and function of IgM: the role of the conserved mu-chain tailpiece glycans. de Lalla C, et al. **Mol Immunol** 1998 Sep;35(13):837–45

IMMUNOGLOBULINS, SURFACE

BIOSYNTHESIS

Expression levels of B cell surface immunoglobulin regulate efficiency of allelic exclusion and size of autoreactive B-1 cell compartment. Watanabe N, et al. **J Exp Med** 1999 Aug 16;190(4):461–69

Angio-associated migratory cell protein is expressed as an extracellular protein by blood-vessel-associated mesenchymal cells. Beckner ME, et al. **Microvasc Res** 1999 May;57(3):347–52

BLOOD

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. Saini SS, et al. **J Immunol** 1999 May 1;162(9):5624–30

IMMUNOLOGY

Antagonistic roles for phospholipase D activities in B cell signaling: while the antigen receptors transduce mitogenic signals via a novel phospholipase D activity, phosphatidylcholine-phospholipase D mediates antiproliferative signals. Gilbert JJ, et al. **J Immunol** 1998 Dec 15;161(12):6575–84

B cell responses to a peptide epitope. VI. The kinetics of antigen recognition modulates B cell-mediated recruitment of T helper subsets. Vijayakrishnan L, et al. **J Immunol** 1998 Nov 1;161(9):4661–70

Generation of acetylcholine receptor-specific human T cell lines using heterobifunctional antibody-targeted antigen presentation. Wang D, et al. **J Neuroimmunol** 1999 Sep 1;99(1):114–21

METABOLISM

Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. de Inés C, et al. **J Immunol** 1999 Oct 1;163(7):3948–56

Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. Serre K, et al. **J Immunol** 1998 Dec 1;161(11):6059–67

PHYSIOLOGY

Membrane IgM-stimulated human B lymphocytes succumb to activation-related apoptosis at a G1-->S transition: influence of ligand affinity and valency. Mongini PK, et al. **Cell Immunol** 1998 Sep 15;188(2):137–50

IMMUNOGLOBULINS, THYROID-STIMULATING

see related
GRAVES' DISEASE
RECEPTORS, THYROTROPIN

ANALYSIS

Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Wallaschofski H, et al. **Clin Endocrinol (Oxf)** 1999 Mar; 50(3):365–72

A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease. Watson PF, et al. **Clin Endocrinol (Oxf)** 1998 Nov;49(5):577–81

Clinical usefulness of TSAb assay with high polyethylene glycol concentrations. Ochi Y, et al. **Horm Res** 1999; 51(3):142–9

BLOOD

Production of bioactive amino-terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor. Costagliola S, et al. **FEBS Lett** 1998 Oct 9;436(3):427–33

Thyroid controversy--stimulating antibodies. Davies TF, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3777–85 (41 ref.)

Development of a luminescent bioassay for thyroid stimulating antibodies. Evans C, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):374–7

Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies. Sakuma R, et al. **J Neurol** 1999 Jun; 246(6):449–53

Elevated anti-galactosyl antibody titers in endemic goiter. Knobel M, et al. **Thyroid** 1999 May;9(5):493–8

Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay. Morgenthaler NG, et al. **Thyroid** 1999 May;9(5):466–75

Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy. Ueta Y, et al. **Thyroid** 1999 Feb;9(2):179–82

Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y, et al. **Thyroid** 1999 Aug;9(8):769–73

Augmentation of thyroid-stimulating antibody-stimulated cyclic adenosine monophosphate response by polyethylene glycol, polyvinyl alcohol, and dextran; highly sensitive porcine thyroid cell thyroid-stimulating antibody assay. Yamashiro K, et al. **Thyroid** 1999 Mar;9(3):263–71

[TSH receptor autoantibody: its historical background and interpretation of the data on TSAb, TSBAb and TBII] Saito J, et al. **Nippon Rinsho** 1999 Aug;57(8):1829–33 (25 ref.) **(Jpn)**

IMMUNOLOGY

Polyethylene glycol augments thyroid cAMP responses by fragments from protease-digested TSAb or TSBAb-IgG. Yamashiro K, et al. **Life Sci** 1999;64(13):1109–16

[Idiopathic myxedema and blocking type antibodies to TSH receptor] Mitsuma T. **Nippon Rinsho** 1999 Aug; 57(8):1759–63 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Mechanism of the augmentative effect of high polyethylene glycol (PEG) concentrations on the thyroid stimulating activity in TSAb-IgG using a porcine thyroid cell assay. Yamashiro K, et al. **Endocr Res** 1999 Feb;25(1):67–75

Augmentation of thyroid-stimulating antibody-stimulated cyclic adenosine monophosphate response by polyethylene glycol, polyvinyl alcohol, and dextran; highly sensitive porcine thyroid cell thyroid-stimulating antibody assay. Yamashiro K, et al. **Thyroid** 1999 Mar;9(3):263–71

IMMUNOGOLD-SILVER TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOGOLD TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOHISTOCHEMISTRY

Immunochemical analysis of laminin during postnatal development of the rat submandibular gland. Trevilatto PC, et al. **Acta Histochem** 1999 Apr;101(2):185–91

Sensitivity and specificity of antibodies on necrotic tumor tissue. Judkins AR, et al. **Am J Clin Pathol** 1998 Nov; 110(5):641–6

Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Prayson RA. **Am J Clin Pathol** 1998 Nov;110(5):629–34

Labels, disclaimers, and rules (oh, my!). Analyte-specific reagents and practice of immunohistochemistry [editorial] Swanson PE. **Am J Clin Pathol** 1999 Apr;111(4):445–8

Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Tworek JA, et al. **Am J Clin Pathol** 1998 Nov;110(5):582–9

Immunolocalization of inducible nitric oxide synthase in human amnion [letter] Thomson A, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):770

Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors. Yamashita K, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):316–22

Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Fend F, et al. **Am J Pathol** 1999 Jan;154(1):61–6

Prognostic factors in breast cancer--with special reference to Ki-67 immunohistochemistry. Railo M. **Ann Chir Gynaecol** 1998;87(3):243–4

Intra-abdominal desmoplastic small round cell tumor: immunohistochemical evidence for up-regulation of autocrine and paracrine growth factors. Froberg K, et al. **Ann Clin Lab Sci** 1998 Nov-Dec;28(6):386–93

Modified true-color computer-assisted image analysis versus subjective scoring of estrogen receptor expression in breast cancer: a comparison. Kohlberger PD, et al. **Anticancer Res** 1999 May-Jun;19(3B):2189–93

Amelogenin protein in tooth germs of the snake Elaphe quadrivirgata, immunohistochemistry, cloning and cDNA sequence. Ishiyama M, et al. **Arch Histol Cytol** 1998 Dec; 61(5):467–74

Immunocytochemical demonstration of the synovial membrane in experimentally induced arthritis of the rat temporomandibular joint. Nozawa-Inoue K, et al. **Arch Histol Cytol** 1998 Dec;61(5):451–66

Immunohistochemical localization of secretory immunoglobulins in the main excretory duct of the human submandibular gland. Perra MT, et al. **Arch Histol Cytol** 1998 Dec;61(5):427–32

IMMUNOHISTOCHEMISTRY

Immunohistochemical localization of pléiotrophin and midkine in the lingual epithelium of the adult rat. Wakisaka S, et al. **Arch Histol Cytol** 1998 Dec;61(5):475–80

Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Chen YX, et al. **Arterioscler Thromb Vasc Biol** 1999 Jan; 19(1):131–9

Immunohistochemical evidence that follicle-stimulating hormone and luteinizing hormone reside in separate cells in the chicken pituitary. Proudman JA, et al. **Biol Reprod** 1999 Jun;60(6):1324–8

Glucocorticoid receptor immunoreactivity in neurons and pituitary cells implicated in reproductive functions in rainbow trout: a double immunohistochemical study. Teitsma CA, et al. **Biol Reprod** 1999 Mar;60(3):642–50

Report from the Biological Stain Commission: FDA issues final rule for classification/reclassification of immunochemistry (IHC) reagents and kits. Taylor CR. **Biotech Histochem** 1998 Jul;73(4):175–7

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Ferrandina G, et al. **Br J Cancer** 1998 Dec;78(12):1645–52

Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry. Perez-Jaffe LA, et al. **Diagn Cytopathol** 1999 Apr; 20(4):219–23

Immunohistochemical detection of cytotoxic lymphocytes in malignant serous effusions. Yu GH, et al. **Diagn Cytopathol** 1999 Jul;21(1):18–21

Immunocytochemical localization of prolactin-releasing peptide in the rat brain. Maruyama M, et al. **Endocrinology** 1999 May;140(5):2326–33

Gastric microcancer with lymph node metastasis: immunohistochemical and DNA analyses. Kimura H, et al. **Endoscopy** 1999 Jun;31(5):S36–7

Immunogold EM reveals a close association of plectin and the desmin cytoskeleton in human skeletal muscle. Schröder R, et al. **Eur J Cell Biol** 1999 Apr;78(4):288–95

Effect of selenium deficiency on cellular and extracellular glutathione peroxidases: immunochemical detection and mRNA analysis in rat kidney and serum. Nakane T, et al. **Free Radic Biol Med** 1998 Sep;25(4–5):504–11

Corticotropin releasing factor in the brain of the gymnotiform fish, Apteronotus leptorhynchus: immunohistochemical studies combined with neuronal tract tracing. Zupanc GK, et al. **Gen Comp Endocrinol** 1999 Jun;114(3):349–64

Calcium binding proteins immunohistochemistry and identification of neurons in the mammalian pineal gland of the African giant rat: Cricetomys gambianus. Bastianelli E, et al. **Gen Physiol Biophys** 1999 Mar;18(1):5–17

Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Mandel U, et al. **Glycobiology** 1999 Jan;9(1):43–52

Distribution of glutathione S-transferases in the human ovary: an immunohistochemical study. Tiltman AJ, et al. **Gynecol Obstet Invest** 1999;47(4):247–50

Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy. Smith NL, et al. **Hum Antibodies** 1999;9(1):61–5

Neuroendocrine carcinomas: role of immunocytochemistry and electron microscopy. Hammond EH, et al. **Hum Pathol** 1998 Dec;29(12):1367–71 (31 ref.)

Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues. Fiorentino M, et al. **Int J Cancer** 1998 Dec 18;79(6):614–8

Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Seo HS, et al. **Int J Cancer** 1998 Dec 9;78(6):760–5

Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. Hofland LJ, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):775–80

Antibody selection for immunohistochemical survey of equine tissue. Kalsow CM, et al. **J Comp Pathol** 1998 Nov; 119(4):467–72

Advantages of immunostaining over DNA analysis using PCR amplification to detect p53 abnormality in long-term formalin-fixed tissues of human colorectal carcinomas [see comments] Matsubayashi H, et al. **J Gastroenterol** 1998 Oct; 33(5):662–9. Comment in: J Gastroenterol 1998 Oct;33(5):777–8.

Immunogold signal amplification: Application of the CARD approach to electron microscopy. Mayer G, et al. **J Histochem Cytochem** 1999 Apr;47(4):421–30

Quantification of protein A-gold staining for peroxisomal enzymes by confocal laser scanning microscopy. Ogiwara N, et al. **J Histochem Cytochem** 1999 Oct;47(10):1343–9

High-resolution immunocytochemical labeling of replicas with ultrasmall gold. Takizawa T. **J Histochem Cytochem** 1999 Apr;47(4):569–74

The potential of in situ hybridization and an immunogold assay to identify Legionella associations with other microorganisms. Desai R, et al. **J Microbiol Methods** 1999 Aug;37(2):155–64

Evidence of androgen receptor expression in lichen sclerosus: an immunohistochemical study. Kohlberger PD, et al. **J Soc Gynecol Investig** 1998 Nov-Dec;5(6):331–3

Use of immunogold with silver enhancement. Oliver C. **Methods Mol Biol** 1999;115:241–5 (12 ref.)

Quantitative aspects of immunogold labeling in embedded and nonembedded sections. Rabouille C. **Methods Mol Biol** 1999;117:125–44 (23 ref.)

Preparation, use, and enlargement of ultrasmall gold particles in immunoelectron microscopy. Baschong W, et al. **Microsc Res Tech** 1998 Jul 1;42(1):66–79 (161 ref.)

Action of gold chloride ("gold toning") on silver-enhanced 1 nm gold markers. Pohl K, et al. **Microsc Res Tech** 1998 Jul 1;42(1):59–65

Immunohistochemical localization of taurine in the retina of developing and adult human and adult monkey. Nag TC, et al. **Neurochem Int** 1998 Aug;33(2):195–200

The role of immunocytochemistry in congenital myopathies. Sewry CA. **Neuromuscul Disord** 1998 Aug;8(6):394–400 (22 ref.)

An alpha2-macroglobulin-serine proteinase complex from human carcinomatous ascites and pleural effusion: isolation, monoclonal antibody preparation, and immunohistochemical study. Arima K, et al. **Oncol Res** 1998;10(10):499–507

Immunohistochemical and molecular analysis of giant cell carcinoma of the pancreas: a report of three cases. Imai Y, et al. **Pancreas** 1999 Apr;18(3):308–15

An immunohistochemical study of type I insulin-like growth factor receptors in the placentae of pregnancies with appropriately grown or growth restricted fetuses. Holmes R, et al. **Placenta** 1999 May;20(4):325–30

Immunohistochemical localization of vascular endothelial growth factor (VEGF) and its two specific receptors, Flt-1 and KDR, in the porcine placenta and non-pregnant uterus. Winther H, et al. **Placenta** 1999 Jan;20(1):35–43

Immunocytochemical characterisation of rabbit and mouse embryonic fibroblasts. Horák V, et al. **Reprod Nutr Dev** 1998 Nov-Dec;38(6):683–95

[Contribution of immunohistochemistry to diagnosis of cutaneous tumors] Kanitakis J, et al. **Ann Dermatol Venereol** 1998 May;125(5):354–69 (143 ref.) **(Fre)**

[A case of hyalinizing spindle cell tumor with giant rosettes in the presacral region. Immunohistochemical and ultrastructural study] de Pinieux G, et al. **Ann Pathol** 1998 Dec;18(6):488–91 (Eng. Abstr.) **(Fre)**

[Localization by immunogold of collagen VI, laminin and fibrillin in the trabecular meshwork of patients with glaucoma] Delaigue O, et al. **J Fr Ophtalmol** 1999 Feb; 22(1):61–6 (Eng. Abstr.) **(Fre)**

[In vitro detection of prostate cancer circulating cells by immunocytochemistry, flow cytometry and RT-PCR PSA] de la Taille A, et al. **Prog Urol** 1998 Dec;8(6):1058–64 (Eng. Abstr.) **(Fre)**

[The first All-Russian workshop on immunohistochemical diagnosis of tumors] Khasanov R, et al. **Arkh Patol** 1999 Jan-Feb;61(1):63–4 **(Rus)**

[Electron-microscopic and immunohistochemical study of the reorganization of the microtubule system in granular cells of frog urinary bladder after water transport induction] Gorshkov AN, et al. **Tsitologiia** 1999;41(1):40–7 (Eng. Abstr.) **(Rus)**

CLASSIFICATION

FDA issues final rule for classification and reclassification of immunochemistry reagents and kits [editorial] Taylor CR. **Am J Clin Pathol** 1999 Apr;111(4):443–4

INSTRUMENTATION

Comparative evaluation of automated systems in immunohistochemistry. Le Neel T, et al. **Clin Chim Acta** 1998 Dec;278(2):185–92

Approach to automation in immunohistochemistry. Moreau A, et al. **Clin Chim Acta** 1998 Dec;278(2):177–84

METHODS

Immunocytochemistry applied to aspiration biopsy cytology. Diagnostic contribution in 100 cases of previously stained, routine specimens. Mitteldorf CA, et al. **Acta Cytol** 1999 Mar-Apr;43(2):218–26

The visualization of a new class of traumatically injured axons through the use of a modified method of microwave antigen retrieval. Stone JR, et al. **Acta Neuropathol (Berl)** 1999 Apr;97(4):335–45

Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Kaplan B, et al. **Am J Clin Pathol** 1999 Sep;112(3):403–7

Fetal cell identifiers: results of microscope slide-based immunocytochemical studies as a function of gestational age and abnormality. Zheng YL, et al. **Am J Obstet Gynecol** 1999 May;180(5):1234–9

Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Geradts J, et al. **Am J Pathol** 1999 Jun; 154(6):1665–71

Use of intervening unstained slides for immunohistochemical stains for high molecular weight cytokeratin on prostate needle biopsies. Green R, et al. **Am J Surg Pathol** 1999 May;23(5):567–70

Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Turner RR, et al. **Am J Surg Pathol** 1999 Mar;23(3):263–7

Immunohistochemical localization of taurine in various tissues of the mouse. Terauchi A, et al. **Amino Acids** 1998; 15(1–2):151–60

Detection of cell and tissue surface antigens using up-converting phosphors: a new reporter technology. Zijlmans HJ, et al. **Anal Biochem** 1999 Feb 1;267(1):30–6

Automatic quantification of immunohistochemically stained cell nuclei based on standard reference cells. Ranefall P, et al. **Anal Cell Pathol** 1998;17(2):111–23

The apoptosis cascade--morphological and immunohistochemical methods for its visualization. Huppertz B, et al. **Anat Embryol (Berl)** 1999 Jul;200(1):1–18 (103 ref.)

Application of labeling techniques to archival temporal bone sections. Tian Q, et al. **Ann Otol Rhinol Laryngol** 1999 Jan; 108(1):47–53

Immunochemical detection and isolation of DNA from metabolically active bacteria. Urbach E, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1207–13

Antigen retrieval immunohistochemistry used for routinely processed celloidin-embedded human temporal bone sections: standardization and development. Shi SR, et al. **Auris Nasus Larynx** 1998 Dec;25(4):425–43 (148 ref.)

A full color system for quantitative assessment of histochemical and immunohistochemical staining patterns. Ma W, et al. **Biotech Histochem** 1999 Jan;74(1):1–9

Comparison of immunohistochemistry with immuneassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Ferrier CM, et al. **Br J Cancer** 1999 Mar;79(9–10):1534–41

Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays. de la Taille A, et al. **Br J Urol** 1998 Sep;82(3):389–92

Synaptophysin immunocytochemistry with thermal intensification: a marker of terminal axonal maturation in the human fetal nervous system. Sarnat HB, et al. **Brain Dev** 1999 Jan;21(1):41–50

Detection of intranucleolar chromatin using an ultrastructural immunolabelling technique. Ghosh S, et al. **Cell Biol Int** 1998;22(9–10):609–14

A comparison of the anti-histone and Apop-Tag technique for demonstrating apoptosis with option for silver enhancement. Al-hazzaa AA, et al. **Cell Biol Int** 1998; 22(4):271–6

Squash procedure for protein immunolocalization in meiotic cells. Page J, et al. **Chromosome Res** 1998 Dec;6(8):639–42

Immunohistochemistry in diagnostic dermatopathology. Hudson AR, et al. **Dermatol Clin** 1999 Jul;17(3):667–89, x (303 ref.)

The flow cytometric cross match. Standardization of quantitative analysis. Brando B, et al. **Eur J Histochem** 1997;41 Suppl 2:107–8

Correlation of cell proliferation and clinical behaviour of early gastric cancer. Immunohistochemical study with "in vivo" bromodeoxyuridine labelling. Ferrari C, et al. **Eur J Histochem** 1997;41 Suppl 2:127–8

Preliminary immunocytochemical study of C cells of the thyroid and parathyroid glands in five species of wild and laboratory rodents. Sawicki B, et al. **Folia Histochem Cytobiol** 1999;37(2):65–6

Multiple epitope labeling by the exclusive use of alkaline phosphatase conjugates in immunohistochemistry. Deininger MH, et al. **Histochem Cell Biol** 1998 Oct; 110(4):425–30

Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in human brain tissue. Kraszpulski M, et al. **Histochem Cell Biol** 1998 Oct;110(4):439–45

Localizing estradiol and other diffusible hormones and drugs by autoradiography and immunocytochemistry [letter; comment] Stumpf WE. **Histochem Cell Biol** 1999 Jan; 111(1):83–6. Comment on: Histochem Cell Biol 1998 Apr;109(4):295–300.

Concentration dependent and adverse effects in immunohistochemistry using the tyramine amplification technique. Mengel M, et al. **Histochem J** 1999 Mar; 31(3):195–200

Biotin inclusions: a potential pitfall in immunohistochemistry avoided [letter; comment] Dodson A, et al. **Histopathology** 1999 Feb;34(2):178–9. Comment on: Histopathology 1997 Nov;31(5):400–7. Comment on: Histopathology 1998 Jul;33(1):87.

Biotin inclusions: a potential pitfall in immunohistochemistry [letter; comment] [see comments] Nayler SJ, et al. **Histopathology** 1998 Jul;33(1):87. Comment on: Histopathology 1997 Nov;31(5):400–7. Comment in: Histopathology 1999 Feb;34(2):178–9.

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Harvey JM, et al. **J Clin Oncol** 1999 May;17(5):1474–81

The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. Sabattini E, et al. **J Clin Pathol** 1998 Jul; 51(7):506–11

High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. Faulkner LB, et al. **J Hematother** 1998 Aug;7(4):361–6

Improved double immunofluorescence for confocal laser scanning microscopy. Kumar RK, et al. **J Histochem Cytochem** 1999 Sep;47(9):1213–8

Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. Lehr HA, et al. **J Histochem Cytochem** 1999 Jan; 47(1):119–26

Visualization of axonally transported horseradish peroxidase using enhanced immunocytochemical detection: a direct comparison with the tetramethylbenzidine method. Romero MI, et al. **J Histochem Cytochem** 1999 Feb; 47(2):265–72

Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. Romijn HJ, et al. **J Histochem Cytochem** 1999 Feb;47(2):229–36

Pretreatment in a high-pressure microwave processor for MIB-1 immunostaining of cytological smears and paraffin tissue sections to visualize the various phases of the mitotic cycle. Suurmeijer AJ, et al. **J Histochem Cytochem** 1999 Aug;47(8):1015–20

A semiquantitative image-analytical method for the recording of dose-response curves in immunocytochemical preparations. Wicht H, et al. **J Histochem Cytochem** 1999 Mar;47(3):411–20

Improved immunodetection of nuclear antigens after sodium dodecyl sulfate treatment of formaldehyde-fixed cells. Wilson DM 3rd, et al. **J Histochem Cytochem** 1999 Aug; 47(8):1095–100

A novel method for concurrent visualization of immunostain under light and electron microscopy in pancreatic islets. Wong FS, et al. **J Histochem Cytochem** 1998 Dec; 46(12):1341–6

Erratum to "Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells" [corrected and republished article originally printed in J Immunol Methods 1998 May 1;214(1–2):97–111] Loré K, et al. **J Immunol Methods** 1998 Sep 1;218(1–2):173–87

A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. Zaki SR, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S36–47

High-pressure freezing for immunocytochemistry. Monaghan P, et al. **J Microsc** 1998 Dec;192 (Pt 3):248–58

A method of combining biocytin tract-tracing with avidin-biotin-peroxidase complex immunocytochemistry for pre-embedding electron microscopic labeling in neonatal tissue. Erişir A, et al. **J Neurosci Methods** 1998 Jun 1;81(1–2):189–97

Pre- or postembedding immunocytochemistry: which to choose for the localization of glial fibrillary acidic protein (GFAP)? Hajós F, et al. **J Neurosci Methods** 1998 Nov 1;85(1):99–105

Species-specific immunostaining of embryonic corneal nerves: techniques for inactivating endogenous peroxidases and demonstration of lateral diffusion of antibodies in the plane of the corneal stroma. Koo SJ, et al. **J Neurosci Methods** 1998 Nov 1;85(1):63–71

Tyramide signal amplification in brain immunocytochemistry: adaptation to electron microscopy. Stanarius A, et al. **J Neurosci Methods** 1999 Apr 1; 88(1):55–61

A method to quantify glial fibrillary acidic protein immunoreactivity on the suprachiasmatic nucleus. Vilaplana J, et al. **J Neurosci Methods** 1999 May 1; 88(2):181–7

Immunohistochemical methods to detect nitrotyrosine. Viera L, et al. **Methods Enzymol** 1999;301:373–81 (34 ref.)

Immunohistochemical detection of cytokines and cell adhesion molecules in the synovial membrane. Parker A, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun; 21(5):311–9

Assessment of cellular localization of the thromboxane A2 receptor by immunocytochemistry. Blackman SC, et al. **Methods Mol Biol** 1999;120:145–71

Processing of cytological specimens. Bratthauer GL. **Methods Mol Biol** 1999;115:63–70 (6 ref.)

Processing of tissue-culture cells. Bratthauer GL. **Methods Mol Biol** 1999;115:71–6 (6 ref.)

Processing of tissue specimens. Bratthauer GL. **Methods Mol Biol** 1999;115:77–84 (11 ref.)

The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Bratthauer GL. **Methods Mol Biol** 1999;115:203–14 (12 ref.)

Immunohistochemical analysis of cyclooxygenase expression in human skin. Buckman SY, et al. **Methods Mol Biol** 1999; 120:35–43

Overview of the clinical immunohistochemistry laboratory: regulations and troubleshooting guidelines. Fetsch PA, et al. **Methods Mol Biol** 1999;115:405–14 (5 ref.)

Overview of immunocytochemical approaches to the differential diagnosis of tumors. Frisman DM. **Methods Mol Biol** 1999;115:415–37 (58 ref.)

Immunohistochemistry using polyester wax. Kent A. **Methods Mol Biol** 1999;97:655–61

Antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. Krenacs L, et al. **Methods Mol Biol** 1999;115:85–93 (19 ref.)

Multiple antigen immunostaining procedures. Krenacs T, et al. **Methods Mol Biol** 1999;115:223–33 (15 ref.)

Overview of antibody use in immunocytochemistry. Mao SY, et al. **Methods Mol Biol** 1999;115:3–10

Immunohistochemistry on whole embryos. Mason I. **Methods Mol Biol** 1999;97:663–6

Localization and distribution of cyclooxygenase-2 in brain tissue by immunohistochemistry. O'Banion MK, et al. **Methods Mol Biol** 1999;120:55–66

Immunocytochemistry of NMDA receptors. Petralia RS, et al. **Methods Mol Biol** 1999;128:73–92 (59 ref.)

Immunohistochemistry and immunocytochemistry. Zheng J. **Methods Mol Biol** 1998;105:307–14 (6 ref.)

Comparison of the immunolabeling of heated and deplasticized epoxy sections on the electron microscopical level. Brorson SH. **Micron** 1999 Aug;30(4):319–24

Comparison of the immunogold labeling of single light chains and whole immunoglobulins with anti-kappa on LR-white and epoxy sections. Brorson SH. **Micron** 1998 Dec; 29(6):439–43

A new protocol to prepare dry plant specimens for electron microscopy and immunocytochemistry. Grote M, et al. **Micron** 1999 Feb;30(1):65–70

Effect of microwave irradiation on antibody labeling efficiency when applied to ultrathin cryosections through fixed biological material. Chicoine L, et al. **Microsc Res Tech** 1998 Jul 1;42(1):24–32

Learning about truth and biases through experience: section surface corrugation, protein denaturation, and staining. Kellenberger E. **Microsc Res Tech** 1998 Jul 1;42(1):33–42

Combined fluorescent and gold immunoprobes: reagents and methods for correlative light and electron microscopy. Powell RD, et al. **Microsc Res Tech** 1998 Jul 1;42(1):2–12

Ultrasmall immunogold particles: important probes for immunocytochemistry. Robinson JM, et al. **Microsc Res Tech** 1998 Jul 1;42(1):13–23

Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34betaE12 to discriminate cancer in prostatic epithelium. Iczkowski KA, et al. **Mod Pathol** 1999 Jan;12(1):1–4

Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer [editorial; comment] Ramnani DM, et al. **Mod Pathol** 1999 May;12(5):443–4. Comment on: Mod Pathol 1999 May;12(5):472–8.

A comparison of manual and semi-automated methods in the assessment of axonal injury. Gentleman SM, et al. **Neuropathol Appl Neurobiol** 1999 Feb;25(1):41–7

Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method [letter] Toda Y, et al. **Pathol Int** 1999 May;49(5):479–83

Two-colour immunocytochemical staining of gamma (gamma) and epsilon (epsilon) type haemoglobin in fetal red cells. Mesker WE, et al. **Prenat Diagn** 1998 Nov; 18(11):1131–7

Antigen retrieval methods for immunohistochemistry. Brown C. **Toxicol Pathol** 1998 Nov-Dec;26(6):830–1 (6 ref.)

Localization of vascular endothelial growth factor in synovial membrane mast cells: examination with "multi-labelling subtraction immunostaining". Yamada T, et al. **Virchows Arch** 1998 Dec;433(6):567–70

Quantitative immunohistochemical analysis of the glutathione S-transferase GSTM1: in situ phenotyping in archival material. Fritz P, et al. **Xenobiotica** 1999 Jul;29(7):693–702

[Immunohistochemical detection of cytokeratins in the irradiated mandibular gland of the Wistar rat] Bartel-Friedrich S, et al. **Laryngorhinootologie** 1999 Jun; 78(6):326–31 (Eng. Abstr.) **(Ger)**

[Use in immunohistochemical studies of a method of restoration of antigenic specificity as affected by microwaves in tissue fixed with formalin and embedded in paraffin] Gurevich LE, et al. **Arkh Patol** 1999 Mar-Apr; 61(2):48–50 (Eng. Abstr.) **(Rus)**

STANDARDS

Extension of useful reagent shelf life beyond manufacturers' recommendations. Cell Markers Committee of the College of American Pathologists. Tubbs RR, et al. **Arch Pathol Lab Med** 1998 Dec;122(12):1051–2

Antigen retrieval immunohistochemistry used for routinely processed celloidin-embedded human temporal bone sections: standardization and development. Shi SR, et al. **Auris Nasus Larynx** 1998 Dec;25(4):425–43 (148 ref.)

Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Barnes DM, et al. **Eur J Cancer** 1998 Oct;34(11):1677–82 (28 ref.)

Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Ruiter DJ, et al. **Eur J Cancer** 1998 Aug; 34(9):1334–40

Issues in immunohistochemistry. Johnson CW. **Toxicol Pathol** 1999 Mar-Apr;27(2):246–8

TRENDS

The everchanging advances in enzyme histochemistry, 1986–1996. Stoward PJ, et al. **Eur J Histochem** 1998;42 Spec No:35–40 (26 ref.)

IMMUNOHISTOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNOLABELING TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOLOGIC ACCESSORY CELLS see **ANTIGEN-PRESENTING CELLS**

IMMUNOLOGIC CAPPING

see related
IMMUNOGLOBULINS, SURFACE

IMMUNOLOGY

Engagement of spectrin and actin in capping of FcgammaRII revealed by studies on permeabilized U937 cells. Kwiatkowska K, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):287–93

IMMUNOLOGIC COMPETENCE see **IMMUNOCOMPETENCE**

IMMUNOLOGIC DEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNOLOGIC DEFICIENCY SYNDROMES

see related
IMMUNOCOMPROMISED HOST

Noninfectious immunologic disorders in adults. Bensch G, et al. **Chest Surg Clin N Am** 1999 Feb;9(1):113–24, ix (38 ref.)

Antibody deficiency, growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy: a novel syndrome. Roifman CM. **Clin Genet** 1999 Feb;55(2):103–9

Autoimmunity with immunodeficiency: a logical paradox [editorial; comment] Seidman EG, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):377–9 (8 ref.) . Comment on: J Pediatr Gastroenterol Nutr 1999 Apr;28(4):393–9.

VIII Meeting of the European Society for Immunodeficiencies, ESID'98. V Meeting of the International Patient Organisation of Primary Immunodeficiencies, IPOPI '98. III Meeting of the International Nursing Group for Immunodeficiencies, INGID '98. Rhodes, Hellas, October 8–11, 1998. Abstracts. **Mol Immunol** 1998 Aug;35(11–12):623–818

Primary immunodeficiency disorders. Mamlock RJ. **Prim Care** 1998 Dec;25(4):739–58 (37 ref.)

Primary Immunodeficiency Association of SA [letter] Swart R. **S Afr Med J** 1999 Apr;89(4):365

Immunodeficiency in a patient with Baller–Gerold syndrome: a reason for early demise? Golombek SG, et al. **South Med J** 1998 Oct;91(10):966–9

[Infections caused by BCG and atypical mycobacteria in children: a new group of immune deficiencies (editorial)] Casanova JL. **Arch Pediatr** 1999 Feb;6(2):139–40 **(Fre)**

[Secondary immunodeficiency syndrome in patients with chronic bronchitis] Guseinov KhIu. **Probl Tuberk** 1999; (2):37–9 (Eng. Abstr.) **(Rus)**

[Immunodeficiencies: an overview and various diagnostic difficulties] Fontán Casariego G. **Sangre (Barc)** 1999 Apr; 44(2):101–6 (45 ref.) **(Spa)**

[Secondary immunodeficiencies] Giraldo Castellano P. **Sangre (Barc)** 1999 Apr;44(2):155–61 (41 ref.) **(Spa)**

[The Spanish Registry of Primary Immunodeficiencies. REDIP-1998] Mila J, et al. **Sangre (Barc)** 1999 Apr; 44(2):163–7 **(Spa)**

BLOOD

Existence of activated and memory CD4+ T cells in peripheral blood and their skin infiltration in CD8 deficiency. Katamura K, et al. **Clin Exp Immunol** 1999 Jan; 115(1):124–30

CHEMICALLY INDUCED

Fetal alcohol exposure attenuates interleukin-1beta-induced fever: neuroimmune mechanisms. Taylor AN, et al. **J Neuroimmunol** 1999 Sep 1;99(1):44–52

Effect of dietary glutamate on chemotherapy-induced immunosuppression. Lin CM, et al. **Nutrition** 1999 Sep; 15(9):687–96

[The effect of erythromycin on immunity in immunodeficiency] Sakaeva DD, et al. **Eksp Klin Farmakol** 1999 Jan-Feb;62(1):50–2 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Monozygotic twin brothers with primary immunodeficiency presenting with metastatic adenocarcinoma of unknown primary. Wood LA, et al. **Acta Oncol** 1998;37(7–8):771–2

Cytomegalovirus retinitis in immunosuppressed children. Baumal CR, et al. **Am J Ophthalmol** 1999 May;127(5):550–8

Immunodeficiency syndromes and recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Dec 10;58(11):565–8 (13 ref.)

Computed tomography scan assessment of lung disease in primary immunodeficiencies. Newson T, et al. **Eur J Pediatr** 1999 Jan;158(1):29–31

The 3rd National AIDS Malignancy Conference. Bethesda,

Maryland, USA. May 26–27, 1999. Abstracts.
J Acquir Immune Defic Syndr 1999 May 1;21(1):A1–41

Persistent Sweet's syndrome occurring in a child with a primary immunodeficiency. Lipp KE, et al.
J Am Acad Dermatol 1999 May;40(5 Pt 2):838–41

Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. Kew OM, et al.
J Clin Microbiol 1998 Oct;36(10):2893–9

Massilia timonae gen. nov., sp. nov., isolated from blood of an immunocompromised patient with cerebellar lesions. La Scola B, et al. **J Clin Microbiol** 1998 Oct;36(10):2847–52

B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. Hjelmström P, et al. **J Immunol** 1998 Nov 1;161(9):4480–3

Congenital hypothyroidism and immunodeficiency: evidence for an endocrine-immune interaction. Pillay K.
J Pediatr Endocrinol Metab 1998 Nov–Dec;11(6):757–61

[Immune deficiency in the genesis of acute postoperative pancreatitis (initial studies)] Dimitrova V, et al.
Khirurgiia (Sofiia) 1998;51(4):14–8 (Eng. Abstr.) **(Bul)**

[Immunology in medical practice. XVIII [correction of XVII]. Children with recurrent airway problems: asthma is not always the cause (published erratum appears in Ned Tijdschr Geneeskd 1999 May 8;143(19):1016)] Arets HG, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):769–72 (Eng. Abstr.) **(Dut)**

[Granulomatous skin lesions in Griscelli disease] Eyer D, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):727–8 **(Fre)**

[Vaccinations and systemic diseases. Vaccinations and immunosuppression] Bouchaud O, et al.
Ann Med Interne (Paris) 1998 Oct;149(6):351–60 (56 ref.) (Eng. Abstr.) **(Fre)**

[The development of intestinal dysbacteriosis in newborn infants with a deficiency of antibodies to the Re-glycolipid] Likhoded VG, et al.
Zh Mikrobiol Epidemiol Immunobiol 1998 Jul–Aug;(4):67–8 (Eng. Abstr.) **(Rus)**

[Ear, nose, and throat manifestations in patients with primary immunodeficiencies] Galicia G, et al. **Rev Alerg Mex** 1999 Jul–Aug;46(4):108–19 (Eng. Abstr.) **(Spa)**

CONGENITAL

Epstein-Barr virus-associated leiomyosarcoma of the thyroid in a child with congenital immunodeficiency: a case report. Tulbah A, et al. **Am J Surg Pathol** 1999 Apr;23(4):473–6

Congenital immunodeficiency syndromes. Williams LW.
Chest Surg Clin N Am 1999 Feb;9(1):239–57 (45 ref.)

Gene therapy for congenital lymphoid immunodeficiency diseases. Weinberg KI, et al. **Semin Hematol** 1998 Oct; 35(4):354–66 (75 ref.)

DIAGNOSIS

How to evaluate suspected immunodeficiency [see comments] Dizon JG, et al. **Pediatr Ann** 1998 Nov; 27(11):743–50 (28 ref.). Comment in: Pediatr Ann 1998 Nov;27(11):708.

[Immunology in medical practice. XVIII [correction of XVII]. Children with recurrent airway problems: asthma is not always the cause (published erratum appears in Ned Tijdschr Geneeskd 1999 May 8;143(19):1016)] Arets HG, et al. **Ned Tijdschr Geneeskd** 1999 Apr 10;143(15):769–72 (Eng. Abstr.) **(Dut)**

[Eosinophilic pustulosis in an infant accompanied by immune deficit] Rybojad M, et al. **Ann Dermatol Venereol** 1999 Jan; 126(1):29–31 (Eng. Abstr.) **(Fre)**

[Intermittent fever with cutaneous manifestations...] Duhamel E, et al. **Rev Med Interne** 1999;20 Suppl 2:281s–282s **(Fre)**

[Flow cytometry in the diagnosis of the primary immunodeficiencies] García Rodríguez MC, et al.
Sangre (Barc) 1999 Apr;44(2):127–33 (27 ref.) **(Spa)**

DRUG THERAPY

Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997–1998. **MMWR Morb Mortal Wkly Rep** 1999 Mar 5;48(8):159–62

Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndromes. Costa-Carvalho BT, et al. **Rev Paul Med** 1998 Sep–Oct;116(5):1815–20

[The effect of thymogen on the postintoxication immunodeficiency state induced by acute acetonitrile poisoning] Zabrodskiĭ PF. **Eksp Klin Farmakol** 1999 May–Jun;62(3):48–9 (Eng. Abstr.) **(Rus)**

[Clinical trial of domestic drug polyoxidonium in secondary immunodeficiency] Borisova AM, et al. **Ter Arkh** 1998; 70(10):52–7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. Buhl AM, et al. **J Immunol** 1999 Apr 15; 162(8):4438–46

Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Suzuki H, et al. **Science** 1999 Jan 15;283(5400):390–2

EPIDEMIOLOGY

Increased incidence of cancer in patients with cartilage-hair hypoplasia. Mäkitie O, et al. **J Pediatr** 1999 Mar; 134(3):315–8

ETIOLOGY

Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Yotnda P, et al. **Exp Hematol** 1999 Sep;27(9):1375–83

[Systemic Salmonella arizonae infections in patients with a deficiency of cell-mediated immunity. A report of 2 cases and a review of the literature] Carfagna P, et al.
Recenti Prog Med 1998 Dec;89(12):632–6 (25 ref.) (Eng. Abstr.) **(Ita)**

[Secondary immunodeficiency syndrome] Kiyokawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):273–6 (13 ref.) **(Jpn)**

[Characteristics of secondary immunodeficiency in patients with neurocirculatory dystonia] Malysheva OA, et al.
Ter Arkh 1999;71(3):67–9 (Eng. Abstr.) **(Rus)**

[Immunosuppression induced by homologous blood transfusion] Fariñas Guerrero F, et al. **Sangre (Barc)** 1998 Jun;43(3):213–7 (61 ref.) **(Spa)**

GENETICS

Aberrant expression of the NF-kappaB and IkappaB proteins in B cells from viable motheaten mice. Khaled AR, et al. **Autoimmunity** 1999;30(2):115–28

Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region [published erratum appears in Blood Cells Mol Dis 1999 Feb;25(1):78] Poltorak A, et al.
Blood Cells Mol Dis 1998 Sep;24(3):340–55

The wst gene regulates multiple forms of thymocyte apoptosis. Potter M, et al. **Cell Immunol** 1998 Sep 15; 188(2):111–7

Genetic effects on immunity new genes - how do they fit? [editorial] Conley ME. **Curr Opin Immunol** 1999 Aug; 11(4):427–30

Allergy, immunology, and related disorders [editorial] Fuleihan RL. **Curr Opin Pediatr** 1998 Dec;10(6):581–3 (11 ref.)

Abnormal methylation does not prevent X inactivation in ICF patients. Bourc'his D, et al. **Cytogenet Cell Genet** 1999; 84(3–4):245–52

Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response. Sterzl J. **Folia Microbiol (Praha)** 1998; 43(5):535–42 (60 ref.)

Molecular basis of hereditary C1q deficiency. Petry F.
Immunobiology 1998 Aug;199(2):286–94 (19 ref.)

Inherited cytokine and cytokine receptor deficiencies in man. Di Santo JP. **Int Rev Immunol** 1998;17(1–4):103–20 (68 ref.)

Corneal transplantation in antibody-deficient hosts. Goslings WR, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):250–3

Expression of properdin in complete and incomplete deficiency: normal in vitro synthesis by monocytes in two cases with properdin deficiency type II due to distinct mutations. Fredrikson GN, et al. **J Clin Immunol** 1998 Jul; 18(4):272–82

Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. Gao JL, et al. **J Exp Med** 1999 Feb 15;189(4):657–62

Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon.
Lekstrom-Himes JA, et al. **J Exp Med** 1999 Jun 7; 189(11):1847–52

Accelerated emigration of B lymphocytes in the Xid mouse. Cariappa A, et al. **J Immunol** 1999 Apr 15;162(8):4417–23

Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. Smyth MJ, et al. **J Immunol** 1999 Aug 1;163(3):1350–3

A FISH study of chromosome fusion in the ICF syndrome: involvement of paracentric heterochromatin but not of the centromeres themselves. Sumner AT, et al.
J Med Genet 1998 Oct;35(10):833–5

Exposing the human nude phenotype [letter] Frank J, et al. **Nature** 1999 Apr 8;398(6727):473–4

Interleukin 12 deficiency associated with recurrent infections. Haraguchi S, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13125–9

Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Kurimasa A, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1403–8

[Genetic defects in control of T cell activation evolving in a syndrome of lymphohistiocytic activation]
Dufourcq-Lagelouse R, et al. **Arch Pediatr** 1999;6 Suppl 2:417s–419s **(Fre)**

[The molecular basis of primary immunodeficiency syndrome and the current therapeutic approach for the disease] Morio T. **Rinsho Byori** 1999 Jun;47(6):519–24 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Physiopathogenesis and molecular bases of the primary immunodeficiencies] García Cabanillas JA, et al.
Sangre (Barc) 1999 Apr;44(2):107–22 (46 ref.) **(Spa)**

[Primary immunodeficiencies and the major histocompatibility system] Gómez de la Concha E, et al.
Sangre (Barc) 1999 Apr;44(2):123–6 (27 ref.) **(Spa)**

IMMUNOLOGY

HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice. Scott DE, et al. **AIDS Res Hum Retroviruses** 1998 Sep 20;14(14):1263–9

Severe B cell deficiency and disrupted splenic architecture in transgenic mice expressing the E41K mutated form of Bruton's tyrosine kinase. Dingjan GM, et al. **EMBO J** 1998 Sep 15;17(18):5309–20

Normal CD40-mediated activation of monocytes and dendritic cells from patients with hyper-IgM syndrome due to a CD40 pathway defect in B cells. Revy P, et al. **Eur J Immunol** 1998 Nov;28(11):3648–54

Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response. Sterzl J. **Folia Microbiol (Praha)** 1998; 43(5):535–42 (60 ref.)

Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Tlaskalová-Hogenová H, et al.
Folia Microbiol (Praha) 1998;43(5):545–50 (50 ref.)

Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Furukawa H, et al. **Hum Immunol** 1999 Jan;60(1):32–40

Defective degranulation and calcium mobilization of bone-marrow derived mast cells from Xid and Btk-deficient mice. Setoguchi R, et al. **Immunol Lett** 1998 Dec;64(2–3):109–18

Selective antipolysaccharide antibody deficiency associated with peripheral blood CD5+ B-cell predominance. Antall PM, et al. **J Allergy Clin Immunol** 1999 Apr;103(4):637–41

Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. Hermans MH, et al.
J Exp Med 1999 Feb 15;189(4):683–92

Glutamate augments retrovirus-induced immunodeficiency through chronic stimulation of the hypothalamic-pituitary-adrenal axis. Espey MG, et al. **J Immunol** 1999 Apr 15; 162(8):4998–5002

Delayed clearance of filarial infection and enhanced Th1 immunity due to modulation of macrophage APC functions in xid mice. Mukhopadhyay S, et al. **J Immunol** 1999 Jul 15;163(2):875–83

Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice. Smyth MJ, et al. **J Immunol** 1999 Aug 1;163(3):1350–3

CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer. Subauste CS, et al. **J Immunol** 1999 Jun 1;162(11):6690–700

Late onset immunodeficiency in a patient with recurrent thymic carcinoma and myasthenia gravis. Schmidt S, et al. **J Neurol Sci** 1998 May 7;157(2):201–5

Ischaemic heart disease in primary immunodeficiency [letter; comment] Hammar N, et al. **Lancet** 1998 Nov 28; 352(9142):1786. Comment on: Lancet 1997 Aug 9;350(9075):430–6. Comment on: Lancet 1998 Sep 19;352(9132):959–60.

Immunological consequences of laparoscopic surgery, speculations on the cause and clinical implications. Sietses C, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):250–8 (85 ref.)

X-linked immunodeficiency affects the outcome of Schistosoma mansoni infection in the murine model. Gaubert S, et al. **Parasite Immunol** 1999 Feb;21(2):89–101

Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. Wasserman RL, et al. **Pediatr Infect Dis J** 1999 Feb; 18(2):157–63 (37 ref.)

Primary antibody deficiency and Crohn's disease. Conlong P, et al. **Postgrad Med J** 1999 Mar;75(881):161–4

Deficient cellular immunity--finding and fixing the defects. Greenberg PD, et al. **Science** 1999 Jul 23;285(5427):546–51 (58 ref.)

[Humoral immune deficits and the skin (editorial)] Lassoued K. **Ann Dermatol Venereol** 1999 Mar;126(3):215–22 **(Fre)**

[Primary immunologic deficiency by deficiency of HLA class II antigens: nine new Tunisian cases] Bejaoui M, et al.
Arch Pediatr 1998 Oct;5(10):1089–93 (Eng. Abstr.) **(Fre)**

[Immune system and immunodeficiency] Sapin MR.
Klin Med (Mosk) 1999;77(1):5–11 (22 ref.) **(Rus)**

METABOLISM

Metabolic and hematologic changes occurring after rapid intravenous infusion of gammaglobulin in patients with antibody deficiency syndromes. Costa-Carvalho BT, et al. **Rev Paul Med** 1998 Sep–Oct;116(5):1815–20

[Metabolic changes induced by protease inhibitors. Expert Workshop of the Curatorium on Immune Deficiency, Munich, 15–17 October 1998, Weimar]
Dtsch Med Wochenschr 1998 Dec 11;123(50 Suppl Stoffwech):1–6 **(Ger)**

PARASITOLOGY

Cryptosporidium in water and the immunocompromised.
Commun Dis Rep CDR Wkly 1999 Aug 13;9(33):289, 292

PATHOLOGY

Combined immunodeficiency associated with increased apoptosis of lymphocytes and radiosensitivity fibroblasts. Peake J, et al. **Cancer Res** 1999 Jul 15;59(14):3454–60

Expression of heat shock protein 70 blocks thymic differentiation of T cells in transgenic mice. Lee WH, et al. **Immunology** 1998 Dec;95(4):559–65

Accelerated emigration of B lymphocytes in the Xid mouse. Cariappa A, et al. **J Immunol** 1999 Apr 15;162(8):4417–23

Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. Rosenkranz AR, et al. **J Immunol** 1998 Dec 15;161(12):6463–7

A mouse carrying genetic defect in the choice between T and B lymphocytes. Tokoro Y, et al. **J Immunol** 1998 Nov 1;161(9):4591–8

PHYSIOPATHOLOGY

Study of gastrointestinal polypeptides controlling gastric acid secretion in patients with primary antibody deficiency. Alonso Falcón F, et al. **Rev Esp Enferm Dig** 1999 Jan; 91(1):47–60 **(Eng, Spa)**

Hepatic dysfunction in a population of antibody-deficient patients: prevalence, aetiology and outcome of PCR screening for hepatitis C and G viruses. O'Leary PF, et al. **Vox Sang** 1999;76(3):144–8

[Primitive immunologic deficiencies in the adult] Oksenhendler E. **Rev Med Interne** 1998;19 Suppl 3:363S–365S **(Fre)**

PREVENTION & CONTROL

Effect of dietary glutamate on chemotherapy-induced immunosuppression. Lin CM, et al. **Nutrition** 1999 Sep; 15(9):687–96

[A trial of the use of an EHF therapy apparatus in preventing immunodeficiency states in acute respiratory diseases] Efimov EI, et al. **Voen Med Zh** 1999 May;320(5):58–9 **(Rus)**

RADIOTHERAPY

[The possibility of immunocorrection in spinal-spinal cord trauma by using intravenous laser irradiation] Stupak VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1999 Jan–Mar; (1):20–5 (Eng. Abstr.) **(Rus)**

SURGERY

Sympathectomy abrogates immunodeficiency associated with protein-energy malnutrition. González-Ariki S, et al. **J Neuroimmunol** 1999 Sep 1;99(1):97–104

THERAPY

Companies cooperate in emergency supply program for IGIV [news] Landis NT. **Am J Health Syst Pharm** 1999 Apr 1;56(7):599

Successful related umbilical cord blood transplantation for graft failure following T cell-depleted non-identical bone marrow transplantation in a child with major histocompatibility complex class II deficiency. Bonduel M, et al. **Bone Marrow Transplant** 1999 Aug;24(4):437–40

Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM. Bordigoni P, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1111–4

Allergy, immunology, and related disorders [editorial] Fuleihan RL. **Curr Opin Pediatr** 1998 Dec;10(6):581–3 (11 ref.)

Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. Peret Filho LA, et al. **J Med Microbiol** 1998 Feb;47(2):111–6

Deficient cellular immunity--finding and fixing the defects. Greenberg PD, et al. **Science** 1999 Jul 23;285(5427):546–51 (58 ref.)

Hematopoietic stem cell transplantation for primary lymphoid immunodeficiencies. Kapoor N, et al. **Semin Hematol** 1998 Oct;35(4):346–53 (50 ref.)

Gene therapy for congenital lymphoid immunodeficiency diseases. Weinberg KI, et al. **Semin Hematol** 1998 Oct; 35(4):354–66 (75 ref.)

Bone marrow transplantation: a natural form of gene therapy. Davenport C, et al. **Transplant Proc** 1998 Nov;30(7):3484–5 (10 ref.)

[Substitution therapy for deficiencies in antibody production by immunoglobulins] Strengers PF. **Arch Pediatr** 1999;6 Suppl 2:423s–424s **(Fre)**

[The molecular basis of primary immunodeficiency syndrome and the current therapeutic approach for the disease] Morio T. **Rinsho Byori** 1999 Jun;47(6):519–24 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Bone marrow transplantation in the primary immunodeficiencies] Madero López L, et al. **Sangre (Barc)** 1999 Apr;44(2):135–41 (61 ref.) **(Spa)**

[Gene therapy of primary immunodeficiencies. Present and future] Serrano F, et al. **Sangre (Barc)** 1999 Apr; 44(2):143–53 (58 ref.) **(Spa)**

VETERINARY

Immunodeficiency syndrome in a 3-year-old llama. Sivasankar M. **Can Vet J** 1999 Apr;40(4):271–2

Kaposi's sarcoma in dog with acquired immunodeficiency after phosphate poisoning. Sýkora B, et al. **Folia Microbiol (Praha)** 1998;43(5):543–4

IMMUNOLOGIC DISEASES

see related

BLOOD PROTEIN DISORDERS

Investigation of the immune system in recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Nov 19–Dec 9; 58(10):517–20 (7 ref.)

Genesis and evolution of diagnostic and clinical immunology. Rose NR. **Clin Diagn Lab Immunol** 1999 May;6(3):289–90

6th Annual Congress of the British Society for Immunology. Harrogate, United Kingdom, 1–4 December 1998. Abstracts. **Immunology** 1998 Dec;95 Suppl 1:1–144

BLOOD

Cysteine and glutathione in catabolic conditions and immunological dysfunction. Dröge W. **Curr Opin Clin Nutr Metab Care** 1999 May;2(3):227–33 (89 ref.)

Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. Varney ML, et al. **J Interferon Cytokine Res** 1999 Apr; 19(4):351–60

[The correction of the immunohormonal disorders in patients with hyperplastic processes in the endometrium] Bespoiasnaia VV. **Lik Sprava** 1999 Apr–May;(3):82–5 (Eng. Abstr.) **(Rus)**

COMPLICATIONS

Is psoriasis a neuroimmunologic disease? Farber EM, et al. **Int J Dermatol** 1999 Jan;38(1):12–5 (35 ref.)

[Immunological disorders in vibration-related illness among miners of Northern regions] Kolesov VG, et al. **Med Tr Prom Ekol** 1998;(10):13–7 (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Immune deficits induced by strenuous exertion under adverse environmental conditions: manifestations and countermeasures. Shephard RJ, et al. **Crit Rev Immunol** 1998;18(6):545–68 (224 ref.)

[Immunology in medical practice. XXI. Laboratory tests for immunologic diseases] Out TA, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1027–33 (30 ref.) (Eng. Abstr.) **(Dut)**

[The diagnosis of disorders of the T-cell immunity component in space flight] Lesniak AT, et al. **Aviakosm Ekolog Med** 1999;33(3):62–7 (Eng. Abstr.) **(Rus)**

[Comparative study of the immune status of preschool children in different districts of Moscow] Petrova IV, et al. **Gig Sanit** 1998 Sep–Oct;(5):31–3 **(Rus)**

[Regression analysis in the assessment of the state of the immune system] Shchegoleva LS, et al. **Klin Lab Diagn** 1999 Mar;(3):13–5 (Eng. Abstr.) **(Rus)**

[The health status assessment in miners and metal workers based on immunological and bacteriological criteria] Trunova OA. **Med Tr Prom Ekol** 1999;(2):22–6 (Eng. Abstr.) **(Rus)**

[Analysis of immune disorders in patients with rheumatoid arthritis and heart involvement] Timofeev VT, et al. **Patol Fiziol Eksp Ter** 1998 Jul–Sep;(3):10–2 (Eng. Abstr.) **(Rus)**

DIET THERAPY

[Reducing diet therapy in the correction of the immune disorders in patients with primary osteoarthrosis] Bakaliuk OI, et al. **Patol Fiziol Eksp Ter** 1998 Oct–Dec;(4):17–20 (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335–48 (112 ref.)

Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)

[New trends in immunodermatology and treatment of skin diseases] Nordlind K, et al. **Lakartidningen** 1999 Feb 24; 96(8):876–81 (28 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

[Frequency of immunologic disorders in acute schizophrenia] Fabisch H, et al. **Fortschr Neurol Psychiatr** 1999 May; 67(5):218–24 (Eng. Abstr.) **(Ger)**

ETIOLOGY

Association of silicone breast implants with immunologic abnormalities: a prospective study. Karlson EW, et al. **Am J Med** 1999 Jan;106(1):11–9

Effect low frequency noise exposure on BALB/c mice splenic lymphocytes. Aguas AP, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A128–31

Self-reported systemic, immune-mediated disorders in patients with and without proplast-teflon implants of the temporomandibular joint. Raphael KG, et al. **J Oral Maxillofac Surg** 1999 Apr;57(4):364–70; discussion 370–1

[Potential mechanism of viral infection in immunological diseases] Saito I. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):412–6 (20 ref.) **(Jpn)**

[Communicative behavioral effects and disorders of immunity] Surinov BP, et al. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1998 Nov–Dec; 48(6):1073–9 (Eng. Abstr.) **(Rus)**

GENETICS

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257–74 (171 ref.)

DSHP: a "power bar" for sustained immune responses? Satterthwaite AB, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13355–7

IMMUNOLOGY

Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1? Calleja E, et al. **Am J Hematol** 1999 Jun;61(2):94–7

Effect low frequency noise exposure on BALB/c mice splenic lymphocytes. Aguas AP, et al. **Aviat Space Environ Med** 1999 Mar;70(3 Pt 2):A128–31

Acquired immunoparalysis in paediatric intensive care: prospective observational study. Peters M, et al. **BMJ** 1999 Sep 4;319(7210):609–10

T cell receptors in health and disease. Introduction. Grunewald J, et al. **Springer Semin Immunopathol** 1999; 21(1):1–4 (6 ref.)

gamma delta T cells, their T cell receptor usage and role in human diseases. Kabelitz D, et al. **Springer Semin Immunopathol** 1999;21(1):55–75 (196 ref.)

[Inflammatory changes and immunological disturbances in stroke] Fiszer U, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1219–27 (30 ref.) (Eng. Abstr.) **(Pol)**

[The correction of the immunohormonal disorders in patients with hyperplastic processes in the endometrium] Bespoiasnaia VV. **Lik Sprava** 1999 Apr–May;(3):82–5 (Eng. Abstr.) **(Rus)**

METABOLISM

Nerve growth factor: a survey of activity on immune and hematopoietic cells. Simone MD, et al. **Hematol Oncol** 1999 Mar;17(1):1–10 (59 ref.)

PARASITOLOGY

Expression of CD30 mRNA, CD30L mRNA and a variant form of CD30 mRNA in restimulated peripheral blood mononuclear cells (PBMC) of patients with helminthic infections resembling a Th2 disease. Kilwinski J, et al. **Clin Exp Immunol** 1999 Jan;115(1):114–9

PATHOLOGY

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Price P, et al. **Immunol Rev** 1999 Feb;167:257–74 (171 ref.)

PHYSIOPATHOLOGY

Requirement of peptidergic sensory innervation for disease activity in murine models of immune hepatitis and protection by beta-adrenergic stimulation. Tiegs G, et al. **J Neuroimmunol** 1999 May 3;96(2):131–43

The prime role of plasma membrane cholesterol in the pathogenesis of immune evasion and clinical manifestations of falciparum malaria. Sein KK, et al. **Med Hypotheses** 1998 Aug;51(2):105–10

The role of integrins in immune-mediated diseases of the nervous system. Archelos JJ, et al. **Trends Neurosci** 1999 Jan;22(1):30–8 (56 ref.)

PREVENTION & CONTROL

Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Weiss M, et al. **Blood** 1999 Jan 15;93(2):425–39 (173 ref.)

[Carbohydrate adaptive substance for prophylaxis of immune disorders and correction of dysbacterioses] Vikha GV, et al. **Aviakosm Ekolog Med** 1998;32(4):21–5 (Eng. Abstr.) **(Rus)**

THERAPY

The new immunosuppressive era (editorial)] Lo Monte AI, et al. **Ann Ital Chir** 1999 Jan–Feb;70(1):1–19 (201 ref.)

Immune deficits induced by strenuous exertion under adverse environmental conditions: manifestations and countermeasures. Shephard RJ, et al. **Crit Rev Immunol** 1998;18(6):545–68 (224 ref.)

Immunologic tolerance for immune system-mediated diseases. Hackett CJ, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):362–70

Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Tsuboi Y, et al. **Ther Apher** 1998 Nov;2(4):297–9

[Immunological imbalance in the newborn infant and its correction in a system to prevent neonatal morbidity and infant mortality] Blokhina IN, et al. **Vestn Ross Akad Med Nauk** 1999;(5):37–40 (Eng. Abstr.) **(Rus)**

IMMUNOLOGIC DISEASES

VETERINARY

Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Gregory CR, et al. **Transplant Proc** 1998 Dec;30(8):4143-8

IMMUNOLOGIC ENHANCEMENT OF GRAFTS see **GRAFT ENHANCEMENT, IMMUNOLOGIC**

IMMUNOLOGIC FACTORS

ANALYSIS

Expression of functional immunomodulatory and anti-inflammatory factors in human milk. Garofalo RP, et al. **Clin Perinatol** 1999 Jun;26(2):361-77 (115 ref.)

PHYSIOLOGY

Immunomodulators in human seminal plasma: a vital protection for spermatozoa in the presence of infection? Kelly RW. **Int J Androl** 1999 Feb;22(1):2-12 (121 ref.)

Modulation of immune system function by measles virus infection: role of soluble factor and direct infection. Fujinami RS, et al. **J Virol** 1998 Dec;72(12):9421-7

SECRETION

Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta. Rocha MFG, et al. **Infect Immun** 1998 Oct;66(10):4910-6

SUPPLY & DISTRIBUTION

Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998. **MMWR Morb Mortal Wkly Rep** 1999 Mar 5;48(8):159-62

IMMUNOLOGIC MARKERS see **BIOLOGICAL MARKERS**

IMMUNOLOGIC MEMORY

Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Nara PL. **Adv Vet Med** 1999;41:115-34 (69 ref.)

Lymphocyte kinetics and precursor frequency-dependent recovery of CD4(+)CD45RA(+)CD62L(+) naive T cells following triple-drug therapy for HIV type 1 infection. Hengel RL, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):435-43

In vivo expansion coincident with excessive in vitro cell death within the memory subset of CD8+ T cells in HIV type 1 infection. Mugnaini EN, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10;15(3):265-72

Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection. Rinaldo CR Jr, et al. **AIDS Res Hum Retroviruses** 1998 Nov 1;14(16):1423-33

Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. Zheng L, et al. **AIDS Res Hum Retroviruses** 1999 Jul 20; 15(11):1011-20

Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Burns J, et al. **Ann Neurol** 1999 Jan; 45(1):33-9

T-cell activation, proliferation, and memory after cardiac transplantation in vivo. Jones ND, et al. **Ann Surg** 1999 Apr;229(4):570-8

Development of T-cell memory against inhalant allergens: risks for the future. Holt PG. **Clin Exp Allergy** 1999 Jun; 29 Suppl 2:8-13 (51 ref.)

The quantitative and qualitative defect of CD4+ CD45RO+ memory-type T cells are involved in the abnormality of TH1 immunity in atopic dermatitis patients. Matsuyama T, et al. **Clin Exp Allergy** 1999 May;29(5):687-94

DNA vaccination favours memory rather than effector B cell responses. Laylor R, et al. **Clin Exp Immunol** 1999 Jul;117(1):106-12

Nickel-induced proliferation of both memory and naive T cells in patch test-negative individuals. Lisby S, et al. **Clin Exp Immunol** 1999 Aug;117(2):217-22

B cell memory and the long-lived plasma cell. McHeyzer-Williams MG, et al. **Curr Opin Immunol** 1999 Apr;11(2):172-9 (75 ref.)

Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Shin HC, et al. **Cytokine** 1999 Apr;11(4):257-66

Role of cytokines in the maintenance of the memory immune response induced by a rat histiocytoma in syngeneic hosts. Nandakumar KS, et al. **Cytokines Cell Mol Ther** 1998 Sep; 4(3):169-75

B cell responses and immune memory. Slifka MK, et al. **Dev Biol Stand** 1998;95:105-15

Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Bachmann MF, et al. **Eur J Immunol** 1999 Jan;29(1):291-9

T cell selection during the evolution of CD8+ T cell memory in vivo. Callan MF, et al. **Eur J Immunol** 1998 Dec;28(12):4382-90

Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Leyendeckers H, et al. **Eur J Immunol** 1999 Apr;29(4):1406-17

Naïve cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: A pitfall for T cell memory studies? Oehen S, et al. **Eur J Immunol** 1999 Feb;29(2):608-14

Characterization of CD4+ T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Price PW, et al. **Eur J Immunol** 1999 Mar;29(3):1051-6

Persisting alloantigen prevents primed CD45RC- CD4 T cells from inducing allograft rejection: implications for immunological memory. Yang CP, et al. **Eur J Immunol** 1999 Jul;29(7):2177-86

Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences. Zimmermann C, et al. **Eur J Immunol** 1999 Jan;29(1):284-90

A comparative study of the calcium system in memory T cells and naive T cells. Sigova A, et al. **FEBS Lett** 1999 Mar 19;447(1):34-8

Clinical significance of CMV-specific T helper responses in lung transplant recipients. Zeevi A, et al. **Hum Immunol** 1998 Dec;59(12):768-75

Following the development of a CD4 T cell response in vivo: from activation to memory formation. Garcia S, et al. **Immunity** 1999 Aug;11(2):163-71

From naive to memory. Development and regulation of CD4+ T cell responses. Carter LL, et al. **Immunol Res** 1998 Aug;18(1):1-13

T-cell populations in the pig intestinal lamina propria: memory cells with unusual phenotypic characteristics. Haverson K, et al. **Immunology** 1999 Jan;96(1):66-73

Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection. Pais TF, et al. **Immunology** 1998 Sep;95(1):69-75

Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Guérin or DNA vaccination. Silva CL, et al. **Immunology** 1999 Aug;97(4):573-81

Unresponsiveness following immunization with the T-cell-independent antigen dextran B512. Can it be abrogated? Sverremark E, et al. **Immunology** 1998 Nov; 95(3):402-8

Survival of long-lived plasma cells is independent of antigen. Manz RA, et al. **Int Immunol** 1998 Nov;10(11):1703-11

Core 2-containing O-glycans on CD43 are preferentially expressed in the memory subset of human CD4 T cells. Mukasa R, et al. **Int Immunol** 1999 Feb;11(2):259-68

Memory CD44(int) CD8 T cells show increased proliferative responses and IFN-gamma production following antigenic challenge in vitro. Pihlgren M, et al. **Int Immunol** 1999 May;11(5):699-706

Memory/effector T cells in TCR transgenic mice develop via recognition of enteric antigens by a second, endogenous TCR. Saparov A, et al. **Int Immunol** 1999 Aug; 11(8):1253-64

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. D'Souza S, et al. **Int J Cancer** 1998 Dec 9;78(6):699-706

Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Mutti L, et al. **Int J Cancer** 1998 Dec 9;78(6):740-9

Smokeless tobacco and nicotine bring about excessive cytokine responses of murine memory T-cells. Petro TM, et al. **Int J Immunopharmacol** 1999 Feb;21(2):103-14

In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination. Schirrmacher V. **Int J Oncol** 1999 Aug;15(2):217-27

Learning, immunology and allergic responses. Slavkin HC. **J Am Dent Assoc** 1999 Jun;130(6):863-7

Natural antibodies in childhood: development, individual stability, and injury effect indicate a contribution to immune memory. Mirilas P, et al. **J Clin Immunol** 1999 Mar; 19(2):109-15

Memory B lymphocytes from secondary lymphoid organs interact with E-selectin through a novel glycoprotein ligand. Montoya MC, et al. **J Clin Invest** 1999 May; 103(9):1317-27

Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. Babcock GJ, et al. **J Exp Med** 1999 Aug 16;190(4):567-76

Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. Bachmann MF, et al. **J Exp Med** 1999 May 17; 189(10):1521-30

Lymph node germinal centers form in the absence of follicular dendritic cell networks. Koni PA, et al. **J Exp Med** 1999 Mar 1;189(5):855-64

Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. Selin LK, et al. **J Exp Med** 1998 Nov 2; 188(9):1705-15

Identification of functional human splenic memory B cells by expression of CD148 and CD27. Tangye SG, et al. **J Exp Med** 1998 Nov 2;188(9):1691-703

Long-term CD8+ T cell memory to Sendai virus elicited by DNA vaccination. Chen Y, et al. **J Gen Virol** 1999 Jun; 80 (Pt 6):1393-9

Effector CD4 T cells are biochemically distinct from the memory subset: evidence for long-term persistence of effectors in vivo. Ahmadzadeh M, et al. **J Immunol** 1999 Sep 15;163(6):3053-63

Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. Allendörfer R, et al. **J Immunol** 1999 Jun 15;162(12):7389-96

STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. Andrew DP, et al. **J Immunol** 1998 Nov 1; 161(9):5027-38

Stability of naive and memory phenotypes on resting CD4 T cells in vivo. Boursalian TE, et al. **J Immunol** 1999 Jan 1;162(1):9-16

TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis. Di Somma MM, et al. **J Immunol** 1999 Apr 1;162(7):3851-8

Enhancement of the Listeria monocytogenes p60-specific CD4 and CD8 T cell memory by nonpathogenic Listeria innocua. Geginat G, et al. **J Immunol** 1999 Apr 15; 162(8):4781-9

Activation of CD4 T cells by somatic transgenesis induces generalized immunity of uncommitted T cells and immunologic memory. Gerloni M, et al. **J Immunol** 1999 Apr 1;162(7):3782-9

Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. Heeger PS, et al. **J Immunol** 1999 Aug 15;163(4):2267-75

Human effector memory T cells express CD86: a functional role in naive T cell priming. Jeannin P, et al. **J Immunol** 1999 Feb 15;162(4):2044-8

Self-restricted dual receptor memory T cells. Lee WT, et al. **J Immunol** 1998 Nov 1;161(9):4513-9

Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. Lefevre EA, et al. **J Immunol** 1999 Aug 1; 163(3):1119-22

Gut-derived intraepithelial lymphocytes induce long term immunity against Toxoplasma gondii. Lepage AC, et al. **J Immunol** 1998 Nov 1;161(9):4902-8

CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. Liao F, et al. **J Immunol** 1999 Jan 1;162(1):186-94

Functional characteristics and survival requirements of memory CD4+ T lymphocytes in vivo. London CA, et al. **J Immunol** 1999 Jan 15;162(2):766-73

Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. Ludewig B, et al. **J Immunol** 1999 Aug 15;163(4):1839-44

Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. Metz DP, et al. **J Immunol** 1998 Dec 1;161(11):5855-61

CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. Nagumo H, et al. **J Immunol** 1998 Dec 15; 161(12):6496-502

B cell responses to a peptide epitope. VIII. Immune complex-mediated regulation of memory B cell generation within germinal centers. Nayak BP, et al. **J Immunol** 1999 Aug 1;163(3):1371-81

Postthymic development of CD28-CD8+ T cell subset: age-associated expansion and shift from memory to naive phenotype. Nociari MM, et al. **J Immunol** 1999 Mar 15; 162(6):3327-35

Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. Oehen S, et al. **J Immunol** 1998 Nov 15; 161(10):5338-46

rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. Ottonello L, et al. **J Immunol** 1999 Jun 1;162(11):6510-7

A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance. Reali E, et al. **J Immunol** 1999 Jan 1;162(1):106-13

Expression of the transcription factor lung Krüppel-like factor is regulated by cytokines and correlates with survival of memory T cells in vitro and in vivo. Schober SL, et al. **J Immunol** 1999 Oct 1;163(7):3662-7

Altered memory T cell differentiation in patients with early rheumatoid arthritis. Skapenko A, et al. **J Immunol** 1999 Jul 1;163(1):491-9

Longitudinal analysis of the acute Sendai virus-specific CD4+ T cell response and memory. Topham DJ, et al. **J Immunol** 1998 Nov 1;161(9):4530-5

Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. Waldrop SL, et al. **J Immunol** 1998 Nov 15; 161(10):5284-95

Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. Weekes MP, et al. **J Immunol** 1999 Jun 15;162(12):7569-77

The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7. Williams MB, et al. **J Immunol** 1998 Oct 15;161(8):4227-35

T cell memory against colon carcinoma is long-lived in the absence of antigen. Xiang R, et al. **J Immunol** 1999 Oct 1;163(7):3676–83

The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. Goldblatt D, et al. **J Infect Dis** 1999 Aug;180(2):538–41

Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. Jenkins DE, et al. **J Infect Dis** 1998 Oct;178(4):940–8

Comparative effects of interleukin-12 and interleukin-4 on cytokine responses by antigen-stimulated memory CD4+ T cells of cattle: IL-12 enhances IFN-gamma production, whereas IL-4 has marginal effects on cytokine expression. Tuo W, et al. **J Interferon Cytokine Res** 1999 Jul; 19(7):741–9

Intracellular analysis of interleukin-2 induction provides direct evidence at the single cell level of differential coactivation requirements for CD45RA+ and CD45RO+ T cell subsets. Woodside DG, et al.
J Interferon Cytokine Res 1999 Jul;19(7):769–79

Interferon-gamma preferentially reduces memory/effector CD8 T lymphocytes in healthy subjects. de Metz J, et al. **J Lab Clin Med** 1999 Aug;134(2):147–53

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. Scheifele DW, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):240–5

Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. Ostrowski MA, et al. **J Virol** 1999 Aug;73(8):6430–5

Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. Redchenko IV, et al.
J Virol 1999 Jan;73(1):334–42

The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. Weekes MP, et al. **J Virol** 1999 Mar; 73(3):2099–108

Development of allergen-specific T-cell memory in atopic and normal children [see comments] Prescott SL, et al. **Lancet** 1999 Jan 16;353(9148):196–200. Comment in: Lancet 1999 Jan 16;353(9148):167–8. Comment in: Lancet 1999 Apr 3;353(9159):1187–8.

Crossreactive B cells are present during a primary but not secondary response in BALB/c mice expressing a bcl-2 transgene. Kuo P, et al. **Mol Immunol** 1999 May;36(7):471–9

Dangerous T-cell amnesia [news; comment] Gorochov G. **Nat Med** 1999 May;5(5):483–4. Comment on: Nat Med 1999 May;5(5):518–25.

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments] Pitcher CJ, et al. **Nat Med** 1999 May;5(5):518–25. Comment in: Nat Med 1999 May;5(5):483–4.

The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Campbell JJ, et al. **Nature** 1999 Aug 19;400(6746):776–80

Modelling T-cell memory by genetic marking of memory T cells in vivo [see comments] Jacob J, et al. **Nature** 1999 Jun 10;399(6736):593–7. Comment in: Nature 1999 Jun 10;399(6736):531–2.

Looking out for memory T cells [news; comment] Rocha B. **Nature** 1999 Jun 10;399(6736):531–2. Comment on: Nature 1999 Jun 10;399(6736):593–7.

CD4dullCD8bright double-positive T-lymphocytes have a phenotype of granzyme Bpos CD8pos memory T-lymphocytes. Rentenaar RJ, et al.
Nephrol Dial Transplant 1999 Jun;14(6):1430–4

Diet and immunological memory of lines of White Leghorn chickens divergently selected for antibody response to sheep red blood cells. Boa-Amponsem K, et al.
Poult Sci 1999 Feb;78(2):165–70

Models of immune memory: on the role of cross-reactive stimulation, competition, and homeostasis in maintaining immune memory. Antia R, et al.
Proc Natl Acad Sci U S A 1998 Dec 8;95(25):14926–31

Functional differences between memory and naive CD8 T cells. Cho BK, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):2976–81

Dichotomy between naïve and memory CD4(+) T cell responses to Fas engagement. Desbarats J, et al.
Proc Natl Acad Sci U S A 1999 Jul 6;96(14):8104–9

A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Ochsenbein AF, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3; 96(16):9293–8

A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope. Stevenson PG, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9281–6

Repertoire shift occurs during the memory maintenance phase of the immune responses and is not affinity-driven. Andersson K, et al. **Scand J Immunol** 1999 Jan;49(1):1–6

Linear differentiation of cytotoxic effectors into memory T lymphocytes. Opferman JT, et al. **Science** 1999 Mar 12; 283(5408):1745–8

Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model. Ichinose Y, et al.
Surg Today 1999;29(4):338–43

Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and L-selectin during primary viral infection in renal allograft recipients. ten Berge IJ, et al. **Transplant Proc** 1998 Dec;30(8):3975–7

Two types of CMV-specific memory responses in lung transplant recipients. Zeevi A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):173–4

Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Johnson CM, et al.
Tuber Lung Dis 1997;78(5–6):257–61

Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer. Mitchell LA, et al.
Vaccine 1999 May 14;17(19):2356–65

Effective in vivo depletion of T cell subpopulations and loss of memory cells in cattle using mouse monoclonal antibodies. Naessens J, et al.
Vet Immunol Immunopathol 1998 Jul 31;64(3):219–34

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Ennis FA, et al.
Virology 1999 Jul 5;259(2):256–61

IMMUNOLOGY

Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Bejarano MT, et al. **Blood** 1998 Dec 1; 92(11):4256–62

The recirculation of naive and memory lymphocytes. Watson SR, et al. **Cell Adhes Commun** 1998;6(2–3):105–10 (51 ref.)

Single-cell analysis of costimulation by B cells, endothelial cells, and fibroblasts demonstrates heterogeneity in responses of CD4(+) memory T cells. Murphy LL, et al.
Cell Immunol 1999 Jun 15;194(2):150–61

Insights into the mechanisms of antibody-affinity maturation and the generation of the memory B-cell compartment using genetically altered mice. Vora KA, et al.
Dev Immunol 1998;6(3–4):305–16 (70 ref.)

Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Giorgi JV, et al. **Immunol Lett** 1999 Mar;66(1-3):105–10

'Naïve' and 'memory' CD4+ T-cells and T-cell receptor (TCR) V beta repertoire dynamics are independent of the levels of viremia following HIV seroconversion. King DJ, et al. **Immunol Lett** 1999 Mar;66(1-3):199–206

Lifespan of human memory T-cells in the absence of T-cell receptor expression. Umeki S, et al. **Immunol Lett** 1998 Jun;62(2):99–104

Peripheral T-cell self-reactivity and immunological memory [letter] DosReis GA, et al. **Immunol Today** 1998 Dec; 19(12):587–8

An experimental study on the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. Yang Y, et al. **J Epidemiol** 1999 Aug;9(4):209–15

How specific should immunological memory be? Borghans JA, et al. **J Immunol** 1999 Jul 15;163(2):569–75 (64 ref.)

Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance. Chung Y, et al. **J Immunol** 1999 Oct 1;163(7):3692–8

The first dose of a Haemophilus influenzae type b conjugate vaccine reactivates memory B cells: evidence for extensive clonal selection, intraclonal affinity maturation, and multiple isotype switches to IgA2. Hougs L, et al.
J Immunol 1999 Jan 1;162(1):224–37

Role of CD28 in the generation of effector and memory responses required for resistance to Toxoplasma gondii. Villegas EN, et al. **J Immunol** 1999 Sep 15;163(6):3344–53

Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. Wills MR, et al. **J Immunol** 1999 Jun 15; 162(12):7080–7

Recall antigen presentation by gamma-interferon-activated microglia results in T cell activation and propagation of the immune response. Hall GL, et al. **J Neuroimmunol** 1999 Aug 3;98(2):105–11

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. Kalams SA, et al. **J Virol** 1999 Aug; 73(8):6721–8

Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2. Mattapallil JJ, et al. **J Virol** 1999 Aug;73(8):6661–9

Functionally heterogeneous CD8(+) T-cell memory is induced by Sendai virus infection of mice. Usherwood EJ, et al. **J Virol** 1999 Sep;73(9):7278–86

Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. Van Epps HL, et al. **J Virol** 1999 Jul;73(7):5301–8

Allergen-specific T-cell memory [letter; comment] Gray D. **Lancet** 1999 Apr 3;353(9159):1187–8. Comment on: Lancet 1999 Jan 16;353(9148):167–8. Comment on: Lancet 1999 Jan 16;353(9148):196–200.

A model of primary HIV-1 infection. Murray JM, et al.
Math Biosci 1998 Dec 15;154(2):57–85

In vivo proliferation of naïve and memory influenza-specific CD8(+) T cells. Flynn KJ, et al.
Proc Natl Acad Sci U S A 1999 Jul 20;96(15):8597–602

Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. Aarvak T, et al.
Scand J Immunol 1999 Jul;50(1):1–9

Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Elliott SL, et al.
Vaccine 1999 Apr 9;17(15–16):2009–19

[Antibody titer, immunologic memory and protective efficiency of the vaccine against Haemophilus influenzae type B. Vaccine Committee of the Spanish Association of Pediatrics] **An Esp Pediatr** 1999 Apr;50(4):341–5 **(Spa)**

PHYSIOLOGY

Maturation of CD4+ lymphocytes in the aged microenvironment results in a memory-enriched population. Timm JA, et al. **J Immunol** 1999 Jan 15; 162(2):711–7

IMMUNOLOGIC MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNOLOGIC RECEPTORS see **RECEPTORS, IMMUNOLOGIC**

IMMUNOLOGIC STIMULATION see **IMMUNIZATION**

IMMUNOLOGIC SUPPRESSOR FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

IMMUNOLOGIC SURVEILLANCE

Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: a possible mechanism for escaping immune surveillance. Aslakson CJ, et al.
Am J Hematol 1999 May;61(1):46–52

Tumor escape from immune surveillance. Costello RT, et al. **Arch Immunol Ther Exp (Warsz)** 1999;47(2):83–8 (58 ref.)

Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Quan N, et al.
Cancer Res 1999 Mar 1;59(5):1080–9

Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha. Nagy N, et al.
Immunol Lett 1998 Dec;64(2–3):153–60

Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance [see comments] Robert C, et al. **J Exp Med** 1999 Feb 15;189(4):627–36. Comment in: J Exp Med 1999 Feb 15;189(4):611–4.

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. Matsui S, et al. **J Immunol** 1999 Jul 1;163(1):184–93

CD40 ligand is pivotal to efficient control of virus replication in mice infected with lymphocytic choriomeningitis virus. Thomsen AR, et al. **J Immunol** 1998 Nov 1;161(9):4583–90

Immune surveillance against a solid tumor fails because of immunological ignorance. Ochsenbein AF, et al.
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2233–8

Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. von Bernstorff W, et al. **Surgery** 1999 Jan;125(1):73–84

[Mechanisms of tumor escape from immunologic response] Costello RT, et al. **Rev Med Interne** 1999 Jul;20(7):579–88 (116 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenetic significance of HTLV-I infection and immune surveillance in HAM] Fujihara K. **Rinsho Shinkeigaku** 1999 Jan;39(1):21–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGIC TECHNIQUES

see related
BLOOD GROUPING AND CROSSMATCHING
IMMUNOLOGIC TESTS
IMMUNOTHERAPY
SEROLOGIC TESTS

Monoclonal antibody MAb-170 for immunoscintigraphic detection of ovarian tumors. Alexander C, et al.
Am J Obstet Gynecol 1999 Sep;181(3):513–7

Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. Martegani MP, et al.
Am J Pathol 1999 Jan;154(1):291–300

Differential diagnosis of gammopathies by capillary electrophoresis and immunosubtraction: analysis of serum samples problematic by agarose gel electrophoresis. Clark R, et al. **Electrophoresis** 1998 Oct;19(14):2479–84

Validation studies of an immunochromatographic 1-step test for the forensic identification of human blood. Hochmeister MN, et al. **J Forensic Sci** 1999 May;44(3):597–602

Expression library screening. Foster GD.
Methods Mol Biol 1998;81:287–91

Tests for BSE evaluated. Bovine spongiform encephalopathy [letter] Moynagh J, et al. **Nature** 1999 Jul 8;400(6740):105

[Asthma remains a major preoccupation for the allergist and the pneumonologist (editorial)] Spertini F.
Rev Med Suisse Romande 1999 Mar;119(3):209 **(Fre)**

[Diagnostic and therapeutic value of synthetic or

recombinant allergens] Spertini F.
Rev Med Suisse Romande 1999 Mar;119(3):235–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Clinical immunology in rheumatology] Speranskii AI.
Vestn Ross Akad Med Nauk 1998;(12):12–5 (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Immunoelectrodes in protein detection: comparison between glassy carbon and a semimetallic Ni/P thin film as binding support. Biological applications. Darbon P, et al.
Anal Chem 1998 Dec 1;70(23):5072–8
Determination of phage antibody affinities to antigen by a microbalance sensor system. Hengerer A, et al.
Biotechniques 1999 May;26(5):956–60, 962, 964

TRENDS

[Immunobiotechnology on the way to 21st century] Vorobiev AA. **Vestn Ross Akad Med Nauk** 1999;(2):65–9 (20 ref.) **(Rus)**

IMMUNOLOGIC TESTS

Comparing the enzyme allergosorbens and coated allergen particle tests for latex allergy: which in vitro test should be chosen by an anesthesiologist? Konrad C, et al.
Anesth Analg 1998 Dec;87(6):1389–92
Immunologic tests in rheumatology. Moder KG.
Ann Allergy Asthma Immunol 1998 Dec;81(6):539–44, 547; quiz 547–8 (25 ref.)
In diagnostic laboratory immunology the robot still needs some careful human guidance [letter; comment] Osterland CK. **Clin Diagn Lab Immunol** 1999 Jul;6(4):643. Comment on: Clin Diagn Lab Immunol 1999 May;6(3):293–4.
The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Valenta R, et al. **Clin Exp Allergy** 1999 Jul;29(7):896–904 (68 ref.)
Sensitivity and specificity of several immunochemical tests for colorectal cancer. Nakama H, et al.
Hepatogastroenterology 1998 Sep–Oct;45(23):1579–82
Role of serology in the diagnosis of Lyme disease [see comments] Brown SL, et al. **JAMA** 1999 Jul 7;282(1):62–6 . Comment in: JAMA 1999 Jul 7;282(1):79–80.
Diagnostic classification of autoantibody repertoires in endocrine ophthalmopathy using an artificial neural network. Grus FH, et al. **Ocul Immunol Inflamm** 1998 Mar; 6(1):43–50
[Laboratory diagnosis of changes in regulation of the immune system] Tolmakova LA, et al. **Med Tekh** 1999 Jul–Aug; (4):18–21 (Eng. Abstr.) **(Rus)**

HISTORY

Genesis and evolution of diagnostic and clinical immunology. Rose NR. **Clin Diagn Lab Immunol** 1999 May;6(3):289–90

INSTRUMENTATION

Total laboratory automation and diagnostic immunology. Tomar R. **Clin Diagn Lab Immunol** 1999 May;6(3):293–4

METHODS

Comparison of hemoglobin A1C results by two different methods on patients with structural hemoglobin variants. Blakney GB, et al. **Clin Biochem** 1998 Nov;31(8):619–26
Detection of allergen-induced basophil activation by expression of CD63 antigen using a tricolour flow cytometric method. Monneret G, et al.
Clin Exp Immunol 1999 Mar;115(3):393–6
New immunological assays for the diagnosis of Helicobacter pylori infection. Vaira D, et al. **Gut** 1999 Jul;45 Suppl 1:I23–7 (51 ref.)
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Verweij PE, et al.
Med Mycol 1998;36 Suppl 1:146–55 (61 ref.)
Evaluation of a rapid test for histidine rich protein 2 for diagnosis of Plasmodium falciparum infection in Cameroonian children. Bechem NN, et al.
Trans R Soc Trop Med Hyg 1999 Jan–Feb;93(1):46
[Immunology of cancer] Abelev GI.
Vestn Ross Akad Med Nauk 1999;(4):21–5 (41 ref.) (Eng. Abstr.) **(Rus)**
[The immunodiagnosis and immunotherapy of tumors] Kadagidze ZG. **Vestn Ross Akad Med Nauk** 1999;(5):19–22 (14 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. Bizzaro N, et al.
J Immunol Methods 1998 Oct 1;219(1–2):99–107
Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. European Concerted Action on Immunological and Virological Markers of HIV Disease Progression. Froebel KS, et al. **J Immunol Methods** 1999 Jul 30; 227(1–2):85–97
Rheumatoid factor--does the patient have arthritis? Patel YI. **S Afr Med J** 1999 Jul;89(7):742–3

STATISTICS & NUMERICAL DATA

Evaluation of the performance of Brazilian blood banks in testing for Chagas' disease. Saéz-Alquézar A, et al.
Vox Sang 1998;74(4):228–31

TRENDS

Clinical laboratory immunology: the future. Fahey JL.
Clin Diagn Lab Immunol 1999 May;6(3):291–2

IMMUNOLOGICAL MODELS see **MODELS, IMMUNOLOGICAL**

IMMUNOLOGY see **ALLERGY AND IMMUNOLOGY**

IMMUNOLOGY, TRANSPLANTATION see **TRANSPLANTATION IMMUNOLOGY**

IMMUNOMAGNETIC BEAD TECHNIQUE see **IMMUNOMAGNETIC SEPARATION**

IMMUNOMAGNETIC PURGING see **IMMUNOMAGNETIC SEPARATION**

IMMUNOMAGNETIC SEPARATION

Eosinophils isolated by magnetic cell sorting respond poorly to lipid chemoattractants. Casale TB, et al.
Ann Allergy Asthma Immunol 1999 Aug;83(2):127–31
Comparison of sensitivity of immunofluorescent microscopy to that of a combination of immunofluorescent microscopy and immunomagnetic separation for detection of Cryptosporidium parvum oocysts in adult bovine feces. Pereira MD, et al. **Appl Environ Microbiol** 1999 Jul; 65(7):3236–9
Evaluation of immunomagnetic separation for recovery of infectious Cryptosporidium parvum oocysts from environmental samples. Rochelle PA, et al.
Appl Environ Microbiol 1999 Feb;65(2):841–5
Magnetic separation to concentrate the estrogen receptor from adipose tissue for western analysis. Welter BH, et al. **Biotechniques** 1999 Aug;27(2):282–6
Quantification of cellular properties from external fields and resulting induced velocity: cellular hydrodynamic diameter. Chalmers JJ, et al. **Biotechnol Bioeng** 1999 Sep 5;64(5):509–18
Quantification of cellular properties from external fields and resulting induced velocity: magnetic susceptibility. Chalmers JJ, et al. **Biotechnol Bioeng** 1999 Sep 5; 64(5):519–26
Improvement of tumor cell depletion by combining immunomagnetic positive selection of CD34-positive hematopoietic stem cells and negative selection (purging) of tumor cells. Hoppe B, et al.
Bone Marrow Transplant 1999 Apr;23(8):809–17
Clinical scale isolation of highly purified peripheral CD34+progenitors for autologous and allogeneic transplantation in children. Lang P, et al.
Bone Marrow Transplant 1999 Sep;24(6):583–9
Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Leung W, et al.
Bone Marrow Transplant 1998 Nov;22(10):971–9
Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent. Marolleau JP, et al. **Bone Marrow Transplant** 1999 Apr;23(8):819–26
Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Martin-Henao GA, et al.
Bone Marrow Transplant 1999 Mar;23(6):579–87
Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Marini FC, et al. **Clin Cancer Res** 1999 Jun;5(6):1557–68
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Mohr M, et al. **Clin Cancer Res** 1999 May;5(5):1035–40
Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Tyer CL, et al. **Clin Cancer Res** 1996 Jan;2(1):81–6
Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Naume B, et al. **Int J Cancer** 1998 Nov 23; 78(5):556–60
Rapid detection of Escherichia coli O157:H7 using immuno-magnetic flow cytometry in ground beef, apple juice, and milk. Seo KH, et al. **Int J Food Microbiol** 1998 Oct 20;44(1–2):115–23
Use of magnetic techniques for the isolation of cells. Safarik I, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 5; 722(1–2):33–53 (126 ref.)
Immunomagnetic isolation of Streptococcus suis serotypes 2 and 1/2 from swine tonsils. Gottschalk M, et al.
J Clin Microbiol 1999 Sep;37(9):2877–81
Performance of the Dynabeads anti-Salmonella system in the detection of Salmonella species in foods, animal feeds, and environmental samples. Shaw SJ, et al. **J Food Prot** 1998 Nov;61(11):1507–10
Removal of erythroid cells from umbilical cord blood mononuclear cell preparations using magnetic beads and a monoclonal antibody against glycophorin A. Elliott SR, et al. **J Immunol Methods** 1998 Aug 1;217(1–2):121–30
Recovery and detection of enterovirus, hepatitis A virus and Norwalk virus in hardshell clams (Mercenaria mercenaria) by RT-PCR methods. Suñén E, et al. **J Virol Methods** 1999 Feb;77(2):179–87
Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Tarella C, et al. **Leukemia** 1999 Sep;13(9):1456–62
Flow cytometry--principles and feasibility in transfusion medicine. Enumeration of epithelial derived tumor cells in peripheral blood. Terstappen LW, et al. **Vox Sang** 1998; 74 Suppl 2:269–74 (12 ref.)

INSTRUMENTATION

Rapid cell isolation by magnetic flow sorting for applications in tissue engineering. Zborowski M, et al. **ASAIO J** 1999 May-Jun;45(3):127–30
Lymphocyte fractionation using immunomagnetic colloid and a dipole magnet flow cell sorter. Moore LR, et al. **J Biochem Biophys Methods** 1998 Sep 24;37(1–2):11–33

METHODS

Isolation of large and pure samples of human erythroid precursors at different stages of maturation using immunomagnetic separation of cells from liquid cultures. Vaisman B, et al. **Acta Haematol** 1999;101(3):135–9
Host protein incorporation is conserved among diverse HIV-1 subtypes [letter] Roberts BD, et al. **AIDS** 1999 Feb 25;13(3):425–7
Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. Sabile A, et al. **Am J Clin Pathol** 1999 Aug;112(2):171–8
Enrichment of immunoglobulin binding Plasmodium falciparum-infected erythrocytes using anti-immunoglobulin-coated magnetic beads. Heddini A, et al. **Am J Trop Med Hyg** 1998 Nov;59(5):663–6
Isolation of Mycobacterium paratuberculosis from milk by immunomagnetic separation. Grant IR, et al.
Appl Environ Microbiol 1998 Sep;64(9):3153–8
Rapid cell isolation by magnetic flow sorting for applications in tissue engineering. Zborowski M, et al. **ASAIO J** 1999 May-Jun;45(3):127–30
Purification of intracellular compartments involved in antigen processing: a new method based on magnetic sorting. Perrin-Cocon LA, et al. **Biochem J** 1999 Feb 15; 338 (Pt 1):123–30
Magnetic cell sorting is a fast and effective method of enriching viable spermatogonia from Djungarian hamster, mouse, and marmoset monkey testes. von Schönfeldt V, et al. **Biol Reprod** 1999 Sep;61(3):582–9
Organelle isolation by magnetic immunoabsorption. Kausch AP, et al. **Biotechniques** 1999 Feb;26(2):336–43
Biopanning phage display libraries using magnetic beads vs. polystyrene plates. McConnell SJ, et al. **Biotechniques** 1999 Feb;26(2):208–10, 214
Theoretical analysis of cell separation based on cell surface marker density. Chalmers JJ, et al. **Biotechnol Bioeng** 1998 Jul 5;59(1):10–20
Clinically applicable bulk isolation of blood CD34+ cells for autografting in children. Kawano Y, et al.
Bone Marrow Transplant 1998 Nov;22(10):1011–7
Different behaviour of fresh and cultured CD34+ cells during immunomagnetic separation. Denning-Kendall PA, et al. **Br J Haematol** 1999 Jun;105(3):780–5
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Voso MT, et al. **Br J Haematol** 1999 Feb; 104(2):382–91
Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Petrarca C, et al. **Cancer Immunol Immunother** 1999 Jan; 47(5):272–7
Immunomagnetic purification of viable primordial germ cells of Japanese quail (Coturnix japonica). Ono T, et al.
Comp Biochem Physiol A Mol Integr Physiol 1999 Feb; 122(2):255–9
Detection of rare MCF-7 breast carcinoma cells from mixtures of human peripheral leukocytes by magnetic deposition analysis. Fang B, et al. **Cytometry** 1999 Aug 1;36(4):294–302
Continuous, flow-through immunomagnetic cell sorting in a quadrupole field. Sun L, et al. **Cytometry** 1998 Dec 1; 33(4):469–75
Immuno-isolation of highly purified peroxisomes using magnetic beads and continuous immunomagnetic sorting. Lüers GH, et al. **Electrophoresis** 1998 Jun;19(7):1205–10
Particle electrophoresis of micrometric-sized superparamagnetic particles designed for magnetic purification of cells. Sestier C, et al. **Electrophoresis** 1998 Oct;19(14):2485–90
Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study. Mapara MY, et al. **Exp Hematol** 1999 Jan;27(1):169–75
Adsorption of endogenous polyphenols relieves the inhibition by fruit juices and fresh produce of immuno-PCR detection

of Escherichia coli O157:H7. Ogunjimi AA, et al. **FEMS Immunol Med Microbiol** 1999 Mar;23(3):213–20

An immunomagnetic separation polymerase chain reaction assay for rapid and ultra-sensitive detection of Cryptosporidium parvum in drinking water. Hallier-Soulier S, et al. **FEMS Microbiol Lett** 1999 Jul 15;176(2):285–9

Immunomagnetic cell sorting--pushing the limits. Thiel A, et al. **Immunotechnology** 1998 Oct;4(2):89–96 (30 ref.)

Evaluation of immunomagnetic separation and plating media for recovery of Salmonella from meat. Ripabelli G, et al. **J Food Prot** 1999 Feb;62(2):198–201

A novel method of cell separation based on dual parameter immunomagnetic cell selection. Partington KM, et al. **J Immunol Methods** 1999 Mar 4;223(2):195–205

Isolation of bovine neutrophils with biomagnetic beads: comparison with standard Percoll density gradient isolation methods. Soltys J, et al. **J Immunol Methods** 1999 Jun 24; 226(1–2):71–84

Comparative studies of magnetic particle-based solid phase fluorogenic and electrochemiluminescent immunoassay. Yu H. **J Immunol Methods** 1998 Sep 1;218(1–2):1–8

Peripheral type benzodiazepine receptor in T lymphocyte rich preparation. Maeda S, et al. **Life Sci** 1998; 63(16):1423–30

Purification of vesicular carriers from rat hepatocytes by magnetic immunoadsorption. Saucan L. **Methods Mol Biol** 1998;108:257–66

Rat retinal ganglion cells culture enriched with the magnetic cell sorter. Shoge K, et al. **Neurosci Lett** 1999 Jan 8; 259(2):111–4

Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation. Cancelas JA, et al. **Transfusion** 1998 Nov-Dec;38(11–12):1063–70

IMMUNOMODULATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPEROXIDASE TECHNIQUES see **IMMUNOENZYME TECHNIQUES**

IMMUNOPHENOTYPING

Belgian consensus recommendations for flow cytometric immunophenotyping. The Belgian Association for Cytometry/Belgische Vereniging voor Cytometrie/Association Belge de Cytométrie. Van Bockstaele DR, et al. **Acta Clin Belg** 1999 Apr;54(2):88–98

Carotid rupture and intraplaque hemorrhage: immunophenotype and role of cells involved [see comments] Milei J, et al. **Am Heart J** 1998 Dec; 136(6):1096–105. Comment in: Am Heart J 1998 Dec;136(6):937–9.

Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Khalidi HS, et al. **Am J Clin Pathol** 1999 Apr;111(4):467–76

Decision-tree approach to the immunophenotype-based prognosis of the B-cell chronic lymphocytic leukemia. Masić N, et al. **Am J Hematol** 1998 Oct;59(2):143–8

Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second- and third-trimester human fetal cord blood hematopoietic stem cells (progenitor cells). Surbek DV, et al. **Am J Obstet Gynecol** 1998 Nov;179(5):1228–33

Flow cytometric immunophenotyping of bone marrow core biopsies: report of 8 patients with previously undiagnosed hematologic malignancy and failed bone marrow aspiration. Dunphy CH, et al. **Arch Pathol Lab Med** 1999 Mar;123(3):206–12

Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis. Tiensiwakul P, et al. **Asian Pac J Allergy Immunol** 1999 Mar;17(1):17–21

Phenotypic analysis and proliferative responses of human endometrial granulated lymphocytes during the menstrual cycle. Searle RF, et al. **Biol Reprod** 1999 Apr;60(4):871–8

Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Czuczman MS, et al. **Blood** 1999 Jun 1; 93(11):3931–9

Immunophenotypic characterisation of cord blood B-lymphocytes. Paloczi K, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S89–91

Immunophenotypic analysis of normal mucosa and squamous cell carcinoma of the oral cavity. Piffkò J, et al. **Cancer Detect Prev** 1999;23(1):45–56

Quality control of flow cytometric immunophenotyping of haematological malignancies. Gratama JW, et al. **Clin Lab Haematol** 1999 Jun;21(3):155–60 (23 ref.)

Morpho-immunophenotypic-genotypic infidelity in synovial sarcoma [letter; comment] Mezzelani A, et al. **Diagn Mol Pathol** 1998 Aug;7(4):232–3. Comment on: Diagn Mol Pathol 1998 Feb;7(1):16–23.

Genotyping for human platelet-specific antigens HPA-1, -2, -3, -4 and -5 in the Slovenian population reveals a slightly increased frequency of HPA-1b and HPA-2b as compared to other European populations. Rožman P, et al. **Eur J Immunogenet** 1999 Aug;26(4):265–9

Analysing the developing lymphocyte system of neonates and infants. de Vries E, et al. **Eur J Pediatr** 1999 Aug; 158(8):611–7 (50 ref.)

Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods. Dworzak MN, et al. **Exp Hematol** 1999 Apr; 27(4):673–81

Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Gramatzki M, et al. **Exp Hematol** 1998 Dec;26(13):1209–14

Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection. Ciudad J, et al. **Haematologica** 1998 Dec;83(12):1069–75

Flow cytometry of cell suspensions from lymph nodes: immunophenotype, DNA content and proliferative rate are strongly correlated with histopathology diagnosis [letter] Sánchez J, et al. **Haematologica** 1999 Aug;84(8):762–3

Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. Dunphy CH. **J Clin Lab Anal** 1999;13(1):19–26

Immunophenotyping of a sarcoidal granuloma in a scar, a manifestation of a possible autoimmune process. Morhenn VB, et al. **J Cutan Med Surg** 1998 Jul;3(1):46–8

Phenotype analysis of peripheral blood mononuclear cells in periparturient dairy cows. Kimura K, et al. **J Dairy Sci** 1999 Feb;82(2):315–9

Stability of naive and memory phenotypes on resting CD4 T cells in vivo. Boursalian TE, et al. **J Immunol** 1999 Jan 1;162(1):9–16

The human B cell response to IL-13 is dependent on cellular phenotype as well as mode of activation. Ford D, et al. **J Immunol** 1999 Sep 15;163(6):3185–93

Postthymic development of CD28-CD8+ T cell subset: age-associated expansion and shift from memory to naive phenotype. Nociari MM, et al. **J Immunol** 1999 Mar 15; 162(6):3327–35

Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. Oehen S, et al. **J Immunol** 1998 Nov 15; 161(10):5338–46

Dose-dependent induction of distinct anergic phenotypes: multiple levels of T cell anergy. Taams LS, et al. **J Immunol** 1999 Feb 15;162(4):1974–81

Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. Ekşioglu-Demiralp E, et al. **J Rheumatol** 1999 Apr;26(4):826–32

Defunct hematopoietic progenitor growth and heterogeneous immunological phenotypes in acquired aplastic anemia of childhood: identification of subsets with decreased hematopoietic progenitors and increased IL15 or IL10 production. Dirksen U, et al. **Klin Padiatr** 1998 Jul-Aug; 210(4):167–72

Immunophenotypic diagnosis of acute leukemia by using decision tree induction. Cualing H, et al. **Lab Invest** 1999 Feb;79(2):205–12

Correspondence re: Immunophenotypic characterization of SIV-infected dendritic cells in the cervix, vagina, and draining lymph nodes of rhesus monkeys, by Hu J, Pope M, Brown C, O'Doherty U, and Miller CJ (Lab Invest 1998;78:435–451) [letter; comment] Nuovo M. **Lab Invest** 1998 Nov;78(11):1343–4. Comment on: Lab Invest 1998 Apr;78(4):435–51.

A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Niehues T, et al. **Leukemia** 1999 Apr;13(4):614–7

The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Khalidi HS, et al. **Mod Pathol** 1998 Dec;11(12):1211–21

Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression. Klobusická M, et al. **Neoplasma** 1998;45(4):237–42

Phenotypic and functional properties of dendritic cells isolated from human peripheral blood in comparison with mononuclear cells and T cells. Huang YM, et al. **Scand J Immunol** 1999 Feb;49(2):177–83

Immunophenotypic characterization of human bone marrow endosteal cells. Sillaber C, et al. **Tissue Antigens** 1999 Jun; 53(6):559–68

Utility of immunophenotypic and immunogenotypic analysis in the study of necrotic lymph nodes. Vega F, et al. **Virchows Arch** 1999 Mar;434(3):245–8

[Immunophenotypic and clinical features of Philadelphia chromosome positive adult lymphocytic leukemia] Li J, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):754–7 (Eng. Abstr.) **(Chi)**

[Immunophenotype of blast crisis in chronic myeloid leukemia] Favre G, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1624–6 (Eng. Abstr.) **(Ger)**

[Phenotypic and functional characterization of porcine T-lymphocytes] Saalmüller A, et al. **Zentralbl Chir** 1998; 123(7):798–802 (43 ref.) (Eng. Abstr.) **(Ger)**

[Advantages of CD45 vs. side scatter based gating in the course of flow cytometric immuno-phenotyping in malignant hematologic diseases] Jáksó P, et al. **Orv Hetil** 1998 Oct 18;139(42):2509–13 (Eng. Abstr.) **(Hun)**

INSTRUMENTATION

Nine color eleven parameter immunophenotyping using three laser flow cytometry. Bigos M, et al. **Cytometry** 1999 May 1;36(1):36–45

METHODS

Evaluation of monoclonal antibody reagents from three different manufacturers using flow cytometric two-color immunophenotyping. Pattanapanyasat K, et al. **Asian Pac J Allergy Immunol** 1998 Dec;16(4):185–92

Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors. Pierelli L, et al. **Br J Haematol** 1998 Sep; 102(5):1139–50

Acute leukaemia immunophenotyping in bone-marrow routine sections. Pileri SA, et al. **Br J Haematol** 1999 May; 105(2):394–401

Comparative flow cytometric study of clonal excess in leukaemic peripheral blood from patients suffering from chronic lymphocytic leukaemia (B-CLL) by different antibodies, staining techniques and the effects of blood storage. Schmidtke G, et al. **Clin Lab Haematol** 1999 Apr; 21(2):103–12

Nine color eleven parameter immunophenotyping using three laser flow cytometry. Bigos M, et al. **Cytometry** 1999 May 1;36(1):36–45

Mean fluorescence intensity of dual stained cells [letter; comment] D'hautcourt JL, et al. **Cytometry** 1999 Feb 15; 38(1):44–6. Comment on: Cytometry 1998 Apr 15;34(2):71–4.

Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry. Macey MG, et al. **Cytometry** 1999 Aug 15;38(4):153–60

Effects of thermal exposure on immunophenotyping combined with in situ PCR, measured by flow cytometry. Mutty CE, et al. **Cytometry** 1999 Aug 1;36(4):303–11

Light scatter and immunophenotypic characteristics of blast cells in typical acute promyelocytic leukemia and its variant. Piedras J, et al. **Cytometry** 1998 Aug 1;32(4):286–90

Evaluation of a flow cytometric method for simultaneous leukocyte phenotyping and quantification by fluorescent microspheres. Schlenke P, et al. **Cytometry** 1998 Nov 1; 33(3):310–7

Four color compensation. Stewart CC, et al. **Cytometry** 1999 Aug 15;38(4):161–75

Novel flow cytometry compensation standards: internally stained fluorescent microspheres with matched emission spectra and long-term stability. Zhang YZ, et al. **Cytometry** 1998 Oct 1;33(2):244–8

Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas. Liu K, et al. **Diagn Cytopathol** 1999 Aug;21(2):98–104

Rapid and simple immunophenotypic characterization of lymphocytes using a new test. Bellido M, et al. **Haematologica** 1998 Aug;83(8):681–5

Human immunotoxicologic markers of chemical exposures: preliminary validation studies. Wartenberg D, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:51–61

A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Weir EG, et al. **Leukemia** 1999 Apr;13(4):558–67

Peripheral blood lymphocyte phenotype can predict rejection episodes after orthotopic liver transplantation. Perdigoto R, et al. **Transplant Proc** 1999 Sep;31(6):2418–20

[Multi-parametric analysis for leukemic immunophenotyping] Ujiie M, et al. **Rinsho Byori** 1998 Nov;46(11):1163–7 (Eng. Abstr.) **(Jpn)**

STANDARDS

Performance of calibration standards for antigen quantitation with flow cytometry. Lenkei R, et al. **Cytometry** 1998 Oct 1;33(2):188–96

TRENDS

The selection of intracellular antibodies. Cattaneo A, et al. **Trends Biotechnol** 1999 Mar;17(3):115–21 (46 ref.)

VETERINARY

Immunophenotypic characterization of lymphomas from the mediastinum of young ferrets. Coleman LA, et al. **Am J Vet Res** 1998 Oct;59(10):1281–6

Lymphoid neoplasia in the koala. Connolly JH, et al. **Aust Vet J** 1998 Dec;76(12):819–25

IMMUNOPHILINS

ANALYSIS

Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays [published erratum appears in Proc Natl Acad Sci U S A 1999 Jun 22;96(13):7610] Remy I, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5394–9

Study of FK-binding protein: FK506-metabolite complexes by electrospray mass spectrometry: correlation to immunosuppressive activity. Trepanier DJ, et al. **Ther Drug Monit** 1999 Jun;21(3):274–80

IMMUNOPHILINS

ANTAGONISTS & INHIBITORS

Immunophilins and immunosuppression by cyclosporins and macrolide structures. Schreier MH.
Acta Derm Venereol Suppl (Stockh) 1994;186:100

Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity. Mealey KL, et al.
Cancer Chemother Pharmacol 1999;44(2):152–8

Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties. Christner C, et al.
J Med Chem 1999 Sep 9;42(18):3615–22

Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations. Lamb ML, et al.
J Med Chem 1998 Oct 8;41(21):3928–39

The discovery of steroids and other novel FKBP inhibitors using a molecular docking program. Burkhard P, et al.
J Mol Biol 1999 Apr 16;287(5):853–8

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Peterson RT, et al.
Proc Natl Acad Sci U S A 1999 Apr 13;96(8):4438–42

BIOSYNTHESIS

Identification of a gluconic acid derivative attached to the N-terminus of histidine-tagged proteins expressed in bacteria. Yan Z, et al. **Biochem Biophys Res Commun** 1999 Sep 7;262(3):793–800

The wheat peptidyl prolyl cis-trans-isomerase FKBP77 is heat induced and developmentally regulated. Kurek I, et al. **Plant Physiol** 1999 Feb;119(2):693–704

CHEMISTRY

Detection and use of pseudo-translation in determination of protein structures. Chook YM, et al.
Acta Crystallogr D Biol Crystallogr 1998 Sep 1;54 (Pt 5):822–7

Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Liang J, et al.
Acta Crystallogr D Biol Crystallogr 1999 Apr;55 (Pt 4):736–44

Mass spectrometric determination of a novel modification of the N-terminus of histidine-tagged proteins expressed in bacteria. Yan Z, et al.
Biochem Biophys Res Commun 1999 Jun 7;259(2):271–82

Synthesis in Escherichia coli of two smaller enzymically active analogues of Coxiella burnetii macrophage infectivity potentiator (CbMip) protein utilizing a single open reading frame from the cbmip gene. Mo YY, et al.
Biochem J 1998 Oct 1;335 (Pt 1):67–77

Chemical inducers of dimerization: the atomic structure of FKBP12–FK1012A–FKBP12. Schultz LW, et al.
Bioorg Med Chem Lett 1998 Jan 6;8(1):1–6

Folding of the human protein FKBP. Lattice Monte-Carlo simulations. Papandreou N, et al. **C R Acad Sci III** 1998 Oct;321(10):835–43

Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Huse M, et al. **Cell** 1999 Feb 5;96(3):425–36

Use of organic solvents and small molecules for locating binding sites on proteins in solutions. Dalvit C, et al.
J Biomol NMR 1999 May;14(1):23–32

32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein. Becker JW, et al. **J Med Chem** 1999 Jul 29;42(15):2798–804

Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. Muegge I, et al. **J Med Chem** 1999 Jul 15;42(14):2498–503

Conformations of peptide fragments from the FK506 binding protein: comparison with the native and urea-unfolded states. Callihan DE, et al. **J Mol Biol** 1999 Feb 5; 285(5):2161–75

Mapping the interactions present in the transition state for unfolding/folding of FKBP12. Fulton KF, et al.
J Mol Biol 1999 Aug 13;291(2):445–61

Folding pathway of FKBP12 and characterisation of the transition state. Main ER, et al. **J Mol Biol** 1999 Aug 13; 291(2):429–44

Does trifluoroethanol affect folding pathways and can it be used as a probe of structure in transition states? Main ER, et al. **Nat Struct Biol** 1999 Sep;6(9):831–5

The effects of N-terminal fragments of immunophilin on phospholipid composition of rat brain and human erythrocyte membranes. Karageuzyan KG.
Neurochem Res 1999 Sep;24(9):1161–7

Molecular anchors with large stability gaps ensure linear binding free energy relationships for hydrophobic substituents. Rejto PA, et al. **Pac Symp Biocomput** 1998; :362–73

Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces [see comments] Briesewitz R, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1953–8 . Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1826–7.

Borrowing to make ends meet [comment] Clardy J.
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1826–7 (11 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1953–8.

GENETICS

Synthesis in Escherichia coli of two smaller enzymically active analogues of Coxiella burnetii macrophage infectivity potentiator (CbMip) protein utilizing a single open reading frame from the cbmip gene. Mo YY, et al.
Biochem J 1998 Oct 1;335 (Pt 1):67–77

muFKBP38: a novel murine immunophilin homolog differentially expressed in Schwannoma cells and central nervous system neurons in vivo. Pedersen KM, et al.
Electrophoresis 1999 Feb;20(2):249–55

Molecular cloning and characterization of Aspergillus nidulans cyclophilin B. Joseph JD, et al.
Fungal Genet Biol 1999 Jun;27(1):55–66

FKBP-type peptidyl-prolyl cis-trans isomerase from a sulfur-dependent hyperthermophilic archaeon, Thermococcus sp. KS-1. Iida T, et al. **Gene** 1998 Nov 19; 222(2):249–55

A novel human gene FKBP6 is deleted in Williams syndrome. Meng X, et al. **Genomics** 1998 Sep 1;52(2):130–7

Molecular cloning, characterization, and chromosomal localization of FKBP23, a novel FK506-binding protein with Ca2+-binding ability. Nakamura T, et al.
Genomics 1998 Nov 15;54(1):89–98

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. Vilella-Bach M, et al. **J Biol Chem** 1999 Feb 12;274(7):4266–72

Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. Reynolds PD, et al. **J Clin Endocrinol Metab** 1999 Feb; 84(2):663–9

A PCR test for the identification and discrimination of Legionella longbeachae serogroups 1 and 2. Saint CP, et al. **J Microbiol Methods** 1999 Sep;37(3):245–53

Identification and characterization of the murine FK506 binding protein (FKBP) 12.6 gene. Bennett JA, et al.
Mamm Genome 1998 Dec;9(12):1069–71

Molecular characterization of FKBP13 from filarial parasites. Ma D, et al. **Mol Biochem Parasitol** 1999 Apr 30; 99(2):263–7

Drug target validation and identification of secondary drug target effects using DNA microarrays [see comments] Marton MJ, et al. **Nat Med** 1998 Nov;4(11):1293–301. Comment in: Nat Med 1998 Nov;4(11):1235–6.

Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin. Xu Q, et al.
Plant J 1998 Aug;15(4):511–9

The wheat peptidyl prolyl cis-trans-isomerase FKBP77 is heat induced and developmentally regulated. Kurek I, et al. **Plant Physiol** 1999 Feb;119(2):693–704

Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein. Chambraud B, et al.
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):2104–9

The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Lee JP, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16; 96(6):3251–6

IMMUNOLOGY

Autoantibodies to FK506 binding protein 12 (FKBP12) in autoimmune diseases. Shinkura N, et al. **Autoimmunity** 1999;29(3):159–70

FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Gold BG. **Drug Metab Rev** 1999 Aug; 31(3):649–63 (75 ref.)

Peptides related to FKBP 39-45 loop possess immunostimulative potency. Siemion IZ, et al. **Peptides** 1998;19(9):1479–87

ISOLATION & PURIFICATION

High-molecular-weight FK506-binding proteins are components of heat-shock protein 90 heterocomplexes in wheat germ lysate. Reddy RK, et al. **Plant Physiol** 1998 Dec;118(4):1395–401

METABOLISM

Involvement of two classes of binding sites in the interactions of cyclophilin B with peripheral blood T-lymphocytes. Denys A, et al. **Biochem J** 1998 Dec 15;336 (Pt 3):689–97

Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Woodfield K, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):287–90

Cyclophilin-D binding proteins. Crompton M, et al.
Biochem Soc Trans 1998 Nov;26(4):S330

Mitochondrial import of cyclophilin-D. Johnson N, et al.
Biochem Soc Trans 1998 Nov;26(4):S329

Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. Keenan T, et al.
Bioorg Med Chem 1998 Aug;6(8):1309–35

Activation and inhibition of skeletal RyR channels by a part of the skeletal DHPR II-III loop: effects of DHPR Ser687 and FKBP12. Dulhunty AF, et al. **Biophys J** 1999 Jul; 77(1):189–203

Cyclophilin B binding to platelets supports calcium-dependent adhesion to collagen. Allain F, et al.
Blood 1999 Aug 1;94(3):976–83

The PIK-related kinases intercept conventional signaling pathways. Kuruvilla FG, et al. **Chem Biol** 1999 May; 6(5):R129–36 (70 ref.)

Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Soldin SJ. **Clin Biochem** 1998 Jul;31(5):381–4 (27 ref.)

Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Crompton M, et al. **Eur J Biochem** 1998 Dec 1; 258(2):729–35

Import and processing of heart mitochondrial cyclophilin D. Johnson N, et al. **Eur J Biochem** 1999 Jul;263(2):353–9

Two distinct regions of cyclophilin B are involved in the recognition of a functional receptor and of glycosaminoglycans on T lymphocytes. Carpentier M, et al. **J Biol Chem** 1999 Apr 16;274(16):10990–8

FK-binding protein is associated with the ryanodine receptor of skeletal muscle in vertebrate animals. Qi Y, et al.
J Biol Chem 1998 Dec 25;273(52):34813–9

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. Vilella-Bach M, et al. **J Biol Chem** 1999 Feb 12;274(7):4266–72

Three amino acid residues determine selective binding of FK506-binding protein 12.6 to the cardiac ryanodine receptor. Xin HB, et al. **J Biol Chem** 1999 May 28; 274(22):15315–9

Immunophilins: beyond immunosuppression. Hamilton GS, et al. **J Med Chem** 1998 Dec 17;41(26):5119–43 (245 ref.)

Receptor-mediated transcytosis of cyclophilin B through the blood-brain barrier. Carpentier M, et al. **J Neurochem** 1999 Jul;73(1):260–70

Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Cruz MC, et al.
Mol Cell Biol 1999 Jun;19(6):4101–12

The 12 kD FK 506 binding protein FKBP12 is released in the male reproductive tract and stimulates sperm motility. Walensky LD, et al. **Mol Med** 1998 Aug;4(8):502–14

Does trifluoroethanol affect folding pathways and can it be used as a probe of structure in transition states? Main ER, et al. **Nat Struct Biol** 1999 Sep;6(9):831–5

A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Costantini LC, et al. **Neurobiol Dis** 1998 Aug; 5(2):97–106

An Arabidopsis immunophilin, AtFKBP12, binds to AtFIP37 (FKBP interacting protein) in an interaction that is disrupted by FK506. Faure JD, et al. **Plant J** 1998 Sep; 15(6):783–9

Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin. Xu Q, et al.
Plant J 1998 Aug;15(4):511–9

Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces [see comments] Briesewitz R, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):1953–8 Comment in: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1826–7.

Borrowing to make ends meet [comment] Clardy J.
Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1826–7 (11 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Mar 2;96(5):1953–8.

PHYSIOLOGY

Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Hultsch T, et al.
Arch Dermatol Res 1998 Sep;290(9):501–7

The mitochondrial permeability transition pore and its role in cell death. Crompton M. **Biochem J** 1999 Jul 15;341 (Pt 2):233–49 (208 ref.)

Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Meyer BK, et al. **Biochemistry** 1999 Jul 13; 38(28):8907–17

Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Göthel SF, et al.
Cell Mol Life Sci 1999 Mar;55(3):423–36 (96 ref.)

cFKBP/SMAP; a novel molecule involved in the regulation of smooth muscle differentiation. Fukuda K, et al.
Development 1998 Sep;125(18):3535–42

Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. Dolinski KJ, et al. **Genetics** 1999 Mar; 151(3):935–44

Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. Gold BG, et al.
J Pharmacol Exp Ther 1999 Jun;289(3):1202–10

The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal-binding protein? Pratt WB, et al.
J Steroid Biochem Mol Biol 1993 Sep;46(3):269–79 (74 ref.)

Modulation of intracellular Ca2+ levels in the heart by sorcin and FKBP12, two accessory proteins of ryanodine receptors. Valdivia HH. **Trends Pharmacol Sci** 1998 Dec; 19(12):479–82 (27 ref.)

IMMUNOPOTENTIATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPRECIPITATION see **PRECIPITIN TESTS**

IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE

DIAGNOSIS

Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis. Fine KD, et al. **Am J Gastroenterol** 1999 May; 94(5):1139-52 (180 ref.)

PATHOLOGY

Immunoproliferative small intestinal disease in South India: a clinical and immunomorphological study. Nair S, et al. **J Gastroenterol Hepatol** 1998 Dec;13(12):1207-11

IMMUNOPROTEINS

CHEMICAL SYNTHESIS

Homogeneous immunoconjugates for boron neutron-capture therapy: design, synthesis, and preliminary characterization. Guan L, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13206-10

IMMUNORADIOMETRIC ASSAY

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome. Ferrandina G, et al. **Br J Cancer** 1998 Dec;78(12):1645-52

METHODS

A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Degorce F, et al. **Br J Cancer** 1999 Jan;79(1):65-71

Clinical validation of a new immunoradiometric assay for intact human osteocalcin. Minisola S, et al. **Calcif Tissue Int** 1999 May;64(5):365-9

Immunoradiometric assay of thyroglobulin in patients with differentiated thyroid carcinomas: need for thyroglobulin recovery tests. Bourrel F, et al. **Clin Chem Lab Med** 1998 Sep;36(9):725-30

Comparison of two immunoradiometric assays for parathyroid hormone-related protein in the evaluation of cancer patients with and without hypercalcemia. de Miguel F, et al. **Clin Chim Acta** 1998 Oct;277(2):171-80

A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Ohta H, et al. **Clin Chim Acta** 1999 Sep;287(1-2):131-43

Technical and clinical comparison of two fully automated methods for the immunoassay of CA 125 in serum. Yan G, et al. **J Immunol Methods** 1999 May 27;225(1-2):1-8

IMMUNOSCINTIGRAPHY, RADIOLABELED see **RADIOIMMUNODETECTION**

IMMUNOSORBENT TECHNIQUES

Rapid and reliable serological diagnosis of enteric fever: comparative sensitivity and specificity of Typhidot and Typhidot-M tests in febrile Malaysian children. Choo KE, et al. **Acta Trop** 1999 Mar 15;72(2):175-83

Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases. Elliott JD, et al. **Autoimmunity** 1998;28(3):163-71

Interaction of steroid--peroxidase conjugates with cellulose immunosorbents in aqueous and micellar media. Eryomin AN, et al. **Biochemistry (Mosc)** 1998 Oct;63(10):1148-59

Microporous microparticles designed as stable immunoadsorbents. Ubrich N, et al. **Biotechnol Bioeng** 1998 Jun 20;58(6):581-6

Preliminary studies on the use of solid-phase immunosorbent techniques for the rapid detection of Wesselsbron virus (WSLV) IgM by haemagglutination-inhibition. Baba SS, et al. **Comp Immunol Microbiol Infect Dis** 1999 Jan; 22(1):71-9

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Freiburghaus C, et al. **Haemophilia** 1998 Jan;4(1):16-20

Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Stegmayr BG, et al. **Int J Artif Organs** 1999 Feb;22(2):81-7

Simultaneous extraction of selected benzodiazepines and benzodiazepine-glucuronides from urine by immunoadsorption. Franzelius C, et al. **J Anal Toxicol** 1998 Sep;22(5):359-62

On-line coupling of immunoaffinity-based solid-phase extraction and gas chromatography for the determination of s-triazines in aqueous samples. Dallüge J, et al. **J Chromatogr A** 1999 Jan 15;830(2):377-86

Identification of complement activators and elucidation of the fate of complement activation products during extracorporeal plasma purification therapy. Fadul JE, et al. **J Clin Apheresis** 1998;13(4):167-73

Adsorption of anaphylatoxins from the plasma of systemic lupus erythematosus patients using dextran sulfate cellulose columns. Matsuki Y, et al. **J Clin Apheresis** 1998; 13(3):108-13

Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays. Betterle C, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):618-22

Combination of immunoadsorption therapy and high-dose methylprednisolone in patients with lupus nephritis; possible indications in patients with early stage. Funauchi M, et al. **J Clin Lab Immunol** 1997;49(2):47-57

Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. Ogata K, et al. **J Dermatol** 1999 Apr;26(4):236-9

A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. Baron AT, et al. **J Immunol Methods** 1998 Oct 1; 219(1-2):23-43

Crow-Fukase syndrome--immunoadsorption plasmapheresis effectively lowers elevated interleukin-6 concentration. Ako S, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):419-22

Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Haas M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2013-6

A method for the purification of cAMP-dependent protein kinase using immunoaffinity chromatography. Cao J, et al. **Protein Expr Purif** 1998 Dec;14(3):418-24

Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Braun N, et al. **Ther Apher** 1999 Aug;3(3):240-5

Evaluation of adsorption selectivity dextran sulfate bound cellulose beads for the removal of anti-DNA antibodies. Hidaka T, et al. **Ther Apher** 1999 Feb;3(1):75-80

C1q: a multifunctional ligand for a new immunoadsorption treatment. Hiepe F, et al. **Ther Apher** 1999 Aug;3(3):246-51

Prominent effect of immunoadsorption plasmapheresis therapy in a patient with chronic inflammatory demyelinating polyneuropathy associated with hepatitis B infection. Inoue A, et al. **Ther Apher** 1998 Nov;2(4):305-7

Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Koll RA. **Ther Apher** 1998 May;2(2):147-52

LDL-Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Koll RA. **Ther Apher** 1998 May;2(2):142-6

Treatment of experimental allergic encephalomyelitis by selective removal of CD4+ T cells. Matsuo H, et al. **Ther Apher** 1997 May;1(2):165-8

Comparison of the adsorption ability between tryptophan and modified tryptophan columns. Odaka M, et al. **Ther Apher** 1997 Nov;1(4):353-5

Immunoadsorption in systemic connective tissue diseases and primary vasculitis [editorial] Schneider M, et al. **Ther Apher** 1997 May;1(2):117-20 (22 ref.)

Reduction of acquired high titer factor VIII antibodies by extracorporeal antibody-based immunoadsorption without additional immunosuppressive therapy [letter] Toepfer M, et al. **Thromb Haemost** 1998 Dec;80(6):1035-6

Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients [see comments] Benny WB, et al. **Transfusion** 1999 Jul;39(7):682-7. Comment in: Transfusion 1999 Jul;39(7):671-3.

[Contribution of ParaSight F to the diagnosis of Plasmodium falciparum malaria] Bellagra N, et al. **Pathol Biol (Paris)** 1998 May;46(5):301-6 (Eng. Abstr.) **(Fre)**

[Clinical immunoadsorption] Toepfer M, et al. **Dtsch Med Wochenschr** 1999 Apr 16;124(15):461-5 (59 ref.) **(Ger)**

[Obtaining antibodies and development of an immunoassay for the detection of Escherichia coli proteins in preparations of human recombinant gamma interferon] Diaz N, et al. **Rev Argent Microbiol** 1998 Apr-Jun; 30(2):64-72 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Tsuboi Y, et al. **Ther Apher** 1998 Nov;2(4):297-9

INSTRUMENTATION

The removal of beta-2-microglobulin by an immunoadsorption wall. Yang TH, et al. **Artif Organs** 1999 Feb;23(2):131-8

Immusorba TR and Immusorba PH: basics of design and features of functions [editorial] Yoshida M, et al. **Ther Apher** 1998 Aug;2(3):185-92

IMMUNOSORBENTS

see related
ENZYME-LINKED IMMUNOSORBENT ASSAY

Purification of prostate-specific antigen from human serum by indirect immunosorption and elution with a hapten. Peter J, et al. **Anal Biochem** 1999 Aug 15;273(1):98-104

Rate-limiting mass transfer in immunosorbents: characterisation of the adsorption of paraquat-protein conjugates to anti-paraquat Sepharose 4B. Horstmann BJ, et al. **Bioseparation** 1998;7(3):145-57

Microporous microparticles designed as stable immunoadsorbents. Ubrich N, et al. **Biotechnol Bioeng** 1998 Jun 20;58(6):581-6

Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. Gaubitz M, et al. **J Autoimmun** 1998 Oct;11(5):495-501

Use of an albumin-binding domain for the selective immobilisation of recombinant capture antibody fragments on ELISA plates. König T, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):73-83

Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients [see comments] Benny WB, et al. **Transfusion** 1999 Jul;39(7):682-7. Comment in: Transfusion 1999 Jul;39(7):671-3.

BLOOD

[The sorption kinetics in an immunosorbent of circulating immune reactants in the blood of patients with systemic lupus erythematosus] Iaremenko OB. **Lik Sprava** 1998 Dec; (8):65-9 (Eng. Abstr.) **(Ukr)**

CHEMICAL SYNTHESIS

Specific immunoadsorbent for myasthenia gravis treatment: development of synthetic peptide designed to remove antiacetylcholine receptor antibody. Miyahara T, et al. **Ther Apher** 1998 Aug;2(3):246-8

CHEMISTRY

Preparation of DNA-immobilized immunoadsorbent for treatment of systemic lupus erythematosus. Zhu B, et al. **J Biomater Sci Polym Ed** 1999;10(3):341-50

Immusorba TR and Immusorba PH: basics of design and features of functions [editorial] Yoshida M, et al. **Ther Apher** 1998 Aug;2(3):185-92

THERAPEUTIC USE

Preparation of DNA-immobilized immunoadsorbent for treatment of systemic lupus erythematosus. Zhu B, et al. **J Biomater Sci Polym Ed** 1999;10(3):341-50

Immunoadsorption plasmapheresis in acute ataxic neuropathy. Sato T, et al. **Ther Apher** 1998 Feb;2(1):71-3

IMMUNOSTIMULANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOSTIMULATING COMPLEXES see **ISCOMS**

IMMUNOSTIMULATION see **IMMUNIZATION**

IMMUNOSUPPRESSED HOST see **IMMUNOCOMPROMISED HOST**

IMMUNOSUPPRESSION

see related
ANTILYMPHOCYTE SERUM
IMMUNE TOLERANCE
IMMUNOCOMPROMISED HOST

Brugia malayi in Mastomys coucha: establishment in immunosuppressed animals. Tyagi K, et al. **Acta Trop** 1998 Sep 15;71(2):189-94

Autoantigens produced in plants for oral tolerance therapy of autoimmune diseases. Ma S, et al. **Adv Exp Med Biol** 1999;464:179-94 (44 ref.)

Cytomegalovirus retinitis in immunosuppressed children. Baumal CR, et al. **Am J Ophthalmol** 1999 May;127(5):550-8

Donor-specific tolerance induction in composite tissue allografts. Foster RD, et al. **Am J Surg** 1998 Nov; 176(5):418-21

A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Raofi V, et al. **Am J Surg** 1999 Apr;177(4):299-302

The new immunosuppressive era (editorial)] Lo Monte AI, et al. **Ann Ital Chir** 1999 Jan-Feb;70(1):1-19 (201 ref.)

Immunosuppression by retroviruses: implications for xenotransplantation. Denner J. **Ann N Y Acad Sci** 1998 Dec 30;862:75-86 (38 ref.)

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ghobrial RM, et al. **Ann Surg** 1999 Jun; 229(6):824-31; discussion 831-3

Microchimerism following allogeneic vascularized bone marrow transplantation--its possible role in induction of posttransplantation tolerance. Durlik M, et al. **Ann Transplant** 1998;3(1):24-6

Graft rejection in sensitized recipients. Kupiec-Węgliński JW. **Ann Transplant** 1996;1(1):34-40 (61 ref.)

Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Graybill JR, et al. **Antimicrob Agents Chemother** 1998 Oct; 42(10):2467-73

Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. Bobé P, et al. **Blood** 1999 Aug 1;94(3):1028-37

Marrow ablative and immunosuppressive effects of

131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Matthews DC, et al. **Blood** 1999 Jan 15;93(2):737-45

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Knoll GA, et al. **BMJ** 1999 Apr 24;318(7191):1104-7

Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection? Yoshida EM, et al. **Can J Gastroenterol** 1998 Sep;12(6):387-9

Protective effects of diallyl sulfide on N-nitrosodimethylamine-induced immunosuppression in mice. Jeong HG, et al. **Cancer Lett** 1998 Dec 11;134(1):73-9

Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease. Oldstone MB, et al. **Cell** 1999 Sep 3;98(5):629-40

Immunotherapy--anergy, deviation or suppression? [editorial] Smith W, et al. **Clin Exp Allergy** 1998 Aug; 28(8):911-6 (63 ref.)

Hepatobiliary scintigraphy in an immunosuppressed patient with hepatocellular dysfunction and acute cholecystitis: diagnostic dilemmas posed by delayed gallbladder visualization. Assi Z, et al. **Clin Nucl Med** 1998 Sep; 23(9):591-3

Intragraft cytokine expression in tolerant rat renal allografts with rapamycin and cyclosporin immunosuppression. Saggi BH, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):90-7

Strategies for tolerance induction in nonhuman primates. Hamawy MM, et al. **Curr Opin Immunol** 1998 Oct; 10(5):513-7 (26 ref.)

New immunosuppressive strategies. Keown PA. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):659-63 (45 ref.)

Effect of pancreas transplantation and immunosuppression on proinsulin secretion. Christiansen E, et al. **Diabet Med** 1998 Sep;15(9):739-46

Severe hepatitis and pure red cell aplasia in adult Still's disease: good response to immunosuppressive therapy. Janssen HL, et al. **Dig Dis Sci** 1999 Aug;44(8):1639-42

Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury. Stover JF, et al. **Eur J Clin Pharmacol** 1998 Sep; 54(7):529-34

Eruptive dermatofibromas and immunosuppression. Gualandri L, et al. **Eur J Dermatol** 1999 Jan-Feb;9(1):45-7

Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Ozsaran AA, et al. **Eur J Gynaecol Oncol** 1999;20(2):127-30

Cis-trans complementation of DQA1-DQB1 genes are modulated by DQ alleles: an immunogenetics analysis of DQ association with the down-regulatory function of CD8 cells in trichosanthin-induced immunosuppression. Chou KY, et al. **Eur J Immunogenet** 1999 Feb;26(1):5-13

Immunostimulatory action of L-4-oxalysine counteracts immunosuppression induced by alpha-fetoprotein. Wang XW, et al. **Eur J Pharmacol** 1998 Jun 12;351(1):105-11

9th International Workshop on Immunodeficient Animals (IWIDA). Prague, Czech Republic, June 15-18, 1997. Proceedings and abstracts. **Folia Microbiol (Praha)** 1998; 43(5):471-559

Gastrointestinal complications of immunosuppression. Nunes FA, et al. **Gastroenterol Clin North Am** 1999 Mar; 28(1):233-45, viii (35 ref.)

Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter [editorial] Martino R, et al. **Haematologica** 1998 Oct;83(10):865-7 (13 ref.)

Immunotoxicological examination of repeated dose combined exposure by dimethoate and two heavy metals in rats. Institóris L, et al. **Hum Exp Toxicol** 1999 Feb;18(2):88-94

Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. Graeb C, et al. **Hum Immunol** 1998 Jul; 59(7):415-25

Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen, II. Cellular, but not humoral, systemic immune responses against rabies virus immune-stimulating complexes are macrophage dependent. Claassen IJ, et al. **Immunology** 1998 Aug; 94(4):455-60

The role of urocanic acid in UVB-induced suppression of immunity to Trichinella spiralis infection in the rat. Garssen J, et al. **Immunology** 1999 Feb;96(2):298-306

Recurrent vulvovaginal candidiasis - allergy or immune deficiency? Clancy R, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2-4):349-50

Prevention of ultraviolet radiation-induced suppression of contact hypersensitivity by Aloe vera gel components. Lee CK, et al. **Int J Immunopharmacol** 1999 May;21(5):303-10

The effects of B-sitosterol (BSS) and B-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation. Bouic PJ, et al. **Int J Sports Med** 1999 May;20(4):258-62

Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. Bocsi J, et al. **J Cancer Res Clin Oncol** 1999; 125(1):9-19

Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. Babcock GJ, et al. **J Exp Med** 1999 Aug 16;190(4):567-76

Measles virus-induced immunosuppression in vitro is associated with deregulation of G1 cell cycle control proteins. Engelking O, et al. **J Gen Virol** 1999 Jul;80 (Pt 7):1599-608

Anti-LFA-1 alpha reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted rats. Harrison PC, et al. **J Heart Lung Transplant** 1999 Apr;18(4):279-84

The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? Papatheodoridis GV, et al. **J Hepatol** 1999 Apr;30(4):731-8 (87 ref.)

Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice. Duong M, et al. **J Infect Dis** 1998 Nov;178(5):1472-82

Donor dendritic cell persistence in organ allograft recipients in the absence of immunosuppression. O'Connell PJ, et al. **J Leukoc Biol** 1999 Aug;66(2):301-5

Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. Zou LP, et al. **J Neuroimmunol** 1999 Feb 1;94(1-2):109-21

Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study [letter] Hao W, et al. **J Neurol** 1999 Aug;246(8):731-5

Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. Yamanaka R, et al. **J Neurooncol** 1999 May;43(1):27-34

Chemotherapy reduces the prevalence of asthma symptoms in children with cancer: implications for the role of airway inflammation in asthma. Jones PD, et al. **J Paediatr Child Health** 1999 Jun;35(3):269-71

Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. Kappagoda C, et al. **J Paediatr Child Health** 1999 Aug;35(4):341-5

The effects of early and delayed immunosuppression in experimental tracheal transplantation with omentopexy. Maksoud-Filho JG, et al. **J Pediatr Surg** 1999 Aug; 34(8):1223-8

Cellular target of UVB-induced DNA damage resulting in local suppression of contact hypersensitivity. Vink AA, et al. **J Photochem Photobiol B** 1998 Jul 10;44(2):107-11 (36 ref.)

Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression. Cassivi SD, et al. **J Thorac Cardiovasc Surg** 1999 Jan;117(1):1-7

Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. Azuma N, et al. **J Vasc Surg** 1999 Apr;29(4):694-702

Early steroid withdrawal in liver transplantation is safe and beneficial. Everson GT, et al. **Liver Transpl Surg** 1999 Jul; 5(4 Suppl 1):S48-57 (23 ref.)

Neoral/cyclosporine-based immunosuppression. Levy GA. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S37-47 (59 ref.)

Intense immunosuppression and stem cell transplantation or rescue for severe systemic lupus erythematosus [editorial]] Marmont AM. **Lupus** 1999;8(4):256-7

Induction of tolerance to hepatitis B virus: can we 'eat the disease' and live with the virus? Ilan Y, et al. **Med Hypotheses** 1999 Jun;52(6):505-9 (41 ref.)

Humoral immunosuppressant activity of aflatoxin ingestion in rabbits measured by response to Mycobacterium bovis antigens using enzyme-linked immunosorbent assay and serum protein electrophoresis. Gabal MA, et al. **Mycoses** 1998 Sep-Oct;41(7-8):303-8

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Ikeda K, et al. **Nat Med** 1999 Aug;5(8):881-7

Focal segmental glomerulosclerosis in a 32-year-old kidney allograft after 7 years without immunosuppression. Trimarchi HM, et al. **Nephron** 1999;82(3):270-3

Subacute measles encephalitis in a young man immunosuppressed for ankylosing spondylitis. Gazzola P, et al. **Neurology** 1999 Mar 23;52(5):1074-7

Acute immunosuppression and syngeneic bone marrow transplantation in ocular autoimmunity abort disease, but do not result in induction of long-term protection. Savion S, et al. **Ocul Immunol Inflamm** 1998 Sep;6(3):163-72

Anti-lymphocyte antibodies late in the course of pediatric renal transplantation. Butani L, et al. **Pediatr Nephrol** 1999 Apr;13(3):192-4

Chronic amphetamine facilitates immunosuppression in response to a novel aversive stimulus: reversal by haloperidol pretreatment. Basso AM, et al. **Pharmacol Biochem Behav** 1999 Feb;62(2):307-14

Impediments to successful immunotherapy. Hersey P. **Pharmacol Ther** 1999 Feb;81(2):111-9 (102 ref.)

Influence of dietary lipid on hapten-specific UV-induced immunosuppression. Okotie-Eboh G, et al. **Photodermatol Photoimmunol Photomed** 1998 Jun-Aug; 14(3-4):116-8

Sex differences in the resistance of turkeys to Escherichia coli challenge after immunosuppression with dexamethasone. Huff GR, et al. **Poult Sci** 1999 Jan; 78(1):38-44

Heme oxygenase induction mediates the photoimmunoprotective activity of UVA radiation in the mouse. Reeve VE, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9317-21

Differential expression of T-cell adhesion molecules and LFA-1-dependent intercellular adhesion in HgCl2-induced autoimmunity and immune suppression. Roos A, et al. **Scand J Immunol** 1998 Oct;48(4):389-96

Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Naquet P, et al. **Semin Immunol** 1999 Feb;11(1):47-55 (83 ref.)

The effects of immunosuppression on the induction and immunogenicity of chemically induced sarcomas. Fisher JC, et al. **Surgery** 1970 Jul;68(1):150-6; discussion 156-7

The role of therapeutic apheresis in the treatment of cancer: a review. Lentz MR. **Ther Apher** 1999 Feb;3(1):40-9 (88 ref.)

Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Noguchi M, et al. **Ther Apher** 1998 May;2(2):109-14

Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia. Ratjen F, et al. **Thorax** 1999 May;54(5):432-6

Quantitative relationships between the suppression of selected immunological parameters and the area under the corticosterone concentration vs. time curve in B6C3F1 mice subjected to exogenous corticosterone or to restraint stress. Pruett SB, et al. **Toxicol Sci** 1999 Jun;49(2):272-80

Preoperative recipient data and immunosuppression levels are predictive of early patient survival after liver transplantation. Avolio AW, et al. **Transpl Int** 1998;11 Suppl 1:S224-30

Obliterative lesions in small airways in an immunosuppressed porcine heterotopic bronchial allograft model. Salminen US, et al. **Transpl Int** 1998;11 Suppl 1:S515-8

Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides. Schorlemmer HU, et al. **Transpl Int** 1998;11 Suppl 1:S448-51

Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study. Tisone G, et al. **Transpl Int** 1998;11 Suppl 1:S267-9

Quantification of immunosuppression by flow cytometric measurement of intracellular cytokine synthesis. van den Berg AP, et al. **Transpl Int** 1998;11 Suppl 1:S318-21

Proceedings of the Jean Borel Symposium. Future prospects for immunomodulation. Florence, Italy, February 16, 1998. **Transplant Proc** 1999 Feb-Mar;31(1-2A):1S-60S

Proceedings of the 1st International Symposium on Transplant Recipient Compliance. Arlington, Virginia, April 3-5, 1998. **Transplant Proc** 1999 Jun;31(4A):1S-88S

"Almost tolerance" in the clinic. Calne R. **Transplant Proc** 1998 Nov;30(7):3846-8 (10 ref.)

Chronologic alteration of suppressive effects of serum from liver-grafted rats against graft versus host disease. Enoki T, et al. **Transplant Proc** 1998 Nov;30(7):3258-9

Coronary arteriosclerosis did not occur in the transplanted hearts of tolerance-induced rats: analysis from platelet-derived growth factor expression. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3871-2

Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors. Katznelson S. **Transplant Proc** 1999 May;31(3B Suppl):22S-24S (15 ref.)

Variation of microchimerism in long-term renal allograft transplantation and progression of immune tolerance. Lee JM, et al. **Transplant Proc** 1998 Nov;30(7):3888-9

T-cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):342-3 (19 ref.)

Immunity and tolerance are related, and governed by antigen migration and localization. Starzl TE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1406-11 (62 ref.)

Acquired tolerance, allograft "acceptance," and immune suppression. Starzl TE. **Transplant Proc** 1998 Nov; 30(7):3845

Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Sykes M, et al. **Transplant Proc** 1998 Dec; 30(8):4020

Which immunosuppression? [comment] Mayer D. **Transplantation** 1999 Apr 15;67(7):937-8. Comment on: Transplantation 1999 Apr 15;67(7):1036-42.

Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Thomas FT, et al. **Transplantation** 1999 Mar 27;67(6):846-54

Role of the thymus in transplantation tolerance in miniature swine: II. Effect of steroids and age on the induction of tolerance to class I mismatched renal allografts. Yamada K, et al. **Transplantation** 1999 Feb 15;67(3):458-67

Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Blajchman MA. **Vox Sang** 1998;74 Suppl 2:315-9 (29 ref.)

[Inflammatory response of the body to surgery illustrated by pro-inflammatory and anti-inflammatory cytokines] Christensen VB, et al. **Ugeskr Laeger** 1998 Nov 23; 160(48):6951-3 (11 ref.) **(Dan)**

[The reaction of the rat thymus to xenotransplantation and immunosuppression] Puchkov VF, et al. **Morfologiia** 1998; 114(4):59-64 (Eng. Abstr.) **(Rus)**

[Physiological analysis of stress-induced changes in the suppressor activity of mouse T-lymphocytes] Fomicheva EE, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 Aug;

84(8):747–54 (Eng. Abstr.) **(Rus)**
[The characteristics of the course of Leishmania and Pneumocystis opportunistic infections in immunosuppressed laboratory animals] Lysenko AIa. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Jan–Feb; (1):69–71 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Kaposi's sarcoma in a heart transplant patient. Gobitti C, et al. **Acta Oncol** 1998;37(7–8):769–70
Aggressive natural killer-like T-cell malignancy with leukemic presentation following solid organ transplantation. Natkunam Y, et al. **Am J Clin Pathol** 1999 May;111(5):663–71
Acute colonic pseudo-obstruction (Ogilvie's syndrome) after renal transplantation. O'Malley KJ, et al. **Am J Surg** 1999 Jun;177(6):492–6 (40 ref.)
Infection and xenotransplantation. Developing strategies to minimize risk. Fishman JA. **Ann N Y Acad Sci** 1998 Dec 30;862:52–66 (78 ref.)
Diagnosis and prevention of fungal infection in the immunocompromized patient. Richardson MD, et al. **Blood Rev** 1998 Dec;12(4):241–54 (114 ref.)
B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Gross TG, et al. **Bone Marrow Transplant** 1999 Feb;23(3):251–8 (42 ref.)
Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Moretti S, et al. **Bone Marrow Transplant** 1998 Jul;22(2):175–80
A clinically aggressive, polymorphic, polyclonal posttransplantation lymphoproliferative disorder. Dunphy CH, et al. **Cancer Genet Cytogenet** 1998 Oct 1;106(1):49–53
Nocardiosis in a recently transplanted renal patient. Reddy SS, et al. **Clin Nephrol** 1998 Aug;50(2):123–7
Nocardial brain abscess in a renal transplant recipient successfully treated with triple antimicrobials. Sabeel A, et al. **Clin Nephrol** 1998 Aug;50(2):128–30
Kaposi's sarcoma after renal transplantation in Turkey. Ecder ST, et al. **Clin Transplant** 1998 Oct;12(5):472–5
Symptom experience associated with maintenance immunosuppression after heart transplantation: patients' appraisal of side effects. Moons P, et al. **Heart Lung** 1998 Sep–Oct;27(5):315–25
Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. Leigh IM, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S49–57 (90 ref.)
Mycobacterium fortuitum panniculitis in a steroid-dependent asthmatic patient. Retief CR, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):650–3
Human phaeohyphomycotic osteomyelitis caused by the coelomycete Phomopsis saccardo 1905: criteria for identification, case history, and therapy. Sutton DA, et al. **J Clin Microbiol** 1999 Mar;37(3):807–11
Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Gubareva LV, et al. **J Infect Dis** 1998 Nov;178(5):1257–62
Systemic suppression of human peripheral blood phagocytic leukocytes after whole-body UVB irradiation. Leino L, et al. **J Leukoc Biol** 1999 May;65(5):573–82
Ulcerative colitis after liver transplant and immunosuppression. Khan S, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):206–9
Aseptic avascular necrosis of the femoral condyles in renal transplant patients: clinical and radiological aspects on 69 knees. Hardy P, et al. **Knee Surg Sports Traumatol Arthrosc** 1998;6(4):209–14
Immunodeficiency-associated lymphoproliferative disorders. Knowles DM. **Mod Pathol** 1999 Feb;12(2):200–17 (92 ref.)
Oral mucositis in myelosuppressive cancer therapy. Epstein JB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Sep;88(3):273–6 (12 ref.)
Primary hepatic carcinoid in a renal transplant patient. Nemes B, et al. **Pathol Oncol Res** 1999;5(1):67–9
Pneumocystis carinii pneumonia in a child receiving ACTH for infantile spasms. Dunagan DP, et al. **Pediatr Pulmonol** 1999 Apr;27(4):286–9 (17 ref.)
The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Tejani AH, et al. **Pediatr Transplant** 1998 Nov;2(4):318–24
Long-term toxicity of immune suppression in juvenile rheumatic diseases. Laxer RM. **Rheumatology (Oxford)** 1999 Aug;38(8):743–6
Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. Niethammer D, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):747–50
The role of immunosuppression in lymphoma formation. Penn I. **Springer Semin Immunopathol** 1998;20(3–4):343–55 (54 ref.)
Renal complications after heart transplantation. Bennett WM. **Transplant Proc** 1999 Feb–Mar;31(1–2):88
The role of laparotomy, gut manipulation and immunosuppression on bacterial translocation from the intestinal tract. Cicalese L, et al. **Transplant Proc** 1999 Jun; 31(4):1922–3
Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 and Epstein–Barr virus in immunosuppressed renal transplant recipients. Demirağ A, et al. **Transplant Proc** 1998 Nov;30(7):3166–7
Candidemia after orthotopic liver transplantation. Joh JW, et al. **Transplant Proc** 1998 Nov;30(7):3273–4
[Progressive multifocal leukoencephalopathy in a female patient after kidney transplantation] Táborský P, et al. **Vnitr Lek** 1998 Feb;44(2):108–10 (Eng. Abstr.) **(Cze)**
[Pulmonary infections other than AIDS] Perdu D, et al. **Presse Med** 1998 May 23–30;27(19):934–40 (39 ref.) **(Fre)**
[Toxoplasmosis and immunosuppression] Djurković-Djaković O. **Srp Arh Celok Lek** 1998 May–Jun; 126(5–6):197–203 (48 ref.) (Eng. Abstr.) **(Scc)**

ECONOMICS

Evaluating strategies for reducing the costs of immunosuppression. Gorman KJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S115–21
The economics of immunosuppression in renal transplantation: a review of recent literature. Hutton J. **Transplant Proc** 1999 Feb–Mar;31(1–2):1328–32 (25 ref.)
Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation. Keown P. **Transplant Proc** 1999 Feb–Mar;31(1–2):1140–1

HISTORY

The development of immunosuppressive therapy: from leukemia to transplantation. Schwartz RS. **Transplant Proc** 1999 Feb–Mar;31(1–2):40–2

METHODS

Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation. Exton MS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1710–7
The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Reisner Y, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:336–48; discussion 348–50 (37 ref.)
Tolerance induction for islet transplantation. Exner BG, et al. **Ann Transplant** 1997;2(3):77–80 (68 ref.)
Protection of heart and rejection of lymphocyte allografts from the same donor in recipients of donor-specific transfusions. Jasklowska-Englisz M, et al. **Ann Transplant** 1998;3(1):28–33
Acquired systemic tolerance to islet allografts induced by intrathymic inoculation of alloantigens--a brief review. Oluwole SF, et al. **Ann Transplant** 1997;2(3):81–5
Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor. del Rosario ML, et al. **Blood** 1999 May 15;93(10):3558–64
Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Greinix HT, et al. **Blood** 1998 Nov 1;92(9):3098–104
The role of the facilitating cell in the establishment of donor chimerism and transplantation tolerance. Davenport C, et al. **Clin Biochem** 1998 Jul;31(5):359–67 (99 ref.)
Humanized monoclonals and other biological initiatives. Halloran PF, et al. **Clin Biochem** 1998 Jul;31(5):353–7 (30 ref.)
Clinical aspects of sensitization. Katznelson S, et al. **Clin Transpl** 1997;:285–96
Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. DeBruyne LA, et al. **Gene Ther** 1998 Aug;5(8):1079–87
Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Lu L, et al. **Gene Ther** 1999 Apr; 6(4):554–63
Transplantation in HCV: whither immunosuppression [comment] Bizollon T, et al. **Gut** 1999 Sep;45(3):327–8. Comment on: Gut 1999 Sep;45(3):427–34.
Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [see comments] Papatheodoridis GV, et al. **Gut** 1999 Sep;45(3):427–34. Comment in: Gut 1999 Sep;45(3):327–8.
The induction of transplantation tolerance by intrathymic (i.t.) delivery of alloantigen: a critical relationship between i.t. deletion, thymic export of new T cells and the timing of transplantation. Jones ND, et al. **Int Immunol** 1998 Nov; 10(11):1637–46
Immunologic tolerance for immune system-mediated diseases. Hackett CJ, et al. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 1):362–70
Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. Balfour IC, et al. **J Heart Lung Transplant** 1999 May;18(5):492–5
Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. Penson MG, et al. **J Heart Lung Transplant** 1999 Jul;18(7):707–13
Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. Lerut JP, et al. **J Hepatol** 1999 Apr;30(4):706–14
Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. Bushell A, et al. **J Immunol** 1999 Feb 1; 162(3):1359–66
Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody. Honey CR, et al. **J Neurosurg** 1999 Jul;91(1):109–13
Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. Halbert CL, et al. **J Virol** 1998 Dec;72(12):9795–805
Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse. Ruckenstein MJ, et al. **Laryngoscope** 1999 Apr;109(4):626–30
Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. Antoniou EA, et al. **Microsurgery** 1999; 19(2):98–102
Correlation between allograft survival and chimeric state after bone marrow infusion in rat small bowel transplantation. Bakonyi Neto A, et al. **Pediatr Transplant** 1999 Feb;3(1):67–73
The anatomic site of photodynamic therapy is a determinant for immunosuppression in a murine model. Musser DA, et al. **Photochem Photobiol** 1999 Feb;69(2):222–5
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Kenyon NS, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8132–7
Immunosuppression in uveitis therapy. Van Gelder RN, et al. **Springer Semin Immunopathol** 1999;21(2):179–90 (38 ref.)
Induction protocols: yesterday, today, and tomorrow. Abramowicz D, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1100–1 (20 ref.)
Does elimination of Kupffer cells prolong survival time in liver transplantation? Akamatsu Y, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):545–7
Enhanced efficacy of repeated anti-CD8 monoclonal antibody therapy by high-dose cyclosporine treatment. Allan JS, et al. **Transplant Proc** 1998 Dec;30(8):4062–3
Tolerance induction by megadose stem cell transplants: synergism between SCA-1+ Lin- cells and nonalloreactive T cells. Bachar-Lustig E, et al. **Transplant Proc** 1998 Dec;30(8):4007–8
Immunosuppression in liver transplantation: a European survey. Bárcena R, et al. **Transplant Proc** 1999 Sep; 31(6):2427–8
Monitoring serum beta-2 microglobulin is useful for detecting patients with increased risk of acute rejection during reduction in immunosuppression. Câmara NO, et al. **Transplant Proc** 1998 Dec;30(8):4158–9
Thymic-independent peripheral tolerance. Chen ZK, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):802–3
Role of donor passenger leukocytes on the induction of tolerance in rat liver transplantation. Chiba S, et al. **Transplant Proc** 1998 Nov;30(7):3852–3
Donor bone marrow, chimerism, histocompatibility and renal allograft rejection. Ciancio G, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):679
On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Daikh DI, et al. **Transplant Proc** 1998 Dec;30(8):4027–8 (8 ref.)
Dissociation between chimerism and skin graft tolerance after neonatal injection of allogenic spleen cells. Donckier V, et al. **Transplant Proc** 1998 Dec;30(8):4018–9
Thymic and liver graft expression of CD95-L tolerizes allogeneic orthotopic liver grafts. Fändrich F, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):438–9
Indirect allorecognition is involved in both acute and chronic allograft rejection. Fluck N, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):842–3
Systemic administration of CTLA4–Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Fu F, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1244
Role of graft cytokine expression in the tolerogenicity of neonatal skin allografts. Gozzo J, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):813
Hyperacute rejection models: ex vivo xenoperfusion systems. Grinyo JM, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):970–1 (15 ref.)
Risk factors in renal transplantation and implications for immunosuppressive therapy. Halloran PF. **Transplant Proc** 1999 Feb–Mar;31(1–2):351–2
Anti-alpha beta-T cell receptor monoclonal antibody induces tolerance without dominant infiltration by Th2 cells into grafts. Hamano K, et al. **Transplant Proc** 1998 Nov; 30(7):3892
Acquired tolerance is induced by MHC-incompatible test skin graft in adult thymectomized rats with chronic drainage of thoracic duct. Hattori Y, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):748
Auxiliary orthotopic xenogeneic liver transplantation using pigs for fulminant hepatic failure: with special reference to the technique and immunosuppression. Hayashi S, et al. **Transplant Proc** 1998 Nov;30(7):3836
Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. He G, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1239–41
Immune tolerance to self-MHC class II antigens after bone marrow transplantation. Hess A, et al. **Transplant Proc** 1999

Feb-Mar;31(1-2):688-9
Successful limb transplantation across a multi-minor barrier facilitated by preceding engraftment of T-cell-purged donor and recipient bone marrow. Hiotis SP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):692-3
Cytokine genotypes in allograft rejection: guidelines for immunosuppression. Hutchinson IV, et al. **Transplant Proc** 1998 Dec;30(8):3991-2 (11 ref.)
Can intraoperative inoculation of donor splenocytes via the portal vein prolong allograft survival? Ishido N, et al. **Transplant Proc** 1998 Nov;30(7):3883-4
Role of microchimerism on long-term graft survival after donor-specific transfusion in a rat heart transplantation model. Ito H, et al. **Transplant Proc** 1998 Nov;30(7):3862-4
Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents. Kim YS, et al. **Transplant Proc** 1998 Dec;30(8):4031-6 (40 ref.)
Donor pretreatment with bone marrow cells for prevention of graft-versus-host reaction after small bowel transplantation. Kimura Y, et al. **Transplant Proc** 1998 Nov; 30(7):3885-7
New usage paradigms in antibody therapy: induction or true prophylaxis? Kirkman RL. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1234-5 (7 ref.)
Abolition of anti-CD4-induced allotransplantation tolerance by exogenous IL-2. Lehmann M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1220-1
Long-term (10-month) pig islet xenograft tolerance using measured total lymphoid irradiation, splenectomy, short-term rabbit antithymocyte globulin, and deoxyspergualin without long-term immunosuppression. Llyung T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):962-3
Study of donor-specific antigens in inducing tolerance and enhancing graft survival. Lu YP, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):846
Irradiation or temporal variations in immunosuppressive schedules do not prevent graft-versus-host disease following rat limb allotransplantation. Lui LT, et al. **Transplant Proc** 1998 Dec;30(8):3960-1
Anergic cells generated in vitro suppress rejection response to islet allografts. Luo Z, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):623
A composite graft of islet plus donor lymph node cells induced donor specific tolerance in a "low responder" rat combination with class I MHC disparity. Maeda A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):749-50
Gene transfer of immunosuppressive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Magee JC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1194
Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Markees TG, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):884-5
Optimal long-term immunotherapy protocols. Mathew TH. **Transplant Proc** 1999 Feb-Mar;31(1-2):1102-3 (5 ref.)
Current use of polyclonal antilymphocyte antibody preparations. Merion RM. **Transplant Proc** 1999 Sep; 31(6):2208-9 (19 ref.)
Modulation of alloimmunity with class I MHC peptides: mechanisms of action. Mhoyan A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1189-91
Effect of simultaneous infusion of donor bone marrow on hamster-to-rat heart xenograft survival. Miyata Y, et al. **Transplant Proc** 1998 Nov;30(7):3869-70
Induction of tolerance to an "untolerizable" strain by double-strain intrathymic inoculation in experimental rat cardiac transplantation. Mohiuddin MM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):838-9
Analysis of donor-specific unresponsiveness to rat allografts by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) plus donor antigen. Motoyama K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1237-8
Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. Murase N, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):565-6
Oral administration of alloantigen induces indefinite prolongation of MHC mismatched cardiac allografts. Niimi M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):892
A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. Nishimura Y, et al. **Transplant Proc** 1998 Nov;30(7):3850-1
Tolerance induction in rat renal allografts by chemical modulation of accessory signals for lymphocyte activation without immunosuppressants. Nose K, et al. **Transplant Proc** 1998 Nov;30(7):3893-4
Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Onodera K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):876-7
Humoral and cell-mediated factors involved in the suppresive regulation induced by special blood derivatives and their clinical relevance. Padanyi A, et al. **Transplant Proc** 1998 Dec;30(8):3967-71
Should aging recipients of kidney grafts receive less immunosuppression? Palomar R, et al. **Transplant Proc** 1999 Sep;31(6):2277-8
New usage paradigms in antibody therapy: safety of the new agents. Pescovitz MD. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1201-2 (27 ref.)
Use of steroids in renal transplantation. Ponticelli C, et al. **Transplant Proc** 1999 Sep;31(6):2210-1 (18 ref.)
Tolerance of rat cardiac allografts does not require donor-type "passenger" antigen presenting cells. Popma SH, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):840-1
Use of gene therapy for tolerogenic signals. Qin L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):882-3
Mechanisms underlying the development of T-cell tolerance following interruption of signalling at the CD28/B7 and CD40/gp39 interface. Rastellini C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):845
Depletion of IL-4 does not prevent tolerance induction in an allogeneic rat kidney transplantation model. Ritter T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):887-8
Induction of islet transplantation tolerance using donor specific transfusion and anti-CD154 monoclonal antibody. Rossini AA, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):629-32 (15 ref.)
Maintenance of acquired thymic tolerance to rat islet allografts by regulatory/suppressor T cells. Saborio DV, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):897
The combined use of sublethal irradiation and costimulatory blockade to generate mixed bone marrow chimeras. Salam A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1197-8
Establishment of chimerism in donors by intraportal injection of recipient-type bone marrow cells with concomitant administration of FK 506 before liver transplantation prolongs liver allograft survival in rats. Sanada O, et al. **Transplant Proc** 1998 Nov;30(7):3860-1
Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. Sasaki K, et al. **Transplant Proc** 1998 Nov;30(7):3459-60
Impact of 70% partial hepatectomy on administration of donor leukocytes in cardiac transplantation in rats. Sato Y, et al. **Transplant Proc** 1998 Nov;30(7):3873-5
Splenectomy improves survival of HDAF transgenic pig kidneys in primates. Schmoeckel M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):961
Tolerance in Mlsa mismatched chimeras prepared with allogeneic bone marrow alone or in combination with syngeneic bone marrow. Sefrioui H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):702-3
Deletion of donor-reactive cells followed by stem cell transplantation in recipients treated with total lymphoid-irradiation as a means for induction of transplantation tolerance to organ allografts and xenografts. Slavin S, et al. **Transplant Proc** 1998 Dec;30(8):4021-2
Tolerance in murine cardiac allografts by concurrent infusion of viable donor antigen-bearing cells. Smith XG, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):133-4
Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction. Soulillou JP. **Transplant Proc** 1999 Feb-Mar;31(1-2A):49S-51S (23 ref.)
Optimal immunosuppression in pancreas transplantation. Stratta RJ. **Transplant Proc** 1999 Feb-Mar;31(1-2):619-21 (17 ref.)
Specific immunosuppression of the indirect recognition pathway. Suciu-Foca N, et al. **Transplant Proc** 1998 Dec; 30(8):4009-10
Specific immunosuppression of the indirect recognition pathway. Suciu-Foca N, et al. **Transplant Proc** 1998 Dec; 30(8):4060-1
Course and mechanism of tolerance induction after mouse liver transplantation. Sugioka A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):459
Prolonged small bowel allograft survival following repeated intrathymic injections of donor splenocytes and peripheral anti-lymphocyte treatment. Sun S, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):588-9
Acceptance of islet allografts transplanted with Fas ligand expressing testicular allografts. Takeda Y, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):624
Islet allografts: rejection and tolerance induction. Turvey SE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):645
Direct allorecognition: a mechanism in intrathymic tolerance induction. Turvey SE, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):844
Corticosteroid withdrawal after heart transplantation. Vázquez de Prada JA, et al. **Transplant Proc** 1999 Sep; 31(6):2212-4
Prolongation of cardiac allograft survival with intracoronary viral interleukin-10 gene transfer. Wang CK, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):951-2
Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Wekerle T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):680
Haematopoietic stem cells transduced with a single donor class I major histocompatibility complex gene can induce operational tolerance to fully allogeneic cardiac allografts. Wong W, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):886
Characteristics of B lymphocyte and natural killer cell xenotolerance in a concordant hamster-to-athymic rat cardiac xenotransplantation model. Xia GL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):926-7
Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Yoshikawa M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):898-9
Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Zheng XX, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):627-8
Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms. Fu F, et al. **Transplantation** 1999 Feb 15;67(3):444-50
Intragraft cytokine expression and tolerance induction in rat renal allografts. Saggi BH, et al. **Transplantation** 1999 Jan 27;67(2):206-10
Demonstration of multilineage chimerism in a nonhuman primate concordant xenograft model. Ko DS, et al. **Xenotransplantation** 1998 Nov;5(4):298-304
Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-alphaGal antibody in the baboon. Lambrigts D, et al. **Xenotransplantation** 1998 Nov;5(4):274-83
[Immunology in medical practice. XXII. T-cells and strategies for tolerance induction] Weenink JJ, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1148-53 (24 ref.) (Eng. Abstr.) **(Dut)**
[Non-specific immunosuppression and multiple sclerosis] Brochet B. **Rev Neurol (Paris)** 1998 Sep;154(8-9):629-34 (48 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Profiles of noncompliance in patients with a functioning renal transplant: a multicenter study. Compliance Study Group. Siegal B, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1326-7

STATISTICS & NUMERICAL DATA

Incidence of side effects of immunosuppressants commonly used in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep;31(6):2519-21

TRENDS

Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Benfield MR, et al. **Pediatr Transplant** 1999 Feb;3(1):27-32
Contemporary immunosuppression in renal transplant recipients: one size does not fit all. Lewis RM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):254-5 (21 ref.)

VETERINARY

The effect of a second dexamethasone treatment on turkeys previously challenged in an experimental Escherichia coli respiratory model of turkey osteomyelitis complex. Huff GR, et al. **Poult Sci** 1999 Aug;78(8):1116-25

IMMUNOSUPPRESSION (PHYSIOLOGY) see **IMMUNE TOLERANCE**

IMMUNOSUPPRESSIVE AGENTS

see related
ANTILYMPHOCYTE SERUM

Pristane-induced arthritis in mice. V. Susceptibility to pristane-induced arthritis is determined by the genetic regulation of the T cell repertoire. Wooley PH, et al. **Arthritis Rheum** 1998 Nov;41(11):2022-31
P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Egashira M, et al. **Blood** 1999 Jan 15;93(2):599-606
New immunosuppressive strategies. Keown PA. **Curr Opin Nephrol Hypertens** 1998 Nov;7(6):659-63 (45 ref.)
Effect of gliotoxin on human polymorphonuclear neutrophils. Shah DT, et al. **Infect Dis Obstet Gynecol** 1998;6(4):168-75
Long-term renal allograft recipients from South-east Asia in the pre-cyclosporin era. Tang S, et al. **Int J Artif Organs** 1999 Mar;22(3):131-7
Poxvirus-encoded serpins do not prevent cytolytic T cell-mediated recovery from primary infections. Müllbacher A, et al. **J Immunol** 1999 Jun 15; 162(12):7315-21
Advertising of "Sandimmun Neoral" [letter] Neild GH. **Lancet** 1999 Feb 13;353(9152):595
What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Song GY, et al. **Surgery** 1999 Aug;126(2):378-83
Immunosuppressive effects of chloroquine: potential effectiveness for treatment of post-transfusion graft-versus-host disease [see comments] Nishimura M, et al. **Transfus Med** 1998 Sep;8(3):209-14. Comment in: Transfus Med 1998 Sep;8(3):169-72.
Guidelines for the Use of Cyclosporine Formulations. Proceedings of a roundtable satellite meeting of the Transplantation Society. Montreal, Canada, 13 July 1998. **Transplant Proc** 1999 May;31(3):1631-84
Generic Immunosuppressants. Proceedings of a symposium. Montreal, Canada, July 12, 1998. **Transplant Proc** 1999 May;31(3A Suppl):1S-34S
Adenovirus-mediated gene transfer of CTLA4IG gene results in prolonged survival of heart allograft. Guang-Lin M, et al. **Transplant Proc** 1998 Nov;30(7):2923-4
Effect of adenovirus-mediated gene transfer with CTLA4-Ig gene in organ transplantation. Hayashi S, et al. **Transplant Proc** 1999 Aug;31(5):1944-5

ADMINISTRATION & DOSAGE

Aplastic anemia in pregnancy: treatment with cyclosporine and granulocyte-colony stimulating factor. Ohba T, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):458–61

Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Casson DH, et al. **Aliment Pharmacol Ther** 1999 Jul;13(7):891–5

Thalidomide approval brings tight restrictions on access [news] **Am J Health Syst Pharm** 1998 Sep 1;55(17):1746, 1749

Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Ahuja M, et al. **Am J Kidney Dis** 1999 Sep; 34(3):521–9

Drug substitution in transplantation [letter] First MR, et al. **Am J Kidney Dis** 1999 Jul;34(1):205–6

Drug substitution in transplantation [letter] Huang M, et al. **Am J Kidney Dis** 1999 Jul;34(1):206

Drug substitution in transplantation: a National Kidney Foundation White Paper. Sabatini S, et al. **Am J Kidney Dis** 1999 Feb;33(2):389–97 (32 ref.)

Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Galindo-Rodriguez G, et al. **Am J Med** 1999 Jan; 106(1):65–9

Reduction of cyclosporine dosage with ketoconazole in a patient with birdshot retinochoroidopathy [letter; comment] Nussenblatt RB. **Am J Ophthalmol** 1998 Nov; 126(5):742. Comment on: Am J Ophthalmol 1998 Jan;125(1):106–8.

Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Brodsky RA, et al. **Ann Intern Med** 1998 Dec 15; 129(12):1031–5

High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis. McColl G, et al. **Ann Intern Med** 1999 Oct 5;131(7):507–9

Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study [published erratum appears in Arch Dermatol 1998 Nov;134(11):1386] Zonneveld IM, et al. **Arch Dermatol** 1998 Sep;134(9):1101–2

Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Breban M, et al. **Arthritis Rheum** 1999 Mar;42(3):580–1

Indications for, and use of, cytotoxic agents in SLE. Klippel JH. **Baillieres Clin Rheumatol** 1998 Aug;12(3):511–27 (54 ref.)

Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Wingard JR, et al. **Biol Blood Marrow Transplant** 1998;4(3):157–63

Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Storb R, et al. **Blood** 1999 Aug 1;94(3):1131–6

Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL, et al. **Bone Marrow Transplant** 1998 Sep;22(6):541–5

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Hartman AR, et al. **Bone Marrow Transplant** 1998 Sep;22(5):439–43

Liposomal busulphan: bioavailability and effect on bone marrow in mice. Hassan Z, et al. **Bone Marrow Transplant** 1998 Nov;22(9):913–8

Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, et al. **Bone Marrow Transplant** 1999 Mar;23(5):443–50

The use of topical cyclosporin A in ocular graft-versus-host-disease. Kiang E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):147–51

Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Schuler US, et al. **Bone Marrow Transplant** 1998 Aug;22(3):241–4

Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect [letter] Shaw PJ, et al. **Bone Marrow Transplant** 1999 Mar;23(6):632–3

High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Simpson DR, et al. **Bone Marrow Transplant** 1998 Aug;22(3):259–64

Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis [letter] Bonnotte B, et al. **Br J Rheumatol** 1998 Dec;37(12):1358–9

Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Grimbacher B, et al. **Br J Rheumatol** 1998 Sep; 37(9):1023–8 (13 ref.)

Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection? Yoshida EM, et al. **Can J Gastroenterol** 1998 Sep;12(6):387–9

Successful treatment of Sjögren's syndrome with cyclophosphamide pulse therapy: report of one case. Chu SM, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul-Aug;39(4):268–70

High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Stiff PJ, et al. **Clin Cancer Res** 1995 Dec; 1(12):1495–502

Cogan's syndrome: unsuccessful outcome with early combination therapy. Covelli M, et al. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):479–83

Possible mechanism underlying the efficacy of low dose cyclosporine in autoimmune diseases [letter] Matsushita M, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):265–6

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Mück W, et al. **Clin Pharmacol Ther** 1999 Mar; 65(3):251–61

Myocarditis of mixed connective tissue disease: favourable outcome after intravenous pulsed cyclophosphamide. Hammann C, et al. **Clin Rheumatol** 1999;18(1):85–7

Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients. Arumugam R, et al. **Clin Transplant** 1998 Dec;12(6):588–92

How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F, et al. **Clin Transplant** 1998 Oct; 12(5):379–90

The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts. Khajehdehi P, et al. **Clin Transplant** 1999 Apr;13(2):176–80

Review of immunosuppressive usage in pancreas transplantation. Stratta RJ. **Clin Transplant** 1999 Feb;13(1 Pt 1):1–12 (86 ref.)

Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Taylor DO, et al. **Clin Transplant** 1999 Aug;13(4):296–9

Tacrolimus in kidney transplantation. Kliem V, et al. **Contrib Nephrol** 1998;124:103–16; discussion 116–25 (73 ref.)

The use of mycophenolate mofetil (Cellcept) in renal transplantation. Vanrenterghem Y. **Contrib Nephrol** 1998; 124:64–9; discussion 69–75 (31 ref.)

Causal inference in a clinical trial: a comparative example. Heitjan DF. **Control Clin Trials** 1999 Aug;20(4):309–18

Survival of rabbit limbal stem cell allografts after administration of cyclosporin A. Xu KP, et al. **Cornea** 1999 Jul;18(4):459–65

Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits. Dias VC, et al. **Dig Dis Sci** 1998 Oct;43(10):2227–36

Acute overdoses of tacrolimus (FK 506). Yeh CN, et al. **Dig Dis Sci** 1999 Aug;44(8):1650–2

Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniasis in chronically infected BALB/c mice. Rousseau D, et al. **Eur Cytokine Netw** 1998 Dec;9(4):655–61

Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers. Chacón M, et al. **Eur J Pharm Sci** 1999 May;8(2):99–107

Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Kolb M, et al. **Eur Respir J** 1998 Dec;12(6):1409–14

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Sandborn WJ, et al. **Gastroenterology** 1999 Sep;117(3):527–35

Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. Iwamoto H, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 May;237(5):407–14

Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Actis GC, et al. **Inflamm Bowel Dis** 1998 Nov;4(4):276–9

A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Cohen RD, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):1–10

Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Maintenance therapy in IBD. Tremaine WJ. **Inflamm Bowel Dis** 1998 Nov;4(4):292–5; discussion 295–301 (34 ref.)

Nanospheres of cyclosporin A: poor oral absorption in dogs. Ford J, et al. **Int J Pharm** 1999 Jun 10;183(1):3–6

Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Ruddy SB, et al. **Int J Pharm** 1999 May 25;182(2):173–86

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis [editorial; comment] Bieber T. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):555–7 (12 ref.). Comment on: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):637–44.

Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. Broeders N, et al. **J Am Soc Nephrol** 1998 Aug; 9(8):1521–5

Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. Nickerson P, et al. **J Am Soc Nephrol** 1999 Aug; 10(8):1801–5

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. Wallace DJ, et al. **J Clin Apheresis** 1998; 13(4):163–6

Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results [see comments] Gurudu SR, et al. **J Clin Gastroenterol** 1999 Sep;29(2):151–4. Comment in: J Clin Gastroenterol 1999 Sep;29(2):115–6.

More evidence of the failure of oral cyclosporine to maintain remission due to intravenous cyclosporine in IBD [editorial; comment] Korelitz BI. **J Clin Gastroenterol** 1999 Sep; 29(2):115–6. Comment on: J Clin Gastroenterol 1999 Sep;29(2):151–3.

The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis. Atakan N, et al. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):240–6

Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. De Geest S, et al. **J Heart Lung Transplant** 1998 Sep; 17(9):854–63

Rescue photochemotherapy for the treatment of acute cardiac rejection in the absence of cyclosporine maintenance therapy [letter] DeNofrio D, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1036–7

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenolate mofetil, cyclosporine A, and donor-specific transfusion. Gibson SW, et al. **J Heart Lung Transplant** 1999 Mar;18(3):185–9

Treatment of humoral rejection after heart transplantation. Grauhan O, et al. **J Heart Lung Transplant** 1998 Dec; 17(12):1184–94

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. Hausen B, et al. **J Heart Lung Transplant** 1999 Feb;18(2):150–9

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. Meiser BM, et al. **J Heart Lung Transplant** 1999 Feb;18(2):143–9

Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen. Nohria A, et al. **J Heart Lung Transplant** 1998 Sep; 17(9):849–53

Short-term cyclosporine induces a remission of autoimmune hepatitis in children. Alvarez F, et al. **J Hepatol** 1999 Feb; 30(2):222–7

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. Wolfhagen FH, et al. **J Hepatol** 1998 Nov;29(5):736–42

Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. Chen W, et al. **J Immunol** 1998 Dec 1; 161(11):6297–304

Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. Newell KA, et al. **J Immunol** 1999 Sep 1;163(5):2358–62

Can skin cancers be minimized or prevented in organ transplant patients? [news] McCann J. **J Natl Cancer Inst** 1999 Jun 2;91(11):911–3

Plasma concentration of hGH and anti-hGH antibodies after subcutaneous administration of hGH for 3 weeks to immunosuppressed pigs. Agersø H, et al. **J Pharmacol Toxicol Methods** 1999 Feb;41(1):1–8

Effects of acute and chronic administration of cyclosporine on dopamine metabolism in the rat cochlea. Esquifino AI, et al. **J Physiol Biochem** 1998 Sep;54(3):149–54

High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. Davis JC Jr, et al. **J Rheumatol** 1998 Sep;25(9):1694–704

A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. Shapiro R, et al. **J Urol** 1998 Dec;160(6 Pt 1):1982–5; discussion 1985–6

Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group. Brennan DC, et al. **Kidney Int** 1999 Aug;56(2):685–91

Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Cantarovich D, et al. **Kidney Int** 1998 Oct;54(4):1351–6

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P, et al. **Kidney Int** 1998 Sep; 54(3):938–44

Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia

Working Group. Führer M, et al. **Klin Padiatr** 1998 Jul-Aug;210(4):173-9

Effect of two cyclosporin regimens on cancer frequency in kidney-graft recipients [letter; comment] Birkeland SA. **Lancet** 1998 Jul 4;352(9121):64. Comment on: Lancet 1998 Feb 28;351(9103):623-8.

Mycophenolate mofetil for Crohn's disease? Lowry PW, et al. **Lancet** 1999 Jul 3;354(9172):3-4

Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Brandenburg U, et al. **Leuk Lymphoma** 1998 Nov;31(5-6):545-50

Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Chiodini B, et al. **Leuk Lymphoma** 1999 May;33(5-6):485-97

Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Casavilla FA, et al. **Liver Transpl Surg** 1998 Nov;4(6):448-54

Treatment needed to achieve remission of SLE [letter] Alarcón-Segovia D. **Lupus** 1999;8(7):566

Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Chan TM, et al. **Lupus** 1999;8(7):545-51

Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Fouillard L, et al. **Lupus** 1999;8(4):320-3

Treatment of chronic bilateral pleural effusions with intravenous immunoglobulin and cyclosporin. Sherer Y, et al. **Lupus** 1999;8(4):324-7

The effect of cyclosporin A on plasma lipids during the first year after renal transplantation. John GT, et al. **Natl Med J India** 1999 Jan-Feb;12(1):14-7

A successful pregnancy in a kidney recipient with tacrolimus (Prograf, FK 506) therapy [letter] Fehrman-Ekholm I, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2982-3

Kaposi's sarcoma after renal transplantation--disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment [letter] Gómez E, et al. **Nephrol Dial Transplant** 1998 Dec; 13(12):3279-80

Reactivation of multisystemic sarcoidosis after immunosuppression withdrawal in a transplanted patient returning to chronic dialysis [letter] Herrero JC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3280-1

Conversion between cyclosporin and tacrolimus--30-fold dose prediction [letter] Higgins RM, et al. **Nephrol Dial Transplant** 1999 Jun;14(6):1609

Interruption of the administration of cyclosporin after renal transplant: long-term results [letter] Solà R, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2981-2

Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Spoendlin M, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1787-91

Effect of ciclosporin on triglyceridemia in long-term renal transplant recipients [letter] Verzola A, et al. **Nephron** 1999 Feb;81(2):240-1

Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Good JL, et al. **Neurology** 1998 Dec;51(6):1735-8

Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Mandler RN, et al. **Neurology** 1998 Oct;51(4):1219-20

Isolated angiitis of the central nervous system: lack of inflammation after long-term treatment. Riemer G, et al. **Neurology** 1999 Jan 1;52(1):196-9

Effective treatment of autoimmune diseases with extremely low dose cyclosporine. Sugiyama M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Feb;21(1):20-8

Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Whitcup SM, et al. **Ocul Immunol Inflamm** 1998 Mar;6(1):51-6

Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations. Medeiros M, et al. **Pediatr Transplant** 1999 Aug;3(3):225-30

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Romine JS, et al. **Proc Assoc Am Physicians** 1999 Jan-Feb; 111(1):35-44

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Nussenblatt RB, et al. **Proc Natl Acad Sci U S A** 1999 Jun 22;96(13):7462-6

Rationale for high-dose cyclophosphamide and medium-dose total body irradiation in the conditioning of children with progressive systemic and polyarticular juvenile chronic arthritis before autologous stem cell transplantation. Vossen JM, et al. **Rheumatology (Oxford)** 1999 Aug;38(8):762-3

Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Qi Z, et al. **Scand J Immunol** 1998 Oct; 48(4):379-88

Natural history and treatment of lupus nephritis. Austin HA, et al. **Semin Nephrol** 1999 Jan;19(1):2-11 (85 ref.)

Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Jones JW Jr, et al. **Surgery** 1999 Aug;126(2):384-8

Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Schmid C, et al. **Thorac Cardiovasc Surg** 1998 Jun;46(3):161-2

WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. Dresske B, et al. **Transpl Immunol** 1998 Dec; 6(4):243-9

A randomised, prospective study on the conversion from cyclosporine-prednisone to cyclosporine-azathioprine at 6 months after renal transplantation. de Sévaux RG, et al. **Transpl Int** 1998;11 Suppl 1:S322-4

Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Filler G, et al. **Transpl Int** 1998;11 Suppl 1:S82-5

Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y, et al. **Transpl Int** 1998;11 Suppl 1:S60-4

Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Margarit C, et al. **Transpl Int** 1998; 11 Suppl 1:S260-6

Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. Morris-Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S78-81

Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. Morris-Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S98-9

Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Pou L, et al. **Transpl Int** 1998;11 Suppl 1:S270-1

Does the switch from sandimmun to Sandimmun neoral reduce patient need for Phenihydine? Rosental R, et al. **Transpl Int** 1998;11 Suppl 1:S337-9

Single-center analysis of the incidence of acute rejection in cadaveric renal allograft recipients induced with low-dose OKT3 with and without mycophenolate mofetil. Abdulbaki A, et al. **Transplant Proc** 1999 Aug;31(5):2112-3

Withdrawal versus continuous cyclosporine therapy in kidney transplant recipients of one-haplotype-matched donors. Chew-Wong A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1106-9

Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral. Chu SH, et al. **Transplant Proc** 1998 Nov;30(7):3521-3

Is azathioprine harmful to chronic viral hepatitis in renal transplantation? A long-term study on azathioprine withdrawal. David-Neto E, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1149-50

Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. Dresske B, et al. **Transplant Proc** 1999 May;31(3):1561-2

Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3535-6

Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter. Gruberg L, et al. **Transplant Proc** 1999 Aug;31(5):2157-8

Recommendations concerning the introduction of generic formulations of cyclosporine. Kahan BD. **Transplant Proc** 1999 May;31(3):1634; discussion 1675-84

Considerations concerning generic formulations of immunosuppressive drugs. Kahan BD. **Transplant Proc** 1999 May;31(3):1635-41

Liquid medication dispensing and dose monitoring: the CycloTech Cyclosporine Oral Solution Dispenser. Rossi SJ, et al. **Transplant Proc** 1999 Jun;31(4A):65S-66S

A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients. Stephan A, et al. **Transplant Proc** 1998 Nov;30(7):3533-4

Corticosteroid withdrawal in renal transplantation. Woodle ES. **Transplant Proc** 1999 Feb-Mar;31(1-2):247-8

Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Yoshikawa M, et al. **Transplant Proc** 1999 Aug;31(5):1939

Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. Yoshimura N, et al. **Transplant Proc** 1998 Nov;30(7):3110-1

Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. Boillot O, et al. **Transplantation** 1998 Nov 15;66(9):1182-5

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bornhäuser M, et al. **Transplantation** 1999 Feb 27;67(4):499-504

Mycophenolate mofetil-induced villous atrophy. Ducloux D, et al. **Transplantation** 1998 Oct 27;66(8):1115-6

Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation. Eisen HJ, et al. **Transplantation** 1999 Sep 15;68(5):663-71

A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Fisher RA, et al. **Transplantation** 1998 Dec 27;66(12):1616-21

Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Hueso M, et al. **Transplantation** 1998 Dec 27;66(12):1727-31

Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys. Jonker M, et al. **Transplantation** 1998 Oct 15;66(7):925-7

Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects [letter] Kandaswamy R, et al. **Transplantation** 1999 Sep 15;68(5):709-10

Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim YS, et al. **Transplantation** 1999 Aug 27;68(4):578-81

Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral [published erratum appears in Transplantation 1999 May 27;67(10):1386] Otto MG, et al. **Transplantation** 1998 Dec 27;66(12):1632-40

Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat. Uchida H, et al. **Transplantation** 1999 May 15;67(9):1269-74

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. van Gelder T, et al. **Transplantation** 1999 Jul 27;68(2):261-6

Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Vu MD, et al. **Transplantation** 1998 Dec 27; 66(12):1575-80

Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig. Yang Z, et al. **Transplantation** 1999 Jun 27;67(12):1517-23

Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice. Koulmanda M, et al. **Xenotransplantation** 1998 Aug;5(3):215-21

[Use of targeted drugs in antineoplastic and immunosuppressive therapy] Rihová B, et al. **Bratisl Lek Listy** 1998 Aug-Sep;99(8-9):439-46 (89 ref.) **(Cze)**

[Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants] van Gelder T, et al. **Ned Tijdschr Geneeskd** 1998 Jul 4;142(27):1550-4 (19 ref.) (Eng. Abstr.) **(Dut)**

[A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation] Roy A, et al. **Ann Chir** 1998;52(8):716-21 (Eng. Abstr.) **(Fre)**

[Active hepatitis B vaccination in ulcerative colitis treated with azathioprine] Hinrichsen H, et al. **Internist (Berl)** 1999 Mar;40(3):327-8 **(Ger)**

[Necrotizing keratitis in chronic polyarthritis. Combined immunosuppressive and surgical therapy] Wiezorrek R, et al. **Ophthalmologe** 1998 Sep;95(9):619-24 (Eng. Abstr.) **(Ger)**

[Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression] Entzian P. **Pneumologie** 1998 Jul;52(7):396-7 **(Ger)**

[Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases] Dejaco C, et al. **Wien Klin Wochenschr** 1998 Sep 4;110(16):579-84 (Eng. Abstr.) **(Ger)**

[Methotrexate in therapy of gastrointestinal diseases] Schröder O, et al. **Z Gastroenterol** 1999 Jul;37(7):623-37 (103 ref.) (Eng. Abstr.) **(Ger)**

[Quantification of cell proliferation with the proliferation marker MIB-1 in endomyocardial biopsies after heart transplantation. An aid in diagnosis of graft rejection needing treatment?] Gerbaulet S, et al. **Z Kardiol** 1998 Aug; 87(8):613-21 (Eng. Abstr.) **(Ger)**

[Switching to Neoral in patients with a stable kidney transplant. Retrospective study] Odone P, et al. **Minerva Urol Nefrol** 1999 Jun;51(2):79-83 (Eng. Abstr.) **(Ita)**

[Preoperative inoculation of CTLA4Ig combined with allogeneic dendritic cells prolongs rat renal allograft survival in a donor-specific fashion] Harada H. **Hokkaido Igaku Zasshi** 1999 May;74(3):189-98 (Eng. Abstr.) **(Jpn)**

[Long-term outcome of topical cyclosporine treatment following penetrating keratoplasty] Inoue K, et al. **Nippon Ganka Gakkai Zasshi** 1999 Apr;103(4):306-10 (Eng. Abstr.) **(Jpn)**

[Suppression of experimental autoimmune uveoretinitis with a combination of cyclosporin and allopurinol] Matuura G, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jan;103(1):26-33 (Eng. Abstr.) **(Jpn)**

[Effects of deoxyspergualin on proliferative glomerulonephritis] Hotta O, et al. **Nippon Jinzo Gakkai Shi** 1999 Jan;41(1):21-8 (Eng. Abstr.) **(Jpn)**

[Unrelated bone marrow transplantation in two severe aplastic anemia patients preconditioned with a regimen of cyclophosphamide, antithymocyte globulin, and total body irradiation] Mizue N, et al. **Rinsho Ketsueki** 1999 Mar; 40(3):213-7 (Eng. Abstr.) **(Jpn)**

[Treatment of aplastic anemia with anti-thymocyte globulin and cyclosporine] Ohnishi S, et al. **Rinsho Ketsueki** 1998 Sep;39(9):640-4 (Eng. Abstr.) **(Jpn)**

[A case of protein-losing gastroenteropathy in association

with mixed connective tissue disease which was successfully treated with cyclophosphamide pulse therapy] Nosho K, et al. **Ryumachi** 1998 Dec;38(6):818–24 (Eng. Abstr.) **(Jpn)**

[Lupus cystitis and peritonitis successfully treated with intravenous cyclophosphamide pulse therapy: a case report] Tsutsumino M, et al. **Ryumachi** 1998 Aug;38(4):611–7 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Pulsed doses of cyclophosphamide in the treatment of Wegener's granulomatosis] Kovačević Z, et al. **Vojnosanit Pregl** 1999 Jan–Feb;56(1):31–7 (Eng. Abstr.) **(Scc)**

[Treatment of non infectious ocular inflammatory disease with low doses of cyclosporin A] Cuchacovich M, et al. **Rev Med Chil** 1999 Mar;127(3):277–85 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Cyclosporine and entrapment neuropathy. Report of two cases. Kaito K, et al. **Acta Haematol** 1998 Dec;100(3):159

The gingival plasma cell infiltrate in renal transplant patients on an immunosuppressive regimen. Saether K, et al. **Acta Odontol Scand** 1998 Oct;56(5):281–7

Brain perfusion imaging in asymptomatic patients receiving cyclosporin. Sheth TN, et al. **AJNR Am J Neuroradiol** 1999 May;20(5):853–6

Shingles during the course of treatment with 6–mercaptopurine for inflammatory bowel disease. Korelitz BI, et al. **Am J Gastroenterol** 1999 Feb;94(2):424–6

Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies [see comments] Abrass CK, et al. **Am J Kidney Dis** 1999 Jan;33(1):11–20 . Comment in: Am J Kidney Dis 1999 Jan;33(1):138–9.

Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. Fassi A, et al. **Am J Kidney Dis** 1999 Feb; 33(2):267–75

Smooth muscle–specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Haas M, et al. **Am J Kidney Dis** 1999 Jul;34(1):69–84

A puzzle solved [editorial; comment] Helderman JH. **Am J Kidney Dis** 1999 Jan;33(1):138–9. Comment on: Am J Kidney Dis 1999 Jan;33(1):11–20.

Incidence and long–term cost of steroid–related side effects after renal transplantation. Veenstra DL, et al. **Am J Kidney Dis** 1999 May;33(5):829–39

Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Weir MR, et al. **Am J Kidney Dis** 1999 Jul;34(1):1–13 (84 ref.)

Cyclosporine–induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease. Porges Y, et al. **Am J Ophthalmol** 1998 Oct;126(4):607–9

Cyclophosphamide–associated uroepithelial toxicity [letter] Aviles RJ, et al. **Ann Intern Med** 1999 Oct 5;131(7):549

Late clonal complications in older patients receiving immunosuppressive therapy for aplastic anemia [letter] Kami M, et al. **Ann Intern Med** 1999 Oct 19;131(8):633–4

Possible interaction between cyclosporine and chloramphenicol [letter] Bui L, et al. **Ann Pharmacother** 1999 Feb;33(2):252–3

Cyclosporine–induced encephalopathy predisposed by diltiazem in a patient with aplastic anemia [letter] Jiang TT, et al. **Ann Pharmacother** 1999 Jun;33(6):750–1

Partial regression of advanced cyclosporin–induced gingival hyperplasia after treatment with azithromycin. A case report. Nowicki M, et al. **Ann Transplant** 1998;3(3):25–7

Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Kaplan MJ, et al. **Arch Dermatol** 1999 May;135(5):553–7

Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent [letter] Campo JV, et al. **Arch Gen Psychiatry** 1998 Nov; 55(11):1050–2

Patients with inflammatory bowel disease: their response to information leaflets about medical therapy in particular azathioprine. Ward B, et al. **Arq Gastroenterol** 1998 Oct–Dec;35(4):264–6

Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. van den Dorpel MA, et al. **Arterioscler Thromb Vasc Biol** 1999 Jun;19(6):1555–8

Squamous cell carcinoma of the nasal septum with Wegener's granulomatosis treated with cyclophosphamide and corticosteroids. Wakisaka N, et al. **Auris Nasus Larynx** 1998 Dec;25(4):393–6 (18 ref.)

A burden to bear in systemic lupus erythematosus (SLE) [letter; comment] Pussell BA. **Aust N Z J Med** 1998 Aug; 28(4):483–4. Comment on: Aust N Z J Med 1998 Feb;28(1):5–11.

Acral keratotic graft versus host disease simulating warts. Kossard S, et al. **Australas J Dermatol** 1999 Aug; 40(3):161–3

Cyclosporine downregulates Fas ligand expression on vascular endothelial cells: implication for accelerated vasculopathy by immunosuppressive therapy. Sata M, et al. **Biochem Biophys Res Commun** 1999 Sep 24;263(2):430–2

Cyclosporin neurotoxicity after chemotherapy. Cyclosporin causes reversible posterior leukoencephalopathy syndrome [letter] Lewis MB. **BMJ** 1999 Jul 3;319(7201):54–5

Cyclosporin neurotoxicity after chemotherapy. Case had features of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome [letter] Pratt G, et al. **BMJ** 1999 Jul 3;319(7201):54; discussion 54–5

Cyclosporin neurotoxicity after chemotherapy. Tweddle DA, et al. **BMJ** 1999 Apr 24;318(7191):1113

High incidence of adeno– and polyomavirus–induced hemorrhagic cystitis in bone marrow allotransplantation for hematological malignancy following T cell depletion and cyclosporine. Childs R, et al. **Bone Marrow Transplant** 1998 Nov;22(9):889–93

HBeAg–negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Kostaridou S, et al. **Bone Marrow Transplant** 1998 Nov;22(9):919–21

Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Steg RE, et al. **Bone Marrow Transplant** 1999 May;23(9):959–62

Ovarian function after autologous bone marrow transplantation in childhood: high–dose busulfan is a major cause of ovarian failure. Teinturier C, et al. **Bone Marrow Transplant** 1998 Nov;22(10):989–94

Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Byrd JC, et al. **Br J Haematol** 1999 May;105(2):445–7

Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Romagnuolo J, et al. **Can J Gastroenterol** 1998 Oct; 12(7):479–83 (24 ref.)

Genotoxic potential of cyclosporin A in patients with renal transplantation. Palanduz S, et al. **Cell Biol Toxicol** 1999 Feb;15(1):13–7

Cyclosporine A–induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism, or both? Borlongan CV, et al. **Cell Transplant** 1999 Jan–Feb;8(1):153–9

Chemotherapy–induced acral erythema (CIAE) with bullous reaction. Azurdia RM, et al. **Clin Exp Dermatol** 1999 Mar; 24(2):64–6

Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Sharma AK, et al. **Clin Infect Dis** 1998 Dec;27(6):1540–1

Toxicology and adverse effects of drugs used for immunosuppression in organ transplantation. Philip AT, et al. **Clin Lab Med** 1998 Dec;18(4):755–65 (22 ref.)

Successful treatment of severe azathioprine–induced hepatic veno–occlusive disease in a kidney–transplanted patient with transjugular intrahepatic portosystemic shunt. Azoulay D, et al. **Clin Nephrol** 1998 Aug;50(2):118–22 (29 ref.)

Nocardial infection in a renal transplant recipient on tacrolimus and mycophenolate mofetil. Magee CC, et al. **Clin Nephrol** 1999 Jul;52(1):44–6

Cyclosporine–induced migraine with severe vomiting causing loss of renal graft. Maghrabi K, et al. **Clin Neurol Neurosurg** 1998 Sep;100(3):224–7

Cyclosporine A neurotoxicity among bone marrow transplant recipients. Shah AK. **Clin Neuropharmacol** 1999 Mar–Apr; 22(2):67–73 (17 ref.)

Distal tubular acidosis induced by FK506. Heering P, et al. **Clin Transplant** 1998 Oct;12(5):465–71

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Henry ML. **Clin Transplant** 1999 Jun;13(3):209–20

Thrombotic microangiopathy after liver–small bowel transplant. Humar A, et al. **Clin Transplant** 1998 Dec; 12(6):600–1

Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case–control study. Sarmiento JM, et al. **Clin Transplant** 1998 Oct;12(5):371–4

Conjunctival epithelial neoplasias in organ transplant patients receiving cyclosporine therapy. Macarez R, et al. **Cornea** 1999 Jul;18(4):495–7

Cyclosporin nephrotoxicity: pathophysiology and comparison with FK–506. Ader JL, et al. **Curr Opin Nephrol Hypertens** 1998 Sep;7(5):539–45 (79 ref.)

An endothelin–transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. Hutchinson IV. **Curr Opin Nephrol Hypertens** 1998 Nov; 7(6):665–71 (90 ref.)

Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Singer NG, et al. **Curr Opin Rheumatol** 1999 May;11(3):173–8 (21 ref.)

Multifocal alopecia areata during systemic cyclosporine A therapy. Cerottini JP, et al. **Dermatology** 1999;198(4):415–7

Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Virgili A, et al. **Dermatology** 1999; 199(1):31–4

Islet transplantation: present and future perspectives. Kenyon NS, et al. **Diabetes Metab Rev** 1998 Dec;14(4):303–13 (100 ref.)

Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Armenti VT, et al. **Drug Saf** 1998 Sep;19(3):219–32 (70 ref.)

Cyclosporin–induced hypertension: incidence, pathogenesis and management. Taler SJ, et al. **Drug Saf** 1999 May; 20(5):437–49 (70 ref.)

Cyclosporin A inhibits Ca2+–mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. Ahlers C, et al. **Eur J Biochem** 1999 Sep;264(3):952–9

Disseminated histoplasmosis successfully treated with liposomal amphotericin B following azathioprine therapy in a patient from a nonendemic area. Poveda F, et al. **Eur J Clin Microbiol Infect Dis** 1998 May;17(5):357–9

Cryptococcal meningitis occurring at 19 months after cladribine therapy for hairy cell leukemia [letter] Ikpeazu EV, et al. **Eur J Haematol** 1998 Oct;61(4):286–7

Gastrointestinal complications of immunosuppression. Nunes FA, et al. **Gastroenterol Clin North Am** 1999 Mar; 28(1):233–45, viii (35 ref.)

Myofibroblast proliferation, fibrosis, and defective pancreatic repair induced by cyclosporin in rats [see comments] Vaquero E, et al. **Gut** 1999 Aug;45(2):269–77. Comment in: Gut 1999 Aug;45(2):167–8.

Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Jones DE, et al. **Hepatology** 1999 Jul;30(1):53–7

Role of sympathetic nervous system in cyclosporine–induced rise in blood pressure. Carvalho MJ, et al. **Hypertension** 1999 Jul;34(1):102–6

Mechanisms of FK 506–induced hypertension in the rat. Takeda Y, et al. **Hypertension** 1999 Jan;33(1):130–6

Chronic rejection and chronic cyclosporin toxicity in renal allografts. Pascual M, et al. **Immunol Today** 1998 Nov; 19(11):514–9

Transplant associated Kaposis sarcoma. Ajithkumar K, et al. **Indian J Cancer** 1998 Dec;35(4):171–2

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Modigliani R. **Inflamm Bowel Dis** 1998 Aug;4(3):244–7; discussion 253–4 (9 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Schölmerich J. **Inflamm Bowel Dis** 1998 Aug;4(3):248–52; discussion 253–4 (21 ref.)

Effects of corticosteroids on HCV infection. Magy N, et al. **Int J Immunopharmacol** 1999 Apr;21(4):253–61

Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year. Hatori M, et al. **Int J Urol** 1998 Nov;5(6):526–33

The importance of obesity and hyperlipidaemia in patients with renal transplants. Locsey L, et al. **Int Urol Nephrol** 1998;30(6):767–75

Skin cancer in kidney and heart transplant recipients and different long–term immunosuppressive therapy regimens. Jensen P, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):177–86

Cyclosporine–associated lymphoma [letter; comment] Zackheim HS. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):1015–6. Comment on: J Am Acad Dermatol 1998 Sep;39(3):464–75.

Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. Lippuner K, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3795–802

Allergic reactions to 6–mercaptopurine during treatment of inflammatory bowel disease. Korelitz BI, et al. **J Clin Gastroenterol** 1999 Jun;28(4):341–4

Verruca vulgaris developing during cyclosporin therapy for psoriasis vulgaris. Irimajiri J, et al. **J Dermatol** 1998 Oct; 25(10):688–90

Hepatitis C virus–related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? Delgado J, et al. **J Heart Lung Transplant** 1999 Jun;18(6):607–10

Tacrolimus (FK 506)–induced hemolytic uremic syndrome after heart transplantation. Walder B, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1004–6

Modulation of nitric oxide improves cyclosporin A–induced hypertension in rats and primates. Bartholomeusz B, et al. **J Hum Hypertens** 1998 Dec;12(12):839–44

Modifying effects of amlodipine on cyclosporin A–induced changes in renal function in patients with psoriasis. Raman GV, et al. **J Hypertens Suppl** 1998 Sep;16(4):S39–41

Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. Schrama YC, et al. **J Hypertens Suppl** 1998 Sep;16(4):S33–8 (89 ref.)

Can skin cancers be minimized or prevented in organ transplant patients? [news] McCann J. **J Natl Cancer Inst** 1999 Jun 2;91(11):911–3

Kaposi's sarcoma in renal transplant recipients: pathogenetic relation between the reduced density of Langerhans cells and cyclosporin–A therapy. Bedani PL, et al. **J Nephrol** 1999 May–Jun;12(3):193–6

Food allergy and tacrolimus [letter; comment] Inui A, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):355–6. Comment on: J Pediatr Gastroenterol Nutr 1997 Aug;25(2):228–9.

Transforming growth factor–beta and the dark side of cyclosporine [news] Jones NL, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):460–1

Cyclosporin A–induced gingival overgrowth in the rat: a histological, ultrastructural and histomorphometric evaluation. Ayanoglou CM, et al. **J Periodontal Res** 1999 Jan;34(1):7–15

Signal recognition particle receptor (SRPR) is downregulated in a rat model of cyclosporin A–induced gingival overgrowth. Marley JJ, et al. **J Periodontal Res** 1999 May;34(4):188–96

Analysis of peripheral blood leukocytes in patients with

cyclosporine A–induced gingival hyperplasia. Cebeci I, et al. **J Periodontol** 1998 Dec;69(12):1435–9
Density of CD1a–labeled Langerhans' cells in normal human gingiva and in nifedipine– and immunosuppressive medication–induced gingival overgrowth. Nurmenniemi PK, et al. **J Periodontol** 1999 Jul;70(7):752–6
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. Asten P, et al. **J Rheumatol** 1999 Aug; 26(8):1705–14
The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients. Mohan P, et al. **J Urol** 1999 Sep;162(3 Pt 1):682–4
Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Benigni A, et al. **Kidney Int** 1999 Feb;55(2):674–85
Cyclosporine–associated thrombotic microangiopathy in renal allografts. Zarifian A, et al. **Kidney Int** 1999 Jun; 55(6):2457–66
Effect of two cyclosporin regimens on cancer frequency in kidney–graft recipients [letter; comment] Birkeland SA. **Lancet** 1998 Jul 4;352(9121):64. Comment on: Lancet 1998 Feb 28;351(9103):623–8.
Post–transplant acute myeloid leukemia (PT–AML). Thalhammer–Scherrer R, et al. **Leukemia** 1999 Mar; 13(3):321–6 (40 ref.)
Diarrhoea secondary to azathioprine in two patients with SLE [letter] Santiago M. **Lupus** 1999;8(7):565
Medically induced gingival hyperplasia [letter; comment] Härkönen M. **Mayo Clin Proc** 1999 Jul;74(7):742–3. Comment on: Mayo Clin Proc 1998 Dec;73(12):1196–9.
Medically induced gingival hyperplasia [see comments] Meraw SJ, et al. **Mayo Clin Proc** 1998 Dec;73(12):1196–9 (42 ref.). Comment in: Mayo Clin Proc 1999 Jul;74(7):742–3.
Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder. Tsai DE, et al. **Med Oncol** 1998 Dec;15(4):279–81
Non–Hodgkin lymphoma after heart–lung transplantation: response to chemotherapy. Haas RJ, et al. **Med Pediatr Oncol** 1999 Mar;32(3):229–30
Successful treatment of monoclonal, aggressive Epstein–Barr virus–associated B–cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia. Perkkiö M, et al. **Med Pediatr Oncol** 1999 Jun;32(6):447–9
Epstein–Barr virus–associated lymphoma after treatment of macroglobulinemia with cladribine [letter] Niesvizky R, et al. **N Engl J Med** 1999 Jul 1;341(1):55
Carcinoma of the corneoscleral limbus in a patient treated with cyclosporine after heart transplantation [letter] Touzeau O, et al. **N Engl J Med** 1999 Jul 29;341(5):374–5
Cyclosporine induces cancer progression by a cell–autonomous mechanism [see comments] Hojo M, et al. **Nature** 1999 Feb 11;397(6719):530–4. Comment in: Nature 1999 Feb 11;397(6719):471–2.
A transformed view of cyclosporine [news; comment] Nabel GJ. **Nature** 1999 Feb 11;397(6719):471–2. Comment on: Nature 1999 Feb 11;397(6719):530–4.
Tacrolimus and gingival hyperplasia [letter] Basile C, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2980–1
Relapse of atypical haemolytic uraemic syndrome after kidney transplantation: role of ATG and failure of mycophenolate mofetil as rescue therapy. Davin JC, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):984–7
Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation--is tacrolimus the answer? [editorial] Grupp C, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1629–31 (28 ref.)
Uneventful re–treatment with cyclosporin in two cases of cyclosporin–induced haemolytic uraemic syndrome. Guella A, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1864–5
Cyclosporin–induced haemolytic–uraemic syndrome presenting as primary graft dysfunction. Kohli HS, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2940–2
Mycophenolate mofetil in cyclosporin–associated thrombotic microangiopathy. Lecornu–Heuze L, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3212–3
Altered flow properties of blood and increased plasma fibrinogen in cyclosporin–treated renal allograft recipients. Linde T, et al. **Nephrol Dial Transplant** 1999 Jun; 14(6):1525–9
Haemolytic–uraemic syndrome after tacrolimus rescue therapy for cortisone–resistant rejection. Schmidt RH, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):979–83
Cervical myxofibrosarcoma in a renal allograft recipient treated with murine anti–CD3 monoclonal antibody therapy [letter] Soper CP, et al. **Nephrol Dial Transplant** 1998 Jul;13(7):1902–3
Relapse of vasculitis, sepsis, or azathioprine allergy? Stratton JD, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2927–8
Severe vital depression as the presenting feature of cyclosporin–A–associated thrombotic microangiopathy. van der Molen LR, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):998–1000
15–Deoxyspergualin and platelet aggregation in vitro [letter] Malyszko JS, et al. **Nephron** 1999;81(3):370–2
Interaction between cyclosporine A and verapamil, felodipine, and isradipine [letter] Yildiz A, et al. **Nephron** 1999 Jan;81(1):117–8
Transient acute myopia induced by antilymphocyte globulins. Milea D, et al. **Ophthalmologica** 1999;213(2):133–4
Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Kotake S, et al. **Ophthalmology** 1999 Mar;106(3):586–9
Erythema elevatum diutinum after liver transplantation: disappearance of the lesions associated with a reduction in cyclosporin dosage [letter] Hernández–Cano N, et al. **Pediatr Dermatol** 1998 Sep–Oct;15(5):411–2
Colitis induced by interaction of cyclosporine A and non–steroidal anti–inflammatory drugs. Constantopoulos A. **Pediatr Int** 1999 Apr;41(2):184–6
The role of early renal biopsy in cyclosporin induced thrombotic microangiopathy. Burke GA, et al. **Pediatr Nephrol** 1999 Sep;13(7):564–6
Was antithymocyte globulin the cause of hemolytic uremic syndrome? Proesmans W. **Pediatr Nephrol** 1998 Oct; 12(8):698–9
Cyclosporine–induced white and grey matter central nervous system lesions in a pediatric renal transplant patient. Jeruss J, et al. **Pediatr Transplant** 1998 Feb;2(1):45–50
Sudden hearing loss associated with tacrolimus in a kidney–pancreas allograft recipient. Min DI, et al. **Pharmacotherapy** 1999 Jul;19(7):891–3
Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Olyaei AJ, et al. **Pharmacotherapy** 1998 Nov–Dec;18(6):1356–9
Breast imaging case of the day. Multiple giant fibroadenomas associated with cyclosporin A therapy. Cyrlak D, et al. **Radiographics** 1999 Mar–Apr;19(2):549–51
The nephrotoxicity of new and old immunosuppressive drugs. Bennett WM. **Ren Fail** 1998 Sep;20(5):687–90 (20 ref.)
FK506 nephrotoxicity. Finn WF. **Ren Fail** 1999 May–Jul; 21(3–4):319–29 (48 ref.)
Relation between urinary cytology abnormalities and cyclosporine A therapy in bone marrow transplant recipients. Sucic M, et al. **Ren Fail** 1998 Jul;20(4):613–20
Hypersensitivity pneumonitis probably caused by cyclosporine. A case report. Roelofs PM, et al. **Respir Med** 1998 Dec;92(12):1368–70
Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Naughton MA, et al. **Rheumatology (Oxford)** 1999 Jul; 38(7):640–4
Normotensive renal failure in a patient with systemic sclerosis and p–antineutrophil cytoplasmic autoantibodies which developed into Paget's disease of bone after immunosuppressive therapy [letter] Villaverde V, et al. **Rheumatology (Oxford)** 1999 Feb;38(2):190–1
Red blood cell rigidification during cyclosporin therapy: a possible early warning signal for adverse reactions. Hardeman MR, et al. **Scand J Clin Lab Invest** 1998 Dec; 58(8):617–23
Hypomagnesemia and mild rhabdomyolysis in living related donor renal transplant recipient treated with cyclosporine A. Cavdar C, et al. **Scand J Urol Nephrol** 1998 Dec; 32(6):415–7
Scanning electron microscopy of cyclosporine–induced gingival overgrowth. Ashrafi SH, et al. **Scanning Microsc** 1996;10(1):219–24; 224–5
Tacrolimus rescue therapy for cyclosporine–induced nephrotoxicity. Hernández–Herrera G, et al. **Transpl Int** 1998;11 Suppl 1:S104–6
Morphological findings in non–episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine. Kyo M, et al. **Transpl Int** 1998;11 Suppl 1:S100–3
Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. Morris–Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S98–9
Does tacrolimus cause more severe anemia than cyclosporine A in children after renal transplantation? Peter C, et al. **Transpl Int** 1998;11 Suppl 1:S328–30
Obliterative lesions in small airways in an immunosuppressed porcine heterotopic bronchial allograft model. Salminen US, et al. **Transpl Int** 1998;11 Suppl 1:S515–8
Kidney graft dysfunction after drug interaction between miocamycin and cyclosporin [letter] Treille S, et al. **Transpl Int** 1999;12(2):157
Differential effects of cyclosporin A and tacrolimus on the production of TGF–beta: implications for the development of obliterative bronchiolitis after lung transplantation. Zhang JG, et al. **Transpl Int** 1998;11 Suppl 1:S325–7
Incidence of side effects of immunosuppressants commonly used in heart transplantation. Almenar L, et al. **Transplant Proc** 1999 Sep;31(6):2519–21
Management of nephrotoxic drugs. Alsina J. **Transplant Proc** 1999 Feb–Mar;31(1–2):1117–9 (36 ref.)
Renal complications after heart transplantation. Bennett WM. **Transplant Proc** 1999 Feb–Mar;31(1–2):88
Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Brattström C, et al. **Transplant Proc** 1998 Dec;30(8):3950–1
Mycophenolate mofetil–induced colonic ulceration in renal transplant recipients. Golconda MS, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):272–3
Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Gómez G, et al. **Transplant Proc** 1999 Sep;31(6):2250–1
Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Gullestad L, et al. **Transplant Proc** 1999 Aug;31(5):2163–5
Cancer risk associated with ATG/OKT3 in renal transplantation. Hibberd AD, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1271–2
Are renal transplant recipients on CsA–based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Jensen P, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1120
Relationship between steroid dosage and osteonecrosis of the femoral head after renal transplantation as measured by magnetic resonance imaging. Kubo T, et al. **Transplant Proc** 1998 Nov;30(7):3039–40
Long–term safety studies: insights into requirements for changing cyclosporine formulations. Lodge JP. **Transplant Proc** 1999 May;31(3):1664–6
Clinical management of tacrolimus drug interactions in renal transplant patients. Moreno M, et al. **Transplant Proc** 1999 Sep;31(6):2252–3
Adverse effects of immunosuppressive drugs on long–term graft outcome. Paul LC. **Transplant Proc** 1998 Dec; 30(8):4001–4 (62 ref.)
Risk factors that influence the incidence and severity of MMF adverse events in renal transplant patients: relationship with corticosteroid dosage, renal function, sex, and patient age. Puig JM, et al. **Transplant Proc** 1999 Sep; 31(6):2270–1
Anemia following renal transplantation. Saito S, et al. **Transplant Proc** 1998 Nov;30(7):3025–6
Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Binet I, et al. **Transplantation** 1999 Mar 27;67(6):918–22
Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Butani L, et al. **Transplantation** 1999 Jul 15;68(1):83–6
Five cases of Kaposi's sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Eberhard OK, et al. **Transplantation** 1999 Jan 15; 67(1):180–4
Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Freise CE, et al. **Transplantation** 1999 Feb 27; 67(4):510–3
Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Guerard A, et al. **Transplantation** 1999 Sep 15;68(5):699–707
Administration of OKT3 as a two–hour infusion does not attenuate first–dose side effects [letter] Kandaswamy R, et al. **Transplantation** 1999 Sep 15;68(5):709–10
A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus [letter] Kessler M, et al. **Transplantation** 1999 Feb 27;67(4):641–3
Posttransplant diabetes in pediatric recipients on tacrolimus [letter; comment] Shapiro R, et al. **Transplantation** 1999 Mar 15;67(5):771. Comment on: Transplantation 1998 Mar 15;65(5):617–9.
FK506–associated thrombotic microangiopathy: report of two cases and review of the literature. Trimarchi HM, et al. **Transplantation** 1999 Feb 27;67(4):539–44 (18 ref.)
Comment on "Efficacy of azithromycin in the treatment of cyclosporine–induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman [letter; comment] Wirnsberger GH, et al. **Transplantation** 1999 May 15;67(9):1289–91. Comment on: Transplantation 1998 Jun 27;65(12):1611–5.
Possible hemolytic uremic syndrome in three cats after renal transplantation and cyclosporine therapy. Aronson LR, et al. **Vet Surg** 1999 May–Jun;28(3):135–40
[Successful pregnancy after heart transplantation] de Jonge N, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1664–8 (Eng. Abstr.) **(Dut)**
[Pregnancy after liver transplantation in Groningen: benign course for mothers and children] Dirken JD, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1658–62 (Eng. Abstr.) **(Dut)**
[Successful pregnancy after liver transplantation] Wildschut HI, et al. **Ned Tijdschr Geneeskd** 1999 Aug 7;143(32):1662–4 (Eng. Abstr.) **(Dut)**
[Clinical case of the month. Hepatoportal sclerosis in a patient treated with azathioprine] Roland S, et al. **Rev Med Liege** 1998 Aug;53(8):450–3 (Eng. Abstr.) **(Fre)**
[Hypersensitivity to azathioprine can simulate an aggravation of myasthenia (letter)] Chevrel G, et al. **Therapie** 1998 Jan–Feb;53(1):77–8 **(Fre)**
[Progressive multifocal leukoencephalopathy as a result of immunosuppressive therapy] Arbusow V, et al. **Dtsch Med Wochenschr** 1999 May 28;124(21):653–6 (Eng. Abstr.) **(Ger)**
[The liver side effects of azathioprine] Böker KH. **Dtsch Med Wochenschr** 1999 Apr 30;124(17):541 **(Ger)**
[Drug–induced gingival hyperplasia] Nohl F, et al. **Ther Umsch** 1998 Sep;55(9):573–5 (Eng. Abstr.) **(Ger)**
[Painless, red–violet skin lesions during immunosuppression] Pfister M, et al. **Ther Umsch** 1998 Sep;55(9):583–5 (Eng. Abstr.) **(Ger)**
[Treatment of the nephrotoxicity of immunosuppressive drugs with insulin–like growth factor–I] Maestri M, et al. **Minerva Chir** 1998 May;53(5):391–6 (Eng. Abstr.) **(Ita)**
[An increase in gingival volume induced by drugs (phenytoin, cyclosporine and calcium antagonists). A review of the literature] Garzino–Demo P, et al. **Minerva Stomatol** 1998 Sep;47(9):387–98 (115 ref.) (Eng. Abstr.) **(Ita)**
[A case of subclinical IgA nephropathy and cyclosporin

associated arteriolopathy diagnosed by non-episode biopsy of graft kidney after renal transplantation] Namba Y, et al. **Hinyokika Kiyo** 1999 May;45(5):349-53 (Eng. Abstr.) **(Jpn)**

[SLE with interstitial pneumonia during cyclophosphamide pulse therapy] Kawamoto S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Jul;36(7):638-43 (Eng. Abstr.) **(Jpn)**

[Fulminant hepatic failure related to immunosuppressive therapy in an asymptomatic HBsAg carrier with idiopathic interstitial pneumonia] Takagi S, et al. **Nihon Kokyuki Gakkai Zasshi** 1998 Oct;36(10):917-22 (Eng. Abstr.) **(Jpn)**

[Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis] Shimizu A, et al. **Nippon Hinyokika Gakkai Zasshi** 1999 Jan;90(1):53-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Case of systemic erythematodes on long-term care with repeated development of severe cytomegalovirus infection] Masago R, et al. **Nippon Naika Gakkai Zasshi** 1998 Aug 10;87(8):1555-6 **(Jpn)**

[Myelodysplastic syndrome (RAEB in T) developed in a renal allograft recipient] Shiraishi J, et al. **Rinsho Ketsueki** 1998 Aug;39(8):600-5 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Rapidly progressive irradiated cervical cancer that metastasized to the liver during therapy for idiopathic thrombocytopenic purpura] Yoshimura T, et al. **Rinsho Ketsueki** 1999 Feb;40(2):150-2 (Eng. Abstr.) **(Jpn)**

[Pneumatosis cystoides intestinalis associated with intravenous pulse cyclophosphamide treatment for systemic lupus erythematosus] Nonaka D, et al. **Ryumachi** 1998 Aug; 38(4):605-10 (Eng. Abstr.) **(Jpn)**

[Immunosuppressive treatment and risks of neoplasms] Magier K, et al. **Pol Merkuriusz Lek** 1999 Jan;6(31):50-2 (33 ref.) (Eng. Abstr.) **(Pol)**

[Effect of human immunoglobulin preparation in resistance to immunosuppressive therapy in a male patient with nephrotic syndrome] Moskaleva ES, et al. **Ter Arkh** 1999; 71(6):75-6 **(Rus)**

[The reflex sympathetic dystrophy syndrome of the lower extremities in patients after kidney transplantation--another complication of cyclosporin A therapy?] Grandtnerová B, et al. **Vnitr Lek** 1998 Feb;44(2):93-7 (Eng. Abstr.) **(Slo)**

[Pulmonary toxicity due to cyclophosphamide (letter)] Solé A, et al. **Arch Bronconeumol** 1999 Apr;35(4):196-7 **(Spa)**

[Immunosuppressors and inflammatory bowel disease (letter)] Aparicio JR, et al. **Gastroenterol Hepatol** 1999 Apr; 22(4):206 **(Spa)**

[Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease] Velicia MR, et al. **Gastroenterol Hepatol** 1999 Apr;22(4):186-7 (15 ref.) (Eng. Abstr.) **(Spa)**

[Methotrexate and hepatitis B (letter; comment)] Callejas Rubio JL, et al. **Rev Clin Esp** 1999 Jun;199(6):409-10. Comment on: Rev Clin Esp 1998 Dec;198(12):822-4. **(Spa)**

ANALYSIS

Placental isoferritin levels in pregnant patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Maymon R, et al. **Am J Reprod Immunol** 1998 Aug; 40(2):95-101

A modified fluorescence polarization immunoassay method incorporating fat emulsion (FE-FPIA) to determine cyclosporin A concentrations in rat skin. Kurosaki Y, et al. **Biol Pharm Bull** 1999 May;22(5):539-42

The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Korecka M, et al. **Clin Chem** 1999 Jul; 45(7):1047-50

Study of FK-binding protein: FK506-metabolite complexes by electrospray mass spectrometry: correlation to immunosuppressive activity. Trepanier DJ, et al. **Ther Drug Monit** 1999 Jun;21(3):274-80

ANTAGONISTS & INHIBITORS

L-propionyl carnitine reduces toxicity correlated to cyclosporine-induced intracellular ATP concentrations. Giovannini L, et al. **Drugs Exp Clin Res** 1999;25(4):173-7

S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. Galán AI, et al. **J Pharmacol Exp Ther** 1999 Aug;290(2):774-81

Vitamin E suppresses cyclosporine A-induced increase in the urinary excretion of arachidonic acid metabolites including F2-isoprostanes in the rat model. Kanji VK, et al. **Transplant Proc** 1999 May;31(3):1724-8

BLOOD

Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Hamwi A, et al. **Am J Clin Pathol** 1999 Sep;112(3):358-65

Absence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamil. Jacob LP, et al. **Am J Kidney Dis** 1999 Feb;33(2):301-3

Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Capone D, et al. **Am J Nephrol** 1999;19(3):411-5

Determination of cyclosporin A in 20% ethanol by a magnetic beads-based immunofluorescence assay. Kiselev MV, et al. **Anal Biochem** 1999 May 1;269(2):393-8

Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Eiermann TH, et al. **Bone Marrow Transplant** 1999 Apr;23(8):779-81

Busulphan level and early mortality in thalassaemia patients after BMT. Li CK, et al. **Bone Marrow Transplant** 1999 Feb;23(4):307-10

Therapeutic drug monitoring of immunosuppressant drugs. Johnston A, et al. **Br J Clin Pharmacol** 1999 Apr; 47(4):339-50 (138 ref.)

Negative correlation between cyclophilin mRNA level in leukocytes of renal allograft recipients and ciclosporin concentration in whole blood. Zhao Q, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 May;19(3):276-8

Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma. Tong AW, et al. **Clin Cancer Res** 1996 Mar;2(3):531-9

Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). Armstrong VW, et al. **Clin Chem** 1998 Dec;44(12):2516-23

Comparison of tacrolimus concentrations measured by the IMx tacrolimus II vs the PRO-TRAC II FK506 ELISA assays. Cao Z, et al. **Clin Chem** 1999 Oct;45(10):1868-70

Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients [see comments] Cole DE, et al. **Clin Chem** 1998 Nov; 44(11):2307-12. Comment in: Clin Chem 1998 Nov;44(11):2238-9.

Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood. MacFarlane GD, et al. **Clin Chem** 1999 Sep;45(9):1449-58

Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Steimer W. **Clin Chem** 1999 Mar;45(3):371-81

Performance of the IMx tacrolimus II assay and practical limits of detection [letter] Tredger JM, et al. **Clin Chem** 1999 Oct;45(10):1881-2

Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays. Wallemacq PE, et al. **Clin Chem** 1999 Mar;45(3):432-5

Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Angelis-Stoforidis P, et al. **Clin Exp Rheumatol** 1999 May-Jun;17(3):313-20

Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506). Chen YW, et al. **Clin Immunol** 1999 Jan;90(1):133-40

Polyclonal/monoclonal ratio in kidney and bone marrow transplanted patients treated with cyclosporine. Capone D, et al. **Clin Transplant** 1998 Oct;12(5):430-3

OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients. Brusa P, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun; 23(2):301-6

Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. Gaspari F, et al. **J Am Soc Nephrol** 1997 Apr;8(4):647-52

High-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. Gummert JF, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22; 721(2):321-6

Simultaneous on-line extraction and analysis of sirolimus (rapamycin) and ciclosporin in blood by liquid chromatography-electrospray mass spectrometry. Kirchner GI, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22;721(2):285-94

Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. Segarra I, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1-2):179-87

Analysis of immunosuppressive proteins in serum of liver-transplanted rats by using an anti-LSF-1 affinity column. Kobayashi S, et al. **J Surg Res** 1998 Nov; 80(1):58-61

Trough blood concentrations in long-term treatment with mycophenolate mofetil [letter] Sanquer S, et al. **Lancet** 1998 May 23;351(9115):1557

Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy [letter] Herzig K, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):521-3

Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Weber LT, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:34-5

Effect of seasonal changes on the cyclosporine A blood levels in renal transplant recipients during childhood [letter] Kavukçu S, et al. **Nephron** 1999;81(3):366-7

Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Akhlaghi F, et al. **Ther Drug Monit** 1999 Feb;21(1):8-16

Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Beal JL, et al. **Ther Drug Monit** 1998 Dec;20(6):685-90

Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation. Brunet M, et al. **Ther Drug Monit** 1998 Dec;20(6):676-9

Prediction of tacrolimus blood levels by using the neural network with genetic algorithm in liver transplantation patients. Chen HY, et al. **Ther Drug Monit** 1999 Feb; 21(1):50-6

Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Dubrey SW, et al. **Ther Drug Monit** 1999 Jun; 21(3):325-6

Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients. Kaplan B, et al. **Ther Drug Monit** 1999 Feb;21(1):44-9

LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood. Kirchner GI, et al. **Ther Drug Monit** 1999 Feb;21(1):116-22

Cyclosporine A blood concentration during pregnancy in renal allograft recipients. Kozlowska-Boszko B, et al. **Transpl Int** 1998;11 Suppl 1:S90-3

Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Pou L, et al. **Transpl Int** 1998;11 Suppl 1:S270-1

Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. Brunet M, et al. **Transplant Proc** 1998 Dec;30(8):4068-9

Mycophenolic acid monitoring: evaluation of the EMIT MPA immunoassay in kidney and lung transplantation. Brunet M, et al. **Transplant Proc** 1999 Sep;31(6):2275-6

Measurement of lymphocyte cyclosporine levels in transplant patients. Masri MA, et al. **Transplant Proc** 1998 Nov; 30(7):3561-2

Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments. Steimer W. **Transplant Proc** 1998 Dec;30(8):4045-7

Unbound cyclosporine and allograft rejection after heart transplantation. Akhlaghi F, et al. **Transplantation** 1999 Jan 15;67(1):54-9

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Grant D, et al. **Transplantation** 1999 Apr 27;67(8):1133-7

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Sheikh AM, et al. **Transplantation** 1999 Jul 27;68(2):307-9

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. van Gelder T, et al. **Transplantation** 1999 Jul 27;68(2):261-6

Comparison of high performance liquid chromatography and immunoassay methods for measurement of cyclosporine A blood concentrations after feline kidney transplantation. McAnulty JF, et al. **Vet Surg** 1998 Nov-Dec;27(6):589-95

[Program of external quality control in cyclosporine dosage: summary and analysis from French laboratories] Marquet P, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):360-3 **(Fre)**

[Measuring cyclosporine levels in whole blood in kidney transplantation] Bottini PV, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):176-8 (Eng. Abstr.) **(Por)**

[Serum cyclosporine levels in patients after kidney transplantation] Karamehić J, et al. **Med Arh** 1998; 52(3):131-2 (Eng. Abstr.) **(Scr)**

[Aseptic thrombosis of the intracranial venous sinuses in a patient with kidney transplantation and toxic levels of cyclosporine (letter)] Guerrero AL, et al. **Med Clin (Barc)** 1999 Feb 20;112(6):238-9 **(Spa)**

CHEMICAL SYNTHESIS

Isoxazolylthioamides as potential immunosuppressants a combinatorial chemistry approach. Albert R, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2203-8

Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity. Armstrong HM, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2089-94

Synthesis and immunosuppressive activity of ruthenium complexes. Bastos CM, et al. **Bioorg Med Chem Lett** 1998 Jan 20;8(2):147-50

C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study. Goulet MT, et al. **Bioorg Med Chem Lett** 1999 Jul 19; 9(14):2085-8

C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential. Goulet MT, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2253-8

Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative. Kawai M, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):935-8

Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Kiuchi M, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):101-6

IMMUNOSUPPRESSIVE AGENTS

Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer). Révész L, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1521-6

Synthesis and immunosuppressant activity of pyrazole carboxamides. Wang AX, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2787-92

Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. Pankiewicz KW, et al. **Curr Med Chem** 1999 Jul;6(7):629-34

Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. Yura H, et al. **J Controlled Release** 1999 Jan 4;57(1):87-99

Rational design of new immunosuppressive drugs. Navia MA. **Transplant Proc** 1999 Feb-Mar;31(1-2):1097-8 (18 ref.)

CHEMISTRY

Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Johnson CE, et al. **Am J Health Syst Pharm** 1999 Jan 15;56(2):164-9

Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents. Batt DG, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1745-50

Glycolipids from sponges. VII. Simplexides, novel immunosuppressive glycolipids from the Caribbean sponge Plakortis simplex. Costantino V, et al. **Bioorg Med Chem Lett** 1999 Jan 18;9(2):271-6

Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):307-12

Degradation products of mycophenolate mofetil in aqueous solution. Hooijmaaijer E, et al. **Drug Dev Ind Pharm** 1999 Mar;25(3):361-5

A re-examination of the association of 'early pregnancy factor' activity with fractions of heterogeneous molecular weight distribution in pregnancy sera. Di Trapani G, et al. **Early Pregnancy** 1997 Dec;3(4):312-22

Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. Vidal C, et al. **J Am Soc Mass Spectrom** 1998 Dec;9(12):1267-74

Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. Fehr T, et al. **J Antibiot (Tokyo)** 1999 May;52(5):474-9

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454-19. II. Physico-chemical properties and structure elucidation. Iijima M, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):25-8

Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. Urata T, et al. **J Controlled Release** 1999 Mar 29;58(2):133-41

Actinobacillus actinomycetemcomitans immunosuppressive protein is a member of the family of cytolethal distending toxins capable of causing a G2 arrest in human T cells. Shenker BJ, et al. **J Immunol** 1999 Apr 15;162(8):4773-80

Isolation, identification and immunosuppressive activity of a new IMM-125 metabolite from human liver microsomes. Identification of its cyclophilin A-IMM-125 metabolite complex by nanospray tandem mass spectrometry. Lhoëst GJ, et al. **J Mass Spectrom** 1998 Oct;33(10):936-42

32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein. Becker JW, et al. **J Med Chem** 1999 Jul 29;42(15):2798-804

Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. Muegge I, et al. **J Med Chem** 1999 Jul 15;42(14):2498-503

Conformational differences of an immunosuppressant peptolide in a single crystal and in a crystal complex with human cyclophilin A. Mikol V, et al. **J Mol Biol** 1998 Oct 23;283(2):451-61

Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution. Miyake K, et al. **J Pharm Sci** 1999 Jan;88(1):39-45

Equilibrium and kinetics of rotamer interconversion in immunosuppressant prodigiosin derivatives in solution. Rizzo V, et al. **J Pharm Sci** 1999 Jan;88(1):73-8

Rational design of new immunosuppressive drugs. Navia MA. **Transplant Proc** 1999 Feb-Mar;31(1-2):1097-8 (18 ref.)

[The role of the structural parts of bacterial lipopolysaccharide in its direct immunosuppressive activity] Borisova EV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr;(2):22-5 (Eng. Abstr.) **(Rus)**

ECONOMICS

Evaluating a benchmarking database and identifying cost reduction opportunities by diagnosis-related group. Knoer SJ, et al. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1102-7

Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil. Wüthrich RP, et al. **Nephrol Dial Transplant** 1999 Feb;14(2):394-9

Mycophenolate mofetil--is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79-82 (19 ref.). Comment in: Pediatr Transplant 1999 Feb;3(1):5-9.

Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Baker GM, et al. **Transplant Proc** 1998 Dec;30(8):4082-4

Pharmacoeconomics of immunosuppressive agents in renal transplant recipients. Bennett WM, et al. **Transplant Proc** 1999 May;31(3A Suppl):6S (0 ref.)

The economics of immunosuppression in renal transplantation: a review of recent literature. Hutton J. **Transplant Proc** 1999 Feb-Mar;31(1-2):1328-32 (25 ref.)

Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation. Keown P. **Transplant Proc** 1999 Feb-Mar;31(1-2):1140-1

Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation. Schnitzler MA, et al. **Transplant Proc** 1999 May;31(3B Suppl):19S-21S

Costs savings associated with thymoglobulin for treatment of acute renal transplant rejection in patient subsets. Schnitzler MA, et al. **Transplant Proc** 1999 May;31(3B Suppl):7S-8S

[Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-0157 Study in 224 patients (Germany)] Bachinger A, et al. **Chirurg** 1998 Sep;69(9):957-62 (Eng. Abstr.) **(Ger)**

HISTORY

Cyclosporin A in patients receiving renal allografts from cadaver donors. 1978 [classical article] Calne RY, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1751-6

Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation. 1964 [classical article] Hill RB Jr, et al. **Rev Med Virol** 1999 Jan-Mar;9(1):5-10; discussion 3-5, 10-4

Antilymphocyte serum, donor bone marrow and tolerance to allografts: the journey is the reward. Monaco AP. **Transplant Proc** 1999 Feb-Mar;31(1-2):67-71

IMMUNOLOGY

Production of antibody against saikosaponin a, an active component of bupleuri radix. Jung DW, et al. **Arch Pharm Res** 1998 Apr;21(2):135-9

Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Le Buanec H, et al. **Biomed Pharmacother** 1999 Aug;53(7):323-8

Human complement component C1q inhibits the infectivity of cell-free HTLV-I. Ikeda F, et al. **J Immunol** 1998 Nov 15;161(10):5712-9

Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. Khattri R, et al. **J Immunol** 1999 May 15;162(10):5784-91

Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. Ruiz PJ, et al. **J Immunol** 1999 Mar 15;162(6):3336-41

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. Aharoni R, et al. **J Neuroimmunol** 1998 Nov 2;91(1-2):135-46

The CTLA-4 gene is associated with multiple sclerosis. Ligers A, et al. **J Neuroimmunol** 1999 Jun 1;97(1-2):182-90

Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteins. Lachgar A, et al. **J Virol** 1999 Feb;73(2):1447-52

Immunosuppressive strategies in transplantation. Denton MD, et al. **Lancet** 1999 Mar 27;353(9158):1083-91 (87 ref.)

Immunization with a synthetic peptide conjugate derived from the N-terminal sequence of either the beta-chain of haemoglobin or the immunosuppressive protein (reOLT 4) reduces the litter size of pregnant rats. Lord R, et al. **Scand J Immunol** 1999 Feb;49(2):162-8

Thalidomide prolongs experimental autoimmune neuritis in Lewis rats. Zhu J, et al. **Scand J Immunol** 1998 Oct;48(4):397-402

Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Knechtle SJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):27S-28S

Pasteurella haemolytica leukotoxin induced apoptosis of bovine lymphocytes involves DNA fragmentation. Sun Y, et al. **Vet Microbiol** 1999 Mar 1;65(2):153-66

[The role of the structural parts of bacterial lipopolysaccharide in its direct immunosuppressive activity] Borisova EV. **Zh Mikrobiol Epidemiol Immunobiol** 1999 Mar-Apr;(2):22-5 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer). Révész L, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1521-6

T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Han SB, et al. **Int J Immunopharmacol** 1998 Jan-Mar;20(1-3):1-13

Isolation and biological activity of a novel cytokine modulator, cytoxazone [letter] Kakeya H, et al. **J Antibiot (Tokyo)** 1998 Dec;51(12):1126-8

Purification of immunosuppressive factor from Capnocytophaga ochracea. Ochiai K, et al. **J Med Microbiol** 1998 Dec;47(12):1087-95

METABOLISM

Expression of regeneration and tolerance factor on B cell chronic lymphocytic leukemias: a possible mechanism for escaping immune surveillance. Aslakson CJ, et al. **Am J Hematol** 1999 May;61(1):46-52

Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Nadler SG, et al. **Biochem Biophys Res Commun** 1998 Dec 9;253(1):176-80

Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity. Sedrani R, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):459-62

Possible interaction between clindamycin and cyclosporin. Thurnheer R, et al. **BMJ** 1999 Jul 17;319(7203):163

Cyclophosphamide metabolism in children with Fanconi's anaemia. Yule SM, et al. **Bone Marrow Transplant** 1999 Jul;24(2):123-8

Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Murthy JN, et al. **Clin Biochem** 1998 Nov;31(8):613-7

Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Schütz E, et al. **Clin Chem** 1999 Mar;45(3):419-22

The biosynthetic gene cluster for the macrolactone ring of the immunosuppressant FK506. Motamedi H, et al. **Eur J Biochem** 1998 Sep 15;256(3):528-34

Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Hanke T, et al. **Immunity** 1999 Jul;11(1):67-77

Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the Fc epsilon RI. Erdei A, et al. **Immunol Lett** 1999 May 3;68(1):79-82

Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Komesli S, et al. **Int J Immunopharmacol** 1999 May;21(5):349-58

Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. Vidal C, et al. **J Am Soc Mass Spectrom** 1998 Dec;9(12):1267-74

ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. Kalman K, et al. **J Biol Chem** 1998 Dec 4;273(49):32697-707

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. Vilella-Bach M, et al. **J Biol Chem** 1999 Feb 12;274(7):4266-72

CTLA-4-Mediated inhibition of early events of T cell proliferation. Brunner MC, et al. **J Immunol** 1999 May 15;162(10):5813-20

An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. Gorczynski RM, et al. **J Immunol** 1999 Aug 1;163(3):1654-60

The ectoenzyme gamma-glutamyl transpeptidase regulates antiproliferative effects of S-nitrosoglutathione on human T and B lymphocytes. Henson SE, et al. **J Immunol** 1999 Aug 15;163(4):1845-52

Immunophilins: beyond immunosuppression. Hamilton GS, et al. **J Med Chem** 1998 Dec 17;41(26):5119-43 (245 ref.)

Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations. Lamb ML, et al. **J Med Chem** 1998 Oct 8;41(21):3928-39

A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Allison JP, et al. **Novartis Found Symp** 1998;215:92-8; discussion 98-102, 186-90 (28 ref.)

Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Imani S, et al. **Pediatr Transplant** 1999 May;3(2):126-30

Influence of external biliary drainage on cyclosporin A (Neoral) absorption in a pediatric liver transplant recipient. Zylber-Katz E, et al. **Pediatr Transplant** 1999 Aug;3(3):243-5

Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and rapamycin. Xu Q, et al. **Plant J** 1998 Aug;15(4):511-9

Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Sheikh AM, et al. **Transplantation** 1999 Jul 27;68(2):307-9

Species differences in the hepatic and intestinal metabolism of cyclosporine. Whalen RD, et al. **Xenobiotica** 1999 Jan;29(1):3-9

PHARMACOKINETICS

Effect of obesity on cyclosporine trough concentrations in psoriasis patients. Shibata N, et al. **Am J Health Syst Pharm** 1998 Aug 1;55(15):1598-602

Possible cyclosporin-danazol interaction in a patient with aplastic anaemia [letter] Borrás-Blasco J, et al. **Am J Hematol** 1999 Sep;62(1):63-4 (5 ref.)

Drug substitution in transplantation [letter] First MR, et al. **Am J Kidney Dis** 1999 Jul;34(1):205-6

Cyclosporine disposition and long-term renal function in a 500-pound kidney transplant recipient. Flechner SM, et

al. **Am J Kidney Dis** 1998 Oct;32(4):E4

Drug substitution in transplantation [letter] Huang M, et al. **Am J Kidney Dis** 1999 Jul;34(1):206

Drug substitution in transplantation: a National Kidney Foundation White Paper. Sabatini S, et al. **Am J Kidney Dis** 1999 Feb;33(2):389–97 (32 ref.)

Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment. Meidlinger P, et al. **Ann Hematol** 1999 Jul;78(7):299–304

Pharmacokinetic interaction between saquinavir and cyclosporine [letter] Brinkman K, et al. **Ann Intern Med** 1998 Dec 1;129(11):914–5

Possible interaction between cyclosporine and chloramphenicol [letter] Bui L, et al. **Ann Pharmacother** 1999 Feb;33(2):252–3

Effect of short-term rifampin on stable cyclosporine concentrations [letter] Freitag VL, et al. **Ann Pharmacother** 1999 Jul–Aug;33(7–8):871–2

Diltiazem increases tacrolimus concentrations. Hebert MF, et al. **Ann Pharmacother** 1999 Jun;33(6):680–2

Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. Serafinowicz A, et al. **Ann Transplant** 1997;2(2):12–5

Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Miyake K, et al. **Biol Pharm Bull** 1999 Jan;22(1):66–72

Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Al-Rawithi S, et al. **Bone Marrow Transplant** 1998 Sep;22(5):485–90

Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Schuler US, et al. **Bone Marrow Transplant** 1998 Aug;22(3):241–4

Cyclophosphamide metabolism in children with Fanconi's anaemia. Yule SM, et al. **Bone Marrow Transplant** 1999 Jul;24(2):123–8

Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients [letter] Billaud EM, et al. **Br J Clin Pharmacol** 1998 Sep; 46(3):271–2

Comparison of the phagocytosis of two types of cyclosporin (SDZ OXL 400 and SDZ IMM 125) by alveolar macrophages from hamsters. Maye I, et al. **Cell Biol Toxicol** 1998 Dec;14(6):411–8

Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. Xu F, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Sep;19(5):443–4

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ. **Clin Biochem** 1998 Jul;31(5):329–33 (10 ref.)

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Shaw LM, et al. **Clin Biochem** 1998 Jul; 31(5):317–22 (42 ref.)

Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Shaw LM, et al. **Clin Biochem** 1998 Jul;31(5):323–8 (22 ref.)

Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Soldin SJ. **Clin Biochem** 1998 Jul;31(5):381–4 (27 ref.)

Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Trepanier DJ, et al. **Clin Biochem** 1998 Jul;31(5):345–51 (49 ref.)

Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. Ferraris J, et al. **Clin Nephrol** 1998 Sep;50(3):172–7

6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Edwards DJ, et al. **Clin Pharmacol Ther** 1999 Mar;65(3):237–44

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Egan LJ, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):29–39

Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral. Mendez R, et al. **Clin Ther** 1999 Jan;21(1):160–71

Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. First MR, et al. **Clin Transplant** 1998 Dec;12(6):518–24

Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. Sagedal S, et al. **Clin Transplant** 1998 Dec;12(6):553–6

Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Crowe A, et al. **Drug Metab Dispos** 1999 May;27(5):627–32

Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. Karanam BV, et al. **Drug Metab Dispos** 1998 Oct;26(10):949–57

The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Möller A, et al. **Drug Metab Dispos** 1999 Jun;27(6):633–6

The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. Caraco Y, et al. **Eur J Clin Pharmacol** 1999 Aug;55(6):475–8

Effect of sulfasalazine on cyclosporin blood concentration [letter] Du Cheyron D, et al. **Eur J Clin Pharmacol** 1999 May;55(3):227–8

Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Wallemacq PE, et al. **Eur J Drug Metab Pharmacokinet** 1998 Jul–Sep; 23(3):367–70

Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. Gaspari F, et al. **J Am Soc Nephrol** 1997 Apr;8(4):647–52

Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Weber LT, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1511–20

Concurrent clarithromycin and cyclosporin A treatment. Sádaba B, et al. **J Antimicrob Chemother** 1998 Sep; 42(3):393–5

Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. Hebert MF, et al. **J Clin Pharmacol** 1999 Jan; 39(1):91–6

Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? Ku YM, et al. **J Clin Pharmacol** 1998 Oct;38(10):959–65

Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. Schroeder TJ, et al. **J Clin Pharmacol** 1998 Sep;38(9):807–14

Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. Yura H, et al. **J Controlled Release** 1999 Jan 4;57(1):87–99

Rezulin (troglitazone) greatly increases cyclosporine metabolism [letter] Frantz RP, et al. **J Heart Lung Transplant** 1998 Oct;17(10):1037–8

Troglitazone, a new antidiabetic agent, decreases cyclosporine level [letter] Park MH, et al. **J Heart Lung Transplant** 1998 Nov;17(11):1139–40

Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats. Ogino Y, et al. **J Pharm Pharmacol** 1999 Jul;51(7):811–5

Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. Shibata N, et al. **J Pharm Pharmacol** 1999 Apr;51(4):397–404

Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. Gaspari F, et al. **Kidney Int** 1998 Dec;54(6):2146–50

Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation. Cooney GF, et al. **Liver Transpl Surg** 1999 Mar;5(2):112–8

Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID, et al. **Liver Transpl Surg** 1999 Mar;5(2):107–11

Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation. van Mourik ID, et al. **Liver Transpl Surg** 1998 Nov;4(6):491–8

Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Smak Gregoor PJ, et al. **Nephrol Dial Transplant** 1999 Mar;14(3):706–8

Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Spoendlin M, et al. **Nephrol Dial Transplant** 1998 Jul; 13(7):1787–91

Pharmacokinetics of mycophenolic acid (MPA) and free MPA in paediatric renal transplant recipients--a multicentre study. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Weber LT, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:33–4

Cyclosporine A monitoring in children: abbreviated area under curve formulas and C2 level. Dello Strologo L, et al. **Pediatr Nephrol** 1999 Feb;13(2):95–7

Abbreviated cyclosporine AUCs on Neoral--the search continues! Filler G, et al. **Pediatr Nephrol** 1999 Feb; 13(2):98–102

Bioavailability of two oral formulations of cyclosporin A in uremic children before renal transplantation [see comments] Medeiros M, et al. **Pediatr Transplant** 1998 May;2(2):145–9 Comment in: Pediatr Transplant 1998 May;2(2):85–6.

Neoral: the microemulsion formulation [editorial; comment] Tejani A. **Pediatr Transplant** 1998 May;2(2):85–6. Comment on: Pediatr Transplant 1998 May;2(2):145–9.

In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Crowe A, et al. **Pharm Res** 1998 Nov;15(11):1666–72

Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. Ferron GM, et al. **Pharm Res** 1998 Dec;15(12):1888–94

Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Hashimoto Y, et al. **Pharm Res** 1998 Oct;15(10):1609–13

Cyclosporine transfer from low- and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity. Wasan KM, et al. **Pharm Res** 1999 Jul;16(7):1067–73

Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Tada H, et al. **Pharmacol Toxicol** 1999 Jun;84(6):241–6

The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis. Knebel W, et al. **Pharmacotherapy** 1998 Nov–Dec;18(6):1224–9

A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Min DI, et al. **Pharmacotherapy** 1999 Jun;19(6):753–9

Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. Lee YH, et al. **Res Commun Mol Pathol Pharmacol** 1998 Dec; 102(3):251–64

Lack of interaction between methotrexate and penicillins [letter; comment] Herrick AL, et al. **Rheumatology (Oxford)** 1999 Mar;38(3):284–5. Comment on: Br J Rheumatol 1998 Jul;37(7):807.

Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Chrzanowska M, et al. **Ther Drug Monit** 1999 Apr;21(2):231–7

Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Regazzi MB, et al. **Ther Drug Monit** 1999 Feb; 21(1):2–7

Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A, et al. **Ther Drug Monit** 1999 Feb;21(1):17–26

Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion. Pescovitz MD, et al. **Transpl Int** 1998;11 Suppl 1:S94–7

Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. Barr WH. **Transplant Proc** 1999 May; 31(3A Suppl):25S–30S (22 ref.)

Scientific and professional concerns regarding product interchange and subsequent monitoring of cyclosporine and other critical dose drugs. Barr WH. **Transplant Proc** 1999 May;31(3):1645–8; discussion 1675–84 (24 ref.)

Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve. Belitsky P, et al. **Transplant Proc** 1999 May; 31(3):1667–8

Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. Fisher RA, et al. **Traasplant Proc** 1999 Feb–Mar;31(1–2):394–5

Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients. Gaston R, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):326–7

Lessons from the Neoral Global Database for renal transplantation. Helderman JH. **Transplant Proc** 1999 May; 31(3):1659–63

Pharmacokinetics of cyclosporine microemulsion in Pakistani renal allograft recipients: correlation of trough peak levels with 7-point and 3-point AUC. Hussain M, et al. **Transplant Proc** 1998 Nov;30(7):3555

Bioequivalence criteria for cyclosporine. Johnston A, et al. **Transplant Proc** 1999 May;31(3):1649–53 (60 ref.)

Effects of rifampin on cyclosporine disposition in kidney recipients with tuberculosis. Kim YH, et al. **Transplant Proc** 1998 Nov;30(7):3570–2

Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients. Lee KL, et al. **Transplant Proc** 1998 Nov;30(7):3526–9

Intestinal metabolism of cyclosporine A in human heart transplant recipients. Lehle K, et al. **Transplant Proc** 1998 Dec;30(8):4044

Relationship of pharmacokinetics to clinical outcomes. Levy GA. **Transplant Proc** 1999 May;31(3):1654–8 (23 ref.)

Bioequivalence study of Cipol-N (cyclosporine microemulsion preparation) in healthy adults. Park MS, et al. **Transplant Proc** 1998 Nov;30(7):3541–6

Population pharmacokinetics of cyclosporine in kidney transplant patients. Porta B, et al. **Transplant Proc** 1999 Sep;31(6):2246–7

Comparison of cyclosporine immunoassays (AxSYM and RIA) for assessing pharmacokinetic parameters in liver transplant patients. Sabaté I, et al. **Transplant Proc** 1999 Sep;31(6):2421–2

A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB, et al. **Transplant Proc** 1998 Dec;30(8):4048–53

Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Shipkova M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1135–7

Low systemic exposure to tacrolimus correlates with acute rejection. Undre NA, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):296–8

Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation. Wollenberg K, et al. **Transplant Proc** 1998 Dec;30(8):4090–1

Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Zanker B, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1167

Comparison of neoral dose monitoring with cyclosporine

through levels versus 2-hr postdose levels in stable liver transplant patients. Cantarovich M, et al. **Transplantation** 1998 Dec 27;66(12):1621-7

Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Kaplan B, et al. **Transplantation** 1999 Jan 27;67(2):333-5

PHARMACOLOGY

Immunophilins and immunosuppression by cyclosporins and macrolide structures. Schreier MH. **Acta Derm Venereol Suppl (Stockh)** 1994;186:100

Effect of antilymphocyte serum on bacterial translocation in mice. Anderlik P, et al. **Acta Microbiol Immunol Hung** 1998;45(2):257-61

Effect of trace element combination on the immune response of rats treated with cytostatic drug. Elekes E, et al. **Acta Microbiol Immunol Hung** 1998;45(2):221-8

Lethal encephalitozoonosis in cyclophosphamide-treated rabbits. Horváth M, et al. **Acta Vet Hung** 1999;47(1):85-93

Suppressive activity of the chloroform extract of Tripterygium wilfordii Hook f on effector T cell activation during Hymenolepis nana infection in mice. Asano K, et al. **Am J Chin Med** 1998;26(2):181-9

Lack of effect of a single oral dose of cyclosporine on systemic blood pressure and on forearm blood flow and vascular resistance in humans. De Lima JJ, et al. **Am J Hypertens** 1998 Nov;11(11 Pt 1):1371-5

CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku. Aoki Y, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):L1164-72

Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. duBell WH, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2041-52

Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. Kanoh S, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):L891-9

Cyclosporin A treatment alters characteristics of Ca2+-release channel in cardiac sarcoplasmic reticulum. Park KS, et al. **Am J Physiol** 1999 Mar;276(3 Pt 2):H865-72

Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Hildner K, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:204-7

Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds. Lanza L, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:193-7

Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus. Ghobrial R, et al. **Ann Transplant** 1996;1(4):22-9

The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Neyts J, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3285-9

Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Weinstein A, et al. **Arch Neurol** 1999 Mar; 56(3):319-24

Age-depending effects of methotrexate treatment on systemic bone turnover in experimental adjuvant arthritis. Segawa Y, et al. **Arzneimittelforschung** 1999 Jan;49(1):38-43

Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Fairbanks LD, et al. **Biochem J** 1999 Aug 15;342 (Pt 1):143-52

Immunosuppressive effects of the heat shock protein 90-binding antibiotic geldanamycin. Sugita T, et al. **Biochem Mol Biol Int** 1999 Apr;47(4):587-95

Selectivity of the molecular chaperone-specific immunosuppressive agent 15-deoxyspergualin: modulation of Hsc70 ATPase activity without compromising DnaJ chaperone interactions. Brodsky JL. **Biochem Pharmacol** 1999 Apr 15;57(8):877-80

A novel series of non-nucleoside inhibitors of inosine 5'-monophosphate dehydrogenase with immunosuppressive activity. Franklin TJ, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):867-76

Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Knecht W, et al. **Biochem Pharmacol** 1998 Nov 1;56(9):1259-64

Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1. Navolotskaya EV, et al. **Biochemistry (Mosc)** 1999 Jul;64(7):758-64

Saccharomyces cerevisiae MLF3/YNL074C gene, encoding a serine-rich protein of unknown function, determines the level of resistance to the novel immunosuppressive drug leflunomide. Fujimura HA. **Biochim Biophys Acta** 1998 Nov 8;1442(2-3):415-8

Change in erythrocyte shape induced by cyclosporine administration. Ohsako M, et al. **Biol Pharm Bull** 1998 Nov; 21(11):1236-9

Development of bioactive functions in Hydrangeae Dulcis Folium. VII. Immunomodulatory activities of thunberginol A and related compounds on lymphocyte proliferation. Shimoda H, et al. **Biol Pharm Bull** 1998 Aug;21(8):809-13

Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Turk BE, et al. **Bioorg Med Chem** 1998 Aug;6(8):1163-9

Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity. Armstrong HM, et al. **Bioorg Med Chem Lett** 1999 Jul 19;9(14):2089-94

Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents. Batt DG, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1745-50

Immunosuppressant activity in human beta-casein fragment analogs. Bhattacharya M, et al. **Bioorg Med Chem Lett** 1998 Feb 17;8(4):327-32

C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study. Goulet MT, et al. **Bioorg Med Chem Lett** 1999 Jul 19; 9(14):2085-8

Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium. Pitts WJ, et al. **Bioorg Med Chem Lett** 1998 Feb 3;8(3):307-12

Synthesis and immunosuppressant activity of pyrazole carboxamides. Wang AX, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2787-92

Selective propagation of retinal pericytes in mixed microvascular cell cultures using L-leucine-methyl ester. Lee CS, et al. **Biotechniques** 1998 Sep;25(3):482-8, 490-2, 494

Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle. Perrin GQ, et al. **Blood** 1999 Jan 1;93(1):208-16

Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes. Contassot E, et al. **Bone Marrow Transplant** 1998 Dec;22(11):1097-102

Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Elmaagacli AH, et al. **Bone Marrow Transplant** 1999 Apr;23(8):771-7

Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Jacobson P, et al. **Bone Marrow Transplant** 1998 Aug;22(3):217-25 (129 ref.)

The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Rosales F, et al. **Bone Marrow Transplant** 1999 May;23(9):861-5

The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Ockenfels HM, et al. **Br J Dermatol** 1998 Sep;139(3):390-5

Effect of 1-beta-D-arabino-furanosyl-cytosine (ara-C) induction of K562 cells on expression of Rh and other blood group active proteins. Wiener E, et al. **Br J Haematol** 1998 Oct;103(1):259-67

UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Hanson DC, et al. **Br J Pharmacol** 1999 Apr;126(8):1707-16

Biphasic effects of cyclosporin A on formyl-methionyl-leucyl-phenylalanine stimulated responses in HL-60 cells differentiated into neutrophils. Nguyen NS, et al. **Br J Pharmacol** 1998 Aug;124(8):1774-80

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Shipkova M, et al. **Br J Pharmacol** 1999 Mar;126(5):1075-82

Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. Squadrito F, et al. **Br J Pharmacol** 1999 May; 127(2):498-504

Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. Yasutsune T, et al. **Br J Pharmacol** 1999 Feb;126(3):717-29

FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. Herr I, et al. **Brain Res** 1999 May 1; 826(2):210-9

Modulating the functions of neutrophils and lipid peroxidation by FK506 in a rat model of thermal injury. Cetinkale O, et al. **Burns** 1999 Mar;25(2):105-12

The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Rinkardt NE, et al. **Can J Vet Res** 1999 Jan; 63(1):18-24

Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of peptide-prolyl isomerase and calcineurin activity. Mealey KL, et al. **Cancer Chemother Pharmacol** 1999;44(2):152-8

Lack of evidence for an immunosuppressive role for MUC1. Paul S, et al. **Cancer Immunol Immunother** 1999 Apr; 48(1):22-8

The in vivo effect of the administration of resistance-modulating agents on rhodamine 123 distribution in mice thymus and lymph nodes. Marques-Santos LF, et al. **Cancer Lett** 1999 Mar 22;137(1):99-106

The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Louro ID, et al. **Cell Growth Differ** 1999 Jul;10(7):503-16

An inhibitor of CD28-CD80 interactions impairs CD28-mediated costimulation of human CD4 T cells. Fine JS, et al. **Cell Immunol** 1999 Jan 10;191(1):49-59

Placental protein 14 functions as a direct T-cell inhibitor. Rachmilewitz J, et al. **Cell Immunol** 1999 Jan 10; 191(1):26-33

Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Perry SS, et al. **Cell Transplant** 1999 Jul-Aug;8(4):339-44

Effects of ciclosporin on whole blood chemiluminescence of renal transplant patients. Chen SY, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul;19(4):372-5

Cyclosporine inhibited calcium-mediated apoptosis of HL-60 cells. Huang QQ, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 May;18(3):262-6

Immunosuppressive effects of intravenous self administration of dihydroetorphine on lymphocyte functions in rats. Wu WR, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jul; 19(4):387-90

Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. Gammie JS, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II163-8; discussion II168-9

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. **Clin Biochem** 1998 Jul;31(5):335-40 (69 ref.)

Effect of combined immunosuppressive drug therapy on small intestinal nutrient transport in the rat. Sigalet DL, et al. **Clin Biochem** 1999 Feb;32(1):51-7

Effect of ethanol on monocytic function in human immunodeficiency virus type 1 infection. Chen H, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):790-8

Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Neurath MF, et al. **Clin Exp Immunol** 1999 Jan;115(1):42-55

Effect of cyclosporin on apoptosis in human cultured monocytic THP-1 cells and synovial macrophages. Cutolo M, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):417-22

Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506). Chen YW, et al. **Clin Immunol** 1999 Jan;90(1):133-40

The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Hale MD, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):672-83

Developmental pharmacodynamics of cyclosporine. Marshall JD, et al. **Clin Pharmacol Ther** 1999 Jul;66(1):66-75

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Mück W, et al. **Clin Pharmacol Ther** 1999 Mar; 65(3):251-61

Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Sanquer S, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):640-8

Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Trapnell CB, et al. **Clin Pharmacol Ther** 1998 Dec;64(6):597-602

Inhibition of mitogen-activated proliferation of human peripheral lymphocytes in vitro by propionic acid. Wajner M, et al. **Clin Sci (Colch)** 1999 Jan;96(1):99-103

Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. Asberg A, et al. **Clin Transplant** 1998 Oct; 12(5):363-70

Protection of corneal allografts by CTLA4-Ig. Gebhardt BM, et al. **Cornea** 1999 May;18(3):314-20

Mizoribine and mycophenolate mofetil. Ishikawa H. **Curr Med Chem** 1999 Jul;6(7):575-97 (82 ref.)

Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. Pankiewicz KW, et al. **Curr Med Chem** 1999 Jul;6(7):629-34

Effect of dietary lipids on hepatic Na+,K(+)-ATPase in cyclosporine A-treated rats: immunocytochemical analysis of alpha1 subunit by confocal laser scanning microscopy imaging. Benkoël L, et al. **Dig Dis Sci** 1999 Aug; 44(8):1643-9

A prospective study on conversion from sandimmune to neoral in stable adult liver transplant recipients. Jain A, et al. **Dig Dis Sci** 1999 Apr;44(4):775-7

Effects of the extract of Spirostachys venenifera Pax on the immune response in mice. Njiro SM. **East Afr Med J** 1998 Oct;75(10):598-601

Effects of immunosuppressant agents on growth hormone release and gene expression. Ohye H, et al. **Endocr J** 1998 Apr;45 Suppl:S93-6

An open comparison of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg. Sáez Barcelona JA, et al. **Eur J Clin Pharmacol** 1999 Apr; 55(2):105-9

Cyclosporine A delays wound healing and apoptosis and suppresses activin beta-A expression in rats. Petri JB, et al. **Eur J Dermatol** 1998 Mar;8(2):104-13

Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Kochi S, et al. **Eur J Pharmacol** 1999 May 21;372(3):287-95

Synergistic effects of pranlukast and leukotriene B4 receptor antagonist on antigen-induced pulmonary reaction. Sakurada T, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):153-9

Cyclosporin-A reduces leukocyte accumulation and protects against myocardial ischaemia reperfusion injury in rats. Squadrito F, et al. **Eur J Pharmacol** 1999 Jan 8; 364(2-3):159-68

Immunosuppressive effects of dihydroetorphine, a potent narcotic analgesic, in dihydroetorphine-dependent mice. Wu WR, et al. **Eur J Pharmacol** 1999 Feb 5;366(2-3):261-9

Identification of cyclosporin A responsive genes in human keratinocytes. Ogo M, et al. **Exp Dermatol** 1999 Aug; 8(4):357-8

Effects of cyclosporin A, FK506 and steroid hormones on hair growth. Tsuji Y, et al. **Exp Dermatol** 1999 Aug; 8(4):366-7

Cyclosporin A increases tear fluid secretion via release of sensory neurotransmitters and muscarinic pathway in mice. Yoshida A, et al. **Exp Eye Res** 1999 May;68(5):541–6

Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG–556. Brenner T, et al. **Exp Neurol** 1998 Dec;154(2):489–98

Tacrolimus (FK506) increases neuronal expression of GAP–43 and improves functional recovery after spinal cord injury in rats. Madsen JR, et al. **Exp Neurol** 1998 Dec;154(2):673–83

Influence of pretreatment with immunosuppressants on O–demethylation of dextromethorphan in isolated perfused rat liver. Hadasová E, et al. **Exp Toxicol Pathol** 1999 Jul; 51(4–5):330–4

Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF–kappaB. Alexanian AR, et al. **FASEB J** 1999 Sep; 13(12):1611–20

Cyclosporin A does not increase the oxidative susceptibility of low density lipoprotein in vitro. Devaraj S, et al. **Free Radic Biol Med** 1999 Apr;26(7–8):1064–8

Inhibition of S6 kinase by rapamycin blocks maturation of Rana dybowskii oocytes. Bandyopadhyay A, et al. **Gen Comp Endocrinol** 1999 Feb;113(2):230–9

Effects of ischaemia–reperfusion and cyclosporin–A on cardiac muscle ultrastructure. Jurado F, et al. **Histol Histopathol** 1998 Jul;13(3):761–74

Cyclosporin A–induced changes of the thymic microenvironment. A review of morphological studies. Milićević NM, et al. **Histol Histopathol** 1998 Oct; 13(4):1183–96 (84 ref.)

Role of nitric oxide in cyclosporine A–induced hypertension. Oriji GK, et al. **Hypertension** 1998 Nov;32(5):849–55

Persistent tolerance induced after portal venous injection of allogeneic cells plus cyclophosphamide treatment. Jin T, et al. **Immunobiology** 1999 Jun;200(2):215–26

Modulation of immune function by a modified bovine whey protein concentrate. Cross ML, et al. **Immunol Cell Biol** 1999 Aug;77(4):345–50

Rapamycin inhibits didemnin B–induced apoptosis in human HL–60 cells: evidence for the possible involvement of FK506–binding protein 25. Johnson KL, et al. **Immunol Cell Biol** 1999 Jun;77(3):242–8

Suppressive effects of antihistaminic and/or anti–PAF agents on passive anaphylactic shock in mice sensitized with allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum. Kimura S, et al. **Immunol Invest** 1998 Dec;27(6):379–93

Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125–kDa GP viral protein. Chepurnov AA, et al. **Immunol Lett** 1999 Jun 1; 68(2–3):257–61

Antibody feedback suppression: towards a unifying concept? Heyman B. **Immunol Lett** 1999 May 3;68(1):41–5 (48 ref.)

Natural killer cell mediated cytotoxicity against VERO target cells; the suppressive effect of pentoxifylline. Nagy Z, et al. **Immunol Lett** 1998 Sep;63(2):121–3

Selective down–regulation of T cell– and non–T cell–derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Rowland TL, et al. **Immunol Lett** 1999 Jun 1;68(2–3):325–32

Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Slauson SD, et al. **Immunol Lett** 1999 Apr 15;67(3):179–83

Immunomodulation by n–3 polyunsaturated fatty acids [letter; comment] Netea MG, et al. **Immunol Today** 1999 Feb;20(2):103. Comment on: Immunol Today 1998 Jun;19(6):244–7.

Immunobiology of zinc and zinc therapy [letter; comment] Reinhold D, et al. **Immunol Today** 1999 Feb;20(2):102–3. Comment on: Immunol Today 1997 Nov;18(11):519–21.

Interleukin–1beta partially alleviates cyclosporin A–induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo. Dalai SK, et al. **Immunology** 1998 Sep;95(1):83–9

Ganglioside GT1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Kanda N, et al. **Immunology** 1999 Apr;96(4):628–33

Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells. Odaka C, et al. **Immunology** 1998 Nov;95(3):370–6

A novel immunosuppressant, FTY720, increases the efficiency of a superantigen–induced peripheral T–cell deletion whilst inhibiting negative selection in the thymus. Shimizu C, et al. **Immunology** 1998 Aug;94(4):503–12

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L–positive T cells in Peyer's patches by FTY720–induced lymphocyte homing. Yanagawa Y, et al. **Immunology** 1998 Dec;95(4):591–4

Regulatory effects of cytokines and cyclosporine A on peripheral blood mononuclear cells from stable multiple sclerosis patients. Guillen C, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):527–49

Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action. Hinman CL, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):483–506

Interleukin–12 overcomes paclitaxel–mediated suppression of T–cell proliferation. Mullins DW, et al. **Immunopharmacol Immunotoxicol** 1998 Nov;20(4):473–92

Effects of glyburide–cyclosporin A interaction on interleukin–2 production in rats. Sireci G, et al. **Immunopharmacol Immunotoxicol** 1999 Aug;21(3):583–98

Effects of a novel purine nucleoside phosphorylase inhibitor, BCX–34, on activation and proliferation of normal human lymphoid cells. Conry RM, et al. **Immunopharmacology** 1998 Jul;40(1):1–9

Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Luo ZJ, et al. **Immunopharmacology** 1999 Apr;41(3):199–207

Immunosuppressive and anti–inflammatory effects of methanolic extract and the polyacetylene isolated from Bidens pilosa L. Pereira RL, et al. **Immunopharmacology** 1999 Jun;43(1):31–7

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Rowland TL, et al. **Immunopharmacology** 1998 Jul;40(1):11–20

Triptolide induces apoptotic death of T lymphocyte. Yang Y, et al. **Immunopharmacology** 1998 Aug;40(2):139–49

Streptococcal pyrogenic exotoxin B induces apoptosis and reduces phagocytic activity in U937 cells. Kuo CF, et al. **Infect Immun** 1999 Jan;67(1):126–30

Kinetics of intraocular cytokines in the suppression of experimental autoimmune uveoretinitis by type I IFN. Okada AA, et al. **Int Immunol** 1998 Dec;10(12):1917–22

Cyclosporine A modulates baroreceptor function in kidney transplant recipients. Gerhardt U, et al. **Int J Cardiol** 1999 Feb 28;68(2):203–8

Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida–infected mice. Badger AM, et al. **Int J Immunopharmacol** 1999 Mar; 21(3):161–76

Delta9–tetrahydrocannabinol suppresses macrophage costimulation by decreasing heat–stable antigen expression. Clements DJ, et al. **Int J Immunopharmacol** 1998 Aug; 20(8):415–28

T–cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Han SB, et al. **Int J Immunopharmacol** 1998 Jan–Mar;20(1–3):1–13

Dose–dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Hoskin DW, et al. **Int J Immunopharmacol** 1998 Sep; 20(9):505–13

Evidence that SMS 201–995 enhances the immunosuppressive effect of FK506. Perego C, et al. **Int J Immunopharmacol** 1998 Sep;20(9):479–90

Early metabolic changes in peripheral blood cells of renal transplant recipients treated with cyclosporine A. Rezzani R, et al. **Int J Immunopharmacol** 1999 Jul;21(7):455–62

Inhibition of anti–CD3 antibody–induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide). Richard M, et al. **Int J Immunopharmacol** 1998 Apr–May;20(4–5):241–52

Beta–estradiol–induced decrease in IL–12 and TNF–alpha expression suppresses macrophage functions in the course of Listeria monocytogenes infection in mice. Salem ML, et al. **Int J Immunopharmacol** 1999 Aug;21(8):481–97

Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. Xu W, et al. **Int J Immunopharmacol** 1999 Jul;21(7):463–72

Cyclosporine–induced lipid peroxidation and propionyl carnitine protective effect. Longoni B, et al. **Int J Tissue React** 1999;21(1):7–11

Newer immunosuppressive drugs: a review. Gummert JF, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1366–80 (211 ref.)

Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. Remuzzi G, et al. **J Am Soc Nephrol** 1999 Jul;10(7):1542–9

The leukotriene B4 receptor antagonist ONO–4057 inhibits nephrotoxic serum nephritis in WKY rats. Suzuki S, et al. **J Am Soc Nephrol** 1999 Feb;10(2):264–70

Attenuation of murine lupus nephritis by mycophenolate mofetil. Van Bruggen MC, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1407–15

IC202A, a new siderophore with immunosuppressive activity produced by Streptoalloteichus sp. 1454–19. I. Taxonomy, fermentation, isolation and biological activity. Iijima M, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):20–4

Isolation and biological activity of a novel cytokine modulator, cytoxazone [letter] Kakeya H, et al. **J Antibiot (Tokyo)** 1998 Dec;51(12):1126–8

Brasilicardin A, a new terpenoid antibiotic from pathogenic Nocardia brasiliensis: fermentation, isolation and biological activity. Komaki H, et al. **J Antibiot (Tokyo)** 1999 Jan; 52(1):13–9

Inhibition of nitric oxide synthase induction by 15–deoxyspergualin in a cultured macrophage cell line, J744A.1 activated with IFN–gamma and LPS. Nosaka C, et al. **J Antibiot (Tokyo)** 1999 Mar;52(3):297–304

Immunosuppressant deoxyspergualin–induced inhibition of cell proliferation is accompanied with an enhanced reduction of tetrazolium salt. Odaka C, et al. **J Antibiot (Tokyo)** 1999 Jan;52(1):45–51

Sanglifehrins A, B, C and D, novel cyclophilin–binding compounds isolated from Streptomyces sp. A92–308110. I. Taxonomy, fermentation, isolation and biological activity. Sanglier JJ, et al. **J Antibiot (Tokyo)** 1999 May; 52(5):466–73

Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats. Chelmicka–Schorr E, et al. **J Autoimmun** 1998 Aug;11(4):329–34

Blood pressure control in kidney transplant recipients: influence of immunosuppression. Gerhardt U, et al. **J Auton Pharmacol** 1999 Feb;19(1):49–54

Immunosuppressant PG490 (triptolide) inhibits T–cell interleukin–2 expression at the level of purine–box/nuclear factor of activated T–cells and NF–kappaB transcriptional activation. Qiu D, et al. **J Biol Chem** 1999 May 7; 274(19):13443–50

Renal cell carcinoma–derived gangliosides suppress nuclear factor–kappaB activation in T cells. Uzzo RG, et al. **J Clin Invest** 1999 Sep;104(6):769–76

Latent Pneumocystis carinii infection in commercial rat colonies: comparison of inductive immunosuppressants plus histopathology, PCR, and serology as detection methods. Weisbroth SH, et al. **J Clin Microbiol** 1999 May; 37(5):1441–6

Lymphocyte suppression by rolipram with other immunosuppressive drugs. Briggs WA, et al. **J Clin Pharmacol** 1999 Aug;39(8):794–9

Immunosuppressive activity of Achillea talagonica on humoral immune responses in experimental animals. Rezacipoor R, et al. **J Ethnopharmacol** 1999 Jun;65(3):273–6

A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells [see comments] Wesley UV, et al. **J Exp Med** 1999 Aug 2;190(3):311–22 . Comment in: J Exp Med 1999 Aug 2;190(3):301–5.

Changes in fecal fat excretion from allo–intestine transplanted rats after discontinuance of immunosuppressive agents. Saito T, et al. **J Gastroenterol** 1999 Apr;34(2):182–8

Hepatitis viruses under immunosuppressive agents. Liaw YF. **J Gastroenterol Hepatol** 1998 Jan;13(1):14–20 (75 ref.)

FK506 promotes liver regeneration by suppressing natural killer cell activity. Tamura F, et al. **J Gastroenterol Hepatol** 1998 Jul;13(7):703–8

Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes–treated rats. Toshima K, et al. **J Gastroenterol Hepatol** 1998 Sep;13 Suppl:S51–4 (19 ref.)

The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. Fansa H, et al. **J Hand Surg [Br]** 1999 Feb;24(1):38–42

Cyclosporine–induced coronary artery constriction--dissociation between thromboxane release and coronary vasospasm. Braun–Dullaeus RC, et al. **J Heart Lung Transplant** 1999 Apr;18(4):328–35

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. Hirt SW, et al. **J Heart Lung Transplant** 1999 Jun;18(6):542–8

Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF–kappaB activation in rat hepatocytes. Kaibori M, et al. **J Hepatol** 1999 Jun; 30(6):1138–45

Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen–presenting cell–derived IL–12. Becher B, et al. **J Immunol** 1999 Jan 15;162(2):684–8

Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite–driven apoptotic death. Brito C, et al. **J Immunol** 1999 Mar 15;162(6):3356–66

Two–domain MHC class II molecules form stable complexes with myelin basic protein 69–89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. Burrows GG, et al. **J Immunol** 1998 Dec 1;161(11):5987–96

Enhancing or suppressive effects of antibodies on processing of a pathogenic T cell epitope in thyroglobulin. Dai Y, et al. **J Immunol** 1999 Jun 15;162(12):6987–92

Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. De Palma R, et al. **J Immunol** 1999 Feb 15;162(4):1982–7

A monoclonal antibody reactive with a 40–kDa molecule on fetal thymocytes and tumor cells blocks proliferation and stimulates aggregation and apoptosis. Fernandes DM, et al. **J Immunol** 1999 Aug 1;163(3):1306–14

Lysophosphatidic acid and sphingosine 1–phosphate protection of T cells from apoptosis in association with suppression of Bax. Goetzl EJ, et al. **J Immunol** 1999 Feb 15;162(4):2049–56

Presence of pentoxifylline during T cell priming increases clonal frequencies in secondary proliferative responses and inhibits apoptosis. Gupta M, et al. **J Immunol** 1999 Jan 15;162(2):689–95

TNF–alpha suppresses IFN–gamma–induced MHC class II expression in HT1080 cells by destabilizing class II trans–activator mRNA. Han Y, et al. **J Immunol** 1999 Aug 1;163(3):1435–40

Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. Large MK, et al. **J Immunol** 1999 Jan 15;162(2):931–8

A Theiler's virus alternatively initiated protein inhibits the generation of H–2K–restricted virus–specific cytotoxicity. Lin X, et al. **J Immunol** 1999 Jan 1;162(1):17–24

Tumor gangliosides inhibit the tumor–specific immune response. McKallip R, et al. **J Immunol** 1999 Oct 1; 163(7):3718–26

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. Manna SK, et al. **J Immunol** 1999 Feb 15;162(4):2095-102

CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. Marriott JB, et al. **J Immunol** 1998 Oct 15;161(8):4236-43

Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. Mashikian MV, et al. **J Immunol** 1999 Sep 15;163(6):3123-30

Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. Matsuda S, et al. **J Immunol** 1999 Mar 15;162(6):3321-6

Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor. Miller JS, et al. **J Immunol** 1999 Jun 15;162(12):7376-82

Cyclosporin A inhibits inositol 1,4,5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages. Misra UK, et al. **J Immunol** 1998 Dec 1;161(11):6122-7

New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. Mortellaro A, et al. **J Immunol** 1999 Jun 15; 162(12):7102-9

A new role for platelet-endothelial cell adhesion molecule-1 (CD31): inhibition of TCR-mediated signal transduction. Newton-Nash DK, et al. **J Immunol** 1999 Jul 15; 163(2):682-8

The MHC class I molecule H-2Dp inhibits murine NK cells via the inhibitory receptor Ly49A. Olsson-Alheim MY, et al. **J Immunol** 1999 Jun 15;162(12):7010-4

The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. Pahlevan AA, et al. **J Immunol** 1999 Oct 1;163(7):3928-35

Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. Powell JD, et al. **J Immunol** 1999 Mar 1;162(5):2775-84

Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. Redford TW, et al. **J Immunol** 1998 Oct 15;161(8):3930-5

CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. Saverino D, et al. **J Immunol** 1999 Jan 15; 162(2):651-8

Inhibition of B cell receptor-mediated apoptosis by IFN. Su L, et al. **J Immunol** 1999 Jun 1;162(11):6317-21

Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. Tinkle SS, et al. **J Immunol** 1999 Sep 1;163(5):2747-53

Thymus-derived glucocorticoids set the thresholds for thymocyte selection by inhibiting TCR-mediated thymocyte activation. Vacchio MS, et al. **J Immunol** 1999 Aug 1;163(3):1327-33

Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. Venkataraman C, et al. **J Immunol** 1999 Apr 1;162(7):4053-61

Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. Vieira PL, et al. **J Immunol** 1998 Nov 15;161(10):5245-51

C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. Wittmann M, et al. **J Immunol** 1999 Jun 1;162(11):6763-9

The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. Zhang J, et al. **J Immunol** 1999 Jun 1;162(11):6359-67

Inhibition of interleukin-2 production and downregulation of IL-2 and transferrin receptors on rat splenic lymphocytes following PAG morphine administration: a role in natural killer and T cell suppression. Gomez-Flores R, et al. **J Interferon Cytokine Res** 1999 Jun;19(6):625-30

Inhibition of activated human mesangial cell proliferation by the natural product of Cordyceps sinensis (H1-A): an implication for treatment of IgA mesangial nephropathy. Lin CY, et al. **J Lab Clin Med** 1999 Jan;133(1):55-63

IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. Wang J, et al. **J Leukoc Biol** 1998 Nov; 64(5):642-9

Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety. Lebreton L, et al. **J Med Chem** 1999 Jan 28;42(2):277-90

Effects of fibroblast-mediated interleukin 3 and interleukin 6 gene therapy on hematopoiesis in mice treated with 5-fluorouracil. Cao X, et al. **J Mol Med** 1998 Oct; 76(11):782-9

Effects of cyclosporine A on the process of vascularization of freely transplanted islets of Langerhans. Vajkoczy P, et al. **J Mol Med** 1999 Jan;77(1):111-4

Oxygen radical production in human mononuclear blood cells is not suppressed by drugs used in clinical islet transplantation. Weinand S, et al. **J Mol Med** 1999 Jan; 77(1):121-2

CTLA-4-Fc treatment of ongoing EAE improves recovery, but has no effect upon relapse rate. Implications for the mechanisms involved in disease perpetuation. Cross AH, et al. **J Neuroimmunol** 1999 May 3;96(2):144-7

Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. McCombe PA, et al. **J Neuroimmunol** 1999 Jun 1;97(1-2):60-9

Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. Lee RK, et al. **J Neurosci** 1999 Feb 1;19(3):940-7

Cyclosporin A reduces the inflammatory response to a multi-mutant herpes simplex virus type-1 leading to improved transgene expression in sympathetic preganglionic neurons in hamsters. Mabon PJ, et al. **J Neurovirol** 1999 Jun;5(3):268-79

Effects of cyclosporin A on alveolar bone: an experimental study in the rat. Fu E, et al. **J Periodontol** 1999 Feb; 70(2):189-94

Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: implications for gingival overgrowth. Myrillas TT, et al. **J Periodontol** 1999 Mar;70(3):294-300

Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model. Mizushima Y, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):849-57

Ebselen protects mice against T cell-dependent, TNF-mediated apoptotic liver injury. Tiegs G, et al. **J Pharmacol Exp Ther** 1998 Dec;287(3):1098-104

Effect of a new immunosuppressant, FTY720, on joint allografts. Watanabe H, et al. **J Reconstr Microsurg** 1999 May;15(4):295-8

Short-term effect of cyclosporine on circulating adrenomedullin after heart transplantation. Geny B, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):391-2

Studies on cell-specific cytotoxicities induced by p-aminophenyl-mercuric acetate (APMA). Kim HM, et al. **J Toxicol Sci** 1998 Oct;23 Suppl 4:653-6 (9 ref.)

Effects of immunosuppressants on platelet-derived growth factor-A chain mRNA expression and coronary arteriosclerosis in rat cardiac allografts. Hachida M, et al. **Jpn Circ J** 1999 Apr;63(4):303-8

The protective effect of cyclosporine A on anti-Fas antibody-induced hepatitis in mice. Okamoto T, et al. **Jpn J Pharmacol** 1999 Apr;79(4):485-8

Effects of immunosuppressants on concanavalin A-induced interleukin-2 mRNA expression in mouse liver. Okamoto T, et al. **Jpn J Pharmacol** 1998 Jul;77(3):261-3

Tyrosine kinase inhibitors and immunosuppressants perturb the myo-inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells. Atta MG, et al. **Kidney Int** 1999 Mar;55(3):956-62

Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Fujihara CK, et al. **Kidney Int** 1998 Nov; 54(5):1510-9

Endothelin release by rabbit proximal tubule cells: modulatory effects of cyclosporine A, tacrolimus, HGF and EGF. Haug C, et al. **Kidney Int** 1998 Nov; 54(5):1626-36

Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Healy E, et al. **Kidney Int** 1998 Dec;54(6):1955-66

Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Romero F, et al. **Kidney Int** 1999 Mar;55(3):945-55

CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1. Navarro-Antolin J, et al. **Kidney Int Suppl** 1998 Dec;68:S20-4

Calcineurin inhibitors and cardiac hypertrophy. Force T, et al. **Lancet** 1999 Apr 17;353(9161):1290-2

Thalidomide in toxic epidermal necrolysis [letter; comment] Klausner JD, et al. **Lancet** 1999 Jan 23;353(9149):324. Comment on: Lancet 1998 Nov 14;352(9140):1586-9.

The effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male rats. López-Calderón A, et al. **Life Sci** 1999;64(17):1473-83

Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells. Pompeo A, et al. **Life Sci** 1999;64(10):837-46

Induction of apoptosis in mouse thymocytes by microcolin A and its synthetic analog. Zhang LH, et al. **Life Sci** 1999; 64(12):1013-28

Cyclosporin A inhibits long-term activation of Na+,K+ pump in phytohemagglutinin-stimulated human lymphocytes. Marakhova II, et al. **Membr Cell Biol** 1998; 12(3):363-74

Effects of saiboku-to on the survival of human eosinophils. Tohda Y, et al. **Methods Find Exp Clin Pharmacol** 1999 Jun;21(5):327-30

Cyclosporin A promotes translational silencing of autocrine interleukin-3 via ribosome-associated deadenylation. Nair AP, et al. **Mol Cell Biol** 1999 Jan;19(1):889-98

Growth inhibition of Saccharomyces cerevisiae by the immunosuppressant leflunomide is due to the inhibition of uracil uptake via Fur4p. Fujimura H. **Mol Gen Genet** 1998 Oct;260(1):102-7

Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins. Amberger A, et al. **Mol Med** 1999 Feb;5(2):117-28

Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. Siemann G, et al. **Mol Pharmacol** 1999 Jun;55(6):1094-100

Transplantation of anergic histoincompatible bone marrow cells [letter] de Carvalho Bittencourt M, et al. **N Engl J Med** 1999 Sep 30;341(14):1081-2

Transplantation of anergic histoincompatible bone marrow allografts [see comments] Guinan EC, et al. **N Engl J Med** 1999 Jun 3;340(22):1704-14. Comment in: N Engl J Med 1999 Jun 3;340(22):1754-6.

The new immunology--the end of immunosuppressive drug therapy? [editorial; comment] Schwartz RS. **N Engl J Med** 1999 Jun 3;340(22):1754-6. Comment on: N Engl J Med 1999 Jun 3;340(22):1704-14.

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Frank DA, et al. **Nat Med** 1999 Apr;5(4):444-7

Drug target validation and identification of secondary drug target effects using DNA microarrays [see comments] Marton MJ, et al. **Nat Med** 1998 Nov;4(11):1293-301. Comment in: Nat Med 1998 Nov;4(11):1235-6.

Enhancement of human platelet aggregation and secretion induced by rapamycin. Babinska A, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3153-9

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Hauser IA, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):58-63

Effect of a novel immunosuppressant, FK 506, on autoimmune glomerulonephritis in Brown Norway rats. Nakahama H, et al. **Nephron** 1999 Feb;81(2):215-20

Cellular signaling mechanisms for stimulation of growth hormone secretion and growth hormone primary transcripts by immunosuppressant agents. FK506 and cyclosporin A, in cultured rat pituitary cells. Ohye H, et al. **Neuroimmunomodulation** 1998 Nov-Dec;5(6):309-17

Cyclosporine-A reduces spontaneous place preference in adult rats. Borlongan CV, et al. **Neurosci Lett** 1999 Jun 4;267(3):169-72

Cyclosporin-A inhibits lipid peroxidation after spinal cord injury in rats. Diaz-Ruiz A, et al. **Neurosci Lett** 1999 Apr 30;266(1):61-4

Discordant effects of rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells. Powers JF, et al. **Neurosci Lett** 1999 Jan 15;259(3):137-40

Chronic cyclosporine-A injection in rats with damaged blood-brain barrier does not impair retention of passive avoidance. Borlongan CV, et al. **Neurosci Res** 1998 Nov; 32(3):195-200

An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate. Moriwaki A, et al. **Neuroscience** 1998 Oct;86(3):855-65

The effect of cyclosporin A on cultured rabbit subconjunctival fibroblast proliferation. Bagci G, et al. **Ophthalmologica** 1999;213(2):114-9

Mucosal mast cell responses and release of mast cell protease-I in infections of mice with Hymenolepis diminuta and H. microstoma: modulation by cyclosporin A. McLauchlan PE, et al. **Parasite Immunol** 1999 Mar; 21(3):151-61

Cyclosporine A preparations and their vehicles induce contraction of the guinea pig gallbladder in vitro: the role of cyclooxygenase metabolites. Yasar U, et al. **Pharmacology** 1999 Jun;58(6):309-18

An Arabidopsis immunophilin, AtFKBP12, binds to AtFIP37 (FKBP interacting protein) in an interaction that is disrupted by FK506. Faure JD, et al. **Plant J** 1998 Sep; 15(6):783-9

Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid [letter] Vieregge B, et al. **Planta Med** 1999 Feb;65(1):80-2

FK506 accelerates functional recovery following nerve grafting in a rat model. Doolabh VB, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1928-36

Mucosal and systemic suppression of the immune response to E. histolytica provoked by metronidazole and mebendazole in Balb/c mice. Moreno-Fierros L, et al. **Proc West Pharmacol Soc** 1998;41:99-102

Recent advances in immunosuppressants. Kundu B, et al. **Prog Drug Res** 1999;52:1-51 (239 ref.)

Comparative effects of betamethasone, cyclosporin and nedocromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharide. Corbel M, et al. **Pulm Pharmacol Ther** 1999;12(3):165-71

Investigation into avian pneumovirus persistence in poults and chicks using cyclosporin A immunosuppression. Khehra RS, et al. **Res Vet Sci** 1999 Apr;66(2):161-3

Cyclosporin A suppresses the induction of nitric oxide synthesis in interferon-gamma-treated L929 fibroblasts. Trajković V, et al. **Scand J Immunol** 1999 Feb;49(2):126-30

Thalidomide prolongs experimental autoimmune neuritis in Lewis rats. Zhu J, et al. **Scand J Immunol** 1998 Oct; 48(4):397-402

Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A [see comments] Aramburu J, et al. **Science** 1999 Sep 24;285(5436):2129-33. Comment in: Science 1999 Sep 24;285(5436):2042.

On the way to a better immunosuppressant? [news; comment] Hagmann M. **Science** 1999 Sep 24;285(5436):2042. Comment on: Science 1999 Sep 24;285(5436):2129-3.

Tolerating differences. Sikorski R, et al. **Science** 1999 Jul 16;285(5426):357–8
Modification of nucleic acid synthesis in regenerating liver by azathioprine. Gonzalez EM, et al. **Surgery** 1970 Jul; 68(1):254–8; discussion 258–9
Suppressed endothelin-1 production by FK506 and cyclosporin A in ischemia/reperfusion of rat small intestine. Soda Y, et al. **Surgery** 1999 Jan;125(1):23–32
Comparison of immunomodulation by cyclosporin A and azathioprine on pancreatic xenograft survival. Gupta RC, et al. **Ther Apher** 1997 Nov;1(4):362–5
The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Yatscoff RW, et al. **Ther Drug Monit** 1998 Oct;20(5):459–63 (26 ref.)
Azathioprine and 6-mercaptopurine alter the nucleotide balance in endothelial cells. Weigel G, et al. **Thromb Res** 1999 Apr 15;94(2):87–94
Salicylate-induced kidney mitochondrial permeability transition is prevented by cyclosporin A. Al-Nasser IA. **Toxicol Lett** 1999 Mar 8;105(1):1–8
In vitro exposure effects of cyclosporin A and bis(tri-n-butyltin)oxide on lymphocyte proliferation, cytokine (receptor) mRNA expression, and cell surface marker expression in rat thymocytes and splenocytes. Vandebriel RJ, et al. **Toxicology** 1999 Jul 1;135(1):49–66
T cell repertoire expression in murine recipients of bone marrow transplant after LF 08-0299 (Tresperimus) administration. Annat J, et al. **Transpl Immunol** 1998 Dec; 6(4):217–24
Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Blaheta RA, et al. **Transpl Immunol** 1998 Dec;6(4):251–9
Methotrexate regulates ICAM-1 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):111–21
Effects of cyclosporine A and methotrexate on CD18 expression in recipients of rat cardiac allografts. Ciesielski CJ, et al. **Transpl Immunol** 1998 Jun;6(2):122–33
Rebound effect of the allogenic T-cell response to donor and third-party lymphocytes after cyclosporine withdrawal in renal transplant recipients. Creemers P, et al. **Transpl Immunol** 1998 Dec;6(4):261–4
An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers. de Vries-van der Zwan A, et al. **Transpl Immunol** 1998 Sep;6(3):147–51
Beneficial and detrimental human leucocyte antigen (HLA)-DR mismatches are not reflected by a differential effect of immunosuppressive drugs on the in vitro alloimmune response. van Beelen E, et al. **Transpl Immunol** 1999 Mar;7(1):59–63
Factors relevant for the induction of rejection by indirect recognition in a rat heart allograft model: effect of CTLA4Ig treatment on indirect alloactivation induced by immunization with donor MHC I peptides. Dufter C, et al. **Transpl Int** 1998;11 Suppl 1:S361–3
Effect of FTY720 on immunoregulation in concordant xenotransplantation. Fukuda Y, et al. **Transpl Int** 1998;11 Suppl 1:S461–4
Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets. Neto AB, et al. **Transpl Int** 1999; 12(3):208–12
Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides. Schorlemmer HU, et al. **Transpl Int** 1998;11 Suppl 1:S448–51
Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Blaheta RA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1250–2
Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. Chávez R, et al. **Transplant Proc** 1999 Sep;31(6):2429
Inhibition of PDGF-stimulated rat smooth muscle cell proliferation by MNA 279 and MNA 715. Czech J, et al. **Transplant Proc** 1998 Dec;30(8):4197–9
Apoptosis of activated peripheral T cells. Genestier L, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2A):33S–38S (87 ref.)
Differences between cyclosporin A and tacrolimus in organ transplantation. Jiang H, et al. **Transplant Proc** 1999 Aug; 31(5):1978–80
IL-10 is an effector molecule mediating urocanic acid-induced immunosuppression. Krulová M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1218–9
Functional characterization of HP12: a novel immunosuppressant purified from Helleborus species. Linke S, et al. **Transplant Proc** 1998 Dec;30(8):4106–7
Immunosuppressive effect of triptolide in vitro. Lu H, et al. **Transplant Proc** 1999 Aug;31(5):2056–7
A novel effect of cyclosporine A on lymphocyte migration to allograft and recipient lymphoid tissue. Maksymowicz M, et al. **Transplant Proc** 1998 Dec;30(8):4054–6
In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. Metcalfe SM, et al. **Transplant Proc** 1998 Dec;30(8):4108–9
Cyclosporin impairs bile duct arterial supply in ischemic livers. Nakache R, et al. **Transplant Proc** 1998 Dec; 30(8):3948
Donor treatment with mycophenolate mofetil protects against ischemia-reperfusion injury. Paul LC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1026
Malononitrilamides prevent and suppress allospecific antibody production. Qi Z, et al. **Transplant Proc** 1998 Dec; 30(8):3980
Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):851–3
SDZ RAD inhibits cold ischemia-induced vascular remodeling. Schuurman HJ, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1024–5
HP12: a highly purified Helleborus species extract strongly potentiates the T-cell suppressive effect of cyclosporine A. Terness P, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1174–5
Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. Wu MS, et al. **Transplant Proc** 1998 Nov;30(7):3565–6
Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. Yokoyama I, et al. **Transplant Proc** 1998 Dec;30(8):4196
Effect of 15-deoxyspergualine on coronary arteriosclerosis and platelet-derived growth factor-A mRNA expression in the transplanted heart. Zhang X, et al. **Transplant Proc** 1999 May;31(3):1706–9
HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Cole MS, et al. **Transplantation** 1999 Aug 27;68(4):563–71
Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Drachenberg CB, et al. **Transplantation** 1999 Aug 15;68(3):396–402
Blood levels of TGF-beta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine [see comments] Hughes JR, et al. **Transplantation** 1999 Aug 27;68(4):583–6. Comment in: Transplantation 1999 Aug 27;68(4):468–9.
Successful nerve regeneration and persistence of donor cells after a limited course of immunosuppression in rat peripheral nerve allografts. Katsube K, et al. **Transplantation** 1998 Sep 27;66(6):772–7
Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Khanna A, et al. **Transplantation** 1999 Feb 27;67(4):614–9
Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Khanna AK, et al. **Transplantation** 1999 Mar 27;67(6):882–9
Cyclosporine induces the expression of the cyclin inhibitor p21. Khanna AK, et al. **Transplantation** 1999 May 15; 67(9):1262–8
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Li Y, et al. **Transplantation** 1998 Nov 27;66(10):1387–8
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Takayama T, et al. **Transplantation** 1998 Dec 27;66(12):1567–74
Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice. Wissing KM, et al. **Transplantation** 1999 Sep 15; 68(5):677–84
Signal-transduction cascades as targets for therapeutic intervention by natural products. Cardenas ME, et al. **Trends Biotechnol** 1998 Oct;16(10):427–33 (71 ref.)
Bovine leukaemia virus envelope peptides cause immunomodulation in BALB/c mice. Kabeya H, et al. **Vet Immunol Immunopathol** 1999 Mar 29;68(1):39–48
The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. Mortola E, et al. **Vet Res Commun** 1998 Dec;22(8):553–63
[The complementarity of pharmacologic action between Tripterygium wilfordii and prednisone] Hu DW, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Feb; 17(2):94–6 (Eng. Abstr.) **(Chi)**
[The vasoconstrictor effect of cyclosporine on the pulmonary vein is mediated by its vehicle: the cremophor] Mathieu P, et al. **Ann Chir** 1998;52(8):821–6 (Eng. Abstr.) **(Fre)**
[Modulation of immune mediated diseases of the eye] Pleyer U, et al. **Klin Monatsbl Augenheilkd** 1999 Mar;214(3):160–70 (106 ref.) (Eng. Abstr.) **(Ger)**
[Genetic methods in experimental xenogenic nerve transplantation] Hebebrand D, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1279–81 (Eng. Abstr.) **(Ger)**
[Clinical and MRI effects of Glatirameracetate] **Nervenarzt** 1999 Aug;70(8 Suppl):1–8 **(Ger)**
[Effect of immunosuppressive agents and antilymphocyte serum on bacterial translocation in mice] Anderlik P, et al. **Acta Pharm Hung** 1999 Apr;69(2):69–71 (Eng. Abstr.) **(Hun)**
[Immunosuppressive drugs and calcineurin] Masugi T, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1739–43 (18 ref.) **(Jpn)**
[Action mechanism of immunosuppressant, ISP-1] Yamaji T, et al. **Tanpakushitsu Kakusan Koso** 1998 Dec;43(16 Suppl):2503–9 (33 ref.) **(Jpn)**
[The differences in liver regenerative rate after partial hepatectomy in rats treated wtih selected immunosuppressants] Polak W, et al. **Pol Merkuriusz Lek** 1999 Feb;6(32):70–2 (Eng. Abstr.) **(Pol)**
[Cyclosporine as an inhibitor of signal transduction. Molecular mechanisms of action (editorial)] Sazykin IuO, et al. **Antibiot Khimioter** 1999;44(3):3–4 **(Rus)**
[Effects of immunosuppressor and cytostatic agents on the extracellular matrix production during experimental neuropathies] Krivoshchapov LG, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):584–7 **(Rus)**
[A comparative study of the mechanisms of the immunosuppressive action of morphine and adrenaline in leukocytes in vitro] Dolmatova LS, et al. **Eksp Klin Farmakol** 1998 Sep-Oct;61(5):37–41 (Eng. Abstr.) **(Rus)**
[Immunity during ampicillin administration against a background of immunosuppression] Sakaeva DD, et al. **Eksp Klin Farmakol** 1998 Nov-Dec;61(6):39–41 (Eng. Abstr.) **(Rus)**
[The inductive immunosuppressive activity of the lipopolysaccharide from Shigella sonnei R forms] Borisova EV. **Mikrobiol Z** 1998 May-Jun;60(3):63–9 (Eng. Abstr.) **(Rus)**
[Separate and combined effects of ionizing radiation and cyclophosphamide on thymus-dependent humoral immune response] Sharetskii AN, et al. **Radiats Biol Radioecol** 1998 Sep-Oct;38(5):696–700 (Eng. Abstr.) **(Rus)**
[Immunosuppressive action of lipopolysaccharide S- and R-forms of Salmonella and the role of lipid A] Borisova EV. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Nov-Dec; (6):20–3 (Eng. Abstr.) **(Rus)**
[The effect of cyclosporine on human endothelial cells in culture] Džirlo-Todorović J. **Med Arh** 1998;52(4):195–8 (Eng. Abstr.) **(Ser)**

POISONING

Cyclosporine neurotoxicity: a review. Gijtenbeek JM, et al. **J Neurol** 1999 May;246(5):339–46 (73 ref.)
Massive ingestion of tacrolimus in a young liver transplant patient. Odoul F, et al. **Transplant Proc** 1998 Dec; 30(8):4327–9
Serious interaction between mibefradil and tacrolimus. Krähenbühl S, et al. **Transplantation** 1998 Oct 27; 66(8):1113–5
Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. Randhawa PS, et al. **Transplantation** 1999 Jan 15;67(1):85–9

STANDARDS

Higher approval standards, consistent practice policies needed for safe use of generic immunosuppressants, say transplant experts [news] Miller JL. **Am J Health Syst Pharm** 1999 Apr 1;56(7):604, 607
Transplant pharmacists' opinions on generic product selection of critical-dose drugs. Vasquez EM, et al. **Am J Health Syst Pharm** 1999 Apr 1;56(7):615–21
Generic immunosuppressants: the European perspective. Christians U. **Transplant Proc** 1999 May;31(3A Suppl):19S–22S (21 ref.)

THERAPEUTIC USE

Morphological assessment of the effects of cyclosporin A on mast cell--nerve relationship in atopic dermatitis. Toyoda M, et al. **Acta Derm Venereol** 1998 Sep;78(5):321–5
Low dose cyclosporin A and methotrexate in the treatment of psoriasis [letter] Wong KC, et al. **Acta Derm Venereol** 1999 Jan;79(1):87
Cyclical immunotherapy in patients with psoriasis. Amerio P, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:101–2
Short-term treatment with cyclosporin in severe psoriasis: four years of experience. Garcovich A, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:92–3
Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Mazzanti G, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:116–7
Psoriasis and cyclosporin: immunohistochemical aspects of the basement membrane. Mondello MR, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:96–8
Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Peluso AM, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:90–1
Methotrexate in psoriatic polyarthritis. Pigatto PD, et al. **Acta Derm Venereol Suppl (Stockh)** 1994;186:114–5
Short-term "cyclosporin A" therapy for psoriatic arthritis. Riccieri V, et al. **Acta Derm Venereol Suppl (Stockh)** 1994; 186:94–5
Angioimmunoblastic lymphadenopathy: treatment in three cases. [letter; comment] Sánchez M, et al. **Acta Haematol** 1998 Dec;100(3):164–5. Comment on: Acta Haematol 1998;99(2):57–64.
Identification of cytomegalovirus (CMV) infection by different laboratory methods in renal transplant recipients undergoing triple-drug immunosupressive treatment. Siennicka J, et al. **Acta Microbiol Pol** 1999;48(1):61–71
Cyclosporine C: a study of wound-healing modulation after trabeculectomy in rabbit. Nuzzi R, et al. **Acta Ophthalmol Scand Suppl** 1998;(227):48–9
Advances in immunosuppression for heart transplantation.

Kobashigawa JA. **Adv Card Surg** 1998;10:155–74 (46 ref.)

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine [editorial] De Boer RJ, et al. **AIDS** 1998 Sep 10;12(13):1567–70 (49 ref.)

Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Stack WA, et al. **Aliment Pharmacol Ther** 1998 Oct;12(10):973–8

Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology. Stack WA, et al. **Aliment Pharmacol Ther** 1999 May;13(5):569–75

Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Bottari V, et al. **Allergy** 1999 May;54(5):507–10

Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitis. Kägi MK, et al. **Allergy** 1999 Jan;54(1):57–63

A strategy for identifying immunosuppressive therapies for Alzheimer disease. Giulian D. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S7–14 (32 ref.)

Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Fellermann K, et al. **Am J Gastroenterol** 1998 Oct; 93(10):1860–6

Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Fernandes NF, et al. **Am J Gastroenterol** 1999 Jan;94(1):241–8 (14 ref.)

Mycophenolate mofetil in patients with Crohn's disease. Fickert P, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2529–32

Severe gastrointestinal hemorrhage due to Mycobacterium avium complex in a patient receiving immunosuppressive therapy. Nguyen HN, et al. **Am J Gastroenterol** 1999 Jan; 94(1):232–5

Role of immunosuppressive therapy in refractory sprue-like disease. Rolny P, et al. **Am J Gastroenterol** 1999 Jan; 94(1):219–25

A diffuse T lymphocytic gastrointestinal mucosal infiltration associated with Sjögren's syndrome resulting in a watery diarrhea syndrome and responsive to immunosuppressive therapy. Sobhani I, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2584–6

Azathioprine in refractory sprue. Vaidya A, et al. **Am J Gastroenterol** 1999 Jul;94(7):1967–9

Possible cyclosporin-danazol interaction in a patient with aplastic anaemia [letter] Borrás-Blasco J, et al. **Am J Hematol** 1999 Sep;62(1):63–4 (5 ref.)

Deficient proliferation of myeloid, erythroid, and multipotent progenitor cells in long-term marrow cultures from patients with aplastic anemia treated with immunosuppressive therapy. Gómez-Morales E, et al. **Am J Hematol** 1998 Oct;59(2):149–55

Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin. Shao Z, et al. **Am J Hematol** 1998 Nov; 59(3):185–91

Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. **Am J Kidney Dis** 1999 Aug;34(2):296–303

Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil therapy in an allograft. Adams PL, et al. **Am J Kidney Dis** 1999 Mar;33(3):552–4

Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Kaplan B, et al. **Am J Kidney Dis** 1999 Jul;34(1):65–8

Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. Neylan JF, et al. **Am J Kidney Dis** 1998 Nov; 32(5):770–7

Resolution of psoriatic skin lesions with fludarabine [letter] Karadoğan I, et al. **Am J Med** 1999 Sep;107(3):300–1

Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. Suki WN, et al. **Am J Nephrol** 1999;19(4):474–9

Antithymocyte globulin treatment of orbital Wegener granulomatosis: a follow-up study. Kool J, et al. **Am J Ophthalmol** 1999 Jun;127(6):738–9

Conditioned immunosuppression makes subtherapeutic cyclosporin effective via splenic innervation. Exton MS, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):R1710–7

Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Lemjabbar H, et al. **Am J Respir Cell Mol Biol** 1999 May; 20(5):903–13

Steroid-refractory neonatal eosinophilic pneumonia responsive to cyclosporin A. Morton RL, et al. **Am J Respir Crit Care Med** 1999 Sep;160(3):1019–22

A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Raofi V, et al. **Am J Surg** 1999 Apr;177(4):299–302

Complete remission of refractory anemia following a single high dose of cyclophosphamide. Ferrara F, et al. **Ann Hematol** 1999 Feb;78(2):87–8

Thymoma-associated pancytopenia: effectiveness of cyclosporine A. Liozon E, et al. **Ann Hematol** 1998 Oct; 77(4):175–8

Granulocyte colony-stimulating factor-supported combined immunosuppressive therapy (antilymphocyte globulin, cyclosporine, and methylprednisolone) in patients with aplastic anemia: tolerability, efficacy, and changes in the progenitor cell compartment. Meidlinger P, et al. **Ann Hematol** 1999 Jul;78(7):299–304

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease. Osaki M, et al. **Ann Hematol** 1999 Feb;78(2):83–6 (16 ref.)

Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases. Pérez-Sánchez I, et al. **Ann Hematol** 1999 Jun;78(6):285–7

Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Daina E, et al. **Ann Intern Med** 1999 Mar 2;130(5):422–6

Vulnerable plaque [letter] de' Clari L. **Ann Intern Med** 1999 Sep 7;131(5):393–4

Mucocutaneous lesions in the Behçet syndrome [letter; comment] Demiroglu H, et al. **Ann Intern Med** 1998 Nov 15;129(10):836. Comment on: Ann Intern Med 1998 Mar 15;128(6):443–50.

Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Tichelli A, et al. **Ann Intern Med** 1999 Feb 2;130(3):193–201

Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies. Neurath MF, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:315–8

Review--the use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product. Potter MA, et al. **Ann N Y Acad Sci** 1999 Jun 18;875:159–74 (26 ref.)

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ghobrial RM, et al. **Ann Surg** 1999 Jun; 229(6):824–31; discussion 831–3

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Jain A, et al. **Ann Surg** 1999 Sep;230(3):441–8; discussion 448–9

Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. Stratta RJ, et al. **Ann Surg** 1999 May;229(5):701–8; discussion 709–12

Induction immunosuppression for lung transplantation with OKT3. Wain JC, et al. **Ann Thorac Surg** 1999 Jan; 67(1):187–93

Effect of Sandimmun Neoral on the level of bivalent cations in erythrocytes of kidney transplant recipients. Babarykin D, et al. **Ann Transplant** 1996;1(2):23–6

The effect of cyclosporine on regulators of fibrinolysis in plasma from renal allograft recipients. Elhasade AS, et al. **Ann Transplant** 1998;3(1):13–8

Sirolimus, a potent new immunosuppressive drug for organ transplantation. Stepkowski SM. **Ann Transplant** 1996; 1(3):19–25 (71 ref.)

Cyclosporine treatment of glomerular diseases. Klein M, et al. **Annu Rev Med** 1999;50:1–15 (69 ref.)

Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. De Celis R, et al. **Arch Androl** 1999 Jan-Feb; 42(1):9–20

Is mycophenolic acid effective for the treatment of pemphigus? [letter; comment] Bystryn JC. **Arch Dermatol** 1999 Jul;135(7):854–5. Comment on: Arch Dermatol 1999 Jan;135(1):54–6.

Mycophenolate is effective in the treatment of pemphigus vulgaris [see comments] Enk AH, et al. **Arch Dermatol** 1999 Jan;135(1):54–6. Comment in: Arch Dermatol 1999 Jan;135(1):76–8. Comment in: Arch Dermatol 1999 Jul;135(7):853–4. Comment in: Arch Dermatol 1999 Jul;135(7):854–5.

Pulse intravenous cyclophosphamide therapy in pemphigus. Fleischli ME, et al. **Arch Dermatol** 1999 Jan;135(1):57–61

Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy [letter] Grundmann-Kollmann M, et al. **Arch Dermatol** 1999 Jun; 135(6):724–5

The role of mycophenolate mofetil in the management of pemphigus [letter; comment] Nousari HC, et al. **Arch Dermatol** 1999 Jul;135(7):853–4. Comment on: Arch Dermatol 1999 Jan;135(1):54–6. Comment on: Arch Dermatol 1999 Jan;135(1):76–8.

Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis [letter] Nousari HC, et al. **Arch Dermatol** 1999 Sep;135(9):1128–9

The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Nousari HC, et al. **Arch Dermatol** 1998 Dec;134(12):1509–11

Treatment of psoriasis with troglitazone therapy [letter] Pershadsingh HA, et al. **Arch Dermatol** 1998 Oct; 134(10):1304–5

Tacrolimus: the drug for the turn of the millennium? Ruzicka T, et al. **Arch Dermatol** 1999 May;135(5):574–80 (76 ref.)

Therapy of pemphigus vulgaris [editorial; comment] [see comments] Stanley JR. **Arch Dermatol** 1999 Jan;135(1):76–8 (33 ref.). Comment on: Arch Dermatol 1999 Jan;135(1):54–6. Comment in: Arch Dermatol 1999 Jul;135(7):853–4.

Improved prognosis for acquired aplastic anaemia. Pitcher LA, et al. **Arch Dis Child** 1999 Feb;80(2):158–62

Multiple sclerosis: therapeutic update. Tselis AC, et al. **Arch Neurol** 1999 Mar;56(3):277–80 (17 ref.)

Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Dees C, et al. **Arch Ophthalmol** 1998 Nov; 116(11):1456–61

Widespread plaque psoriasis responsive to mycophenolate mofetil. Tong DW, et al. **Australas J Dermatol** 1999 Aug; 40(3):135–7

Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Horowitz MM, et al. **Biol Blood Marrow Transplant** 1999;5(3):180–6

Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Burt RK, et al. **Blood** 1998 Nov 15;92(10):3505–14

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Marsh J, et al. **Blood** 1999 Apr 1;93(7):2191–5

Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Zeng W, et al. **Blood** 1999 May 1;93(9):3008–16

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Knoll GA, et al. **BMJ** 1999 Apr 24;318(7191):1104–7

IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Brok HP, et al. **Bone Marrow Transplant** 1998 Nov;22(10):1005–10

Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Grigg A, et al. **Bone Marrow Transplant** 1999 Jan;23(2):107–10

Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications. Jindra P, et al. **Bone Marrow Transplant** 1999 Jul;24(2):215–7

Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. Kleinman MB, et al. **Bone Marrow Transplant** 1999 Jun;23(12):1297–301

Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. Oliveira JS, et al. **Bone Marrow Transplant** 1999 Jan;23(1):99–101

Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Ottolini MG, et al. **Bone Marrow Transplant** 1999 Jul;24(1):41–5

Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. Przepiorka D, et al. **Bone Marrow Transplant** 1999 Jun; 23(12):1291–5

Thalidomide for chronic GVHD [letter; comment] Sastry PS, et al. **Bone Marrow Transplant** 1998 Nov;22(9):933–4. Comment on: Bone Marrow Transplant 1998 Apr;21(7):721–3.

Early post-BMT liver function in children with acute leukemia conditioned for allo-BMT with Busulfan-containing and with FTBI-containing preparative regimens. Wachowiak J, et al. **Bone Marrow Transplant** 1998 Dec;22 Suppl 4:S96–9

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Zander AR, et al. **Bone Marrow Transplant** 1999 May;23(9):889–93

The use of cyclosporin in a child with generalized pustular psoriasis [letter] Alli N, et al. **Br J Dermatol** 1998 Oct; 139(4):754–5

Mycophenolate mofetil for psoriasis [letter; comment] Kirby B, et al. **Br J Dermatol** 1998 Aug;139(2):357. Comment on: Br J Dermatol 1998 Jan;138(1):179–81.

Topical tacrolimus for pyoderma gangrenosum [letter] Reich K, et al. **Br J Dermatol** 1998 Oct;139(4):755–7

Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Worm M, et al. **Br J Dermatol** 1998 Oct; 139(4):704–7

Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Carella AM, et al. **Br J Haematol** 1998 Nov;103(2):565–7

Cladribine for Waldenström's macroglobulinaemia [letter; comment] Delannoy A, et al. **Br J Haematol** 1999 Mar; 104(4):933–4. Comment on: Br J Haematol 1998 Dec;103(3):690–5.

A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. Murata M, et al. **Br J Haematol** 1999 Jun; 105(3):799–802

Successful treatment of acquired myelofibrosis with pure red cell aplasia by cyclosporine [letter] Nemoto Y, et al. **Br J Haematol** 1999 Feb;104(2):422–4

The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia. Sallah S, et al. **Br J Haematol** 1999 Jan;104(1):163-5

High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy. Takami A, et al. **Br J Haematol** 1999 Aug;106(2):377-84

Cyclosporin A therapy in refractory non-infectious childhood uveitis. Kilmartin DJ, et al. **Br J Ophthalmol** 1998 Jul;82(7):737-42

Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Reis A, et al. **Br J Ophthalmol** 1998 Jun;82(6):700-3

Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Stenger AA, et al. **Br J Rheumatol** 1998 Nov;37(11):1157-63

Sodium fusidate and the cytokine response in an experimental model of acute pancreatitis [see comments] Osman MO, et al. **Br J Surg** 1998 Nov;85(11):1487-92. Comment in: Br J Surg 1999 May;86(5):715.

The immunosuppressants cyclosporin A and FK506 equally ameliorate brain damage due to 30-min middle cerebral artery occlusion in hyperglycemic rats. Kuroda S, et al. **Brain Res** 1999 Jul 24;835(2):148-53

Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Uchino H, et al. **Brain Res** 1998 Nov 23;812(1-2):216-26

Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Selby R, et al. **Can J Neurol Sci** 1998 Nov;25(4):295-9

A new translocation (4;12)(q21;q15) after combined immunosuppressive therapy in a case of hypoplastic myelodysplastic syndrome with translocation (12;15)(q23;q12) [letter] Iwanaga M, et al. **Cancer Genet Cytogenet** 1998 Nov;107(1):82-4

The rescue effect of 15-deoxyspergualin on intraperitoneal microencapsulated xenoislets. Hsu BR, et al. **Cell Transplant** 1999 May-Jun;8(3):307-15

Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. Yamasaki T, et al. **Cell Transplant** 1998 Jul-Aug;7(4):403-6

Idiopathic pulmonary fibrosis and cyclosporine: a lesson from single-lung transplantation. Lok SS, et al. **Chest** 1998 Nov; 114(5):1478-81

Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Palmer SM, et al. **Chest** 1999 Jul;116(1):127-33

FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Hwang MW, et al. **Circulation** 1999 Sep 21;100(12):1322-9

Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Poston RS, et al. **Circulation** 1999 Jul 6;100(1):67-74

Thalidomide's tightly controlled "comeback". Calabrese LH. **Cleve Clin J Med** 1999 Mar;66(3):136-8

Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Schönlein purpura. Szer IS. **Cleve Clin J Med** 1999 May;66(5):312-7 (16 ref.)

Humanized monoclonals and other biological initiatives. Halloran PF, et al. **Clin Biochem** 1998 Jul;31(5):353-7 (30 ref.)

Emerging strategies for the clinical application of rapamycin. Kahan BD. **Clin Biochem** 1998 Jul;31(5):341-4 (22 ref.)

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Nicholls AJ. **Clin Biochem** 1998 Jul;31(5):329-33 (10 ref.)

Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Oellerich M, et al. **Clin Biochem** 1998 Jul;31(5):309-16 (22 ref.)

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Sehgal SN. **Clin Biochem** 1998 Jul;31(5):335-40 (69 ref.)

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Shaw LM, et al. **Clin Biochem** 1998 Jul; 31(5):317-22 (42 ref.)

Antisense oligodeoxynucleotides for organ transplantation. Stepkowski SM. **Clin Biochem** 1998 Jul;31(5):375-9 (29 ref.)

Preclinical evaluation of a new immunosuppressive agent, FTY720. Troncoso P, et al. **Clin Biochem** 1998 Jul; 31(5):369-73 (21 ref.)

Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Chambers SK, et al. **Clin Cancer Res** 1996 Oct;2(10):1693-7

Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Chambers SK, et al. **Clin Cancer Res** 1996 Oct;2(10):1699-704

Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers. Ross HJ, et al. **Clin Cancer Res** 1997 Jan;3(1):57-62

Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Stein CM, et al. **Clin Chem** 1999 Sep;45(9):1477-84

CD14++ monocytes, CD14++/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Scherberich JE, et al. **Clin Chem Lab Med** 1999 Mar; 37(3):209-13 (18 ref.)

A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Hern S, et al. **Clin Exp Dermatol** 1998 Jul;23(4):185-8

Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Kaminska R, et al. **Clin Exp Dermatol** 1999 Mar;24(2):81-5

Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes. Stosic-Grujicic S, et al. **Clin Exp Immunol** 1999 Jul; 117(1):44-50

Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Angelis-Stoforidis P, et al. **Clin Exp Rheumatol** 1999 May-Jun;17(3):313-20

Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A [letter] Cantini F, et al. **Clin Exp Rheumatol** 1999 May-Jun;17(3):391-2

Treatment of recurrent oro-genital ulceration with low doses of thalidomide [letter] De Wazières B, et al. **Clin Exp Rheumatol** 1999 May-Jun;17(3):393

Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis [editorial; comment] Ferraccioli GF, et al. **Clin Exp Rheumatol** 1998 Nov-Dec;16(6):662-6 (57 ref.). Comment on: Clin Exp Rheumatol 1998 Nov-Dec;16(6):695-701.

Failure of cyclosporin therapy in type II mixed cryoglobulinemia associated with hepatitis C virus infection [letter] Horsmans Y, et al. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):514-5

Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporin A and methotrexate. Kotaniemi K. **Clin Exp Rheumatol** 1998 Jul-Aug;16(4):469-71

On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Wallace CA. **Clin Exp Rheumatol** 1999 Jul-Aug;17(4):499-504 (40 ref.)

Combination chemotherapy in a patient with severe multiple systemic autoimmune disease. Tamai Y, et al. **Clin Lab Haematol** 1998 Oct;20(5):315-6

Emphysematous cystitis: possible side-effect of cyclophosphamide therapy [letter] Abuzarad H, et al. **Clin Nephrol** 1998 Dec;50(6):394-6

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Boumpas DT, et al. **Clin Nephrol** 1999 Aug;52(2):67-75

OKT3 in renal allografts: survival and complications [letter] D'Souza RJ, et al. **Clin Nephrol** 1999 Apr;51(4):257-8

Resolution of hyperparathyroidism associated with immunosuppressive therapy. Jassal SV, et al. **Clin Nephrol** 1998 Nov;50(5):326-9

Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low dose ciclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Kano K, et al. **Clin Nephrol** 1999 Jul;52(1):19-24

Is cyclosporine A safe in IgA nephropathy and nephrotic syndrome? [letter] Révai T, et al. **Clin Nephrol** 1999 Jul; 52(1):66

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Zeldis JB, et al. **Clin Ther** 1999 Feb;21(2):319-30

Clinical aspects of sensitization. Katznelson S, et al. **Clin Transpl** 1997;:285-96

Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Butcher JA, et al. **Clin Transplant** 1999 Aug;13(4):330-5

Tacrolimus vs Neoral in renal and renal/pancreas transplantation. Ghasemian SR, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):123-5

Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Henry ML. **Clin Transplant** 1999 Jun;13(3):209-20

Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. Kleindienst R, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):65-7

Screening for basiliximab exposure-response relationships in renal allotransplantation. Kovarik JM, et al. **Clin Transplant** 1999 Feb;13(1 Pt 1):32-8

The role of tacrolimus in adult kidney transplantation: a review. Laskow DA, et al. **Clin Transplant** 1998 Dec; 12(6):489-503 (36 ref.)

Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Peddi VR, et al. **Clin Transplant** 1998 Oct; 12(5):401-5

The clinical status of cadaveric renal transplant patients treated for 10 year with cyclosporine therapy. Ponticelli C, et al. **Clin Transplant** 1999 Aug;13(4):324-9

Pregnancies following liver transplantation--how safe are they? A report of 19 cases under cyclosporine A and tacrolimus. Rayes N, et al. **Clin Transplant** 1998 Oct; 12(5):396-400

Intragraft cytokine expression in tolerant rat renal allografts with rapamycin and cyclosporin immunosuppression. Saggi BH, et al. **Clin Transplant** 1999 Feb;13(1 Pt 2):90-7

Improving the therapeutic monitoring of cyclosporin A. Warrens AN, et al. **Clin Transplant** 1999 Apr;13(2):193-200

The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Gao J, et al. **Cornea** 1998 Nov;17(6):654-63

Anti-inflammatory effects of U74389F in a rat model of intestinal ischemia/reperfusion injury [see comments] Stojadinovic A, et al. **Crit Care Med** 1999 Apr;27(4):764-70 . Comment in: Crit Care Med 1999 Apr;27(4):684-5.

The use of antibodies against the IL-2 receptor in transplantation. Waldmann TA, et al. **Curr Opin Immunol** 1998 Oct;10(5):507-12 (66 ref.)

Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease. Hauser IA, et al. **Curr Opin Nephrol Hypertens** 1999 Jan;8(1):1-6

New concepts in treatment protocols for severe systemic vasculitis. Gross WL. **Curr Opin Rheumatol** 1999 Jan; 11(1):41-6 (63 ref.)

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367-79 (100 ref.)

The treatment of bovine collagen allergy with cyclosporin. Baumann LS, et al. **Dermatol Surg** 1999 Mar;25(3):247-9

Partial response of severe alopecia areata to cyclosporine A [letter] Ferrando J, et al. **Dermatology** 1999;199(1):67-9

Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus. Naeyaert JM, et al. **Dermatology** 1999;198(2):145-52 (33 ref.)

Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. Aa double-blind, single-centre, cross-over pilot study. Zurbriggen B, et al. **Dermatology** 1999;198(1):56-60

Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Eriksson JW, et al. **Diabetes Care** 1998 Aug;21(8):1217-20

Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Yoshioka K, et al. **Diabetes Res Clin Pract** 1998 Nov; 42(2):85-9

Newer therapeutic agents for asthma. Deykin A, et al. **Dis Mon** 1999 Apr;45(4):117-44 (98 ref.)

Preparation and testing of cyclosporine microsphere and solution formulations in the treatment of polyarthritis in rats. D'Souza M, et al. **Drug Dev Ind Pharm** 1998 Sep; 24(9):841-52

Drug therapy in the management of type 1 autoimmune hepatitis. Czaja AJ. **Drugs** 1999 Jan;57(1):49-68 (152 ref.)

Basiliximab. Onrust SV, et al. **Drugs** 1999 Feb;57(2):207-13; discussion 214 (28 ref.)

Macrolide immunosuppressants. Mrowietz U. **Eur J Dermatol** 1999 Jul-Aug;9(5):346-51 (52 ref.)

Evidence-based therapy of primary biliary cirrhosis. Heathcote EJ. **Eur J Gastroenterol Hepatol** 1999 Jun; 11(6):607-15 (57 ref.)

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Hellmann A, et al. **Eur J Haematol** 1999 Jul;63(1):35-41

In vitro and in vivo correlation of cyclosporin A-induced apoptosis in acute lymphoblastic leukemia [letter] Sezer O, et al. **Eur J Haematol** 1999 Sep;63(3):207-9

A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis. Okamoto S, et al. **Eur J Immunol** 1999 Jan;29(1):355-66

Immunosuppressive drugs in the treatment of Crohn's disease. Rutgeerts P, et al. **Eur J Surg** 1998 Dec;164(12):911-5 (40 ref.)

Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Adams HP, et al. **Eur Neurol** 1999 Jul;42(1):52-63

The role of azathioprine in the management of retinal vasculitis. Greenwood AJ, et al. **Eye** 1998;12 (Pt 5):783-8

The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: a preliminary study [see comments] Lam DS, et al. **Eye** 1998;12 (Pt 4):615-8. Comment in: Eye 1998 ;12 (Pt 4):609-10.

Diagnosis and treatment of colonic disease in AIDS. Mönkemüller KE, et al. **Gastrointest Endosc Clin N Am** 1998 Oct;8(4):889-911 (118 ref.)

Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Heiligenhaus A, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 May;237(5):435-8

A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Reis A, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Oct;236(10):785-9

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease [see comments] Neurath MF, et al. **Gut** 1999 May; 44(5):625-8. Comment in: Gut 1999 May;44(5):592-3.

Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment. Ollivier S, et al. **Gut** 1999 Sep;45(3):463-4

Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease? [comment] Present DH. **Gut** 1999 May;44(5):592-3. Comment on: Gut 1999 May;44(5):625-8.

Cyclosporin and chronic pancreatitis: a supermodel? [comment] Steer ML. **Gut** 1999 Aug;45(2):167-8. Comment on: Gut 1999 Aug;45(2):269-77.

Prednisone and low-dose activated prothrombin complex concentrates for FVIII inhibitor in nonhaemophilic patients. Ji L, et al. **Haemophilia** 1998 Sep;4(5):721-4

Acquired inhibitor against factor IX in a child: successful treatment with high-dose immunoglobulin and dexamethasone. Mazzucconi MG, et al. **Haemophilia** 1999 Mar;5(2):132-4

Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Arora S, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1724-9

Prednisone withdrawal advocates: beware of recurrent autoimmune hepatitis. Davila R, et al. **Hepatology** 1999 Jul; 30(1):338-9

Immunosuppressive agents in organ transplantation. Magee CC, et al. **Hosp Med** 1999 May;60(5):364-9 (22 ref.)

Treatment of autoimmune premature ovarian failure. Kalantaridou SN, et al. **Hum Reprod** 1999 Jul;14(7):1777-82

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Modigliani R. **Inflamm Bowel Dis** 1998 Aug;4(3):244-7; discussion 253-4 (9 ref.)

Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Schölmerich J. **Inflamm Bowel Dis** 1998 Aug;4(3):248-52; discussion 253-4 (21 ref.)

Methotrexate in refractory Crohn's disease. Vandeputte L, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):11-5

Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Miura H, et al. **Int J Dermatol** 1999 Apr; 38(4):310-4

Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Arrieta O, et al. **Int J Exp Pathol** 1999 Feb;80(1):11-6

Granulocyte colony-stimulating factor (G-CSF) dependent hematopoiesis with monosomy 7 in a patient with severe aplastic anemia after ATG/CsA/G-CSF combined therapy. Nishimura M, et al. **Int J Hematol** 1998 Aug; 68(2):203-11

Inhibition of type II collagen-induced arthritis in rats by triptolide. Gu WZ, et al. **Int J Immunopharmacol** 1998 Aug; 20(8):389-400

Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues. Komesli S, et al. **Int J Immunopharmacol** 1999 May;21(5):349-58

Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Takeuchi I, et al. **Int J Urol** 1998 Sep;5(5):476-81

Cyclosporin A mono-therapy in nephrotic syndrome with contra-indication of steroid therapy. Hayashi T, et al. **Intern Med** 1999 Mar;38(3):272-5

Cytophagic histiocytic panniculitis improved by combined CHOP and cyclosporin A treatment [see comments] Ito M, et al. **Intern Med** 1999 Mar;38(3):296-301. Comment in: Intern Med 1999 Mar;38(3):224-5.

Successful treatment of a patient with febrile, lobular panniculitis (Weber-Christian disease) with oral cyclosporin A: implications for pathogenesis and therapy [see comments] Iwasaki T, et al. **Intern Med** 1999 Jul; 38(7):612-4. Comment in: Intern Med 1999 Jul;38(7):522.

Cytophagic histiocytic panniculitis--what is the best therapy? [editorial; comment] Okamura T, et al. **Intern Med** 1999 Mar;38(3):224-5 (11 ref.). Comment on: Intern Med 1999 Mar;38(3):296-301.

Long-term open-trial of mizoribine with prednisolone in 24 patients with multiple sclerosis: safety, clinical and magnetic resonance imaging outcome. Saida K, et al. **Intern Med** 1999 Aug;38(8):636-42

Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Yoshida T, et al. **Intern Med** 1999 Sep; 38(9):733-8

The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Hingorani M, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):392-9

Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis [editorial; comment] Bieber T. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):555-7 (12 ref.). Comment on: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):637-44.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group [see comments] Boguniewicz M, et al. **J Allergy Clin Immunol** 1998 Oct; 102(4 Pt 1):637-44. Comment in: J Allergy Clin Immunol 1998 Oct;102(4 Pt 1):555-7.

Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. Grundmann-Kollmann M, et al. **J Am Acad Dermatol** 1999 Jun;40(6 Pt 1):957-60

Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. Heilborn JD, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 1):741-9

Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia. Ilyas W, et al. **J Am Acad Dermatol** 1999 Aug;41(2 Pt 2):316-8

Mycophenolate mofetil in autoimmune and inflammatory skin disorders. Nousari HC, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 1):265-8

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. Nousari HC, et al. **J Am Acad Dermatol** 1999 May; 40(5 Pt 1):750-4 (24 ref.)

Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. Weichert G, et al. **J Am Acad Dermatol** 1998 Oct;39(4 Pt 1):648-50

Peripheral ulcerative keratitis--an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy. Wilson DM, et al. **J Am Acad Dermatol** 1999 Feb;40(2 Pt 2):331-4

Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. Dantal J, et al. **J Am Soc Nephrol** 1998 Sep;9(9):1709-15

Mycophenolate mofetil therapy in lupus nephritis: clinical observations. Dooley MA, et al. **J Am Soc Nephrol** 1999 Apr;10(4):833-9

Coinhibition of immune and renin-angiotensin systems reduces the pace of glomerulosclerosis in the rat remnant kidney. Hamar P, et al. **J Am Soc Nephrol** 1999 Jan;10 Suppl 11:S234-8

A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe). Ponticelli C, et al. **J Am Soc Nephrol** 1997 Apr; 8(4):638-46

Thalidomide: the past, present, and future. Porche D. **J Assoc Nurses AIDS Care** 1999 Mar-Apr;10(2):82-4

Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy. Ward L, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):844-52

Long-term cyclosporine for resistant Crohn's disease. Lavy A. **J Clin Gastroenterol** 1999 Apr;28(3):254-5

Combination of immunoadsorption therapy and high-dose methylprednisolone in patients with lupus nephritis; possible indications in patients with early stage. Funauchi M, et al. **J Clin Lab Immunol** 1997;49(2):47-57

Short-term oral cyclosporine for chronic idiopathic urticaria [letter] Ilter N, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):67-9

Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A. Schopf RE, et al. **J Eur Acad Dermatol Venereol** 1998 Nov;11(3):234-9

Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis [letter] Sprecher E, et al. **J Eur Acad Dermatol Venereol** 1999 Mar;12(2):197-8

Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. Muramatsu K, et al. **J Hand Surg [Am]** 1999 May; 24(3):586-93

Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. Balfour IC, et al. **J Heart Lung Transplant** 1999 May;18(5):492-5

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. Cook RC, et al. **J Heart Lung Transplant** 1999 May;18(5):420-4

The impact of cytolytic therapy on bronchiolitis obliterans syndrome. Date H, et al. **J Heart Lung Transplant** 1998 Sep;17(9):869-75

Suggested guidelines for the use of tacrolimus in lung-transplant recipients [editorial] Garrity ER Jr, et al. **J Heart Lung Transplant** 1999 Mar;18(3):175-6

Multiglycosidorum tripterygii, a new immunosuppressant, supresses coronary arteriosclerosis after heart transplantation. Hachida M, et al. **J Heart Lung Transplant** 1999 Mar;18(3):248-54

Anti-LFA-1 alpha reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted rats. Harrison PC, et al. **J Heart Lung Transplant** 1999 Apr;18(4):279-84

The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients. Herzberg GZ, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1195-200

Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. Horning NR, et al. **J Heart Lung Transplant** 1998 Aug;17(8):761-7

Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. Meiser BM, et al. **J Heart Lung Transplant** 1998 Aug;17(8):782-8

Preliminary experience with mycophenolate mofetil used after lung transplantation. O'Hair DP, et al. **J Heart Lung Transplant** 1998 Sep;17(9):864-8

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. Onsager DR, et al. **J Heart Lung Transplant** 1999 May;18(5):448-55

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. Parry N, et al. **J Heart Lung Transplant** 1999 May;18(5):441-7

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. Penson MG, et al. **J Heart Lung Transplant** 1999 Jul;18(7):707-13

European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. Reichart B, et al. **J Heart Lung Transplant** 1998 Aug;17(8):775-81

Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. Ross DJ, et al. **J Heart Lung Transplant** 1998 Aug;17(8):768-74

Incomplete adherence after pediatric heart and heart-lung transplantation. Serrano-Ikkos E, et al. **J Heart Lung Transplant** 1998 Dec;17(12):1177-83

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. Taylor DO, et al. **J Heart Lung Transplant** 1999 Apr;18(4):336-45

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. Zuckermann A, et al. **J Heart Lung Transplant** 1999 May;18(5):432-40

Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies. Konno H, et al. **J Hepatobiliary Pancreat Surg** 1999;6(1):1-6 (30 ref.)

Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. Burak KW, et al. **J Hepatol** 1998 Dec;29(6):990-3

Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode. Lohse AW, et al. **J Hepatol** 1999 Jul;31(1):149-55

The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? Papatheodoridis GV, et al. **J Hepatol** 1999 Apr;30(4):731-8 (87 ref.)

Suppressive effect on Theiler's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. Inoue A, et al. **J Immunol** 1998 Nov 15;161(10):5586-93

Complications of lysinuric protein intolerance must be treated with immunosuppressive drugs [published erratum appears in J Inherit Metab Dis 1999 Feb;22(1):73] Di Rocco M, et al. **J Inherit Metab Dis** 1998 Aug;21(6):675-6

Cytokine mRNA expression in peripheral blood cells of immunosuppressed human islet transplant recipients. El-Ouaghlidi A, et al. **J Mol Med** 1999 Jan;77(1):115-7

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. Gobbini MI, et al. **J Neuroimmunol** 1999 Sep 1;99(1):142-9

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. Miller A, et al. **J Neuroimmunol** 1998 Dec 1;92(1-2):113-21

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Wilson HC, et al. **J Neurol Neurosurg Psychiatry** 1999 May;66(5):575-80

Glucocorticosteroid therapy for multiple sclerosis: a critical review. Andersson PB, et al. **J Neurol Sci** 1998 Sep 18; 160(1):16-25 (89 ref.)

Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. Hirohata S, et al. **J Neurol Sci** 1998 Aug 14;159(2):181-5

Immunosuppression for neural xenografts: a comparison of cyclosporin and anti-CD25 monoclonal antibody. Honey CR, et al. **J Neurosurg** 1999 Jul;91(1):109-13

Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis. Lin WY, et al. **J Nucl Med** 1998 Dec;39(12):2137-41

Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. Debray D, et al. **J Pediatr** 1999 Jul; 135(1):111-4

6-Mercaptopurine in chronic ulcerative colitis: two steps forward with another step back? [editorial; comment] Cuffari C, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan; 28(1):17-8. Comment on: J Pediatr Gastroenterol Nutr 1999 Jan;28(1):54-8.

Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis [see comments] Kader HA, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):54-8. Comment in: J Pediatr Gastroenterol Nutr 1999 Jan;28(1):17-8.

Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia [see comments] Aker M, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):237-9. Comment in: J Pediatr Hematol Oncol 1999 May-Jun;21(3):175-6.

Evans syndrome: successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide [letter; comment] Gombakis N, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):248-9. Comment on: J Pediatr Hematol Oncol 1997 Sep-Oct;19(5):433-7.

Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. Moskowitz IP, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb;21(1):77-9

Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. Bochelen D, et al. **J Pharmacol Exp Ther** 1999 Feb; 288(2):653-9

A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. Adams EM, et al. **J Rheumatol** 1999 Feb;26(2):352-60

Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. Fautrel B, et al. **J Rheumatol** 1999 Feb;26(2):373–8

Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. McMurray RW, et al. **J Rheumatol** 1998 Dec;25(12):2364–70

Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol–8 glyceryl caprylate/caprate. Tran HS, et al. **J Surg Res** 1999 May 15;83(2):136–40

Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. Longoria J, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):714–8

Systemic plasmacytosis and polyclonal gammopathy in a dog. Gookin JL, et al. **J Vet Intern Med** 1998 Nov–Dec; 12(6):471–4

Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj. Hodge S, et al. **J Virol** 1999 Oct;73(10):8630–9

Treatment of pemphigus: a local experience. Akhtar SJ, et al. **JPMA J Pak Med Assoc** 1998 Oct;48(10):300–4

Ciclosporin microemulsion preconcentrate treatment of patients with Behçet's disease. Fujino Y, et al. **Jpn J Ophthalmol** 1999 Jul–Aug;43(4):318–26

Immunosuppression enhances atherogenicity of lipid profile after transplantation. Quaschning T, et al. **Kidney Int Suppl** 1999 Jul;71:S235–7

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [letter] Boletis JN, et al. **Lancet** 1999 Aug 14;354(9178):569–70

Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids [letter] Grotz W, et al. **Lancet** 1998 Oct 10;352(9135):1195

Treatment of IgA nephropathy [comment] Harper L, et al. **Lancet** 1999 Mar 13;353(9156):860–2. Comment on: Lancet 1999 Mar 13;353(9156):883–7.

Rescue therapy with mycophenolate mofetil in refractory uveitis [letter] Kilmartin DJ, et al. **Lancet** 1998 Jul 4; 352(9121):35–6

Search for medical treatment for primary biliary cirrhosis [see comments] LaRusso N. **Lancet** 1997 Oct 11; 350(9084):1046. Comment in: Lancet 1998 Jan 17;351(9097):216.

Thalidomide in toxic epidermal necrolysis [letter; comment] Levy R. **Lancet** 1999 Jan 23;353(9149):324. Comment on: Lancet 1998 Nov 14;352(9140):1586–9.

Tacrolimus in refractory polymyositis with interstitial lung disease [letter] Oddis CV, et al. **Lancet** 1999 May 22; 353(9166):1762–3

Myelodysplastic syndrome in an infant: induction of remission by cyclosporin [letter] Porta F, et al. **Lancet** 1998 Nov 14;352(9140):1600–1

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group [see comments] Smolen JS, et al. **Lancet** 1999 Jan 23;353(9149):259–66. Comment in: Lancet 1999 Jan 23;353(9149):257–8. Comment in: Lancet 1999 May 29;353(9167):1883; discussion 1883–4.

Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera. Bouscary D, et al. **Leuk Lymphoma** 1999 May;33(5–6):607–11

Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia [letter] Blanche P, et al. **Leukemia** 1999 Aug; 13(8):1294

Refractory pure red cell aplasia associated with B-CLL: successful treatment with a combination of fludarabine, cyclosporin A and erythropoietin [letter] Shimoni A, et al. **Leukemia** 1999 Jan;13(1):142–3

Suppressive effects of CTLA4-Ig on nasal allergic reactions in presensitized murine model. Sato J, et al. **Life Sci** 1999; 64(9):785–95

Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. Charco R, et al. **Liver Transpl Surg** 1999 May;5(3):204–8

Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Charlton M, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S107–14

Management of posttransplantation viral hepatitis--hepatitis B. Dickson RC. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S73–8 (40 ref.)

Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Herrero JI, et al. **Liver Transpl Surg** 1999 Sep;5(5):414–20

Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Jain AB, et al. **Liver Transpl Surg** 1999 Mar; 5(2):144–50

Use of antilymphocyte induction therapy in liver transplantation: A European perspective. Langrehr JM, et al. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S71–84 (118 ref.)

Neoral/cyclosporine-based immunosuppression. Levy GA. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S37–47 (59 ref.)

Changing perspectives on the role of corticosteroids after liver transplantation. Lucey MR. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S58–63 (26 ref.)

Mycophenolate mofetil as induction therapy after liver transplantation. McDiarmid SV. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S85–9 (19 ref.)

Treatment of liver allograft rejection. Millis JM. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S98–S106 (22 ref.)

Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Renz JF, et al. **Liver Transpl Surg** 1999 Mar;5(2):136–43

Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation. van Mourik ID, et al. **Liver Transpl Surg** 1998 Nov;4(6):491–8

Use of antilymphocyte induction therapy in liver transplantation. Wall WJ. **Liver Transpl Surg** 1999 Jul;5(4 Suppl 1):S64–70 (45 ref.)

Immunosuppressive therapy of lupus nephritis. Dooley MA, et al. **Lupus** 1998;7(9):630–4 (50 ref.)

Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Tam LS, et al. **Lupus** 1998; 7(7):495–7

Foetal rat pancreatic transplantation: posttransplantation development of foetal pancreatic iso- and allografts and suppression of rejection with mycophenolate mofetil (MMF) and cyclosporine based immunesuppression. du Toit D, et al. **Microsc Res Tech** 1998 Nov 15;43(4):347–55

Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. Antoniou EA, et al. **Microsurgery** 1999; 19(2):98–102

Targeted immunosuppressant on trial for rheumatoid arthritis [news] Bonn D. **Mol Med Today** 1998 Jul;4(7):277

Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment. Levine TD, et al. **Muscle Nerve** 1998 Dec;21(12):1724–8

Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. Barr ML, et al. **N Engl J Med** 1998 Dec 10; 339(24):1744–51

Tacrolimus ointment for atopic dermatitis [letter; comment] Marone G. **N Engl J Med** 1998 Dec 10;339(24):1788; discussion 1788–9. Comment on: N Engl J Med 1997 Sep 18;337(12):816–21.

Does cyclosporin A cause cancer? [letter] Landewé RB, et al. **Nat Med** 1999 Jul;5(7):714

Mycophenolate mofetil for primary biliary cirrhosis and sclerosis cholangitis? [letter; comment] Altschuler EL. **Nephrol Dial Transplant** 1999 Mar;14(3):798–9. Comment on: Nephrol Dial Transplant 1998 May;13(5):1325.

Anti-glomerular basement membrane antibody-mediated nephritis: when not to treat [letter; comment] Andrews PA. **Nephrol Dial Transplant** 1999 Apr;14(4):1032–3. Comment on: Nephrol Dial Transplant 1998 Oct;13(10):2674–8.

Immunosuppressive treatment for sclerosing peritonitis [letter; comment] Fagugli RM, et al. **Nephrol Dial Transplant** 1999 May;14(5):1343–5. Comment on: Nephrol Dial Transplant 1998 Jan;13(1):154–9.

Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? [letter] Fritsche L, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1036–8

Mycophenolate-update after it has come of age [editorial] Grinyó JM. **Nephrol Dial Transplant** 1999 Jan;14(1):31–4 (14 ref.)

Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Grinyó JM, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2601–4

Tacrolimus can resolve cyclosporin-induced gingival hyperplasia [letter] Harikrishnan P, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1805–6

Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Haubitz M, et al. **Nephrol Dial Transplant** 1998 Aug;13(8):2074–6

Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. Kobayashi M, et al. **Nephrol Dial Transplant** 1998 Oct;13(10):2501–8

Mycophenolate mofetil in cyclosporin-associated thrombotic microangiopathy. Lecornu-Heuze L, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3212–3

The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Madsen JK, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2327–34

Retroperitoneal fibrosis and membranous nephropathy. Improvement of both diseases after treatment with steroids and immunosuppressive agents. Moroni G, et al. **Nephrol Dial Transplant** 1999 May;14(5):1303–5

Does cyclosporin have a role in the treatment of membranous nephropathy? [editorial] Ponticelli C, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):23–5 (15 ref.)

Rapamycin on trial [editorial] Sacks SH. **Nephrol Dial Transplant** 1999 Sep;14(9):2087–9 (8 ref.)

Nephrotic syndrome associated with hypocomplementaemic urticarial vasculitis syndrome: successful treatment with cyclosporin A. Soma J, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1753–7

Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. Sud K, et al. **Nephrol Dial Transplant** 1999 Jul;14(7):1698–703

Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil. Wüthrich RP, et al. **Nephrol Dial Transplant** 1999 Feb; 14(2):394–9

Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression. Gómez E, et al. **Nephron** 1999; 82(3):238–45

Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Hansen JM, et al. **Nephron** 1998 Dec;80(4):450–7

Haemolytic-uraemic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil [letter] McGregor DO, et al. **Nephron** 1998 Nov;80(3):365–6

Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. Nakahama H, et al. **Nephron** 1999;81(4):421–7

Decrease of apoptosis rate in patients with renal transplantation treated with mycophenolate mofetil. Pardo-Mindán FJ, et al. **Nephron** 1999;82(3):232–7

Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Kirschner BS. **Neth J Med** 1998 Dec;53(6):S13–8 (13 ref.)

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Goodin DS. **Neuroepidemiology** 1999;18(2):53–63 (33 ref.)

Extended use of glatiramer acetate (Copaxone) for MS [letter; comment] Greenstein JI. **Neurology** 1999 Mar 10; 52(4):897–8. Comment on: Neurology 1998 Mar;50(3):701–8.

Thalidomide shows promising results in patients with multiple myeloma [news] **Oncology (Huntingt)** 1999 May; 13(5):744

Chronic myelogenous leukemia: update on biology and treatment. Faderl S, et al. **Oncology (Huntingt)** 1999 Feb; 13(2):169–80; discussion 181, 184 (75 ref.)

Methotrexate treatment for sarcoid-associated panuveitis. Dev S, et al. **Ophthalmology** 1999 Jan;106(1):111–8

Mycophenolate mofetil therapy [letter; comment] Kilmartin DJ, et al. **Ophthalmology** 1999 Sep;106(9):1645. Comment on: Ophthalmology 1999 Feb;106(2):370–4.

Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease [see comments] Larkin G, et al. **Ophthalmology** 1999 Feb;106(2):370–4. Comment in: Ophthalmology 1999 Sep;106(9):1645.

Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Sloper CM, et al. **Ophthalmology** 1999 Apr;106(4):723–8

Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Walton RC, et al. **Ophthalmology** 1998 Nov;105(11):2028–34

Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. Yang J, et al. **Pathol Int** 1999 Feb;49(2):133–40

Childhood pemphigus vulgaris treated with dapsone: a case report. Bjarnason B, et al. **Pediatr Dermatol** 1998 Sep–Oct; 15(5):381–3

Tacrolimus: effects and side effects. Green MD, et al. **Pediatr Infect Dis J** 1999 Apr;18(4):372–3

Treatment of refractory Evans' syndrome with cyclosporine and prednisone. Uçar B, et al. **Pediatr Int** 1999 Feb; 41(1):104–7

Anti-lymphocyte antibodies late in the course of pediatric renal transplantation. Butani L, et al. **Pediatr Nephrol** 1999 Apr;13(3):192–4

Renal histology and response to cyclosporine in childhood idiopathic nephrotic syndrome [editorial; comment] Niaudet P. **Pediatr Nephrol** 1998 Nov;12(9):744–5. Comment on: Pediatr Nephrol 1998 Nov;12(9):737–43.

Quantitative morphometry of renal biopsies prior to cyclosporine in nephrotic syndrome [see comments] Smoyer WE, et al. **Pediatr Nephrol** 1998 Nov;12(9):737–43 . Comment in: Pediatr Nephrol 1998 Nov;12(9):744–5.

Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome. Takeda A, et al. **Pediatr Nephrol** 1998 Nov;12(9):746–50

Treatment practices of FSGS among North American pediatric nephrologists. Vehaskari VM. **Pediatr Nephrol** 1999 May;13(4):301–3

Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Benfield MR, et al. **Pediatr Transplant** 1999 Feb;3(1):27–32

Mycophenolate mofetil in pediatric renal transplantation [see comments] Benfield MR, et al. **Pediatr Transplant** 1999 Feb; 3(1):33–7. Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.

Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Cao S, et al. **Pediatr Transplant** 1999 Feb;3(1):22–6

Corticosteroid elimination in pediatric solid organ transplantation [editorial; comment] Fine RN, et al. **Pediatr Transplant** 1998 Feb;2(1):3–5 (23 ref.). Comment on: Pediatr Transplant 1998 Feb;2(1):30–4. Comment on: Pediatr Transplant 1998 Feb;2(1):64–9. Comment on: Pediatr Transplant 1998 Feb;2(1):70–5.

Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Furth S, et al. **Pediatr Transplant** 1999 May;

3(2):146–9
Changing cyclosporin A formulation: an analysis in paediatric cardiac transplant recipients. Gennery AR, et al. **Pediatr Transplant** 1999 Aug;3(3):215–8
Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group. Hoyer PF. **Pediatr Transplant** 1998 Feb;2(1):35–9 (24 ref.)
The potential role of rapamycin in pediatric transplantation as observed from adult studies. Kahan BD. **Pediatr Transplant** 1999 Aug;3(3):175–80 (32 ref.)
A prospective trial of steroid cessation after renal transplantation in pediatric patients treated with cyclosporine and mizoribine. Motoyama O, et al. **Pediatr Transplant** 1997 Aug;1(1):29–36
What is the role for mycophenolate mofetil in pediatric renal transplantation? Neu AM, et al. **Pediatr Transplant** 1999 Feb;3(1):83–7
A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients. Roberti I, et al. **Pediatr Transplant** 1999 Aug;3(3):231–5
Mycophenolate mofetil--is it worth the cost? The in-favor opinion [see comments] Seikaly MG. **Pediatr Transplant** 1999 Feb;3(1):79–82 (19 ref.). Comment in: Pediatr Transplant 1999 Feb;3(1):5–9.
Tacrolimus in pediatric renal transplantation: a review. Shapiro R. **Pediatr Transplant** 1998 Nov;2(4):270–6 (50 ref.)
The current status of mycophenolate mofetil in pediatric renal transplantation [editorial; comment] Tönshoff B. **Pediatr Transplant** 1999 Feb;3(1):5–9 (29 ref.). Comment on: Pediatr Transplant 1999 Feb;3(1):33–7. Comment on: Pediatr Transplant 1999 Feb;3(1):79–82.
Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Mehta P, et al. **Pediatrics** 1999 Apr;103(4):e44 (13 ref.)
Thalidomide responsiveness in an infant with Behçet's syndrome. Shek LP, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1295–7
Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Tse JC, et al. **Pharmacotherapy** 1998 Sep–Oct;18(5):988–1000 (81 ref.)
Medications used in the treatment of multiple sclerosis. Schapiro RT. **Phys Med Rehabil Clin N Am** 1999 May; 10(2):437–46, ix (48 ref.)
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1 [see comments] Teitelbaum D, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3842–7. Comment in: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3333–5.
Oral tolerance with copolymer 1 for the treatment of multiple sclerosis [comment] Weiner HL. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3333–5 (53 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Mar 30;96(7):3842–7.
Long-term treatment of lupus nephritis with cyclosporin A. Tam LS, et al. **QJM** 1998 Aug;91(8):573–80
A case of microscopic polyarteritis nodosa with interstitial pneumonia successfully treated with steroid pulse therapy and immunosuppressive agents. Hatama S, et al. **Ren Fail** 1998 Sep;20(5):737–46
Religious reasons for discontinuation of immunosuppressive medications after renal transplant. Subach RA, et al. **Ren Fail** 1999 Mar;21(2):223–6
Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Aaron SD, et al. **Respir Med** 1998 Aug;92(8):1059–65
Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Sato EI, et al. **Rev Assoc Med Bras** 1998 Oct–Dec;44(4):289–93
Methotrexate for sarcoidosis. Baughman RP. **Sarcoidosis Vasc Diffuse Lung Dis** 1998 Sep;15(2):147–9 (27 ref.)
Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Lewis SJ, et al. **Sarcoidosis Vasc Diffuse Lung Dis** 1999 Mar;16(1):87–92
The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A [letter] Capella GL, et al. **Scand J Gastroenterol** 1999 Feb;34(2):220–1
Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus [letter; comment] García-Porrúa C, et al. **Scand J Rheumatol** 1998; 27(6):465–6. Comment on: Scand J Rheumatol 1997;26(1):69.
Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Maeshima E, et al. **Scand J Rheumatol** 1999; 28(1):54–7
Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. Rojkovich B, et al. **Scand J Rheumatol** 1999;28(4):216–21
Ascomycins in dermatology. Paul C, et al. **Semin Cutan Med Surg** 1998 Dec;17(4):256–9 (21 ref.)
Lupus nephritis: novel immunosuppressive modalities and future directions. Tumlin JA. **Semin Nephrol** 1999 Jan; 19(1):67–76 (44 ref.)
Immunosuppression in uveitis therapy. Van Gelder RN, et al. **Springer Semin Immunopathol** 1999;21(2):179–90 (38 ref.)
Immunosuppressive therapy. Jain A, et al. **Surg Clin North Am** 1999 Feb;79(1):59–76 (160 ref.)
Allograft rejection of small bowel transplantation in pigs. Nishida S, et al. **Surg Today** 1998;28(11):1138–45
Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus. Schiel R, et al. **Ther Apher** 1999 Aug;3(3):234–9
Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. Marsh CL. **Ther Drug Monit** 1999 Feb;21(1):27–34
Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. Pou L, et al. **Ther Drug Monit** 1998 Dec;20(6):602–6
Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Kur F, et al. **Thorac Cardiovasc Surg** 1999 Jun;47(3):174–8
A clinical approach to the use of methotrexate for sarcoidosis. Baughman RP, et al. **Thorax** 1999 Aug;54(8):742–6 (61 ref.)
Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Bellotto F, et al. **Thorax** 1999 Apr;54(4):372–4
Long-term azathioprine therapy in two children with steroid-dependent minimal-change nephrotic syndrome. Tanaka H, et al. **Tohoku J Exp Med** 1999 Mar;187(3):273–8
Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Qi Z, et al. **Transpl Immunol** 1998 Jun; 6(2):94–100
Immunosuppression in pancreas transplantation: progress, problems and perspective. Stratta RJ. **Transpl Immunol** 1998 Jun;6(2):69–77 (67 ref.)
Early use of tacrolimus as rescue therapy for refractory liver allograft rejection. Charco R, et al. **Transpl Int** 1998;11 Suppl 1:S313–7
Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. Hauser IA, et al. **Transpl Int** 1998;11 Suppl 1:S73–7
Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. Hernández-Herrera G, et al. **Transpl Int** 1998;11 Suppl 1:S104–6
Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. Horimoto H, et al. **Transpl Int** 1998;11 Suppl 1:S310–2
Tacrolimus for steroid-resistant liver rejection in children. Jara P, et al. **Transpl Int** 1998;11 Suppl 1:S275–7
Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. Jiang H, et al. **Transpl Int** 1999; 12(2):92–9
Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Lange H, et al. **Transpl Int** 1999;12(1):2–9
Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival. Lindner JK, et al. **Transpl Int** 1998;11 Suppl 1:S303–9
Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity. Lipkowitz GS, et al. **Transpl Int** 1999; 12(3):202–7
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Meisel H, et al. **Transpl Int** 1999;12(4):283–7
Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Morris-Stiff G, et al. **Transpl Int** 1998;11 Suppl 1:S334–6
Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: results of an observational study. Morris-Stiff GJ, et al. **Transpl Int** 1999;12(4):288–92
Experience with neoral versus sandimmune in primary liver transplant recipients. Pinson CW, et al. **Transpl Int** 1998; 11 Suppl 1:S278–83
Searching for the optimal management of hepatitis C patients after liver transplantation. Platz KP, et al. **Transpl Int** 1998; 11 Suppl 1:S209–11
Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. Reggiani P, et al. **Transpl Int** 1998;11 Suppl 1:S272–4
Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine. Schorlemmer HU, et al. **Transpl Int** 1998;11 Suppl 1:S340–4
Immunosuppression without prednisone after liver transplantion is safe and associated with normal early graft function: preliminary results of a randomized study. Tisone G, et al. **Transpl Int** 1998;11 Suppl 1:S267–9
Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Vannini SD, et al. **Transpl Int** 1999;12(4):244–9
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. **Transplant Proc** 1999 Feb–Mar; 31(1–2):330–1
Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients. Abouna GM, et al. **Transplant Proc** 1998 Dec;30(8):4077–8
Induction protocols: yesterday, today, and tomorrow. Abramowicz D, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1100–1 (20 ref.)
Treatment with mycophenolate mofetil in kidney transplant patients with organs from donors aged over 60 years: one-year monitoring results. Agraz I, et al. **Transplant Proc** 1999 Sep;31(6):2272–4
Positive effects of tacrolimus in a case of CIDP. Ahlmén J, et al. **Transplant Proc** 1998 Dec;30(8):4194
Enhanced efficacy of repeated anti-CD8 monoclonal antibody therapy by high-dose cyclosporine treatment. Allan JS, et al. **Transplant Proc** 1998 Dec;30(8):4062–3
Generic immunosuppressant use in solid organ transplantation. Alloway RR. **Transplant Proc** 1999 May; 31(3A Suppl):2S–5S (15 ref.)
The replacement of azathioprine by mycophenolate mofetil in pediatric patients with specific risks in renal transplantation. Anguita A, et al. **Transplant Proc** 1999 Sep; 31(6):2279
Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors. Antoniadis A, et al. **Transplant Proc** 1998 Dec;30(8):4085–6
The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases. Bach JF. **Transplant Proc** 1999 Feb–Mar;31(1–2A):16S–18S (19 ref.)
Immunosuppression in liver transplantation: a European survey. Bárcena R, et al. **Transplant Proc** 1999 Sep; 31(6):2427–8
Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Basara N, et al. **Transplant Proc** 1998 Dec;30(8):4087–9
Kidneys from border-age donors in the cyclosporine era: long-term function and outcome. Berardinelli L, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):294–5
In vitro functional properties of antithymocyte globulins: clues for new therapeutic applications? Bonnefoy-Bérard N, et al. **Transplant Proc** 1998 Dec;30(8):4015–7
How to handle mycophenolate mofetil in combination with tacrolimus? Braun F, et al. **Transplant Proc** 1998 Dec; 30(8):4094–5
The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. Braun WE, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1366–9
Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Brennan DC, et al. **Transplant Proc** 1999 May;31(3B Suppl):16S–18S
Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. Brunet M, et al. **Transplant Proc** 1998 Dec;30(8):4068–9
Compliance in pediatric solid organ transplantation. Bunchman TE. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1099
Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. Campistol JM, et al. **Transplant Proc** 1999 Sep;31(6):2267–9
Optimal timing for surveillance endomyocardial biopsies in heart transplant patients receiving antithymocyte globulin induction. Cantarovich M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):79
Increased dosage requirement and rejection after Neoral conversion in pediatric liver transplant patients. Cao S, et al. **Transplant Proc** 1998 Dec;30(8):4322–4
Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients. Carmellini M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1162–4
Primary prophylaxis with tacrolimus in kidney transplants in China. Cheng HM, et al. **Transplant Proc** 1998 Nov; 30(7):3590–1
FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Chiba K, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1230–3
Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups. Cho S, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):322–3
Successful conversion from cyclosporine to azathioprine in elective renal transplant recipients. Chuang FR, et al. **Transplant Proc** 1998 Nov;30(7):3094–6
Oxidation of low-density lipoproteins in renal transplant recipients. Cofan F, et al. **Transplant Proc** 1999 Sep; 31(6):2333–4
Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation. Crespo JF, et al. **Transplant Proc** 1999 Sep;31(6):2261–2
The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis. Cubas A, et al. **Transplant Proc** 1999 Sep;31(6):2265–6
Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy. De Carlis L, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):391–3
Monthly cyclophosphamide pulses in the treatment of

crescentic glomerulonephritis. De La Torre M, et al. **Transplant Proc** 1998 Dec;30(8):3952–4

Study of early corticosteroid withdrawal in cardiac transplantation. Delgado D, et al. **Transplant Proc** 1999 Sep;31(6):2524–5

Effects of leflunomide on experimental autoimmune myocarditis with special reference to the dendritic cells. Dimitrijevic M, et al. **Transplant Proc** 1998 Dec; 30(8):4149–50

Immunosuppression with cyclosporin A in combination with mycophenolate mofetil suppresses rejection of allogeneic fetal rat pancreatic allografts. du Toit DF, et al. **Transplant Proc** 1998 Dec;30(8):4092–3

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups. Ekberg H, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):267–8

Orthotopic small bowel transplantation in pigs without steroids. Escartin A, et al. **Transplant Proc** 1999 Sep; 31(6):2567–8

Excellent long–term survival of low–risk, first renal allografts using cyclosporine/azathioprine double therapy. Faull RJ, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1155–6

Nine–month follow–up of SangCya (Sang–35) in kidney transplant patients after conversion from Sandimmune. First MR, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):324–5

Conversion of stable renal transplant recipients from Sandimmune to Sang–35, a Neoral–equivalent cyclosporine formulation, using a dose–adjusted method. First MR, et al. **Transplant Proc** 1998 Dec;30(8):3955–7

Tacrolimus use in kidney–pancreas recipients is associated with less acute renal dysfunction than cyclosporine. Fleck PR, et al. **Transplant Proc** 1998 Dec;30(8):4070–2

Overview of the clinical experience with Neoral in transplantation. Frei U. **Transplant Proc** 1999 May; 31(3):1669–74 (61 ref.)

Treatment with CTLA4–Ig inhibits rejection of liver allografts from Flt3–ligand–treated donors. Fu F, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):453

Systemic administration of CTLA4–Ig or anti–CD40 ligand antibody inhibits second–set rejection of mouse liver allografts. Fu F, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1244

Effects of deoxyspergualin (DSG) administered in the chronic phase following kidney transplantation. Fudaba Y, et al. **Transplant Proc** 1998 Nov;30(7):3582–3

Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. Fukushima N, et al. **Transplant Proc** 1998 Nov;30(7):3815–7

Use of cyclosporine MEPC (Neoral) in heart transplant recipients. Fukushima N, et al. **Transplant Proc** 1998 Nov; 30(7):3337–8

Cyclosporine in the treatment of steroid–dependent and steroid–resistant idiopathic nephrotic syndrome in children. Garcia C, et al. **Transplant Proc** 1998 Dec;30(8):4156–7

The effect of different immunosuppression on the outcome of pediatric renal transplants. Garcia Meseguer C, et al. **Transplant Proc** 1999 Sep;31(6):2280

Long–term cardiac allograft survival in mice treated with malononitrilamide 715. Gerauer K, et al. **Transplant Proc** 1998 Dec;30(8):4205–6

FK506 rescue therapy for acute renal allograft rejection. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3592–3

FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. Goh BL, et al. **Transplant Proc** 1998 Nov;30(7):3594–5

Comparison of post–liver transplantation electrocardiographic alterations between cyclosporine– and tacrolimus–treated patients. González MG, et al. **Transplant Proc** 1999 Sep;31(6):2423–4

Usefulness of the switch to tacrolimus in liver transplantation. González–Pinto I, et al. **Transplant Proc** 1999 Sep; 31(6):2425–6

The suppression of heart and liver allograft rejection by liver suppressor factor one (LSF–1) and its possible human homologue. Goto S, et al. **Transplant Proc** 1998 Nov; 30(7):3578–9

Mechanisms of suppression of liver allograft rejection by LSF–1. Goto S, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):451–2

Plasma and low–density lipoprotein lipid peroxidation in cyclosporine A–treated children after liver transplant. Granot E, et al. **Transplant Proc** 1998 Dec;30(8):4057–9

Leflunomide effectively treats naturally occurring immune–mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Gregory CR, et al. **Transplant Proc** 1998 Dec;30(8):4143–8

Plasma endothelin in cyclosporine A–treated renal transplant patients. Grekas D, et al. **Transplant Proc** 1999 May; 31(3):1703–5

New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Groth CG, et al. **Transplant Proc** 1998 Dec;30(8):4064–5

Inhibitory effect of 15–deoxyspergualin on coronary arteriosclerosis in the transplanted heart. Hachida M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):143–6

Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. Hachida M, et al. **Transplant Proc** 1999 Aug;31(5):2049–55

FK 506 in cadaveric kidney transplantation from non–heart–beating donors. Hattori R, et al. **Transplant Proc** 1998 Nov;30(7):3801–3

Donor cells that facilitate tolerance to rat heart allografts after posttransplant total lymphoid irradiation and rabbit anti–thymocyte globulin. Hayamizu K, et al. **Transplant Proc** 1999 May;31(3B Suppl):25S–26S

Long–term results and risk factors of quadruple immunosuppression in renal transplantation. Hiesse C, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1111–2

Effect of low–molecular–weight heparin on development of cardiac allograft vascular disease following heart transplantation in rats. Hisatomi K. **Transplant Proc** 1998 Dec;30(8):4337–9

FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. Hoshino Y, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1224–6

Conversion to Sandimmun Neoral in stable renal transplant recipients over 1 year: hepatitis, liver dysfunction, dosing intervals, and therapeutic ranges. Hsieh H, et al. **Transplant Proc** 1998 Nov;30(7):3552–4

Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. Hung CM, et al. **Transplant Proc** 1998 Nov;30(7):3589

Chronic rejection in cyclosporin A treated renal allograft recipients with allopeptide reactive T cells. Iniotaki–Theodoraki A, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1168–70

Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six–month experience. Jirasiritham S, et al. **Transplant Proc** 1998 Nov;30(7):3576–7

Short and long–term results after pretransplant high–dose single ATG–fresenius bolus in cadaveric kidney transplantation. Kaden J, et al. **Transplant Proc** 1998 Dec; 30(8):4011–4

Cyclosporine: a revolution in transplantation. Kahan BD. **Transplant Proc** 1999 Feb–Mar;31(1–2A):14S–15S (27 ref.)

Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. Kandaswamy R, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):602–3

Results of various immunosuppressive regimens at our transplantation center. Karakayali H, et al. **Transplant Proc** 1998 Nov;30(7):3101–2

Cellcept enhances the rate of apoptosis in T cells after renal transplantation. Kasprzycka M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):328

Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. Kato T, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):396

Single–center experience of 60 consecutive simultaneous pancreas–kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. Kaufman DB, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):615–6

Therapeutic strategies for optimal use of novel immunosuppressants. Keown PA. **Transplant Proc** 1999 Jun;31(4):1790–2 (26 ref.)

One–year, single–center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Khosla UM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):274–5

FK–506 (tacrolimus) therapy for an unusual SLE–like disease. Kilian K, et al. **Transplant Proc** 1998 Dec; 30(8):4130–1

Long–term results of cyclosporine monotherapy in renal transplantation. Kim HC, et al. **Transplant Proc** 1998 Nov; 30(7):3539–40

Effect of deflazacort on bone mineral density in renal transplant recipients. Kim MS, et al. **Transplant Proc** 1998 Nov;30(7):3041–2

Neoplanta as a new microemulsion formula of cyclosporine in renal transplantation: comparative study with Neoral for efficacy and safety. Kim SC, et al. **Transplant Proc** 1998 Nov;30(7):3547–8

Immunoglobulin–cytokine fusion molecules: the new generation of immunomodulating agents. Kim YS, et al. **Transplant Proc** 1998 Dec;30(8):4031–6 (40 ref.)

Neoral as the initial immunosuppressant in liver transplantation; conversion from Sandimmune to Neoral in stable patients. Kizilisik AT, et al. **Transplant Proc** 1998 Nov;30(7):3537–8

Monitoring of anti–rejection therapy by serum bile acids after liver transplantation. Klar E, et al. **Transplant Proc** 1998 Nov;30(7):3567–9

Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single–center experience in 40 patients. Kliem V, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1312–3

Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Klupp J, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1113–4

Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. Ko WJ, et al. **Transplant Proc** 1998 Nov;30(7):3339–41

Correlation between Banff classification and reversal of acute renal rejection. Kokado Y, et al. **Transplant Proc** 1998 Nov; 30(7):3064–6

Low–dose tacrolimus (FK 506)–based immunosuppressive protocol in living donor renal transplantation. Kokado Y, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1151–4

Ten years after: long–term effects of cyclosporine–based immunosuppression on renal allograft recipients. Kondo T, et al. **Transplant Proc** 1998 Nov;30(7):3530–2

Nonadherence to immunosuppressive medications: a pilot survey of members of the transplant recipients international organization. Kory L. **Transplant Proc** 1999 Jun; 31(4A):14S–15S

Usefulness of 15–deoxyspergualin for rejection in renal transplantation. Kozaki K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1138–9

Immunosuppressive action of FTY720 for renal allograft a rat model. Kunikata S, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1157–9

Improved outcome of steroid withdrawal in mycophenolate mofetil–treated primary cadaveric renal transplant recipients. Kupin W, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):1131–2

Transplantation without maintenance corticosteroids in 1–haplotype and 2–haplotype HLA matched living–related renal transplant recipients treated with mycophenolate mofetil and cyclosporine. Kupin W, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):744–5

Comparison of two corticosteroid regimens in combination with CellCept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double–blind, randomized, multi–center study. M 55002 Study Group. Lebranchu Y. **Transplant Proc** 1999 Feb–Mar; 31(1–2):249–50

Contemporary immunosuppression in renal transplant recipients: one size does not fit all. Lewis RM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):254–5 (21 ref.)

T–cell growth factors in allograft rejection and tolerance. Li XC, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):342–3 (19 ref.)

Neoral–based immunosuppression in living–related donor liver transplantation. Liu PP, et al. **Transplant Proc** 1998 Nov;30(7):3550–1

Long–term (10–month) pig islet xenograft tolerance using measured total lymphoid irradiation, splenectomy, short–term rabbit antithymocyte globulin, and deoxyspergualin without long–term immunosuppression. Llyung T, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):962–3

Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Lo CM, et al. **Transplant Proc** 1998 Nov;30(7):3587–8

Quadruple induction therapy including antithymocyte globulin or interleukin–2 receptor antibody or FK 506–based induction therapy after liver transplantation. Lohmann R, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):380

Irradiation or temporal variations in immunosuppressive schedules do not prevent graft–versus–host disease following rat limb allotransplantation. Lui LT, et al. **Transplant Proc** 1998 Dec;30(8):3960–1

Comparison of the immunosuppressive and toxic effects of TII and azathioprine. Lulin M, et al. **Transplant Proc** 1998 Nov;30(7):3517–8

Low–dose OKT3 is not effective in the treatment of steroid–resistant acute renal allograft rejections. Lye WC, et al. **Transplant Proc** 1998 Nov;30(7):3106–7

Hepatitis B and C virus–induced diseases and acute rejection after liver transplantation. Maggi U, et al. **Transplant Proc** 1998 Dec;30(8):3946–7

Usefulness of quantitative cytomegalovirus antigenemia determinations in heart transplantation. Manito N, et al. **Transplant Proc** 1999 Sep;31(6):2526–7

Optimal long–term immunotherapy protocols. Mathew TH. **Transplant Proc** 1999 Feb–Mar;31(1–2):1102–3 (5 ref.)

The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Meiser BM, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):84–7

Current use of polyclonal antilymphocyte antibody preparations. Merion RM. **Transplant Proc** 1999 Sep; 31(6):2208–9 (19 ref.)

Depleting effect of antithymocyte globulin on T–lymphocyte subsets in kidney transplantation. Mestre M, et al. **Transplant Proc** 1999 Sep;31(6):2254–5

Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose–Ranging Kidney Transplant Study Group. Miller J. **Transplant Proc** 1999 Feb–Mar;31(1–2):276–7

Cyclosporine in the treatment of autoimmune disorders: a 10–year experience. Mitrovic D, et al. **Transplant Proc** 1998 Dec;30(8):4134

The beneficial effects of FK 506 on living–related renal transplantation in presensitized recipients. Miura S, et al. **Transplant Proc** 1999 Aug;31(5):1973–5

Prolongation of concordant xenograft survival by treatment with FTY720. Miyata Y, et al. **Transplant Proc** 1998 Dec; 30(8):4163–5

Noncompliance after pediatric liver transplantation. Molmenti E, et al. **Transplant Proc** 1999 Feb–Mar; 31(1–2):408

Conversion from cyclosporine to FK 506 as rescue therapy in renal transplantation with poorly steroid–responsive acute rejection. Morales E, et al. **Transplant Proc** 1999 Sep; 31(6):2248–9

Pharmacoeconomic evaluations of immunosuppressive agents. Mozaffari E. **Transplant Proc** 1999 Jun; 31(4A):53S-54S (7 ref.)

Patient compliance with cyclosporine regimen post solid organ transplantation. Mozaffari E, et al. **Transplant Proc** 1999 Jun;31(4A):87S-88S

Is the use of marginal liver grafts justified? Mueller AR, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):401-2

Short- and long-term effects of polyclonal antibodies. Müller TF, et al. **Transplant Proc** 1999 May;31(3B Suppl):12S-15S (21 ref.)

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Mulloy LL, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1210-3

Triple therapy with mycophenolate mofetil versus azathioprine. Muñiz ML, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1144-6

A trial of oral magnesium supplementation in renal transplant recipients receiving cyclosporine. Nguyen T, et al. **Transplant Proc** 1998 Dec;30(8):4317-9

Effect of a new immunosuppressive agent, KF20444, in rat cardiac transplantation. Nomura M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1206-7

Effect of deoxyspergualin on acute and chronic rejection in renal transplantation. Nomura Y, et al. **Transplant Proc** 1998 Nov;30(7):3580-1

Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1999 Feb-Mar;31(1-2):1147-8

Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. Opelz G. **Transplant Proc** 1998 Dec;30(8):4029-30

Effectiveness of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade. Papadimitriou JC, et al. **Transplant Proc** 1998 Dec;30(8):3945

Mycophenolate mofetil in living donor renal allograft recipients. Park K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1133

Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients. Park K, et al. **Transplant Proc** 1998 Nov; 30(7):3575

Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study. Park K, et al. **Transplant Proc** 1998 Nov;30(7):3556-7

Correlation between Banff classification acute rejection scores and reversal of rejection. Park KK, et al. **Transplant Proc** 1998 Nov;30(7):3067-8

New usage paradigms in antibody therapy: safety of the new agents. Pescovitz MD. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1201-2 (27 ref.)

Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. Preuner JG, et al. **Transplant Proc** 1998 Dec;30(8):3943-4

Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients. Puig JM, et al. **Transplant Proc** 1999 Sep;31(6):2259-60

Induction treatment with mycophenolate mofetil, cyclosporine, and low-dose steroids with subsequent early withdrawal in renal transplant patients: results of the Spanish Group. Spanish Group of the CellCept Study. Puig i Mari JM. **Transplant Proc** 1999 Sep;31(6):2256-8

Early steroid withdrawal after liver transplantation. Ramirez CB, et al. **Transplant Proc** 1998 Nov;30(7):3182-3

Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival. Rastellini C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1242-3

Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Rastellini C, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):646-7

Tacrolimus-based immunosuppressive protocols in lung transplantation. Reichenspurner H, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):171-2

Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Reis A, et al. **Transplant Proc** 1998 Dec;30(8):4344-7

Lack of accommodation after long-term survival of hamster xenografts in rats. Ribas Y, et al. **Transplant Proc** 1999 Sep;31(6):2633-4

Does cyclosporine influence the outcome in patients with acute tubular necrosis after renal transplantation. Ritz M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):303

Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. Rodriguez JA, et al. **Transplant Proc** 1999 Sep;31(6):2522-3

Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration. Rodriguez JA, et al. **Transplant Proc** 1999 Sep;31(6):2517-8

Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Sánchez V, et al. **Transplant Proc** 1999 Sep;31(6):2515-6

Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children. Savo AM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1182-3

High risk kidney transplant rejection treatment: cost savings from thymoglobulin. Schnitzler MA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):269-71

Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Schorlemmer HU, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1184-8

Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec;30(8):4153-5

Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4170-3

Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec;30(8):4137-9

Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Schorlemmer HU, et al. **Transplant Proc** 1998 Dec; 30(8):4099-103

The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design. Schroeder TJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):1S-6S (42 ref.)

Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. Schulz T, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):591-2

Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? Scott JS, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):82-3

A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients. Sells RA, et al. **Transplant Proc** 1998 Dec;30(8):4098

Influence of clinical immunosuppression on proinflammatory cytokines and acute-phase proteins. Semenkov VF, et al. **Transplant Proc** 1998 Dec;30(8):4195

Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction. Senn B, et al. **Transplant Proc** 1998 Dec; 30(8):4075-6

Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Seydoux C, et al. **Transplant Proc** 1998 Dec;30(8):4037-43

A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB, et al. **Transplant Proc** 1998 Dec;30(8):4048-53

Validity of open labeled versus blinded trials: a meta-analysis comparing Neoral and Sandimmune. Shah MB, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):217-9

Cyclosporin Neoral and long-term survival of renal grafts. Shaheen FA, et al. **Transplant Proc** 1998 Nov;30(7):3549

Tacrolimus in solid organ transplantation: an update. Shapiro R. **Transplant Proc** 1999 Sep;31(6):2203-5

A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Shapiro R, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1134

A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. Shu KH, et al. **Transplant Proc** 1998 Nov;30(7):3584-6

FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. Song Z, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):981

The effect of cyclosporine vs FK 506 on glucose metabolism. Steinmueller T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1129-30

A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients. Stephan AG, et al. **Transplant Proc** 1998 Nov;30(7):3563-4

IMPDH activity in whole blood and isolated blood cell fraction for monitoring of CellCept-mediated immunosuppression. Storck M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1115-6

Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide. Stosic-Grujicic S, et al. **Transplant Proc** 1998 Dec;30(8):4132-3

Optimal immunosuppression in pancreas transplantation. Stratta RJ. **Transplant Proc** 1999 Feb-Mar;31(1-2):619-21 (17 ref.)

Effects of calcium channel blockers in renal allograft patients receiving cyclosporine. Suh BY, et al. **Transplant Proc** 1998 Nov;30(7):3558-60

Immunosuppressive effect of FTY 720 on rat pancreas allograft. Suzuki K, et al. **Transplant Proc** 1998 Nov; 30(7):3417-8

Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. Suzuki T, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1208-9

Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Szczech LA, et al. **Transplant Proc** 1999 May;31(3B Suppl):9S-11S (14 ref.)

Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. Takeda M, et al. **Transplant Proc** 1998 Nov;30(7):3813-4

Induction and maintenance of tolerance by CTLA-4IG in rat small bowel allografts. Tarumi K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):878-81

Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity. Torras J, et al. **Transplant Proc** 1999 Sep;31(6):2430

Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression. Tsai MK, et al. **Transplant Proc** 1998 Nov;30(7):3125-6

Low systemic exposure to tacrolimus correlates with acute rejection. Undre NA, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):296-8

Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. van den Dorpel MA, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):329

Can antibody prophylaxis allow sparing of other immunosuppressives? Vincenti F, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1246-8

Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Vincenti F. **Transplant Proc** 1999 Sep;31(6):2206-7

Immunosuppressive effect of mycophenolate mofetil with two different dosages in cadaveric renal transplantation: a short study. Wang X, et al. **Transplant Proc** 1998 Nov; 30(7):3573-4

Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Weir MR, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1286-7

Pharmacokinetics of mycophenolic acid in the early period after kidney transplantation. Wollenberg K, et al. **Transplant Proc** 1998 Dec;30(8):4090-1

Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation. Wüthrich RP, et al. **Transplant Proc** 1998 Dec;30(8):4096-7

Preventive efficacy of 15-deoxyspergualin against progression of apoptotic cell death in acute rejection after rat liver transplantation. Yamamoto H, et al. **Transplant Proc** 1998 Dec;30(8):4104-5

Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. Yamashita K, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1178-9

Immunosuppressive effect of FTY 720 on autoimmune diabetes models. Yan H, et al. **Transplant Proc** 1998 Nov; 30(7):3436-7

FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. Yanagawa Y, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1227-9

Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. Yang HC, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1121-4

Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Yoshikawa M, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):898-9

Rescue effect of FTY720 on acute renal rejection in dogs. Yuzawa K, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):872

Nonnephrotoxic, nonatherogenic maintenance therapy in kidney-transplanted patients using MMF-monotherapy: a pilot study. Zanker B, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1142-3

Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Zanker B, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1167

Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. Zuckermann A, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1160-1

Conversion from Sandimmune to Neoral in stable pediatric liver transplant recipients. Zylber-Katz E, et al. **Transplant Proc** 1999 Jun;31(4):1915-7

Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. **Transplantation** 1999 Aug 15;68(3):391-6

Gene expression of the renal endothelin system in renal transplant recipients on cyclosporine A based immunosuppression. Asberg A, et al. **Transplantation** 1999 Apr 15;67(7):1056-60

Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Birkeland SA. **Transplantation** 1998 Nov 15;66(9):1207-10

Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Birkeland SA, et al. **Transplantation** 1999 May 15;67(9):1209-14

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published erratum appears in Transplantation 1999 May 27;67(10):1386] Brennan DC, et al. **Transplantation** 1999 Apr 15;67(7):1011-8

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Cacciarelli TV, et al. **Transplantation** 1998 Oct 27;66(8):1047-52

An analysis of pretransplantation variables associated with

long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Cacciarelli TV, et al. **Transplantation** 1999 Sep 15; 68(5):650-5

"Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Dell'Antonio G, et al. **Transplantation** 1999 Feb 15; 67(3):484-6

Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Dengler TJ, et al. **Transplantation** 1999 Feb 15;67(3):392-8

Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Franz M, et al. **Transplantation** 1998 Nov 15; 66(9):1258-62

Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury [letter] Garcia-Criado FJ, et al. **Transplantation** 1998 Oct 15;66(7):942-3

Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Grant D, et al. **Transplantation** 1999 Apr 27;67(8):1133-7

Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Greenstein S, et al. **Transplantation** 1998 Dec 27;66(12):1718-26

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments] Groth CG, et al. **Transplantation** 1999 Apr 15;67(7):1036-42. Comment in: Transplantation 1999 Apr 15;67(7):937-8.

Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Hausen B, et al. **Transplantation** 1999 Apr 15;67(7):956-62

Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model. Hausen B, et al. **Transplantation** 1999 Feb 15;67(3):354-9

Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Hebert MF, et al. **Transplantation** 1999 Mar 15;67(5):707-12

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Hengster P, et al. **Transplantation** 1999 Jul 27;68(2):310-3

CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis. Herbelin A, et al. **Transplantation** 1999 Sep 15;68(5):616-22

Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Hong JC, et al. **Transplantation** 1999 Sep 15;68(5):701-4

A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Jain AB, et al. **Transplantation** 1998 Nov 27; 66(10):1395-8

Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Jain AB, et al. **Transplantation** 1998 Nov 15;66(9):1193-200

Long-term results of pancreas transplantation under tacrolius immunosuppression. Jordan ML, et al. **Transplantation** 1999 Jan 27;67(2):266-72

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Kahan BD, et al. **Transplantation** 1999 Jan 27;67(2):276-84

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Kahan BD, et al. **Transplantation** 1998 Oct 27;66(8):1040-6

An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy [comment] Kahan BD. **Transplantation** 1999 Jul 15;68(1):12-4. Comment on: Transplantation 1999 Jul 15;68(1):164-5.

Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. Kaufman DB, et al. **Transplantation** 1999 Feb 27;67(4):586-93

A commentary on a randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients [letter] Korvick JA, et al. **Transplantation** 1999 Sep 15;68(5):708-9

Histological outcome of acute cellular rejection in kidney transplantation after treatment with methylprednisolone. Mazzucchi E, et al. **Transplantation** 1999 Feb 15; 67(3):430-4

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B, et al. **Transplantation** 1999 Jan 15;67(1):110-5

The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of lobucavir [1R(1alpha,2beta,3alpha)]-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine against different herpes viruses. Neyts J, et al. **Transplantation** 1999 Mar 15;67(5):760-4

A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Odorico JS, et al. **Transplantation** 1998 Dec 27;66(12):1751-9

Do immunosuppressants directly affect neutrophils, resulting in protection of the liver against ischemia-reperfusion injury? [letter] Ohmori M, et al. **Transplantation** 1998 Oct 15;66(7):940-1

Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. Papadimitriou JC, et al. **Transplantation** 1998 Dec 27;66(12):1741-5

Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Papatheodoridis GV, et al. **Transplantation** 1999 Jul 15;68(1):155-7

Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation [published erratum appears in Transplantation 1999 Feb 15;67(3):495] [see comments] Pascual M, et al. **Transplantation** 1998 Dec 15;66(11):1460-4. Comment in: Transplantation 1999 Aug 27;68(4):592-3.

The clinical usefulness of the renal allograft biopsy in the cyclosporine era: a prospective study. Pascual M, et al. **Transplantation** 1999 Mar 15;67(5):737-41

Early proteinuria in renal transplant recipients treated with cyclosporin. Pérez Fontán M, et al. **Transplantation** 1999 Feb 27;67(4):561-8

Optimization of the immunosuppressive protocol after lung transplantation. Reichenspurner H, et al. **Transplantation** 1999 Jul 15;68(1):67-71

Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Rothwell WS, et al. **Transplantation** 1999 Jul 15;68(1):158-61

FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. Sankary HN, et al. **Transplantation** 1998 Oct 15;66(7):832-7

Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Schrama YC, et al. **Transplantation** 1998 Nov 15;66(9):1175-81

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Shapiro R, et al. **Transplantation** 1999 Feb 15;67(3):411-5

Pediatric renal transplantation under tacrolimus-based immunosuppression. Shapiro R, et al. **Transplantation** 1999 Jan 27;67(2):299-303

Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation. Shen J, et al. **Transplantation** 1998 Sep 27; 66(6):692-8

Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Solez K, et al. **Transplantation** 1998 Dec 27;66(12):1736-40

CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. Tarumi K, et al. **Transplantation** 1999 Feb 27;67(4):520-5

Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. Timmermann W, et al. **Transplantation** 1999 Jun 27;67(12):1555-61

A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Tisone G, et al. **Transplantation** 1999 May 27;67(10):1308-13

Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. Troncoso P, et al. **Transplantation** 1999 Jan 15;67(1):145-51

Long-term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy. Ustüner ET, et al. **Transplantation** 1998 Dec 27; 66(12):1581-7

In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Vallhonrat H, et al. **Transplantation** 1999 Jan 27;67(2):253-8

Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. Vyas S, et al. **Transplantation** 1999 Feb 15;67(3):490-2

Sirolimus: a potent new immunosuppressant for liver transplantation. Watson CJ, et al. **Transplantation** 1999 Feb 27;67(4):505-9

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Woodle ES, et al. **Transplantation** 1999 Sep 15;68(5):608-16

Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Dengler TJ, et al. **Vaccine** 1999 Feb 26; 17(7-8):867-74

Demonstration of multilineage chimerism in a nonhuman primate concordant xenograft model. Ko DS, et al. **Xenotransplantation** 1998 Nov;5(4):298-304

Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-alphaGal antibody in the baboon. Lambrigts D, et al. **Xenotransplantation** 1998 Nov;5(4):274-83

[Advances in the study on immunotherapy of autoimmune disorders] Sun H, et al. **Chung Hua Nei Ko Tsa Chih** 1997 Dec;36(12):836-9 (19 ref.) **(Chi)**

[OKT3 treatment of refractory renal allograft rejection] Xu J, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Apr;35(4):223-5 (Eng. Abstr.) **(Chi)**

[Indications for immunosuppressive therapy in hepatology] Husa P, et al. **Vnitr Lek** 1998 Nov;44(11):665-70 (26 ref.) (Eng. Abstr.) **(Cze)**

[Acquired factor VIII deficiency treated with cyclosporine] Leinøe EB, et al. **Ugeskr Laeger** 1999 Aug 23; 161(34):4762-3 (Eng. Abstr.) **(Dan)**

[Immunosuppressive treatment of patients with a nephrotic syndrome due to minimal change glomerulopathy] Branten AJ, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2832-8 (31 ref.) (Eng. Abstr.) **(Dut)**

[Thalidomide once more in the spotlight (letter; comment)] Bronner GM, et al. **Ned Tijdschr Geneeskd** 1999 Jan 9; 143(2):122. Comment on: Ned Tijdschr Geneeskd 1998 Nov 14;142(46):2509-12. **(Dut)**

[Ofuji's papulo-erythroderma: treatment with cyclosporin A] Jullien D, et al. **Ann Dermatol Venereol** 1998 Sep; 125(9):589-92 (Eng. Abstr.) **(Fre)**

[Immunosuppressive agents in Horton's disease. Which drug for which indication?] Roblot P. **Ann Med Interne (Paris)** 1998 Nov;149(7):441-7 (45 ref.) (Eng. Abstr.) **(Fre)**

[Management of lupus nephritis in Senegal] Diouf B, et al. **Dakar Med** 1997;42(2):145-8 (Eng. Abstr.) **(Fre)**

[Treatment of myasthenia: role of corticoids and immunosuppressive agents (editorial)] Gajdos P. **Presse Med** 1999 Mar 20;28(11):587-9 (Eng. Abstr.) **(Fre)**

[Use of mycophenolate mofetil (MMF) in kidney transplantation: results of a single center trial] Pastural M, et al. **Prog Urol** 1999 Feb;9(1):19-25 (13 ref.) (Eng. Abstr.) **(Fre)**

[Pneumocystis carinii pneumopathy in rheumatoid polyarthritis treated by methotrexate in a patient with pulmonary asbestosis (letter)] Rolland Y, et al. **Rev Med Interne** 1998 Aug;19(8):581-3 **(Fre)**

[Cyclosporin A therapy in a cat with pure red cell aplasia] Mischke R. **Berl Munch Tierarztl Wochenschr** 1998 Nov-Dec;111(11-12):432-7 (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins] Enk AH, et al. **Hautarzt** 1998 Oct;49(10):774-6 (Eng. Abstr.) **(Ger)**

[Mycophenolate mofetil in comparison with other immunosuppressive drugs] Schnülle P, et al. **Internist (Berl)** 1998 Aug;39(8):879-86 (49 ref.) **(Ger)**

[Immunosuppressive therapy in intraocular inflammation. II. Basic principles, indications, contraindications, side-effects] Manthey KF. **Ophthalmologe** 1998 Dec;95(12):846-58 (15 ref.) **(Ger)**

[Immunosuppressive therapy of intraocular inflammation. I. Basic principles, indications, contraindications, side-effects] Manthey KS. **Ophthalmologe** 1998 Nov;95(11):792-804 (15 ref.) **(Ger)**

[Eosinophilic myositis of the extraocular muscles. A case report] Mitra S. **Tierarztl Prax Ausg K Klientiere Heimtiere** 1998 Sep; 26(5):336-40 (Eng. Abstr.) **(Ger)**

[Immunosuppressive therapy in autoimmune diseases] Schwarz-Eywill M. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):93-100 (19 ref.) (Eng. Abstr.) **(Ger)**

[Quality of life following transplantation. The impact ofa new immunosuppressive substance] Lütkes P, et al. **Zentralbl Chir** 1999;124(2):90-4 (Eng. Abstr.) **(Ger)**

[De novo formation of a cavernoma in association with a preformed venous malformation during immunosuppressive treatment] Brunken M, et al. **Zentralbl Neurochir** 1999; 60(2):81-5 (Eng. Abstr.) **(Ger)**

[Nephrotic syndrome refractory to conventional therapy] Ragazzoni E, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):89-94 (Eng. Abstr.) **(Ita)**

[Immunosuppressive treatment strategy in connective tissue diseases] Okada J, et al. **Nippon Rinsho** 1999 Feb; 57(2):432-8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[FK506 for the prophylaxis of graft-versus-host-disease after bone marrow transplantation from HLA-genotypically mismatched unrelated donor] Nishida T, et al. **Rinsho Ketsueki** 1998 Aug;39(8):574-9 (Eng. Abstr.) **(Jpn)**

[Effective treatment combining antithymocyte globulin, cyclosporin A, and granulocyte colony-stimulating factor for atypical paroxysmal nocturnal hemoglobinuria accompanied by bone marrow hypoplasia] Noji H, et al. **Rinsho Ketsueki** 1999 Mar;40(3):240-3 (Eng. Abstr.) **(Jpn)**

[Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors] Yagasaki H, et al. **Rinsho Ketsueki** 1999 May;40(5):382-9 (Eng. Abstr.) **(Jpn)**

[A case of cyclosporin responsive myasthenia gravis with an invasive thymoma] Aoyama K, et al. **Rinsho Shinkeigaku** 1998 May;38(5):465-7 (Eng. Abstr.) **(Jpn)**

[Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis] Wankowicz Z, et al. **Pol Merkuriusz Lek** 1998 Nov; 5(29):304-6 (14 ref.) (Eng. Abstr.) **(Pol)**

[Combined therapy of thrombocytopenia in SLE patient with antiphospholipid syndrome] Reshetniak TM, et al. **Ter Arkh** 1998;70(11):67-8 **(Rus)**

[An unusual effect of cyclosporine A in a patient with chronic lympholeukemia complicated by autoimmune hemolysis

and thrombocytolysis] Vinogradova OA, et al. **Ter Arkh** 1998;70(7):75–7 (12 ref.) **(Rus)**

[Bone marrow transplantation for severe aplastic anemia] Bullorsky EO, et al. **Medicina (B Aires)** 1998;58(2):130–4 (Eng. Abstr.) **(Spa)**

[Safety and efficacy of treatment for severe atopic dermatitis with cyclosporin A and transfer factor] Cordero Miranda MA, et al. **Rev Alerg Mex** 1999 Mar–Apr;46(2):49–57 (Eng. Abstr.) **(Spa)**

[Effect of cyclophosphamide in experimental histoplasmosis in the rat] Gago JG, et al. **Rev Argent Microbiol** 1998 Oct–Dec;30(4):185–9 (Eng. Abstr.) **(Spa)**

[Efficiency of methotrexate in the treatment of cortico-dependent asthmatic patients] Domingo Ribas C, et al. **Rev Clin Esp** 1999 Mar;199(3):142–6 (Eng. Abstr.) **(Spa)**

TOXICITY

Effect of biphenyl dimethyl dicarboxylate on the humoral immunosuppression by ketoconazole in mice. Kim JH, et al. **Arch Pharm Res** 1999 Apr;22(2):124–9

In vitro models to study mechanisms involved in cyclosporine A–mediated glomerular contraction. L'Azou B, et al. **Arch Toxicol** 1999 Aug;73(6):337–45

Indications for, and use of, cytotoxic agents in SLE. Klippel JH. **Baillieres Clin Rheumatol** 1998 Aug;12(3):511–27 (54 ref.)

Immunotoxic effects of organotin compounds in Tapes philippinarum. Cima F, et al. **Chemosphere** 1998 Dec; 37(14–15):3035–45

Different therapeutic and bystander effects by intranasal administration of homologous type II and type IX collagens on the collagen-induced arthritis and pristane-induced arthritis in rats. Lu S, et al. **Clin Immunol** 1999 Jan; 90(1):119–27

Role of corticosteroids in cadmium induced immunotoxicity. Lall SB, et al. **Drug Chem Toxicol** 1999 May;22(2):401–9

New insights into cyclosporine A nephrotoxicity by proteome analysis. Aicher L, et al. **Electrophoresis** 1998 Aug;19(11):1998–2003

Is there a beneficial effect of the calcium channel blocker diltiazem on cyclosporine A nephrotoxicity in rats? Kuhn UD, et al. **Exp Toxicol Pathol** 1998 Sep;50(4–6):484–90

Inhibition of calbindin D28K expression by cyclosporin A in rat kidney: the possible pathogenesis of cyclosporin A–induced hypercalciuria. Yang CW, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1416–26

Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats. Chelmicka-Schorr E, et al. **J Autoimmun** 1998 Aug;11(4):329–34

Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. Johnson DW, et al. **J Pharmacol Exp Ther** 1999 Apr;289(1):535–42

Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. Serkova N, et al. **J Pharmacol Exp Ther** 1999 May;289(2):800–6

Studies of repeated administration of FK-506 on myocardial metabolism in rats. Yoshida A, et al. **J Toxicol Sci** 1998 Dec;23(5):403–9

Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Avdonin PV, et al. **Kidney Int** 1999 Jun;55(6):2407–14

Mechanism of FK 506/520 action on rat renal proximal tubular Na+, K+-ATPase activity. Holtbäck U, et al. **Kidney Int** 1999 Sep;56(3):1014–21

Cyclosporine-induced nephrotoxicity in autoimmune diseases [letter] Ponticelli C, et al. **Kidney Int** 1999 May; 55(5):2075–6

Adenosine receptor antagonism in the prevention of acute cyclosporine A–nephrotoxicity in normal, diabetic and hypertensive rats. Heyne N, et al. **Nephrol Dial Transplant** 1999;14 Suppl 4:23–4

N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Tariq M, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):923–9

Cyclosporin inhibits nitric oxide production in medullary ascending limb cultured cells. Wu MS, et al. **Nephrol Dial Transplant** 1998 Nov;13(11):2814–20

Lacidipine protects against cyclosporine-induced nephrotoxicity in rats. Naidu MU, et al. **Nephron** 1999 Jan; 81(1):60–6

Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Ongrádi J, et al. **Pathol Oncol Res** 1998;4(3):191–9

Rapamycin (sirolimus) inhibits heart cell growth in vitro. Burton PB, et al. **Pediatr Cardiol** 1998 Nov–Dec; 19(6):468–70

An animal model of chronic cyclosporine nephrotoxicity. Porter GA, et al. **Ren Fail** 1999 May–Jul;21(3–4):365–8 (17 ref.)

Aluminum exacerbates cyclosporin induced nephrotoxicity in rats. Tariq M, et al. **Ren Fail** 1999 Jan;21(1):35–48

Renal toxicity of long-term cyclosporin [editorial] Zachariae H. **Scand J Rheumatol** 1999;28(2):65–8 (32 ref.)

Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. Kaminski NE. **Toxicol Lett** 1998 Dec 28;102–103:59–63 (26 ref.)

Down-regulation of protein kinase C: a potential mechanism for 2-amino-3-methylimidazo[4,5-f]quinoline-mediated immunosuppression. Lee YW, et al. **Toxicol Lett** 1998 Dec 28;102–103:79–83

Intestinal T lymphocytes of different rat strains in immunotoxicity. Bruder MC, et al. **Toxicol Pathol** 1999 Mar–Apr;27(2):171–9

In vitro suppressive effect of aflatoxin B1 on murine peritoneal macrophage functions. Moon EY, et al. **Toxicology** 1999 Apr 15;133(2–3):171–9

Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats. Jeong HJ, et al. **Transplant Proc** 1998 Nov;30(7):3596–7

Vitamin E suppresses cyclosporine A–induced increase in the urinary excretion of arachidonic acid metabolites including F2-isoprostanes in the rat model. Kanji VK, et al. **Transplant Proc** 1999 May;31(3):1724–8

Chronopharmacology for deoxyspergualin: toxicity and efficacy in the rat. Uchida H, et al. **Transplantation** 1999 May 15;67(9):1269–74

Tilapia (Oreochromis niloticus) dosed with azathioprine display immune effects similar to those seen in mammals, including apoptosis. Gogal RM Jr, et al. **Vet Immunol Immunopathol** 1999 May;68(2–4):209–27

URINE

Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients. Al-Rawithi S, et al. **Bone Marrow Transplant** 1998 Sep;22(5):485–90

IMMUNOSURVEILLANCE see **MONITORING, IMMUNOLOGIC**

IMMUNOTHERAPY

The effect of chemo- and chemoimmunotherapy on the presence of circulating melanoma cells in peripheral blood. Preliminary results. Szenajch J, et al. **Acta Biochim Pol** 1998;45(1):95–102

Immunological basis for the therapy of multiple sclerosis. Hohlfeld R. **Acta Neurol Belg** 1999 Mar;99(1):40–3 (16 ref.)

Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting. Stinissen P, et al. **Acta Neurol Belg** 1999 Mar;99(1):65–9 (29 ref.)

Allergen-specific immunotherapy for allergic rhinitis: a new insight into its clinical efficacy and mechanism. Ohashi Y, et al. **Acta Otolaryngol Suppl (Stockh)** 1998;538:178–90 (82 ref.)

The labyrinthine ways of cancer immunotherapy--T cell, tumor cell encounter: "how do I lose thee? Let me count the ways". Ellem KA, et al. **Adv Cancer Res** 1998;75:203–49 (247 ref.)

Immunogene therapy of human melanoma. Phase I/II clinical trial. Mackiewicz A, et al. **Adv Exp Med Biol** 1998; 451:557–60

Local immunotherapy. Malling HJ, et al. **Allergy** 1998 Oct; 53(10):933–44 (89 ref.)

Coley toxins immunotherapy: a retrospective review [see comments] Richardson MA, et al. **Altern Ther Health Med** 1999 May;5(3):42–7. Comment in: Altern Ther Health Med 1999 May;5(3):39–40.

Opposite effects of immunotherapy with ovalbumin and the immunodominant T-cell epitope on airway eosinophilia and hyperresponsiveness in a murine model of allergic asthma. Janssen EM, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):21–9

Immunotherapy with antigens and epitopes: pro or con. Rosenwasser LJ, et al. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):4–6 (18 ref.)

First results for resetting the antitumor immune response by immune corrective surgery in colon cancer. Barbera-Guillem E, et al. **Am J Surg** 1998 Oct; 176(4):339–43

Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy. Results of preseasonal treatment in grass pollen rhinitis. Bertoni M, et al. **Ann Allergy Asthma Immunol** 1999 Jan;82(1):47–51

Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology [see comments] Bousquet J, et al. **Ann Allergy Asthma Immunol** 1998 Nov; 81(5 Pt 1):401–5 (57 ref.). Comment in: Ann Allergy Asthma Immunol 1998 Nov;81(5 Pt 1):377.

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Mungan D, et al. **Ann Allergy Asthma Immunol** 1999 May;82(5):485–90

Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy. Bhan R, et al. **Ann Diagn Pathol** 1998 Feb;2(1):55–60

Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation. Brugger W, et al. **Ann N Y Acad Sci** 1999 Apr 30;872:363–71 (22 ref.)

Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. Morse MA, et al. **Ann Surg Oncol** 1999 Mar;6(2):218–23 (71 ref.)

Current perspectives in immunotherapy. Lillehei KO, et al. **Ann Thorac Surg** 1999 Sep;68(3 Suppl):S28–33

Immunologic therapy of multiple sclerosis. Arnason BG. **Annu Rev Med** 1999;50:291–302 (28 ref.)

Dendritic cell vaccines for cancer immunotherapy. Timmerman JM, et al. **Annu Rev Med** 1999;50:507–29 (111 ref.)

The 1st Symposium on Local Cytokine Therapy of Cancer: Interleukin-2, Interferon and Related Cytokines. Hamburg, Germany, 29 April-1 May 1999. Abstracts. **Anticancer Res** 1999 May–Jun;19(3A):1995–2016

Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Csatary LK, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):635–8

Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Hautmann SH, et al. **Anticancer Res** 1999 Jul–Aug;19(4A):2661–3

Clinical experience of EET therapy for 75 advanced cancer patients. Kato M, et al. **Anticancer Res** 1998 Sep–Oct; 18(5D):3941–9

High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Pica F, et al. **Anticancer Res** 1998 Sep–Oct; 18(5A):3571–8

Chemo-immunotherapy in advanced head and neck cancer. Recchia F, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):773–7

What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? Ferguson BJ. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1174–8 (19 ref.)

Allergic fungal rhinosinusitis: experience with immunotherapy. Mabry RL, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1178

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Jensen M, et al. **Biol Blood Marrow Transplant** 1998;4(2):75–83

Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Valenta R, et al. **Biol Chem** 1999 Jul–Aug;380(7–8):815–24 (103 ref.)

CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Buhmann R, et al. **Blood** 1999 Mar 15;93(6):1992–2002

Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors. Fujii S, et al. **Blood** 1999 Jun 15;93(12):4328–35

Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Kutubuddin M, et al. **Blood** 1999 Jan 15;93(2):643–54

Dendritic cells: development, function and potential use for cancer immunotherapy. Avigan D. **Blood Rev** 1999 Mar; 13(1):51–64 (123 ref.)

Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Meehan KR, et al. **Bone Marrow Transplant** 1999 Apr;23(7):667–73

Development of a novel bi-specific monoclonal antibody approach for tumour targeting. Koumarianou AA, et al. **Br J Cancer** 1999 Oct;81(3):431–9

Cellular immunotherapy in haematological malignancies. Reid CD. **Br J Haematol** 1999 Apr;105 Suppl 1:7–10 (31 ref.)

Prospects of immunotherapy for the treatment of prostate carcinoma--a review. Hillman GG, et al. **Cancer Detect Prev** 1999;23(4):333–42 (51 ref.)

Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Gambotto A, et al. **Cancer Gene Ther** 1999 Jan–Feb;6(1):45–53

Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Shi FS, et al. **Cancer Gene Ther** 1999 Jan–Feb; 6(1):81–8

Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Visse E, et al. **Cancer Gene Ther** 1999 Jan–Feb;6(1):37–44

Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Gratama JW, et al. **Cancer Immunol Immunother** 1999 Aug;48(5):263–9

Prerequisites for the immunotherapy of cancer. Pawelec G, et al. **Cancer Immunol Immunother** 1999 Jul;48(4):214–7

Chemotherapy Foundation Symposium XVI. Innovative Cancer Therapy for Tomorrow. New York City, New York, USA. November 11–13, 1998. Abstracts. **Cancer Invest** 1999;17 Suppl 1:1–98

A new hotspot for cancer immunotherapy? [comment] Lewis JJ, et al. **Cancer J Sci Am** 1998 Sep–Oct;4(5):298–9. Comment on: Cancer J Sci Am 1998 Sep–Oct;4(5):316–23.

Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Bauer S, et al. **Cancer Res** 1999 Apr 15;59(8):1961–5

Migration of human dendritic cells after injection in patients with metastatic malignancies. Morse MA, et al. **Cancer Res** 1999 Jan 1;59(1):56–8

Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Richards J, et al. **Cancer Res** 1999 May 1;59(9):2096–101

Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Vollmer CM Jr, et al. **Cancer Res** 1999 Jul 1;59(13):3064–7

The potential of melanoma antigen expression in cancer therapy. Gillespie AM, et al. **Cancer Treat Rev** 1999 Aug;

25(4):219–27 (79 ref.)
Molecular mechanisms of allergen-specific immunotherapy for atopic diseases. Chiang BL.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1998 Sep–Oct;39(5):293–6 (36 ref.)
Colorectal cancer as a model for immunotherapy. Foon KA, et al. **Clin Cancer Res** 1999 Feb;5(2):225–36 (163 ref.)
Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy. Converse PJ, et al. **Clin Diagn Lab Immunol** 1998 Nov;5(6):871–81
Systemic immune response to specific immunotherapy [editorial; comment] Ebner C. **Clin Exp Allergy** 1998 Jul; 28(7):781–3. Comment on: Clin Exp Allergy 1998 Jul;28(7):791–8.
Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients [see comments] Gruber W, et al.
Clin Exp Allergy 1999 Feb;29(2):176–81. Comment in: Clin Exp Allergy 1999 Feb;29(2):143.
Activation of B-lymphocytes during pollen season. Effect of immunotherapy [see comments] Håkansson L, et al.
Clin Exp Allergy 1998 Jul;28(7):791–8. Comment in: Clin Exp Allergy 1998 Jul;28(7):781–3.
Restoration of cytokine imbalance by immunotherapy [editorial; comment] Mavroleon G. **Clin Exp Allergy** 1998 Aug;28(8):917–20 (31 ref.). Comment on: Clin Exp Allergy 1998 Aug;28(8):943–9.
Immunotherapy--anergy, deviation or suppression? [editorial] Smith W, et al. **Clin Exp Allergy** 1998 Aug; 28(8):911–6 (63 ref.)
The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Valenta R, et al. **Clin Exp Allergy** 1999 Jul;29(7):896–904 (68 ref.)
Comparison between the in vitro cytokine production of mononuclear cells of young asthmatics with and without immunotherapy (IT) [see comments] van Bever HP, et al. **Clin Exp Allergy** 1998 Aug;28(8):943–9. Comment in: Clin Exp Allergy 1998 Aug;28(8):917–20.
Do asthmatic children benefit from specific immunotherapy? [editorial; comment] Wahn U. **Clin Exp Allergy** 1999 Feb; 29(2):143 (6 ref.). Comment on: Clin Exp Allergy 1999 Feb;29(2):176–81.
Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12. Shrayer DP, et al.
Clin Exp Metastasis 1999 Feb;17(1):63–70
The effect of anti-gp39 treatment on the intestinal manifestations of acute murine graft-versus-host disease. Stüber E, et al. **Clin Immunol** 1999 Mar;90(3):334–9
Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Wasser SP, et al. **Crit Rev Immunol** 1999;19(1):65–96 (220 ref.)
Cells and cytokines in immunotherapy and gene therapy of cancer. Pawelec G, et al. **Crit Rev Oncog** 1999; 10(1–2):83–127 (382 ref.)
Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. Maloney DG. **Curr Opin Hematol** 1999 Jul;6(4):222–8 (46 ref.)
Immune directed therapy for ovarian carcinoma. Vanderkwaak TJ, et al. **Curr Opin Obstet Gynecol** 1999 Feb;11(1):29–34 (38 ref.)
The use of biological therapy in cancer of the head and neck. Myers JN. **Curr Probl Cancer** 1999 May–Jun;23(3):106–34 (131 ref.)
Long-term extracorporeal photoimmunotherapy for treatment of chronic cutaneous graft-versus-host disease: observations in four patients. Dippel E, et al.
Dermatology 1999;198(4):370–4
Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Leissring MA, et al. **Drugs Aging** 1998 Sep;13(3):193–8 (31 ref.)
Cell microchimerism in patients with recurrent spontaneous abortion: preliminary results. Cadavid A, et al.
Early Pregnancy 1997 Sep;3(3):199–203
Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma. Eggermont AM. **Eur J Cancer** 1998 Jul;34 Suppl 3:S22–6 (47 ref.)
Immunogene therapy of murine fibrosarcoma using IL-15 gene with high translation efficiency. Kimura K, et al.
Eur J Immunol 1999 May;29(5):1532–42
Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. Micheletti F, et al.
Eur J Immunol 1999 Aug;29(8):2579–89
Long-term survival after extended surgical resection of melanoma metastasis and immunotherapy. Meyer T, et al.
Eur J Surg Oncol 1999 Feb;25(1):105–6
Problems raised by the in vitro generation of dendritic cells for use in immunotherapy [letter] Rosenzwajg M, et al.
Exp Hematol 1999 Feb;27(2):387–8
Vascular attack and immunotherapy: a 'two hits' approach to improve biological treatment of cancer [editorial] Dellabona P, et al. **Gene Ther** 1999 Feb;6(2):153–4
Immunotherapy for chronic myeloid leukaemia. Apperley JF, et al. **Hematol Cell Ther** 1998 Oct;40(5):229–32 (23 ref.)
Immunotherapy and experimental approaches for metastatic melanoma. Atkins MB. **Hematol Oncol Clin North Am** 1998 Aug;12(4):877–902, viii (149 ref.)
Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors? Huland E, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1257–62
Stop-flow thoracic perfusion for unresectable pulmonary carcinoma with or without inhalation IL-2 immunotherapy. A prospective randomized study. Lygidakis NJ, et al. **Hepatogastroenterology** 1999 Mar–Apr; 46(26):792–8
Regional IL-2-based immunochemotherapy of colorectal liver metastases. Okuno K, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1263–7 (8 ref.)
Chemotherapy and medical treatment of hepatocellular carcinoma (HCC). Rougier P, et al.
Hepatogastroenterology 1998 Aug;45 Suppl 3:1264–6
Efficacy of anti-intercellular adhesion molecule-1 immunotherapy on immune responses to allogeneic hepatocytes in mice. Bumgardner GL, et al. **Hepatology** 1998 Oct;28(4):1005–12
Immunohistochemically detecting target antigens in patient biopsies for tailoring monoclonal antibody based cancer therapy. Smith NL, et al. **Hum Antibodies** 1999;9(1):61–5
Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins. Xiang J. **Hum Antibodies** 1999;9(1):23–36 (125 ref.)
Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptors. Ito K, et al. **Hum Reprod** 1999 Mar;14(3):650–5
Immunological Approaches to Tumor Therapy. Proceedings of the 4th International Meeting on Idiotypic Network and Tumor Therapy by Gene Therapy and Drug Targeting. Bonn, Germany, March 6–7, 1998. **Hybridoma** 1999 Feb; 18(1):1–112
New perspectives on immunobiology and immunotherapy of melanoma. Nestle FO, et al. **Immunol Today** 1999 Jan; 20(1):5–7
Mechanism and specificity of immunoprotection induced by mycobacterial proteins against experimental tuberculosis in mice. Dhiman N, et al. **Indian J Exp Biol** 1998 Jul; 36(7):663–7
Long-term tumor resistance induced by laser photo-immunotherapy. Chen WR, et al. **Int J Cancer** 1999 May 31;81(5):808–12
Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Federici MF, et al. **Int J Cancer** 1999 Apr 12;81(2):193–8
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Marchand M, et al. **Int J Cancer** 1999 Jan 18;80(2):219–30
Tumor-specific cytokine release by donor T cells induces an effective host anti-tumor response through recruitment of host naive antigen presenting cells. Nagoshi M, et al. **Int J Cancer** 1999 Jan 18;80(2):308–14
Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Pfosser A, et al. **Int J Cancer** 1999 Feb 9;80(4):612–6
Immune and gene therapy for melanoma, and the immunobiology of melanoma. Smith KJ, et al.
Int J Dermatol 1999 Jul;38(7):490–508 (123 ref.)
Lymph nodes and human tumors (review). Lores B, et al.
Int J Mol Med 1998 Apr;1(4):729–33 (51 ref.)
Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. Bratt G, et al.
Int J STD AIDS 1999 Aug;10(8):514–21
Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis. Takashi M, et al. **Int Urol Nephrol** 1998;30(6):713–22
The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Takasaki Y, et al. **Intern Med** 1999 Feb;38(2):175–7 (8 ref.)
Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies. Moss DJ, et al. **J Acquir Immune Defic Syndr** 1999 Aug 1;21 Suppl 1:S80–3 (27 ref.)
Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. Hartl A, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):107–13
The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. Klimek L, et al.
J Allergy Clin Immunol 1999 Jan;103(1 Pt 1):47–53
Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis [see comments] La Rosa M, et al.
J Allergy Clin Immunol 1999 Aug;104(2 Pt 1):425–32. Comment in: J Allergy Clin Immunol 1999 Aug;104(2 Pt 1):267–70.
Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. Lee AN, et al.
J Am Acad Dermatol 1999 Oct;41(4):595–9
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. Nieland JD, et al. **J Cell Biochem** 1999 May 1;73(2):145–52
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. Cangiano T, et al. **J Clin Oncol** 1999 Feb; 17(2):523–8
Measurement and biological correlates of antibody bioactivity during antibody immunotherapies. Hagg DS, et al. **J Immunol Methods** 1998 Oct 1;219(1–2):7–21
RT-PCR quantitation of cytokine responses in vivo from specimens containing small numbers of cells during bioimmunotherapy. Nash MA, et al.
J Immunol Methods 1998 Oct 1;219(1–2):169–79
Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class I, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. Hirose M, et al. **J Immunother** 1999 May;22(3):237–44
Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2. Moltó L, et al. **J Immunother** 1999 May;22(3):260–7
Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer. Rucker R, et al. **J Immunother** 1999 Jan; 22(1):80–4
Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters. Muro MD, et al. **J Investig Allergol Clin Immunol** 1999 May–Jun; 9(3):146–54
Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy. Rogala B, et al.
J Investig Allergol Clin Immunol 1999 May–Jun;9(3):183–9
Potential effect of the administration of substance P and allergen therapy on immunoglobulin E-mediated allergic reactions in human subjects. Patterson R, et al.
J Lab Clin Med 1999 Feb;133(2):189–99
Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy. Apostolopoulos V, et al. **J Mol Med** 1999 May;77(5):427–36 (57 ref.)
Photoimmunotherapy and ovarian cancer: an improbable fiction or a palpable hit? [editorial; comment] Tochner ZA, et al. **J Natl Cancer Inst** 1999 Sep 15;91(18):1526–7. Comment on: J Natl Cancer Inst 1999 Sep 15;91(18):1557–63.
Immunoadsorption therapy for paraneoplastic syndromes. Batchelor TT, et al. **J Neurooncol** 1998 Nov;40(2):131–6
Immunotherapy. Lord GM. **J R Coll Physicians Lond** 1999 Jan–Feb;33(1):61–4
MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases. Dong XD, et al. **J Surg Oncol** 1999 May;71(1):36–45
Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. Naitoh J, et al. **J Urol** 1999 Jul;162(1):46–50
Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. Wagner JR, et al.
J Urol 1999 Jul;162(1):43–5
The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Modiano JF, et al.
J Vet Intern Med 1999 May–Jun;13(3):163–74 (138 ref.)
Keio University International Symposia for Life Sciences and Medicine: Cell Therapy. Tokyo, Japan, January 21–23, 1999. Abstracts. **Keio J Med** 1999 Jan;48 Suppl 1:A1–42
Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group [see comments] **Lancet** 1999 Jul 10;354(9173):116–9. Comment in: Lancet 1999 Jul 10;354(9173):90.
Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer [letter] Maraj BH, et al. **Lancet** 1998 May 23;351(9115):1559–60
Whither Mycobacterium vaccae? [comment] Reichman LB. **Lancet** 1999 Jul 10;354(9173):90. Comment on: Lancet 1999 Jul 10;354(9173):116–9.
Immunotherapy of non-metastatic complication of malignant disease [comment] Stevenson GT. **Lancet** 1999 Jan 30; 353(9150):340. Comment on: Lancet 1999 Jan 30;353(9150):270–3.
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial [see comments] Vermorken JB, et al. **Lancet** 1999 Jan 30;353(9150):345–50. Comment in: Lancet 1999 May 1;353(9163):1524; discussion 1525. Comment in: Lancet 1999 May 1;353(9163):1524–5. Comment in: Lancet 1999 May 1;353(9163):1525–6.
Monoclonal antibodies in the treatment of human B-cell malignancies. Link BK, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):237–49 (89 ref.)
Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Singhal S, et al. **Leuk Lymphoma** 1999 Feb; 32(5–6):505–12
Effects of TGF-beta on the immune system: implications for cancer immunotherapy. de Visser KE, et al.
Leukemia 1999 Aug;13(8):1188–99 (152 ref.)
Cancer immunotherapy: new leads on an elusive goal

[editorial] Goodnow CC. **Med J Aust** 1998 Dec 7-21; 169(11-12):570-1

The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Roilides E, et al. **Med Mycol** 1998;36 Suppl 1:12-25 (191 ref.)

Cancer gene and immunotherapy: rccent developments. Jantscheff P, et al. **Med Oncol** 1999 Jul;16(2):78-85 (112 ref.)

Will modern cancer vaccines reach clinical practice? Masucci G. **Med Oncol** 1999 Apr;16(1):13-6

Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma [letter] Göring HD, et al. **Melanoma Res** 1998 Aug;8(4):379

Immunotherapy for visceral leishmaniasis: ability of factors produced during anti-leishmania responses of skin test positive adults to inhibit peripheral blood mononuclear cell activities associated with visceral leishmaniasis. Holaday BJ. **Mem Inst Oswaldo Cruz** 1999 Jan-Feb;94(1):55-66

Immunotherapy using T cell defined tumor antigens for melanoma. Kawakami Y. **Microbiol Immunol** 1998; 42(12):801-13 (61 ref.)

The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Agrawal B, et al. **Mol Med Today** 1998 Sep;4(9):397-403 (48 ref.)

Pathogenesis and immunointervention strategies for psoriasis. IBC's Inflammatory Skin Disorders. Washington, DC, USA. September 17-18, 1998. Nickoloff BJ. **Mol Med Today** 1998 Dec;4(12):512-3

Heat shock protein--peptide complexes as immunotherapy for human cancer. Przepiorka D, et al. **Mol Med Today** 1998 Nov;4(11):478-84 (48 ref.)

Nasal administration of transforming growth factor-beta1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis. Ishikawa M, et al. **Mult Scler** 1999 Jun;5(3):184-91

Paraneoplastic sensory neuropathy, demyelinating features, and response to immunotherapy [letter; comment] Antoine JC. **Muscle Nerve** 1998 Dec;21(12):1811-3. Comment on: Muscle Nerve 1997 Dec;20(12):1576-82.

Immunotherapy for allergic rhinitis [editorial; comment] Adkinson NF Jr. **N Engl J Med** 1999 Aug 12;341(7):522-4 . Comment on: N Engl J Med 1999 Aug 12;341(7):468-75.

Long-term clinical efficacy of grass-pollen immunotherapy [see comments] Durham SR, et al. **N Engl J Med** 1999 Aug 12;341(7):468-75. Comment in: N Engl J Med 1999 Aug 12;341(7):522-4.

Genentech is poised for an anti-cancer breakthrough. Hoyle R. **Nat Biotechnol** 1998 Oct;16(10):887

Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Bramanti P, et al. **Neurology** 1998 Dec;51(6):1720-3

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Khan OA, et al. **Neurology** 1998 Dec;51(6):1698-702

Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Kuwabara S, et al. **Neurology** 1998 Dec;51(6):1656-60

Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss [editorial; comment] Schwid SR, et al. **Neurology** 1999 Aug 11;53(3):444-5. Comment on: Neurology 1999 Aug 11;53(3):457-65. Comment on: Neurology 1999 Aug 11;53(3):466-72.

Postinfectious pandysautonomia with complete recovery after intravenous immunoglobulin therapy. Venkataraman S, et al. **Neurology** 1998 Dec;51(6):1764-5

Immunotherapy in renal cell carcinoma. Bukowski RM. **Oncology (Huntingt)** 1999 Jun;13(6):801-10; discussion 810, 813 (55 ref.)

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Zehntner S, et al. **Pathology** 1999 May;31(2):116-22

Impediments to successful immunotherapy. Hersey P. **Pharmacol Ther** 1999 Feb;81(2):111-9 (102 ref.)

Immunocytokines: a promising approach to cancer immunotherapy. Lode HN, et al. **Pharmacol Ther** 1998 Dec; 80(3):277-92 (101 ref.)

Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Hu Z, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8161-6

Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Wang CY, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31;96(18):10367-72

Follow-up evaluation of a phase II prostate cancer vaccine trial. Tjoa BA, et al. **Prostate** 1999 Jul 1;40(2):125-9

Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Amigorena S. **Res Immunol** 1998 Sep-Oct; 149(7-8):661-2 (5 ref.)

Cytokines as therapy for opportunistic fungal infections. Kullberg BJ, et al. **Res Immunol** 1998 May-Jun; 149(4-5):478-88; discussion 515 (150 ref.)

Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Maeshima E, et al. **Scand J Rheumatol** 1999; 28(1):54-7

Ganglioside vaccines with emphasis on GM2. Livingston P. **Semin Oncol** 1998 Dec;25(6):636-45 (63 ref.)

Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Ménoret A, et al. **Semin Oncol** 1998 Dec;25(6):654-60 (41 ref.)

Immunization with virus-modified tumor cells. Schirrmacher V, et al. **Semin Oncol** 1998 Dec;25(6):677-96 (66 ref.)

Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Simons JW, et al. **Semin Oncol** 1998 Dec;25(6):661-76 (59 ref.)

Immunotherapeutic approaches to sarcoma. Linehan DC, et al. **Semin Surg Oncol** 1999 Jul-Aug;17(1):72-7 (37 ref.)

Effectiveness of immunochemotherapy for gastric cancer: a review of the current status. Toge T. **Semin Surg Oncol** 1999 Sep;17(2):139-43 (40 ref.)

Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Zhang R, et al. **Thyroid** 1998 Dec;8(12):1137-46

Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2. Calderón-Aranda ES, et al. **Toxicon** 1999 May;37(5):771-82

The development and use of immunotherapy in Africa. Chippaux JP. **Toxicon** 1998 Nov;36(11):1503-6

Immunotherapy for scorpion envenoming in Brazil. Rezende NA, et al. **Toxicon** 1998 Nov;36(11):1507-13

Preliminary study on the expression of HLA-G mRNA in normal placenta and placenta with RSA after immunotherapy. Fan L, et al. **Transplant Proc** 1999 Jun; 31(4):1854-6

Selective immunotherapy of IDDM: a discussion based on new findings from the RIP-LCMV model for autoimmune diabetes. von Herrath MG. **Transplant Proc** 1998 Dec; 30(8):4115-21 (122 ref.)

Dendritic cell-based immunotherapy of renal cell carcinoma. Thurnher M, et al. **Urol Int** 1998;61(2):67-71 (18 ref.)

Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. Mukhopadhyay S, et al. **Vaccine** 1999 Jan 21;17(3):291-300

Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH, et al. **Vox Sang** 1998;74 Suppl 2:483-7 (36 ref.)

Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy. Jurincic-Winkler C, et al. **Zentralbl Bakteriol** 1995 Oct;282(4):409-15

[Therapeutic immuno-intervention in rheumatoid polyarthritis] Sany J. **Rev Med Interne** 1999;20 Suppl 1:33S-34S **(Fre)**

[MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis (see comments)] **Nervenarzt** 1999 Apr;70(4):371-86 (87 ref.) (Eng. Abstr.). Comment in: Nervenarzt 1999 Apr;70(4):297. **(Ger)**

[Immunotherapy of multiple sclerosis. Consensus and controversies (editorial; comment)] Hohlfeld R. **Nervenarzt** 1999 Apr;70(4):297. Comment on: Nervenarzt 1999 Apr;70(4):371-86. **(Ger)**

[Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy?] Mickisch GH. **Urologe A** 1999 Jul;38(4):326-31 (29 ref.) (Eng. Abstr.) **(Ger)**

[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)] Wagner U, et al. **Zentralbl Gynakol** 1999;121(4):190-5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Dendritic cells--strong candidates for immunotherapy] Lund-Johansen F, et al. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2510-4 (40 ref.) (Eng. Abstr.) **(Nor)**

[Present-day concepts concerning immunoprophylaxis and immunotherapy of surgical infections] Pinegin BV, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):61-7 (35 ref.) **(Rus)**

[Etiotropic antibiotic therapy and immunotherapy of patients with pyo-inflammatory processes] Vasina TA, et al. **Antibiot Khimioter** 1998;43(11):28-33 (Eng. Abstr.) **(Rus)**

[Treatment of thrombocytopenias] Bokarev IN. **Klin Med (Mosk)** 1999;77(7):56-9 (0 ref.) **(Rus)**

[Immunotherapy of pulmonary tuberculosis] Khudzik LB, et al. **Probl Tuberk** 1998;(6):23-6 (Eng. Abstr.) **(Rus)**

[The immunological treatment of renal cancer] Tabernero Caturla J, et al. **Med Clin (Barc)** 1999 Mar 13;112(9):340-8 (100 ref.) **(Spa)**

ADVERSE EFFECTS

Acute renal failure after large doses of intravenous immune globulin. Haskin JA, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):800-3

Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma [letter] Micallef IN, et al. **Blood** 1999 Apr 1;93(7):2427-8

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells. Kruit WH, et al. **Cancer Immunol Immunother** 1999 Sep;48(6):331-5

Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer. Onur O, et al. **Clin Rheumatol** 1999;18(1):74-6

Transient leucoderma appearing in an untreated area following contact immunotherapy for alopecia areata. Nasca MR, et al. **Eur J Dermatol** 1998 Mar;8(2):125-6

Vascular leak syndrome: a troublesome side effect of immunotherapy. Immunopharmacology, 39/3 (1998) 255 [letter; comment] Bascon JU. **Immunopharmacology** 1998 Jun;39(3):255, 257. Comment on: Immunopharmacology 1997 Oct;37(2-3):117-32.

Near-fatal anaphylaxis after Hymenoptera venom immunotherapy. Wolf BL, et al. **J Allergy Clin Immunol** 1998 Sep;102(3):527-8

Systemic reactions due to allergen immunotherapy. Karaayvaz M, et al. **J Investig Allergol Clin Immunol** 1999 Jan-Feb;9(1):39-44

Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. Seelig MH, et al. **J Vasc Surg** 1999 Feb;29(2):377-81 (19 ref.)

Diffuse alveolar damage in BCGosis: a rare complication of intravesical bacillus Calmette-Guérin therapy for transitional cell carcinoma. Tan L, et al. **Pathology** 1999 Feb;31(1):55-6

Bladder treatment. Immunotherapy and chemotherapy. Lopez-Beltran A. **Urol Clin North Am** 1999 Aug; 26(3):535-54 (66 ref.)

[Evaluation of allergic-type reactions to antibiotics and rapid immunotherapy] Brunet JL, et al. **Pathol Biol (Paris)** 1999 May;47(5):491-3 (Eng. Abstr.) **(Fre)**

[Clinical evaluation of side effects during immunotherapy with Catalet T in patients with hay fever] Kurowski W, et al. **Pneumonol Alergol Pol** 1997;65(11-12):783-7 (Eng. Abstr.) **(Pol)**

METHODS

Current role of immunotherapy in multiple myeloma. Hájek R, et al. **Acta Med Austriaca** 1998;25(3):79-85 (90 ref.)

Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Boursnell ME, et al. **Adv Exp Med Biol** 1998;451:379-84

Human tumor immunotherapy. New opportunities as well as new challenges. Cerottini JC, et al. **Adv Exp Med Biol** 1998;451:247-50

Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols. Favrot MC, et al. **Adv Exp Med Biol** 1998;451:539-41 (13 ref.)

Potentiation of the bystander effect by immunization combined with suicide gene therapy. Ramesh R, et al. **Adv Exp Med Biol** 1998;451:125-31

Strategies to elicit anti-idiotypic immune response in B-lymphoma patients. Peptide and genetic immunization. Rinaldi M, et al. **Adv Exp Med Biol** 1998;451:323-30 (37 ref.)

Nasal topical immunotherapy [editorial] Muñoz-López F. **Allergol Immunopathol (Madr)** 1999 Jan-Feb;27(1):1-4 (9 ref.) **(Eng, Spa)**

Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Caminschi I, et al. **Am J Respir Cell Mol Biol** 1999 Sep;21(3):347-56

Rush immunotherapy in a dog with severe ragweed and grass pollen allergy. Patterson R, et al. **Ann Allergy Asthma Immunol** 1999 Sep;83(3):213-6

Dendritic cells: a novel therapeutic modality. Luykx-de Bakker SA, et al. **Ann Oncol** 1999 Jan;10(1):21-7 (90 ref.)

Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Jorgensen C, et al. **Ann Rheum Dis** 1999 Mar;58(3):136-41 (48 ref.)

Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma. Elsässer D, et al. **Anticancer Res** 1999 Mar-Apr;19(2C):1525-8

Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-alpha. Tzai TS, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3355-61

Intravesical bacille Calmette-Guérin in the treatment of carcinoma in situ or high-grade superficial bladder carcinoma after radiotherapy for bladder carcinoma. Palou J, et al. **BJU Int** 1999 Mar;83(4):429-31

Targeting cancer therapy. Begent RH. **Br J Cancer** 1999 Jul; 80 Suppl 1:104-9 (27 ref.)

The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens. Litton MJ, et al. **Br J Cancer** 1999 Sep;81(2):359-66

The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation. Haque T, et al. **Br J Haematol** 1999 Aug; 106(2):309-16 (68 ref.)

Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Hrouda D, et al. **Br J Urol** 1998 Oct;82(4):568-73

Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Brown M, et al. **Cancer Gene Ther** 1999 May-Jun;6(3):238-45

Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Saffran DC, et al. **Cancer Gene Ther** 1998 Sep-Oct;5(5):321-30

New chemoimmunotherapy: courtesy of a more flexible Food and Drug Administration. Greenspan EM. **Cancer Invest** 1999;17(5):371-3 (17 ref.)

Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. McHugh RS, et al. **Cancer Res** 1999 May 15;59(10):2433-7

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Bernsen MR, et al. **Cancer Treat Rev** 1999 Apr;25(2):73-82 (123 ref.)

Advances in the biological therapy and gene therapy of malignant disease. Hersh EM, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 2):2623-9 (49 ref.)

Minor histocompatibility antigens as targets for T-cell

therapy after bone marrow transplantation. Warren EH, et al. **Curr Opin Hematol** 1998 Nov;5(6):429–33 (38 ref.)
Immunotherapy safety [letter] Grossan M. **Ear Nose Throat J** 1999 Sep;78(9):665
An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D, et al. **Eur Cytokine Netw** 1999 Mar;10(1):7–15 (48 ref.)
Treatment of neuroblastoma stage 4 with 131I–meta–iodo–benzylguanidine, high–dose chemotherapy and immunotherapy. A pilot study. Klingebiel T, et al. **Eur J Cancer** 1998 Aug;34(9):1398–402
Target molecules for immunotherapy of inflammatory breast carcinomas [letter] Tagliabue E, et al. **Eur J Cancer** 1998 Nov;34(12):1982–3
IL–10–induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. Akdis CA, et al. **FASEB J** 1999 Apr; 13(6):603–9 (74 ref.)
Intratumoral coinjection of adenoviral vectors expressing IL–2 and IL–12 results in enhanced frequency of regression of injected and untreated distal tumors. Addison CL, et al. **Gene Ther** 1998 Oct;5(10):1400–9
Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Diaz RM, et al. **Gene Ther** 1998 Jul;5(7):869–79
Adenovirus–mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Hirschowitz EA, et al. **Gene Ther** 1998 Jul;5(7):975–83
Improving electrotransfection efficiency by post–pulse centrifugation. Li LH, et al. **Gene Ther** 1999 Mar; 6(3):364–72
Can immunotherapy by gene transfer tip the balance against colorectal cancer? Todryk SM, et al. **Gut** 1998 Oct; 43(4):445–9
Immunotherapeutic strategies for cervical squamous carcinoma. van Driel WJ, et al. **Hematol Oncol Clin North Am** 1999 Feb;13(1):259–73 (97 ref.)
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Rosenberg SA. **Immunity** 1999 Mar;10(3):281–7 (79 ref.)
Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. Bergman I, et al. **Int J Cancer** 1999 Aug 12;82(4):538–48
Enhancement of tumor killing using a combination of tumor immunization and HSV–tk suicide gene therapy. Ramesh R, et al. **Int J Cancer** 1999 Jan 29;80(3):380–6
Topical immunotherapy in dermatology. Buckley DA, et al. **Int J Clin Pract** 1999 Mar;53(2):130–7 (135 ref.)
Endotoxin–core antibodies: time for a reappraisal? [editorial; comment] Barclay GR. **Intensive Care Med** 1999 May; 25(5):427–9. Comment on: Intensive Care Med 1999 May;25(5):435–44.
Anticytokine therapy in autoimmune diseases. Nishimoto N, et al. **Intern Med** 1999 Feb;38(2):178–82 (32 ref.)
Sublingual immunotherapy [editorial; comment] Frew AJ, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):267–70 . Comment on: J Allergy Clin Immunol 1999 Aug;104(2 Pt 1):425–32.
Mechanisms of immunotherapeutic intervention by anti–CD40L (CD154) antibody in an animal model of multiple sclerosis. Howard LM, et al. **J Clin Invest** 1999 Jan;103(2):281–90
Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. Boucek RJ Jr, et al. **J Heart Lung Transplant** 1999 May;18(5):460–9
T cells coactivated with immobilized anti–CD3 and anti–CD28 as potential immunotherapy for cancer. Garlie NK, et al. **J Immunother** 1999 Jul;22(4):336–45
Allogeneic cell–mediated and cytokine–activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. Or R, et al. **J Immunother** 1998 Nov; 21(6):447–53
Cellular immunotherapy of advanced human immunodeficiency virus type 1 infection using autologous lymph node lymphocytes: effects on chemokine production. Triozzi PL, et al. **J Infect Dis** 1999 Jan; 179(1):245–8
Enhanced interleukin–2 gene transfer immunotherapy of breast cancer by coexpression of B7–1 and B7–2. Emtage PC, et al. **J Interferon Cytokine Res** 1998 Nov; 18(11):927–37
Inflammation of the brain in Alzheimer's disease: implications for therapy. McGeer PL, et al. **J Leukoc Biol** 1999 Apr; 65(4):409–15 (50 ref.)
T cell mediated immunotherapy for B cell lymphoma. Schultze JL, et al. **J Mol Med** 1999 Mar;77(3):322–31 (134 ref.)
Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo [see comments] Duska LR, et al. **J Natl Cancer Inst** 1999 Sep 15;91(18):1557–63. Comment in: J Natl Cancer Inst 1999 Sep 15;91(18):1526–7.
Neuroblastoma regression and immunity induced by transgenic expression of interleukin–12. Davidoff AM, et al. **J Pediatr Surg** 1999 May;34(5):902–6; discussion 906–7
Adaptive control: a strategy to treat autoimmunity. Sulzer B, et al. **J Theor Biol** 1999 Jan 7;196(1):73–9
Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma. Luo Y, et al. **J Urol** 1999 Oct; 162(4):1519–26
A feasibility study of gene gun mediated immunotherapy for renal cell carcinoma. Seigne J, et al. **J Urol** 1999 Oct; 162(4):1259–63
HAART and host: balancing the response to HIV–1. Highly active antiretroviral therapy [news] Morris K. **Lancet** 1998 Nov 21;352(9141):1686
Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Matthews DC. **Leukemia** 1998 Sep;12 Suppl 1:S33–6 (12 ref.)
Hepatitis B and C: an overview. Bodenheimer HC Jr. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S65–7 (26 ref.)
Management of posttransplantation viral hepatitis C. Shiffman ML. **Liver Transpl Surg** 1998 Sep;4(5 Suppl 1):S79–86 (43 ref.)
Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer. Fleckenstein G, et al. **Med Oncol** 1998 Dec;15(4):212–21 (65 ref.)
Can alpha–immunotherapy succeed where other systemic modalities have failed? [editorial] Allen BJ. **Nucl Med Commun** 1999 Mar;20(3):205–7
Evaluation of UVA–mediated oxidative damage to proteins and lipids in extracorporeal photoimmunotherapy. Reinheckel T, et al. **Photochem Photobiol** 1999 May; 69(5):566–70
Allergen immunotherapy and avoidance. Fawcett WAIV. **Prim Care** 1998 Dec;25(4):869–83 (38 ref.)
Immunotherapy for renal cell cancer. Bower M, et al. **QJM** 1998 Sep;91(9):597–602 (57 ref.)
Immunologic approaches to the treatment of prostate cancer. Harris DT, et al. **Semin Oncol** 1999 Aug;26(4):439–47 (47 ref.)
Recent developments in breast cancer therapy. Hortobagyi GN, et al. **Semin Oncol** 1999 Aug;26(4 Suppl 12):11–20 (149 ref.)
Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Matsumoto G, et al. **Surgery** 1999 Mar;125(3):257–64
One hundred years of cancer immunotherapy: a critical appraisal. Ben–Efraim S. **Tumour Biol** 1999 Jan–Feb; 20(1):1–24 (185 ref.)
[Use of antibodies or their fragments for the treatment of tumors] Douillard JY, et al. **Bull Cancer** 1998 Nov; 85(11):951–9 (29 ref.) (Eng. Abstr.) **(Fre)**
[Immunotherapy of HIV infection] Harrer T. **Wien Med Wochenschr** 1998;148(23–24):560–6 (105 ref.) (Eng. Abstr.) **(Ger)**
[Practical value of immunotherapy in gynecologic oncology] Mallmann P. **Zentralbl Gynakol** 1999;121(4):183–4 **(Ger)**
[Immunotherapy for MDR–TB (multi–drug resistant tuberculosis)––its feasibility] Tsuyuguchi I. **Kekkaku** 1999 Jun;74(6):479–91 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Management of recurrent spontaneous abortion. The efficacy and the problem of immunotherapy] Takeshita T, et al. **Nippon Ika Daigaku Zasshi** 1998 Oct;65(5):421–4 (3 ref.) **(Jpn)**
[New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes] Kawakami Y. **Nippon Naika Gakkai Zasshi** 1998 Dec 10; 87(12):2536–44 (12 ref.) **(Jpn)**
[New therapeutic strategy for autoimmune diseases. 3) Treatment of autoimmune diseases by cytokine signal transduction inhibition] Nishimoto N, et al. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1745–50 (20 ref.) **(Jpn)**
[PRAME protein expressed in leukemia cells as a target molecule for immunotherapy] Ikeda H, et al. **Rinsho Ketsueki** 1999 Jun;40(6):484–6 **(Jpn)**
[The outlook for CD1d–activated dendritic cell immunotherapy] Nieda M, et al. **Rinsho Ketsueki** 1999 Jun; 40(6):472–5 **(Jpn)**
[New therapeutic strategy for malignant lymphoma targeting cell surface antigens] Taji H, et al. **Rinsho Ketsueki** 1999 Jun;40(6):491–3 **(Jpn)**
[BCR/ABL targeted immunotherapy using dendritic cells] Takahashi K, et al. **Rinsho Ketsueki** 1999 Jun;40(6):487–90 **(Jpn)**
[Subclasses of IgG (IgG1–IgG4) in children during specific immunotherapy] Trofimowicz A, et al. **Pol Merkuriusz Lek** 1998 Dec;5(30):354–6 (Eng. Abstr.) **(Pol)**
[Pathogenetic validation of systemic vasculitis treatment] Nasonov EL, et al. **Klin Med (Mosk)** 1999;77(7):15–8 (9 ref.) **(Rus)**
[Changes in functional activity of blood neutrophils in pollenosis patients: effects of specific immunotherapy] Ivanova IP, et al. **Ter Arkh** 1999;71(4):57–60 (Eng. Abstr.) **(Rus)**
[The clinical characteristics and immunotherapy of complicated forms of adenovirus keratoconjunctivitis] Krasnov MM, et al. **Vestn Oftalmol** 1998 Sep–Oct; 114(5):23–8 (Eng. Abstr.) **(Rus)**
[Prospects of immunotropic therapy of traumatic uveitis] Valeeva RG, et al. **Vestn Oftalmol** 1998 Jul–Aug; 114(4):26–8 (9 ref.) (Eng. Abstr.) **(Rus)**
[Immunology of cancer] Abelev GI. **Vestn Ross Akad Med Nauk** 1999;(4):21–5 (41 ref.) (Eng. Abstr.) **(Rus)**
[The immunodiagnosis and immunotherapy of tumors] Kadagidze ZG. **Vestn Ross Akad Med Nauk** 1999;(5):19–22 (14 ref.) (Eng. Abstr.) **(Rus)**
[Effect of homolymph on some elements of antioxidants in peripheral blood of lung cancer patients] Sidorenko IuS, et al. **Vopr Onkol** 1999;45(3):241–4 (Eng. Abstr.) **(Rus)**
[The effect of autolymph on peripheral blood antioxidants in lung cancer patients] Sidorenko IuS, et al. **Vopr Onkol** 1999;45(3):245–8 (Eng. Abstr.) **(Rus)**
[New trends in immunodermatology and treatment of skin diseases] Nordlind K, et al. **Lakartidningen** 1999 Feb 24; 96(8):876–81 (28 ref.) (Eng. Abstr.) **(Swe)**
[Treatment of multiple sclerosis––2. Application of a new immunological basic research is close] Svenningsson A, et al. **Lakartidningen** 1998 Dec 2;95(49):5631–5 (15 ref.) (Eng. Abstr.) **(Swe)**

STANDARDS

[Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology] van Herpen CM, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2613–8 (42 ref.) (Eng. Abstr.) **(Dut)**

STATISTICS & NUMERICAL DATA

Vaccinations and steroids in MS: effects on disease progression and mood. Kollegger H, et al. **Acta Neurol Scand** 1999 Jul;100(1):69–73

TRENDS

Immune therapy for lung cancer: are we getting closer? Bunn PA Jr. **Am J Respir Cell Mol Biol** 1999 Jul;21(1):10–2 (28 ref.)
Immunotherapy for colorectal cancer. Maxwell–Armstrong CA, et al. **Am J Surg** 1999 Apr;177(4):344–8 (64 ref.)
Therapeutic use of monoclonal antibodies: a new era? [news] Zucca E. **Ann Oncol** 1998 Jul;9(7):683–5
Opportunities for future biological therapy in SLE. Wofsy D, et al. **Baillieres Clin Rheumatol** 1998 Aug;12(3):529–41 (51 ref.)
Advances in immunotherapy of hematologic malignancies. Maloney DG. **Curr Opin Hematol** 1998 Jul;5(4):237–43 (39 ref.)
Future perspectives in specific immunotherapy of melanoma. Parmiani G. **Eur J Cancer** 1998 Jul;34 Suppl 3:S42–7 (35 ref.)
Towards immunotherapy of pancreatic cancer. McKenzie IF, et al. **Gut** 1999 Jun;44(6):767–9
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Rosenberg SA. **Immunity** 1999 Mar;10(3):281–7 (79 ref.)
The coming of age of tumour immunotherapy. Ada G. **Immunol Cell Biol** 1999 Apr;77(2):180–5
Advances in cancer immunotherapy. Ockert D, et al. **Immunol Today** 1999 Feb;20(2):63–5 (13 ref.)
Introduction: immunotherapy for multiple myeloma––insights and advances. Stevenson F, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):1–2 (9 ref.)
[Therapeutics of the future for allergy] Sibille G. **Allerg Immunol (Paris)** 1999 Apr;31(4):120–1 (4 ref.) (Eng. Abstr.) **(Fre)**
[Transplantation immunology] Nüsslein H, et al. **Z Arztl Fortbild Qualitatssich** 1999 Mar;93(2):83 **(Ger)**

VETERINARY

Intralesional and topical chemotherapy and immunotherapy. Théon AP. **Vet Clin North Am Equine Pract** 1998 Dec; 14(3):659–71, viii (35 ref.)
Retrospective survey of allergen immunotherapy in canine atopy. Nuttall TJ, et al. **Vet Rec** 1998 Aug 1;143(5):139–42

IMMUNOTHERAPY, ACTIVE

Effect of HIV–specific immune–based therapy in subjects infected with HIV–1 subtype E in Thailand. Churdboonchart V, et al. **AIDS** 1998 Aug 20;12(12):1521–7
Patient acceptance and shortened cycles paint optimistic future for therapeutic vaccine manufacturers [news] **Allergol Immunopathol (Madr)** 1998 Jul–Aug;26(4):201
Immune globulin and vaccine therapy to prevent hepatitis A infection. Levy MJ, et al. **Am J Med** 1998 Nov; 105(5):416–23 (97 ref.)
Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin–2 in peripheral blood lymphocytes. Maraveyas A, et al. **Ann Oncol** 1999 Jul;10(7):817–24
Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Csatary LK, et al. **Anticancer Res** 1999 Jan–Feb;19(1B):629–33
Immunotherapy with recombinant human interleukin 2 in patients with hematological malignancies after bone marrow or peripheral blood stem cell transplantation. Frydecka I, et al. **Arch Immunol Ther Exp (Warsz)** 1999; 47(4):223–7 (40 ref.)
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma––a feasibility study. Reichardt VL, et al. **Blood** 1999 Apr 1;93(7):2411–9
Subcutaneous administration of interleukin–2 and

interferon-alpha 2b in advanced renal cell carcinoma: long-term results. Locatelli MC, et al. **Cancer Detect Prev** 1999;23(2):172-6

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Eggert AA, et al. **Cancer Res** 1999 Jul 15;59(14):3340-5

Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Henry F, et al. **Cancer Res** 1999 Jul 15;59(14):3329-32

Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Ockert D, et al. **Clin Cancer Res** 1996 Jan;2(1):21-8

Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Philip R, et al. **Clin Cancer Res** 1996 Jan;2(1):59-68

Long-term disease-free survival following surgery and active specific immunotherapy with allogeneic vaccine in a patient with high-risk malignant melanoma of the vulva. Piura B, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):83-5

The use of gene transfer in cancer immunotherapy. Dranoff G. **Forum (Genova)** 1998 Oct-Dec;8(4):357-64 (48 ref.)

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Schirrmacher V, et al. **Gene Ther** 1999 Jan; 6(1):63-73

Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Akbar SK, et al. **Immunology** 1999 Jan;96(1):98-108

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Nair SK, et al. **Int J Cancer** 1999 Jul 2;82(1):121-4

Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). Lambert JS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1998 Dec 15;19(5):451-61

Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. Saleh MN, et al. **J Immunother** 1998 Sep;21(5):379-88

Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. Woodlock TJ, et al. **J Immunother** 1999 May;22(3):251-9

Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice. Wu TY, et al. **J Interferon Cytokine Res** 1998 Oct;18(10):829-39

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. Okamoto T, et al. **J Invest Dermatol** 1998 Dec;111(6):1034-9

Induction of human leukocyte antigen (HLA)-A2-restricted and MAGE-3-gene-derived peptide-specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patient. Kanaoka S, et al. **J Surg Oncol** 1999 May;71(1):16-21

BCG immunotherapy of bladder cancer: 20 years on. Alexandroff AB, et al. **Lancet** 1999 May 15; 353(9165):1689-94 (48 ref.)

Immunotherapy for colon cancer [letter; comment] Blot E, et al. **Lancet** 1999 May 1;353(9163):1524; discussion 1525 . Comment on: Lancet 1999 Jan 30;353(9150):345-50. Comment on: Lancet 1999 Jan 30;353(9150):391-9.

Immunotherapy for colon cancer [letter; comment] Bremers AJ, et al. **Lancet** 1999 May 1;353(9163):1524-5. Comment on: Lancet 1999 Jan 30;353(9150):345-50.

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial [see comments] Vermorken JB, et al. **Lancet** 1999 Jan 30;353(9150):345-50 . Comment in: Lancet 1999 May 1;353(9163):1524; discussion 1525. Comment in: Lancet 1999 May 1;353(9163):1524-5. Comment in: Lancet 1999 May 1;353(9163):1525-6.

Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Tripathi PK, et al. **Mol Immunol** 1998 Sep;35(13):853-63

Strategies for the development of vaccines to treat breast cancer. Jäger E, et al. **Recent Results Cancer Res** 1998; 152:94-102 (39 ref.)

Autologous, hapten-modified vaccine as a treatment for human cancers. Berd D, et al. **Semin Oncol** 1998 Dec; 25(6):646-53 (25 ref.)

Active immunotherapy with allogeneic tumor cell vaccines: present status. Chan AD, et al. **Semin Oncol** 1998 Dec; 25(6):611-22 (73 ref.)

Perspective on allogeneic melanoma lysates in active specific immunotherapy. Mitchell MS. **Semin Oncol** 1998 Dec; 25(6):623-35 (29 ref.)

Active immunization against cancer cells: impediments and advances. Velders MP, et al. **Semin Oncol** 1998 Dec; 25(6):697-706 (75 ref.)

Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Schedel I, et al. **Vaccine** 1999 Apr 9; 17(15-16):1837-45

[Experimental study on prevention of pneumoconiosis complicating with tuberculosis by Mycobacterium vaccae] Yang Z, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1997 Dec; 20(6):350-3 (Eng. Abstr.) **(Chi)**

[Outlook for cellular adoptive or vaccine immunotherapy for chronic myeloid leukemia] Buzyn A, et al. **Hematol Cell Ther** 1998 Oct;40(5):222-3 **(Fre)**

[Vaccination therapy of malignant melanoma] Nestle FO, et al. **Ther Umsch** 1999 Jun;56(6):334-7 (Eng. Abstr.) **(Ger)**

[Dendritic cells--strong candidates for immunotherapy] Lund-Johansen F, et al. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2510-4 (40 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Severe uveitis followed by reactive arthritis after bacillus Calmette-Guérin therapy [letter; comment] Chevrel G, et al. **J Rheumatol** 1999 Apr;26(4):1011. Comment on: J Rheumatol 1998 Sep;25(9):1662-5.

Immunotherapy for colon cancer [letter; comment] Lukacs KV, et al. **Lancet** 1999 May 1;353(9163):1525-6. Comment on: Lancet 1999 Jan 30;353(9150):345-50.

Case of the season. Miliary pulmonary granulomatous disease. Secondary to BCG immunotherapy. Page J, et al. **Semin Roentgenol** 1999 Jul;34(3):165-8

METHODS

Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide. Li L, et al. **Biotherapy** 1998;11(4):223-8

Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Kugler A, et al. **Br J Urol** 1998 Oct;82(4):487-93

Immunological properties of gene vaccines delivered by different routes. Oliveira SC, et al. **Braz J Med Biol Res** 1999 Feb;32(2):207-14 (35 ref.)

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Morse MA, et al. **Clin Cancer Res** 1999 Jun; 5(6):1331-8

Immunotherapy of cancer with dendritic cell-based vaccines [editorial] Nair SK. **Gene Ther** 1998 Nov;5(11):1445-6

Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. Yang S, et al. **Gene Ther** 1999 Feb;6(2):253-62

[The efficacy of active specific immunotherapy using modified neoplastic cells in the combined modality treatment of hemoblastoses] Zverkova AS, et al. **Lik Sprava** 1998 Dec;(8):88-94 (Eng. Abstr.) **(Rus)**

TRENDS

New trends in the development of cancer vaccines. Minev BR, et al. **In Vivo** 1998 Nov-Dec;12(6):629-38 (142 ref.)

IMMUNOTHERAPY, ADOPTIVE

Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy. Li PK, et al. **Am J Kidney Dis** 1998 Nov;32(5):813-9

Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles. Goldfarb RH, et al. **Anticancer Res** 1999 May-Jun;19(3A):1663-7

Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation [published erratum appears in Blood 1999 Mar 15;93(6):2141] [see comments] Baurmann H, et al. **Blood** 1998 Nov 15; 92(10):3582-90. Comment in: Blood 1999 Apr 15;93(8):2748-9.

Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Falkenburg JH, et al. **Blood** 1999 Aug 15; 94(4):1201-8

Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Hoyle C, et al. **Blood** 1998 Nov 1;92(9):3318-27

Sialoadhesin-positive host macrophages play an essential role in graft-versus-leukemia reactivity in mice. Müerköster S, et al. **Blood** 1999 Jun 15;93(12):4375-86

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Mutis T, et al. **Blood** 1999 Apr 1;93(7):2336-41

Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Katsanis E, et al. **Bone Marrow Transplant** 1998 Jul;22(2):185-91

Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. Montagna D, et al. **Bone Marrow Transplant** 1998 Oct;22(8):743-50

Targeting human tumours with antigen-specific cytotoxic T-cells. Rickinson AB. **Br J Cancer** 1999 Jul;80 Suppl 1:51-6 (64 ref.)

Successful adoptive immunotherapy for relapse of AML 9 years after T-cell-depleted BMT. Bertz H, et al. **Br J Haematol** 1998 Nov;103(2):563-4

Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Kim JA, et al. **Cancer** 1999 Jul 1;86(1):22-30

Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line. Kim SJ, et al. **Cancer Immunol Immunother** 1999 Jan;47(5):257-64

Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: in vitro and in vivo studies. Leshem B, et al. **Cancer Immunol Immunother** 1999 Jul;48(4):179-88

Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells. Shimizu M, et al. **Cancer Immunol Immunother** 1998 Nov; 47(3):143-8

Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model. Yamamoto T, et al. **Cancer Immunol Immunother** 1999 Jul; 48(4):165-71

Geographical considerations regarding donor leukocyte infusions for the treatment of relapsed hematological malignancies. Spaner D. **Cancer Metastasis Rev** 1998 Jun; 17(2):249-57 (62 ref.)

Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Ganss R, et al. **Cancer Res** 1998 Oct 15;58(20):4673-81

Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Melcher A, et al. **Cancer Res** 1999 Jun 15;59(12):2802-5

Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Nishioka Y, et al. **Cancer Res** 1999 Aug 15;59(16):4035-41

An antigen-targeted approach to adoptive transfer therapy of cancer. Valmori D, et al. **Cancer Res** 1999 May 1; 59(9):2167-73

Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells. Mukai S, et al. **Cell Immunol** 1999 Mar 15;192(2):122-32

Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104. Visonneau S, et al. **Clin Cancer Res** 1997 Oct;3(10):1789-97

Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Visonneau S, et al. **Clin Cancer Res** 1997 Sep;3(9):1491-500

Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Logan TF, et al. **Clin Exp Immunol** 1998 Dec;114(3):347-54

Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Chen L. **Curr Opin Immunol** 1999 Apr; 11(2):219-22 (33 ref.)

Therapeutic modalities. **Curr Opin Oncol** 1998 Nov; 10(6):B209-51

Adoptive immunotherapy after hematopoietic stem cell transplantation. Burt RK, et al. **Curr Opin Oncol** 1998 Nov; 10(6):525-32 (115 ref.)

Costimulatory approaches to adoptive immunotherapy. Liebowitz DN, et al. **Curr Opin Oncol** 1998 Nov; 10(6):533-41 (85 ref.)

Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. Schultze JL, et al. **Curr Opin Oncol** 1998 Nov;10(6):542-7 (31 ref.)

Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Boughton BJ, et al. **Cytokines Cell Mol Ther** 1999 Mar;5(1):1-6

Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Granziero L, et al. **Eur J Immunol** 1999 Apr;29(4):1127-38

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models. Vourka-Karussis U, et al. **Exp Hematol** 1999 Mar;27(3):461-9

Immunological approach to gene therapy of human cancer: improvements through the understanding of mechanism(s) [editorial] Parmiani G. **Gene Ther** 1998 Jul;5(7):863-4

Impact of chimeric immune receptor extracellular protein domains on T cell function. Patel SD, et al. **Gene Ther** 1999 Mar;6(3):412-9

Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. Tsunoda T, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1287-92

Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Ueda Y, et al. **Hepatogastroenterology** 1999 May;46 Suppl 1:1274-9

Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy. Yamaue H, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):620-5

Adjuvant adoptive immunotherapy against hepatocellular carcinoma [letter] Takayama T, et al. **Hepatology** 1998 Nov; 28(5):1436-7

Immunotherapy with T cells bearing chimeric antitumor

receptors [comment] Paillard F. **Hum Gene Ther** 1999 Jan 20;10(2):151–3. Comment on: Hum Gene Ther 1999 Jan 20;10(2):165–73.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases. Hombach A, et al. **Hybridoma** 1999 Feb;18(1):57–61 (10 ref.)

Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Antony S, et al. **Immunol Invest** 1999 Jan; 28(1):1–8

Endogenous and adoptively transferred A–NK and T–LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M, et al. **In Vivo** 1999 May–Jun;13(3):199–204

Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma–specific cytotoxic T cells by bi–specific antibody fragments. Cochlovius B, et al. **Int J Cancer** 1999 May 5;81(3):486–93

Expression of signal transducing T–cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer. Kono K, et al. **Int J Cancer** 1998 Oct 29;78(3):301–5

Intracerebral bispecific ligand–antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Patrick TA, et al. **Int J Cancer** 1998 Nov 9; 78(4):470–9

Cell biology and possible therapeutic applications of anti–CD3–activated killer–T cells (review). Hoskin DW, et al. **Int J Mol Med** 1998 May;1(5):893–902 (117 ref.)

Effects of development of host immunity on the biodistribution of xenogeneic MHC non–restricted cytotoxic T cells: implications for adoptive cell therapy of cancer. Cesano A, et al. **Int J Oncol** 1999 Feb; 14(2):233–44

Biodistribution of human MHC non–restricted TALL–104 killer cells in healthy and tumor bearing mice. Cesano A, et al. **Int J Oncol** 1999 Feb;14(2):245–51

Protection against murine cytomegalovirus retinitis by adoptive transfer of virus–specific CD8+ T cells. Bigger JE, et al. **Invest Ophthalmol Vis Sci** 1999 Oct; 40(11):2608–13

G–CSF–mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation. Mandanas RA, et al. **J Hematother** 1998 Oct;7(5):449–56

Large ex vivo expansion of human umbilical cord blood CD4+ and CD8+ T cells. Skea D, et al. **J Hematother** 1999 Apr;8(2):129–39

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK–92. Tam YK, et al. **J Hematother** 1999 Jun;8(3):281–90

Coinfusion of irradiated splenocytes with low titer tumor–infiltrating lymphocytes augments antitumor efficacy in adoptive immunotherapy. Averbook BJ, et al. **J Immunother** 1999 Mar;22(2):124–34

Adoptive immunotherapy of cancer using monocyte–derived macrophages: rationale, current status, and perspectives. Andreesen R, et al. **J Leukoc Biol** 1998 Oct;64(4):419–26 (82 ref.)

Modeling immunotherapy of the tumor–immune interaction. Kirschner D, et al. **J Math Biol** 1998 Sep;37(3):235–52

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. Höltl L, et al. **J Urol** 1999 Mar;161(3):777–82

Induction of adult T–cell leukemia–like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T–cell–deficient nude rats inoculated with syngeneic human T–cell leukemia virus type 1–immortalized cells. Ohashi T, et al. **J Virol** 1999 Jul;73(7):6031–40

Reduction of end–stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Tsurushima H, et al. **Jpn J Cancer Res** 1999 May;90(5):536–45

The potential for monocyte–mediated immunotherapy during infection and malignancy--Part II: in vivo activation by exogenous cytokines and clinical applications. Williams MA, et al. **Leuk Lymphoma** 1999 Jul;34(3–4):207–30 (123 ref.)

The potential for monocyte–mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Williams MA, et al. **Leuk Lymphoma** 1999 Jun;34(1–2):1–23 (123 ref.)

Adoptive immunotherapy for cutaneous T–cell lymphomas. Sastry PS. **Med Hypotheses** 1999 Apr;52(4):353–4

Activation of autologous or HLA–identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Osman Y, et al. **Oncol Rep** 1999 Sep–Oct;6(5):1057–63

CD80 and IL–2 signals cooperate in the regression of tumors transplanted in congenitally athymic mice. Sobota V, et al. **Oncol Rep** 1999 May–Jun;6(3):669–73

Adoptive immunotherapy. Hurwitz JL, et al. **Pediatr Infect Dis J** 1999 May;18(5):467–8

Adoptive immunotherapy for Epstein–Barr virus–associated lymphoproliferative disorders complicating marrow allografts. O'Reilly RJ, et al. **Springer Semin Immunopathol** 1998;20(3–4):455–91 (228 ref.)

Clinical effect of immunochemotherapy for a patient with advanced gallbladder cancer: report of a case. Murakami K, et al. **Surg Today** 1998;28(9):923–8

Correlation of the therapeutic effect of activated tumor–draining lymph node cells with specific interferon–gamma production in vitro. Sameshima S, et al. **Surg Today** 1999;29(1):55–62

Suicide–gene–transduced T–cells for the regulation of the graft–versus–leukemia effect. Bonini C, et al. **Vox Sang** 1998;74 Suppl 2:341–3 (7 ref.)

Gene and cell transfer for specific immunotherapy. Brenner MK, et al. **Vox Sang** 1998;74 Suppl 2:87–90 (20 ref.)

Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Kolb HJ. **Vox Sang** 1998;74 Suppl 2:321–9 (71 ref.)

EBV specific CTL: a model for immune therapy. Rooney CM, et al. **Vox Sang** 1998;74 Suppl 2:497–8 (6 ref.)

Immunological characteristics of nonpregnant women with unexplained recurrent spontaneous abortion who underwent paternal lymphocytes immunization. Malinowski A, et al. **Zentralbl Gynakol** 1998; 120(10):493–502

[Experimental and clinical research of cytolytic T lymphocytes specific for hepatocellular carcinoma] Shen F, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Feb;35(2):95–9 (Eng. Abstr.) **(Chi)**

[Outlook for cellular adoptive or vaccine immunotherapy for chronic myeloid leukemia] Buzyn A, et al. **Hematol Cell Ther** 1998 Oct;40(5):222–3 **(Fre)**

ADVERSE EFFECTS

GVL and GVHD following the infusion of a limited number of donor CD3 cells in the therapy of leukaemia relapse after bone marrow transplantation [letter] du Toit C, et al. **Eur J Haematol** 1999 Jan;62(1):68–9

METHODS

Stable expression of a retrovirally transferred adhesion molecule in a human tumor–specific CTL clone. Perspectives for the ex vivo manipulation of effector cells used in adoptive immunotherapy. Cochlovius B, et al. **Adv Exp Med Biol** 1998;451:345–8

Adoptive immunotherapy with tumor–infiltrating lymphocytes and subcutaneous recombinant interleukin–2 plus interferon alfa–2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group. Queirolo P, et al. **Ann Surg Oncol** 1999 Apr–May;6(3):272–8

The use of BRM–activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Ebina T, et al. **Biotherapy** 1998;11(4):241–53

Delivery of methoxymorpholinyl doxorubicin by interleukin 2–activated NK cells: effect in mice bearing hepatic metastases. Quintieri L, et al. **Br J Cancer** 1999 Mar; 79(7–8):1067–73

Induction of therapeutic T–cell immunity by tumor targeting with soluble recombinant B7–immunoglobulin costimulatory molecules. Moro M, et al. **Cancer Res** 1999 Jun 1;59(11):2650–6

Long–term connexin–mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Duflot–Dancer A, et al. **Gene Ther** 1998 Oct;5(10):1372–8

Methotrexate selectable retroviral vectors for Gaucher disease. Havenga MJ, et al. **Gene Ther** 1998 Oct; 5(10):1379–88

Vaccine effect of granulocyte–macrophage colony–stimulating factor or CD80 gene–transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Nakazaki Y, et al. **Gene Ther** 1998 Oct;5(10):1355–62

Polyethylenimine–mediated transfection of human monocytes with the IFN–gamma gene: an approach for cancer adoptive immunotherapy. Ringenbach L, et al. **Gene Ther** 1998 Nov;5(11):1508–16

Characterization of genetically altered, interleukin 2–independent natural killer cell lines suitable for adoptive cellular immunotherapy. Tam YK, et al. **Hum Gene Ther** 1999 May 20;10(8):1359–73

Immunotherapy with effector cells and IL–2 of lymph node metastases of human squamous–cell carcinoma of the head and neck established in nude mice. Chikamatsu K, et al. **Int J Cancer** 1999 Aug 12;82(4):532–7

Antigen–specific cytotoxicity and cell number of adoptively transferred T cells are efficiently maintained in vivo by re–stimulation with an antigen/interleukin–2 fusion protein. Kang BY, et al. **Int J Cancer** 1999 Aug 12;82(4):569–73

OK–432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Takahashi K, et al. **Int J Immunopharmacol** 1998 Aug; 20(8):375–88

Lymphotactin gene–modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. Cao X, et al. **J Immunol** 1998 Dec 1;161(11):6238–44

Retrovirally transduced bone marrow–derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. De Veerman M, et al. **J Immunol** 1999 Jan 1;162(1):144–51

Cutting edge: rapid cloning of tumor–specific CTL suitable for adoptive immunotherapy of melanoma. Dunbar PR, et al. **J Immunol** 1999 Jun 15;162(12):6959–62

4–1BBL cooperates with B7–1 and B7–2 in converting a B cell lymphoma cell line into a long–lasting antitumor vaccine. Guinn BA, et al. **J Immunol** 1999 Apr 15; 162(8):5003–10

Induction of antitumor immunity with Fas/APO–1 ligand (CD95L)–transfected neuroblastoma neuro–2a cells. Shimizu M, et al. **J Immunol** 1999 Jun 15;162(12):7350–7

Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene–modified tumor–primed lymph node cells. Tanaka H, et al. **J Immunol** 1999 Mar 15;162(6):3574–82

Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha–galactosylceramide. Toura I, et al. **J Immunol** 1999 Sep 1;163(5):2387–91

Mononuclear–cell immunisation in prevention of recurrent miscarriages: a randomised trial. Ober C, et al. **Lancet** 1999 Jul 31;354(9176):365–9

Why are dendritic cells central to cancer immunotherapy? Colaco CA. **Mol Med Today** 1999 Jan;5(1):14–7 (36 ref.)

Enhancement of interleukin–2–induced lymphokine–activated killer activity by interleukin 7 against autologous human renal cell carcinoma. Kondo M, et al. **Oncology** 1998 Nov–Dec;55(6):588–93

Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Sumareva R, et al. **Radiat Oncol Investig** 1999;7(1):22–9

Adoptive T–cell therapy. Lokhorst HM, et al. **Semin Hematol** 1999 Jan;36(1 Suppl 3):26–9 (6 ref.)

IMMUNOTHERAPY, ALLERGEN see **DESENSITIZATION, IMMUNOLOGIC**

IMMUNOTHERAPY, PASSIVE see **IMMUNIZATION, PASSIVE**

IMMUNOTOXINS

Human pancreatic RNase1–human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas. Psarras K, et al. **Protein Eng** 1998 Dec;11(12):1285–92

ADMINISTRATION & DOSAGE

Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Wenning LA, et al. **Biotechnol Bioeng** 1999 Mar 5; 62(5):562–75

Delivery of methoxymorpholinyl doxorubicin by interleukin 2–activated NK cells: effect in mice bearing hepatic metastases. Quintieri L, et al. **Br J Cancer** 1999 Mar; 79(7–8):1067–73

Pharmacokinetics and antitumor activity of a bivalent disulfide–stabilized Fv immunotoxin with improved antigen binding to erbB2. Bera TK, et al. **Cancer Res** 1999 Aug 15;59(16):4018–22

Host–mediated antibody–dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti–CD7–saporin immunotoxin in a severe combined immunodeficient mouse model of human T–cell acute lymphoblastic leukemia. Flavell DJ, et al. **Cancer Res** 1998 Dec 15;58(24):5787–94

Efficacy of compartmental administration of immunotoxin LMB–1 (B3–LysPE38) in a rat model of carcinomatous meningitis. Bigner DD, et al. **Clin Cancer Res** 1995 Dec; 1(12):1545–55

A possibility to overcome P–glycoprotein (PGP)–mediated multidrug resistance by antibody–targeted drugs conjugated to N–(2–hydroxypropyl)methacrylamide (HPMA) copolymer carrier. St'astný M, et al. **Eur J Cancer** 1999 Mar;35(3):459–66

[Preparation and in vitro activity of monoclonal antibody–pharmorubicin immunoconjugates] Xu FH, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):632–6 (Eng. Abstr.) **(Chi)**

[Targeted immunotherapy for malignant tumors] Turuo T. **Rinsho Ketsueki** 1999 Jun;40(6):476–9 (7 ref.) **(Jpn)**

ADVERSE EFFECTS

Immunological disorders in men exposed to metallic mercury vapour. A review. Moszczyński P. **Cent Eur J Public Health** 1999 Feb;7(1):10–4 (57 ref.)

Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain–containing immunotoxins. Baluna R, et al. **Clin Cancer Res** 1996 Oct;2(10):1705–12

Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody–specific mode: relevance to vascular leak syndrome. Kuan CT, et al. **Clin Cancer Res** 1995 Dec; 1(12):1589–94

A critique of the World Resources Institute's report "Pesticides and the immune system: the public health risks" [see comments] Acquavella J, et al. **Environ Health Perspect** 1998 Feb;106(2):51–4. Comment in: Environ Health Perspect 1998 Feb;106(2):A52–4.

Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. Anderson JM, et al. **J Controlled Release** 1999 Feb 1;57(2):107–13 (21 ref.)

Deficit in selective and divided attention associated with cholinergic basal forebrain immunotoxic lesion produced by 192–saporin; motoric/sensory deficit associated with Purkinje cell immunotoxic lesion produced by

OX7-saporin. Waite JJ, et al. **Neurobiol Learn Mem** 1999 May;71(3):325-52

BLOOD

Development of an immunoassay for BMS-191352, a single-chain immunotoxin, and its application to toxicokinetic studies. Damle B, et al. **J Immunoassay** 1998 May-Aug;19(2-3):145-65

CHEMISTRY

Production and characterisation of a recombinant single-chain anti ErbB2-clavin immunotoxin. D'Alatri L, et al. **Anticancer Res** 1998 Sep-Oct;18(5A):3369-73

Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bera TK, et al. **Bioconjug Chem** 1998 Nov-Dec;9(6):736-43

IMMUNOLOGY

Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Montagna D, et al. **Blood** 1999 May 15;93(10):3550-7

Antiparasite activity of sea-anemone cytolysins on Giardia duodenalis and specific targeting with anti-Giardia antibodies. Tejuca M, et al. **Int J Parasitol** 1999 Mar; 29(3):489-98

Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. Knechtle SJ, et al. **Transplant Proc** 1999 May;31(3B Suppl):27S-28S

Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Rodriguez ME, et al. **Vaccine** 1998 Dec; 16(20):1941-9

ISOLATION & PURIFICATION

Single-step purification of immunotoxins containing a high ionic charge ribosome inactivating protein clavin by carboxymethyl high-performance membrane chromatography. Dosio F, et al. **J Chromatogr A** 1999 Jan 15;830(2):329-35

METABOLISM

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Gu DL, et al. **Cancer Res** 1999 Jun 1;59(11):2608-14

The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. Hauck ML, et al. **Clin Cancer Res** 1998 Sep;4(9):2071-7

Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Schmidt M, et al. **Oncogene** 1999 Mar 4;18(9):1711-21

The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2. Hu HY, et al. **Protein Eng** 1998 Sep; 11(9):811-7

PHARMACOKINETICS

Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Wenning LA, et al. **Biotechnol Bioeng** 1999 Mar 5; 62(5):562-75

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Rosenblum MG, et al. **Cancer Chemother Pharmacol** 1999;44(4):343-8

Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen. Chan MC, et al. **Cancer Immunol Immunother** 1999 Feb; 47(6):321-9

Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Bera TK, et al. **Cancer Res** 1999 Aug 15;59(16):4018-22

In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Perentesis JP, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2217-27

Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Rosenblum MG, et al. **Clin Cancer Res** 1999 Apr;5(4):865-74

Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Uckun FM, et al. **Clin Cancer Res** 1997 Mar;3(3):325-37

In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Waurzyniak B, et al. **Clin Cancer Res** 1997 Jun;3(6):881-90

Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice. Kinuya S, et al. **Jpn J Cancer Res** 1998 Aug;89(8):870-8

Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Muzykantov VR, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2379-84

[Preparation of hepatic targeting antivirus agent NGA-ACV and its targeting property] Fan JZ, et al. **Yao Hsueh Hsueh Pao** 1996;31(8):585-90 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Atochina EN, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):L806-17

Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: effects of physostigmine and FG 7142. McGaughy J, et al. **Behav Neurosci** 1998 Dec; 112(6):1519-25

Interactions between 192-IgG saporin and intraseptal cholinergic and GABAergic drugs: role of cholinergic medial septal neurons in spatial working memory. Pang KC, et al. **Behav Neurosci** 1999 Apr;113(2):265-75

Role of caspases in immunotoxin-induced apoptosis of cancer cells. Keppler-Hafkemeyer A, et al. **Biochemistry** 1998 Dec 1;37(48):16934-42

Quantitative analysis of protein synthesis inhibition and recovery in CRM107 immunotoxin-treated HeLa cells. Wenning LA, et al. **Biotechnol Bioeng** 1998 Feb 20; 57(4):484-96

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Klimka A, et al. **Br J Cancer** 1999 Jun;80(8):1214-22

Differential effects of 192IgG-saporin and NMDA-induced lesions into the basal forebrain on cholinergic activity and taste aversion memory formation. Gutiérrez H, et al. **Brain Res** 1999 Jul 10;834(1-2):136-41

Neural and behavioral effects of intracranial 192 IgG-saporin in neonatal rats: sexually dimorphic effects? Sherren N, et al. **Brain Res Dev Brain Res** 1999 Apr 12;114(1):49-62

Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Arora N, et al. **Cancer Res** 1999 Jan 1;59(1):183-8

Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Husain SR, et al. **Clin Cancer Res** 1997 Feb;3(2):151-6

Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Reiter Y, et al. **Clin Cancer Res** 1996 Feb; 2(2):245-52 (62 ref.)

Changes in electrocortical power and coherence in response to the selective cholinergic immunotoxin 192 IgG-saporin. Holschneider DP, et al. **Exp Brain Res** 1999 May; 126(2):270-80

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Kreitman RJ, et al. **Int J Cancer** 1999 Mar 31; 81(1):148-55

Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Rosendahl A, et al. **Int J Cancer** 1999 Mar 31;81(1):156-63

A membrane-lytic immunoconjugate selective for human tumor T-lymphocytes. Hinman CL, et al. **Int J Immunopharmacol** 1998 Sep;20(9):467-78

Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Barth S, et al. **Int J Mol Med** 1998 Jan;1(1):249-56

An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production. Pullerits T, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):843-9

Responses in the aged rat brain after total immunolesion. Gu Z, et al. **J Neurosci Res** 1998 Oct 1;54(1):7-16

Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells. Gho YS, et al. **Mol Cells** 1999 Feb 28;9(1):31-6

An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. McCoig C, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28;96(20):11482-5

The effect of immunotoxins directed against CD80 and CD86 on primary T-cell alloresponses. Otten HG, et al. **Tissue Antigens** 1998 Sep;52(3):270-4

Immunotoxicity of pesticides: a review. Voccia I, et al. **Toxicol Ind Health** 1999 Jan-Mar;15(1-2):119-32 (115 ref.)

Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. Hamawy MM, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):785

Toward preclinical studies with anti-CD86 immunotoxin. Otten HG, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1236

THERAPEUTIC USE

New drugs in the treatment of Hodgkin's disease. Borchmann P, et al. **Ann Oncol** 1998;9 Suppl 5:S103-8 (52 ref.)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Cheng TL, et al. **Br J Cancer** 1999 Mar;79(9-10):1378-85

Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Scadden DT, et al. **Cancer** 1998 Dec 15;83(12):2580-7

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Moro M, et al. **Cancer Res** 1999 Jun 1;59(11):2650-6

Targeted diagnosis and treatment of superficial bladder cancer with monoclonal antibody BDI-1. Yu L, et al. **Chin Med J (Engl)** 1998 May;111(5):404-7

A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Akamatsu Y, et al. **Clin Cancer Res** 1998 Nov; 4(11):2825-32

Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Benhar I, et al. **Clin Cancer Res** 1995 Sep;1(9):1023-9

Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Dean GS, et al. **Clin Cancer Res** 1998 Oct;4(10):2545-50

Recombinant F(ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Debinski W, et al. **Clin Cancer Res** 1995 Sep;1(9):1015-22

Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Debinski W, et al. **Clin Cancer Res** 1995 Nov;1(11):1253-8

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Hank JA, et al. **Clin Cancer Res** 1996 Dec;2(12):1951-9

Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification. Kasprzyk PG, et al. **Clin Cancer Res** 1996 Jan;2(1):75-80

Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Multani PS, et al. **Clin Cancer Res** 1998 Nov;4(11):2599-604

In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Perentesis JP, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2217-27

Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Rosenblum MG, et al. **Clin Cancer Res** 1999 Apr;5(4):865-74

Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Seon BK, et al. **Clin Cancer Res** 1997 Jul;3(7):1031-44

Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Skrepnik N, et al. **Clin Cancer Res** 1996 Nov;2(11):1851-7

Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy. Buske C, et al. **Eur J Cancer** 1999 Apr; 35(4):549-57 (99 ref.)

A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation. Maurer-Gebhard M, et al. **Hybridoma** 1999 Feb; 18(1):69-75

A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Brenner T, et al. **Immunol Lett** 1999 Jun 1;68(2-3):403-10

Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Boyer CM, et al. **Int J Cancer** 1999 Aug 12;82(4):525-31

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Kahán Z, et al. **Int J Cancer** 1999 Aug 12;82(4):592-8

Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. McLendon RE, et al. **Int J Radiat Oncol Biol Phys** 1999 Sep 1;45(2):491-9

Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results. Clark DS, et al. **J Cataract Refract Surg** 1998 Dec;24(12):1614-20

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. Tolcher AW, et al. **J Clin Oncol** 1999 Feb;17(2):478-84

The use of an anti-CD3 immunotoxin to prevent the development of lymphoproliferative disease in SCID/PBL mice. Clinchy B, et al. **J Immunol Methods** 1998 Sep 1; 218(1-2):141-53

Recombinant oncotoxin AR209 (anti-P185erbB-2)

diminishes human prostate carcinoma xenografts. Skrepnik N, et al. **J Urol** 1999 Mar;161(3):984–9
Monoclonal antibodies in the treatment of human B–cell malignancies. Link BK, et al. **Leuk Lymphoma** 1998 Oct; 31(3–4):237–49 (89 ref.)
Evaluation of temozolomide in a SCID mouse model of human B–cell precursor leukemia. Messinger Y, et al. **Leuk Lymphoma** 1999 Apr;33(3–4):289–93
DT388–GM–CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte–macrophage colony–stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Hall PD, et al. **Leukemia** 1999 Apr; 13(4):629–33
GM–CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM–CSF. Rozemuller H, et al. **Leukemia** 1998 Dec;12(12):1962–70
HIV pathogenesis: gp120–antibody complexes bind CD4 and kill T4 cells--immunotoxin therapy should prevent the progression of HIV to AIDS. Chaplin JW. **Med Hypotheses** 1999 Feb;52(2):133–46 (126 ref.)
Smartbombs and cloaking devices [news; comment] Wagner RW, et al. **Nat Biotechnol** 1999 Mar;17(3):227–8. Comment on: Nat Biotechnol 1999 Mar;17(3):265–70.
Interleukin–4 receptor–directed cytotoxin therapy of AIDS–associated Kaposi's sarcoma tumors in xenograft model [see comments] Husain SR, et al. **Nat Med** 1999 Jul;5(7):817–22. Comment in: Nat Med 1999 Jul;5(7):738–9.
Targeting AIDS–Kaposi's sarcoma [news; comment] Mesri EA. **Nat Med** 1999 Jul;5(7):738–9. Comment on: Nat Med 1999 Jul;5(7):817–22.
Sterically stabilized anti–G(M3), anti–Le(x) immunoliposomes: targeting to B16BL6, HRT–18 cancer cells. Nam SM, et al. **Oncol Res** 1999;11(1):9–16
Synergy between an antiangiogenic integrin alphav antagonist and an antibody–cytokine fusion protein eradicates spontaneous tumor metastases. Lode HN, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1591–6
Preparation of a conjugate of mitomycin C and anti–neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma. Tanaka J, et al. **Surg Today** 1998;28(11):1217–20
Idarubicin–anti–CD3 reduces vascular disease in mouse cardiac allografts. Mottram PL, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1414–5
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Reiter Y, et al. **Trends Biotechnol** 1998 Dec;16(12):513–20 (54 ref.)

TOXICITY

Cytotoxic effect of binar cisplatin immunoconjugate. Plotnikov VM. **Adv Exp Med Biol** 1998;451:151–2
Monoclonal antibody 138H11 against gamma–glutamyltransferase provides a possible tool for targeting calicheamicin theta to renal cell carcinomas. Schmidt CS, et al. **Adv Exp Med Biol** 1998;451:431–6
A humanized single–chain Fv fragment with high targeting potential against human malignant gliomas. Ohtomo T, et al. **Anticancer Res** 1998 Nov–Dec;18(6A):4311–5
Ricin A immunotoxins of IgG and Fab of anti–CALLA monoclonal antibody: effect of water soluble long–chain SPDP on conjugate yield, immunoselectivity and cytotoxicity. Woo BH, et al. **Arch Pharm Res** 1994 Dec; 17(6):452–7
Antiproliferative effect of immunoliposomes containing 5–fluorodeoxyuridine–dipalmitate on colon cancer cells. Koning GA, et al. **Br J Cancer** 1999 Aug;80(11):1718–25
Selective immunotoxin–induced cholinergic deafferentation alters blood flow distribution in the cerebral cortex. Waite JJ, et al. **Brain Res** 1999 Feb 6;818(1):1–11
Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Rosenblum MG, et al. **Cancer Chemother Pharmacol** 1999;44(4):343–8
Selenium effects on gallium arsenide induced biochemical and immunotoxicological changes in rats. Flora SJ, et al. **Chem Biol Interact** 1999 Aug 30;122(1):1–13
In situ (mesocosm) assessment of immunotoxicity risks to small mammals inhabiting petrochemical waste sites. Propst TL, et al. **Chemosphere** 1999 Feb;38(5):1049–67
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Lorimer IA, et al. **Clin Cancer Res** 1995 Aug;1(8):859–64
Induction of apoptosis in multidrug–resistant and radiation–resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony–stimulating factor receptor. Perentesis JP, et al. **Clin Cancer Res** 1997 Mar; 3(3):347–55
Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin–based immunotoxins and its potential inhibition with nonsteroidal anti–inflammatory drugs. Siegall CB, et al. **Clin Cancer Res** 1997 Mar;3(3):339–45
In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti–CD7)–pokeweed antiviral protein immunotoxin. Waurzyniak B, et al. **Clin Cancer Res** 1997 Jun;3(6):881–90
Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192–IgG saporin lesions of the nucleus basalis magnocellularis. Bednar I, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):661–8
Glucose metabolism in cholinoceptive cortical rat brain regions after basal forebrain cholinergic lesion. Mehlhorn G, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):675–90
The behavioral functions of the cholinergic basal forebrain: lessons from 192 IgG–saporin. Wrenn CC, et al. **Int J Dev Neurosci** 1998 Nov–Dec;16(7–8):595–602 (69 ref.)
An in vivo model to study immunotoxin–induced vascular leak in human tissue. Baluna R, et al. **J Immunother** 1999 Jan;22(1):41–7
Lesion of septal–hippocampal neurons with 192 IgG–saporin alters function of M1 muscarinic receptors. Potter PE, et al. **Neuropharmacology** 1999 Apr;38(4):579–86
192 IgG–saporin abolishes p75 neurotrophin receptor immunoreactivity in rat SCN. Moga MM. **Neuroreport** 1998 Oct 5;9(14):3197–200
Evidence for a structural motif in toxins and interleukin–2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Baluna R, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3957–62
The plant ribosome inactivating protein saporin induces micronucleus formation in peripheral human lymphocytes in vitro. Poma A, et al. **Toxicol Lett** 1999 Mar 8; 105(1):67–73
BR96 sFv–PE40 immunotoxin: nonclinical safety assessment. Haggerty HG, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):87–94 (17 ref.)

IMP see **INOSINE MONOPHOSPHATE**

IMP DEHYDROGENASE

ANTAGONISTS & INHIBITORS

A novel series of non–nucleoside inhibitors of inosine 5'–monophosphate dehydrogenase with immunosuppressive activity. Franklin TJ, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):867–76
The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. Korecka M, et al. **Clin Chem** 1999 Jul; 45(7):1047–50
Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)–prone MRLlpr/lpr mice. Jonsson CA, et al. **Clin Exp Immunol** 1999 Jun;116(3):534–41
Induction of inosine monophosphate dehydrogenase activity after long–term treatment with mycophenolate mofetil. Sanquer S, et al. **Clin Pharmacol Ther** 1999 Jun;65(6):640–8
Nucleoside and non–nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Franchetti P, et al. **Curr Med Chem** 1999 Jul;6(7):599–614 (127 ref.)
IMP dehydrogenase : structural aspects of inhibitor binding. Goldstein BM, et al. **Curr Med Chem** 1999 Jul;6(7):519–36 (118 ref.)
IMP dehydrogenase: mechanism of action and inhibition. Hedstrom L. **Curr Med Chem** 1999 Jul;6(7):545–60 (89 ref.)
Mizoribine and mycophenolate mofetil. Ishikawa H. **Curr Med Chem** 1999 Jul;6(7):575–97 (82 ref.)
Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Jayaram HN, et al. **Curr Med Chem** 1999 Jul;6(7):561–74 (81 ref.)
Mechanism–based design of inosine 5–monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5–ethynyl–1–beta–D–ribofuranosylimidazole–4–carboxamide (EICAR) and its derivatives. Minakawa N, et al. **Curr Med Chem** 1999 Jul;6(7):615–28
Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Herrero JI, et al. **Liver Transpl Surg** 1999 Sep;5(5):414–20
Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease [see comments] Larkin G, et al. **Ophthalmology** 1999 Feb;106(2):370–4. Comment in: Ophthalmology 1999 Sep;106(9):1645.
Inhibition of endothelial receptor expression and of T–cell ligand activity by mycophenolate mofetil. Blaheta RA, et al. **Transpl Immunol** 1998 Dec;6(4):251–9

BLOOD

IMPDH activity in whole blood and isolated blood cell fraction for monitoring of CellCept–mediated immunosuppression. Storck M, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):1115–6

CHEMISTRY

Kinetic mechanism of Tritrichomonas foetus inosine 5'–monophosphate dehydrogenase. Digits JA, et al. **Biochemistry** 1999 Feb 23;38(8):2295–306
Acid–base catalysis in the chemical mechanism of inosine monophosphate dehydrogenase. Markham GD, et al. **Biochemistry** 1999 Apr 6;38(14):4433–40
Characteristics and crystal structure of bacterial inosine–5'–monophosphate dehydrogenase. Zhang R, et al. **Biochemistry** 1999 Apr 13;38(15):4691–700
IMP dehydrogenase : structural aspects of inhibitor binding. Goldstein BM, et al. **Curr Med Chem** 1999 Jul;6(7):519–36 (118 ref.)
IMP dehydrogenase: mechanism of action and inhibition. Hedstrom L. **Curr Med Chem** 1999 Jul;6(7):545–60 (89 ref.)
Differential signatures of bacterial and mammalian IMP dehydrogenase enzymes. Zhang R, et al. **Curr Med Chem** 1999 Jul;6(7):537–43
Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Colby TD, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3531–6

GENETICS

Assignment1 of inosine '–monophosphate dehydrogenase type 2 (IMPDH2) to human chromosome band 3p21.2 by in situ hybridization. Kost–Alimova MV, et al. **Cytogenet Cell Genet** 1998;82(3–4):145–6
Inosine–5'–monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Zimmermann AG, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:181–209 (179 ref.)

METABOLISM

Kinetic mechanism of Tritrichomonas foetus inosine 5'–monophosphate dehydrogenase. Digits JA, et al. **Biochemistry** 1999 Feb 23;38(8):2295–306
Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild–type p53 expression under normal growth conditions. Liu Y, et al. **J Cell Physiol** 1998 Nov; 177(2):364–76
Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Colby TD, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3531–6
Inosine–5'–monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Zimmermann AG, et al. **Prog Nucleic Acid Res Mol Biol** 1998;61:181–209 (179 ref.)

PHARMACOLOGY

IMP dehydrogenase: mechanism of action and inhibition. Hedstrom L. **Curr Med Chem** 1999 Jul;6(7):545–60 (89 ref.)

PHYSIOLOGY

Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Jayaram HN, et al. **Curr Med Chem** 1999 Jul;6(7):561–74 (81 ref.)
Inosine monophosphate dehydrogenase: A molecular switch integrating pleiotropic GTP–dependent beta–cell functions. Metz SA, et al. **Proc Assoc Am Physicians** 1999 Jul–Aug; 111(4):335–46 (86 ref.)

IMP NUCLEOTIDASE see **5'–NUCLEOTIDASE**

IMP PHOSPHATASE see **5'–NUCLEOTIDASE**

IMP PYROPHOSPHORYLASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

IMPEDANCE see **ELECTRIC IMPEDANCE**

IMPEDANCE TESTS, ACOUSTIC see **ACOUSTIC IMPEDANCE TESTS**

IMPEDANCE, TRANSTHORACIC see **CARDIOGRAPHY, IMPEDANCE**

IMPETIGO

Paediatric dermatology. Impetigo. Hogan P. **Aust Fam Physician** 1998 Aug;27(8):735–6 (0 ref.)
Impetigo. Malcolm B. **Practitioner** 1998 May;242(1586):405 (0 ref.)
[Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study] Couppié P, et al. **Ann Dermatol Venereol** 1998 Oct;125(10):688–93 (Eng. Abstr.) **(Fre)**
[Impetigo contagiosa (staphylococcal, streptococcal] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):560–3 (10 ref.) **(Jpn)**
[Impetigo bockhart] Takahashi H. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):567–8 (1 ref.) **(Jpn)**

COMPLICATIONS

Case report: benign recurrent abducens nerve palsy in children: another triggering factor: impetigo. Bleik JH, et al. **Binocul Vis Strabismus Q** 1998 Spring–Fall;13(1 1st Qtr):53–4

ETIOLOGY

Tinea corporis with secondary impetigo associated with silicone gel sheeting [letter] Wilson RW, et al. **Plast Reconstr Surg** 1999 Jan;103(1):340

MICROBIOLOGY

Selective distribution of a high–affinity plasminogen–binding site among group A streptococci associated with impetigo. Svensson MD, et al. **Infect Immun** 1999 Aug;67(8):3915–20

PATHOLOGY

Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Breier–Maly J, et al. **Dermatology** 1999; 198(1):61–4

IMPETIGO

Impetigo herpetiformis during the puerperium. Katsambas A, et al. **Dermatology** 1999;198(4):400–2

IMPETIGO CONTAGIOSA see **IMPETIGO**

IMPLANT, MIDDLE EAR see **OSSICULAR PROSTHESIS**

IMPLANT RADIOTHERAPY see **BRACHYTHERAPY**

IMPLANT-SUPPORTED DENTAL PROSTHESIS see **DENTAL PROSTHESIS, IMPLANT-SUPPORTED**

IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE CATHETERS see **CATHETERS, INDWELLING**

IMPLANTABLE DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE INFUSION PUMPS see **INFUSION PUMPS, IMPLANTABLE**

IMPLANTATION, BLASTOCYST see **OVUM IMPLANTATION**

IMPLANTATION, OVUM, DELAYED see **OVUM IMPLANTATION, DELAYED**

IMPLANTS, ABSORBABLE see **ABSORBABLE IMPLANTS**

IMPLANTS, ARTIFICIAL see **PROSTHESES AND IMPLANTS**

IMPLANTS, BREAST see **BREAST IMPLANTS**

IMPLANTS, COCHLEAR see **COCHLEAR IMPLANTS**

IMPLANTS, DENTAL see **DENTAL IMPLANTS**

IMPLANTS, EXPERIMENTAL

Use of titanium prosthesis to bridge a vertebral gap in the spine--a preliminary experimental study. Rikhraj IS, et al. **Ann Acad Med Singapore** 1999 Jan;28(1):20–4

A tissue-engineered conduit for peripheral nerve repair. Hadlock T, et al. **Arch Otolaryngol Head Neck Surg** 1998 Oct;124(10):1081–6

In vivo and in vitro responses to poly(ethylene terephthalate-co-diethylene glycol terephthalate) and polyethylene oxide blends. Barcellos IO, et al. **Biomaterials** 1998 Nov;19(22):2075–82

In vivo performance of a new biodegradable polyester urethane system used as a nerve guidance channel. Borkenhagen M, et al. **Biomaterials** 1998 Dec; 19(23):2155–65

Early peripheral nerve healing in collagen and silicone tube implants: myofibroblasts and the cellular response. Chamberlain LJ, et al. **Biomaterials** 1998 Aug; 19(15):1393–403

In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Draye JP, et al. **Biomaterials** 1998 Sep;19(18):1677–87

Resistance of antibiotic-bonded gelatin-coated polymer meshes to Staphylococcus aureus in a rabbit subcutaneous pouch model. Goëau-Brissonnière O, et al. **Biomaterials** 1999 Feb;20(3):229–32

The effect of hydroxyapatite coating on bony ingrowth into grooved titanium implants. Hayashi K, et al. **Biomaterials** 1999 Jan;20(2):111–9

Biologic response to passive dissolution of titanium craniofacial microplates. Jorgenson DS, et al. **Biomaterials** 1999 Apr;20(7):675–82

Viscous property and osteogenesis induction of hydroxyapatite thermal decomposition product mixed with gelatin implanted into rabbit femurs. Katsumura T, et al. **Biomaterials** 1998 Oct;19(20):1839–44

The effect of solvent extraction and sterilization procedure on the tissue response to Dacron velour. Kilpadi DV, et al. **Biomaterials** 1999 Jan;20(2):129–36

Degradation of double-walled polymer microspheres of PLLA and P(CPP:SA)20:80. II. In vivo degradation. Leach KJ, et al. **Biomaterials** 1998 Nov;19(21):1981–8

Incorporation of three types of bone block implants in the facial skeleton. Merkx MA, et al. **Biomaterials** 1999 Apr; 20(7):639–45

Osteogenic response of the rabbit femur to a hydroxyapatite thermal decomposition product-fibrin glue mixture. Nakamura K, et al. **Biomaterials** 1998 Oct;19(20):1901–7

Osteogenic response of rabbit tibia to hydroxyapatite particle-Plaster of Paris mixture. Sato S, et al. **Biomaterials** 1998 Oct;19(20):1895–900

Attachment of PMMA cement to bone: force measurements in rats. Skripitz R, et al. **Biomaterials** 1999 Feb;20(4):351–6

Initial histological evaluation of anti-washout type fast-setting calcium phosphate cement following subcutaneous implantation. Takechi M, et al. **Biomaterials** 1998 Nov;19(22):2057–63

Chemical changes during in vivo degradation of poly(anhydride-imide) matrices. Uhrich KE, et al. **Biomaterials** 1998 Nov;19(22):2045–50

Bone tissue response to biodegradable polymers used for intra medullary fracture fixation: a long-term in vivo study in sheep femora. van der Elst M, et al. **Biomaterials** 1999 Jan; 20(2):121–8

The role of trabecular demineralized bone in combination with perichondrium in the generation of cartilage grafts. van Osch GJ, et al. **Biomaterials** 1999 Feb;20(3):233–40

Biological evaluation of biphasic calcium phosphate ceramic vertebral laminae. Wang J, et al. **Biomaterials** 1998 Aug; 19(15):1387–92

Mechanical strength of calcium phosphate cement in vivo and in vitro. Yamamoto H, et al. **Biomaterials** 1998 Sep; 19(17):1587–91

Development of bioactive bone cement and its clinical applications. Yamamuro T, et al. **Biomaterials** 1998 Aug; 19(16):1479–82

Association of porous hydroxyapatite and bone marrow cells for bone regeneration. Anselme K, et al. **Bone** 1999 Aug; 25(2 Suppl):51S–54S

Biphasic calcium phosphate/hydrosoluble polymer composites: a new concept for bone and dental substitution biomaterials. Daculsi G, et al. **Bone** 1999 Aug;25(2 Suppl):59S–61S

Short-term effects of mineral particle sizes on cellular degradation activity after implantation of injectable calcium phosphate biomaterials and the consequences for bone substitution. Gauthier O, et al. **Bone** 1999 Aug;25(2 Suppl):71S–74S

Microdamage adjacent to endosseous implants. Huja SS, et al. **Bone** 1999 Aug;25(2):217–22

Evaluation of human recombinant bone morphogenetic protein-2-loaded tricalcium phosphate implants in rabbits' bone defects. Laffargue P, et al. **Bone** 1999 Aug;25(2 Suppl):55S–58S

Raman microspectrometry studies of brushite cement: in vivo evolution in a sheep model. Penel G, et al. **Bone** 1999 Aug; 25(2 Suppl):81S–84S

Influence of sterilization on injectable bone biomaterials. Zahraoui C, et al. **Bone** 1999 Aug;25(2 Suppl):63S–65S

Mandibular lengthening with an implanted motor-driven device: preliminary study in sheep. Ploder O, et al. **Br J Oral Maxillofac Surg** 1999 Aug;37(4):273–6

Ultrastructural study of apatite precipitation in implanted calcium phosphate ceramic: influence of the implantation site. Rohanizadeh R, et al. **Calcif Tissue Int** 1999 May; 64(5):430–6

Bone response to orthodontic loading of endosseous implants in the rabbit calvaria: early continuous distalizing forces. Majzoub Z, et al. **Eur J Orthod** 1999 Jun;21(3):223–30

The use of a dura mater patch to cover oesophageal defects of different sizes: an experimental study in chickens. Delikaris PG, et al. **Eur J Surg** 1999 Feb;165(2):151–7

Glass-ionomer cement: evaluation as an orbital implant. Hintschich C, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Feb;237(2):169–74

Implantable brain chips? Time for debate. Maguire GQ Jr, et al. **Hastings Cent Rep** 1999 Jan-Feb;29(1):7–13 (35 ref.)

Comparison among three different biocoatings for orthopaedic prostheses. An experimental animal study. Rocca M, et al. **Int J Artif Organs** 1998 Sep;21(9):553–8

Reanimation of the lagophthalmos using stainless steel weight implantation; a new approach and prospective evaluation. Kuntheseth S. **Int J Lepr Other Mycobact Dis** 1999 Jun; 67(2):129–32

The early remodeling phases around titanium implants: a histomorphometric assessment of bone quality in a 3- and 6-month study in sheep. Chappard D, et al. **Int J Oral Maxillofac Implants** 1999 Mar-Apr;14(2):189–96

Effects of callus and bonding on strains in bone surrounding an implant under bending. Huja SS, et al. **Int J Oral Maxillofac Implants** 1998 Sep-Oct;13(5):630–8

Wound healing around endosseous implants in experimental diabetes. Nevins ML, et al. **Int J Oral Maxillofac Implants** 1998 Sep-Oct;13(5):620–9

Bone augmentation by recombinant human BMP-2 and collagen on adult rat parietal bone. Murata M, et al. **Int J Oral Maxillofac Surg** 1999 Jun;28(3):232–7

The influence of simultaneous versus delayed placement on the stability of titanium implants in onlay bone grafts. A histologic and biomechanic study in the rabbit. Rasmusson L, et al. **Int J Oral Maxillofac Surg** 1999 Jun;28(3):224–31

Effect of relaparotomy through previously integrated polypropylene and polytetrafluoroethylene experimental implants in the abdominal wall. Bellón JM, et al. **J Am Coll Surg** 1999 May;188(5):466–72

A muscle-powered energy delivery system and means for chronic in vivo testing. Trumble DR, et al. **J Appl Physiol** 1999 Jun;86(6):2106–14

Bone response to implant surface morphology. D'Lima DD, et al. **J Arthroplasty** 1998 Dec;13(8):928–34

Effect of bone quality on the forces generated by compression screws. Faran KJ, et al. **J Biomech** 1999 Aug;32(8):861–4

In vivo biocompatibility and mechanical study of novel bone-bioactive materials for prosthetic implantation. Zhang XS, et al. **J Biomed Mater Res** 1999 Aug; 46(2):279–86

Periodontal repair in dogs: histologic observations of guided tissue regeneration with a prostaglandin E1 analog/methacrylate composite. Trombelli L, et al. **J Clin Periodontol** 1999 Jun;26(6):381–7

Biomechanical and morphometric analysis of hydroxyapatite-coated implants with varying crystallinity. Chang YL, et al. **J Oral Maxillofac Surg** 1999 Sep; 57(9):1096–108; discussion 1108–9

Hyaluronic acid (with fibronectin) as a bioimplant for the vocal fold mucosa. Chan RW, et al. **Laryngoscope** 1999 Jul;109(7 Pt 1):1142–9

Cat peripheral nerve regeneration across 50 mm gap repaired with a novel nerve guide composed of freeze-dried alginate gel. Suzuki Y, et al. **Neurosci Lett** 1999 Jan 8;259(2):75–8

Bone reactions around hydroxyapatite-coated implants in ovariectomized rats. Motohashi M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):145–52

Bone reactions to titanium screw implants in ovariectomized animals. Yamazaki M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Apr;87(4):411–8

Cranial vault expansion using transcutaneously activated magnetic implants. Rinehart G, et al. **Pediatr Neurosurg** 1998 Jun;28(6):293–9

Hyaluronate, tetrachlorodecaoxide, and galactolipid prevent adhesions after implantation of Gore-Tex and dura mater into the abdominal wall in rats. Schier F, et al. **Pediatr Surg Int** 1999;15(3-4):255–9

Osseointegration of preformed polymethylmethacrylate craniofacial prostheses coated with bone marrow-impregnated poly (DL-lactic-co-glycolic acid) foam. Dean D, et al. **Plast Reconstr Surg** 1999 Sep; 104(3):705–12

Implant site for avian microchips [letter] [see comments] Penny D. **Vet Rec** 1998 Sep 5;143(10):288. Comment in: Vet Rec 1998 Sep 12;143(11):315–6.

[Histological evaluation of collagen-hydroxyapatite composite as osseous implants in the repair of mandibular defect] Cheng Y, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1998 Mar;12(2):74–6 (Eng. Abstr.) **(Chi)**

[Interbody arthrodesis using a plasmapore titanium block. Mechanical and histological experimental study in sheep] Tropiano P, et al. **Chirurgie** 1999 Feb;124(1):58–65 (Eng. Abstr.) **(Fre)**

[Artificial trabeculum (MESH). Clinical and histological study in the rabbit] Helies P, et al. **J Fr Ophtalmol** 1998 May;21(5):351–60 (Eng. Abstr.) **(Fre)**

[Does heparin coating improve the biocompatibility poly(D,L)lactide?] Heidemann W, et al. **Biomed Tech (Berl)** 1998;43 Suppl:434–5 **(Ger)**

[Biocompatibility of glass and silicon] Uhlemann J, et al. **Biomed Tech (Berl)** 1998;43 Suppl:438–40 **(Ger)**

[The hemostasis system as an indicator of hemocompatibility of implant materials] Zinner G, et al. **Biomed Tech (Berl)** 1998;43 Suppl:432–3 **(Ger)**

[High tibial osteotomy--primary stability of several implants] Flamme CH, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb; 137(1):48–53 (Eng. Abstr.) **(Ger)**

[Laser mass spectrometric determination of migration of mesh-type (Ni-Ti) prosthetic elements] Leonov BI, et al. **Med Tekh** 1999 May-Jun;(3):3–5 (Eng. Abstr.) **(Rus)**

VETERINARY

Fixation of femoral shaft osteotomy with an intramedullary composite rod: an experimental study on dogs with a two-year follow-up. Kettunen J, et al. **J Biomater Sci Polym Ed** 1999;10(1):33–45

Implant site for avian microchips [letter; comment] Forbes NA, et al. **Vet Rec** 1998 Sep 12;143(11):315–6. Comment on: Vet Rec 1998 Sep 5;143(10):288.

IMPLANTS, MOLTENO see **MOLTENO IMPLANTS**

IMPLOSIVE THERAPY

A brief protocol of cognitive modification and gradual exposure for reduction of fear symptoms of public speaking. Kozasa EH, et al. **J Behav Ther Exp Psychiatry** 1998 Dec; 29(4):317–26

METHODS

Two-phase treatment of panic disorder and posttraumatic stress disorder with associated personality features resulting from childhood abuse: case study. Saper Z, et al. **J Behav Ther Exp Psychiatry** 1998 Jun;29(2):171–8

IMPOTENCE

Male erectile dysfunction [editorial; comment] Samnakay SR. **East Afr Med J** 1998 Nov;75(11):621–2 (5 ref.). Comment on: East Afr Med J 1998 Nov;75(11):623–7.

The 8th World Meeting on Impotence Research. Amsterdam, The Netherlands, 25–28 August 1998. Abstracts. **Int J Impot Res** 1998 Aug;10 Suppl 3:S1–72

Erectile dysfunction in the aging man. Kaiser FE. **Med Clin North Am** 1999 Sep;83(5):1267–78 (43 ref.)

[Erectile dysfunction] Kolomaznik M, et al. **Cas Lek Cesk** 1998 Oct 5;137(19):579–84 (10 ref.) (Eng. Abstr.) **(Cze)**

[Erectile dysfunction. An update] Wagner G, et al. **Ugeskr Laeger** 1999 Mar 1;161(9):1243–8 (Eng. Abstr.) **(Dan)**

[Erectile dysfunction] Isidori A, et al. **Recenti Prog Med** 1999 Jul-Aug;90(7-8):396–402 (19 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Comparison between plasma concentrations of testosterone, nitric oxide and endothelin 1-2 in penile and brachial venous blood: preliminary results in men with psychogenic impotence. Rossi P, et al. **Biomed Pharmacother** 1998; 52(7-8):308-10

An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive [see comments] Ansong KS, et al. **J Urol** 1999 Sep;162(3 Pt 1):719-21. Comment in: J Urol 1999 Sep;162(3 Pt 1):732.

CHEMICALLY INDUCED

Prolactogenic effects of risperidone in male patients--a preliminary study. Shiwach RS, et al. **Acta Psychiatr Scand** 1998 Jul;98(1):81-3

Drug-related erectile dysfunction. Keene LC, et al. **Adverse Drug React Toxicol Rev** 1999 Mar;18(1):5-24 (95 ref.)

Simvastatin seems unlikely to cause impotence [letter] Pedersen TR, et al. **BMJ** 1999 Jan 16;318(7177):192

Sexual dysfunction related to antihypertensive agents: results from the animal model. Srilatha B, et al. **Int J Impot Res** 1999 Apr;11(2):107-13

Headache relief or impotence? [comment] Benjamin N. **Lancet** 1999 Jan 23;353(9149):256-7. Comment on: Lancet 1999 Jan 23;353(9149):287-9.

Sexual dysfunction with protease inhibitors [letter; comment] Colebunders R, et al. **Lancet** 1999 May 22;353(9166):1802 . Comment on: Lancet 1999 Mar 6;353(9155):810-1.

Sexual dysfunction with protease inhibitors [letter] [see comments] Martinez E, et al. **Lancet** 1999 Mar 6; 353(9155):810-1. Comment in: Lancet 1999 May 22;353(9166):1802.

Fluctuating penile erection related with levodopa therapy. Jiménez-Jiménez FJ, et al. **Neurology** 1999 Jan 1;52(1):210

CLASSIFICATION

Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Lizza EF, et al. **Int J Impot Res** 1999 Jun;11(3):141-3

COMPLICATIONS

Erectile dysfunction in the cardiovascular patient [editorial] Smith ER. **Can J Cardiol** 1999 Feb;15(2):233-5, 237 **(Eng, Fre)**

Treatment of erectile dysfunction in men with diabetes [comment] Lipshultz LI, et al. **JAMA** 1999 Feb 3; 281(5):465-6. Comment on: JAMA 1999 Feb 3;281(5):421-6.

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group [see comments] Rendell MS, et al. **JAMA** 1999 Feb 3;281(5):421-6. Comment in: JAMA 1999 Feb 3;281(5):465-6. Comment in: ACP J Club 1999 Jul-Aug;131(1):3.

The Holden Psychological Screening Inventory and sexual efficacy in urological patients with erectile dysfunction. Holden RR. **Psychol Rep** 1999 Feb;84(1):255-8

DIAGNOSIS

Advances in the diagnosis and management of impotence. Wierman ME. **Adv Intern Med** 1999;44:1-17 (42 ref.)

Retrospective analysis of medicolegal cases and evaluation for erectile function. Ozkara H, et al. **Am J Forensic Med Pathol** 1999 Jun;20(2):145-9

Advances in the diagnosis and management of impotence. Wierman ME. **Dis Mon** 1999 Jan;45(1):1-20 (42 ref.)

Erectile dysfunction: a multifaceted disorder. Wierman ME, et al. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):65-74, 77-8, 83-9; discussion 89-90

The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. **Int J Impot Res** 1999 Apr;11(2):59-70; discussion 70-4 (62 ref.)

Correlation of penile duplex ultrasonography, PBI, DICC and angiography in the diagnosis of impotence. McMahon CG. **Int J Impot Res** 1998 Sep;10(3):153-8

The sexual health inventory for men (IIEF-5) [letter] Vroege JA. **Int J Impot Res** 1999 Jun;11(3):177

The Holden Psychological Screening Inventory and sexual efficacy in urological patients with erectile dysfunction. Holden RR. **Psychol Rep** 1999 Feb;84(1):255-8

Evaluation and nonsurgical management of erectile dysfunction. Sharlip ID. **Urol Clin North Am** 1998 Nov; 25(4):647-59, ix (37 ref.)

Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Cappelleri JC, et al. **Urology** 1999 Aug;54(2):346-51

Impact of sildenafil citrate (Viagra) on the DSM-IV diagnosis of male erectile disorder due to psychological factors [letter] Fishbain DA. **Urology** 1999 Sep;54(3):579

Nocturnal electrobioimpedance volumetric assessment of patients with erectile dysfunction. Knoll LD, et al. **Urology** 1999 Jun;53(6):1200-4

Variable response to intracavernous prostaglandin E1 testing for erectile dysfunction. Lehmann K, et al. **Urology** 1999 Sep;54(3):539-43

Efficacy and safety of fixed-dose oral sildenafil [letter] Williams CB. **Urology** 1999 Aug;54(2):384

[Criteria of Rigiscan normalcy in aged men] Zimmern P, et al. **Prog Urol** 1999 Feb;9(1):37-44 (32 ref.) (Eng. Abstr.) **(Fre)**

[Rational diagnosis of erectile dysfunction] Hauck EW, et al. **Urologe A** 1998 Sep;37(5):495-502 (26 ref.) (Eng. Abstr.) **(Ger)**

[Erectile dysfunction. Its diagnosis and treatment] Rolo F, et al. **Acta Med Port** 1999 Jan-Mar;12(1-3):35-8 (Eng. Abstr.) **(Por)**

DRUG THERAPY

Non-surgical treatment of erectile dysfunction. Papp G, et al. **Acta Chir Hung** 1998;37(3-4):183-93 (46 ref.)

Newer pharmacologic alternatives for erectile dysfunction. Viera AJ, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1159-66, 1169, 1172 (23 ref.)

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Conti CR, et al. **Am J Cardiol** 1999 Mar 4;83(5A):29C-34C

Cardiovascular effects of sildenafil citrate and recommendations for its use. Kloner RA, et al. **Am J Cardiol** 1999 Sep 9;84(5B):11N-17N (21 ref.)

Erectile dysfunction and sildenafil citrate and cardiologists [editorial] Kloner RA, et al. **Am J Cardiol** 1999 Feb 15; 83(4):576-82, A7

A new era in the treatment of erectile dysfunction. Padma-Nathan H. **Am J Cardiol** 1999 Sep 9; 84(5B):18N-23N

Cardiovascular data on sildenafil citrate: introduction [published erratum appears in Am J Cardiol 1999 Jul 15;84(2):244] Zusman RM. **Am J Cardiol** 1999 Mar 4; 83(5A):1C-2C

Hypertensive crisis from herbal treatment of impotence [letter] Ruck B, et al. **Am J Emerg Med** 1999 May; 17(3):317-8

Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Giuliano F, et al. **Ann Neurol** 1999 Jul;46(1):15-21

UK consultation rejects restriction of impotence treatment funding [news] Pownall M. **BMJ** 1999 Apr 3;318(7188):892

Views on rationing of treatments for erectile dysfunction are mixed [letter] Riley G, et al. **BMJ** 1999 Jun 26; 318(7200):1763

The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. Williams G, et al. **Br J Urol** 1998 Dec; 82(6):847-54

Viagra! Are we ready? Evans MF. **Can Fam Physician** 1998 Oct;44:2103-5

Good sex is more than just a good erection [news] Kermode-Scott B. **Can Fam Physician** 1999 Jun;45:1616-8

Urologist warns against automatic prescriptions [news] Kermode-Scott B. **Can Fam Physician** 1999 Jun;45:1615-6

A statement on the use of sildenafil in the management of sexual dysfunction in patients with cardiovascular disease. Heart and Stroke Foundation of Canada. Canadian Cardiovascular Society [see comments] **Can J Cardiol** 1999 Apr;15(4):396-9. Comment in: Can J Cardiol 1999 Apr;15(4):475. **(Eng, Fre)**

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Cheitlin MD, et al. **Circulation** 1999 Jan 5-12;99(1):168-77 (33 ref.)

Viagra, the latest cardio-VASCULAR drug [editorial] [see comments] Conti CR. **Clin Cardiol** 1998 Sep;21(9):616. Comment in: Clin Cardiol 1999 Jan;22(1):2.

Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Goldenberg MM. **Clin Ther** 1998 Nov-Dec;20(6):1033-48 (52 ref.)

Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction. Licht MR. **Compr Ther** 1999 Feb;25(2):90-4 (13 ref.)

Opportunities for the treatment of erectile dysfunction by modulation of the NO axis--alternatives to sildenafil citrate. de Mey C. **Curr Med Res Opin** 1998;14(4):187-202 (133 ref.)

Sildenafil: a revolutionary therapy? [editorial] Marshall SM. **Diabet Med** 1998 Nov;15(11):897-9 (14 ref.)

Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Price DE, et al. **Diabet Med** 1998 Oct;15(10):821-5

Comparative tolerability and efficacy of treatments for impotence. Meinhardt W, et al. **Drug Saf** 1999 Feb; 20(2):133-46 (114 ref.)

Sildenafil: a review of its use in erectile dysfunction. Langtry HD, et al. **Drugs** 1999 Jun;57(6):967-89 (80 ref.)

Viagra: what every physician should know. Kloner RA. **Ear Nose Throat J** 1998 Sep;77(9):783-6 (19 ref.)

Reasons of dropout from short- and long-term self-injection therapy for impotence. de la Taille A, et al. **Eur Urol** 1999 Apr;35(4):312-7

Prospective comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction. Martinez-Piñeiro L, et al. **Eur Urol** 1998 Oct; 34(4):350-4

Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. Marquer C, et al. **Fundam Clin Pharmacol** 1998; 12(4):377-87 (44 ref.)

The Viagra revolution. [editorial] Butler RN. **Geriatrics** 1998 Oct;53(10):8-9

Use of intracavernosal alprostadil in erectile dysfunction. Gingell C. **Hosp Med** 1998 Oct;59(10):777

Penile injection in impotency [letter; comment] Gingell JC. **Hosp Med** 1998 Jul;59(7):587. Comment on: Br J Hosp Med 1997 Sep 3-16;58(5):186-8.

Penile injection in impotency [letter; comment] Pryor JP. **Hosp Med** 1998 Jul;59(7):587. Comment on: Br J Hosp Med 1997 Sep 3-16;58(5):186-8.

Sildenafil: desired and undesired effects [editorial] Vallance P. **Hosp Med** 1999 Mar;60(3):158-9

Vitamin V: the sildenafil craze. Kuritzky L. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):163-5 (3 ref.)

Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Tur-Kaspa I, et al. **Hum Reprod** 1999 Jul;14(7):1783-4

Pharmacology of sildenafil citrate. Umrani DN, et al. **Indian J Physiol Pharmacol** 1999 Apr;43(2):160-4 (15 ref.)

Sildenafil (Viagra) 'reaches the parts other drugs cannot reach' [editorial; comment] Jackson G. **Int J Clin Pract** 1998 Sep;52(6):359. Comment on: Int J Clin Pract 1998 Sep;52(6):375-9.

Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group [see comments] Padma-Nathan H, et al. **Int J Clin Pract** 1998 Sep;52(6):375-9. Comment in: Int J Clin Pract 1998 Sep;52(6):359.

Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction. Ghanem H, et al. **Int J Impot Res** 1998 Dec;10(4):211-4

Male erectile dysfunction [letter] Gould D. **Int J Impot Res** 1999 Aug;11(4):237-8

Transcutaneous nitroglycerine in the treatment of erectile dysfunction: a placebo controlled clinical trial. Gramkow J, et al. **Int J Impot Res** 1999 Feb;11(1):35-9

Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Kunelius P, et al. **Int J Impot Res** 1999 Feb;11(1):21-4

Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Porst H, et al. **Int J Impot Res** 1998 Dec;10(4):225-31

Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. Rowland DL, et al. **Int J Impot Res** 1999 Jun;11(3):145-51

A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Sandhu D, et al. **Int J Impot Res** 1999 Apr;11(2):91-7

Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents. Shmueli J, et al. **Int J Impot Res** 1999 Feb;11(1):15-9

Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa. Willke RJ, et al. **Int J Impot Res** 1998 Dec;10(4):239-46

Prolonged nocturnal penile tumescence caused by epinastine. Yamanaka M, et al. **Int J Urol** 1999 Mar;6(3):162-3

Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction. Abdallah HM. **Int Urol Nephrol** 1998;30(5):617-20

Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction. English JC 3rd, et al. **J Am Acad Dermatol** 1998 Nov;39(5 Pt 1):801-3

Oral medications in the management of erectile dysfunction. Lawless C, et al. **J Am Board Fam Pract** 1998 Jul-Aug; 11(4):307-14 (15 ref.)

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. Cheitlin MD, et al. **J Am Coll Cardiol** 1999 Jan;33(1):273-82 (33 ref.)

Sildenafil and erectile dysfunction. Fabbri A, et al. **J Endocrinol Invest** 1999 Jun;22(6):486-92

Therapeutic effect of essential phospholipids on functional sexual disorders in males [letter] Kiriakova N, et al. **J Eur Acad Dermatol Venereol** 1998 Sep;11(2):191-3

Topical and oral agents for erectile dysfunction. Lue TF. **J Formos Med Assoc** 1999 Apr;98(4):233-41 (46 ref.)

Medicalised erections on demand? [editorial] Black D. **J Med Ethics** 1999 Feb;25(1):5-7

Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence. de Tejada IS, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):121-8

Sildenafil (Viagra) has been reported to be an effective treatment for erectile dysfunction [letter] Ivy ME, et al. **J Trauma** 1999 Feb;46(2):357

Re: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting [letter] Hellstrom WJ, et al. **J Urol** 1999 Oct;162(4):1390

Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment [see comments] Jarow JP, et al. **J Urol** 1999 Sep;162(3 Pt 1):722-5. Comment in: J Urol 1999 Sep;162(3 Pt 1):732.

Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction [see comments] McVary KT, et al. **J Urol** 1999 Sep;162(3 Pt 1):726-30; discussion 730-1. Comment in: J Urol 1999 Sep;162(3 Pt 1):732.

The causes of patient dropout from penile self-injection therapy for impotence. Mulhall JP, et al. **J Urol** 1999 Oct; 162(4):1291–4

Re: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial [letter; comment] Scholz M, et al. **J Urol** 1999 Jun;161(6):1914–5. Comment on: J Urol 1997 Oct;158(4):1408–10.

Re: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting [letter; comment] Subramonian K, et al. **J Urol** 1999 Jul; 162(1):168–9. Comment on: J Urol 1998 Dec;160(6 Pt 1):2041–6.

Sildenafil for diabetic men with erectile dysfunction [letter] Garg R, et al. **JAMA** 1999 Sep 8;282(10):939–41

Sildenafil for diabetic men with erectile dysfunction [letter] Karlawish JH, et al. **JAMA** 1999 Sep 8;282(10):940–1

Treatment of erectile dysfunction in men with diabetes [comment] Lipshultz LI, et al. **JAMA** 1999 Feb 3; 281(5):465–6. Comment on: JAMA 1999 Feb 3;281(5):421–6.

Urology. Litwin MS. **JAMA** 1999 Feb 10;281(6):495–6

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group [see comments] Rendell MS, et al. **JAMA** 1999 Feb 3;281(5):421–6. Comment in: JAMA 1999 Feb 3;281(5):465–6. Comment in: ACP J Club 1999 Jul-Aug;131(1):3.

Is management of impotence with sildenafil changing clinical practice? [letter] Garg RK, et al. **Lancet** 1999 Jan 30; 353(9150):375–6

Erectile dysfunction in spina bifida is treatable [letter] Palmer JS, et al. **Lancet** 1999 Jul 10;354(9173):125–6

Retinal side-effects of sildenafil [letter] [see comments] Vobig MA, et al. **Lancet** 1999 Jan 30;353(9150):375. Comment in: Lancet 1999 Jan 30;353(9150):340–1.

When impotence leads contraception [news] Watts J. **Lancet** 1999 Mar 6;353(9155):819

Pharmacotherapeutic advances in the treatment of erectile dysfunction. Nehra A, et al. **Mayo Clin Proc** 1999 Jul; 74(7):709–21 (133 ref.)

An international comparison of the reliability and responsiveness of the Duke Health Profile for measuring health-related quality of life of patients treated with alprostadil for erectile dysfunction. Parkerson GR Jr, et al. **Med Care** 1999 Jan;37(1):56–67

Viagra—beware the quick fix [letter] Hundertmark JD. **Med J Aust** 1998 Nov 2;169(9):504

Impotence, androgens and prostate cancer [letter] Sandeman TF. **Med J Aust** 1998 Oct 5;169(7):400

Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Derry FA, et al. **Neurology** 1998 Dec;51(6):1629–33

Erectile dysfunction and sildenafil. Billner KL. **Nurse Pract** 1998 Nov;23(11):111 (0 ref.)

The impact of first-line antihypertensive drugs on erectile dysfunction. Barksdale JD, et al. **Pharmacotherapy** 1999 May;19(5):573–81 (52 ref.)

Oral sildenafil (Viagra) on trial. van der Linde I. **S Afr Med J** 1998 Oct;88(10):1290

Before and beyond Viagra. van der Linde I. **S Afr Med J** 1998 Oct;88(10):1290–1

A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Maytom MC, et al. **Spinal Cord** 1999 Feb;37(2):110–6

The Marlboro man needs Viagra [news] Davis RM. **Tob Control** 1998 Autumn;7(3):227

Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury. Bodner DR, et al. **Urology** 1999 Jan;53(1):199–202

Oral pharmacotherapy for erectile dysfunction: current perspectives. Burnett AL. **Urology** 1999 Sep;54(3):392–400 (59 ref.)

Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects [published erratum appears in Urology 1999 May;53(5):1072] Dinsmore WW, et al. **Urology** 1999 Apr; 53(4):800–5

Liposome encapsulated prostaglandin E1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients. Foldvari M, et al. **Urology** 1998 Nov;52(5):838–43

Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Kaplan SA, et al. **Urology** 1998 Nov;52(5):739–43

Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. Kedia S, et al. **Urology** 1999 Aug;54(2):308–12

Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil). Lehmann K, et al. **Urology** 1999 Feb;53(2):397–400

Treatment of erectile dysfunction with sildenafil [see comments] Marks LS, et al. **Urology** 1999 Jan;53(1):19–24 . Comment in: Urology 1999 May;53(5):1070–1.

Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. Merrick GS, et al. **Urology** 1999 Jun;53(6):1112–6

Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Montorsi F, et al. **Urology** 1999 May;53(5):1011–8

Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Reiter WJ, et al. **Urology** 1999 Mar;53(3):590–4; discussion 594–5

The Internet and patient education--resources and their reliability: focus on a select urologic topic. Sacchetti P, et al. **Urology** 1999 Jun;53(6):1117–20

Viagra—after one year. Steers WD. **Urology** 1999 Jul; 54(1):12–7 (42 ref.)

Treatment of erectile dysfunction with sildenafil [letter; comment] Wicker PA, et al. **Urology** 1999 May; 53(5):1070–1. Comment on: Urology 1999 Jan;53(1):19–24.

Efficacy and safety of fixed-dose oral sildenafil [letter] Williams CB. **Urology** 1999 Aug;54(2):384

Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Zelefsky MJ, et al. **Urology** 1999 Apr;53(4):775–8

Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Zippe CD, et al. **Urology** 1998 Dec;52(6):963–6

Sildenafil: a milestone in the treatment of impotence. Nachtsheim D. **West J Med** 1998 Aug;169(2):112–3

[Somatization of erectile disorders by the introduction of sildenafil (see comments) (comment)] Hengeveld MW. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2333–6 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2332–3. Comment on: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2333–6. **(Dut)**

[The erection pill (comment)] Lycklama à Nijeholt AA. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2332–3 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2333–6. Comment on: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2337–41. **(Dut)**

[Sildenafil (Viagra) for the treatment of erectile disorder (see comments)] Meuleman EJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 24;142(43):2337–41 (31 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2332–3. Comment in: Ned Tijdschr Geneeskd 1998 Oct 24;142(43):2333–6. **(Dut)**

[The woman and the new methods of treatment of male sexual impotence] Cuzin B. **Ann Urol (Paris)** 1998; 32(6–7):333–5 (Eng. Abstr.) **(Fre)**

[Sildenafil: hopeful or unreasonable? (editorial)] Cour F. **Presse Med** 1998 Jul 4–11;27(24):1225–7 (Eng. Abstr.) **(Fre)**

[Why are auto-intracavernous injections abandon in the long-term?] de la Taille A, et al. **Prog Urol** 1998 Sep; 8(4):529–36 (Eng. Abstr.) **(Fre)**

[Sildenafil] Wespes E, et al. **Rev Med Brux** 1998 Oct;19(5 Pt 1):437–41 (Eng. Abstr.) **(Fre)**

[Drug of the month. Sildenafil (Viagra)] Andrianne R. **Rev Med Liege** 1999 Jan;54(1):58–61 (8 ref.) (Eng. Abstr.) **(Fre)**

[Role of viagra in the treatment of male impotence] Rüedi B. **Rev Med Suisse Romande** 1999 Jun;119(6):449–52 **(Fre)**

[Sildenafil (Viagra) in erectile dysfunction. Effective treatment with noteworthy side effects] Rolf C, et al. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1356–61 (40 ref.) **(Ger)**

[Sildenafil] Sperling H, et al. **Dtsch Med Wochenschr** 1999 Feb 12;124(6):151–3 (0 ref.) **(Ger)**

[Centrum of interest: potency. Hormone substitution for men is topic of discussion] Leinmüller R. **Fortschr Med** 1999 May 10;117(13):18 **(Ger)**

[Therapy recommendations for adverse effects of Viagra and nitrates (NO-donors)] Maisch B. **Herz** 1998 Nov; 23(7):459–60 **(Ger)**

[Erectile dysfunction--problem solved with sildenafil (Viagra)?] Hofer C, et al. **Internist (Berl)** 1998 Dec; 39(12):1232–6 (14 ref.) **(Ger)**

[Sildenafil (Viagra). Hormonal properties, indications and legal problems] Ullrich T, et al. **Med Monatsschr Pharm** 1999 Aug;22(8):233–45 (84 ref.) **(Ger)**

[Pharmacological therapy of erectile dysfunction] Becker AJ, et al. **Urologe A** 1998 Sep;37(5):503–8 (43 ref.) (Eng. Abstr.) **(Ger)**

[Transurethral alprostadil administration with MUSE ("Medicated Urethral System for Erection"). Current overview and personal experiences] Porst H. **Urologe A** 1998 Jul;37(4):410–6 (28 ref.) (Eng. Abstr.) **(Ger)**

[Sildenafil (Viagra). Tolerance, contraindications, drug interactions] Sperling H, et al. **Urologe A** 1999 Mar; 38(2):124–7 (3 ref.) (Eng. Abstr.) **(Ger)**

[The use of PGE1 in the treatment of erectile deficiency] Arena F, et al. **Acta Biomed Ateneo Parmense** 1996; 67(1–2):49–53 (Eng. Abstr.) **(Ita)**

[Viagra: oral therapy of male erectile dysfunction I] Malizia E. **Clin Ter** 1998 Sep-Oct;149(5):369–76 (Eng. Abstr.) **(Ita)**

[Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)] Sandberg M, et al. **Tidsskr Nor Laegeforen** 1999 Mar 10;119(7):945–9 (31 ref.) (Eng. Abstr.) **(Nor)**

[Use of prostaglandin E1 for treatment of erectile dysfunction] Milewczyk P, et al. **Ginekol Pol** 1998 Jul; 69(7):598–602 (Eng. Abstr.) **(Pol)**

[Oral drug therapy options in the treatment of erectile dysfunction] Hrgović Z, et al. **Med Arh** 1998;52(2):67–72 (Eng. Abstr.) **(Scr)**

[Sildenafil and erectile dysfunction] Menárguez Puche JF, et al. **Aten Primaria** 1998 Oct 15;22(6):379–86 (30 ref.) **(Spa)**

[Viagra will be accessible in Sweden] **Lakartidningen** 1998 Sep 23;95(39):4201 **(Swe)**

[A new agent against impotence. Contraindicated in reduced renal and hepatic function, in angina and with simultaneously used nitroglycerin preparations] Hedelin H. **Lakartidningen** 1998 Oct 14;95(42):4558–60 (13 ref.) **(Swe)**

[Improved penile erection is most often good for two persons! (letter)] Sjöstrand M. **Lakartidningen** 1998 Nov 11; 95(46):5139 **(Swe)**

ECONOMICS

UK consultation rejects restriction of impotence treatment funding [news] Pownall M. **BMJ** 1999 Apr 3;318(7188):892

Viagra—it's no free ride [news] van der Linde I. **S Afr Med J** 1998 Nov;88(11):1383

ENZYMOLOGY

Histopathological changes and nitric oxide synthase activity in corpus cavernosum from rats with neurogenic erectile dysfunction. Basar MM, et al. **BJU Int** 1999 Jan;83(1):101–7

Histopathological changes and nitric oxide synthase activity in corpus cavernosum from rats with neurogenic erectile dysfunction [letter] Khan MA, et al. **BJU Int** 1999 Aug; 84(3):387

EPIDEMIOLOGY

The prevalence and etiology of impotence in 101 male hypertensive outpatients. Jensen J, et al. **Am J Hypertens** 1999 Mar;12(3):271–5

The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Ayta IA, et al. **BJU Int** 1999 Jul;84(1):50–6

Barriers to recognition of erectile dysfunction among diabetic Mexican-American men [see comments] Zweifler J, et al. **J Am Board Fam Pract** 1998 Jul-Aug;11(4):259–63. Comment in: J Am Board Fam Pract 1998 Jul-Aug;11(4):327–30.

Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. Catalona WJ, et al. **J Urol** 1999 Aug;162(2):433–8

The epidemiology and pathophysiology of erectile dysfunction. Melman A, et al. **J Urol** 1999 Jan;161(1):5–11 (78 ref.)

Physician attitudes and behaviour regarding erectile dysfunction in at-risk patients from a rural community. Perttula E. **Postgrad Med J** 1999 Feb;75(880):83–5

Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Litwin MS, et al. **Urology** 1999 Sep;54(3):503–8

ETIOLOGY

Radical prostatectomy in the treatment of prostate cancer [letter; comment] Epperson WJ. **Am Fam Physician** 1998 Dec;58(9):1972, 1977–8. Comment on: Am Fam Physician 1998 Apr 1;57(7):1531–9, 1541–2, 1545–7.

Newer pharmacologic alternatives for erectile dysfunction. Viera AJ, et al. **Am Fam Physician** 1999 Sep 15; 60(4):1159–66, 1169, 1172 (23 ref.)

The prevalence and etiology of impotence in 101 male hypertensive outpatients. Jensen J, et al. **Am J Hypertens** 1999 Mar;12(3):271–5

Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction. Wellmer A, et al. **BJU Int** 1999 Jan;83(1):66–70

Prostate cancer: 8. Urinary incontinence and erectile dysfunction. Hassouna MM, et al. **CMAJ** 1999 Jan 12; 160(1):78–86

Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Fedele D, et al. **Diabetes Care** 1998 Nov;21(11):1973–7

Is obesity an underlying factor in erectile dysfunction? Chung WS, et al. **Eur Urol** 1999;36(1):68–70

Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Hatzichristou DG, et al. **Eur Urol** 1999;36(1):60–7

BPH and sexuality. Zlotta AR, et al. **Eur Urol** 1999;36 Suppl 1:107–12 (37 ref.)

Recurrent fainting, dysesthesia, and impotence. Rayder R, et al. **Hosp Pract (Off Ed)** 1999 Jul 15;34(7):52c–52d

Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction. McMahon CG, et al. **Int J Impot Res** 1999 Feb;11(1):47–51

Erectile dysfunction due to a 'hidden' penis after pelvic trauma. Simonis LA, et al. **Int J Impot Res** 1999 Feb; 11(1):53–5

Cigarette smoking and erectile dysfunction. Jeremy JY, et al. **J R Soc Health** 1998 Jun;118(3):151–5 (61 ref.)

Smoking and urological disease. Mikhailidis DP, et al. **J R Soc Health** 1998 Aug;118(4):210–2 (34 ref.)

Erectile dysfunction induced by orthopedic trauma managed with a fracture table: a case report and review of the literature. Chan PT, et al. **J Trauma** 1999 Jul;47(1):183–5 (22 ref.)

Evaluation and therapeutic approaches of voiding and

erectile dysfunction in neurological Behçet's syndrome. Erdoğru T, et al. **J Urol** 1999 Jul;162(1):147–53
Sexual dysfunction after surgery for rectal cancer. Banerjee AK. **Lancet** 1999 Jun 5;353(9168):1900–2
Pharmacotherapeutic advances in the treatment of erectile dysfunction. Nehra A, et al. **Mayo Clin Proc** 1999 Jul; 74(7):709–21 (133 ref.)
Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Derry FA, et al. **Neurology** 1998 Dec;51(6):1629–33
What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. Kochar MS, et al. **Postgrad Med** 1999 Aug;106(2):149–52, 155–7 (17 ref.)
The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Khan MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar; 60(3):169–74 (83 ref.)
Sexual function following radical radiotherapy for bladder cancer. Little FA, et al. **Radiother Oncol** 1998 Nov; 49(2):157–61
Sexological problems after cystectomy: bladder substitution compared with ileal conduit diversion. A questionnaire study of male patients. Bjerre BD, et al. **Scand J Urol Nephrol** 1998 May;32(3):187–93
Erectile dysfunction caused by sacral gun-shot injury. Werner T, et al. **Scand J Urol Nephrol** 1999 Feb;33(1):69–70
A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Maytom MC, et al. **Spinal Cord** 1999 Feb;37(2):110–6
Sexual functioning among stroke patients and their spouses. Korpelainen JT, et al. **Stroke** 1999 Apr;30(4):715–9
The Marlboro man needs Viagra [news] Davis RM. **Tob Control** 1998 Autumn;7(3):227
Impotence after renal transplantation [letter; comment] Nghiem DD. **Transplantation** 1998 Oct 15;66(7):938–9. Comment on: Transplantation 1998 Mar 15;65(5):745–6.
Technetium-99m-labelled RBC erection penogram to differentiate psychogenic from vasculogenic impotence. Shen YY, et al. **Urol Int** 1998 Oct;61(1):27–31
Possible molecular mechanisms of cryoablation-induced impotence in a rat model. El-Sakka A, et al. **Urology** 1998 Dec;52(6):1144–50
Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Turner SL, et al. **Urology** 1999 Jul;54(1):124–9
[Erectile dysfunction secondary to hyperprolactinemia. Apropos of 13 cases] Abram F, et al. **Prog Urol** 1998 Sep; 8(4):537–41 (Eng. Abstr.) **(Fre)**
[Erectile dysfunction after radical prostatectomy: value of preoperative programming of intracavernous injections] Lebret T, et al. **Prog Urol** 1999 Jun;9(3):483–8 (Eng. Abstr.) **(Fre)**
[Sleep apnea and erectile dysfunction] Konermann M, et al. **Dtsch Med Wochenschr** 1999 May 21;124(20):631–5 (37 ref.) **(Ger)**
[Disorders of ejaculation] Glander HJ. **Fortschr Med** 1998 Sep 20;116(26):26–8, 30–1 (24 ref.) (Eng. Abstr.) **(Ger)**
[True ejaculation disorders are rare (interview by Beatrice Wagner)] Vogt HJ. **Fortschr Med** 1998 Sep 20;116(26):32–3 **(Ger)**
[Erectile function after treatment of prostatic carcinoma] Lindner H. **Strahlenther Onkol** 1999 Jan;175(1):44–5 **(Ger)**
[Sexually and drug-stimulated erections are proportional] Lehmann K, et al. **Urologe A** 1999 Mar;38(2):162–7 (Eng. Abstr.) **(Ger)**
[Secondary erectile dysfunction. Is oral medication in the diagnostic phase indicated?] Sperling H, et al. **Urologe A** 1999 Jan;38(1):56–9 (Eng. Abstr.) **(Ger)**
[Erectile dysfunction (editorial)] Stief CG, et al. **Urologe A** 1998 Sep;37(5):486 **(Ger)**
[New animal models for psychogenic impotence: an ethological approach to copulatory disorder induced by social stress] Yoshimura H. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Oct; 18(5):169–80 (77 ref.) (Eng. Abstr.) **(Jpn)**
[A case of primary central nervous system lymphoma with the onset of impotence] Hori T, et al. **Rinsho Shinkeigaku** 1999 Feb–Mar;39(2–3):333–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction. Dahiya R, et al. **Int J Impot Res** 1999 Aug;11(4):201–6

MICROBIOLOGY

Cavernosal cold abscess: a rare cause of impotence. Murali TR, et al. **Br J Urol** 1998 Dec;82(6):929–30

NURSING

Erectile dysfunction and sildenafil. Billner KL. **Nurse Pract** 1998 Nov;23(11):111 (0 ref.)

PATHOLOGY

Ultrastructural features of penile tissue in impotent men. Liu LC, et al. **Br J Urol** 1993 Nov;72(5 Pt 1):635–42
[Erectile dysfunction of vasculogenic origin: ultrastructural evaluation of cavernous myo-endothelial unit as prognostic index of penile revascularization] Lo Forti B, et al. **Ann Ital Chir** 1998 May–Jun;69(3):347–50 (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Neurophysiological evaluation of sexual dysfunction in patients operated for colorectal cancer. Pietrangeli A, et al. **Clin Auton Res** 1998 Dec;8(6):353–7
Perineal floor efficiency in sexually potent and impotent men. Colpi GM, et al. **Int J Impot Res** 1999 Jun;11(3):153–7
Bulbocavernosus-reflex latencies and pudendal nerve SSEP compared to penile vascular testing in 669 patients with erectile failure and other sexual dysfunction. Fabra M, et al. **Int J Impot Res** 1999 Jun;11(3):167–75
Maximisation of the erectile response in the investigation of impotence. Mills RD, et al. **Int J Impot Res** 1999 Feb; 11(1):29–32; discussion 33–4
The epidemiology and pathophysiology of erectile dysfunction. Melman A, et al. **J Urol** 1999 Jan;161(1):5–11 (78 ref.)
Erectile function and dysfunction. Jordan GH. **Postgrad Med** 1999 Feb;105(2):131–4, 137–8, 143–4 passim (31 ref.)

PREVENTION & CONTROL

A plea for preservation of the pelvic autonomic nerves [letter] Maas K, et al. **Lancet** 1999 Aug 28;354(9180):772–3
Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. Klotz L, et al. **Urology** 1998 Oct;52(4):537–42
[Erectile dysfunction after radical prostatectomy: value of preoperative programming of intracavernous injections] Lebret T, et al. **Prog Urol** 1999 Jun;9(3):483–8 (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Comparison between plasma concentrations of testosterone, nitric oxide and endothelin 1-2 in penile and brachial venous blood: preliminary results in men with psychogenic impotence. Rossi P, et al. **Biomed Pharmacother** 1998; 52(7-8):308–10
Interdisciplinary assessment and follow-up of patients with erectile dysfunction--psychiatric aspects. Caspari D, et al. **Int J Impot Res** 1999 Aug;11(4):213–7
Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction. Ghanem H, et al. **Int J Impot Res** 1998 Dec;10(4):211–4
An international comparison of the reliability and responsiveness of the Duke Health Profile for measuring health-related quality of life of patients treated with alprostadil for erectile dysfunction. Parkerson GR Jr, et al. **Med Care** 1999 Jan;37(1):56–67
The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Araujo AB, et al. **Psychosom Med** 1998 Jul–Aug;60(4):458–65
Sexual functioning among stroke patients and their spouses. Korpelainen JT, et al. **Stroke** 1999 Apr;30(4):715–9
Help-seeking decisions among men with impotence. Ansong KS, et al. **Urology** 1998 Nov;52(5):834–7
Impact of sildenafil citrate (Viagra) on the DSM-IV diagnosis of male erectile disorder due to psychological factors [letter] Fishbain DA. **Urology** 1999 Sep;54(3):579
Increased incidence of depressive symptoms in men with erectile dysfunction. Shabsigh R, et al. **Urology** 1998 Nov; 52(5):848–52
Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Tefilli MV, et al. **Urology** 1998 Dec;52(6):1106–12
[Psychological stress factors in erectile dysfunctions. Causal models and empirical results] Hartmann U. **Urologe A** 1998 Sep;37(5):487–94 (Eng. Abstr.) **(Ger)**

REHABILITATION

[Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction] Manning M, et al. **Urologe A** 1998 Sep;37(5):509–15 (66 ref.) (Eng. Abstr.) **(Ger)**
[Physical factors in the treatment and rehabilitation of patients with chronic prostatitis complicated by impotence] Karpukhin IV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar–Apr; (2):25–7 (Eng. Abstr.) **(Rus)**

SURGERY

Penile implants in erectile impotence. The importance of clinical experience on outcome. Küpeli S, et al. **Eur Urol** 1999 Aug;36(2):129–35
Penile prosthesis implantation surgery: a statewide population based analysis of 2354 patients. Jhaveri FM, et al. **Int J Impot Res** 1998 Dec;10(4):251–4
Spontaneous breakage of malleable penile prosthesis. Lee WH, et al. **Int J Impot Res** 1998 Dec;10(4):255–6
Experience with the Ultrex and Ultrex Plus inflatable penile prosthesis: new implantation techniques and surgical outcome. Liberman SN, et al. **Int J Impot Res** 1998 Sep; 10(3):175–9
Re: Long-term followup and selection criteria for penile revascularization in erectile failure [letter] Chiou K, et al. **J Urol** 1999 Oct;162(4):1390–1
Comparison of mechanical reliability of original and enhanced Mentor Alpha I penile prosthesis. Wilson SK, et al. **J Urol** 1999 Sep;162(3 Pt 1):715–8
The use of iliac bone flap as a penile stiffener in a diabetic patient with erectile dysfunction. Aköz T, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1975–8
Clinical experience with Dynaflex penile prostheses in 120 patients. Anafarta K, et al. **Urology** 1998 Dec; 52(6):1098–100
Assessment of psychosexual adjustment after insertion of inflatable penile prosthesis. Tefilli MV, et al. **Urology** 1998 Dec;52(6):1106–12
[Revascularization of the corpora cavernosa in vasculogenic impotence] Sica GS, et al. **Minerva Urol Nefrol** 1999 Jun; 51(2):129–34 (16 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

New treatment options for erectile dysfunction. McMahon CG. **Aust Fam Physician** 1999 Aug;28(8):783–7, 789–90 (10 ref.)
ABC of sexual health: erectile dysfunction. Dinsmore W, et al. **BMJ** 1999 Feb 6;318(7180):387–90 (0 ref.)
Vacuum devices in erectile dysfunction: indications and efficacy. Oakley N, et al. **Br J Urol** 1998 Nov;82(5):673–81 (90 ref.)
Advances in the diagnosis and management of impotence. Wierman ME. **Dis Mon** 1999 Jan;45(1):1–20 (42 ref.)
Management of male erectile dysfunction: a review [see comments] Magoha GA. **East Afr Med J** 1998 Nov; 75(11):623–7 (55 ref.). Comment in: East Afr Med J 1998 Nov;75(11):621–2.
Treatment of erectile dysfunction by an external ischiocavernous muscle stimulator. Derouet H, et al. **Eur Urol** 1998 Oct;34(4):355–9
The effects of ArginMax, a natural dietary supplement for enhancement of male sexual function. Ito T, et al. **Hawaii Med J** 1998 Dec;57(12):741–4
Erectile dysfunction: a multifaceted disorder. Wierman ME, et al. **Hosp Pract (Off Ed)** 1998 Oct 15;33(10):65–74, 77–8, 83–9; discussion 89–90
The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. **Int J Impot Res** 1999 Apr;11(2):59–70; discussion 70–4 (62 ref.)
The use of acupuncture in the treatment of erectile dysfunction. Kho HG, et al. **Int J Impot Res** 1999 Feb; 11(1):41–6
Management of erectile dysfunction [letter] Ralph DJ. **Int J STD AIDS** 1999 Mar;10(3):209
New classification system for erectile dysfunction therapies. Heaton J. **J Androl** 1998 Jul–Aug;19(4):399–404 (26 ref.)
Treatment of impotence by Chinese herbs and acupuncture. Zhu Y, et al. **J Tradit Chin Med** 1997 Sep;17(3):226–37 (21 ref.)
Evaluation and therapeutic approaches of voiding and erectile dysfunction in neurological Behçet's syndrome. Erdoğru T, et al. **J Urol** 1999 Jul;162(1):147–53
Medical therapies for erectile dysfunction [editorial; comment] Montague DK. **J Urol** 1999 Sep;162(3 Pt 1):732 . Comment on: J Urol 1999 Sep;162(3 Pt 1):719–21. Comment on: J Urol 1999 Sep;162(3 Pt 1):722–5. Comment on: J Urol 1999 Sep;162(3 Pt 1):726–30; discussion 730–1.
Outcome of managing impotence in clinical practice. Braatvedt GD. **N Z Med J** 1999 Jul 23;112(1092):272–4
Management of and counseling for psychotropic drug-induced sexual dysfunction. Gutierrez MA, et al. **Pharmacotherapy** 1999 Jul;19(7):823–31 (57 ref.)
Erectile function and dysfunction. Jordan GH. **Postgrad Med** 1999 Feb;105(2):131–4, 137–8, 143–4 passim (31 ref.)
Medical treatment of erectile dysfunction. Burns-Cox N, et al. **Postgrad Med J** 1998 Jun;74(872):336–42 (64 ref.)
Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Champion HC, et al. **Proc Natl Acad Sci U S A** 1999 Sep 28; 96(20):11648–52
Erectile Dysfunction Alliance [letter] Dinsmore WW. **Sex Transm Infect** 1998 Aug;74(4):306
Evaluation and nonsurgical management of erectile dysfunction. Sharlip ID. **Urol Clin North Am** 1998 Nov; 25(4):647–59, ix (37 ref.)
Enhanced external counterpulsation as a new treatment modality for patients with erectile dysfunction. Froschermaier SE, et al. **Urol Int** 1998;61(3):168–71
EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Althof SE, et al. **Urology** 1999 Apr;53(4):793–9
[Urology is more than Viagra. Potpourri of new developments in urology] Hobi C, et al. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2047–51 (3 ref.) **(Ger)**
[Erectile dysfunction. Its diagnosis and treatment] Rolo F, et al. **Acta Med Port** 1999 Jan–Mar;12(1–3):35–8 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Quantitative analysis of penile ultrasonographic shape during the erectile cycle: a new diagnostic tool for erectile dysfunction? Repeatability of the method and preliminary results. Sforza C, et al. **Int J Impot Res** 1998 Dec;

IMPOTENCE

10(4):203–9

Study of cavernosal arterial anatomy using color and power Doppler sonography: impact on hemodynamic parameter measurement. Chiou RK, et al. **J Urol** 1999 Aug; 162(2):358–60

[Vascular exploration of erectile dysfunction] Sussman H. **J Mal Vasc** 1999 May;24(2):143–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[The use of dynamic Doppler color ultrasonography of the penis in the study of erectile dysfunction] Aversa A, et al. **Radiol Med (Torino)** 1999 Jun;97(6):499–505 (Eng. Abstr.) **(Ita)**

VETERINARY

The effect of a surgically created shunt between the corpus cavernosum penis and corpus spongiosum penis of stallions on erectile and ejaculatory function. Schumacher J, et al. **Vet Surg** 1999 Jan–Feb;28(1):21–4

IMPOTENCE, ARTERIOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPOTENCE, VASCULOGENIC

BLOOD

Intracavernosal endothelin levels of impotent men before and after papaverine induced penile erection. Kadioğlu A, et al. **Arch Esp Urol** 1998 Sep;51(7):739–40

DIAGNOSIS

Hemodynamic characterization of a functional erection. Arterial and corporeal veno-occlusive function in patients with a positive intracavernosal injection test. Hatzichristou DG, et al. **Eur Urol** 1999;36(1):60–7

Technetium-99m-labelled RBC erection penogram to differentiate psychogenic from vasculogenic impotence. Shen YY, et al. **Urol Int** 1998 Oct;61(1):27–31

[The relationship of cavernous oxygen tension with erectile dysfunction of vascular origin] Romero-Tejada JC, et al. **Arch Esp Urol** 1998 Nov;51(9):919–22 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. Chen J, et al. **BJU Int** 1999 Feb;83(3):269–73

Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. Dinsmore WW, et al. **BJU Int** 1999 Feb;83(3):274–9

Topical vasoactive cream in the treatment of erectile failure: a prospective, randomized placebo-controlled trial. Le Roux PJ, et al. **BJU Int** 1999 May;83(7):810–1

A KATP-channel opener as a potential treatment modality for erectile dysfunction. Moon DG, et al. **BJU Int** 1999 May;83(7):837–41

Intracavernosal versus intraurethral alprostadil: a prospective randomized study. Shokeir AA, et al. **BJU Int** 1999 May; 83(7):812–5

The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group. **Br J Urol** 1998 Oct;82(4):538–43

Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting [see comments] Fulgham PF, et al. **J Urol** 1998 Dec;160(6 Pt 1):2041–6. Comment in: J Urol 1999 Jul;162(1):168–9.

Oral sildenafil in erectile dysfunction [letter] Chan-Tack KM. **Lancet** 1998 Nov 7;352(9139):1557

[Erectile dysfunction--problem solved with sildenafil (Viagra)?] Hofer C, et al. **Internist (Berl)** 1998 Dec; 39(12):1232–6 (14 ref.) **(Ger)**

[Pharmacological therapy of erectile dysfunction] Becker AJ, et al. **Urologe A** 1998 Sep;37(5):503–8 (43 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Incidence of vasculogenic erectile dysfunction in multiple-region atherosclerosis pathology: diagnosis and therapeutic possibilities] Carini U, et al. **Minerva Cardioangiol** 1998 Sep;46(9):349–50 **(Ita)**

ETIOLOGY

Autonomic nerve involvement and venous leakage in diabetic men with impotence. Colakoglu Z, et al. **BJU Int** 1999 Mar;83(4):453–6

Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Tarcan T, et al. **Br J Urol** 1998 Dec; 82 Suppl 1:26–33 (65 ref.)

Diabetes and vascular impotence: does insulin dependence increase the relative severity? Metro MJ, et al. **Int J Impot Res** 1999 Apr;11(2):87–9

Corporeal veno-occlusive dysfunction: a distal arterial pathology? Wespes E, et al. **J Urol** 1998 Dec;160(6 Pt 1):2054–7

The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Khan MA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar; 60(3):169–74 (83 ref.)

[Sexually and drug-stimulated erections are proportional] Lehmann K, et al. **Urologe A** 1999 Mar;38(2):162–7 (Eng. Abstr.) **(Ger)**

PATHOLOGY

Clinical value of pelvic and penile magnetic resonance angiography in preoperative evaluation of penile revascularization. John H, et al. **Int J Impot Res** 1999 Apr; 11(2):83–6

PHYSIOPATHOLOGY

Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction. Azadzoi KM, et al. **J Urol** 1998 Dec; 160(6 Pt 1):2216–22

REHABILITATION

[Vascular surgery, implant surgery and vacuum erectile aids. Review-overview-prospects of 3 therapy options in erectile dysfunction] Manning M, et al. **Urologe A** 1998 Sep;37(5):509–15 (66 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Long-term followup and selection criteria for penile revascularization in erectile failure. Manning M, et al. **J Urol** 1998 Nov;160(5):1680–4

Patient selection criteria in the surgical treatment of veno-occlusive dysfunction. Sasso F, et al. **J Urol** 1999 Apr;161(4):1145–7

THERAPY

[Long-term results of the veno-occlusive percutaneous treatment of erectile disorders of venous origin] Malossini G, et al. **Arch Ital Urol Androl** 1998 Sep;70(4):203–9 (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Venous incompetence in erectile dysfunction: evaluation with color-coded duplex sonography and cavernosometry/-graphy. Fürst G, et al. **Eur Radiol** 1999; 9(1):35–41

IMPOTENCE, VENOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPRINTING (PSYCHOLOGY)

Violent suicide and obstetric complications. The link is mental illness [editorial; comment] [see comments] Appleby L. **BMJ** 1998 Nov 14;317(7169):1333–4. Comment on: BMJ 1998 Nov 14;317(7169):1346–9. Comment in: BMJ 1999 Mar 13;318(7185):737.

DRUG EFFECTS

Right hemisphere involvement in imprinting memory revealed by glutamate treatment. Johnston AN, et al. **Pharmacol Biochem Behav** 1998 Aug;60(4):863–71

PHYSIOLOGY

Detour behaviour, imprinting and visual lateralization in the domestic chick. Vallortigara G, et al. **Brain Res Cogn Brain Res** 1999 Jan;7(3):307–20

Filial imprinting in domestic chicks is associated with spine pruning in the associative area, dorsocaudal neostriatum. Bock J, et al. **Eur J Neurosci** 1999 Jul;11(7):2566–70

Expression of the GABA(A) receptor gamma 4-subunit gene: anatomical distribution of the corresponding mRNA in the domestic chick forebrain and the effect of imprinting training. Harvey RJ, et al. **Eur J Neurosci** 1998 Sep; 10(9):3024–8

Short communication: hippocampal neuronal activity and imprinting in the behaving domestic chick. Nicol AU, et al. **Eur J Neurosci** 1998 Aug;10(8):2738–41

Induction of the c-fos gene in the chick brain during visual imprinting. Abramova AB, et al. **Neurosci Behav Physiol** 1998 Nov-Dec;28(6):616–9

Right hemisphere involvement in imprinting memory revealed by glutamate treatment. Johnston AN, et al. **Pharmacol Biochem Behav** 1998 Aug;60(4):863–71

Imprinting, learning and development: from behaviour to brain and back. Bolhuis JJ, et al. **Trends Neurosci** 1998 Jul;21(7):306–11 (51 ref.)

Visual imprinting and the neural mechanisms of recognition memory. Horn G. **Trends Neurosci** 1998 Jul;21(7):300–5 (79 ref.)

IMPULSE CONTROL DISORDERS

see related
PARAPHILIAS
SUBSTANCE-RELATED DISORDERS

CHEMICALLY INDUCED

Disentangling disinhibition. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Nov; 37(11):1225–7

COMPLICATIONS

Compulsive sexual behaviors--difficult aeromedical disposition. Koffman RL, et al. **Aviat Space Environ Med** 1998 Oct;69(10):1001–6

DIAGNOSIS

Defining, measuring, and predicting impulsive aggression: a heuristic model. Barratt ES, et al. **Behav Sci Law** 1998 Summer;16(3):285–302 (46 ref.)

Intermittent explosive disorder-revised: development, reliability, and validity of research criteria. Coccaro EF, et al. **Compr Psychiatry** 1998 Nov-Dec;39(6):368–76

Addicted women: when your patient can't stop drinking, smoking, shopping, eating. Carmin CN. **Int J Fertil Womens Med** 1998 Jul-Aug;43(4):179–85

Recognition and treatment of DSM-IV intermittent explosive disorder. McElroy SL. **J Clin Psychiatry** 1999; 60 Suppl 15:12–6

Impulse-control disorders in alcoholics are related to sensation seeking and not to impulsivity. Lejoyeux M, et al. **Psychiatry Res** 1998 Nov 16;81(2):149–55

DRUG THERAPY

Short-term single-blind fluvoxamine treatment of pathological gambling. Hollander E, et al. **Am J Psychiatry** 1998 Dec;155(12):1781–3

The treatment of kleptomania with serotonin reuptake inhibitors. Lepkifker E, et al. **Clin Neuropharmacol** 1999 Jan-Feb;22(1):40–3

Treatment of intermittent explosive disorder with sertraline in 3 patients [letter] Feder R. **J Clin Psychiatry** 1999 Mar; 60(3):195–6

Recognition and treatment of DSM-IV intermittent explosive disorder. McElroy SL. **J Clin Psychiatry** 1999; 60 Suppl 15:12–6

EPIDEMIOLOGY

Childhood conduct problems, hyperactivity-impulsivity, and inattention as predictors of adult criminal activity. Babinski LM, et al. **J Child Psychol Psychiatry** 1999 Mar; 40(3):347–55

Study of impulse-control disorders among alcohol-dependent patients. Lejoyeux M, et al. **J Clin Psychiatry** 1999 May;60(5):302–5

ETIOLOGY

[Impulse control disorders in schizophrenia in children, adolescents and young people] Golik AN. **Zh Nevrol Psikhiatr Im S S Korsakova** 1999;99(7):63–7 (129 ref.) **(Rus)**

GENETICS

Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Lappalainen J, et al. **Arch Gen Psychiatry** 1998 Nov;55(11):989–94

METABOLISM

Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Raine A, et al. **Behav Sci Law** 1998 Summer;16(3):319–32

NURSING

When gambling becomes a losing battle. Eber G. **Am J Nurs** 1999 May;99(5):22

PHYSIOPATHOLOGY

Tapping time at lumbar puncture is longer in pathological male gamblers than in healthy male controls. Nordin C, et al. **J Psychiatr Res** 1998 Nov-Dec;32(6):421–2

[Impulse control disorders and other serotonin function disorders] Pöldinger W. **Schweiz Rundsch Med Prax** 1998 Oct 7;87(41):1348–55 (33 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Legal and ethical duties of the clinician treating a patient who is liable to be impulsively violent. Beck JC. **Behav Sci Law** 1998 Summer;16(3):375–89 (33 ref.)

PSYCHOLOGY

Defining, measuring, and predicting impulsive aggression: a heuristic model. Barratt ES, et al. **Behav Sci Law** 1998 Summer;16(3):285–302 (46 ref.)

Introduction to impulsive aggression. Felthous AR. **Behav Sci Law** 1998 Summer;16(3):281–3 (7 ref.)

Reduced prefrontal and increased subcortical brain functioning assessed using positron emission tomography in predatory and affective murderers. Raine A, et al. **Behav Sci Law** 1998 Summer;16(3):319–32

Comparison of buying behavior in depressed patients presenting with or without compulsive buying. Lejoyeux M, et al. **Compr Psychiatry** 1999 Jan-Feb;40(1):51–6

Sustained attention and impulsivity in children with Tourette syndrome: comorbidity and confounds. Sherman EM, et al. **J Clin Exp Neuropsychol** 1998 Oct;20(5):644–57

Impulsivity: a discussion of clinical and experimental findings. Evenden J. **J Psychopharmacol** 1999;13(2):180–92 (100 ref.)

REHABILITATION

The relationship between substance use disorders, impulse control disorders, and pathological aggression. Brady KT, et al. **Am J Addict** 1998 Summer;7(3):221-30 (82 ref.)

THERAPY

Addicted women: when your patient can't stop drinking, smoking, shopping, eating. Carmin CN.
Int J Fertil Womens Med 1998 Jul-Aug;43(4):179-85

A review of behavioral and pharmacological treatments for habit disorders in individuals with mental retardation. Long ES, et al. **J Behav Ther Exp Psychiatry** 1998 Jun; 29(2):143-56 (100 ref.)

Sexual predators. Zonana HV, et al.
Psychiatr Clin North Am 1999 Mar;22(1):109-27, vii (68 ref.)

Prevalence, assessment, and treatment of pathological gambling: a review. Petry NM, et al. **Psychiatr Serv** 1999 Aug;50(8):1021-7 (70 ref.)

IMPULSE-RIDDEN PERSONALITY see **PERSONALITY DISORDERS**

IMPULSIVE BEHAVIOR

Impulsivity and suicide [letter; comment] Fitzgerald M.
J Am Acad Child Adolesc Psychiatry 1999 Aug;38(8):939-40 . Comment on: J Am Acad Child Adolesc Psychiatry 1998 Sep;37(9):924-32.

Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. Kirby KN, et al. **J Exp Psychol Gen** 1999 Mar;128(1):78-87

Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males. LeMarquand DG, et al. **Neuropsychopharmacology** 1998 Oct;19(4):333-41

The pharmacology of impulsive behaviour in rats II: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and other drugs on fixed consecutive number schedules (FCN 8 and FCN 32). Evenden JL. **Psychopharmacology (Berl)** 1998 Aug;138(3-4):283-94

The pharmacology of impulsive behaviour in rats III: the effects of amphetamine, haloperidol, imipramine, chlordiazepoxide and ethanol on a paced fixed consecutive number schedule. Evenden JL.
Psychopharmacology (Berl) 1998 Aug;138(3-4):295-304

[Classification of pathological drives in children and adolescents] Morozova IG.
Zh Nevrol Psikhiatr Im S S Korsakova 1998;98(9):17-21 (Eng. Abstr.) **(Rus)**

BLOOD

Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients. Apter A, et al. **Biol Psychiatry** 1999 Aug 15; 46(4):532-41

Serum cholesterol and impulsivity in personality disorders. New AS, et al. **Psychiatry Res** 1999 Feb 22;85(2):145-50

CHEMICALLY INDUCED

Increased impulsivity after injected alcohol predicts later alcohol consumption in rats: evidence for "loss-of-control drinking" and marked individual differences. Poulos CX, et al. **Behav Neurosci** 1998 Oct;112(5):1247-57

Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Morgan MJ.
Neuropsychopharmacology 1998 Oct;19(4):252-64

The pharmacology of impulsive behaviour in rats V: the effects of drugs on responding under a discrimination task using unreliable visual stimuli. Evenden J.
Psychopharmacology (Berl) 1999 Apr;143(2):111-22

Ethanol induces impulsive-like responding in a delay-of-reward operant choice procedure: impulsivity predicts autoshaping. Tomie A, et al.
Psychopharmacology (Berl) 1998 Oct;139(4):376-82

CLASSIFICATION

Impulsive and premeditated aggression: a factor analysis of self-reported acts. Barratt ES, et al. **Psychiatry Res** 1999 May 31;86(2):163-73

DIAGNOSIS

Impulsivity: core aspect of borderline personality disorder. Links PS, et al. **J Personal Disord** 1999 Spring;13(1):1-9

Impulse-control disorders in alcoholics are related to sensation seeking and not to impulsivity. Lejoyeux M, et al. **Psychiatry Res** 1998 Nov 16;81(2):149-55

Compulsiveness and impulsiveness: unidimensional or bidimensional constructs? Ketzenberger KE, et al.
Psychol Rep 1998 Aug;83(1):303-6

[The hyperkinetic patient in the light of PASS theory] Pérez-Alvarez F, et al. **Rev Neurol** 1999 Mar 1-15; 28(5):472-5 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Lamotrogine and impulse behaviour [letter] Daly KA, et al. **Can J Psychiatry** 1999 May;44(4):395-6

Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. Kavoussi RJ, et al.
J Clin Psychiatry 1998 Dec;59(12):676-80

The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. Cath DC, et al. **Psychopharmacology (Berl)** 1999 May;144(2):137-43

The pharmacology of impulsive behaviour in rats IV: the effects of selective serotonergic agents on a paced fixed consecutive number schedule. Evenden JL.
Psychopharmacology (Berl) 1998 Dec;140(3):319-30

ETIOLOGY

Cycles and epicycles of autism [letter] Fitzgerald M.
J Autism Dev Disord 1999 Apr;29(2):183

Delay or probability discounting in a model of impulsive behavior: effect of alcohol. Richards JB, et al.
J Exp Anal Behav 1999 Mar;71(2):121-43

Persistent Klüver-Bucy syndrome after bilateral thalamic infarction. Müller A, et al.
Neuropsychiatry Neuropsychol Behav Neurol 1999 Apr; 12(2):136-9

[Murderous impulses in two patients with chronic hepatitis C treated with interferon alpha (letter)] Rifflet H, et al. **Gastroenterol Clin Biol** 1998 Jan;22(1):105-6 **(Fre)**

[Callosal dementia: behavioral disorders related to central and extrapontine myelinolysis] Ghika-Schmid F, et al.
Rev Neurol (Paris) 1999 May;155(5):367-73 (Eng. Abstr.) **(Fre)**

GENETICS

Genetic correlation between performance on an appetitive-signaled nosepoke task and voluntary ethanol consumption. Logue SF, et al. **Alcohol Clin Exp Res** 1998 Dec;22(9):1912-20

Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior. Hallikainen T, et al. **Mol Psychiatry** 1999 Jul;4(4):385-8

Etiology of the impulsivity/aggression relationship: genes or environment? Seroczynski AD, et al. **Psychiatry Res** 1999 Apr 19;86(1):41-57

[Heredity and role of serotonin in aggressive impulsive behavior] Staner L, et al. **Encephale** 1998 Jul-Aug; 24(4):355-64 (90 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Hibbeln JR, et al. **Biol Psychiatry** 1998 Aug 15;44(4):243-9

PHYSIOPATHOLOGY

Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder. Boix F, et al. **Behav Brain Res** 1998 Jul;94(1):153-62

Behavioral disinhibition following basal forebrain excitotoxin lesions: alcohol consumption, defensive aggression, impulsivity and serotonin levels. Johansson AK, et al.
Behav Brain Res 1999 Jul;102(1-2):17-29

Attention deficit/hyperactivity disorder--from brain dysfunctions to behaviour [editorial] Sagvolden T, et al. **Behav Brain Res** 1998 Jul;94(1):1-10 (88 ref.)

The self-mutilative nature of severe onychophagia: a comparison with self-cutting. Wells JH, et al.
Can J Psychiatry 1999 Feb;44(1):40-7

Development of inhibitory control across the life span. Williams BR, et al. **Dev Psychol** 1999 Jan;35(1):205-13

Associations between event-related potentials and measures of attention and inhibition in the Continuous Performance Task in children with ADHD and normal controls. Overtoom CC, et al.
J Am Acad Child Adolesc Psychiatry 1998 Sep;37(9):977-85

Self-reported impulsivity is correlated with laboratory-measured escape behavior. Bjork JM, et al.
J Gen Psychol 1998 Apr;125(2):165-74

PREVENTION & CONTROL

Using rational suicide as an intervention to prevent irrational suicide. Werth JL. **Crisis** 1998;19(4):185-92

PSYCHOLOGY

Impulsive corporal punishment by mothers and antisocial behavior and impulsiveness of children. Straus MA, et al. **Behav Sci Law** 1998 Summer;16(3):353-74

Impulsivity as a correlate of suicidal behavior in adolescent psychiatric inpatients. Horesh N, et al. **Crisis** 1999; 20(1):8-14

Excessive discounting of delayed rewards in substance abusers with gambling problems. Petry NM, et al.
Drug Alcohol Depend 1999 Aug 2;56(1):25-32

Inattention, impulsivity, and hyperactivity from preschool to school age: performance of hard-to-manage boys on laboratory measures. Marakovitz SE, et al.
J Child Psychol Psychiatry 1998 Sep;39(6):841-51

Impulsivity: a discussion of clinical and experimental findings. Evenden J. **J Psychopharmacol** 1999;13(2):180-92 (100 ref.)

Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. Leech SL, et al.
Neurotoxicol Teratol 1999 Mar-Apr;21(2):109-18

Laboratory measures of aggression and impulsivity in women with borderline personality disorder. Dougherty DM, et al. **Psychiatry Res** 1999 Mar 22;85(3):315-26

The Yale Children's Inventory--a screening tool for attention deficits and related disorders. Normative data for boys. Olafsen KS, et al. **Scand J Psychol** 1999 Jun; 40(2):121-5

[Types of impulse control disorders in children and adolescents] Luss LA.
Zh Nevrol Psikhiatr Im S S Korsakova 1998;98(12):14-7 (Eng. Abstr.) **(Rus)**

[Compulsive buying: a new disorder?] de Lucas Taracena MT, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998 Jul-Aug;26(4):264-72 (47 ref.) (Eng. Abstr.) **(Spa)**

[The hyperkinetic patient in the light of PASS theory] Pérez-Alvarez F, et al. **Rev Neurol** 1999 Mar 1-15; 28(5):472-5 (Eng. Abstr.) **(Spa)**

THERAPY

The sexual struggles of 23 clergymen: a follow-up study. Fones CS, et al. **J Sex Marital Ther** 1999 Jul-Sep; 25(3):183-95

IN-HOSPITAL MORTALITY see **HOSPITAL MORTALITY**

IN SITU HYBRIDIZATION

Non-isotopic in situ hybridization of HPV types in cervical intraepithelial lesions in patients with AIDS. Calore EE, et al. **Arch Gynecol Obstet** 1998;262(1-2):75-9

Rapid decalcification using microwaves for in situ hybridization in skeletal tissues. Kaneko M, et al.
Biotech Histochem 1999 Jan;74(1):49-54

Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Lacy MQ, et al.
Blood 1999 Jan 1;93(1):300-5

In situ mRNA hybridization study of the distribution of choline acetyltransferase in the human brain. Kasashima S, et al. **Brain Res** 1998 Sep 21;806(1):8-15

Discrete distribution of the neuropeptide Y Y5 receptor gene in the human brain: an in situ hybridization study. Jacques D, et al. **Brain Res Mol Brain Res** 1998 Oct 30; 61(1-2):100-7

An immunohistochemical and in situ hybridisation study of the postnatal development of uncoupling protein-1 and uncoupling protein-1 mRNA in lamb perirenal adipose tissue. Finn D, et al. **Cell Tissue Res** 1998 Dec;294(3):461-6

CpG islands detected by self-primed in situ labeling (SPRINS). Andersen CL, et al. **Chromosoma** 1998 Sep; 107(4):260-6

Comparative analysis of crossover exchanges and chiasmata in Allium cepa x fistulosum after genomic in situ hybridization (GISH). Stevenson M, et al.
Chromosome Res 1998 Nov;6(7):567-74

Morphological analysis of in situ hybridization signals in cervical intraepithelial neoplasia containing human papillomavirus type 16 or 18: relationship with histological grade and DNA content. Lizard G, et al. **Cytometry** 1998 Aug 15;34(4):180-6

Adapting in situ polymerase chain reaction for genotyping of cells in suspension. Brownie J, et al.
Diagn Mol Pathol 1998 Oct;7(5):241-7

Discrimination of human papillomavirus types in low and high grade cervical squamous neoplasia by in situ hybridization. Southern SA, et al. **Diagn Mol Pathol** 1998 Apr;7(2):114-21

Evidence for a GABAergic projection from the central nucleus of the amygdala to the brainstem of the macaque monkey: a combined retrograde tracing and in situ hybridization study. Jongen-Rêlo AL, et al.
Eur J Neurosci 1998 Sep;10(9):2924-33

Cytogenetic and in situ hybridization findings in 27 patients with atypical B-cell chronic lymphocytic leukaemia [letter] Espinet B, et al. **Haematologica** 1999 Jun;84(6):569-71

Discrepancies between detection of Bcl-2 by in situ hybridization and immunocytochemistry in human prostate cancer tissues. Fiorentino M, et al. **Int J Cancer** 1998 Dec 18;79(6):614-8

Messenger ribonucleic acid in situ hybridization analysis of estrogen receptors alpha and beta in human breast carcinoma. Sasano H, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):781-5

A question of faith--or the philosophy of RNA controls. Ivell R. **J Endocrinol** 1998 Nov;159(2):197-200

Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization. Cook PM, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2411-7

The potential of in situ hybridization and an immunogold assay to identify Legionella associations with other microorganisms. Desai R, et al. **J Microbiol Methods** 1999 Aug;37(2):155-64

Altered subcellular localization patterns of ferritin and beta-actin mRNAs in muscle cultures, resulting from incomplete penetration of digoxigenin-labelled riboprobes. Lu Z, et al. **J Neurocytol** 1998 Jun;27(6):411-8

Differential expression of c-fos mRNA in the rat neocortex by in situ hybridization. Onodera H, et al. **Life Sci** 1999; 64(13):1127-35

In situ hybridization in paracoccidioidomycosis. De Brito T,

et al. **Med Mycol** 1999 Jun;37(3):207–11

Oligodeoxynucleotides as probes for in situ hybridization with transmission electron microscopy to specifically localize phytoplasma in plant cells. Lherminier J, et al. **Mol Cell Probes** 1999 Feb;13(1):41–7

Subcellular localization of mRNA in neuronal cells. Contributions of high-resolution in situ hybridization techniques. Martone ME, et al. **Mol Neurobiol** 1998 Dec; 18(3):227–46 (122 ref.)

Prolonged noxious stimulation increases periaqueductal gray NMDA mRNA expression: a hybridization study using two different rat models for nociception. Renno WM. **Neurobiology (Bp)** 1998;6(3):333–57

Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Ogata A, et al. **Neurosci Lett** 1998 May 1;246(3):173–7

Basics of molecular biology and its applications: III. Polymerase chain reaction and in situ hybridization. Erasmus RT, et al. **P N G Med J** 1996 Dec;39(4):321–8

Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts. Gao J, et al. **Prostate** 1999 Apr 1;39(1):67–70

[Ovarian mucinous tumor of gastric and intestinal type associated with Peutz-Jeghers syndrome: in situ hybridization study of apomucin gene transcripts] Wacrenier A, et al. **Ann Pathol** 1998 Dec;18(6):497–501 (Eng. Abstr.) **(Fre)**

[Clinical usefulness of papillomavirus detection with in situ hybridization in patients with intraepithelial squamous lesions of the cervix uteri (letter)] Garcia-Diaz JD. **Med Clin (Barc)** 1998 Nov 14;111(16):635–6 **(Spa)**

METHODS

Application of an in situ PCR hybridization method to detection of human T-lymphotropic virus type I-infected cells in the lung. Qiu Y, et al. **Acta Med Okayama** 1999 Feb;53(1):1–4

Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications. Davison JM, et al. **Am J Pathol** 1998 Nov;153(5):1401–9

A homogeneous chemiluminescent assay for telomerase. Lackey DB. **Anal Biochem** 1998 Oct 1;263(1):57–61

Detection of Chlamydia pneumoniae by colorimetric in situ hybridization. Alakärppä H, et al. **APMIS** 1999 Apr; 107(4):451–4

In situ identification of cyanobacteria with horseradish peroxidase-labeled, rRNA-targeted oligonucleotide probes. Schönhuber W, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1259–67

Ultrastructural in situ hybridization: a review of technical aspects. Le Guellec D. **Biol Cell** 1998 Jul;90(4):297–306 (51 ref.)

Improvement of nonradioactive DNA in situ hybridization. Haas CJ, et al. **Biotech Histochem** 1998 Jul;73(4):228–32

Fast-in situ hybridization and immunoenzymatic color pigment detection of mouse bone marrow micronucleus. Kolanko CJ, et al. **Biotech Histochem** 1999 May;74(3):111–5

Improved sensitivity for high resolution in situ hybridization using resin extraction of methyl methacrylate embedded material. Saito C, et al. **Biotech Histochem** 1999 Jan; 74(1):40–8

Evaluation of the effects of DNase treatment on signal specificity in RT-PCR and in situ RT-PCR. Ivarsson K, et al. **Biotechniques** 1998 Oct;25(4):630–2, 634, 636 passim

Rational design of oligonucleotide probes to avoid optimization steps in in situ hybridization. Erdtmann-Vourliotis M, et al. **Brain Res Brain Res Protoc** 1999 Apr;4(1):82–91

Advantage of double labeled in situ hybridization for detecting the effects of glucocorticoids on the mRNAs of protooncogenes and neural peptides (TRH) in cultured hypothalamic neurons. Luo LG, et al. **Brain Res Brain Res Protoc** 1999 Jul;4(2):201–8

Highly sensitive radioactive in situ hybridization using full length hydrolyzed riboprobes to detect alpha 2 adrenoceptor subtype mRNAs in adult and developing rat brain. Winzer-Serhan UH, et al. **Brain Res Brain Res Protoc** 1999 Jan;3(3):229–41

Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Aubele M, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):94–102

Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Koo SH, et al. **Cancer Genet Cytogenet** 1999 Apr 15;110(2):87–93

Third-strand in situ hybridization (TISH) to non-denatured metaphase spreads and interphase nuclei. Johnson MD 3rd, et al. **Chromosoma** 1999 Jul;108(3):181–9

Heterochromatin discrimination in Aegilops speltoides by simultaneous genomic in situ hybridization. Belyayev A, et al. **Chromosome Res** 1998 Nov;6(7):559–65

Electron microscopic in situ hybridization of digoxigenin-dUTP-labelled DNA probes with Drosophila melanogaster polytene chromosomes. Semeshin VF, et al. **Chromosome Res** 1998 Aug;6(5):405–10

Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Nilsson C, et al. **Clin Endocrinol (Oxf)** 1998 Sep; 49(3):369–76

Identification and characterization of a de novo partial trisomy 10p by comparative genomic hybridization (CGH). Benzacken B, et al. **Clin Genet** 1998 Oct;54(4):334–40

Detection of numerical chromosome 17 abnormalities in fine-needle aspirates of breast cancer using a novel in situ hybridization signal amplification method. Schmitt FC, et al. **Diagn Cytopathol** 1998 Aug;19(2):141–6

Automated in situ hybridization: diagnostic and research applications. Capodieci P, et al. **Diagn Mol Pathol** 1998 Apr;7(2):69–75 (43 ref.)

In situ hybridization detection of low copy nucleic acid sequences using catalyzed reporter deposition and its usefulness in clinical human papillomavirus typing. Plummer TB, et al. **Diagn Mol Pathol** 1998 Apr;7(2):76–84

Flow cytometry in situ polymerase chain reaction as an innovative approach to HIV-1 proviral DNA detection. Gibellini D, et al. **Eur J Histochem** 1998;42(2):137–41 (16 ref.)

High performance Nanogold-silver in situ hybridisation. Hacker GW. **Eur J Histochem** 1998;42(2):111–20 (70 ref.)

In-situ polymerase chain reaction: foundation of the technology and today's options. Long AA. **Eur J Histochem** 1998;42(2):101–9 (56 ref.)

A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimens. Poulsom R, et al. **Eur J Histochem** 1998;42(2):121–32

Comparison of isotopic and non-isotopic labelling for in situ hybridisation of various mRNA targets with cRNA probes. Steel JH, et al. **Eur J Histochem** 1998;42(2):143–50

Hybridocytochemical detection of mRNA for calcitonin, CGRP, somatostatin and NPY in cultured cells of medullary thyroid carcinoma using immunomax technique. Kasprzak A, et al. **Folia Histochem Cytobiol** 1999; 37(2):59–60

An anchored framework BAC map of mouse chromosome 11 assembled using multiplex oligonucleotide hybridization. Cai WW, et al. **Genomics** 1998 Dec 15;54(3):387–97

Improved mRNA in situ hybridization on formaldehyde-fixed and paraffin-embedded tissue using signal amplification with different haptenized tyramides. Speel EJ, et al. **Histochem Cell Biol** 1998 Dec;110(6):571–7

Comparison of in-situ hybridization, direct and indirect in-situ PCR as well as tyramide signal amplification for the detection of HPV. Wiedorn KH, et al. **Histochem Cell Biol** 1999 Feb;111(2):89–95

Successful application of indirect in-situ polymerase chain reaction to tissues fixed in Bouin's solution. Li Vigni R, et al. **Histopathology** 1999 Aug;35(2):134–43

Characterization of diverse viral vector preparations, using a simple and rapid whole-virion dot-blot method. Nelson DM, et al. **Hum Gene Ther** 1998 Nov 1;9(16):2401–5

In situ hybridization: a molecular approach for the diagnosis of the microsporidian parasite Enterocytozoon bieneusi. Velásquez JN, et al. **Hum Pathol** 1999 Jan;30(1):54–8

Co-localization of HP1 and TP1 transcripts in human spermatids by double electron microscopy in situ hybridization. Siffroi JP, et al. **Int J Androl** 1999 Apr; 22(2):83–90

In situ detection of Aspergillus 18S ribosomal RNA in invasive pulmonary aspergillosis. Kobayashi M, et al. **Intern Med** 1999 Jul;38(7):563–9

The use of molecular technologies for the detection of enteroviral ribonucleic acid in myocarditis. Micevski V. **J Cardiovasc Nurs** 1999 Jul;13(4):78–90 (31 ref.)

Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization. EDTA is highly preferable to a routinely used acid decalcifier. Alers JC, et al. **J Histochem Cytochem** 1999 May;47(5):703–10

High-resolution in situ hybridization and TUNEL staining with free-floating brain sections. Bessert DA, et al. **J Histochem Cytochem** 1999 May;47(5):693–702

Ultrastructural localization of beta-actin and amphoterin mRNA in cultured cells: application of tyramide signal amplification and comparison of detection methods. Punnonen EL, et al. **J Histochem Cytochem** 1999 Jan; 47(1):99–112

Amplification methods to increase the sensitivity of in situ hybridization: play card(s). Speel EJ, et al. **J Histochem Cytochem** 1999 Mar;47(3):281–8 (74 ref.)

An optimized method for in situ hybridization with signal amplification that allows the detection of rare mRNAs. Yang H, et al. **J Histochem Cytochem** 1999 Apr; 47(4):431–46

In situ hybridization analysis of immunoglobulin heavy chain variable gene expression with family specific oligonucleotide probes. Rundle CH, et al. **J Immunol Methods** 1998 Sep 1;218(1-2):31–52

Rapid and easy detection of Helicobacter pylori by in situ hybridization. Park CS, et al. **J Korean Med Sci** 1999 Feb; 14(1):15–20

A non-radioactive in situ hybridization method that does not require RNAse-free conditions. Tongiorgi E, et al. **J Neurosci Methods** 1998 Dec 1;85(2):129–39

Quantitation of multiple gene expression by in situ hybridization autoradiography: accurate normalization using Bayes classifier. Zhao W, et al. **J Neurosci Methods** 1999 Apr 1;88(1):63–70

Reducing the number of microlocations in oligonucleotide microchip matrices by the application of degenerate oligonucleotides. Sachadyn P, et al. **J Theor Biol** 1999 Apr 7;197(3):393–401

In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Hernández-Presa MA, et al. **Kidney Int** 1999 Jan;55(1):209–14

Enumeration of Carnobacterium divergens V41, Carnobacterium piscicola V1 and Lactobacillus brevis LB62 by in situ hybridization-flow cytometry. Connil N, et al. **Lett Appl Microbiol** 1998 Nov;27(5):302–6

Monitoring antisense oligodeoxynucleotide activity in hematopoietic cells. Sokol DL, et al. **Methods** 1999 Mar; 17(3):219–30 (112 ref.)

In situ hybridization with RNA probes. Breier G. **Methods Mol Biol** 1999;96:107–17 (4 ref.)

In situ molecular hybridization techniques for ultrathin sections. Fournier JG, et al. **Methods Mol Biol** 1999; 117:167–81 (40 ref.)

Wholemount in situ hybridization to amphioxus embryos. Holland PW. **Methods Mol Biol** 1999;97:641–4

Wholemount in situ hybridization to Xenopus embryos. Jones CM, et al. **Methods Mol Biol** 1999;97:635–40

In situ hybridization of radioactive riboprobes to RNA in tissue sections. Mahmood R, et al. **Methods Mol Biol** 1999; 97:611–21

In situ hybridization to human chromosomes of an alkaline phosphatase-labeled centromeric probe. Nardone RM. **Methods Mol Biol** 1999;115:365–70 (4 ref.)

mRNA: detection by in Situ and northern hybridization. Parker RM, et al. **Methods Mol Biol** 1999;106:247–83 (30 ref.)

In situ hybridization to sections (nonradioactive). Rex M, et al. **Methods Mol Biol** 1999;97:645–53

In situ hybridization to RNA in whole embryos. Shamim H, et al. **Methods Mol Biol** 1999;97:623–33

In situ RT-PCR and hybridization techniques. Thaker V. **Methods Mol Biol** 1999;115:379–402 (46 ref.)

Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method [see comments] Huang CC, et al. **Mod Pathol** 1998 Oct;11(10):971–7. Comment in: Mod Pathol 1999 Jul;12(7):744–5.

Correspondence re: Huang C-C, Qui J-T, Kashima ML, Kurman RJ, Wu T-C. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol 1998;11:971–7 [letter; comment] Nuovo G. **Mod Pathol** 1999 Jul;12(7):744–5. Comment on: Mod Pathol 1998 Oct;11(10):971–7.

In situ localization of PCR-amplified DNA and cDNA. Nuovo GJ. **Mol Biotechnol** 1998 Aug;10(1):49–62

Quantitative aspects of an in situ hybridization procedure for detecting mRNAs in cells using 96-well microplates. Zreiqat H, et al. **Mol Biotechnol** 1998 Oct;10(2):107–13

In cell amplification. Uhlmann V, et al. **Mol Pathol** 1998 Jun;51(3):119–30 (60 ref.)

A comparison of cytochrome b and DNA hybridization data bearing on the phylogeny of swallows (Aves: Hirundinidae). Sheldon FH, et al. **Mol Phylogenet Evol** 1999 Mar;11(2):320–31

Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Howell WM, et al. **Nat Biotechnol** 1999 Jan;17(1):87–8

EBER oligonucleotide RNA in situ hybridization in EBV associated neoplasms. Tornóczky T, et al. **Pathol Oncol Res** 1998;4(3):201–5

Accurate and high resolution in situ hybridization analysis of gene expression in secondary stem tissues. Regan S, et al. **Plant J** 1999 Aug;19(3):363–9

A rapid and sensitive method for detecting human cells in xenogeneic hosts. Zompa EA, et al. **Transplantation** 1998 Oct 15;66(7):928–31

[Detection of receptor mRNAs using nonradioactive in situ hybridization] Shin M, et al. **Nippon Rinsho** 1998 Jul; 56(7):1667–73 (20 ref.) (Eng. Abstr.) **(Jpn)**

[The expression of c-myc gene detected by in situ hybridization in endometrial hyperplasia] Skrzypczak M, et al. **Ginekol Pol** 1998 Nov;69(11):800–4 (Eng. Abstr.) **(Pol)**

[The application of the hybridization in colonies technic for the identification of toxigenic Vibrio cholerae 01] Bravo Fariñas L, et al. **Rev Cubana Med Trop** 1996;48(3):169–70 (Eng. Abstr.) **(Spa)**

VETERINARY

Detection and distribution of DNA of Actinobacillus pleuropneumoniae in the lungs of naturally infected pigs by in-situ hybridization. Min K, et al. **J Comp Pathol** 1998 Aug;119(2):169–75

In situ hybridization for the detection and localization of swine Chlamydia trachomatis. Chae C, et al. **Vet Pathol** 1999 Mar;36(2):133–7

IN SITU HYBRIDIZATION, FLUORESCENCE

Fluorescence in situ hybridization and surface markers of fine needle aspiration specimen confirm extramedullary myeloblastoma in a patient with chronic myeloid leukemia. Karthaus M, et al. **Acta Haematol** 1998;100(2):91–3

Eosinophils and basophils carry the fused BCR/ABL gene in chronic myelogenous leukemia: direct fluorescence in situ hybridization analysis on blood smears. Lee W, et al. **Acta Haematol** 1998;100(2):106–9

DNA in situ hybridization as an adjunct in tumor diagnosis. Fletcher JA. **Am J Clin Pathol** 1999 Jul;112(1 Suppl 1):S11-8 (27 ref.)

Multiplex-FISH for pre- and postnatal diagnostic applications. Uhrig S, et al. **Am J Hum Genet** 1999 Aug; 65(2):448-62

Sperm aneuploidy among Chinese pesticide factory workers: scoring by the FISH method. Padungtod C, et al. **Am J Ind Med** 1999 Aug;36(2):230-8

Mosaicism in Prader-Willi syndrome: detection using fluorescent in situ hybridization [letter] Golden WL, et al. **Am J Med Genet** 1999 Aug 6;85(4):424-5

Duplication within chromosome 5q characterized by fluorescence in situ hybridization. Mowat D, et al. **Am J Med Genet** 1999 Apr 23;83(5):361-4

Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Glassman AB. **Ann Clin Lab Sci** 1998 Nov-Dec;28(6):324-30 (19 ref.)

Comparison of comparative genomic hybridization, fluorescence in situ hybridization and flow cytometry in urinary bladder cancer. Mahdy E, et al. **Anticancer Res** 1999 Jan-Feb;19(1A):7-12

Conventional cytogenetics alone is not sufficient for identifying interspecies cell line contamination. Multani AS, et al. **Anticancer Res** 1999 May-Jun;19(3A):1753-4

Detection of chromosome 11q13 amplification in head and neck cancer using fluorescence in situ hybridization. Wang MB, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):925-31

In situ detection of rhodococci associated with activated sludge foams. Davenport RJ, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):41-8

Counting and size classification of active soil bacteria by fluorescence in situ hybridization with an rRNA oligonucleotide probe. Christensen H, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1753-61

Community analysis of biofilters using fluorescence in situ hybridization including a new probe for the Xanthomonas branch of the class Proteobacteria. Friedrich U, et al. **Appl Environ Microbiol** 1999 Aug;65(8):3547-54

In situ analysis of nitrifying biofilms as determined by in situ hybridization and the use of microelectrodes. Okabe S, et al. **Appl Environ Microbiol** 1999 Jul;65(7):3182-91

Fluorescence in situ hybridization using 16S rRNA-targeted oligonucleotides reveals localization of methanogens and selected uncultured bacteria in mesophilic and thermophilic sludge granules. Sekiguchi Y, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1280-8

In situ analysis of phototrophic sulfur bacteria in the chemocline of meromictic Lake Cadagno (Switzerland). Tonolla M, et al. **Appl Environ Microbiol** 1999 Mar; 65(3):1325-30

Fluorescence in situ hybridization (FISH) screening of frozen cell lines in large numbers. Lo AW, et al. **Biotechniques** 1999 Mar;26(3):408-10, 412

Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Saitoh K, et al. **Blood** 1998 Oct 15;92(8):2886-92

Interphase FISH: a rapid method for detecting malignant plasma cells in multiple myeloma patients submitted to autologous transplantation. Dascalescu CM, et al. **Bone Marrow Transplant** 1999 Apr;23(7):687-94

Clonality determined by fluorescence in situ hybridization of single-cell aberrations in hematopoietic neoplasias [letter] Gebhart T, et al. **Cancer Genet Cytogenet** 1999 Sep; 113(2):193-4

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Kuipers J, et al. **Cancer Genet Cytogenet** 1999 Mar; 109(2):99-107

Detection of t(12;21) in childhood acute lymphoblastic leukemia by fluorescence in situ hybridization. Spathas DH, et al. **Cancer Genet Cytogenet** 1999 Apr;110(1):7-13

Detection of monosomy 7 in bone marrow by fluorescence in situ hybridization. A study of Fanconi anemia patients and review of the literature. Thurston VC, et al. **Cancer Genet Cytogenet** 1999 Mar;109(2):154-60

Validation of primed in situ labeling (PRINS) for interphase analysis: comparative studies with conventional fluorescence in situ hybridization and chromosome analyses. Velagaleti GV, et al. **Cancer Genet Cytogenet** 1999 Jan 15;108(2):100-6

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays [published erratum appears in Cancer Res 1999 Mar 15;59(6):1388] Bubendorf L, et al. **Cancer Res** 1999 Feb 15;59(4):803-6

Characterisation of the nucleolar organising regions during the cell cycle in two varieties of Petunia hybrida as visualised by fluorescence in situ hybridisation and silver staining. Montijn MB, et al. **Chromosoma** 1998 May; 107(2):80-6

Polymorphism of the nucleolus organizer regions (NORs) in Physalaemus petersi (Amphibia, Anura, Leptodactylidae) detected by silver staining and fluorescence in situ hybridization. Lourenço LB, et al. **Chromosome Res** 1998 Dec;6(8):621-8

ZOO-FISH analysis in a species of the order Chiroptera: Glossophaga soricina (Phyllostomidae). Volleth M, et al. **Chromosome Res** 1999;7(1):57-64

FISH analysis in both classical and atypical cases of Williams-Beuren syndrome. Hou JW, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov-Dec;39(6):398-403

Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma. Takahashi S, et al. **Clin Cancer Res** 1996 Jan;2(1):137-45

The evaluation of 15q proximal duplications by FISH. Riordan D, et al. **Clin Genet** 1998 Dec;54(6):517-21

Mosaic supernumerary marker chromosome identified as a der(3) by FISH [letter] Rothemund H, et al. **Clin Genet** 1998 Dec;54(6):526-7

The importance of cytogenetics and associated molecular techniques in the management of patients with leukaemia. Harrison CJ, et al. **Clin Oncol (R Coll Radiol)** 1998; 10(4):255-61 (54 ref.)

In situ methods for assessment of microorganisms and their activities. Amann R, et al. **Curr Opin Microbiol** 1998 Jun; 1(3):352-8 (66 ref.)

Assignment of the human dynein heavy chain gene DNAH17L to human chromosome 17p12 by in situ hybridization and radiation hybrid mapping. Bartoloni L, et al. **Cytogenet Cell Genet** 1999;84(3-4):188-9

Assignment of DLK1 to human chromosome band 14q32 by in situ hybridization. Gubina E, et al. **Cytogenet Cell Genet** 1999;84(3-4):206-7

Comparative FISH-mapping of six expressed gene loci to river buffalo and sheep chromosomes. Iannuzzi L, et al. **Cytogenet Cell Genet** 1999;84(3-4):161-3

Comparative genomic in situ hybridization discloses recurrent gain of chromosome 4 in experimental gliomas of the rat. Kappler R, et al. **Cytogenet Cell Genet** 1999; 84(3-4):194-8

FISH mapping of the mouse Ret oncogene to the junction of G-bands E3/F1 on chromosome 6 indicates a need for reassessment of the physical and consensus maps. Nitta Y, et al. **Cytogenet Cell Genet** 1999;84(3-4):186-7

Assignment of HSD17B5 encoding type 5 17 beta-hydroxysteroid dehydrogenase to human chromosome bands 10p15-->p14 and mouse chromosome 13 region A2 by in situ hybridization: identification of a new syntenic relationship. Rheault P, et al. **Cytogenet Cell Genet** 1999;84(3-4):241-2

Assignment1 of the PTP-SL/PTPBR7 gene (Ptprr/PTPRR) to mouse chromosome region 8A2 by in situ hybridization. van den Maagdenberg AM, et al. **Cytogenet Cell Genet** 1999;84(3-4):243-4

Assignment of human proliferation associated p100 gene (C20orf1) to human chromosome band 20q11.2 by in situ hybridization. Zhang Y, et al. **Cytogenet Cell Genet** 1999; 84(3-4):182-3

Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy. de Pauw ES, et al. **Cytometry** 1998 Jul 1; 32(3):163-9

High-resolution cytometry of FISH dots in interphase cell nuclei. Kozubek M, et al. **Cytometry** 1999 Aug 1; 36(4):279-93

Development of a preparation and staining method for fetal erythroblasts in maternal blood: simultaneous immunocytochemical staining and FISH analysis. Oosterwijk JC, et al. **Cytometry** 1998 Jul 1;32(3):170-7

Fetal cell detection in maternal blood: a study in 236 samples using erythroblast morphology, DAB and HbF staining, and FISH analysis. Oosterwijk JC, et al. **Cytometry** 1998 Jul 1;32(3):178-85

Chromosome 11 aneuploidy detected by fluorescent in situ hybridization (FISH) in breast cancer: relation with progesterone receptor expression. Mialhe A, et al. **Cytopathology** 1999 Apr;10(2):79-86

Characterization of Aequipecten opercularis (Bivalvia: Pectinidae) chromosomes by different staining techniques and fluorescent in situ hybridization. Insua A, et al. **Genes Genet Syst** 1998 Aug;73(4):193-200

Prepregnancy genetic testing for age-related aneuploidies by polar body analysis. Verlinsky Y, et al. **Genet Test** 1997-98; 1(4):231-5 (13 ref.)

Localization of single- and low-copy sequences on tomato synaptonemal complex spreads using fluorescence in situ hybridization (FISH). Peterson DG, et al. **Genetics** 1999 May;152(1):427-39

Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization [letter] Gutiérrez NC, et al. **Haematologica** 1999 Jan; 84(1):88-90

Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia. Liso V, et al. **Haematologica** 1999 Mar;84(3):212-7

FISH for Y chromosome in women with primary biliary cirrhosis: lack of evidence for leukocyte microchimerism [letter] Rubbia-Brandt L, et al. **Hepatology** 1999 Sep; 30(3):821-2

FISH-detected delay in replication timing of mutated FMR1 alleles on both active and inactive X-chromosomes. Yeshaya J, et al. **Hum Genet** 1999 Jul-Aug;105(1-2):86-97

Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. Fiche M, et al. **Int J Cancer** 1999 Oct 22;84(5):511-5

Monitoring of remission status by fluorescence in situ hybridisation in chronic myeloid leukaemia patients treated with interferon-alpha. Duba HC, et al. **Int J Oncol** 1999 Jan;14(1):145-50

Direct detection and identification of Mycobacterium tuberculosis in smear-positive sputum samples by fluorescence in situ hybridization (FISH) using peptide nucleic acid (PNA) probes. Stender H, et al. **Int J Tuberc Lung Dis** 1999 Sep;3(9):830-7

Genetics of childhood disorders: VI. FISH, FISH, and more FISH. Ward D, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep;38(9):1200-2 (5 ref.)

Improving the fixation method for preimplantation genetic diagnosis by fluorescent in situ hybridization. Xu K, et al. **J Assist Reprod Genet** 1998 Oct;15(9):570-4

Fluorescence In situ hybridization assay using peptide nucleic acid probes for differentiation between tuberculous and nontuberculous mycobacterium species in smears of mycobacterium cultures. Stender H, et al. **J Clin Microbiol** 1999 Sep;37(9):2760-5

Detection of KAL-1 gene deletion with fluorescence in situ hybridization. Hou JW, et al. **J Formos Med Assoc** 1999 Jun;98(6):448-51

Breakpoint mapping by FISH in a Sotos patient with a constitutional translocation t(3;6) [letter] Kok K, et al. **J Med Genet** 1999 Apr;36(4):346-7

Two 22q telomere deletions serendipitously detected by FISH. Precht KS, et al. **J Med Genet** 1998 Nov; 35(11):939-42

A FISH study of chromosome fusion in the ICF syndrome: involvement of paracentric heterochromatin but not of the centromeres themselves. Sumner AT, et al. **J Med Genet** 1998 Oct;35(10):833-5

Four-dimensional factor analysis of confocal image sequences (4D-FAMIS) to detect and characterize low copy numbers of human papillomavirus DNA by FISH in HeLa and SiHa cells. Kahn E, et al. **J Microsc** 1999 Mar;193 (Pt 3):227-43

Detection of numerical chromosome abnormalities in human spermatozoa by three-color fluorescence in situ hybridization. Li P, et al. **J Obstet Gynaecol Res** 1998 Dec; 24(6):385-92

The impact of FISH on our understanding of testicular tumour development [editorial] Ensinger C, et al. **J Pathol** 1998 Nov;186(3):225-6

Fluorescence in situ hybridization analysis of chromosome 12 anomalies in semen cells from patients with carcinoma in situ of the testis. Meng FJ, et al. **J Pathol** 1998 Nov; 186(3):235-9

Visualization of alternative Epstein-Barr virus expression programs by fluorescent in situ hybridization at the cell level. Szeles A, et al. **J Virol** 1999 Jun;73(6):5064-9

Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Alavi S, et al. **Laryngoscope** 1999 Jun;109(6):874-9

Evaluation of fluorochromes for flow cytometric detection of Cryptosporidium parvum oocysts labelled by fluorescent in situ hybridization. Deere D, et al. **Lett Appl Microbiol** 1998 Dec;27(6):352-6

Fish analysis at diagnosis in acute lymphoblastic leukemia. Avet-Loiseau H. **Leuk Lymphoma** 1999 May;33(5-6):441-9 (43 ref.)

Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist? Genevieve F, et al. **Leukemia** 1999 Apr;13(4):641-4

Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Yanagi M, et al. **Leukemia** 1999 Apr;13(4):542-52

Fluorescence in situ hybridization: 1998. Stanley PE, et al. **Luminescence** 1999 Jul-Aug;14(4):221-30

FISH as an adjunct to conventional cytogenetics. Mark HF, et al. **Med Health R I** 1998 Oct;81(10):328-30

rRNA-targeted fluorescent in situ hybridization analysis of bacterial community structure in river water. Kenzaka T, et al. **Microbiology** 1998 Aug;144 (Pt 8):2085-93

Clinical experience of sex determination by fluorescent in-situ hybridization for preimplantation genetic diagnosis. Staessen C, et al. **Mol Hum Reprod** 1999 Apr;5(4):382-9

Cytogenetic study and FISH analysis in lymphocytes of systemic lupus erythematosus (SLE) and systemic sclerosis (SS) patients. Migliore L, et al. **Mutagenesis** 1999 Mar; 14(2):227-31

Detection of aneuploidy by multicolor FISH in mouse sperm after in vivo treatment with acrylamide, colchicine, diazepam or thiabendazole. Schmid TE, et al. **Mutagenesis** 1999 Mar;14(2):173-9

Counting the repetitive kringle-IV repeats in the gene encoding human apolipoprotein(a) by fibre-FISH [letter] Erdel M, et al. **Nat Genet** 1999 Apr;21(4):357-8

Detection of chromosomal abnormalities using fluorescence in situ hybridization (FISH). Jobanputra V, et al. **Natl Med J India** 1998 Nov-Dec;11(6):259-63

Factors associated with maternal cell contamination in amniocentesis samples as evaluated by fluorescent in situ hybridization. Hockstein S, et al. **Obstet Gynecol** 1998 Oct; 92(4 Pt 1):551-6

Utility of fluorescence in situ hybridization in pancreatic ductal adenocarcinoma. Adsay NV, et al. **Pancreas** 1999 Mar;18(2):111-6

Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens. Mark HF, et al. **Pathobiology** 1998;66(5):216–20

Quantitative chromosome map of the polyploid Saccharum spontaneum by multicolor fluorescence in situ hybridization and imaging methods. Ha S, et al. **Plant Mol Biol** 1999 Apr;39(6):1165–73

A prospective comparative study on fluorescence in situ hybridization (FISH) of uncultured amniocytes and standard karyotype analysis. Eiben B, et al. **Prenat Diagn** 1998 Sep;18(9):901–6

Overwhelming maternal cell contamination in amniotic fluid samples from patients with oligohydramnios can lead to false prenatal interphase FISH results [letter] Estabrooks LL, et al. **Prenat Diagn** 1999 Feb;19(2):179–81

Prenatal interphase detection by FISH of a sex chromosome mosaicism when cytogenetics reports a pseudomosaicism. Pettenati MJ, et al. **Prenat Diagn** 1999 Jan;19(1):25–8

FISH analysis of a complex chromosome rearrangement involving nine breakpoints on chromosomes 6, 12, 14 and 16. Phelan MC, et al. **Prenat Diagn** 1998 Nov; 18(11):1174–80

Prenatal diagnosis of mosaicism for tetrasomy 18p: cytogenetic, fish and morphological findings. Pinto MR, et al. **Prenat Diagn** 1998 Oct;18(10):1095–7

Minute chromosomal rearrangements detected prenatally by fluorescence in situ hybridization. Suzumori K, et al. **Prenat Diagn** 1998 Jul;18(7):725–30

Hybridization of chromosome 18 alpha-satellite DNA probe to chromosome 22. Thangavelu M, et al. **Prenat Diagn** 1998 Sep;18(9):922–5

Region-specific FISH probes used to identify and characterize an interstitial paracentric inv(21)(q22.1q22.3). Torchia BS, et al. **Prenat Diagn** 1998 Aug;18(8):849–53

Analysis of chromosome aneuploidy in sperm by fluorescence in situ hybridization--a new approach to the study of male fertility in environmental exposures. Asclepios. Lähdetie J, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:26–7

In situ detection of Escherichia coli cells containing ColE1-related plasmids by hybridization to regulatory RNA II. Juretschko S, et al. **Syst Appl Microbiol** 1999 Feb; 22(1):1–8

Comparative genomic hybridization: FISH and chips in our future? [editorial] Warburton D. **Teratology** 1999 May; 59(5):321–2

Chromosome translocations detected by fluorescence in situ hybridisation (FISH)--a useful tool in population monitoring? Pressl S, et al. **Toxicol Lett** 1998 Aug; 96–97:189–94

[Sex determination of human preimplantation embryo blastomere using dualcolor fluorescence in situ hybridization] Li W, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Aug; 16(4):255–8 (Eng. Abstr.) **(Chi)**

[A DNA probe suitable for the detection of chromosome 21 copy number in human interphase nuclei by fluorescence in situ hybridization] Shi Q, et al. **Chung Hua I Hsueh I Chuan Hsueh Tsa Chih** 1999 Feb 10;16(1):36–40 (Eng. Abstr.) **(Chi)**

[Aneuploidy detection by multi-color fluorescence in situ hybridization in mouse sperm] Wang X, et al. **I Chuan Hsueh Pao** 1999;26(2):112–8 (Eng. Abstr.) **(Chi)**

[Molecular cytogenetic diagnosis of Klinefelter's syndrome in men more frequently detects sex chromosome mosaicism than classical cytogenetic methods] Kurková S, et al. **Cas Lek Cesk** 1999 Apr 19;138(8):235–8 (Eng. Abstr.) **(Cze)**

[Registration of stable aberrations in peripheral blood lymphocytes using G-differential chromosome staining and fluorescence in situ hybridization methods] Obukhova TN, et al. **Radiats Biol Radioecol** 1998 Nov-Dec;38(6):793–9 (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe. Kalir T, et al. **Gynecol Oncol** 1999 Feb;72(2):208–14

METHODS

Sequential G-banding and fluorescent in situ hybridization on peripheral blood, bone marrow, and amniotic fluid samples. Wiktor A, et al. **Am J Med Genet** 1998 Aug 27; 79(1):38–41

Fast-FISH detection and semi-automated image analysis of numerical chromosome aberrations in hematological malignancies. Esa A, et al. **Anal Cell Pathol** 1998; 16(4):211–22

Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Franks AH, et al. **Appl Environ Microbiol** 1998 Sep;64(9):3336–45

Combination of fluorescent in situ hybridization and microautoradiography-a new tool for structure-function analyses in microbial ecology. Lee N, et al. **Appl Environ Microbiol** 1999 Mar;65(3):1289–97

Specific detection of green sulfur bacteria by in situ hybridization with a fluorescently labeled oligonucleotide probe. Tuschak C, et al. **Arch Microbiol** 1999 Mar; 171(4):265–72

Molecular hybridization probes prepared with 4-aminooxybutylamine. Adarichev VA, et al. **Bioconjug Chem** 1998 Nov-Dec;9(6):671–5

Fluorescence in situ hybridization of micronuclei in binucleate fibroblasts: a protocol for cytoplasm preservation. Broome EJ, et al. **Biotechniques** 1999 Apr; 26(4):610–2, 614

Efficient nuclear FISH on paraffin-embedded tissue sections using microwave pretreatment. Bull JH, et al. **Biotechniques** 1999 Mar;26(3):416–8, 422

Extending the useful life span of DNA probes for fluorescence in situ hybridization. Christian AT, et al. **Biotechniques** 1999 Jun;26(6):1068–72

Simple blocking system for use with maleimide-labeled nucleic acid probes. Fung J, et al. **Biotechniques** 1998 Sep; 25(3):390–2, 394

Detection of chromosome aberrations by FISH as a function of cell division cycle (harlequin-FISH). Jordan R, et al. **Biotechniques** 1999 Mar;26(3):532–4

Double FISH and FISH-fluorescence immunolocalization procedures for whole-mount Drosophila ovaries. Saunders C, et al. **Biotechniques** 1999 Feb;26(2):186–8

Tyramide signal amplification (TSA)-FISH applied to mapping PCR-labeled probes less than 1 kb in size. Schriml LM, et al. **Biotechniques** 1999 Sep;27(3):608–13

Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Finelli P, et al. **Blood** 1999 Jul 15; 94(2):724–32

DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Vaandrager JW, et al. **Blood** 1998 Oct 15; 92(8):2871–8

c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Mezzelani A, et al. **Br J Cancer** 1999 May; 80(3–4):519–25

Two-colour FISH detection of the inv(16) in interphase nuclei of patients with acute myeloid leukaemia. Dauwerse HG, et al. **Br J Haematol** 1999 Jul;106(1):111–4

The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Gruszka-Westwood AM, et al. **Br J Haematol** 1999 Mar;104(3):600–4

The impact of the new fish technologies on the cytogenetics of haematological malignancies. Kearney L. **Br J Haematol** 1999 Mar;104(4):648–58 (72 ref.)

Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Krauter J, et al. **Br J Haematol** 1998 Oct;103(1):72–8

Fluorescence in situ hybridization studies of interphase nuclei for assessing response to therapy in patients with chronic myeloid leukemia. Kobzev Y, et al. **Cancer Genet Cytogenet** 1998 Oct 15;106(2):128–34

Fluorescence in situ hybridization on G-banded chromosome preparations mounted with Eukitt in a retrospective study and in routine diagnostics [letter; comment] Liehr T, et al. **Cancer Genet Cytogenet** 1998 Nov;107(1):85–6. Comment on: Cancer Genet Cytogenet 1997 Oct 1;98(1):9–15.

Detection of translocation 8;21 on interphase cells from acute myelocytic leukemia by fluorescence in situ hybridization and its clinical application. Tanaka K, et al. **Cancer Genet Cytogenet** 1999 Aug;113(1):29–35

Direct visualisation of individual gene organisation in Trypanosoma brucei by high-resolution in situ hybridisation. Ersfeld K, et al. **Chromosoma** 1998 Sep; 107(4):237–40

Human sperm chromosome complements in chemotherapy patients and infertile men. Martin R. **Chromosoma** 1998 Dec;107(6–7):523–7

Molecular cytogenetic analysis of tetraploid and hexaploid Aegilops crassa. Badaeva ED, et al. **Chromosome Res** 1998 Dec;6(8):629–37

Cytogenetic alignment of the bovine chromosome 13 genome map by fluorescence in-situ hybridization of human chromosome 10 and 20 comparative markers. Gallagher DS Jr, et al. **Chromosome Res** 1999;7(2):115–9

Fibre-fluorescence in situ hybridization unravels apparently seven DAZ genes or pseudogenes clustered within a Y-chromosome region frequently deleted in azoospermic males. Gläser B, et al. **Chromosome Res** 1998 Sep;6(6):481–6

Eight molecular markers from bovine syntenic groups U2, U5, U24, U14, U12, U28, X and Y were fluorescence in situ mapped to eight river buffalo chromosomes. Iannuzzi L, et al. **Chromosome Res** 1998 Dec;6(8):656–9

Mapping the distribution of the telomeric sequence (T2AG3)n in the Macropodoidea (Marsupialia), by fluorescence in situ hybridization. I. The swamp wallaby, Wallabia bicolor. Metcalfe CJ, et al. **Chromosome Res** 1998 Dec;6(8):603–10

Fibre-fluorescence in situ hybridization directly performed from fresh biological samples: novel perspectives for genetic diagnosis. Pulcini F, et al. **Chromosome Res** 1998 Sep;6(6):501–3

Prenatal identification of de novo marker chromosomes using micro-FISH approach. Xu J, et al. **Clin Genet** 1998 Jun; 53(6):490–6

A versatile image analysis approach for simultaneous chromosome identification and localization of FISH probes. Christian A, et al. **Cytogenet Cell Genet** 1998; 82(3–4):172–9

An optimized, fully automated system for fast and accurate identification of chromosomal rearrangements by multiplex-FISH (M-FISH). Eils R, et al. **Cytogenet Cell Genet** 1998;82(3–4):160–71

Application of FISH for in situ detection and quantification of DNA breakage. Fernández JL, et al. **Cytogenet Cell Genet** 1998;82(3–4):251–6

Differential destabilization of repetitive sequence hybrids in fluorescence in situ hybridization. Hozier JC, et al. **Cytogenet Cell Genet** 1998;83(1–2):60–3

Aneuploidy in pig sperm: multicolor fluorescence in situ hybridization using probes for chromosomes 1, 10, and Y. Rubeš J, et al. **Cytogenet Cell Genet** 1999;85(3–4):200–4

Chromosomal localization of zebrafish AluI repeats by primed in situ (PRINS) labeling. Sola L, et al. **Cytogenet Cell Genet** 1999;84(1–2):28–30

Automatic detection of stable and unstable chromosome aberrations visualized by three-color imaging after fluorescence in situ hybridization with a painting and a pancentromeric DNA probe. Coco-Martin JM, et al. **Cytometry** 1998 Aug 1;32(4):327–36

Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation. Cotteret S, et al. **Cytometry** 1998 Oct 15;34(5):216–22

Intratumor heterogeneity of chromosome 1, 7, 17, and 18 aneusomies obtained by FISH and association with flow cytometric DNA index in human colorectal adenocarcinomas. Di Vinci A, et al. **Cytometry** 1999 Apr 1;35(4):369–75

Hyperdiploidy and apparent aneusomy in mesothelial cells from non-malignant effusions as detected by fluorescence in situ hybridization (FISH). Fiegl M, et al. **Cytometry** 1999 Feb 15;38(1):15–23

c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization. Galteland E, et al. **Cytometry** 1999 Apr 15;38(2):53–60

Advances in the automated detection of metaphase chromosomes labeled with fluorescence dyes. Mascio LN, et al. **Cytometry** 1998 Sep 1;33(1):10–8

Sequential immunotyping and genotyping of tumor cells in bone marrow of cancer patients: a model study. Müller P, et al. **Cytometry** 1998 Dec 1;33(4):492–7

Cross-species colour segmenting: a novel tool in human karyotype analysis. Müller S, et al. **Cytometry** 1998 Dec 1;33(4):445–52

Use of platinum coproporphyrin and delayed luminescence imaging to extend the number of targets FISH karyotyping. Tanke HJ, et al. **Cytometry** 1998 Dec 1;33(4):453–9

Cytogenetic aberrations in myelodysplastic syndrome detected by comparative genomic hybridization and fluorescence in situ hybridization. Wilkens L, et al. **Diagn Mol Pathol** 1999 Mar;8(1):47–53

Numerical and structural chromosomal abnormalities detected in human sperm with a combination of multicolor FISH assays. Baumgartner A, et al. **Environ Mol Mutagen** 1999;33(1):49–58

Cytogenetic analysis of sperm chromosomes and sperm nuclei in a male heterozygous for a reciprocal translocation t(5;7)(q21;q32) by in situ hybridisation. Cifuentes P, et al. **Eur J Hum Genet** 1999 Feb-Mar;7(2):231–8

New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling. Tanke HJ, et al. **Eur J Hum Genet** 1999 Jan;7(1):2–11

Commentary: FISHing for the light at the ends of chromosomes [letter] Verma RS, et al. **Eur J Hum Genet** 1999 May-Jun;7(4):515–7

Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Qian J, et al. **Eur Urol** 1999;35(5–6):479–83 (35 ref.)

Rapid prenatal diagnosis of aneuploidies in uncultured amniocytes by fluorescence in situ hybridization. Evaluation of >3,000 cases. Eiben B, et al. **Fetal Diagn Ther** 1999 Jul-Aug;14(4):193–7

Visualization of a conditionally dispensable chromosome in the filamentous ascomycete Nectria haematococca by fluorescence in situ hybridization. Taga M, et al. **Fungal Genet Biol** 1999 Apr;26(3):169–77

Chromosomal organization of amplified chromosome 12 sequences in mesenchymal tumors detected by fluorescence in situ hybridization. Gisselsson D, et al. **Genes Chromosomes Cancer** 1998 Nov;23(3):203–12

A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia. Grand FH, et al. **Genes Chromosomes Cancer** 1998 Oct;23(2):109–15

Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Korn WM, et al. **Genes Chromosomes Cancer** 1999 Jun;25(2):82–90

Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Rack KA, et al. **Genes Chromosomes Cancer** 1998 Nov;23(3):220–6

Novel method for the production of multiple colour chromosome paints for use in karyotyping by fluorescence in situ hybridisation. Roberts I, et al. **Genes Chromosomes Cancer** 1999 Jul;25(3):241–50

Fluorescence in situ hybridization mapping of breakpoints in pleomorphic adenomas with 8q12-13 abnormalities

identifies a subgroup of tumors without PLAG1 involvement. Röijer E, et al.
Genes Chromosomes Cancer 1999 Jan;24(1):78–82

Cross-species color banding characterization of chromosomal rearrangements in leukemias with incomplete G-band karyotypes. Teixeira MR, et al.
Genes Chromosomes Cancer 1999 Sep;26(1):13–9

Detection of foetal cells in maternal blood and prenatal sex determination by in situ hybridization. Procedure verification. Chiesa J, et al. **Genet Anal** 1999 Apr;15(2):41–5

Nucleus extraction from single mounted tissue sections. Liehr T, et al. **Genet Anal** 1999 Apr;15(2):65–9

FISH landmarks for barley chromosomes (Hordeum vulgare L.). Brown SE, et al. **Genome** 1999 Apr;42(2):274–81

Emerging patterns of comparative genome organization in some mammalian species as revealed by Zoo-FISH. Chowdhary BP, et al. **Genome Res** 1998 Jun;8(6):577–89 (88 ref.)

Mapping ESTs by fiber-FISH. Horelli-Kuitunen N, et al. **Genome Res** 1999 Jan;9(1):62–71

Comparative mapping of mouse and rat chromosomes by fluorescence in situ hybridization. Grützner F, et al.
Genomics 1999 Feb 1;55(3):306–13

Chromosomal localization of the human smoothened gene (SMOH) to 7q32. 3 by fluorescence in situ hybridization and radiation hybrid mapping. Sublett JE, et al.
Genomics 1998 May 15;50(1):112–4

Localization of HuC (ELAVL3) to chromosome 19p13.2 by fluorescence in situ hybridization utilizing a novel tyramide labeling technique. Van Tine BA, et al. **Genomics** 1998 Nov 1;53(3):296–9

May-Grünwald-Giemsa fluorescence in situ hybridization technique applied to a plasma cell leukemia [letter] Lloveras E, et al. **Haematologica** 1999 Jun;84(6):568–9

Fiber-FISH analysis of the 3'-terminal region of the human L-type Ca2+ channel alpha 1C subunit gene. Liu WS, et al. **Hereditas** 1998;129(2):169–75

Embryonic gene expression resolved at the cellular level by fluorescence in situ hybridization. Paratore C, et al.
Histochem Cell Biol 1999 Jun;111(6):435–43

Fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification for sensitive DNA and mRNA detection. van de Corput MP, et al.
Histochem Cell Biol 1998 Oct;110(4):431–7

DNA probes: FISH technology. Talib VH, et al.
Indian J Pathol Microbiol 1998 Jul;41(3):373–5

Rapid method for fluorescent in situ ribosomal RNA labelling of Cryptosporidium parvum. Deere D, et al.
J Appl Microbiol 1998 Nov;85(5):807–18

The use of a ribosomal RNA targeted oligonucleotide probe for fluorescent labelling of viable Cryptosporidium parvum oocysts. Vesey G, et al. **J Appl Microbiol** 1998 Sep; 85(3):429–40

Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests. Bornhäuser M, et al. **J Hematother** 1998 Oct; 7(5):425–30

Sensitive mRNA detection by fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification. van de Corput MP, et al. **J Histochem Cytochem** 1998 Nov; 46(11):1249–59

Clinical applications of two-color telomeric fluorescence in situ hybridization for prenatal diagnosis: identification of chromosomal translocation in five families with recurrent miscarriages or a child with multiple congenital anomalies. Wakui K, et al. **J Hum Genet** 1999;44(2):85–90

Role of multicolor fluorescence in situ hybridization (FISH) in simultaneous detection of probe sets for chromosome 18, X and Y in uncultured amniotic fluid cells. Kim JI, et al. **J Korean Med Sci** 1999 Aug;14(4):438–42

Fluorescence in situ hybridization landmarks for chromosomes of culicoides variipennis (Diptera: Ceratopogonidae). Nunamaker RA, et al.
J Med Entomol 1999 Mar;36(2):171–5

Directly inherited partial trisomy of chromosome 6p identified in a father and daughter by chromosome microdissection. Delatycki MB, et al. **J Med Genet** 1999 Apr;36(4):335–8

Del(18p) shown to be a cryptic translocation using a multiprobe FISH assay for subtelomeric chromosome rearrangements. Horsley SW, et al. **J Med Genet** 1998 Sep; 35(9):722–6

Quantitative imaging and statistical analysis of fluorescence in situ hybridization (FISH) of Aureobasidium pullulans. Spear RN, et al. **J Microbiol Methods** 1999 Mar; 35(2):101–10

Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes [see comments] Henegariu O, et al. **J Mol Med** 1998 Aug; 76(9):648–55. Comment in: J Mol Med 1998 Aug;76(9):601–3.

FISHing for complements on chromosome 12p [comment] Luft FC. **J Mol Med** 1998 Aug;76(9):601–3. Comment on: J Mol Med 1998 Aug;76(9):648–55.

Advanced FISH with directly labeled X, Y and 18 DNA probes as a tool for rapid prenatal diagnosis. Aviram-Goldring A, et al. **J Reprod Med** 1999 Jun; 44(6):497–503

A sensitive fluorescence in situ hybridization technique for detection of porcine reproductive and respiratory syndrome virus. Chueh LL, et al. **J Virol Methods** 1999 May;79(2):133–40

Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. Stowe RP, et al. **J Virol Methods** 1998 Nov;75(1):83–91

Single base discrimination of CENP-B repeats on mouse and human Chromosomes with PNA-FISH. Chen C, et al.
Mamm Genome 1999 Jan;10(1):13–8

Comparison of horse chromosome 3 with donkey and human chromosomes by cross-species painting and heterologous FISH mapping. Raudsepp T, et al. **Mamm Genome** 1999 Mar;10(3):277–82

In situ hybridization with 33P-labeled RNA probes for determination of cellular expression patterns of liver transcription factors in mouse embryos [published erratum appears in Methods 1998 Nov;16(3):359–60] Rausa FM, et al. **Methods** 1998 Sep;16(1):29–41

Fluorescence in situ hybridization analysis of chromosome and chromatin structure. Bickmore W.
Methods Enzymol 1999;304:650–62

Single and double FISH protocols for Drosophila. Hughes SC, et al. **Methods Mol Biol** 1999;122:93–101 (6 ref.)

Fluorescence in situ hybridization using whole chromosome library probes. Nardone RM. **Methods Mol Biol** 1999; 115:371–7 (9 ref.)

Overview of in situ hybridization. Nardone RM.
Methods Mol Biol 1999;115:357–63 (12 ref.)

In situ detection of bacteria in continuous-flow cultures of seawater sediment suspensions with fluorescently labelled rRNA-directed oligonucleotide probes. Bruns A, et al.
Microbiology 1998 Oct;144 (Pt 10):2783–90

Fluorescence in situ hybridization shows spatial distribution of as yet uncultured treponemes in biopsies from digital dermatitis lesions. Moter A, et al. **Microbiology** 1998 Sep; 144 (Pt 9):2459–67

Efficient cell segmentation tool for confocal microscopy tissue images and quantitative evaluation of FISH signals. Adiga PS, et al. **Microsc Res Tech** 1999 Jan 1;44(1):49–68

Feasibility study of repeated fluorescent in-situ hybridization in the same human blastomeres for preimplantation genetic diagnosis. Liu J, et al. **Mol Hum Reprod** 1998 Oct; 4(10):972–7

Scoring criteria for preimplantation genetic diagnosis of numerical abnormalities for chromosomes X, Y, 13, 16, 18 and 21. Munné S, et al. **Mol Hum Reprod** 1998 Sep; 4(9):863–70

Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates. Forus A, et al. **Mol Pathol** 1999 Apr;52(2):68–74

Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. McManus DT, et al. **Mol Pathol** 1999 Apr;52(2):75–7

Frequency, distribution and clonality of chromosome damage in human lymphocytes by multi-color FISH. Johnson KL, et al. **Mutagenesis** 1998 May;13(3):217–27

Dual-colour FISH analysis to characterize a marker chromosome in cytochrome P450 2B1 recombinant V79 Chinese hamster cells. Simi S, et al. **Mutagenesis** 1999 Jan; 14(1):57–61

Detection of structural chromosome damage in rat interphase cells using region-specific fluorescence in situ hybridization probes developed by microdissection. Matsumoto K, et al. **Mutat Res** 1998 Nov 3;421(2):179–90

The influence of age, sex and smoking habits on the background level of fish-detected translocations. Pressl S, et al. **Mutat Res** 1999 Jun 25;442(2):89–95

Poly-FISH: a technique of repeated hybridizations that improves cytogenetic analysis of fetal cells in maternal blood. Zhen DK, et al. **Prenat Diagn** 1998 Nov; 18(11):1181–5

Identification of Staphylococcus carnosus and Staphylococcus warneri isolated from meat by fluorescent in situ hybridization with 16S rRNA-targeted oligonucleotide probes. Gory L, et al.
Syst Appl Microbiol 1999 May;22(2):225–8

Specific oligonucleotide probes for in situ detection of a major group of gram-positive bacteria with low DNA G + C content. Meier H, et al. **Syst Appl Microbiol** 1999 May;22(2):186–96

Double color in situ hybridization of alpha-satellite chromosome 13, 21 specific cosmid clones for a rapid screening of their specificity. Soloviev IV, et al.
Tsitol Genet 1998 Jul-Aug;32(4):60–4

Analysis of aneuploidy for chromosomes 13, 21, X and Y by multicolour fluorescence in situ hybridisation (FISH) in a 47,XYY male. Martin RH, et al. **Zygote** 1999 May; 7(2):131–4

STANDARDS

Increased karyotype precision using fluorescence in situ hybridization and spectral karyotyping in patients with myeloid malignancies. Fleischman EW, et al.
Cancer Genet Cytogenet 1999 Jan 15;108(2):166–70

Prenatal diagnosis of Charcot-Marie-Tooth disease type 1A by interphase fluorescence in situ hybridization. Kashork CD, et al. **Prenat Diagn** 1999 May;19(5):446–9

VETERINARY

Molecular markers for the bovine fibrillin 1 gene (FBN1) map to 10q26. Masabanda J, et al. **Anim Genet** 1998 Dec; 29(6):460–1

FISH mapping and identification of canine chromosomes. Breen M, et al. **J Hered** 1999 Jan-Feb;90(1):27–30

Rapid detection of male-specific DNA sequence in bovine embryos using fluorescence in situ hybridization. Kobayashi J, et al. **Mol Reprod Dev** 1998 Dec;51(4):390–4

FISH and CHIPs [editorial] Claassen E, et al. **Vet Q** 1999 Apr;21(2):42–3

IN SITU LABELING, PRIMED see **PRIMED IN SITU LABELING**

IN SITU NICK-END LABELING

see related
APOPTOSIS
DNA FRAGMENTATION

Histologic sectioning produces TUNEL reactivity. A potential cause of false-positive staining. Sloop GD, et al. **Arch Pathol Lab Med** 1999 Jun;123(6):529–32

Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Tateyama H, et al. **Arch Pathol Lab Med** 1998 Mar; 122(3):252–5

Amplification of mRNAs from single, fixed, TUNEL-positive cells. O'Dell DM, et al. **Biotechniques** 1998 Oct;25(4):566–8, 570

DNA nicks and increased sensitivity of DNA to fluorescence in situ end labeling during functional spermiogenesis. Smith A, et al. **Biotechniques** 1998 Sep;25(3):496–502

Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Kanoh M, et al. **Circulation** 1999 Jun 1;99(21):2757–64

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Parcharidou A, et al.
Eur J Haematol 1999 Jan;62(1):19–26

TUNEL staining of inner ear structures may reflect autolysis, not apoptosis. Nishizaki K, et al. **Hear Res** 1999 Apr; 130(1-2):131–6

Basaloid squamous carcinoma of the esophagus with analysis by in situ nick end labeling and PCNA immunostaining. Koide N, et al. **Hepatogastroenterology** 1999 Jan-Feb; 46(25):265–71

In situ detection of apoptosis at sites of chronic bacterially induced inflammation in human gingiva. Tonetti MS, et al. **Infect Immun** 1998 Nov;66(11):5190–5

Apoptosis and cell proliferation in medullary carcinoma of the breast: a comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry. Kajiwara M, et al. **J Surg Oncol** 1999 Apr;70(4):209–16

Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Watanabe I, et al.
Jpn J Cancer Res 1999 Feb;90(2):188–93

Myofibrillar myopathy: no evidence of apoptosis by TUNEL. Amato AA, et al. **Neurology** 1999 Mar 10;52(4):861–3

TUNEL-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Spooren WP, et al. **Neuroscience** 1998 Jul;85(2):649–51; discussion 653

[Cell kinetics of oral squamous epithelial carcinomas. Determination of the proliferation index and apoptosis rate with the TUNEL method] Junghänel A, et al.
Mund Kiefer Gesichtschir 1998 Sep;2(5):250–5 (Eng. Abstr.) **(Ger)**

METHODS

Confocal-multilabeling, ultrasensitive TUNEL analysis of DNA breaks in individual cells. Kahn E, et al.
Anal Quant Cytol Histol 1999 Feb;21(1):1–7

Detection of apoptosis in hair follicles and acrosyringium of normal human scalp skin by labeling of nick ends of fragmented DNA. Kishimoto S, et al.
Arch Dermatol Res 1999 May;291(5):300–2

Neuronal apoptosis studied by a sequential TUNEL technique: a method for tract-tracing. Hara A, et al.
Brain Res Brain Res Protoc 1999 Jul;4(2):140–6

Ice incubation step allows adherence of archival histological specimens on gelatin-coated slides for TUNEL staining. Seigel GM, et al. **Brain Res Brain Res Protoc** 1998 Nov; 3(2):119–22

Detection of rare apoptotic T cells in vivo. Listman JA, et al. **Cytometry** 1998 Nov 1;33(3):340–7

Application of biotinylated tyramine to amplify reactions with horseradish peroxidase labelling. Surowiak P, et al.
Folia Histochem Cytobiol 1999;37(2):57–8

The distribution of BrdU- and TUNEL-positive cells during odontogenesis in mouse lower first molars. Shigemura N, et al. **Histochem J** 1999 Jun;31(6):367–77

A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma [see comments] Sheridan MT, et al.
Int J Radiat Oncol Biol Phys 1999 Jun 1;44(3):507–12. Comment in: Int J Radiat Oncol Biol Phys 1999 Jun

1;44(3):477-9.
Improved detection of apoptotic cells using a modified in situ TUNEL technique. Cuello-Carrión FD, et al. **J Histochem Cytochem** 1999 Jun;47(6):837-9
Detection of fragmented DNA in apoptotic cells embedded in LR white: A combined histochemical (LM) and ultrastructural (EM) study. Goping G, et al. **J Histochem Cytochem** 1999 Apr;47(4):561-8
Electron microscopic in situ DNA nick end-labeling in combination with immunoelectron microscopy. Ishida-Yamamoto A, et al. **J Histochem Cytochem** 1999 May;47(5):711-7
Annexin V labelling and terminal transferase-mediated DNA end labelling (TUNEL) assay in human arrested embryos. Levy R, et al. **Mol Hum Reprod** 1998 Aug;4(8):775-83
False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate. Stähelin BJ, et al. **Mol Pathol** 1998 Aug;51(4):204-8
Cautionary note on the use of end-labelling DNA fragments for detection of apoptosis. Wolvekamp MC, et al. **Pathology** 1998 Aug;30(3):267-71

IN VIVO NMR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

INADEQUATE PERSONALITY see **PERSONALITY DISORDERS**

INAPPROPRIATE ADH SYNDROME

[Hypo-osmolar hyponatremic syndromes: physiopathology and clinical aspects] Garini G, et al. **Recenti Prog Med** 1999 Feb;90(2):100-8 (43 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Chlorambucil-induced inappropriate antidiuresis in a man with chronic lymphocytic leukemia. Wägner AM, et al. **Ann Hematol** 1999 Jan;78(1):37-8
Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. Garrett CA, et al. **Ann Pharmacother** 1998 Dec;32(12):1306-9
Syndrome of inappropriate secretion of antidiuretic hormone induced by paroxetine [letter] Monmany J, et al. **Arch Intern Med** 1999 Sep 27;159(17):2089-90
SSRI-induced SIADH in older people [letter] Christe C, et al. **J Am Geriatr Soc** 1999 May;47(5):630-1
Hyponatremia in an older patient [letter] Kelly RE, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1037-8
[Hyponatremia and probable inappropriate secretion of antidiuretic hormone due to citalopram (letter)] Pradalier A, et al. **Therapie** 1998 Nov-Dec;53(6):600-2 **(Fre)**
[The inappropriate antidiuretic hormone secretion syndrome and citalopram (letter)] Berrocal E, et al. **Med Clin (Barc)** 1999 Jan 23;112(2):78 (9 ref.) **(Spa)**
[SIADH and treatment with selective inhibitors of serotonin recapture (letter)] Cano Ballesteros JC, et al. **Rev Clin Esp** 1998 Dec;198(12):851-2 **(Spa)**
[Carbamazepine-related SIADH (letter) (see comments)] Pérez-Camarero E, et al. **Rev Neurol** 1998 Sep;27(157):522 . Comment in: Rev Neurol 1999 Jan 16-31;28(2):215. **(Spa)**

COMPLICATIONS

Neuropsychiatric systemic lupus erythematosus and the syndrome of inappropriate secretion of antidiuretic hormone: a case report with very late onset systemic lupus erythematosus. Mirsattari SM, et al. **Br J Rheumatol** 1998 Oct;37(10):1132-4
Hyponatremia due to inappropriate secretion of antidiuretic hormone in a patient with systemic lupus erythematosus [clinical conference] Elisaf MS, et al. **Clin Exp Rheumatol** 1999 Mar-Apr;17(2):223-6
Osmoregulation of vasopressin secretion in patients with the syndrome of inappropriate antidiuresis associated with central nervous system disorders. Kamoi K, et al. **Endocr J** 1999 Apr;46(2):269-77
Asymptomatic hyponatremia due to inappropriate secretion of antidiuretic hormone as the first sign of a small cell lung cancer in an elderly man [see comments] Kamoi K, et al. **Intern Med** 1998 Nov;37(11):950-4. Comment in: Intern Med 1998 Nov;37(11):907-8.
Syndrome of inappropriate secretion of antidiuretic hormone associated with idiopathic normal pressure hydrocephalus. Yoshino M, et al. **Intern Med** 1999 Mar;38(3):290-2
Microencapsulated NaCl for oral salt-replacement therapy in infants [letter] Claviez A, et al. **J Natl Cancer Inst** 1999 Sep 1;91(17):1513-4
Severe hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. A rare initial presentation of tuberculosis [letter] Usalan C, et al. **Nephron** 1998 Oct;80(2):237-8
Hyponatraemia: biochemical and clinical perspectives. Gill G, et al. **Postgrad Med J** 1998 Sep;74(875):516-23
[Acute intermittent porphyria associated with hyperaldosteronism and inappropriate antidiuretic hormone secretion syndrome] Frère T, et al. **Gastroenterol Clin Biol** 1998 Aug-Sep;22(8-9):727-31 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The syndrome of inappropriate antidiuretic hormone secretion of unknown origin. Sterns RH. **Am J Kidney Dis** 1999 Jan;33(1):161-3; discussion 163-5
The role of antidiuretic hormone in hyponatremia in adrenal insufficiency--is the guideline for the diagnosis of syndrome of inappropriate secretion of the antidiuretic hormone appropriate? [editorial; comment] Demura R. **Intern Med** 1999 May;38(5):382-3. Comment on: Intern Med 1999 May;38(5):426-32.
Small cell lung cancer accompanied by lactic acidosis and syndrome of inappropriate secretion of antidiuretic hormone. Fujimura M, et al. **Lung Cancer** 1998 Dec; 22(3):251-4 (15 ref.)
Meningeal carcinomatosis and syndrome of inappropriate antidiuretic hormone in a patient with metastatic carcinoma of the stomach. Mouallem M, et al. **South Med J** 1998 Nov;91(11):1076-8

DRUG THERAPY

Treating the syndrome of inappropriate ADH secretion with isotonic saline. Musch W, et al. **QJM** 1998 Nov; 91(11):749-53
[The use of carbamazepine in the treatment of secondary ADH deficit: on a letter titled SIADH and carbamazepine (letter; comment)] Viñas-Machín PL, et al. **Rev Neurol** 1999 Jan 16-31;28(2):215. Comment on: Rev Neurol 1998 Sep;27(157):522. **(Spa)**

ETIOLOGY

Ganglioglioma of the neurohypophysis with secretion of vasopressin. Fehn M, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):425-30
Hyponatremia in a patient with chronic inflammatory disease. Murakami T, et al. **Intern Med** 1998 Sep;37(9):792-5
Syndrome of inappropriate secretion of antidiuretic hormone in a patient affected by metastatic melanoma. Lo Scocco G, et al. **Melanoma Res** 1998 Aug;8(4):367-9
A syndrome of inappropriate secretion of antidiuretic hormone associated with pleuritis caused by OK-432. Hanagiri T, et al. **Respiration** 1998;65(4):310-2
Syndrome of inappropriate secretion of antidiuretic hormone associated with amyotrophic lateral sclerosis in respiratory failure. Yoshida Y, et al. **Respirology** 1999 Jun;4(2):185-7
Sudden death in two patients with epilepsy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Kloster R, et al. **Seizure** 1998 Oct;7(5):419-20
[Limbic encephalitis and SIADH revealing small-cell anaplastic lung cancer: MRI and immunologic findings] Touzé E, et al. **Rev Neurol (Paris)** 1998 Jul;154(6-7):539-41 (Eng. Abstr.) **(Fre)**
[A case of hepatocellar carcinoma associated with syndrome of inappropriate secretion of antidiuretic hormone] Kamura M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1998 Oct; 95(10):1147-50 **(Jpn)**
[The syndrome of inappropriate secretion of antidiuretic hormone in hypophyseal tumors] Pont'uch P, et al. **Vnitr Lek** 1998 Feb;44(2):104-7 (Eng. Abstr.) **(Slo)**

METABOLISM

Syndrome of inappropriate antidiuretic hormone secretion in children following spinal fusion. Lieh-Lai MW, et al. **Crit Care Med** 1999 Mar;27(3):622-7
Osmoregulation of vasopressin secretion in patients with the syndrome of inappropriate antidiuresis associated with central nervous system disorders. Kamoi K, et al. **Endocr J** 1999 Apr;46(2):269-77

NURSING

Syndrome of inappropriate secretion of antidiuretic hormone in malignancy. Keenan AM. **Semin Oncol Nurs** 1999 Aug; 15(3):160-7 (27 ref.)

PHYSIOPATHOLOGY

Prompt and sustained regulation of aquaporin-2 by arginine vasopressin in collecting duct cells and clinical implication of urinary excretion of aquaporin-2. Ishikawa S, et al. **Adv Exp Med Biol** 1998;449:407-14
Studies of renal aquaporin-2 expression during renal escape from vasopressin-induced antidiuresis. Verbalis JG, et al. **Adv Exp Med Biol** 1998;449:395-406
Bartter's syndrome and pregnancy. Clode N, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Jan;82(1):17-8

INBORN ERRORS OF METABOLISM see **METABOLISM, INBORN ERRORS**

INBREEDING

see related
CONSANGUINITY

The role of consanguinity and inbreeding as a determinant of spontaneous abortion in Karachi, Pakistan. Hussain R. **Ann Hum Genet** 1998 Mar;62 (Pt 2):147-57
Inbreeding and inbreeding depression on reproduction and production traits of White Leghorn lines selected for egg production traits. Sewalem A, et al. **Br Poult Sci** 1999 May; 40(2):203-8
Low susceptibility of specific inbred colonies of rats to nickel tumorigenesis in soft tissue. Ohmori T, et al. **Cancer Lett** 1999 Feb 8;136(1):53-8
The major histocompatibility complex and mate choice: inbreeding avoidance and selection of good genes. Grob B, et al. **Exp Clin Immunogenet** 1998;15(3):119-29 (104 ref.)
Characterization of deleterious mutations in outcrossing populations. Deng HW. **Genetics** 1998 Oct;150(2):945-56
Inbreeding of bottlenecked butterfly populations. Estimation using the likelihood of changes in marker allele frequencies. Saccheri IJ, et al. **Genetics** 1999 Mar;151(3):1053-63
Improving the efficiency of artificial selection: more selection pressure with less inbreeding. Sanchez L, et al. **Genetics** 1999 Mar;151(3):1103-14
The changes in genetic and environmental variance with inbreeding in Drosophila melanogaster. Whitlock MC, et al. **Genetics** 1999 May;152(1):345-53
Allozyme diversity in Leavenworthia populations with different inbreeding levels. Charlesworth D, et al. **Heredity** 1998 Oct;81 (Pt 4):453-61
Maximizing the response of selection with a predefined rate of inbreeding: overlapping generations. Meuwissen TH, et al. **J Anim Sci** 1998 Oct;76(10):2575-83
Biodemography in Siena, Italy. Vienna A, et al. **J Biosoc Sci** 1998 Oct;30(4):521-8
The effects of inbreeding on the lifetime performance of dairy cattle. Smith LA, et al. **J Dairy Sci** 1998 Oct;81(10):2729-37
Breeding systems in Echinococcus granulosus (Cestoda; Taeniidae): selfing or outcrossing? Haag KL, et al. **Parasitology** 1999 Jan;118 (Pt 1):63-71

INBREEDING, HUMAN see **CONSANGUINITY**

INCENTIVE PLANS, EMPLOYEE see **EMPLOYEE INCENTIVE PLANS**

INCENTIVE PLANS, PHYSICIAN see **PHYSICIAN INCENTIVE PLANS**

INCENTIVE REIMBURSEMENT see **REIMBURSEMENT, INCENTIVE**

INCENTIVES see **MOTIVATION**

INCEST

Sibling incest: a Hong Kong experience. Tsun OK. **Child Abuse Negl** 1999 Jan;23(1):71-9
The sexual preferences of incest offenders. Seto MC, et al. **J Abnorm Psychol** 1999 May;108(2):267-72
Play therapy and art therapy for substance abuse clients who have a history of incest victimization. Glover NM. **J Subst Abuse Treat** 1999 Jun;16(4):281-7

HISTORY

"Dangerous girls," family secrets, and incest law in Italy, 1861-1930. Guarnieri P. **Int J Law Psychiatry** 1998 Fall; 21(4):369-83

PREVENTION & CONTROL

Sexual coercion content in 21 sexuality education curricula. Beyer CE, et al. **J Sch Health** 1998 Nov;68(9):370-5

PSYCHOLOGY

Incest survivor mothers: protecting the next generation. Kreklewetz CM, et al. **Child Abuse Negl** 1998 Dec; 22(12):1305-12
Sexual overstimulation as a cause of unstable gender identity in men: a case report. Beatrice J. **J Am Psychoanal Assoc** 1998;46(3):753-76
Adolescent sexual matricide following repetitive mother-son incest. Schlesinger LB. **J Forensic Sci** 1999 Jul;44(4):746-9
False allegations of pregnancy resulting from incestuous rape and physician misconduct: proof positive. Jamieson MA, et al. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):181-4

INCIDENCE

Critical appraisal of the health research literature: prevalence or incidence of a health problem. Loney PL, et al. **Chronic Dis Can** 1998;19(4):170-6 (27 ref.)
Variations in 'avoidable' mortality: a reflection of variations in incidence? Treurniet HF, et al. **Int J Epidemiol** 1999 Apr;28(2):225-32
A non-parametric method for the reconstruction of age- and time-dependent incidence from the prevalence data of irreversible diseases with differential mortality. Brunet RC, et al. **Theor Popul Biol** 1999 Aug;56(1):76-90

INCIDENCE STUDIES see **COHORT STUDIES**

INCIDENT REPORTING, HOSPITAL see **RISK MANAGEMENT**

INCINERATION

The adsorption of heavy metals by different sorbents under various incineration conditions. Chen JC, et al. **Chemosphere** 1998 Dec;37(13):2617-25
Removal of dioxins and furans from flue gases by non-flammable adsorbents in a fixed bed. Fell HJ, et al. **Chemosphere** 1998 Oct-Nov;37(9-12):2327-34

PCDDs and PCDFs concentration in combustion gases and bottom ash from incineration of hospital wastes in Poland. Grochowalski A. **Chemosphere** 1998 Oct–Nov; 37(9–12):2279–91

Relationships between dioxins in soil, air, ash, and emissions from a municipal solid waste incinerator emitting large amounts of dioxins. Lorber M, et al. **Chemosphere** 1998 Oct–Nov;37(9–12):2173–97

Distribution of Pb, V, Cr, Ni, Cd, Cu and Fe in particles formed from the combustion of waste oils. Nerín C, et al. **Chemosphere** 1999 Mar;38(7):1533–40

Is there a strong dioxin: chlorine link in commercial scale systems? Rigo HG, et al. **Chemosphere** 1998 Oct–Nov; 37(9–12):2031–46

Effects of chlorides on emissions of toxic compounds in waste incineration: study on partitioning characteristics of heavy metal. Wang KS, et al. **Chemosphere** 1999 Apr; 38(8):1833–49

A computer program for conducting incinerator risk assessments. Walter MA. **Drug Chem Toxicol** 1999 Feb; 22(1):213–20

Respiratory function as measured by peak expiratory flow rate and PM10: six communities study. Lee JT, et al. **J Expo Anal Environ Epidemiol** 1999 Jul–Aug;9(4):293–9

Effects of extreme heat on teeth with implications for histologic processing. Myers SL, et al. **J Forensic Sci** 1999 Jul;44(4):805–9

Incinerator toxic emissions: a brief summary of human health effects with a note on regulatory control. Rowat SC. **Med Hypotheses** 1999 May;52(5):389–96

[Body burden of polychlorinated biphenyl compounds in whole blood of 7–10-year-old children in the area of a hazardous waste incineration facility] Höldke B, et al. **Gesundheitswesen** 1998 Aug–Sep;60(8–9):505–12 (Eng. Abstr.) **(Ger)**

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. IV. Overview and short comments on the results] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):531–40 (16 ref.) (Eng. Abstr.) **(Ger)**

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. I. Stack gas condensate--sample collection techniques] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):473–85 (Eng. Abstr.) **(Ger)**

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. II. Suitability of fast bacterial tests of emission monitoring] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):487–512 (Eng. Abstr.) **(Ger)**

[Genotoxicity of stack gas condensates of Bavarian waste incineration plants. III. Emission monitoring with a simple UDS assay using the human lung cell lines NCI-H 322 and 358] Raabe F, et al. **Zentralbl Hyg Umweltmed** 1999 Feb;201(6):513–30 (Eng. Abstr.) **(Ger)**

STANDARDS

Surrogate burns in deactivation furnace system. Shah JK. **J Hazard Mater** 1999 May 14;66(3):279–90

INCIPIENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

INCISIVE PAPILLA see **PALATE**

INCISOR

Rapid maxillary expansion with incisor intrusion: a study of vertical control. Pearson LE, et al. **Am J Orthod Dentofacial Orthop** 1999 May;115(5):576–82

Incisor microwear, diet, and tooth use in three Amerindian populations. Ungar PS, et al. **Am J Phys Anthropol** 1999 Jul;109(3):387–96

The effects of different conventions regarding missing primary incisors in epidemiological studies. Hawley GM, et al. **Community Dent Health** 1998 Jun;15(2):115–7

Single-sitting, fiber-reinforced fixed bridges for the missing lateral or central incisors in adolescent patients. Belvedere PC. **Dent Clin North Am** 1998 Oct;42(4):665–82, ix

Clinical application of narrow Brånemark System implants for single-tooth restorations. Polizzi G, et al. **Int J Oral Maxillofac Implants** 1999 Jul–Aug;14(4):496–503

Management of missing maxillary lateral incisors. Sabri R. **J Am Dent Assoc** 1999 Jan;130(1):80–4

Periodontal and pulpal condition of the central incisors after midline osteotomy of the maxilla. Mordenfeld A, et al. **J Oral Maxillofac Surg** 1999 May;57(5):523–9; discussion 529–30

A new approach in restorative treatment of external root resorption. A case report. Dumfahrt H, et al. **J Periodontol** 1998 Aug;69(8):941–7

A long-term evaluation of composite-bonded natural/resin teeth as replacement of lower incisors with terminal periodontitis. Quirynen M, et al. **J Periodontol** 1999 Feb; 70(2):205–12

Interim esthetic restorations in conjunction with anterior implants. Markus SJ. **J Prosthet Dent** 1999 Aug;82(2):233–6

Bonded compomer slope for anterior tooth crossbite correction. Croll TP, et al. **Pediatr Dent** 1999 Jul–Aug; 21(4):293–4

Sequelae and prognosis of intruded primary incisors: a retrospective study. Holan G, et al. **Pediatr Dent** 1999 Jul–Aug;21(4):242–7

The use of a resin-bonded denture to replace primary incisors: case report. Orsi IA, et al. **Pediatr Dent** 1999 Jan–Feb;21(1):64–6

[Determination of the distance between the upper incisors and the laryngoscope blade during laryngoscopy: comparisons of the McCoy, the Macintosh, the Miller, and the Belscope blades] Bito H, et al. **Masui** 1998 Oct; 47(10):1257–61 (Eng. Abstr.) **(Jpn)**

[The extrusion of a retained upper central right incisor into the dentition] Sekletov GA. **Stomatologiia (Mosk)** 1999; 78(4):48–50 (Eng. Abstr.) **(Rus)**

ABNORMALITIES

Treatment of an impacted dilacerated maxillary central incisor. Lin YT. **Am J Orthod Dentofacial Orthop** 1999 Apr;115(4):406–9

Ethnic dental analysis of shovel and Carabelli's traits in a Chinese population. Hsu JW, et al. **Aust Dent J** 1999 Mar; 44(1):40–5

Caucasian evidence [letter; comment] Elworthy S. **Br Dent J** 1999 Jun 26;186(12):602. Comment on: Br Dent J 1998 Oct 24;185(8):386–8.

Supernumaries in the mandibular incisors [letter; comment] Heathcote R. **Br Dent J** 1999 Jun 26;186(12):602. Comment on: Br Dent J 1998 Oct 24;185(8):386–8.

Congenital nasal pyriform aperture stenosis and single central maxillary incisor: CT and MRI findings. Huang JK, et al. **Clin Imaging** 1998 Nov-Dec;22(6):393–7

Morphometrical analysis of main and accessory canals in apical root portion of frontal teeth. Martić D, et al. **Coll Antropol** 1998 Dec;22 Suppl:153–9

Presentation and management of talon cusp. Asadi SG, et al. **JPMA J Pak Med Assoc** 1998 Oct;48(10):314–5

Concomitant hypohyperdontia: simultaneous occurrence of a mesiodens and agenesis of a maxillary lateral incisor. Segura JJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):473–5

Talon cusp affecting permanent maxillary lateral incisors in 2 family members. Segura JJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Jul;88(1):90–2

Dens invaginatus in the maxillary lateral incisor: treatment of 3 cases. Yeh SC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 May;87(5):628–31

Single central maxillary incisor with nasal pyriform aperture stenosis--CT diagnosis prior to tooth eruption. Royal SA, et al. **Pediatr Radiol** 1999 May;29(5):357–9

ANATOMY & HISTOLOGY

Postnatal expression of calretinin-immunoreactivity in periodontal Ruffini endings in the rat incisor: a comparison with protein gene product 9.5 (PGP 9.5)-immunoreactivity. Asahito T, et al. **Arch Histol Cytol** 1999 Mar;62(1):57–69

A radiographic assessment of enamel thickness in human maxillary incisors. Harris EF, et al. **Arch Oral Biol** 1998 Oct;43(10):825–31

The influence of maxillary incisor inclination on arch length. O'Higgins EA, et al. **Br J Orthod** 1999 Jun;26(2):97–102

Width/length ratios of normal clinical crowns of the maxillary anterior dentition in man. Sterrett JD, et al. **J Clin Periodontol** 1999 Mar;26(3):153–7

A calculation method for the range of occluding phase at the lower incisal point during chewing movements using the curved mesh diagram of mandibular excursion (CMDME). Hayasaki H, et al. **J Oral Rehabil** 1999 Mar; 26(3):236–42

Use of lingual frenum in determining the original vertical position of mandibular anterior teeth. Bissasu M. **J Prosthet Dent** 1999 Aug;82(2):177–81

Rationalization of incisor shape: experimental-numerical analysis. Magne P, et al. **J Prosthet Dent** 1999 Mar; 81(3):345–55

BLOOD SUPPLY

Evaluation of a laser Doppler flowmeter to assess blood flow in human primary incisor teeth. Fratkin RD, et al. **Pediatr Dent** 1999 Jan–Feb;21(1):53–6

CHEMISTRY

Scanning electron microscopy and energy-dispersive X-ray analysis of defects in mature rat incisor enamel after thyroparathyroidectomy. Chardin H, et al. **Arch Oral Biol** 1998 Apr;43(4):317–27

A secondary ion mass spectroscopic study of the elemental composition pattern in rat incisor dental enamel during different stages of ameloblast differentiation. Lundgren T, et al. **Arch Oral Biol** 1998 Nov;43(11):841–8

Dental lead levels in residents from industrial and suburban areas of Kuwait. Bu-Olayan AH, et al. **Sci Total Environ** 1999 Feb 9;226(2-3):133–7

CYTOLOGY

Confocal microscopy of dentinal tubules in human tooth stained with alizarin red. Kagayama M, et al. **Anat Embryol (Berl)** 1998 Mar;199(3):233–8

DRUG EFFECTS

Effects of phenylephrine and prazosin on axial movement of the rat incisor and arterial blood pressure. Ohyama N, et al. **Jpn J Pharmacol** 1999 Jul;80(3):271–4

Pathological evaluation of the effects of intentional disocclusion and overloading occlusion in odontogenesis disorders in N-methylnitrosourea-treated hamsters. Kohgo T, et al. **Toxicol Pathol** 1999 Mar-Apr;27(2):226–32

EMBRYOLOGY

Aspects of cell proliferation kinetics of the inner dental epithelium during mouse molar and incisor morphogenesis: a reappraisal of the role of the enamel knot area. Coin R, et al. **Int J Dev Biol** 1999 May;43(3):261–7

Prenatal development of the alveolar bone of human deciduous incisors and canines. Kjaer I, et al. **J Dent Res** 1999 Feb;78(2):667–72

Effects of maternal acetazolamide treatment on body weights and incisor development of the fetal rat. Kojima N, et al. **J Vet Med Sci** 1999 Feb;61(2):143–7

Transformation of tooth type induced by inhibition of BMP signaling. Tucker AS, et al. **Science** 1998 Nov 6; 282(5391):1136–8

ENZYMOLOGY

Cytochrome oxidase activity in the enamel organ during amelogenesis in rat incisors. Ohshima H, et al. **Anat Rec** 1998 Dec;252(4):519–31

GROWTH & DEVELOPMENT

Expression of the mRNA for types I and II interleukin-1 receptors in dental tissues of mice during tooth development. Xu LX, et al. **Calcif Tissue Int** 1998 Oct; 63(4):351–6

In vivo model for the experimental manipulation of calcified tissues: a surgical approach for accessing the odontogenic organ and associated tissues of the rat incisor. Vu DD, et al. **J Histochem Cytochem** 1999 Mar;47(3):323–6

INJURIES

Replantation of avulsed teeth: considerations and complications. Ogunyinka A. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):129–31

The hidden dangers of refrigerated confectionary [letter] Mackie IC. **Br Dent J** 1998 Aug 22;185(4):160

Survey of incisor trauma in second grade students of central Taiwan. Chen YL, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Jun;22(2):212–9

Osteointegration of a replanted tooth followed by RVG densitometry. Radionov D, et al. **Coll Antropol** 1998 Dec; 22 Suppl:161–6

Surgical extrusion of intruded immature permanent incisors: case report and review of the literature. Caliskan MK, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Oct;86(4):461–4

[The effect of the overjet on the incidence and severity of maxillary anterior tooth trauma. The reduction of the overjet as an important factor in the prevention of maxillary anterior tooth trauma?] Schnyder C, et al. **Schweiz Monatsschr Zahnmed** 1999;109(7):739–49 **(Ger, Fre)**

INNERVATION

Differentiating condition-induced facilitation, inhibition and disinhibition in a complex series of reflexes in an electromyogram. van der Glas HW, et al. **Brain Res Brain Res Protoc** 1999 Jan;3(3):291–301

Morphological changes in periodontal mechanoreceptors of mouse maxillary incisors after the experimental induction of anterior crossbite: a light and electron microscopic observation using immunohistochemistry for PGP 9.5. Piyapattamin T, et al. **Eur J Orthod** 1999 Feb;21(1):15–29

METABOLISM

Intermittent inhibition of dentin mineralization of rat incisors under continual infusion of 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) using a subcutaneous mini osmotic pump. Sakai H, et al. **Arch Histol Cytol** 1999 May; 62(2):171–9

Immunocytochemical detection of S-100beta in the periodontal Ruffini endings in the rat incisor. Nakakura-Ohshima K, et al. **Neurosci Lett** 1998 Dec 24; 258(3):163–6

PATHOLOGY

Relapse after orthodontic correction of maxillary median diastema: a follow-up evaluation of consecutive cases. Shashua D, et al. **Angle Orthod** 1999 Jun;69(3):257–63

Transient red discoloration: report of case. Aguiló L, et al. **ASDC J Dent Child** 1998 Sep-Oct;65(5):346–8, 356

Assessing incisor inclination: a non-invasive technique. Richmond S, et al. **Eur J Orthod** 1998 Dec;20(6):721–6

Dimensional changes during veneering procedures on discoloured teeth. Meijering AC, et al. **J Dent** 1998 Sep; 26(7):569–76

The tooth-width relation of the incisors in closed bite. Schuster G. **J Orofac Orthop** 1999;60(2):87–94 **(Eng, Ger)**

INCISOR

PHYSIOLOGY

Cortical bone remodeling/tooth movement ratio during maxillary incisor retraction with tip versus torque movements. Vardimon AD, et al. **Am J Orthod Dentofacial Orthop** 1998 Nov;114(5):520–9

Adrenergic receptors and secretory responses of the rat submandibular salivary gland after periodic incisor reduction. Chiarenza AP, et al. **Arch Oral Biol** 1998 Apr; 43(4):261–7

The length and eruption rates of incisor teeth in rats after one or more of them had been unimpeded. Burn-Murdoch RA. **Eur J Orthod** 1999 Feb;21(1):49–56

No effect of lip bumper therapy on the pressure from the lower lip on the lower incisors. Ingervall B, et al. **Eur J Orthod** 1998 Oct;20(5):525–34

Jaw reflexes evoked by mechanical stimulation of teeth in humans. Yang J, et al. **J Neurophysiol** 1999 May; 81(5):2156–63

Apexification of a primary central incisor: 6-year follow-up. Trairatvorakul C. **Pediatr Dent** 1998 Nov–Dec;20(7):425–7

PHYSIOPATHOLOGY

Directions of orthodontic tooth movements associated with external apical root resorption of the maxillary central incisor [see comments] Parker RJ, et al. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):677–83 . Comment in: Am J Orthod Dentofacial Orthop 1999 Mar;115(3):17A–8A.

Mandibular lateral incisor-canine transposition, concomitant dental anomalies, and genetic control. Peck S, et al. **Angle Orthod** 1998 Oct;68(5):455–66 (53 ref.)

Long-term effect of the chincap on hard and soft tissues. Abu Alhaija ES, et al. **Eur J Orthod** 1999 Jun;21(3):291–8

RADIOGRAPHY

Congenital nasal pyriform aperture stenosis: a diagnostic clue to solitary maxillary central incisor prior to eruption in three infants. Lo FS, et al. **J Otolaryngol** 1999 Feb; 28(1):51–3

SURGERY

Effects of mandibular incisor extraction on anterior occlusion in adults with Class III malocclusion and reduced overbite. Faerovig E, et al. **Am J Orthod Dentofacial Orthop** 1999 Feb;115(2):113–24

In vivo model for the experimental manipulation of calcified tissues: a surgical approach for accessing the odontogenic organ and associated tissues of the rat incisor. Vu DD, et al. **J Histochem Cytochem** 1999 Mar;47(3):323–6

ULTRASTRUCTURE

Scanning electron microscopy and energy-dispersive X-ray analysis of defects in mature rat incisor enamel after thyroparathyroidectomy. Chardin H, et al. **Arch Oral Biol** 1998 Apr;43(4):317–27

Differences in the pattern of lanthanum diffusion into predentine and dentine in mouse incisors and molars. Torres-Quintana MA, et al. **Arch Oral Biol** 1999 Apr; 44(4):351–60

Initial aspects of mineralization at the dentino-enamel junction in embryonic mouse incisor in vivo and in vitro: a tem comparative study. Meyer JM, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar;35(3):159–68

INCLUSION BODIES

Acute promyelocytic leukemia with additional chromosomal abnormalities and absence of Auer rods. Kaleem Z, et al. **Am J Clin Pathol** 1999 Jul;112(1):113–8

Oxidative refolding of recombinant prochymosin. Wei C, et al. **Biochem J** 1999 May 15;340 (Pt 1):345–51

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Saudou F, et al. **Cell** 1998 Oct 2;95(1):55–66

Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? [comment] Sisodia SS. **Cell** 1998 Oct 2;95(1):1–4. Comment on: Cell 1998 Oct 2;95(1):41–53.

Dynamics of in vivo protein aggregation: building inclusion bodies in recombinant bacteria. Carrió MM, et al. **FEMS Microbiol Lett** 1998 Dec 1;169(1):9–15

Crystalloids and crystals in salivary gland lesions [letter] López-Ríos F, et al. **Hum Pathol** 1999 Sep;30(9):1119–20

Characteristics of eosinophilic inclusions within Schistosoma japonicum eggs. Hirata M, et al. **Parasitology** 1999 Mar; 118 (Pt 3):269–74

CHEMISTRY

Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. Lieberman AP, et al. **Ann Neurol** 1999 Aug; 46(2):271–3

A new derivatizing agent, trimethylammoniopropyl methanethiosulphonate, is efficient for preparation of recombinant brain-derived neurotrophic factor from inclusion bodies. Inoue M, et al. **Biotechnol Appl Biochem** 1998 Dec;28 (Pt 3):207–13

Chemical treatment of Escherichia coli. II. Direct extraction of recombinant protein from cytoplasmic inclusion bodies in intact cells. Falconer RJ, et al. **Biotechnol Bioeng** 1998 Feb 20;57(4):381–6

Similarity in moth-fly specific larvicidal activity between two serologically unrelated Bacillus thuringiensis strains. Higuchi K, et al. **FEMS Microbiol Lett** 1998 Dec 15; 169(2):213–8

Biotin inclusions: a potential pitfall in immunohistochemistry avoided [letter; comment] Dodson A, et al. **Histopathology** 1999 Feb;34(2):178–9. Comment on: Histopathology 1997 Nov;31(5):400–7. Comment on: Histopathology 1998 Jul;33(1):87.

Biotin inclusions: a potential pitfall in immunohistochemistry [letter; comment] [see comments] Nayler SJ, et al. **Histopathology** 1998 Jul;33(1):87. Comment on: Histopathology 1997 Nov;31(5):400–7. Comment in: Histopathology 1999 Feb;34(2):178–9.

Multiple oncocytic cysts with tyrosine-crystalloids in the parotid gland. Chaushu G, et al. **Hum Pathol** 1999 Feb; 30(2):237–9

Differential scanning calorimetric study of poly(3-hydroxyoctanoate) inclusions in bacterial cells. Song JJ, et al. **Int J Biol Macromol** 1998 Oct;23(3):165–73

Biochemical characterization of the small heat shock protein IbpB from Escherichia coli. Shearstone JR, et al. **J Biol Chem** 1999 Apr 9;274(15):9937–45

Inclusion body purification and protein refolding using microfiltration and size exclusion chromatography. Batas B, et al. **J Biotechnol** 1999 Feb 19;68(2–3):149–58

Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent--application to a human single-chain Fv fragment. Tsumoto K, et al. **J Immunol Methods** 1998 Oct 1; 219(1–2):119–29

Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. Kimber TE, et al. **J Neurol Sci** 1998 Sep 18;160(1):33–40 (25 ref.)

Induced expression and localization to nuclear-inclusion bodies of hsp70 in varicella-zoster virus-infected human diploid fibroblasts. Ohgitani E, et al. **Microbiol Immunol** 1998;42(11):755–60

Intracellular phosphates in inclusion body myositis--a 31P magnetic resonance spectroscopy study. Argov Z, et al. **Muscle Nerve** 1998 Nov;21(11):1523–5

The presence of FAC1 protein in Hirano bodies. Jordan-Sciutto K, et al. **Neuropathol Appl Neurobiol** 1998 Oct;24(5):359–66

Impaired innervation of cultured human muscle overexpressing betaAPP experimentally and genetically: relevance to inclusion-body myopathies. McFerrin J, et al. **Neuroreport** 1998 Oct 5;9(14):3201–5

Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein. Arai T, et al. **Neurosci Lett** 1999 Jan 8;259(2):83–6

Refolding, purification, and characterization of a loop deletion mutant of human Bcl-2 from bacterial inclusion bodies. Anderson M, et al. **Protein Expr Purif** 1999 Mar; 15(2):162–70

Actin inclusions in stromal cells of fibroepithelial tumor of breast: immunohistochemical and ultrastructural studies. Ng WK, et al. **Ultrastruct Pathol** 1999 May–Jun; 23(3):199–205

DRUG EFFECTS

Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length. Moulder KL, et al. **J Neurosci** 1999 Jan 15;19(2):705–15

ENZYMOLOGY

Generation of catalytically active granzyme K from Escherichia coli inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. Wilharm E, et al. **J Biol Chem** 1999 Sep 17;274(38):27331–7

[Neuronal kinases in glial cytoplasmic inclusions in patients with multiple system atrophy] Nakamura S, et al. **Rinsho Shinkeigaku** 1999 Jan;39(1):13–5 (Eng. Abstr.) **(Jpn)**

GENETICS

Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts? Rubinsztein DC, et al. **J Med Genet** 1999 Apr;36(4):265–70 (40 ref.)

IMMUNOLOGY

T cell receptor beta-chain repertoire in inclusion body myositis. Fyhr IM, et al. **J Neuroimmunol** 1998 Nov 2; 91(1–2):129–34

Mast cell-associated Renaut bodies in the peroneal nerve of a dog with a history of mastocytosis. Dines KC, et al. **J Peripher Nerv Syst** 1999;4(1):19–26

METABOLISM

NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Arima K, et al. **Acta Neuropathol (Berl)** 1998 Nov; 96(5):439–44

Study of some components of the cytoskeleton in muscular disorders with nonspecific cytoplasmic bodies. Caron A, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):267–74

Astrocytic hyaline inclusions contain advanced glycation endproducts in familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation: immunohistochemical and immunoelectron microscopical analyses. Kato S, et al. **Acta Neuropathol (Berl)** 1999 Mar; 97(3):260–6

Advanced glycation endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Shibata N, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):240–6

Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation. Wada M, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):150–6

Lethal osteosclerotic skeletal dysplasia with intracellular inclusion bodies. Brodie SG, et al. **Am J Med Genet** 1999 Apr 23;83(5):372–7

Formation of GFAP cytoplasmic inclusions in astrocytes and their disaggregation by alphaB-crystallin. Koyama Y, et al. **Am J Pathol** 1999 May;154(5):1563–72

Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Stumptner C, et al. **Am J Pathol** 1999 Jun; 154(6):1701–10

Renaturation of recombinant human neurotrophin-3 from inclusion bodies using a suppressor agent of aggregation. Suenaga M, et al. **Biotechnol Appl Biochem** 1998 Oct;28 (Pt 2):119–24

Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Münch G, et al. **Brain Res** 1998 Jun 15;796(1–2):307–10

Mechanisms of mallory body formation induced by okadaic acid in drug-primed mice. Yuan QX, et al. **Exp Mol Pathol** 1998 Oct;65(2):87–103

Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Sieradzan KA, et al. **Exp Neurol** 1999 Mar;156(1):92–9

High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Evert BO, et al. **Hum Mol Genet** 1999 Jul;8(7):1169–76

Lipofuscin turnover [letter; comment] Boulton M, et al. **Invest Ophthalmol Vis Sci** 1999 Jul;40(8):1887–8. Comment on: Invest Ophthalmol Vis Sci 1999 Jan;40(1):175–81.

Reversible accumulation of lipofuscin-like inclusions in the retinal pigment epithelium [see comments] Katz ML, et al. **Invest Ophthalmol Vis Sci** 1999 Jan;40(1):175–81. Comment in: Invest Ophthalmol Vis Sci 1999 Jul;40(8):1887–8.

Polyhydroxyalkanoate inclusion body-associated proteins and coding region in Bacillus megaterium. McCool GJ, et al. **J Bacteriol** 1999 Jan;181(2):585–92

Aggresomes: a cellular response to misfolded proteins. Johnston JA, et al. **J Cell Biol** 1998 Dec 28;143(7):1883–98

Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. Smith DH, et al. **J Neuropathol Exp Neurol** 1999 Sep;58(9):982–92

Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Engelender S, et al. **Nat Genet** 1999 May;22(1):110–4

Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains. Kimura T, et al. **Pathol Int** 1998 Aug;48(8):575–9

PATHOLOGY

Fine needle aspiration cytology and histopathology of crystalloids in a cystic lesion of parotid salivary gland [letter] Boudousquie AC, et al. **Acta Cytol** 1998 Nov–Dec; 42(6):1485–7

Polyglutamine aggregates: a possible component of eosinophilic intracular inclusions in the hippocampal pyramidal neurons of a patient with amyotrophic lateral sclerosis [letter; comment] Altschuler EL. **Acta Neuropathol (Berl)** 1999 Jan;97(1):103–4. Comment on: Acta Neuropathol (Berl) 1997 May;93(5):532–6.

Study of some components of the cytoskeleton in muscular disorders with nonspecific cytoplasmic bodies. Caron A, et al. **Acta Neuropathol (Berl)** 1999 Mar;97(3):267–74

Nuclear inclusions in spinocerebellar ataxia type 1. Duyckaerts C, et al. **Acta Neuropathol (Berl)** 1999 Feb; 97(2):201–7

Immunohistochemical and electron microscopical studies of myocardial inclusions in hereditary myopathy of the diaphragmatic muscles in Holstein-Friesian cattle. Furuoka H, et al. **Acta Neuropathol (Berl)** 1999 Feb;97(2):185–91

Skein-like inclusions in the neostriatum from a case of amyotrophic lateral sclerosis with dementia. Kawashima T, et al. **Acta Neuropathol (Berl)** 1998 Nov;96(5):541–5

Lethal osteosclerotic osteochondrodysplasia with platyspondyly, metaphyseal widening, and intracellular inclusions in sibs. Brodie SG, et al. **Am J Med Genet** 1998 Dec 4;80(4):423–8

Pathogenesis of intraluminal prostatic crystalloids [letter; comment] Papadimitriou JC, et al. **Am J Surg Pathol** 1999 Apr;23(4):489. Comment on: Am J Surg Pathol 1998 Apr;22(4):446–9.

Hyalinizing trabecular adenoma of the thyroid gland: recognition and characterization of its cytoplasmic yellow body. Rothenberg HJ, et al. **Am J Surg Pathol** 1999 Jan; 23(1):118–25

Renal angiomyolipoma resembling gastrointestinal stromal tumor with skenoid fibers. Zámecnik M, et al. **Ann Diagn Pathol** 1999 Apr;3(2):88–91

An autopsy study of the prostate in acquired immunodeficiency syndrome: evidence for excessive apoptosis and intracytoplasmic epithelial inclusions. Dikov DI, et al. **Arch Pathol Lab Med** 1998 Oct;122(10):875–9

Full length huntingtin is not detected in intranuclear inclusions in Huntington's disease brain. Thomas P, et al. **Biochem Soc Trans** 1998 Aug;26(3):S243

Biondi ring tangles in the choroid plexus of Alzheimer's disease and normal aging brains: a quantitative study. Wen GY, et al. **Brain Res** 1999 Jun 19;832(1–2):40–6

Corpora-amylacea and the family of polyglucosan diseases. Cavanagh JB. **Brain Res Brain Res Rev** 1999 Apr; 29(2–3):265–95 (235 ref.)

Malignant meningioma with a new intracytoplasmic inclusion body. Utsuki S, et al. **Clin Neuropathol** 1998 Jul–Aug; 17(4):216–20

Filamentous nerve cell inclusions in neurodegenerative diseases. Goedert M, et al. **Curr Opin Neurobiol** 1998 Oct; 8(5):619–32 (92 ref.)

Diagnostic significance of 'benign pairs' and signet ring cells in fine needle aspirates (FNAs) of the breast. Sturgis CD, et al. **Cytopathology** 1998 Oct;9(5):308–19

Development of intracytoplasmic lumens in colon cancer cells cultured on non-adhesive surface. Bae SI, et al. **Exp Toxicol Pathol** 1999 Jan;51(1):21–6

Multiple myeloma with numerous intranuclear Russell bodies. Martín-Noya A, et al. **Haematologica** 1999 Feb; 84(2):179–80

The first Japanese family with Sebastian platelet syndrome. Tsurusawa M, et al. **Int J Hematol** 1999 Apr;69(3):206–10

Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. Cooper AJ, et al. **J Neurochem** 1999 Mar;72(3):889–99 (98 ref.)

Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. Maat-Schieman ML, et al. **J Neuropathol Exp Neurol** 1999 Feb;58(2):129–37

Curly fiber and tangle-like inclusions in the ependyma and choroid plexus--a pathogenetic relationship with the cortical Alzheimer-type changes? Miklossy J, et al. **J Neuropathol Exp Neurol** 1998 Dec;57(12):1202–12

Laser-Raman microprobe identification of inclusions in capsules associated with silicone gel breast implants. Centeno JA, et al. **Mod Pathol** 1999 Jul;12(7):714–21

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy [letter] Morris HR, et al. **Muscle Nerve** 1999 Jun;22(6):781–2

Inclusion body myositis: abnormal protein accumulation does not trigger apoptosis. Hutchinson DO. **Neurology** 1998 Dec;51(6):1742–5

Corpus amylaceum (polyglucosan body) in the peripheral olfactory system. Leel-Ossy L, et al. **Pathol Oncol Res** 1998;4(3):212–6

Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Goedert M. **Philos Trans R Soc Lond B Biol Sci** 1999 Jun 29; 354(1386):1101–18 (148 ref.)

Inclusion body disease in two captive boas in the Canary islands. Orós J, et al. **Vet Rec** 1998 Sep 5;143(10):283–5

[Neuropathology of the motor neuron disease--Bunina body] Kusaka H. **Rinsho Shinkeigaku** 1999 Jan;39(1):65–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Sebastian platelet syndrome] Maeda M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):320–1 (7 ref.) **(Jpn)**

[May-Hegglin anomaly] Shinjo K, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):56–8 (13 ref.) **(Jpn)**

PHYSIOLOGY

Fusion of Chlamydia trachomatis-containing inclusions is inhibited at low temperatures and requires bacterial protein synthesis. Van Ooij C, et al. **Infect Immun** 1998 Nov; 66(11):5364–71

Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. Perez MK, et al. **J Cell Biol** 1998 Dec 14;143(6):1457–70

Nota bene: triplet repeat diseases. Innocent inclusions. Kelner KL. **Science** 1998 Oct 23;282(5389):643

Ubiquitin, cellular inclusions and their role in neurodegeneration. Alves-Rodrigues A, et al. **Trends Neurosci** 1998 Dec;21(12):516–20 (60 ref.)

ULTRASTRUCTURE

Bunina bodies in amyotrophic lateral sclerosis on Guam: a histochemical, immunohistochemical and ultrastructural investigation. Wada M, et al. **Acta Neuropathol (Berl)** 1999 Aug;98(2):150–6

Sebastian syndrome: case report and review of the literature. Young G, et al. **Am J Hematol** 1999 May;61(1):62–5 (15 ref.)

Clinical, pathologic, and neurochemical studies of an unusual case of neuronal storage disease with lamellar cytoplasmic inclusions: a new genetic disorder? Rose AL, et al. **J Child Neurol** 1999 Feb;14(2):123–9

Three-dimensional analysis of protein aggregate body in Saccharomyces cerevisiae cells. Kamasawa N, et al. **J Electron Microsc (Tokyo)** 1999;48(2):173–6

Pathways for eosinophil lipid body induction: differing signal transduction in cells from normal and hypereosinophilic subjects. Bozza PT, et al. **J Leukoc Biol** 1998 Oct; 64(4):563–9

Co-cultivation of conjunctival epithelial cells and Chlamydia trachomatis: electron microscopic findings. Kim DS, et al. **Korean J Ophthalmol** 1998 Jun;12(1):1–5

Magnetosome size distribution in uncultured rod-shaped bacteria as determined by electron microscopy and electron spectroscopic imaging. Lins U, et al. **Microsc Res Tech** 1998 Sep 15;42(6):459–64

Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle. Fernández R, et al. **Neuromuscul Disord** 1999 May;9(3):136–43

Neuronal intranuclear inclusions in polyglutamine diseases: nuclear weapons or nuclear fallout? Kim TW, et al. **Neuron** 1998 Oct;21(4):657–9 (19 ref.)

Inclusions in lymphoblasts [letter] Maitra A, et al. **Pediatr Dev Pathol** 1998 Nov-Dec;1(6):573

Filamentous intranuclear inclusion bodies in psittacine birds. A structural and ultrastructural study. Scarlata E, et al. **Zentralbl Veterinarmed [B]** 1999 Aug;46(6):375–80

[Needle-like inclusions in liver cells are specific diagnostic signs of porphyria cutanea tarda] Fakan F, et al. **Vnitr Lek** 1998 Jul;44(7):418–22 (Eng. Abstr.) **(Cze)**

[Disappearance of Mallory bodies in the liver of autopsy cases with a history of heavy drinking] Iwaba A, et al. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1999 Jun; 34(3):153–60 (Eng. Abstr.) **(Jpn)**

[Döhle body] Kurokawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):96–7 (7 ref.) **(Jpn)**

[Fechtner syndrome] Ohata M. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):322–5 (15 ref.) **(Jpn)**

[The Sebastian platelet syndrome: description of 2 cases and review of the literature (letter)] Aguilar Franco C, et al. **Sangre (Barc)** 1998 Jun;43(3):262–4 **(Spa)**

VIROLOGY

Localization of the P1 protein of potato Y potyvirus in association with cytoplasmic inclusion bodies and in the cytoplasm of infected cells. Arbatova J, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2319–23

Specific inclusion bodies are associated with replication of lettuce infectious yellows virus RNAs in Nicotiana benthamiana protoplasts. Medina V, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2325–9

[Biotin-rich pseudoherpetic intranuclear inclusions. A diagnostic pitfall] Leteurtre E, et al. **Arch Anat Cytol Pathol** 1999;47(1):44–7 (Eng. Abstr.) **(Fre)**

INCLUSION BODIES, VIRAL

GENETICS

Specific detection of monkeypox virus by polymerase chain reaction. Neubauer H, et al. **J Virol Methods** 1998 Oct; 74(2):201–7

ULTRASTRUCTURE

Infection of the corneal endothelium in herpes simplex keratitis. Holbach LM, et al. **Am J Ophthalmol** 1998 Oct; 126(4):592–4

Intranuclear inclusions in cells infected with Newcastle disease virus. Granzow H, et al. **Zentralbl Veterinarmed [B]** 1999 Aug;46(6):411–21

[Solving the mystery of cellular inclusions. A contribution to the history of virology] Diosi P. **Gesnerus** 1998; 55(3–4):249–69 (Eng. Abstr.) **(Ger)**

VIROLOGY

Inclusion body tracheitis associated with avian adenovirus in turkeys. Crespo R, et al. **Avian Dis** 1998 Jul-Sep; 42(3):589–96

Characterization of fowl adenoviruses from outbreaks of inclusion body hepatitis/hydropericardium syndrome in Chile. Toro H, et al. **Avian Dis** 1999 Apr-Jun;43(2):262–70

INCLUSION DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

INCOME

see related

SALARIES AND FRINGE BENEFITS

Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Chen FM, et al. **Am J Epidemiol** 1998 Dec 15;148(12):1212–8

Increasing response rates for mailed surveys of Medicaid clients and other low-income populations. Gibson PJ, et al. **Am J Epidemiol** 1999 Jun 1;149(11):1057–62

The impact of ethnicity, family income, and parental education on children's health and use of health services. Flores G, et al. **Am J Public Health** 1999 Jul;89(7):1066–71

Income, educational level and body height. Meyer HE, et al. **Ann Hum Biol** 1999 May-Jun;26(3):219–27

A comparison of New York City playground hazards in high- and low-income areas. Suecoff SA, et al. **Arch Pediatr Adolesc Med** 1999 Apr;153(4):363–6

Re-evaluating expectations [letter; comment] Holmwood C. **Aust Fam Physician** 1999 Feb;28(2):103, 105. Comment on: Aust Fam Physician 1998 Nov;27(11):993–8.

Income distribution, socioeconomic status, and self rated health in US. Authors ignored data in their study [letter; comment] Milyo J. **BMJ** 1999 May 22;318(7195):1417–8. Comment on: BMJ 1998 Oct 3;317(7163):917–21.

Anaesthetists consume 3% of trust expenditure but affect 60% of trust income [letter; comment] Sharples A, et al. **BMJ** 1998 Dec 5;317(7172):1587. Comment on: BMJ 1998 Jan 3;316(7124):3–4. Comment on: BMJ 1998 Jun 13;316(7147):1827.

Re: A critical assessment of high-earning orthodontists in the General Dental Services of England and Wales (1990–91)--Turbill, Richmond and Wright [letter; comment] Kerr WJ. **Br J Orthod** 1998 Aug;25(3):237. Comment on: Br J Orthod 1998 Feb;25(1):47–54.

Health in development. Sen A. **Bull World Health Organ** 1999;77(8):619–23

True arbiters of prosperity [letter] Fielding JF. **Can J Gastroenterol** 1999 Jul-Aug;13(6):525

Are you as wealthy as you should be? Lee G. **Can J Gastroenterol** 1999 May;13(4):303–4

Parenting and preschooler attachment among low-income urban African American families. Barnett D, et al. **Child Dev** 1998 Dec;69(6):1657–71

Funding Medicare [letter; comment] Aldis JS. **CMAJ** 1999 Mar 23;160(6):777; discussion 777–9. Comment on: CMAJ 1998 Sep 8;159(5):493–6. Comment on: CMAJ 1998 Sep 8;159(5):497–9; discussion 500–1.

Funding Medicare [letter; comment] Palmer WH. **CMAJ** 1999 Mar 23;160(6):777. Comment on: CMAJ 1998 Sep 8;159(5):493–6. Comment on: CMAJ 1998 Sep 8;159(5):497–9; discussion 500–1.

Physicians' union [letter] Volpintesta EJ. **Conn Med** 1999 Aug;63(8):503

Have family income mobility patterns changed? Gittleman M, et al. **Demography** 1999 Aug;36(3):299–314

Migradollars and mortality: the effects of migration on infant survival in Mexico. Kanaiaupuni SM, et al. **Demography** 1999 Aug;36(3):339–53

After-school activities and the development of low-income urban children: a longitudinal study. Posner JK, et al. **Dev Psychol** 1999 May;35(3):868–79

Do education and income buffer the effects of death of spouse on mortality? Martikainen P, et al. **Epidemiology** 1998 Sep; 9(5):530–4

Age at migration and family dependency among older Mexican immigrants: recent evidence from the Mexican American EPESE. Angel RJ, et al. **Gerontologist** 1999 Feb; 39(1):59–65

Income levels of bad-debt and free-care patients in Massachusetts hospitals. Weissman JS, et al. **Health Aff (Millwood)** 1999 Jul-Aug;18(4):156–66

Income inequality in the UK [editorial] [see comments] Atkinson AB. **Health Econ** 1999 Jun;8(4):283–8. Comment in: Health Econ 1999 Jun;8(4):281–2.

Gender, heroin consumption and economic behaviour. Bretteville-Jensen AL. **Health Econ** 1999 Aug;8(5):379–89

'Our healthier nation'? [editorial] Contoyannis P, et al. **Health Econ** 1999 Jun;8(4):289–96

Income inequality and health: pathways and mechanisms. Kawachi I, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):215–27 (42 ref.)

The association of body mass index with social and economic disadvantage in women and men. Sarlio-Lähteenkorva S, et al. **Int J Epidemiol** 1999 Jun;28(3):445–9

Income inequality, social cohesion, and class relations: a critique of Wilkinson's neo-Durkheimian research program. Muntaner C, et al. **Int J Health Serv** 1999; 29(1):59–81 (127 ref.)

Trends in per-patient gross income to dental practices from insured patients, 1980–1995. Eklund SA, et al. **J Am Dent Assoc** 1998 Nov;129(11):1559–65

Why income is up [letter; comment] Helfman M. **J Am Dent Assoc** 1998 Oct;129(10):1374, 1376. Comment on: J Am Dent Assoc 1998 Aug;129(8):1155–9.

Depression and wealth in older people: when money makes the difference [letter; comment] Almeida OP. **J Am Geriatr Soc** 1998 Oct;46(10):1328–9. Comment on: J Am Geriatr Soc 1998 Jan;46(1):49–57.

Economic reform in private veterinary practice. Lane DM. **J Am Vet Med Assoc** 1999 May 1;214(9):1327–8

Revenue, expense, and returns on resources for US veterinary practices, 1995 and 1997. Wise JK, et al. **J Am Vet Med Assoc** 1999 Jun 15;214(12):1778–80

Earnings and feminization of the veterinary profession [letter] Wolff A. **J Am Vet Med Assoc** 1998 Oct 1;213(7):952; discussion 952,954

Hospital conversion revenue: a critical analysis of present law and future proposals to reform the manner in which revenue generated from hospital conversions is employed. Standish JD. **J Contemp Health Law Policy** 1998 Fall; 15(1):131–82 (0 ref.)

Income inequality, primary care, and health indicators. Shi L, et al. **J Fam Pract** 1999 Apr;48(4):275–84

Description of a mixed ethnic, elderly population. I. Demography, nutrient/energy intakes, and income status. Prothro JW, et al. **J Gerontol A Biol Sci Med Sci** 1999 Jun;54(6):M315–24

INCOME

Paid organ donation--the grey basket concept [editorial] Daar AS. **J Med Ethics** 1998 Dec;24(6):365–8 (24 ref.)
Income characteristics of rural older women and implications for health status. Barnes ND, et al. **J Women Aging** 1999; 11(1):27–37
Early childbearing patterns and women's labor force behavior in later life. Pienta A. **J Women Aging** 1999; 11(1):69–84
Anti-inflammatory inflames Centocor's profits [news] Glaser V. **Nat Biotechnol** 1998 Oct;16(10):900
The rise and fall of levonorgestrel implants: 1992–1996. Berenson AB, et al. **Obstet Gynecol** 1998 Nov;92(5):790–4
Low birth weight: race and maternal nativity--impact of community income. Fang J, et al. **Pediatrics** 1999 Jan; 103(1):E5
Introduction to special issue on the economics of health insurance in low and middle-income countries [editorial] Carrin G, et al. **Soc Sci Med** 1999 Apr;48(7):859–64
Income and health: what is the nature of the relationship? Ecob R, et al. **Soc Sci Med** 1999 Mar;48(5):693–705
The relationship between income inequality and population health [letter; comment] [published erratum appears in Soc Sci Med 1999 Jan;48(2):281] Judge K, et al.
Soc Sci Med 1998 Oct;47(7):983–5. Comment on: Soc Sci Med 1998 Feb-Mar;46(4–5):567–79. Comment on: Soc Sci Med 1998 Aug;47(3):411–2.
Higher earnings, bursting trains and exhausted bodies: the creation of travelling psychosis in post-reform China. Lee S. **Soc Sci Med** 1998 Nov;47(9):1247–61 (81 ref.)
Individual Social Security accounts: issues of administrative feasibility and cost, 1998. Olsen KA, et al.
Soc Secur Bull 1999;62(1):75–90 (103 ref.)
Noncitizens and the Supplemental Security Income program. Parrott TM, et al. **Soc Secur Bull** 1998;61(4):3–31 (0 ref.)
For richer, for poorer, in sickness and in health: older widowed women's health, relationships and financial security. Byles JE, et al. **Women Health** 1999;29(1):15–30
[Income and smoking behavior in Germany--a secondary analysis of data from the 1995 microcensus] Helmert U. **Gesundheitswesen** 1999 Jan;61(1):31–7 (Eng. Abstr.) **(Ger)**
[The use of prosthetic meshes in the surgical treatment of inguinal hernia: the costs and profits for the local health screening unit] Leardi S, et al. **Minerva Chir** 1998 Jun; 53(6):581–5 (Eng. Abstr.) **(Ita)**
[Sources of income after being denied disability pension] Claussen B, et al. **Tidsskr Nor Laegeforen** 1999 Jun 10; 119(15):2187–91 (Eng. Abstr.) **(Nor)**
[Income inequality and health: the case of Rio de Janeiro] Szwarcwald CL, et al. **Cad Saude Publica** 1999 Jan–Mar; 15(1):15–28 (Eng. Abstr.) **(Por)**

CLASSIFICATION

Does it matter who answers the race question? Racial classification and income inequality in Brazil. Telles EE, et al. **Demography** 1998 Nov;35(4):465–74

HISTORY

Historical redistribution under the Social Security Disability Insurance Program. Leimer DR. **Soc Secur Bull** 1998; 61(3):3–19

STATISTICS & NUMERICAL DATA

The integration of primary care sports medicine into an academic emergency medicine practice: academic and revenue enhancement. Veenema KR. **Acad Emerg Med** 1999 Aug;6(8):828–32
The prevalence of low income among childbearing women in California: implications for the private and public sectors. Braveman P, et al. **Am J Public Health** 1999 Jun; 89(6):868–74
Social factors, treatment, and survival in early-stage non-small cell lung cancer. Greenwald HP, et al.
Am J Public Health 1998 Nov;88(11):1681–4
Income inequality and homicide rates in Rio de Janeiro, Brazil. Szwarcwald CL, et al. **Am J Public Health** 1999 Jun;89(6):845–50
Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis [see comments] Kennedy BP, et al. **BMJ** 1998 Oct 3; 317(7163):917–21. Comment in: BMJ 1999 May 22;318(7195):1417–8.
Reducing economic disparity to achieve better health: modelling the effect of adjustments to income adequacy on self-reported morbidity among the elderly in Canada. Cairney J, et al. **Can J Public Health** 1998 Nov–Dec; 89(6):424–8
The gender gap in the economic well-being of nonresident fathers and custodial mothers. Bianchi SM, et al.
Demography 1999 May;36(2):195–203
The impact of wives' earnings on income inequality: issues and estimates. Cancian M, et al. **Demography** 1999 May; 36(2):173–84
The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. Breen N, et al. **Ethn Dis** 1999 Winter;9(1):111–25
Income inequality, social cohesion, and health: clarifying the theory--a reply to Muntaner and Lynch. Wilkinson RG. **Int J Health Serv** 1999;29(3):525–43
Income and expenditures of osteopathic medical colleges. Kowert C. **J Am Osteopath Assoc** 1998 Nov;98(11):595
1997 income of US veterinarians. Wise JK, et al.
J Am Vet Med Assoc 1999 May 15;214(10):1489–91
Do housing tenure and car access predict health because they are simply markers of income or self esteem? A Scottish study. Macintyre S, et al.
J Epidemiol Community Health 1998 Oct;52(10):657–64
Income inequality and mortality in England. Stanistreet D, et al. **J Public Health Med** 1999 Jun;21(2):205–7
Rural women's economic realities [see comments] McLaughlin DK. **J Women Aging** 1998;10(4):41–65 (59 ref.) . Comment in: J Women Aging 1998 ;10(4):81–90.
Socioeconomic status, standard of living, and neurotic disorder [letter; comment] Eichenberger A, et al.
Lancet 1998 Nov 21;352(9141):1706–7. Comment on: Lancet 1998 Aug 22;352(9128):605–9.
General practitioners' knowledge of their patients' socioeconomic data and their ability to identify vulnerable groups. Gulbrandsen P, et al.
Scand J Prim Health Care 1998 Dec;16(4):204–10
Social differences in health in an affluent Danish county. Osler M, et al. **Scand J Soc Med** 1998 Dec;26(4):289–92
Aggregation and the measurement of income inequality: effects on morbidity. Soobader MJ, et al. **Soc Sci Med** 1999 Mar;48(6):733–44
Projecting immigrant earnings: the significance of country of origin. Duleep HO, et al. **Soc Secur Bull** 1998;61(4):32–44
Effect on benefits of earnings at ages 65 or older, 1995. Kestenbaum B, et al. **Soc Secur Bull** 1999;62(1):4–9
Retirement income security in the United Kingdom. Liu L. **Soc Secur Bull** 1999;62(1):23–46 (87 ref.)
The Galveston Plan and Social Security: a comparative analysis of two systems. Wilson TM. **Soc Secur Bull** 1999; 62(1):47–64
Acute appendicitis and dietary fibre intake. Naaeder SB, et al. **West Afr J Med** 1998 Oct–Dec;17(4):264–7

TRENDS

Wealth flow and fertility decline in rural Kenya, 1981–92: a reassessment of the evidence. Dow TE Jr, et al.
Afr J Reprod Health 1997 Sep;1(2):41–66
Discounting costs and effects: a reconsideration. van Hout BA. **Health Econ** 1998 Nov;7(7):581–94
Another vicious cycle? Serb C. **Hosp Health Netw** 1998 Oct 20;72(20):24–8, 30, 3
Projecting immigrant earnings: the significance of country of origin. Duleep HO, et al. **Soc Secur Bull** 1998;61(4):32–44

INCOME TAX

The Budget: bad news for British anaesthetists in the USA [letter] Arrowsmith JE, et al. **Anaesthesia** 1998 Sep; 53(9):933
An equitable way to pay for universal coverage. Rasell E. **Int J Health Serv** 1999;29(1):179–88
Remember your office at gift-giving time. It won't hurt if selections are tax-deductible. Bergeron BP.
Postgrad Med 1998 Dec;104(6):15–6, 21

ECONOMICS

Cost of tax-exempt health benefits in 1998. Sheils J, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):176–81

LEGISLATION & JURISPRUDENCE

Saving tax on holiday and education expenses. Hobson Z. **S Afr Med J** 1999 Jan;89(1):36

INCOMPETENCY, MENTAL see **MENTAL COMPETENCY**

INCOMPLETE VIRUSES see **DEFECTIVE VIRUSES**

INCONTINENCE PADS

UTILIZATION

Pad testing in incontinent women: a review. Ryhammer AM, et al. **Int Urogynecol J Pelvic Floor Dysfunct** 1999; 10(2):111–5 (38 ref.)

INCONTINENTIA PIGMENTI

COMPLICATIONS

Incontinentia pigmenti (Bloch-Sulzberger syndrome): report of case. Welbury TA, et al. **ASDC J Dent Child** 1999 May–Jun;66(3):213–5, 155
Macular vasculopathy and its evolution in incontinentia pigmenti. Goldberg MF. **Ophthalmic Genet** 1998 Sep; 19(3):141–8
Macular vasculopathy and its evolution in incontinentia pigmenti. Goldberg MF. **Trans Am Ophthalmol Soc** 1998; 96:55–65; discussion 65–72

DIAGNOSIS

Clarification of a diagnosis of IP [letter] Roberts JL.
Am J Med Genet 1999 Aug 6;85(4):426; discussion 427
Incontinentia pigmenti (Bloch-Sulzberger-syndrome): case report and differential diagnosisto related dermato-ocular syndromes. Käsmann-Kellner B, et al. **Ophthalmologica** 1999;213(1):63–9

GENETICS

Second trimester miscarriage of a male fetus with incontinentia pigmenti [letter; comment] Devriendt K, et al. **Am J Med Genet** 1998 Nov 16;80(3):298–9. Comment on: Am J Med Genet 1998 Jan 13;75(2):159–63.
Incontinentia pigmenti versus hypomelanosis of Ito: the whys and wherefores of a confusing issue [letter; comment] Happle R. **Am J Med Genet** 1998 Aug 27;79(1):64–5. Comment on: Am J Med Genet 1997 Mar 3;69(1):96–7.
Clarification of a diagnosis of IP [letter] Roberts JL.
Am J Med Genet 1999 Aug 6;85(4):426; discussion 427
X-inactivation and marker studies in three families with incontinentia pigmenti: implications for counselling and gene localisation. Woffendin H, et al. **Clin Genet** 1999 Jan; 55(1):55–60
Central nervous system involvement in incontinentia pigmenti: cranial MRI of two siblings. Aydingöz U, et al.
Neuroradiology 1998 Jun;40(6):364–6

PATHOLOGY

Erythematous and vesicular eruption in a one day old infant. Cockerell CJ, et al. **Dermatol Online J** 1998 Oct;4(1):5
Incontinentia pigmenti: variable disease expression within an affected family. Basarab T, et al.
J Eur Acad Dermatol Venereol 1998 Sep;11(2):173–6

INCONTINENTIA PIGMENTI ACHROMIANS see **PIGMENTATION DISORDERS**

INCREASED GRAVITY see **HYPERGRAVITY**

INCUBATORS

see related
ENVIRONMENT, CONTROLLED
LIFE SUPPORT SYSTEMS

Incubators in Hungarian hospital lobbies allow babies to be abandoned more safely [news] Kovac C. **BMJ** 1999 Jul 24;319(7204):214
Randomised study of skin-to-skin versus incubator care for rewarming low-risk hypothermic neonates [letter] Christensson K, et al. **Lancet** 1998 Oct 3;352(9134):1115

VETERINARY

Development of a simple, portable carbon dioxide incubator for in vitro production of bovine embryos. Suzuki T, et al. **Anim Reprod Sci** 1999 Jan 8;54(3):149–57

INCUBATORS, INFANT

User experience network. Cable failure causes frequent alarms--and loss of control--on Hill-Rom Air-Shields C2HS Isolette infant incubators. **Health Devices** 1999 Aug; 28(8):326–7

ADVERSE EFFECTS

Reversal of access port gaskets on Hill-Rom Air-Shields Isolette infant incubators. **Health Devices** 1998 Sep–Oct; 27(9–10):370–1

STANDARDS

Kangaroo care versus incubator care in the management of well preterm infants--a pilot study. Kambarami RA, et al. **Ann Trop Paediatr** 1998 Jun;18(2):81–6

INCUS

PATHOLOGY

Extensive tympanosclerosis and a short incus. Deguine C, et al. **Ear Nose Throat J** 1999 Apr;78(4):224

SURGERY

Evaluation of a cement incus replacement prosthesis in a temporal bone model. Asai M, et al. **Acta Otolaryngol** 1999; 119(5):573–6
Evidence of residual disease in ossicles of patients undergoing cholesteatoma removal. Dornhoffer JL, et al.
Acta Otolaryngol (Stockh) 1999 Jan;119(1):89–92
Tympanoplasty type II with ionomeric cement and titanium-gold-angle prostheses. Maassen MM, et al.
Am J Otol 1998 Nov;19(6):693–9
A dislocated incus protruding through a traumatic perforation. Ku PK, et al. **Ear Nose Throat J** 1998 Oct; 77(10):804
Revision stapedectomy for incus erosion: long-term hearing. Krieger LW, et al. **Otolaryngol Head Neck Surg** 1998 Oct; 119(4):370–3

INDANS

[Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease] Sugimoto H, et al. **Yakugaku Zasshi** 1999 Feb;119(2):101–13 (27 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Donepezil overdose: a tenfold dosing error. Shepherd G, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):812-5

ADVERSE EFFECTS

Selective COX-2 inhibitors and human inflammatory bowel disease. McCartney SA, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1115-7

Violent behavior-associated with donepezil [letter] Bouman WP, et al. **Am J Psychiatry** 1998 Nov;155(11):1626-7

Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome [letter] Hemingway-Eltomey JM, et al. **Am J Psychiatry** 1999 Sep; 156(9):1470

Behavioral complications associated with donepezil [letter] Wengel SP, et al. **Am J Psychiatry** 1998 Nov; 155(11):1632-3

The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity. Sprung J, et al. **Anesth Analg** 1998 Nov;87(5):1203-5

Mania associated with donepezil [letter] Benazzi F. **Int J Geriatr Psychiatry** 1998 Nov;13(11):814-5

Donepezil and paroxetine: possible drug interaction [letter] Carrier L. **J Am Geriatr Soc** 1999 Aug;47(8):1037

Convulsions induced by donepezil [letter] Babic T, et al. **J Neurol Neurosurg Psychiatry** 1999 Mar;66(3):410

ANALYSIS

Separation of cis-/trans-diastereomers and enantiomers of aminoindanol and aminoindan using capillary electrophoresis. Zhou L, et al. **J Capillary Electrophor** 1997 Nov-Dec;4(6):279-85

BLOOD

Toxicological management of chlorophacinone poisoning. Lagrange F, et al. **Acta Clin Belg Suppl** 1999;1:13-6

Simultaneous determination of donepezil (aricept) enantiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry. Matsui K, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11;729(1-2):147-55

CHEMICAL SYNTHESIS

Exploring structure-activity relationships around the phosphomannose isomerase inhibitor AF14049 via combinatorial synthesis. Bhandari A, et al. **Bioorg Med Chem Lett** 1998 Sep 8;8(17):2303-8

Synthesis and thromboxane A2 antagonistic activity activity of indane derivatives. Shinozaki K, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):401-6

Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones. Dimmock JR, et al. **J Med Chem** 1999 Apr 22;42(8):1358-66

Novel CDC25A phosphatase inhibitors from pyrolysis of 3-alpha-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. Peng H, et al. **J Med Chem** 1998 Nov 19;41(24):4677-80

[Synthesis and pharmacologic evaluation of 3-(2- and 4-pyridinyl)indane-1,3-diones and structural analogues with potential anti-inflammatory and antineoplastic activity] Robert-Piessard S, et al. **Ann Pharm Fr** 1998; 56(4):160-8 (Eng. Abstr.) **(Fre)**

CHEMISTRY

Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Lages AS, et al. **Bioorg Med Chem Lett** 1998 Jan 20;8(2):183-8

Synthetic [5,5] trans-fused indane lactones as inhibitors of thrombin. Pass M, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):431-6

Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. Kryger G, et al. **J Physiol Paris** 1998 Jun-Aug;92(3-4):191-4

Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Kryger G, et al. **Structure Fold Des** 1999 Mar 15;7(3):297-307

ECONOMICS

An economic evaluation of donepezil in the treatment of Alzheimer's disease. Small GW, et al. **Clin Ther** 1998 Jul-Aug;20(4):838-50

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Stewart A, et al. **Int J Geriatr Psychiatry** 1998 Jul;13(7):445-53

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. O'Brien BJ, et al. **J Am Geriatr Soc** 1999 May;47(5):570-8

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease [see comments] Neumann PJ, et al. **Neurology** 1999 Apr 12;52(6):1138-45. Comment in: Neurology 1999 Apr 12;52(6):1115-6.

METABOLISM

Development of a bioconversion process for production of cis-1S,2R-indandiol from indene by recombinant Escherichia coli constructs. Reddy J, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):614-20

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Rogers SL, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:1-6

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Rogers SL, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:7-12

An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:51-5

An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov; 46 Suppl 1:56-60

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:13-8

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:19-24

Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:25-9

Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:30-4

Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov; 46 Suppl 1:35-9

Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:40-4

Pharmacokinetics of Camonagrel in experimental animal: rat, rabbit and dog. Albet C, et al. **Eur J Drug Metab Pharmacokinet** 1998 Apr-Jun; 23(2):251-4

PHARMACOLOGY

Antioxidant, OPC-14117, attenuates edema formation, and subsequent tissue damage following cortical contusion in rats. Mori T, et al. **Acta Neurochir Suppl (Wien)** 1998; 71:120-2

Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Finberg JP, et al. **Adv Neurol** 1999;80:495-9

Protective effects of delapril, indapamide and their combination on stroke occurrence and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Razzetti R, et al. **Arzneimittelforschung** 1998 Nov; 48(11):1083-7

Task-specific enhancement of short-term, but not long-term, memory by class I metabotropic glutamate receptor antagonist 1-aminoindan-1,5-dicarboxylic acid in rats. Christoffersen GR, et al. **Behav Brain Res** 1999 Jun; 101(2):215-26

Assessment of the discriminative stimulus effects of the D3 dopamine antagonist PNU-99194A in rats: comparison with psychomotor stimulants. Baker LE, et al. **Behav Pharmacol** 1997 Jun;8(2-3):243-52

Biological activities of 1,1,6-trisubstituted indanes: beyond magainin 2. Numao N, et al. **Biol Pharm Bull** 1999 Jan; 22(1):73-6

Thrombin inhibitors based on [5,5] trans-fused indane lactams. Pass M, et al. **Bioorg Med Chem Lett** 1999 Jun 21;9(12):1657-62

Synthesis and thromboxane A2 antagonistic activity activity of indane derivatives. Shinozaki K, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):401-6

The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Tiseo PJ, et al. **Br J Clin Pharmacol** 1998 Nov;46 Suppl 1:45-50

Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. Nakai M, et al. **Brain Res Mol Brain Res** 1999 Jan 22;64(1):59-68

Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Lin JH, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):6-10

Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Wang H, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan;19(1):27-30

Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Freed MI, et al. **Clin Pharmacol Ther** 1999 May;65(5):473-82

Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor. Nishime JA, et al. **Drug Metab Dispos** 1999 Sep;27(9):972-6

The dopamine D3 receptor antagonist PNU-99194A fails to block (+)-7-OH-DPAT substitution for D-amphetamine or cocaine. Baker LE, et al. **Eur J Pharmacol** 1998 Oct 2;358(2):101-9

Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Chapman AG, et al. **Eur J Pharmacol** 1999 Feb 26;368(1):17-24

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Huang W, et al. **Eur J Pharmacol** 1999 Feb 5; 366(2-3):127-35

Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Tanaka T, et al. **Eur J Pharmacol** 1998 Sep 11;357(1):53-60

Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Blanchet PJ, et al. **Exp Neurol** 1998 Oct;153(2):214-22

Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. Yoshida K, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):702-8

A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. Audinot V, et al. **J Pharmacol Exp Ther** 1998 Oct; 287(1):187-97

Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. Negus SS, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):60-9

Long-term effects of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients. Matoba M, et al. **Jpn Circ J** 1998 Dec;62(12):900-2

Both dopamine and the putative dopamine D3 receptor antagonist PNU-99194A induce a biphasic inhibition of phorbol ester-stimulated arachidonic acid release from CHO cells transfected with the dopamine D3 receptor. Nilsson CL, et al. **Life Sci** 1999;64(11):939-51

The class I metabotropic glutamate receptor antagonist, AIDA, improves short-term and impairs long-term memory in a spatial task for rats. Christoffersen GR, et al. **Neuropharmacology** 1999 Jun;38(6):817-23

Smooth muscle relaxant activity of pterosin Z and related compounds [letter] Sheridan H, et al. **Planta Med** 1999 Apr; 65(3):271-2

The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice. Manzanedo C, et al. **Psychopharmacology (Berl)** 1999 Mar;143(1):82-8

Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries. MacLean MR, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun; 11(2-3):147-9

Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat. Underwood DC, et al. **Pulm Pharmacol Ther** 1999;12(1):13-26

Endothelin-1 receptor blockade and its effect on chronic rejection. Tang JL, et al. **Transplant Proc** 1999 Feb-Mar; 31(1-2):1249

Endothelin receptor antagonist improves pulmonary hemodynamics during lung ischemia/reperfusion injury. Shennib H, et al. **Transplantation** 1998 Oct 15;66(7):917-37

POISONING

Toxicological management of chlorophacinone poisoning. Lagrange F, et al. **Acta Clin Belg Suppl** 1999;1:13-6

Donepezil overdose: a tenfold dosing error. Shepherd G, et al. **Ann Pharmacother** 1999 Jul-Aug;33(7-8):812-5

Donepezil overdose [letter] Greene YM, et al. **J Clin Psychiatry** 1999 Jan;60(1):56-7

THERAPEUTIC USE

Treating visual hallucinations with donepezil [letter] Burke WJ, et al. **Am J Psychiatry** 1999 Jul;156(7):1117-8

Is the placebo control obsolete in a world after donepezil and vitamin E? [see comments] Karlawish JH, et al. **Arch Neurol** 1998 Nov;55(11):1420-4 (35 ref.). Comment in: Arch Neurol 1998 Nov;55(11):1396-8.

Donepezil in treatment-resistant bipolar disorder. Burt T, et al. **Biol Psychiatry** 1999 Apr 15;45(8):959-64

New drug treatment for Alzheimer's disease. SMAC's advice on use of donepezil is contradictory [letter] Baxter T, et al. **BMJ** 1998 Oct 3;317(7163):946

New drug treatment for Alzheimer's disease. Doctors want to offer more than sympathy [letter; comment] Dening T, et al. **BMJ** 1998 Oct 3;317(7163):945. Comment on: **BMJ** 1998 Mar 7;316(7133):762-4.

New drug treatment for Alzheimer's disease. Drugs should not need to show cost effectiveness to justify their prescription [letter; comment] Evans M. **BMJ** 1998 Oct 3;317(7163):945-6. Comment on: BMJ 1998 Mar 7;316(7133):762-4.

New drug treatment for Alzheimer's disease. Effects of drugs can be variable [letter; comment] Levy R. **BMJ** 1998 Oct 3;317(7163):945. Comment on: BMJ 1998 Mar 7;316(7133):762-4.

Guideline for primary care management of dementia. GPs may want to continue prescribing donepezil for patients [letter; comment] Tapsfield WG, et al. **BMJ** 1999 Mar 13; 318(7185):732. Comment on: BMJ 1998 Sep 19;317(7161):802-8.

Effectiveness of donepezil in treating Alzheimer's disease [letter] Garcia A. **Can Fam Physician** 1999 Aug;45:1858-9

Is donepezil effective for treating Alzheimer's disease? Steele LS, et al. **Can Fam Physician** 1999 Apr;45:917-9

An economic evaluation of donepezil in the treatment of Alzheimer's disease. Small GW, et al. **Clin Ther** 1998

INDANS

Jul-Aug;20(4):838-50

The effects of donepezil in Alzheimer's disease - results from a multinational trial. Burns A, et al. **Dement Geriatr Cogn Disord** 1999 May-Jun;10(3):237-44

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Rogers SL. **Dement Geriatr Cogn Disord** 1998;9 Suppl 3:29-42 (67 ref.)

Donepezil update. **Drug Ther Bull** 1998 Aug;36(8):60-1 (9 ref.)

Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Newby DE, et al. **Eur Heart J** 1998 Dec;19(12):1808-13

Clinical benefits of a new piperidine-class AChE inhibitor. Doody RS. **Eur Neuropsychopharmacol** 1999 Apr;9 Suppl 2:S69-77 (29 ref.)

Clinical profile of donepezil in the treatment of Alzheimer's disease. Doody RS. **Gerontology** 1999;45 Suppl 1:23-32 (62 ref.)

Donepezil for dementia with Lewy bodies: a case study [letter] Aarsland D, et al. **Int J Geriatr Psychiatry** 1999 Jan;14(1):69-72

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Shea C, et al. **Int Psychogeriatr** 1998 Sep;10(3):229-38

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. O'Brien BJ, et al. **J Am Geriatr Soc** 1999 May;47(5):570-8

Donepezil for postoperative delirium associated with Alzheimer's disease [letter] Wengel SP, et al. **J Am Geriatr Soc** 1999 Mar;47(3):379-80

Donepezil for Tourette's disorder and ADHD [letter] Hoopes SP. **J Clin Psychopharmacol** 1999 Aug;19(4):381-2

Donepezil improves symptoms of delirium in dementia: implications for future research. Wengel SP, et al. **J Geriatr Psychiatry Neurol** 1998 Fall;11(3):159-61

Clinical experience with Donepezil (Aricept) in the UK. Wilkinson D. **J Neural Transm Suppl** 1998;54:311-5

Visual form of Alzheimer's disease and its response to anticholinesterase therapy. Warren S, et al. **J Neuroimaging** 1998 Oct;8(4):249-52

Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction. Yoshida K, et al. **Jpn Circ J** 1998 Sep;62(9):680-6

Cholinergic therapy for Down's syndrome [letter] Kishnani PS, et al. **Lancet** 1999 Mar 27;353(9158):1064-5

Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Heise G, et al. **Nephron** 1998 Oct;80(2):220-6

Dementia with Lewy bodies: response of delirium-like features to donepezil. Kaufer DI, et al. **Neurology** 1998 Nov;51(5):1512

Disease, drugs, decisions, and dollars [editorial; comment] Mushlin AI. **Neurology** 1999 Apr 12;52(6):1115-6. Comment on: Neurology 1999 Apr 12;52(6):1138-45.

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease [see comments] Neumann PJ, et al. **Neurology** 1999 Apr 12;52(6):1138-45. Comment in: Neurology 1999 Apr 12;52(6):1115-6.

Efficacy of donepezil in Alzheimer's disease: fact or artifact? [letter; comment] van Gool WA. **Neurology** 1999 Jan 1; 52(1):218-9. Comment on: Neurology 1998 Jan;50(1):136-45.

Treating Alzheimer's disease with cholinergic drugs, Part 2 [news] Terpstra T, et al. **Nurse Pract** 1999 Jan;24(1):117-9

What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Shadlen MF, et al. **Postgrad Med** 1999 Jan;105(1):109-18 (25 ref.)

A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Tanaka T, et al. **Thromb Res** 1998 Sep 1; 91(5):229-35

[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA Azanza JR, et al. **Rev Med Univ Navarra** 1998 Apr-Jun;42(2):109-18 (43 ref.) **(Spa)**

TOXICITY

Reproductive study. II: Prenatal and postnatal development study with candoxatril in Sprague-Dawley rats. Horimoto M, et al. **J Toxicol Sci** 1998 Nov;23 Suppl 5:671-9

Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Treinen KA, et al. **Teratology** 1999 Jan;59(1):51-9

INDAPAMIDE

ADMINISTRATION & DOSAGE

Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Meyrier A, et al. **Am J Hypertens** 1998 Sep;11(9):1087-92

Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives [letter] Forette B. **J Hum Hypertens** 1999 Mar;13(3):211-3

[Efficacy and safety of indapamide 1.5 mg sustained release coated tablets in the therapy of arterial hypertension] Asmar R. **Ann Cardiol Angeiol (Paris)** 1998 Feb; 47(2):94-104 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Use of indapamide in hospital and community clinics and its effect on plasma potassium in Chinese patients. Chang S, et al. **J Clin Pharm Ther** 1998 Aug;23(4):295-302

ANALYSIS

Quantitative determination of indapamide in pharmaceuticals and urine by high-performance liquid chromatography with amperometric detection. Legorburu MJ, et al. **J Chromatogr Sci** 1999 Aug;37(8):283-7

IMMUNOLOGY

Fixed drug eruption induced by indapamide. Cross-reactivity with sulfonamides. De Barrio M, et al. **J Investig Allergol Clin Immunol** 1998 Jul-Aug;8(4):253-5

PHARMACOLOGY

Protective effects of delapril, indapamide and their combination on stroke occurrence and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Razzetti R, et al. **Arzneimittelforschung** 1998 Nov; 48(11):1083-7

The diuretic indapamide increases bone mass and decreases bone resorption in spontaneously hypertensive rats supplemented with sodium. Lalande A, et al. **J Bone Miner Res** 1998 Sep;13(9):1444-50

[Participation of endogenous adrenal dilation factor in the hypotensive effect of indapamide] Medvedeva NA, et al. **Biull Eksp Biol Med** 1998 Nov;126(11):565-8 **(Rus)**

THERAPEUTIC USE

Efficacy of indapamide in central diabetes insipidus. Tetiker T, et al. **Arch Intern Med** 1999 Sep 27;159(17):2085-7

Twenty-four hour antihypertensive efficacy of indapamide, 1.5-mg sustained release: results of two randomized double-blind controlled studies. Mallion JM, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):673-8

PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee. **J Hum Hypertens** 1998 Sep; 12(9):627-9

Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. Ambrosioni E, et al. **J Hypertens** 1998 Nov;16(11):1677-84

Indapamide improves flow-induced dilation in hypertensive rats with a high salt intake. Matrougui K, et al. **J Hypertens** 1998 Oct;16(10):1485-90

[Changes in blood pressure 24 hour monitoring data and quality of life in patients with systolic hypertension treated with arifon] Kobalova ZhD, et al. **Ter Arkh** 1998;70(9):67-9 (Eng. Abstr.) **(Rus)**

URINE

Quantitative determination of indapamide in pharmaceuticals and urine by high-performance liquid chromatography with amperometric detection. Legorburu MJ, et al. **J Chromatogr Sci** 1999 Aug;37(8):283-7

INDAZOLES

ADMINISTRATION & DOSAGE

Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Amadori D, et al. **Breast Cancer Res Treat** 1998 Jun;49(3):209-17

Nitric oxide and sleep in the rat: a puzzling relationship. Burlet S, et al. **Neuroscience** 1999;92(2):627-39

CHEMICAL SYNTHESIS

Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles). Krapcho AP, et al. **J Med Chem** 1998 Dec 31;41(27):5429-44

Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors. Andronati S, et al. **Pharmazie** 1999 Feb;54(2):99-101

CHEMISTRY

Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Kharitonov VG, et al. **Biochemistry** 1999 Aug 17;38(33):10699-706

Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. Rodgers JD, et al. **Bioorg Med Chem Lett** 1998 Apr 7;8(7):715-20

Interactions between lonidamine and beta- or hydroxypropyl-beta-cyclodextrin. Palmieri GF, et al. **Drug Dev Ind Pharm** 1998 Jul;24(7):653-60

METABOLISM

Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Kharitonov VG, et al. **Biochemistry** 1999 Aug 17;38(33):10699-706

Alphavbeta3 integrin binding affinity and specificity of SM256 in various species. Mousa SA, et al. **J Cardiovasc Pharmacol** 1999 Apr;33(4):641-6

PHARMACOKINETICS

Pharmacokinetics of bendazac lysine in 10 Chinese young men. Chen XX, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Mar;18(2):109-11

PHARMACOLOGY

The effects of the nitric oxide synthase inhibitor 7-nitroindazole on ethanol pharmacokinetics in rats after acute and chronic ethanol administration. Vassiljev V, et al. **Alcohol Alcohol** 1998 Nov-Dec;33(6):609-15

Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Kerr JS, et al. **Anticancer Res** 1999 Mar-Apr; 19(2A):959-68

Soluble guanylate cyclase: effect of YC-1 on ligation kinetics with carbon monoxide. Sharma VS, et al. **Biochem Biophys Res Commun** 1999 Jan 8;254(1):188-91

Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone. Dassonneville L, et al. **Biochem Pharmacol** 1999 Oct 15;58(8):1307-12

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Galle J, et al. **Br J Pharmacol** 1999 May; 127(1):195-203

Effects of 7-nitroindazole, a neuronal nitric oxide synthase (nNOS) inhibitor, on locomotor activity and contextual fear conditioning in rats. Maren S. **Brain Res** 1998 Aug 31; 804(1):155-8

Antihelicase action of CI-958, a new drug for prostate cancer. Lun L, et al. **Cancer Chemother Pharmacol** 1998; 42(6):447-53

A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1. Sironi M, et al. **Eur Cytokine Netw** 1999 Sep;10(3):437-42

A neuronal nitric oxide synthase inhibitor 7-nitroindazole reduces the 5-HT1A receptor against 8-OH-DPAT-elicited hyperphagia in rats. Sugimoto Y, et al. **Eur J Pharmacol** 1999 Jul 2;376(1-2):1-5

Role of neuronal nitric oxide synthase in Dahl salt-sensitive hypertension. Tan DY, et al. **Hypertension** 1999 Jan;33(1 Pt 2):456-61

bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. Biroccio A, et al. **Int J Cancer** 1999 Jul 2; 82(1):125-30

Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Villa R, et al. **Int J Oncol** 1999 Jan;14(1):133-8

Effects of 7-nitroindazole on renal sympathetic nerve activity during acute cardiac tamponade in conscious rabbits. Wang YP, et al. **J Auton Nerv Syst** 1999 Feb 15;75(2-3):116-22

Inhibition of bacterial adherence to a high-water-content polymer by a water-soluble, nonsteroidal, anti-inflammatory drug. Arciola CR, et al. **J Biomed Mater Res** 1998 Oct;42(1):1-5

Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. Hoenicka M, et al. **J Mol Med** 1999 Jan;77(1):14-23

Neuronal nitric oxide synthase inhibition reduces MPP+-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. Rose S, et al. **J Neural Transm** 1999;106(5-6):477-86

NMDA receptor-dependent nitric oxide and cGMP synthesis in brain hemispheres and cerebellum during reperfusion after transient forebrain ischemia in gerbils: effect of 7-Nitroindazole. Chalimoniuk M, et al. **J Neurosci Res** 1998 Dec 1;54(5):681-90

A comparative study of the effects of two nitric oxide synthase inhibitors and two nitric oxide donors on temporary focal cerebral ischemia in the Wistar rat. Coert BA, et al. **J Neurosurg** 1999 Feb;90(2):332-8

7-Nitro indazole, a neuron-specific nitric oxide synthase inhibitor, produces amnesia in the chick. Hölscher C. **Learn Mem** 1994 Nov-Dec;1(4):213-6

7-Nitro indazole, a selective neuronal nitric oxide synthase inhibitor in vivo, impairs spatial learning in the rat. Hölscher C, et al. **Learn Mem** 1996 Jan-Feb;2(6):267-78

YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Friebe A, et al. **Mol Pharmacol** 1998 Dec;54(6):962-7

Nitric oxide synthetase activity in cerebral post-ischemic reperfusion and effects of L-N(G)-nitroarginine and 7-nitroindazole on the survival. Sorrenti V, et al. **Neurochem Res** 1999 Jul;24(7):861-6

The nitric oxide synthase inhibitor 7-nitroindazole displays enhanced anxiolytic efficacy without tolerance in rats following subchronic administration. Dunn RW, et al. **Neuropharmacology** 1998 Jul;37(7):899-904

Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. Callahan BT, et al. **Neuroreport** 1998 Aug 24;9(12):2691-5

Evidence that the neuronal nitric oxide synthase inhibitor 7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4-dihydroxyphenylacetic acid. Desvignes C, et al. **Neurosci Lett** 1999 Feb 19;261(3):175-8

Evidence that the neuronal nitric oxide synthase inhibitor

7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4-dihydroxyphenylacetic acid. Desvignes C, et al. **Neurosci Lett** 1999 Apr 2;264(1-3):5-8

Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Ravagnan L, et al. **Oncogene** 1999 Apr 22;18(16):2537-46

Effects of halothane and urethane-chloralose anaesthesia on the pressor and cerebrovascular responses to 7-NITROINDAZOLE, an inhibitor of nitric oxide synthase. Zagvazdin Y, et al. **Pharmacol Res** 1998 Nov; 38(5):339-46

Nitric oxide production in the CA1 field of the gerbil hippocampus after transient forebrain ischemia : effects of 7-nitroindazole and NG-nitro-L-arginine methyl ester. Lei B, et al. **Stroke** 1999 Mar;30(3):669-77

On the selectivity of 7-nitroindazole as an inhibitor of neuronal nitric oxide synthase [letter; comment] Reiner A, et al. **Trends Pharmacol Sci** 1998 Sep;19(9):348-50. Comment on: Trends Pharmacol Sci 1997 Jun;18(6):204-11.

THERAPEUTIC USE

Halothane minimum alveolar anesthetic concentration and neuronal nitric oxide synthase activity of the dorsal horn and the locus ceruleus in rats. Fukuda T, et al. **Anesth Analg** 1999 Oct;89(4):1035-9

7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum. Royland JE, et al. **Brain Res** 1999 Aug 21; 839(1):41-8

Phase II study of CI-958 in colorectal cancer. Shields AF, et al. **Cancer Chemother Pharmacol** 1999;43(2):162-4

DY-9760e, a novel calmodulin antagonist, reduces brain damage induced by transient focal cerebral ischemia. Sato T, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):117-23

Neuronal nitric oxide synthase inhibitor, 7-nitroindazole, delays motor dysfunction and spinal motoneuron degeneration in the wobbler mouse. Ikeda K, et al. **J Neurol Sci** 1998 Sep 18;160(1):9-15

Effects of L-NAME and 7-NI on NOS catalytic activity and behavioral outcome after traumatic brain injury in the rat. Wada K, et al. **J Neurotrauma** 1999 Mar;16(3):203-12

The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force. De Marinis F, et al. **Tumori** 1999 May-Jun;85(3):177-82

TOXICITY

Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. Orlandi L, et al. **Int J Cancer** 1998 Oct 29; 78(3):377-84

INDENES

ANALYSIS

[Gas chromatographic determination of dicyclopentadiene in the work area air] Shumilov NV, et al. **Gig Sanit** 1998 Sep-Oct;(5):77 **(Rus)**

CHEMICAL SYNTHESIS

Stereochemical studies of the isomerization of novel 2-alkyl-9-phenyl-2,3,4,4a- and 2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridines. Upton C, et al. **J Pharm Pharmacol** 1998 Aug;50(8):829-35

CHEMISTRY

Stereochemical studies of the isomerization of novel 2-alkyl-9-phenyl-2,3,4,4a- and 2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridines. Upton C, et al. **J Pharm Pharmacol** 1998 Aug;50(8):829-35

METABOLISM

Development of a bioconversion process for production of cis-1S,2R-indandiol from indene by recombinant Escherichia coli constructs. Reddy J, et al. **Appl Microbiol Biotechnol** 1999 May;51(5):614-20

Isolation and characterization of indene bioconversion genes from Rhodococcus strain I24. Treadway SL, et al. **Appl Microbiol Biotechnol** 1999 Jun;51(6):786-93

Biodegradation of dicyclopentadiene in the field. Stehmeier LG, et al. **Biodegradation** 1999 Apr;10(2):135-48

Characterization of CorR, a transcriptional activator which is required for biosynthesis of the phytotoxin coronatine. Peñaloza-Vázquez A, et al. **J Bacteriol** 1998 Dec; 180(23):6252-9

The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. Reggio PH, et al. **J Med Chem** 1998 Dec 17;41(26):5177-87

Biosynthesis of the Pseudomonas polyketide coronafacic acid requires monofunctional and multifunctional polyketide synthase proteins. Rangaswamy V, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15469-74

PHARMACOLOGY

Antioxidative activity of indenestrol A, a diethylstilbestrol metabolite. Oda T, et al. **Biol Pharm Bull** 1999 Jun; 22(6):586-9

Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells. Sunami T, et al. **Cancer Chemother Pharmacol** 1999;43(5):394-401

Cannabimimetic indoles, pyrroles and indenes. Huffman JW. **Curr Med Chem** 1999 Aug;6(8):705-20 (49 ref.)

A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells. Ohyama T, et al. **Jpn J Cancer Res** 1999 Jun;90(6):691-8

THERAPEUTIC USE

In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Aoyagi Y, et al. **Jpn J Cancer Res** 1999 May;90(5):578-87

INDEPENDENT LIVING see **ACTIVITIES OF DAILY LIVING**

INDEPENDENT PRACTICE ASSOCIATIONS

Independent practitioner associations in New Zealand. Falcon H. **Br Dent J** 1998 Sep 12;185(5):208

ECONOMICS

Determining the most economical SSRI for a Medicare risk contract. Valdez C, et al. **Am J Health Syst Pharm** 1999 Jan 1;56(1):23-4

Blended payment methods in physician organizations under managed care. Robinson JC. **JAMA** 1999 Oct 6; 282(13):1258-63

LEGISLATION & JURISPRUDENCE

Antitrust hammer. Ortolon K. **Tex Med** 1999 Feb;95(2):48-50

ORGANIZATION & ADMINISTRATION

United Health Care of North Carolina. Casey M, et al. **J Rural Health** 1998 Summer;14(3):200-10

An evaluation of pharmaceutical management and budget holding in Pegasus Medical Group. Malcolm L, et al. **N Z Med J** 1999 May 14;112(1087):162-4

STANDARDS

Using a quality scorecard to measure and improve medical groups' performance. Belman MJ, et al. **Jt Comm J Qual Improv** 1999 May;25(5):239-51

Integrating clinical performance improvement across physician organizations: the PhyCor experience. Loeppke R, et al. **Jt Comm J Qual Improv** 1999 Feb;25(2):55-67

UTILIZATION

Variations in primary care physician referral rates. Franks P, et al. **Health Serv Res** 1999 Apr;34(1 Pt 2):323-9

A case study of point-of-service medical use in a managed care plan. Wong HS, et al. **Med Care Res Rev** 1999;56 Suppl 2:85-110

INDEX MEDICUS see **MEDLARS**

INDEXES see **ABSTRACTING AND INDEXING**

INDEXING see **ABSTRACTING AND INDEXING**

INDIAN CORN see **CORN**

INDIAN HEALTH SERVICE (U.S.) see **UNITED STATES INDIAN HEALTH SERVICE**

INDIANS, CENTRAL AMERICAN

Eight thousand years of economic and political history in Latin America revealed by anthropometry. Bogin B, et al. **Ann Hum Biol** 1999 Jul-Aug;26(4):333-51

Risk factors for human T cell lymphotropic virus type II infection among the Guaymi Indians of Panama. Maloney EM, et al. **J Infect Dis** 1999 Sep;180(3):876-9

The JC and BK human polyoma viruses appear to be recent introductions to some South American Indian tribes: there is no serological evidence of cross-reactivity with the simian polyoma virus SV40. Major EO, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15525-30

GENETICS

Genetically unknown foods or thrifty genes? [letter] Baschetti R. **Am J Clin Nutr** 1999 Sep;70(3):420-1

Divergent human Y-chromosome microsatellite evolution rates. Carvalho-Silva DR, et al. **J Mol Evol** 1999 Aug; 49(2):204-14

Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Jorge LF, et al. **Pharmacogenetics** 1999 Apr; 9(2):217-28

HISTORY

Epilepsy and its treatment in the ancient cultures of America. Elferink JG. **Epilepsia** 1999 Jul;40(7):1041-6

PSYCHOLOGY

Cultural variation in management of attention by children and their caregivers. Chavajay P, et al. **Dev Psychol** 1999 Jul;35(4):1079-90

INDIANS, NORTH AMERICAN

see related

UNITED STATES INDIAN HEALTH SERVICE

Factors associated with marijuana use among American Indian adolescents. Novins DK, et al. **Addiction** 1998 Nov; 93(11):1693-702

HIV/AIDS risks among Native American drug users: key findings from focus group interviews and implications for intervention strategies. Baldwin JA, et al. **AIDS Educ Prev** 1999 Aug;11(4):279-92

Native American medicine [published erratum appears in Altern Ther Health Med 1999 Jan;5(1):22] Cohen K. **Altern Ther Health Med** 1998 Nov;4(6):45-57 (97 ref.)

Native American medicine in the treatment of chronic illness: developing an integrated program and evaluating its effectiveness. Mehl-Madrona LE. **Altern Ther Health Med** 1999 Jan;5(1):36-44

Boarding and public schools: Navajo educational attainment, conduct disorder, and alcohol dependency. Henderson E, et al. **Am Indian Alsk Native Ment Health Res** 1998; 8(2):24-45

Presenting characteristics, treatment patterns, and clinical outcomes of non-black minorities in the National Registry of Myocardial Infarction 2. Canto JG, et al. **Am J Cardiol** 1998 Nov 1;82(9):1013-8

Prevention of obesity in American Indian children: the Pathways study. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):745S-824S

Variation by body mass index and age in waist-to-hip ratio associations with glycemic status in an aboriginal population at risk for type 2 diabetes in British Columbia, Canada. Daniel M, et al. **Am J Clin Nutr** 1999 Mar; 69(3):455-60

Practicing participatory research in American Indian communities. Davis SM, et al. **Am J Clin Nutr** 1999 Apr; 69(4 Suppl):755S-759S (37 ref.)

Pathways: a culturally appropriate obesity-prevention program for American Indian schoolchildren. Davis SM, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):796S-802S

Process evaluation in a multisite, primary obesity-prevention trial in American Indian schoolchildren. Helitzer DL, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):816S-824S

The epidemic of obesity in American Indian communities and the need for childhood obesity-prevention programs. Story M, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):747S-754S (78 ref.)

Pathways family intervention for third-grade American Indian children. Teufel NI, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):803S-809S

Portion-size estimation training in second- and third-grade American Indian children. Weber JL, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):782S-787S

Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Gray RS, et al. **Am J Epidemiol** 1998 Nov 1;148(9):869-78

Birth weight and renal disease in Pima Indians with type 2 diabetes mellitus. Nelson RG, et al. **Am J Epidemiol** 1998 Oct 1;148(7):650-6

Genealogy reconstruction from short tandem repeat genotypes in an Amazonian population. Calafell F, et al. **Am J Phys Anthropol** 1998 Feb;108(2):137-46

Os intermetatarseum: a heritable accessory bone of the human foot. Case DT, et al. **Am J Phys Anthropol** 1998 Oct; 107(2):199-209

Body size and physique among Canadians of First Nation and European ancestry. Katzmarzyk PT, et al. **Am J Phys Anthropol** 1999 Feb;108(2):161-72

Collateral relatives of American Indians among the Bronze Age populations of Siberia? Kozintsev AG, et al. **Am J Phys Anthropol** 1999 Feb;108(2):193-204

Hardships of contact: enamel hypoplasias in Tupí-Mondé Amerindians from the Brazilian Amazonia. Santos RV, et al. **Am J Phys Anthropol** 1999 May;109(1):111-27

Plasma phospholipid fatty acids in the central Canadian arctic: biocultural explanations for ethnic differences. Young TK, et al. **Am J Phys Anthropol** 1999 May; 109(1):9-18

Insulin receptor autophosphorylation in cultured myoblasts correlates to glucose disposal in Pima Indians. Youngren JF, et al. **Am J Physiol** 1999 May;276(5 Pt 1):E990-4

Seroepidemiology of California and Bunyamwera serogroup (Bunyaviridae) virus infections in native populations of Alaska. Walters LL, et al. **Am J Trop Med Hyg** 1999 May; 60(5):806-21

A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children. Wolff MC, et al. **Am J Trop Med Hyg** 1999 Feb;60(2):263-6

Cancer prevention among urban southwestern American Indian women: comparison to selected Year 2000 national health objectives. Risendal B, et al. **Ann Epidemiol** 1999 Aug;9(6):383-90

Validation of an electronic, population-based prescription database. Kozyrskyj AL, et al. **Ann Pharmacother** 1998 Nov;32(11):1152-7

Connecting and becoming culturally competent: a Lakota example. Kavanagh K, et al. **ANS Adv Nurs Sci** 1999 Mar;

21(3):9–31
Navajo use of native healers. Kim C, et al. **Arch Intern Med** 1998 Nov 9;158(20):2245–9
Oklahoma Choctaw and systemic sclerosis: the founder effect and genetic susceptibility [editorial] Harley JB, et al. **Arthritis Rheum** 1998 Oct;41(10):1725–8
Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Tan FK, et al. **Arthritis Rheum** 1998 Oct;41(10):1729–37
Dental experiences and parenting practices of Native American mothers and caretakers: what we can learn for the prevention of baby bottle tooth decay. Weinstein P, et al. **ASDC J Dent Child** 1999 Mar–Apr;66(2):120–6, 85
Native American health care services—a dream job. Smith G. **ASHA** 1999 Mar–Apr;41(2):24–7
Pap screening clinics with native women in Skidegate, Haida Gwaii. Need for innovation. Calam B, et al. **Can Fam Physician** 1999 Feb;45:355–60
Comprehensive computerized diabetes registry. Serving the Cree of Eeyou Istchee (eastern James Bay). Dannenbaum D, et al. **Can Fam Physician** 1999 Feb;45:364–70
The three-tier system [editorial] Deagle G. **Can Fam Physician** 1999 Feb;45:247–9, 255–7 **(Eng, Fre)**
Cancer mortality among Native Americans [editorial; comment] Burhansstipanov L. **Cancer** 1998 Dec 1; 83(11):2247–50 (17 ref.). Comment on: Cancer 1998 Dec 1;83(11):2377–83.
Patterns of cancer mortality among Native Americans [see comments] Cobb N, et al. **Cancer** 1998 Dec 1; 83(11):2377–83. Comment in: Cancer 1998 Dec 1;83(11):2247–50.
Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Newkirk MM, et al. **Cell Mol Biol (Noisy-le-grand)** 1998 Nov;44(7):1129–38
Alcohol dependence and domestic violence as sequelae of abuse and conduct disorder in childhood. Kunitz SJ, et al. **Child Abuse Negl** 1998 Nov;22(11):1079–91
Developing mental health services for Native American children. Barlow A, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Jul;7(3):555–77, ix (45 ref.)
Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Howard BV, et al. **Circulation** 1999 May 11;99(18):2389–95
Effect of hypertension on mortality in Pima Indians. Sievers ML, et al. **Circulation** 1999 Jul 6;100(1):33–40
The public health epidemiology of type 2 diabetes in children and adolescents: a case study of American Indian adolescents in the Southwestern United States. Fagot-Campagna A, et al. **Clin Chim Acta** 1999 Aug; 286(1–2):81–95 (51 ref.)
Traditional Native American medicine in dermatology. Weigand DA. **Clin Dermatol** 1999 Jan–Feb;17(1):49–51
Prevalence of gestational diabetes mellitus among Swampy Cree women in Moose Factory, James Bay [see comments] Godwin M, et al. **CMAJ** 1999 May 4;160(9):1299–302. Comment in: CMAJ 1999 May 4;160(9):1315–6.
Ironies most bittersweet [editorial; comment] Hall PF. **CMAJ** 1999 May 4;160(9):1315–6. Comment on: CMAJ 1999 May 4;160(9):1293–7. Comment on: CMAJ 1999 May 4;160(9):1299–1302.
Prevalence of gestational diabetes mellitus among James Bay Cree women in northern Quebec [see comments] Rodrigues S, et al. **CMAJ** 1999 May 4;160(9):1293–7. Comment in: CMAJ 1999 May 4;160(9):1315–6.
Intimate violence in a southwestern American Indian tribal community. Robin RW, et al. **Cult Divers Ment Health** 1998;4(4):335–44
Arthritis and HLA-B27 in native North American tribes. Walsh B, et al. **Curr Opin Rheumatol** 1998 Jul;10(4):319–25 (46 ref.)
Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. Schrauwen P, et al. **Diabetes** 1999 Jan;48(1):146–9
Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Dabelea D, et al. **Diabetes Care** 1999 Jun;22(6):944–50
HDL cholesterol subfractions and risk of developing type 2 diabetes among Pima Indians. Fagot-Campagna A, et al. **Diabetes Care** 1999 Feb;22(2):271–4
Plasma leptin concentrations in Pima Indians living in drastically different environments. Fox C, et al. **Diabetes Care** 1999 Mar;22(3):413–7
Prevalence and correlates of the insulin resistance syndrome among Native Americans. The Inter-Tribal Heart Project. Greenlund KJ, et al. **Diabetes Care** 1999 Mar;22(3):441–7
Hepatocyte nuclear factor-1 alpha G319S. A private mutation in Oji-Cree associated with type 2 diabetes [letter] Hegele RA, et al. **Diabetes Care** 1999 Mar;22(3):524
Long-term effects of the intrauterine environment, birth weight, and breast-feeding in Pima Indians. Pettitt DJ, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B138–41
Increasing prevalence of Type II diabetes in American Indian children. Dabelea D, et al. **Diabetologia** 1998 Aug; 41(8):904–10
Visceral adipose tissue is not increased in Pima Indians compared with equally obese Caucasians and is not related to insulin action or secretion. Gautier JF, et al. **Diabetologia** 1999 Jan;42(1):28–34
Maternal diabetes status does not influence energy expenditure or physical activity in 5-year-old Pima Indian children. Salbe AD, et al. **Diabetologia** 1998 Oct; 41(10):1157–62
Quantitative analysis of rapid pointing movements in Cree subjects exposed to mercury and in subjects with neurological deficits. Beuter A, et al. **Environ Res** 1999 Jan;80(1):50–63
Analysis of rapid alternating movements in Cree subjects exposed to methylmercury and in subjects with neurological deficits. Beuter A, et al. **Environ Res** 1999 Jan;80(1):64–79
American Indians, hunting and fishing rates, risk, and the Idaho National Engineering and Environmental Laboratory. Burger J. **Environ Res** 1999 May;80(4):317–29
Consumption of freshwater fish in Kahnawake: risks and benefits. Chan HM, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S213–S222
Local fish consumption and serum PCB concentrations among Mohawk men at Akwesasne. Fitzgerald EF, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S97–S103
Assessing environmental exposure to PCBs among Mohawks at Akwesasne through the use of geostatistical methods. Hwang SA, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S189–S199
Health-related quality of life for rural American Indians in New Mexico. Gilliland FD, et al. **Ethn Health** 1998 Aug; 3(3):223–9
Sudden infant death syndrome and Canadian Aboriginals: bacteria and infections. Wilson CE. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):221–6
The collaboration process in HIV prevention and evaluation in an urban American Indian clinic for women. Klein D, et al. **Health Educ Behav** 1999 Apr;26(2):239–49
Diabetes research in an American Indian community. Jacobson SF, et al. **Image J Nurs Sch** 1998;30(2):161–5
Motor vehicle related injuries among American Indian and Alaskan Native youth, 1981–92: analysis of a national hospital discharge database. Quinlan KP, et al. **Inj Prev** 1998 Dec;4(4):276–9
Decreased beta2 adrenergic mediated venodilatation in Native Americans. Vajo Z, et al. **Int Angiol** 1998 Dec; 17(4):276–81
The illness known as "twisted mouth" among the Nêhinaw (Cree). Bruyere J, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:67–71
Developing a Code of Research Ethics for research with a Native community in Canada: a report from the Kahnawake Schools Diabetes Prevention Project. Macaulay AC, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:38–40
Chronic lymphocytic leukemia is infrequent in Mexican mestizos. Ruiz-Argüelles GJ, et al. **Int J Hematol** 1999 Jun;69(4):253–5
Obesity and relative subcutaneous fat distribution among Canadians of First Nation and European ancestry. Katzmarzyk PT, et al. **Int J Obes Relat Metab Disord** 1998 Nov;22(11):1127–31
Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia. Heal G, et al. **Int J Tuberc Lung Dis** 1998 Dec;2(12):979–83
Visual acuity screening versus noncycloplegic autorefraction screening for astigmatism in Native American preschool children. Miller JM, et al. **J Aapos** 1999 Jun;3(3):160–5
Dietary intake and body mass index of adults in 2 Ojibwe communities. deGonzague B, et al. **J Am Diet Assoc** 1999 Jun;99(6):710–6
Diet and physical activity patterns of Lakota Indian adults. Harnack L, et al. **J Am Diet Assoc** 1999 Jul;99(7):829–35
Anthropometric characteristics of Mohawk children aged 6 to 11 years: a population perspective. Potvin L, et al. **J Am Diet Assoc** 1999 Aug;99(8):955–61
The effect of aging on bone mineral metabolism and bone mass in Native American women. Perry HM 3rd, et al. **J Am Geriatr Soc** 1998 Nov;46(11):1418–22
Respiratory quotient is inversely associated with muscle sympathetic nerve activity. Snitker S, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):3977–9
In situ lipolytic responses to isoproterenol and physiological stressors are similar in obese Pima Indians and Caucasians [published erratum appears in J Clin Endocrinol Metab 1999 Jan;84(1):322] Snitker S, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4054–8
Improved access to women's health services for Alaska natives through community health aide training. Sox CH, et al. **J Community Health** 1999 Aug;24(4):313–23
Beyond the biopsychosocial model: new approaches to doctor-patient interactions [see comments] Bartz R. **J Fam Pract** 1999 Aug;48(8):601–7. Comment in: J Fam Pract 1999 Aug;48(8):585–7.
Implementing breast and cervical cancer prevention programs among the Houma Indians of southern Louisiana: cultural and ethical considerations. Coughlin SS. **J Health Care Poor Underserved** 1998 Feb;9(1):30–41 (44 ref.)
The protective effectiveness of natural rotavirus infection in an American Indian population. Moulton LH, et al. **J Infect Dis** 1998 Dec;178(6):1562–6
Dr. Kelly West and a brief history of the diabetes epidemic of American Indians [letter] McCampbell A. **J Okla State Med Assoc** 1999 Aug;92(8):444
Juvenile delinquency in American Indian youths: historical and cultural factors. Pfefferbaum B, et al. **J Okla State Med Assoc** 1999 Mar;92(3):121–5
Diabetes mellitus and major depression: considerations for treatment of Native Americans. Warnock JK, et al. **J Okla State Med Assoc** 1998 Dec;91(9):488–93
An examination of ALDH2 genotypes, alcohol metabolism and the flushing response in Native Americans. Gill K, et al. **J Stud Alcohol** 1999 Mar;60(2):149–58
Alcohol dependence and conduct disorder among Navajo Indians. Kunitz SJ, et al. **J Stud Alcohol** 1999 Mar; 60(2):159–67
American Indian heritage and risk factors for renal injury. Kasiske BL, et al. **Kidney Int** 1998 Oct;54(4):1305–10
Screening for type-2 diabetes in aboriginal children in northern Canada [letter] Dean HJ, et al. **Lancet** 1998 Nov 7;352(9139):1523–4
Informed consent for family planning for poor women in Chiapas, Mexico. Kirsch JD, et al. **Lancet** 1999 Jul 31; 354(9176):419–20
Disability and rehabilitation: a context for understanding the American Indian experience. Marshall CA, et al. **Lancet** 1999 Aug 28;354(9180):758–60
Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure? Kiberd BA, et al. **Mayo Clin Proc** 1999 Jun;74(6):559–64
On the rationality of decision-making studies: Part 2: Divergent rationalities. Garro LC. **Med Anthropol Q** 1998 Sep;12(3):341–55
No effect of Trp64Arg beta3-adrenoceptor polymorphism on the plasma leptin concentration in Pima Indians. Snitker S, et al. **Metabolism** 1998 Dec;47(12):1525–7
Hypothalamic-pituitary-adrenal axis and sympathetic nervous system activities in Pima Indians and Caucasians. Tataranni PA, et al. **Metabolism** 1999 Mar;48(3):395–9
Cherokee prescriptions for accupressure and massage. McWhorter JH, et al. **N C Med J** 1998 Nov–Dec;59(6):368
HTLV-II risk factors in Native Americans in Florida. Lowis GW, et al. **Neuroepidemiology** 1999;18(1):37–47
Tremor in Cree subjects exposed to methylmercury: a preliminary study. Beuter A, et al. **Neurotoxicol Teratol** 1998 Nov–Dec;20(6):581–9
Type 2 diabetes among the Pima Indians of Arizona: an epidemic attributable to environmental change? Bennett PH. **Nutr Rev** 1999 May;57(5 Pt 2):S51–4 (15 ref.)
The Pima Indians in Sonora, Mexico. Valencia ME, et al. **Nutr Rev** 1999 May;57(5 Pt 2):S55–7; discussion S57–8 (15 ref.)
Weight-related attitudes and behaviors in fourth grade American Indian children. Stevens J, et al. **Obes Res** 1999 Jan;7(1):34–42
Arrhythmogenic right ventricular dysplasia in an American Indian woman. Galloway JM, et al. **Pacing Clin Electrophysiol** 1999 Jul;22(7):1093–6
Kawasaki syndrome among American Indian and Alaska Native children, 1980 through 1995. Holman RC, et al. **Pediatr Infect Dis J** 1999 May;18(5):451–5
Committee on Native American Child Health and Committee on Infectious Diseases. Immunizations for Native American children. American Academy of Pediatrics. **Pediatrics** 1999 Sep;104(3 Pt 1):564–7
Paleoindian large mammal hunters on the plains of North America. Frison GC. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14576–83
Challenges to Native American health care [see comments] Noren J, et al. **Public Health Rep** 1998 Jan–Feb; 113(1):22–33. Comment in: Public Health 1998 Jan–Feb;113(1):34–5.
Asthma prevalence among American Indian and Alaska Native children. Stout JW, et al. **Public Health Rep** 1999 May–Jun;114(3):257–61
Kennewick man gets his day in the lab [news] Holden C. **Science** 1999 Feb 26;283(5406):1239–40
Rheumatic diseases in North America's indigenous peoples. Peschken CA, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):368–91 (127 ref.)
Relationship of prenatal alcohol use with maternal and prenatal factors in American Indian women. Kvigne VL, et al. **Soc Biol** 1998 Fall-Winter;45(3–4):214–22
Effectiveness of community-directed diabetes prevention and control in a rural Aboriginal population in British Columbia, Canada. Daniel M, et al. **Soc Sci Med** 1999 Mar; 48(6):815–32
Patterns of health seeking behavior during episodes of childhood diarrhea: a study of Tzotzil-speaking Mayans in the highlands of Chiapas, Mexico. Granich R, et al. **Soc Sci Med** 1999 Feb;48(4):489–95
Medicinal plants in Mexico: healers' consensus and cultural importance. Heinrich M, et al. **Soc Sci Med** 1998 Dec; 47(11):1859–71
Indigenous people and the social work profession: defining culturally competent services. Weaver HN. **Soc Work** 1999 May;44(3):217–25
Molecular analysis of HLA class I alleles in the Mexican Seri Indians: implications for their origin. Infante E, et al. **Tissue Antigens** 1999 Jul;54(1):35–42
A combination of traditional wisdom and public health could help. Berger LR. **West J Med** 1999 Jul;171(1):14–5
Type 2 diabetes mellitus in Navajo adolescents. Kim C, et al. **West J Med** 1999 Apr;170(4):210–3
[Glycosilphosphatidylinositol-anchored cell surface protein deficiency in Mexican mestizo patients with aplastic

anemia] Ruiz-Argüelles GJ, et al. **Rev Invest Clin** 1999 Jan-Feb;51(1):5-9 (Eng. Abstr.) **(Spa)**

EDUCATION

Early detection of cervical cancer among Native American women: a qualitative supplement to a quantitative study. Messer L, et al. **Health Educ Behav** 1999 Aug;26(4):547-62

Enhancing Cancer Pain Control among American Indians (ECPCAI): a study of the Ojibwe of Minnesota. Elliott BA, et al. **J Cancer Educ** 1999 Spring;14(1):28-33

GENETICS

ADH and ALDH polymorphisms among Alaska Natives entering treatment for alcoholism. Segal B. **Alaska Med** 1999 Jan-Mar;41(1):9-12, 23

Is a low leptin concentration, a low resting metabolic rate, or both the expression of the "thrifty genotype"? Results from Mexican Pima Indians [see comments] Fox CS, et al. **Am J Clin Nutr** 1998 Nov;68(5):1053-7. Comment in: Am J Clin Nutr 1998 Nov;68(5):991-2.

Genetic and environmental contributions to obesity [editorial; comment] Hill JO. **Am J Clin Nutr** 1998 Nov;68(5):991-2 . Comment on: Am J Clin Nutr 1998 Nov;68(5):1053-7.

Characterization of ancestral and derived Y-chromosome haplotypes of New World native populations. Bianchi NO, et al. **Am J Hum Genet** 1998 Dec;63(6):1862-71

mtDNA haplogroup X: An ancient link between Europe/Western Asia and North America? Brown MD, et al. **Am J Hum Genet** 1998 Dec;63(6):1852-61

An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Hanson RL, et al. **Am J Hum Genet** 1998 Oct;63(4):1130-8

Ancestral Asian source(s) of new world Y-chromosome founder haplotypes. Karafet TM, et al.
Am J Hum Genet 1999 Mar;64(3):817-31

The central Siberian origin for native American Y chromosomes. Santos FR, et al. **Am J Hum Genet** 1999 Feb;64(2):619-28

The apolipoprotein E4 allele is not associated with an abnormal lipid profile in a Native American population following its traditional lifestyle. Aguilar CA, et al.
Atherosclerosis 1999 Feb;142(2):409-14

Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population. Weckmann AL, et al.
Clin Exp Rheumatol 1999 Jan-Feb;17(1):91-4

Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Nowak MP, et al.
Clin Pharmacol Ther 1998 Oct;64(4):378-83

Thrifty gene and hunting as a way of life are evident in a Paleoindian burial [letter] Wendorf M. **Diabetes Care** 1999 Jan;22(1):176

Molecular scanning of the beta-3-adrenergic receptor gene in Pima Indians and Caucasians. Silver K, et al.
Diabetes Metab Res Rev 1999 May-Jun;15(3):175-80

Genetic polymorphism of CYP2D6 in North Indian subjects. Lamba V, et al. **Eur J Clin Pharmacol** 1998 Nov-Dec; 54(9-10):787-91

Heterogeneity of HLA-DR2 haplotypes in Caucasoid Americans, African Americans, Chinese Americans, Native Americans and Xiamen Chinese. Lee A, et al.
Eur J Immunogenet 1999 Aug;26(4):275-80

G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. Hegele RA, et al.
Hypertension 1998 Oct;32(4):688-92

Absence of genetic variation in some obesity candidate genes (GLP1R, ASIP, MC4R, MC5R) among Pima indians. Norman RA, et al. **Int J Obes Relat Metab Disord** 1999 Feb;23(2):163-5

The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. Hegele RA, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):1077-82

Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. Hegele RA, et al. **J Hum Genet** 1999;44(1):10-4

Divergent human Y-chromosome microsatellite evolution rates. Carvalho-Silva DR, et al. **J Mol Evol** 1999 Aug; 49(2):204-14

A cluster of microvillous inclusion disease in the Navajo population. Pohl JF, et al. **J Pediatr** 1999 Jan;134(1):103-6

HLA associations of seropositive rheumatoid arthritis in a Cree and Ojibway population. Oen K, et al.
J Rheumatol 1998 Dec;25(12):2319-23

Ages of mutations on a coalescent tree. Thomson R.
Math Biosci 1998 Oct;153(1):41-61

Genome-wide scan for CAG/CTG repeat expansions in Pimas with early onset of type 2 diabetes mellitus. Wolford JK, et al. **Mol Genet Metab** 1999 Jan;66(1):62-7

Lessons from genetic studies in native Canadian populations. Hegele RA. **Nutr Rev** 1999 May;57(5 Pt 2):S43-9; discussion S49-50 (36 ref.)

Anthropologists probe bones, stones and molecules [news] Culotta E. **Science** 1999 May 14;284(5417):1109,1111

Y chromosomes point to Native American Adam [news] [see comments] Hutardo de Mendoza D, et al. **Science** 1999 Mar 5;283(5407):1439-40. Comment in: Science 1999 Mar 26;283(5410):2017.

Origin of the Amerindians [letter; comment] Pena SD.
Science 1999 Mar 26;283(5410):2017. Comment on: Science 1999 Mar 5;283(5407):1439-40.

HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tan FK, et al.
Tissue Antigens 1999 Jan;53(1):74-80

HISTORY

Were hantaviruses eventually responsible for the lost Anasazi culture? [letter] Chastel C. **Acta Virol** 1998 Nov;42(5):353

Photosensitivity of the American Indian: terminology and historical aspects [letter; comment] Johnson JA, et al.
J Am Acad Dermatol 1998 Oct;39(4 Pt 1):662-4. Comment on: J Am Acad Dermatol 1997 Mar;36(3 Pt 1):504-5.

Do Olmec figurines resemble children with specific dysmorphology syndromes? Pueschel SM.
J Hist Med Allied Sci 1998 Oct;53(4):407-15

Dr. Kelly West and a brief history of the diabetes epidemic of American Indians. Green R.
J Okla State Med Assoc 1999 Jun;92(6):278-84

Medical practices in prehistoric New England. Robinson CT.
Med Health R I 1998 Oct;81(10):315-7

Analysis of ancient DNA from a prehistoric Amerindian cemetery. Stone AC, et al.
Philos Trans R Soc Lond B Biol Sci 1999 Jan 29; 354(1379):153-9

LEGISLATION & JURISPRUDENCE

Initiation of formal death investigation procedures among the Northern Plains Indians: a necessary adjunct in the study of American Indian sudden infant deaths. Randall B, et al. **Am J Forensic Med Pathol** 1999 Mar;20(1):22-6

Who decides the law of the land? Schmidt CC.
Environ Health Perspect 1998 Feb;106(2):A70-2

PSYCHOLOGY

The American Indian Holocaust: healing historical unresolved grief. Brave Heart MY, et al.
Am Indian Alsk Native Ment Health Res 1998;8(2):56-78 (90 ref.)

Teacher, parent, and youth report of problem behaviors among rural American Indian and Caucasian adolescents. Fisher PA, et al.
Am Indian Alsk Native Ment Health Res 1998;8(2):1-23

Factors influencing the pursuit of educational opportunities in American Indian students. Fore CL, et al.
Am Indian Alsk Native Ment Health Res 1998;8(2):46-55

Spatial but not object memory impairments in children with fetal alcohol syndrome. Uecker A, et al.
Am J Ment Retard 1998 Jul;103(1):12-8

Mental health and the academic performance of first nations and majority-culture children. Beiser M, et al.
Am J Orthopsychiatry 1998 Jul;68(3):455-67

Demographics of sexual orientation among American-Indian adolescents. Saewyc EM, et al. **Am J Orthopsychiatry** 1998 Oct;68(4):590-600

Family dysfunction and Native American women who do not seek prenatal care. Tyson H, et al. **Arch Fam Med** 1999 Mar-Apr;8(2):111-7

Electroencephalographic responses to alcohol challenge in Native American Mission Indians. Ehlers CL, et al.
Biol Psychiatry 1999 Mar 15;45(6):776-87

Slipping through sky holes: Yurok body imagery in northern California. Ferreira MK. **Cult Med Psychiatry** 1998 Jun; 22(2):171-202

Narrativity and the representation of experience in American Indian discourses about drinking. Spicer P.
Cult Med Psychiatry 1998 Jun;22(2):139-69

Knowledge, attitudes and behaviors related to physical activity among Native Americans with diabetes. Stolarczyk LM, et al. **Ethn Dis** 1999 Winter;9(1):59-69

Do patients' ethnic and social factors influence the use of do-not-resuscitate orders? Thompson BL, et al.
Ethn Dis 1999 Winter;9(1):132-9

Genetic screening of targeted subpopulations: the role of communal discourse in evaluating sociocultural implications. Foster MW, et al. **Genet Test** 1997-98; 1(4):269-74

Elder abuse: two Native American views. Hudson MF, et al. **Gerontologist** 1998 Oct;38(5):538-48

Correlates of physical and emotional health among Native American adolescents. Cummins JR, et al.
J Adolesc Health 1999 Jan;24(1):38-44

Utilization of alcohol, drug, and mental health treatment services among American Indian adolescent detainees. Novins DK, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Sep;38(9):1102-8

Pro-drinking messages and message environments for young adults: the case of alcohol industry advertising in African American, Latino, and Native American communities. Alaniz ML, et al. **J Public Health Policy** 1998;19(4):447-72

Addressing trauma in substance abuse treatment with American Indian adolescents. Gray N.
J Subst Abuse Treat 1998 Sep-Oct;15(5):393-9 (42 ref.)

Native American suicide rates, acculturation stress and traditional integration. Lester D. **Psychol Rep** 1999 Apr; 84(2):398

Conducting focus groups cross-culturally: experiences with Pacific northwest Indian people. Strickland CJ.
Public Health Nurs 1999 Jun;16(3):190-7

Risk factors for conduct disorder among Navajo Indian men and women. Kunitz SJ, et al.
Soc Psychiatry Psychiatr Epidemiol 1999 Apr;34(4):180-9

Traditional and western healing practices for alcoholism in American Indians and Alaska Natives. Abbott PJ.
Subst Use Misuse 1998 Nov;33(13):2605-46 (95 ref.)

Readiness for drug use prevention in rural minority communities. Plested B, et al. **Subst Use Misuse** 1999 Mar-Apr;34(4-5):521-44

Non-ceremonial tobacco use among southwestern rural American Indians: the New Mexico American Indian Behavioural Risk Factor Survey. Gilliland FD, et al.
Tob Control 1998 Summer;7(2):156-60

Use of hammocks in a rural hospital [letter] Campos-Navarro R. **World Health Forum** 1998;19(4):431-3

STATISTICS & NUMERICAL DATA

Design and statistical analysis for the Pathways study. Davis CE, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):760S-763S

Multisite formative assessment for the Pathways study to prevent obesity in American Indian schoolchildren. Gittelsohn J, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):767S-772S

Physical activity assessment in American Indian schoolchildren in the Pathways study. Going SB, et al.
Am J Clin Nutr 1999 Apr;69(4 Suppl):788S-795S

Body composition assessment in American Indian children. Lohman TG, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):764S-766S

Development of a questionnaire to assess knowledge, attitudes, and behaviors in American Indian children. Stevens J, et al. **Am J Clin Nutr** 1999 Apr;69(4 Suppl):773S-781S

Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. Fabsitz RR, et al. **Am J Epidemiol** 1999 Feb 15;149(4):330-8

Validation of a self-administered questionnaire to screen for prenatal alcohol use in Northern Plains Indian women. Bull LB, et al. **Am J Prev Med** 1999 Apr;16(3):240-3

Hospitalization for motor vehicle injuries among American Indians and Alaska Natives in Washington. Sullivan M, et al. **Am J Prev Med** 1999 Jul;17(1):38-42

Prevalence of adult domestic violence among women seeking routine care in a Native American health care facility. Fairchild DG, et al. **Am J Public Health** 1998 Oct; 88(10):1515-7

Alcohol and fatal crashes among American Indians [letter; comment] Robertson LS. **Am J Public Health** 1999 Aug; 89(8):1270-1. Comment on: Am J Public Health 1997 Feb;87(2):282-5.

Trends in body weight among American Indians: findings from a telephone survey, 1985 through 1996. Will JC, et al. **Am J Public Health** 1999 Mar;89(3):395-8

Oral and genital ulceration: a unique presentation of immunodeficiency in Athabascan-speaking American Indian children with severe combined immunodeficiency. Kwong PC, et al. **Arch Dermatol** 1999 Aug;135(8):927-31

Suicide attempts among American Indian and Alaska Native youth: risk and protective factors. Borowsky IW, et al.
Arch Pediatr Adolesc Med 1999 Jun;153(6):573-80

At risk in two worlds: injury mortality among indigenous people in the US and Australia, 1990-92. Stevenson MR, et al. **Aust N Z J Public Health** 1998 Oct;22(6):641-4

Disease patterns among Canadian aboriginal children. Study in a remote rural setting. Harris SB, et al.
Can Fam Physician 1998 Sep;44:1869-77

Prevalence of low and high birthweight among the James Bay Cree of northern Quebec. Armstrong IE, et al.
Can J Public Health 1998 Nov-Dec;89(6):419-20

Sexual partnering and risk of HIV/STD among Aboriginals. Calzavara LM, et al. **Can J Public Health** 1999 May-Jun; 90(3):186-91

Trends in incidence and treatment for ductal carcinoma in situ in Hispanic, American Indian, and non-Hispanic white women in New Mexico, 1973-1994. Adams-Cameron M, et al. **Cancer** 1999 Mar 1;85(5):1084-90

Suicide in the Northwest Territories: A descriptive review. Isaacs S, et al. **Chronic Dis Can** 1998;19(4):152-6

Untreated acetabular dysplasia of the hip in the Navajo. A 34 year case series followup. Schwend RM, et al.
Clin Orthop 1999 Jul;(364):108-16

Racial inequality in active life among adult Americans. Hayward MD, et al. **Demography** 1999 Feb;36(1):77-91

Effect of glycemia on mortality in Pima Indians with type 2 diabetes. Sievers ML, et al. **Diabetes** 1999 Apr; 48(4):896-902

Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Howard BV, et al. **Diabetes Care** 1998 Aug;21(8):1258-65

Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: the Strong Heart Study. Fagot-Campagna A, et al. **Diabetologia** 1998 Sep; 41(9):1002-9

Seroprevalence of Helicobacter pylori, incidence of gastric cancer, and peptic ulcer-associated hospitalizations in a Canadian Indian population. Bernstein CN, et al.
Dig Dis Sci 1999 Apr;44(4):668-74

Diabetes and obesity in the Louisiana Coushatta Indians. Gordon DL, et al. **Ethn Dis** 1999 Winter;9(1):48-58

Injury hospitalizations among American Indian youth in Washington. Johnson SJ, et al. **Inj Prev** 1999 Jun; 5(2):119-23

The potential for Ontario region's health information system to facilitate case management, program planning, and evaluation and to promote enhanced First Nations' control

INDIANS, NORTH AMERICAN

of health services. Johnson RJ.
Int J Circumpolar Health 1998;57 Suppl 1:671–4
HIV and hepatitis B surveillance in First Nations alcohol and drug treatment centers in British Columbia, Canada. Martin JD, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:280–4
Diabetes mellitus in the First Nations population of British Columbia, Canada. Martin JD, et al.
Int J Circumpolar Health 1998;57 Suppl 1:335–9
The Sioux Lookout Diabetes Program: diabetes prevention and management in northwestern Ontario. Morrison N, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:364–9
Cocaine smokers and injection drug users in Alaska: what distinguishes Native Americans from non-Native Americans? Paschane DM, et al.
Int J Circumpolar Health 1998;57 Suppl 1:474–81
Cancer trends from 1972–1991 for Registered Indians living on Manitoba Reserves. Rosenberg T, et al.
Int J Circumpolar Health 1998;57 Suppl 1:391–8
Colorectal cancer incidence and survival among Alaska Natives, 1969–1993. Brown MO, et al. **Int J Epidemiol** 1998 Jun;27(3):388–96
Prevalence of overweight and obesity in American Indian School children and adolescents in the Aberdeen area: a population study. Zephier E, et al.
Int J Obes Relat Metab Disord 1999 Mar;23 Suppl 2:S28–30
Alaska native suicide: lessons for elder suicide. Kettl P.
Int Psychogeriatr 1998 Jun;10(2):205–11
Sexual orientation, sexual behaviors, and pregnancy among American Indian adolescents. Saewyc EM, et al.
J Adolesc Health 1998 Oct;23(4):238–47
Marijuana use among American Indian adolescents: a growth curve analysis from ages 14 through 20 years. Mitchell CM, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Jan; 38(1):72–8
The health status of American Indians and Alaska Natives: 2. Lessons for cancer educators. Mahoney MC, et al.
J Cancer Educ 1999 Spring;14(1):23–7 (34 ref.)
Epidemiology of tobacco use among Lumbee Indians in North Carolina. Spangler JG, et al. **J Cancer Educ** 1999 Spring;14(1):34–40
From the Centers for Disease Control and Prevention. Decrease in infant mortality and sudden infant death syndrome among Northwest American Indians and Alaskan Natives--Pacific Northwest, 1985–1996. **JAMA** 1999 Apr 21;281(15):1369–70
An epidemic of proteinuria in Pima Indians with type 2 diabetes mellitus. Nelson RG, et al. **Kidney Int** 1998 Dec; 54(6):2081–8
Reducing indigenous mortality in Australia: lessons from other countries [see comments] Ring IT, et al.
Med J Aust 1998 Nov 16;169(10):528–9, 532–3. Comment in: Med J Aust 1999 Feb 15;170(4):190–1.
Prevalence of diagnosed diabetes among American Indians/Alaskan Natives--United States, 1996.
MMWR Morb Mortal Wkly Rep 1998 Oct 30;47(42):901–4
Decrease in infant mortality and sudden infant death syndrome among Northwest American Indians and Alaskan Natives--Pacific Northwest, 1985–1996.
MMWR Morb Mortal Wkly Rep 1999 Mar 12;48(9):181–4
Trends in diarrhea-associated hospitalizations among American Indian and Alaska native children, 1980–1995. Holman RC, et al. **Pediatrics** 1999 Jan;103(1):E11
Preventive health care among rural American Indians in New Mexico. Gilliland FD, et al. **Prev Med** 1999 Feb; 28(2):194–202

INDIANS, SOUTH AMERICAN

Seroepidemiological and molecular studies of human T cell lymphotropic virus type II, subtype b, in isolated groups of Mataco and Toba Indians of northern Argentina. Biglione M, et al. **AIDS Res Hum Retroviruses** 1999 Mar 20;15(5):407–17
Effect of chemotherapy on malaria transmission among Yanomami Amerindians: simulated consequences of placebo treatment. Freeman J, et al.
Am J Trop Med Hyg 1999 May;60(5):774–80
Differential perpetuation of malaria species among Amazonian Yanomami Amerindians. Laserson KF, et al.
Am J Trop Med Hyg 1999 May;60(5):767–73
Prevalence of antibody to human T cell lymphotropic virus types 1/2 among aboriginal groups inhabiting northern Argentina and the Amazon region of Peru. Medeot S, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):623–9
Eight thousand years of economic and political history in Latin America revealed by anthropometry. Bogin B, et al. **Ann Hum Biol** 1999 Jul–Aug;26(4):333–51
Sleep habits in Native Brazilian Bororo children. Reimão R, et al. **Arq Neuropsiquiatr** 1999 Mar;57(1):14–7
Sleep habits in native Brazilian Terena children in the state of Mato Grosso do Sul, Brazil. Reimão R, et al.
Arq Neuropsiquiatr 1998 Dec;56(4):703–7
Cancer cluster among young Indian adults living near power transmission lines in Bom Jesus do Tocantins, Pará, brazil. Koifman S, et al. **Cad Saude Publica** 1998;14 Suppl 3:161–72
Mastoid emissary in Indian skulls. Piasecki K, et al.
Folia Morphol (Warsz) 1998;57(3):269–74
HTLV-I and HTLV-II coexist among the Embera and Inga Amerindians of Colombia [letter] Arango C, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1999 Jan 1;20(1):102–3
HTLV-I/II antibodies among three different Indian groups from Paraguay [letter] de Cabral MB, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1998 Dec 15;19(5):548–9
Nutritional status and dietary habits of Indian children from Alto Xingu (Central Brazil) according to age. Mattos A, et al. **J Am Coll Nutr** 1999 Feb;18(1):88–94
Effects of a traditional lifestyle on the cardiovascular risk profile: the Amondava population of the Brazilian Amazon. Comparison with matched African, Italian and Polish populations. Pavan L, et al. **J Hypertens** 1999 Jun; 17(6):749–56
A new genotype of TT virus (TTV) infection among Colombian native Indians. Tanaka Y, et al.
J Med Virol 1999 Mar;57(3):264–8
The JC and BK human polyoma viruses appear to be recent introductions to some South American Indian tribes: there is no serological evidence of cross-reactivity with the simian polyoma virus SV40. Major EO, et al.
Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15525–30
Re-evaluation of antibiotic and mercury resistance in Escherichia coli populations isolated in 1978 from Amazonian rubber tree tappers and Indians. Nascimento AM, et al. **Res Microbiol** 1999 Jul–Aug;150(6):407–11
The seroprevalence of hepatitis B and C in an Amerindian population in the southwestern Brazilian Amazon. Ferrari JO, et al. **Rev Soc Bras Med Trop** 1999 May–Jun; 32(3):299–302
A new HLA-Cw*15 allele, Cw*1508, identified in the Peruvian population. Sanz L, et al. **Tissue Antigens** 1999 Apr;53(4 Pt 1):391–3
The complete genomic sequence of an HTLV-II isolate from a Guahibo Indian from Venezuela. Dube S, et al.
Virology 1999 Jan 20;253(2):181–92
[Myths concerning malarial transmission among Amazonian Indians and their relation with 2 types of transmission encountered in the Amazonian forest] Molez JF. **Sante** 1999 May–Jun;9(3):157–62 (Eng. Abstr.) **(Fre)**
[Identifying areas of epidemiological stratification in an onchocerciasis focus in Yanomami territory, Roraima, Brazil] Coelho GE, et al. **Cad Saude Publica** 1998 Jul–Sep; 14(3):607–11 (Eng. Abstr.) **(Por)**
[Intestinal parasitism in a Parakanã indigenous community in southwestern Pará State, Brazil] Miranda RA, et al.
Cad Saude Publica 1998 Jul–Sep;14(3):507–11 (Eng. Abstr.) **(Por)**
[Serum lipids and blood pressure levels in the +Mapuche population living in the Chilean region of Araucania] Stockins B, et al. **Rev Med Chil** 1998 Nov;126(11):1291–9 (Eng. Abstr.) **(Spa)**

GENETICS

mtDNA history of the Cayapa Amerinds of Ecuador: detection of additional founding lineages for the Native American populations. Rickards O, et al.
Am J Hum Genet 1999 Aug;65(2):519–30
Beta-fibrinogen allele frequencies in Peruvian Quechua, a high-altitude native population. Rupert JL, et al.
Am J Phys Anthropol 1999 Jun;109(2):181–6
Protein polymorphism in three South Amerindian populations. Clariá DM, et al. **Ann Hum Biol** 1998 Nov–Dec;25(6):581–8
Angiotensin-converting enzyme (ACE) alleles in the Quechua, a high altitude South American native population. Rupert JL, et al. **Ann Hum Biol** 1999 Jul–Aug; 26(4):375–80
New protein genetic studies in six Amazonian Indian populations. Santos SE, et al. **Ann Hum Biol** 1998 Nov–Dec;25(6):505–22
Diversity in protein, nuclear DNA, and mtDNA in South Amerinds--agreement or discrepancy? Bortolini MC, et al. **Ann Hum Genet** 1998 Mar;62 (Pt 2):133–45
Type 2 diabetes mellitus: association study of five candidate genes in an Indian population of Guadeloupe, genetic contribution of FABP2 polymorphism. Boullu-Sanchis S, et al. **Diabetes Metab** 1999 Jun;25(2):150–6
Acetylator phenotypes: allele frequency in northwestern Argentina and review of acetylator distribution in the Americas. Dipierri JE, et al. **Hum Biol** 1998 Oct; 70(5):959–64
Apolipoprotein B genetic variability in Brazilian Indians. Kaufman L, et al. **Hum Biol** 1999 Feb;71(1):87–98
Surnames and genetic structure of a high-altitude Quechua community from the Ichu River Valley, Peruvian Central Andes, 1825–1914. Pettener D, et al. **Hum Biol** 1998 Oct; 70(5):865–87
Determination of the allele frequencies of three polymorphisms in the promoter region of the human protein C gene in three Brazilian ethnic groups. Mendes CP, et al. **Hum Hered** 1999 Jan;49(1):27–30
Divergent human Y-chromosome microsatellite evolution rates. Carvalho-Silva DR, et al. **J Mol Evol** 1999 Aug; 49(2):204–14
Myasthenia gravis and peripheral neuropathy in an Amazon indigenous female. Dias-Tosta E, et al.
Neuromuscul Disord 1999 Jun;9(4):262–3
Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Jorge LF, et al. **Pharmacogenetics** 1999 Apr; 9(2):217–28
Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Muñoz S, et al. **Pharmacogenetics** 1998 Aug;8(4):343–51
Microsatellites provide evidence for Y chromosome diversity among the founders of the New World. Ruiz-Linares A, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6312–7
Origin of the Amerindians [letter; comment] Pena SD.
Science 1999 Mar 26;283(5410):2017. Comment on: Science 1999 Mar 5;283(5407):1439–40.
Novel HLA-A and HLA-B alleles in South American Indians. Marcos CY, et al. **Tissue Antigens** 1999 May; 53(5):476–85
Characterization of the HLA class I genotypes of a Venezuelan Amerindian group by molecular methods. Martinez-Arends A, et al. **Tissue Antigens** 1998 Jul; 52(1):51–6
A novel HLA allele, HLA-B*5113, identified in the Kolla Amerindians of North-West Argentina. Scott I, et al.
Tissue Antigens 1999 Feb;53(2):194–7
[Coastal Chilean populations: genetic markers in four locations] Harb Z, et al. **Rev Med Chil** 1998 Jul; 126(7):753–60 (Eng. Abstr.) **(Spa)**

HISTORY

[Explained quotations: Azara and Indians' medicine (editorial)] Barcat JA. **Medicina (B Aires)** 1999;59(2):215–7 **(Spa)**

STATISTICS & NUMERICAL DATA

Endemic Trypanosoma cruzi infection in Indian populations of the Gran Chaco territory of South America: performance of diagnostic assays and epidemiological features. Basombrio MA, et al. **Ann Trop Med Parasitol** 1999 Jan;93(1):41–8
Prevalence of Plasmodium vivax variants VK247 and P. vivax-like human malaria: a retrospective study in indigenous Indian populations of the Amazon region of Brazil. de Arruda M, et al.
Trans R Soc Trop Med Hyg 1998 Nov–Dec;92(6):628
[The prevalence of intestinal parasitism in native villages of the Tembé tribe, the Brazilian eastern Amazon] Miranda R dos A, et al. **Rev Soc Bras Med Trop** 1999 Jul–Aug; 32(4):389–93 (Eng. Abstr.) **(Por)**
[Demographic aspects in indigenous communities of 3 regions of Colombia] Piñeros-Petersen M, et al.
Salud Publica Mex 1998 Jul–Aug;40(4):324–9 (Eng. Abstr.) **(Spa)**

INDICAN

PHARMACOLOGY

Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin. Dasgupta A, et al. **Ther Drug Monit** 1998 Dec;20(6):658–62

URINE

Precocious puberty in a patient with indicanuria. Büyükgebiz B, et al. **J Pediatr Endocrinol Metab** 1999 Jul–Aug; 12(4):561–3
Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Niwa T, et al.
Miner Electrolyte Metab 1999 Jan–Apr;25(1–2):118–22

INDICATOR DILUTION TECHNIQUES

Cardiac output and central blood volume during hemodialysis: methodology. Krivitski NM, et al.
Adv Ren Replace Ther 1999 Jul;6(3):225–32
Correcting for vitamin A turnover in isotope-dilution studies [letter; comment] Olson JA. **Am J Clin Nutr** 1999 Mar; 69(3):576–7. Comment on: Am J Clin Nutr 1989 Apr;49(4):713–6. Comment on: Am J Clin Nutr 1997 Jul;66(1):67–74. Comment on: Am J Clin Nutr 1998 Jul;68(1):90–5.
Assessment of total body stores of vitamin A in Guatemalan elderly by the deuterated-retinol-dilution method [see comments] Ribaya-Mercado JD, et al. **Am J Clin Nutr** 1999 Feb;69(2):278–84. Comment in: Am J Clin Nutr 1999 Feb;69(2):177–8.
Respiratory physiology teaching: determination of residual volume by applying the indicator-dilution technique. Heller H, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):S53–6
Accounting for the heterogeneity of capillary transit times in modeling multiple indicator dilution data. Audi SH, et al. **Ann Biomed Eng** 1998 Nov–Dec;26(6):914–30
Estimation of organ transport function for recirculating indicator dilution curves. Sparacino G, et al.
Ann Biomed Eng 1998 Jan–Feb;26(1):128–37
Quantitative determination of 2-methoxy-3-isobutylpyrazine in red wines and grapes of Bordeaux using a stable isotope dilution assay. Kotseridis Y, et al. **J Chromatogr A** 1999 May 14;841(2):229–37
Design and analysis of serial limiting dilution assays with small sample sizes. Macken C. **J Immunol Methods** 1999 Jan 1;222(1–2):13–29
The 15N amino acid dilution method allows the determination of the real digestibility and of the ileal endogenous losses of the respective amino acid in pigs. Hess V, et al. **J Nutr** 1998 Nov;128(11):1969–77
Extracellular water: sodium bromide dilution estimates

compared with other markers in patients with acquired immunodeficiency syndrome. Kim J, et al. **JPEN J Parenter Enteral Nutr** 1999 Mar-Apr;23(2):61-6

Detecting oxidative modification of biomolecules with isotope dilution mass spectrometry: sensitive and quantitative assays for oxidized amino acids in proteins and tissues. Heinecke JW, et al. **Methods Enzymol** 1999; 300:124-44

A new technique for measuring cardiac output and shunt fraction during venovenous extracorporeal membrane oxygenation. Linton RA, et al. **Perfusion** 1999 Jan; 14(1):43-7

[Reversal of therapy of postoperative complications by measuring lung water] Mothes H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998; 115:1099-101 (Eng. Abstr.) **(Ger)**

VETERINARY

Effects of repeated urea dilution measurement on feedlot performance and consistency of estimated body composition in steers of different breed types. Wells RS, et al. **J Anim Sci** 1998 Nov;76(11):2799-804

INDICATORS AND REAGENTS

see related
CHELATING AGENTS
DYES
REAGENT KITS, DIAGNOSTIC

Evaluation of a new reagent for preserving fresh blood samples and its potential usefulness for internal quality controls of multichannel hematology analyzers. Springer W, et al. **Am J Clin Pathol** 1999 Mar;111(3):387-96

Labels, disclaimers, and rules (oh, my!). Analyte-specific reagents and practice of immunohistochemistry [editorial] Swanson PE. **Am J Clin Pathol** 1999 Apr;111(4):445-8

Localization of an organic anion transporter-GFP fusion construct (rROAT1-GFP) in intact proximal tubules. Sweet DH, et al. **Am J Physiol** 1999 Jun;276(6 Pt 2):F864-73

A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry. Getz EB, et al. **Anal Biochem** 1999 Aug 15;273(1):73-80

Detection of DBD-carbamoyl amino acids in amino acid sequence and D/L configuration determination of peptides with fluorogenic Edman reagent 7-[(N,N-dimethylamino)sulfonyl]-2,1,3-benzoxadiazol-4-yl isothiocyanate. Huang Y, et al. **Anal Biochem** 1999 Jun 1;270(2):257-67

Development of a chemiluminescent urease activity assay for Helicobacter pylori infection diagnosis in gastric mucosa biopsies. Roda A, et al. **Anal Biochem** 1998 Nov 1;264(1):47-52

Determination of C-21 ketosteroids in serum using trifluoromethanesulfonic acid catalyzed precolumn dansylation and 1,1'-oxalyldiimidazole postcolumn peroxyoxalate chemiluminescence detection. Appelblad P, et al. **Anal Chem** 1998 Dec 1;70(23):5002-9

On-bead combinatorial approach to the design of chiral stationary phases for HPLC. Murer P, et al. **Anal Chem** 1999 Apr 1;71(7):1278-84

Monitoring of rat islet allografts with dithizone after induction of donor specific transplant tolerance by intrathymic administration of soluble alloantigens. Fiedor PS, et al. **Ann Transplant** 1998;3(4):21-30

The green fluorescent protein. Tsien RY. **Annu Rev Biochem** 1998;67:509-44 (114 ref.)

A new photometric assay with bromocresol purple for testing in vitro antitrichomonal activity in aerobic environment. Loiseau PM, et al. **Arzneimittelforschung** 1999 Jan; 49(1):51-5

Evaluation of monoclonal antibody reagents from three different manufacturers using flow cytometric two-color immunophenotyping. Pattanapanyasat K, et al. **Asian Pac J Allergy Immunol** 1998 Dec;16(4):185-92

A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Weber PJ, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):597-600

Model system for plant cell biology: GFP imaging in living onion epidermal cells. Scott A, et al. **Biotechniques** 1999 Jun;26(6):1125, 1128-32

Morphological detection of plasma membrane changes during apoptosis using enhanced green fluorescent protein. Shinbrot E, et al. **Biotechniques** 1999 Jun;26(6):1064-6, 1068

Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Sankaranarayanan R, et al. **Cancer** 1998 Nov 15;83(10):2150-6

Studies towards neoglycoconjugates from the monosaccharide determinant of Vibrio cholerae O:1, serotype Ogawa using the diethyl squarate reagent. Zhang J, et al. **Carbohydr Res** 1998 Nov;313(1):15-20

New tetrazolium method for the histochemical localization of dipeptidyl peptidase IV. Dikov A, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Mar;45(2):225-31

New tetrazolium method for the histochemical demonstration of gamma-glutamyl transpeptidase. Dikov A, et al. **Cell Mol Biol (Noisy-le-grand)** 1999 Mar;45(2):241-8

A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Diwu Z, et al. **Chem Biol** 1999 Jul;6(7):411-8

A FLASH of insight into cellular chemistry: genetically encoded labels for protein visualization in vivo. Luebke KJ. **Chem Biol** 1998 Dec;5(12):R317-22 (24 ref.)

Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Sinatra MA, et al. **Clin Chem** 1999 Jan;45(1):123-6

Effect of the hemoglobin-based oxygen carrier HBOC-201 on laboratory instrumentation: cobas integra, chiron blood gas analyzer 840, Sysmex SE-9000 and BCT. Wolthuis A, et al. **Clin Chem Lab Med** 1999 Jan;37(1):71-6

Simultaneous measurement of catecholamines and kallikrein in urine using boric acid preservative. Lee ZS, et al. **Clin Chim Acta** 1998 Aug 10;276(1):89-102

A simple and sensitive colorimetric assay of zinc in serum using cationic porphyrin. Makino T. **Clin Chim Acta** 1999 Apr;282(1-2):65-76

Performance characteristics of a new synthetic APTT reagent. Ts'ao C, et al. **Clin Lab Haematol** 1998 Oct; 20(5):307-13

Inventory management and reagent supply for automated chemistry. Kuzniar E. **Comb Chem High Throughput Screen** 1999 Aug;2(4):239-47

Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry. Macey MG, et al. **Cytometry** 1999 Aug 15;38(4):153-60

Optical methods for exploring dynamics of single copies of green fluorescent protein. Moerner WE, et al. **Cytometry** 1999 Jul 1;36(3):232-8

Nonradioactive Northern blotting with biotinylated and digoxigenin-labeled RNA probes. Meltzer JC, et al. **Electrophoresis** 1998 Jun;19(8-9):1351-5

Urine glucose testing: another look at its relevance when blood glucose monitoring is unaffordable. Feleke Y, et al. **Ethiop Med J** 1998 Apr;36(2):93-9

Six-year-old archival chromosome preparations are still good biological reagents for repeated primed in situ labelling (rPRINS). Marziliano N, et al. **Eur J Histochem** 1998;42(2):151-5

Antioxidant activity applying an improved ABTS radical cation decolorization assay. Re R, et al. **Free Radic Biol Med** 1999 May;26(9-10):1231-7

Gold chloride technique to study articular innervation. A protocol validated through computer-assisted colorimetry. Gómez-Barrena E, et al. **Histol Histopathol** 1999 Jan; 14(1):69-79

The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Mitchell BS, et al. **Histol Histopathol** 1999 Jan;14(1):217-26 (70 ref.)

Identification of the source of reagent variability in the xanthydrol/urea method. Biles PV, et al. **J AOAC Int** 1998 Nov-Dec;81(6):1155-61

Profiling of organic acids by capillary gas chromatography-mass spectrometry after direct methylation in urine using trimethyloxonium tetrafluoroborate. Liebich HM, et al. **J Chromatogr A** 1999 May 28;843(1-2):237-45

Solid-phase analytical derivatization: enhancement of sensitivity and selectivity of analysis. Rosenfeld JM. **J Chromatogr A** 1999 May 28;843(1-2):19-27 (36 ref.)

Ethanol monitoring of fluid absorption in anesthesiology practice [editorial; comment] Hahn RG. **J Clin Anesth** 1998 Aug;10(5):357-9. Comment on: J Clin Anesth 1998 Aug;10(5):360-5.

Transurethral resection syndrome: effect of the introduction into clinical practice of a new method for monitoring fluid absorption [see comments] Konrad C, et al. **J Clin Anesth** 1998 Aug;10(5):360-5. Comment in: J Clin Anesth 1998 Aug;10(5):357-9.

Evaluation of a leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay [see comments] Bush CE, et al. **J Clin Microbiol** 1998 Nov;36(11):3410-1 . Comment in: J Clin Microbiol 1999 Aug;37(8):2742.

Isolation and detection of Listeria monocytogenes using fluorogenic and chromogenic substrates for phosphatidylinositol-specific phospholipase C. Restaino L, et al. **J Food Prot** 1999 Mar;62(3):244-51

Determination of postmortem interval from old skeletal remains by image analysis of luminol test results. Introna F Jr, et al. **J Forensic Sci** 1999 May;44(3):535-8

Functional characterization and potential applications for enhanced green fluorescent protein- and epitope-fused human M1 muscarinic receptors. Weill C, et al. **J Neurochem** 1999 Aug;73(2):791-801

Pretargeting of bacterial endocarditis in rats with streptavidin and 111In-labeled biotin. Fogarasi M, et al. **J Nucl Med** 1999 Mar;40(3):484-90

2-DE spot amino acid analysis with 9-fluorenylmethyl chloroformate. Wilkins MR, et al. **Methods Mol Biol** 1999; 112:445-60 (13 ref.)

Combined fluorescent and gold immunoprobes: reagents and methods for correlative light and electron microscopy. Powell RD, et al. **Microsc Res Tech** 1998 Jul 1;42(1):2-12

Direct evidence of NO production in rat hippocampus and cortex using a new fluorescent indicator: DAF-2 DA. Kojima H, et al. **Neuroreport** 1998 Oct 26;9(15):3345-8

Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. Finocchiaro R, et al. **Urol Res** 1998;26(6):401-5

[Caged compounds] Katayama Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1917-21 (15 ref.) **(Jpn)**

[Fluorescent probes for detecting active protein kinases in the living cells] Kudo Y, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1922-6 (4 ref.) **(Jpn)**

[Fluorescent calcium indicators] Kudo Y. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1912-6 (8 ref.) **(Jpn)**

[A revolution in Ca2+ imaging] Miyawaki A. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1931-8 (12 ref.) **(Jpn)**

[Measurement of calcium content in the blood and other biological fluids by Arsenazo III complexone] Ovsiannikov AI, et al. **Klin Lab Diagn** 1999 Jan;(1):16-8 (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

CT-guided methylene-blue labelling before thoracoscopic resection of pulmonary nodules. Vandoni RE, et al. **Eur J Cardiothorac Surg** 1998 Sep;14(3):265-70

Ocular drug targeting by liposomes and their corneal interactions. Velpandian T, et al. **J Microencapsul** 1999 Mar-Apr;16(2):243-50

ANALYSIS

Green fluorescent protein in the design of a living biosensing system for L-arabinose. Shetty RS, et al. **Anal Chem** 1999 Feb 15;71(4):763-8

Nitroblue tetrazolium test in patients with renal tumor in the course of embolization. Mantur M, et al. **Rocz Akad Med Bialymst** 1998;43:292-7

CHEMISTRY

Analysis of the Kveim-Siltzbach test reagent for bacterial DNA. Richter E, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1981-4

RNA quantitation by fluorescence-based solution assay: RiboGreen reagent characterization. Jones LJ, et al. **Anal Biochem** 1998 Dec 15;265(2):368-74

Enhanced detection of oligonucleotides in UV MALDI MS using the tetraamine spermine as a matrix additive. Asara JM, et al. **Anal Chem** 1999 Jul 15;71(14):2866-70

Hydroquinone-based derivatization reagents for the quantitation of amines using electrochemical detection. Rose MJ, et al. **Anal Chem** 1999 Jun 1;71(11):2221-30

Crystallization of neutral red vital stain from minimum essential medium due to pH instability [letter] Baker CS. **In Vitro Cell Dev Biol Anim** 1998 Sep;34(8):607-8

Isotope dilution gas chromatographic-mass spectrometric measurement of tricyclic antidepressant drugs. Utility of the 4-carbethoxyhexafluorobutyryl derivatives of secondary amines. Way BA, et al. **J Anal Toxicol** 1998 Sep;22(5):374-82

High-performance liquid chromatographic separation of novel atropic alpha,alpha-disubstituted-beta-amino acids, either on different beta-cyclodextrin-bonded phases or as their 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide derivatives. Török G, et al. **J Chromatogr A** 1999 Jun 18; 846(1-2):83-91

Sodium peroxydisulfate is a stable and cheap substitute for ammonium peroxydisulfate (persulfate) in polyacrylamide gel electrophoresis [letter] Behrman EJ, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19; 723(1-2):325-6

Capillary gas chromatographic determination of putrescine and cadaverine in serum of cancer patients using trifluoroacetylacetone as derivatizing reagent. Khuhawar MY, et al. **J Chromatogr B Biomed Sci Appl** 1999 Feb 19; 723(1-2):17-24

High-performance liquid chromatographic method for rapid and highly sensitive determination of histidine using postcolumn fluorescence detection with o-phthaldialdehyde. Tateda N, et al. **J Chromatogr B Biomed Sci Appl** 1998 Nov 6;718(2):235-41

Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. Cremese M, et al. **J Forensic Sci** 1998 Nov;43(6):1220-4

The effect of luminol on presumptive tests and DNA analysis using the polymerase chain reaction. Gross AM, et al. **J Forensic Sci** 1999 Jul;44(4):837-40

NH4+ utilization and regeneration rates in freshwater lakes determined by GC-MS of derivatised dihydroindophenol. Köster O, et al. **J Microbiol Methods** 1999 Jul;37(1):65-76

Detection of siderophore production from several fungi and bacteria by a modification of chrome azurol S (CAS) agar plate assay. Milagres AM, et al. **J Microbiol Methods** 1999 Jul;37(1):1-6

Plasma analysis of alpha-difluoromethylornithine using pre-column derivatization with naphthalene-2,3-dicarboxaldehyde/CN and multidimensional chromatography. Kilkenny ML, et al. **J Pharm Biomed Anal** 1998 Sep 1;17(6-7):1205-13

Identification of urinary metabolites of clemastine after oral administration to man. Choi MH, et al. **J Pharm Pharmacol** 1999 Jan;51(1):53-9

Parallel synthesis with fluorous reagents and reactants. Curran DP. **Med Res Rev** 1999 Sep;19(5):432-8 (15 ref.)

Phase-trafficking reagents and phase-switching strategies for parallel synthesis. Flynn DL. **Med Res Rev** 1999 Sep; 19(5):408-31 (69 ref.)

Chemical modification of an arginine residue in the ATP-binding site of Ca2+ -transporting ATPase of sarcoplasmic reticulum by phenylglyoxal. Yamamoto H, et al. **Mol Cell Biochem** 1999 Jan;190(1-2):169-77

[Delayed assessment of glucose level bioassays using a chemical stabilizer] Iarmol'chuk GM. **Ukr Biokhim Zh** 1998 Nov-Dec;70(6):147-51 (Eng. Abstr.) **(Ukr)**

CLASSIFICATION

FDA issues final rule for classification and reclassification of immunochemistry reagents and kits [editorial] Taylor CR. **Am J Clin Pathol** 1999 Apr;111(4):443-4

Analyte specific reagents: FDA final rule and implications for your clinical flow cytometry laboratory. Johnson RL. **Cytometry** 1999 Feb 15;38(1):40-1

METABOLISM

Reaction between sheep liver mitochondrial aldehyde dehydrogenase and a chromogenic 'reporter group' reagent. King GJ, et al. **Adv Exp Med Biol** 1999;463:107-13

Enrichment of transiently transfected mesangial cells by cell sorting after cotransfection with GFP. Chen R, et al. **Am J Physiol** 1999 May;276(5 Pt 2):F777-85

Species differences in the glutathione transferase GSTT1-1 activity towards the model substrates methyl chloride and dichloromethane in liver and kidney. Thier R, et al. **Arch Toxicol** 1998 Oct;72(10):622-9

Reactions of 1-methylbenzimidazole derivatives with m-chloroperoxybenzoic acid. Kaiya T, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):625-30

Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein. Mo YY, et al. **Biotechniques** 1998 Dec;25(6):1052-7

GFP:HIV-1 protease production and packaging with a T4 phage expression-packaging processing system. Mullaney JM, et al. **Biotechniques** 1998 Dec;25(6):1008-12

Recombinant Bombyx mori nucleopolyhedrovirus harboring green fluorescent protein. Sehgal D, et al. **Biotechniques** 1998 Dec;25(6):997-1000, 1002, 1004 passim

Replication-deficient adenovirus vector transfer of gfp reporter gene into supraoptic nucleus and subfornical organ neurons. Vasquez EC, et al. **Exp Neurol** 1998 Dec; 154(2):353-65

The correlates and alleged biochemical background of the resazurin reduction test in semen. Zalata AA, et al. **Int J Androl** 1998 Oct;21(5):289-94

Nitroblue tetrazolium reduction of neutrophils in heat stressed goats is not influenced by selenium and vitamin E injection. Katamoto H, et al. **J Vet Med Sci** 1998 Nov; 60(11):1243-9

Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Shashidharan P, et al. **Neuroreport** 1999 Apr 6;10(5):1149-53

Calcium phosphate-mediated transfection of primary cultured brain neurons using GFP expression as a marker: application for single neuron electrophysiology. Watanabe SY, et al. **Neurosci Res** 1999 Jan;33(1):71-8

Indicators and optical configuration for simultaneous high-resolution recording of membrane potential and intracellular calcium using laser scanning microscopy. Bullen A, et al. **Pflugers Arch** 1998 Oct;436(5):788-96

PHARMACOKINETICS

Intensity-dependent effects of acute submaximal exercise on the pharmacokinetics of bromsulphalein in horses. Dyke TM, et al. **Am J Vet Res** 1998 Nov;59(11):1481-7

Light-dependent translocation of a phytochrome B-GFP fusion protein to the nucleus in transgenic Arabidopsis. Yamaguchi R, et al. **J Cell Biol** 1999 May 3;145(3):437-45

In-vivo evaluation of indium-111-diethylenetriaminepentaacetic acid-labelling for determining the sites and rates of protein catabolism in mice. Mukai T, et al. **J Pharm Pharmacol** 1999 Jan; 51(1):15-20

Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Yao Z, et al. **Nucl Med Biol** 1998 Aug; 25(6):557-60

PHARMACOLOGY

Ca2+ activation of hSlo K+ channel is suppressed by N-terminal GFP tag. Meyer E, et al. **Eur J Neurosci** 1999 Mar;11(3):1105-8

Modulation by chloramine-T of 4-aminopyridine-sensitive transient outward current in rabbit atrial cells. Tanaka H, et al. **Eur J Pharmacol** 1998 Sep 25;358(1):85-92

STANDARDS

Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents. Tarelli E, et al. **Biologicals** 1998 Dec;26(4):331-46

Analyte-specific reagents [news] Press RD. **Mol Diagn** 1999 Mar;4(1):71

[Quality control of reactant lots at the Nation Blood Group Reference Center (CNRGS). Data for the year 1998] Noizat-Pirenne F, et al. **Transfus Clin Biol** 1999 Jun; 6(3):195-200 (Eng. Abstr.) **(Fre)**

TOXICITY

Bradykinin mediates myocardial ischaemic preconditioning against free radical injury in guinea-pig isolated heart. Jin ZQ, et al. **Clin Exp Pharmacol Physiol** 1998 Nov; 25(11):932-5

Early bronchial hyperresponsiveness following injection of sephadex beads in the guinea pig: involvement of platelet activating factor and thromboxane A2. Conroy DM, et al. **Inflammation** 1999 Oct;23(5):437-48

INDIGENCY see **POVERTY**

INDIGENCY, MEDICAL see **MEDICAL INDIGENCY**

INDIGENT CARE see **MEDICAL INDIGENCY**

INDIGO CARMINE

ADVERSE EFFECTS

Indigo carmine-induced severe hypotension. Nguyen AC, et al. **Anesth Analg** 1998 Nov;87(5):1194-5

DIAGNOSTIC USE

Chromoendoscopic appearance of collagenous colitis--a case report using indigo carmine. Sato S, et al. **Endoscopy** 1998 Sep;30(7):S80-1

Methylene blue [letter; comment] Hackett ER, et al. **Surg Neurol** 1998 Dec;50(6):608-9. Comment on: Surg Neurol 1998 Mar;49(3):338.

PHARMACOLOGY

Effect of methylene blue, indigo carmine, and Renografin on human sperm motility. Sheynkin YR, et al. **Urology** 1999 Jan;53(1):214-7

INDIGOTINDISULFONATE SODIUM see **INDIGO CARMINE**

INDINAVIR

ADMINISTRATION & DOSAGE

Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy. Mayer KH, et al. **Clin Infect Dis** 1999 Jun;28(6):1252-9

Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy [letter] [see comments] Viganó A, et al. **Lancet** 1998 Dec 12; 352(9144):1905-6. Comment in: Lancet 1999 Mar 6;353(9155):840-1.

Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Carver PL, et al. **Pharm Res** 1999 May;16(5):718-24

ADVERSE EFFECTS

Ketoacidosis associated with protease inhibitor therapy [letter] Besson C, et al. **AIDS** 1998 Jul 30;12(11):1399-400

Changes in renal function associated with indinavir. Boubaker K, et al. **AIDS** 1998 Dec 24;12(18):F249-54

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. Brodie SB, et al. **AIDS** 1998 Dec 24;12(18):2433-7

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. Dieleman JP, et al. **AIDS** 1999 Mar 11;13(4):473-8

Indinavir and thrombocytopenia [letter] Durand JM. **AIDS** 1999 Jan 14;13(1):148-9

Acute porphyria following commencement of indinavir [letter] Fox PA, et al. **AIDS** 1999 Apr 1;13(5):622-3

Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir [letter] Karmochkine M, et al. **AIDS** 1998 Dec 24;12(18):2499

Ureteric obstruction in HIV patients undergoing indinavir therapy [letter; comment] Yanez MH. **AJR Am J Roentgenol** 1999 May;172(5):1452. Comment on: AJR Am J Roentgenol 1998 Sep;171(3):717-20.

Characterization of rash with indinavir in a national patient cohort. Gajewski LK, et al. **Ann Pharmacother** 1999 Jan; 33(1):17-21

Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Trainor LD, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):256-9

Rapid development of indinavir-induced asymptomatic crystalluria in a human immunodeficiency virus-negative patient. Antony SJ. **Clin Infect Dis** 1998 Oct;27(4):911-2

Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Benveniste O, et al. **Clin Infect Dis** 1999 May;28(5):1180-1

Gynecomastia associated with indinavir therapy. Caeiro JP, et al. **Clin Infect Dis** 1998 Dec;27(6):1539-40

Persistent nephrolithiasis after discontinuation of indinavir therapy. Polhemus ME, et al. **Clin Infect Dis** 1998 Dec; 27(6):1536-7

Indinavir-induced nephropathy. Grabe DW, et al. **Clin Nephrol** 1999 Mar;51(3):181-3

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Perazella MA, et al. **Clin Nephrol** 1998 Sep;50(3):194-6 (8 ref.)

Acute renal failure caused by indinavir in a patient with a single functioning kidney. Rodriguez-Hernández MJ, et al. **Eur J Clin Microbiol Infect Dis** 1999 May;18(5):386-7

Urolithiasis and the protease inhibitor indinavir. Hermieu J, et al. **Eur Urol** 1999;35(3):239-41

Painful hyperaesthesia caused by protease inhibitors? [letter] Colebunders R, et al. **Infection** 1998 Jul-Aug;26(4):250-1

Insulin resistance in HIV protease inhibitor-associated diabetes. Yarasheski KE, et al. **J Acquir Immune Defic Syndr** 1999 Jul 1;21(3):209-16

Protease inhibitor-induced lipodystrophy. Williamson K, et al. **J Am Acad Dermatol** 1999 Apr;40(4):635-6

Urolithiasis associated with protease inhibitors. Sundaram CP, et al. **J Endourol** 1999 May;13(4):309-12

Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. Kohan AD, et al. **J Urol** 1999 Jun;161(6):1765-8

Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. Reiter WJ, et al. **J Urol** 1999 Apr;161(4):1082-4

Alopecia associated with indinavir therapy [letter] Bouscarat F, et al. **N Engl J Med** 1999 Aug 19;341(8):618

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor [see comments] Carr A, et al. **N Engl J Med** 1998 Oct 29;339(18):1296. Comment in: N Engl J Med 1999 Mar 25;340(12):969-70.

Renal atrophy associated with long-term treatment with indinavir [letter] [published erratum appears in N Engl J Med 1999 Mar 25;340(12):976] Hanabusa H, et al. **N Engl J Med** 1999 Feb 4;340(5):392-3

Ureteral obstruction secondary to indinavir in the pediatric HIV population. Noble CB, et al. **Pediatr Radiol** 1998 Aug; 28(8):627-9

Stevens-Johnson syndrome caused by indinavir. Teira R, et al. **Scand J Infect Dis** 1998;30(6):634-5

Case no. 3. Right flank pain. Crixivan lithiasis. Schenkman NS. **Tech Urol** 1999 Mar;5(1):59-60

["Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors] Milpied-Homsi B, et al. **Ann Dermatol Venereol** 1999 Mar;126(3):254-6 (Eng. Abstr.) **(Fre)**

[Treatment of complicated renal colic in patients treated with indinavir: value of double J stents] Van Glabeke E, et al. **Prog Urol** 1999 Jun;9(3):470-3 (Eng. Abstr.) **(Fre)**

[Indinavir-associated lipodystrophy] Krautheim A. **Schweiz Rundsch Med Prax** 1999 Feb 11;88(7):285-7 **(Ger)**

[Large, atypical accummulation of adipose tissue in a patient with human immunodeficiency virus infection] Garcia de la Llana F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov; 16(9):431-2 **(Spa)**

[Hydronephrosis caused by indinavir (letter)] Reus S, et al. **Enferm Infecc Microbiol Clin** 1999 Jan;17(1):47-8 **(Spa)**

[Indinavir-induced anuria (letter)] Lacambra Calvet C, et al. **Rev Clin Esp** 1999 Mar;199(3):189 **(Spa)**

ANALYSIS

Identification of in vitro metabolites of Indinavir by "intelligent automated LC-MS/MS" (INTAMS) utilizing triple quadrupole tandem mass spectrometry. Yu X, et al. **J Am Soc Mass Spectrom** 1999 Feb;10(2):175-83

Identification of drug metabolites in biological matrices by intelligent automated liquid chromatography/tandem mass spectrometry. Lopez LL, et al. **Rapid Commun Mass Spectrom** 1998;12(22):1756-60

BLOOD

Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection. Foisy ML, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jan 22;721(2):239-47

Determination of indinavir in plasma by solid-phase extraction and column liquid chromatography. Poirier JM, et al. **Ther Drug Monit** 1999 Aug;21(4):404-10

CEREBROSPINAL FLUID

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. Martin C, et al. **AIDS** 1999 Jul 9;13(10):1227-32

CHEMISTRY

Imaging characteristics of indinavir calculi. Schwartz BF, et al. **J Urol** 1999 Apr;161(4):1085-7

Molecular mechanisms of resistance: free energy calculations of mutation effects on inhibitor binding to HIV-1 protease. Rick SW, et al. **Protein Sci** 1998 Aug;7(8):1750-6

METABOLISM

The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor. Lin JH, et al. **Pharm Biotechnol** 1998; 11:233-55 (28 ref.)

PHARMACOKINETICS

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor

indinavir [letter] Burger DM, et al. **AIDS** 1998 Oct 22; 12(15):2080–2

Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure [letter] Guardiola JM, et al. **AIDS** 1998 Jul 30;12(11):1395

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Hsu A, et al. **Antimicrob Agents Chemother** 1998 Nov;42(11):2784–91

The effect of azithromycin on the pharmacokinetics of indinavir. Foulds G, et al. **J Clin Pharmacol** 1999 Aug; 39(8):842–6

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Murphy RL, et al. **J Infect Dis** 1999 May;179(5):1116–23

Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. Yeh KC, et al. **J Pharm Sci** 1999 May;88(5):568–73

Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy [letter] Bernard L, et al. **Lancet** 1998 Nov 28;352(9142):1757–8

Indinavir concentrations and antiviral effect. Acosta EP, et al. **Pharmacotherapy** 1999 Jun;19(6):708–12

Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Piscitelli SC, et al. **Pharmacotherapy** 1998 Nov-Dec;18(6):1212–6

Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ion-pair reversed-phase high-performance liquid chromatography. Li W, et al. **Ther Drug Monit** 1999 Jun;21(3):360–6

PHARMACOLOGY

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. Schapiro JM, et al. **AIDS** 1999 Feb 25;13(3):359–65

Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. Brown AJ, et al. **AIDS Res Hum Retroviruses** 1999 Feb 10; 15(3):247–53

Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Korting HC, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):2038–42

An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir. Melnick L, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3256–65

Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Tanuri A, et al. **Antimicrob Agents Chemother** 1999 Feb;43(2):253–8

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Gruber A, et al. **Immunopharmacology** 1999 Apr; 41(3):227–34

Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects. Mistry GC, et al. **J Clin Pharmacol** 1999 Jun;39(6):636–42

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. Cassone A, et al. **J Infect Dis** 1999 Aug;180(2):448–53

Ergotism related to concurrent administration of ergotamine tartrate and indinavir [letter] Rosenthal E, et al. **JAMA** 1999 Mar 17;281(11):987

Protease inhibitors enhance levodopa effects in Parkinson's disease [letter] Caparros-Lefebvre D, et al. **Mov Disord** 1999 May;14(3):535

POISONING

Indinavir overdose [letter] Burkhart KK, et al. **J Toxicol Clin Toxicol** 1998;36(7):747

THERAPEUTIC USE

Control of cytomegalovirus retinitis after combination antiretroviral therapy. Ruhswurm I, et al. **Acta Ophthalmol Scand** 1999 Aug;77(4):471–3

Protease inhibitors in antiviral therapy of paediatric HIV disease [letter] Manfredi R, et al. **Acta Paediatr** 1998 Jul; 87(7):814–6

Effect of indinavir on HIV-related wasting. Carbonnel F, et al. **AIDS** 1998 Oct 1;12(14):1777–84

Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. Casado JL, et al. **AIDS** 1998 Jul 30;12(11):F131–5

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). Cohen Stuart JW, et al. **AIDS** 1999 May 7;13(7):F53–8

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. d'Arminio Monforte A, et al. **AIDS** 1998 Sep 10;12(13):1631–7

Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir [letter] Martinelli C, et al. **AIDS** 1998 Sep 10;12(13):1717–9

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. Staszewski S, et al. **AIDS** 1999 May 28;13(8):951–6

Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). Lori F, et al. **AIDS Res Hum Retroviruses** 1999 May 1;15(7):619–24

Indinavir-fluconazole interaction [letter; comment] Bellibas SE. **Antimicrob Agents Chemother** 1999 Feb;43(2):432–3. Comment on: Antimicrob Agents Chemother 1998 Feb;42(2):223–7.

Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Evans TG, et al. **Antiviral Res** 1998 Oct;39(3):163–73

Medical student electives and infectious diseases. Zidovudine alone is not recommended prophylaxis [letter] Meadway J. **BMJ** 1999 Apr 24;318(7191):1145–6

Cicatrization of cytomegalovirus retinitis following introduction of highly active anti-retroviral therapy: uveitis as a possible indicator of good ocular prognosis. Herbort CP, et al. **Graefes Arch Clin Exp Ophthalmol** 1998 Oct; 236(10):795–7

Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor [letter] Nigro L, et al. **Ital J Gastroenterol Hepatol** 1999 Jan-Feb;31(1):85–6

Resolution of recalcitrant hand warts in an HIV-infected patient treated with potent antiretroviral therapy. Spach DH, et al. **J Am Acad Dermatol** 1999 May;40(5 Pt 2):818–21

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. Hirsch M, et al. **J Infect Dis** 1999 Sep;180(3):659–65

Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. Dulioust A, et al. **J Virol** 1999 Jan; 73(1):850–4

Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team [see comments] Havlir DV, et al. **N Engl J Med** 1998 Oct 29; 339(18):1261–8. Comment in: N Engl J Med 1998 Oct 29;339(18):1319–21.

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team [see comments] Pialoux G, et al. **N Engl J Med** 1998 Oct 29;339(18):1269–76 . Comment in: N Engl J Med 1998 Oct 29;339(18):1319–21.

Renal tolerance of indinavir in HIV-positive patients [letter] Guery B, et al. **Nephron** 1999;82(1):72

[Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients] Bobin S, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):418–9 (Eng. Abstr.) **(Fre)**

[Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV] Gavazzi G, et al. **Pathol Biol (Paris)** 1998 Jun;46(6):412–5 (Eng. Abstr.) **(Fre)**

[Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor] Mouroux M, et al. **Pathol Biol (Paris)** 1999 May; 47(5):549–52 (Eng. Abstr.) **(Fre)**

[Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients] Piroth L, et al. **Presse Med** 1999 Feb 27;28(8):381–7 (Eng. Abstr.) **(Fre)**

[Granular lymphocyte-proliferative disorder following initiation of protease inhibitor therapy in a patient with acquired immunodeficiency syndrome] Tanaka K, et al. **Kansenshogaku Zasshi** 1999 Jul;73(7):702–6 (Eng. Abstr.) **(Jpn)**

[Optimization of antiretroviral treatment: new forms of the use of indinavir (letter)] Valencia Ortega ME, et al. **Med Clin (Barc)** 1999 Jun 19;113(2):77–8 **(Spa)**

URINE

Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Trainor LD, et al. **Arch Pathol Lab Med** 1998 Mar;122(3):256–9

Indinavir crystallization and urolithiasis. Grases F, et al. **Int Urol Nephrol** 1999;31(1):23–9

Effect of the sample matrix on the determination of indinavir in human urine by HPLC with turbo ion spray tandem mass spectrometric detection. Fu I, et al. **J Pharm Biomed Anal** 1998 Nov;18(3):347–57

Images in clinical medicine. Indinavir crystalluria. Tsao JW, et al. **N Engl J Med** 1999 Apr 29;340(17):1329

INDIUM

see related
INDIUM RADIOISOTOPES

CHEMISTRY

In vitro corrosion behaviour and microhardness of high-copper amalgams with platinum and indium. Ilikli BG, et al. **J Oral Rehabil** 1999 Feb;26(2):170–6

DIAGNOSTIC USE

Indium-111-chloride scintigraphy visualized gastric involvement in a case of adult T-cell leukemia. Tani A, et al. **Ann Nucl Med** 1999 Jun;13(3):181–3

Experimental evaluation of hepatic functional reserve using 111In colloid for clinical application. Sugiu T, et al. **In Vivo** 1998 May-Jun;12(3):315–9

TOXICITY

Developmental toxicity of indium in cultured rat embryos. Nakajima M, et al. **Teratog Carcinog Mutagen** 1999; 19(3):205–9

Developmental toxicity of indium chloride by intravenous or oral administration in rats. Nakajima M, et al. **Teratog Carcinog Mutagen** 1998;18(5):231–8

INDIUM RADIOISOTOPES

All filter units are not alike: report of a problem encountered during preparation of indium-111 capromab pendetide [letter] Ponto JA. **J Nucl Med Technol** 1998 Dec;26(4):283

115In as a probe for the characterization of therapy bremsstrahlung beams and the detection of photoneutrons. Krmar M, et al. **Med Phys** 1999 Apr;26(4):564–9

A novel 111In-labeled antisense DNA probe with multi-chelating sites (MCS-probe) showing high specific radioactivity and labeling efficiency. Fujibayashi Y, et al. **Nucl Med Biol** 1999 Jan;26(1):17–21

CHEMISTRY

A kit formulation for preparation of [(111)In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Mathias CJ, et al. **Nucl Med Biol** 1998 Aug;25(6):585–7

DIAGNOSTIC USE

A pitfall with the use of 111In-pentetreotide scintigraphy in the resected bronchopulmonary carcinoids follow-up: a case report. Grazia M, et al. **Acta Chir Hung** 1999; 38(1):35–7

Primary cerebral lymphoma visualised by means of In-111-pentetreotide scintigraphy. Roland J, et al. **Acta Neurol Belg** 1998 Dec;98(4):356–9

Assessment of terminal ileal and colonic inflammation in Crohn's disease with 99mTc-WBC. Charron M, et al. **Acta Paediatr** 1999 Feb;88(2):193–8

Indium-111-chloride scintigraphy visualized gastric involvement in a case of adult T-cell leukemia. Tani A, et al. **Ann Nucl Med** 1999 Jun;13(3):181–3

Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer. Volpe CM, et al. **Ann Surg Oncol** 1998 Sep;5(6):489–94

Biodistribution and scintigraphy of [111In]DTPA-adriamycin in mammary tumor-bearing rats. Higuchi T, et al. **Anticancer Drugs** 1999 Jan; 10(1):89–95

Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors. Panza N, et al. **Biomed Pharmacother** 1999 Aug;53(7):319–22

Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Polascik TJ, et al. **Cancer** 1999 Apr 1;85(7):1586–92

Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Boerman OC, et al. **Cancer Res** 1999 Sep 1;59(17):4400–5

Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Briganti V, et al. **Clin Cancer Res** 1997 Dec;3(12 Pt 1):2385–91

In-111 pentetreotide scintigraphy to monitor nonsecreting neuroendocrine tumors. Buffaz PD, et al. **Clin Nucl Med** 1999 Jun;24(6):459–60

Perivalvular abscess complicating infective endocarditis: complementary role of echocardiography and indium-111-labeled leukocytes. Campeau RJ, et al. **Clin Nucl Med** 1998 Sep;23(9):582–4

Indium-111 pentetreotide lung uptake in infectious lung disease. Castellani M, et al. **Clin Nucl Med** 1999 May; 24(5):343–5

Painful Schmorl's node: another cause of vertebral photopenia on Indium-111-labeled leukocyte scintigraphy. Kirkwood ID, et al. **Clin Nucl Med** 1999 Mar;24(3):206–8

Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Krausz Y, et al. **Clin Nucl Med** 1999 Apr; 24(4):256–60

Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. Lin K, et al. **Clin Nucl Med** 1999 Jan;24(1):24–8

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Petronis JD, et al. **Clin Nucl Med** 1998 Oct;23(10):672–7

In-111-labeled leukocyte infection imaging: false-positive results caused by wound dressing and hematoma.

Rajendran JG, et al. **Clin Nucl Med** 1999 Feb;24(2):126-7
Infection of a left ventricular aneurysm and massive splenomegaly demonstrated by In-111-labeled leukocyte scintigraphy. Rose DS, et al. **Clin Nucl Med** 1998 Oct; 23(10):721-2
In-111 octreotide lung uptake in hypersensitive pneumonitis caused by fungal infection. Slavin JD Jr, et al. **Clin Nucl Med** 1998 Dec;23(12):847-8
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Cremonesi M, et al. **Eur J Nucl Med** 1999 Aug;26(8):877-86
Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. de Jong M, et al. **Eur J Nucl Med** 1999 Jul; 26(7):693-8
Somatostatin receptor imaging in patients with sarcoidosis. Kwekkeboom DJ, et al. **Eur J Nucl Med** 1998 Sep; 25(9):1284-92
Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients. Lazzeri E, et al. **Eur J Nucl Med** 1999 Jun;26(6):606-14
Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Nocaudie M, et al. **Eur J Nucl Med** 1999 May;26(5):511-7
Mapping the in vivo distribution of herpes simplex virions [published erratum appears in Hum Gene Ther 1998 Nov 20;9(17):2652] Schellingerhout D, et al. **Hum Gene Ther** 1998 Jul 20;9(11):1543-9
Tumor localization--the ectopic ACTH syndrome [editorial; comment] de Herder WW, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1184-5. Comment on: J Clin Endocrinol Metab 1999 Apr;84(4):1186-92. Comment on: J Clin Endocrinol Metab 1999 Apr;84(4):1193-202.
Comment on primary localization of an ectopic ACTH-producing bronchial carcinoid tumor by indium111 pentetreotide scintigraphy [letter] Reincke M, et al. **J Clin Endocrinol Metab** 1999 Sep;84(9):3399-400; discussion 3402-3
Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients [see comments] Torpy DJ, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1186-92. Comment in: J Clin Endocrinol Metab 1999 Apr;84(4):1184-5.
Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells [see comments] Carrió I, et al. **J Nucl Cardiol** 1998 Nov-Dec; 5(6):551-7. Comment in: J Nucl Cardiol 1998 Nov-Dec;5(6):626-8.
Scleroderma heart disease: an unusual cause of positive antimyosin cardiac imaging. Lekakis J, et al. **J Nucl Cardiol** 1999 Jan-Feb;6(1 Pt 1):91-2
Z2D3 imaging: fringe or frontier? [editorial; comment] Strauss HW. **J Nucl Cardiol** 1998 Nov-Dec;5(6):626-8. Comment on: J Nucl Cardiol 1998 Nov-Dec;5(6):551-7.
111In-labeled antimyosin scintigraphy for detection of cardiac and skeletal muscular involvement in hereditary muscular dystrophy [letter] Ilgin N, et al. **J Nucl Med** 1999 Jul;40(7):1222
Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. Klutmann S, et al. **J Nucl Med** 1998 Nov;39(11):1913-7
Factor analysis of dynamic series (FADS) in somatostatin receptor imaging. Kolesnikov-Gauthier H, et al. **J Nucl Med** 1999 Jan;40(1):33-9
Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. Kurtaran A, et al. **J Nucl Med** 1998 Nov;39(11):1907-9
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Kwekkeboom DJ, et al. **J Nucl Med** 1999 May;40(5):762-7
Biodistribution, radiation dosimetry and pharmacokinetics of 111In-antimyosin in idiopathic inflammatory myopathies. Smith T, et al. **J Nucl Med** 1999 Mar;40(3):464-70
Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. Bohdiewicz PJ. **J Nucl Med Technol** 1998 Sep;26(3):155-63; quiz 170-1
Dual-isotope protocol for indium-111 capromab pendetide monoclonal antibody imaging. Kelty NL, et al. **J Nucl Med Technol** 1998 Sep;26(3):174-7
111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. Michaels EK, et al. **J Urol** 1999 Feb; 161(2):597-8
Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. Musi M, et al. **Lung Cancer** 1998 Nov;22(2):97-102
Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin. Collins DA, et al. **Mayo Clin Proc** 1999 Jul;74(7):687-91
Species difference in radioactivity elimination from liver parenchymal cells after injection of radiolabeled proteins. Mukai T, et al. **Nucl Med Biol** 1999 Apr;26(3):281-9
Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. Buijs WC, et al. **Nucl Med Commun** 1998 Aug; 19(8):743-51
Immunoscintigraphy (BW 250/183) in neonates and infants with fever of unknown origin. Gratz S, et al. **Nucl Med Commun** 1998 Nov;19(11):1037-45
111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Korppi-Tommola T, et al. **Nucl Med Commun** 1999 Feb;20(2):145-52
Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues. Lauriero F, et al. **Nucl Med Commun** 1998 Dec; 19(12):1127-34
In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma. Montravers F, et al. **Nucl Med Commun** 1998 Oct; 19(10):953-61
111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Muros MA, et al. **Nucl Med Commun** 1998 Aug;19(8):735-42
Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody. Muxi A, et al. **Nucl Med Commun** 1999 Feb;20(2):123-30
111In-labelled platelets for assessment of thrombogenicity of new haemodialysis vascular access. Neumann I, et al. **Nucl Med Commun** 1999 May;20(5):445-51
Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Pinkas L, et al. **Nucl Med Commun** 1999 Aug;20(8):689-96 (26 ref.)
Indium-111-oxine labeled leukocyte uptake in Ki-1-positive anaplastic large cell lymphoma. Chiu W, et al. **Pediatr Radiol** 1999 Aug;29(8):631-3
Polyclonal, nonspecific 111In-IgG scintigraphy in the evaluation of complicated osteomyelitis and septic arthritis. Molina-Murphy IL, et al. **Q J Nucl Med** 1999 Mar; 43(1):29-37
In-111 labeled leukocyte scintigraphy in patients with suspected inflammation after failed antibiotic therapy. Nasu R, et al. **Radiat Med** 1998 Sep-Oct;16(5):347-51
Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports. Satta J, et al. **Scand Cardiovasc J** 1999;33(1):49-53 (15 ref.)
Intraoperative detection of lung cancer by octreotide labeled to Indium-111. Pastore V, et al. **Semin Surg Oncol** 1998 Dec;15(4):220-2
Intraoperative scintigraphic detection of abdominal endocrine tumors. Development and evaluation of hand held gamma sensitive probes for 111In. Ohrvall U. **Ups J Med Sci** 1998;103(1):1-34
The relevance of somatostatin receptors in thyroid neoplasia. Ahlman H, et al. **Yale J Biol Med** 1997 Sep-Dec; 70(5-6):523-33
[Intraoperative isotope-controlled probe localization after somatostatin receptor scintigraphy of occult neuroendocrine tumors] Runkel N, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1034-7 (Eng. Abstr.) **(Ger)**
[Reassessment of a combination of cerebrospinal fluid scintigraphy and nasal pledget counts in patients with suspected rhinorrhea] Kosuda S, et al. **Kaku Igaku** 1998 Jul;35(6):435-41 (Eng. Abstr.) **(Jpn)**
[Comparison of endoscopy, radiology and scintigraphy with Tc-99m-exametazine labeled leukocytes and In-111 labeled human polyclonal immunoglobulin G in the diagnosis of inflammatory bowel disease] de Lima Ramos PA, et al. **Med Clin (Barc)** 1998 Sep 12;111(7):241-6 (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. Ryynänen PM, et al. **Ann Nucl Med** 1998 Dec;12(6):313-21
Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Griffiths GL, et al. **Int J Cancer** 1999 Jun 11;81(6):985-92
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. Carrasquillo JA, et al. **J Nucl Med** 1999 Feb;40(2):268-76
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. Virgolini I, et al. **J Nucl Med** 1998 Nov;39(11):1928-36
In-vivo evaluation of indium-111-diethylenetriaminepentaacetic acid-labelling for determining the sites and rates of protein catabolism in mice. Mukai T, et al. **J Pharm Pharmacol** 1999 Jan; 51(1):15-20
Disposition of radioactivity after injection of liver-targeted proteins labeled with 111In or 125I. Effect of labeling on distribution and excretion of radioactivity in rats. Staud F, et al. **J Pharm Sci** 1999 Jun;88(6):577-85
Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Quadri SM, et al. **Q J Nucl Med** 1998 Dec;42(4):250-61

THERAPEUTIC USE

In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. Lukinius A, et al. **Acta Oncol** 1999;38(3):383-7
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Krenning EP, et al. **Ann Oncol** 1999;10 Suppl 2:S23-9
Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Deb N, et al. **Clin Cancer Res** 1996 Aug;2(8):1289-97
Experiences with high dose radiopeptide therapy: the health physics perspective. Espenan GD, et al. **Health Phys** 1999 Mar;76(3):225-35
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Wong JY, et al. **J Nucl Med** 1998 Dec; 39(12):2097-104

INDIVIDUAL DIFFERENCES see **INDIVIDUALITY**

INDIVIDUAL PRACTICE ASSOCIATIONS see **INDEPENDENT PRACTICE ASSOCIATIONS**

INDIVIDUALITY

Individual differences in the biphasic effects of ethanol. Holdstock L, et al. **Alcohol Clin Exp Res** 1998 Dec; 22(9):1903-11
Alcohol and heightened aggression in individual mice. Miczek KA, et al. **Alcohol Clin Exp Res** 1998 Nov; 22(8):1698-705
Problems and prospects for the social support-reactivity hypothesis. Lepore SJ. **Ann Behav Med** 1998 Fall; 20(4):257-69 (93 ref.)
Is instrumental variability abnormally high in children exhibiting ADHD and aggressive behavior? Saldana L, et al. **Behav Brain Res** 1998 Jul;94(1):51-9
Individual differences in response to novelty, amphetamine-induced activity and drug discrimination in rats. Bevins RA, et al. **Behav Pharmacol** 1997 Jun; 8(2-3):113-23
Expanding clinical applications of population pharmacodynamic modelling. Minto C, et al. **Br J Clin Pharmacol** 1998 Oct;46(4):321-33 (90 ref.)
Individual variability and immunity. Cohen JJ. **Brain Behav Immun** 1999 Jun;13(2):76-9 (8 ref.)
Individual differences in prefrontal activation asymmetry predict natural killer cell activity at rest and in response to challenge. Davidson RJ, et al. **Brain Behav Immun** 1999 Jun;13(2):93-108
Introduction beyond stress: the role of individual difference factors in psychoneuroimmunology. Kemeny ME, et al. **Brain Behav Immun** 1999 Jun;13(2):73-5
Individual differences in posttraumatic distress: problems with the DSM-IV model [see comments] Bowman ML. **Can J Psychiatry** 1999 Feb;44(1):21-33 (281 ref.). Comment in: Can J Psychiatry 1999 Feb;44(1):20.
Environmental input and cognitive growth: a study using time-period comparisons. Huttenlocher J, et al. **Child Dev** 1998 Aug;69(4):1012-29
The index of individuality is often a misinterpreted quantity characteristic. Petersen PH, et al. **Clin Chem Lab Med** 1999 Jun;37(6):655-61 (10 ref.)
The enhancement of traditional behavioral couples therapy: consideration of individual factors and dyadic development. Lawrence E, et al. **Clin Psychol Rev** 1998 Sep;18(6):745-64
Spontaneous motor activity in the perinatal infant before and after birth: stability in individual differences. Groome LJ, et al. **Dev Psychobiol** 1999 Jul;35(1):15-24
Intraindividual variability in infant behavior. de Weerth C, et al. **Dev Psychol** 1999 Jul;35(4):1102-12 (55 ref.)
The major histocompatibility complex and the chemosensory signalling of individuality in humans. Eggert F, et al. **Genetica** 1998-99;104(3):265-73
Soluble MHC antigens and olfactory recognition of genetic individuality: the mechanism. Pearse-Pratt R, et al. **Genetica** 1998-99;104(3):223-30 (13 ref.)
The present status of the 'carrier hypothesis' for chemosensory recognition of genetic individuality. Singh PB. **Genetica** 1998-99;104(3):231-3 (22 ref.)
Effects of acute clonidine administration on power spectral analysis of heart rate variability in healthy humans. Lazzeri C, et al. **J Auton Pharmacol** 1998 Oct;18(5):307-12
Individual differences in young children's IQ: a social-developmental perspective. Crandell LE, et al. **J Child Psychol Psychiatry** 1999 Mar;40(3):455-64
Population-based data and the development of individual children: the case of low to moderate lead levels and intelligence. Ruff HA. **J Dev Behav Pediatr** 1999 Feb; 20(1):42-9
Individual differences in reactivity to daily events: examining the roles of stability and level of self-esteem. Greenier KD, et al. **J Pers** 1999 Feb;67(1):185-208
Genetic and environmental influences on individual differences in masculinity, femininity, and gender diagnosticity: analyzing data from a classic twin study. Lippa R, et al. **J Pers** 1999 Feb;67(1):127-55
Individual differences in social comparison: development of a scale of social comparison orientation. Gibbons FX, et al. **J Pers Soc Psychol** 1999 Jan;76(1):129-42
Life events and social support as moderators of individual differences in cardiovascular and cortisol reactivity. Roy MP, et al. **J Pers Soc Psychol** 1998 Nov;75(5):1273-81
Alcohol and retrograde memory effects: role of individual differences. Bruce KR, et al. **J Stud Alcohol** 1999 Jan; 60(1):130-6
Comparing naming, lexical decision, and eye fixation times: word frequency effects and individual differences. Schilling

HH, et al. **Mem Cognit** 1998 Nov;26(6):1270–81

Methodological issues in cross-syndrome comparisons: matching procedures, sensitivity (Se), and specificity (Sp) [comment] Mervis CB, et al.
Monogr Soc Res Child Dev 1999;64(1):115–30; discussion 131–9. Comment on: Monogr Soc Res Child Dev 1999 ;64(1):1–114.

Human cloning [letter] [see comments] Effros RM.
N Engl J Med 1998 Nov 19;339(21):1558; discussion 1559 . Comment in: N Engl J Med 1998 Jul 9;339(2):122–5.

Neuroendocrine-related effects of long-term, 'binge' cocaine administration: diminished individual differences in stress-induced corticosterone response. Sarnyai Z, et al. **Neuroendocrinology** 1998 Nov;68(5):334–44

Areas 3a, 3b, and 1 of human primary somatosensory cortex. Geyer S, et al. **Neuroimage** 1999 Jul;10(1):63–83

Studies of individual differences as a method for discriminating the stages of acquisition of a conditioned reflex. Savonenko AV, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):295–303

Individual differences in textural segregation. Irwin-Chase H, et al. **Percept Mot Skills** 1999 Apr;88(2):485–95

P300 habituation patterns: individual differences from ultradian rhythms. Lin E, et al. **Percept Mot Skills** 1999 Jun;88(3 Pt 2):1111–25

Connectionist investigations of individual differences in Stroop performance. Phaf RH, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):899–914 (21 ref.)

Group and individual gustatory reaction times and Piéron's law. Bonnet C, et al. **Physiol Behav** 1999 Jun;66(4):549–58

Individual differences in radial maze performance and locomotor activity in the meadow vole, Microtus pennsylvanicus. Teskey GC, et al. **Physiol Behav** 1998 Dec 1;65(3):555–61

Individual differences in trajectory of intellectual development over 45 years of adulthood. Arbuckle TY, et al. **Psychol Aging** 1998 Dec;13(4):663–75

Individual differences in P3 scalp distribution in older adults, and their relationship to frontal lobe function. Fabiani M, et al. **Psychophysiology** 1998 Nov;35(6):698–708

Perceived stress, physiologic stress arousal, and premenstrual symptoms: group differences and intra-individual patterns. Woods NF, et al. **Res Nurs Health** 1998 Dec;21(6):511–23

Individual differences, perceived task characteristics, and preferences for teaching and coaching. Chelladurai P, et al. **Res Q Exerc Sport** 1999 Jun;70(2):179–89

Individual and social determinants of shiftwork tolerance. Nachreiner F. **Scand J Work Environ Health** 1998;24 Suppl 3:35–42 (50 ref.)

Paradigms and personhood: a deepening of the dilemmas in ethics and medical ethics. Erde EL. **Theor Med Bioeth** 1999 Apr;20(2):141–60

An individualized teaching and self-medication program to promote compliance in newly transplanted pediatric patients. Girvan C, et al. **Transplant Proc** 1999 Jun; 31(4A):73S–74S

[Is the history of ideas useful for the clinician? The case of the concept of individuality] Fantini B.
Rev Med Suisse Romande 1998 Dec;118(12):995–1000 **(Fre)**

[The crossover effect of the propositional text representation and the mental model:the role of individual differences in spatial imagery ability] Dutke S. **Z Exp Psychol** 1999; 46(3):164–76 (Eng. Abstr.) **(Ger)**

[Individual differences in spatial organization of cortical electrical activity during formation of a set to visual stimuli] Cheremushkin EA. **Fiziol Cheloveka** 1998 Sep-Oct; 24(5):129–31 **(Rus)**

[The individual typological characteristics of normal basic personality traits and their EEG correlations] Ivashchenko OI, et al. **Fiziol Cheloveka** 1999 Mar-Apr;25(2):46–55 **(Rus)**

INDIVIDUATION

The influence of big brothers on the separation-individuation of adolescents from single-parent families. Saintonge S, et al. **Adolescence** 1998 Summer;33(130):343–53

Group psychotherapy treatment of borderline personalities. Roller B, et al. **Int J Group Psychother** 1999 Jul; 49(3):369–85

A model of parental representations, second individuation, and psychological adjustment in late adolescence. Boles SA. **J Clin Psychol** 1999 Apr;55(4):497–512

Adolescent individuation and alcohol use. Baer PE, et al. **J Stud Alcohol Suppl** 1999 Mar;13:52–62

Expressed emotion and differentiation of self in the relatives of stable schizophrenia outpatients. Docherty NM, et al. **Psychiatry** 1998 Winter;61(4):269–78

Theoretical and treatment issues of personality disorders in individualistic and collectivistic societies. Kim HA.
Psychiatry Clin Neurosci 1998 Dec;52 Suppl:S242–5 (12 ref.)

INDO-PACIFIC BEAKED WHALE see **WHALES**

INDOCYANINE GREEN

Measurement of x-ray attenuation coefficients of aqueous solutions of indocyanine green and glycated chitosan. Xu F, et al. **Med Phys** 1999 Jul;26(7):1371–4

ADMINISTRATION & DOSAGE

[Rapid pulse injection of indocyanine green angiography for evaluation of choroidal venous circulation] Kano K.
Nippon Ganka Gakkai Zasshi 1999 Aug;103(8):569–75 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Evaluating new retinal imaging techniques [letter; comment] Fritsche PL, et al. **Arch Ophthalmol** 1999 Jun;117(6):846–7 . Comment on: Arch Ophthalmol 1998 Apr;116(4):521–2.

ANALOGS & DERIVATIVES

Synthesis and reactivities of
3-indocyanine-green-acyl-1,3-thiazolidine-2-thione (ICG-ATT) as a new near-infrared fluorescent-labeling reagent. Hirata T, et al. **Bioorg Med Chem** 1998 Nov; 6(11):2179–84

Hypotensive shock as a complication of infracyanine green injection. Bonte CA, et al. **Retina** 1998;18(5):476–7

ANALYSIS

Measurement of blood concentration of indocyanine green by pulse dye densitometry--comparison with the conventional spectrophotometric method. Imai T, et al. **J Clin Monit Comput** 1998 Dec;14(7–8):477–84

Photostability and thermal stability of indocyanine green. Holzer W, et al. **J Photochem Photobiol B** 1998 Dec; 47(2–3):155–64

CHEMISTRY

Non-covalent labeling of human serum albumin with indocyanine green: a study by capillary electrophoresis with diode laser-induced fluorescence detection. Moody ED, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11; 729(1–2):55–64

DIAGNOSTIC USE

Indocyanine green videoangiography and color Doppler imaging in Behçet's disease. Atmaca LS, et al.
Acta Ophthalmol Scand 1999 Aug;77(4):444–7

Indocyanine green angiography of retinal pigment epithelial tears. Giovannini A, et al. **Acta Ophthalmol Scand** 1999 Feb;77(1):83–7

Indocyanine green angiography in isolated primary retinal arterial macroaneurysms. Gomez-Ulla F, et al.
Acta Ophthalmol Scand 1998 Dec;76(6):671–4

Simultaneous indocyanine green and fluorescein angiography in retinal pigment epithelium tear using the confocal scanning laser ophthalmoscope. Axer-Siegel R, et al.
Am J Ophthalmol 1999 Sep;128(3):331–9

Indocyanine green angiography in enlarged blind spot syndrome. Pece A, et al. **Am J Ophthalmol** 1998 Oct; 126(4):604–7

Indocyanine green angiographic features in tuberculous chorioretinitis. Wolfensberger TJ, et al.
Am J Ophthalmol 1999 Mar;127(3):350–3

Blood volume measurement at the bedside using ICG pulse spectrophotometry [see comments] Haruna M, et al.
Anesthesiology 1998 Dec;89(6):1322–8. Comment in: Anesthesiology 1998 Dec;89(6):1310–2.

Evaluation of the circulation of reconstructive flaps using laser-induced fluorescence of indocyanine green. Still J, et al. **Ann Plast Surg** 1999 Mar;42(3):266–74

Ratio of indocyanine green and glucose dilutions detects capillary protein leakage following endotoxin injection in dogs. Sakai I, et al. **Br J Anaesth** 1998 Aug;81(2):193–7

Indocyanine green angiographic features prognostic of visual outcome in the natural course of patients with age related macular degeneration. Obana A, et al. **Br J Ophthalmol** 1999 Apr;83(4):429–37

Zinn-Haller arterial ring observed by ICG angiography in high myopia [see comments] Ohno-Matsui K, et al.
Br J Ophthalmol 1998 Dec;82(12):1357–62. Comment in: Br J Ophthalmol 1998 Dec;82(12):1351.

Fluorescein and indocyanine green angiography in arteritic anterior ischaemic optic neuropathy [letter] Sadun F, et al. **Br J Ophthalmol** 1998 Nov;82(11):1344–5

Indocyanine green guided laser photocoagulation in patients with occult choroidal neovascularisation. Weinberger AW, et al. **Br J Ophthalmol** 1999 Feb;83(2):168–72

Experimental study of liver dysfunction evaluated by direct indocyanine green clearance using near infrared spectroscopy. El-Desoky A, et al. **Br J Surg** 1999 Aug; 86(8):1005–11

Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Lam CM, et al. **Br J Surg** 1999 Aug;86(8):1012–7

Detection of capillary protein leakage by glucose and indocyanine green dilutions during the early post-burn period. Ishihara H, et al. **Burns** 1998 Sep;24(6):525–31

Indocyanine green angiography of central serous chorioretinopathy. Chen SJ, et al.
Chung Hua I Hsueh Tsa Chih (Taipei) 1999 Sep; 62(9):605–13

Another alternative for cardiac output measurement--pulse dye-densitometry [letter] Iijima T. **Crit Care Med** 1999 Aug;27(8):1693–4

Preoperative detection of occult enterovesical fistulas in patients with Crohn's disease: efficacy of oral or rectal administration of indocyanine green solution. Sou S, et al.
Dis Colon Rectum 1999 Feb;42(2):266–70

Indocyanine green angiographic findings in a case of punctate inner choroidopathy. Akman A, et al.
Eur J Ophthalmol 1998 Jul-Sep;8(3):191–4

Indocyanine green angiography of optic nerve head melanocytoma. Kadayifcilar S, et al. **Eur J Ophthalmol** 1999 Jan-Mar;9(1):68–70

Posterior uveitis: new insights provided by indocyanine green angiography [editorial] Herbort CP. **Eye** 1998;12 (Pt 5):757–9

Indocyanine green angiography in inflammatory eye disease. Howe L, et al. **Eye** 1998;12 (Pt 5):761–7

Indocyanine green angiographic findings in sympathetic ophthalmia. Bernasconi O, et al.
Graefes Arch Clin Exp Ophthalmol 1998 Aug;236(8):635–8

Indocyanine green iris angiography of lung carcinoma metastatic to the iris. Goto T, et al.
Graefes Arch Clin Exp Ophthalmol 1999 Sep;237(9):787–9

Evaluation of microvascularization pattern visibility in human choroidal melanomas: comparison of confocal fluorescein with indocyanine green angiography. Mueller AJ, et al. **Graefes Arch Clin Exp Ophthalmol** 1999 Jun; 237(6):448–56

Angiography of experimental autoimmune uveoretinitis with ultrastructural correlation. Okada AA, et al.
Graefes Arch Clin Exp Ophthalmol 1998 Nov; 236(11):865–72

Dark spots in late-phase indocyanine green angiographic studies in a patient with presumed ocular histoplasmosis syndrome. Weinberger AW, et al.
Graefes Arch Clin Exp Ophthalmol 1999 Jun;237(6):524–6

Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Nonami T, et al.
Hepatogastroenterology 1999 May-Jun;46(27):1669–72

Iris arteriovenous communication: clinical and angiographic features. Parodi MB, et al. **Int Ophthalmol** 1998;22(1):1–5

Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Shiraki K, et al. **Int Ophthalmol** 1997-98;21(5):245–53

Assessment by pulse dye-densitometry indocyanine green (ICG) clearance test of hepatic function of patients before cardiac surgery: its value as a predictor of serious postoperative liver dysfunction. Watanabe Y, et al.
J Cardiothorac Vasc Anesth 1999 Jun;13(3):299–303

A predominant increase of arterial beta-hydroxybutyrate concentration during partial hepatectomies in patients with impaired indocyanine green clearance test. Higashi S, et al. **J Surg Res** 1999 Feb;81(2):243–8

Burn wound assessment in porcine skin using indocyanine green fluorescence. Jerath MR, et al. **J Trauma** 1999 Jun; 46(6):1085–8

Fluorescein and indocyanine green videoangiography of choroidal melanomas. Atmaca LS, et al.
Jpn J Ophthalmol 1999 Jan-Feb;43(1):25–30

Indocyanine green angiography in classic choroidal neovascularization. Gelisken F, et al. **Jpn J Ophthalmol** 1998 Jul-Aug;42(4):300–3

A case of frosted branch angiitis with yellowish-white placoid lesions: fluorescein and indocyanine green angiography findings. Masuda K, et al.
Jpn J Ophthalmol 1998 Nov-Dec;42(6):484–9

Indocyanine green angiographic findings of lacquer cracks in pathologic myopia. Ohno-Matsui K, et al.
Jpn J Ophthalmol 1998 Jul-Aug;42(4):293–9

Progressive changes in the fluorescein and indocyanine green angiogram in acute idiopathic maculopathy. Akduman LS, et al. **Ocul Immunol Inflamm** 1999 Jun;7(2):97–102

Clinical significance of postlaser indocyanine green angiographic hot spots in age-related macular degeneration. Chen CJ, et al. **Ophthalmology** 1999 May; 106(5):925–9; discussion 929–31

Indocyanine green angiography in birdshot chorioretinopathy. Fardeau C, et al. **Ophthalmology** 1999 Oct;106(10):1928–34

Choroidal abnormalities in Behçet disease observed by simultaneous indocyanine green and fluorescein angiography with scanning laser ophthalmoscopy. Matsuo T, et al. **Ophthalmology** 1999 Feb;106(2):295–300

Optociliary veins in optic nerve sheath meningioma. Indocyanine green videoangiography findings.
Muci-Mendoza R, et al. **Ophthalmology** 1999 Feb; 106(2):311–8

Evaluating persistent and recurrent choroidal neovascularization. The role of indocyanine green angiography. Regillo CD, et al. **Ophthalmology** 1998 Oct; 105(10):1821–6

Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes: a revisitation using dynamic indocyanine green angiography. Staurenghi G, et al.
Ophthalmology 1998 Dec;105(12):2297–305

Indocyanine green angiographic features in ocular sarcoidosis. Wolfensberger TJ, et al. **Ophthalmology** 1999 Feb;106(2):285–9

Indocyanine green angiography features in toxoplasmic retinochoroiditis. Auer C, et al. **Retina** 1999;19(1):22–9

Indocyanine green angiography: an evaluation of image enhancement for the identification of occult choroidal neovascular membranes. Maberley DA, et al. **Retina** 1999; 19(1):37–44

Silent occult choroidal vascular abnormalities. Piccolino FC, et al. **Retina** 1999;19(1):30–6

INDOCYANINE GREEN

Fluorescein and indocyanine green angiographic findings in congenital optic disk pit associated with macular detachment. Theodossiadis GP, et al. **Retina** 1999; 19(1):6–11

Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Uyama M, et al. **Retina** 1999;19(1):12–21

Indocyanine green versus fluorescein angiography in the differential diagnosis of arteritic and nonarteritic anterior ischemic optic neuropathy. Valmaggia C, et al. **Retina** 1999; 19(2):131–4

Fluorescein and indocyanine green angiography in vascular chorioretinal diseases. Brancato R, et al. **Semin Ophthalmol** 1998 Dec;13(4):189–98 (29 ref.)

Intraoperative visualization of coronary artery fistula using medical dye [letter; comment] Wollert HG, et al. **Thorac Cardiovasc Surg** 1998 Dec;46(6):382–3. Comment on: Thorac Cardiovasc Surg 1997 Dec;45(6):287–94.

[Indocyanine green angiography of basal laminar drusen in the retinal pigment epithelium associated with vitelliform macular degeneration] Quaranta M, et al. **J Fr Ophtalmol** 1998 Mar;21(3):185–90 (Eng. Abstr.) **(Fre)**

[Rapid pulse injection of indocyanine green angiography for evaluation of choroidal venous circulation] Kano K. **Nippon Ganka Gakkai Zasshi** 1999 Aug;103(8):569–75 (Eng. Abstr.) **(Jpn)**

[Histological proof of indocyanine green angiography--healthy eyes] Matsubara T, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jul;103(7):497–505 (Eng. Abstr.) **(Jpn)**

[Angiographic findings and histological localization of indocyanine green in N-methyl-N-nitrosourea induced retinal degeneration in rats] Nagai Y, et al. **Nippon Ganka Gakkai Zasshi** 1999 Jul;103(7):489–96 (Eng. Abstr.) **(Jpn)**

[Comparison with indocyanine green angiography and immunohistochemical study of choroidal neovascular membrane in age-related macular degeneration] Nakajima M, et al. **Nippon Ganka Gakkai Zasshi** 1999 Mar; 103(3):252–8 (Eng. Abstr.) **(Jpn)**

METABOLISM

Detection of histamine-induced capillary protein leakage and hypovolaemia by determination of indocyanine green and glucose dilution method in dogs. Suzuki A, et al. **Intensive Care Med** 1999 Mar;25(3):304–10

PHARMACOKINETICS

Effects of LPS on transport of indocyanine green and alanine uptake in perfused rat liver. Lund M, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):G91–100

Estimation of blood flow heterogeneity in human skeletal muscle using intravascular tracer data: importance for modeling transcapillary exchange. Vicini P, et al. **Ann Biomed Eng** 1998 Sep–Oct;26(5):764–74

No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. Joo EH, et al. **Arch Pharm Res** 1998 Aug;21(4):411–7

Indocyanine green clearance test in non-cirrhotic hepatitis patients: a comparison and analysis between conventional blood sampling method and Finger Piece Monitoring method. Su MY, et al. **Chang Keng I Hsueh Tsa Chih** 1999 Mar;22(1):17–23

Indocyanine green clearance reflects reperfusion injury following liver transplantation and is an early predictor of graft function. Plevris JN, et al. **J Hepatol** 1999 Jan; 30(1):142–8

Simulation of the initial concentration-time course after intravenous application of the drug. Schröder T, et al. **Medinfo** 1998;9 Pt 1:376–9

Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment. Andersen V, et al. **Scand J Gastroenterol** 1999 Jun;34(6):618–22

Liver blood flow changes during laparoscopic surgery in pigs. A study of hepatic indocyanine green removal. Tuñón MJ, et al. **Surg Endosc** 1999 Jul;13(7):668–72

Indocyanine green clearance as a marker of graft function in liver transplantation. Igea J, et al. **Transplant Proc** 1999 Sep;31(6):2447–8

TOXICITY

Photo-oxidative killing of human colonic cancer cells using indocyanine green and infrared light. Bäumler W, et al. **Br J Cancer** 1999 May;80(3–4):360–3

INDOLEACETIC ACIDS

ANALYSIS

Measurement of soluble tryptophan and total indole-3-acetic acid in Arabidopsis by capillary electrophoresis. Ouyang J, et al. **Anal Biochem** 1999 Jun 15;271(1):100–2

CHEMICAL SYNTHESIS

New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents. Menciu C, et al. **J Med Chem** 1999 Feb 25;42(4):638–48

CHEMISTRY

1-Isobutyl-2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-3-indoleacetic acid. Deepthi S, et al. **Acta Crystallogr C** 1999 Jan 15;55 (Pt 1):100–2

METABOLISM

Oxidation of indole-3-acetic acid by dioxygen catalysed by plant peroxidases: specificity for the enzyme structure. Savitsky PA, et al. **Biochem J** 1999 Jun 15;340 (Pt 3):579–83

Evidence for indole-3-acetic acid binding site in plant peroxidases. Structural similarity between peroxidases and auxin-binding proteins. Savitsky PA, et al. **Biochemistry (Mosc)** 1998 Jun;63(6):629–33

Synthesis and pharmacological evaluation of benzofuran-acetamides as "antinecophobic" mitochondrial DBI receptor complex ligands. Liao Y, et al. **Bioorg Med Chem Lett** 1998 Aug 18;8(16):2099–102

Redundancy as a way of life - IAA metabolism. Normanly J, et al. **Curr Opin Plant Biol** 1999 Jun;2(3):207–13 (62 ref.)

Biosynthesis of indole-3-acetic acid in Azospirillum brasilense. Insights from quantum chemistry. Zakharova EA, et al. **Eur J Biochem** 1999 Feb;259(3):572–6

Toward targeted "oxidation therapy" of cancer: peroxidase-catalysed cytotoxicity of indole-3-acetic acids. Folkes LK, et al. **Int J Radiat Oncol Biol Phys** 1998 Nov 1;42(4):917–20

IAR3 encodes an auxin conjugate hydrolase from Arabidopsis. Davies RT, et al. **Plant Cell** 1999 Mar; 11(3):365–76

Metabolism of indole-3-acetic acid in Arabidopsis. Ostin A, et al. **Plant Physiol** 1998 Sep;118(1):285–96

PHARMACOLOGY

Effect of indole acetic acid on oxygen metabolism in cultured rat neutrophil. Pires de Melo M, et al. **Gen Pharmacol** 1998 Oct;31(4):573–8

Characterization of a protein kinase gene responsive to auxin and gibberellin in cucumber hypocotyls. Chono M, et al. **Plant Cell Physiol** 1998 Sep;39(9):958–67

Differential regulation of genes encoding 1-aminocyclopropane-1-carboxylate (ACC) synthase in etiolated pea seedlings: effects of indole-3-acetic acid, wounding, and ethylene. Peck SC, et al. **Plant Mol Biol** 1998 Dec;38(6):977–82

Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans. Kreiss C, et al. **Regul Pept** 1998 Jun 30;74(2–3):143–9

TOXICITY

Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Folkes LK, et al. **Biochem Pharmacol** 1999 Feb 15;57(4):375–82

INDOLEAMINE 2,3-DIOXYGENASE see **TRYPTOPHAN OXYGENASE**

INDOLES

Ultrasensitive detection of closely related angiotensin I peptides using capillary electrophoresis with near-infrared laser-induced fluorescence detection. Baars MJ, et al. **Anal Chem** 1999 Feb 1;71(3):667–71

Astra blue and basic fuchsin double staining of plant materials. Kraus JE, et al. **Biotech Histochem** 1998 Sep; 73(5):235–43

Indole-positive Vibrio vulnificus isolated from disease outbreaks on a Danish eel farm. Dalsgaard I, et al. **Dis Aquat Organ** 1999 Feb 26;35(3):187–94

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

Denatured states of human carbonic anhydrase II: an NMR study of hydrogen/deuterium exchange at tryptophan-indole-H(N) sites. Jonasson P, et al. **FEBS Lett** 1999 Feb 26;445(2–3):361–5

Observations of high iron diamine-alcian blue stain in uterine cervical glandular lesions. Kase H, et al. **Gynecol Obstet Invest** 1999;48(1):56–60

Microwave staining of intestinal whole-mount preparations with Cuprolinic blue. Van Ginneken C, et al. **Histochem J** 1998 Oct;30(10):703–9

Chemiluminescent assay of beta-D-galactosidase based on indole luminescence. Arakawa H, et al. **J Biolumin Chemilumin** 1998 Nov–Dec;13(6):349–54

Microwave staining of enteric neurons using cuprolinic blue (Quinolinic phthalocyanin) combined with enzyme histochemistry and peroxidase immunohistochemistry. Van Ginneken CJ, et al. **J Histochem Cytochem** 1999 Jan; 47(1):13–22

2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. Earl RA, et al. **J Med Chem** 1998 Nov 5;41(23):4615–22

Measurement of [Ca2+]i in cell suspensions using indo-1. Nelemans A. **Methods Mol Biol** 1999;114:41–7 (21 ref.)

Visualization of membrane domains in Escherichia coli. Fishov I, et al. **Mol Microbiol** 1999 Jun;32(6):1166–72

ADMINISTRATION & DOSAGE

Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Moisan J, et al. **Am J Health Syst Pharm** 1999 Jul 15; 56(14):1437–41

Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Meyrier A, et al. **Am J Hypertens** 1998 Sep;11(9):1087–92

Single-dose tropisetron for preventing postoperative nausea and vomiting after breast surgery. Chan MT, et al. **Anesth Analg** 1998 Oct;87(4):931–5

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. van Gijn R, et al. **Anticancer Drugs** 1999 Jan;10(1):17–23

In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Takahata M, et al. **Antimicrob Agents Chemother** 1999 May;43(5):1077–84

Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. López-Aguilar E, et al. **Arch Med Res** 1999 Mar–Apr;30(2):128–31

The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Riegger G, et al. **Atherosclerosis** 1999 May; 144(1):263–70

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Rothe G, et al. **Atherosclerosis** 1999 May;144(1):251–61

Kinetic and equilibrium studies of incorporation of di-sulfonated aluminum phthalocyanine into unilamellar vesicles. Maman N, et al. **Biochim Biophys Acta** 1999 Aug 20;1420(1-2):168–78

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. Awada A, et al. **Br J Cancer** 1999 Mar;79(9–10):1454–61

Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Münstedt K, et al. **Br J Cancer** 1999 Feb;79(3–4):637–9

A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension. Jhee SS, et al. **Cephalalgia** 1999 Mar; 19(2):95–9

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Ballantyne CM, et al. **Circulation** 1999 Feb 16;99(6):736–43

Comparison of ondansetron and tropisetron combined with droperidol for the prevention of emesis in women with a history of post-operative nausea and vomiting. Koivuranta M, et al. **Eur J Anaesthesiol** 1999 Jun; 16(6):390–5

Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. Cordonnier DJ, et al. **J Am Soc Nephrol** 1999 Jun;10(6):1253–63

Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives [letter] Forette B. **J Hum Hypertens** 1999 Mar;13(3):211–3

Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo. Fukuta Y, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1013–8

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Bakris GL, et al. **Kidney Int** 1998 Oct;54(4):1283–9

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Coppes MJ, et al. **Med Pediatr Oncol** 1999 Aug;33(2):99–105

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group [published erratum appears in Neurology 1999 Jan 15;52(2):435] Lieberman A, et al. **Neurology** 1998 Oct;51(4):1057–62

Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism. Wittke R. **Sports Med** 1999 May;27(5):329–35

Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Dyker AG, et al. **Stroke** 1999 May; 30(5):986–92

Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Topouchian J, et al. **Stroke** 1999 May;30(5):1056–64

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Whitmore JB, et al. **Support Care Cancer** 1998 Sep;6(5):473–8

[The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil] Widimský J, et al. **Vnitr Lek** 1998 Jun;44(6):326–31 (Eng. Abstr.) **(Cze)**

[Pharmacy-clinic medication of the month. Naratriptan (naramig)] Scheen AJ. **Rev Med Liege** 1999 Mar; 54(3):189–91 (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

'Sleep attacks' attributed to new antiparkinsonian drugs [news] **Aust Fam Physician** 1999 Jul;28(7):737

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Gottsäter A, et al. **Blood Coagul Fibrinolysis** 1999 Apr;10(3):133-40

Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors. Koda RT, et al. **Cancer Chemother Pharmacol** 1999;43(6):489-96

Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. Dahlöf CG, et al. **Cephalalgia** 1998 Oct;18(8):546-51

A review of the safety and tolerability of sertindole. Hale AS. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S65-70 (22 ref.)

Drug-induced headaches [letter; comment] Dowson A. **Lancet** 1999 Jul 17;354(9174):254-5. Comment on: Lancet 1999 Jan 30;353(9150):378.

Headache after frequent use of serotonin agonists zolmitriptan and naratriptan [letter] [see comments] Limmroth V, et al. **Lancet** 1999 Jan 30;353(9150):378. Comment in: Lancet 1999 Apr 17;353(9161):1363. Comment in: Lancet 1999 Apr 17;353(9161):1363-4. Comment in: Lancet 1999 Jul 17;354(9174):254-5.

Acute cholestasis during long-term treatment with fluvastatin in a nephrotic patient [letter] Gascón A, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):1038

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Frucht S, et al. **Neurology** 1999 Jun 10;52(9):1908-10

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Leucht S, et al. **Schizophr Res** 1999 Jan 4;35(1):51-68

[Loss of consciousness during treatment with sertindole] Haberfellner EM. **Psychiatr Prax** 1999 May;26(3):150 **(Ger)**

ANALYSIS

Measurement of plasma S-adenosylmethionine and S-adenosylhomocysteine as their fluorescent isoindoles. Capdevila A, et al. **Anal Biochem** 1998 Nov 15;264(2):180-4

Production and characterization of monoclonal antibodies against fumitremorgin B. Liu J, et al. **Biomed Environ Sci** 1998 Dec;11(4):336-44

Immunoaffinity column as cleanup tool for a direct competitive enzyme-linked immunosorbent assay of cyclopiazonic acid in corn, peanuts, and mixed feed. Yu W, et al. **J AOAC Int** 1998 Nov-Dec;81(6):1169-75

Utility of certain pi-acceptors for the spectrophotometric determination of perindopril. Abdellatef HE. **J Pharm Biomed Anal** 1998 Sep;17(8):1267-71

Spectrophotometric and atomic absorption spectrometric determination of ramipril and perindopril through ternary complex formation with eosin and Cu(II). Abdellatef HE, et al. **J Pharm Biomed Anal** 1999 Jan;18(6):1021-7

Biosensor for enantioselective analysis of S-cilazapril, S-trandolapril, and S-pentopril. Aboul-Enein HY, et al. **Pharm Dev Technol** 1999 May;4(2):251-5

Biosensor for the enantioselective analysis of S-perindopril. Aboul-Enein HY, et al. **Prep Biochem Biotechnol** 1999 Feb; 29(1):55-61

ANTAGONISTS & INHIBITORS

GR 127935 reduces basal locomotor activity and prevents RU 24969-, but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Chaouloff F, et al. **Psychopharmacology (Berl)** 1999 Jan;141(3):326-31

BLOOD

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Dimmitt DC, et al. **Biopharm Drug Dispos** 1999 Jan;20(1):41-8

Measurement and pharmacokinetic study of unbound tropisetron in rat blood by microdialysis with high-performance liquid chromatography. Huang CT, et al. **Int J Pharm** 1999 May 25;182(2):237-42

The development of a sensitive and specific enzyme immunoassay for FK480, a novel cholecystokinin type-A receptor antagonist, in human plasma. Nozaki K, et al. **J Pharm Biomed Anal** 1998 Sep;17(8):1381-92

CHEMICAL SYNTHESIS

Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Silvestri R, et al. **Antivir Chem Chemother** 1998 Mar;9(2):139-48

New synthesis of substituted 2-carboxyindole derivatives: versatile introduction of a carbamoylethynyl moiety at the C-3 position. Hewkin CT, et al. **Arch Pharm (Weinheim)** 1999 Feb;332(2):55-8

Cycloalkyl indole-2-carboxylates as useful tools for mapping the "north-eastern" region of the glycine binding site associated with the NMDA receptor. Micheli F, et al. **Arch Pharm (Weinheim)** 1999 Mar;332(3):73-80

A search for new 5-HT1A/5-HT2A receptor ligands. In vitro and in vivo studies of 1-[omega-(4-aryl-1-piperazinyl)alkyl]indolin-2(1H)-ones. Mokrosz MJ, et al. **Arch Pharm (Weinheim)** 1998 Oct; 331(10):325-30

Synthesis and pharmacological evaluation of new (indol-3-yl)alkylamides and alkylamines acting as potential serotonin uptake inhibitors. Fouchard F, et al. **Arzneimittelforschung** 1999 Feb;49(2):96-105

Total synthesis and stereochemistry of cytoblastin. Moreno OA, et al. **Bioorg Med Chem** 1998 Aug;6(8):1243-54

Synthesis and biological activities of spiroheterocyclic growth hormone secretagogues. Chen MH, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1261-6

Synthesis and sar of 2- and 3-substituted 7-azaindoles as potential dopamine D4 ligands. Curtis NR, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):585-8

The novel cyclopropapyrroloindole(CPI) bisalkylators bearing methoxycarbonyl and trifluoromethyl groups. Fukuda Y, et al. **Bioorg Med Chem Lett** 1998 Jun 2; 8(11):1387-90

Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles. Hulme C, et al. **Bioorg Med Chem Lett** 1998 Jan 20;8(2):175-8

The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Hulme C, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1867-72

Orally active indole N-oxide PDE4 inhibitors. Hulme C, et al. **Bioorg Med Chem Lett** 1998 Nov 3;8(21):3053-8

A straightforward synthetic approach for roxindole. Lange JH, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):1055-6

Azepinoindole derivatives with high affinity for brain dopamine and serotonin receptors. Maryanoff BE, et al. **Bioorg Med Chem Lett** 1998 Apr 21;8(8):983-8

Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore. Mathvink RJ, et al. **Bioorg Med Chem Lett** 1999 Jul 5;9(13):1869-74

The synthesis and evaluation of benzannelated-azatoxins: the benzazatoxins. Miller TA, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1065-70

Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction. Neel DA, et al. **Bioorg Med Chem Lett** 1998 Jan 6;8(1):47-50

Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Ohkubo M, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1219-24

New growth hormone secretagogues: C-terminal modified sulfonamide-analogues of NN703. Peschke B, et al. **Bioorg Med Chem Lett** 1999 May 3;9(9):1295-8

Synthesis of pharmacologically active indoles. Hishmat OH, et al. **Boll Chim Farm** 1999 Jun;138(6):259-66

Prostanoids and related compounds. VII. Synthesis and inhibitory activity of 1-isoindolinone derivatives possessing inhibitory activity against thromboxane A2 analog (U-46619)-induced vasoconstriction. Kato Y, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr;47(4):529-35

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl) benzanilide derivatives. Matsuhisa A, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1566-79

4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II). Sawada K, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr; 47(4):481-91

(1-Benzylindole-3-yl)alkanoic acids; novel nonsteroidal inhibitors of steroid 5 alpha-reductase (I). Sawada K, et al. **Chem Pharm Bull (Tokyo)** 1998 Nov;46(11):1683-7

Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Pindur U, et al. **Curr Med Chem** 1999 Jan;6(1):29-69 (79 ref.)

Synthesis and pharmacological investigation of 9-methyl-1,2,3,4,6,7,12,12b-octahydro-7-oxo-indolo[2,3-a]quinolizine. Grandi T, et al. **Farmaco** 1999 Jul 30; 54(7):479-85

Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles. Merino I, et al. **Farmaco** 1999 Apr 30;54(4):255-64

Synthesis and D2-like binding affinity of 4,5-dihydro-1H-benzo[g]indole-3-carboxamide derivatives as conformationally restricted 5-phenyl-pyrrole-3-carboxamide analogs. Pinna GA, et al. **Farmaco** 1998 Oct-Nov;53(10-11):684-9

Preparation and EPR studies of lithium phthalocyanine radical as an oxymetric probe. Afeworki M, et al. **Free Radic Biol Med** 1998 Jul 1;25(1):72-8

New water-soluble duocarmycin derivatives: synthesis and antitumor activity of A-ring pyrrole compounds bearing beta-heteroarylacryloyl groups. Amishiro N, et al. **J Med Chem** 1999 Feb 25;42(4):669-76

Synthesis and antitumor activity of duocarmycin derivatives: modification of segment-A of A-ring pyrrole compounds. Amishiro N, et al. **J Med Chem** 1999 Jul 29;42(15):2946-60

5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. Atwell GJ, et al. **J Med Chem** 1999 Aug 26; 42(17):3400-11

3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. Chambers MS, et al. **J Med Chem** 1999 Feb 25; 42(4):691-705

delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. Coop A, et al. **J Med Chem** 1999 May 6; 42(9):1673-9

Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. Di Fabio R, et al. **J Med Chem** 1999 Sep 9;42(18):3486-93

Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. Gastpar R, et al. **J Med Chem** 1998 Dec 3;41(25):4965-72

Tetrahydrobenzindoles: selective antagonists of the 5-HT7 receptor. Kikuchi C, et al. **J Med Chem** 1999 Feb 25; 42(4):533-5

Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. Milbank JB, et al. **J Med Chem** 1999 Feb 25;42(4):649-58

Synthesis and serotonergic activity of substituted 2, N-benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl) -N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT(1B)-like receptor. Moloney GP, et al. **J Med Chem** 1999 Jul 15;42(14):2504-26

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. Schultz C, et al. **J Med Chem** 1999 Jul 29;42(15):2909-19

Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis. Shah JH, et al. **J Med Chem** 1999 Aug 12;42(16):3014-7

Potent 1,3-disubstituted-9H-pyrido[3,4-b]indoles as new lead compounds in antifilarial chemotherapy. Srivastava SK, et al. **J Med Chem** 1999 May 6;42(9):1667-72

Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor. Sternfeld F, et al. **J Med Chem** 1999 Feb 25;42(4):677-90

Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. Vangveravong S, et al. **J Med Chem** 1998 Dec 3; 41(25):4995-5001

Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles. van Niel MB, et al. **J Med Chem** 1999 Jun 17; 42(12):2087-104

Radiosynthesis of [11C]Lu 29-024: a potential radiotracer for 5HT2 receptors PET studies. Amokhtari M, et al. **Nucl Med Biol** 1998 Aug;25(6):517-22

CHEMISTRY

Substituted indole-2-carboxylates as potent antagonists of the glycine binding site associated with the NMDA receptor. Micheli F, et al. **Arch Pharm (Weinheim)** 1999 Aug;332(8):271-8 (36 ref.)

Molecular recognition between a new pentacyclic acridinium salt and DNA sequences investigated by optical spectroscopic techniques, proton nuclear magnetic resonance spectroscopy, and molecular modeling. Bostock-Smith CE, et al. **Biochemistry** 1999 May 25; 38(21):6723-31

Total synthesis and stereochemistry of cytoblastin. Moreno OA, et al. **Bioorg Med Chem** 1998 Aug;6(8):1243-54

Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Belliotti TR, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1499-502

Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands. de la Figuera N, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):43-8

Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors. Dominguez C, et al. **Bioorg Med Chem Lett** 1999 Apr 5;9(7):925-30

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors. Frenette R, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2391-6

Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones. Jaffar M, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):113-8

Azaindole derivatives with high affinity for the dopamine D4 receptor: synthesis, ligand binding studies and comparison of molecular electrostatic potential maps. Löber S, et al. **Bioorg Med Chem Lett** 1999 Jan 4; 9(1):97-102

Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors. Tamiz AP, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1619-24

The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. Merritt JE, et al. **Cancer Chemother Pharmacol** 1999; 43(5):371-8

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Zaharevitz DW, et al. **Cancer Res** 1999 Jun 1;59(11):2566-9

Cytotoxicity and DNA interaction of the enantiomers of 6-amino-3-(chloromethyl)-1-[(5,6,7-trimethoxyindol-2-yl)carbonyl]indo- line (amino-seco-CI-TMI). Tercel M, et al. **Chem Res Toxicol** 1999 Aug;12(8):700-6

Spectrophotometric determination of trace amounts of hemoglobin using the oxidative decomposition reaction of a copper(II)-phthalocyanine complex. Takahata K, et al. **Clin Chim Acta** 1999 May;283(1-2):129-38

1 - 1. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. Broadbent TA, et al. **Curr Med Chem** 1998 Oct; 5(5):337-52 (146 ref.)

1. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. Broadbent TA, et al. **Curr Med Chem** 1998 Dec; 5(6):469-91 (177 ref.)

Determination of the dissociation constants of ropinirole and some impurities and their quantification using capillary zone electrophoresis. Coufal P, et al. **J Chromatogr B Biomed Sci Appl** 1998 Dec 11; 720(1-2):197-204

Matrix-assisted laser desorption/ionization time-of-flight and nano-electrospray ionization ion trap mass spectrometric characterization of 1-cyano-2-substituted-benz[f]isoindole derivatives of peptides for fluorescence detection. Linnemayr K, et al. **J Mass Spectrom** 1999 Apr;34(4):427-34

32-Indolyl ether derivatives of ascomycin: three-dimensional structures of complexes with FK506-binding protein. Becker JW, et al. **J Med Chem** 1999 Jul 29;42(15):2798-804

Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. Di Fabio R, et al. **J Med Chem** 1999 Sep 9;42(18):3486-93

New generation dopaminergic agents. 6. Structure-activity relationship studies of a series of 4-(aminoethoxy)indole and 4-(aminoethoxy)indolone derivatives based on the newly discovered 3-hydroxyphenoxyethylamine D2 template. Mewshaw RE, et al. **J Med Chem** 1999 Jun 3; 42(11):2007-20

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. Ren J, et al. **J Med Chem** 1999 Sep 23; 42(19):3845-51

Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. Shim JY, et al. **J Med Chem** 1998 Nov 5; 41(23):4521-32

Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. Wang S, et al. **J Med Chem** 1999 Sep 9;42(18):3436-46

Microspheres of chitosan/poly(vinylalcohol) incorporating tetrasulphonated copper (II) phthalocyanine: preparation and characterization. Stolberg J, et al. **J Microencapsul** 1999 Jul-Aug;16(4):431-8

Electron and light microscopy studies on particulate EPR spin probes lithium phthalocyanine, fusinite and synthetic chars. Norby SW, et al. **J Microsc** 1998 Nov;192 (Pt 2):172-85

The characterisation of three substituted zinc phthalocyanines of differing charge for use in photodynamic therapy. A comparative study of their aggregation and photosensitising ability in relation to mTHPC and polyhaematoporphyrin. Ball DJ, et al. **J Photochem Photobiol B** 1998 Aug 21;45(1):28-35

Direct methods in electron crystallography: image processing and solving incommensurate structures. Fan HF. **Microsc Res Tech** 1999 Jul 15;46(2):104-16

Melting studies of short DNA hairpins containing the universal base 5-nitroindole. Vallone PM, et al. **Nucleic Acids Res** 1999 Sep 1;27(17):3589-96

[Chemistry of indoles: new reactivities of indole nucleus and its synthetic application] Murakami Y. **Yakugaku Zasshi** 1999 Jan;119(1):35-60 (50 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children. Tejedor I, et al. **Pharm World Sci** 1999 Apr; 21(2):60-8

ISOLATION & PURIFICATION

Conodiparines A-D, new bisindoles from Tabernaemontana. Reversal of vincristine-resistance with cultured cells. Kam TS, et al. **Bioorg Med Chem Lett** 1998 Jul 7;8(13):1693-6

High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Roberge M, et al. **Cancer Res** 1998 Dec 15;58(24):5701-6

Isolation of indole alkaloids from Catharanthus roseus by centrifugal partition chromatography in the pH-zone refining mode. Renault JH, et al. **J Chromatogr A** 1999 Jul 23;849(2):421-31

A new indole derivative from the red alga Chondria atropurpurea. Isolation, structure determination, and anthelmintic activity. Davyt D, et al. **J Nat Prod** 1998 Dec; 61(12):1560-3

Pyrrolidinoindoline alkaloids from Psychotria oleoides and Psychotria lyciiflora. Jannic V, et al. **J Nat Prod** 1999 Jun; 62(6):838-43

METABOLISM

High affinity of SDZ HTF-919 related molecules for calf and human caudate 5-HT4 receptors. Hoyer D, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:267-8

Regional differences in production of aflatoxin B1 and cyclopiazonic acid by soil isolates of aspergillus flavus along a transect within the United States. Horn BW, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1444-9

Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Yoon JH, et al. **Arch Pharm Res** 1998 Aug; 21(4):385-90

S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Barelli H, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):657-61

Differences in ethidium bromide and 4'-6-diamidino-2-phenylindole staining profiles with regard to DNA fragmentation during apoptosis. Shono M, et al. **Biochem Mol Biol Int** 1998 Dec;46(5):1055-61

Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites. Bailey SM, et al. **Biochem Pharmacol** 1998 Sep 1;56(5):613-21

Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3'-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Chang YC, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):825-34

A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Galzigna L, et al. **Biochim Biophys Acta** 1999 May 24;1427(3):329-36

Nitric oxide-induced oxidation of 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid under aerobic conditions: non-enzymatic route to melanin pigments of potential relevance to skin (photo)protection. Novellino L, et al. **Biochim Biophys Acta** 1998 Sep 16;1425(1):27-35

PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Ashwood V, et al. **Bioorg Med Chem Lett** 1998 Sep 22; 8(18):2589-94

The cruciferous phytoalexins brassinin and cyclobrassinin are intermediates in the biosynthesis of brassilexin. Pedras MS, et al. **Bioorg Med Chem Lett** 1998 Nov 3;8(21):3037-8

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Dimmitt DC, et al. **Biopharm Drug Dispos** 1999 Jan;20(1):41-8

Transient studies of light-adapted cultures of hairy roots of Catharanthus roseus: growth and indole alkaloid accumulation. Bhadra R, et al. **Biotechnol Bioeng** 1998 Dec 20;60(6):670-8

Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. Harper EA, et al. **Br J Pharmacol** 1999 Mar; 126(6):1504-12

Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Murata S, et al. **Br J Pharmacol** 1999 May;127(1):19-26

Neuroprotective action of a novel compound--M50463--in primary cultured neurons. Shimojo M, et al. **Brain Res** 1999 Jan 2;815(1):131-9

Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment. ThyagaRajan S, et al. **Brain Res Bull** 1999 Mar 15;48(5):513-20

Transcriptional activity of quinone methides derived from the tumor promoter butylated hydroxytoluene in HepG2 cells. Desjardins JP, et al. **Cancer Lett** 1998 Sep 25; 131(2):201-7

[3H]MDL 105,519 binds with equal high affinity to both assembled and unassembled NR1 subunits of the NMDA receptor. Chazot PL, et al. **Eur J Pharmacol** 1998 Jul 17; 353(1):137-40

Muscarinic interactions of bisindolylmaleimide analogues. Lazareno S, et al. **Eur J Pharmacol** 1998 Nov 6; 360(2-3):281-4

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Napier C, et al. **Eur J Pharmacol** 1999 Mar 5;368(2-3):259-68

Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. Stiborová M, et al. **Exp Toxicol Pathol** 1999 Jul;51(4-5):421-7

Lipoxygenase/H2O2-catalyzed oxidation of dihdroxyindoles: synthesis of melanin pigments and study of their antioxidant properties. Blarzino C, et al. **Free Radic Biol Med** 1999 Feb;26(3-4):446-53

An indigo-reducing moderate thermophile from a woad vat, Clostridium isatidis sp. nov. Padden AN, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1025-31

Indoleamine-accumulating amacrine cells are presynaptic to rod bipolar cells through GABA(C) receptors. Fletcher EL, et al. **J Comp Neurol** 1999 Oct 11;413(1):155-67

Natural and in vitro coproduction of cyclopiazonic acid and aflatoxins. Martins ML, et al. **J Food Prot** 1999 Mar; 62(3):292-4

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. Ren J, et al. **J Med Chem** 1999 Sep 23; 42(19):3845-51

Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. Dkhissi O, et al. **J Neuroendocrinol** 1998 Nov;10(11):863-9

Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. Lindahl A, et al. **J Pharm Pharmacol** 1998 Jul;50(7):737-44

Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes. Decreau R, et al. **J Photochem Photobiol B** 1999 Jan;48(1):48-56

Changes with age in daytime and nighttime contents of melatonin, indoleamines, and catecholamines in the pineal gland: a comparative study in rat and Syrian hamster. Miguez JM, et al. **J Pineal Res** 1998 Sep;25(2):106-15

Alpha-stat calibration of indo-1 fluorescence and measurement of intracellular free calcium in rat ventricular cells at different temperatures. Wang SQ, et al. **Life Sci** 1999;65(9):871-7

Reducing compounds initiate the TRP2-catalyzed conversion of L-dopachrome to DHICA [letter] Rosengren E, et al. **Melanoma Res** 1998 Oct;8(5):469-70

Production of cyclopiazonic acid by aflatoxigenic and non-aflatoxigenic strains of Aspergillus flavus. Cvetnić Z, et al. **Nahrung** 1998 Oct;42(5):321-3

Big deal about a little insulin [news] Flier JS. **Nat Med** 1999 Jun;5(6):614-5

Complex polyamine effects on [3H]MDL 105,519 binding to the NMDA receptor glycine site. Sharma TA, et al. **Neurochem Int** 1998 Aug;33(2):155-9

Rate of accumulation of Luxol Fast Blue staining material and mitochondrial ATP synthase subunit 9 in motor neuron degeneration mice. Rodman JS, et al. **Neurochem Res** 1998 Oct;23(10):1291-6

5-Methoxytryptophol rhythms in the chick pineal gland: effect of environmental lighting conditions. Zawilska JB, et al. **Neurosci Lett** 1998 Jul 17;251(1):33-6

Linkers designed to intercalate the double helix greatly facilitate DNA alkylation by triplex-forming oligonucleotides carrying a cyclopropapyrroloindole reactive moiety. Dempcy RO, et al. **Nucleic Acids Res** 1999 Jul 15;27(14):2931-7

Solution structure of DAPI selectively bound in the minor groove of a DNA T.T mismatch-containing site: NMR and molecular dynamics studies. Trotta E, et al. **Nucleic Acids Res** 1998 Oct 15;26(20):4706-13

Camalexin accumulation in Arabis lyrata. Zook M, et al. **Phytochemistry** 1998 Dec;49(8):2287-9

Insect melanogenesis. II. Inability of Manduca phenoloxidase to act on 5,6-dihydroxyindole-2-carboxylic acid. Sugumaran M, et al. **Pigment Cell Res** 1999 Apr; 12(2):118-25

Biosynthesis of camalexin from tryptophan pathway intermediates in cell-suspension cultures of Arabidopsis. Zook M. **Plant Physiol** 1998 Dec;118(4):1389-93

Disposition of ropinirole in animals and man. Ramji JV, et al. **Xenobiotica** 1999 Mar;29(3):311-25

PHARMACOKINETICS

Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Brouard R, et al. **Adv Exp Med Biol** 1998;449:455-65

Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. van Gijn R, et al. **Anticancer Drugs** 1999 Jan;10(1):17-23

Oral bioavailability and pharmacokinetics of the new insulin sensitizer DRF-2189 in Wistar rats. Jajoo HK, et al. **Arzneimittelforschung** 1999 Feb;49(2):133-6

Kinetic and equilibrium studies of incorporation of di-sulfonated aluminum phthalocyanine into unilamellar vesicles. Maman N, et al. **Biochim Biophys Acta** 1999 Aug 20;1420(1-2):168-78

Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Wolfe LA, et al. **Bioconjug Chem** 1999 Jan-Feb;10(1):38-48

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. Dimmitt DC, et al. **Biopharm Drug Dispos** 1999 Jan; 20(1):29-39

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Dimmitt DC, et al. **Biopharm Drug Dispos** 1999 Jan;20(1):41-8

Evaluation of the effect of food on the pharmacokinetics of avitriptan. Marathe PH, et al. **Biopharm Drug Dispos** 1998 Sep;19(6):381-94

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Appel-Dingemanse S, et al. **Br J Clin Pharmacol** 1999 May; 47(5):483-91

Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. Ohtawa M, et al. **Br J Clin Pharmacol** 1999 Apr;47(4):383-9

Indole-3-propionate: a potent hydroxyl radical scavenger in

rat brain. Poeggeler B, et al. **Brain Res** 1999 Jan 9; 815(2):382–8

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Dimmitt DC, et al. **Cancer Chemother Pharmacol** 1999;43(2):126–32

Phase I clinical and pharmacokinetic study of carzelesin (U–80244) given daily for five consecutive days. Wolff I, et al. **Clin Cancer Res** 1996 Oct;2(10):1717–23

The 3–hydroxy–3–methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P–450 and implications for metabolic drug interactions. Fischer V, et al. **Drug Metab Dispos** 1999 Mar;27(3):410–6

Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Thalamas C, et al. **Eur J Clin Pharmacol** 1999 Jun;55(4):299–303

Analysis and pharmacokinetics of cyclopiazonic acid in market weight pigs. Byrem TM, et al. **J Anim Sci** 1999 Jan;77(1):173–9

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. Dimmitt DC, et al. **J Clin Pharmacol** 1998 Sep;38(9):798–806

First time in human for GV196771: interspecies scaling applied on dose selection. Iavarone L, et al. **J Clin Pharmacol** 1999 Jun;39(6):560–6

Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects. Sharma A, et al. **J Clin Pharmacol** 1999 Jul;39(7):685–94

Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose–escalation studies. Wong SL, et al. **J Pharm Sci** 1998 Dec;87(12):1629–31

In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. Marathe PH, et al. **J Pharmacokinet Biopharm** 1998 Feb;26(1):1–20

Liposome–bound Zn (II)–phthalocyanine. Mechanisms for cellular uptake and photosensitization. Rodal GH, et al. **J Photochem Photobiol B** 1998 Sep;45(2–3):150–9

Surface activity and concentration dependent intestinal permeability in the rat. Lindahl A, et al. **Pharm Res** 1999 Jan;16(1):97–102

Lack of a pharmacokinetic interaction at steady state between ropinirole and L–dopa in patients with Parkinson's disease. Taylor AC, et al. **Pharmacotherapy** 1999 Feb;19(2):150–6

A comparative study of the cellular uptake and photodynamic efficacy of three novel zinc phthalocyanines of differing charge. Ball DJ, et al. **Photochem Photobiol** 1999 Mar;69(3):390–6

Receptor–mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Brasseur N, et al. **Photochem Photobiol** 1999 Mar;69(3):345–52

Effects of Monastral blue on pulmonary arterial blood pressure and lung and liver particle retention in chickens. Weidner WJ, et al. **Poult Sci** 1999 Jun;78(6):878–82

PHARMACOLOGY

Effects of [Na+]o, [Ca2+]o and cyclopiazonic acid on decline of post–extrasystolic potentiation and twitch kinetics in guinea–pig and human myocardial preparations. Asgrimsson HJ, et al. **Acta Physiol Scand** 1999 Jul; 166(3):195–201

Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Brouard R, et al. **Adv Exp Med Biol** 1998;449:455–65

Designing safe drugs with stereochemistry in mind [editorial; comment] Po AL. **Adverse Drug React Toxicol Rev** 1998 Jun–Sep;17(2–3):60–2. Comment on: Adverse Drug React Toxicol Rev 1998 Jun–Sep;17(2–3):145–90.

CCK–A receptor antagonists have selective effects on nutrient–induced food intake suppression in rats. Trigazis L, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R323–30

Nitric oxide in the pathophysiology of hyperthermic brain injury. Influence of a new anti–oxidant compound H–290/51. A pharmacological study using immunohistochemistry in the rat. Alm P, et al. **Amino Acids** 1998;14(1–3):95–103

Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. Schobel HP, et al. **Angiology** 1998 Sep; 49(9):743–8

Behavioral effects of RS–45041–190, a selective I2 imidazoline ligand, in rats. Jett MF, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:369–71

Different modes of action of the imidazoline compound RX871024 in pancreatic beta–cells. Blocking of K+ channels, mobilization of Ca2+ from endoplasmic reticulum, and interaction with exocytotic machinery. Zaitsev SV, et al. **Ann N Y Acad Sci** 1999 Jun 21;881:241–52

Comparison of the patterns of DNA alkylation by phenol and amino seco–CBI–TMI compounds: use of a PCR method for the facile preparation of single end–labelled double–stranded DNA. Gieseg MA, et al. **Anticancer Drug Des** 1999 Feb;14(1):77–84

Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony–forming assay. Hidalgo M, et al. **Anticancer Drugs** 1999 Mar;10(3):295–302

Potential coanthracyclinic activity of pyridylmethylene–2–indolinones. Andreani A, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3407–9

Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara–C) and induction of cellular apoptosis. Nandy P, et al. **Anticancer Res** 1999 May–Jun;19(3A):1625–33

Anti–estrogenic activities of indole–3–carbinol in cervical cells: implication for prevention of cervical cancer. Yuan F, et al. **Anticancer Res** 1999 May–Jun;19(3A):1673–80

Synthesis and biological evaluation of 5H–indolo [3,2–b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L–737,126. Silvestri R, et al. **Antivir Chem Chemother** 1998 Mar;9(2):139–48

Pyrido [1,2a] indole derivatives identified as novel non–nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Taylor DL, et al. **Antivir Chem Chemother** 1999 Mar;10(2):79–86

Binding interactions and conformational changes induced by sulfonated aluminum phthalocyanines in human serum albumin. Gantchev TG, et al. **Arch Biochem Biophys** 1999 Jun 1;366(1):21–30

Antiinflammatory activity of the platelet–activating factor receptor antagonist A–85783. Travers J, et al. **Arch Dermatol Res** 1998 Oct;290(10):569–73

New synthesis of substituted 2–carboxyindole derivatives: versatile introduction of a carbamoylethynyl moiety at the C–3 position. Hewkin CT, et al. **Arch Pharm (Weinheim)** 1999 Feb;332(2):55–8

HMG–CoA reductase inhibitors reduce MMP–9 secretion by macrophages. Bellosta S, et al. **Arterioscler Thromb Vasc Biol** 1998 Nov;18(11):1671–8

S 17092–1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Barelli H, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):657–61

Effects of imidazoline derivative RX871024 on insulin, glucagon, and somatostatin secretion from isolated perfused rat pancreas. Efanova IB, et al. **Biochem Biophys Res Commun** 1998 Nov 9;252(1):162–5

Niemann–Pick human lymphoblasts are resistant to phthalocyanine 4–photodynamic therapy–induced apoptosis. Separovic D, et al. **Biochem Biophys Res Commun** 1999 May 19;258(3):506–12

The 5–lipoxygenase–activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Datta K, et al. **Biochem J** 1999 Jun 1;340 (Pt 2):371–5

In vitro and in vivo inhibition of human flavin–containing monooxygenase form 3 (FMO3) in the presence of dietary indoles. Cashman JR, et al. **Biochem Pharmacol** 1999 Sep 15;58(6):1047–55

Cytostatic and antiestrogenic effects of 2–(indol–3–ylmethyl)–3,3'–diindolylmethane, a major in vivo product of dietary indole–3–carbinol. Chang YC, et al. **Biochem Pharmacol** 1999 Sep 1;58(5):825–34

Negative regulation by dexamethasone of fluvastatin–inducible CYP2B expression in primary cultures of rat hepatocytes: role of CYP3A. Kocarek TA, et al. **Biochem Pharmacol** 1998 May 1;55(9):1435–43

Modulation of cytochrome P4501A1 activity by ascorbigen in murine hepatoma cells. Stephenson PU, et al. **Biochem Pharmacol** 1999 Oct 1;58(7):1145–53

Protective effect of fluvastatin sodium (XU–62–320), a 3–hydroxy–3–methylglutaryl coenzyme A (HMG–CoA) reductase inhibitor, on oxidative modification of human low–density lipoprotein in vitro. Suzumura K, et al. **Biochem Pharmacol** 1999 Mar 15;57(6):697–703

Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet–derived growth factor beta–receptor (beta–PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Zaman GJ, et al. **Biochem Pharmacol** 1999 Jan 1;57(1):57–64

Mechanisms of action of indole–3–carbinol as a chemopreventive agent. Hudson EA, et al. **Biochem Soc Trans** 1998 Nov;26(4):S370

Bizelesin, a bifunctional cyclopropylpyrroloindole alkylating agent, inhibits simian virus 40 replication in trans by induction of an inhibitor. McHugh MM, et al. **Biochemistry** 1999 Aug 31;38(35):11508–15

Induction of AT–specific DNA–interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA. Woynarowski JM, et al. **Biochim Biophys Acta** 1999 Feb 16;1444(2):201–17

Cycloprodigiosin hydrochloride obtained from Pseudoalteromonas denitrificans is a potent antimalarial agent. Kim HS, et al. **Biol Pharm Bull** 1999 May; 22(5):532–4

Indole and benzimidazole derivatives as steroid 5alpha–reductase inhibitors in the rat prostate. Takami H, et al. **Bioorg Med Chem** 1998 Dec;6(12):2441–8

Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Belliotti TR, et al. **Bioorg Med Chem Lett** 1998 Jun 16;8(12):1499–502

Highly constrained dipeptoid analogues containing a type II'beta–turn mimic as novel and selective CCK–A receptor ligands. de la Figuera N, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):43–8

Substituted indoles as potent and orally active 5–lipoxygenase activating protein (FLAP) inhibitors. Frenette R, et al. **Bioorg Med Chem Lett** 1999 Aug 16;9(16):2391–6

The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Hulme C, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1867–72

Reversal of multidrug resistance (MDR) by aspidofractinine–type indole alkaloids. Kam TS, et al. **Bioorg Med Chem Lett** 1998 Oct 6;8(19):2769–72

New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5–(alpha–azolylbenzyl)–1H–indoles. Le Borgne M, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):333–6

Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline–5–sulfonamide pharmacophore. Mathvink RJ, et al. **Bioorg Med Chem Lett** 1999 Jul 5;9(13):1869–74

Synthesis and biological activities of (–)–6–n–octyl–indolactam–V, a new potent analogue of the tumor promoter (–)–indolactam–V. Nakagawa Y, et al. **Biosci Biotechnol Biochem** 1998 Aug;62(8):1568–73

Water–soluble aluminium phthalocyanine–polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour–bearing mice. Brasseur N, et al. **Br J Cancer** 1999 Jul;80(10):1533–41

Induction of DT–diaphorase by 1,2–dithiole–3–thione and increase of antitumour activity of bioreductive agents. Begleiter A, et al. **Br J Cancer Suppl** 1996 Jul;27:S9–14

The haemodynamic effect of the 5HT1 agonist BMS–180048: a class effect of triptans? Swan L, et al. **Br J Clin Pharmacol** 1999 Feb;47(2):189–94

The effect of steady–state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Taylor A, et al. **Br J Clin Pharmacol** 1999 Feb; 47(2):219–22

Mode of action of ICS 205,930, a novel type of potentiator of responses to glycine in rat spinal neurones. Chesnoy–Marchais D. **Br J Pharmacol** 1999 Feb; 126(3):801–9

Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Coldwell MC, et al. **Br J Pharmacol** 1999 Aug; 127(7):1696–702

G–protein activation at 5–HT1A receptors by the 5–ht1F ligand LY334370 in guinea–pig brain sections and recombinant cell lines. Dupuis DS, et al. **Br J Pharmacol** 1998 May;124(2):283–90

Diazoxide– and leptin–activated K(ATP) currents exhibit differential sensitivity to englitazone and ciclazindol in the rat CRI–G1 insulin–secreting cell line. Harvey J, et al. **Br J Pharmacol** 1998 Aug;124(7):1557–65

Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor–mediated pressor responses in the rat mesenteric arterial bed. Heinemann A, et al. **Br J Pharmacol** 1998 Nov;125(6):1120–7

Electrophysiological studies on oxindole, a neurodepressant tryptophan metabolite. Mannaioni G, et al. **Br J Pharmacol** 1998 Dec;125(8):1751–60

Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic islets. Mourtada M, et al. **Br J Pharmacol** 1999 Jul;127(5):1279–87

Agonist–inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Ross RA, et al. **Br J Pharmacol** 1999 Feb;126(3):665–72

Comparison of contractions produced by carbachol, thapsigargin and cyclopiazonic acid in the guinea–pig tracheal muscle. Takemoto M, et al. **Br J Pharmacol** 1998 Aug;124(7):1449–54

The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. Teh MT, et al. **Br J Pharmacol** 1999 Mar;126(5):1237–45

Improvement of exercise capacity of rats with chronic heart failure by long–term treatment with trandolapril. Yamaguchi F, et al. **Br J Pharmacol** 1999 Apr; 126(7):1585–92

Injection of the protein kinase C inhibitor Ro31–8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Browman KE, et al. **Brain Res** 1998 Dec 14;814(1–2):112–9

NS–257, a novel competitive AMPA receptor antagonist, interacts with kainate and NMDA receptors. Nijholt I, et al. **Brain Res** 1999 Mar 13;821(2):374–82

The bisindolylmaleimide protein kinase C inhibitor, Ro 32–2241, reverses multidrug resistance in KB tumour cells. Merritt JE, et al. **Cancer Chemother Pharmacol** 1999; 43(5):371–8

Antitumour promoting activity of indole–3–carbinol in mouse skin carcinogenesis. Srivastava B, et al. **Cancer Lett** 1998 Dec 11;134(1):91–5

Chemoprevention studies of heterocyclic amine–induced colon carcinogenesis. Xu M, et al. **Cancer Lett** 1999 Sep 1;143(2):179–83

Indole–3–carbinol and tamoxifen cooperate to arrest the cell cycle of MCF–7 human breast cancer cells. Cover CM, et al. **Cancer Res** 1999 Mar 15;59(6):1244–51

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk–1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Fong TA, et al. **Cancer Res** 1999 Jan 1;59(1):99–106

Indole–3–carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Jin L, et al. **Cancer Res** 1999 Aug 15;59(16):3991–7

Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Rabindran SK, et al. **Cancer Res** 1998 Dec 15;58(24):5850–8

Chemoprevention of aflatoxin B1–induced carcinogenesis by

indole-3-carbinol in rat liver--predicting the outcome using early biomarkers. Manson MM, et al. **Carcinogenesis** 1998 Oct;19(10):1829–36

Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. van der Ent M, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):387–94

Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril. van der Ent M, et al. **Cardiovasc Drugs Ther** 1998 Sep;12(4):395–403

Rapid adhesion and spread of non-adherent colon cancer Colo201 cells induced by the protein kinase inhibitors, K252a and KT5720 and suppression of the adhesion by the immunosuppressants FK506 and cyclosporin A. Mohri T, et al. **Cell Struct Funct** 1998 Oct;23(5):255–64

Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cumberbatch MJ, et al. **Cephalalgia** 1998 Dec; 18(10):659–63

Prostanoids and related compounds. VII. Synthesis and inhibitory activity of 1-isoindolinone derivatives possessing inhibitory activity against thromboxane A2 analog (U-46619)-induced vasoconstriction. Kato Y, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr;47(4):529–35

4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II). Sawada K, et al. **Chem Pharm Bull (Tokyo)** 1999 Apr; 47(4):481–91

Martefragin A, a novel indole alkaloid isolated from red alga, inhibits lipid peroxidation. Takahashi S, et al. **Chem Pharm Bull (Tokyo)** 1998 Oct;46(10):1527–9

Action of quinolinic and indolinonic aminoxyls as radical-scavenging antioxidants. Noguchi N, et al. **Chem Phys Lipids** 1999 May;99(1):11–9

Endothelium-dependent effect of perindopril and enalaprilat in rat thoracic aorta. Fang ZY, et al. **Chung Kuo Yao Li Hsueh Pao** 1996 Nov;17(6):519–23

Effects of Ro 31-8220 on lipopolysaccharides-induced hepatotoxicity and release of tumor necrosis factor from rat Kupffer cells. Lin W, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jan;18(1):85–7

Effects of Ro 31-8220 on smooth muscle cell proliferation induced by fibrinogen degradation products. Zhou B, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Sep;18(5):463–5

Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Wada A, et al. **Circulation** 1999 Feb 2;99(4):570–7

A requirement for protein kinase C inhibition for calcium-triggered apoptosis in acute lymphoblastic leukemia cells. Zhu DM, et al. **Clin Cancer Res** 1999 Feb; 5(2):355–60

Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Muir DF, et al. **Clin Pharmacol Ther** 1999 Jul;66(1):85–90

1. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. Broadbent TA, et al. **Curr Med Chem** 1998 Dec; 5(6):469–91 (177 ref.)

1 - 1. The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. Broadbent TA, et al. **Curr Med Chem** 1998 Oct; 5(5):337–52 (146 ref.)

Cannabimimetic indoles, pyrroles and indenes. Huffman JW. **Curr Med Chem** 1999 Aug;6(8):705–20 (49 ref.)

Effects of tropisetron, a 5-HT3 receptor antagonist, on proximal gastric motor and sensory function in nonulcer dyspepsia. Klatt S, et al. **Digestion** 1999 Mar-Apr; 60(2):147–52

Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Marek GJ, et al. **Drug Alcohol Depend** 1998 Jun-Jul;51(1-2):189–98 (80 ref.)

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Fischer V, et al. **Drug Metab Dispos** 1999 Mar;27(3):410–6

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation. Schleim KD, et al. **Endocrinology** 1999 Apr;140(4):1552–8

RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin. Standaert ML, et al. **Endocrinology** 1999 May;140(5):2145–51

EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease. Simoons ML, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J56–60 (44 ref.)

Possible mechanism underlying the potent vasoconstrictor actions of cyclopiazonic acid on dog cerebral arteries. Asano M, et al. **Eur J Pharmacol** 1998 Jul 10; 352(2-3):215–21

Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Buemi M, et al. **Eur J Pharmacol** 1999 Apr 9; 370(2):201–3

Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor. Gupta P, et al. **Eur J Pharmacol** 1999 Feb 19;367(2-3):283–90

A Na+-H+ exchange inhibitor (SM-20550) protects from microvascular deterioration and myocardial injury after reperfusion. Ito Y, et al. **Eur J Pharmacol** 1999 Jun 25; 374(3):355–66

Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. Koffi I, et al. **Eur J Pharmacol** 1998 Nov 13;361(1):51–60

Effects of paxilline on K+ channels in rat mesenteric arterial cells. Li G, et al. **Eur J Pharmacol** 1999 May 7;372(1):103–7

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Middlemiss DN, et al. **Eur J Pharmacol** 1999 Jun 30;375(1-3):359–65

Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Moroni F. **Eur J Pharmacol** 1999 Jun 30;375(1-3):87–100 (183 ref.)

GR46611 potentiates 5-HT1A receptor-mediated locomotor activity in the guinea pig. O'Neill MF, et al. **Eur J Pharmacol** 1999 Apr 9;370(2):85–92

Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. Palma C, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):435–43

Tenidap enhances P2Z/P2X7 receptor signalling in macrophages. Sanz JM, et al. **Eur J Pharmacol** 1998 Aug 21;355(2-3):235–44

BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. Saxena PR, et al. **Eur J Pharmacol** 1998 Jun 26;351(3):329–39

The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum. Watanabe M, et al. **Eur J Pharmacol** 1999 Feb 12; 367(1):19–23

Induction of estradiol-2-hydroxylase and ethoxyresorufin-O-deethylase by 3-substituted indole compounds. Wong DC, et al. **Eur J Pharmacol** 1998 Nov 27;362(1):87–93

Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Yamamoto A, et al. **Eur J Pharmacol** 1998 Nov 13;361(1):143–9

In vitro and in vivo effects of KT6352, a derivative of indolocarbazole compounds, on murine megakaryocytopoiesis. Shiotsu Y, et al. **Exp Hematol** 1998 Dec;26(13):1195–201

Synthesis and antibacterial activity of 2-aryl-2,5-dihydro-3(3H)-oxo-pyridazino[4,3-b]indole-4-carboxylic acids. Palluotto F, et al. **Farmaco** 1999 Mar 31; 54(3):191–4

Evaluation of anti-HIV activity of 5-(2-phenyl-3'-indolal)-2-thiohydantoin. Suzen S, et al. **Farmaco** 1998 Jul 30;53(7):525–7

Prevention of cyclophosphamide-induced micronucleus formation in mouse bone marrow by indole-3-carbinol. Agrawal RC, et al. **Food Chem Toxicol** 1998 Nov; 36(11):975–7

Effect of some indole derivatives on xenobiotic metabolism and xenobiotic-induced toxicity in cultured rat liver slices. Renwick AB, et al. **Food Chem Toxicol** 1999 Jun; 37(6):609–18

Nitroxide radicals protect DNA from damage when illuminated in vitro in the presence of dibenzoylmethane and a common sunscreen ingredient. Damiani E, et al. **Free Radic Biol Med** 1999 Apr;26(7-8):809–16

Effects of a novel, low-molecular weight inhibitor of lipid peroxidation on ischemia-reperfusion injury in isolated rat hearts and in cultured cardiomyocytes. Nagy A, et al. **Free Radic Biol Med** 1998 Jun;24(9):1462–9

The effect of indolinic and quinolinic nitroxide radicals on trout erythrocytes exposed to oxidative stress. Falcioni G, et al. **Free Radic Res** 1998 May;28(5):507–16

ESR studies of a series of phthalocyanines. Mechanism of phototoxicity. Comparative quantitation of O2-. using ESR spin-trapping and cytochrome c reduction techniques. Viola A, et al. **Free Radic Res** 1998 May;28(5):517–32

Different actions in the rat prostatic and epididymal vas deferens of cyclopiazonic acid or ryanodine on noradrenaline-induced contractions. Amobi NI, et al. **Gen Pharmacol** 1999 Feb;32(2):271–8

Effect of pineal indoles on the chick embryo. Ooi VE, et al. **Gen Pharmacol** 1999 Feb;32(2):219–24

Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Yamamoto C, et al. **Hepatology** 1999 Oct; 30(4):894–902

Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration. Prahalada S, et al. **Horm Metab Res** 1999 Feb-Mar;31(2-3):133–7

Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arterioles in rats. Chillon JM, et al. **Hypertension** 1999 Mar;33(3):856–61

Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Tanaka S, et al. **Immunopharmacology** 1998 Jul;40(1):21–6

5/6/7/8 mono or disubstituted 1H/1-phenyl-9H-pyrido [3,4 b] indoles--a new class of antifilarial agents and their relationship with voltage sensitive calcium channels in Setaria cervi. Kapoor S, et al. **Indian J Exp Biol** 1998 Sep; 36(9):887–90

Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia [letter] Saito M, et al. **Int J Hematol** 1999 Jun;69(4):274–6

A substance P receptor antagonist (FK 888) modifies gut alterations induced by ionizing radiation. Esposito V, et al. **Int J Radiat Biol** 1998 Nov;74(5):625–32

The effect of cyclopiazonic acid on the development of pale, soft, and exudative pork from pigs of defined malignant hyperthermia genotype. Byrem TM, et al. **J Anim Sci** 1999 Jan;77(1):166–72

Effects of tryprostatin derivatives on microtubule assembly in vitro and in situ. Kondoh M, et al. **J Antibiot (Tokyo)** 1998 Aug;51(8):801–4

Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. Chakrabarti G, et al. **J Antimicrob Chemother** 1999 Mar; 43(3):359–66

Electromechanical coupling in human vas deferens: effects of agents that modulate intracellular release of calcium. Amobi NI, et al. **J Auton Pharmacol** 1998 Jun;18(3):157–65

Ryanodine- and cyclopiazonic acid-sensitive components in human vas deferens contractions to noradrenaline. Amobi NI, et al. **J Auton Pharmacol** 1998 Jun;18(3):167–76

Inhibition of DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3-methylimidazo[4,5-f]quinoline by dietary indole-3-carbinol in female rats. He YH, et al. **J Biochem Mol Toxicol** 1999;13(5):239–47

Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. Chyan YJ, et al. **J Biol Chem** 1999 Jul 30;274(31):21937–42

Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89. Tong Y, et al. **J Biol Chem** 1998 Nov 20; 273(47):31209–14

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. Murphy MG, et al. **J Bone Miner Res** 1999 Jul; 14(7):1182–8

Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. Drici MD, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):82–8

ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. Fogari R, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):616–20

Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. French General Hospitals National College of Cardiologists. Haïat R, et al. **J Cardiovasc Pharmacol** 1999 Jun;33(6):953–9

Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. Hood S, et al. **J Cardiovasc Pharmacol** 1999 Jul;34(1):89–94

Perindopril effects on angiotensin I elimination in lung after experimental myocardial injury induced by intracoronary microembolization in rats. Kalenikova EI, et al. **J Cardiovasc Pharmacol** 1998 Oct;32(4):608–15

Dexamethasone modulates the expression of endothelin-1 and -A receptors in A7r5 vascular smooth muscle cells. Koshino Y, et al. **J Cardiovasc Pharmacol** 1998 Oct; 32(4):665–72

The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study. Forbat SM, et al. **J Cardiovasc Risk** 1998 Feb;5(1):1–10

The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. Meadowcroft AM, et al. **J Clin Pharmacol** 1999 Apr;39(4):418–24

Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. Gillies LK, et al. **J Hypertens** 1998 Apr; 16(4):477–86

The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b) quinoxaline inhibits neutrophil production of reactive oxygen species. Harbecke O, et al. **J Leukoc Biol** 1999 Jun; 65(6):771–7

Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with beta-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle. Sawada H, et al. **J Mol Cell Cardiol** 1999 May; 31(5):1047–62

10'-Hydroxyusambarensine, a new antimalarial bisindole alkaloid from the roots of Strychnos usambarensis. Frédérich M, et al. **J Nat Prod** 1999 Apr;62(4):619–21

Gö 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase. Behrens MM, et al. **J Neurochem** 1999 Mar;72(3):919–24

Modulation of spontaneous and stimulation-evoked

transmitter release from rat sympathetic neurons by the cognition enhancer linopirdine: insights into its mechanisms of action. Kristufek D, et al. **J Neurochem** 1999 May; 72(5):2083–91

Selective blocking effects of tropisetron and atropine on recombinant glycine receptors. Maksay G, et al. **J Neurochem** 1999 Aug;73(2):802–6

Different contributions of the endothelin ET(A) receptor to hypertension induced by acute or chronic inhibition of nitric oxide synthesis. Hashimoto N, et al. **J Pharm Pharmacol** 1998 Sep;50(9):1051–8

KMD–3213, a uroselective and long–acting alpha(1a)–adrenoceptor antagonist, tested in a novel rat model. Akiyama K, et al. **J Pharmacol Exp Ther** 1999 Oct; 291(1):81–91

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. Bignon E, et al. **J Pharmacol Exp Ther** 1999 May;289(2):742–51

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization. Bignon E, et al. **J Pharmacol Exp Ther** 1999 May;289(2):752–61

Preclinical evaluation of anti–inflammatory activities of the novel pyrrolopyrimidine PNU–142731A, a potential treatment for asthma. Chin JE, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):188–95

Impaired skeletal muscle performance in the early stage of cardiac pressure overload in rabbits: beneficial effects of angiotensin–converting enzyme inhibition. Coirault C, et al. **J Pharmacol Exp Ther** 1999 Oct;291(1):70–5

Competitive antagonism of the mouse 5–hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor. Coultrap SJ, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):76–82

Z–350, a novel compound with alpha 1–adrenoceptor antagonistic and steroid 5 alpha–reductase inhibitory actions: pharmacological properties in vivo. Fukuta Y, et al. **J Pharmacol Exp Ther** 1999 Sep;290(3):1013–8

Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N–methyl–D–aspartate receptor GV196771A. Quartaroli M, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):158–69

Pharmacology of LY315920/S–5920, [[3–(aminooxoacetyl)–2–ethyl–1–(phenylmethyl)–1H–indol–4–yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti–inflammatory drugs, SPI. Snyder DW, et al. **J Pharmacol Exp Ther** 1999 Mar;288(3):1117–24

Comparison of the potassium channel openers, WAY–133537, ZD6169, and celikalim on isolated bladder tissue and In vivo bladder instability in rat. Wojdan A, et al. **J Pharmacol Exp Ther** 1999 Jun;289(3):1410–8

The effect of cyclopiazonic acid on excitation–contraction coupling in guinea–pig ureteric smooth muscle: role of the sarcoplasmic reticulum. Burdyga TV, et al. **J Physiol (Lond)** 1999 Jun 15;517 (Pt 3):855–65

Effect of KW–8232, a novel anti–osteoporotic agent, on bone loss in sciatic neurectomized rats. Uchii M, et al. **Jpn J Pharmacol** 1998 Oct;78(2):241–3

Photodynamic stimulation causes sustained increase in intracellular calcium concentration in cells of small cell lung carcinoma. Hayashi M, et al. **Jpn J Vet Res** 1998 Nov; 46(2–3):65–72

Photodynamic modulation of wound healing with BPD–MA and CASP. Parekh SG, et al. **Lasers Surg Med** 1999; 24(5):375–81

Allosteric effects of four stereoisomers of a fused indole ring system with 3H–N–methylscopolamine and acetylcholine at M1–M4 muscarinic receptors. Lazareno S, et al. **Life Sci** 1999;64(6–7):519–26

Long–term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH–corpulent rat with non–insulin–dependent diabetes mellitus and hypertension. Striffler JS, et al. **Metabolism** 1998 Oct;47(10):1199–204

Endothelin subtype A receptor antagonist induces osteopenia in growing rats. Tsukahara H, et al. **Metabolism** 1998 Nov; 47(11):1403–7

Novel actions of inverse agonists on 5–HT2C receptor systems. Berg KA, et al. **Mol Pharmacol** 1999 May; 55(5):863–72

Big deal about a little insulin [news] Flier JS. **Nat Med** 1999 Jun;5(6):614–5

Bisindolylmaleimide VIII facilitates Fas–mediated apoptosis and inhibits T cell–mediated autoimmune diseases [see comments] Zhou T, et al. **Nat Med** 1999 Jan;5(1):42–8. Comment in: Nat Med 1999 Jan;5(1):19–20.

Z–350, a new chimera compound possessing alpha1–adrenoceptor antagonistic and steroid 5alpha–reductase inhibitory actions. Fukuda Y, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):433–8

Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5–HT1A, 5–HT1B and 5–HT1D receptors. Newman–Tancredi A, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Jun; 359(6):447–53

Porcine carotid vascular effects of eletriptan (UK–116,044): a new 5–HT1B/1D receptor agonist with anti–migraine activity. Willems E, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1998 Aug; 358(2):212–9

HMG–CoA reductase inhibitors and apoptosis [letter] Senatore M, et al. **Nephron** 1999;81(4):439–40

Modulation by dopamine D1–like receptors of synaptic transmission and NMDA receptors in rat nucleus accumbens is attenuated by the protein kinase C inhibitor Ro 32–0432. Chergui K, et al. **Neuropharmacology** 1999 Feb;38(2):223–31

Discriminative stimulus properties of the novel serotonin (5–HT)2C receptor agonist, RO 60–0175: a pharmacological analysis. Dekeyne A, et al. **Neuropharmacology** 1999 Mar;38(3):415–23

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Di Matteo V, et al. **Neuropharmacology** 1999 Aug; 38(8):1195–205

Anxiolytic–like actions of BW 723C86 in the rat Vogel conflict test are 5–HT2B receptor mediated. Kennett GA, et al. **Neuropharmacology** 1998 Dec;37(12):1603–10

Serotonin (5–HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5–HT, release in the frontal cortex in vivo. Millan MJ, et al. **Neuropharmacology** 1998 Jul;37(7):953–5

5–HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5–HT3 receptor antagonism in conscious rats. Smith MI, et al. **Neurosci Lett** 1999 Aug 13;271(1):61–4

Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP–1347/KT–7515 in rats with lesions of nucleus basalis magnocellularis. DiCamillo AM, et al. **Neuroscience** 1998 Sep;86(2):473–83

Preservation of cholinergic activity and prevention of neuron death by CEP–1347/KT–7515 following excitotoxic injury of the nucleus basalis magnocellularis. Saporito MS, et al. **Neuroscience** 1998 Sep;86(2):461–72

Morphine, the NMDA receptor antagonist MK801 and the tachykinin NK1 receptor antagonist RP67580 attenuate the development of inflammation–induced progressive tactile hypersensitivity. Ma QP, et al. **Pain** 1998 Jul;77(1):49–57

Effect of FK480, a CCK–A receptor antagonist, on spontaneously developed chronic pancreatitis in WBN/Kob rats. Ito H, et al. **Pancreas** 1998 Oct; 17(3):295–300

Effect of a new inhibitor of type II phospholipase A2 on experimental acute pancreatitis in rats. Yoshikawa T, et al. **Pancreas** 1999 Aug;19(2):193–8

Anxiolytic–like effects of perospirone, a novel serotonin–2 and dopamine–2 antagonist (SDA)–type antipsychotic agent. Sakamoto H, et al. **Pharmacol Biochem Behav** 1998 Aug;60(4):873–8

Secretory, biosynthetic and cationic responses to 2–(N–PHENYL–INDOYL)IMIDAZOLE in rat pancreatic islets. Louchami K, et al. **Pharmacol Res** 1998 Oct;38(4):305–10

Modulation of drug–metabolising enzyme expression by condensation products of indole–3–ylcarbinol, an inducer in cruciferous vegetables. Vang O, et al. **Pharmacol Toxicol** 1999 Feb;84(2):59–65

A comparative study of the cellular uptake and photodynamic efficacy of three novel zinc phthalocyanines of differing charge. Ball DJ, et al. **Photochem Photobiol** 1999 Mar;69(3):390–6

Laser line–scanning confocal fluorescence imaging of the photodynamic action of aluminum and zinc phthalocyanines in V79–4 Chinese hamster fibroblasts. Scully AD, et al. **Photochem Photobiol** 1998 Aug; 68(2):199–204

The tachykinin NK–1 receptor antagonist, RP–67580, infused into the ventral tegmental area prevents stress–induced analgesia in the formalin test. Altier N, et al. **Physiol Behav** 1999 Jun;66(4):717–21

CholecystokininB receptor antagonist increases food intake in rats. Dorré D, et al. **Physiol Behav** 1998 Aug;65(1):11–4

Effect on locomotion of indole alkaloids from the hooks of uncaria plants. Sakakibara I, et al. **Phytomedicine** 1999 Jul; 6(3):163–8

A high–affinity Ca2+ pump, ECA1, from the endoplasmic reticulum is inhibited by cyclopiazonic acid but not by thapsigargin. Liang F, et al. **Plant Physiol** 1998 Nov; 118(3):817–25

Cytotoxic activity of indole alkaloids from Alstonia macrophylla. Keawpradub N, et al. **Planta Med** 1999 May; 65(4):311–5

Reversal of multidrug resistance by kopsiflorine isolated from Kopsia dasyrachis. Rho MC, et al. **Planta Med** 1999 May; 65(4):307–10

Inhibition of protease–resistant prion protein formation by porphyrins and phthalocyanines. Caughey WS, et al. **Proc Natl Acad Sci U S A** 1998 Oct 13;95(21):12117–22

5–Lipoxygenase inhibitors reduce PC–3 cell proliferation and initiate nonnecrotic cell death. Anderson KM, et al. **Prostate** 1998 Nov 1;37(3):161–73

Effects of the CCK(B) antagonist CI–988 on responses to mCPP in generalized anxiety disorder. Goddard AW, et al. **Psychiatry Res** 1999 Mar 22;85(3):225–40

Comparative effects of novel 5–HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus–maze anxiety in mice. Cao BJ, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):185–94

RU 24969, a 5–HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5–HT1B/1D antagonist. Harrison AA, et al. **Psychopharmacology (Berl)** 1999 Jan;141(3):242–50

Design of subtype selective melatonin receptor agonists and antagonists. Sugden D, et al. **Reprod Nutr Dev** 1999 May–Jun;39(3):335–44

Dysmorphogenic effects of a specific protein kinase C inhibitor during neurulation. Ward KW, et al. **Reprod Toxicol** 1998 Sep–Oct;12(5):525–34

Interaction of perindoprilat with human red blood cells. Piasecka A, et al. **Scand J Clin Lab Invest** 1999 Apr; 59(2):147–52

Discovery of a small molecule insulin mimetic with antidiabetic activity in mice [see comments] Zhang B, et al. **Science** 1999 May 7;284(5416):974–7. Comment in: Science 1999 May 7;284(5416):886.

RU 24969, a 5–HT1B/1A receptor agonist, potentiates cocaine–induced increases in nucleus accumbens dopamine. Parsons LH, et al. **Synapse** 1999 May;32(2):132–5

Prevention of chromosomal aberration in mouse bone marrow by indole–3–carbinol. Agrawal RC, et al. **Toxicol Lett** 1999 Jun 1;106(2–3):137–41

Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1–year follow up. Földes K, et al. **Transpl Int** 1998;11 Suppl 1:S65–8

Efficacy and muscle safety of fluvastatin in cyclosporine–treated cardiac and renal transplant recipients: an exercise provocation test. Schrama YC, et al. **Transplantation** 1998 Nov 15;66(9):1175–81

Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates. Lutsenko SV, et al. **Tumour Biol** 1999 Jul–Aug;20(4):218–24

3,3'–Diindolylmethane induces CYP1A2 in cultured precision–cut human liver slices. Lake BG, et al. **Xenobiotica** 1998 Aug;28(8):803–11

Small synthetic ligands of the cholecystokinin–B/gastrin receptor can mimic the function of endogenous peptide hormones. Beinborn M, et al. **Yale J Biol Med** 1998 May–Aug;71(3–4):337–46

The role of endogenous gastrin in the development of enterochromaffin–like cell carcinoid tumors in Mastomys natalensis: a study with the specific gastrin receptor antagonist AG–041R. Chiba T, et al. **Yale J Biol Med** 1998 May–Aug;71(3–4):247–55

[Effect of KW–8232 on bone turnover in ovariectomized rats] Uchii M, et al. **Nippon Yakurigaku Zasshi** 1998 Nov, 112(5):315–21 (Eng. Abstr.) **(Jpn)**

[Antioxidative effects of fluvastatin, and its major metabolites] Nakashima A, et al. **Yakugaku Zasshi** 1999 Jan;119(1):93–9 (Eng. Abstr.) **(Jpn)**

[Mechanisms of arbidole's immunomodulating action] Glushkov RG, et al. **Vestn Ross Akad Med Nauk** 1999; (3):36–40 (43 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Tropisetron or droperidol in the prevention of postoperative nausea and vomiting. A comparative, randomised, double–blind study in women undergoing laparoscopic cholecystectomy. Jokela R, et al. **Acta Anaesthesiol Scand** 1999 Jul;43(6):645–50

Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non–peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non–pregnant women. Akerlund M, et al. **Adv Exp Med Biol** 1998;449:467–72

Acute anti–ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function. Bartels GL, et al. **Am J Cardiol** 1999 Feb 1;83(3):332–6

Long–term prognostic importance of hyperkinesia following acute myocardial infarction. TRACE Study Group. TRAndolapril Cardiac Evaluation. Kjøller E, et al. **Am J Cardiol** 1999 Mar 1;83(5):655–9

Prospective randomized comparison of tropisetron with and without dexamethasone against high–dose metoclopramide in prophylaxis of acute and delayed cisplatin–induced nausea and vomiting. Malik I, et al. **Am J Clin Oncol** 1999 Apr;22(2):126–30

Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Kuzel MD. **Am J Health Syst Pharm** 1999 Feb 1;56(3):217–24 (42 ref.)

Ambulatory blood pressure and urinary albumin excretion in diabetic (non–insulin–dependent and insulin–dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril. Bauduceau B, et al. **Am J Hypertens** 1998 Sep; 11(9):1065–73

Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large–scale trial. Vaur L, et al. **Am J Hypertens** 1999 Apr;12(4 Pt 1):374–80

Efficiency of 1–year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome. Matzkies FK, et al. **Am J Nephrol** 1999;19(4):492–4

Naratriptan: an alternative for migraine. Dulli DA. **Ann Pharmacother** 1999 Jun;33(6):704–11 (39 ref.)

Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy. Bleiberg H, et al. **Anticancer Drugs** 1998 Oct;9(9):773–7

Growth inhibition induced by Ro 31–8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Begemann M, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3139–52

A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. Kano H, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):414–9

Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Frighetto L, et al. **Can J Anaesth** 1999 Jun;46(6):536–43

Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure. Sami M. **Can J Cardiol** 1999 May; 15 Suppl C:19C–23C

Ropinirole and pramipexole, the new agonists. Hobson DE, et al. **Can J Neurol Sci** 1999 Aug;26 Suppl 2:S27–33 (53 ref.)

Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Ohnishi M, et al. **Cardiovasc Res** 1998 Sep; 39(3):617–24

Subcutaneous naratriptan [editorial; comment] **Cephalalgia** 1998 Sep;18(7):419. Comment on: Cephalalgia 1998 Sep;18(7):476–80.

Effect of subcutaneous naratriptan on forearm blood flow [see comments] Yogendran L, et al. **Cephalalgia** 1998 Sep; 18(7):476–80. Comment in: Cephalalgia 1998 Sep;18(7):419.

Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozotocin-induced diabetic rats. Yan L, et al. **Chin Med J (Engl)** 1998 Apr;111(4):306–8

Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Guethlin M, et al. **Circulation** 1999 Feb 2;99(4):475–81

Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Pedersen OD, et al. **Circulation** 1999 Jul 27; 100(4):376–80

Preclinical antitumor activity of bizelesin in mice. Carter CA, et al. **Clin Cancer Res** 1996 Jul;2(7):1143–9

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. O'Dwyer PJ, et al. **Clin Cancer Res** 1996 Oct;2(10):1685–92

Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Svensson J, et al. **Clin Endocrinol (Oxf)** 1999 Apr; 50(4):451–6

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Lye M, et al. **Coron Artery Dis** 1998;9(9):583–90

Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type I diabetes mellitus. McFarlane R, et al. **Diabet Med** 1999 Jan;16(1):62–6

A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Nakamura J, et al. **Diabetes** 1999 Oct;48(10):2090–5

Fixed combination verapamil SR/trandolapril. Dooley M, et al. **Drugs** 1998 Nov;56(5):837–44; discussion 845–6 (30 ref.)

Fluvastatin: a review of its use in lipid disorders. Langtry HD, et al. **Drugs** 1999 Apr;57(4):583–606 (107 ref.)

Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Peters DC, et al. **Drugs** 1998 Nov;56(5):871–93 (98 ref.)

The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Fox KM, et al. **Eur Heart J** 1998 Sep;19 Suppl J:J52–5

Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group [see comments] Hampton JR, et al. **Eur Heart J** 1998 Dec;19(12):1823–8. Comment in: Eur Heart J 1998 Dec;19(12):1747–9.

A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Serruys PW, et al. **Eur Heart J** 1999 Jan;20(1):58–69

Tropisetron or ondansetron compared with placebo for prevention of postoperative nausea and vomiting. Scholz J, et al. **Eur J Anaesthesiol** 1998 Nov;15(6):676–85

Effect of MEN 11467, a new tachykinin NK1 receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs. Cutrufo C, et al. **Eur J Pharmacol** 1999 Jun 18;374(2):277–83

The antipruritic effect of a 5-HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion--an experimental study. Weisshaar E, et al. **Exp Dermatol** 1999 Aug;8(4):254–60

Sertindole in treating schizophrenia [letter] **Hosp Med** 1998 Feb;59(2):165

Sertindole: a review of clinical efficacy. Kane JM. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S59–63; discussion S63–4 (8 ref.)

The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy. Wehnert A. **Int Clin Psychopharmacol** 1998 Mar;13 Suppl 3:S27–30

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Papadakis JA, et al. **Int J Cardiol** 1999 Jun 1;69(3):237–44

Treatment of chronic heart failure with perindopril in ethnic Sri Lankan patients [letter] Thenabadu PN, et al. **Int J Cardiol** 1999 Apr 30;69(1):109–10

Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Breithaupt-Grögler K, et al. **Int J Clin Pharmacol Ther** 1998 Aug;36(8):425–31

Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. Gustafsson I, et al. **J Am Coll Cardiol** 1999 Jul;34(1):83–9

Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Pepine CJ, et al. **J Am Coll Cardiol** 1998 Nov;32(5):1228–37

Protective effects of cyclopiazonic acid on ischemia-reperfusion injury in rabbit hearts. Avellanal M, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):845–51

Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension. López-Hernández FJ, et al. **J Cardiovasc Pharmacol** 1999 May;33(5):748–55

Angiotensin-converting enzyme inhibition and salt in experimental myocardial infarction. Yoshida K, et al. **J Cardiovasc Pharmacol** 1998 Sep;32(3):357–65

Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group. Kovac A, et al. **J Clin Anesth** 1999 May;11(3):235–41

Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a). Svensson J, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2028–33

Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. Bruckert E, et al. **J Clin Epidemiol** 1999 Jun;52(6):589–94

Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. Schwed A, et al. **J Clin Pharmacol** 1999 Apr;39(4):402–9

PROGRESS: Perindopril pROtection aGainst REcurrent Stroke Study: status in March 1997. PROGRESS Management Committee. **J Hum Hypertens** 1998 Sep; 12(9):627–9

Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. Holzgreve H, et al. **J Hum Hypertens** 1999 Jan;13(1):61–7

Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). Galletti F, et al. **J Hypertens** 1999 Mar;17(3):439–45

Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group. Zannad F, et al. **J Hypertens** 1999 Jan;17(1):137–46

Nausea and vomiting after laparoscopic gynecological surgery: a study of the incidence and the effects of tropisetron prophylaxis. Jakobsson J, et al. **J Laparoendosc Adv Surg Tech A** 1999 Feb;9(1):51–5

Nausea and vomiting after laparoscopic gynecologic surgery: a study of the incidence and the effects of tropisetron prophylaxis. Jakobsson J, et al. **J Laparoendosc Adv Surg Tech A** 1999 Apr;9(2):141–5

Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Coppes MJ, et al. **J Pediatr Hematol Oncol** 1999 Jul-Aug; 21(4):274–83

CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito MS, et al. **J Pharmacol Exp Ther** 1999 Feb;288(2):421–7

An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilms formed in vivo. Wood S, et al. **J Photochem Photobiol B** 1999 May; 50(1):1–7

Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children. Ozkan A, et al. **Jpn J Clin Oncol** 1999 Feb;29(2):92–5

MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Guasch A, et al. **Kidney Int** 1999 Jul;56(1):261–7

Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Martínez-Castelao A, et al. **Kidney Int Suppl** 1999 Jul; 71:S231–4

Trandolapril and human diabetic neuropathy [letter; comment] Bell N, et al. **Lancet** 1999 Mar 13;353(9156):927 . Comment on: Lancet 1998 Dec 19–26;352(9145):1978–81.

Thrombotic vascular events after change of statin [letter; comment] Ikeda U, et al. **Lancet** 1999 Mar 6; 353(9155):844–5. Comment on: Lancet 1998 Dec 5;352(9143):1830–1.

Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial [see comments] Malik RA, et al. **Lancet** 1998 Dec 19–26;352(9145):1978–81. Comment in: Lancet 1999 Mar 13;353(9156):926–7. Comment in: Lancet 1999 Mar 13;353(9156):927.

Trandolapril and human diabetic neuropathy [letter; comment] Stoschitzky K. **Lancet** 1999 Mar 13; 353(9156):926–7. Comment on: Lancet 1998 Dec 19–26;352(9145):1978–81.

Increased thrombotic vascular events after change of statin [letter] [see comments] Thomas M, et al. **Lancet** 1998 Dec 5;352(9143):1830–1. Comment in: Lancet 1999 Mar 6;353(9155):844. Comment in: Lancet 1999 Mar 6;353(9155):844–5. Comment in: Lancet 1999 Mar 6;353(9155):845.

Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Torp-Pedersen C, et al. **Lancet** 1999 Jul 3;354(9172):9–12

Thrombotic vascular events after change of statin [letter; comment] Weiss NS, et al. **Lancet** 1999 Mar 6;353(9155):844 . Comment on: Lancet 1998 Dec 5;352(9143):1830–1.

Thrombotic vascular events after change of statin [letter; comment] Wierzbicki AS, et al. **Lancet** 1999 Mar 6; 353(9155):845. Comment on: Lancet 1998 Dec 5;352(9143):1830–1.

In vitro and in vivo comparison of argon-pumped and diode lasers for photodynamic therapy using second-generation photosensitizers. Hammer-Wilson MJ, et al. **Lasers Surg Med** 1998;23(5):274–80

NXX-066 in patients with Alzheimer's disease: a bridging study. Sramek JJ, et al. **Life Sci** 1999;64(14):1215–21

Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Cooper ME, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):24–7

Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Nankervis A, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):12–5

Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Patel V, et al. **Metabolism** 1998 Dec;47(12 Suppl 1):28–33

Ropinirole for restless legs syndrome. Ondo W. **Mov Disord** 1999 Jan;14(1):138–40

The effects of changing statins on cholesterol levels [letter] Mann S, et al. **N Z Med J** 1999 Jul 9;112(1091):260

Is autoimmunity coming to a Fas(t) end? [news; comment] Brunner T, et al. **Nat Med** 1999 Jan;5(1):19–20. Comment on: Nat Med 1999 Jan;5(1):42–8.

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Hemmelder MH, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):98–104

SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models. Sanger GJ, et al. **Neurogastroenterol Motil** 1998 Aug; 10(4):271–9

A multicenter trial of ropinirole as adjunct treatment for PD [letter] Jeret JS. **Neurology** 1999 Aug 11;53(3):658

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Korczyn AD, et al. **Neurology** 1999 Jul 22;53(2):364–70

Naratriptan is effective and well tolerated in the acute treatment of migraine [letter; comment] Tfelt-Hansen P, et al. **Neurology** 1999 Apr 12;52(6):1300–1. Comment on: Neurology 1997 Dec;49(6):1485–90.

Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. McCreary AC, et al. **Neuropsychopharmacology** 1999 Jun;20(6):556–64

Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Goadsby PJ, et al. **Pain** 1999 Jul;82(1):15–22

Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Stiakaki E, et al. **Pediatr Hematol Oncol** 1999 Mar-Apr;16(2):101–8

Protective effect of perindoprilat in the hypoxemia-induced renal dysfunction in the newborn rabbit. Huet F, et al. **Pediatr Res** 1999 Jan;45(1):138–42

Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Colussi VC, et al. **Photochem Photobiol** 1999 Feb;69(2):236–41

Immunosuppressive effects of silicon phthalocyanine photodynamic therapy. Reddan JC, et al. **Photochem Photobiol** 1999 Jul;70(1):72–7

Effects of anti-emetic drug (tropisetron) on quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Joint Research Group for Tropisetron Double-Blind Comparative Study. Kobayashi K, et al. **Respirology** 1999 Sep;4(3):229–38

Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril. Steigerwalt RD Jr, et al. **Retina** 1998;18(6):539–45

New lead found to a possible "insulin pill" [news; comment] Gura T. **Science** 1999 May 7;284(5416):886. Comment on: Science 1999 May 7;284(5416):974–7.

The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Barbounis V, et al. **Support Care Cancer** 1999 Mar;7(2):79–83

Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Gómez G, et al. **Transplant Proc** 1999 Sep; 31(6):2326–7

[Effects of perindopril on hypertension, serum angiotensin-I-converting enzyme activity and urine level of N-acetyl-beta-D-glucosaminidase] Wang Z, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(3):233-6 (Eng. Abstr.) **(Chi)**

[Dolasetron, droperidol and a combination of both in prevention of postoperative nausea and vomiting after extracapsular cataract extraction under general anesthesia] Eberhart LH, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):345-9 (Eng. Abstr.) **(Ger)**

[Prevention of postoperative nausea and vomiting after hysterectomy with oral dolasetron, intravenous dehydrobenzperidol or a combination of both substances] Triem JG, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):340-4 (Eng. Abstr.) **(Ger)**

[Management of schizophrenic psychoses: a one-year experience with Serdolect] **Fortschr Neurol Psychiatr** 1998 Nov;66(11 Suppl Therapie):1-4 **(Ger)**

[Schizophrenic psychoses: distinct therapeutic advantages of atypical neuroleptics. Serdolect: effective and free of side effects] **Fortschr Neurol Psychiatr** 1998 Oct;66(10 Suppl Schizophre):1-4 **(Ger)**

[Therapy of atherosclerosis: lipid regulation and direct anti-atherosclerotic effect] **Internist (Berl)** 1998 Oct;39(10 Suppl Lipidregul):1-4 **(Ger)**

[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?] **Internist (Berl)** 1999 Mar;40(3 Suppl Gibt Es):1-4 **(Ger)**

[Schizophrenic psychoses: distinct therapeutic advantages of atypical neuroleptics. Serdolect is effective and free of side effects] **Psychiatr Prax** 1998 Sep;25(5 Suppl):1-4 **(Ger)**

[Effect of matrix metalloproteinase inhibitor on experimental pseudomonal corneal ulceration] Kosaku K, et al. **Nippon Ganka Gakkai Zasshi** 1998 Nov;102(11):717-23 (Eng. Abstr.) **(Jpn)**

[Non-SU, insulin secretagogues] Kikuchi M. **Nippon Rinsho** 1999 Mar;57(3):702-8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children] Drinevskii VP, et al. **Antibiot Khimioter** 1998;43(9):29-34 (Eng. Abstr.) **(Rus)**

[The cardioprotective effect of perindopril in rats with experimental cardiosclerosis] Kalenikova EI, et al. **Eksp Klin Farmakol** 1999 Mar-Apr;62(2):16-8 (Eng. Abstr.) **(Rus)**

[Prestarium treatment of essential hypertension] Kakhnovskii IM, et al. **Klin Med (Mosk)** 1998;76(9):52-4 (Eng. Abstr.) **(Rus)**

[Gopten (trandolapril) in the treatment of chronic heart failure in patients with ischemic heart disease] Kakhnovskii IM, et al. **Ter Arkh** 1998;70(8):29-33 (Eng. Abstr.) **(Rus)**

[Long-term monotherapy with prestarium, anap and lomir in patients with mild and moderate arterial hypertension: clinical efficacy, hemodynamics and morphofunctional parameters of heart] Nesterov IuI, et al. **Ter Arkh** 1998; 70(9):64-7 (Eng. Abstr.) **(Rus)**

[Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia] Tvorogova MG, et al. **Ter Arkh** 1998;70(12):8-13 (Eng. Abstr.) **(Rus)**

TOXICITY

Dietary indole derivatives induce apoptosis in human breast cancer cells. Fares FA, et al. **Adv Exp Med Biol** 1998; 451:153-7

Oncogenic potential of bifunctional bioreductive drugs. Hei TK, et al. **Br J Cancer Suppl** 1996 Jul;27:S57-60

Prediction of water solubility and toxicity of substituted indoles to photobacterium Phosphoreum using molecular connectivity indices and quantum chemical parameters. Dai J, et al. **Bull Environ Contam Toxicol** 1998 Nov;61(5):591-9

Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Labourier E, et al. **Cancer Res** 1999 Jan 1;59(1):52-5

Potency of dietary indole-3-carbinol as a promoter of aflatoxin B1-initiated hepatocarcinogenesis: results from a 9000 animal tumor study. Oganesian A, et al. **Carcinogenesis** 1999 Mar;20(3):453-8

Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. Li WW, et al. **Clin Cancer Res** 1995 Jun;1(6):631-6

Inhibition of gastrin-stimulated cell proliferation by the CCK-B/gastrin receptor ligand CI-988. Dethloff LA, et al. **Food Chem Toxicol** 1999 Feb-Mar;37(2-3):105-10

In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. Halkiotis K, et al. **Mutagenesis** 1999 Mar;14(2):193-8

Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Gao XM, et al. **Neuropsychopharmacology** 1998 Nov; 19(5):428-33

The soluble eumelanin precursor 5,6-dihydroxyindole-2-carboxylic acid enhances oxidative damage in human keratinocyte DNA after UVA irradiation. Kipp C, et al. **Photochem Photobiol** 1999 Aug; 70(2):191-8

Tremorgenic mycotoxins paxilline, penitrem and lolitrem B, the non-tremorgenic 31-epilolitrem B and electromyographic activity of the reticulum and rumen of sheep. McLeay LM, et al. **Res Vet Sci** 1999 Apr; 66(2):119-27

INDOLIZINES

CHEMICAL SYNTHESIS

Exploration of beta-turn scaffolding motifs as components of sialyl Le(X) mimetics and their relevance to P-selectin. Hanessian S, et al. **Bioorg Med Chem Lett** 1998 Oct 6; 8(19):2803-8

Design and synthesis of a new type of non steroidal human aromatase inhibitors. Sonnet P, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1041-4

CHEMISTRY

Highly constrained dipeptoid analogues containing a type II'beta-turn mimic as novel and selective CCK-A receptor ligands. de la Figuera N, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):43-8

METABOLISM

Exploration of beta-turn scaffolding motifs as components of sialyl Le(X) mimetics and their relevance to P-selectin. Hanessian S, et al. **Bioorg Med Chem Lett** 1998 Oct 6; 8(19):2803-8

PHARMACOLOGY

Highly constrained dipeptoid analogues containing a type II'beta-turn mimic as novel and selective CCK-A receptor ligands. de la Figuera N, et al. **Bioorg Med Chem Lett** 1999 Jan 4;9(1):43-8

Inhibition of lipid peroxidation mediated by indolizines. Nasir AI, et al. **Bioorg Med Chem Lett** 1998 Jul 21;8(14):1829-32

The effect of castanospermine on embryonic mouse cerebellar neurons in culture. Bird MM. **J Electron Microsc (Tokyo)** 1999;48(3):261-6

Reversal of multidrug resistance by kopsiflorine isolated from Kopsia dasyrachis. Rho MC, et al. **Planta Med** 1999 May; 65(4):307-10

[Effect of norepinephrinergic system on ipalbidine analgesia] Wang LM, et al. **Yao Hsueh Hsueh Pao** 1996;31(11):806-11 (Eng. Abstr.) **(Chi)**

THERAPEUTIC USE

Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms. Yokota Y, et al. **Biochim Biophys Acta** 1999 May 18;1438(2):213-22

INDOLYLETHYLAMINES see **TRYPTAMINES**

INDOMETHACIN

Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Koga H, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G576-82

ADMINISTRATION & DOSAGE

Indomethacin inhibits circulating PGE2 and reverses postexercise suppression of natural killer cell activity. Rhind SG, et al. **Am J Physiol** 1999 May;276(5 Pt 2):R1496-505

Different effects of inhaled aspirinlike drugs on allergen-induced early and late asthmatic responses. Sestini P, et al. **Am J Respir Crit Care Med** 1999 Apr;159(4 Pt 1):1228-33

Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Kienapfel H, et al. **Arch Orthop Trauma Surg** 1999;119(5-6):296-302

Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Homma S, et al. **Chest** 1999 May;115(5):1465-8

pH-sensitive release of indomethacin using lactan-acetate microspheres. Na K, et al. **Drug Dev Ind Pharm** 1998 Jun; 24(6):563-8

Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Rao PR, et al. **Drug Dev Ind Pharm** 1998 Apr;24(4):327-36

The effects of prostaglandin E2 indomethacin & Ginkgo biloba extract on resistance to experimental sepsis. Cantürk NZ, et al. **Indian J Med Res** 1998 Sep;108:88-92

Prevention of heterotopic ossification in hip arthroplasty. The influence of the duration of treatment. Vastel L, et al. **Int Orthop** 1999;23(2):107-10

Chronic indomethacin administration blocks increased body temperature after burn injury in rats. Caldwell FT Jr, et al. **J Burn Care Rehabil** 1998 Nov-Dec;19(6):501-11

Microporous membrane drug delivery system for indomethacin. Elchidana PA, et al. **J Controlled Release** 1999 Jun 2;59(3):279-85

Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. Tammela O, et al. **J Pediatr** 1999 May;134(5):552-7

Pharmacodynamic and pharmacokinetic evaluation of lipid microspheres of indomethacin. Srinath P, et al. **Pharm Acta Helv** 1998 Dec;73(4):199-203

ADVERSE EFFECTS

Effect of glutamine on the intestinal permeability changes induced by indomethacin in humans. Hond ED, et al. **Aliment Pharmacol Ther** 1999 May;13(5):679-85

Selective COX-2 inhibitors and human inflammatory bowel disease. McCartney SA, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1115-7

Indomethacin is inappropriate for use in the geriatric population [letter; comment] Rojas-Fernandez C, et al. **Ann Pharmacother** 1998 Sep;32(9):980. Comment on: Ann Pharmacother 1998 Feb;32(2):201-3.

Re: The debate regarding the risks of tocolytic agents [letter; comment] Humphrey M, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):357-8. Comment on: Aust N Z J Obstet Gynaecol 1998 Feb;38(1):11-6.

The contracted type of endocardial fibroelastosis. Horigome H. **Clin Cardiol** 1999 Apr;22(4):309

Allergic contact dermatitis due to diclofenac and indomethacin. Ueda K, et al. **Contact Dermatitis** 1998 Dec; 39(6):323

Potentiating effect of passive cigarette smoking on gastrointestinal damage induced by indomethacin in rats. Guo X, et al. **Dig Dis Sci** 1999 May;44(5):896-902

Indomethacin and pancreatic enzymes synergistically damage intestine of rats. Kimura RE, et al. **Dig Dis Sci** 1998 Oct; 43(10):2322-32

Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury. Akar F, et al. **Eur J Pharmacol** 1999 Jun 25;374(3):461-70

Prospective evaluation of medication-induced esophageal injury and its relation to esophageal function. Alvares JF, et al. **Indian J Gastroenterol** 1999 Jul-Sep;18(3):115-7

Ketotifen in prevention of indomethacin-induced gastropathy. Narendranathan M, et al. **Indian J Gastroenterol** 1999 Apr-Jun;18(2):76-7

Molecular mechanisms involved in NSAID-induced gastropathy. Morise Z, et al. **J Clin Gastroenterol** 1998;27 Suppl 1:S87-90 (37 ref.)

Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. Dehpour AR, et al. **J Gastroenterol** 1999 Apr;34(2):178-81

Indomethacin-associated bowel perforations: a study of possible risk factors. Shorter NA, et al. **J Pediatr Surg** 1999 Mar;34(3):442-4

Antiulcer effect of lafutidine on indomethacin-induced gastric antral ulcers in refed rats. Onodera S, et al. **Jpn J Pharmacol** 1999 Jul;80(3):229-35

Nonsteroidal anti-inflammatory drug fetal nephrotoxicity. Bernstein J, et al. **Pediatr Dev Pathol** 1998 Mar-Apr; 1(2):153-6

Colitis induced by interaction of cyclosporine A and non-steroidal anti-inflammatory drugs. Constantopoulos A. **Pediatr Int** 1999 Apr;41(2):184-6

Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Hammerman C, et al. **Pediatrics** 1998 Nov;102(5):E56

[Psychiatric side effects of non-steroidal anti-inflammatory agents] Defromont L, et al. **Encephale** 1999 Jan-Feb; 25(1):11-5 (20 ref.) (Eng. Abstr.) **(Fre)**

["Sudden deafness" has not been classified as a side-effect. No compensation from the Drug Insurance Authority] Perman E. **Lakartidningen** 1999 Mar 10;96(10):1208 **(Swe)**

ANALOGS & DERIVATIVES

Anti-inflammatory and ulcerogenic effects of 3-(N,N-diethylamino) propylindometacin HCl. Huang ZL, et al. **Chung Kuo Yao Li Hsueh Pao** 1997 Jul;18(4):306-8

Acyloxymethyl acidic drug derivatives: in vitro hydrolytic reactivity. Redden PR, et al. **Int J Pharm** 1999 Apr 15; 180(2):151-60

ANALYSIS

Cathodic adsorptive stripping voltammetric determination of the anti-inflammatory drug indomethacin. Ali AM. **J Pharm Biomed Anal** 1999 Jan;18(6):1005-12

ANTAGONISTS & INHIBITORS

PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Rosenstock M, et al. **Biochim Biophys Acta** 1999 Aug 25;1440(1):127-37

BLOOD

Plasma indomethacin assay using high-performance liquid chromatography-electrospray-tandem mass spectrometry: application to therapeutic drug monitoring and pharmacokinetic studies. Taylor PJ, et al. **Ther Drug Monit** 1998 Dec;20(6):691-6

INDOMETHACIN

CHEMISTRY

Solid state studies of drug–cyclodextrin inclusion complexes in PEG 6000 prepared by a new method. Wulff M, et al. **Eur J Pharm Sci** 1999 Aug;8(4):269–81

Preparation of spray–dried microspheres of indomethacin and examination of the effects of coating on dissolution rates. Ermiş D, et al. **J Microencapsul** 1999 May–Jun;16(3):315–24

Effect of protective colloids on the induction of polymorphic changes in indomethacin agglomerates after solvent evaporation from o/w emulsions. Lin SY, et al. **J Microencapsul** 1999 Jan–Feb;16(1):39–47

Estimating the critical molecular mobility temperature (T(K)) of amorphous pharmaceuticals [letter] Hancock BC, et al. **Pharm Res** 1998 Nov;15(11):1649–51

Determination of the viscosity of an amorphous drug using thermomechanical analysis (TMA). Hancock BC, et al. **Pharm Res** 1999 May;16(5):672–5

DIAGNOSTIC USE

[A drug test with indomethacin in the diagnosis of subclinical forms of diabetic nephropathy] Man'kovskiĭ BN, et al. **Lik Sprava** 1999 Mar;(2):83–7 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Improved dissolution rate of indomethacin by adsorbents. Alsaidan SM, et al. **Drug Dev Ind Pharm** 1998 Apr; 24(4):389–94

METABOLISM

Interaction of indomethacin and naproxen with gastric surface–active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti–inflammatory drugs (NSAIDs). Giraud MN, et al. **Biochem Pharmacol** 1999 Feb 1;57(3):247–54

Evaluation of a sulfobutyl ether beta–cyclodextrin as a solubilizing/stabilizing agent for several drugs. Ueda H, et al. **Drug Dev Ind Pharm** 1998 Sep;24(9):863–7

Protein binding of some nonsteroidal anti–inflammatory drugs studied by high–performance liquid affinity chromatography. Russeva VN, et al. **Int J Pharm** 1999 Mar 25;180(1):69–74

PHARMACOKINETICS

Placental transfer of sulindac, sulindac sulfide, and indomethacin in a human placental perfusion model. Lampela ES, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):174–80

Cyclic monoterpene extract from cardamom oil as a skin permeation enhancer for indomethacin: in vitro and in vivo studies. Huang YB, et al. **Biol Pharm Bull** 1999 Jun; 22(6):642–6

Effect of geometrical cement size on in vitro and in vivo indomethacin release from self–setting apatite cement. Otsuka M, et al. **J Controlled Release** 1998 Mar 31; 52(3):281–9

Pharmacokinetics of indomethacin in sheep after intravenous and intramuscular administration. Vinagre E, et al. **J Vet Pharmacol Ther** 1998 Aug;21(4):309–14

Pharmacodynamic and pharmacokinetic evaluation of lipid microspheres of indomethacin. Srinath P, et al. **Pharm Acta Helv** 1998 Dec;73(4):199–203

Pharmacokinetics of indomethacin after intraruminal administration to sheep. Vinagre E, et al. **Zentralbl Veterinarmed A** 1999 Aug;46(6):361–6

PHARMACOLOGY

Clonogenic inactivation of colon cancer–derived cells treated with 5–fluorouracil and indomethacin in hybrid spheroids. Djordjevic B, et al. **Acta Oncol** 1998;37(7–8):735–9

Effects of nordihydroguaiaretic acid and indomethacin on the viability and functional activities of normal and carbon tetrachioride–injured rat hepatocytes cultured alone and with Kupffer cells. Makogon NV, et al. **Acta Physiol Pharmacol Bulg** 1998;23(2):33–8

Effects of nitroglycerin and indomethacin on fetal–maternal circulation and on fetal cerebral blood flow and metabolism in sheep. Skarsgard ED, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):440–5

The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia. Zlatnik MG, et al. **Am J Obstet Gynecol** 1999 May;180(5):1191–5

Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol–induced renal vasodilatation in sheep. de Matteo R, et al. **Am J Physiol** 1999 Apr;276(4 Pt 2):R1125–31

Indomethacin increases susceptibility to injury in human gastric cells independent of PG synthesis inhibition. Kokoska ER, et al. **Am J Physiol** 1998 Oct;275(4 Pt 1):G620–8

Inhibition of cyclooxygenase and nitric oxide synthase in hypoxic vasoconstriction and oleic acid–induced lung injury. Leeman M, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1383–90

Meloxicam and indomethacin activity on human matrix metalloproteinases in synovial fluid. Barracchini A, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:665–6

Indomethacin inhibits kidney metastasis in bomirski melanoma–bearing hamsters, and modulates natural killer cytotoxic activity of tumor hosts in vivo and in vitro. Bigda J, et al. **Anticancer Res** 1998 Sep–Oct;18(5A):3549–54

The effect of prostaglandin and its inhibitor on antibody–dependent cellular cytotoxicity against human squamous cell carcinoma of head and neck. Kim CD, et al. **Anticancer Res** 1999 Jan–Feb;19(1A):455–9

Effects of ketoralac tromethamine and indomethacin on primary and secondary bone healing. An experimental study in rats. Reikeraas O, et al. **Arch Orthop Trauma Surg** 1998;118(1–2):50–2

Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild–type p53 and/or up–regulation of c–myc. Zhu GH, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):193–200

In vitro evidence for mitochondrial effects of indomethacin. Jacob M, et al. **Biochem Soc Trans** 1998 Nov;26(4):S315

Non–steroidal anti–inflammatory drug–induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c–myc. Zhu GH, et al. **Br J Cancer** 1999 Feb;79(3–4):393–400

Effect of nimesulide and indomethacin on contractility and the Ca2+ channel current in myometrial smooth muscle from pregnant women. Sawdy R, et al. **Br J Pharmacol** 1998 Nov;125(6):1212–7

Enhanced protection of heat shock in myocardial infarction: inhibition of detrimental effect of systemic hyperthermia. Iliodromitis EK, et al. **Cardiovasc Drugs Ther** 1999 May; 13(3):223–31

Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications [see comments] Castellano AE, et al. **Cephalalgia** 1998 Nov;18(9):622–30. Comment in: Cephalalgia 1998 Nov;18(9):591–2.

Effects of indomethacin on joint damage in rat and rabbit. Wang B, et al. **Chung Kuo Yao Li Hsueh Pao** 1998 Jan; 19(1):70–3

Copper–indomethacinate associated with zwitterionic phospholipids prevents enteropathy in rats: effect on inducible NO synthase. Bertrand V, et al. **Dig Dis Sci** 1999 May;44(5):991–9

Cytokine–induced neutrophil chemoattractants in healing of gastric ulcers in rats: expression of >40–kDa chemoattractant in delayed ulcer healing by indomethacin. Yamada H, et al. **Dig Dis Sci** 1999 May;44(5):889–95

Proteins of rat serum IV. Time–course of acute–phase protein expression and its modulation by indomethacine. Eberini I, et al. **Electrophoresis** 1999 Apr–May;20(4–5):846–53

Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth. Inoue T, et al. **Eur J Pharmacol** 1998 Nov 20;361(2–3):285–91

Doppler sonographic study of the effect of indomethacin on cardiac and pulmonary hemodynamics of the preterm infant. Benders MJ, et al. **Eur J Ultrasound** 1999 May; 9(2):107–16

The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. Franklin IJ, et al. **Eur J Vasc Endovasc Surg** 1999 Jul;18(1):35–42

Modulation of erythropoiesis in rat bone marrow erythroblastic islands by cyclooxygenase inhibition. Kalaidjieva V. **Gen Pharmacol** 1999 Apr;32(4):423–8

Nonsteroidal anti–inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Giambartolomei S, et al. **Hepatology** 1999 Aug;30(2):510–6

Indomethacin inhibits lordosis induced by ring A–reduced progestins: possible role of 3alpha–oxoreduction in progestin–facilitated lordosis. Beyer C, et al. **Horm Behav** 1999 Feb;35(1):1–8

The effects of nonsteroidal anti–inflammatory drugs on immune functions of human peripheral blood mononuclear cells. Tanaka K, et al. **Immunopharmacology** 1998 Nov; 40(3):209–17

Effect of indomethacin on hyperthermia induced by heat stress in broiler chickens. Furlan RL, et al. **Int J Biometeorol** 1998 Dec;42(2):73–6

Inhibitory effects of indomethacin on interleukin–1 and nitric oxide production in rat microglia in vitro. Du ZY, et al. **Int J Immunopharmacol** 1999 Mar;21(3):219–25

Potentiation of bradykinin–induced responses by indomethacin in the intact and denuded epithelium of guinea pig tracheal preparations. Akbar A, et al. **Int J Tissue React** 1998;20(3):95–100

Differential effect of a selective cyclooxygenase–2 inhibitor versus indomethacin on renal blood flow in conscious volume–depleted dogs. Black SC, et al. **J Cardiovasc Pharmacol** 1998 Nov;32(5):686–94

Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase–2 in cancer development. Sawaoka H, et al. **J Clin Gastroenterol** 1998; 27 Suppl 1:S47–52

The structural and electronical factors that contribute affinity for the time–dependent inhibition of PGHS–1 by indomethacin, diclofenac and fenamates. Pouplana R, et al. **J Comput Aided Mol Des** 1999 May;13(3):297–313

Evidence of involvement of guanylate cyclase in the prolongation of caeco–colonic transit time by indomethacin in mice [letter] Robert FS, et al. **J Diarrhoeal Dis Res** 1998 Dec;16(4):256–7

Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down–regulating expression of genes encoding oxidase components. Condino–Neto A, et al. **J Immunol** 1998 Nov 1;161(9):4960–7

Gender–related effects of indomethacin on cerebrovascular CO2 reactivity [see comments] Kastrup A, et al. **J Neurol Sci** 1999 Jan 15;162(2):127–32. Comment in: J Neurol Sci 1999 Jan 15;162(2):113.

Gender differences in cerebral perfusion [editorial; comment] Meyer JS, et al. **J Neurol Sci** 1999 Jan 15;162(2):113. Comment on: J Neurol Sci 1999 Jan 15;162(2):127–32.

Effects of nimesulide and indometacin on COX–1 and COX–2: a comparative study. de Leval X, et al. **J Pharm Belg** 1999 May–Jun;54(3):89–90

Molecular basis of indomethacin–human serum albumin interaction. Trivedi VD, et al. **J Pharm Pharmacol** 1999 May;51(5):591–600

A new ulcer model, "unhealed gastric ulcers", induced by chronic treatment with indomethacin in rats with acetic acid ulcers. Amagase K, et al. **J Physiol Pharmacol** 1999 Jun;50(2):169–81

Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin–induced small intestinal lesions in rats. Konaka A, et al. **J Physiol Pharmacol** 1999 Mar;50(1):25–38

Role of caspase–3 and nitric oxide synthase–2 in gastric mucosal injury induced by indomethacin: effect of sucralfate. Slomiany BL, et al. **J Physiol Pharmacol** 1999 Mar;50(1):3–16

Relationship between vascular endothelial growth factor and angiogenesis in spontaneous and indomethacin–delayed healing of acetic acid–induced gastric ulcers in rats. Suzuki N, et al. **J Physiol Pharmacol** 1998 Dec;49(4):515–27

Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. Miralles M, et al. **J Vasc Surg** 1999 May; 29(5):884–92; discussion 892–3

Effects of indomethacin on the selective release of follicle–stimulating hormone during the period of ovulation in the rat. Shirota M, et al. **J Vet Med Sci** 1998 Oct; 60(10):1059–65

Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Fricker AF, et al. **Kidney Int** 1998 Dec;54(6):2089–97

15–Deoxy–delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene. Sinha D, et al. **Metabolism** 1999 Jun;48(6):786–91

Chemopreventive activity of celecoxib, a specific cyclooxygenase–2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis. Fischer SM, et al. **Mol Carcinog** 1999 Aug;25(4):231–40

Enhanced 9–(2–phosphonylmethoxyethyl)adenine secretion by a specific, indomethacin–sensitive efflux pump in a mutant 9–(2–phosphonylmethoxyethyl)adenine–resistant human erythroleukemia K562 cell line. Haise S, et al. **Mol Pharmacol** 1998 Nov;54(5):907–17

The influence of surgery and anesthesia on lymphocyte functions in breast cancer patients: in vitro effects of indomethacin. Stanojević–Bakić N, et al. **Neoplasma** 1999; 46(1):54–60

Mediation and modulation by eicosanoids of responses of spinal dorsal horn neurons to glutamate and substance P receptor agonists: results with indomethacin in the rat in vivo. Pitcher GM, et al. **Neuroscience** 1999;93(3):1109–21

NSAID–induced cyclooxygenase inhibition differentially depresses long–lasting versus brief synaptically–elicited responses of rat spinal dorsal horn neurons in vivo. Pitcher GM, et al. **Pain** 1999 Aug;82(2):173–86

Cerebrovascular responses to therapeutic dose of indomethacin in newborn pigs. Pourcyrous M, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):582–7

Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco–2 monolayers and excised rat jejunum. Flanagan SD, et al. **Pharm Res** 1999 Feb; 16(2):221–24

Intramuscular administration of cholera toxin in Balb/c mice induces an inflammatory reaction that is prevented by indomethacin. Moreno–Fierros L, et al. **Proc West Pharmacol Soc** 1998;41:103–6

Renal function and urinary prostanoid excretions in salt–depleted women: comparative effects of enalapril and indomethacin treatments. Agnoli GC, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Feb; 60(2):87–93

Effect of a restricted diet on the metabolism of glucose in uteri isolated from immature rats: influence of indomethacin and nordihydroguaiaretic acid. Finkelberg AB, et al. **Prostaglandins Leukot Essent Fatty Acids** 1998 Sep; 59(3):175–9

The reduction in alcohol intake in rats by isoproterenol is attenuated by indomethacin but not enalapril: relationship to blood glucose levels. Grupp LA, et al. **Psychopharmacology (Berl)** 1998 Jul;138(2):167–75

Modulating activity of indomethacin to vincristine cytotoxicity in various human carcinoma cells. Kobayashi S, et al. **Tohoku J Exp Med** 1998 Dec;186(4):313–22

The effects of maternal indomethacin therapy on human fetal branch pulmonary arterial vascular impedance. Rasanen J, et al. **Ultrasound Obstet Gynecol** 1999 Feb;13(2):112–6

Effects of the NSAIDs meloxicam and indomethacin on cartilage proteoglycan synthesis and joint responses to calcium pyrophosphate crystals in dogs. Rainsford KD, et al. **Vet Res Commun** 1999 Mar;23(2):101–13

[Neoplasm–inhibiting effect and sensitivity–promoting effect of indomethacin in vitro] Zhang G, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997;22(6):478–82 (Eng. Abstr.) **(Chi)**

[Effects of interleukin-1beta and indomethacin on interleukin-1beta gene expression in the brain hemispheres] Grebenshchikov AIu, et al. **Biull Eksp Biol Med** 1999 May; 127(5):557-9 **(Rus)**

[Long-term morphofunctional preservation of guinea pig hippocampal slices following short-term treatment with cyclooxygenase inhibitors] Pakhotin PI, et al. **Morfologiia** 1998;114(5):30-4 (Eng. Abstr.) **(Rus)**

POISONING

Incidence and outcome of a 10-fold indomethacin overdose in premature infants. Narayanan M, et al. **J Pediatr** 1999 Jul;135(1):105-7

THERAPEUTIC USE

Study on the course of Cryptosporidium baileyi infection in chickens treated with interleukin-1 or indomethacin. Hornok S, et al. **Acta Vet Hung** 1999;47(2):207-16

Hemodynamic and renal effects of indomethacin in losartan-treated hypertensive individuals. Olsen ME, et al. **Am J Hypertens** 1999 Feb;12(2 Pt 1):209-16

Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Frucht-Pery J, et al. **Am J Ophthalmol** 1999 Feb; 127(2):148-52

Congenital nephrotic syndrome responsive to captopril and indometacin. Heaton PA, et al. **Arch Dis Child** 1999 Aug; 81(2):174-5

Surgical excision of heterotopic bone after hip surgery followed by oral indomethacin application: is there a clinical benefit for the patient? Wick M, et al. **Arch Orthop Trauma Surg** 1999;119(3-4):151-5

The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Panter KR, et al. **Br J Obstet Gynaecol** 1999 May; 106(5):467-73

The effect of indomethacin on the cytokine cascade and body temperature following burn injury in rats. Caldwell FT Jr, et al. **Burns** 1999 Jun;25(4):283-94

Rectal indomethacin reduces postoperative pain and morphine use after cardiac surgery. Rapanos T, et al. **Can J Anaesth** 1999 Aug;46(8):725-30

Indomethacin and nitrate-induced headache [editorial; comment] Thomsen LL. **Cephalalgia** 1998 Nov;18(9):591-2 . Comment on: Cephalalgia 1998 Nov;18(9):622-30.

Indomethacin for brain edema following stroke. Schwarz S, et al. **Cerebrovasc Dis** 1999 Jul-Aug;9(4):248-50

Six-year results of a cementless stem with prophylaxis against heterotopic bone. Wurnig C, et al. **Clin Orthop** 1999 Apr; (361):150-8

Effect of combination of misoprostol and indomethacin on eicosanoid production in carrageenan-induced air pouch inflammation in rats. Sayar K, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):365-71

Effectiveness of indomethacin as an antitumor agent in Colon 26-bearing conventional and nude mice, and telomerase activity in the tumors. Ogino M, et al. **Exp Anim** 1999 Jan;48(1):15-21

Indomethacin reduces the skin thermal damage in hyperthermic treatment of experimental malignant tumors. Ostapenko VV, et al. **In Vivo** 1999 May-Jun;13(3):255-7

Effects of indomethacin on secretory function of synoviocytes from adjuvant arthritis rats. Wang B, et al. **Int J Tissue React** 1998;20(3):91-4

The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. Perico N, et al. **J Am Soc Nephrol** 1998 Dec;9(12):2308-17

Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Ogino M, et al. **Jpn J Cancer Res** 1999 Jul;90(7):758-64

Use of indomethacin in Langerhans cell histiocytosis. Munn SE, et al. **Med Pediatr Oncol** 1999 Apr;32(4):247-9

General short-term indomethacin prophylaxis to prevent heterotopic ossification in total hip arthroplasty. Hofmann S, et al. **Orthopedics** 1999 Feb;22(2):207-11

Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients. Stanojević-Bakić N, et al. **Panminerva Med** 1998 Dec; 40(4):314-8

Indomethacin treatment slows disease progression and enhances a Th1 response in susceptible BALB/c mice infected with Leishmania major. De Freitas LA, et al. **Parasite Immunol** 1999 May;21(5):273-7

Furosemide in indomethacin-treated infants--systematic review and meta-analysis. Brion LP, et al. **Pediatr Nephrol** 1999 Apr;13(3):212-8

Indomethacin improves oxygen-induced retinopathy in the mouse. Nandgaonkar BN, et al. **Pediatr Res** 1999 Aug; 46(2):184-8

The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case. Kobayashi S, et al. **Surg Today** 1999;29(7):666-9

Desmopressin versus indomethacin treatment in primary nocturnal enuresis and the role of prostaglandins. Sener F, et al. **Urology** 1998 Nov;52(5):878-81

TOXICITY

Indomethacin-induced gastric antral damage in hamsters: are neutrophils involved? Fitzpatrick LR, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):195-202

Protective effects of zinc in indomethacin-induced gastric mucosal injury: evidence for a dual mechanism involving lipid peroxidation and nitric oxide. Joseph RM, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):203-8

Influence of rebamipide on indometacin-induced gastric hemorrhage in rats under restraint stress. Yamasaki K, et al. **Arzneimittelforschung** 1999 Apr;49(4):359-65

Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Bertrand V, et al. **Br J Pharmacol** 1998 Aug;124(7):1385-94

Prostaglandin, tumor necrosis factor alpha and neutrophils: causative relationship in indomethacin-induced stomach injuries. Ding SZ, et al. **Eur J Pharmacol** 1998 May 8; 348(2-3):257-63

New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. Sikirić P, et al. **Eur J Pharmacol** 1999 Jan 1;364(1):23-31

Role of nitric oxide in indomethacin-induced gastric mucosal dysfunction in the rat. Gürbüz V, et al. **Exp Physiol** 1999 Mar;84(2):319-32

Role of the proteasome in rat indomethacin-induced gastropathy [see comments] Brand SJ, et al. **Gastroenterology** 1999 Apr;116(4):865-73. Comment in: Gastroenterology 1999 Apr;116(4):994-6.

Less degradation, more shock, please [editorial; comment] Bush KT, et al. **Gastroenterology** 1999 Apr;116(4):994-5. Comment on: Gastroenterology 1999 Apr;116(4):865-73.

Protective effect of melatonin on indomethacin-induced gastric injury in rats. Alarcón de la Lastra C, et al. **J Pineal Res** 1999 Mar;26(2):101-7

Role of antioxidants in gastric mucosal damage induced by indomethacin in rats. Hassan A, et al. **Methods Find Exp Clin Pharmacol** 1998 Dec;20(10):849-54

Indomethacin-induced disturbances in villous microcirculation in the rat ileum. Ruh J, et al. **Microvasc Res** 1999 Sep;58(2):137-43

Protective effect of lactosucrose on intracolonic indomethacin-induced small-intestinal ulcers in rats. Honda K, et al. **Scand J Gastroenterol** 1999 Mar;34(3):264-9

Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. Sigthorsson G, et al. **Scand J Gastroenterol** 1998 Jul;33(7):728-35

URINE

Study of the solid-phase extraction of diclofenac sodium, indomethacin and phenylbutazone for their analysis in human urine by liquid chromatography. Bakkali A, et al. **J Chromatogr B Biomed Sci Appl** 1999 Jun 11; 729(1-2):139-45

INDOOR AIR POLLUTION see **AIR POLLUTION, INDOOR**

INDOOR AIR QUALITY see **AIR POLLUTION, INDOOR**

INDOPACETUS see **WHALES**

INDOPHENOL

ANALOGS & DERIVATIVES

Cardiovascular responses produced by microinjection of serotonin-receptor agonists into the paraventricular nucleus in conscious rats. Bell AA, et al. **J Cardiovasc Pharmacol** 1999 Feb;33(2):175-80

NH4+ utilization and regeneration rates in freshwater lakes determined by GC-MS of derivatised dihydroindophenol. Köster O, et al. **J Microbiol Methods** 1999 Jul;37(1):65-76

Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI). Wettstein JG, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1999 Apr; 23(3):533-44

INDOPROFEN

CHEMISTRY

Computer simulation of the interaction of non-steroidal anti-inflammatory drugs: indoprofen and NS398 with cyclooxygenase. Kothekar V, et al. **J Biomol Struct Dyn** 1999 Feb;16(4):901-15

INDORAMIN

ADVERSE EFFECTS

Cutaneous eruption due to indoramin [letter] Farrell AM, et al. **Clin Exp Dermatol** 1998 Sep;23(5):233

[Hyperprolactinemia induced by indoramin (letter)] Pradalier A, et al. **Therapie** 1998 Sep-Oct;53(5):500-2 **(Fre)**

PHARMACOLOGY

Effects of indoramin in rat vas deferens and aorta: concomitant alpha1-adrenoceptor and neuronal uptake blockade. Pupo AS, et al. **Br J Pharmacol** 1999 Aug; 127(8):1832-6

THERAPEUTIC USE

A prospective placebo controlled double blind randomised study to investigate the use of indoramin to prevent post-operative voiding disorders after surgical treatment for genuine stress incontinence. Watson AJ, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):270-2

INDRI see **STREPSIRHINI**

INDRIIDAE see **STREPSIRHINI**

INDUCER CELLS see **T-LYMPHOCYTES, HELPER-INDUCER**

INDUS DOLPHIN see **DOLPHINS**

INDUSTRIAL ARTS see **TECHNOLOGY**

INDUSTRIAL HEALTH see **OCCUPATIONAL HEALTH**

INDUSTRIAL HYGIENE see **OCCUPATIONAL HEALTH**

INDUSTRIAL MEDICINE see **OCCUPATIONAL MEDICINE**

INDUSTRIAL MICROBIOLOGY

see related
GENETIC ENGINEERING

Industrial microbiologists in the area of microfungi. Szentirmai A. **Acta Microbiol Immunol Hung** 1999; 46(2-3):303-5

New perspectives on microbial dehalogenation of chlorinated solvents: insights from the field. Lee MD, et al. **Annu Rev Microbiol** 1998;52:423-52 (104 ref.)

Surface-active lipids in rhodococci. Lang S, et al. **Antonie Van Leeuwenhoek** 1998 Jul-Oct;74(1-3):59-70 (70 ref.)

High-density Escherichia coli cultures for continuous L(-)-carnitine production. Obón JM, et al. **Appl Microbiol Biotechnol** 1999 Jun;51(6):760-4

Technological and economic aspects of coal biodesulfurisation. Klein J. **Biodegradation** 1998; 9(3-4):293-300

Laboratory evaluation of crude oil biodegradation with commercial or natural microbial inocula. Thouand G, et al. **Can J Microbiol** 1999 Feb;45(2):106-15

Industrial dye decolorization by laccases from ligninolytic fungi. Rodriguez E, et al. **Curr Microbiol** 1999 Jan; 38(1):27-32

Novel approaches for discovering industrial enzymes. Marrs B, et al. **Curr Opin Microbiol** 1999 Jun;2(3):241-5 (40 ref.)

Ecology and industrial microbiology techniques. Web alert. Waterman SR. **Curr Opin Microbiol** 1999 Jun;2(3):231-2

Web alert. Ecology and industrial microbiology techniques. Waterman SR. **Curr Opin Microbiol** 1998 Jun;1(3):265-6

Microbial remediation of NTO in aqueous industrial wastes. Le Campion L, et al. **FEMS Microbiol Lett** 1999 Jul 1; 176(1):197-203

Chromium-tolerant bacteria isolated from industrial effluents and their use in detoxication of hexavalent chromium. Shakoori AR, et al. **Folia Microbiol (Praha)** 1999;44(1):50-4

Value of Discovery is questioned [news] Dorey E. **Nat Biotechnol** 1999 Jun;17(6):530-1

Microbial enzymes: new industrial applications from traditional screening methods. Ogawa J, et al. **Trends Biotechnol** 1999 Jan;17(1):13-21 (63 ref.)

Bacteria designed for bioremediation. Timmis KN, et al. **Trends Biotechnol** 1999 May;17(5):200-4

[Status of local immunity in populations of regions with microbiological and chemical enterprises] Litovskaia AV, et al. **Gig Sanit** 1998 Sep-Oct;(5):52-4 **(Rus)**

[Development of microbiological technology of air deodoration in laboratory-industrial conditions using a pilot plant] Zhukov VG, et al. **Prikl Biokhim Mikrobiol** 1998 Jul-Aug;34(4):370-6 (Eng. Abstr.) **(Rus)**

HISTORY

The genetics of industrial microorganisms: the first half century. Robinson C. **Trends Biotechnol** 1999 May; 17(5):178-81

METHODS

Continuous production of L(+)-lactic acid by Lactobacillus casei in two-stage systems. Bruno-Bárcena JM, et al. **Appl Microbiol Biotechnol** 1999 Mar;51(3):316-24

Dialysis cultures. Pörtner R, et al. **Appl Microbiol Biotechnol** 1998 Oct;50(4):403-14

Flotation characteristics of cyanobacterium Anabaena flos-aquae for gas vesicle production. Kashyap S, et al. **Biotechnol Bioeng** 1998 Dec 5;60(5):636-41

Differentiation of brewing yeast strains by pyrolysis mass spectrometry and Fourier transform infrared spectroscopy. Timmins EM, et al. **Yeast** 1998 Jul;14(10):885-93

INDUSTRIAL NURSING see **OCCUPATIONAL HEALTH NURSING**

INDUSTRIAL OILS

Male torque strength in simulated oil rig tasks: the effects of grease-smeared gloves and handle length, diameter and orientation. Imrhan SN, et al. **Appl Ergon** 1999 Oct; 30(5):455–62

Comparison between supercritical carbon dioxide extraction and aqueous surfactant washing of an oily machining waste. Fu H, et al. **J Hazard Mater** 1999 Jun 11;67(2):197–213

ADVERSE EFFECTS

Substitution of organic solvent cleaning agents in the lithographic printing industry: comment [letter] Packham C. **Ann Occup Hyg** 1999 Aug;43(6):429–30

Contact allergy to 2-aminoethanol (monoethanolamine) in a soluble oil. Bhushan M, et al. **Contact Dermatitis** 1998 Dec;39(6):321

Risk-informed selection of a highway trajectory in the neighborhood of an oil-refinery. Papazoglou IA, et al. **J Hazard Mater** 1999 Jun 11;67(2):111–44

Cancer mortality among workers exposed to chemicals during uranium processing. Ritz B. **J Occup Environ Med** 1999 Jul;41(7):556–66

Multi-elemental analysis of jet engine lubricating oils and hydraulic fluids and their implication in aircraft air quality incidents. van Netten C. **Sci Total Environ** 1999 May 7; 229(1–2):125–9

ANALYSIS

Multi-elemental analysis of jet engine lubricating oils and hydraulic fluids and their implication in aircraft air quality incidents. van Netten C. **Sci Total Environ** 1999 May 7; 229(1–2):125–9

MICROBIOLOGY

Bacterial pollution of cutting fluids: a risk factor for occupational diseases. Jakšić S, et al. **Arh Hig Rada Toksikol** 1998 Sep;49(3):239–44

The degradation of sodium O,O-diethyl dithiophosphate by bacteria from metalworking fluids. Sherburn RE, et al. **Lett Appl Microbiol** 1999 Jan;28(1):61–5

INDUSTRIAL WASTE

Photodegradation of organic waste coupling hydrogenase and titanium dioxide. Mura GM, et al. **Ann N Y Acad Sci** 1999 Jun 30;879:267–75

High-rate anaerobic treatment of wastewater at low temperatures. Lettinga G, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1696–702

Selection of clc, cba, and fcb chlorobenzoate-catabolic genotypes from groundwater and surface waters adjacent to the Hyde park, Niagara Falls, chemical landfill. Peel MC, et al. **Appl Environ Microbiol** 1999 Apr;65(4):1627–35

Degradation of cyanide in agroindustrial or industrial wastewater in an acidification reactor or in a single-step methane reactor by bacteria enriched from soil and peels of cassava. Siller H, et al. **Appl Microbiol Biotechnol** 1998 Sep;50(3):384–9

Oxidation of 2-chlorophenol wastewater by hydrogen peroxide in the presence of basic oxygen furnace slag. Li Y, et al. **Bull Environ Contam Toxicol** 1999 Mar; 62(3):336–43

Influence of dyeing and bleaching industries on ground water of Tirupur, Tamilnadu, India. Senthilnathan S, et al. **Bull Environ Contam Toxicol** 1999 Mar;62(3):330–5

Algae growth potential measurement in distillery wastes. Travieso L, et al. **Bull Environ Contam Toxicol** 1999 Apr; 62(4):483–9

Contribution of nonpolar organic compounds to the toxicity of a chemical works effluent. Yang L, et al. **Bull Environ Contam Toxicol** 1999 Apr;62(4):434–9

Assessment of industrial effluent toxicity using flow-through fish egg/alevins/fry (EAF) Toxicity Test. Yang R, et al. **Bull Environ Contam Toxicol** 1999 Apr;62(4):440–7

The environmental fate of the primary degradation products of alkylphenol ethoxylate surfactants in recycled paper sludge. Hawrelak M, et al. **Chemosphere** 1999 Aug; 39(5):745–52

Dioxin and dibenzofuran concentrations in adipose tissue of a general population from Tarragona, Spain. Schuhmacher M, et al. **Chemosphere** 1999 May;38(11):2475–87

Increased thyroid volume and prevalence of thyroid disorders in an area heavily polluted by polychlorinated biphenyls. Langer P, et al. **Eur J Endocrinol** 1998 Oct; 139(4):402–9

Clostridium methoxybenzovorans sp. nov., a new aromatic o-demethylating homoacetogen from an olive mill wastewater treatment digester. Mechichi T, et al. **Int J Syst Bacteriol** 1999 Jul;49 Pt 3:1201–9

Selective on-line immunoextraction coupled to liquid chromatography for the trace determination of benzidine, congeners and related azo dyes in surface water and industrial effluents. Bouzige M, et al. **J Chromatogr A** 1999 Jun 18;846(1–2):317–29

Application of gas and liquid chromatography–mass spectrometry to the evaluation of pirimiphos methyl degradation products in industrial water under ozone treatment. Chiron S, et al. **J Chromatogr A** 1998 Oct 9; 823(1–2):97–107

Solvent-free method for the determination of polynuclear aromatic hydrocarbons in waste water by solid-phase microextraction–high-performance liquid chromatography with photodiode-array detection. Negrão MR, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):211–8

Survival and chromate reducing ability of Pseudomonas aeruginosa in industrial effluents. Ganguli A, et al. **Lett Appl Microbiol** 1999 Jan;28(1):76–80

Genotoxicity of soil from farmland irrigated with wastewater using three plant bioassays. Cabrera GL, et al. **Mutat Res** 1999 May 19;426(2):211–4

Genotoxicity of leachates from a landfill using three bioassays. Cabrera GL, et al. **Mutat Res** 1999 May 19; 426(2):207–10

Assessment of the genotoxicity of mine-dump material using the Tradescantia-stamen hair (Trad-SHM) and the Tradescantia-micronucleus (Trad-MCN) bioassays. Fomin A, et al. **Mutat Res** 1999 May 19;426(2):173–81

Clastogenicity of chromium contaminated soil samples evaluated by Vicia root-micronucleus assay. Wang H. **Mutat Res** 1999 May 19;426(2):147–9

Nutrient digestibility in food waste ingredients for Pekin and Muscovy ducks. Farhat A, et al. **Poult Sci** 1998 Sep; 77(9):1371–6

The fate of heavy oil wastes in soil microcosms. I: A performance assessment of biotransformation indices. Pollard SJ, et al. **Sci Total Environ** 1999 Feb 2;226(1):1–22

The fate of heavy oil wastes in soil microcosms. II: A performance assessment of source correlation indices. Whittaker M, et al. **Sci Total Environ** 1999 Feb 2; 226(1):23–34

[Industrial waste as indicator of population size: possible utilization in mountain resort tourist stations?] Olive F, et al. **Rev Epidemiol Sante Publique** 1998 Sep;46(4):299–304 (Eng. Abstr.) **(Fre)**

[An alternative approach to the classification of hazards of industrial waste] Antomonov MIu. **Gig Sanit** 1999 Jul–Aug; (4):62–4 **(Rus)**

[Hygienic assessment of damaging exposure of schoolchildren to butyl mercaptan] Tibekin AT. **Gig Sanit** 1998 Sep–Oct; (5):68–9 **(Rus)**

ADVERSE EFFECTS

Morphological masculinization in poeciliid females from a paper mill effluent receiving tributary of the St. Johns River, Florida, USA. Bortone SA, et al. **Bull Environ Contam Toxicol** 1999 Aug;63(2):150–6

Estimation of the hazard concentration of industrial wastewaters using algal bioassay. Gamila HA, et al. **Bull Environ Contam Toxicol** 1999 Sep;63(3):407–14

Mutagenicity tests on the bacteria and the detection of genotoxicity of industrial complex mixtures containing PAHs. Malachová K. **Cent Eur J Public Health** 1998 Nov; 6(4):307–13

Biodegradation and toxicity of wastewater from industry producing mineral fibres for thermal insulation. Tišler T, et al. **Chemosphere** 1999 Mar;38(6):1347–52

Responsiveness of the hypothalamo-pituitary-interrenal axis in an amphibian (Bufo terrestris) exposed to coal combustion wastes. Hopkins WA, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1999 Feb;122(2):191–6

Altered challenge response in whitefish subchronically exposed in areas polluted by bleached kraft mill effluents. Lappivaara J, et al. **Ecotoxicol Environ Saf** 1999 Mar; 42(3):212–22

Indicators of immunotoxicity in populations of cotton rats (Sigmodon hispidus) inhabiting an abandoned oil refinery. McMurry ST, et al. **Ecotoxicol Environ Saf** 1999 Mar; 42(3):223–35

Expression of the vitellogenin gene in the liver of juvenile whitefish (Coregonus lavaretus L. s.l.) exposed to effluents from pulp and paper mills. Mellanen P, et al. **Ecotoxicol Environ Saf** 1999 Jun;43(2):133–7

Chemical wastes, children's health, and the Superfund Basic Research Program. Landrigan PJ, et al. **Environ Health Perspect** 1999 Jun;107(6):423–7 (44 ref.)

Hepatic alterations and induction of micronuclei in rainbow trout (Oncorhynchus mykiss) exposed to a textile industry effluent. Marlasca MJ, et al. **Histol Histopathol** 1998 Jul; 13(3):703–12

Trichloroethylene. I. Carcinogenicity of trichloroethylene. Motohashi N, et al. **In Vivo** 1999 May–Jun;13(3):211–4 (37 ref.)

Environmental exposure to asbestos in asbestos cement workers: a case of additional exposure from indiscriminate use of industrial wastes. Szeszenia-Dąbrowska N, et al. **Int J Occup Med Environ Health** 1998;11(2):171–7

Effects of synthetic pyrethroids and methidation on activities of some digestive enzymes in carp (Cyprinus carpio L.). Simon LM, et al. **J Environ Sci Health B** 1999 Sep; 34(5):819–28

Flow cytometric measurement of micronuclei induced in a permanent fish cell line as a possible screening test for the genotoxicity of industrial waste waters. Kohlpoth M, et al. **Mutagenesis** 1999 Jul;14(4):397–402

A multidisciplinary approach using several biomarkers, including a parasite, as indicators of pollution: a case history from a paper mill in Newfoundland. Khan RA, et al. **Parassitologia** 1997 Sep;39(3):183–8

Audiological disturbances caused by long-term exposure to industrial solvents. Relation to the diagnosis of toxic encephalopathy. Niklasson M, et al. **Scand Audiol** 1998; 27(3):131–6

Lead concentration in blood samples of humans and animals near an industrial waste dump in Sao Paulo, Brazil. Kuno R, et al. **Vet Hum Toxicol** 1999 Aug;41(4):249–51

[The relationship of population morbidity to specific industrial wastes] Sheshunov IV, et al. **Gig Sanit** 1999 May–Jun;(3):5–9 (Eng. Abstr.) **(Rus)**

[A decrease in the motor activity of children under the influence of technogenic air pollution] Ust'iantsev SL, et al. **Gig Sanit** 1999 Mar–Apr;(2):26–8 (Eng. Abstr.) **(Rus)**

[The immunological reactivity of children living under conditions of the action of low doses of ionizing radiation and of industrial waste] Markevych VE, et al. **Lik Sprava** 1999 Apr–May;(3):49–53 (Eng. Abstr.) **(Ukr)**

ANALYSIS

Identification of polar toxicants in industrial wastewaters using toxicity-based fractionation with liquid chromatography/mass spectrometry. Castillo M, et al. **Anal Chem** 1999 Sep 1;71(17):3769–76

Biotechnological possibilities for waste tyre-rubber treatment. Holst O, et al. **Biodegradation** 1998;9(3–4):301–10

Biodegradation of petroleum-based oil wastes through composting. Kirchmann H, et al. **Biodegradation** 1998; 9(2):151–6

Accelerated coffee pulp composting. Sánchez G, et al. **Biodegradation** 1999 Feb;10(1):35–41

Identification of ammonia and volatile phenols as primary toxicants in a coal gasification effluent. Jin H, et al. **Bull Environ Contam Toxicol** 1999 Sep;63(3):399–406

Biological treatment of whey by Tetrahymena pyriformis and impact study on laboratory-scale wastewater lagoon process. Bonnet JL, et al. **Chemosphere** 1999 Jun; 38(13):2979–93

Anaerobic formation and degradation of toxic aromatic compounds in agricultural and communal sewage deposits. Hofmann K, et al. **Chemosphere** 1999 May;38(11):2561–8

Physical-chemical and ecotoxicological evaluation of water based drilling fluids used in Italian off-shore. Terzaghi C, et al. **Chemosphere** 1998 Dec;37(14–15):2859–71

Quantities of bisphenol a leached from plastic waste samples. Yamamoto T, et al. **Chemosphere** 1999 May;38(11):2569–76

Treatment of ethylether in air stream by a biotrickling filter packed with slags. Chou MS, et al. **J Air Waste Manag Assoc** 1999 May;49(5):533–43

Comparative studies of the leachate of an industrial landfill by gas chromatography–mass spectrometry, liquid chromatography–nuclear magnetic resonance and liquid chromatography–mass spectrometry. Benfenati E, et al. **J Chromatogr A** 1999 Jan 29;831(2):243–56

Determination of organic anions in waste liquid of sodium hydrosulfite production by ion chromatography. Ding M, et al. **J Chromatogr A** 1999 Apr 16;839(1–2):233–7

[The use of chromatographic methods in controlling wastes in the pharmaceutical industry] Zinov'eva NP, et al. **Gig Sanit** 1999 May–Jun;(3):66–8 **(Rus)**

INDUSTRIALIZATION see **INDUSTRY**

INDUSTRIALIZED COUNTRIES see **DEVELOPED COUNTRIES**

INDUSTRY

see related
COMMERCE
OCCUPATIONAL DISEASES
OCCUPATIONAL MEDICINE
WORKPLACE

Recent trends and controversies in industry-sponsored clinical trials. Reed CR, et al. **Acad Emerg Med** 1999 Aug; 6(8):833–9 (37 ref.)

A sociological case study of occupational accidents in the Brazilian petrochemical industry. Galli E. **Accid Anal Prev** 1999 Jul;31(4):297–304

Allergic contact dermatitis in American aircraft manufacture. Hackett JP. **Am J Contact Dermat** 1999 Sep;10(3):157–66

Acute traumatic injuries in automotive manufacturing. Warner M, et al. **Am J Ind Med** 1998 Oct;34(4):351–8

Caveat emptor [letter; comment] Brown D. **Am J Orthop** 1998 Oct;27(10):705. Comment on: Am J Orthop 1998 Aug;27(8):545.

Caveat emptor [editorial] [see comments] Gould JS. **Am J Orthop** 1998 Aug;27(8):545. Comment in: Am J Orthop 1998 Oct;27(10):705.

An investigation of factors contributing to styrene and styrene-7,8-oxide exposures in the reinforced-plastics industry. Nylander-French LA, et al. **Ann Occup Hyg** 1999 Feb;43(2):99–105

Proceedings of the 20th Symposium on Biotechnology for Fuels and Chemicals. Gatlinburg, Tennessee, USA. May 3–7, 1998. **Appl Biochem Biotechnol** 1999 Spring; 77–79:1–884

Decolorization and detoxification of extraction-stage effluent from chlorine bleaching of kraft pulp by Rhizopus oryzae. Nagarathnamma R, et al. **Appl Environ Microbiol** 1999 Mar; 65(3):1078–82

The role of 'know-how' in maintenance activities and reliability in a high-risk process control plant. Garrigou A, et al. **Appl Ergon** 1998 Apr;29(2):127–31

The South Karelia Air Pollution Study: changes in respiratory health in relation to emission reduction of

malodorous sulfur compounds from pulp mills. Jaakkola JJ, et al. **Arch Environ Health** 1999 Jul–Aug;54(4):254–63
Quality control of beer hopped with reduced isomerised products. Kátia J, et al. **Arch Latinoam Nutr** 1998 Sep; 48(3):242–6
Air pollution in Sibenik before and after the shutdown of major local industries. Tomić T, et al. **Arh Hig Rada Toksikol** 1998 Mar;49(1):9–18
The new pariahs: discourse on the tobacco industry in the Sydney press, 1993–97. Christofides N, et al. **Aust N Z J Public Health** 1999 Jun;23(3):233–9
Community perceptions about the tobacco industry and tobacco control funding. Wakefield M, et al. **Aust N Z J Public Health** 1999 Jun;23(3):240–4
The chemical control of biofouling in industrial water systems. Cloete TE, et al. **Biodegradation** 1998;9(1):23–37 (83 ref.)
Abatement of volatile organic sulfur compounds in odorous emissions from the bio–industry. Smet E, et al. **Biodegradation** 1998;9(3–4):273–84
Validation of hippuric acid as a biomarker of toluene exposure. Duydu Y, et al. **Bull Environ Contam Toxicol** 1999 Jul;63(1):1–8
Cereal alpha–amylase inhibitors cause occupational sensitization in the wood industry. López–Rico R, et al. **Clin Exp Allergy** 1998 Oct;28(10):1286–91
Prevalence and determinants of current contraceptive method use in a palm oil company in Cameroon. Ekani–Bessala MM, et al. **Contraception** 1998 Jul; 58(1):29–34
Issues of quality and practicability in task analysis: preliminary results from two surveys. Ainsworth L, et al. **Ergonomics** 1998 Nov;41(11):1607–17
Health behavior, quality of work life, and organizational effectiveness in the lumber industry. Donaldson SI, et al. **Health Educ Behav** 1999 Aug;26(4):579–91
Demographic evaluation of the fertility of aluminium industry workers: influence of exposure to heat and static magnetic fields. Mur JM, et al. **Hum Reprod** 1998 Jul; 13(7):2016–9
Awareness of periodontal disease--the role of industry. Ishikawa I, et al. **Int Dent J** 1998 Jun;48(3 Suppl 1):261–7 (68 ref.)
The effects of outsourcing on occupational health and safety: a comparative study of factory–based workers and outworkers in the Australian clothing industry. Mayhew C, et al. **Int J Health Serv** 1999;29(1):83–107
Working with asbestos in Russia [letter] Izmerov N, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):59–61
DBCP in global context: the unchecked power of multinational corporations [editorial] LaDou J. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):151–3
Industry pressures on scientific investigators [letter] Legator MS. **Int J Occup Environ Health** 1998 Apr–Jun;4(2):133
The conflict–prone nature of occupational health research and practice. Nemery B. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):35–7 (12 ref.)
Working with asbestos in Brazil [letter] [see comments] Rangé J. **Int J Occup Environ Health** 1998 Jan–Mar; 4(1):56–8. Comment in: Int J Occup Environ Health 1998 Jul–Sep;4(3):206.
Globally asbestos–free automobiles [letter] Rangé J. **Int J Occup Environ Health** 1999 Jul–Sep;5(3):242–3
Evaluation of pollution prevention options to reduce styrene emissions from fiber–reinforced plastic open molding processes. Nunez CM, et al. **J Air Waste Manag Assoc** 1999 Mar;49(3):256–67
Healthy volunteer effect in industrial workers. Froom P, et al. **J Clin Epidemiol** 1999 Aug;52(8):731–5
Real–time measurement of sub–PPM concentrations of airborne chemicals in semiconductor manufacturing. Corn M, et al. **J Expo Anal Environ Epidemiol** 1993;3 Suppl 1:37–49
High lead exposures resulting from pottery production in a village in Michoacán State, Mexico. Hibbert R, et al. **J Expo Anal Environ Epidemiol** 1999 Jul–Aug;9(4):343–51
Residential proximity to industry and adverse birth outcomes [letter] Bhopal RS, et al. **Lancet** 1999 Sep 11; 354(9182):920–1
Why buy biotech? [editorial; comment] **Nat Biotechnol** 1999 Feb;17(2):111. Comment on: Nat Biotechnol 1999 Feb;17(2):128. Comment on: Nat Biotechnol 1999 Feb;17(2):165–9.
Core ethical values for European bioindustries. Fears R, et al. **Nat Biotechnol** 1999 Feb;17(2):114–5
The new channel on the crisis radar screen. Middleberg D. **Nat Biotechnol** 1998 Oct;16(10):977–8
Japan turns to functional genomics [news] Saegusa A. **Nat Biotechnol** 1999 Jun;17(6):527–8
Industry calls for reform of UK research training [news] Dickson D. **Nat Med** 1998 Nov;4(11):1214
Growing pains of a genomics industry [letter; comment] Huang GM. **Nature** 1998 Nov 26;396(6709):307. Comment on: Nature 1998 Aug 6;394(6693):601–4.
Israeli industry asks for boost to R&D [news] Watzman H. **Nature** 1998 Dec 17;396(6712):611
Combination of low back pain and previous low back pain and shoulder stiffness in construction employees. Shirai Y, et al. **Nippon Ika Daigaku Zasshi** 1998 Aug;65(4):307–11
Trends in rates of occupational fatal injuries in the United States (1983–92). Bailer AJ, et al. **Occup Environ Med** 1998 Jul;55(7):485–9
Occupational risk factors of lung cancer: a hospital based case–control study. Droste JH, et al. **Occup Environ Med** 1999 May;56(5):322–7
Heavy physical work and occurrence of sciatic pain: need for Poisson log linear models or for better data? [letter; comment] Leclerc A, et al. **Occup Environ Med** 1998 Jul; 55(7):503–5. Comment on: Occup Environ Med 1997 Nov;54(11):807–11.
Health effects among workers in sewage treatment plants. Rylander R. **Occup Environ Med** 1999 May;56(5):354–7
Urinary 1–hydroxypyrene concentrations in coke oven workers. Wu MT, et al. **Occup Environ Med** 1998 Jul; 55(7):461–7
Bioavailability of iron in cottonseed meal, ferric sulfate, and two ferrous sulfate by–products of the galvanizing industry. Boling SD, et al. **Poult Sci** 1998 Sep;77(9):1388–92
Climate forcings in the industrial era. Hansen JE, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):12753–8 (47 ref.)
La roca magica: uses of natural zeolites in agriculture and industry. Mumpton FA. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3463–70 (106 ref.)
Relationship between shift work and onset of hypertension in a cohort of manual workers. Morikawa Y, et al. **Scand J Work Environ Health** 1999 Apr;25(2):100–4
Proceedings of the 7th NRSP–7/USDA Workshop Drugs in Aquaculture: Current Status, Future Goals. **Vet Hum Toxicol** 1998;40 Suppl 2:1–64
[Chronic obstructive lung disease in the industrial milieu] Pairon JC, et al. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S34–5 **(Fre)**
[Neurologic side effects of chemicals used in industry] Igisu H, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(27 Pt 2):628–32 (16 ref.) **(Jpn)**
[Some occupational determinants of work disability] Szubert Z, et al. **Med Pr** 1999;50(1):43–50 (Eng. Abstr.) **(Pol)**
[The evaluation of the effect of chemical and radiation factors on the health of the population in an industrial city] Konyshina LG, et al. **Gig Sanit** 1999 Mar–Apr;(2):37–40 (Eng. Abstr.) **(Rus)**
[The hygienic characteristics of the heavy metal pollution of the environment of an industrial region and the immune status of children] Paran'ko NM, et al. **Gig Sanit** 1999 Mar–Apr;(2):51–4 **(Rus)**
[The ecological epidemiological and immunological characteristics of infectious diseases in a large industrial region of the Don Basin (a review of the literature)] Frolov VM, et al. **Lik Sprava** 1999 Apr–May;(3):38–41 (32 ref.) **(Rus)**
[Occupational psychiatry: major stages and prospects of development (review of literature)] Beliaeva GG. **Med Tr Prom Ekol** 1999;(7):33–7 (37 ref.) **(Rus)**
[Today and tomorrow of the Ekaterinburg Medical Scientific Center of Preventive Medicine and Health Protection of Workers of industrial enterprises] Domnin SG. **Med Tr Prom Ekol** 1998;(8):6–10 **(Rus)**
[Combined effect of noise and electromagnetic fields of industrial frequency (experimental study)] Khudnitskii SS, et al. **Med Tr Prom Ekol** 1999;(6):38–40 **(Rus)**
[Analysis of electromagnetic absorption in biologic objects with industrial high–frequency heating of dielectric materials] Rudakov ML. **Med Tr Prom Ekol** 1999;(6):6–10 (Eng. Abstr.) **(Rus)**
[Epidemiology of bronchial asthma in a large industrial region] Leshchenko IV, et al. **Ter Arkh** 1998;70(12):41–3 (Eng. Abstr.) **(Rus)**

ECONOMICS

From concept to market in industrial impedance applications. Davey C, et al. **Ann N Y Acad Sci** 1999 Apr 20;873:239–44
Technological and economic aspects of coal biodesulfurisation. Klein J. **Biodegradation** 1998; 9(3–4):293–300
Continuing medical education and industry support [editorial] Conti CR. **Clin Cardiol** 1999 Jun;22(6):381–2
Losses from the Northridge earthquake: disruption to high–technology industries in the Los Angeles Basin. Suarez–Villa L, et al. **Disasters** 1999 Mar;23(1):19–44
Boom vs. bust. Serb C. **Hosp Health Netw** 1999 Mar; 73(3):58–9, 2
The American health care system [letter] Anstadt GW. **N Engl J Med** 1999 Sep 16;341(12):918
Will investors return to biotechnology? [news] [see comments] Dorey E. **Nat Biotechnol** 1999 Feb;17(2):128. Comment in: Nat Biotechnol 1999 Feb;17(2):111.
Companies chase money in and out of the Eurozone [news] Michael A. **Nat Biotechnol** 1999 Feb;17(2):125–6
Critics question direction of new investment group [news] Michael A. **Nat Biotechnol** 1999 Jun;17(6):528–9
Shoring up the industry's valuations. Nelson TR. **Nat Biotechnol** 1998 Oct;16(10):913–6
Japanese budget boosts biotech [news] Saegusa A. **Nat Biotechnol** 1999 Feb;17(2):126–7
Smaller US firms more aggressive with federal grants [news] Swan N. **Nat Biotechnol** 1998 Dec;16(13):1306
Britain excels in academic capitalism [news] Dickson D. **Nat Med** 1999 Feb;5(2):131–2

HISTORY

Interacting factors affecting illegitimacy in preindustrial northern England. Scott S, et al. **J Biosoc Sci** 1997 Apr; 29(2):151–69

LEGISLATION & JURISPRUDENCE

Trends in hearing protector usage in American manufacturing from 1972 to 1989. Davis RR, et al. **Am Ind Hyg Assoc J** 1998 Oct;59(10):715–22
Comment: the past and future of national comprehensive tobacco control legislation [see comments] Akhter MN, et al. **Am J Public Health** 1998 Nov;88(11):1606–7. Comment in: Am J Public Health 1999 Aug;89(8):1273. Comment in: Am J Public Health 1999 Aug;89(8):1273–4.
The history of DBCP from a judicial perspective. Siegel CS, et al. **Int J Occup Environ Health** 1999 Apr–Jun;5(2):127–35
Cancer: proving the causal link, tobacco radiation and environmental pollution. Day M. **Med Leg J** 1998;66 (Pt 4):141–50
New German government muddies the biotech waters [news] Peerenboom E. **Nat Biotechnol** 1998 Dec;16(13):1304
Italian government rebuffs emerging biotechnology industry [news] Ballmaier M. **Nat Med** 1999 Apr;5(4):363
Workers' right–to–know legislation: does it work? Kahan E, et al. **Occup Med (Lond)** 1999 Jan;49(1):11–5
Tobacco legislation: time to right some wrong [editorial] Hays JT, et al. **Postgrad Med** 1998 Dec;104(6):11–2
[Legal aspects of support to clinics, research and continuing education by industry] Räpple T. **Z Gastroenterol** 1999 Jul; Suppl 2:33–7 **(Ger)**

ORGANIZATION & ADMINISTRATION

The international electronics industry. LaDou J, et al. **Int J Occup Environ Health** 1998 Jan–Mar;4(1):1–18 (26 ref.)
The business value of health care information technology. Frisse MC. **J Am Med Inform Assoc** 1999 Sep–Oct; 6(5):361–7
Clinical care and the factory floor. Panko WB. **J Am Med Inform Assoc** 1999 Sep–Oct;6(5):349–53
The challenge to health informatics for 1999–2000: form creative partnerships with industry and chief information officers to enable people to use information to improve health [editorial] Stead WW. **J Am Med Inform Assoc** 1999 Jan–Feb;6(1):88–9
The impact of lean production and related new systems of work organization on worker health. Landsbergis PA, et al. **J Occup Health Psychol** 1999 Apr;4(2):108–30 (132 ref.)
TBA's structure and focus confuse investors. Thermo BioAnalysis [news] Alper J. **Nat Biotechnol** 1999 Jan; 17(1):13–4
Human ES cells: can you build a business around them? Brower V. **Nat Biotechnol** 1999 Feb;17(2):139–42
Monsanto unaffected by merger halt? [news] Fox JL. **Nat Biotechnol** 1998 Dec;16(13):1307
Celltech, Chiroscience fire merger gun [news] Hodgson J. **Nat Biotechnol** 1999 Aug;17(8):741–2
European biotechnology firms approve of stock market mergers [news] Michael A. **Nat Biotechnol** 1998 Dec; 16(13):1301
Taiwan promotes biotechnology [news] Saegusa A. **Nat Biotechnol** 1998 Dec;16(13):1308–9
[Role of the home health care/visiting nurse in industry: possibilities for visiting nurse station and industry cooperation] Takiguchi M. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:551–5 (Eng. Abstr.) **(Jpn)**

STANDARDS

Improving the quality of health care. Health care through a Six Sigma lens [comment] Buck CR Jr. **Milbank Q** 1998; 76(4):749–53. Comment on: Milbank Q 1998 ;76(4):625–48, 511.
Is health care ready for Six Sigma quality? Chassin MR. **Milbank Q** 1998;76(4):565–91, 510 (62 ref.)
[The Japan industrial standard and the history of the Committee for Standardization of Anesthetic Equipment of the Japanese Society for Anesthesiologist] Sato T. **Masui** 1999 Jun;48(6):670–1 **(Jpn)**

STATISTICS & NUMERICAL DATA

Identification of occupational cancer risks in British Columbia. Part II: A population–based case–control study of 1516 Prostatic cancer cases. Band PR, et al. **J Occup Environ Med** 1999 Apr;41(4):233–47
Industry, occupation, and disability insurance beneficiary work return. Schechter ES. **Soc Secur Bull** 1999; 62(1):10–22

TRENDS

A maturing market for health information technology? [letter; comment] Roper WL, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):255–6. Comment on: Health Aff (Millwood) 1998 Nov–Dec;17(6):9–22. Comment on: Health Aff (Millwood) 1998 Nov–Dec;17(6):23–38.
Count on quality. Larkin H. **Hosp Health Netw** 1998 Oct 5;72(19):32–4, 3
Shrinking membership in the American Society of Animal Science: does the discipline of poultry science give us some clues? Cheeke PR. **J Anim Sci** 1999 Aug;77(8):2031–8
Land of morning calm. Past and future. Lee YT. **Medinfo** 1998;9 Pt 1:1–5
Industry trends. Biotechnology in 1998 and beyond. Persidis A. **Nat Biotechnol** 1998 Dec;16(13):1378–9

INDUSTRY

Japan considers the achievements and pitfalls of its five-year plan [news] Triendl R. **Nat Med** 1999 Jun;5(6):597

[Clinical research today and its promotion by industry--advantages and risks] Creutzfeldt W. **Z Gastroenterol** 1999 Jul;Suppl 2:4-11 **(Ger)**

INERT GAS NARCOSIS

[Medical aspects of diving--a sport for both women and men] Gustavsson LL, et al. **Lakartidningen** 1999 Feb 17; 96(7):749-53 (11 ref.) (Eng. Abstr.) **(Swe)**

PHYSIOPATHOLOGY

Arterial baroreflex control during mild-to-moderate nitrous oxide narcosis. Ostlund A, et al. **Undersea Hyperb Med** 1999 Spring;26(1):15-20

[Pneumologic aspects of diving medicine] Tetzlaff K, et al. **Pneumologie** 1998 Sep;52(9):489-500 (126 ref.) **(Ger)**

INFANT

Erythropoietin mRNA expression in human fetal and neonatal tissue. Dame C, et al. **Blood** 1998 Nov 1; 92(9):3218-25

Gender differences in physiological reactivity to infant cries and smiles in military families. Brewster AL, et al. **Child Abuse Negl** 1998 Aug;22(8):775-88

Invited editorial on "Irregularities and power law distributions in the breathing pattern in preterm and term infants" [editorial; comment] Bruce EN. **J Appl Physiol** 1998 Sep;85(3):787-8. Comment on: J Appl Physiol 1998 Sep;85(3):789-97.

Irregularities and power law distributions in the breathing pattern in preterm and term infants [see comments] Frey U, et al. **J Appl Physiol** 1998 Sep;85(3):789-97. Comment in: J Appl Physiol 1998 Sep;85(3):787-8.

Description and evaluation of a method based on magnetic resonance imaging to estimate adipose tissue volume and total body fat in infants. Olhager E, et al. **Pediatr Res** 1998 Oct;44(4):572-7

PSYCHOLOGY see CHILD PSYCHOLOGY

INFANT BEHAVIOR

Infant acceptance and effectiveness of a new oral liquid medication delivery system. Kraus DM, et al. **Am J Health Syst Pharm** 1999 Jun 1;56(11):1094-101

Neurobehavioral effects of low-level lead exposure in human neonates. Emory E, et al. **Am J Obstet Gynecol** 1999 Jul; 181(1):S2-11

Reflections on measuring pain in infants: dissociation in responsive systems and "honest signalling". Barr RG. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F152-6

Crying in the first year of life: good news in the midst of distress. Barr RG. **Child Care Health Dev** 1998 Sep; 24(5):425-39

Relationships between infant crying, birth complications, and maternal variables. Keller H, et al. **Child Care Health Dev** 1998 Sep;24(5):377-94

Persistent crying in early infancy: a non-trivial condition of risk for the developing mother-infant relationship. Papoušek M, et al. **Child Care Health Dev** 1998 Sep; 24(5):395-424

Links between maternal care and persistent infant crying in the early months. St James-Roberts I, et al. **Child Care Health Dev** 1998 Sep;24(5):353-76

The role of an early intervention on enhancing the quality of mother-infant interaction. Wendland-Carro J, et al. **Child Dev** 1999 May-Jun;70(3):713-21

Ultradian and circadian rhythms of sleep-wake and food-intake behavior during early infancy. Löhr B, et al. **Chronobiol Int** 1999 Mar;16(2):129-48 (54 ref.)

The NICU Network Neurobehavioral Scale. Clinical use with drug exposed infants and their mothers. Boukydis CF, et al. **Clin Perinatol** 1999 Mar;26(1):213-30

Object individuation in infancy: the use of featural information in reasoning about occlusion events. Wilcox T, et al. **Cognit Psychol** 1998 Nov;37(2):97-155

Intraindividual variability in infant behavior. de Weerth C, et al. **Dev Psychol** 1999 Jul;35(4):1102-12 (55 ref.)

Infant arousal in an en-face exchange with a new partner: effects of prematurity and perinatal biological risk. Eckerman CO, et al. **Dev Psychol** 1999 Jan;35(1):282-93

Mother-infant affect synchrony as an antecedent of the emergence of self-control. Feldman R, et al. **Dev Psychol** 1999 Jan;35(1):223-31

Effects of prosodic stress and serial position on syllable omission in first words. Lewis LB, et al. **Dev Psychol** 1999 Jan;35(1):45-59

Word learning in the context of referential and salience cues. Moore C, et al. **Dev Psychol** 1999 Jan;35(1):60-8

Gender differences in emotional expressivity and self-regulation during early infancy. Weinberg MK, et al. **Dev Psychol** 1999 Jan;35(1):175-88

Crying, fussing and colic behaviour in breast- and bottle-fed infants. Lucas A, et al. **Early Hum Dev** 1998 Nov;53(1):9-18

The crying infant. Trocinski DR, et al. **Emerg Med Clin North Am** 1998 Nov;16(4):895-910, vii-viii (65 ref.)

Development, behaviour and temperament: a prospective study of infants conceived through in-vitro fertilization. Gibson FL, et al. **Hum Reprod** 1998 Jun;13(6):1727-32

Discussion: early speech perception and production [comment] Paul R. **J Commun Disord** 1999 Jul-Aug; 32(4):247-50. Comment on: J Commun Disord 1999 Jul-Aug;32(4):207-22. Comment on: J Commun Disord 1999 Jul-Aug;32(4):223-45.

A comparison of newborns' NBAS reflex responses using total and individual scores. Neonatal Behavioral Assessment Scale. Pressler JL, et al. **J Nurs Meas** 1998 Winter;6(2):123-36

Newborn predictors of infant irritability. Keefe MR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):513-20

Assessment of long-chain polyunsaturated fatty acid nutritional supplementation on infant neurobehavioral development and visual acuity. Jacobson SW. **Lipids** 1999 Feb;34(2):151-60 (65 ref.)

Differential calming responses to sucrose taste in crying infants with and without colic. Barr RG, et al. **Pediatrics** 1999 May;103(5):e68

Cranial ultrasound abnormalities identified at birth: their relationship to perinatal risk and neurobehavioral outcome. Behnke M, et al. **Pediatrics** 1999 Apr;103(4):e41

Procedural pain in newborn infants: the influence of intensity and development. Porter FL, et al. **Pediatrics** 1999 Jul; 104(1):e13

Predicting infant temperament from neonatal reactivity for AGA/SGA twin pairs. Riese ML. **Twin Res** 1998 Jun; 1(2):65-70

[Infant cries?!, tears??...and whispers] Armengaud D. **Arch Pediatr** 1999 Aug;6(8):889-92 (Eng. Abstr.) **(Fre)**

[Synchronization between preverbal vocal behavior and motor action in early infancy. II: An acoustical examination of the functional significance of the synchronization] Ejiri K, et al. **Shinrigaku Kenkyu** 1999 Feb;69(6):433-40 (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Diagnosing infantile anorexia: the observation of mother-infant interactions. Chatoor I, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Sep;37(9):959-67

DRUG EFFECTS

Low-level prenatal lead exposure and neurobehavioral development of children in the first year of life: a prospective study in Shanghai. Shen XM, et al. **Environ Res** 1998 Oct;79(1):1-8

The response of crying newborns to sucrose: is it a "sweetness" effect? Barr RG, et al. **Physiol Behav** 1999 May; 66(3):409-17

[Influence of prenatal exposure to low levels of lead on the neuro-behavioral development of neonates] Ma Y, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Oct;77(10):774-5 (Eng. Abstr.) **(Chi)**

ETHNOLOGY

Play in two societies: pervasiveness of process, specificity of structure. Bornstein MH, et al. **Child Dev** 1999 Mar-Apr; 70(2):317-31

PHYSIOLOGY

Neonatal behavioral profile of the offspring of women who continued to exercise regularly throughout pregnancy. Clapp JF 3rd, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):91-4

Childhood derivatives of high and low reactivity in infancy. Kagan J, et al. **Child Dev** 1998 Dec;69(6):1483-93

Infants' learning about words and sounds in relation to objects. Woodward AL, et al. **Child Dev** 1999 Jan-Feb; 70(1):65-77

Quality of general movements in infancy is related to neurological dysfunction, ADHD, and aggressive behaviour. Hadders-Algra M, et al. **Dev Med Child Neurol** 1999 Jun;41(6):381-91

Lateral biases and fluctuations in infants' spontaneous arm movements and reaching. Corbetta D, et al. **Dev Psychobiol** 1999 May;34(4):237-55

Dampening of the cortisol response to handling at 3 months in human infants and its relation to sleep, circadian cortisol activity, and behavioral distress. Larson MC, et al. **Dev Psychobiol** 1998 Dec;33(4):327-37

The development of preterm infants' breastfeeding behavior. Nyqvist KH, et al. **Early Hum Dev** 1999 Jul;55(3):247-64

Self-perception and action in infancy. Rochat P. **Exp Brain Res** 1998 Nov;123(1-2):102-9 (22 ref.)

From the big bang to the brain. Boliek CA, et al. **J Commun Disord** 1999 Jul-Aug;32(4):271-6 (12 ref.)

Precursors to speech in infancy: the prediction of speech and language disorders [see comments] Oller DK, et al. **J Commun Disord** 1999 Jul-Aug;32(4):223-45 (47 ref.). Comment in: J Commun Disord 1999 Jul-Aug;32(4):247-50.

Long- and short-looking infants' recognition of symmetrical and asymmetrical forms. Stoecker JJ, et al. **J Exp Child Psychol** 1998 Oct;71(1):63-78

The influence of neonatal nutrition on behavioral development: a critical appraisal. Wauben IP, et al. **Nutr Rev** 1999 Feb;57(2):35-44 (92 ref.)

PSYCHOLOGY

Influences on infant speech processing: toward a new synthesis. Werker JF, et al. **Annu Rev Psychol** 1999; 50:509-35 (126 ref.)

Infants selectively encode the goal object of an actor's reach. Woodward AL. **Cognition** 1998 Nov;69(1):1-34

The drawbridge phenomenon: representational reasoning or perceptual preference? Rivera SM, et al. **Dev Psychol** 1999 Mar;35(2):427-35

Development of means-end behavior in young infants: pulling a support to retrieve a distant object. Willatts P. **Dev Psychol** 1999 May;35(3):651-67

An event-based analysis of the coordination of early infant vocalizations and facial actions. Yale ME, et al. **Dev Psychol** 1999 Mar;35(2):505-13

Depressed mothers' neonates improve following the MABI and a Brazelton demonstration. Hart S, et al. **J Pediatr Psychol** 1998 Dec;23(6):351-6

The roles of child reactivity and parenting context in infant pain response. Sweet SD, et al. **Pain** 1999 Apr;80(3):655-61

Outcome of idiopathic apparent life-threatening events: infant and mother perspectives. Tirosh E, et al. **Pediatr Pulmonol** 1999 Jul;28(1):47-52

Relationship between rhythmic behavior and canonical babbling in infant vocal development. Ejiri K. **Phonetica** 1998 Oct-Dec;55(4):226-37

Nursing care and the development of sleeping and waking behaviors in preterm infants. Brandon DH, et al. **Res Nurs Health** 1999 Jun;22(3):217-29

[Covariation of parental judgments of child behavioral characteristics with a developmental scale and observation of behaviors] Pauli-Pott U, et al. **Prax Kinderpsychol Kinderpsychiatr** 1999 May-Jun; 48(5):311-25 (Eng. Abstr.) **(Ger)**

INFANT CARE

see related
CHILD CARE
INCUBATORS, INFANT
INTENSIVE CARE, NEONATAL

Prolonged pacifier-sucking and use of a nursing bottle at night: possible risk factors for dental caries in children. Ollila P, et al. **Acta Odontol Scand** 1998 Aug;56(4):233-7

Increased gastroesophageal reflux in infants: can history provide an explanation? [see comments] Callahan CW. **Acta Paediatr** 1998 Dec;87(12):1219-23. Comment in: Acta Paediatr 1999 Apr;88(4):359-60.

Sleeping position, breastfeeding, bedsharing and passive smoking in 3-month-old Swedish infants. Lindgren C, et al. **Acta Paediatr** 1998 Oct;87(10):1028-32

Infant nutritional and health status, feeding practices in rural and urban Albania. Buonomo E, et al. **Ann Ig** 1998 May-Jun;10(3):163-71

Pacifier use and sudden infant death syndrome: results from the CESDI/SUDI case control study. CESDI SUDI Research Team. Fleming PJ, et al. **Arch Dis Child** 1999 Aug;81(2):112-6

Acute respiratory effects of diaper emissions. Anderson RC, et al. **Arch Environ Health** 1999 Sep-Oct;54(5):353-8

Briefing paper: oral aspects of dummy and digit sucking [see comments] Levine RS. **Br Dent J** 1999 Feb 13;186(3):108 . Comment in: Br Dent J 1999 May 8;186(9):428.

Links between maternal care and persistent infant crying in the early months. St James-Roberts I, et al. **Child Care Health Dev** 1998 Sep;24(5):353-76

Sleep/wake states of preterm infants: stability, developmental change, diurnal variation, and relation with caregiving activity. Ingersoll EW, et al. **Child Dev** 1999 Jan-Feb; 70(1):1-10

Effects of skin-to-skin holding on general movements of preterm infants. Constantinou JC, et al. **Clin Pediatr (Phila)** 1999 Aug;38(8):467-71

Boarder babies and placement in foster care. Maza PL. **Clin Perinatol** 1999 Mar;26(1):201-11, ix

The effects of pregnancy planning status on birth outcomes and infant care. Kost K, et al. **Fam Plann Perspect** 1998 Sep-Oct;30(5):223-30

Maternal and infant health problems after normal childbirth: a randomised controlled study in Zambia. Ransjö-Arvidson AB, et al. **J Epidemiol Community Health** 1998 Jun; 52(6):385-91

Why do mothers still sun their infants? Harrison SL, et al. **J Paediatr Child Health** 1999 Jun;35(3):296-9

JAMA Patient Page: newborn care. **JAMA** 1999 Sep 22-29; 282(12):1200

Putting babies "back to sleep" [letter; comment] Moy JG. **JAMA** 1999 Mar 17;281(11):983-4. Comment on: JAMA 1998 Jul 22-29;280(4):329-35. Comment on: JAMA 1998 Jul 22-29;280(4):336-40. Comment on: JAMA 1998 Jul 22-29;280(4):341-6. Comment on: JAMA 1998 Jul 22-29;280(4):373-4.

Neonatal tetanus--Montana, 1998. **MMWR Morb Mortal Wkly Rep** 1998 Nov 6;47(43):928-30

Sudden infant death syndrome [letter; comment] Dallas R. **N Z Med J** 1998 Aug 28;111(1072):327-8. Comment on: N Z Med J 1998 Jun 26;111(1068):219-21.

The efficacy of developmentally sensitive interventions and sucrose for relieving procedural pain in very low birth weight neonates. Stevens B, et al. **Nurs Res** 1999 Jan-Feb; 48(1):35-43

Pacifier use and otitis media in infants twelve months of age or younger. Jackson JM, et al. **Pediatr Dent** 1999 Jul-Aug; 21(4):255-60

The New Moms Project: educating mothers about sun protection in newborn nurseries. Geller AC, et al. **Pediatr Dermatol** 1999 May-Jun;16(3):198-200

Bonding by Kennell & Klaus [letter; comment] **Pediatr Rev** 1998 Dec;19(12):433. Comment on: Pediatr Rev 1998 Jan;19(1):4-12.

Breastfeeding patterns in relation to thumb sucking and pacifier use. Aarts C, et al. **Pediatrics** 1999 Oct;104(4):e50

The effects of early pacifier use on breastfeeding duration. Howard CR, et al. **Pediatrics** 1999 Mar;103(3):E33

The effect of handling and immobilization on the response to acute pain in newborn infants. Porter FL, et al. **Pediatrics** 1998 Dec;102(6):1383-9

Infant feeding practices of low-income, African-American, adolescent mothers: an ecological, multigenerational perspective. Bentley M, et al. **Soc Sci Med** 1999 Oct; 49(8):1085-100

[Infant cries?!, tears??...and whispers] Armengaud D. **Arch Pediatr** 1999 Aug;6(8):889-92 (Eng. Abstr.) **(Fre)**

HISTORY

[Pediatrics and puericulture in the Renaissance. II] Latronico N. **Minerva Pediatr** 1999 May;51(5):179-204 **(Ita)**

[Pediatrics and puericulture in the Roman world] Latronico N. **Minerva Pediatr** 1998 Oct;50(10):433-58 **(Ita)**

[Pediatrics and puericulture in ancient Greece] Latronico N. **Minerva Pediatr** 1998 Sep;50(9):399-414 **(Ita)**

INSTRUMENTATION

Digits vs dummies [letter; comment] Rothschild MB. **Br Dent J** 1999 May 8;186(9):428. Comment on: Br Dent J 1999 Feb 13;186(3):108.

Palatal deformations caused by pacifiers [news] **J Am Dent Assoc** 1999 Apr;130(4):480

METHODS

Care procedures in the healthy full-term newborn infant: a territorial survey. Maffei G, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:7-10

Kangaroo mother care for low birthweight infants: a randomized controlled trial in different settings. Cattaneo A, et al. **Acta Paediatr** 1998 Sep;87(9):976-85

Prevalence and determinants of prone sleeping position in infants: results from two cross-sectional studies on risk factors for SIDS in Germany. Schlaud M, et al. **Am J Epidemiol** 1999 Jul 1;150(1):51-7

Birth-related fatigue in 34-36-week preterm neonates: rapid recovery with very early kangaroo (skin-to-skin) care. Ludington-Hoe SM, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan-Feb;28(1):94-103

Parents' perception of skin-to-skin care with their preterm infants requiring assisted ventilation. Neu M. **J Obstet Gynecol Neonatal Nurs** 1999 Mar-Apr; 28(2):157-64

Kangaroo mother care in low-income countries. International Network in Kangaroo Mother Care. Cattaneo A, et al. **J Trop Pediatr** 1998 Oct;44(5):279-82

Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192-4 (23 ref.)

Using kangaroo care in a clinical setting with fullterm infants having breastfeeding difficulties. Meyer K, et al. **MCN Am J Matern Child Nurs** 1999 Jul-Aug;24(4):190-2

Maternal kangaroo (skin-to-skin) care in the NICU beginning 4 hours postbirth. Moran M, et al. **MCN Am J Matern Child Nurs** 1999 Mar-Apr;24(2):74-9

The GP's role from birth to six months. Sawczenko A, et al. **Practitioner** 1998 Jul;242(1588):528, 532-4, 536 (0 ref.)

Kangaroo mother care. Hann M, et al. **S Afr Med J** 1999 Jan;89(1):37-9

["Kangaroo method" in the care of premature infants admitted to a neonatal intensive care unit] Closa Monasterolo R, et al. **An Esp Pediatr** 1998 Nov;49(5):495-8 (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Intensive intervention for maltreated infants and toddlers in foster care. Zeanah CH, et al. **Child Adolesc Psychiatr Clin N Am** 1998 Apr;7(2):357-71 (19 ref.)

[Care of the newborn at Cotonou. Actual state and difficulties] Ayivi B, et al. **Arch Pediatr** 1999;6 Suppl 2:272s-274s **(Fre)**

[Therapeutic alternatives in neonatology: towards a reduction of the cost of prematurity] Haddad J. **Arch Pediatr** 1999; 6 Suppl 2:278s-280s **(Fre)**

PSYCHOLOGY

Partner support as a mediator of intervention outcome. Heinicke CM, et al. **Am J Orthopsychiatry** 1998 Oct; 68(4):534-41

Parenting of at-risk infants in the face of uncertainty: home apnea monitoring of subsibs. Maclean BL. **J Pediatr Nurs** 1999 Jun;14(3):201-9

Well-being of families with healthy and technology-assisted infants in the home: a comparative study. Stephenson C. **J Pediatr Nurs** 1999 Jun;14(3):164-76

The mother-infant relationship: who controls breastfeeding frequency? Euro-Growth Study Group [letter; comment] Manz F, et al. **Lancet** 1999 Apr 3;353(9159):1152. Comment on: Lancet 1999 Jul 3;354(9172):77-8.

STATISTICS & NUMERICAL DATA

Adolescents' pregnancy intentions: relations to life situations and caretaking behaviors prenatally and 2 years postpartum. Rubin V, et al. **J Adolesc Health** 1999 May; 24(5):313-20

From the Centers for Disease Control and Prevention. Assessment of infant sleeping position--selected states, 1996. **JAMA** 1998 Dec 9;280(22):1899-900

Assessment of infant sleeping position--selected states, 1996. **MMWR Morb Mortal Wkly Rep** 1998 Oct 23;47(41):873-7

Pacifier use and morbidity in the first six months of life. North K, et al. **Pediatrics** 1999 Mar;103(3):E34

TRENDS

Filling the gap: weaning practices of children aged 0-2 years in western metropolitan Melbourne. Graham VA, et al. **J Paediatr Child Health** 1998 Dec;34(6):513-7

Changes in the epidemiologic profile of sudden infant death syndrome as rates decline among California infants: 1990-1995. Adams EJ, et al. **Pediatrics** 1998 Dec; 102(6):1445-51

[What is new in neonatology?] Simeoni U. **Arch Pediatr** 1999 Apr;6(4):447-56 (71 ref.) (Eng. Abstr.) **(Fre)**

INFANT DEVELOPMENT see **CHILD DEVELOPMENT**

INFANT EQUIPMENT

Obui-himo syndrome. Imanishi Y, et al. **Eur Radiol** 1998; 8(7):1248-50

Migration of di-(2-ethylhexyl) phthalate from PVC child articles into saliva and saliva simulant. Steiner I, et al. **Food Addit Contam** 1998 Oct;15(7):812-7

Hepatic and oral trauma in an infant related to improper use of an infant car seat. Zuckerman GB, et al. **J Trauma** 1998 Oct;45(4):838-40

American Academy of Pediatrics. Committee on Injury and Poison Prevention. Safe transportation of newborns at hospital discharge. Bull M, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):986-7

ADVERSE EFFECTS

Highchair accidents. Mayr JM, et al. **Acta Paediatr** 1999 Mar; 88(3):319-22

Intussusception following a baby walker injury. Conners GP, et al. **J Emerg Med** 1999 Mar-Apr;17(2):269-71

Ages of young children who fall down stairs. Ridenour MV. **Percept Mot Skills** 1999 Apr;88(2):669-75

SUPPLY & DISTRIBUTION

National Highway Traffic Safety Administration (NHTSA) notes. Child safety seat distribution: what works? [see comments] Harris JS, et al. **Ann Emerg Med** 1999 Sep; 34(3):403-4. Comment in: Ann Emerg Med 1999 Sep;34(3):404-5.

Child safety seats--improving use step-by-step [comment] Jolly BT. **Ann Emerg Med** 1999 Sep;34(3):404-5. Comment on: Ann Emerg Med 1999 Sep;34(3):403-4.

UTILIZATION

A statewide analysis of child safety seat use and misuse in Michigan. Eby DW, et al. **Accid Anal Prev** 1999 Sep; 31(5):555-66

Parental decisions to use infant walkers. Bar-on ME, et al. **Inj Prev** 1998 Dec;4(4):299-301

Babywalkers: prevalence of use and relationship with other safety practices. Kendrick D, et al. **Inj Prev** 1998 Dec; 4(4):295-8

Seat belt use by children brought to an inner-city hospital. Tun J, et al. **Pediatr Emerg Care** 1999 Jun;15(3):176-8

INFANT FOOD

Prevention of allergies of infants: breast-feeding and special formulas. Influence on the response to immunization. Salvioli GP, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:21-7

Nutritional value of an "anti-regurgitation" formula. Levtchenko E, et al. **Acta Gastroenterol Belg** 1998 Jul-Sep; 61(3):285-7

Influence of breastfeeding and complementary food on growth between 5 and 10 months. Nielsen GA, et al. **Acta Paediatr** 1998 Sep;87(9):911-7

Newborn feeding and screening for phenylketonuria [letter] Ponzone A, et al. **Acta Paediatr** 1999 Mar;88(3):347-8

Fatty acids in substitute formulas for cow's milk allergy. Kaila M, et al. **Allergy** 1999 Jan;54(1):74-7

Cow's milk IgE and IgG antibody responses to cow's milk formulas. Oldaeus G, et al. **Allergy** 1999 Apr;54(4):352-7

Effects of dietary viscosity and energy density on total daily energy consumption by young Peruvian children. Bennett VA, et al. **Am J Clin Nutr** 1999 Aug;70(2):285-91

Soy protein for the prevention and treatment of children with cow-milk allergy. Businco L, et al. **Am J Clin Nutr** 1998 Dec;68(5 Suppl):1447S-1452S (78 ref.)

Threonine kinetics in preterm infants fed their mothers' milk or formula with various ratios of whey to casein. Darling PB, et al. **Am J Clin Nutr** 1999 Jan;69(1):105-14

Age of introduction of complementary foods and growth of term, low-birth-weight, breast-fed infants: a randomized intervention study in Honduras. Dewey KG, et al. **Am J Clin Nutr** 1999 Apr;69(4):679-86

Blood lipid concentrations of docosahexaenoic and arachidonic acids at birth determine their relative postnatal changes in term infants fed breast milk or formula [see comments] Guesnet P, et al. **Am J Clin Nutr** 1999 Aug; 70(2):292-8. Comment in: Am J Clin Nutr 1999 Aug;70(2):181-2.

Daily intake and urinary excretion of genistein and daidzein by infants fed soy- or dairy-based infant formulas. Irvine CH, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1462S-1465S

Leucine metabolism in preterm infants receiving parenteral nutrition with medium-chain compared with long-chain triacylglycerol emulsions. Liet JM, et al. **Am J Clin Nutr** 1999 Mar;69(3):539-43

Plasma lipoprotein fatty acids are altered by the positional distribution of fatty acids in infant formula triacylglycerols and human milk. Nelson CM, et al. **Am J Clin Nutr** 1999 Jul;70(1):62-9

Use of soy-protein formulas and soyfood for feeding infants and children in Asia. Quak SH, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1444S-1446S (16 ref.)

Randomized trial of calcium glycerophosphate-supplemented infant formula to prevent lead absorption. Sargent JD, et al. **Am J Clin Nutr** 1999 Jun;69(6):1224-30

Infant nutritional and health status, feeding practices in rural and urban Albania. Buonomo E, et al. **Ann Ig** 1998 May-Jun;10(3):163-71

Effects of dietary long-chain polyunsaturated fatty acids on plasma amino acids and indices of protein metabolism in infants: results from a randomized clinical trial. Decsi T, et al. **Ann Nutr Metab** 1998;42(4):195-201

Development of intestinal bacterial enzymes in infants--relationship to mode of delivery and type of feeding. Grönlund MM, et al. **APMIS** 1999 Jul; 107(7):655-60

Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Høst A, et al. **Arch Dis Child** 1999 Jul;81(1):80-4 (39 ref.)

Comparison of soy-based formulas with lactose and with sucrose in the treatment of acute diarrhea in infants. Fayad IM, et al. **Arch Pediatr Adolesc Med** 1999 Jul;153(7):675-80

Influence of dietary nucleotides on plasma immunoglobulin levels and lymphocyte subsets of preterm infants. Navarro J, et al. **Biofactors** 1999;10(1):67-76

Effect of two types of fish oil supplementation on plasma and erythrocyte phospholipids in formula-fed term infants. Maurage C, et al. **Biol Neonate** 1998 Dec;74(6):416-29

Intestinal absorption of copper from drinking water containing fulvic acids and an infant formula mixture studied in a suckling rat model. Lind Y, et al. **Biometals** 1999 Jun;12(2):181-7

Effectiveness of treatments for infantile colic. Dietary interventions in breast fed and bottle fed infants should not be pooled [letter; comment] Cates C. **BMJ** 1998 Nov 21;317(7170):1451; discussion 1452. Comment on: BMJ 1998 May 23;316(7144):1563-9.

Effectiveness of treatments for infantile colic. Findings apply only to the most severely affected infants [letter; comment] Crowcroft N. **BMJ** 1998 Nov 21;317(7170):1451; discussion 1452. Comment on: BMJ 1998 May 23;316(7144):1563-9.

Advertising standards authority finds against Nestlé [news] Ferriman A. **BMJ** 1999 Feb 13;318(7181):417

Randomised trial of early diet in preterm babies and later intelligence quotient. Lucas A, et al. **BMJ** 1998 Nov 28; 317(7171):1481-7

National code of marketing of formula milks is not properly enforced in Sri Lanka [letter; comment] Perera T. **BMJ** 1999 Apr 24;318(7191):1140. Comment on: BMJ 1998 Nov 14;317(7169):1386.

Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. Williams J, et al. **BMJ** 1999 Mar 13; 318(7185):693-7

Acute lung injury after tracheal instillation of acidified soya-based or Enfalac formula or human breast milk in rabbits. Chin C, et al. **Can J Anaesth** 1999 Mar;46(3):282-6

Factors influencing infant feeding practices of mothers in Vancouver. Williams PL, et al. **Can J Public Health** 1999 Mar-Apr;90(2):114-9

The influence of early experience with vanillin on food preference later in life. Haller R, et al. **Chem Senses** 1999 Aug;24(4):465-7

Plasma and red blood cell fatty acid composition in small for gestational age term infants fed human milk or formula. Ramirez M, et al. **Clin Nutr** 1998 Aug;17(4):177-83

Principles for formulating parenteral nutrition for neonates [see comments] Ball P. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):261-4 (28 ref.). Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):259-60.

Requirements for long-chain polyunsaturated fatty acids in the preterm infant. Uauy R, et al. **Curr Opin Pediatr** 1999 Apr;11(2):115-20 (53 ref.)

Fatty acid composition of plasma and erythrocytes in term

infants fed human milk and formulae with and without docosahexaenoic and arachidonic acids from egg yolk lecithin. Bondia-Martinez E, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S109-19

Crying, fussing and colic behaviour in breast- and bottle-fed infants. Lucas A, et al. **Early Hum Dev** 1998 Nov;53(1):9-18

Special formulas in infant nutrition: a review. Maldonado J, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S23-32 (79 ref.)

Bone mineralization status measured by dual energy radiographic densitometry in preterm infants fed commercial formulas. Narbona E, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S173-80

Neonatal dietary gangliosides. Rueda R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S135-47 (60 ref.)

Protein in infant formulas. Future aspects of development. Tormo R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S165-72

Complementary foods for infant feeding in developing countries: their nutrient adequacy and improvement. Gibson RS, et al. **Eur J Clin Nutr** 1998 Oct;52(10):764-70

Plasma and erythrocyte alpha-tocopherol and plasma retinol concentrations in term infants fed formula enriched with long-chain polyunsaturated fatty acids. González-Corbella MJ, et al. **Eur J Clin Nutr** 1998 Nov;52(11):813-8

The supplementary feeding of breastfed babies may cause breastfeeding failures: a flawed survey and a false debate [letter] Dickstein M, et al. **Eur J Pediatr** 1998 Oct; 157(10):861-2

The protective effect of breast feeding in relation to sudden infant death syndrome (SIDS): II. The effect of human milk and infant formula preparations on binding of Clostridium perfringens to epithelial cells. Gordon AE, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1; 25(1-2):167-73

The protective effect of breast feeding in relation to sudden infant death syndrome (SIDS): I. The effect of human milk and infant formula preparations on binding of toxigenic Staphylococcus aureus to epithelial cells. Saadi AT, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1-2):155-65

Evaluation of single-cell sources of docosahexaenoic acid and arachidonic acid: 3-month rat oral safety study with an in utero phase. Burns RA, et al. **Food Chem Toxicol** 1999 Jan;37(1):23-36

Food diversity versus breastfeeding choice in determining anthropometric status in rural Kenyan toddlers. Onyango A, et al. **Int J Epidemiol** 1998 Jun;27(3):484-9

Plasma vitamin A and E in preterm babies fed on breast milk or formula milk with or without long-chain polyunsaturated fatty acids. Ghebremeskel K, et al. **Int J Vitam Nutr Res** 1999 Mar;69(2):83-91

Absorption of fat and calcium by infants fed a milk-based formula containing palm olein [see comments] Nelson SE, et al. **J Am Coll Nutr** 1998 Aug;17(4):327-32. Comment in: J Am Coll Nutr 1998 Aug;17(4):303-5.

Early introduction of solid foods among urban African-American participants in WIC. Bronner YL, et al. **J Am Diet Assoc** 1999 Apr;99(4):457-61

Cultural influences on infant feeding beliefs of mothers. Kannan S, et al. **J Am Diet Assoc** 1999 Jan;99(1):88-90

Effects of infant feeding practices and birth spacing on infant and child survival: a reassessment from retrospective and prospective data. Kuate Defo B. **J Biosoc Sci** 1997 Jul; 29(3):303-26

Survival and growth of psychrotrophic Bacillus cereus in dry and reconstituted infant rice cereal. Jaquette CB, et al. **J Food Prot** 1998 Dec;61(12):1629-35

Lactation duration: influences of human milk replacements and formula samples on women planning postpartum employment. Chezem J, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Nov-Dec; 27(6):646-51

Renal solute load and potential renal solute load in infancy. Fomon SJ, et al. **J Pediatr** 1999 Jan;134(1):11-4

The natural history of intolerance to soy and extensively hydrolyzed formula in infants with multiple food protein intolerance. Hill DJ, et al. **J Pediatr** 1999 Jul;135(1):118-21

Short bowel syndrome, intestinal permeability and glutamine [letter; comment] Brewster D, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):614-6. Comment on: J Pediatr Gastroenterol Nutr 1998 Feb;26(2):123-8.

Infant formula with protein-energy ratio of 1.7 g/100 kcal is adequate but may not be safe. Fomon SJ, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):495-501

Elevated intakes of zinc in infant formulas don not interfere with iron absorption in premature infants. Friel JK, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):312-6

High absorption of fortification iron from current infant formulas. Hertrampf E, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):425-30

Intestinal lactobezoars in twins receiving a reconstituted elemental formula. Lowichik A, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):104-7

Evaluation of iron bioavailability in infant weaning foods fortified with haem concentrate. Martinez C, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):419-24

Individualized protein fortification of human milk for preterm infants: comparison of ultrafiltrated human milk protein and a bovine whey fortifier. Polberger S, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):332-8

Allergic colitis in two infants fed with an amino acid formula. Strauss RS, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep; 27(3):362-5

Macronutrient and energy intakes in young children fed milk products containing different quantities and qualities of fat and protein. Svahn JC, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):273-81

Fish oil: for use in infant formula? [editorial; comment] Udall JN Jr. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):244-5 (9 ref.). Comment on: J Pediatr Gastroenterol Nutr 1999 Mar;28(3):276-81.

Gastric emptying in formula-fed and breast-fed infants measured with the 13C-octanoic acid breath test. Van Den Driessche M, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul; 29(1):46-51

Evaluation of a long-chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age. Vanderhoof J, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):318-26

The story of soy formula feeding in infants: a road paved with good intentions [letter] Zoppi G, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):541-3 (39 ref.)

Intestinal flora in breast- and bottle-fed infants. Rubaltelli FF, et al. **J Perinat Med** 1998;26(3):186-91

A comparison of parenteral and enteral feeding in neonatal piglets, including an assessment of the utilization of a glutamine-rich, pediatric elemental diet. Bertolo RF, et al. **JPEN J Parenter Enteral Nutr** 1999 Mar-Apr;23(2):47-55

Feeding a weaning infant [letter; comment] Ewing G, et al. **Lancet** 1999 Jan 23;353(9149):327. Comment on: Lancet 1998 Nov 14;352(9140):1569-70.

Unethical promotion of lactose-free formula [letter] Tahir KI. **Lancet** 1999 Jun 26;353(9171):2247-8

Solid feeding guidelines [see comments] Werk LN, et al. **Lancet** 1998 Nov 14;352(9140):1569-70. Comment in: Lancet 1999 Jan 23;353(9149):327.

n-3 and n-6 fatty acid enrichment by dietary fish oil and phospholipid sources in brain cortical areas and nonneural tissues of formula-fed piglets. Goustard-Langelier B, et al. **Lipids** 1999 Jan;34(1):5-16

Long-chain polyunsaturated fatty acids in diets for infants: choices for recommending and regulating bodies and for manufacturers of dietary products. Koletzko B, et al. **Lipids** 1999 Feb;34(2):215-20 (34 ref.)

Influence of long-chain polyunsaturated fatty acids on infant cognitive function. Willatts P, et al. **Lipids** 1998 Oct; 33(10):973-80

Should nurses offer discharge formula samples to women who plan to breastfeed? James DC, et al. **MCN Am J Matern Child Nurs** 1999 Jul-Aug;24(4):166-7

The effects of prescribed versus ad libitum feedings and formula caloric density on premature infant dietary intake and weight gain. Pridham K, et al. **Nurs Res** 1999 Mar-Apr; 48(2):86-93

Infant feeding practices in a deprived environment: a concern for early introduction of water and glucose D water to neonates. Ojofeitimi EO, et al. **Nutr Health** 1999; 13(1):11-21

Complementary feeding: a global perspective. Michaelsen KF, et al. **Nutrition** 1998 Oct;14(10):763-6 (33 ref.)

Effectiveness of a home-made meat based formula (the Rezza-Cardi diet) as a diagnostic tool in children with food-induced atopic dermatitis. Martino F, et al. **Pediatr Allergy Immunol** 1998 Nov;9(4):192-6

Guideline for weaning (revised edition). Ministry of Health and Welfare, Japan. **Pediatr Int** 1999 Feb;41(1):115-7

Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Carlson SE, et al. **Pediatr Res** 1998 Oct;44(4):491-8

The effect of breast feeding on lymphocyte subpopulations in healthy term infants at 6 months of age. Hawkes JS, et al. **Pediatr Res** 1999 May;45(5 Pt 1):648-51

Human milk and infant formula can induce in vitro adipocyte differentiation in murine 3T3-L1 preadipocytes. Lyle RE, et al. **Pediatr Res** 1998 Nov;44(5):798-803

Iron absorption and red blood cell incorporation in premature infants fed an iron-fortified infant formula. McDonald MC, et al. **Pediatr Res** 1998 Oct;44(4):507-11

Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Shulman RJ, et al. **Pediatr Res** 1998 Oct;44(4):519-23

Iron fortification of infant formulas. American Academy of Pediatrics. Committee on Nutrition. **Pediatrics** 1999 Jul; 104(1 Pt 1):119-23

Dietary long-chain polyunsaturated fatty acids do not influence growth of term infants: A randomized clinical trial. Makrides M, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):468-75

Formula supplementation with long-chain polyunsaturated fatty acids: are there developmental benefits? Scott DT, et al. **Pediatrics** 1998 Nov;102(5):E59

Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75-8 (16 ref.)

Matrix-assisted laser desorption/ionization mass spectrometry in evaluation of protein profiles of infant formulae. Sabbadin S, et al. **Rapid Commun Mass Spectrom** 1999;13(14):1438-43

Infant feeding practices of low-income, African-American, adolescent mothers: an ecological, multigenerational perspective. Bentley M, et al. **Soc Sci Med** 1999 Oct; 49(8):1085-100

[After milk: what, when, how, why?] Turck D. **Arch Pediatr** 1998;5 Suppl 2:205s-209s (15 ref.) **(Fre)**

[Impact on health of early supplementation with rice in infants in Laos (letter)] Graz B. **Med Trop (Mars)** 1999; 59(1):102-3 **(Fre)**

[Infant botulism--rare, but dangerous. Preventive measures: infants must not be given honey!] **Med Monatsschr Pharm** 1999 May;22(5):152-3 **(Ger)**

[Feeding disorders in infancy: feeding interaction concept in diagnosis and treatment] Keren M, et al. **Harefuah** 1998 Sep;135(5-6):193-7, 254 (Eng. Abstr.) **(Heb)**

[Preterm infants: an update on human milk fortifiers (letter)] Toma TS. **Rev Saude Publica** 1998 Jun;32(3):295-6 **(Por)**

[Proteolysis of immunoglobulins--biologically-active supplement in a fermented milk in gastrointestinal system of rats] Gmoshinskii IV, et al. **Vopr Pitan** 1998;(4):5-8 (Eng. Abstr.) **(Rus)**

[A reply about milk porridge. Infant food is also a question of nutritional physiology] Axelsson I, et al. **Lakartidningen** 1999 May 26;96(21):2624-5 **(Swe)**

[Recommendations for prevention of iron deficiency. Delay cow's milk intake as a beverage to infants until 10-12 months of age!] Axelsson I, et al. **Lakartidningen** 1999 May 5;96(18):2206-8 (30 ref.) (Eng. Abstr.) **(Swe)**

[Infant food is not only a question of nutritional physiology. Doubtful to advise against milk with porridge] Stintzing G, et al. **Lakartidningen** 1999 May 12;96(19):2374-6 **(Swe)**

[Storm in a bowl (letter)] Stintzing G, et al. **Lakartidningen** 1999 Jun 30;96(26-27):3155-6 **(Swe)**

ADVERSE EFFECTS

In vivo and in vitro studies on the residual allergenicity of partially hydrolysed infant formulae. Niggemann B, et al. **Acta Paediatr** 1999 Apr;88(4):394-8

Effect of reducing the phytate content and of partially hydrolyzing the protein in soy formula on zinc and copper absorption and status in infant rhesus monkeys and rat pups. Lönnerdal B, et al. **Am J Clin Nutr** 1999 Mar;69(3):490-6

Infant feeding causes all cases of asthma, eczema, and hay fever. Or does it? [comment] David TJ. **Arch Dis Child** 1998 Aug;79(2):97-8. Comment on: Arch Dis Child 1998 Aug;79(2):126-30.

Formula for jaundiced breast-fed infants [letter; comment] Watkinson M. **Arch Pediatr Adolesc Med** 1999 Jun; 153(6):657-8. Comment on: Arch Pediatr Adolesc Med 1998 Dec;152(12):1187-90.

Eighteen-month follow-up of infants fed evaporated milk formula. Friel JK, et al. **Can J Public Health** 1999 Jul-Aug; 90(4):240-3

Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Vaarala O, et al. **Diabetes** 1999 Jul;48(7):1389-94

Isoflavones and soy protein formulas. Cantani A. **Eur Rev Med Pharmacol Sci** 1998 Mar-Apr;2(2):97-8

Cow's milk and type I diabetes: the gut immune system deserves attention. Kolb H, et al. **Immunol Today** 1999 Mar; 20(3):108-10

Soy allergy in infants and children with IgE-associated cow's milk allergy. Zeiger RS, et al. **J Pediatr** 1999 May; 134(5):614-22

Proper use of fluoride products in fluoridated communities [see comments] Horowitz HS. **Lancet** 1999 May 1; 353(9163):1462. Comment in: Lancet 1999 Jul 3;354(9172):74-5.

Estimation of the caries-related risk associated with infant formulas. Erickson PR, et al. **Pediatr Dent** 1998 Nov-Dec; 20(7):395-403

Formula tolerance in postbreastfed and exclusively formula-fed infants. Lloyd B, et al. **Pediatrics** 1999 Jan; 103(1):E7

[Allergy to protein hydrolysates. Report of 30 cases] Ammar F, et al. **Arch Pediatr** 1999 Aug;6(8):837-43 (Eng. Abstr.) **(Fre)**

[Acquired methemoglobinemia: a case report] Benini D, et al. **Pediatr Med Chir** 1998 Nov-Dec;20(6):411-3 (Eng. Abstr.) **(Ita)**

ANALYSIS

Characteristics of the new milks for infants: fatty acids, nucleotides, selenium. Agostoni C, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:29-34

Isoflavones in human breast milk and other biological fluids. Franke AA, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1466S-1473S

Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Setchell KD, et al. **Am J Clin Nutr** 1998 Dec;68(6 Suppl):1453S-1461S (86 ref.)

A randomised controlled study of the effect of long chain polyunsaturated fatty acid supplementation on stool hardness during formula feeding. Forsyth JS, et al. **Arch Dis Child** 1999 Sep;81(3):253-6

Dialyzability of iron, zinc, and copper of different types of infant formulas marketed in Spain. García R, et al. **Biol Trace Elem Res** 1998 Oct;65(1):7-17

Trace elements in formulas based on cow and soy milk and in Austrian cow milk determined by inductively coupled plasma mass spectrometry. Krachler M, et al. **Biol Trace Elem Res** 1998 Oct;65(1):53-74

Iodine in drinking water varies by more than 100-fold in Denmark. Importance for iodine content of infant formulas.

Pedersen KM, et al. **Eur J Endocrinol** 1999 May; 140(5):400–3

Analysis of Norwegian milk and infant formulas for ochratoxin A. Skaug MA. **Food Addit Contam** 1999 Feb; 16(2):75–8

Low biotin content of infant formulas made in Japan. Watanabe T, et al. **Food Addit Contam** 1998 Jul; 15(5):619–25

Effect of food processing on iron availability of African pearl millet weaning foods. Cissé D, et al. **Int J Food Sci Nutr** 1998 Sep;49(5):375–81

Determination of niacin in infant formula and wheat flour by anion-exchange liquid chromatography with solid-phase extraction cleanup. LaCroix DE, et al. **J AOAC Int** 1999 Jan–Feb;82(1):128–33

Preparation of Standard Reference Material 2383 (Baby Food Composite) and use of an interlaboratory comparison exercise for value assignment of its nutrient concentrations. Sharpless KE, et al. **J AOAC Int** 1999 Mar–Apr; 82(2):276–87

Value assignment of retinol, retinyl palmitate, tocopherol, and carotenoid concentrations in Standard Reference Material 2383 (Baby Food Composite). Sharpless KE, et al. **J AOAC Int** 1999 Mar–Apr;82(2):288–96

Determination of polychlorinated biphenyls in soybean infant formulas by gas chromatography. Ramos L, et al. **J Chromatogr A** 1998 Oct 9;823(1–2):365–72

A perfusion reversed-phase chromatographic method for ultrarapid determination of soybean proteins in soybean infant formulas and soybean milks: method development and validation. García MC, et al. **J Chromatogr Sci** 1998 Nov;36(11):527–34

Sterol oxidation in infant milk formulas and milk cereals. Zunin P, et al. **J Dairy Res** 1998 Nov;65(4):591–8

Detection of bovine milk proteins in soymilk by Western blotting. Molina E, et al. **J Food Prot** 1998 Dec; 61(12):1691–4

Liquid concentrates are lower in bioavailable tryptophan than powdered infant formulas, and tryptophan supplementation of formulas increases brain tryptophan and serotonin in rats. Sarwar G, et al. **J Nutr** 1999 Sep;129(9):1692–7

Aluminum contents of human milk, cow's milk, and infant formulas. Fernandez-Lorenzo JR, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):270–5

Oxalate, citrate, and sulfate concentration in human milk compared with formula preparations: influence on urinary anion excretion. Hoppe B, et al. **J Pediatr Gastroenterol Nutr** 1998 Oct;27(4):383–6

Breastmilk nucleotides [editorial] Ebrahim GJ. **J Trop Pediatr** 1998 Dec;44(6):318–9 (11 ref.)

Long-chain polyunsaturated fatty acids, infant formula, and breastfeeding [letter; comment] Campbell C. **Lancet** 1998 Nov 21;352(9141):1703. Comment on: Lancet 1998 Aug 29;352(9129):688–91.

Selenium contents of human milk and infant formulas in Spain. Torres MA, et al. **Sci Total Environ** 1999 Apr 5; 228(2–3):185–92

Daily intake of heavy metals by infants through milk and milk products. Tripathi RM, et al. **Sci Total Environ** 1999 Mar 9;227(2–3):229–35

[Infant growth formulas: useful for whom? (letter)] Nathanson M, et al. **Arch Pediatr** 1999 Jan;6(1):110 **(Fre)**

[Special infant formulas: a review and update (letter; comment)] Sáenz de Urturi Sánchez A, et al. **An Esp Pediatr** 1998 Sep;49(3):322–3. Comment on: An Esp Pediatr 1997 Nov;47(5):455–65. **(Spa)**

ECONOMICS

Enteral glutamine supplementation for very-low-birth-weight infants decreases hospital costs. Dallas MJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov–Dec;22(6):352–6

Health care costs of formula-feeding in the first year of life. Ball TM, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):870–6

Confronting AIDS--a plea for a national dried milk formula. Woods DL. **S Afr Med J** 1998 Aug;88(8):948–9

HISTORY

The relation of the milk supply to infant mortality. 1906 [classical article] Knox JH Jr. **Am J Public Health** 1999 Mar;89(3):408–11

MICROBIOLOGY

Molecular fingerprinting defines a strain of Salmonella enterica serotype Anatum responsible for an international outbreak associated with formula-dried milk. Threlfall EJ, et al. **Epidemiol Infect** 1998 Oct;121(2):289–93

Multiple analysis of a foodborne outbreak caused by infant formula contaminated by an atypical Salmonella virchow strain. Usera MA, et al. **Eur J Clin Microbiol Infect Dis** 1998 Aug;17(8):551–5

Influence of temperature and pH on survival of Escherichia coli O157:H7 in dry foods and growth in reconstituted infant rice cereal. Deng Y, et al. **Int J Food Microbiol** 1998 Dec 22;45(3):173–84

Phenotypic and genotypic typing of food and clinical isolates of Enterobacter sakazakii. Nazarowec-White M, et al. **J Med Microbiol** 1999 Jun;48(6):559–67

Contamination of weaning foods: organisms, channels, and sequelae. Afifi ZE, et al. **J Trop Pediatr** 1998 Dec; 44(6):335–7

Comparison of survival of diarrhoeagenic agents in two local weaning foods (ogi and koko). Bakare S, et al. **J Trop Pediatr** 1998 Dec;44(6):332–4

STANDARDS

Risk factors for enamel fluorosis in optimally fluoridated children born after the US manufacturers' decision to reduce the fluoride concentration of infant formula. Pendrys DG, et al. **Am J Epidemiol** 1998 Nov 15; 148(10):967–74

Pesticides in dietary foods for infants and young children. Report of the Working Group on Pesticides in Baby Foods of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Koletzko B, et al. **Arch Dis Child** 1999 Jan;80(1):91–2

Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i–iv, 2059S–2293S (1034 ref.)

Comments on LSRO report's recommendations on infant formula nutrient requirements [letter] Gelardi RC, et al. **J Nutr** 1999 Jul;129(7):1390–2

Measured consumption of commercial infant food products in German infants: results from the DONALD study. Dortmund Nutritional and Anthropometrical Longitudinally Designed. Kersting M, et al. **J Pediatr Gastroenterol Nutr** 1998 Nov;27(5):547–52

STATISTICS & NUMERICAL DATA

Feeding patterns in the first two years of life in Basra, Iraq. Benyamen YS, et al. **East Mediterr Health J** 1998 Dec; 4(3):448–51

Feeding practices in infants of Bhil tribe in Jhabua District of Madhya Pradesh [letter] Taneja PV, et al. **Indian Pediatr** 1998 Jun;35(6):568

Orthodontic aspects on feeding of young children. 1. A comparison between Swedish and Norwegian-Sami children. Larsson E. **Swed Dent J** 1998;22(3):117–21

SUPPLY & DISTRIBUTION

[Infant growth formulas: useful for whom? (letter)] Nathanson M, et al. **Arch Pediatr** 1999 Jan;6(1):110 **(Fre)**

TOXICITY

Effects of exogenous surfactant on acute lung injury induced by intratracheal instillation of infant formula or human breast milk in rabbits. Nishina K, et al. **Anesthesiology** 1999 Jul;91(1):240–52

UTILIZATION

Infant feeding practices of Anglo American and Asian Indian American mothers. Kannan S, et al. **J Am Coll Nutr** 1999 Jun;18(3):279–86

Soy protein formula. The Australian College of Paediatrics. **J Paediatr Child Health** 1998 Aug;34(4):318–9

INFANT FURNITURE see **INFANT EQUIPMENT**

INFANT HEALTH see **INFANT WELFARE**

INFANT HEALTH SERVICES see **CHILD HEALTH SERVICES**

INFANT, LOW BIRTH WEIGHT

Kangaroo mother care for low birthweight infants: a randomized controlled trial in different settings. Cattaneo A, et al. **Acta Paediatr** 1998 Sep;87(9):976–85

"Idiopathic neutropenia" in very low birthweight infants. Juul SE, et al. **Acta Paediatr** 1998 Sep;87(9):963–8

Validation and use of a simple device to identify low birth weight babies at birth. Lawoyin TO. **Afr J Med Med Sci** 1998 Sep–Dec;27(3–4):143–5

Low-weight neonatal survival paradox in the Czech Republic. Carlson E, et al. **Am J Epidemiol** 1999 Mar 1; 149(5):447–53

Impact of multiple births and elective deliveries on the trends in low birth weight in Norway, 1967–1995. Daltveit AK, et al. **Am J Epidemiol** 1999 Jun 15;149(12):1128–33

Trichomoniasis in pregnant human immunodeficiency virus-infected and human immunodeficiency virus-uninfected congolese women: prevalence, risk factors, and association with low birth weight. Sutton MY, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):656–62

Neonatal resuscitation with the laryngeal mask airway in normal and low birth weight infants. Gandini D, et al. **Anesth Analg** 1999 Sep;89(3):642–3

Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease [see comments] Bhuta T, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F26–33. Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F159.

Maternal birthplace, ethnicity, and low birth weight in California. Fuentes-Afflick E, et al. **Arch Pediatr Adolesc Med** 1998 Nov;152(11):1105–12

Testing the epidemiologic paradox of low birth weight in Latinos. Fuentes-Afflick E, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):147–53

Dorsal penile nerve block vs topical placebo for circumcision in low-birth-weight neonates [see comments] Holliday MA, et al. **Arch Pediatr Adolesc Med** 1999 May; 153(5):476–80. Comment in: Arch Pediatr Adolesc Med 1999 May;153(5):444–5.

A parable wrapped in an enigma: population-based assessments of outcomes among high-risk neonates are even less achievable in the age of clinical informatics. Kirby RS. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):789–92

Seasonality of low birthweight in indigenous Australians: an increase in pre-term birth or intrauterine growth retardation? Rousham EK, et al. **Aust N Z J Public Health** 1998 Oct;22(6):669–72

Incidence of low birth weight in three selected communities of Bangladesh. Nahar N, et al. **Bangladesh Med Res Counc Bull** 1998 Aug;24(2):49–54

Randomized clinical trial of enteral yeast-selenium supplementation in preterm infants. Bogye G, et al. **Biofactors** 1998;8(1–2):139–42

US debates treatment of marginally viable babies [news] Charatan F. **BMJ** 1999 Feb 13;318(7181):418

Catch-up growth in childhood and death from coronary heart disease: longitudinal study. Eriksson JG, et al. **BMJ** 1999 Feb 13;318(7181):427–31

Psychosocial predictors of low birthweight: a prospective study. Paarlberg KM, et al. **Br J Obstet Gynaecol** 1999 Aug;106(8):834–41

Prevalence of low and high birthweight among the James Bay Cree of northern Quebec. Armstrong IE, et al. **Can J Public Health** 1998 Nov–Dec;89(6):419–20

Comparison of the outcome of extremely-low-birth-weight infants between two periods. Tsao PN, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul–Aug;39(4):233–6

Low birth weight and cardiovascular disease: myth or reality? Jones SE, et al. **Curr Opin Lipidol** 1998 Aug; 9(4):309–12 (28 ref.)

Birth weight and the future development of diabetes. A review of the evidence. Phillips DI. **Diabetes Care** 1998 Aug;21 Suppl 2:B150–5 (41 ref.)

Low birthweight: more than a single hit malady of the first months of life [editorial] McLigeyo SO. **East Afr Med J** 1999 Feb;76(2):61–2

Birthweight and neonatal outcome at the Muhimbili Medical Centre, Dar es Salaam, Tanzania. Manji KP, et al. **East Afr Med J** 1998 Jul;75(7):382–7

The effect of ambient carbon monoxide on low birth weight among children born in southern California between 1989 and 1993. Ritz B, et al. **Environ Health Perspect** 1999 Jan; 107(1):17–25

Mortality and hospitalizations of 24-year-old members of the low-birthweight cohort in northern Finland. Xu B, et al. **Epidemiology** 1998 Nov;9(6):662–5

Birth weight of US biracial (black-white) infants: regional differences. Polednak AP, et al. **Ethn Dis** 1998 Autumn; 8(3):340–9

Cardiac surgery with extracorporeal circulation in 23 infants weighing 2500 g or less: short and intermediate term outcome. Beyens T, et al. **Eur J Cardiothorac Surg** 1998 Aug;14(2):165–72

Potential for abusive parenting by rural mothers with low-birth-weight children. Sachs B, et al. **Image J Nurs Sch** 1999;31(1):21–5

Low birth weight prevalence and antenatal care practices in a rural area of Haryana [letter] Aggarwal AK, et al. **Indian Pediatr** 1998 Oct;35(10):1031

Relationship between chemical exposure in the workplace and the risk of premature delivery, low birth weight and intrauterine growth retardation. Makowiec-Dąbrowska T, et al. **Int Arch Occup Environ Health** 1998 Sep;71 Suppl:S64–9

Risk of preterm delivery, low birthweight and growth retardation following spontaneous abortion: a registry-based study in Denmark. Basso O, et al. **Int J Epidemiol** 1998 Aug;27(4):642–6

Low birthweight and prematurity in relation to paternal factors: a study of recurrence. Basso O, et al. **Int J Epidemiol** 1999 Aug;28(4):695–700

Erythromycin treatment of pregnant women to reduce the incidence of low birth weight and preterm deliveries. Paul VK, et al. **Int J Gynaecol Obstet** 1998 Jul;62(1):87–8

Association of genital mycoplasma colonization with low birth weight. Paul VK, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):109–14

Comparison of liveborn and stillborn low birthweight babies and analysis of aetiological factors. Geary M, et al. **Ir Med J** 1997 Nov;90(7):269–71

Birth outcomes for Asian-American adolescents: a high-risk group? Rauh VA, et al. **J Am Med Womens Assoc** 1999 Summer;54(3):121–5

Low birth weight and risk of cardiac arrhythmias in children. Kelmanson IA, et al. **J Cardiovasc Risk** 1998 Feb;5(1):47–51

Neonatal sepsis in hospital born babies. Kaushik SL, et al. **J Commun Dis** 1998 Sep;30(3):147–52

Influence of birth weight on educational outcomes at age 9: the Miami site of the Infant Health and Development Program. Hollomon HA, et al. **J Dev Behav Pediatr** 1998 Dec;19(6):404–10

Is the effect of low birth weight on cardiovascular mortality mediated through high blood pressure? Koupilová I, et al. **J Hypertens** 1999 Jan;17(1):19–25

Low birth weight in relation to sex of baby, maternal age and parity: a hospital based study on Tangsa tribe from Arunachal Pradesh. Mondal B. **J Indian Med Assoc** 1998 Dec;96(12):362–4

Is knowledge of health behavior associated with low birth weight? Mvula MM, et al. **J Matern Fetal Med** 1999 May–Jun;8(3):134–7

Successful modified Norwood operation for hypoplastic left heart syndrome in neonatal period: the first reported case in Thailand. Benjacholamas V, et al. **J Med Assoc Thai** 1998 Oct;81(10):803–6

Rates of perinatal mortality and low birth weight among 3367 consecutive births in south of Beirut. Bittar Z. **J Med Liban** 1998 May–Jun;46(3):126–30

Groups of histopathologic abnormalities in brains of very low birthweight infants. Gilles FH, et al. **J Neuropathol Exp Neurol** 1998 Nov;57(11):1026–34

Thermal management of the low birth weight infant: a cornerstone of neonatology [editorial; comment] Narendran V, et al. **J Pediatr** 1999 May;134(5):529–31. Comment on: J Pediatr 1999 May;134(5):547–51.

Proportional assist ventilation in low birth weight infants with acute respiratory disease: A comparison to assist/control and conventional mechanical ventilation. Schulze A, et al. **J Pediatr** 1999 Sep;135(3):339–44

The role of peritoneal drains in treatment of perforated necrotizing enterocolitis: recommendations from recent experience. Ahmed T, et al. **J Pediatr Surg** 1998 Oct; 33(10):1468–70

Multiple atresias in a low-birth-weight twin. Benson JM, et al. **J Pediatr Surg** 1999 Jun;34(6):1040–2

Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. Kresch MJ, et al. **J Perinatol** 1998 Jul–Aug;18(4):276–83

The risk of teen mothers having low birth weight babies: implications of recent medical research for school health personnel. Roth J, et al. **J Sch Health** 1998 Sep;68(7):271–5 (40 ref.)

Results of 102 cases of complete repair of congenital heart defects in patients weighing 700 to 2500 grams. Reddy VM, et al. **J Thorac Cardiovasc Surg** 1999 Feb;117(2):324–31

Low birthweight in infants born to African HIV-infected women: relationship with maternal body weight during pregnancy: Pregnancy and HIV Study Group (EGE). Castetbon K, et al. **J Trop Pediatr** 1999 Jun;45(3):152–7

Kangaroo mother care in low-income countries. International Network in Kangaroo Mother Care. Cattaneo A, et al. **J Trop Pediatr** 1998 Oct;44(5):279–82

Cup feeding: an alternative to bottle feeding in a neonatal intensive care unit. Gupta A, et al. **J Trop Pediatr** 1999 Apr;45(2):108–10

Weight, length, ponderal index, and intrauterine growth retardation in Brazil. Rondó PH. **J Trop Pediatr** 1998 Dec; 44(6):355–7

Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192–4 (23 ref.)

From the Centers for Disease Control and Prevention. Impact of multiple births on low birthweight--Massachusetts, 1989–1996. **JAMA** 1999 Jun 2;281(21):1980–1

Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group. Davis RL, et al. **JAMA** 1999 Aug 11;282(6):547–53

Molybdenum requirements in low-birth-weight infants receiving parenteral and enteral nutrition. Friel JK, et al. **JPEN J Parenter Enteral Nutr** 1999 May–Jun;23(3):155–9

A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Hoy WE, et al. **Kidney Int** 1999 Sep;56(3):1072–7

Mitochondrial 16189 variant, thinness at birth, and type-2 diabetes. ALSPAC study team. Avon Longitudinal Study of Pregnancy and Childhood [letter] Casteels K, et al. **Lancet** 1999 May 1;353(9163):1499–500

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Hattersley AT, et al. **Lancet** 1999 May 22; 353(9166):1789–92 (43 ref.)

Low birthweight and renal disease in Australian aborigines [letter] Hoy WE, et al. **Lancet** 1998 Dec 5;352(9143):1826–7

Smoking cheroots reduces birthweight [letter] [published erratum appears in Lancet 1999 Jan 30;353(9150):414] McGready R, et al. **Lancet** 1998 Nov 7;352(9139):1521–2

Impact of multiple births on low birthweight--Massachusetts, 1989–1996. **MMWR Morb Mortal Wkly Rep** 1999 Apr 16; 48(14):289–92

Infant mortality and low birthweight in North Carolina: the last 10 years. Surles K, et al. **N C Med J** 1999 May–Jun; 60(3):163–8

First-trimester growth and the risk of low birth weight. Smith GC, et al. **N Engl J Med** 1998 Dec 17; 339(25):1817–22

The insulin gene VNTR, type 2 diabetes and birth weight [letter; comment] Ong KK, et al. **Nat Genet** 1999 Mar; 21(3):262–3. Comment on: Nat Genet 1998 May;19(1):98–100.

The risk of low birth weight associated with vaginal douching. Fiscella K, et al. **Obstet Gynecol** 1998 Dec; 92(6):913–7

Risk of low birth weight infants among black and white parents. Hessol NA, et al. **Obstet Gynecol** 1998 Nov; 92(5):814–22

Relationship of cesarean delivery to lower birth weight-specific neonatal mortality in singleton breech infants in the United States [see comments] Lee KS, et al. **Obstet Gynecol** 1998 Nov;92(5):769–74. Comment in: Obstet Gynecol 1999 Apr;93(4):630–1.

Relationship of cesarean delivery to lower birth weight-specific neonatal mortality in singleton breech infants in the United States [letter; comment] Murphy K, et al. **Obstet Gynecol** 1999 Apr;93(4):630–1. Comment on: Obstet Gynecol 1998 Nov;92(5):769–74.

Small size at birth and later diabetic pregnancy. Plante LA. **Obstet Gynecol** 1998 Nov;92(5):781–4

Pregnancy outcomes and outdoor air pollution: an ecological study in districts of the Czech Republic 1986–8. Bobak M, et al. **Occup Environ Med** 1999 Aug;56(8):539–43

Sociodemographic determinants of low birthweight in Greece: a population study. Lekea-Karanika V, et al. **Paediatr Perinat Epidemiol** 1999 Jan;13(1):65–77

Effect of neck position on endotracheal tube location in low birth weight infants. Rost JR, et al. **Pediatr Pulmonol** 1999 Mar;27(3):199–202

Cerebellar vermis diameter at cranial sonography for assessing gestational age in low-birth-weight infants. Cuddihy SL, et al. **Pediatr Radiol** 1999 Aug;29(8):589–94

Video-assisted thoracoscopic surgery for patent ductus arteriosus in low birth weight neonates and infants. Burke RP, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):227–30

Low birth weight: race and maternal nativity--impact of community income. Fang J, et al. **Pediatrics** 1999 Jan; 103(1):E5

Kangaroo mother care. Hann M, et al. **S Afr Med J** 1999 Jan;89(1):37–9

Risk of low birthweight in social districts of Copenhagen. Lund R, et al. **Scand J Public Health** 1999 Jun;27(2):89–93

Stress and low birth weight: a structural modeling approach using real life stressors. Sheehan TJ. **Soc Sci Med** 1998 Nov;47(10):1503–12

3-D ultrasound quantification of neonatal cerebral ventricles in different head positions. Nagdyman N, et al. **Ultrasound Med Biol** 1999 Jul;25(6):895–900

[Effects of perinatal care on low birth weight] Chen H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Nov; 32(6):363–5 (Eng. Abstr.) **(Chi)**

[Analysis of risk factors for infant deaths in urban and rural areas of Shandong Province] Zhang J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):275–7 (Eng. Abstr.) **(Chi)**

[Low birth weight: rate and risk factors in the Guédianwaye district (suburb of Dakar, Senegal)] Camara B, et al. **Dakar Med** 1995;40(2):213–9 (Eng. Abstr.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of premature rupture of membranes, outside of labor] Batallan A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:292–4 (15 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Which specific measures to consider for the newborn?] Bouillié J. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:314–7 (19 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. During labor, which delivery method should be chosen?] Boulot P. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:295–301 (22 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Labor surveillance in cases of vaginal delivery] Carbonne B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:307–10 (14 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of in utero growth retardation, outside of labor] Fournié A. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec; 27 Suppl 2:289–91 (7 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Anesthesia methods in cesarean cases and vaginal deliveries] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:275–84 (55 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. In cases of cesareans, which particular techniques should be considered (excluding anesthetic techniques)?] Langer B. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:302–6 (19 ref.) **(Fre)**

[Delivery methods for infants of birthweight less than 2500 grams. Description of practices in France. The Obstetricians Sentinel Network A.U.D.I.P.O.G.] Mamelle N. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:269–74 (7 ref.) **(Fre)**

[Delivery methods for infants weighing less than 2500 grams. Which particular preventative modalities should be proposed for natural delivery?] Verspyck E, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Dec;27 Suppl 2:311–3 (13 ref.) **(Fre)**

[Factors associated with low birth weight: a multivariate analysis] Fourn L, et al. **Sante** 1999 Jan–Feb;9(1):7–11 (Eng. Abstr.) **(Fre)**

[Neonatal care of premature infants] Ertl T. **Orv Hetil** 1999 Jul 18;140(29):1611–8 (5011 ref.) (Eng. Abstr.) **(Hun)**

[Surgical management of patent ductus arteriosus in low body weight infants] Uchita S, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Nov;46(11):1088–92 (Eng. Abstr.) **(Jpn)**

[An analysis on a relationship between perinatal mortality and live births of low birthweight, in Kumamoto Prefecture, 1968–1994] Ueda K, et al. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):470–6 (Eng. Abstr.) **(Jpn)**

[Epidemiologic study of birth weight from birth certificates] Costa CE, et al. **Rev Saude Publica** 1998 Aug;32(4):328–34 (Eng. Abstr.) **(Por)**

BLOOD

Relation of hemoglobin measured at different times in pregnancy to preterm birth and low birth weight in Shanghai, China. Zhou LM, et al. **Am J Epidemiol** 1998 Nov 15;148(10):998–1006

Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates. Aronis S, et al. **Biol Neonate** 1998 Nov; 74(5):337–44

[Serine protease inhibitors in newborns. IV. Levels of alpha-2-macroglobulin in serum of eutrophic and hypotrophic newborns and their mothers] Wasiluk A, et al. **Ginekol Pol** 1998 Jul;69(7):590–3 (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

Body position, sleep states, and cardiorespiratory activity in developing low birth weight infants. Sahni R, et al. **Early Hum Dev** 1999 Apr;54(3):197–206

Growth patterns of low-birth-weight infants: 2-year longitudinal study. Jaruratanasirikul S, et al. **J Med Assoc Thai** 1999 Apr;82(4):325–31

Delay of catch-up growth in very low birthweight infants. Kuschel CA, et al. **N Z Med J** 1999 Mar 26;112(1084):94–6

Longitudinal growth of hospitalized very low birth weight infants. Ehrenkranz RA, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):280–9

Neurodevelopment of surviving infants at age two years, with a birthweight less than 2000 g and cared for in neonatal intensive care units (NICU)--results from a population based longitudinal study in Taiwan. Wang ST, et al. **Public Health** 1998 Sep;112(5):331–6

IMMUNOLOGY

The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Wesumperuma HL, et al. **Ann Trop Med Parasitol** 1999 Mar;93(2):169–77

Humoral immunity status in neonates born to pre-eclamptic toxaemia mothers. Das S, et al. **J Indian Med Assoc** 1998 Mar;96(3):77–9

METABOLISM

Gluconeogenesis in very low birth weight infants receiving total parenteral nutrition. Sunehag AL, et al. **Diabetes** 1999 Apr;48(4):791–800

Longitudinal evaluation of salivary cortisol levels in full-term and preterm neonates. Bettendorf M, et al. **Horm Res** 1998; 50(6):303–8

Effect of theophylline on glucose production and lipolysis in preterm infants (< or = 32 weeks). Diderholm B, et al. **Pediatr Res** 1999 May;45(5 Pt 1):674–9

[Studying intestinal maturation in newborn infants by means of stable isotopes] Sáenz de Pipaón M, et al. **Rev Med Univ Navarra** 1998 Apr–Jun;42(2):77–82 (59 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Infants with birth weight 1,000–1,499 grams born in three time periods: has outcome changed over time? [see comments] Piecuch RE, et al. **Clin Pediatr (Phila)** 1998 Sep;37(9):537–45. Comment in: Clin Pediatr (Phila) 1998 Sep;37(9):547–9.

Follow-up of the low-birth-weight infant: where do we go from here? [editorial; comment] Spitzer AR. **Clin Pediatr (Phila)** 1998 Sep;37(9):547–9. Comment on: Clin Pediatr (Phila) 1998 Sep;37(9):537–45.

Inefficient analysis of twin data: is there an association between diabetes and birth weight? [letter] Bring J, et al. **Diabetologia** 1999 Jul;42(7):898–9

Postnatal hemodynamic changes in very-low-birthweight infants. Yanowitz TD, et al. **J Appl Physiol** 1999 Jul; 87(1):370–80

Introducing the law strip: a simple device to screen for, and improve documentation of, low birthweight babies in Nigeria [letter] Lawoyin TO. **J Trop Pediatr** 1999 Apr; 45(2):121–2

Effects of prenatal steroids on water and sodium homeostasis in extremely low birth weight neonates. Omar SA, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):482–8

Does supplementation of formula with evening primrose and fish oils augment long chain polyunsaturated fatty acid status of low birthweight infants to that of breast-fed counterparts? Woltil HA, et al. **Prostaglandins Leukot Essent Fatty Acids** 1999 Mar; 60(3):199–208

PSYCHOLOGY

The Infant Health and Development Program: interim summary. McCormick MC, et al. **J Dev Behav Pediatr** 1998 Oct;19(5):359–70

[Delivery methods for infants weighing less than 2500 grams. Psychological implications] Molénat F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1998 Dec;27 Suppl 2:285–8 (8 ref.) **(Fre)**

INFANT MORTALITY

see related
FETAL DEATH

Perinatal morbidity and mortality rates in twin pregnancies--a 15-year review study from Athens. Liapis AE, et al. **Acta Genet Med Gemellol (Roma)** 1997; 46(4):185–91 (25 ref.)

Socio-demographic risk factors for perinatal mortality. A study of perinatal mortality in the French district of Seine-Saint-Denis. Zeitlin J, et al.
Acta Obstet Gynecol Scand 1998 Sep;77(8):826–35 (33 ref.)

Lack of precision in neonatal death classifications based on the underlying causes of death stated on death certificates. Winbo IG, et al. **Acta Paediatr** 1998 Nov;87(11):1167–72

Optimality of the birth population reduces learning and behaviour disorders and sudden infant death after the first month. Saugstad LF. **Acta Paediatr Suppl** 1999 May; 88(429):9–28 (171 ref.)

Child survival in children born to HIV-2 infected women in Guinea-Bissau, West Africa. Norrgren H, et al.
Acta Trop 1999 Apr 30;72(3):309–15

Child mortality in Stockholm during 1885–1910: the impact of household size and number of children in the family on the risk of death from measles. Burström B, et al.
Am J Epidemiol 1999 Jun 15;149(12):1134–41

Low-weight neonatal survival paradox in the Czech Republic. Carlson E, et al. **Am J Epidemiol** 1999 Mar 1; 149(5):447–53

Recurrence of gestational age in sibships: implications for perinatal mortality. Melve KK, et al. **Am J Epidemiol** 1999 Oct 1;150(7):756–62

Obstetric determinants of neonatal survival: antenatal predictors of neonatal survival and morbidity in extremely low birth weight infants. Bottoms SF, et al.
Am J Obstet Gynecol 1999 Mar;180(3 Pt 1):665–9

Indicated versus spontaneous preterm delivery: An evaluation of neonatal morbidity among infants weighing </=1000 grams at birth. Kimberlin DF, et al.
Am J Obstet Gynecol 1999 Mar;180(3 Pt 1):683–9

Risk factors for neonatal death in twin gestations in the state of South Carolina. Newman RB, et al.
Am J Obstet Gynecol 1999 Mar;180(3 Pt 1):757–62

Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Stevenson DK, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1632–9

Newborn assessment and long-term adverse outcome: a systematic review. van de Riet JE, et al.
Am J Obstet Gynecol 1999 Apr;180(4):1024–9

Retrospective analysis of causes of perinatal mortality in a polluted area. Mikulska M. **Am J Perinatol** 1998 Jun; 15(6):357–61

An alternative method for assessing early mortality in contemporary populations. Wiley AS, et al.
Am J Phys Anthropol 1998 Nov;107(3):315–30

Changes in the black-white infant mortality gap from 1983 to 1991 in the United States. Carmichael SL, et al.
Am J Prev Med 1998 Oct;15(3):220–7

The relation of the milk supply to infant mortality. 1906 [classical article] Knox JH Jr. **Am J Public Health** 1999 Mar;89(3):408–11

The effect of congenital anomalies on mortality risk in white and black infants. Malcoe LH, et al.
Am J Public Health 1999 Jun;89(6):887–92

Consanguinity and recurrence risk of stillbirth and infant death. Stoltenberg C, et al. **Am J Public Health** 1999 Apr; 89(4):517–23

Pediatric wilderness recreational deaths in western Washington State. Newman LM, et al. **Ann Emerg Med** 1998 Dec;32(6):687–92

The path analysis approach for the multivariate analysis of infant mortality data [letter; comment] Susser M, et al.
Ann Epidemiol 1999 Jan;9(1):73–4. Comment on: Ann Epidemiol 1998 May;8(4):262–71.

Mortality from early onset group B streptococcal infection in the United Kingdom. Embleton N, et al.
Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F139–41

Survival and place of delivery following preterm birth: 1994–96. Field D, et al.
Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F111–4

Epidemiology of cerebral palsy [letter; comment] Jessen C, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar; 80(2):F158. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Jul;79(1):F21–5.

Immaturity related lung hypoplasia: comment on current classification in neonatal death statistics [letter] Vrijheid M, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep; 79(2):F159

Artificial neural network for risk assessment in preterm neonates. Zernikow B, et al.
Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F129–34

Suboptimal care implicated in many infant deaths in UK [news] Pownall M. **BMJ** 1999 Jul 10;319(7202):77

Narrowing social inequalities in health? Analysis of trends in mortality among babies of lone mothers (abridged version 1). Whitehead M, et al. **BMJ** 1999 Apr 3; 318(7188):908–12

Neonatal mortality amongst Scottish preterm singleton births (1985–1994). Magowan BA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):1005–10

Teenage pregnancies and risk of late fetal death and infant mortality. Olausson PO, et al. **Br J Obstet Gynaecol** 1999 Feb;106(2):116–21

Factors affecting the mortality of sick newborns admitted to intensive care units. Yau KI, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1999 Mar-Apr;40(2):75–82

Neonatal risk scoring systems. Can they predict mortality and morbidity? Richardson DK, et al. **Clin Perinatol** 1998 Sep;25(3):591–611 (126 ref.)

Outcome of post-term pregnancy: a matched-pair case-control study. Matijević R. **Croat Med J** 1998 Dec; 39(4):430–4

The effect of inbreeding on early childhood mortality: twelve generations of an Amish settlement. Dorsten LE, et al.
Demography 1999 May;36(2):263–71

Birth outcome, not pregnancy process: reply to van der Veen [comment] Frisbie WP, et al. **Demography** 1998 Nov; 35(4):519–27. Comment on: Demography 1998 Nov;35(4):509–17.

Migradollars and mortality: the effects of migration on infant survival in Mexico. Kanaiaupuni SM, et al. **Demography** 1999 Aug;36(3):339–53

Comment on "Compromised birth outcomes and infant mortality among racial and ethnic groups" [comment] [see comments] van der Veen WJ. **Demography** 1998 Nov; 35(4):509–17. Comment on: Demography 1996 Nov;33(4):469–81. Comment in: Demography 1998 Nov;35(4):519.

Birthweight and neonatal outcome at the Muhimbili Medical Centre, Dar es Salaam, Tanzania. Manji KP, et al.
East Afr Med J 1998 Jul;75(7):382–7

Air pollution and infant mortality in Mexico City. Loomis D, et al. **Epidemiology** 1999 Mar;10(2):118–23

Patterns of childhood mortality in three districts of north Gondar Administrative Zone. A community based study using the verbal autopsy method. Fantahun M.
Ethiop Med J 1998 Apr;36(2):71–81

Birth weight of US biracial (black-white) infants: regional differences. Polednak AP, et al. **Ethn Dis** 1998 Autumn; 8(3):340–9

Perinatal mortality in twin pregnancies: a 3-year analysis in Seine Saint-Denis (France). Chitrit Y, et al.
Eur J Obstet Gynecol Reprod Biol 1999 Sep;86(1):23–8

Contribution of congenital malformations to perinatal mortality. A 10 years prospective regional study in The Netherlands. De Galan-Roosen AE, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Sep;80(1):55–61

Declining perinatal mortality in Finland between 1987 and 1994: contribution of different subgroups. Forssas E, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Oct;80(2):177–81

Estonian medical birth registry 1992–1994: association of risk factors with perinatal mortality. Karro H, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Oct;80(2):151–6

Birth-weight-specific perinatal mortality in Japan, 1989–1993: singleton versus multifetal pregnancies. Minakami H, et al. **Gynecol Obstet Invest** 1999;48(1):38–42

Maternal education and fetal and infant mortality in Quebec. Fetal and Infant Mortality Study Group of the Canadian Perinatal Surveillance System [published erratum appears in Health Rep 1998 Winter;10(3):77] Chen J, et al.
Health Rep 1998 Autumn;10(2):53–64 (Eng); 57–70 (Fre) **(Eng, Fre)**

Selective cost of delayed childbearing [letter] Astolfi P, et al. **Hum Reprod** 1999 Feb;14(2):572–3

Early neonatal morbidity and mortality in a city based medical college nursery. Das PK, et al.
Indian J Public Health 1998 Jan-Mar;42(1):9–14

Weight gain during pregnancy--a key factor in perinatal and infant mortality [see comments] Agarwal DK, et al.
Indian Pediatr 1998 Aug;35(8):733–43. Comment in: Indian Pediatr 1998 Dec;35(12):1250–1.

Perinatal and neonatal mortality--a hospital based study [letter] Behl L, et al. **Indian Pediatr** 1998 Jul;35(7):683–4

Perinatal autopsy--a six year study. Dandekar CP, et al.
Indian Pediatr 1998 Jun;35(6):545–8

Weight gain during pregnancy--a key factor in perinatal and infant mortality [letter; comment] Pradhan R.
Indian Pediatr 1998 Dec;35(12):1250–1. Comment on: Indian Pediatr 1998 Aug;35(8):733–43.

Health trends in northern Finland. Näyhä S, et al.
Int J Circumpolar Health 1998 Jul;57(2-3):94–103 (51 ref.)

Maternal predictors of perinatal mortality: the role of birthweight. Forssas E, et al. **Int J Epidemiol** 1999 Jun; 28(3):475–8

Can children's health be predicted by perinatal health? Gissler M, et al. **Int J Epidemiol** 1999 Apr;28(2):276–80

Fatness and muscularity as risk indicators of child mortality in rural Congo. Van den Broeck J, et al.
Int J Epidemiol 1998 Oct;27(5):840–4

NICE, a new cause of death classification for stillbirths and neonatal deaths. Neonatal and Intrauterine Death Classification according to Etiology. Winbo IG, et al.
Int J Epidemiol 1998 Jun;27(3):499–504

Risk factors for meconium aspiration syndrome. Karatekin G, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):295–7

Advances in perinatal medical care--from our experience. Sakamoto S, et al. **Int J Gynaecol Obstet** 1998 Dec;63 Suppl 1:S107–14 (9 ref.)

Effects of infant feeding practices and birth spacing on infant and child survival: a reassessment from retrospective and prospective data. Kuate Defo B. **J Biosoc Sci** 1997 Jul; 29(3):303–26

Measuring excess risk of child mortality: an exploration of DHS I for Burundi, Uganda and Zimbabwe. McMurray C. **J Biosoc Sci** 1997 Jan;29(1):73–91

A phylogenetic analysis of the relationship between sub-adult mortality and mode of subsistence. Sellen DW, et al.
J Biosoc Sci 1999 Jan;31(1):1–16 (59 ref.)

Underregistration of neonatal deaths: an empirical study of the accuracy of infantile vital statistics in Taiwan. Chen LM, et al. **J Epidemiol Community Health** 1998 May; 52(5):289–92

Perinatal death in ethnic minorities in The Netherlands. van Enk A, et al. **J Epidemiol Community Health** 1998 Nov; 52(11):735–9

Rates of perinatal mortality and low birth weight among 3367 consecutive births in south of Beirut. Bittar Z.
J Med Liban 1998 May-Jun;46(3):126–30

Influence of maternal ethnicity on infant mortality in Chicago, 1989–1996. Poma PA, et al.
J Natl Med Assoc 1999 Feb;91(2):87–90

Neurodevelopmental outcome of very low birth weight babies admitted to a Malaysian nursery. Ho JJ, et al.
J Paediatr Child Health 1999 Apr;35(2):175–80

The involvement of two or more systems and the severity of associated anomalies significantly influence mortality in esophageal atresia. Saing H, et al. **J Pediatr Surg** 1998 Nov; 33(11):1596–8

Prenatally diagnosed cystic lymphangioma in infants. Suzuki N, et al. **J Pediatr Surg** 1998 Nov;33(11):1599–604

Increased survival in low birth weight neonates given prophylactic surfactant. Brown DR, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 1):431–5

Perinatal outcome and the social contract--interrelationships between health and humanity. Gorski PA. **J Perinatol** 1998 Jul-Aug;18(4):297–301

Gestational age-specific normal birth weight for Japanese twins. Risk of early neonatal death in small-for-gestational-age and large-for-gestational-age twins. Minakami H, et al. **J Reprod Med** 1999 Jul; 44(7):625–9

Cause-specific mortality in under fives in the urban slums of Lucknow, north India. Awasthi S, et al.
J Trop Pediatr 1998 Dec;44(6):358–61

Outcome for children under 5 years hospitalized with severe acute lower respiratory tract infections in Yemen: a 5 year experience. Banajeh SM. **J Trop Pediatr** 1998 Dec; 44(6):343–6

Assessment of separate contributions to perinatal mortality of infertility history and treatment: a case-control analysis [see comments] Draper ES, et al. **Lancet** 1999 May 22; 353(9166):1746–9. Comment in: Lancet 1999 May 22;353(9166):1724–3.

Childhood mortality in sub-Saharan Africa [letter; comment] [see comments] Müller O, et al. **Lancet** 1999 Feb 20; 353(9153):673. Comment on: Lancet 1998 Dec 12;352(9144):1909. Comment in: Lancet 1999 Jul 3;354(9172):75.

Child mortality in Iraq [letter; comment] Zaidi S. **Lancet** 1997 Oct 11;350(9084):1105. Comment on: Lancet 1995 Dec 2;346(8988):1485.

Sir George Newman, infant diarrhoeal mortality and the paradox of urbanism. Walker-Smith J. **Med Hist** 1998 Jul; 42(3):347–61

Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. Liu JL, et al. **Mol Endocrinol** 1998 Sep;12(9):1452–62

What can be done about infant mortality in Pitt County? Fisher JK. **N C Med J** 1998 Nov-Dec;59(6):349–52

Infant mortality statistics from the 1997 period linked birth/infant death data set. MacDorman MF, et al.
Natl Vital Stat Rep 1999 Jul 30;47(23):1–23

Perinatal mortality in breech presentation sibships. Albrechtsen S, et al. **Obstet Gynecol** 1998 Nov;92(5):775–80

Relationship of cesarean delivery to lower birth weight-specific neonatal mortality in singleton breech infants in the United States [see comments] Lee KS, et al. **Obstet Gynecol** 1998 Nov;92(5):769–74. Comment in: Obstet Gynecol 1999 Apr;93(4):630–1.

Repeated neonatal deaths in families with special reference to causes of death. Alam N, et al.
Paediatr Perinat Epidemiol 1999 Jan;13(1):78–88

Racial differences in birthweight for gestational age and infant mortality in extremely-low-risk US populations. Alexander GR, et al. **Paediatr Perinat Epidemiol** 1999 Apr; 13(2):205–17

Structured review of neonatal deaths in a managed care organisation. Escobar GJ, et al.
Paediatr Perinat Epidemiol 1998 Oct;12(4):422–36

The impact of consanguinity and inbreeding on perinatal mortality in Karachi, Pakistan. Hussain R.
Paediatr Perinat Epidemiol 1998 Oct;12(4):370–82

Fishing for trout in the milk [editorial] Berry PJ.
Pediatr Dev Pathol 1998 Mar-Apr;1(2):99–101 (11 ref.)

Is management of neonatal respiratory distress syndrome feasible in developing countries? Experience from Karachi (Pakistan) [see comments] Bhutta ZA, et al.

Pediatr Pulmonol 1999 May;27(5):305–11. Comment in: Pediatr Pulmonol 1999 May;27(5):303–4.

Neonatal respiratory care and infant mortality in emerging countries [editorial; comment] Sola A, et al. **Pediatr Pulmonol** 1999 May;27(5):303–4 (8 ref.). Comment on: Pediatr Pulmonol 1999 May;27(5):305–11. Comment on: Pediatr Pulmonol 1999 May;27(5):312–7.

Risk of death for small for gestational age very preterm infants [letter] Beeby PJ. **Pediatrics** 1998 Dec;102(6):1497–8

The early history of the infant mortality rate in America: "A reflection upon the past and a prophecy of the future". Brosco JP. **Pediatrics** 1999 Feb;103(2):478–85

Foreign aid, international organizations, and the world's children. Wegman ME. **Pediatrics** 1999 Mar;103(3):646–54

A community–wide infant mortality review: findings and implications. McCloskey L, et al. **Public Health Rep** 1999 Mar–Apr;114(2):165–77

What is the infant mortality rate in South Africa? The need for improved data. Nannan N, et al. **S Afr Med J** 1998 Dec;88(12):1583–7

Infant mortality in the rural Hlabisa health district––estimation using the previous birth technique [letter] Wilkinson D, et al. **S Afr Med J** 1999 Jul;89(7):755

State of South Dakota's child: 1998. Wilson AL. **S D J Med** 1999 Jan;52(1):13–8

Use of a historical register in social epidemiology: child mortality in Stockholm at the turn of the 19th century. Burström B, et al. **Scand J Soc Med** 1998 Sep;26(3):166–72

Confidential regional enquiry into mature stillbirths and neonatal deaths––a multi–disciplinary peer panel perspective of the perinatal care of 238 deaths. Tan KH, et al. **Singapore Med J** 1999 Apr;40(4):251–5

Mate selection and its impact on female marriage age, pregnancy wastages, and first child survival in Tamil Nadu, India. Sureender S, et al. **Soc Biol** 1998 Fall–Winter; 45(3–4):289–301

No fathers' names: a risk factor for infant mortality in the State of Georgia, USA. Gaudino JA Jr, et al. **Soc Sci Med** 1999 Jan;48(2):253–65

Birth intervals, breastfeeding and determinants of childhood mortality in Malawi. Manda SO. **Soc Sci Med** 1999 Feb; 48(3):301–12

Infant mortality: a multi–level analysis of individual and community risk factors. Matteson DW, et al. **Soc Sci Med** 1998 Dec;47(11):1841–54

Childhood conditions that predict survival to advanced ages among African–Americans. Preston SH, et al. **Soc Sci Med** 1998 Nov;47(9):1231–46

Assessing the goodness–of–fit of the Laird and Ware model––an example: the Jimma Infant Survival Differential Longitudinal Study. Lesaffre E, et al. **Stat Med** 1999 Apr 15;18(7):835–54

Associations between wife–beating and fetal and infant death: impressions from a survey in rural India. Jejeebhoy SJ. **Stud Fam Plann** 1998 Sep;29(3):300–8

The effect of child mortality on fertility regulation in rural Bangladesh. Rahman M. **Stud Fam Plann** 1998 Sep; 29(3):268–81

Special care for newborns at a community hospital: a 5–year experience. Borulkar PD, et al. **Trop Doct** 1998 Oct; 28(4):201–3

Socio–demographic determinants of antenatal care. Chandrashekar S, et al. **Trop Doct** 1998 Oct;28(4):206–9

Rapid risk household screening by neonatal arm circumference: results from a cohort study in rural Burkina Faso. Benzler J, et al. **Trop Med Int Health** 1998 Dec; 3(12):962–74

Time trends in twin perinatal mortality in northern England, 1982–94. Northern Region Perinatal Mortality Survey Steering Group. Glinianaia SV, et al. **Twin Res** 1998 Dec; 1(4):189–95

[Pregnancy outcome (perinatal mortality and morbidity) in women with diabetes] Rakhab MA, et al. **Akush Ginekol (Sofiia)** 1998;37(1):17–22 (Eng. Abstr.) **(Bul)**

[Analysis of risk factors for infant deaths in urban and rural areas of Shandong Province] Zhang J, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Sep;31(5):275–7 (Eng. Abstr.) **(Chi)**

[Deaths at the neonatal department. Withholding or interruption of life–support treatment] Bjerager MO, et al. **Ugeskr Laeger** 1999 Mar 29;161(13):1916–9 (Eng. Abstr.) **(Dan)**

[Perinatal audit in the county of Viborg 1994–1996] Krue S, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):31–3 (Eng. Abstr.) **(Dan)**

[The programming hypothesis] Odborg MH, et al. **Ugeskr Laeger** 1999 Jan 25;161(4):441–2 **(Dan)**

[Perinatal deaths in Delft and surrounds, 1983–1992: further reduction is possible by targeting lethal congenital abnormalities and placental insufficiency (letter; comment)] Berkelmans PG. **Ned Tijdschr Geneeskd** 1999 Mar 27; 143(13):700. Comment on: Ned Tijdschr Geneeskd 1999 Jan 16;143(3):152–7. **(Dut)**

[Perinatal mortality in Delft and surrounds, 1983–1992: further reduction is possible by targeting lethal congenital abnormalities and placental insufficiency (see comments)] de Galan–Roosen AE, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):152–7 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):700. **(Dut)**

[Teenage pregnancy distribution by ethnicity in the Netherlands, 1990–1993] van Enk WJ, et al. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):465–71 (Eng. Abstr.) **(Dut)**

[Study of factors associated with early mortality of premature infants at the University Hospital Center of Brazzaville (letter)] Ganga–Zandzou PS, et al. **Arch Pediatr** 1999 Feb; 6(2):227–8 **(Fre)**

[Neonatal mortality in the Tantigou pediatric hospital, Dapaong (north Togo) in 1984–1985 and 1994–1995] Agbèrè AD, et al. **Bull Soc Pathol Exot** 1998;91(4):315–7 (Eng. Abstr.) **(Fre)**

[The information system on perinatality in France. Situation at the national level (editorial)] Blondel B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1998 Oct;27(6):573–6 **(Fre)**

[Fetal and neonatal mortality from 22 weeks of amenorrhea in the Loire area] Branger B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1999 Jul;28(4):373–9 (Eng. Abstr.) **(Fre)**

[When the child does not appear ... supporting parents and medical staff during perinatal death] Fohn B. **Rev Med Liege** 1999 May;54(5):468–76 (Eng. Abstr.) **(Fre)**

[Prenatal protection. Regulations. Perinatal mortality. Epidemiology] Kremp O. **Rev Prat** 1998 Jun 1; 48(11):1233–8 (0 ref.) **(Fre)**

[Advise to pregnant women on the question of "home childbirth––yes or no?" What are the criteria for a planned home delivery?] Heimrath W. **Fortschr Med** 1999 Mar 10; 117(7):20–2 **(Ger)**

[Polysomnography––infant mortality (letter)] Szántó I, et al. **Orv Hetil** 1999 May 23;140(21):1202–3 **(Hun)**

[An analysis on a relationship between perinatal mortality and live births of low birthweight, in Kumamoto Prefecture, 1968–1994] Ueda K, et al. **Nippon Eiseigaku Zasshi** 1998 Jul;53(2):470–6 (Eng. Abstr.) **(Jpn)**

[Perinatal deaths in the county of Ostfold 1989–97] Fossen D, et al. **Tidsskr Nor Laegeforen** 1999 Apr 10;119(9):1272–5 (Eng. Abstr.) **(Nor)**

[Maps of epidemiological rates: a Bayesian approach] Assunção RM, et al. **Cad Saude Publica** 1998 Oct–Dec; 14(4):713–23 (Eng. Abstr.) **(Por)**

[Small for gestational age: risk factor for neonatal mortality] de Almeida MF, et al. **Rev Saude Publica** 1998 Jun; 32(3):217–24 (Eng. Abstr.) **(Por)**

[Predictive value of the "Clinical Risk Index for Babies" for the risk of neonatal death] Matsuoka OT, et al. **Rev Saude Publica** 1998 Dec;32(6):550–5 (Eng. Abstr.) **(Por)**

[Risk factors for perinatal mortality in Pelotas, a southern city of Brazil, 1993] Menezes AM, et al. **Rev Saude Publica** 1998 Jun;32(3):209–16 (Eng. Abstr.) **(Por)**

[Correlation–regression analysis of infant mortality] Tarasova GV. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):24–7 (Eng. Abstr.) **(Rus)**

[Immunological imbalance in the newborn infant and its correction in a system to prevent neonatal morbidity and infant mortality] Blokhina IN, et al. **Vestn Ross Akad Med Nauk** 1999;(5):37–40 (Eng. Abstr.) **(Rus)**

[Infant mortality and sudden infant death in Navarra between 1985 and 1996] Olivera Olmedo JE, et al. **An Esp Pediatr** 1998 Oct;49(4):348–52 (Eng. Abstr.) **(Spa)**

[Perinatal risk factors for mortality in the high–risk newborn] Flores Nava G, et al. **Ginecol Obstet Mex** 1998 Nov; 66:440–3 (Eng. Abstr.) **(Spa)**

[Differences in infant mortality within Bolivia] Darras C. **Rev Panam Salud Publica** 1998 Dec;4(6):393–7 (Eng. Abstr.) **(Spa)**

[An extensive study indicates good prognosis for children with extremely low birth weight] Finnström O, et al. **Lakartidningen** 1999 Mar 31;96(13):1560–2, 1565–7 **(Swe)**

[Increasing infant mortality and tuberculosis in China. A dark picture of public health and health care in China] Lundberg S. **Lakartidningen** 1999 Feb 10;96(6):642–6 **(Swe)**

[More active measures to increase survival in 24 week old gestation infants] Tunell R. **Lakartidningen** 1999 Mar 31; 96(13):1568–9 **(Swe)**

TRENDS

Birth weight and mortality in childhood in Norway. Samuelsen SO, et al. **Am J Epidemiol** 1998 Nov 15; 148(10):983–91

Obstetrical determinants of neonatal neurological morbidity in < or = 1000–gram infants. Goepfert AR, et al. **Am J Perinatol** 1999;16(1):33–42

Obstetric profiles and perinatal mortality among Pacific Island immigrants in New South Wales, 1990–93. Burton AJ, et al. **Aust N Z J Public Health** 1999 Apr;23(2):179–84

Child mortality patterns in rural areas of Anhui and Henan provinces in China, 1990. Jin SG, et al. **Biomed Environ Sci** 1998 Sep;11(3):264–76

Potentially avoidable perinatal deaths in Denmark, Sweden and Lithuania as classified by the Nordic–Baltic classification. Langhoff–Roos J, et al. **Br J Obstet Gynaecol** 1998 Nov;105(11):1189–94

Risk factors for mortality in young children living under various socio–economic conditions in Lahore, Pakistan: with particular reference to inbreeding. Yaqoob M, et al. **Clin Genet** 1998 Nov;54(5):426–34

The effects of infant mortality on fertility revisited: new evidence from Latin America. Palloni A, et al. **Demography** 1999 Feb;36(1):41–58 (56 ref.)

Epidemiology of child deaths due to drowning in Matlab, Bangladesh. Ahmed MK, et al. **Int J Epidemiol** 1999 Apr; 28(2):306–11

Variations in infant mortality rates among municipalities in the state of Ceará, Northeast Brazil: an ecological analysis. Terra de Souza AC, et al. **Int J Epidemiol** 1999 Apr; 28(2):267–75

Infant and child mortality determinants in Bangladesh: are they changing? Majumder AK, et al. **J Biosoc Sci** 1997 Oct;29(4):385–99

Fertility and infant mortality trends in Nicaragua 1964–1993. The role of women's education. Peña R, et al. **J Epidemiol Community Health** 1999 Mar;53(3):132–7

A study of neonatal deaths in the tea gardens of Dibrugarh district of upper Assam. Phukan RK, et al. **J Indian Med Assoc** 1998 Nov;96(11):333–4, 337

Hospital admissions in the first year of life in very preterm infants. Elder DE, et al. **J Paediatr Child Health** 1999 Apr; 35(2):145–50

Trend in mortality from respiratory distress syndrome in the United States, 1970–1995. Lee Ks, et al. **J Pediatr** 1999 Apr;134(4):434–40

From the Centers for Disease Control and Prevention. Decrease in infant mortality and sudden infant death syndrome among Northwest American Indians and Alaskan Natives––Pacific Northwest, 1985–1996. **JAMA** 1999 Apr 21;281(15):1369–70

Improvements in childhood mortality in The Gambia [letter; comment] [see comments] Hill AG, et al. **Lancet** 1999 Jul 3;354(9172):75. Comment on: Lancet 1999 Feb 20;353(9153):673. Comment in: Lancet 1999 Jul 3;354(9172):75.

Why do preterm infants die in the 1990s? Doyle LW, et al. **Med J Aust** 1999 Jun 7;170(11):528–32

Child survival. A fundamental human right. Pham H, et al. **Minn Med** 1999 Jul;82(7):20–6

Decrease in infant mortality and sudden infant death syndrome among Northwest American Indians and Alaskan Natives––Pacific Northwest, 1985–1996. **MMWR Morb Mortal Wkly Rep** 1999 Mar 12;48(9):181–4

Infant mortality and low birthweight in North Carolina: the last 10 years. Surles K, et al. **N C Med J** 1999 May–Jun; 60(3):163–8

Neonatology: will the infant learn to speak? Harding JE. **N Z Med J** 1998 Nov 13;111(1077):434–7

Short–term morbidity and infant mortality among infants who slept supine at 1 month of age––a follow–up report. Dwyer T, et al. **Paediatr Perinat Epidemiol** 1999 Jul; 13(3):302–15

The relationship between Caesarean section and neonatal mortality in very–low–birthweight infants born in Washington State, USA. Jonas HA, et al. **Paediatr Perinat Epidemiol** 1999 Apr;13(2):170–89

Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

Population density and perinatal mortality in Norway and Sweden 1975–1988. Daltveit AK, et al. **Scand J Public Health** 1999 Sep;27(3):213–9

Effects of maternal education on infant mortality and stillbirths in Denmark. Olsen O, et al. **Scand J Public Health** 1999 Jun;27(2):128–36

Socioeconomic correlates of infant mortality in Hong Kong, 1979–93. Wong TW, et al. **Scand J Soc Med** 1998 Dec; 26(4):281–8

Maternal smoking in pregnancy and sex differences in perinatal death between boys and girls. Xu B, et al. **Soc Biol** 1998 Fall–Winter;45(3–4):273–7

Searching for preventable causes of child mortality in Texas: trends in the major causes from 1987 through 1996. Kerr GR, et al. **Tex Med** 1999 Jul;95(7):56–64

[The incidence and structure of perinatal mortality in Bulgaria] Ivanov S, et al. **Akush Ginekol (Sofiia)** 1998; 37(1):12–5 (Eng. Abstr.) **(Bul)**

[Neonatal mortality in the pediatric ward of the regional hospital of Sokode (Togo) during 1984–1985 and 1994–1995] Agbèrè AR, et al. **Tunis Med** 1999 Feb; 77(2):77–81 **(Fre)**

INFANT, NEWBORN

see related
ANIMALS, NEWBORN

Anthropometric indices in singleton term neonates and their possible value in predicting some metabolic problems: a preliminary study. Nte A, et al. **Afr J Med Med Sci** 1997 Sep–Dec;26(3–4):171–3

MR of the normal neonatal brain: assessment of deep structures. Barkovich AJ. **AJNR Am J Neuroradiol** 1998 Sep;19(8):1397–403

The physicochemical environment of the neonatal intestine. Sanderson IR. **Am J Clin Nutr** 1999 May; 69(5):1028S–1034S (52 ref.)

Morbidity assessment index for newborns: a composite tool for measuring newborn health. Verma A, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):701–8

Nasal fossae dimensions in the neonate and young infant: a computed tomographic scan study. Contencin P, et al. **Arch Otolaryngol Head Neck Surg** 1999 Jul;125(7):777–81

Diagnostic image quality of mobile neonatal chest X-rays and the radiation exposure incurred. Lowe A, et al. **Br J Radiol** 1999 Jan;72(853):55-61

ILCOR advisory statement: resuscitation of the newly born infant. An advisory statement from the pediatric working group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Circulation** 1999 Apr 13;99(14):1927-38

How often do parenteral nutrition prescriptions for the newborn need to be individualized? Beecroft C, et al. **Clin Nutr** 1999 Apr;18(2):83-5

Ethical issues surrounding resuscitation. Boyle RJ, et al. **Clin Perinatol** 1999 Sep;26(3):779-92 (73 ref.)

Medication use in neonatal resuscitation. Burchfield DJ. **Clin Perinatol** 1999 Sep;26(3):683-91 (57 ref.)

History of neonatal resuscitation. Tales of heroism and desperation. **Raju TN. Clin Perinatol** 1999 Sep; 26(3):629-40, vi-vii

Delivery room resuscitation of the newborn. Wolkoff LI, et al. **Clin Perinatol** 1999 Sep;26(3):641-58 (45 ref.)

A comparative study of quiet sleep, active sleep, and waking on the first 2 days of life. Carroll DA, et al. **Dev Psychobiol** 1999 Jul;35(1):43-8

Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Doellner H, et al. **Early Hum Dev** 1998 Oct;52(3):251-61

A controlled trial of alternative methods of oral feeding in neonates. Malhotra N, et al. **Early Hum Dev** 1999 Feb; 54(1):29-38

Effect of administering oral and inactivated polio vaccines immediately after birth. Hovi T, et al. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):526-8

Staphylococcus cohnii and Ureaplasma urealyticum in a neonate [letter] Taylor-Robinson D. **Eur J Clin Microbiol Infect Dis** 1999 Jul;18(7):530

Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Eur J Pediatr** 1999 Apr;158(4):345-58 (85 ref.)

Using mothers' and newborns' clinical anthropometric data to analyse birth histories. Raud J, et al. **Ginekol Pol** 1998 Aug;69(8):628-37

Cocaine metabolite kinetics in the newborn. Dempsey D, et al. **J Anal Toxicol** 1999 Jan-Feb;23(1):24-8

Morphology of the cervical vertebrae in the fetal-neonatal human skeleton. Castellana C, et al. **J Anat** 1999 Jan;194 (Pt 1):147-52

A new reference line for measuring the liver size in healthy newborns. Jungthirapanich J, et al. **J Med Assoc Thai** 1998 Dec;81(12):938-43

Newborn predictors of infant irritability. Keefe MR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):513-20

Bedside musical care: applications in pregnancy, childbirth, and neonatal care. Olson SL. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):569-75 (33 ref.)

Measurement of bone mineral content [letter; comment] Picaud JC, et al. **J Pediatr** 1999 Jan;134(1):125-6. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):421-5.

Intestinal flora in breast- and bottle-fed infants. Rubaltelli FF, et al. **J Perinat Med** 1998;26(3):186-91

A comparison of two methods of oral endotracheal tube stabilization in neonatal patients. DeJonge MH, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 1):463-5

Individual sex preferences and the population sex ratio of newborns. Chu CY, et al. **J Theor Biol** 1998 Oct 7; 194(3):383-90

Demography and the canonical ensemble. Smith JD. **Math Biosci** 1998 Nov;153(2):151-61

Birth weight in relation to morbidity and mortality among newborn infants. McIntire DD, et al. **N Engl J Med** 1999 Apr 22;340(16):1234-8

Sex ratios at birth and environmental temperatures. Lerchl A. **Naturwissenschaften** 1999 Jul;86(7):340-2

Some vagaries of neonatal lumbar epidural anaesthesia. Vas L, et al. **Paediatr Anaesth** 1999;9(3):217-23

Microstructural development of human newborn cerebral white matter assessed in vivo by diffusion tensor magnetic resonance imaging. Hüppi PS, et al. **Pediatr Res** 1998 Oct; 44(4):584-90

Description and evaluation of a method based on magnetic resonance imaging to estimate adipose tissue volume and total body fat in infants. Olhager E, et al. **Pediatr Res** 1998 Oct;44(4):572-7

Deformability and geometry of neonatal erythrocytes with irregular shapes. Ruef P, et al. **Pediatr Res** 1999 Jan; 45(1):114-9

Dual energy x-ray absorptiometry of the forearm in preterm and term infants: evaluation of the methodology. Sievänen H, et al. **Pediatr Res** 1999 Jan;45(1):100-5

Rehospitalization in the first two weeks after discharge from the neonatal intensive care unit. Escobar GJ, et al. **Pediatrics** 1999 Jul;104(1):e2

An advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Pediatrics** 1999 Apr;103(4):e56 (85 ref.)

The influence of a clear layer on near-infrared spectrophotometry measurements using a liquid neonatal head phantom. Wolf M, et al. **Phys Med Biol** 1999 Jul; 44(7):1743-53

The response of crying newborns to sucrose: is it a "sweetness" effect? Barr RG, et al. **Physiol Behav** 1999 May; 66(3):409-17

Resuscitation of the newly born infant: an advisory statement from the Pediatric Working Group of the International Liaison Committee on Resuscitation. Kattwinkel J, et al. **Resuscitation** 1999 Feb-Mar;40(2):71-88 (85 ref.)

Neonatal resuscitation--a practical assessment. Whyte SD, et al. **Resuscitation** 1999 Jan;40(1):21-5

Neonatal analgesia and anesthesia. Introduction. Anand KJ. **Semin Perinatol** 1998 Oct;22(5):347-9 (9 ref.)

Neuroblastoma in the neonate. Lukens JN. **Semin Perinatol** 1999 Aug;23(4):263-73 (64 ref.)

Diagnosing intrauterine exposure to cocaine by hair testing: six years of clinical use. Koren G, et al. **Ther Drug Monit** 1998 Oct;20(5):478-80

Special care for newborns at a community hospital: a 5-year experience. Borulkar PD, et al. **Trop Doct** 1998 Oct; 28(4):201-3

[A study on the setting-up a high-risk scoring system for neonatal adverse outcomes] Li H, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1997 Jan;31(1):13-5 (Eng. Abstr.) **(Chi)**

[Care of the newborn at Cotonou. Actual state and difficulties] Ayivi B, et al. **Arch Pediatr** 1999;6 Suppl 2:272s-274s **(Fre)**

[Neonatology in the Maghreb region: cost] Khrouf N. **Arch Pediatr** 1999;6 Suppl 2:275s-277s **(Fre)**

[Temperature measurement in the neonate: the post-mercury era (letter)] Semama DS, et al. **Arch Pediatr** 1999 Jun; 6(6):686-7 **(Fre)**

[Maternal HIV infection and the anthropometric characteristics of children at birth in Burkina Faso. DITRAME Study Group] Sombié I, et al. **Sante** 1999 May-Jun;9(3):173-7 (Eng. Abstr.) **(Fre)**

[Predictors for refusal behavior of the mother towards her unborn and newborn child--first results of a prospective study] Porsch U, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:55-8 **(Ger)**

BLOOD

Evaluation of reactive oxygen metabolites with micromethod in neonates: determination of standards of normality in full-term babies. Parmigiani S, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:103-6

Comparison of absolute cerebral haemoglobin concentration in neonates measured directly and by the oxygen swing method both based on near infrared spectrophotometry. Wolf M, et al. **Adv Exp Med Biol** 1998;454:125-9

Coagulation profile in healthy Nigerian neonates. Okunade MA, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):71-2

Blood lipid concentrations of docosahexaenoic and arachidonic acids at birth determine their relative postnatal changes in term infants fed breast milk or formula [see comments] Guesnet P, et al. **Am J Clin Nutr** 1999 Aug; 70(2):292-8. Comment in: Am J Clin Nutr 1999 Aug;70(2):181-2.

Maternal diet, length of gestation, and long-chain polyunsaturated fatty acid status of infants at birth [editorial; comment] Innis SM. **Am J Clin Nutr** 1999 Aug; 70(2):181-2. Comment on: Am J Clin Nutr 1999 Aug;70(2):292-8.

Neonatal nucleated red blood cell counts in growth-restricted fetuses: relationship to arterial and venous Doppler studies. Baschat AA, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):190-5

Nucleated red blood cells as a marker of acidemia in term neonates. Hanlon-Lundberg KM, et al. **Am J Obstet Gynecol** 1999 Jul;181(1):196-201

Neonatal platelet counts in fetal brain injury. Korst LM, et al. **Am J Perinatol** 1999;16(2):79-83

Use of psychotropic medications during lactation [letter; comment] Longhurst JG, et al. **Am J Psychiatry** 1998 Nov; 155(11):1643-4. Comment on: Am J Psychiatry 1997 Sep;154(9):1255-60.

Neonatal cytokines and coagulation factors in children with cerebral palsy. Nelson KB, et al. **Ann Neurol** 1998 Oct; 44(4):665-75

Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acids. Hara K, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):244-8

Impact of oxygen therapy on antioxidant status in newborns. Relationship with infection risk. Araujo V, et al. **Biofactors** 1998;8(1-2):143-7

Lipid peroxidation and antioxidants in erythrocyte membranes of full-term and preterm newborns. Huertas JR, et al. **Biofactors** 1998;8(1-2):133-7

Maternal and neonatal lead exposure in southern Italy. Carbone R, et al. **Biol Neonate** 1998;73(6):362-6

Human neonatal blood: stem cell content, kinetics of CD34+ cell decline and ex vivo expansion capacity. Li K, et al. **Br J Haematol** 1999 Jan;104(1):178-85

Thyroid function in neonates from goitre prevalent areas in Zimbabwe. Chinyanga E, et al. **Cent Afr J Med** 1998 May; 44(5):127-30

Levels of gonadotropins and adrenocortical hormones in newborns. Wang YM, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov-Dec;39(6):389-92

Cord blood leptin concentrations in relation to intrauterine growth. Varvarigou A, et al. **Clin Endocrinol (Oxf)** 1999 Feb;50(2):177-83

Hematopoietic growth factor levels in term and preterm infants. Rondini G, et al. **Curr Opin Hematol** 1999 May; 6(3):192-7 (59 ref.)

Lymphocyte subpopulations in healthy 1-3-day-old infants. O'Gorman MR, et al. **Cytometry** 1998 Oct 15;34(5):235-41

Influence of caesarean delivery and maternal factors on fat-soluble vitamins in blood from cord and neonates. González-Corbella MJ, et al. **Early Hum Dev** 1998 Dec; 53 Suppl:S121-34

Glutathione S-transferase Alpha 1-1 and aminotransferases in umbilical cord blood. Knapen MF, et al. **Early Hum Dev** 1999 Mar;54(2):129-35

Cerebral blood oxygenation changes induced by auditory stimulation in newborn infants measured by near infrared spectroscopy. Sakatani K, et al. **Early Hum Dev** 1999 Jul; 55(3):229-36

Prothrombin and PIVKA-II levels in cord blood from newborn exposed to anticonvulsants during pregnancy. Howe AM, et al. **Epilepsia** 1999 Jul;40(7):980-4

Functional and structural properties of Na+/K(+)-ATPase enzyme in neonatal erythrocytes. Vásárhelyi B, et al. **Eur J Clin Invest** 1998 Jul;28(7):543-5

Pregnancy-induced hypertension: maternal and neonatal plasma lipid-soluble antioxidant levels and its relationship with fatty acid unsaturation. Oostenbrug GS, et al. **Eur J Clin Nutr** 1998 Oct;52(10):754-9

Intake of long chain w3 polyunsaturated fatty acids during pregnancy and the influence of levels in the mother on newborn levels. Matorras R, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Apr;83(2):179-84

Platelet-activating factor concentrations in healthy and septic neonates. Kültürsay N, et al. **Eur J Pediatr** 1999 Sep; 158(9):740-1

Leptin values in placental cord blood of human newborns with normal intrauterine growth after 30-42 weeks of gestation. Gómez L, et al. **Horm Res** 1999;51(1):10-4

Effect of maternal low dose aspirin on neonatal platelet function. Dasari R, et al. **Indian Pediatr** 1998 Jun; 35(6):507-11

Nucleated red blood cells in fetuses delivered for early onset severe pre-eclampsia. Moser EC, et al. **Int J Gynaecol Obstet** 1999 Feb;64(2):183-5

Insulin, insulin-like growth factor I (IGF-I), IGF-binding protein-1, growth hormone, and feeding in the newborn. Ogilvy-Stuart AL, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3550-7

Comparison of the rates of exchange of lead in the blood of newly born infants and their mothers with lead from their current environment. Gulson BL, et al. **J Lab Clin Med** 1999 Feb;133(2):171-8

Umbilical artery blood gas and lactate in healthy newborns. Chanrachakul B, et al. **J Med Assoc Thai** 1999 Apr; 82(4):388-93

Possible role of plasma neurotensin on growth hormone regulation in neonates. Bozzola M, et al. **J Pediatr Endocrinol Metab** 1998 Sep-Oct;11(5):607-13

Diurnal variation of plasma cortisol levels in infancy. Mantagos S, et al. **J Pediatr Endocrinol Metab** 1998 Jul-Aug;11(4):549-53

G-CSF, GM-CSF and IL-6 levels in cord blood: diminished increase of G-CSF and IL-6 in preterms with perinatal infection compared to term neonates. Weimann E, et al. **J Perinat Med** 1998;26(3):211-8

Placental transfer of IgG antibodies against Haemophilus influenzae type b capsular polysaccharide in Brazilian term and preterm newborns. Nagao AT, et al. **J Trop Pediatr** 1999 Jun;45(3):171-3

Inflammatory cytokines in newborn infants. Sarandakou A, et al. **Mediators Inflamm** 1998;7(5):309-12

Complement system in healthy term newborns: reference values in umbilical cord blood. Sonntag J, et al. **Pediatr Dev Pathol** 1998 Mar-Apr;1(2):131-5

Upregulation of the antithrombotic protein C pathway at birth. Petäjä J, et al. **Pediatr Hematol Oncol** 1998 Nov-Dec; 15(6):489-99

Lipoprotein A profiles in Arab newborns. Alsaeid M, et al. **Pediatr Int** 1999 Feb;41(1):65-9

Heterogeneity in F-actin polymerization of cord blood polymorphonuclear leukocytes stimulated by N-formyl-methionyl-leucyl-phenylalanine. Taniuchi S, et al. **Pediatr Int** 1999 Feb;41(1):37-41

HbF synthesis during stress erythropoiesis as determined by gamma-mRNA/non-alpha-mRNA quantification. Bard H, et al. **Pediatr Res** 1999 May;45(5 Pt 1):684-6

Changes in leptin concentration during the early postnatal period: adjustment to extrauterine life? Hytinantti T, et al. **Pediatr Res** 1999 Feb;45(2):197-201

Impaired signal transduction in neonatal platelets. Israels SJ, et al. **Pediatr Res** 1999 May;45(5 Pt 1):687-91

Passive deformability of mature, immature, and active neutrophils in healthy and septicemic neonates. Linderkamp O, et al. **Pediatr Res** 1998 Dec;44(6):946-50

Dynamic changes in serum leptin concentrations during the fetal and neonatal periods. Matsuda J, et al. **Pediatr Res** 1999 Jan;45(1):71-5

Semiautomated enzyme immunoassay of thyrotropin as a mass screening test for neonatal hypothyroidism. Miyai K, et al. **Pediatr Res** 1984 Dec;18(12):1289-92

Differential effects of glucocorticoids on colony stimulating factors produced by neonatal mononuclear cells. Witek-Janusek L, et al. **Pediatr Res** 1999 Feb;45(2):224-9

Why do newborn infants have a high plasma creatinine? Guignard JP, et al. **Pediatrics** 1999 Apr;103(4):e49

Studies on fetal hemoglobin and gamma globin gene triplication in newborns in Jordan. Sadiq MF. **Proc Natl Sci Counc Repub China B** 1998 Jul;22(3):108–13

Maternal blood group in ABO and Rh systems and somatic condition of newborns. Litwiejko-Pietryńczak E, et al. **Rocz Akad Med Bialymst** 1998;43:154–9

Contact system in healthy term newborns: reference values in cord blood. Sonntag J, et al. **Thromb Res** 1997 Aug 1; 87(3):339–42

[Somatotropin function in term and premature newborns during the first month of life] Radetti G, et al. **Arch Pediatr** 1998;5 Suppl 4:338S–344S (Eng. Abstr.) **(Fre)**

[Serine protease inhibitors in newborns. IV. Levels of alpha-2-macroglobulin in serum of eutrophic and hypotrophic newborns and their mothers] Wasiluk A, et al. **Ginekol Pol** 1998 Jul;69(7):590–3 (Eng. Abstr.) **(Pol)**

[Content of components of the renin-angiotensin-aldosterone system of blood plasma of healthy children in the early neonatal period] Voloshin AN, et al. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):84–8 (Eng. Abstr.) **(Rus)**

[Biologic variation in electrolytes and essential microelements in the blood of neonates and their mothers] Perkov S, et al. **Lijec Vjesn** 1998 Jun;120(6):145–50 (Eng. Abstr.) **(Scr)**

GROWTH & DEVELOPMENT

Prenatal alcohol use among teenagers: effects on neonatal outcomes. Cornelius MD, et al. **Alcohol Clin Exp Res** 1999 Jul;23(7):1238–44

Developmental microbial ecology of the neonatal gastrointestinal tract. Mackie R, et al. **Am J Clin Nutr** 1999 May;69(5):1035S–1045S (135 ref.)

Ontogenetic constraints on neural and behavioral plasticity: evidence from imprinting and face processing. Johnson MH. **Can J Exp Psychol** 1999 Mar;53(1):77–91 (81 ref.)

Thyroid volume, urinary and milk iodine in mothers after delivery and their newborns in iodine-replete country. Tajtakova M, et al. **Endocr Regul** 1999 Mar;33(1):9–15

Application of computed tomography in studies on development of human paranasal sinuses in the early postnatal period. Rzymski K, et al. **Folia Morphol (Warsz)** 1999;58(1):43–51

The prenatal attenuation of brain/body development through interactions between growth hormone, triiodothyronine and testosterone during prenatal development of female neonates. Tan U, et al. **Int J Neurosci** 1998 Sep; 95(3-4):237–45

Long-chain polyunsaturated fatty acids, infant formula, and breastfeeding [letter; comment] Campbell C. **Lancet** 1998 Nov 21;352(9141):1703. Comment on: Lancet 1998 Aug 29;352(9129):688–91.

Changes in ventricular and muscle volumes of neonates. Ichihashi K, et al. **Pediatr Int** 1999 Feb;41(1):8–12

Growth and fatness at three to six years of age of children born small- or large-for-gestational age. Hediger ML, et al. **Pediatrics** 1999 Sep;104(3):e33

The influence of sex and selected paragenetic and environmental factors on the basic anthropometric measurements of newborns in Bialystok. Litwiejko-Pietryńczak E. **Rocz Akad Med Bialymst** 1998; 43:145–53

[Population-demographic structure of the population of Kursk region: anthropometric profile of newborn children] Ivanov VP, et al. **Genetika** 1998 Dec;34(12):1692–8 (Eng. Abstr.) **(Rus)**

[Differences in the structure of the posterior parietal (lumbar) lymphatic bed of the peritoneal cavity in human fetuses and newborns] Shurkus EA, et al. **Morfologiia** 1999; 116(4):36–40 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Collins MD, et al. **Am J Clin Nutr** 1999 May;69(5):1052S–1057S (66 ref.)

Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses. Early E, et al. **Clin Exp Immunol** 1999 Jun; 116(3):527–33

Mode of delivery directs the phagocyte functions of infants for the first 6 months of life. Grönlund MM, et al. **Clin Exp Immunol** 1999 Jun;116(3):521–6

Mononuclear cell subpopulations in preterm and full-term neonates: independent effects of gestational age, neonatal infection, maternal pre-eclampsia, maternal betamethason therapy, and mode of delivery. Kotiranta-Ainamo A, et al. **Clin Exp Immunol** 1999 Feb;115(2):309–14

A mixed population of immature and mature leucocytes in umbilical cord blood results in a reduced expression and function of CR3 (CD11b/CD18). Reddy RK, et al. **Clin Exp Immunol** 1998 Dec;114(3):462–7

Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection. Gessler P, et al. **Eur J Pediatr** 1999 Jun;158(6):497–500

T-cell function in newborn mice and humans. Adkins B. **Immunol Today** 1999 Jul;20(7):330–5 (60 ref.)

Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. Marchant A, et al. **J Immunol** 1999 Aug 15; 163(4):2249–55

Human neonatal natural killer cell cytotoxicity function. Kohl S. **Pediatr Infect Dis J** 1999 Jul;18(7):635–7 (43 ref.)

Heterogeneity in F-actin polymerization of cord blood polymorphonuclear leukocytes stimulated by N-formyl-methionyl-leucyl-phenylalanine. Taniuchi S, et al. **Pediatr Int** 1999 Feb;41(1):37–41

[Ontogeny of the immune system] Millet V, et al. **Arch Pediatr** 1999;6 Suppl 1:14S–9S (Eng. Abstr.) **(Fre)**

[Characteristics of immunoreactivity in neonates and young children. Review of the literature] Dekaris D. **Lijec Vjesn** 1998 Mar-Apr;120(3-4):65–72 (95 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

The effect of labor on the acid-base status of the newborn. Hagelin A, et al. **Acta Obstet Gynecol Scand** 1998 Sep; 77(8):841–4

Protein balance in the first week of life in ventilated neonates receiving parenteral nutrition. Thureen PJ, et al. **Am J Clin Nutr** 1998 Nov;68(5):1128–35

Standard gentamicin dosage regimen in neonates. Langlass TM, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):440–3

Basal vs reflex lacrimation [letter; comment] Baum JL. **Arch Ophthalmol** 1999 Jan;117(1):141. Comment on: Arch Ophthalmol 1998 Jun;116(6):773–6.

Umbilical arterial S-nitrosothiols in stressed newborns: role in perinatal circulatory transition. Gaston B, et al. **Biochem Biophys Res Commun** 1998 Dec 30;253(3):899–901

Erythropoietin mRNA expression in human fetal and neonatal tissue. Dame C, et al. **Blood** 1998 Nov 1; 92(9):3218–25

Comparison of urinary 6beta-hydroxycortisol/cortisol ratio between neonates and their mothers. Nakamura H, et al. **Br J Clin Pharmacol** 1999 Jan;47(1):31–4

The relationship between serum and saliva erythropoietin concentrations in adults, full-term and premature infants. Hung GY, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov-Dec;39(6):380–5

Alveolar fluid clearance in developing lungs and its role in neonatal transition. Jain L. **Clin Perinatol** 1999 Sep; 26(3):585–99 (88 ref.)

Metabolic response to neonatal surgery. Pierro A. **Curr Opin Pediatr** 1999 Jun;11(3):230–6 (65 ref.)

The effect of early feeding on the neonatal blood glucose level at 1-hour of age. Sweet DG, et al. **Early Hum Dev** 1999 May;55(1):63–6

A short-term supplementation of pregnant women before delivery does not improve significantly the vitamin E status of neonates--low efficiency of the vitamin E placental transfer. Léger CL, et al. **Int J Vitam Nutr Res** 1998; 68(5):293–9

A negative iodine balance is found in healthy neonates compared with neonates with thyroid agenesis. Bakker B, et al. **J Endocrinol** 1999 Apr;161(1):115–20

The kinetic profile of vancomycin in neonates. Silva R, et al. **J Pharm Pharmacol** 1998 Nov;50(11):1255–60

Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Makinde AO, et al. **Mol Cell Biochem** 1998 Nov;188(1-2):49–56 (43 ref.)

The distribution of substance P receptor (NK1)-like immunoreactive neurons in the newborn and adult human spinal cord. Ding YQ, et al. **Neurosci Lett** 1999 May 7; 266(2):133–6

System A amino acid transporter activity in human placental microvillous membrane vesicles in relation to various anthropometric measurements in appropriate and small for gestational age babies. Harrington B, et al. **Pediatr Res** 1999 Jun;45(6):810–4

Metabolism of 13C-labeled linoleic acid in newborn infants during the first week of life. Szitanyi P, et al. **Pediatr Res** 1999 May;45(5 Pt 1):669–73

PHYSIOLOGY

Concentrations of essential trace elements in maternal serum and the effect on birth weight and newborn body mass index in sub-arctic and arctic populations of Norway and Russia. Odland JO, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):605–14 (44 ref.)

Hospital policies and their influence on newborn body weight. Mikiel-Kostyra K, et al. **Acta Paediatr** 1999 Jan; 88(1):72–5

Do neonatal pain and stress program the brain's response to future stimuli? [comment] Winberg J. **Acta Paediatr** 1998 Jul;87(7):723–5. Comment on: Acta Paediatr 1998 Jul;87(7):774–9.

The transition from fetus to neonate--an endocrine perspective. Gluckman PD, et al. **Acta Paediatr Suppl** 1999 Feb;88(428):7–11 (34 ref.)

Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Abramovici D, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):221–5

Perinatal and neonatal outcomes in multiple gestations: assisted reproduction versus spontaneous conception. Fitzsimmons BP, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1162–7

Placing the newborn on the maternal abdomen after delivery increases the volume and CD34 cell content in the umbilical cord blood collected: an old maneuver with new applications. Grisaru D, et al. **Am J Obstet Gynecol** 1999 May;180(5):1240–3

Response to cooling temperature in infants born at an altitude of 4,330 meters. Frappell PB, et al. **Am J Respir Crit Care Med** 1998 Dec;158(6):1751–6

Assessment of airway function using partial expiratory flow-volume curves: How reliable are measurements of maximal expiratory flow at frc during early infancy? Henschen M, et al. **Am J Respir Crit Care Med** 1999 Feb; 159(2):480–6

Normal values for total hand length, palm length and middle finger length in Malaysian newborns from 34-42 weeks of gestation. Halder D, et al. **Anthropol Anz** 1999 Mar; 57(1):69–75

Randomised controlled trial of effect of terbutaline before elective caesarean section on postnatal respiration and glucose homeostasis. Eisler G, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F88–92

Postnatal changes of leptin levels in full-term and preterm neonates: their relation to intrauterine growth, gender and testosterone. Ertl T, et al. **Biol Neonate** 1999 Mar; 75(3):167–76

Role of serum leptin in the regulation of weight gain in early infancy. Harigaya A, et al. **Biol Neonate** 1999;75(4):234–8

Clinical usefulness of maternal odor in newborns: soothing and feeding preparatory responses. Sullivan RM, et al. **Biol Neonate** 1998 Dec;74(6):402–8

Assessment of the performances of three oscillometric blood pressure monitors for neonates using a simulator. Papadopoulos G, et al. **Blood Press Monit** 1999 Feb; 4(1):27–33

The effect of povidone-iodine on thyroid function of neonates with different birth sizes. Jeng MJ, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Nov-Dec;39(6):371–5

Brain dysfunction in neonates with cleft palate revealed by the mismatch negativity. Cheour M, et al. **Clin Neurophysiol** 1999 Feb;110(2):324–8

The significance of excessive rhythmic alpha and/or theta frequency activity in the EEG of the neonate. Hrachovy RA, et al. **Clin Neurophysiol** 1999 Mar;110(3):438–44

Capillary refill time in the hands and feet of normal newborn infants. Raju NV, et al. **Clin Pediatr (Phila)** 1999 Mar; 38(3):139–44

Perinatal effects of prenatal drug exposure. Neonatal aspects. Bauer CR. **Clin Perinatol** 1999 Mar;26(1):87–106 (181 ref.)

Physiologic reflexes and their impact on resuscitation of the newborn. Halbower AC, et al. **Clin Perinatol** 1999 Sep; 26(3):621–7, vi (33 ref.)

Pulmonary vascular biology during neonatal transition. Lakshminrusimha S, et al. **Clin Perinatol** 1999 Sep; 26(3):601–19 (120 ref.)

Role of corticosteroids in neonatal blood pressure homeostasis. Sasidharan P. **Clin Perinatol** 1998 Sep; 25(3):723–40, xi (160 ref.)

Apnoea-associated heart rate changes among preterm and full-term infants exposed to hyperthermia. Tirosh E, et al. **Clin Physiol** 1998 Jul;18(4):331–5

Hyperechoic renal papillae as a physiological finding in neonates. Nakamura M, et al. **Clin Radiol** 1999 Apr; 54(4):233–6

Heart rate variability in 1-day-old infants born at 4330 m altitude. Mortola JP, et al. **Clin Sci (Colch)** 1999 Feb; 96(2):147–53

Comparative investigations of algorithms for the detection of breaths in newborns with disturbed respiratory signals. Schmidt M, et al. **Comput Biomed Res** 1998 Dec; 31(6):413–25

Spontaneous motor activity in the perinatal infant before and after birth: stability in individual differences. Groome LJ, et al. **Dev Psychobiol** 1999 Jul;35(1):15–24

Negative emotionality and cortisol during adolescent pregnancy and its effects on infant health and autonomic nervous system reactivity. Ponirakis A, et al. **Dev Psychobiol** 1998 Sep;33(2):163–74

Lateral biases in head turning and the Moro response in the human newborn: are they both vestibular in origin? Rönnqvist L, et al. **Dev Psychobiol** 1998 Dec;33(4):339–49

Olfactory alliesthesia in human neonates: prandial state and stimulus familiarity modulate facial and autonomic responses to milk odors. Soussignan R, et al. **Dev Psychobiol** 1999 Jul;35(1):3–14

Effect of management policy upon 120 Type 1 diabetic pregnancies: policy decisions in practice. Carron Brown S, et al. **Diabet Med** 1999 Jul;16(7):573–8

Effects of fetal and neonatal environment on sympathetic nervous system development. Young JB, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B156–60 (25 ref.)

Identification of noise sources that influence distortion product otoacoustic emission measurements in human neonates. Popelka GR, et al. **Ear Hear** 1998 Aug; 19(4):319–28

Neurological and physical maturation in normal growth singletons from 37 to 41 weeks' gestation. Amiel-Tison C, et al. **Early Hum Dev** 1999 Mar;54(2):145–56

Oral glucose and venepuncture reduce blood sampling pain in newborns. Eriksson M, et al. **Early Hum Dev** 1999 Jul; 55(3):211–8

Immaturity of electrophysiological response of the neonatal auditory brainstem to high repetition rates of click stimulation. Jiang ZD, et al. **Early Hum Dev** 1998 Sep; 52(2):133–43

Maternal nutritional factors: significance for the fetus and the neonate. Urgell MR, et al. **Early Hum Dev** 1998 Dec; 53 Suppl:S61–76 (20 ref.)
Observations on urinary frequency in exclusively breastfed neonates. Eregie CO. **East Afr Med J** 1998 Oct; 75(10):576–8
Enzymic evaluation of thiamin, riboflavin and pyridoxine status of parturient mothers and their newborn infants in a Mediterranean area of Spain. Sánchez DJ, et al. **Eur J Clin Nutr** 1999 Jan;53(1):27–38
Heart rate deceleration during the grasping reflex. Nagy E, et al. **Eur J Pediatr** 1999 Jul;158(7):576–7
Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1–2):90–4 (43 ref.)
Gender distinctions and lateral asymmetry in the low-level auditory brainstem response of the human neonate. Sininger YS, et al. **Hear Res** 1998 Dec;126(1–2):58–66
Change in cardiac diastolic function in neonates. Ichihashi K, et al. **Heart Vessels** 1997;12(5):216–20
Birth of a healthy neonate following the intracytoplasmic injection of testicular spermatozoa from a patient with Klinefelter's syndrome. Ron-el R, et al. **Hum Reprod** 1999 Feb;14(2):368–70
Self-reported ethnic status of delivering women, newborn body mass index, blood or urine concentrations of toxic metals, and essential elements in sera of Norwegian and Russian Arctic populations. Odland JO, et al. **Int J Circumpolar Health** 1999 Jan;58(1):4–13
Perinatal characteristics and schizophrenia: electrodermal activity as a mediating link in a vulnerability-stress perspective. Hultman CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):307–16 (99 ref.)
Responses to maternal separation: mechanisms and mediators. Kuhn CM, et al. **Int J Dev Neurosci** 1998 Jun–Jul; 16(3–4):261–70 (57 ref.)
Pulse oxygen saturation and neurologic assessment in human neonates after vaginal and cesarean delivery. Gonzales GF, et al. **Int J Gynaecol Obstet** 1998 Oct;63(1):63–6
Transient evoked otoacoustic emissions (TEOAEs) in new-borns: normative data. Paludetti G, et al. **Int J Pediatr Otorhinolaryngol** 1999 Mar 15;47(3):235–41
Visual development in preterm and full-term infants: a prospective masked study. Weinacht S, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):346–53
Comparison of liveborn and stillborn low birthweight babies and analysis of aetiological factors. Geary M, et al. **Ir Med J** 1997 Nov;90(7):269–71
Leak measurements in spontaneously breathing premature newborns by using the flow-through technique. Foitzik B, et al. **J Appl Physiol** 1998 Sep;85(3):1187–93
Accuracy of volume measurements in mechanically ventilated newborns: a comparative study of commercial devices. Roske K, et al. **J Clin Monit Comput** 1998 Aug; 14(6):413–20
Vital sign changes during infant magnetic resonance examinations. Taber KH, et al. **J Magn Reson Imaging** 1998 Nov–Dec;8(6):1252–6
Mammalian birth [letter; comment] Pagliotti F, et al. **J Nurse Midwifery** 1999 Jul–Aug;44(4):423–4. Comment on: J Nurse Midwifery 1999 Mar–Apr;44(2):162.
Neonatal skin: the ideal nursing interface. Lott JW, et al. **J Pediatr Nurs** 1998 Oct;13(5):302–6 (11 ref.)
Acoustic analysis of newborn infant cry signals. Fort A, et al. **Med Eng Phys** 1998 Sep;20(6):432–42
Multimodal time-variant signal analysis of neonatal EEG burst patterns. Witte H, et al. **Medinfo** 1998;9 Pt 2:1250–4
A baby with a Babinski reflex [letter; comment] Curless RG. **N Engl J Med** 1999 Jun 17;340(24):1929–30. Comment on: N Engl J Med 1999 Jan 21;340(3):196.
Intestinal blood-flow velocity in uncomplicated preterm infants during the early neonatal period. Maruyama K, et al. **Pediatr Radiol** 1999 Jun;29(6):472–7
Reproducibility of the alternating breath test of fractional inspired O2 in infants. Bouferrache B, et al. **Pediatr Res** 1998 Aug;44(2):239–46
Heart rate modifications related to spontaneous body movements in sleeping premature and full-term newborns. Curzi-Dascalova L, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):515–8
Increased neonatal platelet deposition on subendothelium under flow conditions: the role of plasma von Willebrand factor. Shenkman B, et al. **Pediatr Res** 1999 Feb;45(2):270–5
Procedural pain in newborn infants: the influence of intensity and development. Porter FL, et al. **Pediatrics** 1999 Jul; 104(1):e13
Changes in sleep patterns of young women from late pregnancy to postpartum: relationships to their infants' movements. Nishihara K, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 1):1043–56
Fetal and neonatal hand movement. Sparling JW, et al. **Phys Ther** 1999 Jan;79(1):24–39
Sleep state and vagal regulation of heart period patterns in the human newborn: an extension of the polyvagal theory. Porges SW, et al. **Psychophysiology** 1999 Jan;36(1):14–21
Hemodynamic indexes in newborns using the arteriovenous oxygen content difference. Tapia-Rombo CA, et al. **Rev Invest Clin** 1998 May–Jun;50(3):191–6
Assessment of pain in the neonate. Abu-Saad HH, et al. **Semin Perinatol** 1998 Oct;22(5):402–16 (74 ref.)
Environmental and behavioral strategies to prevent and manage neonatal pain. Franck LS, et al. **Semin Perinatol** 1998 Oct;22(5):434–43 (85 ref.)
Anesthesia for neonatal surgical emergencies. Mellor DJ, et al. **Semin Perinatol** 1998 Oct;22(5):363–79 (74 ref.)
[Monoaminergic neurotransmission and brain dysfunctions in the newborn] Chalon S, et al. **Arch Pediatr** 1999;6 Suppl 2:197s–198s **(Fre)**
[Electroencephalography of the premature and term newborn. Maturational aspects and glossary] Lamblin MD, et al. **Neurophysiol Clin** 1999 Apr;29(2):123–219 (77 ref.) (Eng. Abstr.) **(Fre)**
[Twins: interpretation of height-weight curves at birth] Hennequin Y, et al. **Rev Med Brux** 1999 Apr;20(2):81–5 (Eng. Abstr.) **(Fre)**
[Pain in neonates (see comments)] Rønneberg M, et al. **Tidsskr Nor Laegeforen** 1998 Sep 30;118(23):3610–3 (40 ref.) (Eng. Abstr.). Comment in: Tidsskr Nor Laegeforen 1998 Nov 10;118(27):4270. **(Nor)**
[Trends in female reproductive health and health of newborns in an industrial city] Iaroslavtsev AS. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):6–9 (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Bottle-fed neonates prefer an odor experienced in utero to an odor experienced postnatally in the feeding context. Marlier L, et al. **Dev Psychobiol** 1998 Sep;33(2):133–45
Temperament profiles and their role in neurodevelopmental assessed preterm children at two years of age. Sajaniemi N, et al. **Eur Child Adolesc Psychiatry** 1998 Sep;7(3):145–52
Innate and learned perceptual abilities in the newborn infant. Slater A, et al. **Exp Brain Res** 1998 Nov;123(1–2):90–4 (43 ref.)
Neurobiology of mother-infant interactions: experience and central nervous system plasticity across development and generations. Fleming AS, et al. **Neurosci Biobehav Rev** 1999 May;23(5):673–85 (106 ref.)

URINE

Values for urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in normal healthy infants. Nishida M, et al. **Acta Paediatr Jpn** 1998 Oct; 40(5):424–6
Urinary porphyrin excretion measurements in healthy neonates. Ozalla MD, et al. **J Dermatol** 1999 Jul; 26(7):409–15
Metabolites of a tobacco-specific carcinogen in urine from newborns. Lackmann GM, et al. **J Natl Cancer Inst** 1999 Mar 3;91(5):459–65
Methodologic issues in the measurement of oxytocin in human neonates. White-Traut R, et al. **J Nurs Meas** 1998 Winter;6(2):155–74

INFANT, NEWBORN, DISEASES

see related

ABNORMALITIES

Neonatal Society Meeting. June 1998 and November 1998. Abstracts. **Early Hum Dev** 1999 Feb;54(1):63–95
Neonatal transport: a protocol for ambulance transfer to a neonatal intensive care unit. Gomez MA. **J Perinatol** 1998 Sep–Oct;18(5):411–7
Facial recognition in children after perinatal stroke. Ballantyne AO, et al. **Neuropsychiatry Neuropsychol Behav Neurol** 1999 Apr; 12(2):82–7
Hypercalcemia of the newborn: etiology, evaluation, and management. Rodd C, et al. **Pediatr Nephrol** 1999 Aug; 13(6):542–7 (35 ref.)
Medical and ecological factors in estimating motor outcomes of preschool children. McGrath MM, et al. **Res Nurs Health** 1999 Apr;22(2):155–67
New clinical observations in hemangiomas. Blei F. **Semin Cutan Med Surg** 1999 Sep;18(3):187–94 (106 ref.)
Prospective evaluation of perinatal risk factors for cerebral palsy and delayed development in high risk infants. Kim JN, et al. **Yonsei Med J** 1999 Aug;40(4):363–70
[3rd Francophone Meeting on Neonatology Research. Nantes, France, 12–13 December 1997. Abstracts] **Arch Pediatr** 1999 Mar;6(3):346–70 **(Fre)**

BLOOD

Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Patole S, et al. **Biol Neonate** 1998 Nov;74(5):345–50
Granulocyte colony-stimulating factor in the cord blood of premature neonates born to mothers with pregnancy-induced hypertension. Tsao PN, et al. **J Pediatr** 1999 Jul;135(1):56–9

CHEMICALLY INDUCED

If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? [letter; comment] McNellis D, et al. **Obstet Gynecol** 1999 Jan;93(1):159–60 . Comment on: Obstet Gynecol 1998 Aug;92(2):308–11.

CLASSIFICATION

Perinatal risk and severity of illness in newborns at 6 neonatal intensive care units. Richardson DK, et al. **Am J Public Health** 1999 Apr;89(4):511–6
Structure and performance of different DRG classification systems for neonatal medicine. Muldoon JH. **Pediatrics** 1999 Jan;103(1 Suppl E):302–18 (15 ref.)

DIAGNOSIS

Neonatal pelvic mass. Neonatal ovarian torsion. Kurzrock EA, et al. **Clin Pediatr (Phila)** 1999 Jul;38(7):415; discussion 415–6
Use of newer imaging modalities in the neonate: a rational approach. Chaudhari S. **Indian Pediatr** 1998 May; 35(5):437–45 (16 ref.)
Signs of severe bacterial infection in neonates. Ronfani L, et al. **J Trop Pediatr** 1999 Feb;45(1):48–51
Congenital hemiplegia in children at school age: assessment of hand function in the non-hemiplegic hand and correlation with MRI. Mercuri E, et al. **Neuropediatrics** 1999 Feb;30(1):8–13
Validation of caregiver interviews to diagnose common causes of severe neonatal illness. Kalter HD, et al. **Paediatr Perinat Epidemiol** 1999 Jan;13(1):99–113
Fishing for trout in the milk [editorial] Berry PJ. **Pediatr Dev Pathol** 1998 Mar–Apr;1(2):99–101 (11 ref.)
Computerized EEG monitoring. Rosenblatt B, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):120–7 (24 ref.)
New technologies in pediatric neurology. Near-infrared spectroscopy. Soul JS, et al. **Semin Pediatr Neurol** 1999 Jun;6(2):101–10 (53 ref.)
Simplified monitoring of sick newborns. Daga SR. **Trop Doct** 1998 Oct;28(4):232–4
[Fetomaternal alloimmune thrombocytopenia—possibilities of diagnosis and exchange transfusion] Kořínková P, et al. **Ceska Gynekol** 1999 Jan;64(1):28–31 **(Cze)**
[Urinary antigen test as a screen for the diagnosis of beta-hemolytic streptococcal infections in newborn infants] Hulzebos CV, et al. **Ned Tijdschr Geneeskd** 1998 Aug 29; 142(35):1954–7 (Eng. Abstr.) **(Dut)**
[Vertical HIV-1-transmission. II. HIV-diagnosis in a child] Orendi JM, et al. **Ned Tijdschr Geneeskd** 1998 Dec 12; 142(50):2724–8 (33 ref.) (Eng. Abstr.) **(Dut)**
[Plantar fibromatosis in infants] Pijnenburg MW, et al. **Ned Tijdschr Geneeskd** 1998 Nov 28;142(48):2638–40 (Eng. Abstr.) **(Dut)**
[Pertussis in young infants] Vegelin AL, et al. **Ned Tijdschr Geneeskd** 1998 Dec 5;142(49):2657–60 (Eng. Abstr.) **(Dut)**
[Evaluation of high performance liquid chromatography modular system for the diagnosis of hemoglobinopathies] Lusina D, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec; 56(6):734–9 **(Fre)**
[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**
[Fiberoptic measurement of arterial oxygen saturation in premature and term neonates] Merz U, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):77–80 (Eng. Abstr.) **(Ger)**
[Validity of cardiotocography in the detection of umbilical cord complications] Troeger C, et al. **Zentralbl Gynakol** 1999;121(5):233–8 (Eng. Abstr.) **(Ger)**
[Clinical and laboratory basis for the diagnosis and understanding of neonatal metabolic diseases] Bispo MA, et al. **Acta Med Port** 1998 Jul;11(7):675–81 (7 ref.) (Eng. Abstr.) **(Por)**
[Immunological indicators (IgM and C-reactive protein) in neonatal infections] Vaz FA, et al. **Rev Assoc Med Bras** 1998 Jul–Sep;44(3):185–95 (Eng. Abstr.) **(Por)**
[An expert system to support diagnostic decision making by a neonatologist] Kurakina TIu, et al. **Med Tekh** 1999 Jan–Feb;(1):36–40 (Eng. Abstr.) **(Rus)**
[Diagnosis of the active form of cytomegalovirus infection based on determination of IgG antibodies to the immediate-early cytomegalovirus protein by lanthanide immunofluorescence analysis] Pomelova VG, et al. **Vopr Virusol** 1999 Mar–Apr;44(2):89–92 (Eng. Abstr.) **(Rus)**
[Neonatal screening: should the number of diseases to be detected be increased? (editorial)] Sanjurjo Crespo P. **An Esp Pediatr** 1999 Jun;50(6):539–41 **(Spa)**
[Prevention of severe diseases in apparently healthy newborn infants by new neonatal diagnostic methods] Velázquez A. **Ginecol Obstet Mex** 1999 Feb;67:72–4 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Myeloid colony-stimulating factors: use in the newborn. Sreenan C, et al. **Arch Pediatr Adolesc Med** 1999 Sep; 153(9):984–8 (65 ref.)
Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Patole S, et al. **Biol Neonate** 1998 Nov;74(5):345–50
Prenatal diagnosis of holocarboxylase synthetase deficiency by assay of the enzyme in chorionic villus material followed by prenatal treatment. Thuy LP, et al. **Clin Chim Acta** 1999 Jun 15;284(1):59–68
Safety of gentamicin administered by intravenous bolus in the nursery. Bromiker R, et al. **Clin Pediatr (Phila)** 1999 Jul;38(7):433–5
Nitric oxide inhalation therapy for newborn infants. Skimming JW. **Curr Probl Pediatr** 1998 Sep;28(8):253–64 (110 ref.)
Gentamicin dosage intervals [letter] Davies MW.

J Paediatr Child Health 1999 Aug;35(4):412

[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**

ECONOMICS

Costs of smoking: a focus on maternal, childhood, and other short-run costs. Adams EK, et al. **Med Care Res Rev** 1999 Mar;56(1):3–29

EPIDEMIOLOGY

Neonatology in developing countries: problems, practices and prospects. Dawodu A. **Ann Trop Paediatr** 1998 Sep; 18 Suppl:S73–9 (35 ref.)

Hospital readmission and morbidity following early newborn discharge. Heimler R, et al. **Clin Pediatr (Phila)** 1998 Oct; 37(10):609–15

Surveillance of neonatal group B streptococcal infection in Sunderland. Bignardi GE. **Commun Dis Public Health** 1999 Jan;2(1):64–5

Neonatal morbidities in gestational diabetes mellitus. Persson B, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B79–84 (45 ref.)

Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Kraus FT, et al. **Hum Pathol** 1999 Jul;30(7):759–69

Early neonatal morbidity and mortality in a city based medical college nursery. Das PK, et al. **Indian J Public Health** 1998 Jan–Mar;42(1):9–14

Intrapartum antibiotic prophylaxis increases the incidence of gram-negative neonatal sepsis. Levine EM, et al. **Infect Dis Obstet Gynecol** 1999;7(4):210–3

Iron-deficiency anemia in Nunavik: pregnancy and infancy. Hodgins S, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:135–40

Can children's health be predicted by perinatal health? Gissler M, et al. **Int J Epidemiol** 1999 Apr;28(2):276–80

Neonatal infections with Pseudomonas aeruginosa associated with a water-bath used to thaw fresh frozen plasma. Muyldermans G, et al. **J Hosp Infect** 1998 Aug; 39(4):309–14

Birth weight in relation to morbidity and mortality among newborn infants. McIntire DD, et al. **N Engl J Med** 1999 Apr 22;340(16):1234–8

Chorioamnionitis and the prognosis for term infants. Alexander JM, et al. **Obstet Gynecol** 1999 Aug;94(2):274–8

Neonatal outcomes with placenta previa. Crane JM, et al. **Obstet Gynecol** 1999 Apr;93(4):541–4

Influence of chorioamnionitis on developmental outcome in very low birth weight infants. Dexter SC, et al. **Obstet Gynecol** 1999 Aug;94(2):267–73

Maternal and infant complications in high and normal weight infants by method of delivery. Gregory KD, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 1):507–13

Pregnancy outcome with intrahepatic cholestasis. Heinonen S, et al. **Obstet Gynecol** 1999 Aug;94(2):189–93

Trends in infant leukaemia in West Germany in relation to in utero exposure due to Chernobyl accident. Steiner M, et al. **Radiat Environ Biophys** 1998 Jul;37(2):87–93

[Pregnancy outcome (perinatal mortality and morbidity) in women with diabetes] Rakhab MA, et al. **Akush Ginekol (Sofiia)** 1998;37(1):17–22 (Eng. Abstr.) **(Bul)**

ETIOLOGY

Effect of preeclampsia on mortality, intraventricular hemorrhage, and need for mechanical ventilation in very low-birth-weight infants. Paul DA, et al. **Am J Perinatol** 1998 Jun;15(6):381–6

Perinatal risk and severity of illness in newborns at 6 neonatal intensive care units. Richardson DK, et al. **Am J Public Health** 1999 Apr;89(4):511–6

Systemic lupus erythematosus (SLE) and neonatal morbidity and mortality [letter] Hauser S. **Aust N Z J Med** 1998 Aug; 28(4):482

Congenital diaphragmatic hernia. A cause of persistent pulmonary hypertension of the newborn which lacks an effective therapy. Thébaud B, et al. **Biol Neonate** 1998 Nov; 74(5):323–36 (106 ref.)

Neonatal infections with Pseudomonas aeruginosa associated with a water-bath used to thaw fresh frozen plasma. Muyldermans G, et al. **J Hosp Infect** 1998 Aug; 39(4):309–14

[Gestational diabetes: prognostic significance for the infant] Géronooz I, et al. **Rev Med Liege** 1999 Jun;54(6):517–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Factors related to pathologies in the early neonatal period at the University Hospital Center of Lome (Togo)] Balaka B, et al. **Tunis Med** 1999 Apr;77(4):224–8 (Eng. Abstr.) **(Fre)**

GENETICS

Lethal neonatal autosomal recessive axonal sensorimotor polyneuropathy. Vedanarayanan VV, et al. **Muscle Nerve** 1998 Nov;21(11):1473–7

IMMUNOLOGY

Immaturity of gastrointestinal host defense in newborns and gastrointestinal disease states. Furlano RI, et al. **Adv Pediatr** 1998;45:201–22

Congenital infection and B-cell responses in the newborn [comment] Michie C. **Eur J Pediatr** 1999 Jun;158(6):444–5 . Comment on: Eur J Pediatr 1999 Jun;158(6):463–8.

Alloimmune neonatal neutropenia treated with rHuG-CSF. Ruggiero A, et al. **Pediatr Med Chir** 1999 Jan–Feb; 21(1):27–8

METABOLISM

The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131–9 (88 ref.)

MICROBIOLOGY

Chronic Pseudomonas colonization of the skin, ear and eyes in a child with type I pseudohypoaldosteronism [letter; comment] Garty BZ. **Acta Paediatr** 1999 Apr;88(4):472–3 . Comment on: Acta Paediatr 1998 Apr;87(4):472–4.

Primarily infected cephalhematoma and osteomyelitis in a newborn. Miedema CJ, et al. **Eur J Med Res** 1999 Jan 26;4(1):8–10

[Intrapartum administration of antibiotics in the prevention of neonatal Streptococcus B infections] Horváth B, et al. **Orv Hetil** 1998 Nov 29;139(48):2899–901 (Eng. Abstr.) **(Hun)**

MORTALITY

Morbidity and neurological function of very low birthweight infants from the newborn period to 4 y of age. A prospective study from the south-east region of Sweden. Bylund B, et al. **Acta Paediatr** 1998 Jul;87(7):758–63

Effect of preeclampsia on mortality, intraventricular hemorrhage, and need for mechanical ventilation in very low-birth-weight infants. Paul DA, et al. **Am J Perinatol** 1998 Jun;15(6):381–6

An evaluation of the autopsy following death in a level IV neonatal intensive care unit. Barr P, et al. **J Paediatr Child Health** 1999 Apr;35(2):185–9

Why do preterm infants die in the 1990s? Doyle LW, et al. **Med J Aust** 1999 Jun 7;170(11):528–32

If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? [letter; comment] McNellis D, et al. **Obstet Gynecol** 1999 Jan;93(1):159–60 . Comment on: Obstet Gynecol 1998 Aug;92(2):308–11.

Relationship of cesarean delivery to lower birth weight-specific neonatal mortality in singleton breech infants in the United States [letter; comment] Murphy K, et al. **Obstet Gynecol** 1999 Apr;93(4):630–1. Comment on: Obstet Gynecol 1998 Nov;92(5):769–74.

Conceptualizing child health status: observations from studies of very premature infants. McCormick MC. **Perspect Biol Med** 1999 Spring;42(3):372–86 (57 ref.)

Body temperature and outcome of asphyxiated neonate [letter; comment] Manzar S. **Stroke** 1999 May;30(5):1153. Comment on: Stroke 1998 Dec;29(12):2455–60. Comment on: Stroke 1998 Dec;29(12):2461–6.

PATHOLOGY

Adnexal polyp of neonatal skin observed beyond the neonatal period [letter] Koizumi H, et al. **Acta Derm Venereol** 1998 Sep;78(5):391–2

A radiographic method for assessing lung area in neonates. Dimitriou G, et al. **Br J Radiol** 1999 Apr;72(856):335–8

Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. Lamireau T, et al. **J Hepatol** 1999 Aug;31(2):248–55

Developmental neuropathology and impact of perinatal brain damage. III: gray matter lesions of the neocortex. Marín-Padilla M. **J Neuropathol Exp Neurol** 1999 May; 58(5):407–29

Embolism of fetal brain tissue to the lungs and placenta [letter] Silver MM, et al. **Pediatr Dev Pathol** 1998 Mar–Apr; 1(2):172–3

PHYSIOPATHOLOGY

Early discharge and the neonate [editorial] Spitzer AR. **Clin Pediatr (Phila)** 1998 Oct;37(10):617–9

Childhood systemic lupus erythematosus and neonatal lupus syndrome. Sandborg CI. **Curr Opin Rheumatol** 1998 Sep; 10(5):481–7 (78 ref.)

Does the stomach remain silent after neonatal loss of its original pacemaker?: gastric motility in long-term survivors of neonatal gastric rupture. Chiba T, et al. **Tohoku J Exp Med** 1999 Feb;187(2):89–97

[Pulsations of the umbilical vein: pathophysiologic aspects and fetal outcome] Yaman C, et al. **Z Geburtshilfe Neonatol** 1998 Nov–Dec;202(6):235–9 (Eng. Abstr.) **(Ger)**

[Importance of J. Brazy's neurobiological index. Prediction of the number and severity of complications in very low birth weight infants] Nunes A, et al. **Acta Med Port** 1998 Jul;11(7):615–21 (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Efficacy of zidovudine in preventing HIV transmission from mother to infant. Balsley J. **Am J Med** 1997 May 19; 102(5B):45–6

Management of baby born to mother with tuberculosis. SantoshKumar A. **Indian Pediatr** 1998 Oct;35(10):1045–6

Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. Fiscus SA, et al. **J Infect Dis** 1999 Jul;180(1):99–105

South Africa stands firm on AIDS drug...[news] [see comments] Cherry M. **Nature** 1999 Mar 4;398(6722):8. Comment in: Nature 1999 Apr 15;398(6728):555.

Effectiveness of antenatal steroids in obstetric subgroups. Elimian A, et al. **Obstet Gynecol** 1999 Feb;93(2):174–9

Selection of delivery method in pregnancies complicated by autoimmune thrombocytopenia: a decision analysis. Stamilio DM, et al. **Obstet Gynecol** 1999 Jul;94(1):41–7

[Therapeutic options for HIV-infection should lead to increased utilization of HIV tests (letter; comment)] Boer K. **Ned Tijdschr Geneeskd** 1999 Jun 26;143(26):1395–6. Comment on: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):598–9. **(Dut)**

[Instability also has perinatal consequences: pediatricians can and must act (editorial)] Lejeune C. **Arch Pediatr** 1998 Mar; 5(3):251–4 **(Fre)**

[Newborn infant bacterial infections. Diagnosis, treatment principles, prevention] Maingueneau C, et al. **Rev Prat** 1998 May 15;48(10):1129–35 (0 ref.) **(Fre)**

Parasitic infections in pregnancy and congenital protozoan infections. Part I.: Protozoan infections] Bialek R, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):55–62 (44 ref.) (Eng. Abstr.) **(Ger)**

[Immunological imbalance in the newborn infant and its correction in a system to prevent neonatal morbidity and infant mortality] Blokhina IN, et al. **Vestn Ross Akad Med Nauk** 1999;(5):37–40 (Eng. Abstr.) **(Rus)**

[Justification of a prevention policy of perinatal disease by group B streptococci (GBS). Recommendations] Andreu A, et al. **Enferm Infecc Microbiol Clin** 1999 Mar; 17(3):138–40 (8 ref.) **(Spa)**

PSYCHOLOGY

Treatment of severely diseased newborns: a survey of attitudes among Danish physicians. Norup M. **Acta Paediatr** 1999 Apr;88(4):438–44

RADIOGRAPHY

A radiographic method for assessing lung area in neonates. Dimitriou G, et al. **Br J Radiol** 1999 Apr;72(856):335–8

RADIONUCLIDE IMAGING

Neonatal urinary ascites caused by urinary tract obstruction: two case reports. Sakai K, et al. **Int J Urol** 1998 Jul; 5(4):379–82

SURGERY

Experience with minimally invasive surgery in infants. Rothenberg SS, et al. **Am J Surg** 1998 Dec;176(6):654–8

Resuscitation of the surgical neonate. Chahine AA, et al. **Clin Perinatol** 1999 Sep;26(3):693–715 (38 ref.)

Laparotomy for necrotizing enterocolitis: intensive care nursery compared with operating theatre. Frawley G, et al. **J Paediatr Child Health** 1999 Jun;35(3):291–5

In-situ emergency paediatric surgery in the intensive care unit. Fanning NF, et al. **Pediatr Surg Int** 1998 Oct; 13(8):587–9

THERAPY

Treatment of severely diseased newborns: a survey of attitudes among Danish physicians. Norup M. **Acta Paediatr** 1999 Apr;88(4):438–44

Vibrotactile stimulation for treatment of neonatal apnea: a preliminary study. Lovell JR, et al. **Conn Med** 1999 Jun; 63(6):323–5

Use and misuse of albumin infusions in neonatal care. Greenough A. **Eur J Pediatr** 1998 Sep;157(9):699–702 (35 ref.)

Treating infants who may die [comment] Howe EG. **J Clin Ethics** 1998 Fall;9(3):215–24 (25 ref.). Comment on: J Clin Ethics 1998 Fall;9(3):314–22.

Mortality and neurodevelopmental outcome for infants receiving adrenaline in neonatal resuscitation. O'Donnell AI, et al. **J Paediatr Child Health** 1998 Dec;34(6):551–6

Mucous fistula refeeding in neonates with short bowel syndrome. Al-Harbi K, et al. **J Pediatr Surg** 1999 Jul; 34(7):1100–3

The determinants of protein catabolism in neonates on extracorporeal membrane oxygenation. Shew SB, et al. **J Pediatr Surg** 1999 Jul;34(7):1086–90

New practices in the transitional care center improve outcomes for babies and their families. Forsythe P. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S13–7 (4 ref.)

Decisions regarding treatment of seriously ill newborns [editorial; comment] Fost N. **JAMA** 1999 Jun 2; 281(21):2041–3. Comment on: JAMA 1999 Jun 2;281(21):1991–7.

Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents [see comments] Saigal S, et al. **JAMA** 1999 Jun 2;281(21):1991–7 . Comment in: JAMA 1999 Jun 2;281(21):2041–3.

Quality of life decisions at the beginning of life: ethical considerations. Snyder RD. **Med Law** 1998;17(4):563–9

Neonatology: will the infant learn to speak? Harding JE. **N Z Med J** 1998 Nov 13;111(1077):434–7

Characterization of the triage process in neonatal intensive care. Zupancic JA, et al. **Pediatrics** 1998 Dec;102(6):1432–6
Suicidal paracetamol poisoning of a pregnant woman just before a delivery. Sancewicz-Pach K, et al. **Przegl Lek** 1999;56(6):459–62
[Clinical evaluation on parenteral nutrition in neonatal disease] Li J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(6):527–9, 532 (Eng. Abstr.) **(Chi)**
[Dehydration due to gastro-enteritis in children] Kist-van Holthe JE, et al. **Ned Tijdschr Geneeskd** 1999 Jan 23; 143(4):193–6 (19 ref.) (Eng. Abstr.) **(Dut)**
[What is new in neonatology?] Simeoni U. **Arch Pediatr** 1999 Apr;6(4):447–56 (71 ref.) (Eng. Abstr.) **(Fre)**
[Blood component transfusion in full-term and premature new born infants] Albiero AL, et al. **Rev Assoc Med Bras** 1998 Jul-Sep;44(3):201–9 (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

Continuous monitoring of cardiac output in neonates using an intra-aortic Doppler probe. Ewert P, et al. **Cardiol Young** 1999 Jan;9(1):42–8

VIROLOGY

Efficacy of zidovudine in preventing HIV transmission from mother to infant. Balsley J. **Am J Med** 1997 May 19; 102(5B):45–6
Sequential peripartum herpes simplex virus type 2 disease in parents and their newborn mimicking intrafamily spread of common viruses. Klauber EV, et al. **Am J Perinatol** 1999;16(1):43–5
Perinatal transmission of human papillomavirus from gravidas with latent infections. Tenti P, et al. **Obstet Gynecol** 1999 Apr;93(4):475–9
[Neurological complications of HIV-1 infection in an infant born to a seropositive mother] Tardieu M. **Rev Neurol (Paris)** 1998 Dec;154(12):850–5 (24 ref.) **(Fre)**

INFANT, NEWBORN, INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

INFANT, NEWBORN, SCREENING see **NEONATAL SCREENING**

INFANT NUTRITION

see related
CHILD NUTRITION
MILK
MILK, HUMAN

Plasma lipids and apolipoproteins in breastfed and formula-fed Swedish infants. Akeson PM, et al. **Acta Paediatr** 1999 Jan;88(1):1–6
The role of long chain polyunsaturated fatty acids (LCPUFA) in neonatal nutrition. Gibson RA, et al. **Acta Paediatr** 1998 Oct;87(10):1017–22 (45 ref.)
Hunger behaviour contributes to early nutritional homeostasis [letter] Hawdon JM, et al. **Acta Paediatr** 1999 Jun;88(6):691–2
An updated view of the value of taurine in infant nutrition. Chesney RW, et al. **Adv Pediatr** 1998;45:179–200 (88 ref.)
Protein balance in the first week of life in ventilated neonates receiving parenteral nutrition. Thureen PJ, et al. **Am J Clin Nutr** 1998 Nov;68(5):1128–35
Potential mechanisms of metabolic imprinting that lead to chronic disease. Waterland RA, et al. **Am J Clin Nutr** 1999 Feb;69(2):179–97 (13 ref.)
Nutrition in early life: somatic growth and serum lipids. Boulton TJ, et al. **Ann Med** 1999 Apr;31 Suppl 1:7–12 (46 ref.)
Cardiovascular disease risk factors in young children in the STRIP baby project. Special Turku coronary Risk factor Intervention Project for children. Simell O, et al. **Ann Med** 1999 Apr;31 Suppl 1:55–61
Infant feeding practices in Papua New Guinea. Friesen H, et al. **Ann Trop Paediatr** 1998 Sep;18(3):209–15
Randomised controlled trial of brief neonatal exposure to cows' milk on the development of atopy [see comments] de Jong MH, et al. **Arch Dis Child** 1998 Aug;79(2):126–30 . Comment in: Arch Dis Child 1998 Aug;79(2):97–8. Comment in: Arch Dis Child 1999 Feb;80(2):208.
A randomised controlled study of the effect of long chain polyunsaturated fatty acid supplementation on stool hardness during formula feeding. Forsyth JS, et al. **Arch Dis Child** 1999 Sep;81(3):253–6
Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Høst A, et al. **Arch Dis Child** 1999 Jul;81(1):80–4 (39 ref.)
Iron fortified follow on formula from 9 to 18 months improves iron status but not development or growth: a randomised trial. Morley R, et al. **Arch Dis Child** 1999 Sep; 81(3):247–52
Randomised controlled trial of trophic feeding and gut motility. McClure RJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F54–8
Development of feeding practices during the first 5 years of life. Hammer LD, et al. **Arch Pediatr Adolesc Med** 1999 Feb;153(2):189–94
Sensitivity and specificity of maternal anthropometric measures relative to infant nutritional status. Abikusno N, et al. **Asia Pac J Public Health** 1996–97;9:38–41
Early diet in preterm babies and later intelligence quotient. Surely study showed that breast milk is feed of choice for premature babies [letter] Behrman D, et al. **BMJ** 1999 Jun 12;318(7198):1625
Should industry sponsor research? Funding of research by infant formula companies [letter; comment] Candy DC. **BMJ** 1999 Jan 23;318(7178):260. Comment on: BMJ 1998 Aug 1;317(7154):337–8.
Should industry sponsor research? Portman Group has always openly acknowledged its source of funding [letter; comment] Coussins J. **BMJ** 1999 Jan 23;318(7178):261. Comment on: BMJ 1998 Aug 1;317(7154):336.
Breast feeding reduces morbidity. The risk of HIV transmission requires risk assessment--not a shift to formula feeds [editorial; comment] Latham MC. **BMJ** 1999 May 15;318(7194):1303–4. Comment on: BMJ 1999 May 15;318(7194):1316–20.
Should industry sponsor research? Positive messages on breast feeding would result in need for infant formula decreasing [letter; comment] Porter A. **BMJ** 1999 Jan 23; 318(7178):260–1. Comment on: BMJ 1998 Aug 1;317(7154):337–8.
Should industry sponsor research? Researchers must recognise damage done by overt association with formula manufacturers [letter; comment] Waterston T, et al. **BMJ** 1999 Jan 23;318(7178):260. Comment on: BMJ 1998 Aug 1;317(7154):337–8.
Only full support needed [letter] Zablocki JA. **Can Fam Physician** 1998 Nov;44:2375
Eighteen-month follow-up of infants fed evaporated milk formula. Friel JK, et al. **Can J Public Health** 1999 Jul-Aug; 90(4):240–3
Factors influencing infant feeding practices of mothers in Vancouver. Williams PL, et al. **Can J Public Health** 1999 Mar-Apr;90(2):114–9
How often do parenteral nutrition prescriptions for the newborn need to be individualized? Beecroft C, et al. **Clin Nutr** 1999 Apr;18(2):83–5
Plasma and red blood cell fatty acid composition in small for gestational age term infants fed human milk or formula. Ramirez M, et al. **Clin Nutr** 1998 Aug;17(4):177–83
Nutritional and biochemical properties of human milk, Part I: General aspects, proteins, and carbohydrates. Kunz C, et al. **Clin Perinatol** 1999 Jun;26(2):307–33 (110 ref.)
Principles for formulating parenteral nutrition for neonates [see comments] Ball P. **Curr Opin Clin Nutr Metab Care** 1999 Jul;2(4):261–4 (28 ref.). Comment in: Curr Opin Clin Nutr Metab Care 1999 Jul;2(4):259–60.
Some current controversies on nutritional requirements of full-term and pre-term newborn infants. Bayés R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S3–13 (37 ref.)
Special formulas in infant nutrition: a review. Maldonado J, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S23–32 (79 ref.)
Neonatal dietary gangliosides. Rueda R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S135–47 (60 ref.)
Complementary foods for infant feeding in developing countries: their nutrient adequacy and improvement. Gibson RS, et al. **Eur J Clin Nutr** 1998 Oct;52(10):764–70
Determination of mineral contents in different kinds of milk and estimation of dietary intake in infants. Biego GH, et al. **Food Addit Contam** 1998 Oct;15(7):775–81
Infant nutrition program effectively prevents iron-deficiency anemia in a First Nations community. Sawchuk P, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:189–93
Vitamin intake of 3- to 36-month-old German infants and children--results of the DONALD-Study. Alexy U, et al. **Int J Vitam Nutr Res** 1999 Jul;69(4):285–91
The relationship between infant feeding practices and diarrhoeal infections. Ziyane IS. **J Adv Nurs** 1999 Mar; 29(3):721–6
Infant feeding practices of Anglo American and Asian Indian American mothers. Kannan S, et al. **J Am Coll Nutr** 1999 Jun;18(3):279–86
Nutritional rickets in suburbia. Pugliese MT, et al. **J Am Coll Nutr** 1998 Dec;17(6):637–41
Early introduction of solid foods among urban African-American participants in WIC. Bronner YL, et al. **J Am Diet Assoc** 1999 Apr;99(4):457–61
Bone mineralization and turnover in preterm infants at 8–12 years of age: the effect of early diet. Fewtrell MS, et al. **J Bone Miner Res** 1999 May;14(5):810–20
The weanling's dilemma reconsidered: a biocultural analysis of breastfeeding ecology. McDade TW, et al. **J Dev Behav Pediatr** 1998 Aug;19(4):286–99
Assessment of nutrient requirements for infant formulas [published erratum appears in J Nutr 1999 May;129(5):1090] **J Nutr** 1998 Nov;128(11 Suppl):i-iv, 2059S–2293S (1034 ref.)
Newborn predictors of infant irritability. Keefe MR, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep-Oct;27(5):513–20
Feeding problems in infants with gastro-oesophageal reflux disease: a controlled study. Mathisen B, et al. **J Paediatr Child Health** 1999 Apr;35(2):163–9
Nutrient intake and growth of infants with phenylketonuria undergoing therapy. Acosta PB, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):287–91
Nutrient intakes and growth of very low birth weight infants. Carlson SJ, et al. **J Perinatol** 1998 Jul-Aug;18(4):252–8
Solid feeding guidelines [see comments] Werk LN, et al. **Lancet** 1998 Nov 14;352(9140):1569–70. Comment in: Lancet 1999 Jan 23;353(9149):327.
Statistical considerations in infant nutrition trials. Gore SM. **Lipids** 1999 Feb;34(2):185–97 (9 ref.)
The effects of prescribed versus ad libitum feedings and formula caloric density on premature infant dietary intake and weight gain. Pridham K, et al. **Nurs Res** 1999 Mar-Apr; 48(2):86–93
The influence of neonatal nutrition on behavioral development: a critical appraisal. Wauben IP, et al. **Nutr Rev** 1999 Feb;57(2):35–44 (92 ref.)
Proceedings of the 3rd International Meeting on Advances in Perinatal and Paediatric Nutrition. Manchester, England, September 1997. **Nutrition** 1998 Oct;14(10):743–829
Recent trends in infant nutrition. Lawson M. **Nutrition** 1998 Oct;14(10):755–7 (15 ref.)
Complementary feeding: a global perspective. Michaelsen KF, et al. **Nutrition** 1998 Oct;14(10):763–6 (33 ref.)
Nutrition and cognitive development. Morley R. **Nutrition** 1998 Oct;14(10):752–4 (24 ref.)
Nutritional issues for infants and toddlers. Aldous MB. **Pediatr Ann** 1999 Feb;28(2):101–5 (40 ref.)
A pediatrician's view. Digging up old information about human nutrition [editorial] [see comments] Altemeier WA 3rd. **Pediatr Ann** 1999 Feb;28(2):95–6. Comment in: Pediatr Ann 1999 Mar;28(3):152–3.
The role of nutrition in the overall management of pediatric patients [editorial] Ghishan FK. **Pediatr Ann** 1999 Feb; 28(2):98–9
Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Birch EE, et al. **Pediatr Res** 1998 Aug;44(2):201–9
Nutritional status of Haitian children, 1978–1995: deleterious consequences of political instability and international sanctions. Mulder-Sibanda M. **Rev Panam Salud Publica** 1998 Nov;4(5):346–9
The metabolic needs of critically ill children and neonates. Shew SB, et al. **Semin Pediatr Surg** 1999 Aug;8(3):131–9 (88 ref.)
Protective function of human milk: the milk fat globule. Hamosh M, et al. **Semin Perinatol** 1999 Jun;23(3):242–9 (65 ref.)
Orthodontic aspects on feeding of young children. 1. A comparison between Swedish and Norwegian-Sami children. Larsson E. **Swed Dent J** 1998;22(3):117–21
Macronutrient intake of 1 to 18 year old German children and adolescents. Kersting M, et al. **Z Ernahrungswiss** 1998 Sep;37(3):252–9
[Malnutrition at the beginning of life: long-term effects] Rolland-Cachera MF. **Arch Pediatr** 1998;5 Suppl 2:209s–211s (21 ref.) **(Fre)**
[After milk: what, when, how, why?] Turck D. **Arch Pediatr** 1998;5 Suppl 2:205s–209s (15 ref.) **(Fre)**
[Impact on health of early supplementation with rice in infants in Laos (letter)] Graz B. **Med Trop (Mars)** 1999; 59(1):102–3 **(Fre)**
[Nutritional intakes in a group of infants aged six to fourteen months] Nasraoui A, et al. **Tunis Med** 1999 Mar;77(3):145–8 **(Fre)**
[Feeding disorders in infancy: feeding interaction concept in diagnosis and treatment] Keren M, et al. **Harefuah** 1998 Sep;135(5–6):193–7, 254 (Eng. Abstr.) **(Heb)**
[Evaluation of the effect of a new milk formula with added nucleotides on some gastrointestinal functions. Results of a nation-wide study of 5009 infants. Pediatric Study Group] Alvaro G. **Minerva Pediatr** 1998 Jul-Aug;50(7–8):347–58 (Eng. Abstr.) **(Ita)**
[Importance of juices in nutrition of infants and preschool and school children] Kon' IIa. **Vopr Pitan** 1999;68(2):14–7 (Eng. Abstr.) **(Rus)**
[Anthropometric and nutritional study of full-term newborns. Evaluation of the submandibular adipose skinfold] Fleta Zaragozano J, et al. **An Esp Pediatr** 1999 Apr;50(4):384–8 (Eng. Abstr.) **(Spa)**
[Growth of breastfed and bottle-fed infants up to 2 years of age: CLACYD (Lactation, Alimentation, Growth and Development) study 1993-1995] Agrelo F, et al. **Rev Panam Salud Publica** 1999 Jul;6(1):44–52 (Eng. Abstr.) **(Spa)**
[A reply about milk porridge. Infant food is also a question of nutritional physiology] Axelsson I, et al. **Lakartidningen** 1999 May 26;96(21):2624–5 **(Swe)**
[Storm in a bowl (letter)] Stintzing G, et al. **Lakartidningen** 1999 Jun 30;96(26–27):3155–6 **(Swe)**
[Infant food is not only a question of nutritional physiology. Doubtful to advise against milk with porridge] Stintzing G, et al. **Lakartidningen** 1999 May 12;96(19):2374–6 **(Swe)**

PHYSIOLOGY

Compartmental modeling of human lactation. Novotny JA, et al. **Adv Exp Med Biol** 1998;445:21–33
Plausible explanations for effects of long chain polyunsaturated fatty acids (LCPUFA) on neonates. Kurlak LO, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F148–54 (40 ref.)
The role of human milk fortification for premature infants.

INFANT NUTRITION

Schanler RJ. **Clin Perinatol** 1998 Sep;25(3):645–57, ix (69 ref.)
Oral feeding in infants. Lau C, et al. **Curr Probl Pediatr** 1999 Apr;29(4):105–24 (142 ref.)
Food consumption of young stunted and non-stunted children in rural Zambia. Hautvast JL, et al. **Eur J Clin Nutr** 1999 Jan;53(1):50–9
Supplementary feeding in maternity hospitals and the risk of cow's milk allergy: A prospective study of 6209 infants. Saarinen KM, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):457–61

INFANT NUTRITION DISORDERS

see related
CHILD NUTRITION DISORDERS

COMPLICATIONS

The Barker hypothesis. An analysis. Wilson J. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):1–7 (36 ref.)
[Visceral leishmaniasis and malnutrition: a case report] Hida M, et al. **Arch Pediatr** 1999 Mar;6(3):290–2 (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Visceral leishmaniasis and malnutrition: a case report] Hida M, et al. **Arch Pediatr** 1999 Mar;6(3):290–2 (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Overweight and obesity among mothers of malnourished children--Brazil--PNSN--1989. Rodrigues EM, et al. **Rev Paul Med** 1998 Jul–Aug;116(4):1766–73
[Infant malnutrition and associated maternal factors in a secondary city south of Benin, Ouidah] Agueh VD, et al. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):219–28 (Eng. Abstr.) **(Fre)**
[Nutritional intakes in a group of infants aged six to fourteen months] Nasraoui A, et al. **Tunis Med** 1999 Mar;77(3):145–8 **(Fre)**

ETIOLOGY

[Infant malnutrition and associated maternal factors in a secondary city south of Benin, Ouidah] Agueh VD, et al. **Rev Epidemiol Sante Publique** 1999 Jun;47(3):219–28 (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Hypertonic dehydration resulting from unrecognized inadequate intake of breast milk (letter; comment)] Pollemans C, et al. **Ned Tijdschr Geneeskd** 1998 Aug 1; 142(31):1789. Comment on: Ned Tijdschr Geneeskd 1998 May 2;142(18):993–5. **(Dut)**

INFANT, PREMATURE

Level of anxiety in parents of high-risk premature twins. Zanardo V, et al. **Acta Genet Med Gemellol (Roma)** 1998; 47(1):13–8
Periventricular leukomalacia causes visual impairment in preterm children. A study on the aetiologies of visual impairment in a population-based group of preterm children born 1989–95 in the county of Värmland, Sweden. Jacobson L, et al. **Acta Ophthalmol Scand** 1998 Oct; 76(5):593–8
Visual dysfunction and ocular signs associated with periventricular leukomalacia in children born preterm. Jacobson L. **Acta Ophthalmol Scand** 1999 Jun;77(3):365–6
Confidential enquiry into deaths due to prematurity. Cartlidge PH, et al. **Acta Paediatr** 1999 Feb;88(2):220–3
Comparison of airway pressure-triggered and airflow-triggered ventilation in very immature infants. Dimitriou G, et al. **Acta Paediatr** 1998 Dec;87(12):1256–60
Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Jönsson B, et al. **Acta Paediatr** 1998 Oct;87(10):1079–84
Hepatitis B vaccination in preterm infants [letter; comment] Lau YL. **Acta Paediatr** 1998 Oct;87(10):1100–1. Comment on: Acta Paediatr 1998 Mar;87(3):336–8.
Nursery Neurobiologic Risk Score and outcome at 18 months. Lefebvre F, et al. **Acta Paediatr** 1998 Jul; 87(7):751–7
Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Lin YJ, et al. **Acta Paediatr** 1998 Oct;87(10):1061–5
Survival of a preterm neonate with late onset hydrops fetalis due to parvovirus B19 infection. McNamara PJ, et al. **Acta Paediatr** 1998 Oct;87(10):1088–9
Treatment of extremely premature newborns: a survey of attitudes among Danish physicians. Norup M. **Acta Paediatr** 1998 Aug;87(8):896–902
Clinical relevance of Ureaplasma urealyticum colonization in preterm infants. Ollikainen J, et al. **Acta Paediatr** 1998 Oct;87(10):1075–8
Coma in a premature infant associated with the transdermal absorption of propylene glycol. Peleg O, et al. **Acta Paediatr** 1998 Nov;87(11):1195–6
Sequelae associated with cerebral candidiasis in two premature infants. Scott PA, et al. **Acta Paediatr** 1998 Oct; 87(10):1090–2
Development of perception in action in healthy and at-risk children. van der Meer AL, et al. **Acta Paediatr Suppl** 1999 May;88(429):29–36 (36 ref.)
Whole-body bone mineral content in premature infants measured at full-term age [letter; comment] Lapillonne A, et al. **Am J Clin Nutr** 1999 Jan;69(1):154–6. Comment on: Am J Clin Nutr 1998 Mar;67(3):465–72.
Physical and nonphysical partner abuse and other risk factors for low birth weight among full term and preterm babies: a multiethnic case-control study. Campbell J, et al. **Am J Epidemiol** 1999 Oct 1;150(7):714–26
Recurrence of gestational age in sibships: implications for perinatal mortality. Melve KK, et al. **Am J Epidemiol** 1999 Oct 1;150(7):756–62
Influence of perinatal factors on the onset of puberty in boys and girls: implications for interpretation of link with risk of long term diseases. Persson I, et al. **Am J Epidemiol** 1999 Oct 1;150(7):747–55
Neonatal hyperbilirubinemia associated with Southeast Asian ovalocytosis. Laosombat V, et al. **Am J Hematol** 1999 Feb; 60(2):136–9
Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Banks BA, et al. **Am J Obstet Gynecol** 1999 Sep;181(3):709–17
Parents' report of sensory responsiveness and temperament in preterm infants. Case-Smith J, et al. **Am J Occup Ther** 1998 Jul–Aug;52(7):547–55
Liposomal amphotericin B in neonates with invasive candidiasis. Al Arishi H, et al. **Am J Perinatol** 1998; 15(11):643–8
Has the outcome for extremely low gestational age (ELGA) infants improved following recent advances in neonatal intensive care? Battin M, et al. **Am J Perinatol** 1998 Aug; 15(8):469–77
Echocardiographic evidence of aortopulmonary collaterals in premature infants after closure of ductus arteriosus. Birnbacher R, et al. **Am J Perinatol** 1998;15(10):561–5
Obstetrical determinants of neonatal neurological morbidity in < or = 1000-gram infants. Goepfert AR, et al. **Am J Perinatol** 1999;16(1):33–42
Functional residual capacity and pulmonary mechanics in premature infants receiving a 12-day dexamethasone course. Lee M, et al. **Am J Perinatol** 1999;16(3):151–6
Transient hypertrophic cardiomyopathy in the newborn following multiple doses of antenatal corticosteroids. Yunis KA, et al. **Am J Perinatol** 1999;16(1):17–21
Caffeine overdose in a premature infant: clinical course and pharmacokinetics. Anderson BJ, et al. **Anaesth Intensive Care** 1999 Jun;27(3):307–11
Ontogeny of renal dysplasia in Ivemark syndrome: light and immunohistochemical characterization. Abbi R, et al. **Ann Clin Lab Sci** 1999 Jan–Mar;29(1):9–17
Severe bleeding diathesis in a premature baby with extensive hepatic necrosis due to portal vein thrombosis of prenatal onset [letter] Ries M, et al. **Ann Hematol** 1999 Jul; 78(7):339–40
Validation of a newly developed mini-knemometer for premature infants. Kaempf DE, et al. **Ann Hum Biol** 1999 May–Jun;26(3):259–66
Randomised trial of parental support for families with very preterm children. Avon Premature Infant Project. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F4–11
Reflections on measuring pain in infants: dissociation in responsive systems and "honest signalling". Barr RG. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F152–6
Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants. Carnielli VP, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F44–8
Randomised controlled trial of cisapride in feed intolerance in preterm infants. Enriquez A, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F110–3
Survival and place of delivery following preterm birth: 1994–96. Field D, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F111–4
Outcome at 5–6 years of prematurely born children who received morphine as neonates. MacGregor R, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F40–3
Continuous distending pressure. Morley C. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F152–6 (73 ref.)
Cerebral haemodynamics in preterm infants after exposure to dexamethasone. Pellicer A, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F123–8
Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial. Stenson BJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F212–4
Outcome of very preterm birth: children reviewed with ease at 2 years differ from those followed up with difficulty [see comments] Tin W, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F83–7. Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F158–9.
Randomised double blind trial of morphine versus diamorphine for sedation of preterm neonates. Wood CM, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F34–9
Artificial neural network for risk assessment in preterm neonates. Zernikow B, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F129–34
Very preterm birth, birth trauma, and the risk of anorexia nervosa among girls. Cnattingius S, et al. **Arch Gen Psychiatry** 1999 Jul;56(7):634–8
Use of prenatal phenobarbital in the prevention of subependymal/intraventricular hemorrhage in premature infants. Arroyo-Cabrales LM, et al. **Arch Med Res** 1998 Autumn;29(3):247–51
Lipid intolerance in neonates receiving dexamethasone for bronchopulmonary dysplasia. Amin SB, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):795–800
Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates [published erratum appears in Arch Pediatr Adolesc Med 1999 Aug;153(8):895] Anand KJ, et al. **Arch Pediatr Adolesc Med** 1999 Apr;153(4):331–8
A parable wrapped in an enigma: population-based assessments of outcomes among high-risk neonates are even less achievable in the age of clinical informatics. Kirby RS. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):789–92
Preterm infants 30–36 weeks' gestation in Victoria--where should they be delivered? [see comments] Doyle LW, et al. **Aust N Z J Obstet Gynaecol** 1998 Aug;38(3):298–300 . Comment in: Aust N Z J Obstet Gynaecol 1999 Feb;39(1):140.
Place of birth for preterm infants [letter; comment] Keirse MJ, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):140 . Comment on: Aust N Z J Obstet Gynaecol 1998 Aug;38(3):298–300.
Seasonality of low birthweight in indigenous Australians: an increase in pre-term birth or intrauterine growth retardation? Rousham EK, et al. **Aust N Z J Public Health** 1998 Oct;22(6):669–72
Randomized clinical trial of enteral yeast-selenium supplementation in preterm infants. Bogye G, et al. **Biofactors** 1998;8(1–2):139–42
Severe pulmonary hemorrhage in the premature newborn infant: analysis of presurfactant and surfactant eras. Braun KR, et al. **Biol Neonate** 1999;75(1):18–30
Decreasing reticulocyte counts associated with declining post-dose erythropoietin plasma levels in anaemia of prematurity. Meister B, et al. **Biol Neonate** 1998 Dec; 74(6):409–15
Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Merz U, et al. **Biol Neonate** 1999;75(1):46–53
Early diet in preterm babies and later intelligence quotient. Surely study showed that breast milk is feed of choice for premature babies [letter] Behrman D, et al. **BMJ** 1999 Jun 12;318(7198):1625
Randomised trial of early diet in preterm babies and later intelligence quotient. Lucas A, et al. **BMJ** 1998 Nov 28; 317(7171):1481–7
Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Pawlotsky F, et al. **Br J Clin Pharmacol** 1998 Aug;46(2):163–7
Periventricular leucomalacia and preterm birth have different detrimental effects on postural adjustments. Hadders-Algra M, et al. **Brain** 1999 Apr;122 (Pt 4):727–40
Ethical challenges in the treatment of infants of drug-abusing mothers. Jain R, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):179–88 (37 ref.)
The proportion of high risk preterm infants with postoperative apnea and bradycardia is the same after general and spinal anesthesia [letter] Kunst G, et al. **Can J Anaesth** 1999 Jan;46(1):94–5
Neuroendoscopy in the premature population. Buxton N, et al. **Childs Nerv Syst** 1998 Nov;14(11):649–52
Fibrinolytic agents in the management of posthemorrhagic hydrocephalus in preterm infants: the evidence. Haines SJ, et al. **Childs Nerv Syst** 1999 May;15(5):226–34 (19 ref.)
Bilirubin in the premature: toxic waste or natural defense? Hammermann C, et al. **Clin Chem** 1998 Dec;44(12):2551–3
Comparative study of mortality and morbidity in premature infants (birth weight, < 1,250 g) with candidemia or candidal meningitis. Lee BE, et al. **Clin Infect Dis** 1998 Sep;27(3):559–65
Effects of skin-to-skin holding on general movements of preterm infants. Constantinou JC, et al. **Clin Pediatr (Phila)** 1999 Aug;38(8):467–71
Intervention programs for premature infants. How and do they affect development? Feldman R, et al. **Clin Perinatol** 1998 Sep;25(3):613–26, ix (74 ref.)
The use of human milk and breastfeeding in premature infants. Schanler RJ, et al. **Clin Perinatol** 1999 Jun; 26(2):379–98, vii (118 ref.)
Immunisation of preterm infants. Botham SJ, et al. **Commun Dis Intell** 1998 Oct 1;22(10):218–20
Neonatal hepatic abscess. Vade A, et al. **Comput Med Imaging Graph** 1998 Jul–Aug;22(4):357–9
Erythropoietin in the neonate. Juul SE. **Curr Probl Pediatr** 1999 May–Jun;29(5):129–49 (190 ref.)
Epilepsy in very preterm infants: neonatal cranial ultrasound reveals a high-risk subcategory. Amess PN, et al. **Dev Med Child Neurol** 1998 Nov;40(11):724–30
Eye-movement disorders and visual-perceptual impairment in diplegic children born preterm: a clinical evaluation. Fedrizzi E, et al. **Dev Med Child Neurol** 1998 Oct; 40(10):682–8
Prognostic value of flash visual evoked potentials in preterm infants. Shepherd AJ, et al. **Dev Med Child Neurol** 1999 Jan;41(1):9–15

Nutrition of the fetus and the premature infant. Battaglia FC, et al. **Diabetes Care** 1998 Aug;21 Suppl 2:B70–4 (42 ref.)
Some current controversies on nutritional requirements of full–term and pre–term newborn infants. Bayés R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S3–13 (37 ref.)
Increased serum concentrations of soluble tumor necrosis factor receptors p55 and p75 in early onset neonatal sepsis. Doellner H, et al. **Early Hum Dev** 1998 Oct;52(3):251–61
Postnatal closure of ductus venosus in preterm infants < or = 32 weeks. An ultrasonographic study. Fugelseth D, et al. **Early Hum Dev** 1998 Dec;53(2):163–9
Mechanisms initiating lung injury in the preterm. Jobe AH, et al. **Early Hum Dev** 1998 Nov;53(1):81–94 (66 ref.)
A controlled trial of alternative methods of oral feeding in neonates. Malhotra N, et al. **Early Hum Dev** 1999 Feb; 54(1):29–38
Bone mineralization status measured by dual energy radiographic densitometry in preterm infants fed commercial formulas. Narbona E, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S173–80
White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Perlman JM. **Early Hum Dev** 1998 Dec;53(2):99–120 (134 ref.)
Protein demand in the premature neonate and in the small for gestational age full–term neonate. Robles R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S15–21 (30 ref.)
Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c–mpl) during human fetal development. Sola MC, et al. **Early Hum Dev** 1999 Jan;53(3):239–50
Successful use of an intraosseous infusion in an 800 grams preterm infant. Ramet J, et al. **Eur J Emerg Med** 1998 Sep; 5(3):327–8
Effect of recombinant human erythropoietin in preterm infants. Krallis N, et al. **Eur J Haematol** 1999 Aug; 63(2):71–6
Risk factors associated with preterm (<37+0 weeks) and early preterm birth (<32+0 weeks): univariate and multivariate analysis of 106 345 singleton births from the 1994 statewide perinatal survey of Bavaria. Martius JA, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 80(2):183–9
Meconium stained amniotic fluid in preterm delivery is an independent risk factor for perinatal complications. Mazor M, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 81(1):9–13
School performance and behaviour in extremely preterm growth–retarded infants. Schaap AH, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):43–9
Inhaled salbutamol and beclomethasone for preventing broncho–pulmonary dysplasia: a randomised double–blind study. Denjean A, et al. **Eur J Pediatr** 1998 Nov; 157(11):926–31
Outcome predictors in nitric oxide treated preterm infants. Dimitriou G, et al. **Eur J Pediatr** 1999 Jul;158(7):589–91
Hepatitis B vaccination in preterm infants. Gołębiowska M, et al. **Eur J Pediatr** 1999 Apr;158(4):293–7
Respiratory muscle rigidity in a preterm infant after use of fentanyl during Caesarean section. Lindemann R. **Eur J Pediatr** 1998 Dec;157(12):1012–3
Aseptic sialadenitis in preterm infants associated with long–term oro–gastric tube feeding. Lindgren C, et al. **Eur J Pediatr** 1998 Dec;157(12):1014–6
Dry lung syndrome: complete airway collapse mimicking pulmonary hypoplasia? Losa M, et al. **Eur J Pediatr** 1998 Nov;157(11):935–8
Early versus late dexamethasone treatment in preterm infants at risk for chronic lung disease: a randomized pilot study. Merz U, et al. **Eur J Pediatr** 1999 Apr;158(4):318–22
Prevention of necrotizing enterocolitis in extremely low birth weight infants by IgG feeding? Richter D, et al. **Eur J Pediatr** 1998 Nov;157(11):924–5
The effect of positive endexpiratory pressure, peak inspiratory pressure, and inspiratory time on functional residual capacity in mechanically ventilated preterm infants. Thome U, et al. **Eur J Pediatr** 1998 Oct; 157(10):831–7
Ciprofloxacin in preterm neonates: case report and review of the literature. van den Oever HL, et al. **Eur J Pediatr** 1998 Oct;157(10):843–5 (8 ref.)
Predicting length–of–stay in preterm neonates. Zernikow B, et al. **Eur J Pediatr** 1999 Jan;158(1):59–62
Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. De Jaegere AP, et al. **Eur Respir J** 1998 Oct;12(4):932–4
Changes in survival of twins delivered after twin–twin transfusion syndrome versus preterm singletons over the calendar years 1970–1994. Skupski DW. **Fetal Diagn Ther** 1998 Nov–Dec;13(6):334–8
Risk factors of hypoglycemia in premature infants. Zanardo V, et al. **Fetal Diagn Ther** 1999 Mar–Apr;14(2):63–7
Astroglial reactions in periventricular white matter of maturing human brains. Dąmbska M, et al. **Folia Neuropathol** 1996;34(4):169–72
Reference ranges for cardiac dimensions and blood flow velocity in preterm infants. Skelton R, et al. **Heart** 1998 Sep;80(3):281–5
Geographic differences in seasonality of preterm births in Japan. Matsuda S, et al. **Hum Biol** 1998 Oct;70(5):919–35
Aplasia cutis type–6. Dhinagar S, et al. **Indian Pediatr** 1998 Oct;35(10):1021–4
Gastroesophageal reflux and pulmonary complication in a neonate. Mukhopadhyay K, et al. **Indian Pediatr** 1998 Jul; 35(7):665–8
Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension. Patole S, et al. **Indian Pediatr** 1998 Dec;35(12):1221–4
Prematurity in Greenland. Jacobsen T, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:154
Low birthweight and prematurity in relation to paternal factors: a study of recurrence. Basso O, et al. **Int J Epidemiol** 1999 Aug;28(4):695–700
Auditory screening in high–risk pre–term and full–term neonates using transient evoked otoacoustic emissions and brainstem auditory evoked potentials. Morlet T, et al. **Int J Pediatr Otorhinolaryngol** 1998 Sep 15;45(1):31–40
Plasma vitamin A and E in preterm babies fed on breast milk or formula milk with or without long–chain polyunsaturated fatty acids. Ghebremeskel K, et al. **Int J Vitam Nutr Res** 1999 Mar;69(2):83–91
Color doppler imaging of the central retinal artery in premature infants undergoing examination for retinopathy of prematurity. Holland DR, et al. **J Aapos** 1999 Aug; 3(4):194–8
Mineral composition of meconium: effect of prematurity. Haram–Mourabet S, et al. **J Am Coll Nutr** 1998 Aug; 17(4):356–60
Domestic violence: effect on pregnancy outcome. Fernandez FM, et al. **J Am Osteopath Assoc** 1999 May;99(5):254–6
Bone mineralization and turnover in preterm infants at 8–12 years of age: the effect of early diet. Fewtrell MS, et al. **J Bone Miner Res** 1999 May;14(5):810–20
Role of periodontitis in systemic health: spontaneous preterm birth. Offenbacher S, et al. **J Dent Educ** 1998 Oct; 62(10):852–8 (20 ref.)
Disseminated aspergillosis in a premature neonate [letter] Meessen NE, et al. **J Hosp Infect** 1998 Nov;40(3):249–50
No latent chromosome damage in oxygen–exposed premature neonates. Méhes K, et al. **J Hum Genet** 1999;44(1):40–2
Fetal fibronectin as a marker for an imminent (preterm) delivery. A new technique using the glycoprotein lectin immunosorbent assay. Hampel DJ, et al. **J Immunol Methods** 1999 Apr 22;224(1–2):31–42
A study of neonatal deaths in the tea gardens of Dibrugarh district of upper Assam. Phukan RK, et al. **J Indian Med Assoc** 1998 Nov;96(11):333–4, 337
Maternal chorioamnionitis and umbilical vein interleukin–6 levels for identifying early neonatal sepsis. Smulian JC, et al. **J Matern Fetal Med** 1999 May–Jun;8(3):88–94
Transitioning preterm infants with nasogastric tube supplementation: increased likelihood of breastfeeding. Kliethermes PA, et al. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):264–73
Parents' perception of skin–to–skin care with their preterm infants requiring assisted ventilation. Neu M. **J Obstet Gynecol Neonatal Nurs** 1999 Mar–Apr; 28(2):157–64
Transition time to full nipple feeding for premature infants with a history of lung disease. Pridham K, et al. **J Obstet Gynecol Neonatal Nurs** 1998 Sep–Oct;27(5):533–45
When is conventional ventilation not conventional? [letter] Chavasse R. **J Paediatr Child Health** 1998 Aug;34(4):401
Post–extubation prophylactic nasal continuous positive airway pressure in preterm infants: systematic review and meta–analysis. Davis P, et al. **J Paediatr Child Health** 1999 Aug;35(4):367–71
Antenatal steroids, condition at birth and respiratory morbidity and mortality in very preterm infants. Ee L, et al. **J Paediatr Child Health** 1998 Aug;34(4):377–83
Hospital admissions in the first year of life in very preterm infants. Elder DE, et al. **J Paediatr Child Health** 1999 Apr; 35(2):145–50
Myocardial infarction complicating neonatal enterovirus myocarditis. Hornung TS, et al. **J Paediatr Child Health** 1999 Jun;35(3):309–12
Survival of a 30–week baby with congenital myotonic dystrophy initially ventilated for 55 days. Lee' SY, et al. **J Paediatr Child Health** 1999 Jun;35(3):313–4
Effect of nappy liners on temperature stability in very preterm infants. Monterosso L, et al. **J Paediatr Child Health** 1999 Aug;35(4):363–6
Severe congenital absence of skin in a preterm infant. Ng PC, et al. **J Paediatr Child Health** 1999 Jun;35(3):306–8
Radiofrequency catheter ablation in a haemodynamically compromised premature neonate with hydrops fetalis. Osborn DA, et al. **J Paediatr Child Health** 1999 Aug; 35(4):406–8
Establishment of a normal range of penile length in preterm infants. Tuladhar R, et al. **J Paediatr Child Health** 1998 Oct;34(5):471–3
Head turning and face–down positioning in prone–sleeping premature infants. Constantin E, et al. **J Pediatr** 1999 May; 134(5):558–62
Single–dose dexamethasone treatment of hypotension in preterm infants. Gaissmaier RE, et al. **J Pediatr** 1999 Jun; 134(6):701–5
Systemic to pulmonary collateral arteries [letter; comment] Gillor A, et al. **J Pediatr** 1998 Oct;133(4):585. Comment on: J Pediatr 1997 Nov;131(5):763–5.
Neonatal dopamine pharmacodynamics: lessons from the bedside [editorial; comment] Padbury JF. **J Pediatr** 1998 Dec;133(6):719–20. Comment on: J Pediatr 1998 Dec;133(6):728–34.
Inhaled nitric oxide in the premature infant with severe hypoxemic respiratory failure: a time for caution [editorial; comment] Rosenberg AA. **J Pediatr** 1998 Dec;133(6):720–2 . Comment on: J Pediatr 1998 Dec;133(6):735–9.
Neurodevelopmental outcome with inhaled nitric oxide therapy [letter] Subhedar NV, et al. **J Pediatr** 1999 Aug; 135(2 Pt 1):266–7
Individualized protein fortification of human milk for preterm infants: comparison of ultrafiltrated human milk protein and a bovine whey fortifier. Polberger S, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):332–8
Reference values of body composition obtained by dual energy X–ray absorptiometry in preterm and term neonates. Rigo J, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):184–90
Evaluation of a long–chain polyunsaturated fatty acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants up to 48 weeks postconceptional age. Vanderhoof J, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):318–26
Nursing interventions to reduce stress in parents of hospitalized preterm infants. Griffin T, et al. **J Pediatr Nurs** 1998 Oct;13(5):290–5 (31 ref.)
The nurse parent support tool. Miles MS, et al. **J Pediatr Nurs** 1999 Feb;14(1):44–50
Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis. Adderson EE, et al. **J Pediatr Surg** 1998 Oct;33(10):1463–7
The role of peritoneal drainage for intestinal perforation in infants with and without necrotizing enterocolitis. Rovin JD, et al. **J Pediatr Surg** 1999 Jan;34(1):143–7
Cardiac tamponade: a rare but life–threatening complication of central venous catheters in children. van Engelenburg KC, et al. **J Pediatr Surg** 1998 Dec;33(12):1822–4
Resuscitation of a micropremie: the case of MacDonald versus Milleville [letter; comment] Goldsmith JP, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):502. Comment on: J Perinatol 1998 Jul–Aug;18(4):302–5.
The inadequate male syndrome. Little GA. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):470
A review of guidelines for the discharge of premature infants: opportunities for improving cost effectiveness. Merritt TA, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 2 Su):S27–37 (79 ref.)
Resuscitation of a micropremie: the case of MacDonald v. Milleville [see comments] Paris JJ, et al. **J Perinatol** 1998 Jul–Aug;18(4):302–5. Comment in: J Perinatol 1998 Nov–Dec;18(6 Pt 1):502.
Impact of the perception of viability on resource allocation in the neonatal intensive care unit. Sanders MR, et al. **J Perinatol** 1998 Sep–Oct;18(5):347–51
Cup feeding: an alternative to bottle feeding in a neonatal intensive care unit. Gupta A, et al. **J Trop Pediatr** 1999 Apr;45(2):108–10
Blood transfusion in preterm infants and risk of oxygen radical injury [letter] Manzar S, et al. **J Trop Pediatr** 1998 Dec;44(6):378–80
Kangaroo Mother Care [editorial] Simkiss DE. **J Trop Pediatr** 1999 Aug;45(4):192–4 (23 ref.)
Impact of prematurity on admissions to the neonatal nursery of a rural South African district hospital. Wilkinson D, et al. **J Trop Pediatr** 1999 Apr;45(2):76–80
Sonographic demonstration of a congenital laryngeal cyst. Shita L, et al. **J Ultrasound Med** 1999 Sep;18(9):665–7
From the Centers for Disease Control and Prevention. Preterm singleton births—United States, 1989–1996. **JAMA** 1999 Apr 21;281(15):1370–1
Immunization levels among premature and low–birth–weight infants and risk factors for delayed up–to–date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group. Davis RL, et al. **JAMA** 1999 Aug 11;282(6):547–53
Secular trends in preterm birth: a hospital–based cohort study [published erratum appears in JAMA 1999 Feb 24;281(8):705] Kramer MS, et al. **JAMA** 1998 Dec 2; 280(21):1849–54
Pharmacologic levels of heparin do not destabilize neonatal parenteral nutrition. Silvers KM, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep–Oct;22(5):311–4
Why might infertile couples have problem pregnancies? [comment] Baird DD, et al. **Lancet** 1999 May 22; 353(9166):1724–5. Comment on: Lancet 1999 May 22;353(9166):1746–9.
South African health–budget cuts hit premature newborns [news] [see comments] Baleta A. **Lancet** 1998 Oct 3; 352(9134):1129. Comment in: Lancet 1998 Dec 12;352(9144):1941.
Prophylaxis against respiratory syncytial virus in premature infants [letter] Bont L, et al. **Lancet** 1999 Sep 18; 354(9183):1003–4
South African health–budget cuts hit premature babies [letter; comment] Cooper PA. **Lancet** 1998 Dec 12;352(9144):1941 . Comment on: Lancet 1998 Oct 3;352(9134):1129.
Prothrombotic mutations as a risk factor for preterm birth [letter] Göpel W, et al. **Lancet** 1999 Apr 24; 353(9162):1411–2
Abnormal retinal vascularisation in preterm children as a general vascular phenomenon [letter] [see comments] [published erratum appears in Lancet 1999 Mar 27;353(9158):1104] Hellström A, et al. **Lancet** 1998 Dec 5;352(9143):1827. Comment in: Lancet 1999 Mar

27;353(9158):1099–100.
Delivery of premature newborns and maternal breast–cancer risk [letter] Hsieh CC, et al. **Lancet** 1999 Apr 10; 353(9160):1239
Better born too soon than too small. Lagercrantz H. **Lancet** 1997 Oct 11;350(9084):1044–5
Abnormal retinal vascularisation in preterm children [letter; comment] Minicucci G, et al. **Lancet** 1999 Mar 27; 353(9158):1099–100. Comment on: Lancet 1998 Dec 5;352(9143):1827.
Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm. Stewart AL, et al. **Lancet** 1999 May 15;353(9165):1653–7
Loss to follow–up of preterm and very preterm babies. Turnbull D. **Lancet** 1998 Dec 12;352(9144):1875–6
12000 miles for parental reassurance [letter] van Delft F, et al. **Lancet** 1998 Oct 3;352(9134):1122
Treatment of cutaneous hemangiomas in preterm neonatal twins with the flashlamp–pumped pulsed dye laser [letter] Lask GP. **Lasers Surg Med** 1999;24(1):1–2
Fatty acid profile of buccal cheek cell phospholipids as an index for dietary intake of docosahexaenoic acid in preterm infants. Hoffman DR, et al. **Lipids** 1999 Apr;34(4):337–42
Is the pharmacological use of intravenous magnesium before preterm cerebroprotective or deleterious for premature infants? Possible importance of the use of magnesium sulphate [comment] Durlach J, et al. **Magnes Res** 1998 Dec; 11(4):323–5 (22 ref.). Comment on: Magnes Res 1996 Oct;9(3):217–9.
Why do preterm infants die in the 1990s? Doyle LW, et al. **Med J Aust** 1999 Jun 7;170(11):528–32
Improved outcome of extremely premature infants in the 1990s. Paranka MS, et al. **Mil Med** 1999 Aug;164(8):568–71
Preterm singleton births––United States, 1989–1996. **MMWR Morb Mortal Wkly Rep** 1999 Mar 12;48(9):185–9
The influence of gestational age and smoking habits on the risk of subsequent preterm deliveries. Cnattingius S, et al. **N Engl J Med** 1999 Sep 23;341(13):943–8
Prevention of preterm birth [letter; comment] Devitt N. **N Engl J Med** 1998 Dec 17;339(25):1859–60. Comment on: N Engl J Med 1998 Jul 30;339(5):313–20.
Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. Joseph KS, et al. **N Engl J Med** 1998 Nov 12;339(20):1434–9
Prevention of preterm birth [letter; comment] McGregor JA, et al. **N Engl J Med** 1998 Dec 17;339(25):1858–9; discussion 1860. Comment on: N Engl J Med 1998 Jul 30;339(5):313–20.
Prevention of preterm birth [letter; comment] Sepkowitz S. **N Engl J Med** 1998 Dec 17;339(25):1859; discussion 1860 . Comment on: N Engl J Med 1998 Jul 30;339(5):313–20.
Immunisation of preterm babies. Moyes C. **N Z Med J** 1999 Jul 23;112(1092):263–4
The effects of perinatal hypoxic risk on developmental outcome in early and middle childhood: a twin study. Raz S, et al. **Neuropsychology** 1998 Jul;12(3):459–67
Bone mineralization in preterm infants. Ryan S. **Nutrition** 1998 Oct;14(10):745–7 (14 ref.)
Population–based study of infants born at less than 28 weeks' gestation in New South Wales, Australia, in 1992–3. New South Wales Neonatal Intensive Care Unit Study Group. Sutton L, et al. **Paediatr Perinat Epidemiol** 1999 Jul; 13(3):288–301
Accessory scrotum: an unusual localization of scrotal skin. Korkmaz A, et al. **Pediatr Dermatol** 1999 Mar–Apr; 16(2):142–3
Once daily gentamicin dosing in neonates. de Alba Romero C, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1169–71
A review of the pharmacokinetic and pharmacodynamic characteristics of beta–lactam/beta–lactamase inhibitor combination antibiotics in premature infants. Rubino CM, et al. **Pediatr Infect Dis J** 1998 Dec;17(12):1200–10 (69 ref.)
Pediatric intracranial epidural abscess secondary to an infected scalp vein catheter. Lefkowitz MA, et al. **Pediatr Neurosurg** 1998 Dec;29(6):297–9
Early childhood neurodevelopment in very low birth weight infants with predischarge apnea. Cheung PY, et al. **Pediatr Pulmonol** 1999 Jan;27(1):14–20
Pulmonary function at school–age in surfactant–treated preterm infants. Gappa M, et al. **Pediatr Pulmonol** 1999 Mar;27(3):191–8
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Groneck P, et al. **Pediatr Pulmonol** 1999 Jun;27(6):383–7
Predischarge monitoring of preterm infants. Razi NM, et al. **Pediatr Pulmonol** 1999 Feb;27(2):113–6
Early prediction of neonatal chronic lung disease: a comparison of three scoring methods. Yoder BA, et al. **Pediatr Pulmonol** 1999 Jun;27(6):388–94
Late neurosonographic screening is important to the diagnosis of periventricular leukomalacia and ventricular enlargement in preterm infants. Townsend SF, et al. **Pediatr Radiol** 1999 May;29(5):347–52
Pain in the very preterm baby: 'suffer little children?' McVey C. **Pediatr Rehabil** 1998 Apr–Jun;2(2):47–55 (106 ref.)
Administration of inhaled medication via a tracheostomy in infants with chronic lung disease of prematurity. Subhedar NV, et al. **Pediatr Rehabil** 1999 Apr–Jun;3(2):41–2
Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Carlson SE, et al. **Pediatr Res** 1998 Oct;44(4):491–8
Microstructural development of human newborn cerebral white matter assessed in vivo by diffusion tensor magnetic resonance imaging. Hüppi PS, et al. **Pediatr Res** 1998 Oct; 44(4):584–90
Timing of peak serum cortisol values in preterm infants in low–dose and the standard ACTH tests. Karlsson R, et al. **Pediatr Res** 1999 Mar;45(3):367–9
Bone turnover in preterm infants. Naylor KE, et al. **Pediatr Res** 1999 Mar;45(3):363–6
Airway protection in sleeping infants in response to pharyngeal fluid stimulation in the supine position. Page M, et al. **Pediatr Res** 1998 Nov;44(5):691–8
Milk fat globule glycoproteins in human milk and in gastric aspirates of mother's milk–fed preterm infants. Peterson JA, et al. **Pediatr Res** 1998 Oct;44(4):499–506
Deformability and geometry of neonatal erythrocytes with irregular shapes. Ruef P, et al. **Pediatr Res** 1999 Jan; 45(1):114–9
Dual energy x–ray absorptiometry of the forearm in preterm and term infants: evaluation of the methodology. Sievänen H, et al. **Pediatr Res** 1999 Jan;45(1):100–5
Comparison of pulmonary inflammatory mediators in preterm infants treated with intermittent positive pressure ventilation or high frequency oscillatory ventilation. Thome U, et al. **Pediatr Res** 1998 Sep;44(3):330–7
Peripheral oxygenation in hypotensive preterm babies. Wardle SP, et al. **Pediatr Res** 1999 Mar;45(3):343–9
What's new in perinatology. Chescheir NC, et al. **Pediatr Rev** 1999 Feb;20(2):57–63 (11 ref.)
Risk of death for small for gestational age very preterm infants [letter] Beeby PJ. **Pediatrics** 1998 Dec;102(6):1497–8
The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Brooks SE, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):514–8
Thyroid function and adverse outcome––What is the message? [letter; comment] Dembinski J. **Pediatrics** 1999 Jul;104(1 Pt 1):129–30. Comment on: Pediatrics 1998 May;101(5):903–7.
Effectiveness of RSV–IVIG in premature infants: success in the home [letter; comment] Hayes C, et al. **Pediatrics** 1999 Mar;103(3):698–9. Comment on: Pediatrics 1998 Feb;101(2):320–1.
Rehospitalization for respiratory syncytial virus among premature infants. Joffe S, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):894–9
Experimental validation of neonatal feeding practices [comment] Kliegman RM. **Pediatrics** 1999 Feb;103(2):492–3 . Comment on: Pediatrics 1999 Feb;103(2):434–9.
Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Losonsky GA, et al. **Pediatrics** 1999 Feb;103(2):E14
Comments on palivizumab (Synagis) [comment] Moler FW, et al. **Pediatrics** 1999 Feb;103(2):495–7. Comment on: Pediatrics 1998 Sep;102(3 Pt 1):531–7. Comment on: Pediatrics 1998 Sep;102(3 Pt 1):648–51.
Feeding strategies for premature infants: randomized trial of gastrointestinal priming and tube–feeding method [see comments] Schanler RJ, et al. **Pediatrics** 1999 Feb; 103(2):434–9. Comment in: Pediatrics 1999 Feb;103(2):492–3.
Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation [see comments] Verder H, et al. **Pediatrics** 1999 Feb;103(2):E24. Comment in: Pediatrics 1999 Feb;103(2):E25.
Myoclonic movements in very low birth weight premature infants associated with midazolam intravenous bolus administration [letter] Waisman D, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):579
Cisapride: a survey of the frequency of use and adverse events in premature newborns. Ward RM, et al. **Pediatrics** 1999 Feb;103(2):469–72
Outcomes of extremely premature infants related to their peak serum bilirubin concentrations and exposure to phototherapy. Yeo KL, et al. **Pediatrics** 1998 Dec; 102(6):1426–31
Kinematic and qualitative analysis of lower–extremity movements in preterm infants with brain lesions. van der Heide J, et al. **Phys Ther** 1999 Jun;79(6):546–57
Prematurity, immune function and infant feeding practices. Hampton SM. **Proc Nutr Soc** 1999 Feb;58(1):75–8 (16 ref.)
Developmental intervention for preterm infants diagnosed with periventricular leukomalacia. White–Traut RC, et al. **Res Nurs Health** 1999 Apr;22(2):131–43
Kangaroo mother care. Hann M, et al. **S Afr Med J** 1999 Jan;89(1):37–9
Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. Huang YC, et al. **Scand J Infect Dis** 1998;30(2):137–42
Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Dammann O, et al. **Semin Pediatr Neurol** 1998 Sep;5(3):190–201 (116 ref.)
Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Perlman JM. **Semin Pediatr Neurol** 1998 Sep;5(3):202–10 (89 ref.)
Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Volpe JJ. **Semin Pediatr Neurol** 1998 Sep;5(3):135–51 (138 ref.)
Assessment of pediatric patients for general anesthesia: the child with an upper respiratory infection and the ex–premature infant. Steward DJ. **Semin Pediatr Surg** 1999 Feb;8(1):13–7
Anesthesia for the micropremie. Spaeth JP, et al. **Semin Perinatol** 1998 Oct;22(5):390–401 (50 ref.)
Infantile esotropia in very low birth weight (VLBW) children. Pott JW, et al. **Strabismus** 1999 Jun;7(2):97–102
Blood transfusion in premature or young infants with polyagglutination and activation of the T antigen [published erratum appears in Vox Sang 1999;76(3):191] Engelfriet CP, et al. **Vox Sang** 1999;76(2):128–32
[Effectiveness of videotape education for mothers of prematurity] Chen YJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Dec; 14(12):800–6 (Eng. Abstr.) **(Chi)**
[Psychosocial problems posed by the discharge to the home of premature newborns] Bohu D, et al. **Arch Pediatr** 1999; 6 Suppl 2:264s–266s **(Fre)**
[Should premature infants be vaccinated? (editorial)] Floret D, et al. **Arch Pediatr** 1999 Jun;6(6):607–9 (17 ref.) **(Fre)**
[Pneumopericardium with favorable outcome in a ventilated premature infant] Follet–Bouhamed C, et al. **Arch Pediatr** 1999 Jun;6(6):647–9 (Eng. Abstr.) **(Fre)**
[Study of factors associated with early mortality of premature infants at the University Hospital Center of Brazzaville (letter)] Ganga–Zandzou PS, et al. **Arch Pediatr** 1999 Feb; 6(2):227–8 **(Fre)**
[Conditions and modalities of discharge of the premature newborn] Gold F, et al. **Arch Pediatr** 1999;6 Suppl 2:258s–260s **(Fre)**
[Therapeutic alternatives in neonatology: towards a reduction of the cost of prematurity] Haddad J. **Arch Pediatr** 1999; 6 Suppl 2:278s–280s **(Fre)**
[Consideration of aluminum in the newborn (news)] Jacqz–Aigrain E. **Arch Pediatr** 1998 Jan;5(1):95 **(Fre)**
[The prevention of anemia in premature infants: the role of recombinant human erythropoietin in a level III neonatology department (letter)] Klosowski S, et al. **Arch Pediatr** 1999 May;6(5):592–4 **(Fre)**
[Prematurity and sudden infant death syndrome. Polysomnography in question] Lequien P, et al. **Arch Pediatr** 1999 Jun;6(6):683–5 (16 ref.) (Eng. Abstr.) **(Fre)**
[A Scandinavian experience] Mai D, et al. **Arch Pediatr** 1999; 6 Suppl 2:267s–268s **(Fre)**
[Iron supplementation in preterm infants treated with erythropoietin] Picaud JC, et al. **Arch Pediatr** 1999 Jun; 6(6):657–64 (57 ref.) (Eng. Abstr.) **(Fre)**
–Development and evaluation of transfusion practices in a population of newborn infants less than 33 weeks gestational age (letter)– Pierrat V, et al. **Arch Pediatr** 1998 Mar;5(3):341–2 **(Fre)**
[Incidence, evolution and prognosis of posthemorrhagic ventriculomegaly in a population of newborns of less than 33 weeks gestational age] Pierrat V, et al. **Arch Pediatr** 1998 Sep;5(9):974–81 (Eng. Abstr.) **(Fre)**
[Follow–up of the premature infant at home––cooperation between town and home] Sarlangue J, et al. **Arch Pediatr** 1999;6 Suppl 2:269s–271s **(Fre)**
[Neuro–intellectual prognosis at school age for 62 children born with a gestational age of under 32 weeks] Sizun J, et al. **Arch Pediatr** 1998 Feb;5(2):139–44 (Eng. Abstr.) **(Fre)**
[Can we improve the neuro–intellectual and behavioral prognosis of premature infants by modifying their environment? (editorial)] Sizun J, et al. **Arch Pediatr** 1999 Jan;6(1):7–11 (37 ref.) **(Fre)**
[Discharge to the home of the large premature infant.Findings of North Pas–de–Calais (Epipage). Regional Group of Perinatal Epidemiology] Truffert P, et al. **Arch Pediatr** 1999;6 Suppl 2:261s–263s **(Fre)**
[The role of infertility treatment in very premature births in France. The point of view of the neonatologist] Dehan M. **Contracept Fertil Sex** 1998 Jul–Aug;26(7–8):512–6 (Eng. Abstr.) **(Fre)**
[Intracranial hypertension in a newborn treated with quinolone] Bedu A, et al. **Presse Med** 1998 Jun 27; 27(23):1140–2 (Eng. Abstr.) **(Fre)**
[Prognosis of newborns "at risk": cognitive disorders, motor disorders, difficulties in school and behavior disorders] Christiaens F, et al. **Rev Med Brux** 1999 Jun;20(3):A173–4 **(Fre)**
[Follow–up of premature infants weighing less than 1500 grams] Franco P, et al. **Rev Med Brux** 1999 Jun; 20(3):A171–2 **(Fre)**
[Is Candida septicemia in premature infants a nosocomial infection?] Laskus A, et al. **Mycoses** 1998;41 Suppl 2:37–40 (Eng. Abstr.) **(Ger)**
[Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies] Rink T, et al. **Nuklearmedizin** 1999;38(5):156–9 (Eng. Abstr.) **(Ger)**
[Panorama ultrasound of the spinal canal with determination of the level of the conus medullaris in newborn infants and infants] Staatz G, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Jun;170(6):564–7 (Eng. Abstr.) **(Ger)**
[Iodine concentration in the breast milk of mothers of premature infants] Seibold–Weiger K, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):81–5 (Eng. Abstr.) **(Ger)**
[Coping strategies of high–risk pregnancies with threat of premature birthø Mahler G, et al. **Zentralbl Gynakol** 1999;

121 Suppl 1:31–4 **(Ger)**

[Neonatal care of premature infants] Ertl T. **Orv Hetil** 1999 Jul 18;140(29):1611–8 (5011 ref.) (Eng. Abstr.) **(Hun)**

[Vitality as a therapeutic criterium for extremely premature children? (letter)] Brinchmann BS. **Tidsskr Nor Laegeforen** 1999 Jan 10;119(1):85–6 **(Nor)**

[Children with birth weight 1500 g or under from Troms and Finnmark in the period 1978–1989] Dahl LB, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):180–5 (Eng. Abstr.) **(Nor)**

[Importance of J. Brazy's neurobiological index. Prediction of the number and severity of complications in very low birth weight infants] Nunes A, et al. **Acta Med Port** 1998 Jul;11(7):615–21 (Eng. Abstr.) **(Por)**

[Preterm infants: an update on human milk fortifiers (letter)] Toma TS. **Rev Saude Publica** 1998 Jun;32(3):295–6 **(Por)**

[Neonatal viability and resuscitation in preterm newborns with an extremely low birth weight] Garcia-Alix Pérez A, et al. **An Esp Pediatr** 1999 Jun;50(6):594–602 (64 ref.) **(Spa)**

[Balance of the TH1/TH2 immune response in the materno-fetal interphase in normal and preterm pregnancy. Preliminary results] Tenorio Ramos J, et al. **Ginecol Obstet Mex** 1999 May;67:207–15 (Eng. Abstr.) **(Spa)**

[Preterm delivery: detection of risks and preventive treatment] Althabe F, et al. **Rev Panam Salud Publica** 1999 Jun;5(6):373–85 (71 ref.) (Eng. Abstr.) **(Spa)**

[Efficacy of early erythropoietin use in critically ill, very-low-birthweight premature newborn infants: controlled clinical trial] Lima-Rogel V, et al. **Sangre (Barc)** 1998 Jun;43(3):191–5 (Eng. Abstr.) **(Spa)**

[Being an intern on call when a child is born in the 22nd week of pregnancy] **Lakartidningen** 1999 Aug 11; 96(32–33):3430–1 **(Swe)**

[An extensive study indicates good prognosis for children with extremely low birth weight] Finnström O, et al. **Lakartidningen** 1999 Mar 31;96(13):1560–2, 1565–7 **(Swe)**

[A comment: in the borderland between a late abortion and premature delivery] Högberg U. **Lakartidningen** 1999 Aug 11;96(32–33):3431–2 **(Swe)**

[Our responsibility to the smallest. Care for the extremely premature is a technology beneficial to the entire neonatal care] Lagercrantz H. **Lakartidningen** 1999 Mar 31; 96(13):1540–2 **(Swe)**

[More active measures to increase survival in 24 week old gestation infants] Tunell R. **Lakartidningen** 1999 Mar 31; 96(13):1568–9 **(Swe)**

BLOOD

Comparison of absolute cerebral haemoglobin concentration in neonates measured directly and by the oxygen swing method both based on near infrared spectrophotometry. Wolf M, et al. **Adv Exp Med Biol** 1998;454:125–9

Coagulation profile in healthy Nigerian neonates. Okunade MA, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):71–2

Relation of hemoglobin measured at different times in pregnancy to preterm birth and low birth weight in Shanghai, China. Zhou LM, et al. **Am J Epidemiol** 1998 Nov 15;148(10):998–1006

Continuous neonatal blood gas monitoring using a multiparameter intra-arterial sensor. Morgan C, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F93–8

Arterial oxygen saturation profiles in healthy preterm infants. Ng A, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul; 79(1):F64–6

Impact of oxygen therapy on antioxidant status in newborns. Relationship with infection risk. Araujo V, et al. **Biofactors** 1998;8(1–2):143–7

Lipid peroxidation and antioxidants in erythrocyte membranes of full-term and preterm newborns. Huertas JR, et al. **Biofactors** 1998;8(1–2):133–7

Longitudinal multicentric study of plasma and red blood cell fatty acids and lipids in preterm newborns fed human milk. Babin F, et al. **Biol Neonate** 1999 May;75(5):285–93

Plasma homocysteine concentrations of preterm infants. Hongsprabhas P, et al. **Biol Neonate** 1999 Aug;76(2):65–71

Labeled trimethyllysine load depletes unlabeled carnitine in premature infants without evidence of incorporation. Melegh B, et al. **Biol Neonate** 1999 Jul;76(1):19–25

Lysosomal enzymes in preterm infants with bronchopulmonary dysplasia: a potential diagnostic marker. Goi G, et al. **Clin Chim Acta** 1998 Nov;278(1):23–34

Decreased superoxide production, degranulation, tumor necrosis factor alpha secretion, and CD11b/CD18 receptor expression by adherent monocytes from preterm infants. Kaufman D, et al. **Clin Diagn Lab Immunol** 1999 Jul; 6(4):525–9

Does transient hypothyroxinemia cause abnormal neurodevelopment in premature infants? Paneth N. **Clin Perinatol** 1998 Sep;25(3):627–43

Hematopoietic growth factor levels in term and preterm infants. Rondini G, et al. **Curr Opin Hematol** 1999 May; 6(3):192–7 (59 ref.)

Serial copper and ceruloplasmin levels in African newborns with emphasis on the sick and stable preterm infant, and their antioxidant capacities. Airede AI. **Early Hum Dev** 1998 Oct;52(3):199–210

Umbilical cord blood from preterm human fetuses is rich in committed and primitive hematopoietic progenitors with high proliferative and self-renewal capacity. Wyrsch A, et al. **Exp Hematol** 1999 Aug;27(8):1338–45

Nucleated red blood cells in fetuses delivered for early onset severe pre-eclampsia. Moser EC, et al. **Int J Gynaecol Obstet** 1999 Feb;64(2):183–5

Failure to detect preterm infants at risk of hypoglycemia before discharge. Hume R, et al. **J Pediatr** 1999 Apr; 134(4):499–502

Hypothyroxinemia of prematurity and the risk of cerebral white matter damage. Leviton A, et al. **J Pediatr** 1999 Jun; 134(6):706–11

Plasma somatostatin and cholecystokinin levels in preterm infants during kangaroo care with and without nasogastric tube-feeding. Törnhage CJ, et al. **J Pediatr Endocrinol Metab** 1998 Sep–Oct;11(5):645–51

Plasma somatostatin and cholecystokinin levels in response to feeding in preterm infants. Törnhage CJ, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug;27(2):199–205

Placental transfer of IgG antibodies against Haemophilus influenzae type b capsular polysaccharide in Brazilian term and preterm newborns. Nagao AT, et al. **J Trop Pediatr** 1999 Jun;45(3):171–3

Erythropoietin, given enterally, stimulates erythropoiesis in premature infants [letter] Ballin A, et al. **Lancet** 1999 May 29;353(9167):1849

Erythropoietic quality of maternal milk [letter] Krafft A, et al. **Lancet** 1999 Aug 28;354(9180):778

Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin-releasing hormone treatment. TRH Collaborative Trial Participants. Ballard PL, et al. **Pediatr Res** 1998 Nov;44(5):642–9

Impaired signal transduction in neonatal platelets. Israels SJ, et al. **Pediatr Res** 1999 May;45(5 Pt 1):687–91

Dynamic changes in serum leptin concentrations during the fetal and neonatal periods. Matsuda J, et al. **Pediatr Res** 1999 Jan;45(1):71–5

Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Watts TL, et al. **Pediatr Res** 1999 Jul;46(1):28–32

Neonatal neutrophil activation is a function of labor length in preterm infants. Weinschenk NP, et al. **Pediatr Res** 1998 Dec;44(6):942–5

Differential effects of glucocorticoids on colony stimulating factors produced by neonatal mononuclear cells. Witek-Janusek L, et al. **Pediatr Res** 1999 Feb;45(2):224–9

Why do newborn infants have a high plasma creatinine? Guignard JP, et al. **Pediatrics** 1999 Apr;103(4):e49

Predicting hyperbilirubinemia in newborns: the importance of timing [comment] Maisels MJ, et al. **Pediatrics** 1999 Feb; 103(2):493–5. Comment on: Pediatrics 1999 Jan;103(1):6–14.

Early dexamethasone therapy and blood cell count in preterm infants. Peng CT, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):476–81

Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)

[Somatotropin function in term and premature newborns during the first month of life] Radetti G, et al. **Arch Pediatr** 1998;5 Suppl 4:338S–344S (Eng. Abstr.) **(Fre)**

[Fiberoptic measurement of arterial oxygen saturation in premature and term neonates] Merz U, et al. **Z Geburtshilfe Neonatol** 1999 Mar–Apr;203(2):77–80 (Eng. Abstr.) **(Ger)**

[The characteristics of erythropoiesis in extremely premature neonates in the 1st 2 months of life] Piasetskaia NM. **Lik Sprava** 1999 Apr–May;(3):71–5 (Eng. Abstr.) **(Rus)**

[Glucose homeostasis against a background of respiratory distress in premature infants] Salabai ZV. **Lik Sprava** 1999 Mar;(2):110–2 (Eng. Abstr.) **(Ukr)**

CEREBROSPINAL FLUID

Normal cerebrospinal fluid values in full-term gestation and premature neonates. Nascimento-Carvalho CM, et al. **Arq Neuropsiquiatr** 1998 Sep;56(3A):375–80

GROWTH & DEVELOPMENT

Kangaroo care versus incubator care in the management of well preterm infants--a pilot study. Kambarami RA, et al. **Ann Trop Paediatr** 1998 Jun;18(2):81–6

Requirements for long-chain polyunsaturated fatty acids in the preterm infant. Uauy R, et al. **Curr Opin Pediatr** 1999 Apr;11(2):115–20 (53 ref.)

Temporal organization of sleep-wake states in preterm infants. Holditch-Davis D, et al. **Dev Psychobiol** 1998 Nov; 33(3):257–69

Health status of a population of infants born before 26 weeks gestation derived from routine data collected between 21 and 27 months post-delivery. Bohin S, et al. **Early Hum Dev** 1999 May;55(1):9–18

Premature infants fed mothers' milk to 6 months corrected age demonstrate adequate growth and zinc status in the first year. Wauben I, et al. **Early Hum Dev** 1999 Mar; 54(2):181–94

Developmental pathways leading to externalizing behaviors in 5 year olds born before 29 weeks of gestation. Girouard PC, et al. **J Dev Behav Pediatr** 1998 Aug;19(4):244–53

Long-term outcome of infants at the margin of viability. LeBlanc MH, et al. **J Miss State Med Assoc** 1999 Apr; 40(4):111–4

Transverse cerebellar diameter on cranial ultrasound scan in preterm neonates in an Australian population. Swaminathan M, et al. **J Paediatr Child Health** 1999 Aug; 35(4):346–9

Inaccuracy of Ballard scores before 28 weeks' gestation. National Institute of Child Health and Human Development Neonatal Research Network [see comments] Donovan EF, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):147–52 . Comment in: J Pediatr 1999 Aug;135(2 Pt 1):137–9.

The coming of (gestational) age for preterm infants [editorial; comment] Sola A, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):137–9. Comment on: J Pediatr 1999 Aug;135(2 Pt 1):147–50.

Environmental impact of the NICU on developmental outcomes. Blackburn S. **J Pediatr Nurs** 1998 Oct; 13(5):279–89 (60 ref.)

Thalamocortical development of parvalbumin neurons in normal and periventricular leukomalacia brains. Iai M, et al. **Neuropediatrics** 1999 Feb;30(1):14–8

Muscle power and medical history in high risk preterm infants at 3 months of corrected age. Samsom JF, et al. **Neuropediatrics** 1998 Jun;29(3):127–32

Microstructure of longitudinal 24 hour electroencephalograms in healthy preterm infants. Pan XL, et al. **Pediatr Int** 1999 Feb;41(1):18–27

IMMUNOLOGY

The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Wesumperuma HL, et al. **Ann Trop Med Parasitol** 1999 Mar;93(2):169–77

Immunogenicity of hepatitis B vaccine in preterm infants. Blondheim O, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Nov;79(3):F206–8

Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Robinson MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F69–71

Influence of dietary nucleotides on plasma immunoglobulin levels and lymphocyte subsets of preterm infants. Navarro J, et al. **Biofactors** 1999;10(1):67–76

Mononuclear cell subpopulations in preterm and full-term neonates: independent effects of gestational age, neonatal infection, maternal pre-eclampsia, maternal betamethason therapy, and mode of delivery. Kotiranta-Ainamo A, et al. **Clin Exp Immunol** 1999 Feb;115(2):309–14

Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection. Gessler P, et al. **Eur J Pediatr** 1999 Jun;158(6):497–500

Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants? Bialek R, et al. **Infection** 1998 Nov-Dec;26(6):375–8

Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Linder N, et al. **Infection** 1999 Mar-Apr;27(2):128–31

Placental transfer of maternal rubella antibodies to full-term and preterm infants. Linder N, et al. **Infection** 1999 May-Jun;27(3):203–7

Comparing alloimmunization in preterm infants after transfusion of fresh unmodified versus stored leukocyte-reduced red blood cells. Strauss RG, et al. **J Pediatr Hematol Oncol** 1999 May-Jun;21(3):224–30

Neonatal neutrophil activation is a function of labor length in preterm infants. Weinschenk NP, et al. **Pediatr Res** 1998 Dec;44(6):942–5

A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Carr R, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):796–802

Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Schloesser RL, et al. **Pediatrics** 1999 May;103(5):e60

METABOLISM

Insights into bone metabolism from calcium kinetic studies in children. Abrams SA. **Adv Exp Med Biol** 1998; 445:283–91

Threonine kinetics in preterm infants fed their mothers' milk or formula with various ratios of whey to casein. Darling PB, et al. **Am J Clin Nutr** 1999 Jan;69(1):105–14

Leucine metabolism in preterm infants receiving parenteral nutrition with medium-chain compared with long-chain triacylglycerol emulsions. Liet JM, et al. **Am J Clin Nutr** 1999 Mar;69(3):539–43

Vascular endothelial growth factor in human preterm lung. Lassus P, et al. **Am J Respir Crit Care Med** 1999 May;159(5 Pt 1):1429–33

Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. van Lingen RA, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F59–63

Basal vs reflex lacrimation [letter; comment] Baum JL. **Arch Ophthalmol** 1999 Jan;117(1):141. Comment on: Arch Ophthalmol 1998 Jun;116(6):773–6.

Presence of bleomycin-detectable free iron in the alveolar system of preterm infants. Gerber CE, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):218–22

In vivo measurements of glucose absorption in preterm infants. Shulman RJ. **Biol Neonate** 1999 Jul;76(1):10–8

A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Veng-Pedersen P, et al. **Biopharm Drug Dispos** 1999 May;20(4):217–23

P-selectin expression by endothelial cells is decreased in

neonatal rats and human premature infants. Lorant DE, et al. **Blood** 1999 Jul 15;94(2):600–9

Thyroxine administration to infants of less than 30 weeks gestational age decreases plasma tri-iodothyronine concentrations. van Wassenaer AG, et al. **Eur J Endocrinol** 1998 Nov;139(5):508–15

Longitudinal evaluation of salivary cortisol levels in full-term and preterm neonates. Bettendorf M, et al. **Horm Res** 1998; 50(6):303–8

Elevated intakes of zinc in infant formulas don not interfere with iron absorption in premature infants. Friel JK, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):312–6

Paracetamol pharmacokinetics in the premature neonate; the problem with limited data [letter] Anderson BJ, et al. **Paediatr Anaesth** 1998;8(5):442–4

Effect of theophylline on glucose production and lipolysis in preterm infants (< or = 32 weeks). Diderholm B, et al. **Pediatr Res** 1999 May;45(5 Pt 1):674–9

Zinc absorption, distribution, excretion, and retention by healthy preterm infants. Wastney ME, et al. **Pediatr Res** 1999 Feb;45(2):191–6

PHYSIOLOGY

Evolution of respiratory mechanics in preterm babies after surfactant administration in the neonatal period. Parmigiani S, et al. **Acta Biomed Ateneo Parmense** 1997;68 Suppl 1:65–73

Transepidermal water loss in infants born at 24 and 25 weeks of gestation. Agren J, et al. **Acta Paediatr** 1998 Nov; 87(11):1185–90

Clinical application of the measurement of cord plasma lactate and pyruvate in the assessment of high-risk neonates. Chou YH, et al. **Acta Paediatr** 1998 Jul; 87(7):764–8

Effects of early reduced light exposure on central visual development in preterm infants. Roy MS, et al. **Acta Paediatr** 1999 Apr;88(4):459–61

Growth and body composition of preterm infants: influence of nutrient fortification of mother's milk in hospital and breastfeeding post-hospital discharge. Wauben IP, et al. **Acta Paediatr** 1998 Jul;87(7):780–5

Thymus size in preterm infants evaluated by ultrasound. A preliminary report. Hasselbalch H, et al. **Acta Radiol** 1999 Jan;40(1):37–40

Closure of the ductus venosus in premature infants: findings on real-time gray-scale, color-flow Doppler, and duplex Doppler sonography. Loberant N, et al. **AJR Am J Roentgenol** 1999 Jan;172(1):227–9

Variations in regional cerebral blood volume in neonates associated with nursery care events. Gagnon RE, et al. **Am J Perinatol** 1999;16(1):7–11

Systolic blood pressure in babies of less than 32 weeks gestation in the first year of life. Northern Neonatal Nursing Initiative. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F38–42

Randomised controlled trial of cisapride in preterm neonates for gastric emptying time [letter] Deorari AK, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F159

Effect of feed interval and feed type on splanchnic haemodynamics. Lane AJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F49–53

Postnatal changes of leptin levels in full-term and preterm neonates: their relation to intrauterine growth, gender and testosterone. Ertl T, et al. **Biol Neonate** 1999 Mar; 75(3):167–76

Effect of repeated doses of sucrose during heel stick procedure in preterm neonates. Johnston CC, et al. **Biol Neonate** 1999 Mar;75(3):160–6

Do cry features reflect pain intensity in preterm neonates? A preliminary study. Johnston CC, et al. **Biol Neonate** 1999 Aug;76(2):120–4

Correlation between the serum level of endotoxin and periventricular leukomalacia in preterm infants. Okumura A, et al. **Brain Dev** 1999 Sep;21(6):378–81

Neonatal EEG: a powerful tool in the assessment of brain damage in preterm infants. Watanabe K, et al. **Brain Dev** 1999 Sep;21(6):361–72 (59 ref.)

Sleep/wake states of preterm infants: stability, developmental change, diurnal variation, and relation with caregiving activity. Ingersoll EW, et al. **Child Dev** 1999 Jan–Feb; 70(1):1–10

Early neurological and neuropsychological development of the preterm infant and polyunsaturated fatty acids supply. Bouglé D, et al. **Clin Neurophysiol** 1999 Aug; 110(8):1363–70

Feeding, medical factors, and developmental outcome in premature infants. Morris BH, et al. **Clin Pediatr (Phila)** 1999 Aug;38(8):451–7

Support of gas exchange in the delivery room and beyond: how do we avoid hurting the baby we seek to save? Clark RH. **Clin Perinatol** 1999 Sep;26(3):669–81, vii–viii (68 ref.)

The role of human milk fortification for premature infants. Schanler RJ. **Clin Perinatol** 1998 Sep;25(3):645–57, ix (69 ref.)

Apnoea-associated heart rate changes among preterm and full-term infants exposed to hyperthermia. Tirosh E, et al. **Clin Physiol** 1998 Jul;18(4):331–5

Physiological stability of preterm infants during magnetic resonance imaging. Battin M, et al. **Early Hum Dev** 1998 Sep;52(2):101–10

Cardiorespiratory stability of premature boys and girls during kangaroo care. Fischer CB, et al. **Early Hum Dev** 1998 Sep;52(2):145–53

Serial echocardiographic and Doppler evaluation of left ventricular systolic performance and diastolic filling in premature infants. Harada K, et al. **Early Hum Dev** 1999 Mar;54(2):169–80

Maturation of body and breathing movements in 24–33 week-old fetuses threatening to deliver prematurely. Kisilevsky BS, et al. **Early Hum Dev** 1999 May;55(1):25–38

Development of baroreflex influences on heart rate variability in preterm infants. Mazursky JE, et al. **Early Hum Dev** 1998 Nov;53(1):37–52

The development of preterm infants' breastfeeding behavior. Nyqvist KH, et al. **Early Hum Dev** 1999 Jul;55(3):247–64

The effect of sleep state on electroretinographic (ERG) activity during early human development. Peña M, et al. **Early Hum Dev** 1999 May;55(1):51–62

Maturation of the flash visual evoked potential in preterm infants. Pike AA, et al. **Early Hum Dev** 1999 Apr; 54(3):215–22

Assessment of bone turnover in term and preterm newborns at birth: measurement of urinary collagen crosslink excretion. Tsukahara H, et al. **Early Hum Dev** 1999 Jan; 53(3):185–91

Long term tidal breathing measurements in newborns: influence of a bias flow on ventilatory parameters. Windstetter D, et al. **Eur J Med Res** 1999 Jan 26;4(1):15–22

Pre-term delivery by Caesarean section 'en caul': a case series. Abouzeid H, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 May;84(1):51–3

Cerebral blood flow and neurological outcome in the preterm infant. Baenziger O, et al. **Eur J Pediatr** 1999 Feb; 158(2):138–43

Bone mineralisation in ex-preterm infants aged 8 years. Bowden LS, et al. **Eur J Pediatr** 1999 Aug;158(8):658–61

Click-evoked oto-acoustic emission measurement in preterm infants. Brienesse P, et al. **Eur J Pediatr** 1998 Dec; 157(12):999–1003

Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm child. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Dobson V, et al. **Invest Ophthalmol Vis Sci** 1999 Feb; 40(2):496–503

Visual development in preterm and full-term infants: a prospective masked study. Weinacht S, et al. **Invest Ophthalmol Vis Sci** 1999 Feb;40(2):346–53

Intraocular pressure in premature babies in the first month of life. Ricci B. **J Aapos** 1999 Apr;3(2):125–7

Invited editorial on "Irregularities and power law distributions in the breathing pattern in preterm and term infants" [editorial; comment] Bruce EN. **J Appl Physiol** 1998 Sep;85(3):787–8. Comment on: J Appl Physiol 1998 Sep;85(3):789–97.

Irregularities and power law distributions in the breathing pattern in preterm and term infants [see comments] Frey U, et al. **J Appl Physiol** 1998 Sep;85(3):789–97. Comment in: J Appl Physiol 1998 Sep;85(3):787–8.

Analysis of forced expiratory maneuvers from raised lung volumes in preterm infants. Henschen M, et al. **J Appl Physiol** 1998 Nov;85(5):1989–97

Birth-related fatigue in 34–36-week preterm neonates: rapid recovery with very early kangaroo (skin-to-skin) care. Ludington-Hoe SM, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):94–103

Effects of blood transfusion on left ventricular output in premature babies. Yu CW, et al. **J Paediatr Child Health** 1998 Oct;34(5):444–6

Adrenal function in premature infants during inhaled beclomethasone therapy. Cole CH, et al. **J Pediatr** 1999 Jul;135(1):65–70

Granulocyte colony-stimulating factor in the cord blood of premature neonates born to mothers with pregnancy-induced hypertension. Tsao PN, et al. **J Pediatr** 1999 Jul;135(1):56–9

Anabolic recovery relative to degree of prematurity after acute injury in neonates. Tueting JL, et al. **J Pediatr Surg** 1999 Jan;34(1):13–6; discussion 16–7

Comparison of respiratory function and fluid balance in very low birthweight infants given artificial or natural surfactant or no surfactant treatment. Kavvadia V, et al. **J Perinat Med** 1998;26(6):469–74

Weight-bearing patterns on the knees of preterm infants. Mizrahi J, et al. **Med Eng Phys** 1998 Nov;20(8):625–8

Motor nerve conduction velocity in very preterm infants. Smit BJ, et al. **Muscle Nerve** 1999 Mar;22(3):372–7

Physiological responses of preterm infants to breast-feeding and bottle-feeding with the orthodontic nipple. Dowling DA. **Nurs Res** 1999 Mar–Apr;48(2):78–85

The effects of prescribed versus ad libitum feedings and formula caloric density on premature infant dietary intake and weight gain. Pridham K, et al. **Nurs Res** 1999 Mar–Apr; 48(2):86–93

Bedside application of the Neonatal Facial Coding System in pain assessment of premature neonates. Grunau RE, et al. **Pain** 1998 Jun;76(3):277–86

Laser-Doppler-flowmetry in preterm newborns during apneic events. Sabatino G, et al. **Panminerva Med** 1998 Sep;40(3):174–8

Changes in pulmonary function in preterm infants recovering from RDS following early treatment with ambroxol: results of a randomized trial. Schmalisch G, et al. **Pediatr Pulmonol** 1999 Feb;27(2):104–12

Effects of gestational and postnatal age on body temperature, oxygen consumption, and activity during early skin-to-skin contact between preterm infants of 25–30-week gestation and their mothers. Bauer K, et al. **Pediatr Res** 1998 Aug; 44(2):247–51

Heart rate modifications related to spontaneous body movements in sleeping premature and full-term newborns. Curzi-Dascalova L, et al. **Pediatr Res** 1999 Apr;45(4 Pt 1):515–8

Iron absorption and red blood cell incorporation in premature infants fed an iron-fortified infant formula. McDonald MC, et al. **Pediatr Res** 1998 Oct;44(4):507–11

Adrenal function in preterm infants: ACTH may not be the sole regulator of the fetal zone. Midgley PC, et al. **Pediatr Res** 1998 Dec;44(6):887–93

Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Shulman RJ, et al. **Pediatr Res** 1998 Oct;44(4):519–23

Development of postural adjustments during reaching in preterm infants. van der Fits IB, et al. **Pediatr Res** 1999 Jul;46(1):1–7

More awakenings and heart rate variability during supine sleep in preterm infants. Goto K, et al. **Pediatrics** 1999 Mar; 103(3):603–9

Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula [comment] Schanler RJ, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1150–7. Comment on: Pediatrics 1997 Dec;100(6):1035–9.

The biological clock of very premature primate infants is responsive to light. Hao H, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2426–9

Effects of prone and supine position on sleep characteristics in preterm infants. Goto K, et al. **Psychiatry Clin Neurosci** 1999 Apr;53(2):315–7

Extreme prematurity in healthy 5-year-old children: a re-analysis of sex effects on event-related brain activity. Lavoie ME, et al. **Psychophysiology** 1998 Nov;35(6):679–89

Exhaled nitric oxide in preterm infants. Artlich A, et al. **Respir Physiol** 1998 Nov;114(2):195–200

Regional differences of cerebral hemoglobin concentration in preterm infants measured by near infrared spectrophotometry. Keel M, et al. **Technol Health Care** 1999;7(1):63–73

Thyroid function in the preterm infant. LaFranchi S. **Thyroid** 1999 Jan;9(1):71–8 (33 ref.)

Thyroid function in very preterm newborns: possible implications. Van Wassenaer AG, et al. **Thyroid** 1999 Jan; 9(1):85–91

[Precocious maturation of auditory evoked potentials in prematures: influence of gestational age and sex] Morlet T, et al. **Arch Pediatr** 1999 Jan;6(1):75–8 (Eng. Abstr.) **(Fre)**

[Implementation of an individualized program of sustained development in neonatal intensive care: why, how?] Sizun J, et al. **Arch Pediatr** 1999 Apr;6(4):434–9 (52 ref.) (Eng. Abstr.) **(Fre)**

[Electroencephalography of the premature and term newborn. Maturational aspects and glossary] Lamblin MD, et al. **Neurophysiol Clin** 1999 Apr;29(2):123–219 (77 ref.) (Eng. Abstr.) **(Fre)**

[A model for simulating heat transfer and thermoregulation of premature infants] Bussmann O, et al. **Biomed Tech (Berl)** 1998;43 Suppl:300–1 **(Ger)**

[Axillary versus rectal temperature measurement in premature and newborn infants] Roll C, et al. **Z Geburtshilfe Neonatol** 1998 Sep;202(5):207–11 (Eng. Abstr.) **(Ger)**

[A longitudinal study of hand-mouth contacts of pre-term infants] Takaya R, et al. **No To Hattatsu** 1999 Jul; 31(4):305–9 (Eng. Abstr.) **(Jpn)**

[The predictive value of neonatal neurological assessment and neonatal cranial ultrasonography with respect to the development of very low birth weight premature infants] Mello RR, et al. **Rev Saude Publica** 1998 Oct;32(5):420–9 (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Cranial magnetic resonance imaging and school performance in very low birth weight infants in adolescence. Cooke RW, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep; 81(2):F116–21

Infant arousal in an en-face exchange with a new partner: effects of prematurity and perinatal biological risk. Eckerman CO, et al. **Dev Psychol** 1999 Jan;35(1):282–93

Temperament profiles and their role in neurodevelopmental assessed preterm children at two years of age. Sajaniemi N, et al. **Eur Child Adolesc Psychiatry** 1998 Sep;7(3):145–52

Temperament of preterm infants at 4 months of age: maternal ratings and perceptions. Langkamp DL, et al. **J Dev Behav Pediatr** 1998 Dec;19(6):391–6

Maternal kangaroo (skin-to-skin) care in the NICU beginning 4 hours postbirth. Moran M, et al. **MCN Am J Matern Child Nurs** 1999 Mar–Apr;24(2):74–9

Anxiety of the 8th month in the preterm child. Pisaturo C, et al. **Minerva Pediatr** 1998 Dec;50(12):499–511 **(Eng, Ita)**

Maternal interaction patterns and preschool competence in high-risk children. McGrath MM, et al. **Nurs Res** 1998 Nov–Dec;47(6):309–17

Nursing care and the development of sleeping and waking behaviors in preterm infants. Brandon DH, et al. **Res Nurs Health** 1999 Jun;22(3):217–29

[Clinical significance of attachment research for the premature infant group: an overview of most recent research] Buchheim A, et al.
Z Kinder Jugendpsychiatr Psychother 1999 May; 27(2):125–38 (105 ref.) **(Ger)**

["Kangaroo method" in the care of premature infants admitted to a neonatal intensive care unit] Closa Monasterolo R, et al. **An Esp Pediatr** 1998 Nov;49(5):495–8 (Eng. Abstr.) **(Spa)**

INFANT, PREMATURE, DISEASES

Maternal hypertension and its association with cerebral palsy in very preterm infants [letter; comment] Colditz PB.
Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F158–9 . Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F83–7. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F88–93.

Epidemiological analysis defining concurrent outbreaks of Serratia marcescens and methicillin–resistant Staphylococcus aureus in a neonatal intensive–care unit. Campbell JR, et al. **Infect Control Hosp Epidemiol** 1998 Dec;19(12):924–8

Intestinal lactobezoars in twins receiving a reconstituted elemental formula. Lowichik A, et al.
J Pediatr Gastroenterol Nutr 1999 Jan;28(1):104–7

Clinically significant gastroesophageal reflux in the at–risk premature neonate: relation to cognitive scores, days in the NICU, and total hospital charges. Ferlauto JJ, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):455–9

[Germinal matrix hemorrhage and hydrocephalus in premature infants] Dehara M, et al. **No To Shinkei** 1999 Jul;51(7):627–31 (Eng. Abstr.) **(Jpn)**

BLOOD

Neutropenia in neonates delivered of women with pre–eclampsia. Greco P, et al.
Acta Biomed Ateneo Parmense 1997;68 Suppl 1:91–4

Serum bilirubin and development of chronic lung disease in very low birth weight infants [letter] Schrod L, et al.
Eur J Pediatr 1999 Feb;158(2):169–70

Pharmacokinetics of oral fluconazole in premature infants. Wenzl TG, et al. **Eur J Pediatr** 1998 Aug;157(8):661–2

G–CSF, GM–CSF and IL–6 levels in cord blood: diminished increase of G–CSF and IL–6 in preterms with perinatal infection compared to term neonates. Weimann E, et al.
J Perinat Med 1998;26(3):211–8

Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of alpha–fetoprotein. Hany MA, et al.
Pediatr Hematol Oncol 1998 Sep–Oct;15(5):437–41

CHEMICALLY INDUCED

Adverse effects of prenatal glucocorticoid treatment in the preterm infant. Rubaltelli FF, et al.
Acta Biomed Ateneo Parmense 1997;68 Suppl 1:35–8 (25 ref.)

Methaemoglobinaemia in a premature infant secondary to prilocaine [letter] Ergenekon E, et al. **Acta Paediatr** 1999 Feb;88(2):236

Coma in a premature infant associated with the transdermal absorption of propylene glycol. Peleg O, et al.
Acta Paediatr 1998 Nov;87(11):1195–6

Neonatal transient hypothyroidism: aetiological study. Italian Collaborative Study on Transient Hypothyroidism. Weber G, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul; 79(1):F70–2

Pulmonary haemorrhage in infants with gestational age of less than 30 weeks [letter] De Carolis MP, et al.
Eur J Pediatr 1998 Dec;157(12):1037–8

Respiratory muscle rigidity in a preterm infant after use of fentanyl during Caesarean section. Lindemann R.
Eur J Pediatr 1998 Dec;157(12):1012–3

Indomethacin–associated bowel perforations: a study of possible risk factors. Shorter NA, et al. **J Pediatr Surg** 1999 Mar;34(3):442–4

Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Hammerman C, et al. **Pediatrics** 1998 Nov;102(5):E56

[Incidence of typical nephrocalcinosis ultrasound findings in premature infants during enteral calcium and phosphate administration] Pfitzer A, et al. **Z Geburtshilfe Neonatol** 1998 Jul–Aug;202(4):159–63 (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Classifying brain damage in preterm infants [editorial; comment] Paneth N. **J Pediatr** 1999 May;134(5):527–9. Comment on: J Pediatr 1999 May;134(5):539–46. Comment on: J Pediatr 1999 May;134(5):631–4.

DIAGNOSIS

Artificial neural network for predicting intracranial haemorrhage in preterm neonates. Zernikow B, et al.
Acta Paediatr 1998 Sep;87(9):969–75

Relationship between MR imaging and histopathologic findings of the brain in extremely sick preterm infants. Felderhoff–Mueser U, et al. **AJNR Am J Neuroradiol** 1999 Aug;20(7):1349–57

Pyloric stenosis in the premature infant [letter; comment] Karim A. **Aust Fam Physician** 1998 Nov;27(11):989. Comment on: Aust Fam Physician 1998 Jul;27(7):619.

Feeding, medical factors, and developmental outcome in premature infants. Morris BH, et al. **Clin Pediatr (Phila)** 1999 Aug;38(8):451–7

Nonanion gap metabolic acidosis in a newborn. Jorquera P, et al. **Curr Opin Pediatr** 1999 Apr;11(2):169–73

Cognitive status, language attainment, and prereading skills of 6–year–old very preterm children and their peers: the Bavarian Longitudinal Study. Wolke D, et al.
Dev Med Child Neurol 1999 Feb;41(2):94–109

Acid oro–pharyngeal secretions can predict gastro–oesophageal reflux in preterm infants. James ME, et al. **Eur J Pediatr** 1999 May;158(5):371–4

Modeling analysis of change in neurologic abnormalities in children born prematurely: a novel approach. Anderson A, et al. **J Child Neurol** 1999 Aug;14(8):502–8

Interobserver reliability of the click test: a rapid bedside test to determine surfactant function. Osborn DA, et al.
J Paediatr Child Health 1998 Dec;34(6):544–7

Carbohydrate–deficient glycoprotein syndrome type 1 with profound thrombocytopenia and normal phosphomannomutase and phosphomannose isomerase activities. Acarregui MJ, et al. **J Pediatr** 1998 Nov; 133(5):697–700

Prematurity and hepatoblastoma: more than just an association? [letter; comment] Feusner J, et al.
J Pediatr 1998 Oct;133(4):585–6. Comment on: J Pediatr 1997 Apr;130(4):557–60.

Respiratory effort with airway closure during mixed apneas [letter; comment] Finer NN, et al. **J Pediatr** 1999 Jun; 134(6):796–8. Comment on: J Pediatr 1998 Oct;133(4):509–12.

Airway closure during mixed apneas in preterm infants: is respiratory effort necessary? [see comments] Idiong N, et al. **J Pediatr** 1998 Oct;133(4):509–12. Comment in: J Pediatr 1999 Jun;134(6):796–8.

Gastroesophageal reflux in preterm infants: norms for extended distal esophageal pH monitoring. Ng SC, et al.
J Pediatr Gastroenterol Nutr 1998 Oct;27(4):411–4

Spontaneous intestinal perforation in premature infants: a distinct clinical entity associated with systemic candidiasis. Adderson EE, et al. **J Pediatr Surg** 1998 Oct;33(10):1463–7

The value of standard electroencephalograms in the evaluation of the newborn with recurrent apneas. da Silva O, et al. **J Perinatol** 1998 Sep–Oct;18(5):377–80

False–positive results in premature infants with the Platelia Aspergillus sandwich enzyme–linked immunosorbent assay. Siemann M, et al. **Mycoses** 1998 Nov;41(9–10):373–7

Disseminated candidosis in premature twins. Sood S, et al.
Mycoses 1998 Nov;41(9–10):417–9

Correlation between neonatal cranial ultrasound, MRI in infancy and neurodevelopmental outcome in infants with a large intraventricular haemorrhage with or without unilateral parenchymal involvement. de Vries LS, et al.
Neuropediatrics 1998 Aug;29(4):180–8

Neonatal total parenteral nutrition ascites from liver erosion by umbilical vein catheters. Coley BD, et al.
Pediatr Radiol 1998 Dec;28(12):923–7

Predicting hyperbilirubinemia in newborns: the importance of timing [comment] Maisels MJ, et al. **Pediatrics** 1999 Feb; 103(2):493–5. Comment on: Pediatrics 1999 Jan;103(1):6–14.

Central nervous system candidiasis in very low–birth–weight premature neonates and infants: US characteristics and histopathologic and MR imaging correlates in five patients. Huang CC, et al. **Radiology** 1998 Oct;209(1):49–56

Transillumination for the diagnosis of pneumoperitoneum. Dutta S, et al. **Trop Gastroenterol** 1998 Oct–Dec; 19(4):162–3

[Mortality, morbidity and short–term neurologic outcome of premature infants less than or equal to 32 weeks gestational age in Fort–de–France CHR] Masson P, et al.
Arch Pediatr 1998 Aug;5(8):861–8 (Eng. Abstr.) **(Fre)**

[Prematurity and cerebral lesions] Vermeylen D.
Rev Med Brux 1999 Jun;20(3):A170 **(Fre)**

[Common anemias in neonatology] Humbert J, et al.
Schweiz Rundsch Med Prax 1999 Jan 28;88(5):164–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[Symptomatological patterns of infancy diseases. Presentation of a new Symptom Checklist] Milone A, et al.
Minerva Pediatr 1998 Sep;50(9):385–94 (Eng. Abstr.) **(Ita)**

[Pulmonary function tests as a predictor of chronic lung disease in ventilated preterm infants] Tortorolo L, et al.
Minerva Pediatr 1998 May;50(5):151–6 (Eng. Abstr.) **(Ita)**

[Vitality as a criterion of the prognosis in the treatment of premature children?] Brinchmann BS.
Tidsskr Nor Laegeforen 1999 Aug 30;119(20):2993–5 (Eng. Abstr.) **(Nor)**

[Hearing in premature infants. Evoked–cochlear microphones] Sanjuán Juaristi J.
Acta Otorrinolaringol Esp 1998 Oct;49(7):525–31 (Eng. Abstr.) **(Spa)**

[Sepsis due to azole–resistant Candida albicans in a high–risk premature infant] Martínez Suárez V, et al.
An Esp Pediatr 1999 Jan;50(1):77–8 (22 ref.) **(Spa)**

[Preterm delivery: detection of risks and preventive treatment] Althabe F, et al. **Rev Panam Salud Publica** 1999 Jun;5(6):373–85 (71 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Filgrastim for treatment of neutropenia in a neonate. Berndt EM, et al. **Am J Health Syst Pharm** 1999 May 15; 56(10):995–7

Liposomal amphotericin B in neonates with invasive candidiasis. Al Arishi H, et al. **Am J Perinatol** 1998; 15(11):643–8

The risks and benefits of cisapride [letter] Cairns P.
Arch Dis Child 1999 May;80(5):493

The risks and benefits of cisapride in premature neonates, infants, and children. Lander A, et al. **Arch Dis Child** 1998 Dec;79(6):469–70

Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo–controlled, double–blind trial [see comments] Lauterbach R, et al. **Crit Care Med** 1999 Apr;27(4):807–14 . Comment in: Crit Care Med 1999 Apr;27(4):695–7.

Appraising the potential of pentoxifylline in septic premies [editorial; comment] Zimmerman JJ. **Crit Care Med** 1999 Apr;27(4):695–7 (32 ref.). Comment on: Crit Care Med 1999 Apr;27(4):807–14.

Local low–dose urokinase treatment of acquired intracardiac thrombi in preterm infants. Aspesberro F, et al.
Eur J Pediatr 1999 Sep;158(9):698–701

Inhaled salbutamol and beclomethasone for preventing broncho–pulmonary dysplasia: a randomised double–blind study. Denjean A, et al. **Eur J Pediatr** 1998 Nov; 157(11):926–31

Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia [letter] Lauterbach R, et al. **Eur J Pediatr** 1999 Jul; 158(7):607

Ciprofloxacin in preterm neonates: case report and review of the literature. van den Oever HL, et al.
Eur J Pediatr 1998 Oct;157(10):843–5 (8 ref.)

Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension. Patole S, et al.
Indian Pediatr 1998 Dec;35(12):1221–4

Ochrobactrum anthropi meningitis in a pre–term neonate [letter] Hay AJ, et al. **J Infect** 1999 Mar;38(2):134–5

Incidence and outcome of a 10–fold indomethacin overdose in premature infants. Narayanan M, et al. **J Pediatr** 1999 Jul;135(1):105–7

Inhaled nitric oxide in the premature infant with severe hypoxemic respiratory failure: a time for caution [editorial; comment] Rosenberg AA. **J Pediatr** 1998 Dec;133(6):720–2 . Comment on: J Pediatr 1998 Dec;133(6):735–9.

Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. Tammela O, et al.
J Pediatr 1999 May;134(5):552–7

Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator. Grieg A. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):460–2 (11 ref.)

Fulminant necrotizing enterocolitis in a premature neonate treated for supraventricular tachycardia. Khalak R, et al.
J Perinatol 1998 Jul–Aug;18(4):306–7

Acetazolamide in posthaemorrhagic ventricular dilatation [letter; comment] Raupp P. **Lancet** 1998 Nov 7; 352(9139):1548–9. Comment on: Lancet 1998 Aug 8;352(9126):433–40.

Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature. Rohrer T, et al.
Pediatr Infect Dis J 1999 Apr;18(4):382–6 (27 ref.)

Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Lin YJ, et al.
Pediatr Pulmonol 1999 Jan;27(1):21–6

Bronchodilator delivered by metered dose inhaler and spacer improves respiratory system compliance more than nebulizer–delivered bronchodilator in ventilated premature infants. Sivakumar D, et al. **Pediatr Pulmonol** 1999 Mar; 27(3):208–12

Corticosteroids and chronic lung disease in extremely immature infants: a dilemma. Moriette G, et al.
Pediatr Pulmonol Suppl 1999;18:209–11 (12 ref.)

Administration of inhaled medication via a tracheostomy in infants with chronic lung disease of prematurity. Subhedar NV, et al. **Pediatr Rehabil** 1999 Apr–Jun;3(2):41–2

Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin–releasing hormone treatment. TRH Collaborative Trial Participants. Ballard PL, et al. **Pediatr Res** 1998 Nov;44(5):642–9

Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial. Brown MS, et al.
Pediatrics 1999 Aug;104(2 Pt 1):210–5

Preliminary report: rhG–CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia–associated neutropenia. Kocherlakota P, et al. **Pediatrics** 1998 Nov; 102(5):1107–11

Cisapride: a survey of the frequency of use and adverse events in premature newborns. Ward RM, et al. **Pediatrics** 1999 Feb;103(2):469–72

[Gentamicin dosing regimen for neonates: once daily (letter; comment)] De Hoog M, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1520–1. Comment on: Ned Tijdschr Geneeskd 1998 Mar 14;142(11):583–6. **(Dut)**

[Gentamicin dosing regimen for neonates: once daily (letter; comment)] van Haelst IM, et al. **Ned Tijdschr Geneeskd** 1998 Jun 27;142(26):1521–2. Comment on: Ned Tijdschr Geneeskd 1998 Mar 14;142(11):583–6. **(Dut)**

[Gentamicin dosing regimen for neonates: once daily (letter; comment)] Vervelde ML, et al. **Ned Tijdschr Geneeskd**

1998 Jun 27;142(26):1522–3. Comment on: Ned Tijdschr Geneeskd 1998 Mar 14;142(11):583–6. **(Dut)**

[A comparative study about the therapeutic effect of theophylline and doxapram in apnoeic disorders] Möller JC, et al. **Klin Padiatr** 1999 Mar–Apr;211(2):86–91 (Eng. Abstr.) **(Ger)**

[Continuous insulin perfusion in preterm infants with weight less than 1,500 grams who receive parenteral nutrition (letter)] Tejera Ramirez C, et al. **An Esp Pediatr** 1998 Aug; 49(2):213–5 **(Spa)**

ECONOMICS

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Marchetti A, et al. **Clin Ther** 1999 Apr; 21(4):752–66

Survival after being born too soon, but at what cost? Skuse D. **Lancet** 1999 Jul 31;354(9176):354–5

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants [see comments] Joffe S, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):419–27. Comment in: Pediatrics 1999 Sep;104(3 Pt 1):559–60.

ENZYMOLOGY

Erythrocyte glutathione S transferase as a marker of oxidative stress at birth. Neefjes VM, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep;81(2):F130–3

EPIDEMIOLOGY

Nursery Neurobiologic Risk Score and outcome at 18 months. Lefebvre F, et al. **Acta Paediatr** 1998 Jul; 87(7):751–7

Clinical relevance of Ureaplasma urealyticum colonization in preterm infants. Ollikainen J, et al. **Acta Paediatr** 1998 Oct;87(10):1075–8

Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Stevenson DK, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1632–9

Early onset group B streptococcal neonatal infection in Oxford 1985–96. Moses LM, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F148–9

Comparative study of mortality and morbidity in premature infants (birth weight, < 1,250 g) with candidemia or candidal meningitis. Lee BE, et al. **Clin Infect Dis** 1998 Sep;27(3):559–65

Incidence of rickets of prematurity at Kenyatta National Hospital, Nairobi. Oyatsi DP, et al. **East Afr Med J** 1999 Feb;76(2):63–6

Neonatal neutropenia associated with maternal hypertension poses a risk for nosocomial infection. Gray PH, et al. **Eur J Pediatr** 1999 Jan;158(1):71–3

Incidence of contralateral inguinal hernia: a prospective analysis. Tackett LD, et al. **J Pediatr Surg** 1999 May; 34(5):684–7; discussion 687–8

Periventricular leukomalacia and epilepsy: incidence and seizure pattern. Gurses C, et al. **Neurology** 1999 Jan 15; 52(2):341–5

Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Canterino JC, et al. **Obstet Gynecol** 1999 Mar; 93(3):396–402

Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit. Shah SS, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):591–5

Atypical chronic lung disease patterns in neonates. Charafeddine L, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):759–65

Apnea of prematurity and risk for sudden infant death syndrome [letter] Freed GE, et al. **Pediatrics** 1999 Aug; 104(2 Pt 1):297–8

[Importance of J. Brazy's neurobiological index. Prediction of the number and severity of complications in very low birth weight infants] Nunes A, et al. **Acta Med Port** 1998 Jul;11(7):615–21 (Eng. Abstr.) **(Por)**

ETIOLOGY

Some risk factors for cerebral palsy in very premature infants: importance of premature rupture of membranes and monochorionic twin placentation. Burguet A, et al. **Biol Neonate** 1999 Mar;75(3):177–86

Scar formation after skin injury to the human foetus in utero or the premature neonate. Morrison WA, et al. **Br J Plast Surg** 1999 Jan;52(1):6–11

Aseptic sialadenitis in preterm infants associated with long-term oro-gastric tube feeding. Lindgren C, et al. **Eur J Pediatr** 1998 Dec;157(12):1014–6

Dry lung syndrome: complete airway collapse mimicking pulmonary hypoplasia? Losa M, et al. **Eur J Pediatr** 1998 Nov;157(11):935–8

Cytomegalovirus associated neonatal pneumonia and Wilson-Mikity syndrome: a causal relationship? Reiterer F, et al. **Eur Respir J** 1999 Feb;13(2):460–2

Disseminated intravascular meconium in a newborn with meconium peritonitis. Kolker SE, et al. **Hum Pathol** 1999 May;30(5):592–4

Gastroesophageal reflux and pulmonary complication in a neonate. Mukhopadhyay K, et al. **Indian Pediatr** 1998 Jul; 35(7):665–8

Correlation of coagulation abnormalities with clinical outcome in neonates of mothers with pregnancy induced hypertension. Agarwal K, et al. **J Indian Med Assoc** 1998 Jun;96(6):171–3

Potential risks of chest physiotherapy in preterm infants [letter; comment] Gray PH, et al. **J Pediatr** 1999 Jul; 135(1):131; discussion 132. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):440–4.

Airway closure during mixed apneas in preterm infants: is respiratory effort necessary? [see comments] Idiong N, et al. **J Pediatr** 1998 Oct;133(4):509–12. Comment in: J Pediatr 1999 Jun;134(6):796–8.

Potential risks of chest physiotherapy in preterm infants [letter; comment] Vinçon C. **J Pediatr** 1999 Jul; 135(1):131–2. Comment on: J Pediatr 1998 Mar;132(3 Pt 1):440–4.

Cardiac tamponade: a rare but life-threatening complication of central venous catheters in children. van Engelenburg KC, et al. **J Pediatr Surg** 1998 Dec;33(12):1822–4

Blood transfusion in preterm infants and risk of oxygen radical injury [letter] Manzar S, et al. **J Trop Pediatr** 1998 Dec;44(6):378–80

Autoregulation of cerebral blood flow and brain lesions in newborn infants [see comments] Lou HC. **Lancet** 1998 Oct 31;352(9138):1406. Comment in: Lancet 1998 Dec 19–26;352(9145):2023.

Neonatal morbidity at 34–37 weeks: the role of ruptured membranes. Steinfeld JD, et al. **Obstet Gynecol** 1999 Jul; 94(1):120–3

Perinatal events and the risk of intraparenchymal echodensity in very-low-birthweight neonates. O'Shea TM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):408–21

[Does prenatal administration of thyrotropin releasing hormone contribute to premature delivery?] Binder T, et al. **Ceska Gynekol** 1999 Jan;64(1):10–9 **(Cze)**

[Infection with cytomegalovirus in a premature infant secondary to contamination by breast milk (letter)] de la Gastine G, et al. **Arch Pediatr** 1998 Nov;5(11):1290–1 **(Fre)**

[Introduction: basic aspects, problems and outcome in perinatal neurology] Evrard P. **Arch Pediatr** 1998;5 Suppl 2:166s–167s **(Fre)**

[Peritonitis in the neonatal period] Simão C, et al. **Acta Med Port** 1998 Dec;11(12):1127–9 (11 ref.) (Eng. Abstr.) **(Por)**

[Perinatal risk factors for the development of autonomic disorders in premature newborns] Nadraha OB. **Lik Sprava** 1998 Dec;(8):131–3 (Eng. Abstr.) **(Ukr)**

[The risk factors for early anemia in premature infants] Sekretar LB. **Lik Sprava** 1998 Aug;(6):114–7 (Eng. Abstr.) **(Ukr)**

GENETICS

Resistance to activated protein C in newborns with necrotizing enterocolitis [letter] Göpel W, et al. **Eur J Pediatr** 1999 Jul;158(7):608

IMMUNOLOGY

In vitro immunoglobulin response of fetal B-cells is influenced by perinatal infections and antibiotic treatment: a study in preterm infants [see comments] Cukrowska B, et al. **Eur J Pediatr** 1999 Jun;158(6):463–8. Comment in: Eur J Pediatr 1999 Jun;158(6):444–5.

Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection. Gessler P, et al. **Eur J Pediatr** 1999 Jun;158(6):497–500

[Granulocyte function in premature infants before the 34th week of pregnancy and in mature newborn infants] Habermehl P, et al. **Klin Padiatr** 1999 May–Jun; 211(3):149–53 (Eng. Abstr.) **(Ger)**

METABOLISM

Breath pentane as a marker for lipid peroxidation and adverse outcome in preterm infants. Nycyk JA, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F67–9

Amniotic fluid interleukin-6 and the risk of early-onset sepsis among preterm infants. Figueroa-Damián R, et al. **Arch Med Res** 1999 May–Jun;30(3):198–202

Thyroid function in premature infants. The hypothyroxinemia of prematurity. Fisher DA. **Clin Perinatol** 1998 Dec;25(4):999–1014, viii (53 ref.)

MICROBIOLOGY

Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Jónsson B, et al. **Acta Paediatr** 1998 Oct;87(10):1079–84

Disseminated congenital candidiasis in a premature infant. Waguespack-LaBiche J, et al. **Arch Dermatol** 1999 May; 135(5):510–2

Histologic chorioamnionitis & its association with prematurity in a hospital-based study. Paul VK, et al. **Indian J Med Res** 1998 Dec;108:272–8

Transfer of resistance to oxy-imino-cephalosporins and of extended-spectrum beta-lactamase productions in Klebsiella pneumoniae strains from infected neonates. Blahová J, et al. **Zentralbl Bakteriol** 1998 Jul;288(1):75–86

MORTALITY

Late death of very low birthweight infants. Fillmore EJ, et al. **Acta Paediatr** 1998 Jul;87(7):809–10

Indicated versus spontaneous preterm delivery: An evaluation of neonatal morbidity among infants weighing </=1000 grams at birth. Kimberlin DF, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):683–9

Prematurity in Greenland. Jacobsen T, et al. **Int J Circumpolar Health** 1998;57 Suppl 1:154

Changing mortality and causes of death in infants 23–27 weeks' gestational age. Doyle LW, et al. **J Paediatr Child Health** 1999 Jun;35(3):255–9

Survival and 2-year outcome with expectant management of second-trimester rupture of membranes [see comments] Farooqi A, et al. **Obstet Gynecol** 1998 Dec;92(6):895–901 . Comment in: Obstet Gynecol 1999 Apr;93(4):632–3.

Neonatal morbidity at 34–37 weeks: the role of ruptured membranes. Steinfeld JD, et al. **Obstet Gynecol** 1999 Jul; 94(1):120–3

[Premature delivery in borderline viability of the infant. A recommendations of the German Society of Gynecology and Obstetrics, the German Society of Pediatrics and Adolescent Medicine, the German Society of Perinatal Medicine and the Society of Neonatology and Pediatric Intensive Care Medicine] Pohlandt F. **Z Geburtshilfe Neonatol** 1998 Nov–Dec;202(6):261–3 **(Ger)**

NURSING

Birth-related fatigue in 34–36-week preterm neonates: rapid recovery with very early kangaroo (skin-to-skin) care. Ludington-Hoe SM, et al. **J Obstet Gynecol Neonatal Nurs** 1999 Jan–Feb;28(1):94–103

Distress and growth outcomes in mothers of medically fragile infants. Miles MS, et al. **Nurs Res** 1999 May–Jun; 48(3):129–40

PARASITOLOGY

Nosocomial myiasis in an extremely premature infant caused by the sheep blowfly Lucilia sericata. Amitay M, et al. **Pediatr Infect Dis J** 1998 Nov;17(11):1056–7

PATHOLOGY

A case of panlobar nephroblastomatosis with bilateral Wilms' tumour. The concept of "nephroblastomatosis" and its clinical importance. Lancaster EJ, et al. **Cent Afr J Med** 1998 Jul;44(7):182–7 (15 ref.)

Brain dysgenesis in Cornelia de Lange syndrome. Yamaguchi K, et al. **Clin Neuropathol** 1999 Mar–Apr;18(2):99–105

Magnetic resonance imaging of the brain in a cohort of extremely preterm infants. Maalouf EF, et al. **J Pediatr** 1999 Sep;135(3):351–7

Unusual case of tracheal agenesis. O'Neill D, et al. **Pediatr Dev Pathol** 1999 Mar–Apr;2(2):176–9

Pituitary gland gumma in congenital syphilis after failed maternal treatment: a case report. Benzick AE, et al. **Pediatrics** 1999 Jul;104(1):e4

PHYSIOPATHOLOGY

The effect of phototherapy on cerebral blood flow velocity in preterm infants. Benders MJ, et al. **Acta Paediatr** 1998 Jul;87(7):786–91

The effect of positive endexpiratory pressure, peak inspiratory pressure, and inspiratory time on functional residual capacity in mechanically ventilated preterm infants. Thome U, et al. **Eur J Pediatr** 1998 Oct; 157(10):831–7

Compensated shock and dopamine [letter; comment] Evans N, et al. **J Pediatr** 1999 Jul;135(1):135–6. Comment on: J Pediatr 1998 Dec;133(6):728–34.

Mechanisms of gastroesophageal reflux in healthy premature infants. Omari TI, et al. **J Pediatr** 1998 Nov;133(5):650–4

Neonatal dopamine pharmacodynamics: lessons from the bedside [editorial; comment] Padbury JF. **J Pediatr** 1998 Dec;133(6):719–20. Comment on: J Pediatr 1998 Dec;133(6):728–34.

Regional hemodynamic effects of dopamine in the sick preterm neonate [see comments] Seri I, et al. **J Pediatr** 1998 Dec;133(6):728–34. Comment in: J Pediatr 1998 Dec;133(6):719–20. Comment in: J Pediatr 1999 Jul;135(1)135–6.

Apnoea of prematurity and changes in cerebral oxygenation and cerebral blood volume. Urlesberger B, et al. **Neuropediatrics** 1999 Feb;30(1):29–33

Kinematic and qualitative analysis of lower-extremity movements in preterm infants with brain lesions. van der Heide J, et al. **Phys Ther** 1999 Jun;79(6):546–57

PREVENTION & CONTROL

Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Kovács L, et al. **Acta Paediatr** 1998 Jul;87(7):792–8

Benefits of maternal corticosteroid therapy in infants weighing </=1000 grams at birth after preterm rupture of the amnion. Chapman SJ, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):677–82

Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease [see comments] Bhuta T, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F26–33. Comment in: Arch Dis Child Fetal Neonatal Ed 1999

Mar;80(2):F159.
Maternal hypertension and neurodevelopmental outcome in very preterm infants [see comments] Gray PH, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Sep;79(2):F88–93 . Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Mar;80(2):F158–9.
Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Marchetti A, et al. **Clin Ther** 1999 Apr; 21(4):752–66
Erythropoietin to prevent and treat the anemia of prematurity. Ohls RK. **Curr Opin Pediatr** 1999 Apr; 11(2):108–14 (52 ref.)
Evaluation of the effect of thyroxine supplementation on behavioural outcome in very preterm infants. Briët JM, et al. **Dev Med Child Neurol** 1999 Feb;41(2):87–93
Neonatal outcome of inborn and transported very-low-birth-weight infants: relevance of perinatal factors. Arad I, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Apr;83(2):151–7
Prevention of necrotizing enterocolitis in extremely low birth weight infants by IgG feeding? Richter D, et al. **Eur J Pediatr** 1998 Nov;157(11):924–5
ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. Number 210, October 1998 (Replaces Number 147, December 1994). Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Mar;64(3):334–5
A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Kopelman AE, et al. **J Pediatr** 1999 Sep;135(3):345–50
DNA probe for beta-hemolytic group B Streptococcus. Diagnostic accuracy in threatened preterm labor. Ryan KM, et al. **J Reprod Med** 1999 Jul;44(7):587–91
Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. Leviton LC, et al. **JAMA** 1999 Jan 6;281(1):46–52
Prophylaxis against respiratory syncytial virus in premature infants [letter] Bont L, et al. **Lancet** 1999 Sep 18; 354(9183):1003–4
Chronic lung disease of prematurity--prevention by inhaled corticosteroids? Greenough A. **Lancet** 1999 Jul 24; 354(9175):266–7
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Groneck P, et al. **Pediatr Pulmonol** 1999 Jun;27(6):383–7
Brain damage in preterm newborns: might enhancement of developmentally regulated endogenous protection open a door for prevention? Dammann O, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):541–50 (187 ref.)
Effectiveness of RSV-IVIG in premature infants: success in the home [letter; comment] Hayes C, et al. **Pediatrics** 1999 Mar;103(3):698–9. Comment on: Pediatrics 1998 Feb;101(2):320–1.
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants [see comments] Joffe S, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):419–27. Comment in: Pediatrics 1999 Sep;104(3 Pt 1):559–60.
Comments on palivizumab (Synagis) [comment] Moler FW, et al. **Pediatrics** 1999 Feb;103(2):495–7. Comment on: Pediatrics 1998 Sep;102(3 Pt 1):531–7. Comment on: Pediatrics 1998 Sep;102(3 Pt 1):648–51.
Serial lumbar tapping to prevent posthaemorrhagic hydrocephalus after intracranial haemorrhage in preterm infants. Müller W, et al. **Wien Klin Wochenschr** 1998 Oct 2;110(18):631–4
[The use of Curosurf with premature infants--the prevention or treatment of the neonatal RDS] Iarükova N, et al. **Akush Ginekol (Sofiia)** 1998;37(3):12–4 (Eng. Abstr.) **(Bul)**
[The effect of antenatal corticosteroid prophylaxis in premature newborns with the use of surfactant therapy] Iarükova N, et al. **Akush Ginekol (Sofiia)** 1998;37(2):20–3 (Eng. Abstr.) **(Bul)**
[The prevention of anemia in premature infants: the role of recombinant human erythropoietin in a level III neonatology department (letter)] Klosowski S, et al. **Arch Pediatr** 1999 May;6(5):592–4 **(Fre)**
[A method for reducing the risk of infection in newborn and premature infants with stomas] Schäfer K, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1172–4 (Eng. Abstr.) **(Ger)**
[Preterm premature rupture of membranes in the 19th week of pregnancy. A clinical case] Bastianelli C, et al. **Minerva Ginecol** 1999 Apr;51(4):139–43 (Eng. Abstr.) **(Ita)**
[Immunological imbalance in the newborn infant and its correction in a system to prevent neonatal morbidity and infant mortality] Blokhina IN, et al. **Vestn Ross Akad Med Nauk** 1999;(5):37–40 (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

A preterm infant with knee swelling. Bettencourtt HL. **Clin Pediatr (Phila)** 1999 Jan;38(1):45–7
Neonatal hepatic abscess. Vade A, et al. **Comput Med Imaging Graph** 1998 Jul-Aug;22(4):357–9
Unusual site for oesophageal perforation in an extremely low birth weight infant. Cairns PA, et al. **Eur J Pediatr** 1999 Feb;158(2):152–3 (5 ref.)
Radiological pulmonary changes during gram-negative bacillary nosocomial bloodstream infection in premature infants. Cordero L, et al. **J Perinatol** 1998 Jul-Aug; 18(4):291–6
High-resolution CT findings in Wilson-Mikity syndrome: a case report. Reittner P, et al. **Pediatr Radiol** 1998 Sep; 28(9):691–3

SURGERY

Transseptal illumination in endoscopic fenestration of septum pellucidum in the new-born. Hennig R, et al. **Acta Neurochir (Wien)** 1998;140(9):989–90
Postoperative outcome in high-risk infants undergoing herniorrhaphy: comparison between spinal and general anaesthesia. Somri M, et al. **Anaesthesia** 1998 Aug; 53(8):762–6
Cardiac pacing in premature infants and neonates: steroid eluting leads and automatic output adaptation. Schmid FX, et al. **Ann Thorac Surg** 1999 May;67(5):1400–2
Subtotal cystectomy as a complication of infant hernia repair. Koot VC, et al. **Eur J Surg** 1998 Nov;164(11):873–4
Is surgical closure of patent ductus arteriosus a safe procedure in premature infants? Russell JL, et al. **Int Surg** 1998 Oct-Dec;83(4):358–60
Extensor tendon lacerations in a preterm neonate. Fuller DA, et al. **J Hand Surg [Am]** 1999 May;24(3):628–32
Multiple atresias in a low-birth-weight twin. Benson JM, et al. **J Pediatr Surg** 1999 Jun;34(6):1040–2
Early repair of inguinal hernia in premature babies. Uemura S, et al. **Pediatr Surg Int** 1999;15(1):36–9
[Minimal flow anesthesia in newborn infants--advantages and risks] Gebhardt R, et al. **Anaesthesiol Reanim** 1999; 24(2):41–6 (Eng. Abstr.) **(Ger)**
[Laparoscopy in the newborn infant--indications and procedure] Doede T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:120–3 (Eng. Abstr.) **(Ger)**
[Duplication of the stomach as a rare cause of cystic epigastric tumor] Rudolph J, et al. **Zentralbl Chir** 1998; 123(7):850–4 (26 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Comparison of airway pressure-triggered and airflow-triggered ventilation in very immature infants. Dimitriou G, et al. **Acta Paediatr** 1998 Dec;87(12):1256–60
Effects of a prayer circle on a moribund premature infant. Springer SC, et al. **Altern Ther Health Med** 1999 Mar; 5(2):120, 115–8
Intraosseous lines in preterm and full term neonates. Ellemunter H, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F74–5
Impaired phagocytosis and opsonisation towards group B streptococci in preterm infants [letter; comment] Jaswon MS, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar; 80(2):F160. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Jan;78(1):F46–50.
Randomised controlled trial of trophic feeding and gut motility. McClure RJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F54–8
Prophylactic vs rescue surfactant and antenatal corticosteroids [letter; comment] Tyebkhan J, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F79–80. Comment on: Arch Dis Child Fetal Neonatal Ed 1997 Jul;77(1):F70–4.
Nasal high frequency ventilation in neonates with moderate respiratory insufficiency. van der Hoeven M, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F61–3
Home oxygen therapy for chronic lung disease in very low-birth-weight infants. Chang JH, et al. **Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih** 1998 Jul-Aug;39(4):237–41
Acrodermatitis enteropathica-like rash and enterocolitis. Granel F, et al. **Eur J Dermatol** 1998 Sep;8(6):445–6
Chronic respiratory morbidity following premature delivery--prediction by prolonged respiratory support requirement? Kinali M, et al. **Eur J Pediatr** 1999 Jun; 158(6):493–6
Mortality and neurodevelopmental outcome for infants receiving adrenaline in neonatal resuscitation. O'Donnell AI, et al. **J Paediatr Child Health** 1998 Dec;34(6):551–6
Variations in blood transfusions among newborn intensive care units. SNAP II Study Group [see comments] Bednarek FJ, et al. **J Pediatr** 1998 Nov;133(5):601–7. Comment in: J Pediatr 1998 Nov;133(5):589–90.
Practice variation: implications for neonatal red blood cell transfusions [editorial; comment] Donovan EF. **J Pediatr** 1998 Nov;133(5):589–90. Comment on: J Pediatr 1998 Nov;133(5):601–7.
Early feeding, feeding tolerance, and lactase activity in preterm infants. Shulman RJ, et al. **J Pediatr** 1998 Nov; 133(5):645–9
Randomized comparison of high-frequency ventilation with high-rate intermittent positive pressure ventilation in preterm infants with respiratory failure [see comments] Thome U, et al. **J Pediatr** 1999 Jul;135(1):39–46. Comment in: J Pediatr 1999 Jul;135(1):9–11.
High-frequency ventilation versus conventional ventilation: No winner-but no loser [editorial; comment] Truog WE. **J Pediatr** 1999 Jul;135(1):9–11 (10 ref.). Comment on: J Pediatr 1999 Jul;135(1):39–46.
The role of peritoneal drainage for intestinal perforation in infants with and without necrotizing enterocolitis. Rovin JD, et al. **J Pediatr Surg** 1999 Jan;34(1):143–7
Spontaneous minute ventilation predicts readiness for extubation in mechanically ventilated preterm infants. Wilson BJ Jr, et al. **J Perinatol** 1998 Nov-Dec;18(6 Pt 1):436–9
Balloon valvuloplasty of critical pulmonary valve stenosis in a premature neonate. Hofbeck M, et al. **Pediatr Cardiol** 1999 Mar-Apr;20(2):147–9
Role of rHuEpo on blood transfusions in preterm infants after the fifteenth day of life. Testa M, et al. **Pediatr Hematol Oncol** 1998 Sep-Oct;15(5):415–20
Acetazolamide and furosemide for posthemorrhagic hydrocephalus of the newborn. Libenson MH, et al. **Pediatr Neurol** 1999 Mar;20(3):185–91
Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device. Hudgins RJ, et al. **Pediatr Neurosurg** 1998 Dec;29(6):309–13
Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity. Lin CH, et al. **Pediatr Pulmonol** 1998 Nov;26(5):349–53
Early prediction of neonatal chronic lung disease: a comparison of three scoring methods. Yoder BA, et al. **Pediatr Pulmonol** 1999 Jun;27(6):388–94
Strategy for the prevention and treatment of chronic lung disease of the premature infant. Ogawa Y, et al. **Pediatr Pulmonol Suppl** 1999;18:212–5 (15 ref.)
Congenital cystic adenoid malformation in a pre-term infant: management considerations. Prendergast B, et al. **Pediatr Surg Int** 1998 Nov;14(1-2):92–3
[Clinical evaluation on parenteral nutrition in neonatal disease] Li J, et al. **Hunan I Ko Ta Hsueh Hsueh Pao** 1997; 22(6):527–9, 532 (Eng. Abstr.) **(Chi)**
-Development and evaluation of transfusion practices in a population of newborn infants less than 33 weeks gestational age (letter)- Pierrat V, et al. **Arch Pediatr** 1998 Mar;5(3):341–2 **(Fre)**
[Blood transfusion in very premature infants (letter)] Velin P, et al. **Arch Pediatr** 1998 Aug;5(8):935–6 **(Fre)**
[Prematurity and cerebral lesions] Vermeylen D. **Rev Med Brux** 1999 Jun;20(3):A170 **(Fre)**
[Pulmonary function tests as a predictor of chronic lung disease in ventilated preterm infants] Tortorolo L, et al. **Minerva Pediatr** 1998 May;50(5):151–6 (Eng. Abstr.) **(Ita)**
[Attitudes towards treatment of extremely premature infants in Norwegian obstetric and pediatric departments] Kvestad E, et al. **Tidsskr Nor Laegeforen** 1999 Aug 30; 119(20):3015–8 (Eng. Abstr.) **(Nor)**

ULTRASONOGRAPHY

Nonobstructive cor triatriatum in infancy. Geggel RL, et al. **Clin Pediatr (Phila)** 1999 Aug;38(8):489–91
Infective endocarditis in the premature neonate. Pearlman SA, et al. **Clin Pediatr (Phila)** 1998 Dec;37(12):741–6
A critical review of cranial ultrasounds: is there a closer association between intraventricular blood, white matter abnormalities or cysts, and cerebral palsy? Weiss HE, et al. **Clin Pediatr (Phila)** 1999 Jun;38(6):319–23
White matter disorders of prematurity: association with intraventricular hemorrhage and ventriculomegaly. The Developmental Epidemiology Network [see comments] Kuban K, et al. **J Pediatr** 1999 May;134(5):539–46. Comment in: J Pediatr 1999 May;134(5):527–9.
Sonographic demonstration of a congenital laryngeal cyst. Shita L, et al. **J Ultrasound Med** 1999 Sep;18(9):665–7
Perinatal events and the risk of intraparenchymal echodensity in very-low-birthweight neonates. O'Shea TM, et al. **Paediatr Perinat Epidemiol** 1998 Oct;12(4):408–21
Hyperechoic foci in the thalamic region imaged via the posterior fontanelle: a potential mimic of thalamic pathology. Schlesinger AE, et al. **Pediatr Radiol** 1999 Jul; 29(7):520–3
A new pattern of cerebellar hemorrhages in preterm infants. Merrill JD, et al. **Pediatrics** 1998 Dec;102(6):E62
[Subtotal thrombosis of the juxta-ductal thoracic aorta in a premature 36-week-old infant. Alteplase therapy] Di Bernardo S, et al. **Arch Mal Coeur Vaiss** 1999 May; 92(5):661–5 (Eng. Abstr.) **(Fre)**
[Effect of nitric oxide on the doppler profile of the anterior cerebral artery in the newborn (letter)] Patural H, et al. **Arch Pediatr** 1999 Jan;6(1):107 **(Fre)**
[Placenta morphology and Doppler ultrasound of umbilical cord vessels in premature infants] Weickert U, et al. **Zentralbl Gynakol** 1999;121(1):7–13 (Eng. Abstr.) **(Ger)**

VIROLOGY

Survival of a preterm neonate with late onset hydrops fetalis due to parvovirus B19 infection. McNamara PJ, et al. **Acta Paediatr** 1998 Oct;87(10):1088–9
Sequelae associated with cerebral candidiasis in two premature infants. Scott PA, et al. **Acta Paediatr** 1998 Oct; 87(10):1090–2

INFANT PSYCHOLOGY see **CHILD PSYCHOLOGY**

INFANT RADIANT WARMERS see **INCUBATORS, INFANT**

INFANT, SMALL FOR GESTATIONAL AGE

Cord blood insulin and C-peptide levels: correlations with birthweight [letter] Aygün C, et al. **Acta Paediatr** 1998 Oct; 87(10):1101-2

Physical and nonphysical partner abuse and other risk factors for low birth weight among full term and preterm babies: a multiethnic case-control study. Campbell J, et al. **Am J Epidemiol** 1999 Oct 1;150(7):714-26

Does inadequate prenatal care contribute to growth retardation among second-born African-American babies? McDermott JM, et al. **Am J Epidemiol** 1999 Oct 1; 150(7):706-13

Influence of perinatal factors on the onset of puberty in boys and girls: implications for interpretation of link with risk of long term diseases. Persson I, et al. **Am J Epidemiol** 1999 Oct 1;150(7):747-55

Environmental tobacco smoke exposure and small-for-gestational-age birth. Sadler L, et al. **Am J Epidemiol** 1999 Oct 1;150(7):695-705

Heavy physical work during pregnancy--a risk factor for small-for-gestational-age babies in Poland. Hanke W, et al. **Am J Ind Med** 1999 Jul;36(1):200-5

Maternal occupational exposure to chemical substances and the risk of infants small-for-gestational-age. Seidler A, et al. **Am J Ind Med** 1999 Jul;36(1):213-22

Ultrasonographic measurement of liver length in the small-for-gestational-age fetus. Roberts AB, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):634-8

Differences in respiratory metabolism during treatment of hypoglycemia in infants of diabetic mothers and small-for-gestational-age infants. Kinnala A, et al. **Am J Perinatol** 1998 Jun;15(6):363-7

Does passive smoking in early pregnancy increase the risk of small-for-gestational-age infants? Dejin-Karlsson E, et al. **Am J Public Health** 1998 Oct;88(10):1523-7

Preterm and term births of small for gestational age infants: a population-based study of risk factors among nulliparous women. Clausson B, et al. **Br J Obstet Gynaecol** 1998 Sep; 105(9):1011-7

Doppler fetal circulation in pregnancies complicated by pre-eclampsia or delivery of a small for gestational age baby: 2. Longitudinal analysis. Harrington K, et al. **Br J Obstet Gynaecol** 1999 May;106(5):453-66

Comparison of somatomedin-C (SMC/IGF-I), human placental lactogen and Doppler velocimetry between appropriate and small-for-gestational-age pregnancies. Stefanidis K, et al. **Clin Exp Obstet Gynecol** 1998; 25(1-2):20-2

Protein demand in the premature neonate and in the small for gestational age full-term neonate. Robles R, et al. **Early Hum Dev** 1998 Dec;53 Suppl:S15-21 (30 ref.)

Risk factor patterns for cryptorchidism and hypospadias [see comments] Akre O, et al. **Epidemiology** 1999 Jul;10(4):364-9 . Comment in: Epidemiology 1999 Jul;10(4):352-4.

Effects of short interpregnancy intervals on small-for-gestational age and preterm births. Shults RA, et al. **Epidemiology** 1999 May;10(3):250-4

School performance and behaviour in extremely preterm growth-retarded infants. Schaap AH, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Sep;86(1):43-9

Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A). Verspyck E, et al. **Eur J Obstet Gynecol Reprod Biol** 1999 Apr;83(2):143-4

Detection of small-for-gestational-age infants with poor perinatal outcomes using individualized growth assessment. Hata T, et al. **Gynecol Obstet Invest** 1999;47(3):162-5

Maternal education and risk factors for small-for-gestational-age births. Millar WJ, et al. **Health Rep** 1998 Autumn;10(2):43-51 (Eng); 47-56 (Fre) **(Eng, Fre)**

Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature. Van Erum R, et al. **Horm Res** 1998 Sep;50(3):141-6 (35 ref.)

Increased blood pressure in adolescents who were small for gestational age at birth: a cohort study in Brazil. Barros FC, et al. **Int J Epidemiol** 1999 Aug;28(4):676-81

Comparison of liveborn and stillborn low birthweight babies and analysis of aetiological factors. Geary M, et al. **Ir Med J** 1997 Nov;90(7):269-71

Human growth hormone treatment of short-stature children born small for gestational age: effect on muscle and adipose tissue mass during a 3-year treatment period and after 1 year's withdrawal. Leger J, et al. **J Clin Endocrinol Metab** 1998 Oct;83(10):3512-6

Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants [see comments] Duvanel CB, et al. **J Pediatr** 1999 Apr;134(4):492-8. Comment in: J Pediatr 1999 Apr;134(4):389-91.

Gestational age-specific normal birth weight for Japanese twins. Risk of early neonatal death in small-for-gestational-age and large-for-gestational-age twins. Minakami H, et al. **J Reprod Med** 1999 Jul; 44(7):625-9

Better born too soon than too small. Lagercrantz H. **Lancet** 1997 Oct 11;350(9084):1044-5

Birth weight in relation to morbidity and mortality among newborn infants. McIntire DD, et al. **N Engl J Med** 1999 Apr 22;340(16):1234-8

Intrapartum amniotic fluid index: a poor predictor of abnormal fetal size. Hendrix NW, et al. **Obstet Gynecol** 1998 Nov;92(5):823-7

Interpregnancy interval and disparity in term small for gestational age births between black and white women. James AT, et al. **Obstet Gynecol** 1999 Jan;93(1):109-12

Racial differences in birthweight for gestational age and infant mortality in extremely-low-risk US populations. Alexander GR, et al. **Paediatr Perinat Epidemiol** 1999 Apr; 13(2):205-17

Risk of death for small for gestational age very preterm infants [letter] Beeby PJ. **Pediatrics** 1998 Dec;102(6):1497-8

Muscularity and fatness of infants and young children born small- or large-for-gestational-age. Hediger ML, et al. **Pediatrics** 1998 Nov;102(5):E60

Screening for small-for-gestational-age newborns using serial symphysis-fundal measurements [letter] Pereira C da R, et al. **S Afr Med J** 1999 May;89(5):559-60

Bivariate logistic regression: modelling the association of small for gestational age births in twin gestations. Ananth CV, et al. **Stat Med** 1999 Aug 15;18(15):2011-23

Second-trimester measurements of placental volume by three-dimensional ultrasound to predict small-for-gestational-age infants. Hafner E, et al. **Ultrasound Obstet Gynecol** 1998 Aug;12(2):97-102

Prenatal diagnosis of a lean umbilical cord: a simple marker for the fetus at risk of being small for gestational age at birth [see comments] Raio L, et al. **Ultrasound Obstet Gynecol** 1999 Mar;13(3):176-80. Comment in: Ultrasound Obstet Gynecol 1999 Mar;13(3):157-60.

[Small for gestational age: risk factor for neonatal mortality] de Almeida MF, et al. **Rev Saude Publica** 1998 Jun; 32(3):217-24 (Eng. Abstr.) **(Por)**

BLOOD

Growth hormone, insulin-like growth factor-I and insulin-like growth factor binding protein-3 are regulated differently in small-for-gestational-age and appropriate-for-gestational-age neonates. Cance-Rouzaud A, et al. **Biol Neonate** 1998;73(6):347-55

Adrenal steroid hormones in short children born small for gestational age. Dahlgren J, et al. **Clin Endocrinol (Oxf)** 1998 Sep;49(3):353-61

Plasma and red blood cell fatty acid composition in small for gestational age term infants fed human milk or formula. Ramirez M, et al. **Clin Nutr** 1998 Aug;17(4):177-83

Neonatal hypoglycemia: a little goes a long way [letter; comment] Cowett RM. **J Pediatr** 1999 Apr;134(4):389-91 (17 ref.). Comment on: J Pediatr 1999 Apr;134(4):492-8.

Altered cord serum lipid levels associated with small for gestational age infants. Jones JN, et al. **Obstet Gynecol** 1999 Apr;93(4):527-31

[Somatotropin function in term and premature newborns during the first month of life] Radetti G, et al. **Arch Pediatr** 1998;5 Suppl 4:338S-344S (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Age of introduction of complementary foods and growth of term, low-birth-weight, breast-fed infants: a randomized intervention study in Honduras. Dewey KG, et al. **Am J Clin Nutr** 1999 Apr;69(4):679-86

Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. Hediger ML, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1225-31

Temporal organization of fetal behavior from 24-weeks gestation onwards in normal and complicated pregnancies. Nijhuis IJ, et al. **Dev Psychobiol** 1999 May;34(4):257-68

Increased energy expenditure and fecal fat excretion do not impair weight gain in small-for-gestational-age preterm infants. Böhler T, et al. **Early Hum Dev** 1999 Apr; 54(3):223-34

The neurodevelopmental outcome of term infants with different intrauterine growth characteristics. Roth S, et al. **Early Hum Dev** 1999 May;55(1):39-50

Children born small-for-gestational age: postnatal growth and hormonal status. Albertsson-Wikland K, et al. **Horm Res** 1998;49 Suppl 2:7-13

Growth and fatness at three to six years of age of children born small- or large-for-gestational age. Hediger ML, et al. **Pediatrics** 1999 Sep;104(3):e33

Length and body mass index at birth and target height influences on patterns of postnatal growth in children born small for gestational age. Luo ZC, et al. **Pediatrics** 1998 Dec;102(6):E72

Small for gestational age is not a diagnosis [editorial] Soothill PW, et al. **Ultrasound Obstet Gynecol** 1999 Apr;13(4):225-8 (27 ref.)

METABOLISM

System A amino acid transporter activity in human placental microvillous membrane vesicles in relation to various anthropometric measurements in appropriate and small for gestational age babies. Harrington B, et al. **Pediatr Res** 1999 Jun;45(6):810-4

PHYSIOLOGY

The effect of theophylline on apnoea and hypoxaemic episodes in the premature neonate during the 1st 3 days after birth. du Preez MJ, et al. **Ann Trop Paediatr** 1998 Sep;18(3):217-24

Multiple hormone resistance in short children born with intrauterine growth retardation? Chatelain PG, et al. **Horm Res** 1998;49 Suppl 2:20-2 (26 ref.)

Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. de Zegher F, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1558-61

PSYCHOLOGY

Predicting infant temperament from neonatal reactivity for AGA/SGA twin pairs. Riese ML. **Twin Res** 1998 Jun; 1(2):65-70

INFANT STROLLERS see **INFANT EQUIPMENT**

INFANT SWINGS see **INFANT EQUIPMENT**

INFANT, VERY LOW BIRTH WEIGHT

Morbidity and neurological function of very low birthweight infants from the newborn period to 4 y of age. A prospective study from the south-east region of Sweden. Bylund B, et al. **Acta Paediatr** 1998 Jul;87(7):758-63

Late death of very low birthweight infants. Fillmore EJ, et al. **Acta Paediatr** 1998 Jul;87(7):809-10

Neurosensory outcome and growth at three years in extremely low birthweight infants: follow-up results from the Swedish national prospective study. Finnström O, et al. **Acta Paediatr** 1998 Oct;87(10):1055-60

Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study. Huon C, et al. **Acta Paediatr** 1998 Nov; 87(11):1180-4

Nursery Neurobiologic Risk Score and outcome at 18 months. Lefebvre F, et al. **Acta Paediatr** 1998 Jul; 87(7):751-7

Short interpregnancy intervals and the risk of adverse birth outcomes among five racial/ethnic groups in the United States. Khoshnood B, et al. **Am J Epidemiol** 1998 Oct 15; 148(8):798-805

Obstetric determinants of neonatal survival: antenatal predictors of neonatal survival and morbidity in extremely low birth weight infants. Bottoms SF, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):665-9

Benefits of maternal corticosteroid therapy in infants weighing </=1000 grams at birth after preterm rupture of the amnion. Chapman SJ, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):677-82

Indicated versus spontaneous preterm delivery: An evaluation of neonatal morbidity among infants weighing </=1000 grams at birth. Kimberlin DF, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):683-9

Racial patterns in the effects of tobacco use on fetal growth. Sprauve ME, et al. **Am J Obstet Gynecol** 1999 Jul; 181(1):S22-7

Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Stevenson DK, et al. **Am J Obstet Gynecol** 1998 Dec;179(6 Pt 1):1632-9

Has the outcome for extremely low gestational age (ELGA) infants improved following recent advances in neonatal intensive care? Battin M, et al. **Am J Perinatol** 1998 Aug; 15(8):469-77

Obstetrical determinants of neonatal neurological morbidity in < or = 1000-gram infants. Goepfert AR, et al. **Am J Perinatol** 1999;16(1):33-42

The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. Kimberlin DF, et al. **Am J Perinatol** 1998;15(11):635-41

Effect of preeclampsia on mortality, intraventricular hemorrhage, and need for mechanical ventilation in very low-birth-weight infants. Paul DA, et al. **Am J Perinatol** 1998 Jun;15(6):381-6

Leukemoid reaction in extremely low-birth-weight infants. Rastogi S, et al. **Am J Perinatol** 1999;16(2):93-7

Trends in incidence of cranial ultrasound lesions and cerebral palsy in very low birthweight infants 1982-93. Cooke RW. **Arch Dis Child Fetal Neonatal Ed** 1999 Mar;80(2):F115-7

Randomised, controlled trial of nasal continuous positive airway pressure in the extubation of infants weighing 600 to 1250 g. Davis P, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F54-7

Cognitive, educational and behavioural outcomes at 7 to 8 years [letter; comment] Horwood J, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F78. Comment on: Arch Dis Child Fetal Neonatal Ed 1998 Jul;79(1):F12-20.

Cognitive, educational, and behavioural outcomes at 7 to 8 years in a national very low birthweight cohort [see comments] Horwood LJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1998 Jul;79(1):F12-20. Comment in: Arch Dis Child Fetal Neonatal Ed 1999 Jan;80(1):F78.

Association of blood pressure in adolescence with birthweight. Pharoah PO, et al.

Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F114–8
Artificial neural network for risk assessment in preterm neonates. Zernikow B, et al.
Arch Dis Child Fetal Neonatal Ed 1998 Sep;79(2):F129–34
Mechanisms of blood pressure increase induced by dopamine in hypotensive preterm neonates. Zhang J, et al.
Arch Dis Child Fetal Neonatal Ed 1999 Sep;81(2):F99–F104
Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Redline RW, et al. **Arch Pathol Lab Med** 1998 Dec;122(12):1091–8
Maternal birthplace, ethnicity, and low birth weight in California. Fuentes-Afflick E, et al.
Arch Pediatr Adolesc Med 1998 Nov;152(11):1105–12
Pulmonary hemorrhage: clinical course and outcomes among very low-birth-weight infants. Tomaszewska M, et al.
Arch Pediatr Adolesc Med 1999 Jul;153(7):715–21
Severe pulmonary hemorrhage in the premature newborn infant: analysis of presurfactant and surfactant eras. Braun KR, et al. **Biol Neonate** 1999;75(1):18–30
Complications of airway management in very-low-birth-weight infants. da Silva O, et al.
Biol Neonate 1999;75(1):40–5
Early nasal continuous positive airway pressure and minimal handling in the treatment of very-low-birth-weight infants. Kamper J. **Biol Neonate** 1999 Jun;76 Suppl 1:22–8 (34 ref.)
Neonatal viability in the 1990s: held hostage by technology. Muraskas J, et al. **Camb Q Healthc Ethics** 1999 Spring; 8(2):160–70; discussion 170–2 (43 ref.)
The use of prophylactic intravenous immunoglobulin therapy in very low birthweight infants. Chou YH, et al.
Chang Keng I Hsueh Tsa Chih 1998 Dec;21(4):371–6
Home oxygen therapy for chronic lung disease in very low-birth-weight infants. Chang JH, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1998 Jul–Aug;39(4):237–41
Influence of perinatal factors on limit of viability in extremely low birth weight infants. Su BH, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1999 Mar–Apr;40(2):87–91
Effect of erythromycin on feeding intolerance in very low birth weight infants: a preliminary observation. Su BH, et al.
Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1998 Sep–Oct;39(5):324–6
Comparative study of mortality and morbidity in premature infants (birth weight, < 1,250 g) with candidemia or candidal meningitis. Lee BE, et al. **Clin Infect Dis** 1998 Sep;27(3):559–65
Necrosis related to the use of pulse oximetry in a very-low-birth-weight infant [letter] Botet F, et al.
Clin Pediatr (Phila) 1999 May;38(5):317
Cranial sonography in very-low-birth-weight infants: do all infants need to be screened? Paul DA, et al.
Clin Pediatr (Phila) 1999 Sep;38(9):503–9
Head circumference in ELBW babies is associated with learning difficulties and cognition but not ADHD in the school-aged child. Stathis SL, et al.
Dev Med Child Neurol 1999 Jun;41(6):375–80
Outcomes of children of extremely low birthweight and gestational age in the 1990's. Hack M, et al.
Early Hum Dev 1999 Jan;53(3):193–218 (143 ref.)
Mechanisms initiating lung injury in the preterm. Jobe AH, et al. **Early Hum Dev** 1998 Nov;53(1):81–94 (66 ref.)
Frequency and risk factors in bronchopulmonary dysplasia in a cohort of very low birth weight infants. Korhonen P, et al. **Early Hum Dev** 1999 Apr;54(3):245–58
Successful use of an intraosseous infusion in an 800 grams preterm infant. Ramet J, et al. **Eur J Emerg Med** 1998 Sep; 5(3):327–8
Neonatal outcome of inborn and transported very-low-birth-weight infants: relevance of perinatal factors. Arad I, et al.
Eur J Obstet Gynecol Reprod Biol 1999 Apr;83(2):151–7
Unusual site for oesophageal perforation in an extremely low birth weight infant. Cairns PA, et al. **Eur J Pediatr** 1999 Feb;158(2):152–3 (5 ref.)
Oral iron is sufficient for erythropoietin treatment of very low birth-weight infants. Kivivuori SM, et al.
Eur J Pediatr 1999 Feb;158(2):147–51
Prevention of necrotizing enterocolitis in extremely low birth weight infants by IgG feeding? Richter D, et al.
Eur J Pediatr 1998 Nov;157(11):924–5
Early prediction of chronic lung disease by tracheal aspirate cytology in ventilated newborns. Smets K, et al.
Eur J Pediatr 1999 Mar;158(3):234–7
Guided participation and development of care-giving competencies for families of low birth-weight infants. Pridham KF. **J Adv Nurs** 1998 Nov;28(5):948–58
Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. Hughes CA, et al. **J Dev Behav Pediatr** 1999 Feb;20(1):1–8
An investigation of social and class differences in very-low birth weight outcomes: a continuing public health concern. Longo DR, et al. **J Health Care Finance** 1999 Spring; 25(3):75–89
Prediscbarge screening of very low birthweight infants by click evoked otoacoustic emissions. Gill AW, et al.
J Paediatr Child Health 1998 Oct;34(5):456–9
A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. Cairo MS, et al.
J Pediatr 1999 Jan;134(1):64–70
The outcome of very low birth weight neonates (</=1500 g) rescued by inhaled nitric oxide: neurodevelopment in early childhood [see comments] Cheung PY, et al.
J Pediatr 1998 Dec;133(6):735–9. Comment in: J Pediatr 1998 Dec;133(6):720–2.
Small thymus in very low birth weight infants born to mothers with subclinical chorioamnionitis. De Felice C, et al. **J Pediatr** 1999 Sep;135(3):384–6
The Child Development Inventory: A developmental outcome measure for follow-up of the high-risk infant. Doig KB, et al. **J Pediatr** 1999 Sep;135(3):358–62
Erythropoietin and iron therapy for preterm infants [letter; comment] Kumar P. **J Pediatr** 1999 Apr;134(4):520–2. Comment on: J Pediatr 1998 May;132(5):866–70.
Randomized trial of "slow" versus "fast" feed advancements on the incidence of necrotizing enterocolitis in very low birth weight infants. Rayyis SF, et al. **J Pediatr** 1999 Mar; 134(3):293–7
Maternal psychological distress and parenting stress after the birth of a very low-birth-weight infant. Saigal S.
J Pediatr 1999 Sep;135(3):397
Effect of pulsed dexamethasone therapy on tolerance of intravenously administered lipids in extremely low birth weight infants. Sentipal-Walerius J, et al. **J Pediatr** 1999 Feb;134(2):229–32
Erythropoietin and iron therapy for preterm infants [letter; comment] Vento M, et al. **J Pediatr** 1999 Apr;134(4):520; discussion . 521–2. Comment on: J Pediatr 1998 May;132(5):866–70.
Effect of polyethylene occlusive skin wrapping on heat loss in very low birth weight infants at delivery: a randomized trial [see comments] Vohra S, et al. **J Pediatr** 1999 May; 134(5):547–51. Comment in: J Pediatr 1999 May;134(5):529–31.
Ophthalmologic findings in very low birth weight infants [letter] Asproudis I, et al.
J Pediatr Ophthalmol Strabismus 1998 Jul–Aug;35(4):196–7
Predicting chronic lung disease in very low birthweight infants: comparison of 3 scores. Hentschel J, et al.
J Perinat Med 1998;26(5):378–83
Postnatal change of renal artery blood flow velocity and its relationship with urine volume in very low birth weight infants during the first month of life. Kusuda S, et al.
J Perinat Med 1999;27(2):107–11
Increased survival in low birth weight neonates given prophylactic surfactant. Brown DR, et al. **J Perinatol** 1998 Nov–Dec;18(6 Pt 1):431–5
Very low birth weight infants and their families during the first year of life: comparisons of medical outcomes based on after care services. Finello KM, et al. **J Perinatol** 1998 Sep–Oct;18(5):365–71
Very low birth weight infants and their families during the first year of life: comparisons of psychosocial outcomes based on after-care services. Finello KM, et al.
J Perinatol 1998 Jul–Aug;18(4):266–71
Accelerated discharge of low birth weight infants from neonatal intensive care: a randomized, controlled trial. The Early Discharge Study Group. Gibson E, et al.
J Perinatol 1998 Nov–Dec;18(6 Pt 2 Su):S17–23
Resuscitation of a micropremie: the case of MacDonald versus Milleville [letter; comment] Goldsmith JP, et al.
J Perinatol 1998 Nov–Dec;18(6 Pt 1):502. Comment on: J Perinatol 1998 Jul–Aug;18(4):302–5.
Impact of the perception of viability on resource allocation in the neonatal intensive care unit. Sanders MR, et al.
J Perinatol 1998 Sep–Oct;18(5):347–51
Predictors of breastfeeding in very low birthweight infants at the time of discharge from hospital. Boo NY, et al.
J Trop Pediatr 1999 Aug;45(4):195–201
Relationship between CRIB score and intraventricular haemorrhage in very low birthweight infants [letter] Manzar S. **J Trop Pediatr** 1999 Aug;45(4):252–3
Maternal psychological distress and parenting stress after the birth of a very low-birth-weight infant. Singer LT, et al.
JAMA 1999 Mar 3;281(9):799–805
Enteral glutamine supplementation for very-low-birth-weight infants decreases hospital costs. Dallas MJ, et al. **JPEN J Parenter Enteral Nutr** 1998 Nov–Dec;22(6):352–6
Low 1-year prevalence of atopic eczema in very low birthweight infants [letter] Bührer C, et al. **Lancet** 1999 May 15;353(9165):1674
Survival after being born too soon, but at what cost? Skuse D. **Lancet** 1999 Jul 31;354(9176):354–5
Telematics in the neonatal ICU and beyond: improving care, communication and information sharing. Gray J, et al.
Medinfo 1998;9 Pt 1:294–7
The effect of a neonatal telecardiology system on respiratory therapy in very low birthweight infants. Rendina MC, et al. **Medinfo** 1998;9 Pt 1:298–301
Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. Tyson JE, et al. **N Engl J Med** 1999 Jun 24;340(25):1962–8
Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Alexander JM, et al.
Obstet Gynecol 1999 Apr;93(4):485–8
Influence of chorioamnionitis on developmental outcome in very low birth weight infants. Dexter SC, et al.
Obstet Gynecol 1999 Aug;94(2):267–73
Management of extremely low birth weight infants: perceptions of viability and parental counseling practices. Martinez AM, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 1):520–4
The relationship between Caesarean section and neonatal mortality in very-low-birthweight infants born in Washington State, USA. Jonas HA, et al.
Paediatr Perinat Epidemiol 1999 Apr;13(2):170–89
Changes in the registration of stillbirths < 500 g in Canada, 1985–95. Fetal-Infant Mortality Study Group of the Canadian Perinatal Surveillance System. Joseph KS, et al.
Paediatr Perinat Epidemiol 1999 Jul;13(3):278–87
Perinatal events and the risk of intraparenchymal echodensity in very-low-birthweight neonates. O'Shea TM, et al.
Paediatr Perinat Epidemiol 1998 Oct;12(4):408–21
Association of fungal colonization and invasive disease in very low birth weight infants. Huang YC, et al.
Pediatr Infect Dis J 1998 Sep;17(9):819–22
Prenatal and postnatal histories of very low birthweight infants who developed hepatoblastoma. Maruyama K, et al. **Pediatr Int** 1999 Feb;41(1):82–9
Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Leitch CA, et al.
Pediatr Res 1999 Jul;46(1):109–13
17Beta-estradiol and progesterone supplementation in extremely low-birth-weight infants. Trotter A, et al.
Pediatr Res 1999 Apr;45(4 Pt 1):489–93
Subcapsular hemorrhage of the liver in a very-low-birth-weight neonate: survival after decompression laparotomy. Kosumi T, et al.
Pediatr Surg Int 1999;15(3–4):270–1 (15 ref.)
Babies born with major disabilities [editorial; comment] Myers NA. **Pediatr Surg Int** 1999 Jul;15(5–6):301–2. Comment on: Pediatr Surg Int 1999 Jul;15(5–6):303–9.
Causes of death in the extremely low birth weight infant. Barton L, et al. **Pediatrics** 1999 Feb;103(2):446–51
Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial. Brown MS, et al.
Pediatrics 1999 Aug;104(2 Pt 1):210–5
Atypical chronic lung disease patterns in neonates. Charafeddine L, et al. **Pediatrics** 1999 Apr;103(4 Pt 1):759–65
Cardiopulmonary resuscitation in the very low birth weight infant: the Vermont Oxford Network experience. Finer NN, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):428–34
Intact survival in extremely low birth weight infants after delivery room resuscitation. Finer NN, et al. **Pediatrics** 1999 Oct;104(4):e40
Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. Fuloria M, et al.
Pediatrics 1998 Dec;102(6):1401–6
A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Garland JS, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):91–9
The Vermont Oxford Network: evidence-based quality improvement for neonatology. Horbar JD. **Pediatrics** 1999 Jan;103(1 Suppl E):350–9 (49 ref.)
Randomized placebo-controlled trial of a 42-Day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Kothadia JM, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):22–7
Delivery room management of extremely low birth weight infants: spontaneous breathing or intubation? Lindner W, et al. **Pediatrics** 1999 May;103(5 Pt 1):961–7
The etiology and outcome of cerebral ventriculomegaly at term in very low birth weight preterm infants. Ment LR, et al. **Pediatrics** 1999 Aug;104(2 Pt 1):243–8
Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. O'Shea TM, et al. **Pediatrics** 1999 Jul;104(1 Pt 1):15–21
Measuring the cost of neonatal and perinatal care. Rogowski J. **Pediatrics** 1999 Jan;103(1 Suppl E):329–35
Myoclonic movements in very low birth weight premature infants associated with midazolam intravenous bolus administration [letter] Waisman D, et al. **Pediatrics** 1999 Sep;104(3 Pt 1):579
Population-based study of chronic lung disease in very low birth weight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association. Young TE, et al. **Pediatrics** 1999 Aug; 104(2):e17
Conceptualizing child health status: observations from studies of very premature infants. McCormick MC.
Perspect Biol Med 1999 Spring;42(3):372–86 (57 ref.)
Baby CareLink: development and implementation of a WWW-based system for neonatal home telemedicine. Gray J, et al. **Proc AMIA Symp** 1998;:351–5
The effect of telemedicine on neonatal intensive care unit length of stay in very low birthweight infants. Rendina MC. **Proc AMIA Symp** 1998;:111–5
Central nervous system candidiasis in very low-birth-weight premature neonates and infants: US characteristics and histopathologic and MR imaging correlates in five patients. Huang CC, et al. **Radiology** 1998 Oct;209(1):49–56
Anesthesia for the micropremie. Spaeth JP, et al.
Semin Perinatol 1998 Oct;22(5):390–401 (50 ref.)
Early-onset intraventricular hemorrhage in preterm neonates: incidence of neurodevelopmental handicap. Vohr B, et al. **Semin Perinatol** 1999 Jun;23(3):212–7

Diagnosis of DIC in very low birth weight infants. Shirahata A, et al. **Semin Thromb Hemost** 1998;24(5):467–71
Infantile esotropia in very low birth weight (VLBW) children. Pott JW, et al. **Strabismus** 1999 Jun;7(2):97–102
Prospective study of New Zealand infants with birth weight less than 1500 g and screened for retinopathy of prematurity: visual outcome at age 7–8 years. Saunders RA. **Surv Ophthalmol** 1999 Jan–Feb;43(4):373–4
Accuracy of sonographic estimates of fetal weight in very small infants. Kaaij MW, et al.
Ultrasound Obstet Gynecol 1999 Feb;13(2):99–102
[Incidence, evolution and prognosis of posthemorrhagic ventriculomegaly in a population of newborns of less than 33 weeks gestational age] Pierrat V, et al. **Arch Pediatr** 1998 Sep;5(9):974–81 (Eng. Abstr.) **(Fre)**
[Prognosis of newborns "at risk": cognitive disorders, motor disorders, difficulties in school and behavior disorders] Christiaens F, et al. **Rev Med Brux** 1999 Jun;20(3):A173–4 **(Fre)**
[Follow-up of premature infants weighing less than 1500 grams] Franco P, et al. **Rev Med Brux** 1999 Jun; 20(3):A171–2 **(Fre)**
[A comparative study about the therapeutic effect of theophylline and doxapram in apnoeic disorders] Möller JC, et al. **Klin Padiatr** 1999 Mar–Apr;211(2):86–91 (Eng. Abstr.) **(Ger)**
[Effect of dexamethasone and spironolactone therapy in calcium and phosphate homeostasis in premature infants with a birth weight under 1,500 g] Sonntag J, et al.
Klin Padiatr 1998 Sep–Oct;210(5):354–7 (Eng. Abstr.) **(Ger)**
[Basic patterns of learning disability: follow-up study of very low birth weight children] Ishikawa M.
No To Hattatsu 1999 May;31(3):229–36 (Eng. Abstr.) **(Jpn)**
[Children with birth weight 1500 g or under from Troms and Finnmark in the period 1978–1989] Dahl LB, et al. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):180–5 (Eng. Abstr.) **(Nor)**
[Attitudes towards treatment of extremely premature infants in Norwegian obstetric and pediatric departments] Kvestad E, et al. **Tidsskr Nor Laegeforen** 1999 Aug 30; 119(20):3015–8 (Eng. Abstr.) **(Nor)**
[Children with birth weight 1500 g or under from Nordland in the period 1978–1989] Weidle B, et al.
Tidsskr Nor Laegeforen 1999 Jan 20;119(2):189–93 (Eng. Abstr.) **(Nor)**
[Low birth weight of newborns in industrial region: an analysis of ways of delivery in years 1972–1996] Zak P, et al. **Ginekol Pol** 1998 Dec;69(12):1062–6 (Eng. Abstr.) **(Pol)**
[Importance of J. Brazy's neurobiological index. Prediction of the number and severity of complications in very low birth weight infants] Nunes A, et al. **Acta Med Port** 1998 Jul;11(7):615–21 (Eng. Abstr.) **(Por)**
[Neonatal viability and resuscitation in preterm newborns with an extremely low birth weight] García-Alix Pérez A, et al. **An Esp Pediatr** 1999 Jun;50(6):594–602 (64 ref.) **(Spa)**
[Continuous insulin perfusion in preterm infants with weight less than 1,500 grams who receive parenteral nutrition (letter)] Tejera Ramirez C, et al. **An Esp Pediatr** 1998 Aug; 49(2):213–5 **(Spa)**
[Efficacy of early erythropoietin use in critically ill, very-low-birthweight premature newborn infants: controlled clinical trial] Lima-Rogel V, et al.
Sangre (Barc) 1998 Jun;43(3):191–5 (Eng. Abstr.) **(Spa)**
[An extensive study indicates good prognosis for children with extremely low birth weight] Finnström O, et al.
Lakartidningen 1999 Mar 31;96(13):1560–2, 1565–7 **(Swe)**
[Our responsibility to the smallest. Care for the extremely premature is a technology beneficial to the entire neonatal care] Lagercrantz H. **Lakartidningen** 1999 Mar 31; 96(13):1540–2 **(Swe)**
[More active measures to increase survival in 24 week old gestation infants] Tunell R. **Lakartidningen** 1999 Mar 31; 96(13):1568–9 **(Swe)**

BLOOD

HFE gene mutation and transferrin saturation in very low birthweight infants. Maier RF, et al.
Arch Dis Child Fetal Neonatal Ed 1999 Sep;81(2):F144–5
Serum bilirubin and development of chronic lung disease in very low birth weight infants [letter] Schrod L, et al.
Eur J Pediatr 1999 Feb;158(2):169–70
Hypothyroxinemia in premature infants: is thyroxine treatment necessary? Fisher DA. **Thyroid** 1999 Jul; 9(7):715–20 (40 ref.)
[The dynamics of the alpha 1-protease inhibitor and alpha 2-macroglobulin in very-low-birth-weight newborns] Porozhanova V, et al. **Akush Ginekol (Sofiia)** 1998; 37(3):21–3 (Eng. Abstr.) **(Bul)**

GROWTH & DEVELOPMENT

Predictors of early school age outcomes in very low birth weight children. Taylor HG, et al.
J Dev Behav Pediatr 1998 Aug;19(4):235–43
The influence of growth on development outcome in extremely low birthweight infants at 2 years of age. Connors JM, et al. **J Paediatr Child Health** 1999 Feb; 35(1):37–41
Neurodevelopmental outcome of very low birth weight babies admitted to a Malaysian nursery. Ho JJ, et al.
J Paediatr Child Health 1999 Apr;35(2):175–80
Transverse cerebellar diameter on cranial ultrasound scan in preterm neonates in an Australian population. Swaminathan M, et al. **J Paediatr Child Health** 1999 Aug; 35(4):346–9
Inaccuracy of Ballard scores before 28 weeks' gestation. National Institute of Child Health and Human Development Neonatal Research Network [see comments] Donovan EF, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):147–52 . Comment in: J Pediatr 1999 Aug;135(2 Pt 1):137–9.
The coming of (gestational) age for preterm infants [editorial; comment] Sola A, et al. **J Pediatr** 1999 Aug;135(2 Pt 1):137–9. Comment on: J Pediatr 1999 Aug;135(2 Pt 1):147–50.
Nutrient intakes and growth of very low birth weight infants. Carlson SJ, et al. **J Perinatol** 1998 Jul–Aug;18(4):252–8
The timing of skin acidification in very low birth weight infants. Fox C, et al. **J Perinatol** 1998 Jul–Aug;18(4):272–5
The efficacy of developmentally sensitive interventions and sucrose for relieving procedural pain in very low birth weight neonates. Stevens B, et al. **Nurs Res** 1999 Jan–Feb; 48(1):35–43
Estimated nutritional intake based on the reference growth curves for extremely low birthweight infants. Itabashi K, et al. **Pediatr Int** 1999 Feb;41(1):70–7
Early childhood neurodevelopment in very low birth weight infants with predischarge apnea. Cheung PY, et al.
Pediatr Pulmonol 1999 Jan;27(1):14–20
Changes in lung function between age 8 and 14 years in children with birth weight of less than 1,501 g. Doyle LW, et al. **Pediatr Pulmonol** 1999 Mar;27(3):185–90
Neurodevelopment until the adjusted age of 2 years in extremely low birth weight infants after early intervention--a case-control study. Salokorpi T, et al.
Pediatr Rehabil 1998 Oct–Dec;2(4):157–63

PHYSIOLOGY

Effect of body position on tidal volume and minute ventilation in very low birthweight infants. Itakura Y, et al. **Acta Paediatr Jpn** 1998 Dec;40(6):555–7
Neuromotor ability in 5- to 7-year-old children with very low or extremely low birthweight. Keller H, et al.
Dev Med Child Neurol 1998 Oct;40(10):661–6
Plasma vitamin A levels in the very low birthweight infant--relationship to respiratory outcome. Inder TE, et al. **Early Hum Dev** 1998 Sep;52(2):155–68
Pre-term delivery by Caesarean section 'en caul': a case series. Abouzeid H, et al.
Eur J Obstet Gynecol Reprod Biol 1999 May;84(1):51–3
Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm child. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Dobson V, et al. **Invest Ophthalmol Vis Sci** 1999 Feb; 40(2):496–503
Comparison of respiratory function and fluid balance in very low birthweight infants given artificial or natural surfactant or no surfactant treatment. Kavvadia V, et al.
J Perinat Med 1998;26(6):469–74
Development of postural adjustments during reaching in preterm infants. van der Fits IB, et al. **Pediatr Res** 1999 Jul;46(1):1–7
Neurophysiological measures of reading difficulty in very-low-birthweight children. Khan SC, et al.
Psychophysiology 1999 Jan;36(1):76–85
[Development of formerly preterm infants with a birth weight of below 1500 grams: concept and results of a follow-up program in up to school-aged children in central Switzerland] Schubiger G, et al.
Schweiz Med Wochenschr 1999 Jul 13;129(27–28):1025–32 (Eng. Abstr.) **(Ger)**
[The predictive value of neonatal neurological assessment and neonatal cranial ultrasonography with respect to the development of very low birth weight premature infants] Mello RR, et al. **Rev Saude Publica** 1998 Oct;32(5):420–9 (Eng. Abstr.) **(Por)**
[Lung function in premature infants can be improved. Surfactant therapy and CPAP reduce the need of respiratory support] Blennow M, et al. **Lakartidningen** 1999 Mar 31;96(13):1571–6 (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Cranial magnetic resonance imaging and school performance in very low birth weight infants in adolescence. Cooke RW, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Sep; 81(2):F116–21
Cognitive and educational outcome of very-low-birthweight children in early adolescence. Botting N, et al.
Dev Med Child Neurol 1998 Oct;40(10):652–60
Executive function of children with extremely low birthweight: a case control study [see comments] Harvey JM, et al. **Dev Med Child Neurol** 1999 May;41(5):292–7. Comment in: Dev Med Child Neurol 1999 May;41(5):291.
Infant arousal in an en-face exchange with a new partner: effects of prematurity and perinatal biological risk. Eckerman CO, et al. **Dev Psychol** 1999 Jan;35(1):282–93
Relationship between the Maternal Social Support Index and the Parenting Stress Index in mothers of very-low-birthweight children now age 7. Farel AM, et al. **Psychol Rep** 1998 Aug;83(1):173–4
Neurophysiological measures of reading difficulty in very-low-birthweight children. Khan SC, et al.
Psychophysiology 1999 Jan;36(1):76–85
[Clinical significance of attachment research for the premature infant group: an overview of most recent research] Buchheim A, et al.
Z Kinder Jugendpsychiatr Psychother 1999 May; 27(2):125–38 (105 ref.) **(Ger)**

INFANT WALKERS see **INFANT EQUIPMENT**

INFANT WELFARE

Breast-feeding and infant illness: a dose-response relationship? Raisler J, et al. **Am J Public Health** 1999 Jan; 89(1):25–30
Assessing the effects of welfare reform policies on reproductive and infant health [see comments] Wise P, et al. **Am J Public Health** 1999 Oct;89(10):1514–21 (79 ref.) . Comment in: Am J Public Health 1999 Oct;89(10):1476–8. Comment in: Am J Public Health 1999 Oct;89(10):1479–82.
Experience with minimally invasive surgery in infants. Rothenberg SS, et al. **Am J Surg** 1998 Dec;176(6):654–8
Breast milk contamination in Kazakhstan: implications for infant feeding. Lutter C, et al. **Chemosphere** 1998 Oct–Nov; 37(9–12):1761–72
Higher neonatal morbidity after routine early hospital discharge: are we sending newborns home too early? Lock M, et al. **CMAJ** 1999 Aug 10;161(3):249–53
Health insurance, the quantity and quality of prenatal care, and infant health. Kaestner R. **Inquiry** 1999 Summer; 36(2):162–75
Social, cultural and technological determinants of maternal and neonatal health [editorial] Faúndes A, et al.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S1–2
Appropriate technology: antenatal care. Lumbiganon P.
Int J Gynaecol Obstet 1998 Dec;63 Suppl 1:S91–5 (29 ref.)
Parental education and infant health [see comments] Vogel LD, et al. **N Y State Dent J** 1999 Feb;65(2):26–9. Comment in: N Y State Dent J 1999 Feb;65(2):24–5.
Risk factors in wheezing infants. Karaman O, et al.
Pediatr Int 1999 Apr;41(2):147–50
[Impact on health of early supplementation with rice in infants in Laos (letter)] Graz B. **Med Trop (Mars)** 1999; 59(1):102–3 **(Fre)**
[NSAM's relation towards the Norwegian cohort of newborns/The Norwegian mother and child study (letter)] Gjelsvik B, et al. **Tidsskr Nor Laegeforen** 1999 Aug 10; 119(18):2696 **(Nor)**
[Maternal elimination diet during pregnancy and lactation, and the development of allergies in infants] Oldak E.
Pol Merkuriusz Lek 1998 Dec;5(30):387–9 (29 ref.) (Eng. Abstr.) **(Pol)**
[Diagnosis of maternal and infant health in Palestine] Modol Bresoli X, et al. **Aten Primaria** 1998 Nov 15;22(8):521–6 (Eng. Abstr.) **(Spa)**
[Dynamics of immunoglobulin production in non infected children born from HIV-1 infected mothers: effect of zidovudine] Resino S, et al. **Med Clin (Barc)** 1999 May 1;112(15):568–71 (Eng. Abstr.) **(Spa)**

ETHNOLOGY

The weanling's dilemma reconsidered: a biocultural analysis of breastfeeding ecology. McDade TW, et al.
J Dev Behav Pediatr 1998 Aug;19(4):286–99

STATISTICS & NUMERICAL DATA

Breast-feeding and infant illness: a dose-response relationship? Raisler J, et al. **Am J Public Health** 1999 Jan; 89(1):25–30

TRENDS

Returns on investment in public health: effect of public health expenditures on infant health, 1983–1990. Becker ER, et al. **J Health Care Finance** 1998 Fall;25(1):5–18

INFANTICIDE

Homicide and the baby-sitter [see comments] Dix J.
Am J Forensic Med Pathol 1998 Dec;19(4):321–3. Comment in: Am J Forensic Med Pathol 1999 Mar;20(1):101–2.
Social and forensic aspects of sudden infant death [letter] Sawaguchi T, et al. **Am J Forensic Med Pathol** 1999 Jun; 20(2):215–6
Unexplained deaths in infancy [editorial] [see comments] **Lancet** 1999 Jan 16;353(9148):161. Comment in: Lancet 1999 Feb 27;353(9154):749.
Unexplained deaths in infancy [letter; comment] Davis JA. **Lancet** 1999 Feb 27;353(9154):749. Comment on: Lancet 1999 Jan 16;353(9148):161.
Risk factors for infant homicide [letter; comment] West S. **N Engl J Med** 1999 Mar 18;340(11):895; discussion 895–7 . Comment on: N Engl J Med 1998 Oct 22;339(17):1211–6. Comment on: N Engl J Med 1998 Oct 22;339(17):1239–41.

ETHNOLOGY

Unexplained deaths in infancy [letter; comment] de Meer K. **Lancet** 1999 Feb 27;353(9154):749. Comment on: Lancet 1999 Jan 16;353(9148):161.

PREVENTION & CONTROL

Risk factors for infant homicide [letter; comment] Goldstein RD. **N Engl J Med** 1999 Mar 18;340(11):895; discussion 895–7. Comment on: N Engl J Med 1998 Oct 22;339(17):1211–6.

PSYCHOLOGY

Consistency and change in the behavior of rhesus macaque abusive mothers with successive infants. Maestripieri D, et al. **Dev Psychobiol** 1999 Jan;34(1):29–35

Neonaticide in the city of Rio de Janeiro: forensic and psycholegal perspectives. Mendlowicz MV, et al. **J Forensic Sci** 1999 Jul;44(4):741–5

A comprehensive typology for the biopsychosociocultural evaluation of child-killing behavior. Silva JA, et al. **J Forensic Sci** 1998 Nov;43(6):1112–8

STATISTICS & NUMERICAL DATA

Risk factors for infant homicide [letter; comment] Mendlowicz MV, et al. **N Engl J Med** 1999 Mar 18; 340(11):895; discussion 895–6. Comment on: N Engl J Med 1998 Oct 22;339(17):1211–6.

INFANTILE CORTICAL HYPEROSTOSIS see **HYPEROSTOSIS, CORTICAL, CONGENITAL**

INFANTILE NEUROAXONAL DYSTROPHY see **NEUROAXONAL DYSTROPHIES**

INFANTILE PAPULAR ACRODERMATITIS see **ACRODERMATITIS**

INFANTILE PARALYSIS see **POLIOMYELITIS**

INFANTILE REFSUM DISEASE see **PEROXISOMAL DISORDERS**

INFANTILE SPINAL MUSCULAR ATROPHY see **WERDNIG-HOFFMANN DISEASE**

INFANTILISM, GENITAL see **HYPOGONADISM**

INFANTILISM, SEXUAL see **HYPOGONADISM**

INFARCTION

see related
CEREBRAL INFARCTION
MYOCARDIAL INFARCTION
PULMONARY EMBOLISM
SPLENIC INFARCTION

The long-term effects of prostatic infarction in the rat. Park MS, et al. **Br J Urol** 1998 Oct;82(4):548–51

Sickle cell trait and acute intermittent porphyria leading to small bowel infarction. Budhoo MR, et al. **J R Coll Surg Edinb** 1999 Apr;44(2):130–1

[Small retinal, cochlear, and cerebral infarctions in the young patient, "SICRET" syndrome of Susac syndrome] Mala L, et al. **J Fr Ophtalmol** 1998 May;21(5):375–80 (17 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Warfarin-induced haemorrhagic infarction of the small bowel. Muralikrishnan VP, et al. **Clin Lab Haematol** 1998 Oct;20(5):319–20

Bilateral macular infarction due to diaminodiphenyl sulfone (4,4' DDS) toxicity. Chakrabarti M, et al. **Retina** 1999; 19(1):83–4

COMPLICATIONS

Renal infarction presenting as hypertension following resection of a follicular dendritic sarcoma [letter] Grant J, et al. **Aust N Z J Med** 1999 Apr;29(2):280–1

A case of acute right-sided abdominal pain. Amin Z, et al. **Br J Radiol** 1999 Apr;72(856):421–2

Malakoplakia of epididymis associated with testicular infarction. Grove JD, et al. **Br J Urol** 1993 Nov;72(5 Pt 1):656–7

Status epilepticus and venous infarction in Sturge-Weber syndrome. Coley SC, et al. **Childs Nerv Syst** 1998 Dec; 14(12):693–6

Spontaneous muscle infarction in diabetes: a pain in the leg [editorial; comment] Scobie IN. **Diabet Med** 1999 Feb; 16(2):91–2. Comment on: Diabet Med 1999 Feb;16(2):168–9.

A man with severe, transient hypertension due to acute renal infarction. Fay MF, et al. **J Hum Hypertens** 1999 May; 13(5):343–4

Nonocclusive small bowel infarction in familial dysautonomia syndrome. Kornecki A, et al. **J Pediatr Surg** 1999 Apr; 34(4):623–5

Rupture of a hepatic artery aneurysm and renal infarction: 2 complications of fibromuscular dysplasia that mimic vasculitis. Jones HJ, et al. **J Rheumatol** 1998 Oct; 25(10):2015–8

Massive haemoperitoneum due to rupture of splenic infarct during CAPD. Kanagasundaram NS, et al. **Nephrol Dial Transplant** 1998 Sep;13(9):2380–1

Trigeminal neuralgia resulting from infarction of the root entry zone of the trigeminal nerve: case report [letter] Delitala A, et al. **Neurosurgery** 1999 Jul;45(1):202

Trigeminal neuralgia resulting from infarction of the root entry zone of the trigeminal nerve: case report. Golby AJ, et al. **Neurosurgery** 1998 Sep;43(3):620–2; discussion 622–3

Systemic mast cell disease with splenic infarction: a case report. Maruyama H, et al. **Pathol Int** 1998 May; 48(5):403–11

Correlation between clinical and pathological features of pulmonary thromboemboli and the development of infarcts. Katsumura Y, et al. **Respirology** 1998 Sep;3(3):203–6

Malignant fibrous histiocytoma associated with a bone infarct in a patient with hereditary bone dysplasia. Kenan S, et al. **Skeletal Radiol** 1998 Aug;27(8):463–7 (15 ref.)

[Monoparesis of the left leg with bilateral pyramidal signs due to posterior spinal artery syndrome] Izumi Y, et al. **Rinsho Shinkeigaku** 1998 Jul;38(7):686–8 (Eng. Abstr.) **(Jpn)**

[Midbrain infarction presenting with unilateral blepharoptosis, trochlear nerve paresis and MLF syndrome] Sato K, et al. **Rinsho Shinkeigaku** 1998 Jul; 38(7):689–92 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Presumed venous infarction in spinal decompression sickness. Manabe Y, et al. **AJNR Am J Neuroradiol** 1998 Sep; 19(8):1578–80

Gastrointestinal/genitourinary case of the day. Liver infarction in a patient with sickle cell anemia, splenic atrophy, and gallstones. Atkinson DS Jr, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):788, 792–3

A case of diabetic muscle infarction in Japan. Taira M, et al. **Diabet Med** 1998 Dec;15(12):1065–7

Magnetic resonance imaging of spinal cord infarction after infrarenal vascular surgery [see comments] Paaske WP, et al. **Eur J Vasc Endovasc Surg** 1998 Oct;16(4):362–4. Comment in: Eur J Vasc Endovasc Surg 1999 Jun;17(6):544–5.

The spinal cord descending pathway for micturition: analysis in patients with spinal cord infarction. Inatomi Y, et al. **J Neurol Sci** 1998 May 7;157(2):154–7

A man with diabetes and a swollen leg [see comments] Sagar M, et al. **Lancet** 1999 Jan 9;353(9147):116. Comment in: Lancet 1999 May 1;353(9163):1527–8.

Internal auditory artery infarction: clinicopathologic correlation. Kim JS, et al. **Neurology** 1999 Jan 1;52(1):40–4

Spinal cord infarcts with contrast enhancement of the cauda equina: two cases. Amano Y, et al. **Neuroradiology** 1998 Oct;40(10):669–72

Diabetic muscle infarction presenting as a knee effusion [letter] Penglis PS, et al. **Semin Arthritis Rheum** 1999 Jun; 28(6):421–2

Angiosarcomas associated with bone infarcts. Abdelwahab IF, et al. **Skeletal Radiol** 1998 Oct;27(10):546–51 (17 ref.)

Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Hafner J, et al. **Vasa** 1998 Aug; 27(3):137–43

[Three patients with a kidney infarct] Koek GH, et al. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2473–6 (Eng. Abstr.) **(Dut)**

[Epiploic appendicitis] ter Meulen PH, et al. **Ned Tijdschr Geneeskd** 1999 Jan 16;143(3):159–61 (Eng. Abstr.) **(Dut)**

[Diagnostic imaging of idiopathic segmental infarct of the greater omentum. Diagnostic and physiopathologic considerations (published erratum appears in J Radiol 1998 Dec;79(12):1485)] Barbier C, et al. **J Radiol** 1998 Nov; 79(11):1367–72 (Eng. Abstr.) **(Fre)**

[Radiologic aspects of infarction of the appendix epiploica] Barbier C, et al. **J Radiol** 1998 Dec;79(12):1479–85 (Eng. Abstr.) **(Fre)**

[The role of imaging diagnosis in the study of intestinal infarct] Catalano O, et al. **Minerva Chir** 1998 Jun; 53(6):515–22 (43 ref.) (Eng. Abstr.) **(Ita)**

[Two cases of testicular infarction: the usefulness of enhanced MRI for preoperative diagnosis] Ishizu K, et al. **Hinyokika Kiyo** 1999 Mar;45(3):203–5 (Eng. Abstr.) **(Jpn)**

[Long-term gadolinium-enhancement of cauda equina on MRI in a case of spinal cord infarction after epidural anesthesia] Kawaguchi C, et al. **Rinsho Shinkeigaku** 1998 May;38(5):440–5 (Eng. Abstr.) **(Jpn)**

[Serial MRI study on a case of anterior spinal artery syndrome] Ono K, et al. **Rinsho Shinkeigaku** 1998 Sep; 38(9):806–10 (Eng. Abstr.) **(Jpn)**

[Primary idiopathic segmental infarction of the greater omentum (letter)] Louredo Méndez A, et al. **Rev Esp Enferm Dig** 1999 Feb;91(2):150–1 (6 ref.) **(Spa)**

DRUG THERAPY

Pathologic findings in a steroid-responsive optic nerve infarct in giant-cell arteritis. Kattah JC, et al. **Neurology** 1999 Jul 13;53(1):177–80

ETIOLOGY

Testicular infarction in a patient with epididymitis. Sue SR, et al. **Acad Emerg Med** 1998 Nov;5(11):1128–30

Infarcted lactating adenoma presenting as a rapidly enlarging breast mass. Behrndt VS, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):933–5

Arterial thrombosis leading to intestinal infarction in a patient with Behçet's disease associated with protein C deficiency. Bayraktar Y, et al. **Am J Gastroenterol** 1998 Dec; 93(12):2556–8

Laparoscopy-associated intestinal infarction: A new syndrome? [letter; comment] Pelosi MA 3rd, et al. **Am J Obstet Gynecol** 1999 Mar;180(3 Pt 1):773–4. Comment on: Am J Obstet Gynecol 1998 Sep;179(3 Pt 1):830–1.

Ovarian carcinoma presenting with a splenic infarct [letter] Hausdorff J, et al. **Arch Intern Med** 1999 Sep 13; 159(16):1959

Segmental testicular infarction. Costa M, et al. **BJU Int** 1999 Mar;83(4):525

Primary antiphospholipid syndrome presented by total infarction of right kidney with nephrotic syndrome. Sá H, et al. **Clin Nephrol** 1999 Jul;52(1):56–60 (21 ref.)

Cecal infarct: report of a case. Elnakadi I, et al. **Dis Colon Rectum** 1998 Dec;41(12):1585–6

Transarterial chemoembolization and percutaneous ethanol injection therapy in patients with hepatocellular carcinoma [comment] Kirchhoff T, et al. **Eur J Gastroenterol Hepatol** 1998 Nov;10(11):907–9 (57 ref.). Comment on: Eur J Gastroenterol Hepatol 1998 Nov;10(11):915–8.

Hepatic infarction following percutaneous ethanol injection therapy for hepatocellular carcinoma [see comments] Seki T, et al. **Eur J Gastroenterol Hepatol** 1998 Nov; 10(11):915–8. Comment in: Eur J Gastroenterol Hepatol 1998 Nov;10(11):907–9.

Chiasmal apoplexy, an unusual complication of cerebral glioblastoma [letter] Wright M, et al. **Eye** 1999;13 (Pt 1):120–1

Juxtapapillary nerve fiber layer infarction as a complication of coronary artery bypass surgery. Jarrell RL 3rd, et al. **J Am Optom Assoc** 1998 Dec;69(12):759–65

Elsberg syndrome due to infarction of the conus medullaris associated with a prothrombin mutation [letter] Wildgruber D, et al. **J Neurol** 1999 Jun;246(6):507–8

Posterior optic nerve infarction after lower lid blepharoplasty. Good CD, et al. **J Neuroophthalmol** 1999 Sep;19(3):176–9

Small bowel infarction in a 10-year-old child with a factor V Leiden mutation. Brown P, et al. **J Pediatr Gastroenterol Nutr** 1999 May;28(5):506–9

Paraplegia after coronary bypass operations: relationship to severe hypertension and vascular disease. Thomas NJ, et al. **J Thorac Cardiovasc Surg** 1999 Apr;117(4):834–6

Re: Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia [letter; comment] Kirollos MM. **J Urol** 1999 Jul;162(1):171. Comment on: J Urol 1998 Sep;160(3 Pt 1):792–3.

Embolic testicular infarction secondary to nonbacterial thrombotic endocarditis in Wegener's granulomatosis. Paik ML, et al. **J Urol** 1999 Mar;161(3):919–20

A man with diabetes and a swollen leg [letter; comment] Willenberg HS, et al. **Lancet** 1999 May 1;353(9163):1527–8 . Comment on: Lancet 1999 Jan 9;353(9147):116.

Diabetic muscle infarction: an unusual cause of leg swelling in a diabetic on continuous ambulatory peritoneal dialysis. Bingham C, et al. **Nephrol Dial Transplant** 1998 Sep; 13(9):2377–9

Cholesterol embolism associated with macroscopic renal infarction. Ramos R, et al. **Nephrol Dial Transplant** 1999 Apr;14(4):962–5

Systemic spread of meconium peritonitis. Patton WL, et al. **Pediatr Radiol** 1998 Sep;28(9):714–6

Total gastric replacement following gas bloat in a 21-month-old child. Sowande OA, et al. **Pediatr Surg Int** 1999;15(2):135–6

Mesenteric infarction after aortoiliac surgery on the basis of 1752 operations from the National Vascular Registry. Järvinen O, et al. **World J Surg** 1999 Mar;23(3):243–7

[Bilateral diabetic infarction of the thigh adductor muscles in a diabetic female patient-- A case report and review of the literature] Satoh A, et al. **Rinsho Shinkeigaku** 1999 Feb-Mar;39(2–3):321–6 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Intestinal infarct caused by giant cell arteritis] Kalbermatter V, et al. **Medicina (B Aires)** 1999;59(1):86–9 (Eng. Abstr.) **(Spa)**

GENETICS

Heparin-binding EGF-like growth factor mRNA is upregulated in the peri-infarct region of the remnant kidney model: in vitro evidence suggests a regulatory role in myofibroblast transformation. Kirkland G, et al. **J Am Soc Nephrol** 1998 Aug;9(8):1464–73

Prothrombin G20210A mutation in a child with spinal cord infarction. Young G, et al. **J Pediatr** 1999 Jun;134(6):777–9

[Splenic infarct in heterozygote sickle cell trait (Hb AS)] von Känel R, et al. **Schweiz Med Wochenschr** 1998 Oct 17;128(42):1614–7 (Eng. Abstr.) **(Ger)**

PATHOLOGY

MR features of soft-tissue abnormalities due to acute marrow infarction in five children with sickle cell disease. Frush DP, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):989–93

Fibrocartilagenous embolism: an unusual cause of spinal cord infarction. Yousef OM, et al. **Am J Forensic Med Pathol** 1998 Dec;19(4):395–9

Clinical and radiological aspects of idiopathic diabetic muscle infarction. Rational approach to diagnosis and treatment. Aboulafia AJ, et al. **J Bone Joint Surg Br** 1999 Mar;

81(2):323-6

Remission of primary hyperparathyroidism due to spontaneous infarction of a parathyroid adenoma. Case report and review of the literature. Kovacs KA, et al. **Medicine (Baltimore)** 1998 Nov;77(6):398-402 (26 ref.)

Pathologic findings in a steroid-responsive optic nerve infarct in giant-cell arteritis. Kattah JC, et al. **Neurology** 1999 Jul 13;53(1):177-80

Muscle infarction in patients with diabetes mellitus: MR imaging findings. Jelinek JS, et al. **Radiology** 1999 Apr; 211(1):241-7

[The histological changes and pathogenesis of an infarct of a long bone in soft-tissue trauma to an extremity with damage to the feeding artery] Grigorovskii VV. **Lik Sprava** 1998 Dec;(8):136-40 (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Painful swelling of the thigh in a diabetic patient: diabetic muscle infarction. Lafforgue P, et al. **Diabetes Metab** 1999 Sep;25(3):255-60

Shift from hypermetria to hypometria in an aberrant recovery following cerebellar infarction. Manto MU, et al. **J Neurol Sci** 1998 Apr 15;157(1):42-51

PREVENTION & CONTROL

Infarct size-reducing effect of heat stress and alpha1 adrenoceptors in rats. Joyeux M, et al. **Br J Pharmacol** 1998 Oct;125(4):645-50

RADIOGRAPHY

Cerebellar top-of-the-basilar syndrome. Silverman IE, et al. **Clin Neurol Neurosurg** 1998 Dec;100(4):296-8

Heightened suspicion and rapid evaluation with CT for early diagnosis of partial renal infarction. Lumerman JH, et al. **J Endourol** 1999 Apr;13(3):209-14

Images in hepatology. Gas in the portal vein. Brancatelli G, et al. **J Hepatol** 1999 Jun;30(6):1151

[Computerized tomography features of intestinal infarction: 56 surgically treated patients of which 5 with reversible mesenteric ischemia] Salzano A, et al. **Radiol Med (Torino)** 1999 Apr;97(4):246-50 (Eng. Abstr.) **(Ita)**

[Pulmonary nodules with cavitation and bilateral pleural effusion] Trujillo Santos A, et al. **Rev Clin Esp** 1998 Sep; 198(9):623-4 **(Spa)**

SURGERY

Total gastric replacement following gas bloat in a 21-month-old child. Sowande OA, et al. **Pediatr Surg Int** 1999;15(2):135-6

[Mesenteric infarct--when is the vascular surgeon needed?] Kniemeyer HW. **Zentralbl Chir** 1998;123(12):1411-7 (40 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of mesenteric infarct] Lagana S, et al. **Zentralbl Chir** 1998;123(12):1405-10 (23 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Old and new infarction of an epiploic appendage: ultrasound mimicry of appendicitis. van Breda Vriesman AC, et al. **Abdom Imaging** 1999 Mar-Apr;24(2):129-31

Prenatal sonographic appearance of hemorrhagic cerebellar infarction. Ranzini AC, et al. **J Ultrasound Med** 1998 Nov; 17(11):725-7

Sonographic appearance of omental infarction in children. Schlesinger AE, et al. **Pediatr Radiol** 1999 Aug; 29(8):598-601

VETERINARY

Ovarian torsion as a cause of colic in a neonatal foal [see comments] Valk N, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1454-6. Comment in: J Am Vet Med Assoc 1999 Feb 1;214(3):329-30.

Osteosarcoma at the site of bone infarction associated with total hip arthroplasty in a dog. Marcellin-Little DJ, et al. **Vet Surg** 1999 Jan-Feb;28(1):54-60

VIROLOGY

Intestinal infarction secondary to anti-thrombin III deficiency associated with cytomegalovirus infection [letter] Thomson A, et al. **Aust N Z J Med** 1999 Feb; 29(1):84-5

INFECTION

see related

ANTI-INFECTIVE AGENTS

Vaginal health. Mazza D. **Aust Fam Physician** 1999 Feb; 28(2):162

Infections in intraabdominal surgery. The EURESI Project. European Research Network on Surgical Infections. Holzheimer RG. **Infection** 1998 Sep-Oct;26(5):323-8

Maternal and infant health problems after normal childbirth: a randomised controlled study in Zambia. Ransjö-Arvidson AB, et al. **J Epidemiol Community Health** 1998 Jun; 52(6):385-91

Microbes immunity, and disease. Introduction. Microbe management. Purnell BA, et al. **Science** 1999 May 21; 284(5418):1301

[Acute nasal, sinus and pharyngeal infections in children] Gilain L. **Rev Prat** 1998 Feb 15;48(4):457-61 **(Fre)**

[Acute nasal-sinus infections in the adult] Parietti C, et al. **Rev Prat** 1998 Jan 15;48(2):199-204 **(Fre)**

[3rd Conference of the European Society of Infectious Diseases in Obstetrics and Gynecology (ESIDOG). Vienna, 2-4 May 1997] Hohlagschwandtner M, et al. **Gynakol Geburtshilfliche Rundsch** 1998;38(3):169-70 **(Ger)**

[Infectiology] Ruf BR, et al. **Internist (Berl)** 1999 Apr; 40(4):369-80 (42 ref.) **(Ger)**

[Emerging and re-emerging infectious diseases] Iwamoto A. **Nippon Naika Gakkai Zasshi** 1999 Mar 10;88(3):517-21 (0 ref.) **(Jpn)**

[Current trends in infections] Kimura T. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1842-7 (10 ref.) **(Jpn)**

[Communicable diseases defined in the new 'Infectious Diseases Prevention Law'] Yamazaki S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):425-32 **(Jpn)**

[Contagion, contagious and contagiousness--a linguistic reflection. Infectious is worse than infective, but the worse is full of infection] Hambraeus L. **Lakartidningen** 1999 May 5;96(18):2243-4 **(Swe)**

BLOOD

Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Bux J, et al. **Br J Haematol** 1999 Jun;105(3):616-7

Plasma concentration of cytokine antagonists in patients with infection following liver resection. Kimura F, et al. **Br J Surg** 1998 Dec;85(12):1631-5

Magnetic resonance spectroscopy of serum and acute-phase proteins revisited: a multiparametric statistical analysis of metabolite variations in inflammatory, infectious and miscellaneous diseases. Torri GM, et al. **Clin Chim Acta** 1999 Jan;279(1-2):77-96

High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. Häglin L, et al. **J Intern Med** 1999 Jul;246(1):45-52

CHEMICALLY INDUCED

[Infectious spondylodiscitis after peridural infiltration of prednisolone (letter)] Plubel Y, et al. **Presse Med** 1998 May 23-30;27(19):918 **(Fre)**

[Rationale of infective risk of corticoids] Cozon G. **Rev Pneumol Clin** 1998 Sep;54 Suppl 2:S22-4 **(Fre)**

[Corticoids and infectious risk: point of view of the pneumologist] Didier A. **Rev Pneumol Clin** 1998 Sep;54 Suppl 2:S28-30 **(Fre)**

[Corticoids and infection risk: conclusions, synthesis and perspectives] Jeannin L, et al. **Rev Pneumol Clin** 1998 Sep; 54 Suppl 2:S31 **(Fre)**

[Corticoids and infective risk: point of view of the internist] Wechsler B. **Rev Pneumol Clin** 1998 Sep;54 Suppl 2:S25-7 **(Fre)**

COMPLICATIONS

Anaemia in Nigerian mothers and their children: relative importance of infections and iron deficiency. Adelekan DA, et al. **Afr J Med Med Sci** 1998 Sep-Dec;27(3-4):185-7

A clinical and histologic study of 37 cases of immunoglobulin A-associated vasculitis. Magro CM, et al. **Am J Dermatopathol** 1999 Jun;21(3):234-40

Infections and atherosclerosis: new clues from an old hypothesis? Nieto FJ. **Am J Epidemiol** 1998 Nov 15; 148(10):937-48 (137 ref.)

Neutrophil function and infections in uremia. Hörl WH. **Am J Kidney Dis** 1999 Feb;33(2):xlv-xlviii

Are associations between infection and coronary disease causal or due to confounding? [editorial; comment] Ridker PM. **Am J Med** 1999 Mar;106(3):376-7. Comment on: Am J Med 1999 Mar;106(3):279-84.

The role of the immune system and infection in the effects of psychological factors on the cardiovascular system [letter] Sher L. **Can J Psychiatry** 1998 Nov;43(9):954-5

Body iron stores, infection, and risk of acute myocardial infarction [letter] Do MR. **Circulation** 1999 Jul 27; 100(4):446

Lack of association of infectious agents with risk of future myocardial infarction and stroke: definitive evidence disproving the infection/coronary artery disease hypothesis? [editorial] Epstein SE, et al. **Circulation** 1999 Sep 28;100(13):1366-8 (14 ref.)

Pulmonary edema as an acute complication of ritodrine therapy in the presence of maternal intrauterine infection. Takeuchi K, et al. **Clin Exp Obstet Gynecol** 1998; 25(3):99-100

Infectious complications of propionic acidemia in Saudia Arabia. Al Essa M, et al. **Clin Genet** 1998 Jul;54(1):90-4

A review of selective infections in the adult diabetic. Gleckman RA, et al. **Compr Ther** 1999 Feb;25(2):109-13 (12 ref.)

Infectious diarrhea. Goodman L, et al. **Dis Mon** 1999 Jul; 45(7):268-99 (75 ref.)

Concentrations of cytokines in plasma of patients with large burns: their relation to time after injury, burn size, inflammatory variables, infection, and outcome. Vindenes HA, et al. **Eur J Surg** 1998 Sep;164(9):647-56

Fever of unknown origin--past present and the future. Adhikari PM. **Indian J Med Sci** 1998 Aug;52(8):333-40 (20 ref.)

Interactions between infections/inflammation and risk factors in coronary artery disease [letter; comment] Hellstrom HR. **J Am Coll Cardiol** 1998 Nov;32(5):1484. Comment on: J Am Coll Cardiol 1998 May;31(6):1217-25.

The role of infection in atopic dermatitis. Kanani AS, et al. **J Cutan Med Surg** 1999 Feb;3 Suppl 2:S2-29-S2-32 (39 ref.)

3-Methylglutaconic aciduria associated with hepatosplenomegaly, macrocytic anaemia, fever episodes, recurrent infections, cervical lymphadenopathy and progressive decrease of physical performance. Holtmann MH, et al. **J Inherit Metab Dis** 1998 Aug;21(6):683-5

Aetiology of fever in patients with acute stroke. Georgilis K, et al. **J Intern Med** 1999 Aug;246(2):203-9

High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. Häglin L, et al. **J Intern Med** 1999 Jul;246(1):45-52

Burden of infection on growth failure. Stephensen CB. **J Nutr** 1999 Feb;129(2S Suppl):534S-538S (31 ref.)

Does infection cause atherosclerosis--and most other diseases? [editorial] Bryan CS. **J S C Med Assoc** 1999 Aug; 95(8):309-10

Catabolic consequences of infection and injury: the role of plasma protein (albumin) loss [letter; comment] Stehle G, et al. **JPEN J Parenter Enteral Nutr** 1999 Mar-Apr; 23(2):114-6. Comment on: JPEN J Parenter Enteral Nutr 1998 May-Jun;22(3):156-66.

Interleukin 8 in the tracheobronchial aspirate of infants acts as a neutrophil chemotactic factor in the development of chronic lung disease. Takasaki J, et al. **Pediatr Int** 1999 Feb;41(1):78-81

Fever, weight loss, and night sweats: infection or malignancy? [clinical conference] Winter AJ, et al. **Sex Transm Infect** 1998 Dec;74(6):439-44

Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Hosokawa T, et al. **Ther Apher** 1998 Nov; 2(4):288-91

Early childhood infection and atopic disorder. Farooqi IS, et al. **Thorax** 1998 Nov;53(11):927-32

Infections in asthma and allergy [editorial] Lewis SA. **Thorax** 1998 Nov;53(11):911-2

[Malignant or nonmalignant pericarditis (see comments)] Pogány K, et al. **Ned Tijdschr Geneeskd** 1998 Oct 17; 142(42):2281-4 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Mar 20;143(12):643. **(Dut)**

[Infection and vascular purpura] Lévesque H, et al. **J Mal Vasc** 1999 Jun;24(3):177-82 (30 ref.) (Eng. Abstr.) **(Fre)**

[Interscalene block and infections of the shoulder] Hempel V. **Anaesthesist** 1998 Nov;47(11):940 **(Ger)**

[Diarrhea associated with systemic infection] Iwata S. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):183-4 (2 ref.) **(Jpn)**

[Round Table: Urticaria in relation to infections] Bilbao A, et al. **Allergol Immunopathol (Madr)** 1999 Mar-Apr; 27(2):73-85 (Eng. Abstr.) **(Spa)**

[Sino-bronchial infections and male sterility. Presentation of a new variant] Carrión Valero F, et al. **Arch Bronconeumol** 1998 Sep;34(8):405-8 (Eng. Abstr.) **(Spa)**

[Hypogastric tumor and fever] Borobia FG, et al. **Rev Clin Esp** 1999 Mar;199(3):171-2 **(Spa)**

[Role of infections in arteriosclerotic vascular disease. The beginning of a long path] Ramos Rincón JM, et al. **Rev Clin Esp** 1999 Mar;199(3):153-60 (133 ref.) **(Spa)**

DIAGNOSIS

Enhanced preoperative C-reactive protein plasma levels as a risk factor for postoperative infections after cardiac surgery. Fransen EJ, et al. **Ann Thorac Surg** 1999 Jan; 67(1):134-8

Prevention and management of overwhelming postsplenectomy infection--an update. Brigden ML, et al. **Crit Care Med** 1999 Apr;27(4):836-42 (46 ref.)

Bone and joint infections in children. Spencer CH. **Curr Opin Rheumatol** 1998 Sep;10(5):494-7

Mimickers of hand infections. Louis DS, et al. **Hand Clin** 1998 Nov;14(4):519-29, vii (52 ref.)

A new scoring system for the clinical diagnosis of catheter-related infections. Lugauer S, et al. **Infection** 1999; 27 Suppl 1:S49-53

Fever in immunocompromised patients. Pizzo PA. **N Engl J Med** 1999 Sep 16;341(12):893-900 (32 ref.)

Predictive value for infection of febrile morbidity after vaginal surgery. Shackelford DP, et al. **Obstet Gynecol** 1999 Jun;93(6):928-31

Calcium pyrophosphate deposition disease mimicking infection in the lumbar spine. Bartlett CS 3rd, et al. **Orthopedics** 1999 Jan;22(1):79-81

Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507-24, ix-x (6 ref.)

Intramyocardial electrograms for non-invasive rejection monitoring: initial experience with an infection-specific parameter. Grasser B, et al. **Transpl Int** 1998;11 Suppl 1:S508-11

[Immunology in medical practice. XXI. Laboratory tests for

immunologic diseases] Out TA, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1027–33 (30 ref.) (Eng. Abstr.) **(Dut)**

[Diagnosis and therapy of infections related to catheters] Douard MC. **Presse Med** 1999 Apr 10;28(14):766–8 **(Fre)**

[Methods of investigation in pulmonary infections] Milosevic D, et al. **Presse Med** 1998 May 23–30;27(19):924–6 (19 ref.) **(Fre)**

[Evaluation of procalcitonin levels in patients with systemic inflammatory response syndrome as the diagnosis of infection and the severity of illness] Endo S, et al. **Kansenshogaku Zasshi** 1999 Mar;73(3):197–204 (Eng. Abstr.) **(Jpn)**

[Advances in diagnosis and treatment of infections: discussion] Shimada J, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2280–99 **(Jpn)**

Bacterial toxins and detection methods. Asari S. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):89–95 (6 ref.) (Eng. Abstr.) **(Jpn)**

The principle of diagnostic method and diagnostic imaging for infectious diseases. Niki Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):67–71 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic tests and items to be noted at the diagnostic laboratory] Ueno I, et al. **Rinsho Byori** 1999 Feb;Suppl 109:190–200 (10 ref.) **(Jpn)**

[Hemogram in differential diagnosis of infectious diseases] Bogomolov BP. **Klin Med (Mosk)** 1998;76(12):25–9 (0 ref.) **(Rus)**

DRUG THERAPY

Antioxidant therapy in the prevention of organ dysfunction syndrome and infectious complications after trauma: early results of a prospective randomized study [published erratum appears in Am Surg 1999 Sep;65(9):902] Porter JM, et al. **Am Surg** 1999 May;65(5):478–83

A trial of ciprofloxacin and metronidazole vs gentamicin and metronidazole for penetrating abdominal trauma. Tyburski JG, et al. **Arch Surg** 1998 Dec;133(12):1289–96

Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics [editorial; comment] Conly J. **Can Fam Physician** 1998 Sep;44:1769–73, 1780–4 (30 ref.). Comment on: Can Fam Physician 1998 Sep;44 :1881–8. **(Eng, Fre)**

Controlling antimicrobial resistance. Health Canada proposes an integrated action plan for Canadians. Thomas RE. **Can Fam Physician** 1998 Sep;44:1901–5, 1907 (3 ref.) **(Eng, Fre)**

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov–Dec;44(6):427–35 (23 ref.)

Interventional antimicrobial therapy in febrile neutropenic patients. Maschmeyer G. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):205–12 (38 ref.)

Delay in administering the first dose of antibiotics in patients admitted to hospital with serious infections. Natsch S, et al. **Eur J Clin Microbiol Infect Dis** 1998 Oct;17(10):681–4

Comparing the anti-inflammatory effects of corticotherapy and non-steroid anti-inflammatory drugs in infertile patients with infectious aetiology. Altay B, et al. **Int Urol Nephrol** 1999;31(1):101–6

Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. Sevinç F, et al. **J Antimicrob Chemother** 1999 Apr;43(4):601–6

How do the newer oral antimicrobials stack up against traditional agents? Gleckman R, et al. **Postgrad Med** 1998 Oct;104(4):119–22, 125–6 (22 ref.)

[Optimizing antibiotic therapy in a hospital setting] Guérin JM. **Presse Med** 1999 Jan 9;28(1):20–8 (57 ref.) (Eng. Abstr.) **(Fre)**

[Infection therapy in neutropenia] Adam D. **Dtsch Med Wochenschr** 1999 Apr 9;124 Suppl 1:S2 **(Ger)**

[Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology] Link H, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124 Suppl 1:S3–8 **(Ger)**

[Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology] Maschmeyer G, et al. **Dtsch Med Wochenschr** 1999 Apr 9;124 Suppl 1:S9–13 **(Ger)**

[Clinical effects of combination therapy with cefozopran and tobramycin for severe infections in patients with hematologic diseases] Toyama K, et al. **Jpn J Antibiot** 1999 Feb;52(2):153–61 (Eng. Abstr.) **(Jpn)**

[Advances in diagnosis and treatment of infections: discussion] Shimada J, et al. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2280–99 **(Jpn)**

[The important role of the microbiology laboratory in treating patients with infectious diseases and in controlling hospital infections] Furukawa K. **Rinsho Byori** 1999 Jul; 47(7):651–7 (Eng. Abstr.) **(Jpn)**

[Antibiotics as regulators of inflammatory reactions of the body in infections (editorial)] Nikitin AV. **Antibiot Khimioter** 1998;43(9):3–4 **(Rus)**

[Problems of updating antibacterial therapy] Alekseev GK. **Klin Med (Mosk)** 1999;77(3):4–8 (51 ref.) **(Rus)**

[Non-compliance of the treatment with antibiotics in non-severe acute infections] Gil VF, et al. **Med Clin (Barc)** 1999 May 29;112(19):731–3 (Eng. Abstr.) **(Spa)**

ENZYMOLOGY

Immunohistochemical localization of inducible nitric oxide synthase on human fetal amnion in intra-amniotic infection. Hsu CD, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1271–4

Sepsis is associated with increased ubiquitinconjugating enzyme E214k mRNA in skeletal muscle. Hobler SC, et al. **Am J Physiol** 1999 Feb;276(2 Pt 2):R468–73

EPIDEMIOLOGY

Interactions of infectious symptoms and modifiable risk factors in sudden infant death syndrome. The Nordic Epidemiological SIDS study. Helweg-Larsen K, et al. **Acta Paediatr** 1999 May;88(5):521–7

Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Hübel K, et al. **Ann Hematol** 1999 Feb;78(2):73–7

Male gender is a risk factor for major infections after surgery. Offner PJ, et al. **Arch Surg** 1999 Sep;134(9):935–8; discussion 938–40

Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive. Wheeler JG, et al. **BMJ** 1999 Apr 17; 318(7190):1046–50

Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India. Brabin L, et al. **Bull World Health Organ** 1998;76(3):277–87

Gynecologic cancer and surgical infectious morbidity. Iatrakis G, et al. **Clin Exp Obstet Gynecol** 1998;25(1–2):36–7

Alzheimer's disease in 22 twin pairs--13-year follow-up: hormonal, infectious and traumatic factors. Nee LE, et al. **Dement Geriatr Cogn Disord** 1999 Mar–Apr;10(2):148–51

Emerging and re-emerging infectious diseases. Banker DD. **Indian J Med Sci** 1998 Oct;52(10):458–61 (20 ref.)

Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. Hernández-Cruz B, et al. **J Rheumatol** 1998 Oct;25(10):1900–7

Infections. Osborn JE. **J Urban Health** 1998 Jun;75(2):251–7

Salivary IgA levels and infection risk in elite swimmers. Gleeson M, et al. **Med Sci Sports Exerc** 1999 Jan; 31(1):67–73

IgG subclass deficiency and the day-care generation. Lawton AR. **Pediatr Infect Dis J** 1999 May;18(5):462–6 (32 ref.)

Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis. Theorell T, et al. **Psychosom Med** 1999 May–Jun; 61(3):304–10

WHO report on infectious diseases. **Wkly Epidemiol Rec** 1999 Aug 20;74(33):279 **(Eng, Fre)**

ETIOLOGY

Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Ketterer N, et al. **Am J Med** 1999 Feb;106(2):191–7

Silver coating of medical devices for catheter-associated infections? [letter] Schierholz JM, et al. **Am J Med** 1999 Jul;107(1):101–2

Nitric oxide and infectious diseases. Burgner D, et al. **Arch Dis Child** 1999 Aug;81(2):185–8 (29 ref.)

Male gender is a risk factor for major infections after surgery. Offner PJ, et al. **Arch Surg** 1999 Sep;134(9):935–8; discussion 938–40

A trial of ciprofloxacin and metronidazole vs gentamicin and metronidazole for penetrating abdominal trauma. Tyburski JG, et al. **Arch Surg** 1998 Dec;133(12):1289–96

New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Karthaus M, et al. **Chemotherapy** 1998 Nov–Dec;44(6):427–35 (23 ref.)

Complications of hemodynamic monitoring. Coulter TD, et al. **Clin Chest Med** 1999 Jun;20(2):249–67, vii (138 ref.)

The significance of IgG subclasses and mannan-binding lectin (MBL) for susceptibility to infection in apparently healthy adults with IgA deficiency. Aittoniemi J, et al. **Clin Exp Immunol** 1999 Jun;116(3):505–8

Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group. Vuori E, et al. **Clin Infect Dis** 1998 Sep;27(3):566–72

Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Zügel U, et al. **Clin Microbiol Rev** 1999 Jan;12(1):19–39 (311 ref.)

Surveillance of overwhelming post-splenectomy infection. **Commun Dis Rep CDR Wkly** 1998 Aug 14;8(33): , 292

Natural history and pathogenesis as they affect clinical trials. Moxon ER. **Dev Biol Stand** 1998;95:61–7

European surveillance of infections and risk factors in cancer patients. Buchheidt D, et al. **Eur J Clin Microbiol Infect Dis** 1999 Feb;18(2):161–3

Why patients on long-term intravenous hyperalimentation are prone to infections. Kapadia CR. **Gastroenterology** 1999 Jun;116(6):1495–6

Prediction for the development of postoperative infections in the operation of esophageal cancer compared with gastric surgery. Takesue Y, et al. **Hiroshima J Med Sci** 1998 Sep;47(3):109–13

Passive smoking, sudden infant death syndrome (SIDS) and childhood infections. Dybing E, et al. **Hum Exp Toxicol** 1999 Apr;18(4):202–5 (30 ref.)

Care for kids is care for future. Preventing childhood diseases by stopping children's exposure to tobacco smoke [editorial] Nelson E. **Hum Exp Toxicol** 1999 Apr;18(4):191

Salivary IgA subclasses and infection risk in elite swimmers. Gleeson M, et al. **Immunol Cell Biol** 1999 Aug;77(4):351–5

Strategies for prevention of infection in short-duration neutropenia. Fenelon L. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):590–2

Piercing and tattooing in patients with congenital heart disease: patient and physician perspectives. Cetta F, et al. **J Adolesc Health** 1999 Mar;24(3):160–2

NHLBI/FDA conference on thrombosis and infections with cardiovascular devices. **J Biomed Mater Res** 1998 Dec 5; 42(3):341–6 (0 ref.)

Infected ovarian cyst in a homozygous beta-thalassemic patient. Sukcharoen N, et al. **J Med Assoc Thai** 1999 May; 82(5):511–4

Protein toxins produced by pathogenic vibrios. Shinoda S. **J Nat Toxins** 1999 Jun;8(2):259–69 (78 ref.)

Central venous catheter use and the risk of infection in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Rackoff WR, et al. **J Pediatr Hematol Oncol** 1999 Jul–Aug;21(4):260–7

Swimming and central venous catheter-related infections in the child with cancer. Robbins J, et al. **J Pediatr Oncol Nurs** 1999 Jan;16(1):51–6

Iron and infection. Patruta SI, et al. **Kidney Int Suppl** 1999 Mar;69:S125–30 (75 ref.)

Emerging infectious diseases and risk to the traveler. Freedman DO, et al. **Med Clin North Am** 1999 Jul; 83(4):865–83, v (79 ref.)

Early infections after autologous transplantation for haematological malignancies. Schiødt I, et al. **Med Oncol** 1998 Jul;15(2):103–8

Recurrent infections in haemodialysis patients--do not forget selective immunoglobulin A deficiency. Kuo MC, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3220–2

Potential infections related to anabolic steroid injection in young adolescents [letter] Dickinson BP, et al. **Pediatrics** 1999 Mar;103(3):694

A comparative analysis on the incidence of peritonitis and exit-site infection in CAPD and automated peritoneal dialysis. Rodriguez-Carmona A, et al. **Perit Dial Int** 1999 May–Jun;19(3):253–8

Emerging marine diseases--climate links and anthropogenic factors. Harvell CD, et al. **Science** 1999 Sep 3; 285(5433):1505–10 (113 ref.)

Analysis of failure times for multiple infections following bone marrow transplantation: an application of the multiple failure time proportional hazards model. Hannan PJ, et al. **Stat Med** 1998 Oct 30;17(20):2371–80

Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation. NEMC TNF Study Group. New England Medical Center Tumor Necrosis Factor. Freeman RB Jr, et al. **Transplantation** 1999 Apr 15;67(7):1005–10

Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Passalacqua JA, et al. **Transplantation** 1999 Aug 27; 68(4):535–40

[Risk of infection and locoregional anesthesia] Auboyer C. **Ann Fr Anesth Reanim** 1998;17(10):1257–60 (19 ref.) (Eng. Abstr.) **(Fre)**

[Infectious complications of long term intravenous devices: incidence, risk factors, diagnostic tools] Douard MC, et al. **Pathol Biol (Paris)** 1999 Mar;47(3):288–91 (18 ref.) (Eng. Abstr.) **(Fre)**

[Waterborne microbiological risk assessment: a state of the art and perspectives] Gofti L, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):61–73 (43 ref.) (Eng. Abstr.) **(Fre)**

[Infections and lupus] Le Moing V, et al. **Rev Prat** 1998 Mar 15;48(6):637–42 (26 ref.) (Eng. Abstr.) **(Fre)**

[Infection therapy in neutropenia] Adam D. **Dtsch Med Wochenschr** 1999 Apr 9;124 Suppl 1:S2 **(Ger)**

[Management of severe infection complicating aortofemoral grafts] Karner-Hanusch J, et al. **Wien Klin Wochenschr** 1998 Oct 30;110(20):721–4 (Eng. Abstr.) **(Ger)**

[IgG subclass deficiency and recurrent infections] Sakiyama Y. **Nihon Rinsho Meneki Gakkai Kaishi** 1998 Aug; 21(4):145–9 (16 ref.) **(Jpn)**

[Complications of hematopoietic stem cell transplantation: physiopathology and management. 1. Infections] Gondo H. **Nippon Naika Gakkai Zasshi** 1998 Aug 10; 87(8):1495–501 (11 ref.) **(Jpn)**

[Acute tonsillitis, peritonsillitis, and deep neck infection] Nonomura N. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):304–6 (7 ref.) **(Jpn)**

[Advantages of routine periodic replacement of the central endovenous catheter in total parenteral nutrition] González Avila G, et al. **Nutr Hosp** 1999 Mar-Apr;14(2):67-70 (Eng. Abstr.) **(Spa)**

GENETICS

Proteomics in human disease: cancer, heart and infectious diseases. Jungblut PR, et al. **Electrophoresis** 1999 Jul; 20(10):2100-10 (66 ref.)

Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. Searle S, et al. **J Med Genet** 1999 Apr;36(4):295-9

Genetic control of susceptibility to infections with intracellular pathogens. Skamene E. **Pathol Biol (Paris)** 1998 Nov;46(9):689-92 (0 ref.) **(Eng, Fre)**

Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Knight JC, et al. **Proc Assoc Am Physicians** 1999 Jul-Aug;111(4):290-8 (50 ref.)

A heterozygous mutation of beta-actin associated with neutrophil dysfunction and recurrent infection. Nunoi H, et al. **Proc Natl Acad Sci U S A** 1999 Jul 20;96(15):8693-8

HISTORY

The history of hand infections. Kono M, et al. **Hand Clin** 1998 Nov;14(4):511-8, vii

IMMUNOLOGY

Do infections protect against atopic diseases? [comment] Bråbäck L. **Acta Paediatr** 1999 Jul;88(7):705-8 (27 ref.). Comment on: Acta Paediatr 1999 Jul;88(7):710-4.

Infections in early childhood and risk of atopic disease [see comments] Pekkanen J, et al. **Acta Paediatr** 1999 Jul; 88(7):710-4. Comment in: Acta Paediatr 1999 Jul;88(7):705-8.

Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT. AOX. geriatric network. Girodon F, et al. **Arch Intern Med** 1999 Apr 12; 159(7):748-54

Immunodeficiency syndromes and recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Dec 10;58(11):565-8 (13 ref.)

Investigation of the immune system in recurrent infection. Gaspar HB, et al. **Br J Hosp Med** 1998 Nov 19-Dec 9; 58(10):517-20 (7 ref.)

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589-97 (71 ref.)

Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Zügel U, et al. **Clin Microbiol Rev** 1999 Jan;12(1):19-39 (311 ref.)

The role of B cells in acute and chronic infections. Bachmann MF, et al. **Curr Opin Immunol** 1999 Jun;11(3):332-9 (71 ref.)

Infectious tolerance. Cobbold S, et al. **Curr Opin Immunol** 1998 Oct;10(5):518-24 (74 ref.)

Receptor mediated subversion of macrophage cytokine production by intracellular pathogens. Mosser DM, et al. **Curr Opin Immunol** 1999 Aug;11(4):406-11 (34 ref.)

The role of dendritic cells in the induction and regulation of immunity to microbial infection. Reis e Sousa C, et al. **Curr Opin Immunol** 1999 Aug;11(4):392-9 (76 ref.)

New lessons for immunology at the host-pathogen interface [editorial] Spriggs MK, et al. **Curr Opin Immunol** 1999 Aug; 11(4):363-4

Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Goettsch W, et al. **Environ Health Perspect** 1998 Feb; 106(2):71-7

Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection. Gessler P, et al. **Eur J Pediatr** 1999 Jun;158(6):497-500

Correlates of protection: the crosstalk between immunology and medical microbiology [editorial] van Alphen L. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):3-4

Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora. Tlaskalová-Hogenová H, et al. **Folia Microbiol (Praha)** 1998;43(5):545-50 (50 ref.)

Salivary IgA subclasses and infection risk in elite swimmers. Gleeson M, et al. **Immunol Cell Biol** 1999 Aug;77(4):351-5

10th International Congress of Mucosal Immunology. Amsterdam, The Netherlands, 27 June-1 July, 1999. Proceedings and abstracts. **Immunol Lett** 1999 Jun 15; 69(1):1-216

Cellular mechanisms and molecules in infection immunity. Papers from the 5th Elsinore Meeting on Infection Immunity. Elsinore, Denmark, 29 May-2 June 1998. **Immunol Lett** 1999 Jan;65(1-2):1-140

TCR specificity in infection induced granulomas. Hogan LH, et al. **Immunol Lett** 1999 May 3;68(1):115-20 (36 ref.)

Negative signaling in health and disease. Coggeshall KM. **Immunol Res** 1999;19(1):47-64 (165 ref.)

Atopic disorders: a default pathway in the absence of infection? Erb KJ. **Immunol Today** 1999 Jul;20(7):317-22 (54 ref.)

Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Casadevall A, et al. **Infect Immun** 1999 Aug;67(8):3703-13 (35 ref.)

Superantigens in human disease. Bernal A, et al. **J Clin Immunol** 1999 May;19(3):149-57 (83 ref.)

Heterogeneity of the T cell response to immunodominant determinants within hen eggwhite lysozyme of individual syngeneic hybrid F1 mice: implications for autoimmunity and infection. Moudgil KD, et al. **J Immunol** 1998 Dec 1;161(11):6046-53

On the role of feedback in promoting conflicting goals of the adaptive immune system. Segel LA, et al. **J Immunol** 1999 Aug 1;163(3):1342-9 (24 ref.)

Society for Leukocyte Biology 15th International Congress with the European Macrophage Study Group. Innate resistance to infection. Cambridge, United Kingdom, September 22-26, 1999. Abstracts. **J Leukoc Biol Suppl** 1999;:9-36

Intrathymic immunomodulation and the "infectious" tolerance pathway in allograft recipients. Reemtsen BL, et al. **J Surg Res** 1999 Jun 1;84(1):1-7

Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Würzner R. **Mol Immunol** 1999 Mar-Apr;36(4-5):249-60 (101 ref.)

Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites. Ramasamy R, et al. **Parasite Immunol** 1999 Aug;21(8):397-407

Lymphocyte subsets in human tonsils: the effect of age and infection. Rosenmann E, et al. **Pediatr Allergy Immunol** 1998 Aug;9(3):161-7

The hygiene hypothesis in the development of atopy and asthma--still a matter of controversy? Hertzen LC. **QJM** 1998 Nov;91(11):767-71 (45 ref.)

Phylogenetic perspectives in innate immunity. Hoffmann JA, et al. **Science** 1999 May 21;284(5418):1313-8 (42 ref.)

The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Fraser IP, et al. **Semin Immunol** 1998 Oct;10(5):363-72 (94 ref.)

Innate immune recognition and control of adaptive immune responses. Medzhitov R, et al. **Semin Immunol** 1998 Oct; 10(5):351-3 (23 ref.)

[Pulmonary infections in immune deficiency states. Immunosuppression and its consequences] Lebargy F. **Presse Med** 1998 May 23-30;27(19):921-2 **(Fre)**

[Assessing the immune status in acute infections: a new methodological approach] Zheleznikova GF. **Klin Lab Diagn** 1999 Jan;(1):18-21 (Eng. Abstr.) **(Rus)**

[The mechanisms of the anti-infective protection of the female reproductive tract] Telesheva LF, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug; (4):85-90 (41 ref.) **(Rus)**

METABOLISM

Infection-induced depression of serum retinol--a component of the acute phase response or a consequence? [editorial; comment] Beisel WR. **Am J Clin Nutr** 1998 Nov; 68(5):993-4. Comment on: Am J Clin Nutr 1998 Nov;68(5):1088-94. Comment on: Am J Clin Nutr 1998 Nov;68(5):1095-103.

Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. Hsu CD, et al. **Am J Obstet Gynecol** 1998 Nov; 179(5):1267-70

Sepsis in mice stimulates muscle proteolysis in the absence of IL-6. Williams A, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):R1983-91

Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854-65 (80 ref.)

Body iron stores, infection, and risk of acute myocardial infarction [letter] Do MR. **Circulation** 1999 Jul 27; 100(4):446

Inter-organ protein and carbohydrate metabolic relationships during sepsis: necessary evils or uncanny coincidences? Vary TC. **Curr Opin Clin Nutr Metab Care** 1999 May; 2(3):235-42 (64 ref.)

[Biosynthesis of nitric oxide in infection: should it be induced or avoided? (published erratum appears in Med Trop (Mars) 1999;59(1):8)] Millet P, et al. **Med Trop (Mars)** 1998; 58(4):331-5 (34 ref.) **(Fre)**

[Pharmacokinetic analysis of cefozopran in neonatal infections--population pharmacokinetics using nonmem] Sakurai Y, et al. **Jpn J Antibiot** 1999 Jan;52(1):16-23 (Eng. Abstr.) **(Jpn)**

[Supranormal oxygen delivery] Katsuya H. **Masui** 1998 Dec; 47 Suppl:S81-7 (16 ref.) **(Jpn)**

MICROBIOLOGY

Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Redecke V, et al. **Am J Respir Cell Mol Biol** 1998 Nov; 19(5):721-7

Clinical analyzers. Microbiology. Mouritsen CL, et al. **Anal Chem** 1999 Jun 15;71(12):366R-372R (79 ref.)

Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics [editorial; comment] Conly J. **Can Fam Physician** 1998 Sep;44:1769-73, 1780-4 (30 ref.). Comment on: Can Fam Physician 1998 Sep;44 :1881-8. **(Eng, Fre)**

Controlling antimicrobial resistance. Health Canada proposes an integrated action plan for Canadians. Thomas RE. **Can Fam Physician** 1998 Sep;44:1901-5, 1907 (3 ref.) **(Eng, Fre)**

Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Shenep JL, et al. **Clin Infect Dis** 1998 Dec;27(6):1388-93

Infections in the elderly--new developments. Crossley K, et al. **Curr Clin Top Infect Dis** 1998;18:75-100 (123 ref.)

Infectious agents and the etiology of chronic idiopathic diseases. Fredricks DN, et al. **Curr Clin Top Infect Dis** 1998;18:180-200 (90 ref.)

Procurement, interpretation, and value of postmortem cultures. Roberts FJ. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):821-7 (35 ref.)

Correlates of protection: the crosstalk between immunology and medical microbiology [editorial] van Alphen L. **FEMS Immunol Med Microbiol** 1999 Jan;23(1):3-4

Emerging infectious diseases and pathogens. Chou T. **Nurs Clin North Am** 1999 Jun;34(2):427-42 (47 ref.)

Population biology, evolution, and infectious disease: convergence and synthesis. Levin BR, et al. **Science** 1999 Feb 5;283(5403):806-9 (43 ref.)

[Pulmonary infections in immune deficiency states. Immunosuppression and its consequences] Lebargy F. **Presse Med** 1998 May 23-30;27(19):921-2 **(Fre)**

[Collection of samples, their management and examination to identify the causative organisms] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1998 Nov 10;87(11):2223-7 (4 ref.) **(Jpn)**

The present state and problems of rapid diagnosis of infectious diseases in clinicocytological and histopathological examination. Obana Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):83-7 (8 ref.) **(Jpn)**

[Host microflora and its role in response to infection] Beloborodova NV. **Antibiot Khimioter** 1998;43(9):44-8 **(Rus)**

MORTALITY

Impact of infection on mortality and hospitalization in the North East of England. Wilson D, et al. **J Public Health Med** 1998 Dec;20(4):386-95

Assessing the contribution of age-sex differentials in causes of death due to infectious and parasitic diseases to the trends in age-sex differentials in life expectancy in Mauritius. Bah SM. **Soc Biol** 1998 Fall-Winter; 45(3-4):260-72

PATHOLOGY

Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Ginsburg I. **Med Hypotheses** 1998 Oct; 51(4):337-46 (68 ref.)

A study of nerve fibers and histopathology of postsurgical, postinfectious, and endometriosis-related adhesions. Tulandi T, et al. **Obstet Gynecol** 1998 Nov;92(5):766-8

Influence of genital infection on cervical cytology [see comments] Edwards SK, et al. **Sex Transm Infect** 1998 Aug;74(4):271-3. Comment in: Sex Transm Infect 1998 Dec;74(6):457-8.

The present state and problems of rapid diagnosis of infectious diseases in clinicocytological and histopathological examination. Obana Y. **Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi** 1998; 9(2):83-7 (8 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Intrahepatic STAT-3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat. Andrejko KM, et al. **Am J Physiol** 1998 Dec;275(6 Pt 1):G1423-9

Increased rigidity and priming of polymorphonuclear leukocytes in sepsis [see comments] Drost EM, et al. **Am J Respir Crit Care Med** 1999 Jun;159(6):1696-702. Comment in: Am J Respir Crit Care Med 1999 Jun;159(6):1693.

Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Friman G, et al. **Int J Sports Med** 1998 Jul;19 Suppl 3:S172-82 (85 ref.)

Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. Bertini R, et al. **J Exp Med** 1999 Jun 7;189(11):1783-9

Decreased cerebellar blood flow in postinfectious acute cerebellar ataxia. Nagamitsu S, et al. **J Neurol Neurosurg Psychiatry** 1999 Jul;67(1):109-12

[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945-7 (13 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL see INFECTION CONTROL

RADIONUCLIDE IMAGING

Nuclear medicine's role in infection and inflammation. Corstens FH, et al. **Lancet** 1999 Aug 28;354(9180):765-70 (37 ref.)

Immunoscintigraphy (BW 250/183) in neonates and infants with fever of unknown origin. Gratz S, et al.

Nucl Med Commun 1998 Nov;19(11):1037–45
Radionuclide imaging of nonosseous infection. Palestro CJ, et al. **Q J Nucl Med** 1999 Mar;43(1):46–60 (69 ref.)
Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Weiner RE, et al. **Q J Nucl Med** 1999 Mar;43(1):2–8 (49 ref.)

SURGERY

Repeat ileal pouch-anal anastomosis to salvage septic complications of pelvic pouches: clinical outcome and quality of life assessment. Fazio VW, et al. **Ann Surg** 1998 Oct;228(4):588–97
The treatment of infected non-union of the tibia by compression-distraction techniques using the Ilizarov external fixator. Hosny G, et al. **Int Orthop** 1998; 22(5):298–302
[Management of severe infection complicating aortofemoral grafts] Karner-Hanusch J, et al. **Wien Klin Wochenschr** 1998 Oct 30;110(20):721–4 (Eng. Abstr.) **(Ger)**

THERAPY

Maggots are useful in treating infected or necrotic wounds [letter; comment] Thomas S, et al. **BMJ** 1999 Mar 20; 318(7186):807–8. Comment on: BMJ 1998 Sep 5;317(7159):609–10.
Clinical and scientific importance of source control in abdominal infections: summary of a symposium. Bohnen JM, et al. **Can J Surg** 1999 Apr;42(2):122–6
Passive immunity against human pathogens using bovine antibodies. Weiner C, et al. **Clin Exp Immunol** 1999 May; 116(2):193–205 (100 ref.)
Use of an immunotherapeutic vaccine to treat a life-threatening human arteritic infection caused by Pythium insidiosum. Thitithanyanont A, et al. **Clin Infect Dis** 1998 Dec;27(6):1394–400
Prevention and management of overwhelming postsplenectomy infection--an update. Brigden ML, et al. **Crit Care Med** 1999 Apr;27(4):836–42 (46 ref.)
Bone and joint infections in children. Spencer CH. **Curr Opin Rheumatol** 1998 Sep;10(5):494–7
Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health. Duffy LC, et al. **Dig Dis Sci** 1999 Aug;44(8):1499–505 (60 ref.)
Diabetic hand infections. Gunther SF, et al. **Hand Clin** 1998 Nov;14(4):647–56
Infections of the fingertip. Paronychias and felons. Jebson PJ. **Hand Clin** 1998 Nov;14(4):547–55, viii (31 ref.)
Deep subfascial space infections. Jebson PJ. **Hand Clin** 1998 Nov;14(4):557–66, viii (15 ref.)
The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Williams MA, et al. **Leuk Lymphoma** 1999 Jun;34(1-2):1–23 (123 ref.)
The potential for monocyte-mediated immunotherapy during infection and malignancy--Part II: in vivo activation by exogenous cytokines and clinical applications. Williams MA, et al. **Leuk Lymphoma** 1999 Jul;34(3-4):207–30 (123 ref.)
Pediatric hand disease. Diagnosis and treatment. Ablove RH, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1507–24, ix-x (6 ref.)
[Laparostomy in the treatment of severe intra-abdominal infections] Olejnik J, et al. **Rozhl Chir** 1999 Apr; 78(4):166–70 (Eng. Abstr.) **(Cze)**
[Infections and aging] Cools HJ, et al. **Ned Tijdschr Geneeskd** 1998 Oct 10;142(41):2242–5 (43 ref.) (Eng. Abstr.) **(Dut)**
[Keypoints in response to infections in Japan (editorial)] Shimada J. **Nippon Naika Gakkai Zasshi** 1998 Nov 10; 87(11):2175–8 **(Jpn)**
[Present-day concepts concerning immunoprophylaxis and immunotherapy of surgical infections] Pinegin BV, et al. **Anesteziol Reanimatol** 1999 May-Jun;(3):61–7 (35 ref.) **(Rus)**
[Indications for admission to the intensive care service of adult patients with severe infections] Alvarez Lerma F, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):423–30 (70 ref.) **(Spa)**

TRANSMISSION

Occupational injuries and infection control [letter] McCarthy GM, et al. **Acad Med** 1999 May;74(5):464–5
Infections acquired during cardiopulmonary resuscitation: estimating the risk and defining strategies for prevention. Mejicano GC, et al. **Ann Intern Med** 1998 Nov 15; 129(10):813–28 (212 ref.)
Technology status evaluation: personal protective equipment: November 1998. From the ASGE. American Society for Gastrointestinal Endoscopy. Carr-Locke DL, et al. **Gastrointest Endosc** 1999 Jun;49(6):854–7
Granulomatous inflammation and transmission of infectious disease [letter] Di Perri G, et al. **Immunol Today** 1999 Jul; 20(7):337 (14 ref.)
Food-borne and water-borne infections and the gastroenterologist. [news] Tarr PI, et al. **J Pediatr Gastroenterol Nutr** 1999 Sep;29(3):237–9
[Imported infectious disease] Nagatake T. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):380–3 (7 ref.) **(Jpn)**

ULTRASONOGRAPHY

Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications? Vychytil A, et al. **Am J Kidney Dis** 1999 Apr;33(4):722–7
Infection: ultrasound-guided procedures. Craig JG. **Radiol Clin North Am** 1999 Jul;37(4):669–78 (55 ref.)

URINE

Organ failure, infection, and the systemic inflammatory response syndrome are associated with elevated levels of urinary intestinal fatty acid binding protein: study of 100 consecutive patients in a surgical intensive care unit. Lieberman JM, et al. **J Trauma** 1998 Nov;45(5):900–6
Urinary excretion of podocytes in patients with sepsis [letter] Watanabe T. **Pediatr Nephrol** 1999 Sep;13(7):632–3

VETERINARY

A Saprolegnia parasitica challenge system for rainbow trout: assessment of Pyceze as an anti-fungal agent for both fish and ova. Pottinger TG, et al. **Dis Aquat Organ** 1999 May 12;36(2):129–41
Isolation of Prothoteca zopfii from a case of bovine mastitis in Brazil. de Vargas AC, et al. **Mycopathologia** 1998; 142(3):135–7
Emerging marine diseases--climate links and anthropogenic factors. Harvell CD, et al. **Science** 1999 Sep 3; 285(5433):1505–10 (113 ref.)

VIROLOGY

Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. Cerwenka A, et al. **J Exp Med** 1999 Jan 18;189(2):423–34

INFECTION CONTROL

Occupational injuries and infection control [letter] McCarthy GM, et al. **Acad Med** 1999 May;74(5):464–5
Nonsurgical antimicrobial prophylaxis: guidelines (and bugs) in evolution [editorial; comment] Fish DN. **Am J Health Syst Pharm** 1999 Jun 15;56(12):1199. Comment on: Am J Health Syst Pharm 1999 Jun 15;56(12):1201–50.
Outcomes management: trendy phrase or mandate for survival? [editorial; comment] Baker OG. **Am J Infect Control** 1999 Apr;27(2):77–8. Comment on: Am J Infect Control 1999 Apr;27(2):135–40.
Levels of naturally occurring microorganisms on surgical instruments after clinical use and after washing. Chu NS, et al. **Am J Infect Control** 1999 Aug;27(4):315–9
AJIC's strategic plan [editorial] Larson EL. **Am J Infect Control** 1998 Aug;26(4):385–7
Mandatory infection out-of-control test. Schweon SJ, et al. **Am J Infect Control** 1998 Aug;26(4):449–50
Infection control in long-term care: news from the front [editorial; comment] Strausbaugh LJ. **Am J Infect Control** 1999 Feb;27(1):1–3. Comment on: Am J Infect Control 1999 Feb;27(1):4–9. Comment on: Am J Infect Control 1999 Feb;27(1):10–9. Comment on: Am J Infect Control 1999 Feb;27(1):20–6. Comment on: Am J Infect Control 1999 Feb;27(1):27–34. Comment on: Am J Infect Control 1999 Feb;27(1):64–70.
Infections acquired during cardiopulmonary resuscitation: estimating the risk and defining strategies for prevention. Mejicano GC, et al. **Ann Intern Med** 1998 Nov 15; 129(10):813–28 (212 ref.)
Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Montecalvo MA, et al. **Ann Intern Med** 1999 Aug 17; 131(4):269–72
Occupational exposures to body fluids among medical students. A seven-year longitudinal study [see comments] Osborn EH, et al. **Ann Intern Med** 1999 Jan 5;130(1):45–51 . Comment in: Ann Intern Med 1999 Jan 5;130(1):66–7.
Infection control in outpatient facilities: caveat chirurgia! [letter] Vaghadia H. **Can J Anaesth** 1998 Sep;45(9):914–5
Infection control in the bronchoscopy suite. A review. Mehta AC, et al. **Clin Chest Med** 1999 Mar;20(1):19–32, ix (114 ref.)
Infections associated with implantable cardioverter defibrillators placed transvenously and via thoracotomies: epidemiology, infection control, and management [see comments] Lai KK, et al. **Clin Infect Dis** 1998 Aug; 27(2):265–9. Comment in: Clin Infect Dis 1998 Aug;27(2):270–1.
Infections associated with implantable cardioverter defibrillators--still more questions [editorial; comment] Steckelberg JM, et al. **Clin Infect Dis** 1998 Aug;27(2):270–1 . Comment on: Clin Infect Dis 1998 Aug;27(2):265–9.
Vancomycin-resistant Staphylococcus aureus: infection control considerations. Wenzel RP, et al. **Clin Infect Dis** 1998 Aug;27(2):245–9; quiz 250–1
Managing antibiotic use--impact of infection control [editorial; comment] Wenzel RP, et al. **Clin Infect Dis** 1999 May;28(5):1126–7. Comment on: Clin Infect Dis 1999 May;28(5):1119–25.
Antibiotic resistance: the agricultural connection [letter; comment] Prescott JF. **CMAJ** 1999 Jun 15;160(12):1695–7 . Comment on: CMAJ 1998 Nov 3;159(9):1129–36.
Controversies on diagnosis and prevention of ventilator-associated pneumonia. Bonten MJ. **Diagn Microbiol Infect Dis** 1999 Jul;34(3):199–204 (38 ref.)
Application of data mining to intensive care unit microbiologic data. Moser SA, et al. **Emerg Infect Dis** 1999 May-Jun;5(3):454–7
A transphyletic anti-infectious control strategy based on the killer phenomenon. Conti S, et al. **FEMS Immunol Med Microbiol** 1998 Sep;22(1-2):151–61 (61 ref.)
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Lauria F, et al. **Haematologica** 1999 Jan; 84(1):22–5
Infection control. Battle of the bugs. Godar K, et al. **Hosp Health Netw** 1998 Oct 5;72(19):44, 46
Risk assessment and MRSA [letter] Teare EL. **Hosp Med** 1999 Jan;60(1):70
5th International Conference on the Prevention of Infection. Nice, France, May 6-7, 1998. Abstracts. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):602–10
Caveats regarding the use of control charts [letter] Benneyan JC. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):526–7
Environmental sampling of Acinetobacter baumannii: moistened swabs versus moistened sterile gauze pads [letter] Corbella X, et al. **Infect Control Hosp Epidemiol** 1999 Jul; 20(7):458–60
Bugs are not funny syndrome [letter] Schweon SJ, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):527
A decade of prevalence surveys in a tertiary-care center: trends in nosocomial infection rates, device utilization, and patient acuity. Weinstein JW, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):543–8
Infection control and hospital epidemiology outside the United States [editorial] Widmer AF, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):17–21
Risk of tuberculosis transmission in an adult day-care center [letter] Wolf JE, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):157–8
Infection control and outpatient parenteral antibiotic therapy. Wade BH, et al. **Infect Dis Clin North Am** 1998 Dec; 12(4):979–94 (43 ref.)
Prevention of infections caused by central venous catheters--established and novel measures. Bach A. **Infection** 1999;27 Suppl 1:S11–5 (50 ref.)
An assessment of cross-infection control procedures among English-speaking Caribbean general dental practitioners. A regional preliminary study. Vignarajah S, et al. **Int Dent J** 1998 Apr;48(2):67–76
Microbial resistance and the Infectious Diseases Society of America (IDSA) guidelines. Feld R. **Int J Hematol** 1998 Oct;68 Suppl 1:S27–30
The Japanese experience in various institutions. Urabe A. **Int J Hematol** 1998 Oct;68 Suppl 1:S15–9
Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Zinner SH. **Int J Hematol** 1998 Oct;68 Suppl 1:S31–4
Infection control in outpatient unicomponent penile prosthesis surgery. Ghanem HM, et al. **Int J Impot Res** 1999 Feb;11(1):25–7
Reducing the impact of tuberculosis transmission in institutions: beyond infection control measures. Brewer TF, et al. **Int J Tuberc Lung Dis** 1998 Sep;2(9 Suppl 1):S118–23
4th International Conference of the Hospital Infection Society. 13–17 September 1998. Abstracts. **J Hosp Infect** 1998 Sep;40 Suppl A:144 p.
MRSA in cystic fibrosis. London, 16 June 1997. **J Hosp Infect** 1998 Nov;40(3):179–91 (17 ref.)
Nurses and hospital infection control: knowledge, attitudes and behaviour of Italian operating theatre staff. Angelillo IF, et al. **J Hosp Infect** 1999 Jun;42(2):105–12
Microbiological evaluation of four enteral feeding systems which have been deliberately subjected to faulty handling procedures. Beattie TK, et al. **J Hosp Infect** 1999 May; 42(1):11–20
Early onset pneumonia in neurosurgical intensive care unit patients. Berrouane Y, et al. **J Hosp Infect** 1998 Dec; 40(4):275–80
Computerized tagging of MRSA patients' electronic records [letter; comment] [see comments] Bignardi G, et al. **J Hosp Infect** 1998 Oct;40(2):159–60. Comment on: J Hosp Infect 1998 Jun;39(2):160. Comment in: J Hosp Infect 1999 May;42(1):73.
Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. Bird J, et al. **J Hosp Infect** 1998 Nov;40(3):243–7
Closed tracheal suctioning systems and infection control in the intensive care unit. Blackwood B, et al. **J Hosp Infect** 1998 Aug;39(4):315–21
Is infection control an academic study? Burnie JP. **J Hosp Infect** 1999 Jan;41(1):7–10 (30 ref.)
Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. Chaparro J, et al. **J Hosp Infect** 1998 Dec;40(4):281–5
Infection control policies for anaesthetic equipment must be comprehensive [letter; comment] Cooke RP, et al. **J Hosp Infect** 1998 Aug;39(4):331–2. Comment on: J Hosp Infect 1997 Dec;37(4):263–72.
Testing water quality for automatic washer--disinfectors [letter; comment] Curtis B. **J Hosp Infect** 1999 May; 42(1):74–6. Comment on: J Hosp Infect 1998 May;39(1):63–5.

Glove powder: implications for infection control. Dave J, et al. **J Hosp Infect** 1999 Aug;42(4):283–5 (22 ref.)
Nosocomial infection, indices of intrinsic infection risk, and in-hospital mortality in general surgery. Delgado-Rodriguez M, et al. **J Hosp Infect** 1999 Mar; 41(3):203–11
Pseudo-outbreak of Aeromonas hydrophila isolates related to endoscopy. Esteban J, et al. **J Hosp Infect** 1999 Apr; 41(4):313–6
Controlling MRSA [letter; comment] Farrington M, et al. **J Hosp Infect** 1999 Mar;41(3):251–4. Comment on: J Hosp Infect 1998 Jun;39(2):85–93.
Correlation between surface and air counts of particles carrying aerobic bacteria in operating rooms with turbulent ventilation: an experimental study. Friberg B, et al. **J Hosp Infect** 1999 May;42(1):61–8
Water quality for endoscope washer-disinfectors [letter; comment] Humphreys H, et al. **J Hosp Infect** 1999 May; 42(1):76–8. Comment on: J Hosp Infect 1998 May;39(1):63–5. Comment on: J Hosp Infect 1998 Jun;39(2):149–57.
Subcutaneous fluid administration--better than the intravenous approach? Jain S, et al. **J Hosp Infect** 1999 Apr;41(4):269–72 (13 ref.)
The Internet, infection control, and world domination: http://www.his.org.uk/. Kelsey MC, et al. **J Hosp Infect** 1998 Oct;40(2):91–5
Infection control in high dependency units [letter] King D, et al. **J Hosp Infect** 1999 Jul;42(3):249–50
Detecting legionellosis by unselected culture of respiratory tract secretions and developing links to hospital water strains. Köhler JR, et al. **J Hosp Infect** 1999 Apr; 41(4):301–11
Central venous catheter-related bacteraemia in critically ill neonates: risk factors and impact of a prevention programme. Maas A, et al. **J Hosp Infect** 1998 Nov; 40(3):211–24
Worthwhile infection control information? A report from the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California: 24–27 September 1998. Masterton RG. **J Hosp Infect** 1999 Aug; 42(4):269–74
Disseminated aspergillosis in a premature neonate [letter] Meessen NE, et al. **J Hosp Infect** 1998 Nov;40(3):249–50
First report of MRSA from hospitalized patients in Sudan [letter] Musa HA, et al. **J Hosp Infect** 1999 May;42(1):74
Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control. Nelson RR. **J Hosp Infect** 1999 Aug;42(4):275–82 (70 ref.)
The toilet as a transmission vector of vancomycin-resistant enterococci. Noble MA, et al. **J Hosp Infect** 1998 Nov; 40(3):237–41
Comparative efficiency of nitrocellulose membranes versus RODAC plates in microbial sampling on surfaces. Poletti L, et al. **J Hosp Infect** 1999 Mar;41(3):195–201
An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward. Revathi G, et al. **J Hosp Infect** 1998 Dec; 40(4):295–302 (36 ref.)
Assessing the role of prophylactic antibiotics in clean surgery. Sanderson PJ. **J Hosp Infect** 1999 May;42(1):7–9
Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre [see comments] Thomas SR, et al. **J Hosp Infect** 1998 Nov;40(3):203–9. Comment in: J Hosp Infect 1999 Jun;42(2):161.
Laboratory role in the management of hospital acquired infections. Wilson MP, et al. **J Hosp Infect** 1999 May; 42(1):1–6 (25 ref.)
Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. Do AN, et al. **J Infect Dis** 1999 Feb;179(2):442–8
Ebola hemorrhagic fever: lessons from Kikwit, Democratic Republic of the Congo. Heymann DL, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S283–6
The ethics of xenotransplantation [letter; comment] Bartlett R. **J Med Ethics** 1998 Dec;24(6):414–5. Comment on: J Med Ethics 1998 Feb;24(1):18–24.
Pain management and infection control. Alderman S. **J Nurs Adm** 1999 Sep;29(9):3, 50
Minor surgery in general practice [letter; comment] Lighton L, et al. **J Public Health Med** 1999 Mar;21(1):117. Comment on: J Public Health Med 1998 Jun;20(2):169–74.
Improving infection control in general practice. Farrow SC, et al. **J R Soc Health** 1999 Mar;119(1):17–22
From the Centers for Disease Control and Prevention. Frequency of vaccine-related and therapeutic injections--Romania, 1998. **JAMA** 1999 Jun 2; 281(21):1981–2
Antibiotic resistance--squeezing the balloon? [editorial; comment] [see comments] Burke JP. **JAMA** 1998 Oct 14; 280(14):1270–1. Comment on: JAMA 1998 Oct 14;280(14):1233–7. Comment in: JAMA 1999 Mar 24–31;281(12):1081–2.
Frequency of vaccine-related and therapeutic injections--Romania, 1998. **MMWR Morb Mortal Wkly Rep** 1999 Apr 9;48(13):271–4
Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group [see comments] Smith TL, et al. **N Engl J Med** 1999 Feb 18;340(7):493–501. Comment in: N Engl J Med 1999 Feb 18;340(7):556–7. Comment in: N Engl J Med 1999 Jul 15;341(3):207–8.
Sterilization vs. disinfection vs. clean. Alvarado CJ. **Nurs Clin North Am** 1999 Jun;34(2):483–91 (34 ref.)
Communicable diseases: infection prevention for nurses at work and at home. Bertin ML. **Nurs Clin North Am** 1999 Jun;34(2):509–26
Emerging infectious diseases and pathogens. Chou T. **Nurs Clin North Am** 1999 Jun;34(2):427–42 (47 ref.)
The risk of occupational exposure and infection with infectious disease. Sharbaugh RJ. **Nurs Clin North Am** 1999 Jun;34(2):493–508 (29 ref.)
Enteral tube feeds as a source of infection: can we reduce the risk? [editorial; comment] Anderton A. **Nutrition** 1999 Jan;15(1):55–7. Comment on: Nutrition 1999 Jan;15(1):11–7.
Control of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus in hospitalized children. Fisher MC. **Pediatr Infect Dis J** 1998 Sep; 17(9):825–6
Issues related to human immunodeficiency virus transmission in schools, child care, medical settings, the home, and community. American Academy of Pediatrics. Committee of Pediatric AIDS and Committee on Infectious Diseases. **Pediatrics** 1999 Aug;104(2 Pt 1):318–24 (53 ref.)
Guidelines for the prevention and control of methicillin-resistant Staphylococcus aureus in long-term care facilities. Sioux Falls Task Force on Antimicrobial Resistance [see comments] **S D J Med** 1999 Jul;52(7):235–40 . Comment in: S D J Med 1999 Jul;52(7):233–4.
Reduction in methicillin-resistant Staphylococcus aureus infection rate in a nursing home by aggressive containment strategies [see comments] Jaqua-Stewart MJ, et al. **S D J Med** 1999 Jul;52(7):241–7. Comment in: S D J Med 1999 Jul;52(7):233–4.
Building the better bug. O'Brochta DA, et al. **Sci Am** 1998 Dec;279(6):90–5
Nematode control practices and anthelmintic resistance in dairy calves in the south west of England. Stafford K, et al. **Vet Rec** 1999 Jun 12;144(24):659–61
High frequency of therapeutic injections, Republic of Moldova. **Wkly Epidemiol Rec** 1999 Mar 19;74(11):84–6 **(Eng, Fre)**
[Study of the relationship between the control of environmental microorganism and infection of patients with leukemia after trasplantation of bone marrow] Zhu S, et al. **Wei Sheng Wu Hsueh Pao** 1997 Apr;37(2):142–7 (Eng. Abstr.) **(Chi)**
[Children in day care centers--antibacterial agents instead of good infection control? (letter)] Andersen BM. **Tidsskr Nor Laegeforen** 1999 Jan 20;119(2):263 **(Nor)**
[Influenza outbreaks in nursing homes (letter; comment)] Iversen BG, et al. **Tidsskr Nor Laegeforen** 1999 May 10; 119(12):1802–3. Comment on: Tidsskr Nor Laegeforen 1999 Apr 10;119(9):1336. **(Nor)**
[Hand hygiene] Lystad A. **Tidsskr Nor Laegeforen** 1999 Jun 30;119(17):2454 **(Nor)**
[Prevention of influenza in nursing homes (letter)] Nygaard HA. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2079 **(Nor)**
[Approaches to managing an epidemic process based on self-regulating mechanisms of the parasitic system] Savilov ED. **Dokl Akad Nauk** 1999 Jun;366(4):572–3 **(Rus)**
[What hygienic criteria should apply to community care? The risk of infection is increasing when more and more seriously ill patients are treated outside hospital] Tammelin A, et al. **Lakartidningen** 1998 Nov 18;95(47):5338–40 (Eng. Abstr.) **(Swe)**
[Enormous health care costs are to be expected. The problem of microbial resistance must be seriously considered!] Wilhelmson B. **Lakartidningen** 1999 Apr 21;96(16):1934–7 **(Swe)**

ECONOMICS

The economics of preventing revisions in total hip replacement. Persson U, et al. **Acta Orthop Scand** 1999 Apr; 70(2):163–9
Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Hacek DM, et al. **Am J Clin Pathol** 1999 May;111(5):647–54
Infection control in the respiratory laboratory: risk, costs, expediency [editorial; comment] Pierce RJ. **Aust N Z J Med** 1999 Feb;29(1):3–4. Comment on: Aust N Z J Med 1999 Feb;29(1):9–14.
A cost-analysis of two approaches to infection control in a lung function laboratory [see comments] Side EA, et al. **Aust N Z J Med** 1999 Feb;29(1):9–14. Comment in: Aust N Z J Med 1999 Feb;29(1):3–4.
The costs of healthcare worker respiratory protection and fit-testing programs [see comments] Kellerman SE, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):629–34. Comment in: Infect Control Hosp Epidemiol 1998 Sep;19(9):626–8.
Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Lai KK, et al. **Infect Control Hosp Epidemiol** 1998 Sep; 19(9):647–52
Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Papia G, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):473–7
Barriers to tuberculosis control in urban Zambia: the economic impact and burden on patients prior to diagnosis. Needham DM, et al. **Int J Tuberc Lung Dis** 1998 Oct; 2(10):811–7
Costs of endemic MRSA [letter; comment] [see comments] Bowler IC, et al. **J Hosp Infect** 1998 Oct;40(2):159. Comment on: J Hosp Infect 1998 Jun;39(2):85–93. Comment in: J Hosp Infect 1999 May;42(1):73.
Costs associated with tuberculosis control programs at hospitals caring for children. Kellerman S, et al. **Pediatr Infect Dis J** 1999 Jul;18(7):604–8

INSTRUMENTATION

New technologies: how can journals best serve their readers? [editorial; comment] Springthorpe S. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):463–4. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):465–72. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):514–6. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):458.
[Has disinfection of endoscopes by automatic machines become obligatory?] Delwaide J, et al. **Rev Med Brux** 1999 Feb;20(1):A49–50 **(Fre)**

LEGISLATION & JURISPRUDENCE

Legal and ethical issues in revising human immunodeficiency virus postexposure protocols. Barnes M. **Am J Med** 1997 May 19;102(5B):111–2; discussion 113–4 (05 ref.)
Recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus: a public health agency perspective. Danila RN. **Am J Med** 1997 May 19; 102(5B):98–101 (10 ref.)
Postexposure chemoprophylaxis against HIV: what are the implications for people with AIDS and the organizations that serve them? Hodel D. **Am J Med** 1997 May 19; 102(5B):106–10 (10 ref.)
Rule-makers who establish infection control standards. Yost AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):527–33 (18 ref.)

METHODS

The economics of preventing revisions in total hip replacement. Persson U, et al. **Acta Orthop Scand** 1999 Apr; 70(2):163–9
Evaluating the protective value of hospital gowns... [letter; comment] Belkin NL. **Am J Infect Control** 1999 Apr; 27(2):178–9. Comment on: Am J Infect Control 1998 Apr;26(2):85–93.
Methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii: an unexpected difference in epidemiologic behavior. Bernards AT, et al. **Am J Infect Control** 1998 Dec;26(6):544–51
Reducing the rate of nosocomially transmitted respiratory syncytial virus [published erratum appears in Am J Infect Control 1999 Jun;27(3):303] Karanfil LV, et al. **Am J Infect Control** 1999 Apr;27(2):91–6
Comparison of the microbial barrier properties of a needleless and a conventional needle-based intravenous access system. Luebke MA, et al. **Am J Infect Control** 1998 Aug; 26(4):437–41
Antimicrobial resistance: a worldwide problem for health care institutions [editorial] McGowan JE Jr, et al. **Am J Infect Control** 1998 Dec;26(6):541–3
Impact of a dedicated intravenous therapy team on nosocomial bloodstream infection rates. Meier PA, et al. **Am J Infect Control** 1998 Aug;26(4):388–92
Prevention of infection in the immunocompromised host. Risi GF, et al. **Am J Infect Control** 1998 Dec;26(6):594–604; quiz 605–6 (76 ref.)
Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Zafar AB, et al. **Am J Infect Control** 1998 Dec;26(6):588–93
Postexposure prophylaxis implementation issues. programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)
Silver coating of medical devices for catheter-associated infections? [letter] Schierholz JM, et al. **Am J Med** 1999 Jul;107(1):101–2
Controlling VRE. Jacobson AF, et al. **Am J Nurs** 1999 Jun; 99(6):68
Protecting the future of medicine--from themselves [editorial; comment] Federman DD. **Ann Intern Med** 1999 Jan 5;130(1):66–7. Comment on: Ann Intern Med 1999 Jan 5;130(1):45–51.
Use of DNA fingerprinting to assess tuberculosis infection control. French AL, et al. **Ann Intern Med** 1998 Dec 1; 129(11):856–61
Vaginal health. Mazza D. **Aust Fam Physician** 1999 Feb; 28(2):162
Infection control in the respiratory laboratory: risk, costs, expediency [editorial; comment] Pierce RJ. **Aust N Z J Med** 1999 Feb;29(1):3–4. Comment on: Aust N Z J Med 1999 Feb;29(1):9–14.
A cost-analysis of two approaches to infection control in a lung function laboratory [see comments] Side EA, et al. **Aust N Z J Med** 1999 Feb;29(1):9–14. Comment in: Aust N Z J Med 1999 Feb;29(1):3–4.
Do post-splenectomy patients take prophylactic penicillin? Keenan RD, et al. **Br J Haematol** 1999 May;105(2):509–10
Methicillin-resistant Staphylococcus aureus in burns patients--why all the fuss? Reardon CM, et al. **Burns** 1998 Aug;24(5):393–7
Hand-borne mechanisms of dissemination of hepatitis C virus

in dialysis units: basis for new addenda to the present preventive strategies [letter] Caramelo C, et al. **Clin Nephrol** 1999 Jan;51(1):59–60

Risks of virus transmission associated with animal sera or substitutes and methods of control. Eloit M. **Dev Biol Stand** 1999;99:9–16 (10 ref.)

The plane truth about disinsection [news] **Environ Health Perspect** 1999 Aug;107(8):A397–8

Plasma jet takes off. Frazer L. **Environ Health Perspect** 1999 Aug;107(8):A414–5

Effectiveness of a training program in reducing infections in toddlers attending day care centers [see comments] Carabin H, et al. **Epidemiology** 1999 May;10(3):219–27. Comment in: Epidemiology 1999 May;10(3):209–10.

Technology status evaluation: personal protective equipment: November 1998. From the ASGE. American Society for Gastrointestinal Endoscopy. Carr-Locke DL, et al. **Gastrointest Endosc** 1999 Jun;49(6):854–7

Disease and the deceased [letter; comment] Chaiken B. **Hastings Cent Rep** 1998 Nov–Dec;28(6):4. Comment on: Hastings Cent Rep 1998 May–Jun;28(3):18–9; discussion 19–20.

Incidence of HIV risk and prevention of infection in health care settings. Ram S, et al. **Indian J Med Sci** 1998 Jun; 52(6):239–43

Issues in the management of resistant bacteria in long-term-care facilities. Bradley SF. **Infect Control Hosp Epidemiol** 1999 May;20(5):362–6 (47 ref.)

Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Cornet M, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):508–13

Infection control in gene therapy [see comments] Evans ME, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):568–76 (71 ref.). Comment in: Infect Control Hosp Epidemiol 1999 Aug;20(8):530–2.

Evaluation of a handwashing intervention to reduce respiratory illness rates in senior day-care centers. Falsey AR, et al. **Infect Control Hosp Epidemiol** 1999 Mar; 20(3):200–2

Strategies for prevention of infection in short-duration neutropenia. Fenelon L. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):590–2

Importance of the surveillance method: national prevalence studies on nosocomial infections and the limits of comparison. Gastmeier P, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):661–7

Experience with two validation methods in a prevalence survey on nosocomial infections. Gastmeier P, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):668–73

Implementation of an interactive computer-assisted infection monitoring program at the bedside. Heininger A, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):444–7

Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Jochimsen EM, et al. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):106–9

Results of a comprehensive infection control program for reducing surgical-site infections in coronary artery bypass surgery. McConkey SJ, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):533–8

Selecting respirators for control of worker exposure to infectious aerosols. McCullough NV, et al. **Infect Control Hosp Epidemiol** 1999 Feb;20(2):136–44

Disinfection of endoscopes: review of new chemical sterilants used for high-level disinfection. Rutala WA, et al. **Infect Control Hosp Epidemiol** 1999 Jan;20(1):69–76 (66 ref.)

Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies. Sheppard DC, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):851–3

A convenient way to avoid venipuncture and finger contamination [letter] Shields JW. **Infect Control Hosp Epidemiol** 1999 May;20(5):302

Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Soto NE, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):351–3

New technologies: how can journals best serve their readers? [editorial; comment] Springthorpe S. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):463–4. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):465–72. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):514–6. Comment on: Infect Control Hosp Epidemiol 1999 Jul;20(7):458.

An observational study of hand washing and infection control practices by healthcare workers. Watanakunakorn C, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):858–60

Tuberculosis: what you don't know can hurt you [editorial; comment] Woeltje KF. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):626–8 (12 ref.). Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):629–34. Comment on: Infect Control Hosp Epidemiol 1998 Sep;19(9):635–9.

Simplified surveillance for nosocomial bloodstream infections. Yokoe DS, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):657–60

A new technology of microdispersed silver in polyurethane induces antimicrobial activity in central venous catheters. Guggenbichler JP, et al. **Infection** 1999;27 Suppl 1:S16–23 (49 ref.)

Tuberculosis elimination and the challenge of the long-term completer [editorial; comment] Chaulk CP. **Int J Tuberc Lung Dis** 1999 Apr;3(4):269. Comment on: Int J Tuberc Lung Dis 1999 Apr;3(4):273–80.

Accidental exposures to blood and other body fluids in a large academic medical center [published erratum appears in **J Am Coll Health** 1999 May;47(6):291] Turner HS, et al. **J Am Coll Health** 1999 Mar;47(5):199–206

Importance of air quality and related factors in the prevention of infection in orthopaedic implant surgery [letter; comment] Drabu YJ, et al. **J Hosp Infect** 1998 Dec; 40(4):326. Comment on: J Hosp Infect 1998 Jul;39(3):173–80.

Unnecessary hospital infection control practices in developing countries [letter] Issack MI. **J Hosp Infect** 1999 Aug;42(4):339–41

Efficacy of hand disinfectants against vancomycin-resistant enterococci in vitro. Kampf G, et al. **J Hosp Infect** 1999 Jun;42(2):143–50

Waterbirths: regional audit of infection control practices. Kingsley A, et al. **J Hosp Infect** 1999 Feb;41(2):155–7

Infection control strategies in a neonatal intensive care unit in Argentina. Kurlat I, et al. **J Hosp Infect** 1998 Oct; 40(2):149–54

Efficacy of Directigen RSV testing in patient management following admission from a paediatric emergency department. Lipson SM, et al. **J Hosp Infect** 1999 Apr; 41(4):323–9

US policy for disease control among imported nonhuman primates. DeMarcus TA, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S281–2

Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. Kerstiëns B, et al. **J Infect Dis** 1999 Feb;179 Suppl 1:S263–7

The successful containment of coxsackie B4 infection in a neonatal unit. Austin BJ, et al. **J Paediatr Child Health** 1999 Feb;35(1):102–4

Rubella outbreak, Fort Bragg, North Carolina, 1995: a clash of two preventive strategies. Craig SC, et al. **Mil Med** 1999 Sep;164(9):616–8

Putting infection control principles into practice in home care. Friedman MM, et al. **Nurs Clin North Am** 1999 Jun; 34(2):463–82 (22 ref.)

Common infections acquired in the hospital: the nurse's role in prevention. Steed CJ. **Nurs Clin North Am** 1999 Jun; 34(2):443–61 (22 ref.)

Zoonotic infections. Weber DJ, et al. **Occup Med** 1999 Apr–Jun;14(2):247–84 (222 ref.)

Prevention and control of epidemic keratoconjunctivitis in a teaching eye institute. Gottsch JD, et al. **Ophthalmic Epidemiol** 1999 Mar;6(1):29–39

Infection control practices and the pregnant health care worker. Mirza A, et al. **Pediatr Infect Dis J** 1999 Jan; 18(1):18–22 (51 ref.)

Successful interventions for gram-negative resistance to extended-spectrum beta-lactam antiobiotics. Rice LB. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):120S–128S; discussion 133S–137S (44 ref.)

Decreased antimicrobial resistance after changes in antibiotic use. Smith DW. **Pharmacotherapy** 1999 Aug;19(8 Pt 2):129S–132S; discussion 133S–137S (26 ref.)

Legionella infection and control in occupational and environmental health [published erratum appears in Rev Environ Health 1999 Jan–Mar;14(1):following table of contents] Fujii J, et al. **Rev Environ Health** 1998 Oct–Dec; 13(4):179–203 (46 ref.)

Free drug short course for needle stick injuries [news] van der Linde I. **S Afr Med J** 1998 Sep;88(9):1062–3

Reduction of nosocomial infection in a neonatal intensive care unit (NICU). Ng SP, et al. **Singapore Med J** 1998 Jul;39(7):319–23

New methods of control against postoperative methicillin-resistant Staphylococcus aureus infection. Kusachi S, et al. **Surg Today** 1999;29(8):724–9

Prophylaxis moving to centre stage. Spier RE. **Vaccine** 1999 Jan 28;17(4):396–9

BSE epidemic continues to decline [news] **Vet Rec** 1999 Mar 27;144(13):331–2

[Ventilator-associated pneumonia; controversies with respect to diagnosis, pathogenesis, therapy and prevention] Bonten MJ, et al. **Ned Tijdschr Geneeskd** 1999 Apr 3;143(14):726–30 (24 ref.) (Eng. Abstr.) **(Dut)**

[European strategy for control of resistance to antibiotics] Sprenger MJ, et al. **Ned Tijdschr Geneeskd** 1999 Jun 19; 143(25):1322–5 (Eng. Abstr.) **(Dut)**

[Control of a Serratia marcescens epidemic in neonatology (letter)] Ganga-Zandzou PS, et al. **Arch Pediatr** 1999 Mar; 6(3):343–5 **(Fre)**

[Hygiene and disinfection best practices for home assisted respiratory care] Gautier V. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S141–2 **(Fre)**

[Utility of the Rhame and Sudderth model in nosocomial infection surveillance] Ennigrou S, et al. **Tunis Med** 1999 May;77(5):272–5 (Eng. Abstr.) **(Fre)**

[The management of occupational exposures to biological material in the hospital environment] Giannotta A, et al. **Ann Ig** 1999 Mar–Apr;11(2):117–24 (Eng. Abstr.) **(Ita)**

[The bioluminescence method in evaluating the sanitary and disinfection procedures in a hospital environment] Torre I, et al. **Ann Ig** 1998 Sep–Dec;10(5–6):325–32 (Eng. Abstr.) **(Ita)**

[Advantages of routine periodic replacement of the central endovenous catheter in total parenteral nutrition] González Avila G, et al. **Nutr Hosp** 1999 Mar–Apr;14(2):67–70 (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

CDC releases updated plan for emerging infectious diseases [see comments] Rose VL. **Am Fam Physician** 1999 Apr 15;59(8):2361–2, 2365. Comment in: Am Fam Physician 1999 Apr 15;59(8):2097–8, 2100.

Team approach to infection prevention and control in the nursing home setting [see comments] Ahlbrecht H, et al. **Am J Infect Control** 1999 Feb;27(1):64–70. Comment in: Am J Infect Control 1999 Feb;27(1):1–3.

Intervention for medical students: effective infection control. Calabro K, et al. **Am J Infect Control** 1998 Aug;26(4):431–6

Effective cost-reduction strategies in the management of regulated medical waste. Garcia R. **Am J Infect Control** 1999 Apr;27(2):165–75

APIC and CDC survey of Mycobacterium tuberculosis isolation and control practices in hospitals caring for children. Part 2: Environmental and administrative controls. Association for Professionals in Infection control and Epidemiology, Inc. Kellerman SE, et al. **Am J Infect Control** 1998 Oct;26(5):483–7

APIC and CDC survey of Mycobacterium tuberculosis isolation and control practices in hospitals caring for children. Part 1: Patient and family isolation policies and procedures. Association for Professionals in Infection and Epidemiology, Inc. Kellerman SE, et al. **Am J Infect Control** 1998 Oct;26(5):478–82

Role of surveillance in emerging health systems: measurement is essential but not sufficient [see comments] Lovett LL, et al. **Am J Infect Control** 1999 Apr;27(2):135–40. Comment in: Am J Infect Control 1999 Apr;27(2):77–8.

Who coordinates infection control programs in Australia? Murphy CL, et al. **Am J Infect Control** 1999 Jun; 27(3):291–5

Regionalization of infection prevention and control services in a publicly funded health care system. Wiens RM, et al. **Am J Infect Control** 1998 Aug;26(4):446–8 (5 ref.)

Emergency medical services. Arndt SD. **Am J Med** 1997 May 19;102(5B):104–5 (09 ref.)

Postexposure prophylaxis implementation issues: programmatic concerns in hospitals. Catalano MT. **Am J Med** 1997 May 19;102(5B):95–7 (03 ref.)

Monitoring effectiveness of controlling hospital acquired infections by prevalence surveys. Atukorala SD. **Ceylon Med J** 1998 Sep;43(3):134–7

The origins of DOT [letter; comment] Mitchison DA. **Int J Tuberc Lung Dis** 1998 Oct;2(10):863–5. Comment on: Int J Tuberc Lung Dis 1998 Feb;2(2):95.

Nosocomial infections: prospective survey of incidence in five French intensive care units. Legras A, et al. **Intensive Care Med** 1998 Oct;24(10):1040–6

HCV Infection: Six years after' in a dialysis unit [letter; comment] Brugnano R, et al. **Nephron** 1999 Feb;81(2):244–5 . Comment on: Nephron 1992;61(3):263–5.

The healthcare marketplace in the next millennium and nurses' roles in infection prevention and control. Jackson MM. **Nurs Clin North Am** 1999 Jun;34(2):411–26 (46 ref.)

Winning the battle but losing the war: methicillin-resistant Staphylococcus aureus (MRSA) infection at a teaching hospital. Farrington M, et al. **QJM** 1998 Aug;91(8):539–48

Epidemiology of opisthorchiasis and national control program in Thailand. Jongsuksuntigul P, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):327–32

STANDARDS

Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Hacek DM, et al. **Am J Clin Pathol** 1999 May;111(5):647–54

ASHP Therapeutic Guidelines for Nonsurgical Antimicrobial Prophylaxis. American Society of Health-System Pharmacists [see comments] **Am J Health Syst Pharm** 1999 Jun 15;56(12):1201–50. Comment in: Am J Health Syst Pharm 1999 Jun 15;56(12):1199.

APIC position paper: prevention of device-mediated bloodborne infections to health care workers. Association for Professionals in Infection Control and Epidemiology, Inc. **Am J Infect Control** 1998 Dec;26(6):578–80

Infection control in a Brazilian regional multihospital system. de Oliveira TC, et al. **Am J Infect Control** 1999 Jun; 27(3):262–9

Infection control programs in skilled nursing long-term care facilities: an assessment, 1995 [see comments] Goldrick BA. **Am J Infect Control** 1999 Feb;27(1):4–9. Comment in: Am J Infect Control 1999 Feb;27(1):1–3.

APIC/CHICA-Canada Infection Control and Epidemiology: Professional and Practice Standards. Association for Professionals in Infection Control and Epidemiology, Inc, and the Community and Hospital Infection Control Association-Canada. Horan-Murphy E, et al. **Am J Infect Control** 1999 Feb;27(1):47–51

Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Mangram AJ, et al. **Am J Infect Control** 1999 Apr; 27(2):97–132; quiz 133–4; discussion 96

Joint Commission standards for long-term care infection

control: putting together the process element. Joint Commission on Accreditation of Healthcare Organizations [see comments] Pritchard V. **Am J Infect Control** 1999 Feb; 27(1):27–34. Comment in: Am J Infect Control 1999 Feb;27(1):1–3.

Regional data set of infection rates for long-term care facilities: description of a valuable benchmarking tool [see comments] Stevenson KB. **Am J Infect Control** 1999 Feb; 27(1):20–6. Comment in: Am J Infect Control 1999 Feb;27(1):1–3.

APIC guidelines committee: using science to guide practice. Association for Professionals in Infection Control and Epidemiology. Underwood MA, et al. **Am J Infect Control** 1999 Apr;27(2):141–4

Issues complicating the implementation of postexposure prophylaxis. L'Ecuyer PB, et al. **Am J Med** 1997 May 19; 102(5B):90–4 (50 ref.)

Does art imitate life? [letter] Leibowitz R. **Am J Nurs** 1998 Nov;98(11):18

On target: a tuberculosis control strategy whose time has come [editorial; comment] Reichman LB. **Ann Intern Med** 1999 Oct 19;131(8):617–8. Comment on: Ann Intern Med 1999 Oct 19;131(8):557–63.

Recommended practices for standard and the transmission-based precautions in the perioperative practice setting. Association of Operating Room Nurses. **AORN J** 1999 Feb;69(2):404–6, 409–11

The effect of traffic patterns in the OR on surgical site infections. Pryor F, et al. **AORN J** 1998 Oct;68(4):649–60

Improving glove barrier effectiveness. Rabussay DP, et al. **AORN J** 1997 Dec;66(6):1043–6, 1049–54, 1057–60 passim (55 ref.)

Prion diseases--an evidence-based protocol for infection control. Steelman VM. **AORN J** 1999 May;69(5):946–54, 956–67 passim; quiz 968–76 (94 ref.)

A survey of the implementation of health service guidelines on arrangements for infection control in health trusts in the West Midlands. Hawker JI. **Commun Dis Public Health** 1999 Jan;2(1):54–8

Sigmoidoscopy and rectal biopsy--failure of infection control. **Commun Dis Rep CDR Wkly** 1999 Apr 16; 9(16):139

Infection control during gastrointestinal endoscopy: guidelines for clinical application. From the ASGE. American Society for Gastrointestinal Endoscopy. **Gastrointest Endosc** 1999 Jun;49(6):836–41 (40 ref.)

Varicella serological status of healthcare workers as a guide to whom to test or immunize. Brunell PA, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):355–7

Changing heat and moisture exchangers every 48 hours does not increase the incidence of nosocomial pneumonia. Daumal F, et al. **Infect Control Hosp Epidemiol** 1999 May; 20(5):347–9

The effect of frequency of chart review on the sensitivity of nosocomial infection surveillance in general surgery. Delgado-Rodríguez M, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):208–12

Vancomycin use in a university medical center: effect of a vancomycin continuation form. Evans ME, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):417–20

The relative efficacy of respirators and room ventilation in preventing occupational tuberculosis. Fennelly KP, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):754–9

Lack of transmission of vancomycin-resistant enterococci in three long-term-care facilities. Greenaway CA, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):341–3

Level of suspicion of pulmonary tuberculosis over a 4-year period in a teaching hospital [letter; comment] Labbé AC, et al. **Infect Control Hosp Epidemiol** 1999 Mar;20(3):158–60 . Comment on: Infect Control Hosp Epidemiol 1996 Jul;17(7):412–8.

Varicella-zoster screening and management programs in healthcare facilities in Canada. Lussier N, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):562–3

Trends in compliance with the guidelines for preventing the transmission of Mycobacterium tuberculosis among New Jersey hospitals, 1989 to 1996. Manangan LP, et al. **Infect Control Hosp Epidemiol** 1999 May;20(5):337–40

Occult nosocomial infections. Petignat C, et al. **Infect Control Hosp Epidemiol** 1998 Aug;19(8):593–6

Transmission of measles virus in healthcare settings during a communitywide outbreak. Steingart KR, et al. **Infect Control Hosp Epidemiol** 1999 Feb;20(2):115–9

Gene therapy: a new challenge for infection control [editorial; comment] Weber DJ, et al. **Infect Control Hosp Epidemiol** 1999 Aug;20(8):530–2 Comment on: Infect Control Hosp Epidemiol 1999 Aug;20(8):568–76.

Revised UK guidelines for the control of methicillin-resistant Staphylococcus aureus in hospitals. Chadwick PR. **Int J Antimicrob Agents** 1999 Feb;11(2):89–91

Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association [see comments] [published erratum appears in J Hosp Infect 1999 May;42(1):83] **J Hosp Infect** 1998 Aug; 39(4):253–90. Comment in: J Hosp Infect 1999 Jan;41(1):72–4. Comment in: J Hosp Infect 1999 May;42(1):71–2.

Comparison of effectiveness and required time of two surveillance methods in intensive care patients. Boulétreau A, et al. **J Hosp Infect** 1999 Apr;41(4):281–9

MRSA and hospital control [letter; comment] Chadwick PR, et al. **J Hosp Infect** 1999 May;42(1):73. Comment on: J Hosp Infect 1998 Oct;40(2):159. Comment on: J Hosp Infect 1998 Oct;40(2):159–60.

A control programme for MRSA (methicillin-resistant Staphylococcus aureus) containment in a paediatric intensive care unit: evaluation and impact on infections caused by other micro-organisms. Cosseron-Zerbib M, et al. **J Hosp Infect** 1998 Nov;40(3):225–35

Infection control--evidence into practice. Jenner EA, et al. **J Hosp Infect** 1999 Jun;42(2):91–104 (46 ref.)

Waterbirths: regional audit of infection control practices. Kingsley A, et al. **J Hosp Infect** 1999 Feb;41(2):155–7

Revised guidelines for control of MRSA in hospitals: finding the most useful point [letter; comment] Rahman M, et al. **J Hosp Infect** 1999 May;42(1):71–2. Comment on: J Hosp Infect 1998 Aug;39(4):253–90.

Hospital environmental cleaning standards [letter; comment] Wilcox MH, et al. **J Hosp Infect** 1999 Jun;42(2):168. Comment on: J Hosp Infect 1999 Jan;41(1):72–4.

Evidence-based clinical practice. Goode CJ, et al. **J Nurs Adm** 1999 Jun;29(6):15–21

ACOEM guidelines for protecting health care workers against tuberculosis. American College of Occupational and Environmental Medicine. **J Occup Environ Med** 1998 Sep; 40(9):765–7

Health and safety standards in New Zealand mortuaries. Walls CB. **N Z Med J** 1999 Aug 27;112(1094):311–3

Rule-makers who establish infection control standards. Yost AJ, et al. **Nurs Clin North Am** 1999 Jun;34(2):527–33 (18 ref.)

Risk reduction for exposure to blood-borne pathogens in EMS. National Association of Emergency Medical Services Physicians. Rinnert KJ, et al. **Prehosp Emerg Care** 1998 Jan-Mar;2(1):62–6

A review of infection control practices, risk reduction, and legislative regulations for blood-borne disease: applications for emergency medical services. Rinnert KJ. **Prehosp Emerg Care** 1998 Jan-Mar;2(1):70–5 (40 ref.)

[Surgical wound infection. Review of the guidelines and results of a prevalence study by the Presidio Ospedaliero de Voghera] Cestari V, et al. **Minerva Chir** 1999 May; 54(5):319–23 (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

Statewide Program for Infection Control and Epidemiology spreads computer virus [letter] Clontz EP, et al. **Infect Control Hosp Epidemiol** 1998 Oct;19(10):737–8

Caveats regarding the use of control charts. Humble C. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):865–8

A software program to calculate Goodman and Kruskal's gamma: a method to monitor surgical-site infection rates. Wasser TE. **Infect Control Hosp Epidemiol** 1998 Nov; 19(11):869–71

TRENDS

ASHP statement on the pharmacist's role in infection control. **Am J Health Syst Pharm** 1998 Aug 15;55(16):1724–6

Development of nursing home infection control [editorial] Smith PW. **Infect Control Hosp Epidemiol** 1999 May; 20(5):303–5

Pertussis: an underappreciated risk for nosocomial outbreaks [editorial; comment] Weber DJ, et al. **Infect Control Hosp Epidemiol** 1998 Nov;19(11):825–8. Comment on: Infect Control Hosp Epidemiol 1998 Nov;19(11):861–9.

Swinging back the MRSA pendulum? [letter; comment] Dancer SJ. **J Hosp Infect** 1999 May;42(1):69–71. Comment on: J Hosp Infect 1998 Jun;39(2):85–93.

INFECTION CONTROL, DENTAL

Electro-chemically activated water in dental unit water lines. Marais JT, et al. **Br Dent J** 1999 Aug 14;187(3):154–8

Water, water everywhere but not a drop to drink? Smith AJ, et al. **Br Dent J** 1999 Jan 9;186(1):12–4 (27 ref.)

Bacteremia after oral surgery and antibiotic prophylaxis for endocarditis. Hall G, et al. **Clin Infect Dis** 1999 Jul; 29(1):1–8; quiz 9–10 (86 ref.)

The role of age- and population-based differences in the attitudes, knowledge and infection control practices of Canadian dentists. McCarthy GM, et al. **Community Dent Oral Epidemiol** 1999 Aug;27(4):298–304

Today's minimal requirements for a practical dental office infection control and exposure control program. Terezhalmy GT, et al. **Dent Clin North Am** 1998 Oct; 42(4):629–42

Hepatitis viruses A, B, C, D, E and G: implications for dental personnel. Gillcrist JA. **J Am Dent Assoc** 1999 Apr; 130(4):509–20 (97 ref.)

Dental infection control at the year 2000: accomplishment recognized. Molinari JA. **J Am Dent Assoc** 1999 Sep; 130(9):1291–8 (35 ref.)

HIV/AIDS and infection control practices in dentistry: a rebuttal [see comments] Hardie J. **J Can Dent Assoc** 1999 Jun;65(6):337–40. Comment in: J Can Dent Assoc 1999 Jun;65(6):311.

The truth about HIV/AIDS and infection control practices in dentistry [see comments] Nutt S, et al. **J Can Dent Assoc** 1999 Jun;65(6):334–6. Comment in: J Can Dent Assoc 1999 Jun;65(6):311.

I know where I stand! [editorial; comment] O'Keefe J. **J Can Dent Assoc** 1999 Jun;65(6):311. Comment on: J Can Dent Assoc 1999 Jun;65(6):334–6. Comment on: J Can Dent Assoc 1999 Jun;65(6):337–40.

INSTRUMENTATION

Orthodontic products update. Cross infection control and elastomeric module delivery systems. Davies C. **Br J Orthod** 1998 Nov;25(4):301–3

Assessing the clinical effectiveness of an aerosol reduction device for the air polisher. Muzzin KB, et al. **J Am Dent Assoc** 1999 Sep;130(9):1354–9

LEGISLATION & JURISPRUDENCE

Safety needles [letter; comment] Bertolami CN, et al. **J Am Dent Assoc** 1999 Apr;130(4):472. Comment on: J Am Dent Assoc 1997 Sep;128(9):1253–61.

METHODS

A survey of potential risk factors for HIV transmission through dental practice in Japan. Aizawa F, et al. **Asia Pac J Public Health** 1998;10(1):21–8

Infection control practices of general dental practitioners [letter; comment] Shields JW. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):389. Comment on: Infect Control Hosp Epidemiol 1998 Dec;19(12):888–9.

The effectiveness of two sterilization methods when different precleaning techniques are employed. Pratt LH, et al. **J Dent** 1999 Mar;27(3):247–8

Patient discomfort and cross-infection control in bitewing examination with a storage phosphor plate and a CCD-based sensor. Wenzel A, et al. **J Dent** 1999 Mar; 27(3):243–6

Disinfection of dental diamond burs contaminated with hepatitis B virus. Leontiou AP, et al. **J Prosthet Dent** 1999 Sep;82(3):332–5

Dental precautions for travelers [letter] Florence E, et al. **J Travel Med** 1998 Sep;5(3):159–

Effect of steam sterilization inside the turbine chambers of dental turbines. Andersen HK, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1999 Feb;87(2):184–8

Infection control practices of oral specialists and general dental practitioners [letter; comment] Hardie J. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1998 Dec;86(6):631–2. Comment on: Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998 Jan;85(1):47–54.

STANDARDS

The infection control practices of general dental practitioners [letter; comment] [see comments] Hardie J. **Infect Control Hosp Epidemiol** 1998 Dec;19(12):888–9. Comment on: Infect Control Hosp Epidemiol 1997 Oct;18(10):699–703. Comment in: Lancet 1999 Jun;20(6):389.

INFECTION CONTROL PRACTITIONERS

Infection control team in the operating room: separating aspiration from reality! [editorial] Humphreys H. **J Hosp Infect** 1999 Aug;42(4):265–7

[Ebola virus: what the practitioner needs to know] Georges AJ, et al. **Med Trop (Mars)** 1998;58(2):177–86 (104 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Team approach to infection prevention and control in the nursing home setting [see comments] Ahlbrecht H, et al. **Am J Infect Control** 1999 Feb;27(1):64–70. Comment in: Am J Infect Control 1999 Feb;27(1):1–3.

STANDARDS

Credentialing, diversity, and professional recognition-foundations for an Australian infection control career path. Murphy CL, et al. **Am J Infect Control** 1999 Jun;27(3):240–6

STATISTICS & NUMERICAL DATA

Who coordinates infection control programs in Australia? Murphy CL, et al. **Am J Infect Control** 1999 Jun; 27(3):291–5

Job analysis 1996: Infection control professional. Certification Board in Infection Control and Epidemiology, Inc, 1996 Job Analysis Committee. Turner JG, et al. **Am J Infect Control** 1999 Apr;27(2):145–57

INFECTIOUS ANEMIA VIRUS, EQUINE

Gene transfer vectors derived from equine infectious anemia virus. Olsen JC. **Gene Ther** 1998 Nov;5(11):1481–7

DRUG EFFECTS

The role of oxygen in the antiviral activity of hypericin and hypocrellin. Park J, et al. **Photochem Photobiol** 1998 Oct;

68(4):593–7

ENZYMOLOGY

Crystal structure of dUTPase from equine infectious anaemia virus; active site metal binding in a substrate analogue complex. Dauter Z, et al. **J Mol Biol** 1999 Jan 15; 285(2):655–73

Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Kervinen J, et al. **Protein Sci** 1998 Nov;7(11):2314–23

GENETICS

cDNA excision in stable retroviral cDNA transfectants is prevented by R removal. Rosin-Arbesfeld R, et al. **Biochem Biophys Res Commun** 1998 Sep 29;250(3):747–50

Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome. Stetor SR, et al. **Biochemistry** 1999 Mar 23;38(12):3656–67

Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. Bieniasz PD, et al. **Mol Cell Biol** 1999 Jul;19(7):4592–9

GROWTH & DEVELOPMENT

Long terminal repeat sequences of equine infectious anaemia virus are a major determinant of cell tropism. Payne SL, et al. **J Gen Virol** 1999 Mar;80 (Pt 3):755–9

IMMUNOLOGY

Evaluation of equine infectious anemia virus core proteins produced in a baculovirus expression system in agar gel immunodiffusion test and enzyme-linked immunosorbent assay. Kong XG, et al. **J Vet Med Sci** 1998 Dec; 60(12):1361–2

Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors. Lonning SM, et al. **J Virol** 1999 Apr;73(4):2762–9

Gag protein epitopes recognized by CD4(+) T-helper lymphocytes from equine infectious anemia virus-infected carrier horses. Lonning SM, et al. **J Virol** 1999 May; 73(5):4257–65

Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. Zhang W, et al. **J Virol** 1998 Dec;72(12):9612–20

Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Hammond SA, et al. **Virology** 1999 Sep 30;262(2):416–30

A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Hammond SA, et al. **Virology** 1999 Feb 1;254(1):37–49

Natural variation of equine infectious anemia virus Gag protein cytotoxic T lymphocyte epitopes. Zhang W, et al. **Virology** 1999 Sep 1;261(2):242–52

ISOLATION & PURIFICATION

Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. Russell KE, et al. **Virology** 1999 Jun 20; 259(1):7–19

PATHOGENICITY

Endothelial cell infection in vivo by equine infectious anaemia virus. Oaks JL, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2393–7

Equine endothelial cells support productive infection of equine infectious anemia virus. Maury W, et al. **J Virol** 1998 Nov;72(11):9291–7

PHYSIOLOGY

Model for lentivirus capsid core assembly based on crystal dimers of EIAV p26. Jin Z, et al. **J Mol Biol** 1999 Feb 12;286(1):83–93

Equine endothelial cells support productive infection of equine infectious anemia virus. Maury W, et al. **J Virol** 1998 Nov;72(11):9291–7

Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly. Puffer BA, et al. **J Virol** 1998 Dec;72(12):10218–21

In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Raabe ML, et al. **Virology** 1999 Jul 5;259(2):416–27

INFECTIOUS ARTERITIS VIRUS, EQUINE see **ARTERITIS VIRUS, EQUINE**

INFECTIOUS BOVINE RHINOTRACHEITIS

EPIDEMIOLOGY

An epidemiological and economic simulation model to evaluate the spread and control of infectious bovine rhinotracheitis in The Netherlands. Vonk Noordegraaf A, et al. **Prev Vet Med** 1998 Sep 1;36(3):219–38

PREVENTION & CONTROL

An epidemiological and economic simulation model to evaluate the spread and control of infectious bovine rhinotracheitis in The Netherlands. Vonk Noordegraaf A, et al. **Prev Vet Med** 1998 Sep 1;36(3):219–38

[Fight against infectious bovine rhinotracheitis postponed (letter)] Wille G, et al. **Tijdschr Diergeneeskd** 1999 May 15;124(10):323 **(Dut)**

TRANSMISSION

Airborne transmission of BHV1, BRSV, and BVDV among cattle is possible under experimental conditions. Mars MH, et al. **Vet Microbiol** 1999 Apr 19;66(3):197–207

VIROLOGY

A specific PCR to differentiate between gE negative vaccine and wildtype bovine herpesvirus type 1 strains. Schynts F, et al. **Vet Microbiol** 1999 Apr 19;66(3):187–95

INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFECTIOUS BRONCHITIS VIRUS, AVIAN

The early history of infectious bronchitis. Fabricant J. **Avian Dis** 1998 Oct-Dec;42(4):648–50 (24 ref.)

Influence of inoculation site of combined oil-adjuvanted vaccine on the antibody response in chickens. Deguchi K, et al. **J Vet Med Sci** 1998 Jul;60(7):831–5

CLASSIFICATION

A multiplex PCR for Massachusetts and Arkansas serotypes of infectious bronchitis virus. Wang X, et al. **Mol Cell Probes** 1999 Feb;13(1):1–7

ENZYMOLOGY

Characterisation of a papain-like proteinase domain encoded by ORF1a of the coronavirus IBV and determination of the C-terminal cleavage site of an 87 kDa protein. Lim KP, et al. **Adv Exp Med Biol** 1998;440:173–84

Proteolytic processing of the polyprotein encoded by ORF1b of the coronavirus infectious bronchitis virus (IBV). Liu DX, et al. **Adv Exp Med Biol** 1998;440:149–59

Further characterisation of the coronavirus IBV ORF 1a products encoded by the 3C-like proteinase domain and the flanking regions. Ng LF, et al. **Adv Exp Med Biol** 1998; 440:161–71

Activity of a purified His-tagged 3C-like proteinase from the coronavirus infectious bronchitis virus. Tibbles KW, et al. **Virus Res** 1999 Apr;60(2):137–45

GENETICS

Does IBV change slowly despite the capacity of the spike protein to vary greatly? Cavanagh D, et al. **Adv Exp Med Biol** 1998;440:729–34

Sequence elements involved in the rescue of IBV defective RNA CD-91. Dalton K, et al. **Adv Exp Med Biol** 1998; 440:253–7

Utilising a defective IBV RNA for heterologous gene expression with potential prophylactic application. Evans SA, et al. **Adv Exp Med Biol** 1998;440:687–92

Regulation of mRNA 1 expression by the 5'-untranslated region (5'-UTR) of the coronavirus infectious bronchitis virus (IBV). Liu DX, et al. **Adv Exp Med Biol** 1998; 440:303–11

Rescue of IBV D-RNA by heterologous helper virus strains. Stirrups K, et al. **Adv Exp Med Biol** 1998;440:259–64

Sequence comparison of avian infectious bronchitis virus S1 glycoproteins of the Florida serotype and five variant isolates from Georgia and California. Moore KM, et al. **Virus Genes** 1998;17(1):63–83

IMMUNOLOGY

A monoclonal antibody blocking ELISA for the detection of IBV antibodies in fowl. Moving V, et al. **Adv Exp Med Biol** 1998;440:495–9

Cytotoxic T lymphocyte responses to infectious bronchitis virus infection. Seo SH, et al. **Adv Exp Med Biol** 1998; 440:455–60

A liquid phase blocking ELISA for the detection of antibodies against infectious bronchitis virus. Cardoso TC, et al. **Braz J Med Biol Res** 1999 Jun;32(6):747–52

Immunosuppressive effect of Cryptosporidium baileyi infection on vaccination against avian infectious bronchitis in chicks. Rhee JK, et al. **Korean J Parasitol** 1998 Sep; 36(3):203–6

ISOLATION & PURIFICATION

Isolation of Georgia variant (Georgia isolate 1992) infectious bronchitis virus but not Ornithobacterium rhinotracheale from a Kentucky broiler complex. Erbeck DH, et al. **Avian Dis** 1998 Jul-Sep;42(3):613–7

Serological evidence for a 793/B related avian infectious bronchitis virus in India [letter] Elankumaran S, et al. **Vet Rec** 1999 Mar 13;144(11):299–300

INFECTIOUS BURSAL AGENT see **INFECTIOUS BURSAL DISEASE VIRUS**

INFECTIOUS BURSAL DISEASE VIRUS

Simplified sample processing combined with a sensitive nested polymerase chain reaction assay for detection of infectious bursal disease virus in the bursa of Fabricus. Liu X, et al. **Avian Dis** 1998 Jul-Sep;42(3):480–5

Immunopotentiating effects of Azadirachta indica (Neem) dry leaves powder in broilers, naturally infected with IBD virus. Sadekar RD, et al. **Indian J Exp Biol** 1998 Nov; 36(11):1151–3

Poultry industry strategies for control of immunosuppressive diseases. Fussell LW. **Poult Sci** 1998 Aug;77(8):1193–6 (25 ref.)

Infectious bursal disease and hemorrhagic enteritis. Saif YM. **Poult Sci** 1998 Aug;77(8):1186–9 (29 ref.)

Biochemical and hormonal changes associated with experimental infection of chicks with infectious bursal disease virus. al-Afaleq AI. **Zentralbl Veterinarmed [B]** 1998 Nov;45(9):513–7

CLASSIFICATION

Sequence analysis of the VP2 hypervariable region of nine infectious bursal disease virus isolates from mainland China. Chen HY, et al. **Avian Dis** 1998 Oct-Dec;42(4):762–9

Sequence comparison of the VP2 variable region of infectious bursal disease virus isolates from Vietnam. To H, et al. **J Vet Med Sci** 1999 Apr;61(4):429–32

DRUG EFFECTS

Fluorescence spectroscopy monitoring of the conformational restraint of formaldehyde- and glutaraldehyde-treated infectious bursal disease virus proteins. Cepica A, et al. **Vaccine** 1998 Dec;16(20):1957–61

ENZYMOLOGY

VP1, the putative RNA-dependent RNA polymerase of infectious bursal disease virus, forms complexes with the capsid protein VP3, leading to efficient encapsidation into virus-like particles. Lombardo E, et al. **J Virol** 1999 Aug; 73(8):6973–83

GENETICS

Sequence analysis of Australian infectious bursal disease viruses. Proffitt JM, et al. **Aust Vet J** 1999 Mar;77(3):186–8

Sequence analysis of the VP2 hypervariable region of nine infectious bursal disease virus isolates from mainland China. Chen HY, et al. **Avian Dis** 1998 Oct-Dec;42(4):762–9

Restriction fragment length polymorphisms in the VP2 gene of infectious bursal disease viruses from outside the United States. Jackwood DJ, et al. **Avian Dis** 1999 Apr-Jun; 43(2):310–4

Coding region of segment A sequence of a very virulent isolate of IBDV--comparison with isolates from different countries and virulence. Pitcovski J, et al. **Avian Dis** 1998 Jul-Sep;42(3):497–506

Restriction fragment length polymorphism analysis of highly virulent strains of infectious bursal disease viruses from Holland, Turkey, and Taiwan. Ture O, et al. **Avian Dis** 1998 Jul-Sep;42(3):470–9

Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography. Hu YC, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):721–9

Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Kibenge FS, et al. **Can J Vet Res** 1999 Jan; 63(1):49–55

Tissue culture infectivity of different strains of infectious bursal disease virus is determined by distinct amino acids in VP2. Mundt E. **J Gen Virol** 1999 Aug;80 (Pt 8):2067–76

Adaptation of very virulent infectious bursal disease virus to chicken embryonic fibroblasts by site-directed mutagenesis of residues 279 and 284 of viral coat protein VP2. Lim BL, et al. **J Virol** 1999 Apr;73(4):2854–62

A comparison of two RNA isolation methods for double-stranded RNA of infectious bursal disease virus. Akin A, et al. **J Virol Methods** 1998 Oct;74(2):179–84

IMMUNOLOGY

Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Csatary LK, et al. **Anticancer Res** 1999 Jan-Feb;19(1B):629–33

In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. Gagic M, et al. **Avian Dis** 1999 Apr-Jun;43(2):293–301

Correlation of enzyme-linked immunosorbent assay titers with protection against infectious bursal disease virus. Jackwood DJ, et al. **Avian Dis** 1999 Apr-Jun;43(2):189–97

Failure of viral protein 3 of infectious bursal disease virus produced in prokaryotic and eukaryotic expression systems to protect chickens against the disease. Pitcovski J, et al. **Avian Dis** 1999 Jan-Mar;43(1):8–15

Antigenic and molecular characterization of three infectious bursal disease virus field isolates. Sellers HS, et al.

Avian Dis 1999 Apr-Jun;43(2):198-206

The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease. Jeurissen SH, et al. **Immunology** 1998 Nov;95(3):494-500

Effect of thymus extract on immunologic reactivity of chicken vaccinated with infectious bursal disease virus. Abdel-Fattah AF, et al. **J Vet Med Sci** 1999 Jul;61(7):811-7

Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Tsukamoto K, et al. **Virology** 1999 May 10;257(2):352-62

ISOLATION & PURIFICATION

Chimeric infectious bursal disease virus-like particles expressed in insect cells and purified by immobilized metal affinity chromatography. Hu YC, et al. **Biotechnol Bioeng** 1999 Jun 20;63(6):721-9

Seroprevalence of infectious bursal disease virus in free-living wild birds in Japan. Ogawa M, et al. **J Vet Med Sci** 1998 Nov;60(11):1277-9

Seroprevalence of infectious bursal disease in non-vaccinated indigenous and exotic chickens on selected farms around Gaborone, Botswana. Mushi EZ, et al. **Onderstepoort J Vet Res** 1999 Jun;66(2):135-7

PATHOGENICITY

Response of embryonic chicken lymphocytes to in ovo exposure to lymphotropic viruses. St. Hill CA, et al. **Am J Vet Res** 1999 Aug;60(8):937-41

Some characteristics of a cellular receptor for virulent infectious bursal disease virus by using flow cytometry. Ogawa M, et al. **Arch Virol** 1998;143(12):2327-41

Organ culture of chicken bursa as a model to study the pathogenicity of infectious bursal disease virus isolates. Shakya S, et al. **Avian Dis** 1999 Apr-Jun;43(2):167-71

Alteration of chicken heterophil and macrophage functions by the infectious bursal disease virus. Lam KM. **Microb Pathog** 1998 Sep;25(3):147-55

Susceptibility of local Nigerian and exotic chickens to infectious bursal disease by contact exposure. Okoye JO, et al. **Trop Anim Health Prod** 1999 Apr;31(2):75-81

Lysis of myelocytes in chickens infected with infectious bursal disease virus. Inoue M, et al. **Vet Pathol** 1999 Mar; 36(2):146-51

PHYSIOLOGY

Tissue culture infectivity of different strains of infectious bursal disease virus is determined by distinct amino acids in VP2. Mundt E. **J Gen Virol** 1999 Aug;80 (Pt 8):2067-76

INFECTIOUS DISEASE CONTACT TRACING see **CONTACT TRACING**

INFECTIOUS DISEASE REPORTING see **DISEASE NOTIFICATION**

INFECTIOUS DISEASES see **COMMUNICABLE DISEASES**

INFECTIOUS ENTERITIS VIRUS, FELINE see **PARVOVIRUS, FELINE**

INFECTIOUS ENTERITIS VIRUS OF MINK see **PARVOVIRUS, FELINE**

INFECTIOUS HUMAN WART VIRUS see **PAPILLOMAVIRUS, HUMAN**

INFECTIOUS KERATOCONJUNCTIVITIS see **KERATOCONJUNCTIVITIS, INFECTIOUS**

INFECTIOUS MONONUCLEOSIS

[Infectious mononucleosis] Kobayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(25 Pt 3):145-7 (11 ref.) **(Jpn)**

[Epstein-Barr virus and rheumatic disease] Murakami K. **Ryumachi** 1998 Dec;38(6):849-59 (70 ref.) **(Jpn)**

BLOOD

Neutrophil function capacity to express CD10 is decreased in patients with septic shock [see comments] Martens A, et al. **Crit Care Med** 1999 Mar;27(3):549-53. Comment in: Crit Care Med 1999 Mar;27(3):465-6.

COMPLICATIONS

Acute monoarthritis from infectious mononucleosis. Berger RG, et al. **Am J Med** 1999 Aug;107(2):177-8

A study on Epstein-Barr virus in erythema multiforme. Chen CL, et al. **Arch Dermatol Res** 1998 Aug;290(8):446-9

Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Anderlini P, et al. **Br J Haematol** 1999 Jul;106(1):154-61

Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. White PD, et al. **Br J Psychiatry** 1998 Dec;173:475-81

Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Sleckman BG, et al. **Cancer Epidemiol Biomarkers Prev** 1998 Dec;7(12):1117-21

Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness [see comments] Katon W, et al. **Gen Hosp Psychiatry** 1999 Jan-Feb;21(1):21-9. Comment in: Gen Hosp Psychiatry 1999 Jan-Feb;21(1):18-20.

Anorexia, OCD, and streptococcus [letter; comment] Henry MC, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Mar; 38(3):228-9. Comment on: J Am Acad Child Adolesc Psychiatry 1997 Aug;36(8):1128-33.

Common variable immunodeficiency following Epstein-Barr virus infection. Zuccaro G, et al. **J Clin Lab Immunol** 1997; 49(1):41-5

MR findings in isolated oculomotor nerve palsy associated with infectious mononucleosis caused by Epstein-Barr virus infection. Ishibashi A, et al. **J Comput Assist Tomogr** 1998 Nov-Dec;22(6):995-7

Severe cholestatic jaundice induced by Epstein-Barr virus infection in the elderly. Edoute Y, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):821-4

Infectious mononucleosis and bilateral peritonsillar abscesses resulting in airway obstruction. Burstin PP, et al. **J Laryngol Otol** 1998 Dec;112(12):1186-8

Genital ulceration as a presenting manifestation of infectious mononucleosis. Sisson BA, et al. **J Pediatr Adolesc Gynecol** 1998 Nov;11(4):185-7

Massive splenomegaly and Epstein-Barr virus-associated infectious mononucleosis in a patient with Gaucher disease. Eapen M, et al. **J Pediatr Hematol Oncol** 1999 Jan-Feb; 21(1):47-9

Gene mutation responsible for fatal EBV complication discovered [news] McCarthy M. **Lancet** 1998 Oct 3; 352(9134):1125

Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Hudson LB, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):642-4 (4 ref.)

Pseudoappendicitis preceding infectious mononucleosis. Adcock PM, et al. **Pediatr Emerg Care** 1998 Oct; 14(5):345-6

Immune complex disease associated with Epstein-Barr virus infectious mononucleosis. Lande MB, et al. **Pediatr Nephrol** 1998 Oct;12(8):651-3

Spontaneous splenic rupture in infectious mononucleosis: conservative management with gradual percutaneous drainage of a subcapsular hematoma. Schwarz M, et al. **Pediatr Surg Int** 1999;15(2):139-40

Self-reported infectious mononucleosis and 6 cancers: a population-based, case-control study. Levine R, et al. **Scand J Infect Dis** 1998;30(3):211-4

A boy with fatal infectious mononucleosis suspected as the first Japanese case of X-linked lymphoproliferative syndrome. Tsutsumi H, et al. **Scand J Infect Dis** 1998; 30(6):610-2

[Splenic hematoma during infectious mononucleosis: non-operative treatment (letter)] Lambotte O, et al. **Presse Med** 1998 Feb 7;27(5):209 **(Fre)**

[A case of disseminated hepato-splenic involvement in infectious mononucleosis. Computerized tomography and magnetic resonance findings] Ferrozzi F, et al. **Radiol Med (Torino)** 1998 Sep;96(3):258-60 **(Ita)**

[Agranulocytosis as a complication of acute infectious mononucleosis] Brkić S, et al. **Med Pregl** 1998 Jul-Aug; 51(7-8):355-8 (Eng. Abstr.) **(Scr)**

[Acute oligoarthritis and infection by Epstein-Barr virus (letter)] Gómez N, et al. **Enferm Infecc Microbiol Clin** 1998 Nov;16(9):440-1 **(Spa)**

[Benign medullar oligoblastosis secondary to infectious mononucleosis (letter)] García Fernández JR, et al. **Sangre (Barc)** 1998 Oct;43(5):463 **(Spa)**

DIAGNOSIS

An infectious mononucleosis-like syndrome induced by minocycline: a third pattern of adverse drug reaction. Lupton JR, et al. **Cutis** 1999 Aug;64(2):91-6

Spontaneous splenic rupture and infectious mononucleosis in a forensic setting. Lippstone MB, et al. **Del Med J** 1998 Oct;70(10):433-7

Acute cytomegalovirus meningomyelitis in an immunocompetent patient. De Socio GV, et al. **Eur J Clin Microbiol Infect Dis** 1998 Dec;17(12):885-7

Severe cholestatic jaundice induced by Epstein-Barr virus infection in the elderly. Edoute Y, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):821-4

Infectious mononucleosis in middle age [clinical conference] Auwaerter PG. **JAMA** 1999 Feb 3;281(5):454-9

Acute HIV infection among patients tested for mononucleosis [letter] Rosenberg ES, et al. **N Engl J Med** 1999 Mar 25; 340(12):969

Comparison of three rapid, in-office mononucleosis tests [letter] Schwartz RH. **Pediatr Infect Dis J** 1999 Jan; 18(1):80-1

[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options] Brinkman K, et al. **Ned Tijdschr Geneeskd** 1999 May 29;143(22):1129-33 (Eng. Abstr.) **(Dut)**

[A flash of lightning that makes one anuric] Bouchard O, et al. **Rev Med Interne** 1999;20 Suppl 2:294s-296s **(Fre)**

[Manganese superoxide dismutase-inhibiting autoantibodies in cholestatic Epstein-Barr viral hepatitis] Schaade L, et al. **Dtsch Med Wochenschr** 1998 Dec 4;123(49):1478-82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Mononucleosis infectiosa (Epstein-Barr virus infection)] Junghanss BG. **Schweiz Rundsch Med Prax** 1998 Jul 22; 87(29-30):961-3 **(Ger)**

[Trachelodynia and unusual muscle ache. The first symptoms in an acute peripheral polyneuropathy patient: a 37 year old physician's assistant. Guillain-Barr e syndrome with leg sensorimotor tetraparesis, infectious mononucleosis and low grade hepatitis] Zeller A, et al. **Schweiz Rundsch Med Prax** 1999 Mar 4;88(10):441-3 **(Ger)**

[A case of disseminated hepato-splenic involvement in infectious mononucleosis. Computerized tomography and magnetic resonance findings] Ferrozzi F, et al. **Radiol Med (Torino)** 1998 Sep;96(3):258-60 **(Ita)**

[Multivariate analysis of the associations between laboratory data and clinical features among patients with infectious mononucleosis syndrome] Kato T, et al. **Rinsho Byori** 1998 Oct;46(10):1056-60 (Eng. Abstr.) **(Jpn)**

[Prolonged fever of unknown origin caused by atypical rubeola in a child previously vaccinated simulating infectious mononucleosis (letter)] Labay Matias M, et al. **An Esp Pediatr** 1998 Sep;49(3):321-2 **(Spa)**

DRUG THERAPY

Successful treatment of Epstein-Barr virus infection associated with myocarditis. Baykurt C, et al. **Pediatr Int** 1999 Aug;41(4):389-91

Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Oertel SH, et al. **Transplantation** 1999 Mar 15;67(5):765-7

GENETICS

Determination of Epstein-Barr virus (EBV) load by RT-PCR and cellular dilution. Orentas RJ. **Mol Cell Probes** 1998 Dec;12(6):427-30

IMMUNOLOGY

Detection of abnormal lymphocytes in the blood of Balb/c mice infected with murine gammaherpesvirus strain 72: the analogy with Epstein-Barr virus infection. Mistriková J, et al. **Acta Virol** 1998 Apr;42(2):79-82

Epstein-Barr virus meningoencephalitis with a lymphoma-like response in an immunocompetent host. Schellinger PD, et al. **Ann Neurol** 1999 May;45(5):659-62

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. Rossbach HC, et al. **Bone Marrow Transplant** 1999 Jan;23(1):91-3

Atypical CD3+ CD4(low) cell population in a boy with fatal EBV-infection. Gruber R, et al. **Int Arch Allergy Immunol** 1999 Jan;118(1):74-8

Evaluation of a novel dry latex preparation for demonstration of infectious mononucleosis heterophile antibody in comparison with three established tests. Rogers R, et al. **J Clin Microbiol** 1999 Jan;37(1):95-8

EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. Khanna R, et al. **J Immunol** 1999 Mar 1;162(5):3063-9

METABOLISM

Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Setsuda J, et al. **Am J Pathol** 1999 Jul;155(1):257-65

CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: a possible mechanism of immune evasion in chronic active EBV infection. Ohshima K, et al. **Pathol Int** 1999 Jan;49(1):9-13

PATHOLOGY

Infections affecting blood cell morphology [clinical conference] Phatak PD, et al. **Am J Hematol** 1998 Nov; 59(3):238-41

[A peculiar tonsillitis...] de Ybarlucea LR, et al. **Ann Pathol** 1998 Nov;18(5):433-4 **(Fre)**

[Conjunctival pseudolymphoma in infectious mononucleosis] Spraul CW, et al. **Klin Monatsbl Augenheilkd** 1999 Jul; 215(1):68-9 (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Stewart JP, et al. **Vaccine** 1999 Jan;17(2):152-7

VIROLOGY

Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. Stowe RP, et al. **J Virol Methods** 1998 Nov;75(1):83-91

Detection and quantification of cell-free Epstein-Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay. Zingg W, et al. **J Virol Methods** 1999 May; 79(2):141-8

[Infectious mononucleosis caused by Epstein-Barr virus] Ueda T, et al. **Ryoikibetsu Shokogun Shirizu** 1998;(21 Pt 2):188-91 (8 ref.) **(Jpn)**

INFECTIOUS MONONUCLEOSIS-LIKE SYNDROME, CHRONIC see **FATIGUE SYNDROME, CHRONIC**

INFECTIOUS MONONUCLEOSIS VIRUS see **HERPESVIRUS 4, HUMAN**

INFECTIOUS PANCREATIC NECROSIS VIRUS

CHEMISTRY

Identification of IPNV-specified components released from productively infected RTG-2 cells following massive cytopathic effect. Hjalmarsson A, et al. **Arch Virol** 1999; 144(8):1487-501

GENETICS

Generation of infectious pancreatic necrosis virus from cloned cDNA. Yao K, et al. **J Virol** 1998 Nov; 72(11):8913-20

IMMUNOLOGY

TCID50 determination by an immuno dot blot assay as exemplified in a study of storage conditions of infectious pancreatic necrosis virus. Svensson L, et al. **J Virol Methods** 1999 Jun;80(1):17-24

METABOLISM

Infectious pancreatic necrosis virus: identification of a VP3-containing ribonucleoprotein core structure and evidence for O-linked glycosylation of the capsid protein VP2. Hjalmarsson A, et al. **J Virol** 1999 Apr;73(4):3484-90

PHYSIOLOGY

Viral coinfection in salmonids: infectious pancreatic necrosis virus interferes with infectious hematopoietic necrosis virus. Alonso M, et al. **Arch Virol** 1999;144(4):657-73

Dynamics of nontypical apoptotic morphological changes visualized by green fluorescent protein in living cells with infectious pancreatic necrosis virus infection. Hong JR, et al. **J Virol** 1999 Jun;73(6):5056-63

Apoptosis precedes necrosis of fish cell line with infectious pancreatic necrosis virus infection. Hong JR, et al. **Virology** 1998 Oct 10;250(1):76-84

INFECTIOUS PERITONITIS VIRUS, FELINE

IMMUNOLOGY

Antibody and cytokine responses in kittens during the development of feline infectious peritonitis (FIP). Gunn-Moore DA, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2-4):221-42

Some aspects of humoral and cellular immunity in naturally occuring feline infectious peritonitis. Paltrinieri S, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2-4):205-20

INFECTIOUS PUSTULAR VULVOVAGINITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFERIOR COLLICULUS

ANATOMY & HISTOLOGY

Auditory midbrain laminar structure appears adapted to f0 extraction: further evidence and implications of the double critical bandwidth. Braun M. **Hear Res** 1999 Mar; 129(1-2):71-82

CHEMISTRY

Glutamate receptor phenotypes in the auditory brainstem and mid-brain of the developing rat. Caicedo A, et al. **Eur J Neurosci** 1999 Jan;11(1):51-74

CYTOLOGY

Immunfluorescence study of neuropeptides in identified neurons of the rat auditory superior olivary complex. Reuss S, et al. **Cell Tissue Res** 1999 Jul;297(1):13-21

Transient frequency and intensity sensitivities of central auditory neurons determined with sweep tone. Chiu TW, et al. **Chin J Physiol** 1998 Sep 30;41(3):133-8

Differential projection patterns of superior and inferior collicular neurons onto posterior paralaminar nuclei of the thalamus surrounding the medial geniculate body in the rat. Linke R. **Eur J Neurosci** 1999 Jan;11(1):187-203

Functional neuroanatomy of auditory pathways in the sound-producing fish Pollimyrus. Kozloski J, et al. **J Comp Neurol** 1998 Nov 16;401(2):227-52

Descending auditory pathways: projections from the inferior colliculus contact superior olivary cells that project bilaterally to the cochlear nuclei. Schofield BR, et al. **J Comp Neurol** 1999 Jun 28;409(2):210-23

Topographical distribution of NADPH-diaphorase positive neurons in the cat's inferior colliculus. Paloff AM, et al. **J Hirnforsch** 1998;39(2):231-43

Physiological studies of the precedence effect in the inferior colliculus of the cat. II. Neural mechanisms. Litovsky RY, et al. **J Neurophysiol** 1998 Sep;80(3):1302-16

DRUG EFFECTS

Bicuculline application affects discharge pattern and pulse-duration tuning characteristics of bat inferior collicular neurons. Jen PH, et al. **J Comp Physiol [A]** 1999 Feb;184(2):185-94

Defensive reactions are counteracted by midazolam and muscimol and elicited by activation of glutamate receptors in the inferior colliculus of rats. Pandossio JE, et al. **Psychopharmacology (Berl)** 1999 Mar;142(4):360-8

ENZYMOLOGY

Topographical distribution of NADPH-diaphorase positive neurons in the cat's inferior colliculus. Paloff AM, et al. **J Hirnforsch** 1998;39(2):231-43

METABOLISM

Depolarization selectively increases the expression of the Kv3.1 potassium channel in developing inferior colliculus neurons. Liu SQ, et al. **J Neurosci** 1998 Nov 1; 18(21):8758-69

PHYSIOLOGY

Spatial sound detection and the role of the inferior colliculus in the Long-Evans rat. Zrull MC, et al. **Acta Otolaryngol** 1999;119(3):326-32

The long-term effect of bilateral inferior colliculus ablation on auditory brainstem response in awake cats. **Kaga K**, et al. **Acta Otolaryngol (Stockh)** 1999 Mar;119(2):128-31

Ultrastructural and immunocytochemical characterization of neurons in the rat ventral cochlear nucleus projecting to the inferior colliculus. Alibardi L. **Anat Anz** 1998 Oct; 180(5):415-26

Prepulse inhibition of acoustic or trigeminal startle of rats by unilateral electrical stimulation of the inferior colliculus. Li L, et al. **Behav Neurosci** 1998 Oct;112(5):1187-98

Inputs from three brainstem sources to identified neurons of the mouse inferior colliculus slice. Reetz G, et al. **Brain Res** 1999 Jan 23;816(2):527-43

The effect of sound direction on frequency tuning in mouse inferior collicular neurons. Cain D, et al. **Chin J Physiol** 1999 Mar 31;42(1):1-8

Transient frequency and intensity sensitivities of central auditory neurons determined with sweep tone. Chiu TW, et al. **Chin J Physiol** 1998 Sep 30;41(3):133-8

Plasticity of tonotopic maps in auditory midbrain following partial cochlear damage in the developing chinchilla. Harrison RV, et al. **Exp Brain Res** 1998 Dec;123(4):449-60

Contribution of NMDA and non-NMDA receptors to synaptic transmission from the brachium of the inferior colliculus to the medial subdivision of the medial geniculate nucleus in the rabbit. Webber TJ, et al. **Exp Brain Res** 1999 Feb;124(3):295-303

Auditory midbrain laminar structure appears adapted to f0 extraction: further evidence and implications of the double critical bandwidth. Braun M. **Hear Res** 1999 Mar; 129(1-2):71-82

Effects of stimulus duration on responses of neurons in the chinchilla inferior colliculus. Chen GD. **Hear Res** 1998 Aug;122(1-2):142-50

Post-stimulatory suppression, facilitation and tuning for delays shape responses of inferior colliculus neurons to sequential pure tones. Finlayson PG. **Hear Res** 1999 May; 131(1-2):177-94

In vitro electrophysiology of neurons in subnuclei of rat inferior colliculus. Li Y, et al. **Hear Res** 1998 Jul; 121(1-2):1-10

Monaural response properties of single neurons in the chinchilla inferior colliculus. Nuding SC, et al. **Hear Res** 1999 May;131(1-2):89-106

Simulation of ILD sensitive neurons in the inferior colliculus of the barn owl. Peddicord R. **Hear Res** 1998 Sep; 123(1-2):111-24

Inferior colliculus stimulation and changes in 2f1-f2 distortion product otoacoustic emissions in the rat. Scates KW, et al. **Hear Res** 1999 Feb;128(1-2):51-60

Contribution of the commissure of Probst to binaural evoked responses in the rat's inferior colliculus: interaural time differences. van Adel BA, et al. **Hear Res** 1999 Apr; 130(1-2):115-30

Response magnitude and timing of auditory response initiation in the inferior colliculus of the awake chinchilla. Phillips DP, et al. **J Acoust Soc Am** 1999 May;105(5):2731-7

Age-related synaptic changes in the central nucleus of the inferior colliculus of Fischer-344 rats. Helfert RH, et al. **J Comp Neurol** 1999 Apr 12;406(3):285-98

Input-output relationships of the dorsal nucleus of the lateral lemniscus: possible substrate for the processing of dynamic spatial cues. Shneiderman A, et al. **J Comp Neurol** 1999 Jul 26;410(2):265-76

Inputs to combination-sensitive neurons of the inferior colliculus. Wenstrup JJ, et al. **J Comp Neurol** 1999 Jul 12; 409(4):509-28

Auditory cortical projections to the cat inferior colliculus. Winer JA, et al. **J Comp Neurol** 1998 Oct 19;400(2):147-74

Corticofugal regulation of auditory sensitivity in the bat inferior colliculus. Jen PH, et al. **J Comp Physiol [A]** 1998 Dec;183(6):683-97

Effects of GABA-mediated inhibition on direction-dependent frequency tuning in the frog inferior colliculus. Zhang H, et al. **J Comp Physiol [A]** 1999 Jan; 184(1):85-98

Analysis of the role of inhibition in shaping responses to sinusoidally amplitude-modulated signals in the inferior colliculus. Burger RM, et al. **J Neurophysiol** 1998 Oct; 80(4):1686-701

Single-unit responses in the inferior colliculus of decerebrate cats. II. Sensitivity to interaural level differences. Davis KA, et al. **J Neurophysiol** 1999 Jul;82(1):164-75

Receptive fields and binaural interactions for virtual-space stimuli in the cat inferior colliculus. Delgutte B, et al. **J Neurophysiol** 1999 Jun;81(6):2833-51

Multiple components of ipsilaterally evoked inhibition in the inferior colliculus. Klug A, et al. **J Neurophysiol** 1999 Aug; 82(2):593-610

Physiological studies of the precedence effect in the inferior colliculus of the cat. II. Neural mechanisms. Litovsky RY, et al. **J Neurophysiol** 1998 Sep;80(3):1302-16

Physiological studies of the precedence effect in the inferior colliculus of the cat. I. Correlates of psychophysics. Litovsky RY, et al. **J Neurophysiol** 1998 Sep;80(3):1285-301

Commissural and lemniscal synaptic input to the gerbil inferior colliculus. Moore DR, et al. **J Neurophysiol** 1998 Nov;80(5):2229-36

Desynchronizing responses to correlated noise: A mechanism for binaural masking level differences at the inferior colliculus. Palmer AR, et al. **J Neurophysiol** 1999 Feb; 81(2):722-34

Single-unit responses in the inferior colliculus of decerebrate cats. I. Classification based on frequency response maps. Ramachandran R, et al. **J Neurophysiol** 1999 Jul; 82(1):152-63

Detection of auditory signals by frog inferior collicular neurons in the presence of spatially separated noise. Ratnam R, et al. **J Neurophysiol** 1998 Dec;80(6):2848-59

Serotonin differentially modulates responses to tones and frequency-modulated sweeps in the inferior colliculus. Hurley LM, et al. **J Neurosci** 1999 Sep 15;19(18):8071-82

Sound stimulation increases calcium-binding protein immunoreactivity in the inferior colliculus in mice. Idrizbegovic E, et al. **Neurosci Lett** 1999 Jan 4;259(1):49-52

Direct innervation of identified tectothalamic neurons in the inferior colliculus by axons from the cochlear nucleus. Oliver DL, et al. **Neuroscience** 1999;93(2):643-58

The parabrachial nucleus mediates the decreased cardiac baroreflex sensitivity observed following short-term visceral afferent activation. Saleh TM, et al. **Neuroscience** 1998 Nov;87(1):135-46

Antinociception elicited by aversive stimulation of the inferior colliculus. Castilho VM, et al. **Pharmacol Biochem Behav** 1999 Mar;62(3):425-31

Prepulse inhibition following lesions of the inferior colliculus: prepulse intensity functions. Li L, et al. **Physiol Behav** 1998 Aug;65(1):133-9

Sensory maps on the move [comment] Stryker MP. **Science** 1999 May 7;284(5416):925-6. Comment on: Science 1999 May 7;284(5416):962-5.

Functional selection of adaptive auditory space map by GABAA-mediated inhibition [see comments] Zheng W, et al. **Science** 1999 May 7;284(5416):962-5. Comment in: Science 1999 May 7;284(5416):925-6.

PHYSIOPATHOLOGY

Epileptic discharge of cortical, subcortical and spinal neurons in penicillin induced experimental epilepsy. Mameli O, et al. **Arch Ital Biol** 1999 Feb;137(1):29-46

Differential roles in the neuronal network for audiogenic seizures are observed among the inferior colliculus subnuclei and the amygdala. Chakravarty DN, et al. **Exp Neurol** 1999 May;157(1):135-41

Defective auditory recognition after small hemorrhage in the inferior colliculi. Johkura K, et al. **J Neurol Sci** 1998 Nov 26;161(1):91-6

[Running fit and generalized tonic-clonic seizure are differently controlled by different subtype receptors in the brainstem] Yasuda S, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1998 Aug; 18(4):123-8 (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Preservation of synapses on principal cells of the central nucleus of the inferior colliculus with aging in the CBA mouse. Kazee AM, et al. **Hear Res** 1999 Jul;133(1-2):98-106

Glycine-immunoreactive synapses in the central nucleus of the inferior colliculus. An electron microscopic study in the cat. Liu Y, et al. **Neurosci Lett** 1999 Jul 16;269(3):183-5

INFERIOR PETROSAL SINUS SAMPLING see **PETROSAL SINUS SAMPLING**

INFERIOR VENA CAVA FILTERS see **VENA CAVA FILTERS**

INFERTILITY

Infertility is a family medicine issue [letter] Sylvester H. **Can Fam Physician** 1999 Jul;45:1648

Managed health care coverage for infertility services: understanding adverse selection. Tabbush V, et al. **Curr Opin Obstet Gynecol** 1998 Aug;10(4):341-6

Infertility education in baccalaureate schools of nursing [see comments] Sherrod RA. **J Nurs Educ** 1998 Dec;37(9):412-4

. Comment in: J Nurs Educ 1998 Dec;37(9):383-4.
Society for the Study of Fertility and German Society for the Study of Fertility and Sterility joint winter meeting. Aachen, December 1998. Abstracts. **J Reprod Fertil Abstr Ser** 1998 Dec;(22):1-36
Legal issues in the treatment of infertility. Cady R. **MCN Am J Matern Child Nurs** 1999 Sep-Oct;24(5):264
Efficacy of superovulation and intrauterine insemination in the treatment of infertility [letter; comment] Habbema JD. **N Engl J Med** 1999 Jul 8;341(2):128-9. Comment on: N Engl J Med 1999 Jan 21;340(3):177-83. Comment on: N Engl J Med 1999 Jan 21;340(3):224-6.
The many facets of involuntary childlessness in general practice. Himmel W, et al. **Scand J Prim Health Care** 1999 Mar;17(1):25-9

BLOOD

Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Seifer DB, et al. **Fertil Steril** 1999 Jul;72(1):63-5

CHEMICALLY INDUCED

Cell death genes may hold clues to preserving fertility after chemotherapy [news] Reynolds T. **J Natl Cancer Inst** 1999 Apr 21;91(8):664-6
Effects of occupational solvent exposure on fertility. Lindbohm ML. **Scand J Work Environ Health** 1999;25 Suppl 1:44-6 (10 ref.)

COMPLICATIONS

ABC of sexual health: sexual problems associated with infertility, pregnancy, and ageing. Read J. **BMJ** 1999 Feb 27;318(7183):587-9 (0 ref.)

DIAGNOSIS

Postcoital testing. Postcoital test should be performed as routine infertility test [letter; comment] Cohlen BJ, et al. **BMJ** 1999 Apr 10;318(7189):1008-9. Comment on: BMJ 1998 Aug 22;317(7175):502-5.
Postcoital testing. Criterion for positive test was not given [letter; comment] Hull MG, et al. **BMJ** 1999 Apr 10; 318(7189):1007; discussion 1008-9. Comment on: BMJ 1998 Aug 22;317(7157):502-5.
Breaking bad news concerning fertility. Lalos A. **Hum Reprod** 1999 Mar;14(3):581-5 (25 ref.)
Why the NHS should fund infertility services [editorial] Byrne PA, et al. **Ulster Med J** 1999 May;68(1):2-3
[The family practitioner and the postcoital test (letter)] Lammes FB. **Ned Tijdschr Geneeskd** 1998 Nov 28; 142(48):2646 **(Dut)**

DRUG THERAPY

The clinical efficacy of low-dose step-up follicle stimulating hormone administration for treatment of unexplained infertility. Sengoku K, et al. **Hum Reprod** 1999 Feb; 14(2):349-53

ECONOMICS

Strategies to improve insurance coverage for infertility services [editorial] Gleicher N. **Fertil Steril** 1998 Dec; 70(6):1006-8
Adjusting for "treatment-independent pregnancies" [letter] Mol BW, et al. **Fertil Steril** 1999 Sep;72(3):562-3

EPIDEMIOLOGY

Comparison of infertility rates in communities from boron-rich and boron-poor territories. Tüccar E, et al. **Biol Trace Elem Res** 1998 Winter;66(1-3):401-7
Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Rodriguez C, et al. **Cancer Causes Control** 1998 Dec;9(6):645-51
The use of fecundability in epidemiological surveys. Spira A. **Hum Reprod** 1998 Jul;13(7):1753-6 (15 ref.)
The ecology of low natural fertility in Ladakh. Wiley AS. **J Biosoc Sci** 1998 Oct;30(4):457-80
Epidemiological approaches to infertility. Lumley J. **Reprod Fertil Dev** 1998;10(1):17-21 (29 ref.)
Hospital work and fecundability. Zielhuis G, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:47-8
[Extrauterine pregnancy in Netherlands: patient characteristics, treatment, and pregnancy prognosis] Kock HC, et al. **Ned Tijdschr Geneeskd** 1999 Jun 26; 143(26):1364-8 (Eng. Abstr.) **(Dut)**

ETIOLOGY

Stress and reproductive failure: an evolutionary approach with applications to premature labor. Wasser SK. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 3):S272-4 (50 ref.)
Comparison of infertility rates in communities from boron-rich and boron-poor territories. Tüccar E, et al. **Biol Trace Elem Res** 1998 Winter;66(1-3):401-7
Managing infertility in general practice must include screening for sexual infections [letter] Winter AJ, et al. **BMJ** 1998 Nov 28;317(7171):1526
Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Watson M, et al. **Cancer** 1999 Oct 1;86(7):1231-9
Influence of age, diagnosis, and cycle number on pregnancy rates with gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination. Sahakyan M, et al. **Fertil Steril** 1999 Sep;72(3):500-4
Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218-28 (36 ref.)
Infertility and premature menopause in childhood cancer survivors. Byrne J. **Med Pediatr Oncol** 1999 Jul;33(1):24-8 (11 ref.)
General psychosocial and work-related stress and reduced fertility. Henriksen TB. **Scand J Work Environ Health** 1999; 25 Suppl 1:38-9 (11 ref.)
[Cystic fibrosis. Extra-respiratory manifestations] Durieu I. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S134-5 **(Fre)**
[Fertility and cystic fibrosis. Management at pregnancy] Durieu I. **Rev Mal Respir** 1999 Jun;16(3):347-51 (Eng. Abstr.) **(Fre)**

GENETICS

Analysis of infertile brothers with congenital bilateral absence of vas deferens for mutations in the CFTR gene [letter] Onay T, et al. **Clin Genet** 1999 Jan;55(1):63-4
Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. Herrera E, et al. **EMBO J** 1999 Jun 1;18(11):2950-60
Menstrual disorders and infertility caused by inactivating mutations of the luteinizing hormone receptor gene. Arnhold IJ, et al. **Fertil Steril** 1999 Apr;71(4):597-601 (32 ref.)
Analysis of the sex chromosome constitution of sperm in men with a 47, XYY mosaic karyotype by fluorescence in situ hybridization. Lim AS, et al. **Fertil Steril** 1999 Jul; 72(1):121-3
Cell death genes may hold clues to preserving fertility after chemotherapy [news] Reynolds T. **J Natl Cancer Inst** 1999 Apr 21;91(8):664-6
Genetic issues in assisted reproductive technology. Ahrens M, et al. **Minn Med** 1998 Oct;81(10):43-7 (15 ref.)
Evolutionary forces behind human infertility [letter; comment] Cummins J. **Nature** 1999 Feb 18;397(6720):557-8 . Comment on: Nature 1998 Dec 24-31;396(6713):743-6.

HISTORY

[Desire for children--planned children. Attempt at a historical introduction to the medical problem] Ludwig H. **Ther Umsch** 1999 May;56(5):236-9 **(Ger)**

IMMUNOLOGY

Antisperm antibodies: etiology, pathogenesis, diagnosis, and treatment. Mazumdar S, et al. **Fertil Steril** 1998 Nov; 70(5):799-810 (100 ref.)
Survey of the diagnosis and management of antisperm antibodies. Krapez JA, et al. **Hum Reprod** 1998 Dec; 13(12):3363-7
Immunological assessment of infertility by estimation of antisperm antibodies in infertile couples. Kapoor A, et al. **Indian J Pathol Microbiol** 1999 Jan;42(1):37-43
Correlation between peritoneal fluid and serum antiphospholipid antibodies in women with primary infertility. Ulcová-Gallová Z, et al. **Int J Fertil Womens Med** 1998 Sep-Oct;43(5):267-72
Report from the Society for Gynecologic Investigation, Atlanta, Georgia, March 11-14, 1998. Kutteh WH. **J Reprod Immunol** 1998 Nov;40(2):175-82
Antiphospholipid antibodies: an update from the eighth international symposium. Silver RM. **J Reprod Immunol** 1999 May;43(1):85-9

MICROBIOLOGY

Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India. Brabin L, et al. **Bull World Health Organ** 1998;76(3):277-87
Chlamydial and gonococcal serology in women with tubal infertility. Tyagi P, et al. **Indian J Med Sci** 1998 Jun; 52(6):231-5
Screening for Chlamydia trachomatis and Ureaplasma urealyticum infection in semen from asymptomatic male partners of infertile couples prior to in vitro fertilization. Levy R, et al. **Int J Androl** 1999 Apr;22(2):113-8
[Circulating antibodies against an epitope of the heat-shock protein 60kDA of chlamydia trachomatis in infertile couples. Relation with surface chlamydia trachomatis anti-antigen antibody and E. coli anti-HSP60 antibody and human anti-HSP60] Witkin SS, et al. **Contracept Fertil Sex** 1998 Nov;26(11):suppl I-VI **(Fre)**

PATHOLOGY

Lack of correlation between oocyte-corona-cumulus complex morphology and nuclear maturity of oocytes collected in stimulated cycles for intracytoplasmic sperm injection. Rattanachaiyanont M, et al. **Fertil Steril** 1999 May;71(5):937-40

PHYSIOPATHOLOGY

The contribution of subtle oocyte or sperm dysfunction affecting fertilization in endometriosis-associated or unexplained infertility: a controlled comparison with tubal infertility and use of donor spermatozoa. Hull MG, et al. **Hum Reprod** 1998 Jul;13(7):1825-30
Human and clinical perspectives on leptin. Blum WF, et al. **Proc Nutr Soc** 1998 Aug;57(3):477-85 (78 ref.)
The lack of associations between rheumatoid arthritis and both nulliparity and infertility. Pope JE, et al. **Semin Arthritis Rheum** 1999 Apr;28(5):342-50
[Genetic control of isolating mechanisms in the genus Drosophila] Mitrofanov VG, et al. **Genetika** 1998 Sep; 34(9):1189-99 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Infertility and other fertility related issues in the practice of traditional healers and Christian religious healers in south western Nigeria. Obisesan KA, et al. **Afr J Med Med Sci** 1998 Mar-Jun;27(1-2):51-5
Oral contraceptives: therapeutic uses and quality-of-life benefits--case presentations. Sulak PJ. **Contraception** 1999 Jan;59(1 Suppl):35S-38S
Pharmacological protection of the gonads. Howell SJ, et al. **Med Pediatr Oncol** 1999 Jul;33(1):41-5 (48 ref.)

PSYCHOLOGY

The contribution of adult attachment style to the adjustment to infertility. Mikulincer M, et al. **Br J Med Psychol** 1998 Sep;71 (Pt 3):265-80
The Fertility Problem Inventory: measuring perceived infertility-related stress. Newton CR, et al. **Fertil Steril** 1999 Jul;72(1):54-62
Breaking bad news concerning fertility. Lalos A. **Hum Reprod** 1999 Mar;14(3):581-5 (25 ref.)
Stress and anxiety do not result in pregnancy wastage. Milad MP, et al. **Hum Reprod** 1998 Aug;13(8):2296-300
Does assisted reproduction make an impact on the identity and self-image of infertile couples? Daniels KR. **J Assist Reprod Genet** 1999 Feb;16(2):57-9 (12 ref.)
Gender differences in coping with infertility: a meta-analysis. Jordan C, et al. **J Behav Med** 1999 Aug;22(4):341-58
Infertility at a young age: one patient's story [letter] **J Pediatr Adolesc Gynecol** 1999 Feb;12(1):41-4
Psychological distress and infertility: forty years of research. Brkovich AM, et al. **J Psychosom Obstet Gynaecol** 1998 Dec;19(4):218-28 (36 ref.)
Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Schover LR. **Med Pediatr Oncol** 1999 Jul;33(1):53-9 (44 ref.)
[The family practitioner and the postcoital test (letter)] Lammes FB. **Ned Tijdschr Geneeskd** 1998 Nov 28; 142(48):2646 **(Dut)**
[Psychological study of 20 women after failure of in vitro fertilization] Bourguignon O, et al. **Contracept Fertil Sex** 1998 Sep;26(9):663-73 (Eng. Abstr.) **(Fre)**
[Psychosomatic counseling and management of infertile couples] Bitzer J. **Ther Umsch** 1999 May;56(5):246-50 (Eng. Abstr.) **(Ger)**
[Adoption and/or reproductive medicine] Steck B. **Ther Umsch** 1999 May;56(5):251-9 (45 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Determinants of reproductive outcome after abdominal myomectomy for infertility. Vercellini P, et al. **Fertil Steril** 1999 Jul;72(1):109-14

THERAPY

Management of long-standing unexplained infertility: A prospective study. Aboulghar MA, et al. **Am J Obstet Gynecol** 1999 Aug;181(2):371-5
Recombinant gonadotrophins. Hayden CJ, et al. **Br J Obstet Gynaecol** 1999 Mar;106(3):188-96 (51 ref.)
Entitlement to cloning. Murphy TF. **Camb Q Healthc Ethics** 1999 Summer;8(3):364-8
Timed intercourse after intrauterine insemination for treatment of infertility. Huang FJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct;80(2):257-61
Prospective randomized double-blind trial of the correlation between time of administration and antiestrogenic effects of clomiphene citrate on reproductive end organs. Biljan MM, et al. **Fertil Steril** 1999 Apr;71(4):633-8
Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Cramer DW, et al. **Fertil Steril** 1999 Jul;72(1):83-9
Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. Karande VC, et al. **Fertil Steril** 1999 Mar; 71(3):468-75
Statistically valid infertility research [editorial] Mastroianni L Jr. **Fertil Steril** 1999 Sep;72(3):398-400
Adjusting for "treatment-independent pregnancies" [letter] Mol BW, et al. **Fertil Steril** 1999 Sep;72(3):562-3
Residual effect of clomiphene citrate? [letter] Morán C, et al. **Fertil Steril** 1999 Sep;72(3):566-7
Cost-effective treatment of the infertile couple. Van Voorhis BJ, et al. **Fertil Steril** 1998 Dec;70(6):995-1005 (63 ref.)
Endometrial morphology and ultrasound vascular findings. A randomized trial after intramuscular and vaginal progesterone supplementation in IVF. Ragni G, et al.

Gynecol Obstet Invest 1999;47(3):151–6

Antiphospholipid antibodies in infertile couples with two consecutive miscarriages after in-vitro fertilization and embryo transfer. Egbase PE, et al. **Hum Reprod** 1999 Jun; 14(6):1483–6

Effective treatment of subfertility: introducing the Cochrane Menstrual Disorders and Subfertility Group. Farquhar CM, et al. **Hum Reprod** 1999 Jul;14(7):1678–83

Severe OHSS: patients should be allowed to weigh the morbidity of OHSS against the benefits of parenthood. Mathur RS, et al. **Hum Reprod** 1999 Sep;14(9):2183–5 (15 ref.)

Stress and anxiety do not result in pregnancy wastage. Milad MP, et al. **Hum Reprod** 1998 Aug;13(8):2296–300

Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcome. Nuojua-Huttunen S, et al. **Hum Reprod** 1999 Mar;14(3):698–703

Semen preparation by standard swim-up versus swim-up with test yolk buffer incubation in intrauterine insemination: a randomized study. Ragni G, et al. **Hum Reprod** 1998 Jul; 13(7):1859–63

Patient satisfaction with the management of infertility. Souter VL, et al. **Hum Reprod** 1998 Jul;13(7):1831–6

How concordant are the estimated rates of natural conception and in-vitro fertilization/embryo transfer success? Wiegerinck MA, et al. **Hum Reprod** 1999 Mar;14(3):689–93

Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility. Recombinant Human FSH Product Development Group. **Hum Reprod Update** 1998 Nov–Dec; 4(6):862–81 (53 ref.)

The evaluation of the sperm migration test as a predictor for success with intrauterine insemination. Buckett WM, et al. **Int J Fertil Womens Med** 1998 Sep–Oct;43(5):257–61

Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization. Zeyneloglu HB, et al. **Int J Fertil Womens Med** 1998 Nov–Dec;43(6):300–5

Infertility update: use of assisted reproductive technology. Yoshida TM. **J Am Pharm Assoc (Wash)** 1999 Jan–Feb; 39(1):65–72; quiz 103–4 (60 ref.)

Infertility treatment and multiple birth rates in Britain, 1938–94 [see comments] Murphy M, et al. **J Biosoc Sci** 1997 Apr;29(2):235–43. Comment in: J Biosoc Sci 1998 Jan;30(1):127–8; discussion 128–31.

Epidermal growth factor and leukemia inhibitory factor levels in follicular fluid. Association with in vitro fertilization outcome. Özörnek MH, et al. **J Reprod Med** 1999 Apr;44(4):367–9

Information versus choice in infertility treatment [editorial] **Lancet** 1999 Jun 5;353(9168):1895

Why might infertile couples have problem pregnancies? [comment] Baird DD, et al. **Lancet** 1999 May 22; 353(9166):1724–5. Comment on: Lancet 1999 May 22;353(9166):1746–9.

Move over, Mother Nature. Making babies with mother science. Feldman MK. **Minn Med** 1998 Oct;81(10):16–22

The ethics of egg donation. Kahn JP. **Minn Med** 1998 Oct; 81(10):12–5

Infertility [editorial] Meyer CR. **Minn Med** 1998 Oct;81(10):2

Recent advances in infertility treatment. Session DR, et al. **Minn Med** 1998 Oct;81(10):27–32 (17 ref.)

Discrimination against the infertile. The Supreme Court speaks. Wolf SM. **Minn Med** 1998 Oct;81(10):49–52

Efficacy of superovulation and intrauterine insemination in the treatment of infertility [letter; comment] Dickey R, et al. **N Engl J Med** 1999 Jul 8;341(2):128; discussion 128–9 . Comment on: N Engl J Med 1999 Jan 21;340(3):177–83.

Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network [see comments] Guzick DS, et al. **N Engl J Med** 1999 Jan 21;340(3):177–83. Comment in: N Engl J Med 1999 Jan 21;340(3):224–6. Comment in: N Engl J Med 1999 Jul 8;341(2):128; discussion 128–9. Comment in: N Engl J Med 1999 Jul 8;341(2):128–9.

The management of infertility [editorial; comment] [see comments] te Velde ER, et al. **N Engl J Med** 1999 Jan 21;340(3):224–6. Comment on: N Engl J Med 1999 Jan 21;340(3):177–83. Comment in: N Engl J Med 1999 Jul 8;341(2):128–9.

The management of unexplained infertility. Zayed F, et al. **Obstet Gynecol Surv** 1999 Feb;54(2):121–30

Cognitive-behavioral therapy for idiopathic infertile couples. Tuschen-Caffier B, et al. **Psychother Psychosom** 1999; 68(1):15–21

Assisted reproductive techniques--promises and problems. Chew SC, et al. **Singapore Med J** 1999 Apr;40(4):303–9 (87 ref.)

Why the NHS should fund infertility services [editorial] Byrne PA, et al. **Ulster Med J** 1999 May;68(1):2–3

[Should infertility be treated in couples where one of the partners is HIV seropositive?] Auroux M. **Contracept Fertil Sex** 1999 Feb;27(2):118–20 **(Fre)**

[In vitro fertilization and sperm intracytoplasmic injection: psychological repercussions for the couple] Perez C, et al. **Contracept Fertil Sex** 1998 Oct;26(10):713–7 (Eng. Abstr.) **(Fre)**

[For or against infertility treatment in couples where one partner is HIV seropositive] Plachot M. **Contracept Fertil Sex** 1999 Feb;27(2):120–1 **(Fre)**

[Ethical developments in medically assisted fertility (editorial)] Schoysman R, et al. **Contracept Fertil Sex** 1999 Jan;27(1):7–11 **(Fre)**

[Successful PMA. Review of the activities of the Center for Medically Assisted Procreation of University of Liege, 1985–1997] Dubois M, et al. **Rev Med Liege** 1999 May; 54(5):387–92 (Eng. Abstr.) **(Fre)**

[Desire for children--planned children (editorial)] De Geyter C. **Ther Umsch** 1999 May;56(5):235 **(Ger)**

[Treatment for infertility in HIV positive couples--psychosomatic and ethical considerations] Siedentopf F, et al. **Zentralbl Gynakol** 1999;121 Suppl 1:50–2 **(Ger)**

VETERINARY

Effect of 131I-induced hypothyroidism on indices of reproductive function in adult male dogs. Johnson C, et al. **J Vet Intern Med** 1999 Mar-Apr;13(2):104–10

Relationships between dairy cow mastitis and fertility management and farm performance. Rougoor CW, et al. **Prev Vet Med** 1999 Apr 27;39(4):247–64

VIROLOGY

Screening infertile couples for HIV infection [letter; comment] Abusheikha N, et al. **Fertil Steril** 1998 Oct; 70(4):785–6. Comment on: Fertil Steril 1997 Nov;68(5):820–5.

INFERTILITY AGENTS see **FERTILITY AGENTS**

INFERTILITY AGENTS, FEMALE see **FERTILITY AGENTS, FEMALE**

INFERTILITY, FEMALE

Ovarian cancer in infertility patients. Burmeister L, et al. **Ann Med** 1998 Dec;30(6):525–8 (18 ref.)

Female infertility. Hull MG, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):851–76 (40 ref.)

Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotropic,chronic anovulation: a prospective randomized study. Yarali H, et al. **Fertil Steril** 1999 Aug; 72(2):276–81

Serum total renin levels after ovarian electrocautery in women with polycystic ovary syndrome. Anttila L, et al. **Gynecol Endocrinol** 1998 Oct;12(5):327–31

Co-cultured human embryos may be subjected to widely different microenvironments: pattern of growth factor/cytokine release by Vero cells during the co-culture interval. Desai N, et al. **Hum Reprod** 1998 Jun;13(6):1600–5

Comparison of pregnancy outcome after intracytoplasmic sperm injection and in-vitro fertilization. Govaerts I, et al. **Hum Reprod** 1998 Jun;13(6):1514–8

The role of leukemia inhibitory factor and interleukin-6 in human reproduction. Smith SK, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:237–43; discussion 244–6 (46 ref.)

Does ovulation induction affect the pregnancy rate after laparoscopic treatment of endometriosis? Karabacak O, et al. **Int J Fertil Womens Med** 1999 Jan-Feb;44(1):38–42

Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor [see comments] Tilley SL, et al. **J Clin Invest** 1999 Jun;103(11):1539–45. Comment in: J Clin Invest 1999 Jun;103(11):1481–2.

Well-differentiated endometrial adenocarcinoma in an infertility patient with later conception. A case report. Kowalczyk CL, et al. **J Reprod Med** 1999 Jan;44(1):57–60

The quest of infertile women in squatter settlements of Karachi, Pakistan: a qualitative study. Bhatti LI, et al. **Soc Sci Med** 1999 Sep;49(5):637–49

BLOOD

Chlorinated hydrocarbons in infertile women. Gerhard I, et al. **Environ Res** 1999 May;80(4):299–310

Elevated serum progesterone concentrations during the early follicular phase of the menstrual cycle: clinical significance and therapeutic implications. Keck C, et al. **Gynecol Endocrinol** 1999 Jun;13(3):161–5

Evaluation of serum prolactin levels in patients with endometriosis and infertility. Gregoriou G, et al. **Gynecol Obstet Invest** 1999;48(1):48–51

Similar embryotoxic effects of sera from infertile patients and exogenous interferon-gamma on long-term in-vitro development of mouse embryos. Cameo M, et al. **Hum Reprod** 1999 Apr;14(4):959–63

Increased peripheral androgen activity in infertile Korean women with polycystic ovaries. Roh JS, et al. **Hum Reprod** 1999 Aug;14(8):1934–8

Periovulatory serum inhibin-a in women with a diminished ovarian reserve. Lindheim SR, et al. **J Assist Reprod Genet** 1999 Sep;16(8):450–3

CHEMICALLY INDUCED

Reproductive toxicity potentials of Salvia fruticosa (Labiatae) in rats [published erratum appears in J Ethnopharmacol 1998 Dec;63(3):265] Al-Hamood MH, et al. **J Ethnopharmacol** 1998 May;61(1):67–74

The effect of smelter work on fecundity. Wulff M, et al. **J Occup Environ Med** 1999 Aug;41(8):678–85

Exposure to toluene in the printing industry is associated with subfecundity in women but not in men. Plenge-Bönig A, et al. **Occup Environ Med** 1999 Jul;56(7):443–8

Warning signs. O'Neal MA. **Occup Health Saf** 1997 Dec; 66(12):42–5

A new case of NSAID-induced infertility. Calmels C, et al. **Rev Rhum Engl Ed** 1999 Mar;66(3):167–8

COMPLICATIONS

Ovarian cancer associated with ovulation induction: a case report. Adewole IF, et al. **Afr J Med Med Sci** 1997 Sep-Dec;26(3-4):203–4

Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Johannesson M, et al. **Hum Reprod** 1998 Aug;13(8):2092–7

Successful pregnancy in an infertile patient with conservatively treated endometrial adenocarcinoma after transfer of embryos obtained by intracytoplasmic sperm injection. Shibahara H, et al. **Hum Reprod** 1999 Jul; 14(7):1908–11

Eating disorders and depression in Hungarian women with menstrual disorders and infertility. Resch M, et al. **J Psychosom Obstet Gynaecol** 1999 Sep;20(3):152–7

[The method of treatment of functional evident hyperprolactinemia in sterile women] Dudkiewicz J, et al. **Ginekol Pol** 1998 Dec;69(12):1171–4 (Eng. Abstr.) **(Pol)**

DIAGNOSIS

American Society for Reproductive Immunology report of the Committee for Establishing Criteria for Diagnosis of Reproductive Autoimmune Syndrome. Coulam CB, et al. **Am J Reprod Immunol** 1999 Feb;41(2):121–32

Diagnostic difficulty in polycystic ovary syndrome due to an LH-beta-subunit variant. Kurioka H, et al. **Eur J Endocrinol** 1999 Mar;140(3):235–8

We are overinterpreting the predictive value of serum follicle-stimulating hormone levels [editorial] Barnhart K, et al. **Fertil Steril** 1999 Jul;72(1):8–9

Diagnostic accuracy of transvaginal hydrolaparoscopy in infertility. Campo R, et al. **Fertil Steril** 1999 Jun; 71(6):1157–60

Dynamic studies of fallopian tube physiology in human infertility--state of the art [letter; comment] van der Weiden RM, et al. **Fertil Steril** 1998 Oct;70(4):786–7. Comment on: Fertil Steril 1998 Feb;69(2):216–20.

Diagnosis of subtle ovulation disorders in subfertile women with regular menstrual cycles: cost-effective clinical practice? van Zonneveld P, et al. **Gynecol Endocrinol** 1999 Feb;13(1):42–7

Transvaginal access heralds the end of standard diagnostic laparoscopy in infertility. Brosens I, et al. **Hum Reprod** 1998 Jul;13(7):1762–3 (19 ref.)

Should hysteroscopy be a part of the basic infertility workup? Shushan A, et al. **Hum Reprod** 1999 Aug;14(8):1923–4

Evaluation of the performance of fertiloscopy in 160 consecutive infertile patients with no obvious pathology. Watrelot A, et al. **Hum Reprod** 1999 Mar;14(3):707–11

Diagnostic laparoscopy in primary and secondary infertility. Hovav Y, et al. **J Assist Reprod Genet** 1998 Oct;15(9):535–7

Role of routine diagnostic laparoscopy in the investigation of infertility [editorial; comment] Karande VC. **J Assist Reprod Genet** 1999 Sep;16(8):399–401. Comment on: J Assist Reprod Genet 1999 Sep;16(8):454–5.

Response to Hovav et al. [Diagnostic laparoscopy in primary and secondary infertility (J Assist Reprod Genet 1998;15:535–537)] [letter][see comments] Marik JJ. **J Assist Reprod Genet** 1999 Sep;16(8):454–5. Comment in: J Assist Reprod Genet 1999 Sep;16(8):399–401.

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

Endoscopy of the uterus and its congenital malformations. Cinque B, et al. **Rays** 1998 Oct-Dec;23(4):617–24 **(Eng, Ita)**

Hysteroscopic diagnosis of uterine intracavitary disorders. Gaglione R, et al. **Rays** 1998 Oct-Dec;23(4):655–61 **(Eng, Ita)**

Female infertility: radiology and endoscopy in morphofunctional imaging. Marano P. **Rays** 1998 Oct-Dec; 23(4):597–9 **(Eng, Ita)**

Correlation between endometrial dating of luteal phase days 6 and 10 of the same menstrual cycle. Haddad Filho J, et al. **Rev Paul Med** 1998 May-Jun;116(3):1734–7

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**

[Role of hysteroscopic treatment of the septate uterus resulting in primary sterility] Porcu G, et al. **Contracept Fertil Sex** 1998 Nov;26(11):764–7 **(Fre)**

[The value of hysteroscopy after repeated implantation failures with in vitro fertilization] Schiano A, et al. **Contracept Fertil Sex** 1999 Feb;27(2):129–32 (Eng. Abstr.) **(Fre)**

[Color and power doppler ultrasonographic measurement of the uterine blood flow in subfertile women with unstimulated cycles] Czekierdowski A, et al. **Ginekol Pol** 1998 Dec;69(12):1191–7 (Eng. Abstr.) **(Pol)**

[The concentration of interleukin-2 and interleukin-2 soluble receptors in peritoneal fluid of patients with unexplained infertility] Gogacz M, et al. **Ginekol Pol** 1998 Dec; 69(12):1203–6 (Eng. Abstr.) **(Pol)**

[Chlamydia trachomatis in cervical canal and in the pouch

of Douglas in infertile women] Goluda M, et al. **Ginekol Pol** 1998 Dec;69(12):1153–6 (Eng. Abstr.) **(Pol)**

[Analysis of female infertility structural factors] Grzechocińska B, et al. **Ginekol Pol** 1998 Dec; 69(12):1126–30 (Eng. Abstr.) **(Pol)**

[Cytotoxic activity of NK cells in the presence of the peritoneal fluid fro women with unexplained infertility and with endometriosis related infertility] Jedryka M, et al. **Ginekol Pol** 1998 Dec;69(12):1179–82 (Eng. Abstr.) **(Pol)**

[The cost of laparoscopy in the diagnosis of female infertility] Malinowski A, et al. **Ginekol Pol** 1998 Dec;69(12):1198–202 (Eng. Abstr.) **(Pol)**

[Malonyldialdehyde and total antioxidant status in the peritoneal fluid of infertile women] Polak G, et al. **Ginekol Pol** 1999 Mar;70(3):135–40 (Eng. Abstr.) **(Pol)**

[Endoscopic diagnosis of mechanic sterility] Sobkiewicz S, et al. **Ginekol Pol** 1998 Dec;69(12):1162–6 (Eng. Abstr.) **(Pol)**

[The role of hysteroscopy in the diagnosis of infertility in materials of the 2nd Gynecological Clinic of the Medical Academy in Łódź] Sobkiewicz S, et al. **Ginekol Pol** 1998 Dec;69(12):1146–9 (Eng. Abstr.) **(Pol)**

[Osseous metaplasia of the endometrium as a cause of infertility. Hysteroscopic approach] Garcia León F, et al. **Ginecol Obstet Mex** 1999 Jan;67:37–41 (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Ovarian cancer associated with ovulation induction: a case report. Adewole IF, et al. **Afr J Med Med Sci** 1997 Sep–Dec;26(3–4):203–4

Less miscarriage in pregnancy following Tamoxifen treatment of infertile patients with luteal phase dysfunction as compared to clomiphene treatment. Wu CH. **Early Pregnancy** 1997 Dec;3(4):301–5

Serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate therapy in anovulatory infertile women. Young SL, et al. **Fertil Steril** 1999 Apr;71(4):639–44

Evaluation of ovarian cysts following GnRH-a treatment in patients with polycystic ovarian syndrome. Gregoriou O, et al. **Gynecol Obstet Invest** 1998;46(4):252–5

Endometrial development was improved by transdermal estradiol in patients treated with clomiphene citrate. Shimoya K, et al. **Gynecol Obstet Invest** 1999;47(4):251–4

The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone. Develioglu OH, et al. **Hum Reprod** 1999 May;14(5):1168–74

A randomized controlled trial of three low-dose gonadotrophin protocols for unexplained infertility. Hughes EG, et al. **Hum Reprod** 1998 Jun;13(6):1527–31

Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone. Messinis IE, et al. **Hum Reprod** 1998 Sep;13(9):2415–20

Antioxidants may protect against infertility. Tarin JJ, et al. **Hum Reprod** 1998 Jun;13(6):1415–6

Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Imani B, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1617–22

Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. Sarlis NJ, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1510–2

Superovulation of immature hypothyroid rdw rats by thyroxine therapy and the development of eggs after in vitro fertilization. Jiang JY, et al. **J Reprod Fertil** 1999 May;116(1):19–24

GnRH agonist. Increasing the pregnancy rate after combined treatment with hMG/hCG and direct intraperitoneal insemination. Minoura H, et al. **J Reprod Med** 1999 Jan; 44(1):18–22

Recombinant follicle-stimulating hormone: new biotechnology for infertility. Prevost RR. **Pharmacotherapy** 1998 Sep–Oct;18(5):1001–10 (33 ref.)

[Ultrasonic follow-up of the endometrium in women with sterility after Serpafar treatment] Pünevska M, et al. **Akush Ginekol (Sofiia)** 1998;37(1):30–1 (Eng. Abstr.) **(Bul)**

[Pregnancy and hormone replacement therapy in a patient with resistant ovary syndrome] Nawroth F, et al. **Zentralbl Gynakol** 1999;121(5):255–7 (Eng. Abstr.) **(Ger)**

[The effect of various methods of luteal phase supplementation on serum progesterone level] Jakiel G, et al. **Ginekol Pol** 1998 Dec;69(12):1207–12 (Eng. Abstr.) **(Pol)**

[The influence of bromocriptine treatment on prolactin secretion in infertile women with suspicion of luteal phase insufficiency] Krzemiński A, et al. **Ginekol Pol** 1998 Dec; 69(12):1141–5 (Eng. Abstr.) **(Pol)**

[Heterotopic pregnancy following ovulation induction by clomiphene citrate and prednisone. Report of a case] Tellez Velasco S, et al. **Ginecol Obstet Mex** 1999 Jan;67:1–3 (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Hip fractures among infertile women. Hesdorffer DC, et al. **Am J Epidemiol** 1999 May 1;149(9):810–3

The prevalence of prior infertility in recent mothers [letter] Bruinsma F, et al. **Aust N Z J Public Health** 1998 Dec; 22(7):841–2

Is perforation of the appendix a risk factor for tubal infertility and ectopic pregnancy? An appraisal of the evidence. Urbach DR, et al. **Can J Surg** 1999 Apr;42(2):101–8

Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Canadian Collaborative Group on Endometriosis. Bérubé S, et al. **Epidemiology** 1998 Sep;9(5):504–10

Human fertility does not decline: evidence from Sweden. Akre O, et al. **Fertil Steril** 1999 Jun;71(6):1066–9

Trends and international comparisons in infertility in circumpolar areas. Raitio A, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):123–32 (38 ref.)

Sentinel surveillance of Chlamydia trachomatis in school-going girls vis-à-vis women with secondary infertility [letter] Singh S, et al. **J Trop Pediatr** 1998 Dec; 44(6):377–8

[Social-hygienic study of the epidemiology of primary and secondary female infertility] Konovalov OE. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):10–1 (Eng. Abstr.) **(Rus)**

ETIOLOGY

A cost comparison of infertility treatment for clomiphene resistant polycystic ovary syndrome. Fridström M, et al. **Acta Obstet Gynecol Scand** 1999 Mar;78(3):212–6

IUDs: time for a renaissance [editorial; comment] Grimes DA, et al. **Am Fam Physician** 1998 Dec;58(9):1963–4. Comment on: Am Fam Physician 1998 Dec;58(9):2077–84, 2087–8.

Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Chiarelli AM, et al. **Am J Epidemiol** 1999 Aug 1;150(3):245–54

Effect of acute food deprivation on lactational infertility in rats is reduced by leptin administration. Woodside B, et al. **Am J Physiol** 1998 Jun;274(6 Pt 2):R1653–8

Rare delivery complication caused by an undiagnosed uterine septum. Banerjee N, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):113–5

Clinical presentation of uterine fibroids. Lumsden MA, et al. **Baillieres Clin Obstet Gynaecol** 1998 Jun;12(2):177–95 (88 ref.)

Alcohol consumption is not related to fertility in Italian women [letter; comment] Parazzini F, et al. **BMJ** 1999 Feb 6;318(7180):397. Comment on: BMJ 1998 Aug 22;317(7157):505–10.

Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. Ralph SG, et al. **BMJ** 1999 Jul 24;319(7204):220–3

Screening for coeliac disease in women with a history of recurrent miscarriage or infertility. Kolho KL, et al. **Br J Obstet Gynaecol** 1999 Feb;106(2):171–3

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946–53 (65 ref.)

Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Hensley ML, et al. **Crit Rev Oncol Hematol** 1998 Aug;28(2):121–8 (55 ref.)

Transgenic mice with chronically elevated luteinizing hormone are infertile due to anovulation, defects in uterine receptivity, and midgestation pregnancy failure. Mann RJ, et al. **Endocrinology** 1999 Jun;140(6):2592–601

Paternal Lake Ontario fish consumption and risk of conception delay, New York State Angler Cohort. Buck GM, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S13–S18

Sport-caught fish consumption and conception delay in licensed Michigan anglers. Courval JM, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S183–S188

Hysteroscopic cervical canal shaving: a new therapy for cervical stenosis before embryo transfer in patients undergoing in vitro fertilization. Noyes N. **Fertil Steril** 1999 May;71(5):965–6

Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient. Moore MM, et al. **Gynecol Oncol** 1999 Jun; 73(3):452–4

Smoking and female infertility: a systematic review and meta-analysis [see comments] Augood C, et al. **Human Reprod** 1998 Jun;13(6):1532–9. Comment in: Hum Reprod 1998 Dec;13(12):3576.

Prospective evaluation of falloposcopy. Dechaud H, et al. **Hum Reprod** 1998 Jul;13(7):1815–8

A second look at the embryotoxicity of hydrosalpingeal fluid: an in-vitro assessment in a murine model. Koong MK, et al. **Hum Reprod** 1998 Oct;13(10):2852–6

Cigarette smoking and infertility [letter; comment] Kornya L, et al. **Hum Reprod** 1998 Dec;13(12):3576. Comment on: Hum Reprod 1998 Jun;13(6):1532–9.

What effect does hydrosalpinx have on assisted reproduction? What is the preferred treatment for hydrosalpines? The ovary's perspective. Lass A. **Hum Reprod** 1999 Jul; 14(7):1674–7 (50 ref.)

Malignancy may adversely influence the quality and behaviour of oocytes. Pal L, et al. **Hum Reprod** 1998 Jul; 13(7):1837–40

Hydrosalpinx fluid does not adversely affect the normal development of human embryos and implantation in vitro. Strandell A, et al. **Hum Reprod** 1998 Oct;13(10):2921–5

Indications for cryopreservation of ovarian tissue. Donnez J, et al. **Hum Reprod Update** 1998 May–Jun;4(3):248–59

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May–Jun;4(3):237–47 (110 ref.)

Infertility following pelvic inflammatory disease. Pavletic AJ, et al. **Infect Dis Obstet Gynecol** 1999;7(3):145–52

Effect of peritoneal fluid from endometriosis patients on sperm motion characteristics and acrosome reaction. Sharma RK, et al. **Int J Fertil Womens Med** 1999 Jan–Feb; 44(1):31–7

Epiphenomenal antiovarian antibodies in hypogonadotropic hypogonadism [letter] Demirel LC, et al. **Int J Gynaecol Obstet** 1995 Jun;49(3):333–4

Genital tuberculosis and infertility. John M, et al. **Int J Gynaecol Obstet** 1999 Feb;64(2):193–4

Endometriosis and infertility: an integrated approach. Ledger WL. **Int J Gynaecol Obstet** 1999 Feb;64 Suppl 1:S33–40 (16 ref.)

Ultrasound guided aspiration of endometrioma--a new therapeutic modality to improve reproductive outcome. Mittal S, et al. **Int J Gynaecol Obstet** 1999 Apr;65(1):17–23

Evaluation of endometrial inflammation by quantification of macrophages, T lymphocytes, and interleukin-1 and -6 in human endometrium. Déchaud H, et al. **J Assist Reprod Genet** 1998 Nov;15(10):612–8

A successful pregnancy with in vitro fertilization and embryo transfer in an infertile woman with Kartagener's syndrome: a case report. Lin TK, et al. **J Assist Reprod Genet** 1998 Nov;15(10):625–7

What causes low rates of child-bearing in congenital adrenal hyperplasia? Meyer-Bahlburg HF. **J Clin Endocrinol Metab** 1999 Jun;84(6):1844–7 (58 ref.)

Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. Pal S, et al. **J Med Microbiol** 1998 Jul; 47(7):599–605

Fertility in thalassemia: the Greek experience. Karagiorga-Lagana M. **J Pediatr Endocrinol Metab** 1998; 11 Suppl 3:945–51

Preliminary observations about assisted reproduction in thalassaemia. Negri P, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:929–33

Fertility in female patients with thalassemia. Skordis N, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:935–43

Effect of transport on pulsatile and surge secretion of LH in ewes in the breeding season. Dobson H, et al. **J Reprod Fertil** 1999 May;116(1):1–8

Effect of transport on pituitary responsiveness to exogenous pulsatile GnRH and oestradiol-induced LH release in intact ewes. Phogat JB, et al. **J Reprod Fertil** 1999 May; 116(1):9–18

Screening for hypothyroidism in infertile women. Lincoln SR, et al. **J Reprod Med** 1999 May;44(5):455–7

Immune abnormalities in endometriosis compromising fertility in IVF-ET patients. Lucena E, et al. **J Reprod Med** 1999 May;44(5):458–64

Subfertility associated with minimal to mild endometriosis. Main mechanisms. Panidis DK, et al. **J Reprod Med** 1998 Dec;43(12):1034–42 (45 ref.)

Infertility and pregnancy in epileptic women [comment] Schwartz LB. **Lancet** 1998 Dec 19–26;352(9145):1952–3. Comment on: Lancet 1998 Dec 19–26;352(9145):1970–3.

Infertility, preterm birth, and bacterial vaginosis [letter] Wilson JD, et al. **Lancet** 1999 Aug 7;354(9177):511

Antiphospholipid antibodies and infertility: fact or fallacy. Ware Branch D, et al. **Lupus** 1998;7 Suppl 2:S90–4 (19 ref.)

Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Kennedy CR, et al. **Nat Med** 1999 Feb;5(2):217–20

Tubal factor infertility. Catalano GF, et al. **Rays** 1998 Oct–Dec;23(4):673–82 **(Eng, Ita)**

Tubal catheterization and selective salpingography. Gazzera C, et al. **Rays** 1998 Oct–Dec;23(4):735–41

Endoscopy of ovarian factor sterility. Rossetti A, et al. **Rays** 1998 Oct–Dec;23(4):727–34

Ovarian factor infertility. Summaria V, et al. **Rays** 1998 Oct–Dec;23(4):709–26

Obesity and reproductive disorders: a review. Norman RJ, et al. **Reprod Fertil Dev** 1998;10(1):55–63 (62 ref.)

Shift work and reproductive health. Nurminen T. **Scand J Work Environ Health** 1998;24 Suppl 3:28–34 (27 ref.)

Laparoscopic adhesiolysis for subfertility. Chew S, et al. **Singapore Med J** 1998 Nov;39(11):491–5

[Chlamydia trachomatis--a risk for reproductive capacity in women] Rezáčová J, et al. **Cas Lek Cesk** 1998 Oct 19; 137(20):619–23 (Eng. Abstr.) **(Cze)**

[Chlamydia trachomatis and its role in female infertility] Rezáčová J, et al. **Ceska Gynekol** 1998 Aug;63(4):276–9 (Eng. Abstr.) **(Cze)**

[Hyperandrogenism and fertility] Deneux C, et al. **Ann Endocrinol (Paris)** 1998 Nov;59(4):311–8 (26 ref.) **(Fre)**

[Uterus and diethylstilbestrol: which examinations, which antecedents for an active management? Which treatments?] Aubriot FX, et al. **Contracept Fertil Sex** 1998 Jul–Aug; 26(7–8):598–604 (Eng. Abstr.) **(Fre)**

[Evaluation of follicular reserve] Belaisch-Allart J.

Contracept Fertil Sex 1999 Apr;27(4):259–62 (25 ref.) **(Fre)**

[Adenomyosis and fertility] Cosson M, et al. **Contracept Fertil Sex** 1998 Jul–Aug;26(7–8):605–7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Fertility in women after cancer therapy] Marmor D. **Contracept Fertil Sex** 1999 Jun;27(6):417–22 (54 ref.) (Eng. Abstr.) **(Fre)**

[The value of hysteroscopy after repeated implantation failures with in vitro fertilization] Schiano A, et al. **Contracept Fertil Sex** 1999 Feb;27(2):129–32 (Eng. Abstr.) **(Fre)**

[Eating disorders. Osteoporosis and infertility after anorexia nervosa] Girardon N, et al. **Presse Med** 1999 Jan 16; 28(2):103–5 (Eng. Abstr.) **(Fre)**

[Polycystic ovaries: when to suspect the diagnosis?] Chardonnens D, et al. **Rev Med Suisse Romande** 1999 Jun; 119(6):459–61 (19 ref.) **(Fre)**

[Endometriosis and sterility] Fabré V, et al. **Rev Prat** 1999 Feb 1;49(3):279–81 (Eng. Abstr.) **(Fre)**

[Desire for children in tumor patients] Dällenbach RZ, et al. **Ther Umsch** 1999 May;56(5):276–81 (26 ref.) (Eng. Abstr.) **(Ger)**

[Polycystic ovary syndrome—only relevant in reproductive medicine?] Heim SC, et al. **Ther Umsch** 1999 May; 56(5):271–5 (18 ref.) (Eng. Abstr.) **(Ger)**

[Surgically induced ovulation in the treatment of sterility due to polycystic ovary syndrome and the course of present pregnancies and deliveries] Andrzejewski L, et al. **Ginekol Pol** 1998 Dec;69(12):1167–70 (Eng. Abstr.) **(Pol)**

[Mycoplasma hominis and Ureaplasma urealyticum of cervical canal and in the pouch of Douglas in infertile women: a preliminary report] Elias M, et al. **Ginekol Pol** 1998 Dec;69(12):1150–2 (Eng. Abstr.) **(Pol)**

[The concentration of interleukin-2 and interleukin-2 soluble receptors in peritoneal fluid of patients with unexplained infertility] Gogacz M, et al. **Ginekol Pol** 1998 Dec; 69(12):1203–6 (Eng. Abstr.) **(Pol)**

[Cytotoxic activity of NK cells in the presence of the peritoneal fluid fro women with unexplained infertility and with endometriosis related infertility] Jędryka M, et al. **Ginekol Pol** 1998 Dec;69(12):1179–82 (Eng. Abstr.) **(Pol)**

[Endoscopic diagnosis of mechanic sterility] Sobkiewicz S, et al. **Ginekol Pol** 1998 Dec;69(12):1162–6 (Eng. Abstr.) **(Pol)**

[Endometriosis. Potential mechanism of sterility. Management of patients with endometriosis. Review and reflections] Gómez Arzapalo E, et al. **Ginecol Obstet Mex** 1999 Feb;67:58–63 (24 ref.) (Eng. Abstr.) **(Spa)**

[Determination of the tumor necrosis factor in the peritoneal fluid of gynecologic patients with intraperitoneal infections and endometriosis] Guerra-Infante FM, et al. **Ginecol Obstet Mex** 1999 May;67:221–6 (26 ref.) (Eng. Abstr.) **(Spa)**

[Laparoscopy and hysteroscopy in Müllerian duct malformations: usefulness and reproductive results] Martinez Reveles M, et al. **Ginecol Obstet Mex** 1999 Jan; 67:4–8 (Eng. Abstr.) **(Spa)**

[Catheterization of the tubal ostium using hysteroscopy under laparoscopic guidance] Salazar López-Ortiz C, et al. **Ginecol Obstet Mex** 1999 Feb;67:64–71 (44 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Infertility in a line of mice with the high growth mutation is due to luteal insufficiency resulting from disruption at the hypothalamic-pituitary axis. Cargill SL, et al. **Biol Reprod** 1999 Jul;61(1):283–7

A baboon (Papio hamadryas) with an isochromosome for the long arm of the X. Moore CM, et al. **Cytogenet Cell Genet** 1998;82(1–2):80–2

Increased prevalence of luteinizing hormone beta-subunit variant in Japanese infertility patients. Takahashi K, et al. **Hum Reprod** 1998 Dec;13(12):3338–44

A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. Beau I, et al. **J Clin Invest** 1998 Oct 1;102(7):1352–9

Ovarian cancer and infertility: a genetic link? [letter] Nieto JJ, et al. **Lancet** 1999 Aug 21;354(9179):649

Genetics, age, and infertility. Nasseri A, et al. **Maturitas** 1998 Oct 12;30(2):189–92 (21 ref.)

Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812–8 (19 ref.)

Leukaemia inhibitory factor gene mutations in infertile women. Giess R, et al. **Mol Hum Reprod** 1999 Jun; 5(6):581–6

Single-gene mutations resulting in reproductive dysfunction in women. Adashi EY, et al. **N Engl J Med** 1999 Mar 4; 340(9):709–18 (75 ref.)

Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Hizaki H, et al. **Proc Natl Acad Sci U S A** 1999 Aug 31; 96(18):10501–6

[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318–21 (16 ref.) **(Fre)**

[Is sterility a genetic burden?] Miny P, et al. **Ther Umsch** 1999 May;56(5):265–70 (9 ref.) (Eng. Abstr.) **(Ger)**

[Carrier of numerical chromosome abnormalities in infertile married couples] Dudkiewicz J, et al. **Ginekol Pol** 1998 Dec;69(12):1157–61 (Eng. Abstr.) **(Pol)**

[Pedigree analysis of childless families of reciprocal chromosome translocation carriers] Stasiewicz-Jarocka B, et al. **Ginekol Pol** 1998 Dec;69(12):1183–90 (Eng. Abstr.) **(Pol)**

[Abnormalities of sex chromosomes and relationship with reproduction disorders] Baez-Reyes MR, et al. **Ginecol Obstet Mex** 1998 Sep;66:367–70 (Eng. Abstr.) **(Spa)**

HISTORY

Women, writers, sufferers: Anne Conway and An Collins. Skwire SE. **Lit Med** 1999 Spring;18(1):1–23

Evolution of radiologic procedures in the study of female infertility. Vincenzoni M, et al. **Rays** 1998 Oct–Dec; 23(4):600–2 **(Eng, Ita)**

IMMUNOLOGY

Correlation between beta 2-glycoprotein antibodies and antiphospholipid antibodies in patients with reproductive failure. Chong P, et al. **Am J Reprod Immunol** 1998 Dec; 40(6):414–7

Natural killer cell subpopulations and cytotoxicity for infertile patients undergoing in vitro fertilization. Fukui A, et al. **Am J Reprod Immunol** 1999 Jun;41(6):413–22

Human sperm proteome: immunodominant sperm surface antigens identified with sera from infertile men and women. Shetty J, et al. **Biol Reprod** 1999 Jul;61(1):61–9

Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Luborsky J, et al. **Clin Immunol** 1999 Mar;90(3):368–74

Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin 6 and low levels of granulocyte-macrophage colony-stimulating factor. Calogero AE, et al. **Cytokine** 1998 Oct;10(10):814–8

N-linked glycan of a sperm CD52 glycoform associated with human infertility. Diekman AB, et al. **FASEB J** 1999 Aug; 13(11):1303–13

Binding of human secretory leukocyte protease inhibitor in uterine cervical mucus to immunoglobulins: pathophysiology in immunologic infertility and local immune defense. Hirano M, et al. **Fertil Steril** 1999 Jun; 71(6):1108–14

Increased anticardiolipin antibodies are positively related to the uterine artery pulsatility index in unexplained infertility. Battaglia C, et al. **Hum Reprod** 1998 Dec;13(12):3487–91

Antibodies to Chlamydia trachomatis heat shock proteins in women with tubal factor infertility are associated with prior infection by C. trachomatis but not by C. pneumoniae. Persson K, et al. **Hum Reprod** 1999 Aug;14(8):1969–73

Study on serum sperm agglutination in cases of unexplained infertility. Thakur P, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):343–50

Immunity to heat shock proteins and pregnancy outcome. Witkin SS. **Infect Dis Obstet Gynecol** 1999;7(1–2):35–8 (20 ref.)

Antisperm antibody: a monkey wrench in conception/magic bullet of contraception? Kamada M, et al. **J Med Invest** 1999 Feb;46(1–2):19–28 (51 ref.)

Elevated serum Chlamydia trachomatis IgG antibodies. Association with decreased implantation rates in GIFT. Sharara FI, et al. **J Reprod Med** 1999 Jul;44(7):581–6

[An experimental study on inhibitory effect of Chinese medicine tai-bao on antisperm antibody] Lai AN, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Jun; 17(6):360–2 (Eng. Abstr.) **(Chi)**

[Maternal anti-paternal reactivity—depends on etiology] Schütt C. **Zentralbl Gynakol** 1999;121(4):202–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Local humoral immunity in women with combined forms of infertility] Kornats'ka AH. **Lik Sprava** 1998 Jun;(4):82–4 (Eng. Abstr.) **(Ukr)**

METABOLISM

Expression of alpha6 and beta4 integrin subunits throughout the menstrual cycle: no correlation with uterine receptivity. Murray MJ, et al. **Fertil Steril** 1999 Sep;72(3):522–6

High levels of serum allopregnanolone in women with premature ovarian failure. Bernardi F, et al. **Gynecol Endocrinol** 1998 Oct;12(5):339–45

Fertility and infertility in aging women. Szamatowicz M, et al. **Gynecol Endocrinol** 1998 Dec;12(6):407–13 (31 ref.)

Integrin expression in normal and out-of-phase endometria. Creus M, et al. **Hum Reprod** 1998 Dec;13(12):3460–8

Concentrations of placental protein 14 in uterine flushings from infertile women: validation of the collection technique and method of expression of results. Hamilton JA, et al. **Hum Reprod** 1998 Dec;13(12):3357–62

Differential effect of exogenous human chorionic gonadotrophin on progesterone production from normal or malfunctioning corpus luteum. Momoeda M, et al. **Hum Reprod** 1998 Jul;13(7):1907–11

Infertile women of advanced reproductive age. Variability of day 3 FSH and E2 levels. Buyalos RP, et al. **J Reprod Med** 1998 Dec;43(12):1023–6

Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients. Rey JM, et al. **Mol Hum Reprod** 1998 Jul; 4(7):641–7

[Detection of cadmium and zinc in the blood and follicular fluid in women in the IVF and ET program] Drbohlav P, et al. **Ceska Gynekol** 1998 Aug;63(4):292–300 (Eng. Abstr.) **(Cze)**

[Free radical oxidation of lipids and antioxidant system of blood in infertile women in a radioactive environment] Ivaniota L, et al. **Ukr Biokhim Zh** 1998 Mar–Apr; 70(2):132–5 (Eng. Abstr.) **(Ukr)**

MICROBIOLOGY

Tumor necrosis factor in peritoneal fluid from asymptomatic infertile women. Guerra-Infante FM, et al. **Arch Med Res** 1999 Mar–Apr;30(2):138–43

Presence of the major outer-membrane protein of Chlamydia trachomatis in patients with chronic salpingitis and salpingitis isthmica nodosa with tubal occlusion. Dieterle S, et al. **Fertil Steril** 1998 Oct;70(4):774–6

The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment. Liversedge NH, et al. **Hum Reprod** 1999 Sep; 14(9):2411–5

Antibodies to the chlamydial 60 kilodalton heat shock protein in women with tubal factor infertility. Ault KA, et al. **Infect Dis Obstet Gynecol** 1998;6(4):163–7

NURSING

Culture, conceptive technology, and nursing. Sandelowski M. **Int J Nurs Stud** 1999 Feb;36(1):13–20 (56 ref.)

PATHOLOGY

Characterization of ciliary activity in distal Fallopian tube biopsies of women with obstructive tubal infertility. Leng Z, et al. **Hum Reprod** 1998 Nov;13(11):3121–7

The ultrastructure of fibromyomatous myometrium and its relationship to infertility. Richards PA, et al. **Hum Reprod Update** 1998 Sep–Oct;4(5):520–5 (37 ref.)

The effect of aging on ovarian volume measurements in infertile women. Sharara FI, et al. **Obstet Gynecol** 1999 Jul;94(1):57–60

PHYSIOPATHOLOGY

Pathophysiology of endometriosis-associated infertility. Burns WN, et al. **Clin Obstet Gynecol** 1999 Sep; 42(3):586–610 (226 ref.)

Fertility in perimenopausal women. Cohen MA, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):958–65 (32 ref.)

Effects of epilepsy on women's reproductive health. Morrell MJ. **Epilepsia** 1998;39 Suppl 8:S32–7 (61 ref.)

Exercise and reproductive dysfunction. Chen EC, et al. **Fertil Steril** 1999 Jan;71(1):1–6 (68 ref.)

Increased anticardiolipin antibodies are positively related to the uterine artery pulsatility index in unexplained infertility. Battaglia C, et al. **Hum Reprod** 1998 Dec;13(12):3487–91

Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Clark AM, et al. **Hum Reprod** 1998 Jun;13(6):1502–5

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36–46; discussion 47–51 (47 ref.)

Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Johannesson M, et al. **Hum Reprod** 1998 Aug;13(8):2092–7

A second look at the embryotoxicity of hydrosalpingeal fluid: an in-vitro assessment in a murine model. Koong MK, et al. **Hum Reprod** 1998 Oct;13(10):2852–6

Hydrosalpinx fluid does not adversely affect the normal development of human embryos and implantation in vitro. Strandell A, et al. **Hum Reprod** 1998 Oct;13(10):2921–5

Pain mapping during minilaparoscopy in infertile patients without pathology. Zupi E, et al. **J Am Assoc Gynecol Laparosc** 1999 Feb;6(1):51–4

Autologous endometrial co-culture in patients with repeated failures of implantation after in vitro fertilization-embryo transfer. Barmat LI, et al. **J Assist Reprod Genet** 1999 Mar; 16(3):121–7

Outcome of IVF in patients with endometriosis in comparison with tubal-factor infertility [see comments] Bergendal A, et al. **J Assist Reprod Genet** 1998 Oct;15(9):530–4. Comment in: J Assist Reprod Genet 1998 Oct;15(9):527–9.

Endometrial evaluation is not predictive for in vitro fertilization treatment. Csemiczky G, et al. **J Assist Reprod Genet** 1999 Mar;16(3):113–6

Serum progesterone in predicting pregnancy outcome after assisted reproductive technology. al-Ramahi M, et al. **J Assist Reprod Genet** 1999 Mar;16(3):117–20

Fertility in anovulatory patients after primary cesarean section. Bider D, et al. **J Reprod Med** 1998 Oct; 43(10):869–71

Ovarian reserve tests in infertility practice and normal fertile women. Brockmans FJ, et al. **Maturitas** 1998 Oct 12; 30(2):205–14 (32 ref.)

Short note: melatonin-dependent infertility. Partonen T. **Med Hypotheses** 1999 May;52(5):487–8

Inactivating FSH receptor mutations and gonadal dysfunction. Tapanainen JS, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):129–35 (54 ref.)

[Experimental study of effect on tonifying kidney herbs in

pituitary ovary adrenal gland of androgen sterilized rats] Gui SQ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Dec; 17(12):735–8 (Eng. Abstr.) **(Chi)**

[How to assess ovarian reserve in 1999?] Hédon B, et al. **Contracept Fertil Sex** 1999 Jun;27(6):412–6 (18 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The reproductive system after childhood cancer [letter] Morice P, et al. **Br J Obstet Gynaecol** 1999 May; 106(5):511–2

Radical trachelectomy: a way to preserve fertility in the treatment of early cervical cancer. Shepherd JH, et al. **Br J Obstet Gynaecol** 1998 Aug;105(8):912–6

Impact of lifestyle choices on female infertility. Silva PD, et al. **J Reprod Med** 1999 Mar;44(3):288–96 (121 ref.)

Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Peppercorn PD, et al. **Radiology** 1999 Aug; 212(2):395–9

PSYCHOLOGY

Gender differences in psychological reactions to infertility among couples seeking IVF- and ICSI-treatment. Hjelmstedt A, et al. **Acta Obstet Gynecol Scand** 1999 Jan; 78(1):42–8

Why are infertile patients not using psychosocial counselling? Boivin J, et al. **Hum Reprod** 1999 May;14(5):1384–91

Psychiatric morbidity in couples attending a fertility service. Guerra D, et al. **Hum Reprod** 1998 Jun;13(6):1733–6

Life after infertility treatment: a long-term investigation of marital and sexual function. Leiblum SR, et al. **Hum Reprod** 1998 Dec;13(12):3569–74

Psychosocial experiences in women facing fertility problems--a comparative survey. Oddens BJ, et al. **Hum Reprod** 1999 Jan;14(1):255–61

Sociodemographic factors in mental disorders associated with infertility in Nigeria. Aghanwa HS, et al. **J Psychosom Res** 1999 Feb;46(2):117–23

Grief, depression, and coping in women undergoing infertility treatment. Lukse MP, et al. **Obstet Gynecol** 1999 Feb; 93(2):245–51

Women and infertility. Rosenthal M. **Psychopharmacol Bull** 1998;34(3):307–8 (10 ref.)

Representations of reproductive technology in women's narratives of infertility. Kirkman M, et al. **Women Health** 1999;29(2):17–36

[Infertility and some of its psychosocial aspects] Bielawska-Batorowicz E. **Ginekol Pol** 1998 Dec; 69(12):1116–25 (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Diagnostic quality in hysterosalpingography. Comparison between iodixanol and iotrolan. Lindequist S, et al. **Acta Radiol** 1998 Nov;39(6):730–3

Evaluation of the performance of hysterosalpingo contrast sonography in 500 consecutive, unselected, infertile women. Hamilton JA, et al. **Hum Reprod** 1998 Jun; 13(6):1519–26

Radiologic imaging of the fallopian tubes. Valentini AL, et al. **Rays** 1998 Oct-Dec;23(4):662–72 **(Eng, Ita)**

RADIOTHERAPY

Cancer risk following radiotherapy for infertility or menstrual disorders. Ron E, et al. **Int J Cancer** 1999 Sep 9;82(6):795–8

REHABILITATION

[Recovered reproductive function in female patient with sever genital tuberculosis] Sotskaia OL. **Probl Tuberk** 1998; (5):19–21 (Eng. Abstr.) **(Rus)**

SURGERY

Laparoscopic myomectomy and pregnancy outcome in infertile patients. Ribeiro SC, et al. **Fertil Steril** 1999 Mar; 71(3):571–4

The role of laparoscopy in the management of the infertility patient. Kosasa TS. **Hawaii Med J** 1999 Jan;58(1):10–1

Laparoscopic fimbrioplasty: an evaluation of 35 cases. Audebert AJ, et al. **Hum Reprod** 1998 Jun;13(6):1496–9

Hysteroscopic metroplasty in diethylstilboestrol-exposed and hypoplastic uterus: a report on 24 cases. Garbin O, et al. **Hum Reprod** 1998 Oct;13(10):2751–5

Resection of uterine septum using gynaecoradiological techniques. Karande VC, et al. **Hum Reprod** 1999 May; 14(5):1226–9

Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi. Parazzini F. **Hum Reprod** 1999 May;14(5):1332–4

Management of septate uterus by flexible hysteroscopy and Nd:YAG laser. Jourdain O, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):159–62

Factors affecting postoperative pregnancy rate after endoscopic management of large endometriomata. Milingos S, et al. **Int J Gynaecol Obstet** 1998 Nov;63(2):129–37

Utility of early second-look laparoscopy after infertility surgery. Ozaki T, et al. **J Am Assoc Gynecol Laparosc** 1999 May;6(2):165–8

Laparoscopically assisted extracorporeal neosalpingostomy. A case report. Van Geem TA. **J Reprod Med** 1998 Aug; 43(8):699–702

Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Varasteh NN, et al. **Obstet Gynecol** 1999 Aug;94(2):168–71

Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Vercellini P, et al. **Obstet Gynecol** 1999 Sep;94(3):341–7

Laparoscopic adhesiolysis for subfertility. Chew S, et al. **Singapore Med J** 1998 Nov;39(11):491–5

[Hysteroscopic surgery and fertility] Cravello L, et al. **Contracept Fertil Sex** 1998 Jul-Aug;26(7–8):589–92 (25 ref.) (Eng. Abstr.) **(Fre)**

[Myomectomy by laparoscopy and infertility: status of the controversy] Dubuisson JB, et al. **Contracept Fertil Sex** 1998 Oct;26(10):728–31 (42 ref.) (Eng. Abstr.) **(Fre)**

[Indications for hysteroscopy in infertility] Martenne Duplan J. **Contracept Fertil Sex** 1998 Oct;26(10):700–4 (17 ref.) **(Fre)**

[Role of hysteroscopic treatment of the septate uterus resulting in primary sterility] Porcu G, et al. **Contracept Fertil Sex** 1998 Nov;26(11):764–7 **(Fre)**

[Are there still indications for tubal surgery in infertility? (editorial)] Dubuisson JB. **Presse Med** 1998 Nov 14; 27(35):1793–4 (Eng. Abstr.) **(Fre)**

[The influence of cumulative dexamethasone, promethazine and dextran 70 used as protection against intraperitoneal adhesions on selected parameters of humoral immunity in women operated on for infertility] Puchalski A. **Ann Acad Med Stetin** 1998;44:115–36 (Eng. Abstr.) **(Pol)**

[Surgically induced ovulation in the treatment of steriliy due to polycystic ovary syndrome and the course of present pregnancies and deliveries] Andrzejewski L, et al. **Ginekol Pol** 1998 Dec;69(12):1167–70 (Eng. Abstr.) **(Pol)**

[The effectiveness of hysteroscopic intrauterine septum resection in terms of reproductive outcome] Szamatowicz J, et al. **Ginekol Pol** 1998 Oct;69(10):757–60 (Eng. Abstr.) **(Pol)**

[Results of laparoscopic treatment of infertility] Zołnierczyk P, et al. **Ginekol Pol** 1998 Dec;69(12):1137–40 (Eng. Abstr.) **(Pol)**

[Clinical evaluation of patients submitted to open vs conventional gynecologic laparoscopy] Kably Ambe A, et al. **Ginecol Obstet Mex** 1999 Jun;67:261–6 (Eng. Abstr.) **(Spa)**

THERAPY

Successful pregnancies following laser-induced interstitial thermotherapy (LITT) for treatment of large uterine leiomyomas by a minimally invasive method. Chapman R. **Acta Obstet Gynecol Scand** 1998 Nov;77(10):1024–5

Obstetric outcome in patients with unexplained infertility: comparison of treatment-related and spontaneous pregnancies. Isaksson R, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):849–53

Ovarian hyperstimulation syndrome caused by GnRH-analogue treatment without gonadotropin therapy in a patient with polycystic ovarian syndrome. Jirecek S, et al. **Acta Obstet Gynecol Scand** 1998 Oct;77(9):940–1

Pregnancies in women with Turner's syndrome. Hovatta O. **Ann Med** 1999 Apr;31(2):106–10 (46 ref.)

Royal College of Obstetricians and Gynaecologists Evidence-based Clinical Guidelines. Guideline Summary No. 2: the initial investigation and management of the infertile couple. **BJU Int** 1999 Apr;83(6):636–40

Royal College of Obstetricians and Gynaecologists Evidence-based Clinical Guidelines. Guideline Summary No. 3: the management of infertility in secondary care. **BJU Int** 1999 Apr;83(6):641–5

Spontaneous pregnancy occurring in a donor oocyte cycle: a case report. Hannoun A, et al. **Clin Exp Obstet Gynecol** 1998;25(3):97–8

Fertility in perimenopausal women. Cohen MA, et al. **Clin Obstet Gynecol** 1998 Dec;41(4):958–65 (32 ref.)

Endometriosis and assisted reproductive technologies. Dokras A, et al. **Clin Obstet Gynecol** 1999 Sep;42(3):687–98 (52 ref.)

Infertility in the older woman. Schmidt-Sarosi C. **Clin Obstet Gynecol** 1998 Dec;41(4):940–50 (58 ref.)

The metamorphosis of fertility management: lessons from assisted reproductive technology [editorial] Hershlag A. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):271–3

Freezing of oocytes. Porcu E. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):297–300 (44 ref.)

Low-dose FSH stimulation in polycystic ovary syndrome: comparison of 3 FSH-preparations. Strowitzki T, et al. **Exp Clin Endocrinol Diabetes** 1998;106(5):435–9

Lack of insulin-like growth factor binding protein-3 variation after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome undergoing in vitro fertilization. Amato G, et al. **Fertil Steril** 1999 Sep; 72(3):454–7

Pharmacokinetics of exogenous gonadotropin and ovarian response in in vitro fertilization. Nagata Y, et al. **Fertil Steril** 1999 Aug;72(2):235–9

Clinical application of a new assisted hatching method using a piezo-micromanipulator for morphologically low-quality embryos in poor-prognosis infertile patients. Nakayama T, et al. **Fertil Steril** 1999 Jun;71(6):1014–8

Prediction of the rates of fertilization, cleavage, and pregnancy success by cumulus-coronal morphology in an in vitro fertilization program. Ng ST, et al. **Fertil Steril** 1999 Sep;72(3):412–7

Hysteroscopic cervical canal shaving: a new therapy for cervical stenosis before embryo transfer in patients undergoing in vitro fertilization. Noyes N. **Fertil Steril** 1999 May;71(5):965–6

Reference values for the midluteal plasma progesterone concentration: evidence from human menopausal gonadotropin-stimulated pregnancy cycles. Sallam HN, et al. **Fertil Steril** 1999 Apr;71(4):711–4

Spontaneous conception after the birth of infants conceived through in vitro fertilization treatment. Shimizu Y, et al. **Fertil Steril** 1999 Jan;71(1):35–9

Fallopian sperm perfusion versus intrauterine insemination: a randomized controlled trial and metaanalysis of the literature. Trout SW, et al. **Fertil Steril** 1999 May; 71(5):881–5

Serum pregnancy-specific beta1-glycoprotein before embryo transfer is related to endometrial thickness and to outcome prognosis in women undergoing in-vitro fertilization treatment. Bersinger NA, et al. **Hum Reprod** 1998 Jul; 13(7):1962–7

Pregnancy rates after in-vitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta-analysis of published comparative studies. Camus E, et al. **Hum Reprod** 1999 May;14(5):1243–9

Follicle stimulating hormone and its receptor: future perspectives. Chappel S, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:18–35; discussion 47–51 (77 ref.)

New approaches to ovarian stimulation. Diedrich K, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:1–13; discussion 14–7 (43 ref.)

Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Doldi N, et al. **Hum Reprod** 1999 Mar;14(3):601–5

Why do some women undergo termination of pregnancy after successful IVF treatment? Edozien L. **Hum Reprod** 1998 Sep;13(9):2377–8

New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127–36; discussion 145–7 (12 ref.)

Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Fauser BC. **Hum Reprod** 1998 Jun;13 Suppl 3:36–46; discussion 47–51 (47 ref.)

Contralateral ovulation shortens follicular phase length and favours pre-embryo development during ovarian stimulation with clomiphene citrate. Fukuda M, et al. **Hum Reprod** 1998 Jun;13(6):1590–4

A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hedon B, et al. **Hum Reprod** 1998 Oct;13(10):2688–92

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients. Jansen CA, et al. **Hum Reprod** 1998 Nov;13(11):2995–9

Effect of in-utero diethylstilboestrol exposure on human oocyte quality and fertilization in a programme of in-vitro fertilization. Kerjean A, et al. **Hum Reprod** 1999 Jun; 14(6):1578–81

The experiences of couples who have had infertility treatment in the United Kingdom: results of a survey performed in 1997. Kerr J, et al. **Hum Reprod** 1999 Apr;14(4):934–8

What effect does hydrosalpinx have on assisted reproduction? What is the preferred treatment for hydrosalpines? The ovary's perspective. Lass A. **Hum Reprod** 1999 Jul; 14(7):1674–7 (50 ref.)

Life after infertility treatment: a long-term investigation of marital and sexual function. Leiblum SR, et al. **Hum Reprod** 1998 Dec;13(12):3569–74

Semen quality: is there a paternal effect on pregnancy outcome in in-vitro fertilization/intracytoplasmic sperm injection? Oehninger S, et al. **Hum Reprod** 1998 Aug; 13(8):2161–4

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Olivennes F, et al. **Hum Reprod** 1998 Sep; 13(9):2411–4

Artificial insemination by husband in unexplained infertility compared with infertility associated with peritoneal endometriosis. Omland AK, et al. **Hum Reprod** 1998 Sep; 13(9):2602–5

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Peñarrubia J, et al. **Hum Reprod** 1998 Dec;13(12):3315–8

Questioning the efficacy of Fallopian tube sperm perfusion. El Sadek MM, et al. **Hum Reprod** 1998 Nov;13(11):3053–6

Successful pregnancy in an infertile patient with conservatively treated endometrial adenocarcinoma after transfer of embryos obtained by intracytoplasmic sperm injection. Shibahara H, et al. **Hum Reprod** 1999 Jul; 14(7):1908–11

The outcome of in-vitro fertilization treatment by egg

donation and intracytoplasmatic sperm injection for severe male factor infertility: a preliminary report. Shulman A, et al. **Hum Reprod** 1998 Aug;13(8):2158–60

Indications for cryopreservation of ovarian tissue. Donnez J, et al. **Hum Reprod Update** 1998 May–Jun;4(3):248–59

The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Newton H. **Hum Reprod Update** 1998 May–Jun;4(3):237–47 (110 ref.)

Semen quality changes among 2343 healthy Slovenian men included in an IVF–ET programme from 1983 to 1996. Zorn B, et al. **Int J Androl** 1999 Jun;22(3):178–83

Fallopian sperm perfusion (FSP) using Foley's balloon system versus intrauterine insemination (IUI) in the treatment of infertility. Maheshwari A, et al. **Int J Gynaecol Obstet** 1999 Jun;65(3):313–5

Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring. Murad NM. **Int J Gynaecol Obstet** 1998 Dec;63(3):271–6

No show is a major problem in planning appointments for infertility patients. Redmond ML, et al. **Ir Med J** 1998 Dec;91(6):198–9

Does assisted reproduction make an impact on the identity and self-esteem of infertile women during the transition to parenthood? McMahon CA. **J Assist Reprod Genet** 1999 Feb;16(2):59–62 (19 ref.)

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

Twin delivery after myomectomy, in vitro fertilization, and embryo reduction in an infertile woman. Inovay J, et al. **J Matern Fetal Med** 1999 Jul–Aug;8(4):200–2

Preliminary observations about assisted reproduction in thalassaemia. Negri P, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:929–33

Fertility in female patients with thalassemia. Skordis N, et al. **J Pediatr Endocrinol Metab** 1998;11 Suppl 3:935–43

The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1–2):261–70 (21 ref.)

Controlled ovarian hyperstimulation and intrauterine insemination in subfertility. How many treatment cycles are sufficient? Yang JH, et al. **J Reprod Med** 1998 Oct; 43(10):903–8

Substitution of acupuncture for HCG in ovulation induction. Cai X. **J Tradit Chin Med** 1997 Jun;17(2):119–21

Assessment of separate contributions to perinatal mortality of infertility history and treatment: a case-control analysis [see comments] Draper ES, et al. **Lancet** 1999 May 22; 353(9166):1746–9. Comment in: Lancet 1999 May 22;353(9166):1724–3.

Melatonin-dependent infertility. Partonen T. **Med Hypotheses** 1999 Mar;52(3):269–70

Compensating egg donors. Is the money worth it? Barlyn S. **N J Med** 1999 Sep;96(9):33–5

Multiple cerebral infarctions associated with ovarian hyperstimulation syndrome. Yoshii F, et al. **Neurology** 1999 Jul 13;53(1):225–7

Infertility treatment and informed consent: current practices of reproductive endocrinologists. Houmard BS, et al. **Obstet Gynecol** 1999 Feb;93(2):252–7

Grief, depression, and coping in women undergoing infertility treatment. Lukse MP, et al. **Obstet Gynecol** 1999 Feb; 93(2):245–51

Tubal catheterization and selective salpingography. Gazzera C, et al. **Rays** 1998 Oct–Dec;23(4):735–41

The pattern of changes in ovarian stromal and uterine artery blood flow velocities during in vitro fertilization treatment and its relationship with outcome of the cycle. Engmann L, et al. **Ultrasound Obstet Gynecol** 1999 Jan;13(1):26–33

[The indispensable anamnesis: in-vitro fertilization in a woman under treatment for melanoma (comment)] Merkus JM, et al. **Ned Tijdschr Geneeskd** 1998 Sep 19; 142(38):2073–5 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Sep 19;142(38):2087–90. **(Dut)**

[Medical treatment of infertility: therapeutic guide. I. In women] Cohen J. **Contracept Fertil Sex** 1999 Jan; 27(1):23–34 (18 ref.) **(Fre)**

[Selective salpingography in the treatment of infertility caused by proximal tubal obstruction: apropos of 122 cases treated in Dakar] Ba SD, et al. **Sante** 1999 Mar–Apr; 9(2):81–4 (Eng. Abstr.) **(Fre)**

[A fluoroscopy-controlled transcervical fallopian tube recanalization] Schmitz-Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1999 Feb;170(2):229–31 **(Ger)**

[From theory to clinical practice: recombinant FSH in daily practice] Kably Ambe A, et al. **Ginecol Obstet Mex** 1999 Aug;67:408–13 (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Transvaginal sonohysterography and hysteroscopy in the evaluation of female infertility, habitual abortion or metrorrhagia. A comparative study. Grønlund L, et al. **Acta Obstet Gynecol Scand** 1999 May;78(5):415–8

Screening sonohysterography in infertility. Darwish AM, et al. **Gynecol Obstet Invest** 1999;48(1):43–7

Routine use of saline hysterosonography in 500 consecutive, unselected, infertile women. Hamilton JA, et al. **Hum Reprod** 1998 Sep;13(9):2463–73

Hysterosalpingo contrast sonography (HyCoSy) with SH U 454 (Echovist) for the assessment of tubal patency. Reis MM, et al. **Hum Reprod** 1998 Nov;13(11):3049–52

Laparoscopy-assisted intrapelvic sonography with a high-frequency, real-time miniature transducer for assessment of the Fallopian tube: a preliminary report. Senoh D, et al. **Hum Reprod** 1999 Mar;14(3):704–6

Uterine intracavitary disorders: role of sonography and combination with other radiologic techniques. Mirk P, et al. **Rays** 1998 Oct–Dec;23(4):625–36 **(Eng, Ita)**

[Ultrasonic follow-up of the endometrium in women with sterility after Serpafar treatment] Pünevska M, et al. **Akush Ginekol (Sofiia)** 1998;37(1):30–1 (Eng. Abstr.) **(Bul)**

VETERINARY

Evaluation of reproductive failure of female pigs based on slaughterhouse material and herd record survey. Heinonen M, et al. **Anim Reprod Sci** 1998 Sep 11;52(3):235–44

The use of milk progesterone profiles to characterise components of subfertility in milked dairy cows. Lamming GE, et al. **Anim Reprod Sci** 1998 Sep 11;52(3):175–90

Humoral immune response to equine chorionic gonadotropin in ewes: association with major histocompatibility complex and interference with subsequent fertility. Roy F, et al. **Biol Reprod** 1999 Jul;61(1):209–18

The negative effect of repeated equine chorionic gonadotropin treatment on subsequent fertility in Alpine goats is due to a humoral immune response involving the major histocompatibility complex. Roy F, et al. **Biol Reprod** 1999 Apr;60(4):805–13

The effects of Tritrichomonas foetus and nutritional status on the fertility of cows on a community pasture in Saskatchewan. Stewart RJ, et al. **Can Vet J** 1998 Oct; 39(10):638–41

A baboon (Papio hamadryas) with an isochromosome for the long arm of the X. Moore CM, et al. **Cytogenet Cell Genet** 1998;82(1–2):80–2

Infertility and abortion among first-lactation dairy cows seropositive or seronegative for Leptospira interrogans serovar hardjo. Guitian J, et al. **J Am Vet Med Assoc** 1999 Aug 15;215(4):515–8

Prevalence of Coxiella burnetii infection in dairy cattle with reproductive disorders. To H, et al. **J Vet Med Sci** 1998 Jul;60(7):859–61

Incidence of gross reproductive abnormalities in small east African zebu cattle. Assey RJ, et al. **Trop Anim Health Prod** 1998 Dec;30(6):361–8

Evidence of reproductive failure and lack of perinatal transmission of Bartonella henselae in experimentally infected cats. Guptill L, et al. **Vet Immunol Immunopathol** 1998 Oct 23;65(2–4):177–89

Pregnancy rate after ultrasound-guided follicle aspiration in nonlactating cows from different breeds. Schernthaner W, et al. **Zentralbl Veterinarmed A** 1999 Feb;46(1):33–7

[The prevention of pneumovagina and the effect of the Caslick operation on fertility: a retrospective study] van Ittersum AR, et al. **Tijdschr Diergeneeskd** 1999 May 1; 124(9):281–3 (Eng. Abstr.) **(Dut)**

[Postpartum anestrus in dairy cattle--a review] Opsomer G, et al. **Tierarztl Prax Ausg G Grosstiere Nutztiere** 1999 Feb; 27(1):30–5 (34 ref.) (Eng. Abstr.) **(Ger)**

INFERTILITY, MALE

Pentoxifylline stimulates various sperm motion parameters and cervical mucus penetrability in patients with asthenozoospermia. Nassar A, et al. **Andrologia** 1999 Jan; 31(1):9–15

Teratozoospermia and its effect on male fertility potential. Szczygiel M, et al. **Andrologia** 1999 Mar;31(2):63–75 (107 ref.)

Male sterility in transgenic mice expressing activin betaA subunit gene in testis. Tanimoto Y, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):699–705

Male fertility disorders. Hargreave T, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):765–82, vii–viii (66 ref.)

Fertilization after standard in vitro fertilization versus intracytoplasmic sperm injection in subfertile males using sibling oocytes. Pisarska MD, et al. **Fertil Steril** 1999 Apr; 71(4):627–32

Male infertility update. The ESHRE Capri Workshop Group. **Hum Reprod** 1998 Jul;13(7):2025–32 (93 ref.)

Does ovarian hyperstimulation syndrome affect the quality of oocytes? Akagbosu F, et al. **Hum Reprod** 1998 Sep; 13(9):2583–4

Controlled ovarian hyperstimulation and intrauterine insemination for treating male subfertility: a controlled study. Cohlen BJ, et al. **Hum Reprod** 1998 Jun;13(6):1553–8

Comparison of pregnancy outcome after intracytoplasmic sperm injection and in-vitro fertilization. Govaerts I, et al. **Hum Reprod** 1998 Jun;13(6):1514–8

Failure of pregnancy after intracytoplasmic sperm injection with decapitated spermatozoa: case report. Saïas-Magnan J, et al. **Hum Reprod** 1999 Aug;14(8):1989–92

The applicability of the flow cytometric sperm chromatin structure assay in epidemiological studies. Asclepios. Spanò M, et al. **Hum Reprod** 1998 Sep;13(9):2495–505

Influence of seminal plasma on cryopreservation of human spermatozoa in a biological material-free medium: study of normal and low-quality semen. Grizard G, et al. **Int J Androl** 1999 Jun;22(3):190–6

Effect of freeze-thawing procedure on chromatin stability, morphological alteration and membrane integrity of human spermatozoa in fertile and subfertile men. Hammadeh ME, et al. **Int J Androl** 1999 Jun;22(3):155–62

Bioethics and law forum [letter] Lamb DJ, et al. **J Androl** 1999 Jul–Aug;20(4):454–5

GIFT–ICSI for the treatment of male-factor infertility for patients with religious objections to in vitro fertilization: a case report. Allan JA, et al. **J Assist Reprod Genet** 1999 Feb;16(2):108–9

Improvement of semen quality in infected asymptomatic infertile male after bacteriological cure. Cardoso EM, et al. **Medicina (B Aires)** 1998;58(2):160–4

Reproductive health in males with cystic fibrosis: knowledge, attitudes, and experience of patients and parents [letter; comment] Madge SL, et al. **Pediatr Pulmonol** 1999 Apr; 27(4):293. Comment on: Pediatr Pulmonol 1998 Apr;25(4):226–30.

[Severe male infertility. Genetic investigation and counseling prior to intracytoplasmic sperm injection] Mikkelsen L. **Ugeskr Laeger** 1999 Apr 19;161(16):2348–51 (19 ref.) (Eng. Abstr.) **(Dan)**

[Efficacy of simultaneous use of cryopreserved semen, controlled ovarian hyperstimulation and intrauterine insemination in the treatment of sterility caused by hypergonadotropic azoospermia] Kably Ambe A, et al. **Ginecol Obstet Mex** 1999 Feb;67:53–7 (Eng. Abstr.) **(Spa)**

[Assisted fertilization in male sterility is not without risks. Genetic aberrations can be transmitted to children and grandchildren] Bui TH, et al. **Lakartidningen** 1998 Nov 25;95(48):5430–2 (33 ref.) **(Swe)**

[Infertile men, wherever they live, should have a chance to become genetic fathers] Westlander G, et al. **Lakartidningen** 1999 Feb 10;96(6):618–9 **(Swe)**

BLOOD

Serum levels of inhibin B in men with different causes of spermatogenic failure. Bohring C, et al. **Andrologia** 1999 May;31(3):137–41

Hormonal profile of infertile Makkans. Khan ZA, et al. **Int Urol Nephrol** 1998;30(4):499–505

CHEMICALLY INDUCED

Chloroquine reduces fertilizing capacity of epididyma sperm in rats. Adeeko AO, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):63–4

Improvement in semen quality associated with decreasing occupational lead exposure. Viskum S, et al. **Am J Ind Med** 1999 Mar;35(3):257–63

Male infertility: possible association with valproate exposure. Yerby MS, et al. **Epilepsia** 1999 Apr;40(4):520–1

A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years' experience. Lass A, et al. **Hum Reprod** 1998 Nov;13(11):3256–61

Occupational risk to male reproduction [editorial; comment] Bonde JP. **Int Arch Occup Environ Health** 1999 May; 72(3):133–4 (17 ref.). Comment on: Int Arch Occup Environ Health 1999 May;72(3):135–41.

Male reproductive pattern in a glass producing area. Wingren G, et al. **Int J Occup Med Environ Health** 1998;11(3):227–34

Reproductive toxicity potentials of Salvia fruticosa (Labiatae) in rats [published erratum appears in J Ethnopharmacol 1998 Dec;63(3):265] Al-Hamood MH, et al. **J Ethnopharmacol** 1998 May;61(1):67–74

Pesticide exposure and decreased fertilisation rates in vitro [letter] Tielemans E, et al. **Lancet** 1999 Aug 7; 354(9177):484–5

Warning signs. O'Neal MA. **Occup Health Saf** 1997 Dec; 66(12):42–5

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:40–3 (8 ref.)

Objectives, designs and populations of the European Asclepios study on occupational hazards to male reproductive capability. Bonde JP, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:49–61; discussion 76–8

Time to pregnancy and occupational lead exposure. Asclepios. Joffe M, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:64–5; discussion 76–8

Time to pregnancy for men occupationally exposed to styrene in several European reinforced plastics companies. Asclepios. Kolstad HA, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:66–9; discussion 76–8

Time to pregnancy and paternal exposure to pesticides in preliminary results from Danish and French studies. Asclepios. Thonneau P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:62–3; discussion 76–8

COMPLICATIONS

Chlamydial infection in asymptomatic infertile men attending an andrology clinic. Bornman MS, et al. **Arch Androl** 1998 Nov–Dec;41(3):203–8

Risk of testicular cancer in subfertile men: case-control study [see comments] Møller H, et al. **BMJ** 1999 Feb 27; 318(7183):559–62. Comment in: BMJ 1999 Jun 5;318(7197):1556.

[Carcinoma in situ of the testis in infertile men. Experience

in a medically assisted reproduction program] Zorn B, et al. **Contracept Fertil Sex** 1999 Jan;27(1):41–6 (Eng. Abstr.) **(Fre)**

[Sino-bronchial infections and male sterility. Presentation of a new variant] Carrión Valero F, et al. **Arch Bronconeumol** 1998 Sep;34(8):405–8 (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Correlation of smoking and coffee drinking with sperm progressive motility in infertile males. Adelusi B, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):47–50

Quantitative ultramorphological (QUM) analysis of human sperm: diagnosis and management of male infertility. Bartoov B, et al. **Arch Androl** 1999 May–Jun;42(3):161–77

Quantitative ultramorphological analysis of human sperm: fifteen years of experience in the diagnosis and management of male factor infertility. Bartoov B, et al. **Arch Androl** 1999 Jul–Aug;43(1):13–25

Intrauterine insemination IUI: the effect of ovarian stimulation and infertility diagnosis on pregnancy outcome. Hannoun A, et al. **Clin Exp Obstet Gynecol** 1998; 25(4):144–6

Meta-analysis for the diagnostic accuracy of a test? [letter; comment] Huszar G. **Fertil Steril** 1999 Feb;71(2):389–91. Comment on: Fertil Steril 1998 Apr;69(4):727–34. Comment on: Fertil Steril 1999 Feb;71(2):391–2.

Meta-analysis for the diagnostic accuracy of a test? [editorial; comment] McDonough PG. **Fertil Steril** 1999 Feb; 71(2):391–2. Comment on: Fertil Steril 1999 Feb;71(2):389–90.

Factors influencing the variable incidence of Y chromosome microdeletions in infertile patients. Calogero AE, et al. **Hum Reprod** 1999 Feb;14(2):275

Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic. Evenson DP, et al. **Hum Reprod** 1999 Apr;14(4):1039–49

A prospective analysis of the accuracy of the TEST-yolk buffer enhanced hamster egg penetration test and acrosin activity in discriminating fertile from infertile males. Romano R, et al. **Hum Reprod** 1998 Aug;13(8):2115–21

Glycodelins: role in regulation of reproduction, potential for contraceptive development and diagnosis of male infertility. Seppälä M, et al. **Hum Reprod** 1998 Jun;13 Suppl 3:262–9; discussion 270 (39 ref.)

Use of failed-fertilized oocytes for diagnostic zona binding purposes after sperm binding improvement with a modified medium. Henkel R, et al. **J Assist Reprod Genet** 1999 Jan; 16(1):24–9

Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)

Is the free androgen index a useful clinical marker in male patients? Brannian JD, et al. **S D J Med** 1998 Dec; 51(12):449–51

Unilateral obstruction of the vas deferens diagnosed by seminal vesicle aspiration. Seifman BD, et al. **Tech Urol** 1999 Jun;5(2):113–5

Male infertility. Evaluation and nonsurgical therapy. Chuang AT, et al. **Urol Clin North Am** 1998 Nov;25(4):703–13, x (40 ref.)

Seminal plasma biochemical markers and their association with semen analysis findings. Diamandis EP, et al. **Urology** 1999 Mar;53(3):596–603

[The family practitioner and the postcoital test (comment) (see comments)] Bossuyt PM, et al. **Ned Tijdschr Geneeskd** 1998 Sep 12;142(37):2028–9 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1998 Sep 12;142(37):2056–7. Comment in: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2646. **(Dut)**

[Postcoital test--a useful aid for the family physician (see comments)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1998 Sep 12;142(37):2056–7 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Sep 12;142(37):2028–9. Comment in: Ned Tijdschr Geneeskd 1998 Nov 28;142(48):2646. **(Dut)**

[The family physician and the postcoital test (letter)] Ponsioen BP. **Ned Tijdschr Geneeskd** 1998 Oct 3; 142(40):2216 **(Dut)**

[Intra-spermatic L-carnitine and survival of sperm motility] Mazzilli F, et al. **Minerva Ginecol** 1999 Apr;51(4):129–34 (Eng. Abstr.) **(Ita)**

[Changes in morphological picture of the semen in the group of men from infertile couples in the Lower Silesia in 1977–1993] Pająk J, et al. **Ginekol Pol** 1999 Jan;70(1):20–5 (Eng. Abstr.) **(Pol)**

[Nordic unity on sperm analysis. Better diagnostics for infertile men] Kvist U. **Lakartidningen** 1998 Oct 21; 95(43):4748 **(Swe)**

DRUG THERAPY

Conception rate after treatment of male idiopathic infertility with pure human follicle stimulating hormone [letter; comment] Glander HJ, et al. **Andrologia** 1999 Jan; 31(1):55–6. Comment on: Andrologia 1997 Jan–Feb;29(1):23–8.

Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. Meistrich ML, et al. **Cancer Res** 1999 Aug 1;59(15):3557–60

Therapy with growth hormone: major prospects for the treatment of male subfertility? Breier BH, et al. **Endocr J** 1998 Apr;45 Suppl:S53–60 (31 ref.)

Antioxidant treatment for male subfertility: a promise that remains unfulfilled. Ford WC, et al. **Hum Reprod** 1998 Jun; 13(6):1416–9

Free radicals, antioxidants and human spermatozoa: clinical implications. Geva E, et al. **Hum Reprod** 1998 Jun; 13(6):1422–4

A rationale for glutathione therapy. Lenzi A, et al. **Hum Reprod** 1998 Jun;13(6):1419–22

Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Liu PY, et al. **Hum Reprod** 1999 Jun;14(6):1540–5

Is antioxidant therapy a promising strategy to improve human reproduction? Are anti-oxidants useful in the treatment of male infertility? Martin-Du Pan RC, et al. **Hum Reprod** 1998 Nov;13(11):2984–5 (25 ref.)

Antioxidants may protect against infertility. Tarin JJ, et al. **Hum Reprod** 1998 Jun;13(6):1415–6

Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. Ochsenkühn R, et al. **Int J Androl** 1999 Jun;22(3):173–7

[Medical treatment of infertility: therapeutic guide. II. In males] Cohen J. **Contracept Fertil Sex** 1999 Feb; 27(2):107–13 (0 ref.) **(Fre)**

[In vivo scavenging effect of ethylcysteine on reactive oxygen species in human semen] Akiyama M. **Nippon Hinyokika Gakkai Zasshi** 1999 Mar;90(3):421–8 (Eng. Abstr.) **(Jpn)**

ECONOMICS

Vasectomy related infertility: a major and costly medical problem [see comments] Jequier AM. **Hum Reprod** 1998 Jul;13(7):1757–9. Comment in: Hum Reprod 1998 Jul;13(7):1759–60.

ENZYMOLOGY

Human sperm endothelial nitric oxide synthase expression: correlation with sperm motility. O'Bryan MK, et al. **Fertil Steril** 1998 Dec;70(6):1143–7

Telomerase activity in the testis of infertile patients with selected causes. Fujisawa M, et al. **Hum Reprod** 1998 Jun; 13(6):1476–9

Seminal fructose levels in male infertility: relationship with sperm characteristics. Andrade-Rocha FT. **Int Urol Nephrol** 1999;31(1):107–11

Studies on the relationship between urokinase plasminogen activator (uPA) and human sperm motility. Huang X, et al. **J Tongji Med Univ** 1997;17(4):213–7

EPIDEMIOLOGY

Secular trends in sperm variables for groups of men in fertile and infertile couples. Ulstein M, et al. **Acta Obstet Gynecol Scand** 1999 Apr;78(4):332–5

Trends and international comparisons in infertility in circumpolar areas. Raitio A, et al. **Int J Circumpolar Health** 1998 Jul;57(2–3):123–32 (38 ref.)

Male reproductive pattern in a glass producing area. Wingren G, et al. **Int J Occup Med Environ Health** 1998;11(3):227–34

Testicular suture: a significant risk factor for infertility among formerly cryptorchid men. Coughlin MT, et al. **J Pediatr Surg** 1998 Dec;33(12):1790–3

Critical aspects of male fertility in the assessment of exposure to lead. Apostoli P, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:40–3 (8 ref.)

Analysis of chromosome aneuploidy in sperm by fluorescence in situ hybridization--a new approach to the study of male fertility in environmental exposures. Asclepios. Lähdetie J, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:26–7

Flow cytometric sperm chromatin structure assay as an independent descriptor of human semen quality. Spanò M, et al. **Scand J Work Environ Health** 1999;25 Suppl 1:28–30; discussion 76–8

[Analysis of decline in seminal fluid in the Italian population during the past 15 years] Bilotta P, et al. **Minerva Ginecol** 1999 Jun;51(6):223–31 (53 ref.) (Eng. Abstr.) **(Ita)**

[Evaluation of reproductive disorders in men occupational exposed to lead] Sitarek K, et al. **Med Pr** 1998;49(2):137–45 (Eng. Abstr.) **(Pol)**

ETIOLOGY

Biophysical and biochemical analysis of semen in infertile Nigerian males. Adejuwon CA, et al. **Afr J Med Med Sci** 1996 Sep;25(3):217–9

Correlation of smoking and coffee drinking with sperm progressive motility in infertile males. Adelusi B, et al. **Afr J Med Med Sci** 1998 Mar–Jun;27(1–2):47–50

Fructose concentration in seminal fluids and the deoxyribonucleic acid content of spermatozoa from infertile human males. Oforofuo IA, et al. **Afr J Reprod Health** 1997 Mar;1(1):89–96

Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. De Celis R, et al. **Arch Androl** 1999 Jan–Feb; 42(1):9–20

Absence of effect of recombinant growth hormone to classic gonadotropin treatment on spermatogenesis of patients with severe hypogonadotropic hypogonadism. Giagulli VA. **Arch Androl** 1999 Jul–Aug;43(1):47–53

Contribution of the assisted reproductive technologies to fertility in males suffering spinal cord injury. Taylor Z, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):84–7

The effects of experimental varicocele on testicular histology and fertility in monorchic adult rats. Asci R, et al. **BJU Int** 1999 Mar;83(4):493–7

Paediatric andrology: the impact of environmental pollutants. Kennedy WA2nd, et al. **BJU Int** 1999 Jan;83(2):195–200

The undescended testis: considerations and impact on fertility. Leissner J, et al. **BJU Int** 1999 May;83(8):885–91; quiz 891–2 (41 ref.)

Successful testicular sperm extraction and fertilization in an azoospermic man with postpubertal mumps orchitis. Lin YM, et al. **BJU Int** 1999 Mar;83(4):526–7

The hormonal assessment of the infertile male [letter; comment] Pandiyan N. **BJU Int** 1999 Apr;83(6):738–9. Comment on: Br J Urol 1998 Jul;82(1):69–75.

The reproductive system after childhood cancer. Levitt GA, et al. **Br J Obstet Gynaecol** 1998 Sep;105(9):946–53 (65 ref.)

A follow-up study of semen quality and fertility in men with varicocele testis and in control subjects. Lund L, et al. **Br J Urol** 1998 Nov;82(5):682–6

Reproductive effects of nontesticular illness. Baker HW. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):831–50 (96 ref.)

Declining male fertility and environmental factors. Giwercman A, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):807–30, viii (122 ref.)

Treatment of varicocele for male infertility: a comparative study evaluating currently used approaches. Barbalias GA, et al. **Eur Urol** 1998;34(5):393–8

Abnormal sperm parameters in humans are indicative of an abortive apoptotic mechanism linked to the Fas-mediated pathway. Sakkas D, et al. **Exp Cell Res** 1999 Sep 15; 251(2):350–5

Occupationally related exposures and reduced semen quality: a case-control study. Tielemans E, et al. **Fertil Steril** 1999 Apr;71(4):690–6

Birth of healthy children after intracytoplasmic sperm injection in two couples with male Kartagener's syndrome. von Zumbusch A, et al. **Fertil Steril** 1998 Oct;70(4):643–6

Rapid decline of fertility in a case of adrenoleukodystrophy. Aversa A, et al. **Hum Reprod** 1998 Sep;13(9):2474–9

Transurethral deroofing of midline prostatic cyst for subfertile men. Cornel EB, et al. **Hum Reprod** 1999 Sep; 14(9):2297–300

Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Liu PY, et al. **Hum Reprod** 1999 Jun;14(6):1540–5

Do men undergoing sterilizing cancer treatments have a fertile future? Naysmith TE, et al. **Hum Reprod** 1998 Nov; 13(11):3250–5

Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Nieschlag E, et al. **Hum Reprod** 1998 Aug;13(8):2147–50

Assisted reproduction for infertile patients with 9 + 0 immotile spermatozoa associated with autosomal dominant polycystic kidney disease [published erratum appears in Hum Reprod 1999 Jun;14(6):1166] Okada H, et al. **Hum Reprod** 1999 Jan;14(1):110–3

A birth in non-mosaic Klinefelter's syndrome after testicular fine needle aspiration, intracytoplasmic sperm injection and preimplantation genetic diagnosis. Reubinoff BE, et al. **Hum Reprod** 1998 Jul;13(7):1887–92

Occupational heat exposure and male fertility: a review. Thonneau P, et al. **Hum Reprod** 1998 Aug;13(8):2122–5 (34 ref.)

Comparing the anti-inflammatory effects of corticotherapy and non-steroid anti-inflammatory drugs in infertile patients with infectious aetiology. Altay B, et al. **Int Urol Nephrol** 1999;31(1):101–6

Cellular and molecular causes of male infertility in spinal cord injury. Rajasekaran M, et al. **J Androl** 1999 May–Jun; 20(3):326–30 (52 ref.)

The Amoroso Lecture. The human spermatozoon--a cell in crisis? Aitken RJ. **J Reprod Fertil** 1999 Jan;115(1):1–7 (49 ref.)

Hemochromatosis and male infertility. Oehninger S, et al. **Obstet Gynecol** 1998 Oct;92(4 Pt 2):652–3

Is infertility after surgery for cryptorchidism congenital or acquired? Cortes D, et al. **Pediatr Surg Int** 1998 Nov; 14(1–2):6–8

Cryptorchidism and infertility [editorial] Schärli AF. **Pediatr Surg Int** 1998 Nov;14(1–2):1

Individual prognosis for changes in sperm quality on the basis of perceived stress. Pook M, et al. **Psychother Psychosom** 1999 Mar–Apr;68(2):95–101

Cystic fibrosis and reproduction. Phillipson G. **Reprod Fertil Dev** 1998;10(1):113–9 (44 ref.)

A comprehensive approach to the management of male infertility following spinal cord injury. Rutkowski SB, et al. **Spinal Cord** 1999 Jul;37(7):508–14

Spinal cord injured men and infertility [letter] Stien R. **Spinal Cord** 1999 Jul;37(7):527

Primary male infertility caused by congenital prostatic cyst: sonographic and magnetic resonance imaging findings. Aalame NM, et al. **Urol Int** 1998 Oct;61(1):58–61

Evaluation of the relationship between semen parameters, pregnancy rate of wives of infertile men with varicocele, and gonadotropin-releasing hormone test before and after

varicocelectomy. Segenreich E, et al. **Urology** 1998 Nov; 52(5):853–7

[Treatment of male infertility after oncologic therapy: preventive autologous sperm preservation versus testicular biopsy and oocyte fertilization with testicular spermatozoa] Sobek A, et al. **Ceska Gynekol** 1998 Jun;63(3):196–9 (Eng. Abstr.) **(Cze)**

[Agenesis of the vas deferens in male infertility. A tentative classification based on 39 cases] Robert F, et al. **Presse Med** 1999 Jan 23;28(3):116–21 (Eng. Abstr.) **(Fre)**

[Etiology and treatment of sterility due to azoospermia] Martin-du Pan RC, et al. **Rev Med Suisse Romande** 1999 Jun;119(6):453–7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Long-term tumor control and fertility after para-aortic limited radiotherapy of stage I seminoma] Sedlmayer F, et al. **Strahlenther Onkol** 1999 Jul;175(7):320–4 (Eng. Abstr.) **(Ger)**

[Desire for children in tumor patients] Dällenbach RZ, et al. **Ther Umsch** 1999 May;56(5):276–81 (26 ref.) (Eng. Abstr.) **(Ger)**

[Medical examination and therapy in infertility] Derouet H. **Urologe A** 1999 Jul;38(4):380–7 (17 ref.) **(Ger)**

[Andrologic aspects in reproductive health care] Artiukhin AA. **Med Tr Prom Ekol** 1999;(3):16–9 (Eng. Abstr.) **(Rus)**

[Cystic dysplasia in the seminal vesicle. Case report and literature review] Dominguez Dominguez M, et al. **Actas Urol Esp** 1999 Jun;23(6):532–5 (Eng. Abstr.) **(Spa)**

GENETICS

Severe male infertility. Impact of genetic factors on diagnosis and counselling. Lidegaard O, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):799–803

Germ-cell nondisjunction in testes biopsies of men with idiopathic infertility. Huang WJ, et al. **Am J Hum Genet** 1999 Jun;64(6):1638–45

Herpesvirus thymidine kinase transgenes that do not cause male sterility are aberrantly transcribed and translated in the testis. Ellison AR, et al. **Biochim Biophys Acta** 1998 Oct 23;1442(1):28–38

Intracytoplasmic sperm injection pregnancy with trisomy 20p and monosomy 22q in a newborn resulting from a balanced paternal translocation. Belin V, et al. **Biol Neonate** 1999; 75(6):398–401

Mice carrying two t haplotypes: sperm populations with reduced Zona pellucida binding are deficient in capacitation. Si Y, et al. **Biol Reprod** 1999 Jul;61(1):305–11

Human sperm chromosome complements in chemotherapy patients and infertile men. Martin R. **Chromosoma** 1998 Dec;107(6–7):523–7

Analysis of the transactivation domain of the androgen receptor in patients with male infertility. Wang Q, et al. **Clin Genet** 1998 Sep;54(3):185–92

Advances in Y chromosome mapping. Yen PH. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):275–81 (71 ref.)

The genetic basis of male infertility. Bhasin S, et al. **Endocrinol Metab Clin North Am** 1998 Dec;27(4):783–805, viii (165 ref.)

Learning to knock out male infertility [news] May M. **Environ Health Perspect** 1998 Mar;106(3):A132–3

Chromosome studies in 1792 males prior to intra-cytoplasmic sperm injection: the Dutch experience. Tuerlings JH, et al. **Eur J Hum Genet** 1998 May-Jun;6(3):194–200

Genetic abnormalities and male infertility. A comprehensive review. Thielemans BF, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):217–25 (85 ref.)

Male infertility associated with a unique 8;22 translocation. Mark HF, et al. **Exp Mol Pathol** 1999 Sep;67(1):57–61

Characterization of aneuploidy rates, protamine levels, ultrastructure, and functional ability of round-headed sperm from two siblings and implications for intracytoplasmic sperm injection. Carrell DT, et al. **Fertil Steril** 1999 Mar;71(3):511–6

Is it better to find Adam or study spermatogenesis? --a difference opinion [editorial; comment] McDonough PG. **Fertil Steril** 1999 Aug;72(2):376–8. Comment on: Fertil Steril 1999 Aug;72(2):375–6.

The locus of sY84 is not associated with spermatogenesis--"is it better to find Adam or study spermatogenesis?--a different opinion" [letter] [see comments] Tseng SL, et al. **Fertil Steril** 1999 Aug;72(2):375–6. Comment in: Fertil Steril 1999 Aug;72(2):376–8.

Y chromosome and male infertility. Krausz C, et al. **Front Biosci** 1999 Jan 15;4:E1–8 (62 ref.)

Genetic testing for male infertility: a postulated role for mutations in sperm nuclear matrix attachment regions. Kramer JA, et al. **Genet Test** 1997;1(2):125–9

Inheritance of male hybrid sterility in the house musk shrew (Suncus murinus, Insectivora, Soricidae). Axenovich TI, et al. **Genome** 1998 Dec;41(6):825–31

Genetic findings in congenital bilateral aplasia of vas deferens patients and identification of six novel mutatations. Mutations in brief no. 138. Online. de Meeus A, et al. **Hum Mutat** 1998;11(6):480

Study of aneuploidy in normal and abnormal germ cells from semen of fertile and infertile men. Bernardini L, et al. **Hum Reprod** 1998 Dec;13(12):3406–13

Factors influencing the variable incidence of Y chromosome microdeletions in infertile patients. Calogero AE, et al. **Hum Reprod** 1999 Feb;14(2):275

Genetic contribution to male infertility. Chandley AC. **Hum Reprod** 1998 Jun;13 Suppl 3:76–83; discussion 84–8 (43 ref.)

Acephalic spermatozoa and abnormal development of the head-neck attachment: a human syndrome of genetic origin. Chemes HE, et al. **Hum Reprod** 1999 Jul; 14(7):1811–8

Absence of testicular DAZ gene expression in idiopathic severe testiculopathies. Ferlin A, et al. **Hum Reprod** 1999 Sep;14(9):2286–92

Subfertile men with constitutive chromosome abnormalities do not necessarily refrain from intracytoplasmic sperm injection treatment: a follow-up study on 75 Dutch patients. Giltay JC, et al. **Hum Reprod** 1999 Feb; 14(2):318–20

Frequency of CFTR gene mutations in males participating in an ICSI programme. Jakubiczka S, et al. **Hum Reprod** 1999 Jul;14(7):1833–4

Genetic evaluation of infertile men. Kleiman SE, et al. **Hum Reprod** 1999 Jan;14(1):33–8

Male infertility: analysis of the markers and genes on the human Y chromosome. Kostiner DR, et al. **Hum Reprod** 1998 Nov;13(11):3032–8 (53 ref.)

Screening for microdeletions of Y chromosome genes in patients undergoing intracytoplasmic sperm injection. Krausz C, et al. **Hum Reprod** 1999 Jul;14(7):1717–21

Abnormalities for chromosomes 13 and 21 detected in spermatozoa from infertile men. McInnes B, et al. **Hum Reprod** 1998 Oct;13(10):2787–90

Klinefelter's syndrome in the male infertility clinic. Okada H, et al. **Hum Reprod** 1999 Apr;14(4):946–52

Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Page DC, et al. **Hum Reprod** 1999 Jul;14(7):1722–6

Principles of sequence-tagged site selection in screening for Y deletions [comment] [see comments] Pryor JL, et al. **Hum Reprod** 1998 Jul;13(7):1768 (2 ref.). Comment on: Hum Reprod 1998 Jul;13(7):1764–8. Comment in: Hum Reprod 1999 Feb;14(2):572.

Current status of the molecular diagnosis of Y-chromosomal microdeletions in the work-up of male infertility. Initiative for international quality control [see comments] Simoni M, et al. **Hum Reprod** 1998 Jul;13(7):1764–8 (32 ref.). Comment in: Hum Reprod 1998 Jul;13(7):1768. Comment in: Hum Reprod 1999 Feb;14(2):572.

Screening male intracytoplasmic sperm injection candidates for mutations of the follicle stimulating hormone receptor gene. Tuerlings JH, et al. **Hum Reprod** 1998 Aug; 13(8):2098–101

Developmental and genetic disorders in spermatogenesis. Diemer T, et al. **Hum Reprod Update** 1999 Mar-Apr; 5(2):120–40 (154 ref.)

The H-mshi antigen is conserved among standard BALB/cBy, C57BL/6J, and wild-derived CAST/Ei and SPRET/Ei inbred strains of mice. Hildebrandt AL, et al. **Immunogenetics** 1999 Jul;49(7–8):666–72

Screening for microdeletions on the long arm of chromosome Y in 53 infertile men. Seifer I, et al. **Int J Androl** 1999 Jun;22(3):148–54

Three-generation evaluation of Y-chromosome microdeletion. Kleiman SE, et al. **J Androl** 1999 May-Jun; 20(3):394–8

Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. Korpelainen EI, et al. **J Cell Biol** 1998 Dec 14;143(6):1705–12

Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. Simoni M, et al. **J Clin Endocrinol Metab** 1999 Feb;84(2):751–5

Detection of numerical chromosome abnormalities in human spermatozoa by three-color fluorescence in situ hybridization. Li P, et al. **J Obstet Gynaecol Res** 1998 Dec; 24(6):385–92

Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene [see comments] Dowsing AT, et al. **Lancet** 1999 Aug 21;354(9179):640–3 . Comment in: Lancet 1999 Aug 21;354(9179):611–2.

Mouse male sterility and histoincompatibility (mshi) maps between the D10Mit51/168/212 cluster and D10Mit213 Rule MC, et al. **Mamm Genome** 1999 May;10(5):447–50

Mapping and cloning recombinant breakpoints demarcating the hybrid sterility 6-specific sperm tail assembly defect. Samant SA, et al. **Mamm Genome** 1999 Feb;10(2):88–94

An exon map of the AZFc male infertility region of the human Y chromosome. Wong J, et al. **Mamm Genome** 1999 Jan;10(1):57–61

Knockout mouse model and gametogenic failure. Grootegoed JA, et al. **Mol Cell Endocrinol** 1998 Oct 25; 145(1–2):161–6 (45 ref.)

Genetics of male infertility. Hargreave TB, et al. **Mol Cell Endocrinol** 1998 Oct 25;145(1–2):143–51 (67 ref.)

Fertility and infertility: genetic contributions from the hypothalamic-pituitary-gonadal axis. Achermann JC, et al. **Mol Endocrinol** 1999 Jun;13(6):812–8 (19 ref.)

Screening for cystic fibrosis transmembrane conductance regulator gene mutations in men included in an intracytoplasmic sperm injection programme. Boucher D, et al. **Mol Hum Reprod** 1999 Jun;5(6):587–93

Interstitial and terminal deletion of chromosome Y in a male individual with cryptozoospermia. Duell T, et al. **Mol Hum Reprod** 1998 Apr;4(4):325–31

Mutations in the promoter region of the androgen receptor gene are not common in males with idiopathic infertility. Ghadessy FJ, et al. **Mol Hum Reprod** 1999 Mar;5(3):287–90

Analysis of Yq microdeletions in infertile males by PCR and DNA hybridization techniques. Grimaldi P, et al. **Mol Hum Reprod** 1998 Dec;4(12):1116–21

Multiple deletions of mitochondrial DNA are associated with the decline of motility and fertility of human spermatozoa. Kao SH, et al. **Mol Hum Reprod** 1998 Jul;4(7):657–66

Human chromosome deletions in Yq11, AZF candidate genes and male infertility: history and update. Vogt PH. **Mol Hum Reprod** 1998 Aug;4(8):739–44 (51 ref.)

Genetic concerns for the subfertile male in the era of ICSI. Kim ED, et al. **Prenat Diagn** 1998 Dec;18(13):1349–65 (130 ref.)

Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. Robertson KM, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7986–91

Identification of morc (microrchidia), a mutation that results in arrest of spermatogenesis at an early meiotic stage in the mouse. Watson ML, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14361–6

The Y-chromosome and reproductive disorders. McDonough PG. **Reprod Fertil Dev** 1998;10(1):1–16 (76 ref.)

Genetic disorders and spermatogenesis. McLachlan RI, et al. **Reprod Fertil Dev** 1998;10(1):97–104 (52 ref.)

Y chromosome and male infertility. Cooke HJ. **Rev Reprod** 1999 Jan;4(1):5–10 (40 ref.)

Origin of DNA damage in ejaculated human spermatozoa. Sakkas D, et al. **Rev Reprod** 1999 Jan;4(1):31–7 (59 ref.)

Cytogenetic study in 102 infertile men. Gündüz G, et al. **Urol Int** 1998 Oct;61(1):32–4

[A clinico-genetic study of male infertility with globozoospermia] Stanislavov R, et al. **Akush Ginekol (Sofiia)** 1998;37(4):20–2 (Eng. Abstr.) **(Bul)**

[Physiopathology of gonadotropic control of gametogenesis] Deneux C, et al. **Ann Biol Clin (Paris)** 1999 May; 57(3):318–21 (16 ref.) **(Fre)**

[Genetic control of spermatogenesis: Y chromosome and male infertility] Krausz C, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):309–17 (50 ref.) **(Fre)**

[Genetic causes of male infertility] Seifer I, et al. **Ann Biol Clin (Paris)** 1999 May;57(3):301–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Search for microdeletions in the long arm of chromosome Y in 48 infertile men] Seifer I, et al. **C R Seances Soc Biol Fil** 1998;192(4):725–32 (Eng. Abstr.) **(Fre)**

[Y chromosome microdeletions in male infertility] Siffroi JP, et al. **Contracept Fertil Sex** 1998 Dec;26(12):825–9 (34 ref.) **(Fre)**

[Genetic male infertility] Van Steirteghem A, et al. **Rev Prat** 1999 Jun 15;49(12):1309–13 (Eng. Abstr.) **(Fre)**

[Is sterility a genetic burden?] Miny P, et al. **Ther Umsch** 1999 May;56(5):265–70 (9 ref.) (Eng. Abstr.) **(Ger)**

[Carrier of numerical chromosome abnormalities in infertile married couples] Dudkiewicz J, et al. **Ginekol Pol** 1998 Dec;69(12):1157–61 (Eng. Abstr.) **(Pol)**

[Pedigree analysis of childless families of reciprocal chromosome translocation carriers] Stasiewicz-Jarocka B, et al. **Ginekol Pol** 1998 Dec;69(12):1183–90 (Eng. Abstr.) **(Pol)**

[Abnormalities of sex chromosomes and relationship with reproduction disorders] Baez-Reyes MR, et al. **Ginecol Obstet Mex** 1998 Sep;66:367–70 (Eng. Abstr.) **(Spa)**

[Male infertility is often of genetic origin. Y chromosome deletions are discovered by the PCR technique] Arver S, et al. **Lakartidningen** 1998 Nov 25;95(48):5485–6 (9 ref.) **(Swe)**

IMMUNOLOGY

Quantification of C3 and C4 in infertile men with antisperm antibody in their seminal plasma. Rahimi A, et al. **Am J Reprod Immunol** 1999 May;41(5):330–6

Human sperm proteome: immunodominant sperm surface antigens identified with sera from infertile men and women. Shetty J, et al. **Biol Reprod** 1999 Jul;61(1):61–9

Postcoital testing. Male partner should be assessed [letter; comment] Hendry WF. **BMJ** 1999 Apr 10; 318(7189):1007–8; discussion 1008–9. Comment on: BMJ 1998 Aug 22;317(7157):502–5.

The characterization of human spermatozoa membrane proteins--surface antigens and immunological infertility. Bohring C, et al. **Electrophoresis** 1999 Apr-May; 20(4–5):971–6

Fertilization antigen-1 removes antisperm autoantibodies from spermatozoa of infertile men and results in increased rates of acrosome reaction. Menge AC, et al. **Fertil Steril** 1999 Feb;71(2):256–60

METABOLISM

Increased levels of interleukin-8 in human seminal plasma. Koumantakis E, et al. **Andrologia** 1998 Nov;30(6):339–43

Determination of interleukin-11 in seminal plasma and elevated IL-11 in seminal plasma of infertile patients with urogenital infection. Matalliotakis I, et al. **Arch Androl** 1998

Nov-Dec;41(3):177-83
Decreased levels of interleukin-12 are not correlated with leukocyte concentration and superoxide dismutase activity in semen of infertile men. Naz RK, et al. **Arch Androl** 1998 Sep-Oct;41(2):91-6
Decreased expression of the c-kit receptor is associated with increased apoptosis in subfertile human testes. Feng HL, et al. **Fertil Steril** 1999 Jan;71(1):85-9
Seminal transforming growth factor-beta in normal and infertile men. Loras B, et al. **Hum Reprod** 1999 Jun; 14(6):1534-9
Screening male intracytoplasmic sperm injection candidates for mutations of the follicle stimulating hormone receptor gene. Tuerlings JH, et al. **Hum Reprod** 1998 Aug; 13(8):2098-101
Flow cytometry isolation and reverse transcriptase-polymerase chain reaction characterization of human round spermatids in infertile patients. Ziyyat A, et al. **Hum Reprod** 1999 Feb;14(2):379-87
Modulation of insulin-like growth factor-1 in the seminal plasma of infertile men. Colombo JB, et al. **J Androl** 1999 Jan-Feb;20(1):118-25
Secretion of testosterone and its delta4 precursor steroids into spermatic vein blood in men with varicocele-associated infertility. Winters SJ, et al. **J Clin Endocrinol Metab** 1999 Mar;84(3):997-1001
Re: Reactive oxygen species production by the spermatozoa of patients with idiopathic infertility: relationship to seminal plasma antioxidants [letter; comment] Durak I, et al. **J Urol** 1999 May;161(5):1583-4. Comment on: J Urol 1997 Jan;157(1):140-3.
Varicocele is associated with elevated spermatozoal reactive oxygen species production and diminished seminal plasma antioxidant capacity. Hendin BN, et al. **J Urol** 1999 Jun; 161(6):1831-4
Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility. He S, et al. **Mol Hum Reprod** 1999 Jun;5(6):513-9
Secretory leukocyte protease inhibitor (SLP) concentrations in seminal plasma: SLPI restores sperm motility reduced by elastase. Moriyama A, et al. **Mol Hum Reprod** 1998 Oct;4(10):946-50
Reactive oxygen species in male infertility. Review of literature and personal observations. Conte G, et al. **Panminerva Med** 1999 Mar;41(1):45-53 (58 ref.)
Selenium's role in infertility explained [news; comment] Strauss E. **Science** 1999 Aug 27;285(5432):1339. Comment on: Science 1999 Aug 27;285(5432):1393-6.

MICROBIOLOGY

Chlamydia trachomatis detected by ligase chain reaction in the semen of asymptomatic patients without pyospermia or pyuria. Fujisawa M, et al. **Arch Androl** 1999 Jan-Feb; 42(1):41-4
Genital Ureaplasma urealyticum infection in varicocele-related infertility. Li H, et al. **Chin Med J (Engl)** 1997 Nov;110(11):865-8
Seminal tract infections: impact on male fertility and treatment options. Keck C, et al. **Hum Reprod Update** 1998 Nov-Dec;4(6):891-903 (132 ref.)
Chlamydia trachomatis and male infertility: chlamydia-IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response. Ochsendorf FR, et al. **J Eur Acad Dermatol Venereol** 1999 Mar; 12(2):143-52
Antibiotic therapy for seminal infection. Effect on antioxidant activity and T-helper cytokines. Omu AE, et al. **J Reprod Med** 1998 Oct;43(10):857-64

PATHOLOGY

Correlation of cell counts and indices in testicular FNAC with histology in male infertility. Batra VV, et al. **Acta Cytol** 1999 Jul-Aug;43(4):617-23
Mast cells in testicular biopsies of infertile men with 'mixed atrophy' of seminiferous tubules. Ježek D, et al. **Andrologia** 1999 Jul;31(4):203-10
A percutaneous large-needle aspiration biopsy technique for histologic examination of the testis in infertile patients. Carpi A, et al. **Fertil Steril** 1999 Apr;71(4):756-60
Spermac stain analysis of human sperm acrosomes. Chan PJ, et al. **Fertil Steril** 1999 Jul;72(1):124-8
Dynamic aspects concerned with the mechanism of separating motile sperm from nonmotile sperm, leukocytes, and debris with the use of high-density Percoll gradients [see comments] Makler A, et al. **Fertil Steril** 1998 Nov; 70(5):961-6. Comment in: Fertil Steril 1999 Apr;71(4):778-9.
What are the germ cell phenotypes from infertile men telling us about spermatogenesis? Escalier D. **Histol Histopathol** 1999 Jul;14(3):959-71 (113 ref.)
Study of aneuploidy in normal and abnormal germ cells from semen of fertile and infertile men. Bernardini L, et al. **Hum Reprod** 1998 Dec;13(12):3406-13
Acephalic spermatozoa and abnormal development of the head-neck attachment: a human syndrome of genetic origin. Chemes HE, et al. **Hum Reprod** 1999 Jul; 14(7):1811-8
Vigorous prostatic massage: a simple method to retrieve spermatozoa for intracytoplasmic sperm injection in psychogenic anejaculation: case report. Fahmy I, et al. **Hum Reprod** 1999 Aug;14(8):2050-3
Round spermatids from hybrid sterile mice can initiate normal embryo development. Sasagawa I, et al. **Hum Reprod** 1998 Nov;13(11):3099-102
Reversion of the differentiated phenotype and maturation block in Sertoli cells in pathological human testis. Steger K, et al. **Hum Reprod** 1999 Jan;14(1):136-43
Flow cytometry isolation and reverse transcriptase-polymerase chain reaction characterization of human round spermatids in infertile patients. Ziyyat A, et al. **Hum Reprod** 1999 Feb;14(2):379-87
Differences in the DNA-stainability of spermatozoa from fertile and suspected infertile men. Bito M, et al. **Int J Androl** 1999 Aug;22(4):275-81
Quantitative evaluation of biopty gun testis needle biopsy. Correlation between biopsy score of varicocele-bearing testis and sperm count. Uygur MC, et al. **J Reprod Med** 1999 May;44(5):445-9
Germ cell apoptosis in men with complete and incomplete spermiogenesis failure. Tesarik J, et al. **Mol Hum Reprod** 1998 Aug;4(8):757-62
Yield and efficacy of biopty gun testis needle biopsy. Morey AF, et al. **Urology** 1999 Mar;53(3):604-7

PHYSIOPATHOLOGY

DNA strand breaks in human spermatozoa: a possible factor, to be considered in couples suffering from unexplained infertility. Høst E, et al. **Acta Obstet Gynecol Scand** 1999 Aug;78(7):622-5
Prostate-specific antigen (PSA) in human seminal plasma. Schieferstein G. **Arch Androl** 1999 May-Jun;42(3):193-7
Nocturnal sperm emission in men with psychogenic anejaculation. Hovav Y, et al. **Fertil Steril** 1999 Aug; 72(2):364-5
Vascular endothelial growth factor and its receptors in male fertility. Obermair A, et al. **Fertil Steril** 1999 Aug; 72(2):269-75
Evolution of semen quality in North-eastern Spain: a study in 22,759 infertile men over a 36 year period. Andolz P, et al. **Hum Reprod** 1999 Mar;14(3):731-5
Klinefelter's syndrome in the male infertility clinic. Okada H, et al. **Hum Reprod** 1999 Apr;14(4):946-52
Cellular and molecular causes of male infertility in spinal cord injury. Rajasekaran M, et al. **J Androl** 1999 May-Jun; 20(3):326-30 (52 ref.)
Destruction of protamine in human sperm inhibits sperm binding and penetration in the zona-free hamster penetration test but increases sperm head decondensation and male pronuclear formation in the hamster-ICSI assay. Ahmadi A, et al. **J Assist Reprod Genet** 1999 Mar; 16(3):128-32
Altered sperm function or sperm antibodies are not associated with chlamydial antibodies in infertile men with leucocytospermia. Habermann B, et al. **J Eur Acad Dermatol Venereol** 1999 Jan;12(1):25-9
Short note: melatonin-dependent infertility. Partonen T. **Med Hypotheses** 1999 May;52(5):487-8

PREVENTION & CONTROL

[A strategy for the prevention of male infertility] Comhaire FH, et al. **Verh K Acad Geneeskd Belg** 1999;61(3):441-52; discussion 453-5 (35 ref.) (Eng. Abstr.) **(Dut)**

PSYCHOLOGY

Gender differences in psychological reactions to infertility among couples seeking IVF- and ICSI-treatment. Hjelmstedt A, et al. **Acta Obstet Gynecol Scand** 1999 Jan; 78(1):42-8
Sexual satisfaction in male infertility. Müller MJ, et al. **Arch Androl** 1999 May-Jun;42(3):137-43
Nocturnal sperm emission in men with psychogenic anejaculation. Hovav Y, et al. **Fertil Steril** 1999 Aug; 72(2):364-5
Why are infertile patients not using psychosocial counselling? Boivin J, et al. **Hum Reprod** 1999 May;14(5):1384-91
Psychiatric morbidity in couples attending a fertility service. Guerra D, et al. **Hum Reprod** 1998 Jun;13(6):1733-6
Coping with infertility: distress and changes in sperm quality. Pook M, et al. **Hum Reprod** 1999 Jun;14(6):1487-92
[Coping with involuntary childlessness in men] Küchenhoff J, et al. **Psychother Psychosom Med Psychol** 1999 Jul; 49(7):225-34 (Eng. Abstr.) **(Ger)**
[Sexual dissatisfaction and somatic complaints in male infertility] Schilling G, et al. **Psychother Psychosom Med Psychol** 1999 Aug;49(8):256-63 (36 ref.) (Eng. Abstr.) **(Ger)**
[Unfulfilled desire for children--what is the grief for men?] Küchenhoff J. **Ther Umsch** 1999 May;56(5):260-4 (Eng. Abstr.) **(Ger)**
[Infertility and some of its psychosocial aspects] Bielawska-Batorowicz E. **Ginekol Pol** 1998 Dec; 69(12):1116-25 (Eng. Abstr.) **(Pol)**

SURGERY

Spontaneous pregnancy following therapeutic approach of an infertile man with aspermia/obstructive azoospermia. Papadimas J, et al. **Arch Androl** 1999 Mar-Apr;42(2):105-8
Improvement of sperm count and motility after ligation of varicoceles detected with colour Doppler ultrasonography. Pierik FH, et al. **Int J Androl** 1998 Oct;21(5):256-60

THERAPY

Obstetric outcome in patients with unexplained infertility: comparison of treatment-related and spontaneous pregnancies. Isaksson R, et al. **Acta Obstet Gynecol Scand** 1998 Sep;77(8):849-53
Scleroembolization techniques in the treatment of varicocele. Belgrano E, et al. **Ann Urol (Paris)** 1999;33(3):203-9
Quantitative ultramorphological (QUM) analysis of human sperm: diagnosis and management of male infertility. Bartoov B, et al. **Arch Androl** 1999 May-Jun;42(3):161-77
Contribution of the assisted reproductive technologies to fertility in males suffering spinal cord injury. Taylor Z, et al. **Aust N Z J Obstet Gynaecol** 1999 Feb;39(1):84-7
Royal College of Obstetricians and Gynaecologists Evidence-based Clinical Guidelines. Guideline Summary No. 3: the management of infertility in secondary care. **BJU Int** 1999 Apr;83(6):641-5
Royal College of Obstetricians and Gynaecologists Evidence-based Clinical Guidelines. Guideline Summary No. 2: the initial investigation and management of the infertile couple. **BJU Int** 1999 Apr;83(6):636-40
Assisted reproduction for testicular failure: management of germ cell maturation arrest. Tesarik J, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):283-8 (48 ref.)
Intracytoplasmic sperm injection in the treatment of male subfertility. Gordts S, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Dec;81(2):207-11
Intrauterine insemination as first line treatment of unexplained and male factor infertility. Keck C, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Aug;79(2):193-7
The effect of the duration of GnRH-agonist down regulation before ovarian stimulation on the biological and clinical outcome after intracytoplasmic sperm injection. Loutradis D, et al. **Eur J Obstet Gynecol Reprod Biol** 1998 Oct; 80(2):251-5
Numerical dose-compensated in vitro fertilization inseminations yield high fertilization and pregnancy rates. Benoff S, et al. **Fertil Steril** 1999 Jun;71(6):1019-28
Treatment of severe male infertility by micromanipulation-assisted fertilization: news and views. Tesarik J, et al. **Front Biosci** 1998 Dec 15;3:E238-46
The use of intracytoplasmic sperm injection with electroejaculates from anejaculatory men. Chung PH, et al. **Hum Reprod** 1998 Jul;13(7):1854-8
Relationship between psychological stress and semen quality among in-vitro fertilization patients. Clarke RN, et al. **Hum Reprod** 1999 Mar;14(3):753-8
Pregnancies after activated oocyte transfer: a new option for infertility treatment. Dale B, et al. **Hum Reprod** 1999 Jul; 14(7):1771-2
Clinical application of new micromanipulative technologies to treat the male. Devroey P. **Hum Reprod** 1998 Jun;13 Suppl 3:112-22; discussion 123-6 (44 ref.)
Cytogenetic analysis of unfertilized oocytes following intracytoplasmic sperm injection using spermatozoa from a globozoospermic man. Edirisinghe WR, et al. **Hum Reprod** 1998 Nov;13(11):3094-8
New approaches to achieving human fertilization: a résumé. Edwards RG. **Hum Reprod** 1998 Jun;13 Suppl 3:127-36; discussion 145-7 (12 ref.)
Fertility of ejaculated and testicular megalohead spermatozoa with intracytoplasmic sperm injection. Kahraman S, et al. **Hum Reprod** 1999 Mar;14(3):726-30
The experiences of couples who have had infertility treatment in the United Kingdom: results of a survey performed in 1997. Kerr J, et al. **Hum Reprod** 1999 Apr;14(4):934-8
Triplet pregnancy and delivery after intracytoplasmic injection of round-headed spermatozoa. Kilani ZM, et al. **Hum Reprod** 1998 Aug;13(8):2177-9
Screening for microdeletions of Y chromosome genes in patients undergoing intracytoplasmic sperm injection. Krausz C, et al. **Hum Reprod** 1999 Jul;14(7):1717-21
Triplet pregnancy achieved through intracytoplasmic sperm injection with spermatozoa obtained by prostatic massage of a paraplegic patient: case report. Marina S, et al. **Hum Reprod** 1999 Jun;14(6):1546-8
Update on treatment of varicocele: counselling as effective as occlusion of the vena spermatica. Nieschlag E, et al. **Hum Reprod** 1998 Aug;13(8):2147-50
The outcome of intracytoplasmic sperm injection in patients with retrograde ejaculation. Nikolettos N, et al. **Hum Reprod** 1999 Sep;14(9):2293-6
Semen quality: is there a paternal effect on pregnancy outcome in in-vitro fertilization/intracytoplasmic sperm injection? Oehninger S, et al. **Hum Reprod** 1998 Aug; 13(8):2161-4
Assisted reproduction for infertile patients with 9 + 0 immotile spermatozoa associated with autosomal dominant polycystic kidney disease [published erratum appears in Hum Reprod 1999 Jun;14(6):1166] Okada H, et al. **Hum Reprod** 1999 Jan;14(1):110-3
Artificial insemination by husband in unexplained infertility compared with infertility associated with peritoneal endometriosis. Omland AK, et al. **Hum Reprod** 1998 Sep; 13(9):2602-5
Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Page DC, et al. **Hum Reprod** 1999 Jul;14(7):1722-6
Pregnancies, growth and development of children conceived by subzonal injection of spermatozoa. Patrat C, et al. **Hum Reprod** 1999 Sep;14(9):2404-10

Spermatid injection: reconsidering spermatid injection. Prapas Y, et al. **Hum Reprod** 1999 Sep;14(9):2186–8 (36 ref.)
Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Rongières-Bertrand C, et al. **Hum Reprod** 1999 Mar;14(3):683–8
Sperm treatment with extracellular ATP increases fertilization rates in in-vitro fertilization for male factor infertility. Rossato M, et al. **Hum Reprod** 1999 Mar; 14(3):694–7
The outcome of in-vitro fertilization treatment by egg donation and intracytoplasmatic sperm injection for severe male factor infertility: a preliminary report. Shulman A, et al. **Hum Reprod** 1998 Aug;13(8):2158–60
Controlled comparison of conventional in-vitro fertilization and intracytoplasmic sperm injection in patients with asthenozoospermia. Verheyen G, et al. **Hum Reprod** 1999 Sep;14(9):2313–9
Can we justify spermatid microinjection for severe male factor infertility? Aslam I, et al. **Hum Reprod Update** 1998 May–Jun;4(3):213–22 (93 ref.)
Semen retrieval by penile vibratory stimulation in men with spinal cord injury. Brackett NL. **Hum Reprod Update** 1999 May–Jun;5(3):216–22 (46 ref.)
Methods of semen collection not based on masturbation or surgical sperm retrieval. Gerris J. **Hum Reprod Update** 1999 May–Jun;5(3):211–5 (20 ref.)
Non-surgical sperm recovery: part I. Tournaye H. **Hum Reprod Update** 1999 May–Jun;5(3):210
Clinical review 100: Evaluation and treatment of the infertile couple. Forti G, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4177–88 (43 ref.)
The impact of HIV on a fertility problems clinic. Hargreave TB, et al. **J Reprod Immunol** 1998 Dec;41(1–2):261–70 (21 ref.)
Analysis on the therapeutic effect of combined use of acupuncture and mediation in 297 cases of male sterility. Zheng Z. **J Tradit Chin Med** 1997 Sep;17(3):190–3
Male infertility—realistic treatment options [editorial; comment] McClure RD. **J Urol** 1999 Apr;161(4):1166–7. Comment on: J Urol 1999 Apr;161(4):1153–6. Comment on: J Urol 1999 Apr;161(4):1157–62. Comment on: J Urol 1999 Apr;161(4):1163–5.
Restoration of fertility by in-vitro spermatogenesis [letter] [see comments] Tesarik J, et al. **Lancet** 1999 Feb 13; 353(9152):555–6. Comment in: Lancet 1999 Feb 13;353(9152):516–7. Comment in: Lancet 1999 May 15;353(9165):1707–8.
Melatonin-dependent infertility. Partonen T. **Med Hypotheses** 1999 Mar;52(3):269–70
Widening perspectives of intracytoplasmic sperm injection [news; comment] Edwards RG. **Nat Med** 1999 Apr; 5(4):377–8. Comment on: Nat Med 1999 Apr;5(4):431–3.
The clinical management of male infertility. Razvi K, et al. **Singapore Med J** 1999 Apr;40(4):291–7 (61 ref.)
A comprehensive approach to the management of male infertility following spinal cord injury. Rutkowski SB, et al. **Spinal Cord** 1999 Jul;37(7):508–14
Treatment of infertility [clinical conference] Sønksen J, et al. **Spinal Cord** 1999 Feb;37(2):89–95 (46 ref.)
Male infertility. Evaluation and nonsurgical therapy. Chuang AT, et al. **Urol Clin North Am** 1998 Nov;25(4):703–13, x (40 ref.)
[Pathogenesis and combined treatment of sterility in men with varicocele] Chen C, et al. **Chung Hua Wai Ko Tsa Chih** 1997 Mar;35(3):168–9 (Eng. Abstr.) **(Chi)**
[Treatment of infertility in nonobstructive azoospermia using the TESE method (testicular sperm extraction)—clinical results] Sobek A, et al. **Ceska Gynekol** 1998 Oct; 63(5):405–10 (Eng. Abstr.) **(Cze)**
[Treatment of infertility in non-obstructive azoospermia using the TESE (testicular sperm extraction) method—clinical study] Sobek A, et al. **Ceska Gynekol** 1998 Aug;63(4):287–91 (Eng. Abstr.) **(Cze)**
[Infertility and some of its psychosocial aspects] Bielawska-Batorowicz E. **Ginekol Pol** 1998 Dec; 69(12):1116–25 (Eng. Abstr.) **(Pol)**

VETERINARY

Characterization of the semen quality of postpuberal boars with spontaneous unilateral abdominal cryptorchidism on the right side. Pinart E, et al. **Anim Reprod Sci** 1999 Apr 31;55(3–4):269–78
Prevalence of morphologic defects in spermatozoa from beef bulls. Johnson KR, et al. **J Am Vet Med Assoc** 1998 Nov 15;213(10):1468–71
Identifying potentially subfertile toms via a sperm-binding assay. Gill SP, et al. **Poult Sci** 1999 Aug;78(8):1208–18
New approach to the therapeutic treatment of infertility in the male dog. Fuentes VO, et al. **Vet Rec** 1998 Oct 31; 143(18):507–8
Reduced fertility after artificial insemination in a ram with a high incidence of knobbed acrosomes. Söderquist L. **Vet Rec** 1998 Aug 22;143(8):227–8

VIROLOGY

Detection of herpes simplex virus DNA in human spermatozoa by in situ hybridization technique. Kotronias D, et al. **In Vivo** 1998 Jul–Aug;12(4):391–4

INFIBULATION see **CIRCUMCISION, FEMALE**

INFLAMMATION

see related
ACUTE-PHASE REACTION
ANTI-INFLAMMATORY AGENTS

Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Sakkinen PA, et al. **Am J Epidemiol** 1999 Feb 1;149(3):261–7
Genes that regulate eosinophilic inflammation. Broide DH, et al. **Am J Hum Genet** 1999 Aug;65(2):302–7 (33 ref.)
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Redman CW, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):499–506 (75 ref.)
Characterization of the integrin and activation steps mediating human eosinophil and neutrophil adhesion to chronically inflamed airway endothelium. McNulty CA, et al. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1251–9
Early-onset inflammatory responses in vivo to adenoviral vectors in the presence or absence of lipopolysaccharide-induced inflammation. Thorne PS, et al. **Am J Respir Cell Mol Biol** 1999 Jun;20(6):1155–64
Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Asimakopoulos G, et al. **Ann Thorac Surg** 1998 Dec;66(6):2135–44 (89 ref.)
Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Kranzhöfer R, et al. **Biochem Biophys Res Commun** 1999 Apr 21;257(3):826–8
Inflammation, antichymotrypsin, and lipid metabolism: autogenic etiology of Alzheimer's disease. Janciauskiene S, et al. **Bioessays** 1998 Dec;20(12):1039–46 (50 ref.)
IkappaB–NF-kappaB structures: at the interface of inflammation control [comment] Baeuerle PA. **Cell** 1998 Dec 11;95(6):729–31 (17 ref.). Comment on: Cell 1998 Dec 11;95(6):749–58. Comment on: Cell 1998 Dec 11;95(6):759–70.
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Cushman M, et al. **Circulation** 1999 Aug 17;100(7):717–22
Immune and inflammatory responses in sudden infant death syndrome. Forsyth KD. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):79–83 (27 ref.)
Inflammatory responses in sudden infant death syndrome — past and present views. Vege A, et al. **FEMS Immunol Med Microbiol** 1999 Aug 1;25(1–2):67–78 (135 ref.)
Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Otake K, et al. **Hum Gene Ther** 1998 Oct 10;9(15):2207–22
New aspects of neutrophils in chronic inflammation. Proceedings of a symposium to the 3rd World Congress on Inflammation. Tokyo, Japan, November 16, 1997. **Inflamm Res** 1998 Oct;47 Suppl 3:S121–78
The effects of B-sitosterol (BSS) and B-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation. Bouic PJ, et al. **Int J Sports Med** 1999 May;20(4):258–62
Society for Leukocyte Biology 15th International Congress with the European Macrophage Study Group. Innate resistance to infection. Cambridge, United Kingdom, September 22–26, 1999. Abstracts. **J Leukoc Biol Suppl** 1999;:9–36
Possible role of ovarian epithelial inflammation in ovarian cancer. Ness RB, et al. **J Natl Cancer Inst** 1999 Sep 1; 91(17):1459–67 (144 ref.)
Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. Fitch MT, et al. **J Neurosci** 1999 Oct 1;19(19):8182–98
Meeting report: the Banff Inflammation Workshop [news] Wallace JL, et al. **J Pediatr Gastroenterol Nutr** 1999 Jul; 29(1):9
Neutrophil activation and mediators of inflammation in chronic venous insufficiency. Smith PD. **J Vasc Res** 1999; 36 Suppl 1:24–36 (48 ref.)
Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Deng MC, et al. **Thorac Cardiovasc Surg** 1999 Feb;47 Suppl 2:326–31
[A new concept for drugs to reduce fever and inflammation] Sheng ZY. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1997 Oct; 17(10):628–9 **(Chi)**
[Pathophysiology of inflammation and mechanisms of action of anti-inflammatory agents] Kawai S. **Nippon Rinsho** 1999 Feb;57(2):298–303 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Chemokines and inflammation] Inadera H, et al. **Nippon Ronen Igakkai Zasshi** 1999 Feb;36(2):82–9 (48 ref.) **(Jpn)**

BLOOD

Fibrinogen as a marker of inflammation: a clinical view. Andreotti F, et al. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S3–4 (23 ref.)
Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. Ng T. **Br J Hosp Med** 1998 Nov 19–Dec 9;58(10):521–3 (17 ref.)
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Koenig W, et al. **Circulation** 1999 Jan 19;99(2):237–42
Low levels of plasma proteins: malnutrition or inflammation? Johnson AM. **Clin Chem Lab Med** 1999 Feb;37(2):91–6 (55 ref.)
Haemorheology and the inflammatory process. Rampling MW. **Clin Hemorheol Microcirc** 1998 Oct;19(2):129–32 (24 ref.)
Sustained high-level production of murine chemokine C10 during chronic inflammation. Wu Y, et al. **Cytokine** 1999 Jul;11(7):523–30
Changes in serum concentration of a serum amyloid P-like pentraxin in Atlantic salmon, Salmo salar L., during infection and inflammation. Lund V, et al. **Dev Comp Immunol** 1999 Jan–Feb;23(1):61–70
Proteins of rat serum: III. Gender-related differences in protein concentration under baseline conditions and upon experimental inflammation as evaluated by two-dimensional electrophoresis. Miller I, et al. **Electrophoresis** 1999 Apr–May;20(4–5):836–45
Inflammation and outcome in unstable angina [editorial; comment] Curzen N, et al. **Eur Heart J** 1999 Apr; 20(8):554–5 (10 ref.). Comment on: Eur Heart J 1999 Apr;20(8):562–74.
Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Verheggen PW, et al. **Eur Heart J** 1999 Apr;20(8):567–74
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. van Baal WM, et al. **Fertil Steril** 1999 Apr;71(4):663–70
Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. Fabris C, et al. **J Interferon Cytokine Res** 1998 Sep;18(9):705–9
Neutrophilia of infection/inflammation: are we really dealing with "inflamed" leukocytes? Sasson Y, et al. **J Med** 1998; 29(3–4):217–29
A low molar ratio of retinol binding protein to transthyretin indicates vitamin A deficiency during inflammation: studies in rats and a posterior analysis of vitamin A–supplemented children with measles. Rosales FJ, et al. **J Nutr** 1998 Oct; 128(10):1681–7
Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. Ostrowski K, et al. **J Physiol (Lond)** 1999 Feb 15;515 (Pt 1):287–91
Cultured human monocytes release proinflammatory cytokines in response to myelin basic protein. Baron P, et al. **Neurosci Lett** 1998 Aug 21;252(3):151–4
The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Maes M, et al. **Psychoneuroendocrinology** 1999 May;24(4):371–83
The leukocyte adhesiveness/aggregation test as an inflammation-related, plasma-dependent agglutination phenomenon. Zeltser D, et al. **Scand J Clin Lab Invest** 1998 Nov;58(7):593–601
[The eosinophilic leukocyte as a key cell of inflammation in atopic bronchial asthma] Fassakhov RS. **Patol Fiziol Eksp Ter** 1999 Jan–Mar;(1):22–4 (14 ref.) **(Rus)**

CHEMICALLY INDUCED

Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Furrer H, et al. **Am J Med** 1999 Mar;106(3):371–2
In vitro effects of different formulations of bovine collagen on cultured human skin. Trasciatti S, et al. **Biomaterials** 1998 May;19(10):897–903
Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Suo Z, et al. **Brain Res** 1998 Oct 5;807(1–2):110–7
Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic-pituitary-adrenal axis and sympathetic nervous system. Woiciechowsky C, et al. **Brain Res** 1999 Jan 23;816(2):563–71
Pulmonary inflammation without bronchial hyperresponsiveness in vivo or in vitro after sephadex instillation in pigs. McFawn PK, et al. **Clin Exp Pharmacol Physiol** 1999 Feb;26(2):105–8
Involvement of superoxide and nitric oxide on airway inflammation and hyperresponsiveness induced by diesel exhaust particles in mice. Lim HB, et al. **Free Radic Biol Med** 1998 Oct;25(6):635–44
Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation. Romay C, et al. **Inflamm Res** 1998 Aug;47(8):334–8
Inflammatory cell recruitment, distribution, and chemiluminescence response at IgG precoated- and thiol functionalized gold surfaces. Källtorp M, et al. **J Biomed Mater Res** 1999 Nov;47(2):251–9

Influence of biphasic calcium phosphate granulometry on bone ingrowth, ceramic resorption, and inflammatory reactions: preliminary in vitro and in vivo study. Malard O, et al. **J Biomed Mater Res** 1999 Jul;46(1):103–11

Comparison of acute endotoxin-induced lesions in A/J and C57BL/6J mice. O'Malley J, et al. **J Hered** 1998 Nov–Dec; 89(6):525–30

The proinflammatory and chondral activities of leukemia inhibitory factor in goat joints are partially a function of interleukin-1. Bell MC, et al. **J Interferon Cytokine Res** 1999 Feb;19(2):197–208

Proinflammatory cytokines lowering erythropoietin production. Jelkmann W. **J Interferon Cytokine Res** 1998 Aug;18(8):555–9 (61 ref.)

The inflammatory and cytotoxic effects of a nitric oxide releasing cream on normal skin. Ormerod AD, et al. **J Invest Dermatol** 1999 Sep;113(3):392–7

Cytokine-induced inflammation and long-term stroke functional outcome. Vila N, et al. **J Neurol Sci** 1999 Jan 15;162(2):185–8

Cytokine-induced acute inflammation in the brain and spinal cord. Schnell L, et al. **J Neuropathol Exp Neurol** 1999 Mar; 58(3):245–54

Local inflammation, lethality and cytokine release in mice injected with Bothrops atrox venom. Barros SF, et al. **Mediators Inflamm** 1998;7(5):339–46

The inflammatory reaction induced by formalin in the rat paw. Damas J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):220–7

Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats. Nakagawa T, et al. **Neurosci Lett** 1999 Apr 9;265(1):64–6

Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Hao JX, et al. **Pain** 1998 Jun;76(3):385–93

Topical anti-inflammatory activity of human recombinant epidermal growth factor. Casacó A, et al. **Skin Pharmacol Appl Skin Physiol** 1999 Jan–Apr; 12(1–2):79–84

A chimeric aryl hydrocarbon receptor knockout mouse model indicates that aryl hydrocarbon receptor activation in hematopoietic cells contributes to the hepatic lesions induced by 2,3,7, 8-tetrachlorodibenzo-p-dioxin. Thurmond TS, et al. **Toxicol Appl Pharmacol** 1999 Jul 1; 158(1):33–40

COMPLICATIONS

Inflammation and the mental state before an acute coronary event. Appels A. **Ann Med** 1999 Apr;31 Suppl 1:41–4

Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Ridker PM. **Blood Coagul Fibrinolysis** 1999 Feb;10 Suppl 1:S9–12 (32 ref.)

Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Lindner MD, et al. **Exp Clin Psychopharmacol** 1999 Aug;7(3):187–97

The importance of inflammatory mechanisms for the development of Alzheimer's disease. Eikelenboom P, et al. **Exp Gerontol** 1999 Jun;34(3):453–61 (37 ref.)

Inflammation, sepsis, and coagulation. Esmon CT, et al. **Haematologica** 1999 Mar;84(3):254–9 (24 ref.)

Inflammation in asthma: the cornerstone of the disease and target of therapy. Busse WW. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 2):S17–22 (78 ref.)

Metaplastic polyp of the colon develops in response to inflammation. Higaki S, et al. **J Gastroenterol Hepatol** 1999 Jul;14(7):709–14

Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha [see comments] Allen DA, et al. **J Investig Med** 1999 May;47(5):204–11. Comment in: J Investig Med 1999 May;47(5):203.

Optic disc edema in neonatal onset multisystem inflammatory disease (NOMID). Lee AG, et al. **J Neuroophthalmol** 1999 Sep;19(3):180–1

An explanation for growth impairment in chronic inflammation. Otley AR, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):350–1

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Zimmermann J, et al. **Kidney Int** 1999 Feb;55(2):648–58

Chronic inflammation and cancer: potential role of Bcl-2 gene family members as regulators of cellular antioxidant status. Frommel TO, et al. **Med Hypotheses** 1999 Jan; 52(1):27–30 (29 ref.)

Atherosclerosis--an inflammatory disease [letter; comment] Weissberg PL, et al. **N Engl J Med** 1999 Jun 17; 340(24):1928–9. Comment on: N Engl J Med 1999 Jan 14;340(2):115–26.

Infection, inflammation, and cancer [news; comment] Darveau R. **Nat Biotechnol** 1999 Jan;17(1):19. Comment on: Nat Biotechnol 1999 Jan;17(1):37–41.

Presentation of tumoral calcinosis with systemic signs pointing to inflammatory disease [letter] Borrás M, et al. **Nephrol Dial Transplant** 1998 Dec;13(12):3277–9

Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. O'Gorman P, et al. **Nutr Cancer** 1998;32(2):76–80

Morphine, the NMDA receptor antagonist MK801 and the tachykinin NK1 receptor antagonist RP67580 attenuate the development of inflammation-induced progressive tactile hypersensitivity. Ma QP, et al. **Pain** 1998 Jul;77(1):49–57

[Hyponatremia and inflammation] Ohta M, et al. **Rinsho Byori** 1999 May;47(5):408–16 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Phospholipase A2: its usefulness in laboratory diagnostics. Kaiser E. **Crit Rev Clin Lab Sci** 1999 Apr;36(2):65–163 (700 ref.)

A proposed 30–45 minute 4 page standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes. Pincus T, et al. **J Rheumatol** 1999 Feb; 26(2):473–80

Respiratory tract inflammation in swine confinement workers studied using induced sputum and exhaled nitric oxide. Von Essen SG, et al. **J Toxicol Clin Toxicol** 1998;36(6):557–65

Acute-phase proteins and other systemic responses to inflammation [published erratum appears in N Engl J Med 1999 Apr 29;340(17):1376] Gabay C, et al. **N Engl J Med** 1999 Feb 11;340(6):448–54 (64 ref.)

Markers of allergy & inflammation. Warner JO, et al. **Pediatr Allergy Immunol** 1998;9(11 Suppl):53–7 (33 ref.)

Procalcitonin as a marker of systemic inflammation after conventional or minimally invasive coronary artery bypass grafting. Kilger E, et al. **Thorac Cardiovasc Surg** 1998 Jun; 46(3):130–3

[Laboratory tests and clinical practice: from diagnosis of an inflammatory syndrome to colon cancer screening] Gulbis B. **Rev Med Brux** 1998 Sep;19(4):A248–51 (15 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic methods and prophylaxis of purulent inflammation in postsurgical wounds] Mamedov LA, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):477–9 **(Rus)**

DRUG THERAPY

Effect of plant flavonoids on immune and inflammatory cell function. Middleton E Jr. **Adv Exp Med Biol** 1998; 439:175–82 (27 ref.)

Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Tyrrell DJ, et al. **Adv Pharmacol** 1999;46:151–208 (349 ref.)

Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783. Travers J, et al. **Arch Dermatol Res** 1998 Oct;290(10):569–73

Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; correlation with decreased cytokine production. Zimecki M, et al. **Arch Immunol Ther Exp (Warsz)** 1998;46(6):361–5

Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Dickneite G, et al. **Arterioscler Thromb Vasc Biol** 1999 Jun;19(6):1566–72

Ibuprofen: new explanation for an old phenomenon. Stuhlmeier KM, et al. **Biochem Pharmacol** 1999 Feb 1; 57(3):313–20

Anti-inflammatory/antiarthritic ketonic bisphosphonic acid esters. Schlachter ST, et al. **Bioorg Med Chem Lett** 1998 May 5;8(9):1093–6

Dual effects of a homeopathic mineral complex on carrageenan-induced oedema in rats. Bertani S, et al. **Br Homeopath J** 1999 Jul;88(3):101–5

Modulation of acute and chronic inflammatory processes by cacospongionolide B, a novel inhibitor of human synovial phospholipase A2. García Pastor P, et al. **Br J Pharmacol** 1999 Jan;126(1):301–11

IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Haskó G, et al. **Br J Pharmacol** 1999 Jul;127(6):1295–304 (129 ref.)

CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy. Scherberich JE, et al. **Clin Chem Lab Med** 1999 Mar; 37(3):209–13 (18 ref.)

Therapeutic approaches to the treatment of neuroinflammatory diseases. Hays SJ. **Curr Pharm Des** 1998 Aug;4(4):335–48 (112 ref.)

Adenosine kinase inhibitors. Kowaluk EA, et al. **Curr Pharm Des** 1998 Oct;4(5):403–16 (178 ref.)

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Mollison KW, et al. **Curr Pharm Des** 1998 Oct; 4(5):367–79 (100 ref.)

Inhibitors of tryptase for the treatment of mast cell–mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)

The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Juergens UR, et al. **Eur J Med Res** 1998 Dec 16;3(12):539–45

Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043. Fujie K, et al. **Eur J Pharmacol** 1999 Jun 11; 374(1):117–25

Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Pfeilschifter J, et al. **Eur J Pharmacol** 1999 Jun 30;375(1–3):237–45 (103 ref.)

Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. Przewłocka B, et al. **Eur J Pharmacol** 1999 Feb 19;367(2–3):189–96

Effect of alpha-trinositol on carrageenan-induced rat paw edema and lowering of interstitial fluid pressure. Reed RK, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):279–84

Effects of yohimbine on naloxone-induced antinociception in a rat model of inflammatory hyperalgesia. Tsuruoka M, et al. **Eur J Pharmacol** 1998 May 8;348(2–3):161–5

Pharmacological evaluation of 1-(carboxymethyl)-3,5-diphenyl-2-methylbenzene, a novel arylacetic acid with potential anti-inflammatory properties. Cutler SJ, et al. **Inflamm Res** 1998 Jul; 47(7):316–24

Therapeutic Regulation of Inflammation and Angiogenesis in Cancer, Arthritis, and Asthma, Sixth Annual Midwest Meeting, Chicago, IL, USA, March 16, 1998. Djuric S, et al. **Inflamm Res** 1999 Mar;48(3):101–3

Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation. Romay C, et al. **Inflamm Res** 1998 Aug;47(8):334–8

Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in mice. Santos AR, et al. **Inflamm Res** 1998 Jul;47(7):302–7

Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247–54 (97 ref.)

Antiinflammatory effect of the aqueous extract from Rumex patientia L. roots. Süleyman H, et al. **J Ethnopharmacol** 1999 May;65(2):141–8

Effects of petrosaspongiolide M, a novel phospholipase A2 inhibitor, on acute and chronic inflammation. García-Pastor P, et al. **J Pharmacol Exp Ther** 1999 Apr; 289(1):166–72

Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. Machelska H, et al. **J Pharmacol Exp Ther** 1999 Jul;290(1):354–61

Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. Ishii T, et al. **Jpn J Pharmacol** 1998 Dec;78(4):505–9

Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Ben-Chetrit E, et al. **Med Hypotheses** 1998 Nov; 51(5):377–80

Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF. **Med Hypotheses** 1998 Jul;51(1):11–5 (63 ref.)

A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Lee JK, et al. **Nat Med** 1998 Dec;4(12):1383–91

Calcitonin gene-related peptide improves skin flap survival and tissue inflammation. Gherardini G, et al. **Neuropeptides** 1998 Jun;32(3):269–73

Topical antiinflammatory activity of phytosterols isolated from Eryngium foetidum on chronic and acute inflammation models. García MD, et al. **Phytother Res** 1999 Feb;13(1):78–80

CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS. Molina PE, et al. **Shock** 1998 Nov; 10(5):329–34

Antithrombin III treatment improves parameters of acute inflammation in a highly histoincompatible model of rat lung allograft rejection. Okada Y, et al. **Transplantation** 1999 Feb 27;67(4):526–8

[Selective inhibition of cyclooxygense (COX-2)] Gömör B. **Orv Hetil** 1999 Feb 21;140(8):395–9 (37 ref.) (Eng. Abstr.) **(Hun)**

[Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases] Navashin PS, et al. **Antibiot Khimioter** 1998;43(12):30–8 (46 ref.) **(Rus)**

[Antibiotics as regulators of inflammatory reactions of the body in infections (editorial)] Nikitin AV. **Antibiot Khimioter** 1998;43(9):3–4 **(Rus)**

[Use of spiramycin in the treatment of inflammatory diseases ot the respiratory tract in children in ambulatory conditions] Otsiians EN, et al. **Antibiot Khimioter** 1998; 43(11):34–7 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Neutral endopeptidase 24.11: its physiologic and possibly pathophysiologic role in inflammation with special effect on respiratory inflammation. Koehne P, et al. **Allergy** 1998 Nov;53(11):1023–42 (248 ref.)

Role and regulation of cyclooxygenase-2 during inflammation. Simon LS. **Am J Med** 1999 May 31; 106(5B):37S–42S (14 ref.)

Phospholipase A2: its usefulness in laboratory diagnostics. Kaiser E. **Crit Rev Clin Lab Sci** 1999 Apr;36(2):65–163 (700 ref.)

Modulation of drug metabolism in infectious and inflammatory diseases. Iber H, et al. **Drug Metab Rev** 1999 Feb;31(1):29–41 (41 ref.)

Different response to inflammation of the multiple mRNAs of rat N-acetylglucosaminyltransferase I with variable 5'-untranslated sequences. Fukada T, et al. **FEBS Lett** 1998 Oct 2;436(2):228–32

Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J, et al. **Inflamm Res** 1999 May;48(5):247–54 (97 ref.)

Decreased expression of angiotensin-converting enzyme in the airway epithelium of asthmatic subjects is associated with eosinophil inflammation. Roisman GL, et al. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 1):402–10

Expression of gelatinase A and its activator MT1-MMP in

the inflammatory periprosthetic response to polyethylene. Nawrocki B, et al. **J Bone Miner Res** 1999 Feb;14(2):288–94

The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. Anderson MM, et al. **J Clin Invest** 1999 Jul; 104(1):103–13

Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. Hale KK, et al. **J Immunol** 1999 Apr 1;162(7):4246–52

Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. Heinecke JW. **J Lab Clin Med** 1999 Apr;133(4):321–5 (32 ref.)

Protective effects of poly (ADP-ribose) synthase inhibitors in zymosan-activated plasma induced paw edema. Cuzzocrea S, et al. **Life Sci** 1999;65(9):957–64

Inflammation-induced up-regulation of protein kinase Cgamma immunoreactivity in rat spinal cord correlates with enhanced nociceptive processing. Martin WJ, et al. **Neuroscience** 1999;88(4):1267–74

Pharmacological analysis of cyclooxygenase-1 in inflammation. Smith CJ, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13313–8

Soluble epoxide hydrolase in rat inflammatory cells is indistinguishable from soluble epoxide hydrolase in rat liver. Draper AJ, et al. **Toxicol Sci** 1999 Jul;50(1):30–5

[Focalized matrix proteolysis and inflammation] Gaudin P, et al. **Ann Biol Clin (Paris)** 1998 Nov–Dec;56(6):661–9 (62 ref.) (Eng. Abstr.) **(Fre)**

[Granzyme B: an essential protease for the inflammatory response] Berthou C, et al. **Pathol Biol (Paris)** 1998 Oct; 46(8):617–24 (35 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Ikizler TA, et al. **Kidney Int** 1999 May; 55(5):1945–51

Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Stenvinkel P, et al. **Kidney Int** 1999 May;55(5):1899–911

ETIOLOGY

Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Elenkov IJ, et al. **Ann N Y Acad Sci** 1999 Jun 22; 876:1–11; discussion 11–3 (59 ref.)

The painful red foot–inflammation or ischaemia? Humphreys W. **BMJ** 1999 Apr 3;318(7188):925–6

Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Vergnolle N, et al. **Br J Pharmacol** 1999 Jul;127(5):1083–90

The nonspecific inflammatory response to injury. Mayers I, et al. **Can J Anaesth** 1998 Sep;45(9):871–9 (94 ref.)

The gut as a potential trigger of exercise-induced inflammatory responses. Marshall JC. **Can J Physiol Pharmacol** 1998 May;76(5):479–84 (54 ref.)

Radical species in inflammation and overtraining. Tiidus PM. **Can J Physiol Pharmacol** 1998 May;76(5):533–8 (77 ref.)

Regulation of CD40L expression by cyclic AMP: contrasting proinflammatory and inhibitory actions. Wingett DG, et al. **Cell Immunol** 1999 Mar 15;192(2):203–12

Annexin I degradation in bronchoalveolar lavage fluids from healthy smokers: a possible mechanism of inflammation. Vishwanatha JK, et al. **Clin Cancer Res** 1998 Oct; 4(10):2559–64

The inflammatory response in CD1 mice shortly after infection with a CagA+/VacA+ Helicobacter pylori strain. van Doorn NE, et al. **Clin Exp Immunol** 1999 Mar; 115(3):421–7

Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Simons JP, et al. **Clin Sci (Colch)** 1999 Aug;97(2):215–23

The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Finkelman FD, et al. **Curr Opin Immunol** 1999 Aug; 11(4):420–6 (84 ref.)

Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Bennet W, et al. **Diabetes** 1999 Oct;48(10):1907–14

Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. Lyoumi S, et al. **Eur J Biochem** 1999 Apr;261(1):190–6

Sports-induced inflammation in the lower extremities. Aronen JG, et al. **Hosp Pract (Off Ed)** 1999 Feb 15; 34(2):51–5, 59–60, 66–7

Mechanisms of inflammation: symposium of the Sonderforschungsbereich (SFB 244), Hannover, Germany, 4–5 June 1998. Witte T, et al. **Inflamm Res** 1998 Nov; 47(11):419–20

Ventilator-induced lung inflammation: is it always harmful? [letter] Plötz FB, et al. **Intensive Care Med** 1999 Feb; 25(2):236

Mediators of inflammation and the inflammatory process. White M. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S378–81 (42 ref.)

Mechanisms of fibrinogen domains: biomaterial interactions. Tang L. **J Biomater Sci Polym Ed** 1998;9(12):1257–66

Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit. Giannoudis PV, et al. **J Bone Joint Surg Br** 1999 Mar;81(2):356–61

Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene. Nawrocki B, et al. **J Bone Miner Res** 1999 Feb;14(2):288–94

Pressure is proinflammatory in lung venular capillaries. Kuebler WM, et al. **J Clin Invest** 1999 Aug;104(4):495–502

Essential role of P-selectin in the initiation of the inflammatory response induced by hemorrhage and reinfusion. Scalia R, et al. **J Exp Med** 1999 Mar 15; 189(6):931–8

Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. Yang L, et al. **J Exp Med** 1998 Nov 2;188(9):1739–50

Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. Ajuebor MN, et al. **J Immunol** 1999 Feb 1;162(3):1685–91

Malnutrition modifies pig small intestinal inflammatory responses to rotavirus. Zijlstra RT, et al. **J Nutr** 1999 Apr; 129(4):838–43

Pharmacological evidence supporting a role for IL-1, IL-2 and serotonin in the inflammation induced by Schistosoma mansoni Soluble Egg Antigen (SEA) in rat paws. Pacheco CM, et al. **Mediators Inflamm** 1998;7(4):261–7

Epidural analgesia and intrapartum fever: placental findings. Dashe JS, et al. **Obstet Gynecol** 1999 Mar;93(3):341–4

Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits. Baufreton C, et al. **Perfusion** 1998 Nov;13(6):419–27

Inflammatory reactions following homograft insertion in children with congenital heart disease. Atiq M, et al. **Scand Cardiovasc J** 1998;32(5):285–8

Platelet activation and cytokine production during hypothermic cardiopulmonary bypass--a possible correlation? Ferroni P, et al. **Thromb Haemost** 1998 Jul; 80(1):58–64

[Overweight as a risk factor for cardiovascular diseases and its possible significance as a promotor of an increased inflammatory reaction] Halle M, et al. **Dtsch Med Wochenschr** 1999 Jul 30;124(30):905–9 (50 ref.) **(Ger)**

[Free radicals and their role in inflammation] Soteras F. **Arch Bronconeumol** 1999 May;35 Suppl 3:3–9 (50 ref.) **(Spa)**

GENETICS

Regulation of Spi 2.1 and 2.2 gene expression after turpentine inflammation: discordant responses to IL-6. Berry SA, et al. **Am J Physiol** 1999 Jun;276(6 Pt 1):C1374–82

Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Braeckman L, et al. **Atherosclerosis** 1999 Apr;143(2):383–8

Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Michaluart P, et al. **Cancer Res** 1999 May 15;59(10):2347–52

Guinea pig alpha 1-microglobulin/bikunin: cDNA sequencing, tissue expression and expression during acute phase. Yoshida K, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1999 Feb; 122(2):165–72

Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Liu L, et al. **Gene** 1998 Nov 19;222(2):237–44

A novel set of hepatic mRNAs preferentially expressed during an acute inflammation in rat represents mostly intracellular proteins. Olivier E, et al. **Genomics** 1999 May 1;57(3):352–64

The hereditary periodic fever syndromes: molecular analysis of a new family of inflammatory diseases. Centola M, et al. **Hum Mol Genet** 1998;7(10):1581–8 (81 ref.)

Inflammatory disease in HLA-B27 transgenic rats. Taurog JD, et al. **Immunol Rev** 1999 Jun;169:209–23 (83 ref.)

The role of C/EBP isoforms in the control of inflammatory and native immunity functions. Poli V. **J Biol Chem** 1998 Nov 6;273(45):29279–82 (69 ref.)

Identification of a novel inflammation-protective locus in the Fischer rat. Listwak S, et al. **Mamm Genome** 1999 Apr; 10(4):362–5

Chronic inflammation and cancer: potential role of Bcl-2 gene family members as regulators of cellular antioxidant status. Frommel TO, et al. **Med Hypotheses** 1999 Jan; 52(1):27–30 (29 ref.)

C/EBPalpha is critical for the neonatal acute-phase response to inflammation. Burgess-Beusse BL, et al. **Mol Cell Biol** 1998 Dec;18(12):7269–77

K-ras gene point mutation in neogenetic lesions of subpleural fibrotic lesions: either an early genetic event in lung cancer development or a non-specific genetic change during the inflammatory reparative process. Maeshima AM, et al. **Pathol Int** 1999 May;49(5):411–8

Genetic component in the inflammatory response induced by bacterial lipopolysaccharide. De Maio A, et al. **Shock** 1998 Nov;10(5):319–23

IMMUNOLOGY

Major depression and activation of the inflammatory response system. Maes M. **Adv Exp Med Biol** 1999;461:25–46 (173 ref.)

Interleukin-12: a cytokine at the interface of inflammation and immunity. Trinchieri G. **Adv Immunol** 1998;70:83–243 (754 ref.)

Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Iwasaki A, et al. **Am J Physiol** 1999 May;276(5 Pt 1):G1074–8 (24 ref.)

Mechanisms responsible for enhanced inflammatory response to ischemia-reperfusion in diabetes. Salas A, et al. **Am J Physiol** 1998 Nov;275(5 Pt 2):H1773–81

The function of cell adhesion molecules in lung inflammation: more questions than answers. DeLisser HM, et al. **Am J Respir Cell Mol Biol** 1998 Oct;19(4):533–6 (53 ref.)

Transforming growth factor-beta secreted from CD4(+) T cells ameliorates antigen-induced eosinophilic inflammation. A novel high-dose tolerance in the trachea. Haneda K, et al. **Am J Respir Cell Mol Biol** 1999 Aug; 21(2):268–74

Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. McLane MP, et al. **Am J Respir Cell Mol Biol** 1998 Nov;19(5):713–20

The role of alpha4 (CD49d) and beta2 (CD18) integrins in eosinophil and neutrophil migration to allergic lung inflammation in the Brown Norway rat. Schneider T, et al. **Am J Respir Cell Mol Biol** 1999 Mar;20(3):448–57

Inflammatory response to chronic otitis media in DiGeorge syndrome: a case study using immunohistochemistry on archival temporal bone sections. Ganbo T, et al. **Ann Otol Rhinol Laryngol** 1999 Aug;108(8):756–61

Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Locati M, et al. **Annu Rev Med** 1999;50:425–40 (78 ref.)

Immunomodulating effects of HMR 3004 on pulmonary inflammation caused by heat-killed Streptococcus pneumoniae in mice. Duong M, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3309–12

Onset and persistence of the allergic inflammation: a molecular explanation? Spinozzi F. **Arch Immunol Ther Exp (Warsz)** 1998;46(5):277–84 (44 ref.)

Neuropeptides: mediators of inflammation and tissue repair? Schäffer M, et al. **Arch Surg** 1998 Oct;133(10):1107–16 (170 ref.)

The acute inflammatory response and its regulation. Ward PA, et al. **Arch Surg** 1999 Jun;134(6):666–9 (23 ref.)

New mechanisms by which secretory phospholipase A2 stimulates neutrophils to provoke the release of cytotoxic agents. Zallen G, et al. **Arch Surg** 1998 Nov; 133(11):1229–33

Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation. Vallhonrat H, et al. **ASAIO J** 1999 Jan–Feb;45(1):113–4

You can lead a macrophage to an inflammatory site but can you make it eat? Hart SP, et al. **Biochem Soc Trans** 1998 Nov;26(4):650–2 (18 ref.)

Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. Conti P, et al. **Br J Haematol** 1998 Dec;103(3):798–803

Mycoplasma fermentans glycolipid triggers inflammatory response in rat astrocytes. Ben-Menachem G, et al. **Brain Res** 1998 Aug 24;803(1–2):34–8

Immune responses to inflammation and trauma: a physical training module. Toronto, Ontario, Canada. July 10–11, 1997. **Can J Physiol Pharmacol** 1998 May;76(5):469–597

Adhesion molecules during immune response to exercise. Gabriel HH, et al. **Can J Physiol Pharmacol** 1998 May; 76(5):512–23

Physical exercise as a human model of limited inflammatory response. Shek PN, et al. **Can J Physiol Pharmacol** 1998 May;76(5):589–97 (71 ref.)

Immune responses to inflammation and trauma: a physical training model. Shephard RJ, et al. **Can J Physiol Pharmacol** 1998 May;76(5):469–72 (33 ref.)

Expression profile of vascular cell adhesion molecule-1 (CD106) in inflammatory foci using rhenium-188 labelled monoclonal antibody in mice. Kairemo KJ, et al. **Cell Adhes Commun** 1998 Jun;5(4):325–33

Enzymatically inactive eosinophil peroxidase inhibits proinflammatory cytokine transcription and secretion by macrophages. Lincoln JA, et al. **Cell Immunol** 1999 Aug 25;196(1):23–33

Interleukin-5 and allergic inflammation [editorial; comment] O'Byrne PM, et al. **Clin Exp Allergy** 1999 May;29(5):573–5 . Comment on: Clin Exp Allergy 1999 May;29(5):595–603.

Semantics, inflammation, cytokines and common sense. Kushner I. **Cytokine Growth Factor Rev** 1998 Sep–Dec; 9(3–4):191–6 (63 ref.)

Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9–23 (148 ref.)

Mechanisms of cell signaling in immune-mediated inflammation. Bayón Y, et al. **Cytokines Cell Mol Ther** 1998 Dec;4(4):275–86 (140 ref.)

Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. McKay LI, et al.

Endocr Rev 1999 Aug;20(4):435–59 (271 ref.)

The role of fibroblasts from oropharyngeal mucosa in producing proinflammatory and mitogenic cytokines without prior stimulation. Knerer B, et al. **Eur Arch Otorhinolaryngol** 1999;256(5):266–70

SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Elliott DE, et al. **Eur J Immunol** 1999 Aug;29(8):2454–63

Immunohistochemical investigation of evolving inflammation in lesions of acne vulgaris. Layton AM, et al. **Exp Dermatol** 1998 Aug;7(4):191–7

Differential blood–brain barrier breakdown and leucocyte recruitment following excitotoxic lesions in juvenile and adult rats. Bolton SJ, et al. **Exp Neurol** 1998 Nov; 154(1):231–40

Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Eikelenboom P, et al. **Exp Neurol** 1998 Nov;154(1):89–98 (121 ref.)

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Kurkowska-Jastrzębska I, et al. **Exp Neurol** 1999 Mar;156(1):50–61

10th International Congress of Mucosal Immunology. Amsterdam, The Netherlands, 27 June–1 July, 1999. Proceedings and abstracts. **Immunol Lett** 1999 Jun 15; 69(1):1–216

Preferential tissue localization of bovine gamma delta T cell subsets defined by anti-T cell receptor for antigen antibodies. Wilson E, et al. **Immunol Lett** 1998 Nov; 64(1):39–44

Inflammatory disease in HLA-B27 transgenic rats. Taurog JD, et al. **Immunol Rev** 1999 Jun;169:209–23 (83 ref.)

Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Ostergaard C, et al. **Infect Immun** 1999 Jul;67(7):3430–6

Innate Immunity: The Bridge between Adaptive Immunity and Inflammation, December 17, 1998, New York Academy of Sciences, New York, NY, USA. Barton BE. **Inflamm Res** 1999 May;48(5):232–5

Interleukin-15 and its role in chronic inflammatory diseases. Kirman I, et al. **Inflamm Res** 1998 Jul;47(7):285–9 (47 ref.)

Procoagulant and anticoagulant activities of resident and inflammatory peritoneal cells. Pejler G. **Inflamm Res** 1999 Jun;48(6):344–50

Secretory phospholipase A2: a putative mediator of airway inflammation. De Marino V, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):200–1

Hemopoietic mechanisms in allergic airway inflammation. Denburg JA, et al. **Int Arch Allergy Immunol** 1998 Nov; 117(3):155–9 (55 ref.)

Anti-inflammatory activity in human skin: it prevents edema formation in vitro. Dorsch W, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):236–9

Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice. Kasai M, et al. **Int Arch Allergy Immunol** 1998 Sep;117 Suppl 1:14–9

Changes in inflammatory cells and airway remodeling after beclomethasone dipropionate administration. Sano Y, et al. **Int Arch Allergy Immunol** 1999 Feb–Apr;118(2–4):341–2

Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. Nel AE, et al. **J Allergy Clin Immunol** 1998 Oct;102(4 Pt 1):539–54 (115 ref.)

Apoptosis of eosinophils and lymphocytes in allergic inflammation. Ohta K, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):14–21 (57 ref.)

STAT6 is required for the anti-inflammatory activity of interleukin-4 in mouse peritoneal macrophages. Ohmori Y, et al. **J Biol Chem** 1998 Oct 30;273(44):29202–9

Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. Hansen G, et al. **J Clin Invest** 1999 Jan;103(2):175–83

Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. Clynes R, et al. **J Exp Med** 1999 Jan 4;189(1):179–85

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. Douni E, et al. **J Exp Med** 1998 Oct 5;188(7):1343–52

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation [comment] Sallusto F, et al. **J Exp Med** 1999 Feb 15;189(4):611–4 (33 ref.). Comment on: J Exp Med 1999 Feb 15;189(4):627–35.

Endothelial cell "memory" of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. Wolff B, et al. **J Exp Med** 1998 Nov 2;188(9):1757–62

Differential induction of adhesion molecule and chemokine expression by LTalpha3 and LTalphabeta in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. Cuff CA, et al. **J Immunol** 1999 May 15;162(10):5965–72

Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. Suffredini AF, et al. **J Infect Dis** 1999 May;179(5):1278–82

Neutrophilia of infection/inflammation: are we really dealing with "inflamed" leukocytes? Sasson Y, et al. **J Med** 1998; 29(3–4):217–29

Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon [see comments] Cella M, et al. **Nat Med** 1999 Aug;5(8):919–23 . Comment in: Nat Med 1999 Aug;5(8):868–70.

Pain control in inflammation governed by selectins [see comments] Machelska H, et al. **Nat Med** 1998 Dec; 4(12):1425–8. Comment in: Nat Med 1998 Dec;4(12):1359–60.

Can inflammation relieve pain? [news; comment] Porreca F, et al. **Nat Med** 1998 Dec;4(12):1359–60. Comment on: Nat Med 1998 Dec;4(12):1425–8.

Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation. Buku A. **Peptides** 1999; 20(3):415–20 (39 ref.)

New therapeutic targets for rheumatoid arthritis. Dinant HJ, et al. **Pharm World Sci** 1999 Apr;21(2):49–59 (109 ref.)

T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Dent AL, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13823–8

Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Trahey M, et al. **Proc Natl Acad Sci U S A** 1999 Mar 16;96(6):3006–11

Role of inflammation in the pathogenesis of unstable coronary artery diseases. Biasucci LM, et al. **Scand J Clin Lab Invest Suppl** 1999;230:12–22 (64 ref.)

Regulation of the proinflammatory effects of Fas ligand (CD95L). Chen JJ, et al. **Science** 1998 Nov 27; 282(5394):1714–7

The traffic of resting lymphocytes through delayed hypersensitivity and chronic inflammatory lesions: a dynamic equilibrium. Seabrook T, et al. **Semin Immunol** 1999 Apr;11(2):115–23 (41 ref.)

Endothelial cell determinants of susceptibility to neutrophil-mediated killing. Murphy HS, et al. **Shock** 1999 Aug;12(2):111–7

Immunobiology of dendritic cells in the respiratory tract: steady-state and inflammatory sentinels? McWilliam AS, et al. **Toxicol Lett** 1998 Dec 28;102–103:323–9 (19 ref.)

Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury. Beekhuizen H, et al. **Transplant Proc** 1998 Dec;30(8):4251–6 (65 ref.)

Biological factors that affect CD95 ligand-mediated inflammation. Seino K, et al. **Transplant Proc** 1999 Feb–Mar;31(1–2):893–5

Attempts to reveal the mechanism of CD95-ligand-mediated inflammation. Seino K, et al. **Transplant Proc** 1999 Aug; 31(5):1942–3

The macrophage--a cell for all seasons. Morrissette N, et al. **Trends Cell Biol** 1999 May;9(5):199–201 (0 ref.)

[An experimental study of cellular response on implanted intraocular lens] Zhou Z, et al. **Chung Hua Yen Ko Tsa Chih** 1997 Jan;33(1):53–5 (Eng. Abstr.) **(Chi)**

[Inflammatory response of the body to surgery illustrated by pro-inflammatory and anti-inflammatory cytokines] Christensen VB, et al. **Ugeskr Laeger** 1998 Nov 23; 160(48):6951–3 (11 ref.) **(Dan)**

[Inflammatory cytokines and chemokines in acute inflammatory disease] Geiser T. **Schweiz Med Wochenschr** 1999 Apr 10;129(14):540–6 (27 ref.) (Eng. Abstr.) **(Ger)**

[Inflammatory changes and immunological disturbances in stroke] Fiszer U, et al. **Neurol Neurochir Pol** 1998 Sep–Oct; 32(5):1219–27 (30 ref.) (Eng. Abstr.) **(Pol)**

[Inflammatory response in pneumonia] Montón C, et al. **Arch Bronconeumol** 1998 Nov;34 Suppl 2:11–6 (35 ref.) **(Spa)**

METABOLISM

Flavonoids: inhibitors of cytokine induced gene expression. Gerritsen ME. **Adv Exp Med Biol** 1998;439:183–90 (29 ref.)

Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. McKellar Q, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1988–92

Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Matsumoto T, et al. **Antimicrob Agents Chemother** 1999 Mar;43(3):697–8

Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Wise R, et al. **Antimicrob Agents Chemother** 1999 Jun; 43(6):1508–10

Expression of the transforming growth factor beta isoforms in inflammatory cells of nasal polyps. Coste A, et al. **Arch Otolaryngol Head Neck Surg** 1998 Dec;124(12):1361–6

Changes of tissue factor activity on inflammatory stimulus and aging in rat. Han YN, et al. **Arch Pharm Res** 1998 Oct;21(5):549–54

Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Maeda H, et al. **Biochemistry (Mosc)** 1998 Jul; 63(7):854–65 (80 ref.)

Examination of the metabolic status of rat air pouch inflammatory exudate by high field proton NMR spectroscopy. Claxson A, et al. **Biochim Biophys Acta** 1999 May 31;1454(1):57–70

Accumulation of fibrinogen-coated microparticles at a fibrin(ogen)-rich inflammatory site. Deanglis AP, et al. **Biotechnol Appl Biochem** 1999 Jun;29 (Pt 3):251–61

Inflammation-induced changes in peripheral glutamate receptor populations. Carlton SM, et al. **Brain Res** 1999 Feb 27;820(1–2):63–70

Rapid sodium channel augmentation in response to inflammation induced by complete Freund's adjuvant. Gould HJ 3rd, et al. **Brain Res** 1998 Aug 17;802(1–2):69–74

An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Gelman L, et al. **Cell Mol Life Sci** 1999 Jun;55(6–7):932–43 (141 ref.)

Inhibition of nuclear factor-kappa B nuclear localization reduces human E-selectin expression and the systemic inflammatory response. Boyle EM Jr, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II282–8

Activation and regulation of NFkappaB during acute inflammation. Lentsch AB, et al. **Clin Chem Lab Med** 1999 Mar;37(3):205–8 (28 ref.)

STAT6 deficiency in a mouse model of allergen-induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells [see comments] Miyata S, et al. **Clin Exp Allergy** 1999 Jan;29(1):114–23. Comment in: Clin Exp Allergy 1999 Jan;29(1):12–6.

Soluble cytokine receptors: basic immunology and clinical applications. Fernandez-Botran R. **Crit Rev Clin Lab Sci** 1999 Jun;36(3):165–224 (243 ref.)

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Pineda Torra I, et al. **Curr Opin Lipidol** 1999 Apr; 10(2):151–9 (97 ref.)

Heme and acute inflammation role in vivo of heme in the hepatic expression of positive acute-phase reactants in rats. Lyoumi S, et al. **Eur J Biochem** 1999 Apr;261(1):190–6

SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Elliott DE, et al. **Eur J Immunol** 1999 Aug;29(8):2454–63

Effect of combination of misoprostol and indomethacin on eicosanoid production in carrageenan-induced air pouch inflammation in rats. Sayar K, et al. **Eur J Pharmacol** 1999 Mar 26;369(3):365–71

The importance of inflammatory mechanisms in Alzheimer disease. McGeer EG, et al. **Exp Gerontol** 1998 Aug; 33(5):371–8 (22 ref.)

Experimental study of oxidative DNA damage. Loft S, et al. **Free Radic Res** 1998 Dec;29(6):525–39 (149 ref.)

Biology of basophils and their role in allergic inflammation. Chugh L. **Indian J Chest Dis Allied Sci** 1998 Oct–Dec; 40(4):257–67 (56 ref.)

Deacylation of purified lipopolysaccharides by cellular and extracellular components of a sterile rabbit peritoneal inflammatory exudate. Weinrauch Y, et al. **Infect Immun** 1999 Jul;67(7):3376–82

Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. Matsukawa A, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S137–44 (61 ref.)

Procoagulant and anticoagulant activities of resident and inflammatory peritoneal cells. Pejler G. **Inflamm Res** 1999 Jun;48(6):344–50

Down-regulation of liver RNA breakdown by turpentine administration in the starved rat: autophagy and relevant factors. Saadane A, et al. **Inflamm Res** 1999 Apr;48(4):210–7

Increase in histamine production by inflammatory exudate in the chronic phase of allergic inflammation in rats. Hirasawa N, et al. **Inflammation** 1998 Oct;22(5):471–82

Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. Vonk AG, et al. **J Antimicrob Chemother** 1998 Oct;42(4):469–74

Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen. Falcone DJ, et al. **J Biol Chem** 1998 Nov 20;273(47):31480–5

A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. Kozik A, et al. **J Biol Chem** 1998 Dec 11;273(50):33224–9

Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. Riley JK, et al. **J Biol Chem** 1999 Jun 4;274(23):16513–21

In vitro evaluation of the inflammatory potential of the silk fibroin. Santin M, et al. **J Biomed Mater Res** 1999 Sep 5;46(3):382–9

The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Singh R, et al. **J Clin Invest** 1999 Jun;103(11):1561–70

Persistent expression of serum amyloid A during experimentally induced chronic inflammatory condition in rabbit involves differential activation of SAF, NF-kappa B, and C/EBP transcription factors. Ray A, et al. **J Immunol** 1999 Aug 15;163(4):2143–50

Up-regulation of endothelial cell binding proteins/receptors for complement component C1q by inflammatory cytokines [see comments] Guo WX, et al. **J Lab Clin Med** 1999 Jun; 133(6):541–50. Comment in: J Lab Clin Med 1999 Jun;133(6):520–2.

Chronic protein undernutrition and an acute inflammatory stimulus elicit different protein kinetic responses in plasma but not in muscle of piglets. Jahoor F, et al. **J Nutr** 1999 Mar;129(3):693–9

Role of mast cells as a trigger of inflammation in Helicobacter pylori infection. Yamamoto J, et al.

J Physiol Pharmacol 1999 Mar;50(1):17–23

Chemokine production by human chondrocytes. Pulsatelli L, et al. **J Rheumatol** 1999 Sep;26(9):1992–2001

Increased proinflammatory cytokines production by ergotamine in male BALB/c mice. Filipov NM, et al. **J Toxicol Environ Health** 1999 Oct 15;58(3):145–55

Amplified proinflammatory cytokine expression and toxicity in mice coexposed to lipopolysaccharide and the trichothecene vomitoxin (deoxynivalenol). Zhou HR, et al. **J Toxicol Environ Health** 1999 May 28;57(2):115–36

Cimetidine inhibits nitric oxide associated nitrate production in a soft-tissue inflammation model in the horse. Hunter RP, et al. **J Vet Pharmacol Ther** 1999 Apr;22(2):136–47

A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. Lees P, et al. **J Vet Pharmacol Ther** 1999 Apr;22(2):96–106

A single stranded DNA-binding protein, ssCRE-BP/Pur alpha, in rat lung and its increase in allergic airway inflammation. Wei EQ, et al. **Jpn J Pharmacol** 1998 Dec; 78(4):419–27

Constitutive protein expression of monocyte chemotactic protein-1 (MCP-1) by myelomonocytic cell lines and regulation of the secretion by anti- and proinflammatory stimuli. Steube KG, et al. **Leuk Res** 1999 Sep;23(9):843–9

Inflammatory mediators regulate cathepsin S in macrophages and microglia: A role in attenuating heparan sulfate interactions. Liuzzo JP, et al. **Mol Med** 1999 May; 5(5):320–33

Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation. Zhang Y, et al. **Neuroreport** 1998 Aug 24;9(12):2833–6

Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Willard LB, et al. **Neuroscience** 1999 Jan;88(1):193–200

Comparison of pulmonary inflammatory mediators in preterm infants treated with intermittent positive pressure ventilation or high frequency oscillatory ventilation. Thome U, et al. **Pediatr Res** 1998 Sep;44(3):330–7

Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations-induced paw edema model in the rat. Blais C Jr, et al. **Peptides** 1999; 20(3):343–52

Hepatic gene expression and cytokine responses to sterile inflammation: comparison with cecal ligation and puncture sepsis in the rat. Bazel S, et al. **Shock** 1999 May; 11(5):347–55

Simultaneous targeting or multiple pathways of shock: how promising, how novel? [editorial; comment] Szabó C. **Shock** 1999 Apr;11(4):296–7. Comment on: Shock 1999 Apr;11(4):264–8.

Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Gadient RA, et al. **Stem Cells** 1999;17(3):127–37 (163 ref.)

Platelet contribution to leukotriene production in inflammation: in vivo evidence in the rabbit. Evangelista V, et al. **Thromb Haemost** 1999 Mar;81(3):442–8

Formation of complement split products and proinflammatory cytokines by reinfusion of shed autologous blood. Bengtsson A, et al. **Toxicol Lett** 1998 Nov 23;100–101:129–33

Effect of environmental pollutants on the production of pro-inflammatory cytokines by normal human dermal keratinocytes. Ushio H, et al. **Toxicol Lett** 1999 Mar 8; 105(1):17–24

[The effect of gamma-hydroxybutyrate (GHB) on proinflammatory cytokine gene expression in coronary surgical procedures] Kleinschmidt S, et al. **Anaesthesist** 1998 Aug;47(8):651–62 (Eng. Abstr.) **(Ger)**

[Effects of hydroxysterols on expression of inflammatory cytokine genes and their level in macrophages tolerant to endotoxin] Dushkin MI, et al. **Biull Eksp Biol Med** 1999 Jan;127(1):71–4 **(Rus)**

MICROBIOLOGY

Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Redecke V, et al. **Am J Respir Cell Mol Biol** 1998 Nov; 19(5):721–7

Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following subcutaneous administration. McKellar Q, et al. **Antimicrob Agents Chemother** 1999 Aug;43(8):1988–92

[Bacterial flora of odontogenic and non-odontogenic inflammations of the oro-facial region] Szontágh E, et al. **Fogorv Sz** 1999 Feb;92(2):45–50 (Eng. Abstr.) **(Hun)**

[Host microflora and its role in response to infection] Beloborodova NV. **Antibiot Khimioter** 1998;43(9):44–8 **(Rus)**

MORTALITY

Genetic component in the inflammatory response induced by bacterial lipopolysaccharide. De Maio A, et al. **Shock** 1998 Nov;10(5):319–23

PATHOLOGY

Mucous-cell metaplasia and inflammatory-cell recruitment are dissociated in allergic mice after antibody- and drug-dependent cell depletion in a murine model of asthma. Haile S, et al. **Am J Respir Cell Mol Biol** 1999 May; 20(5):891–902

Measurement variability and diagnostic sensitivity of gastric mucosal inflammatory cell morphometry. Ballanti P, et al. **Anal Quant Cytol Histol** 1999 Feb;21(1):21–8

Local inflammation may influence oral tumor cell differentiation. Arany I, et al. **Anticancer Res** 1999 Mar-Apr;19(2A):1065–7

In vitro prostanoid release from spinal cord following peripheral inflammation: effects of substance P, NMDA and capsaicin. Dirig DM, et al. **Br J Pharmacol** 1999 Mar; 126(6):1333–40

New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Chen F, et al. **Clin Chem** 1999 Jan;45(1):7–17 (116 ref.)

Critically ill patients: immunological evidence of inflammation in muscle biopsy. Bazzi P, et al. **Clin Neuropathol** 1999 Jan-Feb;18(1):23–30

The myofibroblast as an inflammatory cell in pulmonary fibrosis. Phan SH, et al. **Curr Top Pathol** 1999;93:173–82 (57 ref.)

Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Mukaida N, et al. **Cytokine Growth Factor Rev** 1998 Mar;9(1):9–23 (148 ref.)

Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. Duan WM, et al. **Eur J Neurosci** 1998 Aug;10(8):2595–606

Involvement of bradykinin B1 and B2 receptors in pulmonary leukocyte accumulation induced by Sephadex beads in guinea pigs. Perron MS, et al. **Eur J Pharmacol** 1999 Jul 2;376(1–2):83–9

Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Sullivan P, et al. **Eur Respir J** 1998 Oct; 12(4):811–5

Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice. Penkowa M, et al. **Exp Neurol** 1999 Mar;156(1):149–64

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Goulding NJ, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S158–65 (68 ref.)

Extracellular matrix (ECM) mediated adhesion and signaling in inflammation and cancer: new concepts, New York Academy of Sciences, May 21, 1998. Morgan DW, et al. **Inflamm Res** 1999 Mar;48(3):104–5

Apoptosis in inflammatory diseases. Simon HU. **Int Arch Allergy Immunol** 1999 Feb-Apr;118(2–4):261–2

Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Neumann B, et al. **Int Immunol** 1999 Feb; 11(2):217–27

Effect of beta-agonists on inflammatory cells. Barnes PJ. **J Allergy Clin Immunol** 1999 Aug;104(2 Pt 2):S10–7 (109 ref.)

Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis [comment] Firestein GS. **J Clin Invest** 1999 Jan;103(1):3–4. Comment on: J Clin Invest 1999 Jan;103(1):47–54.

Inflammatory metastatic melanoma. Flórez A, et al. **J Cutan Pathol** 1999 Feb;26(2):105–8

Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. Hale KK, et al. **J Immunol** 1999 Apr 1;162(7):4246–52

Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. Suffredini AF, et al. **J Infect Dis** 1999 May;179(5):1278–82

Histopathological changes after induced injury in leeches. de Eguileor M, et al. **J Invertebr Pathol** 1999 Jul; 74(1):14–28

Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha [see comments] Allen DA, et al. **J Investig Med** 1999 May;47(5):204–11. Comment in: J Investig Med 1999 May;47(5):203.

Priming of human neutrophils by peroxynitrite: potential role in enhancement of the local inflammatory response. Rohn TT, et al. **J Leukoc Biol** 1999 Jan;65(1):59–70

Novel roles for chemokines and fibroblasts in interstitial fibrosis. Hogaboam CM, et al. **Kidney Int** 1998 Dec; 54(6):2152–9 (64 ref.)

Inflammation causes a long-term hyperexcitability in the nociceptive sensory neurons of Aplysia. Farr M, et al. **Learn Mem** 1999 May-Jun;6(3):331–40

Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Baroni GS, et al. **Liver** 1999 Jun; 19(3):212–9

Could synergistic interactions among reactive oxygen species, proteinases, membrane-perforating enzymes, hydrolases, microbial hemolysins and cytokines be the main cause of tissue damage in infectious and inflammatory conditions? Ginsburg I. **Med Hypotheses** 1998 Oct; 51(4):337–46 (68 ref.)

Endothelial gaps as sites for plasma leakage in inflammation. McDonald DM, et al. **Microcirculation** 1999 Mar;6(1):7–22 (50 ref.)

Idiopathic fibroinflammatory (fibrosing/sclerosing) lesions of the mediastinum: a study of 30 cases with emphasis on morphologic heterogeneity. Flieder DB, et al. **Mod Pathol** 1999 Mar;12(3):257–64

Chronic motor axonal neuropathy: pathological evidence of inflammatory polyradiculoneuropathy. Gorson KC, et al. **Muscle Nerve** 1999 Feb;22(2):266–70

Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Gahtan E, et al. **Neurosci Biobehav Rev** 1999 May;23(5):615–33 (197 ref.)

Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Willard LB, et al. **Neuroscience** 1999 Jan;88(1):193–200

Relationship between inflammatory cells in bronchoalveolar lavage fluid and pathologic changes in the lung interstitium. Yoshii C, et al. **Respiration** 1998;65(5):386–92

B1 receptors as a new inflammatory target. Could this B the 1? Ahluwalia A, et al. **Trends Pharmacol Sci** 1999 Mar; 20(3):100–4

Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Mennicken F, et al. **Trends Pharmacol Sci** 1999 Feb;20(2):73–8 (83 ref.)

Ultrastructural study of the destructive and repair processes in pulmonary inflammation and following endobronchial laser therapy. Polosukhin VV. **Virchows Arch** 1999 Jul; 435(1):13–9

[The state of the lymphatic system in inflammation of the internal sexual organs] Borodin IuI, et al. **Morfologiia** 1999; 115(2):30–3 (Eng. Abstr.) **(Rus)**

[The role of inflammation in the pathogenesis and prognosis of unstable angina] Miranda-Guardiola F, et al. **Rev Esp Cardiol** 1999;52 Suppl 1:13–22 (58 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Interleukin-15 is not a constitutive cytokine in the epidermis, but is inducible in culture or inflammatory conditions. Han GW, et al. **Acta Derm Venereol** 1999 Jan;79(1):37–40

Inflammation and brain function under basal conditions and during long-term elevation of brain corticotropin-releasing hormone levels. Linthorst AC, et al. **Adv Exp Med Biol** 1999;461:129–52 (83 ref.)

Dynamic regulation of proinflammatory cytokines. Watkins LR, et al. **Adv Exp Med Biol** 1999;461:153–78 (194 ref.)

Chemokines in inflammatory states. Conti P, et al. **Allergy Asthma Proc** 1999 Jul-Aug;20(4):205–8 (31 ref.)

Interleukin-10 regulates quartz-induced pulmonary inflammation in rats. Driscoll KE, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L887–94

Clara cell secretory protein decreases lung inflammation after acute virus infection. Harrod KS, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L924–30

Nitric Oxide. III. A molecular prelude to intestinal inflammation. Miller MJ, et al. **Am J Physiol** 1999 Apr; 276(4 Pt 1):G795–9 (25 ref.)

Functional alterations in jejunal myenteric neurons during inflammation in nematode-infected guinea pigs. Palmer JM, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):G922–35

Mechanism of suppressed neutrophil mobilization in a mouse model for binge drinking: role of glucocorticoids. Vinson RB, et al. **Am J Physiol** 1998 Oct;275(4 Pt 2):R1049–57

Cellular and biochemical response of the human lung after intrapulmonary instillation of ferric oxide particles. Lay JC, et al. **Am J Respir Cell Mol Biol** 1999 Apr;20(4):631–42

Continuing inflammation does enhance spinally mediated antinociception by neostigmine in the rat model [letter] Buerkle H, et al. **Anesth Analg** 1999 Jul;89(1):255–6

Ketamine inhibits the proinflammatory cytokine-induced reduction of cardiac intracellular cAMP accumulation. Hill GE, et al. **Anesth Analg** 1998 Nov;87(5):1015–9

Peptide modulation of fever and inflammation within the brain. Catania A, et al. **Ann N Y Acad Sci** 1998 Sep 29; 856:62–8 (54 ref.)

Gender differences in adrenal and gonadal responses to inflammatory aggression. Da Silva JA, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:148–51

Role of IL-10 in inflammation. Studies using cytokine knockout mice. Leon LR, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:69–75

Heat shock proteins and the inflammatory response. Moseley PL. **Ann N Y Acad Sci** 1998 Sep 29;856:206–13 (45 ref.)

Proinflammatory cytokines and treatment of disease. van der Meer JW, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:243–51 (59 ref.)

Delineation of the proinflammatory cytokine cascade in fever induction. Zetterström M, et al. **Ann N Y Acad Sci** 1998 Sep 29;856:48–52 (18 ref.)

Inflammatory mediators, cells and their products in acute host alloresponsiveness. Tilney NL, et al. **Ann Transplant** 1996;1(3):5–13 (97 ref.)

Microglia as mediators of inflammatory and degenerative diseases. González-Scarano F, et al. **Annu Rev Neurosci** 1999;22:219–40 (134 ref.)

Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Tibbetts TA, et al. **Biol Reprod** 1999 May;60(5):1158–65

The effects of inflammation and inflammatory mediators on nociceptive behaviour induced by ATP analogues in the rat. Hamilton SG, et al. **Br J Pharmacol** 1999 Jan; 126(1):326–32

Dorsolateral funiculus-lesions unmask inhibitory or disfacilitatory mechanisms which modulate the effects of innocuous mechanical stimulation on spinal Fos expression after inflammation. Wei F, et al. **Brain Res** 1999 Feb 27;

820(1-2):112-6
Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Baveye S, et al. **Clin Chem Lab Med** 1999 Mar;37(3):281-6 (54 ref.)
Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Oberhoffer M, et al. **Clin Chem Lab Med** 1999 Mar;37(3):363-8
Kinetics of apoptosis in the lung of mice with allergic airway inflammation [see comments] Kodama T, et al. **Clin Exp Allergy** 1998 Nov;28(11):1435-43. Comment in: Clin Exp Allergy 1998 Nov;28(11):1321-4.
Inflammation, leukotrienes and the pathogenesis of the late asthmatic response [editorial; comment] Wenzel SE. **Clin Exp Allergy** 1999 Jan;29(1):1-3. Comment on: Clin Exp Allergy 1999 Jan;29(1):42-51.
Effects of alimentary whole proteins versus their small peptide hydrolysates on liver and skeletal muscle during the acute inflammation phase in the rat. Zarrabian S, et al. **Clin Nutr** 1998 Aug;17(4):169-76
Laser Doppler perfusion imaging for the documentation of flare-up in contact allergy to gold. Möller H, et al. **Contact Dermatitis** 1999 Sep;41(3):131-5
How bacteria initiate inflammation: aspects of the emerging story. Hersh D, et al. **Curr Opin Microbiol** 1998 Feb; 1(1):43-8 (53 ref.)
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Heemskerk VH, et al. **Cytokine Growth Factor Rev** 1999 Mar;10(1):5-14 (109 ref.)
Cytokine regulation of cellular adhesion molecule expression in inflammation. Meager A. **Cytokine Growth Factor Rev** 1999 Mar;10(1):27-39 (113 ref.)
Adhesion molecules in inflammatory diseases. González-Amaro R, et al. **Drugs** 1998 Dec;56(6):977-88 (126 ref.)
CRF type I receptor-deficient mice exhibit a pronounced pituitary-adrenal response to local inflammation. Turnbull AV, et al. **Endocrinology** 1999 Feb;140(2):1013-7
Inflammation, tumor necrosis factor, and toxicology [editorial] Luster MI. **Environ Health Perspect** 1998 Sep; 106(9):A418-9
Inhalation of cold air increases the number of inflammatory cells in the lungs in healthy subjects. Larsson K, et al. **Eur Respir J** 1998 Oct;12(4):825-30
Some aspects of the inflammatory process. Maślińska D, et al. **Folia Neuropathol** 1998;36(4):199-204 (36 ref.)
Central modulation of formalin-induced acute peripheral inflammation & pain by some putative amino acid neurotransmitters in rats. Dumka VK, et al. **Indian J Med Res** 1998 Oct;108:149-52
Airway responsiveness to methacholine: effects of deep inhalations and airway inflammation. Brusasco V, et al. **J Appl Physiol** 1999 Aug;87(2):567-73
Effects of airway inflammation on cough response in the guinea pig. Xiang A, et al. **J Appl Physiol** 1998 Nov; 85(5):1847-54
Inflammatory and motor responses by tachykinins in the guinea-pig oesophageal sphincter. Conte B, et al. **J Auton Pharmacol** 1998 Oct;18(5):313-7
Inflammatory mediators and stroke: new opportunities for novel therapeutics. Barone FC, et al. **J Cereb Blood Flow Metab** 1999 Aug;19(8):819-34 (203 ref.)
Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. Folz RJ, et al. **J Clin Invest** 1999 Apr;103(7):1055-66
Persistent Fos protein expression after orofacial deep or cutaneous tissue inflammation in rats: implications for persistent orofacial pain. Zhou Q, et al. **J Comp Neurol** 1999 Sep 20;412(2):276-91
Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195-8 (29 ref.)
A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187-93 (34 ref.)
Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. Bertini R, et al. **J Exp Med** 1999 Jun 7;189(11):1783-9
Effect of local corticosteroids on early inflammatory function in surgical wound of rats. Nguyen H, et al. **J Foot Ankle Surg** 1998 Jul-Aug;37(4):313-8
Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. Cuff CA, et al. **J Immunol** 1998 Dec 15;161(12):6853-60
Inflammatory alterations in the myocardial microcirculation. Hansen PR. **J Mol Cell Cardiol** 1998 Dec;30(12):2555-9 (45 ref.)
Peripheral inflammation is associated with decreased veratridine-induced release of GABA in the rat ventrocaudal periaqueductal gray: microdialysis study. Renno WM, et al. **J Neurol Sci** 1999 Mar 1;163(2):105-10
Annexin I is a local mediator in neural-endocrine feedback control of inflammation. Green PG, et al. **J Neurophysiol** 1998 Dec;80(6):3120-6
Peripheral inflammation facilitates Abeta fiber-mediated synaptic input to the substantia gelatinosa of the adult rat spinal cord. Baba H, et al. **J Neurosci** 1999 Jan 15; 19(2):859-67
Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. Cartmell T, et al. **J Neurosci** 1999 Feb 15;19(4):1517-23
Sex steroid regulation of the inflammatory response: sympathoadrenal dependence in the female rat. Green PG, et al. **J Neurosci** 1999 May 15;19(10):4082-9
Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. Honor P, et al. **J Neurosci** 1999 Sep 1;19(17):7670-8
Brain sites of action of endogenous interleukin-1 in the febrile response to localized inflammation in the rat. Cartmell T, et al. **J Physiol (Lond)** 1999 Jul 15;518 (Pt 2):585-94
Novel roles for chemokines and fibroblasts in interstitial fibrosis. Hogaboam CM, et al. **Kidney Int** 1998 Dec; 54(6):2152-9 (64 ref.)
Effect of somatostatin on beta-endorphin release in rat experimental chronic inflammation. Corsi MM, et al. **Life Sci** 1999;64(24):2247-54
Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier--implications for use of glucosamine in inflammatory disorders. McCarty MF. **Med Hypotheses** 1998 Jul;51(1):11-5 (63 ref.)
Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Sharief MK. **Mult Scler** 1998 Jun; 4(3):169-73 (35 ref.)
Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Miwa K, et al. **Nat Med** 1998 Nov;4(11):1287-92
How the immune system puts the brain to sleep [news; comment] Straub RH, et al. **Nat Med** 1999 Aug;5(8):877-9 . Comment on: Nat Med 1999 Aug;5(8):913-8.
Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Torpy DJ, et al. **Neuroimmunomodulation** 1999 May-Jun;6(3):182-6
The effect of intrathecal neuropeptide Y on the flexor reflex in rats after carrageenan-induced inflammation. Xu IS, et al. **Neuropeptides** 1998 Oct;32(5):447-52
A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Khasar SG, et al. **Neurosci Lett** 1998 Oct 30;256(1):17-20
Tumour necrosis factor alpha induces only minor inflammatory changes in the central nervous system, but augments experimental meningitis. Angstwurm K, et al. **Neuroscience** 1998 Sep;86(2):627-34
A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance. Kwak JY, et al. **Neuroscience** 1998 Sep;86(2):619-26
Inflammation-induced up-regulation of protein kinase Cgamma immunoreactivity in rat spinal cord correlates with enhanced nociceptive processing. Martin WJ, et al. **Neuroscience** 1999;88(4):1267-74
Peripheral inflammation increases the capsaicin sensitivity of dorsal root ganglion neurons in a nerve growth factor-dependent manner. Nicholas RS, et al. **Neuroscience** 1999;91(4):1425-33
Response properties of hind limb single motor units in normal rats and after carrageenan-induced inflammation. Solano R, et al. **Neuroscience** 1999;90(4):1393-402
Nucleus reticularis gigantocellularis and nucleus raphe magnus in the brain stem exert opposite effects on behavioral hyperalgesia and spinal Fos protein expression after peripheral inflammation [published erratum appears in Pain 1999 May;81(1-2):215-9] Wei F, et al. **Pain** 1999 Mar;80(1-2):127-41
Infiltration of inflammatory cells through brain endothelium. Couraud PO. **Pathol Biol (Paris)** 1998 Mar;46(3):176-80
Inflammatory pathogenesis of cortical polymicrogyria: an autopsy study. Toti P, et al. **Pediatr Res** 1998 Sep; 44(3):291-6
Does a high peritoneal transport rate reflect a state of chronic inflammation? Wang T, et al. **Perit Dial Int** 1999 Jan-Feb; 19(1):17-22
Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia. Gold MS. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7645-9 (69 ref.)
Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Karalis KP, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):7093-7
Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Lim LH, et al. **Proc Natl Acad Sci U S A** 1998 Nov 24;95(24):14535-9
Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Mannion RJ, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9385-90
Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Woolf CJ, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):7723-30 (83 ref.)
Dietary lipids and the inflammatory response. Grimble RF. **Proc Nutr Soc** 1998 Nov;57(4):535-42 (47 ref.)
Inflammation in the CNS: balance between immunological privilege and immune responses. Matyszak MK. **Prog Neurobiol** 1998 Oct;56(1):19-35 (131 ref.)
Striated muscle microvascular response to zymosan-induced generalized inflammation in awake hamsters. Geeraedts LM Jr, et al. **Shock** 1998 Aug;10(2):103-9
Alveolar neutrophil oxidative burst and beta2 integrin expression in experimental acute pulmonary inflammation are not modified by inhaled nitric oxide. Kermarrec N, et al. **Shock** 1998 Aug;10(2):129-34
Induction of organ dysfunction and activation of inflammatory markers in donor liver and kidney during hypotensive brain death. van der Hoeven JA, et al. **Transplant Proc** 1999 Feb-Mar;31(1-2):1006-7
[Adhesion receptors of the vascular endothelium and their role in acute inflammation] Bělohlávková S, et al. **Cesk Fysiol** 1999 May;48(2):51-61 (47 ref.) (Eng. Abstr.) **(Cze)**
[Inflammatory mechanisms of renal fibrosis: glomerulonephritis] Baud L, et al. **Bull Acad Natl Med** 1999;183(1):23-31 (27 ref.) (Eng. Abstr.) **(Fre)**
[Inflammatory response. Part 1] Haeffner-Cavaillon N. **Rev Med Interne** 1998 Aug;19(8):585-8 **(Fre)**
[Inflammatory response. II] Haeffner-Cavaillon N. **Rev Med Interne** 1998 Oct;19(10):748-50 **(Fre)**
[Nuclear transcription factor kappa B (NF-kappa B)] Mercié P, et al. **Rev Med Interne** 1998 Dec;19(12):945-7 (13 ref.) (Eng. Abstr.) **(Fre)**
[Staphylococcal persistence factors in the prognostication of the course of pyo-inflammatory diseases] Bukharin OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Sep-Oct; (5):27-30 (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Kruzel ML, et al. **Adv Exp Med Biol** 1998;443:167-73 (38 ref.)
Stimulation of cerebellar fastigial nucleus inhibits interleukin-1beta-induced cerebrovascular inflammation. Galea E, et al. **Am J Physiol** 1998 Dec;275(6 Pt 2):H2053-63
Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Möllhoff T, et al. **Anesthesiology** 1999 Jan; 90(1):72-80
Reducing inflammatory reactions by heparin-coated circuit [letter; comment] Wan S, et al. **Ann Thorac Surg** 1998 Nov; 66(5):1868. Comment on: Ann Thorac Surg 1997 Dec;64(6):1790-4.
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Cunha FQ, et al. **Br J Pharmacol** 1999 Jan; 126(1):45-50
Systemic anti-inflammatory effect induced by counter-irritation through a local release of somatostatin from nociceptors. Szolcsányi J, et al. **Br J Pharmacol** 1998 Oct;125(4):916-22
Hybrid artificial lung with interleukin-10 and endothelial constitutive nitric oxide synthase gene-transfected endothelial cells attenuates inflammatory reactions induced by cardiopulmonary bypass. Ohata T, et al. **Circulation** 1998 Nov 10;98(19 Suppl):II269-74
Dopexamine reduces the incidence of acute inflammation in the gut mucosa after abdominal surgery in high-risk patients [see comments] Byers RJ, et al. **Crit Care Med** 1999 Sep;27(9):1787-93. Comment in: Crit Care Med 1999 Sep;27(9):2038-9.
Dopexamine protects the gut mucosa during major surgery? [editorial; comment] Mythen M. **Crit Care Med** 1999 Sep; 27(9):2038-9. Comment on: Crit Care Med 1999 Sep;27(9):1787-93.
Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. Hamilton LC, et al. **FASEB J** 1999 Feb;13(2):245-51
Effects of tramadol on experimental inflammation. Bianchi M, et al. **Fundam Clin Pharmacol** 1999;13(2):220-5
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. Escofier N, et al. **Fundam Clin Pharmacol** 1999;13(1):96-101
Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. Fujie K, et al. **Inflamm Res** 1999 Mar;48(3):160-7
Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8) Mukaida N, et al. **Inflamm Res** 1998 Oct;47 Suppl 3:S151-7
Suppression of carrageenan-induced inflammation in vivo by an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F. Tao X, et al. **Inflamm Res** 1999 Mar; 48(3):139-48
Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice. Kasai M, et al. **Int Arch Allergy Immunol** 1998 Sep;117 Suppl 1:14-9
Use of postoperative steroids to reduce pain and inflammation. Fleischli JW, et al. **J Foot Ankle Surg** 1999 May-Jun;38(3):232-7 (31 ref.)
Dietary retinol inhibits inflammatory responses of rats treated with monocrotaline. Swamidas GP, et al. **J Nutr** 1999 Jul; 129(7):1285-90
Interleukin-10 inhibits cytokine synthesis in monocytes stimulated by titanium particles: evidence of an anti-inflammatory regulatory pathway. Pollice PF, et al. **J Orthop Res** 1998 Nov;16(6):697-704
Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. Cuzzocrea S, et al. **J Pineal Res** 1999 Aug;27(1):9-14
An anti-inflammatory role for glucocorticoids in the ovaries? Hillier SG, et al. **J Reprod Immunol** 1998 Aug;39(1-2):21-7 (36 ref.)
Role of arachidonic acid in the regulation of the inflammatory response in TNF-alpha-treated rats. Ling PR, et al. **JPEN J Parenter Enteral Nutr** 1998 Sep-Oct;

22(5):268–75
Effect of somatostatin on beta-endorphin release in rat experimental chronic inflammation. Corsi MM, et al. **Life Sci** 1999;64(24):2247–54
A novel anti-inflammatory activity of lysozyme: modulation of serum complement activation. Ogundele MO. **Mediators Inflamm** 1998;7(5):363–5
Inhibition of systemic inflammation by central action of the neuropeptide alpha-melanocyte- stimulating hormone. Delgado Hernández R, et al. **Neuroimmunomodulation** 1999 May–Jun;6(3):187–92
Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. Woo PC, et al. **Pharmacol Res** 1999 Jan;39(1):49–54
Intramuscular administration of cholera toxin in Balb/c mice induces an inflammatory reaction that is prevented by indomethacin. Moreno-Fierros L, et al. **Proc West Pharmacol Soc** 1998;41:103–6
Administration of interleukin-12 prevents mite Der p 1 allergen-IgE antibody production and airway eosinophil infiltration in an animal model of airway inflammation. Lee YL, et al. **Scand J Immunol** 1999 Mar;49(3):229–36
[Diagnostic methods and prophylaxis of purulent inflammation in postsurgical wounds] Mamedov LA, et al. **Biull Eksp Biol Med** 1999 Apr;127(4):477–9 **(Rus)**

PSYCHOLOGY

Major depression and activation of the inflammatory response system. Maes M. **Adv Exp Med Biol** 1999;461:25–46 (173 ref.)
Reduction in peripheral inflammation by changes in attention. Gentle MJ, et al. **Physiol Behav** 1999 Apr;66(2):289–92
Relationship of body energy status to inflammation-induced anorexia and weight loss. Lennie TA. **Physiol Behav** 1998 Jun 15;64(4):475–81

RADIONUCLIDE IMAGING

In vivo evaluation in mice and metabolism in blood of human volunteers of [123I]iodo-PK11195: a possible single-photon emission tomography tracer for visualization of inflammation. Dumont F, et al. **Eur J Nucl Med** 1999 Mar; 26(3):194–200
Nuclear medicine imaging in infection and inflammation. Peters AM. **J R Coll Physicians Lond** 1998 Nov–Dec; 32(6):512–9 (30 ref.)
Nuclear medicine's role in infection and inflammation. Corstens FH, et al. **Lancet** 1999 Aug 28;354(9180):765–70 (37 ref.)
67Ga planar imaging with a low-energy collimator and scatter correction using the triple energy window method. Okada J, et al. **Nucl Med Commun** 1999 Jul;20(7):647–57
Radionuclide imaging of nonosseous infection. Palestro CJ, et al. **Q J Nucl Med** 1999 Mar;43(1):46–60 (69 ref.)
Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Weiner RE, et al. **Q J Nucl Med** 1999 Mar;43(1):2–8 (49 ref.)
In-111 labeled leukocyte scintigraphy in patients with suspected inflammation after failed antibiotic therapy. Nasu R, et al. **Radiat Med** 1998 Sep–Oct;16(5):347–51

RADIOTHERAPY

Radiobiological mechanisms of anti-inflammatory radiotherapy. Trott KR, et al. **Radiother Oncol** 1999 Jun; 51(3):197–203 (44 ref.)
[Results of analgetic radiotherapy of inflammation of the calcaneus using 6 MV photons] Heyd R, et al. **Rontgenpraxis** 1999;52(1):26–32 **(Ger)**

THERAPY

Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Rieben R, et al. **Blood** 1999 Feb 1;93(3):942–51
Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. Yang XD, et al. **J Leukoc Biol** 1999 Sep; 66(3):401–10
C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Kirschfink M, et al. **Mol Immunol** 1999 Mar–Apr;36(4–5):225–32 (85 ref.)
Autologous stem cell therapy for treatment of severe inflammatory autoimmune diseases. van Bekkum DW. **Neth J Med** 1998 Sep;53(3):130–3 (18 ref.)
Application of gene therapy to acute inflammatory diseases. Moldawer LL, et al. **Shock** 1999 Aug;12(2):83–101 (183 ref.)
[Research on the endothelium and new therapeutic strategies in tumors and cardiovascular diseases] Dejana E. **Recenti Prog Med** 1999 Feb;90(2):64–8 **(Ita)**
[Etiotropic antibiotic therapy and immunotherapy of patients with pyo-inflammatory processes] Vasina TA, et al. **Antibiot Khimioter** 1998;43(11):28–33 (Eng. Abstr.) **(Rus)**
[Free radical mechanisms of low-intensive laser radiation] Chichuk TV, et al. **Vestn Ross Akad Med Nauk** 1999; (2):27–32 (54 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Functional responses of neonatal chicken and turkey heterophils following stimulation by inflammatory agonists. Kogut MH, et al. **Am J Vet Res** 1998 Nov;59(11):1404–8
Inflammatory diseases of the central nervous system in dogs. Thomas WB. **Clin Tech Small Anim Pract** 1998 Aug; 13(3):167–78 (86 ref.)
Neutrophil and macrophage responses to inflammation in the peritoneal cavity of rainbow trout Oncorhynchus mykiss. A light and electron microscopic cytochemical study. Afonso A, et al. **Dis Aquat Organ** 1998 Sep 11;34(1):27–37
The intramammary inflammatory response of genetically resistant Merino ewes infected with Haemonchus contortus. Thamsborg SM, et al. **Int J Parasitol** 1999 Mar; 29(3):451–8
Effect of dietary energy level and oil source on broiler performance and response to an inflammatory challenge. Korver DR, et al. **Poult Sci** 1998 Aug;77(8):1217–27
Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Gregory CR, et al. **Transplant Proc** 1998 Dec;30(8):4143–8
Acute phase proteins in cattle: discrimination between acute and chronic inflammation. Horadagoda NU, et al. **Vet Rec** 1999 Apr 17;144(16):437–41
[Breath condensate--a medium obtained by a noninvasive method for the detection of inflammation mediators of the lung] Reinhold P, et al. **Berl Munch Tierarztl Wochenschr** 1999 Jun–Jul; 112(6–7):254–9 (Eng. Abstr.) **(Ger)**

VIROLOGY

Cytomegalovirus infection. Regulation of inflammation. Hunninghake GW, et al. **Am J Respir Cell Mol Biol** 1999 Aug;21(2):150–2 (41 ref.)
Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma [comment] Mesri EA. **Blood** 1999 Jun 15;93(12):4031–3 (18 ref.). Comment on: Blood 1999 Jun 15;93(12):4034–43. Comment on: Blood 1999 Jun 15;93(12):4044–58.

INFLAMMATION MEDIATORS

Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Asimakopoulos G, et al. **Ann Thorac Surg** 1998 Dec;66(6):2135–44 (89 ref.)
[Cytophysiology of lung bronchiolar secretory cells--source of inflammation "antimediators"] Romanova LK, et al. **Arkh Patol** 1999 Mar–Apr;61(2):20–7 (Eng. Abstr.) **(Rus)**

ANALYSIS

Gene expressions of antiinflammatory mediators in THR retrieved interfacial membranes. Nabae M, et al. **Acta Orthop Scand** 1999 Apr;70(2):149–54
Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. Fernvik E, et al. **Allergy** 1999 May;54(5):455–63
Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Winther L, et al. **Allergy** 1999 May; 54(5):436–45
Azelastine reduces mediators of inflammation in patients with nasal polyps. Mösges R, et al. **Allergy Asthma Proc** 1998 Nov–Dec;19(6):379–83
Relationship between induced sputum cell counts and fluid-phase eosinophil cationic protein and clinical or physiologic profiles in mild asthma. Gutiérrez V, et al. **Ann Allergy Asthma Immunol** 1999 Jun;82(6):559–65
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Frostegård J, et al. **Atherosclerosis** 1999 Jul;145(1):33–43
Serum eosinophil cationic protein and bronchial responsiveness in pediatric and adolescent asthma patients. Gruber W, et al. **Chest** 1999 Aug;116(2):301–5
Inflammatory mediators in bronchoalveolar lavage samples from children with and without asthma. Ennis M, et al. **Clin Exp Allergy** 1999 Mar;29(3):362–6
Induced sputum eosinophil cationic protein (ECP) measurement in asthma and chronic obstructive airway disease (COAD) [see comments] Gibson PG, et al. **Clin Exp Allergy** 1998 Sep;28(9):1081–8. Comment in: Clin Exp Allergy 1998 Sep;28(9):1047–9.
Can eosinophil-derived proteins be used to diagnose or to monitor childhood asthma? [editorial; comment] Hoekstra MO. **Clin Exp Allergy** 1999 Jul;29(7):873–4 (17 ref.). Comment on: Clin Exp Allergy 1999 Jul;29(7):926–32.
Lack of relationship between eosinophil cationic protein and eosinophil protein X in nasal lavage and urine and the severity of childhood asthma in a 6-month follow-up study [see comments] Wojnarowski C, et al. **Clin Exp Allergy** 1999 Jul;29(7):926–32. Comment in: Clin Exp Allergy 1999 Jul;29(7):873–4.
Expression of functional immunomodulatory and anti-inflammatory factors in human milk. Garofalo RP, et al. **Clin Perinatol** 1999 Jun;26(2):361–77 (115 ref.)
Inflammatory mediators in saliva of patients with rapidly progressive periodontitis during war stress induced incidence increase. Aurer A, et al. **Coll Antropol** 1999 Jun; 23(1):117–24
The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome [see comments] Pugin J, et al. **Crit Care Med** 1999 Feb;27(2):304–12. Comment in: Crit Care Med 1999 Feb;27(2):237–8.
Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. Grootendorst DC, et al. **Eur Respir J** 1999 Mar;13(3):647–53
Diagnosing occupational asthma: use of induced sputum [see comments] Lemière C, et al. **Eur Respir J** 1999 Mar; 13(3):482–8. Comment in: Eur Respir J 1999 Mar;13(3):477–8.
NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Mattes J, et al. **Eur Respir J** 1999 Jun; 13(6):1391–5
Alpha2-macroglobulin and eosinophil cationic protein in the allergic airway mucosa in seasonal allergic rhinitis. Meyer P, et al. **Eur Respir J** 1999 Mar;13(3):633–7
Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Pesci A, et al. **Eur Respir J** 1998 Aug;12(2):380–6
Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Piacentini GL, et al. **Eur Respir J** 1999 Jun;13(6):1386–90
Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. Akiyama H, et al. **Glia** 1999 Feb 15;25(4):324–31
A quantitative immunohistochemical study on the time-dependent course of acute inflammatory cellular response to human brain injury. Hausmann R, et al. **Int J Legal Med** 1999;112(4):227–32
Histamine and tryptase in nasal lavage fluid after allergen challenge: effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine. Jacobi HH, et al. **J Allergy Clin Immunol** 1999 May;103(5 Pt 1):768–72
RANTES, macrophage-inhibitory protein 1alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children. Teran LM, et al. **J Infect Dis** 1999 Mar;179(3):677–81
The relationship between concentrations of proinflammatory cytokines within gingiva and the adjacent sulcular depth. McGee JM, et al. **J Periodontol** 1998 Aug;69(8):865–71
Ratio of eosinophil cationic protein/eosinophil count as a new marker in children with acute asthma. Imai C, et al. **Pediatr Int** 1999 Apr;41(2):142–6
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Groneck P, et al. **Pediatr Pulmonol** 1999 Jun;27(6):383–7
Quantification of cytokines and inflammatory mediators in samples of nasopharyngeal secretions with unknown dilution. Heikkinen T, et al. **Pediatr Res** 1999 Feb; 45(2):230–4
Suppression of airway inflammation by theophylline in adult bronchial asthma. Horiguchi T, et al. **Respiration** 1999; 66(2):124–7

ANTAGONISTS & INHIBITORS

The taming of IL-12: suppressing the production of proinflammatory cytokines. Sutterwala FS, et al. **J Leukoc Biol** 1999 May;65(5):543–51 (82 ref.)
Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome. Lo CJ, et al. **J Surg Res** 1998 Oct; 79(2):179–84
Inhibition of proinflammatory cytokine production by pravastatin [letter] Rosenson RS, et al. **Lancet** 1999 Mar 20;353(9157):983–4
Glomerulonephritis [letter] Wardle EN. **Lancet** 1999 Jul 31; 354(9176):429

BLOOD

Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. Adelson PD, et al. **Acta Neurochir Suppl (Wien)** 1998;71:104–6
Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Chen CC, et al. **Am J Gastroenterol** 1999 Jan;94(1):213–8
Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Straub RH, et al. **Am J Gastroenterol** 1998 Nov;93(11):2197–202
Mechanical ventilation affects local and systemic cytokines in an animal model of acute respiratory distress syndrome. Chiumello D, et al. **Am J Respir Crit Care Med** 1999 Jul; 160(1):109–16
Prediction of clinical severity and outcome of ventilator-associated pneumonia. Comparison of simplified acute physiology score with systemic inflammatory mediators. Froon AH, et al. **Am J Respir Crit Care Med** 1998 Oct;158(4):1026–31
Influence of different autotransfusion devices on the quality of salvaged blood. Reents W, et al. **Ann Thorac Surg** 1999 Jul;68(1):58–62
Effects of pranlukast hydrate on serum eosinophil cationic protein levels in patients with adult bronchial asthma. Horiguchi T, et al. **Arzneimittelforschung** 1999 Jan;

49(1):35-7

Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Granerus G, et al. **Br J Dermatol** 1998 Nov;139(5):858-61

Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Wolter JM, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):260-5

Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks FM, et al. **Herz** 1999 Feb; 24(1):51-6 (16 ref.)

Serum eosinophil cationic protein (ECP) as a mediator of inflammation in acute asthma, during resolution and during the monitoring of stable asthmatic patients treated with inhaled steroids according to a dose reduction schedule. Kunkel G, et al. **Inflamm Res** 1999 Feb;48(2):94-100

Effects of long-term hemofiltration on circulating mediators and superoxide production during continuous endotoxin administration. Ishihara S, et al. **J Trauma** 1999 May; 46(5):894-9

Inflammatory cytokines in newborn infants. Sarandakou A, et al. **Mediators Inflamm** 1998;7(5):309-12

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Lin A, et al. **Schizophr Res** 1998 Jun 22;32(1):9-15

[Levels of eosinophil cationic protein in serum of infants with wheezy bronchitis] Bręborowicz A, et al. **Pneumonol Alergol Pol** 1998;66(7-8):361-7 (Eng. Abstr.) **(Pol)**

[Anti-inflammatory cytokine in early diagnosis of endometritis after Cesarean section] Belokrinitskaia TE, et al. **Klin Lab Diagn** 1999 Apr;(4):24, 33-5 (Eng. Abstr.) **(Rus)**

CEREBROSPINAL FLUID

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Lanzrein AS, et al. **Alzheimer Dis Assoc Disord** 1998 Sep;12(3):215-27

Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Sharief MK, et al. **Neurology** 1999 Apr 12;52(6):1289-91

IMMUNOLOGY

Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Anwaar I, et al. **Cerebrovasc Dis** 1998 Nov-Dec;8(6):310-7

Interaction of human mast cell tryptase with endothelial cells to stimulate inflammatory cell recruitment. Compton SJ, et al. **Int Arch Allergy Immunol** 1999 Feb-Apr; 118(2-4):204-5

Inflammatory mediators in heart failure: homogeneity through heterogeneity [comment] Mann DL. **Lancet** 1999 May 29;353(9167):1812-3. Comment on: Lancet 1999 May 29;353(9167):1838-42.

[The role of inflammation mediators in bronchial asthma and chronic obstructive pulmonary disease (editorial)] Chciałowski A, et al. **Pol Merkuriusz Lek** 1999 Jan; 6(31):1-4 (34 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Kinetics of inflammatory parameters after intestinal ischemia reperfusion injury. Braun F, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):226-8

Asthma: an inflammatory mediator soup. Björnsdottir US, et al. **Allergy** 1999;54 Suppl 49:55-61

Is childhood asthma an inflammatory disease? van Aalderen WM, et al. **Allergy** 1999;54 Suppl 49:62-7

Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Carlson M, et al. **Am J Gastroenterol** 1999 Jul;94(7):1876-83

Sex steroids regulate pro- and anti-inflammatory cytokine release by macrophages after trauma-hemorrhage. Angele MK, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):C35-42

Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall. Dai J, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1907-13

Cerebrovascular cytokine responses during coronary artery bypass surgery: specific production of interleukin-8 and its attenuation by hypothermic cardiopulmonary bypass. Nandate K, et al. **Anesth Analg** 1999 Oct;89(4):823-8

Sex hormones modulate inflammatory mediators produced by macrophages. D'Agostino P, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:426-9

Expression of bone-resorptive and regulatory cytokines in murine periapical inflammation. Kawashima N, et al. **Arch Oral Biol** 1999 Jan;44(1):55-66

Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Melchiorri C, et al. **Arthritis Rheum** 1998 Dec;41(12):2165-74

A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Plötz FB, et al. **Artif Organs** 1992 Aug;16(4):366-70

Comparative evaluation of the inflammatory mediators in patients undergoing laparoscopic versus conventional cholecystectomy. Chaudhary D, et al. **Aust N Z J Surg** 1999 May;69(5):369-72

Involvement of endothelin-1 in up-regulation of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. Slomiany BL, et al. **Biochem Biophys Res Commun** 1999 Apr 29;258(1):17-20

Dephosphorylation of the catenins p120 and p100 in endothelial cells in response to inflammatory stimuli. Ratcliffe MJ, et al. **Biochem J** 1999 Mar 1;338 (Pt 2):471-8

Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. Ng T. **Br J Hosp Med** 1998 Nov 19-Dec 9;58(10):521-3 (17 ref.)

Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. Ren L, et al. **Brain Res Mol Brain Res** 1999 Mar 5;65(2):198-205

Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Nicoletti A, et al. **Cardiovasc Res** 1999 Mar;41(3):532-43 (123 ref.)

Neuroendocrine-induced synthesis of bone marrow-derived cytokines with inflammatory immunomodulating properties. Whetsell M, et al. **Cell Immunol** 1999 Mar 15; 192(2):159-66

Choosing the appropriate control [letter; comment] Morris PE, et al. **Chest** 1999 Apr;115(4):1214-5. Comment on: Chest 1998 Jun;113(6):1632-9.

Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Rajavashisth TB, et al. **Circulation** 1999 Jun 22;99(24):3103-9

Pharmacological regulation of mediator release from human mast cells [editorial; comment] Forsythe P, et al. **Clin Exp Allergy** 1998 Oct;28(10):1171-3. Comment on: Clin Exp Allergy 1998 Oct;28(10):1228-36.

The effects of anti-asthma drugs on mediator release from cultured human mast cells [see comments] Shichijo M, et al. **Clin Exp Allergy** 1998 Oct;28(10):1228-36. Comment in: Clin Exp Allergy 1998 Oct;28(10):1171-3.

Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhinitics following exposure to nitrogen dioxide [see comments] Wang JH, et al. **Clin Exp Allergy** 1999 Feb;29(2):234-40. Comment in: Clin Exp Allergy 1999 Feb;29(2):150-4.

The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Smith CW, et al. **Clin Exp Metastasis** 1998 Oct;16(7):655-64

The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization. Lu PD, et al. **Clin Immunol** 1999 Mar;90(3):360-7

Regulation and metabolism of arachidonic acid. Seeds MC, et al. **Clin Rev Allergy Immunol** 1999 Spring-Summer; 17(1-2):5-26 (114 ref.)

Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo. Utsunomiya I, et al. **Cytokine** 1998 Dec;10(12):956-63

Novel pathways for negative regulation of inflammatory cytokines centered on receptor expression. Mantovani A, et al. **Dev Biol Stand** 1999;97:97-104 (50 ref.)

Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. Suarez-Pinzon W, et al. **Diabetes** 1999 Jan;48(1):21-8

Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro. Juergens UR, et al. **Eur J Med Res** 1998 Nov 17;3(11):508-10

Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: role of prostaglandins and modulation by paracetamol. Landolfi C, et al. **Eur J Pharmacol** 1998 Oct 30;360(1):55-64

The sialyl Lewis X analogue, CY-1503, down-regulates leucocyte-endothelium interactions and the inflammatory response. Garcia-Criado FJ, et al. **Eur J Surg** 1999 Jul; 165(7):690-7

Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Artuc M, et al. **Exp Dermatol** 1999 Feb;8(1):1-16 (195 ref.)

The importance of inflammatory mechanisms in Alzheimer disease. McGeer EG, et al. **Exp Gerontol** 1998 Aug; 33(5):371-8 (22 ref.)

Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Paris D, et al. **Exp Neurol** 1999 May;157(1):211-21

Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines. Bidri M, et al. **Immunopharmacology** 1999 Jun;43(1):75-86

Autoregulatory effect of interleukin-10 on proinflammatory cytokine production by Porphyromonas gingivalis lipopolysaccharide-tolerant human monocytes. Shimauchi H, et al. **Infect Immun** 1999 May;67(5):2153-9

Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Blann AD, et al. **Inflammation** 1998 Oct; 22(5):483-91

Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. Bayram H, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):93-9

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients and the effect of diesel exhaust particles in vitro. Bayram H, et al. **J Allergy Clin Immunol** 1998 Nov;102(5):771-82

Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the mucosa of the small intestine in infants with cow's milk-sensitive enteropathy. Chung HL, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1195-201

The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. Klimek L, et al. **J Allergy Clin Immunol** 1999 Jan;103(1 Pt 1):47-53

Clinical manifestations of the release of histamine and other inflammatory mediators. Naclerio R. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S382-5 (42 ref.)

The significance of sputum ECP levels in differential diagnosis of asthma in children. Yazicioğlu M, et al. **J Asthma** 1999 Sep;36(6):493-502

Roles of Trp31 in high membrane binding and proinflammatory activity of human group V phospholipase A2. Han SK, et al. **J Biol Chem** 1999 Apr 23; 274(17):11881-8

Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines. Hu MC, et al. **J Biol Chem** 1999 Mar 12;274(11):7095-102

Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity. Majcherczyk PA, et al. **J Biol Chem** 1999 Apr 30;274(18):12537-43

The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. Hermann P, et al. **J Cell Biol** 1999 Feb 22;144(4):767-75

Influence of OAS-1000 on mediators of inflammation. Scherl DS, et al. **J Clin Periodontol** 1999 Apr;26(4):246-51

Direct interaction between gingival fibroblasts and lymphoid cells induces inflammatory cytokine mRNA expression in gingival fibroblasts. Murakami S, et al. **J Dent Res** 1999 Jan;78(1):69-76

C-reactive protein: a physiological activator of interleukin 6 receptor shedding. Jones SA, et al. **J Exp Med** 1999 Feb 1;189(3):599-604

Hepatic Kupffer cell blockade reduces mortality of acute hemorrhagic pancreatitis in mice. Gloor B, et al. **J Gastrointest Surg** 1998 Sep-Oct;2(5):430-5

Enzyme histochemistry of tryptase in stomach mucosal mast cells of the mouse. Valchanov KP, et al. **J Histochem Cytochem** 1999 May;47(5):617-22

Differential induction of adhesion molecule and chemokine expression by LTalpha3 and LTalphabeta in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. Cuff CA, et al. **J Immunol** 1999 May 15;162(10):5965-72

Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. Ensoli F, et al. **J Immunol** 1999 May 15;162(10):6268-77

Mast cells express novel CD8 molecules that selectively modulate mediator secretion. Lin TJ, et al. **J Immunol** 1998 Dec 1;161(11):6265-72

Local production of inflammatory mediators in an experimental model of acute obstructive pyelonephritis. Kaboré AF, et al. **J Infect Dis** 1999 May;179(5):1162-72

Bacterial peptidoglycan polysaccharides in sterile human spleen induce proinflammatory cytokine production by human blood cells. Schrijver IA, et al. **J Infect Dis** 1999 Jun;179(6):1459-68

Inhibitors of PI 3-kinase and MEK kinase differentially affect mediator secretion from immunologically activated human basophils. Gibbs BF, et al. **J Leukoc Biol** 1999 Jun; 65(6):883-90

Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. Buckley MG, et al. **J Pathol** 1998 Sep;186(1):67-74

Increased concentrations of eosinophilic cationic protein in whole-gut lavage fluid from children with inflammatory bowel disease. Troncone R, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):164-8

Progress in understanding ventilator-induced lung injury [editorial; comment] Hudson LD. **JAMA** 1999 Jul 7; 282(1):77-8. Comment on: JAMA 1999 Jul 7;282(1):54-61.

Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial [see comments] Ranieri VM, et al. **JAMA** 1999 Jul 7;282(1):54-61. Comment in: JAMA 1999 Jul 7;282(1):77-8.

Statins and monocytes [letter] Ikeda U, et al. **Lancet** 1999 Jun 12;353(9169):2070

Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease [see comments] Schreiber S, et al. **Lancet** 1999 Feb 6;353(9151):459-61. Comment in: Lancet 1999 Feb 6;353(9151):425-6.

Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men. Kelley DS, et al. **Lipids** 1999 Apr; 34(4):317–24

Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Spokas EG, et al. **Methods Mol Biol** 1999;120:213–47 (145 ref.)

Evaluation of the efficacy of a bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release. Garry MG, et al. **Pain** 1999 Jul; 82(1):49–55

Inflammatory mediators of asthma: an update. Barnes PJ, et al. **Pharmacol Rev** 1998 Dec;50(4):515–96 (1481 ref.)

Complement, cytokines, and adhesion molecule expression in inflammatory reactions. Czermak BJ, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):306–12 (29 ref.)

Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Maes M, et al. **Psychiatry Res** 1999 Mar 22;85(3):275–91

Immunopathologic responses to non-lethal sepsis. Ebong SJ, et al. **Shock** 1999 Aug;12(2):118–26

Inflammatory cytokine production enhancement in the presence of lipopolysaccharide after hepatic resection in cirrhotic patients. Sato T, et al. **Ther Apher** 1997 Feb; 1(1):75–8

Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. Fearon KC, et al. **World J Surg** 1999 Jun;23(6):584–8 (25 ref.)

[Histamine as a mediator of allergic inflammation (editorial)] Pietrzkowicz M, et al. **Pol Merkuriusz Lek** 1999 May; 6(35):232–5 (46 ref.) (Eng. Abstr.) **(Pol)**

[Host microflora and its role in response to infection] Beloborodova NV. **Antibiot Khimioter** 1998;43(9):44–8 **(Rus)**

PHARMACOLOGY

Release of granule proteins from human eosinophils stimulated with mast-cell mediators. Takafuji S, et al. **Allergy** 1998 Oct;53(10):951–6

Effects of eosinophil granule major basic protein on phosphatidylcholine secretion in rat type II pneumocytes. Okumura M, et al. **Am J Physiol** 1999 May;276(5 Pt 1):L763–8

Pre- and postjunctional effects of inflammatory mediators in horse airways. Olszewski MA, et al. **Am J Physiol** 1999 Aug;277(2 Pt 1):L327–33

Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Pugin J, et al. **Am J Respir Cell Mol Biol** 1999 Mar; 20(3):458–64

Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Piscaglia F, et al. **Biochem Pharmacol** 1999 Jul 1;58(1):157–65

The effects of inflammation and inflammatory mediators on nociceptive behaviour induced by ATP analogues in the rat. Hamilton SG, et al. **Br J Pharmacol** 1999 Jan; 126(1):326–32

Taurine chloramine inhibits production of nitric oxide and prostaglandin E2 in activated C6 glioma cells by suppressing inducible nitric oxide synthase and cyclooxygenase-2 expression. Liu Y, et al. **Brain Res Mol Brain Res** 1998 Aug 31;59(2):189–95

The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Pariante CM, et al. **Endocrinology** 1999 Sep;140(9):4359–66

Taurine chloramine down-regulates the generation of murine neutrophil inflammatory mediators. Marcinkiewicz J, et al. **Immunopharmacology** 1998 Jul;40(1):27–38

In vitro effect of the extract and the 1,7-dihydroxy-2,3-dimethoxy xanthone from Polygala cyparissias on the contractions induced by inflammatory mediators and ovalbumin in normal and actively sensitised trachea from guinea pig. El Sayah M, et al. **Inflamm Res** 1999 Apr;48(4):218–23

Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. Aksoy MO, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1081–91

Proinflammatory macrophage-activating properties of the novel phospholipid diacylglycerol pyrophosphate. Balboa MA, et al. **J Biol Chem** 1999 Jan 1;274(1):522–6

Nitric oxide inhibits microvascular protein leakage induced by leukocyte adhesion-independent and adhesion-dependent inflammatory mediators. Johnston B, et al. **Microcirculation** 1999 Jun;6(2):153–62

The inflammatory reaction induced by formalin in the rat paw. Damas J, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1999 Mar; 359(3):220–7

Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Tonussi CR, et al. **Pain** 1999 Jul;82(1):81–7

Regulation of cytokine-induced neutrophil chemoattractant in rat bone marrow-derived macrophages by inflammatory mediators. Crippen TL, et al. **Pathobiology** 1998; 66(6):293–301

PHYSIOLOGY

Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Witko-Sarsat V, et al. **Adv Nephrol Necker Hosp** 1998; 28:321–41 (80 ref.)

Human eosinophil granule major basic protein and its novel homolog. Plager DA, et al. **Allergy** 1998;53(45 Suppl):33–40 (73 ref.)

Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. McGeer PL, et al. **Alzheimer Dis Assoc Disord** 1998;12 Suppl 2:S1–6 (40 ref.)

Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Guimbaud R, et al. **Am J Gastroenterol** 1998 Dec;93(12):2397–404

Mediators of anaphylaxis but not activated neutrophils augment cholinergic responses of equine small airways. Olszewski MA, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):L522–9

Interactions between prolactin and the proinflammatory cytokine network in juvenile chronic arthritis. Picco P, et al. **Ann N Y Acad Sci** 1999 Jun 22;876:262–5

Involvement of nitric oxide and biopterin in proinflammatory cytokine-induced apoptotic cell death in mouse osteoblastic cell line MC3T3-E1. Mogi M, et al. **Biochem Pharmacol** 1999 Aug 15;58(4):649–54

Effects of inflammatory mediators on gut sensitivity. Bueno L, et al. **Can J Gastroenterol** 1999 Mar;13 Suppl A:42A–46A (25 ref.)

Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Kessler P, et al. **Circulation** 1999 Apr 13; 99(14):1878–84

Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Svanborg C, et al. **Curr Opin Microbiol** 1999 Feb;2(1):99–105 (59 ref.)

New developments in the role of cytokines and chemokines in inflammatory myopathies. Lundberg IE, et al. **Curr Opin Rheumatol** 1998 Nov;10(6):521–9 (53 ref.)

Interleukin-8: An autocrine inflammatory mediator. Atta-ur-Rahman, et al. **Curr Pharm Des** 1999 Apr; 5(4):241–53 (175 ref.)

Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Rice KD, et al. **Curr Pharm Des** 1998 Oct; 4(5):381–96 (122 ref.)

Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Vallières L, et al. **Endocrinology** 1999 Sep;140(9):3890–903

Nerve injury and inflammatory cytokines modulate gap junctions in the peripheral nervous system. Chandross KJ. **Glia** 1998 Sep;24(1):21–31 (172 ref.)

Mediators of inflammation: production and implication in inflammatory bowel disease. Kolios G, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1601–9 (38 ref.)

Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. Lügering N, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):338–44 (62 ref.)

Mediators of inflammation and the inflammatory process. White M. **J Allergy Clin Immunol** 1999 Mar;103(3 Pt 2):S378–81 (42 ref.)

Emerging evidence for inflammation in conditions frequently affecting older adults: report of a symposium. Hamerman D, et al. **J Am Geriatr Soc** 1999 Aug;47(8):1016–25

Proinflammatory mediator release in response to particle challenge: studies using the bone harvest chamber. Trindade MC, et al. **J Biomed Mater Res** 1999;48(4):434–9

Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. Critchley HO, et al. **J Clin Endocrinol Metab** 1999 Jan; 84(1):240–8

Substance P regulates somatostatin expression in inflammation. Blum AM, et al. **J Immunol** 1998 Dec 1; 161(11):6316–22

Regulation of inflammatory responses by oncostatin M. Wallace PM, et al. **J Immunol** 1999 May 1;162(9):5547–55

Prostanoids: early mediators in the secondary injury that develops after unilateral pulmonary contusion. Davis KA, et al. **J Trauma** 1999 May;46(5):824–31; discussion 831–2

Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Sengoelge G, et al. **Kidney Int** 1998 Nov;54(5):1637–51

Mediators in polytrauma--pathophysiological significance and clinical relevance. Rose S, et al. **Langenbecks Arch Surg** 1998 Aug;383(3–4):199–208 (81 ref.)

The potential role of nitric oxide in multiple sclerosis. Giovannoni G, et al. **Mult Scler** 1998 Jun;4(3):212–6

Regulation of beta2-microglobulin expression in different human cell lines by proinflammatory cytokines. Vraetz T, et al. **Nephrol Dial Transplant** 1999 Sep;14(9):2137–43

The role of cytokines in bacterial pneumonia: an inflammatory balancing act. Moore TA, et al. **Proc Assoc Am Physicians** 1998 Jul–Aug;110(4):297–305 (81 ref.)

[Inflammatory mediator and organ dysfunction syndrome] Shimada H, et al. **Nippon Geka Gakkai Zasshi** 1998 Aug; 99(8):490–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Problems and perspective approaches to correction of mediator response in sepsis] Mironov PI, et al. **Anesteziol Reanimatol** 1999 May–Jun;(3):54–9 (50 ref.) **(Rus)**

[The regulatory functions of pro-inflammatory cytokines and acute-phase proteins] Freidlin IS, et al. **Vestn Ross Akad Med Nauk** 1999;(5):28–32 (23 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Antimicrobial effects of antiinflammatory drugs, antiinflammatory effects of antimicrobial drugs. Bannwarth B. **Rev Rhum Engl Ed** 1999 Jan 30;66(1 Suppl):73S–76S (44 ref.)

URINE

Urinary mediators and asthma [editorial; comment] Dworski R, et al. **Clin Exp Allergy** 1998 Nov;28(11):1309–12. Comment on: Clin Exp Allergy 1998 Nov;28(11):1332–9.

Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions [see comments] O'Sullivan S, et al. **Clin Exp Allergy** 1998 Nov;28(11):1332–9. Comment in: Clin Exp Allergy 1998 Nov;28(11):1309–12.

INFLAMMATORY BOWEL DISEASES

Inflammatory bowel disease in the elderly. Lindner AE. **Clin Geriatr Med** 1999 Aug;15(3):487–97 (37 ref.)

Inflammatory bowel disease in the pregnant woman. Hanan IM. **Compr Ther** 1998 Sep;24(9):409–14

Inflammatory bowel disease in pediatric and adolescent patients. Baldassano RN, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):445–58 (61 ref.)

Current theories on the causes of inflammatory bowel disease. Papadakis KA, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):283–96 (96 ref.)

Enteroscopy in small intestinal inflammatory diseases. Gay GJ, et al. **Gastrointest Endosc Clin N Am** 1999 Jan; 9(1):115–23 (38 ref.)

Clinical pearls from the 1998 FMAC/CMAC meeting. Wolf DC. **Inflamm Bowel Dis** 1999 May;5(2):144–5

Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. Irvine EJ. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S23–7 (14 ref.)

Impact of inflammatory bowel disease on educational achievements and work prospects. Mayberry JF. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S34–6 (9 ref.)

Nitric oxide and inflammatory bowel disease [letter; comment] Rabinowitz SS. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):372–3. Comment on: J Pediatr Gastroenterol Nutr 1998 Jan;26(1):34–8.

Practice guidelines for inflammatory bowel disease: an instrument for assessment. Tremaine WJ, et al. **Mayo Clin Proc** 1999 May;74(5):495–501

Inflammatory bowel disease. Griffiths AM. **Nutrition** 1998 Oct;14(10):788–91 (44 ref.)

Production and evaluation of guidelines for the management of inflammatory bowel disease: the Leicester experience. Read AM, et al. **Postgrad Med J** 1999 Mar;75(881):147–50

BLOOD

Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Straub RH, et al. **Am J Gastroenterol** 1998 Nov;93(11):2197–202

Serum ionized versus total magnesium in patients with intestinal or liver disease. Saha H, et al. **Clin Chem Lab Med** 1998 Sep;36(9):715–8

Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Giacomelli R, et al. **Clin Exp Immunol** 1999 Jan;115(1):72–7

Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease [see comments] Frenzer A, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):950–4. Comment in: J Gastroenterol Hepatol 1998 Sep;13(9):863–4.

The significance of pANCA in inflammatory bowel disease [editorial; comment] Radford-Smith GL, et al. **J Gastroenterol Hepatol** 1998 Sep;13(9):863–4. Comment on: J Gastroenterol Hepatol 1998 Sep;13(9):950–4.

Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. Heits F, et al. **J Interferon Cytokine Res** 1999 Jul;19(7):757–60

High prevalence of hyperchomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Cattaneo M, et al. **Thromb Haemost** 1998 Oct;80(4):542–5

[Erythropoietin in non-specific intestinal inflammation] Hertlová M, et al. **Vnitr Lek** 1998 Aug;44(8):451–5 (Eng. Abstr.) **(Cze)**

[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations] Klotz U. **Med Klin** 1999 Feb 15; 94 Suppl 1:16–22 (53 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Isotretinoin: possible component cause of inflammatory bowel disease [letter] Prokop LD. **Am J Gastroenterol** 1999

Sep;94(9):2568
Fall in MMR vaccine coverage reported as further evidence of vaccine safety is published.
Commun Dis Rep CDR Wkly 1999 Jun 25;9(26):227, 230
Idiopathic inflammatory bowel disease associated with colonic tattooing with india ink preparation--case report and review of literature. Gopal DV, et al.
Gastrointest Endosc 1999 May;49(5):636-9 (19 ref.)
Intestinal permeability and inflammation in patients on NSAIDs. Sigthorsson G, et al. **Gut** 1998 Oct;43(4):506-11
[Isotretinoin in inflammatory bowel diseases] Jansen T, et al. **Hautarzt** 1998 Aug;49(8):672-3 **(Ger)**
[Immunosuppressors and inflammatory bowel disease (letter)] Aparicio JR, et al. **Gastroenterol Hepatol** 1999 Apr; 22(4):206 **(Spa)**

COMPLICATIONS

Thromboembolism in inflammatory bowel disease. Schapira M, et al. **Acta Gastroenterol Belg** 1999 Apr-Jun;62(2):182-6 (55 ref.)
Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? [see comments] Barthet M, et al. **Am J Gastroenterol** 1999 Aug;94(8):2141-8 (42 ref.). Comment in: Am J Gastroenterol 1999 Aug;94(8):2001.
Evolution of osteopenia in inflammatory bowel disease. Dinca M, et al. **Am J Gastroenterol** 1999 May;94(5):1292-7
Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Novacek G, et al. **Am J Gastroenterol** 1999 Mar;94(3):685-90
Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Valentine JF, et al.
Am J Gastroenterol 1999 Apr;94(4):878-83 (40 ref.)
Benign anal lesions, inflammatory bowel disease and risk for high-risk human papillomavirus-positive and -negative anal carcinoma. Frisch M, et al. **Br J Cancer** 1998 Dec; 78(11):1534-8
Primary malignancies as a secondary disease [editorial; comment] Ekbom A. **Cancer Causes Control** 1998 Aug; 9(4):355-6. Comment on: Cancer Causes Control 1998 Aug;9(4):389-92. Comment on: Cancer Causes Control 1998 Aug;9(4):403-10.
Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Das KM. **Dig Dis Sci** 1999 Jan;44(1):1-13 (118 ref.)
Cytomegaloviral enterocolitis: clinical associations and outcome. Kaufman HS, et al. **Dis Colon Rectum** 1999 Jan; 42(1):24-30
A strategy for osteoporosis in gastroenterology. Scott EM, et al. **Eur J Gastroenterol Hepatol** 1998 Aug;10(8):689-96; discussion 696-8 (80 ref.)
Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423-43, ix (160 ref.)
Cancer risk in patients with inflammatory bowel disease. Lewis JD, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):459-77, x (101 ref.)
Hepatobiliary manifestations of inflammatory bowel disease. Raj V, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):491-513 (140 ref.)
Inflammatory bowel disease and the risk of thrombosis [letter; comment] Cattaneo M, et al. **Gastroenterology** 1999 Jul; 117(1):280-1. Comment on: Gastroenterology 1998 Oct;115(4):830-4.
Thrombosis, factor V Leiden, and inflammatory bowel disease [letter; comment] Shanahan F. **Gastroenterology** 1999 Mar;116(3):778-9. Comment on: Gastroenterology 1998 Oct;115(4):830-4.
Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Pardi DS, et al. **Gastrointest Endosc** 1999 Feb;49(2):153-7
The colon and PSC: new liver, new danger? [comment] Chapman RW. **Gut** 1998 Nov;43(5):595-6. Comment on: Gut 1998 Nov;43(5):639-44.
Hepatobiliary complications of inflammatory bowel disease: overview of the issues. Balistreri WF.
Inflamm Bowel Dis 1998 Aug;4(3):220-4 (37 ref.)
Bones and Crohn's: problems and solutions. Buchman AL. **Inflamm Bowel Dis** 1999 Aug;5(3):212-27 (214 ref.)
An approach to perirectal disease in inflammatory bowel disease. Cohen Z. **Inflamm Bowel Dis** 1999 Aug; 5(3):228-30; discussion 234
Risk factors and distinguishing features of cancer in IBD. Ekbom A. **Inflamm Bowel Dis** 1998 Aug;4(3):235-43 (86 ref.)
Malignancy and aneuploidy: prevention and early detection. Kirschner B. **Inflamm Bowel Dis** 1998 Aug;4(3):216-20 (25 ref.)
Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Schulte C, et al. **Inflamm Bowel Dis** 1998 Nov;4(4):268-75
Inflammatory bowel disease and osteoporosis [editorial] Ljunghall S, et al. **Ital J Gastroenterol Hepatol** 1999 Mar; 31(2):103-9 (86 ref.)
Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate [see comments] Mouzas IA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug; 30(4):421-5 (44 ref.). Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):426-7.
Fibromyalgia in inflammatory bowel disease. Buskila D, et al. **J Rheumatol** 1999 May;26(5):1167-71
Retinal vasculitis revealed by fluorescein angiography in patients with inflammatory bowel disease. Matsuo T, et al. **Jpn J Ophthalmol** 1998 Sep-Oct;42(5):398-400
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-1999. A 15-year-old girl with abdominal pain and bloody stools [clinical conference] **N Engl J Med** 1999 Jan 21;340(3):215-21
Metabolic problems in inflammatory bowel disease. Allan RN. **Neth J Med** 1998 Dec;53(6):S9-12 (13 ref.)
Growth failure in inflammatory bowel disease [editorial] McCartney S, et al. **Nutrition** 1999 Feb;15(2):169-71 (24 ref.)
Inflammatory bowel diseases and the oral cavity. Siegel MA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Jan;87(1):12-4
Metabolic bone disease in patients with inflammatory bowel disease [editorial] Bjarnason I. **Rheumatology (Oxford)** 1999 Sep;38(9):801-4
The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A [letter] Capella GL, et al.
Scand J Gastroenterol 1999 Feb;34(2):220-1
Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Rasmussen HH, et al.
Scand J Gastroenterol 1999 Feb;34(2):199-201
Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Schulte C, et al.
Scand J Gastroenterol 1999 Jul;34(7):696-702
[Thrombotic symptoms in inflammatory intestinal disease (letter)] Bujanda L, et al. **Gastroenterol Hepatol** 1998 Dec; 21(10):498-9 **(Spa)**

DIAGNOSIS

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al.
Aliment Pharmacol Ther 1998 Nov;12(11):1039-53 (127 ref.)
Calcaneal ultrasound bone densitometry in inflammatory bowel disease--a comparison with double x-ray densitometry of the lumbar spine. Fries W, et al.
Am J Gastroenterol 1998 Dec;93(12):2339-44
Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Roozendaal C, et al. **Clin Exp Immunol** 1999 May; 116(2):206-13 (106 ref.)
Inflammatory bowel disease. Schölmerich J. **Endoscopy** 1999 Jan;31(1):66-73 (40 ref.)
Imaging modalities in inflammatory bowel disease. Scotiniotis I, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):391-421, ix (37 ref.)
Is antibody testing for inflammatory bowel disease clinically useful? Panaccione R, et al. **Gastroenterology** 1999 Apr; 116(4):1001-2; discussion 1002-3
Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. Heikenen JB, et al.
Inflamm Bowel Dis 1999 Aug;5(3):158-60
The utility of ANCA and ASCA in inflammatory bowel disease. Targan SR. **Inflamm Bowel Dis** 1999 Feb;5(1):61-3; discussion 66-7 (7 ref.)
Inflammatory bowel disease in Saudi Arabia: presentation and initial management. Isbister WH, et al.
J Gastroenterol Hepatol 1998 Nov;13(11):1119-24
Serologic testing for inflammatory bowel disease. Hoffenberg EJ, et al. **J Pediatr** 1999 Apr;134(4):447-52
Appropriate investigation of inflammatory bowel disease in children. Stringer MD, et al. **J R Soc Med** 1998 Nov; 91(11):589-91
Findings of colonoscopy in children: experience from Kuwait. Kalaoui M, et al. **J Trop Pediatr** 1998 Dec; 44(6):371-5
Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. El Maghraoui A, et al.
Rheumatology (Oxford) 1999 Jun;38(6):543-6
[A child with puzzling complaints--does he have a disease? (see comments)] de Ridder L, et al.
Ned Tijdschr Geneeskd 1998 Dec 19;142(51):2769-72 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Dec 19;142(51):2769-72. Comment in: Ned Tijdschr Geneeskd 1999 Apr 24;143(17):919. **(Dut)**
[Unconventional imaging techniques in inflammatory bowel diseases] Wasser MN, et al. **Ned Tijdschr Geneeskd** 1998 Oct 3;142(40):2179-86 (31 ref.) (Eng. Abstr.) **(Dut)**
[Chronic inflammatory bowel diseases in the child: clinical aspects] Hugot JP, et al. **Arch Pediatr** 1998;5 Suppl 2:101s-104s (17 ref.) **(Fre)**
[Diagnostic and therapeutic management of patients with chronic inflammatory bowel disease] Grandbastien B, et al. **Rev Epidemiol Sante Publique** 1999 Mar;47(1):45-53 (Eng. Abstr.) **(Fre)**
[Inflammatory bowel disease in children] Goulet O.
Rev Prat 1998 Feb 15;48(4):403-9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Interventional endoscopy in chronic inflammatory bowel disease] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):967-71 (41 ref.) **(Ger)**
[Guidelines for the anatomopathological diagnosis of chronic idiopathic inflammatory bowel disease] Cornaggia M, et al. **Pathologica** 1999 Feb;91(1):42-8 (7 ref.) **(Ita)**
[Comparison of endoscopy, radiology and scintigraphy with Tc-99m-exametazine labeled leukocytes and In-111 labeled human polyclonal immunoglobulin G in the diagnosis of inflammatory bowel disease] de Lima Ramos PA, et al. **Med Clin (Barc)** 1998 Sep 12;111(7):241-6 (Eng. Abstr.) **(Spa)**
[Inflammatory bowel disease in children and adolescents. When can the diagnosis be excluded without a referral to a pediatric gastroenterologist?] Bennet R. **Lakartidningen** 1999 Jan 6;96(1-2):49-51 **(Swe)**

DIET THERAPY

Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Green TJ, et al.
Can J Gastroenterol 1998 Nov-Dec;12(8):544-9
Nutrition and inflammatory bowel disease. Han PD, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):423-43, ix (160 ref.)
Nutritional modulation of gut inflammation. Rowlands BJ, et al. **Proc Nutr Soc** 1998 Aug;57(3):395-401 (49 ref.)
[Food as complement to drugs. Special diet with cereals for relief in inflammatory bowel disease] Orn P.
Lakartidningen 1999 Jun 2;96(22):2757-60 **(Swe)**

DRUG THERAPY

Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Marteau P, et al.
Aliment Pharmacol Ther 1998 Nov;12(11):1101-8
Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Simmonds NJ, et al. **Aliment Pharmacol Ther** 1999 Mar; 13(3):363-72
For pancreatitis in inflammatory bowel disease, treat the bowel [editorial; comment] Conwell DL, et al.
Am J Gastroenterol 1999 Aug;94(8):2001. Comment on: Am J Gastroenterol 1999 Aug;94(8):2141-8.
Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies. Neurath MF, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:315-8
Patients with inflammatory bowel disease: their response to information leaflets about medical therapy in particular azathioprine. Ward B, et al. **Arq Gastroenterol** 1998 Oct-Dec;35(4):264-6
Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia. Yamada H, et al. **Biopharm Drug Dispos** 1999 Mar;20(2):77-83
Antibiotics. Borgaonkar MR, et al. **Can J Gastroenterol** 1998 Sep;12(6):390-1
Malpractice and avascular necrosis: legal outcomes. Carter RM. **Can J Gastroenterol** 1999 Jan-Feb;13(1):79-84
Stereoselective metabolism of tazofelone, an anti-inflammatory bowel disease agent, in rats and dogs and in human liver microsomes. Clay MP, et al.
Chirality 1999;11(3):233-40
Lipid treatment of inflammatory bowel disease. Endres S, et al. **Curr Opin Clin Nutr Metab Care** 1999 Mar; 2(2):117-20 (21 ref.)
Medical therapy of inflammatory bowel disease for the 21st century. Robinson M. **Eur J Surg Suppl** 1998;(582):90-8 (64 ref.)
Medical therapy of specific clinical presentations. Michetti P, et al. **Gastroenterol Clin North Am** 1999 Jun; 28(2):353-70, viii (146 ref.)
Medical therapy for inflammatory bowel disease. Stein RB, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):297-321 (252 ref.)
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction [letter; comment] Lowry PW, et al. **Gastroenterology** 1999 Jun;116(6):1505-6. Comment on: Gastroenterology 1998 Jan;114(1):15-22.
Effect of short-term topical corticosteroid treatment on mucosal enzyme systems in patients with distal inflammatory bowel disease. Scheurlen C, et al.
Hepatogastroenterology 1998 Sep-Oct;45(23):1539-45
Novel treatments in inflammatory bowel disease. Pathmakanthan S, et al. **Hosp Med** 1999 Jan;60(1):19-23 (20 ref.)
Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Egan LJ, et al.
Inflamm Bowel Dis 1999 Aug;5(3):167-73
Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Modigliani R.
Inflamm Bowel Dis 1998 Aug;4(3):244-7; discussion 253-4 (9 ref.)
Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Schölmerich J.
Inflamm Bowel Dis 1998 Aug;4(3):248-52; discussion 253-4 (21 ref.)
Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. Korelitz BI, et al.
J Clin Gastroenterol 1999 Jun;28(4):341-4
More evidence of the failure of oral cyclosporine to maintain remission due to intravenous cyclosporine in IBD [editorial; comment] Korelitz BI. **J Clin Gastroenterol** 1999 Sep; 29(2):115-6. Comment on: J Clin Gastroenterol 1999 Sep;29(2):151-3.
Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel

disease (IBD). Leopold CS, et al. **J Drug Target** 1998; 6(2):85–94

Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Day R, et al. **Lancet** 1999 Jul 3; 354(9172):62–5 (37 ref.)

Protease inhibitors on trial for inflammatory bowel disease [news] Bonn D. **Mol Med Today** 1998 Nov;4(11):461

The simultaneous treatment of inflammatory bowel diseases and associated pyoderma gangrenosum with oral cyclosporin A [letter] Capella GL, et al. **Scand J Gastroenterol** 1999 Feb;34(2):220–1

[Pregnancy outcome in inflammatory bowel diseases] Tennenbaum R, et al. **Gastroenterol Clin Biol** 1999 May; 23(5):464–9 (Eng. Abstr.) **(Fre)**

[Osteoporosis in chronic inflammatory bowel diseases—what is the value of fluoride therapy? Symposium: "Osteopenia, osteoporosis in chronic inflammatory bowel diseases". Saalfelden, 10 October 1998] **Dtsch Med Wochenschr** 1998 Dec;123(51–52 Suppl Osteoporos):1–4 **(Ger)**

[Budesonide for chronic inflammatory bowel diseases] Nguyen HN. **Dtsch Med Wochenschr** 1998 Oct 16; 123(42):1258–9 **(Ger)**

["Targeted delivery" in the gastrointestinal tract] Leopold CS. **Med Klin** 1999 Feb 15;94 Suppl 1:6–11 (78 ref.) (Eng. Abstr.) **(Ger)**

[Galenic aspects and therapy of chronic inflammatory bowel diseases. Introduction] Schölmerich J. **Med Klin** 1999 Feb 15;94 Suppl 1:3 **(Ger)**

[Methotrexate in therapy of gastrointestinal diseases] Schröder O, et al. **Z Gastroenterol** 1999 Jul;37(7):623–37 (103 ref.) (Eng. Abstr.) **(Ger)**

[Effect of plaunotol on trinitrobenzene sulfonic acid and acetic acid induced colonic lesions in rats] Makino M, et al. **Nippon Yakurigaku Zasshi** 1998 Aug;112(2):97–106 (Eng. Abstr.) **(Jpn)**

ECONOMICS

[Cost of early management of chronic inflammatory intestinal disease] Rolland N, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):483–8 (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Expression of matrix metalloproteases in inflammatory bowel disease. Baugh MD, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:249–53

TNF-alpha-converting enzyme activity in colonic biopsy specimens from patients with inflammatory bowel disease revealed by mRNA and in vitro assay. Føgh P, et al. **Ann N Y Acad Sci** 1999 Jun 30;878:692–5

High expression of inducible nitric oxide synthase correlates with intestinal inflammation of interleukin-2-deficient mice. Harren M, et al. **Ann N Y Acad Sci** 1998 Nov 17; 859:210–5

Investigation of the expression of IL-1beta converting enzyme and apoptosis in normal and inflammatory bowel disease (IBD) mucosal macrophages. McAlindon ME, et al. **Clin Exp Immunol** 1999 May;116(2):251–7

EPIDEMIOLOGY

Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. de Boer AG, et al. **Eur J Gastroenterol Hepatol** 1998 Sep; 10(9):783–9

Epidemiology and the natural course of inflammatory bowel disease. Andres PG, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):225–81, vii (125 ref.)

What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients? Bayraktar Y, et al. **Hepatogastroenterology** 1998 Nov–Dec; 45(24):2064–72

Stress and physical activity: are they risk factors for IBD? [comment] Cottone M. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):252–3. Comment on: Ital J Gastroenterol Hepatol 1998 Jun;30(3):247–51.

Preillness non dietary factors and habits in inflammatory bowel disease [see comments] Klein I, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):247–51. Comment in: Ital J Gastroenterol Hepatol 1998 Jun;30(3):252–3.

Estimated incidence of inflammatory bowel disease in Argentina and Panama (1987–1993). Linares de la Cal JA, et al. **Rev Esp Enferm Dig** 1999 Apr;91(4):277–86 **(Eng, Spa)**

Incidence of inflammatory bowel disease in the 02 health area of Castellon (1992–1996). Monferrer Guardiola R, et al. **Rev Esp Enferm Dig** 1999 Jan;91(1):33–46 **(Eng, Spa)**

Bowel inflammation and the spondyloarthropathies. De Keyser F, et al. **Rheum Dis Clin North Am** 1998 Nov; 24(4):785–813, ix-x (146 ref.)

[Tobacco and chronic inflammatory bowel disease (editorial; comment)] García Paredes J. **Rev Esp Enferm Dig** 1998 Dec;90(12):829–32. Comment on: Rev Esp Enferm Dig 1998 Dec;90(12):833–40. Comment on: Rev Esp Enferm Dig 1998 Dec;90(12):870–6. **(Spa)**

ETIOLOGY

Review article: the potential role of nitric oxide in chronic inflammatory bowel disorders. Perner A, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):135–44 (92 ref.)

Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: update. Amin J, et al. **Commun Dis Intell** 1999 Aug 5;23(8):222

Genetics of inflammatory bowel disease. The candidate gene approach: susceptibility versus disease heterogeneity. Peña AS. **Dig Dis** 1998 Nov–Dec;16(6):356–63 (89 ref.)

Epidemiology and the natural course of inflammatory bowel disease. Andres PG, et al. **Gastroenterol Clin North Am** 1999 Jun;28(2):225–81, vii (125 ref.)

Early virus infections and inflammatory bowel disease: back to the drawing board? [editorial; comment] Ekbom A. **Gastroenterology** 1999 Apr;116(4):988–9. Comment on: Gastroenterology 1999 Apr;116(4):796–803.

Paramyxovirus infections in childhood and subsequent inflammatory bowel disease [see comments] Montgomery SM, et al. **Gastroenterology** 1999 Apr;116(4):796–803. Comment in: Gastroenterology 1999 Apr;116(4):988–90.

Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Bhan AK, et al. **Immunol Rev** 1999 Jun;169:195–207 (135 ref.)

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Kollias G, et al. **Immunol Rev** 1999 Jun;169:175–94 (198 ref.)

Multiple lymphomatous polyposis presenting as inflammatory bowel disease. Srivastava A, et al. **Indian J Gastroenterol** 1998 Oct–Dec;17(4):151–2

Etiopathogenesis of inflammatory bowel disease: a pediatric perspective. Seidman E. **Inflamm Bowel Dis** 1998 Aug; 4(3):204–9 (65 ref.)

Etiology of the inflammatory bowel diseases. Hugot JP, et al. **Int J Colorectal Dis** 1999 Feb;14(1):2–9 (52 ref.)

A role for transcription factor NF-kappa B in intestinal inflammation. Schottelius AJ, et al. **Int J Colorectal Dis** 1999 Feb;14(1):18–28 (132 ref.)

Is there a link between measles and inflammatory bowel disease? [see comments] Feeney M, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):383–4. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):378–82.

Cancer, inflammatory bowel disease, and the fecal stream [editorial; comment] Floch MH. **J Clin Gastroenterol** 1998 Dec;27(4):283–4. Comment on: J Clin Gastroenterol 1998 Sep;27(2):99–100.

Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. Liu Z, et al. **J Immunol** 1999 Oct 1; 163(7):4049–57

Clonal expansion of CD4+ TCRbetabeta+ T cells in TCR alpha-chain- deficient mice by gut-derived antigens. Takahashi I, et al. **J Immunol** 1999 Feb 1;162(3):1843–50

Inflammatory bowel disease, autism, and the measles, mumps, and rubella vaccine. Akobeng AK, et al. **J Pediatr Gastroenterol Nutr** 1999 Mar;28(3):351–2

Measles vaccination and inflammatory bowel disease. Stokkers PC, et al. **J Pediatr Gastroenterol Nutr** 1998 Aug; 27(2):239–40

Toward a biobehavioral model of visceral hypersensitivity in irritable bowel syndrome [editorial] Naliboff BD, et al. **J Psychosom Res** 1998 Dec;45(6):485–92 (48 ref.)

A nutritional component to inflammatory bowel disease: the contribution of meat to fecal sulfide excretion [editorial] Magee E. **Nutrition** 1999 Mar;15(3):244–6 (45 ref.)

[Pathogenesis: immunologic, infectious and genetic aspects] Colombel JF, et al. **Arch Pediatr** 1998;5 Suppl 2:97s–100s (38 ref.) **(Fre)**

[Progress in research of etiology and pathogenesis of chronic inflammatory bowel diseases] Dignass A, et al. **Internist (Berl)** 1998 Oct;39(10):1004–12 (56 ref.) **(Ger)**

[Intestinal complications of celiac disease in adults. A case of ulcerative enteritis] Salerno G, et al. **Radiol Med (Torino)** 1999 Jan–Feb;97(1–2):94–5 **(Ita)**

[Cytokines and gut] Shimada T, et al. **Nippon Rinsho** 1998 Sep;56(9):2235–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Hampe J, et al. **Am J Hum Genet** 1999 Mar;64(3):808–16

Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Cavanaugh JA, et al. **Ann Hum Genet** 1998 Jul;62 (Pt 4):291–8

Regulation of protein-DNA interactions at the interferon-gamma gene promoter by corticosteroids. Implications for inflammatory bowel diseases. Barbulescu K, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:194–7

Risk of colorectal cancer in relatives of patients with inflammatory bowel disease (Denmark) [see comments] Fonager K, et al. **Cancer Causes Control** 1998 Aug; 9(4):389–92. Comment in: Cancer Causes Control 1998 Aug;9(4):355–6.

Importance of CD44 variant isoforms in mouse models for inflammatory bowel disease. Günthert U. **Curr Top Microbiol Immunol** 1999;246:307–12; discussion 313 (25 ref.)

Proceedings of the World Congresses of Gastroenterology. Vienna, Austria, September 6–11, 1998. **Dig Dis** 1998 Nov–Dec;16(6):327–78

Genetic epidemiology in inflammatory bowel disease. Binder V. **Dig Dis** 1998 Nov–Dec;16(6):351–5 (27 ref.)

Genetics of IBD: Where do we stand? Introduction. Colombel JF. **Dig Dis** 1998 Nov–Dec;16(6):349–50

Genome-wide scanning in inflammatory bowel diseases. Hugot JP, et al. **Dig Dis** 1998 Nov–Dec;16(6):364–9 (31 ref.)

Genetics of inflammatory bowel disease. The candidate gene approach: susceptibility versus disease heterogeneity. Peña AS. **Dig Dis** 1998 Nov–Dec;16(6):356–63 (89 ref.)

Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Over HH, et al. **Eur J Gastroenterol Hepatol** 1998 Oct;10(10):827–9

Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Annese V, et al. **Eur J Hum Genet** 1999 Jul;7(5):567–73

NF-kappaB in IBD: does binding to DNA imply transcriptional activity? [letter; comment] Andresen L, et al. **Gastroenterology** 1999 Jun;116(6):1504–5. Comment on: Gastroenterology 1998 Aug;115(2):357–69.

Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16 [see comments] Curran ME, et al. **Gastroenterology** 1998 Nov;115(5):1066–71. Comment in: Gastroenterology 1998 Nov;115(5):1286–9.

Absence of linkage between inflammatory bowel disease and selected loci on chromosomes 3, 7, 12, and 16 [see comments] Rioux JD, et al. **Gastroenterology** 1998 Nov; 115(5):1062–5. Comment in: Gastroenterology 1998 Nov;115(5):1286–9.

Thrombosis, factor V Leiden, and inflammatory bowel disease [letter; comment] Shanahan F. **Gastroenterology** 1999 Mar;116(3):778–9. Comment on: Gastroenterology 1998 Oct;115(4):830–4.

Factor V Leiden mutation in patients with inflammatory bowel disease [letter; comment] Spannagl M, et al. **Gastroenterology** 1999 Jul;117(1):280. Comment on: Gastroenterology 1998 Oct;115(4):830–4.

Anticipating the onset of inflammatory bowel disease [comment] Colombel JF, et al. **Gut** 1999 Jun;44(6):773–4 . Comment on: Gut 1999 Jun;44(6):808–11.

Why children with inflammatory bowel disease are diagnosed at a younger age than their affected parent [see comments] Lee JC, et al. **Gut** 1999 Jun;44(6):808–11. Comment in: Gut 1999 Jun;44(6):773–4.

Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Mahmud N, et al. **Gut** 1999 Sep;45(3):389–94

IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Nemetz A, et al. **Immunogenetics** 1999 Jun;49(6):527–31

The interferon-gamma gene as a positional and functional candidate gene for inflammatory bowel disease. Hampe J, et al. **Int J Colorectal Dis** 1998;13(5–6):260–3

Inflammatory bowel disease and the genes for the natural resistance-associated macrophage protein-1 and the interferon-gamma receptor 1. Stokkers PC, et al. **Int J Colorectal Dis** 1999 Feb;14(1):13–7

A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. Panwala CM, et al. **J Immunol** 1998 Nov 15;161(10):5733–44

The hunt for inflammatory bowel disease susceptibility genes: where are linkage studies taking us? [news] Griffiths AM, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):2–3

Specific-pathogen-free conditions enhance inflammatory bowel disease in T-cell receptor knockout, but not C3H/HeJBir mice [letter; comment] Patterson MM, et al. **Lab Anim Sci** 1998 Oct;48(5):432–3. Comment on: Lab Anim Sci 1997 Dec;47(6):650–5.

CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Wittig B, et al. **Lab Invest** 1999 Jun; 79(6):747–59

Low prevalence of the APC I1307K sequence in Jewish and non-Jewish patients with inflammatory bowel disease. Yin J, et al. **Oncogene** 1999 Jul 1;18(26):3902–4

Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Heliö T, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):170–4

Significant differences in the interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease. Nemetz A, et al. **Scand J Gastroenterol** 1999 Feb; 34(2):175–9

HISTORY

Historical origins of medical and surgical therapy of inflammatory bowel disease. Kirsner JB. **Lancet** 1998 Oct 17;352(9136):1303–5

IMMUNOLOGY

Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis. Roozendaal C, et al. **Adv Exp Med Biol** 1998;443:313–9

Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Sugi K, et al. **Am J Gastroenterol** 1999 May;94(5):1304–12

Regulation of protein-DNA interactions at the interferon-gamma gene promoter by corticosteroids. Implications for inflammatory bowel diseases. Barbulescu

K, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:194–7

T cells in mouse models of gut inflammation. Simpson SJ, et al. **Chem Immunol** 1998;71:118–38 (82 ref.)

Accumulation of immunoglobulin-containing cells in the gut mucosa and presence of faecal immunoglobulin in severe combined immunodeficient (scid) mice with T cell-induced inflammatory bowel disease (IBD). Bregenholt S, et al. **Clin Exp Immunol** 1998 Oct;114(1):19–25

Pulmonary granulocyte kinetics in relation to endothelial and granulocyte activation. Ussov WY, et al. **Clin Sci (Colch)** 1999 May;96(5):525–31

Importance of CD44 variant isoforms in mouse models for inflammatory bowel disease. Günthert U. **Curr Top Microbiol Immunol** 1999;246:307–12; discussion 313 (25 ref.)

Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Koutroubakis IE, et al. **Dig Dis Sci** 1998 Nov;43(11):2507–12

An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D, et al. **Eur Cytokine Netw** 1999 Mar;10(1):7–15 (48 ref.)

Glucocorticoid receptor activity in inflammatory bowel disease: hindsight or foresight? [comment] Stange EF. **Eur J Clin Invest** 1999 Apr;29(4):278–9. Comment on: Eur J Clin Invest 1999 Apr;29(4):330–6.

Proliferation and apoptosis of lamina propria CD4+ T cells from scid mice with inflammatory bowel disease. Bregenholt S, et al. **Eur J Immunol** 1998 Nov; 28(11):3655–63

Genes, bacteria, and T cells: ingredients for inflammatory bowel disease. Shanahan F, et al. **Gastroenterology** 1998 Dec;115(6):1595–6

T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans [see comments] Duchmann R, et al. **Gut** 1999 Jun;44(6):812–8. Comment in: Gut 1999 Jun;44(6):774–5.

Intolerance of the dirty intestine [comment] Macpherson AJ, et al. **Gut** 1999 Jun;44(6):774–5. Comment on: Gut 1999 Jun;44(6):812–18.

Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Wedemeyer J, et al. **Gut** 1999 May;44(5):629–35

Aberrant mucosal cytokines: the key to the pathogenesis of IBD? Shah SA. **Inflamm Bowel Dis** 1999 May;5(2):146–7

Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review). Baumgart DC, et al. **Int J Mol Med** 1998 Feb;1(2):315–32 (268 ref.)

Salivary SIgA and SIgA 1 in coeliac disease, inflammatory bowel disease and controls. Warner RH, et al. **Ir J Med Sci** 1999 Jan–Mar;168(1):33–5

Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Amati L, et al. **Ital J Gastroenterol Hepatol** 1999 May;31(4):313–25 (153 ref.)

Measles IgM immunoreactivity in patients with inflammatory bowel disease [see comments] Balzola FA, et al. **Ital J Gastroenterol Hepatol** 1998 Aug;30(4):378–82. Comment in: Ital J Gastroenterol Hepatol 1998 Aug;30(4):383–4.

Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. Lügering N, et al. **Ital J Gastroenterol Hepatol** 1998 Jun;30(3):338–44 (62 ref.)

Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. Dohi T, et al. **J Exp Med** 1999 Apr 19;189(8):1169–80

Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. Iijima H, et al. **J Exp Med** 1999 Sep 6;190(5):607–15

Proinflammatory cytokines in IBD [editorial; comment] Asakura H. **J Gastroenterol** 1999 Feb;34(1):149–51 (13 ref.) . Comment on: J Gastroenterol 1999 Feb;34(1):66–74.

A quantitative immunohistochemical evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel disease. Yamagata K, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):801–8

Colitis-inducing potency of CD4+ T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype. Claesson MH, et al. **J Immunol** 1999 Mar 15; 162(6):3702–10

Regulation of T cell activation in vitro and in vivo by targeting the OX40–OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40–IgG fusion protein, but not with an OX40 ligand–IgG fusion protein. Higgins LM, et al. **J Immunol** 1999 Jan 1; 162(1):486–93

Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. Liu Z, et al. **J Immunol** 1999 Oct 1; 163(7):4049–57

Clonal expansion of CD4+ TCRbetabeta+ T cells in TCR alpha-chain- deficient mice by gut-derived antigens. Takahashi I, et al. **J Immunol** 1999 Feb 1;162(3):1843–50

Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Peterson RL, et al. **Lab Invest** 1998 Dec;78(12):1503–12

CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Wittig B, et al. **Lab Invest** 1999 Jun; 79(6):747–59

The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Qiu BS, et al. **Nat Med** 1999 Oct;5(10):1178–82

Expression of alpha5 (CD49e) and alpha6 (CD49f) integrin subunits on T cells in the circulation and the lamina propria of normal and inflammatory bowel disease colonic mucosa. Pilling JE, et al. **Scand J Immunol** 1998 Oct;48(4):425–8

Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Strober W, et al. **Scand J Immunol** 1998 Nov;48(5):453–8 (59 ref.)

The role of IL-10 in inflammatory bowel disease: "of mice and men". Leach MW, et al. **Toxicol Pathol** 1999 Jan–Feb; 27(1):123–33 (137 ref.)

[Differential diagnosis of chronic inflammatory bowel diseases. Value of determination of autoantibodies pANCA, ASCA AND PAB (perinuclear antineutrophil cytoplasmic antibody, antibody against Saccharomyces cerevisiae, antibody against pancreas)] Seibold F, et al. **Fortschr Med** 1999 Feb 28;117(6):42–3 **(Ger)**

[The intestinal immune system in children and their disorders] Votava-Raić A, et al. **Lijec Vjesn** 1998 Mar–Apr; 120(3–4):72–9 (70 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

Glucose metabolism and insulin sensitivity in inactive inflammatory bowel disease. Capristo E, et al. **Aliment Pharmacol Ther** 1999 Feb;13(2):209–17

Calcaneal ultrasound bone densitometry in inflammatory bowel disease--a comparison with double x-ray densitometry of the lumbar spine. Fries W, et al. **Am J Gastroenterol** 1998 Dec;93(12):2339–44

Evidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states. Saubermann LJ, et al. **Am J Physiol** 1999 Mar;276(3 Pt 1):G613–21

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Egan LJ, et al. **Clin Pharmacol Ther** 1999 Jan;65(1):29–39

Nitric oxide and inflammatory bowel diseases. Guslandi M. **Eur J Clin Invest** 1998 Nov;28(11):904–7 (42 ref.)

Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Faure C, et al. **Eur J Clin Pharmacol** 1998 Sep;54(7):555–60

NF-kappaB in IBD: does binding to DNA imply transcriptional activity? [letter; comment] Andresen L, et al. **Gastroenterology** 1999 Jun;116(6):1504–5. Comment on: Gastroenterology 1998 Aug;115(2):357–69.

Divergency of leptin response in intestinal inflammation. Ballinger A. **Gut** 1999 May;44(5):588–9

Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Bischoff SC, et al. **Gut** 1999 May;44(5):643–52

Activation of NFkappaB in inflammatory bowel disease [letter; comment] Schmid RM, et al. **Gut** 1998 Oct; 43(4):587–8. Comment on: Gut 1998 Apr;42(4):477–84.

Growth factors in inflammatory bowel disease. Beck PL, et al. **Inflamm Bowel Dis** 1999 Feb;5(1):44–60 (244 ref.)

Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/plasmenyl-ethanolamine in the mucosa in inflammatory bowel disease. Morita H, et al. **J Gastroenterol** 1999 Feb;34(1):46–53

Increased concentrations of eosinophilic cationic protein in whole-gut lavage fluid from children with inflammatory bowel disease. Troncone R, et al. **J Pediatr Gastroenterol Nutr** 1999 Feb;28(2):164–8

Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Somers GR, et al. **Lab Invest** 1998 Nov;78(11):1375–83

Multivariate identification of metabolic features in inflammatory bowel disease. Capristo E, et al. **Metabolism** 1999 Aug;48(8):952–6

A nutritional component to inflammatory bowel disease: the contribution of meat to fecal sulfide excretion [editorial] Magee E. **Nutrition** 1999 Mar;15(3):244–6 (45 ref.)

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Røseth AG, et al. **Scand J Gastroenterol** 1999 Jan; 34(1):50–4

Site-specific changes in transforming growth factor-alpha and -beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Xian CJ, et al. **Scand J Gastroenterol** 1999 Jun;34(6):591–600

MICROBIOLOGY

Intestinal inflammation and the gut microflora. McKay DM. **Can J Gastroenterol** 1999 Jul-Aug;13(6):509–16 (110 ref.)

Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? [editorial; comments] Campieri M, et al. **Gastroenterology** 1999 May;116(5):1246–9

Genes, bacteria, and T cells: ingredients for inflammatory bowel disease. Shanahan F, et al. **Gastroenterology** 1998 Dec;115(6):1595–6

Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Kallinowski F, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1552–8

Correlation of cecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease. Onderdonk AB, et al. **Infect Immun** 1998 Dec;66(12):6022–3

Colonization of microflora in mice: mucosal defense against luminal bacteria. Fukushima K, et al. **J Gastroenterol** 1999 Feb;34(1):54–60

Helicobacter pylori-positive gastritis in pediatric patients with chronic inflammatory bowel disease. Kolho KL, et al. **J Pediatr Gastroenterol Nutr** 1998 Sep;27(3):292–5

MORTALITY

Mortality and causes of death in patients with chronic inflammatory bowel disease in Gijón, Asturias (Spain). Saro Gismera C, et al. **Rev Esp Enferm Dig** 1999 Mar; 91(3):199–208 **(Eng, Spa)**

PARASITOLOGY

Cryptosporidium parvum initiates inflammatory bowel disease in germfree T cell receptor-alpha-deficient mice. Sacco RE, et al. **Am J Pathol** 1998 Dec;153(6):1717–22

PATHOLOGY

Selective COX-2 inhibitors and human inflammatory bowel disease. McCartney SA, et al. **Aliment Pharmacol Ther** 1999 Aug;13(8):1115–7

Presence of novel forms in the colon of inflammatory bowel disease patients [letter] Gottfried IS, et al. **Am J Gastroenterol** 1999 Feb;94(2):537–9

A new look at the anal transitional zone with reference to restorative protocolectomy and the columnar cuff. Thompson-Fawcett MW, et al. **Br J Surg** 1998 Nov; 85(11):1517–21

Lactulose and neomycin attenuate leukocyte-endothelial cell adhesion in an animal model of inflammatory bowel disease. Arndt H, et al. **Eur J Gastroenterol Hepatol** 1998 Apr; 10(4):339–43

Glial cells, mucosal integrity, and inflammatory bowel disease. Shanahan F, et al. **Gastroenterology** 1999 Feb; 116(2):493–4

Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Higgins LM, et al. **Infect Immun** 1999 Jun;67(6):3031–9

Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease. Ina K, et al. **J Gastroenterol Hepatol** 1999 Jan;14(1):46–53

A quantitative immunohistochemical evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel disease. Yamagata K, et al. **J Gastroenterol Hepatol** 1998 Aug;13(8):801–8

Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Somers GR, et al. **Lab Invest** 1998 Nov;78(11):1375–83

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2–1999. A 15-year-old girl with abdominal pain and bloody stools [clinical conference] **N Engl J Med** 1999 Jan 21;340(3):215–21

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Røseth AG, et al. **Scand J Gastroenterol** 1999 Jan; 34(1):50–4

Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Tanaka M, et al. **Scand J Gastroenterol** 1999 Jan; 34(1):55–67

PHYSIOPATHOLOGY

Experimental models to study molecular mechanisms underlying intestinal inflammation. Elson CO, et al. **Ann N Y Acad Sci** 1998 Nov 17;859:85–95 (46 ref.)

Nutrition in inflammatory bowel disease. Murch SH, et al. **Baillieres Clin Gastroenterol** 1998 Dec;12(4):719–38 (86 ref.)

Glucocorticoid receptor activity in inflammatory bowel disease: hindsight or foresight? [comment] Stange EF. **Eur J Clin Invest** 1999 Apr;29(4):278–9. Comment on: Eur J Clin Invest 1999 Apr;29(4):330–6.

Gender specific alterations of body composition in patients with inflammatory bowel disease compared with controls. Geerling BJ, et al. **Eur J Clin Nutr** 1999 Jun;53(6):479–85

Mediators of inflammation: production and implication in inflammatory bowel disease. Kolios G, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1601–9 (38 ref.)

Metabolic bone disease in adults with inflammatory bowel disease. Adachi JD, et al. **Inflamm Bowel Dis** 1999 Aug; 5(3):200–11 (137 ref.)

Bone mineral metabolism in pediatric inflammatory bowel disease. Issenman RM. **Inflamm Bowel Dis** 1999 Aug; 5(3):192–9 (86 ref.)

Does microcirculation play a role in the pathogenesis of inflammatory bowel diseases? Answers from intravital microscopic studies in animal models. Foitzik T, et al. **Int J Colorectal Dis** 1999 Feb;14(1):29–34

Quality of life in inflammatory bowel disease: background and definitions. Ferry GD. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S15–8 (28 ref.)

Local and systemic effects of macrophage cytokines in

intestinal inflammation. Murch SH. **Nutrition** 1998 Oct; 14(10):780–3 (38 ref.)
Relationship between smoking and colonic involvement in inflammatory bowel disease [see comments] Bustamante M, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):833–40. Comment in: Rev Esp Enferm Dig 1998 Dec;90(12):829–32. **(Eng, Spa)**
[Nitric oxide and inflammatory bowel disease (see comments)] García-González MA, et al. **Rev Esp Enferm Dig** 1998 Dec;90(12):870–6 (61 ref.) (Eng. Abstr.). Comment in: Rev Esp Enferm Dig 1998 Dec;90(12):829–32. **(Spa)**

PREVENTION & CONTROL

Protective effect of taurine on TNBS-induced inflammatory bowel disease in rats. Son MW, et al. **Arch Pharm Res** 1998 Oct;21(5):531–6
Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. Iijima H, et al. **J Exp Med** 1999 Sep 6;190(5):607–15

PSYCHOLOGY

Quality of life of parents and siblings of children with inflammatory bowel disease. Akobeng AK, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S40–2
Assessment of quality of life in the younger child: the use of an animated computer program. Büller H. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S53–5 (11 ref.)
Inflammatory bowel disease in children and adolescents: mental health and family functioning. Engstrom I. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S28–33 (21 ref.)
Potential uses for quality-of-life measures in childhood inflammatory bowel disease. Koot HM, et al. **J Pediatr Gastroenterol Nutr** 1999 Apr;28(4):S56–61 (20 ref.)
The importance of the family context in inflammatory bowel disease. Gerson MJ, et al. **Mt Sinai J Med** 1998 Oct–Nov; 65(5–6):398–403
Stress and mind-body impact on the course of inflammatory bowel diseases. Anton PA. **Semin Gastrointest Dis** 1999 Jan;10(1):14–9 (52 ref.)

RADIOGRAPHY

Polypoid and pseudopolypoid lesions of inflammatory bowel disease: diagnosis on double-contrast enema. De Backer AI, et al. **Acta Gastroenterol Belg** 1999 Apr–Jun;62(2):190–5 (24 ref.)

RADIONUCLIDE IMAGING

Comparison of the sensitivity of early versus delayed imaging with Tc-99m HMPAO WBC in children with inflammatory bowel disease. Charron M, et al. **Clin Nucl Med** 1998 Oct;23(10):649–53
Clinical applications of technetium Tc 99m hexamethyl propylene amine oxime leukocyte scan in children with inflammatory bowel disease. Del Rosario MA, et al. **J Pediatr Gastroenterol Nutr** 1999 Jan;28(1):63–70
Characterization of late abdominal accumulation of 99Tcm-HMPAO leukocytes in a large population of children. Charron M, et al. **Nucl Med Commun** 1998 Aug; 19(8):753–9
Clinical applications of radiolabeled blood elements in inflammatory bowel disease. Martin-Comin J, et al. **Q J Nucl Med** 1999 Mar;43(1):74–82 (74 ref.)
Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Charron M, et al. **Radiology** 1999 Aug;212(2):507–13
[Scintigraphic assessment of the severity of inflammatory bowel disease using Tc 99m exametazime-labeled leukocytes] de Lima Ramos PA, et al. **Rev Esp Med Nucl** 1998;17(5):351–7 (Eng. Abstr.) **(Spa)**

SURGERY

Coming of age with an ostomy. Life with a stoma may be especially difficult for teens. O'Brien BK. **Am J Nurs** 1999 Aug;99(8):71–6
Continent ileostomy can be offered as an option to patients who fail the ileal pouch-anal anastomosis (IPAA) [letter] Behrens DT, et al. **Dis Colon Rectum** 1999 May;42(5):686
Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Kallinowski F, et al. **Hepatogastroenterology** 1998 Sep–Oct;45(23):1552–8
Colorectal surgery. Oliver GC. **J Am Coll Surg** 1999 Feb; 188(2):111–7 (48 ref.)
Laparoscopic-assisted bowel resections in inflammatory bowel disease: state of the art. Bemelman WA, et al. **Neth J Med** 1998 Dec;53(6):S39–46 (45 ref.)
Influence of the smoking habit in the surgery of inflammatory bowel disease. Medina C, et al. **Rev Esp Enferm Dig** 1998 Nov;90(11):771–8 **(Eng, Spa)**
Laparoscopically assisted bowel surgery for inflammatory bowel disease. The combined experiences of two academic centers. Meijerink WJ, et al. **Surg Endosc** 1999 Sep; 13(9):882–6
[Emergency surgery in inflammatory bowel disease. Experience in 26 cases] D'Addazio G, et al. **Minerva Chir** 1998 Dec;53(12):1001–7 (Eng. Abstr.) **(Ita)**

THERAPY

Review article: The management of inflammatory bowel disease during pregnancy. Subhani JM, et al. **Aliment Pharmacol Ther** 1998 Nov;12(11):1039–53 (127 ref.)
Nonorthodox therapeutic practices in inflammatory bowel disease [letter; comment] Guslandi M. **Am J Gastroenterol** 1999 Mar;94(3):854–5. Comment on: Am J Gastroenterol 1998 May;93(5):673–5.
An international survey of the use and attitudes regarding alternative medicine by patients with inflammatory bowel disease. Rawsthorne P, et al. **Am J Gastroenterol** 1999 May; 94(5):1298–303
Complementary and alternative medicine use by patients with inflammatory bowel disease: An Internet survey. Hilsden RJ, et al. **Can J Gastroenterol** 1999 May;13(4):327–32
Gastroenterology and nutrition [editorial] Hyams JS. **Curr Opin Pediatr** 1998 Oct;10(5):491–2
Inflammatory bowel disease: potential therapeutic strategies. Nielsen OH, et al. **Cytokines Cell Mol Ther** 1997 Dec; 3(4):267–81 (184 ref.)
An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D, et al. **Eur Cytokine Netw** 1999 Mar;10(1):7–15 (48 ref.)
Novel therapies for inflammatory bowel disease. Sands BE. **Gastroenterol Clin North Am** 1999 Jun;28(2):323–51 (220 ref.)
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? [editorial; comments] Campieri M, et al. **Gastroenterology** 1999 May;116(5):1246–9
Quality of life in patients receiving home parenteral nutrition. Jeppesen PB, et al. **Gut** 1999 Jun;44(6):844–52
Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Ruther U, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):691–9
Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Less commonly used therapies for IBD or treatments on the fringe. Burakoff R. **Inflamm Bowel Dis** 1998 Nov;4(4):308–13; discussion 313–7 (34 ref.)
Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease. Hilsden RJ, et al. **Inflamm Bowel Dis** 1998 Nov;4(4):318–23 (32 ref.)
Initial maintenance therapy (relapse prevention) and therapy of steroid resistance and dependence. Winter H. **Inflamm Bowel Dis** 1998 Aug;4(3):209–13 (33 ref.)
Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Kirschner BS. **Neth J Med** 1998 Dec;53(6):S13–8 (13 ref.)
Experimental immunomodulatory therapy of inflammatory bowel disease. Schreiber S. **Neth J Med** 1998 Dec; 53(6):S24–31 (55 ref.)
Therapeutic cytapheresis for inflammatory bowel disease. Sawada K, et al. **Ther Apher** 1998 May;2(2):90–2
Inflammatory bowel disease: current therapy and future options. Tandan M. **Trop Gastroenterol** 1998 Oct–Dec; 19(4):130–5 (45 ref.)
[Treatment of chronic inflammatory bowel diseases in the child] Goulet O, et al. **Arch Pediatr** 1998;5 Suppl 2:105s–108s (17 ref.) **(Fre)**
[Cost of early management of chronic inflammatory intestinal disease] Rolland N, et al. **Gastroenterol Clin Biol** 1999 Apr; 23(4):483–8 (Eng. Abstr.) **(Fre)**
[Inflammatory bowel disease in children] Goulet O. **Rev Prat** 1998 Feb 15;48(4):403–9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Interventional endoscopy in chronic inflammatory bowel disease] Rosenbaum A, et al. **Dtsch Med Wochenschr** 1999 Aug 20;124(33):967–71 (41 ref.) **(Ger)**

ULTRASONOGRAPHY

Doppler sonography of hemodynamic changes of the inferior mesenteric artery in inflammatory bowel disease: preliminary data. Mirk P, et al. **AJR Am J Roentgenol** 1999 Aug;173(2):381–7
Catheter probe assisted endoluminal US in inflammatory bowel disease. Soweid AM, et al. **Gastrointest Endosc** 1999 Jul;50(1):41–6
The accuracy of abdominal ultrasound in the assessment of bowel disorders. Hollerbach S, et al. **Scand J Gastroenterol** 1998 Nov;33(11):1201–8
[Diagnosis of chronic inflammatory bowel disease by ultrasonography] Limberg B. **Z Gastroenterol** 1999 Jun; 37(6):495–508 (Eng. Abstr.) **(Ger)**
[Three-dimensional rectal ultrasonography in inflammatory bowel diseases] Szilvás A, et al. **Orv Hetil** 1998 Nov 1; 139(44):2645–8 (Eng. Abstr.) **(Hun)**
[The clinical and echographic assessment of thyroid function and structure in patients with a chronic inflammatory intestinal disease] Messina G, et al. **Recenti Prog Med** 1999 Jan;90(1):13–6 (Eng. Abstr.) **(Ita)**

VETERINARY

Radiographic, ultrasonographic, and endoscopic findings in cats with inflammatory bowel disease of the stomach and small intestine: 33 cases (1990–1997). Baez JL, et al. **J Am Vet Med Assoc** 1999 Aug 1;215(3):349–54
Inflammatory bowel disease in horses: 11 cases (1988–1998). Scott EA, et al. **J Am Vet Med Assoc** 1999 May 15; 214(10):1527–30
Enterohepatic lesions in SCID mice infected with Helicobacter bilis. Franklin CL, et al. **Lab Anim Sci** 1998 Aug;48(4):334–9
Evaluation of B and T lymphocytes and plasma cells in colonic mucosa from healthy dogs and from dogs with inflammatory bowel disease. Stonehewer J, et al. **Res Vet Sci** 1998 Jul–Aug;65(1):59–63
Inflammatory bowel disease. Current perspectives. Jergens AE. **Vet Clin North Am Small Anim Pract** 1999 Mar; 29(2):501–21, vii (92 ref.)

VIROLOGY

IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus related disease? [letter; comment] Fisher NC. **Eur J Gastroenterol Hepatol** 1998 Apr;10(4):355–6. Comment on: Eur J Gastroenterol Hepatol 1997 Jul;9(7):661–3.
Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease). Ruther U, et al. **Hepatogastroenterology** 1998 May–Jun;45(21):691–9

INFLAMMATORY RESPONSE SYNDROME, SYSTEMIC see **SEPSIS SYNDROME**

INFLATION, ECONOMIC

STATISTICS & NUMERICAL DATA

The misery index and suicide. Yang B, et al. **Psychol Rep** 1999 Jun;84(3 Pt 2):1086

INFLUENZA

First International Symposium on Influenza and Other Respiratory Viruses: summary and overview: Kapalua, Maui, Hawaii, December 4–6, 1998. Kaiser L, et al. **Antiviral Res** 1999 Jul;42(3):149–75 (94 ref.)
Hospitalizing influenza in adults. Kaiser L, et al. **Curr Clin Top Infect Dis** 1999;19:112–34 (103 ref.)
Reported influenza in pregnancy and childhood tumour. Linos A, et al. **Eur J Epidemiol** 1998 Jul;14(5):471–5
FluNet as a tool for global monitoring of influenza on the Web. Flahault A, et al. **JAMA** 1998 Oct 21;280(15):1330–2
Influenza information spreads across the web. Larkin M. **Lancet** 1999 Jan 2;353(9146):77
It's cold and flu season on the screen. Hallberg J. **Minn Med** 1999 Jan;82(1):44–5
Influenza update. Ottolini MG. **Pediatr Rev** 1999 Jan;20(1):33
A rational strategy for influenza. Venkatesan P, et al. **Practitioner** 1997 Sep;241(1578):536–9 (18 ref.)
The bird flu--what lies ahead? [editorial] Tsang T. **Singapore Med J** 1999 Jan;40(1):1–2
[Influenza] Pozzetto B. **Rev Prat** 1998 Jan 1;48(1):107–12 **(Fre)**
[Clinical features of the new influenza virus infection] Tanabe O. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):77–9 (8 ref.) **(Jpn)**
[Influenza virus pneumonia] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1999;(24 Pt 2):83–6 (15 ref.) **(Jpn)**

BLOOD

Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans. Kallas EG, et al. **J Interferon Cytokine Res** 1999 Jul;19(7):751–5

CHEMICALLY INDUCED

Influenza myositis and rhabdomyolysis in an HIV positive man: was zidovudine a co-factor? [letter] Guha I, et al. **Sex Transm Infect** 1999 Jun;75(3):204–5

COMPLICATIONS

Time-series analysis of the relation between influenza virus and hospital admissions of the elderly in Ontario, Canada, for pneumonia, chronic lung disease, and congestive heart failure. Upshur RE, et al. **Am J Epidemiol** 1999 Jan 1; 149(1):85–92
Hematologic abnormalities associated with influenza A infection: a report of 3 cases. Rice J, et al. **Am J Med Sci** 1998 Dec;316(6):401–3
Hemiballismus associated with Influenza A infection. Yoshikawa H, et al. **Brain Dev** 1999 Mar;21(2):132–4
Toxic shock syndrome following influenza A infection [letter] Sharkey R, et al. **Intensive Care Med** 1999 Mar; 25(3):335–6
Respiratory virus infections in immunocompromised patients [editorial] Muir D, et al. **J Med Microbiol** 1998 Jul; 47(7):561–2
Parainfectious conus myelitis. Pradhan S, et al. **J Neurol Sci** 1998 Dec 11;161(2):156–62
Amantadine and pneumonia in elderly stroke patients [letter; comment] Trivalle C, et al. **Lancet** 1999 Jun 19; 353(9170):2157. Comment on: Lancet 1999 Apr 3;353(9159):1157.
Defective corticogenesis and reduction in Reelin immunoreactivity in cortex and hippocampus of prenatally infected neonatal mice. Fatemi SH, et al.

Mol Psychiatry 1999 Mar;4(2):145–54

Efficacy of antibiotics against influenza-like illness in an influenza epidemic. Maeda S, et al. **Pediatr Int** 1999 Jun; 41(3):274–6

Selective, reversible thalamic involvement with influenza A infection [letter] Yoshikawa H, et al. **Pediatrics** 1998 Dec; 102(6):1494–5

[Orthopnea: not always of cardiac origin (see comments)] Oranen BI, et al. **Ned Tijdschr Geneeskd** 1999 May 1; 143(18):921–4 (32 ref.) (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1999 Jul 3;143(27):1443–4. **(Dut)**

[Influenza and asthma] Murris-Espin M, et al. **Rev Mal Respir** 1999 Feb;16(1):9–15 (46 ref.) (Eng. Abstr.) **(Fre)**

[Use of amantadine for influenza A encephalopathy] Miura M, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):840–4 (Eng. Abstr.) **(Jpn)**

[Aspergillosis following influenza A infection] Funabiki Y, et al. **Nippon Ronen Igakkai Zasshi** 1999 Apr;36(4):274–8 (Eng. Abstr.) **(Jpn)**

[A case of myasthenia gravis with transient remission after influenza A virus infection] Yamada K, et al. **No To Hattatsu** 1999 Jan;31(1):70–4 (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The diagnosis and management of influenza. An update. Sintchenko V, et al. **Aust Fam Physician** 1999 Apr; 28(4):313–7 (13 ref.)

1997–1998 influenza season: Canadian laboratory diagnoses and strain characterization. Li Y. **Can Commun Dis Rep** 1999 Jan 15;25(2):9–12 **(Eng, Fre)**

Evaluation of an indirect immunofluorescence assay and two cell lines in the detection of influenza B virus in nasopharyngeal samples. Reina J, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):532–4

Comparison of RT-PCR with other diagnostic assays for rapid detection of influenza viruses. Pregliasco F, et al. **J Med Virol** 1998 Oct;56(2):168–73

[Medical audit: influenza. Group of Physicians for Quality Assurance, Fribourg] Carrel J. **Rev Med Suisse Romande** 1999 Mar;119(3):249–50 **(Fre)**

[I have influenza] Raetzo MA, et al. **Schweiz Rundsch Med Prax** 1999 Mar 11;88(11):479–82 **(Ger)**

[Evaluation of a rapid enzyme immunoassay membrane test for diagnosis of influenza A virus infection] Shimizu H, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):827–33 (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Antiviral effect of gingyo-san, a traditional Chinese herbal medicine, on influenza A2 virus infection in mice. Kobayashi M, et al. **Am J Chin Med** 1999;27(1):53–62

Influenza prevention and treatment: current practices and new horizons [editorial] Belshe RB. **Ann Intern Med** 1999 Oct 19;131(8):621–4

Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Martínez-Cáceres EM, et al. **Ann Neurol** 1998 Oct; 44(4):682–5

Approaches and strategies for the treatment of influenza virus infections. Colacino JM, et al. **Antivir Chem Chemother** 1999 Jul;10(4):155–85 (222 ref.)

Long-term stability of the anti-influenza A compounds--amantadine and rimantadine. Scholtissek C, et al. **Antiviral Res** 1998 Jun;38(3):213–5

The diagnosis and management of influenza. An update. Sintchenko V, et al. **Aust Fam Physician** 1999 Apr; 28(4):313–7 (13 ref.)

The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Kido H, et al. **Biopolymers** 1999; 51(1):79–86

Influenza drug to undergo "fast track" assessment by NICE [news] Jones J. **BMJ** 1999 Aug 14;319(7207):400

Antipyretic activity of gingyo-san, a traditional medicine, in influenza virus-infected mice. Kurokawa M, et al. **Chem Pharm Bull (Tokyo)** 1998 Sep;46(9):1444–7

Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Dines GD, et al. **Drug Saf** 1998 Sep;19(3):233–41 (19 ref.)

New approaches to influenza chemotherapy. Neuraminidase inhibitors. Calfee DP, et al. **Drugs** 1998 Oct;56(4):537–53 (63 ref.)

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Gubareva LV, et al. **J Infect Dis** 1998 Nov;178(5):1257–62

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. Monto AS, et al. **J Infect Dis** 1999 Aug; 180(2):254–61

Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. Skoner DP, et al. **J Infect Dis** 1999 Jul;180(1):10–4

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Hayden FG, et al. **JAMA** 1999 Oct 6;282(13):1240–6

Progress treating, preventing influenza [news] Stephenson J. **JAMA** 1998 Nov 25;280(20):1729–30

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [see comments] [published errata appear in Lancet 1999 Feb 6;353(9151):504 and 1999 Mar 27;353(9158):1104] **Lancet** 1998 Dec 12;352(9144):1877–81. Comment in: Lancet 1998 Dec 12;352(9144):1872–3. Comment in: Lancet 1999 Feb 20;353(9153):668–9. Comment in: Lancet 1999 Feb 20;353(9153):669.

Treating influenza with zanamivir [letter; comment] Fleming DM. **Lancet** 1999 Feb 20;353(9153):668–9. Comment on: Lancet 1998 Dec 12;352(9144):1872–3. Comment on: Lancet 1998 Dec 12;352(9144):1877–81.

New ways to tackle influenza highlighted at ICAAC. Interscience Conference on Antimicrobial Agents and Chemotherapy [news] Ostroff S, et al. **Lancet** 1998 Oct 3;352(9134):1123

Treating influenza with zanamivir [comment] [see comments] Read RC. **Lancet** 1998 Dec 12;352(9144):1872–3. Comment on: Lancet 1998 Dec 12;352(9144):1877–81. Comment in: Lancet 1999 Feb 20;353(9153):668–9. Comment in: Lancet 1999 Feb 20;353(9153):669.

Treating influenza with zanamivir. Management of Influenza in the Southern Hemisphere Trialists [letter; comment] Silagy CA. **Lancet** 1999 Feb 20;353(9153):669. Comment on: Lancet 1998 Dec 12;352(9144):1872–3. Comment on: Lancet 1998 Dec 12;352(9144):1877–81.

Morphine reduces pulmonary inflammation in response to influenza infection. Coussons-Read ME, et al. **Life Sci** 1999;65(11):1141–52

Glaxo's antiviral ills not deemed contagious [news] Dove A. **Nat Biotechnol** 1999 Apr;17(4):322–3

Neuraminidase inhibitors take bite out of influenza [news] Glaser V. **Nat Biotechnol** 1998 Nov;16(11):1002

Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Mizuta T, et al. **Nat Biotechnol** 1999 Jun; 17(6):583–7

Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21–2, 25–8 passim; quiz 38–9 (35 ref.)

Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of Stachyflin and its derivatives. Yagi S, et al. **Pharm Res** 1999 Jul;16(7):1041–6

[Influenza: new therapeutic perspectives] Bricaire F. **Presse Med** 1998 Dec;27 Suppl 5:24–6 (Eng. Abstr.) **(Fre)**

[A grip grippe? (editorial)] Heinzl S. **Med Monatsschr Pharm** 1998 Dec;21(12):365 **(Ger)**

[Cost of medication for influenza infected elderly inpatients] Hara Y, et al. **Kansenshogaku Zasshi** 1999 Jul;73(7):689–93 (Eng. Abstr.) **(Jpn)**

[Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children] Drinevskii VP, et al. **Antibiot Khimioter** 1998;43(9):29–34 (Eng. Abstr.) **(Rus)**

[Effect of liposomal beta-carotene on experimentally lethal influenza infection] Sukhinin VP, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):163–7 (Eng. Abstr.) **(Rus)**

ECONOMICS

Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza [letter; comment] Boersma B, et al. **Am J Infect Control** 1999 Apr; 27(2):177–8. Comment on: Am J Infect Control 1998 Jun;26(3):367–8.

Potential cost savings attributable to influenza vaccination of school-aged children. White T, et al. **Pediatrics** 1999 Jun;103(6):e73

[Cost of medication for influenza infected elderly inpatients] Hara Y, et al. **Kansenshogaku Zasshi** 1999 Jul;73(7):689–93 (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors. Zhang L, et al. **Bioorg Med Chem Lett** 1999 Jul 5;9(13):1751–6

EPIDEMIOLOGY

Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Neuzil KM, et al. **Am J Epidemiol** 1998 Dec 1;148(11):1094–102

Influenza in travellers to Alaska, the Yukon Territory, and on west coast cruise ships, summer of 1999. **Can Commun Dis Rep** 1999 Aug 15;25(16):137–9; discussion 139–41 **(Eng, Fre)**

Respiratory virus surveillance. FluWatch Project. Buck P, et al. **Can Commun Dis Rep** 1999 Feb 15;25(4):35–6 **(Eng, Fre)**

Influenza in Canada--1997–1998 season [published erratum appears in Can Comun Dis Rep 1998 Dec 1;24(23):192] Buck P, et al. **Can Commun Dis Rep** 1998 Nov 1; 24(21):169–76 **(Eng, Fre)**

1997–1998 influenza season: Canadian laboratory diagnoses and strain characterization. Li Y. **Can Commun Dis Rep** 1999 Jan 15;25(2):9–12 **(Eng, Fre)**

Respiratory virus surveillance. FluWatch project. Pelletier L, et al. **Can Commun Dis Rep** 1999 Mar 15;25(6):62–4 **(Eng, Fre)**

Evaluation of clinical case definitions of influenza: detailed investigation of patients during the 1995–1996 epidemic in France. Carrat F, et al. **Clin Infect Dis** 1999 Feb; 28(2):283–90

Annual report of the National Influenza Surveillance Scheme, 1998. Halliday L, et al. **Commun Dis Intell** 1999 Jul 8;23(7):185–92

Influenza surveillance in England and Wales: October 1997 to June 1998. Dedman DJ, et al. **Commun Dis Public Health** 1998 Dec;1(4):244–51

Fifty years of influenza surveillance [editorial] Ellis J, et al. **Commun Dis Public Health** 1999 Jun;2(2):81–2

Influenza activity starts while Christmas interrupts surveillance. **Commun Dis Rep CDR Wkly** 1999 Jan 8; 9(2):9, 12

Influenza on a cruise ship in the Mediterranean. **Commun Dis Rep CDR Wkly** 1999 Jun 11;9(24):209, 212

Acute respiratory infections, and influenza vaccine for 1999/2000. **Commun Dis Rep CDR Wkly** 1999 Mar 5; 9(10):87, 90

Recent increases in influenza and other respiratory infections [published erratum appears in Commun Dis Rep CDR Wkly 1999 Jan 22;9(4):32] **Commun Dis Rep CDR Wkly** 1999 Jan 15;9(3):17, 20

Influenza surveillance 1998/99. **Commun Dis Rep CDR Wkly** 1998 Oct 2;8(40):353

Avian strain of influenza A virus isolated from humans in Hong Kong. **Commun Dis Rep CDR Wkly** 1999 Apr 9; 9(15):131, 134

Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993–4; cigarette smoking as a risk factor and the efficacy of influenza vaccination. Nicholson KG, et al. **Epidemiol Infect** 1999 Aug; 123(1):103–8

The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands. Fleming DM, et al. **Eur J Epidemiol** 1999 May;15(5):467–73

A space-time criterion for early detection of epidemics of influenza-like-illness. Toubiana L, et al. **Eur J Epidemiol** 1998 Jul;14(5):465–70

Non-influenza respiratory viruses may overlap and obscure influenza activity. Drinka PJ, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1087–93

Surveillance of influenza-like illness in France. The example of the 1995/1996 epidemic. Carrat F, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:32S–38S

Programme for the surveillance of influenza in Portugal: results of the period 1990–1996. Falcão IM, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:39S–42S

Surveillance of influenza in Wales: interpreting sentinel general practice rates using contemporaneous laboratory data. Opportunities and limitations. Thomas DR, et al. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:28S–31S

A study of reasons for an increase in acute respiratory tract infections reported by influenza sentinel practices in Germany. Uphoff H. **J Epidemiol Community Health** 1998 Apr;52 Suppl 1:43S–45S

Natural and 'in vitro' selected antigenic variants of influenza A virus (H2N2). Natali A, et al. **J Infect** 1998 Jul; 37(1):19–23

Influenza [editorial] Ebrahim GJ. **J Trop Pediatr** 1998 Oct; 44(5):254–5

From the Centers for Disease Control and Prevention. Update: influenza activity--worldwide, April-September 1998. **JAMA** 1998 Nov 18;280(19):1650–1

From the Centers for Disease Control and Prevention. Update: influenza activity--United States, 1998–99 season. **JAMA** 1999 Feb 24;281(8):695–6

From the Centers for Disease Control and Prevention. Outbreak of influenza A infection among travelers--Alaska and the Yukon Territory, May-June 1999. **JAMA** 1999 Jul 28;282(4):318–9

From the Centers for Disease Control and Prevention. Update: influenza activity--United States and worldwide, 1998–99 season, and composition of the 1999–2000 influenza vaccine. **JAMA** 1999 Jun 16;281(23):2178–80

From the Centers for Disease Control and Prevention. Update: influenza activity--United States, 1998–99 season. **JAMA** 1999 Apr 7;281(13):1165–7

Influenza-associated morbidity and mortality in young and middle-aged women [see comments] Neuzil KM, et al. **JAMA** 1999 Mar 10;281(10):901–7. Comment in: JAMA 1999 Mar 10;281(10):944–5.

European Influenza Surveillance Scheme on the Internet. Snacken R, et al. **Methods Inf Med** 1998 Sep;37(3):266–70

Update: influenza activity--United States, 1998–99 season. **MMWR Morb Mortal Wkly Rep** 1998 Nov 20;47(45):984, 991

Outbreak of influenza A infection among travelers--Alaska and the Yukon Territory, May-June 1999. **MMWR Morb Mortal Wkly Rep** 1999 Jul 2;48(25):545–6, 555

Update: influenza activity--United States, 1998–99 season. **MMWR Morb Mortal Wkly Rep** 1999 Mar 12;48(9):177–81

Update: influenza activity--United States and worldwide, 1998–99 season, and composition of the 1999–2000 influenza vaccine. **MMWR Morb Mortal Wkly Rep** 1999 May 14; 48(18):374–8

Update: influenza activity--United States, 1998-99 season. **MMWR Morb Mortal Wkly Rep** 1999 Jan 22;48(2):25-7
New clues to the emergence of flu pandemics [news] Claas EC, et al. **Nat Med** 1998 Oct;4(10):1122-3
Protecting Japan from influenza [letter; comment] Inoue K. **Nat Med** 1999 Jun;5(6):592. Comment on: Nat Med 1999 Apr;5(4):384-5.
Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9363-7
The geographical spread of influenza. Bonabeau E, et al. **Proc R Soc Lond B Biol Sci** 1998 Dec 22;265(1413):2421-5
Influenza virus epidemiological surveillance in Argentina, 1987-1993, with molecular characterization of 1990 and 1993 isolates. Uez OC, et al. **Rev Panam Salud Publica** 1998 Dec;4(6):405-10
Influenza in the world. **Wkly Epidemiol Rec** 1999 Feb 12; 74(6):41-5 **(Eng, Fre)**
Influenza. **Wkly Epidemiol Rec** 1999 Feb 12;74(6):46-8
Recommended composition of influenza virus vaccines for use in the 1999-2000 season. **Wkly Epidemiol Rec** 1999 Feb 26;74(8):57-61
Influenza. **Wkly Epidemiol Rec** 1999 Mar 19;74(11):86-7 **(Eng, Fre)**
[The influenza season 1997/'98 and the vaccine composition for 1998/'99] Claas EC, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2423-7 (Eng. Abstr.) **(Dut)**
[Influenza A (H5N1) in Hong Kong: Forerunner of a pandemic or just a scientifically interesting phenomenon and a useful exercise in pandemiology?] de Jong JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1252-6 (14 ref.) (Eng. Abstr.) **(Dut)**
[The resources of the social network of single person households during acute illness. Basic data for home care planning in an influenza epidemic] Wettstein A, et al. **Soz Praventivmed** 1999;44(3):107-16 (Eng. Abstr.) **(Ger)**
[Impact of influenza A virus infection as a cause of pediatric hospitalization and use of rapid antigen test of influenza A virus] Mitamura K, et al. **Kansenshogaku Zasshi** 1998 Sep;72(9):883-9 (Eng. Abstr.) **(Jpn)**
[Outbreak of influenza B virus infections in summer season] Sahara K, et al. **Kansenshogaku Zasshi** 1999 Mar; 73(3):253-4 **(Jpn)**
[Excess mortality from influenza epidemics in Japan, 1980-1994] Tachibana T, et al. **Nippon Koshu Eisei Zasshi** 1999 Apr;46(4):263-74 (Eng. Abstr.) **(Jpn)**
[Influenza outbreaks in nursing homes (letter; comment)] Iversen BG, et al. **Tidsskr Nor Laegeforen** 1999 May 10; 119(12):1802-3. Comment on: Tidsskr Nor Laegeforen 1999 Apr 10;119(9):1336. **(Nor)**
[Influenza in 1997] Kuszewski K, et al. **Przegl Epidemiol** 1999; 53(1-2):45-8 (Eng. Abstr.) **(Pol)**

ETHNOLOGY

Horizons Project wants physicians to increase the rate of influenza/pneumococcal immunizations among elderly blacks. Malone L. **Tenn Med** 1998 Nov;91(11):422-3

ETIOLOGY

Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Martinez-Cáceres EM, et al. **Ann Neurol** 1998 Oct; 44(4):682-5
Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. Mounts AW, et al. **J Infect Dis** 1999 Aug;180(2):505-8
The role of interferon in influenza virus tissue tropism. Garcia-Sastre A, et al. **J Virol** 1998 Nov;72(11):8550-8
The effect of smoking on influenza, influenza vaccination efficacy and on the antibody response to influenza vaccination. Cruijff M, et al. **Vaccine** 1999 Feb 5; 17(5):426-32

HISTORY

The dispersal of the 1918 influenza virus on the Seward Peninsula, Alaska: an ethnohistoric reconstruction. Ganley ML. **Int J Circumpolar Health** 1998;57 Suppl 1:247-51
The 1918 flu and other influenza pandemics: "over there" and back again. Reid AH, et al. **Lab Invest** 1999 Feb; 79(2):95-101
The 1918 'Spanish' flu: pearls from swine? [news] [see comments] Shortridge KF. **Nat Med** 1999 Apr;5(4):384-5. Comment in: Nat Med 1999 Jun;5(6):592.
[80 year since the Spanish flu epidemic. Influenza claimed more lives than World War I] Tallerud B. **Lakartidningen** 1998 Dec 9;95(50):5798-1, 5804 **(Swe)**

IMMUNOLOGY

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Beyer WE, et al. **Arch Intern Med** 1999 Jan 25;159(2):182-8
Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Colamussi ML, et al. **Blood** 1999 Apr 1;93(7):2395-403
The roles of IL-1, IL-6, and TNFalpha in the feeding responses to endotoxin and influenza virus infection in mice. Swiergiel AH, et al. **Brain Behav Immun** 1999 Sep; 13(3):252-65
Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults. McElhaney JE, et al. **Clin Diagn Lab Immunol** 1998 Nov; 5(6):840-4
Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Yasui H, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):186-92
Systemic T cell expansion during localized viral infection. Haanen JB, et al. **Eur J Immunol** 1999 Apr;29(4):1168-74
Spontaneous mutation at position 114 in H-2Kd affects cytotoxic T cell responses to influenza virus infection. Müllbacher A, et al. **Eur J Immunol** 1999 Apr; 29(4):1228-34
Immunodeficient mouse models in the characterization of the protective immunity to influenza virus. Bot A, et al. **Folia Microbiol (Praha)** 1998;43(5):477-8
Influenza vaccine: are those at risk taking it? [letter] Bedford D, et al. **Ir Med J** 1999 Jan-Feb;92(1):246
Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. Voeten JT, et al. **J Clin Microbiol** 1998 Dec;36(12):3527-31
Mucosal immunity to influenza without IgA: an IgA knockout mouse model. Mbawuike IN, et al. **J Immunol** 1999 Mar 1;162(5):2530-7
Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. Fritz RS, et al. **J Infect Dis** 1999 Sep;180(3):586-93
Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. Moran TM, et al. **J Infect Dis** 1999 Sep;180(3):579-85
Androstenediol (AED) prevents neuroendocrine-mediated suppression of the immune response to an influenza viral infection. Padgett DA, et al. **J Neuroimmunol** 1999 Aug 3;98(2):121-9
Fish oil feeding delays influenza virus clearance and impairs production of interferon-gamma and virus-specific immunoglobulin A in the lungs of mice [published erratum appears in J Nutr 1999 Jun;129(6):1237] Byleveld PM, et al. **J Nutr** 1999 Feb;129(2):328-35
Interferon-induced antiviral resistance. A mathematical model of regulation of Mx1 protein induction and action. Bazhan SI, et al. **J Theor Biol** 1999 Jun 7;198(3):375-93
Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. Takada A, et al. **J Virol** 1999 Oct;73(10):8303-7
Influenza virus serology--a comparative study. Rothbarth PH, et al. **J Virol Methods** 1999 Mar;78(1-2):163-9
Insufficient resistance of trehalose-6,6-dimycolate-treated T-cell receptor delta gene mutant (TCR delta-/-) mice against influenza virus infection. Hoq MM, et al. **Microbiol Immunol** 1999;43(5):491-3
Influenza immunization of schoolchildren: can we interrupt community epidemics? Poland GA, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1280-2
Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Baumgarth N, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2250-5
Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. Belz GT, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13812-7
Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. de Jong JC, et al. **Vaccine** 1999 Mar 17;17(11-12):1321-8
Modified M2 proteins produce heterotypic immunity against influenza A virus. Frace AM, et al. **Vaccine** 1999 May 4; 17(18):2237-44
Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization. Gross PA, et al. **Vaccine** 1999 May 4;17(18):2284-9
IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Lee SW, et al. **Vaccine** 1999 Feb 5;17(5):490-6
Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Rimmelzwaan GF, et al. **Vaccine** 1999 Jun 4;17(20-21):2512-6
Immunization with the N-terminal region of the nonstructural protein NS1 promotes survival after challenge with lethal influenza A virus dose. Tamura M, et al. **Viral Immunol** 1998;11(3):131-5
Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Mozdzanowska K, et al. **Virology** 1999 Feb 1;254(1):138-46
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Nguyen HH, et al. **Virology** 1999 Feb 1;254(1):50-60

METABOLISM

The role of endothelin in mediating virus-induced changes in endothelinB receptor density in mouse airways. Henry PJ, et al. **Eur Respir J** 1999 Jul;14(1):92-7

MORTALITY

Mortality associated with an influenza outbreak on a dementia care unit. Brandeis GH, et al. **Alzheimer Dis Assoc Disord** 1998 Sep;12(3):140-5
Flu vaccination decreases relative morbidity risk for people with diabetes [news] Vinicor F. **J Ark Med Soc** 1998 Oct; 95(5):182
[Influenza and mortality] Bentzen J, et al. **Ugeskr Laeger** 1999 Apr 5;161(14):2101 **(Dan)**

PATHOLOGY

Virological and pathomorphological aspects in experimental infections with some triassociated pneumotropic viruses in the white mouse. Petica M, et al. **Rom J Virol** 1997 Jan-Dec;48(1-4):27-42

PHYSIOPATHOLOGY

Exacerbation of influenzavirus pneumonia by intranasal administration of surfactant in a mouse model. Iwasaki T, et al. **Arch Virol** 1999;144(4):675-85
Influenza A virus infection increases IgE production and airway responsiveness in aerosolized antigen-exposed mice. Suzuki S, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):732-40
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Garcia-Sastre A, et al. **Virology** 1998 Dec 20;252(2):324-30

PREVENTION & CONTROL

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. Kroon FP, et al. **AIDS** 1998 Dec 3;12(17):F217-23
Advisory Committee on Immunization Practices issues recommendations for the 1999-2000 influenza season. Rose VL. **Am Fam Physician** 1999 Jul;60(1):309-10, 313-4
Additional cost savings of an effective employee influenza program on prevention of nosocomial influenza [letter; comment] Boersma B, et al. **Am J Infect Control** 1999 Apr; 27(2):177-8. Comment on: Am J Infect Control 1998 Jun;26(3):367-8.
"McFlu". The Monroe County, New York, Medicare vaccine demonstration. Barker WH, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):118-27
Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Mac Donald R, et al. **Am J Prev Med** 1999 Apr;16(3):173-7
Public health in managed care: a randomized controlled trial of the effectiveness of postcard reminders. Clayton AE, et al. **Am J Public Health** 1999 Aug;89(8):1235-7
Influenza prevention and treatment: current practices and new horizons [editorial] Belshe RB. **Ann Intern Med** 1999 Oct 19;131(8):621-4
Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Tasker SA, et al. **Ann Intern Med** 1999 Sep 21;131(6):430-3
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Calfee DP, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1616-20
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Beyer WE, et al. **Arch Intern Med** 1999 Jan 25;159(2):182-8
Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. Drinka PJ, et al. **Arch Intern Med** 1998 Oct 26; 158(19):2155-9
Influenza vaccination in bedridden patients [letter] Fukushima T, et al. **Arch Intern Med** 1999 Feb 8; 159(3):316-7
Effect of prednisone on response to influenza virus vaccine in asthmatic children. Fairchok MP, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1191-5
Age is not only criterion for flu vaccine [letter] Nguyen-Van-Tam JS, et al. **BMJ** 1998 Oct 3;317(7163):946
Influenza vaccination among the elderly in Italy. Pregliasco F, et al. **Bull World Health Organ** 1999;77(2):127-31
An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998-1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1-12 (45 ref.) **(Eng, Fre)**
Cold/flu knowledge, attitudes and health care practices: results of a two-city telephone survey. Vingilis ER, et al. **Can J Public Health** 1999 May-Jun;90(3):205-8
Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996-1997. Beran J, et al. **Cent Eur J Public Health** 1998 Nov;6(4):269-73
Underused options for preventing and treating influenza. Mossad SB. **Cleve Clin J Med** 1999 Jan;66(1):19-23 (19 ref.)
Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Yasui H, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):186-92
Influenza, influenza virus vaccine, and human immunodeficiency virus infection [editorial; comment] Couch RB. **Clin Infect Dis** 1999 Mar;28(3):548-51. Comment on: Clin Infect Dis 1999 Mar;28(3):541-7.
Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Webster RG.

Clin Infect Dis 1999 Feb;28(2):225–9 (26 ref.)
Preparing for the flu season [published erratum appears in CMAJ 1998 Nov 17;159(10):1244] **CMAJ** 1998 Oct 20; 159(8):981–2
Fifty years of influenza surveillance [editorial] Ellis J, et al. **Commun Dis Public Health** 1999 Jun;2(2):81–2
Strain designation for influenza viruses [editorial] Ellis J, et al. **Commun Dis Public Health** 1999 Sep;2(3):157–9
Influenza immunisation and health care workers and other occupational groups. **Commun Dis Rep CDR Wkly** 1999 Aug 13;9(33):289, 292
Protective cellular immunity against influenza virus induced by plasmid inoculation of newborn mice. Bot A, et al. **Dev Immunol** 1998;5(3):197–210
Preparing for pandemic influenza: the need for enhanced surveillance. Gensheimer KF, et al. **Emerg Infect Dis** 1999 Mar–Apr;5(2):297–9
The next influenza pandemic: lessons from Hong Kong, 1997. Snacken R, et al. **Emerg Infect Dis** 1999 Mar–Apr; 5(2):195–203 (37 ref.)
The relentless flu drug [news] **Environ Health Perspect** 1998 Aug;106(8):A372–3
Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993–4: cigarette smoking as a risk factor and the efficacy of influenza vaccination. Nicholson KG, et al. **Epidemiol Infect** 1999 Aug; 123(1):103–8
Influenza vaccine in immunogenically naive healthy infants [letter] Donatelli I, et al. **Eur J Pediatr** 1998 Nov; 157(11):949–50
It'll only hurt a second? Microeconomic determinants of who gets flu shots. Mullahy J. **Health Econ** 1999 Feb;8(1):9–24
Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Ben-Yedidia T, et al. **Immunol Lett** 1998 Nov;64(1):9–15
Influenza vaccination in long-term-care facilities: structuring programs for success. McArthur MA, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):499–503
Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Ben-Yedidia T, et al. **Int Immunol** 1999 Jul;11(7):1043–51
How to improve the uptake of influenza vaccination in older persons at risk. Igoe G, et al. **Ir J Med Sci** 1999 Apr–Jun; 168(2):107–8
Influenza vaccine update. **J Ark Med Soc** 1998 Oct; 95(5):207–8
Flu vaccination decreases relative morbidity risk for people with diabetes [news] Vinicor F. **J Ark Med Soc** 1998 Oct; 95(5):182
Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. Operschall E, et al. **J Clin Virol** 1999 Jun;13(1–2):17–27
Influenza vaccination in heart transplant recipients. Fraund S, et al. **J Heart Lung Transplant** 1999 Mar;18(3):220–5
Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. Gubareva LV, et al. **J Infect Dis** 1998 Dec;178(6):1592–6
Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Li S, et al. **J Infect Dis** 1999 May;179(5):1132–8
Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **J Med Assoc Ga** 1998 Nov; 87(4):330
Influenza immunization recommendations for 1997–98. **J Miss State Med Assoc** 1998 Nov;39(11):424
"Life preserver" diabetes/flu campaign now being launched. McIlwain JS. **J Miss State Med Assoc** 1998 Nov;39(11):422
Workplace influenza immunization update [letter] Burris J, et al. **J Occup Environ Med** 1999 Jun;41(6):415
Comparison of influenza immunization rates for Oklahoma Medicare patients: 1995, 1996 and 1997. Millar JS, et al. **J Okla State Med Assoc** 1998 Dec;91(9):509–13
DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Kodihalli S, et al. **J Virol** 1999 Mar;73(3):2094–8
A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903–11
Protection against a lethal avian influenza A virus in a mammalian system. Riberdy JM, et al. **J Virol** 1999 Feb; 73(2):1453–9
From the Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged > or = 65 years--United States, 1997. **JAMA** 1998 Dec 2;280(21):1818–9
From the Centers for Disease Control and Prevention. Update: influenza activity--United States and worldwide, 1998–99 season, and composition of the 1999–2000 influenza vaccine. **JAMA** 1999 Jun 16;281(23):2178–80
JAMA patient page: flu. **JAMA** 1999 Mar 10;281(10):962
Influenza control--unfinished business [editorial; comment] Glezen WP. **JAMA** 1999 Mar 10;281(10):944–5. Comment on: JAMA 1999 Mar 10;281(10):901–7. Comment on: JAMA 1999 Mar 10;281(10):908–13.
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Hayden FG, et al. **JAMA** 1999 Oct 6;282(13):1240–6
Millennial influenza vaccine [news] Marwick C. **JAMA** 1999 Mar 10;281(10):887–8
Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial [see comments] Monto AS, et al. **JAMA** 1999 Jul 7;282(1):31–5. Comment in: JAMA 1999 Jul 7;282(1):75–7.
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial [see commentss] Nichol KL, et al. **JAMA** 1999 Jul 14;282(2):137–44
New options for prevention and control of influenza [editorial; comment] Patriarca PA. **JAMA** 1999 Jul 7; 282(1):75–7. Comment on: JAMA 1999 Jul 7;282(1):31–5.
Intranasal influenza vaccine: adding to the armamentarium for influenza control [editorial; comment] Poland GA, et al. **JAMA** 1999 Jul 14;282(2):182–4. Comment on: JAMA 1999 Jul 14;282(2):137–44.
Progress treating, preventing influenza [news] Stephenson J. **JAMA** 1998 Nov 25;280(20):1729–30
Effectiveness of influenza vaccine in health care professionals: a randomized trial [see comments] Wilde JA, et al. **JAMA** 1999 Mar 10;281(10):908–13. Comment in: JAMA 1999 Mar 10;281(10):944–5.
Failure to immunize the elderly: a systems problem or a statement of personal values? Fowles JB, et al. **Jt Comm J Qual Improv** 1998 Dec;24(12):704–10
Amantadine and pneumonia in elderly stroke patients [letter; comment] Chan NN. **Lancet** 1999 Jun 19;353(9170):2156–7 . Comment on: Lancet 1999 Apr 3;353(9159):1157.
Implications of age-based policies for influenza immunisation [letter] Watkins J, et al. **Lancet** 1999 Jan 16;353(9148):208–9
Efficacy of anti-influenza peptide vaccine in aged mice. Ben-Yedidia T, et al. **Mech Ageing Dev** 1998 Aug 1; 104(1):11–23
Meta-analysis of effectiveness of interventions to increase influenza immunization rates among high-risk population groups. Sarnoff R, et al. **Med Care Res Rev** 1998 Dec; 55(4):432–56
Time preferences and preventive health behavior: acceptance of the influenza vaccine. Chapman GB, et al. **Med Decis Making** 1999 Jul–Sep;19(3):307–14
Adult immunization: influenza and pneumonia. Maxim R. **Med Health R I** 1999 Jul;82(7):268–9
Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **Med Health R I** 1998 Oct; 81(10):321
Influenza vaccine, 1999–2000. **Med Lett Drugs Ther** 1999 Sep 10;41(1061):82–3
Update: influenza activity--United States and worldwide, 1998–99 season, and composition of the 1999–2000 influenza vaccine. **MMWR Morb Mortal Wkly Rep** 1999 May 14; 48(18):374–8
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). **MMWR Morb Mortal Wkly Rep** 1999 Apr 30; 48(RR-4):1–28
Influenzal and pneumococcal immunizations. A survey of policies and practices in North Carolina. Mims SR. **N C Med J** 1998 Sep–Oct;59(5):290–2
Doctors should add a flu shot to care regimen for diabetics [letter] Vinicor F. **N C Med J** 1998 Nov–Dec;59(6):340
What are the prospects for a universal influenza vaccine? [news; comment] Kilbourne ED. **Nat Med** 1999 Oct; 5(10):1119–20. Comment on: Nat Med 1999 Oct;5(10):1157–63.
A universal influenza A vaccine based on the extracellular domain of the M2 protein [see comments] Neirynck S, et al. **Nat Med** 1999 Oct;5(10):1157–63. Comment in: Nat Med 1999 Oct;5(10):1119–20.
Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21–2, 25–8 passim; quiz 38–9 (35 ref.)
Influenza immunization of schoolchildren: can we interrupt community epidemics? Poland GA, et al. **Pediatrics** 1999 Jun;103(6 Pt 1):1280–2
WHO tags 1999–2000 vaccine, prepares flu pandemic plan [news] **Public Health Rep** 1999 May–Jun;114(3):211
A double-blind placebo-controlled study of the effect of influenza vaccination on airway responsiveness in asthma. Reid DW, et al. **Respir Med** 1998 Aug;92(8):1010–1
Decision on influenza vaccination among the elderly. A questionnaire study based on the Health Belief Model and the Multidimensional Locus of Control Theory. Nexøe J, et al. **Scand J Prim Health Care** 1999 Jun;17(2):105–10
Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184–95 (116 ref.)
Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **Tenn Med** 1998 Nov;91(11):423
A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Babai I, et al. **Vaccine** 1999 Mar 5; 17(9–10):1223–38
A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Babai I, et al. **Vaccine** 1999 Mar 5;17(9–10):1239–50
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Berglund P, et al. **Vaccine** 1999 Feb 5;17(5):497–507
The plea against annual influenza vaccination? 'The Hoskins' Paradox' revisited. Beyer WE, et al. **Vaccine** 1998 Dec; 16(20):1929–32
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z, et al. **Vaccine** 1999 Feb 26;17(7–8):653–9
Modified M2 proteins produce heterotypic immunity against influenza A virus. Frace AM, et al. **Vaccine** 1999 May 4; 17(18):2237–44
Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory. Matsuki N, et al. **Vaccine** 1999 Mar 5;17(9–10):1161–8
Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Schilling M, et al. **Vaccine** 1998 Nov; 16(18):1771–4
Opportunities not missed--systematic influenza and pneumococcal immunization in a public inner-city emergency department. Slobodkin D, et al. **Vaccine** 1998 Nov;16(19):1795–802
Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Treanor JJ, et al. **Vaccine** 1998 Nov;16(18):1756–60
Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Wong JP, et al. **Vaccine** 1999 Mar 26; 17(13–14):1788–95
Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Pertmer TM, et al. **Virology** 1999 May 10; 257(2):406–14
Flu vaccination decreases morbidity risk for diabetics [letter] Vinicor F. **W V Med J** 1998 Sep–Oct;94(5):271
Influenza. Gross-Schulman S, et al. **West J Med** 1998 Dec; 169(6):377–8
Recommended composition of influenza virus vaccines for use in the 1999–2000 season. **Wkly Epidemiol Rec** 1999 Feb 26;74(8):57–61
Recommendation for the composition of influenza virus vaccines for use in 1999. **Wkly Epidemiol Rec** 1998 Oct 2;73(40):305–8 **(Eng, Fre)**
Adult immunization deserves physician involvement. Gold JA. **WMJ** 1998 Oct;97(9):59
[Role of antineuraminidase antibodies in protection against influenza] Aymard M, et al. **Bull Acad Natl Med** 1998; 182(8):1723–36; discussion 1736–7 (Eng. Abstr.) **(Fre)**
[Anticipating "flu mist"--soon a must] Gnehm HE. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2023–6 (8 ref.) **(Ger)**
[Immunogenicity and efficacy field evaluation (1994–1995 season) of influenza vaccine in a noninstitutionalized elderly population] Sandrini MC, et al. **Ann Ig** 1997 Sep–Oct; 9(5):373–9 **(Ita)**
[Prevention of influenza in nursing homes (letter)] Nygaard HA. **Tidsskr Nor Laegeforen** 1999 May 30;119(14):2079 **(Nor)**
[An evaluation of the epidemiological and economic efficacy of immunizing adults with the Vaxigrippe vaccine] Sharipova IS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul–Aug;(4):46–9 (Eng. Abstr.) **(Rus)**
[Impact of various strategies on the rates of flu vaccination in the elderly] Puig-Barberà J, et al. **Aten Primaria** 1999 Apr 15;23(6):339–45 (Eng. Abstr.) **(Spa)**
[Why should all persons over age 65 years be vaccinated against influenza?] Linde A, et al. **Lakartidningen** 1998 Oct 21;95(43):4744–8 (20 ref.) **(Swe)**

THERAPY

A homeopathic nosode for influenza-like syndromes. de Lange de Klerk E. **Forsch Komplementarmed** 1999 Feb; 6(1):31; discussion 31–2
[Medical audit: influenza. Group of Physicians for Quality Assurance, Fribourg] Carrel J. **Rev Med Suisse Romande** 1999 Mar;119(3):249–50 **(Fre)**
[I have influenza] Raetzo MA, et al. **Schweiz Rundsch Med Prax** 1999 Mar 11;88(11):479–82 **(Ger)**

TRANSMISSION

Spread of influenza A virus infection in hospitalised patients with cancer [letter] Schepetiuk S, et al. **Aust N Z J Med** 1998 Aug;28(4):475–6
[Transmission of viruses (letter)] Tholhuijsen L. **Tijdschr Diergeneeskd** 1999 Mar 15;124(6):192 **(Dut)**

VETERINARY

The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379–87 (11 ref.)
Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Rees WA, et al. **Am J Vet Res** 1999 Jul;60(7):888–94
Epizootic of equine influenza in 1969 in Poland. Kita J. **Arch Vet Pol** 1993;33(3–4):139–45
Effect of moderate exercise on the severity of clinical signs associated with influenza virus infection in horses. Gross DK, et al. **Equine Vet J** 1998 Nov;30(6):489–97
Investigations on the ability of clenbuterol hydrochloride to reduce clinical signs and inflammation associated with equine influenza A infection. Kästner SB, et al. **Equine Vet J** 1999 Mar;31(2):160–8
Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. Morley PS,

et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):61–6
Questions validity of equine vaccine field studies [letter] Piontkowski MD. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):620–1
Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9363–7
The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Guthrie AJ, et al. **Rev Sci Tech** 1999 Apr;18(1):179–85 (6 ref.)
Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. de Jong JC, et al. **Vaccine** 1999 Mar 17;17(11–12):1321–8
Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Lunn DP, et al. **Vaccine** 1999 May 4;17(18):2245–58
A PCR based method for the identification of equine influenza virus from clinical samples. Oxburgh L, et al. **Vet Microbiol** 1999 Jun 30;67(3):161–74
Bovine influenza [letter] Crawshaw TR, et al. **Vet Rec** 1998 Sep 26;143(13):372
Risk indicators for the seroprevalence of Mycoplasma hyopneumoniae, porcine influenza viruses and Aujeszky's disease virus in slaughter pigs from fattening pig herds. Maes D, et al. **Zentralbl Veterinarmed [B]** 1999 Jun; 46(5):341–52

VIROLOGY

Spontaneous release of stable viral double-stranded RNA into the extracellular medium by influenza virus-infected MDCK epithelial cells: implications for the viral acute phase response. Majde JA, et al. **Arch Virol** 1998; 143(12):2371–80
A novel amino acid substitution at the receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated from 6 cases with acute encephalopathy during the 1997–1998 season in Tokyo. Mori SI, et al. **Arch Virol** 1999; 144(1):147–55
Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Akhtar N, et al. **Circulation** 1999 Apr 20; 99(15):2011–8
Isolation of type B influenza virus from the blood of children. Xu H, et al. **Clin Infect Dis** 1998 Sep;27(3):654–5
Diminished IL-10 production in subjects with allergy after infection with influenza A virus. Gentile DA, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1045–8
Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. Magnard C, et al. **J Med Virol** 1999 Oct;59(2):215–20
Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. Gao P, et al. **J Virol** 1999 Apr;73(4):3184–9
The role of interferon in influenza virus tissue tropism. García-Sastre A, et al. **J Virol** 1998 Nov;72(11):8550–8
A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903–11
Human infection with influenza H9N2 [letter] Peiris M, et al. **Lancet** 1999 Sep 11;354(9182):916–7
Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene [see comments] Reid AH, et al. **Proc Natl Acad Sci U S A** 1999 Feb 16;96(4):1651–6. Comment in: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1164–6.
1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164–6 (31 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651–6.
Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997–1998. Bender C, et al. **Virology** 1999 Feb 1;254(1):115–23
Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Xu X, et al. **Virology** 1999 Aug 15;261(1):15–9

INFLUENZA A VIRUS

Antiviral effect of gingyo-san, a traditional Chinese herbal medicine, on influenza A2 virus infection in mice. Kobayashi M, et al. **Am J Chin Med** 1999;27(1):53–62
Duration of antiviral prophylaxis during nursing home outbreaks of influenza A: a comparison of 2 protocols. Drinka PJ, et al. **Arch Intern Med** 1998 Oct 26; 158(19):2155–9
Hemiballismus associated with Influenza A infection. Yoshikawa H, et al. **Brain Dev** 1999 Mar;21(2):132–4
Influenza surveillance in England and Wales: October 1997 to June 1998. Dedman DJ, et al. **Commun Dis Public Health** 1998 Dec;1(4):244–51
Effect of moderate exercise on the severity of clinical signs associated with influenza virus infection in horses. Gross DK, et al. **Equine Vet J** 1998 Nov;30(6):489–97
Investigations on the ability of clenbuterol hydrochloride to reduce clinical signs and inflammation associated with equine influenza A infection. Kästner SB, et al. **Equine Vet J** 1999 Mar;31(2):160–8
Systemic T cell expansion during localized viral infection. Haanen JB, et al. **Eur J Immunol** 1999 Apr;29(4):1168–74
Toxic shock syndrome following influenza A infection [letter] Sharkey R, et al. **Intensive Care Med** 1999 Mar; 25(3):335–6
Diminished IL-10 production in subjects with allergy after infection with influenza A virus. Gentile DA, et al. **J Allergy Clin Immunol** 1999 Jun;103(6):1045–8
Influenza A virus infection increases IgE production and airway responsiveness in aerosolized antigen-exposed mice. Suzuki S, et al. **J Allergy Clin Immunol** 1998 Nov; 102(5):732–40
Interferon-induced antiviral resistance. A mathematical model of regulation of Mx1 protein induction and action. Bazhan SI, et al. **J Theor Biol** 1999 Jun 7;198(3):375–93
From the Centers for Disease Control and Prevention. Outbreak of influenza A infection among travelers--Alaska and the Yukon Territory, May–June 1999. **JAMA** 1999 Jul 28;282(4):318–9
Morphine reduces pulmonary inflammation in response to influenza infection. Coussons-Read ME, et al. **Life Sci** 1999;65(11):1141–52
The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Guthrie AJ, et al. **Rev Sci Tech** 1999 Apr;18(1):179–85 (6 ref.)
Oligomerization of the influenza virus nucleoprotein: identification of positive and negative sequence elements. Elton D, et al. **Virology** 1999 Jul 20;260(1):190–200
[A case of influenza A virus associated encephalopathy with bilateral thalamic hemorrhage] Shinjoh M, et al. **Kansenshogaku Zasshi** 1999 Aug;73(8):778–82 (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)
Total chemical synthesis of the integral membrane protein influenza A virus M2: role of its C-terminal domain in tetramer assembly. Kochendoerfer GG, et al. **Biochemistry** 1999 Sep 14;38(37):11905–13
Defining the transmembrane helix of M2 protein from influenza A by molecular dynamics simulations in a lipid bilayer. Forrest LR, et al. **Biophys J** 1999 Apr; 76(4):1886–96
Relationship of membrane sidedness to the effects of the lipophosphoglycan of Leishmania donovani on the fusion of influenza virus. Razinkov V, et al. **Eur J Biochem** 1999 Jun;262(3):890–9
M protein correlates with the receptor-binding specificity of haemagglutinin protein of reassortant influenza A (H1N1) virus. Tong N, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2425–34
The M1 and NP proteins of influenza A virus form homo- but not heterooligomeric complexes when coexpressed in BHK-21 cells. Zhao H, et al. **J Gen Virol** 1998 Oct;79 (Pt 10):2435–46
A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein. Gerentes L, et al. **J Virol Methods** 1998 Aug; 73(2):185–95
Changes in H3 influenza A virus receptor specificity during replication in humans. Ryan-Poirier K, et al. **Virus Res** 1998 Aug;56(2):169–76

CLASSIFICATION

Cocirculation of two distinct lineages of equine influenza virus subtype H3N8. Oxburgh L, et al. **J Clin Microbiol** 1999 Sep;37(9):3005–9

DRUG EFFECTS

Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY, et al. **Clin Pharmacokinet** 1999; 36 Suppl 1:v–ix (24 ref.)
Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. Plotch SJ, et al. **J Virol** 1999 Jan; 73(1):140–51
In vitro and in vivo anti-influenza A virus activity of antisense oligonucleotides. Abe T, et al. **Nucleosides Nucleotides** 1999 Jun–Jul;18(6–7):1685–8

ENZYMOLOGY

Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. Doan L, et al. **Biochemistry** 1999 Apr 27; 38(17):5612–9
Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase. Jones PS, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):605–10
Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase. Smith PW, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):611–4
Synthesis of bromoindolyl 4,7-di-O-methyl-Neu5Ac: specificity toward influenza A and B viruses. Liav A, et al. **Carbohydr Res** 1999 Apr 30;317(1–4):198–203
Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. Kobasa D, et al. **J Virol** 1999 Aug;73(8):6743–51
Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Mizuta T, et al. **Nat Biotechnol** 1999 Jun; 17(6):583–7

GENETICS

Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. Poon LL, et al. **J Virol** 1999 Apr;73(4):3473–6
A hairpin loop at the 5' end of influenza A virus virion RNA is required for synthesis of poly(A)+ mRNA in vitro. Pritlove DC, et al. **J Virol** 1999 Mar;73(3):2109–14
Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication. Zheng H, et al. **J Virol** 1999 Jun; 73(6):5240–3
Generation of influenza transfectants using purified recombinant nucleocapsid protein. Shaw MW, et al. **J Virol Methods** 1998 Dec;76(1–2):149–51
Generation of influenza A viruses entirely from cloned cDNAs [see comments] Neumann G, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9345–50. Comment in: Proc Natl Acad Sci U S A 1999 Aug 3;96(16):8804–6.
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z, et al. **Vaccine** 1999 Feb 26;17(7–8):653–9
A classical bipartite nuclear localization signal on Thogoto and influenza A virus nucleoproteins. Weber F, et al. **Virology** 1998 Oct 10;250(1):9–18
A novel spliced transcript of influenza A/WSN/33 virus. Shih SR, et al. **Virus Genes** 1998;17(2):179–83
Influence of host species on the evolution of the nonstructural (NS) gene of influenza A viruses. Kawaoka Y, et al. **Virus Res** 1998 Jun;55(2):143–56
[Comparison of the synonymous and non-synonymous substitution rates in various regions of the neuraminidase and hemagglutinin genes of the influenza A virus] Makarova KS, et al. **Genetika** 1998 Aug;34(8):1040–4 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Elongation of the N-acyl side chain of sialic acids in MDCK II cells inhibits influenza A virus infection. Keppler OT, et al. **Biochem Biophys Res Commun** 1998 Dec 18; 253(2):437–42
Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. Voeten JT, et al. **Vaccine** 1999 Apr 9; 17(15–16):1942–50

IMMUNOLOGY

Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A. Martinet W, et al. **Arch Virol** 1998;143(10):2011–9
Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)
Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults. McElhaney JE, et al. **Clin Diagn Lab Immunol** 1998 Nov; 5(6):840–4
Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Yasui H, et al. **Clin Diagn Lab Immunol** 1999 Mar;6(2):186–92
Protective cellular immunity against influenza virus induced by plasmid inoculation of newborn mice. Bot A, et al. **Dev Immunol** 1998;5(3):197–210
Immunodeficient mouse models in the characterization of the protective immunity to influenza virus. Bot A, et al. **Folia Microbiol (Praha)** 1998;43(5):477–8
Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Prechl J, et al. **Immunopharmacology** 1999 May;42(1–3):159–65
Efficacy of a commercial vaccine for preventing disease caused by influenza virus infection in horses. Morley PS, et al. **J Am Vet Med Assoc** 1999 Jul 1;215(1):61–6
Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice. Karupiah G, et al. **J Exp Med** 1998 Oct 19;188(8):1541–6
Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition. Collins EJ, et al. **J Immunol** 1999 Jan 1;162(1):331–7
Three different MHC class I molecules bind the same CTL epitope of the influenza virus in a primate species with limited MHC class I diversity. Evans DT, et al. **J Immunol** 1999 Apr 1;162(7):3970–7
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. Fu TM, et al. **J Immunol** 1999 Apr 1;162(7):4163–70
Androstenediol (AED) prevents neuroendocrine-mediated suppression of the immune response to an influenza viral infection. Padgett DA, et al. **J Neuroimmunol** 1999 Aug 3;98(2):121–9
Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. Tamura M, et al.

J Virol 1998 Nov;72(11):9404–6

Influenza virus serology--a comparative study. Rothbarth PH, et al. **J Virol Methods** 1999 Mar;78(1–2):163–9

A universal influenza A vaccine based on the extracellular domain of the M2 protein [see comments] Neirynck S, et al. **Nat Med** 1999 Oct;5(10):1157–63. Comment in: Nat Med 1999 Oct;5(10):1119–20.

Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. Belz GT, et al. **Proc Natl Acad Sci U S A** 1998 Nov 10;95(23):13812–7

Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Bunting KD, et al. **Proc Natl Acad Sci U S A** 1999 Jan 5;96(1):232–7

Ontogeny of T cell tolerance to peripherally expressed antigens. Morgan DJ, et al. **Proc Natl Acad Sci U S A** 1999 Mar 30;96(7):3854–8

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Babai I, et al. **Vaccine** 1999 Mar 5; 17(9–10):1223–38

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Babai I, et al. **Vaccine** 1999 Mar 5;17(9–10):1239–50

Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice [published erratum appears in Vaccine 1999 Mar 17;17(11–12):1581] Bender BS, et al. **Vaccine** 1998 Nov;16(18):1748–55

Modified M2 proteins produce heterotypic immunity against influenza A virus. Frace AM, et al. **Vaccine** 1999 May 4; 17(18):2237–44

Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Fu TM, et al. **Vaccine** 1998 Nov; 16(18):1711–7

Biodegradable microspheres containing influenza A vaccine: immune response in mice. Hilbert AK, et al. **Vaccine** 1999 Mar 5;17(9–10):1065–73

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE. **Vaccine** 1999 Apr 9;17(15–16):2073–80

Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Rimmelzwaan GF, et al. **Vaccine** 1999 Jun 4;17(20–21):2512–6

Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Treanor JJ, et al. **Vaccine** 1998 Nov;16(18):1756–60

Detection of antibodies to influenza A virus in cattle in association with respiratory disease and reduced milk yield. Brown IH, et al. **Vet Rec** 1998 Dec 5;143(23):637–8

Costimulatory activity of inactivated influenza virus in response of human peripheral blood mononuclear cells to phytohemagglutinin A and anti-CD3 antibody. Eisenthal A, et al. **Viral Immunol** 1998;11(3):137–45

Immunization with the N-terminal region of the nonstructural protein NS1 promotes survival after challenge with lethal influenza A virus dose. Tamura M, et al. **Viral Immunol** 1998;11(3):131–5

A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Kistner O, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):207–14

[Role of antineuraminidase antibodies in protection against influenza] Aymard M, et al. **Bull Acad Natl Med** 1998; 182(8):1723–36; discussion 1736–7 (Eng. Abstr.) **(Fre)**

[Impact of influenza A virus infection as a cause of pediatric hospitalization and use of rapid antigen test of influenza A virus] Mitamura K, et al. **Kansenshogaku Zasshi** 1998 Sep;72(9):883–9 (Eng. Abstr.) **(Jpn)**

[A common antigenic epitope in influenza A virus (H1, H2, H5, H6) hemagglutinin] Smirnov IuA, et al. **Vopr Virusol** 1999 May-Jun;44(3):111–5 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Spread of influenza A virus infection in hospitalised patients with cancer [letter] Schepetiuk S, et al. **Aust N Z J Med** 1998 Aug;28(4):475–6

Clinical diversity in acute necrotizing encephalopathy. Yoshikawa H, et al. **J Child Neurol** 1999 Apr;14(4):249–55

Influenza A H9N2: aspects of laboratory diagnosis. Peiris M, et al. **J Clin Microbiol** 1999 Oct;37(10):3426–7

A PCR based method for the identification of equine influenza virus from clinical samples. Oxburgh L, et al. **Vet Microbiol** 1999 Jun 30;67(3):161–74

Bovine influenza [letter] Crawshaw TR, et al. **Vet Rec** 1998 Sep 26;143(13):372

Recommendation for the composition of influenza virus vaccines for use in 1999. **Wkly Epidemiol Rec** 1998 Oct 2;73(40):305–8 **(Eng, Fre)**

METABOLISM

Domain-structure of cytoplasmic border region is main determinant for palmitoylation of influenza virus hemagglutinin (H7). Ponimaskin E, et al. **Virology** 1998 Sep 30;249(2):325–35

Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Shimizu K, et al. **Virology** 1999 Feb 15;254(2):213–9

Phosphorylation of the M2 protein of influenza A virus is not essential for virus viability. Thomas JM, et al. **Virology** 1998 Dec 5;252(1):54–64

PATHOGENICITY

The role of endothelin in mediating virus-induced changes in endothelinB receptor density in mouse airways. Henry PJ, et al. **Eur Respir J** 1999 Jul;14(1):92–7

Influenza virus overcomes apoptosis by rapid multiplication. Kurokawa M, et al. **Int J Mol Med** 1999 May;3(5):527–30

Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses. Kido H, et al. **Mol Cells** 1999 Jun 30;9(3):235–44 (37 ref.)

New clues to the emergence of flu pandemics [news] Claas EC, et al. **Nat Med** 1998 Oct;4(10):1122–3

[How can the carbohydrate moiety of influenza virus HA contribute to the initiation of viral infection?] Ohuchi M, et al. **Uirusu** 1998 Jun;48(1):1–8 (26 ref.) **(Jpn)**

[Strain-dependent disruption of the functional activity of bone marrow stromal cells from mice infected with influenza A] Lavrov VF, et al. **Vopr Virusol** 1999 Mar-Apr; 44(2):72–5 (Eng. Abstr.) **(Rus)**

[Sensitivity of white mice to influenza virus (A/Aichi/2/68) in aerogenic infection] Sergeev AN, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):69–71 (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Inhibition of influenza A virus reproduction by a ribozyme targeted against PB1 mRNA. Lazarev VN, et al. **Antiviral Res** 1999 May;42(1):47–57

Influenza A virus infection modulates the expression of type IV collagenase in epithelial cells. Yeo SJ, et al. **Arch Virol** 1999;144(7):1361–70

Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Reuter JD, et al. **Bioconjug Chem** 1999 Mar-Apr;10(2):271–8

Relationship of membrane sidedness to the effects of the lipophosphoglycan of Leishmania donovani on the fusion of influenza virus. Razinkov V, et al. **Eur J Biochem** 1999 Jun;262(3):890–9

Influenza virus overcomes apoptosis by rapid multiplication. Kurokawa M, et al. **Int J Mol Med** 1999 May;3(5):527–30

Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. Schultz-Cherry S, et al. **J Clin Microbiol** 1998 Dec;36(12):3718–20

Selective targeting of habenular, thalamic midline and monoaminergic brainstem neurons by neurotropic influenza A virus in mice. Mori I, et al. **J Neurovirol** 1999 Aug; 5(4):355–62

Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. Gao P, et al. **J Virol** 1999 Apr;73(4):3184–9

Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. Hatada E, et al. **J Virol** 1999 Mar;73(3):2425–33

Inhibition of influenza virus replication by nitric oxide. Rimmelzwaan GF, et al. **J Virol** 1999 Oct;73(10):8880–3

Recruitment of apoptotic cysteine proteases (caspases) in influenza virus-induced cell death. Takizawa T, et al. **Microbiol Immunol** 1999;43(3):245–52

[Analysis of the mechanism of cell depolarization at initial stages of virus-cell interaction] Bakirov TS, et al. **Dokl Akad Nauk** 1998 Nov;363(2):258–9 **(Rus)**

[Differences in properties and structure of hemagglutinins from influenza virus variants, adapted to lungs of mice and beta-inhibitors from murine serum] Shilov AA, et al. **Dokl Akad Nauk** 1999 Mar;365(3):406–8 **(Rus)**

[Formation of two types of a proteolytically cleaved nucleoprotein in cells, infected by influenza virus] Semenova NP, et al. **Vopr Virusol** 1999 Mar-Apr;44(2):65–9 (Eng. Abstr.) **(Rus)**

INFLUENZA A VIRUS, AVIAN

Characteristics of H7N2 (nonpathogenic) avian influenza virus infections in commercial layers, in Pennsylvania, 1997–98. Ziegler AF, et al. **Avian Dis** 1999 Jan-Mar; 43(1):142–9

Avian strain of influenza A virus isolated from humans in Hong Kong. **Commun Dis Rep CDR Wkly** 1999 Apr 9; 9(15):131, 134

Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. Mounts AW, et al. **J Infect Dis** 1999 Aug;180(2):505–8

The bird flu--what lies ahead? [editorial] Tsang T. **Singapore Med J** 1999 Jan;40(1):1–2

[H 5 N1 avian influenza in Hong Kong] Tashiro M. **Uirusu** 1998 Dec;48(2):211–21 (21 ref.) **(Jpn)**

CLASSIFICATION

Antigenic and genetic analyses of H5 influenza viruses isolated from ducks in Asia. Imai M, et al. **Jpn J Vet Res** 1999 Feb;46(4):171–7

Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9363–7

Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Shortridge KF, et al. **Virology** 1998 Dec 20;252(2):331–42

DRUG EFFECTS

Antibacterial, antifungal and antiviral activity of propolis of different geographic origin. Kujumgiev A, et al. **J Ethnopharmacol** 1999 Mar;64(3):235–40

ENZYMOLOGY

Analysis of the binding of the Fab fragment of monoclonal antibody NC10 to influenza virus N9 neuraminidase from tern and whale using the BIAcore biosensor: effect of immobilization level and flow rate on kinetic analysis. Kortt AA, et al. **Anal Biochem** 1999 Aug 15;273(1):133–41

Molecular mapping of influenza virus RNA polymerase by site-specific antibodies. Masunaga K, et al. **Virology** 1999 Mar 30;256(1):130–41

GENETICS

Molecular characterization of the hemagglutinin gene and oral immunization with a waterfowl-origin avian influenza virus. Crawford JM, et al. **Avian Dis** 1998 Jul-Sep; 42(3):486–96

Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype. Brown IH, et al. **J Gen Virol** 1998 Dec;79 (Pt 12):2947–55

Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. Stech J, et al. **J Virol** 1999 Mar;73(3):1878–84

Phylogenetic analysis of H7 avian influenza viruses isolated from the live bird markets of the Northeast United States. Suarez DL, et al. **J Virol** 1999 May;73(5):3567–73

Rapid evolution of H5N1 influenza viruses in chickens in Hong Kong. Zhou NN, et al. **J Virol** 1999 Apr; 73(4):3366–74

Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. Zhou NN, et al. **J Virol** 1999 Oct;73(10):8851–6

Antigenic and genetic analyses of H5 influenza viruses isolated from ducks in Asia. Imai M, et al. **Jpn J Vet Res** 1999 Feb;46(4):171–7

Picture story. Fight the flu. **Nat Struct Biol** 1998 Dec; 5(12):1032

Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al. **Proc Natl Acad Sci U S A** 1999 Aug 3;96(16):9363–7

Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Garcia-Sastre A, et al. **Virology** 1998 Dec 20;252(2):324–30

Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Xu X, et al. **Virology** 1999 Aug 15;261(1):15–9

[Different patterns of molecular evolution of influenza A viruses in avian and human population] Makarova KS, et al. **Genetika** 1998 Jul;34(7):890–6 (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Evaluation of antibody responses of emus (Dromaius novaehollandiae) to avian influenza virus infection. Zhou EM, et al. **Avian Dis** 1998 Oct-Dec;42(4):757–61

Evaluation of a competitive ELISA for detection of antibodies against avian influenza virus nucleoprotein. Zhou EM, et al. **Avian Dis** 1998 Jul-Sep;42(3):517–22

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. Rowe T, et al. **J Clin Microbiol** 1999 Apr;37(4):937–43

Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. Jameson J, et al. **J Immunol** 1999 Jun 15;162(12):7578–83

DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Kodihalli S, et al. **J Virol** 1999 Mar;73(3):2094–8

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903–11

Protection against a lethal avian influenza A virus in a mammalian system. Riberdy JM, et al. **J Virol** 1999 Feb; 73(2):1453–9

Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. Takada A, et al. **J Virol** 1999 Oct;73(10):8303–7

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Rimmelzwaan GF, et al. **Vaccine** 1999 Mar 17;17(11–12):1355–8

[Dependence of antigenic properties of human and avian influenza A virus NP proteins on strain variations in the amino acid sequence] Krichevets SG, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):158–62 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Comparison of an antigen-capture enzyme immunoassay with virus isolation for avian influenza from field samples. Davison S, et al. **Avian Dis** 1998 Oct-Dec;42(4):791–5

The first case of H5N1 avian influenza infection in a human

with complications of adult respiratory distress syndrome and Reye's syndrome. Ku AS, et al.
J Paediatr Child Health 1999 Apr;35(2):207-9

[Influenza A (H5N1) in Hong Kong: Forerunner of a pandemic or just a scientifically interesting phenomenon and a useful exercise in pandemiology?] de Jong JC, et al. **Ned Tijdschr Geneeskd** 1998 May 30;142(22):1252-6 (14 ref.) (Eng. Abstr.) **(Dut)**

METABOLISM

The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Matrosovich M, et al. **J Virol** 1999 Feb;73(2):1146-55

PATHOGENICITY

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903-11

Picture story. Fight the flu. **Nat Struct Biol** 1998 Dec; 5(12):1032

PHYSIOLOGY

Strain-specific differences in the effect of influenza A virus neuraminidase on vector-expressed hemagglutinin. Kaverin NV, et al. **Arch Virol** 1999;144(4):781-6

Influenza viruses select ordered lipid domains during budding from the plasma membrane. Scheiffele P, et al.
J Biol Chem 1999 Jan 22;274(4):2038-44

Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. Gubareva LV, et al.
J Infect Dis 1998 Dec;178(6):1592-6

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. Moran TM, et al.
J Infect Dis 1999 Sep;180(3):579-85

The in situ spatial arrangement of the influenza A virus matrix protein M1 assessed by tritium bombardment. Shishkov AV, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6; 96(14):7827-30

INFLUENZA A VIRUS, HUMAN

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Tasker SA, et al. **Ann Intern Med** 1999 Sep 21;131(6):430-3

Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Calfee DP, et al. **Antimicrob Agents Chemother** 1999 Jul;43(7):1616-20

Exacerbation of influenzavirus pneumonia by intranasal administration of surfactant in a mouse model. Iwasaki T, et al. **Arch Virol** 1999;144(4):675-85

Influenza in travellers to Alaska, the Yukon Territory, and on west coast cruise ships, summer of 1999.
Can Commun Dis Rep 1999 Aug 15;25(16):137-9; discussion 139-41 **(Eng, Fre)**

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Pöltl-Frank F, et al. **Clin Exp Immunol** 1999 Sep; 117(3):496-503

Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: separation of attachment and fusion functions on different molecules. Patterson SM, et al. **Gene Ther** 1999 Apr;6(4):694-702

Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. Fritz RS, et al.
J Infect Dis 1999 Sep;180(3):586-93

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. Monto AS, et al. **J Infect Dis** 1999 Aug; 180(2):254-61

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [see comments] [published errata appear in Lancet 1999 Feb 6;353(9151):504 and 1999 Mar 27;353(9158):1104] **Lancet** 1998 Dec 12;352(9144):1877-81. Comment in: Lancet 1998 Dec 12;352(9144):1872-3. Comment in: Lancet 1999 Feb 20;353(9153):668-9. Comment in: Lancet 1999 Feb 20;353(9153):669.

Outbreak of influenza A infection among travelers--Alaska and the Yukon Territory, May-June 1999.
MMWR Morb Mortal Wkly Rep 1999 Jul 2;48(25):545-6, 555

Detection of influenza virus induced DNA damage by comet assay. Vijaya Lakshmi AN, et al. **Mutat Res** 1999 Jun 7; 442(1):53-8

Efficacy of antibiotics against influenza-like illness in an influenza epidemic. Maeda S, et al. **Pediatr Int** 1999 Jun; 41(3):274-6

Virological and pathomorphological aspects in experimental infections with some triassociated pneumotropic viruses in the white mouse. Petica M, et al. **Rom J Virol** 1997 Jan-Dec;48(1-4):27-42

The influenza virus M2 ion channel protein: probing the structure of the transmembrane domain in intact cells by using engineered disulfide cross-linking. Bauer CM, et al.
Virology 1999 Feb 1;254(1):196-209

[Use of amantadine for influenza A encephalopathy] Miura M, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):840-4 (Eng. Abstr.) **(Jpn)**

[Aspergillosis following influenza A infection] Funabiki Y, et al. **Nippon Ronen Igakkai Zasshi** 1999 Apr;36(4):274-8 (Eng. Abstr.) **(Jpn)**

[A case of myasthenia gravis with transient remission after influenza A virus infection] Yamada K, et al.
No To Hattatsu 1999 Jan;31(1):70-4 (Eng. Abstr.) **(Jpn)**

[Clinical features of the new influenza virus infection] Tanabe O. **Ryoikibetsu Shokogun Shirizu** 1999;(23 Pt 1):77-9 (8 ref.) **(Jpn)**

[A modification to the chloroform-methanol method of isolating the matrix protein of the influenza virus] Gordienko AI, et al. **Mikrobiol Z** 1998 May-Jun;60(3):91-5 (Eng. Abstr.) **(Rus)**

CHEMISTRY

Crystal structures of HLA-A*0201 complexed with antigenic peptides with either the amino- or carboxyl-terminal group substituted by a methyl group. Bouvier M, et al.
Proteins 1998 Oct 1;33(1):97-106

CLASSIFICATION

Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. Stockton J, et al.
J Clin Microbiol 1998 Oct;36(10):2990-5

Natural and 'in vitro' selected antigenic variants of influenza A virus (H2N2). Natali A, et al. **J Infect** 1998 Jul; 37(1):19-23

Human infection with influenza H9N2 [letter] Peiris M, et al. **Lancet** 1999 Sep 11;354(9182):916-7

Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al.
Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9363-7

[The characterization of influenza viruses by the immunoperoxidase method using monoclonal antibodies. Its setup and validation] Oropesa Fernández S, et al.
Rev Cubana Med Trop 1996;48(3):149-54 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Thujaplicin-copper chelates inhibit replication of human influenza viruses. Miyamoto D, et al. **Antiviral Res** 1998 Aug;39(2):89-100

Identification of a novel HA conformational change inhibitor of human influenza virus. Yoshimoto J, et al.
Arch Virol 1999;144(5):865-78

Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. Skoner DP, et al. **J Infect Dis** 1999 Jul;180(1):10-4

Optimization of in situ cellular ELISA performed on influenza A virus-infected monolayers for screening of antiviral agents. Myc A, et al. **J Virol Methods** 1999 Feb; 77(2):165-77

[Influenza: new therapeutic perspectives] Bricaire F.
Presse Med 1998 Dec;27 Suppl 5:24-6 (Eng. Abstr.) **(Fre)**

[Stabilization of influenza virus with antioxidants] Poryvaev VD, et al. **Vopr Virusol** 1999 Jan-Feb;44(1):24-9 (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Tai CY, et al. **Antimicrob Agents Chemother** 1998 Dec;42(12):3234-41

Role of neuraminidase in influenza virus-induced apoptosis. Morris SJ, et al. **J Gen Virol** 1999 Jan;80 (Pt 1):137-46

GENETICS

A novel amino acid substitution at the receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated from 6 cases with acute encephalopathy during the 1997-1998 season in Tokyo. Mori SI, et al. **Arch Virol** 1999; 144(1):147-55

Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype. Brown IH, et al.
J Gen Virol 1998 Dec;79 (Pt 12):2947-55

Biochemical and genetic evidence for complex formation between the influenza A virus NS1 protein and the interferon-induced PKR protein kinase. Tan SL, et al.
J Interferon Cytokine Res 1998 Sep;18(9):757-66

Effect of inhibitors in clinical specimens on Taq and Tth DNA polymerase-based PCR amplification of influenza A virus. Poddar SK, et al. **J Med Microbiol** 1998 Dec; 47(12):1131-5

Temperature-sensitive lesions in two influenza A viruses defective for replicative transcription disrupt RNA binding by the nucleoprotein. Medcalf L, et al. **J Virol** 1999 Sep; 73(9):7349-56

Mutational analysis of influenza A virus nucleoprotein: identification of mutations that affect RNA replication. Mena I, et al. **J Virol** 1999 Feb;73(2):1186-94

Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. Zhou NN, et al. **J Virol** 1999 Oct;73(10):8851-6

The 1918 'Spanish' flu: pearls from swine? [news] [see comments] Shortridge KF. **Nat Med** 1999 Apr;5(4):384-5 . Comment in: Nat Med 1999 Jun;5(6):592.

Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Guan Y, et al.
Proc Natl Acad Sci U S A 1999 Aug 3;96(16):9363-7

Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene [see comments] Reid AH, et al.
Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651-6. Comment in: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1164-6.

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164-6 (31 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651-6.

Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Bender C, et al. **Virology** 1999 Feb 1;254(1):115-23

Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Xu X, et al. **Virology** 1999 Aug 15;261(1):15-9

Genetic analysis of mouse-adapted influenza A virus identifies roles for the NA, PB1, and PB2 genes in virulence. Brown EG, et al. **Virus Res** 1999 May; 61(1):63-76

Identification of the 5' terminal structure of influenza virus genome RNA by a newly developed enzymatic method. Honda A, et al. **Virus Res** 1998 Jun;55(2):199-206

[Different patterns of molecular evolution of influenza A viruses in avian and human population] Makarova KS, et al. **Genetika** 1998 Jul;34(7):890-6 (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Long-term stability of the anti-influenza A compounds--amantadine and rimantadine. Scholtissek C, et al. **Antiviral Res** 1998 Jun;38(3):213-5

IMMUNOLOGY

Host responses to respiratory virus infection and immunization. Crowe JE Jr.
Curr Top Microbiol Immunol 1999;236:191-214 (235 ref.)

Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993-4: cigarette smoking as a risk factor and the efficacy of influenza vaccination. Nicholson KG, et al. **Epidemiol Infect** 1999 Aug; 123(1):103-8

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Ben-Yedidia T, et al. **Int Immunol** 1999 Jul;11(7):1043-51

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Le Gal FA, et al. **Int Immunol** 1999 Aug; 11(8):1351-6

Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. Ohmit SE, et al. **J Am Geriatr Soc** 1999 Feb; 47(2):165-71

Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. Voeten JT, et al.
J Clin Microbiol 1998 Dec;36(12):3527-31

Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. Operschall E, et al. **J Clin Virol** 1999 Jun;13(1-2):17-27

Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. Pirhonen J, et al. **J Immunol** 1999 Jun 15;162(12):7322-9

Natural and 'in vitro' selected antigenic variants of influenza A virus (H2N2). Natali A, et al. **J Infect** 1998 Jul; 37(1):19-23

Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. de Bruijn IA, et al. **J Infect Dis** 1999 Jan;179(1):31-6

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. Ferko B, et al. **J Infect Dis** 1998 Nov; 178(5):1359-68

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Li S, et al.
J Infect Dis 1999 May;179(5):1132-8

Influence of the amino acid differences between the hemagglutinin HA1 domains of influenza virus H1N1 strains on their reaction with antibody. Drescher J, et al.
J Med Virol 1999 Apr;57(4):397-404

Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. Glück U, et al. **J Virol** 1999 Sep;73(9):7780-6

Human cytotoxic T-lymphocyte repertoire to influenza A viruses. Jameson J, et al. **J Virol** 1998 Nov;72(11):8682-9

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903-11

Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Baumgarth N, et al. **Proc Natl Acad Sci U S A** 1999 Mar 2;96(5):2250-5

INFLUENZA A VIRUS, HUMAN

A double-blind placebo-controlled study of the effect of influenza vaccination on airway responsiveness in asthma. Reid DW, et al. **Respir Med** 1998 Aug;92(8):1010–1

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Deliyannis G, et al. **Vaccine** 1998 Dec;16(20):2058–68

Induction of antibody response by DNA immunization of newborn baboons against influenza virus. Bot A, et al. **Viral Immunol** 1999;12(2):91–6

Augmentation of human influenza A virus–specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Ennis FA, et al. **Virology** 1999 Jul 5;259(2):256–61

Treatment of influenza virus–infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Mozdzanowska K, et al. **Virology** 1999 Feb 1;254(1):138–46

Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Nguyen HH, et al. **Virology** 1999 Feb 1;254(1):50–60

Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Pertmer TM, et al. **Virology** 1999 May 10; 257(2):406–14

[Evaluation of a rapid enzyme immunoassay membrane test for diagnosis of influenza A virus infection] Shimizu H, et al. **Kansenshogaku Zasshi** 1998 Aug;72(8):827–33 (Eng. Abstr.) **(Jpn)**

[The effect of influenza virus hemagglutinin on erythrocytes and thrombocytes] Zhilinskaia IN, et al. **Izv Akad Nauk Ser Biol** 1999 May-Jun;(3):355–8 (Eng. Abstr.) **(Rus)**

[Dependence of antigenic properties of human and avian influenza A virus NP proteins on strain variations in the amino acid sequence] Krichevets SG, et al. **Vopr Virusol** 1999 Jul-Aug;44(4):158–62 (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

Non-influenza respiratory viruses may overlap and obscure influenza activity. Drinka PJ, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1087–93

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. Hayden FG, et al. **JAMA** 1999 Oct 6;282(13):1240–6

[Fast detection and characterization of influenza A and B viruses in nasopharyngeal secretions by the immunoperoxidase method] Oropesa Fernández S, et al. **Rev Cubana Med Trop** 1998;50(1):36–41 (Eng. Abstr.) **(Spa)**

METABOLISM

Synthetic sialylphosphatidylethanolamine derivatives bind to human influenza A viruses and inhibit viral infection. Guo CT, et al. **Glycoconj J** 1998 Nov;15(11):1099–108

Selective perturbation of early endosome and/or trans-Golgi network pH but not lysosome pH by dose-dependent expression of influenza M2 protein. Henkel JR, et al. **J Biol Chem** 1999 Apr 2;274(14):9854–60

Influenza A virus up-regulates neutrophil adhesion molecules and adhesion to biological surfaces. Hartshorn KL, et al. **J Leukoc Biol** 1999 May;65(5):614–22

Experimentally based orientational refinement of membrane protein models: A structure for the Influenza A M2 H+ channel. Kukol A, et al. **J Mol Biol** 1999 Feb 26; 286(3):951–62

Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. Elton D, et al. **J Virol** 1999 Sep;73(9):7357–67

The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Matrosovich M, et al. **J Virol** 1999 Feb;73(2):1146–55

Association of influenza virus matrix protein with ribonucleoproteins. Ye Z, et al. **J Virol** 1999 Sep; 73(9):7467–73

Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Gambaryan AS, et al. **Virology** 1999 Jun 5;258(2):232–9

PATHOGENICITY

The role of interferon in influenza virus tissue tropism. Garcia-Sastre A, et al. **J Virol** 1998 Nov;72(11):8550–8

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. Lu X, et al. **J Virol** 1999 Jul;73(7):5903–11

Genetic analysis of mouse-adapted influenza A virus identifies roles for the NA, PB1, and PB2 genes in virulence. Brown EG, et al. **Virus Res** 1999 May; 61(1):63–76

PHYSIOLOGY

Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines. Noma K, et al. **Arch Virol** 1998;143(10):1893–909

Interactions of influenza virus with cultured cells: detailed kinetic modeling of binding and endocytosis. Nunes-Correia I, et al. **Biochemistry** 1999 Jan 19; 38(3):1095–101

Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Colamussi ML, et al. **Blood** 1999 Apr 1;93(7):2395–403

Binding of bacteria to HEp-2 cells infected with influenza A virus. El Ahmer OR, et al. **FEMS Immunol Med Microbiol** 1999 Apr;23(4):331–41

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. Moran TM, et al. **J Infect Dis** 1999 Sep;180(3):579–85

Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans. Kallas EG, et al. **J Interferon Cytokine Res** 1999 Jul;19(7):751–5

Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. Rimmelzwaan GF, et al. **J Virol Methods** 1998 Sep; 74(1):57–66

Membrane fusion by surrogate receptor-bound influenza haemagglutinin. Millar BM, et al. **Virology** 1999 May 10; 257(2):415–23

Interference by a non-defective variant of influenza A virus is due to enhanced RNA synthesis and assembly. Bailly JE, et al. **Virus Res** 1998 Sep;57(1):81–100

[Antitumor activity of cold-adapted strains of influenza virus in a model transformed murine tumor cells] Kiseleva IV, et al. **Vopr Virusol** 1999 Jan-Feb;44(1):29–32 (Eng. Abstr.) **(Rus)**

INFLUENZA A VIRUS, PORCINE

CLASSIFICATION

Continued circulation of reassortant H1N2 influenza viruses in pigs in Japan. Ito T, et al. **Arch Virol** 1998;143(9):1773–82

GENETICS

Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. Stech J, et al. **J Virol** 1999 Mar;73(3):1878–84

Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. Zhou NN, et al. **J Virol** 1999 Oct;73(10):8851–6

1918 Spanish influenza: the secrets remain elusive [comment] Webster RG. **Proc Natl Acad Sci U S A** 1999 Feb 16; 96(4):1164–6 (31 ref.). Comment on: Proc Natl Acad Sci U S A 1999 Feb 16;96(4):1651–6.

IMMUNOLOGY

Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. Jameson J, et al. **J Immunol** 1999 Jun 15;162(12):7578–83

Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. de Jong JC, et al. **Vaccine** 1999 Mar 17;17(11-12):1321–8

INFLUENZA B VIRUS

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Gubareva LV, et al. **J Infect Dis** 1998 Nov;178(5):1257–62

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. Monto AS, et al. **J Infect Dis** 1999 Aug; 180(2):254–61

Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group [see comments] [published errata appear in Lancet 1999 Feb 6;353(9151):504 and 1999 Mar 27;353(9158):1104] **Lancet** 1998 Dec 12;352(9144):1877–81. Comment in: Lancet 1998 Dec 12;352(9144):1872–3. Comment in: Lancet 1999 Feb 20;353(9153):668–9. Comment in: Lancet 1999 Feb 20;353(9153):669.

[Outbreak of influenza B virus infections in summer season] Sahara K, et al. **Kansenshogaku Zasshi** 1999 Mar; 73(3):253–4 **(Jpn)**

CLASSIFICATION

Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. Stockton J, et al. **J Clin Microbiol** 1998 Oct;36(10):2990–5

[The characterization of influenza viruses by the immunoperoxidase method using monoclonal antibodies. Its setup and validation] Oropesa Fernández S, et al. **Rev Cubana Med Trop** 1996;48(3):149–54 (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Identification of a novel HA conformational change inhibitor of human influenza virus. Yoshimoto J, et al. **Arch Virol** 1999;144(5):865–78

Zanamivir. A potent and selective inhibitor of influenza A and B viruses. Aoki FY, et al. **Clin Pharmacokinet** 1999; 36 Suppl 1:v–ix (24 ref.)

ENZYMOLOGY

Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase. Jones PS, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):605–10

Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase. Smith PW, et al. **Bioorg Med Chem Lett** 1999 Feb 22;9(4):611–4

Synthesis of bromoindolyl 4,7-di-O-methyl-Neu5Ac: specificity toward influenza A and B viruses. Liav A, et al. **Carbohydr Res** 1999 Apr 30;317(1–4):198–203

GENETICS

Isolation and characterization of a transfectant influenza B virus altered in RNA segment 6. Rowley KV, et al. **J Gen Virol** 1999 Sep;80 (Pt 9):2353–9

Genetic characterization of the hemagglutinin of two strains of influenza B virus co-circulated in Taiwan. Chan CH, et al. **J Med Virol** 1999 Oct;59(2):208–14

Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. Lindstrom SE, et al. **J Virol** 1999 May;73(5):4413–26

Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. McCullers JA, et al. **J Virol** 1999 Sep;73(9):7343–8

IMMUNOLOGY

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Ben-Yedidia T, et al. **Int Immunol** 1999 Jul;11(7):1043–51

Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. Voeten JT, et al. **J Clin Microbiol** 1998 Dec;36(12):3527–31

Rapid detection and identification of two lineages of influenza B strains with monoclonal antibodies. Nakagawa N, et al. **J Virol Methods** 1999 Apr;79(1):113–20

Influenza virus serology--a comparative study. Rothbarth PH, et al. **J Virol Methods** 1999 Mar;78(1–2):163–9

Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Kriesel JD, et al. **Vaccine** 1999 Apr 9; 17(15–16):1883–8

Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Treanor JJ, et al. **Vaccine** 1998 Nov;16(18):1756–60

A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Kistner O, et al. **Wien Klin Wochenschr** 1999 Mar 12;111(5):207–14

ISOLATION & PURIFICATION

Isolation of type B influenza virus from the blood of children. Xu H, et al. **Clin Infect Dis** 1998 Sep;27(3):654–5

Evaluation of an indirect immunofluorescence assay and two cell lines in the detection of influenza B virus in nasopharyngeal samples. Reina J, et al. **Eur J Clin Microbiol Infect Dis** 1998 Jul;17(7):532–4

Non-influenza respiratory viruses may overlap and obscure influenza activity. Drinka PJ, et al. **J Am Geriatr Soc** 1999 Sep;47(9):1087–93

Rapid detection and identification of two lineages of influenza B strains with monoclonal antibodies. Nakagawa N, et al. **J Virol Methods** 1999 Apr;79(1):113–20

Recommendation for the composition of influenza virus vaccines for use in 1999. **Wkly Epidemiol Rec** 1998 Oct 2;73(40):305–8 **(Eng, Fre)**

[Fast detection and characterization of influenza A and B viruses in nasopharyngeal secretions by the immunoperoxidase method] Oropesa Fernández S, et al. **Rev Cubana Med Trop** 1998;50(1):36–41 (Eng. Abstr.) **(Spa)**

METABOLISM

Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Gambaryan AS, et al. **Virology** 1999 Jun 5;258(2):232–9

PATHOGENICITY

Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome. Crocker JF, et al. **Clin Invest Med** 1998 Aug-Oct;21(4–5):192–202

PHYSIOLOGY

Suppression of endothelin system in Vero cells latently infected with influenza virus B/Lee/40. Hayase Y, et al. **Arch Virol** 1999;144(7):1421–7

Endogenous protease-dependent replication of human influenza viruses in two MDCK cell lines. Noma K, et al. **Arch Virol** 1998;143(10):1893–909

Coinfection with influenza B virus does not affect association of Neisseria meningitidis with human nasopharyngeal mucosa in organ culture. Read RC, et al. **Infect Immun** 1999 Jun;67(6):3082–6

Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. Schultz-Cherry S, et al. **J Clin Microbiol** 1998 Dec;36(12):3718-20

Inhibition of influenza virus replication by nitric oxide. Rimmelzwaan GF, et al. **J Virol** 1999 Oct;73(10):8880-3

INFLUENZA C VIRUS see **INFLUENZAVIRUS C**

INFLUENZA D VIRUS see **PARAINFLUENZA VIRUS 1, HUMAN**

INFLUENZA VACCINE

The equine influenza surveillance program. Mumford JA. **Adv Vet Med** 1999;41:379-87 (11 ref.)

Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. Nichol KL. **Am J Med** 1998 Nov; 105(5):385-92

Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Nichol KL, et al. **Ann Intern Med** 1999 Mar 2;130(5):397-403

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Tasker SA, et al. **Ann Intern Med** 1999 Sep 21;131(6):430-3

Evaluation of antibody responses of emus (Dromaius novaehollandiae) to avian influenza virus infection. Zhou EM, et al. **Avian Dis** 1998 Oct-Dec;42(4):757-61

Age is not only criterion for flu vaccine [letter] Nguyen-Van-Tam JS, et al. **BMJ** 1998 Oct 3;317(7163):946

An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 1998-1999 season. **Can Commun Dis Rep** 1998 Jul 1;24:1-12 (45 ref.) **(Eng, Fre)**

Influenza vaccination of high-risk children: a survey of three physician groups. Ipp M, et al. **Can J Public Health** 1998 Nov-Dec;89(6):415-8

Influenza A among community-dwelling elderly persons in Leicestershire during winter 1993-4; cigarette smoking as a risk factor and the efficacy of influenza vaccination. Nicholson KG, et al. **Epidemiol Infect** 1999 Aug; 123(1):103-8

A managed care organization's attempt to increase influenza and pneumococcal immunizations for older adults in an acute care setting. Bloom HG, et al. **J Am Geriatr Soc** 1999 Jan;47(1):106-10

Mailed reminders for area-wide influenza immunization: a randomized controlled trial. Smith DM, et al. **J Am Geriatr Soc** 1999 Jan;47(1):1-5

Measuring the effects of reminders for outpatient influenza immunizations at the point of clinical opportunity. Tang PC, et al. **J Am Med Inform Assoc** 1999 Mar-Apr; 6(2):115-21

Effects of inactivated influenza virus vaccination on bronchial reactivity symptom scores and peak expiratory flow variability in patients with asthma. Sener M, et al. **J Asthma** 1999;36(2):165-9

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. Moran TM, et al. **J Infect Dis** 1999 Sep;180(3):579-85

Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **J Med Assoc Ga** 1998 Nov; 87(4):330

From the Centers for Disease Control and Prevention. Update: influenza activity--United States and worldwide, 1998-99 season, and composition of the 1999-2000 influenza vaccine. **JAMA** 1999 Jun 16;281(23):2178-80

JAMA patient page: flu. **JAMA** 1999 Mar 10;281(10):962

Influenza control--unfinished business [editorial; comment] Glezen WP. **JAMA** 1999 Mar 10;281(10):944-5. Comment on: JAMA 1999 Mar 10;281(10):901-7. Comment on: JAMA 1999 Mar 10;281(10):908-13.

Millennial influenza vaccine [news] Marwick C. **JAMA** 1999 Mar 10;281(10):887-8

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial [see commentss] Nichol KL, et al. **JAMA** 1999 Jul 14;282(2):137-44

Intranasal influenza vaccine: adding to the armamentarium for influenza control [editorial; comment] Poland GA, et al. **JAMA** 1999 Jul 14;282(2):182-4. Comment on: JAMA 1999 Jul 14;282(2):137-44.

Effectiveness of influenza vaccine in health care professionals: a randomized trial [see comments] Wilde JA, et al. **JAMA** 1999 Mar 10;281(10):908-13. Comment in: JAMA 1999 Mar 10;281(10):944-5.

Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **Med Health R I** 1998 Oct; 81(10):321

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). **MMWR Morb Mortal Wkly Rep** 1999 Apr 30; 48(RR-4):1-28

Update: influenza activity--United States and worldwide, 1998-99 season, and composition of the 1999-2000 influenza vaccine. **MMWR Morb Mortal Wkly Rep** 1999 May 14; 48(18):374-8

Influenza vaccination status of persons aged 65-79 years--Allegheny County, Pennsylvania, February-March 1997. **MMWR Morb Mortal Wkly Rep** 1998 Dec 25; 47(50):1094-7

WHO tags 1999-2000 vaccine, prepares flu pandemic plan [news] **Public Health Rep** 1999 May-Jun;114(3):211

Recommendations pertaining to the use of viral vaccines: influenza. **S Afr Med J** 1999 Feb;89(2):138

Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. Hilgers LA, et al. **Vaccine** 1999 Jan 21;17(3):219-28

Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory. Matsuki N, et al. **Vaccine** 1999 Mar 5;17(9-10):1161-8

A comprehensive influenza campaign in a managed care setting. Pearson DC, et al. **Vaccine** 1998 Nov; 16(18):1718-21

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Rimmelzwaan GF, et al. **Vaccine** 1999 Mar 17;17(11-12):1355-8

[Impact of various strategies on the rates of flu vaccination in the elderly] Puig-Barberà J, et al. **Aten Primaria** 1999 Apr 15;23(6):339-45 (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Health care workers: vectors of influenza virus? Low vaccination rate among hospital health care workers. Beguin C, et al. **Am J Med Qual** 1998 Winter;13(4):223-7

"McFlu". The Monroe County, New York, Medicare vaccine demonstration. Barker WH, et al. **Am J Prev Med** 1999 Apr;16(3 Suppl):118-27

Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Mac Donald R, et al. **Am J Prev Med** 1999 Apr;16(3):173-7

Demonstration of the feasibility of emergency department immunization against influenza and pneumococcus. Slobodkin D, et al. **Ann Emerg Med** 1998 Nov;32(5):537-43

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Beyer WE, et al. **Arch Intern Med** 1999 Jan 25;159(2):182-8

Influenza vaccination in bedridden patients [letter] Fukushima T, et al. **Arch Intern Med** 1999 Feb 8; 159(3):316-7

Benefits of influenza vaccination for bedridden patients [letter] Fukushima T, et al. **Arch Intern Med** 1999 Jun 14; 159(11):1258

Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Coombes AG, et al. **Biomaterials** 1998 Jun;19(11-12):1073-81

Influenza vaccination among the elderly in Italy. Pregliasco F, et al. **Bull World Health Organ** 1999;77(2):127-31

Underused options for preventing and treating influenza. Mossad SB. **Cleve Clin J Med** 1999 Jan;66(1):19-23 (19 ref.)

Influenza, influenza virus vaccine, and human immunodeficiency virus infection [editorial; comment] Couch RB. **Clin Infect Dis** 1999 Mar;28(3):548-51. Comment on: Clin Infect Dis 1999 Mar;28(3):541-7.

Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Webster A, et al. **Clin Pharmacokinet** 1999;36 Suppl 1:51-8

Preparing for the flu season [published erratum appears in CMAJ 1998 Nov 17;159(10):1244] **CMAJ** 1998 Oct 20; 159(8):981-2

Acute respiratory infections, and influenza vaccine for 1999/2000. **Commun Dis Rep CDR Wkly** 1999 Mar 5; 9(10):87, 90

Influenza vaccine in immunogenically naive healthy infants [letter] Donatelli I, et al. **Eur J Pediatr** 1998 Nov; 157(11):949-50

Influenza vaccination in long-term-care facilities: structuring programs for success. McArthur MA, et al. **Infect Control Hosp Epidemiol** 1999 Jul;20(7):499-503

Effects of zinc supplementation on the immune system and on antibody response to multivalent influenza vaccine in hemodialysis patients. Türk S, et al. **Int J Artif Organs** 1998 May;21(5):274-8

How to improve the uptake of influenza vaccination in older persons at risk. Igoe G, et al. **Ir J Med Sci** 1999 Apr-Jun; 168(2):107-8

Influenza vaccine: are those at risk taking it? [letter] Bedford D, et al. **Ir Med J** 1999 Jan-Feb;92(1):246

Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. Ohmit SE, et al. **J Am Geriatr Soc** 1999 Feb; 47(2):165-71

Influenza vaccine update. **J Ark Med Soc** 1998 Oct; 95(5):207-8

Flu vaccination decreases relative morbidity risk for people with diabetes [news] Vinicor F. **J Ark Med Soc** 1998 Oct; 95(5):182

Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. Chattaraj SC, et al. **J Controlled Release** 1999 Mar 29;58(2):223-32

Influenza immunization among Medicare beneficiaries enrolled in a health maintenance organization: 1994. Florida Medical Quality Assurance, Inc. **J Fla Med Assoc** 1998 Apr;85(1):19-20

Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. de Bruijn IA, et al. **J Infect Dis** 1999 Jan;179(1):31-6

Design and development of adjuvant-active nonionic block copolymers. Newman MJ, et al. **J Pharm Sci** 1998 Nov; 87(11):1357-62

Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. Glück U, et al. **J Virol** 1999 Sep;73(9):7780-6

From the Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults aged > or = 65 years--United States, 1997. **JAMA** 1998 Dec 2;280(21):1818-9

Time preferences and preventive health behavior: acceptance of the influenza vaccine. Chapman GB, et al. **Med Decis Making** 1999 Jul-Sep;19(3):307-14

Influenza vaccine, 1999-2000. **Med Lett Drugs Ther** 1999 Sep 10;41(1061):82-3

Influenzal and pneumococcal immunizations. A survey of policies and practices in North Carolina. Mims SR. **N C Med J** 1998 Sep-Oct;59(5):290-2

Influenza viral infections: presentation, prevention, and treatment. Kennedy MM. **Nurse Pract** 1998 Sep;23(9):17, 21-2, 25-8 passim; quiz 38-9 (35 ref.)

Clinical effectiveness, policies, and practices for influenza and pneumococcal vaccines. Nguyen-Van-Tam JS, et al. **Semin Respir Infect** 1999 Jun;14(2):184-95 (116 ref.)

Flu vaccination decreases relative morbidity risk for people with diabetes. Vinicor F. **Tenn Med** 1998 Nov;91(11):423

The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Barchfeld GL, et al. **Vaccine** 1999 Feb 26;17(7-8):695-704

Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Glück R. **Vaccine** 1999 Mar 26;17(13-14):1782-7

Intradermal DNA immunization by using jet-injectors in mice and monkeys. Haensler J, et al. **Vaccine** 1999 Feb 26;17(7-8):628-38

Biodegradable microspheres containing influenza A vaccine: immune response in mice. Hilbert AK, et al. **Vaccine** 1999 Mar 5;17(9-10):1065-73

Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Honkanen PO, et al. **Vaccine** 1999 Jun 4;17(20-21):2493-500

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Minutello M, et al. **Vaccine** 1999 Jan;17(2):99-104

Opportunities not missed--systematic influenza and pneumococcal immunization in a public inner-city emergency department. Slobodkin D, et al. **Vaccine** 1998 Nov;16(19):1795-802

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Ennis FA, et al. **Virology** 1999 Jul 5;259(2):256-61

Adult immunization deserves physician involvement. Gold JA. **WMJ** 1998 Oct;97(9):59

[Anticipating "flu mist"--soon a must] Gnehm HE. **Schweiz Med Wochenschr** 1998 Dec 26;128(51-52):2023-6 (8 ref.) **(Ger)**

[Immunogenicity and efficacy field evaluation (1994-1995 season) of influenza vaccine in a noninstitutionalized elderly population] Sandrini MC, et al. **Ann Ig** 1997 Sep-Oct; 9(5):373-9 **(Ita)**

[Adverse effects associated with influenza vaccine in pediatrics] Martin Moreno V, et al. **Rev Esp Salud Publica** 1998 Jul-Aug;72(4):319-29 (50 ref.) (Eng. Abstr.) **(Spa)**

[Why should all persons over age 65 years be vaccinated against influenza?] Linde A, et al. **Lakartidningen** 1998 Oct 21;95(43):4744-8 (20 ref.) **(Swe)**

ADVERSE EFFECTS

Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study. Cummins D, et al. **Clin Lab Haematol** 1998 Oct;20(5):285-7

Thrombotic thrombocytopenic purpura following influenza vaccination--a brief case report. Ramakrishnan N, et al. **Conn Med** 1998 Oct;62(10):587-8

Safety of influenza vaccine in heart transplant recipients. Blumberg EA, et al. **J Heart Lung Transplant** 1998 Nov; 17(11):1075-80

Safe administration of influenza vaccine to patients with egg allergy. James JM, et al. **J Pediatr** 1998 Nov;133(5):624-8

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines [see comments] Lasky T, et al. **N Engl J Med** 1998 Dec 17;339(25):1797-802. Comment in: N Engl J Med 1998 Dec 17;339(25):1845-6.

Influenza vaccination and the Guillain-Barré syndrome [editorial; comment] Ropper AH, et al. **N Engl J Med** 1998 Dec 17;339(25):1845-6. Comment on: N Engl J Med 1998 Dec 17;339(25):1797-802.

Pneumonitis secondary to the influenza vaccine. Johnston SD, et al. **Postgrad Med J** 1998 Sep;74(875):541-2

Hemiparesis following influenza vaccination. Selvaraj N, et al. **Postgrad Med J** 1998 Oct;74(876):633-5

A double-blind placebo-controlled study of the effect of

influenza vaccination on airway responsiveness in asthma. Reid DW, et al. **Respir Med** 1998 Aug;92(8):1010–1

Vascular purpura and cryoglobulinemia after influenza vaccination. Case-report and literature review [letter] Lohse A, et al. **Rev Rhum Engl Ed** 1999 Jun;66(6):359–60

Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Jackson LA, et al. **Vaccine** 1999 Apr 9;17(15–16):1905–9

Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination. Spila-Alegiani S, et al. **Vaccine** 1999 Apr 9; 17(15–16):1898–904

[Meningoencephalitis: an unusual complication of influenza vaccine (letter)] Blanco A, et al. **Med Clin (Barc)** 1999 May 1;112(15):597 **(Spa)**

CLASSIFICATION

Recommendation for the composition of influenza virus vaccines for use in 1999. **Wkly Epidemiol Rec** 1998 Oct 2;73(40):305–8 **(Eng, Fre)**

ECONOMICS

Potential cost savings attributable to influenza vaccination of school-aged children. White T, et al. **Pediatrics** 1999 Jun;103(6):e73

IMMUNOLOGY

Serological response to influenza vaccination and nutritional and functional status of patients in geriatric medical long-term care. Potter JM, et al. **Age Ageing** 1999 Mar; 28(2):141–5

Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial. Provinciali M, et al. **Age Ageing** 1998 Nov; 27(6):715–22

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. Kroon FP, et al. **AIDS** 1998 Dec 3;12(17):F217–23

Vaccination and HIV-1 replication during highly active antiretroviral therapy [letter] Kroon FP, et al. **AIDS** 1999 Jan 14;13(1):135–6

The postvaccination antibody response to influenza virus proteins. Cox RJ, et al. **APMIS** 1999 Mar;107(3):289–96

Effect of prednisone on response to influenza virus vaccine in asthmatic children. Fairchok MP, et al. **Arch Pediatr Adolesc Med** 1998 Dec;152(12):1191–5

Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza A. Martinet W, et al. **Arch Virol** 1998;143(10):2011–9

Learning from our foes: a novel vaccine concept for influenza virus. Palese P, et al. **Arch Virol Suppl** 1999;15:131–8 (22 ref.)

Seroconversion after influenza vaccination in patients with lung cancer. Anderson H, et al. **Br J Cancer** 1999 Apr; 80(1–2):219–20

Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996–1997. Beran J, et al. **Cent Eur J Public Health** 1998 Nov;6(4):269–73

Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Saurwein-Teissl M, et al. **Clin Exp Immunol** 1998 Nov;114(2):271–6

Influenza, influenza virus vaccine, and human immunodeficiency virus infection [editorial; comment] Couch RB. **Clin Infect Dis** 1999 Mar;28(3):548–51. Comment on: Clin Infect Dis 1999 Mar;28(3):541–7.

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response [see comments] Fuller JD, et al. **Clin Infect Dis** 1999 Mar; 28(3):541–7. Comment in: Clin Infect Dis 1999 Mar;28(3):548–51.

Towards a protein vaccine for nontypeable Haemophilus influenzae. Kyd JM, et al. **Clin Infect Dis** 1999 Feb; 28(2):238

Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Webster RG. **Clin Infect Dis** 1999 Feb;28(2):225–9 (26 ref.)

Protective cellular immunity against influenza virus induced by plasmid inoculation of newborn mice. Bot A, et al. **Dev Immunol** 1998;5(3):197–210

Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Saelens X, et al. **Eur J Biochem** 1999 Feb;260(1):166–75

Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Menegon T, et al. **Eur J Epidemiol** 1999 Jul;15(6):573–6

Dose-dependent antibody response to influenza H1N1 vaccine component in elderly nursing home patients. Remarque EJ, et al. **Exp Gerontol** 1999 Jan;34(1):109–15

Influenza vaccination in elderly people. Remarque EJ. **Exp Gerontol** 1999 Jun;34(3):445–52 (43 ref.)

Dendritic cell responsiveness to stimulation with influenza vaccine is unimpaired in old age. Saurwein-Teissl M, et al. **Exp Gerontol** 1998 Sep;33(6):625–31

Immunodeficient mouse models in the characterization of the protective immunity to influenza virus. Bot A, et al. **Folia Microbiol (Praha)** 1998;43(5):477–8

Antibody response to 1995–1996 influenza vaccine in institutionalized and non-institutionalized elderly women. Iorio AM, et al. **Gerontology** 1999 Jan-Feb;45(1):31–8

Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. Sha Z, et al. **Immunobiology** 1999 Feb; 200(1):21–30

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Ben-Yedidia T, et al. **Immunol Lett** 1998 Nov;64(1):9–15

Determination of cytokine co-expression in individual splenic CD4+ and CD8+ T cells from influenza virus-immune mice. Falchetti R, et al. **Immunology** 1998 Nov;95(3):346–51

Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Barackman JD, et al. **Infect Immun** 1999 Aug;67(8):4276–9

Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Ben-Yedidia T, et al. **Int Immunol** 1999 Jul;11(7):1043–51

Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. Operschall E, et al. **J Clin Virol** 1999 Jun;13(1–2):17–27

Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. Chattaraj SC, et al. **J Controlled Release** 1999 Mar 29;58(2):223–32

Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects. Fülöp T Jr, et al. **J Gerontol A Biol Sci Med Sci** 1999 Feb;54(2):M59–64

Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. de Bruijn IA, et al. **J Infect Dis** 1999 Jan;179(1):31–6

Detection of intracellular antigen-specific cytokines in human T cell populations. Kallas EG, et al. **J Infect Dis** 1999 May;179(5):1124–31

Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. Li S, et al. **J Infect Dis** 1999 May;179(5):1132–8

Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. el-Madhun AS, et al. **J Infect Dis** 1998 Oct;178(4):933–9

DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. Kodihalli S, et al. **J Virol** 1999 Mar;73(3):2094–8

Protection against a lethal avian influenza A virus in a mammalian system. Riberdy JM, et al. **J Virol** 1999 Feb; 73(2):1453–9

Attenuated vesicular stomatitis viruses as vaccine vectors. Roberts A, et al. **J Virol** 1999 May;73(5):3723–32

Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. Takada A, et al. **J Virol** 1999 Oct;73(10):8303–7

Chronic stress in elderly carers of dementia patients and influenza vaccine [letter; comment] Desai A, et al. **Lancet** 1999 Jun 5;353(9168):1969–70. Comment on: Lancet 1999 Feb 20;353(9153):627–31.

Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination [see comments] Vedhara K, et al. **Lancet** 1999 Feb 20;353(9153):627–31. Comment in: Lancet 1999 Jun 5;353(9168):1969–70.

Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Brydak LB, et al. **Leuk Lymphoma** 1999 Jan;32(3–4):369–74

Efficacy of anti-influenza peptide vaccine in aged mice. Ben-Yedidia T, et al. **Mech Ageing Dev** 1998 Aug 1; 104(1):11–23

The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Ben-Yehuda A, et al. **Mech Ageing Dev** 1998 May 15;102(2–3):299–306

Influenza and pneumococcal vaccine receipt in older persons with chronic disease: a population-based study. Petersen RL, et al. **Med Care** 1999 May;37(5):502–9

What are the prospects for a universal influenza vaccine? [news; comment] Kilbourne ED. **Nat Med** 1999 Oct; 5(10):1119–20. Comment on: Nat Med 1999 Oct;5(10):1157–63.

The immune response induced by a split influenza vaccine. Studies on cellular immunity. Alexandrescu V, et al. **Roum Arch Microbiol Immunol** 1997 Jul-Dec; 56(3–4):155–64

Influenza vaccination in liver transplant recipients. Burbach G, et al. **Transplantation** 1999 Mar 15;67(5):753–5

Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Dengler TJ, et al. **Transplantation** 1998 Nov 27;66(10):1340–7

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Babai I, et al. **Vaccine** 1999 Mar 5; 17(9–10):1223–38

A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Babai I, et al. **Vaccine** 1999 Mar 5;17(9–10):1239–50

Immune response to influenza vaccination in a large healthy elderly population. Bernstein E, et al. **Vaccine** 1999 Jan; 17(1):82–94

The plea against annual influenza vaccination? 'The Hoskins' Paradox' revisited. Beyer WE, et al. **Vaccine** 1998 Dec; 16(20):1929–32

Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Crawford J, et al. **Vaccine** 1999 May 4;17(18):2265–74

The effect of smoking on influenza, influenza vaccination efficacy and on the antibody response to influenza vaccination. Cruijff M, et al. **Vaccine** 1999 Feb 5; 17(5):426–32

Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy. de Jong JC, et al. **Vaccine** 1999 Mar 17;17(11–12):1321–8

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Deliyannis G, et al. **Vaccine** 1998 Dec;16(20):2058–68

Modified M2 proteins produce heterotypic immunity against influenza A virus. Frace AM, et al. **Vaccine** 1999 May 4; 17(18):2237–44

Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Fu TM, et al. **Vaccine** 1998 Nov; 16(18):1711–7

Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Gonzalo RM, et al. **Vaccine** 1999 Feb 26; 17(7–8):887–92

Biodegradable microspheres containing influenza A vaccine: immune response in mice. Hilbert AK, et al. **Vaccine** 1999 Mar 5;17(9–10):1065–73

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE. **Vaccine** 1999 Apr 9;17(15–16):2073–80

Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Kriesel JD, et al. **Vaccine** 1999 Apr 9; 17(15–16):1883–8

IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Lee SW, et al. **Vaccine** 1999 Feb 5;17(5):490–6

Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Lunn DP, et al. **Vaccine** 1999 May 4;17(18):2245–58

Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults. McElhaney JE, et al. **Vaccine** 1998 Nov;16(18):1742–7

Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Rimmelzwaan GF, et al. **Vaccine** 1999 Jun 4;17(20–21):2512–6

Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Sambhara S, et al. **Vaccine** 1998 Nov;16(18):1698–704

Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Treanor JJ, et al. **Vaccine** 1998 Nov;16(18):1756–60

Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Tsunoda I, et al. **Vaccine** 1999 Feb 26;17(7–8):675–85

Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Verweij WR, et al. **Vaccine** 1998 Dec; 16(20):2069–76

Induction of antibody response by DNA immunization of newborn baboons against influenza virus. Bot A, et al. **Viral Immunol** 1999;12(2):91–6

Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein. Pertmer TM, et al. **Virology** 1999 May 10; 257(2):406–14

Recommended composition of influenza virus vaccines for use in the 1999–2000 season. **Wkly Epidemiol Rec** 1999 Feb 26;74(8):57–61

[Safe administration of influenza vaccine in asthmatic children] Kawahara H, et al. **Arerugi** 1998 Jul;47(7):679–86 (Eng. Abstr.) **(Jpn)**

[Antibody response to a single injection of influenza vaccine among geriatric inpatients vaccinated annually] Ikematsu H, et al. **Kansenshogaku Zasshi** 1998 Sep;72(9):905–11 (Eng. Abstr.) **(Jpn)**

[The choice of the optimal schedules in the vaccination procedure against influenza in elderly subjects] Burtseva EI, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1998 Jul-Aug;(4):40–5 (Eng. Abstr.) **(Rus)**

[An evaluation of the epidemiological and economic efficacy of immunizing adults with the Vaxigrippe vaccine] Sharipova IS, et al.

Zh Mikrobiol Epidemiol Immunobiol 1998 Jul-Aug;(4):46-9 (Eng. Abstr.) **(Rus)**

METABOLISM

Cytokine production after influenza vaccination in a healthy elderly population. Bernstein ED, et al. **Vaccine** 1998 Nov; 16(18):1722-31

PHARMACOKINETICS

Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Bryant ML, et al. **Nucl Med Commun** 1999 Feb;20(2):171-4

STANDARDS

Questions validity of equine vaccine field studies [letter] Piontkowski MD. **J Am Vet Med Assoc** 1999 Sep 1; 215(5):620-1

The role of sodium bisulfite in the 1996-1997 USA influenza vaccine recall. Poland GA. **Vaccine** 1998 Nov; 16(19):1865-8

[The influenza season 1997/'98 and the vaccine composition for 1998/'99] Claas EC, et al. **Ned Tijdschr Geneeskd** 1998 Oct 31;142(44):2423-7 (Eng. Abstr.) **(Dut)**

SUPPLY & DISTRIBUTION

What caused the winter crisis in the NHS? [news] Woodman R. **BMJ** 1999 Jan 16;318(7177):145

THERAPEUTIC USE

Advisory Committee on Immunization Practices issues recommendations for the 1999-2000 influenza season. Rose VL. **Am Fam Physician** 1999 Jul;60(1):309-10, 313-4

Protecting Japan from influenza [letter; comment] Inoue K. **Nat Med** 1999 Jun;5(6):592. Comment on: Nat Med 1999 Apr;5(4):384-5.

A universal influenza A vaccine based on the extracellular domain of the M2 protein [see comments] Neirynck S, et al. **Nat Med** 1999 Oct;5(10):1157-63. Comment in: Nat Med 1999 Oct;5(10):1119-20.

Immune response to influenza vaccination in a large healthy elderly population. Bernstein E, et al. **Vaccine** 1999 Jan; 17(1):82-94

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Chen Z, et al. **Vaccine** 1999 Feb 26;17(7-8):653-9

INFLUENZA VIRUS, AVIAN see **INFLUENZA A VIRUS, AVIAN**

INFLUENZA VIRUS, EQUINE see **INFLUENZA A VIRUS**

INFLUENZA VIRUS, PORCINE see **INFLUENZA A VIRUS, PORCINE**

INFLUENZA VIRUS TYPE A, HUMAN see **INFLUENZA A VIRUS, HUMAN**

INFLUENZA VIRUSES see **ORTHOMYXOVIRIDAE**

INFLUENZA VIRUSES TYPE A see **INFLUENZA A VIRUS**

INFLUENZA VIRUSES TYPE B see **INFLUENZA B VIRUS**

INFLUENZA VIRUSES TYPE C see **INFLUENZAVIRUS C**

INFLUENZA VIRUSES TYPE D see **THOGOTO-LIKE VIRUSES**

INFLUENZAVIRUS A, B

Amantadine and pneumonia in elderly stroke patients [letter; comment] Chan NN. **Lancet** 1999 Jun 19;353(9170):2156-7 . Comment on: Lancet 1999 Apr 3;353(9159):1157.

Amantadine and pneumonia in elderly stroke patients [letter; comment] Trivalle C, et al. **Lancet** 1999 Jun 19; 353(9170):2157. Comment on: Lancet 1999 Apr 3;353(9159):1157.

DRUG EFFECTS

Synthesis and anti-influenza virus activity of novel pyrimidine derivatives. Hisaki M, et al. **Antiviral Res** 1999 Jun;42(2):121-37

ISOLATION & PURIFICATION

Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. Magnard C, et al. **J Med Virol** 1999 Oct;59(2):215-20

Influenza virus epidemiological surveillance in Argentina, 1987-1993, with molecular characterization of 1990 and 1993 isolates. Uez OC, et al. **Rev Panam Salud Publica** 1998 Dec;4(6):405-10

INFLUENZAVIRUS C

CHEMISTRY

Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus. Rosenthal PB, et al. **Nature** 1998 Nov 5;396(6706):92-6

ENZYMOLOGY

X-ray crystallographic determination of the structure of the influenza C virus haemagglutinin-esterase-fusion glycoprotein. Zhang X, et al. **Acta Crystallogr D Biol Crystallogr** 1999 May;55(5):945-61

Study of the O-acetylesterase activity of five influenza C virus strains. Sánchez-Bernal C, et al. **Arch Virol** 1998; 143(9):1783-90

GENETICS

Influenza C virus persistence depends on exceptional steps in viral RNA synthesis and transport. Zach A, et al. **Arch Virol** 1999;144(3):463-78

Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence. Pekosz A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13233-8

The ORF, regulated synthesis, and persistence-specific variation of influenza C viral NS1 protein. Marschall M, et al. **Virology** 1999 Jan 20;253(2):208-18

Identification of the 5' terminal structure of influenza virus genome RNA by a newly developed enzymatic method. Honda A, et al. **Virus Res** 1998 Jun;55(2):199-206

IMMUNOLOGY

Location of a linear epitope recognized by monoclonal antibody S16 on the hemagglutinin-esterase glycoprotein of influenza C virus. Muraki Y, et al. **Virus Res** 1999 May; 61(1):53-61

METABOLISM

The cytoplasmic tail of the influenza C virus glycoprotein HEF negatively affects transport to the cell surface. Oeffner F, et al. **J Gen Virol** 1999 Feb;80 (Pt 2):363-9

Influenza C virus CM2 protein is produced from a 374-amino-acid protein (P42) by signal peptidase cleavage. Hongo S, et al. **J Virol** 1999 Jan;73(1):46-50

Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus. Klausegger A, et al. **J Virol** 1999 May;73(5):3737-43

Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence. Pekosz A, et al. **Proc Natl Acad Sci U S A** 1998 Oct 27;95(22):13233-8

Phosphorylation of influenza C virus CM2 protein. Tada Y, et al. **Virus Res** 1998 Nov;58(1-2):65-72

PHYSIOLOGY

Cell surface expression of biologically active influenza C virus HEF glycoprotein expressed from cDNA. Pekosz A, et al. **J Virol** 1999 Oct;73(10):8808-12

A persistent variant of influenza C virus fails to interact with actin filaments during viral assembly. Hechtfischer A, et al. **Virus Res** 1999 Jun;61(2):113-24

INFLUENZAVIRUS D see **THOGOTO-LIKE VIRUSES**

INFORMATION CENTERS

The Health Outreach Program for the Elderly (HOPE) database. Siwek D. **Alzheimer Dis Assoc Disord** 1999 Apr-Jun;13 Suppl 1:S101-5

The Missouri Developmental Disability Resource Center: a Web site responding to the critical need for information of parents with a child with a disability. Downing RE, et al. **Behav Res Methods Instrum Comput** 1999 May; 31(2):292-8

SAMA supports tobacco control [news] van Wyk M. **S Afr Med J** 1998 Dec;88(12):1543

ORGANIZATION & ADMINISTRATION

Computerized pediatric telephone triage and advice programs at children's hospitals: operating and financial characteristics. Melzer SM, et al. **Arch Pediatr Adolesc Med** 1999 Aug;153(8):858-63

Mass casualties: an organizational model of a hospital information center in Tel Aviv. Drory M, et al. **Soc Work Health Care** 1998;27(4):83-96

INFORMATION DISPLAY see **DATA DISPLAY**

INFORMATION DISSEMINATION see **INFORMATION SERVICES**

INFORMATION MANAGEMENT

Using ethnography to investigate life scientists' information needs. Forsythe DE. **Bull Med Libr Assoc** 1998 Jul; 86(3):402-9

New definition for nursing informatics needed [letter; comment] Staggers N, et al. **Image J Nurs Sch** 1998; 30(2):110. Comment on: Image J Nurs Sch 1996 Winter;28(4):309-13.

Information technology in primary health care. Lovell NH, et al. **Int J Med Inf** 1999 Jul;55(1):9-22

Clinical care and the factory floor. Panko WB. **J Am Med Inform Assoc** 1999 Sep-Oct;6(5):349-53

A design model for computer-based guideline implementation based on information management services. Shiffman RN, et al. **J Am Med Inform Assoc** 1999 Mar-Apr;6(2):99-103

Information technology outside health care: what does it matter to us? Tuttle MS. **J Am Med Inform Assoc** 1999 Sep-Oct;6(5):354-60

Personal privacy versus public accountability: a technological solution to an ethical dilemma. Pandiani JA, et al. **J Behav Health Serv Res** 1998 Nov;25(4):456-63

Knowledge workers and knowledge-intense organizations, Part 1: A promising framework for nursing and healthcare. Sorrells-Jones J, et al. **J Nurs Adm** 1999 Jul-Aug; 29(7-8):12-8

The future clinical trial: computerized data management. Ritschel WA, et al. **Methods Find Exp Clin Pharmacol** 1998 Jul-Aug;20(6):517-26

Use of the WWW for distributed knowledge engineering for an EMR: the KnowledgeBank concept. Middleton B, et al. **Proc AMIA Symp** 1998;:126-30

Linking information needs with evaluation: the role of task identification. Weir CR. **Proc AMIA Symp** 1998;:310-4

The role of IPA/medical group network model managed care organizations in STD control: is information technology the key? Finch M. **Sex Transm Dis** 1999 Apr; 26(4 Suppl):S23-5; discussion S26-7

Handling information in public health planning [editorial; comment] Kidson C. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):189-90. Comment on: Southeast Asian J Trop Med Public Health 1998 Jun;29(2):191-212. Comment on: Southeast Asian J Trop Med Public Health 1998 Jun;29(2):201-2.

International population movements and public health in the Mekong region: an overview of some issues concerning mapping [see comments] Stern A. **Southeast Asian J Trop Med Public Health** 1998 Jun; 29(2):201-12. Comment in: Southeast Asian J Trop Med Public Health 1998 Jun;29(2):189-90.

EDUCATION

Teaching the fundamentals of information systems management in health care. Lecture and practical training for students of medical informatics. Knaup P, et al. **Int J Med Inf** 1998 Jun;50(1-3):195-205

HMI education for HIMs. Roberts R, et al. **Int J Med Inf** 1998 Jun;50(1-3):43-7

Innovative informatics education: aligning theory and practice through strategic partnership. Miller K, et al. **Medinfo** 1998;9 Pt 2:752-5

LEGISLATION & JURISPRUDENCE

Ill-advised 'freedom' of scientific information [editorial] **Nature** 1999 Feb 11;397(6719):455

Scientists fight for right to withhold data [news] Macilwain C. **Nature** 1999 Feb 11;397(6719):459

A solution to concerns over public access to scientific data. Cohen LR, et al. **Science** 1999 Jul 23;285(5427):535-6

Public access to data [editorial] Frankel MS. **Science** 1999 Feb 19;283(5405):1114

Plan for divulging raw data eases fears [news] Kaiser J. **Science** 1999 Feb 12;283(5404):914-5

Data disclosure. Congress votes down delay in access law [news] [published erratum appears in Science 1999 Aug 6;285(5429):838] Kaiser J. **Science** 1999 Jul 23;285(5427):511

MANPOWER

Preparing chief information officers for the clinical information systems environment. Valenta AL, et al. **Acad Med** 1999 May;74(5):511-5 (14 ref.)

METHODS

Data management in occupational medicine. Schumann SC, et al. **Occup Med** 1998 Oct-Dec;13(4):735-46, iv (8 ref.)

[Quality documentation with an Anaesthesia Information Management System (AIMS)] Junger A, et al. **Anaesthesist** 1999 Aug;48(8):523-32 (Eng. Abstr.) **(Ger)**

[Quality and management of preoperative patient information. Results of conventional and computer based documentation] Müller RT, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan-Feb;137(1):87-92 (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Personalized health care and business success: can informatics bring us to the promised land? Ozbolt JG. **J Am Med Inform Assoc** 1999 Sep-Oct;6(5):368-73

Computer-facilitated collaboration: experiences building SNOMED-RT. Levy DH, et al. **Proc AMIA Symp** 1998; :870-4

Factors influencing malaria endemicity in Yunnan Province, PR China (analysis of spatial pattern by GIS). Geographical Information System [see comments] Hu H, et al. **Southeast Asian J Trop Med Public Health** 1998 Jun;

29(2):191–200. Comment in: Southeast Asian J Trop Med Public Health 1998 Jun;29(2):189–90.

[The use of modern information technologies for enhancing efficiency in the management of scientific research in the Ministry of Public Health system] Kartysh AP, et al. **Lik Sprava** 1998 Aug;(6):168–73 **(Ukr)**

STANDARDS

[Quality and management of preoperative patient information. Results of conventional and computer based documentation] Müller RT, et al. **Z Orthop Ihre Grenzgeb** 1999 Jan–Feb;137(1):87–92 (Eng. Abstr.) **(Ger)**

TRENDS

Information management in medicine. Candler C. **J Okla State Med Assoc** 1999 Aug;92(8):435–6

INFORMATION PROCESSING, AUTOMATIC see **AUTOMATIC DATA PROCESSING**

INFORMATION PROCESSING, HUMAN see **MENTAL PROCESSES**

INFORMATION RETRIEVAL see **INFORMATION STORAGE AND RETRIEVAL**

INFORMATION RETRIEVAL SYSTEMS see **INFORMATION SYSTEMS**

INFORMATION SCIENCE

On representation of metabolic pathways. Michal G. **Biosystems** 1998 Jun–Jul;47(1–2):1–7

Computation with the KEGG pathway database. Ogata H, et al. **Biosystems** 1998 Jun–Jul;47(1–2):119–28

The information behaviors of life and health scientists and health care providers: characteristics of the research literature. Detlefsen EG. **Bull Med Libr Assoc** 1998 Jul; 86(3):385–90

Citation analysis in journal rankings: medical informatics in the library and information science literature. Vishwanatham R. **Bull Med Libr Assoc** 1998 Oct; 86(4):518–22

Chemoinformatics--a new name for an old problem? Hann M, et al. **Curr Opin Chem Biol** 1999 Aug;3(4):379–83 (35 ref.)

Observers' report. Hartley DS 3rd. **Psychopharmacol Bull** 1998;34(3):361–8

EDUCATION

Information technology education for health professionals: opportunities and challenges. Haque SS, et al. **J Allied Health** 1998 Fall;27(3):167–72

STATISTICS & NUMERICAL DATA

Postcard from Riyadh: too much data, not enough wisdom [editorial; comment] Hall J. **Aust N Z J Surg** 1999 Jun; 69(6):409. Comment on: Aust N Z J Surg 1999 Jun;69(6):411–2.

On interpreting data [see comments] Isbister WH. **Aust N Z J Surg** 1999 Jun;69(6):411–2. Comment in: Aust N Z J Surg 1999 Jun;69(6):409.

TRENDS

[The digital revolution in Japan] Tsukio Y. **Nippon Geka Gakkai Zasshi** 1999 Apr;100(4):282–4 (Eng. Abstr.) **(Jpn)**

INFORMATION SERVICES

see related

LIBRARIES

Mislabeled study [letter] Klein-Fedyshin MS, et al. **Acad Med** 1999 Sep;74(9):943

Information needs and information-seeking behaviors of on-call radiology residents. D'Alessandro MP, et al. **Acad Radiol** 1999 Jan;6(1):16–21

Distributing working versions of published mathematical models for biological systems via the Internet. Wastney ME, et al. **Adv Exp Med Biol** 1998;445:131–5

Position papers, consensus reports, and guidelines: are they necessary? [editorial; comment] Muñoz-López F. **Allergol Immunopathol (Madr)** 1998 Jul–Aug;26(4):167–70 . Comment on: Allergol Immunopathol (Madr) 1998 Jul–Aug;26(4):171–94. **(Eng, Spa)**

Disseminating the results of clinical trials to community-based practitioners: is anyone listening? [editorial; comment] Goldberg RJ, et al. **Am Heart J** 1999 Jan;137(1):4–7. Comment on: Am Heart J 1999 Jan;137(1):79–92.

Digestive disease resources on the Internet. Gumber SC, et al. **Am J Gastroenterol** 1999 Aug;94(8):2022–32

Rules set for dissemination of off-label-use information [news] Miller JL. **Am J Health Syst Pharm** 1999 Feb 1; 56(3):204

Keeping up with drug information [editorial] Sellers JA. **Am J Health Syst Pharm** 1999 Apr 1;56(7):613

Provider group characteristics & quality report card performance: a cross-sectional study in a managed care setting. Simon LP, et al. **Am J Med Qual** 1999 May–Jun; 14(3):138–45

A computerized learning tool. Gound P, et al. **Am J Nurs** 1998 Nov;98(11):56–8

Surgical Internet at a glance: the Virtual Hospital. Allen J. **Am J Surg** 1999 Jul;178(1):1

Medical information on the Internet. Rampil IJ. **Anesthesiology** 1998 Nov;89(5):1233–45 (13 ref.)

Internet resources for balloon and other endometrial ablation. Drake C. **AORN J** 1999 Jul;70(1):131–2

Internet resources for perioperative care of burns. Drake C. **AORN J** 1999 Jun;69(6):1250, 1253–4

Smart searching on the World Wide Web. Ennis DM. **Appl Occup Environ Hyg** 1999 Aug;14(8):515–8

Disseminating medical knowledge: the PROforma approach. Fox J, et al. **Artif Intell Med** 1998 Sep–Oct;14(1–2):157–81

Supporting tools for guideline development and dissemination. Quaglini S, et al. **Artif Intell Med** 1998 Sep–Oct;14(1–2):119–37

Clinical cancer trial information and specimen resources. Horton RM, et al. **Biotechniques** 1998 Sep;25(3):396–8

Computer hardware resources on the internet. Horton RM. **Biotechniques** 1998 Nov;25(5):804, 806

Sharing decisions with patients: is the information good enough? Coulter A, et al. **BMJ** 1999 Jan 30; 318(7179):318–22

Meeting the information and budgetary requirements of primary care groups. Gilley J. **BMJ** 1999 Jan 16; 318(7177):168–9; discussion 169–70

Evidence based patient information. Computers can be used to tailor information to patients [letter; comment] Jones R. **BMJ** 1999 Feb 13;318(7181):461–2. Comment on: BMJ 1998 Jul 25;317(7153):225–6.

Sharing data to prevent injuries. Lyons RA, et al. **BMJ** 1999 Aug 7;319(7206):372–3

Health information and interaction on the internet: a survey of female urinary incontinence. Sandvik H. **BMJ** 1999 Jul 3;319(7201):29–32

In pursuit of excellence for patients with cancer: the Scottish Cancer Therapy Network model. Stroner PL, et al. **Br J Cancer** 1999 Apr;79(11–12):1641–5 (25 ref.)

RheumaNet--a novel Internet-based rheumatology information network in Germany. Specker C, et al. **Br J Rheumatol** 1998 Sep;37(9):1015–9

Performing continuous quality improvement for a digital health sciences library through an electronic mail analysis. D'Alessandro DM, et al. **Bull Med Libr Assoc** 1998 Oct; 86(4):594–601

The information behaviors of life and health scientists and health care providers: characteristics of the research literature. Detlefsen EG. **Bull Med Libr Assoc** 1998 Jul; 86(3):385–90

Using ethnography to investigate life scientists' information needs. Forsythe DE. **Bull Med Libr Assoc** 1998 Jul; 86(3):402–9

Delivering health information statewide via the Internet in a collaborative environment: impact on individual member institutions. McCray JC. **Bull Med Libr Assoc** 1999 Jul; 87(3):264–9

Evidence-based practice. McKibbon KA. **Bull Med Libr Assoc** 1998 Jul;86(3):396–401

Selection of useful links for an Australian Medical Association Web site. Yue W, et al. **Bull Med Libr Assoc** 1999 Jul;87(3):343–6

Vaccine safety resource materials for health-care providers and the public. Pless R. **Can Commun Dis Rep** 1998 Sep 1;24(17):141–4 **(Eng, Fre)**

Worlds without borders. Malik P. **Can J Cardiol** 1998 Nov; 14(11):1325, 1328

Current status of education and treatment resources for lymphedema. Thiadens SR. **Cancer** 1998 Dec 15;83(12 Suppl American):2864–8 (2 ref.)

No impact from active dissemination of the Ottawa Ankle Rules: further evidence of the need for local implementation of practice guidelines. Cameron C, et al. **CMAJ** 1999 Apr 20;160(8):1165–8

Access to medical and health information in the developing world: an essential tool for change in medical education [editorial] Haddad H, et al. **CMAJ** 1999 Jan 12;160(1):63–4

Is Internet-based disease management on the way? OReilly M. **CMAJ** 1999 Apr 6;160(7):1039

Breast cancer online: helping patients navigate the Web. Pinker S. **CMAJ** 1999 Jan 26;160(2):239

Private company offers hope to cancer patients--for a price. Sibbald B. **CMAJ** 1999 Jun 1;160(11):1619–21

Contraceptive methods: knowledge sources rated by women and men. Virjo I, et al. **Contraception** 1999 Apr; 59(4):257–63

Skin Cap: what have we learned, and when did we learn it? [editorial] Smith K. **Dermatol Online J** 1997 Dec; 3(2):11c

Proposed model of the relationship of risk information seeking and processing to the development of preventive behaviors. Griffin RJ, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S230–S245

Epidemiology of contact dermatitis. The information network of departments of dermatology (IVDK) in Germany. Uter W, et al. **Eur J Dermatol** 1998 Jan–Feb; 8(1):36–40 (29 ref.)

Making report cards work. Wicks EK, et al. **Health Aff (Millwood)** 1999 Mar–Apr;18(2):152–5

Report cards. Cleveland's Phoenix [news] Greene J. **Hosp Health Netw** 1999 Jul;73(7):14, 16

Dermatology resources on the internet: a practical guide for dermatologists. Sitaru C. **Int J Dermatol** 1998 Sep; 37(9):641–7 (15 ref.)

Fostering a security culture: a model code of ethics for health information professionals. Kluge EH. **Int J Med Inf** 1998 Mar;49(1):105–10

The Internal Medicine Center--an integrated solution for information on internal medicine on the World Wide Web. Kumar G, et al. **Int J Med Inf** 1999 Jul;55(1):77–81

Public disclosure of health care performance reports: a response from the UK [comment] Coles J. **Int J Qual Health Care** 1999 Apr;11(2):104–5. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

Public disclosure of health care performance reports: what do we lose in giving information? [comment] Collopy BT. **Int J Qual Health Care** 1999 Apr;11(2):99–101. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

Public disclosure of health care performance reports: comments and reflections from Sweden [comment] Mebius C. **Int J Qual Health Care** 1999 Apr;11(2):102–3. Comment on: Int J Qual Health Care 1999 Apr;11(2):93–8.

Reporting comparative results from hospital patient surveys. Rogers G, et al. **Int J Qual Health Care** 1999 Jun; 11(3):251–9

Effective reports for health care quality data: lessons from a CAHPS demonstration in Washington State. Veroff DR, et al. **Int J Qual Health Care** 1998 Dec;10(6):555–60

The early experiences of a national system for the identification and assessment of emerging health care technologies in Sweden. Carlsson P, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):687–94

Scanning the horizon for emerging health technologies. Conclusions from a European Workshop. Carlsson P, et al. **Int J Technol Assess Health Care** 1998 Fall; 14(4):695–704

Basis for decisions on emerging health technology. A Danish feasibility study. Jørgensen T, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):624–35

Implementing early warning messages on emerging health technologies. Mowatt G, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):663–70

Early warning of new health care technologies in the United Kingdom. Stevens A, et al. **Int J Technol Assess Health Care** 1998 Fall;14(4):680–6

The identification of new health care technologies by the Health Council of The Netherlands. ten Velden GH. **Int J Technol Assess Health Care** 1998 Fall;14(4):671–9

Internet information sources for the identification of emerging health technologies. A starting point. Trindade E, et al. **Int J Technol Assess Health Care** 1998 Fall; 14(4):644–51

Irish health care Web sites: a review. O'Mahony B. **Ir Med J** 1999 May–Jun;92(4):334–7

Good practice from Australasia on dissemination of best evidence-based practice [editorial] Smith JP. **J Adv Nurs** 1999 May;29(5):1027

CliniWeb: Managing clinical information on the World-Wide-Web [letter; comment] Thirion B, et al. **J Am Med Inform Assoc** 1997 Jan–Feb;4(1):71. Comment on: J Am Med Inform Assoc 1996 Jul–Aug;3(4):273–80.

Podiatric medical resources on the Internet. A second update. Fikar CR. **J Am Podiatr Med Assoc** 1998 Sep;88(9):462–6

Searching for HIV/AIDS information on the World Wide Web. Mann CE. **J Assoc Nurses AIDS Care** 1999 Mar–Apr; 10(2):79–81

A multifaceted educational approach to increasing awareness and use of physician data query (PDQ). Thiemann KM, et al. **J Cancer Educ** 1999 Summer;14(2):78–82

Teaching students about nursing and the environment: Part 2--Legislation and resources. McGuire SL, et al. **J Community Health Nurs** 1999;16(2):81–94

A keyword search system for medical doctors to introduce their patients to specialists. Hanada E, et al. **J Med Syst** 1999 Feb;23(1):73–6

MisHIN: an outreach program to help practicing physicians keep up with medical literature. Seltzer AM, et al. **J Miss State Med Assoc** 1999 Jun;40(6):196–7

Information dissemination and marketing in California. Harlow J, et al. **J Nurs Adm** 1999 Apr;29(4):6–8

Nursing's role in NetWellness: a children and adolescent health information resource via the Web. Hern MJ, et al. **J Pediatr Nurs** 1999 Aug;14(4):222–30

What have new efforts to change professional practice achieved? Cochrane Effective Practice and Organization of Care Group. Grimshaw JM, et al. **J R Soc Med** 1998; 91 Suppl 35:20–5 (23 ref.)

Accessing Useful Information: Challenges in Health Policy and Public Health. Proceedings of a national forum. March 23, 1998. **J Urban Health** 1998 Dec;75(4):777–895

Meeting information needs in health policy and public health: priorities for the National Library of Medicine and The National Network of Libraries of Medicine. Humphreys BL. **J Urban Health** 1998 Dec;75(4):878–83 (4 ref.)

Challenges to accessing useful information in health policy and public health: an introduction to a national forum held at the New York Academy of Medicine, March 23, 1998. Lasker RD. **J Urban Health** 1998 Dec;75(4):779–84 (0 ref.)

Information needs in public health and health policy: results of recent studies. O'Carroll PW, et al. **J Urban Health** 1998 Dec;75(4):785–93 (3 ref.)

Information resources for public health practice. Rambo N.

J Urban Health 1998 Dec;75(4):807-25 (8 ref.)
Meeting information needs in health policy and public health: roles for the Centers for Disease Control and Prevention. Ross D. **J Urban Health** 1998 Dec;75(4):884-7 (2 ref.)
Hospital peer review and clinical privileges actions: to report or not report [editorial; comment] Brennan TA. **JAMA** 1999 Jul 28;282(4):381-2. Comment on: JAMA 1999 Jul 28;282(4):349-55.
Cancer information from the National Cancer Center, Japan. Information Committee of the National Cancer Center, Tokyo [editorial] Shinkai T, et al. **Jpn J Clin Oncol** 1998 Dec;28(12):717-20
Public disclosure of performance information in Pennsylvania: impact on hospital charges and the views of hospital executives. Maxwell CI.
Jt Comm J Qual Improv 1998 Sep;24(9):491-502
Public disclosure of performance data: does the public get what the public wants? Davies HT, et al. **Lancet** 1999 May 15;353(9165):1639-40
Exploring medical genetics on the web. Larkin M.
Lancet 1998 Nov 21;352(9141):1714
Knowledge discovery and case based reasoning in health promotion: development of a help-desk for prevention of occupational injuries. Chowdhury S, et al. **Medinfo** 1998; 9 Pt 1:513-6
University medical information network--past, present, and future. Kiuchi T, et al. **Medinfo** 1998;9 Pt 1:420-4
A model for enhancing worldwide personal health and wellness. Marine S, et al. **Medinfo** 1998;9 Pt 2:1265-8
Medical Internet exchange project in Japan. Mizushima H, et al. **Medinfo** 1998;9 Pt 1:417-9
The information needs of health agency board members: a health information system challenge. Zelmer AC, et al. **Medinfo** 1998;9 Pt 2:1167-70
Evaluation of medical internet sites. Adelhard K, et al.
Methods Inf Med 1999 Jun;38(2):75-9
New US cancer genetics network announced [news] Senior K. **Mol Med Today** 1998 Nov;4(11):459-60
"E-biomed" and clinical research [letter] Bell C, et al.
N Engl J Med 1999 Sep 30;341(14):1080-1; discussion 1081
Evidenced-based guidelines for public health nursing practice. Strohschein S, et al. **Nurs Outlook** 1999 Mar-Apr; 47(2):84-9
Electronic research dissemination [editorial] Dougherty MC. **Nurs Res** 1999 Sep-Oct;48(5):239
HEDIS for the primary care provider: getting an "A" on the managed care report card. Buppert C. **Nurse Pract** 1999 Jan;24(1):84-6, 88-9, 92-4 passim
Web site design and development issues: the Washington State Breast and Cervical Health Program Web Site Demonstration Project. Bush NE, et al.
Oncol Nurs Forum 1999 Jun;26(5):857-65
Cancer connect: a resource for patients and physicians. Fiers J, et al. **Oncol Nurs Forum** 1999 Apr;26(3):514
Patients in cyberspace: information or confusion? [editorial] Ayonrinde O. **Postgrad Med J** 1998 Aug;74(874):449-50
Quit Today! A targeted communications campaign to increase use of the cancer information service by African American smokers. Boyd NR, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S50-60
Effectiveness of a telephone outcall intervention to promote screening mammography among low-income women. Crane LA, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S39-49
Cancer information service-initiated outcalls to promote screening mammography among low-income and minority women: design and feasibility testing. Crane LA, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S29-38
The cancer information service research consortium. Marcus AC. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S1-2
Increasing fruit and vegetable consumption among callers to the CIS: results from a randomized trial. Marcus AC, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S16-28
A self-help intervention for African American smokers: tailoring cancer information service counseling for a special population. Orleans CT, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S61-70
Designing HeartCare: custom computerized home care for patients recovering from CABG surgery. Brennan PF, et al. **Proc AMIA Symp** 1998;:381-5
Web sites worth watching. **Psychiatr Serv** 1998 Dec; 49(12):1557
Web sites worth watching. **Psychiatr Serv** 1999 Feb;50(2):182
NHLBI Website: asthma management [news]
Public Health Rep 1999 Mar-Apr;114(2):104
AHCPR offers resources for consumers, providers, and health agencies. Agency for Health Care Policy and Research [news] **Public Health Rep** 1999 Mar-Apr; 114(2):107
Information exchange in an epilepsy forum on the World Wide Web. Hoch DB, et al. **Seizure** 1999 Feb;8(1):30-4
Prostate cancer research and the National Cancer Institute. Brawley OW, et al. **Semin Urol Oncol** 1998 Nov; 16(4):235-40 (26 ref.)
Hierarchies and cliques in the social networks of health care professionals: implications for the design of dissemination strategies. West E, et al. **Soc Sci Med** 1999 Mar; 48(5):633-46
Provider profiles on-line--making health care choices easier for consumers. Williams B. **Tenn Med** 1999 Jul;92(7):253-4
Evidence-based medicine [letter; comment] Roper T.
Vet Rec 1998 Dec 5;143(23):644. Comment on: Vet Rec 1998 Nov 28;143(22):619.
[Robots and news reports. Fears of the year 2000 (editorial)] Vallancien G. **Presse Med** 1999 Jun 5;28(20):1073-4
(Fre)
[Information and education interventions on hygiene levels of a population in which trachoma exists in a hyperendemic and serious form] Chraibi-Hasseini K, et al.
Rev Int Trach Pathol Oculi Trop Subtrop Sante Publique 1997;74:45-55 (Eng. Abstr.) **(Fre)**
[Information and disinformation. Repercussions on serious public health problems] Marchetti D. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S193-4 **(Fre)**
[Significance of CD-ROM in medicine] Reiss M, et al.
Wien Med Wochenschr 1999;149(1):1-3 (11 ref.) (Eng. Abstr.) **(Ger)**
[Informationization policies of local governments] Misono S. **Nippon Geka Gakkai Zasshi** 1999 Apr;100(4):285-9 (Eng. Abstr.) **(Jpn)**
[Current status of cancer therapy. 6. Cancer information network] Mizushima H. **Nippon Naika Gakkai Zasshi** 1998 Sep 10;87(9):1777-81 **(Jpn)**
[Do public health practitioners have satisfactory access to important information sources?] Forsetlund L, et al.
Tidsskr Nor Laegeforen 1999 Jun 30;119(17):2456-62 (Eng. Abstr.) **(Nor)**
[New technology--old habits] Nylenna M.
Tidsskr Nor Laegeforen 1999 Jun 30;119(17):2451 **(Nor)**
[Procuring information on the Internet: research on tropical medicine and infectious diseases] Gomes SP.
Rev Soc Bras Med Trop 1999 Mar-Apr;32(2):213-7
(Por)
[The current neurosurgical resources on the Internet] Sakovich VP, et al.
Zh Vopr Neirokhir Im N N Burdenko 1999 Apr-Jun;(2):3-7 (Eng. Abstr.) **(Rus)**
[Information services in occupational medicine--comments] Huršidić-Radulović A. **Arh Hig Rada Toksikol** 1998 Sep; 49(3):277-9 (Eng. Abstr.) **(Scr)**
[Information network handling of some bioethics-related topics] Velayos JL, et al. **Rev Med Univ Navarra** 1997 Jul-Sep;41(3):198-9 **(Spa)**

ECONOMICS

A penny for your thoughts, but hundreds of dollars for your operation [editorial] Goldwyn RM. **Plast Reconstr Surg** 1998 Nov;102(6):2253

LEGISLATION & JURISPRUDENCE

Freedom of information, strongly held views and waiting lists [editorial] Milner PC. **J Public Health Med** 1998 Sep; 20(3):247-8

ORGANIZATION & ADMINISTRATION

Using modern information technology to profile faculty activities. Lombardo J, et al. **Acad Med** 1998 Dec; 73(12):1267-73
Problem-solving for better health: literature as a resource. Akhigbe F. **Afr J Med Med Sci** 1997 Sep-Dec; 26(3-4):205-8 (21 ref.)
Broadcasting clinical guidelines on the Internet: will physicians tune in? Furrow BR. **Am J Law Med** 1999; 25(2-3):403-21
Reflective choice in health care: using information technology to present allocation options. Rai AK.
Am J Law Med 1999;25(2-3):387-402
Survey of health maintenance organization instructions to members concerning emergency department and 911 use [see comments] Neely KW, et al. **Ann Emerg Med** 1999 Jul;34(1):19-24. Comment in: Ann Emerg Med 1999 Jul;34(1):95-7.
Introduction of a recorded health information line into a pediatric practice. Kempe A, et al.
Arch Pediatr Adolesc Med 1999 Jun;153(6):604-10
The NHS's new information strategy. Emphasises putting information to work for patients and staff, not technology [editorial] Wyatt J, et al. **BMJ** 1998 Oct 3;317(7163):900
Zimbabwean people with head noises are offered help [news] **Cent Afr J Med** 1998 Nov;44(11):296
OSLER marks first birthday with contest. Green D.
CMAJ 1999 Mar 23;160(6):873
Ciguatera fish poisoning [letter; comment] Meyer EG.
CMAJ 1999 Apr 20;160(8):1127. Comment on: CMAJ 1998 Dec 1;159(11):1394.
A possible digital domain for nursing. Yensen J.
Comput Nurs 1999 Jan-Feb;17(1):14-5
Expanding Internet access for health care consumers. Wilkins AS. **Health Care Manage Rev** 1999 Summer;24(3):30-41 (44 ref.)
Specific issues related to developing, disseminating, and implementing pediatric practice guidelines for physicians, patients, families, and other stakeholders. Bauchner H, et al. **Health Serv Res** 1998 Oct;33(4 Pt 2):1161-77 (51 ref.)
AHCPR focuses on information for health care decision makers. Eisenberg JM. **Health Serv Res** 1998 Oct;33(4 Pt 1):767-81 (11 ref.)
The role of information dissemination in sustainability of international partnerships. Delclos GL, et al.
Int J Occup Environ Health 1999 Jul-Sep;5(3):203-8 (14 ref.)
SAM's role in the dissemination of information. Society for Adolescent Medicine. Barnes HV, et al.
J Adolesc Health 1998 Dec;23(6 Suppl):148-51
Easy-to-read consumer communications: a missing link in Medicaid managed care. Root J, et al.
J Health Polit Policy Law 1999 Feb;24(1):1-26
Implementation of the ANA report card. Moore K, et al. **J Nurs Adm** 1999 Jun;29(6):48-54
The uses of comparative information in perinatal care. Gagnon DE. **J Perinatol** 1998 Nov-Dec;18(6 Pt 2 Su):S6-9 (5 ref.)
A knowledge-based health service: how do the new initiatives work? Stevens A, et al. **J R Soc Med** 1998;91 Suppl 35:26-31 (26 ref.)
Strategies for addressing priority information problems in health policy and public health. Lasker RD.
J Urban Health 1998 Dec;75(4):888-95 (0 ref.)
Clinical practice guidelines on the Internet. A structured, scalable approach. Dolin RH, et al. **MD Comput** 1999 Mar-Apr;16(2):60-4
Communicating with the public, communicating with each other. DeCoster C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS279-90
Making survey results easy to report to consumers: how reporting needs guided survey design in CAHPS. Consumer Assessment of Health Plans Study. McGee J, et al. **Med Care** 1999 Mar;37(3 Suppl):MS32-40
From research to policy: what have we learned? Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS291-305 (37 ref.)
Labeling and filtering of medical information on the Internet. Eysenbach G, et al. **Methods Inf Med** 1999 Jun;38(2):80-8
Disseminating our breakthroughs: enacting a strategic framework. Brooten D, et al. **Nurs Outlook** 1999 May-Jun; 47(3):133-7
Electronic commerce and Internet-based health care. Pesut DJ. **Nurs Outlook** 1998 Sep-Oct;46(5):201
Creating your own medical Web site. It's not as hard as you might think. Bergeron BP. **Postgrad Med** 1999 Jul; 106(1):17-8, 21
Balancing research and service: the experience of the cancer information service. Fleisher L, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S84-92
Information technologies within the cancer information service: factors related to innovation adoption. Johnson JD, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S71-83
The cancer information service research consortium: a brief retrospective and a preview of the future. Marcus AC.
Prev Med 1998 Sep-Oct;27(5 Pt 2):S93-100
The cancer information service research consortium: an emerging laboratory for cancer control research. Marcus AC, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 2):S3-15
HCFA establishes official website for Medicare information [news] **Public Health Rep** 1998 Sep-Oct;113(5):385
The British Asthma Guidelines--their production, dissemination and implementation. British Asthma Guidelines Co-ordinating Committee. Partridge MR, et al.
Respir Med 1998 Aug;92(8):1046-52
[Surveillance of communicable diseases in the European Union (see comments)] Sprenger MJ, et al.
Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2418-23 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Oct 31;142(44):2388-90. **(Dut)**
[Internet for physicians: a tool for today and tomorrow] Boyer C, et al. **Rev Med Suisse Romande** 1999 Feb; 119(2):137-44 (14 ref.) (Eng. Abstr.) **(Fre)**
[Continuing medical education in the Internet era] Harmel A, et al. **Tunis Med** 1999 Jun-Jul;77(6-7):349-60 **(Fre)**
[Information access in primary care] Rodriguez del Castillo M. **Aten Primaria** 1999 Jun 15;24(1):44-7 **(Spa)**

STANDARDS

A review of the quality of trauma protocols on the Internet. Branfoot T, et al. **Injury** 1999 Jan;30(1):1-7 (11 ref.)
Which are the best information sources for identifying emerging health care technologies? An international Delphi survey. Robert G, et al.
Int J Technol Assess Health Care 1998 Fall;14(4):636-43
Injury control strategies: extending the quality and quantity of data relating to road traffic accidents in children. Henson R, et al. **J Accid Emerg Med** 1999 Mar;16(2):87-90 (33 ref.)
Dealing with the police. Howarth PA.
J Accid Emerg Med 1999 Jul;16(4):287-8
The quality of information on the World Wide Web. Hersh W. **J Am Coll Dent** 1999 Summer;66(2):43-5
The quality of surgical information on the Internet. McKinley J, et al. **J R Coll Surg Edinb** 1999 Aug;44(4):265-8
Assessment of an electronic mailing list for orthopaedic and trauma surgery. McLauchlan GJ, et al.
J R Coll Surg Edinb 1999 Feb;44(1):36-9
Applied information quality: a framework for thinking about the quality of specific information. Bradley J.
J Urban Health 1998 Dec;75(4):864-77 (8 ref.)
Grading the graders: how hospitals in California and New York perceive and interpret their report cards. Romano PS, et al. **Med Care** 1999 Mar;37(3):295-305
The Health On the Net Code of Conduct for medical and health web sites. Boyer C, et al. **Medinfo** 1998;9 Pt 2:1163-6
Achieving standardization of health information in Canada by the year 2000. Fitzgerald C, et al. **Medinfo** 1998;9 Pt 1:425-8
Information needs of naval primary care providers and patients at sea. D'Alessandro DM, et al. **Mil Med** 1999 Feb;164(2):127-31
[Risk of disinformation on the Internet. Quality labeling of medical websites is tested] Levi R. **Lakartidningen** 1999

Apr 7;96(14):1737–40 **(Swe)**

STATISTICS & NUMERICAL DATA

Cancer coverage in mass-circulating Canadian women's magazines. Hoffman-Goetz L., et al. **Can J Public Health** 1999 Jan-Feb;90(1):55–9

What clinical information resources are available in family physicians' offices? Ely JW, et al. **J Fam Pract** 1999 Feb; 48(2):135–9

Long-term evaluation of the CancerNet WWW service. Quade G, et al. **Medinfo** 1998;9 Pt 1:327–31

SUPPLY & DISTRIBUTION

Public disclosure of health care performance reports: experience, evidence and issues for policy [see comments] Leatherman S, et al. **Int J Qual Health Care** 1999 Apr; 11(2):93–8. Comment in: Int J Qual Health Care 1999 Apr;11(2):99–101. Comment in: Int J Qual Health Care 1999 Apr;11(2):102–3. Comment in: Int J Qual Health Care 1999 Apr;11(2):104–5.

The effect of price information on test-ordering behavior and patient outcomes in a pediatric emergency department. Hampers LC, et al. **Pediatrics** 1999 Apr;103(4 Pt 2):877–82

TRENDS

Taking a corporate approach to information technology in an academic medical center. Beck JR, et al. **Acad Med** 1999 Sep;74(9):996–1001

"A world of knowledge at your fingertips": the promise, reality, and future directions of on-line information retrieval. Hersh W. **Acad Med** 1999 Mar;74(3):240–3

From the past: historical resources and the virtual library [comment] McClure LW. **Bull Med Libr Assoc** 1999 Jan; 87(1):87–8. Comment on: Bull Med Libr Assoc 1999 Jan;87(1):9–19.

An honest broker [editorial] Chambers DW. **J Am Coll Dent** 1999 Summer;66(2):2–4

Finding POEMs in the medical literature. Ebell MH, et al. **J Fam Pract** 1999 May;48(5):350–5

Publishing paradigms [editorial] **Nat Genet** 1999 Apr; 21(4):341–2

At the crossroads: the intersection of the Internet and clinical oncology. Pergament D, et al. **Oncology (Huntingt)** 1999 Apr;13(4):577–83; discussion 583–6

[Information exchange via internet--possibilities, limits, future] Schmiedl S, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:892–5 (Eng. Abstr.) **(Ger)**

[New information sources] Steurer J. **Schweiz Med Wochenschr** 1998 Dec 26;128(51–52):2052–5 (4 ref.) **(Ger)**

[Quality assurance of scientific information and databanks] Schweim HG, et al. **Z Arztl Fortbild Qualitatssich** 1998 Dec;92(10):723–8 (34 ref.) (Eng. Abstr.) **(Ger)**

UTILIZATION

Dissemination of guidelines: which sources do physicians use in order to be informed? Grol R, et al. **Int J Qual Health Care** 1998 Apr;10(2):135–40

Use of outcome data by purchasers and consumers: new strategies and new dilemmas. Hibbard JH. **Int J Qual Health Care** 1998 Dec;10(6):503–8

Hospital peer review and the National Practitioner Data Bank: clinical privileges action reports [see comments] Baldwin LM, et al. **JAMA** 1999 Jul 28;282(4):349–55. Comment in: JAMA 1999 Jul 28;282(4):381–2.

Information needs research in the era of the digital medical library. Lomax EC, et al. **Proc AMIA Symp** 1998;:658–62

Evaluation of a national breast cancer information service: the Iranian experience. Montazeri A, et al. **Support Care Cancer** 1999 May;7(3):154–7

INFORMATION STORAGE AND RETRIEVAL

Information needs and information-seeking behaviors of on-call radiology residents. D'Alessandro MP, et al. **Acad Radiol** 1999 Jan;6(1):16–21

Deposition of macromolecular structures. Keller PA, et al. **Acta Crystallogr D Biol Crystallogr** 1998 Nov 1;54(1 (Pt 6)):1105–8

Electronically accessing the scientific literature: web-based MEDLINE searches. Bar-Zion Y. **Am J Orthod Dentofacial Orthop** 1999 Aug;116(2):229–31

IR-MALDI-mass analysis of electroblotted proteins directly from the membrane: comparison of different membranes, application to on-membrane digestion, and protein identification by database searching. Schleuder D, et al. **Anal Chem** 1999 Aug 1;71(15):3238–47

Internet resources for balloon and other endometrial ablation. Drake C. **AORN J** 1999 Jul;70(1):131–2

Urology sites on the Internet and search tips for Internet browsers. Sjogren D. **AORN J** 1999 Jan;69(1):270–1

Searching for volunteer opportunities; hints for group e-mail. Sjogren D. **AORN J** 1999 Feb;69(2):426–7

Investigating prion diseases on the Internet. Sjogren D. **AORN J** 1999 May;69(5):1039–40

Monitoring wound infection after surgery: the quest for useful information at a reasonable cost [editorial; comment] Hall JC. **Aust N Z J Surg** 1999 Feb;69(2):84. Comment on: Aust N Z J Surg 1999 Feb;69(2):117–20.

Wrapping SRS with CORBA: from textual data to distributed objects. Coupaye T. **Bioinformatics** 1999 Apr;15(4):333–8

Motif-based searching in TOPS protein topology databases. Gilbert D, et al. **Bioinformatics** 1999 Apr;15(4):317–26

Evidence based case reports. Results of search strategy should be given for readers [letter; comment] Bates D. **BMJ** 1998 Nov 14;317(7169):1387. Comment on: BMJ 1998 May 30;316(7145):1660–1. Comment on: BMJ 1998 May 30;316(7145):1676.

Usefulness of contacting other experts when conducting literature searches. Secondary citation of work that was not published did not set good example [letter] Chariot P, et al. **BMJ** 1999 Jul 24;319(7204):259–60; discussion 260

Usefulness of contacting other experts when conducting literature searches. Study only "proves" what librarians knew anyway [letter] Due S. **BMJ** 1999 Jul 24; 319(7204):260

Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. McManus RJ, et al. **BMJ** 1998 Dec 5;317(7172):1562–3 (5 ref.)

Review of randomised controlled trials of traditional Chinese medicine. Tang JL, et al. **BMJ** 1999 Jul 17;319(7203):160–1

Successful web searching. Downes PK. **Br Dent J** 1998 Oct 24;185(8):393–9

Comprehensiveness of systematic review [letter; comment] Lawrie SM. **Br J Psychiatry** 1998 Jul;173:87–8. Comment on: Br J Psychiatry 1998 Feb;172:110–20. Comment on: Br J Psychiatry 1998 May;172:450–1.

Characteristics of reference transactions--challenges to librarians' roles. Li J, et al. **Bull Med Libr Assoc** 1998 Oct; 86(4):610–2

Searching online and Web-based resources for information on natural products used as drugs. Stone VL, et al. **Bull Med Libr Assoc** 1998 Oct;86(4):523–7

Kinetic parameters of cholinesterase interactions with organophosphates: retrieval and comparison tools available through ESTHER database: ESTerases, alpha/beta Hydrolase Enzymes and Relatives. Chatonnet A, et al. **Chem Biol Interact** 1999 May 14;119–120:567–76

Bibliographic information retrieval in the field of artificial nutrition. Farriol M, et al. **Clin Nutr** 1998 Oct;17(5):217–22

Trends in medical information retrieval on Internet. Baujard O, et al. **Comput Biol Med** 1998 Sep;28(5):589–601

Myocardial infarction--pinpointing the key indicators in the 12-lead ECG using data mining. Burn-Thornton KE, et al. **Comput Biomed Res** 1998 Aug;31(4):293–303

Iterated sequence databank search methods. Taylor WR, et al. **Comput Chem** 1999 Jun 15;23(3–4):365–85

Assessment of commercial compression algorithms, of the lossy DCT and lossless types, applied to diagnostic digital image files. Okkalides D. **Comput Med Imaging Graph** 1998 Jan-Feb;22(1):25–30

Image storing system for radiation therapy (radiation oncology information system: ROIS) as a branch of diagnostic PACS; implementation and evaluation. Yamada T, et al. **Comput Med Imaging Graph** 1999 Mar-Apr; 23(2):111–7

A study of the application sharing capabilities in telemedicine. Mattioli P, et al. **Comput Methods Programs Biomed** 1999 Feb;58(2):89–97

Using ARROWSMITH: a computer-assisted approach to formulating and assessing scientific hypotheses. Smalheiser NR, et al. **Comput Methods Programs Biomed** 1998 Nov; 57(3):149–53

Improved glycemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses. Strowig SM, et al. **Diabetes Care** 1998 Oct;21(10):1694–8

Motifer, a search tool for finding amino acid sequence patterns from nucleotide sequence databases. Jörnvall H. **FEBS Lett** 1999 Jul 30;456(1):85–8

Romping with CD-ROM [editorial] Lutter LD. **Foot Ankle Int** 1998 Oct;19(10):651–2

The efficacy of using search engines in procuring information about orthopaedic foot and ankle problems from the World Wide Web. Nogler M, et al. **Foot Ankle Int** 1999 May; 20(5):322–5

E-mail attachment problems. Busby B. **Health Phys** 1999 Apr;76(4):347–8

Diagnostic imaging. Pictures of health [news] Kelleher K. **Hosp Health Netw** 1999 Sep;73(9):20, 22

Towards improved information retrieval from medical sources. Kagolovsky Y, et al. **Int J Med Inf** 1998 Aug-Sep; 51(2–3):181–95

Standard Generalized Markup Language for self-defining structured reports. Kahn CE Jr. **Int J Med Inf** 1999 Feb-Mar;53(2–3):203–11

Providing dermatological photographs using the multimedia extension of the international computer database for radiation accident case histories. Kindler H, et al. **Int J Med Inf** 1998 Jul;51(1):39–50

The art and science of searching MEDLINE to answer clinical questions. Finding the right number of articles. Allison JJ, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):281–96 (59 ref.)

Image acquisition context: procedure description attributes for clinically relevant indexing and selective retrieval of biomedical images. Bidgood WD Jr, et al. **J Am Med Inform Assoc** 1999 Jan-Feb;6(1):61–75

A model for enhancing Internet medical document retrieval with "medical core metadata." Malet G, et al. **J Am Med Inform Assoc** 1999 Mar-Apr;6(2):163–72

Data extraction and ad hoc query of an entity-attribute-value database. Nadkarni PM, et al. **J Am Med Inform Assoc** 1998 Nov-Dec;5(6):511–27

The granularity of medical narratives and its effect on the speed and completeness of information retrieval. Tange HJ, et al. **J Am Med Inform Assoc** 1998 Nov-Dec;5(6):571–82

Location and indexing of articles written by podiatric physicians. Parkinson A, et al. **J Am Podiatr Med Assoc** 1998 Oct;88(10):514–6

Migration from hierarchal storage management to ASM storage server: a case study. Baune D, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):75–7

Integrating legacy systems: the information broker. Krumm JM, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):201–2

Content-based image retrieval in picture archiving and communications systems. Qi H, et al. **J Digit Imaging** 1999 May;12(2 Suppl 1):81–3

Searching the medical literature using CD-ROMs. Basic information and useful tips with special emphasis on MEDLINE. Farha AA, et al. **J Med Liban** 1998 Jan-Feb; 46(1):48–51

Gleaning non-trivial structural, functional and evolutionary information about proteins by iterative database searches. Aravind L, et al. **J Mol Biol** 1999 Apr 16;287(5):1023–40

Improving searching skills and evidence retrieval. Rosenberg WM, et al. **J R Coll Physicians Lond** 1998 Nov-Dec; 32(6):557–63

Web-based resources for retrieving health policy information: NLM and beyond. Cahn MA, et al. **J Urban Health** 1998 Dec;75(4):826–41 (26 ref.)

Sources used in health policy research and implications for information retrieval systems. Gray BH. **J Urban Health** 1998 Dec;75(4):842–52 (0 ref.)

The retrieval problem for health policy and public health: knowledge bases and search engines. Lynch C. **J Urban Health** 1998 Dec;75(4):794–806 (0 ref.)

Estimating time to conduct a meta-analysis from number of citations retrieved [letter] Allen IE, et al. **JAMA** 1999 Aug 18;282(7):634–5

How well do physicians use electronic information retrieval systems? A framework for investigation and systematic review [see comments] Hersh WR, et al. **JAMA** 1998 Oct 21;280(15):1347–52 (35 ref.). Comment in: JAMA 1998 Oct 21;280(15):1363. Comment in: JAMA 1999 Apr 14;281(14):1272–3.

Electronic information retrieval by physicians and medical librarians [letter; comment] Killoran E. **JAMA** 1999 Apr 14;281(14):1272–3. Comment on: JAMA 1998 Oct 21;280(15):1347–52.

What's amiss with web search engines? Larkin M. **Lancet** 1999 Jul 17;354(9174):260

Helping clinicians to find data and avoid delays [see comments] Nygren E, et al. **Lancet** 1998 Oct 31; 352(9138):1462–6. Comment in: Lancet 1998 Dec 19–26;352(9145):2025.

Clinical practice guidelines on the Internet. A structured, scalable approach. Dolin RH, et al. **MD Comput** 1999 Mar-Apr;16(2):60–4

InfoRetriever: rapid access to evidence-based information on a hand-held computer. Ebell MH, et al. **MD Comput** 1998 Sep-Oct;15(5):289, 292–7

Investigating a concept-based tool to enhance the process of curriculum development: an example for healthcare education. Alpay L, et al. **Medinfo** 1998;9 Pt 2:780–4

Automatic extraction of linguistic knowledge from an international classification. Baud R, et al. **Medinfo** 1998;9 Pt 1:581–5

A multi-agent softbot to retrieve medical information on Internet. Baujard O, et al. **Medinfo** 1998;9 Pt 1:150–4

Conceptual integration of information databases into an Intranet. Joubert M, et al. **Medinfo** 1998;9 Pt 1:161–5

A structured model for evaluation of information retrieval (IR). Kagolovsky Y, et al. **Medinfo** 1998;9 Pt 1:171–5

UMLS-based access to CPR data. van Mulligen EM. **Medinfo** 1998;9 Pt 1:166–70

Alternative ways for knowledge collection, indexing and robust language retrieval. Baud RH, et al. **Methods Inf Med** 1998 Nov;37(4–5):315–26

ArchiMed: a medical information and retrieval system. Dorda W, et al. **Methods Inf Med** 1999 Mar;38(1):16–24

Labeling and filtering of medical information on the Internet. Eysenbach G, et al. **Methods Inf Med** 1999 Jun;38(2):80–8

Medical record management systems: criticisms and new perspectives. Frénot S, et al. **Methods Inf Med** 1999 Jun; 38(2):89–95

Term domain distribution analysis: a data mining tool for text databases. Goldman JA, et al. **Methods Inf Med** 1999 Jun;38(2):96–101

For the record: addressing the questions of medical recordkeeping. Brusstar G. **Mich Med** 1999 Mar; 98(3):24–31

Surfing medical Internet sites. Gavorin R. **Mich Med** 1999 Apr;98(4):6–7

Securing public access to genomic information: the race is on [news] Brookbank C. **Mol Med Today** 1999 Jun; 5(6):235–6

Public access to data may be closer than you think. Eisenstein RI, et al. **Nat Biotechnol** 1999 Jun;17(6):604–5

Just try to be specific... [letter; comment] Chiu AL, et al. **Nature** 1999 Sep 9;401(6749):111. Comment on: Nature

1999 Jul 8;400(6740):107-9.
Using peer review as a guide to quality [letter; comment] Fainzilber M. **Nature** 1999 Sep 9;401(6749):111. Comment on: Nature 1999 Jul 8;400(6740):107-9.
A science-oriented search engine could solve web problems... [letter; comment] Gardner M. **Nature** 1999 Sep 9; 401(6749):111. Comment on: Nature 1999 Jul 8;400(6740):107-9.
Accessibility of information on the web [see comments] Lawrence S, et al. **Nature** 1999 Jul 8;400(6740):107-9. Comment in: Nature 1999 Sep 9;401(6749):111.
Virgil database for rich links (1999 update). Achard F, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):113-4
GenBank. Benson DA, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):12-7
The Genome Sequence DataBase: towards an integrated functional genomics resource. Skupski MP, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):35-8
The EMBL Nucleotide Sequence Database. Stoesser G, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):18-24
DNA Data Bank of Japan dealing with large-scale data submission. Sugawara H, et al. **Nucleic Acids Res** 1999 Jan 1;27(1):25-8
Patience with patents [editorial] Fowler C. **Ophthalmic Physiol Opt** 1998 Jul;18(4):317-8
Toward information extraction: identifying protein names from biological papers. Fukuda K, et al. **Pac Symp Biocomput** 1998;:707-18
Are the hinges on your 'electronic closet' ready to burst? pgmdigdoc@mcgraw-hill.com Bergeron BP. **Postgrad Med** 1999 Feb;105(2):21-2
Towards interoperability of information sources within a hospital Intranet. Aymard S, et al. **Proc AMIA Symp** 1998; :638-42
The evolution of an integrated timeline for oncology patient healthcare. Bui AA, et al. **Proc AMIA Symp** 1998;:165-9
Automatic query mapping among genomic databases: a pilot exploration. Cheung KH, et al. **Proc AMIA Symp** 1998; :942-6
Using computer modeling to help identify patient subgroups in clinical data repositories. Cooper GF, et al. **Proc AMIA Symp** 1998;:180-4
Evaluating lexical variant generation to improve information retrieval. Divita G, et al. **Proc AMIA Symp** 1998;:775-9
Information retrieval at the millenium. Hersh W. **Proc AMIA Symp** 1998;:38-45 (39 ref.)
SAPHIRE International: a tool for cross-language information retrieval. Hersh WR, et al. **Proc AMIA Symp** 1998;:673-7
MYCIN II: design and implementation of a therapy reference with complex content-based indexing. Kim DK, et al. **Proc AMIA Symp** 1998;:175-9
Unified modeling language and design of a case-based retrieval system in medical imaging. LeBozec C, et al. **Proc AMIA Symp** 1998;:887-91
Towards knowledge-based retrieval of medical images. The role of semantic indexing, image content representation and knowledge-based retrieval. Lowe HJ, et al. **Proc AMIA Symp** 1998;:882-6
Data mining by clinicians. Nigrin DJ, et al. **Proc AMIA Symp** 1998;:957-61
A graphical tool for ad hoc query generation. Stoffel K, et al. **Proc AMIA Symp** 1998;:503-7
MediAgent: a WWW-based scalable and self-learning medical search engine. Tay J, et al. **Proc AMIA Symp** 1998; :597-601
Self-contained patient data in ORCA to cope with an evolving vocabulary. van Ginneken AM, et al. **Proc AMIA Symp** 1998;:190-4
Linking multiple heterogeneous data sources to practice guidelines. van Wingerde FJ, et al. **Proc AMIA Symp** 1998; :391-5
Knowledge discovery and data mining to assist natural language understanding. Wilcox A, et al. **Proc AMIA Symp** 1998;:835-9
Developing search strategies for detecting high quality reviews in a hypertext test collection. Zacks MP, et al. **Proc AMIA Symp** 1998;:663-7
Automated knowledge extraction from the UMLS. Zeng Q, et al. **Proc AMIA Symp** 1998;:568-72
MedBytes. Franke J. **Tex Med** 1999 Jul;95(7):24
Kleisli: a new tool for data integration in biology. Chung SY, et al. **Trends Biotechnol** 1999 Sep;17(9):351-5 (29 ref.)
The well-built clinical question: the key to finding the best evidence efficiently. Armstrong EC. **WMJ** 1999 Mar-Apr; 98(2):25-8
Finding the evidence. Buchanan J, et al. **WMJ** 1999 Mar-Apr;98(2):29-33
[The practice of systematic reviews. II. Searching and selection of studies] Assendelft WJ, et al. **Ned Tijdschr Geneeskd** 1999 Mar 27;143(13):656-61 (30 ref.) (Eng. Abstr.) **(Dut)**
[International bibliographic databases--Current Contents on disk and in FTP format (Internet): presentation and guide] Bloch-Mouillet E. **Sante** 1999 May-Jun;9(3):183-9 (Eng. Abstr.) **(Fre)**
[Information retrieval on ethical problems by online consultation of bioethics bibliographic data bases] Pizzarelli S. **Ann Ist Super Sanita** 1998;34(2):285-8 (Eng. Abstr.) **(Ita)**
[Internet biomedical databases: the MEDLINE paradigm. Users' guide] Tringali M. **Recenti Prog Med** 1998 Sep; 89(9):425-8 (Eng. Abstr.) **(Ita)**
[Strategies for efficient bibliographic searches. Bibliometrics. Critical evaluation] García Río F. **Arch Bronconeumol** 1999 Feb;35 Suppl 1:27-30 **(Spa)**
[Bibliographic searching. Introduction and theoretical basis] Urbano C, et al. **Aten Primaria** 1999 Mar 31;23(5):306-9 **(Spa)**

STANDARDS

The effect of abbreviations on MEDLINE searching. Federiuk CS. **Acad Emerg Med** 1999 Apr;6(4):292-6
Identification of randomized controlled trials from the emergency medicine literature: comparison of hand searching versus MEDLINE searching. Langham J, et al. **Ann Emerg Med** 1999 Jul;34(1):25-34
Comparison of literature searches on quality and costs for health technology assessment using the MEDLINE and EMBASE databases. Topfer LA, et al. **Int J Technol Assess Health Care** 1999 Spring;15(2):297-303
Using the World Wide Web to answer clinical questions: how efficient are different methods of information retrieval? Graber MA, et al. **J Fam Pract** 1999 Jul;48(7):520-4
Quality of public health information: lessons from the field. Bialek R. **J Urban Health** 1998 Dec;75(4):853-63 (9 ref.)
Strategies for addressing priority information problems in health policy and public health. Lasker RD. **J Urban Health** 1998 Dec;75(4):888-95 (0 ref.)
The need to work together. Service seeks to streamline disability information retrieval. Sasso HS. **Mich Med** 1999 May;98(5):36-8
[Review of the literature, search of reports and critical reading of articles in cancerology] Bonichon F, et al. **Bull Cancer** 1998 Oct;85(10):867-85 (109 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Is information knowledge? Does it matter? [editorial] Clearihan L. **Aust Fam Physician** 1999 May;28(5):417

UTILIZATION

Factors affecting the diffusion of online end user literature searching. Ash JS. **Bull Med Libr Assoc** 1999 Jan; 87(1):58-66
A global perspective on nurses' Internet access and information utilization. Uhlenhopp MB, et al. **Oncol Nurs Forum** 1998 Nov-Dec;25(10 Suppl):27-32 (16 ref.)

INFORMATION SYSTEMS

Design of a state-based workers' compensation information system. Maizlish N, et al. **Am J Ind Med** 1999 Jun; 35(6):564-73
Technical note: Modeling primate occlusal topography using geographic information systems technology. Zuccotti LF, et al. **Am J Phys Anthropol** 1998 Sep;107(1):137-42
Geographic information systems [letter; comment] Khan OA. **Am J Public Health** 1999 Jul;89(7):1125. Comment on: Am J Public Health 1998 Sep;88(9):1406-7.
Geographic information systems and the environmental risk of schistosomiasis in Bahia, Brazil. Bavia ME, et al. **Am J Trop Med Hyg** 1999 Apr;60(4):566-72
Application of risk analysis and geographic information system technologies to the prevention of diarrheal diseases in Nigeria. Njemanze PC, et al. **Am J Trop Med Hyg** 1999 Sep;61(3):356-60
A "geographic information systems" based technique for the study of microvascular networks. Roth NM, et al. **Ann Biomed Eng** 1999 Jan-Feb;27(1):42-7
Empirical derivation of an electronic clinically useful problem statement system [see comments] Brown SH, et al. **Ann Intern Med** 1999 Jul 20;131(2):117-26. Comment in: Ann Intern Med 1999 Jul 20;131(2):146-7.
Reduction of medical verbiage: fewer words, more meaning [editorial; comment] Voytovich AE. **Ann Intern Med** 1999 Jul 20;131(2):146-7. Comment on: Ann Intern Med 1999 Jul 20;131(2):117-26.
Potential meets reality: GIS and public health research in Australia. O'Dwyer LA, et al. **Aust N Z J Public Health** 1998 Dec;22(7):819-23
Making sense of the electronic resource marketplace: trends in health-related electronic resources. Blansit BD, et al. **Bull Med Libr Assoc** 1999 Jul;87(3):243-50
The Western New York Health Resources Project: developing access to local health information. Gray SA, et al. **Bull Med Libr Assoc** 1998 Jul;86(3):335-9
Challenges of developing a cervical screening information system: the Ontario pilot project. Marrett LD, et al. **Cancer Prev Control** 1998 Oct;2(5):221-7
Developing a cervical screening information system [editorial] Stuart G. **Cancer Prev Control** 1998 Oct;2(5):210
Privacy policy [letter; comment] Cellini L. **CMAJ** 1999 Apr 6;160(7):988. Comment on: CMAJ 1998 Dec 1;159(11):1378-80.
Winter can be fun until the injuries start [news] Sibbald B. **CMAJ** 1999 Feb 9;160(3):302
The telemedicine information exchange: an online resource. Brown NA. **Comput Biol Med** 1998 Sep;28(5):509-18
Development of medical information transfer system using personal-agent optical disks. Okabe T, et al. **Comput Methods Programs Biomed** 1998 Aug-Sep; 57(1-2):79-83
Designing an information technology application for use in community-focused nursing education. Nightingale Tracker Field Test Nurse Team. **Comput Nurs** 1999 Mar-Apr;17(2):73-81
From computer technology to information technology. Findings from a national study of nursing education. Carty B, et al. **Comput Nurs** 1998 Sep-Oct;16(5):259-65
Temporal and geographical distributions of reported cases of Escherichia coli O157:H7 infection in Ontario. Michel P, et al. **Epidemiol Infect** 1999 Apr;122(2):193-200
Participatory design of an Internet-based information system for aging services professionals. Ellis RD, et al. **Gerontologist** 1998 Dec;38(6):743-8
A new proposal for cooperation in HIT development [letter; comment] Cantlon G. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):257-9. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):9-22. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):41-3.
Health information: a broader view [letter; comment] Detmer DE, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):256-9 . Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):9-22.
'After the chaos': expected benefits of health information management [comment] Kelly JT. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):39-40. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):9-22. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):23-38.
Pursuing the promise of an information-age health care system [see comments] Kendall DB, et al. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):41-3. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):257-9.
Release 0.0: clinical information technology in the real world [see comments] Kleinke JD. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):23-38. Comment in: Health Aff (Millwood) 1998 Nov-Dec;17(6):39-40. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):255-6; discussion 258-9. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):256; discussion 258-9.
Health information policy: on preparing for the next war [see comments] Moran DW. **Health Aff (Millwood)** 1998 Nov-Dec;17(6):9-22. Comment in: Health Aff (Millwood) 1998 Nov-Dec;17(6):39-40. Comment in: Health Aff (Millwood) 1998 Nov-Dec;17(6):44-6. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):255-6; discussion 258-9. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):256; discussion 258-9. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):256-7; discussion 258-9. Comment in: Health Aff (Millwood) 1999 Mar-Apr;18(2):257-9.
A maturing market for health information technology? [letter; comment] Roper WL, et al. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):255-6. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):9-22. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):23-38.
Information technology: value to patients [letter; comment] Rossé C. **Health Aff (Millwood)** 1999 Mar-Apr;18(2):256. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):9-22. Comment on: Health Aff (Millwood) 1998 Nov-Dec;17(6):23-38.
Technology. Hooray, we're average! [news] **Hosp Health Netw** 1998 Nov 20;72(22):14
CORBA security services for health information systems. Blobel B, et al. **Int J Med Inf** 1998 Oct-Dec;52(1-3):29-37
The standard 'Healthcare Information Systems Architecture' and the DHE middleware. Ferrara FM. **Int J Med Inf** 1998 Oct-Dec;52(1-3):39-51
The role of group support technology in developing the HEALNet research agenda. Goel V, et al. **Int J Med Inf** 1998 Aug-Sep;51(2-3):215-9
Discourse structures in medical reports--watch out! The generation of referentially coherent and valid text knowledge bases in the MEDSYNDIKATE system. Hahn U, et al. **Int J Med Inf** 1999 Jan;53(1):1-28
Standard Generalized Markup Language for self-defining structured reports. Kahn CE Jr. **Int J Med Inf** 1999 Feb-Mar;53(2-3):203-11
Cognitive evaluation of decision making processes and assessment of information technology in medicine. Kushniruk AW, et al. **Int J Med Inf** 1998 Aug-Sep; 51(2-3):83-90
Towards specialised middleware for healthcare information systems. Spahni S, et al. **Int J Med Inf** 1999 Feb-Mar; 53(2-3):193-201
Synchronous and asynchronous brain-state-in-a-box information system neural models. Chan HY, et al. **Int J Neural Syst** 1999 Feb;9(1):61-74
RUOK 4 Y2K? **Iowa Med** 1999 May-Jun;89(3):14
The business value of health care information technology. Frisse MC. **J Am Med Inform Assoc** 1999 Sep-Oct; 6(5):361-7
Use of an automated anesthesia information system to determine reference limits for vital signs during cesarean section. Dexter F, et al. **J Clin Monit Comput** 1998 Dec; 14(7-8):491-8
Effects of information technology on dairy farms in The Netherlands: an empirical analysis of milk production records. Van Asseldonk MA, et al. **J Dairy Sci** 1998 Oct; 81(10):2752-9
A model for achieving total quality-management information technology infrastructure within an integrated delivery

system. Tan JK. **J Digit Imaging** 1998 Nov;11(4 Suppl 2):35–41

The Clinical Oncology Information Network (COIN) Project: background, purpose and products. Karp SJ. **J Eval Clin Pract** 1999 May;5(2):179–87

A geographical information system technique for record-matching in a study of cancer deaths in welders. de Silva SR, et al. **J Occup Environ Med** 1999 Jun; 41(6):464–8

Information resources for public health practice. Rambo N. **J Urban Health** 1998 Dec;75(4):807–25 (8 ref.)

High-quality clinical databases: breaking down barriers [see comments] Black N. **Lancet** 1999 Apr 10;353(9160):1205–6 . Comment in: Lancet 1999 Jul 3;354(9172):75.

MARVIN, multi-agent softbot to retrieve multilingual medical information on the Web. Baujard O, et al. **Med Inform (Lond)** 1998 Jul–Sep;23(3):187–91

Lessons learned from an Internet GP information system. Briggs JS, et al. **Med Inform (Lond)** 1998 Jul–Sep; 23(3):245–52

A WWW-based information system on resistance of bacteria to antibiotics. Schindler J, et al. **Med Inform (Lond)** 1998 Jul–Sep;23(3):179–85

Organizational & medical ontologies for co-operative patient management. Falasconi S, et al. **Medinfo** 1998;9 Pt 2:1192–6

A integrative molecular information system. Hofestädt R. **Medinfo** 1998;9 Pt 1:361–4

Information overload: opportunities and challenges for the GP's desktop. Noone J, et al. **Medinfo** 1998;9 Pt 2:1287–91

Middleware for healthcare information systems. Spahni S, et al. **Medinfo** 1998;9 Pt 1:212–6

A support system to make care plan of elders. Tsutomu M, et al. **Medinfo** 1998;9 Pt 1:117–20

Analysis and design of an ontology for intensive care diagnoses. de Keizer NF, et al. **Methods Inf Med** 1999 Jun; 38(2):102–12

The medical software quality deployment method. Hallberg N, et al. **Methods Inf Med** 1999 Mar;38(1):66–73

Flood warnings [letter] Blackmore S. **Nature** 1999 Jul 29; 400(6743):398

Radiation oncology digital image chart system (RO-DICS) at Samsung Medical Center. Huh SJ, et al. **Nippon Igaku Hoshasen Gakkai Zasshi** 1998 Oct; 58(12):712–5

Using sequence logos and information analysis of Lrp DNA binding sites to investigate discrepancies between natural selection and SELEX. Shultzaberger RK, et al. **Nucleic Acids Res** 1999 Feb 1;27(3):882–7

DBGET/LinkDB: an integrated database retrieval system. Fujibuchi W, et al. **Pac Symp Biocomput** 1998;:683–94

CATCH/IT: a data warehouse to support comprehensive assessment for tracking community health. Berndt DJ, et al. **Proc AMIA Symp** 1998;:250–4

Requirements for an on-line knowledge-based anatomy information system. Brinkley JF, et al. **Proc AMIA Symp** 1998;:892–6

Evaluating lexical variant generation to improve information retrieval. Divita G, et al. **Proc AMIA Symp** 1998;:775–9

Process modelling and simulation for managing clinical care in the community. Kay S, et al. **Proc AMIA Symp** 1998; :270–4

Updating a bibliography using the related articles function within PubMed. Liu X, et al. **Proc AMIA Symp** 1998;:750–4

Scaling an expert system data mart: more facilities in real-time. McNamee LA, et al. **Proc AMIA Symp** 1998; :498–502

Linking information needs with evaluation: the role of task identification. Weir CR. **Proc AMIA Symp** 1998;:310–4

Software, hardware, and data for new GIS users. **Public Health Rep** 1999 Jul–Aug;114(4):362–73

Geographic information systems and public health: mapping the future. Richards TB, et al. **Public Health Rep** 1999 Jul–Aug;114(4):359–60

Comparative evaluation of underlying causes of death processed by the Automated Classification of Medical Entities and the Underlying Cause of Death Selection Systems. Santo AH, et al. **Rev Saude Publica** 1998 Feb; 32(1):1–6

Open laboratory information systems: a case study. Solberg HE, et al. **Scand J Clin Lab Invest** 1999 Feb;59(1):33–45

DOE builds a web site for the physical sciences [news] Marshall E. **Science** 1999 Aug 6;285(5429):811

Y2K activities at the Tennessee Medical Association. Grant JH, et al. **Tenn Med** 1999 May;92(5):165–7

[Systems of geographic information and the campaign against tropical diseases] Nuttall I, et al. **Med Trop (Mars)** 1998; 58(3):221–7 **(Fre)**

[Computer-based patient information. Legal bases, concept and 10-year experience] Müller RT, et al. **Orthopade** 1999 Mar;28(3):243–9 (Eng. Abstr.) **(Ger)**

[Use of hypertext as information and training tools in the prevention of occupational risk] Franco G. **G Ital Med Lav Ergon** 1998 Jul–Sep;20(3):115–22 (Eng. Abstr.) **(Ita)**

[Role of information system for the health care delivery in community] Kaihara S. **Hokkaido Igaku Zasshi** 1999 Jan; 74(1):3–6 (Eng. Abstr.) **(Jpn)**

[Development of NIHS Information and Computing Infrastructure (NICI)] Nakata K, et al. **Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku** 1998;(116):92–100 (7 ref.) (Eng. Abstr.) **(Jpn)**

[The use of computers and networking in the neurosurgical field] Oizumi T, et al. **Rinsho Byori** 1999 Feb;47(2):119–25 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Expert systems and automatic diagnostic systems in histopathology--a review] Tamai S. **Rinsho Byori** 1999 Feb;47(2):126–31 (22 ref.) (Eng. Abstr.) **(Jpn)**

[WinDiet. Support decision system for the assessment of nutritional status and diet prescription] Esteves EA, et al. **Arch Latinoam Nutr** 1998 Sep;48(3):236–41 (Eng. Abstr.) **(Por)**

[Linkage of environmental and health data: health risk analysis of the Rio de Janeiro water supply by using geographical information systems] Barcellos C, et al. **Cad Saude Publica** 1998 Jul–Sep;14(3):597–605 (Eng. Abstr.) **(Por)**

[Epidemiologic study of birth weight from birth certificates] Costa CE, et al. **Rev Saude Publica** 1998 Aug;32(4):328–34 (Eng. Abstr.) **(Por)**

[Batch processing of causes of death based on the underlying cause of death selection system] Pinheiro CE, et al. **Rev Saude Publica** 1998 Feb;32(1):72–3 **(Por)**

[Computerized technologies in public health administration] Khal'fin RA, et al. **Med Tekh** 1999 Jul–Aug;(4):39–44 (Eng. Abstr.) **(Rus)**

[Provision of information on the activities of the State Sanitary-Epidemiologic Service] Kutstenko GI, et al. **Probl Sotsialnoi Gig Istor Med** 1998 May–Jun;(3):53–5 (Eng. Abstr.) **(Rus)**

[Systematic model of the sanologic status of children and adolescents] Simonov SN. **Probl Sotsialnoi Gig Istor Med** 1998 Sep–Oct;(5):27–30 (Eng. Abstr.) **(Rus)**

[An information system for automated cytogenetic image processing: analysis of interphase chromatin of nerve cells of embryonic brain of rats with varying nervous system excitability] Dudkin KN, et al. **Tsitologiia** 1999; 41(3–4):237–49 (Eng. Abstr.) **(Rus)**

ECONOMICS

The costs of computing for primary care groups. Inequity persists between former fundholders and non-fundholders [editorial] Willis A. **BMJ** 1998 Nov 7;317(7168):1265–6

INSTRUMENTATION

Technical evaluation of five glucose meters with data management capabilities. Chance JJ, et al. **Am J Clin Pathol** 1999 Apr;111(4):547–56

LEGISLATION & JURISPRUDENCE

Federal regulations governing health information security published. Ziel SE. **AORN J** 1998 Nov;68(5):866–8

ORGANIZATION & ADMINISTRATION

Clinical engineering and information systems: bridging the gap [interview by Brian Porras] Athanassiades D, et al. **Biomed Instrum Technol** 1999 May–Jun;33(3):199–203

Integrating clinical engineering and information systems. Hatem MB. **Biomed Instrum Technol** 1999 Jul–Aug; 33(4):295–7

The Virtual Hospital: experiences in creating and sustaining a digital library. D'Alessandro MP, et al. **Bull Med Libr Assoc** 1998 Oct;86(4):553–63

The Information Commons: a model for (physical) digital resource centers. Duncan JM. **Bull Med Libr Assoc** 1998 Oct;86(4):576–82

Conceptual development of an information systems framework for improving continuity in epidemiological research. Linger H, et al. **Eur J Epidemiol** 1998 Sep; 14(6):587–93 (16 ref.)

Availability of health data: requirements and solutions. Espinosa AL. **Int J Med Inf** 1998 Mar;49(1):97–104

Lessons from a failed information systems initiative: issues for complex organisations. Southon G, et al. **Int J Med Inf** 1999 Jul;55(1):33–46

Building health plan databases to risk adjust outcomes and payments. Hornbrook MC, et al. **Int J Qual Health Care** 1998 Dec;10(6):531–8

Nursing administrators and clinical information systems: shaping the future. FitzHenry F. **J Nurs Adm** 1998 Nov; 28(11):24, 38, 45 passim

Increasing the acceptance of clinical information systems. Anderson JD. **MD Comput** 1999 Jan–Feb;16(1):62–5

System analysis and design in five easy steps. Kiel JM. **MD Comput** 1999 Mar–Apr;16(2):29–30

Countdown to the new millennium. Contingency planning for healthcare. Klein S. **MD Comput** 1999 Jul–Aug; 16(4):30–2

The population's use of pharmaceuticals. Metge C, et al. **Med Care** 1999 Jun;37(6 Suppl):JS42–59

Managing health services: how the Population Health Information System (POPULIS) works for policymakers. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS27–41 (68 ref.)

Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Roos NP, et al. **Med Care** 1999 Jun;37(6 Suppl):JS10–4

Establishing a population data-based policy unit. Roos NP. **Med Care** 1999 Jun;37(6 Suppl):JS15–26 (29 ref.)

Adding up provincial expenditures on health care for Manitobans: a POPULIS project. Population Health Information System. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS60–82

Using the POPULIS framework for interprovincial comparisons of expenditures on health care. Population Health Information System. Shanahan M, et al. **Med Care** 1999 Jun;37(6 Suppl):JS83–100

Heuristic walkthrough evaluation of a prototype computer network service for occupational therapists. Hallberg N, et al. **Medinfo** 1998;9 Pt 2:869–73

Object technology: raising the standards for healthcare information systems. Pollard DL, et al. **Medinfo** 1998;9 Pt 1:217–21

The Virtual Naval Hospital: a digital library for naval primary care providers and patients. D'Alessandro MP, et al. **Mil Med** 1998 Nov;163(11):775–80

Harnessing innovative technologies: what can you do with a shoe? Brennan PF. **Nurs Outlook** 1999 May–Jun; 47(3):128–32 (14 ref.)

2001 Census output areas: from concept to prototype. Martin D. **Popul Trends** 1998 Winter;(94):19–24

Health information identification and de-identification toolkit. Kohane IS, et al. **Proc AMIA Symp** 1998;:356–60

[More information on infectious diseases provided by a national information system] Sprenger MJ, et al. **Ned Tijdschr Geneeskd** 1998 Aug 22;142(34):1923–6 (Eng. Abstr.) **(Dut)**

[Program of medical information systems and resource allocation. How to optimize?] Vergnenegre A. **Rev Mal Respir** 1999 Jan;16 Suppl 3:S22–3 **(Fre)**

[Patterns of care in community mental health services in Lombardy] Lora A, et al. **Epidemiol Psichiatr Soc** 1998 May–Aug;7(2):98–109 (Eng. Abstr.) **(Ita)**

[The state computerized information system for monitoring the epidemic process in Ukraine. The monitoring technology] Bogatyreva RV, et al. **Lik Sprava** 1999 Apr–May;(3):3–12 **(Rus)**

STANDARDS

The efficacy of using search engines in procuring information about orthopaedic foot and ankle problems from the World Wide Web. Nogler M, et al. **Foot Ankle Int** 1999 May; 20(5):322–5

Need for standards in health information [comment] McDonald CJ. **Health Aff (Millwood)** 1998 Nov–Dec; 17(6):44–6. Comment on: Health Aff (Millwood) 1998 Nov–Dec;17(6):9–22.

Definition of race and ethnicity in older people in Medicare and Medicaid. Pan CX, et al. **J Am Geriatr Soc** 1999 Jun; 47(6):730–3

Standards move to center stage. Chute CG. **MD Comput** 1999 Jan–Feb;16(1):29–32

Enhancing security and improving interoperability in healthcare information systems. Gritzalis DA. **Med Inform (Lond)** 1998 Oct–Dec;23(4):309–23

Confronting Y2K physician practice guidelines. Parratt J. **N J Med** 1999 Aug;96(8):43–5

Setting standards for nursing data sets in information systems. Averill CB, et al. **Proc AMIA Symp** 1998;:745–9

STATISTICS & NUMERICAL DATA

Tops in info tech [news] Serb C. **Hosp Health Netw** 1999 Apr;73(4):20

TRENDS

Trends. Info tech meets biz strategy [news] **Hosp Health Netw** 1998 Oct 20;72(20):13

Organizational issues in health informatics: a model approach. Aarts J, et al. **Int J Med Inf** 1998 Oct–Dec;52(1–3):235–42

The Creation of a global telemedical information society. Marsh A. **Int J Med Inf** 1998 Apr;49(2):173–93

Security in health-care information systems--current trends. Smith E, et al. **Int J Med Inf** 1999 Apr;54(1):39–54

[Current status and trends in the development of medical information systems for morphological research (editorial)] Matsionis AE, et al. **Arkh Patol** 1999 May–Jun;61(3):3–6 (Eng. Abstr.) **(Rus)**

UTILIZATION

Modeling utilization of planned information technology. Stettheimer TD, et al. **Proc AMIA Symp** 1998;:290–4

INFORMATION THEORY

Organisms, organizations and interactions: an information theory approach to biocultural evolution. Wallace R, et al. **Biosystems** 1999 Aug;51(2):101–19

Relative entropy as a measure of diagnostic information. Benish WA. **Med Decis Making** 1999 Apr–Jun;19(2):202–6

Multi-modal volume registration by maximization of mutual information. Wells WM 3rd, et al. **Med Image Anal** 1996 Mar;1(1):35–51

The coding of information by spiking neurons: an analytical study. Deco G, et al. **Network** 1998 Aug;9(3):303–17

Theory and implementation of infomax filters for the retina. Haft M, et al. **Network** 1998 Feb;9(1):39–71

Model-independent mean-field theory as a local method for approximate propagation of information. Haft M, et al. **Network** 1999 Feb;10(1):93–105

Nonlinear feedforward networks with stochastic outputs: infomax implies redundancy reduction. Nadal JP, et al.

Network 1998 May;9(2):207–17
Spatiotemporal coding in the cortex: information flow–based learning in spiking neural networks. Deco G, et al. **Neural Comput** 1999 May 15;11(4):919–34
Performance of visually triggered wrist movements task in monkey: an application of information theory to evaluate deficits following unilateral substantia nigra pars reticulata lesion. Lestienne FG, et al. **Neurosci Lett** 1998 Jul 31; 251(3):177–80
Using information theory to discover side chain rotamer classes: analysis of the effects of local backbone structure. Fetrow JS, et al. **Pac Symp Biocomput** 1999;:278–89
Self–assembling automata: a model of conformational self–assembly. Saitou K. **Pac Symp Biocomput** 1998;:609–20
An information theoretic view of gapped and other alignments. Schmidt JP. **Pac Symp Biocomput** 1998;:561–72
Application of a novel and fast information–theoretic method to the discovery of higher–order correlations in protein databases. Steeg EW, et al. **Pac Symp Biocomput** 1998; :573–84
On the application of information theory to neural spike trains. Strong SP, et al. **Pac Symp Biocomput** 1998;:621–32
[Disorders of information exchange as a basis for disease formation and the second law of thermodynamics for living thermodynamic systems] Frolov VA, et al. **Patol Fiziol Eksp Ter** 1998 Jul–Sep;(3):3–6 (Eng. Abstr.) **(Rus)**

INFORMED CONSENT

see related
HUMAN EXPERIMENTATION
TRUTH DISCLOSURE

Can acutely ill patients consent to research? Resolving an ethical dilemma with facts [editorial; comment] Fost N. **Acad Emerg Med** 1999 Aug;6(8):772–4 (11 ref.). Comment on: Acad Emerg Med 1999 Aug;6(8):776–80.
Emergency medicine's "illusion of efficacy" and the public perception of resuscitation research [editorial] Lewis RJ. **Acad Emerg Med** 1999 Aug;6(8):771–2
Informed consent: the most important protector [editorial; comment] Prentice ED. **Acad Emerg Med** 1999 Aug; 6(8):774–5. Comment on: Acad Emerg Med 1999 Aug;6(8):776–80.
Do patients with acute medical conditions have the capacity to give informed consent for emergency medicine research? [see comments] Smithline HA, et al. **Acad Emerg Med** 1999 Aug;6(8):776–80. Comment in: Acad Emerg Med 1999 Aug;6(8):772–4. Comment in: Acad Emerg Med 1999 Aug;6(8):774–5.
Understanding informed consent. Macklin R. **Acta Oncol** 1999;38(1):83–7
FDA medical device regulation and informed consent. Smith JJ, et al. **AJNR Am J Neuroradiol** 1998 Nov–Dec; 19(10):1815–7
Observations on the standard of care [letter; comment] Alexander JE. **AJR Am J Roentgenol** 1999 Jul;173(1):238–9 . Comment on: AJR Am J Roentgenol 1998 Oct;171(4):1156–7.
Assessment of mental competency in community–dwelling elderly. Schmand B, et al. **Alzheimer Dis Assoc Disord** 1999 Apr–Jun;13(2):80–7
The potential postfertilization effect with use of the IUD [letter] Larimore WL. **Am Fam Physician** 1999 Sep 1; 60(3):761–3
The Pap smear, automated rescreening, and negligent nondisclosure [see comments] Godfrey SE. **Am J Clin Pathol** 1999 Jan;111(1):14–7. Comment in: Am J Clin Pathol 1999 Aug;112(2):273–4. Comment in: Am J Clin Pathol 1999 Aug;112(2):274–80.
Patient recall and appropriate timing for obtaining informed consent for endoscopic procedures. Proctor DD, et al. **Am J Gastroenterol** 1999 Apr;94(4):967–71
Reflective choice in health care: using information technology to present allocation options. Rai AK. **Am J Law Med** 1999;25(2–3):387–402
Advancing the cause of informed consent: moving from disclosure to understanding [editorial; comment] Braddock CH 3rd. **Am J Med** 1998 Oct;105(4):354–5. Comment on: Am J Med 1998 Oct;105(4):266–74.
What should men know about prostate–specific antigen screening before giving informed consent? Chan EC, et al. **Am J Med** 1998 Oct;105(4):266–74
The continuing legacy of the Tuskegee Syphilis Study: considerations for clinical investigation [see comments] Corbie–Smith G. **Am J Med Sci** 1999 Jan;317(1):5–8. Comment in: Am J Med Sci 1999 Jan;317(1):1–4. Comment in: Am J Med Sci 1999 May;317(5):353.
Orthodontics and patients with temporomandibular disorders: inform before you perform. Sondhi A. **Am J Orthod Dentofacial Orthop** 1999 May;115(5):551–2
Guidelines for assessing the decision–making capacities of potential research subjects with cognitive impairment. American Psychiatric Association. **Am J Psychiatry** 1998 Nov;155(11):1649–50
Competence of depressed patients for consent to research. Appelbaum PS, et al. **Am J Psychiatry** 1999 Sep; 156(9):1380–4
Informed consent: assessment of comprehension [see comments] Wirshing DA, et al. **Am J Psychiatry** 1998 Nov; 155(11):1508–11. Comment in: Am J Psychiatry 1998 Nov;155(11):1486–8.
An unexpected complication of the intubating laryngeal mask [letter; comment] Scott DJ. **Anaesthesia** 1999 Jul; 54(7):710–1. Comment on: Anaesthesia 1999 Feb;54(2):166–7.
Informed consent for suppositories [letter] Stocker M. **Anaesthesia** 1998 Aug;53(8):828
Goals– and values–directed approach to informed consent in the "DNR" patient presenting for surgery: more demanding of the anesthesiologist? [editorial; comment] Jackson SH, et al. **Anesthesiology** 1999 Jan;90(1):3–6. Comment on: Anesthesiology 1999 Jan;90(1):289–95.
Informed consent and "reform" Jehovah's Witness patients [letter; comment] Shander A. **Anesthesiology** 1999 Jun; 90(6):1787. Comment on: Anesthesiology 1998 Aug;89(2):537.
Informed consent for research: the achievements of the past and the challenges of the future [editorial; comment] Truog RD, et al. **Anesthesiology** 1999 Jun;90(6):1499–501. Comment on: Anesthesiology 1999 Jun;90(6):1756–65.
Acting without asking: an ethical analysis of the Food and Drug Administration waiver of informed consent for emergency research. Adams JG, et al. **Ann Emerg Med** 1999 Feb;33(2):218–23
Initial experience using the Food and Drug administration guidelines for emergency research without consent. Kremers MS, et al. **Ann Emerg Med** 1999 Feb;33(2):224–9
Characteristics of primary HIV infection [letter; comment] Silvers AA. **Ann Intern Med** 1999 Jan 5;130(1):80–1. Comment on: Ann Intern Med 1998 Apr 15;128(8):613–20.
Lawyers out of hospitals, doctors out of court [letter; comment] Visvanathan R. **Ann R Coll Surg Engl** 1999 Jan; 81(1 Suppl):46. Comment on: Ann R Coll Surg Engl 1998 Sep;80(5 Suppl):206–7.
Informed consent, parental awareness, and reasons for participating in a randomised controlled study. van Stuijvenberg M, et al. **Arch Dis Child** 1998 Aug;79(2):120–5
Consent for electroconvulsive therapy [letter; comment] James N. **Aust N Z J Psychiatry** 1998 Dec;32(6):891. Comment on: Aust N Z J Psychiatry 1997 Dec;31(6):909.
Theories of consent [see comments] Alderson P, et al. **BMJ** 1998 Nov 7;317(7168):1313–5 (18 ref.). Comment in: BMJ 1999 Mar 13;318(7185):735–6.
Consent of relatives is neither necessary nor sufficient for treating incompetent adults [letter; comment] Allmark P. **BMJ** 1999 Mar 13;318(7185):736. Comment on: BMJ 1998 May 23;316(7144):1608. Comment on: BMJ 1998 Nov 14;317(7169):1386.
Antenatal screening. Obtaining selective consent to scanning, rather than screening, is possible [letter; comment] Baillie C, et al. **BMJ** 1999 Mar 20;318(7186):805. Comment on: BMJ 1998 Sep 12;317(7160):694–5.
Breast screening. Informed consent for mammographic screening [letter; comment] Baum M. **BMJ** 1999 Mar 20; 318(7186):810. Comment on: BMJ 1999 Mar 6;318(7184):621.
Informed consent. Numbers inform the debate [letter; comment] Baum M. **BMJ** 1998 Oct 3;317(7163):947. Comment on: BMJ 1998 Mar 28;316(7136):949–51. Comment on: BMJ 1998 Mar 28;316(7136):1000–5.
Informed consent. Explicit consent is not needed for studies using medical records [letter; comment] Brewster DH, et al. **BMJ** 1998 Oct 3;317(7163):948. Comment on: BMJ 1998 Mar 28;316(7136):1000–5.
Presumed consent. We know that our daughter lives on [letter] Cansdale S, et al. **BMJ** 1999 May 29; 318(7196):1490–1
Full information about trials might be given retrospectively to participants [letter; comment] Clement S. **BMJ** 1999 Mar 13;318(7185):736. Comment on: BMJ 1998 Mar 28;316(7136):1000–5.
Can children and young people consent to be tested for adult onset genetic disorders? Dickenson DL. **BMJ** 1999 Apr 17;318(7190):1063–5 (27 ref.)
Anaesthetists do not need separate consent before surgery [news] Dobson R. **BMJ** 1999 Jul 17;319(7203):142
English teenager given heart transplant against her will [news] Dyer C. **BMJ** 1999 Jul 24;319(7204):209
Screening for nuchal translucency. Screening provides reliable information on which care can be based [letter] Eustace DL. **BMJ** 1998 Sep 12;317(7160):748
Antenatal screening. Women are being given incomplete information [letter; comment] Fitzgerald T. **BMJ** 1999 Mar 20;318(7186):805–6. Comment on: BMJ 1996 Nov 16;313(7067):1251–3. Comment on: BMJ 1996 Nov 16;313(7067):1253–4. Comment on: BMJ 1996 Nov 16;313(7067):1254–5. Comment on: BMJ 1998 Sep 12;317(7160):694–5. Comment on: BMJ 1998 Sep 12;317(7160):748.
Commentary: weighing burdens and benefits rather than competence. Geller G. **BMJ** 1999 Apr 17;318(7190):1065–6
Presumed consent. If this is introduced, people will have to have all relevant information [letter] Hill DJ, et al. **BMJ** 1999 May 29;318(7196):1490
Informed consent. Consent might have been obtained under duress [letter; comment] Josse SE. **BMJ** 1998 Oct 3; 317(7163):948. Comment on: BMJ 1998 Mar 28;316(7136):949–51. Comment on: BMJ 1998 Mar 28;316(7136):1000–5. Comment on: BMJ 1998 Mar 28;316(7136):1008.
Informed consent. "Technical" consent is inevitable in some circumstances [letter; comment] Kestin IG. **BMJ** 1998 Oct 3;317(7163):947–8. Comment on: BMJ 1998 Mar 28;316(7136):1000–5.
Competency, consent, and the duty of care [letter] McIvor RJ. **BMJ** 1999 Apr 3;318(7188):943
Doctors take kidney from patient incapable of giving consent [news] Mudur G. **BMJ** 1999 Mar 20;318(7186):753
Screening for nuchal translucency. Patients give consent by attending for ultrasound scans [letter] Nash TG. **BMJ** 1998 Sep 12;317(7160):749
Videos, photographs, and patient consent. Most patients agree to be videoed for teaching and publication purposes [letter] Nicholl D, et al. **BMJ** 1998 Nov 28;317(7171):1523
Informed consent. Screening programmes need consent forms [letter; comment] Nottingham J. **BMJ** 1998 Oct 3; 317(7163):948–9. Comment on: BMJ 1998 Mar 28;316(7136):1000–5.
Women must be given fully informed information about cervical screening [letter] Nottingham J. **BMJ** 1999 Jun 5;318(7197):1555–6
Videos, photographs, and patient consent. Medical educationalists can free themselves from constraints of "real world" images [letter; comment] Pallen M, et al. **BMJ** 1998 Nov 28;317(7171):1522. Comment on: BMJ 1998 Mar 28;316(7136):1009–11.
Most doctors see consent from functionalist perspective [letter; comment] Peters E, et al. **BMJ** 1999 Mar 13; 318(7185):735–6. Comment on: BMJ 1998 Nov 7;317(7168):1313–5.
Informed consent. Parents have views on how it should be obtained [letter; comment] Wilcox DT, et al. **BMJ** 1998 Oct 3;317(7163):949. Comment on: BMJ 1994 May 7;308(6938):1182–3.
Informed consent. Policy has loopholes [letter; comment] Winter AJ, et al. **BMJ** 1998 Oct 3;317(7163):949. Comment on: BMJ 1998 Mar 28;316(7136):949–51.
The basis of informed consent for BMT patients. Jacoby LH, et al. **Bone Marrow Transplant** 1999 Apr;23(7):711–7
Bone marrow donation without consent? [letter] Reid MM. **Br J Haematol** 1998 Nov;103(2):582–3
Consenting and consulting for cosmetic surgery. Ward CM. **Br J Plast Surg** 1998 Oct;51(7):547–50
Informed consent in patients with acute abdominal pain [letter; comment] Daniels IR, et al. **Br J Surg** 1999 Mar; 86(3):426. Comment on: Br J Surg 1998 Sep;85(9):1278–80.
Informed consent in patients with acute abdominal pain [letter; comment] Richardson NG, et al. **Br J Surg** 1999 Mar;86(3):426. Comment on: Br J Surg 1998 Sep;85(9):1278–80.
Moral agency and the family: the case of living related organ transplantation. Crouch RA, et al. **Camb Q Healthc Ethics** 1999 Summer;8(3):275–87
Informed consent in the genetic age. Goldworth A. **Camb Q Healthc Ethics** 1999 Summer;8(3):393–400
Voices from the silent world of doctor and patient. Starr J, et al. **Camb Q Healthc Ethics** 1999 Spring;8(2):129–38
Documenting informed consent for antipsychotic medication [editorial; comment] Holzapfel S. **Can Fam Physician** 1999 Jun;45:1403–4, 1415–6. Comment on: Can Fam Physician 1999 Jun;45 :1502–8. **(Eng, Fre)**
Technique is not enough [letter] Joynes A. **Can Fam Physician** 1999 Sep;45:2038
Informed consent for antipsychotic medication [see comments] Schachter D, et al. **Can Fam Physician** 1999 Jun;45:1502–8. Comment in: Can Fam Physician 1999 Jun;45 :1403–4, 1415–6.
Ethical ramifications of alternative means of recruiting research participants from cancer registries. Sugarman J, et al. **Cancer** 1999 Aug 15;86(4):647–51
Opportunities for promoting palliative medicine in cancer research. Sachs GA. **Cancer Invest** 1998;16(7):503–8
Promoting informed decision making: hormone replacement therapy. Bastian L, et al. **Cancer Treat Res** 1998;97:129–47 (98 ref.)
Clinical risk management: principles of consent and patient information. McIlwain JC. **Clin Otolaryngol** 1999 Aug; 24(4):255–61
Determinants of familial consent to organ donation in the hospital setting. McNamara P, et al. **Clin Transpl** 1997; :219–29
Informed consent in a different key: physicians' practice profiles and the patient's right to know [editorial; comment] Kluge EH. **CMAJ** 1999 May 4;160(9):1321–2. Comment on: CMAJ 1999 May 4;160(9):1323–4.
New ethical obligations accompany new HIV drugs, conference told. Silversides A. **CMAJ** 1999 Jul 27; 161(2):187
Does the CMA's privacy code go too far? Or far enough? [letter] Wiebe E. **CMAJ** 1999 Mar 23;160(6):781–2; discussion 782–4
Signed consent for publication [letter; comment] Wong HC. **CMAJ** 1999 Feb 9;160(3):315. Comment on: CMAJ 1998 Sep 8;159(5):503–4.
Improving informed consent in clinical trials: a duty to experiment. Lavori PW, et al. **Control Clin Trials** 1999 Apr; 20(2):187–93
Zelen randomization: attitudes of parents participating in a neonatal clinical trial. Snowdon C, et al. **Control Clin Trials** 1999 Apr;20(2):149–71
Bridging the knowledge gap and communicating uncertainties for informed consent in cervical cytology screening: we need unbiased information and a culture change. Anderson CM, et al. **Cytopathology** 1999 Aug; 10(4):221–8 (28 ref.)

Patients' assessment and recall of surgical information after laparoscopic cholecystectomy. Kriwanek S, et al. **Dig Surg** 1998;15(6):669–73

Communicating their individual results to participants in an environmental exposure study: insights from clinical ethics. Deck W, et al. **Environ Res** 1999 Feb;80(2 Pt 2):S223–S229

Informed consent to anaesthesia [editorial] Barneschi MG, et al. **Eur J Anaesthesiol** 1998 Sep;15(5):517–9

Informed consent and patient participation in the medical encounter: a list of questions for an informed choice about the type of anaesthesia. Paci E, et al. **Eur J Anaesthesiol** 1999 Mar;16(3):160–5

The general psychiatrist's evaluation of competency. Miller MC. **Harv Rev Psychiatry** 1999 Sep–Oct;7(3):172–6 (18 ref.)

Research in developing countries: taking "benefit" seriously. Glantz LH, et al. **Hastings Cent Rep** 1998 Nov–Dec; 28(6):38–42 (18 ref.)

Why study informed consent? [letter] Slovenko R. **Hastings Cent Rep** 1999 Jul–Aug;29(4):4

Empirical research on informed consent. An annotated bibliography. Sugarman J, et al. **Hastings Cent Rep** 1999 Jan–Feb;29(1):S1–42

Making responsible decisions. An interpretive ethic for genetic decisionmaking. White MT. **Hastings Cent Rep** 1999 Jan–Feb;29(1):14–21 (7 ref.)

Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART). Quantification of risks as part of informed consent. Kemmann E. **Hum Reprod** 1998 Jul; 13(7):1777 (3 ref.)

Occupational exposure and voluntary human immunodeficiency virus testing: a survey of Maryland hospitals. Solomon L, et al. **Infect Control Hosp Epidemiol** 1999 Jun;20(6):430–2

ACOG committee opinion. Sterilization of women, including those with mental disabilities. Number 216, April 1999 (replaces number 63, September 1988, and number 73, September 1989). Committee on Ethics. The American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jun;65(3):317–20 (3 ref.)

Method for assessment of competency to consent in the mentally ill. Rationale, development, and comparison with the medically ill. Kitamura F, et al. **Int J Law Psychiatry** 1998 Summer;21(3):223–44

Information in the ICU: are we being honest with our patients? The results of a European questionnaire [see comments] Vincent JL. **Intensive Care Med** 1998 Dec; 24(12):1251–6 Comment in: Intensive Care Med 1998 Dec;24(12):1257–8.

The issue of informed consent in medical law. Doran K. **Ir Med J** 1998 Dec;91(6):214

The capacity of minors to consent to medical treatment: Section 23 of the Non-Fatal Offences Against the Person Act 1997 [editorial] Doran K. **Ir Med J** 1997 Nov;90(7):254

The issue of consent in medical law: exceptions to the informed consent rule. Doran K. **Ir Med J** 1999 Jan–Feb; 92(1):245

Lethal autonomy: the malfunction of the informed consent mechanism within the context of prenatal diagnosis of genetic variants. Dunne C, et al. **Issues Law Med** 1998 Fall; 14(2):165–202

Report of John G. Gianopoulos. Gianopoulos JG. **Issues Law Med** 1999 Spring;14(4):425–32

Parental autonomy and consent to treatment. Taylor B. **J Adv Nurs** 1999 Mar;29(3):570–6 (33 ref.)

Application of a bogus testing procedure to determine college students' utilization of genetic screening for alcoholism. Thombs DL, et al. **J Am Coll Health** 1998 Nov; 47(3):103–12

Informing patients about treatment alternatives. Christensen GJ. **J Am Dent Assoc** 1999 May;130(5):730–2

Informed consent for research on human subjects with dementia. AGS Ethics Committee. American Geriatrics Society. **J Am Geriatr Soc** 1998 Oct;46(10):1308–10

In re: Fellows LK, competency and consent in dementia [letter; comment] MacLean DS. **J Am Geriatr Soc** 1999 Mar;47(3):377–8. Comment on: J Am Geriatr Soc 1998 Jul;46(7):922–6.

Phakic intraocular lenses and patient consent [editorial] Rosen ES. **J Cataract Refract Surg** 1999 Feb;25(2):153–5 (10 ref.)

Ethical concerns [letter] Seiler T. **J Cataract Refract Surg** 1999 Feb;25(2):156

Assessing competency without judging merit. May T. **J Clin Ethics** 1998 Fall;9(3):247–57 (23 ref.)

Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. Chlebowski RT, et al. **J Clin Oncol** 1999 Jan;17(1):130–42

Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. Daugherty CK. **J Clin Oncol** 1999 May;17(5):1601–17

Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? [see comments] O'Dell KJ, et al. **J Fam Pract** 1999 Sep; 48(9):682–8. Comment in: J Fam Pract 1999 Sep;48(9):679–81.

Assessment of patient capacity to consent to treatment. Etchells E, et al. **J Gen Intern Med** 1999 Jan;14(1):27–34

Informed consent and the redefining of conception: a decision ill-conceived? Spinnato JA. **J Matern Fetal Med** 1998 Nov–Dec;7(6):264–8

Family consent, communication, and advance directives for cancer disclosure: a Japanese case and discussion. Akabayashi A, et al. **J Med Ethics** 1999 Aug;25(4):296–301

Can the written information to research subjects be improved?--an empirical study [see comments] Bjørn E, et al. **J Med Ethics** 1999 Jun;25(3):263–7. Comment in: J Med Ethics 1999 Jun;25(3):219–20.

Tell me what's wrong with me: a discourse analysis approach to the concept of patient autonomy. Nessa J, et al. **J Med Ethics** 1998 Dec;24(6):394–400

Protective truthfulness: the Chinese way of safeguarding patients in informed treatment decisions. Pang MC. **J Med Ethics** 1999 Jun;25(3):247–53

Commentary: what we have here, is a failure to communicate [see comments] Brody H. **J Med Philos** 1999 Feb; 24(1):28–33. Comment in: J Med Philos 1999 Feb;24(1):18–27.

Informed consent to septoplasty: an anecdote from the field. Erde EL. **J Med Philos** 1999 Feb;24(1):11–7

A commentary on 'Informed consent to septoplasty: an anecdote from the field' [comment] Erde EL. **J Med Philos** 1999 Feb;24(1):18–27. Comment on: J Med Philos 1999 Feb;24(1):28–33. Comment on: J Med Philos 1999 Feb;24(1):34–42.

Genotyping in clinical trials: towards a principle of informed request. Sass HM. **J Med Philos** 1998 Jun;23(3):288–96

Enhancing clinician provision of informed consent and counseling: some pedagogical strategies [see comments] Wear S. **J Med Philos** 1999 Feb;24(1):34–42. Comment in: J Med Philos 1999 Feb;24(1):18–27.

Abandoning informed consent: an idea whose time has not yet come. White BC, et al. **J Med Philos** 1998 Aug; 23(5):477–99

Organ donation: the family's right to make an informed choice. Beaulieu D. **J Neurosci Nurs** 1999 Feb;31(1):37–42 (25 ref.)

I think they're doing research on my patients, but I can't get anyone to listen. Jackson BS, et al. **J Nurs Adm** 1998 Oct;28(10):9–12

A reasonable approach to patient consent for publication [letter] Leonard MS. **J Oral Maxillofac Surg** 1998 Nov; 56(11):1364

Should nurses practice therapeutic touch? Should nursing schools teach therapeutic touch? [letter; comment] Snyder M. **J Prof Nurs** 1999 May–Jun;15(3):201. Comment on: J Prof Nurs 1998 Jul–Aug;14(4):254–7.

Psychological distress among cancer patients and informed consent. Montgomery C, et al. **J Psychosom Res** 1999 Mar; 46(3):241–5

Consent obtained by the junior house officer--is it informed? Huntley JS, et al. **J R Soc Med** 1998 Oct;91(10):528–30

Listening to children: have we gone too far (or not far enough)? Lansdown R. **J R Soc Med** 1998 Sep;91(9):457–61

Issues of consent in colonoscopy: if a patient says 'stop' should we continue? [see comments] Ward B, et al. **J R Soc Med** 1999 Mar;92(3):132–3. Comment in: J R Soc Med 1999 Jun;92(6):326.

Non-communication between ophthalmologists and optometrists. Whittaker KW, et al. **J R Soc Med** 1999 May; 92(5):247–8

Informed consent in school health research: why, how, and making it easy. Ross JG, et al. **J Sch Health** 1999 May; 69(5):171–6 (14 ref.)

When is informed consent "informed"? [editorial] Kavic MS. **J Soc Laparoendosc Surg** 1997 Oct–Dec;1(4):313–4

Unlicensed vaccines and bioweapon defense in World War II [letter] Furmanski M. **JAMA** 1999 Sep 1;282(9):822

Updating protections for human subjects involved in research. Project on Informed Consent, Human Research Ethics Group [see comments] Moreno J, et al. **JAMA** 1998 Dec 9;280(22):1951–8. Comment in: JAMA 1999 May 12;281(18):1697–8.

Probing informed consent in schizophrenia research [news] Stephenson J. **JAMA** 1999 Jun 23–30;281(24):2273–4

FDA weighs communicating drug-related risk to patients [news] Stephenson J. **JAMA** 1999 Aug 11;282(6):515

The perils of paediatric research [editorial] [see comments] **Lancet** 1999 Feb 27;353(9154):685. Comment in: Lancet 1999 May 1;353(9163):1530–1.

Informed consent: what did the doctor say? [letter] Alfonsi P. **Lancet** 1999 Aug 7;354(9177):518

Informed consent: what did the doctor say? [letter; comment] Gattellari M, et al. **Lancet** 1999 May 15;353(9165):1713. Comment on: Lancet 1999 Feb 20;353(9153):645.

Hidden data and abuse in research come to light in the USA [news] Greenberg DS. **Lancet** 1997 Oct 11;350(9084):1083

Informed consent: what did the doctor say? [letter; comment] Heneghan C. **Lancet** 1999 May 15;353(9165):1713. Comment on: Lancet 1999 Feb 20;353(9153):645.

Antenatal screening for Down's syndrome [letter; comment] [see comments] Madhok R. **Lancet** 1998 Oct 3; 352(9134):1145. Comment on: Lancet 1998 Aug 1;352(9125):337–8. Comment on: Lancet 1998 Aug 1;352(9125):343–6. Comment in: Lancet 1998 Nov 14;352(9140):1631–2.

Consent, information, and neonatal research [letter; comment] Tarnow-Mordi W. **Lancet** 1999 May 1; 353(9163):1530–1. Comment on: Lancet 1999 Feb 27;353(9154):685.

Antenatal screening for Down's syndrome [letter; comment] [see comments] Venn-Treloar JM. **Lancet** 1998 Oct 3; 352(9134):1145. Comment on: Lancet 1998 Aug 1;352(9125):337–8. Comment in: Lancet 1998 Nov 14;352(9140):1631–2. Comment in: Lancet 1998 Dec 5;352(9143):1862.

Informed consent in clinical training--patient experiences and motives for participating. Lynøe N, et al. **Med Educ** 1998 Sep;32(5):465–71

Supporting the bereaved relative: reflections on the actor's experience. Sutton RB. **Med Educ** 1998 Nov;32(6):622–9

Surgery and the randomised controlled trial: past, present and future [letter; comment] Hugh TB. **Med J Aust** 1999 Mar 1;170(5):237–8. Comment on: Med J Aust 1998 Oct 5;169(7):348–9. Comment on: Med J Aust 1998 Oct 5;169(7):380–3.

Decision making in CPR [letter; comment] Nocera T. **Med J Aust** 1999 Jan 4;170(1):45–6. Comment on: Med J Aust 1998 Aug 3;169(3):128–31.

Posthumous conception and the need for consent [letter; comment] Parker MH. **Med J Aust** 1999 May 3; 170(9):452–3. Comment on: Med J Aust 1999 Jan 18;170(2):53–4.

Posthumous conception and the need for consent [editorial] [see comments] Schiff AR. **Med J Aust** 1999 Jan 18; 170(2):53–4. Comment in: Med J Aust 1999 May 3;170(9):452–3.

Informed consent for a clinical trial in Thailand [letter; comment] Achrekar A, et al. **N Engl J Med** 1998 Oct 29; 339(18):1331–2. Comment on: N Engl J Med 1997 Sep 18;337(12):853–6. Comment on: N Engl J Med 1997 Oct 2;337(14):1003–5.

Ethical and human-rights issues in research on mental disorders that may affect decision-making capacity. Capron AM. **N Engl J Med** 1999 May 6;340(18):1430–4

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Carome MA. **N Engl J Med** 1999 Aug 5;341(6):448–9; discussion 450. Comment on: N Engl J Med 1999 Mar 11;340(10):804–7.

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Dresser R. **N Engl J Med** 1999 Aug 5;341(6):449; discussion 450. Comment on: N Engl J Med 1999 Mar 11;340(10):804–7.

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Grodin MA. **N Engl J Med** 1999 Aug 5;341(6):449; discussion 450. Comment on: N Engl J Med 1999 Mar 11;340(10):804–7.

Is informed consent always necessary for randomized, controlled trials? [letter] [see comments] Johnson JR. **N Engl J Med** 1999 Aug 5;341(6):449; discussion 450. Comment in: N Engl J Med 1999 Mar 11;340(10):804–7.

Is informed consent always necessary for randomized, controlled trials? [letter; comment] King NM, et al. **N Engl J Med** 1999 Aug 5;341(6):449–50; discussion 450 . Comment on: N Engl J Med 1999 Mar 11;340(10):804–7.

How to resolve an ethical dilemma concerning randomized clinical trials. Marquis D. **N Engl J Med** 1999 Aug 26; 341(9):691–3

Is informed consent always necessary for randomized, controlled trials? [letter] [see comments] Silverman H. **N Engl J Med** 1999 Aug 5;341(6):449; discussion 450. Comment in: N Engl J Med 1999 Mar 11;340(10):804–7.

Lorazepam for the prevention of recurrent seizures related to alcohol [letter] Sosis MB. **N Engl J Med** 1999 Aug 19; 341(8):609; discussion 610

Is informed consent always necessary for randomized, controlled trials? [letter; comment] Tenery RM Jr. **N Engl J Med** 1999 Aug 5;341(6):450. Comment on: N Engl J Med 1999 Mar 11;340(10):804–7.

Is informed consent always necessary for randomized, controlled trials? [see comments] Truog RD, et al. **N Engl J Med** 1999 Mar 11;340(10):804–7. Comment in: N Engl J Med 1999 Aug 5;341(6):448–9; discussion 450. Comment in: N Engl J Med 1999 Aug 5;341(6):449; discussion 450. Comment in: N Engl J Med 1999 Aug 5;341(6):449–50; discussion 450.

Booklet on abortion [letter] MacLean N. **N Z Med J** 1999 Feb 26;112(1082):60

Informed consent: what do patients want to know? Newton-Howes PA, et al. **N Z Med J** 1998 Sep 11; 111(1073):340–2

British MRC reprimanded over clinical test record [news] Dickson D. **Nat Med** 1998 Jul;4(7):752

No-consent trials raise concern [news] Dove A. **Nat Med** 1999 Mar;5(3):250–1

Consent issues in the management of cerebrovascular diseases: a position paper of the American Academy of Neurology Ethics and Humanities Subcommittee. **Neurology** 1999 Jul 13;53(1):9–11

Managing the informed consent process in large multicenter projects. Mark BA, et al. **Nurs Res** 1999 Mar–Apr; 48(2):114–7 (10 ref.)

Informed consent for obesity surgery. Mason EE, et al. **Obes Surg** 1998 Aug;8(4):419–28

Informed consent, patient choice, and physician responsibility [editorial] Cruikshank DP. **Obstet Gynecol** 1999 Jul; 94(1):142–3

Contesting consent: the challenge to compulsory neonatal screening for PKU. Paul D. **Perspect Biol Med** 1999 Winter;42(2):207–19

Holy Grail, sliding scale, and refusal as symptom: competency determinations for medical and psychiatric patients. Farr M. **Pharos** 1999 Spring;62(2):2–9 (15 ref.)

Prerandomization of clinical trials: a more ethical way for performing cleft palate research [editorial] Berkowitz S. **Plast Reconstr Surg** 1998 Oct;102(5):1724–8

Informed consent to serum screening for Down syndrome:

are women given adequate information? Gekas J, et al. **Prenat Diagn** 1999 Jan;19(1):1–7

Competence to consent to voluntary psychiatric hospitalization: a test of a standard proposed by APA. American Psychiatric Association. Appelbaum BC, et al. **Psychiatr Serv** 1998 Sep;49(9):1193–6

The views and outcomes of consenting and non-consenting patients receiving ECT. Wheeldon TJ, et al. **Psychol Med** 1999 Jan;29(1):221–3

AIDS and informed consent [letter; comment] Edge B. **S Afr Med J** 1999 Mar;89(3):218, 220. Comment on: S Afr Med J 1998 Dec;88(12):1535–6.

AIDS and informed consent [letter] [see comments] van Niekerk JJ. **S Afr Med J** 1998 Dec;88(12):1535–6. Comment in: S Afr Med J 1999 Mar;89(3):218, 220.

Panel tightens rules on mental disorders [news] Marshall E. **Science** 1998 Nov 27;282(5394):1617

Panel proposes tighter rules for tissue studies [news] Marshall E. **Science** 1998 Dec 18;282(5397):2165–6

Panel pulls back report after NIH critique [news] Marshall E. **Science** 1998 Oct 30;282(5390):857,859

IRB review and consent in human tissue research. Merz JF, et al. **Science** 1999 Mar 12;283(5408):1647–8

Executive dysfunction and loss of capacity to consent to medical treatment in patients with Alzheimer's disease. Marson D, et al. **Semin Clin Neuropsychiatry** 1999 Jan; 4(1):41–9

Consent (assent) for research with pediatric patients. Broome ME. **Semin Oncol Nurs** 1999 May;15(2):96–103 (23 ref.)

The ethical foundation of informed consent in clinical research. McCabe MS. **Semin Oncol Nurs** 1999 May; 15(2):76–80 (18 ref.)

Improving understanding of the informed consent process and document. Meade CD. **Semin Oncol Nurs** 1999 May; 15(2):124–37 (135 ref.)

National efforts to improve the informed consent process. Padberg RM, et al. **Semin Oncol Nurs** 1999 May; 15(2):138–44 (16 ref.)

Genetic testing and informed consent. Rieger PT, et al. **Semin Oncol Nurs** 1999 May;15(2):104–15 (48 ref.)

The nurse's role in the informed consent process. Rosse PA, et al. **Semin Oncol Nurs** 1999 May;15(2):116–23 (28 ref.)

Barriers to informed consent. Taylor HA. **Semin Oncol Nurs** 1999 May;15(2):89–95 (35 ref.)

Sexually transmitted diseases and communications with general practitioners [letter; comment] Hiscock E. **Sex Transm Infect** 1999 Jun;75(3):204. Comment on: Sex Transm Infect 1999 Feb;75(1):45–8.

Informed consent for clinical trials: in search of the "best" method. Edwards SJ, et al. **Soc Sci Med** 1998 Dec; 47(11):1825–40 (42 ref.)

Attitudes towards informed consent, confidentiality, and substitute treatment decisions in southern African medical students: a case study from Zimbabwe. Hipshman L. **Soc Sci Med** 1999 Aug;49(3):313–28

An evaluation of the informed consent procedure used during a trial of a Haemophilus influenzae type B conjugate vaccine undertaken in The Gambia, West Africa. Leach A, et al. **Soc Sci Med** 1999 Jan;48(2):139–48

Loss prevention case of the month. Learn from and respond to the record. Avery JK. **Tenn Med** 1999 Sep;92(9):336–7

Legal issues associated with sexual activity between adults and minors in Texas: a review. Smith PB, et al. **Tex Med** 1999 Jul;95(7):65–9

Making decisions about life-sustaining medical treatment in patients with dementia. The problem of patient decision-making capacity. Derse AR. **Theor Med Bioeth** 1999 Jan;20(1):55–67 (42 ref.)

Whose consent is it anyway? A poststructuralist framing of the person in medical decision-making. Marta J. **Theor Med Bioeth** 1998 Aug;19(4):353–70 (33 ref.)

Informed consent from recipients of marginal donor organs. Sells RA. **Transplant Proc** 1999 Feb–Mar;31(1–2):1324–5

Nonbeneficial or futile medical treatment: conflict resolution guidelines for the San Francisco Bay area. Bay Area Network of Ethics Committees (BANEC) Nonbeneficial Treatment Working Group [see comments] **West J Med** 1999 May;170(5):287–90. Comment in: West J Med 1999 May;170(5):291. Comment in: West J Med 1999 May;170(5):291–2.

[Patient information concerning trials (editorial)] Andersen D. **Ugeskr Laeger** 1999 May 3;161(18):2650 **(Dan)**

[How detailed information and how long consideration time do the potential trial subjects want?] Madsen SM, et al. **Ugeskr Laeger** 1999 May 3;161(18):2661–6 (Eng. Abstr.) **(Dan)**

[On the treatment of chronically incapacitated (letter)] Vognsen HJ. **Ugeskr Laeger** 1999 Jun 7;161(23):3479 **(Dan)**

[Emphasizing of ethical criteria for medical scientific reporting and the Declaration of Helsinki (editorial; comment)] **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):33–6 (Eng. Abstr.). Comment on: Ned Tijdschr Geneeskd 1999 Feb 27;143(9):494–5. **(Dut)**

[Emphasizing of ethical criteria for medical scientific reporting and the Declaration of Helsinki (letter; comment)] Gebhardt DO. **Ned Tijdschr Geneeskd** 1999 Feb 27;143(9):494–5. Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):33–6. **(Dut)**

[Informed consent: myth or reality?] Werquin JP. **Acta Stomatol Belg** 1997 Mar;94(1):33–7 (Eng. Abstr.) **(Fre)**

[Informed consent for implantation of automatic defibrillator] **Arch Mal Coeur Vaiss** 1999 Jun;92(6):767–8 **(Fre)**

[Synthesis and conclusions. Factual therapeutics, good practices and decision personalized to the patient] Queneau P. **Bull Acad Natl Med** 1998;182(7):1449–54 **(Fre)**

[Informing the patient. A threat for the surgeon or bouncing opportunity? (editorial)] Cardin JJ. **J Chir (Paris)** 1998 Oct; 135(4):146–7 **(Fre)**

[Surgical follow-up and importance of information and consent on behalf of patients undergoing esthetic blepharoplasty] Berros P, et al. **J Fr Ophtalmol** 1999 Jun–Jul;22(6):656–8 (Eng. Abstr.) **(Fre)**

[Reflections on patient information (editorial)] Lebuisson DA. **J Fr Ophtalmol** 1999 Jun–Jul;22(6):623–5 **(Fre)**

[Professional responsibility in refractive surgery] Saragoussi JJ. **J Fr Ophtalmol** 1999 Jun–Jul;22(6):676–8 **(Fre)**

[Patient information and informed consent (editorial; comment)] Hazebroucq V. **J Radiol** 1999 May;80(5):411–2 . Comment on: J Radiol 1999 May;80(5):437–40. **(Fre)**

[What should we truthfully tell the cancer patient?] Hoerni B. **Rev Prat** 1999 Jan 1;49(1):5–6 **(Fre)**

[Informed consent forms as proof (see comments)] Schlund GH. **Anaesthesist** 1998 Dec;47(12):1007–10. Comment in: Anaesthesist 1999 Apr;48(4):284–7. **(Ger)**

[Physician liability and patient information related to blood and plasma product safety] Bock RW. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Aug; 34(8):501–3 (0 ref.) **(Ger)**

[Obligation for an explanation about reactions after a preventive vaccination] Schäfer AT. **Dtsch Med Wochenschr** 1998 Oct 23;123(43):1294 **(Ger)**

[Suicide of psychiatric inpatients assisted by euthanasia advocacy groups. Cases of assisted suicide?] Strnad J, et al. **Nervenarzt** 1999 Jul;70(7):645–9 (Eng. Abstr.) **(Ger)**

[The problem of consent in anesthesia and intensive care. The proposal of SIAARTI (editorial)] Martinelli G. **Minerva Anestesiol** 1999 May;65(5):191–2 **(Ita)**

[Is the informed consent always required?] Tobias JS. **Recenti Prog Med** 1998 Nov;89(11):549–51 **(Ita)**

[The evaluation of the pre-operative interviews using information sheets] Yoneyama E, et al. **Masui** 1998 Aug; 47(8):1002–6 (Eng. Abstr.) **(Jpn)**

[Evaluation of general medical awareness and extent of preoperative explanation of surgical patients] Gabriel M, et al. **Przegl Lek** 1999;56(2):121–5 (Eng. Abstr.) **(Pol)**

[Do we need written consent for transfusion therapy? (letter)] Vuk T, et al. **Lijec Vjesn** 1998 Sep;120(9):297–8 **(Scr)**

[Evaluation of informed consent in ear, nose, and throat practice] Calvo Boizas E, et al. **Acta Otorrinolaringol Esp** 1999 Apr;50(3):215–7 (Eng. Abstr.) **(Spa)**

[Informed consent in complementary explorations and invasive procedures] Pascual Torres D. **Gastroenterol Hepatol** 1998 Nov;21(9):464–8 (29 ref.) **(Spa)**

[Informed or uninformed consent? The danger of defensive medicine (editorial; comment)] Broggi Trias MA. **Med Clin (Barc)** 1999 Jan 30;112(3):95–6. Comment on: Med Clin (Barc) 1999 Jan 30;112(3):90–4. **(Spa)**

[The information to be given by a resident physician for a correct consent (letter)] de Nadal J, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):158; discussion 158–9 **(Spa)**

[Training in communication and informed consent in our residency system: what information can and should the resident give? (see comments)] Garrido Sanjuán JA. **Med Clin (Barc)** 1998 Dec 5;111(19):739–41. Comment in: Med Clin (Barc) 1999 Jul 3;113(4):157–8; discussion 158–9. **(Spa)**

[The information to be given by a resident physician for correct consent (letter; comment)] Martín Escudero JC, et al. **Med Clin (Barc)** 1999 Jul 3;113(4):157–8; discussion 158–9. Comment on: Med Clin (Barc) 1998 Dec 5;111(19):739–41. **(Spa)**

[An analysis of patient information sheets for obtaining informed consent in clinical trials (see comments)] Ordovás Baines JP, et al. **Med Clin (Barc)** 1999 Jan 30;112(3):90–4 (Eng. Abstr.). Comment in: Med Clin (Barc) 1999 Jan 30;112(3):95–6. **(Spa)**

[Preoperative information and informed consent from surgical patients (letter; comment)] Gómez Arnau JI. **Rev Esp Anestesiol Reanim** 1998 Nov;45(9):401. Comment on: Rev Esp Anestesiol Reanim 1998 Apr;45(4):130–5. **(Spa)**

[Informed consent in cardiac rehabilitation (letter)] de Pablo Zarzosa C, et al. **Rev Esp Cardiol** 1999 May;52(5):362–3 **(Spa)**

[Informed consent in nuclear medicine [editorial]] La Banda JP, et al. **Rev Esp Med Nucl** 1999 Jun;18(3):159–67 **(Spa)**

[Review of informed consent for transfusion (letter)] Durán JM, et al. **Sangre (Barc)** 1999 Jun;44(3):238 **(Spa)**

[Confusing verdict after well-founded consent] Löwdahl KK. **Lakartidningen** 1999 Jul 14;96(28–29):3235–6 **(Swe)**

[Time to change the basis for forming of judgements by the research ethics committees? The treatment of persons involved in trials should be scrutinized for scientific quality] Lynöe N, et al. **Lakartidningen** 1999 Feb 3;96(5):490–2 **(Swe)**

[The concept of compulsion in psychiatry: going back to the terminology of LSPV would make the meaning clearer] Nilstun T, et al. **Lakartidningen** 1999 May 19; 96(20):2447–50 **(Swe)**

HISTORY

Henry Knowles Beecher and the development of informed consent in anesthesia research [see comments] Kopp VJ. **Anesthesiology** 1999 Jun;90(6):1756–65. Comment in: Anesthesiology 1999 Jun;90(6):1499–501.

A historical perspective of informed consent in clinical practice and research. Nelson-Marten P, et al. **Semin Oncol Nurs** 1999 May;15(2):81–8

LEGISLATION & JURISPRUDENCE

Consent documents, reproductive issues, and the inclusion of women in clinical trials. Nolan MT, et al. **Acad Med** 1999 Mar;74(3):275–81

The duty to disclose. Berlin L. **AJR Am J Roentgenol** 1998 Dec;171(6):1463–7

Informed consent when using medical devices for indications not approved by the Food and Drug Administration. Smith JJ, et al. **AJR Am J Roentgenol** 1999 Oct;173(4):879–82

Informed consent and general surgeons' attitudes toward the use of pain medication in the acute abdomen [see comments] Graber MA, et al. **Am J Emerg Med** 1999 Mar; 17(2):113–6. Comment in: Am J Emerg Med 1999 Mar;17(2):207.

Withholding pain medication in the ED because of legal fears--bad practice for a bad reason [editorial; comment] Kapp MB. **Am J Emerg Med** 1999 Mar;17(2):207. Comment on: Am J Emerg Med 1999 Mar;17(2):113–6.

Protecting soldiers from friendly fire: the consent requirement for using investigational drugs and vaccines in combat. Annas GJ. **Am J Law Med** 1998;24(2–3):245–60

Waived consent for emergency research. Fost N. **Am J Law Med** 1998;24(2–3):163–83 (144 ref.)

Research with children. Glantz LH. **Am J Law Med** 1998; 24(2–3):213–44 (332 ref.)

Do the dead have interests? Policy issues for research after life. Nelkin D, et al. **Am J Law Med** 1998;24(2–3):261–91 (288 ref.)

Informed consent in the electronic age. Rosoff AJ. **Am J Law Med** 1999;25(2–3):367–86

Litigation, legislation, and ethics. A matter of degrees. **Am J Orthod Dentofacial Orthop** 1998 Nov;114(5):606–8

Ethics case analysis: the extraction of the wrong tooth. Chiodo G, et al. **Am J Orthod Dentofacial Orthop** 1998 Dec;114(6):721–3

Admission of Alzheimer's disease patients to locked special care facilities against their will [letter; comment] Crumpacker DW, et al. **Am J Psychiatry** 1999 May; 156(5):805. Comment on: Am J Psychiatry 1997 Aug;154(8):1070–5.

Emergency informed consent [editorial; comment] [see comments] Pearson KS. **Anesthesiology** 1998 Nov; 89(5):1047–9. Comment on: Anesthesiology 1998 Nov;89(5):1052–9. Comment in: Anesthesiology 1999 Jul;91(1):323–4.

Legislative aspects of organ and tissue donation in Belgium. Roels B, et al. **Ann Transplant** 1996;1(4):39–43

Informed consent: how much information is enough? Stanley BM, et al. **Aust N Z J Surg** 1998 Nov;68(11):788–91

A child's right to circumcision. Freeman MD. **BJU Int** 1999 Jan;83 Suppl 1:74–8

Involuntary circumcision: the legal issues. Van Howe RS, et al. **BJU Int** 1999 Jan;83 Suppl 1:63–73 (148 ref.)

Relative's consent to treatment of patient is not needed [letter; comment] [see comments] Hooker J. **BMJ** 1998 Nov 14; 317(7169):1386. Comment on: BMJ 1998 May 23;316(7144):1608. Comment in: BMJ 1999 Mar 13;318(7185):736.

Law and ethics of gamete storage and informed consent as illustrated by the Diane Blood case, and an appraisal of international standards. Yap LB. **Br J Fam Plann** 1999 Jan; 24(4):164–7

When parental consent is not enough. Winkelaar PG. **Can Fam Physician** 1998 Oct;44:2091

Psychiatrists' documentation of informed consent. Schachter D, et al. **Can J Psychiatry** 1998 Dec;43(10):1012–7

Edgar Mannheimer lecture. Termination, consent and innovation: ethical and legal aspects of paediatric cardiology. Shinebourne EA. **Cardiol Young** 1998 Oct; 8(4):428–36

Testing for HIV infection and the law. Nyapadi TJ. **Cent Afr J Med** 1999 Feb;45(2):49–51

The medical record. Informing your patients before they consent. Gorney M, et al. **Clin Plast Surg** 1999 Jan; 26(1):57–68, vi–vii

Forced cesareans. Ikemoto LC. **Curr Opin Obstet Gynecol** 1998 Dec;10(6):465–8 (17 ref.)

Informed consent in the emergency department. Moskop JC. **Emerg Med Clin North Am** 1999 May;17(2):327–40, ix–x (19 ref.)

The law, adolescents, and the APOE epsilon 4 genotype: a view from Canada. Caulfield TA. **Genet Test** 1999; 3(1):107–13 (50 ref.)

Children's rights [letter] Dickenson DL. **Hastings Cent Rep** 1999 Jan–Feb;29(1):5

Frozen embryo disposition [letter; comment] Forster HP. **Hastings Cent Rep** 1999 Mar–Apr;29(2):4–5. Comment on: Hastings Cent Rep 1998 Jul–Aug;28(4):22–3.

Medicolegal issues in clinical practice. Arnott S. **Hosp Med** 1998 Feb;59(2):149–53

The ethics of informed consent among storyteller cultures. Casteel JK. **Int J Circumpolar Health** 1998;57 Suppl 1:41–2

ACOG committee opinion. Liability implications of recording procedures or treatments. Number 207, September 1998. Committee on Professional Liability. American College of Obstetricians and Gynecologists. **Int J Gynaecol Obstet** 1999 Jan;64(1):95

Image of psychiatric patients' competency to give informed consent to treatment in Japan. I. A factor analytic study. Kitamura T, et al. **Int J Law Psychiatry** 1999 Jan–Feb; 22(1):45–54

Image of psychiatric patients' competency to give informed consent to treatment in Japan. II. A case vignette study of competency judgements. Kitamura T, et al. **Int J Law Psychiatry** 1999 Mar–Apr;22(2):133–42

Clinical assessment of competency to consent to psychiatric hospitalization. Melamed Y, et al. **Int J Law Psychiatry** 1999 Jan–Feb;22(1):55–64

Karlin v. Foust United States District Court western District of Wisconsin June 19, 1997. Bostrom B. **Issues Law Med** 1999 Spring;14(4):377–88

Report of Basil Jackson, M.D., Ph.D., Th.D., J.D., D.Litt. Jackson B. **Issues Law Med** 1999 Spring;14(4):443–52

Report of Sandra Mahkorn, M.D., M.P.H., M.S. Mahkorn S. **Issues Law Med** 1999 Spring;14(4):433–41

Report of Anne C. Speckhard, Ph.D. Speckhard AC. **Issues Law Med** 1999 Spring;14(4):453–63

Report of Peter R. Uhlenberg, Ph D. Uhlenberg PR. **Issues Law Med** 1999 Spring;14(4):391–423

The doctrine of informed consent: a tale of two cultures and two legal traditions. Walter P. **Issues Law Med** 1999 Spring; 14(4):357–73 (53 ref.)

Informed consent and the law. Sfikas PM. **J Am Dent Assoc** 1998 Nov;129(11):1613–4

Informed consent and the law. Sfikas PM. **J Am Dent Assoc** 1998 Oct;129(10):1471–3

Cultural diversity and informed consent [see comments] Agard E, et al. **J Clin Ethics** 1998 Summer;9(2):173–6. Comment in: J Clin Ethics 1998 Summer;9(2):177–8. Comment in: J Clin Ethics 1998 Summer;9(2):191–3.

Respect for autonomy and a couple's decision [comment] d'Agostino M. **J Clin Ethics** 1998 Summer;9(2):177–8. Comment on: J Clin Ethics 1998 Summer;9(2):173–6.

Commentary: "missing" patients by seeing only their cultures [comment] Howe EG. **J Clin Ethics** 1998 Summer; 9(2):191–3. Comment on: J Clin Ethics 1998 Summer;9(2):173–6. Comment on: J Clin Ethics 1998 Summer;9(2):179–9.

Disclosure of operating practices by managed-care organizations to consumers of healthcare: obligations of informed consent. Khanna V, et al. **J Clin Ethics** 1998 Fall; 9(3):291–6 (27 ref.)

Lake v. Arnold: the disabled and the confused jurisprudence of 42 U.S.C. section 1985(3). Hans MC. **J Contemp Health Law Policy** 1999 Spring;15(2):673–710

Far beyond informed consent. US research institutions keep close watch on OPRR's suspensions [interview] Russell-Einhorn M, et al. **J Investig Med** 1999 Jul; 47(6):259–66

The emerging convergence of the doctrine of informed consent and judicial reinterpretation of the Employee Retirement Income Security Act. Blackmon W. **J Leg Med** 1998 Sep;19(3):377–95 (101 ref.)

Informed consent: an Australian case study [letter; comment] Theisler CW. **J Manipulative Physiol Ther** 1999 Feb; 22(2):119. Comment on: J Manipulative Physiol Ther 1998 Jun;21(5):348–55.

'Wrongful life' lawsuits for faulty genetic counselling: should the impaired newborn be entitled to sue? [see comments] Shapira A. **J Med Ethics** 1998 Dec;24(6):369–75 (4 ref.). Comment in: J Med Ethics 1998 Dec;24(6):363–4.

Informed consent issues in assisted reproduction. Reame N. **J Obstet Gynecol Neonatal Nurs** 1999 May–Jun;28(3):331–8 (31 ref.)

Research based on archived information and samples. Recommendations from the Royal College of Physicians Committee on Ethical Issues in Medicine. **J R Coll Physicians Lond** 1999 May–Jun;33(3):264–6 (15 ref.)

The Bournewood case [letter; comment] Shah A, et al. **J R Soc Med** 1998 Sep;91(9):507–8. Comment on: J R Soc Med 1998 Jul;91(7):349–51.

Working through the public disclosure process mandated by use of 21 CFR 50.24 (exception to informed consent): guidelines for success. Santora TA, et al. **J Trauma** 1998 Nov;45(5):907–13

Violations of informed consent during war. Schofer JM. **JAMA** 1999 May 5;281(17):1657

Lack of consent and misconduct [letter] Carr I. **Lancet** 1998 May 23;351(9115):1592

Informed consent for family planning for poor women in Chiapas, Mexico. Kirsch JD, et al. **Lancet** 1999 Jul 31; 354(9176):419–20

Internet survey research and consent [letter; comment] Karlinsky H. **MD Comput** 1998 Sep–Oct;15(5):285. Comment on: MD Comput 1998 Mar–Apr;15(2):116–20.

Informed consent for medical interventions under Turkish law. Ozsunay E, et al. **Med Law** 1998;17(3):429–35

Medical confidentiality and detainees. Schütte P. **Med Law** 1998;17(3):351–7

Informed consent to medical treatment--the Israeli experience. Weil Z. **Med Law** 1998;17(2):243–61

Medicolegal aspects of self-harm [letter; comment] Bouchier H. **N Z Med J** 1998 Sep 11;111(1073):349 discussion 350 . Comment on: N Z Med J 1998 Jul 10;111(1069):255–8.

Medicolegal aspects of self-harm [letter; comment] McCleave NR. **N Z Med J** 1998 Sep 11;111(1073):349–50 . Comment on: N Z Med J 1998 Jul 10;111(1069):255–8.

Documentation and informed consent. Weintraub MI. **Neurol Clin** 1999 May;17(2):371–81 (29 ref.)

It keeps happening! Avery JK. **Tenn Med** 1999 Feb;92(2):48–9

Developing regulations for research involving adults who lack decision-making capacity. Fleischman AR. **Trans Am Clin Climatol Assoc** 1999;110:131–43; discussion 143–5

The continued vitality of a patient's informed consent, or, when the patient says 'no'. Barratt K, et al. **WMJ** 1999 Mar–Apr;98(2):60–1

[Informed well-considered consent ('informed consent'): an end or a means? (letter)] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1999 May 22;143(21):1115–6 **(Dut)**

[Supervision of medical scientific research with mentally competent subjects is impossible without reviewing (comment) (see comments)] Roscam Abbing HD. **Ned Tijdschr Geneeskd** 1999 Jan 2;143(1):8–10 (Eng. Abstr.) . Comment on: Ned Tijdschr Geneeskd 1999 Jan 2;143(1):45–50. Comment in: Ned Tijdschr Geneeskd 1999 Mar 27;143(13):700–1. **(Dut)**

[Informed well-considered consent ('informed consent'): an end or a means?] Schellings R, et al. **Ned Tijdschr Geneeskd** 1999 May 15;143(20):1033–7 (35 ref.) (Eng. Abstr.) **(Dut)**

[The Organ Donation Law: changes in the procurement of organs and tissues for transplantation (see comments)] van der Vliet JA, et al. **Ned Tijdschr Geneeskd** 1998 Dec 26; 142(52):2830–2 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Dec 26;142(52):2838–43. Comment in: Ned Tijdschr Geneeskd 1998 Dec 26;142(52):2865–9. **(Dut)**

[Physicians' duty to inform in the jurisprudence of the Appeals Court] Sargos P. **Ann Chir Plast Esthet** 1998 Dec; 43(6):668–73 **(Fre)**

[Patient education by the surgeon. Judicial aspects, ethical aspects, deontologic aspects] Sargos P, et al. **Chirurgie** 1998 Feb;123(1):85–95; discussion 95–6 (Eng. Abstr.) **(Fre)**

[Consent: between legality and legitimacy or between "formal" and "informed" consent] Lachaux B, et al. **Encephale** 1998 Nov–Dec;24(6):503–16 (55 ref.) (Eng. Abstr.) **(Fre)**

[Patient information and obtaining informed consent in laparoscopic surgery] Rougé C, et al. **J Chir (Paris)** 1997 Dec;134(7–8):340–4 (Eng. Abstr.) **(Fre)**

[Consent and patient information] Rougé-Maillard C, et al. **Rev Stomatol Chir Maxillofac** 1999 May;100(2):88–94 **(Fre)**

[The evidence for successful patient explanation in the case of neglected documentation. The judgement of the Higher Regional Court of Oldenburg of 2 December 1997] Rieger HJ. **Dtsch Med Wochenschr** 1998 Nov 6;123(45):1362–3 **(Ger)**

[Therapy of children and adolescents. Competence for informed consent. Legal Case Series in General Practice, 4: Informed consent] Sautter R. **Fortschr Med** 1999 Feb 20;117(5):54 **(Ger)**

[When will the lean years end? Keratoplasty in Germany (news)] Mehrle G. **Klin Monatsbl Augenheilkd** 1998 Dec; 213(6):aA1 **(Ger)**

[Psychiatric evaluation in accordance with the transsexualism regulation. An experience-based plea for guidelines and against arbitrary bias] Langer D, et al. **Nervenarzt** 1997 Nov;68(11):862–9 (Eng. Abstr.) **(Ger)**

[Strategy for informed consent before a planned live kidney donation] Werner W, et al. **Urologe A** 1999 Jul;38(4):364–9 (Eng. Abstr.) **(Ger)**

[Human dignity ... is vulnerable! (editorial; comment)] Feuser G. **Wien Klin Wochenschr** 1997 Dec 12;109(23):907–9. Comment on: Wien Klin Wochenschr 1997 Dec 12;109(23):925–31. **(Ger)**

[Revision of the medical malpractice law? Need for action and reform from the viewpoint of the physician] Bushe KA. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):564–7 (Eng. Abstr.) **(Ger)**

[Revision of the medical malpractice law? Malpractice in an international comparison] Deutsch E. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):574–8 (Eng. Abstr.) **(Ger)**

[Withholding medical care as physical injury--refusal to treat from the viewpoint of the lawyer. Special aspects of therapy in children] Dierks C. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):560–2 (Eng. Abstr.) **(Ger)**

[Medical care as physical injury from the viewpoint of the law and jurisdiction] Gropp W. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):536–42 (34 ref.) (Eng. Abstr.) **(Ger)**

[Withholding medical care as a physical injury--refusal to treat from the viewpoint of the pediatrician. Special aspects of therapy in children] Helge H. **Z Arztl Fortbild Qualitatssich** 1998 Oct;92(8–9):559–60 **(Ger)**

[Revision of the medical malpractice law--legal aspects] Schreiber HL. **Z Arztl Fortbild Qualitatssich** 1998 Oct; 92(8–9):568–74 (Eng. Abstr.) **(Ger)**

[Position regarding revision of the medical malpractice law] von Bülow D. **Z Arztl Fortbild Qualitatssich** 1998 Oct; 92(8–9):578–80 (Eng. Abstr.) **(Ger)**

[Judges are only human as well ... (editorial)] Ratzel R. **Z Geburtshilfe Neonatol** 1998 Sep;202(5):181 **(Ger)**

[American and European legislation on bioethics evaluation of clinical experimentation] Scuderi G. **Ann Ist Super Sanita** 1998;34(2):179–85 (Eng. Abstr.) **(Ita)**

[Informed consent in cardiology. The Committee on Informed Consent of the Commission on Professional Matters of the Sociedad Española de Cardiología] de los Reyes López M, et al. **Rev Esp Cardiol** 1998 Oct; 51(10):782–96 (39 ref.) (Eng. Abstr.) **(Spa)**

[Informed consent in the treatment of differentiated neoplasms of the thyroids] La Banda JP, et al. **Rev Esp Med Nucl** 1999;18(2):122–6 **(Spa)**

STATISTICS & NUMERICAL DATA

Ethical issues in informed consent with substance abusers. McCrady BS, et al. **J Consult Clin Psychol** 1999 Apr; 67(2):186–93

The impact of requiring patient authorization for use of data in medical records research. Yawn BP, et al. **J Fam Pract** 1998 Nov;47(5):361–5

Are efforts at expanding the donor pool misdirected? Rayburn BK, et al. **J Heart Lung Transplant** 1998 Oct; 17(10):998–1003 (40 ref.)

Informed consent. Evaluation of the information provided to patients before anaesthesia and surgery. Osuna E, et al. **Med Law** 1998;17(4):511–8

Informed consent and approval by institutional review boards in published reports on clinical trials [letter] [published erratum appears in N Engl J Med 1999 Aug 5;341(6):460] Ruiz-Canela M, et al. **N Engl J Med** 1999 Apr 8; 340(14):1114–5

Infertility treatment and informed consent: current practices of reproductive endocrinologists. Houmard BS, et al. **Obstet Gynecol** 1999 Feb;93(2):252–7

INFRARED RAYS

Effects on human epidermis of chronic suberythemal exposure to pure infrared radiation [letter] Edwards C, et al. **Arch Dermatol** 1999 May;135(5):608–9

Radiation inducible DNA repair processes in eukaryotes. Eckardt-Schupp F, et al. **Biochimie** 1999 Jan–Feb; 81(1–2):161–71 (102 ref.)

Composite films of Prussian blue and N-substituted polypyrroles: covalent immobilization of enzymes and application to near infrared optical biosensing. Koncki R, et al. **Biosens Bioelectron** 1999 Jan 1;14(1):87–92

Photo-oxidative killing of human colonic cancer cells using indocyanine green and infrared light. Bäumler W, et al. **Br J Cancer** 1999 May;80(3–4):360–3

Afferent projections of infrared-sensitive sensilla in the beetle Melanophila acuminata (Coleoptera: Buprestidae). Gronenberg W, et al. **Cell Tissue Res** 1999 Aug; 297(2):311–8

Accuracy of an infrared tympanic thermometer. Amoateng-Adjepong Y, et al. **Chest** 1999 Apr; 115(4):1002–5

Neonatal infrared axillary thermometry. Seguin J, et al. **Clin Pediatr (Phila)** 1999 Jan;38(1):35–40

Non-coherent near infrared radiation protects normal human dermal fibroblasts from solar ultraviolet toxicity. Menezes S, et al. **J Invest Dermatol** 1998 Oct;111(4):629–33

Principles and performance of an electron spin echo spectrometer using far infrared lasers as excitation sources. Moll HP, et al. **J Magn Reson** 1999 Mar;137(1):46–58

Primary and secondary mechanisms of action of visible to near-IR radiation on cells. Karu T. **J Photochem Photobiol B** 1999 Mar;49(1):1–17 (151 ref.)

Effects of infrared radiation on intraosseous blood flow and oxygen tension in the rat tibia. Kobu Y. **Kobe J Med Sci** 1999 Feb;45(1):27–39

In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Weissleder R, et al. **Nat Biotechnol** 1999 Apr;17(4):375–8

Infrared-based neuronavigation and cortical motor stimulation in the management of central-region tumors. Wagner W, et al. **Stereotact Funct Neurosurg** 1997;68(1–4 Pt 1):112–6

[The effect of far infrared rays on the survival of randomized skin flap in the rat: an experimental study] Jiang P, et al. **Chung Kuo Hsiu Fu Chung Chien Wai Ko Tsa Chih** 1997 Mar;11(2):69–71 (Eng. Abstr.) **(Chi)**

[Effect of infrared rays on the eye in progressive myopia] Kuběna T, et al. **Cesk Slov Oftalmol** 1999 May;55(3):155–9 (Eng. Abstr.) **(Cze)**

[Hyperthermia-induced priming effect in neutrophil granulocytes] Löer D, et al. **Forsch Komplementarmed** 1999 Apr;6(2):86–8 (Eng. Abstr.) **(Ger)**

[Infrared thermographic imaging of normal vulva and uterine cervix: a preliminary report] Sikorski R, et al. **Ginekol Pol** 1998 Dec;69(12):1268–72 (Eng. Abstr.) **(Pol)**

[Two-step exposure of biological objects to infrared laser and microwave radiation] Kol'tsov IuV, et al. **Biofizika** 1999 Mar–Apr;44(2):378–81 (Eng. Abstr.) **(Rus)**

[Clinical efficiency of infrared impulse laser therapy in patients with rheumatoid arthritis] Ilich-Stoianovich O, et al. **Klin Med (Mosk)** 1999;77(6):20–3 **(Rus)**

[The effect of low-intensity physical therapeutic factors on the microsomal oxidative systems of the liver in an experiment] Zolotareva TA, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 May-Jun; (3):34-7 (Eng. Abstr.) **(Rus)**

[Infrared photocoagulation in the treatment of hemorrhoids] Charúa Guindic L, et al. **Rev Gastroenterol Mex** 1998 Jul-Sep;63(3):131-4 (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Optical radiation hazards of welding arcs. Tenkate TD. **Rev Environ Health** 1998 Jul-Sep;13(3):131-46 (99 ref.)

DIAGNOSTIC USE

Near infra-red interactance for nutritional assessment of dialysis patients. Kalantar-Zadeh K, et al. **Nephrol Dial Transplant** 1999 Jan;14(1):169-75

Functional imaging of the brain by infrared radiation (thermoencephaloscopy). Shevelev IA. **Prog Neurobiol** 1998 Oct;56(3):269-305 (198 ref.)

[Infrared and video oculography--alternatives to electrooculography?] Schmid-Priscoveanu A, et al. **HNO** 1999 May;47(5):472-8 (Eng. Abstr.) **(Ger)**

[Low-intensity infrared laser radiation in the diagnosis and combined treatment of acute nonspecific lymphadenitis of the face and neck in children] Oasevich IA, et al. **Stomatologiia (Mosk)** 1999;78(2):28-30 (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Evidence that irradiation of far-infrared rays inhibits mammary tumour growth in SHN mice. Nagasawa H, et al. **Anticancer Res** 1999 May-Jun;19(3A):1797-800

Rheumatoid arthritis-affected temporomandibular joint pain analgesia by linear polarized near infrared irradiation. Yokoyama K, et al. **Can J Anaesth** 1999 Jul;46(7):683-7

[Molecular mechanisms of lipid metabolism disruptions in the white rat brain during acute edema and normalizing effects of low-energy infrared laser radiation] Karagezian KG, et al. **Dokl Akad Nauk** 1998 Sep;362(2):266-8 **(Rus)**

[The effect of low-intensity laser radiation in the infrared and red ranges on arterial pressure regulation in patients with borderline hypertension] Shuvalova IN, et al. **Lik Sprava** 1998 Oct-Nov;(7):141-3 (Eng. Abstr.) **(Rus)**

[The prevention of inflammatory complications in mandibular fractures by using infrared laser and magnetic-laser radiation] Makarenkov VV, et al. **Stomatologiia (Mosk)** 1998;77(4):20-2 (Eng. Abstr.) **(Rus)**

[Low-intensity infrared laser radiation in the diagnosis and combined treatment of acute nonspecific lymphadenitis of the face and neck in children] Oasevich IA, et al. **Stomatologiia (Mosk)** 1999;78(2):28-30 (Eng. Abstr.) **(Rus)**

[Low-intensity infrared laser radiation in the treatment of bronchial asthma patients] Aleksandrova OIu, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Jul-Aug;(4):12-7 **(Rus)**

[A comparative analysis of the action of red and infrared laser radiation and ultrasound on the regeneration of locally irradiated skeletal muscle and on immune system function in the rat] Subkova SM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Nov-Dec; (6):11-6 (Eng. Abstr.) **(Rus)**

[The clinical efficacy of a one-time course of infrared laser irradiation in stenocardia patients based on 6-month follow-up data] Vasil'ev AP, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1999 Mar-Apr;(2):5-6 (Eng. Abstr.) **(Rus)**

[The combined action of infrared radiation and permanent and alternating magnetic fields in experimental atherosclerosis] Zubkova SM, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1998 Jul-Aug;(4):31-6 (Eng. Abstr.) **(Rus)**

INFRARED SPECTROPHOTOMETRY see **SPECTROPHOTOMETRY, INFRARED**

INFRATENTORIAL NEOPLASMS

PATHOLOGY

Clusters of histologic characteristics in children with infratentorial neuroglial tumors. The Childhood Brain Tumor Consortium. Gilles FH, et al. **J Neurooncol** 1998 Aug;39(1):51-63

SURGERY

Operative approach to mediosuperior cerebellar tumors: occipital interhemispheric transtentorial approach. Kurokawa Y, et al. **Surg Neurol** 1999 Apr;51(4):421-5

INFUNDIBULAR NUCLEUS see **ARCUATE NUCLEUS**

INFUNDIBULAR STENOSIS, PULMONARY see **PULMONARY SUBVALVULAR STENOSIS**

INFUSION PUMPS

Sudden death due to intravenous infusion of hair conditioner. Knight DM, et al. **Am J Forensic Med Pathol** 1998 Sep; 19(3):252-4

Multidisciplinary approach to improving pediatric home infusion. Johnson KA, et al. **Am J Health Syst Pharm** 1999 Mar 1;56(5):473-4

Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial [see comments] Guinn DA, et al. **Am J Obstet Gynecol** 1998 Oct; 179(4):874-8. Comment in: Am J Obstet Gynecol 1999 Jun;180(6 Pt 1):1593-4; discussion 1594-5.

Safety and efficacy of target controlled infusion (Diprifusor) vs manually controlled infusion of propofol for anaesthesia. Hunt-Smith J, et al. **Anaesth Intensive Care** 1999 Jun; 27(3):260-4

Infusion devices: most do not measure the volume infused [letter] Amoore J, et al. **Anaesthesia** 1998 Dec; 53(12):1231-2

Pressures in epidural filters and catheters [letter] Briggs ED, et al. **Anaesthesia** 1999 Feb;54(2):200-1

A dangerous fault with a PCA pump [letter] Christie L, et al. **Anaesthesia** 1998 Aug;53(8):827

An in vitro evaluation of flow from multihole epidural catheters during continuous infusion with four different infusion pumps. McAtamney D, et al. **Anaesthesia** 1999 Jul;54(7):664-9

Pumps for epidural catheters [letter] Wiltshire R, et al. **Anaesthesia** 1999 Jun;54(6):613

Unintentional recirculation with the Rapid Infusion System [letter] Lustik SJ, et al. **Anesth Analg** 1999 Oct;89(4):1069

Major ambulatory surgery with continuous regional anesthesia and a disposable infusion pump. Klein SM, et al. **Anesthesiology** 1999 Aug;91(2):563-5

A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Zahnd D, et al. **Ann Oncol** 1999 Jun;10(6):727-9

Continuous infusion of recombinant activated factor VII: stability in infusion pump systems. Bonde C, et al. **Blood Coagul Fibrinolysis** 1998 Mar;9 Suppl 1:S103-5

Manual pump failure [letter] Jolly DT. **Can J Anaesth** 1999 Feb;46(2):201-2

Infusion pump performance in an MR environment. Williams EJ, et al. **Eur J Anaesthesiol** 1999 Jul;16(7):468-72

Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a minipump infusion device. Hurst D, et al. **Haemophilia** 1998 Nov;4(6):785-9

Innovative ambulatory drug delivery system using an electrolytic hydrogel infusion pump. Kim HC, et al. **IEEE Trans Biomed Eng** 1999 Jun;46(6):663-9

A general solution for nonparametric control of a linear system using computer-controlled infusion pumps. Verotta D. **IEEE Trans Biomed Eng** 1999 Jan;46(1):44-50

The analgesic bag in cancer pain [letter] Mercadante S, et al. **J Pain Symptom Manage** 1998 Dec;16(6):352-4

The innovative use of a patient-controlled analgesia pump for the management of cardiac angina. Mulligan MA. **J Palliat Care** 1998 Winter;14(4):47-9

The effect of syringe size on the performance of an infusion pump. Kim DW, et al. **Paediatr Anaesth** 1999;9(4):335-7

Outcomes after single injection caudal epidural versus continuous infusion epidural via caudal approach for postoperative analgesia in infants and children undergoing patent ductus arteriosus ligation. Lin YC, et al. **Paediatr Anaesth** 1999;9(2):139-43

Intrathecal drug therapy. Nance P, et al. **Phys Med Rehabil Clin N Am** 1999 May;10(2):385-401, viii-ix (100 ref.)

Continuous sciatic nerve infusion: expanded case report describing a new approach. Sutherland ID. **Reg Anesth Pain Med** 1998 Sep-Oct;23(5):496-501

The use of the Haemonetic Rapid Infusion System (RIS) has dramatically reduced the duration and frequency of significant intraoperative hypotension and hypothermia that can occur in major cases [letter; comment] Minore WS. **Resuscitation** 1997 Nov;35(3):273-4. Comment on: Resuscitation 1996 Apr;31(2):127-33.

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12-5 (39 ref.)

Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Gilmer-Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):6-11

[Acute pain service. Organization and results] Bredahl C, et al. **Ugeskr Laeger** 1998 Oct 12;160(42):6070-4 (Eng. Abstr.) **(Dan)**

[Predictability and precision of "target-controlled infusion" (TCI) of propofol with the "Diprifusor TCI" system] Fechner J, et al. **Anaesthesist** 1998 Aug;47(8):663-8 (Eng. Abstr.) **(Ger)**

[Subcutaneous infusion anesthesia with prilocaine diluted with Ringer's lactate] Breuninger H, et al. **Hautarzt** 1998 Sep;49(9):709-13 (Eng. Abstr.) **(Ger)**

[Evaluation of estimated blood concentration of propofol on wake-up using "ConGrase", a software to control the syringe pump for propofol infusion] Nagata O, et al. **Masui** 1998 Oct;47(10):1246-52 (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Maintenance issues with Alaris (or IVAC) signature edition infusion pumps. **Health Devices** 1999 Mar;28(3):117, 119

Self-intoxication with morphine obtained from an infusion pump. Gock SB, et al. **J Anal Toxicol** 1999 Mar-Apr; 23(2):130-3

STANDARDS

Ways to avoid needle-hub contamination [letter; comment] Shields JW. **Infect Control Hosp Epidemiol** 1999 Feb; 20(2):92. Comment on: Infect Control Hosp Epidemiol 1998 Oct;19(10):739.

[New standards for infusion pumps--with shortages physicians should know about] Boström U. **Lakartidningen** 1999 Mar 17;96(11):1327-8 **(Swe)**

INFUSION PUMPS, EXTERNAL see **INFUSION PUMPS**

INFUSION PUMPS, IMPLANTABLE

see related
DRUG IMPLANTS

Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report. Meythaler JM, et al. **Am J Phys Med Rehabil** 1999 May-Jun;78(3):247-54

Implantable pain therapies--what training is required? [editorial; comment] Palmer PP. **Anesth Analg** 1999 Jun; 88(6):1203-4. Comment on: Anesth Analg 1999 Jun;88(6):1311-6.

Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Biffi R, et al. **Ann Oncol** 1998 Jul; 9(7):767-73

Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation [see comments] Bloom AI, et al. **Ann Surg Oncol** 1999 Jun; 6(4):350-8. Comment in: Ann Surg Oncol 1999 Jun;6(4):328-9.

Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Kubek MJ, et al. **Brain Res** 1998 Nov 2;809(2):189-97

First clinical experience with a high-capacity implantable infusion pump for continuous intravenous chemotherapy. Damascelli B, et al. **Cardiovasc Intervent Radiol** 1999 Jan; 22(1):37-43

Implanted insulin pump may represent a chance for young women with unstable type 1 diabetes to give birth [letter] Belicar P, et al. **Diabetes Care** 1999 Jun;22(6):1001-2

Implantable hepatic arterial infusion device: placement without laparotomy via an intercostal artery. Castaing D, et al. **J Am Coll Surg** 1998 Nov;187(5):565-8

Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. Seno H, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):811-6

Managing chronic nonmalignant pain with continuous intrathecal morphine. Valentino L, et al. **J Neurosci Nurs** 1998 Aug;30(4):233-9, 243-4

Therapeutic applications of implantable drug delivery systems. Dash AK, et al. **J Pharmacol Toxicol Methods** 1998 Jul;40(1):1-12 (57 ref.)

A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. Ikeda T, et al. **Jpn J Clin Oncol** 1999 Jan;29(1):23-7

Utility and complications of permanent venous access devices (PVAD) in oncological treatments. Follow-up of 100 cases. Groebli Y, et al. **Panminerva Med** 1999 Jun;41(2):89-92

[A continuous and constant rate administration method--mini-osmotic pump] Chen Z, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Aug; 13(3):278-80 (Eng. Abstr.) **(Chi)**

[A case of local recurrence of rectal cancer responding to local intraarterial infusion therapy] Otani S, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1355-7 (Eng. Abstr.) **(Jpn)**

[Successful combination chemotherapy for a case of small cell carcinoma of the rectum with multiple liver metastasis] Sakamoto Y, et al. **Gan To Kagaku Ryoho** 1999 Mar; 26(4):543-7 (Eng. Abstr.) **(Jpn)**

[Experience of cancer home chemotherapy with cooperation between hospital and clinic] Sawada K, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:625-30 (Eng. Abstr.) **(Jpn)**

[Nursing situation in outpatient chemotherapy following surgery for gastric cancer] Suzuki M, et al. **Gan To Kagaku Ryoho** 1998 Dec;25 Suppl 4:615-8 (Eng. Abstr.) **(Jpn)**

[Palliation for a recurrent lung cancer patient with superior vena cava syndrome by arterial infusion of CDDP through the implantable port system--a case report] Taira N, et al. **Gan To Kagaku Ryoho** 1999 Mar;26(4):531-3 (Eng. Abstr.) **(Jpn)**

[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers] Tsuji A, et al. **Gan To Kagaku Ryoho** 1999 Jun;26(7):933-8 (Eng. Abstr.) **(Jpn)**

[Intra-arterial chemotherapy for invasive bladder cancer] Ozono S, et al. **Hinyokika Kiyo** 1999 Feb;45(2):133-7 (Eng. Abstr.) **(Jpn)**

[Intra-arterial chemotherapy via reservoir system for advanced bladder cancer and prostate cancer] Takahashi Y, et al. **Hinyokika Kiyo** 1999 Feb;45(2):159-61 (Eng. Abstr.) **(Jpn)**

[Means of effective and practical intra-arterial chemotherapy for locally invasive bladder cancer--with special reference

to clinical analysis of bladder cancer patients treated by intermittent intra-arterial infusion using an implantable port system] Takashima S, et al. **Hinyokika Kiyo** 1999 Feb; 45(2):127-31 (Eng. Abstr.) **(Jpn)**

[A case of advanced hepatocellular carcinoma treated by repeated arterial infusion chemotherapy of 5-FU, LV, CDDP with an implanted reservoir] Imamoto E, et al. **Nippon Shokakibyo Gakkai Zasshi** 1999 Jun;96(6):675-9 **(Jpn)**

[Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity] Berg-Johnsen J, et al. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3256-60 (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. Al-Khodairy AT, et al. **Am J Phys Med Rehabil** 1999 May-Jun;78(3):272-7

Surgical experience with implantable insulin pumps. Department of Veterans Affairs Implantable Insulin Pump Study Group. Thompson JS, et al. **Am J Surg** 1998 Dec; 176(6):622-6

Hepatic arterial infusion chemotherapy using percutaneous catheter placement with an implantable port: assessment of factors affecting patency of the hepatic artery. Seki H, et al. **Clin Radiol** 1999 Apr;54(4):221-7

A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Croxatto HB, et al. **Hum Reprod** 1999 Apr;14(4):976-81

The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Zhu P, et al. **Hum Reprod** 1999 Apr;14(4):970-5

[Septicemia due to Corynebacterium aquaticum in an HIV-seropositive patient with an implantable chamber catheter (letter)] Vasseur E, et al. **Presse Med** 1998 Oct 3;27(29):1476-7 **(Fre)**

ECONOMICS

[Elements for a cost/utility analysis of long term intravenous devices] Belouet C, et al. **Pathol Biol (Paris)** 1999 Mar; 47(3):282-7 (Eng. Abstr.) **(Fre)**

[Technology under the skin] Wester K. **Tidsskr Nor Laegeforen** 1998 Sep 10;118(21):3255 **(Nor)**

PSYCHOLOGY

[Psychological impact of presence of an implantable catheter in patients with serious illnesses] Zivkovic L. **Pathol Biol (Paris)** 1999 Mar;47(3):292-6 (8 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. Stocchi F, et al. **Mov Disord** 1999 Mar;14(2):358

[Clinical experiences of implantable vascular access device, "Vital Port" for arterial infusion chemotherapy] Takayasu Y, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1283-8 (Eng. Abstr.) **(Jpn)**

[New standards for infusion pumps--with shortages physicians should know about] Boström U. **Lakartidningen** 1999 Mar 17;96(11):1327-8 **(Swe)**

TRENDS

Implantable insulin pumps. Selam JL. **Lancet** 1999 Jul 17; 354(9174):178-9

INFUSION THERAPY, HOME see **HOME INFUSION THERAPY**

INFUSIONS, INTRA-ARTERIAL

Clinical results of transcatheter arterial infusion for uterine cervical cancer. Nagata Y, et al. **Am J Clin Oncol** 1999 Feb;22(1):97-102

Stages III and IV squamous cell carcinoma of the mouth: three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Hirai T, et al. **Cardiovasc Intervent Radiol** 1999 May-Jun; 22(3):201-5

Transcatheter arterial infusion therapy in the treatment of advanced pancreatic cancer: a feasibility study. Shibuya K, et al. **Cardiovasc Intervent Radiol** 1999 May-Jun; 22(3):196-200

Elevated plasma atrial natriuretic peptide levels after occlusion of the thoracic aorta [see comments] Berkenstadt H, et al. **Chest** 1999 Jan;115(1):130-4. Comment in: Chest 1999 Jan;115(1):7-8.

Bronchial artery chemotherapy--a future? [editorial; comment] Maddaus MA. **Chest** 1999 May;115(5):1230-1. Comment on: Chest 1999 May;115(5):1424-8.

Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study [see comments] Osaki T, et al. **Chest** 1999 May; 115(5):1424-8. Comment in: Chest 1999 May;115(5):1230-1.

Circulating natriuretic peptides: a biologic marker of tissue injury? [editorial; comment] Rubinstein I, et al. **Chest** 1999 Jan;115(1):7-8. Comment on: Chest 1999 Jan;115(1):130-4.

Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma--results of long-term follow-up. Asahara T, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1042-8

Hepatic arterial infusion chemotherapy of cisplatin for biliary cystadenocarcinoma. Hanazaki K, et al. **Hepatogastroenterology** 1999 Jan-Feb;46(25):462-4

Combined therapy with radiofrequency thermal ablation and intra-arterial infusion chemotherapy for hepatic metastases from colorectal cancer. Kainuma O, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1071-7

Stop-flow thoracic perfusion for unresectable pulmonary carcinoma with or without inhalation IL-2 immunotherapy. A prospective randomized study. Lygidakis NJ, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):792-8

Targeting locoregional immunochemotherapy with new drugs in metastatic liver disease: a promising alternative. Lygidakis NJ, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):2248-51

Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Tanaka K, et al. **Hepatogastroenterology** 1999 Mar-Apr;46(26):1083-8

Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Tzoracoleftherakis EE, et al. **Hepatogastroenterology** 1999 Mar-Apr; 46(26):1122-5

New techniques: splenic artery embolization followed by intraarterial infusion chemotherapy for the treatment of pancreatic cancer. Yoshida H, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):2024-7

Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. Seno H, et al. **J Gastroenterol Hepatol** 1999 Aug;14(8):811-6

Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Rudroff C, et al. **Langenbecks Arch Surg** 1999 Jun;384(3):243-9

Study of catheter designs and drug mixing processes using 2D steady numerical simulations. Mongrain R, et al. **Med Biol Eng Comput** 1999 Jan;37(1):64-70

Microsurgical technique to improve the insertion of totally implantable arterial device (TIAD) in presence of hepatic artery anomalies. Puleo S, et al. **Microsurgery** 1998; 18(8):476-8

Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. de Baere T, et al. **Radiology** 1999 Sep; 212(3):665-8

[The status of regional long-term chemotherapy in liver metastasis] Lorenz M, et al. **Chirurg** 1999 Feb;70(2):141-53 (74 ref.) (Eng. Abstr.) **(Ger)**

[Locoregional therapy methods] Kubicka S, et al. **Internist (Berl)** 1998 Nov;39(11):1139-47 (49 ref.) **(Ger)**

[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases] Gassel HJ, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1458-60 (Eng. Abstr.) **(Ger)**

[Locoregional and systemic therapy of advanced pancreatic carcinoma] Gebauer T, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1344-7 (Eng. Abstr.) **(Ger)**

[Isolated hypoxic perfusion with mitomycin C confers no benefit for patients with advanced pancreatic carcinoma] Petrowsky H, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1351-3 (Eng. Abstr.) **(Ger)**

[Multicenter phase II study of the Liver Metastases Study Group of weekly intra-arterial 24-hour high dose therapy with 5-FU and folinic acid (FA) in liver metastases of colorectal tumors] Staib-Sebler E, et al. **Langenbecks Arch Chir Suppl Kongressbd** 1998;115:1441-4 (Eng. Abstr.) **(Ger)**

[Value of locoregional chemotherapy in liver metastases of breast carcinoma] Zimmermann T, et al. **Zentralbl Chir** 1998;123 Suppl 5:159-61 (Eng. Abstr.) **(Ger)**

[Prolonged regional intra-arterial therapy in multimodal treatment of patients with severe skeletal trauma] Khomutov VA, et al. **Anesteziol Reanimatol** 1999 Mar-Apr;(2):19-22 (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation [see comments] Bloom AI, et al. **Ann Surg Oncol** 1999 Jun; 6(4):350-8. Comment in: Ann Surg Oncol 1999 Jun;6(4):328-9.

Coil embolism as rescue--the solution to misperfusion [editorial; comment] Nagorney DM. **Ann Surg Oncol** 1999 Jun;6(4):328-9. Comment on: Ann Surg Oncol 1999 Jun;6(4):350-8.

INSTRUMENTATION

A new alternative technique to preserve native flow, for continuous hepatic artery chemotherapy, in presence of a right hepatic artery arising from superior mesenteric artery. Di Carlo I, et al. **Hepatogastroenterology** 1999 May-Jun;46(27):1692-4

Efficacy of repeated percutaneous isolated liver chemoperfusion in local control of unresectable hepatocellular carcinoma. Ku Y, et al. **Hepatogastroenterology** 1998 Nov-Dec;45(24):1961-5

The risk of infection associated with intra-arterial catheters for cancer chemotherapy. Raad I, et al. **Infect Control Hosp Epidemiol** 1998 Sep;19(9):640-2

[Adjuvant regional arterial port chemotherapy after resection of colorectal liver metastases] Riesener KP, et al. **Chirurg** 1998 Jul;69(7):741-6 (Eng. Abstr.) **(Ger)**

[Clinical experiences of implantable vascular access device, "Vital Port" for arterial infusion chemotherapy] Takayasu Y, et al. **Gan To Kagaku Ryoho** 1999 Aug;26(9):1283-8 (Eng. Abstr.) **(Jpn)**

METHODS

Extrahepatic regional chemotherapy: use of technetium-99m labeled macroaggregated albumin. Pelosi E, et al. **Am J Clin Oncol** 1999 Jun;22(3):315-9

Retrograde intra-arterial infusion of prostaglandin E1 and heparin for the no-reflow phenomenon after oromandibular reconstruction with a free fibular flap. Hataya Y, et al. **Ann Plast Surg** 1999 Jan;42(1):92-5

Local delivery in coronary artery disease: an overview for the interventional cardiologist. Chandrasekar B, et al. **Indian Heart J** 1999 Jan-Feb;51(1):21-6 (57 ref.)

[An experimental study of local chemotherapy for metastatic lung tumor--isolated lung perfusion and pulmonary artery infusion] Omiya H, et al. **Jpn J Thorac Cardiovasc Surg** 1998 Oct;46(10):976-82 (Eng. Abstr.) **(Jpn)**

[Intra-arterial regional perfusion in destructive forms of acute pancreatitis] Vafin AZ, et al. **Vestn Khir Im I I Grek** 1999; 158(1):30-5 (Eng. Abstr.) **(Rus)**

INFUSIONS, INTRA-OSSEOUS see **INFUSIONS, INTRAOSSEOUS**

INFUSIONS, INTRAOSSEOUS

Intraosseous vascular access: from the archives to the ABC [editorial; comment] Bohn D. **Crit Care Med** 1999 Jun; 27(6):1053-4. Comment on: Crit Care Med 1999 Jun;27(6):1147-52.

Use of intraosseous blood to assess blood chemistries and hemoglobin during cardiopulmonary resuscitation with drug infusions [see comments] Johnson L, et al. **Crit Care Med** 1999 Jun;27(6):1147-52. Comment in: Crit Care Med 1999 Jun;27(6):1053-4.

The calcaneum as a site for intraosseous infusion. McCarthy G, et al. **J Accid Emerg Med** 1998 Nov;15(6):421

[Retrospective study of 32 cases of intraosseous perfusion] Claudet I, et al. **Arch Pediatr** 1999 May;6(5):516-9 (Eng. Abstr.) **(Fre)**

METHODS

Intraosseous lines in preterm and full term neonates. Ellemunter H, et al. **Arch Dis Child Fetal Neonatal Ed** 1999 Jan;80(1):F74-5

Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Wenzel V, et al. **Crit Care Med** 1999 Aug;27(8):1565-9

[Intraosseous infusion in children] Claudet I, et al. **Ann Fr Anesth Reanim** 1999 Mar;18(3):313-8 (Eng. Abstr.) **(Fre)**

INFUSIONS, INTRAVENOUS

see related
IMMUNOGLOBULINS, INTRAVENOUS

The U.S. home infusion market. Monk-Tutor MR. **Am J Health Syst Pharm** 1998 Oct 1;55(19):2019-25

ADVERSE EFFECTS

Superficial radial neuropathy caused by intravenous injection. Sheu JJ, et al. **Acta Neurol Belg** 1999 Jun;99(2):138-9

Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion. Arbour RB. **Am J Crit Care** 1999 Jan;8(1):499-506

Recrudescence of opioid effects after intraoperative remifentanil infusion complicated by infiltration of the intravenous catheter [letter] Cucchiaro G, et al. **Anesth Analg** 1998 Dec;87(6):1458

Intraoperative burns secondary to warmed i.v. bags: a warning. Rosenfield LK, et al. **Anesthesiology** 1999 Feb; 90(2):616-8

Effect of prolonged infusion on vein calibre: a prospective study. Everitt NJ. **Ann R Coll Surg Engl** 1999 Mar; 81(2):109-12

Hospital-acquired malaria in Nottingham. **Commun Dis Rep CDR Wkly** 1999 Apr 2;9(14):123

Risk of contamination from air vents during intravenous fluid administration. Useh MF, et al. **East Afr Med J** 1998 Jun; 75(6):322-6

Line-associated bloodstream infections in pediatric intensive-care-unit patients associated with a needleless device and intermittent intravenous therapy. McDonald LC, et al. **Infect Control Hosp Epidemiol** 1998 Oct; 19(10):772-7

Positive intravenous line tip cultures as predictors of bacteraemia. Peacock SJ, et al. **J Hosp Infect** 1998 Sep; 40(1):35-8

Experimental infusion phlebitis: tolerance pH of peripheral

vein. Kuwahara T, et al. **J Toxicol Sci** 1999 May; 24(2):113–21

Blastoschizomyces capitatus infection after contamination of fluids for intravenous application. Mathews MS, et al. **Mycoses** 1998 Nov;41(9–10):427–8

Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin [see comments] O'Brien TJ, et al. **Neurology** 1998 Oct; 51(4):1034–9. Comment in: Neurology 1998 Oct;51(4):942–3.

Pediatric intracranial epidural abscess secondary to an infected scalp vein catheter. Lefkowitz MA, et al. **Pediatr Neurosurg** 1998 Dec;29(6):297–9

Median nerve compression with tumescent fluid administration [letter; comment] Duncan RE. **Plast Reconstr Surg** 1999 Mar;103(3):1095. Comment on: Plast Reconstr Surg 1998 Jul;102(1):235–7.

Acute carpal tunnel syndrome: related to the tumescent technique? [letter; comment] Worland RG. **Plast Reconstr Surg** 1999 Mar;103(3):1094–5. Comment on: Plast Reconstr Surg 1998 Jul;102(1):235–7.

[Venous access in oncology] Lesimple T, et al. **Presse Med** 1998 Oct 31;27(33):1694–701 (30 ref.) (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Intravenous fluids and bupivacaine are contraindicated in tumescent liposuction [letter; comment] Klein JA. **Plast Reconstr Surg** 1998 Dec;102(7):2516–9. Comment on: Plast Reconstr Surg 1997 Feb;99(2):514–9; discussion 520–6.

ECONOMICS

[Elements for a cost/utility analysis of long term intravenous devices] Belouet C, et al. **Pathol Biol (Paris)** 1999 Mar; 47(3):282–7 (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Advocacy group targets PVC i.v. equipment [news] Landis NT. **Am J Health Syst Pharm** 1999 May 15;56(10):937–8

Comparison of the microbial barrier properties of a needleless and a conventional needle-based intravenous access system. Luebke MA, et al. **Am J Infect Control** 1998 Aug; 26(4):437–41

Homogenous mixing of propofol emulsion into an infusion solution [letter] Aida S, et al. **Anaesthesia** 1999 Jul; 54(7):716–7

Defeating proprietary technology [letter] Krock JL, et al. **Anesthesiology** 1998 Nov;89(5):1292

Intraoperative burns secondary to warmed i.v. bags: a warning. Rosenfield LK, et al. **Anesthesiology** 1999 Feb; 90(2):616–8

PVC bags considerably reduce availability of diazepam. Mahomed K, et al. **Cent Afr J Med** 1998 Jul;44(7):171–3

The use of the Port-A-Cath in children with haemophilia--a review. Van Den Berg HM, et al. **Haemophilia** 1998 Jul; 4(4):418–20 (11 ref.)

Efficacy of paraformaldehyde tablets in sterilization of polyvinyl-chloride tubing [letter] Sharma S. **Indian J Ophthalmol** 1998 Sep;46(3):174–5

A randomized trial of 72- versus 24-hour intravenous tubing set changes in newborns receiving lipid therapy. Matlow AG, et al. **Infect Control Hosp Epidemiol** 1999 Jul; 20(7):487–93

Endemic nosocomial gram-negative bacteraemias resulting from contamination of intravenous heparin infusions. Playford EG, et al. **J Hosp Infect** 1999 May;42(1):21–6

Improving patient outcomes through CQI: vascular access planning. Barton AJ, et al. **J Nurs Care Qual** 1998 Dec; 13(2):77–85

Effect of flow rate and insulin priming on the recovery of insulin from microbore infusion tubing. Fuloria M, et al. **Pediatrics** 1998 Dec;102(6):1401–6

[Postoperative ventilatory depression after flushing of the infusion line (comment)] Nouri M, et al. **Ann Fr Anesth Reanim** 1999 Aug;18(7):814–5. Comment on: Ann Fr Anesth Reanim 1999 Mar;18(3):358–9. **(Fre)**

METHODS

Forearm venous pressures and blood back flow [letter] Veasey K, et al. **Anaesthesia** 1999 Sep;54(9):917

Venous cannulation in small infants: a simple method to improve success [letter] Steward DJ. **Anesthesiology** 1999 Mar;90(3):930–1

Continuous infusion of beta-lactam antibiotics. Grant E, et al. **Conn Med** 1999 May;63(5):275–7

Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Wenzel V, et al. **Crit Care Med** 1999 Aug;27(8):1565–9

Method for continuous infusion into the portal vein of mice. Patijn GA, et al. **Lab Anim Sci** 1998 Aug;48(4):379–83

Safety, efficacy, and acceptability of home intravenous therapy administered by parents of pediatric oncology patients. Hooker L, et al. **Med Pediatr Oncol** 1999 Jun; 32(6):421–6

Intravenous infusion techniques: how to do it and why we should do it. Glass PS. **Minerva Anestesiol** 1999 May; 65(5):219–31 (35 ref.)

Reader raises concerns regarding changing i.v. administration sets [letter; comment] Knapp TR. **Oncol Nurs Forum** 1999 Apr;26(3):495–6. Comment on: Oncol Nurs Forum 1998 Jun;25(5):907–13.

Intravenous access in infants and children. Stovroff M, et al. **Pediatr Clin North Am** 1998 Dec;45(6):1373–93, viii (47 ref.)

NURSING

Impact of a dedicated intravenous therapy team on nosocomial bloodstream infection rates. Meier PA, et al. **Am J Infect Control** 1998 Aug;26(4):388–92

STANDARDS

Improving patient outcomes through CQI: vascular access planning. Barton AJ, et al. **J Nurs Care Qual** 1998 Dec; 13(2):77–85

INFUSIONS, PARENTERAL

see related
FLUID THERAPY
HOME INFUSION THERAPY

Sonographic assessment of an inaccessible chemotherapy infusion port. Kalbhen CL, et al. **AJR Am J Roentgenol** 1999 Sep;173(3):671–2

Mixture experiments with the oil phase of parenteral emulsions. Jumaa M, et al. **Eur J Pharm Biopharm** 1998 Sep;46(2):161–7

ADVERSE EFFECTS

Tensile properties of the knee-joint capsule at an elevated intraarticular pressure. Sperber A, et al. **Acta Orthop Scand** 1998 Oct;69(5):484–8

Parenteral infusions bacterial contamination in a multi-institutional survey in Mexico: considerations for nosocomial mortality. Macías AE, et al. **Am J Infect Control** 1999 Jun;27(3):285–90

[Drug injection method risky for transmission of blood-borne diseases: are we careful enough?] Bravo Portela MJ, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):289–301 (63 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Renal medullary interstitial infusion of norepinephrine in anesthetized rabbits: methodological considerations. Correia AG, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R112–22

Subcutaneous infusion or hypodermoclysis: a practical approach. Ferry M, et al. **J Am Geriatr Soc** 1999 Jan; 47(1):93–5 (29 ref.)

Prevention of precipitation of phenytoin in an infusion fluid by hydroxypropyl beta-cyclodextrin. McDonald C, et al. **J Clin Pharm Ther** 1998 Jun;23(3):235–9

Managing chronic nonmalignant pain with continuous intrathecal morphine. Valentino L, et al. **J Neurosci Nurs** 1998 Aug;30(4):233–9, 243–4

[Hypodermoclysis, a neglected approach] Mancini I, et al. **Rev Med Brux** 1998 Sep;19(4):A327–31 (Eng. Abstr.) **(Fre)**

INFUSIONS, REGIONAL ARTERIAL see **INFUSIONS, INTRA-ARTERIAL**

INFUSORIAL EARTH see **KIESELGUHR**

INFUSORS see **INFUSION PUMPS**

INGUINAL CANAL

A pilot study on early post-operative morbidity and technique of inguinal node dissection in vulval carcinoma. Kehoe S, et al. **Eur J Gynaecol Oncol** 1998;19(4):374–6

Inguinal abscess: an unusual presentation of infection around total hip replacement. Nadeem RD, et al. **J Arthroplasty** 1999 Aug;14(5):630–2

ANATOMY & HISTOLOGY

Transverse subgluteal-ilioinguinal approach to the acetabulum. Amr S. **Microsurgery** 1998;18(7):432–41 (65 ref.)

[Anthropometric measurements of the male inguinal canal] Valenti G, et al. **Minerva Chir** 1998 Sep;53(9):715–8 (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Access to occluded infrainguinal bypass grafts with a loopsnare. Nosher JL, et al. **J Vasc Surg** 1999 Apr; 29(4):745–7

INJURIES

Penetrating sledding injuries to the lower torso--2 case reports. O'Brien K, et al. **CMAJ** 1999 Feb 9;160(3):353–4

The incidence and differential diagnosis of acute groin injuries in male soccer players. Ekstrand J, et al. **Scand J Med Sci Sports** 1999 Apr;9(2):98–103

INNERVATION

Anatomic basis of chronic groin pain with special reference to sports hernia. Akita K, et al. **Surg Radiol Anat** 1999; 21(1):1–5

PATHOLOGY

Papillary clear cell adenocarcinoma of the groin arising from endometriosis. Klein AE, et al. **Clin Orthop** 1999 Apr; (361):192–8

[Extrarenal nodular nephrogenic blastema in the inguinal canal: report of two cases] Irimescu D, et al. **Ann Pathol** 1999 Mar;19(1):26–9 (Eng. Abstr.) **(Fre)**

[Inguinal tumor as the first manifestation of a pancreatic pseudocyst] Gutiérrez Macías A, et al. **Gastroenterol Hepatol** 1998 Dec;21(10):486–8 (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The value of intraoperative laparoscopic examination of the contralateral inguinal ring during hernia repair in children. Birk D, et al. **J Laparoendosc Adv Surg Tech A** 1998 Dec; 8(6):373–9

Contractility and electrophysiological parameters of cremaster muscles of boys with a hernia or undescended testis. Bingöl-Koloğlu M, et al. **J Pediatr Surg** 1998 Oct; 33(10):1490–4

RADIONUCLIDE IMAGING

Fluorine-18 fluorodeoxyglucose uptake in the retractile testis. Fujii H, et al. **Clin Nucl Med** 1999 May;24(5):323–5

INGUINAL HERNIA see **HERNIA, INGUINAL**

INHALATION ANESTHETICS see **ANESTHETICS, INHALATION**

INHALATION BURNS see **BURNS, INHALATION**

INHALATION DEVICES see **NEBULIZERS AND VAPORIZERS**

INHALATION DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

INHALATION EXPOSURE

A comparison of worker exposure to inhalable and total dust, inorganic arsenic, and borates using two types of particulate sampling assemblies in a borate mining and processing facility. Katchen MA, et al. **Biol Trace Elem Res** 1998 Winter;66(1–3):59–64

Phencyclidine- and diazepam-like discriminative stimulus effects of inhalants in mice. Bowen SE, et al. **Exp Clin Psychopharmacol** 1999 Feb;7(1):28–37

Experimental approaches for studies of particulate matter: the case for stronger consideration of dosimetric and exposure issues [editorial] Everitt J. **Exp Lung Res** 1998 Nov-Dec;24(6):705–7 (4 ref.)

Lung exposure from inhalation of radon progeny: calculated from in vivo measurements of 210Pb in the skull. Laurer GR, et al. **Health Phys** 1999 Apr;76(4):380–7

Acute airway effects of formaldehyde and ozone in BALB/c mice. Nielsen GD, et al. **Hum Exp Toxicol** 1999 Jun; 18(6):400–9

Sulphur dioxide sensitivity and plasma antioxidants in adult subjects with asthma. Trenga CA, et al. **Occup Environ Med** 1999 Aug;56(8):544–7

[Starch aspiration] Volk O, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1999 Jun; 34(6):376–8 (Eng. Abstr.) **(Ger)**

[Effects of iron-containing welding smoke on pathological changes in the body (review of the literature)] Lubianova IP. **Med Tr Prom Ekol** 1998;(9):27–37 (123 ref.) **(Rus)**

ADVERSE EFFECTS

Zinc exposure in Chinese foundry workers. Martin CJ, et al. **Am J Ind Med** 1999 Jun;35(6):574–80

Long-term inhalable particles and other air pollutants related to mortality in nonsmokers [see comments] Abbey DE, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):373–82. Comment in: Am J Respir Crit Care Med 1999 Feb;159(2):354–6.

Persistent airway inflammation but accommodated antioxidant and lung function responses after repeated daily exposure to nitrogen dioxide. Blomberg A, et al. **Am J Respir Crit Care Med** 1999 Feb;159(2):536–43

All but quiet on the particulate front [editorial; comment] Brunekreef B. **Am J Respir Crit Care Med** 1999 Feb; 159(2):354–6 (16 ref.). Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):365–72. Comment on: Am J Respir Crit Care Med 1999 Feb;159(2):373–82.

Oxygen saturation, pulse rate, and particulate air pollution: A daily time-series panel study [see comments] Pope CA3rd, et al. **Am J Respir Crit Care Med** 1999 Feb; 159(2):365–72. Comment in: Am J Respir Crit Care Med 1999 Feb;159(2):354–6.

The South Karelia Air Pollution Study: changes in respiratory health in relation to emission reduction of malodorous sulfur compounds from pulp mills. Jaakkola JJ, et al. **Arch Environ Health** 1999 Jul–Aug;54(4):254–63

Wegener's granulomatosis: role of environmental exposures. Duna GF, et al. **Clin Exp Rheumatol** 1998 Nov–Dec; 16(6):669–74

Hyperventilation following a large-scale hazardous-materials incident. Burgess JL, et al. **Int J Occup Environ Health**

INHALATION EXPOSURE

1999 Jul-Sep;5(3):194-7

Use of bronchopulmonary lavage for eliminating inhaled fume particles from a patient with arc welder's lung. Yamada G, et al. **Intern Med** 1998 Nov;37(11):962-4

Investigation of a cluster of leukaemia in the Illawarra region of New South Wales, 1989-1996 [see comments] Westley-Wise VJ, et al. **Med J Aust** 1999 Aug 16; 171(4):178-83. Comment in: Med J Aust 1999 Aug 16;171(4):172.

Genotoxicity in workers exposed to methyl bromide. Calvert GM, et al. **Mutat Res** 1998 Sep 11;417(2-3):115-28

Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. Andersen ME, et al. **Neurotoxicology** 1999 Apr-Jun;20(2-3):161-71 (51 ref.)

Systemic sclerosis (scleroderma) in two iron ore mines. Martin JR, et al. **Occup Med (Lond)** 1999 Apr;49(3):161-9

[Legal protection for expectant mothers and personnel exposed to inhalation anesthetics in recovery room and surgical intensive care units. Gesundheitswesen 60 (1998) 586:91 (letter; comment)] Heese B. **Gesundheitswesen** 1999 Mar;61(3):155-6. Comment on: Gesundheitswesen 1998 Oct;60(10):586-91. **(Ger)**

[Occupational and environmental bronchial asthma] Baur X. **Internist (Berl)** 1999 Aug;40(8):844-8 (18 ref.) **(Ger)**

ANALYSIS

Inhaled cellulosic and plastic fibers found in human lung tissue. Pauly JL, et al.
Cancer Epidemiol Biomarkers Prev 1998 May;7(5):419-28

Estimation of the percutaneous absorption of styrene in an industrial situation. Limasset JC, et al.
Int Arch Occup Environ Health 1999 Jan;72(1):46-51

Contribution of aerosols generated during mixing and loading of pesticides to operator inhalation exposure. Wolf TM, et al. **Toxicol Lett** 1999 Mar 8;105(1):31-8

PREVENTION & CONTROL

The South Karelia Air Pollution Study: changes in respiratory health in relation to emission reduction of malodorous sulfur compounds from pulp mills. Jaakkola JJ, et al. **Arch Environ Health** 1999 Jul-Aug;54(4):254-63

STATISTICS & NUMERICAL DATA

Asthma and chemical bronchitis in vanadium plant workers. Irsigler GB, et al. **Am J Ind Med** 1999 Apr;35(4):366-74

INHALATION INJURY, SMOKE see **SMOKE INHALATION INJURY**

INHALATION OF DRUGS see **ADMINISTRATION, INHALATION**

INHALATION PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

INHALATION THERAPY see **RESPIRATORY THERAPY**

INHALATORS see **NEBULIZERS AND VAPORIZERS**

INHALERS see **NEBULIZERS AND VAPORIZERS**

INHALING see **ASPIRATION**

INHIBIN

ANALYSIS

Alpha-inhibin immunostaining in diagnostic pathology. Matias-Guiu X, et al. **Adv Anat Pathol** 1998 Jul;5(4):263-7

Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors. Yamashita K, et al. **Am J Obstet Gynecol** 1999 Feb;180(2 Pt 1):316-22

Evolution of an inhibin A ELISA method: implications for Down's syndrome screening. Wallace EM, et al.
Ann Clin Biochem 1998 Sep;35 (Pt 5):656-64

Identification of a nuclear localization signal in activin/inhibin betaA subunit; intranuclear betaA in rat spermatogenic cells. Bläuer M, et al. **Biol Reprod** 1999 Mar; 60(3):588-93

Activin family members in the developing chick retina: expression patterns, protein distribution, and in vitro effects. Belecky-Adams TL, et al. **Dev Biol** 1999 Jun 1; 210(1):107-23

Metastatic granulosa-cell tumor in the liver: cytopathologic findings and staining with inhibin. Ali SZ.
Diagn Cytopathol 1998 Oct;19(4):293-7

Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid. Di Loreto C, et al.
Eur J Endocrinol 1999 Aug;141(2):190-4

Malignant fibrothecomatous tumour of the ovary: diagnostic value of anti-inhibin immunostaining. McCluggage WG, et al. **J Clin Pathol** 1998 Nov;51(11):868-71

A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC-11. Phillips DJ, et al. **J Endocrinol** 1999 Jul;162(1):111-6

Immunohistochemical localization of alpha- and betaA-subunits of inhibin/activin in human normal endocrine cells and related tumors of the digestive system. La Rosa S, et al. **Virchows Arch** 1999 Jan;434(1):29-36

ANTAGONISTS & INHIBITORS

Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. Ishisaki A, et al.
J Biol Chem 1999 May 7;274(19):13637-42

BIOSYNTHESIS

Positive association between expression of follicle-stimulating hormone beta and activin betaB-subunit genes in boars. Li MD, et al.
Biol Reprod 1998 Oct;59(4):978-82

Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Sidis Y, et al.
Biol Reprod 1998 Oct;59(4):807-12

Expression and function of activin beta A during mouse cardiac cushion tissue formation. Moore CS, et al.
Dev Dyn 1998 Aug;212(4):548-62

Expression of activin and follistatin in the rat hypothalamus: anatomical association with gonadotropin-releasing hormone neurons and possible role of central activin in the regulation of luteinizing hormone release. MacConell LA, et al. **Endocrine** 1998 Dec;9(3):233-41

Dimeric inhibin A and B production are differentially regulated by hormones and local factors in rat granulosa cells. Lanuza GM, et al. **Endocrinology** 1999 Jun; 140(6):2549-54

Advance in the study of inhibin, activin and follistatin production in pregnant women. Qu J, et al.
Eur J Obstet Gynecol Reprod Biol 1998 Dec;81(2):141-8 (88 ref.)

Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements. Baker RJ, et al.
Hum Pathol 1999 Jun;30(6):671-9

Follistatin and activin A production by the male reproductive tract. Anderson RA, et al. **Hum Reprod** 1998 Dec; 13(12):3319-25

Expression of bovine activin-A and inhibin-A in recombinant baculovirus-infected Spodoptera frugiperda Sf 21 insect cells. Cronin CN, et al. **Int J Biochem Cell Biol** 1998 Oct; 30(10):1129-45

Inhibition of rat mammary tumorigenesis by human chorionic gonadotropin associated with increased expression of inhibin. Srivastava P, et al. **Mol Carcinog** 1999 Sep; 26(1):10-9

Differential expression pattern of inhibin alpha and betaA subunits in the ovaries of postnatal and prepubertal lambs. Braw-Tal R, et al. **Reprod Fertil Dev** 1997;9(8):825-32

BLOOD

Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia. Aquilina J, et al.
Am J Obstet Gynecol 1999 Jul;181(1):131-6

Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Silver HM, et al.
Am J Obstet Gynecol 1999 May;180(5):1131-7

Maternal serum alpha-fetoprotein and dimeric inhibin A detect aneuploidies other than Down syndrome. Wenstrom KD, et al. **Am J Obstet Gynecol** 1998 Oct;179(4):966-70

Identification of the source of inhibins at the time of conception provides a diagnostic role for them in very early pregnancy. Lockwood GM, et al.
Am J Reprod Immunol 1998 Nov;40(5):303-8

Serum levels of inhibin B in men with different causes of spermatogenic failure. Bohring C, et al. **Andrologia** 1999 May;31(3):137-41

Circulating levels of inhibin in hemodialysis males. Sasagawa I, et al. **Arch Androl** 1998 Nov-Dec;41(3):167-71

Maternal serum inhibin A can predict pre-eclampsia. Cuckle H, et al. **Br J Obstet Gynaecol** 1998 Oct;105(10):1101-3

Combined inhibin and CA125 assays in the detection of ovarian cancer. Robertson DM, et al. **Clin Chem** 1999 May; 45(5):651-8

Inhibin forms in serum from postmenopausal women with ovarian cancers. Robertson DM, et al.
Clin Endocrinol (Oxf) 1999 Mar;50(3):381-6

Endocrine assays to predict preterm delivery. Jackson M, et al. **Clin Perinatol** 1998 Dec;25(4):837-57, vi (77 ref.)

Endocrine analytes in multiple-marker screening. Lambert-Messerlian GM, et al. **Clin Perinatol** 1998 Dec; 25(4):963-81, vii (95 ref.)

Influence of age and sex on serum concentrations of total dimeric activin A [see comments] Loria P, et al.
Eur J Endocrinol 1998 Nov;139(5):487-92. Comment in: Eur J Endocrinol 1998 Nov;139(5):469-71.

Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea. Petraglia F, et al. **Fertil Steril** 1998 Nov;70(5):907-12

Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Santoro N, et al. **Fertil Steril** 1999 Apr;71(4):658-62

Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Seifer DB, et al.
Fertil Steril 1999 Jul;72(1):63-5

Secretion of activin A in recurrent epithelial ovarian carcinoma. Lambert-Messerlian GM, et al.
Gynecol Oncol 1999 Jul;74(1):93-7

Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. Santala M, et al.
Gynecol Oncol 1998 Dec;71(3):465-8

Evaluation of serum inhibin A as a surveillance marker after conservative management of tubal pregnancy. D'Antona D, et al. **Hum Reprod** 1998 Aug;13(8):2305-7

Incipient ovarian failure associated with raised levels of follicle stimulating hormone and reduced levels of inhibin A in older sheep. de Souza CJ, et al. **Hum Reprod** 1998 Nov;13(11):3016-22

Inhibin B plasma concentrations in oligozoospermic subjects before and after therapy with follicle stimulating hormone. Foresta C, et al. **Hum Reprod** 1999 Apr;14(4):906-12

A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy. Fowler PA, et al. **Hum Reprod** 1998 Dec; 13(12):3530-6

Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hall JE, et al. **Hum Reprod** 1999 Feb;14(2):409-15

Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. O'Connor AE, et al. **Hum Reprod** 1999 Mar;14(3):827-32

Evidence that in a physiological setting Sertoli cell number is the major determinant of circulating concentrations of inhibin B in the adult male rhesus monkey (Macaca mulatta). Ramaswamy S, et al. **J Androl** 1999 May-Jun; 20(3):430-4

Inhibin B levels in plasma of the male rat from birth to adulthood: effect of experimental manipulation of Sertoli cell number. Sharpe RM, et al. **J Androl** 1999 Jan-Feb; 20(1):94-101

Periovulatory serum inhibin-a in women with a diminished ovarian reserve. Lindheim SR, et al.
J Assist Reprod Genet 1999 Sep;16(8):450-3

The utility of serum progesterone and inhibin A for monitoring natural-cycle IVF-ET. Lindheim SR, et al.
J Assist Reprod Genet 1998 Oct;15(9):538-41

Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of serum inhibin B levels. Andersson AM, et al. **J Clin Endocrinol Metab** 1998 Dec; 83(12):4451-8

Diurnal rhythm in serum levels of inhibin B in normal men: relation to testicular steroids and gonadotropins. Carlsen E, et al. **J Clin Endocrinol Metab** 1999 May;84(5):1664-9

Undetectable inhibin B serum levels in men after testicular irradiation. Petersen PM, et al.
J Clin Endocrinol Metab 1999 Jan;84(1):213-5

Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples. von Eckardstein S, et al.
J Clin Endocrinol Metab 1999 Jul;84(7):2496-501

Current state of second trimester screening for Down's syndrome [editorial; comment] Canick JA.
J Med Screen 1998;5(3):113-4. Comment on: J Med Screen 1998 ;5(3):115-9.

Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A [see comments] Haddow JE, et al. **J Med Screen** 1998;5(3):115-9. Comment in: J Med Screen 1998 ;5(3):113-4.

Serum inhibin levels before and after gonadotropin stimulation in cryptorchid boys under age 4 years. Longui CA, et al. **J Pediatr Endocrinol Metab** 1998 Nov-Dec; 11(6):687-92

Effects of anabolic steroid (19-nortestosterone) on the secretion of testicular hormones in the stallion. Nagata S, et al. **J Reprod Fertil** 1999 Mar;115(2):373-9

Inhibin and ovarian cancer. Burger HG, et al.
J Reprod Immunol 1998 Aug;39(1-2):77-87

Serum inhibin B levels and the response to gonadotropin stimulation test in pubertal boys with varicocele. Carrillo A, et al. **J Urol** 1999 Sep;162(3 Pt 1):875-7

Inhibin A and B in peri- and postmenopause. Ala-Fossi SL, et al. **Maturitas** 1998 Nov 16;30(3):273-81

Biphasic increase in serum inhibin B during puberty: a longitudinal study of healthy Finnish boys. Raivio T, et al. **Pediatr Res** 1998 Oct;44(4):552-6

Effect of maternal age curve on the predicted detection rate in maternal serum screening for Down syndrome. Cuckle HS. **Prenat Diagn** 1998 Nov;18(11):1127-30

Regression curves for maternal serum inhibin A [letter] Cuckle HS, et al. **Prenat Diagn** 1999 Mar;19(3):289-90

Inhibin A and pro-alpha C inhibin in Down syndrome and normal pregnancies. D'Antona D, et al. **Prenat Diagn** 1998 Nov;18(11):1122-6

The effect of smoking in pregnancy on maternal serum inhibin A levels. Ferriman EL, et al. **Prenat Diagn** 1999 Apr;19(4):372-4

Second-trimester maternal serum inhibin-A screening for fetal Down syndrome in Asian women. Lam YH, et al. **Prenat Diagn** 1999 May;19(5):463-7

Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Lambert-Messerlian GM, et al. **Prenat Diagn** 1998 Oct;18(10):1061-7

Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free beta-hCG levels. Räty R, et al. **Prenat Diagn** 1999 Feb;19(2):122-7

The pattern of maternal serum inhibin-A concentrations in

the second trimester of pregnancy. Wati HC, et al. **Prenat Diagn** 1998 Aug;18(8):846–8

The clinical and biologic significance of serum inhibins in subfertile men. Mahmoud AM, et al. **Reprod Toxicol** 1998 Nov–Dec;12(6):591–9

[Serum inhibin B as a marker of spermatogenesis] Andersson AM, et al. **Ugeskr Laeger** 1999 Jan 4;161(1):51 **(Dan)**

GENETICS

Male sterility in transgenic mice expressing activin betaA subunit gene in testis. Tanimoto Y, et al. **Biochem Biophys Res Commun** 1999 Jun 16;259(3):699–705

Quantification of inhibin/activin alpha and betaA subunit messenger ribonucleic acid by competitive reverse transcription-polymerase chain reaction in chicken granulosa cells during follicular development. Safi M, et al. **Biol Reprod** 1998 Nov;59(5):1047–54

Dominant-negative Smad2 mutants inhibit activin/Vg1 signaling and disrupt axis formation in Xenopus. Hoodless PA, et al. **Dev Biol** 1999 Mar 15;207(2):364–79

Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation. Takabe K, et al. **Endocrinology** 1999 Jul; 140(7):3125–32

Inhibin subunit gene expression in ovarian cancer. Fuller PJ, et al. **Gynecol Oncol** 1999 May;73(2):273–9

Hepatocyte growth factor regulates activin betaA mRNA in submandibular gland [letter] Furue M, et al. **In Vitro Cell Dev Biol Anim** 1998 Jul–Aug;34(7):520–3

Expression of inhibin/activin subunits and their receptors and binding proteins in human preimplantation embryos. He ZY, et al. **J Assist Reprod Genet** 1999 Feb;16(2):73–80

Promoter activity of the zebrafish bhikhari retroelement requires an intact activin signaling pathway. Vogel AM, et al. **Mech Dev** 1999 Jul;85(1–2):133–46

Co-ordinate expression of activin A and its type I receptor mRNAs during phorbol ester-induced differentiation of human K562 erythroleukemia cells. Hildén K, et al. **Mol Cell Endocrinol** 1999 Jul 20;153(1–2):137–45

Hormonal regulation of proliferation of granulosa and Leydig cell lines derived from gonadal tumors of transgenic mice expressing the inhibin-alpha subunit promoter/simian virus 40 T-antigen fusion gene. Rilianawati, et al. **Mol Cell Endocrinol** 1999 Mar 25;149(1–2):9–17

Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Kumar TR, et al. **Mol Endocrinol** 1999 Jun; 13(6):851–65

Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Sakai H, et al. **Prostate** 1999 Mar 1;38(4):278–84

IMMUNOLOGY

Effect of long-term immunization against inhibin on sperm output in bulls. Bame JH, et al. **Biol Reprod** 1999 Jun; 60(6):1360–6

Granulosa cell tumour of the testis displaying immunoreactivity for inhibin. Morgan DR, et al. **BJU Int** 1999 Apr;83(6):731–2

Immunocytochemical staining of ovarian cyst aspirates with monoclonal antibody against inhibin. McCluggage WG, et al. **Cytopathology** 1998 Oct;9(5):336–42

A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Renshaw AA, et al. **Mod Pathol** 1998 Dec;11(12):1160–4

Activin antiserum infused into the lateral hypothalamic area affects operant behavior of rats fed lysine-deficient diet. Hawkins RL, et al. **Proc Soc Exp Biol Med** 1998 Nov; 219(2):149–53

METABOLISM

Inhibin is not an immunohistochemical marker for hepatocellular carcinoma. An example of the potential pitfall in diagnostic immunohistochemistry caused by endogenous biotin. Iezzoni JC, et al. **Am J Clin Pathol** 1999 Feb;111(2):229–34

Increased midtrimester amniotic fluid activin A: a risk factor for subsequent fetal death. Petraglia F, et al. **Am J Obstet Gynecol** 1999 Jan;180(1 Pt 1):194–7

Intrafollicular content of luteinizing hormone receptor, alpha-inhibin, and aromatase in relation to follicular growth, estrous cycle stage, and oocyte competence for in vitro maturation in the mare. Goudet G, et al. **Biol Reprod** 1999 May;60(5):1120–7

Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A. Koseki T, et al. **Cell Signal** 1998 Jul;10(7):517–21

Inhibins: paracrine and endocrine effects in female reproductive function. Petraglia F, et al. **Curr Opin Obstet Gynecol** 1999 Jun;11(3):241–7 (53 ref.)

Interference with brachyury function inhibits convergent extension, causes apoptosis, and reveals separate requirements in the FGF and activin signalling pathways. Conlon FL, et al. **Dev Biol** 1999 Sep 1;213(1):85–100

Time course of ion channel development in Xenopus muscle induced in vitro by activin. Currie DA, et al. **Dev Biol** 1999 May 1;209(1):40–51

Control of digit formation by activin signalling. Merino R, et al. **Development** 1999 May;126(10):2161–70

Activin and inhibin binding to the soluble extracellular domain of activin receptor II. Donaldson CJ, et al. **Endocrinology** 1999 Apr;140(4):1760–6

Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocyte growth and function. Franzén A, et al. **Endocrinology** 1999 Sep;140(9):4300–10

Identification of high affinity binding sites for inhibin on ovine pituitary cells in culture [see comments] Hertan R, et al. **Endocrinology** 1999 Jan;140(1):6–12. Comment in: Endocrinology 1999 Jan;140(1):3–5.

Differential localization of inhibin subunit proteins in the ovine testis during fetal gonadal development. Jarred RA, et al. **Endocrinology** 1999 Feb;140(2):979–86

Hope, hypothesis, and the inhibin receptor. Does specific inhibin binding suggest there is a specific inhibin receptor? [editorial; comment] Woodruff TK. **Endocrinology** 1999 Jan;140(1):3–5 (16 ref.). Comment on: Endocrinology 1999 Jan;140(1):6–12.

Inhibins, activins and follistatins: a review of complex regulators of the reproductive system. Renier MA, et al. **Eur J Contracept Reprod Health Care** 1998 Sep;3(3):129–35 (49 ref.)

Amniotic fluid concentrations of dimeric inhibins, activin A and follistatin in pregnancy. Muttukrishna S, et al. **Eur J Endocrinol** 1999 May;140(5):420–4

Drosophila dSmad2 and Atr-1 transmit activin/TGFbeta signals. Das P, et al. **Genes Cells** 1999 Feb;4(2):123–34

Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle. Florio P, et al. **Hum Reprod** 1998 Sep;13(9):2606–11

Immunolocalization of inhibin and activin subunits in human endometrium across the menstrual cycle. Leung PH, et al. **Hum Reprod** 1998 Dec;13(12):3469–77

Inhibin A, inhibin B and activin A concentrations in follicular fluid from women with polycystic ovary syndrome. Magoffin DA, et al. **Hum Reprod** 1998 Oct;13(10):2693–8

Follistatin and activin A in extra-embryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Riley SC, et al. **Hum Reprod** 1998 Sep;13(9):2624–8

Follicular fluid immunoreactive-inhibin concentrations in relation to follicular diameter and estradiol-17 beta, progesterone and testosterone concentrations in individual ovarian follicles in buffalo, Bubalus bubalis. Palta P, et al. **Indian J Exp Biol** 1998 Aug;36(8):768–74

Follicle-stimulating hormone and testosterone stimulation of immature and mature Sertoli cells in vitro: inhibin and N-cadherin levels and round spermatid binding. Lampa J, et al. **J Androl** 1999 May–Jun;20(3):399–406

Activin/follistatin and atherosclerosis--a review. Kozaki K, et al. **J Atheroscler Thromb** 1998;5(1):36–40 (41 ref.)

Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors. Wuytens G, et al. **J Biol Chem** 1999 Apr 2;274(14):9821–7

Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. Piek E, et al. **J Cell Physiol** 1999 Aug;180(2):141–9

Both inhibin A and B respond to exogenous follicle-stimulating hormone in the follicular phase of the human menstrual cycle. Burger HG, et al. **J Clin Endocrinol Metab** 1998 Nov;83(11):4167–9

Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development. Welt CK, et al. **J Clin Endocrinol Metab** 1999 Jun;84(6):2163–9

The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. Munro LM, et al. **J Endocrinol** 1999 May;161(2):341–7

Inhibin and reproductive aging in women. Soules MR, et al. **Maturitas** 1998 Oct 12;30(2):193–204 (16 ref.)

Protein kinase A is involved in the induction of early mesodermal marker genes by activin. Joore J, et al. **Mech Dev** 1998 Dec;79(1–2):5–15

Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Iczkowski KA, et al. **Mod Pathol** 1998 Aug;11(8):774–9

PHARMACOLOGY

Differentially expressed genes in activin-induced apoptotic LNCaP cells. Lin S, et al. **Biochem Biophys Res Commun** 1999 Apr 2;257(1):187–92

Activin A and follistatin regulate developmental competence of In vitro-produced bovine embryos. Yoshioka K, et al. **Biol Reprod** 1998 Nov;59(5):1017–22

Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. Huber TL, et al. **Blood** 1998 Dec 1;92(11):4128–37

Local administration of activin promotes fracture healing in the rat fibula fracture model. Sakai R, et al. **Bone** 1999 Aug;25(2):191–6

Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Nüsing RM, et al. **Br J Pharmacol** 1999 Jun;127(4):919–26

Regulation of hypothalamic somatostatin and growth hormone releasing hormone mRNA levels by inhibin. Carro E, et al. **Brain Res Mol Brain Res** 1999 Mar 20; 66(1–2):191–4

The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Hashimoto O, et al. **Cell Signal** 1998 Nov;10(10):743–9

Activin A and follistatin influence expression of somatostatin in the ciliary ganglion in vivo. Darland DC, et al. **Dev Biol** 1998 Oct 15;202(2):293–303

Regulation of avian cardiac myogenesis by activin/TGFbeta and bone morphogenetic proteins. Ladd AN, et al. **Dev Biol** 1998 Dec 15;204(2):407–19

Activin-induced factors maintain goosecoid transcription through a paired homeodomain binding site. McKendry R, et al. **Dev Biol** 1998 Dec 1;204(1):172–86

Activin and TGFbeta limit murine primordial germ cell proliferation. Richards AJ, et al. **Dev Biol** 1999 Mar 15; 207(2):470–5

Blood cell induction in Xenopus animal cap explants: effects of fibroblast growth factor, bone morphogenetic proteins, and activin. Miyanaga Y, et al. **Dev Genes Evol** 1999 Feb; 209(2):69–76

Endoderm differentiation and inductive effect of activin-treated ectoderm in Xenopus. Ninomiya H, et al. **Dev Growth Differ** 1999 Aug;41(4):391–400

Cytochalasin B inhibits morphogenetic movement and muscle differentiation of activin-treated ectoderm in Xenopus. Tamai K, et al. **Dev Growth Differ** 1999 Feb;41(1):41–9

Involvement of Smad proteins in the differentiation of pancreatic AR42J cells induced by activin A. Zhang YQ, et al. **Diabetologia** 1999 Jun;42(6):719–27

Is gonadotrope expression of the gonadotropin releasing hormone receptor gene mediated by autocrine/paracrine stimulation of an activin response element? Duval DL, et al. **Endocrinology** 1999 Apr;140(4):1949–52

A comparative study on transforming growth factor-beta and activin A for preantral follicles from adult, immature, and diethylstilbestrol-primed immature mice. Liu X, et al. **Endocrinology** 1999 Jun;140(6):2480–5

Activin A and TGF-beta stimulate phosphorylation of focal adhesion proteins and cytoskeletal reorganization in rat aortic smooth muscle cells. Riedy MC, et al. **Exp Cell Res** 1999 Aug 25;251(1):194–202

Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Alak BM, et al. **Fertil Steril** 1998 Dec;70(6):1126–30

Growth of HPV-18 immortalized human prostatic intraepithelial neoplasia cell lines. Influence of IL-10, follistatin, activin-A, and DHT. Wang M, et al. **Int J Oncol** 1999 Jun;14(6):1185–95

Regulation of gonadotrophin secretion by inhibin, testosterone and gonadotrophin-releasing hormone in pituitary cell cultures of male monkeys. Fingscheidt U, et al. **J Endocrinol** 1998 Oct;159(1):103–10

Effects of activin on hormone secretion by single female rat pituitary cells: analysis by cell immunoblot assay. Miyamoto S, et al. **J Endocrinol** 1999 Jun;161(3):375–82

Changes in the suppressive effects of recombinant inhibin A on FSH secretion in ram lambs during sexual maturation: evidence for alterations in the clearance rate of inhibin. Tilbrook AJ, et al. **J Endocrinol** 1999 May;161(2):219–29

Seasonal changes in the negative feedback regulation of the secretion of the gonadotrophins by testosterone and inhibin in rams. Tilbrook AJ, et al. **J Endocrinol** 1999 Jan; 160(1):155–67

Inhibitory action of the gonadopeptide inhibin on amphibian (Rana pipiens) steroidogenesis and oocyte maturation. Lin YW, et al. **J Exp Zool** 1999 Jul 1;284(2):232–40

Activin A regulates the production of mature interleukin-1beta and interleukin-1 receptor antagonist in human monocytic cells. Ohguchi M, et al. **J Interferon Cytokine Res** 1998 Jul;18(7):491–8

Activin A induces terminal differentiation of cultured human keratinocytes. Seishima M, et al. **J Invest Dermatol** 1999 Apr;112(4):432–6

Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2. Russell CE, et al. **Mol Cell Endocrinol** 1999 Feb 25;148(1–2):129–36

Activin co-operates with fibroblast growth factor 2 to regulate tyrosine hydroxylase expression in the basal forebrain ventricular zone progenitors. Daadi M, et al. **Neuroscience** 1998 Oct;86(3):867–80

PHYSIOLOGY

Effect of long-term immunization against inhibin on sperm output in bulls. Bame JH, et al. **Biol Reprod** 1999 Jun; 60(6):1360–6

Secretion of ovarian inhibin and its physiologic roles in the regulation of follicle-stimulating hormone secretion during the estrous cycle of the female guinea pig. Shi F, et al. **Biol Reprod** 1999 Jan;60(1):78–84

Expression of the activin axis and neuronal rescue effects of recombinant activin A following hypoxic-ischemic brain injury in the infant rat. Wu DD, et al. **Brain Res** 1999 Jul 24;835(2):369–78

Cells' perception of position in a concentration gradient. Gurdon JB, et al. **Cell** 1998 Oct 16;95(2):159–62 (21 ref.)

Expression and function of activin beta A during mouse cardiac cushion tissue formation. Moore CS, et al. **Dev Dyn** 1998 Aug;212(4):548–62

Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): regulation by cell surface follistatin. Delbaere A, et al. **Endocrinology** 1999 Jun;140(6):2463–70

Activin from secondary follicles causes small preantral follicles to remain dormant at the resting stage. Mizunuma H, et al. **Endocrinology** 1999 Jan;140(1):37–42

Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation. Takabe K, et al. **Endocrinology** 1999 Jul;

140(7):3125–32
Activin: an endocrine or paracrine agent? [comment] Welt CK, et al. **Eur J Endocrinol** 1998 Nov;139(5):469–71. Comment on: Eur J Endocrinol 1998 Nov;139(5):487–92.
Activin: a novel player in tissue repair processes. Hübner G, et al. **Histol Histopathol** 1999 Jan;14(1):295–304 (61 ref.)
Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin A, oestradiol, or inhibin B? Lahlou N, et al. **Hum Reprod** 1999 May;14(5):1190–3
Inhibins and activins in human ovulation, conception and pregnancy. Lockwood GM, et al. **Hum Reprod Update** 1998 May–Jun;4(3):284–95 (111 ref.)
Effects of hepatocyte growth factor (HGF) and activin A on the morphogenesis of rat submandibular gland-derived epithelial cells in serum-free collagen gel culture. Furue M, et al. **In Vitro Cell Dev Biol Anim** 1999 Mar;35(3):131–5
Role of activin and other peptide growth factors in body patterning in the early amphibian embryo. Asashima M, et al. **Int Rev Cytol** 1999;191:1–52 (171 ref.)
The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis. Yeo CY, et al. **J Biol Chem** 1999 Sep 10;274(37):26584–90
Activin A and follistatin: their role in the acute phase reaction and inflammation. de Kretser DM, et al. **J Endocrinol** 1999 May;161(2):195–8 (29 ref.)
Novel cardiovascular actions of the activins. Molloy CJ, et al. **J Endocrinol** 1999 May;161(2):179–85 (52 ref.)
A novel role of activin in inflammation and repair. Munz B, et al. **J Endocrinol** 1999 May;161(2):187–93 (34 ref.)
Active immunization with a synthetic fragment of pig inhibin alpha-subunit increases ovulation rate and embryo production in superovulated ewes but season affects its efficiency. D'Alessandro A, et al. **J Reprod Fertil** 1999 Jan; 115(1):185–91
Effect of immunization against the amino-terminal peptide (alpha N) of the alpha 43-subunit of inhibin on follicular atresia and expression of tissue inhibitor of matrix metalloproteinase (TIMP-1) in ovarian follicles of sheep. Dhar A, et al. **J Reprod Fertil** 1998 Sep;114(1):147–55
Mechanisms of protein feedback on gonadotropin secretion. de Kretser DM, et al. **J Reprod Immunol** 1998 Aug; 39(1–2):1–12 (65 ref.)
Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells. Wang Q, et al. **J Urol** 1999 Apr;161(4):1378–84
Cell survival effect of activin against heat shock stress on OVCAR3. Fukuda J, et al. **Life Sci** 1998;63(25):2209–20
Defective whisker follicles and altered brainstem patterns in activin and follistatin knockout mice. Jhaveri S, et al. **Mol Cell Neurosci** 1998 Nov;12(4–5):206–19
Inhibin suppresses in vivo growth hormone secretion. Carro E, et al. **Neuroendocrinology** 1998 Nov;68(5):293–6
A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Shimizu K, et al. **Proc Natl Acad Sci U S A** 1999 Jun 8;96(12):6791–6
Activin as a morphogen in Xenopus mesoderm induction. McDowell N, et al. **Semin Cell Dev Biol** 1999 Jun; 10(3):311–7 (39 ref.)

SECRETION

Inhibin secretion in the mare: localization of inhibin alpha, betaA, and betaB subunits in the ovary. Nagamine N, et al. **Biol Reprod** 1998 Dec;59(6):1392–8
Secretion of ovarian inhibin and its physiologic roles in the regulation of follicle-stimulating hormone secretion during the estrous cycle of the female guinea pig. Shi F, et al. **Biol Reprod** 1999 Jan;60(1):78–84
Hormonal regulation of inhibin B secretion by immature rat sertoli cells in vitro: possible use as a bioassay for estrogen detection. Depuydt CE, et al. **J Androl** 1999 Jan–Feb; 20(1):54–62
Follicle-stimulating hormone-inhibin B interactions during the follicular phase of the primate menstrual cycle revealed by gonadotropin-releasing hormone antagonist and antiestrogen treatment. Fraser HM, et al. **J Clin Endocrinol Metab** 1999 Apr;84(4):1365–9
Female reproductive aging is marked by decreased secretion of dimeric inhibin. Welt CK, et al. **J Clin Endocrinol Metab** 1999 Jan;84(1):105–11

THERAPEUTIC USE

Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Hughes PE, et al. **Neuroscience** 1999;92(1):197–209

INHIBITION (PSYCHOLOGY)

Inhibitory motor control in stop paradigms: review and reinterpretation of neural mechanisms. Band GP, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):179–211 (104 ref.)
Goal neglect and inhibitory limitations: dissociable causes of interference effects in conflict situations. De Jong R, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):379–94
Facilitatory and inhibitory effects of masked prime stimuli on motor activation and behavioural performance. Eimer M. **Acta Psychol (Amst)** 1999 Apr;101(2–3):293–313
ERP components in Go/Nogo tasks and their relation to inhibition. Falkenstein M, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):267–91
Cortico-spinal inhibition reflects time but not event preparation: neural mechanisms of preparation dissociated by transcranial magnetic stimulation. Hasbroucq T, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):243–66
Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Knight RT, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):159–78 (115 ref.)
Varieties of inhibition: manifestations in cognition, event-related potentials and aging. Kok A. **Acta Psychol (Amst)** 1999 Apr;101(2–3):129–58 (138 ref.)
Task coordination and aging: explorations of executive control processes in the task switching paradigm. Kramer AF, et al. **Acta Psychol (Amst)** 1999 Apr;101(2–3):339–78
Inhibition, disclosure, and health: don't simply slash the Gordian knot. Traue HC, et al. **Adv Mind Body Med** 1999 Summer;15(3):184–93
Impasse or pseudo-impasse in the psychotherapy of an inhibited writer. Burnstein LJ, et al. **Am J Psychother** 1999 Winter;53(1):74–81
Anger inhibition, cardiovascular recovery, and vagal function: a model of the link between hostility and cardiovascular disease. Brosschot JF, et al. **Ann Behav Med** 1998 Fall;20(4):326–32
Neuroelectric mapping reveals precursor of stop failures in children with attention deficits. Brandeis D, et al. **Behav Brain Res** 1998 Jul;94(1):111–25
Response inhibition and response re-engagement in attention-deficit/hyperactivity disorder, disruptive, anxious and normal children. Oosterlaan J, et al. **Behav Brain Res** 1998 Jul;94(1):33–43
Inhibitory dysfunction in hyperactive boys. Rubia K, et al. **Behav Brain Res** 1998 Jul;94(1):25–32
The role of interval underestimation in hyperactive children's failure to suppress responses over time. Sonuga-Barke EJ, et al. **Behav Brain Res** 1998 Jul;94(1):45–50
Immobility responses in Lurcher mutant mice. Lalonde R. **Behav Genet** 1998 Jul;28(4):309–14
Stress enhances excitatory trace eyeblink conditioning and opposes acquisition of inhibitory conditioning. Beylin AV, et al. **Behav Neurosci** 1998 Dec;112(6):1327–38
Effects of isolation rearing on startle reactivity, habituation, and prepulse inhibition in male Lewis, Sprague-Dawley, and Fischer F344 rats. Varty GB, et al. **Behav Neurosci** 1998 Dec;112(6):1450–7
Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Gouzoulis-Mayfrank E, et al. **Behav Pharmacol** 1998 Nov; 9(7):561–6
Effects of single oral administrations of haloperidol and d-amphetamine on prepulse inhibition of the acoustic startle reflex in healthy male volunteers. Kumari V, et al. **Behav Pharmacol** 1998 Nov;9(7):567–76
Psychopharmacology of latent inhibition: a neural network approach. Schmajuk NA, et al. **Behav Pharmacol** 1998 Dec; 9(8):711–30
Psychopathological correlates of self-reported behavioural inhibition in normal children. Muris P, et al. **Behav Res Ther** 1999 Jun;37(6):575–84
Thought-action fusion as a causal factor in the development of intrusions. Rassin E, et al. **Behav Res Ther** 1999 Mar; 37(3):231–7
Enhanced visual latent inhibition in obsessive-compulsive disorder. Swerdlow NR, et al. **Biol Psychiatry** 1999 Feb 15;45(4):482–8
Socially inhibited individuals show heightened DTH response during intense social engagement. Cole SW, et al. **Brain Behav Immun** 1999 Jun;13(2):187–200
Individual and developmental differences in disengagement of fixation in early infancy. Frick JE, et al. **Child Dev** 1999 May–Jun;70(3):537–48
Longitudinal and concurrent relations among temperament, ability estimation, and injury proneness. Schwebel DC, et al. **Child Dev** 1999 May–Jun;70(3):700–12
School failure in early adolescence: the psychopathological risk. Masi G, et al. **Child Psychiatry Hum Dev** 1998 Winter; 29(2):127–40
Inhibition of the expression of conditioned cardiac responses in the developing rat. Hunt PS, et al. **Dev Psychobiol** 1998 Nov;33(3):221–33
Prenatal stress suppresses rat pup ultrasonic vocalization and myoclonic twitching in response to separation. Morgan KN, et al. **Dev Psychobiol** 1999 Apr;34(3):205–15
Mother-infant affect synchrony as an antecedent of the emergence of self-control. Feldman R, et al. **Dev Psychol** 1999 Jan;35(1):223–31
Development of inhibitory control across the life span. Williams BR, et al. **Dev Psychol** 1999 Jan;35(1):205–13
Alcohol and disinhibition. Källmén H, et al. **Eur Addict Res** 1998 Dec;4(4):150–62 (176 ref.)
An alcohol model of impaired inhibitory control and its treatment in humans. Fillmore MT, et al. **Exp Clin Psychopharmacol** 1999 Feb;7(1):49–55
Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: implications for a neurodevelopmental animal model of schizophrenia. Shalev U, et al. **Int J Dev Neurosci** 1998 Jun–Jul;16(3–4):279–88
Success and failure in the measurement of restraint: notes and data. van Strien T. **Int J Eat Disord** 1999 May; 25(4):441–9
Programming or inhibiting action: evidence for differential autonomic nervous system response patterns. Collet C, et al. **Int J Psychophysiol** 1999 Jun;32(3):261–76
The NoGo-anteriorization as a neurophysiological standard-index for cognitive response control. Fallgatter AJ, et al. **Int J Psychophysiol** 1999 Jun;32(3):233–8
Linking self-reported childhood behavioral inhibition to adolescent social phobia. Hayward C, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Dec; 37(12):1308–16
Behavioral inhibition in children from families at high risk for developing alcoholism [see comments] Hill SY, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Apr;38(4):410–7 . Comment in: J Am Acad Child Adolesc Psychiatry 1999 Apr;38(4):417–20.
Associations between event-related potentials and measures of attention and inhibition in the Continuous Performance Task in children with ADHD and normal controls. Overtoom CC, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Sep;37(9):977–85
Adolescent social anxiety as an outcome of inhibited temperament in childhood. Schwartz CE, et al. **J Am Acad Child Adolesc Psychiatry** 1999 Aug; 38(8):1008–15
Behavioral inhibition and developmental risk [comment] Weinberg NZ. **J Am Acad Child Adolesc Psychiatry** 1999 Apr;38(4):417–20. Comment on: J Am Acad Child Adolesc Psychiatry 1999 Apr;38(4):410–7.
Disentangling disinhibition. Wilens TE, et al. **J Am Acad Child Adolesc Psychiatry** 1998 Nov; 37(11):1225–7
Mathematics anxiety and working memory: support for the existence of a deficient inhibition mechanism. Hopko DR, et al. **J Anxiety Disord** 1998 Jul–Aug;12(4):343–55
The dominance of behavioural activation over behavioural inhibition in conduct disordered boys with or without attention deficit hyperactivity disorder. Matthys W, et al. **J Child Psychol Psychiatry** 1998 Jul;39(5):643–51
The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD. van der Meere J, et al. **J Child Psychol Psychiatry** 1999 Feb;40(2):291–8
Analysis of error types in the trial making test evidences an inhibitory deficit in dementia of the Alzheimer type. Amieva H, et al. **J Clin Exp Neuropsychol** 1998 Apr; 20(2):280–5
Blocking a selective association in pigeons [published erratum appears in J Exp Anal Behav 1999 Jul;72(1):138] Weiss SJ, et al. **J Exp Anal Behav** 1999 Jan;71(1):13–24
The effects of misleading and inconsistent postevent information on children's recollections of criterion-learned information. Lee K, et al. **J Exp Child Psychol** 1999 Jul; 73(3):161–82
Exploratory studies of inhibitory conditioning in honeybees (Apis mellifera). Couvillon PA, et al. **J Exp Psychol Anim Behav Process** 1999 Jan;25(1):103–12
Comparator mechanisms and conditioned inhibition: conditioned stimulus preexposure disrupts Pavlovian conditioned inhibition but not explicitly unpaired inhibition. Friedman BX, et al. **J Exp Psychol Anim Behav Process** 1998 Oct;24(4):453–66
Latent inhibition and perceptual learning in a swimming-pool navigation task. Prados J, et al. **J Exp Psychol Anim Behav Process** 1999 Jan;25(1):37–44
Inhibition of return to successively stimulated locations in a sequential visual search paradigm. Danziger S, et al. **J Exp Psychol Hum Percept Perform** 1998 Oct; 24(5):1467–75
Symbolic distance between numerosity and identity modulates Stroop interference. Pavese A, et al. **J Exp Psychol Hum Percept Perform** 1998 Oct; 24(5):1535–45
Inhibition of return in discrimination tasks. Pratt J, et al. **J Exp Psychol Hum Percept Perform** 1999 Feb;25(1):229–42
Attentional control during visual search: the effect of irrelevant singletons. Theeuwes J, et al. **J Exp Psychol Hum Percept Perform** 1998 Oct; 24(5):1342–53
Brain activation and pupil response during covert performance of the Stroop Color Word task. Brown GG, et al. **J Int Neuropsychol Soc** 1999 May;5(4):308–19
Timing and force control during a sequential tapping task in children with and without motor coordination problems. Piek JP, et al. **J Int Neuropsychol Soc** 1999 May;5(4):320–9
A computer controlled analysis of freezing behaviour. Richmond MA, et al. **J Neurosci Methods** 1998 Dec 31; 86(1):91–9
Enhancement of latent inhibition in the rat at a high dose of clozapine. Trimble KM, et al. **J Psychopharmacol** 1998; 12(2):215–9
Cognitive functioning and the inhibition of alcohol-induced aggression. Hoaken PN, et al. **J Stud Alcohol** 1998 Sep; 59(5):599–607
The time-course of negative priming: little evidence for episodic trace retrieval. Conway AR. **Mem Cognit** 1999 Jul;27(4):575–83
The antisaccade: a review of basic research and clinical studies. Everling S, et al. **Neuropsychologia** 1998 Sep; 36(9):885–99 (133 ref.)
The absent mind: further investigations of sustained attention to response. Manly T, et al. **Neuropsychologia** 1999 Jun; 37(6):661–70
Quantitative modeling of visual attention processes in patients with Parkinson's disease: effects of stimulus integrality on

selective attention and dimensional integration. Filoteo JV, et al. **Neuropsychology** 1999 Apr;13(2):206–22
Spatial and semantic inhibitory processing in schizophrenia. Fuentes LJ, et al. **Neuropsychology** 1999 Apr;13(2):259–70
Inhibition and habituation: preserved mechanisms of attentional selection in aging and Alzheimer's disease. Langley LK, et al. **Neuropsychology** 1998 Jul;12(3):353–66
The hypothetical pathogenetic role of inhibition of pleasure and muscular tension in uterine fibroma. Ruggieri V, et al. **Percept Mot Skills** 1998 Dec;87(3 Pt 2):1455–62
Examining the effect of practice on inhibition of return in static displays. Pratt J, et al. **Percept Psychophys** 1999 May; 61(4):756–65
Inhibition of return to color: a replication and nonextension of Law, Pratt, and Abrams (1995) [comment] Taylor TL, et al. **Percept Psychophys** 1998 Nov;60(8):1452–5; discussion 1455–6. Comment on: Percept Psychophys 1995 Apr;57(3):402–8.
Scene-based and object-centered inhibition of return: evidence for dual orienting mechanisms. Tipper SP, et al. **Percept Psychophys** 1999 Jan;61(1):50–60
Isolation rearing enhances acquisition in a conditioned inhibition paradigm. Harmer CJ, et al. **Physiol Behav** 1998 Dec 1;65(3):525–33
Right hemispheric dominance of inhibitory control: an event-related functional MRI study. Garavan H, et al. **Proc Natl Acad Sci U S A** 1999 Jul 6;96(14):8301–6
Production and perception of "verbosity" in younger and older adults. James LE, et al. **Psychol Aging** 1998 Sep; 13(3):355–67
Attentional capture and aging: implications for visual search performance and oculomotor control. Kramer AF, et al. **Psychol Aging** 1999 Mar;14(1):135–54
Inhibition in the processing of garden-path sentences. May CP, et al. **Psychol Aging** 1999 Jun;14(2):304–13
Does competition enhance or inhibit motor performance: a meta-analysis. Stanne MB, et al. **Psychol Bull** 1999 Jan; 125(1):133–54
Scales for teachers' assessment of inhibition and security seeking in kindergarten children. Koomen HM, et al. **Psychol Rep** 1999 Jun;84(3 Pt 1):767–72
Knowing in the context of acting: the task dynamics of the A-not-B error. Smith LB, et al. **Psychol Rev** 1999 Apr; 106(2):235–60
Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Grauer SM, et al. **Psychopharmacology (Berl)** 1999 Feb;141(4):405–12
Involvement of the medial geniculate body in prepulse inhibition of acoustic startle. Zhang J, et al. **Psychopharmacology (Berl)** 1999 Jan;141(2):189–96
The effects of cueing target location and response mode on interference and negative priming using a visual selection paradigm. Richards A. **Q J Exp Psychol A** 1999 May; 52(2):449–63
Semantic similarity and immediate serial recall: is there a detrimental effect on order information? Saint-Aubin J, et al. **Q J Exp Psychol A** 1999 May;52(2):367–94
Retrospective revaluation and inhibitory associations: does perceptual learning modulate our perception of the contingencies between events? Graham S. **Q J Exp Psychol B** 1999 May;52(2):159–85
Antisaccade task performance in questionnaire-identified schizotypes. Gooding DC. **Schizophr Res** 1999 Jan 11; 35(2):157–66
[Effects of antidepressants on symptoms, of inhibition] de Carvalho W. **Encephale** 1998 Sep-Oct;24(5):456–61 (7 ref.) **(Fre)**

INHIBITION, NEURAL see **NEURAL INHIBITION**

INHIBITORY CONCENTRATION 50

see related
MICROBIAL SENSITIVITY TESTS

INIA see **DOLPHINS**

INIIDAE see **DOLPHINS**

INITIATOR CODON see **CODON, INITIATOR**

INJECTIONS

Contamination susceptibility of three needleless and one standard needle injection systems. Ho AM, et al. **Can J Anaesth** 1999 Mar;46(3):290–3
Reasons of dropout from short- and long-term self-injection therapy for impotence. de la Taille A, et al. **Eur Urol** 1999 Apr;35(4):312–7
Is there a future for spermatid injections? Vanderzwalmen P, et al. **Hum Reprod** 1998 Dec;13 Suppl 4:71–84 (48 ref.)
From the Centers for Disease Control and Prevention. Frequency of vaccine-related and therapeutic injections--Romania, 1998. **JAMA** 1999 Jun 2; 281(21):1981–2
Eradication efforts need needle-free delivery [news] Voelker R. **JAMA** 1999 May 26;281(20):1879–81
Frequency of vaccine-related and therapeutic injections--Romania, 1998. **MMWR Morb Mortal Wkly Rep** 1999 Apr 9;48(13):271–4
Injectable tissue-engineered cartilage using a fibrin glue polymer. Silverman RP, et al. **Plast Reconstr Surg** 1999 Jun;103(7):1809–18
Injections and self-help: risk and trust in Ugandan health care. Birungi H. **Soc Sci Med** 1998 Nov;47(10):1455–62
[Manufacturing of cidofovir for intravitreal injections in cytomegalovirus retinitis (letter; comment)] Mucci M. **Rev Med Suisse Romande** 1998 Sep;118(9):819–20. Comment on: Rev Med Suisse Romande 1998 Mar;118(3):263–5. **(Fre)**
[Quality in compliance and prescription of nursing treatment orders for injectable drugs] de León R, et al. **Aten Primaria** 1998 Oct 31;22(7):411–6 (Eng. Abstr.) **(Spa)**
[Amnioinfusion or not during labor? Better documentation and more trials can answer the question] Wallin G. **Lakartidningen** 1999 Mar 3;96(9):1017–9 (30 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Major complications of percutaneous embolization of skull-base tumors. Casasco A, et al. **AJNR Am J Neuroradiol** 1999 Jan;20(1):179–81
The effects of EMLA and a topical formulation of 4% amethocaine (Ametop) on pain associated with retrobulbar injection. Browne J, et al. **Anaesthesia** 1999 Jun;54(6):596–8
Strict temperature control has no effect on injection pain with propofol [letter] Uda R, et al. **Anesthesiology** 1999 Aug;91(2):591–2
Intraorbital needle fragment: a rare complication of retrobulbar injection. Lam SC, et al. **Arch Ophthalmol** 1999 Aug;117(8):1089–90
Painful pricks [letter; comment] Paul Y. **Indian Pediatr** 1998 Apr;35(4):379–81. Comment on: Indian Pediatr 1997 Dec;34(12):1140.
Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. Hutin YJ, et al. **Int J Epidemiol** 1999 Aug;28(4):782–6
Systemic effects and side effects of interstitial techniques used in liver tissue. Brunken C, et al. **J Am Coll Surg** 1999 Jun; 188(6):636–42
Scleral perforation during retrobulbar and peribulbar anesthesia: risk factors and outcome in 50,000 consecutive injections. Edge R, et al. **J Cataract Refract Surg** 1999 Sep; 25(9):1237–44
Ocular explosion during cataract surgery: a clinical, histopathological, experimental, and biophysical study. Bullock JD, et al. **Trans Am Ophthalmol Soc** 1998; 96:243–76; discussion 276–81
[Because of one too many injection...] Olivetti L, et al. **Radiol Med (Torino)** 1998 Nov;96(5):539–41 **(Ita)**

INSTRUMENTATION

Clinical response and patient acceptance of a prefilled, disposable insulin pen injector for insulin-treated diabetes. Chen HS, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1999 Jul;62(7):455–60
An inexpensive infusion cannula for injection of tumescent mixtures for liposuction [letter] Rangaswamy M. **Plast Reconstr Surg** 1999 Jun;103(7):2090–1

METHODS

Biopersistence and durability of nine mineral fibre types in rat lungs over 12 months. Searl A, et al. **Ann Occup Hyg** 1999 Apr;43(3):143–53
Is endoscopic paravascular injection of sclerosing agents reasonable in the control of GI bleeding? Tatemichi M, et al. **Gastrointest Endosc** 1999 Oct;50(4):499–505
Anaphylaxis and epinephrine auto-injector training: who will teach the teachers? Grouhi M, et al. **J Allergy Clin Immunol** 1999 Jul;104(1):190–3
CT-guided sacroiliac joint injections. Pulisetti D, et al. **J Spinal Disord** 1999 Aug;12(4):310–2
Comparison of transurethral versus periurethral collagen injection in women with intrinsic sphincter deficiency. Faerber GJ, et al. **Tech Urol** 1998 Sep;4(3):124–7
[Treatment of CMV retinitis with intravitreal foscarnet] Cochereau I, et al. **J Fr Ophtalmol** 1998 Dec;21(10):723–6 (Eng. Abstr.) **(Fre)**
[Experience in preparing injection solutions in the pharmacy of a military hospital] Chirkov AI, et al. **Voen Med Zh** 1999 May;320(5):73–4 **(Rus)**

PSYCHOLOGY

Exposure to disgust-evoking imagery and information processing biases in blood-injection-injury phobia. Sawchuk CN, et al. **Behav Res Ther** 1999 Mar;37(3):249–57

STANDARDS

Challenging traditional insulin injection practices. Fleming DR. **Am J Nurs** 1999 Feb;99(2):72–4
Shake, rattle, or roll? [letter] Mulryan K. **Am J Nurs** 1999 Jul;99(7):14–6

UTILIZATION

High frequency of therapeutic injections, Republic of Moldova. **Wkly Epidemiol Rec** 1999 Mar 19;74(11):84–6 **(Eng, Fre)**

INJECTIONS, EPIDURAL

see related
ANESTHESIA, EPIDURAL

The epidural potato! [letter] Tuckey J. **Anaesthesia** 1998 Dec; 53(12):1232
A clinical diagnosis of inadvertent epidural administration of potassium chloride. Peduto VA, et al. **Eur J Anaesthesiol** 1999 Jun;16(6):410–2
Outcomes after single injection caudal epidural versus continuous infusion epidural via caudal approach for postoperative analgesia in infants and children undergoing patent ductus arteriosus ligation. Lin YC, et al. **Paediatr Anaesth** 1999;9(2):139–43

ADVERSE EFFECTS

Epidural and subarachnoidal pneumocephalus after epidural technique. Mateo E, et al. **Eur J Anaesthesiol** 1999 Jun; 16(6):413–7
Pneumocephalus following inadvertent intrathecal puncture during epidural anesthesia: a case report and review of the literature. Sherer DM, et al. **J Matern Fetal Med** 1999 May-Jun;8(3):138–40 (16 ref.)
Mycobacterium fortuitum meningitis associated with an epidural catheter: case report and a review of the literature. Madaras-Kelly KJ, et al. **Pharmacotherapy** 1999 May; 19(5):661–6 (26 ref.)
Cervical epidural steroid injection with intrinsic spinal cord damage [letter; comment] Manchikanti L. **Spine** 1999 Jun 1;24(11):1170–2. Comment on: Spine 1998 Oct 1;23(19):2137–42; discussion 2141–2.
Iatrogenic Mycobacterium infection after an epidural injection. O'Brien DP, et al. **Spine** 1999 Jun 15; 24(12):1257–9

METHODS

Epidural/perineural injection [letter; comment] Aprill CN. **Eur Spine J** 1999;8(1):81–2. Comment on: Eur Spine J 1997;6(5):357–61.

INJECTIONS, INTRA-ARTICULAR

ADVERSE EFFECTS

Paraspinal abscess following facet joint injection. Cook NJ, et al. **Clin Rheumatol** 1999;18(1):52–3
[Embolia cutis medicamentosa (Nicolau syndrome) after intra-articular injection] Beissert S, et al. **Hautarzt** 1999 Mar;50(3):214–6 (Eng. Abstr.) **(Ger)**

INJECTIONS, INTRADERMAL

METHODS

Practice tips. Intracutaneous sterile water injections for low back pain during labour. Reynolds JL. **Can Fam Physician** 1998 Nov;44:2391–2
Administration of the BCG vaccination using the multipuncture method in schoolchildren: a comparison with the intradermal method. Al Jarad N, et al. **Thorax** 1999 Sep;54(9):762–4

INJECTIONS, INTRALESIONAL

Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. Boucher Y, et al. **Br J Cancer** 1998 Dec;78(11):1442–8
[Is therapy with local filtration at primary care clinics feasible? (letter)] Fernández-Hita A, et al. **Aten Primaria** 1999 Jun 30;24(2):117–8 **(Spa)**
[Infiltration of soft parts: indications and risks (letter; comment)] Sanz Rodrigo C, et al. **Aten Primaria** 1999 Jun 30;24(2):118–9. Comment on: Aten Primaria 1999 Jan;23(1):4–7. **(Spa)**

INSTRUMENTATION

Prognosis of small hepatocellular carcinoma after laparoscopic ethanol injection. Kawamoto C, et al. **Gastrointest Endosc** 1999 Aug;50(2):214–20

METHODS

Successful infiltration of the flexor tendon sheath. Vanderhooft E, et al. **Am J Orthop** 1999 May;28(5):298–300
Rigid endoscopy for monitoring indirect vocal fold injection. Ford CN, et al. **Laryngoscope** 1998 Oct;108(10):1584–6
Echolaparoscopic-guided alcohol injection of liver metastases. Incarbone R, et al. **Surg Laparosc Endosc** 1998 Oct;8(5):390–2
[Femoral head osteonecrosis: original extra-articular cementoplasty technique. A series of 20 cases] Bresler F, et al. **Acta Orthop Belg** 1999;65 Suppl 1:95–6 **(Fre)**
[Treatment of hip necrosis by sequestrectomy and replacement with bone cement] Hernigou P. **Acta Orthop Belg** 1999;65 Suppl 1:89–94 **(Fre)**

INJECTIONS, INTRAMUSCULAR

ADVERSE EFFECTS

Globe perforation during botulinum toxin injection [letter]

INJECTIONS, INTRAMUSCULAR

Mohan M, et al. **Br J Ophthalmol** 1999 Apr;83(4):503–4
Gas gangrene following intramuscular injection of vitamin B–complex. Chaudhry R, et al. **Indian J Pathol Microbiol** 1998 Jul;41(3):357–9
Two cases of gigantic dystrophic calcinosis cutis caused by subcutaneous and/or intramuscular injections. Kanda A, et al. **J Dermatol** 1999 Jun;26(6):371–4
Bilateral gluteal dystrophic calcification—a case report. Yang CC, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1999 Jan;15(1):56–61
Abscess related to anabolic–androgenic steroid injection. Rich JD, et al. **Med Sci Sports Exerc** 1999 Feb;31(2):207–9
Rat ultrasound model for measuring pain resulting from intramuscularly injected antimicrobials. Dinh HK, et al. **PDA J Pharm Sci Technol** 1999 Jan–Feb;53(1):40–3
Potential infections related to anabolic steroid injection in young adolescents [letter] Dickinson BP, et al. **Pediatrics** 1999 Mar;103(3):694
IMpact–RSV Study Group report [letter] Zempsky WT, et al. **Pediatrics** 1999 Oct;104(4 Pt 1):993–4; discussion 995
[Intramuscular injections in Sub–saharan African children, apropos of a frequently misunderstood pathology: the complications related to intramuscular quinine injections] Barennes H. **Bull Soc Pathol Exot** 1999 Feb;92(1):33–7 (43 ref.) (Eng. Abstr.) **(Fre)**
[Abscess formation after intra–gluteal injection. Series: legal cases from praxis no 5: defective injections] Cyran W. **Fortschr Med** 1999 Apr 20;117(11):48–9 **(Ger)**
[The clinical picture, diagnosis and treatment of postinjection cicatricial contractures of the mandible] Semkin VA, et al. **Stomatologiia (Mosk)** 1998;77(5):30–1 (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Needle length and injection technique for efficient intramuscular vaccine delivery. Aggarwal A. **Indian Pediatr** 1998 Apr;35(4):389–91
Needles for immunizations: select the right tool for the job. Grabenstein JD. **J Am Pharm Assoc (Wash)** 1998 Nov–Dec; 38(6):774

METHODS

Practice tip. Minimising the pain of injections. Beavis M. **Aust Fam Physician** 1999 Mar;28(3):273
Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Carruthers A, et al. **Dermatol Surg** 1998 Nov;24(11):1189–94 (11 ref.)
Electromyographic guidance in injecting botulinum toxin. Klein AW, et al. **Dermatol Surg** 1998 Nov;24(11):1184–6 (10 ref.)

INJECTIONS, INTRASPINAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRATHECAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRAVENOUS

ADVERSE EFFECTS

Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil [letter] Paraná R, et al. **Am J Gastroenterol** 1999 Mar;94(3):857–8
Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double–blinded study. Ambesh SP, et al. **Anesth Analg** 1999 Jul;89(1):197–9
Automatic autoinjectors hazard: penetration through bone [letter] Amitai Y, et al. **Ann Pharmacother** 1999 Jun; 33(6):751–2
Injection pain with propofol: the effectiveness of thiopentone on induction. Cheng KI, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1998 Aug; 14(8):480–5
Efficacy of parental application of eutectic mixture of local anesthetics for intravenous insertion. Koh JL, et al. **Pediatrics** 1999 Jun;103(6):e79
Tumescent liposuction and median nerve compression [letter] Young KB, et al. **Plast Reconstr Surg** 1999 Apr; 103(5):1533–4
Air embolism after intravenous injection of contrast material. Ie SR, et al. **South Med J** 1999 Sep;92(9):930–3
[Venous access in oncology] Lesimple T, et al. **Presse Med** 1998 Oct 31;27(33):1694–701 (30 ref.) (Eng. Abstr.) **(Fre)**
[Early and late treatment of iatrogenic injection damage] von Heimburg D, et al. **Chirurg** 1998 Dec;69(12):1378–82 (Eng. Abstr.) **(Ger)**
[Drug injection method risky for transmission of blood–borne diseases: are we careful enough?] Bravo Portela MJ, et al. **Rev Esp Salud Publica** 1998 Jul–Aug;72(4):289–301 (63 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Potential for cross–contamination from use of a needleless injector. Weintraub AM, et al. **Am J Infect Control** 1998 Aug;26(4):442–5
Automatic autoinjectors hazard: penetration through bone [letter] Amitai Y, et al. **Ann Pharmacother** 1999 Jun; 33(6):751–2
An automated injection system (with patient selection) for SPECT imaging in seizure localization. Sepkuty JP, et al. **Epilepsia** 1998 Dec;39(12):1350–6

METHODS

Prospective randomized study for an injection protocol for intravenous contrast media in abdominal and pelvic helical CT. Gocke P, et al. **Acta Radiol** 1999 Sep;40(5):515–20
Design of optimal two–sample bolus injection tests for measuring low plasma clearance rates. Thomaseth K. **Comput Methods Programs Biomed** 1999 Feb;58(2):147–58
Percutaneous intravenous injection in neonatal mice. Sands MS, et al. **Lab Anim Sci** 1999 Jun;49(3):328–30
Successful treatment of red–back spider bite using a Bier's block technique [letter] Fatovich DM, et al. **Med J Aust** 1999 Apr 5;170(7):342–3

INJECTIONS, JET

Painless intravenous catheterization by intradermal jet injection of lidocaine: a randomized trial. Zsigmond EK, et al. **J Clin Anesth** 1999 Mar;11(2):87–94
Eradication efforts need needle–free delivery [news] Voelker R. **JAMA** 1999 May 26;281(20):1879–81

ADVERSE EFFECTS

Can jet–injector devices transmit pathogens? **J Occup Environ Med** 1999 Jul;41(7):533–4

INSTRUMENTATION

Fluid mechanics analysis of a spring–loaded jet injector. Baker AB, et al. **IEEE Trans Biomed Eng** 1999 Feb; 46(2):235–42
Subcutaneous administration of midazolam: a comparison of the Bioject jet injector with the conventional syringe and needle. Bennett J, et al. **J Oral Maxillofac Surg** 1998 Nov; 56(11):1249–54

INJECTIONS, SCLEROSING see **SCLEROSING SOLUTIONS**

INJECTIONS, SPINAL

see related
ANESTHESIA, EPIDURAL
ANESTHESIA, SPINAL

The neurotoxicity of drugs given intrathecally (spinal). Hodgson PS, et al. **Anesth Analg** 1999 Apr;88(4):797–809 (83 ref.)
Illicit substance abuse via an implanted intrathecal pump. Burton AW, et al. **Anesthesiology** 1998 Nov;89(5):1264–7
Practical issues when using neuraxial infusion. Krames ES. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):37–44 (28 ref.)

ADVERSE EFFECTS

A sheep model for continuous intrathecal infusion of test substances. Hassenbusch SJ, et al. **Hum Exp Toxicol** 1999 Feb;18(2):82–7
Effects of epidural steroids on lumbar dura material properties. Slucky AV, et al. **J Spinal Disord** 1999 Aug; 12(4):331–40
Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics [letter] Lo SK, et al. **Lancet** 1999 Jun 12;353(9169):2038–9
Complications of neuraxial infusion in cancer patients. Du Pen S. **Oncology (Huntingt)** 1999 May;13(5 Suppl 2):45–51

INSTRUMENTATION

Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Gilmer–Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):12–5 (39 ref.)
Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Gilmer–Hill HS, et al. **Surg Neurol** 1999 Jan;51(1):6–11

METHODS

A sheep model for continuous intrathecal infusion of test substances. Hassenbusch SJ, et al. **Hum Exp Toxicol** 1999 Feb;18(2):82–7
The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection. Cruaud O, et al. **Int J Pharm** 1999 Jan 25;177(2):247–57

INJECTIONS, SUBCUTANEOUS

ADVERSE EFFECTS

Two cases of gigantic dystrophic calcinosis cutis caused by subcutaneous and/or intramuscular injections. Kanda A, et al. **J Dermatol** 1999 Jun;26(6):371–4

INSTRUMENTATION

Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Lteif AN, et al. **Diabetes Care** 1999 Jan;22(1):137–40

METHODS

Cutis/subcutis thickness at insulin injection sites and localization of simulated insulin boluses in children with type 1 diabetes mellitus: need for individualization of injection technique? Birkebaek NH, et al. **Diabet Med** 1998 Nov;15(11):965–71
Subcutaneous infusion or hypodermoclysis: a practical approach. Ferry M, et al. **J Am Geriatr Soc** 1999 Jan; 47(1):93–5 (29 ref.)
The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. Rubin JP, et al. **Plast Reconstr Surg** 1999 Mar;103(3):990–6; discussion 997–1002

STANDARDS

Shake, rattle, or roll? [letter] Springs MH. **Am J Nurs** 1999 Jul;99(7):14–6

INJURIES see **WOUNDS AND INJURIES**

INJURIES, MULTIPLE see **MULTIPLE TRAUMA**

INJURIES, NONPENETRATING see **WOUNDS, NONPENETRATING**

INJURY SEVERITY SCORE

APACHE II and ISS scores as predictors of nosocomial infections in trauma patients. Hurr H, et al. **Am J Infect Control** 1999 Apr;27(2):79–83
Organ injury scaling system can be used to predict length of stay in patients with penetrating neck injuries. Atta HM. **Am Surg** 1999 Jun;65(6):575–7
Severity of upper limb injuries in snowboarding. Sasaki K, et al. **Arch Orthop Trauma Surg** 1999;119(5–6):292–5
Development and validation of the injury severity assessment survey/parent report: a new injury severity assessment survey. Durbin DR, et al. **Arch Pediatr Adolesc Med** 1999 Apr;153(4):404–8
Adult splenic injuries: treatment patterns and predictive indicators. Sanders MN, et al. **Aust N Z J Surg** 1999 Jun; 69(6):430–2
Employment of trauma and injury severity score and a severity characterization of trauma in the outcome evaluation of trauma care and their research advances. Zhu P, et al. **Chin Med J (Engl)** 1998 Feb;111(2):169–73 (22 ref.)
The Pediatric Risk of Mortality (PRISM) Score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Castello FV, et al. **Crit Care Med** 1999 May;27(5):985–8
Measures of injury severity in childhood: a critical overview. Beattie TF, et al. **Inj Prev** 1998 Sep;4(3):228–31 (26 ref.)
The hand injury severity scoring system and workers' compensation cases in Wisconsin, USA. van der Molen AB, et al. **J Hand Surg [Br]** 1999 Apr;24(2):184–6
Organ injuries associated with femoral fractures: implications for severity of injury in motor vehicle collisions. Adili A, et al. **J Trauma** 1999 Mar;46(3):386–91
Comparison of alternative methods for assessing injury severity based on anatomic descriptors. Sacco WJ, et al. **J Trauma** 1999 Sep;47(3):441–6; discussion 446–7
Evaluation of skiing injuries by Injury Severity Score. Bergstrøm KA, et al. **Scand J Med Sci Sports** 1999 Apr; 9(2):110–3
Recognizing, scoring, and predicting blast injuries. Cernak I, et al. **World J Surg** 1999 Jan;23(1):44–53
[How to describe and evaluate the clinical gravity of a head injury in order to define a therapeutic strategy at a given moment?] **Ann Fr Anesth Reanim** 1999 Jan;18(1):27–35 (29 ref.) **(Fre)**

INK

Occupational dermatitis to ultraviolet–cured acrylic–based inks in computer hard disc manufacturing. Skotnicki S, et al. **Am J Contact Dermat** 1998 Sep;9(3):179–81

INLAY CASTING WAX

DIAGNOSTIC USE

Using orthodontic wax to create a diagnostic cast. Brooks SA Sr. **J Am Dent Assoc** 1999 May;130(5):743

INLAYS

A 5–year clinical evaluation of ceramic inlays (Cerec) cemented with a dual–cured or chemically cured resin composite luting agent. Sjögren G, et al. **Acta Odontol Scand** 1998 Oct;56(5):263–7
A milled ceramic inlay/onlay system: a report from a series of cases. Shearer AC, et al. **Br Dent J** 1998 Sep 26; 185(6):283–6
In–office inlays with today's new materials. Abel MG. **Dent Clin North Am** 1998 Oct;42(4):657–64
In–vitro study of fracture strength and marginal adaptation of fibre–reinforced adhesive fixed partial inlay dentures. Behr M, et al. **J Dent** 1999 Feb;27(2):163–8
Survival rate of ceramic inlays. Fuzzi M, et al. **J Dent** 1998 Sep;26(7):623–6
IPS Empress inlays and onlays after four years—a clinical study. Krämer N, et al. **J Dent** 1999 Jul;27(5):325–31
Marginal leakage in class II–restorations after use of ceramic–inserts luted with different materials. Hahn P, et al. **J Oral Rehabil** 1998 Aug;25(8):567–74

Effects of post-curing by heat on the mechanical properties of visible-light cured inlay composites. Khan AM, et al. **J Oral Rehabil** 1993 Nov;20(6):605-14

Influence of polymerization initiator for base monomer on microwave curing of composite resin inlays. Urabe H, et al. **J Oral Rehabil** 1999 May;26(5):442-6

Amalgam alternatives-microleakage evaluation of clinical procedures. Part II: direct/indirect composite inlay systems. Ziskind D, et al. **J Oral Rehabil** 1998 Jul; 25(7):502-6

Fracture resistance of teeth restored with onlays of three contemporary tooth-colored resin-bonded restorative materials. Brunton PA, et al. **J Prosthet Dent** 1999 Aug; 82(2):167-71

One-year clinical evaluation of composite and ceramic inlays in posterior teeth. Scheibenbogen A, et al. **J Prosthet Dent** 1998 Oct;80(4):410-6

METHODS

Cuspal deflection during polymerisation of composite lutes of ceramic inlays. Martin N, et al. **J Dent** 1999 Jan; 27(1):29-36

The management of endodontically treated teeth using a Computer-Aided Design and Computer-Assisted Manufacturing/Computer-Aided Design and Computer-Integrated Manufacturing system. Foerster JG, et al. **Mil Med** 1999 Jan;164(1):37-40 (21 ref.)

[Resin-bonded inlay bridges made of glass-fiber-reinforced composites. A step-by-step description of their clinical use] Göhring TN, et al. **Schweiz Monatsschr Zahnmed** 1999; 109(4):368-84 **(Ger, Fre)**

STANDARDS

[In vivo and in vitro study of the marginal sealing in ceramic-covered gold inlays] Kaán B, et al. **Fogorv Sz** 1998 Dec;91(12):363-73 (Eng. Abstr.) **(Hun)**

INNATE BEHAVIOR see **INSTINCT**

INNOMINATE ARTERY see **BRACHIOCEPHALIC TRUNK**

INNOMINATE VEINS see **BRACHIOCEPHALIC VEINS**

INNOVATION DIFFUSION see **DIFFUSION OF INNOVATION**

INOCULATION LYMPHORETICULOSIS see **CAT-SCRATCH DISEASE**

INORGANIC CARBON COMPOUNDS see **CARBON COMPOUNDS, INORGANIC**

INORGANIC CHEMICALS

[Methods for assay of antibacterial activity of inorganic antibacterial agents] Feng N, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1998 Sep;32(5):315-6 (16 ref.) **(Chi)**

CHEMISTRY

Pharmacological applications of inorganic complexes. Bakhtiar R, et al. **Gen Pharmacol** 1999 May;32(5):525-40 (93 ref.)

METABOLISM

Modulation of chloride, potassium and bicarbonate transport by muscarinic receptors in a human adenocarcinoma cell line. Holliday ND, et al. **Br J Pharmacol** 1999 Jan; 126(1):269-79

PHARMACOKINETICS

Formal analysis of electrogenic sodium, potassium, chloride and bicarbonate transport in mouse colon epithelium. Cuthbert AW, et al. **Br J Pharmacol** 1999 Jan;126(1):358-64

PHARMACOLOGY

Pharmacological applications of inorganic complexes. Bakhtiar R, et al. **Gen Pharmacol** 1999 May;32(5):525-40 (93 ref.)

TOXICITY

[The atomic volumes of chemical elements as indices of their acute toxicity] Sidorenko GI, et al. **Gig Sanit** 1999 Mar-Apr;(2):50-1 **(Rus)**

INORGANIC CHEMISTRY see **CHEMISTRY, INORGANIC**

INOSINATE PHOSPHATASE see **5'-NUCLEOTIDASE**

INOSINE

Long RNA hairpins that contain inosine are present in Caenorhabditis elegans poly(A)+ RNA. Morse DP, et al. **Proc Natl Acad Sci U S A** 1999 May 25;96(11):6048-53

[The construction and use of inosine-containing primers for searching for and identifying the genes of insecticidal crystal proteins in Bacillus thuringiensis] Rymar' SE, et al. **Tsitol Genet** 1999 Mar-Apr;33(2):74-8 (Eng. Abstr.) **(Rus)**

ANALOGS & DERIVATIVES

Lipase-catalyzed protection of the hydroxy groups of the nucleosides inosine and 2'-deoxyinosine: a new chemoenzymatic synthesis of the antiviral drug 2',3'-dideoxyinosine. Ciuffreda P, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1577-82

Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies. Becker HF, et al. **RNA** 1999 Jul;5(7):865-75

BLOOD

Can oxypurines plasma levels classify the type of physical exercise? Bianchi GP, et al. **J Sports Med Phys Fitness** 1999 Jun;39(2):123-7

CHEMISTRY

FTIR and UV spectroscopy of parallel-stranded DNAs with mixed A*T/G*C sequences and their A*T/I*C analogues. Mohammadi S, et al. **Biochemistry** 1998 Nov 24; 37(47):16529-37

Lipase-catalyzed protection of the hydroxy groups of the nucleosides inosine and 2'-deoxyinosine: a new chemoenzymatic synthesis of the antiviral drug 2',3'-dideoxyinosine. Ciuffreda P, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1577-82

Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies. Becker HF, et al. **RNA** 1999 Jul;5(7):865-75

GENETICS

Editing of messenger RNA precursors and of tRNAs by adenosine to inosine conversion. Keller W, et al. **FEBS Lett** 1999 Jun 4;452(1-2):71-6 (44 ref.)

METABOLISM

Cardiac endothelial transport and metabolism of adenosine and inosine. Schwartz LM, et al. **Am J Physiol** 1999 Sep; 277(3 Pt 2):H1241-51

Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Pröpsting MJ, et al. **Biochem Biophys Res Commun** 1999 Jul 5;260(2):313-7

Enhanced accumulation of pericardial fluid adenosine and inosine in patients with coronary artery disease. Fazekas L, et al. **Life Sci** 1999;65(10):1005-12

PHARMACOLOGY

Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Litsky ML, et al. **Brain Res** 1999 Mar 13; 821(2):426-32

PHYSIOLOGY

TIT for TAT: the properties of inosine and adenosine in TATA box DNA. Pastor N, et al. **J Biomol Struct Dyn** 1999 Feb;16(4):787-810

THERAPEUTIC USE

A novel, biodegradable polymer conduit delivers neurotrophins and promotes nerve regeneration. Hadlock T, et al. **Laryngoscope** 1999 Sep;109(9):1412-6

INOSINE MONOPHOSPHATE

CHEMISTRY

The binding of inosine monophosphate to Escherichia coli carbamoyl phosphate synthetase. Thoden JB, et al. **J Biol Chem** 1999 Aug 6;274(32):22502-7

Interaction of Et2SnCl2 with 5'-IMP and 5'-GMP. Yang Z, et al. **J Inorg Biochem** 1998 Dec;72(3-4):133-40

METABOLISM

Muscle IMP accumulation during fatiguing submaximal exercise in endurance trained and untrained men. Baldwin J, et al. **Am J Physiol** 1999 Jul;277(1 Pt 2):R295-300

Photoaffinity labeling with the activator IMP and site-directed mutagenesis of histidine 995 of carbamoyl phosphate synthetase from Escherichia coli demonstrate that the binding site for IMP overlaps with that for the inhibitor UMP. Bueso J, et al. **Biochemistry** 1999 Mar 30; 38(13):3910-7

Sex difference in plasma ammonia but not in muscle inosine monophosphate accumulation following sprint exercise in humans. Esbjörnsson-Liljedahl M, et al. **Eur J Appl Physiol** 1999 Apr;79(5):404-8

Activity of IMP- and AMP-preferring isoforms of 5'-nucleotidase from human seminal plasma with AMP analogues. Minelli A, et al. **Mol Genet Metab** 1999 Jan; 66(1):49-55

PHARMACOLOGY

Product activation of human erythrocyte AMP deaminase. Mosharov EV, et al. **FEBS Lett** 1998 Nov 27;440(1-2):64-6

INOSINE PHOSPHORYLASE see **PURINE-NUCLEOSIDE PHOSPHORYLASE**

INOSINE POLYNUCLEOTIDES see **POLY I**

INOSINE PRANOBEX

THERAPEUTIC USE

Isoprinosine does not protect against frequent respiratory tract infections in childhood. Litzman J, et al. **Eur J Pediatr** 1999 Jan;158(1):32-7

Beta-interferon plus inosiplex in the treatment of subacute sclerosing panencephalitis. Anlar B, et al. **J Child Neurol** 1998 Nov;13(11):557-9

Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. Gokcil Z, et al. **J Neurol Sci** 1999 Jan 1;162(1):62-4

INOSINE TRIPHOSPHATE

PHARMACOLOGY

Inositol 1,4,5-trisphosphate-sensitive Ca2+ stores in rat supraoptic neurons: involvement in histamine-induced enhancement of depolarizing afterpotentials. Li Z, et al. **Neuroscience** 1999;93(2):667-74

PHYSIOLOGY

Radial localization of inositol 1,4,5-trisphosphate-sensitive Ca2+ release sites in Xenopus oocytes resolved by axial confocal linescan imaging. Callamaras N, et al. **J Gen Physiol** 1999 Feb;113(2):199-213

INOSINIC ACID see **INOSINE MONOPHOSPHATE**

INOSINIC ACID DEHYDROGENASE see **IMP DEHYDROGENASE**

INOSIPLEX see **INOSINE PRANOBEX**

INOSITOL

ANALOGS & DERIVATIVES

Myo-inositol hexasulfate is a potent inhibitor of Aspergillus ficuum phytase. Ullah AH, et al. **Biochem Biophys Res Commun** 1998 Oct 9;251(1):260-3

Derivatives of 1,3,5-triamino-1,3,5-trideoxy-cis-inositol as versatile pentadentate ligands for protein labeling with Re-186/188. prelabeling, biodistribution, and X-ray structural studies. Kramer A, et al. **Bioconjug Chem** 1998 Nov-Dec;9(6):691-702

Synthesis and evaluation of glucocerebrosidase inhibitory activity of anhydro deoxyinositols from (+)-epi- and (-)-vibo-quercitols. Ogawa S, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1493-8

Substrate specificity of 2-deoxy-scyllo-inosose synthase, the starter enzyme for 2-deoxystreptamine biosynthesis, toward deoxyglucose-6-phosphates and proposed mechanism. Iwase N, et al. **Biosci Biotechnol Biochem** 1998 Dec;62(12):2396-407

Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor [letter] Hayakawa T, et al. **Diabetes Care** 1999 Feb;22(2):366-7

Lack of kinetic interaction between digoxin and voglibose [letter] Kusumoto M, et al. **Eur J Clin Pharmacol** 1999 Mar;55(1):79-80

Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. Ishida H, et al. **Horm Metab Res** 1998 Nov;30(11):673-8

A synthetic, nitrogenated antimetastatic and anti-angiogenic compound with low toxicity in vivo. Cerutti ML, et al. **Int J Oncol** 1999 Mar;14(3):585-91

Three diabetic cases of acute dizziness due to initial administration of voglibose. Bando Y, et al. **Intern Med** 1998 Sep;37(9):753-6

Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. Nestler JE. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):197-204

Effect of an alpha-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients. Saito N, et al. **J Int Med Res** 1998 Oct-Nov;26(5):219-32

A functional myo-inositol catabolism pathway is essential for rhizopine utilization by Sinorhizobium meliloti. Galbraith MP, et al. **Microbiology** 1998 Oct;144 (Pt 10):2915-24

A model for the catabolism of rhizopine in Rhizobium leguminosarum involves a ferredoxin oxygenase complex and the inositol degradative pathway. Bahar M, et al. **Mol Plant Microbe Interact** 1998 Nov;11(11):1057-68

Effects of fluorinated inositols on the phosphoinositide metabolism and the proliferation of Trypanosoma cruzi. Einicker-Lamas M, et al. **Parasitol Res** 1999 Mar; 85(3):232-8

ANALYSIS

Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol. Novak JE, et al. **J Neurochem** 1999 Apr;72(4):1431-40

[Synthesis of inositol-containing glycophospholipids] Stepanov AE, et al. **Bioorg Khim** 1998 Oct;24(10):731-46 (77 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

In vivo brain myo-inositol levels in children with Down syndrome. Berry GT, et al. **J Pediatr** 1999 Jul;135(1):94-7

CHEMICAL SYNTHESIS

Synthesis and evaluation of glucocerebrosidase inhibitory activity of anhydro deoxyinositols from (+)-epi- and (-)-vibo-quercitols. Ogawa S, et al. **Bioorg Med Chem Lett** 1999 Jun 7;9(11):1493-8

METABOLISM

Nuclear inositol signaling: a structural and functional approach. York JD, et al. **Adv Enzyme Regul** 1998; 38:365-74

Sodium-dependent uptake of [3H]scyllo-inositol by Tetrahymena: incorporation into phosphatidylinositol, phosphatidylinositol-linked glycans, and polyphosphoinositols. Ryals PE, et al. **Arch Biochem Biophys** 1999 Jun 15;366(2):261-6

Inositol acylation of glycosylphosphatidylinositols in the pathogenic fungus Cryptococcus neoformans and the model yeast Saccharomyces cerevisiae. Franzot SP, et al. **Biochem J** 1999 May 15;340 (Pt 1):25-32

Opposing effects of tumour necrosis factor alpha and hyperosmolarity on Na+/myo-inositol co-transporter mRNA levels and myo-inositol accumulation by 3T3-L1 adipocytes. Yorek MA, et al. **Biochem J** 1998 Dec 1;336 (Pt 2):317-25

Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia. Yorek MA, et al. **Biochim Biophys Acta** 1999 Mar 25; 1437(3):287-300

Inositol levels are decreased in postmortem brain of schizophrenic patients. Shimon H, et al. **Biol Psychiatry** 1998 Sep 15;44(6):428-32

Mechanisms of osmolyte release. Kinne RK. **Contrib Nephrol** 1998;123:34-49 (78 ref.)

Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils. Suzuki K, et al. **Diabet Med** 1999 Jan; 16(1):67-73

The role of inositol 1,4,5-trisphosphate 5-phosphatase in inositol signaling in the CNS of larval Manduca sexta. Qazi S, et al. **Insect Biochem Mol Biol** 1999 Feb;29(2):161-75

The role of phosphatases in inositol signaling reactions. Majerus PW, et al. **J Biol Chem** 1999 Apr 16; 274(16):10669-72 (57 ref.)

Effect of dibutyryl cyclic AMP on the kinetics of myo-inositol transport in cultured astrocytes. Isaacks RE, et al. **J Neurochem** 1999 Jul;73(1):105-11

Correlation between cognitive status and cerebral inositol in Alzheimer-type dementia [letter] Salvan AM, et al. **J Neurol** 1998 Oct;245(10):686-8

Effect of osmolality and anion channel inhibitors on myo-inositol efflux in cultured astrocytes. Isaacks RE, et al. **J Neurosci Res** 1999 Sep 15;57(6):866-71

Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. Frey R, et al. **J Psychiatr Res** 1998 Nov-Dec;32(6):411-20

Tyrosine kinase inhibitors and immunosuppressants perturb the myo-inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells. Atta MG, et al. **Kidney Int** 1999 Mar;55(3):956-62

Osmotic regulation of the Na+/myo-inositol cotransporter and postinduction normalization. Yorek MA, et al. **Kidney Int** 1999 Jan;55(1):215-24

Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt-Jakob disease. Behar KL, et al. **Magn Reson Imaging** 1998 Oct; 16(8):963-8

Effects of gender and region on proton MRS of normal human brain. Komoroski RA, et al. **Magn Reson Imaging** 1999 Apr;17(3):427-33

Reproducibility of 1H-MRS in vivo. Brooks WM, et al. **Magn Reson Med** 1999 Jan;41(1):193-7

A functional myo-inositol catabolism pathway is essential for rhizopine utilization by Sinorhizobium meliloti. Galbraith MP, et al. **Microbiology** 1998 Oct;144 (Pt 10):2915-24

Pleiotropic effects of the opi1 regulatory mutation of yeast: its effects on growth and on phospholipid and inositol metabolism. Jiranek V, et al. **Microbiology** 1998 Oct;144 (Pt 10):2739-48

Pleiotropic alterations in lipid metabolism in yeast sac1 mutants: relationship to "bypass Sec14p" and inositol auxotrophy. Rivas MP, et al. **Mol Biol Cell** 1999 Jul; 10(7):2235-50

A model for the catabolism of rhizopine in Rhizobium leguminosarum involves a ferredoxin oxygenase complex and the inositol degradative pathway. Bahar M, et al. **Mol Plant Microbe Interact** 1998 Nov;11(11):1057-68

Response to hypertonicity in mesothelial cells: role of Na+/myo-inositol co-transporter. Matsuoka Y, et al. **Nephrol Dial Transplant** 1999 May;14(5):1217-23

Effect of ammonia and methionine sulfoximine on myo-inositol transport in cultured astrocytes. Isaacks RE, et al. **Neurochem Res** 1999 Jan;24(1):51-9

Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Lubrich B, et al. **Neuropsychopharmacology** 1999 Oct; 21(4):519-29

The yeast inositol-sensitive upstream activating sequence, UASINO, responds to nitrogen availability. Griac P, et al. **Nucleic Acids Res** 1999 May 1;27(9):2043-50

Expression of aldose reductase, sorbitol dehydrogenase and Na+/myo-inositol and Na+/Cl-/betaine transporter mRNAs in individual cells of the kidney during changes in the diuretic state. Burger-Kentischer A, et al. **Pflugers Arch** 1999 Jan;437(2):248-54

[Effects of repeated nicotine uptake on brain inositol levels] Wang H, et al. **Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih** 1997 Feb; 13(1):68-70 (Eng. Abstr.) **(Chi)**

[State of the pulmonary surfactant system and myo-inositol content in biological substrates] Kovalenko LV, et al. **Fiziol Cheloveka** 1998 Sep-Oct;24(5):16-20 **(Rus)**

PHARMACOKINETICS

Effects of fluorinated inositols on the phosphoinositide metabolism and the proliferation of Trypanosoma cruzi. Einicker-Lamas M, et al. **Parasitol Res** 1999 Mar; 85(3):232-8

PHARMACOLOGY

Decreases in Raf-1 levels in galactosaemic lens epithelial cells are partially reversed by myo-inositol. Takemoto DJ. **Acta Diabetol** 1998 Oct;35(3):145-9

Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Jyonouchi H, et al. **Carcinogenesis** 1999 Jan;20(1):139-45

The effects of lithium on vascular development in the chick area vasculosa. Giles JJ, et al. **J Anat** 1999 Feb;194 (Pt 2):197-205

Acute myo-inositol enhances swimming activity in goldfish (short communication). Levine J, et al. **J Neural Transm** 1999;106(5-6):433-41

Using amino-cerv after cervical LEEP. Gimpelson RJ, et al. **J Reprod Med** 1999 Mar;44(3):275-8

Effect of inositol treatment on the behavior of rhesus monkeys: preliminary results. Einat H, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1998 Aug; 22(6):999-1005

Inositol reduces depressive-like behaviors in two different animal models of depression. Einat H, et al. **Psychopharmacology (Berl)** 1999 May;144(2):158-62

Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats. Kofman O, et al. **Psychopharmacology (Berl)** 1998 Oct;139(3):239-42

THERAPEUTIC USE

Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Levine J, et al. **Biol Psychiatry** 1999 Feb 1;45(3):270-3

Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Witschi H, et al. **Carcinogenesis** 1999 Jul; 20(7):1375-8

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. Nestler JE, et al. **N Engl J Med** 1999 Apr 29;340(17):1314-20

INOSITOL CYCLASE see **MYO-INOSITOL-1-PHOSPHATE SYNTHASE**

INOSITOL HEXAPHOSPHATE see **PHYTIC ACID**

INOSITOL-1-PHOSPHATE SYNTHASE see **MYO-INOSITOL-1-PHOSPHATE SYNTHASE**

INOSITOL PHOSPHATES

Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells. Wilcox RA, et al. **Methods Mol Biol** 1999;114:193-208 (26 ref.)

ADMINISTRATION & DOSAGE

Topical D-myo-inositol-1,2,6-trisphosphate and hexylbetaine treatment reduces albumin extravasation in experimental rat skin burn injury. Tarnow P, et al. **Burns** 1998 Aug;24(5):460-3

ANALYSIS

A multi-well filtration assay for quantitation of inositol phosphates in biological samples. Chengalvala M, et al. **J Biochem Biophys Methods** 1999 Feb 8;38(3):163-70

Measurement of inositol (poly)phosphate formation using [3H]inositol labeling protocols in permeabilized cells. Swigart P, et al. **Methods Mol Biol** 1999;114:165-73 (6 ref.)

BIOSYNTHESIS

Superoxide anion-induced formation of inositol phosphates involves tyrosine kinase activation in smooth muscle cells from rat mesenteric artery. Wu L, et al. **Biochem Biophys Res Commun** 1999 Jun 7;259(2):239-43

Identification and purification of diphosphoinositol pentakisphosphate kinase, which synthesizes the inositol pyrophosphate bis(diphospho)inositol tetrakisphosphate. Huang CF, et al. **Biochemistry** 1998 Oct 20; 37(42):14998-5004

PKCbetaI mediates the inhibition of P2Y receptor-induced inositol phosphate formation in endothelial cells. Chen BC, et al. **Br J Pharmacol** 1999 Aug;127(8):1908-14

Pharmacology of [3H]-pyrilamine binding and of the histamine-induced inositol phosphates generation, intracellular Ca2+ -mobilization and cytokine release from human corneal epithelial cells. Sharif NA, et al. **Br J Pharmacol** 1998 Nov;125(6):1336-44

Relationship between dopamine agonist stimulation of inositol phosphate formation and cytidine diphosphate-diacylglycerol accumulation in brain slices. Undie AS. **Brain Res** 1999 Jan 23;816(2):286-94

A tyrosine kinase signaling pathway, regulated by calcium entry and dissociated from tyrosine phosphorylation of phospholipase Cgamma-1, is involved in inositol phosphate production by activated G protein-coupled receptors in myometrium. Palmier B, et al. **J Pharmacol Exp Ther** 1999 May;289(2):1022-30

cGMP inhibition of endothelin-stimulated inositol phosphate production in the fetal lamb pulmonary artery. Millard SL, et al. **Pulm Pharmacol Ther** 1998 Apr-Jun;11(2-3):201-4

Excitatory amino acid-induced inositol phosphate formation in cultured retinal pigment epithelium. Fragoso G, et al. **Vis Neurosci** 1999 Mar-Apr;16(2):263-9

[Formation of inositol triphosphate in lymphocytes of rat spleen in the early stages after x-irradiation] Matyshevs'ka OP. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):94-100 (Eng. Abstr.) **(Ukr)**

CHEMICAL SYNTHESIS

Syntheses of D- and L-myo-inositol 1,2,4,5-tetrakisphosphate and stereoselectivity of the I(1,4,5)P3 receptor binding. Chung SK, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):659-62

Syntheses of two enantiomeric pairs of myo-inositol(1,2,4,5,6) and -(1,2,3,4,5) pentakisphosphate. Chung SK, et al. **Bioorg Med Chem Lett** 1998 Jun 16; 8(12):1503-6

Synthesis of methyl beta-D-arabinofuranoside 5-[1D (and L)-myo-inositol 1-phosphate], the capping motif of the lipoarabinomannan of Mycobacterium smegmatis. Désiré J, et al. **Carbohydr Res** 1999 Apr 30;317(1-4):110-8

Enzyme-assisted total synthesis of the optical antipodes D-myo-inositol 3,4,5-trisphosphate and D-myo-inositol 1,5, 6-trisphosphate: aspects of their structure-activity relationship to biologically active inositol phosphates. Adelt S, et al. **J Med Chem** 1999 Apr 8;42(7):1262-73

Synthesis, calcium mobilizing, and physicochemical properties of D-chiro-inositol 1,3,4,6-tetrakisphosphate, a novel and potent ligand at the D-myo-inositol 1,4,5-trisphosphate receptor. Liu C, et al. **J Med Chem** 1999 Jun 3;42(11):1991-8

CHEMISTRY

Structural and biochemical evaluation of the interaction of the phosphatidylinositol 3-kinase p85alpha Src homology 2 domains with phosphoinositides and inositol polyphosphates. Surdo PL, et al. **J Biol Chem** 1999 May 28;274(22):15678-85

ISOLATION & PURIFICATION

Novel glycoinositolphosphosphingolipids, basidiolipids, from Agaricus. Jennemann R, et al. **Eur J Biochem** 1999 Jan; 259(1-2):331-8

METABOLISM

Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists. Egan C, et al. **Ann N Y Acad Sci** 1998 Dec 15;861:136-9

Tissue-specific expression and endogenous subcellular distribution of the inositol 1,3,4,5-tetrakisphosphate-binding proteins GAP1(IP4BP) and GAP1(m). Lockyer PJ, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):421-6

Inositol hexakisphosphate in Schizosaccharomyces pombe: synthesis from Ins(1,4,5)P3 and osmotic regulation. Ongusaha PP, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):671-9

Alpha1-adrenoceptor-mediated formation of glycerophosphoinositol 4-phosphate in rat heart: possible role in the positive inotropic response. Debetto P, et al. **Biochem Pharmacol** 1999 Nov 1;58(9):1437-46

Identification of rat brain p42(IP4), a high-affinity inositol(1,3,4, 5)tetrakisphosphate/phosphatidylinositol(3,4,5) trisphosphate binding protein. Aggensteiner M, et al. **Biochim Biophys Acta** 1998 Sep 8;1387(1-2):117-28

Bridging the GAP in inositol 1,3,4,5-tetrakisphosphate signalling. Cullen PJ. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):35-47 (85 ref.)

The versatility of inositol phosphates as cellular signals. Shears SB. **Biochim Biophys Acta** 1998 Dec 8; 1436(1-2):49-67 (200 ref.)

Glycosyl phosphatidylinositol (GPI)/inositolphosphate glycan (IPG): an intracellular signalling system involved in the control of thyroid cell proliferation. Petitfrere E,

et al. **Biochimie** 1998 Dec;80(12):1063-7
Diphosphoinositol polyphosphates: the final frontier for inositide research? Safrany ST, et al. **Biol Chem** 1999 Jul-Aug;380(7-8):945-51 (59 ref.)
Syntheses of D- and L-myo-inositol 1,2,4,5-tetrakisphosphate and stereoselectivity of the I(1,4,5)P3 receptor binding. Chung SK, et al. **Bioorg Med Chem Lett** 1998 Mar 17;8(6):659-62
Potentiation of adenosine A1 receptor-mediated inositol phospholipid hydrolysis by tyrosine kinase inhibitors in CHO cells. Dickenson JM, et al. **Br J Pharmacol** 1998 Nov; 125(5):1049-57
Dissociation of intracellular Ca2+ release and Ca2+ entry response to 5-hydroxytryptamine in cultured canine tracheal smooth muscle cells. Yang CM. **Cell Signal** 1998 Nov;10(10):735-42
Inositol 1,3,4,5-tetrakisphosphate as a second messenger--a special role in neurones? Irvine RF, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):49-57 (50 ref.)
Role of synaptotagmin, a Ca2+ and inositol polyphosphate binding protein, in neurotransmitter release and neurite outgrowth. Mikoshiba K, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):59-67 (46 ref.)
Intracellular glucose switches between cyclic ADP-ribose and inositol trisphosphate triggering of cytosolic Ca2+ spiking. Cancela JM, et al. **Curr Biol** 1998 Jul 16;8(15):865-8
Overexpression of G11alpha and isoforms of phospholipase C in islet beta-cells reveals a lack of correlation between inositol phosphate accumulation and insulin secretion. Gasa R, et al. **Diabetes** 1999 May;48(5):1035-44
Recombinant p42IP4, a brain-specific 42-kDa high-affinity Ins(1,3,4,5)P4 receptor protein, specifically interacts with lipid membranes containing Ptd-Ins(3,4,5)P3. Hanck T, et al. **Eur J Biochem** 1999 Apr;261(2):577-84
Human 5-HT1B receptor stimulated inositol phospholipid hydrolysis in CHO cells: synergy with Gq-coupled receptors. Dickenson JM, et al. **Eur J Pharmacol** 1998 May 8;348(2-3):279-85
Involvement of G-protein betagamma subunits in coupling the adenosine A1 receptor to phospholipase C in transfected CHO cells. Dickenson JM, et al. **Eur J Pharmacol** 1998 Aug 14;355(1):85-93
Muscarinic cholinoceptor subtypes mediating tracheal smooth muscle contraction and inositol phosphate generation in guinea pig and rat. Preuss JM, et al. **Eur J Pharmacol** 1999 May 21;372(3):269-77
The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity. Pesesse X, et al. **FEBS Lett** 1998 Oct 23;437(3):301-3
Pyrimidinoceptor potentiation by ATP in NG108-15 cells. Sak K, et al. **FEBS Lett** 1998 Nov 13;439(1-2):107-9
Inositol polyphosphate-mediated iron transport in Pseudomonas aeruginosa. Hirst PH, et al. **J Appl Microbiol** 1999 Mar;86(3):537-43
Inositol 1,3,4-trisphosphate acts in vivo as a specific regulator of cellular signaling by inositol 3,4,5,6-tetrakisphosphate. Yang X, et al. **J Biol Chem** 1999 Jul 2;274(27):18973-80
A novel calcium sensor stimulating inositol phosphate formation and [Ca2+]i signaling expressed by GCT23 osteoclast-like cells. Seuwen K, et al. **Proc Assoc Am Physicians** 1999 Jan-Feb;111(1):70-81
Effect of BIBP3226 on inositol phosphate accumulation and cytosolic calcium level in control and NPY Y1 receptor expressing CHO-K1 cells. Vanderheyden PM, et al. **Regul Pept** 1998 Sep 25;75-76:191-9
Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate. Baraldi E, et al. **Structure** 1999 Apr 15;7(4):449-60
Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones. Beinborn M, et al. **Yale J Biol Med** 1998 May-Aug;71(3-4):337-46
[Contents of inositol phosphates and response to phenylephrine in aorta from both young and old rats] Wang S, et al. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1997 Apr; 19(2):116-9 (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

A membrane-permeant, bioactivatable derivative of Ins(1,3,4)P3 and its effect on Cl(-)-secretion from T84 cells. Rudolf MT, et al. **Bioorg Med Chem Lett** 1998 Jul 21; 8(14):1857-60

PHARMACOLOGY

Inositol phosphates with different numbers of phosphate groups influence iron absorption in humans. Sandberg AS, et al. **Am J Clin Nutr** 1999 Aug;70(2):240-6
Properties of hemoglobin and dextran-hemoglobin rightshifted by oxidized inositol tetrakisphosphate. Xue H, et al. **Artif Organs** 1992 Aug;16(4):427-31
Modulation of Ins(2,4,5)P3-stimulated Ca2+ mobilization by ins(1,3,4, 5)P4: enhancement by activated G-proteins, and evidence for the involvement of a GAP1 protein, a putative Ins(1,3,4,5)P4 receptor. Loomis-Husselbee JW, et al. **Biochem J** 1998 May 1;331 (Pt 3):947-52
Inositol polyphosphates regulate the membrane interactions of the endosomal p100, G-protein-related protein. Kassessinoff TA, et al. **Biochim Biophys Acta** 1998 Oct 2;1394(1):111-20
Effect of alpha-trinositol on interstitial fluid pressure, oedema generation and albumin extravasation in experimental frostbite in the rat. Berg A, et al. **Br J Pharmacol** 1999 Mar;126(6):1367-74
Signaling of lysophosphatidic acid-evoked chloride current: calcium release from inositol trisphosphate-sensitive store. Kakizawa K, et al. **Brain Res Mol Brain Res** 1998 Oct 30;61(1-2):232-7
Cell interactions with collagen matrices in vivo and in vitro depend on phosphatidylinositol 3-kinase and free cytoplasmic calcium. Ahlén K, et al. **Cell Adhes Commun** 1998 Sep;5(6):461-73
Acetylcholine activates intracellular movement of insulin granules in pancreatic beta-cells via inositol trisphosphate-dependent [correction of triphosphate-dependent] mobilization of intracellular Ca2+ [published erratum appears in Diabetes 1999 Jan;48(1):233] Niwa T, et al. **Diabetes** 1998 Nov; 47(11):1699-706
Growth hormone (GH)-releasing factor differentially activates cyclic adenosine 3',5'-monophosphate- and inositol phosphate-dependent pathways to stimulate GH release in two porcine somatotrope subpopulations. Ramirez JL, et al. **Endocrinology** 1999 Apr;140(4):1752-9
D-myo inositol 1,2,6, triphosphate (alpha-trinositol, pp56): selective antagonist at neuropeptide Y (NPY) Y-receptors or selective inhibitor of phosphatidylinositol cell signaling? Bell D, et al. **Gen Pharmacol** 1998 Nov;31(5):689-96 (79 ref.)
Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. Larner J, et al. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):127-37
Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. Nestler JE. **J Basic Clin Physiol Pharmacol** 1998;9(2-4):197-204
Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3'-nucleotidase inhibited by inositol 1,4-bisphosphate. Spiegelberg BD, et al. **J Biol Chem** 1999 May 7;274(19):13619-28
Inositol 1,3,4,5-tetrakisphosphate enhances long-term potentiation by regulating Ca2+ entry in rat hippocampus. Szinyei C, et al. **J Physiol (Lond)** 1999 May 1;516 (Pt 3):855-68

PHYSIOLOGY

Inositol 1,3,4-trisphosphate acts in vivo as a specific regulator of cellular signaling by inositol 3,4,5,6-tetrakisphosphate. Yang X, et al. **J Biol Chem** 1999 Jul 2;274(27):18973-80
Involvement of protein tyrosine kinase in the InsP3-induced activation of Ca2+-dependent Cl- currents in cultured cells of the rat retinal pigment epithelium. Strauss O, et al. **J Membr Biol** 1999 Jun 1;169(3):141-53
In vivo functional analysis of Drosophila Gap1: involvement of Ca2+ and IP4 regulation. Powe AC Jr, et al. **Mech Dev** 1999 Mar;81(1-2):89-101
[Roles of inositol polyphosphates in the regulation of exocytosis] Ohara-Imaizumi M, et al. **Tanpakushitsu Kakusan Koso** 1998 Sep;43(12 Suppl):1789-93 (17 ref.) **(Jpn)**

THERAPEUTIC USE

Effect of alpha-trinositol on carrageenan-induced rat paw edema and lowering of interstitial fluid pressure. Reed RK, et al. **Eur J Pharmacol** 1999 Jul 9;376(3):279-84

INOSITOL PHOSPHOGLYCERIDES see **PHOSPHATIDYLINOSITOLS**

INOSITOL 1,4,5-TRIPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

INOSITOL 1,4,5-TRISPHOSPHATE

Differential expression patterns of inositol trisphosphate receptor types 1 and 3 in the rat suprachiasmatic nucleus. Hamada T, et al. **Brain Res** 1999 Aug 14;838(1-2):131-5
Localization of type I inositol 1,4,5-triphosphate receptor in the outer segments of mammalian cones. Wang TL, et al. **J Neurosci** 1999 Jun 1;19(11):4221-8
Characterization of major phosphoproteins in the cGMP-mediated protein phosphorylation system of vascular smooth muscle membranes. Fujita S, et al. **J Vasc Res** 1999 Jul-Aug;36(4):299-310
Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells. Wilcox RA, et al. **Methods Mol Biol** 1999;114:193-208 (26 ref.)

ANALOGS & DERIVATIVES

Synthesis and evaluation of 1-position-modified inositol 1,4,5-trisphosphate analogs. Inoue T, et al. **Bioorg Med Chem Lett** 1999 Jun 21;9(12):1697-702
Determination of time-dependent inositol-1,4,5-trisphosphate concentrations during calcium release in a smooth muscle cell. Fink CC, et al. **Biophys J** 1999 Jul;77(1):617-28
Use of phosphorofluoridate analogues of D-myo-inositol 1,4,5-trisphosphate to assess the involvement of ionic interactions in its recognition by the receptor and metabolising enzymes. Yoshimura K, et al. **Cell Signal** 1999 Feb;11(2):117-25
Inositol-trisphosphate-dependent intercellular calcium signaling in and between astrocytes and endothelial cells. Leybaert L, et al. **Glia** 1998 Dec;24(4):398-407
New developments in the molecular pharmacology of the myo-inositol 1,4,5-trisphosphate receptor. Wilcox RA, et al. **Trends Pharmacol Sci** 1998 Nov;19(11):467-75 (62 ref.)

ANALYSIS

Measurement of inositol(1,4,5)trisphosphate using a stereospecific radioreceptor mass assay. Smart D. **Methods Mol Biol** 1999;114:175-83 (11 ref.)
Inositol 1,4,5-trisphosphate mass assay. Zhang L. **Methods Mol Biol** 1998;105:77-87 (13 ref.)

ANTAGONISTS & INHIBITORS

Cyclosporin A inhibits inositol 1,4,5-trisphosphate binding to its receptors and release of calcium from intracellular stores in peritoneal macrophages. Misra UK, et al. **J Immunol** 1998 Dec 1;161(11):6122-7
Intrinsic inhibitor of inositol 1,4,5-trisphosphate binding. Hirata M, et al. **Mol Cell Biochem** 1999 Jan;190(1-2):179-84

BIOSYNTHESIS

Hypoxia enhances cellular proliferation and inositol 1,4, 5-triphosphate generation in fibroblasts from bovine pulmonary artery but not from mesenteric artery. Welsh DJ, et al. **Am J Respir Crit Care Med** 1998 Dec; 158(6):1757-62
Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha1B-adrenergic receptors. Harrison SN, et al. **Circ Res** 1998 Dec 14-28;83(12):1232-40
Inhibition of inositol(1,4,5)Trisphosphate generation by endothelin-1 during postischemic reperfusion: A novel antiarrhythmic mechanism. Woodcock EA, et al. **Circulation** 1999 Feb 16;99(6):823-8
Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Novakova M, et al. **Eur J Pharmacol** 1998 Jul 24; 353(2-3):315-27
ADP, adrenaline and serotonin stimulate inositol 1,4,5-trisphosphate production in human platelets. Vanags DM, et al. **Eur J Pharmacol** 1998 Sep 25;358(1):93-100
A mammalian sperm cytosolic phospholipase C activity generates inositol trisphosphate and causes Ca2+ release in sea urchin egg homogenates. Jones KT, et al. **FEBS Lett** 1998 Oct 23;437(3):297-300
IP3 production in A10 cells, an established aortic smooth muscle cultured cell line: effects of agonist administration procedure and culture conditions. Ishibashi T, et al. **Gen Pharmacol** 1999 Jan;32(1):115-21
Bruton's tyrosine kinase activity and inositol 1,4,5-trisphosphate production are not altered in DT40 lymphoma B cells exposed to power line frequency magnetic fields. Miller SC, et al. **J Biol Chem** 1998 Dec 4;273(49):32618-26

CHEMISTRY

Simplification of adenophostin A defines a minimal structure for potent glucopyranoside-based mimics of D-myo-inositol 1,4,5-trisphosphate. Marwood RD, et al. **Bioorg Med Chem Lett** 1999 Feb 8;9(3):453-8

METABOLISM

A1 adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle. Abebe W, et al. **Am J Physiol** 1998 Nov;275(5 Pt 1):L990-7
Aging does not alter phosphoinositide hydrolysis in the rat cochlear lateral wall. Ogawa K, et al. **Auris Nasus Larynx** 1999 Jan;26(1):1-4
Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both abolished by neomycin in rabbit heart. Bauer B, et al. **Basic Res Cardiol** 1999 Feb;94(1):31-40
Aldolase A Ins(1,4,5)P3-binding domains as determined by site-directed mutagenesis. Baron CB, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):805-12
Regulation of cerebellar Ins(1,4,5)P3 receptor by interaction between Ins(1,4,5)P3 and Ca2+. Coquil JF, et al. **Biochem J** 1999 Aug 1;341 (Pt 3):697-704
Muscle-specific mRNA isoform encodes a protein composed mainly of the N-terminal 175 residues of type 2 Ins(1,4,5)P3 receptor. Futatsugi A, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):559-63
Kinetics of elementary Ca2+ puffs evoked in Xenopus oocytes by different Ins(1,4,5)P3 receptor agonists. Marchant JS, et al. **Biochem J** 1998 Sep 15;334 (Pt 3):505-9
Inositol hexakisphosphate in Schizosaccharomyces pombe: synthesis from Ins(1,4,5)P3 and osmotic regulation. Ongusaha PP, et al. **Biochem J** 1998 Nov 1;335 (Pt 3):671-9
Molecular recognition of adenophostin, a very potent Ca2+ inducer, at the D-myo-inositol 1,4,5-trisphosphate receptor. Hotoda H, et al. **Biochemistry** 1999 Jul 20; 38(29):9234-41
Phosphatidic acid increases inositol-1,4,5,-trisphosphate and [Ca2+]i levels in neonatal rat cardiomyocytes. Liu P, et al. **Biochim Biophys Acta** 1999 Aug 25;1440(1):89-99
Characterization of inositol-1,4,5-trisphosphate-gated channels in the plasma membrane of rat olfactory neurons. Lischka FW, et al. **Biophys J** 1999 Mar;76(3):1410-22

Complex relationship between Ins(1,4,5)P3 accumulation and Ca2+ -signalling in a human neuroblastoma reveled by cellular differentiation. Martin AK, et al. **Br J Pharmacol** 1999 Apr;126(7):1559-66

Inositol-1,4,5-trisphosphate accumulation induced by urinary pheromones in female rat vomeronasal epithelium. Sasaki K, et al. **Brain Res** 1999 Mar 27;823(1-2):161-8

Changes in IP3R1 and SERCA2b mRNA levels in the gerbil brain after chronic ethanol administration and transient cerebral ischemia-reperfusion. Xia J, et al. **Brain Res Mol Brain Res** 1998 May;56(1-2):22-8

Ins(1,4,5)P3 and cardiac dysfunction. Woodcock EA, et al. **Cardiovasc Res** 1998 Nov;40(2):251-6 (68 ref.)

Activation of heterologously expressed Drosophila TRPL channels: Ca2+ is not required and InsP3 is not sufficient. Hardie RC, et al. **Cell Calcium** 1998 Sep;24(3):153-63

Determination of the inositol (1,4,5) trisphosphate requirement for histamine- and substance P-induced Ca2+ mobilisation in human U373 MG astrocytoma cells. Young KW, et al. **Cell Calcium** 1998 Jul;24(1):59-70

Membrane association of a new inositol 1,4,5-trisphosphate binding protein, p130 is not dependent on the pleckstrin homology domain. Takeuchi H, et al. **Chem Phys Lipids** 1999 Apr;98(1-2):35-47

Expression and distribution of the type 1 and type 3 inositol 1,4, 5-trisphosphate receptor in developing vascular smooth muscle. Tasker PN, et al. **Circ Res** 1999 Mar 19; 84(5):536-42

Alterations in Ca2+ storage and mobilization in submandibular acinar cells of reserpine-treated rats. Martinez JR, et al. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1998 Aug;120(2):201-9

The Golgi apparatus is an inositol 1,4,5-trisphosphate-sensitive Ca2+ store, with functional properties distinct from those of the endoplasmic reticulum. Pinton P, et al. **EMBO J** 1998 Sep 15;17(18):5298-308

Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. Williams RS, et al. **EMBO J** 1999 May 17;18(10):27>-45

Magnolol induces cytosolic-free Ca2+ elevation in rat neutrophils primarily via inositol trisphosphate signalling pathway. Wang JP, et al. **Eur J Pharmacol** 1998 Jul 10; 352(2-3):329-34

Calcium release from InsP3-sensitive internal stores initiates action potential in Chara. Biskup B, et al. **FEBS Lett** 1999 Jun 18;453(1-2):72-6

Priming of human neutrophil superoxide generation by tumour necrosis factor-alpha is signalled by enhanced phosphatidylinositol 3,4,5-trisphosphate but not inositol 1,4,5-trisphosphate accumulation. Condliffe AM, et al. **FEBS Lett** 1998 Nov 13;439(1-2):147-51

The inositol (1,4,5)-trisphosphate 3-kinase of Xenopus oocyte is activated by CaMKII and involved in the regulation of InsP3-mediated Ca2+ release. Hague F, et al. **FEBS Lett** 1999 Apr 16;449(1):70-4

Relationship between inositol 1,4,5-trisphosphate receptor isoforms and subcellular Ca2+ signaling patterns in nonpigmented ciliary epithelia. Hirata K, et al. **Invest Ophthalmol Vis Sci** 1999 Aug;40(9):2046-53

Mitochondria suppress local feedback activation of inositol 1,4, 5-trisphosphate receptors by Ca2+. Hajnóczky G, et al. **J Biol Chem** 1999 May 14;274(20):14157-62

ATP regulation of type 1 inositol 1,4,5-trisphosphate receptor channel gating by allosteric tuning of Ca(2+) activation. Mak DO, et al. **J Biol Chem** 1999 Aug 6; 274(32):22231-7

The bell-shaped Ca2+ dependence of the inositol 1,4, 5-trisphosphate-induced Ca2+ release is modulated by Ca2+/calmodulin. Missiaen L, et al. **J Biol Chem** 1999 May 14;274(20):13748-51

Modulation of inositol 1,4,5-trisphosphate binding to the recombinant ligand-binding site of the type-1 inositol 1,4, 5-trisphosphate receptor by Ca2+ and calmodulin. Sipma H, et al. **J Biol Chem** 1999 Apr 23;274(17):12157-62

Trypsinized cerebellar inositol 1,4,5-trisphosphate receptor. Structural and functional coupling of cleaved ligand binding and channel domains. Yoshikawa F, et al. **J Biol Chem** 1999 Jan 1;274(1):316-27

Cooperative formation of the ligand-binding site of the inositol 1,4, 5-trisphosphate receptor by two separable domains. Yoshikawa F, et al. **J Biol Chem** 1999 Jan 1; 274(1):328-34

Inositol 1,4,5-trisphosphate receptor down-regulation is activated directly by inositol 1,4,5-trisphosphate binding. Studies with binding-defective mutant receptors. Zhu CC, et al. **J Biol Chem** 1999 Feb 5;274(6):3476-84

Synthesis, calcium mobilizing, and physicochemical properties of D-chiro-inositol 1,3,4,6-tetrakisphosphate, a novel and potent ligand at the D-myo-inositol 1,4,5-trisphosphate receptor. Liu C, et al. **J Med Chem** 1999 Jun 3;42(11):1991-8

Type I inositol 1,4,5-trisphosphate receptor knock-out mice: their phenotypes and their meaning in neuroscience and clinical practice. Matsumoto M, et al. **J Mol Med** 1999 May;77(5):406-11 (36 ref.)

Effect of chronic hypoxia on alpha-1 adrenoceptor-mediated inositol 1,4,5-trisphosphate signaling in ovine uterine artery. Hu XQ, et al. **J Pharmacol Exp Ther** 1999 Mar; 288(3):977-83

cGMP inhibits IP3-induced Ca2+ release in intact rat megakaryocytes via cGMP- and cAMP-dependent protein kinases. Tertyshnikova S, et al. **J Physiol (Lond)** 1998 Oct 1;512 (Pt 1):89-96

Local calcium signalling by inositol-1,4,5-trisphosphate in Purkinje cell dendrites. Finch EA, et al. **Nature** 1998 Dec 24-31;396(6713):753-6

Type III InsP3 receptor channel stays open in the presence of increased calcium. Hagar RE, et al. **Nature** 1998 Nov 5;396(6706):81-4

Functional interaction between InsP3 receptors and store-operated Htrp3 channels. Kiselyov K, et al. **Nature** 1998 Dec 3;396(6710):478-82

P2Y and P2U receptors differentially release intracellular Ca2+ via the phospholipase c/inositol 1,4,5-triphosphate pathway in astrocytes from the dorsal spinal cord. Idestrup CP, et al. **Neuroscience** 1998 Oct;86(3):913-23

The relationship between activation of phosphoinositide-specific phospholipase C and growth stimulation by Ca2+-mobilizing hormones in hepatocytes. Sandnes D, et al. **Pharmacol Toxicol** 1999 May;84(5):234-40

Effect of concomitant beta-adrenoceptor stimulation on alpha 1-adrenoceptor-mediated increase of inositol-1,4,5-trisphosphate mass in adult rat cardiomyocytes. Viko H, et al. **Pharmacol Toxicol** 1998 Jul;83(1):23-8

Inositol 1,4,5-trisphosphate [correction of tris-phosphate] activation of inositol trisphosphate [correction of tris-phosphate] receptor Ca2+ channel by ligand tuning of Ca2+ inhibition [published erratum appears in Proc Natl Acad Sci U S A 1999 Mar 16;96(6):3330] Mak DO, et al. **Proc Natl Acad Sci U S A** 1998 Dec 22;95(26):15821-5

Transient and sustained increases in inositol 1,4,5-trisphosphate precede the differential growth response in gravistimulated maize pulvini. Perera IY, et al. **Proc Natl Acad Sci U S A** 1999 May 11;96(10):5838-43

pHo, pHi, and PCO2 in stimulation of IP3 and [Ca2+]c in piglet cerebrovascular smooth muscle. Albuquerque ML, et al. **Proc Soc Exp Biol Med** 1998 Dec;219(3):226-34

Spatiotemporal dynamics of inositol 1,4,5-trisphosphate that underlies complex Ca2+ mobilization patterns. Hirose K, et al. **Science** 1999 May 28;284(5419):1527-30

Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Takei K, et al. **Science** 1998 Nov 27;282(5394):1705-8

[The amounts of inositol 1,4,5-triphosphate and it response to epidermal growth factor and laminin of carcinoma substrains with high or low metastatic potentials] Hu X, et al. **Chung Hua I Hsueh Tsa Chih** 1997 Sep;77(9):665-7 (Eng. Abstr.) **(Chi)**

[Alteration of inositol phosphate metabolism in aortic smooth muscle cells from spontaneously hypertensive rat] Hu SJ, et al. **Sheng Li Hsueh Pao** 1997 Feb;49(1):95-8 (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

Differential modulation of caffeine- and IP3-induced calcium release in cultured arterial tissue. Dreja K, et al. **Am J Physiol** 1999 May;276(5 Pt 1):C1115-20

Antibodies against the PH domain of phospholipase C-delta1 inhibit Ins(1,4,5)P3-mediated Ca2+ release from the endoplasmic reticulum. Matsuki N, et al. **Biochem Biophys Res Commun** 1999 Jun 24;260(1):42-7

Development of nuclear transfer and parthenogenetic rabbit embryos activated with inositol 1,4,5-trisphosphate. Mitalipov SM, et al. **Biol Reprod** 1999 Apr;60(4):821-7

Inositol-1,4,5-trisphosphate increases contractions but not L-type calcium current in guinea pig ventricular myocytes. Saeki T, et al. **Cardiovasc Res** 1999 Mar;41(3):620-8

Imaging of quantal calcium release in the inositol 1,4,5-trisphosphate-sensitive organelles of permeabilized HSY cells. Tanimura A, et al. **Cell Struct Funct** 1998 Jun; 23(3):129-35

Imaging of calcium release in inositol 1,4,5-trisphosphate-sensitive internal stores in permeabilized HSY cells using fluorescent indicators. Tanimura A, et al. **Cell Struct Funct** 1998 Feb;23(1):1-7

Calmodulin inhibits inositol 1,4,5-trisphosphate-induced calcium release through the purified and reconstituted inositol 1,4,5-trisphosphate receptor type 1. Hirota J, et al. **FEBS Lett** 1999 Aug 6;456(2):322-6

Adenophostin A and inositol 1,4,5-trisphosphate differentially activate Cl- currents in Xenopus oocytes because of disparate Ca2+ release kinetics. Machaca K, et al. **J Biol Chem** 1999 Feb 19;274(8):4824-31

Kinetic control of multiple forms of Ca(2+) spikes by inositol trisphosphate in pancreatic acinar cells. Ito K, et al. **J Cell Biol** 1999 Jul 26;146(2):405-13

Regulation of type 1 inositol 1,4,5-trisphosphate-gated calcium channels by InsP3 and calcium: Simulation of single channel kinetics based on ligand binding and electrophysiological analysis. Moraru II, et al. **J Gen Physiol** 1999 Jun;113(6):837-49

ADP and inositol trisphosphate evoke oscillations of a monovalent cation conductance in rat megakaryocytes. Hussain JF, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):791-801

InsP3, but not novel Ca2+ releasers, contributes to agonist-initiated contraction in rabbit airway smooth muscle. Iizuka K, et al. **J Physiol (Lond)** 1998 Sep 15;511 (Pt 3):915-33

Mitochondrial regulation of the cytosolic Ca2+ concentration and the InsP3-sensitive Ca2+ store in guinea-pig colonic smooth muscle. McCarron JG, et al. **J Physiol (Lond)** 1999 Apr 1;516 (Pt 1):149-61

Low-conductivity calcium channels in the macrophage plasma membrane: activation by inositol-1,4,5-triphosphate. Semenova SB, et al. **Neurosci Behav Physiol** 1999 May-Jun;29(3):339-45

Miniature Ca2+ channels in excised plasma-membrane patches: activation by IP3. Kiselyov KI, et al. **Pflugers Arch** 1999 Jan;437(2):305-14

IP3-induced Ca2+ release in A7r5 vascular smooth-muscle cells represents a partial emptying of the stores and not an all-or-none Ca2+ release of separate quanta. Missiaen L, et al. **Pflugers Arch** 1999 Apr;437(5):691-4

PHYSIOLOGY

Norepinephrine-induced Ca(2+) waves depend on InsP(3) and ryanodine receptor activation in vascular myocytes. Boittin FX, et al. **Am J Physiol** 1999 Jul;277(1 Pt 1):C139-51

Protein-protein interactions in intracellular Ca2+-release channel function. MacKrill JJ. **Biochem J** 1999 Feb 1;337 (Pt 3):345-61 (220 ref.)

Regulatory and spatial aspects of inositol trisphosphate-mediated calcium signals. Horne JH. **Cell Biochem Biophys** 1999;30(2):267-86 (64 ref.)

The physiologic concentration of inositol 1,4,5-trisphosphate in the oocytes of Xenopus laevis. Luzzi V, et al. **J Biol Chem** 1998 Oct 30;273(44):28657-62

Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. Haughey NJ, et al. **J Neurochem** 1999 Oct;73(4):1363-74

Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. Leissring MA, et al. **J Neurochem** 1999 Mar; 72(3):1061-8

ATP-Induced Ca(2+) release in cochlear outer hair cells: localization of an inositol triphosphate-gated Ca(2+) store to the base of the sensory hair bundle. Mammano F, et al. **J Neurosci** 1999 Aug 15;19(16):6918-29

Hemispheric asymmetry of macroscopic and elementary calcium signals mediated by InsP3 in Xenopus oocytes. Callamaras N, et al. **J Physiol (Lond)** 1998 Sep 1;511 (Pt 2):395-405

The role of inositol trisphosphate-induced Ca2+ release from IP3-receptor in the rat suprachiasmatic nucleus on circadian entrainment mechanism. Hamada T, et al. **Neurosci Lett** 1999 Mar 26;263(2-3):125-8

Inositol-1,4,5-trisphosphate-mediated rescue of cerebellar long-term depression in subtype 1 metabotropic glutamate receptor mutant mouse. Daniel H, et al. **Neuroscience** 1999; 92(1):1-6

Selective inhibition of inositol 1,4,5-triphosphate-induced Ca2+ release in the CA1 region of the hippocampus in the ischemic gerbil. Nagata E, et al. **Neuroscience** 1999; 93(3):995-1001

Protein kinase C and IP3 in photoresponses of functionally intact rod outer segments: constraints about their role. Jindrová H, et al. **Physiol Res** 1998;47(4):285-90 (39 ref.)

[Low conductivity calcium channels in the plasmatic membrane of macrophages: activation with inositol 1,4,5-triphosphate] Semenova SB, et al. **Ross Fiziol Zh Im I M Sechenova** 1998 May-Jun; 84(5-6):417-25 (Eng. Abstr.) **(Rus)**

[Role of inositol triphosphate in the formation of the calcium signal in T-lymphocytes] Matyshevskaia OP. **Ukr Biokhim Zh** 1998 Jul-Aug;70(4):3-15 (69 ref.) (Eng. Abstr.) **(Rus)**

INOTROPIC AGENTS, POSITIVE CARDIAC see **CARDIOTONIC AGENTS**

INOTROPISM see **MUSCLE CONTRACTION**

INOTROPISM, CARDIAC see **MYOCARDIAL CONTRACTION**

INOVIRIDAE

GENETICS

Analysis of clinical and environmental strains of nontoxigenic Vibrio cholerae for susceptibility to CTXPhi: molecular basis for origination of new strains with epidemic potential. Faruque SM, et al. **Infect Immun** 1998 Dec;66(12):5819-25

INOVIRUS

CHEMISTRY

Raman markers of nonaromatic side chains in an alpha-helix assembly: Ala, Asp, Glu, Gly, Ile, Leu, Lys, Ser, and Val residues of phage fd subunits. Overman SA, et al. **Biochemistry** 1999 Mar 30;38(13):4018-27

Demonstration by ultraviolet resonance Raman spectroscopy of differences in DNA organization and interactions in filamentous viruses Pf1 and fd. Wen ZQ, et al. **Biochemistry** 1999 Mar 9;38(10):3148-56

Crystal structure of the two N-terminal domains of g3p from filamentous phage fd at 1.9 A: evidence for conformational lability. Holliger P, et al. **J Mol Biol** 1999 May 14; 288(4):649-57

Functionally important correlated motions in the

single-stranded DNA-binding protein encoded by filamentous phage Pf3. Horstink LM, et al. **J Mol Biol** 1999 Apr 2;287(3):569-77

Structure of the capsid of Pf3 filamentous phage determined from X-ray fibre diffraction data at 3.1 A resolution. Welsh LC, et al. **J Mol Biol** 1998;283(1):155-77

Analysis of X-ray diffraction from fibres of Pf1 Inovirus (filamentous bacteriophage) shows that the DNA in the virion is not highly ordered. Welsh LC, et al. **J Mol Biol** 1998 Dec 18;284(5):1265-71 (27 ref.)

GENETICS

Factors limiting display of foreign peptides on the major coat protein of filamentous bacteriophage capsids and a potential role for leader peptidase. Malik P, et al. **FEBS Lett** 1998 Oct 2;436(2):263-6

T cell proliferation-augmenting activities of the gene 3 protein derived from a phage library clone with CD80-binding activity. Fukumoto T, et al. **J Immunol** 1998 Dec 15;161(12):6622-8

Isolation of chloroform-resistant mutants of filamentous phage: localization in models of phage structure. Oh JS, et al. **J Mol Biol** 1999 Apr 2;287(3):449-57

Effects of temperature and Y21M mutation on conformational heterogeneity of the major coat protein (pVIII) of filamentous bacteriophage fd. Tan WM, et al. **J Mol Biol** 1999 Feb 26;286(3):787-96

Functional analysis of the O antigen glucosylation gene cluster of Shigella flexneri bacteriophage SfX. Guan S, et al. **Microbiology** 1999 May;145 (Pt 5):1263-73

Selecting proteins with improved stability by a phage-based method. Sieber V, et al. **Nat Biotechnol** 1998 Oct; 16(10):955-60

IMMUNOLOGY

Toward selection of internalizing antibodies from phage libraries. Becerril B, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):386-93

Epitope structures recognised by antibodies against the major coat protein (g8p) of filamentous bacteriophage fd (Inoviridae). Kneissel S, et al. **J Mol Biol** 1999 Apr 23; 288(1):21-8

METABOLISM

Toward selection of internalizing antibodies from phage libraries. Becerril B, et al. **Biochem Biophys Res Commun** 1999 Feb 16;255(2):386-93

Display of functional alphabeta single-chain T-cell receptor molecules on the surface of bacteriophage. Weidanz JA, et al. **J Immunol Methods** 1998 Dec 1;221(1-2):59-76

Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions. Hansen MR, et al. **Nat Struct Biol** 1998 Dec;5(12):1065-74

An aqueous channel for filamentous phage export [see comments] Marciano DK, et al. **Science** 1999 May 28; 284(5419):1516-9. Comment in: Science 1999 May 28;284(5419):1475, 1777.

Hole-istic medicine [comment] Zimmerberg J. **Science** 1999 May 28;284(5419):1475, 1477. Comment on: Science 1999 May 28;284(5419):1516-9.

Interaction of the globular domains of pIII protein of filamentous bacteriophage fd with the F-pilus of Escherichia coli. Deng LW, et al. **Virology** 1999 Jan 20; 253(2):271-7

PATHOGENICITY

The adsorption protein genes of Xanthomonas campestris filamentous phages determining host specificity. Lin NT, et al. **J Bacteriol** 1999 Apr;181(8):2465-71

ULTRASTRUCTURE

Isolation of chloroform-resistant mutants of filamentous phage: localization in models of phage structure. Oh JS, et al. **J Mol Biol** 1999 Apr 2;287(3):449-57

INPATIENTS

A long-term follow-up study of adolescent psychiatric in-patients. Part I. Predictors of early death. Kjelsberg E, et al. **Acta Psychiatr Scand** 1999 Apr;99(4):231-6

Therapeutic alliance in cognitive therapy for schizophrenic and other long-term mentally ill patients: development and relationship to outcome in an in-patient treatment programme. Svensson B, et al. **Acta Psychiatr Scand** 1999 Apr;99(4):281-7

A long-term follow-up of adolescent psychiatric in-patients [editorial] Tómasson K. **Acta Psychiatr Scand** 1999 Apr; 99(4):229-30

Peak time of occurrence of myocardial ischemia in the coronary care unit. Pelter MM, et al. **Am J Crit Care** 1998 Nov;7(6):411-7

The utility of an in-hospital observation period after discontinuing intravenous antibiotics. Dunn AS, et al. **Am J Med** 1999 Jan;106(1):6-10

A series of hospitalized patients with elevated digoxin levels [letter; comment] Olivero JJ. **Am J Med** 1999 Apr; 106(4):489. Comment on: Am J Med 1998 Aug;105(2):110-5.

Hypocholesterolaemia in a hospital population. Crook MA, et al. **Ann Clin Biochem** 1999 Sep;36 (Pt 5):613-6

Review of investigation and management of severe hyponatraemia in a hospital population [letter; comment] al-Jubouri MA. **Ann Clin Biochem** 1999 Jul;36 (Pt 4):531-2 . Comment on: Ann Clin Biochem 1999 Mar;36(Pt 2):158-62.

Diagnosis of thyroid disease in hospitalized patients: a systematic review. Attia J, et al. **Arch Intern Med** 1999 Apr 12;159(7):658-65 (38 ref.)

In-hospital cardiopulmonary resuscitation: prearrest morbidity and outcome. de Vos R, et al. **Arch Intern Med** 1999 Apr 26;159(8):845-50

Screening for Helicobacter pylori and nonsteroidal anti-inflammatory drug use in medicare patients hospitalized with peptic ulcer disease. Hood HM, et al. **Arch Intern Med** 1999 Jan 25;159(2):149-54

Do we need a clinical decision rule for the discontinuation of cardiac arrest resuscitations? [editorial; comment] Sanders AB. **Arch Intern Med** 1999 Jan 25;159(2):119-21 . Comment on: Arch Intern Med 1999 Jan 25;159(2):129-34.

Derivation of a clinical decision rule for the discontinuation of in-hospital cardiac arrest resuscitations [see comments] van Walraven C, et al. **Arch Intern Med** 1999 Jan 25; 159(2):129-34. Comment in: Arch Intern Med 1999 Jan 25;159(2):119-21.

Functional outcome of inpatient rehabilitation in persons with brain tumors. O'Dell MW, et al. **Arch Phys Med Rehabil** 1998 Dec;79(12):1530-4

Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Biasucci LM, et al. **Circulation** 1999 Apr 27; 99(16):2079-84

Improving preventive care [letter; comment] Gilchrist DM. **CMAJ** 1999 Jul 27;161(2):126-7. Comment on: CMAJ 1999 Apr 20;160(8):1137-40.

Relocating elderly people and nursing staff from the NHS to the independent sector. Lee S. **J Adv Nurs** 1998 Oct; 28(4):859-64

How patients spend their time in a hospice and in an oncological unit. Rasmussen BH, et al. **J Adv Nurs** 1998 Oct;28(4):818-28

Optimal management of the patient with an episode of atrial fibrillation in and out of the hospital: acute cardioversion or not? Knight BP, et al. **J Cardiovasc Electrophysiol** 1999 Mar;10(3):425-32 (53 ref.)

The case for inpatient initiation of antiarrhythmic therapy. Myerburg RJ, et al. **J Cardiovasc Electrophysiol** 1999 Mar; 10(3):482-7 (23 ref.)

Outpatient preoperative evaluation clinic can lead to a rapid shift from inpatient to outpatient surgery: a retrospective review of perioperative setting and outcome. Pollard JB, et al. **J Clin Anesth** 1999 Feb;11(1):39-45

Decrease in emergency room or urgent care visits due to management of bronchial asthma inpatients and outpatients with pharmaceutical services. Watanabe T, et al. **J Clin Pharm Ther** 1998 Aug;23(4):303-9

In-hospital smoking cessation programs: who responds, who doesn't? Smith PM, et al. **J Consult Clin Psychol** 1999 Feb; 67(1):19-27

Delirium in hospitalized older patients: recognition and risk factors. Inouye SK. **J Geriatr Psychiatry Neurol** 1998 Fall; 11(3):118-25; discussion 157-8

Urinary sodium excretion and blood pressure in chronic psychiatric in-patients. Lip GY, et al. **J Hum Hypertens** 1999 Jul;13(7):461-6

Out-patient versus in-hospital ambulatory 24-h blood pressure monitoring in heart transplant recipients. Vanhaecke J, et al. **J Hum Hypertens** 1999 Mar; 13(3):199-202

Impact of written information on knowledge and preferences for cardiopulmonary resuscitation. Kerridge IH, et al. **Med J Aust** 1999 Sep 6;171(5):239-42

How do patients who die at home differ from those who die elsewhere? [letter] Rees WD. **Palliat Med** 1999 Mar; 13(2):169-70

Prevalence of anti-Toxocara antibodies in a random sample of inpatients at a children's hospital in Vitória, Espírito Santo, Brazil. Moreira-Silva SF, et al. **Rev Inst Med Trop Sao Paulo** 1998 Jul-Aug;40(4):259-61

Is it possible to predict the efficacy at discharge of inhospital rheumatology department management of disk-related sciatica? A study in 150 patients. Berthelot JM, et al. **Rev Rhum Engl Ed** 1999 Apr;66(4):207-13

[Acute bronchiolitis seen in ambulatory and hospital patients is different according to age and severity (letter)] Jafalian L, et al. **Arch Pediatr** 1998 Oct;5(10):1170 **(Fre)**

[Taking into account patients' expectations in the improvement of quality of health care: results of a survey of 500 hospitalized patients (letter)] Salomon L, et al. **Rev Epidemiol Sante Publique** 1998 Nov;46(5):427-9 **(Fre)**

[Rationale of inpatient care--towards a new payment system] Robra BP, et al. **Gesundheitswesen** 1999 Feb;61(2):70-7 (Eng. Abstr.) **(Ger)**

[Critical life events during the course of 2 years of 'major depression.' A prospective study with inpatients] Reck C, et al. **Nervenarzt** 1999 Jul;70(7):637-44 (Eng. Abstr.) **(Ger)**

[Folic acid deficiency in chronically hospitalized mental patients] Fuchs I, et al. **Harefuah** 1998 Sep;135(5-6):186-7, 255 (Eng. Abstr.) **(Heb)**

[Tuberculosis outbreak among inpatients] Takamatsu I, et al. **Kekkaku** 1999 Apr;74(4):397-404 (Eng. Abstr.) **(Jpn)**

[A Polish multicenter survey of antimicrobial susceptibility and prevalence of beta-lactamase production among bacterial pathogens isolated from hospitalized and ambulatory patients] Zwolska Z, et al. **Pol Merkuriusz Lek** 1998 May;4(23):241-6 (Eng. Abstr.) **(Pol)**

[Direct coronary angioplasty versus thrombolysis in the acute phase of myocardial infarction--inpatient outcome] Fazendas P, et al. **Rev Port Cardiol** 1998 Oct;17(10):789-92 (Eng. Abstr.) **(Por)**

[Iatrogeny in hospitalized elderly patients] Carvalho-Filho ET, et al. **Rev Saude Publica** 1998 Feb;32(1):36-42 (Eng. Abstr.) **(Por)**

CLASSIFICATION

Improving the ability to detect the impact of labor on patient outcomes. Minnick AF, et al. **J Nurs Adm** 1998 Dec; 28(12):17-21

Influences on nursing care volume. Arndt M, et al. **J Soc Health Syst** 1998;5(4):38-49

Classifying psychiatric inpatients: seeking better measures. Durbin J, et al. **Med Care** 1999 Apr;37(4):415-23

Comparison of professional judgment versus an algorithm for nutrition status classification. Lowery JC, et al. **Med Care** 1998 Nov;36(11):1578-88

HISTORY

Historical overview of inpatient care of mental patients who are deaf. Vernon M, et al. **Am Ann Deaf** 1999 Mar; 144(1):51-61

A tale of two centuries: voices of the past and present. Mohr WK. **Arch Psychiatr Nurs** 1998 Dec;12(6):301-10

PSYCHOLOGY

Medical students' perception of inpatients' anxiety, self-esteem, purpose-in-life and health locus of control as compared with nursing practitioners'. Nagata H, et al. **Acta Med Okayama** 1999 Jun;53(3):141-5

Nursing practitioners' perception of inpatients' anxiety, self-esteem, purpose-in-life and health locus of control. Nagata H, et al. **Acta Med Okayama** 1998 Oct;52(5):271-8

A tale of two centuries: voices of the past and present. Mohr WK. **Arch Psychiatr Nurs** 1998 Dec;12(6):301-10

Euthanasia and the terminally ill: can the civil killing of others be eroded? Kelleher MJ, et al. **Crisis** 1998; 19(3):116-8

Prevalence of malingering in inpatient suicide ideators and attempters. Rissmiller DJ, et al. **Crisis** 1998;19(2):62-6

Objective and subjective quality of life of first-admitted women and men with schizophrenia. Röder-Wanner UU, et al. **Eur Arch Psychiatry Clin Neurosci** 1998;248(5):250-8

A comparison of descriptive characteristics of male outpatients and inpatients with affective disorders. Mendlowicz MV, et al. **Int Clin Psychopharmacol** 1998 Nov;13(6):245-52

An anthropological interpretation of nurses' and patients' perceptions of the use of space and touch. Edwards SC. **J Adv Nurs** 1998 Oct;28(4):809-17

Religious activity improves life satisfaction for some physicians and older patients. Ayele H, et al. **J Am Geriatr Soc** 1999 Apr;47(4):453-5

Behavior sequences of long-term care residents and their social partners. Rose MS, et al. **J Gerontol B Psychol Sci Soc Sci** 1999 Mar;54(2):S75-83

Detection and treatment of psychiatric illness in a general medical ward: a modified cost-benefit analysis [see comments] Gater RA, et al. **J Psychosom Res** 1998 Nov; 45(5):437-48. Comment in: J Psychosom Res 1998 Nov;45(5):433-6.

The lesson of Icarus [letter; comment] Levenson JL. **J Psychosom Res** 1998 Nov;45(5):433-6. Comment on: J Psychosom Res 1998 Nov;45(5):437-48.

Analysis of violent behavior in Vietnam combat veteran psychiatric inpatients with posttraumatic stress disorder. McFall M, et al. **J Trauma Stress** 1999 Jul;12(3):501-17

Do our patients understand? A comparison of understanding in adult inpatients and schoolchildren. Taylor EM, et al. **N Z Med J** 1998 Nov 27;111(1078):449-51

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Freeman JA, et al. **Neurology** 1999 Jan 1;52(1):50-6

Delirium in the hospitalized elderly: nursing assessment and management. Milisen K, et al. **Nurs Clin North Am** 1998 Sep;33(3):417-39 (86 ref.)

The drawback of the Hospital Anxiety and Depression Scale in the assessment of depression in hospice inpatients. Urch CE, et al. **Palliat Med** 1998 Sep;12(5):395-6

Psycho-social determinants and motivational phases in smoking behavior of cardiac inpatients. Bolman C, et al. **Prev Med** 1998 Sep-Oct;27(5 Pt 1):738-47

Characteristics of patients adhering to a hospital's no-smoking policy. Emmons KM, et al. **Prev Med** 1998 Nov-Dec;27(6):846-53

Crowding and aggression on inpatient psychiatric wards. Nijman HL, et al. **Psychiatr Serv** 1999 Jun;50(6):830-1

A tentative model of aggression on inpatient psychiatric wards. Nijman HL, et al. **Psychiatr Serv** 1999 Jun; 50(6):832-4

Screening for anxiety and depression in adult general medical in-patients in a Scottish District General Hospital.

INPATIENTS

Beausang P, et al. **Scott Med J** 1998 Dec;43(6):177–80

"You don't give me flowers anymore": an analysis of gift-giving to medical and psychiatric inpatients. Wiener A, et al. **Soc Psychiatry Psychiatr Epidemiol** 1999 Mar; 34(3):136–40

The fake patient: a research experiment in a Ghanaian hospital. Van der Geest S, et al. **Soc Sci Med** 1998 Nov; 47(9):1373–81

[Process and outcome quality in inpatient care: a contribution to evaluation and quality assurance in child and adolescent psychiatry] Reisel B, et al.
Prax Kinderpsychol Kinderpsychiatr 1998 Dec; 47(10):705–21 (Eng. Abstr.) **(Ger)**

[Child and adolescent psychiatric services in the canton of Zurich: a comparison of outpatients, day clinic, and inpatient referral populations] von Aster M, et al.
Prax Kinderpsychol Kinderpsychiatr 1998 Nov;47(9):668–82 (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Ethnic disparities in patient recall of physician recommendations of diagnostic and treatment procedures for coronary disease [published erratum appears in Am J Epidemiol 1999 Mar 1;149(5):489] Sanderson BK, et al. **Am J Epidemiol** 1998 Oct 15;148(8):741–9

Significance of polymicrobic bacteriuria in a teaching hospital in Trinidad. Orrett FA. **Cent Afr J Med** 1998 Nov; 44(11):283–6

Clinical relevance of thiamine status amongst hospitalized elderly patients. Pepersack T, et al. **Gerontology** 1999; 45(2):96–101

Appendectomy in Sweden 1989–1993 assessed by the Inpatient Registry. Blomqvist P, et al. **J Clin Epidemiol** 1998 Oct;51(10):859–65

Delirium: prevention, treatment, and outcome studies. Cole MG, et al. **J Geriatr Psychiatry Neurol** 1998 Fall; 11(3):126–37; discussion 157–8

Factors influencing CPR outcome in Siriraj Hospital. Suraseranivongse S, et al. **J Med Assoc Thai** 1998 Nov; 81(11):835–43

Malnutrition in hospitals: a report on the Professorial Inaugural Lecture, delivered by Professor Susan Holmes presented at Canterbury Christ Church College, June 17th 1998. Brandon H. **J R Soc Health** 1998 Aug;118(4):245

Adverse drug reactions in hospitalized patients [letter; comment] Bush T. **JAMA** 1998 Nov 25;280(20):1742; discussion 1743–4. Comment on: JAMA 1995 Jul 5;274(1):29–34. Comment on: JAMA 1998 Apr 15;279(15):1200–5.

Adverse drug reactions in hospitalized patients [letter; comment] Fremont-Smith K. **JAMA** 1998 Nov 25; 280(20):1741; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5.

Adverse drug reactions in hospitalized patients [letter; comment] Hanzlick R, et al. **JAMA** 1998 Nov 25; 280(20):1742; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Adverse drug reactions in hospitalized patients [letter; comment] Hui KK. **JAMA** 1998 Nov 25;280(20):1742–3; discussion 1743–4. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Adverse drug reactions in hospitalized patients [letter; comment] Kravitz GR. **JAMA** 1998 Nov 25;280(20):1741; discussion 1743–4. Comment on: JAMA 1995 Jul 5;274(1):29–34. Comment on: JAMA 1998 Apr 15;279(15):1200–5. Comment on: JAMA 1998 Apr 15;279(15):1216–7.

Markers of inappropriate placement in acute psychiatric inpatient care: a five hospital study. Bartlett C, et al.
Soc Psychiatry Psychiatr Epidemiol 1999 Jul;34(7):367–75

Effects of distances to hospital and GP surgery on hospital inpatient episodes, controlling for needs and provision. Haynes R, et al. **Soc Sci Med** 1999 Aug;49(3):425–33

INR see **INTERNATIONAL NORMALIZED RATIO**

INSANITY DEFENSE

The 'special verdict' [letter] Robertson S.
Aust N Z J Psychiatry 1998 Oct;32(5):730

An administrative model for close monitoring and managing high risk individuals. Bigelow DA, et al.
Behav Sci Law 1999;17(2):227–35

Introduction to mental illness and criminal responsibility. Felthous AR. **Behav Sci Law** 1999;17(2):143–6

The medico-legal status of young sex offenders: forensic psychiatric evaluations in Sweden 1988–1995. Långström N, et al. **Behav Sci Law** 1999;17(2):219–25

Voluntary intoxication and criminal responsibility. Marlowe DB, et al. **Behav Sci Law** 1999;17(2):195–217

Craziness and criminal responsibility. Morse SJ.
Behav Sci Law 1999;17(2):147–64

The R-CRAS and insanity evaluations: a re-examination of construct validity. Rogers Criminal Responsibility Assessment Scales. Rogers R, et al. **Behav Sci Law** 1999; 17(2):181–94

The mental disability requirement in the insanity defense. Slovenko R. **Behav Sci Law** 1999;17(2):165–80

The medical model of mental illness. Its application to the insanity defense. Gerard JB. **Int J Law Psychiatry** 1999 Jan–Feb;22(1):65–78

The iller the killer, the worse the purpose [letter; comment] Gordon AG. **J Am Acad Psychiatry Law** 1998;26(4):683–6 . Comment on: J Am Acad Psychiatry Law 1997;25(2):161–71.

Reply: Staring down "the dark emptiness of legal jargon" [letter; comment] Haycock J, et al.
J Am Acad Psychiatry Law 1999;27(1):171–8. Comment on: J Am Acad Psychiatry Law 1997;25(2):161–71.

An examination of gender and racial differences among Missouri insanity acquittees. Linhorst DM, et al.
J Am Acad Psychiatry Law 1998;26(3):411–24

The development of internal forensic review boards in the management of hospitalized insanity acquittees. Patterson RF, et al. **J Am Acad Psychiatry Law** 1998;26(4):661–4

MMPI-2 profiles of NGRI and civil patients. Moskowitz JL, et al. **J Clin Psychol** 1999 May;55(5):659–68

Empirical research on the insanity defense and attempted reforms: evidence toward informed policy. Borum R, et al. **Law Hum Behav** 1999 Jun;23(3):375–93 (71 ref.)

Empirical research on the insanity defense and attempted reforms: evidence toward informed policy. Borum R, et al. **Law Hum Behav** 1999 Feb;23(1):117–35 (69 ref.)

The effects of motive information and crime unusualness on jurors' judgments in insanity cases. Pickel KL.
Law Hum Behav 1998 Oct;22(5):571–84

A controlled evaluation of assessments by doctors and nurses in a magistrates' court mental health assessment and diversion scheme. Chambers C, et al. **Med Sci Law** 1999 Jan;39(1):38–48

A follow-up study of mentally disordered offenders after a court diversion scheme: six-month and one-year comparison. Chung MC, et al. **Med Sci Law** 1999 Jan; 39(1):31–7

A change of direction in the disposal of mentally disordered offenders: the impact of the Crime (Sentences) Act 1997 [see comments] Laing JM. **Med Sci Law** 1998 Oct; 38(4):301–10. Comment in: Med Sci Law 1999 Jan;39(1):90.

Mental responsibility. Mackay of the Clashfern Lord.
Med Sci Law 1998 Oct;38(4):281–2

A change of direction in the disposal of mentally disordered offenders: the impact of the Crime (Sentences) Act 1977 [letter; comment] Prins H. **Med Sci Law** 1999 Jan;39(1):90 . Comment on: Med Sci Law 1998 Oct;38(4):301–10.

A confusion of tongues: competence, insanity, psychiatry, and the law. Gutheil TG. **Psychiatr Serv** 1999 Jun; 50(6):767–73

Preparation and draft of mental health law in China. Liu X. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S250–1

Culture, law and psychiatry in Hawaii. Schultz-Ross RA, et al. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S374–6

Human rights of psychiatrically disturbed persons in the tropical Pacific. Wilson LG. **Psychiatry Clin Neurosci** 1998 Dec;52 Suppl:S252–5

[Analyses of expert's testimonies about 22 mental patients occurred in trip] Wang Z. **Fa I Hsueh Tsa Chih** 1997; 13(3):145–6 inside back cover (Eng. Abstr.) **(Chi)**

[Habitual shoplifting in multi-infarct syndrome] Pillmann F, et al. **Arch Kriminol** 1998 Sep-Oct;202(3–4):65–8 (Eng. Abstr.) **(Ger)**

HISTORY

Canadian landmark case: Regina v. Swain: translating M'Naughton into twentieth century Canadian. Glancy GD, et al. **J Am Acad Psychiatry Law** 1999;27(2):301–7

STATISTICS & NUMERICAL DATA

Length of stay, leave and re-offending by patients from a Queensland security patients hospital. Green B, et al.
Aust N Z J Psychiatry 1998 Dec;32(6):839–47

Identifying insanity acquittals: is it any easier? Cirincione C, et al. **Law Hum Behav** 1999 Aug;23(4):487–97

INSECT BITES AND STINGS

Delayed toxic reaction following massive bee envenomation. Kolecki P. **Ann Emerg Med** 1999 Jan;33(1):114–6

Unusual summertime foreign body in the esophagus. Kesseler P, et al. **Endoscopy** 1999 Mar;31(3):S24

Infectivity of Plasmodium berghei sporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials. Vaughan JA, et al.
Infect Immun 1999 Aug;67(8):4285–9

Determination of sample sizes for the estimation of Onchocerca volvulus (Filarioidea: Onchocercidae) infection rates in biting populations of Simulium ochraceum s.l. (Diptera: Simuliidae) and its application to ivermectin control programs. Basáñez MG, et al. **J Med Entomol** 1998 Sep;35(5):745–57

Effect of diet on biting, oviposition, and survival of Aedes aegypti (Diptera: Culicidae). Canyon DV, et al.
J Med Entomol 1999 May;36(3):301–8

Malaria-infective biting at different hours of the night. Maxwell CA, et al. **Med Vet Entomol** 1998 Jul;12(3):325–7

Can mosquitoes transmit AIDS? Bockarie MJ, et al.
P N G Med J 1996 Sep;39(3):205–7 (6 ref.)

Blackflies bite a resident of suburban Johannesburg. Jupp PG, et al. **S Afr Med J** 1999 Apr;89(4):388–9

Predicting key malaria transmission factors, biting and entomological inoculation rates, using modelled soil moisture in Kenya. Patz JA, et al.
Trop Med Int Health 1998 Oct;3(10):818–27

Mass envenomations by honey bees and wasps. Vetter RS, et al. **West J Med** 1999 Apr;170(4):223–7 (59 ref.)

[The aggressive cycle of Anopheles gambiae s.s. inside houses and malaria transmission in the Bouake region (Côte d'Ivoire). Value of using impregnated mosquito nets] Dossou-Yovo J, et al. **Bull Soc Pathol Exot** 1999 Jul; 92(3):198–200 (Eng. Abstr.) **(Fre)**

[Determination of HIV protein 24 in feces of Triatoma infestans fed with blood from AIDS patients] Nuzzo SF, et al. **Rev Saude Publica** 1998 Oct;32(5):464–6 (Eng. Abstr.) **(Por)**

[Venomous stings in the tropical world: bite and sting accident by a bumblebee swarm in a rainy Venezuelan forest] Rodriguez-Acosta A, et al.
Rev Cubana Med Trop 1998;50(1):5–7 (Eng. Abstr.) **(Spa)**

[Annoyances of summer--current data on stings and bites] Foucard T, et al. **Lakartidningen** 1999 Jun 23;96(25):3044–6 **(Swe)**

COMPLICATIONS

Natural killer cell-derived large granular lymphocyte lymphoma of lung developed in a patient with hypersensitivity to mosquito bites and reactivated Epstein-Barr virus infection. Mizuki M, et al.
Am J Hematol 1998 Dec;59(4):309–15

Nephrotic syndrome with mesangial proliferative glomerulonephritis induced by multiple wasp stings. Tauk B, et al. **Am J Nephrol** 1999;19(1):70–2

Pathogenesis of envenomation [letter] King MS.
Ann Emerg Med 1999 Sep;34(3):411–2

Bee sting dysphagia [letter; comment] DeGrandi-Hoffman G, et al. **Ann Intern Med** 1999 Jun 1;130(11):943. Comment on: Ann Intern Med 1998 Aug 1;129(3):253.

Bee sting dysphagia [letter; comment] Levine MI.
Ann Intern Med 1999 Jun 1;130(11):943. Comment on: Ann Intern Med 1998 Aug 1;129(3):253.

Dialysis or plasmapheresis for acute renal failure due to Africanized honeybee stings [letter; comment] Beccari M. **Arch Intern Med** 1998 Jun 14;159(11):1255–6. Comment on: Arch Intern Med 1998 Apr 27;158(8):925–7.

Eosinophilic foreign body granuloma after multiple self-administered bee stings. Park JH, et al.
Br J Dermatol 1998 Dec;139(6):1102–5

Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Tsuge I, et al. **Clin Exp Immunol** 1999 Mar;115(3):385–92

Cutaneous nocardiosis caused by Nocardia brasiliensis after an insect bite. Paredes BE, et al. **Dermatology** 1999; 198(2):159–61

Acute rhabdomyolysis and intravascular hemolysis following extensive wasp stings. Chao SC, et al. **Int J Dermatol** 1999 Feb;38(2):135–7

Wells' syndrome triggered by centipede bite. Friedman IS, et al. **Int J Dermatol** 1998 Aug;37(8):602–5

Placental abruption and intrauterine death following an ant sting. Rizk DE, et al. **Int J Gynaecol Obstet** 1998 Oct; 63(1):71–2

Insect bite as possible cause of eosinophilic pustular dermatosis [letter] Horiuchi Y. **J Dermatol** 1999 Mar; 26(3):196–7

Serum sickness-like syndrome due to mosquito bite. Gaig P, et al. **J Investig Allergol Clin Immunol** 1999 May-Jun; 9(3):190–2

Cerebral infarction: a rare complication of wasp sting [letter] Crawley F, et al. **J Neurol Neurosurg Psychiatry** 1999 Apr; 66(4):550–1

Simvastatin treatment in nephrotic syndrome associated with a bee sting [see comments] Révai T, et al.
J R Soc Med 1999 Jan;92(1):23–4. Comment in: J R Soc Med 1999 Mar;92(3):158.

Temporal arteritis after Hymenoptera sting [letter] Schoen EJ. **J Rheumatol** 1998 Oct;25(10):2040–2

Parkinsonism after a wasp sting. Leopold NA, et al.
Mov Disord 1999 Jan;14(1):122–7

Acute renal failure following multiple wasp stings. Thiruventhiran T, et al. **Nephrol Dial Transplant** 1999 Jan; 14(1):214–7 (25 ref.)

Hemorrhagic syndrome and acute renal failure in a pregnant woman after contact with Lonomia caterpillars: a case report. Fan HW, et al. **Rev Inst Med Trop Sao Paulo** 1998 Mar-Apr;40(2):119–20

[A severe anaphylactic shock caused by spraying the oak processionary caterpillar (Thaumetopoea processionea) in North Brabant (see comments)] Bosma AH, et al.
Ned Tijdschr Geneeskd 1998 Jul 4;142(27):1567–9 (Eng. Abstr.). Comment in: Ned Tijdschr Geneeskd 1998 Nov 7;142(45):2488. **(Dut)**

[Serious anaphylactic reaction related to the fight against the oak processionary caterpillar (Thaumetopoea processionea) in Noord-Brabant (letter; comment)] Licht IF, et al. **Ned Tijdschr Geneeskd** 1998 Nov 7;142(45):2488 . Comment on: Ned Tijdschr Geneeskd 1998 Jul 4;142(27):1567–9. **(Dut)**

[The wasp/mosquito syndrome] Sabbah A, et al.
Allerg Immunol (Paris) 1999 Jun;31(6):175–84 (Eng. Abstr.) **(Fre)**

[Massive poisoning by African bee stings] Bourgain C, et al. **Presse Med** 1998 Jun 20;27(22):1099–101 (Eng. Abstr.)